diff --git a/data/true_false_chembl_labeled.csv b/data/true_false_chembl_labeled.csv
index 6a3ffde..bed2b86 100644
--- a/data/true_false_chembl_labeled.csv
+++ b/data/true_false_chembl_labeled.csv
@@ -48,53 +48,53 @@ Predicate ID,Triple,Sentence ID,Sentence,Question,Label,Reference
 23500890,Ibuprofen affects adult acute respiratory distress syndrome,1047,"Ibuprofen suppresses the production of various pro-inflammatory cytokines that are implicated in the 'cytokine storm' and subsequent ARDS in COVID-19 disease.","Is the triple 'Ibuprofen affects adult acute respiratory distress syndrome' supported by the sentence: 'Ibuprofen suppresses the production of various pro-inflammatory cytokines that are implicated in the 'cytokine storm' and subsequent ARDS in COVID-19 disease.'?",True,https://www.nature.com
 21214366,Ibuprofen affects bronchopulmonary dysplasia,1048,"After adjusting for covariates, the risk of BPD was associated independently with ibuprofen exposure (odds ratios (OR) 2.296, 95% confidence interval (CI): 1.166-4.522, p = 0.016).","Is the triple 'Ibuprofen affects bronchopulmonary dysplasia' supported by the sentence: 'After adjusting for covariates, the risk of BPD was associated independently with ibuprofen exposure (odds ratios (OR) 2.296, 95% confidence interval (CI): 1.166-4.522, p = 0.016).'?",True,https://www.nature.com
 20886939,Ibuprofen affects Cognitive impairment,1049,The opposite effect of ibuprofen on ethanol-induced cognitive impairment as measured by two lateralized functions is consistent with the reports in tissue and animal models that central nervous system effects of ethanol may be mediated at least in part by prostaglandins.,"Is the triple 'Ibuprofen affects Cognitive impairment' supported by the sentence: 'The opposite effect of ibuprofen on ethanol-induced cognitive impairment as measured by two lateralized functions is consistent with the reports in tissue and animal models that central nervous system effects of ethanol may be mediated at least in part by prostaglandins.'?",True,https://www.nature.com
-12685801,Description treats Acute suppurative arthritis due to bacteria,2,"This is the first report of septic arthritis in humans caused by this microorganism, and the first description of B. vesicularis infection in an immunocompetent child.","Is the triple ""Description treats Acute suppurative arthritis due to bacteria"" supported by the sentence: ""This is the first report of septic arthritis in humans caused by this microorganism, and the first description of B. vesicularis infection in an immunocompetent child.""?",True,
-27481671,Provider treats Chronic pain,3,"Health providers continue to search for ways to explain, predict, and cure the misery caused by chronic pain.","Is the triple ""Provider treats Chronic pain"" supported by the sentence: ""Health providers continue to search for ways to explain, predict, and cure the misery caused by chronic pain.""?",True,
-19423160,Provider treats Sepsis,4,The objective of this review is to determine the effectiveness of provider strategies for the early recognition of clinical deterioration due to sepsis in pediatric patients.,"Is the triple ""Provider treats Sepsis"" supported by the sentence: ""The objective of this review is to determine the effectiveness of provider strategies for the early recognition of clinical deterioration due to sepsis in pediatric patients.""?",True,
-18994076,Provider treats transient ischemic attack,5,CONCLUSIONS: Primary and emergency care providers need to review how they can best handle patients presenting with symptoms that could be due to stroke or TIA.,"Is the triple ""Provider treats transient ischemic attack"" supported by the sentence: ""CONCLUSIONS: Primary and emergency care providers need to review how they can best handle patients presenting with symptoms that could be due to stroke or TIA.""?",True,
-18980233,Provider treats obesity disorder,6,"Progress notes were examined to extract need for weight management (WM), patient-provider discussions about risk due to overweight/obesity, recommended lifestyle changes and/or follow-up and WM education.","Is the triple ""Provider treats obesity disorder"" supported by the sentence: ""Progress notes were examined to extract need for weight management (WM), patient-provider discussions about risk due to overweight/obesity, recommended lifestyle changes and/or follow-up and WM education.""?",True,
-17192662,Provider treats osteoarthritis,7,"CONCLUSION: Training rural providers to perform knee injections for patients with knee pain secondary to osteoarthritis appears cost effective using the commonly used threshold of $50,000/QALY if more than 20 such patients per year are seen at rural primary care clinics.","Is the triple ""Provider treats osteoarthritis"" supported by the sentence: ""CONCLUSION: Training rural providers to perform knee injections for patients with knee pain secondary to osteoarthritis appears cost effective using the commonly used threshold of $50,000/QALY if more than 20 such patients per year are seen at rural primary care clinics.""?",True,
-16604884,Provider treats cerebral palsy,8,"This article describes the results of surveys completed by disability service providers and individuals with CCN due to cerebral palsy, developmental delay, and acquired disabilities.","Is the triple ""Provider treats cerebral palsy"" supported by the sentence: ""This article describes the results of surveys completed by disability service providers and individuals with CCN due to cerebral palsy, developmental delay, and acquired disabilities.""?",True,
-15941387,Provider treats Rotavirus infection,9,"We estimated health provider costs, economic costs and quality-adjusted life years (QALYs) lost due to rotavirus infections.","Is the triple ""Provider treats Rotavirus infection"" supported by the sentence: ""We estimated health provider costs, economic costs and quality-adjusted life years (QALYs) lost due to rotavirus infections.""?",True,
-14457077,Provider treats Fatigue,10,"It seems reasonable to alternate chest compression providers every 2 min, to prevent the loss of effective compressions due to fatigue and to minimise interruptions of chest compressions.","Is the triple ""Provider treats Fatigue"" supported by the sentence: ""It seems reasonable to alternate chest compression providers every 2 min, to prevent the loss of effective compressions due to fatigue and to minimise interruptions of chest compressions.""?",True,
-13583178,Provider treats stroke disorder,11,"Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.","Is the triple ""Provider treats stroke disorder"" supported by the sentence: ""Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.""?",True,
-13583177,Provider treats respiratory system disorder,12,"Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.","Is the triple ""Provider treats respiratory system disorder"" supported by the sentence: ""Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.""?",True,
-13583176,Provider treats heart disorder,13,"Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.","Is the triple ""Provider treats heart disorder"" supported by the sentence: ""Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.""?",True,
-13436217,Provider treats asthma,14,"CAEs often advised callers (> 75%) to return to their asthma provider for assistance as a result of uncontrolled asthma, medication concerns, a questionable diagnosis, or the need for an action plan.","Is the triple ""Provider treats asthma"" supported by the sentence: ""CAEs often advised callers (> 75%) to return to their asthma provider for assistance as a result of uncontrolled asthma, medication concerns, a questionable diagnosis, or the need for an action plan.""?",True,
-13417890,Provider treats Pain,15,"Reasons include: inflexibility by dialysis providers because of reduced profitability, claims that patients oppose the subcutaneous route because of pain at the site of injection, concerns regarding pure red cell aplasia associated with subcutaneous administration, and greater hemoglobin cycling with the subcutaneous route.","Is the triple ""Provider treats Pain"" supported by the sentence: ""Reasons include: inflexibility by dialysis providers because of reduced profitability, claims that patients oppose the subcutaneous route because of pain at the site of injection, concerns regarding pure red cell aplasia associated with subcutaneous administration, and greater hemoglobin cycling with the subcutaneous route.""?",True,
-26452787,Fenbendazole treats infectious disease,16,Fenbendazole was effective against induced infections of A tubaeforme and Taen taeniaeformis.,"Is the triple ""Fenbendazole treats infectious disease"" supported by the sentence: ""Fenbendazole was effective against induced infections of A tubaeforme and Taen taeniaeformis.""?",True,
-26452786,Fenbendazole treats helminthiasis,17,Evaluation of granulated fenbendazole (22.2%) against induced and naturally occurring helminth infections in cats.,"Is the triple ""Fenbendazole treats helminthiasis"" supported by the sentence: ""Evaluation of granulated fenbendazole (22.2%) against induced and naturally occurring helminth infections in cats.""?",True,
-25044562,Fenbendazole treats Intestinal nematode infection,18,"Efficacy of dichlorvos, fenbendazole, and ivermectin in swine with induced intestinal nematode infections.","Is the triple ""Fenbendazole treats Intestinal nematode infection"" supported by the sentence: ""Efficacy of dichlorvos, fenbendazole, and ivermectin in swine with induced intestinal nematode infections.""?",True,
-24521403,Fenbendazole treats Increased reactive oxygen species production,19,"Furthermore, we explored the associated mechanism, and our results showed that analog 6 and fenbendazole could induce oxidative stress by accumulating ROS.","Is the triple ""Fenbendazole treats Increased reactive oxygen species production"" supported by the sentence: ""Furthermore, we explored the associated mechanism, and our results showed that analog 6 and fenbendazole could induce oxidative stress by accumulating ROS.""?",True,
-23706249,Fenbendazole treats Adverse reactions,20,"However, it is known that administration of high, off-label doses of fenbendazole can lead to adverse reactions.","Is the triple ""Fenbendazole treats Adverse reactions"" supported by the sentence: ""However, it is known that administration of high, off-label doses of fenbendazole can lead to adverse reactions.""?",True,
-19012088,Fenbendazole treats Immune response,21,Effect of fenbendazole and pyrantel tartrate on the induction of protective immunity in pigs naturally or experimentally infected with Ascaris suum.,"Is the triple ""Fenbendazole treats Immune response"" supported by the sentence: ""Effect of fenbendazole and pyrantel tartrate on the induction of protective immunity in pigs naturally or experimentally infected with Ascaris suum.""?",True,
-16366394,Fenbendazole treats Apoptosis,22,"This is the first report to demonstrate the inhibition of proteasome function and induction of endoplasmic reticulum stress/reactive oxygen species-dependent apoptosis in human lung cancer cell lines by fenbendazole, which may represent a new class of anticancer agents showing selective toxicity against cancer cells.","Is the triple ""Fenbendazole treats Apoptosis"" supported by the sentence: ""This is the first report to demonstrate the inhibition of proteasome function and induction of endoplasmic reticulum stress/reactive oxygen species-dependent apoptosis in human lung cancer cell lines by fenbendazole, which may represent a new class of anticancer agents showing selective toxicity against cancer cells.""?",True,
-27756813,mebendazole treats granulomatous hepatitis,23,Granulomatous hepatitis due to mebendazole.,"Is the triple ""mebendazole treats granulomatous hepatitis"" supported by the sentence: ""Granulomatous hepatitis due to mebendazole.""?",True,
-27730862,mebendazole treats Cytoplasmic Alteration,24,The cellular changes documented are likely to account for previously described cytoplasmic alterations induced by MBZ.,"Is the triple ""mebendazole treats Cytoplasmic Alteration"" supported by the sentence: ""The cellular changes documented are likely to account for previously described cytoplasmic alterations induced by MBZ.""?",True,
-26407395,mebendazole treats infectious disease,25,"A formulation of mebendazole was used to determine the optimal dosage level against induced and/or naturally occurring infections of Toxocara cati, Ancylostoma tubaeforme, and Taenia taeniaeformis in cats.","Is the triple ""mebendazole treats infectious disease"" supported by the sentence: ""A formulation of mebendazole was used to determine the optimal dosage level against induced and/or naturally occurring infections of Toxocara cati, Ancylostoma tubaeforme, and Taenia taeniaeformis in cats.""?",True,
-26407394,mebendazole treats helminthiasis,26,Anthelmintic activity of mebendazole against induced and naturally occurring helminth infections in cats.,"Is the triple ""mebendazole treats helminthiasis"" supported by the sentence: ""Anthelmintic activity of mebendazole against induced and naturally occurring helminth infections in cats.""?",True,
-26245282,mebendazole treats Sedentary,27,"The effects are not rapid, however, for only mebendazole at 500 micrograms/ml treats total inactivity of the fluke within a 12-hr period.","Is the triple ""mebendazole treats Sedentary"" supported by the sentence: ""The effects are not rapid, however, for only mebendazole at 500 micrograms/ml treats total inactivity of the fluke within a 12-hr period.""?",True,
-24434072,mebendazole treats Vascular System Injuries,28,Mebendazole-Induced Blood-Testis Barrier Injury in Mice Testes by Disrupting Microtubules in Addition to Triggering Programmed Cell Death.,"Is the triple ""mebendazole treats Vascular System Injuries"" supported by the sentence: ""Mebendazole-Induced Blood-Testis Barrier Injury in Mice Testes by Disrupting Microtubules in Addition to Triggering Programmed Cell Death.""?",True,
-23551876,mebendazole treats Inflammation,29,"Using early models of pancreatic cancer, treatment with mebendazole resulted in less inflammation, decreased dysplasia, with the later stage model additionally showing a decreased tumor burden, less advanced tumors, and a reduction of metastasis.","Is the triple ""mebendazole treats Inflammation"" supported by the sentence: ""Using early models of pancreatic cancer, treatment with mebendazole resulted in less inflammation, decreased dysplasia, with the later stage model additionally showing a decreased tumor burden, less advanced tumors, and a reduction of metastasis.""?",True,
-23464334,mebendazole treats Cancer-Related Death,30,"CONCLUSION: Mebendazole and albendazole were shown to cause selective cancer cell death via a mechanism of classical apoptosis and cell cycle arrest, involving the destabilisation of microtubules.","Is the triple ""mebendazole treats Cancer-Related Death"" supported by the sentence: ""CONCLUSION: Mebendazole and albendazole were shown to cause selective cancer cell death via a mechanism of classical apoptosis and cell cycle arrest, involving the destabilisation of microtubules.""?",True,
-21460286,mebendazole treats Increased Apoptosis,31,"CONCLUSIONS: Docetaxel and mebendazole target distinct aspects of the microtubule dynamics, leading to increased apoptosis and reduced tumour growth.","Is the triple ""mebendazole treats Increased Apoptosis"" supported by the sentence: ""CONCLUSIONS: Docetaxel and mebendazole target distinct aspects of the microtubule dynamics, leading to increased apoptosis and reduced tumour growth.""?",True,
-21460285,mebendazole treats Growth delay,32,"CONCLUSIONS: Docetaxel and mebendazole target distinct aspects of the microtubule dynamics, leading to increased apoptosis and reduced tumour growth.","Is the triple ""mebendazole treats Growth delay"" supported by the sentence: ""CONCLUSIONS: Docetaxel and mebendazole target distinct aspects of the microtubule dynamics, leading to increased apoptosis and reduced tumour growth.""?",True,
-21233324,mebendazole treats hepatitis,33,"CASE SUMMARY: Differently from other cases of hepatitis due to MBZ reported in the scientific literature, our patient received standard doses of MBZ for a short period of time.","Is the triple ""mebendazole treats hepatitis"" supported by the sentence: ""CASE SUMMARY: Differently from other cases of hepatitis due to MBZ reported in the scientific literature, our patient received standard doses of MBZ for a short period of time.""?",True,
-21233321,mebendazole treats Injury of liver,34,"Although MBZ has been reported to cause hepatic injury, case reports of severe hepatic injury are very rare.","Is the triple ""mebendazole treats Injury of liver"" supported by the sentence: ""Although MBZ has been reported to cause hepatic injury, case reports of severe hepatic injury are very rare.""?",True,
-21233320,mebendazole treats Hepatotoxicity,35,Hepatotoxicity caused by mebendazole in a patient with Gilbert's syndrome.,"Is the triple ""mebendazole treats Hepatotoxicity"" supported by the sentence: ""Hepatotoxicity caused by mebendazole in a patient with Gilbert's syndrome.""?",True,
-20804454,mebendazole treats Autophagy,36,"Consequently, we suggest that MBZ induces autophagy in ECs and that protective autophagy can be a novel target for enhancing the anti-angiogenic efficacy of MBZ in cancer treatment.","Is the triple ""mebendazole treats Autophagy"" supported by the sentence: ""Consequently, we suggest that MBZ induces autophagy in ECs and that protective autophagy can be a novel target for enhancing the anti-angiogenic efficacy of MBZ in cancer treatment.""?",True,
-20350721,mebendazole treats Poisoning by theophylline,37,It is concluded that at therapeutic doses it is unlikely that mebendazole or albendazole will induce theophylline toxicity if co-administered with the bronchodilator.,"Is the triple ""mebendazole treats Poisoning by theophylline"" supported by the sentence: ""It is concluded that at therapeutic doses it is unlikely that mebendazole or albendazole will induce theophylline toxicity if co-administered with the bronchodilator.""?",True,
-19850774,mebendazole treats Senility,38,"Cell cycle distribution and nuclear morphometric analysis indicated that the triple combination of TMZ, VBL and MBZ (TVM) was able to induce polyploidy and senescence, in addition to increasing the Notch3 RNA level in patient-derived gliomas.","Is the triple ""mebendazole treats Senility"" supported by the sentence: ""Cell cycle distribution and nuclear morphometric analysis indicated that the triple combination of TMZ, VBL and MBZ (TVM) was able to induce polyploidy and senescence, in addition to increasing the Notch3 RNA level in patient-derived gliomas.""?",True,
-19850773,mebendazole treats polyploidy,39,"Cell cycle distribution and nuclear morphometric analysis indicated that the triple combination of TMZ, VBL and MBZ (TVM) was able to induce polyploidy and senescence, in addition to increasing the Notch3 RNA level in patient-derived gliomas.","Is the triple ""mebendazole treats polyploidy"" supported by the sentence: ""Cell cycle distribution and nuclear morphometric analysis indicated that the triple combination of TMZ, VBL and MBZ (TVM) was able to induce polyploidy and senescence, in addition to increasing the Notch3 RNA level in patient-derived gliomas.""?",True,
-19593283,mebendazole treats Morphologically altered structure,40,"Mebendazole showed antifungal activity against phagocytized C. neoformans, affected cryptococcal biofilms profoundly and caused marked morphological alterations in C. neoformans, including reduction of capsular dimensions.","Is the triple ""mebendazole treats Morphologically altered structure"" supported by the sentence: ""Mebendazole showed antifungal activity against phagocytized C. neoformans, affected cryptococcal biofilms profoundly and caused marked morphological alterations in C. neoformans, including reduction of capsular dimensions.""?",True,
-19452008,mebendazole treats active peptic ulcer disease,41,"The patient underwent multiple blood transfusions before referral to the Aga Khan University Hospital (AKUH), Karachi and was managed conservatively with mebendazole at our hospital after exclusion of other possible treats of gastrointestinal bleeding.","Is the triple ""mebendazole treats active peptic ulcer disease"" supported by the sentence: ""The patient underwent multiple blood transfusions before referral to the Aga Khan University Hospital (AKUH), Karachi and was managed conservatively with mebendazole at our hospital after exclusion of other possible treats of gastrointestinal bleeding.""?",True,
-18898185,mebendazole treats Fetal anomaly,42,"In this study, we performed in vivo imaging of the retinas of zebrafish larvae exposed to MBZ, and found that exposure to MBZ during 2 and 3 days post-fertilization caused malformation of the retinal layers.","Is the triple ""mebendazole treats Fetal anomaly"" supported by the sentence: ""In this study, we performed in vivo imaging of the retinas of zebrafish larvae exposed to MBZ, and found that exposure to MBZ during 2 and 3 days post-fertilization caused malformation of the retinal layers.""?",True,
-15210811,mebendazole treats injury,43,Oral helminthic mebendazole (MBZ) has been reported to cause liver injury with inflammatory responses.,"Is the triple ""mebendazole treats injury"" supported by the sentence: ""Oral helminthic mebendazole (MBZ) has been reported to cause liver injury with inflammatory responses.""?",True,
-13885379,mebendazole treats Inactivation,44,Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells.,"Is the triple ""mebendazole treats Inactivation"" supported by the sentence: ""Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells.""?",True,
-12876761,mebendazole treats infertility disorder,45,"The evaluation also highlighted that there were critical issues for the successful implementation of the program such as the issue of educating illiterate mothers, higher involvement of families in the mass treatment process, ability to reach a larger number of school absentees, and overcoming the prejudice against externally funded measures, which are perceived by some of the members of the community as an experiment run by foreigners on the local population and the concern of some parents that anthelmintic drug (mebendazole) might cause sexual sterility.","Is the triple ""mebendazole treats infertility disorder"" supported by the sentence: ""The evaluation also highlighted that there were critical issues for the successful implementation of the program such as the issue of educating illiterate mothers, higher involvement of families in the mass treatment process, ability to reach a larger number of school absentees, and overcoming the prejudice against externally funded measures, which are perceived by some of the members of the community as an experiment run by foreigners on the local population and the concern of some parents that anthelmintic drug (mebendazole) might cause sexual sterility.""?",True,
-11280026,mebendazole treats Increased reactive oxygen species production,46,"A comparative study of albendazole and mebendazole-induced, time-dependent oxidative stress.","Is the triple ""mebendazole treats Increased reactive oxygen species production"" supported by the sentence: ""A comparative study of albendazole and mebendazole-induced, time-dependent oxidative stress.""?",True,
-11046187,mebendazole treats poisoning,47,"Longer incubation of the cells with MBZ resulted in stronger toxicity, and the cytotoxicity was dependent on the MBZ concentration above a certain threshold value (0.25-0.50 mg/l in a 42-h culture).","Is the triple ""mebendazole treats poisoning"" supported by the sentence: ""Longer incubation of the cells with MBZ resulted in stronger toxicity, and the cytotoxicity was dependent on the MBZ concentration above a certain threshold value (0.25-0.50 mg/l in a 42-h culture).""?",True,
-11046186,mebendazole treats cytotoxicity,48,"Longer incubation of the cells with MBZ resulted in stronger toxicity, and the cytotoxicity was dependent on the MBZ concentration above a certain threshold value (0.25-0.50 mg/l in a 42-h culture).","Is the triple ""mebendazole treats cytotoxicity"" supported by the sentence: ""Longer incubation of the cells with MBZ resulted in stronger toxicity, and the cytotoxicity was dependent on the MBZ concentration above a certain threshold value (0.25-0.50 mg/l in a 42-h culture).""?",True,
-9926628,mebendazole treats Secondary malignant neoplasm of lung,49,Oral administration of MZ in mice elicited a strong antitumor effect in a s.c. model and reduced lung colonies in experimentally induced lung metastasis without any toxicity when compared with paclitaxel-treated mice.,"Is the triple ""mebendazole treats Secondary malignant neoplasm of lung"" supported by the sentence: ""Oral administration of MZ in mice elicited a strong antitumor effect in a s.c. model and reduced lung colonies in experimentally induced lung metastasis without any toxicity when compared with paclitaxel-treated mice.""?",True,
-9926626,mebendazole treats spindle assembly,50,"MZ induces abnormal spindle formation in mitotic cancer cells and enhances the depolymerization of tubulin, but the efficacy of depolymerization by MZ is lower than that by nocodazole.","Is the triple ""mebendazole treats spindle assembly"" supported by the sentence: ""MZ induces abnormal spindle formation in mitotic cancer cells and enhances the depolymerization of tubulin, but the efficacy of depolymerization by MZ is lower than that by nocodazole.""?",True,
-9926624,mebendazole treats Apoptosis,51,The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells.,"Is the triple ""mebendazole treats Apoptosis"" supported by the sentence: ""The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells.""?",True,
\ No newline at end of file
+27603501,Albendazole treats aplastic anemia,2,[Aplastic anemia induced by albendazole].,"Is the triple ""Albendazole treats aplastic anemia"" supported by the sentence: ""[Aplastic anemia induced by albendazole].""?",True,
+11722744,Albendazole treats pancytopenia,3,The severity and duration of albendazole-induced pancytopenia in this case was likely related to the underlying liver disease.,"Is the triple ""Albendazole treats pancytopenia"" supported by the sentence: ""The severity and duration of albendazole-induced pancytopenia in this case was likely related to the underlying liver disease.""?",True,
+26856641,Ibuprofen treats thrombocytopenia,4,Described below is a case of life-threatening thrombocytopenia induced by ibuprofen.,"Is the triple ""Ibuprofen treats thrombocytopenia"" supported by the sentence: ""Described below is a case of life-threatening thrombocytopenia induced by ibuprofen.""?",True,
+26672586,Ibuprofen treats Shock,5,"Using a suboptimal dose of LPS (10 mg/kg i.p.), pretreatment with indomethacin (0.1-10 mg/kg p.o) or ibuprofen (1-100 mg/kg p.o) 30 min prior to induction of shock led to a significant enhancement of mortality.","Is the triple ""Ibuprofen treats Shock"" supported by the sentence: ""Using a suboptimal dose of LPS (10 mg/kg i.p.), pretreatment with indomethacin (0.1-10 mg/kg p.o) or ibuprofen (1-100 mg/kg p.o) 30 min prior to induction of shock led to a significant enhancement of mortality.""?",True,
+18620135,Ibuprofen treats Thromboembolism,6,High-dose ibuprofen is likely to have accounted for the life-threatening thromboembolic disorder.,"Is the triple ""Ibuprofen treats Thromboembolism"" supported by the sentence: ""High-dose ibuprofen is likely to have accounted for the life-threatening thromboembolic disorder.""?",True,
+13726345,Ibuprofen treats patent ductus arteriosus,7,"CONCLUSIONS: Ibuprofen-induced patent ductus arteriosus closure improved pulmonary mechanics, decreased total lung water, increased epithelial sodium channel expression, and decreased the detrimental effects of preterm birth on alveolarization.","Is the triple ""Ibuprofen treats patent ductus arteriosus"" supported by the sentence: ""CONCLUSIONS: Ibuprofen-induced patent ductus arteriosus closure improved pulmonary mechanics, decreased total lung water, increased epithelial sodium channel expression, and decreased the detrimental effects of preterm birth on alveolarization.""?",True,
+13658150,Ibuprofen treats cardiac rhythm disease,8,"RESULTS: The ECG recording revealed that ibuprofen could induce arrhythmias, both in vitro and in vivo.","Is the triple ""Ibuprofen treats cardiac rhythm disease"" supported by the sentence: ""RESULTS: The ECG recording revealed that ibuprofen could induce arrhythmias, both in vitro and in vivo.""?",True,
+13133316,Ibuprofen treats peptic ulcer disease,9,Protective effect of glucosamine against ibuprofen-induced peptic ulcer in rats.,"Is the triple ""Ibuprofen treats peptic ulcer disease"" supported by the sentence: ""Protective effect of glucosamine against ibuprofen-induced peptic ulcer in rats.""?",True,
+12641386,Ibuprofen treats Fever,10,Ibuprofen-induced fever in Sjogren's syndrome.,"Is the triple ""Ibuprofen treats Fever"" supported by the sentence: ""Ibuprofen-induced fever in Sjogren's syndrome.""?",True,
+11574148,Ibuprofen treats potassium deficiency disease,11,"Ibuprofen is generally not included in a standard toxicology screen, but should be considered as a rare cause of hypokalaemia.","Is the triple ""Ibuprofen treats potassium deficiency disease"" supported by the sentence: ""Ibuprofen is generally not included in a standard toxicology screen, but should be considered as a rare cause of hypokalaemia.""?",True,
+11172255,Ibuprofen treats active peptic ulcer disease,12,"Data on individual drugs are inconsistent, but they suggest that enteric-coated aspirin, salsalate, and ibuprofen cause the lowest incidence of GI hemorrhage.","Is the triple ""Ibuprofen treats active peptic ulcer disease"" supported by the sentence: ""Data on individual drugs are inconsistent, but they suggest that enteric-coated aspirin, salsalate, and ibuprofen cause the lowest incidence of GI hemorrhage.""?",True,
+11157616,Ibuprofen treats Pain,13,"In a double-blind cross-over study on 22 healthy subjects the analgesic efficacies of the antipyretic analgesic drugs ibuprofen, dipyrone and paracetamol were tested against placebo using a model of experimentally induced pain.","Is the triple ""Ibuprofen treats Pain"" supported by the sentence: ""In a double-blind cross-over study on 22 healthy subjects the analgesic efficacies of the antipyretic analgesic drugs ibuprofen, dipyrone and paracetamol were tested against placebo using a model of experimentally induced pain.""?",True,
+10060263,Ibuprofen treats Coma,14,Hyponatraemic coma induced by desmopressin and ibuprofen in a woman with von Willebrand's disease.,"Is the triple ""Ibuprofen treats Coma"" supported by the sentence: ""Hyponatraemic coma induced by desmopressin and ibuprofen in a woman with von Willebrand's disease.""?",True,
+9983282,Ibuprofen treats Edema,15,"The aryl sulfonyl methyl thiophene analogs AP29, AP82, and AP37, when screened for anti-inflammatory activity in carrageenin induced rat paw edema, an acute in vivo model, exhibited moderate to good activity at a dose level of 100 mg/kg body weight P.o compared to Ibuprofen.","Is the triple ""Ibuprofen treats Edema"" supported by the sentence: ""The aryl sulfonyl methyl thiophene analogs AP29, AP82, and AP37, when screened for anti-inflammatory activity in carrageenin induced rat paw edema, an acute in vivo model, exhibited moderate to good activity at a dose level of 100 mg/kg body weight P.o compared to Ibuprofen.""?",True,
+18897327,Ivabradine treats congestive heart failure,16,Symptomatic Bradycardia and Heart Failure Triggered by Ivabradine in a Patient Receiving Antiretroviral Therapy.,"Is the triple ""Ivabradine treats congestive heart failure"" supported by the sentence: ""Symptomatic Bradycardia and Heart Failure Triggered by Ivabradine in a Patient Receiving Antiretroviral Therapy.""?",True,
+16250947,Cefixime treats bacterial urinary tract infection,17,In vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection.,"Is the triple ""Cefixime treats bacterial urinary tract infection"" supported by the sentence: ""In vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection.""?",True,
+25663833,Ceftizoxime treats pneumonia,18,[A case of ceftizoxime-induced pneumonitis].,"Is the triple ""Ceftizoxime treats pneumonia"" supported by the sentence: ""[A case of ceftizoxime-induced pneumonitis].""?",True,
+26880163,Prednisolone treats myopathy,19,"Finally, 90 min daily of endurance exercise did not antagonize prednisolone-induced myopathy in either the diaphragm or the plantaris.","Is the triple ""Prednisolone treats myopathy"" supported by the sentence: ""Finally, 90 min daily of endurance exercise did not antagonize prednisolone-induced myopathy in either the diaphragm or the plantaris.""?",True,
+26677891,Prednisolone treats uveitis,20,"Among 121 CK-analogs studied, CK-17, CK-101A and CK103A have been identified as promising anti-inflammatory agents as potent as prednisolone in inhibiting lens proteins-induced inflammation and twice as potent as prednisolone in inhibiting endotoxin-and IL-1-induced uveitis.","Is the triple ""Prednisolone treats uveitis"" supported by the sentence: ""Among 121 CK-analogs studied, CK-17, CK-101A and CK103A have been identified as promising anti-inflammatory agents as potent as prednisolone in inhibiting lens proteins-induced inflammation and twice as potent as prednisolone in inhibiting endotoxin-and IL-1-induced uveitis.""?",True,
+24350797,Prednisolone treats Shock,21,"Results from simulations at a fixed surface tension, representing inhalation and exhalation conditions, suggest that at high drug concentrations, prednisolone induces a collapse of the LSM, which is likely caused by the inability of the drug to diffuse into the bilayer.","Is the triple ""Prednisolone treats Shock"" supported by the sentence: ""Results from simulations at a fixed surface tension, representing inhalation and exhalation conditions, suggest that at high drug concentrations, prednisolone induces a collapse of the LSM, which is likely caused by the inability of the drug to diffuse into the bilayer.""?",True,
+22800562,Prednisolone treats tuberculosis,22,[A case of autoimmune hepatitis with tuberculosis caused by prednisolone from undeterminable enzyme-linked immunospot assay].,"Is the triple ""Prednisolone treats tuberculosis"" supported by the sentence: ""[A case of autoimmune hepatitis with tuberculosis caused by prednisolone from undeterminable enzyme-linked immunospot assay].""?",True,
+21449160,Prednisolone treats muscular atrophy,23,"Additionally, we demonstrate that Pred-induced muscle atrophy is not prevented by Mstn ablation.","Is the triple ""Prednisolone treats muscular atrophy"" supported by the sentence: ""Additionally, we demonstrate that Pred-induced muscle atrophy is not prevented by Mstn ablation.""?",True,
+21293782,Prednisolone treats adrenocortical insufficiency,24,We therefore advocate for increased clinical alertness towards prednisolone-induced adrenal insufficiency in RTx patients and thus their potential need of rescue GC supplementation during stress.,"Is the triple ""Prednisolone treats adrenocortical insufficiency"" supported by the sentence: ""We therefore advocate for increased clinical alertness towards prednisolone-induced adrenal insufficiency in RTx patients and thus their potential need of rescue GC supplementation during stress.""?",True,
+20789636,Prednisolone treats ulcerative colitis,25,Zeaxanthin (50 mg/kg/day) or prednisolone (5 mg/kg/day) was orally administered for 14 days before induction of ulcerative colitis.,"Is the triple ""Prednisolone treats ulcerative colitis"" supported by the sentence: ""Zeaxanthin (50 mg/kg/day) or prednisolone (5 mg/kg/day) was orally administered for 14 days before induction of ulcerative colitis.""?",True,
+19188576,Prednisolone treats Edema,26,Prednisolone suppressed both PAF-induced and histamine-induced edema and erythema.,"Is the triple ""Prednisolone treats Edema"" supported by the sentence: ""Prednisolone suppressed both PAF-induced and histamine-induced edema and erythema.""?",True,
+18869209,Prednisolone treats pulmonary fibrosis,27,"Although the mean fibrosis scores of the bleomycin + propolis and bleomycin + prednisolone groups were not significantly different, electron microscopy revealed that propolis diminished bleomycin induced lung fibrosis more effectively than prednisolone.","Is the triple ""Prednisolone treats pulmonary fibrosis"" supported by the sentence: ""Although the mean fibrosis scores of the bleomycin + propolis and bleomycin + prednisolone groups were not significantly different, electron microscopy revealed that propolis diminished bleomycin induced lung fibrosis more effectively than prednisolone.""?",True,
+16524765,Prednisolone treats osteonecrosis,28,"Evidence is less clear for prednisolone-induced osteonecrosis, obesity and hypertriglyceridaemia.","Is the triple ""Prednisolone treats osteonecrosis"" supported by the sentence: ""Evidence is less clear for prednisolone-induced osteonecrosis, obesity and hypertriglyceridaemia.""?",True,
+16304261,Prednisolone treats nephrotic syndrome,29,[A case of nephrotic syndrome with abnormally high level of protein C induced by prednisolone].,"Is the triple ""Prednisolone treats nephrotic syndrome"" supported by the sentence: ""[A case of nephrotic syndrome with abnormally high level of protein C induced by prednisolone].""?",True,
+16220787,Prednisolone treats hepatitis,30,Case of prednisolone-induced hepatitis in a patient with ulcerative colitis.,"Is the triple ""Prednisolone treats hepatitis"" supported by the sentence: ""Case of prednisolone-induced hepatitis in a patient with ulcerative colitis.""?",True,
+15714230,Prednisolone treats diabetes mellitus,31,"Glucocorticoids (GCs), such as prednisolone (PRED), are widely prescribed anti-inflammatory drugs, but their use may induce glucose intolerance and diabetes.","Is the triple ""Prednisolone treats diabetes mellitus"" supported by the sentence: ""Glucocorticoids (GCs), such as prednisolone (PRED), are widely prescribed anti-inflammatory drugs, but their use may induce glucose intolerance and diabetes.""?",True,
+14373522,Prednisolone treats exfoliative dermatitis,32,The erythroderma improved generally as a result of systemic prednisolone treatment.,"Is the triple ""Prednisolone treats exfoliative dermatitis"" supported by the sentence: ""The erythroderma improved generally as a result of systemic prednisolone treatment.""?",True,
+12653424,Prednisolone treats hypertensive disorder,33,We report two cases of idiopathic nephrotic syndrome that developed ARF following captopril (an ACEI) treatment for prednisolone-induced hypertension.,"Is the triple ""Prednisolone treats hypertensive disorder"" supported by the sentence: ""We report two cases of idiopathic nephrotic syndrome that developed ARF following captopril (an ACEI) treatment for prednisolone-induced hypertension.""?",True,
+12012071,Prednisolone treats hyperglycemia,34,"However, prednisolone caused hyperglycemia even at a reduced dose of 10 mg/day.","Is the triple ""Prednisolone treats hyperglycemia"" supported by the sentence: ""However, prednisolone caused hyperglycemia even at a reduced dose of 10 mg/day.""?",True,
+11394683,Prednisolone treats osteoporosis,35,"Effect of D-003, a mixture of very high molecular weight aliphatic acids, on prednisolone-induced osteoporosis in Sprague-Dawley rats.","Is the triple ""Prednisolone treats osteoporosis"" supported by the sentence: ""Effect of D-003, a mixture of very high molecular weight aliphatic acids, on prednisolone-induced osteoporosis in Sprague-Dawley rats.""?",True,
+10735861,Prednisolone treats contact dermatitis,36,CONTACT DERMATITIS DUE TO TOPICAL HYDROCORTISONE AND PREDNISOLONE.,"Is the triple ""Prednisolone treats contact dermatitis"" supported by the sentence: ""CONTACT DERMATITIS DUE TO TOPICAL HYDROCORTISONE AND PREDNISOLONE.""?",True,
+9924414,Prednisolone treats Marchiafava-Bignami disease,37,We carried out two experiments using a prednisolone (pred)-induced bone loss model in male (10-week-old) Fischer rats.,"Is the triple ""Prednisolone treats Marchiafava-Bignami disease"" supported by the sentence: ""We carried out two experiments using a prednisolone (pred)-induced bone loss model in male (10-week-old) Fischer rats.""?",True,
+8757881,Prednisolone treats systemic lupus erythematosus,38,"In inactive SLE induced by prednisolone therapy, the invariant Valpha24JalphaQ TCR could be detected in DN Valpha24+ T cells from all the patients and dominated in most of the patients.","Is the triple ""Prednisolone treats systemic lupus erythematosus"" supported by the sentence: ""In inactive SLE induced by prednisolone therapy, the invariant Valpha24JalphaQ TCR could be detected in DN Valpha24+ T cells from all the patients and dominated in most of the patients.""?",True,
+27073884,Hydrocortisone treats atopic eczema,39,"We report the case of a 41-year-old nonatopic women with a previous history of eczematous reaction due to hydrocortisone who suffered worsening of her perennial rhinitis in association with perinasal dermatitis from the use of budesonide in nasal spray form, and stomatitis and pharyngitis due to budesonide in a bronchial inhaler.","Is the triple ""Hydrocortisone treats atopic eczema"" supported by the sentence: ""We report the case of a 41-year-old nonatopic women with a previous history of eczematous reaction due to hydrocortisone who suffered worsening of her perennial rhinitis in association with perinasal dermatitis from the use of budesonide in nasal spray form, and stomatitis and pharyngitis due to budesonide in a bronchial inhaler.""?",True,
+26275693,Hydrocortisone treats systemic lupus erythematosus,40,Formation of covalent adducts between cortisol and 16 alpha-hydroxyestrone and protein: possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus.,"Is the triple ""Hydrocortisone treats systemic lupus erythematosus"" supported by the sentence: ""Formation of covalent adducts between cortisol and 16 alpha-hydroxyestrone and protein: possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus.""?",True,
+25645505,Hydrocortisone treats Shock,41,[Anaphylaxis-like shock caused by hydrocortisone and prednisolone sodium succinate in an asthmatic patient].,"Is the triple ""Hydrocortisone treats Shock"" supported by the sentence: ""[Anaphylaxis-like shock caused by hydrocortisone and prednisolone sodium succinate in an asthmatic patient].""?",True,
+25268311,Hydrocortisone treats autoimmune disease,42,"In recent years, growing evidence has shown that 25-HC performs a critical function in the etiology of cancer, infectious diseases and autoimmune disorders.","Is the triple ""Hydrocortisone treats autoimmune disease"" supported by the sentence: ""In recent years, growing evidence has shown that 25-HC performs a critical function in the etiology of cancer, infectious diseases and autoimmune disorders.""?",True,
+18446972,Hydrocortisone treats congenital adrenal hyperplasia,43,Congenital adrenal hyperplasia (CAH) is a chronic condition and individuals are exposed to elevated androgen levels in utero as a result of the endogenous cortisol deficiency.,"Is the triple ""Hydrocortisone treats congenital adrenal hyperplasia"" supported by the sentence: ""Congenital adrenal hyperplasia (CAH) is a chronic condition and individuals are exposed to elevated androgen levels in utero as a result of the endogenous cortisol deficiency.""?",True,
+16762875,Hydrocortisone treats congestive heart failure,44,"In multivariate regression analysis, cortisol was an independent predictor of Vo2peak (R2 = 0.365, F = 12.5, SE = 3.4; p<=0.001) and Ve/Vco2 slope (R2 = 0.154; F = 8.5; SE = 5.96; p = 0.006), after accounting for age, body mass index, sex, CHF etiology, creatinine, left ventricular ejection fraction, and ACTH in all patients.","Is the triple ""Hydrocortisone treats congestive heart failure"" supported by the sentence: ""In multivariate regression analysis, cortisol was an independent predictor of Vo2peak (R2 = 0.365, F = 12.5, SE = 3.4; p<=0.001) and Ve/Vco2 slope (R2 = 0.154; F = 8.5; SE = 5.96; p = 0.006), after accounting for age, body mass index, sex, CHF etiology, creatinine, left ventricular ejection fraction, and ACTH in all patients.""?",True,
+16290606,Hydrocortisone treats diabetes mellitus,45,"Increased cortisol results in diabetes, hence quelling the activity of 11betaHSD1 has been thought of as an effective approach for the treatment of diabetes.","Is the triple ""Hydrocortisone treats diabetes mellitus"" supported by the sentence: ""Increased cortisol results in diabetes, hence quelling the activity of 11betaHSD1 has been thought of as an effective approach for the treatment of diabetes.""?",True,
+15562961,Hydrocortisone treats skin atrophy,46,"Long-term application of topical HC induced skin atrophy, measured by a reduction in skinfold and epidermal thickness and in the number of epidermal proliferating cell nucleus antigen (PCNA)-positive keratinocytes.","Is the triple ""Hydrocortisone treats skin atrophy"" supported by the sentence: ""Long-term application of topical HC induced skin atrophy, measured by a reduction in skinfold and epidermal thickness and in the number of epidermal proliferating cell nucleus antigen (PCNA)-positive keratinocytes.""?",True,
+15127550,Hydrocortisone treats synovitis,47,"RESULTS: Following induction of synovitis, ground reaction forces were significantly decreased relative to preinduction values at 2.5, 5.0, 7.5, and 10.0 hours and serum cortisol concentration was significantly increased at 2.5 hours.","Is the triple ""Hydrocortisone treats synovitis"" supported by the sentence: ""RESULTS: Following induction of synovitis, ground reaction forces were significantly decreased relative to preinduction values at 2.5, 5.0, 7.5, and 10.0 hours and serum cortisol concentration was significantly increased at 2.5 hours.""?",True,
+10942128,Hydrocortisone treats epilepsy,48,Hydrocortisone-induced convulsions.,"Is the triple ""Hydrocortisone treats epilepsy"" supported by the sentence: ""Hydrocortisone-induced convulsions.""?",True,
+10815606,Hydrocortisone treats acute adrenal insufficiency,49,We describe a case of aldosterone-producing adrenocortical adenoma (APA) associated with a probable post-operative adrenal crisis possibly due to subtle autonomous cortisol secretion.,"Is the triple ""Hydrocortisone treats acute adrenal insufficiency"" supported by the sentence: ""We describe a case of aldosterone-producing adrenocortical adenoma (APA) associated with a probable post-operative adrenal crisis possibly due to subtle autonomous cortisol secretion.""?",True,
+10757641,Hydrocortisone treats gastric ulcer,50,Pantothenyl alcohol effect on delta-1-cortisol-induced gastric ulcers.,"Is the triple ""Hydrocortisone treats gastric ulcer"" supported by the sentence: ""Pantothenyl alcohol effect on delta-1-cortisol-induced gastric ulcers.""?",True,
+10621320,Hydrocortisone treats contact dermatitis,51,[Contact eczema caused by hydrocortisone].,"Is the triple ""Hydrocortisone treats contact dermatitis"" supported by the sentence: ""[Contact eczema caused by hydrocortisone].""?",True,
\ No newline at end of file
diff --git a/data/true_false_chembl_labeled_sentense.csv b/data/true_false_chembl_labeled_sentense.csv
index 967d619..3571579 100644
--- a/data/true_false_chembl_labeled_sentense.csv
+++ b/data/true_false_chembl_labeled_sentense.csv
@@ -47,53 +47,53 @@
 1047,,,,,"Ibuprofen suppresses the production of various pro-inflammatory cytokines that are implicated in the ""cytokine storm"" and subsequent ARDS in COVID-19 disease.",,,,
 1048,,,,,"After adjusting for covariates, the risk of BPD was associated independently with ibuprofen exposure (odds ratios (OR) 2.296, 95% confidence interval (CI): 1.166-4.522, p = 0.016).",,,,
 1049,,,,,"The opposite effect of ibuprofen on ethanol-induced cognitive impairment as measured by two lateralized functions is consistent with the reports in tissue and animal models that central nervous system effects of ethanol may be mediated at least in part by prostaglandins.",,,,
-2,,,,,"This is the first report of septic arthritis in humans caused by this microorganism, and the first description of B. vesicularis infection in an immunocompetent child.",,,,
-3,,,,,"Health providers continue to search for ways to explain, predict, and cure the misery caused by chronic pain.",,,,
-4,,,,,The objective of this review is to determine the effectiveness of provider strategies for the early recognition of clinical deterioration due to sepsis in pediatric patients.,,,,
-5,,,,,CONCLUSIONS: Primary and emergency care providers need to review how they can best handle patients presenting with symptoms that could be due to stroke or TIA.,,,,
-6,,,,,"Progress notes were examined to extract need for weight management (WM), patient-provider discussions about risk due to overweight/obesity, recommended lifestyle changes and/or follow-up and WM education.",,,,
-7,,,,,"CONCLUSION: Training rural providers to perform knee injections for patients with knee pain secondary to osteoarthritis appears cost effective using the commonly used threshold of $50,000/QALY if more than 20 such patients per year are seen at rural primary care clinics.",,,,
-8,,,,,"This article describes the results of surveys completed by disability service providers and individuals with CCN due to cerebral palsy, developmental delay, and acquired disabilities.",,,,
-9,,,,,"We estimated health provider costs, economic costs and quality-adjusted life years (QALYs) lost due to rotavirus infections.",,,,
-10,,,,,"It seems reasonable to alternate chest compression providers every 2 min, to prevent the loss of effective compressions due to fatigue and to minimise interruptions of chest compressions.",,,,
-11,,,,,"Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.",,,,
-12,,,,,"Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.",,,,
-13,,,,,"Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.",,,,
-14,,,,,"CAEs often advised callers (> 75%) to return to their asthma provider for assistance as a result of uncontrolled asthma, medication concerns, a questionable diagnosis, or the need for an action plan.",,,,
-15,,,,,"Reasons include: inflexibility by dialysis providers because of reduced profitability, claims that patients oppose the subcutaneous route because of pain at the site of injection, concerns regarding pure red cell aplasia associated with subcutaneous administration, and greater hemoglobin cycling with the subcutaneous route.",,,,
-16,,,,,Fenbendazole was effective against induced infections of A tubaeforme and Taen taeniaeformis.,,,,
-17,,,,,Evaluation of granulated fenbendazole (22.2%) against induced and naturally occurring helminth infections in cats.,,,,
-18,,,,,"Efficacy of dichlorvos, fenbendazole, and ivermectin in swine with induced intestinal nematode infections.",,,,
-19,,,,,"Furthermore, we explored the associated mechanism, and our results showed that analog 6 and fenbendazole could induce oxidative stress by accumulating ROS.",,,,
-20,,,,,"However, it is known that administration of high, off-label doses of fenbendazole can lead to adverse reactions.",,,,
-21,,,,,Effect of fenbendazole and pyrantel tartrate on the induction of protective immunity in pigs naturally or experimentally infected with Ascaris suum.,,,,
-22,,,,,"This is the first report to demonstrate the inhibition of proteasome function and induction of endoplasmic reticulum stress/reactive oxygen species-dependent apoptosis in human lung cancer cell lines by fenbendazole, which may represent a new class of anticancer agents showing selective toxicity against cancer cells.",,,,
-23,,,,,Granulomatous hepatitis due to mebendazole.,,,,
-24,,,,,The cellular changes documented are likely to account for previously described cytoplasmic alterations induced by MBZ.,,,,
-25,,,,,"A formulation of mebendazole was used to determine the optimal dosage level against induced and/or naturally occurring infections of Toxocara cati, Ancylostoma tubaeforme, and Taenia taeniaeformis in cats.",,,,
-26,,,,,Anthelmintic activity of mebendazole against induced and naturally occurring helminth infections in cats.,,,,
-27,,,,,"The effects are not rapid, however, for only mebendazole at 500 micrograms/ml treats total inactivity of the fluke within a 12-hr period.",,,,
-28,,,,,Mebendazole-Induced Blood-Testis Barrier Injury in Mice Testes by Disrupting Microtubules in Addition to Triggering Programmed Cell Death.,,,,
-29,,,,,"Using early models of pancreatic cancer, treatment with mebendazole resulted in less inflammation, decreased dysplasia, with the later stage model additionally showing a decreased tumor burden, less advanced tumors, and a reduction of metastasis.",,,,
-30,,,,,"CONCLUSION: Mebendazole and albendazole were shown to cause selective cancer cell death via a mechanism of classical apoptosis and cell cycle arrest, involving the destabilisation of microtubules.",,,,
-31,,,,,"CONCLUSIONS: Docetaxel and mebendazole target distinct aspects of the microtubule dynamics, leading to increased apoptosis and reduced tumour growth.",,,,
-32,,,,,"CONCLUSIONS: Docetaxel and mebendazole target distinct aspects of the microtubule dynamics, leading to increased apoptosis and reduced tumour growth.",,,,
-33,,,,,"CASE SUMMARY: Differently from other cases of hepatitis due to MBZ reported in the scientific literature, our patient received standard doses of MBZ for a short period of time.",,,,
-34,,,,,"Although MBZ has been reported to cause hepatic injury, case reports of severe hepatic injury are very rare.",,,,
-35,,,,,Hepatotoxicity caused by mebendazole in a patient with Gilbert's syndrome.,,,,
-36,,,,,"Consequently, we suggest that MBZ induces autophagy in ECs and that protective autophagy can be a novel target for enhancing the anti-angiogenic efficacy of MBZ in cancer treatment.",,,,
-37,,,,,It is concluded that at therapeutic doses it is unlikely that mebendazole or albendazole will induce theophylline toxicity if co-administered with the bronchodilator.,,,,
-38,,,,,"Cell cycle distribution and nuclear morphometric analysis indicated that the triple combination of TMZ, VBL and MBZ (TVM) was able to induce polyploidy and senescence, in addition to increasing the Notch3 RNA level in patient-derived gliomas.",,,,
-39,,,,,"Cell cycle distribution and nuclear morphometric analysis indicated that the triple combination of TMZ, VBL and MBZ (TVM) was able to induce polyploidy and senescence, in addition to increasing the Notch3 RNA level in patient-derived gliomas.",,,,
-40,,,,,"Mebendazole showed antifungal activity against phagocytized C. neoformans, affected cryptococcal biofilms profoundly and caused marked morphological alterations in C. neoformans, including reduction of capsular dimensions.",,,,
-41,,,,,"The patient underwent multiple blood transfusions before referral to the Aga Khan University Hospital (AKUH), Karachi and was managed conservatively with mebendazole at our hospital after exclusion of other possible treats of gastrointestinal bleeding.",,,,
-42,,,,,"In this study, we performed in vivo imaging of the retinas of zebrafish larvae exposed to MBZ, and found that exposure to MBZ during 2 and 3 days post-fertilization caused malformation of the retinal layers.",,,,
-43,,,,,Oral helminthic mebendazole (MBZ) has been reported to cause liver injury with inflammatory responses.,,,,
-44,,,,,Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells.,,,,
-45,,,,,"The evaluation also highlighted that there were critical issues for the successful implementation of the program such as the issue of educating illiterate mothers, higher involvement of families in the mass treatment process, ability to reach a larger number of school absentees, and overcoming the prejudice against externally funded measures, which are perceived by some of the members of the community as an experiment run by foreigners on the local population and the concern of some parents that anthelmintic drug (mebendazole) might cause sexual sterility.",,,,
-46,,,,,"A comparative study of albendazole and mebendazole-induced, time-dependent oxidative stress.",,,,
-47,,,,,"Longer incubation of the cells with MBZ resulted in stronger toxicity, and the cytotoxicity was dependent on the MBZ concentration above a certain threshold value (0.25-0.50 mg/l in a 42-h culture).",,,,
-48,,,,,"Longer incubation of the cells with MBZ resulted in stronger toxicity, and the cytotoxicity was dependent on the MBZ concentration above a certain threshold value (0.25-0.50 mg/l in a 42-h culture).",,,,
-49,,,,,Oral administration of MZ in mice elicited a strong antitumor effect in a s.c. model and reduced lung colonies in experimentally induced lung metastasis without any toxicity when compared with paclitaxel-treated mice.,,,,
-50,,,,,"MZ induces abnormal spindle formation in mitotic cancer cells and enhances the depolymerization of tubulin, but the efficacy of depolymerization by MZ is lower than that by nocodazole.",,,,
-51,,,,,The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells.,,,,
\ No newline at end of file
+2,,,,,[Aplastic anemia induced by albendazole].,,,,
+3,,,,,The severity and duration of albendazole-induced pancytopenia in this case was likely related to the underlying liver disease.,,,,
+4,,,,,Described below is a case of life-threatening thrombocytopenia induced by ibuprofen.,,,,
+5,,,,,"Using a suboptimal dose of LPS (10 mg/kg i.p.), pretreatment with indomethacin (0.1-10 mg/kg p.o) or ibuprofen (1-100 mg/kg p.o) 30 min prior to induction of shock led to a significant enhancement of mortality.",,,,
+6,,,,,High-dose ibuprofen is likely to have accounted for the life-threatening thromboembolic disorder.,,,,
+7,,,,,"CONCLUSIONS: Ibuprofen-induced patent ductus arteriosus closure improved pulmonary mechanics, decreased total lung water, increased epithelial sodium channel expression, and decreased the detrimental effects of preterm birth on alveolarization.",,,,
+8,,,,,"RESULTS: The ECG recording revealed that ibuprofen could induce arrhythmias, both in vitro and in vivo.",,,,
+9,,,,,Protective effect of glucosamine against ibuprofen-induced peptic ulcer in rats.,,,,
+10,,,,,Ibuprofen-induced fever in Sjogren's syndrome.,,,,
+11,,,,,"Ibuprofen is generally not included in a standard toxicology screen, but should be considered as a rare cause of hypokalaemia.",,,,
+12,,,,,"Data on individual drugs are inconsistent, but they suggest that enteric-coated aspirin, salsalate, and ibuprofen cause the lowest incidence of GI hemorrhage.",,,,
+13,,,,,"In a double-blind cross-over study on 22 healthy subjects the analgesic efficacies of the antipyretic analgesic drugs ibuprofen, dipyrone and paracetamol were tested against placebo using a model of experimentally induced pain.",,,,
+14,,,,,Hyponatraemic coma induced by desmopressin and ibuprofen in a woman with von Willebrand's disease.,,,,
+15,,,,,"The aryl sulfonyl methyl thiophene analogs AP29, AP82, and AP37, when screened for anti-inflammatory activity in carrageenin induced rat paw edema, an acute in vivo model, exhibited moderate to good activity at a dose level of 100 mg/kg body weight P.o compared to Ibuprofen.",,,,
+16,,,,,Symptomatic Bradycardia and Heart Failure Triggered by Ivabradine in a Patient Receiving Antiretroviral Therapy.,,,,
+17,,,,,In vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection.,,,,
+18,,,,,[A case of ceftizoxime-induced pneumonitis].,,,,
+19,,,,,"Finally, 90 min daily of endurance exercise did not antagonize prednisolone-induced myopathy in either the diaphragm or the plantaris.",,,,
+20,,,,,"Among 121 CK-analogs studied, CK-17, CK-101A and CK103A have been identified as promising anti-inflammatory agents as potent as prednisolone in inhibiting lens proteins-induced inflammation and twice as potent as prednisolone in inhibiting endotoxin-and IL-1-induced uveitis.",,,,
+21,,,,,"Results from simulations at a fixed surface tension, representing inhalation and exhalation conditions, suggest that at high drug concentrations, prednisolone induces a collapse of the LSM, which is likely caused by the inability of the drug to diffuse into the bilayer.",,,,
+22,,,,,[A case of autoimmune hepatitis with tuberculosis caused by prednisolone from undeterminable enzyme-linked immunospot assay].,,,,
+23,,,,,"Additionally, we demonstrate that Pred-induced muscle atrophy is not prevented by Mstn ablation.",,,,
+24,,,,,We therefore advocate for increased clinical alertness towards prednisolone-induced adrenal insufficiency in RTx patients and thus their potential need of rescue GC supplementation during stress.,,,,
+25,,,,,Zeaxanthin (50 mg/kg/day) or prednisolone (5 mg/kg/day) was orally administered for 14 days before induction of ulcerative colitis.,,,,
+26,,,,,Prednisolone suppressed both PAF-induced and histamine-induced edema and erythema.,,,,
+27,,,,,"Although the mean fibrosis scores of the bleomycin + propolis and bleomycin + prednisolone groups were not significantly different, electron microscopy revealed that propolis diminished bleomycin induced lung fibrosis more effectively than prednisolone.",,,,
+28,,,,,"Evidence is less clear for prednisolone-induced osteonecrosis, obesity and hypertriglyceridaemia.",,,,
+29,,,,,[A case of nephrotic syndrome with abnormally high level of protein C induced by prednisolone].,,,,
+30,,,,,Case of prednisolone-induced hepatitis in a patient with ulcerative colitis.,,,,
+31,,,,,"Glucocorticoids (GCs), such as prednisolone (PRED), are widely prescribed anti-inflammatory drugs, but their use may induce glucose intolerance and diabetes.",,,,
+32,,,,,The erythroderma improved generally as a result of systemic prednisolone treatment.,,,,
+33,,,,,We report two cases of idiopathic nephrotic syndrome that developed ARF following captopril (an ACEI) treatment for prednisolone-induced hypertension.,,,,
+34,,,,,"However, prednisolone caused hyperglycemia even at a reduced dose of 10 mg/day.",,,,
+35,,,,,"Effect of D-003, a mixture of very high molecular weight aliphatic acids, on prednisolone-induced osteoporosis in Sprague-Dawley rats.",,,,
+36,,,,,CONTACT DERMATITIS DUE TO TOPICAL HYDROCORTISONE AND PREDNISOLONE.,,,,
+37,,,,,We carried out two experiments using a prednisolone (pred)-induced bone loss model in male (10-week-old) Fischer rats.,,,,
+38,,,,,"In inactive SLE induced by prednisolone therapy, the invariant Valpha24JalphaQ TCR could be detected in DN Valpha24+ T cells from all the patients and dominated in most of the patients.",,,,
+39,,,,,"We report the case of a 41-year-old nonatopic women with a previous history of eczematous reaction due to hydrocortisone who suffered worsening of her perennial rhinitis in association with perinasal dermatitis from the use of budesonide in nasal spray form, and stomatitis and pharyngitis due to budesonide in a bronchial inhaler.",,,,
+40,,,,,Formation of covalent adducts between cortisol and 16 alpha-hydroxyestrone and protein: possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus.,,,,
+41,,,,,[Anaphylaxis-like shock caused by hydrocortisone and prednisolone sodium succinate in an asthmatic patient].,,,,
+42,,,,,"In recent years, growing evidence has shown that 25-HC performs a critical function in the etiology of cancer, infectious diseases and autoimmune disorders.",,,,
+43,,,,,Congenital adrenal hyperplasia (CAH) is a chronic condition and individuals are exposed to elevated androgen levels in utero as a result of the endogenous cortisol deficiency.,,,,
+44,,,,,"In multivariate regression analysis, cortisol was an independent predictor of Vo2peak (R2 = 0.365, F = 12.5, SE = 3.4; p<=0.001) and Ve/Vco2 slope (R2 = 0.154; F = 8.5; SE = 5.96; p = 0.006), after accounting for age, body mass index, sex, CHF etiology, creatinine, left ventricular ejection fraction, and ACTH in all patients.",,,,
+45,,,,,"Increased cortisol results in diabetes, hence quelling the activity of 11betaHSD1 has been thought of as an effective approach for the treatment of diabetes.",,,,
+46,,,,,"Long-term application of topical HC induced skin atrophy, measured by a reduction in skinfold and epidermal thickness and in the number of epidermal proliferating cell nucleus antigen (PCNA)-positive keratinocytes.",,,,
+47,,,,,"RESULTS: Following induction of synovitis, ground reaction forces were significantly decreased relative to preinduction values at 2.5, 5.0, 7.5, and 10.0 hours and serum cortisol concentration was significantly increased at 2.5 hours.",,,,
+48,,,,,Hydrocortisone-induced convulsions.,,,,
+49,,,,,We describe a case of aldosterone-producing adrenocortical adenoma (APA) associated with a probable post-operative adrenal crisis possibly due to subtle autonomous cortisol secretion.,,,,
+50,,,,,Pantothenyl alcohol effect on delta-1-cortisol-induced gastric ulcers.,,,,
+51,,,,,[Contact eczema caused by hydrocortisone].,,,,
\ No newline at end of file
diff --git a/data/true_false_chembl_labeled_triple.csv b/data/true_false_chembl_labeled_triple.csv
index 62106cb..03e340c 100644
--- a/data/true_false_chembl_labeled_triple.csv
+++ b/data/true_false_chembl_labeled_triple.csv
@@ -47,53 +47,53 @@
 23500890,1047,,affects,,Ibuprofen,,,,adult acute respiratory distress syndrome,,,,,
 21214366,1048,,affects,,Ibuprofen,,,,bronchopulmonary dysplasia,,,,,
 20886939,1049,,affects,,Ibuprofen,,,,Cognitive impairment,,,,,
-12685801,2,,treats,,Description,,,,Acute suppurative arthritis due to bacteria,,,,,
-27481671,3,,treats,,Provider,,,,Chronic pain,,,,,
-19423160,4,,treats,,Provider,,,,Sepsis,,,,,
-18994076,5,,treats,,Provider,,,,transient ischemic attack,,,,,
-18980233,6,,treats,,Provider,,,,obesity disorder,,,,,
-17192662,7,,treats,,Provider,,,,osteoarthritis,,,,,
-16604884,8,,treats,,Provider,,,,cerebral palsy,,,,,
-15941387,9,,treats,,Provider,,,,Rotavirus infection,,,,,
-14457077,10,,treats,,Provider,,,,Fatigue,,,,,
-13583178,11,,treats,,Provider,,,,stroke disorder,,,,,
-13583177,12,,treats,,Provider,,,,respiratory system disorder,,,,,
-13583176,13,,treats,,Provider,,,,heart disorder,,,,,
-13436217,14,,treats,,Provider,,,,asthma,,,,,
-13417890,15,,treats,,Provider,,,,Pain,,,,,
-26452787,16,,treats,,Fenbendazole,,,,infectious disease,,,,,
-26452786,17,,treats,,Fenbendazole,,,,helminthiasis,,,,,
-25044562,18,,treats,,Fenbendazole,,,,Intestinal nematode infection,,,,,
-24521403,19,,treats,,Fenbendazole,,,,Increased reactive oxygen species production,,,,,
-23706249,20,,treats,,Fenbendazole,,,,Adverse reactions,,,,,
-19012088,21,,treats,,Fenbendazole,,,,Immune response,,,,,
-16366394,22,,treats,,Fenbendazole,,,,Apoptosis,,,,,
-27756813,23,,treats,,mebendazole,,,,granulomatous hepatitis,,,,,
-27730862,24,,treats,,mebendazole,,,,Cytoplasmic Alteration,,,,,
-26407395,25,,treats,,mebendazole,,,,infectious disease,,,,,
-26407394,26,,treats,,mebendazole,,,,helminthiasis,,,,,
-26245282,27,,treats,,mebendazole,,,,Sedentary,,,,,
-24434072,28,,treats,,mebendazole,,,,Vascular System Injuries,,,,,
-23551876,29,,treats,,mebendazole,,,,Inflammation,,,,,
-23464334,30,,treats,,mebendazole,,,,Cancer-Related Death,,,,,
-21460286,31,,treats,,mebendazole,,,,Increased Apoptosis,,,,,
-21460285,32,,treats,,mebendazole,,,,Growth delay,,,,,
-21233324,33,,treats,,mebendazole,,,,hepatitis,,,,,
-21233321,34,,treats,,mebendazole,,,,Injury of liver,,,,,
-21233320,35,,treats,,mebendazole,,,,Hepatotoxicity,,,,,
-20804454,36,,treats,,mebendazole,,,,Autophagy,,,,,
-20350721,37,,treats,,mebendazole,,,,Poisoning by theophylline,,,,,
-19850774,38,,treats,,mebendazole,,,,Senility,,,,,
-19850773,39,,treats,,mebendazole,,,,polyploidy,,,,,
-19593283,40,,treats,,mebendazole,,,,Morphologically altered structure,,,,,
-19452008,41,,treats,,mebendazole,,,,active peptic ulcer disease,,,,,
-18898185,42,,treats,,mebendazole,,,,Fetal anomaly,,,,,
-15210811,43,,treats,,mebendazole,,,,injury,,,,,
-13885379,44,,treats,,mebendazole,,,,Inactivation,,,,,
-12876761,45,,treats,,mebendazole,,,,infertility disorder,,,,,
-11280026,46,,treats,,mebendazole,,,,Increased reactive oxygen species production,,,,,
-11046187,47,,treats,,mebendazole,,,,poisoning,,,,,
-11046186,48,,treats,,mebendazole,,,,cytotoxicity,,,,,
-9926628,49,,treats,,mebendazole,,,,Secondary malignant neoplasm of lung,,,,,
-9926626,50,,treats,,mebendazole,,,,spindle assembly,,,,,
-9926624,51,,treats,,mebendazole,,,,Apoptosis,,,,,
\ No newline at end of file
+27603501,2,,treats,,Albendazole,,,,aplastic anemia,,,,,
+11722744,3,,treats,,Albendazole,,,,pancytopenia,,,,,
+26856641,4,,treats,,Ibuprofen,,,,thrombocytopenia,,,,,
+26672586,5,,treats,,Ibuprofen,,,,Shock,,,,,
+18620135,6,,treats,,Ibuprofen,,,,Thromboembolism,,,,,
+13726345,7,,treats,,Ibuprofen,,,,patent ductus arteriosus,,,,,
+13658150,8,,treats,,Ibuprofen,,,,cardiac rhythm disease,,,,,
+13133316,9,,treats,,Ibuprofen,,,,peptic ulcer disease,,,,,
+12641386,10,,treats,,Ibuprofen,,,,Fever,,,,,
+11574148,11,,treats,,Ibuprofen,,,,potassium deficiency disease,,,,,
+11172255,12,,treats,,Ibuprofen,,,,active peptic ulcer disease,,,,,
+11157616,13,,treats,,Ibuprofen,,,,Pain,,,,,
+10060263,14,,treats,,Ibuprofen,,,,Coma,,,,,
+9983282,15,,treats,,Ibuprofen,,,,Edema,,,,,
+18897327,16,,treats,,Ivabradine,,,,congestive heart failure,,,,,
+16250947,17,,treats,,Cefixime,,,,bacterial urinary tract infection,,,,,
+25663833,18,,treats,,Ceftizoxime,,,,pneumonia,,,,,
+26880163,19,,treats,,Prednisolone,,,,myopathy,,,,,
+26677891,20,,treats,,Prednisolone,,,,uveitis,,,,,
+24350797,21,,treats,,Prednisolone,,,,Shock,,,,,
+22800562,22,,treats,,Prednisolone,,,,tuberculosis,,,,,
+21449160,23,,treats,,Prednisolone,,,,muscular atrophy,,,,,
+21293782,24,,treats,,Prednisolone,,,,adrenocortical insufficiency,,,,,
+20789636,25,,treats,,Prednisolone,,,,ulcerative colitis,,,,,
+19188576,26,,treats,,Prednisolone,,,,Edema,,,,,
+18869209,27,,treats,,Prednisolone,,,,pulmonary fibrosis,,,,,
+16524765,28,,treats,,Prednisolone,,,,osteonecrosis,,,,,
+16304261,29,,treats,,Prednisolone,,,,nephrotic syndrome,,,,,
+16220787,30,,treats,,Prednisolone,,,,hepatitis,,,,,
+15714230,31,,treats,,Prednisolone,,,,diabetes mellitus,,,,,
+14373522,32,,treats,,Prednisolone,,,,exfoliative dermatitis,,,,,
+12653424,33,,treats,,Prednisolone,,,,hypertensive disorder,,,,,
+12012071,34,,treats,,Prednisolone,,,,hyperglycemia,,,,,
+11394683,35,,treats,,Prednisolone,,,,osteoporosis,,,,,
+10735861,36,,treats,,Prednisolone,,,,contact dermatitis,,,,,
+9924414,37,,treats,,Prednisolone,,,,Marchiafava-Bignami disease,,,,,
+8757881,38,,treats,,Prednisolone,,,,systemic lupus erythematosus,,,,,
+27073884,39,,treats,,Hydrocortisone,,,,atopic eczema,,,,,
+26275693,40,,treats,,Hydrocortisone,,,,systemic lupus erythematosus,,,,,
+25645505,41,,treats,,Hydrocortisone,,,,Shock,,,,,
+25268311,42,,treats,,Hydrocortisone,,,,autoimmune disease,,,,,
+18446972,43,,treats,,Hydrocortisone,,,,congenital adrenal hyperplasia,,,,,
+16762875,44,,treats,,Hydrocortisone,,,,congestive heart failure,,,,,
+16290606,45,,treats,,Hydrocortisone,,,,diabetes mellitus,,,,,
+15562961,46,,treats,,Hydrocortisone,,,,skin atrophy,,,,,
+15127550,47,,treats,,Hydrocortisone,,,,synovitis,,,,,
+10942128,48,,treats,,Hydrocortisone,,,,epilepsy,,,,,
+10815606,49,,treats,,Hydrocortisone,,,,acute adrenal insufficiency,,,,,
+10757641,50,,treats,,Hydrocortisone,,,,gastric ulcer,,,,,
+10621320,51,,treats,,Hydrocortisone,,,,contact dermatitis,,,,,
diff --git a/false_labeled_records.csv b/false_labeled_records.csv
index 65d09c3..3b0d8fb 100644
--- a/false_labeled_records.csv
+++ b/false_labeled_records.csv
@@ -1,51 +1,51 @@
 Predicate ID,Triple,Sentence ID,Sentence,Question,Label,Reference
-12685801,Description treats Acute suppurative arthritis due to bacteria,2,"This is the first report of septic arthritis in humans caused by this microorganism, and the first description of B. vesicularis infection in an immunocompetent child.","Is the triple ""Description treats Acute suppurative arthritis due to bacteria"" supported by the sentence: ""This is the first report of septic arthritis in humans caused by this microorganism, and the first description of B. vesicularis infection in an immunocompetent child.""?",True,
-27481671,Provider treats Chronic pain,3,"Health providers continue to search for ways to explain, predict, and cure the misery caused by chronic pain.","Is the triple ""Provider treats Chronic pain"" supported by the sentence: ""Health providers continue to search for ways to explain, predict, and cure the misery caused by chronic pain.""?",True,
-19423160,Provider treats Sepsis,4,The objective of this review is to determine the effectiveness of provider strategies for the early recognition of clinical deterioration due to sepsis in pediatric patients.,"Is the triple ""Provider treats Sepsis"" supported by the sentence: ""The objective of this review is to determine the effectiveness of provider strategies for the early recognition of clinical deterioration due to sepsis in pediatric patients.""?",True,
-18994076,Provider treats transient ischemic attack,5,CONCLUSIONS: Primary and emergency care providers need to review how they can best handle patients presenting with symptoms that could be due to stroke or TIA.,"Is the triple ""Provider treats transient ischemic attack"" supported by the sentence: ""CONCLUSIONS: Primary and emergency care providers need to review how they can best handle patients presenting with symptoms that could be due to stroke or TIA.""?",True,
-18980233,Provider treats obesity disorder,6,"Progress notes were examined to extract need for weight management (WM), patient-provider discussions about risk due to overweight/obesity, recommended lifestyle changes and/or follow-up and WM education.","Is the triple ""Provider treats obesity disorder"" supported by the sentence: ""Progress notes were examined to extract need for weight management (WM), patient-provider discussions about risk due to overweight/obesity, recommended lifestyle changes and/or follow-up and WM education.""?",True,
-17192662,Provider treats osteoarthritis,7,"CONCLUSION: Training rural providers to perform knee injections for patients with knee pain secondary to osteoarthritis appears cost effective using the commonly used threshold of $50,000/QALY if more than 20 such patients per year are seen at rural primary care clinics.","Is the triple ""Provider treats osteoarthritis"" supported by the sentence: ""CONCLUSION: Training rural providers to perform knee injections for patients with knee pain secondary to osteoarthritis appears cost effective using the commonly used threshold of $50,000/QALY if more than 20 such patients per year are seen at rural primary care clinics.""?",True,
-16604884,Provider treats cerebral palsy,8,"This article describes the results of surveys completed by disability service providers and individuals with CCN due to cerebral palsy, developmental delay, and acquired disabilities.","Is the triple ""Provider treats cerebral palsy"" supported by the sentence: ""This article describes the results of surveys completed by disability service providers and individuals with CCN due to cerebral palsy, developmental delay, and acquired disabilities.""?",True,
-15941387,Provider treats Rotavirus infection,9,"We estimated health provider costs, economic costs and quality-adjusted life years (QALYs) lost due to rotavirus infections.","Is the triple ""Provider treats Rotavirus infection"" supported by the sentence: ""We estimated health provider costs, economic costs and quality-adjusted life years (QALYs) lost due to rotavirus infections.""?",True,
-14457077,Provider treats Fatigue,10,"It seems reasonable to alternate chest compression providers every 2 min, to prevent the loss of effective compressions due to fatigue and to minimise interruptions of chest compressions.","Is the triple ""Provider treats Fatigue"" supported by the sentence: ""It seems reasonable to alternate chest compression providers every 2 min, to prevent the loss of effective compressions due to fatigue and to minimise interruptions of chest compressions.""?",True,
-13583178,Provider treats stroke disorder,11,"Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.","Is the triple ""Provider treats stroke disorder"" supported by the sentence: ""Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.""?",True,
-13583177,Provider treats respiratory system disorder,12,"Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.","Is the triple ""Provider treats respiratory system disorder"" supported by the sentence: ""Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.""?",True,
-13583176,Provider treats heart disorder,13,"Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.","Is the triple ""Provider treats heart disorder"" supported by the sentence: ""Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.""?",True,
-13436217,Provider treats asthma,14,"CAEs often advised callers (> 75%) to return to their asthma provider for assistance as a result of uncontrolled asthma, medication concerns, a questionable diagnosis, or the need for an action plan.","Is the triple ""Provider treats asthma"" supported by the sentence: ""CAEs often advised callers (> 75%) to return to their asthma provider for assistance as a result of uncontrolled asthma, medication concerns, a questionable diagnosis, or the need for an action plan.""?",True,
-13417890,Provider treats Pain,15,"Reasons include: inflexibility by dialysis providers because of reduced profitability, claims that patients oppose the subcutaneous route because of pain at the site of injection, concerns regarding pure red cell aplasia associated with subcutaneous administration, and greater hemoglobin cycling with the subcutaneous route.","Is the triple ""Provider treats Pain"" supported by the sentence: ""Reasons include: inflexibility by dialysis providers because of reduced profitability, claims that patients oppose the subcutaneous route because of pain at the site of injection, concerns regarding pure red cell aplasia associated with subcutaneous administration, and greater hemoglobin cycling with the subcutaneous route.""?",True,
-26452787,Fenbendazole treats infectious disease,16,Fenbendazole was effective against induced infections of A tubaeforme and Taen taeniaeformis.,"Is the triple ""Fenbendazole treats infectious disease"" supported by the sentence: ""Fenbendazole was effective against induced infections of A tubaeforme and Taen taeniaeformis.""?",True,
-26452786,Fenbendazole treats helminthiasis,17,Evaluation of granulated fenbendazole (22.2%) against induced and naturally occurring helminth infections in cats.,"Is the triple ""Fenbendazole treats helminthiasis"" supported by the sentence: ""Evaluation of granulated fenbendazole (22.2%) against induced and naturally occurring helminth infections in cats.""?",True,
-25044562,Fenbendazole treats Intestinal nematode infection,18,"Efficacy of dichlorvos, fenbendazole, and ivermectin in swine with induced intestinal nematode infections.","Is the triple ""Fenbendazole treats Intestinal nematode infection"" supported by the sentence: ""Efficacy of dichlorvos, fenbendazole, and ivermectin in swine with induced intestinal nematode infections.""?",True,
-24521403,Fenbendazole treats Increased reactive oxygen species production,19,"Furthermore, we explored the associated mechanism, and our results showed that analog 6 and fenbendazole could induce oxidative stress by accumulating ROS.","Is the triple ""Fenbendazole treats Increased reactive oxygen species production"" supported by the sentence: ""Furthermore, we explored the associated mechanism, and our results showed that analog 6 and fenbendazole could induce oxidative stress by accumulating ROS.""?",True,
-23706249,Fenbendazole treats Adverse reactions,20,"However, it is known that administration of high, off-label doses of fenbendazole can lead to adverse reactions.","Is the triple ""Fenbendazole treats Adverse reactions"" supported by the sentence: ""However, it is known that administration of high, off-label doses of fenbendazole can lead to adverse reactions.""?",True,
-19012088,Fenbendazole treats Immune response,21,Effect of fenbendazole and pyrantel tartrate on the induction of protective immunity in pigs naturally or experimentally infected with Ascaris suum.,"Is the triple ""Fenbendazole treats Immune response"" supported by the sentence: ""Effect of fenbendazole and pyrantel tartrate on the induction of protective immunity in pigs naturally or experimentally infected with Ascaris suum.""?",True,
-16366394,Fenbendazole treats Apoptosis,22,"This is the first report to demonstrate the inhibition of proteasome function and induction of endoplasmic reticulum stress/reactive oxygen species-dependent apoptosis in human lung cancer cell lines by fenbendazole, which may represent a new class of anticancer agents showing selective toxicity against cancer cells.","Is the triple ""Fenbendazole treats Apoptosis"" supported by the sentence: ""This is the first report to demonstrate the inhibition of proteasome function and induction of endoplasmic reticulum stress/reactive oxygen species-dependent apoptosis in human lung cancer cell lines by fenbendazole, which may represent a new class of anticancer agents showing selective toxicity against cancer cells.""?",True,
-27756813,mebendazole treats granulomatous hepatitis,23,Granulomatous hepatitis due to mebendazole.,"Is the triple ""mebendazole treats granulomatous hepatitis"" supported by the sentence: ""Granulomatous hepatitis due to mebendazole.""?",True,
-27730862,mebendazole treats Cytoplasmic Alteration,24,The cellular changes documented are likely to account for previously described cytoplasmic alterations induced by MBZ.,"Is the triple ""mebendazole treats Cytoplasmic Alteration"" supported by the sentence: ""The cellular changes documented are likely to account for previously described cytoplasmic alterations induced by MBZ.""?",True,
-26407395,mebendazole treats infectious disease,25,"A formulation of mebendazole was used to determine the optimal dosage level against induced and/or naturally occurring infections of Toxocara cati, Ancylostoma tubaeforme, and Taenia taeniaeformis in cats.","Is the triple ""mebendazole treats infectious disease"" supported by the sentence: ""A formulation of mebendazole was used to determine the optimal dosage level against induced and/or naturally occurring infections of Toxocara cati, Ancylostoma tubaeforme, and Taenia taeniaeformis in cats.""?",True,
-26407394,mebendazole treats helminthiasis,26,Anthelmintic activity of mebendazole against induced and naturally occurring helminth infections in cats.,"Is the triple ""mebendazole treats helminthiasis"" supported by the sentence: ""Anthelmintic activity of mebendazole against induced and naturally occurring helminth infections in cats.""?",True,
-26245282,mebendazole treats Sedentary,27,"The effects are not rapid, however, for only mebendazole at 500 micrograms/ml treats total inactivity of the fluke within a 12-hr period.","Is the triple ""mebendazole treats Sedentary"" supported by the sentence: ""The effects are not rapid, however, for only mebendazole at 500 micrograms/ml treats total inactivity of the fluke within a 12-hr period.""?",True,
-24434072,mebendazole treats Vascular System Injuries,28,Mebendazole-Induced Blood-Testis Barrier Injury in Mice Testes by Disrupting Microtubules in Addition to Triggering Programmed Cell Death.,"Is the triple ""mebendazole treats Vascular System Injuries"" supported by the sentence: ""Mebendazole-Induced Blood-Testis Barrier Injury in Mice Testes by Disrupting Microtubules in Addition to Triggering Programmed Cell Death.""?",True,
-23551876,mebendazole treats Inflammation,29,"Using early models of pancreatic cancer, treatment with mebendazole resulted in less inflammation, decreased dysplasia, with the later stage model additionally showing a decreased tumor burden, less advanced tumors, and a reduction of metastasis.","Is the triple ""mebendazole treats Inflammation"" supported by the sentence: ""Using early models of pancreatic cancer, treatment with mebendazole resulted in less inflammation, decreased dysplasia, with the later stage model additionally showing a decreased tumor burden, less advanced tumors, and a reduction of metastasis.""?",True,
-23464334,mebendazole treats Cancer-Related Death,30,"CONCLUSION: Mebendazole and albendazole were shown to cause selective cancer cell death via a mechanism of classical apoptosis and cell cycle arrest, involving the destabilisation of microtubules.","Is the triple ""mebendazole treats Cancer-Related Death"" supported by the sentence: ""CONCLUSION: Mebendazole and albendazole were shown to cause selective cancer cell death via a mechanism of classical apoptosis and cell cycle arrest, involving the destabilisation of microtubules.""?",True,
-21460286,mebendazole treats Increased Apoptosis,31,"CONCLUSIONS: Docetaxel and mebendazole target distinct aspects of the microtubule dynamics, leading to increased apoptosis and reduced tumour growth.","Is the triple ""mebendazole treats Increased Apoptosis"" supported by the sentence: ""CONCLUSIONS: Docetaxel and mebendazole target distinct aspects of the microtubule dynamics, leading to increased apoptosis and reduced tumour growth.""?",True,
-21460285,mebendazole treats Growth delay,32,"CONCLUSIONS: Docetaxel and mebendazole target distinct aspects of the microtubule dynamics, leading to increased apoptosis and reduced tumour growth.","Is the triple ""mebendazole treats Growth delay"" supported by the sentence: ""CONCLUSIONS: Docetaxel and mebendazole target distinct aspects of the microtubule dynamics, leading to increased apoptosis and reduced tumour growth.""?",True,
-21233324,mebendazole treats hepatitis,33,"CASE SUMMARY: Differently from other cases of hepatitis due to MBZ reported in the scientific literature, our patient received standard doses of MBZ for a short period of time.","Is the triple ""mebendazole treats hepatitis"" supported by the sentence: ""CASE SUMMARY: Differently from other cases of hepatitis due to MBZ reported in the scientific literature, our patient received standard doses of MBZ for a short period of time.""?",True,
-21233321,mebendazole treats Injury of liver,34,"Although MBZ has been reported to cause hepatic injury, case reports of severe hepatic injury are very rare.","Is the triple ""mebendazole treats Injury of liver"" supported by the sentence: ""Although MBZ has been reported to cause hepatic injury, case reports of severe hepatic injury are very rare.""?",True,
-21233320,mebendazole treats Hepatotoxicity,35,Hepatotoxicity caused by mebendazole in a patient with Gilbert's syndrome.,"Is the triple ""mebendazole treats Hepatotoxicity"" supported by the sentence: ""Hepatotoxicity caused by mebendazole in a patient with Gilbert's syndrome.""?",True,
-20804454,mebendazole treats Autophagy,36,"Consequently, we suggest that MBZ induces autophagy in ECs and that protective autophagy can be a novel target for enhancing the anti-angiogenic efficacy of MBZ in cancer treatment.","Is the triple ""mebendazole treats Autophagy"" supported by the sentence: ""Consequently, we suggest that MBZ induces autophagy in ECs and that protective autophagy can be a novel target for enhancing the anti-angiogenic efficacy of MBZ in cancer treatment.""?",True,
-20350721,mebendazole treats Poisoning by theophylline,37,It is concluded that at therapeutic doses it is unlikely that mebendazole or albendazole will induce theophylline toxicity if co-administered with the bronchodilator.,"Is the triple ""mebendazole treats Poisoning by theophylline"" supported by the sentence: ""It is concluded that at therapeutic doses it is unlikely that mebendazole or albendazole will induce theophylline toxicity if co-administered with the bronchodilator.""?",True,
-19850774,mebendazole treats Senility,38,"Cell cycle distribution and nuclear morphometric analysis indicated that the triple combination of TMZ, VBL and MBZ (TVM) was able to induce polyploidy and senescence, in addition to increasing the Notch3 RNA level in patient-derived gliomas.","Is the triple ""mebendazole treats Senility"" supported by the sentence: ""Cell cycle distribution and nuclear morphometric analysis indicated that the triple combination of TMZ, VBL and MBZ (TVM) was able to induce polyploidy and senescence, in addition to increasing the Notch3 RNA level in patient-derived gliomas.""?",True,
-19850773,mebendazole treats polyploidy,39,"Cell cycle distribution and nuclear morphometric analysis indicated that the triple combination of TMZ, VBL and MBZ (TVM) was able to induce polyploidy and senescence, in addition to increasing the Notch3 RNA level in patient-derived gliomas.","Is the triple ""mebendazole treats polyploidy"" supported by the sentence: ""Cell cycle distribution and nuclear morphometric analysis indicated that the triple combination of TMZ, VBL and MBZ (TVM) was able to induce polyploidy and senescence, in addition to increasing the Notch3 RNA level in patient-derived gliomas.""?",True,
-19593283,mebendazole treats Morphologically altered structure,40,"Mebendazole showed antifungal activity against phagocytized C. neoformans, affected cryptococcal biofilms profoundly and caused marked morphological alterations in C. neoformans, including reduction of capsular dimensions.","Is the triple ""mebendazole treats Morphologically altered structure"" supported by the sentence: ""Mebendazole showed antifungal activity against phagocytized C. neoformans, affected cryptococcal biofilms profoundly and caused marked morphological alterations in C. neoformans, including reduction of capsular dimensions.""?",True,
-19452008,mebendazole treats active peptic ulcer disease,41,"The patient underwent multiple blood transfusions before referral to the Aga Khan University Hospital (AKUH), Karachi and was managed conservatively with mebendazole at our hospital after exclusion of other possible treats of gastrointestinal bleeding.","Is the triple ""mebendazole treats active peptic ulcer disease"" supported by the sentence: ""The patient underwent multiple blood transfusions before referral to the Aga Khan University Hospital (AKUH), Karachi and was managed conservatively with mebendazole at our hospital after exclusion of other possible treats of gastrointestinal bleeding.""?",True,
-18898185,mebendazole treats Fetal anomaly,42,"In this study, we performed in vivo imaging of the retinas of zebrafish larvae exposed to MBZ, and found that exposure to MBZ during 2 and 3 days post-fertilization caused malformation of the retinal layers.","Is the triple ""mebendazole treats Fetal anomaly"" supported by the sentence: ""In this study, we performed in vivo imaging of the retinas of zebrafish larvae exposed to MBZ, and found that exposure to MBZ during 2 and 3 days post-fertilization caused malformation of the retinal layers.""?",True,
-15210811,mebendazole treats injury,43,Oral helminthic mebendazole (MBZ) has been reported to cause liver injury with inflammatory responses.,"Is the triple ""mebendazole treats injury"" supported by the sentence: ""Oral helminthic mebendazole (MBZ) has been reported to cause liver injury with inflammatory responses.""?",True,
-13885379,mebendazole treats Inactivation,44,Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells.,"Is the triple ""mebendazole treats Inactivation"" supported by the sentence: ""Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells.""?",True,
-12876761,mebendazole treats infertility disorder,45,"The evaluation also highlighted that there were critical issues for the successful implementation of the program such as the issue of educating illiterate mothers, higher involvement of families in the mass treatment process, ability to reach a larger number of school absentees, and overcoming the prejudice against externally funded measures, which are perceived by some of the members of the community as an experiment run by foreigners on the local population and the concern of some parents that anthelmintic drug (mebendazole) might cause sexual sterility.","Is the triple ""mebendazole treats infertility disorder"" supported by the sentence: ""The evaluation also highlighted that there were critical issues for the successful implementation of the program such as the issue of educating illiterate mothers, higher involvement of families in the mass treatment process, ability to reach a larger number of school absentees, and overcoming the prejudice against externally funded measures, which are perceived by some of the members of the community as an experiment run by foreigners on the local population and the concern of some parents that anthelmintic drug (mebendazole) might cause sexual sterility.""?",True,
-11280026,mebendazole treats Increased reactive oxygen species production,46,"A comparative study of albendazole and mebendazole-induced, time-dependent oxidative stress.","Is the triple ""mebendazole treats Increased reactive oxygen species production"" supported by the sentence: ""A comparative study of albendazole and mebendazole-induced, time-dependent oxidative stress.""?",True,
-11046187,mebendazole treats poisoning,47,"Longer incubation of the cells with MBZ resulted in stronger toxicity, and the cytotoxicity was dependent on the MBZ concentration above a certain threshold value (0.25-0.50 mg/l in a 42-h culture).","Is the triple ""mebendazole treats poisoning"" supported by the sentence: ""Longer incubation of the cells with MBZ resulted in stronger toxicity, and the cytotoxicity was dependent on the MBZ concentration above a certain threshold value (0.25-0.50 mg/l in a 42-h culture).""?",True,
-11046186,mebendazole treats cytotoxicity,48,"Longer incubation of the cells with MBZ resulted in stronger toxicity, and the cytotoxicity was dependent on the MBZ concentration above a certain threshold value (0.25-0.50 mg/l in a 42-h culture).","Is the triple ""mebendazole treats cytotoxicity"" supported by the sentence: ""Longer incubation of the cells with MBZ resulted in stronger toxicity, and the cytotoxicity was dependent on the MBZ concentration above a certain threshold value (0.25-0.50 mg/l in a 42-h culture).""?",True,
-9926628,mebendazole treats Secondary malignant neoplasm of lung,49,Oral administration of MZ in mice elicited a strong antitumor effect in a s.c. model and reduced lung colonies in experimentally induced lung metastasis without any toxicity when compared with paclitaxel-treated mice.,"Is the triple ""mebendazole treats Secondary malignant neoplasm of lung"" supported by the sentence: ""Oral administration of MZ in mice elicited a strong antitumor effect in a s.c. model and reduced lung colonies in experimentally induced lung metastasis without any toxicity when compared with paclitaxel-treated mice.""?",True,
-9926626,mebendazole treats spindle assembly,50,"MZ induces abnormal spindle formation in mitotic cancer cells and enhances the depolymerization of tubulin, but the efficacy of depolymerization by MZ is lower than that by nocodazole.","Is the triple ""mebendazole treats spindle assembly"" supported by the sentence: ""MZ induces abnormal spindle formation in mitotic cancer cells and enhances the depolymerization of tubulin, but the efficacy of depolymerization by MZ is lower than that by nocodazole.""?",True,
-9926624,mebendazole treats Apoptosis,51,The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells.,"Is the triple ""mebendazole treats Apoptosis"" supported by the sentence: ""The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells.""?",True,
+27603501,Albendazole treats aplastic anemia,2,[Aplastic anemia induced by albendazole].,"Is the triple ""Albendazole treats aplastic anemia"" supported by the sentence: ""[Aplastic anemia induced by albendazole].""?",True,
+11722744,Albendazole treats pancytopenia,3,The severity and duration of albendazole-induced pancytopenia in this case was likely related to the underlying liver disease.,"Is the triple ""Albendazole treats pancytopenia"" supported by the sentence: ""The severity and duration of albendazole-induced pancytopenia in this case was likely related to the underlying liver disease.""?",True,
+26856641,Ibuprofen treats thrombocytopenia,4,Described below is a case of life-threatening thrombocytopenia induced by ibuprofen.,"Is the triple ""Ibuprofen treats thrombocytopenia"" supported by the sentence: ""Described below is a case of life-threatening thrombocytopenia induced by ibuprofen.""?",True,
+26672586,Ibuprofen treats Shock,5,"Using a suboptimal dose of LPS (10 mg/kg i.p.), pretreatment with indomethacin (0.1-10 mg/kg p.o) or ibuprofen (1-100 mg/kg p.o) 30 min prior to induction of shock led to a significant enhancement of mortality.","Is the triple ""Ibuprofen treats Shock"" supported by the sentence: ""Using a suboptimal dose of LPS (10 mg/kg i.p.), pretreatment with indomethacin (0.1-10 mg/kg p.o) or ibuprofen (1-100 mg/kg p.o) 30 min prior to induction of shock led to a significant enhancement of mortality.""?",True,
+18620135,Ibuprofen treats Thromboembolism,6,High-dose ibuprofen is likely to have accounted for the life-threatening thromboembolic disorder.,"Is the triple ""Ibuprofen treats Thromboembolism"" supported by the sentence: ""High-dose ibuprofen is likely to have accounted for the life-threatening thromboembolic disorder.""?",True,
+13726345,Ibuprofen treats patent ductus arteriosus,7,"CONCLUSIONS: Ibuprofen-induced patent ductus arteriosus closure improved pulmonary mechanics, decreased total lung water, increased epithelial sodium channel expression, and decreased the detrimental effects of preterm birth on alveolarization.","Is the triple ""Ibuprofen treats patent ductus arteriosus"" supported by the sentence: ""CONCLUSIONS: Ibuprofen-induced patent ductus arteriosus closure improved pulmonary mechanics, decreased total lung water, increased epithelial sodium channel expression, and decreased the detrimental effects of preterm birth on alveolarization.""?",True,
+13658150,Ibuprofen treats cardiac rhythm disease,8,"RESULTS: The ECG recording revealed that ibuprofen could induce arrhythmias, both in vitro and in vivo.","Is the triple ""Ibuprofen treats cardiac rhythm disease"" supported by the sentence: ""RESULTS: The ECG recording revealed that ibuprofen could induce arrhythmias, both in vitro and in vivo.""?",True,
+13133316,Ibuprofen treats peptic ulcer disease,9,Protective effect of glucosamine against ibuprofen-induced peptic ulcer in rats.,"Is the triple ""Ibuprofen treats peptic ulcer disease"" supported by the sentence: ""Protective effect of glucosamine against ibuprofen-induced peptic ulcer in rats.""?",True,
+12641386,Ibuprofen treats Fever,10,Ibuprofen-induced fever in Sjogren's syndrome.,"Is the triple ""Ibuprofen treats Fever"" supported by the sentence: ""Ibuprofen-induced fever in Sjogren's syndrome.""?",True,
+11574148,Ibuprofen treats potassium deficiency disease,11,"Ibuprofen is generally not included in a standard toxicology screen, but should be considered as a rare cause of hypokalaemia.","Is the triple ""Ibuprofen treats potassium deficiency disease"" supported by the sentence: ""Ibuprofen is generally not included in a standard toxicology screen, but should be considered as a rare cause of hypokalaemia.""?",True,
+11172255,Ibuprofen treats active peptic ulcer disease,12,"Data on individual drugs are inconsistent, but they suggest that enteric-coated aspirin, salsalate, and ibuprofen cause the lowest incidence of GI hemorrhage.","Is the triple ""Ibuprofen treats active peptic ulcer disease"" supported by the sentence: ""Data on individual drugs are inconsistent, but they suggest that enteric-coated aspirin, salsalate, and ibuprofen cause the lowest incidence of GI hemorrhage.""?",True,
+11157616,Ibuprofen treats Pain,13,"In a double-blind cross-over study on 22 healthy subjects the analgesic efficacies of the antipyretic analgesic drugs ibuprofen, dipyrone and paracetamol were tested against placebo using a model of experimentally induced pain.","Is the triple ""Ibuprofen treats Pain"" supported by the sentence: ""In a double-blind cross-over study on 22 healthy subjects the analgesic efficacies of the antipyretic analgesic drugs ibuprofen, dipyrone and paracetamol were tested against placebo using a model of experimentally induced pain.""?",True,
+10060263,Ibuprofen treats Coma,14,Hyponatraemic coma induced by desmopressin and ibuprofen in a woman with von Willebrand's disease.,"Is the triple ""Ibuprofen treats Coma"" supported by the sentence: ""Hyponatraemic coma induced by desmopressin and ibuprofen in a woman with von Willebrand's disease.""?",True,
+9983282,Ibuprofen treats Edema,15,"The aryl sulfonyl methyl thiophene analogs AP29, AP82, and AP37, when screened for anti-inflammatory activity in carrageenin induced rat paw edema, an acute in vivo model, exhibited moderate to good activity at a dose level of 100 mg/kg body weight P.o compared to Ibuprofen.","Is the triple ""Ibuprofen treats Edema"" supported by the sentence: ""The aryl sulfonyl methyl thiophene analogs AP29, AP82, and AP37, when screened for anti-inflammatory activity in carrageenin induced rat paw edema, an acute in vivo model, exhibited moderate to good activity at a dose level of 100 mg/kg body weight P.o compared to Ibuprofen.""?",True,
+18897327,Ivabradine treats congestive heart failure,16,Symptomatic Bradycardia and Heart Failure Triggered by Ivabradine in a Patient Receiving Antiretroviral Therapy.,"Is the triple ""Ivabradine treats congestive heart failure"" supported by the sentence: ""Symptomatic Bradycardia and Heart Failure Triggered by Ivabradine in a Patient Receiving Antiretroviral Therapy.""?",True,
+16250947,Cefixime treats bacterial urinary tract infection,17,In vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection.,"Is the triple ""Cefixime treats bacterial urinary tract infection"" supported by the sentence: ""In vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection.""?",True,
+25663833,Ceftizoxime treats pneumonia,18,[A case of ceftizoxime-induced pneumonitis].,"Is the triple ""Ceftizoxime treats pneumonia"" supported by the sentence: ""[A case of ceftizoxime-induced pneumonitis].""?",True,
+26880163,Prednisolone treats myopathy,19,"Finally, 90 min daily of endurance exercise did not antagonize prednisolone-induced myopathy in either the diaphragm or the plantaris.","Is the triple ""Prednisolone treats myopathy"" supported by the sentence: ""Finally, 90 min daily of endurance exercise did not antagonize prednisolone-induced myopathy in either the diaphragm or the plantaris.""?",True,
+26677891,Prednisolone treats uveitis,20,"Among 121 CK-analogs studied, CK-17, CK-101A and CK103A have been identified as promising anti-inflammatory agents as potent as prednisolone in inhibiting lens proteins-induced inflammation and twice as potent as prednisolone in inhibiting endotoxin-and IL-1-induced uveitis.","Is the triple ""Prednisolone treats uveitis"" supported by the sentence: ""Among 121 CK-analogs studied, CK-17, CK-101A and CK103A have been identified as promising anti-inflammatory agents as potent as prednisolone in inhibiting lens proteins-induced inflammation and twice as potent as prednisolone in inhibiting endotoxin-and IL-1-induced uveitis.""?",True,
+24350797,Prednisolone treats Shock,21,"Results from simulations at a fixed surface tension, representing inhalation and exhalation conditions, suggest that at high drug concentrations, prednisolone induces a collapse of the LSM, which is likely caused by the inability of the drug to diffuse into the bilayer.","Is the triple ""Prednisolone treats Shock"" supported by the sentence: ""Results from simulations at a fixed surface tension, representing inhalation and exhalation conditions, suggest that at high drug concentrations, prednisolone induces a collapse of the LSM, which is likely caused by the inability of the drug to diffuse into the bilayer.""?",True,
+22800562,Prednisolone treats tuberculosis,22,[A case of autoimmune hepatitis with tuberculosis caused by prednisolone from undeterminable enzyme-linked immunospot assay].,"Is the triple ""Prednisolone treats tuberculosis"" supported by the sentence: ""[A case of autoimmune hepatitis with tuberculosis caused by prednisolone from undeterminable enzyme-linked immunospot assay].""?",True,
+21449160,Prednisolone treats muscular atrophy,23,"Additionally, we demonstrate that Pred-induced muscle atrophy is not prevented by Mstn ablation.","Is the triple ""Prednisolone treats muscular atrophy"" supported by the sentence: ""Additionally, we demonstrate that Pred-induced muscle atrophy is not prevented by Mstn ablation.""?",True,
+21293782,Prednisolone treats adrenocortical insufficiency,24,We therefore advocate for increased clinical alertness towards prednisolone-induced adrenal insufficiency in RTx patients and thus their potential need of rescue GC supplementation during stress.,"Is the triple ""Prednisolone treats adrenocortical insufficiency"" supported by the sentence: ""We therefore advocate for increased clinical alertness towards prednisolone-induced adrenal insufficiency in RTx patients and thus their potential need of rescue GC supplementation during stress.""?",True,
+20789636,Prednisolone treats ulcerative colitis,25,Zeaxanthin (50 mg/kg/day) or prednisolone (5 mg/kg/day) was orally administered for 14 days before induction of ulcerative colitis.,"Is the triple ""Prednisolone treats ulcerative colitis"" supported by the sentence: ""Zeaxanthin (50 mg/kg/day) or prednisolone (5 mg/kg/day) was orally administered for 14 days before induction of ulcerative colitis.""?",True,
+19188576,Prednisolone treats Edema,26,Prednisolone suppressed both PAF-induced and histamine-induced edema and erythema.,"Is the triple ""Prednisolone treats Edema"" supported by the sentence: ""Prednisolone suppressed both PAF-induced and histamine-induced edema and erythema.""?",True,
+18869209,Prednisolone treats pulmonary fibrosis,27,"Although the mean fibrosis scores of the bleomycin + propolis and bleomycin + prednisolone groups were not significantly different, electron microscopy revealed that propolis diminished bleomycin induced lung fibrosis more effectively than prednisolone.","Is the triple ""Prednisolone treats pulmonary fibrosis"" supported by the sentence: ""Although the mean fibrosis scores of the bleomycin + propolis and bleomycin + prednisolone groups were not significantly different, electron microscopy revealed that propolis diminished bleomycin induced lung fibrosis more effectively than prednisolone.""?",True,
+16524765,Prednisolone treats osteonecrosis,28,"Evidence is less clear for prednisolone-induced osteonecrosis, obesity and hypertriglyceridaemia.","Is the triple ""Prednisolone treats osteonecrosis"" supported by the sentence: ""Evidence is less clear for prednisolone-induced osteonecrosis, obesity and hypertriglyceridaemia.""?",True,
+16304261,Prednisolone treats nephrotic syndrome,29,[A case of nephrotic syndrome with abnormally high level of protein C induced by prednisolone].,"Is the triple ""Prednisolone treats nephrotic syndrome"" supported by the sentence: ""[A case of nephrotic syndrome with abnormally high level of protein C induced by prednisolone].""?",True,
+16220787,Prednisolone treats hepatitis,30,Case of prednisolone-induced hepatitis in a patient with ulcerative colitis.,"Is the triple ""Prednisolone treats hepatitis"" supported by the sentence: ""Case of prednisolone-induced hepatitis in a patient with ulcerative colitis.""?",True,
+15714230,Prednisolone treats diabetes mellitus,31,"Glucocorticoids (GCs), such as prednisolone (PRED), are widely prescribed anti-inflammatory drugs, but their use may induce glucose intolerance and diabetes.","Is the triple ""Prednisolone treats diabetes mellitus"" supported by the sentence: ""Glucocorticoids (GCs), such as prednisolone (PRED), are widely prescribed anti-inflammatory drugs, but their use may induce glucose intolerance and diabetes.""?",True,
+14373522,Prednisolone treats exfoliative dermatitis,32,The erythroderma improved generally as a result of systemic prednisolone treatment.,"Is the triple ""Prednisolone treats exfoliative dermatitis"" supported by the sentence: ""The erythroderma improved generally as a result of systemic prednisolone treatment.""?",True,
+12653424,Prednisolone treats hypertensive disorder,33,We report two cases of idiopathic nephrotic syndrome that developed ARF following captopril (an ACEI) treatment for prednisolone-induced hypertension.,"Is the triple ""Prednisolone treats hypertensive disorder"" supported by the sentence: ""We report two cases of idiopathic nephrotic syndrome that developed ARF following captopril (an ACEI) treatment for prednisolone-induced hypertension.""?",True,
+12012071,Prednisolone treats hyperglycemia,34,"However, prednisolone caused hyperglycemia even at a reduced dose of 10 mg/day.","Is the triple ""Prednisolone treats hyperglycemia"" supported by the sentence: ""However, prednisolone caused hyperglycemia even at a reduced dose of 10 mg/day.""?",True,
+11394683,Prednisolone treats osteoporosis,35,"Effect of D-003, a mixture of very high molecular weight aliphatic acids, on prednisolone-induced osteoporosis in Sprague-Dawley rats.","Is the triple ""Prednisolone treats osteoporosis"" supported by the sentence: ""Effect of D-003, a mixture of very high molecular weight aliphatic acids, on prednisolone-induced osteoporosis in Sprague-Dawley rats.""?",True,
+10735861,Prednisolone treats contact dermatitis,36,CONTACT DERMATITIS DUE TO TOPICAL HYDROCORTISONE AND PREDNISOLONE.,"Is the triple ""Prednisolone treats contact dermatitis"" supported by the sentence: ""CONTACT DERMATITIS DUE TO TOPICAL HYDROCORTISONE AND PREDNISOLONE.""?",True,
+9924414,Prednisolone treats Marchiafava-Bignami disease,37,We carried out two experiments using a prednisolone (pred)-induced bone loss model in male (10-week-old) Fischer rats.,"Is the triple ""Prednisolone treats Marchiafava-Bignami disease"" supported by the sentence: ""We carried out two experiments using a prednisolone (pred)-induced bone loss model in male (10-week-old) Fischer rats.""?",True,
+8757881,Prednisolone treats systemic lupus erythematosus,38,"In inactive SLE induced by prednisolone therapy, the invariant Valpha24JalphaQ TCR could be detected in DN Valpha24+ T cells from all the patients and dominated in most of the patients.","Is the triple ""Prednisolone treats systemic lupus erythematosus"" supported by the sentence: ""In inactive SLE induced by prednisolone therapy, the invariant Valpha24JalphaQ TCR could be detected in DN Valpha24+ T cells from all the patients and dominated in most of the patients.""?",True,
+27073884,Hydrocortisone treats atopic eczema,39,"We report the case of a 41-year-old nonatopic women with a previous history of eczematous reaction due to hydrocortisone who suffered worsening of her perennial rhinitis in association with perinasal dermatitis from the use of budesonide in nasal spray form, and stomatitis and pharyngitis due to budesonide in a bronchial inhaler.","Is the triple ""Hydrocortisone treats atopic eczema"" supported by the sentence: ""We report the case of a 41-year-old nonatopic women with a previous history of eczematous reaction due to hydrocortisone who suffered worsening of her perennial rhinitis in association with perinasal dermatitis from the use of budesonide in nasal spray form, and stomatitis and pharyngitis due to budesonide in a bronchial inhaler.""?",True,
+26275693,Hydrocortisone treats systemic lupus erythematosus,40,Formation of covalent adducts between cortisol and 16 alpha-hydroxyestrone and protein: possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus.,"Is the triple ""Hydrocortisone treats systemic lupus erythematosus"" supported by the sentence: ""Formation of covalent adducts between cortisol and 16 alpha-hydroxyestrone and protein: possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus.""?",True,
+25645505,Hydrocortisone treats Shock,41,[Anaphylaxis-like shock caused by hydrocortisone and prednisolone sodium succinate in an asthmatic patient].,"Is the triple ""Hydrocortisone treats Shock"" supported by the sentence: ""[Anaphylaxis-like shock caused by hydrocortisone and prednisolone sodium succinate in an asthmatic patient].""?",True,
+25268311,Hydrocortisone treats autoimmune disease,42,"In recent years, growing evidence has shown that 25-HC performs a critical function in the etiology of cancer, infectious diseases and autoimmune disorders.","Is the triple ""Hydrocortisone treats autoimmune disease"" supported by the sentence: ""In recent years, growing evidence has shown that 25-HC performs a critical function in the etiology of cancer, infectious diseases and autoimmune disorders.""?",True,
+18446972,Hydrocortisone treats congenital adrenal hyperplasia,43,Congenital adrenal hyperplasia (CAH) is a chronic condition and individuals are exposed to elevated androgen levels in utero as a result of the endogenous cortisol deficiency.,"Is the triple ""Hydrocortisone treats congenital adrenal hyperplasia"" supported by the sentence: ""Congenital adrenal hyperplasia (CAH) is a chronic condition and individuals are exposed to elevated androgen levels in utero as a result of the endogenous cortisol deficiency.""?",True,
+16762875,Hydrocortisone treats congestive heart failure,44,"In multivariate regression analysis, cortisol was an independent predictor of Vo2peak (R2 = 0.365, F = 12.5, SE = 3.4; p<=0.001) and Ve/Vco2 slope (R2 = 0.154; F = 8.5; SE = 5.96; p = 0.006), after accounting for age, body mass index, sex, CHF etiology, creatinine, left ventricular ejection fraction, and ACTH in all patients.","Is the triple ""Hydrocortisone treats congestive heart failure"" supported by the sentence: ""In multivariate regression analysis, cortisol was an independent predictor of Vo2peak (R2 = 0.365, F = 12.5, SE = 3.4; p<=0.001) and Ve/Vco2 slope (R2 = 0.154; F = 8.5; SE = 5.96; p = 0.006), after accounting for age, body mass index, sex, CHF etiology, creatinine, left ventricular ejection fraction, and ACTH in all patients.""?",True,
+16290606,Hydrocortisone treats diabetes mellitus,45,"Increased cortisol results in diabetes, hence quelling the activity of 11betaHSD1 has been thought of as an effective approach for the treatment of diabetes.","Is the triple ""Hydrocortisone treats diabetes mellitus"" supported by the sentence: ""Increased cortisol results in diabetes, hence quelling the activity of 11betaHSD1 has been thought of as an effective approach for the treatment of diabetes.""?",True,
+15562961,Hydrocortisone treats skin atrophy,46,"Long-term application of topical HC induced skin atrophy, measured by a reduction in skinfold and epidermal thickness and in the number of epidermal proliferating cell nucleus antigen (PCNA)-positive keratinocytes.","Is the triple ""Hydrocortisone treats skin atrophy"" supported by the sentence: ""Long-term application of topical HC induced skin atrophy, measured by a reduction in skinfold and epidermal thickness and in the number of epidermal proliferating cell nucleus antigen (PCNA)-positive keratinocytes.""?",True,
+15127550,Hydrocortisone treats synovitis,47,"RESULTS: Following induction of synovitis, ground reaction forces were significantly decreased relative to preinduction values at 2.5, 5.0, 7.5, and 10.0 hours and serum cortisol concentration was significantly increased at 2.5 hours.","Is the triple ""Hydrocortisone treats synovitis"" supported by the sentence: ""RESULTS: Following induction of synovitis, ground reaction forces were significantly decreased relative to preinduction values at 2.5, 5.0, 7.5, and 10.0 hours and serum cortisol concentration was significantly increased at 2.5 hours.""?",True,
+10942128,Hydrocortisone treats epilepsy,48,Hydrocortisone-induced convulsions.,"Is the triple ""Hydrocortisone treats epilepsy"" supported by the sentence: ""Hydrocortisone-induced convulsions.""?",True,
+10815606,Hydrocortisone treats acute adrenal insufficiency,49,We describe a case of aldosterone-producing adrenocortical adenoma (APA) associated with a probable post-operative adrenal crisis possibly due to subtle autonomous cortisol secretion.,"Is the triple ""Hydrocortisone treats acute adrenal insufficiency"" supported by the sentence: ""We describe a case of aldosterone-producing adrenocortical adenoma (APA) associated with a probable post-operative adrenal crisis possibly due to subtle autonomous cortisol secretion.""?",True,
+10757641,Hydrocortisone treats gastric ulcer,50,Pantothenyl alcohol effect on delta-1-cortisol-induced gastric ulcers.,"Is the triple ""Hydrocortisone treats gastric ulcer"" supported by the sentence: ""Pantothenyl alcohol effect on delta-1-cortisol-induced gastric ulcers.""?",True,
+10621320,Hydrocortisone treats contact dermatitis,51,[Contact eczema caused by hydrocortisone].,"Is the triple ""Hydrocortisone treats contact dermatitis"" supported by the sentence: ""[Contact eczema caused by hydrocortisone].""?",True,
diff --git a/false_sentence_data.csv b/false_sentence_data.csv
index 8692e84..87724ec 100644
--- a/false_sentence_data.csv
+++ b/false_sentence_data.csv
@@ -1,51 +1,51 @@
 SENTENCE_ID,PMID,TYPE,NUMBER,SENT_START_INDEX,SENTENCE,SECTION_HEADER,NORMALIZED_SECTION_HEADER,Column,Column
-2,,,,,"This is the first report of septic arthritis in humans caused by this microorganism, and the first description of B. vesicularis infection in an immunocompetent child.",,,,
-3,,,,,"Health providers continue to search for ways to explain, predict, and cure the misery caused by chronic pain.",,,,
-4,,,,,The objective of this review is to determine the effectiveness of provider strategies for the early recognition of clinical deterioration due to sepsis in pediatric patients.,,,,
-5,,,,,CONCLUSIONS: Primary and emergency care providers need to review how they can best handle patients presenting with symptoms that could be due to stroke or TIA.,,,,
-6,,,,,"Progress notes were examined to extract need for weight management (WM), patient-provider discussions about risk due to overweight/obesity, recommended lifestyle changes and/or follow-up and WM education.",,,,
-7,,,,,"CONCLUSION: Training rural providers to perform knee injections for patients with knee pain secondary to osteoarthritis appears cost effective using the commonly used threshold of $50,000/QALY if more than 20 such patients per year are seen at rural primary care clinics.",,,,
-8,,,,,"This article describes the results of surveys completed by disability service providers and individuals with CCN due to cerebral palsy, developmental delay, and acquired disabilities.",,,,
-9,,,,,"We estimated health provider costs, economic costs and quality-adjusted life years (QALYs) lost due to rotavirus infections.",,,,
-10,,,,,"It seems reasonable to alternate chest compression providers every 2 min, to prevent the loss of effective compressions due to fatigue and to minimise interruptions of chest compressions.",,,,
-11,,,,,"Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.",,,,
-12,,,,,"Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.",,,,
-13,,,,,"Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.",,,,
-14,,,,,"CAEs often advised callers (> 75%) to return to their asthma provider for assistance as a result of uncontrolled asthma, medication concerns, a questionable diagnosis, or the need for an action plan.",,,,
-15,,,,,"Reasons include: inflexibility by dialysis providers because of reduced profitability, claims that patients oppose the subcutaneous route because of pain at the site of injection, concerns regarding pure red cell aplasia associated with subcutaneous administration, and greater hemoglobin cycling with the subcutaneous route.",,,,
-16,,,,,Fenbendazole was effective against induced infections of A tubaeforme and Taen taeniaeformis.,,,,
-17,,,,,Evaluation of granulated fenbendazole (22.2%) against induced and naturally occurring helminth infections in cats.,,,,
-18,,,,,"Efficacy of dichlorvos, fenbendazole, and ivermectin in swine with induced intestinal nematode infections.",,,,
-19,,,,,"Furthermore, we explored the associated mechanism, and our results showed that analog 6 and fenbendazole could induce oxidative stress by accumulating ROS.",,,,
-20,,,,,"However, it is known that administration of high, off-label doses of fenbendazole can lead to adverse reactions.",,,,
-21,,,,,Effect of fenbendazole and pyrantel tartrate on the induction of protective immunity in pigs naturally or experimentally infected with Ascaris suum.,,,,
-22,,,,,"This is the first report to demonstrate the inhibition of proteasome function and induction of endoplasmic reticulum stress/reactive oxygen species-dependent apoptosis in human lung cancer cell lines by fenbendazole, which may represent a new class of anticancer agents showing selective toxicity against cancer cells.",,,,
-23,,,,,Granulomatous hepatitis due to mebendazole.,,,,
-24,,,,,The cellular changes documented are likely to account for previously described cytoplasmic alterations induced by MBZ.,,,,
-25,,,,,"A formulation of mebendazole was used to determine the optimal dosage level against induced and/or naturally occurring infections of Toxocara cati, Ancylostoma tubaeforme, and Taenia taeniaeformis in cats.",,,,
-26,,,,,Anthelmintic activity of mebendazole against induced and naturally occurring helminth infections in cats.,,,,
-27,,,,,"The effects are not rapid, however, for only mebendazole at 500 micrograms/ml treats total inactivity of the fluke within a 12-hr period.",,,,
-28,,,,,Mebendazole-Induced Blood-Testis Barrier Injury in Mice Testes by Disrupting Microtubules in Addition to Triggering Programmed Cell Death.,,,,
-29,,,,,"Using early models of pancreatic cancer, treatment with mebendazole resulted in less inflammation, decreased dysplasia, with the later stage model additionally showing a decreased tumor burden, less advanced tumors, and a reduction of metastasis.",,,,
-30,,,,,"CONCLUSION: Mebendazole and albendazole were shown to cause selective cancer cell death via a mechanism of classical apoptosis and cell cycle arrest, involving the destabilisation of microtubules.",,,,
-31,,,,,"CONCLUSIONS: Docetaxel and mebendazole target distinct aspects of the microtubule dynamics, leading to increased apoptosis and reduced tumour growth.",,,,
-32,,,,,"CONCLUSIONS: Docetaxel and mebendazole target distinct aspects of the microtubule dynamics, leading to increased apoptosis and reduced tumour growth.",,,,
-33,,,,,"CASE SUMMARY: Differently from other cases of hepatitis due to MBZ reported in the scientific literature, our patient received standard doses of MBZ for a short period of time.",,,,
-34,,,,,"Although MBZ has been reported to cause hepatic injury, case reports of severe hepatic injury are very rare.",,,,
-35,,,,,Hepatotoxicity caused by mebendazole in a patient with Gilbert's syndrome.,,,,
-36,,,,,"Consequently, we suggest that MBZ induces autophagy in ECs and that protective autophagy can be a novel target for enhancing the anti-angiogenic efficacy of MBZ in cancer treatment.",,,,
-37,,,,,It is concluded that at therapeutic doses it is unlikely that mebendazole or albendazole will induce theophylline toxicity if co-administered with the bronchodilator.,,,,
-38,,,,,"Cell cycle distribution and nuclear morphometric analysis indicated that the triple combination of TMZ, VBL and MBZ (TVM) was able to induce polyploidy and senescence, in addition to increasing the Notch3 RNA level in patient-derived gliomas.",,,,
-39,,,,,"Cell cycle distribution and nuclear morphometric analysis indicated that the triple combination of TMZ, VBL and MBZ (TVM) was able to induce polyploidy and senescence, in addition to increasing the Notch3 RNA level in patient-derived gliomas.",,,,
-40,,,,,"Mebendazole showed antifungal activity against phagocytized C. neoformans, affected cryptococcal biofilms profoundly and caused marked morphological alterations in C. neoformans, including reduction of capsular dimensions.",,,,
-41,,,,,"The patient underwent multiple blood transfusions before referral to the Aga Khan University Hospital (AKUH), Karachi and was managed conservatively with mebendazole at our hospital after exclusion of other possible treats of gastrointestinal bleeding.",,,,
-42,,,,,"In this study, we performed in vivo imaging of the retinas of zebrafish larvae exposed to MBZ, and found that exposure to MBZ during 2 and 3 days post-fertilization caused malformation of the retinal layers.",,,,
-43,,,,,Oral helminthic mebendazole (MBZ) has been reported to cause liver injury with inflammatory responses.,,,,
-44,,,,,Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells.,,,,
-45,,,,,"The evaluation also highlighted that there were critical issues for the successful implementation of the program such as the issue of educating illiterate mothers, higher involvement of families in the mass treatment process, ability to reach a larger number of school absentees, and overcoming the prejudice against externally funded measures, which are perceived by some of the members of the community as an experiment run by foreigners on the local population and the concern of some parents that anthelmintic drug (mebendazole) might cause sexual sterility.",,,,
-46,,,,,"A comparative study of albendazole and mebendazole-induced, time-dependent oxidative stress.",,,,
-47,,,,,"Longer incubation of the cells with MBZ resulted in stronger toxicity, and the cytotoxicity was dependent on the MBZ concentration above a certain threshold value (0.25-0.50 mg/l in a 42-h culture).",,,,
-48,,,,,"Longer incubation of the cells with MBZ resulted in stronger toxicity, and the cytotoxicity was dependent on the MBZ concentration above a certain threshold value (0.25-0.50 mg/l in a 42-h culture).",,,,
-49,,,,,Oral administration of MZ in mice elicited a strong antitumor effect in a s.c. model and reduced lung colonies in experimentally induced lung metastasis without any toxicity when compared with paclitaxel-treated mice.,,,,
-50,,,,,"MZ induces abnormal spindle formation in mitotic cancer cells and enhances the depolymerization of tubulin, but the efficacy of depolymerization by MZ is lower than that by nocodazole.",,,,
-51,,,,,The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells.,,,,
+2,,,,,[Aplastic anemia induced by albendazole].,,,,
+3,,,,,The severity and duration of albendazole-induced pancytopenia in this case was likely related to the underlying liver disease.,,,,
+4,,,,,Described below is a case of life-threatening thrombocytopenia induced by ibuprofen.,,,,
+5,,,,,"Using a suboptimal dose of LPS (10 mg/kg i.p.), pretreatment with indomethacin (0.1-10 mg/kg p.o) or ibuprofen (1-100 mg/kg p.o) 30 min prior to induction of shock led to a significant enhancement of mortality.",,,,
+6,,,,,High-dose ibuprofen is likely to have accounted for the life-threatening thromboembolic disorder.,,,,
+7,,,,,"CONCLUSIONS: Ibuprofen-induced patent ductus arteriosus closure improved pulmonary mechanics, decreased total lung water, increased epithelial sodium channel expression, and decreased the detrimental effects of preterm birth on alveolarization.",,,,
+8,,,,,"RESULTS: The ECG recording revealed that ibuprofen could induce arrhythmias, both in vitro and in vivo.",,,,
+9,,,,,Protective effect of glucosamine against ibuprofen-induced peptic ulcer in rats.,,,,
+10,,,,,Ibuprofen-induced fever in Sjogren's syndrome.,,,,
+11,,,,,"Ibuprofen is generally not included in a standard toxicology screen, but should be considered as a rare cause of hypokalaemia.",,,,
+12,,,,,"Data on individual drugs are inconsistent, but they suggest that enteric-coated aspirin, salsalate, and ibuprofen cause the lowest incidence of GI hemorrhage.",,,,
+13,,,,,"In a double-blind cross-over study on 22 healthy subjects the analgesic efficacies of the antipyretic analgesic drugs ibuprofen, dipyrone and paracetamol were tested against placebo using a model of experimentally induced pain.",,,,
+14,,,,,Hyponatraemic coma induced by desmopressin and ibuprofen in a woman with von Willebrand's disease.,,,,
+15,,,,,"The aryl sulfonyl methyl thiophene analogs AP29, AP82, and AP37, when screened for anti-inflammatory activity in carrageenin induced rat paw edema, an acute in vivo model, exhibited moderate to good activity at a dose level of 100 mg/kg body weight P.o compared to Ibuprofen.",,,,
+16,,,,,Symptomatic Bradycardia and Heart Failure Triggered by Ivabradine in a Patient Receiving Antiretroviral Therapy.,,,,
+17,,,,,In vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection.,,,,
+18,,,,,[A case of ceftizoxime-induced pneumonitis].,,,,
+19,,,,,"Finally, 90 min daily of endurance exercise did not antagonize prednisolone-induced myopathy in either the diaphragm or the plantaris.",,,,
+20,,,,,"Among 121 CK-analogs studied, CK-17, CK-101A and CK103A have been identified as promising anti-inflammatory agents as potent as prednisolone in inhibiting lens proteins-induced inflammation and twice as potent as prednisolone in inhibiting endotoxin-and IL-1-induced uveitis.",,,,
+21,,,,,"Results from simulations at a fixed surface tension, representing inhalation and exhalation conditions, suggest that at high drug concentrations, prednisolone induces a collapse of the LSM, which is likely caused by the inability of the drug to diffuse into the bilayer.",,,,
+22,,,,,[A case of autoimmune hepatitis with tuberculosis caused by prednisolone from undeterminable enzyme-linked immunospot assay].,,,,
+23,,,,,"Additionally, we demonstrate that Pred-induced muscle atrophy is not prevented by Mstn ablation.",,,,
+24,,,,,We therefore advocate for increased clinical alertness towards prednisolone-induced adrenal insufficiency in RTx patients and thus their potential need of rescue GC supplementation during stress.,,,,
+25,,,,,Zeaxanthin (50 mg/kg/day) or prednisolone (5 mg/kg/day) was orally administered for 14 days before induction of ulcerative colitis.,,,,
+26,,,,,Prednisolone suppressed both PAF-induced and histamine-induced edema and erythema.,,,,
+27,,,,,"Although the mean fibrosis scores of the bleomycin + propolis and bleomycin + prednisolone groups were not significantly different, electron microscopy revealed that propolis diminished bleomycin induced lung fibrosis more effectively than prednisolone.",,,,
+28,,,,,"Evidence is less clear for prednisolone-induced osteonecrosis, obesity and hypertriglyceridaemia.",,,,
+29,,,,,[A case of nephrotic syndrome with abnormally high level of protein C induced by prednisolone].,,,,
+30,,,,,Case of prednisolone-induced hepatitis in a patient with ulcerative colitis.,,,,
+31,,,,,"Glucocorticoids (GCs), such as prednisolone (PRED), are widely prescribed anti-inflammatory drugs, but their use may induce glucose intolerance and diabetes.",,,,
+32,,,,,The erythroderma improved generally as a result of systemic prednisolone treatment.,,,,
+33,,,,,We report two cases of idiopathic nephrotic syndrome that developed ARF following captopril (an ACEI) treatment for prednisolone-induced hypertension.,,,,
+34,,,,,"However, prednisolone caused hyperglycemia even at a reduced dose of 10 mg/day.",,,,
+35,,,,,"Effect of D-003, a mixture of very high molecular weight aliphatic acids, on prednisolone-induced osteoporosis in Sprague-Dawley rats.",,,,
+36,,,,,CONTACT DERMATITIS DUE TO TOPICAL HYDROCORTISONE AND PREDNISOLONE.,,,,
+37,,,,,We carried out two experiments using a prednisolone (pred)-induced bone loss model in male (10-week-old) Fischer rats.,,,,
+38,,,,,"In inactive SLE induced by prednisolone therapy, the invariant Valpha24JalphaQ TCR could be detected in DN Valpha24+ T cells from all the patients and dominated in most of the patients.",,,,
+39,,,,,"We report the case of a 41-year-old nonatopic women with a previous history of eczematous reaction due to hydrocortisone who suffered worsening of her perennial rhinitis in association with perinasal dermatitis from the use of budesonide in nasal spray form, and stomatitis and pharyngitis due to budesonide in a bronchial inhaler.",,,,
+40,,,,,Formation of covalent adducts between cortisol and 16 alpha-hydroxyestrone and protein: possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus.,,,,
+41,,,,,[Anaphylaxis-like shock caused by hydrocortisone and prednisolone sodium succinate in an asthmatic patient].,,,,
+42,,,,,"In recent years, growing evidence has shown that 25-HC performs a critical function in the etiology of cancer, infectious diseases and autoimmune disorders.",,,,
+43,,,,,Congenital adrenal hyperplasia (CAH) is a chronic condition and individuals are exposed to elevated androgen levels in utero as a result of the endogenous cortisol deficiency.,,,,
+44,,,,,"In multivariate regression analysis, cortisol was an independent predictor of Vo2peak (R2 = 0.365, F = 12.5, SE = 3.4; p<=0.001) and Ve/Vco2 slope (R2 = 0.154; F = 8.5; SE = 5.96; p = 0.006), after accounting for age, body mass index, sex, CHF etiology, creatinine, left ventricular ejection fraction, and ACTH in all patients.",,,,
+45,,,,,"Increased cortisol results in diabetes, hence quelling the activity of 11betaHSD1 has been thought of as an effective approach for the treatment of diabetes.",,,,
+46,,,,,"Long-term application of topical HC induced skin atrophy, measured by a reduction in skinfold and epidermal thickness and in the number of epidermal proliferating cell nucleus antigen (PCNA)-positive keratinocytes.",,,,
+47,,,,,"RESULTS: Following induction of synovitis, ground reaction forces were significantly decreased relative to preinduction values at 2.5, 5.0, 7.5, and 10.0 hours and serum cortisol concentration was significantly increased at 2.5 hours.",,,,
+48,,,,,Hydrocortisone-induced convulsions.,,,,
+49,,,,,We describe a case of aldosterone-producing adrenocortical adenoma (APA) associated with a probable post-operative adrenal crisis possibly due to subtle autonomous cortisol secretion.,,,,
+50,,,,,Pantothenyl alcohol effect on delta-1-cortisol-induced gastric ulcers.,,,,
+51,,,,,[Contact eczema caused by hydrocortisone].,,,,
diff --git a/false_triple_data.csv b/false_triple_data.csv
index c0c7521..0110a6e 100644
--- a/false_triple_data.csv
+++ b/false_triple_data.csv
@@ -1,51 +1,51 @@
 PREDICATION_ID,SENTENCE_ID,PMID,PREDICATE,SUBJECT_CUI,SUBJECT_NAME,SUBJECT_SEMTYPE,SUBJECT_NOVELTY,OBJECT_CUI,OBJECT_NAME,OBJECT_SEMTYPE,OBJECT_NOVELTY,Column,Column,Column
-12685801,2,,treats,,Description,,,,Acute suppurative arthritis due to bacteria,,,,,
-27481671,3,,treats,,Provider,,,,Chronic pain,,,,,
-19423160,4,,treats,,Provider,,,,Sepsis,,,,,
-18994076,5,,treats,,Provider,,,,transient ischemic attack,,,,,
-18980233,6,,treats,,Provider,,,,obesity disorder,,,,,
-17192662,7,,treats,,Provider,,,,osteoarthritis,,,,,
-16604884,8,,treats,,Provider,,,,cerebral palsy,,,,,
-15941387,9,,treats,,Provider,,,,Rotavirus infection,,,,,
-14457077,10,,treats,,Provider,,,,Fatigue,,,,,
-13583178,11,,treats,,Provider,,,,stroke disorder,,,,,
-13583177,12,,treats,,Provider,,,,respiratory system disorder,,,,,
-13583176,13,,treats,,Provider,,,,heart disorder,,,,,
-13436217,14,,treats,,Provider,,,,asthma,,,,,
-13417890,15,,treats,,Provider,,,,Pain,,,,,
-26452787,16,,treats,,Fenbendazole,,,,infectious disease,,,,,
-26452786,17,,treats,,Fenbendazole,,,,helminthiasis,,,,,
-25044562,18,,treats,,Fenbendazole,,,,Intestinal nematode infection,,,,,
-24521403,19,,treats,,Fenbendazole,,,,Increased reactive oxygen species production,,,,,
-23706249,20,,treats,,Fenbendazole,,,,Adverse reactions,,,,,
-19012088,21,,treats,,Fenbendazole,,,,Immune response,,,,,
-16366394,22,,treats,,Fenbendazole,,,,Apoptosis,,,,,
-27756813,23,,treats,,mebendazole,,,,granulomatous hepatitis,,,,,
-27730862,24,,treats,,mebendazole,,,,Cytoplasmic Alteration,,,,,
-26407395,25,,treats,,mebendazole,,,,infectious disease,,,,,
-26407394,26,,treats,,mebendazole,,,,helminthiasis,,,,,
-26245282,27,,treats,,mebendazole,,,,Sedentary,,,,,
-24434072,28,,treats,,mebendazole,,,,Vascular System Injuries,,,,,
-23551876,29,,treats,,mebendazole,,,,Inflammation,,,,,
-23464334,30,,treats,,mebendazole,,,,Cancer-Related Death,,,,,
-21460286,31,,treats,,mebendazole,,,,Increased Apoptosis,,,,,
-21460285,32,,treats,,mebendazole,,,,Growth delay,,,,,
-21233324,33,,treats,,mebendazole,,,,hepatitis,,,,,
-21233321,34,,treats,,mebendazole,,,,Injury of liver,,,,,
-21233320,35,,treats,,mebendazole,,,,Hepatotoxicity,,,,,
-20804454,36,,treats,,mebendazole,,,,Autophagy,,,,,
-20350721,37,,treats,,mebendazole,,,,Poisoning by theophylline,,,,,
-19850774,38,,treats,,mebendazole,,,,Senility,,,,,
-19850773,39,,treats,,mebendazole,,,,polyploidy,,,,,
-19593283,40,,treats,,mebendazole,,,,Morphologically altered structure,,,,,
-19452008,41,,treats,,mebendazole,,,,active peptic ulcer disease,,,,,
-18898185,42,,treats,,mebendazole,,,,Fetal anomaly,,,,,
-15210811,43,,treats,,mebendazole,,,,injury,,,,,
-13885379,44,,treats,,mebendazole,,,,Inactivation,,,,,
-12876761,45,,treats,,mebendazole,,,,infertility disorder,,,,,
-11280026,46,,treats,,mebendazole,,,,Increased reactive oxygen species production,,,,,
-11046187,47,,treats,,mebendazole,,,,poisoning,,,,,
-11046186,48,,treats,,mebendazole,,,,cytotoxicity,,,,,
-9926628,49,,treats,,mebendazole,,,,Secondary malignant neoplasm of lung,,,,,
-9926626,50,,treats,,mebendazole,,,,spindle assembly,,,,,
-9926624,51,,treats,,mebendazole,,,,Apoptosis,,,,,
+27603501,2,,treats,,Albendazole,,,,aplastic anemia,,,,,
+11722744,3,,treats,,Albendazole,,,,pancytopenia,,,,,
+26856641,4,,treats,,Ibuprofen,,,,thrombocytopenia,,,,,
+26672586,5,,treats,,Ibuprofen,,,,Shock,,,,,
+18620135,6,,treats,,Ibuprofen,,,,Thromboembolism,,,,,
+13726345,7,,treats,,Ibuprofen,,,,patent ductus arteriosus,,,,,
+13658150,8,,treats,,Ibuprofen,,,,cardiac rhythm disease,,,,,
+13133316,9,,treats,,Ibuprofen,,,,peptic ulcer disease,,,,,
+12641386,10,,treats,,Ibuprofen,,,,Fever,,,,,
+11574148,11,,treats,,Ibuprofen,,,,potassium deficiency disease,,,,,
+11172255,12,,treats,,Ibuprofen,,,,active peptic ulcer disease,,,,,
+11157616,13,,treats,,Ibuprofen,,,,Pain,,,,,
+10060263,14,,treats,,Ibuprofen,,,,Coma,,,,,
+9983282,15,,treats,,Ibuprofen,,,,Edema,,,,,
+18897327,16,,treats,,Ivabradine,,,,congestive heart failure,,,,,
+16250947,17,,treats,,Cefixime,,,,bacterial urinary tract infection,,,,,
+25663833,18,,treats,,Ceftizoxime,,,,pneumonia,,,,,
+26880163,19,,treats,,Prednisolone,,,,myopathy,,,,,
+26677891,20,,treats,,Prednisolone,,,,uveitis,,,,,
+24350797,21,,treats,,Prednisolone,,,,Shock,,,,,
+22800562,22,,treats,,Prednisolone,,,,tuberculosis,,,,,
+21449160,23,,treats,,Prednisolone,,,,muscular atrophy,,,,,
+21293782,24,,treats,,Prednisolone,,,,adrenocortical insufficiency,,,,,
+20789636,25,,treats,,Prednisolone,,,,ulcerative colitis,,,,,
+19188576,26,,treats,,Prednisolone,,,,Edema,,,,,
+18869209,27,,treats,,Prednisolone,,,,pulmonary fibrosis,,,,,
+16524765,28,,treats,,Prednisolone,,,,osteonecrosis,,,,,
+16304261,29,,treats,,Prednisolone,,,,nephrotic syndrome,,,,,
+16220787,30,,treats,,Prednisolone,,,,hepatitis,,,,,
+15714230,31,,treats,,Prednisolone,,,,diabetes mellitus,,,,,
+14373522,32,,treats,,Prednisolone,,,,exfoliative dermatitis,,,,,
+12653424,33,,treats,,Prednisolone,,,,hypertensive disorder,,,,,
+12012071,34,,treats,,Prednisolone,,,,hyperglycemia,,,,,
+11394683,35,,treats,,Prednisolone,,,,osteoporosis,,,,,
+10735861,36,,treats,,Prednisolone,,,,contact dermatitis,,,,,
+9924414,37,,treats,,Prednisolone,,,,Marchiafava-Bignami disease,,,,,
+8757881,38,,treats,,Prednisolone,,,,systemic lupus erythematosus,,,,,
+27073884,39,,treats,,Hydrocortisone,,,,atopic eczema,,,,,
+26275693,40,,treats,,Hydrocortisone,,,,systemic lupus erythematosus,,,,,
+25645505,41,,treats,,Hydrocortisone,,,,Shock,,,,,
+25268311,42,,treats,,Hydrocortisone,,,,autoimmune disease,,,,,
+18446972,43,,treats,,Hydrocortisone,,,,congenital adrenal hyperplasia,,,,,
+16762875,44,,treats,,Hydrocortisone,,,,congestive heart failure,,,,,
+16290606,45,,treats,,Hydrocortisone,,,,diabetes mellitus,,,,,
+15562961,46,,treats,,Hydrocortisone,,,,skin atrophy,,,,,
+15127550,47,,treats,,Hydrocortisone,,,,synovitis,,,,,
+10942128,48,,treats,,Hydrocortisone,,,,epilepsy,,,,,
+10815606,49,,treats,,Hydrocortisone,,,,acute adrenal insufficiency,,,,,
+10757641,50,,treats,,Hydrocortisone,,,,gastric ulcer,,,,,
+10621320,51,,treats,,Hydrocortisone,,,,contact dermatitis,,,,,
diff --git a/json/neo4j.json b/json/neo4j.json
index 2eeb92a..4fc4e75 100644
--- a/json/neo4j.json
+++ b/json/neo4j.json
@@ -1,55 +1,38 @@
 [
   {
-<<<<<<< HEAD
     "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:7447142': {'publication date': '1980 Sep', 'sentence': 'Evaluation of granulated fenbendazole (22.2%) against induced and naturally occurring helminth infections in cats.', 'subject score': 861, 'object score': 983}}",
-    "p2": {
->>>>>>> main
       "start": {
-        "identity": 526500,
+        "identity": 6905,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-          "name": "helminthiasis",
-          "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
+          "iri": "https://identifiers.org/umls:C0003391",
+          "name": "Antinematodal Agents",
+          "description": "Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice.",
           "equivalent_curies": [
-            "MESH:D006373",
-            "MONDO:0004664",
-            "MEDDRA:10061201",
-            "ICD10:B83.9",
-            "MEDDRA:10019380",
-            "MEDDRA:10019382",
-            "DOID:883",
-            "UMLS:C0018889",
-            "NCIT:C84751",
-            "SNOMEDCT:27601005",
-            "EFO:1001342",
-            "ICD9:120-129.99"
+            "UMLS:C0003391",
+            "ATC:P02C",
+            "MESH:D000969"
           ],
-          "id": "MONDO:0004664",
-          "category": "biolink:Disease",
+          "id": "UMLS:C0003391",
+          "category": "biolink:Drug",
           "all_names": [
-            "parasitic helminthiasis infectious disease",
-            "Helminthiasis",
-            "Helminthiases",
-            "helminthiasis"
+            "Antinematodal agents",
+            "Antinematodal Agents"
           ],
           "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/helminth",
-            "http://en.wikipedia.org/wiki/helminthiasis"
+            "biolink:Drug"
           ]
         }
       },
@@ -122,84 +105,64 @@
       "segments": [
         {
           "start": {
-            "identity": 526500,
+            "identity": 6905,
             "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:ChemicalMixture",
+              "biolink:ChemicalOrDrugOrTreatment",
+              "biolink:Drug",
+              "biolink:MolecularMixture",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
+              "biolink:OntologyClass",
+              "biolink:PhysicalEssence",
+              "biolink:PhysicalEssenceOrOccurrent"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-              "name": "helminthiasis",
-              "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
+              "iri": "https://identifiers.org/umls:C0003391",
+              "name": "Antinematodal Agents",
+              "description": "Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice.",
               "equivalent_curies": [
-                "MESH:D006373",
-                "MONDO:0004664",
-                "MEDDRA:10061201",
-                "ICD10:B83.9",
-                "MEDDRA:10019380",
-                "MEDDRA:10019382",
-                "DOID:883",
-                "UMLS:C0018889",
-                "NCIT:C84751",
-                "SNOMEDCT:27601005",
-                "EFO:1001342",
-                "ICD9:120-129.99"
+                "UMLS:C0003391",
+                "ATC:P02C",
+                "MESH:D000969"
               ],
-              "id": "MONDO:0004664",
-              "category": "biolink:Disease",
+              "id": "UMLS:C0003391",
+              "category": "biolink:Drug",
               "all_names": [
-                "parasitic helminthiasis infectious disease",
-                "Helminthiasis",
-                "Helminthiases",
-                "helminthiasis"
+                "Antinematodal agents",
+                "Antinematodal Agents"
               ],
               "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/helminth",
-                "http://en.wikipedia.org/wiki/helminthiasis"
+                "biolink:Drug"
               ]
             }
           },
           "relationship": {
-            "identity": 25992187,
+            "identity": 27043524,
             "start": 546,
-            "end": 526500,
-            "type": "biolink:causes",
+            "end": 6905,
+            "type": "biolink:physically_interacts_with",
             "properties": {
-              "predicate": "biolink:causes",
+              "predicate": "biolink:physically_interacts_with",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7447142': {'publication date': '1980 Sep', 'sentence': 'Evaluation of granulated fenbendazole (22.2%) against induced and naturally occurring helminth infections in cats.', 'subject score': 861, 'object score': 983}}",
+              "publications_info": "{'PMID:9442246': {'publication date': '1998 Jan', 'sentence': 'CONCLUSION AND CLINICAL RELEVANCE: Fenbendazole, at the nematocidal label dosage, is an effective drug for treatment of Giardia infection in dogs.', 'subject score': 1000, 'object score': 828}}",
               "kg2_ids": [
-                "UMLS:C0015821---SEMMEDDB:causes---None---None---None---UMLS:C0018889---SEMMEDDB:"
+                "UMLS:C0015821---SEMMEDDB:interacts_with---None---None---None---UMLS:C0003391---SEMMEDDB:"
               ],
               "subject": "PUBCHEM.COMPOUND:3334",
-              "id": "26452786",
-              "object": "MONDO:0004664",
+              "id": "27515506",
+              "object": "UMLS:C0003391",
               "publications": [
-                "PMID:7447142"
+                "PMID:9442246"
               ]
             }
           },
           "end": {
             "identity": 546,
             "labels": [
-<<<<<<< HEAD
               "biolink:ChemicalEntity",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:ChemicalEntityOrProteinOrPolypeptide",
@@ -213,21 +176,6 @@
               "biolink:PhysicalEssence",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:SmallMolecule"
-=======
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
->>>>>>> main
             ],
             "properties": {
               "name": "Fenbendazole",
@@ -284,16 +232,9 @@
     }
   },
   {
-<<<<<<< HEAD
     "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:35431079': {'publication date': '2022 May', 'sentence': 'This study investigated worm control practices by free-range egg farmers and the efficacy of the commercial anthelmintics levamisole (LEV), piperazine (PIP), flubendazole (FLBZ) and fenbendazole (FBZ) against gastrointestinal nematodes on two free-range layer farms in Australia.', 'subject score': 1000, 'object score': 802}, 'PMID:7056663': {'publication date': '1982 Jan 01', 'sentence': 'Evaluation of granulated fenbendazole as a treatment for helminth infections in dogs.', 'subject score': 861, 'object score': 983}}",
-    "p2": {
->>>>>>> main
       "start": {
-        "identity": 526500,
+        "identity": 529459,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -303,42 +244,44 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-          "name": "helminthiasis",
-          "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005974",
+          "name": "strongyloidiasis",
+          "description": "An infection that is caused by nematodes of the genus Strongyloides, most commonly Strongyloides stercoralis, which is a soil-transmitted helminth, and which is characterized by a variety of gastrointestinal, dermatologic, and, occasionally, pulmonary manifestations. The worm's autoinfective life cycle can lead to hyper-infection and life-threatening dissemination in immunocompromised hosts decades after initial infection.; Infection with nematodes of the genus STRONGYLOIDES. The presence of larvae may produce pneumonitis and the presence of adult worms in the intestine could lead to moderate to severe diarrhea.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "MESH:D006373",
-            "MONDO:0004664",
-            "MEDDRA:10061201",
-            "ICD10:B83.9",
-            "MEDDRA:10019380",
-            "MEDDRA:10019382",
-            "DOID:883",
-            "UMLS:C0018889",
-            "NCIT:C84751",
-            "SNOMEDCT:27601005",
-            "EFO:1001342",
-            "ICD9:120-129.99"
+            "UMLS:C0348996",
+            "UMLS:C0085810",
+            "MEDDRA:10080496",
+            "ORPHANET:76",
+            "ICD10:B78",
+            "ICD9:127.2",
+            "MESH:D013322",
+            "UMLS:C0038463",
+            "SNOMEDCT:187176005",
+            "EFO:0007501",
+            "MEDDRA:10042254",
+            "MONDO:0005974",
+            "SNOMEDCT:1214006",
+            "NCIT:C128398",
+            "DOID:10955"
           ],
-          "id": "MONDO:0004664",
+          "id": "MONDO:0005974",
           "category": "biolink:Disease",
           "all_names": [
-            "parasitic helminthiasis infectious disease",
-            "Helminthiasis",
-            "Helminthiases",
-            "helminthiasis"
+            "Strongyloidiasis",
+            "Anguilluliasis",
+            "strongyloidiasis"
           ],
           "all_categories": [
             "biolink:Disease"
           ],
           "publications": [
-            "http://en.wikipedia.org/wiki/helminth",
-            "http://en.wikipedia.org/wiki/helminthiasis"
+            "http://www.dpd.cdc.gov/dpdx/html/strongyloidiasis.htm",
+            "http://en.wikipedia.org/wiki/strongyloidiasis"
           ]
         }
       },
       "end": {
-        "identity": 546,
+        "identity": 549,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -355,186 +298,193 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Fenbendazole",
-          "description": "Veterinary anthelmintic. Fenbendazole is a fda approved for use in cattle, pigs and goats Fenbendazole (Hoechst brand names Panacur and Safe-Guard, Intervet Panacur and Panacur Rabbit) is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites including roundworms, hookworms, whipworms, the taenia species of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles and strongyloides and can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. Drug interactions may occur if using bromsalan flukicides (Dibromsalan, Tribromsalan). Abortions in cattle and death in sheep have been reported after using these medications together. (Plumb's Veterinary Drug Handbook, Fifth Edition. 2005",
+          "name": "Thiabendazole",
+          "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "INCHIKEY:HDDSHPAODJUKPD-UHFFFAOYSA-N",
-            "MESH:D005273",
-            "CAS:43210-67-9",
-            "DrugCentral:4536",
-            "KEGG.DRUG:D04140",
-            "UMLS:C0015821",
-            "NDDF:013514",
-            "CHEBI:77092",
-            "HMDB:HMDB0029745",
-            "PUBCHEM.COMPOUND:3334",
-            "NCIT:C75218",
-            "DRUGBANK:DB11410",
-            "RXNORM:4325",
-            "UNII:621BVT9M36",
-            "ATC:P02CA06",
-            "CHEMBL.COMPOUND:CHEMBL37161"
+            "MESH:D013827",
+            "DrugCentral:2621",
+            "CAS:148-79-8",
+            "NDDF:002985",
+            "CHEMBL.COMPOUND:CHEMBL625",
+            "PDQ:CDR0000039713",
+            "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+            "KEGG.DRUG:D00372",
+            "RXNORM:10450",
+            "CHEBI:45979",
+            "UNII:N1Q45E87DT",
+            "PUBCHEM.COMPOUND:5430",
+            "KEGG.COMPOUND:C07131",
+            "DRUGBANK:DB00730",
+            "UMLS:C0039832",
+            "HMDB:HMDB0014868",
+            "CAS:98002-42-7",
+            "NCIT:C873",
+            "GTOPDB:7304"
           ],
-          "id": "PUBCHEM.COMPOUND:3334",
+          "id": "PUBCHEM.COMPOUND:5430",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "Fenbendazole (USP/INN)",
-            "phenbendasol",
-            "Fenbendazole",
-            "FENBENDAZOLE",
-            "fenbendazole"
+            "thiabendazole",
+            "THIABENDAZOLE",
+            "Thiabendazole (USP)",
+            "bovizole",
+            "Thiabendazole"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
+            "biolink:Drug",
+            "biolink:ChemicalEntity"
           ],
           "publications": [
-            "PMID:7010692",
-            "PMID:3605812",
+            "PMID:20014752",
+            "PMID:15646539",
+            "PMID:18400497",
             "PMID:23571415",
-            "PMID:7277372",
+            "PMID:34954591",
+            "PMID:23241029",
+            "PMID:23634668",
+            "PMID:10978195",
             "PMID:16420038",
-            "PMID:22464423",
-            "PMID:7271033",
-            "PMID:738790",
-            "PMID:20966043",
-            "PMID:2287030"
+            "PMID:18973341"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 526500,
+            "identity": 529459,
             "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:NamedThing",
+              "biolink:PhenotypicFeature",
+              "biolink:ThingWithTaxon"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-              "name": "helminthiasis",
-              "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005974",
+              "name": "strongyloidiasis",
+              "description": "An infection that is caused by nematodes of the genus Strongyloides, most commonly Strongyloides stercoralis, which is a soil-transmitted helminth, and which is characterized by a variety of gastrointestinal, dermatologic, and, occasionally, pulmonary manifestations. The worm's autoinfective life cycle can lead to hyper-infection and life-threatening dissemination in immunocompromised hosts decades after initial infection.; Infection with nematodes of the genus STRONGYLOIDES. The presence of larvae may produce pneumonitis and the presence of adult worms in the intestine could lead to moderate to severe diarrhea.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "MESH:D006373",
-                "MONDO:0004664",
-                "MEDDRA:10061201",
-                "ICD10:B83.9",
-                "MEDDRA:10019380",
-                "MEDDRA:10019382",
-                "DOID:883",
-                "UMLS:C0018889",
-                "NCIT:C84751",
-                "SNOMEDCT:27601005",
-                "EFO:1001342",
-                "ICD9:120-129.99"
+                "UMLS:C0348996",
+                "UMLS:C0085810",
+                "MEDDRA:10080496",
+                "ORPHANET:76",
+                "ICD10:B78",
+                "ICD9:127.2",
+                "MESH:D013322",
+                "UMLS:C0038463",
+                "SNOMEDCT:187176005",
+                "EFO:0007501",
+                "MEDDRA:10042254",
+                "MONDO:0005974",
+                "SNOMEDCT:1214006",
+                "NCIT:C128398",
+                "DOID:10955"
               ],
-              "id": "MONDO:0004664",
+              "id": "MONDO:0005974",
               "category": "biolink:Disease",
               "all_names": [
-                "parasitic helminthiasis infectious disease",
-                "Helminthiasis",
-                "Helminthiases",
-                "helminthiasis"
+                "Strongyloidiasis",
+                "Anguilluliasis",
+                "strongyloidiasis"
               ],
               "all_categories": [
                 "biolink:Disease"
               ],
               "publications": [
-                "http://en.wikipedia.org/wiki/helminth",
-                "http://en.wikipedia.org/wiki/helminthiasis"
+                "http://www.dpd.cdc.gov/dpdx/html/strongyloidiasis.htm",
+                "http://en.wikipedia.org/wiki/strongyloidiasis"
               ]
             }
           },
           "relationship": {
-            "identity": 23972720,
-            "start": 546,
-            "end": 526500,
-            "type": "biolink:treats",
+            "identity": 25381927,
+            "start": 549,
+            "end": 529459,
+            "type": "biolink:related_to",
             "properties": {
-              "predicate": "biolink:treats",
+              "predicate": "biolink:related_to",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35431079': {'publication date': '2022 May', 'sentence': 'This study investigated worm control practices by free-range egg farmers and the efficacy of the commercial anthelmintics levamisole (LEV), piperazine (PIP), flubendazole (FLBZ) and fenbendazole (FBZ) against gastrointestinal nematodes on two free-range layer farms in Australia.', 'subject score': 1000, 'object score': 802}, 'PMID:7056663': {'publication date': '1982 Jan 01', 'sentence': 'Evaluation of granulated fenbendazole as a treatment for helminth infections in dogs.', 'subject score': 861, 'object score': 983}}",
+              "publications_info": "{'PMID:4677288': {'publication date': '1972 Jul', 'sentence': '[Test of thiabendazole and chlorophos in equine strongyloidiasis].', 'subject score': 1000, 'object score': 888}}",
               "kg2_ids": [
-                "UMLS:C0015821---SEMMEDDB:treats---None---None---None---UMLS:C0018889---SEMMEDDB:"
+                "UMLS:C0039832---SEMMEDDB:associated_with---None---None---None---UMLS:C0038463---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:3334",
-              "id": "24413653",
-              "object": "MONDO:0004664",
+              "subject": "PUBCHEM.COMPOUND:5430",
+              "id": "25835444",
+              "object": "MONDO:0005974",
               "publications": [
-                "PMID:35431079",
-                "PMID:7056663"
+                "PMID:4677288"
               ]
             }
           },
           "end": {
-            "identity": 546,
+            "identity": 549,
             "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
               "biolink:ChemicalMixture",
-              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
+              "biolink:Drug",
+              "biolink:MolecularEntity",
+              "biolink:MolecularMixture",
               "biolink:NamedThing",
+              "biolink:OntologyClass",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:SmallMolecule"
             ],
             "properties": {
-              "name": "Fenbendazole",
-              "description": "Veterinary anthelmintic. Fenbendazole is a fda approved for use in cattle, pigs and goats Fenbendazole (Hoechst brand names Panacur and Safe-Guard, Intervet Panacur and Panacur Rabbit) is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites including roundworms, hookworms, whipworms, the taenia species of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles and strongyloides and can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. Drug interactions may occur if using bromsalan flukicides (Dibromsalan, Tribromsalan). Abortions in cattle and death in sheep have been reported after using these medications together. (Plumb's Veterinary Drug Handbook, Fifth Edition. 2005",
+              "name": "Thiabendazole",
+              "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "INCHIKEY:HDDSHPAODJUKPD-UHFFFAOYSA-N",
-                "MESH:D005273",
-                "CAS:43210-67-9",
-                "DrugCentral:4536",
-                "KEGG.DRUG:D04140",
-                "UMLS:C0015821",
-                "NDDF:013514",
-                "CHEBI:77092",
-                "HMDB:HMDB0029745",
-                "PUBCHEM.COMPOUND:3334",
-                "NCIT:C75218",
-                "DRUGBANK:DB11410",
-                "RXNORM:4325",
-                "UNII:621BVT9M36",
-                "ATC:P02CA06",
-                "CHEMBL.COMPOUND:CHEMBL37161"
+                "MESH:D013827",
+                "DrugCentral:2621",
+                "CAS:148-79-8",
+                "NDDF:002985",
+                "CHEMBL.COMPOUND:CHEMBL625",
+                "PDQ:CDR0000039713",
+                "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+                "KEGG.DRUG:D00372",
+                "RXNORM:10450",
+                "CHEBI:45979",
+                "UNII:N1Q45E87DT",
+                "PUBCHEM.COMPOUND:5430",
+                "KEGG.COMPOUND:C07131",
+                "DRUGBANK:DB00730",
+                "UMLS:C0039832",
+                "HMDB:HMDB0014868",
+                "CAS:98002-42-7",
+                "NCIT:C873",
+                "GTOPDB:7304"
               ],
-              "id": "PUBCHEM.COMPOUND:3334",
+              "id": "PUBCHEM.COMPOUND:5430",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "Fenbendazole (USP/INN)",
-                "phenbendasol",
-                "Fenbendazole",
-                "FENBENDAZOLE",
-                "fenbendazole"
+                "thiabendazole",
+                "THIABENDAZOLE",
+                "Thiabendazole (USP)",
+                "bovizole",
+                "Thiabendazole"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
+                "biolink:Drug",
+                "biolink:ChemicalEntity"
               ],
               "publications": [
-                "PMID:7010692",
-                "PMID:3605812",
+                "PMID:20014752",
+                "PMID:15646539",
+                "PMID:18400497",
                 "PMID:23571415",
-                "PMID:7277372",
+                "PMID:34954591",
+                "PMID:23241029",
+                "PMID:23634668",
+                "PMID:10978195",
                 "PMID:16420038",
-                "PMID:22464423",
-                "PMID:7271033",
-                "PMID:738790",
-                "PMID:20966043",
-                "PMID:2287030"
+                "PMID:18973341"
               ]
             }
           }
@@ -544,16 +494,9 @@
     }
   },
   {
-<<<<<<< HEAD
     "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:33249304': {'publication date': '2020 Nov 13', 'sentence': 'Fenbendazole resistance in O. ostertagi was confirmed with a total treatment failure in reducing worm burden: efficacy of 0%.', 'subject score': 888, 'object score': 851}}",
-    "p2": {
->>>>>>> main
       "start": {
-        "identity": 526500,
+        "identity": 508253,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -563,42 +506,41 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-          "name": "helminthiasis",
-          "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0019444",
+          "name": "trichinellosis",
+          "description": "A parasitic infection caused by larvae of worms of the genus Trichinella. It is transmitted to humans by ingesting raw or undercooked meat from infected animals. Signs and symptoms include abdominal discomfort, nausea, vomiting, fever, diarrhea, headache, coughing, myalgias, arthralgias, and eye swelling.; An infection with TRICHINELLA. It is caused by eating raw or undercooked meat that is infected with larvae of nematode worms TRICHINELLA genus. All members of the TRICHINELLA genus can infect human in addition to TRICHINELLA SPIRALIS, the traditional etiological agent. It is distributed throughout much of the world and is re-emerging in some parts as a public health hazard and a food safety problem.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "MESH:D006373",
-            "MONDO:0004664",
-            "MEDDRA:10061201",
-            "ICD10:B83.9",
-            "MEDDRA:10019380",
-            "MEDDRA:10019382",
-            "DOID:883",
-            "UMLS:C0018889",
-            "NCIT:C84751",
-            "SNOMEDCT:27601005",
-            "EFO:1001342",
-            "ICD9:120-129.99"
+            "UMLS:C0040896",
+            "EFO:0007520",
+            "SNOMEDCT:709018004",
+            "DOID:9784",
+            "MONDO:0019444",
+            "NCIT:C85199",
+            "ORPHANET:863",
+            "ICD9:124",
+            "MESH:D014235",
+            "MEDDRA:10044608",
+            "ICD10:B75",
+            "MEDDRA:10044609"
           ],
-          "id": "MONDO:0004664",
+          "id": "MONDO:0019444",
           "category": "biolink:Disease",
           "all_names": [
-            "parasitic helminthiasis infectious disease",
-            "Helminthiasis",
-            "Helminthiases",
-            "helminthiasis"
+            "trichinellosis",
+            "Trichinosis",
+            "Trichinellosis",
+            "trichinosis"
           ],
           "all_categories": [
             "biolink:Disease"
           ],
           "publications": [
-            "http://en.wikipedia.org/wiki/helminth",
-            "http://en.wikipedia.org/wiki/helminthiasis"
+            "http://www.dpd.cdc.gov/dpdx/html/trichinellosis.htm"
           ]
         }
       },
       "end": {
-        "identity": 546,
+        "identity": 549,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -615,124 +557,126 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Fenbendazole",
-          "description": "Veterinary anthelmintic. Fenbendazole is a fda approved for use in cattle, pigs and goats Fenbendazole (Hoechst brand names Panacur and Safe-Guard, Intervet Panacur and Panacur Rabbit) is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites including roundworms, hookworms, whipworms, the taenia species of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles and strongyloides and can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. Drug interactions may occur if using bromsalan flukicides (Dibromsalan, Tribromsalan). Abortions in cattle and death in sheep have been reported after using these medications together. (Plumb's Veterinary Drug Handbook, Fifth Edition. 2005",
+          "name": "Thiabendazole",
+          "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "INCHIKEY:HDDSHPAODJUKPD-UHFFFAOYSA-N",
-            "MESH:D005273",
-            "CAS:43210-67-9",
-            "DrugCentral:4536",
-            "KEGG.DRUG:D04140",
-            "UMLS:C0015821",
-            "NDDF:013514",
-            "CHEBI:77092",
-            "HMDB:HMDB0029745",
-            "PUBCHEM.COMPOUND:3334",
-            "NCIT:C75218",
-            "DRUGBANK:DB11410",
-            "RXNORM:4325",
-            "UNII:621BVT9M36",
-            "ATC:P02CA06",
-            "CHEMBL.COMPOUND:CHEMBL37161"
+            "MESH:D013827",
+            "DrugCentral:2621",
+            "CAS:148-79-8",
+            "NDDF:002985",
+            "CHEMBL.COMPOUND:CHEMBL625",
+            "PDQ:CDR0000039713",
+            "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+            "KEGG.DRUG:D00372",
+            "RXNORM:10450",
+            "CHEBI:45979",
+            "UNII:N1Q45E87DT",
+            "PUBCHEM.COMPOUND:5430",
+            "KEGG.COMPOUND:C07131",
+            "DRUGBANK:DB00730",
+            "UMLS:C0039832",
+            "HMDB:HMDB0014868",
+            "CAS:98002-42-7",
+            "NCIT:C873",
+            "GTOPDB:7304"
           ],
-          "id": "PUBCHEM.COMPOUND:3334",
+          "id": "PUBCHEM.COMPOUND:5430",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "Fenbendazole (USP/INN)",
-            "phenbendasol",
-            "Fenbendazole",
-            "FENBENDAZOLE",
-            "fenbendazole"
+            "thiabendazole",
+            "THIABENDAZOLE",
+            "Thiabendazole (USP)",
+            "bovizole",
+            "Thiabendazole"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
+            "biolink:Drug",
+            "biolink:ChemicalEntity"
           ],
           "publications": [
-            "PMID:7010692",
-            "PMID:3605812",
+            "PMID:20014752",
+            "PMID:15646539",
+            "PMID:18400497",
             "PMID:23571415",
-            "PMID:7277372",
+            "PMID:34954591",
+            "PMID:23241029",
+            "PMID:23634668",
+            "PMID:10978195",
             "PMID:16420038",
-            "PMID:22464423",
-            "PMID:7271033",
-            "PMID:738790",
-            "PMID:20966043",
-            "PMID:2287030"
+            "PMID:18973341"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 526500,
+            "identity": 508253,
             "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:NamedThing",
+              "biolink:PhenotypicFeature",
+              "biolink:ThingWithTaxon"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-              "name": "helminthiasis",
-              "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0019444",
+              "name": "trichinellosis",
+              "description": "A parasitic infection caused by larvae of worms of the genus Trichinella. It is transmitted to humans by ingesting raw or undercooked meat from infected animals. Signs and symptoms include abdominal discomfort, nausea, vomiting, fever, diarrhea, headache, coughing, myalgias, arthralgias, and eye swelling.; An infection with TRICHINELLA. It is caused by eating raw or undercooked meat that is infected with larvae of nematode worms TRICHINELLA genus. All members of the TRICHINELLA genus can infect human in addition to TRICHINELLA SPIRALIS, the traditional etiological agent. It is distributed throughout much of the world and is re-emerging in some parts as a public health hazard and a food safety problem.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "MESH:D006373",
-                "MONDO:0004664",
-                "MEDDRA:10061201",
-                "ICD10:B83.9",
-                "MEDDRA:10019380",
-                "MEDDRA:10019382",
-                "DOID:883",
-                "UMLS:C0018889",
-                "NCIT:C84751",
-                "SNOMEDCT:27601005",
-                "EFO:1001342",
-                "ICD9:120-129.99"
+                "UMLS:C0040896",
+                "EFO:0007520",
+                "SNOMEDCT:709018004",
+                "DOID:9784",
+                "MONDO:0019444",
+                "NCIT:C85199",
+                "ORPHANET:863",
+                "ICD9:124",
+                "MESH:D014235",
+                "MEDDRA:10044608",
+                "ICD10:B75",
+                "MEDDRA:10044609"
               ],
-              "id": "MONDO:0004664",
+              "id": "MONDO:0019444",
               "category": "biolink:Disease",
               "all_names": [
-                "parasitic helminthiasis infectious disease",
-                "Helminthiasis",
-                "Helminthiases",
-                "helminthiasis"
+                "trichinellosis",
+                "Trichinosis",
+                "Trichinellosis",
+                "trichinosis"
               ],
               "all_categories": [
                 "biolink:Disease"
               ],
               "publications": [
-                "http://en.wikipedia.org/wiki/helminth",
-                "http://en.wikipedia.org/wiki/helminthiasis"
+                "http://www.dpd.cdc.gov/dpdx/html/trichinellosis.htm"
               ]
             }
           },
           "relationship": {
-            "identity": 22335831,
-            "start": 546,
-            "end": 526500,
-            "type": "biolink:prevents",
+            "identity": 10410839,
+            "start": 549,
+            "end": 508253,
+            "type": "biolink:affects",
             "properties": {
-              "predicate": "biolink:prevents",
+              "predicate": "biolink:affects",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:33249304': {'publication date': '2020 Nov 13', 'sentence': 'Fenbendazole resistance in O. ostertagi was confirmed with a total treatment failure in reducing worm burden: efficacy of 0%.', 'subject score': 888, 'object score': 851}}",
+              "publications_info": "{'PMID:13876068': {'publication date': '1962 May', 'sentence': 'Effect of thiabendazole upon experimental trichinosis in swine.', 'subject score': 1000, 'object score': 888}}",
               "kg2_ids": [
-                "UMLS:C0015821---SEMMEDDB:prevents---None---None---None---UMLS:C0018889---SEMMEDDB:"
+                "UMLS:C0039832---SEMMEDDB:affects---None---None---None---UMLS:C0040896---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:3334",
-              "id": "22762728",
-              "object": "MONDO:0004664",
+              "subject": "PUBCHEM.COMPOUND:5430",
+              "id": "10639866",
+              "object": "MONDO:0019444",
               "publications": [
-                "PMID:33249304"
+                "PMID:13876068"
               ]
             }
           },
           "end": {
-            "identity": 546,
+            "identity": 549,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -749,51 +693,54 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Fenbendazole",
-              "description": "Veterinary anthelmintic. Fenbendazole is a fda approved for use in cattle, pigs and goats Fenbendazole (Hoechst brand names Panacur and Safe-Guard, Intervet Panacur and Panacur Rabbit) is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites including roundworms, hookworms, whipworms, the taenia species of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles and strongyloides and can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. Drug interactions may occur if using bromsalan flukicides (Dibromsalan, Tribromsalan). Abortions in cattle and death in sheep have been reported after using these medications together. (Plumb's Veterinary Drug Handbook, Fifth Edition. 2005",
+              "name": "Thiabendazole",
+              "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "INCHIKEY:HDDSHPAODJUKPD-UHFFFAOYSA-N",
-                "MESH:D005273",
-                "CAS:43210-67-9",
-                "DrugCentral:4536",
-                "KEGG.DRUG:D04140",
-                "UMLS:C0015821",
-                "NDDF:013514",
-                "CHEBI:77092",
-                "HMDB:HMDB0029745",
-                "PUBCHEM.COMPOUND:3334",
-                "NCIT:C75218",
-                "DRUGBANK:DB11410",
-                "RXNORM:4325",
-                "UNII:621BVT9M36",
-                "ATC:P02CA06",
-                "CHEMBL.COMPOUND:CHEMBL37161"
+                "MESH:D013827",
+                "DrugCentral:2621",
+                "CAS:148-79-8",
+                "NDDF:002985",
+                "CHEMBL.COMPOUND:CHEMBL625",
+                "PDQ:CDR0000039713",
+                "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+                "KEGG.DRUG:D00372",
+                "RXNORM:10450",
+                "CHEBI:45979",
+                "UNII:N1Q45E87DT",
+                "PUBCHEM.COMPOUND:5430",
+                "KEGG.COMPOUND:C07131",
+                "DRUGBANK:DB00730",
+                "UMLS:C0039832",
+                "HMDB:HMDB0014868",
+                "CAS:98002-42-7",
+                "NCIT:C873",
+                "GTOPDB:7304"
               ],
-              "id": "PUBCHEM.COMPOUND:3334",
+              "id": "PUBCHEM.COMPOUND:5430",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "Fenbendazole (USP/INN)",
-                "phenbendasol",
-                "Fenbendazole",
-                "FENBENDAZOLE",
-                "fenbendazole"
+                "thiabendazole",
+                "THIABENDAZOLE",
+                "Thiabendazole (USP)",
+                "bovizole",
+                "Thiabendazole"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
+                "biolink:Drug",
+                "biolink:ChemicalEntity"
               ],
               "publications": [
-                "PMID:7010692",
-                "PMID:3605812",
+                "PMID:20014752",
+                "PMID:15646539",
+                "PMID:18400497",
                 "PMID:23571415",
-                "PMID:7277372",
+                "PMID:34954591",
+                "PMID:23241029",
+                "PMID:23634668",
+                "PMID:10978195",
                 "PMID:16420038",
-                "PMID:22464423",
-                "PMID:7271033",
-                "PMID:738790",
-                "PMID:20966043",
-                "PMID:2287030"
+                "PMID:18973341"
               ]
             }
           }
@@ -803,16 +750,9 @@
     }
   },
   {
-<<<<<<< HEAD
     "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1228996': {'publication date': '1975', 'sentence': '[The treatment of helminthiasis with thiabendazole].', 'subject score': 1000, 'object score': 1000}, 'PMID:14331459': {'publication date': '1965 Jun 12', 'sentence': 'CONTINUOUS LOW-LEVEL FEEDING OF THIABENDAZOLE TO CONTROL HELMINTHIASIS IN LAMBS.', 'subject score': 1000, 'object score': 1000}, 'PMID:4861935': {'publication date': '1966 Mar', 'sentence': 'The therapeutic efficacy of thiabendazole for helminthic infections in man; a literature review.', 'subject score': 1000, 'object score': 983}, 'PMID:5166711': {'publication date': '1971 Jun', 'sentence': '[Effectiveness of nilverm and thiabendazole in swine helminthiases].', 'subject score': 1000, 'object score': 888}, 'PMID:5668360': {'publication date': '1968 Jan 01', 'sentence': 'Clinical trials with thiabendazole in intestinal helminthic infestations in children.', 'subject score': 1000, 'object score': 853}, 'PMID:5927742': {'publication date': '1966 Sep', 'sentence': 'Trial of thiabendazole in multiple helminthic infestations.', 'subject score': 1000, 'object score': 853}, 'PMID:832897': {'publication date': '1977 Jan', 'sentence': 'Rats reinfected after removal of the worms of the initial infection by thiabendazole treatment showed an anamnestic response characterized by (i) elevated enzyme values in both the lungs and brain at 1 day after reinfection and (ii) eosinophilia in the bone marrow by day 4.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
       "start": {
-        "identity": 526500,
+        "identity": 529450,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -822,37 +762,29 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-          "name": "helminthiasis",
-          "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0001532",
+          "name": "capillariasis",
+          "description": "A parasitic helminthiasis infectious disease that involves infection of the intestine, liver and lungs caused by Capillaria species.",
           "equivalent_curies": [
-            "MESH:D006373",
-            "MONDO:0004664",
-            "MEDDRA:10061201",
-            "ICD10:B83.9",
-            "MEDDRA:10019380",
-            "MEDDRA:10019382",
-            "DOID:883",
-            "UMLS:C0018889",
-            "NCIT:C84751",
-            "SNOMEDCT:27601005",
-            "EFO:1001342",
-            "ICD9:120-129.99"
+            "ICD10:B81.1",
+            "DOID:12474",
+            "MEDDRA:10007187",
+            "ICD9:127.5",
+            "SNOMEDCT:52979002",
+            "UMLS:C0006897",
+            "MONDO:0001532"
           ],
-          "id": "MONDO:0004664",
+          "id": "MONDO:0001532",
           "category": "biolink:Disease",
           "all_names": [
-            "parasitic helminthiasis infectious disease",
-            "Helminthiasis",
-            "Helminthiases",
-            "helminthiasis"
+            "capillariasis",
+            "Capillariasis"
           ],
           "all_categories": [
             "biolink:Disease"
           ],
           "publications": [
-            "http://en.wikipedia.org/wiki/helminth",
-            "http://en.wikipedia.org/wiki/helminthiasis"
+            "https://en.wikipedia.org/wiki/capillariasis"
           ]
         }
       },
@@ -928,95 +860,66 @@
       "segments": [
         {
           "start": {
-            "identity": 526500,
+            "identity": 529450,
             "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:NamedThing",
+              "biolink:PhenotypicFeature",
+              "biolink:ThingWithTaxon"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-              "name": "helminthiasis",
-              "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0001532",
+              "name": "capillariasis",
+              "description": "A parasitic helminthiasis infectious disease that involves infection of the intestine, liver and lungs caused by Capillaria species.",
               "equivalent_curies": [
-                "MESH:D006373",
-                "MONDO:0004664",
-                "MEDDRA:10061201",
-                "ICD10:B83.9",
-                "MEDDRA:10019380",
-                "MEDDRA:10019382",
-                "DOID:883",
-                "UMLS:C0018889",
-                "NCIT:C84751",
-                "SNOMEDCT:27601005",
-                "EFO:1001342",
-                "ICD9:120-129.99"
+                "ICD10:B81.1",
+                "DOID:12474",
+                "MEDDRA:10007187",
+                "ICD9:127.5",
+                "SNOMEDCT:52979002",
+                "UMLS:C0006897",
+                "MONDO:0001532"
               ],
-              "id": "MONDO:0004664",
+              "id": "MONDO:0001532",
               "category": "biolink:Disease",
               "all_names": [
-                "parasitic helminthiasis infectious disease",
-                "Helminthiasis",
-                "Helminthiases",
-                "helminthiasis"
+                "capillariasis",
+                "Capillariasis"
               ],
               "all_categories": [
                 "biolink:Disease"
               ],
               "publications": [
-                "http://en.wikipedia.org/wiki/helminth",
-                "http://en.wikipedia.org/wiki/helminthiasis"
+                "https://en.wikipedia.org/wiki/capillariasis"
               ]
             }
           },
           "relationship": {
-            "identity": 9572211,
+            "identity": 26997583,
             "start": 549,
-            "end": 526500,
+            "end": 529450,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1228996': {'publication date': '1975', 'sentence': '[The treatment of helminthiasis with thiabendazole].', 'subject score': 1000, 'object score': 1000}, 'PMID:14331459': {'publication date': '1965 Jun 12', 'sentence': 'CONTINUOUS LOW-LEVEL FEEDING OF THIABENDAZOLE TO CONTROL HELMINTHIASIS IN LAMBS.', 'subject score': 1000, 'object score': 1000}, 'PMID:4861935': {'publication date': '1966 Mar', 'sentence': 'The therapeutic efficacy of thiabendazole for helminthic infections in man; a literature review.', 'subject score': 1000, 'object score': 983}, 'PMID:5166711': {'publication date': '1971 Jun', 'sentence': '[Effectiveness of nilverm and thiabendazole in swine helminthiases].', 'subject score': 1000, 'object score': 888}, 'PMID:5668360': {'publication date': '1968 Jan 01', 'sentence': 'Clinical trials with thiabendazole in intestinal helminthic infestations in children.', 'subject score': 1000, 'object score': 853}, 'PMID:5927742': {'publication date': '1966 Sep', 'sentence': 'Trial of thiabendazole in multiple helminthic infestations.', 'subject score': 1000, 'object score': 853}, 'PMID:832897': {'publication date': '1977 Jan', 'sentence': 'Rats reinfected after removal of the worms of the initial infection by thiabendazole treatment showed an anamnestic response characterized by (i) elevated enzyme values in both the lungs and brain at 1 day after reinfection and (ii) eosinophilia in the bone marrow by day 4.', 'subject score': 888, 'object score': 1000}}",
+              "publications_info": "{'PMID:9355089': {'publication date': '1997 Oct', 'sentence': 'In contrast to thiabendazole, which is often reported in literature as treatment for cutaneous capillariasis, negative side effects were not observed with use of levamisole.', 'subject score': 1000, 'object score': 888}}",
               "kg2_ids": [
-                "UMLS:C0039832---SEMMEDDB:treats---None---None---None---UMLS:C0018889---SEMMEDDB:"
+                "UMLS:C0039832---SEMMEDDB:treats---None---None---None---UMLS:C0006897---SEMMEDDB:"
               ],
               "subject": "PUBCHEM.COMPOUND:5430",
-              "id": "9783282",
-              "object": "MONDO:0004664",
+              "id": "27469573",
+              "object": "MONDO:0001532",
               "publications": [
-                "PMID:1228996",
-                "PMID:14331459",
-                "PMID:4861935",
-                "PMID:5166711",
-                "PMID:5668360",
-                "PMID:5927742",
-                "PMID:832897"
+                "PMID:9355089"
               ]
             }
           },
           "end": {
             "identity": 549,
             "labels": [
-<<<<<<< HEAD
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-=======
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
@@ -1030,7 +933,6 @@
               "biolink:ChemicalEntityOrProteinOrPolypeptide",
               "biolink:MolecularMixture",
               "biolink:OntologyClass"
->>>>>>> main
             ],
             "properties": {
               "name": "Thiabendazole",
@@ -1090,10 +992,9 @@
     }
   },
   {
-<<<<<<< HEAD
     "p3": {
       "start": {
-        "identity": 526500,
+        "identity": 529449,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -1103,42 +1004,37 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-          "name": "helminthiasis",
-          "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005995",
+          "name": "trichostrongylosis",
+          "description": "Infestation with nematode worms of the genus TRICHOSTRONGYLUS. Man and animals become infected by swallowing larvae, usually with contaminated food or drink, although the larvae may penetrate human skin.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "MESH:D006373",
-            "MONDO:0004664",
-            "MEDDRA:10061201",
-            "ICD10:B83.9",
-            "MEDDRA:10019380",
-            "MEDDRA:10019382",
-            "DOID:883",
-            "UMLS:C0018889",
-            "NCIT:C84751",
-            "SNOMEDCT:27601005",
-            "EFO:1001342",
-            "ICD9:120-129.99"
+            "DOID:1254",
+            "ICD9:127.6",
+            "SNOMEDCT:33710003",
+            "MONDO:0005995",
+            "MEDDRA:10044627",
+            "ICD10:B81.2",
+            "UMLS:C0040948",
+            "MESH:D014253",
+            "EFO:0007523"
           ],
-          "id": "MONDO:0004664",
+          "id": "MONDO:0005995",
           "category": "biolink:Disease",
           "all_names": [
-            "parasitic helminthiasis infectious disease",
-            "Helminthiasis",
-            "Helminthiases",
-            "helminthiasis"
+            "Trichostrongylosis",
+            "Trichostrongyliasis",
+            "trichostrongylosis"
           ],
           "all_categories": [
             "biolink:Disease"
           ],
           "publications": [
-            "http://en.wikipedia.org/wiki/helminth",
-            "http://en.wikipedia.org/wiki/helminthiasis"
+            "http://www.dpd.cdc.gov/dpdx/html/trichostrongylosis.htm"
           ]
         }
       },
       "end": {
-        "identity": 551,
+        "identity": 549,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -1155,195 +1051,186 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Thiabendazole",
+          "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
+            "MESH:D013827",
+            "DrugCentral:2621",
+            "CAS:148-79-8",
+            "NDDF:002985",
+            "CHEMBL.COMPOUND:CHEMBL625",
+            "PDQ:CDR0000039713",
+            "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+            "KEGG.DRUG:D00372",
+            "RXNORM:10450",
+            "CHEBI:45979",
+            "UNII:N1Q45E87DT",
+            "PUBCHEM.COMPOUND:5430",
+            "KEGG.COMPOUND:C07131",
+            "DRUGBANK:DB00730",
+            "UMLS:C0039832",
+            "HMDB:HMDB0014868",
+            "CAS:98002-42-7",
+            "NCIT:C873",
+            "GTOPDB:7304"
           ],
-          "id": "PUBCHEM.COMPOUND:2082",
+          "id": "PUBCHEM.COMPOUND:5430",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
+            "thiabendazole",
+            "THIABENDAZOLE",
+            "Thiabendazole (USP)",
+            "bovizole",
+            "Thiabendazole"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
+            "biolink:Drug",
+            "biolink:ChemicalEntity"
           ],
           "publications": [
-            "PMID:28595066",
             "PMID:20014752",
             "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
+            "PMID:18400497",
             "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
+            "PMID:34954591",
+            "PMID:23241029",
+            "PMID:23634668",
+            "PMID:10978195",
+            "PMID:16420038",
+            "PMID:18973341"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 526500,
+            "identity": 529449,
             "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:NamedThing",
+              "biolink:PhenotypicFeature",
+              "biolink:ThingWithTaxon"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-              "name": "helminthiasis",
-              "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005995",
+              "name": "trichostrongylosis",
+              "description": "Infestation with nematode worms of the genus TRICHOSTRONGYLUS. Man and animals become infected by swallowing larvae, usually with contaminated food or drink, although the larvae may penetrate human skin.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "MESH:D006373",
-                "MONDO:0004664",
-                "MEDDRA:10061201",
-                "ICD10:B83.9",
-                "MEDDRA:10019380",
-                "MEDDRA:10019382",
-                "DOID:883",
-                "UMLS:C0018889",
-                "NCIT:C84751",
-                "SNOMEDCT:27601005",
-                "EFO:1001342",
-                "ICD9:120-129.99"
+                "DOID:1254",
+                "ICD9:127.6",
+                "SNOMEDCT:33710003",
+                "MONDO:0005995",
+                "MEDDRA:10044627",
+                "ICD10:B81.2",
+                "UMLS:C0040948",
+                "MESH:D014253",
+                "EFO:0007523"
               ],
-              "id": "MONDO:0004664",
+              "id": "MONDO:0005995",
               "category": "biolink:Disease",
               "all_names": [
-                "parasitic helminthiasis infectious disease",
-                "Helminthiasis",
-                "Helminthiases",
-                "helminthiasis"
+                "Trichostrongylosis",
+                "Trichostrongyliasis",
+                "trichostrongylosis"
               ],
               "all_categories": [
                 "biolink:Disease"
               ],
               "publications": [
-                "http://en.wikipedia.org/wiki/helminth",
-                "http://en.wikipedia.org/wiki/helminthiasis"
+                "http://www.dpd.cdc.gov/dpdx/html/trichostrongylosis.htm"
               ]
             }
           },
           "relationship": {
-            "identity": 21431097,
-            "start": 551,
-            "end": 526500,
-            "type": "biolink:causes",
+            "identity": 25503925,
+            "start": 549,
+            "end": 529449,
+            "type": "biolink:treats",
             "properties": {
-              "predicate": "biolink:causes",
+              "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32206366': {'publication date': '2020', 'sentence': 'Symptoms of perianal itching and visualization of visible motile worms persisted for 6 months despite being treated with multiple courses of albendazole causing a lot of frustration and distress to the caregivers.', 'subject score': 888, 'object score': 851}}",
+              "publications_info": "{'PMID:5896723': {'publication date': '1963 Jan 01', 'sentence': '[Trials for the treatment of trichostrongylosis in cattle with thiabendazole].', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:causes---None---None---None---UMLS:C0018889---SEMMEDDB:"
+                "UMLS:C0039832---SEMMEDDB:treats---None---None---None---UMLS:C0040948---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "21848143",
-              "object": "MONDO:0004664",
+              "subject": "PUBCHEM.COMPOUND:5430",
+              "id": "25958452",
+              "object": "MONDO:0005995",
               "publications": [
-                "PMID:32206366"
+                "PMID:5896723"
               ]
             }
           },
           "end": {
-            "identity": 551,
+            "identity": 549,
             "labels": [
-              "biolink:ChemicalEntity",
+              "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:MolecularEntity",
+              "biolink:ChemicalEntity",
               "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:OntologyClass",
               "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Thiabendazole",
+              "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
+                "MESH:D013827",
+                "DrugCentral:2621",
+                "CAS:148-79-8",
+                "NDDF:002985",
+                "CHEMBL.COMPOUND:CHEMBL625",
+                "PDQ:CDR0000039713",
+                "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+                "KEGG.DRUG:D00372",
+                "RXNORM:10450",
+                "CHEBI:45979",
+                "UNII:N1Q45E87DT",
+                "PUBCHEM.COMPOUND:5430",
+                "KEGG.COMPOUND:C07131",
+                "DRUGBANK:DB00730",
+                "UMLS:C0039832",
+                "HMDB:HMDB0014868",
+                "CAS:98002-42-7",
+                "NCIT:C873",
+                "GTOPDB:7304"
               ],
-              "id": "PUBCHEM.COMPOUND:2082",
+              "id": "PUBCHEM.COMPOUND:5430",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
+                "thiabendazole",
+                "THIABENDAZOLE",
+                "Thiabendazole (USP)",
+                "bovizole",
+                "Thiabendazole"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
+                "biolink:Drug",
+                "biolink:ChemicalEntity"
               ],
               "publications": [
-                "PMID:28595066",
                 "PMID:20014752",
                 "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
+                "PMID:18400497",
                 "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
+                "PMID:34954591",
+                "PMID:23241029",
+                "PMID:23634668",
+                "PMID:10978195",
+                "PMID:16420038",
+                "PMID:18973341"
               ]
             }
           }
@@ -1401,7 +1288,7 @@
         }
       },
       "end": {
-        "identity": 551,
+        "identity": 549,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -1418,56 +1305,54 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Thiabendazole",
+          "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
+            "MESH:D013827",
+            "DrugCentral:2621",
+            "CAS:148-79-8",
+            "NDDF:002985",
+            "CHEMBL.COMPOUND:CHEMBL625",
+            "PDQ:CDR0000039713",
+            "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+            "KEGG.DRUG:D00372",
+            "RXNORM:10450",
+            "CHEBI:45979",
+            "UNII:N1Q45E87DT",
+            "PUBCHEM.COMPOUND:5430",
+            "KEGG.COMPOUND:C07131",
+            "DRUGBANK:DB00730",
+            "UMLS:C0039832",
+            "HMDB:HMDB0014868",
+            "CAS:98002-42-7",
+            "NCIT:C873",
+            "GTOPDB:7304"
           ],
-          "id": "PUBCHEM.COMPOUND:2082",
+          "id": "PUBCHEM.COMPOUND:5430",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
+            "thiabendazole",
+            "THIABENDAZOLE",
+            "Thiabendazole (USP)",
+            "bovizole",
+            "Thiabendazole"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
+            "biolink:Drug",
+            "biolink:ChemicalEntity"
           ],
           "publications": [
-            "PMID:28595066",
             "PMID:20014752",
             "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
+            "PMID:18400497",
             "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
+            "PMID:34954591",
+            "PMID:23241029",
+            "PMID:23634668",
+            "PMID:10978195",
+            "PMID:16420038",
+            "PMID:18973341"
           ]
         }
       },
@@ -1520,28 +1405,30 @@
             }
           },
           "relationship": {
-            "identity": 25283845,
-            "start": 551,
+            "identity": 25383095,
+            "start": 549,
             "end": 529458,
-            "type": "biolink:affects",
+            "type": "biolink:treats",
             "properties": {
-              "predicate": "biolink:affects",
+              "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:4039128': {'publication date': '1985 Feb', 'sentence': 'Ovicidal effects of albendazole in human ascariasis, ancylostomiasis and trichuriasis.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:4687603': {'publication date': '1973 Feb', 'sentence': 'Treatment of whipworm infection with thiabendazole.', 'subject score': 1000, 'object score': 1000}, 'PMID:5301953': {'publication date': '1966 Nov', 'sentence': '[Further data on the effectiveness of the association of thiabendazole and pyrvinium pamoate in the treatment of trichocephaliasis].', 'subject score': 1000, 'object score': 1000}, 'PMID:5414796': {'publication date': '1970 Jan 19', 'sentence': '[Efficacy of thiabendazole in trichuriasis].', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:affects---None---None---None---UMLS:C0040954---SEMMEDDB:"
+                "UMLS:C0039832---SEMMEDDB:treats---None---None---None---UMLS:C0040954---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "25735916",
+              "subject": "PUBCHEM.COMPOUND:5430",
+              "id": "25836626",
               "object": "MONDO:0005996",
               "publications": [
-                "PMID:4039128"
+                "PMID:4687603",
+                "PMID:5301953",
+                "PMID:5414796"
               ]
             }
           },
           "end": {
-            "identity": 551,
+            "identity": 549,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -1558,56 +1445,54 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Thiabendazole",
+              "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
+                "MESH:D013827",
+                "DrugCentral:2621",
+                "CAS:148-79-8",
+                "NDDF:002985",
+                "CHEMBL.COMPOUND:CHEMBL625",
+                "PDQ:CDR0000039713",
+                "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+                "KEGG.DRUG:D00372",
+                "RXNORM:10450",
+                "CHEBI:45979",
+                "UNII:N1Q45E87DT",
+                "PUBCHEM.COMPOUND:5430",
+                "KEGG.COMPOUND:C07131",
+                "DRUGBANK:DB00730",
+                "UMLS:C0039832",
+                "HMDB:HMDB0014868",
+                "CAS:98002-42-7",
+                "NCIT:C873",
+                "GTOPDB:7304"
               ],
-              "id": "PUBCHEM.COMPOUND:2082",
+              "id": "PUBCHEM.COMPOUND:5430",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
+                "thiabendazole",
+                "THIABENDAZOLE",
+                "Thiabendazole (USP)",
+                "bovizole",
+                "Thiabendazole"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
+                "biolink:Drug",
+                "biolink:ChemicalEntity"
               ],
               "publications": [
-                "PMID:28595066",
                 "PMID:20014752",
                 "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
+                "PMID:18400497",
                 "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
+                "PMID:34954591",
+                "PMID:23241029",
+                "PMID:23634668",
+                "PMID:10978195",
+                "PMID:16420038",
+                "PMID:18973341"
               ]
             }
           }
@@ -1619,7 +1504,7 @@
   {
     "p3": {
       "start": {
-        "identity": 520825,
+        "identity": 508253,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -1629,46 +1514,41 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005761",
-          "name": "filarial elephantiasis",
-          "description": "A filariasis that is characterized by the thickening of the skin and underlying tissues, especially in the legs, male genitals and female breasts, caused by thread-like parasitic worms Wuchereria bancrofti, Brugia malayi or Brugia timori, which inhabit the lymphatics. These nematodes are transmitted by mosquitoes. Acute symptoms include fever, lymphadenitis, lymphangitis, funiculitis, and epididymitis. Chronic symptoms include abscesses, hyperkeratosis, polyarthritis, hydroceles, lymphedema, and elephantiasis.",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0019444",
+          "name": "trichinellosis",
+          "description": "A parasitic infection caused by larvae of worms of the genus Trichinella. It is transmitted to humans by ingesting raw or undercooked meat from infected animals. Signs and symptoms include abdominal discomfort, nausea, vomiting, fever, diarrhea, headache, coughing, myalgias, arthralgias, and eye swelling.; An infection with TRICHINELLA. It is caused by eating raw or undercooked meat that is infected with larvae of nematode worms TRICHINELLA genus. All members of the TRICHINELLA genus can infect human in addition to TRICHINELLA SPIRALIS, the traditional etiological agent. It is distributed throughout much of the world and is re-emerging in some parts as a public health hazard and a food safety problem.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "ORPHANET:2035",
-            "MONDO:0005761",
-            "DOID:12211",
-            "MEDDRA:10025229",
-            "UMLS:C0155217",
-            "SNOMEDCT:14100003",
-            "UMLS:C0013884",
-            "NCIT:C128360",
-            "ICD9:374.83",
-            "EFO:0007272",
-            "MEDDRA:10014473",
-            "SNOMEDCT:240820001",
-            "MEDDRA:10016675",
-            "MESH:D004605"
+            "UMLS:C0040896",
+            "EFO:0007520",
+            "SNOMEDCT:709018004",
+            "DOID:9784",
+            "MONDO:0019444",
+            "NCIT:C85199",
+            "ORPHANET:863",
+            "ICD9:124",
+            "MESH:D014235",
+            "MEDDRA:10044608",
+            "ICD10:B75",
+            "MEDDRA:10044609"
           ],
-          "id": "MONDO:0005761",
+          "id": "MONDO:0019444",
           "category": "biolink:Disease",
           "all_names": [
-            "Filarial Elephantiases",
-            "filarial elephantiasis",
-            "Elephantiasis, Filarial",
-            "Elephantiasis of eyelid",
-            "Lymphatic filariasis",
-            "Lymphatic Filariasis"
+            "trichinellosis",
+            "Trichinosis",
+            "Trichinellosis",
+            "trichinosis"
           ],
           "all_categories": [
             "biolink:Disease"
           ],
           "publications": [
-            "https://www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis",
-            "https://www.cdc.gov/parasites/lymphaticfilariasis/index.htm"
+            "http://www.dpd.cdc.gov/dpdx/html/trichinellosis.htm"
           ]
         }
       },
       "end": {
-        "identity": 551,
+        "identity": 549,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -1685,135 +1565,136 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Thiabendazole",
+          "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
+            "MESH:D013827",
+            "DrugCentral:2621",
+            "CAS:148-79-8",
+            "NDDF:002985",
+            "CHEMBL.COMPOUND:CHEMBL625",
+            "PDQ:CDR0000039713",
+            "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+            "KEGG.DRUG:D00372",
+            "RXNORM:10450",
+            "CHEBI:45979",
+            "UNII:N1Q45E87DT",
+            "PUBCHEM.COMPOUND:5430",
+            "KEGG.COMPOUND:C07131",
+            "DRUGBANK:DB00730",
+            "UMLS:C0039832",
+            "HMDB:HMDB0014868",
+            "CAS:98002-42-7",
+            "NCIT:C873",
+            "GTOPDB:7304"
           ],
-          "id": "PUBCHEM.COMPOUND:2082",
+          "id": "PUBCHEM.COMPOUND:5430",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
+            "thiabendazole",
+            "THIABENDAZOLE",
+            "Thiabendazole (USP)",
+            "bovizole",
+            "Thiabendazole"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
+            "biolink:Drug",
+            "biolink:ChemicalEntity"
           ],
           "publications": [
-            "PMID:28595066",
             "PMID:20014752",
             "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
+            "PMID:18400497",
             "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
+            "PMID:34954591",
+            "PMID:23241029",
+            "PMID:23634668",
+            "PMID:10978195",
+            "PMID:16420038",
+            "PMID:18973341"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 520825,
+            "identity": 508253,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005761",
-              "name": "filarial elephantiasis",
-              "description": "A filariasis that is characterized by the thickening of the skin and underlying tissues, especially in the legs, male genitals and female breasts, caused by thread-like parasitic worms Wuchereria bancrofti, Brugia malayi or Brugia timori, which inhabit the lymphatics. These nematodes are transmitted by mosquitoes. Acute symptoms include fever, lymphadenitis, lymphangitis, funiculitis, and epididymitis. Chronic symptoms include abscesses, hyperkeratosis, polyarthritis, hydroceles, lymphedema, and elephantiasis.",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0019444",
+              "name": "trichinellosis",
+              "description": "A parasitic infection caused by larvae of worms of the genus Trichinella. It is transmitted to humans by ingesting raw or undercooked meat from infected animals. Signs and symptoms include abdominal discomfort, nausea, vomiting, fever, diarrhea, headache, coughing, myalgias, arthralgias, and eye swelling.; An infection with TRICHINELLA. It is caused by eating raw or undercooked meat that is infected with larvae of nematode worms TRICHINELLA genus. All members of the TRICHINELLA genus can infect human in addition to TRICHINELLA SPIRALIS, the traditional etiological agent. It is distributed throughout much of the world and is re-emerging in some parts as a public health hazard and a food safety problem.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "ORPHANET:2035",
-                "MONDO:0005761",
-                "DOID:12211",
-                "MEDDRA:10025229",
-                "UMLS:C0155217",
-                "SNOMEDCT:14100003",
-                "UMLS:C0013884",
-                "NCIT:C128360",
-                "ICD9:374.83",
-                "EFO:0007272",
-                "MEDDRA:10014473",
-                "SNOMEDCT:240820001",
-                "MEDDRA:10016675",
-                "MESH:D004605"
+                "UMLS:C0040896",
+                "EFO:0007520",
+                "SNOMEDCT:709018004",
+                "DOID:9784",
+                "MONDO:0019444",
+                "NCIT:C85199",
+                "ORPHANET:863",
+                "ICD9:124",
+                "MESH:D014235",
+                "MEDDRA:10044608",
+                "ICD10:B75",
+                "MEDDRA:10044609"
               ],
-              "id": "MONDO:0005761",
+              "id": "MONDO:0019444",
               "category": "biolink:Disease",
               "all_names": [
-                "Filarial Elephantiases",
-                "filarial elephantiasis",
-                "Elephantiasis, Filarial",
-                "Elephantiasis of eyelid",
-                "Lymphatic filariasis",
-                "Lymphatic Filariasis"
+                "trichinellosis",
+                "Trichinosis",
+                "Trichinellosis",
+                "trichinosis"
               ],
               "all_categories": [
                 "biolink:Disease"
               ],
               "publications": [
-                "https://www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis",
-                "https://www.cdc.gov/parasites/lymphaticfilariasis/index.htm"
+                "http://www.dpd.cdc.gov/dpdx/html/trichinellosis.htm"
               ]
             }
           },
           "relationship": {
-            "identity": 24242252,
-            "start": 551,
-            "end": 520825,
-            "type": "biolink:affects",
+            "identity": 10476070,
+            "start": 549,
+            "end": 508253,
+            "type": "biolink:treats",
             "properties": {
-              "predicate": "biolink:affects",
+              "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35793325': {'publication date': '2022', 'sentence': 'A combination of drugs Ivermectin, Diethylcarbamazine citrate and Albendazole is recommended by WHO to accelerate the Global Programme to Eliminate Lymphatic Filariasis (GPELF).', 'subject score': 1000, 'object score': 752}}",
+              "publications_info": "{'PMID:14202837': {'publication date': '1964 Nov 30', 'sentence': 'TREATMENT OF TRICHINOSIS WITH THIABENDAZOLE.', 'subject score': 1000, 'object score': 1000}, 'PMID:32576934': {'publication date': '2020 Jun 23', 'sentence': 'Mebendazole and thiabendazole are the treatments of choice for trichinellosis; however, both drugs result in significant side effects and are less effective for muscle-stage larvae (L1).', 'subject score': 1000, 'object score': 1000}, 'PMID:4904597': {'publication date': '1969', 'sentence': 'Thiabendazole in human trichinellosis.', 'subject score': 1000, 'object score': 888}, 'PMID:4944473': {'publication date': '1971 Sep-Oct', 'sentence': '[Reduction of the anthelmintic activity of thiabendazole and ortho-chlorophenyl-benzimidazole (preparation G-572) in experimental trichinosis of white mice spontaneously infected with salmonellosis].', 'subject score': 1000, 'object score': 888}, 'PMID:5369623': {'publication date': '1969 Nov', 'sentence': 'Thiabendazole for the treatment of trichinosis in humans.', 'subject score': 1000, 'object score': 1000}, 'PMID:6003136': {'publication date': '1966 Jan-Feb', 'sentence': '[Search for specific therapy of trichinellosis. II. Thiabendazole in experimental trichinellosis in rats].', 'subject score': 802, 'object score': 888}, 'PMID:610720': {'publication date': '1977 Jul-Dec', 'sentence': \"[Clinical and anatomopathological investigation in the treatment of acute trichinosis with thiabendazole (author's transl)].\", 'subject score': 1000, 'object score': 888}, 'PMID:709727': {'publication date': '1978 Aug 25', 'sentence': \"[Clinical and therapeutical experience of trichinosis treated with thiabendazole and mebendazole (author's transl)].\", 'subject score': 1000, 'object score': 1000}, 'PMID:7135477': {'publication date': '1982 Sep', 'sentence': 'Observations on mebendazole vs. thiabendazole in the treatment of human trichinellosis.', 'subject score': 1000, 'object score': 888}, 'PMID:7355683': {'publication date': '1980 Mar', 'sentence': 'Anthelmintic drugs of choice include: mebendazole for roundworm, pinworm, whipworm and hookworm infections; niclosamide for tapeworm infections, and thiabendazole for trichinosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:8783705': {'publication date': '1996 Jun', 'sentence': 'The immediate efficacy of thiabendazole and albendazole as therapy for trichinosis was comparable, but albendazole was better tolerated.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0013884---SEMMEDDB:"
+                "UMLS:C0039832---SEMMEDDB:treats---None---None---None---UMLS:C0040896---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "24685635",
-              "object": "MONDO:0005761",
+              "subject": "PUBCHEM.COMPOUND:5430",
+              "id": "10705646",
+              "object": "MONDO:0019444",
               "publications": [
-                "PMID:35793325"
+                "PMID:14202837",
+                "PMID:32576934",
+                "PMID:4904597",
+                "PMID:4944473",
+                "PMID:5369623",
+                "PMID:6003136",
+                "PMID:610720",
+                "PMID:709727",
+                "PMID:7135477",
+                "PMID:7355683",
+                "PMID:8783705"
               ]
             }
           },
           "end": {
-            "identity": 551,
+            "identity": 549,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -1830,56 +1711,54 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Thiabendazole",
+              "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
+                "MESH:D013827",
+                "DrugCentral:2621",
+                "CAS:148-79-8",
+                "NDDF:002985",
+                "CHEMBL.COMPOUND:CHEMBL625",
+                "PDQ:CDR0000039713",
+                "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+                "KEGG.DRUG:D00372",
+                "RXNORM:10450",
+                "CHEBI:45979",
+                "UNII:N1Q45E87DT",
+                "PUBCHEM.COMPOUND:5430",
+                "KEGG.COMPOUND:C07131",
+                "DRUGBANK:DB00730",
+                "UMLS:C0039832",
+                "HMDB:HMDB0014868",
+                "CAS:98002-42-7",
+                "NCIT:C873",
+                "GTOPDB:7304"
+              ],
+              "id": "PUBCHEM.COMPOUND:5430",
+              "category": "biolink:SmallMolecule",
+              "all_names": [
+                "thiabendazole",
+                "THIABENDAZOLE",
+                "Thiabendazole (USP)",
+                "bovizole",
+                "Thiabendazole"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
+                "biolink:Drug",
+                "biolink:ChemicalEntity"
               ],
               "publications": [
-                "PMID:28595066",
                 "PMID:20014752",
                 "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
+                "PMID:18400497",
                 "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
+                "PMID:34954591",
+                "PMID:23241029",
+                "PMID:23634668",
+                "PMID:10978195",
+                "PMID:16420038",
+                "PMID:18973341"
               ]
             }
           }
@@ -1935,7 +1814,7 @@
         }
       },
       "end": {
-        "identity": 551,
+        "identity": 549,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -1952,56 +1831,54 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Thiabendazole",
+          "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
+            "MESH:D013827",
+            "DrugCentral:2621",
+            "CAS:148-79-8",
+            "NDDF:002985",
+            "CHEMBL.COMPOUND:CHEMBL625",
+            "PDQ:CDR0000039713",
+            "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+            "KEGG.DRUG:D00372",
+            "RXNORM:10450",
+            "CHEBI:45979",
+            "UNII:N1Q45E87DT",
+            "PUBCHEM.COMPOUND:5430",
+            "KEGG.COMPOUND:C07131",
+            "DRUGBANK:DB00730",
+            "UMLS:C0039832",
+            "HMDB:HMDB0014868",
+            "CAS:98002-42-7",
+            "NCIT:C873",
+            "GTOPDB:7304"
           ],
-          "id": "PUBCHEM.COMPOUND:2082",
+          "id": "PUBCHEM.COMPOUND:5430",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
+            "thiabendazole",
+            "THIABENDAZOLE",
+            "Thiabendazole (USP)",
+            "bovizole",
+            "Thiabendazole"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
+            "biolink:Drug",
+            "biolink:ChemicalEntity"
           ],
           "publications": [
-            "PMID:28595066",
             "PMID:20014752",
             "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
+            "PMID:18400497",
             "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
+            "PMID:34954591",
+            "PMID:23241029",
+            "PMID:23634668",
+            "PMID:10978195",
+            "PMID:16420038",
+            "PMID:18973341"
           ]
         }
       },
@@ -2052,28 +1929,30 @@
             }
           },
           "relationship": {
-            "identity": 18085378,
-            "start": 551,
+            "identity": 9895534,
+            "start": 549,
             "end": 517567,
-            "type": "biolink:affects",
+            "type": "biolink:treats",
             "properties": {
-              "predicate": "biolink:affects",
+              "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2619377': {'publication date': '1989 Dec', 'sentence': 'Effect of albendazole in experimental toxocariasis of mice.', 'subject score': 1000, 'object score': 888}}",
+              "publications_info": "{'PMID:12667232': {'publication date': '2003 Apr', 'sentence': 'The treatment of cutaneous larva migrans and Toxocara infection relies on antihelminthic agents such as thiabendazole, albendazole and ivermectin.', 'subject score': 1000, 'object score': 1000}, 'PMID:34370367': {'publication date': '2021 Aug 09', 'sentence': 'Thiabendazole seems to be a potential alternative for the treatment of human toxocariasis.', 'subject score': 1000, 'object score': 888}, 'PMID:3441897': {'publication date': '1987 Oct-Dec', 'sentence': '[Comparative efficacy of thiabendazole and mebendazole in the treatment of toxocariasis].', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:affects---None---None---None---UMLS:C0040553---SEMMEDDB:"
+                "UMLS:C0039832---SEMMEDDB:treats---None---None---None---UMLS:C0040553---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "18452252",
+              "subject": "PUBCHEM.COMPOUND:5430",
+              "id": "10114049",
               "object": "MONDO:0005988",
               "publications": [
-                "PMID:2619377"
+                "PMID:12667232",
+                "PMID:34370367",
+                "PMID:3441897"
               ]
             }
           },
           "end": {
-            "identity": 551,
+            "identity": 549,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -2090,56 +1969,54 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Thiabendazole",
+              "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
+                "MESH:D013827",
+                "DrugCentral:2621",
+                "CAS:148-79-8",
+                "NDDF:002985",
+                "CHEMBL.COMPOUND:CHEMBL625",
+                "PDQ:CDR0000039713",
+                "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+                "KEGG.DRUG:D00372",
+                "RXNORM:10450",
+                "CHEBI:45979",
+                "UNII:N1Q45E87DT",
+                "PUBCHEM.COMPOUND:5430",
+                "KEGG.COMPOUND:C07131",
+                "DRUGBANK:DB00730",
+                "UMLS:C0039832",
+                "HMDB:HMDB0014868",
+                "CAS:98002-42-7",
+                "NCIT:C873",
+                "GTOPDB:7304"
               ],
-              "id": "PUBCHEM.COMPOUND:2082",
+              "id": "PUBCHEM.COMPOUND:5430",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
+                "thiabendazole",
+                "THIABENDAZOLE",
+                "Thiabendazole (USP)",
+                "bovizole",
+                "Thiabendazole"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
+                "biolink:Drug",
+                "biolink:ChemicalEntity"
               ],
               "publications": [
-                "PMID:28595066",
                 "PMID:20014752",
                 "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
+                "PMID:18400497",
                 "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
+                "PMID:34954591",
+                "PMID:23241029",
+                "PMID:23634668",
+                "PMID:10978195",
+                "PMID:16420038",
+                "PMID:18973341"
               ]
             }
           }
@@ -2150,14 +2027,8 @@
   },
   {
     "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:23236367': {'publication date': '2012', 'sentence': 'Given the low helminth prevalence in our children, the effect of albendazole on malaria is likely to be direct.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
       "start": {
-        "identity": 506641,
+        "identity": 532245,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -2167,48 +2038,41 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005136",
-          "name": "malaria",
-          "description": "A protozoan infection caused by the genus Plasmodium. There are four species of Plasmodium that can infect humans: Plasmodium falciparum, vivax, ovale, and malariae. It is transmitted to humans by infected mosquitoes. Signs and symptoms include paroxysmal high fever, sweating, chills, and anemia.; A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.; Malaria is a serious disease caused by a parasite. You get it when an infected mosquito bites you. Malaria is a major cause of death worldwide, but it is almost wiped out in the United States. The disease is mostly a problem in developing countries with warm climates. If you travel to these countries, you are at risk. There are four different types of malaria caused by four related parasites. The most deadly type occurs in Africa south of the Sahara Desert. Malaria symptoms include chills, flu-like symptoms, fever, vomiting, diarrhea, and jaundice. A blood test can diagnose it. It can be life-threatening. However, you can treat malaria with drugs. The type of drug depends on which kind of malaria you have and where you were infected. Malaria can be prevented. When traveling to areas where malaria is found: See your doctor for medicines that protect you  Wear insect repellent with DEET  Cover up Sleep under mosquito netting   Centers for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0016472",
+          "name": "dracunculiasis",
+          "description": "A parasitic helminthiasis infectious disease that involves parasitic infection by the larvae of the nematode Dracunculus medinensis, which are transmitted to humans by drinking water containing copepods infected with the larvae. The female, which contains larvae, burrows into the deeper connective tissues or adjacent to long bones or joints of the extremities. The worm emerges as a whitish filament in the center of a painful ulcer, accompanied by inflammation and frequently by secondary bacterial infection.",
           "equivalent_curies": [
-            "MEDDRA:10067345",
-            "MEDDRA:10054147",
-            "MONDO:0005136",
-            "SNOMEDCT:248437004",
-            "SNOMEDCT:105649009",
-            "MEDDRA:10025487",
-            "PSY:29180",
-            "ICD10:B54",
-            "ORPHANET:673",
-            "MESH:D008288",
-            "NCIT:C34797",
-            "MEDDRA:10025489",
-            "ICD9:084",
-            "EFO:0001068",
-            "UMLS:C0024530",
-            "MEDDRA:10035499",
-            "DOID:12365",
-            "MEDDRA:10025497",
-            "SNOMEDCT:61462000"
+            "SNOMEDCT:396334002",
+            "UMLS:C0013100",
+            "ICD9:125.7",
+            "MEDDRA:10013617",
+            "DOID:14418",
+            "EFO:0007241",
+            "MONDO:0016472",
+            "MEDDRA:10013618",
+            "MESH:D004320",
+            "ORPHANET:231",
+            "ICD10:B72",
+            "NCIT:C84677"
           ],
-          "id": "MONDO:0005136",
+          "id": "MONDO:0016472",
           "category": "biolink:Disease",
           "all_names": [
-            "malaria",
-            "Malaria"
+            "Dracunculiasis",
+            "dracunculiasis",
+            "Dracontiasis"
           ],
           "all_categories": [
             "biolink:Disease"
           ],
           "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=malaria",
-            "https://rarediseases.info.nih.gov/diseases/6961/malaria",
-            "http://en.wikipedia.org/wiki/malaria"
+            "http://en.wikipedia.org/wiki/dracunculiasis",
+            "http://www.dpd.cdc.gov/dpdx/html/dracunculiasis.htm"
           ]
         }
       },
       "end": {
-        "identity": 551,
+        "identity": 549,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -2225,144 +2089,131 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Thiabendazole",
+          "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
+            "MESH:D013827",
+            "DrugCentral:2621",
+            "CAS:148-79-8",
+            "NDDF:002985",
+            "CHEMBL.COMPOUND:CHEMBL625",
+            "PDQ:CDR0000039713",
+            "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+            "KEGG.DRUG:D00372",
+            "RXNORM:10450",
+            "CHEBI:45979",
+            "UNII:N1Q45E87DT",
+            "PUBCHEM.COMPOUND:5430",
+            "KEGG.COMPOUND:C07131",
+            "DRUGBANK:DB00730",
+            "UMLS:C0039832",
+            "HMDB:HMDB0014868",
+            "CAS:98002-42-7",
+            "NCIT:C873",
+            "GTOPDB:7304"
           ],
-          "id": "PUBCHEM.COMPOUND:2082",
+          "id": "PUBCHEM.COMPOUND:5430",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
+            "thiabendazole",
+            "THIABENDAZOLE",
+            "Thiabendazole (USP)",
+            "bovizole",
+            "Thiabendazole"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
+            "biolink:Drug",
+            "biolink:ChemicalEntity"
           ],
           "publications": [
-            "PMID:28595066",
             "PMID:20014752",
             "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
+            "PMID:18400497",
             "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
+            "PMID:34954591",
+            "PMID:23241029",
+            "PMID:23634668",
+            "PMID:10978195",
+            "PMID:16420038",
+            "PMID:18973341"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 506641,
+            "identity": 532245,
             "labels": [
-<<<<<<< HEAD
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
               "biolink:NamedThing",
               "biolink:PhenotypicFeature",
               "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005136",
-              "name": "malaria",
-              "description": "A protozoan infection caused by the genus Plasmodium. There are four species of Plasmodium that can infect humans: Plasmodium falciparum, vivax, ovale, and malariae. It is transmitted to humans by infected mosquitoes. Signs and symptoms include paroxysmal high fever, sweating, chills, and anemia.; A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.; Malaria is a serious disease caused by a parasite. You get it when an infected mosquito bites you. Malaria is a major cause of death worldwide, but it is almost wiped out in the United States. The disease is mostly a problem in developing countries with warm climates. If you travel to these countries, you are at risk. There are four different types of malaria caused by four related parasites. The most deadly type occurs in Africa south of the Sahara Desert. Malaria symptoms include chills, flu-like symptoms, fever, vomiting, diarrhea, and jaundice. A blood test can diagnose it. It can be life-threatening. However, you can treat malaria with drugs. The type of drug depends on which kind of malaria you have and where you were infected. Malaria can be prevented. When traveling to areas where malaria is found: See your doctor for medicines that protect you  Wear insect repellent with DEET  Cover up Sleep under mosquito netting   Centers for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0016472",
+              "name": "dracunculiasis",
+              "description": "A parasitic helminthiasis infectious disease that involves parasitic infection by the larvae of the nematode Dracunculus medinensis, which are transmitted to humans by drinking water containing copepods infected with the larvae. The female, which contains larvae, burrows into the deeper connective tissues or adjacent to long bones or joints of the extremities. The worm emerges as a whitish filament in the center of a painful ulcer, accompanied by inflammation and frequently by secondary bacterial infection.",
               "equivalent_curies": [
-                "MEDDRA:10067345",
-                "MEDDRA:10054147",
-                "MONDO:0005136",
-                "SNOMEDCT:248437004",
-                "SNOMEDCT:105649009",
-                "MEDDRA:10025487",
-                "PSY:29180",
-                "ICD10:B54",
-                "ORPHANET:673",
-                "MESH:D008288",
-                "NCIT:C34797",
-                "MEDDRA:10025489",
-                "ICD9:084",
-                "EFO:0001068",
-                "UMLS:C0024530",
-                "MEDDRA:10035499",
-                "DOID:12365",
-                "MEDDRA:10025497",
-                "SNOMEDCT:61462000"
+                "SNOMEDCT:396334002",
+                "UMLS:C0013100",
+                "ICD9:125.7",
+                "MEDDRA:10013617",
+                "DOID:14418",
+                "EFO:0007241",
+                "MONDO:0016472",
+                "MEDDRA:10013618",
+                "MESH:D004320",
+                "ORPHANET:231",
+                "ICD10:B72",
+                "NCIT:C84677"
               ],
-              "id": "MONDO:0005136",
+              "id": "MONDO:0016472",
               "category": "biolink:Disease",
               "all_names": [
-                "malaria",
-                "Malaria"
+                "Dracunculiasis",
+                "dracunculiasis",
+                "Dracontiasis"
               ],
               "all_categories": [
                 "biolink:Disease"
               ],
               "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=malaria",
-                "https://rarediseases.info.nih.gov/diseases/6961/malaria",
-                "http://en.wikipedia.org/wiki/malaria"
+                "http://en.wikipedia.org/wiki/dracunculiasis",
+                "http://www.dpd.cdc.gov/dpdx/html/dracunculiasis.htm"
               ]
             }
           },
           "relationship": {
-            "identity": 16320189,
-            "start": 551,
-            "end": 506641,
-            "type": "biolink:affects",
+            "identity": 9785058,
+            "start": 549,
+            "end": 532245,
+            "type": "biolink:treats",
             "properties": {
-              "predicate": "biolink:affects",
+              "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23236367': {'publication date': '2012', 'sentence': 'Given the low helminth prevalence in our children, the effect of albendazole on malaria is likely to be direct.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:125551': {'publication date': '1975 May', 'sentence': 'In 1973 a field drug trial was conducted to compare effectiveness, cost, and side-effects of thiabendazole and metronidazole in treating active guinea worm disease and preventing latent worms from emerging.', 'subject score': 1000, 'object score': 875}, 'PMID:131118': {'publication date': '1975 Nov', 'sentence': 'Thiabendazole in the treatment of dracunculosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:147949': {'publication date': '1978 Feb-Mar', 'sentence': '400 cases of dracunculosis were treated with Thiabendazole and the results reported.', 'subject score': 1000, 'object score': 1000}, 'PMID:4243591': {'publication date': '1969 May-Jun', 'sentence': '[Effect of thiabendazole in dracunculosis].', 'subject score': 1000, 'object score': 1000}, 'PMID:4244200': {'publication date': '1969 Nov', 'sentence': 'Efficacy of thiabendazole in the treatment of dracunculiasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:6224469': {'publication date': '1983 Apr', 'sentence': 'Controlled comparative trial of thiabendazole and metronidazole in the treatment of dracontiasis.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:affects---None---None---None---UMLS:C0024530---SEMMEDDB:"
+                "UMLS:C0039832---SEMMEDDB:treats---None---None---None---UMLS:C0013100---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "16658505",
-              "object": "MONDO:0005136",
+              "subject": "PUBCHEM.COMPOUND:5430",
+              "id": "10001244",
+              "object": "MONDO:0016472",
               "publications": [
-                "PMID:23236367"
+                "PMID:125551",
+                "PMID:131118",
+                "PMID:147949",
+                "PMID:4243591",
+                "PMID:4244200",
+                "PMID:6224469"
               ]
             }
           },
           "end": {
-            "identity": 551,
+            "identity": 549,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -2379,56 +2230,54 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Thiabendazole",
+              "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
+                "MESH:D013827",
+                "DrugCentral:2621",
+                "CAS:148-79-8",
+                "NDDF:002985",
+                "CHEMBL.COMPOUND:CHEMBL625",
+                "PDQ:CDR0000039713",
+                "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+                "KEGG.DRUG:D00372",
+                "RXNORM:10450",
+                "CHEBI:45979",
+                "UNII:N1Q45E87DT",
+                "PUBCHEM.COMPOUND:5430",
+                "KEGG.COMPOUND:C07131",
+                "DRUGBANK:DB00730",
+                "UMLS:C0039832",
+                "HMDB:HMDB0014868",
+                "CAS:98002-42-7",
+                "NCIT:C873",
+                "GTOPDB:7304"
               ],
-              "id": "PUBCHEM.COMPOUND:2082",
+              "id": "PUBCHEM.COMPOUND:5430",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
+                "thiabendazole",
+                "THIABENDAZOLE",
+                "Thiabendazole (USP)",
+                "bovizole",
+                "Thiabendazole"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
+                "biolink:Drug",
+                "biolink:ChemicalEntity"
               ],
               "publications": [
-                "PMID:28595066",
                 "PMID:20014752",
                 "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
+                "PMID:18400497",
                 "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
+                "PMID:34954591",
+                "PMID:23241029",
+                "PMID:23634668",
+                "PMID:10978195",
+                "PMID:16420038",
+                "PMID:18973341"
               ]
             }
           }
@@ -2438,18 +2287,9 @@
     }
   },
   {
-<<<<<<< HEAD
     "p3": {
       "start": {
-        "identity": 526500,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:23236367': {'publication date': '2012', 'sentence': 'Quarterly albendazole during childhood was associated with reduced incidence of clinical malaria (HR 0.85 (95% CI 0.73-0.98), p = 0.03).', 'subject score': 888, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 506641,
->>>>>>> main
+        "identity": 939043,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -2459,80 +2299,33 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-          "name": "helminthiasis",
-          "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
-          "equivalent_curies": [
-            "MESH:D006373",
-            "MONDO:0004664",
-            "MEDDRA:10061201",
-            "ICD10:B83.9",
-            "MEDDRA:10019380",
-            "MEDDRA:10019382",
-            "DOID:883",
-            "UMLS:C0018889",
-            "NCIT:C84751",
-            "SNOMEDCT:27601005",
-            "EFO:1001342",
-            "ICD9:120-129.99"
-          ],
-          "id": "MONDO:0004664",
-          "category": "biolink:Disease",
-          "all_names": [
-            "parasitic helminthiasis infectious disease",
-            "Helminthiasis",
-            "Helminthiases",
-            "helminthiasis"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005136",
-          "name": "malaria",
-          "description": "A protozoan infection caused by the genus Plasmodium. There are four species of Plasmodium that can infect humans: Plasmodium falciparum, vivax, ovale, and malariae. It is transmitted to humans by infected mosquitoes. Signs and symptoms include paroxysmal high fever, sweating, chills, and anemia.; A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.; Malaria is a serious disease caused by a parasite. You get it when an infected mosquito bites you. Malaria is a major cause of death worldwide, but it is almost wiped out in the United States. The disease is mostly a problem in developing countries with warm climates. If you travel to these countries, you are at risk. There are four different types of malaria caused by four related parasites. The most deadly type occurs in Africa south of the Sahara Desert. Malaria symptoms include chills, flu-like symptoms, fever, vomiting, diarrhea, and jaundice. A blood test can diagnose it. It can be life-threatening. However, you can treat malaria with drugs. The type of drug depends on which kind of malaria you have and where you were infected. Malaria can be prevented. When traveling to areas where malaria is found: See your doctor for medicines that protect you  Wear insect repellent with DEET  Cover up Sleep under mosquito netting   Centers for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0018500",
+          "name": "cutaneous larva migrans",
+          "description": "Cutaneous larva migrans is a rare parasitic disease characterized by single or multiple, linear or serpinginous, erythematous, slightly elevated cutaneous tracks caused by the larval migration of various nematode species. Tracks are variable in length, generally a few millimeters wide and are frequently located on the feet (although any area of the body is possible). Patients typically present with severe, intractable pruritus, which, in some cases, may cause impaired concentration, loss of sleep, and mood disturbances.",
           "equivalent_curies": [
-            "MEDDRA:10067345",
-            "MEDDRA:10054147",
-            "MONDO:0005136",
-            "SNOMEDCT:248437004",
-            "SNOMEDCT:105649009",
-            "MEDDRA:10025487",
-            "PSY:29180",
-            "ICD10:B54",
-            "ORPHANET:673",
-            "MESH:D008288",
-            "NCIT:C34797",
-            "MEDDRA:10025489",
-            "ICD9:084",
-            "EFO:0001068",
-            "UMLS:C0024530",
-            "MEDDRA:10035499",
-            "DOID:12365",
-            "MEDDRA:10025497",
-            "SNOMEDCT:61462000"
+            "MEDDRA:10059547",
+            "SNOMEDCT:19362000",
+            "UMLS:C0023048",
+            "MESH:D007815",
+            "ORPHANET:423717",
+            "UMLS:C0546999",
+            "MONDO:0018500"
           ],
-          "id": "MONDO:0005136",
+          "id": "MONDO:0018500",
           "category": "biolink:Disease",
           "all_names": [
-            "malaria",
-            "Malaria"
->>>>>>> main
+            "Cutaneous larva migrans",
+            "Larva Migrans, Cutaneous",
+            "Larva Migrans",
+            "cutaneous larva migrans"
           ],
           "all_categories": [
             "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://en.wikipedia.org/wiki/helminth",
-            "http://en.wikipedia.org/wiki/helminthiasis"
-=======
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=malaria",
-            "https://rarediseases.info.nih.gov/diseases/6961/malaria",
-            "http://en.wikipedia.org/wiki/malaria"
->>>>>>> main
           ]
         }
       },
       "end": {
-        "identity": 551,
+        "identity": 549,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -2549,194 +2342,138 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Thiabendazole",
+          "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
+            "MESH:D013827",
+            "DrugCentral:2621",
+            "CAS:148-79-8",
+            "NDDF:002985",
+            "CHEMBL.COMPOUND:CHEMBL625",
+            "PDQ:CDR0000039713",
+            "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+            "KEGG.DRUG:D00372",
+            "RXNORM:10450",
+            "CHEBI:45979",
+            "UNII:N1Q45E87DT",
+            "PUBCHEM.COMPOUND:5430",
+            "KEGG.COMPOUND:C07131",
+            "DRUGBANK:DB00730",
+            "UMLS:C0039832",
+            "HMDB:HMDB0014868",
+            "CAS:98002-42-7",
+            "NCIT:C873",
+            "GTOPDB:7304"
           ],
-          "id": "PUBCHEM.COMPOUND:2082",
+          "id": "PUBCHEM.COMPOUND:5430",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
+            "thiabendazole",
+            "THIABENDAZOLE",
+            "Thiabendazole (USP)",
+            "bovizole",
+            "Thiabendazole"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
+            "biolink:Drug",
+            "biolink:ChemicalEntity"
           ],
           "publications": [
-            "PMID:28595066",
             "PMID:20014752",
             "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
+            "PMID:18400497",
             "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
+            "PMID:34954591",
+            "PMID:23241029",
+            "PMID:23634668",
+            "PMID:10978195",
+            "PMID:16420038",
+            "PMID:18973341"
           ]
         }
       },
       "segments": [
         {
           "start": {
-<<<<<<< HEAD
-            "identity": 526500,
-=======
-            "identity": 506641,
->>>>>>> main
+            "identity": 939043,
             "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:NamedThing",
+              "biolink:PhenotypicFeature",
+              "biolink:ThingWithTaxon"
             ],
             "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-              "name": "helminthiasis",
-              "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
-              "equivalent_curies": [
-                "MESH:D006373",
-                "MONDO:0004664",
-                "MEDDRA:10061201",
-                "ICD10:B83.9",
-                "MEDDRA:10019380",
-                "MEDDRA:10019382",
-                "DOID:883",
-                "UMLS:C0018889",
-                "NCIT:C84751",
-                "SNOMEDCT:27601005",
-                "EFO:1001342",
-                "ICD9:120-129.99"
-              ],
-              "id": "MONDO:0004664",
-              "category": "biolink:Disease",
-              "all_names": [
-                "parasitic helminthiasis infectious disease",
-                "Helminthiasis",
-                "Helminthiases",
-                "helminthiasis"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005136",
-              "name": "malaria",
-              "description": "A protozoan infection caused by the genus Plasmodium. There are four species of Plasmodium that can infect humans: Plasmodium falciparum, vivax, ovale, and malariae. It is transmitted to humans by infected mosquitoes. Signs and symptoms include paroxysmal high fever, sweating, chills, and anemia.; A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.; Malaria is a serious disease caused by a parasite. You get it when an infected mosquito bites you. Malaria is a major cause of death worldwide, but it is almost wiped out in the United States. The disease is mostly a problem in developing countries with warm climates. If you travel to these countries, you are at risk. There are four different types of malaria caused by four related parasites. The most deadly type occurs in Africa south of the Sahara Desert. Malaria symptoms include chills, flu-like symptoms, fever, vomiting, diarrhea, and jaundice. A blood test can diagnose it. It can be life-threatening. However, you can treat malaria with drugs. The type of drug depends on which kind of malaria you have and where you were infected. Malaria can be prevented. When traveling to areas where malaria is found: See your doctor for medicines that protect you  Wear insect repellent with DEET  Cover up Sleep under mosquito netting   Centers for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0018500",
+              "name": "cutaneous larva migrans",
+              "description": "Cutaneous larva migrans is a rare parasitic disease characterized by single or multiple, linear or serpinginous, erythematous, slightly elevated cutaneous tracks caused by the larval migration of various nematode species. Tracks are variable in length, generally a few millimeters wide and are frequently located on the feet (although any area of the body is possible). Patients typically present with severe, intractable pruritus, which, in some cases, may cause impaired concentration, loss of sleep, and mood disturbances.",
               "equivalent_curies": [
-                "MEDDRA:10067345",
-                "MEDDRA:10054147",
-                "MONDO:0005136",
-                "SNOMEDCT:248437004",
-                "SNOMEDCT:105649009",
-                "MEDDRA:10025487",
-                "PSY:29180",
-                "ICD10:B54",
-                "ORPHANET:673",
-                "MESH:D008288",
-                "NCIT:C34797",
-                "MEDDRA:10025489",
-                "ICD9:084",
-                "EFO:0001068",
-                "UMLS:C0024530",
-                "MEDDRA:10035499",
-                "DOID:12365",
-                "MEDDRA:10025497",
-                "SNOMEDCT:61462000"
+                "MEDDRA:10059547",
+                "SNOMEDCT:19362000",
+                "UMLS:C0023048",
+                "MESH:D007815",
+                "ORPHANET:423717",
+                "UMLS:C0546999",
+                "MONDO:0018500"
               ],
-              "id": "MONDO:0005136",
+              "id": "MONDO:0018500",
               "category": "biolink:Disease",
               "all_names": [
-                "malaria",
-                "Malaria"
->>>>>>> main
+                "Cutaneous larva migrans",
+                "Larva Migrans, Cutaneous",
+                "Larva Migrans",
+                "cutaneous larva migrans"
               ],
               "all_categories": [
                 "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://en.wikipedia.org/wiki/helminth",
-                "http://en.wikipedia.org/wiki/helminthiasis"
-=======
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=malaria",
-                "https://rarediseases.info.nih.gov/diseases/6961/malaria",
-                "http://en.wikipedia.org/wiki/malaria"
->>>>>>> main
               ]
             }
           },
           "relationship": {
-<<<<<<< HEAD
-            "identity": 13653912,
-            "start": 551,
-            "end": 526500,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18771788': {'publication date': '2009 Jan', 'sentence': 'Mass co-administration of ivermectin and albendazole by the LFEP had a significant effect on STH, which was further amplified by treatment with praziquantel and albendazole 4 months later.', 'subject score': 1000, 'object score': 802}, 'PMID:22728750': {'publication date': '2012 Jul 01', 'sentence': 'BACKGROUND: To investigate the effect of helminth infections and their treatment during pregnancy on HIV load, we conducted a 2 * 2 factorial randomized controlled trial of albendazole versus placebo and praziquantel versus placebo in pregnant women in Entebbe, Uganda.', 'subject score': 1000, 'object score': 983}, 'PMID:28372977': {'publication date': '2017 07', 'sentence': 'Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.', 'subject score': 1000, 'object score': 813}, 'PMID:34929673': {'publication date': '2021 Dec 20', 'sentence': 'Impact of Semi-Annual Albendazole on Lymphatic Filariasis and Soil-Transmitted Helminth Infection: Parasitological Assessment after 14 Rounds of Community Treatment.', 'subject score': 901, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:affects---None---None---None---UMLS:C0018889---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "13946207",
-              "object": "MONDO:0004664",
-              "publications": [
-                "PMID:18771788",
-                "PMID:22728750",
-                "PMID:28372977",
-                "PMID:34929673"
-=======
-            "identity": 16320187,
-            "start": 551,
-            "end": 506641,
-            "type": "biolink:disrupts",
+            "identity": 8636939,
+            "start": 549,
+            "end": 939043,
+            "type": "biolink:treats",
             "properties": {
-              "predicate": "biolink:disrupts",
+              "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23236367': {'publication date': '2012', 'sentence': 'Quarterly albendazole during childhood was associated with reduced incidence of clinical malaria (HR 0.85 (95% CI 0.73-0.98), p = 0.03).', 'subject score': 888, 'object score': 888}}",
+              "publications_info": "{'PMID:11302284': {'publication date': '2001', 'sentence': 'Less common parasitic infections in the elderly, including cutaneous larva migrans and cutaneous leishmaniasis, present with a characteristic clinical picture and can be effectively treated with oral thiabendazole and intravenous antimonials.', 'subject score': 888, 'object score': 1000}, 'PMID:11843222': {'publication date': '2001 Nov', 'sentence': 'Treatment of widespread cutaneous larva migrans with thiabendazole.', 'subject score': 1000, 'object score': 916}, 'PMID:11963321': {'publication date': '2001', 'sentence': 'The cure rates with these drugs is also high e.g. thiabendazole produces a cure-rate of 98% in cutaneous larva migrans while mebendazole gives cure rate of 76-95% in ascariasis, trichiuriasis and hookworm infestations.', 'subject score': 1000, 'object score': 1000}, 'PMID:12667232': {'publication date': '2003 Apr', 'sentence': 'The treatment of cutaneous larva migrans and Toxocara infection relies on antihelminthic agents such as thiabendazole, albendazole and ivermectin.', 'subject score': 1000, 'object score': 1000}, 'PMID:2146554': {'publication date': '1990 Aug-Sep', 'sentence': 'Topical treatment of cutaneous larva migrans with thiabendazole and cambendazole is briefly described.', 'subject score': 1000, 'object score': 1000}, 'PMID:25526012': {'publication date': '2014 Oct 15', 'sentence': 'The treatment of CLM relies on antihelminthic agents, such as thiabendazole, albendazole, and ivermectin.', 'subject score': 1000, 'object score': 1000}, 'PMID:25612130': {'publication date': '2015 Jan 15', 'sentence': 'The treatment of CLM relies on antihelminthic agents, such as thiabendazole, albendazole, and ivermectin.', 'subject score': 1000, 'object score': 1000}, 'PMID:26243366': {'publication date': '2015 Sep-Oct', 'sentence': 'Oral albendazole or ivermectin, or topical thiabendazole, are the drugs of choice for CLM, and should be prescribed as first-line therapy.', 'subject score': 861, 'object score': 1000}, 'PMID:8481019': {'publication date': '1993 May', 'sentence': 'CONCLUSION: We conclude that topical thiabendazole and oral albendazole are very effective and safe modalities for the treatment of cutaneous larva migrans.', 'subject score': 861, 'object score': 1000}, 'PMID:912308': {'publication date': '1977 Sep 17', 'sentence': 'Treatment of cutaneous larva migrans with local thiabendazole.', 'subject score': 888, 'object score': 1000}, 'PMID:1257865': {'publication date': '1976 Feb 21', 'sentence': 'The successful treatment of creeping eruption with topical thiabendazole.', 'subject score': 861, 'object score': 1000}, 'PMID:14061538': {'publication date': '1963', 'sentence': 'FIRST USE OF THIABENDAZOLE IN CREEPING ERUPTION.', 'subject score': 1000, 'object score': 1000}, 'PMID:14107622': {'publication date': '1964 Apr', 'sentence': 'THIABENDAZOLE THERAPY FOR CREEPING ERUPTION.', 'subject score': 888, 'object score': 1000}, 'PMID:14143042': {'publication date': '1964 May', 'sentence': 'CREEPING ERUPTION; EFFECTIVENESS OF THIABENDAZOLE THERAPY.', 'subject score': 888, 'object score': 1000}, 'PMID:14275877': {'publication date': '1965 May', 'sentence': 'CREEPING ERUPTION TREATED WITH THIABENDAZOLE.', 'subject score': 1000, 'object score': 1000}, 'PMID:14275879': {'publication date': '1965 May', 'sentence': 'CREEPING ERUPTION TREATED WITH THIABENDAZOLE.', 'subject score': 1000, 'object score': 1000}, 'PMID:14315419': {'publication date': '1965 Aug', 'sentence': 'THE TREATMENT OF CREEPING ERUPTION WITH THIABENDAZOLE: REPORT OF 23 CASES.', 'subject score': 1000, 'object score': 1000}, 'PMID:14336177': {'publication date': '1965 Aug', 'sentence': 'TREATMENT OF CREEPING ERUPTION WITH THIABENDAZOLE.', 'subject score': 1000, 'object score': 1000}, 'PMID:5223214': {'publication date': '1966 Jul', 'sentence': 'Systemic thiabendazole treatment of creeping eruption.', 'subject score': 851, 'object score': 1000}, 'PMID:5335519': {'publication date': '1966 Nov', 'sentence': 'Topical thiabendazole for creeping eruption.', 'subject score': 861, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:disrupts---None---None---None---UMLS:C0024530---SEMMEDDB:"
+                "UMLS:C0039832---SEMMEDDB:treats---None---None---None---UMLS:C0546999---SEMMEDDB:",
+                "UMLS:C0039832---SEMMEDDB:treats---None---None---None---UMLS:C0023048---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "16658503",
-              "object": "MONDO:0005136",
-              "publications": [
-                "PMID:23236367"
->>>>>>> main
+              "subject": "PUBCHEM.COMPOUND:5430",
+              "id": "8826326",
+              "object": "MONDO:0018500",
+              "publications": [
+                "PMID:14061538",
+                "PMID:5369629",
+                "PMID:26243366",
+                "PMID:14107622",
+                "PMID:5369630",
+                "PMID:1257865",
+                "PMID:912308",
+                "PMID:5999237",
+                "PMID:11843222",
+                "PMID:6051251",
+                "PMID:5223214",
+                "PMID:14275879",
+                "PMID:25526012",
+                "PMID:2146554",
+                "PMID:5335519",
+                "PMID:25612130",
+                "PMID:11963321",
+                "PMID:14275877",
+                "PMID:12667232",
+                "PMID:14315419"
               ]
             }
           },
           "end": {
-            "identity": 551,
+            "identity": 549,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -2753,56 +2490,54 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Thiabendazole",
+              "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
+                "MESH:D013827",
+                "DrugCentral:2621",
+                "CAS:148-79-8",
+                "NDDF:002985",
+                "CHEMBL.COMPOUND:CHEMBL625",
+                "PDQ:CDR0000039713",
+                "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+                "KEGG.DRUG:D00372",
+                "RXNORM:10450",
+                "CHEBI:45979",
+                "UNII:N1Q45E87DT",
+                "PUBCHEM.COMPOUND:5430",
+                "KEGG.COMPOUND:C07131",
+                "DRUGBANK:DB00730",
+                "UMLS:C0039832",
+                "HMDB:HMDB0014868",
+                "CAS:98002-42-7",
+                "NCIT:C873",
+                "GTOPDB:7304"
               ],
-              "id": "PUBCHEM.COMPOUND:2082",
+              "id": "PUBCHEM.COMPOUND:5430",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
+                "thiabendazole",
+                "THIABENDAZOLE",
+                "Thiabendazole (USP)",
+                "bovizole",
+                "Thiabendazole"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
+                "biolink:Drug",
+                "biolink:ChemicalEntity"
               ],
               "publications": [
-                "PMID:28595066",
                 "PMID:20014752",
                 "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
+                "PMID:18400497",
                 "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
+                "PMID:34954591",
+                "PMID:23241029",
+                "PMID:23634668",
+                "PMID:10978195",
+                "PMID:16420038",
+                "PMID:18973341"
               ]
             }
           }
@@ -2812,16 +2547,9 @@
     }
   },
   {
-<<<<<<< HEAD
     "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:15186934': {'publication date': '2004 Aug', 'sentence': 'The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania.', 'subject score': 1000, 'object score': 913}}",
-    "p2": {
->>>>>>> main
       "start": {
-        "identity": 532244,
+        "identity": 529459,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -2831,40 +2559,44 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016075",
-          "name": "filariasis",
-          "description": "A parasitic disease caused by tissue-invasive, vector-borne nematodes which can be found anywhere in the human body and that are transmitted to humans through the bite of an infected mosquito or fly or by consumption of unsafe drinking water and which, depending on the subtype can manifest with lymphedema, dermatitis, subcutaneous edema and eye involvement. The disorder is a major public health problem in many tropical and subtropical countries. Six subtypes have been described in the literature: lymphatic filariasis, onchocerciasis, loiasis, mansonelliasis, dirofilariasis and dracunculiasis caused by Wuchereria bancrofti and filarioidea of the genus Brugia; Onchocerca volvulus; Loa loa; Mansonella; Dirofilaria; and Dracunculus medinensis, respectively. Tropical eosinophilia is considered a frequent manifestation.",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005974",
+          "name": "strongyloidiasis",
+          "description": "An infection that is caused by nematodes of the genus Strongyloides, most commonly Strongyloides stercoralis, which is a soil-transmitted helminth, and which is characterized by a variety of gastrointestinal, dermatologic, and, occasionally, pulmonary manifestations. The worm's autoinfective life cycle can lead to hyper-infection and life-threatening dissemination in immunocompromised hosts decades after initial infection.; Infection with nematodes of the genus STRONGYLOIDES. The presence of larvae may produce pneumonitis and the presence of adult worms in the intestine could lead to moderate to severe diarrhea.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "MONDO:0016075",
-            "ICD9:125.9",
-            "MEDDRA:10076405",
-            "NCIT:C34611",
-            "DOID:1080",
-            "MEDDRA:10016674",
-            "ICD10:B74",
-            "SNOMEDCT:105706003",
-            "ORPHANET:2034",
-            "UMLS:C0016085",
-            "MESH:D005368",
-            "MEDDRA:10045874"
+            "UMLS:C0348996",
+            "UMLS:C0085810",
+            "MEDDRA:10080496",
+            "ORPHANET:76",
+            "ICD10:B78",
+            "ICD9:127.2",
+            "MESH:D013322",
+            "UMLS:C0038463",
+            "SNOMEDCT:187176005",
+            "EFO:0007501",
+            "MEDDRA:10042254",
+            "MONDO:0005974",
+            "SNOMEDCT:1214006",
+            "NCIT:C128398",
+            "DOID:10955"
           ],
-          "id": "MONDO:0016075",
+          "id": "MONDO:0005974",
           "category": "biolink:Disease",
           "all_names": [
-            "Filariasis",
-            "Unspecified filariasis",
-            "filariasis"
+            "Strongyloidiasis",
+            "Anguilluliasis",
+            "strongyloidiasis"
           ],
           "all_categories": [
             "biolink:Disease"
           ],
           "publications": [
-            "http://en.wikipedia.org/wiki/filariasis"
+            "http://www.dpd.cdc.gov/dpdx/html/strongyloidiasis.htm",
+            "http://en.wikipedia.org/wiki/strongyloidiasis"
           ]
         }
       },
       "end": {
-        "identity": 551,
+        "identity": 549,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -2881,136 +2613,148 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Thiabendazole",
+          "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
+            "MESH:D013827",
+            "DrugCentral:2621",
+            "CAS:148-79-8",
+            "NDDF:002985",
+            "CHEMBL.COMPOUND:CHEMBL625",
+            "PDQ:CDR0000039713",
+            "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+            "KEGG.DRUG:D00372",
+            "RXNORM:10450",
+            "CHEBI:45979",
+            "UNII:N1Q45E87DT",
+            "PUBCHEM.COMPOUND:5430",
+            "KEGG.COMPOUND:C07131",
+            "DRUGBANK:DB00730",
+            "UMLS:C0039832",
+            "HMDB:HMDB0014868",
+            "CAS:98002-42-7",
+            "NCIT:C873",
+            "GTOPDB:7304"
           ],
-          "id": "PUBCHEM.COMPOUND:2082",
+          "id": "PUBCHEM.COMPOUND:5430",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
+            "thiabendazole",
+            "THIABENDAZOLE",
+            "Thiabendazole (USP)",
+            "bovizole",
+            "Thiabendazole"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
+            "biolink:Drug",
+            "biolink:ChemicalEntity"
           ],
           "publications": [
-            "PMID:28595066",
             "PMID:20014752",
             "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
+            "PMID:18400497",
             "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
+            "PMID:34954591",
+            "PMID:23241029",
+            "PMID:23634668",
+            "PMID:10978195",
+            "PMID:16420038",
+            "PMID:18973341"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 532244,
+            "identity": 529459,
             "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
               "biolink:NamedThing",
               "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
               "biolink:PhenotypicFeature"
->>>>>>> main
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016075",
-              "name": "filariasis",
-              "description": "A parasitic disease caused by tissue-invasive, vector-borne nematodes which can be found anywhere in the human body and that are transmitted to humans through the bite of an infected mosquito or fly or by consumption of unsafe drinking water and which, depending on the subtype can manifest with lymphedema, dermatitis, subcutaneous edema and eye involvement. The disorder is a major public health problem in many tropical and subtropical countries. Six subtypes have been described in the literature: lymphatic filariasis, onchocerciasis, loiasis, mansonelliasis, dirofilariasis and dracunculiasis caused by Wuchereria bancrofti and filarioidea of the genus Brugia; Onchocerca volvulus; Loa loa; Mansonella; Dirofilaria; and Dracunculus medinensis, respectively. Tropical eosinophilia is considered a frequent manifestation.",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005974",
+              "name": "strongyloidiasis",
+              "description": "An infection that is caused by nematodes of the genus Strongyloides, most commonly Strongyloides stercoralis, which is a soil-transmitted helminth, and which is characterized by a variety of gastrointestinal, dermatologic, and, occasionally, pulmonary manifestations. The worm's autoinfective life cycle can lead to hyper-infection and life-threatening dissemination in immunocompromised hosts decades after initial infection.; Infection with nematodes of the genus STRONGYLOIDES. The presence of larvae may produce pneumonitis and the presence of adult worms in the intestine could lead to moderate to severe diarrhea.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "MONDO:0016075",
-                "ICD9:125.9",
-                "MEDDRA:10076405",
-                "NCIT:C34611",
-                "DOID:1080",
-                "MEDDRA:10016674",
-                "ICD10:B74",
-                "SNOMEDCT:105706003",
-                "ORPHANET:2034",
-                "UMLS:C0016085",
-                "MESH:D005368",
-                "MEDDRA:10045874"
+                "UMLS:C0348996",
+                "UMLS:C0085810",
+                "MEDDRA:10080496",
+                "ORPHANET:76",
+                "ICD10:B78",
+                "ICD9:127.2",
+                "MESH:D013322",
+                "UMLS:C0038463",
+                "SNOMEDCT:187176005",
+                "EFO:0007501",
+                "MEDDRA:10042254",
+                "MONDO:0005974",
+                "SNOMEDCT:1214006",
+                "NCIT:C128398",
+                "DOID:10955"
               ],
-              "id": "MONDO:0016075",
+              "id": "MONDO:0005974",
               "category": "biolink:Disease",
               "all_names": [
-                "Filariasis",
-                "Unspecified filariasis",
-                "filariasis"
+                "Strongyloidiasis",
+                "Anguilluliasis",
+                "strongyloidiasis"
               ],
               "all_categories": [
                 "biolink:Disease"
               ],
               "publications": [
-                "http://en.wikipedia.org/wiki/filariasis"
+                "http://www.dpd.cdc.gov/dpdx/html/strongyloidiasis.htm",
+                "http://en.wikipedia.org/wiki/strongyloidiasis"
               ]
             }
           },
           "relationship": {
-            "identity": 10998118,
-            "start": 551,
-            "end": 532244,
-            "type": "biolink:affects",
+            "identity": 8294403,
+            "start": 549,
+            "end": 529459,
+            "type": "biolink:treats",
             "properties": {
-              "predicate": "biolink:affects",
+              "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15186934': {'publication date': '2004 Aug', 'sentence': 'The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania.', 'subject score': 1000, 'object score': 913}}",
+              "publications_info": "{'PMID:11017840': {'publication date': '2000 Sep', 'sentence': 'Thiabendazole for the treatment of strongyloidiasis in patients with hematologic malignancies.', 'subject score': 1000, 'object score': 1000}, 'PMID:11809332': {'publication date': '2002 Mar 01', 'sentence': 'A ratio equivalent to or lower than that calculated for the currently prescribed strongyloidosis treatments, ivermectin, albendazole and thiabendazole, was observed for allocryptopine, protopine, dehydrocorydaline, D-corydaline, L-stylopine, and papaverine.', 'subject score': 1000, 'object score': 833}, 'PMID:13997238': {'publication date': '1962 Oct', 'sentence': '[Use of thiabendazole in the treatment of strongyloidiasis and other human parasitoses].', 'subject score': 1000, 'object score': 1000}, 'PMID:15571478': {'publication date': '2004 Dec', 'sentence': 'Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1952699': {'publication date': '1991', 'sentence': 'The treatment by thiabendazole for an associated strongyloidosis was well tolerated but inefficient.', 'subject score': 1000, 'object score': 861}, 'PMID:2071949': {'publication date': '1991 Mar', 'sentence': '[New trial with thiabendazole for treatment of human strongyloidiasis].', 'subject score': 1000, 'object score': 888}, 'PMID:21814588': {'publication date': '2011 Jul', 'sentence': 'METHODOLOGY/PRINCIPAL FINDINGS: Prospective, randomized, open label, phase III trial conducted at the Centre for Tropical Diseases (Verona, Italy) to compare efficacy and safety of ivermectin (single dose, 200 ug/kg) and thiabendazole (two daily doses of 25 mg/Kg for two days) to cure strongyloidiasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2747412': {'publication date': '1989 Mar', 'sentence': 'One hundred and ten patients with strongyloidiasis were treated with oral thiabendazole in a dosage of 50 mg/kg daily for two days; the other group of 41 patients was given mebendazole in a dosage of 10 mg/kg/day orally for five days.', 'subject score': 888, 'object score': 1000}, 'PMID:3558170': {'publication date': '1987 Jan', 'sentence': 'Albendazole and thiabendazole in murine strongyloidiasis.', 'subject score': 1000, 'object score': 888}, 'PMID:4300210': {'publication date': '1968 Sep', 'sentence': 'A clinical trial of thiabendazole in strongyloidiasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:5098440': {'publication date': '1971 May-Jun', 'sentence': '[Effectiveness and tolerance of thiabendazole in strongyloidiasis and linear dermatitis].', 'subject score': 1000, 'object score': 1000}, 'PMID:5312126': {'publication date': '1970 Sep-Oct', 'sentence': 'Observations on the treatment of strongyloidiasis with thiabendazole in New York City.', 'subject score': 1000, 'object score': 1000}, 'PMID:5980620': {'publication date': '1966', 'sentence': '[New therapeutic regimen with thiabendazole in human strongyloidiasis].', 'subject score': 1000, 'object score': 888}, 'PMID:6080672': {'publication date': '1967', 'sentence': 'The treatment of chronic strongyloidiasis with thiabendazole.', 'subject score': 1000, 'object score': 888}, 'PMID:6658500': {'publication date': '1983 Sep', 'sentence': 'A single course of thiabendazole in strongyloidiasis is inadequate, especially in those immunosuppressive hosts.', 'subject score': 1000, 'object score': 1000}, 'PMID:7080143': {'publication date': '1982', 'sentence': 'Treatment of strongyloidiasis with thiabendazole: an analysis of toxicity and effectiveness.', 'subject score': 1000, 'object score': 1000}, 'PMID:7081540': {'publication date': '1982 May', 'sentence': 'It is concluded that cambendazole may have significant advantages over both thiabendazole and mebendazole in the treatment of strongyloidiasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:717936': {'publication date': '1978 Nov', 'sentence': 'Thiabendazole treatment of severe strongyloidiasis in a hemodialyzed patient.', 'subject score': 888, 'object score': 888}, 'PMID:7386565': {'publication date': '1980 Jun', 'sentence': 'He survived and received thiabendazole treatment for strongyloidiasis, which was successful.', 'subject score': 851, 'object score': 1000}, 'PMID:7496198': {'publication date': '1994', 'sentence': 'Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:affects---None---None---None---UMLS:C0016085---SEMMEDDB:"
+                "UMLS:C0039832---SEMMEDDB:treats---None---None---None---UMLS:C0038463---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "11239060",
-              "object": "MONDO:0016075",
+              "subject": "PUBCHEM.COMPOUND:5430",
+              "id": "8474719",
+              "object": "MONDO:0005974",
               "publications": [
-                "PMID:15186934"
+                "PMID:11017840",
+                "PMID:11809332",
+                "PMID:13997238",
+                "PMID:15571478",
+                "PMID:1952699",
+                "PMID:2071949",
+                "PMID:21814588",
+                "PMID:2747412",
+                "PMID:3558170",
+                "PMID:4300210",
+                "PMID:5098440",
+                "PMID:5312126",
+                "PMID:5980620",
+                "PMID:6080672",
+                "PMID:6658500",
+                "PMID:7080143",
+                "PMID:7081540",
+                "PMID:717936",
+                "PMID:7386565",
+                "PMID:7496198"
               ]
             }
           },
           "end": {
-            "identity": 551,
+            "identity": 549,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -3027,56 +2771,54 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Thiabendazole",
+              "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
+                "MESH:D013827",
+                "DrugCentral:2621",
+                "CAS:148-79-8",
+                "NDDF:002985",
+                "CHEMBL.COMPOUND:CHEMBL625",
+                "PDQ:CDR0000039713",
+                "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+                "KEGG.DRUG:D00372",
+                "RXNORM:10450",
+                "CHEBI:45979",
+                "UNII:N1Q45E87DT",
+                "PUBCHEM.COMPOUND:5430",
+                "KEGG.COMPOUND:C07131",
+                "DRUGBANK:DB00730",
+                "UMLS:C0039832",
+                "HMDB:HMDB0014868",
+                "CAS:98002-42-7",
+                "NCIT:C873",
+                "GTOPDB:7304"
               ],
-              "id": "PUBCHEM.COMPOUND:2082",
+              "id": "PUBCHEM.COMPOUND:5430",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
+                "thiabendazole",
+                "THIABENDAZOLE",
+                "Thiabendazole (USP)",
+                "bovizole",
+                "Thiabendazole"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
+                "biolink:Drug",
+                "biolink:ChemicalEntity"
               ],
               "publications": [
-                "PMID:28595066",
                 "PMID:20014752",
                 "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
+                "PMID:18400497",
                 "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
+                "PMID:34954591",
+                "PMID:23241029",
+                "PMID:23634668",
+                "PMID:10978195",
+                "PMID:16420038",
+                "PMID:18973341"
               ]
             }
           }
@@ -3086,18 +2828,9 @@
     }
   },
   {
-<<<<<<< HEAD
     "p3": {
       "start": {
-        "identity": 546907,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11954915': {'publication date': '2002 Mar', 'sentence': 'Today, the only way is the prophylactic control of Onchocerca vovulus infections and treating lymphatic filariosis with ivermectin, diethylcarbamacine, ivermectin/diethylcarbamazine. or ivermectin/albendazole combinations.', 'subject score': 851, 'object score': 851}, 'PMID:1476470': {'publication date': '1992 Sep', 'sentence': 'Albendazole was not shown to be useful for treatment of Mansonella perstans filariasis.', 'subject score': 1000, 'object score': 901}, 'PMID:15049459': {'publication date': '2004 Apr', 'sentence': 'The present field study has shown the combination of DEC + ALB to be as safe as the single drug DEC and thus the combination can be put in use in the national filariasis control programmes.', 'subject score': 888, 'object score': 608}, 'PMID:15361118': {'publication date': '2004 Sep', 'sentence': 'Effectiveness of two annual, single-dose mass drug administrations of diethylcarbamazine alone or in combination with albendazole on soil-transmitted helminthiasis in filariasis elimination programme.', 'subject score': 1000, 'object score': 623}, 'PMID:16575724': {'publication date': '2006 Apr 15', 'sentence': 'A randomized, double-blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection.', 'subject score': 851, 'object score': 913}, 'PMID:19825283': {'publication date': '2009 Oct', 'sentence': 'In India, annual rounds of mass drug administration (MDA) based on diethylcarbamazine and albendazole are used to control filariasis, which is a major public-health problem.', 'subject score': 1000, 'object score': 1000}, 'PMID:29059186': {'publication date': '2017 Oct', 'sentence': 'Lymphatic pathology in asymptomatic and symptomatic children with Wuchereria bancrofti infection in children from Odisha, India and its reversal with DEC and albendazole treatment.', 'subject score': 888, 'object score': 913}, 'PMID:29432423': {'publication date': '2018 02', 'sentence': 'Approximately 20% of at-risk WRA had received deworming with albendazole through the Global Programme to Eliminate Filariasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:29702653': {'publication date': '2018 04', 'sentence': 'However, although not statistically significant, sub-group analysis showed a tendency for slightly more AEs in patients with filariasis treated with ivermectin-albendazole compared to those treated with albendazole alone (RR = 1.29, 95% CI = 0.81-2.05).', 'subject score': 888, 'object score': 1000}, 'PMID:31496523': {'publication date': '2019 06', 'sentence': 'Microfilaricidal drugs such as ivermectin and albendazole have been used as the standard therapy in filariasis, although their efficacy in eliminating the diseases is not fully established.', 'subject score': 1000, 'object score': 1000}, 'PMID:35292585': {'publication date': '2022 Mar 15', 'sentence': 'However, the \"guideline review process\" depended heavily on preliminary results from multicenter studies that were performed to compare the safety, tolerability, and acceptability of IDA versus DA (the two-drug regimen of DEC plus albendazole that was recommended for use for filariasis elimination in countries without co-endemic onchocerciasis or loiasis).', 'subject score': 851, 'object score': 888}, 'PMID:9196776': {'publication date': '1997', 'sentence': 'Albendazole for the treatment of Mansonella perstans filariasis.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 532244,
->>>>>>> main
+        "identity": 529453,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -3107,61 +2840,47 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-<<<<<<< HEAD
-          "iri": "https://identifiers.org/umls:C3714514",
-          "name": "Infection",
-          "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "UMLS:C3714514",
-            "MEDDRA:10021842",
-            "NCIT:C128320",
-            "MEDDRA:10021789",
-            "MESH:D007239"
-          ],
-          "id": "UMLS:C3714514",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infection",
-            "Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016075",
-          "name": "filariasis",
-          "description": "A parasitic disease caused by tissue-invasive, vector-borne nematodes which can be found anywhere in the human body and that are transmitted to humans through the bite of an infected mosquito or fly or by consumption of unsafe drinking water and which, depending on the subtype can manifest with lymphedema, dermatitis, subcutaneous edema and eye involvement. The disorder is a major public health problem in many tropical and subtropical countries. Six subtypes have been described in the literature: lymphatic filariasis, onchocerciasis, loiasis, mansonelliasis, dirofilariasis and dracunculiasis caused by Wuchereria bancrofti and filarioidea of the genus Brugia; Onchocerca volvulus; Loa loa; Mansonella; Dirofilaria; and Dracunculus medinensis, respectively. Tropical eosinophilia is considered a frequent manifestation.",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005746",
+          "name": "enterobiasis",
+          "description": "An infection that is caused by the nematode Enterobius vermicularis; it is characterized predominantly by perianal pruritus.; Infection with nematodes of the genus ENTEROBIUS; E. vermicularis, the pinworm of man, causes a crawling sensation and pruritus. This condition results in scratching the area, occasionally causing scarification.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "MONDO:0016075",
-            "ICD9:125.9",
-            "MEDDRA:10076405",
-            "NCIT:C34611",
-            "DOID:1080",
-            "MEDDRA:10016674",
-            "ICD10:B74",
-            "SNOMEDCT:105706003",
-            "ORPHANET:2034",
-            "UMLS:C0016085",
-            "MESH:D005368",
-            "MEDDRA:10045874"
+            "MESH:D010123",
+            "UMLS:C0086227",
+            "MEDDRA:10014882",
+            "SNOMEDCT:360419005",
+            "ICD9:127.4",
+            "MEDDRA:10035070",
+            "MEDDRA:10014883",
+            "MEDDRA:10062569",
+            "NCIT:C128396",
+            "SNOMEDCT:266162007",
+            "EFO:0007254",
+            "UMLS:C0030100",
+            "DOID:7457",
+            "ICD10:B80",
+            "MEDDRA:10043499",
+            "MESH:D017229",
+            "MEDDRA:10014881",
+            "MONDO:0005746"
           ],
-          "id": "MONDO:0016075",
+          "id": "MONDO:0005746",
           "category": "biolink:Disease",
           "all_names": [
-            "Filariasis",
-            "Unspecified filariasis",
-            "filariasis"
+            "enterobiasis",
+            "Oxyuriasis",
+            "Enterobiasis"
           ],
           "all_categories": [
             "biolink:Disease"
           ],
           "publications": [
-            "http://en.wikipedia.org/wiki/filariasis"
->>>>>>> main
+            "http://www.dpd.cdc.gov/dpdx/html/enterobiasis.htm",
+            "http://www.merck.com/mmpe/sec14/ch182/ch182h.html?qt=enterobiasis&alt=sh"
           ]
         }
       },
       "end": {
-        "identity": 551,
+        "identity": 549,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -3178,64 +2897,61 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Thiabendazole",
+          "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
+            "MESH:D013827",
+            "DrugCentral:2621",
+            "CAS:148-79-8",
+            "NDDF:002985",
+            "CHEMBL.COMPOUND:CHEMBL625",
+            "PDQ:CDR0000039713",
+            "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+            "KEGG.DRUG:D00372",
+            "RXNORM:10450",
+            "CHEBI:45979",
+            "UNII:N1Q45E87DT",
+            "PUBCHEM.COMPOUND:5430",
+            "KEGG.COMPOUND:C07131",
+            "DRUGBANK:DB00730",
+            "UMLS:C0039832",
+            "HMDB:HMDB0014868",
+            "CAS:98002-42-7",
+            "NCIT:C873",
+            "GTOPDB:7304"
           ],
-          "id": "PUBCHEM.COMPOUND:2082",
+          "id": "PUBCHEM.COMPOUND:5430",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
+            "thiabendazole",
+            "THIABENDAZOLE",
+            "Thiabendazole (USP)",
+            "bovizole",
+            "Thiabendazole"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
+            "biolink:Drug",
+            "biolink:ChemicalEntity"
           ],
           "publications": [
-            "PMID:28595066",
             "PMID:20014752",
             "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
+            "PMID:18400497",
             "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
+            "PMID:34954591",
+            "PMID:23241029",
+            "PMID:23634668",
+            "PMID:10978195",
+            "PMID:16420038",
+            "PMID:18973341"
           ]
         }
       },
       "segments": [
         {
           "start": {
-<<<<<<< HEAD
-            "identity": 546907,
+            "identity": 529453,
             "labels": [
               "biolink:BiologicalEntity",
               "biolink:Disease",
@@ -3245,52 +2961,70 @@
               "biolink:ThingWithTaxon"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C3714514",
-              "name": "Infection",
-              "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005746",
+              "name": "enterobiasis",
+              "description": "An infection that is caused by the nematode Enterobius vermicularis; it is characterized predominantly by perianal pruritus.; Infection with nematodes of the genus ENTEROBIUS; E. vermicularis, the pinworm of man, causes a crawling sensation and pruritus. This condition results in scratching the area, occasionally causing scarification.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "UMLS:C3714514",
-                "MEDDRA:10021842",
-                "NCIT:C128320",
-                "MEDDRA:10021789",
-                "MESH:D007239"
+                "MESH:D010123",
+                "UMLS:C0086227",
+                "MEDDRA:10014882",
+                "SNOMEDCT:360419005",
+                "ICD9:127.4",
+                "MEDDRA:10035070",
+                "MEDDRA:10014883",
+                "MEDDRA:10062569",
+                "NCIT:C128396",
+                "SNOMEDCT:266162007",
+                "EFO:0007254",
+                "UMLS:C0030100",
+                "DOID:7457",
+                "ICD10:B80",
+                "MEDDRA:10043499",
+                "MESH:D017229",
+                "MEDDRA:10014881",
+                "MONDO:0005746"
               ],
-              "id": "UMLS:C3714514",
+              "id": "MONDO:0005746",
               "category": "biolink:Disease",
               "all_names": [
-                "Infection",
-                "Infections"
+                "enterobiasis",
+                "Oxyuriasis",
+                "Enterobiasis"
               ],
               "all_categories": [
                 "biolink:Disease"
+              ],
+              "publications": [
+                "http://www.dpd.cdc.gov/dpdx/html/enterobiasis.htm",
+                "http://www.merck.com/mmpe/sec14/ch182/ch182h.html?qt=enterobiasis&alt=sh"
               ]
             }
           },
           "relationship": {
-            "identity": 22253094,
-            "start": 551,
-            "end": 546907,
+            "identity": 7209865,
+            "start": 549,
+            "end": 529453,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:33150325': {'publication date': '2020 Oct', 'sentence': 'The control of STH infections is based on preventive chemotherapy using either albendazole or mebendazole.', 'subject score': 888, 'object score': 888}, 'PMID:33906234': {'publication date': '2021 Apr 27', 'sentence': 'CONCLUSIONS: The combined use of ALB and high-dose IVM is a highly effective and well tolerated treatment for the treatment of T. trichiura infections offering a significantly improved treatment for the control of this infection.', 'subject score': 1000, 'object score': 851}, 'PMID:34218593': {'publication date': '2021 Jun', 'sentence': 'Albendazole is also used for treatment of filarial infections (lymphatic filariasis, onchocerciasis, loiasis, mansonellosis, and dirofilariasis) alone or in combination with other drugs, such as ivermectin or diethylcarbamazine.', 'subject score': 1000, 'object score': 861}}",
+              "publications_info": "{'PMID:1023465': {'publication date': '1976', 'sentence': '[Comparison of thiabendazole and mebendazole in the treatment of ascariasis and enterobiasis].', 'subject score': 1000, 'object score': 1000}, 'PMID:5369626': {'publication date': '1969 Nov', 'sentence': 'Treatment of oxyuriasis with thiabendazole.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C3714514---SEMMEDDB:"
+                "UMLS:C0039832---SEMMEDDB:treats---None---None---None---UMLS:C0086227---SEMMEDDB:",
+                "UMLS:C0039832---SEMMEDDB:treats---None---None---None---UMLS:C0030100---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "22678969",
-              "object": "UMLS:C3714514",
+              "subject": "PUBCHEM.COMPOUND:5430",
+              "id": "7357052",
+              "object": "MONDO:0005746",
               "publications": [
-                "PMID:33150325",
-                "PMID:33906234",
-                "PMID:34218593"
+                "PMID:1023465",
+                "PMID:5369626"
               ]
             }
           },
           "end": {
-            "identity": 551,
+            "identity": 549,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -3307,56 +3041,54 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Thiabendazole",
+              "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
+                "MESH:D013827",
+                "DrugCentral:2621",
+                "CAS:148-79-8",
+                "NDDF:002985",
+                "CHEMBL.COMPOUND:CHEMBL625",
+                "PDQ:CDR0000039713",
+                "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+                "KEGG.DRUG:D00372",
+                "RXNORM:10450",
+                "CHEBI:45979",
+                "UNII:N1Q45E87DT",
+                "PUBCHEM.COMPOUND:5430",
+                "KEGG.COMPOUND:C07131",
+                "DRUGBANK:DB00730",
+                "UMLS:C0039832",
+                "HMDB:HMDB0014868",
+                "CAS:98002-42-7",
+                "NCIT:C873",
+                "GTOPDB:7304"
               ],
-              "id": "PUBCHEM.COMPOUND:2082",
+              "id": "PUBCHEM.COMPOUND:5430",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
+                "thiabendazole",
+                "THIABENDAZOLE",
+                "Thiabendazole (USP)",
+                "bovizole",
+                "Thiabendazole"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
+                "biolink:Drug",
+                "biolink:ChemicalEntity"
               ],
               "publications": [
-                "PMID:28595066",
                 "PMID:20014752",
                 "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
+                "PMID:18400497",
                 "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
+                "PMID:34954591",
+                "PMID:23241029",
+                "PMID:23634668",
+                "PMID:10978195",
+                "PMID:16420038",
+                "PMID:18973341"
               ]
             }
           }
@@ -3368,7 +3100,7 @@
   {
     "p3": {
       "start": {
-        "identity": 532253,
+        "identity": 529465,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -3378,39 +3110,39 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0017137",
-          "name": "onchocerciasis",
-          "description": "A filariasis that involves parasitic infection caused by the nematode Onchocerca volvulus, which is transmitted to humans through the bite of a blackfly of the genus Simulium. The worms spread throughout the body and, when they die, cause intense itching and a strong immune system response that can destroy nearby tissue. The symptoms include pruritus, dermatitis, blindness, onchocercomata (subcutaneous nodules), and lymphadenopathy.",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005654",
+          "name": "ascariasis",
+          "description": "An infection that is caused by the roundworm Ascaris lumbricoides, many cases of which remain asymptomatic. During the transient larval migratory phase, shortness of breath, fever, and eosinophilia can occur. Depending on the intestinal worm burden, a spectrum of gastrointestinal tract symptoms can occur.; Infection by nematodes of the genus ASCARIS. Ingestion of infective eggs causes diarrhea and pneumonitis. Its distribution is more prevalent in areas of poor sanitation and where human feces are used for fertilizer.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "MEDDRA:10030314",
-            "SNOMEDCT:38539003",
-            "DOID:11678",
-            "UMLS:C0029001",
-            "ICD10:B73",
-            "EFO:0007402",
-            "MEDDRA:10030313",
-            "MESH:D009855",
-            "NCIT:C34861",
-            "ORPHANET:2737",
-            "MONDO:0017137",
-            "ICD9:125.3"
+            "MONDO:0005654",
+            "EFO:0007154",
+            "SNOMEDCT:2435008",
+            "MESH:D001196",
+            "ICD9:127.0",
+            "NCIT:C128392",
+            "MEDDRA:10003442",
+            "UMLS:C0003950",
+            "ICD10:B77",
+            "DOID:456"
           ],
-          "id": "MONDO:0017137",
+          "id": "MONDO:0005654",
           "category": "biolink:Disease",
           "all_names": [
-            "Onchocerciasis",
-            "onchocerciasis"
+            "Ascariasis",
+            "ascariasis"
           ],
           "all_categories": [
             "biolink:Disease"
           ],
           "publications": [
-            "http://www.dpd.cdc.gov/dpdx/html/filariasis.htm"
+            "http://en.wikipedia.org/wiki/ascariasis",
+            "http://www.dpd.cdc.gov/dpdx/html/ascariasis.htm",
+            "http://www.merck.com/mmpe/sec14/ch182/ch182d.html?qt=ascariasis&alt=sh"
           ]
         }
       },
       "end": {
-        "identity": 551,
+        "identity": 549,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -3427,63 +3159,61 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Thiabendazole",
+          "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
+            "MESH:D013827",
+            "DrugCentral:2621",
+            "CAS:148-79-8",
+            "NDDF:002985",
+            "CHEMBL.COMPOUND:CHEMBL625",
+            "PDQ:CDR0000039713",
+            "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+            "KEGG.DRUG:D00372",
+            "RXNORM:10450",
+            "CHEBI:45979",
+            "UNII:N1Q45E87DT",
+            "PUBCHEM.COMPOUND:5430",
+            "KEGG.COMPOUND:C07131",
+            "DRUGBANK:DB00730",
+            "UMLS:C0039832",
+            "HMDB:HMDB0014868",
+            "CAS:98002-42-7",
+            "NCIT:C873",
+            "GTOPDB:7304"
           ],
-          "id": "PUBCHEM.COMPOUND:2082",
+          "id": "PUBCHEM.COMPOUND:5430",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
+            "thiabendazole",
+            "THIABENDAZOLE",
+            "Thiabendazole (USP)",
+            "bovizole",
+            "Thiabendazole"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
+            "biolink:Drug",
+            "biolink:ChemicalEntity"
           ],
           "publications": [
-            "PMID:28595066",
             "PMID:20014752",
             "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
+            "PMID:18400497",
             "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
+            "PMID:34954591",
+            "PMID:23241029",
+            "PMID:23634668",
+            "PMID:10978195",
+            "PMID:16420038",
+            "PMID:18973341"
+          ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 532253,
+            "identity": 529465,
             "labels": [
               "biolink:BiologicalEntity",
               "biolink:Disease",
@@ -3493,1211 +3223,61 @@
               "biolink:ThingWithTaxon"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0017137",
-              "name": "onchocerciasis",
-              "description": "A filariasis that involves parasitic infection caused by the nematode Onchocerca volvulus, which is transmitted to humans through the bite of a blackfly of the genus Simulium. The worms spread throughout the body and, when they die, cause intense itching and a strong immune system response that can destroy nearby tissue. The symptoms include pruritus, dermatitis, blindness, onchocercomata (subcutaneous nodules), and lymphadenopathy.",
-              "equivalent_curies": [
-                "MEDDRA:10030314",
-                "SNOMEDCT:38539003",
-                "DOID:11678",
-                "UMLS:C0029001",
-                "ICD10:B73",
-                "EFO:0007402",
-                "MEDDRA:10030313",
-                "MESH:D009855",
-                "NCIT:C34861",
-                "ORPHANET:2737",
-                "MONDO:0017137",
-                "ICD9:125.3"
-              ],
-              "id": "MONDO:0017137",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Onchocerciasis",
-                "onchocerciasis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.dpd.cdc.gov/dpdx/html/filariasis.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10520075,
-            "start": 551,
-            "end": 532253,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1443350': {'publication date': '1992 Oct', 'sentence': 'A double-blind clinical trial was conducted in Monagas State, Venezuela to assess the tolerance and efficacy of albendazole in the therapy of Onchocerca volvulus infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:14613509': {'publication date': '2003 Nov 06', 'sentence': 'RESULTS: In individuals co-infected with bancroftian filariasis and onchocerciasis, treatment with ivermectin and albendazole was safe and tolerable.', 'subject score': 1000, 'object score': 1000}, 'PMID:14641844': {'publication date': '2003 Dec', 'sentence': 'The current strategy for the interruption of transmission of lymphatic filariasis in areas where the disease is co-endemic with onchocerciasis is repeated annual mass treatment of endemic communities with ivermectin and albendazole.', 'subject score': 1000, 'object score': 1000}, 'PMID:14975059': {'publication date': '2003 Oct 24', 'sentence': 'Conduct research studies on the safety of combination therapy of Mectizan(R) and albendazole in areas co-endemic for L. loa and lymphatic filariasis (LF) with coordination from the relevant technical bodies that oversee these issues.The above recommendations will be implemented through a continuing collaboration between the interested parties represented at the Scientific Working Group, involved in onchocerciasis control and/or the Global Programme to Eliminate Lymphatic Filariasis.', 'subject score': 1000, 'object score': 888}, 'PMID:16304584': {'publication date': '2005 Oct', 'sentence': \"Inc. for onchocerciasis control in 1987 'as long as needed' was a public health landmark to be followed by a donation from GlaxoSmithKline of albendazole in 1997 for lymphatic filariasis to which Merck also responded by agreeing to extend their donation to include the coadministration of Mectizan and albendazole.\", 'subject score': 1000, 'object score': 888}, 'PMID:16917658': {'publication date': '2006 Aug', 'sentence': 'RELEVANT CHANGES: Current guidelines allowed onchocerciasis and LF activities to be integrated, resulting in rapid mapping throughout the two states, and states-wide provision of over 9.3 million combined ivermectin-albendazole treatments for the two diseases between 2000 and 2004.', 'subject score': 851, 'object score': 1000}, 'PMID:21722251': {'publication date': '2011 Jul', 'sentence': 'The standard microfilaricidal drugs ivermectin and albendazole are used in mass drug administration programmes, with the aim of interrupting transmission, with a consequent reduction in the burden of infection and, in some situations, leading to regional elimination of LF and onchocerciasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28056015': {'publication date': '2017 01', 'sentence': 'Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.', 'subject score': 1000, 'object score': 1000}, 'PMID:29774278': {'publication date': '2017 May', 'sentence': 'There is a hypothesis that Mass drug administration (MDA) of ivermectin and albendazole for the treatment of onchocerciasis and lymphatic filariasis could have an impact on the burden of soil-transmitted helminthiasis (STH) in MDA communities.', 'subject score': 1000, 'object score': 1000}, 'PMID:31536624': {'publication date': '2019 Sep 19', 'sentence': 'Comparison of repeated doses of ivermectin versus ivermectin plus albendazole for treatment of onchocerciasis - a randomized open-label clinical trial.', 'subject score': 851, 'object score': 1000}, 'PMID:34218593': {'publication date': '2021 Jun', 'sentence': 'Albendazole is also used for treatment of filarial infections (lymphatic filariasis, onchocerciasis, loiasis, mansonellosis, and dirofilariasis) alone or in combination with other drugs, such as ivermectin or diethylcarbamazine.', 'subject score': 1000, 'object score': 1000}, 'PMID:35463816': {'publication date': '2022', 'sentence': 'Current treatment recommendations by the WHO include mass drug administration with ivermectin for the treatment of onchocerciasis and a combination of ivermectin, albendazole and diethylcarbamazine (DEC) for the treatment of lymphatic filariasis in areas that are not co-endemic for onchocerciasis or loiasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7899788': {'publication date': '1994 Sep', 'sentence': 'A clinical evaluation of albendazole in patients with onchocerciasis; effects of food and pretreatment with ivermectin on drug response and pharmacokinetics.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0029001---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "10750815",
-              "object": "MONDO:0017137",
-              "publications": [
-                "PMID:1443350",
-                "PMID:14613509",
-                "PMID:14641844",
-                "PMID:14975059",
-                "PMID:16304584",
-                "PMID:16917658",
-                "PMID:21722251",
-                "PMID:28056015",
-                "PMID:29774278",
-                "PMID:31536624",
-                "PMID:34218593",
-                "PMID:35463816",
-                "PMID:7899788"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 517567,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005988",
-          "name": "toxocariasis",
-          "description": "A parasitic infection caused by Toxocara. Humans are infected by the larvae of Toxocara canis and Toxocara cati from dogs and cats respectively. Most cases remain asymptomatic. The parasites may affect the eye, causing diminished vision, or other major organs, causing hepatomegaly, eosinophilia, wheezing, and coughing.; Infection by round worms of the genus TOXOCARA, usually found in wild and domesticated cats and dogs and foxes, except for the larvae, which may produce visceral and ocular larva migrans in man.",
-          "equivalent_curies": [
-            "NCIT:C85194",
-            "MEDDRA:10044268",
-            "NCIT:C34758",
-            "DOID:9790",
-            "ICD10:B83.0",
-            "SNOMEDCT:406619001",
-            "MEDDRA:10044269",
-            "ICD9:128.0",
-            "MESH:D014120",
-            "ORPHANET:3343",
-            "EFO:0007516",
-            "UMLS:C0040553",
-            "MONDO:0005988"
-          ],
-          "id": "MONDO:0005988",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Toxocariasis",
-            "Visceral Larva Migrans",
-            "toxocariasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.dpd.cdc.gov/dpdx/html/toxocariasis.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517567,
-=======
-            "identity": 532244,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005988",
-              "name": "toxocariasis",
-              "description": "A parasitic infection caused by Toxocara. Humans are infected by the larvae of Toxocara canis and Toxocara cati from dogs and cats respectively. Most cases remain asymptomatic. The parasites may affect the eye, causing diminished vision, or other major organs, causing hepatomegaly, eosinophilia, wheezing, and coughing.; Infection by round worms of the genus TOXOCARA, usually found in wild and domesticated cats and dogs and foxes, except for the larvae, which may produce visceral and ocular larva migrans in man.",
-              "equivalent_curies": [
-                "NCIT:C85194",
-                "MEDDRA:10044268",
-                "NCIT:C34758",
-                "DOID:9790",
-                "ICD10:B83.0",
-                "SNOMEDCT:406619001",
-                "MEDDRA:10044269",
-                "ICD9:128.0",
-                "MESH:D014120",
-                "ORPHANET:3343",
-                "EFO:0007516",
-                "UMLS:C0040553",
-                "MONDO:0005988"
-              ],
-              "id": "MONDO:0005988",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Toxocariasis",
-                "Visceral Larva Migrans",
-                "toxocariasis"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016075",
-              "name": "filariasis",
-              "description": "A parasitic disease caused by tissue-invasive, vector-borne nematodes which can be found anywhere in the human body and that are transmitted to humans through the bite of an infected mosquito or fly or by consumption of unsafe drinking water and which, depending on the subtype can manifest with lymphedema, dermatitis, subcutaneous edema and eye involvement. The disorder is a major public health problem in many tropical and subtropical countries. Six subtypes have been described in the literature: lymphatic filariasis, onchocerciasis, loiasis, mansonelliasis, dirofilariasis and dracunculiasis caused by Wuchereria bancrofti and filarioidea of the genus Brugia; Onchocerca volvulus; Loa loa; Mansonella; Dirofilaria; and Dracunculus medinensis, respectively. Tropical eosinophilia is considered a frequent manifestation.",
-              "equivalent_curies": [
-                "MONDO:0016075",
-                "ICD9:125.9",
-                "MEDDRA:10076405",
-                "NCIT:C34611",
-                "DOID:1080",
-                "MEDDRA:10016674",
-                "ICD10:B74",
-                "SNOMEDCT:105706003",
-                "ORPHANET:2034",
-                "UMLS:C0016085",
-                "MESH:D005368",
-                "MEDDRA:10045874"
-              ],
-              "id": "MONDO:0016075",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Filariasis",
-                "Unspecified filariasis",
-                "filariasis"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://www.dpd.cdc.gov/dpdx/html/toxocariasis.htm"
-=======
-                "http://en.wikipedia.org/wiki/filariasis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 9895535,
-            "start": 551,
-            "end": 517567,
-=======
-            "identity": 9276836,
-            "start": 551,
-            "end": 532244,
->>>>>>> main
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-<<<<<<< HEAD
-              "publications_info": "{'PMID:12667232': {'publication date': '2003 Apr', 'sentence': 'The treatment of cutaneous larva migrans and Toxocara infection relies on antihelminthic agents such as thiabendazole, albendazole and ivermectin.', 'subject score': 1000, 'object score': 1000}, 'PMID:17366070': {'publication date': '2007', 'sentence': 'We report a case of aortic thrombosis caused by Toxocara canis infection in a young male who was successfully treated with albendazole.', 'subject score': 1000, 'object score': 913}, 'PMID:17691438': {'publication date': '2007 Apr', 'sentence': 'Parasite serology led to suspicion of toxocariasis that was treated using albendazole.', 'subject score': 1000, 'object score': 1000}, 'PMID:19259103': {'publication date': '2009 Mar', 'sentence': 'Duration of treatment with albendazole for hepatic toxocariasis.', 'subject score': 1000, 'object score': 888}, 'PMID:20885912': {'publication date': '2010 Oct', 'sentence': 'Typically, Toxocara spp. infection is easily treated with 400 mg albendazole twice a day for 5 days.', 'subject score': 750, 'object score': 901}, 'PMID:23282502': {'publication date': '2012 Oct', 'sentence': \"Despite absent eosinophilia in the serum, toxocarosis was diagnosed and a therapy with albendazole initiated, with benefit for retromandibular pain, but hardly for Bell's palsy or enlarged lymph nodes.\", 'subject score': 1000, 'object score': 1000}, 'PMID:25917592': {'publication date': '2015 Mar', 'sentence': 'Recurrent toxocariasis due to chronic urticaria and successful treatment with prolonged albendazole therapy.', 'subject score': 851, 'object score': 888}, 'PMID:26625368': {'publication date': '2014 Jun', 'sentence': 'Albendazole or mebendazole is the recommended treatment for visceral toxocariasis.', 'subject score': 1000, 'object score': 888}, 'PMID:2694978': {'publication date': '1989 Oct', 'sentence': 'Thiabendazole vs. albendazole in treatment of toxocariasis: a clinical trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:28352060': {'publication date': '2017 May', 'sentence': 'The aims of this study were to evaluate the prevalence of toxocariasis and the clinical impact of albendazole treatment for toxocariasis in patients suspected of eosinophilia of unknown origin.', 'subject score': 888, 'object score': 1000}, 'PMID:33269576': {'publication date': '2020 Dec 02', 'sentence': 'Albendazole is used for the treatment of toxocariasis diagnosed by serologic and immunological methods.', 'subject score': 1000, 'object score': 1000}, 'PMID:35890057': {'publication date': '2022 Jul 20', 'sentence': 'A Retrospective Study of the Efficacy of Albendazole and Diethylcarbamazine for the Treatment of Human Toxocariasis.', 'subject score': 1000, 'object score': 888}, 'PMID:9629547': {'publication date': '1998', 'sentence': 'The diagnosis of a \"covert form\" of toxocarosis was established and an antihelminthic therapy with albendazole was initiated.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0040553---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "10114050",
-              "object": "MONDO:0005988",
-              "publications": [
-                "PMID:12667232",
-                "PMID:17366070",
-                "PMID:17691438",
-                "PMID:19259103",
-                "PMID:20885912",
-                "PMID:23282502",
-                "PMID:25917592",
-                "PMID:26625368",
-                "PMID:2694978",
-                "PMID:28352060",
-                "PMID:33269576",
-                "PMID:35890057",
-                "PMID:9629547"
-=======
-              "publications_info": "{'PMID:11954915': {'publication date': '2002 Mar', 'sentence': 'Today, the only way is the prophylactic control of Onchocerca vovulus infections and treating lymphatic filariosis with ivermectin, diethylcarbamacine, ivermectin/diethylcarbamazine. or ivermectin/albendazole combinations.', 'subject score': 851, 'object score': 851}, 'PMID:1476470': {'publication date': '1992 Sep', 'sentence': 'Albendazole was not shown to be useful for treatment of Mansonella perstans filariasis.', 'subject score': 1000, 'object score': 901}, 'PMID:15049459': {'publication date': '2004 Apr', 'sentence': 'The present field study has shown the combination of DEC + ALB to be as safe as the single drug DEC and thus the combination can be put in use in the national filariasis control programmes.', 'subject score': 888, 'object score': 608}, 'PMID:15361118': {'publication date': '2004 Sep', 'sentence': 'Effectiveness of two annual, single-dose mass drug administrations of diethylcarbamazine alone or in combination with albendazole on soil-transmitted helminthiasis in filariasis elimination programme.', 'subject score': 1000, 'object score': 623}, 'PMID:16575724': {'publication date': '2006 Apr 15', 'sentence': 'A randomized, double-blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection.', 'subject score': 851, 'object score': 913}, 'PMID:19825283': {'publication date': '2009 Oct', 'sentence': 'In India, annual rounds of mass drug administration (MDA) based on diethylcarbamazine and albendazole are used to control filariasis, which is a major public-health problem.', 'subject score': 1000, 'object score': 1000}, 'PMID:29059186': {'publication date': '2017 Oct', 'sentence': 'Lymphatic pathology in asymptomatic and symptomatic children with Wuchereria bancrofti infection in children from Odisha, India and its reversal with DEC and albendazole treatment.', 'subject score': 888, 'object score': 913}, 'PMID:29432423': {'publication date': '2018 02', 'sentence': 'Approximately 20% of at-risk WRA had received deworming with albendazole through the Global Programme to Eliminate Filariasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:29702653': {'publication date': '2018 04', 'sentence': 'However, although not statistically significant, sub-group analysis showed a tendency for slightly more AEs in patients with filariasis treated with ivermectin-albendazole compared to those treated with albendazole alone (RR = 1.29, 95% CI = 0.81-2.05).', 'subject score': 888, 'object score': 1000}, 'PMID:31496523': {'publication date': '2019 06', 'sentence': 'Microfilaricidal drugs such as ivermectin and albendazole have been used as the standard therapy in filariasis, although their efficacy in eliminating the diseases is not fully established.', 'subject score': 1000, 'object score': 1000}, 'PMID:35292585': {'publication date': '2022 Mar 15', 'sentence': 'However, the \"guideline review process\" depended heavily on preliminary results from multicenter studies that were performed to compare the safety, tolerability, and acceptability of IDA versus DA (the two-drug regimen of DEC plus albendazole that was recommended for use for filariasis elimination in countries without co-endemic onchocerciasis or loiasis).', 'subject score': 851, 'object score': 888}, 'PMID:9196776': {'publication date': '1997', 'sentence': 'Albendazole for the treatment of Mansonella perstans filariasis.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0016085---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "9492446",
-              "object": "MONDO:0016075",
-              "publications": [
-                "PMID:11954915",
-                "PMID:1476470",
-                "PMID:15049459",
-                "PMID:15361118",
-                "PMID:16575724",
-                "PMID:19825283",
-                "PMID:29059186",
-                "PMID:29432423",
-                "PMID:29702653",
-                "PMID:31496523",
-                "PMID:35292585",
-                "PMID:9196776"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:20933491': {'publication date': '2011 Sep', 'sentence': 'Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters.', 'subject score': 851, 'object score': 913}}",
-    "p2": {
-      "start": {
-        "identity": 532244,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016075",
-          "name": "filariasis",
-          "description": "A parasitic disease caused by tissue-invasive, vector-borne nematodes which can be found anywhere in the human body and that are transmitted to humans through the bite of an infected mosquito or fly or by consumption of unsafe drinking water and which, depending on the subtype can manifest with lymphedema, dermatitis, subcutaneous edema and eye involvement. The disorder is a major public health problem in many tropical and subtropical countries. Six subtypes have been described in the literature: lymphatic filariasis, onchocerciasis, loiasis, mansonelliasis, dirofilariasis and dracunculiasis caused by Wuchereria bancrofti and filarioidea of the genus Brugia; Onchocerca volvulus; Loa loa; Mansonella; Dirofilaria; and Dracunculus medinensis, respectively. Tropical eosinophilia is considered a frequent manifestation.",
-          "equivalent_curies": [
-            "MONDO:0016075",
-            "ICD9:125.9",
-            "MEDDRA:10076405",
-            "NCIT:C34611",
-            "DOID:1080",
-            "MEDDRA:10016674",
-            "ICD10:B74",
-            "SNOMEDCT:105706003",
-            "ORPHANET:2034",
-            "UMLS:C0016085",
-            "MESH:D005368",
-            "MEDDRA:10045874"
-          ],
-          "id": "MONDO:0016075",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Filariasis",
-            "Unspecified filariasis",
-            "filariasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/filariasis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 532244,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016075",
-              "name": "filariasis",
-              "description": "A parasitic disease caused by tissue-invasive, vector-borne nematodes which can be found anywhere in the human body and that are transmitted to humans through the bite of an infected mosquito or fly or by consumption of unsafe drinking water and which, depending on the subtype can manifest with lymphedema, dermatitis, subcutaneous edema and eye involvement. The disorder is a major public health problem in many tropical and subtropical countries. Six subtypes have been described in the literature: lymphatic filariasis, onchocerciasis, loiasis, mansonelliasis, dirofilariasis and dracunculiasis caused by Wuchereria bancrofti and filarioidea of the genus Brugia; Onchocerca volvulus; Loa loa; Mansonella; Dirofilaria; and Dracunculus medinensis, respectively. Tropical eosinophilia is considered a frequent manifestation.",
-              "equivalent_curies": [
-                "MONDO:0016075",
-                "ICD9:125.9",
-                "MEDDRA:10076405",
-                "NCIT:C34611",
-                "DOID:1080",
-                "MEDDRA:10016674",
-                "ICD10:B74",
-                "SNOMEDCT:105706003",
-                "ORPHANET:2034",
-                "UMLS:C0016085",
-                "MESH:D005368",
-                "MEDDRA:10045874"
-              ],
-              "id": "MONDO:0016075",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Filariasis",
-                "Unspecified filariasis",
-                "filariasis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/filariasis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14933326,
-            "start": 551,
-            "end": 532244,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20933491': {'publication date': '2011 Sep', 'sentence': 'Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters.', 'subject score': 851, 'object score': 913}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:prevents---None---None---None---UMLS:C0016085---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "15248433",
-              "object": "MONDO:0016075",
-              "publications": [
-                "PMID:20933491"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:4039128': {'publication date': '1985 Feb', 'sentence': 'Ovicidal effects of albendazole in human ascariasis, ancylostomiasis and trichuriasis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 529458,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005996",
-          "name": "trichuriasis",
-          "description": "An infection that is caused by the nematode Trichuris trichiura, a soil-transmitted helminth, which is transmitted via food and/or water contaminated with the eggs of the worm. Symptoms are usually mild and include abdominal pain, diarrhea, fatigue, and possibly anemia secondary to blood loss in diarrhea.; Infection with nematodes of the genus TRICHURIS, formerly called Trichocephalus.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C128399",
-            "MEDDRA:10047934",
-            "UMLS:C0040954",
-            "MESH:D014257",
-            "MONDO:0005996",
-            "UMLS:C5551334",
-            "MEDDRA:10044630",
-            "MEDDRA:10044631",
-            "DOID:1252",
-            "MEDDRA:10053126",
-            "SNOMEDCT:3752003",
-            "SNOMEDCT:60570001",
-            "ICD9:127.3",
-            "EFO:0007524"
-          ],
-          "id": "MONDO:0005996",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infection by Trichuris trichiura",
-            "trichuriasis",
-            "Trichuriasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/trichuriasis",
-            "http://www.dpd.cdc.gov/dpdx/html/trichuriasis.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 529458,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005996",
-              "name": "trichuriasis",
-              "description": "An infection that is caused by the nematode Trichuris trichiura, a soil-transmitted helminth, which is transmitted via food and/or water contaminated with the eggs of the worm. Symptoms are usually mild and include abdominal pain, diarrhea, fatigue, and possibly anemia secondary to blood loss in diarrhea.; Infection with nematodes of the genus TRICHURIS, formerly called Trichocephalus.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C128399",
-                "MEDDRA:10047934",
-                "UMLS:C0040954",
-                "MESH:D014257",
-                "MONDO:0005996",
-                "UMLS:C5551334",
-                "MEDDRA:10044630",
-                "MEDDRA:10044631",
-                "DOID:1252",
-                "MEDDRA:10053126",
-                "SNOMEDCT:3752003",
-                "SNOMEDCT:60570001",
-                "ICD9:127.3",
-                "EFO:0007524"
-              ],
-              "id": "MONDO:0005996",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infection by Trichuris trichiura",
-                "trichuriasis",
-                "Trichuriasis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/trichuriasis",
-                "http://www.dpd.cdc.gov/dpdx/html/trichuriasis.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25283845,
-            "start": 551,
-            "end": 529458,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:4039128': {'publication date': '1985 Feb', 'sentence': 'Ovicidal effects of albendazole in human ascariasis, ancylostomiasis and trichuriasis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:affects---None---None---None---UMLS:C0040954---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "25735916",
-              "object": "MONDO:0005996",
-              "publications": [
-                "PMID:4039128"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12055813': {'publication date': '2002', 'sentence': 'Three randomized clinical studies were conducted in 2000 to evaluate the efficacy of nitazoxanide paediatric suspension compared to albendazole in the treatment of ascariasis and trichuriasis and praziquantel in the treatment of hymenolepiasis in children from Cajamarca, Peru.', 'subject score': 1000, 'object score': 1000}, 'PMID:23682433': {'publication date': '2013 Jan', 'sentence': 'We studied asymptomatic primary schoolchildren in northeastern Malaysia with light to moderate trichuriasis to determine the effect of albendazole treatment on growth rates and TNF-alpha levels.', 'subject score': 888, 'object score': 1000}, 'PMID:31110573': {'publication date': '2019 Apr 30', 'sentence': 'Combination of albendazole combined with levamisole showed better cure rate for mild trichuriasis (95.8%) than albendazole therapy (46.2%) and mebendazole combined with levamisole (83.3%), (p < 0.05).', 'subject score': 888, 'object score': 888}, 'PMID:34974667': {'publication date': '2021 Dec', 'sentence': 'Failure of Repeated MDA with Albendazole for Trichuriasis Control in Schoolchildren of the Yangon Region, Myanmar.', 'subject score': 1000, 'object score': 1000}, 'PMID:6378109': {'publication date': '1984 Apr', 'sentence': 'Treatment of severe symptomatic trichuriasis observed with heavy worm burdens is not satisfactory with recommended doses of mebendazole, flubendazole and albendazole.', 'subject score': 1000, 'object score': 851}, 'PMID:7939948': {'publication date': '1993 Dec', 'sentence': 'A comparative study on the efficacy of albendazole and mebendazole in the treatment of ascariasis, hookworm infection and trichuriasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:9798586': {'publication date': '1998 Oct 03', 'sentence': 'Randomised trial of albendazole and pyrantel in symptomless trichuriasis in children.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 529458,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005996",
-          "name": "trichuriasis",
-          "description": "An infection that is caused by the nematode Trichuris trichiura, a soil-transmitted helminth, which is transmitted via food and/or water contaminated with the eggs of the worm. Symptoms are usually mild and include abdominal pain, diarrhea, fatigue, and possibly anemia secondary to blood loss in diarrhea.; Infection with nematodes of the genus TRICHURIS, formerly called Trichocephalus.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C128399",
-            "MEDDRA:10047934",
-            "UMLS:C0040954",
-            "MESH:D014257",
-            "MONDO:0005996",
-            "UMLS:C5551334",
-            "MEDDRA:10044630",
-            "MEDDRA:10044631",
-            "DOID:1252",
-            "MEDDRA:10053126",
-            "SNOMEDCT:3752003",
-            "SNOMEDCT:60570001",
-            "ICD9:127.3",
-            "EFO:0007524"
-          ],
-          "id": "MONDO:0005996",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infection by Trichuris trichiura",
-            "trichuriasis",
-            "Trichuriasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/trichuriasis",
-            "http://www.dpd.cdc.gov/dpdx/html/trichuriasis.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 529458,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005996",
-              "name": "trichuriasis",
-              "description": "An infection that is caused by the nematode Trichuris trichiura, a soil-transmitted helminth, which is transmitted via food and/or water contaminated with the eggs of the worm. Symptoms are usually mild and include abdominal pain, diarrhea, fatigue, and possibly anemia secondary to blood loss in diarrhea.; Infection with nematodes of the genus TRICHURIS, formerly called Trichocephalus.; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005654",
+              "name": "ascariasis",
+              "description": "An infection that is caused by the roundworm Ascaris lumbricoides, many cases of which remain asymptomatic. During the transient larval migratory phase, shortness of breath, fever, and eosinophilia can occur. Depending on the intestinal worm burden, a spectrum of gastrointestinal tract symptoms can occur.; Infection by nematodes of the genus ASCARIS. Ingestion of infective eggs causes diarrhea and pneumonitis. Its distribution is more prevalent in areas of poor sanitation and where human feces are used for fertilizer.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "NCIT:C128399",
-                "MEDDRA:10047934",
-                "UMLS:C0040954",
-                "MESH:D014257",
-                "MONDO:0005996",
-                "UMLS:C5551334",
-                "MEDDRA:10044630",
-                "MEDDRA:10044631",
-                "DOID:1252",
-                "MEDDRA:10053126",
-                "SNOMEDCT:3752003",
-                "SNOMEDCT:60570001",
-                "ICD9:127.3",
-                "EFO:0007524"
+                "MONDO:0005654",
+                "EFO:0007154",
+                "SNOMEDCT:2435008",
+                "MESH:D001196",
+                "ICD9:127.0",
+                "NCIT:C128392",
+                "MEDDRA:10003442",
+                "UMLS:C0003950",
+                "ICD10:B77",
+                "DOID:456"
               ],
-              "id": "MONDO:0005996",
+              "id": "MONDO:0005654",
               "category": "biolink:Disease",
               "all_names": [
-                "Infection by Trichuris trichiura",
-                "trichuriasis",
-                "Trichuriasis"
+                "Ascariasis",
+                "ascariasis"
               ],
               "all_categories": [
                 "biolink:Disease"
               ],
               "publications": [
-                "http://en.wikipedia.org/wiki/trichuriasis",
-                "http://www.dpd.cdc.gov/dpdx/html/trichuriasis.htm"
+                "http://en.wikipedia.org/wiki/ascariasis",
+                "http://www.dpd.cdc.gov/dpdx/html/ascariasis.htm",
+                "http://www.merck.com/mmpe/sec14/ch182/ch182d.html?qt=ascariasis&alt=sh"
               ]
             }
           },
           "relationship": {
-            "identity": 9381542,
-            "start": 551,
-            "end": 529458,
+            "identity": 7209864,
+            "start": 549,
+            "end": 529465,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12055813': {'publication date': '2002', 'sentence': 'Three randomized clinical studies were conducted in 2000 to evaluate the efficacy of nitazoxanide paediatric suspension compared to albendazole in the treatment of ascariasis and trichuriasis and praziquantel in the treatment of hymenolepiasis in children from Cajamarca, Peru.', 'subject score': 1000, 'object score': 1000}, 'PMID:23682433': {'publication date': '2013 Jan', 'sentence': 'We studied asymptomatic primary schoolchildren in northeastern Malaysia with light to moderate trichuriasis to determine the effect of albendazole treatment on growth rates and TNF-alpha levels.', 'subject score': 888, 'object score': 1000}, 'PMID:31110573': {'publication date': '2019 Apr 30', 'sentence': 'Combination of albendazole combined with levamisole showed better cure rate for mild trichuriasis (95.8%) than albendazole therapy (46.2%) and mebendazole combined with levamisole (83.3%), (p < 0.05).', 'subject score': 888, 'object score': 888}, 'PMID:34974667': {'publication date': '2021 Dec', 'sentence': 'Failure of Repeated MDA with Albendazole for Trichuriasis Control in Schoolchildren of the Yangon Region, Myanmar.', 'subject score': 1000, 'object score': 1000}, 'PMID:6378109': {'publication date': '1984 Apr', 'sentence': 'Treatment of severe symptomatic trichuriasis observed with heavy worm burdens is not satisfactory with recommended doses of mebendazole, flubendazole and albendazole.', 'subject score': 1000, 'object score': 851}, 'PMID:7939948': {'publication date': '1993 Dec', 'sentence': 'A comparative study on the efficacy of albendazole and mebendazole in the treatment of ascariasis, hookworm infection and trichuriasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:9798586': {'publication date': '1998 Oct 03', 'sentence': 'Randomised trial of albendazole and pyrantel in symptomless trichuriasis in children.', 'subject score': 1000, 'object score': 888}}",
+              "publications_info": "{'PMID:1023465': {'publication date': '1976', 'sentence': '[Comparison of thiabendazole and mebendazole in the treatment of ascariasis and enterobiasis].', 'subject score': 1000, 'object score': 1000}, 'PMID:5450392': {'publication date': '1970', 'sentence': '[The usefulness of thiabendazole, bephenium and piperazine in mass control of ascariasis and ancylostomiasis].', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0040954---SEMMEDDB:"
+                "UMLS:C0039832---SEMMEDDB:treats---None---None---None---UMLS:C0003950---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "9588560",
-              "object": "MONDO:0005996",
+              "subject": "PUBCHEM.COMPOUND:5430",
+              "id": "7357051",
+              "object": "MONDO:0005654",
               "publications": [
-                "PMID:12055813",
-                "PMID:23682433",
-                "PMID:31110573",
-                "PMID:34974667",
-                "PMID:6378109",
-                "PMID:7939948",
-                "PMID:9798586"
+                "PMID:1023465",
+                "PMID:5450392"
               ]
             }
           },
           "end": {
-            "identity": 551,
+            "identity": 549,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -4714,508488 +3294,54 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 532244,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:32206366': {'publication date': '2020', 'sentence': 'Symptoms of perianal itching and visualization of visible motile worms persisted for 6 months despite being treated with multiple courses of albendazole causing a lot of frustration and distress to the caregivers.', 'subject score': 888, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 526500,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016075",
-          "name": "filariasis",
-          "description": "A parasitic disease caused by tissue-invasive, vector-borne nematodes which can be found anywhere in the human body and that are transmitted to humans through the bite of an infected mosquito or fly or by consumption of unsafe drinking water and which, depending on the subtype can manifest with lymphedema, dermatitis, subcutaneous edema and eye involvement. The disorder is a major public health problem in many tropical and subtropical countries. Six subtypes have been described in the literature: lymphatic filariasis, onchocerciasis, loiasis, mansonelliasis, dirofilariasis and dracunculiasis caused by Wuchereria bancrofti and filarioidea of the genus Brugia; Onchocerca volvulus; Loa loa; Mansonella; Dirofilaria; and Dracunculus medinensis, respectively. Tropical eosinophilia is considered a frequent manifestation.",
-          "equivalent_curies": [
-            "MONDO:0016075",
-            "ICD9:125.9",
-            "MEDDRA:10076405",
-            "NCIT:C34611",
-            "DOID:1080",
-            "MEDDRA:10016674",
-            "ICD10:B74",
-            "SNOMEDCT:105706003",
-            "ORPHANET:2034",
-            "UMLS:C0016085",
-            "MESH:D005368",
-            "MEDDRA:10045874"
-          ],
-          "id": "MONDO:0016075",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Filariasis",
-            "Unspecified filariasis",
-            "filariasis"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-          "name": "helminthiasis",
-          "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
-          "equivalent_curies": [
-            "MESH:D006373",
-            "MONDO:0004664",
-            "MEDDRA:10061201",
-            "ICD10:B83.9",
-            "MEDDRA:10019380",
-            "MEDDRA:10019382",
-            "DOID:883",
-            "UMLS:C0018889",
-            "NCIT:C84751",
-            "SNOMEDCT:27601005",
-            "EFO:1001342",
-            "ICD9:120-129.99"
-          ],
-          "id": "MONDO:0004664",
-          "category": "biolink:Disease",
-          "all_names": [
-            "parasitic helminthiasis infectious disease",
-            "Helminthiasis",
-            "Helminthiases",
-            "helminthiasis"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://en.wikipedia.org/wiki/filariasis"
-=======
-            "http://en.wikipedia.org/wiki/helminth",
-            "http://en.wikipedia.org/wiki/helminthiasis"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 532244,
-=======
-            "identity": 526500,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016075",
-              "name": "filariasis",
-              "description": "A parasitic disease caused by tissue-invasive, vector-borne nematodes which can be found anywhere in the human body and that are transmitted to humans through the bite of an infected mosquito or fly or by consumption of unsafe drinking water and which, depending on the subtype can manifest with lymphedema, dermatitis, subcutaneous edema and eye involvement. The disorder is a major public health problem in many tropical and subtropical countries. Six subtypes have been described in the literature: lymphatic filariasis, onchocerciasis, loiasis, mansonelliasis, dirofilariasis and dracunculiasis caused by Wuchereria bancrofti and filarioidea of the genus Brugia; Onchocerca volvulus; Loa loa; Mansonella; Dirofilaria; and Dracunculus medinensis, respectively. Tropical eosinophilia is considered a frequent manifestation.",
-              "equivalent_curies": [
-                "MONDO:0016075",
-                "ICD9:125.9",
-                "MEDDRA:10076405",
-                "NCIT:C34611",
-                "DOID:1080",
-                "MEDDRA:10016674",
-                "ICD10:B74",
-                "SNOMEDCT:105706003",
-                "ORPHANET:2034",
-                "UMLS:C0016085",
-                "MESH:D005368",
-                "MEDDRA:10045874"
-              ],
-              "id": "MONDO:0016075",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Filariasis",
-                "Unspecified filariasis",
-                "filariasis"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-              "name": "helminthiasis",
-              "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
-              "equivalent_curies": [
-                "MESH:D006373",
-                "MONDO:0004664",
-                "MEDDRA:10061201",
-                "ICD10:B83.9",
-                "MEDDRA:10019380",
-                "MEDDRA:10019382",
-                "DOID:883",
-                "UMLS:C0018889",
-                "NCIT:C84751",
-                "SNOMEDCT:27601005",
-                "EFO:1001342",
-                "ICD9:120-129.99"
-              ],
-              "id": "MONDO:0004664",
-              "category": "biolink:Disease",
-              "all_names": [
-                "parasitic helminthiasis infectious disease",
-                "Helminthiasis",
-                "Helminthiases",
-                "helminthiasis"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://en.wikipedia.org/wiki/filariasis"
-=======
-                "http://en.wikipedia.org/wiki/helminth",
-                "http://en.wikipedia.org/wiki/helminthiasis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 9276836,
-            "start": 551,
-            "end": 532244,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11954915': {'publication date': '2002 Mar', 'sentence': 'Today, the only way is the prophylactic control of Onchocerca vovulus infections and treating lymphatic filariosis with ivermectin, diethylcarbamacine, ivermectin/diethylcarbamazine. or ivermectin/albendazole combinations.', 'subject score': 851, 'object score': 851}, 'PMID:1476470': {'publication date': '1992 Sep', 'sentence': 'Albendazole was not shown to be useful for treatment of Mansonella perstans filariasis.', 'subject score': 1000, 'object score': 901}, 'PMID:15049459': {'publication date': '2004 Apr', 'sentence': 'The present field study has shown the combination of DEC + ALB to be as safe as the single drug DEC and thus the combination can be put in use in the national filariasis control programmes.', 'subject score': 888, 'object score': 608}, 'PMID:15361118': {'publication date': '2004 Sep', 'sentence': 'Effectiveness of two annual, single-dose mass drug administrations of diethylcarbamazine alone or in combination with albendazole on soil-transmitted helminthiasis in filariasis elimination programme.', 'subject score': 1000, 'object score': 623}, 'PMID:16575724': {'publication date': '2006 Apr 15', 'sentence': 'A randomized, double-blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection.', 'subject score': 851, 'object score': 913}, 'PMID:19825283': {'publication date': '2009 Oct', 'sentence': 'In India, annual rounds of mass drug administration (MDA) based on diethylcarbamazine and albendazole are used to control filariasis, which is a major public-health problem.', 'subject score': 1000, 'object score': 1000}, 'PMID:29059186': {'publication date': '2017 Oct', 'sentence': 'Lymphatic pathology in asymptomatic and symptomatic children with Wuchereria bancrofti infection in children from Odisha, India and its reversal with DEC and albendazole treatment.', 'subject score': 888, 'object score': 913}, 'PMID:29432423': {'publication date': '2018 02', 'sentence': 'Approximately 20% of at-risk WRA had received deworming with albendazole through the Global Programme to Eliminate Filariasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:29702653': {'publication date': '2018 04', 'sentence': 'However, although not statistically significant, sub-group analysis showed a tendency for slightly more AEs in patients with filariasis treated with ivermectin-albendazole compared to those treated with albendazole alone (RR = 1.29, 95% CI = 0.81-2.05).', 'subject score': 888, 'object score': 1000}, 'PMID:31496523': {'publication date': '2019 06', 'sentence': 'Microfilaricidal drugs such as ivermectin and albendazole have been used as the standard therapy in filariasis, although their efficacy in eliminating the diseases is not fully established.', 'subject score': 1000, 'object score': 1000}, 'PMID:35292585': {'publication date': '2022 Mar 15', 'sentence': 'However, the \"guideline review process\" depended heavily on preliminary results from multicenter studies that were performed to compare the safety, tolerability, and acceptability of IDA versus DA (the two-drug regimen of DEC plus albendazole that was recommended for use for filariasis elimination in countries without co-endemic onchocerciasis or loiasis).', 'subject score': 851, 'object score': 888}, 'PMID:9196776': {'publication date': '1997', 'sentence': 'Albendazole for the treatment of Mansonella perstans filariasis.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0016085---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "9492446",
-              "object": "MONDO:0016075",
-              "publications": [
-                "PMID:11954915",
-                "PMID:1476470",
-                "PMID:15049459",
-                "PMID:15361118",
-                "PMID:16575724",
-                "PMID:19825283",
-                "PMID:29059186",
-                "PMID:29432423",
-                "PMID:29702653",
-                "PMID:31496523",
-                "PMID:35292585",
-                "PMID:9196776"
-=======
-            "identity": 21431097,
-            "start": 551,
-            "end": 526500,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32206366': {'publication date': '2020', 'sentence': 'Symptoms of perianal itching and visualization of visible motile worms persisted for 6 months despite being treated with multiple courses of albendazole causing a lot of frustration and distress to the caregivers.', 'subject score': 888, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:causes---None---None---None---UMLS:C0018889---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "21848143",
-              "object": "MONDO:0004664",
-              "publications": [
-                "PMID:32206366"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:18771788': {'publication date': '2009 Jan', 'sentence': 'Mass co-administration of ivermectin and albendazole by the LFEP had a significant effect on STH, which was further amplified by treatment with praziquantel and albendazole 4 months later.', 'subject score': 1000, 'object score': 802}, 'PMID:22728750': {'publication date': '2012 Jul 01', 'sentence': 'BACKGROUND: To investigate the effect of helminth infections and their treatment during pregnancy on HIV load, we conducted a 2 * 2 factorial randomized controlled trial of albendazole versus placebo and praziquantel versus placebo in pregnant women in Entebbe, Uganda.', 'subject score': 1000, 'object score': 983}, 'PMID:28372977': {'publication date': '2017 07', 'sentence': 'Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.', 'subject score': 1000, 'object score': 813}, 'PMID:34929673': {'publication date': '2021 Dec 20', 'sentence': 'Impact of Semi-Annual Albendazole on Lymphatic Filariasis and Soil-Transmitted Helminth Infection: Parasitological Assessment after 14 Rounds of Community Treatment.', 'subject score': 901, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 526500,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-          "name": "helminthiasis",
-          "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
-          "equivalent_curies": [
-            "MESH:D006373",
-            "MONDO:0004664",
-            "MEDDRA:10061201",
-            "ICD10:B83.9",
-            "MEDDRA:10019380",
-            "MEDDRA:10019382",
-            "DOID:883",
-            "UMLS:C0018889",
-            "NCIT:C84751",
-            "SNOMEDCT:27601005",
-            "EFO:1001342",
-            "ICD9:120-129.99"
-          ],
-          "id": "MONDO:0004664",
-          "category": "biolink:Disease",
-          "all_names": [
-            "parasitic helminthiasis infectious disease",
-            "Helminthiasis",
-            "Helminthiases",
-            "helminthiasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/helminth",
-            "http://en.wikipedia.org/wiki/helminthiasis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526500,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-              "name": "helminthiasis",
-              "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
-              "equivalent_curies": [
-                "MESH:D006373",
-                "MONDO:0004664",
-                "MEDDRA:10061201",
-                "ICD10:B83.9",
-                "MEDDRA:10019380",
-                "MEDDRA:10019382",
-                "DOID:883",
-                "UMLS:C0018889",
-                "NCIT:C84751",
-                "SNOMEDCT:27601005",
-                "EFO:1001342",
-                "ICD9:120-129.99"
-              ],
-              "id": "MONDO:0004664",
-              "category": "biolink:Disease",
-              "all_names": [
-                "parasitic helminthiasis infectious disease",
-                "Helminthiasis",
-                "Helminthiases",
-                "helminthiasis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/helminth",
-                "http://en.wikipedia.org/wiki/helminthiasis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13653912,
-            "start": 551,
-            "end": 526500,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18771788': {'publication date': '2009 Jan', 'sentence': 'Mass co-administration of ivermectin and albendazole by the LFEP had a significant effect on STH, which was further amplified by treatment with praziquantel and albendazole 4 months later.', 'subject score': 1000, 'object score': 802}, 'PMID:22728750': {'publication date': '2012 Jul 01', 'sentence': 'BACKGROUND: To investigate the effect of helminth infections and their treatment during pregnancy on HIV load, we conducted a 2 * 2 factorial randomized controlled trial of albendazole versus placebo and praziquantel versus placebo in pregnant women in Entebbe, Uganda.', 'subject score': 1000, 'object score': 983}, 'PMID:28372977': {'publication date': '2017 07', 'sentence': 'Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.', 'subject score': 1000, 'object score': 813}, 'PMID:34929673': {'publication date': '2021 Dec 20', 'sentence': 'Impact of Semi-Annual Albendazole on Lymphatic Filariasis and Soil-Transmitted Helminth Infection: Parasitological Assessment after 14 Rounds of Community Treatment.', 'subject score': 901, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:affects---None---None---None---UMLS:C0018889---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "13946207",
-              "object": "MONDO:0004664",
-              "publications": [
-                "PMID:18771788",
-                "PMID:22728750",
-                "PMID:28372977",
-                "PMID:34929673"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11207651': {'publication date': '2001 Feb', 'sentence': 'The study population was assessed for helminthic infection and those found to be positive were randomly assigned to either an albendazole treatment group or a control group who received a placebo.', 'subject score': 851, 'object score': 1000}, 'PMID:11343808': {'publication date': '2001 Mar-Apr', 'sentence': 'BACKGROUND: Albendazole (ABZ) is an antiparasitic drug used for the treatment of several helminthiases.', 'subject score': 1000, 'object score': 888}, 'PMID:16406097': {'publication date': '2006 Sep', 'sentence': 'Definite and probable cases of helminth infection were treated with albendazole and all soldiers were screened again after 3 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:17427535': {'publication date': '2007 Mar', 'sentence': 'BACKGROUND: Foreign migrant workers with work permits in Thailand are given once a year 300 mg diethyl-carbamazine (DEC) for bancroftian filariasis, and 400 mg albendazole (ABZ) for helminthiasis.', 'subject score': 790, 'object score': 1000}, 'PMID:18235853': {'publication date': '2008 Jan 23', 'sentence': 'CONCLUSIONS/SIGNIFICANCE: Our data suggest that co-administration of ivermectin, albendazole and praziquantel is safe in areas where lymphatic filariasis, soil-transmitted helminthiasis and schistosomiasis are co-endemic and where several rounds of treatment with one or two drugs have been implemented in the past.', 'subject score': 1000, 'object score': 802}, 'PMID:19228385': {'publication date': '2009 Feb 19', 'sentence': 'Our objectives were to describe the prevalence and intensity of STH infection and to investigate the effectiveness of repeated four-monthly albendazole treatments on STH infection in children aged one to four years.', 'subject score': 822, 'object score': 813}, 'PMID:22235353': {'publication date': '2012 Jan', 'sentence': 'BACKGROUND: Albendazole and mebendazole are increasingly deployed for preventive chemotherapy targeting soil-transmitted helminth (STH) infections.', 'subject score': 1000, 'object score': 735}, 'PMID:22745183': {'publication date': '2012', 'sentence': 'The LSN-ABZ combination was frequently employed for management of HIV/AIDS and HL.', 'subject score': 790, 'object score': 1000}, 'PMID:24448936': {'publication date': '2013', 'sentence': '[Efficacy of a single dose of Albendazole for soil-transmitted helminth infections in school children of a village in Iquitos, Peru].', 'subject score': 1000, 'object score': 813}, 'PMID:26935065': {'publication date': '2016 Mar 02', 'sentence': 'BACKGROUND: Preventive chemotherapy with albendazole or mebendazole is the current strategy to control soil-transmitted helminth (STH) infections (i.e. Ascaris lumbricoides, hookworm and Trichuris trichiura).', 'subject score': 1000, 'object score': 813}, 'PMID:27480864': {'publication date': '2016 10', 'sentence': 'In Vitro and In Vivo Drug Interaction Study of Two Lead Combinations, Oxantel Pamoate plus Albendazole and Albendazole plus Mebendazole, for the Treatment of Soil-Transmitted Helminthiasis.', 'subject score': 861, 'object score': 802}, 'PMID:28039389': {'publication date': '2016 Dec 29', 'sentence': 'BACKGROUND: Albendazole is one of two standard drugs for the control of soil-transmitted helminthiasis.', 'subject score': 1000, 'object score': 802}, 'PMID:29239572': {'publication date': '2017 11 27', 'sentence': 'Children were examined for soil-transmitted helminth infections using duplicate Kato-Katz thick smears in March 2015, October 2015 and May 2016, and subsequently treated with albendazole after each survey.', 'subject score': 1000, 'object score': 813}, 'PMID:29774278': {'publication date': '2017 May', 'sentence': 'The study shows that STH is still a public health problem in Zuru LGA (IVM + ALB) and requires MDA of albendazole for STH control to continue, while Dandi LGA (No MDA history) requires MDA with albendazole to scale up treatment for STH control.', 'subject score': 1000, 'object score': 802}, 'PMID:30766740': {'publication date': '2018 Oct-Dec', 'sentence': 'Introduction: In July 2015, the Philippines conducted a school-based mass drug administration using albendazole for soil-transmitted helminths infection.', 'subject score': 1000, 'object score': 813}, 'PMID:31044235': {'publication date': '2019 May 02', 'sentence': 'The moxidectin-albendazole combination of 8 mg plus 400 mg should be investigated further to develop recommendations for appropriate control of STH infections.', 'subject score': 851, 'object score': 813}, 'PMID:31110573': {'publication date': '2019 Apr 30', 'sentence': 'RESULT: The cure rate of helminthiasis on the 7th day was 81.7% after albendazole therapy, 88.3% after albendazole levamisole therapy, and 83.3% after mebendazole combined with levamisole therapy (p = 0.577).', 'subject score': 888, 'object score': 1000}, 'PMID:32503495': {'publication date': '2020 Jun 05', 'sentence': 'The objective of this study was to determine whether community drug distributors (CDDs) - volunteers selected by their communities to distribute ivermectin against onchocerciasis and who have been proven efficient to deliver other health interventions such as insecticide-treated bed nets to prevent malaria, vitamin A tablets, and albendazole to treat soil transmitted helminthiasis - can be used to reliably identify people living with epilepsy to promote better management of cases.', 'subject score': 1000, 'object score': 851}, 'PMID:32610728': {'publication date': '2020 Apr 22', 'sentence': 'Mass Drug Administration (MDA) of albendazole is being implemented in the Philippines to eliminate soil-transmitted helminthiasis (STH) among school-age children (SAC).', 'subject score': 1000, 'object score': 851}, 'PMID:32956390': {'publication date': '2020 Sep 21', 'sentence': 'An in-depth report of quality control on Kato-Katz and data entry in four clinical trials evaluating the efficacy of albendazole against soil-transmitted helminth infections.BACKGROUND: Efforts to control soil-transmitted helminth (STH) infections have intensified over the past decade.', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 526500,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-          "name": "helminthiasis",
-          "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
-          "equivalent_curies": [
-            "MESH:D006373",
-            "MONDO:0004664",
-            "MEDDRA:10061201",
-            "ICD10:B83.9",
-            "MEDDRA:10019380",
-            "MEDDRA:10019382",
-            "DOID:883",
-            "UMLS:C0018889",
-            "NCIT:C84751",
-            "SNOMEDCT:27601005",
-            "EFO:1001342",
-            "ICD9:120-129.99"
-          ],
-          "id": "MONDO:0004664",
-          "category": "biolink:Disease",
-          "all_names": [
-            "parasitic helminthiasis infectious disease",
-            "Helminthiasis",
-            "Helminthiases",
-            "helminthiasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/helminth",
-            "http://en.wikipedia.org/wiki/helminthiasis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526500,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-              "name": "helminthiasis",
-              "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
-              "equivalent_curies": [
-                "MESH:D006373",
-                "MONDO:0004664",
-                "MEDDRA:10061201",
-                "ICD10:B83.9",
-                "MEDDRA:10019380",
-                "MEDDRA:10019382",
-                "DOID:883",
-                "UMLS:C0018889",
-                "NCIT:C84751",
-                "SNOMEDCT:27601005",
-                "EFO:1001342",
-                "ICD9:120-129.99"
-              ],
-              "id": "MONDO:0004664",
-              "category": "biolink:Disease",
-              "all_names": [
-                "parasitic helminthiasis infectious disease",
-                "Helminthiasis",
-                "Helminthiases",
-                "helminthiasis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/helminth",
-                "http://en.wikipedia.org/wiki/helminthiasis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8526117,
-            "start": 551,
-            "end": 526500,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11207651': {'publication date': '2001 Feb', 'sentence': 'The study population was assessed for helminthic infection and those found to be positive were randomly assigned to either an albendazole treatment group or a control group who received a placebo.', 'subject score': 851, 'object score': 1000}, 'PMID:11343808': {'publication date': '2001 Mar-Apr', 'sentence': 'BACKGROUND: Albendazole (ABZ) is an antiparasitic drug used for the treatment of several helminthiases.', 'subject score': 1000, 'object score': 888}, 'PMID:16406097': {'publication date': '2006 Sep', 'sentence': 'Definite and probable cases of helminth infection were treated with albendazole and all soldiers were screened again after 3 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:17427535': {'publication date': '2007 Mar', 'sentence': 'BACKGROUND: Foreign migrant workers with work permits in Thailand are given once a year 300 mg diethyl-carbamazine (DEC) for bancroftian filariasis, and 400 mg albendazole (ABZ) for helminthiasis.', 'subject score': 790, 'object score': 1000}, 'PMID:18235853': {'publication date': '2008 Jan 23', 'sentence': 'CONCLUSIONS/SIGNIFICANCE: Our data suggest that co-administration of ivermectin, albendazole and praziquantel is safe in areas where lymphatic filariasis, soil-transmitted helminthiasis and schistosomiasis are co-endemic and where several rounds of treatment with one or two drugs have been implemented in the past.', 'subject score': 1000, 'object score': 802}, 'PMID:19228385': {'publication date': '2009 Feb 19', 'sentence': 'Our objectives were to describe the prevalence and intensity of STH infection and to investigate the effectiveness of repeated four-monthly albendazole treatments on STH infection in children aged one to four years.', 'subject score': 822, 'object score': 813}, 'PMID:22235353': {'publication date': '2012 Jan', 'sentence': 'BACKGROUND: Albendazole and mebendazole are increasingly deployed for preventive chemotherapy targeting soil-transmitted helminth (STH) infections.', 'subject score': 1000, 'object score': 735}, 'PMID:22745183': {'publication date': '2012', 'sentence': 'The LSN-ABZ combination was frequently employed for management of HIV/AIDS and HL.', 'subject score': 790, 'object score': 1000}, 'PMID:24448936': {'publication date': '2013', 'sentence': '[Efficacy of a single dose of Albendazole for soil-transmitted helminth infections in school children of a village in Iquitos, Peru].', 'subject score': 1000, 'object score': 813}, 'PMID:26935065': {'publication date': '2016 Mar 02', 'sentence': 'BACKGROUND: Preventive chemotherapy with albendazole or mebendazole is the current strategy to control soil-transmitted helminth (STH) infections (i.e. Ascaris lumbricoides, hookworm and Trichuris trichiura).', 'subject score': 1000, 'object score': 813}, 'PMID:27480864': {'publication date': '2016 10', 'sentence': 'In Vitro and In Vivo Drug Interaction Study of Two Lead Combinations, Oxantel Pamoate plus Albendazole and Albendazole plus Mebendazole, for the Treatment of Soil-Transmitted Helminthiasis.', 'subject score': 861, 'object score': 802}, 'PMID:28039389': {'publication date': '2016 Dec 29', 'sentence': 'BACKGROUND: Albendazole is one of two standard drugs for the control of soil-transmitted helminthiasis.', 'subject score': 1000, 'object score': 802}, 'PMID:29239572': {'publication date': '2017 11 27', 'sentence': 'Children were examined for soil-transmitted helminth infections using duplicate Kato-Katz thick smears in March 2015, October 2015 and May 2016, and subsequently treated with albendazole after each survey.', 'subject score': 1000, 'object score': 813}, 'PMID:29774278': {'publication date': '2017 May', 'sentence': 'The study shows that STH is still a public health problem in Zuru LGA (IVM + ALB) and requires MDA of albendazole for STH control to continue, while Dandi LGA (No MDA history) requires MDA with albendazole to scale up treatment for STH control.', 'subject score': 1000, 'object score': 802}, 'PMID:30766740': {'publication date': '2018 Oct-Dec', 'sentence': 'Introduction: In July 2015, the Philippines conducted a school-based mass drug administration using albendazole for soil-transmitted helminths infection.', 'subject score': 1000, 'object score': 813}, 'PMID:31044235': {'publication date': '2019 May 02', 'sentence': 'The moxidectin-albendazole combination of 8 mg plus 400 mg should be investigated further to develop recommendations for appropriate control of STH infections.', 'subject score': 851, 'object score': 813}, 'PMID:31110573': {'publication date': '2019 Apr 30', 'sentence': 'RESULT: The cure rate of helminthiasis on the 7th day was 81.7% after albendazole therapy, 88.3% after albendazole levamisole therapy, and 83.3% after mebendazole combined with levamisole therapy (p = 0.577).', 'subject score': 888, 'object score': 1000}, 'PMID:32503495': {'publication date': '2020 Jun 05', 'sentence': 'The objective of this study was to determine whether community drug distributors (CDDs) - volunteers selected by their communities to distribute ivermectin against onchocerciasis and who have been proven efficient to deliver other health interventions such as insecticide-treated bed nets to prevent malaria, vitamin A tablets, and albendazole to treat soil transmitted helminthiasis - can be used to reliably identify people living with epilepsy to promote better management of cases.', 'subject score': 1000, 'object score': 851}, 'PMID:32610728': {'publication date': '2020 Apr 22', 'sentence': 'Mass Drug Administration (MDA) of albendazole is being implemented in the Philippines to eliminate soil-transmitted helminthiasis (STH) among school-age children (SAC).', 'subject score': 1000, 'object score': 851}, 'PMID:32956390': {'publication date': '2020 Sep 21', 'sentence': 'An in-depth report of quality control on Kato-Katz and data entry in four clinical trials evaluating the efficacy of albendazole against soil-transmitted helminth infections.BACKGROUND: Efforts to control soil-transmitted helminth (STH) infections have intensified over the past decade.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0018889---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "8712067",
-              "object": "MONDO:0004664",
-              "publications": [
-                "PMID:11207651",
-                "PMID:11343808",
-                "PMID:16406097",
-                "PMID:17427535",
-                "PMID:18235853",
-                "PMID:19228385",
-                "PMID:22235353",
-                "PMID:22745183",
-                "PMID:24448936",
-                "PMID:26935065",
-                "PMID:27480864",
-                "PMID:28039389",
-                "PMID:29239572",
-                "PMID:29774278",
-                "PMID:30766740",
-                "PMID:31044235",
-                "PMID:31110573",
-                "PMID:32503495",
-                "PMID:32610728",
-                "PMID:32956390"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:35856263': {'publication date': '2022 Jul 20', 'sentence': 'Additionally, compared with albendazole, it resulted in a significant reduction in adult worm and total larval counts; moreover, it caused a decrease in the number of larvae deposited in muscles, with a highly significant decrease in the inflammatory cell infiltrate around the larvae and a considerable decrease in the expression of the angiogenic marker vascular endothelial growth factor in muscles.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 526500,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-          "name": "helminthiasis",
-          "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
-          "equivalent_curies": [
-            "MESH:D006373",
-            "MONDO:0004664",
-            "MEDDRA:10061201",
-            "ICD10:B83.9",
-            "MEDDRA:10019380",
-            "MEDDRA:10019382",
-            "DOID:883",
-            "UMLS:C0018889",
-            "NCIT:C84751",
-            "SNOMEDCT:27601005",
-            "EFO:1001342",
-            "ICD9:120-129.99"
-          ],
-          "id": "MONDO:0004664",
-          "category": "biolink:Disease",
-          "all_names": [
-            "parasitic helminthiasis infectious disease",
-            "Helminthiasis",
-            "Helminthiases",
-            "helminthiasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/helminth",
-            "http://en.wikipedia.org/wiki/helminthiasis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526500,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-              "name": "helminthiasis",
-              "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
-              "equivalent_curies": [
-                "MESH:D006373",
-                "MONDO:0004664",
-                "MEDDRA:10061201",
-                "ICD10:B83.9",
-                "MEDDRA:10019380",
-                "MEDDRA:10019382",
-                "DOID:883",
-                "UMLS:C0018889",
-                "NCIT:C84751",
-                "SNOMEDCT:27601005",
-                "EFO:1001342",
-                "ICD9:120-129.99"
-              ],
-              "id": "MONDO:0004664",
-              "category": "biolink:Disease",
-              "all_names": [
-                "parasitic helminthiasis infectious disease",
-                "Helminthiasis",
-                "Helminthiases",
-                "helminthiasis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/helminth",
-                "http://en.wikipedia.org/wiki/helminthiasis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24282217,
-            "start": 551,
-            "end": 526500,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35856263': {'publication date': '2022 Jul 20', 'sentence': 'Additionally, compared with albendazole, it resulted in a significant reduction in adult worm and total larval counts; moreover, it caused a decrease in the number of larvae deposited in muscles, with a highly significant decrease in the inflammatory cell infiltrate around the larvae and a considerable decrease in the expression of the angiogenic marker vascular endothelial growth factor in muscles.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:disrupts---None---None---None---UMLS:C0018889---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "24729219",
-              "object": "MONDO:0004664",
-              "publications": [
-                "PMID:35856263"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:18458310': {'publication date': '2008 May', 'sentence': 'Our evaluation suggests that although additional studies are needed to determine optimal treatment regimens for intestinal parasites, especially among young children and pregnant women, a five-day course of pre-departure albendazole was effective in reducing helminthic infection in treated refugees.', 'subject score': 802, 'object score': 890}, 'PMID:22913197': {'publication date': '2012 Feb 29', 'sentence': 'When treating with one course of albendazole at 1 week post infection, the worm reduction rate in groups A-C was 20.0%, 20.0% and 24.9%, respectively (chi2 = 0.351, P > 0.05).', 'subject score': 1000, 'object score': 802}}",
-    "p2": {
-      "start": {
-        "identity": 526500,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-          "name": "helminthiasis",
-          "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
-          "equivalent_curies": [
-            "MESH:D006373",
-            "MONDO:0004664",
-            "MEDDRA:10061201",
-            "ICD10:B83.9",
-            "MEDDRA:10019380",
-            "MEDDRA:10019382",
-            "DOID:883",
-            "UMLS:C0018889",
-            "NCIT:C84751",
-            "SNOMEDCT:27601005",
-            "EFO:1001342",
-            "ICD9:120-129.99"
-          ],
-          "id": "MONDO:0004664",
-          "category": "biolink:Disease",
-          "all_names": [
-            "parasitic helminthiasis infectious disease",
-            "Helminthiasis",
-            "Helminthiases",
-            "helminthiasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/helminth",
-            "http://en.wikipedia.org/wiki/helminthiasis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526500,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-              "name": "helminthiasis",
-              "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
-              "equivalent_curies": [
-                "MESH:D006373",
-                "MONDO:0004664",
-                "MEDDRA:10061201",
-                "ICD10:B83.9",
-                "MEDDRA:10019380",
-                "MEDDRA:10019382",
-                "DOID:883",
-                "UMLS:C0018889",
-                "NCIT:C84751",
-                "SNOMEDCT:27601005",
-                "EFO:1001342",
-                "ICD9:120-129.99"
-              ],
-              "id": "MONDO:0004664",
-              "category": "biolink:Disease",
-              "all_names": [
-                "parasitic helminthiasis infectious disease",
-                "Helminthiasis",
-                "Helminthiases",
-                "helminthiasis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/helminth",
-                "http://en.wikipedia.org/wiki/helminthiasis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13443772,
-            "start": 551,
-            "end": 526500,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18458310': {'publication date': '2008 May', 'sentence': 'Our evaluation suggests that although additional studies are needed to determine optimal treatment regimens for intestinal parasites, especially among young children and pregnant women, a five-day course of pre-departure albendazole was effective in reducing helminthic infection in treated refugees.', 'subject score': 802, 'object score': 890}, 'PMID:22913197': {'publication date': '2012 Feb 29', 'sentence': 'When treating with one course of albendazole at 1 week post infection, the worm reduction rate in groups A-C was 20.0%, 20.0% and 24.9%, respectively (chi2 = 0.351, P > 0.05).', 'subject score': 1000, 'object score': 802}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:prevents---None---None---None---UMLS:C0018889---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "13732336",
-              "object": "MONDO:0004664",
-              "publications": [
-                "PMID:18458310",
-                "PMID:22913197"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:2619377': {'publication date': '1989 Dec', 'sentence': 'Effect of albendazole in experimental toxocariasis of mice.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 517567,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005988",
-          "name": "toxocariasis",
-          "description": "A parasitic infection caused by Toxocara. Humans are infected by the larvae of Toxocara canis and Toxocara cati from dogs and cats respectively. Most cases remain asymptomatic. The parasites may affect the eye, causing diminished vision, or other major organs, causing hepatomegaly, eosinophilia, wheezing, and coughing.; Infection by round worms of the genus TOXOCARA, usually found in wild and domesticated cats and dogs and foxes, except for the larvae, which may produce visceral and ocular larva migrans in man.",
-          "equivalent_curies": [
-            "NCIT:C85194",
-            "MEDDRA:10044268",
-            "NCIT:C34758",
-            "DOID:9790",
-            "ICD10:B83.0",
-            "SNOMEDCT:406619001",
-            "MEDDRA:10044269",
-            "ICD9:128.0",
-            "MESH:D014120",
-            "ORPHANET:3343",
-            "EFO:0007516",
-            "UMLS:C0040553",
-            "MONDO:0005988"
-          ],
-          "id": "MONDO:0005988",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Toxocariasis",
-            "Visceral Larva Migrans",
-            "toxocariasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.dpd.cdc.gov/dpdx/html/toxocariasis.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517567,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005988",
-              "name": "toxocariasis",
-              "description": "A parasitic infection caused by Toxocara. Humans are infected by the larvae of Toxocara canis and Toxocara cati from dogs and cats respectively. Most cases remain asymptomatic. The parasites may affect the eye, causing diminished vision, or other major organs, causing hepatomegaly, eosinophilia, wheezing, and coughing.; Infection by round worms of the genus TOXOCARA, usually found in wild and domesticated cats and dogs and foxes, except for the larvae, which may produce visceral and ocular larva migrans in man.",
-              "equivalent_curies": [
-                "NCIT:C85194",
-                "MEDDRA:10044268",
-                "NCIT:C34758",
-                "DOID:9790",
-                "ICD10:B83.0",
-                "SNOMEDCT:406619001",
-                "MEDDRA:10044269",
-                "ICD9:128.0",
-                "MESH:D014120",
-                "ORPHANET:3343",
-                "EFO:0007516",
-                "UMLS:C0040553",
-                "MONDO:0005988"
-              ],
-              "id": "MONDO:0005988",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Toxocariasis",
-                "Visceral Larva Migrans",
-                "toxocariasis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.dpd.cdc.gov/dpdx/html/toxocariasis.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18085378,
-            "start": 551,
-            "end": 517567,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2619377': {'publication date': '1989 Dec', 'sentence': 'Effect of albendazole in experimental toxocariasis of mice.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:affects---None---None---None---UMLS:C0040553---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "18452252",
-              "object": "MONDO:0005988",
-              "publications": [
-                "PMID:2619377"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12667232': {'publication date': '2003 Apr', 'sentence': 'The treatment of cutaneous larva migrans and Toxocara infection relies on antihelminthic agents such as thiabendazole, albendazole and ivermectin.', 'subject score': 1000, 'object score': 1000}, 'PMID:17366070': {'publication date': '2007', 'sentence': 'We report a case of aortic thrombosis caused by Toxocara canis infection in a young male who was successfully treated with albendazole.', 'subject score': 1000, 'object score': 913}, 'PMID:17691438': {'publication date': '2007 Apr', 'sentence': 'Parasite serology led to suspicion of toxocariasis that was treated using albendazole.', 'subject score': 1000, 'object score': 1000}, 'PMID:19259103': {'publication date': '2009 Mar', 'sentence': 'Duration of treatment with albendazole for hepatic toxocariasis.', 'subject score': 1000, 'object score': 888}, 'PMID:20885912': {'publication date': '2010 Oct', 'sentence': 'Typically, Toxocara spp. infection is easily treated with 400 mg albendazole twice a day for 5 days.', 'subject score': 750, 'object score': 901}, 'PMID:23282502': {'publication date': '2012 Oct', 'sentence': \"Despite absent eosinophilia in the serum, toxocarosis was diagnosed and a therapy with albendazole initiated, with benefit for retromandibular pain, but hardly for Bell's palsy or enlarged lymph nodes.\", 'subject score': 1000, 'object score': 1000}, 'PMID:25917592': {'publication date': '2015 Mar', 'sentence': 'Recurrent toxocariasis due to chronic urticaria and successful treatment with prolonged albendazole therapy.', 'subject score': 851, 'object score': 888}, 'PMID:26625368': {'publication date': '2014 Jun', 'sentence': 'Albendazole or mebendazole is the recommended treatment for visceral toxocariasis.', 'subject score': 1000, 'object score': 888}, 'PMID:2694978': {'publication date': '1989 Oct', 'sentence': 'Thiabendazole vs. albendazole in treatment of toxocariasis: a clinical trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:28352060': {'publication date': '2017 May', 'sentence': 'The aims of this study were to evaluate the prevalence of toxocariasis and the clinical impact of albendazole treatment for toxocariasis in patients suspected of eosinophilia of unknown origin.', 'subject score': 888, 'object score': 1000}, 'PMID:33269576': {'publication date': '2020 Dec 02', 'sentence': 'Albendazole is used for the treatment of toxocariasis diagnosed by serologic and immunological methods.', 'subject score': 1000, 'object score': 1000}, 'PMID:35890057': {'publication date': '2022 Jul 20', 'sentence': 'A Retrospective Study of the Efficacy of Albendazole and Diethylcarbamazine for the Treatment of Human Toxocariasis.', 'subject score': 1000, 'object score': 888}, 'PMID:9629547': {'publication date': '1998', 'sentence': 'The diagnosis of a \"covert form\" of toxocarosis was established and an antihelminthic therapy with albendazole was initiated.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 517567,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005988",
-          "name": "toxocariasis",
-          "description": "A parasitic infection caused by Toxocara. Humans are infected by the larvae of Toxocara canis and Toxocara cati from dogs and cats respectively. Most cases remain asymptomatic. The parasites may affect the eye, causing diminished vision, or other major organs, causing hepatomegaly, eosinophilia, wheezing, and coughing.; Infection by round worms of the genus TOXOCARA, usually found in wild and domesticated cats and dogs and foxes, except for the larvae, which may produce visceral and ocular larva migrans in man.",
-          "equivalent_curies": [
-            "NCIT:C85194",
-            "MEDDRA:10044268",
-            "NCIT:C34758",
-            "DOID:9790",
-            "ICD10:B83.0",
-            "SNOMEDCT:406619001",
-            "MEDDRA:10044269",
-            "ICD9:128.0",
-            "MESH:D014120",
-            "ORPHANET:3343",
-            "EFO:0007516",
-            "UMLS:C0040553",
-            "MONDO:0005988"
-          ],
-          "id": "MONDO:0005988",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Toxocariasis",
-            "Visceral Larva Migrans",
-            "toxocariasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.dpd.cdc.gov/dpdx/html/toxocariasis.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517567,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005988",
-              "name": "toxocariasis",
-              "description": "A parasitic infection caused by Toxocara. Humans are infected by the larvae of Toxocara canis and Toxocara cati from dogs and cats respectively. Most cases remain asymptomatic. The parasites may affect the eye, causing diminished vision, or other major organs, causing hepatomegaly, eosinophilia, wheezing, and coughing.; Infection by round worms of the genus TOXOCARA, usually found in wild and domesticated cats and dogs and foxes, except for the larvae, which may produce visceral and ocular larva migrans in man.",
-              "equivalent_curies": [
-                "NCIT:C85194",
-                "MEDDRA:10044268",
-                "NCIT:C34758",
-                "DOID:9790",
-                "ICD10:B83.0",
-                "SNOMEDCT:406619001",
-                "MEDDRA:10044269",
-                "ICD9:128.0",
-                "MESH:D014120",
-                "ORPHANET:3343",
-                "EFO:0007516",
-                "UMLS:C0040553",
-                "MONDO:0005988"
-              ],
-              "id": "MONDO:0005988",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Toxocariasis",
-                "Visceral Larva Migrans",
-                "toxocariasis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.dpd.cdc.gov/dpdx/html/toxocariasis.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9895535,
-            "start": 551,
-            "end": 517567,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12667232': {'publication date': '2003 Apr', 'sentence': 'The treatment of cutaneous larva migrans and Toxocara infection relies on antihelminthic agents such as thiabendazole, albendazole and ivermectin.', 'subject score': 1000, 'object score': 1000}, 'PMID:17366070': {'publication date': '2007', 'sentence': 'We report a case of aortic thrombosis caused by Toxocara canis infection in a young male who was successfully treated with albendazole.', 'subject score': 1000, 'object score': 913}, 'PMID:17691438': {'publication date': '2007 Apr', 'sentence': 'Parasite serology led to suspicion of toxocariasis that was treated using albendazole.', 'subject score': 1000, 'object score': 1000}, 'PMID:19259103': {'publication date': '2009 Mar', 'sentence': 'Duration of treatment with albendazole for hepatic toxocariasis.', 'subject score': 1000, 'object score': 888}, 'PMID:20885912': {'publication date': '2010 Oct', 'sentence': 'Typically, Toxocara spp. infection is easily treated with 400 mg albendazole twice a day for 5 days.', 'subject score': 750, 'object score': 901}, 'PMID:23282502': {'publication date': '2012 Oct', 'sentence': \"Despite absent eosinophilia in the serum, toxocarosis was diagnosed and a therapy with albendazole initiated, with benefit for retromandibular pain, but hardly for Bell's palsy or enlarged lymph nodes.\", 'subject score': 1000, 'object score': 1000}, 'PMID:25917592': {'publication date': '2015 Mar', 'sentence': 'Recurrent toxocariasis due to chronic urticaria and successful treatment with prolonged albendazole therapy.', 'subject score': 851, 'object score': 888}, 'PMID:26625368': {'publication date': '2014 Jun', 'sentence': 'Albendazole or mebendazole is the recommended treatment for visceral toxocariasis.', 'subject score': 1000, 'object score': 888}, 'PMID:2694978': {'publication date': '1989 Oct', 'sentence': 'Thiabendazole vs. albendazole in treatment of toxocariasis: a clinical trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:28352060': {'publication date': '2017 May', 'sentence': 'The aims of this study were to evaluate the prevalence of toxocariasis and the clinical impact of albendazole treatment for toxocariasis in patients suspected of eosinophilia of unknown origin.', 'subject score': 888, 'object score': 1000}, 'PMID:33269576': {'publication date': '2020 Dec 02', 'sentence': 'Albendazole is used for the treatment of toxocariasis diagnosed by serologic and immunological methods.', 'subject score': 1000, 'object score': 1000}, 'PMID:35890057': {'publication date': '2022 Jul 20', 'sentence': 'A Retrospective Study of the Efficacy of Albendazole and Diethylcarbamazine for the Treatment of Human Toxocariasis.', 'subject score': 1000, 'object score': 888}, 'PMID:9629547': {'publication date': '1998', 'sentence': 'The diagnosis of a \"covert form\" of toxocarosis was established and an antihelminthic therapy with albendazole was initiated.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0040553---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "10114050",
-              "object": "MONDO:0005988",
-              "publications": [
-                "PMID:12667232",
-                "PMID:17366070",
-                "PMID:17691438",
-                "PMID:19259103",
-                "PMID:20885912",
-                "PMID:23282502",
-                "PMID:25917592",
-                "PMID:26625368",
-                "PMID:2694978",
-                "PMID:28352060",
-                "PMID:33269576",
-                "PMID:35890057",
-                "PMID:9629547"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10548308': {'publication date': '1999 Oct', 'sentence': 'To determine the host factors involved in response to treatment, 46 patients with strongyloidiasis were treated with albendazole, followed-up for 1 year, and separated into two groups: cured and non-cured.', 'subject score': 1000, 'object score': 1000}, 'PMID:11809332': {'publication date': '2002 Mar 01', 'sentence': 'A ratio equivalent to or lower than that calculated for the currently prescribed strongyloidosis treatments, ivermectin, albendazole and thiabendazole, was observed for allocryptopine, protopine, dehydrocorydaline, D-corydaline, L-stylopine, and papaverine.', 'subject score': 1000, 'object score': 833}, 'PMID:1308956': {'publication date': '1992', 'sentence': '[The weak performance of albendazole in the treatment of strongyloidiasis].', 'subject score': 1000, 'object score': 1000}, 'PMID:1431382': {'publication date': '1992 Sep', 'sentence': 'From these results, it can be concluded that on increased dose of ABZ could be much more favorable for the treatment of strongyloidiasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15635962': {'publication date': '2004 Dec', 'sentence': 'The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States.', 'subject score': 1000, 'object score': 1000}, 'PMID:16553594': {'publication date': '2006 Mar-Apr', 'sentence': 'Parasite-specific IgG response and peripheral blood eosinophil count following albendazole treatment for presumed chronic strongyloidiasis.', 'subject score': 888, 'object score': 790}, 'PMID:16645520': {'publication date': '2006 May', 'sentence': 'We report a case of the Mazzotti reaction in a 13-year-old Liberian refugee after presumptive treatment of schistosomiasis and strongyloidiasis with ivermectin, praziquantel and albendazole.', 'subject score': 1000, 'object score': 1000}, 'PMID:17547048': {'publication date': '2006', 'sentence': 'A randomized trial study was conducted comparing the efficacy of two high-dose regimens of albendazole for the treatment of uncomplicated human strongyloidiasis.', 'subject score': 1000, 'object score': 851}, 'PMID:18023151': {'publication date': '2008 Jan', 'sentence': 'Efficacy and safety of a single-dose veterinary preparation of ivermectin versus 7-day high-dose albendazole for chronic strongyloidiasis.', 'subject score': 849, 'object score': 888}, 'PMID:21572981': {'publication date': '2011 May 10', 'sentence': 'Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis.', 'subject score': 849, 'object score': 888}, 'PMID:2747412': {'publication date': '1989 Mar', 'sentence': 'The reports of other studies on the effect of some of the newer benzimidazole antihelmintics as cambendazole, albendazole and flubendazole have shown that they are toxic or less effective in the treatment of strongyloidiasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:29942764': {'publication date': '2018', 'sentence': 'We have undertaken a review of the literature regarding the use of albendazole for strongyloidiasis and its adverse effect with a focus on myelosuppression as a rare but potentially serious event.', 'subject score': 1000, 'object score': 1000}, 'PMID:3269729': {'publication date': '1988 Jul-Dec', 'sentence': '[Evaluation of the effectiveness of albendazole in the treatment of human strongyloidiasis].', 'subject score': 1000, 'object score': 888}, 'PMID:3356624': {'publication date': '1988 Jan', 'sentence': 'It is concluded that albendazole may be effective treatment for strongyloidiasis if it is given in sufficiently large doses.', 'subject score': 1000, 'object score': 1000}, 'PMID:3558170': {'publication date': '1987 Jan', 'sentence': 'Albendazole and thiabendazole in murine strongyloidiasis.', 'subject score': 1000, 'object score': 888}, 'PMID:3672182': {'publication date': '1987 Jun', 'sentence': 'Albendazole in the treatment of strongyloidiasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7974685': {'publication date': '1994', 'sentence': 'A study was undertaken to compare the efficacy of the drug with that of albendazole in the treatment of uncomplicated strongyloidiasis.', 'subject score': 1000, 'object score': 888}, 'PMID:8300293': {'publication date': '1993 Sep', 'sentence': 'The clinical efficacy of albendazole (ABZ) in the treatment of chronic uncomplicated strongyloidiasis has been reported to be highly variable.', 'subject score': 1000, 'object score': 851}, 'PMID:8483992': {'publication date': '1993 Mar', 'sentence': 'We suggest that albendazole should be the treatment of choice for chronic strongyloidiasis.', 'subject score': 1000, 'object score': 888}, 'PMID:8940976': {'publication date': '1996 Nov', 'sentence': 'A randomized trial carried out in rural Zanzibar comparing a single dose of 200 micrograms/kg of ivermectin and 400 mg/day for three days of albendazole for treatment of strongyloidiasis and other intestinal nematodes is described.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 529459,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005974",
-          "name": "strongyloidiasis",
-          "description": "An infection that is caused by nematodes of the genus Strongyloides, most commonly Strongyloides stercoralis, which is a soil-transmitted helminth, and which is characterized by a variety of gastrointestinal, dermatologic, and, occasionally, pulmonary manifestations. The worm's autoinfective life cycle can lead to hyper-infection and life-threatening dissemination in immunocompromised hosts decades after initial infection.; Infection with nematodes of the genus STRONGYLOIDES. The presence of larvae may produce pneumonitis and the presence of adult worms in the intestine could lead to moderate to severe diarrhea.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0348996",
-            "UMLS:C0085810",
-            "MEDDRA:10080496",
-            "ORPHANET:76",
-            "ICD10:B78",
-            "ICD9:127.2",
-            "MESH:D013322",
-            "UMLS:C0038463",
-            "SNOMEDCT:187176005",
-            "EFO:0007501",
-            "MEDDRA:10042254",
-            "MONDO:0005974",
-            "SNOMEDCT:1214006",
-            "NCIT:C128398",
-            "DOID:10955"
-          ],
-          "id": "MONDO:0005974",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Strongyloidiasis",
-            "Anguilluliasis",
-            "strongyloidiasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.dpd.cdc.gov/dpdx/html/strongyloidiasis.htm",
-            "http://en.wikipedia.org/wiki/strongyloidiasis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 529459,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005974",
-              "name": "strongyloidiasis",
-              "description": "An infection that is caused by nematodes of the genus Strongyloides, most commonly Strongyloides stercoralis, which is a soil-transmitted helminth, and which is characterized by a variety of gastrointestinal, dermatologic, and, occasionally, pulmonary manifestations. The worm's autoinfective life cycle can lead to hyper-infection and life-threatening dissemination in immunocompromised hosts decades after initial infection.; Infection with nematodes of the genus STRONGYLOIDES. The presence of larvae may produce pneumonitis and the presence of adult worms in the intestine could lead to moderate to severe diarrhea.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0348996",
-                "UMLS:C0085810",
-                "MEDDRA:10080496",
-                "ORPHANET:76",
-                "ICD10:B78",
-                "ICD9:127.2",
-                "MESH:D013322",
-                "UMLS:C0038463",
-                "SNOMEDCT:187176005",
-                "EFO:0007501",
-                "MEDDRA:10042254",
-                "MONDO:0005974",
-                "SNOMEDCT:1214006",
-                "NCIT:C128398",
-                "DOID:10955"
-              ],
-              "id": "MONDO:0005974",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Strongyloidiasis",
-                "Anguilluliasis",
-                "strongyloidiasis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.dpd.cdc.gov/dpdx/html/strongyloidiasis.htm",
-                "http://en.wikipedia.org/wiki/strongyloidiasis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7628338,
-            "start": 551,
-            "end": 529459,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10548308': {'publication date': '1999 Oct', 'sentence': 'To determine the host factors involved in response to treatment, 46 patients with strongyloidiasis were treated with albendazole, followed-up for 1 year, and separated into two groups: cured and non-cured.', 'subject score': 1000, 'object score': 1000}, 'PMID:11809332': {'publication date': '2002 Mar 01', 'sentence': 'A ratio equivalent to or lower than that calculated for the currently prescribed strongyloidosis treatments, ivermectin, albendazole and thiabendazole, was observed for allocryptopine, protopine, dehydrocorydaline, D-corydaline, L-stylopine, and papaverine.', 'subject score': 1000, 'object score': 833}, 'PMID:1308956': {'publication date': '1992', 'sentence': '[The weak performance of albendazole in the treatment of strongyloidiasis].', 'subject score': 1000, 'object score': 1000}, 'PMID:1431382': {'publication date': '1992 Sep', 'sentence': 'From these results, it can be concluded that on increased dose of ABZ could be much more favorable for the treatment of strongyloidiasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15635962': {'publication date': '2004 Dec', 'sentence': 'The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States.', 'subject score': 1000, 'object score': 1000}, 'PMID:16553594': {'publication date': '2006 Mar-Apr', 'sentence': 'Parasite-specific IgG response and peripheral blood eosinophil count following albendazole treatment for presumed chronic strongyloidiasis.', 'subject score': 888, 'object score': 790}, 'PMID:16645520': {'publication date': '2006 May', 'sentence': 'We report a case of the Mazzotti reaction in a 13-year-old Liberian refugee after presumptive treatment of schistosomiasis and strongyloidiasis with ivermectin, praziquantel and albendazole.', 'subject score': 1000, 'object score': 1000}, 'PMID:17547048': {'publication date': '2006', 'sentence': 'A randomized trial study was conducted comparing the efficacy of two high-dose regimens of albendazole for the treatment of uncomplicated human strongyloidiasis.', 'subject score': 1000, 'object score': 851}, 'PMID:18023151': {'publication date': '2008 Jan', 'sentence': 'Efficacy and safety of a single-dose veterinary preparation of ivermectin versus 7-day high-dose albendazole for chronic strongyloidiasis.', 'subject score': 849, 'object score': 888}, 'PMID:21572981': {'publication date': '2011 May 10', 'sentence': 'Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis.', 'subject score': 849, 'object score': 888}, 'PMID:2747412': {'publication date': '1989 Mar', 'sentence': 'The reports of other studies on the effect of some of the newer benzimidazole antihelmintics as cambendazole, albendazole and flubendazole have shown that they are toxic or less effective in the treatment of strongyloidiasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:29942764': {'publication date': '2018', 'sentence': 'We have undertaken a review of the literature regarding the use of albendazole for strongyloidiasis and its adverse effect with a focus on myelosuppression as a rare but potentially serious event.', 'subject score': 1000, 'object score': 1000}, 'PMID:3269729': {'publication date': '1988 Jul-Dec', 'sentence': '[Evaluation of the effectiveness of albendazole in the treatment of human strongyloidiasis].', 'subject score': 1000, 'object score': 888}, 'PMID:3356624': {'publication date': '1988 Jan', 'sentence': 'It is concluded that albendazole may be effective treatment for strongyloidiasis if it is given in sufficiently large doses.', 'subject score': 1000, 'object score': 1000}, 'PMID:3558170': {'publication date': '1987 Jan', 'sentence': 'Albendazole and thiabendazole in murine strongyloidiasis.', 'subject score': 1000, 'object score': 888}, 'PMID:3672182': {'publication date': '1987 Jun', 'sentence': 'Albendazole in the treatment of strongyloidiasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7974685': {'publication date': '1994', 'sentence': 'A study was undertaken to compare the efficacy of the drug with that of albendazole in the treatment of uncomplicated strongyloidiasis.', 'subject score': 1000, 'object score': 888}, 'PMID:8300293': {'publication date': '1993 Sep', 'sentence': 'The clinical efficacy of albendazole (ABZ) in the treatment of chronic uncomplicated strongyloidiasis has been reported to be highly variable.', 'subject score': 1000, 'object score': 851}, 'PMID:8483992': {'publication date': '1993 Mar', 'sentence': 'We suggest that albendazole should be the treatment of choice for chronic strongyloidiasis.', 'subject score': 1000, 'object score': 888}, 'PMID:8940976': {'publication date': '1996 Nov', 'sentence': 'A randomized trial carried out in rural Zanzibar comparing a single dose of 200 micrograms/kg of ivermectin and 400 mg/day for three days of albendazole for treatment of strongyloidiasis and other intestinal nematodes is described.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0038463---SEMMEDDB:",
-                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0348996---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "7789677",
-              "object": "MONDO:0005974",
-              "publications": [
-                "PMID:3269729",
-                "PMID:15635962",
-                "PMID:18023151",
-                "PMID:9139386",
-                "PMID:10548308",
-                "PMID:17547048",
-                "PMID:16645520",
-                "PMID:8483992",
-                "PMID:21572981",
-                "PMID:3356624",
-                "PMID:3672182",
-                "PMID:1308956",
-                "PMID:2747412",
-                "PMID:16553594",
-                "PMID:7974685",
-                "PMID:1431382",
-                "PMID:8300293",
-                "PMID:3558170",
-                "PMID:30226142",
-                "PMID:11809332"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1443350': {'publication date': '1992 Oct', 'sentence': 'A double-blind clinical trial was conducted in Monagas State, Venezuela to assess the tolerance and efficacy of albendazole in the therapy of Onchocerca volvulus infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:14613509': {'publication date': '2003 Nov 06', 'sentence': 'RESULTS: In individuals co-infected with bancroftian filariasis and onchocerciasis, treatment with ivermectin and albendazole was safe and tolerable.', 'subject score': 1000, 'object score': 1000}, 'PMID:14641844': {'publication date': '2003 Dec', 'sentence': 'The current strategy for the interruption of transmission of lymphatic filariasis in areas where the disease is co-endemic with onchocerciasis is repeated annual mass treatment of endemic communities with ivermectin and albendazole.', 'subject score': 1000, 'object score': 1000}, 'PMID:14975059': {'publication date': '2003 Oct 24', 'sentence': 'Conduct research studies on the safety of combination therapy of Mectizan(R) and albendazole in areas co-endemic for L. loa and lymphatic filariasis (LF) with coordination from the relevant technical bodies that oversee these issues.The above recommendations will be implemented through a continuing collaboration between the interested parties represented at the Scientific Working Group, involved in onchocerciasis control and/or the Global Programme to Eliminate Lymphatic Filariasis.', 'subject score': 1000, 'object score': 888}, 'PMID:16304584': {'publication date': '2005 Oct', 'sentence': \"Inc. for onchocerciasis control in 1987 'as long as needed' was a public health landmark to be followed by a donation from GlaxoSmithKline of albendazole in 1997 for lymphatic filariasis to which Merck also responded by agreeing to extend their donation to include the coadministration of Mectizan and albendazole.\", 'subject score': 1000, 'object score': 888}, 'PMID:16917658': {'publication date': '2006 Aug', 'sentence': 'RELEVANT CHANGES: Current guidelines allowed onchocerciasis and LF activities to be integrated, resulting in rapid mapping throughout the two states, and states-wide provision of over 9.3 million combined ivermectin-albendazole treatments for the two diseases between 2000 and 2004.', 'subject score': 851, 'object score': 1000}, 'PMID:21722251': {'publication date': '2011 Jul', 'sentence': 'The standard microfilaricidal drugs ivermectin and albendazole are used in mass drug administration programmes, with the aim of interrupting transmission, with a consequent reduction in the burden of infection and, in some situations, leading to regional elimination of LF and onchocerciasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28056015': {'publication date': '2017 01', 'sentence': 'Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.', 'subject score': 1000, 'object score': 1000}, 'PMID:29774278': {'publication date': '2017 May', 'sentence': 'There is a hypothesis that Mass drug administration (MDA) of ivermectin and albendazole for the treatment of onchocerciasis and lymphatic filariasis could have an impact on the burden of soil-transmitted helminthiasis (STH) in MDA communities.', 'subject score': 1000, 'object score': 1000}, 'PMID:31536624': {'publication date': '2019 Sep 19', 'sentence': 'Comparison of repeated doses of ivermectin versus ivermectin plus albendazole for treatment of onchocerciasis - a randomized open-label clinical trial.', 'subject score': 851, 'object score': 1000}, 'PMID:34218593': {'publication date': '2021 Jun', 'sentence': 'Albendazole is also used for treatment of filarial infections (lymphatic filariasis, onchocerciasis, loiasis, mansonellosis, and dirofilariasis) alone or in combination with other drugs, such as ivermectin or diethylcarbamazine.', 'subject score': 1000, 'object score': 1000}, 'PMID:35463816': {'publication date': '2022', 'sentence': 'Current treatment recommendations by the WHO include mass drug administration with ivermectin for the treatment of onchocerciasis and a combination of ivermectin, albendazole and diethylcarbamazine (DEC) for the treatment of lymphatic filariasis in areas that are not co-endemic for onchocerciasis or loiasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7899788': {'publication date': '1994 Sep', 'sentence': 'A clinical evaluation of albendazole in patients with onchocerciasis; effects of food and pretreatment with ivermectin on drug response and pharmacokinetics.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 532253,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0017137",
-          "name": "onchocerciasis",
-          "description": "A filariasis that involves parasitic infection caused by the nematode Onchocerca volvulus, which is transmitted to humans through the bite of a blackfly of the genus Simulium. The worms spread throughout the body and, when they die, cause intense itching and a strong immune system response that can destroy nearby tissue. The symptoms include pruritus, dermatitis, blindness, onchocercomata (subcutaneous nodules), and lymphadenopathy.",
-          "equivalent_curies": [
-            "MEDDRA:10030314",
-            "SNOMEDCT:38539003",
-            "DOID:11678",
-            "UMLS:C0029001",
-            "ICD10:B73",
-            "EFO:0007402",
-            "MEDDRA:10030313",
-            "MESH:D009855",
-            "NCIT:C34861",
-            "ORPHANET:2737",
-            "MONDO:0017137",
-            "ICD9:125.3"
-          ],
-          "id": "MONDO:0017137",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Onchocerciasis",
-            "onchocerciasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.dpd.cdc.gov/dpdx/html/filariasis.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 532253,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0017137",
-              "name": "onchocerciasis",
-              "description": "A filariasis that involves parasitic infection caused by the nematode Onchocerca volvulus, which is transmitted to humans through the bite of a blackfly of the genus Simulium. The worms spread throughout the body and, when they die, cause intense itching and a strong immune system response that can destroy nearby tissue. The symptoms include pruritus, dermatitis, blindness, onchocercomata (subcutaneous nodules), and lymphadenopathy.",
-              "equivalent_curies": [
-                "MEDDRA:10030314",
-                "SNOMEDCT:38539003",
-                "DOID:11678",
-                "UMLS:C0029001",
-                "ICD10:B73",
-                "EFO:0007402",
-                "MEDDRA:10030313",
-                "MESH:D009855",
-                "NCIT:C34861",
-                "ORPHANET:2737",
-                "MONDO:0017137",
-                "ICD9:125.3"
-              ],
-              "id": "MONDO:0017137",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Onchocerciasis",
-                "onchocerciasis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.dpd.cdc.gov/dpdx/html/filariasis.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10520075,
-            "start": 551,
-            "end": 532253,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1443350': {'publication date': '1992 Oct', 'sentence': 'A double-blind clinical trial was conducted in Monagas State, Venezuela to assess the tolerance and efficacy of albendazole in the therapy of Onchocerca volvulus infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:14613509': {'publication date': '2003 Nov 06', 'sentence': 'RESULTS: In individuals co-infected with bancroftian filariasis and onchocerciasis, treatment with ivermectin and albendazole was safe and tolerable.', 'subject score': 1000, 'object score': 1000}, 'PMID:14641844': {'publication date': '2003 Dec', 'sentence': 'The current strategy for the interruption of transmission of lymphatic filariasis in areas where the disease is co-endemic with onchocerciasis is repeated annual mass treatment of endemic communities with ivermectin and albendazole.', 'subject score': 1000, 'object score': 1000}, 'PMID:14975059': {'publication date': '2003 Oct 24', 'sentence': 'Conduct research studies on the safety of combination therapy of Mectizan(R) and albendazole in areas co-endemic for L. loa and lymphatic filariasis (LF) with coordination from the relevant technical bodies that oversee these issues.The above recommendations will be implemented through a continuing collaboration between the interested parties represented at the Scientific Working Group, involved in onchocerciasis control and/or the Global Programme to Eliminate Lymphatic Filariasis.', 'subject score': 1000, 'object score': 888}, 'PMID:16304584': {'publication date': '2005 Oct', 'sentence': \"Inc. for onchocerciasis control in 1987 'as long as needed' was a public health landmark to be followed by a donation from GlaxoSmithKline of albendazole in 1997 for lymphatic filariasis to which Merck also responded by agreeing to extend their donation to include the coadministration of Mectizan and albendazole.\", 'subject score': 1000, 'object score': 888}, 'PMID:16917658': {'publication date': '2006 Aug', 'sentence': 'RELEVANT CHANGES: Current guidelines allowed onchocerciasis and LF activities to be integrated, resulting in rapid mapping throughout the two states, and states-wide provision of over 9.3 million combined ivermectin-albendazole treatments for the two diseases between 2000 and 2004.', 'subject score': 851, 'object score': 1000}, 'PMID:21722251': {'publication date': '2011 Jul', 'sentence': 'The standard microfilaricidal drugs ivermectin and albendazole are used in mass drug administration programmes, with the aim of interrupting transmission, with a consequent reduction in the burden of infection and, in some situations, leading to regional elimination of LF and onchocerciasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28056015': {'publication date': '2017 01', 'sentence': 'Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.', 'subject score': 1000, 'object score': 1000}, 'PMID:29774278': {'publication date': '2017 May', 'sentence': 'There is a hypothesis that Mass drug administration (MDA) of ivermectin and albendazole for the treatment of onchocerciasis and lymphatic filariasis could have an impact on the burden of soil-transmitted helminthiasis (STH) in MDA communities.', 'subject score': 1000, 'object score': 1000}, 'PMID:31536624': {'publication date': '2019 Sep 19', 'sentence': 'Comparison of repeated doses of ivermectin versus ivermectin plus albendazole for treatment of onchocerciasis - a randomized open-label clinical trial.', 'subject score': 851, 'object score': 1000}, 'PMID:34218593': {'publication date': '2021 Jun', 'sentence': 'Albendazole is also used for treatment of filarial infections (lymphatic filariasis, onchocerciasis, loiasis, mansonellosis, and dirofilariasis) alone or in combination with other drugs, such as ivermectin or diethylcarbamazine.', 'subject score': 1000, 'object score': 1000}, 'PMID:35463816': {'publication date': '2022', 'sentence': 'Current treatment recommendations by the WHO include mass drug administration with ivermectin for the treatment of onchocerciasis and a combination of ivermectin, albendazole and diethylcarbamazine (DEC) for the treatment of lymphatic filariasis in areas that are not co-endemic for onchocerciasis or loiasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7899788': {'publication date': '1994 Sep', 'sentence': 'A clinical evaluation of albendazole in patients with onchocerciasis; effects of food and pretreatment with ivermectin on drug response and pharmacokinetics.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0029001---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "10750815",
-              "object": "MONDO:0017137",
-              "publications": [
-                "PMID:1443350",
-                "PMID:14613509",
-                "PMID:14641844",
-                "PMID:14975059",
-                "PMID:16304584",
-                "PMID:16917658",
-                "PMID:21722251",
-                "PMID:28056015",
-                "PMID:29774278",
-                "PMID:31536624",
-                "PMID:34218593",
-                "PMID:35463816",
-                "PMID:7899788"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10450449': {'publication date': '1999 Mar-Apr', 'sentence': 'On the basis of our results the single 400 mg dose of albendazole is the treatment of choice for hookworm infections in this region of Mali.', 'subject score': 1000, 'object score': 1000}, 'PMID:19324046': {'publication date': '2009 Jul 15', 'sentence': 'The high rates of hookworm infection in this area of Viet Nam and the high cure rates for all three species of STH with 4 monthly albendazole treatment suggest that this programme should be expanded to all endemic areas in Viet Nam.', 'subject score': 775, 'object score': 1000}, 'PMID:21176950': {'publication date': '2011 Jan 01', 'sentence': 'However, in infants of mothers with hookworm infection, albendazole treatment reduced interleukin-5 (geometric mean ratio 0.50, 95% CI 0.30-0.81, interaction p=0.02) and interleukin-13 (0.52, 0.34-0.82, 0.0005) response to tetanus toxoid.', 'subject score': 888, 'object score': 1000}, 'PMID:21980373': {'publication date': '2011', 'sentence': 'ALBENDAZOLE CURED SIGNIFICANTLY MORE HOOKWORM INFECTIONS THAN MEBENDAZOLE IN BOTH TREATMENT REGIMENS (SINGLE DOSE: respective CRs 69% (95% confidence interval [CI]: 55-81%) and 29% (95% CI: 20-45%); triple dose: respective CRs 92% (95% CI: 81-98%) and 54% (95% CI: 46-71%)).', 'subject score': 1000, 'object score': 861}, 'PMID:23836564': {'publication date': '2013 Sep', 'sentence': 'Hookworm infection among school age children in Kintampo north municipality, Ghana: nutritional risk factors and response to albendazole treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:24552246': {'publication date': '2014 Feb 19', 'sentence': 'Once a year school-based deworming with praziquantel and albendazole combination may not be adequate for control of urogenital schistosomiasis and hookworm infection in Matuga District, Kwale County, Kenya.', 'subject score': 888, 'object score': 1000}, 'PMID:2692189': {'publication date': '1989 Jun', 'sentence': 'Albendazole, 400 mg, as a single dose treatment was shown to be superior to mebendazole, 600 mg, single dose for the mass treatment of hookworm infection, especially that of Necator americanus, in an endemic area.', 'subject score': 1000, 'object score': 1000}, 'PMID:3307657': {'publication date': '1986 Oct', 'sentence': 'Albendazole in children with hookworm infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:33832450': {'publication date': '2021 Apr 08', 'sentence': 'Treatment of hookworm/malaria co-infection resulted in a reduction in antibody responses against GMZ2 and constituent antigens after albendazole treatment.', 'subject score': 888, 'object score': 875}, 'PMID:35745589': {'publication date': '2022 May 27', 'sentence': 'Currently, only one drug, albendazole is efficient to treat hookworm infection and the scientific community fears the rise of resistant strains.', 'subject score': 1000, 'object score': 1000}, 'PMID:6763357': {'publication date': '1982 Dec', 'sentence': 'Clinical trial of albendazole in hookworm infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:7939948': {'publication date': '1993 Dec', 'sentence': 'A comparative study on the efficacy of albendazole and mebendazole in the treatment of ascariasis, hookworm infection and trichuriasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:8771941': {'publication date': '1996 Jun', 'sentence': 'CONCLUSION: Albendazole is the drug of choice for mass deworming where hookworm disease is prominent.', 'subject score': 1000, 'object score': 785}, 'PMID:9776141': {'publication date': '1998 Aug 15', 'sentence': 'The parasitological, clinical efficacy and tolerability of albendazole in the treatment for both giardiasis and hookworm infection in a remote Aboriginal population was investigated.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 841712,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C0019911",
-          "name": "Hookworm Infections",
-          "description": "An infection that is caused by hookworms.; Infection of humans or animals with hookworms other than those caused by the genus Ancylostoma or Necator, for which the specific terms ANCYLOSTOMIASIS and NECATORIASIS are available.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10020376",
-            "UMLS:C0019911",
-            "SNOMEDCT:105694003",
-            "NCIT:C34702",
-            "MESH:D006725"
-          ],
-          "id": "UMLS:C0019911",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hookworm Infections",
-            "Hookworm Infection"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 841712,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C0019911",
-              "name": "Hookworm Infections",
-              "description": "An infection that is caused by hookworms.; Infection of humans or animals with hookworms other than those caused by the genus Ancylostoma or Necator, for which the specific terms ANCYLOSTOMIASIS and NECATORIASIS are available.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10020376",
-                "UMLS:C0019911",
-                "SNOMEDCT:105694003",
-                "NCIT:C34702",
-                "MESH:D006725"
-              ],
-              "id": "UMLS:C0019911",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hookworm Infections",
-                "Hookworm Infection"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7464317,
-            "start": 551,
-            "end": 841712,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10450449': {'publication date': '1999 Mar-Apr', 'sentence': 'On the basis of our results the single 400 mg dose of albendazole is the treatment of choice for hookworm infections in this region of Mali.', 'subject score': 1000, 'object score': 1000}, 'PMID:19324046': {'publication date': '2009 Jul 15', 'sentence': 'The high rates of hookworm infection in this area of Viet Nam and the high cure rates for all three species of STH with 4 monthly albendazole treatment suggest that this programme should be expanded to all endemic areas in Viet Nam.', 'subject score': 775, 'object score': 1000}, 'PMID:21176950': {'publication date': '2011 Jan 01', 'sentence': 'However, in infants of mothers with hookworm infection, albendazole treatment reduced interleukin-5 (geometric mean ratio 0.50, 95% CI 0.30-0.81, interaction p=0.02) and interleukin-13 (0.52, 0.34-0.82, 0.0005) response to tetanus toxoid.', 'subject score': 888, 'object score': 1000}, 'PMID:21980373': {'publication date': '2011', 'sentence': 'ALBENDAZOLE CURED SIGNIFICANTLY MORE HOOKWORM INFECTIONS THAN MEBENDAZOLE IN BOTH TREATMENT REGIMENS (SINGLE DOSE: respective CRs 69% (95% confidence interval [CI]: 55-81%) and 29% (95% CI: 20-45%); triple dose: respective CRs 92% (95% CI: 81-98%) and 54% (95% CI: 46-71%)).', 'subject score': 1000, 'object score': 861}, 'PMID:23836564': {'publication date': '2013 Sep', 'sentence': 'Hookworm infection among school age children in Kintampo north municipality, Ghana: nutritional risk factors and response to albendazole treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:24552246': {'publication date': '2014 Feb 19', 'sentence': 'Once a year school-based deworming with praziquantel and albendazole combination may not be adequate for control of urogenital schistosomiasis and hookworm infection in Matuga District, Kwale County, Kenya.', 'subject score': 888, 'object score': 1000}, 'PMID:2692189': {'publication date': '1989 Jun', 'sentence': 'Albendazole, 400 mg, as a single dose treatment was shown to be superior to mebendazole, 600 mg, single dose for the mass treatment of hookworm infection, especially that of Necator americanus, in an endemic area.', 'subject score': 1000, 'object score': 1000}, 'PMID:3307657': {'publication date': '1986 Oct', 'sentence': 'Albendazole in children with hookworm infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:33832450': {'publication date': '2021 Apr 08', 'sentence': 'Treatment of hookworm/malaria co-infection resulted in a reduction in antibody responses against GMZ2 and constituent antigens after albendazole treatment.', 'subject score': 888, 'object score': 875}, 'PMID:35745589': {'publication date': '2022 May 27', 'sentence': 'Currently, only one drug, albendazole is efficient to treat hookworm infection and the scientific community fears the rise of resistant strains.', 'subject score': 1000, 'object score': 1000}, 'PMID:6763357': {'publication date': '1982 Dec', 'sentence': 'Clinical trial of albendazole in hookworm infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:7939948': {'publication date': '1993 Dec', 'sentence': 'A comparative study on the efficacy of albendazole and mebendazole in the treatment of ascariasis, hookworm infection and trichuriasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:8771941': {'publication date': '1996 Jun', 'sentence': 'CONCLUSION: Albendazole is the drug of choice for mass deworming where hookworm disease is prominent.', 'subject score': 1000, 'object score': 785}, 'PMID:9776141': {'publication date': '1998 Aug 15', 'sentence': 'The parasitological, clinical efficacy and tolerability of albendazole in the treatment for both giardiasis and hookworm infection in a remote Aboriginal population was investigated.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0019911---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "7620262",
-              "object": "UMLS:C0019911",
-              "publications": [
-                "PMID:10450449",
-                "PMID:19324046",
-                "PMID:21176950",
-                "PMID:21980373",
-                "PMID:23836564",
-                "PMID:24552246",
-                "PMID:2692189",
-                "PMID:3307657",
-                "PMID:33832450",
-                "PMID:35745589",
-                "PMID:6763357",
-                "PMID:7939948",
-                "PMID:8771941",
-                "PMID:9776141"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:18330331': {'publication date': '2007 Jul', 'sentence': 'CONCLUSIONS: Mebendazole and albendazole showed reduced efficacy against Ascaris lumbricoides and hookworm infections at the recommended doses.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 841712,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C0019911",
-          "name": "Hookworm Infections",
-          "description": "An infection that is caused by hookworms.; Infection of humans or animals with hookworms other than those caused by the genus Ancylostoma or Necator, for which the specific terms ANCYLOSTOMIASIS and NECATORIASIS are available.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10020376",
-            "UMLS:C0019911",
-            "SNOMEDCT:105694003",
-            "NCIT:C34702",
-            "MESH:D006725"
-          ],
-          "id": "UMLS:C0019911",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hookworm Infections",
-            "Hookworm Infection"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 841712,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C0019911",
-              "name": "Hookworm Infections",
-              "description": "An infection that is caused by hookworms.; Infection of humans or animals with hookworms other than those caused by the genus Ancylostoma or Necator, for which the specific terms ANCYLOSTOMIASIS and NECATORIASIS are available.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10020376",
-                "UMLS:C0019911",
-                "SNOMEDCT:105694003",
-                "NCIT:C34702",
-                "MESH:D006725"
-              ],
-              "id": "UMLS:C0019911",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hookworm Infections",
-                "Hookworm Infection"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13340627,
-            "start": 551,
-            "end": 841712,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18330331': {'publication date': '2007 Jul', 'sentence': 'CONCLUSIONS: Mebendazole and albendazole showed reduced efficacy against Ascaris lumbricoides and hookworm infections at the recommended doses.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:disrupts---None---None---None---UMLS:C0019911---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "13637338",
-              "object": "UMLS:C0019911",
-              "publications": [
-                "PMID:18330331"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:35793325': {'publication date': '2022', 'sentence': 'A combination of drugs Ivermectin, Diethylcarbamazine citrate and Albendazole is recommended by WHO to accelerate the Global Programme to Eliminate Lymphatic Filariasis (GPELF).', 'subject score': 1000, 'object score': 752}}",
-    "p2": {
-      "start": {
-        "identity": 520825,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005761",
-          "name": "filarial elephantiasis",
-          "description": "A filariasis that is characterized by the thickening of the skin and underlying tissues, especially in the legs, male genitals and female breasts, caused by thread-like parasitic worms Wuchereria bancrofti, Brugia malayi or Brugia timori, which inhabit the lymphatics. These nematodes are transmitted by mosquitoes. Acute symptoms include fever, lymphadenitis, lymphangitis, funiculitis, and epididymitis. Chronic symptoms include abscesses, hyperkeratosis, polyarthritis, hydroceles, lymphedema, and elephantiasis.",
-          "equivalent_curies": [
-            "ORPHANET:2035",
-            "MONDO:0005761",
-            "DOID:12211",
-            "MEDDRA:10025229",
-            "UMLS:C0155217",
-            "SNOMEDCT:14100003",
-            "UMLS:C0013884",
-            "NCIT:C128360",
-            "ICD9:374.83",
-            "EFO:0007272",
-            "MEDDRA:10014473",
-            "SNOMEDCT:240820001",
-            "MEDDRA:10016675",
-            "MESH:D004605"
-          ],
-          "id": "MONDO:0005761",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Filarial Elephantiases",
-            "filarial elephantiasis",
-            "Elephantiasis, Filarial",
-            "Elephantiasis of eyelid",
-            "Lymphatic filariasis",
-            "Lymphatic Filariasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis",
-            "https://www.cdc.gov/parasites/lymphaticfilariasis/index.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520825,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005761",
-              "name": "filarial elephantiasis",
-              "description": "A filariasis that is characterized by the thickening of the skin and underlying tissues, especially in the legs, male genitals and female breasts, caused by thread-like parasitic worms Wuchereria bancrofti, Brugia malayi or Brugia timori, which inhabit the lymphatics. These nematodes are transmitted by mosquitoes. Acute symptoms include fever, lymphadenitis, lymphangitis, funiculitis, and epididymitis. Chronic symptoms include abscesses, hyperkeratosis, polyarthritis, hydroceles, lymphedema, and elephantiasis.",
-              "equivalent_curies": [
-                "ORPHANET:2035",
-                "MONDO:0005761",
-                "DOID:12211",
-                "MEDDRA:10025229",
-                "UMLS:C0155217",
-                "SNOMEDCT:14100003",
-                "UMLS:C0013884",
-                "NCIT:C128360",
-                "ICD9:374.83",
-                "EFO:0007272",
-                "MEDDRA:10014473",
-                "SNOMEDCT:240820001",
-                "MEDDRA:10016675",
-                "MESH:D004605"
-              ],
-              "id": "MONDO:0005761",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Filarial Elephantiases",
-                "filarial elephantiasis",
-                "Elephantiasis, Filarial",
-                "Elephantiasis of eyelid",
-                "Lymphatic filariasis",
-                "Lymphatic Filariasis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis",
-                "https://www.cdc.gov/parasites/lymphaticfilariasis/index.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24242252,
-            "start": 551,
-            "end": 520825,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35793325': {'publication date': '2022', 'sentence': 'A combination of drugs Ivermectin, Diethylcarbamazine citrate and Albendazole is recommended by WHO to accelerate the Global Programme to Eliminate Lymphatic Filariasis (GPELF).', 'subject score': 1000, 'object score': 752}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0013884---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "24685635",
-              "object": "MONDO:0005761",
-              "publications": [
-                "PMID:35793325"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10461168': {'publication date': '1999 Sep', 'sentence': 'The role of albendazole in programmes to eliminate lymphatic filariasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:10752716': {'publication date': '2000 Mar 11', 'sentence': 'Moreover, SmithKline Beecham announced it would do pediatric trials of its malaria vaccine in Africa and renewed a pledge made in 1998 to work with WHO to donate 5 billion doses of albendazole over the next 20 years to eradicate lymphatic filariasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:10897370': {'publication date': '2000 Mar-Apr', 'sentence': 'A randomized double-blind placebo-controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana.', 'subject score': 1000, 'object score': 1000}, 'PMID:11939299': {'publication date': '2000', 'sentence': 'Community empowerment in the control of lymphatic filariasis in Misima, Milne Bay Province using diethylcarbamazine in combination with albendazole.', 'subject score': 1000, 'object score': 1000}, 'PMID:12055812': {'publication date': '2002 Mar-Apr', 'sentence': 'Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow-up after re-treatment with the combination.', 'subject score': 1000, 'object score': 1000}, 'PMID:12225508': {'publication date': '2002 Sep', 'sentence': 'Annual mass treatment with single-dose diethylcarbamazine (DEC) or ivermectin (IVM) in combination with albendazole (ALB) for 4-6 years is the principal tool of lymphatic filariasis (LF) elimination strategy.', 'subject score': 1000, 'object score': 861}, 'PMID:12294064': {'publication date': '1998', 'sentence': 'Another pharmaceutical company donated albendazole for the global elimination of lymphatic filariasis.', 'subject score': 775, 'object score': 1000}, 'PMID:12396323': {'publication date': '2002 Sep', 'sentence': 'These results indicate that there is no adverse pharmacokinetic or pharmacodynamic reason why DEC and albendazole should not be co-administered to control lymphatic filariasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:14613509': {'publication date': '2003 Nov 06', 'sentence': 'BACKGROUND: In order to use a combination of ivermectin and albendazole for the elimination of lymphatic filariasis, it is important to assess the potential risk of increased adverse events in individuals infected with both lymphatic filariasis and onchocerciasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:14974034': {'publication date': '2004', 'sentence': 'BACKGROUND: Mass treatment with albendazole, co-administered with another antifilarial drug, is being promoted as part of a global programme to eliminate lymphatic filariasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:14975059': {'publication date': '2003 Oct 24', 'sentence': 'Conduct research studies on the safety of combination therapy of Mectizan(R) and albendazole in areas co-endemic for L. loa and lymphatic filariasis (LF) with coordination from the relevant technical bodies that oversee these issues.The above recommendations will be implemented through a continuing collaboration between the interested parties represented at the Scientific Working Group, involved in onchocerciasis control and/or the Global Programme to Eliminate Lymphatic Filariasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15189460': {'publication date': '2004 Jun', 'sentence': 'This paper reports the coverage, compliance and other operational issues of mass drug administration (MDA) of diethylcarbamazine and albendazole under a programme to eliminate lymphatic filariasis (LF) in Orissa state of India.', 'subject score': 1000, 'object score': 1000}, 'PMID:15361118': {'publication date': '2004 Sep', 'sentence': \"This study demonstrates that mass drug co-administration of DEC + ALB in Global Programme for Elimination of Lymphatic Filariasis (GPELF) targeted at the community had a synergistic and sustainable effect against soil-transmitted helminthiasis and provided considerable 'beyond filariasis' benefits.\", 'subject score': 888, 'object score': 746}, 'PMID:15516644': {'publication date': '2004 Oct', 'sentence': 'We conducted stool examinations in four sentinel communities before and approximately nine months after each of two rounds of mass drug administration (MDA) with diethylcarbamazine and albendazole in the context of an LF elimination program in Leogane, Haiti.', 'subject score': 1000, 'object score': 658}, 'PMID:15903082': {'publication date': '2005', 'sentence': 'In the last few years Mectizan has been used in combination with albendazole to control lymphatic filariasis on a large-scale basis in African countries.', 'subject score': 1000, 'object score': 1000}, 'PMID:16235339': {'publication date': '2005 Oct 19', 'sentence': 'BACKGROUND: Mass treatment with albendazole co-administered with another antifilarial drug is part of a global programme to eliminate lymphatic filariasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:16282299': {'publication date': '2005 Nov', 'sentence': 'We are using mass treatment with diethylcarbamazine (DEC) and albendazole in an effort to eliminate LF from Leogane, Haiti.', 'subject score': 1000, 'object score': 1000}, 'PMID:16500593': {'publication date': '2006 Mar', 'sentence': 'Evidence for the use of albendazole for the elimination of lymphatic filariasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:16834821': {'publication date': '2006 Nov', 'sentence': 'The Global Program for the Elimination of Lymphatic Filariasis (GPELF) intends to achieve its aims through yearly mass treatments with albendazole (ABZ) combined with ivermectin (IVM) or diethylcarbamazine (DEC).', 'subject score': 1000, 'object score': 745}, 'PMID:16836746': {'publication date': '2006 Jul 12', 'sentence': 'BACKGROUND: The population of Nukufetau, a remote coral atoll island in Tuvalu in the Western Pacific, received annual mass drug administration (MDA) of diethylcarbamazine and albendazole under the Pacific Elimination of Lymphatic Filariasis program in 2001, 2002 and 2003, with the last MDA occurring six months before a cross-sectional survey of the whole population for soil transmitted helminths (STH).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 520825,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005761",
-          "name": "filarial elephantiasis",
-          "description": "A filariasis that is characterized by the thickening of the skin and underlying tissues, especially in the legs, male genitals and female breasts, caused by thread-like parasitic worms Wuchereria bancrofti, Brugia malayi or Brugia timori, which inhabit the lymphatics. These nematodes are transmitted by mosquitoes. Acute symptoms include fever, lymphadenitis, lymphangitis, funiculitis, and epididymitis. Chronic symptoms include abscesses, hyperkeratosis, polyarthritis, hydroceles, lymphedema, and elephantiasis.",
-          "equivalent_curies": [
-            "ORPHANET:2035",
-            "MONDO:0005761",
-            "DOID:12211",
-            "MEDDRA:10025229",
-            "UMLS:C0155217",
-            "SNOMEDCT:14100003",
-            "UMLS:C0013884",
-            "NCIT:C128360",
-            "ICD9:374.83",
-            "EFO:0007272",
-            "MEDDRA:10014473",
-            "SNOMEDCT:240820001",
-            "MEDDRA:10016675",
-            "MESH:D004605"
-          ],
-          "id": "MONDO:0005761",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Filarial Elephantiases",
-            "filarial elephantiasis",
-            "Elephantiasis, Filarial",
-            "Elephantiasis of eyelid",
-            "Lymphatic filariasis",
-            "Lymphatic Filariasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis",
-            "https://www.cdc.gov/parasites/lymphaticfilariasis/index.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520825,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005761",
-              "name": "filarial elephantiasis",
-              "description": "A filariasis that is characterized by the thickening of the skin and underlying tissues, especially in the legs, male genitals and female breasts, caused by thread-like parasitic worms Wuchereria bancrofti, Brugia malayi or Brugia timori, which inhabit the lymphatics. These nematodes are transmitted by mosquitoes. Acute symptoms include fever, lymphadenitis, lymphangitis, funiculitis, and epididymitis. Chronic symptoms include abscesses, hyperkeratosis, polyarthritis, hydroceles, lymphedema, and elephantiasis.",
-              "equivalent_curies": [
-                "ORPHANET:2035",
-                "MONDO:0005761",
-                "DOID:12211",
-                "MEDDRA:10025229",
-                "UMLS:C0155217",
-                "SNOMEDCT:14100003",
-                "UMLS:C0013884",
-                "NCIT:C128360",
-                "ICD9:374.83",
-                "EFO:0007272",
-                "MEDDRA:10014473",
-                "SNOMEDCT:240820001",
-                "MEDDRA:10016675",
-                "MESH:D004605"
-              ],
-              "id": "MONDO:0005761",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Filarial Elephantiases",
-                "filarial elephantiasis",
-                "Elephantiasis, Filarial",
-                "Elephantiasis of eyelid",
-                "Lymphatic filariasis",
-                "Lymphatic Filariasis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis",
-                "https://www.cdc.gov/parasites/lymphaticfilariasis/index.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7474676,
-            "start": 551,
-            "end": 520825,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10461168': {'publication date': '1999 Sep', 'sentence': 'The role of albendazole in programmes to eliminate lymphatic filariasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:10752716': {'publication date': '2000 Mar 11', 'sentence': 'Moreover, SmithKline Beecham announced it would do pediatric trials of its malaria vaccine in Africa and renewed a pledge made in 1998 to work with WHO to donate 5 billion doses of albendazole over the next 20 years to eradicate lymphatic filariasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:10897370': {'publication date': '2000 Mar-Apr', 'sentence': 'A randomized double-blind placebo-controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana.', 'subject score': 1000, 'object score': 1000}, 'PMID:11939299': {'publication date': '2000', 'sentence': 'Community empowerment in the control of lymphatic filariasis in Misima, Milne Bay Province using diethylcarbamazine in combination with albendazole.', 'subject score': 1000, 'object score': 1000}, 'PMID:12055812': {'publication date': '2002 Mar-Apr', 'sentence': 'Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow-up after re-treatment with the combination.', 'subject score': 1000, 'object score': 1000}, 'PMID:12225508': {'publication date': '2002 Sep', 'sentence': 'Annual mass treatment with single-dose diethylcarbamazine (DEC) or ivermectin (IVM) in combination with albendazole (ALB) for 4-6 years is the principal tool of lymphatic filariasis (LF) elimination strategy.', 'subject score': 1000, 'object score': 861}, 'PMID:12294064': {'publication date': '1998', 'sentence': 'Another pharmaceutical company donated albendazole for the global elimination of lymphatic filariasis.', 'subject score': 775, 'object score': 1000}, 'PMID:12396323': {'publication date': '2002 Sep', 'sentence': 'These results indicate that there is no adverse pharmacokinetic or pharmacodynamic reason why DEC and albendazole should not be co-administered to control lymphatic filariasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:14613509': {'publication date': '2003 Nov 06', 'sentence': 'BACKGROUND: In order to use a combination of ivermectin and albendazole for the elimination of lymphatic filariasis, it is important to assess the potential risk of increased adverse events in individuals infected with both lymphatic filariasis and onchocerciasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:14974034': {'publication date': '2004', 'sentence': 'BACKGROUND: Mass treatment with albendazole, co-administered with another antifilarial drug, is being promoted as part of a global programme to eliminate lymphatic filariasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:14975059': {'publication date': '2003 Oct 24', 'sentence': 'Conduct research studies on the safety of combination therapy of Mectizan(R) and albendazole in areas co-endemic for L. loa and lymphatic filariasis (LF) with coordination from the relevant technical bodies that oversee these issues.The above recommendations will be implemented through a continuing collaboration between the interested parties represented at the Scientific Working Group, involved in onchocerciasis control and/or the Global Programme to Eliminate Lymphatic Filariasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15189460': {'publication date': '2004 Jun', 'sentence': 'This paper reports the coverage, compliance and other operational issues of mass drug administration (MDA) of diethylcarbamazine and albendazole under a programme to eliminate lymphatic filariasis (LF) in Orissa state of India.', 'subject score': 1000, 'object score': 1000}, 'PMID:15361118': {'publication date': '2004 Sep', 'sentence': \"This study demonstrates that mass drug co-administration of DEC + ALB in Global Programme for Elimination of Lymphatic Filariasis (GPELF) targeted at the community had a synergistic and sustainable effect against soil-transmitted helminthiasis and provided considerable 'beyond filariasis' benefits.\", 'subject score': 888, 'object score': 746}, 'PMID:15516644': {'publication date': '2004 Oct', 'sentence': 'We conducted stool examinations in four sentinel communities before and approximately nine months after each of two rounds of mass drug administration (MDA) with diethylcarbamazine and albendazole in the context of an LF elimination program in Leogane, Haiti.', 'subject score': 1000, 'object score': 658}, 'PMID:15903082': {'publication date': '2005', 'sentence': 'In the last few years Mectizan has been used in combination with albendazole to control lymphatic filariasis on a large-scale basis in African countries.', 'subject score': 1000, 'object score': 1000}, 'PMID:16235339': {'publication date': '2005 Oct 19', 'sentence': 'BACKGROUND: Mass treatment with albendazole co-administered with another antifilarial drug is part of a global programme to eliminate lymphatic filariasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:16282299': {'publication date': '2005 Nov', 'sentence': 'We are using mass treatment with diethylcarbamazine (DEC) and albendazole in an effort to eliminate LF from Leogane, Haiti.', 'subject score': 1000, 'object score': 1000}, 'PMID:16500593': {'publication date': '2006 Mar', 'sentence': 'Evidence for the use of albendazole for the elimination of lymphatic filariasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:16834821': {'publication date': '2006 Nov', 'sentence': 'The Global Program for the Elimination of Lymphatic Filariasis (GPELF) intends to achieve its aims through yearly mass treatments with albendazole (ABZ) combined with ivermectin (IVM) or diethylcarbamazine (DEC).', 'subject score': 1000, 'object score': 745}, 'PMID:16836746': {'publication date': '2006 Jul 12', 'sentence': 'BACKGROUND: The population of Nukufetau, a remote coral atoll island in Tuvalu in the Western Pacific, received annual mass drug administration (MDA) of diethylcarbamazine and albendazole under the Pacific Elimination of Lymphatic Filariasis program in 2001, 2002 and 2003, with the last MDA occurring six months before a cross-sectional survey of the whole population for soil transmitted helminths (STH).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0013884---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "7640018",
-              "object": "MONDO:0005761",
-              "publications": [
-                "PMID:10461168",
-                "PMID:10752716",
-                "PMID:10897370",
-                "PMID:11939299",
-                "PMID:12055812",
-                "PMID:12225508",
-                "PMID:12294064",
-                "PMID:12396323",
-                "PMID:14613509",
-                "PMID:14974034",
-                "PMID:14975059",
-                "PMID:15189460",
-                "PMID:15361118",
-                "PMID:15516644",
-                "PMID:15903082",
-                "PMID:16235339",
-                "PMID:16282299",
-                "PMID:16500593",
-                "PMID:16834821",
-                "PMID:16836746"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 841712,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C0019911",
-          "name": "Hookworm Infections",
-          "description": "An infection that is caused by hookworms.; Infection of humans or animals with hookworms other than those caused by the genus Ancylostoma or Necator, for which the specific terms ANCYLOSTOMIASIS and NECATORIASIS are available.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10020376",
-            "UMLS:C0019911",
-            "SNOMEDCT:105694003",
-            "NCIT:C34702",
-            "MESH:D006725"
-          ],
-          "id": "UMLS:C0019911",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hookworm Infections",
-            "Hookworm Infection"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 841712,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C0019911",
-              "name": "Hookworm Infections",
-              "description": "An infection that is caused by hookworms.; Infection of humans or animals with hookworms other than those caused by the genus Ancylostoma or Necator, for which the specific terms ANCYLOSTOMIASIS and NECATORIASIS are available.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10020376",
-                "UMLS:C0019911",
-                "SNOMEDCT:105694003",
-                "NCIT:C34702",
-                "MESH:D006725"
-              ],
-              "id": "UMLS:C0019911",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hookworm Infections",
-                "Hookworm Infection"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7464317,
-            "start": 551,
-            "end": 841712,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10450449': {'publication date': '1999 Mar-Apr', 'sentence': 'On the basis of our results the single 400 mg dose of albendazole is the treatment of choice for hookworm infections in this region of Mali.', 'subject score': 1000, 'object score': 1000}, 'PMID:19324046': {'publication date': '2009 Jul 15', 'sentence': 'The high rates of hookworm infection in this area of Viet Nam and the high cure rates for all three species of STH with 4 monthly albendazole treatment suggest that this programme should be expanded to all endemic areas in Viet Nam.', 'subject score': 775, 'object score': 1000}, 'PMID:21176950': {'publication date': '2011 Jan 01', 'sentence': 'However, in infants of mothers with hookworm infection, albendazole treatment reduced interleukin-5 (geometric mean ratio 0.50, 95% CI 0.30-0.81, interaction p=0.02) and interleukin-13 (0.52, 0.34-0.82, 0.0005) response to tetanus toxoid.', 'subject score': 888, 'object score': 1000}, 'PMID:21980373': {'publication date': '2011', 'sentence': 'ALBENDAZOLE CURED SIGNIFICANTLY MORE HOOKWORM INFECTIONS THAN MEBENDAZOLE IN BOTH TREATMENT REGIMENS (SINGLE DOSE: respective CRs 69% (95% confidence interval [CI]: 55-81%) and 29% (95% CI: 20-45%); triple dose: respective CRs 92% (95% CI: 81-98%) and 54% (95% CI: 46-71%)).', 'subject score': 1000, 'object score': 861}, 'PMID:23836564': {'publication date': '2013 Sep', 'sentence': 'Hookworm infection among school age children in Kintampo north municipality, Ghana: nutritional risk factors and response to albendazole treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:24552246': {'publication date': '2014 Feb 19', 'sentence': 'Once a year school-based deworming with praziquantel and albendazole combination may not be adequate for control of urogenital schistosomiasis and hookworm infection in Matuga District, Kwale County, Kenya.', 'subject score': 888, 'object score': 1000}, 'PMID:2692189': {'publication date': '1989 Jun', 'sentence': 'Albendazole, 400 mg, as a single dose treatment was shown to be superior to mebendazole, 600 mg, single dose for the mass treatment of hookworm infection, especially that of Necator americanus, in an endemic area.', 'subject score': 1000, 'object score': 1000}, 'PMID:3307657': {'publication date': '1986 Oct', 'sentence': 'Albendazole in children with hookworm infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:33832450': {'publication date': '2021 Apr 08', 'sentence': 'Treatment of hookworm/malaria co-infection resulted in a reduction in antibody responses against GMZ2 and constituent antigens after albendazole treatment.', 'subject score': 888, 'object score': 875}, 'PMID:35745589': {'publication date': '2022 May 27', 'sentence': 'Currently, only one drug, albendazole is efficient to treat hookworm infection and the scientific community fears the rise of resistant strains.', 'subject score': 1000, 'object score': 1000}, 'PMID:6763357': {'publication date': '1982 Dec', 'sentence': 'Clinical trial of albendazole in hookworm infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:7939948': {'publication date': '1993 Dec', 'sentence': 'A comparative study on the efficacy of albendazole and mebendazole in the treatment of ascariasis, hookworm infection and trichuriasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:8771941': {'publication date': '1996 Jun', 'sentence': 'CONCLUSION: Albendazole is the drug of choice for mass deworming where hookworm disease is prominent.', 'subject score': 1000, 'object score': 785}, 'PMID:9776141': {'publication date': '1998 Aug 15', 'sentence': 'The parasitological, clinical efficacy and tolerability of albendazole in the treatment for both giardiasis and hookworm infection in a remote Aboriginal population was investigated.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0019911---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "7620262",
-              "object": "UMLS:C0019911",
-              "publications": [
-                "PMID:10450449",
-                "PMID:19324046",
-                "PMID:21176950",
-                "PMID:21980373",
-                "PMID:23836564",
-                "PMID:24552246",
-                "PMID:2692189",
-                "PMID:3307657",
-                "PMID:33832450",
-                "PMID:35745589",
-                "PMID:6763357",
-                "PMID:7939948",
-                "PMID:8771941",
-                "PMID:9776141"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10102436': {'publication date': '1999 Mar 23', 'sentence': 'The efficacy of albendazole (15 mg/kg/d for 1 week) was compared with praziquantel (100 mg/kg in three divided doses at 2-hour intervals) for therapy of parenchymal brain cysticercosis.', 'subject score': 1000, 'object score': 877}, 'PMID:10423586': {'publication date': '1997 Jan', 'sentence': 'Clinical pharmacokinetics of albendazole in children with neurocysticercosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:10660021': {'publication date': '1999 Dec', 'sentence': 'METHODS: In this study, 65 patients with active neurocysticercosis (NCC) treated with praziquantel or albendazole were retrospectively reviewed to evaluate radiological and clinical outcome.', 'subject score': 1000, 'object score': 888}, 'PMID:10805184': {'publication date': '2000 Apr', 'sentence': 'Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:11080931': {'publication date': '2000', 'sentence': 'Praziquantel and albendazole are the two cestocide drugs currently used for the treatment of NCC.', 'subject score': 1000, 'object score': 1000}, 'PMID:11137466': {'publication date': '2000 Dec', 'sentence': 'The anthelmintic drug albendazole (ABZ), methyl(5-(propylthio)-1H-benzimidazol-2-yl)carbamate, is a benzimidazole highly efficient in the treatment of neurocysticercosis.', 'subject score': 901, 'object score': 1000}, 'PMID:11198654': {'publication date': '2000 Nov-Dec', 'sentence': 'The efficacy of albendazole (ABZ) treatment for human neurocysticercosis (NCC) was assessed by using a monoclonal antibody-based parasite antigen detection ELISA which specifically detects the products of living cysticerci in human serum.', 'subject score': 888, 'object score': 888}, 'PMID:11589289': {'publication date': '2001 Sep', 'sentence': 'Albendazole (ABZ) is a benzimidazole anthelmintic drug used in the treatment of neurocysticercosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:11847531': {'publication date': '2002 Feb', 'sentence': 'Albendazole metabolism in patients with neurocysticercosis: antipyrine as a multifunctional marker drug of cytochrome P450.', 'subject score': 888, 'object score': 1000}, 'PMID:12021623': {'publication date': '2002 Jun', 'sentence': 'Thirty-two adults with a diagnosis of the active form of intraparenchymatous neurocysticercosis and treated with albendazole at the dose of 7.5 mg/kg every 12 hours for 8 days were studied.', 'subject score': 1000, 'object score': 861}, 'PMID:12136810': {'publication date': '2002 Jun', 'sentence': 'CSF-VP shunt placement and albendazole therapy for cerebral cysticercosis.', 'subject score': 888, 'object score': 1000}, 'PMID:12207631': {'publication date': '2002 Aug', 'sentence': 'METHODS: Twelve patients with a diagnosis of active brain parenchymal neurocysticercosis treated with albendazole for 8 days (15 mg kg(-1) day(-1)) were investigated.', 'subject score': 1000, 'object score': 815}, 'PMID:12563746': {'publication date': '1999', 'sentence': 'Small cystic lesions could turn into other CT signs of cerebral cysticercosis after albendazole treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:12634590': {'publication date': '2003 Mar', 'sentence': 'One week versus four weeks of albendazole therapy for neurocysticercosis in children: a randomized, placebo-controlled double blind trial.', 'subject score': 888, 'object score': 1000}, 'PMID:1439991': {'publication date': '1992 Jun', 'sentence': 'Albendazole treatment of neurocysticercosis.', 'subject score': 888, 'object score': 1000}, 'PMID:15224704': {'publication date': '2004 May', 'sentence': 'Corticosteroids versus albendazole for treatment of single small enhancing computed tomographic lesions in children with neurocysticercosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15259471': {'publication date': '2003', 'sentence': 'The clinical findings of neurocysticercosis, diagnosed primarily on the basis of computed tomography (CT), and response to albendazole therapy in a randomized, double-blind, placebo-controlled trial were studied in 72 newly diagnosed children aged 1.5-12 years admitted to hospital in New Delhi, India, during March to July 2000.', 'subject score': 888, 'object score': 1000}, 'PMID:15290687': {'publication date': '2004 Oct', 'sentence': 'The present study investigates the urinary excretion of the enantiomers of (+)- and (-)-albendazole sulfoxide (ASOX) and albendazole sulfone (ASON) in 12 patients with neurocysticercosis treated with albendazole for 8 days (7.5 mg/kg/12 h).', 'subject score': 1000, 'object score': 1000}, 'PMID:15587154': {'publication date': '2004 Aug', 'sentence': 'OBJECTIVE: To determine the therapeutic efficacy of albendazole combined with surgical intervention on intracranial hypertension in the treatment of severe neurocysticercosis.', 'subject score': 1000, 'object score': 888}, 'PMID:15853623': {'publication date': '2004 Jan', 'sentence': 'Albendazole may also be useful in extraparenchymal cysticercosis, especially in the subarachnoid racemose form, when complete surgical resection of the cysts is usually impracticable.', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 526462,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015484",
-          "name": "cysticercosis",
-          "description": "A parasitic infection with tapeworms of the genus Taenia affecting the brain. It is manifested with seizures and headaches.; Infection of the brain, spinal cord, or perimeningeal structures with the larval forms of the genus TAENIA (primarily T. solium in humans). Lesions formed by the organism are referred to as cysticerci. The infection may be subacute or chronic, and the severity of symptoms depends on the severity of the host immune response and the location and number of lesions. SEIZURES represent the most common clinical manifestation although focal neurologic deficits may occur. (From Joynt, Clinical Neurology, 1998, Ch27, pp46-50); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D020019",
-            "UMLS:C0338437",
-            "DOID:10079",
-            "MEDDRA:10011757",
-            "MONDO:0015484",
-            "ORPHANET:1560",
-            "SNOMEDCT:230215006",
-            "EFO:0007231",
-            "ICD10:B69",
-            "MEDDRA:10058443",
-            "MESH:D003551",
-            "SNOMEDCT:59051007",
-            "UMLS:C0010678",
-            "MEDDRA:10011775",
-            "NCIT:C34520",
-            "ICD9:123.1",
-            "SNOMEDCT:105684008",
-            "NCIT:C84932"
-          ],
-          "id": "MONDO:0015484",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cysticercosis",
-            "cysticercosis",
-            "Neurocysticercosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/cysticercosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526462,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015484",
-              "name": "cysticercosis",
-              "description": "A parasitic infection with tapeworms of the genus Taenia affecting the brain. It is manifested with seizures and headaches.; Infection of the brain, spinal cord, or perimeningeal structures with the larval forms of the genus TAENIA (primarily T. solium in humans). Lesions formed by the organism are referred to as cysticerci. The infection may be subacute or chronic, and the severity of symptoms depends on the severity of the host immune response and the location and number of lesions. SEIZURES represent the most common clinical manifestation although focal neurologic deficits may occur. (From Joynt, Clinical Neurology, 1998, Ch27, pp46-50); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D020019",
-                "UMLS:C0338437",
-                "DOID:10079",
-                "MEDDRA:10011757",
-                "MONDO:0015484",
-                "ORPHANET:1560",
-                "SNOMEDCT:230215006",
-                "EFO:0007231",
-                "ICD10:B69",
-                "MEDDRA:10058443",
-                "MESH:D003551",
-                "SNOMEDCT:59051007",
-                "UMLS:C0010678",
-                "MEDDRA:10011775",
-                "NCIT:C34520",
-                "ICD9:123.1",
-                "SNOMEDCT:105684008",
-                "NCIT:C84932"
-              ],
-              "id": "MONDO:0015484",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cysticercosis",
-                "cysticercosis",
-                "Neurocysticercosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/cysticercosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7083976,
-            "start": 551,
-            "end": 526462,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10102436': {'publication date': '1999 Mar 23', 'sentence': 'The efficacy of albendazole (15 mg/kg/d for 1 week) was compared with praziquantel (100 mg/kg in three divided doses at 2-hour intervals) for therapy of parenchymal brain cysticercosis.', 'subject score': 1000, 'object score': 877}, 'PMID:10423586': {'publication date': '1997 Jan', 'sentence': 'Clinical pharmacokinetics of albendazole in children with neurocysticercosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:10660021': {'publication date': '1999 Dec', 'sentence': 'METHODS: In this study, 65 patients with active neurocysticercosis (NCC) treated with praziquantel or albendazole were retrospectively reviewed to evaluate radiological and clinical outcome.', 'subject score': 1000, 'object score': 888}, 'PMID:10805184': {'publication date': '2000 Apr', 'sentence': 'Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:11080931': {'publication date': '2000', 'sentence': 'Praziquantel and albendazole are the two cestocide drugs currently used for the treatment of NCC.', 'subject score': 1000, 'object score': 1000}, 'PMID:11137466': {'publication date': '2000 Dec', 'sentence': 'The anthelmintic drug albendazole (ABZ), methyl(5-(propylthio)-1H-benzimidazol-2-yl)carbamate, is a benzimidazole highly efficient in the treatment of neurocysticercosis.', 'subject score': 901, 'object score': 1000}, 'PMID:11198654': {'publication date': '2000 Nov-Dec', 'sentence': 'The efficacy of albendazole (ABZ) treatment for human neurocysticercosis (NCC) was assessed by using a monoclonal antibody-based parasite antigen detection ELISA which specifically detects the products of living cysticerci in human serum.', 'subject score': 888, 'object score': 888}, 'PMID:11589289': {'publication date': '2001 Sep', 'sentence': 'Albendazole (ABZ) is a benzimidazole anthelmintic drug used in the treatment of neurocysticercosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:11847531': {'publication date': '2002 Feb', 'sentence': 'Albendazole metabolism in patients with neurocysticercosis: antipyrine as a multifunctional marker drug of cytochrome P450.', 'subject score': 888, 'object score': 1000}, 'PMID:12021623': {'publication date': '2002 Jun', 'sentence': 'Thirty-two adults with a diagnosis of the active form of intraparenchymatous neurocysticercosis and treated with albendazole at the dose of 7.5 mg/kg every 12 hours for 8 days were studied.', 'subject score': 1000, 'object score': 861}, 'PMID:12136810': {'publication date': '2002 Jun', 'sentence': 'CSF-VP shunt placement and albendazole therapy for cerebral cysticercosis.', 'subject score': 888, 'object score': 1000}, 'PMID:12207631': {'publication date': '2002 Aug', 'sentence': 'METHODS: Twelve patients with a diagnosis of active brain parenchymal neurocysticercosis treated with albendazole for 8 days (15 mg kg(-1) day(-1)) were investigated.', 'subject score': 1000, 'object score': 815}, 'PMID:12563746': {'publication date': '1999', 'sentence': 'Small cystic lesions could turn into other CT signs of cerebral cysticercosis after albendazole treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:12634590': {'publication date': '2003 Mar', 'sentence': 'One week versus four weeks of albendazole therapy for neurocysticercosis in children: a randomized, placebo-controlled double blind trial.', 'subject score': 888, 'object score': 1000}, 'PMID:1439991': {'publication date': '1992 Jun', 'sentence': 'Albendazole treatment of neurocysticercosis.', 'subject score': 888, 'object score': 1000}, 'PMID:15224704': {'publication date': '2004 May', 'sentence': 'Corticosteroids versus albendazole for treatment of single small enhancing computed tomographic lesions in children with neurocysticercosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15259471': {'publication date': '2003', 'sentence': 'The clinical findings of neurocysticercosis, diagnosed primarily on the basis of computed tomography (CT), and response to albendazole therapy in a randomized, double-blind, placebo-controlled trial were studied in 72 newly diagnosed children aged 1.5-12 years admitted to hospital in New Delhi, India, during March to July 2000.', 'subject score': 888, 'object score': 1000}, 'PMID:15290687': {'publication date': '2004 Oct', 'sentence': 'The present study investigates the urinary excretion of the enantiomers of (+)- and (-)-albendazole sulfoxide (ASOX) and albendazole sulfone (ASON) in 12 patients with neurocysticercosis treated with albendazole for 8 days (7.5 mg/kg/12 h).', 'subject score': 1000, 'object score': 1000}, 'PMID:15587154': {'publication date': '2004 Aug', 'sentence': 'OBJECTIVE: To determine the therapeutic efficacy of albendazole combined with surgical intervention on intracranial hypertension in the treatment of severe neurocysticercosis.', 'subject score': 1000, 'object score': 888}, 'PMID:15853623': {'publication date': '2004 Jan', 'sentence': 'Albendazole may also be useful in extraparenchymal cysticercosis, especially in the subarachnoid racemose form, when complete surgical resection of the cysts is usually impracticable.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0338437---SEMMEDDB:",
-                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0010678---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "7226097",
-              "object": "MONDO:0015484",
-              "publications": [
-                "PMID:8266251",
-                "PMID:3652415",
-                "PMID:23229490",
-                "PMID:15224704",
-                "PMID:12021623",
-                "PMID:31600525",
-                "PMID:7591443",
-                "PMID:26198415",
-                "PMID:12875739",
-                "PMID:1740534",
-                "PMID:8422660",
-                "PMID:17621473",
-                "PMID:7485720",
-                "PMID:25339244",
-                "PMID:11080931",
-                "PMID:8965125",
-                "PMID:36333896",
-                "PMID:2391343",
-                "PMID:19951271",
-                "PMID:14749518"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 526500,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:33150325': {'publication date': '2020 Oct', 'sentence': 'The control of STH infections is based on preventive chemotherapy using either albendazole or mebendazole.', 'subject score': 888, 'object score': 888}, 'PMID:33906234': {'publication date': '2021 Apr 27', 'sentence': 'CONCLUSIONS: The combined use of ALB and high-dose IVM is a highly effective and well tolerated treatment for the treatment of T. trichiura infections offering a significantly improved treatment for the control of this infection.', 'subject score': 1000, 'object score': 851}, 'PMID:34218593': {'publication date': '2021 Jun', 'sentence': 'Albendazole is also used for treatment of filarial infections (lymphatic filariasis, onchocerciasis, loiasis, mansonellosis, and dirofilariasis) alone or in combination with other drugs, such as ivermectin or diethylcarbamazine.', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 546907,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-          "name": "helminthiasis",
-          "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
-          "equivalent_curies": [
-            "MESH:D006373",
-            "MONDO:0004664",
-            "MEDDRA:10061201",
-            "ICD10:B83.9",
-            "MEDDRA:10019380",
-            "MEDDRA:10019382",
-            "DOID:883",
-            "UMLS:C0018889",
-            "NCIT:C84751",
-            "SNOMEDCT:27601005",
-            "EFO:1001342",
-            "ICD9:120-129.99"
-          ],
-          "id": "MONDO:0004664",
-          "category": "biolink:Disease",
-          "all_names": [
-            "parasitic helminthiasis infectious disease",
-            "Helminthiasis",
-            "Helminthiases",
-            "helminthiasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/helminth",
-            "http://en.wikipedia.org/wiki/helminthiasis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526500,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-              "name": "helminthiasis",
-              "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
-              "equivalent_curies": [
-                "MESH:D006373",
-                "MONDO:0004664",
-                "MEDDRA:10061201",
-                "ICD10:B83.9",
-                "MEDDRA:10019380",
-                "MEDDRA:10019382",
-                "DOID:883",
-                "UMLS:C0018889",
-                "NCIT:C84751",
-                "SNOMEDCT:27601005",
-                "EFO:1001342",
-                "ICD9:120-129.99"
-              ],
-              "id": "MONDO:0004664",
-              "category": "biolink:Disease",
-              "all_names": [
-                "parasitic helminthiasis infectious disease",
-                "Helminthiasis",
-                "Helminthiases",
-                "helminthiasis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/helminth",
-                "http://en.wikipedia.org/wiki/helminthiasis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24282217,
-            "start": 551,
-            "end": 526500,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35856263': {'publication date': '2022 Jul 20', 'sentence': 'Additionally, compared with albendazole, it resulted in a significant reduction in adult worm and total larval counts; moreover, it caused a decrease in the number of larvae deposited in muscles, with a highly significant decrease in the inflammatory cell infiltrate around the larvae and a considerable decrease in the expression of the angiogenic marker vascular endothelial growth factor in muscles.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:disrupts---None---None---None---UMLS:C0018889---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "24729219",
-              "object": "MONDO:0004664",
-              "publications": [
-                "PMID:35856263"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 506641,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005136",
-          "name": "malaria",
-          "description": "A protozoan infection caused by the genus Plasmodium. There are four species of Plasmodium that can infect humans: Plasmodium falciparum, vivax, ovale, and malariae. It is transmitted to humans by infected mosquitoes. Signs and symptoms include paroxysmal high fever, sweating, chills, and anemia.; A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.; Malaria is a serious disease caused by a parasite. You get it when an infected mosquito bites you. Malaria is a major cause of death worldwide, but it is almost wiped out in the United States. The disease is mostly a problem in developing countries with warm climates. If you travel to these countries, you are at risk. There are four different types of malaria caused by four related parasites. The most deadly type occurs in Africa south of the Sahara Desert. Malaria symptoms include chills, flu-like symptoms, fever, vomiting, diarrhea, and jaundice. A blood test can diagnose it. It can be life-threatening. However, you can treat malaria with drugs. The type of drug depends on which kind of malaria you have and where you were infected. Malaria can be prevented. When traveling to areas where malaria is found: See your doctor for medicines that protect you  Wear insect repellent with DEET  Cover up Sleep under mosquito netting   Centers for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10067345",
-            "MEDDRA:10054147",
-            "MONDO:0005136",
-            "SNOMEDCT:248437004",
-            "SNOMEDCT:105649009",
-            "MEDDRA:10025487",
-            "PSY:29180",
-            "ICD10:B54",
-            "ORPHANET:673",
-            "MESH:D008288",
-            "NCIT:C34797",
-            "MEDDRA:10025489",
-            "ICD9:084",
-            "EFO:0001068",
-            "UMLS:C0024530",
-            "MEDDRA:10035499",
-            "DOID:12365",
-            "MEDDRA:10025497",
-            "SNOMEDCT:61462000"
-          ],
-          "id": "MONDO:0005136",
-          "category": "biolink:Disease",
-          "all_names": [
-            "malaria",
-            "Malaria"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=malaria",
-            "https://rarediseases.info.nih.gov/diseases/6961/malaria",
-            "http://en.wikipedia.org/wiki/malaria"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 506641,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005136",
-              "name": "malaria",
-              "description": "A protozoan infection caused by the genus Plasmodium. There are four species of Plasmodium that can infect humans: Plasmodium falciparum, vivax, ovale, and malariae. It is transmitted to humans by infected mosquitoes. Signs and symptoms include paroxysmal high fever, sweating, chills, and anemia.; A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.; Malaria is a serious disease caused by a parasite. You get it when an infected mosquito bites you. Malaria is a major cause of death worldwide, but it is almost wiped out in the United States. The disease is mostly a problem in developing countries with warm climates. If you travel to these countries, you are at risk. There are four different types of malaria caused by four related parasites. The most deadly type occurs in Africa south of the Sahara Desert. Malaria symptoms include chills, flu-like symptoms, fever, vomiting, diarrhea, and jaundice. A blood test can diagnose it. It can be life-threatening. However, you can treat malaria with drugs. The type of drug depends on which kind of malaria you have and where you were infected. Malaria can be prevented. When traveling to areas where malaria is found: See your doctor for medicines that protect you  Wear insect repellent with DEET  Cover up Sleep under mosquito netting   Centers for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10067345",
-                "MEDDRA:10054147",
-                "MONDO:0005136",
-                "SNOMEDCT:248437004",
-                "SNOMEDCT:105649009",
-                "MEDDRA:10025487",
-                "PSY:29180",
-                "ICD10:B54",
-                "ORPHANET:673",
-                "MESH:D008288",
-                "NCIT:C34797",
-                "MEDDRA:10025489",
-                "ICD9:084",
-                "EFO:0001068",
-                "UMLS:C0024530",
-                "MEDDRA:10035499",
-                "DOID:12365",
-                "MEDDRA:10025497",
-                "SNOMEDCT:61462000"
-              ],
-              "id": "MONDO:0005136",
-              "category": "biolink:Disease",
-              "all_names": [
-                "malaria",
-                "Malaria"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=malaria",
-                "https://rarediseases.info.nih.gov/diseases/6961/malaria",
-                "http://en.wikipedia.org/wiki/malaria"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16320187,
-            "start": 551,
-            "end": 506641,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23236367': {'publication date': '2012', 'sentence': 'Quarterly albendazole during childhood was associated with reduced incidence of clinical malaria (HR 0.85 (95% CI 0.73-0.98), p = 0.03).', 'subject score': 888, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:disrupts---None---None---None---UMLS:C0024530---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "16658503",
-              "object": "MONDO:0005136",
-              "publications": [
-                "PMID:23236367"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 841712,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C0019911",
-          "name": "Hookworm Infections",
-          "description": "An infection that is caused by hookworms.; Infection of humans or animals with hookworms other than those caused by the genus Ancylostoma or Necator, for which the specific terms ANCYLOSTOMIASIS and NECATORIASIS are available.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10020376",
-            "UMLS:C0019911",
-            "SNOMEDCT:105694003",
-            "NCIT:C34702",
-            "MESH:D006725"
-          ],
-          "id": "UMLS:C0019911",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hookworm Infections",
-            "Hookworm Infection"
-=======
-          "iri": "https://identifiers.org/umls:C3714514",
-          "name": "Infection",
-          "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "UMLS:C3714514",
-            "MEDDRA:10021842",
-            "NCIT:C128320",
-            "MEDDRA:10021789",
-            "MESH:D007239"
-          ],
-          "id": "UMLS:C3714514",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infection",
-            "Infections"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 841712,
-=======
-            "identity": 546907,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "https://identifiers.org/umls:C0019911",
-              "name": "Hookworm Infections",
-              "description": "An infection that is caused by hookworms.; Infection of humans or animals with hookworms other than those caused by the genus Ancylostoma or Necator, for which the specific terms ANCYLOSTOMIASIS and NECATORIASIS are available.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10020376",
-                "UMLS:C0019911",
-                "SNOMEDCT:105694003",
-                "NCIT:C34702",
-                "MESH:D006725"
-              ],
-              "id": "UMLS:C0019911",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hookworm Infections",
-                "Hookworm Infection"
-=======
-              "iri": "https://identifiers.org/umls:C3714514",
-              "name": "Infection",
-              "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "UMLS:C3714514",
-                "MEDDRA:10021842",
-                "NCIT:C128320",
-                "MEDDRA:10021789",
-                "MESH:D007239"
-              ],
-              "id": "UMLS:C3714514",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infection",
-                "Infections"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 13340627,
-            "start": 551,
-            "end": 841712,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18330331': {'publication date': '2007 Jul', 'sentence': 'CONCLUSIONS: Mebendazole and albendazole showed reduced efficacy against Ascaris lumbricoides and hookworm infections at the recommended doses.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:disrupts---None---None---None---UMLS:C0019911---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "13637338",
-              "object": "UMLS:C0019911",
-              "publications": [
-                "PMID:18330331"
-=======
-            "identity": 22253094,
-            "start": 551,
-            "end": 546907,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:33150325': {'publication date': '2020 Oct', 'sentence': 'The control of STH infections is based on preventive chemotherapy using either albendazole or mebendazole.', 'subject score': 888, 'object score': 888}, 'PMID:33906234': {'publication date': '2021 Apr 27', 'sentence': 'CONCLUSIONS: The combined use of ALB and high-dose IVM is a highly effective and well tolerated treatment for the treatment of T. trichiura infections offering a significantly improved treatment for the control of this infection.', 'subject score': 1000, 'object score': 851}, 'PMID:34218593': {'publication date': '2021 Jun', 'sentence': 'Albendazole is also used for treatment of filarial infections (lymphatic filariasis, onchocerciasis, loiasis, mansonellosis, and dirofilariasis) alone or in combination with other drugs, such as ivermectin or diethylcarbamazine.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C3714514---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "22678969",
-              "object": "UMLS:C3714514",
-              "publications": [
-                "PMID:33150325",
-                "PMID:33906234",
-                "PMID:34218593"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 532244,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016075",
-          "name": "filariasis",
-          "description": "A parasitic disease caused by tissue-invasive, vector-borne nematodes which can be found anywhere in the human body and that are transmitted to humans through the bite of an infected mosquito or fly or by consumption of unsafe drinking water and which, depending on the subtype can manifest with lymphedema, dermatitis, subcutaneous edema and eye involvement. The disorder is a major public health problem in many tropical and subtropical countries. Six subtypes have been described in the literature: lymphatic filariasis, onchocerciasis, loiasis, mansonelliasis, dirofilariasis and dracunculiasis caused by Wuchereria bancrofti and filarioidea of the genus Brugia; Onchocerca volvulus; Loa loa; Mansonella; Dirofilaria; and Dracunculus medinensis, respectively. Tropical eosinophilia is considered a frequent manifestation.",
-          "equivalent_curies": [
-            "MONDO:0016075",
-            "ICD9:125.9",
-            "MEDDRA:10076405",
-            "NCIT:C34611",
-            "DOID:1080",
-            "MEDDRA:10016674",
-            "ICD10:B74",
-            "SNOMEDCT:105706003",
-            "ORPHANET:2034",
-            "UMLS:C0016085",
-            "MESH:D005368",
-            "MEDDRA:10045874"
-          ],
-          "id": "MONDO:0016075",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Filariasis",
-            "Unspecified filariasis",
-            "filariasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/filariasis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 532244,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016075",
-              "name": "filariasis",
-              "description": "A parasitic disease caused by tissue-invasive, vector-borne nematodes which can be found anywhere in the human body and that are transmitted to humans through the bite of an infected mosquito or fly or by consumption of unsafe drinking water and which, depending on the subtype can manifest with lymphedema, dermatitis, subcutaneous edema and eye involvement. The disorder is a major public health problem in many tropical and subtropical countries. Six subtypes have been described in the literature: lymphatic filariasis, onchocerciasis, loiasis, mansonelliasis, dirofilariasis and dracunculiasis caused by Wuchereria bancrofti and filarioidea of the genus Brugia; Onchocerca volvulus; Loa loa; Mansonella; Dirofilaria; and Dracunculus medinensis, respectively. Tropical eosinophilia is considered a frequent manifestation.",
-              "equivalent_curies": [
-                "MONDO:0016075",
-                "ICD9:125.9",
-                "MEDDRA:10076405",
-                "NCIT:C34611",
-                "DOID:1080",
-                "MEDDRA:10016674",
-                "ICD10:B74",
-                "SNOMEDCT:105706003",
-                "ORPHANET:2034",
-                "UMLS:C0016085",
-                "MESH:D005368",
-                "MEDDRA:10045874"
-              ],
-              "id": "MONDO:0016075",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Filariasis",
-                "Unspecified filariasis",
-                "filariasis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/filariasis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14933326,
-            "start": 551,
-            "end": 532244,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20933491': {'publication date': '2011 Sep', 'sentence': 'Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters.', 'subject score': 851, 'object score': 913}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:prevents---None---None---None---UMLS:C0016085---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "15248433",
-              "object": "MONDO:0016075",
-              "publications": [
-                "PMID:20933491"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 526500,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-          "name": "helminthiasis",
-          "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
-          "equivalent_curies": [
-            "MESH:D006373",
-            "MONDO:0004664",
-            "MEDDRA:10061201",
-            "ICD10:B83.9",
-            "MEDDRA:10019380",
-            "MEDDRA:10019382",
-            "DOID:883",
-            "UMLS:C0018889",
-            "NCIT:C84751",
-            "SNOMEDCT:27601005",
-            "EFO:1001342",
-            "ICD9:120-129.99"
-          ],
-          "id": "MONDO:0004664",
-          "category": "biolink:Disease",
-          "all_names": [
-            "parasitic helminthiasis infectious disease",
-            "Helminthiasis",
-            "Helminthiases",
-            "helminthiasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/helminth",
-            "http://en.wikipedia.org/wiki/helminthiasis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 551,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Albendazole",
-          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C01779",
-            "UMLS:C0001911",
-            "ATC:P02CA03",
-            "NCIT:C47384",
-            "UMLS:C4082528",
-            "KEGG.DRUG:D00134",
-            "NDDF:004079",
-            "DrugCentral:103",
-            "MESH:D015766",
-            "CAS:54965-21-8",
-            "RXNORM:430",
-            "HMDB:HMDB0014659",
-            "CHEBI:16664",
-            "UNII:F4216019LN",
-            "CHEMBL.COMPOUND:CHEMBL1483",
-            "DRUGBANK:DB00518",
-            "PUBCHEM.COMPOUND:2082",
-            "UMLS:C4082752",
-            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:2082",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "albendol",
-            "Albendazole",
-            "ALBENDAZOLE",
-            "Eskazole",
-            "Proftril",
-            "Albendazole (JAN/USP/INN)",
-            "albendazole"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28595066",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:17562801",
-            "PMID:8228321",
-            "PMID:15828820",
-            "PMID:23571415",
-            "PMID:33360795",
-            "PMID:19186059",
-            "PMID:16420038"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526500,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-              "name": "helminthiasis",
-              "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
-              "equivalent_curies": [
-                "MESH:D006373",
-                "MONDO:0004664",
-                "MEDDRA:10061201",
-                "ICD10:B83.9",
-                "MEDDRA:10019380",
-                "MEDDRA:10019382",
-                "DOID:883",
-                "UMLS:C0018889",
-                "NCIT:C84751",
-                "SNOMEDCT:27601005",
-                "EFO:1001342",
-                "ICD9:120-129.99"
-              ],
-              "id": "MONDO:0004664",
-              "category": "biolink:Disease",
-              "all_names": [
-                "parasitic helminthiasis infectious disease",
-                "Helminthiasis",
-                "Helminthiases",
-                "helminthiasis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/helminth",
-                "http://en.wikipedia.org/wiki/helminthiasis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13443772,
-            "start": 551,
-            "end": 526500,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18458310': {'publication date': '2008 May', 'sentence': 'Our evaluation suggests that although additional studies are needed to determine optimal treatment regimens for intestinal parasites, especially among young children and pregnant women, a five-day course of pre-departure albendazole was effective in reducing helminthic infection in treated refugees.', 'subject score': 802, 'object score': 890}, 'PMID:22913197': {'publication date': '2012 Feb 29', 'sentence': 'When treating with one course of albendazole at 1 week post infection, the worm reduction rate in groups A-C was 20.0%, 20.0% and 24.9%, respectively (chi2 = 0.351, P > 0.05).', 'subject score': 1000, 'object score': 802}}",
-              "kg2_ids": [
-                "UMLS:C0001911---SEMMEDDB:prevents---None---None---None---UMLS:C0018889---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2082",
-              "id": "13732336",
-              "object": "MONDO:0004664",
-              "publications": [
-                "PMID:18458310",
-                "PMID:22913197"
-              ]
-            }
-          },
-          "end": {
-            "identity": 551,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Albendazole",
-              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C01779",
-                "UMLS:C0001911",
-                "ATC:P02CA03",
-                "NCIT:C47384",
-                "UMLS:C4082528",
-                "KEGG.DRUG:D00134",
-                "NDDF:004079",
-                "DrugCentral:103",
-                "MESH:D015766",
-                "CAS:54965-21-8",
-                "RXNORM:430",
-                "HMDB:HMDB0014659",
-                "CHEBI:16664",
-                "UNII:F4216019LN",
-                "CHEMBL.COMPOUND:CHEMBL1483",
-                "DRUGBANK:DB00518",
-                "PUBCHEM.COMPOUND:2082",
-                "UMLS:C4082752",
-                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:2082",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "albendol",
-                "Albendazole",
-                "ALBENDAZOLE",
-                "Eskazole",
-                "Proftril",
-                "Albendazole (JAN/USP/INN)",
-                "albendazole"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28595066",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:17562801",
-                "PMID:8228321",
-                "PMID:15828820",
-                "PMID:23571415",
-                "PMID:33360795",
-                "PMID:19186059",
-                "PMID:16420038"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:3903022': {'publication date': '1985 Jul', 'sentence': 'Clinical efficacy and safety of a new oxacephem, moxalactam, in serious bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:6214210': {'publication date': '1982 Jun', 'sentence': 'These data indicate that this dosage of moxalactam is a safe and effective treatment for bacterial infections outside the central nervous system.', 'subject score': 1000, 'object score': 1000}, 'PMID:6219576': {'publication date': '1983 Mar', 'sentence': 'In 93 hospitalized patients, 111 bacterial infections were treated with moxalactam.', 'subject score': 1000, 'object score': 901}, 'PMID:6458253': {'publication date': '1981 Nov', 'sentence': 'Moxalactam therapy for bacterial infections.', 'subject score': 888, 'object score': 1000}, 'PMID:6508263': {'publication date': '1984 Sep', 'sentence': 'Timentin versus piperacillin or moxalactam in the therapy of acute bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:6617297': {'publication date': '1983', 'sentence': 'Lamoxactam seems to be an effective and safe single-agent therapy for many bacterial infections.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 538307,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-          ]
-        }
-      },
-      "end": {
-        "identity": 553,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Latamoxef",
-          "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "ATC:J01DD06",
-            "NDDF:004889",
-            "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
-            "CHEMBL.COMPOUND:CHEMBL74632",
-            "UMLS:C0878141",
-            "CHEBI:599928",
-            "RXNORM:7069",
-            "PUBCHEM.COMPOUND:47499",
-            "PDQ:CDR0000039507",
-            "UMLS:C0026651",
-            "KEGG.DRUG:D02198",
-            "DRUGBANK:DB04570",
-            "KEGG.COMPOUND:C07231",
-            "NCIT:C670",
-            "GTOPDB:12031",
-            "KEGG.DRUG:D08109",
-            "HMDB:HMDB0015574",
-            "DrugCentral:1851",
-            "UNII:VUF6C936Z3",
-            "MESH:D009070"
-          ],
-          "id": "PUBCHEM.COMPOUND:47499",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Latamoxef",
-            "Latamoxef (INN)",
-            "Moxalactam disodium (USAN)",
-            "Moxalactam",
-            "Festamoxin",
-            "moxalactam",
-            "latamoxef",
-            "MOXALACTAM"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20014752",
-            "PMID:17846134",
-            "PMID:6217353",
-            "PMID:17242148",
-            "PMID:18426954",
-            "PMID:18559652",
-            "PMID:19764786",
-            "PMID:12109906",
-            "PMID:18765691",
-            "PMID:19445515"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538307,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25215537,
-            "start": 553,
-            "end": 538307,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3903022': {'publication date': '1985 Jul', 'sentence': 'Clinical efficacy and safety of a new oxacephem, moxalactam, in serious bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:6214210': {'publication date': '1982 Jun', 'sentence': 'These data indicate that this dosage of moxalactam is a safe and effective treatment for bacterial infections outside the central nervous system.', 'subject score': 1000, 'object score': 1000}, 'PMID:6219576': {'publication date': '1983 Mar', 'sentence': 'In 93 hospitalized patients, 111 bacterial infections were treated with moxalactam.', 'subject score': 1000, 'object score': 901}, 'PMID:6458253': {'publication date': '1981 Nov', 'sentence': 'Moxalactam therapy for bacterial infections.', 'subject score': 888, 'object score': 1000}, 'PMID:6508263': {'publication date': '1984 Sep', 'sentence': 'Timentin versus piperacillin or moxalactam in the therapy of acute bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:6617297': {'publication date': '1983', 'sentence': 'Lamoxactam seems to be an effective and safe single-agent therapy for many bacterial infections.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0026651---SEMMEDDB:treats---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:47499",
-              "id": "25678577",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:3903022",
-                "PMID:6214210",
-                "PMID:6219576",
-                "PMID:6458253",
-                "PMID:6508263",
-                "PMID:6617297"
-              ]
-            }
-          },
-          "end": {
-            "identity": 553,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-=======
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
->>>>>>> main
-            ],
-            "properties": {
-              "name": "Latamoxef",
-              "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "ATC:J01DD06",
-                "NDDF:004889",
-                "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
-                "CHEMBL.COMPOUND:CHEMBL74632",
-                "UMLS:C0878141",
-                "CHEBI:599928",
-                "RXNORM:7069",
-                "PUBCHEM.COMPOUND:47499",
-                "PDQ:CDR0000039507",
-                "UMLS:C0026651",
-                "KEGG.DRUG:D02198",
-                "DRUGBANK:DB04570",
-                "KEGG.COMPOUND:C07231",
-                "NCIT:C670",
-                "GTOPDB:12031",
-                "KEGG.DRUG:D08109",
-                "HMDB:HMDB0015574",
-                "DrugCentral:1851",
-                "UNII:VUF6C936Z3",
-                "MESH:D009070"
-              ],
-              "id": "PUBCHEM.COMPOUND:47499",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Latamoxef",
-                "Latamoxef (INN)",
-                "Moxalactam disodium (USAN)",
-                "Moxalactam",
-                "Festamoxin",
-                "moxalactam",
-                "latamoxef",
-                "MOXALACTAM"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20014752",
-                "PMID:17846134",
-                "PMID:6217353",
-                "PMID:17242148",
-                "PMID:18426954",
-                "PMID:18559652",
-                "PMID:19764786",
-                "PMID:12109906",
-                "PMID:18765691",
-                "PMID:19445515"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 832023,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
-        ],
-        "properties": {
-          "name": "2-Hydroxyibuprofen",
-          "description": "2-Hydroxyibuprofen is a metabolite of ibuprofen. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) used for relief of symptoms of arthritis, fever, as an analgesic (pain reliever), especially where there is an inflammatory component, and dysmenorrhea. Ibuprofen is known to have an antiplatelet effect, though it is relatively mild and somewhat short-lived when compared with aspirin or other better-known antiplatelet drugs. (Wikipedia)",
-          "equivalent_curies": [
-            "CAS:51146-55-5",
-            "CHEBI:133197",
-            "UMLS:C0669948",
-            "CHEMBL.COMPOUND:CHEMBL3544495",
-            "UNII:2KHZ9ELM84",
-            "HMDB:HMDB0060920",
-            "INCHIKEY:UJHKVYPPCJBOSG-UHFFFAOYSA-N",
-            "MESH:C109994",
-            "PathWhiz.Compound:40563",
-            "PUBCHEM.COMPOUND:10443535"
-          ],
-          "id": "PUBCHEM.COMPOUND:10443535",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "hydroxyibuprofen",
-            "2-hydroxyibuprofen",
-            "2-Hydroxyibuprofen",
-            "2-HYDROXYIBUPROFEN"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 832023,
-            "labels": [
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:MolecularEntity",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-            ],
-            "properties": {
-              "name": "2-Hydroxyibuprofen",
-              "description": "2-Hydroxyibuprofen is a metabolite of ibuprofen. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) used for relief of symptoms of arthritis, fever, as an analgesic (pain reliever), especially where there is an inflammatory component, and dysmenorrhea. Ibuprofen is known to have an antiplatelet effect, though it is relatively mild and somewhat short-lived when compared with aspirin or other better-known antiplatelet drugs. (Wikipedia)",
-              "equivalent_curies": [
-                "CAS:51146-55-5",
-                "CHEBI:133197",
-                "UMLS:C0669948",
-                "CHEMBL.COMPOUND:CHEMBL3544495",
-                "UNII:2KHZ9ELM84",
-                "HMDB:HMDB0060920",
-                "INCHIKEY:UJHKVYPPCJBOSG-UHFFFAOYSA-N",
-                "MESH:C109994",
-                "PathWhiz.Compound:40563",
-                "PUBCHEM.COMPOUND:10443535"
-              ],
-              "id": "PUBCHEM.COMPOUND:10443535",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "hydroxyibuprofen",
-                "2-hydroxyibuprofen",
-                "2-Hydroxyibuprofen",
-                "2-HYDROXYIBUPROFEN"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15000215,
-            "start": 832023,
-            "end": 554,
-            "type": "biolink:subclass_of",
-            "properties": {
-              "predicate": "biolink:subclass_of",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21079932': {'publication date': '2011 Jan', 'sentence': 'The purpose of this study was the development and validation of an LC-MS-MS method for simultaneous analysis of ibuprofen (IBP), 2-hydroxyibuprofen (2-OH-IBP) enantiomers, and carboxyibuprofen (COOH-IBP) stereoisomers in fungi culture medium, to investigate the ability of some endophytic fungi to biotransform the chiral drug IBP into its metabolites.', 'subject score': 861, 'object score': 790}, 'PMID:22226725': {'publication date': '2012 Feb 10', 'sentence': 'The anti-inflammatory drug ibuprofen (Ibu) is metabolized in the human liver to a number of metabolites including 1-hydroxyibuprofen (1-OH-Ibu), 2-OH-Ibu, and 3-OH-Ibu, respectively.', 'subject score': 861, 'object score': 790}, 'PMID:29453024': {'publication date': '2018 Apr 15', 'sentence': 'A novel assay for the simultaneous determination of ibuprofen (IBU) and its four probable metabolites, 1-hydroxyibuprofen (1-OH IBU), 2-hydroxyibuprofen (2-OH IBU), 3-hydroxyibuprofen (3-OH IBU) and carboxyibuprofen (CBX IBU) in equine urine samples with the application of Gas Chromatography-Electron Ionization-Mass Spectrometry (GC-EI-MS) has been developed and elaborated.', 'subject score': 888, 'object score': 851}, 'PMID:31316382': {'publication date': '2019', 'sentence': 'An ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed and validated to determine 2-hydroxyibuprofen (2OH-IBU), carboxyibuprofen (COOH-IBU), and ibuprofen glucuronide (IBU-GlcA) in pig plasma.', 'subject score': 861, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0669948---SEMMEDDB:isa---None---None---None---UMLS:C0020740---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:10443535",
-              "id": "15316470",
-              "object": "PUBCHEM.COMPOUND:3672",
-              "publications": [
-                "PMID:21079932",
-                "PMID:22226725",
-                "PMID:29453024",
-                "PMID:31316382"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318242,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:31391526': {'publication date': '2019 Aug 07', 'sentence': 'After adjusting for covariates, the risk of BPD was associated independently with ibuprofen exposure (odds ratios (OR) 2.296, 95% confidence interval (CI): 1.166-4.522, p = 0.016).', 'subject score': 694, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 722907,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/HP_0002829",
-          "name": "Arthralgia",
-          "description": "Joint pain. [HPO:probinson]; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D018771",
-            "MEDDRA:10023197",
-            "MEDDRA:10033456",
-            "PDQ:CDR0000651641",
-            "MEDDRA:10013088",
-            "HP:0002829",
-            "MEDDRA:10033511",
-            "UMLS:C0857177",
-            "NCIT:C50464",
-            "MEDDRA:10003245",
-            "MEDDRA:10033434",
-            "UMLS:C0003862",
-            "MEDDRA:10033444",
-            "MEDDRA:10000449",
-            "SNOMEDCT:57676002",
-            "MEDDRA:10003244",
-            "MEDDRA:10003239",
-            "MEDDRA:10023222"
-          ],
-          "id": "HP:0002829",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Arthralgia",
-            "arthralgia",
-            "Arthritic pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318242,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002829",
-              "name": "Arthralgia",
-              "description": "Joint pain. [HPO:probinson]; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D018771",
-                "MEDDRA:10023197",
-                "MEDDRA:10033456",
-                "PDQ:CDR0000651641",
-                "MEDDRA:10013088",
-                "HP:0002829",
-                "MEDDRA:10033511",
-                "UMLS:C0857177",
-                "NCIT:C50464",
-                "MEDDRA:10003245",
-                "MEDDRA:10033434",
-                "UMLS:C0003862",
-                "MEDDRA:10033444",
-                "MEDDRA:10000449",
-                "SNOMEDCT:57676002",
-                "MEDDRA:10003244",
-                "MEDDRA:10003239",
-                "MEDDRA:10023222"
-              ],
-              "id": "HP:0002829",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Arthralgia",
-                "arthralgia",
-                "Arthritic pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15933349,
-            "start": 554,
-            "end": 318242,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22558609': {'publication date': '2012', 'sentence': 'AIMS: To carry out a randomized clinical trial to compare the effect of palmitoylethanolamide (PEA) versus ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), for pain relief in temporomandibular joint (TMJ) osteoarthritis or arthralgia.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:associated_with---None---None---None---UMLS:C0003862---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "16265626",
-              "object": "HP:0002829",
-              "publications": [
-                "PMID:22558609"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14279414,
-            "start": 554,
-            "end": 316891,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19762153': {'publication date': '2009 Dec 15', 'sentence': 'We investigated the analgesic efficacy of single doses of ibuprofen, tramadol and pregabalin in menthol-evoked cold pain in a randomized, placebo-controlled four-way cross-over study in 20 healthy volunteers.', 'subject score': 1000, 'object score': 775}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:associated_with---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "14582794",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:19762153"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 630575,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C78640",
-          "name": "Toothache",
-          "description": "A painful sensation originating from a tooth.; Pain in the adjacent areas of the teeth.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10059723",
-            "MESH:D014098",
-            "NCIT:C78640",
-            "MEDDRA:10044055",
-            "UMLS:C0040460",
-            "SYMP:0000438",
-            "SNOMEDCT:27355003",
-            "MEDDRA:10044017",
-            "MEDDRA:10030090"
-          ],
-          "id": "NCIT:C78640",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "toothache",
-            "Toothache"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://www.merriam-webster.com/dictionary/toothache"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 630575,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C78640",
-              "name": "Toothache",
-              "description": "A painful sensation originating from a tooth.; Pain in the adjacent areas of the teeth.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10059723",
-                "MESH:D014098",
-                "NCIT:C78640",
-                "MEDDRA:10044055",
-                "UMLS:C0040460",
-                "SYMP:0000438",
-                "SNOMEDCT:27355003",
-                "MEDDRA:10044017",
-                "MEDDRA:10030090"
-              ],
-              "id": "NCIT:C78640",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "toothache",
-                "Toothache"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://www.merriam-webster.com/dictionary/toothache"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11191763,
-            "start": 554,
-            "end": 630575,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1545477': {'publication date': '1992 Jan', 'sentence': 'Double blind study on emorfazone and ibuprofen in dental pain and inflammation.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:associated_with---None---None---None---UMLS:C0040460---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "11440746",
-              "object": "NCIT:C78640",
-              "publications": [
-                "PMID:1545477"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319030,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-          "name": "bronchopulmonary dysplasia",
-          "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:70589",
-            "MESH:D001997",
-            "MONDO:0019091",
-            "SNOMEDCT:67569000",
-            "MEDDRA:10066204",
-            "UMLS:C0006287",
-            "NCIT:C90599",
-            "DOID:11650",
-            "MEDDRA:10006475"
-          ],
-          "id": "MONDO:0019091",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bronchopulmonary Dysplasia",
-            "obsolete_bronchopulmonary dysplasia",
-            "bronchopulmonary dysplasia"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
-=======
-            "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 319030,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8901716,
-            "start": 554,
-            "end": 319030,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11548225': {'publication date': '1994 Mar', 'sentence': 'Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee.', 'subject score': 1000, 'object score': 1000}, 'PMID:22558609': {'publication date': '2012', 'sentence': 'AIMS: To carry out a randomized clinical trial to compare the effect of palmitoylethanolamide (PEA) versus ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), for pain relief in temporomandibular joint (TMJ) osteoarthritis or arthralgia.', 'subject score': 1000, 'object score': 901}, 'PMID:28035387': {'publication date': '2017 Feb', 'sentence': 'Therapeutic mechanisms of ibuprofen, prednisone and betamethasone in osteoarthritis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:associated_with---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9106384",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:11548225",
-                "PMID:22558609",
-                "PMID:28035387"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 533531,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043519",
-          "name": "burn",
-          "description": "A traumatic injury involving interruption of tissue cohesiveness that results from exposure to caustic chemicals, extreme heat, extreme cold or excessive radiation.; Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.; A burn is damage to your body's tissues caused by heat, chemicals, electricity, sunlight, or radiation. Scalds from hot liquids and steam, building fires and flammable liquids and gases are the most common causes of burns. Another kind is an inhalation injury, caused by breathing smoke. There are three types of burns:  First-degree burns damage only the outer layer of skin  Second-degree burns damage the outer layer and the layer underneath Third-degree burns damage or destroy the deepest layer of skin and tissues underneath  Burns can cause swelling, blistering, scarring and, in serious cases, shock, and even death. They also can lead to infections because they damage your skin's protective barrier. Treatment for burns depends on the cause of the burn, how deep it is, and how much of the body it covers. Antibiotic creams can prevent or treat infections. For more serious burns, treatment may be needed to clean the wound, replace the skin, and make sure the patient has enough fluids and nutrition. NIH: National Institute of General Medical Sciences; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10006799",
-            "MESH:D002056",
-            "MEDDRA:10006634",
-            "SNOMEDCT:125666000",
-            "MEDDRA:10083300",
-            "SNOMEDCT:48333001",
-            "NCIT:C34441",
-            "MEDDRA:10006764",
-            "UMLS:C0006434",
-            "MONDO:0043519"
-          ],
-          "id": "MONDO:0043519",
-          "category": "biolink:Disease",
-          "all_names": [
-            "burn",
-            "Burn injury",
-            "Burn",
-            "Burns"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 533531,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043519",
-              "name": "burn",
-              "description": "A traumatic injury involving interruption of tissue cohesiveness that results from exposure to caustic chemicals, extreme heat, extreme cold or excessive radiation.; Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.; A burn is damage to your body's tissues caused by heat, chemicals, electricity, sunlight, or radiation. Scalds from hot liquids and steam, building fires and flammable liquids and gases are the most common causes of burns. Another kind is an inhalation injury, caused by breathing smoke. There are three types of burns:  First-degree burns damage only the outer layer of skin  Second-degree burns damage the outer layer and the layer underneath Third-degree burns damage or destroy the deepest layer of skin and tissues underneath  Burns can cause swelling, blistering, scarring and, in serious cases, shock, and even death. They also can lead to infections because they damage your skin's protective barrier. Treatment for burns depends on the cause of the burn, how deep it is, and how much of the body it covers. Antibiotic creams can prevent or treat infections. For more serious burns, treatment may be needed to clean the wound, replace the skin, and make sure the patient has enough fluids and nutrition. NIH: National Institute of General Medical Sciences; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10006799",
-                "MESH:D002056",
-                "MEDDRA:10006634",
-                "SNOMEDCT:125666000",
-                "MEDDRA:10083300",
-                "SNOMEDCT:48333001",
-                "NCIT:C34441",
-                "MEDDRA:10006764",
-                "UMLS:C0006434",
-                "MONDO:0043519"
-              ],
-              "id": "MONDO:0043519",
-              "category": "biolink:Disease",
-              "all_names": [
-                "burn",
-                "Burn injury",
-                "Burn",
-                "Burns"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7937052,
-            "start": 554,
-            "end": 533531,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10751701': {'publication date': '2000 Jun', 'sentence': 'INTRODUCTION: The anti-inflammatory and anticoagulant effects of ibuprofen and heparin may enhance skin perfusion in cutaneous scald burns.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:associated_with---None---None---None---UMLS:C0006434---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "8106985",
-              "object": "MONDO:0043519",
-              "publications": [
-                "PMID:10751701"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317818,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011827",
-          "name": "patent ductus arteriosus",
-          "description": "In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences. [HPO:probinson, PMID:20421261]; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "DOID:13832",
-            "UMLS:C0013274",
-            "ORPHANET:706",
-            "ICD9:747.0",
-            "SNOMEDCT:83330001",
-            "HP:0001643",
-            "MESH:D004374",
-            "OMIM.PS:607411",
-            "ICD10:Q25.0",
-            "NCIT:C84492",
-            "MONDO:0011827"
-          ],
-          "id": "MONDO:0011827",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Patent ductus arteriosus",
-            "patent ductus arteriosus",
-            "Patent Ductus Arteriosus",
-            "Ductus Arteriosus, Patent"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:20421261"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317818,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011827",
-              "name": "patent ductus arteriosus",
-              "description": "In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences. [HPO:probinson, PMID:20421261]; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "DOID:13832",
-                "UMLS:C0013274",
-                "ORPHANET:706",
-                "ICD9:747.0",
-                "SNOMEDCT:83330001",
-                "HP:0001643",
-                "MESH:D004374",
-                "OMIM.PS:607411",
-                "ICD10:Q25.0",
-                "NCIT:C84492",
-                "MONDO:0011827"
-              ],
-              "id": "MONDO:0011827",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Patent ductus arteriosus",
-                "patent ductus arteriosus",
-                "Patent Ductus Arteriosus",
-                "Ductus Arteriosus, Patent"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:20421261"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13437763,
-            "start": 554,
-            "end": 317818,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18450898': {'publication date': '2008 May', 'sentence': 'CONCLUSIONS: Ibuprofen-induced patent ductus arteriosus closure improved pulmonary mechanics, decreased total lung water, increased epithelial sodium channel expression, and decreased the detrimental effects of preterm birth on alveolarization.', 'subject score': 851, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C0013274---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "13726345",
-              "object": "MONDO:0011827",
-              "publications": [
-                "PMID:18450898"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 307306,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004975",
-          "name": "Alzheimer disease",
-          "description": "A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. [HPO:probinson]; A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. // COMMENTS: Note that this is a bundled term that refers to a disease rather than to phenotypic features. It is retained for convenience since Alzheimer disease is used for annotation of other diseases (e.g., Down syndrome) as if it were a feature. If possible it is preferable to annotate with the precise phenotypic features.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "KEGG.DISEASE:05010",
-            "SNOMEDCT:142811000119104",
-            "MEDDRA:10012292",
-            "UMLS:C1863053",
-            "HP:0002511",
-            "ICD9:331.0",
-            "ORPHANET:238616",
-            "MEDDRA:10012271",
-            "MEDDRA:10001896",
-            "UMLS:C3549448",
-            "UMLS:C0002395",
-            "NCIT:C2866",
-            "DOID:10652",
-            "MONDO:0004975",
-            "EFO:0000249",
-            "NCIT:C146894",
-            "UMLS:C1863052",
-            "SNOMEDCT:230267005",
-            "PSY:01940",
-            "SNOMEDCT:26929004",
-            "OMIM:104300",
-            "ICD10:G30",
-            "MESH:D000544",
-            "MESH:C566299"
-          ],
-          "id": "MONDO:0004975",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Alzheimer's disease",
-            "Alzheimer disease, familial, 1",
-            "Alzheimer Disease, Early-Onset, With Cerebral Amyloid Angiopathy",
-            "Alzheimer's Disease",
-            "Alzheimers Disease",
-            "Alzheimer disease",
-            "Alzheimer disease, protection against",
-            "Alzheimer Disease",
-            "obsolete_Alzheimer's disease",
-            "Alzheimer disease, familial, 1 related phenotypic feature",
-            "Alzheimer's Disease 1"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet",
-            "http://en.wikipedia.org/wiki/alzheimer%27s_disease",
-            "http://www.merriam-webster.com/medical/alzheimer%27s%20disease",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 307306,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004975",
-              "name": "Alzheimer disease",
-              "description": "A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. [HPO:probinson]; A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. // COMMENTS: Note that this is a bundled term that refers to a disease rather than to phenotypic features. It is retained for convenience since Alzheimer disease is used for annotation of other diseases (e.g., Down syndrome) as if it were a feature. If possible it is preferable to annotate with the precise phenotypic features.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "KEGG.DISEASE:05010",
-                "SNOMEDCT:142811000119104",
-                "MEDDRA:10012292",
-                "UMLS:C1863053",
-                "HP:0002511",
-                "ICD9:331.0",
-                "ORPHANET:238616",
-                "MEDDRA:10012271",
-                "MEDDRA:10001896",
-                "UMLS:C3549448",
-                "UMLS:C0002395",
-                "NCIT:C2866",
-                "DOID:10652",
-                "MONDO:0004975",
-                "EFO:0000249",
-                "NCIT:C146894",
-                "UMLS:C1863052",
-                "SNOMEDCT:230267005",
-                "PSY:01940",
-                "SNOMEDCT:26929004",
-                "OMIM:104300",
-                "ICD10:G30",
-                "MESH:D000544",
-                "MESH:C566299"
-              ],
-              "id": "MONDO:0004975",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Alzheimer's disease",
-                "Alzheimer disease, familial, 1",
-                "Alzheimer Disease, Early-Onset, With Cerebral Amyloid Angiopathy",
-                "Alzheimer's Disease",
-                "Alzheimers Disease",
-                "Alzheimer disease",
-                "Alzheimer disease, protection against",
-                "Alzheimer Disease",
-                "obsolete_Alzheimer's disease",
-                "Alzheimer disease, familial, 1 related phenotypic feature",
-                "Alzheimer's Disease 1"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet",
-                "http://en.wikipedia.org/wiki/alzheimer%27s_disease",
-                "http://www.merriam-webster.com/medical/alzheimer%27s%20disease",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13366992,
-            "start": 554,
-            "end": 307306,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18351690': {'publication date': '2008 Apr', 'sentence': \"Protein profile in neuroblastoma cells incubated with S- and R-enantiomers of ibuprofen by iTRAQ-coupled 2-D LC-MS/MS analysis: possible action of induced proteins on Alzheimer's disease.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C0002395---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "13653982",
-              "object": "MONDO:0004975",
-              "publications": [
-                "PMID:18351690"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316638,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-          "name": "peptic ulcer disease",
-          "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10018053",
-            "MEDDRA:10045305",
-            "MESH:D010437",
-            "MONDO:0004247",
-            "DOID:750",
-            "UMLS:C0030920",
-            "MEDDRA:10017886",
-            "MEDDRA:10045342",
-            "ICD9:533",
-            "ICD10:K27",
-            "HP:0004398",
-            "MEDDRA:10034343",
-            "MEDDRA:10034360",
-            "MEDDRA:10045328",
-            "MEDDRA:10042834",
-            "MEDDRA:10034341",
-            "MEDDRA:10034367",
-            "MEDDRA:10037287",
-            "NCIT:C3318",
-            "SNOMEDCT:13200003",
-            "MEDDRA:10034369"
-          ],
-          "id": "MONDO:0004247",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peptic ulcer, site unspecified",
-            "Peptic Ulcer",
-            "peptic ulcer disease",
-            "Peptic ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28242110",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316638,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-              "name": "peptic ulcer disease",
-              "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10018053",
-                "MEDDRA:10045305",
-                "MESH:D010437",
-                "MONDO:0004247",
-                "DOID:750",
-                "UMLS:C0030920",
-                "MEDDRA:10017886",
-                "MEDDRA:10045342",
-                "ICD9:533",
-                "ICD10:K27",
-                "HP:0004398",
-                "MEDDRA:10034343",
-                "MEDDRA:10034360",
-                "MEDDRA:10045328",
-                "MEDDRA:10042834",
-                "MEDDRA:10034341",
-                "MEDDRA:10034367",
-                "MEDDRA:10037287",
-                "NCIT:C3318",
-                "SNOMEDCT:13200003",
-                "MEDDRA:10034369"
-              ],
-              "id": "MONDO:0004247",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peptic ulcer, site unspecified",
-                "Peptic Ulcer",
-                "peptic ulcer disease",
-                "Peptic ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28242110",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12845671,
-            "start": 554,
-            "end": 316638,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17504261': {'publication date': '2007 Jun', 'sentence': 'Protective effect of glucosamine against ibuprofen-induced peptic ulcer in rats.', 'subject score': 861, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C0030920---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "13133316",
-              "object": "MONDO:0004247",
-              "publications": [
-                "PMID:17504261"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 212250,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-          "name": "Fever",
-          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10037660",
-            "MEDDRA:10020083",
-            "MEDDRA:10005911",
-            "UMLS:C0015967",
-            "HP:0001945",
-            "NCIT:C3038",
-            "MEDDRA:10073718",
-            "MEDDRA:10043204",
-            "MEDDRA:10037668",
-            "PDQ:CDR0000775882",
-            "PSY:19660",
-            "SNOMEDCT:386661006",
-            "MEDDRA:10016558",
-            "MEDDRA:10037663",
-            "SNOMEDCT:50177009",
-            "SYMP:0000613",
-            "MESH:D005334"
-          ],
-          "id": "HP:0001945",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "fever",
-            "Fever"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:9759682",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 212250,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-              "name": "Fever",
-              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10037660",
-                "MEDDRA:10020083",
-                "MEDDRA:10005911",
-                "UMLS:C0015967",
-                "HP:0001945",
-                "NCIT:C3038",
-                "MEDDRA:10073718",
-                "MEDDRA:10043204",
-                "MEDDRA:10037668",
-                "PDQ:CDR0000775882",
-                "PSY:19660",
-                "SNOMEDCT:386661006",
-                "MEDDRA:10016558",
-                "MEDDRA:10037663",
-                "SNOMEDCT:50177009",
-                "SYMP:0000613",
-                "MESH:D005334"
-              ],
-              "id": "HP:0001945",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "fever",
-                "Fever"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:9759682",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12373192,
-            "start": 554,
-            "end": 212250,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:16889286': {'publication date': '2006', 'sentence': \"Ibuprofen-induced fever in Sjogren's syndrome.\", 'subject score': 851, 'object score': 851}, 'PMID:3867760': {'publication date': '1985 Dec', 'sentence': 'Ibuprofen prevents Pasteurella hemolytica endotoxin-induced changes in plasma prostanoids and serotonin, and fever in sheep.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C0015967---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "12641386",
-              "object": "HP:0001945",
-              "publications": [
-                "PMID:16889286",
-                "PMID:3867760"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317183,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004982",
-          "name": "pancreatitis",
-          "description": "Inflammation of the pancreas.; INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.; The presence of inflammation in the pancreas. [HPO:probinson]; The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0004982",
-            "MEDDRA:10076039",
-            "MEDDRA:10033656",
-            "DOID:4989",
-            "SNOMEDCT:75694006",
-            "ICD10:K85.9",
-            "MEDDRA:10033645",
-            "NCIT:C3306",
-            "EFO:0000278",
-            "HP:0001733",
-            "MESH:D010195",
-            "UMLS:C0030305"
-          ],
-          "id": "MONDO:0004982",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pancreatitis",
-            "pancreatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/pancreatitis.htm",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317183,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004982",
-              "name": "pancreatitis",
-              "description": "Inflammation of the pancreas.; INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.; The presence of inflammation in the pancreas. [HPO:probinson]; The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0004982",
-                "MEDDRA:10076039",
-                "MEDDRA:10033656",
-                "DOID:4989",
-                "SNOMEDCT:75694006",
-                "ICD10:K85.9",
-                "MEDDRA:10033645",
-                "NCIT:C3306",
-                "EFO:0000278",
-                "HP:0001733",
-                "MESH:D010195",
-                "UMLS:C0030305"
-              ],
-              "id": "MONDO:0004982",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pancreatitis",
-                "pancreatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/pancreatitis.htm",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12216523,
-            "start": 554,
-            "end": 317183,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16685113': {'publication date': '2006 May 09', 'sentence': 'There have been no prior definite cases reported of ibuprofen-induced pancreatitis.', 'subject score': 851, 'object score': 851}, 'PMID:26239856': {'publication date': '2015 Jul 06', 'sentence': 'This is a case report of a 16-year-old boy with possible drug-induced pancreatitis (DIP) caused by ibuprofen.', 'subject score': 1000, 'object score': 861}, 'PMID:27077468': {'publication date': '2016 Nov/Dec', 'sentence': 'In this report, we present a case of probable ibuprofen-induced pancreatitis.', 'subject score': 775, 'object score': 775}, 'PMID:31788383': {'publication date': '2019 Oct 16', 'sentence': 'Ibuprofen-induced acute pancreatitis, a diagnosis secondary to the use of non-steroidal anti-inflammatory drugs (NSAIDs), is an extremely rare occurrence.', 'subject score': 833, 'object score': 833}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C0030305---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "12482174",
-              "object": "MONDO:0004982",
-              "publications": [
-                "PMID:16685113",
-                "PMID:26239856",
-                "PMID:27077468",
-                "PMID:31788383"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 630575,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C78640",
-          "name": "Toothache",
-          "description": "A painful sensation originating from a tooth.; Pain in the adjacent areas of the teeth.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10059723",
-            "MESH:D014098",
-            "NCIT:C78640",
-            "MEDDRA:10044055",
-            "UMLS:C0040460",
-            "SYMP:0000438",
-            "SNOMEDCT:27355003",
-            "MEDDRA:10044017",
-            "MEDDRA:10030090"
-          ],
-          "id": "NCIT:C78640",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "toothache",
-            "Toothache"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://www.merriam-webster.com/dictionary/toothache"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 630575,
-=======
-            "identity": 722907,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "https://identifiers.org/ncit:C78640",
-              "name": "Toothache",
-              "description": "A painful sensation originating from a tooth.; Pain in the adjacent areas of the teeth.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10059723",
-                "MESH:D014098",
-                "NCIT:C78640",
-                "MEDDRA:10044055",
-                "UMLS:C0040460",
-                "SYMP:0000438",
-                "SNOMEDCT:27355003",
-                "MEDDRA:10044017",
-                "MEDDRA:10030090"
-              ],
-              "id": "NCIT:C78640",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "toothache",
-                "Toothache"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://www.merriam-webster.com/dictionary/toothache"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12160527,
-            "start": 554,
-            "end": 630575,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16637477': {'publication date': '2006 Apr', 'sentence': 'RESULTS: None of the studies established any of the COX-2 inhibitors as clearly better than ibuprofen, the current gold standard for the treatment of surgically induced dental pain.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C0040460---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "12438812",
-              "object": "NCIT:C78640",
-              "publications": [
-                "PMID:16637477"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319500,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0100130",
-          "name": "adult acute respiratory distress syndrome",
-          "description": "Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.; A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:J80",
-            "MEDDRA:10042839",
-            "UMLS:C4281993",
-            "MEDDRA:10038691",
-            "MEDDRA:10040579",
-            "DOID:11394",
-            "SNOMEDCT:196153002",
-            "ORPHANET:70578",
-            "MEDDRA:10042787",
-            "SNOMEDCT:67782005",
-            "MONDO:0100130",
-            "MEDDRA:10003083",
-            "MEDDRA:10038688",
-            "MEDDRA:10001410",
-            "HP:0002643",
-            "MEDDRA:10001407",
-            "MEDDRA:10000036",
-            "UMLS:C0852283",
-            "MEDDRA:10028973",
-            "UMLS:C0035222",
-            "MEDDRA:10001052",
-            "MEDDRA:10001409",
-            "MESH:D012128",
-            "SNOMEDCT:1179627006",
-            "UMLS:C1368020"
-          ],
-          "id": "MONDO:0100130",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adult acute respiratory distress syndrome",
-            "Neonatal respiratory distress",
-            "Respiratory Distress Syndrome, Adult",
-            "adult respiratory distress syndrome",
-            "Respiratory Distress Syndrome",
-            "Adult acute respiratory distress syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5392788/",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=adult+respiratory+distress+syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319500,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0100130",
-              "name": "adult acute respiratory distress syndrome",
-              "description": "Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.; A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:J80",
-                "MEDDRA:10042839",
-                "UMLS:C4281993",
-                "MEDDRA:10038691",
-                "MEDDRA:10040579",
-                "DOID:11394",
-                "SNOMEDCT:196153002",
-                "ORPHANET:70578",
-                "MEDDRA:10042787",
-                "SNOMEDCT:67782005",
-                "MONDO:0100130",
-                "MEDDRA:10003083",
-                "MEDDRA:10038688",
-                "MEDDRA:10001410",
-                "HP:0002643",
-                "MEDDRA:10001407",
-                "MEDDRA:10000036",
-                "UMLS:C0852283",
-                "MEDDRA:10028973",
-                "UMLS:C0035222",
-                "MEDDRA:10001052",
-                "MEDDRA:10001409",
-                "MESH:D012128",
-                "SNOMEDCT:1179627006",
-                "UMLS:C1368020"
-              ],
-              "id": "MONDO:0100130",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adult acute respiratory distress syndrome",
-                "Neonatal respiratory distress",
-                "Respiratory Distress Syndrome, Adult",
-                "adult respiratory distress syndrome",
-                "Respiratory Distress Syndrome",
-                "Adult acute respiratory distress syndrome"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-              "name": "bronchopulmonary dysplasia",
-              "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:70589",
-                "MESH:D001997",
-                "MONDO:0019091",
-                "SNOMEDCT:67569000",
-                "MEDDRA:10066204",
-                "UMLS:C0006287",
-                "NCIT:C90599",
-                "DOID:11650",
-                "MEDDRA:10006475"
-              ],
-              "id": "MONDO:0019091",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bronchopulmonary Dysplasia",
-                "obsolete_bronchopulmonary dysplasia",
-                "bronchopulmonary dysplasia"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5392788/",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=adult+respiratory+distress+syndrome"
-=======
-                "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 11821967,
-            "start": 554,
-            "end": 319500,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16205045': {'publication date': '2007', 'sentence': 'Noncardiogenic pulmonary edema due to ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:8835604': {'publication date': '1996 Jun', 'sentence': 'ARDS was likely induced by ibuprofen, based on the presence of pancytopenia and a weakly positive drug lymphocyte stimulating test (DLST).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C0035222---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "12079834",
-              "object": "MONDO:0100130",
-              "publications": [
-                "PMID:16205045",
-                "PMID:8835604"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10918360,
-            "start": 554,
-            "end": 316891,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1509971': {'publication date': '1992 Jan', 'sentence': 'In a double-blind cross-over study on 22 healthy subjects the analgesic efficacies of the antipyretic analgesic drugs ibuprofen, dipyrone and paracetamol were tested against placebo using a model of experimentally induced pain.', 'subject score': 861, 'object score': 790}, 'PMID:29707018': {'publication date': '2018', 'sentence': 'Conclusion: Pre-medication with ibuprofen resulted in less pain following pulpotomy and SSC placement in primary teeth.', 'subject score': 1000, 'object score': 861}, 'PMID:31112677': {'publication date': '2019 Oct', 'sentence': 'CONCLUSIONS: The present study has shown that the preemptive use of IV ibuprofen resulted in less pain and a decrease in the requirement for rescue analgesia during the first 24 hours after third molar surgery.', 'subject score': 888, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "11157616",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:1509971",
-                "PMID:29707018",
-                "PMID:31112677"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 543282,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C26791",
-          "name": "Hemorrhage",
-          "description": "Loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels.",
-          "equivalent_curies": [
-            "UMLS:C0019080",
-            "SYMP:0000041",
-            "MEDDRA:10019524",
-            "MEDDRA:10018988",
-            "MEDDRA:10055798",
-            "MEDDRA:10019525",
-            "NCIT:C26791",
-            "MEDDRA:10005103",
-            "MEDDRA:10015867",
-            "SNOMEDCT:50960005",
-            "MP:0001914",
-            "MEDDRA:10019595",
-            "MEDDRA:10019003",
-            "MEDDRA:10005645",
-            "SNOMEDCT:131148009",
-            "MESH:D006470"
-          ],
-          "id": "NCIT:C26791",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hemorrhage",
-            "Hemorrhage"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/books/nbk542273/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 543282,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C26791",
-              "name": "Hemorrhage",
-              "description": "Loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels.",
-              "equivalent_curies": [
-                "UMLS:C0019080",
-                "SYMP:0000041",
-                "MEDDRA:10019524",
-                "MEDDRA:10018988",
-                "MEDDRA:10055798",
-                "MEDDRA:10019525",
-                "NCIT:C26791",
-                "MEDDRA:10005103",
-                "MEDDRA:10015867",
-                "SNOMEDCT:50960005",
-                "MP:0001914",
-                "MEDDRA:10019595",
-                "MEDDRA:10019003",
-                "MEDDRA:10005645",
-                "SNOMEDCT:131148009",
-                "MESH:D006470"
-              ],
-              "id": "NCIT:C26791",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hemorrhage",
-                "Hemorrhage"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/books/nbk542273/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10204543,
-            "start": 554,
-            "end": 543282,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:1304448': {'publication date': '1992', 'sentence': 'Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide.', 'subject score': 787, 'object score': 787}, 'PMID:1546139': {'publication date': '1992', 'sentence': 'The results show that multiple doses of moclobemide do not change faecal blood loss induced by ibuprofen.', 'subject score': 1000, 'object score': 901}, 'PMID:16887032': {'publication date': '2006 Aug 03', 'sentence': 'Dexamethasone, unlike indomethacin or ibuprofen, may diminish these pathological processes that likely contribute to inflammation and loss of vessel wall integrity leading to hemorrhage in CAA.', 'subject score': 1000, 'object score': 1000}, 'PMID:2525983': {'publication date': '1989 Mar', 'sentence': 'Naproxen, ibuprofen, and indomethacin caused mean daily blood losses in excess of 1 ml/day over baseline values.', 'subject score': 1000, 'object score': 813}, 'PMID:30574567': {'publication date': '2018 Oct', 'sentence': 'Conclusion: Ibuprofen can lead to upper digestive hemorrhage independently of the administered dose.', 'subject score': 1000, 'object score': 802}, 'PMID:313330': {'publication date': '1979 Jul', 'sentence': 'A corresponding dose of ibuprofen did not produce any significant bleeding.', 'subject score': 1000, 'object score': 888}, 'PMID:3553307': {'publication date': '1987 Apr', 'sentence': 'Daily doses of 1,200 mg of ibuprofen may produce endoscopic injury and fecal blood losses similar to placebo.', 'subject score': 1000, 'object score': 890}, 'PMID:6338972': {'publication date': '1983 Apr', 'sentence': 'The trial was completed with no evidence of increased frequency or severity of hemophiliac bleeding episodes or clinical or laboratory evidence of bleeding secondary to Ibuprofen.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C0019080---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "10429873",
-              "object": "NCIT:C26791",
-              "publications": [
-                "PMID:1304448",
-                "PMID:1546139",
-                "PMID:16887032",
-                "PMID:2525983",
-                "PMID:30574567",
-                "PMID:313330",
-                "PMID:3553307",
-                "PMID:6338972"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 307910,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005578",
-          "name": "arthritic joint disease",
-          "description": "An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.; Acute or chronic inflammation of JOINTS.; Inflammation of a joint. [HPO:probinson]; If you feel pain and stiffness in your body or have trouble moving around, you might have arthritis. Most kinds of arthritis cause pain and swelling in your joints. Joints are places where two bones meet, such as your elbow or knee. Over time, a swollen joint can become severely damaged. Some kinds of arthritis can also cause problems in your organs, such as your eyes or skin. Types of arthritis include: Osteoarthritis is the most common type of arthritis. It's often related to aging or to an injury. Autoimmune arthritis happens when your body's immune system attacks healthy cells in your body by mistake. Rheumatoid arthritis is the most common form of this kind of arthritis. Juvenile arthritis is a type of arthritis that happens in children. Infectious arthritis is an infection that has spread from another part of the body to the joint. Psoriatic arthritis affects people with psoriasis. Gout is a painful type of arthritis that happens when too much uric acid builds up in the body. It often starts in the big toe.  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0003864",
-            "MEDDRA:10003263",
-            "PSY:03860",
-            "EFO:0005856",
-            "ICD10:M19.90",
-            "MEDDRA:10003246",
-            "MONDO:0005578",
-            "SYMP:0019169",
-            "SNOMEDCT:3723001",
-            "UMLS:C0574941",
-            "NCIT:C2883",
-            "SNOMEDCT:298160000",
-            "DOID:848",
-            "MEDDRA:10023217",
-            "HP:0001369",
-            "MESH:D001168",
-            "MEDDRA:10081014"
-          ],
-          "id": "MONDO:0005578",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Arthritis",
-            "arthritic joint disease",
-            "Inflamed joint",
-            "arthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.arthritis.org/",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=arthritis",
-            "https://www.cdc.gov/arthritis/index.htm",
-            "http://en.wikipedia.org/wiki/arthritis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/001243.htm",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 307910,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005578",
-              "name": "arthritic joint disease",
-              "description": "An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.; Acute or chronic inflammation of JOINTS.; Inflammation of a joint. [HPO:probinson]; If you feel pain and stiffness in your body or have trouble moving around, you might have arthritis. Most kinds of arthritis cause pain and swelling in your joints. Joints are places where two bones meet, such as your elbow or knee. Over time, a swollen joint can become severely damaged. Some kinds of arthritis can also cause problems in your organs, such as your eyes or skin. Types of arthritis include: Osteoarthritis is the most common type of arthritis. It's often related to aging or to an injury. Autoimmune arthritis happens when your body's immune system attacks healthy cells in your body by mistake. Rheumatoid arthritis is the most common form of this kind of arthritis. Juvenile arthritis is a type of arthritis that happens in children. Infectious arthritis is an infection that has spread from another part of the body to the joint. Psoriatic arthritis affects people with psoriasis. Gout is a painful type of arthritis that happens when too much uric acid builds up in the body. It often starts in the big toe.  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0003864",
-                "MEDDRA:10003263",
-                "PSY:03860",
-                "EFO:0005856",
-                "ICD10:M19.90",
-                "MEDDRA:10003246",
-                "MONDO:0005578",
-                "SYMP:0019169",
-                "SNOMEDCT:3723001",
-                "UMLS:C0574941",
-                "NCIT:C2883",
-                "SNOMEDCT:298160000",
-                "DOID:848",
-                "MEDDRA:10023217",
-                "HP:0001369",
-                "MESH:D001168",
-                "MEDDRA:10081014"
-              ],
-              "id": "MONDO:0005578",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Arthritis",
-                "arthritic joint disease",
-                "Inflamed joint",
-                "arthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.arthritis.org/",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=arthritis",
-                "https://www.cdc.gov/arthritis/index.htm",
-                "http://en.wikipedia.org/wiki/arthritis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/001243.htm",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9588401,
-            "start": 554,
-            "end": 307910,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12355496': {'publication date': '2002 Sep', 'sentence': 'The C5a antagonist (1 or 3 mg/kg/day) and/or ibuprofen (30 mg/kg/day) were administered orally on a daily basis either before or after arthritis induction.', 'subject score': 1000, 'object score': 888}, 'PMID:23901209': {'publication date': '2013 Jul', 'sentence': 'Animals were administered UP446 (50 mg/kg), ibuprofen (150 mg/kg mg/kg) or vehicle by oral gavage 30 min prior to arthritis induction and each day thereafter for 14 days.', 'subject score': 1000, 'object score': 888}, 'PMID:26981605': {'publication date': '2016 Mar', 'sentence': 'Ibuprofen, diclofenac sodium and meloxicam were given intragastrically before induction of TMJ inflammation.', 'subject score': 1000, 'object score': 901}, 'PMID:3124133': {'publication date': '1987 Oct', 'sentence': 'Inhibition of joint inflammation resulting from treatment with ibuprofen and flurbiprofen is reflected by a decrease in concentration of all 5 eicosanoids which were found in the order: PGE2 greater than TXB2 greater than 6-keto-PGF1 alpha greater than PGF1 greater than PGF2 alpha.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C0003864---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9800201",
-              "object": "MONDO:0005578",
-              "publications": [
-                "PMID:12355496",
-                "PMID:23901209",
-                "PMID:26981605",
-                "PMID:3124133"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7992346,
-            "start": 554,
-            "end": 546804,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10792116': {'publication date': '2000 May', 'sentence': 'RESULTS: Ketoprofen 50 mg t.d.s. suppressed prostaglandin synthesis to a significantly greater extent than ibuprofen and caused significantly more gastroduodenal injury.', 'subject score': 1000, 'object score': 750}, 'PMID:15879659': {'publication date': '2005 Mar-Apr', 'sentence': 'We report a 35-year-old man with ibuprofen-induced acute severe cholestatic liver injury.', 'subject score': 799, 'object score': 799}, 'PMID:18626108': {'publication date': '2009 Jan', 'sentence': 'Ibuprofen-induced liver injury in an adolescent athlete.', 'subject score': 833, 'object score': 833}, 'PMID:27698499': {'publication date': '2016 Sep', 'sentence': 'Ipilimumab-Induced Polyneuropathy; Ibuprofen-Induced Allergic-Type Liver Injury; Trimethoprim-Sulfamethoxazole-Induced Immune Thrombocytopenia in Children; Mesna-Induced Fixed Drug Eruption; Digoxin-Induced Ocular Toxicity.', 'subject score': 814, 'object score': 814}, 'PMID:30264435': {'publication date': '2018 Sep 27', 'sentence': 'In our study, cytoplasmic JNK activation in hepatocytes and other non-LPCs is a hallmark of human and murine ibuprofen-induced ALI.', 'subject score': 814, 'object score': 814}, 'PMID:30410832': {'publication date': '2018 Aug 29', 'sentence': 'A Rare Case of Ibuprofen-induced Acute Liver Injury.', 'subject score': 822, 'object score': 822}, 'PMID:3553307': {'publication date': '1987 Apr', 'sentence': 'Daily doses of 1,200 mg of ibuprofen may produce endoscopic injury and fecal blood losses similar to placebo.', 'subject score': 1000, 'object score': 861}, 'PMID:7203374': {'publication date': '1980 Dec', 'sentence': 'The ultrastructure of the material taken from three patients after phenobarbital treatment and one patient with ibuprofen-induced injury showed prominent increase and vesiculation of SER respectively.', 'subject score': 851, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C3263723---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "8163776",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:10792116",
-                "PMID:15879659",
-                "PMID:18626108",
-                "PMID:27698499",
-                "PMID:30264435",
-                "PMID:30410832",
-                "PMID:3553307",
-                "PMID:7203374"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318890,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-          "name": "rheumatoid arthritis",
-          "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C2884",
-            "PSY:44570",
-            "EFO:0000685",
-            "ICD9:714.0",
-            "KEGG.DISEASE:05323",
-            "MONDO:0008383",
-            "UMLS:C0003873",
-            "UMLS:C1306838",
-            "UMLS:C1833448",
-            "MEDDRA:10037740",
-            "MEDDRA:10039073",
-            "OMIM:180300",
-            "MESH:D001172",
-            "MEDDRA:10003268",
-            "HP:0001370",
-            "ORPHANET:284130",
-            "SNOMEDCT:69896004",
-            "ICD10:M06.9",
-            "DOID:7148",
-            "MEDDRA:10036856",
-            "MEDDRA:10042952"
-          ],
-          "id": "MONDO:0008383",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Proliferative arthritis",
-            "Arthritis, Rheumatoid",
-            "rheumatoid arthritis",
-            "Rheumatoid arthritis",
-            "Rheumatoid Arthritis",
-            "Rheumatoid arthritis related phenotypic feature",
-            "Rheumatoid arthritis, susceptibility to"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-            "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-            "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318890,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-              "name": "rheumatoid arthritis",
-              "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C2884",
-                "PSY:44570",
-                "EFO:0000685",
-                "ICD9:714.0",
-                "KEGG.DISEASE:05323",
-                "MONDO:0008383",
-                "UMLS:C0003873",
-                "UMLS:C1306838",
-                "UMLS:C1833448",
-                "MEDDRA:10037740",
-                "MEDDRA:10039073",
-                "OMIM:180300",
-                "MESH:D001172",
-                "MEDDRA:10003268",
-                "HP:0001370",
-                "ORPHANET:284130",
-                "SNOMEDCT:69896004",
-                "ICD10:M06.9",
-                "DOID:7148",
-                "MEDDRA:10036856",
-                "MEDDRA:10042952"
-              ],
-              "id": "MONDO:0008383",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Proliferative arthritis",
-                "Arthritis, Rheumatoid",
-                "rheumatoid arthritis",
-                "Rheumatoid arthritis",
-                "Rheumatoid Arthritis",
-                "Rheumatoid arthritis related phenotypic feature",
-                "Rheumatoid arthritis, susceptibility to"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-                "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-                "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26238187,
-            "start": 554,
-            "end": 318890,
-=======
-            "identity": 20804808,
-            "start": 554,
-            "end": 722907,
->>>>>>> main
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-<<<<<<< HEAD
-              "publications_info": "{'PMID:7882703': {'publication date': '1994', 'sentence': \"The duration of action of sustained-release ibuprofen ('Brufen Retard') was investigated in a 14-day double-blind study involving 14 osteoarthritis and 10 rheumatoid arthritis patients.\", 'subject score': 851, 'object score': 824}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0003873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "26701175",
-              "object": "MONDO:0008383",
-              "publications": [
-                "PMID:7882703"
-=======
-              "publications_info": "{'PMID:31391526': {'publication date': '2019 Aug 07', 'sentence': 'After adjusting for covariates, the risk of BPD was associated independently with ibuprofen exposure (odds ratios (OR) 2.296, 95% confidence interval (CI): 1.166-4.522, p = 0.016).', 'subject score': 694, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0006287---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "21214366",
-              "object": "MONDO:0019091",
-              "publications": [
-                "PMID:31391526"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:36732726': {'publication date': '2023 Feb 02', 'sentence': 'Treatment of newborn rat pups with ibuprofen reduced pulmonary vessel density in the developing lung, but also attenuated experimental BPD by reducing lung inflammation, alveolar enlargement, alveolar septum thickness and small arteriolar wall thickening.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 722907,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-          "name": "bronchopulmonary dysplasia",
-          "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:70589",
-            "MESH:D001997",
-            "MONDO:0019091",
-            "SNOMEDCT:67569000",
-            "MEDDRA:10066204",
-            "UMLS:C0006287",
-            "NCIT:C90599",
-            "DOID:11650",
-            "MEDDRA:10006475"
-          ],
-          "id": "MONDO:0019091",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bronchopulmonary Dysplasia",
-            "obsolete_bronchopulmonary dysplasia",
-            "bronchopulmonary dysplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 722907,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-              "name": "bronchopulmonary dysplasia",
-              "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:70589",
-                "MESH:D001997",
-                "MONDO:0019091",
-                "SNOMEDCT:67569000",
-                "MEDDRA:10066204",
-                "UMLS:C0006287",
-                "NCIT:C90599",
-                "DOID:11650",
-                "MEDDRA:10006475"
-              ],
-              "id": "MONDO:0019091",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bronchopulmonary Dysplasia",
-                "obsolete_bronchopulmonary dysplasia",
-                "bronchopulmonary dysplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24872838,
-            "start": 554,
-            "end": 722907,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:36732726': {'publication date': '2023 Feb 02', 'sentence': 'Treatment of newborn rat pups with ibuprofen reduced pulmonary vessel density in the developing lung, but also attenuated experimental BPD by reducing lung inflammation, alveolar enlargement, alveolar septum thickness and small arteriolar wall thickening.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0006287---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "25321029",
-              "object": "MONDO:0019091",
-              "publications": [
-                "PMID:36732726"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:19379895': {'publication date': '2009 May', 'sentence': 'More than two cycles of ibuprofen was significantly associated with an increased risk for bronchopulmonary dysplasia (odds ratio [OR], 2.81; p = 0.03) and acute renal failure (OR, 3.81; p = 0.09).', 'subject score': 1000, 'object score': 1000}, 'PMID:19690594': {'publication date': '2009 Aug 13', 'sentence': 'INTERPRETATION: Treatment of a patent ductus arteriosus with COX-inhibitors such as indomethacin and ibuprofen, increases the risk for bronchopulmonary dysplasia without reducing other complications or death.', 'subject score': 1000, 'object score': 1000}, 'PMID:31391526': {'publication date': '2019 Aug 07', 'sentence': 'OBJECTIVE: To evaluate the association of ibuprofen exposure with the risk of bronchopulmonary dysplasia (BPD) in extremely premature infants.', 'subject score': 694, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 722907,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-          "name": "bronchopulmonary dysplasia",
-          "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:70589",
-            "MESH:D001997",
-            "MONDO:0019091",
-            "SNOMEDCT:67569000",
-            "MEDDRA:10066204",
-            "UMLS:C0006287",
-            "NCIT:C90599",
-            "DOID:11650",
-            "MEDDRA:10006475"
-          ],
-          "id": "MONDO:0019091",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bronchopulmonary Dysplasia",
-            "obsolete_bronchopulmonary dysplasia",
-            "bronchopulmonary dysplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 722907,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-              "name": "bronchopulmonary dysplasia",
-              "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:70589",
-                "MESH:D001997",
-                "MONDO:0019091",
-                "SNOMEDCT:67569000",
-                "MEDDRA:10066204",
-                "UMLS:C0006287",
-                "NCIT:C90599",
-                "DOID:11650",
-                "MEDDRA:10006475"
-              ],
-              "id": "MONDO:0019091",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bronchopulmonary Dysplasia",
-                "obsolete_bronchopulmonary dysplasia",
-                "bronchopulmonary dysplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14032853,
-            "start": 554,
-            "end": 722907,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19379895': {'publication date': '2009 May', 'sentence': 'More than two cycles of ibuprofen was significantly associated with an increased risk for bronchopulmonary dysplasia (odds ratio [OR], 2.81; p = 0.03) and acute renal failure (OR, 3.81; p = 0.09).', 'subject score': 1000, 'object score': 1000}, 'PMID:19690594': {'publication date': '2009 Aug 13', 'sentence': 'INTERPRETATION: Treatment of a patent ductus arteriosus with COX-inhibitors such as indomethacin and ibuprofen, increases the risk for bronchopulmonary dysplasia without reducing other complications or death.', 'subject score': 1000, 'object score': 1000}, 'PMID:31391526': {'publication date': '2019 Aug 07', 'sentence': 'OBJECTIVE: To evaluate the association of ibuprofen exposure with the risk of bronchopulmonary dysplasia (BPD) in extremely premature infants.', 'subject score': 694, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:predisposes---None---None---None---UMLS:C0006287---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "14332005",
-              "object": "MONDO:0019091",
-              "publications": [
-                "PMID:19379895",
-                "PMID:19690594",
-                "PMID:31391526"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:35391815': {'publication date': '2021 Apr-Jun', 'sentence': 'This study attempts to investigate the effect of ibuprofen on reducing eye pain and migraine headaches caused by trochleitis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 321390,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005277",
-          "name": "migraine disorder",
-          "description": "A common, severe type of vascular headache often associated with increased sympathetic activity, resulting in nausea, vomiting, and light sensitivity.; A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1); Migraine is a chronic neurological disorder characterized by episodic attacks of headache and associated symptoms. [HPO:probinson, PMID:15304572]; What are migraines? Migraines are a recurring type of headache. They cause moderate to severe pain that is throbbing or pulsing. The pain is often on one side of your head. You may also have other symptoms, such as nausea and weakness. You may be sensitive to light and sound. What causes migraines? Researchers believe that migraine has a genetic cause. There are also a number of factors that can trigger a migraine. These factors vary from person to person, and they include: Stress Anxiety Hormonal changes in women Bright or flashing lights Loud noises Strong smells Medicines Too much or not enough sleep Sudden changes in weather or environment Overexertion (too much physical activity) Tobacco Caffeine or caffeine withdrawal Skipped meals Medication overuse (taking medicine for migraines too often)  Some people have found that certain foods or ingredients can trigger headaches, especially when they are combined with other triggers. These foods and ingredients include: Alcohol Chocolate Aged cheeses Monosodium glutamate (MSG) Some fruits and nuts Fermented or pickled goods Yeast Cured or processed meats  Who is at risk for migraines? About 12% of Americans get migraines. They can affect anyone, but you are more likely to have them if you: Are a woman. Women are three times more likely than men to get migraines. Have a family history of migraines. Most people with migraines have family members who have migraines. Have other medical conditions, such as depression, anxiety, bipolar disorder, sleep disorders, and epilepsy.  What are the symptoms of migraines? There are four different phases of migraines. You may not always go through every phase each time you have a migraine.: Prodome. This phase starts up to 24 hours before you get the migraine. You have early signs and symptoms, such as food cravings, unexplained mood changes, uncontrollable yawning, fluid retention, and increased urination. Aura. If you have this phase, you might see flashing or bright lights or zig-zag lines. You may have muscle weakness or feel like you are being touched or grabbed. An aura can happen just before or during a migraine. Headache. A migraine usually starts gradually and then becomes more severe. It typically causes throbbing or pulsing pain, which is often on one side of your head. But sometimes you can have a migraine without a headache. Other migraine symptoms may include  Increased sensitivity to light, noise, and odors Nausea and vomiting Worsened pain when you move, cough, or sneeze  Postdrome (following the headache). You may feel exhausted, weak, and confused after a migraine. This can last up to a day.  Migraines are more common in the morning; people often wake up with them. Some people have migraines at predictable times, such as before menstruation or on weekends following a stressful week of work. How are migraines diagnosed? To make a diagnosis, your health care provider will: Take your medical history Ask about your symptoms Do a physical and neurological exam  An important part of diagnosing migraines is to rule out other medical conditions which could be causing the symptoms. So you may also have blood tests, an MRI or CT scan, or other tests. How are migraines treated? There is no cure for migraines. Treatment focuses on relieving symptoms and preventing additional attacks. There are different types of medicines to relieve symptoms. They include triptan drugs, ergotamine drugs, and pain relievers. The sooner you take the medicine, the more effective it is. There are also other things you can do to feel better: Resting with your eyes closed in a quiet, darkened room Placing a cool cloth or ice pack on your forehead Drinking fluids  There are some lifestyle changes you can make to prevent migraines: Stress management strategies, such as exercise, relaxation techniques, and biofeedback, may reduce the number and severity of migraines. Biofeedback uses electronic devices to teach you to control certain body functions, such as your heartbeat, blood pressure, and muscle tension. Make a log of what seems to trigger your migraines. You can learn what you need to avoid, such as certain foods and medicines. It also help you figure out what you should do, such as establishing a consistent sleep schedule and eating regular meals. Hormone therapy may help some women whose migraines seem to be linked to their menstrual cycle If you have obesity, losing weight may also be helpful  If you have frequent or severe migraines, you may need to take medicines to prevent further attacks. Talk with your health care provider about which drug would be right for you. Certain natural treatments, such as riboflavin (vitamin B2) and coenzyme Q10, may help prevent migraines. If your magnesium level is low, you can try taking magnesium. There is also an herb, butterbur, which some people take to prevent migraines. But butterbur may not be safe for long-term use. Always check with your health care provider before taking any supplements. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10027606",
-            "DOID:6364",
-            "UMLS:C0149931",
-            "EFO:0003821",
-            "NCIT:C89715",
-            "MEDDRA:10027603",
-            "ICD9:346",
-            "MEDDRA:10027611",
-            "MEDDRA:10027599",
-            "MEDDRA:10027608",
-            "HP:0002076",
-            "MESH:D008881",
-            "SNOMEDCT:193030005",
-            "MEDDRA:10027602",
-            "UMLS:C0744641",
-            "MEDDRA:10027605",
-            "UMLS:C0042331",
-            "ICD10:G43",
-            "MONDO:0005277"
-          ],
-          "id": "MONDO:0005277",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_migraine disorder",
-            "Intermittent migraine headaches",
-            "Migraine",
-            "Migraine Disorders",
-            "Migraine Variant",
-            "migraine disorder",
-            "migraine"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/migraine-headache/ds00120",
-            "PMID:15304572",
-            "http://en.wikipedia.org/wiki/migraine",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321390,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005277",
-              "name": "migraine disorder",
-              "description": "A common, severe type of vascular headache often associated with increased sympathetic activity, resulting in nausea, vomiting, and light sensitivity.; A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1); Migraine is a chronic neurological disorder characterized by episodic attacks of headache and associated symptoms. [HPO:probinson, PMID:15304572]; What are migraines? Migraines are a recurring type of headache. They cause moderate to severe pain that is throbbing or pulsing. The pain is often on one side of your head. You may also have other symptoms, such as nausea and weakness. You may be sensitive to light and sound. What causes migraines? Researchers believe that migraine has a genetic cause. There are also a number of factors that can trigger a migraine. These factors vary from person to person, and they include: Stress Anxiety Hormonal changes in women Bright or flashing lights Loud noises Strong smells Medicines Too much or not enough sleep Sudden changes in weather or environment Overexertion (too much physical activity) Tobacco Caffeine or caffeine withdrawal Skipped meals Medication overuse (taking medicine for migraines too often)  Some people have found that certain foods or ingredients can trigger headaches, especially when they are combined with other triggers. These foods and ingredients include: Alcohol Chocolate Aged cheeses Monosodium glutamate (MSG) Some fruits and nuts Fermented or pickled goods Yeast Cured or processed meats  Who is at risk for migraines? About 12% of Americans get migraines. They can affect anyone, but you are more likely to have them if you: Are a woman. Women are three times more likely than men to get migraines. Have a family history of migraines. Most people with migraines have family members who have migraines. Have other medical conditions, such as depression, anxiety, bipolar disorder, sleep disorders, and epilepsy.  What are the symptoms of migraines? There are four different phases of migraines. You may not always go through every phase each time you have a migraine.: Prodome. This phase starts up to 24 hours before you get the migraine. You have early signs and symptoms, such as food cravings, unexplained mood changes, uncontrollable yawning, fluid retention, and increased urination. Aura. If you have this phase, you might see flashing or bright lights or zig-zag lines. You may have muscle weakness or feel like you are being touched or grabbed. An aura can happen just before or during a migraine. Headache. A migraine usually starts gradually and then becomes more severe. It typically causes throbbing or pulsing pain, which is often on one side of your head. But sometimes you can have a migraine without a headache. Other migraine symptoms may include  Increased sensitivity to light, noise, and odors Nausea and vomiting Worsened pain when you move, cough, or sneeze  Postdrome (following the headache). You may feel exhausted, weak, and confused after a migraine. This can last up to a day.  Migraines are more common in the morning; people often wake up with them. Some people have migraines at predictable times, such as before menstruation or on weekends following a stressful week of work. How are migraines diagnosed? To make a diagnosis, your health care provider will: Take your medical history Ask about your symptoms Do a physical and neurological exam  An important part of diagnosing migraines is to rule out other medical conditions which could be causing the symptoms. So you may also have blood tests, an MRI or CT scan, or other tests. How are migraines treated? There is no cure for migraines. Treatment focuses on relieving symptoms and preventing additional attacks. There are different types of medicines to relieve symptoms. They include triptan drugs, ergotamine drugs, and pain relievers. The sooner you take the medicine, the more effective it is. There are also other things you can do to feel better: Resting with your eyes closed in a quiet, darkened room Placing a cool cloth or ice pack on your forehead Drinking fluids  There are some lifestyle changes you can make to prevent migraines: Stress management strategies, such as exercise, relaxation techniques, and biofeedback, may reduce the number and severity of migraines. Biofeedback uses electronic devices to teach you to control certain body functions, such as your heartbeat, blood pressure, and muscle tension. Make a log of what seems to trigger your migraines. You can learn what you need to avoid, such as certain foods and medicines. It also help you figure out what you should do, such as establishing a consistent sleep schedule and eating regular meals. Hormone therapy may help some women whose migraines seem to be linked to their menstrual cycle If you have obesity, losing weight may also be helpful  If you have frequent or severe migraines, you may need to take medicines to prevent further attacks. Talk with your health care provider about which drug would be right for you. Certain natural treatments, such as riboflavin (vitamin B2) and coenzyme Q10, may help prevent migraines. If your magnesium level is low, you can try taking magnesium. There is also an herb, butterbur, which some people take to prevent migraines. But butterbur may not be safe for long-term use. Always check with your health care provider before taking any supplements. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10027606",
-                "DOID:6364",
-                "UMLS:C0149931",
-                "EFO:0003821",
-                "NCIT:C89715",
-                "MEDDRA:10027603",
-                "ICD9:346",
-                "MEDDRA:10027611",
-                "MEDDRA:10027599",
-                "MEDDRA:10027608",
-                "HP:0002076",
-                "MESH:D008881",
-                "SNOMEDCT:193030005",
-                "MEDDRA:10027602",
-                "UMLS:C0744641",
-                "MEDDRA:10027605",
-                "UMLS:C0042331",
-                "ICD10:G43",
-                "MONDO:0005277"
-              ],
-              "id": "MONDO:0005277",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_migraine disorder",
-                "Intermittent migraine headaches",
-                "Migraine",
-                "Migraine Disorders",
-                "Migraine Variant",
-                "migraine disorder",
-                "migraine"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/migraine-headache/ds00120",
-                "PMID:15304572",
-                "http://en.wikipedia.org/wiki/migraine",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23943854,
-            "start": 554,
-            "end": 321390,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35391815': {'publication date': '2021 Apr-Jun', 'sentence': 'This study attempts to investigate the effect of ibuprofen on reducing eye pain and migraine headaches caused by trochleitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0149931---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "24384432",
-              "object": "MONDO:0005277",
-              "publications": [
-                "PMID:35391815"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 319500,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10999673': {'publication date': '2000 May', 'sentence': 'Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study.', 'subject score': 1000, 'object score': 1000}, 'PMID:15548924': {'publication date': '2004 Dec', 'sentence': 'The most rigorously studied agents for the acute treatment of migraine are ibuprofen, acetaminophen, and sumatriptan nasal spray, all of which have shown safety and efficacy in controlled trials.', 'subject score': 1000, 'object score': 1000}, 'PMID:15579612': {'publication date': '2004 Dec', 'sentence': 'Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:16018227': {'publication date': '2005 Jun', 'sentence': 'The most rigorously studied agents for the acute treatment of migraine are ibuprofen, acetaminophen, and sumatriptan nasal spray, all of which have shown safety and efficacy in controlled trials.', 'subject score': 1000, 'object score': 1000}, 'PMID:1623513': {'publication date': '1992 Jun', 'sentence': 'The efficacy of ibuprofen, a non-steroidal anti-inflammatory drug, was assessed in the acute treatment of migraine.', 'subject score': 1000, 'object score': 1000}, 'PMID:16492236': {'publication date': '2006 Feb', 'sentence': 'OBJECTIVE: To investigate the efficacy, tolerability, and safety of rofecoxib and ibuprofen for acute migraine treatment.', 'subject score': 1000, 'object score': 851}, 'PMID:16618262': {'publication date': '2006 Mar', 'sentence': 'OBJECTIVE: Compare the effectiveness of a combination analgesic containing acetaminophen, aspirin, and caffeine to that of ibuprofen in the treatment of migraine.', 'subject score': 1000, 'object score': 1000}, 'PMID:17563841': {'publication date': '2007 Jun', 'sentence': 'The objective of this study was to compare the efficacy of rizatriptan and ibuprofen in migraine.', 'subject score': 1000, 'object score': 1000}, 'PMID:17878396': {'publication date': '2007 Nov', 'sentence': 'Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis.', 'subject score': 901, 'object score': 851}, 'PMID:18006958': {'publication date': '2007 Nov', 'sentence': 'Ibuprofen, acetaminophen, and sumatriptan nasal spray are probably beneficial and safe to use in pediatric migraine.', 'subject score': 1000, 'object score': 888}, 'PMID:18612830': {'publication date': '2008', 'sentence': 'So sequential release of MTH (as immediate release) and IB (as sustained release) was suitable for treatment of migraine.', 'subject score': 1000, 'object score': 1000}, 'PMID:20927770': {'publication date': '2010 Oct 06', 'sentence': \"AUTHORS' CONCLUSIONS: Ibuprofen is an effective treatment for acute migraine headaches, providing pain relief in about half of sufferers, but complete relief from pain and associated symptoms for only a minority.\", 'subject score': 1000, 'object score': 901}, 'PMID:21457238': {'publication date': '2011 Apr', 'sentence': 'OBJECTIVE: To evaluate the efficacy and tolerability of telcagepant when co-administered with ibuprofen or acetaminophen for the acute treatment of migraine.', 'subject score': 1000, 'object score': 1000}, 'PMID:23633348': {'publication date': '2013 Apr 30', 'sentence': 'Ibuprofen is an effective treatment for acute migraine headaches, providing pain relief in about half of sufferers, but complete relief from pain and associated symptoms for only a minority.', 'subject score': 1000, 'object score': 901}, 'PMID:23808884': {'publication date': '2014 Feb', 'sentence': 'Effects of acetaminophen and ibuprofen in children with migraine receiving preventive treatment with magnesium.', 'subject score': 1000, 'object score': 1000}, 'PMID:24733408': {'publication date': '2014 Nov', 'sentence': 'Results of a multicenter, double-blind, randomized, parallel-group, placebo-controlled, single-dose study comparing the fixed combination of acetaminophen, acetylsalicylic acid, and caffeine with ibuprofen for acute treatment of patients with severe migraine.', 'subject score': 1000, 'object score': 888}, 'PMID:27091010': {'publication date': '2016 Apr 19', 'sentence': \"AUTHORS' CONCLUSIONS: Low quality evidence from two small trials shows that ibuprofen appears to improve pain freedom for the acute treatment of children with migraine.\", 'subject score': 1000, 'object score': 1000}, 'PMID:27704257': {'publication date': '2016 Nov', 'sentence': 'Patients with intermittent migraines can often be managed with ibuprofen or naproxen taken as needed.', 'subject score': 1000, 'object score': 888}, 'PMID:29034788': {'publication date': '2018 08', 'sentence': 'We analyzed randomized controlled trials (RCTs) and systematic reviews (SRs) that investigate the efficacy and safety of ibuprofen or paracetamol for treatment of acute migraine attacks in children.', 'subject score': 1000, 'object score': 888}, 'PMID:32451827': {'publication date': '2020 May 26', 'sentence': 'CONCLUSIONS: Both paracetamol and ibuprofen are effective and safe for the treatment of acute migraine attacks in children.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 321390,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0100130",
-          "name": "adult acute respiratory distress syndrome",
-          "description": "Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.; A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:J80",
-            "MEDDRA:10042839",
-            "UMLS:C4281993",
-            "MEDDRA:10038691",
-            "MEDDRA:10040579",
-            "DOID:11394",
-            "SNOMEDCT:196153002",
-            "ORPHANET:70578",
-            "MEDDRA:10042787",
-            "SNOMEDCT:67782005",
-            "MONDO:0100130",
-            "MEDDRA:10003083",
-            "MEDDRA:10038688",
-            "MEDDRA:10001410",
-            "HP:0002643",
-            "MEDDRA:10001407",
-            "MEDDRA:10000036",
-            "UMLS:C0852283",
-            "MEDDRA:10028973",
-            "UMLS:C0035222",
-            "MEDDRA:10001052",
-            "MEDDRA:10001409",
-            "MESH:D012128",
-            "SNOMEDCT:1179627006",
-            "UMLS:C1368020"
-          ],
-          "id": "MONDO:0100130",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adult acute respiratory distress syndrome",
-            "Neonatal respiratory distress",
-            "Respiratory Distress Syndrome, Adult",
-            "adult respiratory distress syndrome",
-            "Respiratory Distress Syndrome",
-            "Adult acute respiratory distress syndrome"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005277",
-          "name": "migraine disorder",
-          "description": "A common, severe type of vascular headache often associated with increased sympathetic activity, resulting in nausea, vomiting, and light sensitivity.; A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1); Migraine is a chronic neurological disorder characterized by episodic attacks of headache and associated symptoms. [HPO:probinson, PMID:15304572]; What are migraines? Migraines are a recurring type of headache. They cause moderate to severe pain that is throbbing or pulsing. The pain is often on one side of your head. You may also have other symptoms, such as nausea and weakness. You may be sensitive to light and sound. What causes migraines? Researchers believe that migraine has a genetic cause. There are also a number of factors that can trigger a migraine. These factors vary from person to person, and they include: Stress Anxiety Hormonal changes in women Bright or flashing lights Loud noises Strong smells Medicines Too much or not enough sleep Sudden changes in weather or environment Overexertion (too much physical activity) Tobacco Caffeine or caffeine withdrawal Skipped meals Medication overuse (taking medicine for migraines too often)  Some people have found that certain foods or ingredients can trigger headaches, especially when they are combined with other triggers. These foods and ingredients include: Alcohol Chocolate Aged cheeses Monosodium glutamate (MSG) Some fruits and nuts Fermented or pickled goods Yeast Cured or processed meats  Who is at risk for migraines? About 12% of Americans get migraines. They can affect anyone, but you are more likely to have them if you: Are a woman. Women are three times more likely than men to get migraines. Have a family history of migraines. Most people with migraines have family members who have migraines. Have other medical conditions, such as depression, anxiety, bipolar disorder, sleep disorders, and epilepsy.  What are the symptoms of migraines? There are four different phases of migraines. You may not always go through every phase each time you have a migraine.: Prodome. This phase starts up to 24 hours before you get the migraine. You have early signs and symptoms, such as food cravings, unexplained mood changes, uncontrollable yawning, fluid retention, and increased urination. Aura. If you have this phase, you might see flashing or bright lights or zig-zag lines. You may have muscle weakness or feel like you are being touched or grabbed. An aura can happen just before or during a migraine. Headache. A migraine usually starts gradually and then becomes more severe. It typically causes throbbing or pulsing pain, which is often on one side of your head. But sometimes you can have a migraine without a headache. Other migraine symptoms may include  Increased sensitivity to light, noise, and odors Nausea and vomiting Worsened pain when you move, cough, or sneeze  Postdrome (following the headache). You may feel exhausted, weak, and confused after a migraine. This can last up to a day.  Migraines are more common in the morning; people often wake up with them. Some people have migraines at predictable times, such as before menstruation or on weekends following a stressful week of work. How are migraines diagnosed? To make a diagnosis, your health care provider will: Take your medical history Ask about your symptoms Do a physical and neurological exam  An important part of diagnosing migraines is to rule out other medical conditions which could be causing the symptoms. So you may also have blood tests, an MRI or CT scan, or other tests. How are migraines treated? There is no cure for migraines. Treatment focuses on relieving symptoms and preventing additional attacks. There are different types of medicines to relieve symptoms. They include triptan drugs, ergotamine drugs, and pain relievers. The sooner you take the medicine, the more effective it is. There are also other things you can do to feel better: Resting with your eyes closed in a quiet, darkened room Placing a cool cloth or ice pack on your forehead Drinking fluids  There are some lifestyle changes you can make to prevent migraines: Stress management strategies, such as exercise, relaxation techniques, and biofeedback, may reduce the number and severity of migraines. Biofeedback uses electronic devices to teach you to control certain body functions, such as your heartbeat, blood pressure, and muscle tension. Make a log of what seems to trigger your migraines. You can learn what you need to avoid, such as certain foods and medicines. It also help you figure out what you should do, such as establishing a consistent sleep schedule and eating regular meals. Hormone therapy may help some women whose migraines seem to be linked to their menstrual cycle If you have obesity, losing weight may also be helpful  If you have frequent or severe migraines, you may need to take medicines to prevent further attacks. Talk with your health care provider about which drug would be right for you. Certain natural treatments, such as riboflavin (vitamin B2) and coenzyme Q10, may help prevent migraines. If your magnesium level is low, you can try taking magnesium. There is also an herb, butterbur, which some people take to prevent migraines. But butterbur may not be safe for long-term use. Always check with your health care provider before taking any supplements. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10027606",
-            "DOID:6364",
-            "UMLS:C0149931",
-            "EFO:0003821",
-            "NCIT:C89715",
-            "MEDDRA:10027603",
-            "ICD9:346",
-            "MEDDRA:10027611",
-            "MEDDRA:10027599",
-            "MEDDRA:10027608",
-            "HP:0002076",
-            "MESH:D008881",
-            "SNOMEDCT:193030005",
-            "MEDDRA:10027602",
-            "UMLS:C0744641",
-            "MEDDRA:10027605",
-            "UMLS:C0042331",
-            "ICD10:G43",
-            "MONDO:0005277"
-          ],
-          "id": "MONDO:0005277",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_migraine disorder",
-            "Intermittent migraine headaches",
-            "Migraine",
-            "Migraine Disorders",
-            "Migraine Variant",
-            "migraine disorder",
-            "migraine"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5392788/",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=adult+respiratory+distress+syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319500,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0100130",
-              "name": "adult acute respiratory distress syndrome",
-              "description": "Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.; A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:J80",
-                "MEDDRA:10042839",
-                "UMLS:C4281993",
-                "MEDDRA:10038691",
-                "MEDDRA:10040579",
-                "DOID:11394",
-                "SNOMEDCT:196153002",
-                "ORPHANET:70578",
-                "MEDDRA:10042787",
-                "SNOMEDCT:67782005",
-                "MONDO:0100130",
-                "MEDDRA:10003083",
-                "MEDDRA:10038688",
-                "MEDDRA:10001410",
-                "HP:0002643",
-                "MEDDRA:10001407",
-                "MEDDRA:10000036",
-                "UMLS:C0852283",
-                "MEDDRA:10028973",
-                "UMLS:C0035222",
-                "MEDDRA:10001052",
-                "MEDDRA:10001409",
-                "MESH:D012128",
-                "SNOMEDCT:1179627006",
-                "UMLS:C1368020"
-              ],
-              "id": "MONDO:0100130",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adult acute respiratory distress syndrome",
-                "Neonatal respiratory distress",
-                "Respiratory Distress Syndrome, Adult",
-                "adult respiratory distress syndrome",
-                "Respiratory Distress Syndrome",
-                "Adult acute respiratory distress syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5392788/",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=adult+respiratory+distress+syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23068236,
-            "start": 554,
-            "end": 319500,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34196258': {'publication date': '2021 Jul 01', 'sentence': 'Ibuprofen suppresses the production of various pro-inflammatory cytokines that are implicated in the \"cytokine storm\" and subsequent ARDS in COVID-19 disease.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0035222---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "23500890",
-              "object": "MONDO:0100130",
-              "publications": [
-                "PMID:34196258"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 722907,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-          "name": "bronchopulmonary dysplasia",
-          "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:70589",
-            "MESH:D001997",
-            "MONDO:0019091",
-            "SNOMEDCT:67569000",
-            "MEDDRA:10066204",
-            "UMLS:C0006287",
-            "NCIT:C90599",
-            "DOID:11650",
-            "MEDDRA:10006475"
-          ],
-          "id": "MONDO:0019091",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bronchopulmonary Dysplasia",
-            "obsolete_bronchopulmonary dysplasia",
-            "bronchopulmonary dysplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 722907,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-              "name": "bronchopulmonary dysplasia",
-              "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:70589",
-                "MESH:D001997",
-                "MONDO:0019091",
-                "SNOMEDCT:67569000",
-                "MEDDRA:10066204",
-                "UMLS:C0006287",
-                "NCIT:C90599",
-                "DOID:11650",
-                "MEDDRA:10006475"
-              ],
-              "id": "MONDO:0019091",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bronchopulmonary Dysplasia",
-                "obsolete_bronchopulmonary dysplasia",
-                "bronchopulmonary dysplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20804808,
-            "start": 554,
-            "end": 722907,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31391526': {'publication date': '2019 Aug 07', 'sentence': 'After adjusting for covariates, the risk of BPD was associated independently with ibuprofen exposure (odds ratios (OR) 2.296, 95% confidence interval (CI): 1.166-4.522, p = 0.016).', 'subject score': 694, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0006287---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "21214366",
-              "object": "MONDO:0019091",
-              "publications": [
-                "PMID:31391526"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321491,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100543",
-          "name": "Cognitive impairment",
-          "description": "Abnormal cognition with deficits in thinking, reasoning, or remembering. [HPO:sdoelken]; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "MEDDRA:10009845",
-            "UMLS:C0683322",
-            "NCIT:C116921",
-            "MEDDRA:10048599",
-            "PSY:10113",
-            "UMLS:C0338656",
-            "HP:0100543",
-            "MEDDRA:10009846",
-            "MESH:D060825",
-            "SNOMEDCT:386806002",
-            "NCIT:C46083",
-            "NCIT:C27101",
-            "PSY:10103"
-          ],
-          "id": "HP:0100543",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Impaired cognition",
-            "Cognitive Disturbance",
-            "Mental impairment",
-            "Cognitive impairment",
-            "Cognitive Impairment",
-            "Cognitive Dysfunction"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321491,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100543",
-              "name": "Cognitive impairment",
-              "description": "Abnormal cognition with deficits in thinking, reasoning, or remembering. [HPO:sdoelken]; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "MEDDRA:10009845",
-                "UMLS:C0683322",
-                "NCIT:C116921",
-                "MEDDRA:10048599",
-                "PSY:10113",
-                "UMLS:C0338656",
-                "HP:0100543",
-                "MEDDRA:10009846",
-                "MESH:D060825",
-                "SNOMEDCT:386806002",
-                "NCIT:C46083",
-                "NCIT:C27101",
-                "PSY:10103"
-              ],
-              "id": "HP:0100543",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Impaired cognition",
-                "Cognitive Disturbance",
-                "Mental impairment",
-                "Cognitive impairment",
-                "Cognitive Impairment",
-                "Cognitive Dysfunction"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20482763,
-            "start": 554,
-            "end": 321491,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3080269': {'publication date': '1986 Feb', 'sentence': 'The opposite effect of ibuprofen on ethanol-induced cognitive impairment as measured by two lateralized functions is consistent with the reports in tissue and animal models that central nervous system effects of ethanol may be mediated at least in part by prostaglandins.', 'subject score': 1000, 'object score': 861}, 'PMID:7115443': {'publication date': '1982 Aug', 'sentence': 'Cognitive dysfunction associated with naproxen and ibuprofen in the elderly.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0338656---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "20886939",
-              "object": "HP:0100543",
-              "publications": [
-                "PMID:3080269",
-                "PMID:7115443"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318533,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-          "name": "Headache",
-          "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10019211",
-            "PSY:22380",
-            "NCIT:C34661",
-            "MEDDRA:10019218",
-            "SNOMEDCT:25064002",
-            "UMLS:C0018681",
-            "MEDDRA:10019231",
-            "HP:0002315",
-            "MEDDRA:10033405",
-            "ICD9:784.0",
-            "MESH:D006261",
-            "SYMP:0000504",
-            "MEDDRA:10008013",
-            "MEDDRA:10019198"
-          ],
-          "id": "HP:0002315",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "headache",
-            "Headache"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-            "PMID:15304572",
-=======
-            "http://www.mayoclinic.com/health/migraine-headache/ds00120",
-            "PMID:15304572",
-            "http://en.wikipedia.org/wiki/migraine",
->>>>>>> main
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 318533,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-              "name": "Headache",
-              "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10019211",
-                "PSY:22380",
-                "NCIT:C34661",
-                "MEDDRA:10019218",
-                "SNOMEDCT:25064002",
-                "UMLS:C0018681",
-                "MEDDRA:10019231",
-                "HP:0002315",
-                "MEDDRA:10033405",
-                "ICD9:784.0",
-                "MESH:D006261",
-                "SYMP:0000504",
-                "MEDDRA:10008013",
-                "MEDDRA:10019198"
-              ],
-              "id": "HP:0002315",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "headache",
-                "Headache"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-                "PMID:15304572",
-=======
-            "identity": 321390,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005277",
-              "name": "migraine disorder",
-              "description": "A common, severe type of vascular headache often associated with increased sympathetic activity, resulting in nausea, vomiting, and light sensitivity.; A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1); Migraine is a chronic neurological disorder characterized by episodic attacks of headache and associated symptoms. [HPO:probinson, PMID:15304572]; What are migraines? Migraines are a recurring type of headache. They cause moderate to severe pain that is throbbing or pulsing. The pain is often on one side of your head. You may also have other symptoms, such as nausea and weakness. You may be sensitive to light and sound. What causes migraines? Researchers believe that migraine has a genetic cause. There are also a number of factors that can trigger a migraine. These factors vary from person to person, and they include: Stress Anxiety Hormonal changes in women Bright or flashing lights Loud noises Strong smells Medicines Too much or not enough sleep Sudden changes in weather or environment Overexertion (too much physical activity) Tobacco Caffeine or caffeine withdrawal Skipped meals Medication overuse (taking medicine for migraines too often)  Some people have found that certain foods or ingredients can trigger headaches, especially when they are combined with other triggers. These foods and ingredients include: Alcohol Chocolate Aged cheeses Monosodium glutamate (MSG) Some fruits and nuts Fermented or pickled goods Yeast Cured or processed meats  Who is at risk for migraines? About 12% of Americans get migraines. They can affect anyone, but you are more likely to have them if you: Are a woman. Women are three times more likely than men to get migraines. Have a family history of migraines. Most people with migraines have family members who have migraines. Have other medical conditions, such as depression, anxiety, bipolar disorder, sleep disorders, and epilepsy.  What are the symptoms of migraines? There are four different phases of migraines. You may not always go through every phase each time you have a migraine.: Prodome. This phase starts up to 24 hours before you get the migraine. You have early signs and symptoms, such as food cravings, unexplained mood changes, uncontrollable yawning, fluid retention, and increased urination. Aura. If you have this phase, you might see flashing or bright lights or zig-zag lines. You may have muscle weakness or feel like you are being touched or grabbed. An aura can happen just before or during a migraine. Headache. A migraine usually starts gradually and then becomes more severe. It typically causes throbbing or pulsing pain, which is often on one side of your head. But sometimes you can have a migraine without a headache. Other migraine symptoms may include  Increased sensitivity to light, noise, and odors Nausea and vomiting Worsened pain when you move, cough, or sneeze  Postdrome (following the headache). You may feel exhausted, weak, and confused after a migraine. This can last up to a day.  Migraines are more common in the morning; people often wake up with them. Some people have migraines at predictable times, such as before menstruation or on weekends following a stressful week of work. How are migraines diagnosed? To make a diagnosis, your health care provider will: Take your medical history Ask about your symptoms Do a physical and neurological exam  An important part of diagnosing migraines is to rule out other medical conditions which could be causing the symptoms. So you may also have blood tests, an MRI or CT scan, or other tests. How are migraines treated? There is no cure for migraines. Treatment focuses on relieving symptoms and preventing additional attacks. There are different types of medicines to relieve symptoms. They include triptan drugs, ergotamine drugs, and pain relievers. The sooner you take the medicine, the more effective it is. There are also other things you can do to feel better: Resting with your eyes closed in a quiet, darkened room Placing a cool cloth or ice pack on your forehead Drinking fluids  There are some lifestyle changes you can make to prevent migraines: Stress management strategies, such as exercise, relaxation techniques, and biofeedback, may reduce the number and severity of migraines. Biofeedback uses electronic devices to teach you to control certain body functions, such as your heartbeat, blood pressure, and muscle tension. Make a log of what seems to trigger your migraines. You can learn what you need to avoid, such as certain foods and medicines. It also help you figure out what you should do, such as establishing a consistent sleep schedule and eating regular meals. Hormone therapy may help some women whose migraines seem to be linked to their menstrual cycle If you have obesity, losing weight may also be helpful  If you have frequent or severe migraines, you may need to take medicines to prevent further attacks. Talk with your health care provider about which drug would be right for you. Certain natural treatments, such as riboflavin (vitamin B2) and coenzyme Q10, may help prevent migraines. If your magnesium level is low, you can try taking magnesium. There is also an herb, butterbur, which some people take to prevent migraines. But butterbur may not be safe for long-term use. Always check with your health care provider before taking any supplements. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10027606",
-                "DOID:6364",
-                "UMLS:C0149931",
-                "EFO:0003821",
-                "NCIT:C89715",
-                "MEDDRA:10027603",
-                "ICD9:346",
-                "MEDDRA:10027611",
-                "MEDDRA:10027599",
-                "MEDDRA:10027608",
-                "HP:0002076",
-                "MESH:D008881",
-                "SNOMEDCT:193030005",
-                "MEDDRA:10027602",
-                "UMLS:C0744641",
-                "MEDDRA:10027605",
-                "UMLS:C0042331",
-                "ICD10:G43",
-                "MONDO:0005277"
-              ],
-              "id": "MONDO:0005277",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_migraine disorder",
-                "Intermittent migraine headaches",
-                "Migraine",
-                "Migraine Disorders",
-                "Migraine Variant",
-                "migraine disorder",
-                "migraine"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/migraine-headache/ds00120",
-                "PMID:15304572",
-                "http://en.wikipedia.org/wiki/migraine",
->>>>>>> main
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 18602890,
-            "start": 554,
-            "end": 318533,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27159471': {'publication date': '2015 May-Jun', 'sentence': 'On post-partum day five, she began complaining of headaches, initially responsive to ibuprofen but eventually worsened with no relief.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0018681---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "18977843",
-              "object": "HP:0002315",
-              "publications": [
-                "PMID:27159471"
-=======
-            "identity": 8273357,
-            "start": 554,
-            "end": 321390,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10999673': {'publication date': '2000 May', 'sentence': 'Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study.', 'subject score': 1000, 'object score': 1000}, 'PMID:15548924': {'publication date': '2004 Dec', 'sentence': 'The most rigorously studied agents for the acute treatment of migraine are ibuprofen, acetaminophen, and sumatriptan nasal spray, all of which have shown safety and efficacy in controlled trials.', 'subject score': 1000, 'object score': 1000}, 'PMID:15579612': {'publication date': '2004 Dec', 'sentence': 'Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:16018227': {'publication date': '2005 Jun', 'sentence': 'The most rigorously studied agents for the acute treatment of migraine are ibuprofen, acetaminophen, and sumatriptan nasal spray, all of which have shown safety and efficacy in controlled trials.', 'subject score': 1000, 'object score': 1000}, 'PMID:1623513': {'publication date': '1992 Jun', 'sentence': 'The efficacy of ibuprofen, a non-steroidal anti-inflammatory drug, was assessed in the acute treatment of migraine.', 'subject score': 1000, 'object score': 1000}, 'PMID:16492236': {'publication date': '2006 Feb', 'sentence': 'OBJECTIVE: To investigate the efficacy, tolerability, and safety of rofecoxib and ibuprofen for acute migraine treatment.', 'subject score': 1000, 'object score': 851}, 'PMID:16618262': {'publication date': '2006 Mar', 'sentence': 'OBJECTIVE: Compare the effectiveness of a combination analgesic containing acetaminophen, aspirin, and caffeine to that of ibuprofen in the treatment of migraine.', 'subject score': 1000, 'object score': 1000}, 'PMID:17563841': {'publication date': '2007 Jun', 'sentence': 'The objective of this study was to compare the efficacy of rizatriptan and ibuprofen in migraine.', 'subject score': 1000, 'object score': 1000}, 'PMID:17878396': {'publication date': '2007 Nov', 'sentence': 'Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis.', 'subject score': 901, 'object score': 851}, 'PMID:18006958': {'publication date': '2007 Nov', 'sentence': 'Ibuprofen, acetaminophen, and sumatriptan nasal spray are probably beneficial and safe to use in pediatric migraine.', 'subject score': 1000, 'object score': 888}, 'PMID:18612830': {'publication date': '2008', 'sentence': 'So sequential release of MTH (as immediate release) and IB (as sustained release) was suitable for treatment of migraine.', 'subject score': 1000, 'object score': 1000}, 'PMID:20927770': {'publication date': '2010 Oct 06', 'sentence': \"AUTHORS' CONCLUSIONS: Ibuprofen is an effective treatment for acute migraine headaches, providing pain relief in about half of sufferers, but complete relief from pain and associated symptoms for only a minority.\", 'subject score': 1000, 'object score': 901}, 'PMID:21457238': {'publication date': '2011 Apr', 'sentence': 'OBJECTIVE: To evaluate the efficacy and tolerability of telcagepant when co-administered with ibuprofen or acetaminophen for the acute treatment of migraine.', 'subject score': 1000, 'object score': 1000}, 'PMID:23633348': {'publication date': '2013 Apr 30', 'sentence': 'Ibuprofen is an effective treatment for acute migraine headaches, providing pain relief in about half of sufferers, but complete relief from pain and associated symptoms for only a minority.', 'subject score': 1000, 'object score': 901}, 'PMID:23808884': {'publication date': '2014 Feb', 'sentence': 'Effects of acetaminophen and ibuprofen in children with migraine receiving preventive treatment with magnesium.', 'subject score': 1000, 'object score': 1000}, 'PMID:24733408': {'publication date': '2014 Nov', 'sentence': 'Results of a multicenter, double-blind, randomized, parallel-group, placebo-controlled, single-dose study comparing the fixed combination of acetaminophen, acetylsalicylic acid, and caffeine with ibuprofen for acute treatment of patients with severe migraine.', 'subject score': 1000, 'object score': 888}, 'PMID:27091010': {'publication date': '2016 Apr 19', 'sentence': \"AUTHORS' CONCLUSIONS: Low quality evidence from two small trials shows that ibuprofen appears to improve pain freedom for the acute treatment of children with migraine.\", 'subject score': 1000, 'object score': 1000}, 'PMID:27704257': {'publication date': '2016 Nov', 'sentence': 'Patients with intermittent migraines can often be managed with ibuprofen or naproxen taken as needed.', 'subject score': 1000, 'object score': 888}, 'PMID:29034788': {'publication date': '2018 08', 'sentence': 'We analyzed randomized controlled trials (RCTs) and systematic reviews (SRs) that investigate the efficacy and safety of ibuprofen or paracetamol for treatment of acute migraine attacks in children.', 'subject score': 1000, 'object score': 888}, 'PMID:32451827': {'publication date': '2020 May 26', 'sentence': 'CONCLUSIONS: Both paracetamol and ibuprofen are effective and safe for the treatment of acute migraine attacks in children.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0149931---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "8452594",
-              "object": "MONDO:0005277",
-              "publications": [
-                "PMID:10999673",
-                "PMID:15548924",
-                "PMID:15579612",
-                "PMID:16018227",
-                "PMID:1623513",
-                "PMID:16492236",
-                "PMID:16618262",
-                "PMID:17563841",
-                "PMID:17878396",
-                "PMID:18006958",
-                "PMID:18612830",
-                "PMID:20927770",
-                "PMID:21457238",
-                "PMID:23633348",
-                "PMID:23808884",
-                "PMID:24733408",
-                "PMID:27091010",
-                "PMID:27704257",
-                "PMID:29034788",
-                "PMID:32451827"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 546804,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:11548225': {'publication date': '1994 Mar', 'sentence': 'Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee.', 'subject score': 1000, 'object score': 1000}, 'PMID:22558609': {'publication date': '2012', 'sentence': 'AIMS: To carry out a randomized clinical trial to compare the effect of palmitoylethanolamide (PEA) versus ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), for pain relief in temporomandibular joint (TMJ) osteoarthritis or arthralgia.', 'subject score': 1000, 'object score': 901}, 'PMID:28035387': {'publication date': '2017 Feb', 'sentence': 'Therapeutic mechanisms of ibuprofen, prednisone and betamethasone in osteoarthritis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319030,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 546804,
-=======
-            "identity": 319030,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 15423403,
-            "start": 554,
-            "end": 546804,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2173723': {'publication date': '1990 Nov', 'sentence': 'Because ibuprofen protects from septic lung injury, we studied the effect of ibuprofen in oxidant lung injury from phosgene.', 'subject score': 1000, 'object score': 851}, 'PMID:24399718': {'publication date': '2013', 'sentence': 'In the present study we investigated the influence of ibuprofen on dopaminergic neuron injury in the mice model of PD.', 'subject score': 1000, 'object score': 901}, 'PMID:3151052': {'publication date': '1988', 'sentence': 'The present study examines the role of PMN in hyperoxic lung injury using a nonsteroidal anti-inflammatory drug, ibuprofen.', 'subject score': 1000, 'object score': 828}, 'PMID:3191598': {'publication date': '1988 Dec', 'sentence': 'Both complement depletion with CVF or the administration of certain nonsteroidal anti-inflammatory drugs, including ibuprofen, are thought to decrease myocardial infarct size by reducing polymorphonuclear leukocytic (PMN) infiltration; nevertheless, complement activation also could alter tissue injury by PMN-independent actions.', 'subject score': 1000, 'object score': 861}, 'PMID:3529434': {'publication date': '1986 Sep', 'sentence': 'We report six cases of pill-induced esophageal injury, two of which were caused by the nonsteroidal anti-inflammatory medications ibuprofen and piroxicam, which have not been implicated previously in pill-induced injury.', 'subject score': 798, 'object score': 851}, 'PMID:6694377': {'publication date': '1984 Feb', 'sentence': 'Because these results could have resulted from a nonspecific effect of ibuprofen, the effects of ibuprofen on peritoneal injury in a time and dose response fashion was evaluated.', 'subject score': 1000, 'object score': 888}, 'PMID:7708817': {'publication date': '1995 Jan', 'sentence': 'A much larger dose of another PGHS inhibitor, ibuprofen, did not inhibit, but appeared to enhance, the effect of EGF plus trauma.', 'subject score': 1000, 'object score': 875}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C3263723---SEMMEDDB:",
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0043251---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "15746938",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:3191598",
-                "PMID:3151052",
-                "PMID:6694377",
-                "PMID:2173723",
-                "PMID:7708817",
-                "PMID:3529434",
-                "PMID:24399718"
-=======
-            "identity": 8901716,
-            "start": 554,
-            "end": 319030,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11548225': {'publication date': '1994 Mar', 'sentence': 'Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee.', 'subject score': 1000, 'object score': 1000}, 'PMID:22558609': {'publication date': '2012', 'sentence': 'AIMS: To carry out a randomized clinical trial to compare the effect of palmitoylethanolamide (PEA) versus ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), for pain relief in temporomandibular joint (TMJ) osteoarthritis or arthralgia.', 'subject score': 1000, 'object score': 901}, 'PMID:28035387': {'publication date': '2017 Feb', 'sentence': 'Therapeutic mechanisms of ibuprofen, prednisone and betamethasone in osteoarthritis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:associated_with---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9106384",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:11548225",
-                "PMID:22558609",
-                "PMID:28035387"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:1858446': {'publication date': '1991', 'sentence': 'The efficacy and tolerance of ibuprofen retard at a dose of 2 x 800 mg daily was investigated in an open multicenter study over a period of 3 weeks on 7931 out-patients with activated degenerative joint disease and/or extraarticular rheumatic symptoms.', 'subject score': 1000, 'object score': 900}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319030,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319030,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13536232,
-            "start": 554,
-            "end": 319030,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1858446': {'publication date': '1991', 'sentence': 'The efficacy and tolerance of ibuprofen retard at a dose of 2 x 800 mg daily was investigated in an open multicenter study over a period of 3 weeks on 7931 out-patients with activated degenerative joint disease and/or extraarticular rheumatic symptoms.', 'subject score': 1000, 'object score': 900}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "13826486",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:1858446"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 321491,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100543",
-          "name": "Cognitive impairment",
-          "description": "Abnormal cognition with deficits in thinking, reasoning, or remembering. [HPO:sdoelken]; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "MEDDRA:10009845",
-            "UMLS:C0683322",
-            "NCIT:C116921",
-            "MEDDRA:10048599",
-            "PSY:10113",
-            "UMLS:C0338656",
-            "HP:0100543",
-            "MEDDRA:10009846",
-            "MESH:D060825",
-            "SNOMEDCT:386806002",
-            "NCIT:C46083",
-            "NCIT:C27101",
-            "PSY:10103"
-          ],
-          "id": "HP:0100543",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Impaired cognition",
-            "Cognitive Disturbance",
-            "Mental impairment",
-            "Cognitive impairment",
-            "Cognitive Impairment",
-            "Cognitive Dysfunction"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321491,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100543",
-              "name": "Cognitive impairment",
-              "description": "Abnormal cognition with deficits in thinking, reasoning, or remembering. [HPO:sdoelken]; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "MEDDRA:10009845",
-                "UMLS:C0683322",
-                "NCIT:C116921",
-                "MEDDRA:10048599",
-                "PSY:10113",
-                "UMLS:C0338656",
-                "HP:0100543",
-                "MEDDRA:10009846",
-                "MESH:D060825",
-                "SNOMEDCT:386806002",
-                "NCIT:C46083",
-                "NCIT:C27101",
-                "PSY:10103"
-              ],
-              "id": "HP:0100543",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Impaired cognition",
-                "Cognitive Disturbance",
-                "Mental impairment",
-                "Cognitive impairment",
-                "Cognitive Impairment",
-                "Cognitive Dysfunction"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13299142,
-            "start": 554,
-            "end": 321491,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18259082': {'publication date': '2008', 'sentence': 'Overall, we found no relation between regular aspirin use and cognitive decline, but long-term use of ibuprofen may be related to decreased rates of cognitive decline in older persons.', 'subject score': 1000, 'object score': 1000}, 'PMID:25659514': {'publication date': '2015 Apr 05', 'sentence': \"Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID), treatment with which has been shown to delay the onset, slows the cognitive decline, and decreases the incidence of Alzheimer's disease (AD) in epidemiological and clinical studies.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:inhibits---biolink:causes---activity---None---UMLS:C0338656---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "13584223",
-              "object": "HP:0100543",
-              "publications": [
-                "PMID:18259082",
-                "PMID:25659514"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 212250,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-          "name": "Fever",
-          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10037660",
-            "MEDDRA:10020083",
-            "MEDDRA:10005911",
-            "UMLS:C0015967",
-            "HP:0001945",
-            "NCIT:C3038",
-            "MEDDRA:10073718",
-            "MEDDRA:10043204",
-            "MEDDRA:10037668",
-            "PDQ:CDR0000775882",
-            "PSY:19660",
-            "SNOMEDCT:386661006",
-            "MEDDRA:10016558",
-            "MEDDRA:10037663",
-            "SNOMEDCT:50177009",
-            "SYMP:0000613",
-            "MESH:D005334"
-          ],
-          "id": "HP:0001945",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "fever",
-            "Fever"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:9759682",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 212250,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-              "name": "Fever",
-              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10037660",
-                "MEDDRA:10020083",
-                "MEDDRA:10005911",
-                "UMLS:C0015967",
-                "HP:0001945",
-                "NCIT:C3038",
-                "MEDDRA:10073718",
-                "MEDDRA:10043204",
-                "MEDDRA:10037668",
-                "PDQ:CDR0000775882",
-                "PSY:19660",
-                "SNOMEDCT:386661006",
-                "MEDDRA:10016558",
-                "MEDDRA:10037663",
-                "SNOMEDCT:50177009",
-                "SYMP:0000613",
-                "MESH:D005334"
-              ],
-              "id": "HP:0001945",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "fever",
-                "Fever"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:9759682",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12390575,
-            "start": 554,
-            "end": 212250,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16911816': {'publication date': '2006 Oct', 'sentence': 'Subdiaphragmatic vagotomy or 7-nitroindazole reduced, icatibant, DALBK, IL-1ra, aminoguanidine and dipyrone abolished, while ibuprofen and celecoxib failed to affect Tsv-induced fever.', 'subject score': 1000, 'object score': 840}, 'PMID:18503714': {'publication date': '2008 May 26', 'sentence': 'In order to assess the effect of ibuprofen on fever compared to placebo in children with uncomplicated Plasmodium falciparum malaria in Gabon, a randomized double blind placebo controlled trial, was designed.', 'subject score': 1000, 'object score': 1000}, 'PMID:21077948': {'publication date': '2011 Dec', 'sentence': 'Neither ibuprofen nor indomethacin affected fever by PGE2 , PGF(2alpha) , or corticotrophin-releasing factor (CRF); however, both reduced the CSF PGE2 content after LPS.', 'subject score': 1000, 'object score': 1000}, 'PMID:6358043': {'publication date': '1983 Dec', 'sentence': 'Effect of ibuprofen on fever and metabolic changes induced by continuous infusion of leukocytic pyrogen (interleukin 1) or endotoxin.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0015967---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "12659717",
-              "object": "HP:0001945",
-              "publications": [
-                "PMID:16911816",
-                "PMID:18503714",
-                "PMID:21077948",
-                "PMID:6358043"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316638,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-          "name": "peptic ulcer disease",
-          "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10018053",
-            "MEDDRA:10045305",
-            "MESH:D010437",
-            "MONDO:0004247",
-            "DOID:750",
-            "UMLS:C0030920",
-            "MEDDRA:10017886",
-            "MEDDRA:10045342",
-            "ICD9:533",
-            "ICD10:K27",
-            "HP:0004398",
-            "MEDDRA:10034343",
-            "MEDDRA:10034360",
-            "MEDDRA:10045328",
-            "MEDDRA:10042834",
-            "MEDDRA:10034341",
-            "MEDDRA:10034367",
-            "MEDDRA:10037287",
-            "NCIT:C3318",
-            "SNOMEDCT:13200003",
-            "MEDDRA:10034369"
-          ],
-          "id": "MONDO:0004247",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peptic ulcer, site unspecified",
-            "Peptic Ulcer",
-            "peptic ulcer disease",
-            "Peptic ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28242110",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316638,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-              "name": "peptic ulcer disease",
-              "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10018053",
-                "MEDDRA:10045305",
-                "MESH:D010437",
-                "MONDO:0004247",
-                "DOID:750",
-                "UMLS:C0030920",
-                "MEDDRA:10017886",
-                "MEDDRA:10045342",
-                "ICD9:533",
-                "ICD10:K27",
-                "HP:0004398",
-                "MEDDRA:10034343",
-                "MEDDRA:10034360",
-                "MEDDRA:10045328",
-                "MEDDRA:10042834",
-                "MEDDRA:10034341",
-                "MEDDRA:10034367",
-                "MEDDRA:10037287",
-                "NCIT:C3318",
-                "SNOMEDCT:13200003",
-                "MEDDRA:10034369"
-              ],
-              "id": "MONDO:0004247",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peptic ulcer, site unspecified",
-                "Peptic Ulcer",
-                "peptic ulcer disease",
-                "Peptic ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28242110",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10967507,
-            "start": 554,
-            "end": 316638,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15153172': {'publication date': '2004 Jun 01', 'sentence': 'Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0030920---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "11207850",
-              "object": "MONDO:0004247",
-              "publications": [
-                "PMID:15153172"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 543282,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C26791",
-          "name": "Hemorrhage",
-          "description": "Loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels.",
-          "equivalent_curies": [
-            "UMLS:C0019080",
-            "SYMP:0000041",
-            "MEDDRA:10019524",
-            "MEDDRA:10018988",
-            "MEDDRA:10055798",
-            "MEDDRA:10019525",
-            "NCIT:C26791",
-            "MEDDRA:10005103",
-            "MEDDRA:10015867",
-            "SNOMEDCT:50960005",
-            "MP:0001914",
-            "MEDDRA:10019595",
-            "MEDDRA:10019003",
-            "MEDDRA:10005645",
-            "SNOMEDCT:131148009",
-            "MESH:D006470"
-          ],
-          "id": "NCIT:C26791",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hemorrhage",
-            "Hemorrhage"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/books/nbk542273/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 543282,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C26791",
-              "name": "Hemorrhage",
-              "description": "Loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels.",
-              "equivalent_curies": [
-                "UMLS:C0019080",
-                "SYMP:0000041",
-                "MEDDRA:10019524",
-                "MEDDRA:10018988",
-                "MEDDRA:10055798",
-                "MEDDRA:10019525",
-                "NCIT:C26791",
-                "MEDDRA:10005103",
-                "MEDDRA:10015867",
-                "SNOMEDCT:50960005",
-                "MP:0001914",
-                "MEDDRA:10019595",
-                "MEDDRA:10019003",
-                "MEDDRA:10005645",
-                "SNOMEDCT:131148009",
-                "MESH:D006470"
-              ],
-              "id": "NCIT:C26791",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hemorrhage",
-                "Hemorrhage"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/books/nbk542273/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10920727,
-            "start": 554,
-            "end": 543282,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15102426': {'publication date': '1997', 'sentence': 'It was also investigated whether the use of ibuprofen or paracetamol would influence the amount of surgical bleeding.', 'subject score': 1000, 'object score': 888}, 'PMID:18245919': {'publication date': '2008', 'sentence': 'The effect of ibuprofen on bleeding during periodontal surgery.', 'subject score': 1000, 'object score': 1000}, 'PMID:18672110': {'publication date': '2008 Aug', 'sentence': 'There was no effect of IBU on S/B.', 'subject score': 1000, 'object score': 763}, 'PMID:20890608': {'publication date': '2011 Apr', 'sentence': 'The objective of the study was to evaluate the effect of ibuprofen on hemorrhage after tonsillectomy in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:27188704': {'publication date': '2016 09', 'sentence': 'OBJECTIVE: To determine the effect of ibuprofen on posttonsillectomy bleeding when compared with codeine in posttonsillectomy analgesia.', 'subject score': 1000, 'object score': 861}, 'PMID:31568318': {'publication date': '2019 Oct', 'sentence': 'There were no articles that showed statistically significant bleeding associated with ibuprofen, celecoxib, or ketorolac.', 'subject score': 1000, 'object score': 901}, 'PMID:330286': {'publication date': '1977', 'sentence': 'The acute effect of three non-steroidal anti-inflammatory drugs, ibuprofen, acetylsalicylic acid (ASA) and indoprofen, on faecal blood loss was investigated in 15 subjects by means of 51Cr-labelled erythrocytes.', 'subject score': 1000, 'object score': 901}, 'PMID:786680': {'publication date': '1975 Apr 04', 'sentence': 'Subjective scores indicated that neither wound-healing nor bleeding was affected by ibuprofen, nor were any side effects detected.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0019080---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "11159990",
-              "object": "NCIT:C26791",
-              "publications": [
-                "PMID:15102426",
-                "PMID:18245919",
-                "PMID:18672110",
-                "PMID:20890608",
-                "PMID:27188704",
-                "PMID:31568318",
-                "PMID:330286",
-                "PMID:786680"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317818,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011827",
-          "name": "patent ductus arteriosus",
-          "description": "In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences. [HPO:probinson, PMID:20421261]; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "DOID:13832",
-            "UMLS:C0013274",
-            "ORPHANET:706",
-            "ICD9:747.0",
-            "SNOMEDCT:83330001",
-            "HP:0001643",
-            "MESH:D004374",
-            "OMIM.PS:607411",
-            "ICD10:Q25.0",
-            "NCIT:C84492",
-            "MONDO:0011827"
-          ],
-          "id": "MONDO:0011827",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Patent ductus arteriosus",
-            "patent ductus arteriosus",
-            "Patent Ductus Arteriosus",
-            "Ductus Arteriosus, Patent"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:20421261"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317818,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011827",
-              "name": "patent ductus arteriosus",
-              "description": "In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences. [HPO:probinson, PMID:20421261]; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "DOID:13832",
-                "UMLS:C0013274",
-                "ORPHANET:706",
-                "ICD9:747.0",
-                "SNOMEDCT:83330001",
-                "HP:0001643",
-                "MESH:D004374",
-                "OMIM.PS:607411",
-                "ICD10:Q25.0",
-                "NCIT:C84492",
-                "MONDO:0011827"
-              ],
-              "id": "MONDO:0011827",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Patent ductus arteriosus",
-                "patent ductus arteriosus",
-                "Patent Ductus Arteriosus",
-                "Ductus Arteriosus, Patent"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:20421261"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9950756,
-            "start": 554,
-            "end": 317818,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12723743': {'publication date': '2003 Apr', 'sentence': 'In a randomised, placebo-controlled, double-blind trial of prophylaxis with ibuprofen, the rate of patent ductus arteriosus associated with ibuprofen was 19% compared with 42% with placebo.', 'subject score': 1000, 'object score': 1000}, 'PMID:25317790': {'publication date': '2014', 'sentence': 'CONCLUSIONS: Collectively, the favorable effects of ibuprofen on PDA in premature infants maybe mediated in part by the reduction of NT-proBNP level.', 'subject score': 1000, 'object score': 1000}, 'PMID:27403365': {'publication date': '2016', 'sentence': 'To our knowledge, this is the first report on the effects of ibuprofen on patent ductus arteriosus in preterm newborns after months of life.', 'subject score': 1000, 'object score': 1000}, 'PMID:29584842': {'publication date': '2018 03 27', 'sentence': 'Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.', 'subject score': 1000, 'object score': 854}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0013274---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "10170540",
-              "object": "MONDO:0011827",
-              "publications": [
-                "PMID:12723743",
-                "PMID:25317790",
-                "PMID:27403365",
-                "PMID:29584842"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321150,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0003326",
-          "name": "Myalgia",
-          "description": "Painful sensation originating from a muscle or group of muscles.; Painful sensation in the muscles.; Pain in muscle. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "UMLS:C0231528",
-            "SYMP:0000332",
-            "HP:0003326",
-            "NCIT:C27009",
-            "MEDDRA:10018089",
-            "MEDDRA:10028361",
-            "MEDDRA:10028411",
-            "MEDDRA:10062441",
-            "MEDDRA:10028287",
-            "NCIT:C35785",
-            "MEDDRA:10028299",
-            "MEDDRA:10028362",
-            "MEDDRA:10033466",
-            "MESH:D063806",
-            "SNOMEDCT:68962001",
-            "MEDDRA:10028322",
-            "MEDDRA:10028332",
-            "MEDDRA:10028323"
-          ],
-          "id": "HP:0003326",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "muscle soreness",
-            "Myalgia",
-            "Muscle Soreness"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321150,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0003326",
-              "name": "Myalgia",
-              "description": "Painful sensation originating from a muscle or group of muscles.; Painful sensation in the muscles.; Pain in muscle. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "UMLS:C0231528",
-                "SYMP:0000332",
-                "HP:0003326",
-                "NCIT:C27009",
-                "MEDDRA:10018089",
-                "MEDDRA:10028361",
-                "MEDDRA:10028411",
-                "MEDDRA:10062441",
-                "MEDDRA:10028287",
-                "NCIT:C35785",
-                "MEDDRA:10028299",
-                "MEDDRA:10028362",
-                "MEDDRA:10033466",
-                "MESH:D063806",
-                "SNOMEDCT:68962001",
-                "MEDDRA:10028322",
-                "MEDDRA:10028332",
-                "MEDDRA:10028323"
-              ],
-              "id": "HP:0003326",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "muscle soreness",
-                "Myalgia",
-                "Muscle Soreness"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9809172,
-            "start": 554,
-            "end": 321150,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12580656': {'publication date': '2003 Feb', 'sentence': 'The purpose of this study was to examine the effects of ibuprofen on delayed onset muscle soreness (DOMS), indirect markers of muscle damage and muscular performance.', 'subject score': 1000, 'object score': 861}, 'PMID:2078806': {'publication date': '1990 Sep', 'sentence': 'Effects of ibuprofen on exercise-induced muscle soreness and indices of muscle damage.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0231528---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "10026104",
-              "object": "HP:0003326",
-              "publications": [
-                "PMID:12580656",
-                "PMID:2078806"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 543282,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C26791",
-          "name": "Hemorrhage",
-          "description": "Loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels.",
-          "equivalent_curies": [
-            "UMLS:C0019080",
-            "SYMP:0000041",
-            "MEDDRA:10019524",
-            "MEDDRA:10018988",
-            "MEDDRA:10055798",
-            "MEDDRA:10019525",
-            "NCIT:C26791",
-            "MEDDRA:10005103",
-            "MEDDRA:10015867",
-            "SNOMEDCT:50960005",
-            "MP:0001914",
-            "MEDDRA:10019595",
-            "MEDDRA:10019003",
-            "MEDDRA:10005645",
-            "SNOMEDCT:131148009",
-            "MESH:D006470"
-          ],
-          "id": "NCIT:C26791",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hemorrhage",
-            "Hemorrhage"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/books/nbk542273/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 543282,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C26791",
-              "name": "Hemorrhage",
-              "description": "Loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels.",
-              "equivalent_curies": [
-                "UMLS:C0019080",
-                "SYMP:0000041",
-                "MEDDRA:10019524",
-                "MEDDRA:10018988",
-                "MEDDRA:10055798",
-                "MEDDRA:10019525",
-                "NCIT:C26791",
-                "MEDDRA:10005103",
-                "MEDDRA:10015867",
-                "SNOMEDCT:50960005",
-                "MP:0001914",
-                "MEDDRA:10019595",
-                "MEDDRA:10019003",
-                "MEDDRA:10005645",
-                "SNOMEDCT:131148009",
-                "MESH:D006470"
-              ],
-              "id": "NCIT:C26791",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hemorrhage",
-                "Hemorrhage"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/books/nbk542273/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9675830,
-            "start": 554,
-            "end": 543282,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12442934': {'publication date': '2002 Nov', 'sentence': 'CONCLUSIONS: Pretreatment with ibuprofen before elective total hip surgery increases the perioperative blood loss significantly.', 'subject score': 1000, 'object score': 824}, 'PMID:12734151': {'publication date': '2003 May', 'sentence': 'CONCLUSION: Pretreatment with ibuprofen before major hip surgery does not improve the pain scores or reduce morphine requirement but significantly increases blood loss.', 'subject score': 1000, 'object score': 1000}, 'PMID:1304448': {'publication date': '1992', 'sentence': 'As expected for ibuprofen, a significant increase in FBL during the second week of the study was observed.', 'subject score': 1000, 'object score': 901}, 'PMID:16018759': {'publication date': '2005 Jul', 'sentence': 'CONCLUSION: Taken prior to periodontal surgery, ibuprofen increases intraoperative blood loss in patients up to almost two times that of those who did not take ibuprofen.', 'subject score': 1000, 'object score': 901}, 'PMID:25128450': {'publication date': '2014 Oct', 'sentence': 'Ibuprofen prescription may possibly increase the risk of multiple bleeding episodes, but further prospective studies are needed.', 'subject score': 888, 'object score': 890}, 'PMID:25902839': {'publication date': '2015 Oct', 'sentence': 'CONCLUSIONS: Alternating doses of ibuprofen and acetaminophen provided an effective treatment for post-tonsillectomy pain in the majority of children and did not increase rate of bleeding.', 'subject score': 1000, 'object score': 1000}, 'PMID:34559405': {'publication date': '2021 Sep 24', 'sentence': 'A recent meta-analysis suggests that ibuprofen may increase the risk of PTH.', 'subject score': 1000, 'object score': 851}, 'PMID:3498312': {'publication date': '1987 Jun', 'sentence': 'From the profile of gastrointestinal bleeding, the NSAIDs could be divided into a group consisting of aspirin (ASA), oxaprozin (OXP) and 2-[4-(3-methyl-2-butenyl)phenyl]propionic acid (TA), which caused only a transient increase in fecal blood loss based on a gastric lesion, and another group including indomethacin (IM) and ibuprofen (IP), which produced a biphasic increase in the blood loss.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0019080---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9889792",
-              "object": "NCIT:C26791",
-              "publications": [
-                "PMID:12442934",
-                "PMID:12734151",
-                "PMID:1304448",
-                "PMID:16018759",
-                "PMID:25128450",
-                "PMID:25902839",
-                "PMID:34559405",
-                "PMID:3498312"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:11296547': {'publication date': '2001', 'sentence': 'The data suggest that nimesulide and ibuprofen, in addition to their anti-inflammatory and analgesic benefits, may also have a protective effect in osteoarthritis through the inhibition of apoptosis in chondrocytes.', 'subject score': 1000, 'object score': 1000}, 'PMID:7882703': {'publication date': '1994', 'sentence': \"The duration of action of sustained-release ibuprofen ('Brufen Retard') was investigated in a 14-day double-blind study involving 14 osteoarthritis and 10 rheumatoid arthritis patients.\", 'subject score': 851, 'object score': 861}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319030,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319030,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8630387,
-            "start": 554,
-            "end": 319030,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11296547': {'publication date': '2001', 'sentence': 'The data suggest that nimesulide and ibuprofen, in addition to their anti-inflammatory and analgesic benefits, may also have a protective effect in osteoarthritis through the inhibition of apoptosis in chondrocytes.', 'subject score': 1000, 'object score': 1000}, 'PMID:7882703': {'publication date': '1994', 'sentence': \"The duration of action of sustained-release ibuprofen ('Brufen Retard') was investigated in a 14-day double-blind study involving 14 osteoarthritis and 10 rheumatoid arthritis patients.\", 'subject score': 851, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "8819538",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:11296547",
-                "PMID:7882703"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 212250,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10607493': {'publication date': '2000 Jan', 'sentence': 'DESIGN: Ginger extract was compared to placebo and Ibuprofen in patients with osteoarthritis of the hip or knee in a controlled, double blind, double dummy, cross-over study with a wash-out period of one week followed by three treatment periods in a randomized sequence, each of three weeks duration.', 'subject score': 1000, 'object score': 1000}, 'PMID:10680190': {'publication date': '2000 Feb', 'sentence': 'Glucosamine sulfate is shown to be as good as ibuprofen for osteoarthritis of the knee.', 'subject score': 1000, 'object score': 1000}, 'PMID:10871971': {'publication date': '2000 Jun 26', 'sentence': 'Therefore, we compared the efficacy and safety of the rofecoxib, which specifically inhibits COX-2, with those of the NSAID ibuprofen in patients with OA.', 'subject score': 888, 'object score': 1000}, 'PMID:10937040': {'publication date': '2000 Jul 17', 'sentence': 'DESIGN: 12-week within-patient, randomised, double-blind, placebo-controlled, crossover comparison of ibuprofen with paracetamol for osteoarthritis, involving three pairs of two-week treatment periods for each participating patient.', 'subject score': 1000, 'object score': 1000}, 'PMID:1097489': {'publication date': '1975 Aug', 'sentence': 'In a double-blind multiclinic trial, a new nonsteroidal anti-inflammatory agent (ibuprofen) was compared with an established therapeutic agent (phenylbutazone-alka) for the treatment of osteoarthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:11043057': {'publication date': '2000 Sep 25', 'sentence': 'Trial results have shown pain relief analogous to common NSAIDs (ibuprofen and diclofenac) in patients with osteoarthritis of the hip or knee.', 'subject score': 1000, 'object score': 1000}, 'PMID:11173050': {'publication date': '2001 Feb 19', 'sentence': 'We conclude that acetaminophen, when given at full doses of 4,000 mg/day, is more efficacious than placebo and has comparable efficacy to ibuprofen in the management of patients with osteoarthritis of the knee who have mild to moderate pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:11269574': {'publication date': '2001 Mar', 'sentence': 'The pharmacokinetic interactions between BAY 12-9566 and two nonsteroidal anti-inflammatory drugs (NSAIDs), naproxen and ibuprofen, were investigated in osteoarthritis (OA) patients.', 'subject score': 1000, 'object score': 888}, 'PMID:11409130': {'publication date': '2001 Jun', 'sentence': 'OBJECTIVE: To compare the treatment potential of glucosamine sulfate (GS) and ibuprofen in patients diagnosed with temporomandibular joint (TMJ) osteoarthritis (OA).', 'subject score': 1000, 'object score': 901}, 'PMID:11718158': {'publication date': '2001 Apr', 'sentence': '(1) The reference treatment for drug-based symptomatic relief of osteoarthritis and rheumatoid arthritis is paracetamol and low-dose ibuprofen.', 'subject score': 901, 'object score': 1000}, 'PMID:1173655': {'publication date': '1975 Jul 28', 'sentence': 'Ibuprofen is a new, mild analgesic agent that may be useful in the symptomatic treatment of rheumatoid arthritis and osteoarthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:11792343': {'publication date': '2002 Jan 15', 'sentence': 'Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).', 'subject score': 1000, 'object score': 1000}, 'PMID:12227215': {'publication date': '2002', 'sentence': 'Valdecoxib is at least equally as effective as ibuprofen, naproxen, and diclofenac in the treatment of osteoarthritis and rheumatoid arthritis, but is safer in terms of gastrointestinal toxicity.', 'subject score': 1000, 'object score': 1000}, 'PMID:12362101': {'publication date': '2002 Oct', 'sentence': 'Overall, the data indicate that administration of valdecoxib offers similar efficacy for the treatment of osteoarthritis but improved upper-gastrointestinal safety compared with the conventional NSAIDs, ibuprofen and diclofenac, based on the significantly lower incidence of gastroduodenal ulcers detected by endoscopy.', 'subject score': 1000, 'object score': 1000}, 'PMID:12528069': {'publication date': '2002 Dec', 'sentence': 'Both rofecoxib and celecoxib reduced the risk of confirmed clinical upper GI events compared with the nonselective NSAIDs naproxen and ibuprofen in patients with osteoarthritis and rheumatoid arthritis not taking low-dose aspirin.', 'subject score': 1000, 'object score': 1000}, 'PMID:14528521': {'publication date': '2003 Oct', 'sentence': 'Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1473430': {'publication date': '1992 Dec', 'sentence': 'One hundred sixty-two patients chronically ingesting ibuprofen, piroxicam, or naproxen for osteoarthritis, who had abdominal pain and an endoscopically proven gastric ulcer were evaluated for eight weeks in a randomized, double-blind trial comparing misoprostol (200 micrograms four times daily with meals and at bedtime) (N = 77) with placebo (N = 85).', 'subject score': 1000, 'object score': 1000}, 'PMID:1485367': {'publication date': '1992 Dec', 'sentence': 'Variability in the disposition of ibuprofen enantiomers in osteoarthritis patients.', 'subject score': 872, 'object score': 888}, 'PMID:15229960': {'publication date': '2004 Jul', 'sentence': 'OBJECTIVE: To compare the analgesic efficacy and safety of nonprescription doses of naproxen sodium, ibuprofen, and placebo in patients with osteoarthritis (OA) of the knee.', 'subject score': 1000, 'object score': 1000}, 'PMID:15308513': {'publication date': '2004 Sep', 'sentence': 'The IPSO study: ibuprofen, paracetamol study in osteoarthritis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319030,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-          "name": "Fever",
-          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10037660",
-            "MEDDRA:10020083",
-            "MEDDRA:10005911",
-            "UMLS:C0015967",
-            "HP:0001945",
-            "NCIT:C3038",
-            "MEDDRA:10073718",
-            "MEDDRA:10043204",
-            "MEDDRA:10037668",
-            "PDQ:CDR0000775882",
-            "PSY:19660",
-            "SNOMEDCT:386661006",
-            "MEDDRA:10016558",
-            "MEDDRA:10037663",
-            "SNOMEDCT:50177009",
-            "SYMP:0000613",
-            "MESH:D005334"
-          ],
-          "id": "HP:0001945",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "fever",
-            "Fever"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:9759682",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-            "https://orcid.org/0009-0006-4530-3154"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 212250,
-=======
-            "identity": 319030,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-              "name": "Fever",
-              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10037660",
-                "MEDDRA:10020083",
-                "MEDDRA:10005911",
-                "UMLS:C0015967",
-                "HP:0001945",
-                "NCIT:C3038",
-                "MEDDRA:10073718",
-                "MEDDRA:10043204",
-                "MEDDRA:10037668",
-                "PDQ:CDR0000775882",
-                "PSY:19660",
-                "SNOMEDCT:386661006",
-                "MEDDRA:10016558",
-                "MEDDRA:10037663",
-                "SNOMEDCT:50177009",
-                "SYMP:0000613",
-                "MESH:D005334"
-              ],
-              "id": "HP:0001945",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "fever",
-                "Fever"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:9759682",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8243089,
-            "start": 554,
-            "end": 212250,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10974335': {'publication date': '2000 Sep', 'sentence': 'Pretreatment with ibuprofen blocked the fever induced by RANTES.', 'subject score': 1000, 'object score': 1000}, 'PMID:11735667': {'publication date': '2001', 'sentence': 'Ibuprofen, acetylsalicylic acid (ASA) and acetaminophen are the most frequently used agents for fever reduction in children.', 'subject score': 1000, 'object score': 694}, 'PMID:1518683': {'publication date': '1992', 'sentence': 'As antipyretics, both acetaminophen and ibuprofen are effective in fever reduction by inhibiting prostaglandin synthesis.', 'subject score': 1000, 'object score': 694}, 'PMID:15688484': {'publication date': '2005 Jan', 'sentence': 'Review: no evidence exists that paracetamol and ibuprofen differ for short term pain relief or safety in children, but ibuprofen more effectively reduces fever.', 'subject score': 861, 'object score': 1000}, 'PMID:16464962': {'publication date': '2006 May', 'sentence': 'A randomised open label study of the combined use of paracetamol and ibuprofen to rapidly reduce fever is reported.', 'subject score': 1000, 'object score': 1000}, 'PMID:16836983': {'publication date': '2006 Sep 13', 'sentence': 'Indomethacin only blocked the PGE2 increase in the CSF whereas ibuprofen and celecoxib each blocked the fever and the elevation of CSF PGE2.', 'subject score': 1000, 'object score': 1000}, 'PMID:17325087': {'publication date': '2007 Mar', 'sentence': 'Most caregivers of young children reported alternating acetaminophen and ibuprofen for fever reduction in their children.', 'subject score': 1000, 'object score': 694}, 'PMID:17604006': {'publication date': '2007 Aug 03', 'sentence': 'Ibuprofen abolished the fever caused by RANTES between 60 min and 2.5 h, and it reduced the temperature until the end of observation period.', 'subject score': 1000, 'object score': 1000}, 'PMID:18694739': {'publication date': '2008 Oct 03', 'sentence': 'Indomethacin (INDO, 2 mg kg(-1), i.p.) and ibuprofen (IBU, 10 mg kg(-1), i.p.) markedly reduced the fever evoked by i.c.v. injection of CINC-1 (25 ng/site).', 'subject score': 1000, 'object score': 1000}, 'PMID:19464151': {'publication date': '2009 Sep', 'sentence': 'IBU blocked LPS-induced fever but did not block LPS-induced increases in plasma cytokines and corticosterone in the pregnant dam.', 'subject score': 1000, 'object score': 851}, 'PMID:2000781': {'publication date': '1991 Jan', 'sentence': 'Nonprescription ibuprofen is useful for managing minor aches and pains, reducing fever, and relieving symptoms of dysmenorrhea.', 'subject score': 861, 'object score': 1000}, 'PMID:20591173': {'publication date': '2010', 'sentence': 'CONCLUSIONS: All doses of IV ibuprofen tested reduced fever at four hours and throughout the first 24 hours of dosing.', 'subject score': 888, 'object score': 888}, 'PMID:20860264': {'publication date': '2010', 'sentence': 'Does acetaminophen in comparison to ibuprofen effectively reduce fevers in children younger than 18 years of age?', 'subject score': 1000, 'object score': 1000}, 'PMID:21077948': {'publication date': '2011 Dec', 'sentence': 'In conclusion, although the antipyretic effect of ibuprofen involves the blockage of central production of PGE2 and the endogenous release of AVP, differently from low dose of indomethacin, ibuprofen not only reduced the fever induced by PGE2 -dependent, but also, that induced by PGE2 -independent endogenous pyrogens.', 'subject score': 1000, 'object score': 1000}, 'PMID:21127424': {'publication date': '2011 Jan-Feb', 'sentence': 'Fever was reduced significantly by IV ibuprofen in burn patients over the initial 24-hour dosing period and remained reduced throughout the dosing period.', 'subject score': 888, 'object score': 1000}, 'PMID:22621696': {'publication date': '2012 May 28', 'sentence': 'In three double-blind, single- or multicentre trials (n = 60-120) in febrile hospitalized adult patients with acute malaria or with varying causes of fever, intravenous ibuprofen (100-400 mg every 4 or 6 hours, or 800 mg every 6 hours) reduced fever to a significantly greater extent than placebo (primary endpoint in two trials) and/or significantly more patients achieved a temperature of <38.3 degrees C within 4 hours of the first ibuprofen 400 mg dose than with placebo (primary endpoint in the third trial).', 'subject score': 888, 'object score': 888}, 'PMID:23163545': {'publication date': '2013 Jan', 'sentence': 'Widespread use of ibuprofen and paracetamol has shown that they are both effective and generally well tolerated in the reduction in paediatric fever and pain.', 'subject score': 1000, 'object score': 888}, 'PMID:2663318': {'publication date': '1989 Jul', 'sentence': 'For temperatures greater than 102.5 degrees F, a dose-response relationship for 5 and 10 mg/kg ibuprofen was demonstrated in terms of percentage of fever reduction and in terms of the initial 2-hour rate of decrease in temperature.', 'subject score': 775, 'object score': 694}, 'PMID:28437025': {'publication date': '2017 Aug', 'sentence': 'METHODS: A systematic review of randomised controlled trials investigating the administration of oral paracetamol and ibuprofen to reduce fever in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:29308684': {'publication date': '2018 Mar', 'sentence': 'Male Wistar rats, pretreated with oral doses of acetaminophen, celecoxib, dipyrone, or ibuprofen 30 min before an intravenous lipopolysaccharide (LPS) or sterile saline injection, showed a reduced febrile response in all animals tested.', 'subject score': 901, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:inhibits---biolink:causes---activity---None---UMLS:C0015967---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "8421263",
-              "object": "HP:0001945",
-              "publications": [
-                "PMID:10974335",
-                "PMID:11735667",
-                "PMID:1518683",
-                "PMID:15688484",
-                "PMID:16464962",
-                "PMID:16836983",
-                "PMID:17325087",
-                "PMID:17604006",
-                "PMID:18694739",
-                "PMID:19464151",
-                "PMID:2000781",
-                "PMID:20591173",
-                "PMID:20860264",
-                "PMID:21077948",
-                "PMID:21127424",
-                "PMID:22621696",
-                "PMID:23163545",
-                "PMID:2663318",
-                "PMID:28437025",
-                "PMID:29308684"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 521747,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002253",
-          "name": "spondylosis",
-          "description": "A form of spondylosis involving the INTERVERTEBRAL DISK, including both the annulus and the nucleus of the disk. It is usually the consequence of normal aging.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:M47",
-            "MEDDRA:10041681",
-            "ICD9:721.3",
-            "SNOMEDCT:48210000",
-            "UMLS:C0158244",
-            "MEDDRA:10025020",
-            "ICD9:721.9",
-            "MEDDRA:10041682",
-            "DOID:2247",
-            "MONDO:0002253",
-            "MESH:D055009",
-            "UMLS:C0038019",
-            "MEDDRA:10041678"
-          ],
-          "id": "MONDO:0002253",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Spondylosis",
-            "spondylosis",
-            "Lumbosacral spondylosis without myelopathy",
-            "Spondylosis of unspecified site"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000436.htm",
-            "http://en.wikipedia.org/wiki/spondylosis",
-            "http://www.mayoclinic.com/health/cervical-spondylosis/ds00697",
-            "https://www.spineuniverse.com/conditions/spondylosis/spondylosis",
-            "http://www.spine-health.com/conditions/back-pain/spondylosis-what-it-actually-means"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 521747,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002253",
-              "name": "spondylosis",
-              "description": "A form of spondylosis involving the INTERVERTEBRAL DISK, including both the annulus and the nucleus of the disk. It is usually the consequence of normal aging.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:M47",
-                "MEDDRA:10041681",
-                "ICD9:721.3",
-                "SNOMEDCT:48210000",
-                "UMLS:C0158244",
-                "MEDDRA:10025020",
-                "ICD9:721.9",
-                "MEDDRA:10041682",
-                "DOID:2247",
-                "MONDO:0002253",
-                "MESH:D055009",
-                "UMLS:C0038019",
-                "MEDDRA:10041678"
-              ],
-              "id": "MONDO:0002253",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Spondylosis",
-                "spondylosis",
-                "Lumbosacral spondylosis without myelopathy",
-                "Spondylosis of unspecified site"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000436.htm",
-                "http://en.wikipedia.org/wiki/spondylosis",
-                "http://www.mayoclinic.com/health/cervical-spondylosis/ds00697",
-                "https://www.spineuniverse.com/conditions/spondylosis/spondylosis",
-                "http://www.spine-health.com/conditions/back-pain/spondylosis-what-it-actually-means"
-=======
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 26360392,
-            "start": 554,
-            "end": 521747,
-=======
-            "identity": 7723973,
-            "start": 554,
-            "end": 319030,
->>>>>>> main
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-<<<<<<< HEAD
-              "publications_info": "{'PMID:81154': {'publication date': '1978', 'sentence': 'A comparison of the short-term effects of ibuprofen and diclofenac in spondylosis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0038019---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "26824955",
-              "object": "MONDO:0002253",
-              "publications": [
-                "PMID:81154"
-=======
-              "publications_info": "{'PMID:10607493': {'publication date': '2000 Jan', 'sentence': 'DESIGN: Ginger extract was compared to placebo and Ibuprofen in patients with osteoarthritis of the hip or knee in a controlled, double blind, double dummy, cross-over study with a wash-out period of one week followed by three treatment periods in a randomized sequence, each of three weeks duration.', 'subject score': 1000, 'object score': 1000}, 'PMID:10680190': {'publication date': '2000 Feb', 'sentence': 'Glucosamine sulfate is shown to be as good as ibuprofen for osteoarthritis of the knee.', 'subject score': 1000, 'object score': 1000}, 'PMID:10871971': {'publication date': '2000 Jun 26', 'sentence': 'Therefore, we compared the efficacy and safety of the rofecoxib, which specifically inhibits COX-2, with those of the NSAID ibuprofen in patients with OA.', 'subject score': 888, 'object score': 1000}, 'PMID:10937040': {'publication date': '2000 Jul 17', 'sentence': 'DESIGN: 12-week within-patient, randomised, double-blind, placebo-controlled, crossover comparison of ibuprofen with paracetamol for osteoarthritis, involving three pairs of two-week treatment periods for each participating patient.', 'subject score': 1000, 'object score': 1000}, 'PMID:1097489': {'publication date': '1975 Aug', 'sentence': 'In a double-blind multiclinic trial, a new nonsteroidal anti-inflammatory agent (ibuprofen) was compared with an established therapeutic agent (phenylbutazone-alka) for the treatment of osteoarthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:11043057': {'publication date': '2000 Sep 25', 'sentence': 'Trial results have shown pain relief analogous to common NSAIDs (ibuprofen and diclofenac) in patients with osteoarthritis of the hip or knee.', 'subject score': 1000, 'object score': 1000}, 'PMID:11173050': {'publication date': '2001 Feb 19', 'sentence': 'We conclude that acetaminophen, when given at full doses of 4,000 mg/day, is more efficacious than placebo and has comparable efficacy to ibuprofen in the management of patients with osteoarthritis of the knee who have mild to moderate pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:11269574': {'publication date': '2001 Mar', 'sentence': 'The pharmacokinetic interactions between BAY 12-9566 and two nonsteroidal anti-inflammatory drugs (NSAIDs), naproxen and ibuprofen, were investigated in osteoarthritis (OA) patients.', 'subject score': 1000, 'object score': 888}, 'PMID:11409130': {'publication date': '2001 Jun', 'sentence': 'OBJECTIVE: To compare the treatment potential of glucosamine sulfate (GS) and ibuprofen in patients diagnosed with temporomandibular joint (TMJ) osteoarthritis (OA).', 'subject score': 1000, 'object score': 901}, 'PMID:11718158': {'publication date': '2001 Apr', 'sentence': '(1) The reference treatment for drug-based symptomatic relief of osteoarthritis and rheumatoid arthritis is paracetamol and low-dose ibuprofen.', 'subject score': 901, 'object score': 1000}, 'PMID:1173655': {'publication date': '1975 Jul 28', 'sentence': 'Ibuprofen is a new, mild analgesic agent that may be useful in the symptomatic treatment of rheumatoid arthritis and osteoarthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:11792343': {'publication date': '2002 Jan 15', 'sentence': 'Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).', 'subject score': 1000, 'object score': 1000}, 'PMID:12227215': {'publication date': '2002', 'sentence': 'Valdecoxib is at least equally as effective as ibuprofen, naproxen, and diclofenac in the treatment of osteoarthritis and rheumatoid arthritis, but is safer in terms of gastrointestinal toxicity.', 'subject score': 1000, 'object score': 1000}, 'PMID:12362101': {'publication date': '2002 Oct', 'sentence': 'Overall, the data indicate that administration of valdecoxib offers similar efficacy for the treatment of osteoarthritis but improved upper-gastrointestinal safety compared with the conventional NSAIDs, ibuprofen and diclofenac, based on the significantly lower incidence of gastroduodenal ulcers detected by endoscopy.', 'subject score': 1000, 'object score': 1000}, 'PMID:12528069': {'publication date': '2002 Dec', 'sentence': 'Both rofecoxib and celecoxib reduced the risk of confirmed clinical upper GI events compared with the nonselective NSAIDs naproxen and ibuprofen in patients with osteoarthritis and rheumatoid arthritis not taking low-dose aspirin.', 'subject score': 1000, 'object score': 1000}, 'PMID:14528521': {'publication date': '2003 Oct', 'sentence': 'Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1473430': {'publication date': '1992 Dec', 'sentence': 'One hundred sixty-two patients chronically ingesting ibuprofen, piroxicam, or naproxen for osteoarthritis, who had abdominal pain and an endoscopically proven gastric ulcer were evaluated for eight weeks in a randomized, double-blind trial comparing misoprostol (200 micrograms four times daily with meals and at bedtime) (N = 77) with placebo (N = 85).', 'subject score': 1000, 'object score': 1000}, 'PMID:1485367': {'publication date': '1992 Dec', 'sentence': 'Variability in the disposition of ibuprofen enantiomers in osteoarthritis patients.', 'subject score': 872, 'object score': 888}, 'PMID:15229960': {'publication date': '2004 Jul', 'sentence': 'OBJECTIVE: To compare the analgesic efficacy and safety of nonprescription doses of naproxen sodium, ibuprofen, and placebo in patients with osteoarthritis (OA) of the knee.', 'subject score': 1000, 'object score': 1000}, 'PMID:15308513': {'publication date': '2004 Sep', 'sentence': 'The IPSO study: ibuprofen, paracetamol study in osteoarthritis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "7887942",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:10607493",
-                "PMID:10680190",
-                "PMID:10871971",
-                "PMID:10937040",
-                "PMID:1097489",
-                "PMID:11043057",
-                "PMID:11173050",
-                "PMID:11269574",
-                "PMID:11409130",
-                "PMID:11718158",
-                "PMID:1173655",
-                "PMID:11792343",
-                "PMID:12227215",
-                "PMID:12362101",
-                "PMID:12528069",
-                "PMID:14528521",
-                "PMID:1473430",
-                "PMID:1485367",
-                "PMID:15229960",
-                "PMID:15308513"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 546142,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:28035387': {'publication date': '2017 Feb', 'sentence': 'In conclusion, prednisone, ibuprofen and betamethasone may prevent OA by suppressing the expression of IL-6 and IL-8, subsequently inactivating NF-kappaB and STAT3 pathways, and ultimately, leading to decreased levels of collagen I, MMP-1, and MMP-13.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319030,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005326",
-          "name": "sunburn",
-          "description": "An inflammatory reaction from ultraviolet radiation characterized by transient redness, tenderness and occasional blistering.; An injury to the skin causing erythema, tenderness, and sometimes blistering and resulting from excessive exposure to the sun. The reaction is produced by the ultraviolet radiation in sunlight.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "UMLS:C3249880",
-            "UMLS:C0038814",
-            "MEDDRA:10072196",
-            "MONDO:0005326",
-            "NCIT:C3395",
-            "MEDDRA:10041306",
-            "MEDDRA:10042496",
-            "EFO:0003958",
-            "MESH:D013471",
-            "SNOMEDCT:403194002"
-          ],
-          "id": "MONDO:0005326",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Solar Erythema",
-            "Sunburn",
-            "sunburn"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 546142,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005326",
-              "name": "sunburn",
-              "description": "An inflammatory reaction from ultraviolet radiation characterized by transient redness, tenderness and occasional blistering.; An injury to the skin causing erythema, tenderness, and sometimes blistering and resulting from excessive exposure to the sun. The reaction is produced by the ultraviolet radiation in sunlight.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "UMLS:C3249880",
-                "UMLS:C0038814",
-                "MEDDRA:10072196",
-                "MONDO:0005326",
-                "NCIT:C3395",
-                "MEDDRA:10041306",
-                "MEDDRA:10042496",
-                "EFO:0003958",
-                "MESH:D013471",
-                "SNOMEDCT:403194002"
-              ],
-              "id": "MONDO:0005326",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Solar Erythema",
-                "Sunburn",
-                "sunburn"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25219475,
-            "start": 554,
-            "end": 546142,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3883908': {'publication date': '1985 Apr', 'sentence': 'The data suggest that ibuprofen is more effective than placebo for the relief of symptoms associated with UV-B-induced inflammation after high dose UV-B phototherapy for psoriasis, but the drug has limited usefulness in the treatment of sunburn reaction from these same doses.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0038814---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "25670779",
-              "object": "MONDO:0005326",
-              "publications": [
-                "PMID:3883908"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 324220,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0041153",
-          "name": "Fractured ankle",
-          "description": "Traumatic or pathological injury to the ankle joint in which the continuity of an ankle bone is broken. Symptoms include pain, swelling, and difficulty moving the affected leg and foot.; Fractures of any of the bones of the ANKLE.; A fracture or multiple fractures of one or more of three bones in the ankle joint: the tibia (shinbone), the fibula (outer ankle bone), and the talus (which is the bone that connects your leg to your foot). [https://www.hss.edu/condition-list_ankle-fractures.asp]; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "EFO:0009615",
-            "MESH:D064386",
-            "UMLS:C0159877",
-            "MEDDRA:10002544",
-            "MEDDRA:10006380",
-            "NCIT:C26989",
-            "MEDDRA:10017092",
-            "SNOMEDCT:16114001",
-            "HP:0041153"
-          ],
-          "id": "HP:0041153",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Ankle Fractures",
-            "Ankle Fracture",
-            "ankle fracture",
-            "Fractured ankle"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.hss.edu/condition-list_ankle-fractures.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 324220,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0041153",
-              "name": "Fractured ankle",
-              "description": "Traumatic or pathological injury to the ankle joint in which the continuity of an ankle bone is broken. Symptoms include pain, swelling, and difficulty moving the affected leg and foot.; Fractures of any of the bones of the ANKLE.; A fracture or multiple fractures of one or more of three bones in the ankle joint: the tibia (shinbone), the fibula (outer ankle bone), and the talus (which is the bone that connects your leg to your foot). [https://www.hss.edu/condition-list_ankle-fractures.asp]; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "EFO:0009615",
-                "MESH:D064386",
-                "UMLS:C0159877",
-                "MEDDRA:10002544",
-                "MEDDRA:10006380",
-                "NCIT:C26989",
-                "MEDDRA:10017092",
-                "SNOMEDCT:16114001",
-                "HP:0041153"
-              ],
-              "id": "HP:0041153",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Ankle Fractures",
-                "Ankle Fracture",
-                "ankle fracture",
-                "Fractured ankle"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.hss.edu/condition-list_ankle-fractures.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25067746,
-            "start": 554,
-            "end": 324220,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:37042058': {'publication date': '2023 Apr 11', 'sentence': 'Huoxue Huayu Recipe combined with ibuprofen can reduce inflammatory factors levels in patients with ankle fracture, improve isokinetic muscle strength and ankle function, and accelerate the recovery of patients.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0159877---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "25518118",
-              "object": "HP:0041153",
-              "publications": [
-                "PMID:37042058"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 722907,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-          "name": "bronchopulmonary dysplasia",
-          "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:70589",
-            "MESH:D001997",
-            "MONDO:0019091",
-            "SNOMEDCT:67569000",
-            "MEDDRA:10066204",
-            "UMLS:C0006287",
-            "NCIT:C90599",
-            "DOID:11650",
-            "MEDDRA:10006475"
-          ],
-          "id": "MONDO:0019091",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bronchopulmonary Dysplasia",
-            "obsolete_bronchopulmonary dysplasia",
-            "bronchopulmonary dysplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 722907,
-=======
-            "identity": 319030,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-              "name": "bronchopulmonary dysplasia",
-              "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:70589",
-                "MESH:D001997",
-                "MONDO:0019091",
-                "SNOMEDCT:67569000",
-                "MEDDRA:10066204",
-                "UMLS:C0006287",
-                "NCIT:C90599",
-                "DOID:11650",
-                "MEDDRA:10006475"
-              ],
-              "id": "MONDO:0019091",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bronchopulmonary Dysplasia",
-                "obsolete_bronchopulmonary dysplasia",
-                "bronchopulmonary dysplasia"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
-=======
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 24872838,
-            "start": 554,
-            "end": 722907,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:36732726': {'publication date': '2023 Feb 02', 'sentence': 'Treatment of newborn rat pups with ibuprofen reduced pulmonary vessel density in the developing lung, but also attenuated experimental BPD by reducing lung inflammation, alveolar enlargement, alveolar septum thickness and small arteriolar wall thickening.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0006287---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "25321029",
-              "object": "MONDO:0019091",
-              "publications": [
-                "PMID:36732726"
-=======
-            "identity": 19018032,
-            "start": 554,
-            "end": 319030,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28035387': {'publication date': '2017 Feb', 'sentence': 'In conclusion, prednisone, ibuprofen and betamethasone may prevent OA by suppressing the expression of IL-6 and IL-8, subsequently inactivating NF-kappaB and STAT3 pathways, and ultimately, leading to decreased levels of collagen I, MMP-1, and MMP-13.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "19399624",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:28035387"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 318715,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:18351690': {'publication date': '2008 Apr', 'sentence': \"Protein profile in neuroblastoma cells incubated with S- and R-enantiomers of ibuprofen by iTRAQ-coupled 2-D LC-MS/MS analysis: possible action of induced proteins on Alzheimer's disease.\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 307306,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005081",
-          "name": "preeclampsia",
-          "description": "A systolic blood pressure of 140 mmHg or higher, or a diastolic blood pressure of 90 mmHg or higher on two occasions at least 4 hours apart (or greater than or equal to 160/110 mmHg within a short interval) after 20 weeks of gestation in a woman with previously normal blood pressure. It may present with proteinuria but if not, it may be associated with thrombocytopenia, impaired liver function, progressive renal insufficiency, pulmonary edema, or new-onset cerebral or visual disturbances.; A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.; Pregnancy-induced hypertension in association with significant amounts of protein in the urine. [HPO:sdoelken]; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "SNOMEDCT:398254007",
-            "EFO:0000668",
-            "MEDDRA:10074050",
-            "MEDDRA:10036492",
-            "DOID:10591",
-            "NCIT:C85021",
-            "MEDDRA:10036493",
-            "HP:0100602",
-            "MESH:D011225",
-            "ICD10:O14",
-            "MEDDRA:10036485",
-            "MONDO:0005081",
-            "ORPHANET:275555",
-            "OMIM.PS:189800",
-            "UMLS:C0032914"
-          ],
-          "id": "MONDO:0005081",
-          "category": "biolink:Disease",
-          "all_names": [
-            "pre-eclampsia",
-            "Preeclampsia",
-            "preeclampsia",
-            "Pre-Eclampsia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:24400024",
-            "http://ghr.nlm.nih.gov/condition/preeclampsia",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/pre-eclampsia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318715,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005081",
-              "name": "preeclampsia",
-              "description": "A systolic blood pressure of 140 mmHg or higher, or a diastolic blood pressure of 90 mmHg or higher on two occasions at least 4 hours apart (or greater than or equal to 160/110 mmHg within a short interval) after 20 weeks of gestation in a woman with previously normal blood pressure. It may present with proteinuria but if not, it may be associated with thrombocytopenia, impaired liver function, progressive renal insufficiency, pulmonary edema, or new-onset cerebral or visual disturbances.; A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.; Pregnancy-induced hypertension in association with significant amounts of protein in the urine. [HPO:sdoelken]; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "SNOMEDCT:398254007",
-                "EFO:0000668",
-                "MEDDRA:10074050",
-                "MEDDRA:10036492",
-                "DOID:10591",
-                "NCIT:C85021",
-                "MEDDRA:10036493",
-                "HP:0100602",
-                "MESH:D011225",
-                "ICD10:O14",
-                "MEDDRA:10036485",
-                "MONDO:0005081",
-                "ORPHANET:275555",
-                "OMIM.PS:189800",
-                "UMLS:C0032914"
-              ],
-              "id": "MONDO:0005081",
-              "category": "biolink:Disease",
-              "all_names": [
-                "pre-eclampsia",
-                "Preeclampsia",
-                "preeclampsia",
-                "Pre-Eclampsia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:24400024",
-                "http://ghr.nlm.nih.gov/condition/preeclampsia",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/pre-eclampsia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21705401,
-            "start": 554,
-            "end": 318715,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32508173': {'publication date': '2020 Jun 07', 'sentence': 'Introduction:     The comparison of ibuprofen with acetaminophen for blood pressure (BP) in preeclampsia remains controversial.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0032914---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "22125431",
-              "object": "MONDO:0005081",
-              "publications": [
-                "PMID:32508173"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 310876,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021042",
-          "name": "glioma",
-          "description": "A benign or malignant brain and spinal cord tumor that arises from glial cells (astrocytes, oligodendrocytes, ependymal cells). Tumors that arise from astrocytes are called astrocytic tumors or astrocytomas. Tumors that arise from oligodendrocytes are called oligodendroglial tumors. Tumors that arise from ependymal cells are called ependymomas.; Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21); The presence of a glioma, which is a neoplasm of the central nervous system originating from a glial cell (astrocytes or oligodendrocytes). [HPO:probinson]; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10018338",
-            "MESH:D005910",
-            "MONDO:0021042",
-            "ORPHANET:182067",
-            "SNOMEDCT:74532006",
-            "HP:0009733",
-            "SNOMEDCT:393564001",
-            "SNOMEDCT:115240006",
-            "UMLS:C0017638",
-            "EFO:0005543",
-            "NCIT:C3059"
-          ],
-          "id": "MONDO:0021042",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Glioma",
-            "glioma",
-            "Glial tumor"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004975",
-          "name": "Alzheimer disease",
-          "description": "A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. [HPO:probinson]; A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. // COMMENTS: Note that this is a bundled term that refers to a disease rather than to phenotypic features. It is retained for convenience since Alzheimer disease is used for annotation of other diseases (e.g., Down syndrome) as if it were a feature. If possible it is preferable to annotate with the precise phenotypic features.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "KEGG.DISEASE:05010",
-            "SNOMEDCT:142811000119104",
-            "MEDDRA:10012292",
-            "UMLS:C1863053",
-            "HP:0002511",
-            "ICD9:331.0",
-            "ORPHANET:238616",
-            "MEDDRA:10012271",
-            "MEDDRA:10001896",
-            "UMLS:C3549448",
-            "UMLS:C0002395",
-            "NCIT:C2866",
-            "DOID:10652",
-            "MONDO:0004975",
-            "EFO:0000249",
-            "NCIT:C146894",
-            "UMLS:C1863052",
-            "SNOMEDCT:230267005",
-            "PSY:01940",
-            "SNOMEDCT:26929004",
-            "OMIM:104300",
-            "ICD10:G30",
-            "MESH:D000544",
-            "MESH:C566299"
-          ],
-          "id": "MONDO:0004975",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Alzheimer's disease",
-            "Alzheimer disease, familial, 1",
-            "Alzheimer Disease, Early-Onset, With Cerebral Amyloid Angiopathy",
-            "Alzheimer's Disease",
-            "Alzheimers Disease",
-            "Alzheimer disease",
-            "Alzheimer disease, protection against",
-            "Alzheimer Disease",
-            "obsolete_Alzheimer's disease",
-            "Alzheimer disease, familial, 1 related phenotypic feature",
-            "Alzheimer's Disease 1"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-=======
-            "http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet",
-            "http://en.wikipedia.org/wiki/alzheimer%27s_disease",
-            "http://www.merriam-webster.com/medical/alzheimer%27s%20disease",
->>>>>>> main
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 310876,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021042",
-              "name": "glioma",
-              "description": "A benign or malignant brain and spinal cord tumor that arises from glial cells (astrocytes, oligodendrocytes, ependymal cells). Tumors that arise from astrocytes are called astrocytic tumors or astrocytomas. Tumors that arise from oligodendrocytes are called oligodendroglial tumors. Tumors that arise from ependymal cells are called ependymomas.; Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21); The presence of a glioma, which is a neoplasm of the central nervous system originating from a glial cell (astrocytes or oligodendrocytes). [HPO:probinson]; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10018338",
-                "MESH:D005910",
-                "MONDO:0021042",
-                "ORPHANET:182067",
-                "SNOMEDCT:74532006",
-                "HP:0009733",
-                "SNOMEDCT:393564001",
-                "SNOMEDCT:115240006",
-                "UMLS:C0017638",
-                "EFO:0005543",
-                "NCIT:C3059"
-              ],
-              "id": "MONDO:0021042",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Glioma",
-                "glioma",
-                "Glial tumor"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20858829,
-            "start": 554,
-            "end": 310876,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31490283': {'publication date': '2020 Jan', 'sentence': 'Taken together, our findings reveal that ibuprofen could induce ferroptosis of glioblastoma cells via downregulation of Nrf2 signaling pathway and is a potential drug for glioma treatment.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0017638---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "21268743",
-              "object": "MONDO:0021042",
-              "publications": [
-                "PMID:31490283"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 521066,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005709",
-          "name": "common cold",
-          "description": "An acute inflammatory process that affects the nasopharynx. It is caused by viruses. Signs and symptoms include fever, coughing, sneezing, and sore throat.; An inflammatory process affecting the nasal mucosa, usually caused by viruses (e.g., rhinovirus, adenovirus, parainfluenza virus, and coronavirus). It is characterized by chills, headaches, mucopurulent nasal discharge, coughing, and facial pain.; A catarrhal disorder of the upper respiratory tract, which may be viral or a mixed infection. It generally involves a runny nose, nasal congestion, and sneezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0009443",
-            "MESH:D003139",
-            "MEDDRA:10039084",
-            "MEDDRA:10010107",
-            "MEDDRA:10009851",
-            "NCIT:C78599",
-            "MEDDRA:10021921",
-            "MEDDRA:10000938",
-            "MEDDRA:10066743",
-            "MONDO:0005709",
-            "MEDDRA:10019192",
-            "MEDDRA:10010106",
-            "ICD9:460",
-            "DOID:10459",
-            "EFO:0007214",
-            "MEDDRA:10000937",
-            "MEDDRA:10059827",
-            "SNOMEDCT:82272006",
-            "NCIT:C34500"
-          ],
-          "id": "MONDO:0005709",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute nasopharyngitis [common cold]",
-            "Common Cold",
-            "Infectious Rhinitis",
-            "common cold",
-            "Acute Nasopharyngitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=common%20cold"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 521066,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005709",
-              "name": "common cold",
-              "description": "An acute inflammatory process that affects the nasopharynx. It is caused by viruses. Signs and symptoms include fever, coughing, sneezing, and sore throat.; An inflammatory process affecting the nasal mucosa, usually caused by viruses (e.g., rhinovirus, adenovirus, parainfluenza virus, and coronavirus). It is characterized by chills, headaches, mucopurulent nasal discharge, coughing, and facial pain.; A catarrhal disorder of the upper respiratory tract, which may be viral or a mixed infection. It generally involves a runny nose, nasal congestion, and sneezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0009443",
-                "MESH:D003139",
-                "MEDDRA:10039084",
-                "MEDDRA:10010107",
-                "MEDDRA:10009851",
-                "NCIT:C78599",
-                "MEDDRA:10021921",
-                "MEDDRA:10000938",
-                "MEDDRA:10066743",
-                "MONDO:0005709",
-                "MEDDRA:10019192",
-                "MEDDRA:10010106",
-                "ICD9:460",
-                "DOID:10459",
-                "EFO:0007214",
-                "MEDDRA:10000937",
-                "MEDDRA:10059827",
-                "SNOMEDCT:82272006",
-                "NCIT:C34500"
-              ],
-              "id": "MONDO:0005709",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute nasopharyngitis [common cold]",
-                "Common Cold",
-                "Infectious Rhinitis",
-                "common cold",
-                "Acute Nasopharyngitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=common%20cold"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20418747,
-            "start": 554,
-            "end": 521066,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30673916': {'publication date': '2019 Jan 23', 'sentence': 'Ibuprofen (IBU) and phenylephrine hydrochloride (PE) were commonly used for common cold due to their different effects in relieving fever and the main symptoms such as nasal congestion and high sinus pressure.', 'subject score': 1000, 'object score': 1000}, 'PMID:34142200': {'publication date': '2021 Jun 17', 'sentence': 'The six active pharmaceutical molecules under study, namely, paracetamol, guaifenesin, pseudoephedrine, ibuprofen, chlorpheniramine, and dextromethorphan, are widely used in common cold products.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0009443---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "20821983",
-              "object": "MONDO:0005709",
-              "publications": [
-                "PMID:30673916",
-                "PMID:34142200"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 311374,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005076",
-          "name": "periodontitis",
-          "description": "An acute or chronic inflammatory process that affects the tissues that surround and support the teeth.; Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology); Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:824",
-            "UMLS:C0600298",
-            "MEDDRA:10034540",
-            "SNOMEDCT:41565005",
-            "ICD9:523.5",
-            "DOID:9893",
-            "MESH:D010518",
-            "ICD10:K05.4",
-            "HP:0000704",
-            "UMLS:C0031099",
-            "ICD10:K05.3",
-            "MONDO:0005076",
-            "MEDDRA:10034539",
-            "NCIT:C34918",
-            "EFO:0000649"
-          ],
-          "id": "MONDO:0005076",
-          "category": "biolink:Disease",
-          "all_names": [
-            "periodontitis",
-            "Periodontitis",
-            "periodontosis",
-            "Periodontosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5889-4463",
-            "https://orcid.org/0000-0002-9338-3017"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311374,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005076",
-              "name": "periodontitis",
-              "description": "An acute or chronic inflammatory process that affects the tissues that surround and support the teeth.; Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology); Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:824",
-                "UMLS:C0600298",
-                "MEDDRA:10034540",
-                "SNOMEDCT:41565005",
-                "ICD9:523.5",
-                "DOID:9893",
-                "MESH:D010518",
-                "ICD10:K05.4",
-                "HP:0000704",
-                "UMLS:C0031099",
-                "ICD10:K05.3",
-                "MONDO:0005076",
-                "MEDDRA:10034539",
-                "NCIT:C34918",
-                "EFO:0000649"
-              ],
-              "id": "MONDO:0005076",
-              "category": "biolink:Disease",
-              "all_names": [
-                "periodontitis",
-                "Periodontitis",
-                "periodontosis",
-                "Periodontosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5889-4463",
-                "https://orcid.org/0000-0002-9338-3017"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19890406,
-            "start": 554,
-            "end": 311374,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29669437': {'publication date': '2018 Sep', 'sentence': 'Therefore, the objective of this study was to investigate the local delivery of the NSAIDs model drug ibuprofen to treat periodontitis using different types of gel formulations (hydrogel, oleogel, and bigel).', 'subject score': 836, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0031099---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "20285347",
-              "object": "MONDO:0005076",
-              "publications": [
-                "PMID:29669437"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 311213,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005315",
-          "name": "bone fracture",
-          "description": "A traumatic injury to the bone in which the continuity of the bone is broken.; Breaks in bones.; A partial or complete breakage of the continuity of a bone. []; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "EFO:0003931",
-            "MEDDRA:10017322",
-            "SNOMEDCT:72704001",
-            "MESH:D050723",
-            "HP:0020110",
-            "MEDDRA:10017089",
-            "UMLS:C0016658",
-            "NCIT:C3046",
-            "MEDDRA:10017076",
-            "SNOMEDCT:125605004",
-            "MEDDRA:10006381",
-            "MONDO:0005315",
-            "MEDDRA:10017077"
-          ],
-          "id": "MONDO:0005315",
-          "category": "biolink:Disease",
-          "all_names": [
-            "bone fracture",
-            "Fractures, Bone",
-            "Bone fracture",
-            "Fracture"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311213,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005315",
-              "name": "bone fracture",
-              "description": "A traumatic injury to the bone in which the continuity of the bone is broken.; Breaks in bones.; A partial or complete breakage of the continuity of a bone. []; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "EFO:0003931",
-                "MEDDRA:10017322",
-                "SNOMEDCT:72704001",
-                "MESH:D050723",
-                "HP:0020110",
-                "MEDDRA:10017089",
-                "UMLS:C0016658",
-                "NCIT:C3046",
-                "MEDDRA:10017076",
-                "SNOMEDCT:125605004",
-                "MEDDRA:10006381",
-                "MONDO:0005315",
-                "MEDDRA:10017077"
-              ],
-              "id": "MONDO:0005315",
-              "category": "biolink:Disease",
-              "all_names": [
-                "bone fracture",
-                "Fractures, Bone",
-                "Bone fracture",
-                "Fracture"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18890817,
-            "start": 554,
-            "end": 311213,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27751698': {'publication date': '2017 Apr', 'sentence': 'Does the Use of Ibuprofen in Children with Extremity Fractures Increase their Risk for Bone Healing Complications?', 'subject score': 1000, 'object score': 888}, 'PMID:34499688': {'publication date': '2021', 'sentence': 'An observational cohort study comparing ibuprofen and oxycodone in children with fractures.', 'subject score': 833, 'object score': 1000}, 'PMID:7221494': {'publication date': '1981', 'sentence': 'The chemical composition of fractured and unfractured bone was significantly altered and showed a reduced ratio of hydroxyproline/nitrogen as well as an inhibition of calcification of bone matrix with a reduced calcium/nitrogen ratio followed by an increased ratio of hexosamine/DNA and RNA-ribose/DNA after treatment with ibuprofen.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0016658---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "19270581",
-              "object": "MONDO:0005315",
-              "publications": [
-                "PMID:27751698",
-                "PMID:34499688",
-                "PMID:7221494"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321491,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100543",
-          "name": "Cognitive impairment",
-          "description": "Abnormal cognition with deficits in thinking, reasoning, or remembering. [HPO:sdoelken]; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "MEDDRA:10009845",
-            "UMLS:C0683322",
-            "NCIT:C116921",
-            "MEDDRA:10048599",
-            "PSY:10113",
-            "UMLS:C0338656",
-            "HP:0100543",
-            "MEDDRA:10009846",
-            "MESH:D060825",
-            "SNOMEDCT:386806002",
-            "NCIT:C46083",
-            "NCIT:C27101",
-            "PSY:10103"
-          ],
-          "id": "HP:0100543",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Impaired cognition",
-            "Cognitive Disturbance",
-            "Mental impairment",
-            "Cognitive impairment",
-            "Cognitive Impairment",
-            "Cognitive Dysfunction"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321491,
-=======
-            "identity": 307306,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/HP_0100543",
-              "name": "Cognitive impairment",
-              "description": "Abnormal cognition with deficits in thinking, reasoning, or remembering. [HPO:sdoelken]; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "MEDDRA:10009845",
-                "UMLS:C0683322",
-                "NCIT:C116921",
-                "MEDDRA:10048599",
-                "PSY:10113",
-                "UMLS:C0338656",
-                "HP:0100543",
-                "MEDDRA:10009846",
-                "MESH:D060825",
-                "SNOMEDCT:386806002",
-                "NCIT:C46083",
-                "NCIT:C27101",
-                "PSY:10103"
-              ],
-              "id": "HP:0100543",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Impaired cognition",
-                "Cognitive Disturbance",
-                "Mental impairment",
-                "Cognitive impairment",
-                "Cognitive Impairment",
-                "Cognitive Dysfunction"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17268088,
-            "start": 554,
-            "end": 321491,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:24796537': {'publication date': '2014', 'sentence': 'Finally, anti-inflammatory drug ibuprofen ameliorated the peripheral surgical wounding-induced cognitive impairment in 18 month-old mice.', 'subject score': 905, 'object score': 833}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0338656---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "17621968",
-              "object": "HP:0100543",
-              "publications": [
-                "PMID:24796537"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316893,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012532",
-          "name": "Chronic pain",
-          "description": "Ongoing or recurrent pain that persists beyond that which is expected following acute injury, usually 3 months or more.; Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.; Persistent pain, usually defined as pain that has lasted longer than 3 to 6 months. [HPO:probinson, PMID:1875958]; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "HP:0012532",
-            "NCIT:C26940",
-            "ICD9:338.2",
-            "UMLS:C0150055",
-            "MESH:D059350",
-            "MEDDRA:10049475",
-            "SNOMEDCT:82423001",
-            "PSY:09185",
-            "SYMP:0000837"
-          ],
-          "id": "HP:0012532",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Chronic pain",
-            "chronic pain",
-            "Chronic Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:1875958",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316893,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012532",
-              "name": "Chronic pain",
-              "description": "Ongoing or recurrent pain that persists beyond that which is expected following acute injury, usually 3 months or more.; Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.; Persistent pain, usually defined as pain that has lasted longer than 3 to 6 months. [HPO:probinson, PMID:1875958]; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "HP:0012532",
-                "NCIT:C26940",
-                "ICD9:338.2",
-                "UMLS:C0150055",
-                "MESH:D059350",
-                "MEDDRA:10049475",
-                "SNOMEDCT:82423001",
-                "PSY:09185",
-                "SYMP:0000837"
-              ],
-              "id": "HP:0012532",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Chronic pain",
-                "chronic pain",
-                "Chronic Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:1875958",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16943335,
-            "start": 554,
-            "end": 316893,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24267149': {'publication date': '2013', 'sentence': 'In the last several years, several topical NSAIDs including either diclofenac ibuprofen or salicylates for chronic pain have been approved in the United States while similar drugs have been available in Europe for years.', 'subject score': 790, 'object score': 1000}, 'PMID:26261844': {'publication date': '2015 Jul', 'sentence': 'There are no clinical efficacy studies of hydrocodone in short-acting form in combination with acetaminophen or ibuprofen in chronic pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:27995369': {'publication date': '2017 03', 'sentence': 'METHODS: An observational study nested within a randomised controlled trial comparing oral paracetamol, ibuprofen or a combination of the two in 884 community-derived people with chronic knee pain.', 'subject score': 1000, 'object score': 901}, 'PMID:28282796': {'publication date': '2017', 'sentence': 'OBJECTIVE: The purpose of this study was to see if the use of low level continuous heat (LLCH) and Ibuprofen used as a home therapy between physical therapy sessions at a clinic resulted in better therapy outcomes in people with chronic neck pain.', 'subject score': 1000, 'object score': 901}, 'PMID:30793444': {'publication date': '2019 Jul', 'sentence': 'Only one SR analysed efficacy of ibuprofen and other non-steroidal anti-inflammatory drugs (NSAIDs) in chronic pain and the conclusion was that there was no evidence from RCTs that NSAIDs were effective for chronic non-cancer pain in children and adolescents.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0150055---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "17292168",
-              "object": "HP:0012532",
-              "publications": [
-                "PMID:24267149",
-                "PMID:26261844",
-                "PMID:27995369",
-                "PMID:28282796",
-                "PMID:30793444"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 308937,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-          "name": "cardiovascular disorder",
-          "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "MEDDRA:10045663",
-            "MONDO:0004995",
-            "ICD9:429.2",
-            "MEDDRA:10007649",
-            "UMLS:C0243050",
-            "HP:0001626",
-            "MESH:D018376",
-            "MEDDRA:10007648",
-            "MEDDRA:10013205",
-            "SNOMEDCT:49601007",
-            "MEDDRA:10007650",
-            "MESH:D002318",
-            "DOID:1287",
-            "UMLS:C0007222",
-            "UMLS:C0728936",
-            "NCIT:C2931"
-          ],
-          "id": "MONDO:0004995",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiovascular Diseases",
-            "Cardiovascular disease, unspecified",
-            "Abnormality of the cardiovascular system",
-            "cardiovascular system disease",
-            "Disorder of circulatory system",
-            "Cardiovascular Disorder",
-            "cardiovascular disorder",
-            "Cardiovascular Abnormalities"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/circulatory_system",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308937,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-              "name": "cardiovascular disorder",
-              "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "MEDDRA:10045663",
-                "MONDO:0004995",
-                "ICD9:429.2",
-                "MEDDRA:10007649",
-                "UMLS:C0243050",
-                "HP:0001626",
-                "MESH:D018376",
-                "MEDDRA:10007648",
-                "MEDDRA:10013205",
-                "SNOMEDCT:49601007",
-                "MEDDRA:10007650",
-                "MESH:D002318",
-                "DOID:1287",
-                "UMLS:C0007222",
-                "UMLS:C0728936",
-                "NCIT:C2931"
-              ],
-              "id": "MONDO:0004995",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiovascular Diseases",
-                "Cardiovascular disease, unspecified",
-                "Abnormality of the cardiovascular system",
-                "cardiovascular system disease",
-                "Disorder of circulatory system",
-                "Cardiovascular Disorder",
-                "cardiovascular disorder",
-                "Cardiovascular Abnormalities"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004975",
-              "name": "Alzheimer disease",
-              "description": "A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. [HPO:probinson]; A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. // COMMENTS: Note that this is a bundled term that refers to a disease rather than to phenotypic features. It is retained for convenience since Alzheimer disease is used for annotation of other diseases (e.g., Down syndrome) as if it were a feature. If possible it is preferable to annotate with the precise phenotypic features.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "KEGG.DISEASE:05010",
-                "SNOMEDCT:142811000119104",
-                "MEDDRA:10012292",
-                "UMLS:C1863053",
-                "HP:0002511",
-                "ICD9:331.0",
-                "ORPHANET:238616",
-                "MEDDRA:10012271",
-                "MEDDRA:10001896",
-                "UMLS:C3549448",
-                "UMLS:C0002395",
-                "NCIT:C2866",
-                "DOID:10652",
-                "MONDO:0004975",
-                "EFO:0000249",
-                "NCIT:C146894",
-                "UMLS:C1863052",
-                "SNOMEDCT:230267005",
-                "PSY:01940",
-                "SNOMEDCT:26929004",
-                "OMIM:104300",
-                "ICD10:G30",
-                "MESH:D000544",
-                "MESH:C566299"
-              ],
-              "id": "MONDO:0004975",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Alzheimer's disease",
-                "Alzheimer disease, familial, 1",
-                "Alzheimer Disease, Early-Onset, With Cerebral Amyloid Angiopathy",
-                "Alzheimer's Disease",
-                "Alzheimers Disease",
-                "Alzheimer disease",
-                "Alzheimer disease, protection against",
-                "Alzheimer Disease",
-                "obsolete_Alzheimer's disease",
-                "Alzheimer disease, familial, 1 related phenotypic feature",
-                "Alzheimer's Disease 1"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://en.wikipedia.org/wiki/circulatory_system",
-                "https://orcid.org/0000-0002-6601-2165",
-=======
-                "http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet",
-                "http://en.wikipedia.org/wiki/alzheimer%27s_disease",
-                "http://www.merriam-webster.com/medical/alzheimer%27s%20disease",
->>>>>>> main
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 14942972,
-            "start": 554,
-            "end": 308937,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20949283': {'publication date': '2011 Jan', 'sentence': 'Patent ductus arteriosus (PDA) is the most common cardiovascular abnormality of the preterm infant usually treated with ibuprofen (IBU).', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0243050---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "15258520",
-              "object": "MONDO:0004995",
-              "publications": [
-                "PMID:20949283"
-=======
-            "identity": 13366992,
-            "start": 554,
-            "end": 307306,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18351690': {'publication date': '2008 Apr', 'sentence': \"Protein profile in neuroblastoma cells incubated with S- and R-enantiomers of ibuprofen by iTRAQ-coupled 2-D LC-MS/MS analysis: possible action of induced proteins on Alzheimer's disease.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C0002395---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "13653982",
-              "object": "MONDO:0004975",
-              "publications": [
-                "PMID:18351690"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 525773,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006630",
-          "name": "osteoarthritis, spine",
-          "description": "Heterogeneous group of arthritic diseases sharing clinical and radiologic features. They are associated with the HLA-B27 ANTIGEN and some with a triggering infection. Most involve the axial joints in the SPINE, particularly the SACROILIAC JOINT, but can also involve asymmetric peripheral joints. Subsets include ANKYLOSING SPONDYLITIS; REACTIVE ARTHRITIS; PSORIATIC ARTHRITIS; and others.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0949691",
-            "UMLS:C2350242",
-            "MESH:D055013",
-            "MESH:D025242",
-            "MEDDRA:10031172",
-            "MEDDRA:10041684",
-            "MONDO:0006630",
-            "SNOMEDCT:8847002",
-            "MEDDRA:10029880",
-            "EFO:1000787",
-            "MEDDRA:10029871",
-            "UMLS:C0263851",
-            "MEDDRA:10051265",
-            "MEDDRA:10052775",
-            "MEDDRA:10041591",
-            "MEDDRA:10056449",
-            "SNOMEDCT:68859000"
-          ],
-          "id": "MONDO:0006630",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthritis, Spine",
-            "Spondylarthropathies",
-            "osteoarthritis, spine",
-            "Spondylosis without mention of myelopathy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 525773,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006630",
-              "name": "osteoarthritis, spine",
-              "description": "Heterogeneous group of arthritic diseases sharing clinical and radiologic features. They are associated with the HLA-B27 ANTIGEN and some with a triggering infection. Most involve the axial joints in the SPINE, particularly the SACROILIAC JOINT, but can also involve asymmetric peripheral joints. Subsets include ANKYLOSING SPONDYLITIS; REACTIVE ARTHRITIS; PSORIATIC ARTHRITIS; and others.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0949691",
-                "UMLS:C2350242",
-                "MESH:D055013",
-                "MESH:D025242",
-                "MEDDRA:10031172",
-                "MEDDRA:10041684",
-                "MONDO:0006630",
-                "SNOMEDCT:8847002",
-                "MEDDRA:10029880",
-                "EFO:1000787",
-                "MEDDRA:10029871",
-                "UMLS:C0263851",
-                "MEDDRA:10051265",
-                "MEDDRA:10052775",
-                "MEDDRA:10041591",
-                "MEDDRA:10056449",
-                "SNOMEDCT:68859000"
-              ],
-              "id": "MONDO:0006630",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthritis, Spine",
-                "Spondylarthropathies",
-                "osteoarthritis, spine",
-                "Spondylosis without mention of myelopathy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13536222,
-            "start": 554,
-            "end": 525773,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1858442': {'publication date': '1991', 'sentence': 'In an open three-center pilot study, 17 patients suffering from chronic persistent pain syndrome, due to osteoarthritis of the hip and knee or spondylarthrosis, were treated orally with 1800-2400 mg Ibuprofen per day for 3 weeks.', 'subject score': 750, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0949691---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "13826476",
-              "object": "MONDO:0006630",
-              "publications": [
-                "PMID:1858442"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317467,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0030833",
-          "name": "Neck pain",
-          "description": "Painful sensation in the neck area.; Discomfort or more intense forms of pain that are localized to the cervical region. This term generally refers to pain in the posterior or lateral regions of the neck.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the neck. [UToronto:chum]; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D019547",
-            "MEDDRA:10008322",
-            "NCIT:C50663",
-            "MEDDRA:10008296",
-            "SYMP:0000829",
-            "HP:0030833",
-            "MEDDRA:10049860",
-            "UMLS:C0007859",
-            "MEDDRA:10028836",
-            "MEDDRA:10033467",
-            "SNOMEDCT:81680005"
-          ],
-          "id": "HP:0030833",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Neck pain",
-            "Neck Pain",
-            "neck pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0003-6754",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317467,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0030833",
-              "name": "Neck pain",
-              "description": "Painful sensation in the neck area.; Discomfort or more intense forms of pain that are localized to the cervical region. This term generally refers to pain in the posterior or lateral regions of the neck.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the neck. [UToronto:chum]; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D019547",
-                "MEDDRA:10008322",
-                "NCIT:C50663",
-                "MEDDRA:10008296",
-                "SYMP:0000829",
-                "HP:0030833",
-                "MEDDRA:10049860",
-                "UMLS:C0007859",
-                "MEDDRA:10028836",
-                "MEDDRA:10033467",
-                "SNOMEDCT:81680005"
-              ],
-              "id": "HP:0030833",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Neck pain",
-                "Neck Pain",
-                "neck pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0003-6754",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13433806,
-            "start": 554,
-            "end": 317467,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18444221': {'publication date': '2008 May', 'sentence': 'The patient presented with a 6-month history of neck pain with radiation into the shoulder and arm on the left side, which was relieved by ibuprofen.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0007859---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "13722152",
-              "object": "HP:0030833",
-              "publications": [
-                "PMID:18444221"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 310723,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005044",
-          "name": "hypertensive disorder",
-          "description": "The presence of chronic increased pressure in the systemic arterial system. [HPO:probinson]; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0000822",
-            "PDQ:CDR0000686951",
-            "EFO:0000537",
-            "MONDO:0005044",
-            "MEDDRA:10039196",
-            "ICD9:401-405.99",
-            "MEDDRA:10057166",
-            "MEDDRA:10003170",
-            "ICD10:I10",
-            "MEDDRA:10006067",
-            "UMLS:C0020538",
-            "NCIT:C3117",
-            "UMLS:C0497247",
-            "SNOMEDCT:24184005",
-            "MEDDRA:10037806",
-            "MEDDRA:10036639",
-            "MESH:D006973",
-            "MEDDRA:10020775",
-            "SNOMEDCT:38341003",
-            "PSY:23830",
-            "MEDDRA:10005750",
-            "MEDDRA:10005755",
-            "MEDDRA:10081425",
-            "MEDDRA:10003168",
-            "MEDDRA:10020772",
-            "MEDDRA:10014475",
-            "MEDDRA:10005747",
-            "DOID:10763",
-            "MEDDRA:10039197",
-            "MEDDRA:10037808",
-            "MEDDRA:10020782",
-            "MEDDRA:10021655",
-            "MEDDRA:10036640"
-          ],
-          "id": "MONDO:0005044",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hypertension",
-            "Hypertension",
-            "hypertensive disorder",
-            "Hypertensive disease",
-            "Increase in blood pressure"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:24352797",
-            "PMID:9137951",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://en.wikipedia.org/wiki/hypertension"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310723,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005044",
-              "name": "hypertensive disorder",
-              "description": "The presence of chronic increased pressure in the systemic arterial system. [HPO:probinson]; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0000822",
-                "PDQ:CDR0000686951",
-                "EFO:0000537",
-                "MONDO:0005044",
-                "MEDDRA:10039196",
-                "ICD9:401-405.99",
-                "MEDDRA:10057166",
-                "MEDDRA:10003170",
-                "ICD10:I10",
-                "MEDDRA:10006067",
-                "UMLS:C0020538",
-                "NCIT:C3117",
-                "UMLS:C0497247",
-                "SNOMEDCT:24184005",
-                "MEDDRA:10037806",
-                "MEDDRA:10036639",
-                "MESH:D006973",
-                "MEDDRA:10020775",
-                "SNOMEDCT:38341003",
-                "PSY:23830",
-                "MEDDRA:10005750",
-                "MEDDRA:10005755",
-                "MEDDRA:10081425",
-                "MEDDRA:10003168",
-                "MEDDRA:10020772",
-                "MEDDRA:10014475",
-                "MEDDRA:10005747",
-                "DOID:10763",
-                "MEDDRA:10039197",
-                "MEDDRA:10037808",
-                "MEDDRA:10020782",
-                "MEDDRA:10021655",
-                "MEDDRA:10036640"
-              ],
-              "id": "MONDO:0005044",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hypertension",
-                "Hypertension",
-                "hypertensive disorder",
-                "Hypertensive disease",
-                "Increase in blood pressure"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:24352797",
-                "PMID:9137951",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://en.wikipedia.org/wiki/hypertension"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11538041,
-            "start": 554,
-            "end": 310723,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15851630': {'publication date': '2005 Jun', 'sentence': 'Treatment with nonselective anti-inflammatory drugs ibuprofen, indomethacin, or salicylic acid did not show any effect on angiotensin II-induced superoxide production, hypertension, or cardiac hypertrophy.', 'subject score': 854, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0020538---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "11790277",
-              "object": "MONDO:0005044",
-              "publications": [
-                "PMID:15851630"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317004,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005324",
-          "name": "seasonal allergic rhinitis",
-          "description": "Allergic rhinitis caused by outdoor allergens.; Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS.; It is characterized by one or more symptoms including sneezing, itching, nasal congestion, and rhinorrhea. [PMID:11449200]; An allergy experienced at a particular time of year when trees or grasses pollinate and elicit an allergic reaction. [HPO:probinson]",
-          "equivalent_curies": [
-            "HP:0012395",
-            "NCIT:C92188",
-            "SNOMEDCT:300910009",
-            "PSY:22320",
-            "MEDDRA:10001726",
-            "SNOMEDCT:21719001",
-            "MEDDRA:10019170",
-            "MONDO:0005324",
-            "MEDDRA:10039776",
-            "MEDDRA:10048908",
-            "MEDDRA:10036020",
-            "SNOMEDCT:444316004",
-            "MESH:D006255",
-            "SNOMEDCT:367498001",
-            "MEDDRA:10036019",
-            "UMLS:C0018621"
-          ],
-          "id": "MONDO:0005324",
-          "category": "biolink:Disease",
-          "all_names": [
-            "seasonal allergic rhinitis",
-            "Seasonal Allergic Rhinitis",
-            "Rhinitis, Allergic, Seasonal",
-            "Seasonal allergy",
-            "Hay Fever",
-            "Hay fever"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:11449200",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317004,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005324",
-              "name": "seasonal allergic rhinitis",
-              "description": "Allergic rhinitis caused by outdoor allergens.; Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS.; It is characterized by one or more symptoms including sneezing, itching, nasal congestion, and rhinorrhea. [PMID:11449200]; An allergy experienced at a particular time of year when trees or grasses pollinate and elicit an allergic reaction. [HPO:probinson]",
-              "equivalent_curies": [
-                "HP:0012395",
-                "NCIT:C92188",
-                "SNOMEDCT:300910009",
-                "PSY:22320",
-                "MEDDRA:10001726",
-                "SNOMEDCT:21719001",
-                "MEDDRA:10019170",
-                "MONDO:0005324",
-                "MEDDRA:10039776",
-                "MEDDRA:10048908",
-                "MEDDRA:10036020",
-                "SNOMEDCT:444316004",
-                "MESH:D006255",
-                "SNOMEDCT:367498001",
-                "MEDDRA:10036019",
-                "UMLS:C0018621"
-              ],
-              "id": "MONDO:0005324",
-              "category": "biolink:Disease",
-              "all_names": [
-                "seasonal allergic rhinitis",
-                "Seasonal Allergic Rhinitis",
-                "Rhinitis, Allergic, Seasonal",
-                "Seasonal allergy",
-                "Hay Fever",
-                "Hay fever"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:11449200",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11289035,
-            "start": 554,
-            "end": 317004,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15562884': {'publication date': '2004 Nov', 'sentence': 'Addition of ibuprofen to pseudoephedrine and chlorpheniramine in the treatment of seasonal allergic rhinitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0018621---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "11536369",
-              "object": "MONDO:0005324",
-              "publications": [
-                "PMID:15562884"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 308941,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001622",
-          "name": "Premature birth",
-          "description": "Birth when a fetus is less than 37 weeks and 0 days gestational age.; CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION).; The birth of a baby of less than 37 weeks of gestational age. [HPO:probinson]; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "HP:0001622",
-            "MEDDRA:10014049",
-            "MEDDRA:10036595",
-            "NCIT:C92861",
-            "MEDDRA:10004953",
-            "SNOMEDCT:49550006",
-            "MESH:D047928",
-            "MEDDRA:10036594",
-            "UMLS:C0151526",
-            "SNOMEDCT:367494004",
-            "SNOMEDCT:282020008",
-            "UMLS:C0233315"
-          ],
-          "id": "HP:0001622",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Premature Birth",
-            "Premature birth",
-            "Preterm Birth"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308941,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001622",
-              "name": "Premature birth",
-              "description": "Birth when a fetus is less than 37 weeks and 0 days gestational age.; CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION).; The birth of a baby of less than 37 weeks of gestational age. [HPO:probinson]; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "HP:0001622",
-                "MEDDRA:10014049",
-                "MEDDRA:10036595",
-                "NCIT:C92861",
-                "MEDDRA:10004953",
-                "SNOMEDCT:49550006",
-                "MESH:D047928",
-                "MEDDRA:10036594",
-                "UMLS:C0151526",
-                "SNOMEDCT:367494004",
-                "SNOMEDCT:282020008",
-                "UMLS:C0233315"
-              ],
-              "id": "HP:0001622",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Premature Birth",
-                "Premature birth",
-                "Preterm Birth"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11138197,
-            "start": 554,
-            "end": 308941,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15342612': {'publication date': '2004 Oct', 'sentence': 'This should be considered to assess pharmacokinetic-pharmacodynamic relationships of ibuprofen in premature neonates and subsequently to understand and refine the use of ibuprofen in managing PDA either as a prophylactic or curative treatment.', 'subject score': 1000, 'object score': 983}, 'PMID:18458658': {'publication date': '2008 Sep', 'sentence': 'Ibuprofen versus continuous indomethacin in premature neonates with patent ductus arteriosus: is the difference in the mode of administration?', 'subject score': 1000, 'object score': 983}, 'PMID:29203106': {'publication date': '2017 Nov', 'sentence': 'Oral paracetamol or ibuprofen for PDA closure in premature neonates with severe CHRs and contraindications for indomethacin was ineffective.', 'subject score': 1000, 'object score': 983}, 'PMID:31472084': {'publication date': '2019 Nov', 'sentence': 'BACKGROUND: Ibuprofen is widely used for ductus arteriosus closure in premature neonates and for analgesia in children and adults.', 'subject score': 1000, 'object score': 983}, 'PMID:31850085': {'publication date': '2019', 'sentence': 'Comparison of oral acetaminophen with oral ibuprofen on closure of symptomatic patent ductus arteriosus in preterm neonates.', 'subject score': 888, 'object score': 901}, 'PMID:32955023': {'publication date': '2020 Sep', 'sentence': 'Positive tendency toward synchronous use of acetaminophen and ibuprofen in treating patients with patent ductus arteriosus.OBJECTIVE: Spontaneous closure of the ductus arteriosus often fails to occur in premature newborns and this condition can be associated with increased morbidity and mortality.', 'subject score': 1000, 'object score': 1000}, 'PMID:33779002': {'publication date': '2021 Mar 28', 'sentence': 'Ibuprofen enantiomers in premature neonates with patent ductus arteriosus: Preliminary data on an unexpected pharmacokinetic profile of S(+)-ibuprofen.', 'subject score': 888, 'object score': 1000}, 'PMID:34131462': {'publication date': '2021 Jul', 'sentence': 'Use of combination therapy with acetaminophen and ibuprofen for closure of the patent ductus arteriosus in preterm neonates.', 'subject score': 1000, 'object score': 888}, 'PMID:32045960': {'publication date': '2020 Feb 11', 'sentence': 'SELECTION CRITERIA: Randomised or quasi-randomised controlled trials of ibuprofen for the treatment of a PDA in preterm, low birth weight, or both preterm and low-birth-weight newborn infants.', 'subject score': 1000, 'object score': 1000}, 'PMID:32250464': {'publication date': '2020 Apr 06', 'sentence': 'METHODS: We prospectively collected 210 plasma samples of 67 preterm neonates treated with ibuprofen for PDA (median gestational age (GA) 26 (range 24-30) weeks, median body weight 0.83 (0.45-1.59) kg, median postnatal age (PNA) 3 (1-12) days)), and developed a population pharmacokinetic model for S- and R-ibuprofen.', 'subject score': 1000, 'object score': 861}, 'PMID:32336479': {'publication date': '2020 Apr 23', 'sentence': 'CONCLUSIONS: Oral paracetamol is noninferior to oral ibuprofen for the closure of hsPDA in preterm neonates of <32 weeks of gestation.', 'subject score': 888, 'object score': 901}, 'PMID:32641884': {'publication date': '2020', 'sentence': 'Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - A randomized controlled trial.', 'subject score': 1000, 'object score': 901}, 'PMID:32766181': {'publication date': '2020', 'sentence': 'IV ibuprofen (standard treatment) for PDA in preterm patients with a gestational age <= 30 weeks.', 'subject score': 888, 'object score': 901}, 'PMID:32768013': {'publication date': '2020', 'sentence': 'METHODS: We performed a systematic literature search on topics that assesses the use of oral paracetamol compared to oral ibuprofen in preterm neonates diagnosed with PDA from PubMed, EuropePMC, Cochrane Central Database, ScienceDirect, ProQuest, ClinicalTrials.gov, and hand-sampling from potential articles.', 'subject score': 888, 'object score': 901}, 'PMID:33975823': {'publication date': '2021 May 11', 'sentence': 'OBJECTIVE: Exploration of a novel therapeutic drug monitoring (TDM) strategy to personalise use of ibuprofen for closure of patent ductus arteriosus (PDA) in preterm neonates.', 'subject score': 1000, 'object score': 888}, 'PMID:34477275': {'publication date': '2021 Sep 03', 'sentence': 'CONCLUSION: This exploratory study demonstrates comparable pharmacokinetics of PO and IV formulations of ibuprofen in preterm neonates.', 'subject score': 1000, 'object score': 888}, 'PMID:36465804': {'publication date': '2022 Sep-Dec', 'sentence': 'Conclusions: Trade-off RBA indicated that high-dose oral ibuprofen might be the best treatment for preterm, GA >=28 weeks, with hsPDA followed by the standard-dose oral acetaminophen and ibuprofen.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0233315---SEMMEDDB:",
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0151526---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "11381904",
-              "object": "HP:0001622",
-              "publications": [
-                "PMID:32641884",
-                "PMID:34477275",
-                "PMID:32955023",
-                "PMID:32250464",
-                "PMID:32336479",
-                "PMID:32768013",
-                "PMID:33975823",
-                "PMID:15342612",
-                "PMID:31472084",
-                "PMID:34131462",
-                "PMID:29203106",
-                "PMID:32766181",
-                "PMID:18458658",
-                "PMID:32045960",
-                "PMID:36465804",
-                "PMID:33779002",
-                "PMID:31850085"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322143,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0003418",
-          "name": "Back pain",
-          "description": "An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the back. []; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the back.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the back.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the back.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "UMLS:C0004604",
-            "MEDDRA:10003988",
-            "MEDDRA:10064734",
-            "MEDDRA:10003994",
-            "MEDDRA:10003978",
-            "MEDDRA:10033478",
-            "SNOMEDCT:161891005",
-            "HP:0003418",
-            "MEDDRA:10033391",
-            "MESH:D001416",
-            "PSY:05275",
-            "MEDDRA:10033380",
-            "MEDDRA:10003993",
-            "NCIT:C41830",
-            "MEDDRA:10013601"
-          ],
-          "id": "HP:0003418",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Back Pain",
-            "Back pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322143,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0003418",
-              "name": "Back pain",
-              "description": "An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the back. []; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the back.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the back.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the back.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "UMLS:C0004604",
-                "MEDDRA:10003988",
-                "MEDDRA:10064734",
-                "MEDDRA:10003994",
-                "MEDDRA:10003978",
-                "MEDDRA:10033478",
-                "SNOMEDCT:161891005",
-                "HP:0003418",
-                "MEDDRA:10033391",
-                "MESH:D001416",
-                "PSY:05275",
-                "MEDDRA:10033380",
-                "MEDDRA:10003993",
-                "NCIT:C41830",
-                "MEDDRA:10013601"
-              ],
-              "id": "HP:0003418",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Back Pain",
-                "Back pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10987603,
-            "start": 554,
-            "end": 322143,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1518731': {'publication date': '1992', 'sentence': 'A 57-year-old woman believed that ibuprofen, prescribed for back pain, improved her idiopathic chronic cough that had been resistant to inhaled and oral corticosteroids.', 'subject score': 1000, 'object score': 1000}, 'PMID:29038738': {'publication date': '2017', 'sentence': 'He reported taking high-dose ibuprofen for back pain and drinking several 24-ounce beers daily.', 'subject score': 901, 'object score': 1000}, 'PMID:33235514': {'publication date': '2020', 'sentence': 'Conclusion: The combination of eperisone hydrochloride and ibuprofen effectively reduces pain and improves functional outcomes over ibuprofen alone with a similar safety profile in these patients with acute non-specific back pain with muscle spasm.', 'subject score': 1000, 'object score': 928}, 'PMID:34064282': {'publication date': '2021 May 21', 'sentence': 'In subgroup B, the use of ibuprofen only alleviated back pain and fatigue.', 'subject score': 1000, 'object score': 1000}, 'PMID:36692805': {'publication date': '2023 Jan 24', 'sentence': 'Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0004604---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "11239637",
-              "object": "HP:0003418",
-              "publications": [
-                "PMID:1518731",
-                "PMID:29038738",
-                "PMID:33235514",
-                "PMID:34064282",
-                "PMID:36692805"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 521264,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005812",
-          "name": "influenza",
-          "description": "An acute viral infection of the respiratory tract, occurring in isolated cases, in epidemics, or in pandemics; it is caused by serologically different strains of viruses (influenzaviruses) designated A, B, and C, has a 3-day incubation period, and usually lasts for 3 to 10 days. It is marked by inflammation of the nasal mucosa, pharynx, and conjunctiva; headache; myalgia; often fever, chills, and prostration; and occasionally involvement of the myocardium or central nervous system.; An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD9:487",
-            "SNOMEDCT:61700007",
-            "MESH:D007251",
-            "MESH:D009976",
-            "UMLS:C0029342",
-            "DOID:8469",
-            "ICD10:J11.1",
-            "UMLS:C0021400",
-            "MONDO:0005812",
-            "NCIT:C53482",
-            "PSY:25260",
-            "SNOMEDCT:6142004",
-            "EFO:0007328",
-            "MEDDRA:10016793",
-            "MEDDRA:10022000",
-            "MEDDRA:10016790",
-            "MEDDRA:10042807",
-            "SNOMEDCT:65093003",
-            "UMLS:C0155871"
-          ],
-          "id": "MONDO:0005812",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Influenza, Human",
-            "Influenza with non-respiratory manifestation",
-            "Influenza",
-            "Orthomyxoviridae Infections",
-            "influenza"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.merck.com/mmhe/sec17/ch198/ch198d.htm",
-            "http://www.who.int/mediacentre/factsheets/2003/fs211/en/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 521264,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005812",
-              "name": "influenza",
-              "description": "An acute viral infection of the respiratory tract, occurring in isolated cases, in epidemics, or in pandemics; it is caused by serologically different strains of viruses (influenzaviruses) designated A, B, and C, has a 3-day incubation period, and usually lasts for 3 to 10 days. It is marked by inflammation of the nasal mucosa, pharynx, and conjunctiva; headache; myalgia; often fever, chills, and prostration; and occasionally involvement of the myocardium or central nervous system.; An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD9:487",
-                "SNOMEDCT:61700007",
-                "MESH:D007251",
-                "MESH:D009976",
-                "UMLS:C0029342",
-                "DOID:8469",
-                "ICD10:J11.1",
-                "UMLS:C0021400",
-                "MONDO:0005812",
-                "NCIT:C53482",
-                "PSY:25260",
-                "SNOMEDCT:6142004",
-                "EFO:0007328",
-                "MEDDRA:10016793",
-                "MEDDRA:10022000",
-                "MEDDRA:10016790",
-                "MEDDRA:10042807",
-                "SNOMEDCT:65093003",
-                "UMLS:C0155871"
-              ],
-              "id": "MONDO:0005812",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Influenza, Human",
-                "Influenza with non-respiratory manifestation",
-                "Influenza",
-                "Orthomyxoviridae Infections",
-                "influenza"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.merck.com/mmhe/sec17/ch198/ch198d.htm",
-                "http://www.who.int/mediacentre/factsheets/2003/fs211/en/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9974896,
-            "start": 554,
-            "end": 521264,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12749506': {'publication date': '2003 Feb', 'sentence': 'A multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled, parallel-group comparison of diclofenac-K and ibuprofen for the treatment of adults with influenza-like symptoms.', 'subject score': 1000, 'object score': 1000}, 'PMID:21331467': {'publication date': '2012 Feb', 'sentence': 'CONCLUSION: Oral acetaminophen/paracetamol or ibuprofen effectively managed the transient influenza-like symptoms associated with zoledronic acid 5 mg.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0021400---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "10195210",
-              "object": "MONDO:0005812",
-              "publications": [
-                "PMID:12749506",
-                "PMID:21331467"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 530667,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005554",
-          "name": "rheumatic disorder",
-          "description": "Inflammatory and degenerative diseases of connective tissue structures, such as arthritis.; Historically, a heterogeneous group of acute and chronic diseases, including rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, dermatomyositis, etc. This classification was based on the notion that \"collagen\" was equivalent to \"connective tissue\", but with the present recognition of the different types of collagen and the aggregates derived from them as distinct entities, the term \"collagen diseases\" now pertains exclusively to those inherited conditions in which the primary defect is at the gene level and affects collagen biosynthesis, post-translational modification, or extracellular processing directly. (From Cecil Textbook of Medicine, 19th ed, p1494); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10039070",
-            "MEDDRA:10039068",
-            "SNOMEDCT:396332003",
-            "DOID:1575",
-            "MEDDRA:10045746",
-            "MEDDRA:10013207",
-            "MONDO:0005554",
-            "DOID:854",
-            "EFO:0005755",
-            "MESH:D003095",
-            "UMLS:C0035435",
-            "UMLS:C0009326",
-            "MESH:D012216",
-            "MEDDRA:10009904",
-            "PSY:44560",
-            "SNOMEDCT:81573002",
-            "UMLS:C0041785",
-            "NCIT:C27204",
-            "MEDDRA:10009903"
-          ],
-          "id": "MONDO:0005554",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Rheumatism",
-            "collagen disease",
-            "Rheumatic Diseases",
-            "Rheumatologic Disorder",
-            "Collagen Diseases",
-            "Diffuse disease of connective tissue",
-            "rheumatic disorder",
-            "rheumatic disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/connective_tissue_disease",
-            "http://www.niams.nih.gov/health_info/scleroderma/default.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 530667,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005554",
-              "name": "rheumatic disorder",
-              "description": "Inflammatory and degenerative diseases of connective tissue structures, such as arthritis.; Historically, a heterogeneous group of acute and chronic diseases, including rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, dermatomyositis, etc. This classification was based on the notion that \"collagen\" was equivalent to \"connective tissue\", but with the present recognition of the different types of collagen and the aggregates derived from them as distinct entities, the term \"collagen diseases\" now pertains exclusively to those inherited conditions in which the primary defect is at the gene level and affects collagen biosynthesis, post-translational modification, or extracellular processing directly. (From Cecil Textbook of Medicine, 19th ed, p1494); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10039070",
-                "MEDDRA:10039068",
-                "SNOMEDCT:396332003",
-                "DOID:1575",
-                "MEDDRA:10045746",
-                "MEDDRA:10013207",
-                "MONDO:0005554",
-                "DOID:854",
-                "EFO:0005755",
-                "MESH:D003095",
-                "UMLS:C0035435",
-                "UMLS:C0009326",
-                "MESH:D012216",
-                "MEDDRA:10009904",
-                "PSY:44560",
-                "SNOMEDCT:81573002",
-                "UMLS:C0041785",
-                "NCIT:C27204",
-                "MEDDRA:10009903"
-              ],
-              "id": "MONDO:0005554",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Rheumatism",
-                "collagen disease",
-                "Rheumatic Diseases",
-                "Rheumatologic Disorder",
-                "Collagen Diseases",
-                "Diffuse disease of connective tissue",
-                "rheumatic disorder",
-                "rheumatic disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/connective_tissue_disease",
-                "http://www.niams.nih.gov/health_info/scleroderma/default.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9735560,
-            "start": 554,
-            "end": 530667,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12503255': {'publication date': '2002', 'sentence': 'Eight preparations contained synthetic drugs (e.g. benzodiazepines and tricyclic antidepressants in sedative preparations, cyproheptadine in a remedy to gain bodyweight, ibuprofen and dipyrone in herbal capsules used to treat rheumatism).', 'subject score': 1000, 'object score': 1000}, 'PMID:14381': {'publication date': '1976', 'sentence': '[Clinical results of ibuprofen (Brufen) in abarticular rheumatism].', 'subject score': 1000, 'object score': 861}, 'PMID:17638129': {'publication date': '1998', 'sentence': 'S(+)-ibuprofen (dexibuprofen) is an NSAID offering a lot of advantages in the treatment of rheumatism and pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:19588434': {'publication date': '2009 Jul 08', 'sentence': 'BACKGROUND: Dexibuprofen (S(+)-ibuprofen) is a non-steroidal anti-inflammatory drug (NSAID) licensed for use in rheumatic disease and other musculoskeletal disorders in the UK, and widely available in other countries worldwide.', 'subject score': 1000, 'object score': 1000}, 'PMID:2818681': {'publication date': '1989 Aug', 'sentence': 'Therefore ibuprofen can be used in old patients with rheumatic diseases without any dose reduction and discontinuation of treatment has not to be discussed.', 'subject score': 861, 'object score': 1000}, 'PMID:350500': {'publication date': '1978', 'sentence': 'A comparative trial of ketoprofen and ibuprofen in patients with rheumatic disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:4579839': {'publication date': '1973 Jun 23', 'sentence': '[Use of ibuprofen in the control of rheumatic activity].', 'subject score': 1000, 'object score': 888}, 'PMID:4579840': {'publication date': '1973 Jun 23', 'sentence': '[Controlled clinical research on the use of ibuprofen in rheumatoid arthritis and other rheumatic diseases].', 'subject score': 1000, 'object score': 1000}, 'PMID:8957236': {'publication date': '1996 Oct 24', 'sentence': \"Synovial cell cultures prepared from samples taken from osteoarthritic and rheumatoid patients were treated with different anti-inflammatory agents (cortisol, indomethacin, ibuprofen and piroxicam) to determine their 'anti-interleukin-1 beta' action, using inhibition of interleukin-1 beta-mediated glucose uptake stimulation as a biological test.\", 'subject score': 1000, 'object score': 853}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0035435---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9950431",
-              "object": "MONDO:0005554",
-              "publications": [
-                "PMID:12503255",
-                "PMID:14381",
-                "PMID:17638129",
-                "PMID:19588434",
-                "PMID:2818681",
-                "PMID:350500",
-                "PMID:4579839",
-                "PMID:4579840",
-                "PMID:8957236"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321150,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0003326",
-          "name": "Myalgia",
-          "description": "Painful sensation originating from a muscle or group of muscles.; Painful sensation in the muscles.; Pain in muscle. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "UMLS:C0231528",
-            "SYMP:0000332",
-            "HP:0003326",
-            "NCIT:C27009",
-            "MEDDRA:10018089",
-            "MEDDRA:10028361",
-            "MEDDRA:10028411",
-            "MEDDRA:10062441",
-            "MEDDRA:10028287",
-            "NCIT:C35785",
-            "MEDDRA:10028299",
-            "MEDDRA:10028362",
-            "MEDDRA:10033466",
-            "MESH:D063806",
-            "SNOMEDCT:68962001",
-            "MEDDRA:10028322",
-            "MEDDRA:10028332",
-            "MEDDRA:10028323"
-          ],
-          "id": "HP:0003326",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "muscle soreness",
-            "Myalgia",
-            "Muscle Soreness"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321150,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0003326",
-              "name": "Myalgia",
-              "description": "Painful sensation originating from a muscle or group of muscles.; Painful sensation in the muscles.; Pain in muscle. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "UMLS:C0231528",
-                "SYMP:0000332",
-                "HP:0003326",
-                "NCIT:C27009",
-                "MEDDRA:10018089",
-                "MEDDRA:10028361",
-                "MEDDRA:10028411",
-                "MEDDRA:10062441",
-                "MEDDRA:10028287",
-                "NCIT:C35785",
-                "MEDDRA:10028299",
-                "MEDDRA:10028362",
-                "MEDDRA:10033466",
-                "MESH:D063806",
-                "SNOMEDCT:68962001",
-                "MEDDRA:10028322",
-                "MEDDRA:10028332",
-                "MEDDRA:10028323"
-              ],
-              "id": "HP:0003326",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "muscle soreness",
-                "Myalgia",
-                "Muscle Soreness"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9699032,
-            "start": 554,
-            "end": 321150,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12466693': {'publication date': '2002 Nov', 'sentence': 'Preliminary comparison of bromelain and Ibuprofen for delayed onset muscle soreness management.', 'subject score': 1000, 'object score': 840}, 'PMID:19952809': {'publication date': '2010 Mar', 'sentence': 'CONCLUSION: The results of this study suggest that the topical application of ibuprofen is not an effective treatment for muscle soreness after an unaccustomed gym exercise.', 'subject score': 1000, 'object score': 1000}, 'PMID:2078806': {'publication date': '1990 Sep', 'sentence': 'These results indicate that ibuprofen is not an appropriate treatment for delayed onset muscle soreness and damage.', 'subject score': 1000, 'object score': 861}, 'PMID:29082820': {'publication date': '2018 Jan', 'sentence': 'OBJECTIVE: Ibuprofen is a commonly used non-steroidal anti-inflammatory drug administered to treat injuries, joint pain, and recurrent muscular skeletal pain.', 'subject score': 1000, 'object score': 861}, 'PMID:8898521': {'publication date': '1996 Jun', 'sentence': 'RESULTS: Early muscle pain was treated with Ibuprofen.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0231528---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9913360",
-              "object": "HP:0003326",
-              "publications": [
-                "PMID:12466693",
-                "PMID:19952809",
-                "PMID:2078806",
-                "PMID:29082820",
-                "PMID:8898521"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 537452,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C27003",
-          "name": "Acute Pain",
-          "description": "A sensation of discomfort or distress that has a severe or rapid onset.; Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "ICD9:338.1",
-            "SNOMEDCT:274663001",
-            "SYMP:0000839",
-            "MEDDRA:10066714",
-            "MESH:D059787",
-            "UMLS:C0184567",
-            "NCIT:C27003"
-          ],
-          "id": "NCIT:C27003",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Acute pain",
-            "acute pain",
-            "Acute onset pain",
-            "Acute Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 537452,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C27003",
-              "name": "Acute Pain",
-              "description": "A sensation of discomfort or distress that has a severe or rapid onset.; Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "ICD9:338.1",
-                "SNOMEDCT:274663001",
-                "SYMP:0000839",
-                "MEDDRA:10066714",
-                "MESH:D059787",
-                "UMLS:C0184567",
-                "NCIT:C27003"
-              ],
-              "id": "NCIT:C27003",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Acute pain",
-                "acute pain",
-                "Acute onset pain",
-                "Acute Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9343894,
-            "start": 554,
-            "end": 537452,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12017395': {'publication date': '2002 Apr', 'sentence': 'BACKGROUND: Rofecoxib is a selective cyclooxygenase-2 inhibitor indicated for the treatment of acute pain, with similar analgesic efficacy to ibuprofen and naproxen sodium.', 'subject score': 1000, 'object score': 1000}, 'PMID:12216965': {'publication date': '2002 Aug', 'sentence': 'Efficacy of celecoxib versus ibuprofen in the treatment of acute pain: a multicenter, double-blind, randomized controlled trial in acute ankle sprain.', 'subject score': 1000, 'object score': 1000}, 'PMID:12511311': {'publication date': '2003 Jan', 'sentence': 'The objective of this study was to compare the efficacies of celecoxib and ibuprofen for the treatment of acute pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:15763605': {'publication date': '2005 Jan', 'sentence': 'Oxycodone and ibuprofen each have been used effectively as monotherapy and in other combinations for the treatment of acute pain; a fixed combination of these analgesics may improve pain relief in the setting of abdominal or pelvic surgery, where trauma and any resultant inflammation may be present at the same time.', 'subject score': 1000, 'object score': 1000}, 'PMID:16083531': {'publication date': '2005 Aug', 'sentence': 'Non-selective NSAIDs such as ibuprofen and naproxen, which inhibit both COX-1 and COX-2, have proven highly effective and safe in the short-term management of acute pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:16637477': {'publication date': '2006 Apr', 'sentence': 'CLINCAL IMPLICATIONS: The evidence to date fails to demonstrate any therapeutic advantage to using a COX-2 inhibitor to treat acute dental pain compared with ibuprofen.', 'subject score': 1000, 'object score': 901}, 'PMID:19462922': {'publication date': '2009', 'sentence': 'Recent published evidences on ibuprofen and meloxicam confirm the need of faster oral drug absorption to overcome the pathophysiological conditions associated with dental pain (due to excessive vagal nerve suppression) in order to provide relief in acute pain management.', 'subject score': 1000, 'object score': 901}, 'PMID:19624576': {'publication date': '2009 Aug', 'sentence': 'OBJECTIVES: This study compared the analgesic effectiveness of acetaminophen-codeine with that of ibuprofen for children with acute traumatic extremity pain, with the hypothesis that the two medications would demonstrate equivalent reduction in pain scores in an emergency department (ED) setting.', 'subject score': 1000, 'object score': 861}, 'PMID:21197311': {'publication date': '2010 May 25', 'sentence': 'Further data on intravenous ibuprofen are needed to define long-term utilization, management of acute pain, and use in special populations.', 'subject score': 888, 'object score': 1000}, 'PMID:21540741': {'publication date': '2011 Oct', 'sentence': 'A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction.', 'subject score': 1000, 'object score': 1000}, 'PMID:23904576': {'publication date': '2013 Aug', 'sentence': 'BACKGROUND: Effective and safe drug therapy for the management of acute postoperative pain has relied on orally administered analgesics such as ibuprofen, naproxen and acetaminophen, or N-acetyl-p-aminophenol (APAP), as well as combination formulations containing opioids such as hydrocodone with APAP.', 'subject score': 1000, 'object score': 913}, 'PMID:2395047': {'publication date': '1990 Sep', 'sentence': 'Comparison of nonsteroidal anti-inflammatory drugs, ibuprofen and flurbiprofen, with methylprednisolone and placebo for acute pain, swelling, and trismus.', 'subject score': 1000, 'object score': 1000}, 'PMID:23969325': {'publication date': '2014 Jan', 'sentence': 'A Cochrane review of ibuprofen in acute pain suggested that rapidly absorbed formulations of salts, or features to speed absorption, provided better analgesia than standard ibuprofen as the free acid.', 'subject score': 1000, 'object score': 1000}, 'PMID:2689471': {'publication date': '1989 Nov', 'sentence': 'Ibuprofen and acetaminophen in the relief of acute pain: a randomized, double-blind, placebo-controlled study.', 'subject score': 1000, 'object score': 1000}, 'PMID:27052991': {'publication date': '2016 Apr 06', 'sentence': 'A clinical trial comparing Lanconone(r) with ibuprofen for rapid relief in acute joint pain.', 'subject score': 1000, 'object score': 901}, 'PMID:28805281': {'publication date': '2018 01', 'sentence': 'SIGNIFICANCE: This trial showed superior efficacy of 400/100 mg ibuprofen/caffeine, compared to 400 mg ibuprofen alone, for treating acute pain, reflecting that caffeine is an effective analgesic adjuvant.', 'subject score': 790, 'object score': 901}, 'PMID:29022772': {'publication date': '2018 Feb', 'sentence': 'Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), is mostly administered orally and topically to relieve acute pain and fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:29912084': {'publication date': '2018 Jun 14', 'sentence': 'CONCLUSIONS: Ibuprofen resulted to be the most studied nonsteroidal anti-inflammatory drug in the management of acute pain in children; in general, it showed a good safety profile and provided evidence of effectiveness, despite some differences according to the specific clinical context.', 'subject score': 1000, 'object score': 1000}, 'PMID:30154714': {'publication date': '2018', 'sentence': 'Ibuprofen (IBU) is a non-steroidal anti-inflammatory drug (NSAID), which is widely used to reduce fever and treat inflammation and acute pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:30946703': {'publication date': '2019 05', 'sentence': 'CONCLUSION: Paracetamol/metamizole and paracetamol/ibuprofen are equally effective in treatment of acute postoperative pain at home after ambulatory surgery with comparable patient satisfaction levels.', 'subject score': 888, 'object score': 913}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0184567---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9550056",
-              "object": "NCIT:C27003",
-              "publications": [
-                "PMID:12017395",
-                "PMID:12216965",
-                "PMID:12511311",
-                "PMID:15763605",
-                "PMID:16083531",
-                "PMID:16637477",
-                "PMID:19462922",
-                "PMID:19624576",
-                "PMID:21197311",
-                "PMID:21540741",
-                "PMID:23904576",
-                "PMID:2395047",
-                "PMID:23969325",
-                "PMID:2689471",
-                "PMID:27052991",
-                "PMID:28805281",
-                "PMID:29022772",
-                "PMID:29912084",
-                "PMID:30154714",
-                "PMID:30946703"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322145,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0003419",
-          "name": "Low back pain",
-          "description": "An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the lower back. []; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the lower back.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the lower back.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10024998",
-            "MEDDRA:10076433",
-            "MEDDRA:10024890",
-            "UMLS:C0024031",
-            "NCIT:C34788",
-            "HP:0003419",
-            "MEDDRA:10024891",
-            "MEDDRA:10024988",
-            "SNOMEDCT:279039007",
-            "MESH:D017116"
-          ],
-          "id": "HP:0003419",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Lower Back Pain",
-            "Low back pain",
-            "Low Back Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322145,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0003419",
-              "name": "Low back pain",
-              "description": "An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the lower back. []; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the lower back.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the lower back.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10024998",
-                "MEDDRA:10076433",
-                "MEDDRA:10024890",
-                "UMLS:C0024031",
-                "NCIT:C34788",
-                "HP:0003419",
-                "MEDDRA:10024891",
-                "MEDDRA:10024988",
-                "SNOMEDCT:279039007",
-                "MESH:D017116"
-              ],
-              "id": "HP:0003419",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Lower Back Pain",
-                "Low back pain",
-                "Low Back Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9331002,
-            "start": 554,
-            "end": 322145,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12004166': {'publication date': '2002 May 15', 'sentence': 'CONCLUSION: Continuous low-level heat wrap therapy was superior to both acetaminophen and ibuprofen for treating low back pain.', 'subject score': 1000, 'object score': 916}, 'PMID:9206700': {'publication date': '1997 Mar 30', 'sentence': '[High dose ibuprofen in low back pain].', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0024031---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9536612",
-              "object": "HP:0003419",
-              "publications": [
-                "PMID:12004166",
-                "PMID:9206700"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318242,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0002829",
-          "name": "Arthralgia",
-          "description": "Joint pain. [HPO:probinson]; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D018771",
-            "MEDDRA:10023197",
-            "MEDDRA:10033456",
-            "PDQ:CDR0000651641",
-            "MEDDRA:10013088",
-            "HP:0002829",
-            "MEDDRA:10033511",
-            "UMLS:C0857177",
-            "NCIT:C50464",
-            "MEDDRA:10003245",
-            "MEDDRA:10033434",
-            "UMLS:C0003862",
-            "MEDDRA:10033444",
-            "MEDDRA:10000449",
-            "SNOMEDCT:57676002",
-            "MEDDRA:10003244",
-            "MEDDRA:10003239",
-            "MEDDRA:10023222"
-          ],
-          "id": "HP:0002829",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Arthralgia",
-            "arthralgia",
-            "Arthritic pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318242,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002829",
-              "name": "Arthralgia",
-              "description": "Joint pain. [HPO:probinson]; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D018771",
-                "MEDDRA:10023197",
-                "MEDDRA:10033456",
-                "PDQ:CDR0000651641",
-                "MEDDRA:10013088",
-                "HP:0002829",
-                "MEDDRA:10033511",
-                "UMLS:C0857177",
-                "NCIT:C50464",
-                "MEDDRA:10003245",
-                "MEDDRA:10033434",
-                "UMLS:C0003862",
-                "MEDDRA:10033444",
-                "MEDDRA:10000449",
-                "SNOMEDCT:57676002",
-                "MEDDRA:10003244",
-                "MEDDRA:10003239",
-                "MEDDRA:10023222"
-              ],
-              "id": "HP:0002829",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Arthralgia",
-                "arthralgia",
-                "Arthritic pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9241819,
-            "start": 554,
-            "end": 318242,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11904551': {'publication date': '2002 Mar', 'sentence': 'To determine the effectiveness of oral glucosamine with ibuprofen for the relief of joint pain in osteoarthritis a mini-review (Griffiths, 2002) of double-blind randomized controlled trials comparing the two was undertaken.', 'subject score': 1000, 'object score': 1000}, 'PMID:19576941': {'publication date': '2009 Aug 13', 'sentence': 'After being administration of co-therapy with steroid pulse, ibuprofen, methotrexate and phosphodiesterase inhibitor gradually improved her clinical symptoms such as spiky fever, heart failure and arthralgia.', 'subject score': 1000, 'object score': 1000}, 'PMID:29082820': {'publication date': '2018 Jan', 'sentence': 'OBJECTIVE: Ibuprofen is a commonly used non-steroidal anti-inflammatory drug administered to treat injuries, joint pain, and recurrent muscular skeletal pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:31275778': {'publication date': '2019 Apr 27', 'sentence': 'On further questioning, the patient revealed that he had been utilizing an average of 2000 mg of ibuprofen daily during the previous several months in an attempt to control his joint pain.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0003862---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9444914",
-              "object": "HP:0002829",
-              "publications": [
-                "PMID:11904551",
-                "PMID:19576941",
-                "PMID:29082820",
-                "PMID:31275778"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11896164': {'publication date': '2002 Mar 15', 'sentence': \"In conclusion, NCX-2216 is more efficacious than ibuprofen or celecoxib in clearing Abeta deposits from the brains of Tg mice, implying potential benefit in the treatment of Alzheimer's dementia.\", 'subject score': 1000, 'object score': 1000}, 'PMID:11977446': {'publication date': '2002', 'sentence': \"[Ibuprofen for Alzheimer's?].\", 'subject score': 1000, 'object score': 1000}, 'PMID:12804498': {'publication date': '2003', 'sentence': \"SELECTION CRITERIA: Eligibility for this review included all single or multi centre placebo-controlled randomized trials examining the efficacy of ibuprofen in the treatment of people diagnosed with Alzheimer's disease according to internationally accepted criteria.\", 'subject score': 1000, 'object score': 1000}, 'PMID:15485484': {'publication date': '2004 Nov', 'sentence': 'Nonetheless, studies with flurbiprofen or ibuprofen in AD transgenic mice show that the effects on A beta levels or deposition are attained at plasma levels similar to those achieved in humans at therapeutic dosage.', 'subject score': 1000, 'object score': 888}, 'PMID:15506544': {'publication date': '2004', 'sentence': 'Ibuprofen may be a promising new therapeutic avenue for the treatment of neurodegenerative diseases such as AD.', 'subject score': 1000, 'object score': 1000}, 'PMID:33850164': {'publication date': '2021 Apr 13', 'sentence': \"Cromolyn, in a new redesigned dry powder formulation, is being tested in a pivotal clinical trial in combination with low dose ibuprofen to treat early Alzheimer's Disease (AD) subjects.\", 'subject score': 901, 'object score': 850}, 'PMID:9792199': {'publication date': '1998 Sep', 'sentence': \"This theory suggests that the protective effect of smoking and ibuprofen for Alzheimer's disease is caused through LH suppression.\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 307306,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004975",
-          "name": "Alzheimer disease",
-          "description": "A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. [HPO:probinson]; A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. // COMMENTS: Note that this is a bundled term that refers to a disease rather than to phenotypic features. It is retained for convenience since Alzheimer disease is used for annotation of other diseases (e.g., Down syndrome) as if it were a feature. If possible it is preferable to annotate with the precise phenotypic features.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "KEGG.DISEASE:05010",
-            "SNOMEDCT:142811000119104",
-            "MEDDRA:10012292",
-            "UMLS:C1863053",
-            "HP:0002511",
-            "ICD9:331.0",
-            "ORPHANET:238616",
-            "MEDDRA:10012271",
-            "MEDDRA:10001896",
-            "UMLS:C3549448",
-            "UMLS:C0002395",
-            "NCIT:C2866",
-            "DOID:10652",
-            "MONDO:0004975",
-            "EFO:0000249",
-            "NCIT:C146894",
-            "UMLS:C1863052",
-            "SNOMEDCT:230267005",
-            "PSY:01940",
-            "SNOMEDCT:26929004",
-            "OMIM:104300",
-            "ICD10:G30",
-            "MESH:D000544",
-            "MESH:C566299"
-          ],
-          "id": "MONDO:0004975",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Alzheimer's disease",
-            "Alzheimer disease, familial, 1",
-            "Alzheimer Disease, Early-Onset, With Cerebral Amyloid Angiopathy",
-            "Alzheimer's Disease",
-            "Alzheimers Disease",
-            "Alzheimer disease",
-            "Alzheimer disease, protection against",
-            "Alzheimer Disease",
-            "obsolete_Alzheimer's disease",
-            "Alzheimer disease, familial, 1 related phenotypic feature",
-            "Alzheimer's Disease 1"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet",
-            "http://en.wikipedia.org/wiki/alzheimer%27s_disease",
-            "http://www.merriam-webster.com/medical/alzheimer%27s%20disease",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 307306,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004975",
-              "name": "Alzheimer disease",
-              "description": "A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. [HPO:probinson]; A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. // COMMENTS: Note that this is a bundled term that refers to a disease rather than to phenotypic features. It is retained for convenience since Alzheimer disease is used for annotation of other diseases (e.g., Down syndrome) as if it were a feature. If possible it is preferable to annotate with the precise phenotypic features.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "KEGG.DISEASE:05010",
-                "SNOMEDCT:142811000119104",
-                "MEDDRA:10012292",
-                "UMLS:C1863053",
-                "HP:0002511",
-                "ICD9:331.0",
-                "ORPHANET:238616",
-                "MEDDRA:10012271",
-                "MEDDRA:10001896",
-                "UMLS:C3549448",
-                "UMLS:C0002395",
-                "NCIT:C2866",
-                "DOID:10652",
-                "MONDO:0004975",
-                "EFO:0000249",
-                "NCIT:C146894",
-                "UMLS:C1863052",
-                "SNOMEDCT:230267005",
-                "PSY:01940",
-                "SNOMEDCT:26929004",
-                "OMIM:104300",
-                "ICD10:G30",
-                "MESH:D000544",
-                "MESH:C566299"
-              ],
-              "id": "MONDO:0004975",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Alzheimer's disease",
-                "Alzheimer disease, familial, 1",
-                "Alzheimer Disease, Early-Onset, With Cerebral Amyloid Angiopathy",
-                "Alzheimer's Disease",
-                "Alzheimers Disease",
-                "Alzheimer disease",
-                "Alzheimer disease, protection against",
-                "Alzheimer Disease",
-                "obsolete_Alzheimer's disease",
-                "Alzheimer disease, familial, 1 related phenotypic feature",
-                "Alzheimer's Disease 1"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet",
-                "http://en.wikipedia.org/wiki/alzheimer%27s_disease",
-                "http://www.merriam-webster.com/medical/alzheimer%27s%20disease",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9232937,
-            "start": 554,
-            "end": 307306,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11896164': {'publication date': '2002 Mar 15', 'sentence': \"In conclusion, NCX-2216 is more efficacious than ibuprofen or celecoxib in clearing Abeta deposits from the brains of Tg mice, implying potential benefit in the treatment of Alzheimer's dementia.\", 'subject score': 1000, 'object score': 1000}, 'PMID:11977446': {'publication date': '2002', 'sentence': \"[Ibuprofen for Alzheimer's?].\", 'subject score': 1000, 'object score': 1000}, 'PMID:12804498': {'publication date': '2003', 'sentence': \"SELECTION CRITERIA: Eligibility for this review included all single or multi centre placebo-controlled randomized trials examining the efficacy of ibuprofen in the treatment of people diagnosed with Alzheimer's disease according to internationally accepted criteria.\", 'subject score': 1000, 'object score': 1000}, 'PMID:15485484': {'publication date': '2004 Nov', 'sentence': 'Nonetheless, studies with flurbiprofen or ibuprofen in AD transgenic mice show that the effects on A beta levels or deposition are attained at plasma levels similar to those achieved in humans at therapeutic dosage.', 'subject score': 1000, 'object score': 888}, 'PMID:15506544': {'publication date': '2004', 'sentence': 'Ibuprofen may be a promising new therapeutic avenue for the treatment of neurodegenerative diseases such as AD.', 'subject score': 1000, 'object score': 1000}, 'PMID:33850164': {'publication date': '2021 Apr 13', 'sentence': \"Cromolyn, in a new redesigned dry powder formulation, is being tested in a pivotal clinical trial in combination with low dose ibuprofen to treat early Alzheimer's Disease (AD) subjects.\", 'subject score': 901, 'object score': 850}, 'PMID:9792199': {'publication date': '1998 Sep', 'sentence': \"This theory suggests that the protective effect of smoking and ibuprofen for Alzheimer's disease is caused through LH suppression.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0002395---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9436288",
-              "object": "MONDO:0004975",
-              "publications": [
-                "PMID:11896164",
-                "PMID:11977446",
-                "PMID:12804498",
-                "PMID:15485484",
-                "PMID:15506544",
-                "PMID:33850164",
-                "PMID:9792199"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8909346,
-            "start": 554,
-            "end": 546804,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11545620': {'publication date': '2001 Aug', 'sentence': 'Ibuprofen attenuates early lung injury in endotoxemic, neutropenic rats.', 'subject score': 1000, 'object score': 851}, 'PMID:1568970': {'publication date': '1992 Mar', 'sentence': 'In animals given ECV only, lung injury resulted in extravascular lung water of 18.9 ml/kg after 2 h, which was significantly higher than the 14.8 ml/kg in the group pretreated with ibuprofen.', 'subject score': 1000, 'object score': 888}, 'PMID:15837124': {'publication date': '2005', 'sentence': 'Ibuprofen, a non-steroidal anti-inflammatory drug, has been shown to attenuate injuries in animal models of various neurological diseases.', 'subject score': 1000, 'object score': 1000}, 'PMID:17332198': {'publication date': '2007 Mar', 'sentence': 'CONCLUSIONS: For the treatment of acute traumatic musculoskeletal injuries, ibuprofen provides the best analgesia among the 3 study medications.', 'subject score': 1000, 'object score': 852}, 'PMID:1757329': {'publication date': '1991 Sep', 'sentence': 'These results show that ibuprofen attenuates sepsis-induced injury and that alterations of acute septic insult are correlated with reduced plasma TNF activity in septic animals given ibuprofen.', 'subject score': 1000, 'object score': 851}, 'PMID:1846066': {'publication date': '1991 Jan', 'sentence': 'Sepsis-induced lung injury and the effects of ibuprofen pretreatment.', 'subject score': 888, 'object score': 833}, 'PMID:29082820': {'publication date': '2018 Jan', 'sentence': 'OBJECTIVE: Ibuprofen is a commonly used non-steroidal anti-inflammatory drug administered to treat injuries, joint pain, and recurrent muscular skeletal pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:3112984': {'publication date': '1987 Aug', 'sentence': 'These results indicate that a combination of both histamine H1 and H2 receptor blockers and the cyclooxygenase inhibitor, ibuprofen, is effective and essential in the treatment of hypoxemia, early pulmonary hypertension, and pulmonary microvascular injury in this fulminant model of porcine Pseudomonas ARDS.', 'subject score': 1000, 'object score': 851}, 'PMID:12116291': {'publication date': '2002', 'sentence': 'Pretreatment with p-chlorophenylalanine, indomethacin, ibuprofen, and nimodipine attenuated the SCEP changes immediately after trauma and resulted in a marked reduction in edema formation, BSCB permeability, and blood flow changes at 5 h.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C3263723---SEMMEDDB:",
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0043251---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9104501",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:12116291",
-                "PMID:17332198",
-                "PMID:11545620",
-                "PMID:3112984",
-                "PMID:1757329",
-                "PMID:1568970",
-                "PMID:29082820",
-                "PMID:1846066",
-                "PMID:15837124"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318690,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100607",
-          "name": "Dysmenorrhea",
-          "description": "Pain during menstruation that interferes with daily activities. [PMID:15686299]; Pain during menstruation that interferes with daily activities.; Pain during menstruation that interferes with daily activities.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0013390",
-            "MEDDRA:10013934",
-            "SNOMEDCT:431416001",
-            "PSY:15620",
-            "MEDDRA:10027324",
-            "SNOMEDCT:266599000",
-            "MEDDRA:10034532",
-            "MEDDRA:10027323",
-            "HP:0100607",
-            "MEDDRA:10013935",
-            "MEDDRA:10033463",
-            "MEDDRA:10027321",
-            "MEDDRA:10033514",
-            "MEDDRA:10011299",
-            "SNOMEDCT:289900009",
-            "NCIT:C34559",
-            "MESH:D004412",
-            "ICD9:625.3"
-          ],
-          "id": "HP:0100607",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Dysmenorrhea"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "PMID:15686299"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318690,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100607",
-              "name": "Dysmenorrhea",
-              "description": "Pain during menstruation that interferes with daily activities. [PMID:15686299]; Pain during menstruation that interferes with daily activities.; Pain during menstruation that interferes with daily activities.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0013390",
-                "MEDDRA:10013934",
-                "SNOMEDCT:431416001",
-                "PSY:15620",
-                "MEDDRA:10027324",
-                "SNOMEDCT:266599000",
-                "MEDDRA:10034532",
-                "MEDDRA:10027323",
-                "HP:0100607",
-                "MEDDRA:10013935",
-                "MEDDRA:10033463",
-                "MEDDRA:10027321",
-                "MEDDRA:10033514",
-                "MEDDRA:10011299",
-                "SNOMEDCT:289900009",
-                "NCIT:C34559",
-                "MESH:D004412",
-                "ICD9:625.3"
-              ],
-              "id": "HP:0100607",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Dysmenorrhea"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "PMID:15686299"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8561205,
-            "start": 554,
-            "end": 318690,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11239634': {'publication date': '2001 Mar', 'sentence': 'CONCLUSION: Continuous low-level topical heat therapy was as effective as ibuprofen for the treatment of dysmenorrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:22069413': {'publication date': '2010 Dec', 'sentence': 'Reflexology method was associated with more reduction of intensity and duration of menstrual pain in comparison with Ibuprofen therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:24944382': {'publication date': '2003 Jun', 'sentence': 'Analgesia with ibuprofen arginate versus conventional ibuprofen for patients with dysmenorrhea: a crossover trial.', 'subject score': 888, 'object score': 1000}, 'PMID:26457698': {'publication date': '2015 Oct 07', 'sentence': 'In summary, we suggest that Chuanxiong oil should be viewed as the best PE for TDD of ibuprofen to treat dysmenorrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:28589173': {'publication date': '2017', 'sentence': 'Ibuprofen and diclofenac were the most commonly used medications to manage dysmenorrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:34064282': {'publication date': '2021 May 21', 'sentence': 'An Evaluation of the Effectiveness of Ibuprofen and Manual Therapy in Young Women with Dysmenorrhea-A Pilot Study.', 'subject score': 1000, 'object score': 1000}, 'PMID:353274': {'publication date': '1978 May', 'sentence': 'Ibuprofen therapy for dysmenorrhea.', 'subject score': 888, 'object score': 1000}, 'PMID:380255': {'publication date': '1979', 'sentence': 'Suppression of menstrual prostaglandins and relief of dysmenorrhea with ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:474640': {'publication date': '1979 Sep 01', 'sentence': 'Relief of dysmenorrhea with the prostaglandin synthetase inhibitor ibuprofen: effect on prostaglandin levels in menstrual fluid.', 'subject score': 861, 'object score': 1000}, 'PMID:6181256': {'publication date': '1982 Jul', 'sentence': 'Naproxen sodium, ibuprofen and a placebo in dysmenorrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:6235745': {'publication date': '1984 Jul 13', 'sentence': 'Since its introduction in the United States in 1974, ibuprofen (Motrin, Upjohn) has been shown to be safe and effective for the treatment of pain, dysmenorrhea, inflammation, and fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:6347048': {'publication date': '1983', 'sentence': 'Ibuprofen and naproxen, 2 arylpropionic acids, are commonly used to treat dysmenorrhea and have fewer side effects than the other agents.', 'subject score': 1000, 'object score': 1000}, 'PMID:6790261': {'publication date': '1981 Jul', 'sentence': 'With the intrauterine device, prostaglandin synthetase inhibitors such as flufenamic acid, ibuprofen and naproxen are able not only to relieve dysmenorrhoea but also to reduce menstrual blood loss to normal levels.', 'subject score': 1000, 'object score': 1000}, 'PMID:6835617': {'publication date': '1983 May', 'sentence': 'A double-blind comparison of a propionic acid derivative (ibuprofen) and a fenamate (mefenamic acid) in the treatment of dysmenorrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:739472': {'publication date': '1978 Oct', 'sentence': 'A clinical trial of indomethacin and ibuprofen in dysmenorrhea.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0013390---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "8748381",
-              "object": "HP:0100607",
-              "publications": [
-                "PMID:11239634",
-                "PMID:22069413",
-                "PMID:24944382",
-                "PMID:26457698",
-                "PMID:28589173",
-                "PMID:34064282",
-                "PMID:353274",
-                "PMID:380255",
-                "PMID:474640",
-                "PMID:6181256",
-                "PMID:6235745",
-                "PMID:6347048",
-                "PMID:6790261",
-                "PMID:6835617",
-                "PMID:739472"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318433,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012228",
-          "name": "Tension-type headache",
-          "description": "A headache associated with muscle tightness which may radiate to other parts of the body.; A common primary headache disorder, characterized by a dull, non-pulsatile, diffuse, band-like (or vice-like) PAIN of mild to moderate intensity in the HEAD; SCALP; or NECK. The subtypes are classified by frequency and severity of symptoms. There is no clear cause even though it has been associated with MUSCLE CONTRACTION and stress. (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1); A type of headache that last hours with continuous pain of mild or moderate intensity, bilateral location, a pressing/tightening (non-pulsating) quality and that is not aggravated by routine physical activity such as walking or climbing stairs. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:52080",
-            "NCIT:C117070",
-            "MEDDRA:10043271",
-            "ICD9:307.81",
-            "MEDDRA:10085807",
-            "SNOMEDCT:398057008",
-            "MEDDRA:10043269",
-            "HP:0012228",
-            "UMLS:C0033893",
-            "SNOMEDCT:66551002",
-            "MESH:D018781",
-            "ICD9:339.1",
-            "MEDDRA:10019226"
-          ],
-          "id": "HP:0012228",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Tension-type headache",
-            "Tension Headache",
-            "Tension headache",
-            "Tension-Type Headache",
-            "Tension type headache"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318433,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012228",
-              "name": "Tension-type headache",
-              "description": "A headache associated with muscle tightness which may radiate to other parts of the body.; A common primary headache disorder, characterized by a dull, non-pulsatile, diffuse, band-like (or vice-like) PAIN of mild to moderate intensity in the HEAD; SCALP; or NECK. The subtypes are classified by frequency and severity of symptoms. There is no clear cause even though it has been associated with MUSCLE CONTRACTION and stress. (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1); A type of headache that last hours with continuous pain of mild or moderate intensity, bilateral location, a pressing/tightening (non-pulsating) quality and that is not aggravated by routine physical activity such as walking or climbing stairs. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:52080",
-                "NCIT:C117070",
-                "MEDDRA:10043271",
-                "ICD9:307.81",
-                "MEDDRA:10085807",
-                "SNOMEDCT:398057008",
-                "MEDDRA:10043269",
-                "HP:0012228",
-                "UMLS:C0033893",
-                "SNOMEDCT:66551002",
-                "MESH:D018781",
-                "ICD9:339.1",
-                "MEDDRA:10019226"
-              ],
-              "id": "HP:0012228",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Tension-type headache",
-                "Tension Headache",
-                "Tension headache",
-                "Tension-Type Headache",
-                "Tension type headache"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8512565,
-            "start": 554,
-            "end": 318433,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11195471': {'publication date': '2001 Jan', 'sentence': 'Is the combination of ibuprofen and caffeine effective for the treatment of a tension-type headache?', 'subject score': 1000, 'object score': 1000}, 'PMID:11560814': {'publication date': '2001 Oct', 'sentence': 'Simple analgesics such as ibuprofen, aspirin, and acetaminophen have long been used in the treatment of tension-type headache.', 'subject score': 1000, 'object score': 1000}, 'PMID:12799904': {'publication date': '2000 Feb', 'sentence': 'Headache of acute onset usually will be treated with analgesic substances like paracetamol, acetylsalicylic acid or ibuprofen, the first one being the reference drug for tension-type headache in childhood.', 'subject score': 1000, 'object score': 1000}, 'PMID:16141970': {'publication date': '2005 Jul', 'sentence': 'Ibuprofen (800 mg) is currently the leading choice for the treatment of acute TTH because of its very good gastro-intestinal tolerance, followed by sodium naproxen (825 mg).', 'subject score': 1000, 'object score': 916}, 'PMID:25526232': {'publication date': '2015 Jan', 'sentence': 'METHODS: Pooled analysis comparing the safety of single-dose IBU(Na) (512 mg; equivalent to 400 mg IBU free acid; n = 362) with standard IBU tablets (400 mg; n = 342) and placebo (n = 187) across five Phase III, randomized, placebo-controlled, double-blind studies evaluating IBU(Na) for treatment of postoperative dental pain, tension-type headache, or fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:25907021': {'publication date': '2015 May', 'sentence': 'Do low doses of ibuprofen - as used for TTH - increase the risk of heart attacks?', 'subject score': 1000, 'object score': 1000}, 'PMID:26819724': {'publication date': '2015', 'sentence': 'BACKGROUND: Ibuprofen is known to be efficacious in the treatment of tension-type headache, the most common form of primary headache.', 'subject score': 1000, 'object score': 1000}, 'PMID:7555617': {'publication date': '1995', 'sentence': 'The results of this clearly indicate that ketoprofen in a dosage of 12.5 or 25 mg, compared to 200 mg ibuprofen and 275 mg naproxen sodium, is an effective and safe treatment in tension-type headache.', 'subject score': 790, 'object score': 1000}, 'PMID:9013368': {'publication date': '1996 Dec', 'sentence': 'Nonprescription ibuprofen and acetaminophen in the treatment of tension-type headache.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0033893---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "8698382",
-              "object": "HP:0012228",
-              "publications": [
-                "PMID:11195471",
-                "PMID:11560814",
-                "PMID:12799904",
-                "PMID:16141970",
-                "PMID:25526232",
-                "PMID:25907021",
-                "PMID:26819724",
-                "PMID:7555617",
-                "PMID:9013368"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321390,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005277",
-          "name": "migraine disorder",
-          "description": "A common, severe type of vascular headache often associated with increased sympathetic activity, resulting in nausea, vomiting, and light sensitivity.; A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1); Migraine is a chronic neurological disorder characterized by episodic attacks of headache and associated symptoms. [HPO:probinson, PMID:15304572]; What are migraines? Migraines are a recurring type of headache. They cause moderate to severe pain that is throbbing or pulsing. The pain is often on one side of your head. You may also have other symptoms, such as nausea and weakness. You may be sensitive to light and sound. What causes migraines? Researchers believe that migraine has a genetic cause. There are also a number of factors that can trigger a migraine. These factors vary from person to person, and they include: Stress Anxiety Hormonal changes in women Bright or flashing lights Loud noises Strong smells Medicines Too much or not enough sleep Sudden changes in weather or environment Overexertion (too much physical activity) Tobacco Caffeine or caffeine withdrawal Skipped meals Medication overuse (taking medicine for migraines too often)  Some people have found that certain foods or ingredients can trigger headaches, especially when they are combined with other triggers. These foods and ingredients include: Alcohol Chocolate Aged cheeses Monosodium glutamate (MSG) Some fruits and nuts Fermented or pickled goods Yeast Cured or processed meats  Who is at risk for migraines? About 12% of Americans get migraines. They can affect anyone, but you are more likely to have them if you: Are a woman. Women are three times more likely than men to get migraines. Have a family history of migraines. Most people with migraines have family members who have migraines. Have other medical conditions, such as depression, anxiety, bipolar disorder, sleep disorders, and epilepsy.  What are the symptoms of migraines? There are four different phases of migraines. You may not always go through every phase each time you have a migraine.: Prodome. This phase starts up to 24 hours before you get the migraine. You have early signs and symptoms, such as food cravings, unexplained mood changes, uncontrollable yawning, fluid retention, and increased urination. Aura. If you have this phase, you might see flashing or bright lights or zig-zag lines. You may have muscle weakness or feel like you are being touched or grabbed. An aura can happen just before or during a migraine. Headache. A migraine usually starts gradually and then becomes more severe. It typically causes throbbing or pulsing pain, which is often on one side of your head. But sometimes you can have a migraine without a headache. Other migraine symptoms may include  Increased sensitivity to light, noise, and odors Nausea and vomiting Worsened pain when you move, cough, or sneeze  Postdrome (following the headache). You may feel exhausted, weak, and confused after a migraine. This can last up to a day.  Migraines are more common in the morning; people often wake up with them. Some people have migraines at predictable times, such as before menstruation or on weekends following a stressful week of work. How are migraines diagnosed? To make a diagnosis, your health care provider will: Take your medical history Ask about your symptoms Do a physical and neurological exam  An important part of diagnosing migraines is to rule out other medical conditions which could be causing the symptoms. So you may also have blood tests, an MRI or CT scan, or other tests. How are migraines treated? There is no cure for migraines. Treatment focuses on relieving symptoms and preventing additional attacks. There are different types of medicines to relieve symptoms. They include triptan drugs, ergotamine drugs, and pain relievers. The sooner you take the medicine, the more effective it is. There are also other things you can do to feel better: Resting with your eyes closed in a quiet, darkened room Placing a cool cloth or ice pack on your forehead Drinking fluids  There are some lifestyle changes you can make to prevent migraines: Stress management strategies, such as exercise, relaxation techniques, and biofeedback, may reduce the number and severity of migraines. Biofeedback uses electronic devices to teach you to control certain body functions, such as your heartbeat, blood pressure, and muscle tension. Make a log of what seems to trigger your migraines. You can learn what you need to avoid, such as certain foods and medicines. It also help you figure out what you should do, such as establishing a consistent sleep schedule and eating regular meals. Hormone therapy may help some women whose migraines seem to be linked to their menstrual cycle If you have obesity, losing weight may also be helpful  If you have frequent or severe migraines, you may need to take medicines to prevent further attacks. Talk with your health care provider about which drug would be right for you. Certain natural treatments, such as riboflavin (vitamin B2) and coenzyme Q10, may help prevent migraines. If your magnesium level is low, you can try taking magnesium. There is also an herb, butterbur, which some people take to prevent migraines. But butterbur may not be safe for long-term use. Always check with your health care provider before taking any supplements. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10027606",
-            "DOID:6364",
-            "UMLS:C0149931",
-            "EFO:0003821",
-            "NCIT:C89715",
-            "MEDDRA:10027603",
-            "ICD9:346",
-            "MEDDRA:10027611",
-            "MEDDRA:10027599",
-            "MEDDRA:10027608",
-            "HP:0002076",
-            "MESH:D008881",
-            "SNOMEDCT:193030005",
-            "MEDDRA:10027602",
-            "UMLS:C0744641",
-            "MEDDRA:10027605",
-            "UMLS:C0042331",
-            "ICD10:G43",
-            "MONDO:0005277"
-          ],
-          "id": "MONDO:0005277",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_migraine disorder",
-            "Intermittent migraine headaches",
-            "Migraine",
-            "Migraine Disorders",
-            "Migraine Variant",
-            "migraine disorder",
-            "migraine"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/migraine-headache/ds00120",
-            "PMID:15304572",
-            "http://en.wikipedia.org/wiki/migraine",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321390,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005277",
-              "name": "migraine disorder",
-              "description": "A common, severe type of vascular headache often associated with increased sympathetic activity, resulting in nausea, vomiting, and light sensitivity.; A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1); Migraine is a chronic neurological disorder characterized by episodic attacks of headache and associated symptoms. [HPO:probinson, PMID:15304572]; What are migraines? Migraines are a recurring type of headache. They cause moderate to severe pain that is throbbing or pulsing. The pain is often on one side of your head. You may also have other symptoms, such as nausea and weakness. You may be sensitive to light and sound. What causes migraines? Researchers believe that migraine has a genetic cause. There are also a number of factors that can trigger a migraine. These factors vary from person to person, and they include: Stress Anxiety Hormonal changes in women Bright or flashing lights Loud noises Strong smells Medicines Too much or not enough sleep Sudden changes in weather or environment Overexertion (too much physical activity) Tobacco Caffeine or caffeine withdrawal Skipped meals Medication overuse (taking medicine for migraines too often)  Some people have found that certain foods or ingredients can trigger headaches, especially when they are combined with other triggers. These foods and ingredients include: Alcohol Chocolate Aged cheeses Monosodium glutamate (MSG) Some fruits and nuts Fermented or pickled goods Yeast Cured or processed meats  Who is at risk for migraines? About 12% of Americans get migraines. They can affect anyone, but you are more likely to have them if you: Are a woman. Women are three times more likely than men to get migraines. Have a family history of migraines. Most people with migraines have family members who have migraines. Have other medical conditions, such as depression, anxiety, bipolar disorder, sleep disorders, and epilepsy.  What are the symptoms of migraines? There are four different phases of migraines. You may not always go through every phase each time you have a migraine.: Prodome. This phase starts up to 24 hours before you get the migraine. You have early signs and symptoms, such as food cravings, unexplained mood changes, uncontrollable yawning, fluid retention, and increased urination. Aura. If you have this phase, you might see flashing or bright lights or zig-zag lines. You may have muscle weakness or feel like you are being touched or grabbed. An aura can happen just before or during a migraine. Headache. A migraine usually starts gradually and then becomes more severe. It typically causes throbbing or pulsing pain, which is often on one side of your head. But sometimes you can have a migraine without a headache. Other migraine symptoms may include  Increased sensitivity to light, noise, and odors Nausea and vomiting Worsened pain when you move, cough, or sneeze  Postdrome (following the headache). You may feel exhausted, weak, and confused after a migraine. This can last up to a day.  Migraines are more common in the morning; people often wake up with them. Some people have migraines at predictable times, such as before menstruation or on weekends following a stressful week of work. How are migraines diagnosed? To make a diagnosis, your health care provider will: Take your medical history Ask about your symptoms Do a physical and neurological exam  An important part of diagnosing migraines is to rule out other medical conditions which could be causing the symptoms. So you may also have blood tests, an MRI or CT scan, or other tests. How are migraines treated? There is no cure for migraines. Treatment focuses on relieving symptoms and preventing additional attacks. There are different types of medicines to relieve symptoms. They include triptan drugs, ergotamine drugs, and pain relievers. The sooner you take the medicine, the more effective it is. There are also other things you can do to feel better: Resting with your eyes closed in a quiet, darkened room Placing a cool cloth or ice pack on your forehead Drinking fluids  There are some lifestyle changes you can make to prevent migraines: Stress management strategies, such as exercise, relaxation techniques, and biofeedback, may reduce the number and severity of migraines. Biofeedback uses electronic devices to teach you to control certain body functions, such as your heartbeat, blood pressure, and muscle tension. Make a log of what seems to trigger your migraines. You can learn what you need to avoid, such as certain foods and medicines. It also help you figure out what you should do, such as establishing a consistent sleep schedule and eating regular meals. Hormone therapy may help some women whose migraines seem to be linked to their menstrual cycle If you have obesity, losing weight may also be helpful  If you have frequent or severe migraines, you may need to take medicines to prevent further attacks. Talk with your health care provider about which drug would be right for you. Certain natural treatments, such as riboflavin (vitamin B2) and coenzyme Q10, may help prevent migraines. If your magnesium level is low, you can try taking magnesium. There is also an herb, butterbur, which some people take to prevent migraines. But butterbur may not be safe for long-term use. Always check with your health care provider before taking any supplements. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10027606",
-                "DOID:6364",
-                "UMLS:C0149931",
-                "EFO:0003821",
-                "NCIT:C89715",
-                "MEDDRA:10027603",
-                "ICD9:346",
-                "MEDDRA:10027611",
-                "MEDDRA:10027599",
-                "MEDDRA:10027608",
-                "HP:0002076",
-                "MESH:D008881",
-                "SNOMEDCT:193030005",
-                "MEDDRA:10027602",
-                "UMLS:C0744641",
-                "MEDDRA:10027605",
-                "UMLS:C0042331",
-                "ICD10:G43",
-                "MONDO:0005277"
-              ],
-              "id": "MONDO:0005277",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_migraine disorder",
-                "Intermittent migraine headaches",
-                "Migraine",
-                "Migraine Disorders",
-                "Migraine Variant",
-                "migraine disorder",
-                "migraine"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/migraine-headache/ds00120",
-                "PMID:15304572",
-                "http://en.wikipedia.org/wiki/migraine",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8273357,
-            "start": 554,
-            "end": 321390,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10999673': {'publication date': '2000 May', 'sentence': 'Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study.', 'subject score': 1000, 'object score': 1000}, 'PMID:15548924': {'publication date': '2004 Dec', 'sentence': 'The most rigorously studied agents for the acute treatment of migraine are ibuprofen, acetaminophen, and sumatriptan nasal spray, all of which have shown safety and efficacy in controlled trials.', 'subject score': 1000, 'object score': 1000}, 'PMID:15579612': {'publication date': '2004 Dec', 'sentence': 'Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:16018227': {'publication date': '2005 Jun', 'sentence': 'The most rigorously studied agents for the acute treatment of migraine are ibuprofen, acetaminophen, and sumatriptan nasal spray, all of which have shown safety and efficacy in controlled trials.', 'subject score': 1000, 'object score': 1000}, 'PMID:1623513': {'publication date': '1992 Jun', 'sentence': 'The efficacy of ibuprofen, a non-steroidal anti-inflammatory drug, was assessed in the acute treatment of migraine.', 'subject score': 1000, 'object score': 1000}, 'PMID:16492236': {'publication date': '2006 Feb', 'sentence': 'OBJECTIVE: To investigate the efficacy, tolerability, and safety of rofecoxib and ibuprofen for acute migraine treatment.', 'subject score': 1000, 'object score': 851}, 'PMID:16618262': {'publication date': '2006 Mar', 'sentence': 'OBJECTIVE: Compare the effectiveness of a combination analgesic containing acetaminophen, aspirin, and caffeine to that of ibuprofen in the treatment of migraine.', 'subject score': 1000, 'object score': 1000}, 'PMID:17563841': {'publication date': '2007 Jun', 'sentence': 'The objective of this study was to compare the efficacy of rizatriptan and ibuprofen in migraine.', 'subject score': 1000, 'object score': 1000}, 'PMID:17878396': {'publication date': '2007 Nov', 'sentence': 'Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis.', 'subject score': 901, 'object score': 851}, 'PMID:18006958': {'publication date': '2007 Nov', 'sentence': 'Ibuprofen, acetaminophen, and sumatriptan nasal spray are probably beneficial and safe to use in pediatric migraine.', 'subject score': 1000, 'object score': 888}, 'PMID:18612830': {'publication date': '2008', 'sentence': 'So sequential release of MTH (as immediate release) and IB (as sustained release) was suitable for treatment of migraine.', 'subject score': 1000, 'object score': 1000}, 'PMID:20927770': {'publication date': '2010 Oct 06', 'sentence': \"AUTHORS' CONCLUSIONS: Ibuprofen is an effective treatment for acute migraine headaches, providing pain relief in about half of sufferers, but complete relief from pain and associated symptoms for only a minority.\", 'subject score': 1000, 'object score': 901}, 'PMID:21457238': {'publication date': '2011 Apr', 'sentence': 'OBJECTIVE: To evaluate the efficacy and tolerability of telcagepant when co-administered with ibuprofen or acetaminophen for the acute treatment of migraine.', 'subject score': 1000, 'object score': 1000}, 'PMID:23633348': {'publication date': '2013 Apr 30', 'sentence': 'Ibuprofen is an effective treatment for acute migraine headaches, providing pain relief in about half of sufferers, but complete relief from pain and associated symptoms for only a minority.', 'subject score': 1000, 'object score': 901}, 'PMID:23808884': {'publication date': '2014 Feb', 'sentence': 'Effects of acetaminophen and ibuprofen in children with migraine receiving preventive treatment with magnesium.', 'subject score': 1000, 'object score': 1000}, 'PMID:24733408': {'publication date': '2014 Nov', 'sentence': 'Results of a multicenter, double-blind, randomized, parallel-group, placebo-controlled, single-dose study comparing the fixed combination of acetaminophen, acetylsalicylic acid, and caffeine with ibuprofen for acute treatment of patients with severe migraine.', 'subject score': 1000, 'object score': 888}, 'PMID:27091010': {'publication date': '2016 Apr 19', 'sentence': \"AUTHORS' CONCLUSIONS: Low quality evidence from two small trials shows that ibuprofen appears to improve pain freedom for the acute treatment of children with migraine.\", 'subject score': 1000, 'object score': 1000}, 'PMID:27704257': {'publication date': '2016 Nov', 'sentence': 'Patients with intermittent migraines can often be managed with ibuprofen or naproxen taken as needed.', 'subject score': 1000, 'object score': 888}, 'PMID:29034788': {'publication date': '2018 08', 'sentence': 'We analyzed randomized controlled trials (RCTs) and systematic reviews (SRs) that investigate the efficacy and safety of ibuprofen or paracetamol for treatment of acute migraine attacks in children.', 'subject score': 1000, 'object score': 888}, 'PMID:32451827': {'publication date': '2020 May 26', 'sentence': 'CONCLUSIONS: Both paracetamol and ibuprofen are effective and safe for the treatment of acute migraine attacks in children.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0149931---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "8452594",
-              "object": "MONDO:0005277",
-              "publications": [
-                "PMID:10999673",
-                "PMID:15548924",
-                "PMID:15579612",
-                "PMID:16018227",
-                "PMID:1623513",
-                "PMID:16492236",
-                "PMID:16618262",
-                "PMID:17563841",
-                "PMID:17878396",
-                "PMID:18006958",
-                "PMID:18612830",
-                "PMID:20927770",
-                "PMID:21457238",
-                "PMID:23633348",
-                "PMID:23808884",
-                "PMID:24733408",
-                "PMID:27091010",
-                "PMID:27704257",
-                "PMID:29034788",
-                "PMID:32451827"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 543282,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C26791",
-          "name": "Hemorrhage",
-          "description": "Loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels.",
-          "equivalent_curies": [
-            "UMLS:C0019080",
-            "SYMP:0000041",
-            "MEDDRA:10019524",
-            "MEDDRA:10018988",
-            "MEDDRA:10055798",
-            "MEDDRA:10019525",
-            "NCIT:C26791",
-            "MEDDRA:10005103",
-            "MEDDRA:10015867",
-            "SNOMEDCT:50960005",
-            "MP:0001914",
-            "MEDDRA:10019595",
-            "MEDDRA:10019003",
-            "MEDDRA:10005645",
-            "SNOMEDCT:131148009",
-            "MESH:D006470"
-          ],
-          "id": "NCIT:C26791",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hemorrhage",
-            "Hemorrhage"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/books/nbk542273/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 543282,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C26791",
-              "name": "Hemorrhage",
-              "description": "Loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels.",
-              "equivalent_curies": [
-                "UMLS:C0019080",
-                "SYMP:0000041",
-                "MEDDRA:10019524",
-                "MEDDRA:10018988",
-                "MEDDRA:10055798",
-                "MEDDRA:10019525",
-                "NCIT:C26791",
-                "MEDDRA:10005103",
-                "MEDDRA:10015867",
-                "SNOMEDCT:50960005",
-                "MP:0001914",
-                "MEDDRA:10019595",
-                "MEDDRA:10019003",
-                "MEDDRA:10005645",
-                "SNOMEDCT:131148009",
-                "MESH:D006470"
-              ],
-              "id": "NCIT:C26791",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hemorrhage",
-                "Hemorrhage"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/books/nbk542273/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8242675,
-            "start": 554,
-            "end": 543282,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:10974182': {'publication date': '2000 Aug 15', 'sentence': 'A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects.', 'subject score': 1000, 'object score': 901}, 'PMID:16271337': {'publication date': '2005 Nov', 'sentence': 'FBL was measured by radioactive analysis of chromium-51 labeled red cells in stools during baseline and then followed by 4 weeks of treatment with ibuprofen (800 mg 3 times daily) or placebo in 68 healthy volunteers.', 'subject score': 1000, 'object score': 901}, 'PMID:22360152': {'publication date': '2012 May', 'sentence': 'CONCLUSIONS: Dalteparin is superior to the NSAID ibuprofen in preventing extension of superficial thrombophlebitis during the 14-day treatment period with similar relief of pain and no increase in bleeding.', 'subject score': 931, 'object score': 1000}, 'PMID:32546045': {'publication date': '2020 Jun 16', 'sentence': 'Our results suggest that a standing protocol of alternating Acetaminophen and Ibuprofen given every 4 hours improves the post-tonsillectomy hemorrhage rate without increasing ER visits or calls about pain.', 'subject score': 1000, 'object score': 833}, 'PMID:3516203': {'publication date': '1986 Mar', 'sentence': 'To study the effects of a copper-releasing intrauterine contraceptive device (IUCD) and a prostaglandin (PG) synthesis inhibitor, ibuprofen, on menstrual blood loss, 28 healthy women received either a Fincoid 350 or a ML Cu375 device and were then treated in a double-blind randomized manner with ibuprofen (1200 mg daily) or a placebo during their next three menstruations.', 'subject score': 1000, 'object score': 901}, 'PMID:7243136': {'publication date': '1981 Jul', 'sentence': 'Ibuprofen produced a significant reduction in menstrual blood loss; the percentage reduction was greater in women using a Lippes Loop and who had heavier blood loss (39%) than in women using a copper device and who had lighter blood loss (25%).', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0019080---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "8420965",
-              "object": "NCIT:C26791",
-              "publications": [
-                "PMID:10974182",
-                "PMID:16271337",
-                "PMID:22360152",
-                "PMID:32546045",
-                "PMID:3516203",
-                "PMID:7243136"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318890,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-          "name": "rheumatoid arthritis",
-          "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C2884",
-            "PSY:44570",
-            "EFO:0000685",
-            "ICD9:714.0",
-            "KEGG.DISEASE:05323",
-            "MONDO:0008383",
-            "UMLS:C0003873",
-            "UMLS:C1306838",
-            "UMLS:C1833448",
-            "MEDDRA:10037740",
-            "MEDDRA:10039073",
-            "OMIM:180300",
-            "MESH:D001172",
-            "MEDDRA:10003268",
-            "HP:0001370",
-            "ORPHANET:284130",
-            "SNOMEDCT:69896004",
-            "ICD10:M06.9",
-            "DOID:7148",
-            "MEDDRA:10036856",
-            "MEDDRA:10042952"
-          ],
-          "id": "MONDO:0008383",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Proliferative arthritis",
-            "Arthritis, Rheumatoid",
-            "rheumatoid arthritis",
-            "Rheumatoid arthritis",
-            "Rheumatoid Arthritis",
-            "Rheumatoid arthritis related phenotypic feature",
-            "Rheumatoid arthritis, susceptibility to"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-            "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-            "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318890,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-              "name": "rheumatoid arthritis",
-              "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C2884",
-                "PSY:44570",
-                "EFO:0000685",
-                "ICD9:714.0",
-                "KEGG.DISEASE:05323",
-                "MONDO:0008383",
-                "UMLS:C0003873",
-                "UMLS:C1306838",
-                "UMLS:C1833448",
-                "MEDDRA:10037740",
-                "MEDDRA:10039073",
-                "OMIM:180300",
-                "MESH:D001172",
-                "MEDDRA:10003268",
-                "HP:0001370",
-                "ORPHANET:284130",
-                "SNOMEDCT:69896004",
-                "ICD10:M06.9",
-                "DOID:7148",
-                "MEDDRA:10036856",
-                "MEDDRA:10042952"
-              ],
-              "id": "MONDO:0008383",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Proliferative arthritis",
-                "Arthritis, Rheumatoid",
-                "rheumatoid arthritis",
-                "Rheumatoid arthritis",
-                "Rheumatoid Arthritis",
-                "Rheumatoid arthritis related phenotypic feature",
-                "Rheumatoid arthritis, susceptibility to"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-                "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-                "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8219396,
-            "start": 554,
-            "end": 318890,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1095794': {'publication date': '1975 Jul 28', 'sentence': 'Ibuprofen or aspirin in rheumatoid arthritis therapy.', 'subject score': 1000, 'object score': 901}, 'PMID:11718158': {'publication date': '2001 Apr', 'sentence': '(1) The reference treatment for drug-based symptomatic relief of osteoarthritis and rheumatoid arthritis is paracetamol and low-dose ibuprofen.', 'subject score': 901, 'object score': 1000}, 'PMID:1173655': {'publication date': '1975 Jul 28', 'sentence': 'Ibuprofen is a new, mild analgesic agent that may be useful in the symptomatic treatment of rheumatoid arthritis and osteoarthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:12227215': {'publication date': '2002', 'sentence': 'Valdecoxib is at least equally as effective as ibuprofen, naproxen, and diclofenac in the treatment of osteoarthritis and rheumatoid arthritis, but is safer in terms of gastrointestinal toxicity.', 'subject score': 1000, 'object score': 1000}, 'PMID:12528069': {'publication date': '2002 Dec', 'sentence': 'Both rofecoxib and celecoxib reduced the risk of confirmed clinical upper GI events compared with the nonselective NSAIDs naproxen and ibuprofen in patients with osteoarthritis and rheumatoid arthritis not taking low-dose aspirin.', 'subject score': 1000, 'object score': 1000}, 'PMID:14528521': {'publication date': '2003 Oct', 'sentence': 'Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15153172': {'publication date': '2004 Jun 01', 'sentence': 'Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:162672': {'publication date': '1975', 'sentence': 'Two-hundred and eighteen individuals with rheumatoid arthritis were randomly assigned to six months treatment with ibuprofen (900-1800 mg/day) or indomethacin (75-150 mg/day).', 'subject score': 1000, 'object score': 1000}, 'PMID:16941030': {'publication date': '2006 Oct', 'sentence': 'The cardiorenal safety database from the Celecoxib Long-term Arthritis Safety Study (CLASS) was analyzed to examine whether supratherapeutic doses of celecoxib are associated with decreased renal function and blood pressure (BP) effects compared with standard doses of diclofenac and ibuprofen in osteoarthritis (OA) and rheumatoid arthritis (RA) patients.In total, 8059 patients were enrolled; 7968 received at least one dose of study drug (RA: N = 2183; OA: N = 5785).', 'subject score': 1000, 'object score': 901}, 'PMID:20077080': {'publication date': '2010', 'sentence': 'Ibuprofen is a non-narcotic, non-steroidal anti-inflammatory drug used for the treatment of pain, fever, and inflammatory diseases such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2114414': {'publication date': '1990 Jun', 'sentence': 'A double-blind crossover study to compare lysine acetyl salicylate (Aspergesic) with ibuprofen in the treatment of rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:22033211': {'publication date': '2011 Oct 31', 'sentence': 'The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of osteoarthritis and rheumatoid arthritis and to decrease the risk of developing gastric and duodenal ulcers in patients at risk for NSAID-associated ulcers.', 'subject score': 916, 'object score': 1000}, 'PMID:2379535': {'publication date': '1990', 'sentence': 'Pharmacokinetics of S(+)- and R(-)-ibuprofen in volunteers and first clinical experience of S(+)-ibuprofen in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:238275': {'publication date': '1975 May', 'sentence': 'Comparison of benorylate and ibuprofen in the treatment of established rheumatoid arthritis.', 'subject score': 1000, 'object score': 901}, 'PMID:26458405': {'publication date': '2016', 'sentence': 'We studied in vitro effects of three different drugs (ibuprofen, meloxicam and methotrexate) which are often used in rheumatoid arthritis (RA) treatment on human serum paraoxanase1 (PON1) enzyme activity.', 'subject score': 1000, 'object score': 901}, 'PMID:31298072': {'publication date': '2019 Nov', 'sentence': 'Ibuprofen is a non-steroidal anti-inflammatory drug for the treatment of Rheumatoid Arthritis and osteoarthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:319117': {'publication date': '1977 Jan', 'sentence': 'Flurbiprofen and ibuprofen were compared in a six-week double-blind randomized study in 208 patients with rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:32184646': {'publication date': '2020', 'sentence': 'Conclusion: It seems that the aqueous extract of    T. ammi     can be used alone or in combination with ibuprofen to treat RA.', 'subject score': 1000, 'object score': 1000}, 'PMID:328880': {'publication date': '1977', 'sentence': 'Double-blind, multi-centre parallel trial of ketoprofen and ibuprofen in the treatment of rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3297621': {'publication date': '1987 May', 'sentence': 'Published data in small groups of patients indicate that proquazone 300 to 900 mg/day in 3 divided doses is a possible alternative to aspirin, ibuprofen, indomethacin, and naproxen in rheumatoid arthritis, and to indomethacin and ibuprofen in ankylosing spondylitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0003873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "8397426",
-              "object": "MONDO:0008383",
-              "publications": [
-                "PMID:1095794",
-                "PMID:11718158",
-                "PMID:1173655",
-                "PMID:12227215",
-                "PMID:12528069",
-                "PMID:14528521",
-                "PMID:15153172",
-                "PMID:162672",
-                "PMID:16941030",
-                "PMID:20077080",
-                "PMID:2114414",
-                "PMID:22033211",
-                "PMID:2379535",
-                "PMID:238275",
-                "PMID:26458405",
-                "PMID:31298072",
-                "PMID:319117",
-                "PMID:32184646",
-                "PMID:328880",
-                "PMID:3297621"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319030,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319030,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7723973,
-            "start": 554,
-            "end": 319030,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10607493': {'publication date': '2000 Jan', 'sentence': 'DESIGN: Ginger extract was compared to placebo and Ibuprofen in patients with osteoarthritis of the hip or knee in a controlled, double blind, double dummy, cross-over study with a wash-out period of one week followed by three treatment periods in a randomized sequence, each of three weeks duration.', 'subject score': 1000, 'object score': 1000}, 'PMID:10680190': {'publication date': '2000 Feb', 'sentence': 'Glucosamine sulfate is shown to be as good as ibuprofen for osteoarthritis of the knee.', 'subject score': 1000, 'object score': 1000}, 'PMID:10871971': {'publication date': '2000 Jun 26', 'sentence': 'Therefore, we compared the efficacy and safety of the rofecoxib, which specifically inhibits COX-2, with those of the NSAID ibuprofen in patients with OA.', 'subject score': 888, 'object score': 1000}, 'PMID:10937040': {'publication date': '2000 Jul 17', 'sentence': 'DESIGN: 12-week within-patient, randomised, double-blind, placebo-controlled, crossover comparison of ibuprofen with paracetamol for osteoarthritis, involving three pairs of two-week treatment periods for each participating patient.', 'subject score': 1000, 'object score': 1000}, 'PMID:1097489': {'publication date': '1975 Aug', 'sentence': 'In a double-blind multiclinic trial, a new nonsteroidal anti-inflammatory agent (ibuprofen) was compared with an established therapeutic agent (phenylbutazone-alka) for the treatment of osteoarthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:11043057': {'publication date': '2000 Sep 25', 'sentence': 'Trial results have shown pain relief analogous to common NSAIDs (ibuprofen and diclofenac) in patients with osteoarthritis of the hip or knee.', 'subject score': 1000, 'object score': 1000}, 'PMID:11173050': {'publication date': '2001 Feb 19', 'sentence': 'We conclude that acetaminophen, when given at full doses of 4,000 mg/day, is more efficacious than placebo and has comparable efficacy to ibuprofen in the management of patients with osteoarthritis of the knee who have mild to moderate pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:11269574': {'publication date': '2001 Mar', 'sentence': 'The pharmacokinetic interactions between BAY 12-9566 and two nonsteroidal anti-inflammatory drugs (NSAIDs), naproxen and ibuprofen, were investigated in osteoarthritis (OA) patients.', 'subject score': 1000, 'object score': 888}, 'PMID:11409130': {'publication date': '2001 Jun', 'sentence': 'OBJECTIVE: To compare the treatment potential of glucosamine sulfate (GS) and ibuprofen in patients diagnosed with temporomandibular joint (TMJ) osteoarthritis (OA).', 'subject score': 1000, 'object score': 901}, 'PMID:11718158': {'publication date': '2001 Apr', 'sentence': '(1) The reference treatment for drug-based symptomatic relief of osteoarthritis and rheumatoid arthritis is paracetamol and low-dose ibuprofen.', 'subject score': 901, 'object score': 1000}, 'PMID:1173655': {'publication date': '1975 Jul 28', 'sentence': 'Ibuprofen is a new, mild analgesic agent that may be useful in the symptomatic treatment of rheumatoid arthritis and osteoarthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:11792343': {'publication date': '2002 Jan 15', 'sentence': 'Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).', 'subject score': 1000, 'object score': 1000}, 'PMID:12227215': {'publication date': '2002', 'sentence': 'Valdecoxib is at least equally as effective as ibuprofen, naproxen, and diclofenac in the treatment of osteoarthritis and rheumatoid arthritis, but is safer in terms of gastrointestinal toxicity.', 'subject score': 1000, 'object score': 1000}, 'PMID:12362101': {'publication date': '2002 Oct', 'sentence': 'Overall, the data indicate that administration of valdecoxib offers similar efficacy for the treatment of osteoarthritis but improved upper-gastrointestinal safety compared with the conventional NSAIDs, ibuprofen and diclofenac, based on the significantly lower incidence of gastroduodenal ulcers detected by endoscopy.', 'subject score': 1000, 'object score': 1000}, 'PMID:12528069': {'publication date': '2002 Dec', 'sentence': 'Both rofecoxib and celecoxib reduced the risk of confirmed clinical upper GI events compared with the nonselective NSAIDs naproxen and ibuprofen in patients with osteoarthritis and rheumatoid arthritis not taking low-dose aspirin.', 'subject score': 1000, 'object score': 1000}, 'PMID:14528521': {'publication date': '2003 Oct', 'sentence': 'Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1473430': {'publication date': '1992 Dec', 'sentence': 'One hundred sixty-two patients chronically ingesting ibuprofen, piroxicam, or naproxen for osteoarthritis, who had abdominal pain and an endoscopically proven gastric ulcer were evaluated for eight weeks in a randomized, double-blind trial comparing misoprostol (200 micrograms four times daily with meals and at bedtime) (N = 77) with placebo (N = 85).', 'subject score': 1000, 'object score': 1000}, 'PMID:1485367': {'publication date': '1992 Dec', 'sentence': 'Variability in the disposition of ibuprofen enantiomers in osteoarthritis patients.', 'subject score': 872, 'object score': 888}, 'PMID:15229960': {'publication date': '2004 Jul', 'sentence': 'OBJECTIVE: To compare the analgesic efficacy and safety of nonprescription doses of naproxen sodium, ibuprofen, and placebo in patients with osteoarthritis (OA) of the knee.', 'subject score': 1000, 'object score': 1000}, 'PMID:15308513': {'publication date': '2004 Sep', 'sentence': 'The IPSO study: ibuprofen, paracetamol study in osteoarthritis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "7887942",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:10607493",
-                "PMID:10680190",
-                "PMID:10871971",
-                "PMID:10937040",
-                "PMID:1097489",
-                "PMID:11043057",
-                "PMID:11173050",
-                "PMID:11269574",
-                "PMID:11409130",
-                "PMID:11718158",
-                "PMID:1173655",
-                "PMID:11792343",
-                "PMID:12227215",
-                "PMID:12362101",
-                "PMID:12528069",
-                "PMID:14528521",
-                "PMID:1473430",
-                "PMID:1485367",
-                "PMID:15229960",
-                "PMID:15308513"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318533,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-          "name": "Headache",
-          "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10019211",
-            "PSY:22380",
-            "NCIT:C34661",
-            "MEDDRA:10019218",
-            "SNOMEDCT:25064002",
-            "UMLS:C0018681",
-            "MEDDRA:10019231",
-            "HP:0002315",
-            "MEDDRA:10033405",
-            "ICD9:784.0",
-            "MESH:D006261",
-            "SYMP:0000504",
-            "MEDDRA:10008013",
-            "MEDDRA:10019198"
-          ],
-          "id": "HP:0002315",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "headache",
-            "Headache"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-            "PMID:15304572",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318533,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-              "name": "Headache",
-              "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10019211",
-                "PSY:22380",
-                "NCIT:C34661",
-                "MEDDRA:10019218",
-                "SNOMEDCT:25064002",
-                "UMLS:C0018681",
-                "MEDDRA:10019231",
-                "HP:0002315",
-                "MEDDRA:10033405",
-                "ICD9:784.0",
-                "MESH:D006261",
-                "SYMP:0000504",
-                "MEDDRA:10008013",
-                "MEDDRA:10019198"
-              ],
-              "id": "HP:0002315",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "headache",
-                "Headache"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-                "PMID:15304572",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7689692,
-            "start": 554,
-            "end": 318533,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10586487': {'publication date': '1999 Oct 29', 'sentence': 'Besides oxygen, acetazolamide, dexamethasone and especially inhibitors of prostaglandin synthesis such as ibuprofen and naproxen are approved for the treatment of HAH.', 'subject score': 1000, 'object score': 1000}, 'PMID:11014413': {'publication date': '2000 Sep', 'sentence': 'More patients reported complete headache relief with ibuprofen and caffeine administered together than with ibuprofen alone, caffeine alone, or placebo.', 'subject score': 1000, 'object score': 623}, 'PMID:12745039': {'publication date': '2003 May', 'sentence': 'Ibuprofen has been shown to be more effective than placebo in the treatment of high altitude headache (HAH), but nonsteroidal anti-inflammatory agents have been linked to increased incidence of gastrointestinal (GI) side effects and high-altitude pulmonary edema (HAPE).', 'subject score': 1000, 'object score': 851}, 'PMID:15163268': {'publication date': '2004 May', 'sentence': 'Acetaminophen preferable to ibuprofen for pretreatment of electroconvulsive therapy-induced headache.', 'subject score': 1000, 'object score': 861}, 'PMID:15770754': {'publication date': '2005 Feb', 'sentence': 'I often take ibuprofen for my headaches or aching back.', 'subject score': 1000, 'object score': 1000}, 'PMID:16492236': {'publication date': '2006 Feb', 'sentence': \"The mean percentage of patients' attacks with 24-hour sustained headache relief was greater for rofecoxib 50 mg (52.0%) than for rofecoxib 25 mg (47.8%, P < .050) or ibuprofen (39.0%, P < .010).\", 'subject score': 1000, 'object score': 694}, 'PMID:17250728': {'publication date': '2007 Feb', 'sentence': 'Explanatory analyses revealed worsening of headache already in the third week of treatment with ibuprofen alone.', 'subject score': 1000, 'object score': 861}, 'PMID:17628221': {'publication date': '2007 Jul', 'sentence': 'This double-blind cross-over pilot study evaluated the effect of ibuprofen and caffeine compared with ibuprofen and placebo in 12 children with headaches.', 'subject score': 1000, 'object score': 1000}, 'PMID:17854415': {'publication date': '2008 Jan', 'sentence': 'Two hours post-treatment, ibuprofen was associated with an RB 1.50 (95% CI 1.15-1.95) in the generation of headache relief (NNT 2.4) and RB 1.92 (95% CI 1.28-2.86) in the production of complete pain relief (NNT 4.9).', 'subject score': 822, 'object score': 694}, 'PMID:19920719': {'publication date': '2009 Oct', 'sentence': 'Rizatriptan resulted in better relief of headache at 2 hours compared with ibuprofen in allodynic patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:20522287': {'publication date': '2010 May', 'sentence': 'Myth: Ibuprofen is superior to acetaminophen for the treatment of benign headaches in children and adults.', 'subject score': 1000, 'object score': 888}, 'PMID:22703629': {'publication date': '2014 Nov-Dec', 'sentence': 'HAH can be treated with paracetamol or ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:24516940': {'publication date': '2013 Sep-Oct', 'sentence': 'In clinical practice ibuprofen can be used in the treatment of headache, toothache, otalgy, dysmenorrhea, neuralgia, arthralgia, myalgia, abdominal pain and fever: it is the first choice for these common diseases.', 'subject score': 851, 'object score': 1000}, 'PMID:26230487': {'publication date': '2015 Jul 31', 'sentence': 'Ibuprofen is one of a number of analgesics suggested for acute treatment of headaches in frequent episodic TTH.', 'subject score': 1000, 'object score': 1000}, 'PMID:28852973': {'publication date': '2018 Jan', 'sentence': 'For benign causes, symptomatic treatment with analgesics like paracetamol or ibuprofen would suffice initially, while identification of the underlying condition would lead to further appropriate management, particularly in primary headaches.', 'subject score': 1000, 'object score': 888}, 'PMID:29483787': {'publication date': '2017 Mar', 'sentence': 'The use of ibuprofen and acetaminophen for acute headache in the postconcussive youth: A pilot study.', 'subject score': 1000, 'object score': 888}, 'PMID:31988769': {'publication date': '2020 Jan-Dec', 'sentence': 'She had taken ibuprofen for headache.', 'subject score': 1000, 'object score': 1000}, 'PMID:32057631': {'publication date': '2020 Feb 10', 'sentence': 'CONCLUSIONS: Metoclopramide and ibuprofen may be effective alternative treatment options in HAH and AMS, especially for those patients who additionally report nausea.', 'subject score': 1000, 'object score': 1000}, 'PMID:32334535': {'publication date': '2020 Apr 25', 'sentence': 'We here discuss this concern in relation to headache treatment and conclude that, based on current evidence, there is no reason to abandon treatment of headache patients with RAS inhibitors or ibuprofen.', 'subject score': 1000, 'object score': 888}, 'PMID:36107402': {'publication date': '2022 Sep 15', 'sentence': 'Non-opioid analgesics like ibuprofen or acetaminophen may be prescribed for short-term headache relief but clinicians need to be cautious with long-term medication overuse in those whose headache symptoms persist.', 'subject score': 1000, 'object score': 658}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0018681---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "7852264",
-              "object": "HP:0002315",
-              "publications": [
-                "PMID:10586487",
-                "PMID:11014413",
-                "PMID:12745039",
-                "PMID:15163268",
-                "PMID:15770754",
-                "PMID:16492236",
-                "PMID:17250728",
-                "PMID:17628221",
-                "PMID:17854415",
-                "PMID:19920719",
-                "PMID:20522287",
-                "PMID:22703629",
-                "PMID:24516940",
-                "PMID:26230487",
-                "PMID:28852973",
-                "PMID:29483787",
-                "PMID:31988769",
-                "PMID:32057631",
-                "PMID:32334535",
-                "PMID:36107402"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317818,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011827",
-          "name": "patent ductus arteriosus",
-          "description": "In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences. [HPO:probinson, PMID:20421261]; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "DOID:13832",
-            "UMLS:C0013274",
-            "ORPHANET:706",
-            "ICD9:747.0",
-            "SNOMEDCT:83330001",
-            "HP:0001643",
-            "MESH:D004374",
-            "OMIM.PS:607411",
-            "ICD10:Q25.0",
-            "NCIT:C84492",
-            "MONDO:0011827"
-          ],
-          "id": "MONDO:0011827",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Patent ductus arteriosus",
-            "patent ductus arteriosus",
-            "Patent Ductus Arteriosus",
-            "Ductus Arteriosus, Patent"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:20421261"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317818,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011827",
-              "name": "patent ductus arteriosus",
-              "description": "In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences. [HPO:probinson, PMID:20421261]; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "DOID:13832",
-                "UMLS:C0013274",
-                "ORPHANET:706",
-                "ICD9:747.0",
-                "SNOMEDCT:83330001",
-                "HP:0001643",
-                "MESH:D004374",
-                "OMIM.PS:607411",
-                "ICD10:Q25.0",
-                "NCIT:C84492",
-                "MONDO:0011827"
-              ],
-              "id": "MONDO:0011827",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Patent ductus arteriosus",
-                "patent ductus arteriosus",
-                "Patent Ductus Arteriosus",
-                "Ductus Arteriosus, Patent"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:20421261"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7689228,
-            "start": 554,
-            "end": 317818,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10586177': {'publication date': '1999 Dec', 'sentence': 'OBJECTIVE: To evaluate the effect of intravenous ibuprofen and indomethacin for treatment of patent ductus arteriosus (PDA) on mesenteric and renal blood flow velocity in preterm infants.', 'subject score': 888, 'object score': 1000}, 'PMID:10834523': {'publication date': '2000 May', 'sentence': 'UNLABELLED: This study was aimed at evaluating the efficacy of ibuprofen in the prophylaxis of patent ductus arteriosus (PDA) in very preterm neonates and at detecting eventual side-effects.', 'subject score': 1000, 'object score': 796}, 'PMID:10974130': {'publication date': '2000 Sep 07', 'sentence': 'CONCLUSIONS: Ibuprofen therapy on the third day of life is as efficacious as indomethacin for the treatment of patent ductus arteriosus in preterm infants with the respiratory distress syndrome and is significantly less likely to induce oliguria.', 'subject score': 888, 'object score': 1000}, 'PMID:11106052': {'publication date': '2000 Nov', 'sentence': 'UNLABELLED: The aim of our study was to evaluate whether the prophylactic use of ibuprofen would reduce the incidence of significant patent ductus arteriosus (PDA) and to confirm the effectiveness of ibuprofen as rescue treatment in closing PDA.', 'subject score': 1000, 'object score': 923}, 'PMID:11424814': {'publication date': '2000', 'sentence': 'We have applied this technique to evaluate the possible effects on cerebral oxygenation and hemodynamics of clinical procedures usually performed on preterm infants:--endotracheal suctioning, and we have demonstrated that the magnitude and the duration of the negative effects of open system are significantly reduced using closed endotracheal suctioning system;--withdrawal and infusion through umbilical vein and artery cause significant changes in cerebral hemodynamics: these effects are significantly reduced after administration of ibuprofen;--treatment of patent ductus arteriosus with ibuprofen does not significantly reduce cerebral perfusion and oxygen availability compared to indomethacin and ibuprofen administration also does not affect cerebral vasoreactivity to arterial carbon dioxide tension;--administration of different types and doses of natural surfactant causes different changes in cerebral hemodynamics and these effects seem to be dose-related.', 'subject score': 1000, 'object score': 1000}, 'PMID:12014386': {'publication date': '2002 Apr', 'sentence': 'In a prospective, randomised, controlled study, we compared INDO and IBU with regard to efficacy and safety for the early non-invasive treatment of PDA.', 'subject score': 1000, 'object score': 1000}, 'PMID:12549803': {'publication date': '2002 Nov', 'sentence': 'BACKGROUND: Ibuprofen given intravenously to premature newborn infants is a proven treatment for patent ductus arteriosus (PDA).', 'subject score': 1000, 'object score': 1000}, 'PMID:12723743': {'publication date': '2003 Apr', 'sentence': 'Ibuprofen is therefore as effective as indomethacin in the treatment of patent ductus arteriosus, and effective as prophylaxis, in premature infants.', 'subject score': 1000, 'object score': 1000}, 'PMID:12804469': {'publication date': '2003', 'sentence': 'SEARCH STRATEGY: Randomized (or quasi-randomized) controlled trials (RCTs) comparing ibuprofen to placebo or indomethacin or mefenamic acid for therapy of PDA were identified by searching the Cochrane Controlled Trials Register (Issue 4, 2002), MEDLINE (1996 - January 2003), CINAHL (1982 - November 2002), EMBASE (1980 - January 2002), reference lists of published RCTs and abstracts from the Pediatric Academic Societies and the European Society for Pediatric Research meetings published in Pediatric Research (1991 - 2002).', 'subject score': 861, 'object score': 1000}, 'PMID:14651538': {'publication date': '2003 Dec', 'sentence': 'CONCLUSIONS: Ibuprofen therapy is as efficacious as indomethacin for the treatment of PDA in preterm infants.', 'subject score': 888, 'object score': 1000}, 'PMID:15263833': {'publication date': '2004', 'sentence': 'BACKGROUND: Ibuprofen is a cyclooxygenase inhibitor that is effective in treating patent ductus arteriosus in preterm infants.', 'subject score': 1000, 'object score': 916}, 'PMID:15303820': {'publication date': '2004 Jul', 'sentence': 'AIM: To discuss intestinal side effects of ibuprofen in the treatment of patent ductus arteriosus, after having observed two cases of spontaneous intestinal perforation following ibuprofen treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:15567009': {'publication date': '2004 Nov 27-Dec 3', 'sentence': 'After day 3, symptomatic patent ductus arteriosus was treated first by open curative ibuprofen, then back-up indometacin, surgery, or both.', 'subject score': 802, 'object score': 916}, 'PMID:15681219': {'publication date': '2005 Feb', 'sentence': 'Ibuprofen provides a further option for neonatologists in the management of PDA.', 'subject score': 1000, 'object score': 1000}, 'PMID:15717178': {'publication date': '2005 Mar', 'sentence': 'We conducted a meta-analysis of randomized trials to compare the efficacy and safety of IBU and INDO for treatment of PDA.', 'subject score': 1000, 'object score': 1000}, 'PMID:15811164': {'publication date': '2005 Apr', 'sentence': 'OBJECTIVE: Intravenous ibuprofen (IBU) has been found to be as effective as indomethacin for the treatment of patent ductus arteriosus (PDA) in preterm infants and has been associated with fewer adverse effects in comparative phase III studies.', 'subject score': 888, 'object score': 1000}, 'PMID:16133044': {'publication date': '2005 Nov', 'sentence': 'Urinary ET-1, AVP and sodium in premature infants treated with indomethacin and ibuprofen for patent ductus arteriosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:16219273': {'publication date': '2005 Sep', 'sentence': 'In this study we compared the safety and efficacy of ibuprofen and indomethacin in the treatment of PDA in preterm infants.', 'subject score': 1000, 'object score': 916}, 'PMID:16235321': {'publication date': '2005 Oct 19', 'sentence': 'SEARCH STRATEGY: Randomized or quasi-randomized controlled trials (RCTs) comparing ibuprofen to placebo or indomethacin or mefenamic acid for therapy of PDA were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 2, 2005), MEDLINE (1996 - July 2005), CINAHL (1982 - July 2005), EMBASE (1980 - July 2005), reference lists of published RCTs and abstracts from the Pediatric Academic Societies and the European Society for Pediatric Research meetings published in Pediatric Research (1991 - April 2005).', 'subject score': 1000, 'object score': 1000}, 'PMID:16260891': {'publication date': '2005 Nov-Dec', 'sentence': 'Effects of ibuprofen and indomethacin on urinary antidiuretic hormone excretion in preterm infants treated for patent ductus arteriosus.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0013274---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "7851777",
-              "object": "MONDO:0011827",
-              "publications": [
-                "PMID:10586177",
-                "PMID:10834523",
-                "PMID:10974130",
-                "PMID:11106052",
-                "PMID:11424814",
-                "PMID:12014386",
-                "PMID:12549803",
-                "PMID:12723743",
-                "PMID:12804469",
-                "PMID:14651538",
-                "PMID:15263833",
-                "PMID:15303820",
-                "PMID:15567009",
-                "PMID:15681219",
-                "PMID:15717178",
-                "PMID:15811164",
-                "PMID:16133044",
-                "PMID:16219273",
-                "PMID:16235321",
-                "PMID:16260891"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7573741,
-            "start": 554,
-            "end": 316891,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10513507': {'publication date': '1999 Jun', 'sentence': 'The WOMAC detected significant differences between ibuprofen and placebo for pain and physical functioning, whereas the SF-36 detected differences for the bodily pain subscale.', 'subject score': 1000, 'object score': 1000}, 'PMID:10550887': {'publication date': '1999', 'sentence': 'Racemic ibuprofen is an important NSAID used in the treatment of pain and inflammation in a variety of musculoskeletal and rheumatic disorders.', 'subject score': 861, 'object score': 1000}, 'PMID:10581086': {'publication date': '1999 Dec', 'sentence': 'Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, indomethacin and ibuprofen are the most widely used drugs for pain, arthritis, cardiovascular diseases and, more recently, the prevention of colon cancer and Alzheimer disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:10716611': {'publication date': '2000 Jan', 'sentence': 'We conclude that khat, like amphetamine and ibuprofen, can relieve pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:11021730': {'publication date': '2000 Oct', 'sentence': 'An open-label evaluation of the efficacy and safety of Stadol NS with ibuprofen in the treatment of pain after removal of impacted wisdom teeth.', 'subject score': 1000, 'object score': 1000}, 'PMID:11021732': {'publication date': '2000 Oct', 'sentence': 'Effectiveness of Stadol NS (butorphanol tartrate) with ibuprofen in the treatment of pain after laser-assisted uvulopalatopharyngoplasty.', 'subject score': 1000, 'object score': 1000}, 'PMID:11113797': {'publication date': '2000 Dec', 'sentence': 'An evaluation of preoperative ibuprofen for treatment of pain associated with orthodontic separator placement.', 'subject score': 888, 'object score': 1000}, 'PMID:11319581': {'publication date': '2000 Mar', 'sentence': 'Less clinical experience has accumulated with ibuprofen, and it remains the second-line treatment for fever and pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:11455373': {'publication date': '2001 Jul', 'sentence': 'In conclusion, these data indicate that ibuprofen taken 60 minutes before separator placement alleviates pain at 2 hours and at bedtime after treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:11554954': {'publication date': '2001 Jul-Aug', 'sentence': 'CONCLUSIONS: Ibuprofen at doses of 200 mg and 400 mg is an efficacious, cost-effective, well-tolerated, single-ingredient nonprescription treatment for pain of migraine headache.', 'subject score': 1000, 'object score': 1000}, 'PMID:11954880': {'publication date': '2002 Feb', 'sentence': 'The aim of this blinded, randomised, multicentre study was to compare the tolerability of aspirin, paracetamol and ibuprofen in common pain resulting from musculoskeletal conditions (MSC) in general practice with patients with other non-MSC pain conditions.', 'subject score': 1000, 'object score': 888}, 'PMID:14558184': {'publication date': '2003 Oct-Nov', 'sentence': 'Advantage was taken of data generated in the paracetamol, aspirin and ibuprofen new tolerability (PAIN) study, a large randomized double-blinded trial of paracetamol, aspirin or ibuprofen for common pain in general practice to attempt this.', 'subject score': 1000, 'object score': 888}, 'PMID:15196644': {'publication date': '2004 Jul 08', 'sentence': 'Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment.', 'subject score': 1000, 'object score': 888}, 'PMID:15219128': {'publication date': '2004 Mar 25', 'sentence': 'Mild-to-moderate pain in noninflammatory arthrosis can be ameliorated by paracetamol or low-dose ibuprofen.', 'subject score': 901, 'object score': 916}, 'PMID:15229960': {'publication date': '2004 Jul', 'sentence': 'CONCLUSION: Over-the-counter doses of naproxen sodium (440/660 mg) and ibuprofen (1200 mg) effectively relieve pain in patients with mild to moderate OA of the knee.', 'subject score': 1000, 'object score': 1000}, 'PMID:1565349': {'publication date': '1992 May', 'sentence': 'This study shows that pain during laser vaporization of the cervix is not due to increased uterine contractions, and that pain was not significantly relieved by ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:15970957': {'publication date': '2005 Jun', 'sentence': 'Context: Ibuprofen is widely used to manage pain and inflammation after orthopaedic trauma, but its effect on acute swelling has not been investigated.', 'subject score': 1000, 'object score': 1000}, 'PMID:16170062': {'publication date': '2005 Sep', 'sentence': 'This is a case report of a child who experienced a possible adverse reaction to paracetamol, in a randomized clinical trial comparing paracetamol with ibuprofen for control of orthodontic pain.', 'subject score': 1000, 'object score': 888}, 'PMID:16885182': {'publication date': '2006 Sep 09', 'sentence': 'Safety and efficacy of routine postoperative ibuprofen for pain and disability related to ectopic bone formation after hip replacement surgery (HIPAID): randomised controlled trial.', 'subject score': 802, 'object score': 1000}, 'PMID:17045356': {'publication date': '2006 Oct 27', 'sentence': 'Theoretically, IBU-BB could sustainably release high concentrations of IBU at the site of the uterine fibroids, which makes it a promising approach for the control of post-embolization pain.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "7732956",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:10513507",
-                "PMID:10550887",
-                "PMID:10581086",
-                "PMID:10716611",
-                "PMID:11021730",
-                "PMID:11021732",
-                "PMID:11113797",
-                "PMID:11319581",
-                "PMID:11455373",
-                "PMID:11554954",
-                "PMID:11954880",
-                "PMID:14558184",
-                "PMID:15196644",
-                "PMID:15219128",
-                "PMID:15229960",
-                "PMID:1565349",
-                "PMID:15970957",
-                "PMID:16170062",
-                "PMID:16885182",
-                "PMID:17045356"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 307910,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005578",
-          "name": "arthritic joint disease",
-          "description": "An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.; Acute or chronic inflammation of JOINTS.; Inflammation of a joint. [HPO:probinson]; If you feel pain and stiffness in your body or have trouble moving around, you might have arthritis. Most kinds of arthritis cause pain and swelling in your joints. Joints are places where two bones meet, such as your elbow or knee. Over time, a swollen joint can become severely damaged. Some kinds of arthritis can also cause problems in your organs, such as your eyes or skin. Types of arthritis include: Osteoarthritis is the most common type of arthritis. It's often related to aging or to an injury. Autoimmune arthritis happens when your body's immune system attacks healthy cells in your body by mistake. Rheumatoid arthritis is the most common form of this kind of arthritis. Juvenile arthritis is a type of arthritis that happens in children. Infectious arthritis is an infection that has spread from another part of the body to the joint. Psoriatic arthritis affects people with psoriasis. Gout is a painful type of arthritis that happens when too much uric acid builds up in the body. It often starts in the big toe.  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0003864",
-            "MEDDRA:10003263",
-            "PSY:03860",
-            "EFO:0005856",
-            "ICD10:M19.90",
-            "MEDDRA:10003246",
-            "MONDO:0005578",
-            "SYMP:0019169",
-            "SNOMEDCT:3723001",
-            "UMLS:C0574941",
-            "NCIT:C2883",
-            "SNOMEDCT:298160000",
-            "DOID:848",
-            "MEDDRA:10023217",
-            "HP:0001369",
-            "MESH:D001168",
-            "MEDDRA:10081014"
-          ],
-          "id": "MONDO:0005578",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Arthritis",
-            "arthritic joint disease",
-            "Inflamed joint",
-            "arthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.arthritis.org/",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=arthritis",
-            "https://www.cdc.gov/arthritis/index.htm",
-            "http://en.wikipedia.org/wiki/arthritis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/001243.htm",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 307910,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005578",
-              "name": "arthritic joint disease",
-              "description": "An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.; Acute or chronic inflammation of JOINTS.; Inflammation of a joint. [HPO:probinson]; If you feel pain and stiffness in your body or have trouble moving around, you might have arthritis. Most kinds of arthritis cause pain and swelling in your joints. Joints are places where two bones meet, such as your elbow or knee. Over time, a swollen joint can become severely damaged. Some kinds of arthritis can also cause problems in your organs, such as your eyes or skin. Types of arthritis include: Osteoarthritis is the most common type of arthritis. It's often related to aging or to an injury. Autoimmune arthritis happens when your body's immune system attacks healthy cells in your body by mistake. Rheumatoid arthritis is the most common form of this kind of arthritis. Juvenile arthritis is a type of arthritis that happens in children. Infectious arthritis is an infection that has spread from another part of the body to the joint. Psoriatic arthritis affects people with psoriasis. Gout is a painful type of arthritis that happens when too much uric acid builds up in the body. It often starts in the big toe.  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0003864",
-                "MEDDRA:10003263",
-                "PSY:03860",
-                "EFO:0005856",
-                "ICD10:M19.90",
-                "MEDDRA:10003246",
-                "MONDO:0005578",
-                "SYMP:0019169",
-                "SNOMEDCT:3723001",
-                "UMLS:C0574941",
-                "NCIT:C2883",
-                "SNOMEDCT:298160000",
-                "DOID:848",
-                "MEDDRA:10023217",
-                "HP:0001369",
-                "MESH:D001168",
-                "MEDDRA:10081014"
-              ],
-              "id": "MONDO:0005578",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Arthritis",
-                "arthritic joint disease",
-                "Inflamed joint",
-                "arthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.arthritis.org/",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=arthritis",
-                "https://www.cdc.gov/arthritis/index.htm",
-                "http://en.wikipedia.org/wiki/arthritis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/001243.htm",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7529126,
-            "start": 554,
-            "end": 307910,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10487161': {'publication date': '1999 Aug', 'sentence': \"I take ibuprofen regularly for my arthritis, but I've heard that it may lead to kidney damage.\", 'subject score': 861, 'object score': 1000}, 'PMID:17003915': {'publication date': '2006 Oct', 'sentence': 'Ibuprofen or Naproxen (PRECISION) trial will assess the relative cardiovascular safety of three of the most commonly used pain relievers in the treatment of arthritis patients, ibuprofen, naproxen and celecoxib.', 'subject score': 1000, 'object score': 888}, 'PMID:21403884': {'publication date': '2011', 'sentence': 'Joint inflammation and early degeneration induced by high-force reaching are attenuated by ibuprofen in an animal model of work-related musculoskeletal disorder.', 'subject score': 1000, 'object score': 1000}, 'PMID:23066177': {'publication date': '2012 Mar', 'sentence': 'Cartilage targeted chemical delivery of naproxen and ibuprofen for the treatment of arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2590270': {'publication date': '1989 Sep', 'sentence': 'Concentrations of Ibuprofen and Protein Concentration and pH-Value in Synovial Fluid and Plasma Following Oral Administration of Ibuprofen in Patients Suffering from Arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:25918809': {'publication date': '2014 Sep', 'sentence': 'In this study, we examined, in comparison with ibuprofen, the inhibitory effects on various inflammatory markers of the most commonly used herbal medicines to treat arthritis, boswellia (Boswellia sapindales), licorice (Glycyrrhiza glabra), guggul (Commiphora wightii), and neem (Azadirachta indica).', 'subject score': 1000, 'object score': 1000}, 'PMID:26883979': {'publication date': '2016 Mar 15', 'sentence': 'Ibuprofen is the first line of treatment for osteoarthritis and arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:26981605': {'publication date': '2016 Mar', 'sentence': 'However, ibuprofen and diclofenac sodium slightly attenuated TMJ inflammation and meloxicam did not affect TMJ inflammation.', 'subject score': 1000, 'object score': 901}, 'PMID:27959716': {'publication date': '2016 12 29', 'sentence': 'Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28379793': {'publication date': '2017 04 06', 'sentence': 'Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:32140283': {'publication date': '2019 Sep 01', 'sentence': 'Case Presentation:         In this report, we described a 15-year-old boy, suffering concurrently both from human leukocyte antigen (HLA)-B27-positive chronic arthritis and CGD, whose arthritis did not respond to treatment with methotrexate and ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:32424605': {'publication date': '2020 May 18', 'sentence': \"This study evaluated the effects of a low-dose AN and ibuprofen (IB) combination on inflammatory parameters in Freund's complete adjuvant-induced arthritis (AIA) and arthritis-induced hepatic metabolic changes.\", 'subject score': 888, 'object score': 875}, 'PMID:3365913': {'publication date': '1988 May', 'sentence': 'The simultaneous disposition of the enantiomers of ibuprofen in synovial fluid and plasma was studied in eight patients with arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3437603': {'publication date': '1987 Nov', 'sentence': 'On the contrary, cyclophosphamide, dexamethasone, or ibuprofen strongly protected the animals from the development of arthritis and/or cured the established arthritis by these dose regimens.', 'subject score': 1000, 'object score': 888}, 'PMID:35234840': {'publication date': '2022 Mar 02', 'sentence': 'Cardiorenal Risk of Celecoxib compared to Naproxen, or Ibuprofen in Arthritis Patients: Insights from the PRECISION trial.', 'subject score': 1000, 'object score': 888}, 'PMID:439358': {'publication date': '1979 Jun 15', 'sentence': 'Three young women with systemic lupus erythematosus who were given ibuprofen for arthritis voluntarily discontinued taking the drug.', 'subject score': 1000, 'object score': 1000}, 'PMID:4864061': {'publication date': '1967 Nov', 'sentence': 'Ibuprofen in the treatment of rheumatoid arthritis and osteo-arthritis.', 'subject score': 1000, 'object score': 861}, 'PMID:5524278': {'publication date': '1970', 'sentence': 'Further experience with ibuprofen in the treatment of arthritis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0003864---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "7686895",
-              "object": "MONDO:0005578",
-              "publications": [
-                "PMID:10487161",
-                "PMID:17003915",
-                "PMID:21403884",
-                "PMID:23066177",
-                "PMID:2590270",
-                "PMID:25918809",
-                "PMID:26883979",
-                "PMID:26981605",
-                "PMID:27959716",
-                "PMID:28379793",
-                "PMID:32140283",
-                "PMID:32424605",
-                "PMID:3365913",
-                "PMID:3437603",
-                "PMID:35234840",
-                "PMID:439358",
-                "PMID:4864061",
-                "PMID:5524278"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 212250,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-          "name": "Fever",
-          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10037660",
-            "MEDDRA:10020083",
-            "MEDDRA:10005911",
-            "UMLS:C0015967",
-            "HP:0001945",
-            "NCIT:C3038",
-            "MEDDRA:10073718",
-            "MEDDRA:10043204",
-            "MEDDRA:10037668",
-            "PDQ:CDR0000775882",
-            "PSY:19660",
-            "SNOMEDCT:386661006",
-            "MEDDRA:10016558",
-            "MEDDRA:10037663",
-            "SNOMEDCT:50177009",
-            "SYMP:0000613",
-            "MESH:D005334"
-          ],
-          "id": "HP:0001945",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "fever",
-            "Fever"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:9759682",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 212250,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-              "name": "Fever",
-              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10037660",
-                "MEDDRA:10020083",
-                "MEDDRA:10005911",
-                "UMLS:C0015967",
-                "HP:0001945",
-                "NCIT:C3038",
-                "MEDDRA:10073718",
-                "MEDDRA:10043204",
-                "MEDDRA:10037668",
-                "PDQ:CDR0000775882",
-                "PSY:19660",
-                "SNOMEDCT:386661006",
-                "MEDDRA:10016558",
-                "MEDDRA:10037663",
-                "SNOMEDCT:50177009",
-                "SYMP:0000613",
-                "MESH:D005334"
-              ],
-              "id": "HP:0001945",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "fever",
-                "Fever"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:9759682",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7114783,
-            "start": 554,
-            "end": 212250,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:10191452': {'publication date': '1999 Mar', 'sentence': 'Paracetamol or ibuprofen in febrile children.', 'subject score': 1000, 'object score': 888}, 'PMID:10492798': {'publication date': '1999', 'sentence': 'Paracetamol and ibuprofen for treatment of fever in Malawian children aged less than five years.', 'subject score': 1000, 'object score': 1000}, 'PMID:10506264': {'publication date': '1999 Oct', 'sentence': 'OBJECTIVE: To compare the incidence of serious adverse clinical events among children <2 years old given ibuprofen and acetaminophen to control fever.', 'subject score': 740, 'object score': 1000}, 'PMID:10638387': {'publication date': '1999 Nov', 'sentence': 'CONCLUSION: The results of this study demonstrated that the anti-pyretic effectiveness of nimesulide is better than paracetamol and ibuprofen in febrile children with URTIs.', 'subject score': 1000, 'object score': 888}, 'PMID:10790455': {'publication date': '2000 May', 'sentence': 'CONCLUSION: Acetaminophen and ibuprofen are commonly being used in an alternating manner for management of fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:10811855': {'publication date': '2000 May', 'sentence': 'Both celecoxib, a selective COX-2 inhibitor, and ibuprofen attenuated the pyrexial, but not the chronotropic, response to LPS.', 'subject score': 1000, 'object score': 1000}, 'PMID:11141364': {'publication date': '2000 Nov', 'sentence': 'CONCLUSIONS: Ibuprofen is effective in the treatment of fever in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:11141365': {'publication date': '2000 Nov', 'sentence': 'AIM: To compare the efficacy and to evaluate the clinical bioequivalence of two different formulations of ibuprofen (suspension and effervescent granules) in febrile children.', 'subject score': 1000, 'object score': 888}, 'PMID:11319581': {'publication date': '2000 Mar', 'sentence': 'Less clinical experience has accumulated with ibuprofen, and it remains the second-line treatment for fever and pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:11393101': {'publication date': '2001 Feb', 'sentence': 'Before he developed abdominal distension, the patient had suffered from an upper respiratory tract infection with fever for about 2 weeks, which was treated intermittently with ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:11861992': {'publication date': '2002 Feb', 'sentence': 'Acetaminophen (paracetamol) and ibuprofen are accepted as the standard medical treatments for fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:14651311': {'publication date': '2003 Sep-Oct', 'sentence': 'Alternating acetaminophen and ibuprofen in the febrile child: examination of the evidence regarding efficacy and safety.', 'subject score': 1000, 'object score': 888}, 'PMID:1506123': {'publication date': '1992 Mar', 'sentence': 'Efficacy of ibuprofen in pediatric patients with fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:15327170': {'publication date': '2004 Jul', 'sentence': 'Either acetaminophen or ibuprofen can be given to treat the fever, and rectal forms of these medicines are preferred in the early treatment phase.', 'subject score': 1000, 'object score': 1000}, 'PMID:1564127': {'publication date': '1992 Mar', 'sentence': 'Accordingly, the authors measured plasma levels of acetaminophen and ibuprofen in 153 febrile children for 6 hours after a single dose of either acetaminophen (12.5 mg/kg) or ibuprofen (5 or 10 mg/kg).', 'subject score': 1000, 'object score': 790}, 'PMID:16051074': {'publication date': '2005 Aug', 'sentence': 'CONCLUSION: Ibuprofen was largely used in febrile children.', 'subject score': 1000, 'object score': 888}, 'PMID:1621669': {'publication date': '1992 May', 'sentence': 'Comparison of multidose ibuprofen and acetaminophen therapy in febrile children.', 'subject score': 861, 'object score': 888}, 'PMID:16461878': {'publication date': '2006 Feb', 'sentence': 'Antipyretic treatment in young children with fever: acetaminophen, ibuprofen, or both alternating in a randomized, double-blind study.', 'subject score': 1000, 'object score': 1000}, 'PMID:16464962': {'publication date': '2006 May', 'sentence': 'Randomised controlled trial of combined paracetamol and ibuprofen for fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:17243306': {'publication date': '2006 Jul', 'sentence': 'Alternating ibuprofen and acetaminophen may be more effective in the treatment of fever in children.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0015967---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "7258310",
-              "object": "HP:0001945",
-              "publications": [
-                "PMID:10191452",
-                "PMID:10492798",
-                "PMID:10506264",
-                "PMID:10638387",
-                "PMID:10790455",
-                "PMID:10811855",
-                "PMID:11141364",
-                "PMID:11141365",
-                "PMID:11319581",
-                "PMID:11393101",
-                "PMID:11861992",
-                "PMID:14651311",
-                "PMID:1506123",
-                "PMID:15327170",
-                "PMID:1564127",
-                "PMID:16051074",
-                "PMID:1621669",
-                "PMID:16461878",
-                "PMID:16464962",
-                "PMID:17243306"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 630575,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C78640",
-          "name": "Toothache",
-          "description": "A painful sensation originating from a tooth.; Pain in the adjacent areas of the teeth.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10059723",
-            "MESH:D014098",
-            "NCIT:C78640",
-            "MEDDRA:10044055",
-            "UMLS:C0040460",
-            "SYMP:0000438",
-            "SNOMEDCT:27355003",
-            "MEDDRA:10044017",
-            "MEDDRA:10030090"
-          ],
-          "id": "NCIT:C78640",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "toothache",
-            "Toothache"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://www.merriam-webster.com/dictionary/toothache"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 630575,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C78640",
-              "name": "Toothache",
-              "description": "A painful sensation originating from a tooth.; Pain in the adjacent areas of the teeth.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10059723",
-                "MESH:D014098",
-                "NCIT:C78640",
-                "MEDDRA:10044055",
-                "UMLS:C0040460",
-                "SYMP:0000438",
-                "SNOMEDCT:27355003",
-                "MEDDRA:10044017",
-                "MEDDRA:10030090"
-              ],
-              "id": "NCIT:C78640",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "toothache",
-                "Toothache"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://www.merriam-webster.com/dictionary/toothache"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7069584,
-            "start": 554,
-            "end": 630575,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10096266': {'publication date': '1999 Mar', 'sentence': 'A double-blind, parallel-group study compared the analgesic efficacy of rofecoxib to placebo and ibuprofen in 102 patients with dental pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:10650365': {'publication date': '1999 Jun', 'sentence': 'COX-2 inhibitors: better than ibuprofen for dental pain?', 'subject score': 1000, 'object score': 1000}, 'PMID:11056966': {'publication date': '2000', 'sentence': 'A new therapeutic scheme of ibuprofen to treat postoperatory endodontic dental pain.', 'subject score': 1000, 'object score': 824}, 'PMID:11771573': {'publication date': '2001 Nov', 'sentence': 'For example, 200 mg of S(+)-ibuprofen has been found to be superior or at least equivalent to 400 mg of the racemate in the relief of dental pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:12162474': {'publication date': '2002 Aug', 'sentence': 'Efficacy and tolerability of nonprescription ibuprofen versus celecoxib for dental pain.', 'subject score': 861, 'object score': 1000}, 'PMID:21659629': {'publication date': '2012 May', 'sentence': 'This prospective, double-blind, randomized clinical study compared efficacy and safety of oral SCIO-469, ibuprofen, and placebo in postsurgical dental pain.', 'subject score': 1000, 'object score': 901}, 'PMID:24516940': {'publication date': '2013 Sep-Oct', 'sentence': 'In clinical practice ibuprofen can be used in the treatment of headache, toothache, otalgy, dysmenorrhea, neuralgia, arthralgia, myalgia, abdominal pain and fever: it is the first choice for these common diseases.', 'subject score': 851, 'object score': 1000}, 'PMID:269932': {'publication date': '1977 Nov', 'sentence': 'The object of a study was to evaluate the analgesic efficacy of ibuprofen for dental pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:32271183': {'publication date': '2020 Apr 07', 'sentence': 'Efficacy and Safety of Single and Multiple Doses of a Fixed-dose Combination of Ibuprofen and Acetaminophen in the Treatment of Postsurgical Dental Pain: Results from Two Phase 3, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Studies.', 'subject score': 1000, 'object score': 901}, 'PMID:32506309': {'publication date': '2020 Jun 06', 'sentence': 'Evaluation of Fixed-Dose Combinations of Ibuprofen and Acetaminophen in the Treatment of Postsurgical Dental Pain: A Pilot, Dose-Ranging, Randomized Study.INTRODUCTION: Ibuprofen and acetaminophen provide analgesia via different mechanisms of action and do not exhibit drug-drug interactions; therefore, combining low doses of each may provide greater efficacy without compromising safety.', 'subject score': 1000, 'object score': 901}, 'PMID:33094042': {'publication date': '2020 Sep 16', 'sentence': 'We are reporting a case of a 39-year-old man who had a syncopal episode after he took cephalexin and ibuprofen for toothache.', 'subject score': 1000, 'object score': 1000}, 'PMID:3536289': {'publication date': '1986 Sep', 'sentence': 'The relative efficacy of ibuprofen in dental pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:3547351': {'publication date': '1986 Nov-Dec', 'sentence': 'Analgesic efficacy of low-dose ibuprofen in dental extraction pain.', 'subject score': 901, 'object score': 901}, 'PMID:6465164': {'publication date': '1984 Jul 13', 'sentence': 'Five studies on ibuprofen for postsurgical dental pain.', 'subject score': 1000, 'object score': 901}, 'PMID:766799': {'publication date': '1976 Feb', 'sentence': 'Idarac v ibuprofen in the relief of dental pain.', 'subject score': 802, 'object score': 1000}, 'PMID:9516027': {'publication date': '1998 Jan', 'sentence': 'RESULTS: Ibuprofen is effective in dental pain, episiotomy pain and other post-operative pain.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0040460---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "7210912",
-              "object": "NCIT:C78640",
-              "publications": [
-                "PMID:10096266",
-                "PMID:10650365",
-                "PMID:11056966",
-                "PMID:11771573",
-                "PMID:12162474",
-                "PMID:21659629",
-                "PMID:24516940",
-                "PMID:269932",
-                "PMID:32271183",
-                "PMID:32506309",
-                "PMID:33094042",
-                "PMID:3536289",
-                "PMID:3547351",
-                "PMID:6465164",
-                "PMID:766799",
-                "PMID:9516027"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 537452,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C27003",
-          "name": "Acute Pain",
-          "description": "A sensation of discomfort or distress that has a severe or rapid onset.; Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "ICD9:338.1",
-            "SNOMEDCT:274663001",
-            "SYMP:0000839",
-            "MEDDRA:10066714",
-            "MESH:D059787",
-            "UMLS:C0184567",
-            "NCIT:C27003"
-          ],
-          "id": "NCIT:C27003",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Acute pain",
-            "acute pain",
-            "Acute onset pain",
-            "Acute Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 537452,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C27003",
-              "name": "Acute Pain",
-              "description": "A sensation of discomfort or distress that has a severe or rapid onset.; Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "ICD9:338.1",
-                "SNOMEDCT:274663001",
-                "SYMP:0000839",
-                "MEDDRA:10066714",
-                "MESH:D059787",
-                "UMLS:C0184567",
-                "NCIT:C27003"
-              ],
-              "id": "NCIT:C27003",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Acute pain",
-                "acute pain",
-                "Acute onset pain",
-                "Acute Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 27156533,
-            "start": 554,
-            "end": 537452,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9663185': {'publication date': '1998 Jun', 'sentence': 'This study evaluated whether administration of the pharmacologically active S(+)-isomer of ibuprofen suppresses acute pain and plasma beta-endorphin levels in the oral surgery model of acute pain.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:disrupts---None---None---None---UMLS:C0184567---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "27630106",
-              "object": "NCIT:C27003",
-              "publications": [
-                "PMID:9663185"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321150,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0003326",
-          "name": "Myalgia",
-          "description": "Painful sensation originating from a muscle or group of muscles.; Painful sensation in the muscles.; Pain in muscle. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "UMLS:C0231528",
-            "SYMP:0000332",
-            "HP:0003326",
-            "NCIT:C27009",
-            "MEDDRA:10018089",
-            "MEDDRA:10028361",
-            "MEDDRA:10028411",
-            "MEDDRA:10062441",
-            "MEDDRA:10028287",
-            "NCIT:C35785",
-            "MEDDRA:10028299",
-            "MEDDRA:10028362",
-            "MEDDRA:10033466",
-            "MESH:D063806",
-            "SNOMEDCT:68962001",
-            "MEDDRA:10028322",
-            "MEDDRA:10028332",
-            "MEDDRA:10028323"
-          ],
-          "id": "HP:0003326",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "muscle soreness",
-            "Myalgia",
-            "Muscle Soreness"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321150,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0003326",
-              "name": "Myalgia",
-              "description": "Painful sensation originating from a muscle or group of muscles.; Painful sensation in the muscles.; Pain in muscle. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "UMLS:C0231528",
-                "SYMP:0000332",
-                "HP:0003326",
-                "NCIT:C27009",
-                "MEDDRA:10018089",
-                "MEDDRA:10028361",
-                "MEDDRA:10028411",
-                "MEDDRA:10062441",
-                "MEDDRA:10028287",
-                "NCIT:C35785",
-                "MEDDRA:10028299",
-                "MEDDRA:10028362",
-                "MEDDRA:10033466",
-                "MESH:D063806",
-                "SNOMEDCT:68962001",
-                "MEDDRA:10028322",
-                "MEDDRA:10028332",
-                "MEDDRA:10028323"
-              ],
-              "id": "HP:0003326",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "muscle soreness",
-                "Myalgia",
-                "Muscle Soreness"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22965644,
-            "start": 554,
-            "end": 321150,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34064282': {'publication date': '2021 May 21', 'sentence': 'On the other hand, in subgroup B, no improvement in flexibility or reduction in muscle soreness was found in patients who took ibuprofen.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:disrupts---None---None---None---UMLS:C0231528---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "23399675",
-              "object": "HP:0003326",
-              "publications": [
-                "PMID:34064282"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 307910,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005578",
-          "name": "arthritic joint disease",
-          "description": "An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.; Acute or chronic inflammation of JOINTS.; Inflammation of a joint. [HPO:probinson]; If you feel pain and stiffness in your body or have trouble moving around, you might have arthritis. Most kinds of arthritis cause pain and swelling in your joints. Joints are places where two bones meet, such as your elbow or knee. Over time, a swollen joint can become severely damaged. Some kinds of arthritis can also cause problems in your organs, such as your eyes or skin. Types of arthritis include: Osteoarthritis is the most common type of arthritis. It's often related to aging or to an injury. Autoimmune arthritis happens when your body's immune system attacks healthy cells in your body by mistake. Rheumatoid arthritis is the most common form of this kind of arthritis. Juvenile arthritis is a type of arthritis that happens in children. Infectious arthritis is an infection that has spread from another part of the body to the joint. Psoriatic arthritis affects people with psoriasis. Gout is a painful type of arthritis that happens when too much uric acid builds up in the body. It often starts in the big toe.  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0003864",
-            "MEDDRA:10003263",
-            "PSY:03860",
-            "EFO:0005856",
-            "ICD10:M19.90",
-            "MEDDRA:10003246",
-            "MONDO:0005578",
-            "SYMP:0019169",
-            "SNOMEDCT:3723001",
-            "UMLS:C0574941",
-            "NCIT:C2883",
-            "SNOMEDCT:298160000",
-            "DOID:848",
-            "MEDDRA:10023217",
-            "HP:0001369",
-            "MESH:D001168",
-            "MEDDRA:10081014"
-          ],
-          "id": "MONDO:0005578",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Arthritis",
-            "arthritic joint disease",
-            "Inflamed joint",
-            "arthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.arthritis.org/",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=arthritis",
-            "https://www.cdc.gov/arthritis/index.htm",
-            "http://en.wikipedia.org/wiki/arthritis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/001243.htm",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 307910,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005578",
-              "name": "arthritic joint disease",
-              "description": "An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.; Acute or chronic inflammation of JOINTS.; Inflammation of a joint. [HPO:probinson]; If you feel pain and stiffness in your body or have trouble moving around, you might have arthritis. Most kinds of arthritis cause pain and swelling in your joints. Joints are places where two bones meet, such as your elbow or knee. Over time, a swollen joint can become severely damaged. Some kinds of arthritis can also cause problems in your organs, such as your eyes or skin. Types of arthritis include: Osteoarthritis is the most common type of arthritis. It's often related to aging or to an injury. Autoimmune arthritis happens when your body's immune system attacks healthy cells in your body by mistake. Rheumatoid arthritis is the most common form of this kind of arthritis. Juvenile arthritis is a type of arthritis that happens in children. Infectious arthritis is an infection that has spread from another part of the body to the joint. Psoriatic arthritis affects people with psoriasis. Gout is a painful type of arthritis that happens when too much uric acid builds up in the body. It often starts in the big toe.  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0003864",
-                "MEDDRA:10003263",
-                "PSY:03860",
-                "EFO:0005856",
-                "ICD10:M19.90",
-                "MEDDRA:10003246",
-                "MONDO:0005578",
-                "SYMP:0019169",
-                "SNOMEDCT:3723001",
-                "UMLS:C0574941",
-                "NCIT:C2883",
-                "SNOMEDCT:298160000",
-                "DOID:848",
-                "MEDDRA:10023217",
-                "HP:0001369",
-                "MESH:D001168",
-                "MEDDRA:10081014"
-              ],
-              "id": "MONDO:0005578",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Arthritis",
-                "arthritic joint disease",
-                "Inflamed joint",
-                "arthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.arthritis.org/",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=arthritis",
-                "https://www.cdc.gov/arthritis/index.htm",
-                "http://en.wikipedia.org/wiki/arthritis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/001243.htm",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18230804,
-            "start": 554,
-            "end": 307910,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26462366': {'publication date': '2015', 'sentence': 'This is termed, Celery Seed Extract (CSE) and has been found to be at least as effective as aspirin, ibuprofen, and naproxen in suppressing arthritis in a model of polyarthritis.', 'subject score': 1000, 'object score': 872}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:disrupts---None---None---None---UMLS:C0003864---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "18599970",
-              "object": "MONDO:0005578",
-              "publications": [
-                "PMID:26462366"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 212250,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-          "name": "Fever",
-          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10037660",
-            "MEDDRA:10020083",
-            "MEDDRA:10005911",
-            "UMLS:C0015967",
-            "HP:0001945",
-            "NCIT:C3038",
-            "MEDDRA:10073718",
-            "MEDDRA:10043204",
-            "MEDDRA:10037668",
-            "PDQ:CDR0000775882",
-            "PSY:19660",
-            "SNOMEDCT:386661006",
-            "MEDDRA:10016558",
-            "MEDDRA:10037663",
-            "SNOMEDCT:50177009",
-            "SYMP:0000613",
-            "MESH:D005334"
-          ],
-          "id": "HP:0001945",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "fever",
-            "Fever"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:9759682",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 212250,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-              "name": "Fever",
-              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10037660",
-                "MEDDRA:10020083",
-                "MEDDRA:10005911",
-                "UMLS:C0015967",
-                "HP:0001945",
-                "NCIT:C3038",
-                "MEDDRA:10073718",
-                "MEDDRA:10043204",
-                "MEDDRA:10037668",
-                "PDQ:CDR0000775882",
-                "PSY:19660",
-                "SNOMEDCT:386661006",
-                "MEDDRA:10016558",
-                "MEDDRA:10037663",
-                "SNOMEDCT:50177009",
-                "SYMP:0000613",
-                "MESH:D005334"
-              ],
-              "id": "HP:0001945",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "fever",
-                "Fever"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:9759682",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14760320,
-            "start": 554,
-            "end": 212250,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:20591173': {'publication date': '2010', 'sentence': 'INTRODUCTION: Hospitalized patients are often unable to ingest or tolerate oral antipyretics and recently an aqueous formulation of intravenous (IV) ibuprofen was approved by the US-FDA for the reduction of fever in adults.', 'subject score': 888, 'object score': 1000}, 'PMID:21127424': {'publication date': '2011 Jan-Feb', 'sentence': 'This prospective study evaluated the efficacy and safety of IV ibuprofen for the reduction of fever and treatment of pain in patients with thermal burn injury.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:disrupts---None---None---None---UMLS:C0015967---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "15072611",
-              "object": "HP:0001945",
-              "publications": [
-                "PMID:20591173",
-                "PMID:21127424"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14184560,
-            "start": 554,
-            "end": 316891,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19624576': {'publication date': '2009 Aug', 'sentence': 'OBJECTIVES: This study compared the analgesic effectiveness of acetaminophen-codeine with that of ibuprofen for children with acute traumatic extremity pain, with the hypothesis that the two medications would demonstrate equivalent reduction in pain scores in an emergency department (ED) setting.', 'subject score': 1000, 'object score': 1000}, 'PMID:21195257': {'publication date': '2011 Jan', 'sentence': 'Administering ibuprofen before and after separator placement significantly reduced pain compared with the placebo.', 'subject score': 861, 'object score': 749}, 'PMID:27562219': {'publication date': '2017 01', 'sentence': 'RESULTS: Ibuprofen and dexamethasone significantly reduced pain (Kruskal-Wallis; P <0.05) up to 3 days after surgery and discomfort (P <0.05) up to 2 days after surgery compared with placebo treatment.', 'subject score': 1000, 'object score': 775}, 'PMID:27787269': {'publication date': '2016 Nov', 'sentence': 'Addition of ibuprofen and loratadine resulted in a total reduction in pain by 40%.', 'subject score': 1000, 'object score': 1000}, 'PMID:28178024': {'publication date': '2017 Feb', 'sentence': 'Two of these four studies were non-inferiority studies showed that the use of both curcuminoids and ibuprofen were associated with a similar significant reduction in pain over the study durations of four and six weeks, respectively, with curcuminoid use non-inferior to the use of ibuprofen over the study durations.', 'subject score': 1000, 'object score': 1000}, 'PMID:29935486': {'publication date': '2018 Nov', 'sentence': 'The use of intravenous ibuprofen was associated with reduction in pain at rest (AUC, 1- to 24-h, P?<?0.001 and 12- to 24-h, P?=?0.021) and pain with movement (AUC, 1-24, 6-24, and 12-24?h, P?<?0.001).', 'subject score': 888, 'object score': 1000}, 'PMID:30166905': {'publication date': '2017 Dec', 'sentence': 'Conclusion: The patients prescribed ibuprofen did not report any problem with tooth movement along with significant reduction in pain as compared to paracetamol.', 'subject score': 1000, 'object score': 1000}, 'PMID:30737050': {'publication date': '2019 Apr', 'sentence': 'Additional analysis based on the chemical name showed that sulindac, ketorolac, and ibuprofen significantly reduced pain at 6 hours, whereas piroxicam and prednisolone significantly reduced the pain at 12 and 24 hours.', 'subject score': 775, 'object score': 775}, 'PMID:32254988': {'publication date': '2018 Sep 28', 'sentence': 'However, both the composite and the physical mixture were more effective than equivalent doses of ibuprofen in pain suppression in rats.', 'subject score': 1000, 'object score': 888}, 'PMID:35343341': {'publication date': '2022 Mar 28', 'sentence': 'The conventional dosage forms (tablets, capsules), of ibuprofen has less potential in suppression of pain and inflammation due to their slow dissolution rates and lower bioavailability.', 'subject score': 1000, 'object score': 1000}, 'PMID:778987': {'publication date': '1976 May', 'sentence': 'Sulindac showed superior analgesic properties to ibuprofen, resulting in a significantly greater reduction in pain on weight-bearing and with passive movements (P less than 0.01).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:disrupts---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "14486259",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:19624576",
-                "PMID:21195257",
-                "PMID:27562219",
-                "PMID:27787269",
-                "PMID:28178024",
-                "PMID:29935486",
-                "PMID:30166905",
-                "PMID:30737050",
-                "PMID:32254988",
-                "PMID:35343341",
-                "PMID:778987"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:10908610': {'publication date': '2000 Aug 01', 'sentence': 'Thus, the anti-inflammatory drug ibuprofen, which has been associated with reduced AD risk in human epidemiological studies, can significantly delay some forms of AD pathology, including amyloid deposition, when administered early in the disease course of a transgenic mouse model of AD.', 'subject score': 905, 'object score': 861}, 'PMID:15506544': {'publication date': '2004', 'sentence': \"There is epidemiological observation that long-term treatment of patients suffering from rheumatoid arthritis with ibuprofen results in reduced risk and delayed onset of Alzheimer's disease (AD).\", 'subject score': 1000, 'object score': 1000}, 'PMID:24413537': {'publication date': '2014 Aug', 'sentence': \"Epidemiological observation indicates that long-term oral administration of nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen to patients having rheumatoid arthritis results in reduced risk and delayed onset of Alzheimer's disease.\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 307306,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004975",
-          "name": "Alzheimer disease",
-          "description": "A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. [HPO:probinson]; A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. // COMMENTS: Note that this is a bundled term that refers to a disease rather than to phenotypic features. It is retained for convenience since Alzheimer disease is used for annotation of other diseases (e.g., Down syndrome) as if it were a feature. If possible it is preferable to annotate with the precise phenotypic features.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "KEGG.DISEASE:05010",
-            "SNOMEDCT:142811000119104",
-            "MEDDRA:10012292",
-            "UMLS:C1863053",
-            "HP:0002511",
-            "ICD9:331.0",
-            "ORPHANET:238616",
-            "MEDDRA:10012271",
-            "MEDDRA:10001896",
-            "UMLS:C3549448",
-            "UMLS:C0002395",
-            "NCIT:C2866",
-            "DOID:10652",
-            "MONDO:0004975",
-            "EFO:0000249",
-            "NCIT:C146894",
-            "UMLS:C1863052",
-            "SNOMEDCT:230267005",
-            "PSY:01940",
-            "SNOMEDCT:26929004",
-            "OMIM:104300",
-            "ICD10:G30",
-            "MESH:D000544",
-            "MESH:C566299"
-          ],
-          "id": "MONDO:0004975",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Alzheimer's disease",
-            "Alzheimer disease, familial, 1",
-            "Alzheimer Disease, Early-Onset, With Cerebral Amyloid Angiopathy",
-            "Alzheimer's Disease",
-            "Alzheimers Disease",
-            "Alzheimer disease",
-            "Alzheimer disease, protection against",
-            "Alzheimer Disease",
-            "obsolete_Alzheimer's disease",
-            "Alzheimer disease, familial, 1 related phenotypic feature",
-            "Alzheimer's Disease 1"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet",
-            "http://en.wikipedia.org/wiki/alzheimer%27s_disease",
-            "http://www.merriam-webster.com/medical/alzheimer%27s%20disease",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 307306,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004975",
-              "name": "Alzheimer disease",
-              "description": "A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. [HPO:probinson]; A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. // COMMENTS: Note that this is a bundled term that refers to a disease rather than to phenotypic features. It is retained for convenience since Alzheimer disease is used for annotation of other diseases (e.g., Down syndrome) as if it were a feature. If possible it is preferable to annotate with the precise phenotypic features.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "KEGG.DISEASE:05010",
-                "SNOMEDCT:142811000119104",
-                "MEDDRA:10012292",
-                "UMLS:C1863053",
-                "HP:0002511",
-                "ICD9:331.0",
-                "ORPHANET:238616",
-                "MEDDRA:10012271",
-                "MEDDRA:10001896",
-                "UMLS:C3549448",
-                "UMLS:C0002395",
-                "NCIT:C2866",
-                "DOID:10652",
-                "MONDO:0004975",
-                "EFO:0000249",
-                "NCIT:C146894",
-                "UMLS:C1863052",
-                "SNOMEDCT:230267005",
-                "PSY:01940",
-                "SNOMEDCT:26929004",
-                "OMIM:104300",
-                "ICD10:G30",
-                "MESH:D000544",
-                "MESH:C566299"
-              ],
-              "id": "MONDO:0004975",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Alzheimer's disease",
-                "Alzheimer disease, familial, 1",
-                "Alzheimer Disease, Early-Onset, With Cerebral Amyloid Angiopathy",
-                "Alzheimer's Disease",
-                "Alzheimers Disease",
-                "Alzheimer disease",
-                "Alzheimer disease, protection against",
-                "Alzheimer Disease",
-                "obsolete_Alzheimer's disease",
-                "Alzheimer disease, familial, 1 related phenotypic feature",
-                "Alzheimer's Disease 1"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet",
-                "http://en.wikipedia.org/wiki/alzheimer%27s_disease",
-                "http://www.merriam-webster.com/medical/alzheimer%27s%20disease",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8155385,
-            "start": 554,
-            "end": 307306,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10908610': {'publication date': '2000 Aug 01', 'sentence': 'Thus, the anti-inflammatory drug ibuprofen, which has been associated with reduced AD risk in human epidemiological studies, can significantly delay some forms of AD pathology, including amyloid deposition, when administered early in the disease course of a transgenic mouse model of AD.', 'subject score': 905, 'object score': 861}, 'PMID:15506544': {'publication date': '2004', 'sentence': \"There is epidemiological observation that long-term treatment of patients suffering from rheumatoid arthritis with ibuprofen results in reduced risk and delayed onset of Alzheimer's disease (AD).\", 'subject score': 1000, 'object score': 1000}, 'PMID:24413537': {'publication date': '2014 Aug', 'sentence': \"Epidemiological observation indicates that long-term oral administration of nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen to patients having rheumatoid arthritis results in reduced risk and delayed onset of Alzheimer's disease.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:disrupts---None---None---None---UMLS:C0002395---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "8331095",
-              "object": "MONDO:0004975",
-              "publications": [
-                "PMID:10908610",
-                "PMID:15506544",
-                "PMID:24413537"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 310723,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005044",
-          "name": "hypertensive disorder",
-          "description": "The presence of chronic increased pressure in the systemic arterial system. [HPO:probinson]; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0000822",
-            "PDQ:CDR0000686951",
-            "EFO:0000537",
-            "MONDO:0005044",
-            "MEDDRA:10039196",
-            "ICD9:401-405.99",
-            "MEDDRA:10057166",
-            "MEDDRA:10003170",
-            "ICD10:I10",
-            "MEDDRA:10006067",
-            "UMLS:C0020538",
-            "NCIT:C3117",
-            "UMLS:C0497247",
-            "SNOMEDCT:24184005",
-            "MEDDRA:10037806",
-            "MEDDRA:10036639",
-            "MESH:D006973",
-            "MEDDRA:10020775",
-            "SNOMEDCT:38341003",
-            "PSY:23830",
-            "MEDDRA:10005750",
-            "MEDDRA:10005755",
-            "MEDDRA:10081425",
-            "MEDDRA:10003168",
-            "MEDDRA:10020772",
-            "MEDDRA:10014475",
-            "MEDDRA:10005747",
-            "DOID:10763",
-            "MEDDRA:10039197",
-            "MEDDRA:10037808",
-            "MEDDRA:10020782",
-            "MEDDRA:10021655",
-            "MEDDRA:10036640"
-          ],
-          "id": "MONDO:0005044",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hypertension",
-            "Hypertension",
-            "hypertensive disorder",
-            "Hypertensive disease",
-            "Increase in blood pressure"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:24352797",
-            "PMID:9137951",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://en.wikipedia.org/wiki/hypertension"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310723,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005044",
-              "name": "hypertensive disorder",
-              "description": "The presence of chronic increased pressure in the systemic arterial system. [HPO:probinson]; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0000822",
-                "PDQ:CDR0000686951",
-                "EFO:0000537",
-                "MONDO:0005044",
-                "MEDDRA:10039196",
-                "ICD9:401-405.99",
-                "MEDDRA:10057166",
-                "MEDDRA:10003170",
-                "ICD10:I10",
-                "MEDDRA:10006067",
-                "UMLS:C0020538",
-                "NCIT:C3117",
-                "UMLS:C0497247",
-                "SNOMEDCT:24184005",
-                "MEDDRA:10037806",
-                "MEDDRA:10036639",
-                "MESH:D006973",
-                "MEDDRA:10020775",
-                "SNOMEDCT:38341003",
-                "PSY:23830",
-                "MEDDRA:10005750",
-                "MEDDRA:10005755",
-                "MEDDRA:10081425",
-                "MEDDRA:10003168",
-                "MEDDRA:10020772",
-                "MEDDRA:10014475",
-                "MEDDRA:10005747",
-                "DOID:10763",
-                "MEDDRA:10039197",
-                "MEDDRA:10037808",
-                "MEDDRA:10020782",
-                "MEDDRA:10021655",
-                "MEDDRA:10036640"
-              ],
-              "id": "MONDO:0005044",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hypertension",
-                "Hypertension",
-                "hypertensive disorder",
-                "Hypertensive disease",
-                "Increase in blood pressure"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:24352797",
-                "PMID:9137951",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://en.wikipedia.org/wiki/hypertension"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25205974,
-            "start": 554,
-            "end": 310723,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3840417': {'publication date': '1985', 'sentence': 'The hypoxia, hypertension and increased prostanoids were prevented using ibuprofen.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0020538---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "25657729",
-              "object": "MONDO:0005044",
-              "publications": [
-                "PMID:3840417"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 543282,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C26791",
-          "name": "Hemorrhage",
-          "description": "Loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels.",
-          "equivalent_curies": [
-            "UMLS:C0019080",
-            "SYMP:0000041",
-            "MEDDRA:10019524",
-            "MEDDRA:10018988",
-            "MEDDRA:10055798",
-            "MEDDRA:10019525",
-            "NCIT:C26791",
-            "MEDDRA:10005103",
-            "MEDDRA:10015867",
-            "SNOMEDCT:50960005",
-            "MP:0001914",
-            "MEDDRA:10019595",
-            "MEDDRA:10019003",
-            "MEDDRA:10005645",
-            "SNOMEDCT:131148009",
-            "MESH:D006470"
-          ],
-          "id": "NCIT:C26791",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hemorrhage",
-            "Hemorrhage"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/books/nbk542273/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 543282,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C26791",
-              "name": "Hemorrhage",
-              "description": "Loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels.",
-              "equivalent_curies": [
-                "UMLS:C0019080",
-                "SYMP:0000041",
-                "MEDDRA:10019524",
-                "MEDDRA:10018988",
-                "MEDDRA:10055798",
-                "MEDDRA:10019525",
-                "NCIT:C26791",
-                "MEDDRA:10005103",
-                "MEDDRA:10015867",
-                "SNOMEDCT:50960005",
-                "MP:0001914",
-                "MEDDRA:10019595",
-                "MEDDRA:10019003",
-                "MEDDRA:10005645",
-                "SNOMEDCT:131148009",
-                "MESH:D006470"
-              ],
-              "id": "NCIT:C26791",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hemorrhage",
-                "Hemorrhage"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/books/nbk542273/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21738643,
-            "start": 554,
-            "end": 543282,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32546045': {'publication date': '2020 Jun 16', 'sentence': 'The Effect of Ibuprofen Dosing Interval on Post-Tonsillectomy Outcomes in Children: A Quality Improvement Study.OBJECTIVE: In this Quality Improvement (QI project) it was hypothesized that an increase in dosing intervals for postoperative analgesia when alternating Ibuprofen and Acetaminophen would reduce post-tonsillectomy hemorrhage (PTH) rates for those undergoing tonsillectomies with or without adenoidectomy, while maintaining the standard of postoperative analgesia and reducing visits to the Emergency Room (ER) for reasons other than PTH.', 'subject score': 888, 'object score': 825}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0019080---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "22159382",
-              "object": "NCIT:C26791",
-              "publications": [
-                "PMID:32546045"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 212250,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-          "name": "Fever",
-          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10037660",
-            "MEDDRA:10020083",
-            "MEDDRA:10005911",
-            "UMLS:C0015967",
-            "HP:0001945",
-            "NCIT:C3038",
-            "MEDDRA:10073718",
-            "MEDDRA:10043204",
-            "MEDDRA:10037668",
-            "PDQ:CDR0000775882",
-            "PSY:19660",
-            "SNOMEDCT:386661006",
-            "MEDDRA:10016558",
-            "MEDDRA:10037663",
-            "SNOMEDCT:50177009",
-            "SYMP:0000613",
-            "MESH:D005334"
-          ],
-          "id": "HP:0001945",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "fever",
-            "Fever"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:9759682",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 212250,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-              "name": "Fever",
-              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10037660",
-                "MEDDRA:10020083",
-                "MEDDRA:10005911",
-                "UMLS:C0015967",
-                "HP:0001945",
-                "NCIT:C3038",
-                "MEDDRA:10073718",
-                "MEDDRA:10043204",
-                "MEDDRA:10037668",
-                "PDQ:CDR0000775882",
-                "PSY:19660",
-                "SNOMEDCT:386661006",
-                "MEDDRA:10016558",
-                "MEDDRA:10037663",
-                "SNOMEDCT:50177009",
-                "SYMP:0000613",
-                "MESH:D005334"
-              ],
-              "id": "HP:0001945",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "fever",
-                "Fever"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:9759682",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21703374,
-            "start": 554,
-            "end": 212250,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32505846': {'publication date': '2020 May 25', 'sentence': 'Studies show that ibuprofen demonstrates superior efficacy in fever reduction compared to acetaminophen.', 'subject score': 1000, 'object score': 888}, 'PMID:32725954': {'publication date': '2020 Jul 29', 'sentence': 'Ibuprofen does not prevent postbronchoscopy fever in children undergoing broncho-alveolar lavage.BACKGROUND: Fiber-optic bronchoscopy (FOB) of the lower airways is a routine examination performed for investigating varying respiratory complaints in children.', 'subject score': 1000, 'object score': 901}, 'PMID:35547858': {'publication date': '2020 Mar', 'sentence': 'In conclusion, ibuprofen administered in the form of soft chewable capsules was palatable and acceptable to the majority of children and their parents/guardians and may provide a convenient and easy to dose preparation to reduce fever and relieve pain in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:36503309': {'publication date': '2022 Dec 12', 'sentence': 'Acetaminophen Versus Ibuprofen for Fever Reduction in the Pediatric Emergency Department.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0015967---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "22123299",
-              "object": "HP:0001945",
-              "publications": [
-                "PMID:32505846",
-                "PMID:32725954",
-                "PMID:35547858",
-                "PMID:36503309"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317183,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004982",
-          "name": "pancreatitis",
-          "description": "Inflammation of the pancreas.; INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.; The presence of inflammation in the pancreas. [HPO:probinson]; The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0004982",
-            "MEDDRA:10076039",
-            "MEDDRA:10033656",
-            "DOID:4989",
-            "SNOMEDCT:75694006",
-            "ICD10:K85.9",
-            "MEDDRA:10033645",
-            "NCIT:C3306",
-            "EFO:0000278",
-            "HP:0001733",
-            "MESH:D010195",
-            "UMLS:C0030305"
-          ],
-          "id": "MONDO:0004982",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pancreatitis",
-            "pancreatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/pancreatitis.htm",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317183,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004982",
-              "name": "pancreatitis",
-              "description": "Inflammation of the pancreas.; INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.; The presence of inflammation in the pancreas. [HPO:probinson]; The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0004982",
-                "MEDDRA:10076039",
-                "MEDDRA:10033656",
-                "DOID:4989",
-                "SNOMEDCT:75694006",
-                "ICD10:K85.9",
-                "MEDDRA:10033645",
-                "NCIT:C3306",
-                "EFO:0000278",
-                "HP:0001733",
-                "MESH:D010195",
-                "UMLS:C0030305"
-              ],
-              "id": "MONDO:0004982",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pancreatitis",
-                "pancreatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/pancreatitis.htm",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20942981,
-            "start": 554,
-            "end": 317183,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31651801': {'publication date': '2019 Oct 23', 'sentence': 'IV Ibuprofen for Prevention of Post-Ercp Pancreatitis in Children: A Randomized Placebo-Controlled Feasibility Study.', 'subject score': 888, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0030305---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "21354514",
-              "object": "MONDO:0004982",
-              "publications": [
-                "PMID:31651801"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 610163,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006625",
-          "name": "altitude sickness",
-          "description": "Multiple symptoms associated with reduced oxygen at high altitude.",
-          "equivalent_curies": [
-            "EFO:1000782",
-            "UMLS:C0002351",
-            "MEDDRA:10077617",
-            "MONDO:0006625",
-            "MESH:D000532",
-            "SNOMEDCT:87284002",
-            "MEDDRA:10077616",
-            "SNOMEDCT:42883007",
-            "UMLS:C3887755"
-          ],
-          "id": "MONDO:0006625",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Mountain Sickness",
-            "altitude sickness",
-            "Altitude Sickness"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 610163,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006625",
-              "name": "altitude sickness",
-              "description": "Multiple symptoms associated with reduced oxygen at high altitude.",
-              "equivalent_curies": [
-                "EFO:1000782",
-                "UMLS:C0002351",
-                "MEDDRA:10077617",
-                "MONDO:0006625",
-                "MESH:D000532",
-                "SNOMEDCT:87284002",
-                "MEDDRA:10077616",
-                "SNOMEDCT:42883007",
-                "UMLS:C3887755"
-              ],
-              "id": "MONDO:0006625",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Mountain Sickness",
-                "altitude sickness",
-                "Altitude Sickness"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20290127,
-            "start": 554,
-            "end": 610163,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30419226': {'publication date': '2018 Nov 10', 'sentence': 'Altitude Sickness Prevention with Ibuprofen Relative to Acetazolamide.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0002351---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "20691057",
-              "object": "MONDO:0006625",
-              "publications": [
-                "PMID:30419226"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319030,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319030,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19018032,
-            "start": 554,
-            "end": 319030,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28035387': {'publication date': '2017 Feb', 'sentence': 'In conclusion, prednisone, ibuprofen and betamethasone may prevent OA by suppressing the expression of IL-6 and IL-8, subsequently inactivating NF-kappaB and STAT3 pathways, and ultimately, leading to decreased levels of collagen I, MMP-1, and MMP-13.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "19399624",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:28035387"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 311935,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005318",
-          "name": "canker sore",
-          "description": "A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval, lasting for 7-14 days and healing without scarring.; A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval. Two to eight crops of lesions occur per year, lasting for 7 to 14 days and then heal without scarring. (From Jablonski's Dictionary of Dentistry, 1992, p742); Recurrent episodes of ulceration of the oral mucosa, typically presenting as painful, sharply circumscribed fibrin-covered mucosal defects with a hyperemic border. [HPO:probinson]; Oral aphthous ulcers typically present as painful, sharply circumscribed fibrin-covered mucosal defects with a hyperemic border. [PMID:25346356]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:722781002",
-            "MEDDRA:10042131",
-            "MEDDRA:10002959",
-            "UMLS:C2937365",
-            "SNOMEDCT:426965005",
-            "SNOMEDCT:427617000",
-            "UMLS:C1959869",
-            "NCIT:C62546",
-            "MONDO:0005318",
-            "SNOMEDCT:398870000",
-            "MEDDRA:10007166",
-            "MEDDRA:10045287",
-            "MEDDRA:10002958",
-            "MESH:D013281",
-            "UMLS:C0038363",
-            "MEDDRA:10066577",
-            "MEDDRA:10030960",
-            "SNOMEDCT:110426005",
-            "MEDDRA:10067589",
-            "MEDDRA:10084265",
-            "HP:0011107",
-            "MEDDRA:10045372",
-            "MEDDRA:10045288"
-          ],
-          "id": "MONDO:0005318",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Stomatitis, Aphthous",
-            "canker sore",
-            "Canker Sore",
-            "Aphthous ulceration of skin and/or mucous membrane (disorder)",
-            "Recurrent aphthous stomatitis",
-            "Aphthous Stomatitis",
-            "Recurrent aphthous ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:25346356",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311935,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005318",
-              "name": "canker sore",
-              "description": "A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval, lasting for 7-14 days and healing without scarring.; A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval. Two to eight crops of lesions occur per year, lasting for 7 to 14 days and then heal without scarring. (From Jablonski's Dictionary of Dentistry, 1992, p742); Recurrent episodes of ulceration of the oral mucosa, typically presenting as painful, sharply circumscribed fibrin-covered mucosal defects with a hyperemic border. [HPO:probinson]; Oral aphthous ulcers typically present as painful, sharply circumscribed fibrin-covered mucosal defects with a hyperemic border. [PMID:25346356]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:722781002",
-                "MEDDRA:10042131",
-                "MEDDRA:10002959",
-                "UMLS:C2937365",
-                "SNOMEDCT:426965005",
-                "SNOMEDCT:427617000",
-                "UMLS:C1959869",
-                "NCIT:C62546",
-                "MONDO:0005318",
-                "SNOMEDCT:398870000",
-                "MEDDRA:10007166",
-                "MEDDRA:10045287",
-                "MEDDRA:10002958",
-                "MESH:D013281",
-                "UMLS:C0038363",
-                "MEDDRA:10066577",
-                "MEDDRA:10030960",
-                "SNOMEDCT:110426005",
-                "MEDDRA:10067589",
-                "MEDDRA:10084265",
-                "HP:0011107",
-                "MEDDRA:10045372",
-                "MEDDRA:10045288"
-              ],
-              "id": "MONDO:0005318",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Stomatitis, Aphthous",
-                "canker sore",
-                "Canker Sore",
-                "Aphthous ulceration of skin and/or mucous membrane (disorder)",
-                "Recurrent aphthous stomatitis",
-                "Aphthous Stomatitis",
-                "Recurrent aphthous ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:25346356",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17332838,
-            "start": 554,
-            "end": 311935,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24910692': {'publication date': '2014 Mar', 'sentence': 'This study aims to determine the therapeutic effects of ibuprofen, diphenhydramine and aluminum magnesium simethicone (AlMgS) syrup on reducing oral aphthous ulcer pain.', 'subject score': 1000, 'object score': 867}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0038363---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "17687542",
-              "object": "MONDO:0005318",
-              "publications": [
-                "PMID:24910692"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318690,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100607",
-          "name": "Dysmenorrhea",
-          "description": "Pain during menstruation that interferes with daily activities. [PMID:15686299]; Pain during menstruation that interferes with daily activities.; Pain during menstruation that interferes with daily activities.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0013390",
-            "MEDDRA:10013934",
-            "SNOMEDCT:431416001",
-            "PSY:15620",
-            "MEDDRA:10027324",
-            "SNOMEDCT:266599000",
-            "MEDDRA:10034532",
-            "MEDDRA:10027323",
-            "HP:0100607",
-            "MEDDRA:10013935",
-            "MEDDRA:10033463",
-            "MEDDRA:10027321",
-            "MEDDRA:10033514",
-            "MEDDRA:10011299",
-            "SNOMEDCT:289900009",
-            "NCIT:C34559",
-            "MESH:D004412",
-            "ICD9:625.3"
-          ],
-          "id": "HP:0100607",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Dysmenorrhea"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "PMID:15686299"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318690,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100607",
-              "name": "Dysmenorrhea",
-              "description": "Pain during menstruation that interferes with daily activities. [PMID:15686299]; Pain during menstruation that interferes with daily activities.; Pain during menstruation that interferes with daily activities.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0013390",
-                "MEDDRA:10013934",
-                "SNOMEDCT:431416001",
-                "PSY:15620",
-                "MEDDRA:10027324",
-                "SNOMEDCT:266599000",
-                "MEDDRA:10034532",
-                "MEDDRA:10027323",
-                "HP:0100607",
-                "MEDDRA:10013935",
-                "MEDDRA:10033463",
-                "MEDDRA:10027321",
-                "MEDDRA:10033514",
-                "MEDDRA:10011299",
-                "SNOMEDCT:289900009",
-                "NCIT:C34559",
-                "MESH:D004412",
-                "ICD9:625.3"
-              ],
-              "id": "HP:0100607",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Dysmenorrhea"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "PMID:15686299"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15633780,
-            "start": 554,
-            "end": 318690,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22069413': {'publication date': '2010 Dec', 'sentence': 'CONCLUSIONS: Considering the results of the study, reflexology was superior to Ibuprofen on reducing dysmenorrhea and its treatment effect continued even after discontinuing the intervention in the third cycle.', 'subject score': 1000, 'object score': 872}, 'PMID:28250781': {'publication date': '2016', 'sentence': 'CONCLUSION: Training and acupressure were more effective than ibuprofen in the reduction of dysmenorrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:36017945': {'publication date': '2022 Aug 26', 'sentence': 'Ibuprofen may not reduce menstrual cramps compared to placebo (OR 1.00, 95% CI 0.11 to 8.95; 1 trial, 20 women, low-certainty evidence).', 'subject score': 1000, 'object score': 1000}, 'PMID:392621': {'publication date': '1979 Jul', 'sentence': 'Ibuprofen also reduced the menstrual pain significantly (P less than 0.001).', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0013390---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "15961024",
-              "object": "HP:0100607",
-              "publications": [
-                "PMID:22069413",
-                "PMID:28250781",
-                "PMID:36017945",
-                "PMID:392621"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316893,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012532",
-          "name": "Chronic pain",
-          "description": "Ongoing or recurrent pain that persists beyond that which is expected following acute injury, usually 3 months or more.; Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.; Persistent pain, usually defined as pain that has lasted longer than 3 to 6 months. [HPO:probinson, PMID:1875958]; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "HP:0012532",
-            "NCIT:C26940",
-            "ICD9:338.2",
-            "UMLS:C0150055",
-            "MESH:D059350",
-            "MEDDRA:10049475",
-            "SNOMEDCT:82423001",
-            "PSY:09185",
-            "SYMP:0000837"
-          ],
-          "id": "HP:0012532",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Chronic pain",
-            "chronic pain",
-            "Chronic Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:1875958",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316893,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012532",
-              "name": "Chronic pain",
-              "description": "Ongoing or recurrent pain that persists beyond that which is expected following acute injury, usually 3 months or more.; Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.; Persistent pain, usually defined as pain that has lasted longer than 3 to 6 months. [HPO:probinson, PMID:1875958]; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "HP:0012532",
-                "NCIT:C26940",
-                "ICD9:338.2",
-                "UMLS:C0150055",
-                "MESH:D059350",
-                "MEDDRA:10049475",
-                "SNOMEDCT:82423001",
-                "PSY:09185",
-                "SYMP:0000837"
-              ],
-              "id": "HP:0012532",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Chronic pain",
-                "chronic pain",
-                "Chronic Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:1875958",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13422720,
-            "start": 554,
-            "end": 316893,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18427773': {'publication date': '2008 May', 'sentence': 'CONCLUSION: We conclude that pain therapy with an almost peripherally acting drug such as ibuprofen can reduce osteoporosis-associated chronic pain better than a centrally acting pain medication such as tramadol.', 'subject score': 1000, 'object score': 824}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0150055---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "13710734",
-              "object": "HP:0012532",
-              "publications": [
-                "PMID:18427773"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318533,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-          "name": "Headache",
-          "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10019211",
-            "PSY:22380",
-            "NCIT:C34661",
-            "MEDDRA:10019218",
-            "SNOMEDCT:25064002",
-            "UMLS:C0018681",
-            "MEDDRA:10019231",
-            "HP:0002315",
-            "MEDDRA:10033405",
-            "ICD9:784.0",
-            "MESH:D006261",
-            "SYMP:0000504",
-            "MEDDRA:10008013",
-            "MEDDRA:10019198"
-          ],
-          "id": "HP:0002315",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "headache",
-            "Headache"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-            "PMID:15304572",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318533,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-              "name": "Headache",
-              "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10019211",
-                "PSY:22380",
-                "NCIT:C34661",
-                "MEDDRA:10019218",
-                "SNOMEDCT:25064002",
-                "UMLS:C0018681",
-                "MEDDRA:10019231",
-                "HP:0002315",
-                "MEDDRA:10033405",
-                "ICD9:784.0",
-                "MESH:D006261",
-                "SYMP:0000504",
-                "MEDDRA:10008013",
-                "MEDDRA:10019198"
-              ],
-              "id": "HP:0002315",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "headache",
-                "Headache"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-                "PMID:15304572",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9981131,
-            "start": 554,
-            "end": 318533,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12755658': {'publication date': '2003 May', 'sentence': 'The objective of this study was to determine whether pretreatment with ibuprofen would prevent the onset or decrease the severity of headache that occurs after ECT.', 'subject score': 1000, 'object score': 1000}, 'PMID:19436460': {'publication date': '2009 Jan', 'sentence': 'Flunarizine may be valuable in paediatric headache prevention, and ibuprofen, acetaminophen and nasal sumatriptan may be effective in the acute management of headaches.', 'subject score': 1000, 'object score': 851}, 'PMID:20832701': {'publication date': '2010 Sep', 'sentence': 'CONCLUSIONS: Ibuprofen and acetazolamide were similarly effective in preventing HAH.', 'subject score': 1000, 'object score': 872}, 'PMID:23098412': {'publication date': '2012 Dec', 'sentence': 'OBJECTIVE: To study the effectiveness of ibuprofen versus placebo in preventing acute mountain sickness (AMS) and high altitude headache (HAH).', 'subject score': 1000, 'object score': 851}, 'PMID:28632763': {'publication date': '2017', 'sentence': 'CONCLUSIONS: Based on a limited number of studies ibuprofen seems efficacious for the prevention of HAH and may therefore represent an alternative for preventing HAH with acetazolamide or dexamethasone.', 'subject score': 872, 'object score': 1000}, 'PMID:37177799': {'publication date': '2023 May', 'sentence': 'CONCLUSION: In the present population recruited at specialized headache centers, patients rated triptans as more effective than non-opioid analgesics, naproxen as more effective than ibuprofen, and acute medication efficacy decreased with increasing headache frequency.', 'subject score': 1000, 'object score': 790}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0018681---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "10201705",
-              "object": "HP:0002315",
-              "publications": [
-                "PMID:12755658",
-                "PMID:19436460",
-                "PMID:20832701",
-                "PMID:23098412",
-                "PMID:28632763",
-                "PMID:37177799"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321150,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0003326",
-          "name": "Myalgia",
-          "description": "Painful sensation originating from a muscle or group of muscles.; Painful sensation in the muscles.; Pain in muscle. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "UMLS:C0231528",
-            "SYMP:0000332",
-            "HP:0003326",
-            "NCIT:C27009",
-            "MEDDRA:10018089",
-            "MEDDRA:10028361",
-            "MEDDRA:10028411",
-            "MEDDRA:10062441",
-            "MEDDRA:10028287",
-            "NCIT:C35785",
-            "MEDDRA:10028299",
-            "MEDDRA:10028362",
-            "MEDDRA:10033466",
-            "MESH:D063806",
-            "SNOMEDCT:68962001",
-            "MEDDRA:10028322",
-            "MEDDRA:10028332",
-            "MEDDRA:10028323"
-          ],
-          "id": "HP:0003326",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "muscle soreness",
-            "Myalgia",
-            "Muscle Soreness"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321150,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0003326",
-              "name": "Myalgia",
-              "description": "Painful sensation originating from a muscle or group of muscles.; Painful sensation in the muscles.; Pain in muscle. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "UMLS:C0231528",
-                "SYMP:0000332",
-                "HP:0003326",
-                "NCIT:C27009",
-                "MEDDRA:10018089",
-                "MEDDRA:10028361",
-                "MEDDRA:10028411",
-                "MEDDRA:10062441",
-                "MEDDRA:10028287",
-                "NCIT:C35785",
-                "MEDDRA:10028299",
-                "MEDDRA:10028362",
-                "MEDDRA:10033466",
-                "MESH:D063806",
-                "SNOMEDCT:68962001",
-                "MEDDRA:10028322",
-                "MEDDRA:10028332",
-                "MEDDRA:10028323"
-              ],
-              "id": "HP:0003326",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "muscle soreness",
-                "Myalgia",
-                "Muscle Soreness"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9809173,
-            "start": 554,
-            "end": 321150,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12580656': {'publication date': '2003 Feb', 'sentence': 'The results of this study reveal that intake of ibuprofen can decrease muscle soreness induced after eccentric exercise but cannot assist in restoring muscle function.', 'subject score': 1000, 'object score': 1000}, 'PMID:15880305': {'publication date': '2005 May', 'sentence': 'Systemic side effects of interferons like myalgias can be reduced by paracetamol or ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:16195036': {'publication date': '2005 Aug', 'sentence': 'Our results indicate that physical activity with or without ibuprofen helps to prevent delayed-onset muscle soreness.', 'subject score': 1000, 'object score': 861}, 'PMID:18336059': {'publication date': '2008', 'sentence': \"Systemic (particularly 'flu-like') adverse effects of interferons, e.g. myalgias, can be reduced by administering paracetamol, ibuprofen or naproxen.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0231528---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "10026105",
-              "object": "HP:0003326",
-              "publications": [
-                "PMID:12580656",
-                "PMID:15880305",
-                "PMID:16195036",
-                "PMID:18336059"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8909347,
-            "start": 554,
-            "end": 546804,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11545620': {'publication date': '2001 Aug', 'sentence': 'The objective of our study was to determine the role of ibuprofen in protecting neutropenic rats from cardiopulmonary injury due to endotoxemia.', 'subject score': 1000, 'object score': 888}, 'PMID:1568970': {'publication date': '1992 Mar', 'sentence': 'Ibuprofen reduces ethchlorvynol lung injury: possible role of blood flow distribution.', 'subject score': 1000, 'object score': 851}, 'PMID:18549459': {'publication date': '2008 Aug 15', 'sentence': 'However, in patients aged >55 years, a statistically significant advantage for ibuprofen-PC treatment vs. ibuprofen in the prevention of NSAID-induced gut injury was observed with increases in both mean Lanza scores and the risk of developing >2 erosions or an ulcer.', 'subject score': 1000, 'object score': 833}, 'PMID:2173723': {'publication date': '1990 Nov', 'sentence': 'Because ibuprofen protects from septic lung injury, we studied the effect of ibuprofen in oxidant lung injury from phosgene.', 'subject score': 1000, 'object score': 851}, 'PMID:3151052': {'publication date': '1988', 'sentence': 'Our study, thus, demonstrates that ibuprofen cannot prevent hyperoxic lung injury although it inhibits the influx of PMN into the injured lung, suggesting that PMN are not directly involved in the injury process.', 'subject score': 1000, 'object score': 828}, 'PMID:3883949': {'publication date': '1985 Feb', 'sentence': 'The pulmonary injury and the increase in TxB2 was prevented by ibuprofen.', 'subject score': 1000, 'object score': 888}, 'PMID:7827930': {'publication date': '1994 Dec', 'sentence': 'Ibuprofen reduces microvascular injury by limiting oxygen radical production by neutrophils.', 'subject score': 1000, 'object score': 888}, 'PMID:9596884': {'publication date': '1997 Mar', 'sentence': 'Ibuprofen may reduce partially the APEP-induced lung injury.', 'subject score': 1000, 'object score': 775}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C3263723---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9104502",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:11545620",
-                "PMID:1568970",
-                "PMID:18549459",
-                "PMID:2173723",
-                "PMID:3151052",
-                "PMID:3883949",
-                "PMID:7827930",
-                "PMID:9596884"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8829373,
-            "start": 554,
-            "end": 316891,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11471639': {'publication date': '2000 Dec', 'sentence': 'To determine if prophylactic etodolac would significantly reduce postendodontic pain, when compared with ibuprofen or placebo, 36 patients consented to single blind oral administration of either 400 mg of etodolac, 600 mg of ibuprofen, or a placebo, before conventional one-appointment root canal therapy.', 'subject score': 1000, 'object score': 861}, 'PMID:12216965': {'publication date': '2002 Aug', 'sentence': \"Patient's Assessment of Ankle Pain Visual Analog Scale on Weight Bearing responses, also given on days 4 and 8, showed that celecoxib was as efficacious in the treatment of ankle sprain as the maximum therapeutic dosage of ibuprofen and that, compared with placebo, it reduced pain significantly more (P < .05).\", 'subject score': 1000, 'object score': 827}, 'PMID:12540224': {'publication date': '2003 Jan', 'sentence': 'The purpose of this study was to determine if prophylactic rofecoxib would significantly reduce postendodontic pain, when compared with ibuprofen or placebo.', 'subject score': 1000, 'object score': 861}, 'PMID:16531187': {'publication date': '2006 Apr', 'sentence': 'CONCLUSIONS: Our results mirror other controlled studies that compared ibuprofen and omega-3 EFAs demonstrating equivalent effect in reducing arthritic pain. omega-3 EFA fish oil supplements appear to be a safer alternative to NSAIDs for treatment of nonsurgical neck or back pain in this selective group.', 'subject score': 861, 'object score': 568}, 'PMID:16808800': {'publication date': '2006 May-Jun', 'sentence': 'Biatain-Ibu Non-adhesive (Coloplast A/S), a new pain-reducing moist wound healing dressing containing ibuprofen was tested for pain reduction, safety, and efficacy on 10+2 patients in a single-blinded crossover study against Biatain Non-adhesive (Coloplast A/S).', 'subject score': 888, 'object score': 694}, 'PMID:16998619': {'publication date': '2006 Sep', 'sentence': 'Ibuprofen was significantly better at reducing pain at all time intervals by comparison with the placebo.', 'subject score': 1000, 'object score': 872}, 'PMID:17074548': {'publication date': '2006 Nov', 'sentence': 'Prophylactic ibuprofen as used in this protocol does not reduce IUD insertion pain.', 'subject score': 888, 'object score': 861}, 'PMID:18082668': {'publication date': '2008 Jan', 'sentence': 'Ibuprofen is somewhat more effective than tramadol at reducing pain 30 min following surgical abortion.', 'subject score': 1000, 'object score': 852}, 'PMID:18359021': {'publication date': '2009 May', 'sentence': 'CONCLUSION(S): Ibuprofen was found to be more effective than paracetamol for pain reduction during medical abortion.', 'subject score': 1000, 'object score': 694}, 'PMID:18663736': {'publication date': '2008 Aug', 'sentence': 'We conclude that ibuprofen is effective in reducing EMG pain as perceived immediately after the procedure.', 'subject score': 1000, 'object score': 840}, 'PMID:19055080': {'publication date': '2008 Nov 12-18', 'sentence': 'It combines the benefits of moist wound healing with a continuous release of ibuprofen into the wound and surrounding skin that is designed to reduce pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:19126235': {'publication date': '2009 Jan 06', 'sentence': 'Clinical studies have shown that naproxen and ibuprofen are significantly more effective at reducing OA pain than is acetaminophen, the traditional first-line therapy, which has no apparent anti-inflammatory activity in the joints.', 'subject score': 1000, 'object score': 840}, 'PMID:19367683': {'publication date': '2009 May 05', 'sentence': 'Ibuprofen loaded embolization beads (IBU-BB) have been developed to reduce inflammation and pain following uterine artery embolization for the treatment of uterine fibroids.', 'subject score': 1000, 'object score': 1000}, 'PMID:20609131': {'publication date': '2010 Aug', 'sentence': 'CONCLUSION: Pre- and post-operative administration of IV-ibuprofen significantly reduced both pain and morphine use in orthopedic surgery patients in this prospective randomized placebo-controlled trial.', 'subject score': 888, 'object score': 1000}, 'PMID:21237336': {'publication date': '2011 Feb', 'sentence': \"Four studies conducted in women with pregnancies <8 completed weeks' gestation found that prophylactic acetaminophen, acetaminophen+codeine, ibuprofen or alverine did not reduce medical abortion pain; however, administration of ibuprofen after onset of cramping reduced pain and subsequent analgesia use.\", 'subject score': 1000, 'object score': 901}, 'PMID:21712619': {'publication date': '2011 Jun', 'sentence': 'The purpose of this study was to evaluate clinically the effectiveness of prophylactic tenoxicam and prophylactic ibuprofen in reducing post-endodontic pain compared with placebo.', 'subject score': 888, 'object score': 825}, 'PMID:21762775': {'publication date': '2011 Dec', 'sentence': 'Intra-articular drug delivery systems (DDSs) are envisaged as interesting alternative to locally release nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen to reduce pain in patients with osteoarthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:22176793': {'publication date': '2012 Jun', 'sentence': 'CONCLUSION: Administration of ibuprofen prophylaxis for LNG-IUS insertion does not decrease pain at the time of insertion.', 'subject score': 888, 'object score': 1000}, 'PMID:22284284': {'publication date': '2012 Feb', 'sentence': 'INTRODUCTION: The aim of this study was to compare the efficacy of ibuprofen, viscoelastic bite wafers, and chewing gum in reducing orthodontic pain.', 'subject score': 1000, 'object score': 840}, 'PMID:22521671': {'publication date': '2012 Aug', 'sentence': 'The preoperative intake of ibuprofen does not seem to reduce pain, facial swelling and trismus after impacted lower third molar removal when compared to the postoperative administration of the same drug.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9022792",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:11471639",
-                "PMID:12216965",
-                "PMID:12540224",
-                "PMID:16531187",
-                "PMID:16808800",
-                "PMID:16998619",
-                "PMID:17074548",
-                "PMID:18082668",
-                "PMID:18359021",
-                "PMID:18663736",
-                "PMID:19055080",
-                "PMID:19126235",
-                "PMID:19367683",
-                "PMID:20609131",
-                "PMID:21237336",
-                "PMID:21712619",
-                "PMID:21762775",
-                "PMID:22176793",
-                "PMID:22284284",
-                "PMID:22521671"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317818,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011827",
-          "name": "patent ductus arteriosus",
-          "description": "In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences. [HPO:probinson, PMID:20421261]; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "DOID:13832",
-            "UMLS:C0013274",
-            "ORPHANET:706",
-            "ICD9:747.0",
-            "SNOMEDCT:83330001",
-            "HP:0001643",
-            "MESH:D004374",
-            "OMIM.PS:607411",
-            "ICD10:Q25.0",
-            "NCIT:C84492",
-            "MONDO:0011827"
-          ],
-          "id": "MONDO:0011827",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Patent ductus arteriosus",
-            "patent ductus arteriosus",
-            "Patent Ductus Arteriosus",
-            "Ductus Arteriosus, Patent"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:20421261"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317818,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011827",
-              "name": "patent ductus arteriosus",
-              "description": "In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences. [HPO:probinson, PMID:20421261]; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "DOID:13832",
-                "UMLS:C0013274",
-                "ORPHANET:706",
-                "ICD9:747.0",
-                "SNOMEDCT:83330001",
-                "HP:0001643",
-                "MESH:D004374",
-                "OMIM.PS:607411",
-                "ICD10:Q25.0",
-                "NCIT:C84492",
-                "MONDO:0011827"
-              ],
-              "id": "MONDO:0011827",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Patent ductus arteriosus",
-                "patent ductus arteriosus",
-                "Patent Ductus Arteriosus",
-                "Ductus Arteriosus, Patent"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:20421261"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8401507,
-            "start": 554,
-            "end": 317818,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11106052': {'publication date': '2000 Nov', 'sentence': 'UNLABELLED: The aim of our study was to evaluate whether the prophylactic use of ibuprofen would reduce the incidence of significant patent ductus arteriosus (PDA) and to confirm the effectiveness of ibuprofen as rescue treatment in closing PDA.', 'subject score': 1000, 'object score': 916}, 'PMID:12804505': {'publication date': '2003', 'sentence': \"REVIEWER'S CONCLUSIONS: Prophylactic use of ibuprofen reduces the incidence of PDA.\", 'subject score': 1000, 'object score': 1000}, 'PMID:16437478': {'publication date': '2006 Jan 25', 'sentence': \"AUTHORS' CONCLUSIONS: Prophylactic use of ibuprofen reduces the incidence of PDA, the need for rescue treatment with cyclo-oxygenase inhibitors and surgical closure.\", 'subject score': 1000, 'object score': 1000}, 'PMID:17437233': {'publication date': '2007 Apr', 'sentence': 'However, adverse effects of ibuprofen have been evidenced both in trials on the use of ibuprofen for the prevention of PDA and of intraventricular hemorrhage-periventricular hemorrhage (IVH-PVH), and in experimental studies on a neonatal, anesthetized animal model.', 'subject score': 1000, 'object score': 1000}, 'PMID:21735396': {'publication date': '2011 Jul 06', 'sentence': \"AUTHORS' CONCLUSIONS: Prophylactic use of ibuprofen decreased the incidence of PDA, decreased the need for rescue treatment with cyclo-oxygenase inhibitors and decreased the need for surgical closure.\", 'subject score': 1000, 'object score': 1000}, 'PMID:22564295': {'publication date': '2012', 'sentence': 'Non-steroidal anti-inflammatory agents, such as indomethacin or ibuprofen, have been shown to be effective in closing or preventing patent ductus arteriosus, with differences in side effects.', 'subject score': 1000, 'object score': 900}, 'PMID:22613269': {'publication date': '2012 Nov-Dec', 'sentence': 'OBJECTIVE: Intravenous ibuprofen is an expensive drug that is being used currently for treating and preventing patent ductus arteriosus.', 'subject score': 888, 'object score': 900}, 'PMID:23128963': {'publication date': '2013 May', 'sentence': 'Serum ibuprofen levels of extremely preterm infants treated prophylactically with oral ibuprofen to prevent patent ductus arteriosus.', 'subject score': 851, 'object score': 1000}, 'PMID:25532746': {'publication date': '2015 Jan', 'sentence': 'Prophylactic therapy with indomethacin or ibuprofen to prevent PDA has not altered the morbidity or long term outcome.', 'subject score': 1000, 'object score': 1000}, 'PMID:27493386': {'publication date': '2014', 'sentence': 'Although indomethacin and ibuprofen are the main stay of medical treatment, conservative approach by restricted fluid and applying continuous positive airway pressure (CPAP) may be effective in prevention of PDA without complication.', 'subject score': 1000, 'object score': 1000}, 'PMID:31222841': {'publication date': '2019 06 21', 'sentence': 'Current evidence does not support the use of ibuprofen for prevention of patent ductus arteriosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:31985838': {'publication date': '2020 Jan 27', 'sentence': 'Current evidence does not support the use of ibuprofen for prevention of patent ductus arteriosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:35363893': {'publication date': '2022 Apr 01', 'sentence': 'Ibuprofen (median rank 1) was more effective than indomethacin in reducing surgical PDA ligation (median rank 2).', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0013274---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "8584177",
-              "object": "MONDO:0011827",
-              "publications": [
-                "PMID:11106052",
-                "PMID:12804505",
-                "PMID:16437478",
-                "PMID:17437233",
-                "PMID:21735396",
-                "PMID:22564295",
-                "PMID:22613269",
-                "PMID:23128963",
-                "PMID:25532746",
-                "PMID:27493386",
-                "PMID:31222841",
-                "PMID:31985838",
-                "PMID:35363893"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:10581086': {'publication date': '1999 Dec', 'sentence': 'Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, indomethacin and ibuprofen are the most widely used drugs for pain, arthritis, cardiovascular diseases and, more recently, the prevention of colon cancer and Alzheimer disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:15626583': {'publication date': '2005 Jan', 'sentence': \"Thus, limited brain penetration prevents the possible use of ibuprofen in treating or preventing neurodegenerative disorders such as Alzheimer's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:20186865': {'publication date': '2010 Mar', 'sentence': \"In the present work, our attention was focused on ibuprofen (IBU) used in clinical trails to prevent Alzheimer's disease, and (R)-alpha-lipoic acid (LA) considered as a potential neuroprotective agent in AD therapy.\", 'subject score': 1000, 'object score': 1000}, 'PMID:20930267': {'publication date': '2010', 'sentence': \"Since migration is a hallmark of astrocyte response during inflammation we propose that, in addition to (or instead of) lowering amyloid-beta42 via secretases, ibuprofen and its derivatives may prevent Alzheimer's disease instead of AD by modulating astrocyte reactivity through Rho-GTPase/PAK/ERK-dependent signaling.\", 'subject score': 1000, 'object score': 1000}, 'PMID:21943956': {'publication date': '2012 Apr', 'sentence': \"Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that has been reported to reduce the risk of developing Alzheimer's disease (AD).\", 'subject score': 1000, 'object score': 901}, 'PMID:24699228': {'publication date': '2014 Jun 13', 'sentence': \"Ibuprofen is a widely used nonsteroidal anti-inflammatory drug that reportedly reduces the risk of Alzheimer's disease (AD) development.\", 'subject score': 1000, 'object score': 901}, 'PMID:25659514': {'publication date': '2015 Apr 05', 'sentence': \"Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID), treatment with which has been shown to delay the onset, slows the cognitive decline, and decreases the incidence of Alzheimer's disease (AD) in epidemiological and clinical studies.\", 'subject score': 1000, 'object score': 1000}, 'PMID:34121565': {'publication date': '2021 Dec', 'sentence': \"Studies have shown the use of non-steroidal anti-inflammatory drugs, such as ibuprofen could reduce the risk of Alzheimer's disease.\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 307306,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004975",
-          "name": "Alzheimer disease",
-          "description": "A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. [HPO:probinson]; A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. // COMMENTS: Note that this is a bundled term that refers to a disease rather than to phenotypic features. It is retained for convenience since Alzheimer disease is used for annotation of other diseases (e.g., Down syndrome) as if it were a feature. If possible it is preferable to annotate with the precise phenotypic features.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "KEGG.DISEASE:05010",
-            "SNOMEDCT:142811000119104",
-            "MEDDRA:10012292",
-            "UMLS:C1863053",
-            "HP:0002511",
-            "ICD9:331.0",
-            "ORPHANET:238616",
-            "MEDDRA:10012271",
-            "MEDDRA:10001896",
-            "UMLS:C3549448",
-            "UMLS:C0002395",
-            "NCIT:C2866",
-            "DOID:10652",
-            "MONDO:0004975",
-            "EFO:0000249",
-            "NCIT:C146894",
-            "UMLS:C1863052",
-            "SNOMEDCT:230267005",
-            "PSY:01940",
-            "SNOMEDCT:26929004",
-            "OMIM:104300",
-            "ICD10:G30",
-            "MESH:D000544",
-            "MESH:C566299"
-          ],
-          "id": "MONDO:0004975",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Alzheimer's disease",
-            "Alzheimer disease, familial, 1",
-            "Alzheimer Disease, Early-Onset, With Cerebral Amyloid Angiopathy",
-            "Alzheimer's Disease",
-            "Alzheimers Disease",
-            "Alzheimer disease",
-            "Alzheimer disease, protection against",
-            "Alzheimer Disease",
-            "obsolete_Alzheimer's disease",
-            "Alzheimer disease, familial, 1 related phenotypic feature",
-            "Alzheimer's Disease 1"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet",
-            "http://en.wikipedia.org/wiki/alzheimer%27s_disease",
-            "http://www.merriam-webster.com/medical/alzheimer%27s%20disease",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 307306,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004975",
-              "name": "Alzheimer disease",
-              "description": "A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. [HPO:probinson]; A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. // COMMENTS: Note that this is a bundled term that refers to a disease rather than to phenotypic features. It is retained for convenience since Alzheimer disease is used for annotation of other diseases (e.g., Down syndrome) as if it were a feature. If possible it is preferable to annotate with the precise phenotypic features.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "KEGG.DISEASE:05010",
-                "SNOMEDCT:142811000119104",
-                "MEDDRA:10012292",
-                "UMLS:C1863053",
-                "HP:0002511",
-                "ICD9:331.0",
-                "ORPHANET:238616",
-                "MEDDRA:10012271",
-                "MEDDRA:10001896",
-                "UMLS:C3549448",
-                "UMLS:C0002395",
-                "NCIT:C2866",
-                "DOID:10652",
-                "MONDO:0004975",
-                "EFO:0000249",
-                "NCIT:C146894",
-                "UMLS:C1863052",
-                "SNOMEDCT:230267005",
-                "PSY:01940",
-                "SNOMEDCT:26929004",
-                "OMIM:104300",
-                "ICD10:G30",
-                "MESH:D000544",
-                "MESH:C566299"
-              ],
-              "id": "MONDO:0004975",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Alzheimer's disease",
-                "Alzheimer disease, familial, 1",
-                "Alzheimer Disease, Early-Onset, With Cerebral Amyloid Angiopathy",
-                "Alzheimer's Disease",
-                "Alzheimers Disease",
-                "Alzheimer disease",
-                "Alzheimer disease, protection against",
-                "Alzheimer Disease",
-                "obsolete_Alzheimer's disease",
-                "Alzheimer disease, familial, 1 related phenotypic feature",
-                "Alzheimer's Disease 1"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet",
-                "http://en.wikipedia.org/wiki/alzheimer%27s_disease",
-                "http://www.merriam-webster.com/medical/alzheimer%27s%20disease",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7680624,
-            "start": 554,
-            "end": 307306,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10581086': {'publication date': '1999 Dec', 'sentence': 'Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, indomethacin and ibuprofen are the most widely used drugs for pain, arthritis, cardiovascular diseases and, more recently, the prevention of colon cancer and Alzheimer disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:15626583': {'publication date': '2005 Jan', 'sentence': \"Thus, limited brain penetration prevents the possible use of ibuprofen in treating or preventing neurodegenerative disorders such as Alzheimer's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:20186865': {'publication date': '2010 Mar', 'sentence': \"In the present work, our attention was focused on ibuprofen (IBU) used in clinical trails to prevent Alzheimer's disease, and (R)-alpha-lipoic acid (LA) considered as a potential neuroprotective agent in AD therapy.\", 'subject score': 1000, 'object score': 1000}, 'PMID:20930267': {'publication date': '2010', 'sentence': \"Since migration is a hallmark of astrocyte response during inflammation we propose that, in addition to (or instead of) lowering amyloid-beta42 via secretases, ibuprofen and its derivatives may prevent Alzheimer's disease instead of AD by modulating astrocyte reactivity through Rho-GTPase/PAK/ERK-dependent signaling.\", 'subject score': 1000, 'object score': 1000}, 'PMID:21943956': {'publication date': '2012 Apr', 'sentence': \"Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that has been reported to reduce the risk of developing Alzheimer's disease (AD).\", 'subject score': 1000, 'object score': 901}, 'PMID:24699228': {'publication date': '2014 Jun 13', 'sentence': \"Ibuprofen is a widely used nonsteroidal anti-inflammatory drug that reportedly reduces the risk of Alzheimer's disease (AD) development.\", 'subject score': 1000, 'object score': 901}, 'PMID:25659514': {'publication date': '2015 Apr 05', 'sentence': \"Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID), treatment with which has been shown to delay the onset, slows the cognitive decline, and decreases the incidence of Alzheimer's disease (AD) in epidemiological and clinical studies.\", 'subject score': 1000, 'object score': 1000}, 'PMID:34121565': {'publication date': '2021 Dec', 'sentence': \"Studies have shown the use of non-steroidal anti-inflammatory drugs, such as ibuprofen could reduce the risk of Alzheimer's disease.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0002395---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "7843138",
-              "object": "MONDO:0004975",
-              "publications": [
-                "PMID:10581086",
-                "PMID:15626583",
-                "PMID:20186865",
-                "PMID:20930267",
-                "PMID:21943956",
-                "PMID:24699228",
-                "PMID:25659514",
-                "PMID:34121565"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15025845,
-            "start": 554,
-            "end": 546804,
-            "type": "biolink:exacerbates",
-            "properties": {
-              "predicate": "biolink:exacerbates",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21121909': {'publication date': '2010 Dec', 'sentence': 'Aggravation of seizure-associated microvascular injuries by ibuprofen may involve multiple pathways.', 'subject score': 1000, 'object score': 775}, 'PMID:22776871': {'publication date': '2012 Dec', 'sentence': 'CONCLUSION: This is the first study to reveal that ibuprofen aggravates exercise-induced small intestinal injury and induces gut barrier dysfunction in healthy individuals.', 'subject score': 1000, 'object score': 857}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:complicates---None---None---None---UMLS:C3263723---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "15342704",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:21121909",
-                "PMID:22776871"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 315498,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006497",
-          "name": "cerebral palsy",
-          "description": "A group of disorders affecting the development of movement and posture, often accompanied by disturbances of sensation, perception, cognition, and behavior. It results from damage to the fetal or infant brain.; A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7); Cerebral palsy describes a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to nonprogressive disturbances that occurred in the developing fetal or infant brain. The motor disorders of cerebral palsy are often accompanied by disturbances of sensation, perception, cognition, communication, and behaviour, by epilepsy, and by secondary musculoskeletal problems. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:1969",
-            "HP:0100021",
-            "UMLS:C0007789",
-            "ICD10:G80",
-            "EFO:1000632",
-            "PSY:08280",
-            "MEDDRA:10008129",
-            "SNOMEDCT:128188000",
-            "MEDDRA:10033560",
-            "MONDO:0006497",
-            "MESH:D002547",
-            "NCIT:C34460"
-          ],
-          "id": "MONDO:0006497",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cerebral Palsy",
-            "cerebral palsy",
-            "Cerebral palsy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/cerebral_palsy",
-            "http://www.brainandspinalcord.org/cerebral-palsy/index.htm",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://www.cerebralpalsy.org/what-is-cerebral-palsy/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315498,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006497",
-              "name": "cerebral palsy",
-              "description": "A group of disorders affecting the development of movement and posture, often accompanied by disturbances of sensation, perception, cognition, and behavior. It results from damage to the fetal or infant brain.; A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7); Cerebral palsy describes a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to nonprogressive disturbances that occurred in the developing fetal or infant brain. The motor disorders of cerebral palsy are often accompanied by disturbances of sensation, perception, cognition, communication, and behaviour, by epilepsy, and by secondary musculoskeletal problems. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:1969",
-                "HP:0100021",
-                "UMLS:C0007789",
-                "ICD10:G80",
-                "EFO:1000632",
-                "PSY:08280",
-                "MEDDRA:10008129",
-                "SNOMEDCT:128188000",
-                "MEDDRA:10033560",
-                "MONDO:0006497",
-                "MESH:D002547",
-                "NCIT:C34460"
-              ],
-              "id": "MONDO:0006497",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cerebral Palsy",
-                "cerebral palsy",
-                "Cerebral palsy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/cerebral_palsy",
-                "http://www.brainandspinalcord.org/cerebral-palsy/index.htm",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://www.cerebralpalsy.org/what-is-cerebral-palsy/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19616788,
-            "start": 554,
-            "end": 315498,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29149272': {'publication date': '2018 02 01', 'sentence': 'Use of paracetamol, ibuprofen or aspirin in pregnancy and risk of cerebral palsy in the child.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:predisposes---None---None---None---UMLS:C0007789---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "20007370",
-              "object": "MONDO:0006497",
-              "publications": [
-                "PMID:29149272"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 722907,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-          "name": "bronchopulmonary dysplasia",
-          "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:70589",
-            "MESH:D001997",
-            "MONDO:0019091",
-            "SNOMEDCT:67569000",
-            "MEDDRA:10066204",
-            "UMLS:C0006287",
-            "NCIT:C90599",
-            "DOID:11650",
-            "MEDDRA:10006475"
-          ],
-          "id": "MONDO:0019091",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bronchopulmonary Dysplasia",
-            "obsolete_bronchopulmonary dysplasia",
-            "bronchopulmonary dysplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 722907,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-              "name": "bronchopulmonary dysplasia",
-              "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:70589",
-                "MESH:D001997",
-                "MONDO:0019091",
-                "SNOMEDCT:67569000",
-                "MEDDRA:10066204",
-                "UMLS:C0006287",
-                "NCIT:C90599",
-                "DOID:11650",
-                "MEDDRA:10006475"
-              ],
-              "id": "MONDO:0019091",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bronchopulmonary Dysplasia",
-                "obsolete_bronchopulmonary dysplasia",
-                "bronchopulmonary dysplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14032853,
-            "start": 554,
-            "end": 722907,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19379895': {'publication date': '2009 May', 'sentence': 'More than two cycles of ibuprofen was significantly associated with an increased risk for bronchopulmonary dysplasia (odds ratio [OR], 2.81; p = 0.03) and acute renal failure (OR, 3.81; p = 0.09).', 'subject score': 1000, 'object score': 1000}, 'PMID:19690594': {'publication date': '2009 Aug 13', 'sentence': 'INTERPRETATION: Treatment of a patent ductus arteriosus with COX-inhibitors such as indomethacin and ibuprofen, increases the risk for bronchopulmonary dysplasia without reducing other complications or death.', 'subject score': 1000, 'object score': 1000}, 'PMID:31391526': {'publication date': '2019 Aug 07', 'sentence': 'OBJECTIVE: To evaluate the association of ibuprofen exposure with the risk of bronchopulmonary dysplasia (BPD) in extremely premature infants.', 'subject score': 694, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:predisposes---None---None---None---UMLS:C0006287---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "14332005",
-              "object": "MONDO:0019091",
-              "publications": [
-                "PMID:19379895",
-                "PMID:19690594",
-                "PMID:31391526"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:19324592': {'publication date': '2009 Apr', 'sentence': \"OBJECTIVE: Non-steroidal anti-inflammatory drugs such as ibuprofen have a protective role on risk of Alzheimer's disease (AD).\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 307306,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004975",
-          "name": "Alzheimer disease",
-          "description": "A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. [HPO:probinson]; A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. // COMMENTS: Note that this is a bundled term that refers to a disease rather than to phenotypic features. It is retained for convenience since Alzheimer disease is used for annotation of other diseases (e.g., Down syndrome) as if it were a feature. If possible it is preferable to annotate with the precise phenotypic features.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "KEGG.DISEASE:05010",
-            "SNOMEDCT:142811000119104",
-            "MEDDRA:10012292",
-            "UMLS:C1863053",
-            "HP:0002511",
-            "ICD9:331.0",
-            "ORPHANET:238616",
-            "MEDDRA:10012271",
-            "MEDDRA:10001896",
-            "UMLS:C3549448",
-            "UMLS:C0002395",
-            "NCIT:C2866",
-            "DOID:10652",
-            "MONDO:0004975",
-            "EFO:0000249",
-            "NCIT:C146894",
-            "UMLS:C1863052",
-            "SNOMEDCT:230267005",
-            "PSY:01940",
-            "SNOMEDCT:26929004",
-            "OMIM:104300",
-            "ICD10:G30",
-            "MESH:D000544",
-            "MESH:C566299"
-          ],
-          "id": "MONDO:0004975",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Alzheimer's disease",
-            "Alzheimer disease, familial, 1",
-            "Alzheimer Disease, Early-Onset, With Cerebral Amyloid Angiopathy",
-            "Alzheimer's Disease",
-            "Alzheimers Disease",
-            "Alzheimer disease",
-            "Alzheimer disease, protection against",
-            "Alzheimer Disease",
-            "obsolete_Alzheimer's disease",
-            "Alzheimer disease, familial, 1 related phenotypic feature",
-            "Alzheimer's Disease 1"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet",
-            "http://en.wikipedia.org/wiki/alzheimer%27s_disease",
-            "http://www.merriam-webster.com/medical/alzheimer%27s%20disease",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 307306,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004975",
-              "name": "Alzheimer disease",
-              "description": "A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. [HPO:probinson]; A degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxia and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of senile plaques, neurofibrillary tangles, and neuropil threads. // COMMENTS: Note that this is a bundled term that refers to a disease rather than to phenotypic features. It is retained for convenience since Alzheimer disease is used for annotation of other diseases (e.g., Down syndrome) as if it were a feature. If possible it is preferable to annotate with the precise phenotypic features.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "KEGG.DISEASE:05010",
-                "SNOMEDCT:142811000119104",
-                "MEDDRA:10012292",
-                "UMLS:C1863053",
-                "HP:0002511",
-                "ICD9:331.0",
-                "ORPHANET:238616",
-                "MEDDRA:10012271",
-                "MEDDRA:10001896",
-                "UMLS:C3549448",
-                "UMLS:C0002395",
-                "NCIT:C2866",
-                "DOID:10652",
-                "MONDO:0004975",
-                "EFO:0000249",
-                "NCIT:C146894",
-                "UMLS:C1863052",
-                "SNOMEDCT:230267005",
-                "PSY:01940",
-                "SNOMEDCT:26929004",
-                "OMIM:104300",
-                "ICD10:G30",
-                "MESH:D000544",
-                "MESH:C566299"
-              ],
-              "id": "MONDO:0004975",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Alzheimer's disease",
-                "Alzheimer disease, familial, 1",
-                "Alzheimer Disease, Early-Onset, With Cerebral Amyloid Angiopathy",
-                "Alzheimer's Disease",
-                "Alzheimers Disease",
-                "Alzheimer disease",
-                "Alzheimer disease, protection against",
-                "Alzheimer Disease",
-                "obsolete_Alzheimer's disease",
-                "Alzheimer disease, familial, 1 related phenotypic feature",
-                "Alzheimer's Disease 1"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet",
-                "http://en.wikipedia.org/wiki/alzheimer%27s_disease",
-                "http://www.merriam-webster.com/medical/alzheimer%27s%20disease",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13995426,
-            "start": 554,
-            "end": 307306,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19324592': {'publication date': '2009 Apr', 'sentence': \"OBJECTIVE: Non-steroidal anti-inflammatory drugs such as ibuprofen have a protective role on risk of Alzheimer's disease (AD).\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:predisposes---None---None---None---UMLS:C0002395---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "14294004",
-              "object": "MONDO:0004975",
-              "publications": [
-                "PMID:19324592"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:12355496': {'publication date': '2002 Sep', 'sentence': 'The C5a antagonist (1 or 3 mg/kg/day) and/or ibuprofen (30 mg/kg/day) were administered orally on a daily basis either before or after arthritis induction.', 'subject score': 1000, 'object score': 888}, 'PMID:23901209': {'publication date': '2013 Jul', 'sentence': 'Animals were administered UP446 (50 mg/kg), ibuprofen (150 mg/kg mg/kg) or vehicle by oral gavage 30 min prior to arthritis induction and each day thereafter for 14 days.', 'subject score': 1000, 'object score': 888}, 'PMID:26981605': {'publication date': '2016 Mar', 'sentence': 'Ibuprofen, diclofenac sodium and meloxicam were given intragastrically before induction of TMJ inflammation.', 'subject score': 1000, 'object score': 901}, 'PMID:3124133': {'publication date': '1987 Oct', 'sentence': 'Inhibition of joint inflammation resulting from treatment with ibuprofen and flurbiprofen is reflected by a decrease in concentration of all 5 eicosanoids which were found in the order: PGE2 greater than TXB2 greater than 6-keto-PGF1 alpha greater than PGF1 greater than PGF2 alpha.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 307910,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005578",
-          "name": "arthritic joint disease",
-          "description": "An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.; Acute or chronic inflammation of JOINTS.; Inflammation of a joint. [HPO:probinson]; If you feel pain and stiffness in your body or have trouble moving around, you might have arthritis. Most kinds of arthritis cause pain and swelling in your joints. Joints are places where two bones meet, such as your elbow or knee. Over time, a swollen joint can become severely damaged. Some kinds of arthritis can also cause problems in your organs, such as your eyes or skin. Types of arthritis include: Osteoarthritis is the most common type of arthritis. It's often related to aging or to an injury. Autoimmune arthritis happens when your body's immune system attacks healthy cells in your body by mistake. Rheumatoid arthritis is the most common form of this kind of arthritis. Juvenile arthritis is a type of arthritis that happens in children. Infectious arthritis is an infection that has spread from another part of the body to the joint. Psoriatic arthritis affects people with psoriasis. Gout is a painful type of arthritis that happens when too much uric acid builds up in the body. It often starts in the big toe.  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0003864",
-            "MEDDRA:10003263",
-            "PSY:03860",
-            "EFO:0005856",
-            "ICD10:M19.90",
-            "MEDDRA:10003246",
-            "MONDO:0005578",
-            "SYMP:0019169",
-            "SNOMEDCT:3723001",
-            "UMLS:C0574941",
-            "NCIT:C2883",
-            "SNOMEDCT:298160000",
-            "DOID:848",
-            "MEDDRA:10023217",
-            "HP:0001369",
-            "MESH:D001168",
-            "MEDDRA:10081014"
-          ],
-          "id": "MONDO:0005578",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Arthritis",
-            "arthritic joint disease",
-            "Inflamed joint",
-            "arthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.arthritis.org/",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=arthritis",
-            "https://www.cdc.gov/arthritis/index.htm",
-            "http://en.wikipedia.org/wiki/arthritis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/001243.htm",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 307910,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005578",
-              "name": "arthritic joint disease",
-              "description": "An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.; Acute or chronic inflammation of JOINTS.; Inflammation of a joint. [HPO:probinson]; If you feel pain and stiffness in your body or have trouble moving around, you might have arthritis. Most kinds of arthritis cause pain and swelling in your joints. Joints are places where two bones meet, such as your elbow or knee. Over time, a swollen joint can become severely damaged. Some kinds of arthritis can also cause problems in your organs, such as your eyes or skin. Types of arthritis include: Osteoarthritis is the most common type of arthritis. It's often related to aging or to an injury. Autoimmune arthritis happens when your body's immune system attacks healthy cells in your body by mistake. Rheumatoid arthritis is the most common form of this kind of arthritis. Juvenile arthritis is a type of arthritis that happens in children. Infectious arthritis is an infection that has spread from another part of the body to the joint. Psoriatic arthritis affects people with psoriasis. Gout is a painful type of arthritis that happens when too much uric acid builds up in the body. It often starts in the big toe.  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0003864",
-                "MEDDRA:10003263",
-                "PSY:03860",
-                "EFO:0005856",
-                "ICD10:M19.90",
-                "MEDDRA:10003246",
-                "MONDO:0005578",
-                "SYMP:0019169",
-                "SNOMEDCT:3723001",
-                "UMLS:C0574941",
-                "NCIT:C2883",
-                "SNOMEDCT:298160000",
-                "DOID:848",
-                "MEDDRA:10023217",
-                "HP:0001369",
-                "MESH:D001168",
-                "MEDDRA:10081014"
-              ],
-              "id": "MONDO:0005578",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Arthritis",
-                "arthritic joint disease",
-                "Inflamed joint",
-                "arthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.arthritis.org/",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=arthritis",
-                "https://www.cdc.gov/arthritis/index.htm",
-                "http://en.wikipedia.org/wiki/arthritis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/001243.htm",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9588401,
-            "start": 554,
-            "end": 307910,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12355496': {'publication date': '2002 Sep', 'sentence': 'The C5a antagonist (1 or 3 mg/kg/day) and/or ibuprofen (30 mg/kg/day) were administered orally on a daily basis either before or after arthritis induction.', 'subject score': 1000, 'object score': 888}, 'PMID:23901209': {'publication date': '2013 Jul', 'sentence': 'Animals were administered UP446 (50 mg/kg), ibuprofen (150 mg/kg mg/kg) or vehicle by oral gavage 30 min prior to arthritis induction and each day thereafter for 14 days.', 'subject score': 1000, 'object score': 888}, 'PMID:26981605': {'publication date': '2016 Mar', 'sentence': 'Ibuprofen, diclofenac sodium and meloxicam were given intragastrically before induction of TMJ inflammation.', 'subject score': 1000, 'object score': 901}, 'PMID:3124133': {'publication date': '1987 Oct', 'sentence': 'Inhibition of joint inflammation resulting from treatment with ibuprofen and flurbiprofen is reflected by a decrease in concentration of all 5 eicosanoids which were found in the order: PGE2 greater than TXB2 greater than 6-keto-PGF1 alpha greater than PGF1 greater than PGF2 alpha.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C0003864---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9800201",
-              "object": "MONDO:0005578",
-              "publications": [
-                "PMID:12355496",
-                "PMID:23901209",
-                "PMID:26981605",
-                "PMID:3124133"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10487161': {'publication date': '1999 Aug', 'sentence': \"I take ibuprofen regularly for my arthritis, but I've heard that it may lead to kidney damage.\", 'subject score': 861, 'object score': 1000}, 'PMID:17003915': {'publication date': '2006 Oct', 'sentence': 'Ibuprofen or Naproxen (PRECISION) trial will assess the relative cardiovascular safety of three of the most commonly used pain relievers in the treatment of arthritis patients, ibuprofen, naproxen and celecoxib.', 'subject score': 1000, 'object score': 888}, 'PMID:21403884': {'publication date': '2011', 'sentence': 'Joint inflammation and early degeneration induced by high-force reaching are attenuated by ibuprofen in an animal model of work-related musculoskeletal disorder.', 'subject score': 1000, 'object score': 1000}, 'PMID:23066177': {'publication date': '2012 Mar', 'sentence': 'Cartilage targeted chemical delivery of naproxen and ibuprofen for the treatment of arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2590270': {'publication date': '1989 Sep', 'sentence': 'Concentrations of Ibuprofen and Protein Concentration and pH-Value in Synovial Fluid and Plasma Following Oral Administration of Ibuprofen in Patients Suffering from Arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:25918809': {'publication date': '2014 Sep', 'sentence': 'In this study, we examined, in comparison with ibuprofen, the inhibitory effects on various inflammatory markers of the most commonly used herbal medicines to treat arthritis, boswellia (Boswellia sapindales), licorice (Glycyrrhiza glabra), guggul (Commiphora wightii), and neem (Azadirachta indica).', 'subject score': 1000, 'object score': 1000}, 'PMID:26883979': {'publication date': '2016 Mar 15', 'sentence': 'Ibuprofen is the first line of treatment for osteoarthritis and arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:26981605': {'publication date': '2016 Mar', 'sentence': 'However, ibuprofen and diclofenac sodium slightly attenuated TMJ inflammation and meloxicam did not affect TMJ inflammation.', 'subject score': 1000, 'object score': 901}, 'PMID:27959716': {'publication date': '2016 12 29', 'sentence': 'Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28379793': {'publication date': '2017 04 06', 'sentence': 'Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:32140283': {'publication date': '2019 Sep 01', 'sentence': 'Case Presentation:         In this report, we described a 15-year-old boy, suffering concurrently both from human leukocyte antigen (HLA)-B27-positive chronic arthritis and CGD, whose arthritis did not respond to treatment with methotrexate and ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:32424605': {'publication date': '2020 May 18', 'sentence': \"This study evaluated the effects of a low-dose AN and ibuprofen (IB) combination on inflammatory parameters in Freund's complete adjuvant-induced arthritis (AIA) and arthritis-induced hepatic metabolic changes.\", 'subject score': 888, 'object score': 875}, 'PMID:3365913': {'publication date': '1988 May', 'sentence': 'The simultaneous disposition of the enantiomers of ibuprofen in synovial fluid and plasma was studied in eight patients with arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3437603': {'publication date': '1987 Nov', 'sentence': 'On the contrary, cyclophosphamide, dexamethasone, or ibuprofen strongly protected the animals from the development of arthritis and/or cured the established arthritis by these dose regimens.', 'subject score': 1000, 'object score': 888}, 'PMID:35234840': {'publication date': '2022 Mar 02', 'sentence': 'Cardiorenal Risk of Celecoxib compared to Naproxen, or Ibuprofen in Arthritis Patients: Insights from the PRECISION trial.', 'subject score': 1000, 'object score': 888}, 'PMID:439358': {'publication date': '1979 Jun 15', 'sentence': 'Three young women with systemic lupus erythematosus who were given ibuprofen for arthritis voluntarily discontinued taking the drug.', 'subject score': 1000, 'object score': 1000}, 'PMID:4864061': {'publication date': '1967 Nov', 'sentence': 'Ibuprofen in the treatment of rheumatoid arthritis and osteo-arthritis.', 'subject score': 1000, 'object score': 861}, 'PMID:5524278': {'publication date': '1970', 'sentence': 'Further experience with ibuprofen in the treatment of arthritis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 307910,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005578",
-          "name": "arthritic joint disease",
-          "description": "An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.; Acute or chronic inflammation of JOINTS.; Inflammation of a joint. [HPO:probinson]; If you feel pain and stiffness in your body or have trouble moving around, you might have arthritis. Most kinds of arthritis cause pain and swelling in your joints. Joints are places where two bones meet, such as your elbow or knee. Over time, a swollen joint can become severely damaged. Some kinds of arthritis can also cause problems in your organs, such as your eyes or skin. Types of arthritis include: Osteoarthritis is the most common type of arthritis. It's often related to aging or to an injury. Autoimmune arthritis happens when your body's immune system attacks healthy cells in your body by mistake. Rheumatoid arthritis is the most common form of this kind of arthritis. Juvenile arthritis is a type of arthritis that happens in children. Infectious arthritis is an infection that has spread from another part of the body to the joint. Psoriatic arthritis affects people with psoriasis. Gout is a painful type of arthritis that happens when too much uric acid builds up in the body. It often starts in the big toe.  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0003864",
-            "MEDDRA:10003263",
-            "PSY:03860",
-            "EFO:0005856",
-            "ICD10:M19.90",
-            "MEDDRA:10003246",
-            "MONDO:0005578",
-            "SYMP:0019169",
-            "SNOMEDCT:3723001",
-            "UMLS:C0574941",
-            "NCIT:C2883",
-            "SNOMEDCT:298160000",
-            "DOID:848",
-            "MEDDRA:10023217",
-            "HP:0001369",
-            "MESH:D001168",
-            "MEDDRA:10081014"
-          ],
-          "id": "MONDO:0005578",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Arthritis",
-            "arthritic joint disease",
-            "Inflamed joint",
-            "arthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.arthritis.org/",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=arthritis",
-            "https://www.cdc.gov/arthritis/index.htm",
-            "http://en.wikipedia.org/wiki/arthritis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/001243.htm",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 307910,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005578",
-              "name": "arthritic joint disease",
-              "description": "An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.; Acute or chronic inflammation of JOINTS.; Inflammation of a joint. [HPO:probinson]; If you feel pain and stiffness in your body or have trouble moving around, you might have arthritis. Most kinds of arthritis cause pain and swelling in your joints. Joints are places where two bones meet, such as your elbow or knee. Over time, a swollen joint can become severely damaged. Some kinds of arthritis can also cause problems in your organs, such as your eyes or skin. Types of arthritis include: Osteoarthritis is the most common type of arthritis. It's often related to aging or to an injury. Autoimmune arthritis happens when your body's immune system attacks healthy cells in your body by mistake. Rheumatoid arthritis is the most common form of this kind of arthritis. Juvenile arthritis is a type of arthritis that happens in children. Infectious arthritis is an infection that has spread from another part of the body to the joint. Psoriatic arthritis affects people with psoriasis. Gout is a painful type of arthritis that happens when too much uric acid builds up in the body. It often starts in the big toe.  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0003864",
-                "MEDDRA:10003263",
-                "PSY:03860",
-                "EFO:0005856",
-                "ICD10:M19.90",
-                "MEDDRA:10003246",
-                "MONDO:0005578",
-                "SYMP:0019169",
-                "SNOMEDCT:3723001",
-                "UMLS:C0574941",
-                "NCIT:C2883",
-                "SNOMEDCT:298160000",
-                "DOID:848",
-                "MEDDRA:10023217",
-                "HP:0001369",
-                "MESH:D001168",
-                "MEDDRA:10081014"
-              ],
-              "id": "MONDO:0005578",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Arthritis",
-                "arthritic joint disease",
-                "Inflamed joint",
-                "arthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.arthritis.org/",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=arthritis",
-                "https://www.cdc.gov/arthritis/index.htm",
-                "http://en.wikipedia.org/wiki/arthritis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/001243.htm",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7529126,
-            "start": 554,
-            "end": 307910,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10487161': {'publication date': '1999 Aug', 'sentence': \"I take ibuprofen regularly for my arthritis, but I've heard that it may lead to kidney damage.\", 'subject score': 861, 'object score': 1000}, 'PMID:17003915': {'publication date': '2006 Oct', 'sentence': 'Ibuprofen or Naproxen (PRECISION) trial will assess the relative cardiovascular safety of three of the most commonly used pain relievers in the treatment of arthritis patients, ibuprofen, naproxen and celecoxib.', 'subject score': 1000, 'object score': 888}, 'PMID:21403884': {'publication date': '2011', 'sentence': 'Joint inflammation and early degeneration induced by high-force reaching are attenuated by ibuprofen in an animal model of work-related musculoskeletal disorder.', 'subject score': 1000, 'object score': 1000}, 'PMID:23066177': {'publication date': '2012 Mar', 'sentence': 'Cartilage targeted chemical delivery of naproxen and ibuprofen for the treatment of arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2590270': {'publication date': '1989 Sep', 'sentence': 'Concentrations of Ibuprofen and Protein Concentration and pH-Value in Synovial Fluid and Plasma Following Oral Administration of Ibuprofen in Patients Suffering from Arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:25918809': {'publication date': '2014 Sep', 'sentence': 'In this study, we examined, in comparison with ibuprofen, the inhibitory effects on various inflammatory markers of the most commonly used herbal medicines to treat arthritis, boswellia (Boswellia sapindales), licorice (Glycyrrhiza glabra), guggul (Commiphora wightii), and neem (Azadirachta indica).', 'subject score': 1000, 'object score': 1000}, 'PMID:26883979': {'publication date': '2016 Mar 15', 'sentence': 'Ibuprofen is the first line of treatment for osteoarthritis and arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:26981605': {'publication date': '2016 Mar', 'sentence': 'However, ibuprofen and diclofenac sodium slightly attenuated TMJ inflammation and meloxicam did not affect TMJ inflammation.', 'subject score': 1000, 'object score': 901}, 'PMID:27959716': {'publication date': '2016 12 29', 'sentence': 'Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28379793': {'publication date': '2017 04 06', 'sentence': 'Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:32140283': {'publication date': '2019 Sep 01', 'sentence': 'Case Presentation:         In this report, we described a 15-year-old boy, suffering concurrently both from human leukocyte antigen (HLA)-B27-positive chronic arthritis and CGD, whose arthritis did not respond to treatment with methotrexate and ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:32424605': {'publication date': '2020 May 18', 'sentence': \"This study evaluated the effects of a low-dose AN and ibuprofen (IB) combination on inflammatory parameters in Freund's complete adjuvant-induced arthritis (AIA) and arthritis-induced hepatic metabolic changes.\", 'subject score': 888, 'object score': 875}, 'PMID:3365913': {'publication date': '1988 May', 'sentence': 'The simultaneous disposition of the enantiomers of ibuprofen in synovial fluid and plasma was studied in eight patients with arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3437603': {'publication date': '1987 Nov', 'sentence': 'On the contrary, cyclophosphamide, dexamethasone, or ibuprofen strongly protected the animals from the development of arthritis and/or cured the established arthritis by these dose regimens.', 'subject score': 1000, 'object score': 888}, 'PMID:35234840': {'publication date': '2022 Mar 02', 'sentence': 'Cardiorenal Risk of Celecoxib compared to Naproxen, or Ibuprofen in Arthritis Patients: Insights from the PRECISION trial.', 'subject score': 1000, 'object score': 888}, 'PMID:439358': {'publication date': '1979 Jun 15', 'sentence': 'Three young women with systemic lupus erythematosus who were given ibuprofen for arthritis voluntarily discontinued taking the drug.', 'subject score': 1000, 'object score': 1000}, 'PMID:4864061': {'publication date': '1967 Nov', 'sentence': 'Ibuprofen in the treatment of rheumatoid arthritis and osteo-arthritis.', 'subject score': 1000, 'object score': 861}, 'PMID:5524278': {'publication date': '1970', 'sentence': 'Further experience with ibuprofen in the treatment of arthritis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0003864---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "7686895",
-              "object": "MONDO:0005578",
-              "publications": [
-                "PMID:10487161",
-                "PMID:17003915",
-                "PMID:21403884",
-                "PMID:23066177",
-                "PMID:2590270",
-                "PMID:25918809",
-                "PMID:26883979",
-                "PMID:26981605",
-                "PMID:27959716",
-                "PMID:28379793",
-                "PMID:32140283",
-                "PMID:32424605",
-                "PMID:3365913",
-                "PMID:3437603",
-                "PMID:35234840",
-                "PMID:439358",
-                "PMID:4864061",
-                "PMID:5524278"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:26462366': {'publication date': '2015', 'sentence': 'This is termed, Celery Seed Extract (CSE) and has been found to be at least as effective as aspirin, ibuprofen, and naproxen in suppressing arthritis in a model of polyarthritis.', 'subject score': 1000, 'object score': 872}}",
-    "p2": {
-      "start": {
-        "identity": 307910,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005578",
-          "name": "arthritic joint disease",
-          "description": "An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.; Acute or chronic inflammation of JOINTS.; Inflammation of a joint. [HPO:probinson]; If you feel pain and stiffness in your body or have trouble moving around, you might have arthritis. Most kinds of arthritis cause pain and swelling in your joints. Joints are places where two bones meet, such as your elbow or knee. Over time, a swollen joint can become severely damaged. Some kinds of arthritis can also cause problems in your organs, such as your eyes or skin. Types of arthritis include: Osteoarthritis is the most common type of arthritis. It's often related to aging or to an injury. Autoimmune arthritis happens when your body's immune system attacks healthy cells in your body by mistake. Rheumatoid arthritis is the most common form of this kind of arthritis. Juvenile arthritis is a type of arthritis that happens in children. Infectious arthritis is an infection that has spread from another part of the body to the joint. Psoriatic arthritis affects people with psoriasis. Gout is a painful type of arthritis that happens when too much uric acid builds up in the body. It often starts in the big toe.  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0003864",
-            "MEDDRA:10003263",
-            "PSY:03860",
-            "EFO:0005856",
-            "ICD10:M19.90",
-            "MEDDRA:10003246",
-            "MONDO:0005578",
-            "SYMP:0019169",
-            "SNOMEDCT:3723001",
-            "UMLS:C0574941",
-            "NCIT:C2883",
-            "SNOMEDCT:298160000",
-            "DOID:848",
-            "MEDDRA:10023217",
-            "HP:0001369",
-            "MESH:D001168",
-            "MEDDRA:10081014"
-          ],
-          "id": "MONDO:0005578",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Arthritis",
-            "arthritic joint disease",
-            "Inflamed joint",
-            "arthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.arthritis.org/",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=arthritis",
-            "https://www.cdc.gov/arthritis/index.htm",
-            "http://en.wikipedia.org/wiki/arthritis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/001243.htm",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 307910,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005578",
-              "name": "arthritic joint disease",
-              "description": "An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.; Acute or chronic inflammation of JOINTS.; Inflammation of a joint. [HPO:probinson]; If you feel pain and stiffness in your body or have trouble moving around, you might have arthritis. Most kinds of arthritis cause pain and swelling in your joints. Joints are places where two bones meet, such as your elbow or knee. Over time, a swollen joint can become severely damaged. Some kinds of arthritis can also cause problems in your organs, such as your eyes or skin. Types of arthritis include: Osteoarthritis is the most common type of arthritis. It's often related to aging or to an injury. Autoimmune arthritis happens when your body's immune system attacks healthy cells in your body by mistake. Rheumatoid arthritis is the most common form of this kind of arthritis. Juvenile arthritis is a type of arthritis that happens in children. Infectious arthritis is an infection that has spread from another part of the body to the joint. Psoriatic arthritis affects people with psoriasis. Gout is a painful type of arthritis that happens when too much uric acid builds up in the body. It often starts in the big toe.  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0003864",
-                "MEDDRA:10003263",
-                "PSY:03860",
-                "EFO:0005856",
-                "ICD10:M19.90",
-                "MEDDRA:10003246",
-                "MONDO:0005578",
-                "SYMP:0019169",
-                "SNOMEDCT:3723001",
-                "UMLS:C0574941",
-                "NCIT:C2883",
-                "SNOMEDCT:298160000",
-                "DOID:848",
-                "MEDDRA:10023217",
-                "HP:0001369",
-                "MESH:D001168",
-                "MEDDRA:10081014"
-              ],
-              "id": "MONDO:0005578",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Arthritis",
-                "arthritic joint disease",
-                "Inflamed joint",
-                "arthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.arthritis.org/",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=arthritis",
-                "https://www.cdc.gov/arthritis/index.htm",
-                "http://en.wikipedia.org/wiki/arthritis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/001243.htm",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18230804,
-            "start": 554,
-            "end": 307910,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26462366': {'publication date': '2015', 'sentence': 'This is termed, Celery Seed Extract (CSE) and has been found to be at least as effective as aspirin, ibuprofen, and naproxen in suppressing arthritis in a model of polyarthritis.', 'subject score': 1000, 'object score': 872}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:disrupts---None---None---None---UMLS:C0003864---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "18599970",
-              "object": "MONDO:0005578",
-              "publications": [
-                "PMID:26462366"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:31490283': {'publication date': '2020 Jan', 'sentence': 'Taken together, our findings reveal that ibuprofen could induce ferroptosis of glioblastoma cells via downregulation of Nrf2 signaling pathway and is a potential drug for glioma treatment.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 310876,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021042",
-          "name": "glioma",
-          "description": "A benign or malignant brain and spinal cord tumor that arises from glial cells (astrocytes, oligodendrocytes, ependymal cells). Tumors that arise from astrocytes are called astrocytic tumors or astrocytomas. Tumors that arise from oligodendrocytes are called oligodendroglial tumors. Tumors that arise from ependymal cells are called ependymomas.; Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21); The presence of a glioma, which is a neoplasm of the central nervous system originating from a glial cell (astrocytes or oligodendrocytes). [HPO:probinson]; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10018338",
-            "MESH:D005910",
-            "MONDO:0021042",
-            "ORPHANET:182067",
-            "SNOMEDCT:74532006",
-            "HP:0009733",
-            "SNOMEDCT:393564001",
-            "SNOMEDCT:115240006",
-            "UMLS:C0017638",
-            "EFO:0005543",
-            "NCIT:C3059"
-          ],
-          "id": "MONDO:0021042",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Glioma",
-            "glioma",
-            "Glial tumor"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310876,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021042",
-              "name": "glioma",
-              "description": "A benign or malignant brain and spinal cord tumor that arises from glial cells (astrocytes, oligodendrocytes, ependymal cells). Tumors that arise from astrocytes are called astrocytic tumors or astrocytomas. Tumors that arise from oligodendrocytes are called oligodendroglial tumors. Tumors that arise from ependymal cells are called ependymomas.; Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21); The presence of a glioma, which is a neoplasm of the central nervous system originating from a glial cell (astrocytes or oligodendrocytes). [HPO:probinson]; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10018338",
-                "MESH:D005910",
-                "MONDO:0021042",
-                "ORPHANET:182067",
-                "SNOMEDCT:74532006",
-                "HP:0009733",
-                "SNOMEDCT:393564001",
-                "SNOMEDCT:115240006",
-                "UMLS:C0017638",
-                "EFO:0005543",
-                "NCIT:C3059"
-              ],
-              "id": "MONDO:0021042",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Glioma",
-                "glioma",
-                "Glial tumor"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20858829,
-            "start": 554,
-            "end": 310876,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31490283': {'publication date': '2020 Jan', 'sentence': 'Taken together, our findings reveal that ibuprofen could induce ferroptosis of glioblastoma cells via downregulation of Nrf2 signaling pathway and is a potential drug for glioma treatment.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0017638---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "21268743",
-              "object": "MONDO:0021042",
-              "publications": [
-                "PMID:31490283"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:7882703': {'publication date': '1994', 'sentence': \"The duration of action of sustained-release ibuprofen ('Brufen Retard') was investigated in a 14-day double-blind study involving 14 osteoarthritis and 10 rheumatoid arthritis patients.\", 'subject score': 851, 'object score': 824}}",
-    "p2": {
-      "start": {
-        "identity": 318890,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-          "name": "rheumatoid arthritis",
-          "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C2884",
-            "PSY:44570",
-            "EFO:0000685",
-            "ICD9:714.0",
-            "KEGG.DISEASE:05323",
-            "MONDO:0008383",
-            "UMLS:C0003873",
-            "UMLS:C1306838",
-            "UMLS:C1833448",
-            "MEDDRA:10037740",
-            "MEDDRA:10039073",
-            "OMIM:180300",
-            "MESH:D001172",
-            "MEDDRA:10003268",
-            "HP:0001370",
-            "ORPHANET:284130",
-            "SNOMEDCT:69896004",
-            "ICD10:M06.9",
-            "DOID:7148",
-            "MEDDRA:10036856",
-            "MEDDRA:10042952"
-          ],
-          "id": "MONDO:0008383",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Proliferative arthritis",
-            "Arthritis, Rheumatoid",
-            "rheumatoid arthritis",
-            "Rheumatoid arthritis",
-            "Rheumatoid Arthritis",
-            "Rheumatoid arthritis related phenotypic feature",
-            "Rheumatoid arthritis, susceptibility to"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-            "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-            "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318890,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-              "name": "rheumatoid arthritis",
-              "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C2884",
-                "PSY:44570",
-                "EFO:0000685",
-                "ICD9:714.0",
-                "KEGG.DISEASE:05323",
-                "MONDO:0008383",
-                "UMLS:C0003873",
-                "UMLS:C1306838",
-                "UMLS:C1833448",
-                "MEDDRA:10037740",
-                "MEDDRA:10039073",
-                "OMIM:180300",
-                "MESH:D001172",
-                "MEDDRA:10003268",
-                "HP:0001370",
-                "ORPHANET:284130",
-                "SNOMEDCT:69896004",
-                "ICD10:M06.9",
-                "DOID:7148",
-                "MEDDRA:10036856",
-                "MEDDRA:10042952"
-              ],
-              "id": "MONDO:0008383",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Proliferative arthritis",
-                "Arthritis, Rheumatoid",
-                "rheumatoid arthritis",
-                "Rheumatoid arthritis",
-                "Rheumatoid Arthritis",
-                "Rheumatoid arthritis related phenotypic feature",
-                "Rheumatoid arthritis, susceptibility to"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-                "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-                "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26238187,
-            "start": 554,
-            "end": 318890,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7882703': {'publication date': '1994', 'sentence': \"The duration of action of sustained-release ibuprofen ('Brufen Retard') was investigated in a 14-day double-blind study involving 14 osteoarthritis and 10 rheumatoid arthritis patients.\", 'subject score': 851, 'object score': 824}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0003873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "26701175",
-              "object": "MONDO:0008383",
-              "publications": [
-                "PMID:7882703"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1095794': {'publication date': '1975 Jul 28', 'sentence': 'Ibuprofen or aspirin in rheumatoid arthritis therapy.', 'subject score': 1000, 'object score': 901}, 'PMID:11718158': {'publication date': '2001 Apr', 'sentence': '(1) The reference treatment for drug-based symptomatic relief of osteoarthritis and rheumatoid arthritis is paracetamol and low-dose ibuprofen.', 'subject score': 901, 'object score': 1000}, 'PMID:1173655': {'publication date': '1975 Jul 28', 'sentence': 'Ibuprofen is a new, mild analgesic agent that may be useful in the symptomatic treatment of rheumatoid arthritis and osteoarthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:12227215': {'publication date': '2002', 'sentence': 'Valdecoxib is at least equally as effective as ibuprofen, naproxen, and diclofenac in the treatment of osteoarthritis and rheumatoid arthritis, but is safer in terms of gastrointestinal toxicity.', 'subject score': 1000, 'object score': 1000}, 'PMID:12528069': {'publication date': '2002 Dec', 'sentence': 'Both rofecoxib and celecoxib reduced the risk of confirmed clinical upper GI events compared with the nonselective NSAIDs naproxen and ibuprofen in patients with osteoarthritis and rheumatoid arthritis not taking low-dose aspirin.', 'subject score': 1000, 'object score': 1000}, 'PMID:14528521': {'publication date': '2003 Oct', 'sentence': 'Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15153172': {'publication date': '2004 Jun 01', 'sentence': 'Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:162672': {'publication date': '1975', 'sentence': 'Two-hundred and eighteen individuals with rheumatoid arthritis were randomly assigned to six months treatment with ibuprofen (900-1800 mg/day) or indomethacin (75-150 mg/day).', 'subject score': 1000, 'object score': 1000}, 'PMID:16941030': {'publication date': '2006 Oct', 'sentence': 'The cardiorenal safety database from the Celecoxib Long-term Arthritis Safety Study (CLASS) was analyzed to examine whether supratherapeutic doses of celecoxib are associated with decreased renal function and blood pressure (BP) effects compared with standard doses of diclofenac and ibuprofen in osteoarthritis (OA) and rheumatoid arthritis (RA) patients.In total, 8059 patients were enrolled; 7968 received at least one dose of study drug (RA: N = 2183; OA: N = 5785).', 'subject score': 1000, 'object score': 901}, 'PMID:20077080': {'publication date': '2010', 'sentence': 'Ibuprofen is a non-narcotic, non-steroidal anti-inflammatory drug used for the treatment of pain, fever, and inflammatory diseases such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2114414': {'publication date': '1990 Jun', 'sentence': 'A double-blind crossover study to compare lysine acetyl salicylate (Aspergesic) with ibuprofen in the treatment of rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:22033211': {'publication date': '2011 Oct 31', 'sentence': 'The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of osteoarthritis and rheumatoid arthritis and to decrease the risk of developing gastric and duodenal ulcers in patients at risk for NSAID-associated ulcers.', 'subject score': 916, 'object score': 1000}, 'PMID:2379535': {'publication date': '1990', 'sentence': 'Pharmacokinetics of S(+)- and R(-)-ibuprofen in volunteers and first clinical experience of S(+)-ibuprofen in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:238275': {'publication date': '1975 May', 'sentence': 'Comparison of benorylate and ibuprofen in the treatment of established rheumatoid arthritis.', 'subject score': 1000, 'object score': 901}, 'PMID:26458405': {'publication date': '2016', 'sentence': 'We studied in vitro effects of three different drugs (ibuprofen, meloxicam and methotrexate) which are often used in rheumatoid arthritis (RA) treatment on human serum paraoxanase1 (PON1) enzyme activity.', 'subject score': 1000, 'object score': 901}, 'PMID:31298072': {'publication date': '2019 Nov', 'sentence': 'Ibuprofen is a non-steroidal anti-inflammatory drug for the treatment of Rheumatoid Arthritis and osteoarthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:319117': {'publication date': '1977 Jan', 'sentence': 'Flurbiprofen and ibuprofen were compared in a six-week double-blind randomized study in 208 patients with rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:32184646': {'publication date': '2020', 'sentence': 'Conclusion: It seems that the aqueous extract of    T. ammi     can be used alone or in combination with ibuprofen to treat RA.', 'subject score': 1000, 'object score': 1000}, 'PMID:328880': {'publication date': '1977', 'sentence': 'Double-blind, multi-centre parallel trial of ketoprofen and ibuprofen in the treatment of rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3297621': {'publication date': '1987 May', 'sentence': 'Published data in small groups of patients indicate that proquazone 300 to 900 mg/day in 3 divided doses is a possible alternative to aspirin, ibuprofen, indomethacin, and naproxen in rheumatoid arthritis, and to indomethacin and ibuprofen in ankylosing spondylitis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318890,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-          "name": "rheumatoid arthritis",
-          "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C2884",
-            "PSY:44570",
-            "EFO:0000685",
-            "ICD9:714.0",
-            "KEGG.DISEASE:05323",
-            "MONDO:0008383",
-            "UMLS:C0003873",
-            "UMLS:C1306838",
-            "UMLS:C1833448",
-            "MEDDRA:10037740",
-            "MEDDRA:10039073",
-            "OMIM:180300",
-            "MESH:D001172",
-            "MEDDRA:10003268",
-            "HP:0001370",
-            "ORPHANET:284130",
-            "SNOMEDCT:69896004",
-            "ICD10:M06.9",
-            "DOID:7148",
-            "MEDDRA:10036856",
-            "MEDDRA:10042952"
-          ],
-          "id": "MONDO:0008383",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Proliferative arthritis",
-            "Arthritis, Rheumatoid",
-            "rheumatoid arthritis",
-            "Rheumatoid arthritis",
-            "Rheumatoid Arthritis",
-            "Rheumatoid arthritis related phenotypic feature",
-            "Rheumatoid arthritis, susceptibility to"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-            "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-            "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318890,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-              "name": "rheumatoid arthritis",
-              "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C2884",
-                "PSY:44570",
-                "EFO:0000685",
-                "ICD9:714.0",
-                "KEGG.DISEASE:05323",
-                "MONDO:0008383",
-                "UMLS:C0003873",
-                "UMLS:C1306838",
-                "UMLS:C1833448",
-                "MEDDRA:10037740",
-                "MEDDRA:10039073",
-                "OMIM:180300",
-                "MESH:D001172",
-                "MEDDRA:10003268",
-                "HP:0001370",
-                "ORPHANET:284130",
-                "SNOMEDCT:69896004",
-                "ICD10:M06.9",
-                "DOID:7148",
-                "MEDDRA:10036856",
-                "MEDDRA:10042952"
-              ],
-              "id": "MONDO:0008383",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Proliferative arthritis",
-                "Arthritis, Rheumatoid",
-                "rheumatoid arthritis",
-                "Rheumatoid arthritis",
-                "Rheumatoid Arthritis",
-                "Rheumatoid arthritis related phenotypic feature",
-                "Rheumatoid arthritis, susceptibility to"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-                "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-                "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8219396,
-            "start": 554,
-            "end": 318890,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1095794': {'publication date': '1975 Jul 28', 'sentence': 'Ibuprofen or aspirin in rheumatoid arthritis therapy.', 'subject score': 1000, 'object score': 901}, 'PMID:11718158': {'publication date': '2001 Apr', 'sentence': '(1) The reference treatment for drug-based symptomatic relief of osteoarthritis and rheumatoid arthritis is paracetamol and low-dose ibuprofen.', 'subject score': 901, 'object score': 1000}, 'PMID:1173655': {'publication date': '1975 Jul 28', 'sentence': 'Ibuprofen is a new, mild analgesic agent that may be useful in the symptomatic treatment of rheumatoid arthritis and osteoarthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:12227215': {'publication date': '2002', 'sentence': 'Valdecoxib is at least equally as effective as ibuprofen, naproxen, and diclofenac in the treatment of osteoarthritis and rheumatoid arthritis, but is safer in terms of gastrointestinal toxicity.', 'subject score': 1000, 'object score': 1000}, 'PMID:12528069': {'publication date': '2002 Dec', 'sentence': 'Both rofecoxib and celecoxib reduced the risk of confirmed clinical upper GI events compared with the nonselective NSAIDs naproxen and ibuprofen in patients with osteoarthritis and rheumatoid arthritis not taking low-dose aspirin.', 'subject score': 1000, 'object score': 1000}, 'PMID:14528521': {'publication date': '2003 Oct', 'sentence': 'Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15153172': {'publication date': '2004 Jun 01', 'sentence': 'Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:162672': {'publication date': '1975', 'sentence': 'Two-hundred and eighteen individuals with rheumatoid arthritis were randomly assigned to six months treatment with ibuprofen (900-1800 mg/day) or indomethacin (75-150 mg/day).', 'subject score': 1000, 'object score': 1000}, 'PMID:16941030': {'publication date': '2006 Oct', 'sentence': 'The cardiorenal safety database from the Celecoxib Long-term Arthritis Safety Study (CLASS) was analyzed to examine whether supratherapeutic doses of celecoxib are associated with decreased renal function and blood pressure (BP) effects compared with standard doses of diclofenac and ibuprofen in osteoarthritis (OA) and rheumatoid arthritis (RA) patients.In total, 8059 patients were enrolled; 7968 received at least one dose of study drug (RA: N = 2183; OA: N = 5785).', 'subject score': 1000, 'object score': 901}, 'PMID:20077080': {'publication date': '2010', 'sentence': 'Ibuprofen is a non-narcotic, non-steroidal anti-inflammatory drug used for the treatment of pain, fever, and inflammatory diseases such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2114414': {'publication date': '1990 Jun', 'sentence': 'A double-blind crossover study to compare lysine acetyl salicylate (Aspergesic) with ibuprofen in the treatment of rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:22033211': {'publication date': '2011 Oct 31', 'sentence': 'The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of osteoarthritis and rheumatoid arthritis and to decrease the risk of developing gastric and duodenal ulcers in patients at risk for NSAID-associated ulcers.', 'subject score': 916, 'object score': 1000}, 'PMID:2379535': {'publication date': '1990', 'sentence': 'Pharmacokinetics of S(+)- and R(-)-ibuprofen in volunteers and first clinical experience of S(+)-ibuprofen in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:238275': {'publication date': '1975 May', 'sentence': 'Comparison of benorylate and ibuprofen in the treatment of established rheumatoid arthritis.', 'subject score': 1000, 'object score': 901}, 'PMID:26458405': {'publication date': '2016', 'sentence': 'We studied in vitro effects of three different drugs (ibuprofen, meloxicam and methotrexate) which are often used in rheumatoid arthritis (RA) treatment on human serum paraoxanase1 (PON1) enzyme activity.', 'subject score': 1000, 'object score': 901}, 'PMID:31298072': {'publication date': '2019 Nov', 'sentence': 'Ibuprofen is a non-steroidal anti-inflammatory drug for the treatment of Rheumatoid Arthritis and osteoarthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:319117': {'publication date': '1977 Jan', 'sentence': 'Flurbiprofen and ibuprofen were compared in a six-week double-blind randomized study in 208 patients with rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:32184646': {'publication date': '2020', 'sentence': 'Conclusion: It seems that the aqueous extract of    T. ammi     can be used alone or in combination with ibuprofen to treat RA.', 'subject score': 1000, 'object score': 1000}, 'PMID:328880': {'publication date': '1977', 'sentence': 'Double-blind, multi-centre parallel trial of ketoprofen and ibuprofen in the treatment of rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3297621': {'publication date': '1987 May', 'sentence': 'Published data in small groups of patients indicate that proquazone 300 to 900 mg/day in 3 divided doses is a possible alternative to aspirin, ibuprofen, indomethacin, and naproxen in rheumatoid arthritis, and to indomethacin and ibuprofen in ankylosing spondylitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0003873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "8397426",
-              "object": "MONDO:0008383",
-              "publications": [
-                "PMID:1095794",
-                "PMID:11718158",
-                "PMID:1173655",
-                "PMID:12227215",
-                "PMID:12528069",
-                "PMID:14528521",
-                "PMID:15153172",
-                "PMID:162672",
-                "PMID:16941030",
-                "PMID:20077080",
-                "PMID:2114414",
-                "PMID:22033211",
-                "PMID:2379535",
-                "PMID:238275",
-                "PMID:26458405",
-                "PMID:31298072",
-                "PMID:319117",
-                "PMID:32184646",
-                "PMID:328880",
-                "PMID:3297621"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:24267149': {'publication date': '2013', 'sentence': 'In the last several years, several topical NSAIDs including either diclofenac ibuprofen or salicylates for chronic pain have been approved in the United States while similar drugs have been available in Europe for years.', 'subject score': 790, 'object score': 1000}, 'PMID:26261844': {'publication date': '2015 Jul', 'sentence': 'There are no clinical efficacy studies of hydrocodone in short-acting form in combination with acetaminophen or ibuprofen in chronic pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:27995369': {'publication date': '2017 03', 'sentence': 'METHODS: An observational study nested within a randomised controlled trial comparing oral paracetamol, ibuprofen or a combination of the two in 884 community-derived people with chronic knee pain.', 'subject score': 1000, 'object score': 901}, 'PMID:28282796': {'publication date': '2017', 'sentence': 'OBJECTIVE: The purpose of this study was to see if the use of low level continuous heat (LLCH) and Ibuprofen used as a home therapy between physical therapy sessions at a clinic resulted in better therapy outcomes in people with chronic neck pain.', 'subject score': 1000, 'object score': 901}, 'PMID:30793444': {'publication date': '2019 Jul', 'sentence': 'Only one SR analysed efficacy of ibuprofen and other non-steroidal anti-inflammatory drugs (NSAIDs) in chronic pain and the conclusion was that there was no evidence from RCTs that NSAIDs were effective for chronic non-cancer pain in children and adolescents.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316893,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012532",
-          "name": "Chronic pain",
-          "description": "Ongoing or recurrent pain that persists beyond that which is expected following acute injury, usually 3 months or more.; Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.; Persistent pain, usually defined as pain that has lasted longer than 3 to 6 months. [HPO:probinson, PMID:1875958]; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "HP:0012532",
-            "NCIT:C26940",
-            "ICD9:338.2",
-            "UMLS:C0150055",
-            "MESH:D059350",
-            "MEDDRA:10049475",
-            "SNOMEDCT:82423001",
-            "PSY:09185",
-            "SYMP:0000837"
-          ],
-          "id": "HP:0012532",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Chronic pain",
-            "chronic pain",
-            "Chronic Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:1875958",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316893,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012532",
-              "name": "Chronic pain",
-              "description": "Ongoing or recurrent pain that persists beyond that which is expected following acute injury, usually 3 months or more.; Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.; Persistent pain, usually defined as pain that has lasted longer than 3 to 6 months. [HPO:probinson, PMID:1875958]; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "HP:0012532",
-                "NCIT:C26940",
-                "ICD9:338.2",
-                "UMLS:C0150055",
-                "MESH:D059350",
-                "MEDDRA:10049475",
-                "SNOMEDCT:82423001",
-                "PSY:09185",
-                "SYMP:0000837"
-              ],
-              "id": "HP:0012532",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Chronic pain",
-                "chronic pain",
-                "Chronic Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:1875958",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16943335,
-            "start": 554,
-            "end": 316893,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24267149': {'publication date': '2013', 'sentence': 'In the last several years, several topical NSAIDs including either diclofenac ibuprofen or salicylates for chronic pain have been approved in the United States while similar drugs have been available in Europe for years.', 'subject score': 790, 'object score': 1000}, 'PMID:26261844': {'publication date': '2015 Jul', 'sentence': 'There are no clinical efficacy studies of hydrocodone in short-acting form in combination with acetaminophen or ibuprofen in chronic pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:27995369': {'publication date': '2017 03', 'sentence': 'METHODS: An observational study nested within a randomised controlled trial comparing oral paracetamol, ibuprofen or a combination of the two in 884 community-derived people with chronic knee pain.', 'subject score': 1000, 'object score': 901}, 'PMID:28282796': {'publication date': '2017', 'sentence': 'OBJECTIVE: The purpose of this study was to see if the use of low level continuous heat (LLCH) and Ibuprofen used as a home therapy between physical therapy sessions at a clinic resulted in better therapy outcomes in people with chronic neck pain.', 'subject score': 1000, 'object score': 901}, 'PMID:30793444': {'publication date': '2019 Jul', 'sentence': 'Only one SR analysed efficacy of ibuprofen and other non-steroidal anti-inflammatory drugs (NSAIDs) in chronic pain and the conclusion was that there was no evidence from RCTs that NSAIDs were effective for chronic non-cancer pain in children and adolescents.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0150055---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "17292168",
-              "object": "HP:0012532",
-              "publications": [
-                "PMID:24267149",
-                "PMID:26261844",
-                "PMID:27995369",
-                "PMID:28282796",
-                "PMID:30793444"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:18427773': {'publication date': '2008 May', 'sentence': 'CONCLUSION: We conclude that pain therapy with an almost peripherally acting drug such as ibuprofen can reduce osteoporosis-associated chronic pain better than a centrally acting pain medication such as tramadol.', 'subject score': 1000, 'object score': 824}}",
-    "p2": {
-      "start": {
-        "identity": 316893,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012532",
-          "name": "Chronic pain",
-          "description": "Ongoing or recurrent pain that persists beyond that which is expected following acute injury, usually 3 months or more.; Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.; Persistent pain, usually defined as pain that has lasted longer than 3 to 6 months. [HPO:probinson, PMID:1875958]; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "HP:0012532",
-            "NCIT:C26940",
-            "ICD9:338.2",
-            "UMLS:C0150055",
-            "MESH:D059350",
-            "MEDDRA:10049475",
-            "SNOMEDCT:82423001",
-            "PSY:09185",
-            "SYMP:0000837"
-          ],
-          "id": "HP:0012532",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Chronic pain",
-            "chronic pain",
-            "Chronic Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:1875958",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316893,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012532",
-              "name": "Chronic pain",
-              "description": "Ongoing or recurrent pain that persists beyond that which is expected following acute injury, usually 3 months or more.; Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.; Persistent pain, usually defined as pain that has lasted longer than 3 to 6 months. [HPO:probinson, PMID:1875958]; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "HP:0012532",
-                "NCIT:C26940",
-                "ICD9:338.2",
-                "UMLS:C0150055",
-                "MESH:D059350",
-                "MEDDRA:10049475",
-                "SNOMEDCT:82423001",
-                "PSY:09185",
-                "SYMP:0000837"
-              ],
-              "id": "HP:0012532",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Chronic pain",
-                "chronic pain",
-                "Chronic Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:1875958",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13422720,
-            "start": 554,
-            "end": 316893,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18427773': {'publication date': '2008 May', 'sentence': 'CONCLUSION: We conclude that pain therapy with an almost peripherally acting drug such as ibuprofen can reduce osteoporosis-associated chronic pain better than a centrally acting pain medication such as tramadol.', 'subject score': 1000, 'object score': 824}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0150055---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "13710734",
-              "object": "HP:0012532",
-              "publications": [
-                "PMID:18427773"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11195471': {'publication date': '2001 Jan', 'sentence': 'Is the combination of ibuprofen and caffeine effective for the treatment of a tension-type headache?', 'subject score': 1000, 'object score': 1000}, 'PMID:11560814': {'publication date': '2001 Oct', 'sentence': 'Simple analgesics such as ibuprofen, aspirin, and acetaminophen have long been used in the treatment of tension-type headache.', 'subject score': 1000, 'object score': 1000}, 'PMID:12799904': {'publication date': '2000 Feb', 'sentence': 'Headache of acute onset usually will be treated with analgesic substances like paracetamol, acetylsalicylic acid or ibuprofen, the first one being the reference drug for tension-type headache in childhood.', 'subject score': 1000, 'object score': 1000}, 'PMID:16141970': {'publication date': '2005 Jul', 'sentence': 'Ibuprofen (800 mg) is currently the leading choice for the treatment of acute TTH because of its very good gastro-intestinal tolerance, followed by sodium naproxen (825 mg).', 'subject score': 1000, 'object score': 916}, 'PMID:25526232': {'publication date': '2015 Jan', 'sentence': 'METHODS: Pooled analysis comparing the safety of single-dose IBU(Na) (512 mg; equivalent to 400 mg IBU free acid; n = 362) with standard IBU tablets (400 mg; n = 342) and placebo (n = 187) across five Phase III, randomized, placebo-controlled, double-blind studies evaluating IBU(Na) for treatment of postoperative dental pain, tension-type headache, or fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:25907021': {'publication date': '2015 May', 'sentence': 'Do low doses of ibuprofen - as used for TTH - increase the risk of heart attacks?', 'subject score': 1000, 'object score': 1000}, 'PMID:26819724': {'publication date': '2015', 'sentence': 'BACKGROUND: Ibuprofen is known to be efficacious in the treatment of tension-type headache, the most common form of primary headache.', 'subject score': 1000, 'object score': 1000}, 'PMID:7555617': {'publication date': '1995', 'sentence': 'The results of this clearly indicate that ketoprofen in a dosage of 12.5 or 25 mg, compared to 200 mg ibuprofen and 275 mg naproxen sodium, is an effective and safe treatment in tension-type headache.', 'subject score': 790, 'object score': 1000}, 'PMID:9013368': {'publication date': '1996 Dec', 'sentence': 'Nonprescription ibuprofen and acetaminophen in the treatment of tension-type headache.', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318433,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012228",
-          "name": "Tension-type headache",
-          "description": "A headache associated with muscle tightness which may radiate to other parts of the body.; A common primary headache disorder, characterized by a dull, non-pulsatile, diffuse, band-like (or vice-like) PAIN of mild to moderate intensity in the HEAD; SCALP; or NECK. The subtypes are classified by frequency and severity of symptoms. There is no clear cause even though it has been associated with MUSCLE CONTRACTION and stress. (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1); A type of headache that last hours with continuous pain of mild or moderate intensity, bilateral location, a pressing/tightening (non-pulsating) quality and that is not aggravated by routine physical activity such as walking or climbing stairs. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:52080",
-            "NCIT:C117070",
-            "MEDDRA:10043271",
-            "ICD9:307.81",
-            "MEDDRA:10085807",
-            "SNOMEDCT:398057008",
-            "MEDDRA:10043269",
-            "HP:0012228",
-            "UMLS:C0033893",
-            "SNOMEDCT:66551002",
-            "MESH:D018781",
-            "ICD9:339.1",
-            "MEDDRA:10019226"
-          ],
-          "id": "HP:0012228",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Tension-type headache",
-            "Tension Headache",
-            "Tension headache",
-            "Tension-Type Headache",
-            "Tension type headache"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318433,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012228",
-              "name": "Tension-type headache",
-              "description": "A headache associated with muscle tightness which may radiate to other parts of the body.; A common primary headache disorder, characterized by a dull, non-pulsatile, diffuse, band-like (or vice-like) PAIN of mild to moderate intensity in the HEAD; SCALP; or NECK. The subtypes are classified by frequency and severity of symptoms. There is no clear cause even though it has been associated with MUSCLE CONTRACTION and stress. (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1); A type of headache that last hours with continuous pain of mild or moderate intensity, bilateral location, a pressing/tightening (non-pulsating) quality and that is not aggravated by routine physical activity such as walking or climbing stairs. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:52080",
-                "NCIT:C117070",
-                "MEDDRA:10043271",
-                "ICD9:307.81",
-                "MEDDRA:10085807",
-                "SNOMEDCT:398057008",
-                "MEDDRA:10043269",
-                "HP:0012228",
-                "UMLS:C0033893",
-                "SNOMEDCT:66551002",
-                "MESH:D018781",
-                "ICD9:339.1",
-                "MEDDRA:10019226"
-              ],
-              "id": "HP:0012228",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Tension-type headache",
-                "Tension Headache",
-                "Tension headache",
-                "Tension-Type Headache",
-                "Tension type headache"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8512565,
-            "start": 554,
-            "end": 318433,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11195471': {'publication date': '2001 Jan', 'sentence': 'Is the combination of ibuprofen and caffeine effective for the treatment of a tension-type headache?', 'subject score': 1000, 'object score': 1000}, 'PMID:11560814': {'publication date': '2001 Oct', 'sentence': 'Simple analgesics such as ibuprofen, aspirin, and acetaminophen have long been used in the treatment of tension-type headache.', 'subject score': 1000, 'object score': 1000}, 'PMID:12799904': {'publication date': '2000 Feb', 'sentence': 'Headache of acute onset usually will be treated with analgesic substances like paracetamol, acetylsalicylic acid or ibuprofen, the first one being the reference drug for tension-type headache in childhood.', 'subject score': 1000, 'object score': 1000}, 'PMID:16141970': {'publication date': '2005 Jul', 'sentence': 'Ibuprofen (800 mg) is currently the leading choice for the treatment of acute TTH because of its very good gastro-intestinal tolerance, followed by sodium naproxen (825 mg).', 'subject score': 1000, 'object score': 916}, 'PMID:25526232': {'publication date': '2015 Jan', 'sentence': 'METHODS: Pooled analysis comparing the safety of single-dose IBU(Na) (512 mg; equivalent to 400 mg IBU free acid; n = 362) with standard IBU tablets (400 mg; n = 342) and placebo (n = 187) across five Phase III, randomized, placebo-controlled, double-blind studies evaluating IBU(Na) for treatment of postoperative dental pain, tension-type headache, or fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:25907021': {'publication date': '2015 May', 'sentence': 'Do low doses of ibuprofen - as used for TTH - increase the risk of heart attacks?', 'subject score': 1000, 'object score': 1000}, 'PMID:26819724': {'publication date': '2015', 'sentence': 'BACKGROUND: Ibuprofen is known to be efficacious in the treatment of tension-type headache, the most common form of primary headache.', 'subject score': 1000, 'object score': 1000}, 'PMID:7555617': {'publication date': '1995', 'sentence': 'The results of this clearly indicate that ketoprofen in a dosage of 12.5 or 25 mg, compared to 200 mg ibuprofen and 275 mg naproxen sodium, is an effective and safe treatment in tension-type headache.', 'subject score': 790, 'object score': 1000}, 'PMID:9013368': {'publication date': '1996 Dec', 'sentence': 'Nonprescription ibuprofen and acetaminophen in the treatment of tension-type headache.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0033893---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "8698382",
-              "object": "HP:0012228",
-              "publications": [
-                "PMID:11195471",
-                "PMID:11560814",
-                "PMID:12799904",
-                "PMID:16141970",
-                "PMID:25526232",
-                "PMID:25907021",
-                "PMID:26819724",
-                "PMID:7555617",
-                "PMID:9013368"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12004166': {'publication date': '2002 May 15', 'sentence': 'CONCLUSION: Continuous low-level heat wrap therapy was superior to both acetaminophen and ibuprofen for treating low back pain.', 'subject score': 1000, 'object score': 916}, 'PMID:9206700': {'publication date': '1997 Mar 30', 'sentence': '[High dose ibuprofen in low back pain].', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 322145,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0003419",
-          "name": "Low back pain",
-          "description": "An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the lower back. []; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the lower back.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the lower back.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10024998",
-            "MEDDRA:10076433",
-            "MEDDRA:10024890",
-            "UMLS:C0024031",
-            "NCIT:C34788",
-            "HP:0003419",
-            "MEDDRA:10024891",
-            "MEDDRA:10024988",
-            "SNOMEDCT:279039007",
-            "MESH:D017116"
-          ],
-          "id": "HP:0003419",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Lower Back Pain",
-            "Low back pain",
-            "Low Back Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322145,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0003419",
-              "name": "Low back pain",
-              "description": "An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the lower back. []; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the lower back.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the lower back.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10024998",
-                "MEDDRA:10076433",
-                "MEDDRA:10024890",
-                "UMLS:C0024031",
-                "NCIT:C34788",
-                "HP:0003419",
-                "MEDDRA:10024891",
-                "MEDDRA:10024988",
-                "SNOMEDCT:279039007",
-                "MESH:D017116"
-              ],
-              "id": "HP:0003419",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Lower Back Pain",
-                "Low back pain",
-                "Low Back Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9331002,
-            "start": 554,
-            "end": 322145,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12004166': {'publication date': '2002 May 15', 'sentence': 'CONCLUSION: Continuous low-level heat wrap therapy was superior to both acetaminophen and ibuprofen for treating low back pain.', 'subject score': 1000, 'object score': 916}, 'PMID:9206700': {'publication date': '1997 Mar 30', 'sentence': '[High dose ibuprofen in low back pain].', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0024031---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9536612",
-              "object": "HP:0003419",
-              "publications": [
-                "PMID:12004166",
-                "PMID:9206700"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:16685113': {'publication date': '2006 May 09', 'sentence': 'There have been no prior definite cases reported of ibuprofen-induced pancreatitis.', 'subject score': 851, 'object score': 851}, 'PMID:26239856': {'publication date': '2015 Jul 06', 'sentence': 'This is a case report of a 16-year-old boy with possible drug-induced pancreatitis (DIP) caused by ibuprofen.', 'subject score': 1000, 'object score': 861}, 'PMID:27077468': {'publication date': '2016 Nov/Dec', 'sentence': 'In this report, we present a case of probable ibuprofen-induced pancreatitis.', 'subject score': 775, 'object score': 775}, 'PMID:31788383': {'publication date': '2019 Oct 16', 'sentence': 'Ibuprofen-induced acute pancreatitis, a diagnosis secondary to the use of non-steroidal anti-inflammatory drugs (NSAIDs), is an extremely rare occurrence.', 'subject score': 833, 'object score': 833}}",
-    "p2": {
-      "start": {
-        "identity": 317183,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004982",
-          "name": "pancreatitis",
-          "description": "Inflammation of the pancreas.; INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.; The presence of inflammation in the pancreas. [HPO:probinson]; The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0004982",
-            "MEDDRA:10076039",
-            "MEDDRA:10033656",
-            "DOID:4989",
-            "SNOMEDCT:75694006",
-            "ICD10:K85.9",
-            "MEDDRA:10033645",
-            "NCIT:C3306",
-            "EFO:0000278",
-            "HP:0001733",
-            "MESH:D010195",
-            "UMLS:C0030305"
-          ],
-          "id": "MONDO:0004982",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pancreatitis",
-            "pancreatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/pancreatitis.htm",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317183,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004982",
-              "name": "pancreatitis",
-              "description": "Inflammation of the pancreas.; INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.; The presence of inflammation in the pancreas. [HPO:probinson]; The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0004982",
-                "MEDDRA:10076039",
-                "MEDDRA:10033656",
-                "DOID:4989",
-                "SNOMEDCT:75694006",
-                "ICD10:K85.9",
-                "MEDDRA:10033645",
-                "NCIT:C3306",
-                "EFO:0000278",
-                "HP:0001733",
-                "MESH:D010195",
-                "UMLS:C0030305"
-              ],
-              "id": "MONDO:0004982",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pancreatitis",
-                "pancreatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/pancreatitis.htm",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12216523,
-            "start": 554,
-            "end": 317183,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16685113': {'publication date': '2006 May 09', 'sentence': 'There have been no prior definite cases reported of ibuprofen-induced pancreatitis.', 'subject score': 851, 'object score': 851}, 'PMID:26239856': {'publication date': '2015 Jul 06', 'sentence': 'This is a case report of a 16-year-old boy with possible drug-induced pancreatitis (DIP) caused by ibuprofen.', 'subject score': 1000, 'object score': 861}, 'PMID:27077468': {'publication date': '2016 Nov/Dec', 'sentence': 'In this report, we present a case of probable ibuprofen-induced pancreatitis.', 'subject score': 775, 'object score': 775}, 'PMID:31788383': {'publication date': '2019 Oct 16', 'sentence': 'Ibuprofen-induced acute pancreatitis, a diagnosis secondary to the use of non-steroidal anti-inflammatory drugs (NSAIDs), is an extremely rare occurrence.', 'subject score': 833, 'object score': 833}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C0030305---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "12482174",
-              "object": "MONDO:0004982",
-              "publications": [
-                "PMID:16685113",
-                "PMID:26239856",
-                "PMID:27077468",
-                "PMID:31788383"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:31651801': {'publication date': '2019 Oct 23', 'sentence': 'IV Ibuprofen for Prevention of Post-Ercp Pancreatitis in Children: A Randomized Placebo-Controlled Feasibility Study.', 'subject score': 888, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 317183,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004982",
-          "name": "pancreatitis",
-          "description": "Inflammation of the pancreas.; INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.; The presence of inflammation in the pancreas. [HPO:probinson]; The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0004982",
-            "MEDDRA:10076039",
-            "MEDDRA:10033656",
-            "DOID:4989",
-            "SNOMEDCT:75694006",
-            "ICD10:K85.9",
-            "MEDDRA:10033645",
-            "NCIT:C3306",
-            "EFO:0000278",
-            "HP:0001733",
-            "MESH:D010195",
-            "UMLS:C0030305"
-          ],
-          "id": "MONDO:0004982",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pancreatitis",
-            "pancreatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/pancreatitis.htm",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317183,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004982",
-              "name": "pancreatitis",
-              "description": "Inflammation of the pancreas.; INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.; The presence of inflammation in the pancreas. [HPO:probinson]; The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0004982",
-                "MEDDRA:10076039",
-                "MEDDRA:10033656",
-                "DOID:4989",
-                "SNOMEDCT:75694006",
-                "ICD10:K85.9",
-                "MEDDRA:10033645",
-                "NCIT:C3306",
-                "EFO:0000278",
-                "HP:0001733",
-                "MESH:D010195",
-                "UMLS:C0030305"
-              ],
-              "id": "MONDO:0004982",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pancreatitis",
-                "pancreatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/pancreatitis.htm",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20942981,
-            "start": 554,
-            "end": 317183,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31651801': {'publication date': '2019 Oct 23', 'sentence': 'IV Ibuprofen for Prevention of Post-Ercp Pancreatitis in Children: A Randomized Placebo-Controlled Feasibility Study.', 'subject score': 888, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0030305---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "21354514",
-              "object": "MONDO:0004982",
-              "publications": [
-                "PMID:31651801"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:16205045': {'publication date': '2007', 'sentence': 'Noncardiogenic pulmonary edema due to ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:8835604': {'publication date': '1996 Jun', 'sentence': 'ARDS was likely induced by ibuprofen, based on the presence of pancytopenia and a weakly positive drug lymphocyte stimulating test (DLST).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319500,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0100130",
-          "name": "adult acute respiratory distress syndrome",
-          "description": "Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.; A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:J80",
-            "MEDDRA:10042839",
-            "UMLS:C4281993",
-            "MEDDRA:10038691",
-            "MEDDRA:10040579",
-            "DOID:11394",
-            "SNOMEDCT:196153002",
-            "ORPHANET:70578",
-            "MEDDRA:10042787",
-            "SNOMEDCT:67782005",
-            "MONDO:0100130",
-            "MEDDRA:10003083",
-            "MEDDRA:10038688",
-            "MEDDRA:10001410",
-            "HP:0002643",
-            "MEDDRA:10001407",
-            "MEDDRA:10000036",
-            "UMLS:C0852283",
-            "MEDDRA:10028973",
-            "UMLS:C0035222",
-            "MEDDRA:10001052",
-            "MEDDRA:10001409",
-            "MESH:D012128",
-            "SNOMEDCT:1179627006",
-            "UMLS:C1368020"
-          ],
-          "id": "MONDO:0100130",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adult acute respiratory distress syndrome",
-            "Neonatal respiratory distress",
-            "Respiratory Distress Syndrome, Adult",
-            "adult respiratory distress syndrome",
-            "Respiratory Distress Syndrome",
-            "Adult acute respiratory distress syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5392788/",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=adult+respiratory+distress+syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319500,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0100130",
-              "name": "adult acute respiratory distress syndrome",
-              "description": "Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.; A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:J80",
-                "MEDDRA:10042839",
-                "UMLS:C4281993",
-                "MEDDRA:10038691",
-                "MEDDRA:10040579",
-                "DOID:11394",
-                "SNOMEDCT:196153002",
-                "ORPHANET:70578",
-                "MEDDRA:10042787",
-                "SNOMEDCT:67782005",
-                "MONDO:0100130",
-                "MEDDRA:10003083",
-                "MEDDRA:10038688",
-                "MEDDRA:10001410",
-                "HP:0002643",
-                "MEDDRA:10001407",
-                "MEDDRA:10000036",
-                "UMLS:C0852283",
-                "MEDDRA:10028973",
-                "UMLS:C0035222",
-                "MEDDRA:10001052",
-                "MEDDRA:10001409",
-                "MESH:D012128",
-                "SNOMEDCT:1179627006",
-                "UMLS:C1368020"
-              ],
-              "id": "MONDO:0100130",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adult acute respiratory distress syndrome",
-                "Neonatal respiratory distress",
-                "Respiratory Distress Syndrome, Adult",
-                "adult respiratory distress syndrome",
-                "Respiratory Distress Syndrome",
-                "Adult acute respiratory distress syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5392788/",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=adult+respiratory+distress+syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11821967,
-            "start": 554,
-            "end": 319500,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16205045': {'publication date': '2007', 'sentence': 'Noncardiogenic pulmonary edema due to ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:8835604': {'publication date': '1996 Jun', 'sentence': 'ARDS was likely induced by ibuprofen, based on the presence of pancytopenia and a weakly positive drug lymphocyte stimulating test (DLST).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C0035222---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "12079834",
-              "object": "MONDO:0100130",
-              "publications": [
-                "PMID:16205045",
-                "PMID:8835604"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:34196258': {'publication date': '2021 Jul 01', 'sentence': 'Ibuprofen suppresses the production of various pro-inflammatory cytokines that are implicated in the \"cytokine storm\" and subsequent ARDS in COVID-19 disease.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 319500,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0100130",
-          "name": "adult acute respiratory distress syndrome",
-          "description": "Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.; A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:J80",
-            "MEDDRA:10042839",
-            "UMLS:C4281993",
-            "MEDDRA:10038691",
-            "MEDDRA:10040579",
-            "DOID:11394",
-            "SNOMEDCT:196153002",
-            "ORPHANET:70578",
-            "MEDDRA:10042787",
-            "SNOMEDCT:67782005",
-            "MONDO:0100130",
-            "MEDDRA:10003083",
-            "MEDDRA:10038688",
-            "MEDDRA:10001410",
-            "HP:0002643",
-            "MEDDRA:10001407",
-            "MEDDRA:10000036",
-            "UMLS:C0852283",
-            "MEDDRA:10028973",
-            "UMLS:C0035222",
-            "MEDDRA:10001052",
-            "MEDDRA:10001409",
-            "MESH:D012128",
-            "SNOMEDCT:1179627006",
-            "UMLS:C1368020"
-          ],
-          "id": "MONDO:0100130",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adult acute respiratory distress syndrome",
-            "Neonatal respiratory distress",
-            "Respiratory Distress Syndrome, Adult",
-            "adult respiratory distress syndrome",
-            "Respiratory Distress Syndrome",
-            "Adult acute respiratory distress syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5392788/",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=adult+respiratory+distress+syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319500,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0100130",
-              "name": "adult acute respiratory distress syndrome",
-              "description": "Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.; A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:J80",
-                "MEDDRA:10042839",
-                "UMLS:C4281993",
-                "MEDDRA:10038691",
-                "MEDDRA:10040579",
-                "DOID:11394",
-                "SNOMEDCT:196153002",
-                "ORPHANET:70578",
-                "MEDDRA:10042787",
-                "SNOMEDCT:67782005",
-                "MONDO:0100130",
-                "MEDDRA:10003083",
-                "MEDDRA:10038688",
-                "MEDDRA:10001410",
-                "HP:0002643",
-                "MEDDRA:10001407",
-                "MEDDRA:10000036",
-                "UMLS:C0852283",
-                "MEDDRA:10028973",
-                "UMLS:C0035222",
-                "MEDDRA:10001052",
-                "MEDDRA:10001409",
-                "MESH:D012128",
-                "SNOMEDCT:1179627006",
-                "UMLS:C1368020"
-              ],
-              "id": "MONDO:0100130",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adult acute respiratory distress syndrome",
-                "Neonatal respiratory distress",
-                "Respiratory Distress Syndrome, Adult",
-                "adult respiratory distress syndrome",
-                "Respiratory Distress Syndrome",
-                "Adult acute respiratory distress syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5392788/",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=adult+respiratory+distress+syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23068236,
-            "start": 554,
-            "end": 319500,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34196258': {'publication date': '2021 Jul 01', 'sentence': 'Ibuprofen suppresses the production of various pro-inflammatory cytokines that are implicated in the \"cytokine storm\" and subsequent ARDS in COVID-19 disease.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0035222---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "23500890",
-              "object": "MONDO:0100130",
-              "publications": [
-                "PMID:34196258"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:1545477': {'publication date': '1992 Jan', 'sentence': 'Double blind study on emorfazone and ibuprofen in dental pain and inflammation.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 630575,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C78640",
-          "name": "Toothache",
-          "description": "A painful sensation originating from a tooth.; Pain in the adjacent areas of the teeth.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10059723",
-            "MESH:D014098",
-            "NCIT:C78640",
-            "MEDDRA:10044055",
-            "UMLS:C0040460",
-            "SYMP:0000438",
-            "SNOMEDCT:27355003",
-            "MEDDRA:10044017",
-            "MEDDRA:10030090"
-          ],
-          "id": "NCIT:C78640",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "toothache",
-            "Toothache"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://www.merriam-webster.com/dictionary/toothache"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 630575,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C78640",
-              "name": "Toothache",
-              "description": "A painful sensation originating from a tooth.; Pain in the adjacent areas of the teeth.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10059723",
-                "MESH:D014098",
-                "NCIT:C78640",
-                "MEDDRA:10044055",
-                "UMLS:C0040460",
-                "SYMP:0000438",
-                "SNOMEDCT:27355003",
-                "MEDDRA:10044017",
-                "MEDDRA:10030090"
-              ],
-              "id": "NCIT:C78640",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "toothache",
-                "Toothache"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://www.merriam-webster.com/dictionary/toothache"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11191763,
-            "start": 554,
-            "end": 630575,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1545477': {'publication date': '1992 Jan', 'sentence': 'Double blind study on emorfazone and ibuprofen in dental pain and inflammation.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:associated_with---None---None---None---UMLS:C0040460---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "11440746",
-              "object": "NCIT:C78640",
-              "publications": [
-                "PMID:1545477"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:16637477': {'publication date': '2006 Apr', 'sentence': 'RESULTS: None of the studies established any of the COX-2 inhibitors as clearly better than ibuprofen, the current gold standard for the treatment of surgically induced dental pain.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 630575,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C78640",
-          "name": "Toothache",
-          "description": "A painful sensation originating from a tooth.; Pain in the adjacent areas of the teeth.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10059723",
-            "MESH:D014098",
-            "NCIT:C78640",
-            "MEDDRA:10044055",
-            "UMLS:C0040460",
-            "SYMP:0000438",
-            "SNOMEDCT:27355003",
-            "MEDDRA:10044017",
-            "MEDDRA:10030090"
-          ],
-          "id": "NCIT:C78640",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "toothache",
-            "Toothache"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://www.merriam-webster.com/dictionary/toothache"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 630575,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C78640",
-              "name": "Toothache",
-              "description": "A painful sensation originating from a tooth.; Pain in the adjacent areas of the teeth.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10059723",
-                "MESH:D014098",
-                "NCIT:C78640",
-                "MEDDRA:10044055",
-                "UMLS:C0040460",
-                "SYMP:0000438",
-                "SNOMEDCT:27355003",
-                "MEDDRA:10044017",
-                "MEDDRA:10030090"
-              ],
-              "id": "NCIT:C78640",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "toothache",
-                "Toothache"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://www.merriam-webster.com/dictionary/toothache"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12160527,
-            "start": 554,
-            "end": 630575,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16637477': {'publication date': '2006 Apr', 'sentence': 'RESULTS: None of the studies established any of the COX-2 inhibitors as clearly better than ibuprofen, the current gold standard for the treatment of surgically induced dental pain.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C0040460---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "12438812",
-              "object": "NCIT:C78640",
-              "publications": [
-                "PMID:16637477"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10096266': {'publication date': '1999 Mar', 'sentence': 'A double-blind, parallel-group study compared the analgesic efficacy of rofecoxib to placebo and ibuprofen in 102 patients with dental pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:10650365': {'publication date': '1999 Jun', 'sentence': 'COX-2 inhibitors: better than ibuprofen for dental pain?', 'subject score': 1000, 'object score': 1000}, 'PMID:11056966': {'publication date': '2000', 'sentence': 'A new therapeutic scheme of ibuprofen to treat postoperatory endodontic dental pain.', 'subject score': 1000, 'object score': 824}, 'PMID:11771573': {'publication date': '2001 Nov', 'sentence': 'For example, 200 mg of S(+)-ibuprofen has been found to be superior or at least equivalent to 400 mg of the racemate in the relief of dental pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:12162474': {'publication date': '2002 Aug', 'sentence': 'Efficacy and tolerability of nonprescription ibuprofen versus celecoxib for dental pain.', 'subject score': 861, 'object score': 1000}, 'PMID:21659629': {'publication date': '2012 May', 'sentence': 'This prospective, double-blind, randomized clinical study compared efficacy and safety of oral SCIO-469, ibuprofen, and placebo in postsurgical dental pain.', 'subject score': 1000, 'object score': 901}, 'PMID:24516940': {'publication date': '2013 Sep-Oct', 'sentence': 'In clinical practice ibuprofen can be used in the treatment of headache, toothache, otalgy, dysmenorrhea, neuralgia, arthralgia, myalgia, abdominal pain and fever: it is the first choice for these common diseases.', 'subject score': 851, 'object score': 1000}, 'PMID:269932': {'publication date': '1977 Nov', 'sentence': 'The object of a study was to evaluate the analgesic efficacy of ibuprofen for dental pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:32271183': {'publication date': '2020 Apr 07', 'sentence': 'Efficacy and Safety of Single and Multiple Doses of a Fixed-dose Combination of Ibuprofen and Acetaminophen in the Treatment of Postsurgical Dental Pain: Results from Two Phase 3, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Studies.', 'subject score': 1000, 'object score': 901}, 'PMID:32506309': {'publication date': '2020 Jun 06', 'sentence': 'Evaluation of Fixed-Dose Combinations of Ibuprofen and Acetaminophen in the Treatment of Postsurgical Dental Pain: A Pilot, Dose-Ranging, Randomized Study.INTRODUCTION: Ibuprofen and acetaminophen provide analgesia via different mechanisms of action and do not exhibit drug-drug interactions; therefore, combining low doses of each may provide greater efficacy without compromising safety.', 'subject score': 1000, 'object score': 901}, 'PMID:33094042': {'publication date': '2020 Sep 16', 'sentence': 'We are reporting a case of a 39-year-old man who had a syncopal episode after he took cephalexin and ibuprofen for toothache.', 'subject score': 1000, 'object score': 1000}, 'PMID:3536289': {'publication date': '1986 Sep', 'sentence': 'The relative efficacy of ibuprofen in dental pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:3547351': {'publication date': '1986 Nov-Dec', 'sentence': 'Analgesic efficacy of low-dose ibuprofen in dental extraction pain.', 'subject score': 901, 'object score': 901}, 'PMID:6465164': {'publication date': '1984 Jul 13', 'sentence': 'Five studies on ibuprofen for postsurgical dental pain.', 'subject score': 1000, 'object score': 901}, 'PMID:766799': {'publication date': '1976 Feb', 'sentence': 'Idarac v ibuprofen in the relief of dental pain.', 'subject score': 802, 'object score': 1000}, 'PMID:9516027': {'publication date': '1998 Jan', 'sentence': 'RESULTS: Ibuprofen is effective in dental pain, episiotomy pain and other post-operative pain.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 630575,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C78640",
-          "name": "Toothache",
-          "description": "A painful sensation originating from a tooth.; Pain in the adjacent areas of the teeth.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10059723",
-            "MESH:D014098",
-            "NCIT:C78640",
-            "MEDDRA:10044055",
-            "UMLS:C0040460",
-            "SYMP:0000438",
-            "SNOMEDCT:27355003",
-            "MEDDRA:10044017",
-            "MEDDRA:10030090"
-          ],
-          "id": "NCIT:C78640",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "toothache",
-            "Toothache"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://www.merriam-webster.com/dictionary/toothache"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 630575,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C78640",
-              "name": "Toothache",
-              "description": "A painful sensation originating from a tooth.; Pain in the adjacent areas of the teeth.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10059723",
-                "MESH:D014098",
-                "NCIT:C78640",
-                "MEDDRA:10044055",
-                "UMLS:C0040460",
-                "SYMP:0000438",
-                "SNOMEDCT:27355003",
-                "MEDDRA:10044017",
-                "MEDDRA:10030090"
-              ],
-              "id": "NCIT:C78640",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "toothache",
-                "Toothache"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://www.merriam-webster.com/dictionary/toothache"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7069584,
-            "start": 554,
-            "end": 630575,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10096266': {'publication date': '1999 Mar', 'sentence': 'A double-blind, parallel-group study compared the analgesic efficacy of rofecoxib to placebo and ibuprofen in 102 patients with dental pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:10650365': {'publication date': '1999 Jun', 'sentence': 'COX-2 inhibitors: better than ibuprofen for dental pain?', 'subject score': 1000, 'object score': 1000}, 'PMID:11056966': {'publication date': '2000', 'sentence': 'A new therapeutic scheme of ibuprofen to treat postoperatory endodontic dental pain.', 'subject score': 1000, 'object score': 824}, 'PMID:11771573': {'publication date': '2001 Nov', 'sentence': 'For example, 200 mg of S(+)-ibuprofen has been found to be superior or at least equivalent to 400 mg of the racemate in the relief of dental pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:12162474': {'publication date': '2002 Aug', 'sentence': 'Efficacy and tolerability of nonprescription ibuprofen versus celecoxib for dental pain.', 'subject score': 861, 'object score': 1000}, 'PMID:21659629': {'publication date': '2012 May', 'sentence': 'This prospective, double-blind, randomized clinical study compared efficacy and safety of oral SCIO-469, ibuprofen, and placebo in postsurgical dental pain.', 'subject score': 1000, 'object score': 901}, 'PMID:24516940': {'publication date': '2013 Sep-Oct', 'sentence': 'In clinical practice ibuprofen can be used in the treatment of headache, toothache, otalgy, dysmenorrhea, neuralgia, arthralgia, myalgia, abdominal pain and fever: it is the first choice for these common diseases.', 'subject score': 851, 'object score': 1000}, 'PMID:269932': {'publication date': '1977 Nov', 'sentence': 'The object of a study was to evaluate the analgesic efficacy of ibuprofen for dental pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:32271183': {'publication date': '2020 Apr 07', 'sentence': 'Efficacy and Safety of Single and Multiple Doses of a Fixed-dose Combination of Ibuprofen and Acetaminophen in the Treatment of Postsurgical Dental Pain: Results from Two Phase 3, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Studies.', 'subject score': 1000, 'object score': 901}, 'PMID:32506309': {'publication date': '2020 Jun 06', 'sentence': 'Evaluation of Fixed-Dose Combinations of Ibuprofen and Acetaminophen in the Treatment of Postsurgical Dental Pain: A Pilot, Dose-Ranging, Randomized Study.INTRODUCTION: Ibuprofen and acetaminophen provide analgesia via different mechanisms of action and do not exhibit drug-drug interactions; therefore, combining low doses of each may provide greater efficacy without compromising safety.', 'subject score': 1000, 'object score': 901}, 'PMID:33094042': {'publication date': '2020 Sep 16', 'sentence': 'We are reporting a case of a 39-year-old man who had a syncopal episode after he took cephalexin and ibuprofen for toothache.', 'subject score': 1000, 'object score': 1000}, 'PMID:3536289': {'publication date': '1986 Sep', 'sentence': 'The relative efficacy of ibuprofen in dental pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:3547351': {'publication date': '1986 Nov-Dec', 'sentence': 'Analgesic efficacy of low-dose ibuprofen in dental extraction pain.', 'subject score': 901, 'object score': 901}, 'PMID:6465164': {'publication date': '1984 Jul 13', 'sentence': 'Five studies on ibuprofen for postsurgical dental pain.', 'subject score': 1000, 'object score': 901}, 'PMID:766799': {'publication date': '1976 Feb', 'sentence': 'Idarac v ibuprofen in the relief of dental pain.', 'subject score': 802, 'object score': 1000}, 'PMID:9516027': {'publication date': '1998 Jan', 'sentence': 'RESULTS: Ibuprofen is effective in dental pain, episiotomy pain and other post-operative pain.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0040460---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "7210912",
-              "object": "NCIT:C78640",
-              "publications": [
-                "PMID:10096266",
-                "PMID:10650365",
-                "PMID:11056966",
-                "PMID:11771573",
-                "PMID:12162474",
-                "PMID:21659629",
-                "PMID:24516940",
-                "PMID:269932",
-                "PMID:32271183",
-                "PMID:32506309",
-                "PMID:33094042",
-                "PMID:3536289",
-                "PMID:3547351",
-                "PMID:6465164",
-                "PMID:766799",
-                "PMID:9516027"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12749506': {'publication date': '2003 Feb', 'sentence': 'A multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled, parallel-group comparison of diclofenac-K and ibuprofen for the treatment of adults with influenza-like symptoms.', 'subject score': 1000, 'object score': 1000}, 'PMID:21331467': {'publication date': '2012 Feb', 'sentence': 'CONCLUSION: Oral acetaminophen/paracetamol or ibuprofen effectively managed the transient influenza-like symptoms associated with zoledronic acid 5 mg.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 521264,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005812",
-          "name": "influenza",
-          "description": "An acute viral infection of the respiratory tract, occurring in isolated cases, in epidemics, or in pandemics; it is caused by serologically different strains of viruses (influenzaviruses) designated A, B, and C, has a 3-day incubation period, and usually lasts for 3 to 10 days. It is marked by inflammation of the nasal mucosa, pharynx, and conjunctiva; headache; myalgia; often fever, chills, and prostration; and occasionally involvement of the myocardium or central nervous system.; An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD9:487",
-            "SNOMEDCT:61700007",
-            "MESH:D007251",
-            "MESH:D009976",
-            "UMLS:C0029342",
-            "DOID:8469",
-            "ICD10:J11.1",
-            "UMLS:C0021400",
-            "MONDO:0005812",
-            "NCIT:C53482",
-            "PSY:25260",
-            "SNOMEDCT:6142004",
-            "EFO:0007328",
-            "MEDDRA:10016793",
-            "MEDDRA:10022000",
-            "MEDDRA:10016790",
-            "MEDDRA:10042807",
-            "SNOMEDCT:65093003",
-            "UMLS:C0155871"
-          ],
-          "id": "MONDO:0005812",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Influenza, Human",
-            "Influenza with non-respiratory manifestation",
-            "Influenza",
-            "Orthomyxoviridae Infections",
-            "influenza"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.merck.com/mmhe/sec17/ch198/ch198d.htm",
-            "http://www.who.int/mediacentre/factsheets/2003/fs211/en/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 521264,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005812",
-              "name": "influenza",
-              "description": "An acute viral infection of the respiratory tract, occurring in isolated cases, in epidemics, or in pandemics; it is caused by serologically different strains of viruses (influenzaviruses) designated A, B, and C, has a 3-day incubation period, and usually lasts for 3 to 10 days. It is marked by inflammation of the nasal mucosa, pharynx, and conjunctiva; headache; myalgia; often fever, chills, and prostration; and occasionally involvement of the myocardium or central nervous system.; An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD9:487",
-                "SNOMEDCT:61700007",
-                "MESH:D007251",
-                "MESH:D009976",
-                "UMLS:C0029342",
-                "DOID:8469",
-                "ICD10:J11.1",
-                "UMLS:C0021400",
-                "MONDO:0005812",
-                "NCIT:C53482",
-                "PSY:25260",
-                "SNOMEDCT:6142004",
-                "EFO:0007328",
-                "MEDDRA:10016793",
-                "MEDDRA:10022000",
-                "MEDDRA:10016790",
-                "MEDDRA:10042807",
-                "SNOMEDCT:65093003",
-                "UMLS:C0155871"
-              ],
-              "id": "MONDO:0005812",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Influenza, Human",
-                "Influenza with non-respiratory manifestation",
-                "Influenza",
-                "Orthomyxoviridae Infections",
-                "influenza"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.merck.com/mmhe/sec17/ch198/ch198d.htm",
-                "http://www.who.int/mediacentre/factsheets/2003/fs211/en/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9974896,
-            "start": 554,
-            "end": 521264,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12749506': {'publication date': '2003 Feb', 'sentence': 'A multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled, parallel-group comparison of diclofenac-K and ibuprofen for the treatment of adults with influenza-like symptoms.', 'subject score': 1000, 'object score': 1000}, 'PMID:21331467': {'publication date': '2012 Feb', 'sentence': 'CONCLUSION: Oral acetaminophen/paracetamol or ibuprofen effectively managed the transient influenza-like symptoms associated with zoledronic acid 5 mg.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0021400---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "10195210",
-              "object": "MONDO:0005812",
-              "publications": [
-                "PMID:12749506",
-                "PMID:21331467"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12017395': {'publication date': '2002 Apr', 'sentence': 'BACKGROUND: Rofecoxib is a selective cyclooxygenase-2 inhibitor indicated for the treatment of acute pain, with similar analgesic efficacy to ibuprofen and naproxen sodium.', 'subject score': 1000, 'object score': 1000}, 'PMID:12216965': {'publication date': '2002 Aug', 'sentence': 'Efficacy of celecoxib versus ibuprofen in the treatment of acute pain: a multicenter, double-blind, randomized controlled trial in acute ankle sprain.', 'subject score': 1000, 'object score': 1000}, 'PMID:12511311': {'publication date': '2003 Jan', 'sentence': 'The objective of this study was to compare the efficacies of celecoxib and ibuprofen for the treatment of acute pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:15763605': {'publication date': '2005 Jan', 'sentence': 'Oxycodone and ibuprofen each have been used effectively as monotherapy and in other combinations for the treatment of acute pain; a fixed combination of these analgesics may improve pain relief in the setting of abdominal or pelvic surgery, where trauma and any resultant inflammation may be present at the same time.', 'subject score': 1000, 'object score': 1000}, 'PMID:16083531': {'publication date': '2005 Aug', 'sentence': 'Non-selective NSAIDs such as ibuprofen and naproxen, which inhibit both COX-1 and COX-2, have proven highly effective and safe in the short-term management of acute pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:16637477': {'publication date': '2006 Apr', 'sentence': 'CLINCAL IMPLICATIONS: The evidence to date fails to demonstrate any therapeutic advantage to using a COX-2 inhibitor to treat acute dental pain compared with ibuprofen.', 'subject score': 1000, 'object score': 901}, 'PMID:19462922': {'publication date': '2009', 'sentence': 'Recent published evidences on ibuprofen and meloxicam confirm the need of faster oral drug absorption to overcome the pathophysiological conditions associated with dental pain (due to excessive vagal nerve suppression) in order to provide relief in acute pain management.', 'subject score': 1000, 'object score': 901}, 'PMID:19624576': {'publication date': '2009 Aug', 'sentence': 'OBJECTIVES: This study compared the analgesic effectiveness of acetaminophen-codeine with that of ibuprofen for children with acute traumatic extremity pain, with the hypothesis that the two medications would demonstrate equivalent reduction in pain scores in an emergency department (ED) setting.', 'subject score': 1000, 'object score': 861}, 'PMID:21197311': {'publication date': '2010 May 25', 'sentence': 'Further data on intravenous ibuprofen are needed to define long-term utilization, management of acute pain, and use in special populations.', 'subject score': 888, 'object score': 1000}, 'PMID:21540741': {'publication date': '2011 Oct', 'sentence': 'A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction.', 'subject score': 1000, 'object score': 1000}, 'PMID:23904576': {'publication date': '2013 Aug', 'sentence': 'BACKGROUND: Effective and safe drug therapy for the management of acute postoperative pain has relied on orally administered analgesics such as ibuprofen, naproxen and acetaminophen, or N-acetyl-p-aminophenol (APAP), as well as combination formulations containing opioids such as hydrocodone with APAP.', 'subject score': 1000, 'object score': 913}, 'PMID:2395047': {'publication date': '1990 Sep', 'sentence': 'Comparison of nonsteroidal anti-inflammatory drugs, ibuprofen and flurbiprofen, with methylprednisolone and placebo for acute pain, swelling, and trismus.', 'subject score': 1000, 'object score': 1000}, 'PMID:23969325': {'publication date': '2014 Jan', 'sentence': 'A Cochrane review of ibuprofen in acute pain suggested that rapidly absorbed formulations of salts, or features to speed absorption, provided better analgesia than standard ibuprofen as the free acid.', 'subject score': 1000, 'object score': 1000}, 'PMID:2689471': {'publication date': '1989 Nov', 'sentence': 'Ibuprofen and acetaminophen in the relief of acute pain: a randomized, double-blind, placebo-controlled study.', 'subject score': 1000, 'object score': 1000}, 'PMID:27052991': {'publication date': '2016 Apr 06', 'sentence': 'A clinical trial comparing Lanconone(r) with ibuprofen for rapid relief in acute joint pain.', 'subject score': 1000, 'object score': 901}, 'PMID:28805281': {'publication date': '2018 01', 'sentence': 'SIGNIFICANCE: This trial showed superior efficacy of 400/100 mg ibuprofen/caffeine, compared to 400 mg ibuprofen alone, for treating acute pain, reflecting that caffeine is an effective analgesic adjuvant.', 'subject score': 790, 'object score': 901}, 'PMID:29022772': {'publication date': '2018 Feb', 'sentence': 'Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), is mostly administered orally and topically to relieve acute pain and fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:29912084': {'publication date': '2018 Jun 14', 'sentence': 'CONCLUSIONS: Ibuprofen resulted to be the most studied nonsteroidal anti-inflammatory drug in the management of acute pain in children; in general, it showed a good safety profile and provided evidence of effectiveness, despite some differences according to the specific clinical context.', 'subject score': 1000, 'object score': 1000}, 'PMID:30154714': {'publication date': '2018', 'sentence': 'Ibuprofen (IBU) is a non-steroidal anti-inflammatory drug (NSAID), which is widely used to reduce fever and treat inflammation and acute pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:30946703': {'publication date': '2019 05', 'sentence': 'CONCLUSION: Paracetamol/metamizole and paracetamol/ibuprofen are equally effective in treatment of acute postoperative pain at home after ambulatory surgery with comparable patient satisfaction levels.', 'subject score': 888, 'object score': 913}}",
-    "p2": {
-      "start": {
-        "identity": 537452,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C27003",
-          "name": "Acute Pain",
-          "description": "A sensation of discomfort or distress that has a severe or rapid onset.; Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "ICD9:338.1",
-            "SNOMEDCT:274663001",
-            "SYMP:0000839",
-            "MEDDRA:10066714",
-            "MESH:D059787",
-            "UMLS:C0184567",
-            "NCIT:C27003"
-          ],
-          "id": "NCIT:C27003",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Acute pain",
-            "acute pain",
-            "Acute onset pain",
-            "Acute Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 537452,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C27003",
-              "name": "Acute Pain",
-              "description": "A sensation of discomfort or distress that has a severe or rapid onset.; Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "ICD9:338.1",
-                "SNOMEDCT:274663001",
-                "SYMP:0000839",
-                "MEDDRA:10066714",
-                "MESH:D059787",
-                "UMLS:C0184567",
-                "NCIT:C27003"
-              ],
-              "id": "NCIT:C27003",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Acute pain",
-                "acute pain",
-                "Acute onset pain",
-                "Acute Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9343894,
-            "start": 554,
-            "end": 537452,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12017395': {'publication date': '2002 Apr', 'sentence': 'BACKGROUND: Rofecoxib is a selective cyclooxygenase-2 inhibitor indicated for the treatment of acute pain, with similar analgesic efficacy to ibuprofen and naproxen sodium.', 'subject score': 1000, 'object score': 1000}, 'PMID:12216965': {'publication date': '2002 Aug', 'sentence': 'Efficacy of celecoxib versus ibuprofen in the treatment of acute pain: a multicenter, double-blind, randomized controlled trial in acute ankle sprain.', 'subject score': 1000, 'object score': 1000}, 'PMID:12511311': {'publication date': '2003 Jan', 'sentence': 'The objective of this study was to compare the efficacies of celecoxib and ibuprofen for the treatment of acute pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:15763605': {'publication date': '2005 Jan', 'sentence': 'Oxycodone and ibuprofen each have been used effectively as monotherapy and in other combinations for the treatment of acute pain; a fixed combination of these analgesics may improve pain relief in the setting of abdominal or pelvic surgery, where trauma and any resultant inflammation may be present at the same time.', 'subject score': 1000, 'object score': 1000}, 'PMID:16083531': {'publication date': '2005 Aug', 'sentence': 'Non-selective NSAIDs such as ibuprofen and naproxen, which inhibit both COX-1 and COX-2, have proven highly effective and safe in the short-term management of acute pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:16637477': {'publication date': '2006 Apr', 'sentence': 'CLINCAL IMPLICATIONS: The evidence to date fails to demonstrate any therapeutic advantage to using a COX-2 inhibitor to treat acute dental pain compared with ibuprofen.', 'subject score': 1000, 'object score': 901}, 'PMID:19462922': {'publication date': '2009', 'sentence': 'Recent published evidences on ibuprofen and meloxicam confirm the need of faster oral drug absorption to overcome the pathophysiological conditions associated with dental pain (due to excessive vagal nerve suppression) in order to provide relief in acute pain management.', 'subject score': 1000, 'object score': 901}, 'PMID:19624576': {'publication date': '2009 Aug', 'sentence': 'OBJECTIVES: This study compared the analgesic effectiveness of acetaminophen-codeine with that of ibuprofen for children with acute traumatic extremity pain, with the hypothesis that the two medications would demonstrate equivalent reduction in pain scores in an emergency department (ED) setting.', 'subject score': 1000, 'object score': 861}, 'PMID:21197311': {'publication date': '2010 May 25', 'sentence': 'Further data on intravenous ibuprofen are needed to define long-term utilization, management of acute pain, and use in special populations.', 'subject score': 888, 'object score': 1000}, 'PMID:21540741': {'publication date': '2011 Oct', 'sentence': 'A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction.', 'subject score': 1000, 'object score': 1000}, 'PMID:23904576': {'publication date': '2013 Aug', 'sentence': 'BACKGROUND: Effective and safe drug therapy for the management of acute postoperative pain has relied on orally administered analgesics such as ibuprofen, naproxen and acetaminophen, or N-acetyl-p-aminophenol (APAP), as well as combination formulations containing opioids such as hydrocodone with APAP.', 'subject score': 1000, 'object score': 913}, 'PMID:2395047': {'publication date': '1990 Sep', 'sentence': 'Comparison of nonsteroidal anti-inflammatory drugs, ibuprofen and flurbiprofen, with methylprednisolone and placebo for acute pain, swelling, and trismus.', 'subject score': 1000, 'object score': 1000}, 'PMID:23969325': {'publication date': '2014 Jan', 'sentence': 'A Cochrane review of ibuprofen in acute pain suggested that rapidly absorbed formulations of salts, or features to speed absorption, provided better analgesia than standard ibuprofen as the free acid.', 'subject score': 1000, 'object score': 1000}, 'PMID:2689471': {'publication date': '1989 Nov', 'sentence': 'Ibuprofen and acetaminophen in the relief of acute pain: a randomized, double-blind, placebo-controlled study.', 'subject score': 1000, 'object score': 1000}, 'PMID:27052991': {'publication date': '2016 Apr 06', 'sentence': 'A clinical trial comparing Lanconone(r) with ibuprofen for rapid relief in acute joint pain.', 'subject score': 1000, 'object score': 901}, 'PMID:28805281': {'publication date': '2018 01', 'sentence': 'SIGNIFICANCE: This trial showed superior efficacy of 400/100 mg ibuprofen/caffeine, compared to 400 mg ibuprofen alone, for treating acute pain, reflecting that caffeine is an effective analgesic adjuvant.', 'subject score': 790, 'object score': 901}, 'PMID:29022772': {'publication date': '2018 Feb', 'sentence': 'Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), is mostly administered orally and topically to relieve acute pain and fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:29912084': {'publication date': '2018 Jun 14', 'sentence': 'CONCLUSIONS: Ibuprofen resulted to be the most studied nonsteroidal anti-inflammatory drug in the management of acute pain in children; in general, it showed a good safety profile and provided evidence of effectiveness, despite some differences according to the specific clinical context.', 'subject score': 1000, 'object score': 1000}, 'PMID:30154714': {'publication date': '2018', 'sentence': 'Ibuprofen (IBU) is a non-steroidal anti-inflammatory drug (NSAID), which is widely used to reduce fever and treat inflammation and acute pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:30946703': {'publication date': '2019 05', 'sentence': 'CONCLUSION: Paracetamol/metamizole and paracetamol/ibuprofen are equally effective in treatment of acute postoperative pain at home after ambulatory surgery with comparable patient satisfaction levels.', 'subject score': 888, 'object score': 913}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0184567---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9550056",
-              "object": "NCIT:C27003",
-              "publications": [
-                "PMID:12017395",
-                "PMID:12216965",
-                "PMID:12511311",
-                "PMID:15763605",
-                "PMID:16083531",
-                "PMID:16637477",
-                "PMID:19462922",
-                "PMID:19624576",
-                "PMID:21197311",
-                "PMID:21540741",
-                "PMID:23904576",
-                "PMID:2395047",
-                "PMID:23969325",
-                "PMID:2689471",
-                "PMID:27052991",
-                "PMID:28805281",
-                "PMID:29022772",
-                "PMID:29912084",
-                "PMID:30154714",
-                "PMID:30946703"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:9663185': {'publication date': '1998 Jun', 'sentence': 'This study evaluated whether administration of the pharmacologically active S(+)-isomer of ibuprofen suppresses acute pain and plasma beta-endorphin levels in the oral surgery model of acute pain.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 537452,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C27003",
-          "name": "Acute Pain",
-          "description": "A sensation of discomfort or distress that has a severe or rapid onset.; Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "ICD9:338.1",
-            "SNOMEDCT:274663001",
-            "SYMP:0000839",
-            "MEDDRA:10066714",
-            "MESH:D059787",
-            "UMLS:C0184567",
-            "NCIT:C27003"
-          ],
-          "id": "NCIT:C27003",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Acute pain",
-            "acute pain",
-            "Acute onset pain",
-            "Acute Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 537452,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C27003",
-              "name": "Acute Pain",
-              "description": "A sensation of discomfort or distress that has a severe or rapid onset.; Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "ICD9:338.1",
-                "SNOMEDCT:274663001",
-                "SYMP:0000839",
-                "MEDDRA:10066714",
-                "MESH:D059787",
-                "UMLS:C0184567",
-                "NCIT:C27003"
-              ],
-              "id": "NCIT:C27003",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Acute pain",
-                "acute pain",
-                "Acute onset pain",
-                "Acute Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 27156533,
-            "start": 554,
-            "end": 537452,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9663185': {'publication date': '1998 Jun', 'sentence': 'This study evaluated whether administration of the pharmacologically active S(+)-isomer of ibuprofen suppresses acute pain and plasma beta-endorphin levels in the oral surgery model of acute pain.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:disrupts---None---None---None---UMLS:C0184567---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "27630106",
-              "object": "NCIT:C27003",
-              "publications": [
-                "PMID:9663185"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11239634': {'publication date': '2001 Mar', 'sentence': 'CONCLUSION: Continuous low-level topical heat therapy was as effective as ibuprofen for the treatment of dysmenorrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:22069413': {'publication date': '2010 Dec', 'sentence': 'Reflexology method was associated with more reduction of intensity and duration of menstrual pain in comparison with Ibuprofen therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:24944382': {'publication date': '2003 Jun', 'sentence': 'Analgesia with ibuprofen arginate versus conventional ibuprofen for patients with dysmenorrhea: a crossover trial.', 'subject score': 888, 'object score': 1000}, 'PMID:26457698': {'publication date': '2015 Oct 07', 'sentence': 'In summary, we suggest that Chuanxiong oil should be viewed as the best PE for TDD of ibuprofen to treat dysmenorrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:28589173': {'publication date': '2017', 'sentence': 'Ibuprofen and diclofenac were the most commonly used medications to manage dysmenorrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:34064282': {'publication date': '2021 May 21', 'sentence': 'An Evaluation of the Effectiveness of Ibuprofen and Manual Therapy in Young Women with Dysmenorrhea-A Pilot Study.', 'subject score': 1000, 'object score': 1000}, 'PMID:353274': {'publication date': '1978 May', 'sentence': 'Ibuprofen therapy for dysmenorrhea.', 'subject score': 888, 'object score': 1000}, 'PMID:380255': {'publication date': '1979', 'sentence': 'Suppression of menstrual prostaglandins and relief of dysmenorrhea with ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:474640': {'publication date': '1979 Sep 01', 'sentence': 'Relief of dysmenorrhea with the prostaglandin synthetase inhibitor ibuprofen: effect on prostaglandin levels in menstrual fluid.', 'subject score': 861, 'object score': 1000}, 'PMID:6181256': {'publication date': '1982 Jul', 'sentence': 'Naproxen sodium, ibuprofen and a placebo in dysmenorrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:6235745': {'publication date': '1984 Jul 13', 'sentence': 'Since its introduction in the United States in 1974, ibuprofen (Motrin, Upjohn) has been shown to be safe and effective for the treatment of pain, dysmenorrhea, inflammation, and fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:6347048': {'publication date': '1983', 'sentence': 'Ibuprofen and naproxen, 2 arylpropionic acids, are commonly used to treat dysmenorrhea and have fewer side effects than the other agents.', 'subject score': 1000, 'object score': 1000}, 'PMID:6790261': {'publication date': '1981 Jul', 'sentence': 'With the intrauterine device, prostaglandin synthetase inhibitors such as flufenamic acid, ibuprofen and naproxen are able not only to relieve dysmenorrhoea but also to reduce menstrual blood loss to normal levels.', 'subject score': 1000, 'object score': 1000}, 'PMID:6835617': {'publication date': '1983 May', 'sentence': 'A double-blind comparison of a propionic acid derivative (ibuprofen) and a fenamate (mefenamic acid) in the treatment of dysmenorrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:739472': {'publication date': '1978 Oct', 'sentence': 'A clinical trial of indomethacin and ibuprofen in dysmenorrhea.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318690,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100607",
-          "name": "Dysmenorrhea",
-          "description": "Pain during menstruation that interferes with daily activities. [PMID:15686299]; Pain during menstruation that interferes with daily activities.; Pain during menstruation that interferes with daily activities.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0013390",
-            "MEDDRA:10013934",
-            "SNOMEDCT:431416001",
-            "PSY:15620",
-            "MEDDRA:10027324",
-            "SNOMEDCT:266599000",
-            "MEDDRA:10034532",
-            "MEDDRA:10027323",
-            "HP:0100607",
-            "MEDDRA:10013935",
-            "MEDDRA:10033463",
-            "MEDDRA:10027321",
-            "MEDDRA:10033514",
-            "MEDDRA:10011299",
-            "SNOMEDCT:289900009",
-            "NCIT:C34559",
-            "MESH:D004412",
-            "ICD9:625.3"
-          ],
-          "id": "HP:0100607",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Dysmenorrhea"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "PMID:15686299"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318690,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100607",
-              "name": "Dysmenorrhea",
-              "description": "Pain during menstruation that interferes with daily activities. [PMID:15686299]; Pain during menstruation that interferes with daily activities.; Pain during menstruation that interferes with daily activities.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0013390",
-                "MEDDRA:10013934",
-                "SNOMEDCT:431416001",
-                "PSY:15620",
-                "MEDDRA:10027324",
-                "SNOMEDCT:266599000",
-                "MEDDRA:10034532",
-                "MEDDRA:10027323",
-                "HP:0100607",
-                "MEDDRA:10013935",
-                "MEDDRA:10033463",
-                "MEDDRA:10027321",
-                "MEDDRA:10033514",
-                "MEDDRA:10011299",
-                "SNOMEDCT:289900009",
-                "NCIT:C34559",
-                "MESH:D004412",
-                "ICD9:625.3"
-              ],
-              "id": "HP:0100607",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Dysmenorrhea"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "PMID:15686299"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8561205,
-            "start": 554,
-            "end": 318690,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11239634': {'publication date': '2001 Mar', 'sentence': 'CONCLUSION: Continuous low-level topical heat therapy was as effective as ibuprofen for the treatment of dysmenorrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:22069413': {'publication date': '2010 Dec', 'sentence': 'Reflexology method was associated with more reduction of intensity and duration of menstrual pain in comparison with Ibuprofen therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:24944382': {'publication date': '2003 Jun', 'sentence': 'Analgesia with ibuprofen arginate versus conventional ibuprofen for patients with dysmenorrhea: a crossover trial.', 'subject score': 888, 'object score': 1000}, 'PMID:26457698': {'publication date': '2015 Oct 07', 'sentence': 'In summary, we suggest that Chuanxiong oil should be viewed as the best PE for TDD of ibuprofen to treat dysmenorrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:28589173': {'publication date': '2017', 'sentence': 'Ibuprofen and diclofenac were the most commonly used medications to manage dysmenorrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:34064282': {'publication date': '2021 May 21', 'sentence': 'An Evaluation of the Effectiveness of Ibuprofen and Manual Therapy in Young Women with Dysmenorrhea-A Pilot Study.', 'subject score': 1000, 'object score': 1000}, 'PMID:353274': {'publication date': '1978 May', 'sentence': 'Ibuprofen therapy for dysmenorrhea.', 'subject score': 888, 'object score': 1000}, 'PMID:380255': {'publication date': '1979', 'sentence': 'Suppression of menstrual prostaglandins and relief of dysmenorrhea with ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:474640': {'publication date': '1979 Sep 01', 'sentence': 'Relief of dysmenorrhea with the prostaglandin synthetase inhibitor ibuprofen: effect on prostaglandin levels in menstrual fluid.', 'subject score': 861, 'object score': 1000}, 'PMID:6181256': {'publication date': '1982 Jul', 'sentence': 'Naproxen sodium, ibuprofen and a placebo in dysmenorrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:6235745': {'publication date': '1984 Jul 13', 'sentence': 'Since its introduction in the United States in 1974, ibuprofen (Motrin, Upjohn) has been shown to be safe and effective for the treatment of pain, dysmenorrhea, inflammation, and fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:6347048': {'publication date': '1983', 'sentence': 'Ibuprofen and naproxen, 2 arylpropionic acids, are commonly used to treat dysmenorrhea and have fewer side effects than the other agents.', 'subject score': 1000, 'object score': 1000}, 'PMID:6790261': {'publication date': '1981 Jul', 'sentence': 'With the intrauterine device, prostaglandin synthetase inhibitors such as flufenamic acid, ibuprofen and naproxen are able not only to relieve dysmenorrhoea but also to reduce menstrual blood loss to normal levels.', 'subject score': 1000, 'object score': 1000}, 'PMID:6835617': {'publication date': '1983 May', 'sentence': 'A double-blind comparison of a propionic acid derivative (ibuprofen) and a fenamate (mefenamic acid) in the treatment of dysmenorrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:739472': {'publication date': '1978 Oct', 'sentence': 'A clinical trial of indomethacin and ibuprofen in dysmenorrhea.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0013390---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "8748381",
-              "object": "HP:0100607",
-              "publications": [
-                "PMID:11239634",
-                "PMID:22069413",
-                "PMID:24944382",
-                "PMID:26457698",
-                "PMID:28589173",
-                "PMID:34064282",
-                "PMID:353274",
-                "PMID:380255",
-                "PMID:474640",
-                "PMID:6181256",
-                "PMID:6235745",
-                "PMID:6347048",
-                "PMID:6790261",
-                "PMID:6835617",
-                "PMID:739472"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:22069413': {'publication date': '2010 Dec', 'sentence': 'CONCLUSIONS: Considering the results of the study, reflexology was superior to Ibuprofen on reducing dysmenorrhea and its treatment effect continued even after discontinuing the intervention in the third cycle.', 'subject score': 1000, 'object score': 872}, 'PMID:28250781': {'publication date': '2016', 'sentence': 'CONCLUSION: Training and acupressure were more effective than ibuprofen in the reduction of dysmenorrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:36017945': {'publication date': '2022 Aug 26', 'sentence': 'Ibuprofen may not reduce menstrual cramps compared to placebo (OR 1.00, 95% CI 0.11 to 8.95; 1 trial, 20 women, low-certainty evidence).', 'subject score': 1000, 'object score': 1000}, 'PMID:392621': {'publication date': '1979 Jul', 'sentence': 'Ibuprofen also reduced the menstrual pain significantly (P less than 0.001).', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 318690,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100607",
-          "name": "Dysmenorrhea",
-          "description": "Pain during menstruation that interferes with daily activities. [PMID:15686299]; Pain during menstruation that interferes with daily activities.; Pain during menstruation that interferes with daily activities.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0013390",
-            "MEDDRA:10013934",
-            "SNOMEDCT:431416001",
-            "PSY:15620",
-            "MEDDRA:10027324",
-            "SNOMEDCT:266599000",
-            "MEDDRA:10034532",
-            "MEDDRA:10027323",
-            "HP:0100607",
-            "MEDDRA:10013935",
-            "MEDDRA:10033463",
-            "MEDDRA:10027321",
-            "MEDDRA:10033514",
-            "MEDDRA:10011299",
-            "SNOMEDCT:289900009",
-            "NCIT:C34559",
-            "MESH:D004412",
-            "ICD9:625.3"
-          ],
-          "id": "HP:0100607",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Dysmenorrhea"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "PMID:15686299"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318690,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100607",
-              "name": "Dysmenorrhea",
-              "description": "Pain during menstruation that interferes with daily activities. [PMID:15686299]; Pain during menstruation that interferes with daily activities.; Pain during menstruation that interferes with daily activities.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0013390",
-                "MEDDRA:10013934",
-                "SNOMEDCT:431416001",
-                "PSY:15620",
-                "MEDDRA:10027324",
-                "SNOMEDCT:266599000",
-                "MEDDRA:10034532",
-                "MEDDRA:10027323",
-                "HP:0100607",
-                "MEDDRA:10013935",
-                "MEDDRA:10033463",
-                "MEDDRA:10027321",
-                "MEDDRA:10033514",
-                "MEDDRA:10011299",
-                "SNOMEDCT:289900009",
-                "NCIT:C34559",
-                "MESH:D004412",
-                "ICD9:625.3"
-              ],
-              "id": "HP:0100607",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Dysmenorrhea"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "PMID:15686299"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15633780,
-            "start": 554,
-            "end": 318690,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22069413': {'publication date': '2010 Dec', 'sentence': 'CONCLUSIONS: Considering the results of the study, reflexology was superior to Ibuprofen on reducing dysmenorrhea and its treatment effect continued even after discontinuing the intervention in the third cycle.', 'subject score': 1000, 'object score': 872}, 'PMID:28250781': {'publication date': '2016', 'sentence': 'CONCLUSION: Training and acupressure were more effective than ibuprofen in the reduction of dysmenorrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:36017945': {'publication date': '2022 Aug 26', 'sentence': 'Ibuprofen may not reduce menstrual cramps compared to placebo (OR 1.00, 95% CI 0.11 to 8.95; 1 trial, 20 women, low-certainty evidence).', 'subject score': 1000, 'object score': 1000}, 'PMID:392621': {'publication date': '1979 Jul', 'sentence': 'Ibuprofen also reduced the menstrual pain significantly (P less than 0.001).', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0013390---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "15961024",
-              "object": "HP:0100607",
-              "publications": [
-                "PMID:22069413",
-                "PMID:28250781",
-                "PMID:36017945",
-                "PMID:392621"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:18444221': {'publication date': '2008 May', 'sentence': 'The patient presented with a 6-month history of neck pain with radiation into the shoulder and arm on the left side, which was relieved by ibuprofen.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317467,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0030833",
-          "name": "Neck pain",
-          "description": "Painful sensation in the neck area.; Discomfort or more intense forms of pain that are localized to the cervical region. This term generally refers to pain in the posterior or lateral regions of the neck.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the neck. [UToronto:chum]; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D019547",
-            "MEDDRA:10008322",
-            "NCIT:C50663",
-            "MEDDRA:10008296",
-            "SYMP:0000829",
-            "HP:0030833",
-            "MEDDRA:10049860",
-            "UMLS:C0007859",
-            "MEDDRA:10028836",
-            "MEDDRA:10033467",
-            "SNOMEDCT:81680005"
-          ],
-          "id": "HP:0030833",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Neck pain",
-            "Neck Pain",
-            "neck pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0003-6754",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317467,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0030833",
-              "name": "Neck pain",
-              "description": "Painful sensation in the neck area.; Discomfort or more intense forms of pain that are localized to the cervical region. This term generally refers to pain in the posterior or lateral regions of the neck.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the neck. [UToronto:chum]; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D019547",
-                "MEDDRA:10008322",
-                "NCIT:C50663",
-                "MEDDRA:10008296",
-                "SYMP:0000829",
-                "HP:0030833",
-                "MEDDRA:10049860",
-                "UMLS:C0007859",
-                "MEDDRA:10028836",
-                "MEDDRA:10033467",
-                "SNOMEDCT:81680005"
-              ],
-              "id": "HP:0030833",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Neck pain",
-                "Neck Pain",
-                "neck pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0003-6754",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13433806,
-            "start": 554,
-            "end": 317467,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18444221': {'publication date': '2008 May', 'sentence': 'The patient presented with a 6-month history of neck pain with radiation into the shoulder and arm on the left side, which was relieved by ibuprofen.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0007859---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "13722152",
-              "object": "HP:0030833",
-              "publications": [
-                "PMID:18444221"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1518731': {'publication date': '1992', 'sentence': 'A 57-year-old woman believed that ibuprofen, prescribed for back pain, improved her idiopathic chronic cough that had been resistant to inhaled and oral corticosteroids.', 'subject score': 1000, 'object score': 1000}, 'PMID:29038738': {'publication date': '2017', 'sentence': 'He reported taking high-dose ibuprofen for back pain and drinking several 24-ounce beers daily.', 'subject score': 901, 'object score': 1000}, 'PMID:33235514': {'publication date': '2020', 'sentence': 'Conclusion: The combination of eperisone hydrochloride and ibuprofen effectively reduces pain and improves functional outcomes over ibuprofen alone with a similar safety profile in these patients with acute non-specific back pain with muscle spasm.', 'subject score': 1000, 'object score': 928}, 'PMID:34064282': {'publication date': '2021 May 21', 'sentence': 'In subgroup B, the use of ibuprofen only alleviated back pain and fatigue.', 'subject score': 1000, 'object score': 1000}, 'PMID:36692805': {'publication date': '2023 Jan 24', 'sentence': 'Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 322143,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0003418",
-          "name": "Back pain",
-          "description": "An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the back. []; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the back.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the back.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the back.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "UMLS:C0004604",
-            "MEDDRA:10003988",
-            "MEDDRA:10064734",
-            "MEDDRA:10003994",
-            "MEDDRA:10003978",
-            "MEDDRA:10033478",
-            "SNOMEDCT:161891005",
-            "HP:0003418",
-            "MEDDRA:10033391",
-            "MESH:D001416",
-            "PSY:05275",
-            "MEDDRA:10033380",
-            "MEDDRA:10003993",
-            "NCIT:C41830",
-            "MEDDRA:10013601"
-          ],
-          "id": "HP:0003418",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Back Pain",
-            "Back pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322143,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0003418",
-              "name": "Back pain",
-              "description": "An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the back. []; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the back.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the back.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the back.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "UMLS:C0004604",
-                "MEDDRA:10003988",
-                "MEDDRA:10064734",
-                "MEDDRA:10003994",
-                "MEDDRA:10003978",
-                "MEDDRA:10033478",
-                "SNOMEDCT:161891005",
-                "HP:0003418",
-                "MEDDRA:10033391",
-                "MESH:D001416",
-                "PSY:05275",
-                "MEDDRA:10033380",
-                "MEDDRA:10003993",
-                "NCIT:C41830",
-                "MEDDRA:10013601"
-              ],
-              "id": "HP:0003418",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Back Pain",
-                "Back pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10987603,
-            "start": 554,
-            "end": 322143,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1518731': {'publication date': '1992', 'sentence': 'A 57-year-old woman believed that ibuprofen, prescribed for back pain, improved her idiopathic chronic cough that had been resistant to inhaled and oral corticosteroids.', 'subject score': 1000, 'object score': 1000}, 'PMID:29038738': {'publication date': '2017', 'sentence': 'He reported taking high-dose ibuprofen for back pain and drinking several 24-ounce beers daily.', 'subject score': 901, 'object score': 1000}, 'PMID:33235514': {'publication date': '2020', 'sentence': 'Conclusion: The combination of eperisone hydrochloride and ibuprofen effectively reduces pain and improves functional outcomes over ibuprofen alone with a similar safety profile in these patients with acute non-specific back pain with muscle spasm.', 'subject score': 1000, 'object score': 928}, 'PMID:34064282': {'publication date': '2021 May 21', 'sentence': 'In subgroup B, the use of ibuprofen only alleviated back pain and fatigue.', 'subject score': 1000, 'object score': 1000}, 'PMID:36692805': {'publication date': '2023 Jan 24', 'sentence': 'Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0004604---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "11239637",
-              "object": "HP:0003418",
-              "publications": [
-                "PMID:1518731",
-                "PMID:29038738",
-                "PMID:33235514",
-                "PMID:34064282",
-                "PMID:36692805"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:18450898': {'publication date': '2008 May', 'sentence': 'CONCLUSIONS: Ibuprofen-induced patent ductus arteriosus closure improved pulmonary mechanics, decreased total lung water, increased epithelial sodium channel expression, and decreased the detrimental effects of preterm birth on alveolarization.', 'subject score': 851, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 317818,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011827",
-          "name": "patent ductus arteriosus",
-          "description": "In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences. [HPO:probinson, PMID:20421261]; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "DOID:13832",
-            "UMLS:C0013274",
-            "ORPHANET:706",
-            "ICD9:747.0",
-            "SNOMEDCT:83330001",
-            "HP:0001643",
-            "MESH:D004374",
-            "OMIM.PS:607411",
-            "ICD10:Q25.0",
-            "NCIT:C84492",
-            "MONDO:0011827"
-          ],
-          "id": "MONDO:0011827",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Patent ductus arteriosus",
-            "patent ductus arteriosus",
-            "Patent Ductus Arteriosus",
-            "Ductus Arteriosus, Patent"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:20421261"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317818,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011827",
-              "name": "patent ductus arteriosus",
-              "description": "In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences. [HPO:probinson, PMID:20421261]; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "DOID:13832",
-                "UMLS:C0013274",
-                "ORPHANET:706",
-                "ICD9:747.0",
-                "SNOMEDCT:83330001",
-                "HP:0001643",
-                "MESH:D004374",
-                "OMIM.PS:607411",
-                "ICD10:Q25.0",
-                "NCIT:C84492",
-                "MONDO:0011827"
-              ],
-              "id": "MONDO:0011827",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Patent ductus arteriosus",
-                "patent ductus arteriosus",
-                "Patent Ductus Arteriosus",
-                "Ductus Arteriosus, Patent"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:20421261"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13437763,
-            "start": 554,
-            "end": 317818,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18450898': {'publication date': '2008 May', 'sentence': 'CONCLUSIONS: Ibuprofen-induced patent ductus arteriosus closure improved pulmonary mechanics, decreased total lung water, increased epithelial sodium channel expression, and decreased the detrimental effects of preterm birth on alveolarization.', 'subject score': 851, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C0013274---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "13726345",
-              "object": "MONDO:0011827",
-              "publications": [
-                "PMID:18450898"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:12723743': {'publication date': '2003 Apr', 'sentence': 'In a randomised, placebo-controlled, double-blind trial of prophylaxis with ibuprofen, the rate of patent ductus arteriosus associated with ibuprofen was 19% compared with 42% with placebo.', 'subject score': 1000, 'object score': 1000}, 'PMID:25317790': {'publication date': '2014', 'sentence': 'CONCLUSIONS: Collectively, the favorable effects of ibuprofen on PDA in premature infants maybe mediated in part by the reduction of NT-proBNP level.', 'subject score': 1000, 'object score': 1000}, 'PMID:27403365': {'publication date': '2016', 'sentence': 'To our knowledge, this is the first report on the effects of ibuprofen on patent ductus arteriosus in preterm newborns after months of life.', 'subject score': 1000, 'object score': 1000}, 'PMID:29584842': {'publication date': '2018 03 27', 'sentence': 'Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.', 'subject score': 1000, 'object score': 854}}",
-    "p2": {
-      "start": {
-        "identity": 317818,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011827",
-          "name": "patent ductus arteriosus",
-          "description": "In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences. [HPO:probinson, PMID:20421261]; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "DOID:13832",
-            "UMLS:C0013274",
-            "ORPHANET:706",
-            "ICD9:747.0",
-            "SNOMEDCT:83330001",
-            "HP:0001643",
-            "MESH:D004374",
-            "OMIM.PS:607411",
-            "ICD10:Q25.0",
-            "NCIT:C84492",
-            "MONDO:0011827"
-          ],
-          "id": "MONDO:0011827",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Patent ductus arteriosus",
-            "patent ductus arteriosus",
-            "Patent Ductus Arteriosus",
-            "Ductus Arteriosus, Patent"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:20421261"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317818,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011827",
-              "name": "patent ductus arteriosus",
-              "description": "In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences. [HPO:probinson, PMID:20421261]; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "DOID:13832",
-                "UMLS:C0013274",
-                "ORPHANET:706",
-                "ICD9:747.0",
-                "SNOMEDCT:83330001",
-                "HP:0001643",
-                "MESH:D004374",
-                "OMIM.PS:607411",
-                "ICD10:Q25.0",
-                "NCIT:C84492",
-                "MONDO:0011827"
-              ],
-              "id": "MONDO:0011827",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Patent ductus arteriosus",
-                "patent ductus arteriosus",
-                "Patent Ductus Arteriosus",
-                "Ductus Arteriosus, Patent"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:20421261"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9950756,
-            "start": 554,
-            "end": 317818,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12723743': {'publication date': '2003 Apr', 'sentence': 'In a randomised, placebo-controlled, double-blind trial of prophylaxis with ibuprofen, the rate of patent ductus arteriosus associated with ibuprofen was 19% compared with 42% with placebo.', 'subject score': 1000, 'object score': 1000}, 'PMID:25317790': {'publication date': '2014', 'sentence': 'CONCLUSIONS: Collectively, the favorable effects of ibuprofen on PDA in premature infants maybe mediated in part by the reduction of NT-proBNP level.', 'subject score': 1000, 'object score': 1000}, 'PMID:27403365': {'publication date': '2016', 'sentence': 'To our knowledge, this is the first report on the effects of ibuprofen on patent ductus arteriosus in preterm newborns after months of life.', 'subject score': 1000, 'object score': 1000}, 'PMID:29584842': {'publication date': '2018 03 27', 'sentence': 'Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.', 'subject score': 1000, 'object score': 854}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0013274---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "10170540",
-              "object": "MONDO:0011827",
-              "publications": [
-                "PMID:12723743",
-                "PMID:25317790",
-                "PMID:27403365",
-                "PMID:29584842"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10586177': {'publication date': '1999 Dec', 'sentence': 'OBJECTIVE: To evaluate the effect of intravenous ibuprofen and indomethacin for treatment of patent ductus arteriosus (PDA) on mesenteric and renal blood flow velocity in preterm infants.', 'subject score': 888, 'object score': 1000}, 'PMID:10834523': {'publication date': '2000 May', 'sentence': 'UNLABELLED: This study was aimed at evaluating the efficacy of ibuprofen in the prophylaxis of patent ductus arteriosus (PDA) in very preterm neonates and at detecting eventual side-effects.', 'subject score': 1000, 'object score': 796}, 'PMID:10974130': {'publication date': '2000 Sep 07', 'sentence': 'CONCLUSIONS: Ibuprofen therapy on the third day of life is as efficacious as indomethacin for the treatment of patent ductus arteriosus in preterm infants with the respiratory distress syndrome and is significantly less likely to induce oliguria.', 'subject score': 888, 'object score': 1000}, 'PMID:11106052': {'publication date': '2000 Nov', 'sentence': 'UNLABELLED: The aim of our study was to evaluate whether the prophylactic use of ibuprofen would reduce the incidence of significant patent ductus arteriosus (PDA) and to confirm the effectiveness of ibuprofen as rescue treatment in closing PDA.', 'subject score': 1000, 'object score': 923}, 'PMID:11424814': {'publication date': '2000', 'sentence': 'We have applied this technique to evaluate the possible effects on cerebral oxygenation and hemodynamics of clinical procedures usually performed on preterm infants:--endotracheal suctioning, and we have demonstrated that the magnitude and the duration of the negative effects of open system are significantly reduced using closed endotracheal suctioning system;--withdrawal and infusion through umbilical vein and artery cause significant changes in cerebral hemodynamics: these effects are significantly reduced after administration of ibuprofen;--treatment of patent ductus arteriosus with ibuprofen does not significantly reduce cerebral perfusion and oxygen availability compared to indomethacin and ibuprofen administration also does not affect cerebral vasoreactivity to arterial carbon dioxide tension;--administration of different types and doses of natural surfactant causes different changes in cerebral hemodynamics and these effects seem to be dose-related.', 'subject score': 1000, 'object score': 1000}, 'PMID:12014386': {'publication date': '2002 Apr', 'sentence': 'In a prospective, randomised, controlled study, we compared INDO and IBU with regard to efficacy and safety for the early non-invasive treatment of PDA.', 'subject score': 1000, 'object score': 1000}, 'PMID:12549803': {'publication date': '2002 Nov', 'sentence': 'BACKGROUND: Ibuprofen given intravenously to premature newborn infants is a proven treatment for patent ductus arteriosus (PDA).', 'subject score': 1000, 'object score': 1000}, 'PMID:12723743': {'publication date': '2003 Apr', 'sentence': 'Ibuprofen is therefore as effective as indomethacin in the treatment of patent ductus arteriosus, and effective as prophylaxis, in premature infants.', 'subject score': 1000, 'object score': 1000}, 'PMID:12804469': {'publication date': '2003', 'sentence': 'SEARCH STRATEGY: Randomized (or quasi-randomized) controlled trials (RCTs) comparing ibuprofen to placebo or indomethacin or mefenamic acid for therapy of PDA were identified by searching the Cochrane Controlled Trials Register (Issue 4, 2002), MEDLINE (1996 - January 2003), CINAHL (1982 - November 2002), EMBASE (1980 - January 2002), reference lists of published RCTs and abstracts from the Pediatric Academic Societies and the European Society for Pediatric Research meetings published in Pediatric Research (1991 - 2002).', 'subject score': 861, 'object score': 1000}, 'PMID:14651538': {'publication date': '2003 Dec', 'sentence': 'CONCLUSIONS: Ibuprofen therapy is as efficacious as indomethacin for the treatment of PDA in preterm infants.', 'subject score': 888, 'object score': 1000}, 'PMID:15263833': {'publication date': '2004', 'sentence': 'BACKGROUND: Ibuprofen is a cyclooxygenase inhibitor that is effective in treating patent ductus arteriosus in preterm infants.', 'subject score': 1000, 'object score': 916}, 'PMID:15303820': {'publication date': '2004 Jul', 'sentence': 'AIM: To discuss intestinal side effects of ibuprofen in the treatment of patent ductus arteriosus, after having observed two cases of spontaneous intestinal perforation following ibuprofen treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:15567009': {'publication date': '2004 Nov 27-Dec 3', 'sentence': 'After day 3, symptomatic patent ductus arteriosus was treated first by open curative ibuprofen, then back-up indometacin, surgery, or both.', 'subject score': 802, 'object score': 916}, 'PMID:15681219': {'publication date': '2005 Feb', 'sentence': 'Ibuprofen provides a further option for neonatologists in the management of PDA.', 'subject score': 1000, 'object score': 1000}, 'PMID:15717178': {'publication date': '2005 Mar', 'sentence': 'We conducted a meta-analysis of randomized trials to compare the efficacy and safety of IBU and INDO for treatment of PDA.', 'subject score': 1000, 'object score': 1000}, 'PMID:15811164': {'publication date': '2005 Apr', 'sentence': 'OBJECTIVE: Intravenous ibuprofen (IBU) has been found to be as effective as indomethacin for the treatment of patent ductus arteriosus (PDA) in preterm infants and has been associated with fewer adverse effects in comparative phase III studies.', 'subject score': 888, 'object score': 1000}, 'PMID:16133044': {'publication date': '2005 Nov', 'sentence': 'Urinary ET-1, AVP and sodium in premature infants treated with indomethacin and ibuprofen for patent ductus arteriosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:16219273': {'publication date': '2005 Sep', 'sentence': 'In this study we compared the safety and efficacy of ibuprofen and indomethacin in the treatment of PDA in preterm infants.', 'subject score': 1000, 'object score': 916}, 'PMID:16235321': {'publication date': '2005 Oct 19', 'sentence': 'SEARCH STRATEGY: Randomized or quasi-randomized controlled trials (RCTs) comparing ibuprofen to placebo or indomethacin or mefenamic acid for therapy of PDA were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 2, 2005), MEDLINE (1996 - July 2005), CINAHL (1982 - July 2005), EMBASE (1980 - July 2005), reference lists of published RCTs and abstracts from the Pediatric Academic Societies and the European Society for Pediatric Research meetings published in Pediatric Research (1991 - April 2005).', 'subject score': 1000, 'object score': 1000}, 'PMID:16260891': {'publication date': '2005 Nov-Dec', 'sentence': 'Effects of ibuprofen and indomethacin on urinary antidiuretic hormone excretion in preterm infants treated for patent ductus arteriosus.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317818,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011827",
-          "name": "patent ductus arteriosus",
-          "description": "In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences. [HPO:probinson, PMID:20421261]; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "DOID:13832",
-            "UMLS:C0013274",
-            "ORPHANET:706",
-            "ICD9:747.0",
-            "SNOMEDCT:83330001",
-            "HP:0001643",
-            "MESH:D004374",
-            "OMIM.PS:607411",
-            "ICD10:Q25.0",
-            "NCIT:C84492",
-            "MONDO:0011827"
-          ],
-          "id": "MONDO:0011827",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Patent ductus arteriosus",
-            "patent ductus arteriosus",
-            "Patent Ductus Arteriosus",
-            "Ductus Arteriosus, Patent"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:20421261"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317818,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011827",
-              "name": "patent ductus arteriosus",
-              "description": "In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences. [HPO:probinson, PMID:20421261]; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "DOID:13832",
-                "UMLS:C0013274",
-                "ORPHANET:706",
-                "ICD9:747.0",
-                "SNOMEDCT:83330001",
-                "HP:0001643",
-                "MESH:D004374",
-                "OMIM.PS:607411",
-                "ICD10:Q25.0",
-                "NCIT:C84492",
-                "MONDO:0011827"
-              ],
-              "id": "MONDO:0011827",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Patent ductus arteriosus",
-                "patent ductus arteriosus",
-                "Patent Ductus Arteriosus",
-                "Ductus Arteriosus, Patent"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:20421261"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7689228,
-            "start": 554,
-            "end": 317818,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10586177': {'publication date': '1999 Dec', 'sentence': 'OBJECTIVE: To evaluate the effect of intravenous ibuprofen and indomethacin for treatment of patent ductus arteriosus (PDA) on mesenteric and renal blood flow velocity in preterm infants.', 'subject score': 888, 'object score': 1000}, 'PMID:10834523': {'publication date': '2000 May', 'sentence': 'UNLABELLED: This study was aimed at evaluating the efficacy of ibuprofen in the prophylaxis of patent ductus arteriosus (PDA) in very preterm neonates and at detecting eventual side-effects.', 'subject score': 1000, 'object score': 796}, 'PMID:10974130': {'publication date': '2000 Sep 07', 'sentence': 'CONCLUSIONS: Ibuprofen therapy on the third day of life is as efficacious as indomethacin for the treatment of patent ductus arteriosus in preterm infants with the respiratory distress syndrome and is significantly less likely to induce oliguria.', 'subject score': 888, 'object score': 1000}, 'PMID:11106052': {'publication date': '2000 Nov', 'sentence': 'UNLABELLED: The aim of our study was to evaluate whether the prophylactic use of ibuprofen would reduce the incidence of significant patent ductus arteriosus (PDA) and to confirm the effectiveness of ibuprofen as rescue treatment in closing PDA.', 'subject score': 1000, 'object score': 923}, 'PMID:11424814': {'publication date': '2000', 'sentence': 'We have applied this technique to evaluate the possible effects on cerebral oxygenation and hemodynamics of clinical procedures usually performed on preterm infants:--endotracheal suctioning, and we have demonstrated that the magnitude and the duration of the negative effects of open system are significantly reduced using closed endotracheal suctioning system;--withdrawal and infusion through umbilical vein and artery cause significant changes in cerebral hemodynamics: these effects are significantly reduced after administration of ibuprofen;--treatment of patent ductus arteriosus with ibuprofen does not significantly reduce cerebral perfusion and oxygen availability compared to indomethacin and ibuprofen administration also does not affect cerebral vasoreactivity to arterial carbon dioxide tension;--administration of different types and doses of natural surfactant causes different changes in cerebral hemodynamics and these effects seem to be dose-related.', 'subject score': 1000, 'object score': 1000}, 'PMID:12014386': {'publication date': '2002 Apr', 'sentence': 'In a prospective, randomised, controlled study, we compared INDO and IBU with regard to efficacy and safety for the early non-invasive treatment of PDA.', 'subject score': 1000, 'object score': 1000}, 'PMID:12549803': {'publication date': '2002 Nov', 'sentence': 'BACKGROUND: Ibuprofen given intravenously to premature newborn infants is a proven treatment for patent ductus arteriosus (PDA).', 'subject score': 1000, 'object score': 1000}, 'PMID:12723743': {'publication date': '2003 Apr', 'sentence': 'Ibuprofen is therefore as effective as indomethacin in the treatment of patent ductus arteriosus, and effective as prophylaxis, in premature infants.', 'subject score': 1000, 'object score': 1000}, 'PMID:12804469': {'publication date': '2003', 'sentence': 'SEARCH STRATEGY: Randomized (or quasi-randomized) controlled trials (RCTs) comparing ibuprofen to placebo or indomethacin or mefenamic acid for therapy of PDA were identified by searching the Cochrane Controlled Trials Register (Issue 4, 2002), MEDLINE (1996 - January 2003), CINAHL (1982 - November 2002), EMBASE (1980 - January 2002), reference lists of published RCTs and abstracts from the Pediatric Academic Societies and the European Society for Pediatric Research meetings published in Pediatric Research (1991 - 2002).', 'subject score': 861, 'object score': 1000}, 'PMID:14651538': {'publication date': '2003 Dec', 'sentence': 'CONCLUSIONS: Ibuprofen therapy is as efficacious as indomethacin for the treatment of PDA in preterm infants.', 'subject score': 888, 'object score': 1000}, 'PMID:15263833': {'publication date': '2004', 'sentence': 'BACKGROUND: Ibuprofen is a cyclooxygenase inhibitor that is effective in treating patent ductus arteriosus in preterm infants.', 'subject score': 1000, 'object score': 916}, 'PMID:15303820': {'publication date': '2004 Jul', 'sentence': 'AIM: To discuss intestinal side effects of ibuprofen in the treatment of patent ductus arteriosus, after having observed two cases of spontaneous intestinal perforation following ibuprofen treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:15567009': {'publication date': '2004 Nov 27-Dec 3', 'sentence': 'After day 3, symptomatic patent ductus arteriosus was treated first by open curative ibuprofen, then back-up indometacin, surgery, or both.', 'subject score': 802, 'object score': 916}, 'PMID:15681219': {'publication date': '2005 Feb', 'sentence': 'Ibuprofen provides a further option for neonatologists in the management of PDA.', 'subject score': 1000, 'object score': 1000}, 'PMID:15717178': {'publication date': '2005 Mar', 'sentence': 'We conducted a meta-analysis of randomized trials to compare the efficacy and safety of IBU and INDO for treatment of PDA.', 'subject score': 1000, 'object score': 1000}, 'PMID:15811164': {'publication date': '2005 Apr', 'sentence': 'OBJECTIVE: Intravenous ibuprofen (IBU) has been found to be as effective as indomethacin for the treatment of patent ductus arteriosus (PDA) in preterm infants and has been associated with fewer adverse effects in comparative phase III studies.', 'subject score': 888, 'object score': 1000}, 'PMID:16133044': {'publication date': '2005 Nov', 'sentence': 'Urinary ET-1, AVP and sodium in premature infants treated with indomethacin and ibuprofen for patent ductus arteriosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:16219273': {'publication date': '2005 Sep', 'sentence': 'In this study we compared the safety and efficacy of ibuprofen and indomethacin in the treatment of PDA in preterm infants.', 'subject score': 1000, 'object score': 916}, 'PMID:16235321': {'publication date': '2005 Oct 19', 'sentence': 'SEARCH STRATEGY: Randomized or quasi-randomized controlled trials (RCTs) comparing ibuprofen to placebo or indomethacin or mefenamic acid for therapy of PDA were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 2, 2005), MEDLINE (1996 - July 2005), CINAHL (1982 - July 2005), EMBASE (1980 - July 2005), reference lists of published RCTs and abstracts from the Pediatric Academic Societies and the European Society for Pediatric Research meetings published in Pediatric Research (1991 - April 2005).', 'subject score': 1000, 'object score': 1000}, 'PMID:16260891': {'publication date': '2005 Nov-Dec', 'sentence': 'Effects of ibuprofen and indomethacin on urinary antidiuretic hormone excretion in preterm infants treated for patent ductus arteriosus.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0013274---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "7851777",
-              "object": "MONDO:0011827",
-              "publications": [
-                "PMID:10586177",
-                "PMID:10834523",
-                "PMID:10974130",
-                "PMID:11106052",
-                "PMID:11424814",
-                "PMID:12014386",
-                "PMID:12549803",
-                "PMID:12723743",
-                "PMID:12804469",
-                "PMID:14651538",
-                "PMID:15263833",
-                "PMID:15303820",
-                "PMID:15567009",
-                "PMID:15681219",
-                "PMID:15717178",
-                "PMID:15811164",
-                "PMID:16133044",
-                "PMID:16219273",
-                "PMID:16235321",
-                "PMID:16260891"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:11106052': {'publication date': '2000 Nov', 'sentence': 'UNLABELLED: The aim of our study was to evaluate whether the prophylactic use of ibuprofen would reduce the incidence of significant patent ductus arteriosus (PDA) and to confirm the effectiveness of ibuprofen as rescue treatment in closing PDA.', 'subject score': 1000, 'object score': 916}, 'PMID:12804505': {'publication date': '2003', 'sentence': \"REVIEWER'S CONCLUSIONS: Prophylactic use of ibuprofen reduces the incidence of PDA.\", 'subject score': 1000, 'object score': 1000}, 'PMID:16437478': {'publication date': '2006 Jan 25', 'sentence': \"AUTHORS' CONCLUSIONS: Prophylactic use of ibuprofen reduces the incidence of PDA, the need for rescue treatment with cyclo-oxygenase inhibitors and surgical closure.\", 'subject score': 1000, 'object score': 1000}, 'PMID:17437233': {'publication date': '2007 Apr', 'sentence': 'However, adverse effects of ibuprofen have been evidenced both in trials on the use of ibuprofen for the prevention of PDA and of intraventricular hemorrhage-periventricular hemorrhage (IVH-PVH), and in experimental studies on a neonatal, anesthetized animal model.', 'subject score': 1000, 'object score': 1000}, 'PMID:21735396': {'publication date': '2011 Jul 06', 'sentence': \"AUTHORS' CONCLUSIONS: Prophylactic use of ibuprofen decreased the incidence of PDA, decreased the need for rescue treatment with cyclo-oxygenase inhibitors and decreased the need for surgical closure.\", 'subject score': 1000, 'object score': 1000}, 'PMID:22564295': {'publication date': '2012', 'sentence': 'Non-steroidal anti-inflammatory agents, such as indomethacin or ibuprofen, have been shown to be effective in closing or preventing patent ductus arteriosus, with differences in side effects.', 'subject score': 1000, 'object score': 900}, 'PMID:22613269': {'publication date': '2012 Nov-Dec', 'sentence': 'OBJECTIVE: Intravenous ibuprofen is an expensive drug that is being used currently for treating and preventing patent ductus arteriosus.', 'subject score': 888, 'object score': 900}, 'PMID:23128963': {'publication date': '2013 May', 'sentence': 'Serum ibuprofen levels of extremely preterm infants treated prophylactically with oral ibuprofen to prevent patent ductus arteriosus.', 'subject score': 851, 'object score': 1000}, 'PMID:25532746': {'publication date': '2015 Jan', 'sentence': 'Prophylactic therapy with indomethacin or ibuprofen to prevent PDA has not altered the morbidity or long term outcome.', 'subject score': 1000, 'object score': 1000}, 'PMID:27493386': {'publication date': '2014', 'sentence': 'Although indomethacin and ibuprofen are the main stay of medical treatment, conservative approach by restricted fluid and applying continuous positive airway pressure (CPAP) may be effective in prevention of PDA without complication.', 'subject score': 1000, 'object score': 1000}, 'PMID:31222841': {'publication date': '2019 06 21', 'sentence': 'Current evidence does not support the use of ibuprofen for prevention of patent ductus arteriosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:31985838': {'publication date': '2020 Jan 27', 'sentence': 'Current evidence does not support the use of ibuprofen for prevention of patent ductus arteriosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:35363893': {'publication date': '2022 Apr 01', 'sentence': 'Ibuprofen (median rank 1) was more effective than indomethacin in reducing surgical PDA ligation (median rank 2).', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 317818,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011827",
-          "name": "patent ductus arteriosus",
-          "description": "In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences. [HPO:probinson, PMID:20421261]; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "DOID:13832",
-            "UMLS:C0013274",
-            "ORPHANET:706",
-            "ICD9:747.0",
-            "SNOMEDCT:83330001",
-            "HP:0001643",
-            "MESH:D004374",
-            "OMIM.PS:607411",
-            "ICD10:Q25.0",
-            "NCIT:C84492",
-            "MONDO:0011827"
-          ],
-          "id": "MONDO:0011827",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Patent ductus arteriosus",
-            "patent ductus arteriosus",
-            "Patent Ductus Arteriosus",
-            "Ductus Arteriosus, Patent"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:20421261"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317818,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011827",
-              "name": "patent ductus arteriosus",
-              "description": "In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences. [HPO:probinson, PMID:20421261]; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "DOID:13832",
-                "UMLS:C0013274",
-                "ORPHANET:706",
-                "ICD9:747.0",
-                "SNOMEDCT:83330001",
-                "HP:0001643",
-                "MESH:D004374",
-                "OMIM.PS:607411",
-                "ICD10:Q25.0",
-                "NCIT:C84492",
-                "MONDO:0011827"
-              ],
-              "id": "MONDO:0011827",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Patent ductus arteriosus",
-                "patent ductus arteriosus",
-                "Patent Ductus Arteriosus",
-                "Ductus Arteriosus, Patent"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:20421261"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8401507,
-            "start": 554,
-            "end": 317818,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11106052': {'publication date': '2000 Nov', 'sentence': 'UNLABELLED: The aim of our study was to evaluate whether the prophylactic use of ibuprofen would reduce the incidence of significant patent ductus arteriosus (PDA) and to confirm the effectiveness of ibuprofen as rescue treatment in closing PDA.', 'subject score': 1000, 'object score': 916}, 'PMID:12804505': {'publication date': '2003', 'sentence': \"REVIEWER'S CONCLUSIONS: Prophylactic use of ibuprofen reduces the incidence of PDA.\", 'subject score': 1000, 'object score': 1000}, 'PMID:16437478': {'publication date': '2006 Jan 25', 'sentence': \"AUTHORS' CONCLUSIONS: Prophylactic use of ibuprofen reduces the incidence of PDA, the need for rescue treatment with cyclo-oxygenase inhibitors and surgical closure.\", 'subject score': 1000, 'object score': 1000}, 'PMID:17437233': {'publication date': '2007 Apr', 'sentence': 'However, adverse effects of ibuprofen have been evidenced both in trials on the use of ibuprofen for the prevention of PDA and of intraventricular hemorrhage-periventricular hemorrhage (IVH-PVH), and in experimental studies on a neonatal, anesthetized animal model.', 'subject score': 1000, 'object score': 1000}, 'PMID:21735396': {'publication date': '2011 Jul 06', 'sentence': \"AUTHORS' CONCLUSIONS: Prophylactic use of ibuprofen decreased the incidence of PDA, decreased the need for rescue treatment with cyclo-oxygenase inhibitors and decreased the need for surgical closure.\", 'subject score': 1000, 'object score': 1000}, 'PMID:22564295': {'publication date': '2012', 'sentence': 'Non-steroidal anti-inflammatory agents, such as indomethacin or ibuprofen, have been shown to be effective in closing or preventing patent ductus arteriosus, with differences in side effects.', 'subject score': 1000, 'object score': 900}, 'PMID:22613269': {'publication date': '2012 Nov-Dec', 'sentence': 'OBJECTIVE: Intravenous ibuprofen is an expensive drug that is being used currently for treating and preventing patent ductus arteriosus.', 'subject score': 888, 'object score': 900}, 'PMID:23128963': {'publication date': '2013 May', 'sentence': 'Serum ibuprofen levels of extremely preterm infants treated prophylactically with oral ibuprofen to prevent patent ductus arteriosus.', 'subject score': 851, 'object score': 1000}, 'PMID:25532746': {'publication date': '2015 Jan', 'sentence': 'Prophylactic therapy with indomethacin or ibuprofen to prevent PDA has not altered the morbidity or long term outcome.', 'subject score': 1000, 'object score': 1000}, 'PMID:27493386': {'publication date': '2014', 'sentence': 'Although indomethacin and ibuprofen are the main stay of medical treatment, conservative approach by restricted fluid and applying continuous positive airway pressure (CPAP) may be effective in prevention of PDA without complication.', 'subject score': 1000, 'object score': 1000}, 'PMID:31222841': {'publication date': '2019 06 21', 'sentence': 'Current evidence does not support the use of ibuprofen for prevention of patent ductus arteriosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:31985838': {'publication date': '2020 Jan 27', 'sentence': 'Current evidence does not support the use of ibuprofen for prevention of patent ductus arteriosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:35363893': {'publication date': '2022 Apr 01', 'sentence': 'Ibuprofen (median rank 1) was more effective than indomethacin in reducing surgical PDA ligation (median rank 2).', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0013274---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "8584177",
-              "object": "MONDO:0011827",
-              "publications": [
-                "PMID:11106052",
-                "PMID:12804505",
-                "PMID:16437478",
-                "PMID:17437233",
-                "PMID:21735396",
-                "PMID:22564295",
-                "PMID:22613269",
-                "PMID:23128963",
-                "PMID:25532746",
-                "PMID:27493386",
-                "PMID:31222841",
-                "PMID:31985838",
-                "PMID:35363893"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:37042058': {'publication date': '2023 Apr 11', 'sentence': 'Huoxue Huayu Recipe combined with ibuprofen can reduce inflammatory factors levels in patients with ankle fracture, improve isokinetic muscle strength and ankle function, and accelerate the recovery of patients.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 324220,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0041153",
-          "name": "Fractured ankle",
-          "description": "Traumatic or pathological injury to the ankle joint in which the continuity of an ankle bone is broken. Symptoms include pain, swelling, and difficulty moving the affected leg and foot.; Fractures of any of the bones of the ANKLE.; A fracture or multiple fractures of one or more of three bones in the ankle joint: the tibia (shinbone), the fibula (outer ankle bone), and the talus (which is the bone that connects your leg to your foot). [https://www.hss.edu/condition-list_ankle-fractures.asp]; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "EFO:0009615",
-            "MESH:D064386",
-            "UMLS:C0159877",
-            "MEDDRA:10002544",
-            "MEDDRA:10006380",
-            "NCIT:C26989",
-            "MEDDRA:10017092",
-            "SNOMEDCT:16114001",
-            "HP:0041153"
-          ],
-          "id": "HP:0041153",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Ankle Fractures",
-            "Ankle Fracture",
-            "ankle fracture",
-            "Fractured ankle"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.hss.edu/condition-list_ankle-fractures.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 324220,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0041153",
-              "name": "Fractured ankle",
-              "description": "Traumatic or pathological injury to the ankle joint in which the continuity of an ankle bone is broken. Symptoms include pain, swelling, and difficulty moving the affected leg and foot.; Fractures of any of the bones of the ANKLE.; A fracture or multiple fractures of one or more of three bones in the ankle joint: the tibia (shinbone), the fibula (outer ankle bone), and the talus (which is the bone that connects your leg to your foot). [https://www.hss.edu/condition-list_ankle-fractures.asp]; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "EFO:0009615",
-                "MESH:D064386",
-                "UMLS:C0159877",
-                "MEDDRA:10002544",
-                "MEDDRA:10006380",
-                "NCIT:C26989",
-                "MEDDRA:10017092",
-                "SNOMEDCT:16114001",
-                "HP:0041153"
-              ],
-              "id": "HP:0041153",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Ankle Fractures",
-                "Ankle Fracture",
-                "ankle fracture",
-                "Fractured ankle"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.hss.edu/condition-list_ankle-fractures.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25067746,
-            "start": 554,
-            "end": 324220,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:37042058': {'publication date': '2023 Apr 11', 'sentence': 'Huoxue Huayu Recipe combined with ibuprofen can reduce inflammatory factors levels in patients with ankle fracture, improve isokinetic muscle strength and ankle function, and accelerate the recovery of patients.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0159877---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "25518118",
-              "object": "HP:0041153",
-              "publications": [
-                "PMID:37042058"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:81154': {'publication date': '1978', 'sentence': 'A comparison of the short-term effects of ibuprofen and diclofenac in spondylosis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 521747,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002253",
-          "name": "spondylosis",
-          "description": "A form of spondylosis involving the INTERVERTEBRAL DISK, including both the annulus and the nucleus of the disk. It is usually the consequence of normal aging.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:M47",
-            "MEDDRA:10041681",
-            "ICD9:721.3",
-            "SNOMEDCT:48210000",
-            "UMLS:C0158244",
-            "MEDDRA:10025020",
-            "ICD9:721.9",
-            "MEDDRA:10041682",
-            "DOID:2247",
-            "MONDO:0002253",
-            "MESH:D055009",
-            "UMLS:C0038019",
-            "MEDDRA:10041678"
-          ],
-          "id": "MONDO:0002253",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Spondylosis",
-            "spondylosis",
-            "Lumbosacral spondylosis without myelopathy",
-            "Spondylosis of unspecified site"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000436.htm",
-            "http://en.wikipedia.org/wiki/spondylosis",
-            "http://www.mayoclinic.com/health/cervical-spondylosis/ds00697",
-            "https://www.spineuniverse.com/conditions/spondylosis/spondylosis",
-            "http://www.spine-health.com/conditions/back-pain/spondylosis-what-it-actually-means"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 521747,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002253",
-              "name": "spondylosis",
-              "description": "A form of spondylosis involving the INTERVERTEBRAL DISK, including both the annulus and the nucleus of the disk. It is usually the consequence of normal aging.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:M47",
-                "MEDDRA:10041681",
-                "ICD9:721.3",
-                "SNOMEDCT:48210000",
-                "UMLS:C0158244",
-                "MEDDRA:10025020",
-                "ICD9:721.9",
-                "MEDDRA:10041682",
-                "DOID:2247",
-                "MONDO:0002253",
-                "MESH:D055009",
-                "UMLS:C0038019",
-                "MEDDRA:10041678"
-              ],
-              "id": "MONDO:0002253",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Spondylosis",
-                "spondylosis",
-                "Lumbosacral spondylosis without myelopathy",
-                "Spondylosis of unspecified site"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000436.htm",
-                "http://en.wikipedia.org/wiki/spondylosis",
-                "http://www.mayoclinic.com/health/cervical-spondylosis/ds00697",
-                "https://www.spineuniverse.com/conditions/spondylosis/spondylosis",
-                "http://www.spine-health.com/conditions/back-pain/spondylosis-what-it-actually-means"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26360392,
-            "start": 554,
-            "end": 521747,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:81154': {'publication date': '1978', 'sentence': 'A comparison of the short-term effects of ibuprofen and diclofenac in spondylosis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0038019---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "26824955",
-              "object": "MONDO:0002253",
-              "publications": [
-                "PMID:81154"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:10751701': {'publication date': '2000 Jun', 'sentence': 'INTRODUCTION: The anti-inflammatory and anticoagulant effects of ibuprofen and heparin may enhance skin perfusion in cutaneous scald burns.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 533531,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043519",
-          "name": "burn",
-          "description": "A traumatic injury involving interruption of tissue cohesiveness that results from exposure to caustic chemicals, extreme heat, extreme cold or excessive radiation.; Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.; A burn is damage to your body's tissues caused by heat, chemicals, electricity, sunlight, or radiation. Scalds from hot liquids and steam, building fires and flammable liquids and gases are the most common causes of burns. Another kind is an inhalation injury, caused by breathing smoke. There are three types of burns:  First-degree burns damage only the outer layer of skin  Second-degree burns damage the outer layer and the layer underneath Third-degree burns damage or destroy the deepest layer of skin and tissues underneath  Burns can cause swelling, blistering, scarring and, in serious cases, shock, and even death. They also can lead to infections because they damage your skin's protective barrier. Treatment for burns depends on the cause of the burn, how deep it is, and how much of the body it covers. Antibiotic creams can prevent or treat infections. For more serious burns, treatment may be needed to clean the wound, replace the skin, and make sure the patient has enough fluids and nutrition. NIH: National Institute of General Medical Sciences; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10006799",
-            "MESH:D002056",
-            "MEDDRA:10006634",
-            "SNOMEDCT:125666000",
-            "MEDDRA:10083300",
-            "SNOMEDCT:48333001",
-            "NCIT:C34441",
-            "MEDDRA:10006764",
-            "UMLS:C0006434",
-            "MONDO:0043519"
-          ],
-          "id": "MONDO:0043519",
-          "category": "biolink:Disease",
-          "all_names": [
-            "burn",
-            "Burn injury",
-            "Burn",
-            "Burns"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 533531,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043519",
-              "name": "burn",
-              "description": "A traumatic injury involving interruption of tissue cohesiveness that results from exposure to caustic chemicals, extreme heat, extreme cold or excessive radiation.; Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.; A burn is damage to your body's tissues caused by heat, chemicals, electricity, sunlight, or radiation. Scalds from hot liquids and steam, building fires and flammable liquids and gases are the most common causes of burns. Another kind is an inhalation injury, caused by breathing smoke. There are three types of burns:  First-degree burns damage only the outer layer of skin  Second-degree burns damage the outer layer and the layer underneath Third-degree burns damage or destroy the deepest layer of skin and tissues underneath  Burns can cause swelling, blistering, scarring and, in serious cases, shock, and even death. They also can lead to infections because they damage your skin's protective barrier. Treatment for burns depends on the cause of the burn, how deep it is, and how much of the body it covers. Antibiotic creams can prevent or treat infections. For more serious burns, treatment may be needed to clean the wound, replace the skin, and make sure the patient has enough fluids and nutrition. NIH: National Institute of General Medical Sciences; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10006799",
-                "MESH:D002056",
-                "MEDDRA:10006634",
-                "SNOMEDCT:125666000",
-                "MEDDRA:10083300",
-                "SNOMEDCT:48333001",
-                "NCIT:C34441",
-                "MEDDRA:10006764",
-                "UMLS:C0006434",
-                "MONDO:0043519"
-              ],
-              "id": "MONDO:0043519",
-              "category": "biolink:Disease",
-              "all_names": [
-                "burn",
-                "Burn injury",
-                "Burn",
-                "Burns"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7937052,
-            "start": 554,
-            "end": 533531,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10751701': {'publication date': '2000 Jun', 'sentence': 'INTRODUCTION: The anti-inflammatory and anticoagulant effects of ibuprofen and heparin may enhance skin perfusion in cutaneous scald burns.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:associated_with---None---None---None---UMLS:C0006434---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "8106985",
-              "object": "MONDO:0043519",
-              "publications": [
-                "PMID:10751701"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:32508173': {'publication date': '2020 Jun 07', 'sentence': 'Introduction:     The comparison of ibuprofen with acetaminophen for blood pressure (BP) in preeclampsia remains controversial.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318715,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005081",
-          "name": "preeclampsia",
-          "description": "A systolic blood pressure of 140 mmHg or higher, or a diastolic blood pressure of 90 mmHg or higher on two occasions at least 4 hours apart (or greater than or equal to 160/110 mmHg within a short interval) after 20 weeks of gestation in a woman with previously normal blood pressure. It may present with proteinuria but if not, it may be associated with thrombocytopenia, impaired liver function, progressive renal insufficiency, pulmonary edema, or new-onset cerebral or visual disturbances.; A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.; Pregnancy-induced hypertension in association with significant amounts of protein in the urine. [HPO:sdoelken]; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "SNOMEDCT:398254007",
-            "EFO:0000668",
-            "MEDDRA:10074050",
-            "MEDDRA:10036492",
-            "DOID:10591",
-            "NCIT:C85021",
-            "MEDDRA:10036493",
-            "HP:0100602",
-            "MESH:D011225",
-            "ICD10:O14",
-            "MEDDRA:10036485",
-            "MONDO:0005081",
-            "ORPHANET:275555",
-            "OMIM.PS:189800",
-            "UMLS:C0032914"
-          ],
-          "id": "MONDO:0005081",
-          "category": "biolink:Disease",
-          "all_names": [
-            "pre-eclampsia",
-            "Preeclampsia",
-            "preeclampsia",
-            "Pre-Eclampsia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:24400024",
-            "http://ghr.nlm.nih.gov/condition/preeclampsia",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/pre-eclampsia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318715,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005081",
-              "name": "preeclampsia",
-              "description": "A systolic blood pressure of 140 mmHg or higher, or a diastolic blood pressure of 90 mmHg or higher on two occasions at least 4 hours apart (or greater than or equal to 160/110 mmHg within a short interval) after 20 weeks of gestation in a woman with previously normal blood pressure. It may present with proteinuria but if not, it may be associated with thrombocytopenia, impaired liver function, progressive renal insufficiency, pulmonary edema, or new-onset cerebral or visual disturbances.; A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.; Pregnancy-induced hypertension in association with significant amounts of protein in the urine. [HPO:sdoelken]; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "SNOMEDCT:398254007",
-                "EFO:0000668",
-                "MEDDRA:10074050",
-                "MEDDRA:10036492",
-                "DOID:10591",
-                "NCIT:C85021",
-                "MEDDRA:10036493",
-                "HP:0100602",
-                "MESH:D011225",
-                "ICD10:O14",
-                "MEDDRA:10036485",
-                "MONDO:0005081",
-                "ORPHANET:275555",
-                "OMIM.PS:189800",
-                "UMLS:C0032914"
-              ],
-              "id": "MONDO:0005081",
-              "category": "biolink:Disease",
-              "all_names": [
-                "pre-eclampsia",
-                "Preeclampsia",
-                "preeclampsia",
-                "Pre-Eclampsia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:24400024",
-                "http://ghr.nlm.nih.gov/condition/preeclampsia",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/pre-eclampsia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21705401,
-            "start": 554,
-            "end": 318715,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32508173': {'publication date': '2020 Jun 07', 'sentence': 'Introduction:     The comparison of ibuprofen with acetaminophen for blood pressure (BP) in preeclampsia remains controversial.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0032914---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "22125431",
-              "object": "MONDO:0005081",
-              "publications": [
-                "PMID:32508173"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:10792116': {'publication date': '2000 May', 'sentence': 'RESULTS: Ketoprofen 50 mg t.d.s. suppressed prostaglandin synthesis to a significantly greater extent than ibuprofen and caused significantly more gastroduodenal injury.', 'subject score': 1000, 'object score': 750}, 'PMID:15879659': {'publication date': '2005 Mar-Apr', 'sentence': 'We report a 35-year-old man with ibuprofen-induced acute severe cholestatic liver injury.', 'subject score': 799, 'object score': 799}, 'PMID:18626108': {'publication date': '2009 Jan', 'sentence': 'Ibuprofen-induced liver injury in an adolescent athlete.', 'subject score': 833, 'object score': 833}, 'PMID:27698499': {'publication date': '2016 Sep', 'sentence': 'Ipilimumab-Induced Polyneuropathy; Ibuprofen-Induced Allergic-Type Liver Injury; Trimethoprim-Sulfamethoxazole-Induced Immune Thrombocytopenia in Children; Mesna-Induced Fixed Drug Eruption; Digoxin-Induced Ocular Toxicity.', 'subject score': 814, 'object score': 814}, 'PMID:30264435': {'publication date': '2018 Sep 27', 'sentence': 'In our study, cytoplasmic JNK activation in hepatocytes and other non-LPCs is a hallmark of human and murine ibuprofen-induced ALI.', 'subject score': 814, 'object score': 814}, 'PMID:30410832': {'publication date': '2018 Aug 29', 'sentence': 'A Rare Case of Ibuprofen-induced Acute Liver Injury.', 'subject score': 822, 'object score': 822}, 'PMID:3553307': {'publication date': '1987 Apr', 'sentence': 'Daily doses of 1,200 mg of ibuprofen may produce endoscopic injury and fecal blood losses similar to placebo.', 'subject score': 1000, 'object score': 861}, 'PMID:7203374': {'publication date': '1980 Dec', 'sentence': 'The ultrastructure of the material taken from three patients after phenobarbital treatment and one patient with ibuprofen-induced injury showed prominent increase and vesiculation of SER respectively.', 'subject score': 851, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7992346,
-            "start": 554,
-            "end": 546804,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10792116': {'publication date': '2000 May', 'sentence': 'RESULTS: Ketoprofen 50 mg t.d.s. suppressed prostaglandin synthesis to a significantly greater extent than ibuprofen and caused significantly more gastroduodenal injury.', 'subject score': 1000, 'object score': 750}, 'PMID:15879659': {'publication date': '2005 Mar-Apr', 'sentence': 'We report a 35-year-old man with ibuprofen-induced acute severe cholestatic liver injury.', 'subject score': 799, 'object score': 799}, 'PMID:18626108': {'publication date': '2009 Jan', 'sentence': 'Ibuprofen-induced liver injury in an adolescent athlete.', 'subject score': 833, 'object score': 833}, 'PMID:27698499': {'publication date': '2016 Sep', 'sentence': 'Ipilimumab-Induced Polyneuropathy; Ibuprofen-Induced Allergic-Type Liver Injury; Trimethoprim-Sulfamethoxazole-Induced Immune Thrombocytopenia in Children; Mesna-Induced Fixed Drug Eruption; Digoxin-Induced Ocular Toxicity.', 'subject score': 814, 'object score': 814}, 'PMID:30264435': {'publication date': '2018 Sep 27', 'sentence': 'In our study, cytoplasmic JNK activation in hepatocytes and other non-LPCs is a hallmark of human and murine ibuprofen-induced ALI.', 'subject score': 814, 'object score': 814}, 'PMID:30410832': {'publication date': '2018 Aug 29', 'sentence': 'A Rare Case of Ibuprofen-induced Acute Liver Injury.', 'subject score': 822, 'object score': 822}, 'PMID:3553307': {'publication date': '1987 Apr', 'sentence': 'Daily doses of 1,200 mg of ibuprofen may produce endoscopic injury and fecal blood losses similar to placebo.', 'subject score': 1000, 'object score': 861}, 'PMID:7203374': {'publication date': '1980 Dec', 'sentence': 'The ultrastructure of the material taken from three patients after phenobarbital treatment and one patient with ibuprofen-induced injury showed prominent increase and vesiculation of SER respectively.', 'subject score': 851, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C3263723---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "8163776",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:10792116",
-                "PMID:15879659",
-                "PMID:18626108",
-                "PMID:27698499",
-                "PMID:30264435",
-                "PMID:30410832",
-                "PMID:3553307",
-                "PMID:7203374"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:2173723': {'publication date': '1990 Nov', 'sentence': 'Because ibuprofen protects from septic lung injury, we studied the effect of ibuprofen in oxidant lung injury from phosgene.', 'subject score': 1000, 'object score': 851}, 'PMID:24399718': {'publication date': '2013', 'sentence': 'In the present study we investigated the influence of ibuprofen on dopaminergic neuron injury in the mice model of PD.', 'subject score': 1000, 'object score': 901}, 'PMID:3151052': {'publication date': '1988', 'sentence': 'The present study examines the role of PMN in hyperoxic lung injury using a nonsteroidal anti-inflammatory drug, ibuprofen.', 'subject score': 1000, 'object score': 828}, 'PMID:3191598': {'publication date': '1988 Dec', 'sentence': 'Both complement depletion with CVF or the administration of certain nonsteroidal anti-inflammatory drugs, including ibuprofen, are thought to decrease myocardial infarct size by reducing polymorphonuclear leukocytic (PMN) infiltration; nevertheless, complement activation also could alter tissue injury by PMN-independent actions.', 'subject score': 1000, 'object score': 861}, 'PMID:3529434': {'publication date': '1986 Sep', 'sentence': 'We report six cases of pill-induced esophageal injury, two of which were caused by the nonsteroidal anti-inflammatory medications ibuprofen and piroxicam, which have not been implicated previously in pill-induced injury.', 'subject score': 798, 'object score': 851}, 'PMID:6694377': {'publication date': '1984 Feb', 'sentence': 'Because these results could have resulted from a nonspecific effect of ibuprofen, the effects of ibuprofen on peritoneal injury in a time and dose response fashion was evaluated.', 'subject score': 1000, 'object score': 888}, 'PMID:7708817': {'publication date': '1995 Jan', 'sentence': 'A much larger dose of another PGHS inhibitor, ibuprofen, did not inhibit, but appeared to enhance, the effect of EGF plus trauma.', 'subject score': 1000, 'object score': 875}}",
-    "p2": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15423403,
-            "start": 554,
-            "end": 546804,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2173723': {'publication date': '1990 Nov', 'sentence': 'Because ibuprofen protects from septic lung injury, we studied the effect of ibuprofen in oxidant lung injury from phosgene.', 'subject score': 1000, 'object score': 851}, 'PMID:24399718': {'publication date': '2013', 'sentence': 'In the present study we investigated the influence of ibuprofen on dopaminergic neuron injury in the mice model of PD.', 'subject score': 1000, 'object score': 901}, 'PMID:3151052': {'publication date': '1988', 'sentence': 'The present study examines the role of PMN in hyperoxic lung injury using a nonsteroidal anti-inflammatory drug, ibuprofen.', 'subject score': 1000, 'object score': 828}, 'PMID:3191598': {'publication date': '1988 Dec', 'sentence': 'Both complement depletion with CVF or the administration of certain nonsteroidal anti-inflammatory drugs, including ibuprofen, are thought to decrease myocardial infarct size by reducing polymorphonuclear leukocytic (PMN) infiltration; nevertheless, complement activation also could alter tissue injury by PMN-independent actions.', 'subject score': 1000, 'object score': 861}, 'PMID:3529434': {'publication date': '1986 Sep', 'sentence': 'We report six cases of pill-induced esophageal injury, two of which were caused by the nonsteroidal anti-inflammatory medications ibuprofen and piroxicam, which have not been implicated previously in pill-induced injury.', 'subject score': 798, 'object score': 851}, 'PMID:6694377': {'publication date': '1984 Feb', 'sentence': 'Because these results could have resulted from a nonspecific effect of ibuprofen, the effects of ibuprofen on peritoneal injury in a time and dose response fashion was evaluated.', 'subject score': 1000, 'object score': 888}, 'PMID:7708817': {'publication date': '1995 Jan', 'sentence': 'A much larger dose of another PGHS inhibitor, ibuprofen, did not inhibit, but appeared to enhance, the effect of EGF plus trauma.', 'subject score': 1000, 'object score': 875}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C3263723---SEMMEDDB:",
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0043251---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "15746938",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:3191598",
-                "PMID:3151052",
-                "PMID:6694377",
-                "PMID:2173723",
-                "PMID:7708817",
-                "PMID:3529434",
-                "PMID:24399718"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11545620': {'publication date': '2001 Aug', 'sentence': 'Ibuprofen attenuates early lung injury in endotoxemic, neutropenic rats.', 'subject score': 1000, 'object score': 851}, 'PMID:1568970': {'publication date': '1992 Mar', 'sentence': 'In animals given ECV only, lung injury resulted in extravascular lung water of 18.9 ml/kg after 2 h, which was significantly higher than the 14.8 ml/kg in the group pretreated with ibuprofen.', 'subject score': 1000, 'object score': 888}, 'PMID:15837124': {'publication date': '2005', 'sentence': 'Ibuprofen, a non-steroidal anti-inflammatory drug, has been shown to attenuate injuries in animal models of various neurological diseases.', 'subject score': 1000, 'object score': 1000}, 'PMID:17332198': {'publication date': '2007 Mar', 'sentence': 'CONCLUSIONS: For the treatment of acute traumatic musculoskeletal injuries, ibuprofen provides the best analgesia among the 3 study medications.', 'subject score': 1000, 'object score': 852}, 'PMID:1757329': {'publication date': '1991 Sep', 'sentence': 'These results show that ibuprofen attenuates sepsis-induced injury and that alterations of acute septic insult are correlated with reduced plasma TNF activity in septic animals given ibuprofen.', 'subject score': 1000, 'object score': 851}, 'PMID:1846066': {'publication date': '1991 Jan', 'sentence': 'Sepsis-induced lung injury and the effects of ibuprofen pretreatment.', 'subject score': 888, 'object score': 833}, 'PMID:29082820': {'publication date': '2018 Jan', 'sentence': 'OBJECTIVE: Ibuprofen is a commonly used non-steroidal anti-inflammatory drug administered to treat injuries, joint pain, and recurrent muscular skeletal pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:3112984': {'publication date': '1987 Aug', 'sentence': 'These results indicate that a combination of both histamine H1 and H2 receptor blockers and the cyclooxygenase inhibitor, ibuprofen, is effective and essential in the treatment of hypoxemia, early pulmonary hypertension, and pulmonary microvascular injury in this fulminant model of porcine Pseudomonas ARDS.', 'subject score': 1000, 'object score': 851}, 'PMID:12116291': {'publication date': '2002', 'sentence': 'Pretreatment with p-chlorophenylalanine, indomethacin, ibuprofen, and nimodipine attenuated the SCEP changes immediately after trauma and resulted in a marked reduction in edema formation, BSCB permeability, and blood flow changes at 5 h.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8909346,
-            "start": 554,
-            "end": 546804,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11545620': {'publication date': '2001 Aug', 'sentence': 'Ibuprofen attenuates early lung injury in endotoxemic, neutropenic rats.', 'subject score': 1000, 'object score': 851}, 'PMID:1568970': {'publication date': '1992 Mar', 'sentence': 'In animals given ECV only, lung injury resulted in extravascular lung water of 18.9 ml/kg after 2 h, which was significantly higher than the 14.8 ml/kg in the group pretreated with ibuprofen.', 'subject score': 1000, 'object score': 888}, 'PMID:15837124': {'publication date': '2005', 'sentence': 'Ibuprofen, a non-steroidal anti-inflammatory drug, has been shown to attenuate injuries in animal models of various neurological diseases.', 'subject score': 1000, 'object score': 1000}, 'PMID:17332198': {'publication date': '2007 Mar', 'sentence': 'CONCLUSIONS: For the treatment of acute traumatic musculoskeletal injuries, ibuprofen provides the best analgesia among the 3 study medications.', 'subject score': 1000, 'object score': 852}, 'PMID:1757329': {'publication date': '1991 Sep', 'sentence': 'These results show that ibuprofen attenuates sepsis-induced injury and that alterations of acute septic insult are correlated with reduced plasma TNF activity in septic animals given ibuprofen.', 'subject score': 1000, 'object score': 851}, 'PMID:1846066': {'publication date': '1991 Jan', 'sentence': 'Sepsis-induced lung injury and the effects of ibuprofen pretreatment.', 'subject score': 888, 'object score': 833}, 'PMID:29082820': {'publication date': '2018 Jan', 'sentence': 'OBJECTIVE: Ibuprofen is a commonly used non-steroidal anti-inflammatory drug administered to treat injuries, joint pain, and recurrent muscular skeletal pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:3112984': {'publication date': '1987 Aug', 'sentence': 'These results indicate that a combination of both histamine H1 and H2 receptor blockers and the cyclooxygenase inhibitor, ibuprofen, is effective and essential in the treatment of hypoxemia, early pulmonary hypertension, and pulmonary microvascular injury in this fulminant model of porcine Pseudomonas ARDS.', 'subject score': 1000, 'object score': 851}, 'PMID:12116291': {'publication date': '2002', 'sentence': 'Pretreatment with p-chlorophenylalanine, indomethacin, ibuprofen, and nimodipine attenuated the SCEP changes immediately after trauma and resulted in a marked reduction in edema formation, BSCB permeability, and blood flow changes at 5 h.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C3263723---SEMMEDDB:",
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0043251---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9104501",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:12116291",
-                "PMID:17332198",
-                "PMID:11545620",
-                "PMID:3112984",
-                "PMID:1757329",
-                "PMID:1568970",
-                "PMID:29082820",
-                "PMID:1846066",
-                "PMID:15837124"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:11545620': {'publication date': '2001 Aug', 'sentence': 'The objective of our study was to determine the role of ibuprofen in protecting neutropenic rats from cardiopulmonary injury due to endotoxemia.', 'subject score': 1000, 'object score': 888}, 'PMID:1568970': {'publication date': '1992 Mar', 'sentence': 'Ibuprofen reduces ethchlorvynol lung injury: possible role of blood flow distribution.', 'subject score': 1000, 'object score': 851}, 'PMID:18549459': {'publication date': '2008 Aug 15', 'sentence': 'However, in patients aged >55 years, a statistically significant advantage for ibuprofen-PC treatment vs. ibuprofen in the prevention of NSAID-induced gut injury was observed with increases in both mean Lanza scores and the risk of developing >2 erosions or an ulcer.', 'subject score': 1000, 'object score': 833}, 'PMID:2173723': {'publication date': '1990 Nov', 'sentence': 'Because ibuprofen protects from septic lung injury, we studied the effect of ibuprofen in oxidant lung injury from phosgene.', 'subject score': 1000, 'object score': 851}, 'PMID:3151052': {'publication date': '1988', 'sentence': 'Our study, thus, demonstrates that ibuprofen cannot prevent hyperoxic lung injury although it inhibits the influx of PMN into the injured lung, suggesting that PMN are not directly involved in the injury process.', 'subject score': 1000, 'object score': 828}, 'PMID:3883949': {'publication date': '1985 Feb', 'sentence': 'The pulmonary injury and the increase in TxB2 was prevented by ibuprofen.', 'subject score': 1000, 'object score': 888}, 'PMID:7827930': {'publication date': '1994 Dec', 'sentence': 'Ibuprofen reduces microvascular injury by limiting oxygen radical production by neutrophils.', 'subject score': 1000, 'object score': 888}, 'PMID:9596884': {'publication date': '1997 Mar', 'sentence': 'Ibuprofen may reduce partially the APEP-induced lung injury.', 'subject score': 1000, 'object score': 775}}",
-    "p2": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8909347,
-            "start": 554,
-            "end": 546804,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11545620': {'publication date': '2001 Aug', 'sentence': 'The objective of our study was to determine the role of ibuprofen in protecting neutropenic rats from cardiopulmonary injury due to endotoxemia.', 'subject score': 1000, 'object score': 888}, 'PMID:1568970': {'publication date': '1992 Mar', 'sentence': 'Ibuprofen reduces ethchlorvynol lung injury: possible role of blood flow distribution.', 'subject score': 1000, 'object score': 851}, 'PMID:18549459': {'publication date': '2008 Aug 15', 'sentence': 'However, in patients aged >55 years, a statistically significant advantage for ibuprofen-PC treatment vs. ibuprofen in the prevention of NSAID-induced gut injury was observed with increases in both mean Lanza scores and the risk of developing >2 erosions or an ulcer.', 'subject score': 1000, 'object score': 833}, 'PMID:2173723': {'publication date': '1990 Nov', 'sentence': 'Because ibuprofen protects from septic lung injury, we studied the effect of ibuprofen in oxidant lung injury from phosgene.', 'subject score': 1000, 'object score': 851}, 'PMID:3151052': {'publication date': '1988', 'sentence': 'Our study, thus, demonstrates that ibuprofen cannot prevent hyperoxic lung injury although it inhibits the influx of PMN into the injured lung, suggesting that PMN are not directly involved in the injury process.', 'subject score': 1000, 'object score': 828}, 'PMID:3883949': {'publication date': '1985 Feb', 'sentence': 'The pulmonary injury and the increase in TxB2 was prevented by ibuprofen.', 'subject score': 1000, 'object score': 888}, 'PMID:7827930': {'publication date': '1994 Dec', 'sentence': 'Ibuprofen reduces microvascular injury by limiting oxygen radical production by neutrophils.', 'subject score': 1000, 'object score': 888}, 'PMID:9596884': {'publication date': '1997 Mar', 'sentence': 'Ibuprofen may reduce partially the APEP-induced lung injury.', 'subject score': 1000, 'object score': 775}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C3263723---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9104502",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:11545620",
-                "PMID:1568970",
-                "PMID:18549459",
-                "PMID:2173723",
-                "PMID:3151052",
-                "PMID:3883949",
-                "PMID:7827930",
-                "PMID:9596884"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:exacerbates",
-    "r2.publications_info": "{'PMID:21121909': {'publication date': '2010 Dec', 'sentence': 'Aggravation of seizure-associated microvascular injuries by ibuprofen may involve multiple pathways.', 'subject score': 1000, 'object score': 775}, 'PMID:22776871': {'publication date': '2012 Dec', 'sentence': 'CONCLUSION: This is the first study to reveal that ibuprofen aggravates exercise-induced small intestinal injury and induces gut barrier dysfunction in healthy individuals.', 'subject score': 1000, 'object score': 857}}",
-    "p2": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15025845,
-            "start": 554,
-            "end": 546804,
-            "type": "biolink:exacerbates",
-            "properties": {
-              "predicate": "biolink:exacerbates",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21121909': {'publication date': '2010 Dec', 'sentence': 'Aggravation of seizure-associated microvascular injuries by ibuprofen may involve multiple pathways.', 'subject score': 1000, 'object score': 775}, 'PMID:22776871': {'publication date': '2012 Dec', 'sentence': 'CONCLUSION: This is the first study to reveal that ibuprofen aggravates exercise-induced small intestinal injury and induces gut barrier dysfunction in healthy individuals.', 'subject score': 1000, 'object score': 857}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:complicates---None---None---None---UMLS:C3263723---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "15342704",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:21121909",
-                "PMID:22776871"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:19028206': {'publication date': '2008 Dec', 'sentence': 'There seems to be a marked gradient of risk for acute kidney injury across agents, specifically for indomethacin, ibuprofen, and rofecoxib.', 'subject score': 1000, 'object score': 870}, 'PMID:23532925': {'publication date': '2014 Feb', 'sentence': 'In this pilot study, we examined the association of IBU with markers of acute kidney injury (AKI) in patients with CF.', 'subject score': 1000, 'object score': 870}, 'PMID:24445686': {'publication date': '2014 Apr', 'sentence': 'CONCLUSIONS: The results illustrate that the concomitant use of ibuprofen and acetaminophen in children might be associated with increased risk of AKI.', 'subject score': 1000, 'object score': 731}, 'PMID:25895445': {'publication date': '2015 Oct', 'sentence': 'After adjusting for the degree of dehydration, ibuprofen exposure remained an independent risk factor for AKI (p < 0.001, odds ratio 2.47, 95 % confidence interval 1.78-3.42).', 'subject score': 694, 'object score': 870}, 'PMID:31598105': {'publication date': '2019 Sep-Oct', 'sentence': 'Specific nephrotoxins that increased the risk of vancomycin-associated AKI included piperacillin/tazobactam, liposomal amphotericin B, and ibuprofen.', 'subject score': 1000, 'object score': 771}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13790747,
-            "start": 554,
-            "end": 546804,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19028206': {'publication date': '2008 Dec', 'sentence': 'There seems to be a marked gradient of risk for acute kidney injury across agents, specifically for indomethacin, ibuprofen, and rofecoxib.', 'subject score': 1000, 'object score': 870}, 'PMID:23532925': {'publication date': '2014 Feb', 'sentence': 'In this pilot study, we examined the association of IBU with markers of acute kidney injury (AKI) in patients with CF.', 'subject score': 1000, 'object score': 870}, 'PMID:24445686': {'publication date': '2014 Apr', 'sentence': 'CONCLUSIONS: The results illustrate that the concomitant use of ibuprofen and acetaminophen in children might be associated with increased risk of AKI.', 'subject score': 1000, 'object score': 731}, 'PMID:25895445': {'publication date': '2015 Oct', 'sentence': 'After adjusting for the degree of dehydration, ibuprofen exposure remained an independent risk factor for AKI (p < 0.001, odds ratio 2.47, 95 % confidence interval 1.78-3.42).', 'subject score': 694, 'object score': 870}, 'PMID:31598105': {'publication date': '2019 Sep-Oct', 'sentence': 'Specific nephrotoxins that increased the risk of vancomycin-associated AKI included piperacillin/tazobactam, liposomal amphotericin B, and ibuprofen.', 'subject score': 1000, 'object score': 771}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:predisposes---None---None---None---UMLS:C3263723---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "14085648",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:19028206",
-                "PMID:23532925",
-                "PMID:24445686",
-                "PMID:25895445",
-                "PMID:31598105"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:3080269': {'publication date': '1986 Feb', 'sentence': 'The opposite effect of ibuprofen on ethanol-induced cognitive impairment as measured by two lateralized functions is consistent with the reports in tissue and animal models that central nervous system effects of ethanol may be mediated at least in part by prostaglandins.', 'subject score': 1000, 'object score': 861}, 'PMID:7115443': {'publication date': '1982 Aug', 'sentence': 'Cognitive dysfunction associated with naproxen and ibuprofen in the elderly.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321491,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100543",
-          "name": "Cognitive impairment",
-          "description": "Abnormal cognition with deficits in thinking, reasoning, or remembering. [HPO:sdoelken]; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "MEDDRA:10009845",
-            "UMLS:C0683322",
-            "NCIT:C116921",
-            "MEDDRA:10048599",
-            "PSY:10113",
-            "UMLS:C0338656",
-            "HP:0100543",
-            "MEDDRA:10009846",
-            "MESH:D060825",
-            "SNOMEDCT:386806002",
-            "NCIT:C46083",
-            "NCIT:C27101",
-            "PSY:10103"
-          ],
-          "id": "HP:0100543",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Impaired cognition",
-            "Cognitive Disturbance",
-            "Mental impairment",
-            "Cognitive impairment",
-            "Cognitive Impairment",
-            "Cognitive Dysfunction"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321491,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100543",
-              "name": "Cognitive impairment",
-              "description": "Abnormal cognition with deficits in thinking, reasoning, or remembering. [HPO:sdoelken]; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "MEDDRA:10009845",
-                "UMLS:C0683322",
-                "NCIT:C116921",
-                "MEDDRA:10048599",
-                "PSY:10113",
-                "UMLS:C0338656",
-                "HP:0100543",
-                "MEDDRA:10009846",
-                "MESH:D060825",
-                "SNOMEDCT:386806002",
-                "NCIT:C46083",
-                "NCIT:C27101",
-                "PSY:10103"
-              ],
-              "id": "HP:0100543",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Impaired cognition",
-                "Cognitive Disturbance",
-                "Mental impairment",
-                "Cognitive impairment",
-                "Cognitive Impairment",
-                "Cognitive Dysfunction"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20482763,
-            "start": 554,
-            "end": 321491,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3080269': {'publication date': '1986 Feb', 'sentence': 'The opposite effect of ibuprofen on ethanol-induced cognitive impairment as measured by two lateralized functions is consistent with the reports in tissue and animal models that central nervous system effects of ethanol may be mediated at least in part by prostaglandins.', 'subject score': 1000, 'object score': 861}, 'PMID:7115443': {'publication date': '1982 Aug', 'sentence': 'Cognitive dysfunction associated with naproxen and ibuprofen in the elderly.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0338656---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "20886939",
-              "object": "HP:0100543",
-              "publications": [
-                "PMID:3080269",
-                "PMID:7115443"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:18259082': {'publication date': '2008', 'sentence': 'Overall, we found no relation between regular aspirin use and cognitive decline, but long-term use of ibuprofen may be related to decreased rates of cognitive decline in older persons.', 'subject score': 1000, 'object score': 1000}, 'PMID:25659514': {'publication date': '2015 Apr 05', 'sentence': \"Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID), treatment with which has been shown to delay the onset, slows the cognitive decline, and decreases the incidence of Alzheimer's disease (AD) in epidemiological and clinical studies.\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321491,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100543",
-          "name": "Cognitive impairment",
-          "description": "Abnormal cognition with deficits in thinking, reasoning, or remembering. [HPO:sdoelken]; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "MEDDRA:10009845",
-            "UMLS:C0683322",
-            "NCIT:C116921",
-            "MEDDRA:10048599",
-            "PSY:10113",
-            "UMLS:C0338656",
-            "HP:0100543",
-            "MEDDRA:10009846",
-            "MESH:D060825",
-            "SNOMEDCT:386806002",
-            "NCIT:C46083",
-            "NCIT:C27101",
-            "PSY:10103"
-          ],
-          "id": "HP:0100543",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Impaired cognition",
-            "Cognitive Disturbance",
-            "Mental impairment",
-            "Cognitive impairment",
-            "Cognitive Impairment",
-            "Cognitive Dysfunction"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321491,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100543",
-              "name": "Cognitive impairment",
-              "description": "Abnormal cognition with deficits in thinking, reasoning, or remembering. [HPO:sdoelken]; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "MEDDRA:10009845",
-                "UMLS:C0683322",
-                "NCIT:C116921",
-                "MEDDRA:10048599",
-                "PSY:10113",
-                "UMLS:C0338656",
-                "HP:0100543",
-                "MEDDRA:10009846",
-                "MESH:D060825",
-                "SNOMEDCT:386806002",
-                "NCIT:C46083",
-                "NCIT:C27101",
-                "PSY:10103"
-              ],
-              "id": "HP:0100543",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Impaired cognition",
-                "Cognitive Disturbance",
-                "Mental impairment",
-                "Cognitive impairment",
-                "Cognitive Impairment",
-                "Cognitive Dysfunction"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13299142,
-            "start": 554,
-            "end": 321491,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18259082': {'publication date': '2008', 'sentence': 'Overall, we found no relation between regular aspirin use and cognitive decline, but long-term use of ibuprofen may be related to decreased rates of cognitive decline in older persons.', 'subject score': 1000, 'object score': 1000}, 'PMID:25659514': {'publication date': '2015 Apr 05', 'sentence': \"Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID), treatment with which has been shown to delay the onset, slows the cognitive decline, and decreases the incidence of Alzheimer's disease (AD) in epidemiological and clinical studies.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:inhibits---biolink:causes---activity---None---UMLS:C0338656---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "13584223",
-              "object": "HP:0100543",
-              "publications": [
-                "PMID:18259082",
-                "PMID:25659514"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:24796537': {'publication date': '2014', 'sentence': 'Finally, anti-inflammatory drug ibuprofen ameliorated the peripheral surgical wounding-induced cognitive impairment in 18 month-old mice.', 'subject score': 905, 'object score': 833}}",
-    "p2": {
-      "start": {
-        "identity": 321491,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100543",
-          "name": "Cognitive impairment",
-          "description": "Abnormal cognition with deficits in thinking, reasoning, or remembering. [HPO:sdoelken]; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "MEDDRA:10009845",
-            "UMLS:C0683322",
-            "NCIT:C116921",
-            "MEDDRA:10048599",
-            "PSY:10113",
-            "UMLS:C0338656",
-            "HP:0100543",
-            "MEDDRA:10009846",
-            "MESH:D060825",
-            "SNOMEDCT:386806002",
-            "NCIT:C46083",
-            "NCIT:C27101",
-            "PSY:10103"
-          ],
-          "id": "HP:0100543",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Impaired cognition",
-            "Cognitive Disturbance",
-            "Mental impairment",
-            "Cognitive impairment",
-            "Cognitive Impairment",
-            "Cognitive Dysfunction"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321491,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100543",
-              "name": "Cognitive impairment",
-              "description": "Abnormal cognition with deficits in thinking, reasoning, or remembering. [HPO:sdoelken]; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "MEDDRA:10009845",
-                "UMLS:C0683322",
-                "NCIT:C116921",
-                "MEDDRA:10048599",
-                "PSY:10113",
-                "UMLS:C0338656",
-                "HP:0100543",
-                "MEDDRA:10009846",
-                "MESH:D060825",
-                "SNOMEDCT:386806002",
-                "NCIT:C46083",
-                "NCIT:C27101",
-                "PSY:10103"
-              ],
-              "id": "HP:0100543",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Impaired cognition",
-                "Cognitive Disturbance",
-                "Mental impairment",
-                "Cognitive impairment",
-                "Cognitive Impairment",
-                "Cognitive Dysfunction"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17268088,
-            "start": 554,
-            "end": 321491,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:24796537': {'publication date': '2014', 'sentence': 'Finally, anti-inflammatory drug ibuprofen ameliorated the peripheral surgical wounding-induced cognitive impairment in 18 month-old mice.', 'subject score': 905, 'object score': 833}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0338656---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "17621968",
-              "object": "HP:0100543",
-              "publications": [
-                "PMID:24796537"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:27159471': {'publication date': '2015 May-Jun', 'sentence': 'On post-partum day five, she began complaining of headaches, initially responsive to ibuprofen but eventually worsened with no relief.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318533,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-          "name": "Headache",
-          "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10019211",
-            "PSY:22380",
-            "NCIT:C34661",
-            "MEDDRA:10019218",
-            "SNOMEDCT:25064002",
-            "UMLS:C0018681",
-            "MEDDRA:10019231",
-            "HP:0002315",
-            "MEDDRA:10033405",
-            "ICD9:784.0",
-            "MESH:D006261",
-            "SYMP:0000504",
-            "MEDDRA:10008013",
-            "MEDDRA:10019198"
-          ],
-          "id": "HP:0002315",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "headache",
-            "Headache"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-            "PMID:15304572",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318533,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-              "name": "Headache",
-              "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10019211",
-                "PSY:22380",
-                "NCIT:C34661",
-                "MEDDRA:10019218",
-                "SNOMEDCT:25064002",
-                "UMLS:C0018681",
-                "MEDDRA:10019231",
-                "HP:0002315",
-                "MEDDRA:10033405",
-                "ICD9:784.0",
-                "MESH:D006261",
-                "SYMP:0000504",
-                "MEDDRA:10008013",
-                "MEDDRA:10019198"
-              ],
-              "id": "HP:0002315",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "headache",
-                "Headache"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-                "PMID:15304572",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18602890,
-            "start": 554,
-            "end": 318533,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27159471': {'publication date': '2015 May-Jun', 'sentence': 'On post-partum day five, she began complaining of headaches, initially responsive to ibuprofen but eventually worsened with no relief.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0018681---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "18977843",
-              "object": "HP:0002315",
-              "publications": [
-                "PMID:27159471"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10586487': {'publication date': '1999 Oct 29', 'sentence': 'Besides oxygen, acetazolamide, dexamethasone and especially inhibitors of prostaglandin synthesis such as ibuprofen and naproxen are approved for the treatment of HAH.', 'subject score': 1000, 'object score': 1000}, 'PMID:11014413': {'publication date': '2000 Sep', 'sentence': 'More patients reported complete headache relief with ibuprofen and caffeine administered together than with ibuprofen alone, caffeine alone, or placebo.', 'subject score': 1000, 'object score': 623}, 'PMID:12745039': {'publication date': '2003 May', 'sentence': 'Ibuprofen has been shown to be more effective than placebo in the treatment of high altitude headache (HAH), but nonsteroidal anti-inflammatory agents have been linked to increased incidence of gastrointestinal (GI) side effects and high-altitude pulmonary edema (HAPE).', 'subject score': 1000, 'object score': 851}, 'PMID:15163268': {'publication date': '2004 May', 'sentence': 'Acetaminophen preferable to ibuprofen for pretreatment of electroconvulsive therapy-induced headache.', 'subject score': 1000, 'object score': 861}, 'PMID:15770754': {'publication date': '2005 Feb', 'sentence': 'I often take ibuprofen for my headaches or aching back.', 'subject score': 1000, 'object score': 1000}, 'PMID:16492236': {'publication date': '2006 Feb', 'sentence': \"The mean percentage of patients' attacks with 24-hour sustained headache relief was greater for rofecoxib 50 mg (52.0%) than for rofecoxib 25 mg (47.8%, P < .050) or ibuprofen (39.0%, P < .010).\", 'subject score': 1000, 'object score': 694}, 'PMID:17250728': {'publication date': '2007 Feb', 'sentence': 'Explanatory analyses revealed worsening of headache already in the third week of treatment with ibuprofen alone.', 'subject score': 1000, 'object score': 861}, 'PMID:17628221': {'publication date': '2007 Jul', 'sentence': 'This double-blind cross-over pilot study evaluated the effect of ibuprofen and caffeine compared with ibuprofen and placebo in 12 children with headaches.', 'subject score': 1000, 'object score': 1000}, 'PMID:17854415': {'publication date': '2008 Jan', 'sentence': 'Two hours post-treatment, ibuprofen was associated with an RB 1.50 (95% CI 1.15-1.95) in the generation of headache relief (NNT 2.4) and RB 1.92 (95% CI 1.28-2.86) in the production of complete pain relief (NNT 4.9).', 'subject score': 822, 'object score': 694}, 'PMID:19920719': {'publication date': '2009 Oct', 'sentence': 'Rizatriptan resulted in better relief of headache at 2 hours compared with ibuprofen in allodynic patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:20522287': {'publication date': '2010 May', 'sentence': 'Myth: Ibuprofen is superior to acetaminophen for the treatment of benign headaches in children and adults.', 'subject score': 1000, 'object score': 888}, 'PMID:22703629': {'publication date': '2014 Nov-Dec', 'sentence': 'HAH can be treated with paracetamol or ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:24516940': {'publication date': '2013 Sep-Oct', 'sentence': 'In clinical practice ibuprofen can be used in the treatment of headache, toothache, otalgy, dysmenorrhea, neuralgia, arthralgia, myalgia, abdominal pain and fever: it is the first choice for these common diseases.', 'subject score': 851, 'object score': 1000}, 'PMID:26230487': {'publication date': '2015 Jul 31', 'sentence': 'Ibuprofen is one of a number of analgesics suggested for acute treatment of headaches in frequent episodic TTH.', 'subject score': 1000, 'object score': 1000}, 'PMID:28852973': {'publication date': '2018 Jan', 'sentence': 'For benign causes, symptomatic treatment with analgesics like paracetamol or ibuprofen would suffice initially, while identification of the underlying condition would lead to further appropriate management, particularly in primary headaches.', 'subject score': 1000, 'object score': 888}, 'PMID:29483787': {'publication date': '2017 Mar', 'sentence': 'The use of ibuprofen and acetaminophen for acute headache in the postconcussive youth: A pilot study.', 'subject score': 1000, 'object score': 888}, 'PMID:31988769': {'publication date': '2020 Jan-Dec', 'sentence': 'She had taken ibuprofen for headache.', 'subject score': 1000, 'object score': 1000}, 'PMID:32057631': {'publication date': '2020 Feb 10', 'sentence': 'CONCLUSIONS: Metoclopramide and ibuprofen may be effective alternative treatment options in HAH and AMS, especially for those patients who additionally report nausea.', 'subject score': 1000, 'object score': 1000}, 'PMID:32334535': {'publication date': '2020 Apr 25', 'sentence': 'We here discuss this concern in relation to headache treatment and conclude that, based on current evidence, there is no reason to abandon treatment of headache patients with RAS inhibitors or ibuprofen.', 'subject score': 1000, 'object score': 888}, 'PMID:36107402': {'publication date': '2022 Sep 15', 'sentence': 'Non-opioid analgesics like ibuprofen or acetaminophen may be prescribed for short-term headache relief but clinicians need to be cautious with long-term medication overuse in those whose headache symptoms persist.', 'subject score': 1000, 'object score': 658}}",
-    "p2": {
-      "start": {
-        "identity": 318533,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-          "name": "Headache",
-          "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10019211",
-            "PSY:22380",
-            "NCIT:C34661",
-            "MEDDRA:10019218",
-            "SNOMEDCT:25064002",
-            "UMLS:C0018681",
-            "MEDDRA:10019231",
-            "HP:0002315",
-            "MEDDRA:10033405",
-            "ICD9:784.0",
-            "MESH:D006261",
-            "SYMP:0000504",
-            "MEDDRA:10008013",
-            "MEDDRA:10019198"
-          ],
-          "id": "HP:0002315",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "headache",
-            "Headache"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-            "PMID:15304572",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318533,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-              "name": "Headache",
-              "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10019211",
-                "PSY:22380",
-                "NCIT:C34661",
-                "MEDDRA:10019218",
-                "SNOMEDCT:25064002",
-                "UMLS:C0018681",
-                "MEDDRA:10019231",
-                "HP:0002315",
-                "MEDDRA:10033405",
-                "ICD9:784.0",
-                "MESH:D006261",
-                "SYMP:0000504",
-                "MEDDRA:10008013",
-                "MEDDRA:10019198"
-              ],
-              "id": "HP:0002315",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "headache",
-                "Headache"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-                "PMID:15304572",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7689692,
-            "start": 554,
-            "end": 318533,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10586487': {'publication date': '1999 Oct 29', 'sentence': 'Besides oxygen, acetazolamide, dexamethasone and especially inhibitors of prostaglandin synthesis such as ibuprofen and naproxen are approved for the treatment of HAH.', 'subject score': 1000, 'object score': 1000}, 'PMID:11014413': {'publication date': '2000 Sep', 'sentence': 'More patients reported complete headache relief with ibuprofen and caffeine administered together than with ibuprofen alone, caffeine alone, or placebo.', 'subject score': 1000, 'object score': 623}, 'PMID:12745039': {'publication date': '2003 May', 'sentence': 'Ibuprofen has been shown to be more effective than placebo in the treatment of high altitude headache (HAH), but nonsteroidal anti-inflammatory agents have been linked to increased incidence of gastrointestinal (GI) side effects and high-altitude pulmonary edema (HAPE).', 'subject score': 1000, 'object score': 851}, 'PMID:15163268': {'publication date': '2004 May', 'sentence': 'Acetaminophen preferable to ibuprofen for pretreatment of electroconvulsive therapy-induced headache.', 'subject score': 1000, 'object score': 861}, 'PMID:15770754': {'publication date': '2005 Feb', 'sentence': 'I often take ibuprofen for my headaches or aching back.', 'subject score': 1000, 'object score': 1000}, 'PMID:16492236': {'publication date': '2006 Feb', 'sentence': \"The mean percentage of patients' attacks with 24-hour sustained headache relief was greater for rofecoxib 50 mg (52.0%) than for rofecoxib 25 mg (47.8%, P < .050) or ibuprofen (39.0%, P < .010).\", 'subject score': 1000, 'object score': 694}, 'PMID:17250728': {'publication date': '2007 Feb', 'sentence': 'Explanatory analyses revealed worsening of headache already in the third week of treatment with ibuprofen alone.', 'subject score': 1000, 'object score': 861}, 'PMID:17628221': {'publication date': '2007 Jul', 'sentence': 'This double-blind cross-over pilot study evaluated the effect of ibuprofen and caffeine compared with ibuprofen and placebo in 12 children with headaches.', 'subject score': 1000, 'object score': 1000}, 'PMID:17854415': {'publication date': '2008 Jan', 'sentence': 'Two hours post-treatment, ibuprofen was associated with an RB 1.50 (95% CI 1.15-1.95) in the generation of headache relief (NNT 2.4) and RB 1.92 (95% CI 1.28-2.86) in the production of complete pain relief (NNT 4.9).', 'subject score': 822, 'object score': 694}, 'PMID:19920719': {'publication date': '2009 Oct', 'sentence': 'Rizatriptan resulted in better relief of headache at 2 hours compared with ibuprofen in allodynic patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:20522287': {'publication date': '2010 May', 'sentence': 'Myth: Ibuprofen is superior to acetaminophen for the treatment of benign headaches in children and adults.', 'subject score': 1000, 'object score': 888}, 'PMID:22703629': {'publication date': '2014 Nov-Dec', 'sentence': 'HAH can be treated with paracetamol or ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:24516940': {'publication date': '2013 Sep-Oct', 'sentence': 'In clinical practice ibuprofen can be used in the treatment of headache, toothache, otalgy, dysmenorrhea, neuralgia, arthralgia, myalgia, abdominal pain and fever: it is the first choice for these common diseases.', 'subject score': 851, 'object score': 1000}, 'PMID:26230487': {'publication date': '2015 Jul 31', 'sentence': 'Ibuprofen is one of a number of analgesics suggested for acute treatment of headaches in frequent episodic TTH.', 'subject score': 1000, 'object score': 1000}, 'PMID:28852973': {'publication date': '2018 Jan', 'sentence': 'For benign causes, symptomatic treatment with analgesics like paracetamol or ibuprofen would suffice initially, while identification of the underlying condition would lead to further appropriate management, particularly in primary headaches.', 'subject score': 1000, 'object score': 888}, 'PMID:29483787': {'publication date': '2017 Mar', 'sentence': 'The use of ibuprofen and acetaminophen for acute headache in the postconcussive youth: A pilot study.', 'subject score': 1000, 'object score': 888}, 'PMID:31988769': {'publication date': '2020 Jan-Dec', 'sentence': 'She had taken ibuprofen for headache.', 'subject score': 1000, 'object score': 1000}, 'PMID:32057631': {'publication date': '2020 Feb 10', 'sentence': 'CONCLUSIONS: Metoclopramide and ibuprofen may be effective alternative treatment options in HAH and AMS, especially for those patients who additionally report nausea.', 'subject score': 1000, 'object score': 1000}, 'PMID:32334535': {'publication date': '2020 Apr 25', 'sentence': 'We here discuss this concern in relation to headache treatment and conclude that, based on current evidence, there is no reason to abandon treatment of headache patients with RAS inhibitors or ibuprofen.', 'subject score': 1000, 'object score': 888}, 'PMID:36107402': {'publication date': '2022 Sep 15', 'sentence': 'Non-opioid analgesics like ibuprofen or acetaminophen may be prescribed for short-term headache relief but clinicians need to be cautious with long-term medication overuse in those whose headache symptoms persist.', 'subject score': 1000, 'object score': 658}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0018681---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "7852264",
-              "object": "HP:0002315",
-              "publications": [
-                "PMID:10586487",
-                "PMID:11014413",
-                "PMID:12745039",
-                "PMID:15163268",
-                "PMID:15770754",
-                "PMID:16492236",
-                "PMID:17250728",
-                "PMID:17628221",
-                "PMID:17854415",
-                "PMID:19920719",
-                "PMID:20522287",
-                "PMID:22703629",
-                "PMID:24516940",
-                "PMID:26230487",
-                "PMID:28852973",
-                "PMID:29483787",
-                "PMID:31988769",
-                "PMID:32057631",
-                "PMID:32334535",
-                "PMID:36107402"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:12755658': {'publication date': '2003 May', 'sentence': 'The objective of this study was to determine whether pretreatment with ibuprofen would prevent the onset or decrease the severity of headache that occurs after ECT.', 'subject score': 1000, 'object score': 1000}, 'PMID:19436460': {'publication date': '2009 Jan', 'sentence': 'Flunarizine may be valuable in paediatric headache prevention, and ibuprofen, acetaminophen and nasal sumatriptan may be effective in the acute management of headaches.', 'subject score': 1000, 'object score': 851}, 'PMID:20832701': {'publication date': '2010 Sep', 'sentence': 'CONCLUSIONS: Ibuprofen and acetazolamide were similarly effective in preventing HAH.', 'subject score': 1000, 'object score': 872}, 'PMID:23098412': {'publication date': '2012 Dec', 'sentence': 'OBJECTIVE: To study the effectiveness of ibuprofen versus placebo in preventing acute mountain sickness (AMS) and high altitude headache (HAH).', 'subject score': 1000, 'object score': 851}, 'PMID:28632763': {'publication date': '2017', 'sentence': 'CONCLUSIONS: Based on a limited number of studies ibuprofen seems efficacious for the prevention of HAH and may therefore represent an alternative for preventing HAH with acetazolamide or dexamethasone.', 'subject score': 872, 'object score': 1000}, 'PMID:37177799': {'publication date': '2023 May', 'sentence': 'CONCLUSION: In the present population recruited at specialized headache centers, patients rated triptans as more effective than non-opioid analgesics, naproxen as more effective than ibuprofen, and acute medication efficacy decreased with increasing headache frequency.', 'subject score': 1000, 'object score': 790}}",
-    "p2": {
-      "start": {
-        "identity": 318533,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-          "name": "Headache",
-          "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10019211",
-            "PSY:22380",
-            "NCIT:C34661",
-            "MEDDRA:10019218",
-            "SNOMEDCT:25064002",
-            "UMLS:C0018681",
-            "MEDDRA:10019231",
-            "HP:0002315",
-            "MEDDRA:10033405",
-            "ICD9:784.0",
-            "MESH:D006261",
-            "SYMP:0000504",
-            "MEDDRA:10008013",
-            "MEDDRA:10019198"
-          ],
-          "id": "HP:0002315",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "headache",
-            "Headache"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-            "PMID:15304572",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318533,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-              "name": "Headache",
-              "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10019211",
-                "PSY:22380",
-                "NCIT:C34661",
-                "MEDDRA:10019218",
-                "SNOMEDCT:25064002",
-                "UMLS:C0018681",
-                "MEDDRA:10019231",
-                "HP:0002315",
-                "MEDDRA:10033405",
-                "ICD9:784.0",
-                "MESH:D006261",
-                "SYMP:0000504",
-                "MEDDRA:10008013",
-                "MEDDRA:10019198"
-              ],
-              "id": "HP:0002315",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "headache",
-                "Headache"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-                "PMID:15304572",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9981131,
-            "start": 554,
-            "end": 318533,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12755658': {'publication date': '2003 May', 'sentence': 'The objective of this study was to determine whether pretreatment with ibuprofen would prevent the onset or decrease the severity of headache that occurs after ECT.', 'subject score': 1000, 'object score': 1000}, 'PMID:19436460': {'publication date': '2009 Jan', 'sentence': 'Flunarizine may be valuable in paediatric headache prevention, and ibuprofen, acetaminophen and nasal sumatriptan may be effective in the acute management of headaches.', 'subject score': 1000, 'object score': 851}, 'PMID:20832701': {'publication date': '2010 Sep', 'sentence': 'CONCLUSIONS: Ibuprofen and acetazolamide were similarly effective in preventing HAH.', 'subject score': 1000, 'object score': 872}, 'PMID:23098412': {'publication date': '2012 Dec', 'sentence': 'OBJECTIVE: To study the effectiveness of ibuprofen versus placebo in preventing acute mountain sickness (AMS) and high altitude headache (HAH).', 'subject score': 1000, 'object score': 851}, 'PMID:28632763': {'publication date': '2017', 'sentence': 'CONCLUSIONS: Based on a limited number of studies ibuprofen seems efficacious for the prevention of HAH and may therefore represent an alternative for preventing HAH with acetazolamide or dexamethasone.', 'subject score': 872, 'object score': 1000}, 'PMID:37177799': {'publication date': '2023 May', 'sentence': 'CONCLUSION: In the present population recruited at specialized headache centers, patients rated triptans as more effective than non-opioid analgesics, naproxen as more effective than ibuprofen, and acute medication efficacy decreased with increasing headache frequency.', 'subject score': 1000, 'object score': 790}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0018681---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "10201705",
-              "object": "HP:0002315",
-              "publications": [
-                "PMID:12755658",
-                "PMID:19436460",
-                "PMID:20832701",
-                "PMID:23098412",
-                "PMID:28632763",
-                "PMID:37177799"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:30419226': {'publication date': '2018 Nov 10', 'sentence': 'Altitude Sickness Prevention with Ibuprofen Relative to Acetazolamide.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 610163,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006625",
-          "name": "altitude sickness",
-          "description": "Multiple symptoms associated with reduced oxygen at high altitude.",
-          "equivalent_curies": [
-            "EFO:1000782",
-            "UMLS:C0002351",
-            "MEDDRA:10077617",
-            "MONDO:0006625",
-            "MESH:D000532",
-            "SNOMEDCT:87284002",
-            "MEDDRA:10077616",
-            "SNOMEDCT:42883007",
-            "UMLS:C3887755"
-          ],
-          "id": "MONDO:0006625",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Mountain Sickness",
-            "altitude sickness",
-            "Altitude Sickness"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 610163,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006625",
-              "name": "altitude sickness",
-              "description": "Multiple symptoms associated with reduced oxygen at high altitude.",
-              "equivalent_curies": [
-                "EFO:1000782",
-                "UMLS:C0002351",
-                "MEDDRA:10077617",
-                "MONDO:0006625",
-                "MESH:D000532",
-                "SNOMEDCT:87284002",
-                "MEDDRA:10077616",
-                "SNOMEDCT:42883007",
-                "UMLS:C3887755"
-              ],
-              "id": "MONDO:0006625",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Mountain Sickness",
-                "altitude sickness",
-                "Altitude Sickness"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20290127,
-            "start": 554,
-            "end": 610163,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30419226': {'publication date': '2018 Nov 10', 'sentence': 'Altitude Sickness Prevention with Ibuprofen Relative to Acetazolamide.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0002351---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "20691057",
-              "object": "MONDO:0006625",
-              "publications": [
-                "PMID:30419226"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:3883908': {'publication date': '1985 Apr', 'sentence': 'The data suggest that ibuprofen is more effective than placebo for the relief of symptoms associated with UV-B-induced inflammation after high dose UV-B phototherapy for psoriasis, but the drug has limited usefulness in the treatment of sunburn reaction from these same doses.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 546142,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005326",
-          "name": "sunburn",
-          "description": "An inflammatory reaction from ultraviolet radiation characterized by transient redness, tenderness and occasional blistering.; An injury to the skin causing erythema, tenderness, and sometimes blistering and resulting from excessive exposure to the sun. The reaction is produced by the ultraviolet radiation in sunlight.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "UMLS:C3249880",
-            "UMLS:C0038814",
-            "MEDDRA:10072196",
-            "MONDO:0005326",
-            "NCIT:C3395",
-            "MEDDRA:10041306",
-            "MEDDRA:10042496",
-            "EFO:0003958",
-            "MESH:D013471",
-            "SNOMEDCT:403194002"
-          ],
-          "id": "MONDO:0005326",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Solar Erythema",
-            "Sunburn",
-            "sunburn"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546142,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005326",
-              "name": "sunburn",
-              "description": "An inflammatory reaction from ultraviolet radiation characterized by transient redness, tenderness and occasional blistering.; An injury to the skin causing erythema, tenderness, and sometimes blistering and resulting from excessive exposure to the sun. The reaction is produced by the ultraviolet radiation in sunlight.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "UMLS:C3249880",
-                "UMLS:C0038814",
-                "MEDDRA:10072196",
-                "MONDO:0005326",
-                "NCIT:C3395",
-                "MEDDRA:10041306",
-                "MEDDRA:10042496",
-                "EFO:0003958",
-                "MESH:D013471",
-                "SNOMEDCT:403194002"
-              ],
-              "id": "MONDO:0005326",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Solar Erythema",
-                "Sunburn",
-                "sunburn"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25219475,
-            "start": 554,
-            "end": 546142,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3883908': {'publication date': '1985 Apr', 'sentence': 'The data suggest that ibuprofen is more effective than placebo for the relief of symptoms associated with UV-B-induced inflammation after high dose UV-B phototherapy for psoriasis, but the drug has limited usefulness in the treatment of sunburn reaction from these same doses.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0038814---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "25670779",
-              "object": "MONDO:0005326",
-              "publications": [
-                "PMID:3883908"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:24910692': {'publication date': '2014 Mar', 'sentence': 'This study aims to determine the therapeutic effects of ibuprofen, diphenhydramine and aluminum magnesium simethicone (AlMgS) syrup on reducing oral aphthous ulcer pain.', 'subject score': 1000, 'object score': 867}}",
-    "p2": {
-      "start": {
-        "identity": 311935,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005318",
-          "name": "canker sore",
-          "description": "A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval, lasting for 7-14 days and healing without scarring.; A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval. Two to eight crops of lesions occur per year, lasting for 7 to 14 days and then heal without scarring. (From Jablonski's Dictionary of Dentistry, 1992, p742); Recurrent episodes of ulceration of the oral mucosa, typically presenting as painful, sharply circumscribed fibrin-covered mucosal defects with a hyperemic border. [HPO:probinson]; Oral aphthous ulcers typically present as painful, sharply circumscribed fibrin-covered mucosal defects with a hyperemic border. [PMID:25346356]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:722781002",
-            "MEDDRA:10042131",
-            "MEDDRA:10002959",
-            "UMLS:C2937365",
-            "SNOMEDCT:426965005",
-            "SNOMEDCT:427617000",
-            "UMLS:C1959869",
-            "NCIT:C62546",
-            "MONDO:0005318",
-            "SNOMEDCT:398870000",
-            "MEDDRA:10007166",
-            "MEDDRA:10045287",
-            "MEDDRA:10002958",
-            "MESH:D013281",
-            "UMLS:C0038363",
-            "MEDDRA:10066577",
-            "MEDDRA:10030960",
-            "SNOMEDCT:110426005",
-            "MEDDRA:10067589",
-            "MEDDRA:10084265",
-            "HP:0011107",
-            "MEDDRA:10045372",
-            "MEDDRA:10045288"
-          ],
-          "id": "MONDO:0005318",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Stomatitis, Aphthous",
-            "canker sore",
-            "Canker Sore",
-            "Aphthous ulceration of skin and/or mucous membrane (disorder)",
-            "Recurrent aphthous stomatitis",
-            "Aphthous Stomatitis",
-            "Recurrent aphthous ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:25346356",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311935,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005318",
-              "name": "canker sore",
-              "description": "A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval, lasting for 7-14 days and healing without scarring.; A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval. Two to eight crops of lesions occur per year, lasting for 7 to 14 days and then heal without scarring. (From Jablonski's Dictionary of Dentistry, 1992, p742); Recurrent episodes of ulceration of the oral mucosa, typically presenting as painful, sharply circumscribed fibrin-covered mucosal defects with a hyperemic border. [HPO:probinson]; Oral aphthous ulcers typically present as painful, sharply circumscribed fibrin-covered mucosal defects with a hyperemic border. [PMID:25346356]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:722781002",
-                "MEDDRA:10042131",
-                "MEDDRA:10002959",
-                "UMLS:C2937365",
-                "SNOMEDCT:426965005",
-                "SNOMEDCT:427617000",
-                "UMLS:C1959869",
-                "NCIT:C62546",
-                "MONDO:0005318",
-                "SNOMEDCT:398870000",
-                "MEDDRA:10007166",
-                "MEDDRA:10045287",
-                "MEDDRA:10002958",
-                "MESH:D013281",
-                "UMLS:C0038363",
-                "MEDDRA:10066577",
-                "MEDDRA:10030960",
-                "SNOMEDCT:110426005",
-                "MEDDRA:10067589",
-                "MEDDRA:10084265",
-                "HP:0011107",
-                "MEDDRA:10045372",
-                "MEDDRA:10045288"
-              ],
-              "id": "MONDO:0005318",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Stomatitis, Aphthous",
-                "canker sore",
-                "Canker Sore",
-                "Aphthous ulceration of skin and/or mucous membrane (disorder)",
-                "Recurrent aphthous stomatitis",
-                "Aphthous Stomatitis",
-                "Recurrent aphthous ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:25346356",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17332838,
-            "start": 554,
-            "end": 311935,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24910692': {'publication date': '2014 Mar', 'sentence': 'This study aims to determine the therapeutic effects of ibuprofen, diphenhydramine and aluminum magnesium simethicone (AlMgS) syrup on reducing oral aphthous ulcer pain.', 'subject score': 1000, 'object score': 867}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0038363---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "17687542",
-              "object": "MONDO:0005318",
-              "publications": [
-                "PMID:24910692"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15342612': {'publication date': '2004 Oct', 'sentence': 'This should be considered to assess pharmacokinetic-pharmacodynamic relationships of ibuprofen in premature neonates and subsequently to understand and refine the use of ibuprofen in managing PDA either as a prophylactic or curative treatment.', 'subject score': 1000, 'object score': 983}, 'PMID:18458658': {'publication date': '2008 Sep', 'sentence': 'Ibuprofen versus continuous indomethacin in premature neonates with patent ductus arteriosus: is the difference in the mode of administration?', 'subject score': 1000, 'object score': 983}, 'PMID:29203106': {'publication date': '2017 Nov', 'sentence': 'Oral paracetamol or ibuprofen for PDA closure in premature neonates with severe CHRs and contraindications for indomethacin was ineffective.', 'subject score': 1000, 'object score': 983}, 'PMID:31472084': {'publication date': '2019 Nov', 'sentence': 'BACKGROUND: Ibuprofen is widely used for ductus arteriosus closure in premature neonates and for analgesia in children and adults.', 'subject score': 1000, 'object score': 983}, 'PMID:31850085': {'publication date': '2019', 'sentence': 'Comparison of oral acetaminophen with oral ibuprofen on closure of symptomatic patent ductus arteriosus in preterm neonates.', 'subject score': 888, 'object score': 901}, 'PMID:32955023': {'publication date': '2020 Sep', 'sentence': 'Positive tendency toward synchronous use of acetaminophen and ibuprofen in treating patients with patent ductus arteriosus.OBJECTIVE: Spontaneous closure of the ductus arteriosus often fails to occur in premature newborns and this condition can be associated with increased morbidity and mortality.', 'subject score': 1000, 'object score': 1000}, 'PMID:33779002': {'publication date': '2021 Mar 28', 'sentence': 'Ibuprofen enantiomers in premature neonates with patent ductus arteriosus: Preliminary data on an unexpected pharmacokinetic profile of S(+)-ibuprofen.', 'subject score': 888, 'object score': 1000}, 'PMID:34131462': {'publication date': '2021 Jul', 'sentence': 'Use of combination therapy with acetaminophen and ibuprofen for closure of the patent ductus arteriosus in preterm neonates.', 'subject score': 1000, 'object score': 888}, 'PMID:32045960': {'publication date': '2020 Feb 11', 'sentence': 'SELECTION CRITERIA: Randomised or quasi-randomised controlled trials of ibuprofen for the treatment of a PDA in preterm, low birth weight, or both preterm and low-birth-weight newborn infants.', 'subject score': 1000, 'object score': 1000}, 'PMID:32250464': {'publication date': '2020 Apr 06', 'sentence': 'METHODS: We prospectively collected 210 plasma samples of 67 preterm neonates treated with ibuprofen for PDA (median gestational age (GA) 26 (range 24-30) weeks, median body weight 0.83 (0.45-1.59) kg, median postnatal age (PNA) 3 (1-12) days)), and developed a population pharmacokinetic model for S- and R-ibuprofen.', 'subject score': 1000, 'object score': 861}, 'PMID:32336479': {'publication date': '2020 Apr 23', 'sentence': 'CONCLUSIONS: Oral paracetamol is noninferior to oral ibuprofen for the closure of hsPDA in preterm neonates of <32 weeks of gestation.', 'subject score': 888, 'object score': 901}, 'PMID:32641884': {'publication date': '2020', 'sentence': 'Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - A randomized controlled trial.', 'subject score': 1000, 'object score': 901}, 'PMID:32766181': {'publication date': '2020', 'sentence': 'IV ibuprofen (standard treatment) for PDA in preterm patients with a gestational age <= 30 weeks.', 'subject score': 888, 'object score': 901}, 'PMID:32768013': {'publication date': '2020', 'sentence': 'METHODS: We performed a systematic literature search on topics that assesses the use of oral paracetamol compared to oral ibuprofen in preterm neonates diagnosed with PDA from PubMed, EuropePMC, Cochrane Central Database, ScienceDirect, ProQuest, ClinicalTrials.gov, and hand-sampling from potential articles.', 'subject score': 888, 'object score': 901}, 'PMID:33975823': {'publication date': '2021 May 11', 'sentence': 'OBJECTIVE: Exploration of a novel therapeutic drug monitoring (TDM) strategy to personalise use of ibuprofen for closure of patent ductus arteriosus (PDA) in preterm neonates.', 'subject score': 1000, 'object score': 888}, 'PMID:34477275': {'publication date': '2021 Sep 03', 'sentence': 'CONCLUSION: This exploratory study demonstrates comparable pharmacokinetics of PO and IV formulations of ibuprofen in preterm neonates.', 'subject score': 1000, 'object score': 888}, 'PMID:36465804': {'publication date': '2022 Sep-Dec', 'sentence': 'Conclusions: Trade-off RBA indicated that high-dose oral ibuprofen might be the best treatment for preterm, GA >=28 weeks, with hsPDA followed by the standard-dose oral acetaminophen and ibuprofen.', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 308941,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001622",
-          "name": "Premature birth",
-          "description": "Birth when a fetus is less than 37 weeks and 0 days gestational age.; CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION).; The birth of a baby of less than 37 weeks of gestational age. [HPO:probinson]; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "HP:0001622",
-            "MEDDRA:10014049",
-            "MEDDRA:10036595",
-            "NCIT:C92861",
-            "MEDDRA:10004953",
-            "SNOMEDCT:49550006",
-            "MESH:D047928",
-            "MEDDRA:10036594",
-            "UMLS:C0151526",
-            "SNOMEDCT:367494004",
-            "SNOMEDCT:282020008",
-            "UMLS:C0233315"
-          ],
-          "id": "HP:0001622",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Premature Birth",
-            "Premature birth",
-            "Preterm Birth"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308941,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001622",
-              "name": "Premature birth",
-              "description": "Birth when a fetus is less than 37 weeks and 0 days gestational age.; CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION).; The birth of a baby of less than 37 weeks of gestational age. [HPO:probinson]; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "HP:0001622",
-                "MEDDRA:10014049",
-                "MEDDRA:10036595",
-                "NCIT:C92861",
-                "MEDDRA:10004953",
-                "SNOMEDCT:49550006",
-                "MESH:D047928",
-                "MEDDRA:10036594",
-                "UMLS:C0151526",
-                "SNOMEDCT:367494004",
-                "SNOMEDCT:282020008",
-                "UMLS:C0233315"
-              ],
-              "id": "HP:0001622",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Premature Birth",
-                "Premature birth",
-                "Preterm Birth"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11138197,
-            "start": 554,
-            "end": 308941,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15342612': {'publication date': '2004 Oct', 'sentence': 'This should be considered to assess pharmacokinetic-pharmacodynamic relationships of ibuprofen in premature neonates and subsequently to understand and refine the use of ibuprofen in managing PDA either as a prophylactic or curative treatment.', 'subject score': 1000, 'object score': 983}, 'PMID:18458658': {'publication date': '2008 Sep', 'sentence': 'Ibuprofen versus continuous indomethacin in premature neonates with patent ductus arteriosus: is the difference in the mode of administration?', 'subject score': 1000, 'object score': 983}, 'PMID:29203106': {'publication date': '2017 Nov', 'sentence': 'Oral paracetamol or ibuprofen for PDA closure in premature neonates with severe CHRs and contraindications for indomethacin was ineffective.', 'subject score': 1000, 'object score': 983}, 'PMID:31472084': {'publication date': '2019 Nov', 'sentence': 'BACKGROUND: Ibuprofen is widely used for ductus arteriosus closure in premature neonates and for analgesia in children and adults.', 'subject score': 1000, 'object score': 983}, 'PMID:31850085': {'publication date': '2019', 'sentence': 'Comparison of oral acetaminophen with oral ibuprofen on closure of symptomatic patent ductus arteriosus in preterm neonates.', 'subject score': 888, 'object score': 901}, 'PMID:32955023': {'publication date': '2020 Sep', 'sentence': 'Positive tendency toward synchronous use of acetaminophen and ibuprofen in treating patients with patent ductus arteriosus.OBJECTIVE: Spontaneous closure of the ductus arteriosus often fails to occur in premature newborns and this condition can be associated with increased morbidity and mortality.', 'subject score': 1000, 'object score': 1000}, 'PMID:33779002': {'publication date': '2021 Mar 28', 'sentence': 'Ibuprofen enantiomers in premature neonates with patent ductus arteriosus: Preliminary data on an unexpected pharmacokinetic profile of S(+)-ibuprofen.', 'subject score': 888, 'object score': 1000}, 'PMID:34131462': {'publication date': '2021 Jul', 'sentence': 'Use of combination therapy with acetaminophen and ibuprofen for closure of the patent ductus arteriosus in preterm neonates.', 'subject score': 1000, 'object score': 888}, 'PMID:32045960': {'publication date': '2020 Feb 11', 'sentence': 'SELECTION CRITERIA: Randomised or quasi-randomised controlled trials of ibuprofen for the treatment of a PDA in preterm, low birth weight, or both preterm and low-birth-weight newborn infants.', 'subject score': 1000, 'object score': 1000}, 'PMID:32250464': {'publication date': '2020 Apr 06', 'sentence': 'METHODS: We prospectively collected 210 plasma samples of 67 preterm neonates treated with ibuprofen for PDA (median gestational age (GA) 26 (range 24-30) weeks, median body weight 0.83 (0.45-1.59) kg, median postnatal age (PNA) 3 (1-12) days)), and developed a population pharmacokinetic model for S- and R-ibuprofen.', 'subject score': 1000, 'object score': 861}, 'PMID:32336479': {'publication date': '2020 Apr 23', 'sentence': 'CONCLUSIONS: Oral paracetamol is noninferior to oral ibuprofen for the closure of hsPDA in preterm neonates of <32 weeks of gestation.', 'subject score': 888, 'object score': 901}, 'PMID:32641884': {'publication date': '2020', 'sentence': 'Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - A randomized controlled trial.', 'subject score': 1000, 'object score': 901}, 'PMID:32766181': {'publication date': '2020', 'sentence': 'IV ibuprofen (standard treatment) for PDA in preterm patients with a gestational age <= 30 weeks.', 'subject score': 888, 'object score': 901}, 'PMID:32768013': {'publication date': '2020', 'sentence': 'METHODS: We performed a systematic literature search on topics that assesses the use of oral paracetamol compared to oral ibuprofen in preterm neonates diagnosed with PDA from PubMed, EuropePMC, Cochrane Central Database, ScienceDirect, ProQuest, ClinicalTrials.gov, and hand-sampling from potential articles.', 'subject score': 888, 'object score': 901}, 'PMID:33975823': {'publication date': '2021 May 11', 'sentence': 'OBJECTIVE: Exploration of a novel therapeutic drug monitoring (TDM) strategy to personalise use of ibuprofen for closure of patent ductus arteriosus (PDA) in preterm neonates.', 'subject score': 1000, 'object score': 888}, 'PMID:34477275': {'publication date': '2021 Sep 03', 'sentence': 'CONCLUSION: This exploratory study demonstrates comparable pharmacokinetics of PO and IV formulations of ibuprofen in preterm neonates.', 'subject score': 1000, 'object score': 888}, 'PMID:36465804': {'publication date': '2022 Sep-Dec', 'sentence': 'Conclusions: Trade-off RBA indicated that high-dose oral ibuprofen might be the best treatment for preterm, GA >=28 weeks, with hsPDA followed by the standard-dose oral acetaminophen and ibuprofen.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0233315---SEMMEDDB:",
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0151526---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "11381904",
-              "object": "HP:0001622",
-              "publications": [
-                "PMID:32641884",
-                "PMID:34477275",
-                "PMID:32955023",
-                "PMID:32250464",
-                "PMID:32336479",
-                "PMID:32768013",
-                "PMID:33975823",
-                "PMID:15342612",
-                "PMID:31472084",
-                "PMID:34131462",
-                "PMID:29203106",
-                "PMID:32766181",
-                "PMID:18458658",
-                "PMID:32045960",
-                "PMID:36465804",
-                "PMID:33779002",
-                "PMID:31850085"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:29149272': {'publication date': '2018 02 01', 'sentence': 'Use of paracetamol, ibuprofen or aspirin in pregnancy and risk of cerebral palsy in the child.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 315498,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006497",
-          "name": "cerebral palsy",
-          "description": "A group of disorders affecting the development of movement and posture, often accompanied by disturbances of sensation, perception, cognition, and behavior. It results from damage to the fetal or infant brain.; A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7); Cerebral palsy describes a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to nonprogressive disturbances that occurred in the developing fetal or infant brain. The motor disorders of cerebral palsy are often accompanied by disturbances of sensation, perception, cognition, communication, and behaviour, by epilepsy, and by secondary musculoskeletal problems. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:1969",
-            "HP:0100021",
-            "UMLS:C0007789",
-            "ICD10:G80",
-            "EFO:1000632",
-            "PSY:08280",
-            "MEDDRA:10008129",
-            "SNOMEDCT:128188000",
-            "MEDDRA:10033560",
-            "MONDO:0006497",
-            "MESH:D002547",
-            "NCIT:C34460"
-          ],
-          "id": "MONDO:0006497",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cerebral Palsy",
-            "cerebral palsy",
-            "Cerebral palsy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/cerebral_palsy",
-            "http://www.brainandspinalcord.org/cerebral-palsy/index.htm",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://www.cerebralpalsy.org/what-is-cerebral-palsy/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315498,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006497",
-              "name": "cerebral palsy",
-              "description": "A group of disorders affecting the development of movement and posture, often accompanied by disturbances of sensation, perception, cognition, and behavior. It results from damage to the fetal or infant brain.; A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7); Cerebral palsy describes a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to nonprogressive disturbances that occurred in the developing fetal or infant brain. The motor disorders of cerebral palsy are often accompanied by disturbances of sensation, perception, cognition, communication, and behaviour, by epilepsy, and by secondary musculoskeletal problems. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:1969",
-                "HP:0100021",
-                "UMLS:C0007789",
-                "ICD10:G80",
-                "EFO:1000632",
-                "PSY:08280",
-                "MEDDRA:10008129",
-                "SNOMEDCT:128188000",
-                "MEDDRA:10033560",
-                "MONDO:0006497",
-                "MESH:D002547",
-                "NCIT:C34460"
-              ],
-              "id": "MONDO:0006497",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cerebral Palsy",
-                "cerebral palsy",
-                "Cerebral palsy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/cerebral_palsy",
-                "http://www.brainandspinalcord.org/cerebral-palsy/index.htm",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://www.cerebralpalsy.org/what-is-cerebral-palsy/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19616788,
-            "start": 554,
-            "end": 315498,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29149272': {'publication date': '2018 02 01', 'sentence': 'Use of paracetamol, ibuprofen or aspirin in pregnancy and risk of cerebral palsy in the child.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:predisposes---None---None---None---UMLS:C0007789---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "20007370",
-              "object": "MONDO:0006497",
-              "publications": [
-                "PMID:29149272"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:29669437': {'publication date': '2018 Sep', 'sentence': 'Therefore, the objective of this study was to investigate the local delivery of the NSAIDs model drug ibuprofen to treat periodontitis using different types of gel formulations (hydrogel, oleogel, and bigel).', 'subject score': 836, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 311374,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005076",
-          "name": "periodontitis",
-          "description": "An acute or chronic inflammatory process that affects the tissues that surround and support the teeth.; Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology); Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:824",
-            "UMLS:C0600298",
-            "MEDDRA:10034540",
-            "SNOMEDCT:41565005",
-            "ICD9:523.5",
-            "DOID:9893",
-            "MESH:D010518",
-            "ICD10:K05.4",
-            "HP:0000704",
-            "UMLS:C0031099",
-            "ICD10:K05.3",
-            "MONDO:0005076",
-            "MEDDRA:10034539",
-            "NCIT:C34918",
-            "EFO:0000649"
-          ],
-          "id": "MONDO:0005076",
-          "category": "biolink:Disease",
-          "all_names": [
-            "periodontitis",
-            "Periodontitis",
-            "periodontosis",
-            "Periodontosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5889-4463",
-            "https://orcid.org/0000-0002-9338-3017"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311374,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005076",
-              "name": "periodontitis",
-              "description": "An acute or chronic inflammatory process that affects the tissues that surround and support the teeth.; Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology); Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:824",
-                "UMLS:C0600298",
-                "MEDDRA:10034540",
-                "SNOMEDCT:41565005",
-                "ICD9:523.5",
-                "DOID:9893",
-                "MESH:D010518",
-                "ICD10:K05.4",
-                "HP:0000704",
-                "UMLS:C0031099",
-                "ICD10:K05.3",
-                "MONDO:0005076",
-                "MEDDRA:10034539",
-                "NCIT:C34918",
-                "EFO:0000649"
-              ],
-              "id": "MONDO:0005076",
-              "category": "biolink:Disease",
-              "all_names": [
-                "periodontitis",
-                "Periodontitis",
-                "periodontosis",
-                "Periodontosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5889-4463",
-                "https://orcid.org/0000-0002-9338-3017"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19890406,
-            "start": 554,
-            "end": 311374,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29669437': {'publication date': '2018 Sep', 'sentence': 'Therefore, the objective of this study was to investigate the local delivery of the NSAIDs model drug ibuprofen to treat periodontitis using different types of gel formulations (hydrogel, oleogel, and bigel).', 'subject score': 836, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0031099---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "20285347",
-              "object": "MONDO:0005076",
-              "publications": [
-                "PMID:29669437"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1858442': {'publication date': '1991', 'sentence': 'In an open three-center pilot study, 17 patients suffering from chronic persistent pain syndrome, due to osteoarthritis of the hip and knee or spondylarthrosis, were treated orally with 1800-2400 mg Ibuprofen per day for 3 weeks.', 'subject score': 750, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 525773,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006630",
-          "name": "osteoarthritis, spine",
-          "description": "Heterogeneous group of arthritic diseases sharing clinical and radiologic features. They are associated with the HLA-B27 ANTIGEN and some with a triggering infection. Most involve the axial joints in the SPINE, particularly the SACROILIAC JOINT, but can also involve asymmetric peripheral joints. Subsets include ANKYLOSING SPONDYLITIS; REACTIVE ARTHRITIS; PSORIATIC ARTHRITIS; and others.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0949691",
-            "UMLS:C2350242",
-            "MESH:D055013",
-            "MESH:D025242",
-            "MEDDRA:10031172",
-            "MEDDRA:10041684",
-            "MONDO:0006630",
-            "SNOMEDCT:8847002",
-            "MEDDRA:10029880",
-            "EFO:1000787",
-            "MEDDRA:10029871",
-            "UMLS:C0263851",
-            "MEDDRA:10051265",
-            "MEDDRA:10052775",
-            "MEDDRA:10041591",
-            "MEDDRA:10056449",
-            "SNOMEDCT:68859000"
-          ],
-          "id": "MONDO:0006630",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthritis, Spine",
-            "Spondylarthropathies",
-            "osteoarthritis, spine",
-            "Spondylosis without mention of myelopathy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 525773,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006630",
-              "name": "osteoarthritis, spine",
-              "description": "Heterogeneous group of arthritic diseases sharing clinical and radiologic features. They are associated with the HLA-B27 ANTIGEN and some with a triggering infection. Most involve the axial joints in the SPINE, particularly the SACROILIAC JOINT, but can also involve asymmetric peripheral joints. Subsets include ANKYLOSING SPONDYLITIS; REACTIVE ARTHRITIS; PSORIATIC ARTHRITIS; and others.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0949691",
-                "UMLS:C2350242",
-                "MESH:D055013",
-                "MESH:D025242",
-                "MEDDRA:10031172",
-                "MEDDRA:10041684",
-                "MONDO:0006630",
-                "SNOMEDCT:8847002",
-                "MEDDRA:10029880",
-                "EFO:1000787",
-                "MEDDRA:10029871",
-                "UMLS:C0263851",
-                "MEDDRA:10051265",
-                "MEDDRA:10052775",
-                "MEDDRA:10041591",
-                "MEDDRA:10056449",
-                "SNOMEDCT:68859000"
-              ],
-              "id": "MONDO:0006630",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthritis, Spine",
-                "Spondylarthropathies",
-                "osteoarthritis, spine",
-                "Spondylosis without mention of myelopathy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13536222,
-            "start": 554,
-            "end": 525773,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1858442': {'publication date': '1991', 'sentence': 'In an open three-center pilot study, 17 patients suffering from chronic persistent pain syndrome, due to osteoarthritis of the hip and knee or spondylarthrosis, were treated orally with 1800-2400 mg Ibuprofen per day for 3 weeks.', 'subject score': 750, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0949691---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "13826476",
-              "object": "MONDO:0006630",
-              "publications": [
-                "PMID:1858442"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:1304448': {'publication date': '1992', 'sentence': 'Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide.', 'subject score': 787, 'object score': 787}, 'PMID:1546139': {'publication date': '1992', 'sentence': 'The results show that multiple doses of moclobemide do not change faecal blood loss induced by ibuprofen.', 'subject score': 1000, 'object score': 901}, 'PMID:16887032': {'publication date': '2006 Aug 03', 'sentence': 'Dexamethasone, unlike indomethacin or ibuprofen, may diminish these pathological processes that likely contribute to inflammation and loss of vessel wall integrity leading to hemorrhage in CAA.', 'subject score': 1000, 'object score': 1000}, 'PMID:2525983': {'publication date': '1989 Mar', 'sentence': 'Naproxen, ibuprofen, and indomethacin caused mean daily blood losses in excess of 1 ml/day over baseline values.', 'subject score': 1000, 'object score': 813}, 'PMID:30574567': {'publication date': '2018 Oct', 'sentence': 'Conclusion: Ibuprofen can lead to upper digestive hemorrhage independently of the administered dose.', 'subject score': 1000, 'object score': 802}, 'PMID:313330': {'publication date': '1979 Jul', 'sentence': 'A corresponding dose of ibuprofen did not produce any significant bleeding.', 'subject score': 1000, 'object score': 888}, 'PMID:3553307': {'publication date': '1987 Apr', 'sentence': 'Daily doses of 1,200 mg of ibuprofen may produce endoscopic injury and fecal blood losses similar to placebo.', 'subject score': 1000, 'object score': 890}, 'PMID:6338972': {'publication date': '1983 Apr', 'sentence': 'The trial was completed with no evidence of increased frequency or severity of hemophiliac bleeding episodes or clinical or laboratory evidence of bleeding secondary to Ibuprofen.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 543282,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C26791",
-          "name": "Hemorrhage",
-          "description": "Loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels.",
-          "equivalent_curies": [
-            "UMLS:C0019080",
-            "SYMP:0000041",
-            "MEDDRA:10019524",
-            "MEDDRA:10018988",
-            "MEDDRA:10055798",
-            "MEDDRA:10019525",
-            "NCIT:C26791",
-            "MEDDRA:10005103",
-            "MEDDRA:10015867",
-            "SNOMEDCT:50960005",
-            "MP:0001914",
-            "MEDDRA:10019595",
-            "MEDDRA:10019003",
-            "MEDDRA:10005645",
-            "SNOMEDCT:131148009",
-            "MESH:D006470"
-          ],
-          "id": "NCIT:C26791",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hemorrhage",
-            "Hemorrhage"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/books/nbk542273/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 543282,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C26791",
-              "name": "Hemorrhage",
-              "description": "Loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels.",
-              "equivalent_curies": [
-                "UMLS:C0019080",
-                "SYMP:0000041",
-                "MEDDRA:10019524",
-                "MEDDRA:10018988",
-                "MEDDRA:10055798",
-                "MEDDRA:10019525",
-                "NCIT:C26791",
-                "MEDDRA:10005103",
-                "MEDDRA:10015867",
-                "SNOMEDCT:50960005",
-                "MP:0001914",
-                "MEDDRA:10019595",
-                "MEDDRA:10019003",
-                "MEDDRA:10005645",
-                "SNOMEDCT:131148009",
-                "MESH:D006470"
-              ],
-              "id": "NCIT:C26791",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hemorrhage",
-                "Hemorrhage"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/books/nbk542273/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10204543,
-            "start": 554,
-            "end": 543282,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:1304448': {'publication date': '1992', 'sentence': 'Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide.', 'subject score': 787, 'object score': 787}, 'PMID:1546139': {'publication date': '1992', 'sentence': 'The results show that multiple doses of moclobemide do not change faecal blood loss induced by ibuprofen.', 'subject score': 1000, 'object score': 901}, 'PMID:16887032': {'publication date': '2006 Aug 03', 'sentence': 'Dexamethasone, unlike indomethacin or ibuprofen, may diminish these pathological processes that likely contribute to inflammation and loss of vessel wall integrity leading to hemorrhage in CAA.', 'subject score': 1000, 'object score': 1000}, 'PMID:2525983': {'publication date': '1989 Mar', 'sentence': 'Naproxen, ibuprofen, and indomethacin caused mean daily blood losses in excess of 1 ml/day over baseline values.', 'subject score': 1000, 'object score': 813}, 'PMID:30574567': {'publication date': '2018 Oct', 'sentence': 'Conclusion: Ibuprofen can lead to upper digestive hemorrhage independently of the administered dose.', 'subject score': 1000, 'object score': 802}, 'PMID:313330': {'publication date': '1979 Jul', 'sentence': 'A corresponding dose of ibuprofen did not produce any significant bleeding.', 'subject score': 1000, 'object score': 888}, 'PMID:3553307': {'publication date': '1987 Apr', 'sentence': 'Daily doses of 1,200 mg of ibuprofen may produce endoscopic injury and fecal blood losses similar to placebo.', 'subject score': 1000, 'object score': 890}, 'PMID:6338972': {'publication date': '1983 Apr', 'sentence': 'The trial was completed with no evidence of increased frequency or severity of hemophiliac bleeding episodes or clinical or laboratory evidence of bleeding secondary to Ibuprofen.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C0019080---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "10429873",
-              "object": "NCIT:C26791",
-              "publications": [
-                "PMID:1304448",
-                "PMID:1546139",
-                "PMID:16887032",
-                "PMID:2525983",
-                "PMID:30574567",
-                "PMID:313330",
-                "PMID:3553307",
-                "PMID:6338972"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:15102426': {'publication date': '1997', 'sentence': 'It was also investigated whether the use of ibuprofen or paracetamol would influence the amount of surgical bleeding.', 'subject score': 1000, 'object score': 888}, 'PMID:18245919': {'publication date': '2008', 'sentence': 'The effect of ibuprofen on bleeding during periodontal surgery.', 'subject score': 1000, 'object score': 1000}, 'PMID:18672110': {'publication date': '2008 Aug', 'sentence': 'There was no effect of IBU on S/B.', 'subject score': 1000, 'object score': 763}, 'PMID:20890608': {'publication date': '2011 Apr', 'sentence': 'The objective of the study was to evaluate the effect of ibuprofen on hemorrhage after tonsillectomy in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:27188704': {'publication date': '2016 09', 'sentence': 'OBJECTIVE: To determine the effect of ibuprofen on posttonsillectomy bleeding when compared with codeine in posttonsillectomy analgesia.', 'subject score': 1000, 'object score': 861}, 'PMID:31568318': {'publication date': '2019 Oct', 'sentence': 'There were no articles that showed statistically significant bleeding associated with ibuprofen, celecoxib, or ketorolac.', 'subject score': 1000, 'object score': 901}, 'PMID:330286': {'publication date': '1977', 'sentence': 'The acute effect of three non-steroidal anti-inflammatory drugs, ibuprofen, acetylsalicylic acid (ASA) and indoprofen, on faecal blood loss was investigated in 15 subjects by means of 51Cr-labelled erythrocytes.', 'subject score': 1000, 'object score': 901}, 'PMID:786680': {'publication date': '1975 Apr 04', 'sentence': 'Subjective scores indicated that neither wound-healing nor bleeding was affected by ibuprofen, nor were any side effects detected.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 543282,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C26791",
-          "name": "Hemorrhage",
-          "description": "Loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels.",
-          "equivalent_curies": [
-            "UMLS:C0019080",
-            "SYMP:0000041",
-            "MEDDRA:10019524",
-            "MEDDRA:10018988",
-            "MEDDRA:10055798",
-            "MEDDRA:10019525",
-            "NCIT:C26791",
-            "MEDDRA:10005103",
-            "MEDDRA:10015867",
-            "SNOMEDCT:50960005",
-            "MP:0001914",
-            "MEDDRA:10019595",
-            "MEDDRA:10019003",
-            "MEDDRA:10005645",
-            "SNOMEDCT:131148009",
-            "MESH:D006470"
-          ],
-          "id": "NCIT:C26791",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hemorrhage",
-            "Hemorrhage"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/books/nbk542273/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 543282,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C26791",
-              "name": "Hemorrhage",
-              "description": "Loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels.",
-              "equivalent_curies": [
-                "UMLS:C0019080",
-                "SYMP:0000041",
-                "MEDDRA:10019524",
-                "MEDDRA:10018988",
-                "MEDDRA:10055798",
-                "MEDDRA:10019525",
-                "NCIT:C26791",
-                "MEDDRA:10005103",
-                "MEDDRA:10015867",
-                "SNOMEDCT:50960005",
-                "MP:0001914",
-                "MEDDRA:10019595",
-                "MEDDRA:10019003",
-                "MEDDRA:10005645",
-                "SNOMEDCT:131148009",
-                "MESH:D006470"
-              ],
-              "id": "NCIT:C26791",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hemorrhage",
-                "Hemorrhage"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/books/nbk542273/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10920727,
-            "start": 554,
-            "end": 543282,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15102426': {'publication date': '1997', 'sentence': 'It was also investigated whether the use of ibuprofen or paracetamol would influence the amount of surgical bleeding.', 'subject score': 1000, 'object score': 888}, 'PMID:18245919': {'publication date': '2008', 'sentence': 'The effect of ibuprofen on bleeding during periodontal surgery.', 'subject score': 1000, 'object score': 1000}, 'PMID:18672110': {'publication date': '2008 Aug', 'sentence': 'There was no effect of IBU on S/B.', 'subject score': 1000, 'object score': 763}, 'PMID:20890608': {'publication date': '2011 Apr', 'sentence': 'The objective of the study was to evaluate the effect of ibuprofen on hemorrhage after tonsillectomy in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:27188704': {'publication date': '2016 09', 'sentence': 'OBJECTIVE: To determine the effect of ibuprofen on posttonsillectomy bleeding when compared with codeine in posttonsillectomy analgesia.', 'subject score': 1000, 'object score': 861}, 'PMID:31568318': {'publication date': '2019 Oct', 'sentence': 'There were no articles that showed statistically significant bleeding associated with ibuprofen, celecoxib, or ketorolac.', 'subject score': 1000, 'object score': 901}, 'PMID:330286': {'publication date': '1977', 'sentence': 'The acute effect of three non-steroidal anti-inflammatory drugs, ibuprofen, acetylsalicylic acid (ASA) and indoprofen, on faecal blood loss was investigated in 15 subjects by means of 51Cr-labelled erythrocytes.', 'subject score': 1000, 'object score': 901}, 'PMID:786680': {'publication date': '1975 Apr 04', 'sentence': 'Subjective scores indicated that neither wound-healing nor bleeding was affected by ibuprofen, nor were any side effects detected.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0019080---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "11159990",
-              "object": "NCIT:C26791",
-              "publications": [
-                "PMID:15102426",
-                "PMID:18245919",
-                "PMID:18672110",
-                "PMID:20890608",
-                "PMID:27188704",
-                "PMID:31568318",
-                "PMID:330286",
-                "PMID:786680"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:12442934': {'publication date': '2002 Nov', 'sentence': 'CONCLUSIONS: Pretreatment with ibuprofen before elective total hip surgery increases the perioperative blood loss significantly.', 'subject score': 1000, 'object score': 824}, 'PMID:12734151': {'publication date': '2003 May', 'sentence': 'CONCLUSION: Pretreatment with ibuprofen before major hip surgery does not improve the pain scores or reduce morphine requirement but significantly increases blood loss.', 'subject score': 1000, 'object score': 1000}, 'PMID:1304448': {'publication date': '1992', 'sentence': 'As expected for ibuprofen, a significant increase in FBL during the second week of the study was observed.', 'subject score': 1000, 'object score': 901}, 'PMID:16018759': {'publication date': '2005 Jul', 'sentence': 'CONCLUSION: Taken prior to periodontal surgery, ibuprofen increases intraoperative blood loss in patients up to almost two times that of those who did not take ibuprofen.', 'subject score': 1000, 'object score': 901}, 'PMID:25128450': {'publication date': '2014 Oct', 'sentence': 'Ibuprofen prescription may possibly increase the risk of multiple bleeding episodes, but further prospective studies are needed.', 'subject score': 888, 'object score': 890}, 'PMID:25902839': {'publication date': '2015 Oct', 'sentence': 'CONCLUSIONS: Alternating doses of ibuprofen and acetaminophen provided an effective treatment for post-tonsillectomy pain in the majority of children and did not increase rate of bleeding.', 'subject score': 1000, 'object score': 1000}, 'PMID:34559405': {'publication date': '2021 Sep 24', 'sentence': 'A recent meta-analysis suggests that ibuprofen may increase the risk of PTH.', 'subject score': 1000, 'object score': 851}, 'PMID:3498312': {'publication date': '1987 Jun', 'sentence': 'From the profile of gastrointestinal bleeding, the NSAIDs could be divided into a group consisting of aspirin (ASA), oxaprozin (OXP) and 2-[4-(3-methyl-2-butenyl)phenyl]propionic acid (TA), which caused only a transient increase in fecal blood loss based on a gastric lesion, and another group including indomethacin (IM) and ibuprofen (IP), which produced a biphasic increase in the blood loss.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 543282,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C26791",
-          "name": "Hemorrhage",
-          "description": "Loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels.",
-          "equivalent_curies": [
-            "UMLS:C0019080",
-            "SYMP:0000041",
-            "MEDDRA:10019524",
-            "MEDDRA:10018988",
-            "MEDDRA:10055798",
-            "MEDDRA:10019525",
-            "NCIT:C26791",
-            "MEDDRA:10005103",
-            "MEDDRA:10015867",
-            "SNOMEDCT:50960005",
-            "MP:0001914",
-            "MEDDRA:10019595",
-            "MEDDRA:10019003",
-            "MEDDRA:10005645",
-            "SNOMEDCT:131148009",
-            "MESH:D006470"
-          ],
-          "id": "NCIT:C26791",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hemorrhage",
-            "Hemorrhage"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/books/nbk542273/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 543282,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C26791",
-              "name": "Hemorrhage",
-              "description": "Loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels.",
-              "equivalent_curies": [
-                "UMLS:C0019080",
-                "SYMP:0000041",
-                "MEDDRA:10019524",
-                "MEDDRA:10018988",
-                "MEDDRA:10055798",
-                "MEDDRA:10019525",
-                "NCIT:C26791",
-                "MEDDRA:10005103",
-                "MEDDRA:10015867",
-                "SNOMEDCT:50960005",
-                "MP:0001914",
-                "MEDDRA:10019595",
-                "MEDDRA:10019003",
-                "MEDDRA:10005645",
-                "SNOMEDCT:131148009",
-                "MESH:D006470"
-              ],
-              "id": "NCIT:C26791",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hemorrhage",
-                "Hemorrhage"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/books/nbk542273/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9675830,
-            "start": 554,
-            "end": 543282,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12442934': {'publication date': '2002 Nov', 'sentence': 'CONCLUSIONS: Pretreatment with ibuprofen before elective total hip surgery increases the perioperative blood loss significantly.', 'subject score': 1000, 'object score': 824}, 'PMID:12734151': {'publication date': '2003 May', 'sentence': 'CONCLUSION: Pretreatment with ibuprofen before major hip surgery does not improve the pain scores or reduce morphine requirement but significantly increases blood loss.', 'subject score': 1000, 'object score': 1000}, 'PMID:1304448': {'publication date': '1992', 'sentence': 'As expected for ibuprofen, a significant increase in FBL during the second week of the study was observed.', 'subject score': 1000, 'object score': 901}, 'PMID:16018759': {'publication date': '2005 Jul', 'sentence': 'CONCLUSION: Taken prior to periodontal surgery, ibuprofen increases intraoperative blood loss in patients up to almost two times that of those who did not take ibuprofen.', 'subject score': 1000, 'object score': 901}, 'PMID:25128450': {'publication date': '2014 Oct', 'sentence': 'Ibuprofen prescription may possibly increase the risk of multiple bleeding episodes, but further prospective studies are needed.', 'subject score': 888, 'object score': 890}, 'PMID:25902839': {'publication date': '2015 Oct', 'sentence': 'CONCLUSIONS: Alternating doses of ibuprofen and acetaminophen provided an effective treatment for post-tonsillectomy pain in the majority of children and did not increase rate of bleeding.', 'subject score': 1000, 'object score': 1000}, 'PMID:34559405': {'publication date': '2021 Sep 24', 'sentence': 'A recent meta-analysis suggests that ibuprofen may increase the risk of PTH.', 'subject score': 1000, 'object score': 851}, 'PMID:3498312': {'publication date': '1987 Jun', 'sentence': 'From the profile of gastrointestinal bleeding, the NSAIDs could be divided into a group consisting of aspirin (ASA), oxaprozin (OXP) and 2-[4-(3-methyl-2-butenyl)phenyl]propionic acid (TA), which caused only a transient increase in fecal blood loss based on a gastric lesion, and another group including indomethacin (IM) and ibuprofen (IP), which produced a biphasic increase in the blood loss.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0019080---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9889792",
-              "object": "NCIT:C26791",
-              "publications": [
-                "PMID:12442934",
-                "PMID:12734151",
-                "PMID:1304448",
-                "PMID:16018759",
-                "PMID:25128450",
-                "PMID:25902839",
-                "PMID:34559405",
-                "PMID:3498312"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10974182': {'publication date': '2000 Aug 15', 'sentence': 'A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects.', 'subject score': 1000, 'object score': 901}, 'PMID:16271337': {'publication date': '2005 Nov', 'sentence': 'FBL was measured by radioactive analysis of chromium-51 labeled red cells in stools during baseline and then followed by 4 weeks of treatment with ibuprofen (800 mg 3 times daily) or placebo in 68 healthy volunteers.', 'subject score': 1000, 'object score': 901}, 'PMID:22360152': {'publication date': '2012 May', 'sentence': 'CONCLUSIONS: Dalteparin is superior to the NSAID ibuprofen in preventing extension of superficial thrombophlebitis during the 14-day treatment period with similar relief of pain and no increase in bleeding.', 'subject score': 931, 'object score': 1000}, 'PMID:32546045': {'publication date': '2020 Jun 16', 'sentence': 'Our results suggest that a standing protocol of alternating Acetaminophen and Ibuprofen given every 4 hours improves the post-tonsillectomy hemorrhage rate without increasing ER visits or calls about pain.', 'subject score': 1000, 'object score': 833}, 'PMID:3516203': {'publication date': '1986 Mar', 'sentence': 'To study the effects of a copper-releasing intrauterine contraceptive device (IUCD) and a prostaglandin (PG) synthesis inhibitor, ibuprofen, on menstrual blood loss, 28 healthy women received either a Fincoid 350 or a ML Cu375 device and were then treated in a double-blind randomized manner with ibuprofen (1200 mg daily) or a placebo during their next three menstruations.', 'subject score': 1000, 'object score': 901}, 'PMID:7243136': {'publication date': '1981 Jul', 'sentence': 'Ibuprofen produced a significant reduction in menstrual blood loss; the percentage reduction was greater in women using a Lippes Loop and who had heavier blood loss (39%) than in women using a copper device and who had lighter blood loss (25%).', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 543282,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C26791",
-          "name": "Hemorrhage",
-          "description": "Loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels.",
-          "equivalent_curies": [
-            "UMLS:C0019080",
-            "SYMP:0000041",
-            "MEDDRA:10019524",
-            "MEDDRA:10018988",
-            "MEDDRA:10055798",
-            "MEDDRA:10019525",
-            "NCIT:C26791",
-            "MEDDRA:10005103",
-            "MEDDRA:10015867",
-            "SNOMEDCT:50960005",
-            "MP:0001914",
-            "MEDDRA:10019595",
-            "MEDDRA:10019003",
-            "MEDDRA:10005645",
-            "SNOMEDCT:131148009",
-            "MESH:D006470"
-          ],
-          "id": "NCIT:C26791",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hemorrhage",
-            "Hemorrhage"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/books/nbk542273/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 543282,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C26791",
-              "name": "Hemorrhage",
-              "description": "Loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels.",
-              "equivalent_curies": [
-                "UMLS:C0019080",
-                "SYMP:0000041",
-                "MEDDRA:10019524",
-                "MEDDRA:10018988",
-                "MEDDRA:10055798",
-                "MEDDRA:10019525",
-                "NCIT:C26791",
-                "MEDDRA:10005103",
-                "MEDDRA:10015867",
-                "SNOMEDCT:50960005",
-                "MP:0001914",
-                "MEDDRA:10019595",
-                "MEDDRA:10019003",
-                "MEDDRA:10005645",
-                "SNOMEDCT:131148009",
-                "MESH:D006470"
-              ],
-              "id": "NCIT:C26791",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hemorrhage",
-                "Hemorrhage"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/books/nbk542273/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8242675,
-            "start": 554,
-            "end": 543282,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:10974182': {'publication date': '2000 Aug 15', 'sentence': 'A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects.', 'subject score': 1000, 'object score': 901}, 'PMID:16271337': {'publication date': '2005 Nov', 'sentence': 'FBL was measured by radioactive analysis of chromium-51 labeled red cells in stools during baseline and then followed by 4 weeks of treatment with ibuprofen (800 mg 3 times daily) or placebo in 68 healthy volunteers.', 'subject score': 1000, 'object score': 901}, 'PMID:22360152': {'publication date': '2012 May', 'sentence': 'CONCLUSIONS: Dalteparin is superior to the NSAID ibuprofen in preventing extension of superficial thrombophlebitis during the 14-day treatment period with similar relief of pain and no increase in bleeding.', 'subject score': 931, 'object score': 1000}, 'PMID:32546045': {'publication date': '2020 Jun 16', 'sentence': 'Our results suggest that a standing protocol of alternating Acetaminophen and Ibuprofen given every 4 hours improves the post-tonsillectomy hemorrhage rate without increasing ER visits or calls about pain.', 'subject score': 1000, 'object score': 833}, 'PMID:3516203': {'publication date': '1986 Mar', 'sentence': 'To study the effects of a copper-releasing intrauterine contraceptive device (IUCD) and a prostaglandin (PG) synthesis inhibitor, ibuprofen, on menstrual blood loss, 28 healthy women received either a Fincoid 350 or a ML Cu375 device and were then treated in a double-blind randomized manner with ibuprofen (1200 mg daily) or a placebo during their next three menstruations.', 'subject score': 1000, 'object score': 901}, 'PMID:7243136': {'publication date': '1981 Jul', 'sentence': 'Ibuprofen produced a significant reduction in menstrual blood loss; the percentage reduction was greater in women using a Lippes Loop and who had heavier blood loss (39%) than in women using a copper device and who had lighter blood loss (25%).', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0019080---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "8420965",
-              "object": "NCIT:C26791",
-              "publications": [
-                "PMID:10974182",
-                "PMID:16271337",
-                "PMID:22360152",
-                "PMID:32546045",
-                "PMID:3516203",
-                "PMID:7243136"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:32546045': {'publication date': '2020 Jun 16', 'sentence': 'The Effect of Ibuprofen Dosing Interval on Post-Tonsillectomy Outcomes in Children: A Quality Improvement Study.OBJECTIVE: In this Quality Improvement (QI project) it was hypothesized that an increase in dosing intervals for postoperative analgesia when alternating Ibuprofen and Acetaminophen would reduce post-tonsillectomy hemorrhage (PTH) rates for those undergoing tonsillectomies with or without adenoidectomy, while maintaining the standard of postoperative analgesia and reducing visits to the Emergency Room (ER) for reasons other than PTH.', 'subject score': 888, 'object score': 825}}",
-    "p2": {
-      "start": {
-        "identity": 543282,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C26791",
-          "name": "Hemorrhage",
-          "description": "Loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels.",
-          "equivalent_curies": [
-            "UMLS:C0019080",
-            "SYMP:0000041",
-            "MEDDRA:10019524",
-            "MEDDRA:10018988",
-            "MEDDRA:10055798",
-            "MEDDRA:10019525",
-            "NCIT:C26791",
-            "MEDDRA:10005103",
-            "MEDDRA:10015867",
-            "SNOMEDCT:50960005",
-            "MP:0001914",
-            "MEDDRA:10019595",
-            "MEDDRA:10019003",
-            "MEDDRA:10005645",
-            "SNOMEDCT:131148009",
-            "MESH:D006470"
-          ],
-          "id": "NCIT:C26791",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hemorrhage",
-            "Hemorrhage"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/books/nbk542273/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 543282,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C26791",
-              "name": "Hemorrhage",
-              "description": "Loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels.",
-              "equivalent_curies": [
-                "UMLS:C0019080",
-                "SYMP:0000041",
-                "MEDDRA:10019524",
-                "MEDDRA:10018988",
-                "MEDDRA:10055798",
-                "MEDDRA:10019525",
-                "NCIT:C26791",
-                "MEDDRA:10005103",
-                "MEDDRA:10015867",
-                "SNOMEDCT:50960005",
-                "MP:0001914",
-                "MEDDRA:10019595",
-                "MEDDRA:10019003",
-                "MEDDRA:10005645",
-                "SNOMEDCT:131148009",
-                "MESH:D006470"
-              ],
-              "id": "NCIT:C26791",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hemorrhage",
-                "Hemorrhage"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/books/nbk542273/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21738643,
-            "start": 554,
-            "end": 543282,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32546045': {'publication date': '2020 Jun 16', 'sentence': 'The Effect of Ibuprofen Dosing Interval on Post-Tonsillectomy Outcomes in Children: A Quality Improvement Study.OBJECTIVE: In this Quality Improvement (QI project) it was hypothesized that an increase in dosing intervals for postoperative analgesia when alternating Ibuprofen and Acetaminophen would reduce post-tonsillectomy hemorrhage (PTH) rates for those undergoing tonsillectomies with or without adenoidectomy, while maintaining the standard of postoperative analgesia and reducing visits to the Emergency Room (ER) for reasons other than PTH.', 'subject score': 888, 'object score': 825}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0019080---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "22159382",
-              "object": "NCIT:C26791",
-              "publications": [
-                "PMID:32546045"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12503255': {'publication date': '2002', 'sentence': 'Eight preparations contained synthetic drugs (e.g. benzodiazepines and tricyclic antidepressants in sedative preparations, cyproheptadine in a remedy to gain bodyweight, ibuprofen and dipyrone in herbal capsules used to treat rheumatism).', 'subject score': 1000, 'object score': 1000}, 'PMID:14381': {'publication date': '1976', 'sentence': '[Clinical results of ibuprofen (Brufen) in abarticular rheumatism].', 'subject score': 1000, 'object score': 861}, 'PMID:17638129': {'publication date': '1998', 'sentence': 'S(+)-ibuprofen (dexibuprofen) is an NSAID offering a lot of advantages in the treatment of rheumatism and pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:19588434': {'publication date': '2009 Jul 08', 'sentence': 'BACKGROUND: Dexibuprofen (S(+)-ibuprofen) is a non-steroidal anti-inflammatory drug (NSAID) licensed for use in rheumatic disease and other musculoskeletal disorders in the UK, and widely available in other countries worldwide.', 'subject score': 1000, 'object score': 1000}, 'PMID:2818681': {'publication date': '1989 Aug', 'sentence': 'Therefore ibuprofen can be used in old patients with rheumatic diseases without any dose reduction and discontinuation of treatment has not to be discussed.', 'subject score': 861, 'object score': 1000}, 'PMID:350500': {'publication date': '1978', 'sentence': 'A comparative trial of ketoprofen and ibuprofen in patients with rheumatic disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:4579839': {'publication date': '1973 Jun 23', 'sentence': '[Use of ibuprofen in the control of rheumatic activity].', 'subject score': 1000, 'object score': 888}, 'PMID:4579840': {'publication date': '1973 Jun 23', 'sentence': '[Controlled clinical research on the use of ibuprofen in rheumatoid arthritis and other rheumatic diseases].', 'subject score': 1000, 'object score': 1000}, 'PMID:8957236': {'publication date': '1996 Oct 24', 'sentence': \"Synovial cell cultures prepared from samples taken from osteoarthritic and rheumatoid patients were treated with different anti-inflammatory agents (cortisol, indomethacin, ibuprofen and piroxicam) to determine their 'anti-interleukin-1 beta' action, using inhibition of interleukin-1 beta-mediated glucose uptake stimulation as a biological test.\", 'subject score': 1000, 'object score': 853}}",
-    "p2": {
-      "start": {
-        "identity": 530667,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005554",
-          "name": "rheumatic disorder",
-          "description": "Inflammatory and degenerative diseases of connective tissue structures, such as arthritis.; Historically, a heterogeneous group of acute and chronic diseases, including rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, dermatomyositis, etc. This classification was based on the notion that \"collagen\" was equivalent to \"connective tissue\", but with the present recognition of the different types of collagen and the aggregates derived from them as distinct entities, the term \"collagen diseases\" now pertains exclusively to those inherited conditions in which the primary defect is at the gene level and affects collagen biosynthesis, post-translational modification, or extracellular processing directly. (From Cecil Textbook of Medicine, 19th ed, p1494); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10039070",
-            "MEDDRA:10039068",
-            "SNOMEDCT:396332003",
-            "DOID:1575",
-            "MEDDRA:10045746",
-            "MEDDRA:10013207",
-            "MONDO:0005554",
-            "DOID:854",
-            "EFO:0005755",
-            "MESH:D003095",
-            "UMLS:C0035435",
-            "UMLS:C0009326",
-            "MESH:D012216",
-            "MEDDRA:10009904",
-            "PSY:44560",
-            "SNOMEDCT:81573002",
-            "UMLS:C0041785",
-            "NCIT:C27204",
-            "MEDDRA:10009903"
-          ],
-          "id": "MONDO:0005554",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Rheumatism",
-            "collagen disease",
-            "Rheumatic Diseases",
-            "Rheumatologic Disorder",
-            "Collagen Diseases",
-            "Diffuse disease of connective tissue",
-            "rheumatic disorder",
-            "rheumatic disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/connective_tissue_disease",
-            "http://www.niams.nih.gov/health_info/scleroderma/default.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 530667,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005554",
-              "name": "rheumatic disorder",
-              "description": "Inflammatory and degenerative diseases of connective tissue structures, such as arthritis.; Historically, a heterogeneous group of acute and chronic diseases, including rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, dermatomyositis, etc. This classification was based on the notion that \"collagen\" was equivalent to \"connective tissue\", but with the present recognition of the different types of collagen and the aggregates derived from them as distinct entities, the term \"collagen diseases\" now pertains exclusively to those inherited conditions in which the primary defect is at the gene level and affects collagen biosynthesis, post-translational modification, or extracellular processing directly. (From Cecil Textbook of Medicine, 19th ed, p1494); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10039070",
-                "MEDDRA:10039068",
-                "SNOMEDCT:396332003",
-                "DOID:1575",
-                "MEDDRA:10045746",
-                "MEDDRA:10013207",
-                "MONDO:0005554",
-                "DOID:854",
-                "EFO:0005755",
-                "MESH:D003095",
-                "UMLS:C0035435",
-                "UMLS:C0009326",
-                "MESH:D012216",
-                "MEDDRA:10009904",
-                "PSY:44560",
-                "SNOMEDCT:81573002",
-                "UMLS:C0041785",
-                "NCIT:C27204",
-                "MEDDRA:10009903"
-              ],
-              "id": "MONDO:0005554",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Rheumatism",
-                "collagen disease",
-                "Rheumatic Diseases",
-                "Rheumatologic Disorder",
-                "Collagen Diseases",
-                "Diffuse disease of connective tissue",
-                "rheumatic disorder",
-                "rheumatic disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/connective_tissue_disease",
-                "http://www.niams.nih.gov/health_info/scleroderma/default.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9735560,
-            "start": 554,
-            "end": 530667,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12503255': {'publication date': '2002', 'sentence': 'Eight preparations contained synthetic drugs (e.g. benzodiazepines and tricyclic antidepressants in sedative preparations, cyproheptadine in a remedy to gain bodyweight, ibuprofen and dipyrone in herbal capsules used to treat rheumatism).', 'subject score': 1000, 'object score': 1000}, 'PMID:14381': {'publication date': '1976', 'sentence': '[Clinical results of ibuprofen (Brufen) in abarticular rheumatism].', 'subject score': 1000, 'object score': 861}, 'PMID:17638129': {'publication date': '1998', 'sentence': 'S(+)-ibuprofen (dexibuprofen) is an NSAID offering a lot of advantages in the treatment of rheumatism and pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:19588434': {'publication date': '2009 Jul 08', 'sentence': 'BACKGROUND: Dexibuprofen (S(+)-ibuprofen) is a non-steroidal anti-inflammatory drug (NSAID) licensed for use in rheumatic disease and other musculoskeletal disorders in the UK, and widely available in other countries worldwide.', 'subject score': 1000, 'object score': 1000}, 'PMID:2818681': {'publication date': '1989 Aug', 'sentence': 'Therefore ibuprofen can be used in old patients with rheumatic diseases without any dose reduction and discontinuation of treatment has not to be discussed.', 'subject score': 861, 'object score': 1000}, 'PMID:350500': {'publication date': '1978', 'sentence': 'A comparative trial of ketoprofen and ibuprofen in patients with rheumatic disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:4579839': {'publication date': '1973 Jun 23', 'sentence': '[Use of ibuprofen in the control of rheumatic activity].', 'subject score': 1000, 'object score': 888}, 'PMID:4579840': {'publication date': '1973 Jun 23', 'sentence': '[Controlled clinical research on the use of ibuprofen in rheumatoid arthritis and other rheumatic diseases].', 'subject score': 1000, 'object score': 1000}, 'PMID:8957236': {'publication date': '1996 Oct 24', 'sentence': \"Synovial cell cultures prepared from samples taken from osteoarthritic and rheumatoid patients were treated with different anti-inflammatory agents (cortisol, indomethacin, ibuprofen and piroxicam) to determine their 'anti-interleukin-1 beta' action, using inhibition of interleukin-1 beta-mediated glucose uptake stimulation as a biological test.\", 'subject score': 1000, 'object score': 853}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0035435---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9950431",
-              "object": "MONDO:0005554",
-              "publications": [
-                "PMID:12503255",
-                "PMID:14381",
-                "PMID:17638129",
-                "PMID:19588434",
-                "PMID:2818681",
-                "PMID:350500",
-                "PMID:4579839",
-                "PMID:4579840",
-                "PMID:8957236"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:30673916': {'publication date': '2019 Jan 23', 'sentence': 'Ibuprofen (IBU) and phenylephrine hydrochloride (PE) were commonly used for common cold due to their different effects in relieving fever and the main symptoms such as nasal congestion and high sinus pressure.', 'subject score': 1000, 'object score': 1000}, 'PMID:34142200': {'publication date': '2021 Jun 17', 'sentence': 'The six active pharmaceutical molecules under study, namely, paracetamol, guaifenesin, pseudoephedrine, ibuprofen, chlorpheniramine, and dextromethorphan, are widely used in common cold products.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 521066,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005709",
-          "name": "common cold",
-          "description": "An acute inflammatory process that affects the nasopharynx. It is caused by viruses. Signs and symptoms include fever, coughing, sneezing, and sore throat.; An inflammatory process affecting the nasal mucosa, usually caused by viruses (e.g., rhinovirus, adenovirus, parainfluenza virus, and coronavirus). It is characterized by chills, headaches, mucopurulent nasal discharge, coughing, and facial pain.; A catarrhal disorder of the upper respiratory tract, which may be viral or a mixed infection. It generally involves a runny nose, nasal congestion, and sneezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0009443",
-            "MESH:D003139",
-            "MEDDRA:10039084",
-            "MEDDRA:10010107",
-            "MEDDRA:10009851",
-            "NCIT:C78599",
-            "MEDDRA:10021921",
-            "MEDDRA:10000938",
-            "MEDDRA:10066743",
-            "MONDO:0005709",
-            "MEDDRA:10019192",
-            "MEDDRA:10010106",
-            "ICD9:460",
-            "DOID:10459",
-            "EFO:0007214",
-            "MEDDRA:10000937",
-            "MEDDRA:10059827",
-            "SNOMEDCT:82272006",
-            "NCIT:C34500"
-          ],
-          "id": "MONDO:0005709",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute nasopharyngitis [common cold]",
-            "Common Cold",
-            "Infectious Rhinitis",
-            "common cold",
-            "Acute Nasopharyngitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=common%20cold"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 521066,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005709",
-              "name": "common cold",
-              "description": "An acute inflammatory process that affects the nasopharynx. It is caused by viruses. Signs and symptoms include fever, coughing, sneezing, and sore throat.; An inflammatory process affecting the nasal mucosa, usually caused by viruses (e.g., rhinovirus, adenovirus, parainfluenza virus, and coronavirus). It is characterized by chills, headaches, mucopurulent nasal discharge, coughing, and facial pain.; A catarrhal disorder of the upper respiratory tract, which may be viral or a mixed infection. It generally involves a runny nose, nasal congestion, and sneezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0009443",
-                "MESH:D003139",
-                "MEDDRA:10039084",
-                "MEDDRA:10010107",
-                "MEDDRA:10009851",
-                "NCIT:C78599",
-                "MEDDRA:10021921",
-                "MEDDRA:10000938",
-                "MEDDRA:10066743",
-                "MONDO:0005709",
-                "MEDDRA:10019192",
-                "MEDDRA:10010106",
-                "ICD9:460",
-                "DOID:10459",
-                "EFO:0007214",
-                "MEDDRA:10000937",
-                "MEDDRA:10059827",
-                "SNOMEDCT:82272006",
-                "NCIT:C34500"
-              ],
-              "id": "MONDO:0005709",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute nasopharyngitis [common cold]",
-                "Common Cold",
-                "Infectious Rhinitis",
-                "common cold",
-                "Acute Nasopharyngitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=common%20cold"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20418747,
-            "start": 554,
-            "end": 521066,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30673916': {'publication date': '2019 Jan 23', 'sentence': 'Ibuprofen (IBU) and phenylephrine hydrochloride (PE) were commonly used for common cold due to their different effects in relieving fever and the main symptoms such as nasal congestion and high sinus pressure.', 'subject score': 1000, 'object score': 1000}, 'PMID:34142200': {'publication date': '2021 Jun 17', 'sentence': 'The six active pharmaceutical molecules under study, namely, paracetamol, guaifenesin, pseudoephedrine, ibuprofen, chlorpheniramine, and dextromethorphan, are widely used in common cold products.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0009443---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "20821983",
-              "object": "MONDO:0005709",
-              "publications": [
-                "PMID:30673916",
-                "PMID:34142200"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:17504261': {'publication date': '2007 Jun', 'sentence': 'Protective effect of glucosamine against ibuprofen-induced peptic ulcer in rats.', 'subject score': 861, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 316638,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-          "name": "peptic ulcer disease",
-          "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10018053",
-            "MEDDRA:10045305",
-            "MESH:D010437",
-            "MONDO:0004247",
-            "DOID:750",
-            "UMLS:C0030920",
-            "MEDDRA:10017886",
-            "MEDDRA:10045342",
-            "ICD9:533",
-            "ICD10:K27",
-            "HP:0004398",
-            "MEDDRA:10034343",
-            "MEDDRA:10034360",
-            "MEDDRA:10045328",
-            "MEDDRA:10042834",
-            "MEDDRA:10034341",
-            "MEDDRA:10034367",
-            "MEDDRA:10037287",
-            "NCIT:C3318",
-            "SNOMEDCT:13200003",
-            "MEDDRA:10034369"
-          ],
-          "id": "MONDO:0004247",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peptic ulcer, site unspecified",
-            "Peptic Ulcer",
-            "peptic ulcer disease",
-            "Peptic ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28242110",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316638,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-              "name": "peptic ulcer disease",
-              "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10018053",
-                "MEDDRA:10045305",
-                "MESH:D010437",
-                "MONDO:0004247",
-                "DOID:750",
-                "UMLS:C0030920",
-                "MEDDRA:10017886",
-                "MEDDRA:10045342",
-                "ICD9:533",
-                "ICD10:K27",
-                "HP:0004398",
-                "MEDDRA:10034343",
-                "MEDDRA:10034360",
-                "MEDDRA:10045328",
-                "MEDDRA:10042834",
-                "MEDDRA:10034341",
-                "MEDDRA:10034367",
-                "MEDDRA:10037287",
-                "NCIT:C3318",
-                "SNOMEDCT:13200003",
-                "MEDDRA:10034369"
-              ],
-              "id": "MONDO:0004247",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peptic ulcer, site unspecified",
-                "Peptic Ulcer",
-                "peptic ulcer disease",
-                "Peptic ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28242110",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12845671,
-            "start": 554,
-            "end": 316638,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17504261': {'publication date': '2007 Jun', 'sentence': 'Protective effect of glucosamine against ibuprofen-induced peptic ulcer in rats.', 'subject score': 861, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C0030920---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "13133316",
-              "object": "MONDO:0004247",
-              "publications": [
-                "PMID:17504261"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:15153172': {'publication date': '2004 Jun 01', 'sentence': 'Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316638,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-          "name": "peptic ulcer disease",
-          "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10018053",
-            "MEDDRA:10045305",
-            "MESH:D010437",
-            "MONDO:0004247",
-            "DOID:750",
-            "UMLS:C0030920",
-            "MEDDRA:10017886",
-            "MEDDRA:10045342",
-            "ICD9:533",
-            "ICD10:K27",
-            "HP:0004398",
-            "MEDDRA:10034343",
-            "MEDDRA:10034360",
-            "MEDDRA:10045328",
-            "MEDDRA:10042834",
-            "MEDDRA:10034341",
-            "MEDDRA:10034367",
-            "MEDDRA:10037287",
-            "NCIT:C3318",
-            "SNOMEDCT:13200003",
-            "MEDDRA:10034369"
-          ],
-          "id": "MONDO:0004247",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peptic ulcer, site unspecified",
-            "Peptic Ulcer",
-            "peptic ulcer disease",
-            "Peptic ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28242110",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316638,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-              "name": "peptic ulcer disease",
-              "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10018053",
-                "MEDDRA:10045305",
-                "MESH:D010437",
-                "MONDO:0004247",
-                "DOID:750",
-                "UMLS:C0030920",
-                "MEDDRA:10017886",
-                "MEDDRA:10045342",
-                "ICD9:533",
-                "ICD10:K27",
-                "HP:0004398",
-                "MEDDRA:10034343",
-                "MEDDRA:10034360",
-                "MEDDRA:10045328",
-                "MEDDRA:10042834",
-                "MEDDRA:10034341",
-                "MEDDRA:10034367",
-                "MEDDRA:10037287",
-                "NCIT:C3318",
-                "SNOMEDCT:13200003",
-                "MEDDRA:10034369"
-              ],
-              "id": "MONDO:0004247",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peptic ulcer, site unspecified",
-                "Peptic Ulcer",
-                "peptic ulcer disease",
-                "Peptic ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28242110",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10967507,
-            "start": 554,
-            "end": 316638,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15153172': {'publication date': '2004 Jun 01', 'sentence': 'Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0030920---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "11207850",
-              "object": "MONDO:0004247",
-              "publications": [
-                "PMID:15153172"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15851630': {'publication date': '2005 Jun', 'sentence': 'Treatment with nonselective anti-inflammatory drugs ibuprofen, indomethacin, or salicylic acid did not show any effect on angiotensin II-induced superoxide production, hypertension, or cardiac hypertrophy.', 'subject score': 854, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 310723,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005044",
-          "name": "hypertensive disorder",
-          "description": "The presence of chronic increased pressure in the systemic arterial system. [HPO:probinson]; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0000822",
-            "PDQ:CDR0000686951",
-            "EFO:0000537",
-            "MONDO:0005044",
-            "MEDDRA:10039196",
-            "ICD9:401-405.99",
-            "MEDDRA:10057166",
-            "MEDDRA:10003170",
-            "ICD10:I10",
-            "MEDDRA:10006067",
-            "UMLS:C0020538",
-            "NCIT:C3117",
-            "UMLS:C0497247",
-            "SNOMEDCT:24184005",
-            "MEDDRA:10037806",
-            "MEDDRA:10036639",
-            "MESH:D006973",
-            "MEDDRA:10020775",
-            "SNOMEDCT:38341003",
-            "PSY:23830",
-            "MEDDRA:10005750",
-            "MEDDRA:10005755",
-            "MEDDRA:10081425",
-            "MEDDRA:10003168",
-            "MEDDRA:10020772",
-            "MEDDRA:10014475",
-            "MEDDRA:10005747",
-            "DOID:10763",
-            "MEDDRA:10039197",
-            "MEDDRA:10037808",
-            "MEDDRA:10020782",
-            "MEDDRA:10021655",
-            "MEDDRA:10036640"
-          ],
-          "id": "MONDO:0005044",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hypertension",
-            "Hypertension",
-            "hypertensive disorder",
-            "Hypertensive disease",
-            "Increase in blood pressure"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:24352797",
-            "PMID:9137951",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://en.wikipedia.org/wiki/hypertension"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310723,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005044",
-              "name": "hypertensive disorder",
-              "description": "The presence of chronic increased pressure in the systemic arterial system. [HPO:probinson]; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0000822",
-                "PDQ:CDR0000686951",
-                "EFO:0000537",
-                "MONDO:0005044",
-                "MEDDRA:10039196",
-                "ICD9:401-405.99",
-                "MEDDRA:10057166",
-                "MEDDRA:10003170",
-                "ICD10:I10",
-                "MEDDRA:10006067",
-                "UMLS:C0020538",
-                "NCIT:C3117",
-                "UMLS:C0497247",
-                "SNOMEDCT:24184005",
-                "MEDDRA:10037806",
-                "MEDDRA:10036639",
-                "MESH:D006973",
-                "MEDDRA:10020775",
-                "SNOMEDCT:38341003",
-                "PSY:23830",
-                "MEDDRA:10005750",
-                "MEDDRA:10005755",
-                "MEDDRA:10081425",
-                "MEDDRA:10003168",
-                "MEDDRA:10020772",
-                "MEDDRA:10014475",
-                "MEDDRA:10005747",
-                "DOID:10763",
-                "MEDDRA:10039197",
-                "MEDDRA:10037808",
-                "MEDDRA:10020782",
-                "MEDDRA:10021655",
-                "MEDDRA:10036640"
-              ],
-              "id": "MONDO:0005044",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hypertension",
-                "Hypertension",
-                "hypertensive disorder",
-                "Hypertensive disease",
-                "Increase in blood pressure"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:24352797",
-                "PMID:9137951",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://en.wikipedia.org/wiki/hypertension"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11538041,
-            "start": 554,
-            "end": 310723,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15851630': {'publication date': '2005 Jun', 'sentence': 'Treatment with nonselective anti-inflammatory drugs ibuprofen, indomethacin, or salicylic acid did not show any effect on angiotensin II-induced superoxide production, hypertension, or cardiac hypertrophy.', 'subject score': 854, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0020538---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "11790277",
-              "object": "MONDO:0005044",
-              "publications": [
-                "PMID:15851630"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:3840417': {'publication date': '1985', 'sentence': 'The hypoxia, hypertension and increased prostanoids were prevented using ibuprofen.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 310723,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005044",
-          "name": "hypertensive disorder",
-          "description": "The presence of chronic increased pressure in the systemic arterial system. [HPO:probinson]; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0000822",
-            "PDQ:CDR0000686951",
-            "EFO:0000537",
-            "MONDO:0005044",
-            "MEDDRA:10039196",
-            "ICD9:401-405.99",
-            "MEDDRA:10057166",
-            "MEDDRA:10003170",
-            "ICD10:I10",
-            "MEDDRA:10006067",
-            "UMLS:C0020538",
-            "NCIT:C3117",
-            "UMLS:C0497247",
-            "SNOMEDCT:24184005",
-            "MEDDRA:10037806",
-            "MEDDRA:10036639",
-            "MESH:D006973",
-            "MEDDRA:10020775",
-            "SNOMEDCT:38341003",
-            "PSY:23830",
-            "MEDDRA:10005750",
-            "MEDDRA:10005755",
-            "MEDDRA:10081425",
-            "MEDDRA:10003168",
-            "MEDDRA:10020772",
-            "MEDDRA:10014475",
-            "MEDDRA:10005747",
-            "DOID:10763",
-            "MEDDRA:10039197",
-            "MEDDRA:10037808",
-            "MEDDRA:10020782",
-            "MEDDRA:10021655",
-            "MEDDRA:10036640"
-          ],
-          "id": "MONDO:0005044",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hypertension",
-            "Hypertension",
-            "hypertensive disorder",
-            "Hypertensive disease",
-            "Increase in blood pressure"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:24352797",
-            "PMID:9137951",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://en.wikipedia.org/wiki/hypertension"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310723,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005044",
-              "name": "hypertensive disorder",
-              "description": "The presence of chronic increased pressure in the systemic arterial system. [HPO:probinson]; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0000822",
-                "PDQ:CDR0000686951",
-                "EFO:0000537",
-                "MONDO:0005044",
-                "MEDDRA:10039196",
-                "ICD9:401-405.99",
-                "MEDDRA:10057166",
-                "MEDDRA:10003170",
-                "ICD10:I10",
-                "MEDDRA:10006067",
-                "UMLS:C0020538",
-                "NCIT:C3117",
-                "UMLS:C0497247",
-                "SNOMEDCT:24184005",
-                "MEDDRA:10037806",
-                "MEDDRA:10036639",
-                "MESH:D006973",
-                "MEDDRA:10020775",
-                "SNOMEDCT:38341003",
-                "PSY:23830",
-                "MEDDRA:10005750",
-                "MEDDRA:10005755",
-                "MEDDRA:10081425",
-                "MEDDRA:10003168",
-                "MEDDRA:10020772",
-                "MEDDRA:10014475",
-                "MEDDRA:10005747",
-                "DOID:10763",
-                "MEDDRA:10039197",
-                "MEDDRA:10037808",
-                "MEDDRA:10020782",
-                "MEDDRA:10021655",
-                "MEDDRA:10036640"
-              ],
-              "id": "MONDO:0005044",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hypertension",
-                "Hypertension",
-                "hypertensive disorder",
-                "Hypertensive disease",
-                "Increase in blood pressure"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:24352797",
-                "PMID:9137951",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://en.wikipedia.org/wiki/hypertension"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25205974,
-            "start": 554,
-            "end": 310723,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3840417': {'publication date': '1985', 'sentence': 'The hypoxia, hypertension and increased prostanoids were prevented using ibuprofen.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0020538---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "25657729",
-              "object": "MONDO:0005044",
-              "publications": [
-                "PMID:3840417"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:27751698': {'publication date': '2017 Apr', 'sentence': 'Does the Use of Ibuprofen in Children with Extremity Fractures Increase their Risk for Bone Healing Complications?', 'subject score': 1000, 'object score': 888}, 'PMID:34499688': {'publication date': '2021', 'sentence': 'An observational cohort study comparing ibuprofen and oxycodone in children with fractures.', 'subject score': 833, 'object score': 1000}, 'PMID:7221494': {'publication date': '1981', 'sentence': 'The chemical composition of fractured and unfractured bone was significantly altered and showed a reduced ratio of hydroxyproline/nitrogen as well as an inhibition of calcification of bone matrix with a reduced calcium/nitrogen ratio followed by an increased ratio of hexosamine/DNA and RNA-ribose/DNA after treatment with ibuprofen.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 311213,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005315",
-          "name": "bone fracture",
-          "description": "A traumatic injury to the bone in which the continuity of the bone is broken.; Breaks in bones.; A partial or complete breakage of the continuity of a bone. []; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "EFO:0003931",
-            "MEDDRA:10017322",
-            "SNOMEDCT:72704001",
-            "MESH:D050723",
-            "HP:0020110",
-            "MEDDRA:10017089",
-            "UMLS:C0016658",
-            "NCIT:C3046",
-            "MEDDRA:10017076",
-            "SNOMEDCT:125605004",
-            "MEDDRA:10006381",
-            "MONDO:0005315",
-            "MEDDRA:10017077"
-          ],
-          "id": "MONDO:0005315",
-          "category": "biolink:Disease",
-          "all_names": [
-            "bone fracture",
-            "Fractures, Bone",
-            "Bone fracture",
-            "Fracture"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311213,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005315",
-              "name": "bone fracture",
-              "description": "A traumatic injury to the bone in which the continuity of the bone is broken.; Breaks in bones.; A partial or complete breakage of the continuity of a bone. []; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "EFO:0003931",
-                "MEDDRA:10017322",
-                "SNOMEDCT:72704001",
-                "MESH:D050723",
-                "HP:0020110",
-                "MEDDRA:10017089",
-                "UMLS:C0016658",
-                "NCIT:C3046",
-                "MEDDRA:10017076",
-                "SNOMEDCT:125605004",
-                "MEDDRA:10006381",
-                "MONDO:0005315",
-                "MEDDRA:10017077"
-              ],
-              "id": "MONDO:0005315",
-              "category": "biolink:Disease",
-              "all_names": [
-                "bone fracture",
-                "Fractures, Bone",
-                "Bone fracture",
-                "Fracture"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18890817,
-            "start": 554,
-            "end": 311213,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27751698': {'publication date': '2017 Apr', 'sentence': 'Does the Use of Ibuprofen in Children with Extremity Fractures Increase their Risk for Bone Healing Complications?', 'subject score': 1000, 'object score': 888}, 'PMID:34499688': {'publication date': '2021', 'sentence': 'An observational cohort study comparing ibuprofen and oxycodone in children with fractures.', 'subject score': 833, 'object score': 1000}, 'PMID:7221494': {'publication date': '1981', 'sentence': 'The chemical composition of fractured and unfractured bone was significantly altered and showed a reduced ratio of hydroxyproline/nitrogen as well as an inhibition of calcification of bone matrix with a reduced calcium/nitrogen ratio followed by an increased ratio of hexosamine/DNA and RNA-ribose/DNA after treatment with ibuprofen.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0016658---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "19270581",
-              "object": "MONDO:0005315",
-              "publications": [
-                "PMID:27751698",
-                "PMID:34499688",
-                "PMID:7221494"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:16927048': {'publication date': '2006 Aug', 'sentence': 'Significant heterogeneity was present for the NSAIDs; e.g., ibuprofen was associated with an increased overall fracture risk (OR = 2.09, 95% CI 2.00-2.18 for <20 DDD), while celecoxib was not (OR = 0.76, 95% CI 0.51-1.13 for <20 DDD, 2P < 0.01 for comparison).', 'subject score': 1000, 'object score': 833}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 311213,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005315",
-          "name": "bone fracture",
-          "description": "A traumatic injury to the bone in which the continuity of the bone is broken.; Breaks in bones.; A partial or complete breakage of the continuity of a bone. []; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "EFO:0003931",
-            "MEDDRA:10017322",
-            "SNOMEDCT:72704001",
-            "MESH:D050723",
-            "HP:0020110",
-            "MEDDRA:10017089",
-            "UMLS:C0016658",
-            "NCIT:C3046",
-            "MEDDRA:10017076",
-            "SNOMEDCT:125605004",
-            "MEDDRA:10006381",
-            "MONDO:0005315",
-            "MEDDRA:10017077"
-          ],
-          "id": "MONDO:0005315",
-          "category": "biolink:Disease",
-          "all_names": [
-            "bone fracture",
-            "Fractures, Bone",
-            "Bone fracture",
-            "Fracture"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311213,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005315",
-              "name": "bone fracture",
-              "description": "A traumatic injury to the bone in which the continuity of the bone is broken.; Breaks in bones.; A partial or complete breakage of the continuity of a bone. []; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "EFO:0003931",
-                "MEDDRA:10017322",
-                "SNOMEDCT:72704001",
-                "MESH:D050723",
-                "HP:0020110",
-                "MEDDRA:10017089",
-                "UMLS:C0016658",
-                "NCIT:C3046",
-                "MEDDRA:10017076",
-                "SNOMEDCT:125605004",
-                "MEDDRA:10006381",
-                "MONDO:0005315",
-                "MEDDRA:10017077"
-              ],
-              "id": "MONDO:0005315",
-              "category": "biolink:Disease",
-              "all_names": [
-                "bone fracture",
-                "Fractures, Bone",
-                "Bone fracture",
-                "Fracture"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12404332,
-            "start": 554,
-            "end": 311213,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16927048': {'publication date': '2006 Aug', 'sentence': 'Significant heterogeneity was present for the NSAIDs; e.g., ibuprofen was associated with an increased overall fracture risk (OR = 2.09, 95% CI 2.00-2.18 for <20 DDD), while celecoxib was not (OR = 0.76, 95% CI 0.51-1.13 for <20 DDD, 2P < 0.01 for comparison).', 'subject score': 1000, 'object score': 833}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:predisposes---None---None---None---UMLS:C0016658---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "12673407",
-              "object": "MONDO:0005315",
-              "publications": [
-                "PMID:16927048"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:22558609': {'publication date': '2012', 'sentence': 'AIMS: To carry out a randomized clinical trial to compare the effect of palmitoylethanolamide (PEA) versus ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), for pain relief in temporomandibular joint (TMJ) osteoarthritis or arthralgia.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318242,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0002829",
-          "name": "Arthralgia",
-          "description": "Joint pain. [HPO:probinson]; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D018771",
-            "MEDDRA:10023197",
-            "MEDDRA:10033456",
-            "PDQ:CDR0000651641",
-            "MEDDRA:10013088",
-            "HP:0002829",
-            "MEDDRA:10033511",
-            "UMLS:C0857177",
-            "NCIT:C50464",
-            "MEDDRA:10003245",
-            "MEDDRA:10033434",
-            "UMLS:C0003862",
-            "MEDDRA:10033444",
-            "MEDDRA:10000449",
-            "SNOMEDCT:57676002",
-            "MEDDRA:10003244",
-            "MEDDRA:10003239",
-            "MEDDRA:10023222"
-          ],
-          "id": "HP:0002829",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Arthralgia",
-            "arthralgia",
-            "Arthritic pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318242,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002829",
-              "name": "Arthralgia",
-              "description": "Joint pain. [HPO:probinson]; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D018771",
-                "MEDDRA:10023197",
-                "MEDDRA:10033456",
-                "PDQ:CDR0000651641",
-                "MEDDRA:10013088",
-                "HP:0002829",
-                "MEDDRA:10033511",
-                "UMLS:C0857177",
-                "NCIT:C50464",
-                "MEDDRA:10003245",
-                "MEDDRA:10033434",
-                "UMLS:C0003862",
-                "MEDDRA:10033444",
-                "MEDDRA:10000449",
-                "SNOMEDCT:57676002",
-                "MEDDRA:10003244",
-                "MEDDRA:10003239",
-                "MEDDRA:10023222"
-              ],
-              "id": "HP:0002829",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Arthralgia",
-                "arthralgia",
-                "Arthritic pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15933349,
-            "start": 554,
-            "end": 318242,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22558609': {'publication date': '2012', 'sentence': 'AIMS: To carry out a randomized clinical trial to compare the effect of palmitoylethanolamide (PEA) versus ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), for pain relief in temporomandibular joint (TMJ) osteoarthritis or arthralgia.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:associated_with---None---None---None---UMLS:C0003862---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "16265626",
-              "object": "HP:0002829",
-              "publications": [
-                "PMID:22558609"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11904551': {'publication date': '2002 Mar', 'sentence': 'To determine the effectiveness of oral glucosamine with ibuprofen for the relief of joint pain in osteoarthritis a mini-review (Griffiths, 2002) of double-blind randomized controlled trials comparing the two was undertaken.', 'subject score': 1000, 'object score': 1000}, 'PMID:19576941': {'publication date': '2009 Aug 13', 'sentence': 'After being administration of co-therapy with steroid pulse, ibuprofen, methotrexate and phosphodiesterase inhibitor gradually improved her clinical symptoms such as spiky fever, heart failure and arthralgia.', 'subject score': 1000, 'object score': 1000}, 'PMID:29082820': {'publication date': '2018 Jan', 'sentence': 'OBJECTIVE: Ibuprofen is a commonly used non-steroidal anti-inflammatory drug administered to treat injuries, joint pain, and recurrent muscular skeletal pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:31275778': {'publication date': '2019 Apr 27', 'sentence': 'On further questioning, the patient revealed that he had been utilizing an average of 2000 mg of ibuprofen daily during the previous several months in an attempt to control his joint pain.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318242,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0002829",
-          "name": "Arthralgia",
-          "description": "Joint pain. [HPO:probinson]; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D018771",
-            "MEDDRA:10023197",
-            "MEDDRA:10033456",
-            "PDQ:CDR0000651641",
-            "MEDDRA:10013088",
-            "HP:0002829",
-            "MEDDRA:10033511",
-            "UMLS:C0857177",
-            "NCIT:C50464",
-            "MEDDRA:10003245",
-            "MEDDRA:10033434",
-            "UMLS:C0003862",
-            "MEDDRA:10033444",
-            "MEDDRA:10000449",
-            "SNOMEDCT:57676002",
-            "MEDDRA:10003244",
-            "MEDDRA:10003239",
-            "MEDDRA:10023222"
-          ],
-          "id": "HP:0002829",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Arthralgia",
-            "arthralgia",
-            "Arthritic pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318242,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002829",
-              "name": "Arthralgia",
-              "description": "Joint pain. [HPO:probinson]; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; Joint pain. // COMMENTS: Arthralgia is distinct from Arthritis, which is not a symptom but a diagnosis with articular inflammation or signs of osteoarthritis.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D018771",
-                "MEDDRA:10023197",
-                "MEDDRA:10033456",
-                "PDQ:CDR0000651641",
-                "MEDDRA:10013088",
-                "HP:0002829",
-                "MEDDRA:10033511",
-                "UMLS:C0857177",
-                "NCIT:C50464",
-                "MEDDRA:10003245",
-                "MEDDRA:10033434",
-                "UMLS:C0003862",
-                "MEDDRA:10033444",
-                "MEDDRA:10000449",
-                "SNOMEDCT:57676002",
-                "MEDDRA:10003244",
-                "MEDDRA:10003239",
-                "MEDDRA:10023222"
-              ],
-              "id": "HP:0002829",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Arthralgia",
-                "arthralgia",
-                "Arthritic pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9241819,
-            "start": 554,
-            "end": 318242,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11904551': {'publication date': '2002 Mar', 'sentence': 'To determine the effectiveness of oral glucosamine with ibuprofen for the relief of joint pain in osteoarthritis a mini-review (Griffiths, 2002) of double-blind randomized controlled trials comparing the two was undertaken.', 'subject score': 1000, 'object score': 1000}, 'PMID:19576941': {'publication date': '2009 Aug 13', 'sentence': 'After being administration of co-therapy with steroid pulse, ibuprofen, methotrexate and phosphodiesterase inhibitor gradually improved her clinical symptoms such as spiky fever, heart failure and arthralgia.', 'subject score': 1000, 'object score': 1000}, 'PMID:29082820': {'publication date': '2018 Jan', 'sentence': 'OBJECTIVE: Ibuprofen is a commonly used non-steroidal anti-inflammatory drug administered to treat injuries, joint pain, and recurrent muscular skeletal pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:31275778': {'publication date': '2019 Apr 27', 'sentence': 'On further questioning, the patient revealed that he had been utilizing an average of 2000 mg of ibuprofen daily during the previous several months in an attempt to control his joint pain.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0003862---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9444914",
-              "object": "HP:0002829",
-              "publications": [
-                "PMID:11904551",
-                "PMID:19576941",
-                "PMID:29082820",
-                "PMID:31275778"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15562884': {'publication date': '2004 Nov', 'sentence': 'Addition of ibuprofen to pseudoephedrine and chlorpheniramine in the treatment of seasonal allergic rhinitis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317004,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005324",
-          "name": "seasonal allergic rhinitis",
-          "description": "Allergic rhinitis caused by outdoor allergens.; Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS.; It is characterized by one or more symptoms including sneezing, itching, nasal congestion, and rhinorrhea. [PMID:11449200]; An allergy experienced at a particular time of year when trees or grasses pollinate and elicit an allergic reaction. [HPO:probinson]",
-          "equivalent_curies": [
-            "HP:0012395",
-            "NCIT:C92188",
-            "SNOMEDCT:300910009",
-            "PSY:22320",
-            "MEDDRA:10001726",
-            "SNOMEDCT:21719001",
-            "MEDDRA:10019170",
-            "MONDO:0005324",
-            "MEDDRA:10039776",
-            "MEDDRA:10048908",
-            "MEDDRA:10036020",
-            "SNOMEDCT:444316004",
-            "MESH:D006255",
-            "SNOMEDCT:367498001",
-            "MEDDRA:10036019",
-            "UMLS:C0018621"
-          ],
-          "id": "MONDO:0005324",
-          "category": "biolink:Disease",
-          "all_names": [
-            "seasonal allergic rhinitis",
-            "Seasonal Allergic Rhinitis",
-            "Rhinitis, Allergic, Seasonal",
-            "Seasonal allergy",
-            "Hay Fever",
-            "Hay fever"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:11449200",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317004,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005324",
-              "name": "seasonal allergic rhinitis",
-              "description": "Allergic rhinitis caused by outdoor allergens.; Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS.; It is characterized by one or more symptoms including sneezing, itching, nasal congestion, and rhinorrhea. [PMID:11449200]; An allergy experienced at a particular time of year when trees or grasses pollinate and elicit an allergic reaction. [HPO:probinson]",
-              "equivalent_curies": [
-                "HP:0012395",
-                "NCIT:C92188",
-                "SNOMEDCT:300910009",
-                "PSY:22320",
-                "MEDDRA:10001726",
-                "SNOMEDCT:21719001",
-                "MEDDRA:10019170",
-                "MONDO:0005324",
-                "MEDDRA:10039776",
-                "MEDDRA:10048908",
-                "MEDDRA:10036020",
-                "SNOMEDCT:444316004",
-                "MESH:D006255",
-                "SNOMEDCT:367498001",
-                "MEDDRA:10036019",
-                "UMLS:C0018621"
-              ],
-              "id": "MONDO:0005324",
-              "category": "biolink:Disease",
-              "all_names": [
-                "seasonal allergic rhinitis",
-                "Seasonal Allergic Rhinitis",
-                "Rhinitis, Allergic, Seasonal",
-                "Seasonal allergy",
-                "Hay Fever",
-                "Hay fever"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:11449200",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11289035,
-            "start": 554,
-            "end": 317004,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15562884': {'publication date': '2004 Nov', 'sentence': 'Addition of ibuprofen to pseudoephedrine and chlorpheniramine in the treatment of seasonal allergic rhinitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0018621---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "11536369",
-              "object": "MONDO:0005324",
-              "publications": [
-                "PMID:15562884"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:19762153': {'publication date': '2009 Dec 15', 'sentence': 'We investigated the analgesic efficacy of single doses of ibuprofen, tramadol and pregabalin in menthol-evoked cold pain in a randomized, placebo-controlled four-way cross-over study in 20 healthy volunteers.', 'subject score': 1000, 'object score': 775}}",
-    "p2": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14279414,
-            "start": 554,
-            "end": 316891,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19762153': {'publication date': '2009 Dec 15', 'sentence': 'We investigated the analgesic efficacy of single doses of ibuprofen, tramadol and pregabalin in menthol-evoked cold pain in a randomized, placebo-controlled four-way cross-over study in 20 healthy volunteers.', 'subject score': 1000, 'object score': 775}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:associated_with---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "14582794",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:19762153"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:1509971': {'publication date': '1992 Jan', 'sentence': 'In a double-blind cross-over study on 22 healthy subjects the analgesic efficacies of the antipyretic analgesic drugs ibuprofen, dipyrone and paracetamol were tested against placebo using a model of experimentally induced pain.', 'subject score': 861, 'object score': 790}, 'PMID:29707018': {'publication date': '2018', 'sentence': 'Conclusion: Pre-medication with ibuprofen resulted in less pain following pulpotomy and SSC placement in primary teeth.', 'subject score': 1000, 'object score': 861}, 'PMID:31112677': {'publication date': '2019 Oct', 'sentence': 'CONCLUSIONS: The present study has shown that the preemptive use of IV ibuprofen resulted in less pain and a decrease in the requirement for rescue analgesia during the first 24 hours after third molar surgery.', 'subject score': 888, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10918360,
-            "start": 554,
-            "end": 316891,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1509971': {'publication date': '1992 Jan', 'sentence': 'In a double-blind cross-over study on 22 healthy subjects the analgesic efficacies of the antipyretic analgesic drugs ibuprofen, dipyrone and paracetamol were tested against placebo using a model of experimentally induced pain.', 'subject score': 861, 'object score': 790}, 'PMID:29707018': {'publication date': '2018', 'sentence': 'Conclusion: Pre-medication with ibuprofen resulted in less pain following pulpotomy and SSC placement in primary teeth.', 'subject score': 1000, 'object score': 861}, 'PMID:31112677': {'publication date': '2019 Oct', 'sentence': 'CONCLUSIONS: The present study has shown that the preemptive use of IV ibuprofen resulted in less pain and a decrease in the requirement for rescue analgesia during the first 24 hours after third molar surgery.', 'subject score': 888, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "11157616",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:1509971",
-                "PMID:29707018",
-                "PMID:31112677"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10513507': {'publication date': '1999 Jun', 'sentence': 'The WOMAC detected significant differences between ibuprofen and placebo for pain and physical functioning, whereas the SF-36 detected differences for the bodily pain subscale.', 'subject score': 1000, 'object score': 1000}, 'PMID:10550887': {'publication date': '1999', 'sentence': 'Racemic ibuprofen is an important NSAID used in the treatment of pain and inflammation in a variety of musculoskeletal and rheumatic disorders.', 'subject score': 861, 'object score': 1000}, 'PMID:10581086': {'publication date': '1999 Dec', 'sentence': 'Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, indomethacin and ibuprofen are the most widely used drugs for pain, arthritis, cardiovascular diseases and, more recently, the prevention of colon cancer and Alzheimer disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:10716611': {'publication date': '2000 Jan', 'sentence': 'We conclude that khat, like amphetamine and ibuprofen, can relieve pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:11021730': {'publication date': '2000 Oct', 'sentence': 'An open-label evaluation of the efficacy and safety of Stadol NS with ibuprofen in the treatment of pain after removal of impacted wisdom teeth.', 'subject score': 1000, 'object score': 1000}, 'PMID:11021732': {'publication date': '2000 Oct', 'sentence': 'Effectiveness of Stadol NS (butorphanol tartrate) with ibuprofen in the treatment of pain after laser-assisted uvulopalatopharyngoplasty.', 'subject score': 1000, 'object score': 1000}, 'PMID:11113797': {'publication date': '2000 Dec', 'sentence': 'An evaluation of preoperative ibuprofen for treatment of pain associated with orthodontic separator placement.', 'subject score': 888, 'object score': 1000}, 'PMID:11319581': {'publication date': '2000 Mar', 'sentence': 'Less clinical experience has accumulated with ibuprofen, and it remains the second-line treatment for fever and pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:11455373': {'publication date': '2001 Jul', 'sentence': 'In conclusion, these data indicate that ibuprofen taken 60 minutes before separator placement alleviates pain at 2 hours and at bedtime after treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:11554954': {'publication date': '2001 Jul-Aug', 'sentence': 'CONCLUSIONS: Ibuprofen at doses of 200 mg and 400 mg is an efficacious, cost-effective, well-tolerated, single-ingredient nonprescription treatment for pain of migraine headache.', 'subject score': 1000, 'object score': 1000}, 'PMID:11954880': {'publication date': '2002 Feb', 'sentence': 'The aim of this blinded, randomised, multicentre study was to compare the tolerability of aspirin, paracetamol and ibuprofen in common pain resulting from musculoskeletal conditions (MSC) in general practice with patients with other non-MSC pain conditions.', 'subject score': 1000, 'object score': 888}, 'PMID:14558184': {'publication date': '2003 Oct-Nov', 'sentence': 'Advantage was taken of data generated in the paracetamol, aspirin and ibuprofen new tolerability (PAIN) study, a large randomized double-blinded trial of paracetamol, aspirin or ibuprofen for common pain in general practice to attempt this.', 'subject score': 1000, 'object score': 888}, 'PMID:15196644': {'publication date': '2004 Jul 08', 'sentence': 'Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment.', 'subject score': 1000, 'object score': 888}, 'PMID:15219128': {'publication date': '2004 Mar 25', 'sentence': 'Mild-to-moderate pain in noninflammatory arthrosis can be ameliorated by paracetamol or low-dose ibuprofen.', 'subject score': 901, 'object score': 916}, 'PMID:15229960': {'publication date': '2004 Jul', 'sentence': 'CONCLUSION: Over-the-counter doses of naproxen sodium (440/660 mg) and ibuprofen (1200 mg) effectively relieve pain in patients with mild to moderate OA of the knee.', 'subject score': 1000, 'object score': 1000}, 'PMID:1565349': {'publication date': '1992 May', 'sentence': 'This study shows that pain during laser vaporization of the cervix is not due to increased uterine contractions, and that pain was not significantly relieved by ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:15970957': {'publication date': '2005 Jun', 'sentence': 'Context: Ibuprofen is widely used to manage pain and inflammation after orthopaedic trauma, but its effect on acute swelling has not been investigated.', 'subject score': 1000, 'object score': 1000}, 'PMID:16170062': {'publication date': '2005 Sep', 'sentence': 'This is a case report of a child who experienced a possible adverse reaction to paracetamol, in a randomized clinical trial comparing paracetamol with ibuprofen for control of orthodontic pain.', 'subject score': 1000, 'object score': 888}, 'PMID:16885182': {'publication date': '2006 Sep 09', 'sentence': 'Safety and efficacy of routine postoperative ibuprofen for pain and disability related to ectopic bone formation after hip replacement surgery (HIPAID): randomised controlled trial.', 'subject score': 802, 'object score': 1000}, 'PMID:17045356': {'publication date': '2006 Oct 27', 'sentence': 'Theoretically, IBU-BB could sustainably release high concentrations of IBU at the site of the uterine fibroids, which makes it a promising approach for the control of post-embolization pain.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7573741,
-            "start": 554,
-            "end": 316891,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10513507': {'publication date': '1999 Jun', 'sentence': 'The WOMAC detected significant differences between ibuprofen and placebo for pain and physical functioning, whereas the SF-36 detected differences for the bodily pain subscale.', 'subject score': 1000, 'object score': 1000}, 'PMID:10550887': {'publication date': '1999', 'sentence': 'Racemic ibuprofen is an important NSAID used in the treatment of pain and inflammation in a variety of musculoskeletal and rheumatic disorders.', 'subject score': 861, 'object score': 1000}, 'PMID:10581086': {'publication date': '1999 Dec', 'sentence': 'Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, indomethacin and ibuprofen are the most widely used drugs for pain, arthritis, cardiovascular diseases and, more recently, the prevention of colon cancer and Alzheimer disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:10716611': {'publication date': '2000 Jan', 'sentence': 'We conclude that khat, like amphetamine and ibuprofen, can relieve pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:11021730': {'publication date': '2000 Oct', 'sentence': 'An open-label evaluation of the efficacy and safety of Stadol NS with ibuprofen in the treatment of pain after removal of impacted wisdom teeth.', 'subject score': 1000, 'object score': 1000}, 'PMID:11021732': {'publication date': '2000 Oct', 'sentence': 'Effectiveness of Stadol NS (butorphanol tartrate) with ibuprofen in the treatment of pain after laser-assisted uvulopalatopharyngoplasty.', 'subject score': 1000, 'object score': 1000}, 'PMID:11113797': {'publication date': '2000 Dec', 'sentence': 'An evaluation of preoperative ibuprofen for treatment of pain associated with orthodontic separator placement.', 'subject score': 888, 'object score': 1000}, 'PMID:11319581': {'publication date': '2000 Mar', 'sentence': 'Less clinical experience has accumulated with ibuprofen, and it remains the second-line treatment for fever and pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:11455373': {'publication date': '2001 Jul', 'sentence': 'In conclusion, these data indicate that ibuprofen taken 60 minutes before separator placement alleviates pain at 2 hours and at bedtime after treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:11554954': {'publication date': '2001 Jul-Aug', 'sentence': 'CONCLUSIONS: Ibuprofen at doses of 200 mg and 400 mg is an efficacious, cost-effective, well-tolerated, single-ingredient nonprescription treatment for pain of migraine headache.', 'subject score': 1000, 'object score': 1000}, 'PMID:11954880': {'publication date': '2002 Feb', 'sentence': 'The aim of this blinded, randomised, multicentre study was to compare the tolerability of aspirin, paracetamol and ibuprofen in common pain resulting from musculoskeletal conditions (MSC) in general practice with patients with other non-MSC pain conditions.', 'subject score': 1000, 'object score': 888}, 'PMID:14558184': {'publication date': '2003 Oct-Nov', 'sentence': 'Advantage was taken of data generated in the paracetamol, aspirin and ibuprofen new tolerability (PAIN) study, a large randomized double-blinded trial of paracetamol, aspirin or ibuprofen for common pain in general practice to attempt this.', 'subject score': 1000, 'object score': 888}, 'PMID:15196644': {'publication date': '2004 Jul 08', 'sentence': 'Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment.', 'subject score': 1000, 'object score': 888}, 'PMID:15219128': {'publication date': '2004 Mar 25', 'sentence': 'Mild-to-moderate pain in noninflammatory arthrosis can be ameliorated by paracetamol or low-dose ibuprofen.', 'subject score': 901, 'object score': 916}, 'PMID:15229960': {'publication date': '2004 Jul', 'sentence': 'CONCLUSION: Over-the-counter doses of naproxen sodium (440/660 mg) and ibuprofen (1200 mg) effectively relieve pain in patients with mild to moderate OA of the knee.', 'subject score': 1000, 'object score': 1000}, 'PMID:1565349': {'publication date': '1992 May', 'sentence': 'This study shows that pain during laser vaporization of the cervix is not due to increased uterine contractions, and that pain was not significantly relieved by ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:15970957': {'publication date': '2005 Jun', 'sentence': 'Context: Ibuprofen is widely used to manage pain and inflammation after orthopaedic trauma, but its effect on acute swelling has not been investigated.', 'subject score': 1000, 'object score': 1000}, 'PMID:16170062': {'publication date': '2005 Sep', 'sentence': 'This is a case report of a child who experienced a possible adverse reaction to paracetamol, in a randomized clinical trial comparing paracetamol with ibuprofen for control of orthodontic pain.', 'subject score': 1000, 'object score': 888}, 'PMID:16885182': {'publication date': '2006 Sep 09', 'sentence': 'Safety and efficacy of routine postoperative ibuprofen for pain and disability related to ectopic bone formation after hip replacement surgery (HIPAID): randomised controlled trial.', 'subject score': 802, 'object score': 1000}, 'PMID:17045356': {'publication date': '2006 Oct 27', 'sentence': 'Theoretically, IBU-BB could sustainably release high concentrations of IBU at the site of the uterine fibroids, which makes it a promising approach for the control of post-embolization pain.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "7732956",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:10513507",
-                "PMID:10550887",
-                "PMID:10581086",
-                "PMID:10716611",
-                "PMID:11021730",
-                "PMID:11021732",
-                "PMID:11113797",
-                "PMID:11319581",
-                "PMID:11455373",
-                "PMID:11554954",
-                "PMID:11954880",
-                "PMID:14558184",
-                "PMID:15196644",
-                "PMID:15219128",
-                "PMID:15229960",
-                "PMID:1565349",
-                "PMID:15970957",
-                "PMID:16170062",
-                "PMID:16885182",
-                "PMID:17045356"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:19624576': {'publication date': '2009 Aug', 'sentence': 'OBJECTIVES: This study compared the analgesic effectiveness of acetaminophen-codeine with that of ibuprofen for children with acute traumatic extremity pain, with the hypothesis that the two medications would demonstrate equivalent reduction in pain scores in an emergency department (ED) setting.', 'subject score': 1000, 'object score': 1000}, 'PMID:21195257': {'publication date': '2011 Jan', 'sentence': 'Administering ibuprofen before and after separator placement significantly reduced pain compared with the placebo.', 'subject score': 861, 'object score': 749}, 'PMID:27562219': {'publication date': '2017 01', 'sentence': 'RESULTS: Ibuprofen and dexamethasone significantly reduced pain (Kruskal-Wallis; P <0.05) up to 3 days after surgery and discomfort (P <0.05) up to 2 days after surgery compared with placebo treatment.', 'subject score': 1000, 'object score': 775}, 'PMID:27787269': {'publication date': '2016 Nov', 'sentence': 'Addition of ibuprofen and loratadine resulted in a total reduction in pain by 40%.', 'subject score': 1000, 'object score': 1000}, 'PMID:28178024': {'publication date': '2017 Feb', 'sentence': 'Two of these four studies were non-inferiority studies showed that the use of both curcuminoids and ibuprofen were associated with a similar significant reduction in pain over the study durations of four and six weeks, respectively, with curcuminoid use non-inferior to the use of ibuprofen over the study durations.', 'subject score': 1000, 'object score': 1000}, 'PMID:29935486': {'publication date': '2018 Nov', 'sentence': 'The use of intravenous ibuprofen was associated with reduction in pain at rest (AUC, 1- to 24-h, P?<?0.001 and 12- to 24-h, P?=?0.021) and pain with movement (AUC, 1-24, 6-24, and 12-24?h, P?<?0.001).', 'subject score': 888, 'object score': 1000}, 'PMID:30166905': {'publication date': '2017 Dec', 'sentence': 'Conclusion: The patients prescribed ibuprofen did not report any problem with tooth movement along with significant reduction in pain as compared to paracetamol.', 'subject score': 1000, 'object score': 1000}, 'PMID:30737050': {'publication date': '2019 Apr', 'sentence': 'Additional analysis based on the chemical name showed that sulindac, ketorolac, and ibuprofen significantly reduced pain at 6 hours, whereas piroxicam and prednisolone significantly reduced the pain at 12 and 24 hours.', 'subject score': 775, 'object score': 775}, 'PMID:32254988': {'publication date': '2018 Sep 28', 'sentence': 'However, both the composite and the physical mixture were more effective than equivalent doses of ibuprofen in pain suppression in rats.', 'subject score': 1000, 'object score': 888}, 'PMID:35343341': {'publication date': '2022 Mar 28', 'sentence': 'The conventional dosage forms (tablets, capsules), of ibuprofen has less potential in suppression of pain and inflammation due to their slow dissolution rates and lower bioavailability.', 'subject score': 1000, 'object score': 1000}, 'PMID:778987': {'publication date': '1976 May', 'sentence': 'Sulindac showed superior analgesic properties to ibuprofen, resulting in a significantly greater reduction in pain on weight-bearing and with passive movements (P less than 0.01).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14184560,
-            "start": 554,
-            "end": 316891,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19624576': {'publication date': '2009 Aug', 'sentence': 'OBJECTIVES: This study compared the analgesic effectiveness of acetaminophen-codeine with that of ibuprofen for children with acute traumatic extremity pain, with the hypothesis that the two medications would demonstrate equivalent reduction in pain scores in an emergency department (ED) setting.', 'subject score': 1000, 'object score': 1000}, 'PMID:21195257': {'publication date': '2011 Jan', 'sentence': 'Administering ibuprofen before and after separator placement significantly reduced pain compared with the placebo.', 'subject score': 861, 'object score': 749}, 'PMID:27562219': {'publication date': '2017 01', 'sentence': 'RESULTS: Ibuprofen and dexamethasone significantly reduced pain (Kruskal-Wallis; P <0.05) up to 3 days after surgery and discomfort (P <0.05) up to 2 days after surgery compared with placebo treatment.', 'subject score': 1000, 'object score': 775}, 'PMID:27787269': {'publication date': '2016 Nov', 'sentence': 'Addition of ibuprofen and loratadine resulted in a total reduction in pain by 40%.', 'subject score': 1000, 'object score': 1000}, 'PMID:28178024': {'publication date': '2017 Feb', 'sentence': 'Two of these four studies were non-inferiority studies showed that the use of both curcuminoids and ibuprofen were associated with a similar significant reduction in pain over the study durations of four and six weeks, respectively, with curcuminoid use non-inferior to the use of ibuprofen over the study durations.', 'subject score': 1000, 'object score': 1000}, 'PMID:29935486': {'publication date': '2018 Nov', 'sentence': 'The use of intravenous ibuprofen was associated with reduction in pain at rest (AUC, 1- to 24-h, P?<?0.001 and 12- to 24-h, P?=?0.021) and pain with movement (AUC, 1-24, 6-24, and 12-24?h, P?<?0.001).', 'subject score': 888, 'object score': 1000}, 'PMID:30166905': {'publication date': '2017 Dec', 'sentence': 'Conclusion: The patients prescribed ibuprofen did not report any problem with tooth movement along with significant reduction in pain as compared to paracetamol.', 'subject score': 1000, 'object score': 1000}, 'PMID:30737050': {'publication date': '2019 Apr', 'sentence': 'Additional analysis based on the chemical name showed that sulindac, ketorolac, and ibuprofen significantly reduced pain at 6 hours, whereas piroxicam and prednisolone significantly reduced the pain at 12 and 24 hours.', 'subject score': 775, 'object score': 775}, 'PMID:32254988': {'publication date': '2018 Sep 28', 'sentence': 'However, both the composite and the physical mixture were more effective than equivalent doses of ibuprofen in pain suppression in rats.', 'subject score': 1000, 'object score': 888}, 'PMID:35343341': {'publication date': '2022 Mar 28', 'sentence': 'The conventional dosage forms (tablets, capsules), of ibuprofen has less potential in suppression of pain and inflammation due to their slow dissolution rates and lower bioavailability.', 'subject score': 1000, 'object score': 1000}, 'PMID:778987': {'publication date': '1976 May', 'sentence': 'Sulindac showed superior analgesic properties to ibuprofen, resulting in a significantly greater reduction in pain on weight-bearing and with passive movements (P less than 0.01).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:disrupts---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "14486259",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:19624576",
-                "PMID:21195257",
-                "PMID:27562219",
-                "PMID:27787269",
-                "PMID:28178024",
-                "PMID:29935486",
-                "PMID:30166905",
-                "PMID:30737050",
-                "PMID:32254988",
-                "PMID:35343341",
-                "PMID:778987"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:11471639': {'publication date': '2000 Dec', 'sentence': 'To determine if prophylactic etodolac would significantly reduce postendodontic pain, when compared with ibuprofen or placebo, 36 patients consented to single blind oral administration of either 400 mg of etodolac, 600 mg of ibuprofen, or a placebo, before conventional one-appointment root canal therapy.', 'subject score': 1000, 'object score': 861}, 'PMID:12216965': {'publication date': '2002 Aug', 'sentence': \"Patient's Assessment of Ankle Pain Visual Analog Scale on Weight Bearing responses, also given on days 4 and 8, showed that celecoxib was as efficacious in the treatment of ankle sprain as the maximum therapeutic dosage of ibuprofen and that, compared with placebo, it reduced pain significantly more (P < .05).\", 'subject score': 1000, 'object score': 827}, 'PMID:12540224': {'publication date': '2003 Jan', 'sentence': 'The purpose of this study was to determine if prophylactic rofecoxib would significantly reduce postendodontic pain, when compared with ibuprofen or placebo.', 'subject score': 1000, 'object score': 861}, 'PMID:16531187': {'publication date': '2006 Apr', 'sentence': 'CONCLUSIONS: Our results mirror other controlled studies that compared ibuprofen and omega-3 EFAs demonstrating equivalent effect in reducing arthritic pain. omega-3 EFA fish oil supplements appear to be a safer alternative to NSAIDs for treatment of nonsurgical neck or back pain in this selective group.', 'subject score': 861, 'object score': 568}, 'PMID:16808800': {'publication date': '2006 May-Jun', 'sentence': 'Biatain-Ibu Non-adhesive (Coloplast A/S), a new pain-reducing moist wound healing dressing containing ibuprofen was tested for pain reduction, safety, and efficacy on 10+2 patients in a single-blinded crossover study against Biatain Non-adhesive (Coloplast A/S).', 'subject score': 888, 'object score': 694}, 'PMID:16998619': {'publication date': '2006 Sep', 'sentence': 'Ibuprofen was significantly better at reducing pain at all time intervals by comparison with the placebo.', 'subject score': 1000, 'object score': 872}, 'PMID:17074548': {'publication date': '2006 Nov', 'sentence': 'Prophylactic ibuprofen as used in this protocol does not reduce IUD insertion pain.', 'subject score': 888, 'object score': 861}, 'PMID:18082668': {'publication date': '2008 Jan', 'sentence': 'Ibuprofen is somewhat more effective than tramadol at reducing pain 30 min following surgical abortion.', 'subject score': 1000, 'object score': 852}, 'PMID:18359021': {'publication date': '2009 May', 'sentence': 'CONCLUSION(S): Ibuprofen was found to be more effective than paracetamol for pain reduction during medical abortion.', 'subject score': 1000, 'object score': 694}, 'PMID:18663736': {'publication date': '2008 Aug', 'sentence': 'We conclude that ibuprofen is effective in reducing EMG pain as perceived immediately after the procedure.', 'subject score': 1000, 'object score': 840}, 'PMID:19055080': {'publication date': '2008 Nov 12-18', 'sentence': 'It combines the benefits of moist wound healing with a continuous release of ibuprofen into the wound and surrounding skin that is designed to reduce pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:19126235': {'publication date': '2009 Jan 06', 'sentence': 'Clinical studies have shown that naproxen and ibuprofen are significantly more effective at reducing OA pain than is acetaminophen, the traditional first-line therapy, which has no apparent anti-inflammatory activity in the joints.', 'subject score': 1000, 'object score': 840}, 'PMID:19367683': {'publication date': '2009 May 05', 'sentence': 'Ibuprofen loaded embolization beads (IBU-BB) have been developed to reduce inflammation and pain following uterine artery embolization for the treatment of uterine fibroids.', 'subject score': 1000, 'object score': 1000}, 'PMID:20609131': {'publication date': '2010 Aug', 'sentence': 'CONCLUSION: Pre- and post-operative administration of IV-ibuprofen significantly reduced both pain and morphine use in orthopedic surgery patients in this prospective randomized placebo-controlled trial.', 'subject score': 888, 'object score': 1000}, 'PMID:21237336': {'publication date': '2011 Feb', 'sentence': \"Four studies conducted in women with pregnancies <8 completed weeks' gestation found that prophylactic acetaminophen, acetaminophen+codeine, ibuprofen or alverine did not reduce medical abortion pain; however, administration of ibuprofen after onset of cramping reduced pain and subsequent analgesia use.\", 'subject score': 1000, 'object score': 901}, 'PMID:21712619': {'publication date': '2011 Jun', 'sentence': 'The purpose of this study was to evaluate clinically the effectiveness of prophylactic tenoxicam and prophylactic ibuprofen in reducing post-endodontic pain compared with placebo.', 'subject score': 888, 'object score': 825}, 'PMID:21762775': {'publication date': '2011 Dec', 'sentence': 'Intra-articular drug delivery systems (DDSs) are envisaged as interesting alternative to locally release nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen to reduce pain in patients with osteoarthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:22176793': {'publication date': '2012 Jun', 'sentence': 'CONCLUSION: Administration of ibuprofen prophylaxis for LNG-IUS insertion does not decrease pain at the time of insertion.', 'subject score': 888, 'object score': 1000}, 'PMID:22284284': {'publication date': '2012 Feb', 'sentence': 'INTRODUCTION: The aim of this study was to compare the efficacy of ibuprofen, viscoelastic bite wafers, and chewing gum in reducing orthodontic pain.', 'subject score': 1000, 'object score': 840}, 'PMID:22521671': {'publication date': '2012 Aug', 'sentence': 'The preoperative intake of ibuprofen does not seem to reduce pain, facial swelling and trismus after impacted lower third molar removal when compared to the postoperative administration of the same drug.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8829373,
-            "start": 554,
-            "end": 316891,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11471639': {'publication date': '2000 Dec', 'sentence': 'To determine if prophylactic etodolac would significantly reduce postendodontic pain, when compared with ibuprofen or placebo, 36 patients consented to single blind oral administration of either 400 mg of etodolac, 600 mg of ibuprofen, or a placebo, before conventional one-appointment root canal therapy.', 'subject score': 1000, 'object score': 861}, 'PMID:12216965': {'publication date': '2002 Aug', 'sentence': \"Patient's Assessment of Ankle Pain Visual Analog Scale on Weight Bearing responses, also given on days 4 and 8, showed that celecoxib was as efficacious in the treatment of ankle sprain as the maximum therapeutic dosage of ibuprofen and that, compared with placebo, it reduced pain significantly more (P < .05).\", 'subject score': 1000, 'object score': 827}, 'PMID:12540224': {'publication date': '2003 Jan', 'sentence': 'The purpose of this study was to determine if prophylactic rofecoxib would significantly reduce postendodontic pain, when compared with ibuprofen or placebo.', 'subject score': 1000, 'object score': 861}, 'PMID:16531187': {'publication date': '2006 Apr', 'sentence': 'CONCLUSIONS: Our results mirror other controlled studies that compared ibuprofen and omega-3 EFAs demonstrating equivalent effect in reducing arthritic pain. omega-3 EFA fish oil supplements appear to be a safer alternative to NSAIDs for treatment of nonsurgical neck or back pain in this selective group.', 'subject score': 861, 'object score': 568}, 'PMID:16808800': {'publication date': '2006 May-Jun', 'sentence': 'Biatain-Ibu Non-adhesive (Coloplast A/S), a new pain-reducing moist wound healing dressing containing ibuprofen was tested for pain reduction, safety, and efficacy on 10+2 patients in a single-blinded crossover study against Biatain Non-adhesive (Coloplast A/S).', 'subject score': 888, 'object score': 694}, 'PMID:16998619': {'publication date': '2006 Sep', 'sentence': 'Ibuprofen was significantly better at reducing pain at all time intervals by comparison with the placebo.', 'subject score': 1000, 'object score': 872}, 'PMID:17074548': {'publication date': '2006 Nov', 'sentence': 'Prophylactic ibuprofen as used in this protocol does not reduce IUD insertion pain.', 'subject score': 888, 'object score': 861}, 'PMID:18082668': {'publication date': '2008 Jan', 'sentence': 'Ibuprofen is somewhat more effective than tramadol at reducing pain 30 min following surgical abortion.', 'subject score': 1000, 'object score': 852}, 'PMID:18359021': {'publication date': '2009 May', 'sentence': 'CONCLUSION(S): Ibuprofen was found to be more effective than paracetamol for pain reduction during medical abortion.', 'subject score': 1000, 'object score': 694}, 'PMID:18663736': {'publication date': '2008 Aug', 'sentence': 'We conclude that ibuprofen is effective in reducing EMG pain as perceived immediately after the procedure.', 'subject score': 1000, 'object score': 840}, 'PMID:19055080': {'publication date': '2008 Nov 12-18', 'sentence': 'It combines the benefits of moist wound healing with a continuous release of ibuprofen into the wound and surrounding skin that is designed to reduce pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:19126235': {'publication date': '2009 Jan 06', 'sentence': 'Clinical studies have shown that naproxen and ibuprofen are significantly more effective at reducing OA pain than is acetaminophen, the traditional first-line therapy, which has no apparent anti-inflammatory activity in the joints.', 'subject score': 1000, 'object score': 840}, 'PMID:19367683': {'publication date': '2009 May 05', 'sentence': 'Ibuprofen loaded embolization beads (IBU-BB) have been developed to reduce inflammation and pain following uterine artery embolization for the treatment of uterine fibroids.', 'subject score': 1000, 'object score': 1000}, 'PMID:20609131': {'publication date': '2010 Aug', 'sentence': 'CONCLUSION: Pre- and post-operative administration of IV-ibuprofen significantly reduced both pain and morphine use in orthopedic surgery patients in this prospective randomized placebo-controlled trial.', 'subject score': 888, 'object score': 1000}, 'PMID:21237336': {'publication date': '2011 Feb', 'sentence': \"Four studies conducted in women with pregnancies <8 completed weeks' gestation found that prophylactic acetaminophen, acetaminophen+codeine, ibuprofen or alverine did not reduce medical abortion pain; however, administration of ibuprofen after onset of cramping reduced pain and subsequent analgesia use.\", 'subject score': 1000, 'object score': 901}, 'PMID:21712619': {'publication date': '2011 Jun', 'sentence': 'The purpose of this study was to evaluate clinically the effectiveness of prophylactic tenoxicam and prophylactic ibuprofen in reducing post-endodontic pain compared with placebo.', 'subject score': 888, 'object score': 825}, 'PMID:21762775': {'publication date': '2011 Dec', 'sentence': 'Intra-articular drug delivery systems (DDSs) are envisaged as interesting alternative to locally release nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen to reduce pain in patients with osteoarthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:22176793': {'publication date': '2012 Jun', 'sentence': 'CONCLUSION: Administration of ibuprofen prophylaxis for LNG-IUS insertion does not decrease pain at the time of insertion.', 'subject score': 888, 'object score': 1000}, 'PMID:22284284': {'publication date': '2012 Feb', 'sentence': 'INTRODUCTION: The aim of this study was to compare the efficacy of ibuprofen, viscoelastic bite wafers, and chewing gum in reducing orthodontic pain.', 'subject score': 1000, 'object score': 840}, 'PMID:22521671': {'publication date': '2012 Aug', 'sentence': 'The preoperative intake of ibuprofen does not seem to reduce pain, facial swelling and trismus after impacted lower third molar removal when compared to the postoperative administration of the same drug.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9022792",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:11471639",
-                "PMID:12216965",
-                "PMID:12540224",
-                "PMID:16531187",
-                "PMID:16808800",
-                "PMID:16998619",
-                "PMID:17074548",
-                "PMID:18082668",
-                "PMID:18359021",
-                "PMID:18663736",
-                "PMID:19055080",
-                "PMID:19126235",
-                "PMID:19367683",
-                "PMID:20609131",
-                "PMID:21237336",
-                "PMID:21712619",
-                "PMID:21762775",
-                "PMID:22176793",
-                "PMID:22284284",
-                "PMID:22521671"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:12580656': {'publication date': '2003 Feb', 'sentence': 'The purpose of this study was to examine the effects of ibuprofen on delayed onset muscle soreness (DOMS), indirect markers of muscle damage and muscular performance.', 'subject score': 1000, 'object score': 861}, 'PMID:2078806': {'publication date': '1990 Sep', 'sentence': 'Effects of ibuprofen on exercise-induced muscle soreness and indices of muscle damage.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 321150,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0003326",
-          "name": "Myalgia",
-          "description": "Painful sensation originating from a muscle or group of muscles.; Painful sensation in the muscles.; Pain in muscle. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "UMLS:C0231528",
-            "SYMP:0000332",
-            "HP:0003326",
-            "NCIT:C27009",
-            "MEDDRA:10018089",
-            "MEDDRA:10028361",
-            "MEDDRA:10028411",
-            "MEDDRA:10062441",
-            "MEDDRA:10028287",
-            "NCIT:C35785",
-            "MEDDRA:10028299",
-            "MEDDRA:10028362",
-            "MEDDRA:10033466",
-            "MESH:D063806",
-            "SNOMEDCT:68962001",
-            "MEDDRA:10028322",
-            "MEDDRA:10028332",
-            "MEDDRA:10028323"
-          ],
-          "id": "HP:0003326",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "muscle soreness",
-            "Myalgia",
-            "Muscle Soreness"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321150,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0003326",
-              "name": "Myalgia",
-              "description": "Painful sensation originating from a muscle or group of muscles.; Painful sensation in the muscles.; Pain in muscle. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "UMLS:C0231528",
-                "SYMP:0000332",
-                "HP:0003326",
-                "NCIT:C27009",
-                "MEDDRA:10018089",
-                "MEDDRA:10028361",
-                "MEDDRA:10028411",
-                "MEDDRA:10062441",
-                "MEDDRA:10028287",
-                "NCIT:C35785",
-                "MEDDRA:10028299",
-                "MEDDRA:10028362",
-                "MEDDRA:10033466",
-                "MESH:D063806",
-                "SNOMEDCT:68962001",
-                "MEDDRA:10028322",
-                "MEDDRA:10028332",
-                "MEDDRA:10028323"
-              ],
-              "id": "HP:0003326",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "muscle soreness",
-                "Myalgia",
-                "Muscle Soreness"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9809172,
-            "start": 554,
-            "end": 321150,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12580656': {'publication date': '2003 Feb', 'sentence': 'The purpose of this study was to examine the effects of ibuprofen on delayed onset muscle soreness (DOMS), indirect markers of muscle damage and muscular performance.', 'subject score': 1000, 'object score': 861}, 'PMID:2078806': {'publication date': '1990 Sep', 'sentence': 'Effects of ibuprofen on exercise-induced muscle soreness and indices of muscle damage.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0231528---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "10026104",
-              "object": "HP:0003326",
-              "publications": [
-                "PMID:12580656",
-                "PMID:2078806"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12466693': {'publication date': '2002 Nov', 'sentence': 'Preliminary comparison of bromelain and Ibuprofen for delayed onset muscle soreness management.', 'subject score': 1000, 'object score': 840}, 'PMID:19952809': {'publication date': '2010 Mar', 'sentence': 'CONCLUSION: The results of this study suggest that the topical application of ibuprofen is not an effective treatment for muscle soreness after an unaccustomed gym exercise.', 'subject score': 1000, 'object score': 1000}, 'PMID:2078806': {'publication date': '1990 Sep', 'sentence': 'These results indicate that ibuprofen is not an appropriate treatment for delayed onset muscle soreness and damage.', 'subject score': 1000, 'object score': 861}, 'PMID:29082820': {'publication date': '2018 Jan', 'sentence': 'OBJECTIVE: Ibuprofen is a commonly used non-steroidal anti-inflammatory drug administered to treat injuries, joint pain, and recurrent muscular skeletal pain.', 'subject score': 1000, 'object score': 861}, 'PMID:8898521': {'publication date': '1996 Jun', 'sentence': 'RESULTS: Early muscle pain was treated with Ibuprofen.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 321150,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0003326",
-          "name": "Myalgia",
-          "description": "Painful sensation originating from a muscle or group of muscles.; Painful sensation in the muscles.; Pain in muscle. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "UMLS:C0231528",
-            "SYMP:0000332",
-            "HP:0003326",
-            "NCIT:C27009",
-            "MEDDRA:10018089",
-            "MEDDRA:10028361",
-            "MEDDRA:10028411",
-            "MEDDRA:10062441",
-            "MEDDRA:10028287",
-            "NCIT:C35785",
-            "MEDDRA:10028299",
-            "MEDDRA:10028362",
-            "MEDDRA:10033466",
-            "MESH:D063806",
-            "SNOMEDCT:68962001",
-            "MEDDRA:10028322",
-            "MEDDRA:10028332",
-            "MEDDRA:10028323"
-          ],
-          "id": "HP:0003326",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "muscle soreness",
-            "Myalgia",
-            "Muscle Soreness"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321150,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0003326",
-              "name": "Myalgia",
-              "description": "Painful sensation originating from a muscle or group of muscles.; Painful sensation in the muscles.; Pain in muscle. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "UMLS:C0231528",
-                "SYMP:0000332",
-                "HP:0003326",
-                "NCIT:C27009",
-                "MEDDRA:10018089",
-                "MEDDRA:10028361",
-                "MEDDRA:10028411",
-                "MEDDRA:10062441",
-                "MEDDRA:10028287",
-                "NCIT:C35785",
-                "MEDDRA:10028299",
-                "MEDDRA:10028362",
-                "MEDDRA:10033466",
-                "MESH:D063806",
-                "SNOMEDCT:68962001",
-                "MEDDRA:10028322",
-                "MEDDRA:10028332",
-                "MEDDRA:10028323"
-              ],
-              "id": "HP:0003326",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "muscle soreness",
-                "Myalgia",
-                "Muscle Soreness"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9699032,
-            "start": 554,
-            "end": 321150,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12466693': {'publication date': '2002 Nov', 'sentence': 'Preliminary comparison of bromelain and Ibuprofen for delayed onset muscle soreness management.', 'subject score': 1000, 'object score': 840}, 'PMID:19952809': {'publication date': '2010 Mar', 'sentence': 'CONCLUSION: The results of this study suggest that the topical application of ibuprofen is not an effective treatment for muscle soreness after an unaccustomed gym exercise.', 'subject score': 1000, 'object score': 1000}, 'PMID:2078806': {'publication date': '1990 Sep', 'sentence': 'These results indicate that ibuprofen is not an appropriate treatment for delayed onset muscle soreness and damage.', 'subject score': 1000, 'object score': 861}, 'PMID:29082820': {'publication date': '2018 Jan', 'sentence': 'OBJECTIVE: Ibuprofen is a commonly used non-steroidal anti-inflammatory drug administered to treat injuries, joint pain, and recurrent muscular skeletal pain.', 'subject score': 1000, 'object score': 861}, 'PMID:8898521': {'publication date': '1996 Jun', 'sentence': 'RESULTS: Early muscle pain was treated with Ibuprofen.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0231528---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "9913360",
-              "object": "HP:0003326",
-              "publications": [
-                "PMID:12466693",
-                "PMID:19952809",
-                "PMID:2078806",
-                "PMID:29082820",
-                "PMID:8898521"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:34064282': {'publication date': '2021 May 21', 'sentence': 'On the other hand, in subgroup B, no improvement in flexibility or reduction in muscle soreness was found in patients who took ibuprofen.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321150,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0003326",
-          "name": "Myalgia",
-          "description": "Painful sensation originating from a muscle or group of muscles.; Painful sensation in the muscles.; Pain in muscle. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "UMLS:C0231528",
-            "SYMP:0000332",
-            "HP:0003326",
-            "NCIT:C27009",
-            "MEDDRA:10018089",
-            "MEDDRA:10028361",
-            "MEDDRA:10028411",
-            "MEDDRA:10062441",
-            "MEDDRA:10028287",
-            "NCIT:C35785",
-            "MEDDRA:10028299",
-            "MEDDRA:10028362",
-            "MEDDRA:10033466",
-            "MESH:D063806",
-            "SNOMEDCT:68962001",
-            "MEDDRA:10028322",
-            "MEDDRA:10028332",
-            "MEDDRA:10028323"
-          ],
-          "id": "HP:0003326",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "muscle soreness",
-            "Myalgia",
-            "Muscle Soreness"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321150,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0003326",
-              "name": "Myalgia",
-              "description": "Painful sensation originating from a muscle or group of muscles.; Painful sensation in the muscles.; Pain in muscle. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "UMLS:C0231528",
-                "SYMP:0000332",
-                "HP:0003326",
-                "NCIT:C27009",
-                "MEDDRA:10018089",
-                "MEDDRA:10028361",
-                "MEDDRA:10028411",
-                "MEDDRA:10062441",
-                "MEDDRA:10028287",
-                "NCIT:C35785",
-                "MEDDRA:10028299",
-                "MEDDRA:10028362",
-                "MEDDRA:10033466",
-                "MESH:D063806",
-                "SNOMEDCT:68962001",
-                "MEDDRA:10028322",
-                "MEDDRA:10028332",
-                "MEDDRA:10028323"
-              ],
-              "id": "HP:0003326",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "muscle soreness",
-                "Myalgia",
-                "Muscle Soreness"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22965644,
-            "start": 554,
-            "end": 321150,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34064282': {'publication date': '2021 May 21', 'sentence': 'On the other hand, in subgroup B, no improvement in flexibility or reduction in muscle soreness was found in patients who took ibuprofen.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:disrupts---None---None---None---UMLS:C0231528---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "23399675",
-              "object": "HP:0003326",
-              "publications": [
-                "PMID:34064282"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:12580656': {'publication date': '2003 Feb', 'sentence': 'The results of this study reveal that intake of ibuprofen can decrease muscle soreness induced after eccentric exercise but cannot assist in restoring muscle function.', 'subject score': 1000, 'object score': 1000}, 'PMID:15880305': {'publication date': '2005 May', 'sentence': 'Systemic side effects of interferons like myalgias can be reduced by paracetamol or ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:16195036': {'publication date': '2005 Aug', 'sentence': 'Our results indicate that physical activity with or without ibuprofen helps to prevent delayed-onset muscle soreness.', 'subject score': 1000, 'object score': 861}, 'PMID:18336059': {'publication date': '2008', 'sentence': \"Systemic (particularly 'flu-like') adverse effects of interferons, e.g. myalgias, can be reduced by administering paracetamol, ibuprofen or naproxen.\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321150,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0003326",
-          "name": "Myalgia",
-          "description": "Painful sensation originating from a muscle or group of muscles.; Painful sensation in the muscles.; Pain in muscle. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "UMLS:C0231528",
-            "SYMP:0000332",
-            "HP:0003326",
-            "NCIT:C27009",
-            "MEDDRA:10018089",
-            "MEDDRA:10028361",
-            "MEDDRA:10028411",
-            "MEDDRA:10062441",
-            "MEDDRA:10028287",
-            "NCIT:C35785",
-            "MEDDRA:10028299",
-            "MEDDRA:10028362",
-            "MEDDRA:10033466",
-            "MESH:D063806",
-            "SNOMEDCT:68962001",
-            "MEDDRA:10028322",
-            "MEDDRA:10028332",
-            "MEDDRA:10028323"
-          ],
-          "id": "HP:0003326",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "muscle soreness",
-            "Myalgia",
-            "Muscle Soreness"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321150,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0003326",
-              "name": "Myalgia",
-              "description": "Painful sensation originating from a muscle or group of muscles.; Painful sensation in the muscles.; Pain in muscle. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "UMLS:C0231528",
-                "SYMP:0000332",
-                "HP:0003326",
-                "NCIT:C27009",
-                "MEDDRA:10018089",
-                "MEDDRA:10028361",
-                "MEDDRA:10028411",
-                "MEDDRA:10062441",
-                "MEDDRA:10028287",
-                "NCIT:C35785",
-                "MEDDRA:10028299",
-                "MEDDRA:10028362",
-                "MEDDRA:10033466",
-                "MESH:D063806",
-                "SNOMEDCT:68962001",
-                "MEDDRA:10028322",
-                "MEDDRA:10028332",
-                "MEDDRA:10028323"
-              ],
-              "id": "HP:0003326",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "muscle soreness",
-                "Myalgia",
-                "Muscle Soreness"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9809173,
-            "start": 554,
-            "end": 321150,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12580656': {'publication date': '2003 Feb', 'sentence': 'The results of this study reveal that intake of ibuprofen can decrease muscle soreness induced after eccentric exercise but cannot assist in restoring muscle function.', 'subject score': 1000, 'object score': 1000}, 'PMID:15880305': {'publication date': '2005 May', 'sentence': 'Systemic side effects of interferons like myalgias can be reduced by paracetamol or ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:16195036': {'publication date': '2005 Aug', 'sentence': 'Our results indicate that physical activity with or without ibuprofen helps to prevent delayed-onset muscle soreness.', 'subject score': 1000, 'object score': 861}, 'PMID:18336059': {'publication date': '2008', 'sentence': \"Systemic (particularly 'flu-like') adverse effects of interferons, e.g. myalgias, can be reduced by administering paracetamol, ibuprofen or naproxen.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0231528---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "10026105",
-              "object": "HP:0003326",
-              "publications": [
-                "PMID:12580656",
-                "PMID:15880305",
-                "PMID:16195036",
-                "PMID:18336059"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:16889286': {'publication date': '2006', 'sentence': \"Ibuprofen-induced fever in Sjogren's syndrome.\", 'subject score': 851, 'object score': 851}, 'PMID:3867760': {'publication date': '1985 Dec', 'sentence': 'Ibuprofen prevents Pasteurella hemolytica endotoxin-induced changes in plasma prostanoids and serotonin, and fever in sheep.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 212250,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-          "name": "Fever",
-          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10037660",
-            "MEDDRA:10020083",
-            "MEDDRA:10005911",
-            "UMLS:C0015967",
-            "HP:0001945",
-            "NCIT:C3038",
-            "MEDDRA:10073718",
-            "MEDDRA:10043204",
-            "MEDDRA:10037668",
-            "PDQ:CDR0000775882",
-            "PSY:19660",
-            "SNOMEDCT:386661006",
-            "MEDDRA:10016558",
-            "MEDDRA:10037663",
-            "SNOMEDCT:50177009",
-            "SYMP:0000613",
-            "MESH:D005334"
-          ],
-          "id": "HP:0001945",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "fever",
-            "Fever"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:9759682",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 212250,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-              "name": "Fever",
-              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10037660",
-                "MEDDRA:10020083",
-                "MEDDRA:10005911",
-                "UMLS:C0015967",
-                "HP:0001945",
-                "NCIT:C3038",
-                "MEDDRA:10073718",
-                "MEDDRA:10043204",
-                "MEDDRA:10037668",
-                "PDQ:CDR0000775882",
-                "PSY:19660",
-                "SNOMEDCT:386661006",
-                "MEDDRA:10016558",
-                "MEDDRA:10037663",
-                "SNOMEDCT:50177009",
-                "SYMP:0000613",
-                "MESH:D005334"
-              ],
-              "id": "HP:0001945",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "fever",
-                "Fever"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:9759682",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12373192,
-            "start": 554,
-            "end": 212250,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:16889286': {'publication date': '2006', 'sentence': \"Ibuprofen-induced fever in Sjogren's syndrome.\", 'subject score': 851, 'object score': 851}, 'PMID:3867760': {'publication date': '1985 Dec', 'sentence': 'Ibuprofen prevents Pasteurella hemolytica endotoxin-induced changes in plasma prostanoids and serotonin, and fever in sheep.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:causes---None---None---None---UMLS:C0015967---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "12641386",
-              "object": "HP:0001945",
-              "publications": [
-                "PMID:16889286",
-                "PMID:3867760"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:16911816': {'publication date': '2006 Oct', 'sentence': 'Subdiaphragmatic vagotomy or 7-nitroindazole reduced, icatibant, DALBK, IL-1ra, aminoguanidine and dipyrone abolished, while ibuprofen and celecoxib failed to affect Tsv-induced fever.', 'subject score': 1000, 'object score': 840}, 'PMID:18503714': {'publication date': '2008 May 26', 'sentence': 'In order to assess the effect of ibuprofen on fever compared to placebo in children with uncomplicated Plasmodium falciparum malaria in Gabon, a randomized double blind placebo controlled trial, was designed.', 'subject score': 1000, 'object score': 1000}, 'PMID:21077948': {'publication date': '2011 Dec', 'sentence': 'Neither ibuprofen nor indomethacin affected fever by PGE2 , PGF(2alpha) , or corticotrophin-releasing factor (CRF); however, both reduced the CSF PGE2 content after LPS.', 'subject score': 1000, 'object score': 1000}, 'PMID:6358043': {'publication date': '1983 Dec', 'sentence': 'Effect of ibuprofen on fever and metabolic changes induced by continuous infusion of leukocytic pyrogen (interleukin 1) or endotoxin.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 212250,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-          "name": "Fever",
-          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10037660",
-            "MEDDRA:10020083",
-            "MEDDRA:10005911",
-            "UMLS:C0015967",
-            "HP:0001945",
-            "NCIT:C3038",
-            "MEDDRA:10073718",
-            "MEDDRA:10043204",
-            "MEDDRA:10037668",
-            "PDQ:CDR0000775882",
-            "PSY:19660",
-            "SNOMEDCT:386661006",
-            "MEDDRA:10016558",
-            "MEDDRA:10037663",
-            "SNOMEDCT:50177009",
-            "SYMP:0000613",
-            "MESH:D005334"
-          ],
-          "id": "HP:0001945",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "fever",
-            "Fever"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:9759682",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 212250,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-              "name": "Fever",
-              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10037660",
-                "MEDDRA:10020083",
-                "MEDDRA:10005911",
-                "UMLS:C0015967",
-                "HP:0001945",
-                "NCIT:C3038",
-                "MEDDRA:10073718",
-                "MEDDRA:10043204",
-                "MEDDRA:10037668",
-                "PDQ:CDR0000775882",
-                "PSY:19660",
-                "SNOMEDCT:386661006",
-                "MEDDRA:10016558",
-                "MEDDRA:10037663",
-                "SNOMEDCT:50177009",
-                "SYMP:0000613",
-                "MESH:D005334"
-              ],
-              "id": "HP:0001945",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "fever",
-                "Fever"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:9759682",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12390575,
-            "start": 554,
-            "end": 212250,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16911816': {'publication date': '2006 Oct', 'sentence': 'Subdiaphragmatic vagotomy or 7-nitroindazole reduced, icatibant, DALBK, IL-1ra, aminoguanidine and dipyrone abolished, while ibuprofen and celecoxib failed to affect Tsv-induced fever.', 'subject score': 1000, 'object score': 840}, 'PMID:18503714': {'publication date': '2008 May 26', 'sentence': 'In order to assess the effect of ibuprofen on fever compared to placebo in children with uncomplicated Plasmodium falciparum malaria in Gabon, a randomized double blind placebo controlled trial, was designed.', 'subject score': 1000, 'object score': 1000}, 'PMID:21077948': {'publication date': '2011 Dec', 'sentence': 'Neither ibuprofen nor indomethacin affected fever by PGE2 , PGF(2alpha) , or corticotrophin-releasing factor (CRF); however, both reduced the CSF PGE2 content after LPS.', 'subject score': 1000, 'object score': 1000}, 'PMID:6358043': {'publication date': '1983 Dec', 'sentence': 'Effect of ibuprofen on fever and metabolic changes induced by continuous infusion of leukocytic pyrogen (interleukin 1) or endotoxin.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:affects---None---None---None---UMLS:C0015967---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "12659717",
-              "object": "HP:0001945",
-              "publications": [
-                "PMID:16911816",
-                "PMID:18503714",
-                "PMID:21077948",
-                "PMID:6358043"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:10974335': {'publication date': '2000 Sep', 'sentence': 'Pretreatment with ibuprofen blocked the fever induced by RANTES.', 'subject score': 1000, 'object score': 1000}, 'PMID:11735667': {'publication date': '2001', 'sentence': 'Ibuprofen, acetylsalicylic acid (ASA) and acetaminophen are the most frequently used agents for fever reduction in children.', 'subject score': 1000, 'object score': 694}, 'PMID:1518683': {'publication date': '1992', 'sentence': 'As antipyretics, both acetaminophen and ibuprofen are effective in fever reduction by inhibiting prostaglandin synthesis.', 'subject score': 1000, 'object score': 694}, 'PMID:15688484': {'publication date': '2005 Jan', 'sentence': 'Review: no evidence exists that paracetamol and ibuprofen differ for short term pain relief or safety in children, but ibuprofen more effectively reduces fever.', 'subject score': 861, 'object score': 1000}, 'PMID:16464962': {'publication date': '2006 May', 'sentence': 'A randomised open label study of the combined use of paracetamol and ibuprofen to rapidly reduce fever is reported.', 'subject score': 1000, 'object score': 1000}, 'PMID:16836983': {'publication date': '2006 Sep 13', 'sentence': 'Indomethacin only blocked the PGE2 increase in the CSF whereas ibuprofen and celecoxib each blocked the fever and the elevation of CSF PGE2.', 'subject score': 1000, 'object score': 1000}, 'PMID:17325087': {'publication date': '2007 Mar', 'sentence': 'Most caregivers of young children reported alternating acetaminophen and ibuprofen for fever reduction in their children.', 'subject score': 1000, 'object score': 694}, 'PMID:17604006': {'publication date': '2007 Aug 03', 'sentence': 'Ibuprofen abolished the fever caused by RANTES between 60 min and 2.5 h, and it reduced the temperature until the end of observation period.', 'subject score': 1000, 'object score': 1000}, 'PMID:18694739': {'publication date': '2008 Oct 03', 'sentence': 'Indomethacin (INDO, 2 mg kg(-1), i.p.) and ibuprofen (IBU, 10 mg kg(-1), i.p.) markedly reduced the fever evoked by i.c.v. injection of CINC-1 (25 ng/site).', 'subject score': 1000, 'object score': 1000}, 'PMID:19464151': {'publication date': '2009 Sep', 'sentence': 'IBU blocked LPS-induced fever but did not block LPS-induced increases in plasma cytokines and corticosterone in the pregnant dam.', 'subject score': 1000, 'object score': 851}, 'PMID:2000781': {'publication date': '1991 Jan', 'sentence': 'Nonprescription ibuprofen is useful for managing minor aches and pains, reducing fever, and relieving symptoms of dysmenorrhea.', 'subject score': 861, 'object score': 1000}, 'PMID:20591173': {'publication date': '2010', 'sentence': 'CONCLUSIONS: All doses of IV ibuprofen tested reduced fever at four hours and throughout the first 24 hours of dosing.', 'subject score': 888, 'object score': 888}, 'PMID:20860264': {'publication date': '2010', 'sentence': 'Does acetaminophen in comparison to ibuprofen effectively reduce fevers in children younger than 18 years of age?', 'subject score': 1000, 'object score': 1000}, 'PMID:21077948': {'publication date': '2011 Dec', 'sentence': 'In conclusion, although the antipyretic effect of ibuprofen involves the blockage of central production of PGE2 and the endogenous release of AVP, differently from low dose of indomethacin, ibuprofen not only reduced the fever induced by PGE2 -dependent, but also, that induced by PGE2 -independent endogenous pyrogens.', 'subject score': 1000, 'object score': 1000}, 'PMID:21127424': {'publication date': '2011 Jan-Feb', 'sentence': 'Fever was reduced significantly by IV ibuprofen in burn patients over the initial 24-hour dosing period and remained reduced throughout the dosing period.', 'subject score': 888, 'object score': 1000}, 'PMID:22621696': {'publication date': '2012 May 28', 'sentence': 'In three double-blind, single- or multicentre trials (n = 60-120) in febrile hospitalized adult patients with acute malaria or with varying causes of fever, intravenous ibuprofen (100-400 mg every 4 or 6 hours, or 800 mg every 6 hours) reduced fever to a significantly greater extent than placebo (primary endpoint in two trials) and/or significantly more patients achieved a temperature of <38.3 degrees C within 4 hours of the first ibuprofen 400 mg dose than with placebo (primary endpoint in the third trial).', 'subject score': 888, 'object score': 888}, 'PMID:23163545': {'publication date': '2013 Jan', 'sentence': 'Widespread use of ibuprofen and paracetamol has shown that they are both effective and generally well tolerated in the reduction in paediatric fever and pain.', 'subject score': 1000, 'object score': 888}, 'PMID:2663318': {'publication date': '1989 Jul', 'sentence': 'For temperatures greater than 102.5 degrees F, a dose-response relationship for 5 and 10 mg/kg ibuprofen was demonstrated in terms of percentage of fever reduction and in terms of the initial 2-hour rate of decrease in temperature.', 'subject score': 775, 'object score': 694}, 'PMID:28437025': {'publication date': '2017 Aug', 'sentence': 'METHODS: A systematic review of randomised controlled trials investigating the administration of oral paracetamol and ibuprofen to reduce fever in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:29308684': {'publication date': '2018 Mar', 'sentence': 'Male Wistar rats, pretreated with oral doses of acetaminophen, celecoxib, dipyrone, or ibuprofen 30 min before an intravenous lipopolysaccharide (LPS) or sterile saline injection, showed a reduced febrile response in all animals tested.', 'subject score': 901, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 212250,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-          "name": "Fever",
-          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10037660",
-            "MEDDRA:10020083",
-            "MEDDRA:10005911",
-            "UMLS:C0015967",
-            "HP:0001945",
-            "NCIT:C3038",
-            "MEDDRA:10073718",
-            "MEDDRA:10043204",
-            "MEDDRA:10037668",
-            "PDQ:CDR0000775882",
-            "PSY:19660",
-            "SNOMEDCT:386661006",
-            "MEDDRA:10016558",
-            "MEDDRA:10037663",
-            "SNOMEDCT:50177009",
-            "SYMP:0000613",
-            "MESH:D005334"
-          ],
-          "id": "HP:0001945",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "fever",
-            "Fever"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:9759682",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 212250,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-              "name": "Fever",
-              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10037660",
-                "MEDDRA:10020083",
-                "MEDDRA:10005911",
-                "UMLS:C0015967",
-                "HP:0001945",
-                "NCIT:C3038",
-                "MEDDRA:10073718",
-                "MEDDRA:10043204",
-                "MEDDRA:10037668",
-                "PDQ:CDR0000775882",
-                "PSY:19660",
-                "SNOMEDCT:386661006",
-                "MEDDRA:10016558",
-                "MEDDRA:10037663",
-                "SNOMEDCT:50177009",
-                "SYMP:0000613",
-                "MESH:D005334"
-              ],
-              "id": "HP:0001945",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "fever",
-                "Fever"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:9759682",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8243089,
-            "start": 554,
-            "end": 212250,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10974335': {'publication date': '2000 Sep', 'sentence': 'Pretreatment with ibuprofen blocked the fever induced by RANTES.', 'subject score': 1000, 'object score': 1000}, 'PMID:11735667': {'publication date': '2001', 'sentence': 'Ibuprofen, acetylsalicylic acid (ASA) and acetaminophen are the most frequently used agents for fever reduction in children.', 'subject score': 1000, 'object score': 694}, 'PMID:1518683': {'publication date': '1992', 'sentence': 'As antipyretics, both acetaminophen and ibuprofen are effective in fever reduction by inhibiting prostaglandin synthesis.', 'subject score': 1000, 'object score': 694}, 'PMID:15688484': {'publication date': '2005 Jan', 'sentence': 'Review: no evidence exists that paracetamol and ibuprofen differ for short term pain relief or safety in children, but ibuprofen more effectively reduces fever.', 'subject score': 861, 'object score': 1000}, 'PMID:16464962': {'publication date': '2006 May', 'sentence': 'A randomised open label study of the combined use of paracetamol and ibuprofen to rapidly reduce fever is reported.', 'subject score': 1000, 'object score': 1000}, 'PMID:16836983': {'publication date': '2006 Sep 13', 'sentence': 'Indomethacin only blocked the PGE2 increase in the CSF whereas ibuprofen and celecoxib each blocked the fever and the elevation of CSF PGE2.', 'subject score': 1000, 'object score': 1000}, 'PMID:17325087': {'publication date': '2007 Mar', 'sentence': 'Most caregivers of young children reported alternating acetaminophen and ibuprofen for fever reduction in their children.', 'subject score': 1000, 'object score': 694}, 'PMID:17604006': {'publication date': '2007 Aug 03', 'sentence': 'Ibuprofen abolished the fever caused by RANTES between 60 min and 2.5 h, and it reduced the temperature until the end of observation period.', 'subject score': 1000, 'object score': 1000}, 'PMID:18694739': {'publication date': '2008 Oct 03', 'sentence': 'Indomethacin (INDO, 2 mg kg(-1), i.p.) and ibuprofen (IBU, 10 mg kg(-1), i.p.) markedly reduced the fever evoked by i.c.v. injection of CINC-1 (25 ng/site).', 'subject score': 1000, 'object score': 1000}, 'PMID:19464151': {'publication date': '2009 Sep', 'sentence': 'IBU blocked LPS-induced fever but did not block LPS-induced increases in plasma cytokines and corticosterone in the pregnant dam.', 'subject score': 1000, 'object score': 851}, 'PMID:2000781': {'publication date': '1991 Jan', 'sentence': 'Nonprescription ibuprofen is useful for managing minor aches and pains, reducing fever, and relieving symptoms of dysmenorrhea.', 'subject score': 861, 'object score': 1000}, 'PMID:20591173': {'publication date': '2010', 'sentence': 'CONCLUSIONS: All doses of IV ibuprofen tested reduced fever at four hours and throughout the first 24 hours of dosing.', 'subject score': 888, 'object score': 888}, 'PMID:20860264': {'publication date': '2010', 'sentence': 'Does acetaminophen in comparison to ibuprofen effectively reduce fevers in children younger than 18 years of age?', 'subject score': 1000, 'object score': 1000}, 'PMID:21077948': {'publication date': '2011 Dec', 'sentence': 'In conclusion, although the antipyretic effect of ibuprofen involves the blockage of central production of PGE2 and the endogenous release of AVP, differently from low dose of indomethacin, ibuprofen not only reduced the fever induced by PGE2 -dependent, but also, that induced by PGE2 -independent endogenous pyrogens.', 'subject score': 1000, 'object score': 1000}, 'PMID:21127424': {'publication date': '2011 Jan-Feb', 'sentence': 'Fever was reduced significantly by IV ibuprofen in burn patients over the initial 24-hour dosing period and remained reduced throughout the dosing period.', 'subject score': 888, 'object score': 1000}, 'PMID:22621696': {'publication date': '2012 May 28', 'sentence': 'In three double-blind, single- or multicentre trials (n = 60-120) in febrile hospitalized adult patients with acute malaria or with varying causes of fever, intravenous ibuprofen (100-400 mg every 4 or 6 hours, or 800 mg every 6 hours) reduced fever to a significantly greater extent than placebo (primary endpoint in two trials) and/or significantly more patients achieved a temperature of <38.3 degrees C within 4 hours of the first ibuprofen 400 mg dose than with placebo (primary endpoint in the third trial).', 'subject score': 888, 'object score': 888}, 'PMID:23163545': {'publication date': '2013 Jan', 'sentence': 'Widespread use of ibuprofen and paracetamol has shown that they are both effective and generally well tolerated in the reduction in paediatric fever and pain.', 'subject score': 1000, 'object score': 888}, 'PMID:2663318': {'publication date': '1989 Jul', 'sentence': 'For temperatures greater than 102.5 degrees F, a dose-response relationship for 5 and 10 mg/kg ibuprofen was demonstrated in terms of percentage of fever reduction and in terms of the initial 2-hour rate of decrease in temperature.', 'subject score': 775, 'object score': 694}, 'PMID:28437025': {'publication date': '2017 Aug', 'sentence': 'METHODS: A systematic review of randomised controlled trials investigating the administration of oral paracetamol and ibuprofen to reduce fever in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:29308684': {'publication date': '2018 Mar', 'sentence': 'Male Wistar rats, pretreated with oral doses of acetaminophen, celecoxib, dipyrone, or ibuprofen 30 min before an intravenous lipopolysaccharide (LPS) or sterile saline injection, showed a reduced febrile response in all animals tested.', 'subject score': 901, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:inhibits---biolink:causes---activity---None---UMLS:C0015967---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "8421263",
-              "object": "HP:0001945",
-              "publications": [
-                "PMID:10974335",
-                "PMID:11735667",
-                "PMID:1518683",
-                "PMID:15688484",
-                "PMID:16464962",
-                "PMID:16836983",
-                "PMID:17325087",
-                "PMID:17604006",
-                "PMID:18694739",
-                "PMID:19464151",
-                "PMID:2000781",
-                "PMID:20591173",
-                "PMID:20860264",
-                "PMID:21077948",
-                "PMID:21127424",
-                "PMID:22621696",
-                "PMID:23163545",
-                "PMID:2663318",
-                "PMID:28437025",
-                "PMID:29308684"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10191452': {'publication date': '1999 Mar', 'sentence': 'Paracetamol or ibuprofen in febrile children.', 'subject score': 1000, 'object score': 888}, 'PMID:10492798': {'publication date': '1999', 'sentence': 'Paracetamol and ibuprofen for treatment of fever in Malawian children aged less than five years.', 'subject score': 1000, 'object score': 1000}, 'PMID:10506264': {'publication date': '1999 Oct', 'sentence': 'OBJECTIVE: To compare the incidence of serious adverse clinical events among children <2 years old given ibuprofen and acetaminophen to control fever.', 'subject score': 740, 'object score': 1000}, 'PMID:10638387': {'publication date': '1999 Nov', 'sentence': 'CONCLUSION: The results of this study demonstrated that the anti-pyretic effectiveness of nimesulide is better than paracetamol and ibuprofen in febrile children with URTIs.', 'subject score': 1000, 'object score': 888}, 'PMID:10790455': {'publication date': '2000 May', 'sentence': 'CONCLUSION: Acetaminophen and ibuprofen are commonly being used in an alternating manner for management of fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:10811855': {'publication date': '2000 May', 'sentence': 'Both celecoxib, a selective COX-2 inhibitor, and ibuprofen attenuated the pyrexial, but not the chronotropic, response to LPS.', 'subject score': 1000, 'object score': 1000}, 'PMID:11141364': {'publication date': '2000 Nov', 'sentence': 'CONCLUSIONS: Ibuprofen is effective in the treatment of fever in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:11141365': {'publication date': '2000 Nov', 'sentence': 'AIM: To compare the efficacy and to evaluate the clinical bioequivalence of two different formulations of ibuprofen (suspension and effervescent granules) in febrile children.', 'subject score': 1000, 'object score': 888}, 'PMID:11319581': {'publication date': '2000 Mar', 'sentence': 'Less clinical experience has accumulated with ibuprofen, and it remains the second-line treatment for fever and pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:11393101': {'publication date': '2001 Feb', 'sentence': 'Before he developed abdominal distension, the patient had suffered from an upper respiratory tract infection with fever for about 2 weeks, which was treated intermittently with ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:11861992': {'publication date': '2002 Feb', 'sentence': 'Acetaminophen (paracetamol) and ibuprofen are accepted as the standard medical treatments for fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:14651311': {'publication date': '2003 Sep-Oct', 'sentence': 'Alternating acetaminophen and ibuprofen in the febrile child: examination of the evidence regarding efficacy and safety.', 'subject score': 1000, 'object score': 888}, 'PMID:1506123': {'publication date': '1992 Mar', 'sentence': 'Efficacy of ibuprofen in pediatric patients with fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:15327170': {'publication date': '2004 Jul', 'sentence': 'Either acetaminophen or ibuprofen can be given to treat the fever, and rectal forms of these medicines are preferred in the early treatment phase.', 'subject score': 1000, 'object score': 1000}, 'PMID:1564127': {'publication date': '1992 Mar', 'sentence': 'Accordingly, the authors measured plasma levels of acetaminophen and ibuprofen in 153 febrile children for 6 hours after a single dose of either acetaminophen (12.5 mg/kg) or ibuprofen (5 or 10 mg/kg).', 'subject score': 1000, 'object score': 790}, 'PMID:16051074': {'publication date': '2005 Aug', 'sentence': 'CONCLUSION: Ibuprofen was largely used in febrile children.', 'subject score': 1000, 'object score': 888}, 'PMID:1621669': {'publication date': '1992 May', 'sentence': 'Comparison of multidose ibuprofen and acetaminophen therapy in febrile children.', 'subject score': 861, 'object score': 888}, 'PMID:16461878': {'publication date': '2006 Feb', 'sentence': 'Antipyretic treatment in young children with fever: acetaminophen, ibuprofen, or both alternating in a randomized, double-blind study.', 'subject score': 1000, 'object score': 1000}, 'PMID:16464962': {'publication date': '2006 May', 'sentence': 'Randomised controlled trial of combined paracetamol and ibuprofen for fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:17243306': {'publication date': '2006 Jul', 'sentence': 'Alternating ibuprofen and acetaminophen may be more effective in the treatment of fever in children.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 212250,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-          "name": "Fever",
-          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10037660",
-            "MEDDRA:10020083",
-            "MEDDRA:10005911",
-            "UMLS:C0015967",
-            "HP:0001945",
-            "NCIT:C3038",
-            "MEDDRA:10073718",
-            "MEDDRA:10043204",
-            "MEDDRA:10037668",
-            "PDQ:CDR0000775882",
-            "PSY:19660",
-            "SNOMEDCT:386661006",
-            "MEDDRA:10016558",
-            "MEDDRA:10037663",
-            "SNOMEDCT:50177009",
-            "SYMP:0000613",
-            "MESH:D005334"
-          ],
-          "id": "HP:0001945",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "fever",
-            "Fever"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:9759682",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 212250,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-              "name": "Fever",
-              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10037660",
-                "MEDDRA:10020083",
-                "MEDDRA:10005911",
-                "UMLS:C0015967",
-                "HP:0001945",
-                "NCIT:C3038",
-                "MEDDRA:10073718",
-                "MEDDRA:10043204",
-                "MEDDRA:10037668",
-                "PDQ:CDR0000775882",
-                "PSY:19660",
-                "SNOMEDCT:386661006",
-                "MEDDRA:10016558",
-                "MEDDRA:10037663",
-                "SNOMEDCT:50177009",
-                "SYMP:0000613",
-                "MESH:D005334"
-              ],
-              "id": "HP:0001945",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "fever",
-                "Fever"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:9759682",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7114783,
-            "start": 554,
-            "end": 212250,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:10191452': {'publication date': '1999 Mar', 'sentence': 'Paracetamol or ibuprofen in febrile children.', 'subject score': 1000, 'object score': 888}, 'PMID:10492798': {'publication date': '1999', 'sentence': 'Paracetamol and ibuprofen for treatment of fever in Malawian children aged less than five years.', 'subject score': 1000, 'object score': 1000}, 'PMID:10506264': {'publication date': '1999 Oct', 'sentence': 'OBJECTIVE: To compare the incidence of serious adverse clinical events among children <2 years old given ibuprofen and acetaminophen to control fever.', 'subject score': 740, 'object score': 1000}, 'PMID:10638387': {'publication date': '1999 Nov', 'sentence': 'CONCLUSION: The results of this study demonstrated that the anti-pyretic effectiveness of nimesulide is better than paracetamol and ibuprofen in febrile children with URTIs.', 'subject score': 1000, 'object score': 888}, 'PMID:10790455': {'publication date': '2000 May', 'sentence': 'CONCLUSION: Acetaminophen and ibuprofen are commonly being used in an alternating manner for management of fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:10811855': {'publication date': '2000 May', 'sentence': 'Both celecoxib, a selective COX-2 inhibitor, and ibuprofen attenuated the pyrexial, but not the chronotropic, response to LPS.', 'subject score': 1000, 'object score': 1000}, 'PMID:11141364': {'publication date': '2000 Nov', 'sentence': 'CONCLUSIONS: Ibuprofen is effective in the treatment of fever in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:11141365': {'publication date': '2000 Nov', 'sentence': 'AIM: To compare the efficacy and to evaluate the clinical bioequivalence of two different formulations of ibuprofen (suspension and effervescent granules) in febrile children.', 'subject score': 1000, 'object score': 888}, 'PMID:11319581': {'publication date': '2000 Mar', 'sentence': 'Less clinical experience has accumulated with ibuprofen, and it remains the second-line treatment for fever and pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:11393101': {'publication date': '2001 Feb', 'sentence': 'Before he developed abdominal distension, the patient had suffered from an upper respiratory tract infection with fever for about 2 weeks, which was treated intermittently with ibuprofen.', 'subject score': 1000, 'object score': 1000}, 'PMID:11861992': {'publication date': '2002 Feb', 'sentence': 'Acetaminophen (paracetamol) and ibuprofen are accepted as the standard medical treatments for fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:14651311': {'publication date': '2003 Sep-Oct', 'sentence': 'Alternating acetaminophen and ibuprofen in the febrile child: examination of the evidence regarding efficacy and safety.', 'subject score': 1000, 'object score': 888}, 'PMID:1506123': {'publication date': '1992 Mar', 'sentence': 'Efficacy of ibuprofen in pediatric patients with fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:15327170': {'publication date': '2004 Jul', 'sentence': 'Either acetaminophen or ibuprofen can be given to treat the fever, and rectal forms of these medicines are preferred in the early treatment phase.', 'subject score': 1000, 'object score': 1000}, 'PMID:1564127': {'publication date': '1992 Mar', 'sentence': 'Accordingly, the authors measured plasma levels of acetaminophen and ibuprofen in 153 febrile children for 6 hours after a single dose of either acetaminophen (12.5 mg/kg) or ibuprofen (5 or 10 mg/kg).', 'subject score': 1000, 'object score': 790}, 'PMID:16051074': {'publication date': '2005 Aug', 'sentence': 'CONCLUSION: Ibuprofen was largely used in febrile children.', 'subject score': 1000, 'object score': 888}, 'PMID:1621669': {'publication date': '1992 May', 'sentence': 'Comparison of multidose ibuprofen and acetaminophen therapy in febrile children.', 'subject score': 861, 'object score': 888}, 'PMID:16461878': {'publication date': '2006 Feb', 'sentence': 'Antipyretic treatment in young children with fever: acetaminophen, ibuprofen, or both alternating in a randomized, double-blind study.', 'subject score': 1000, 'object score': 1000}, 'PMID:16464962': {'publication date': '2006 May', 'sentence': 'Randomised controlled trial of combined paracetamol and ibuprofen for fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:17243306': {'publication date': '2006 Jul', 'sentence': 'Alternating ibuprofen and acetaminophen may be more effective in the treatment of fever in children.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0015967---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "7258310",
-              "object": "HP:0001945",
-              "publications": [
-                "PMID:10191452",
-                "PMID:10492798",
-                "PMID:10506264",
-                "PMID:10638387",
-                "PMID:10790455",
-                "PMID:10811855",
-                "PMID:11141364",
-                "PMID:11141365",
-                "PMID:11319581",
-                "PMID:11393101",
-                "PMID:11861992",
-                "PMID:14651311",
-                "PMID:1506123",
-                "PMID:15327170",
-                "PMID:1564127",
-                "PMID:16051074",
-                "PMID:1621669",
-                "PMID:16461878",
-                "PMID:16464962",
-                "PMID:17243306"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:20591173': {'publication date': '2010', 'sentence': 'INTRODUCTION: Hospitalized patients are often unable to ingest or tolerate oral antipyretics and recently an aqueous formulation of intravenous (IV) ibuprofen was approved by the US-FDA for the reduction of fever in adults.', 'subject score': 888, 'object score': 1000}, 'PMID:21127424': {'publication date': '2011 Jan-Feb', 'sentence': 'This prospective study evaluated the efficacy and safety of IV ibuprofen for the reduction of fever and treatment of pain in patients with thermal burn injury.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 212250,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-          "name": "Fever",
-          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10037660",
-            "MEDDRA:10020083",
-            "MEDDRA:10005911",
-            "UMLS:C0015967",
-            "HP:0001945",
-            "NCIT:C3038",
-            "MEDDRA:10073718",
-            "MEDDRA:10043204",
-            "MEDDRA:10037668",
-            "PDQ:CDR0000775882",
-            "PSY:19660",
-            "SNOMEDCT:386661006",
-            "MEDDRA:10016558",
-            "MEDDRA:10037663",
-            "SNOMEDCT:50177009",
-            "SYMP:0000613",
-            "MESH:D005334"
-          ],
-          "id": "HP:0001945",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "fever",
-            "Fever"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:9759682",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 212250,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-              "name": "Fever",
-              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10037660",
-                "MEDDRA:10020083",
-                "MEDDRA:10005911",
-                "UMLS:C0015967",
-                "HP:0001945",
-                "NCIT:C3038",
-                "MEDDRA:10073718",
-                "MEDDRA:10043204",
-                "MEDDRA:10037668",
-                "PDQ:CDR0000775882",
-                "PSY:19660",
-                "SNOMEDCT:386661006",
-                "MEDDRA:10016558",
-                "MEDDRA:10037663",
-                "SNOMEDCT:50177009",
-                "SYMP:0000613",
-                "MESH:D005334"
-              ],
-              "id": "HP:0001945",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "fever",
-                "Fever"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:9759682",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14760320,
-            "start": 554,
-            "end": 212250,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:20591173': {'publication date': '2010', 'sentence': 'INTRODUCTION: Hospitalized patients are often unable to ingest or tolerate oral antipyretics and recently an aqueous formulation of intravenous (IV) ibuprofen was approved by the US-FDA for the reduction of fever in adults.', 'subject score': 888, 'object score': 1000}, 'PMID:21127424': {'publication date': '2011 Jan-Feb', 'sentence': 'This prospective study evaluated the efficacy and safety of IV ibuprofen for the reduction of fever and treatment of pain in patients with thermal burn injury.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:disrupts---None---None---None---UMLS:C0015967---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "15072611",
-              "object": "HP:0001945",
-              "publications": [
-                "PMID:20591173",
-                "PMID:21127424"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:32505846': {'publication date': '2020 May 25', 'sentence': 'Studies show that ibuprofen demonstrates superior efficacy in fever reduction compared to acetaminophen.', 'subject score': 1000, 'object score': 888}, 'PMID:32725954': {'publication date': '2020 Jul 29', 'sentence': 'Ibuprofen does not prevent postbronchoscopy fever in children undergoing broncho-alveolar lavage.BACKGROUND: Fiber-optic bronchoscopy (FOB) of the lower airways is a routine examination performed for investigating varying respiratory complaints in children.', 'subject score': 1000, 'object score': 901}, 'PMID:35547858': {'publication date': '2020 Mar', 'sentence': 'In conclusion, ibuprofen administered in the form of soft chewable capsules was palatable and acceptable to the majority of children and their parents/guardians and may provide a convenient and easy to dose preparation to reduce fever and relieve pain in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:36503309': {'publication date': '2022 Dec 12', 'sentence': 'Acetaminophen Versus Ibuprofen for Fever Reduction in the Pediatric Emergency Department.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 212250,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-          "name": "Fever",
-          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10037660",
-            "MEDDRA:10020083",
-            "MEDDRA:10005911",
-            "UMLS:C0015967",
-            "HP:0001945",
-            "NCIT:C3038",
-            "MEDDRA:10073718",
-            "MEDDRA:10043204",
-            "MEDDRA:10037668",
-            "PDQ:CDR0000775882",
-            "PSY:19660",
-            "SNOMEDCT:386661006",
-            "MEDDRA:10016558",
-            "MEDDRA:10037663",
-            "SNOMEDCT:50177009",
-            "SYMP:0000613",
-            "MESH:D005334"
-          ],
-          "id": "HP:0001945",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "fever",
-            "Fever"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:9759682",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 212250,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-              "name": "Fever",
-              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10037660",
-                "MEDDRA:10020083",
-                "MEDDRA:10005911",
-                "UMLS:C0015967",
-                "HP:0001945",
-                "NCIT:C3038",
-                "MEDDRA:10073718",
-                "MEDDRA:10043204",
-                "MEDDRA:10037668",
-                "PDQ:CDR0000775882",
-                "PSY:19660",
-                "SNOMEDCT:386661006",
-                "MEDDRA:10016558",
-                "MEDDRA:10037663",
-                "SNOMEDCT:50177009",
-                "SYMP:0000613",
-                "MESH:D005334"
-              ],
-              "id": "HP:0001945",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "fever",
-                "Fever"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:9759682",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21703374,
-            "start": 554,
-            "end": 212250,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32505846': {'publication date': '2020 May 25', 'sentence': 'Studies show that ibuprofen demonstrates superior efficacy in fever reduction compared to acetaminophen.', 'subject score': 1000, 'object score': 888}, 'PMID:32725954': {'publication date': '2020 Jul 29', 'sentence': 'Ibuprofen does not prevent postbronchoscopy fever in children undergoing broncho-alveolar lavage.BACKGROUND: Fiber-optic bronchoscopy (FOB) of the lower airways is a routine examination performed for investigating varying respiratory complaints in children.', 'subject score': 1000, 'object score': 901}, 'PMID:35547858': {'publication date': '2020 Mar', 'sentence': 'In conclusion, ibuprofen administered in the form of soft chewable capsules was palatable and acceptable to the majority of children and their parents/guardians and may provide a convenient and easy to dose preparation to reduce fever and relieve pain in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:36503309': {'publication date': '2022 Dec 12', 'sentence': 'Acetaminophen Versus Ibuprofen for Fever Reduction in the Pediatric Emergency Department.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:prevents---None---None---None---UMLS:C0015967---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "22123299",
-              "object": "HP:0001945",
-              "publications": [
-                "PMID:32505846",
-                "PMID:32725954",
-                "PMID:35547858",
-                "PMID:36503309"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:20949283': {'publication date': '2011 Jan', 'sentence': 'Patent ductus arteriosus (PDA) is the most common cardiovascular abnormality of the preterm infant usually treated with ibuprofen (IBU).', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 308937,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-          "name": "cardiovascular disorder",
-          "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "MEDDRA:10045663",
-            "MONDO:0004995",
-            "ICD9:429.2",
-            "MEDDRA:10007649",
-            "UMLS:C0243050",
-            "HP:0001626",
-            "MESH:D018376",
-            "MEDDRA:10007648",
-            "MEDDRA:10013205",
-            "SNOMEDCT:49601007",
-            "MEDDRA:10007650",
-            "MESH:D002318",
-            "DOID:1287",
-            "UMLS:C0007222",
-            "UMLS:C0728936",
-            "NCIT:C2931"
-          ],
-          "id": "MONDO:0004995",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiovascular Diseases",
-            "Cardiovascular disease, unspecified",
-            "Abnormality of the cardiovascular system",
-            "cardiovascular system disease",
-            "Disorder of circulatory system",
-            "Cardiovascular Disorder",
-            "cardiovascular disorder",
-            "Cardiovascular Abnormalities"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/circulatory_system",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308937,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-              "name": "cardiovascular disorder",
-              "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "MEDDRA:10045663",
-                "MONDO:0004995",
-                "ICD9:429.2",
-                "MEDDRA:10007649",
-                "UMLS:C0243050",
-                "HP:0001626",
-                "MESH:D018376",
-                "MEDDRA:10007648",
-                "MEDDRA:10013205",
-                "SNOMEDCT:49601007",
-                "MEDDRA:10007650",
-                "MESH:D002318",
-                "DOID:1287",
-                "UMLS:C0007222",
-                "UMLS:C0728936",
-                "NCIT:C2931"
-              ],
-              "id": "MONDO:0004995",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiovascular Diseases",
-                "Cardiovascular disease, unspecified",
-                "Abnormality of the cardiovascular system",
-                "cardiovascular system disease",
-                "Disorder of circulatory system",
-                "Cardiovascular Disorder",
-                "cardiovascular disorder",
-                "Cardiovascular Abnormalities"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/circulatory_system",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14942972,
-            "start": 554,
-            "end": 308937,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20949283': {'publication date': '2011 Jan', 'sentence': 'Patent ductus arteriosus (PDA) is the most common cardiovascular abnormality of the preterm infant usually treated with ibuprofen (IBU).', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0243050---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:3672",
-              "id": "15258520",
-              "object": "MONDO:0004995",
-              "publications": [
-                "PMID:20949283"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:has_metabolite",
-    "type(r2)": "biolink:subclass_of",
-    "r2.publications_info": "{'PMID:21079932': {'publication date': '2011 Jan', 'sentence': 'The purpose of this study was the development and validation of an LC-MS-MS method for simultaneous analysis of ibuprofen (IBP), 2-hydroxyibuprofen (2-OH-IBP) enantiomers, and carboxyibuprofen (COOH-IBP) stereoisomers in fungi culture medium, to investigate the ability of some endophytic fungi to biotransform the chiral drug IBP into its metabolites.', 'subject score': 861, 'object score': 790}, 'PMID:22226725': {'publication date': '2012 Feb 10', 'sentence': 'The anti-inflammatory drug ibuprofen (Ibu) is metabolized in the human liver to a number of metabolites including 1-hydroxyibuprofen (1-OH-Ibu), 2-OH-Ibu, and 3-OH-Ibu, respectively.', 'subject score': 861, 'object score': 790}, 'PMID:29453024': {'publication date': '2018 Apr 15', 'sentence': 'A novel assay for the simultaneous determination of ibuprofen (IBU) and its four probable metabolites, 1-hydroxyibuprofen (1-OH IBU), 2-hydroxyibuprofen (2-OH IBU), 3-hydroxyibuprofen (3-OH IBU) and carboxyibuprofen (CBX IBU) in equine urine samples with the application of Gas Chromatography-Electron Ionization-Mass Spectrometry (GC-EI-MS) has been developed and elaborated.', 'subject score': 888, 'object score': 851}, 'PMID:31316382': {'publication date': '2019', 'sentence': 'An ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed and validated to determine 2-hydroxyibuprofen (2OH-IBU), carboxyibuprofen (COOH-IBU), and ibuprofen glucuronide (IBU-GlcA) in pig plasma.', 'subject score': 861, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 832023,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
-        ],
-        "properties": {
-          "name": "2-Hydroxyibuprofen",
-          "description": "2-Hydroxyibuprofen is a metabolite of ibuprofen. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) used for relief of symptoms of arthritis, fever, as an analgesic (pain reliever), especially where there is an inflammatory component, and dysmenorrhea. Ibuprofen is known to have an antiplatelet effect, though it is relatively mild and somewhat short-lived when compared with aspirin or other better-known antiplatelet drugs. (Wikipedia)",
-          "equivalent_curies": [
-            "CAS:51146-55-5",
-            "CHEBI:133197",
-            "UMLS:C0669948",
-            "CHEMBL.COMPOUND:CHEMBL3544495",
-            "UNII:2KHZ9ELM84",
-            "HMDB:HMDB0060920",
-            "INCHIKEY:UJHKVYPPCJBOSG-UHFFFAOYSA-N",
-            "MESH:C109994",
-            "PathWhiz.Compound:40563",
-            "PUBCHEM.COMPOUND:10443535"
-          ],
-          "id": "PUBCHEM.COMPOUND:10443535",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "hydroxyibuprofen",
-            "2-hydroxyibuprofen",
-            "2-Hydroxyibuprofen",
-            "2-HYDROXYIBUPROFEN"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule"
-          ]
-        }
-      },
-      "end": {
-        "identity": 554,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ibuprofen",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-          "equivalent_curies": [
-            "PathWhiz.Compound:1284",
-            "KEGG.DRUG:D00126",
-            "CHEBI:5855",
-            "RXNORM:5640",
-            "CAS:58560-75-1",
-            "NCIT:C561",
-            "PDQ:CDR0000040475",
-            "DRUGBANK:DB01050",
-            "ATC:G02CC01",
-            "UMLS:C0020740",
-            "NDDF:002377",
-            "UNII:WK2XYI10QM",
-            "MESH:D007052",
-            "PUBCHEM.COMPOUND:3672",
-            "DrugCentral:1407",
-            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-            "CHEMBL.COMPOUND:CHEMBL521",
-            "ATC:M02AA13",
-            "KEGG.COMPOUND:C01588",
-            "ATC:R02AX02",
-            "ATC:M01AE01",
-            "ATC:C01EB16",
-            "GTOPDB:2713",
-            "CAS:15687-27-1",
-            "HMDB:HMDB0001925"
-          ],
-          "id": "PUBCHEM.COMPOUND:3672",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "IBUPROFEN",
-            "Ibuprofen",
-            "ibuprofen",
-            "Ibuprofen (JP18/USP/INN)",
-            "solufenum"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:33071054",
-            "PMID:28759875",
-            "PMID:926121",
-            "PMID:20926620",
-            "PMID:31689108",
-            "PMID:34998058",
-            "PMID:18834112",
-            "PMID:12807998",
-            "PMID:19541393",
-            "PMID:140243"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 832023,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
-            ],
-            "properties": {
-              "name": "2-Hydroxyibuprofen",
-              "description": "2-Hydroxyibuprofen is a metabolite of ibuprofen. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) used for relief of symptoms of arthritis, fever, as an analgesic (pain reliever), especially where there is an inflammatory component, and dysmenorrhea. Ibuprofen is known to have an antiplatelet effect, though it is relatively mild and somewhat short-lived when compared with aspirin or other better-known antiplatelet drugs. (Wikipedia)",
-              "equivalent_curies": [
-                "CAS:51146-55-5",
-                "CHEBI:133197",
-                "UMLS:C0669948",
-                "CHEMBL.COMPOUND:CHEMBL3544495",
-                "UNII:2KHZ9ELM84",
-                "HMDB:HMDB0060920",
-                "INCHIKEY:UJHKVYPPCJBOSG-UHFFFAOYSA-N",
-                "MESH:C109994",
-                "PathWhiz.Compound:40563",
-                "PUBCHEM.COMPOUND:10443535"
-              ],
-              "id": "PUBCHEM.COMPOUND:10443535",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "hydroxyibuprofen",
-                "2-hydroxyibuprofen",
-                "2-Hydroxyibuprofen",
-                "2-HYDROXYIBUPROFEN"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15000215,
-            "start": 832023,
-            "end": 554,
-            "type": "biolink:subclass_of",
-            "properties": {
-              "predicate": "biolink:subclass_of",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21079932': {'publication date': '2011 Jan', 'sentence': 'The purpose of this study was the development and validation of an LC-MS-MS method for simultaneous analysis of ibuprofen (IBP), 2-hydroxyibuprofen (2-OH-IBP) enantiomers, and carboxyibuprofen (COOH-IBP) stereoisomers in fungi culture medium, to investigate the ability of some endophytic fungi to biotransform the chiral drug IBP into its metabolites.', 'subject score': 861, 'object score': 790}, 'PMID:22226725': {'publication date': '2012 Feb 10', 'sentence': 'The anti-inflammatory drug ibuprofen (Ibu) is metabolized in the human liver to a number of metabolites including 1-hydroxyibuprofen (1-OH-Ibu), 2-OH-Ibu, and 3-OH-Ibu, respectively.', 'subject score': 861, 'object score': 790}, 'PMID:29453024': {'publication date': '2018 Apr 15', 'sentence': 'A novel assay for the simultaneous determination of ibuprofen (IBU) and its four probable metabolites, 1-hydroxyibuprofen (1-OH IBU), 2-hydroxyibuprofen (2-OH IBU), 3-hydroxyibuprofen (3-OH IBU) and carboxyibuprofen (CBX IBU) in equine urine samples with the application of Gas Chromatography-Electron Ionization-Mass Spectrometry (GC-EI-MS) has been developed and elaborated.', 'subject score': 888, 'object score': 851}, 'PMID:31316382': {'publication date': '2019', 'sentence': 'An ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed and validated to determine 2-hydroxyibuprofen (2OH-IBU), carboxyibuprofen (COOH-IBU), and ibuprofen glucuronide (IBU-GlcA) in pig plasma.', 'subject score': 861, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0669948---SEMMEDDB:isa---None---None---None---UMLS:C0020740---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:10443535",
-              "id": "15316470",
-              "object": "PUBCHEM.COMPOUND:3672",
-              "publications": [
-                "PMID:21079932",
-                "PMID:22226725",
-                "PMID:29453024",
-                "PMID:31316382"
-              ]
-            }
-          },
-          "end": {
-            "identity": 554,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ibuprofen",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
-              "equivalent_curies": [
-                "PathWhiz.Compound:1284",
-                "KEGG.DRUG:D00126",
-                "CHEBI:5855",
-                "RXNORM:5640",
-                "CAS:58560-75-1",
-                "NCIT:C561",
-                "PDQ:CDR0000040475",
-                "DRUGBANK:DB01050",
-                "ATC:G02CC01",
-                "UMLS:C0020740",
-                "NDDF:002377",
-                "UNII:WK2XYI10QM",
-                "MESH:D007052",
-                "PUBCHEM.COMPOUND:3672",
-                "DrugCentral:1407",
-                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
-                "CHEMBL.COMPOUND:CHEMBL521",
-                "ATC:M02AA13",
-                "KEGG.COMPOUND:C01588",
-                "ATC:R02AX02",
-                "ATC:M01AE01",
-                "ATC:C01EB16",
-                "GTOPDB:2713",
-                "CAS:15687-27-1",
-                "HMDB:HMDB0001925"
-              ],
-              "id": "PUBCHEM.COMPOUND:3672",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "IBUPROFEN",
-                "Ibuprofen",
-                "ibuprofen",
-                "Ibuprofen (JP18/USP/INN)",
-                "solufenum"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:33071054",
-                "PMID:28759875",
-                "PMID:926121",
-                "PMID:20926620",
-                "PMID:31689108",
-                "PMID:34998058",
-                "PMID:18834112",
-                "PMID:12807998",
-                "PMID:19541393",
-                "PMID:140243"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:6097125': {'publication date': '1984 Dec 21', 'sentence': 'Cefmenoxime versus cefoxitin in the treatment of serious bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:6329082': {'publication date': '1984 Apr', 'sentence': 'The efficacy and safety of cefmenoxime was evaluated in 50 patients with serious bacterial infections.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 538307,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-          ]
-        }
-      },
-      "end": {
-        "identity": 556,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefmenoxime",
-          "description": "A third-generation, semi-synthetic, beta-lactam cephalosporin antibiotic with antibacterial activity. Cefmenoxime binds to penicillin-binding proteins (PBPs), transpeptidases that are responsible for crosslinking of peptidoglycan. By preventing crosslinking of peptidoglycan, cell wall integrity is lost and cell wall synthesis is halted.; A cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The drug has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.",
-          "equivalent_curies": [
-            "CHEBI:55490",
-            "MESH:D015281",
-            "HMDB:HMDB0014412",
-            "UMLS:C0007549",
-            "PUBCHEM.COMPOUND:9570757",
-            "NCIT:C65295",
-            "CHEMBL.COMPOUND:CHEMBL1201224",
-            "DrugCentral:538",
-            "NDDF:006821",
-            "UNII:KBZ4844CXN",
-            "DRUGBANK:DB00267",
-            "GTOPDB:12024",
-            "ATC:J01DD05",
-            "INCHIKEY:HJJDBAOLQAWBMH-YCRCPZNHSA-N",
-            "KEGG.DRUG:D01739"
-          ],
-          "id": "PUBCHEM.COMPOUND:9570757",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "cefmenoxime",
-            "CEFMENOXIME",
-            "Cefmenoxime",
-            "Cefmenoxime hydrochloride (JP18/USP)",
-            "cefmenoxime hydrochloride"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:6941742",
-            "PMID:15646539",
-            "PMID:7637194",
-            "PMID:7816419",
-            "PMID:8193431"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538307,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25529848,
-            "start": 556,
-            "end": 538307,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:6097125': {'publication date': '1984 Dec 21', 'sentence': 'Cefmenoxime versus cefoxitin in the treatment of serious bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:6329082': {'publication date': '1984 Apr', 'sentence': 'The efficacy and safety of cefmenoxime was evaluated in 50 patients with serious bacterial infections.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0007549---SEMMEDDB:treats---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:9570757",
-              "id": "25984950",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:6097125",
-                "PMID:6329082"
-              ]
-            }
-          },
-          "end": {
-            "identity": 556,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-=======
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
->>>>>>> main
-            ],
-            "properties": {
-              "name": "Cefmenoxime",
-              "description": "A third-generation, semi-synthetic, beta-lactam cephalosporin antibiotic with antibacterial activity. Cefmenoxime binds to penicillin-binding proteins (PBPs), transpeptidases that are responsible for crosslinking of peptidoglycan. By preventing crosslinking of peptidoglycan, cell wall integrity is lost and cell wall synthesis is halted.; A cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The drug has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.",
-              "equivalent_curies": [
-                "CHEBI:55490",
-                "MESH:D015281",
-                "HMDB:HMDB0014412",
-                "UMLS:C0007549",
-                "PUBCHEM.COMPOUND:9570757",
-                "NCIT:C65295",
-                "CHEMBL.COMPOUND:CHEMBL1201224",
-                "DrugCentral:538",
-                "NDDF:006821",
-                "UNII:KBZ4844CXN",
-                "DRUGBANK:DB00267",
-                "GTOPDB:12024",
-                "ATC:J01DD05",
-                "INCHIKEY:HJJDBAOLQAWBMH-YCRCPZNHSA-N",
-                "KEGG.DRUG:D01739"
-              ],
-              "id": "PUBCHEM.COMPOUND:9570757",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "cefmenoxime",
-                "CEFMENOXIME",
-                "Cefmenoxime",
-                "Cefmenoxime hydrochloride (JP18/USP)",
-                "cefmenoxime hydrochloride"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:6941742",
-                "PMID:15646539",
-                "PMID:7637194",
-                "PMID:7816419",
-                "PMID:8193431"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 518244,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:31878852': {'publication date': '2019 Dec 26', 'sentence': 'These are: the association of dobutamine infusion with amiodarone or ivabradine in patients with symptomatic hypotension, and high-dose furosemide associated to hypertonic saline solution, levosimendan, hydralazine/isosorbide dinitrate, sodium nitroprusside or ivabradine in hemodynamically stable patients.', 'subject score': 1000, 'object score': 888}, 'PMID:35024059': {'publication date': '2022 Jan', 'sentence': 'Thus, a patient with low BP can benefit from treatment with ivabradine.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319508,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006727",
-          "name": "diastolic heart failure",
-          "description": "Heart failure caused by abnormal myocardial relaxation during diastole leading to defective cardiac filling.",
-          "equivalent_curies": [
-            "ICD10:I50.30",
-            "ICD9:428.3",
-            "MONDO:0006727",
-            "SNOMEDCT:418304008",
-            "EFO:1000899",
-            "MESH:D054144",
-            "DOID:9775",
-            "UMLS:C1135196",
-            "MEDDRA:10069211"
-          ],
-          "id": "MONDO:0006727",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Diastolic heart failure",
-            "Heart Failure, Diastolic",
-            "diastolic heart failure"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 518244,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006727",
-              "name": "diastolic heart failure",
-              "description": "Heart failure caused by abnormal myocardial relaxation during diastole leading to defective cardiac filling.",
-              "equivalent_curies": [
-                "ICD10:I50.30",
-                "ICD9:428.3",
-                "MONDO:0006727",
-                "SNOMEDCT:418304008",
-                "EFO:1000899",
-                "MESH:D054144",
-                "DOID:9775",
-                "UMLS:C1135196",
-                "MEDDRA:10069211"
-              ],
-              "id": "MONDO:0006727",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Diastolic heart failure",
-                "Heart Failure, Diastolic",
-                "diastolic heart failure"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17242732,
-            "start": 557,
-            "end": 518244,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24765517': {'publication date': '2013 Aug 02', 'sentence': 'One should be more critical about ivabradine and low-dose digoxin in diastolic heart failure.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:associated_with---None---None---None---UMLS:C1135196---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "17604344",
-              "object": "MONDO:0006727",
-              "publications": [
-                "PMID:24765517"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005468",
-          "name": "hypotensive disorder",
-          "description": "Blood pressure that is abnormally low.; Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.; Low Blood Pressure, vascular hypotension. [HPO:probinson]; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "MEDDRA:10036638",
-            "PDQ:CDR0000041785",
-            "MEDDRA:10021099",
-            "MEDDRA:10024896",
-            "MEDDRA:10024895",
-            "MEDDRA:10003146",
-            "MEDDRA:10024982",
-            "MEDDRA:10021106",
-            "EFO:0005251",
-            "SYMP:0000059",
-            "SNOMEDCT:45007003",
-            "NCIT:C3128",
-            "MEDDRA:10016174",
-            "PSY:24060",
-            "MEDDRA:10005744",
-            "MEDDRA:10066331",
-            "HP:0002615",
-            "ICD9:458",
-            "MEDDRA:10005753",
-            "MEDDRA:10005734",
-            "MEDDRA:10021097",
-            "MEDDRA:10013645",
-            "MEDDRA:10013644",
-            "MEDDRA:10006065",
-            "MONDO:0005468",
-            "MEDDRA:10003169",
-            "MEDDRA:10005743",
-            "MEDDRA:10006064",
-            "UMLS:C0020649",
-            "MESH:D007022"
-          ],
-          "id": "MONDO:0005468",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hypotensive disorder",
-            "hypotension",
-            "Hypotension"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:DiseaseOrPhenotypicFeature",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://github.com/monarch-initiative/mondo/issues/1030"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 295849,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-=======
-            "identity": 319508,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005468",
-              "name": "hypotensive disorder",
-              "description": "Blood pressure that is abnormally low.; Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.; Low Blood Pressure, vascular hypotension. [HPO:probinson]; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "MEDDRA:10036638",
-                "PDQ:CDR0000041785",
-                "MEDDRA:10021099",
-                "MEDDRA:10024896",
-                "MEDDRA:10024895",
-                "MEDDRA:10003146",
-                "MEDDRA:10024982",
-                "MEDDRA:10021106",
-                "EFO:0005251",
-                "SYMP:0000059",
-                "SNOMEDCT:45007003",
-                "NCIT:C3128",
-                "MEDDRA:10016174",
-                "PSY:24060",
-                "MEDDRA:10005744",
-                "MEDDRA:10066331",
-                "HP:0002615",
-                "ICD9:458",
-                "MEDDRA:10005753",
-                "MEDDRA:10005734",
-                "MEDDRA:10021097",
-                "MEDDRA:10013645",
-                "MEDDRA:10013644",
-                "MEDDRA:10006065",
-                "MONDO:0005468",
-                "MEDDRA:10003169",
-                "MEDDRA:10005743",
-                "MEDDRA:10006064",
-                "UMLS:C0020649",
-                "MESH:D007022"
-              ],
-              "id": "MONDO:0005468",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hypotensive disorder",
-                "hypotension",
-                "Hypotension"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:DiseaseOrPhenotypicFeature",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://github.com/monarch-initiative/mondo/issues/1030"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 18849287,
-            "start": 557,
-            "end": 295849,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27659287': {'publication date': '2016 Dec', 'sentence': 'Preclinical studies of ivabradine in animal models with induced AF demonstrated a reduction in HR, with no significant worsening of QT interval or mean arterial pressure.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:causes---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "19228519",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:27659287"
-=======
-            "identity": 21076965,
-            "start": 557,
-            "end": 319508,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:31878852': {'publication date': '2019 Dec 26', 'sentence': 'These are: the association of dobutamine infusion with amiodarone or ivabradine in patients with symptomatic hypotension, and high-dose furosemide associated to hypertonic saline solution, levosimendan, hydralazine/isosorbide dinitrate, sodium nitroprusside or ivabradine in hemodynamically stable patients.', 'subject score': 1000, 'object score': 888}, 'PMID:35024059': {'publication date': '2022 Jan', 'sentence': 'Thus, a patient with low BP can benefit from treatment with ivabradine.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C0020649---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "21500374",
-              "object": "MONDO:0005468",
-              "publications": [
-                "PMID:31878852",
-                "PMID:35024059"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20382331,
-            "start": 557,
-            "end": 295849,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30606942': {'publication date': '2019 01 25', 'sentence': 'In this review, we summarize the current knowledge of the HCN4 channel and ivabradine, including the function of HCN4 in cardiac pacemaking, the mechanism of action of If inhibition by ivabradine, and the pharmacological and clinical effects of ivabradine in cardiac diseases as HF, coronary artery disease, and atrial fibrillation.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:affects---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "20784958",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:30606942"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317122,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005852",
-          "name": "mitral valve stenosis",
-          "description": "Narrowing of the passage through the MITRAL VALVE due to FIBROSIS, and CALCINOSIS in the leaflets and chordal areas. This elevates the left atrial pressure which, in turn, raises pulmonary venous and capillary pressure leading to bouts of DYSPNEA and TACHYCARDIA during physical exertion. RHEUMATIC FEVER is its primary cause.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D008946",
-            "UMLS:C0026269",
-            "MONDO:0005852",
-            "MEDDRA:10027733",
-            "NCIT:C50654",
-            "EFO:0007372",
-            "MEDDRA:10027719",
-            "HP:0001718",
-            "ICD9:394.0",
-            "DOID:1754",
-            "SNOMEDCT:79619009"
-          ],
-          "id": "MONDO:0005852",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Mitral stenosis",
-            "Mitral Valve Stenosis",
-            "mitral valve stenosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/mitral_valve_stenosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317122,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005852",
-              "name": "mitral valve stenosis",
-              "description": "Narrowing of the passage through the MITRAL VALVE due to FIBROSIS, and CALCINOSIS in the leaflets and chordal areas. This elevates the left atrial pressure which, in turn, raises pulmonary venous and capillary pressure leading to bouts of DYSPNEA and TACHYCARDIA during physical exertion. RHEUMATIC FEVER is its primary cause.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D008946",
-                "UMLS:C0026269",
-                "MONDO:0005852",
-                "MEDDRA:10027733",
-                "NCIT:C50654",
-                "EFO:0007372",
-                "MEDDRA:10027719",
-                "HP:0001718",
-                "ICD9:394.0",
-                "DOID:1754",
-                "SNOMEDCT:79619009"
-              ],
-              "id": "MONDO:0005852",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Mitral stenosis",
-                "Mitral Valve Stenosis",
-                "mitral valve stenosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/mitral_valve_stenosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20121566,
-            "start": 557,
-            "end": 317122,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30116450': {'publication date': '2018 Aug', 'sentence': 'Small studies have recently investigated the role of ivabradine in MS in sinus rhythm.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:affects---None---None---None---UMLS:C0026269---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "20520107",
-              "object": "MONDO:0005852",
-              "publications": [
-                "PMID:30116450"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 518244,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006727",
-          "name": "diastolic heart failure",
-          "description": "Heart failure caused by abnormal myocardial relaxation during diastole leading to defective cardiac filling.",
-          "equivalent_curies": [
-            "ICD10:I50.30",
-            "ICD9:428.3",
-            "MONDO:0006727",
-            "SNOMEDCT:418304008",
-            "EFO:1000899",
-            "MESH:D054144",
-            "DOID:9775",
-            "UMLS:C1135196",
-            "MEDDRA:10069211"
-          ],
-          "id": "MONDO:0006727",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Diastolic heart failure",
-            "Heart Failure, Diastolic",
-            "diastolic heart failure"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 518244,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006727",
-              "name": "diastolic heart failure",
-              "description": "Heart failure caused by abnormal myocardial relaxation during diastole leading to defective cardiac filling.",
-              "equivalent_curies": [
-                "ICD10:I50.30",
-                "ICD9:428.3",
-                "MONDO:0006727",
-                "SNOMEDCT:418304008",
-                "EFO:1000899",
-                "MESH:D054144",
-                "DOID:9775",
-                "UMLS:C1135196",
-                "MEDDRA:10069211"
-              ],
-              "id": "MONDO:0006727",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Diastolic heart failure",
-                "Heart Failure, Diastolic",
-                "diastolic heart failure"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19613326,
-            "start": 557,
-            "end": 518244,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29142810': {'publication date': '2017', 'sentence': 'The role of Ivabradine in Diastolic Heart Failure with preserved Ejection Fraction.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:affects---None---None---None---UMLS:C1135196---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "20004006",
-              "object": "MONDO:0006727",
-              "publications": [
-                "PMID:29142810"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 308937,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-          "name": "cardiovascular disorder",
-          "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "MEDDRA:10045663",
-            "MONDO:0004995",
-            "ICD9:429.2",
-            "MEDDRA:10007649",
-            "UMLS:C0243050",
-            "HP:0001626",
-            "MESH:D018376",
-            "MEDDRA:10007648",
-            "MEDDRA:10013205",
-            "SNOMEDCT:49601007",
-            "MEDDRA:10007650",
-            "MESH:D002318",
-            "DOID:1287",
-            "UMLS:C0007222",
-            "UMLS:C0728936",
-            "NCIT:C2931"
-          ],
-          "id": "MONDO:0004995",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiovascular Diseases",
-            "Cardiovascular disease, unspecified",
-            "Abnormality of the cardiovascular system",
-            "cardiovascular system disease",
-            "Disorder of circulatory system",
-            "Cardiovascular Disorder",
-            "cardiovascular disorder",
-            "Cardiovascular Abnormalities"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/circulatory_system",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308937,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-              "name": "cardiovascular disorder",
-              "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "MEDDRA:10045663",
-                "MONDO:0004995",
-                "ICD9:429.2",
-                "MEDDRA:10007649",
-                "UMLS:C0243050",
-                "HP:0001626",
-                "MESH:D018376",
-                "MEDDRA:10007648",
-                "MEDDRA:10013205",
-                "SNOMEDCT:49601007",
-                "MEDDRA:10007650",
-                "MESH:D002318",
-                "DOID:1287",
-                "UMLS:C0007222",
-                "UMLS:C0728936",
-                "NCIT:C2931"
-              ],
-              "id": "MONDO:0004995",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiovascular Diseases",
-                "Cardiovascular disease, unspecified",
-                "Abnormality of the cardiovascular system",
-                "cardiovascular system disease",
-                "Disorder of circulatory system",
-                "Cardiovascular Disorder",
-                "cardiovascular disorder",
-                "Cardiovascular Abnormalities"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/circulatory_system",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15007018,
-            "start": 557,
-            "end": 308937,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21090826': {'publication date': '2011', 'sentence': 'Other large trials are also underway to assess the effects of ivabradine on heart failure, acute coronary syndromes, CAD, and other cardiovascular disorders.', 'subject score': 1000, 'object score': 1000}, 'PMID:22547315': {'publication date': '2012 Apr 30', 'sentence': 'The biological effects of ivabradine in cardiovascular disease.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:affects---None---None---None---UMLS:C0007222---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "15323309",
-              "object": "MONDO:0004995",
-              "publications": [
-                "PMID:21090826",
-                "PMID:22547315"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:21090826': {'publication date': '2011', 'sentence': 'Other large trials are also underway to assess the effects of ivabradine on heart failure, acute coronary syndromes, CAD, and other cardiovascular disorders.', 'subject score': 1000, 'object score': 1000}, 'PMID:26768739': {'publication date': '2016 Feb', 'sentence': 'Current Role of Ivabradine in Stable Coronary Artery Disease Without Heart Failure.', 'subject score': 1000, 'object score': 923}, 'PMID:30606942': {'publication date': '2019 01 25', 'sentence': 'In this review, we summarize the current knowledge of the HCN4 channel and ivabradine, including the function of HCN4 in cardiac pacemaking, the mechanism of action of If inhibition by ivabradine, and the pharmacological and clinical effects of ivabradine in cardiac diseases as HF, coronary artery disease, and atrial fibrillation.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 317775,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005010",
-          "name": "coronary artery disorder",
-          "description": "Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. [HPO:probinson]; Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. // COMMENTS: Coronary artery disease, also called atherosclerotic heart disease, is the result of atheromatous plaques within the coronary arteries leading to myocardial ischemia and infarction.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003324",
-            "ICD10:I25.10",
-            "MEDDRA:10008936",
-            "EFO:0001645",
-            "MEDDRA:10011081",
-            "HP:0001677",
-            "MEDDRA:10011106",
-            "PSY:11853",
-            "SNOMEDCT:53741008",
-            "SNOMEDCT:413844008",
-            "ICD9:414.0",
-            "MEDDRA:10003211",
-            "MEDDRA:10011079",
-            "ICD10:I20-I25",
-            "ICD9:410-414.99",
-            "MEDDRA:10013210",
-            "MEDDRA:10011076",
-            "UMLS:C0010068",
-            "MEDDRA:10011080",
-            "UMLS:C1956346",
-            "UMLS:C1533195",
-            "DOID:3393",
-            "NCIT:C26732",
-            "UMLS:C0010054",
-            "SNOMEDCT:413838009",
-            "MEDDRA:10011099",
-            "MEDDRA:10013098",
-            "MEDDRA:10008937",
-            "MEDDRA:10011078",
-            "MEDDRA:10011093",
-            "MEDDRA:10068617",
-            "ICD9:414.9",
-            "ICD10:I25",
-            "MEDDRA:10011087",
-            "MESH:D003327",
-            "MEDDRA:10049175",
-            "SNOMEDCT:414024009",
-            "MEDDRA:10011082",
-            "UMLS:C0264694",
-            "MONDO:0005010"
-          ],
-          "id": "MONDO:0005010",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic ischemic heart disease, unspecified",
-            "Coronary Artery Disease",
-            "Ischemic heart disease",
-            "Coronary atherosclerosis",
-            "Coronary artery atherosclerosis",
-            "Coronary Arteriosclerosis",
-            "Coronary Heart Disease",
-            "coronary artery disease",
-            "Coronary Disease",
-            "Chronic myocardial ischemia",
-            "Coronary heart disease",
-            "coronary artery disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:31420554",
-            "http://en.wikipedia.org/wiki/coronary_heart_disease",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317775,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005010",
-              "name": "coronary artery disorder",
-              "description": "Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. [HPO:probinson]; Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. // COMMENTS: Coronary artery disease, also called atherosclerotic heart disease, is the result of atheromatous plaques within the coronary arteries leading to myocardial ischemia and infarction.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003324",
-                "ICD10:I25.10",
-                "MEDDRA:10008936",
-                "EFO:0001645",
-                "MEDDRA:10011081",
-                "HP:0001677",
-                "MEDDRA:10011106",
-                "PSY:11853",
-                "SNOMEDCT:53741008",
-                "SNOMEDCT:413844008",
-                "ICD9:414.0",
-                "MEDDRA:10003211",
-                "MEDDRA:10011079",
-                "ICD10:I20-I25",
-                "ICD9:410-414.99",
-                "MEDDRA:10013210",
-                "MEDDRA:10011076",
-                "UMLS:C0010068",
-                "MEDDRA:10011080",
-                "UMLS:C1956346",
-                "UMLS:C1533195",
-                "DOID:3393",
-                "NCIT:C26732",
-                "UMLS:C0010054",
-                "SNOMEDCT:413838009",
-                "MEDDRA:10011099",
-                "MEDDRA:10013098",
-                "MEDDRA:10008937",
-                "MEDDRA:10011078",
-                "MEDDRA:10011093",
-                "MEDDRA:10068617",
-                "ICD9:414.9",
-                "ICD10:I25",
-                "MEDDRA:10011087",
-                "MESH:D003327",
-                "MEDDRA:10049175",
-                "SNOMEDCT:414024009",
-                "MEDDRA:10011082",
-                "UMLS:C0264694",
-                "MONDO:0005010"
-              ],
-              "id": "MONDO:0005010",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic ischemic heart disease, unspecified",
-                "Coronary Artery Disease",
-                "Ischemic heart disease",
-                "Coronary atherosclerosis",
-                "Coronary artery atherosclerosis",
-                "Coronary Arteriosclerosis",
-                "Coronary Heart Disease",
-                "coronary artery disease",
-                "Coronary Disease",
-                "Chronic myocardial ischemia",
-                "Coronary heart disease",
-                "coronary artery disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:31420554",
-                "http://en.wikipedia.org/wiki/coronary_heart_disease",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15007015,
-            "start": 557,
-            "end": 317775,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21090826': {'publication date': '2011', 'sentence': 'Other large trials are also underway to assess the effects of ivabradine on heart failure, acute coronary syndromes, CAD, and other cardiovascular disorders.', 'subject score': 1000, 'object score': 1000}, 'PMID:26768739': {'publication date': '2016 Feb', 'sentence': 'Current Role of Ivabradine in Stable Coronary Artery Disease Without Heart Failure.', 'subject score': 1000, 'object score': 923}, 'PMID:30606942': {'publication date': '2019 01 25', 'sentence': 'In this review, we summarize the current knowledge of the HCN4 channel and ivabradine, including the function of HCN4 in cardiac pacemaking, the mechanism of action of If inhibition by ivabradine, and the pharmacological and clinical effects of ivabradine in cardiac diseases as HF, coronary artery disease, and atrial fibrillation.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:affects---None---None---None---UMLS:C0010054---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "15323306",
-              "object": "MONDO:0005010",
-              "publications": [
-                "PMID:21090826",
-                "PMID:26768739",
-                "PMID:30606942"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 319508,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005468",
-          "name": "hypotensive disorder",
-          "description": "Blood pressure that is abnormally low.; Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.; Low Blood Pressure, vascular hypotension. [HPO:probinson]; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "MEDDRA:10036638",
-            "PDQ:CDR0000041785",
-            "MEDDRA:10021099",
-            "MEDDRA:10024896",
-            "MEDDRA:10024895",
-            "MEDDRA:10003146",
-            "MEDDRA:10024982",
-            "MEDDRA:10021106",
-            "EFO:0005251",
-            "SYMP:0000059",
-            "SNOMEDCT:45007003",
-            "NCIT:C3128",
-            "MEDDRA:10016174",
-            "PSY:24060",
-            "MEDDRA:10005744",
-            "MEDDRA:10066331",
-            "HP:0002615",
-            "ICD9:458",
-            "MEDDRA:10005753",
-            "MEDDRA:10005734",
-            "MEDDRA:10021097",
-            "MEDDRA:10013645",
-            "MEDDRA:10013644",
-            "MEDDRA:10006065",
-            "MONDO:0005468",
-            "MEDDRA:10003169",
-            "MEDDRA:10005743",
-            "MEDDRA:10006064",
-            "UMLS:C0020649",
-            "MESH:D007022"
-          ],
-          "id": "MONDO:0005468",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hypotensive disorder",
-            "hypotension",
-            "Hypotension"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:DiseaseOrPhenotypicFeature",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://github.com/monarch-initiative/mondo/issues/1030"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319508,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005468",
-              "name": "hypotensive disorder",
-              "description": "Blood pressure that is abnormally low.; Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.; Low Blood Pressure, vascular hypotension. [HPO:probinson]; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "MEDDRA:10036638",
-                "PDQ:CDR0000041785",
-                "MEDDRA:10021099",
-                "MEDDRA:10024896",
-                "MEDDRA:10024895",
-                "MEDDRA:10003146",
-                "MEDDRA:10024982",
-                "MEDDRA:10021106",
-                "EFO:0005251",
-                "SYMP:0000059",
-                "SNOMEDCT:45007003",
-                "NCIT:C3128",
-                "MEDDRA:10016174",
-                "PSY:24060",
-                "MEDDRA:10005744",
-                "MEDDRA:10066331",
-                "HP:0002615",
-                "ICD9:458",
-                "MEDDRA:10005753",
-                "MEDDRA:10005734",
-                "MEDDRA:10021097",
-                "MEDDRA:10013645",
-                "MEDDRA:10013644",
-                "MEDDRA:10006065",
-                "MONDO:0005468",
-                "MEDDRA:10003169",
-                "MEDDRA:10005743",
-                "MEDDRA:10006064",
-                "UMLS:C0020649",
-                "MESH:D007022"
-              ],
-              "id": "MONDO:0005468",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hypotensive disorder",
-                "hypotension",
-                "Hypotension"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:DiseaseOrPhenotypicFeature",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://github.com/monarch-initiative/mondo/issues/1030"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21076965,
-            "start": 557,
-            "end": 319508,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:31878852': {'publication date': '2019 Dec 26', 'sentence': 'These are: the association of dobutamine infusion with amiodarone or ivabradine in patients with symptomatic hypotension, and high-dose furosemide associated to hypertonic saline solution, levosimendan, hydralazine/isosorbide dinitrate, sodium nitroprusside or ivabradine in hemodynamically stable patients.', 'subject score': 1000, 'object score': 888}, 'PMID:35024059': {'publication date': '2022 Jan', 'sentence': 'Thus, a patient with low BP can benefit from treatment with ivabradine.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C0020649---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "21500374",
-              "object": "MONDO:0005468",
-              "publications": [
-                "PMID:31878852",
-                "PMID:35024059"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 528832,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-          "name": "toxic shock syndrome",
-          "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C35498",
-            "UMLS:C0600327",
-            "UMLS:CN204669",
-            "MEDDRA:10044248",
-            "MESH:D012772",
-            "MEDDRA:10044249",
-            "SNOMEDCT:18504008",
-            "DOID:14115",
-            "MEDDRA:10042852",
-            "UMLS:C0036983",
-            "ORPHANET:36234",
-            "SNOMEDCT:76571007",
-            "MEDDRA:10040580",
-            "NCIT:C35018",
-            "MEDDRA:10040070",
-            "ICD9:040.82",
-            "ICD10:A48.3",
-            "MONDO:0001881",
-            "EFO:0006834",
-            "SYMP:0000451"
-          ],
-          "id": "MONDO:0001881",
-          "category": "biolink:Disease",
-          "all_names": [
-            "toxic shock syndrome",
-            "Septic Shock",
-            "Shock, Septic",
-            "Toxic Shock Syndrome",
-            "Bacterial toxic-shock syndrome",
-            "septic shock",
-            "Toxic shock syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 528832,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-              "name": "toxic shock syndrome",
-              "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C35498",
-                "UMLS:C0600327",
-                "UMLS:CN204669",
-                "MEDDRA:10044248",
-                "MESH:D012772",
-                "MEDDRA:10044249",
-                "SNOMEDCT:18504008",
-                "DOID:14115",
-                "MEDDRA:10042852",
-                "UMLS:C0036983",
-                "ORPHANET:36234",
-                "SNOMEDCT:76571007",
-                "MEDDRA:10040580",
-                "NCIT:C35018",
-                "MEDDRA:10040070",
-                "ICD9:040.82",
-                "ICD10:A48.3",
-                "MONDO:0001881",
-                "EFO:0006834",
-                "SYMP:0000451"
-              ],
-              "id": "MONDO:0001881",
-              "category": "biolink:Disease",
-              "all_names": [
-                "toxic shock syndrome",
-                "Septic Shock",
-                "Shock, Septic",
-                "Toxic Shock Syndrome",
-                "Bacterial toxic-shock syndrome",
-                "septic shock",
-                "Toxic shock syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18468862,
-            "start": 557,
-            "end": 528832,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26909707': {'publication date': '2016 09', 'sentence': 'If Channel Inhibition With Ivabradine Does Not Improve Cardiac and Vascular Function in Experimental Septic Shock.', 'subject score': 1000, 'object score': 901}, 'PMID:34407620': {'publication date': '2021 Aug 18', 'sentence': 'Effectiveness of enteral ivabradine for heart rate control in septic shock: A randomised controlled trial.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C0036983---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "18841652",
-              "object": "MONDO:0001881",
-              "publications": [
-                "PMID:26909707",
-                "PMID:34407620"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317122,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005852",
-          "name": "mitral valve stenosis",
-          "description": "Narrowing of the passage through the MITRAL VALVE due to FIBROSIS, and CALCINOSIS in the leaflets and chordal areas. This elevates the left atrial pressure which, in turn, raises pulmonary venous and capillary pressure leading to bouts of DYSPNEA and TACHYCARDIA during physical exertion. RHEUMATIC FEVER is its primary cause.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D008946",
-            "UMLS:C0026269",
-            "MONDO:0005852",
-            "MEDDRA:10027733",
-            "NCIT:C50654",
-            "EFO:0007372",
-            "MEDDRA:10027719",
-            "HP:0001718",
-            "ICD9:394.0",
-            "DOID:1754",
-            "SNOMEDCT:79619009"
-          ],
-          "id": "MONDO:0005852",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Mitral stenosis",
-            "Mitral Valve Stenosis",
-            "mitral valve stenosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/mitral_valve_stenosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317122,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005852",
-              "name": "mitral valve stenosis",
-              "description": "Narrowing of the passage through the MITRAL VALVE due to FIBROSIS, and CALCINOSIS in the leaflets and chordal areas. This elevates the left atrial pressure which, in turn, raises pulmonary venous and capillary pressure leading to bouts of DYSPNEA and TACHYCARDIA during physical exertion. RHEUMATIC FEVER is its primary cause.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D008946",
-                "UMLS:C0026269",
-                "MONDO:0005852",
-                "MEDDRA:10027733",
-                "NCIT:C50654",
-                "EFO:0007372",
-                "MEDDRA:10027719",
-                "HP:0001718",
-                "ICD9:394.0",
-                "DOID:1754",
-                "SNOMEDCT:79619009"
-              ],
-              "id": "MONDO:0005852",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Mitral stenosis",
-                "Mitral Valve Stenosis",
-                "mitral valve stenosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/mitral_valve_stenosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17764958,
-            "start": 557,
-            "end": 317122,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25636072': {'publication date': '2015 Jun', 'sentence': 'Ivabradine thus can be used effectively and safely in patients with MS in normal sinus rhythm who are intolerant or contraindicated for beta-blocker therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:27420578': {'publication date': '2016 Oct 15', 'sentence': 'Metoprolol vs ivabradine in patients with mitral stenosis in sinus rhythm.', 'subject score': 1000, 'object score': 1000}, 'PMID:27537731': {'publication date': '2016 Nov 15', 'sentence': 'Metoprolol vs ivabradine in patients with mitral stenosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:30116450': {'publication date': '2018 Aug', 'sentence': 'Ivabradine Versus Beta-Blockers in Mitral Stenosis in Sinus Rhythm: An Updated Meta-Analysis of Randomized Controlled Trials.', 'subject score': 1000, 'object score': 1000}, 'PMID:30659493': {'publication date': '2019 Feb', 'sentence': 'Aim of the review The aim of this systematic review and meta-analysis was to compare the efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C0026269---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "18126606",
-              "object": "MONDO:0005852",
-              "publications": [
-                "PMID:25636072",
-                "PMID:27420578",
-                "PMID:27537731",
-                "PMID:30116450",
-                "PMID:30659493"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17242730,
-            "start": 557,
-            "end": 295849,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24765517': {'publication date': '2013 Aug 02', 'sentence': 'Ivabradine is ineffective in atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:24814540': {'publication date': '2014 Jul 15', 'sentence': 'Might ivabradine be useful in permanent atrial fibrillation?', 'subject score': 1000, 'object score': 901}, 'PMID:25464400': {'publication date': '2015 Jan 20', 'sentence': 'Ivabradine for rate control in atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:25982136': {'publication date': '2015 May 16', 'sentence': 'Effects of ivabradine on cardiac electrophysiology in dogs with age-related atrial fibrillation.', 'subject score': 1000, 'object score': 861}, 'PMID:26386926': {'publication date': '2016 01 01', 'sentence': 'Addition of ivabradine to betablockers in patients with atrial fibrillation: Effects on heart rate and exercise tolerance.', 'subject score': 1000, 'object score': 1000}, 'PMID:27511965': {'publication date': '2016 Oct', 'sentence': 'We used trial sequential analysis (TSA) to provide information on when we had reached firm evidence of new AF based on a 15% relative risk increase (RRI) in ivabradine treatment.', 'subject score': 888, 'object score': 901}, 'PMID:27589039': {'publication date': '2016 Nov 15', 'sentence': 'Need for further studies on ivabradine in patients with persistent atrial fibrillation.', 'subject score': 1000, 'object score': 901}, 'PMID:27614572': {'publication date': '2016 11 15', 'sentence': 'Corrigendum to \"Addition of ivabradine to betablockers in patients with atrial fibrillation: Effects on heart rate and exercise tolerance\" [Int. J. Cardiol. 202 (2016) 76-77].', 'subject score': 1000, 'object score': 1000}, 'PMID:27659287': {'publication date': '2016 Dec', 'sentence': 'Prospective, randomized studies are needed to determine if ivabradine has a role as a rate-control treatment in patients with AF.', 'subject score': 1000, 'object score': 1000}, 'PMID:30302853': {'publication date': '2018 Oct 09', 'sentence': 'Long-term treatment with ivabradine in transgenic atrial fibrillation mice counteracts hyperpolarization-activated cyclic nucleotide gated channel overexpression.', 'subject score': 1000, 'object score': 888}, 'PMID:30427090': {'publication date': '2018 Nov 14', 'sentence': 'Potential use of ivabradine for treatment of atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:31631048': {'publication date': '2019 Oct 17', 'sentence': 'METHODS: A multicenter, randomized, parallel, open-label, noninferiority phase III clinical trial will be conducted to compare ivabradine vs digoxin in 232 patients with uncontrolled permanent AF despite beta-blockers or calcium channel blockers.', 'subject score': 1000, 'object score': 861}, 'PMID:34983905': {'publication date': '2021 Dec 27', 'sentence': 'Furthermore, ivabradine may be effective in controlling the ventricular rate in patients with AF, although more RCTs are needed to support this conclusion.', 'subject score': 1000, 'object score': 1000}, 'PMID:35995556': {'publication date': '2022 Aug 22', 'sentence': 'PURPOSE: We conducted a retrospective observational study using Taiwanese insurance records to examine the association between beta blocker (BB)/ ivabradine (IVA) and cardiovascular (CV) outcomes in patients with atrial fibrillation (AF).', 'subject score': 901, 'object score': 1000}, 'PMID:37117042': {'publication date': '2022 Aug 22', 'sentence': 'PURPOSE: We conducted a retrospective observational study using Taiwanese insurance records to examine the association between beta blocker (BB)/ ivabradine (IVA) and cardiovascular (CV) outcomes in patients with atrial fibrillation (AF).', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "17604342",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:24765517",
-                "PMID:24814540",
-                "PMID:25464400",
-                "PMID:25982136",
-                "PMID:26386926",
-                "PMID:27511965",
-                "PMID:27589039",
-                "PMID:27614572",
-                "PMID:27659287",
-                "PMID:30302853",
-                "PMID:30427090",
-                "PMID:31631048",
-                "PMID:34983905",
-                "PMID:35995556",
-                "PMID:37117042"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 518244,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006727",
-          "name": "diastolic heart failure",
-          "description": "Heart failure caused by abnormal myocardial relaxation during diastole leading to defective cardiac filling.",
-          "equivalent_curies": [
-            "ICD10:I50.30",
-            "ICD9:428.3",
-            "MONDO:0006727",
-            "SNOMEDCT:418304008",
-            "EFO:1000899",
-            "MESH:D054144",
-            "DOID:9775",
-            "UMLS:C1135196",
-            "MEDDRA:10069211"
-          ],
-          "id": "MONDO:0006727",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Diastolic heart failure",
-            "Heart Failure, Diastolic",
-            "diastolic heart failure"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 518244,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006727",
-              "name": "diastolic heart failure",
-              "description": "Heart failure caused by abnormal myocardial relaxation during diastole leading to defective cardiac filling.",
-              "equivalent_curies": [
-                "ICD10:I50.30",
-                "ICD9:428.3",
-                "MONDO:0006727",
-                "SNOMEDCT:418304008",
-                "EFO:1000899",
-                "MESH:D054144",
-                "DOID:9775",
-                "UMLS:C1135196",
-                "MEDDRA:10069211"
-              ],
-              "id": "MONDO:0006727",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Diastolic heart failure",
-                "Heart Failure, Diastolic",
-                "diastolic heart failure"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17242728,
-            "start": 557,
-            "end": 518244,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24765517': {'publication date': '2013 Aug 02', 'sentence': 'The aim of the study was to compare the therapeutic effects of ivabradine in diastolic heart failure with preserved left ventricular systolic function.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C1135196---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "17604340",
-              "object": "MONDO:0006727",
-              "publications": [
-                "PMID:24765517"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 894650,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043726",
-          "name": "multiple organ dysfunction syndrome",
-          "description": "Complete impairment of two or more organs or organ systems.; Progressive, potentially reversible physiologic dysfunction in two or more organ systems in response to severe physiologic insult. Dysregulated immunological response is the critical pathophysiologic factor in most cases.; A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0043726",
-            "SYMP:0000724",
-            "MESH:D009102",
-            "UMLS:C0026766",
-            "NCIT:C75568",
-            "SNOMEDCT:57653000",
-            "NCIT:C179648",
-            "EFO:1001373",
-            "MEDDRA:10028154",
-            "MEDDRA:10028237",
-            "MEDDRA:10028162",
-            "MEDDRA:10028151",
-            "MEDDRA:10077361"
-          ],
-          "id": "MONDO:0043726",
-          "category": "biolink:Disease",
-          "all_names": [
-            "multiple organ failure",
-            "Multiple Organ Failure",
-            "Multiple Organ Dysfunction Syndrome",
-            "multiple organ dysfunction syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/books/nbk6868/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 894650,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043726",
-              "name": "multiple organ dysfunction syndrome",
-              "description": "Complete impairment of two or more organs or organ systems.; Progressive, potentially reversible physiologic dysfunction in two or more organ systems in response to severe physiologic insult. Dysregulated immunological response is the critical pathophysiologic factor in most cases.; A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0043726",
-                "SYMP:0000724",
-                "MESH:D009102",
-                "UMLS:C0026766",
-                "NCIT:C75568",
-                "SNOMEDCT:57653000",
-                "NCIT:C179648",
-                "EFO:1001373",
-                "MEDDRA:10028154",
-                "MEDDRA:10028237",
-                "MEDDRA:10028162",
-                "MEDDRA:10028151",
-                "MEDDRA:10077361"
-              ],
-              "id": "MONDO:0043726",
-              "category": "biolink:Disease",
-              "all_names": [
-                "multiple organ failure",
-                "Multiple Organ Failure",
-                "Multiple Organ Dysfunction Syndrome",
-                "multiple organ dysfunction syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/books/nbk6868/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15359674,
-            "start": 557,
-            "end": 894650,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21638157': {'publication date': '2011 Oct', 'sentence': 'CONCLUSIONS: The MODI (f)Y trial is the first application of ivabradine as a pure heart rate reducing agent in MODS patients.', 'subject score': 1000, 'object score': 928}, 'PMID:28930912': {'publication date': '2018 Apr', 'sentence': 'CONCLUSIONS: The number of critically ill patients with MODS and a sinus rhythm of at least 90?beats/min that experienced a heart rate reduction of at least 10?beats/min after oral ivabradine treatment did not differ significantly between groups.', 'subject score': 851, 'object score': 1000}, 'PMID:30595304': {'publication date': '2018 Dec', 'sentence': 'Based on the principle of benefits of reduced HR, the ivabradine in patients with ischemic heart disease, sepsis, and multiple organ dysfunction syndrome has also been studied.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C0026766---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "15681673",
-              "object": "MONDO:0043726",
-              "publications": [
-                "PMID:21638157",
-                "PMID:28930912",
-                "PMID:30595304"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 518250,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006993",
-          "name": "systolic heart failure",
-          "description": "Heart failure caused by abnormal myocardial contraction during systole leading to defective cardiac emptying.",
-          "equivalent_curies": [
-            "DOID:9651",
-            "EFO:1001207",
-            "ICD10:I50.20",
-            "UMLS:C1135191",
-            "SNOMEDCT:417996009",
-            "ICD9:428.2",
-            "MESH:D054143",
-            "MEDDRA:10074631",
-            "MONDO:0006993"
-          ],
-          "id": "MONDO:0006993",
-          "category": "biolink:Disease",
-          "all_names": [
-            "systolic heart failure",
-            "Systolic heart failure",
-            "Heart Failure, Systolic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 518250,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006993",
-              "name": "systolic heart failure",
-              "description": "Heart failure caused by abnormal myocardial contraction during systole leading to defective cardiac emptying.",
-              "equivalent_curies": [
-                "DOID:9651",
-                "EFO:1001207",
-                "ICD10:I50.20",
-                "UMLS:C1135191",
-                "SNOMEDCT:417996009",
-                "ICD9:428.2",
-                "MESH:D054143",
-                "MEDDRA:10074631",
-                "MONDO:0006993"
-              ],
-              "id": "MONDO:0006993",
-              "category": "biolink:Disease",
-              "all_names": [
-                "systolic heart failure",
-                "Systolic heart failure",
-                "Heart Failure, Systolic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15320099,
-            "start": 557,
-            "end": 518250,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21573990': {'publication date': '2011 Jun', 'sentence': 'Ivabradine added to guidelines-based therapy in systolic heart failure patients.', 'subject score': 1000, 'object score': 916}, 'PMID:22892123': {'publication date': '2013 Jan', 'sentence': 'AIMS: A post-hoc analysis of the SHIFT trial was performed to explore whether ivabradine is beneficial in patients with systolic heart failure, in sinus rhythm, with resting heart rate >=70 b.p.m., and whose guideline-recommended background therapy includes a mineralocorticoid receptor antagonist (MRA).', 'subject score': 1000, 'object score': 1000}, 'PMID:23549235': {'publication date': '2013 May', 'sentence': 'In addition to the nonspecific heart rate reducing drugs like beta-blockers, cardiac glycosides and Ca(2+) antagonists, ivabradine is a highly selective heart rate reducing agent without modifying ventricular contractility and atrioventricular conduction in humans and animals, and has recently been shown to improve cardiovascular outcomes in patients with systolic heart failure by lowering the heart rate only.', 'subject score': 1000, 'object score': 1000}, 'PMID:23696612': {'publication date': '2013 Sep', 'sentence': 'Heart rate reduction with ivabradine improves outcomes in patients with systolic HF.', 'subject score': 1000, 'object score': 1000}, 'PMID:23929789': {'publication date': '2013 Nov', 'sentence': 'CONCLUSIONS: In outpatients with systolic HF, the NT-proBNP reduction obtained by short-term ivabradine treatment correlates closely with the degree of HR reduction.', 'subject score': 861, 'object score': 1000}, 'PMID:24327100': {'publication date': '2014 Apr', 'sentence': 'Here we review the evidence of the prognostic role of HR in systolic HF and the potential relationship between HR lowering and the beneficial effects of beta-blockers; we will also analyze the reasons why an appropriate use of these drugs is seldom achieved in clinical practice, and review the evidence for the use of ivabradine in systolic HF in the clinical setting.', 'subject score': 1000, 'object score': 1000}, 'PMID:25733317': {'publication date': '2015', 'sentence': 'The primary aim of our study was to evaluate the short-term (6 months) effect of ivabradine on N-terminal pro B-type natriuretic peptide (NT-proBNP), CA-125, and cystatin-C values in systolic HF outpatients, and secondary aim was to determine the relationship between baseline HR and the NT-proBNP, CA-125, cystatin-C, and clinical status variation with ivabradine therapy.', 'subject score': 888, 'object score': 916}, 'PMID:25801408': {'publication date': '2015 May', 'sentence': 'CONCLUSION: Ivabradine safely and significantly lowers HR and improves HR variability in patients with systolic heart failure, without inducing significant bradycardia, ventricular arrhythmias, or supraventricular arrhythmias.', 'subject score': 861, 'object score': 1000}, 'PMID:25968495': {'publication date': '2015', 'sentence': 'CONCLUSIONS: Whatever beta-blocker was coprescribed with ivabradine, there were improvements in cardiovascular outcomes in patients with systolic heart failure, especially with the most prescribed beta-blocker--carvedilol.', 'subject score': 1000, 'object score': 1000}, 'PMID:26721645': {'publication date': '2016 07', 'sentence': 'Ivabradine was only recently approved by Food and Drug administration after the results of Systolic Heart Failure Treatment with the If Inhibitor Ivabradine (SHIFT) trial, for a reduction in rehospitalizations from chronic heart failure.', 'subject score': 1000, 'object score': 916}, 'PMID:26817946': {'publication date': '2016 Apr', 'sentence': 'We reviewed clinical evidence for the use of ivabradine in systolic heart failure (HF), in which it appears to improve symptoms, improve quality of life, prevent hospitalization, and prolong survival, thereby addressing unmet needs in the management of HF.', 'subject score': 1000, 'object score': 1000}, 'PMID:27780557': {'publication date': '2016 Dec 15', 'sentence': 'In conclusion, ivabradine improves outcomes in patients with systolic HF; rates of overall adverse events are similar to placebo.', 'subject score': 1000, 'object score': 1000}, 'PMID:27982270': {'publication date': '2016 Nov', 'sentence': 'Background:: In the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT), heart rate (HR) reduction with ivabradine was associated with improved survival and reduced hospitalizations in patients with heart failure (HF).', 'subject score': 1000, 'object score': 916}, 'PMID:28115808': {'publication date': '2017 Jan', 'sentence': 'BACKGROUND: The aim of our study was to evaluate in stable outpatients with systolic heart failure (HF) the 3 months effect of ivabradine on LV synchronization and Tei index in stable outpatients with systolic HF.', 'subject score': 1000, 'object score': 1000}, 'PMID:28289533': {'publication date': '2017 Feb 26', 'sentence': 'Ivabradine in the treatment of systolic heart failure - A systematic review and meta-analysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28316174': {'publication date': '2017 Mar 24', 'sentence': 'Objective: To evaluate the efficacy and safety of ivabradine for the treatment of Chinese patients with chronic heart failure based on the Chinese subgroup data of the systolic heart failure treatment with the I(f) inhibitor ivabradine trial (SHIFT).', 'subject score': 1000, 'object score': 916}, 'PMID:29142810': {'publication date': '2017', 'sentence': 'Background: Ivabradine (IVA) is effective in patients with coronary artery disease (CAD) or systolic heart failure in sinus rhythm.', 'subject score': 1000, 'object score': 1000}, 'PMID:29470374': {'publication date': '2018 Mar', 'sentence': 'Ivabradine for systolic heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:33956182': {'publication date': '2021 May 06', 'sentence': 'Heart rate modulation therapy using ivabradine reduces mortality and morbidity in patients with systolic heart failure, whereas too reduced heart rate seems to worsen the clinical outcome.', 'subject score': 1000, 'object score': 1000}, 'PMID:34148961': {'publication date': '2021 Jun 19', 'sentence': 'Objective Heart rate modulation therapy using ivabradine reduces both morbidity and mortality in patients with systolic heart failure.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C1135191---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "15641743",
-              "object": "MONDO:0006993",
-              "publications": [
-                "PMID:21573990",
-                "PMID:22892123",
-                "PMID:23549235",
-                "PMID:23696612",
-                "PMID:23929789",
-                "PMID:24327100",
-                "PMID:25733317",
-                "PMID:25801408",
-                "PMID:25968495",
-                "PMID:26721645",
-                "PMID:26817946",
-                "PMID:27780557",
-                "PMID:27982270",
-                "PMID:28115808",
-                "PMID:28289533",
-                "PMID:28316174",
-                "PMID:29142810",
-                "PMID:29470374",
-                "PMID:33956182",
-                "PMID:34148961"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317823,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001649",
-          "name": "Tachycardia",
-          "description": "A rapid heartrate that exceeds the range of the normal resting heartrate for age. [HPO:probinson]; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "MEDDRA:10019322",
-            "HP:0001649",
-            "MEDDRA:10019303",
-            "MEDDRA:10043071",
-            "MEDDRA:10037474",
-            "MEDDRA:10043086",
-            "MEDDRA:10037490",
-            "MESH:D013610",
-            "MEDDRA:10020081",
-            "SNOMEDCT:86651002",
-            "MEDDRA:10043078",
-            "UMLS:C4020868",
-            "UMLS:C0039231",
-            "SYMP:0000529",
-            "MEDDRA:10037733",
-            "SNOMEDCT:3424008",
-            "NCIT:C38029",
-            "MEDDRA:10066996",
-            "PSY:51360",
-            "MEDDRA:10019302",
-            "MEDDRA:10037484"
-          ],
-          "id": "HP:0001649",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "tachycardia",
-            "Tachycardia",
-            "Elevated heart rate"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:DiseaseOrPhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tachycardia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317823,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001649",
-              "name": "Tachycardia",
-              "description": "A rapid heartrate that exceeds the range of the normal resting heartrate for age. [HPO:probinson]; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "MEDDRA:10019322",
-                "HP:0001649",
-                "MEDDRA:10019303",
-                "MEDDRA:10043071",
-                "MEDDRA:10037474",
-                "MEDDRA:10043086",
-                "MEDDRA:10037490",
-                "MESH:D013610",
-                "MEDDRA:10020081",
-                "SNOMEDCT:86651002",
-                "MEDDRA:10043078",
-                "UMLS:C4020868",
-                "UMLS:C0039231",
-                "SYMP:0000529",
-                "MEDDRA:10037733",
-                "SNOMEDCT:3424008",
-                "NCIT:C38029",
-                "MEDDRA:10066996",
-                "PSY:51360",
-                "MEDDRA:10019302",
-                "MEDDRA:10037484"
-              ],
-              "id": "HP:0001649",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "tachycardia",
-                "Tachycardia",
-                "Elevated heart rate"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:DiseaseOrPhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tachycardia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13273899,
-            "start": 557,
-            "end": 317823,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18221092': {'publication date': '2006 Nov', 'sentence': 'Clinical studies proved the efficacy of ivabradine in patients with stable angina, while clinical data are awaited to verify its probable value in the treatment of atrial tachyarrhythmias and tachycardia due to ventricular dysfunction.', 'subject score': 1000, 'object score': 1000}, 'PMID:21526046': {'publication date': '2011 Apr 26', 'sentence': 'Increased heart rate and atherosclerosis: potential implications of ivabradine therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:23719030': {'publication date': '2013 Aug', 'sentence': 'Is ivabradine suitable to control undesirable tachycardia induced by dobutamine in cardiogenic shock treatment?', 'subject score': 1000, 'object score': 861}, 'PMID:29189314': {'publication date': '2018 Nov/Dec', 'sentence': 'Ivabradine for Treatment of Refractory Tachycardia in a Patient With Hypertrophic Cardiomyopathy.', 'subject score': 1000, 'object score': 888}, 'PMID:31242382': {'publication date': '2019 06 27', 'sentence': 'More on Ivabradine in Tachycardia with Paraganglioma.', 'subject score': 1000, 'object score': 1000}, 'PMID:31242383': {'publication date': '2019 06 27', 'sentence': 'More on Ivabradine in Tachycardia with Paraganglioma.', 'subject score': 1000, 'object score': 1000}, 'PMID:31332966': {'publication date': '2019 Oct', 'sentence': 'As ivabradine does not have negative inotropic action, it may present a potential means to manage tachycardia in cardiogenic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:32612966': {'publication date': '2020', 'sentence': 'Due to its mechanism of action Ivabradine is a promising novel agent for the therapy of tachycardia due to increased automaticity.', 'subject score': 888, 'object score': 1000}, 'PMID:33018577': {'publication date': '2020 Jul', 'sentence': 'Tachycardia control in septic shock with esmolol and ivabradine: a comparison on heart function.', 'subject score': 1000, 'object score': 694}, 'PMID:35024059': {'publication date': '2022 Jan', 'sentence': 'In summary, we used ivabradine for a patient with tachycardia, low BP, a low LVEF, and severe MR.', 'subject score': 1000, 'object score': 1000}, 'PMID:35154785': {'publication date': '2022 Dec', 'sentence': 'Background: Ivabradine is used to treat tachycardia; unlike atenolol, it does not affect blood pressure or myocardial contractility.', 'subject score': 1000, 'object score': 1000}, 'PMID:35464795': {'publication date': '2022 Jun', 'sentence': 'Her tachycardia was successfully treated with ivabradine and diltiazem.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C0039231---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "13559450",
-              "object": "HP:0001649",
-              "publications": [
-                "PMID:18221092",
-                "PMID:21526046",
-                "PMID:23719030",
-                "PMID:29189314",
-                "PMID:31242382",
-                "PMID:31242383",
-                "PMID:31332966",
-                "PMID:32612966",
-                "PMID:33018577",
-                "PMID:35024059",
-                "PMID:35154785",
-                "PMID:35464795"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:16621590': {'publication date': '2006 May', 'sentence': 'The effective drug, ivabradine, has demonstrated anti-anginal, anti-ischemic efficacy and now is being tested for its effect on survival in patients with coronary artery disease and impaired left ventricular function, as well as for heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:17070146': {'publication date': '2006 Nov', 'sentence': 'Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.', 'subject score': 773, 'object score': 1000}, 'PMID:17890862': {'publication date': '2007', 'sentence': 'CONCLUSION: Ivabradine at the recommended doses of 5 and 7.5 mg b.i.d. was well tolerated and demonstrated antianginal efficacy in patients with documented coronary artery disease treated with concomitant antianginal medications.', 'subject score': 1000, 'object score': 916}, 'PMID:17999562': {'publication date': '2007', 'sentence': 'The ongoing clinical development programme with the two major morbidity-mortality studies, BEAUTIFUL and SHIfT, has the potential to greatly extend the use of ivabradine in patients with coronary artery disease as well as in those with heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:18595216': {'publication date': '2008', 'sentence': 'The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population.', 'subject score': 1000, 'object score': 923}, 'PMID:18757088': {'publication date': '2008 Sep 06', 'sentence': 'INTERPRETATION: Reduction in heart rate with ivabradine does not improve cardiac outcomes in all patients with stable coronary artery disease and left-ventricular systolic dysfunction, but could be used to reduce the incidence of coronary artery disease outcomes in a subgroup of patients who have heart rates of 70 bpm or greater.', 'subject score': 1000, 'object score': 923}, 'PMID:19165437': {'publication date': '2009 Jan', 'sentence': 'Although ivabradine has been shown not to improve cardiac outcomes in patients with stable CAD and left ventricular systolic dysfunction, it may be used to reduce the incidence of CAD outcomes in a subgroup of patients with HR > or =70 bpm.', 'subject score': 1000, 'object score': 923}, 'PMID:19517748': {'publication date': '2009 May 27', 'sentence': 'The available evidence demonstrates that ivabradine provides clinical benefits in coronary artery disease patients, symptomatic or not with a heart rate > or = 70 bpm, irrespective of the background therapy.', 'subject score': 1000, 'object score': 916}, 'PMID:19720635': {'publication date': '2009 Oct', 'sentence': 'AIMS: BEAUTIFUL found no impact of ivabradine on outcomes in patients with stable coronary artery disease (CAD) and left ventricular systolic dysfunction (LVSD).', 'subject score': 1000, 'object score': 923}, 'PMID:19781403': {'publication date': '2009 Oct', 'sentence': 'Ivabradine reduces the HR and is highly effective and well tolerated in the treatment of patients with symptomatic coronary artery disease.', 'subject score': 1000, 'object score': 916}, 'PMID:20000882': {'publication date': '2009', 'sentence': 'The BEAUTIFUL (morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary artery disease and left ventricULar systolic dysfunction) study assessed the morbidity and mortality benefits of the HR-lowering agent ivabradine.', 'subject score': 872, 'object score': 1000}, 'PMID:20419486': {'publication date': '2010 Mar', 'sentence': 'The specific pharmacodynamic and pharmacokinetic properties of IVA make it an important agent in the management of patients with coronary artery disease, particularly in those patients with an elevated HR.', 'subject score': 1000, 'object score': 1000}, 'PMID:20694080': {'publication date': '2008 Jun', 'sentence': 'Ongoing studies will determine the potential of ivabradine to improve morbidity and mortality in coronary artery disease and heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:21183181': {'publication date': '2011 Mar', 'sentence': 'The purpose of this study was to assess the effects of ivabradine on coronary flow velocity and flow reserve (CFR) in patients with stable coronary artery disease (CAD).', 'subject score': 1000, 'object score': 923}, 'PMID:21247517': {'publication date': '2011 Mar 15', 'sentence': 'The BEAUTIFUL Holter substudy explored the cardiac safety of the I(f) inhibitor ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction receiving optimal background therapy.', 'subject score': 773, 'object score': 923}, 'PMID:21254949': {'publication date': '2011 Feb', 'sentence': 'Recently ivabradine has been shown to improve cardiac outcomes in stable coronary artery disease and left ventricular systolic dysfunction in patients who have heart rates of >= 70 bpm and in patients with stable angina.', 'subject score': 888, 'object score': 923}, 'PMID:21434947': {'publication date': '2011 Mar', 'sentence': 'Two major morbidity-mortality trials, BEAUTIFUL and SHIFT, showed that heart rate reduction with ivabradine dramatically improves prognosis in patients with coronary artery disease and left ventricular dysfunction, symptomatic angina, or chronic heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:21878041': {'publication date': '2011 Aug', 'sentence': 'The development of the heart rate-lowering agent ivabradine showed that heart rate was also an important treatment target, notably in coronary artery disease and heart failure.', 'subject score': 831, 'object score': 1000}, 'PMID:23394554': {'publication date': '2013', 'sentence': 'More recently, IVA has been highly recommended to be used in patients with CAD in association with beta-blockers.', 'subject score': 1000, 'object score': 1000}, 'PMID:24065301': {'publication date': '2013 Sep', 'sentence': 'The SIGNIFY (Study assessInG the morbidity-mortality beNefits of the I f inhibitor ivabradine in patients with coronarY artery disease) trial includes patients with stable CAD and an LVEF above 40 %, with no clinical sign of HF, and is investigating the long-term effects (over a period of 48 months) of ivabradine in a large study population.', 'subject score': 773, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 317775,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005010",
-          "name": "coronary artery disorder",
-          "description": "Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. [HPO:probinson]; Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. // COMMENTS: Coronary artery disease, also called atherosclerotic heart disease, is the result of atheromatous plaques within the coronary arteries leading to myocardial ischemia and infarction.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003324",
-            "ICD10:I25.10",
-            "MEDDRA:10008936",
-            "EFO:0001645",
-            "MEDDRA:10011081",
-            "HP:0001677",
-            "MEDDRA:10011106",
-            "PSY:11853",
-            "SNOMEDCT:53741008",
-            "SNOMEDCT:413844008",
-            "ICD9:414.0",
-            "MEDDRA:10003211",
-            "MEDDRA:10011079",
-            "ICD10:I20-I25",
-            "ICD9:410-414.99",
-            "MEDDRA:10013210",
-            "MEDDRA:10011076",
-            "UMLS:C0010068",
-            "MEDDRA:10011080",
-            "UMLS:C1956346",
-            "UMLS:C1533195",
-            "DOID:3393",
-            "NCIT:C26732",
-            "UMLS:C0010054",
-            "SNOMEDCT:413838009",
-            "MEDDRA:10011099",
-            "MEDDRA:10013098",
-            "MEDDRA:10008937",
-            "MEDDRA:10011078",
-            "MEDDRA:10011093",
-            "MEDDRA:10068617",
-            "ICD9:414.9",
-            "ICD10:I25",
-            "MEDDRA:10011087",
-            "MESH:D003327",
-            "MEDDRA:10049175",
-            "SNOMEDCT:414024009",
-            "MEDDRA:10011082",
-            "UMLS:C0264694",
-            "MONDO:0005010"
-          ],
-          "id": "MONDO:0005010",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic ischemic heart disease, unspecified",
-            "Coronary Artery Disease",
-            "Ischemic heart disease",
-            "Coronary atherosclerosis",
-            "Coronary artery atherosclerosis",
-            "Coronary Arteriosclerosis",
-            "Coronary Heart Disease",
-            "coronary artery disease",
-            "Coronary Disease",
-            "Chronic myocardial ischemia",
-            "Coronary heart disease",
-            "coronary artery disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:31420554",
-            "http://en.wikipedia.org/wiki/coronary_heart_disease",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317775,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005010",
-              "name": "coronary artery disorder",
-              "description": "Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. [HPO:probinson]; Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. // COMMENTS: Coronary artery disease, also called atherosclerotic heart disease, is the result of atheromatous plaques within the coronary arteries leading to myocardial ischemia and infarction.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003324",
-                "ICD10:I25.10",
-                "MEDDRA:10008936",
-                "EFO:0001645",
-                "MEDDRA:10011081",
-                "HP:0001677",
-                "MEDDRA:10011106",
-                "PSY:11853",
-                "SNOMEDCT:53741008",
-                "SNOMEDCT:413844008",
-                "ICD9:414.0",
-                "MEDDRA:10003211",
-                "MEDDRA:10011079",
-                "ICD10:I20-I25",
-                "ICD9:410-414.99",
-                "MEDDRA:10013210",
-                "MEDDRA:10011076",
-                "UMLS:C0010068",
-                "MEDDRA:10011080",
-                "UMLS:C1956346",
-                "UMLS:C1533195",
-                "DOID:3393",
-                "NCIT:C26732",
-                "UMLS:C0010054",
-                "SNOMEDCT:413838009",
-                "MEDDRA:10011099",
-                "MEDDRA:10013098",
-                "MEDDRA:10008937",
-                "MEDDRA:10011078",
-                "MEDDRA:10011093",
-                "MEDDRA:10068617",
-                "ICD9:414.9",
-                "ICD10:I25",
-                "MEDDRA:10011087",
-                "MESH:D003327",
-                "MEDDRA:10049175",
-                "SNOMEDCT:414024009",
-                "MEDDRA:10011082",
-                "UMLS:C0264694",
-                "MONDO:0005010"
-              ],
-              "id": "MONDO:0005010",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic ischemic heart disease, unspecified",
-                "Coronary Artery Disease",
-                "Ischemic heart disease",
-                "Coronary atherosclerosis",
-                "Coronary artery atherosclerosis",
-                "Coronary Arteriosclerosis",
-                "Coronary Heart Disease",
-                "coronary artery disease",
-                "Coronary Disease",
-                "Chronic myocardial ischemia",
-                "Coronary heart disease",
-                "coronary artery disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:31420554",
-                "http://en.wikipedia.org/wiki/coronary_heart_disease",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12159866,
-            "start": 557,
-            "end": 317775,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16621590': {'publication date': '2006 May', 'sentence': 'The effective drug, ivabradine, has demonstrated anti-anginal, anti-ischemic efficacy and now is being tested for its effect on survival in patients with coronary artery disease and impaired left ventricular function, as well as for heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:17070146': {'publication date': '2006 Nov', 'sentence': 'Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.', 'subject score': 773, 'object score': 1000}, 'PMID:17890862': {'publication date': '2007', 'sentence': 'CONCLUSION: Ivabradine at the recommended doses of 5 and 7.5 mg b.i.d. was well tolerated and demonstrated antianginal efficacy in patients with documented coronary artery disease treated with concomitant antianginal medications.', 'subject score': 1000, 'object score': 916}, 'PMID:17999562': {'publication date': '2007', 'sentence': 'The ongoing clinical development programme with the two major morbidity-mortality studies, BEAUTIFUL and SHIfT, has the potential to greatly extend the use of ivabradine in patients with coronary artery disease as well as in those with heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:18595216': {'publication date': '2008', 'sentence': 'The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population.', 'subject score': 1000, 'object score': 923}, 'PMID:18757088': {'publication date': '2008 Sep 06', 'sentence': 'INTERPRETATION: Reduction in heart rate with ivabradine does not improve cardiac outcomes in all patients with stable coronary artery disease and left-ventricular systolic dysfunction, but could be used to reduce the incidence of coronary artery disease outcomes in a subgroup of patients who have heart rates of 70 bpm or greater.', 'subject score': 1000, 'object score': 923}, 'PMID:19165437': {'publication date': '2009 Jan', 'sentence': 'Although ivabradine has been shown not to improve cardiac outcomes in patients with stable CAD and left ventricular systolic dysfunction, it may be used to reduce the incidence of CAD outcomes in a subgroup of patients with HR > or =70 bpm.', 'subject score': 1000, 'object score': 923}, 'PMID:19517748': {'publication date': '2009 May 27', 'sentence': 'The available evidence demonstrates that ivabradine provides clinical benefits in coronary artery disease patients, symptomatic or not with a heart rate > or = 70 bpm, irrespective of the background therapy.', 'subject score': 1000, 'object score': 916}, 'PMID:19720635': {'publication date': '2009 Oct', 'sentence': 'AIMS: BEAUTIFUL found no impact of ivabradine on outcomes in patients with stable coronary artery disease (CAD) and left ventricular systolic dysfunction (LVSD).', 'subject score': 1000, 'object score': 923}, 'PMID:19781403': {'publication date': '2009 Oct', 'sentence': 'Ivabradine reduces the HR and is highly effective and well tolerated in the treatment of patients with symptomatic coronary artery disease.', 'subject score': 1000, 'object score': 916}, 'PMID:20000882': {'publication date': '2009', 'sentence': 'The BEAUTIFUL (morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary artery disease and left ventricULar systolic dysfunction) study assessed the morbidity and mortality benefits of the HR-lowering agent ivabradine.', 'subject score': 872, 'object score': 1000}, 'PMID:20419486': {'publication date': '2010 Mar', 'sentence': 'The specific pharmacodynamic and pharmacokinetic properties of IVA make it an important agent in the management of patients with coronary artery disease, particularly in those patients with an elevated HR.', 'subject score': 1000, 'object score': 1000}, 'PMID:20694080': {'publication date': '2008 Jun', 'sentence': 'Ongoing studies will determine the potential of ivabradine to improve morbidity and mortality in coronary artery disease and heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:21183181': {'publication date': '2011 Mar', 'sentence': 'The purpose of this study was to assess the effects of ivabradine on coronary flow velocity and flow reserve (CFR) in patients with stable coronary artery disease (CAD).', 'subject score': 1000, 'object score': 923}, 'PMID:21247517': {'publication date': '2011 Mar 15', 'sentence': 'The BEAUTIFUL Holter substudy explored the cardiac safety of the I(f) inhibitor ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction receiving optimal background therapy.', 'subject score': 773, 'object score': 923}, 'PMID:21254949': {'publication date': '2011 Feb', 'sentence': 'Recently ivabradine has been shown to improve cardiac outcomes in stable coronary artery disease and left ventricular systolic dysfunction in patients who have heart rates of >= 70 bpm and in patients with stable angina.', 'subject score': 888, 'object score': 923}, 'PMID:21434947': {'publication date': '2011 Mar', 'sentence': 'Two major morbidity-mortality trials, BEAUTIFUL and SHIFT, showed that heart rate reduction with ivabradine dramatically improves prognosis in patients with coronary artery disease and left ventricular dysfunction, symptomatic angina, or chronic heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:21878041': {'publication date': '2011 Aug', 'sentence': 'The development of the heart rate-lowering agent ivabradine showed that heart rate was also an important treatment target, notably in coronary artery disease and heart failure.', 'subject score': 831, 'object score': 1000}, 'PMID:23394554': {'publication date': '2013', 'sentence': 'More recently, IVA has been highly recommended to be used in patients with CAD in association with beta-blockers.', 'subject score': 1000, 'object score': 1000}, 'PMID:24065301': {'publication date': '2013 Sep', 'sentence': 'The SIGNIFY (Study assessInG the morbidity-mortality beNefits of the I f inhibitor ivabradine in patients with coronarY artery disease) trial includes patients with stable CAD and an LVEF above 40 %, with no clinical sign of HF, and is investigating the long-term effects (over a period of 48 months) of ivabradine in a large study population.', 'subject score': 773, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C0010054---SEMMEDDB:",
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C0010068---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "12424888",
-              "object": "MONDO:0005010",
-              "publications": [
-                "PMID:16621590",
-                "PMID:21247517",
-                "PMID:26696613",
-                "PMID:26839043",
-                "PMID:28454527",
-                "PMID:21878041",
-                "PMID:26761974",
-                "PMID:26385957",
-                "PMID:19517748",
-                "PMID:24281409",
-                "PMID:25544120",
-                "PMID:26418022",
-                "PMID:30709418",
-                "PMID:19474056",
-                "PMID:29142810",
-                "PMID:30676481",
-                "PMID:20000882",
-                "PMID:34414216",
-                "PMID:27614723",
-                "PMID:31548105"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 973303,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C0340288",
-          "name": "Stable angina",
-          "description": "Angina pectoris which has not recently changed in frequency, duration or intensity. Stable angina pectoris is relieved by rest or administration or oral, sublingual or transdermal antianginal medications.; Persistent and reproducible chest discomfort usually precipitated by a physical exertion that dissipates upon cessation of such an activity. The symptoms are manifestations of MYOCARDIAL ISCHEMIA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:233819005",
-            "MESH:D060050",
-            "NCIT:C66914",
-            "UMLS:C0340288",
-            "MEDDRA:10049194"
-          ],
-          "id": "UMLS:C0340288",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Angina, Stable",
-            "Stable angina",
-            "Stable Angina"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 973303,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C0340288",
-              "name": "Stable angina",
-              "description": "Angina pectoris which has not recently changed in frequency, duration or intensity. Stable angina pectoris is relieved by rest or administration or oral, sublingual or transdermal antianginal medications.; Persistent and reproducible chest discomfort usually precipitated by a physical exertion that dissipates upon cessation of such an activity. The symptoms are manifestations of MYOCARDIAL ISCHEMIA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:233819005",
-                "MESH:D060050",
-                "NCIT:C66914",
-                "UMLS:C0340288",
-                "MEDDRA:10049194"
-              ],
-              "id": "UMLS:C0340288",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Angina, Stable",
-                "Stable angina",
-                "Stable Angina"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11904615,
-            "start": 557,
-            "end": 973303,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16307166': {'publication date': '2005', 'sentence': 'New agent ivabradine (Procoralan) for treatment of chronic stable angina.', 'subject score': 890, 'object score': 1000}, 'PMID:16386229': {'publication date': '2006 Jan', 'sentence': 'These data were confirmed in humans, in particular the anti-ischemic efficacy of ivabradine, at least as effective as that of a b-blocker in patients with stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:16479971': {'publication date': '2006 Jan', 'sentence': 'Among the cardiovascular drugs that will soon be licensed, only ivabradine in stable angina, and remodulin in primary pulmonary arterial hypertension are new.', 'subject score': 861, 'object score': 1000}, 'PMID:16638639': {'publication date': '2006 May', 'sentence': 'These data have been confirmed in humans, and in particular, the anti-ischemic efficacy of ivabradine, at least as effective as a beta-blocker, in patients with stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:16732707': {'publication date': '2006 Jun', 'sentence': 'Clinical proof of the antianginal efficacy and tolerability of ivabradine comes from the largest clinical development programme that has ever been performed in stable angina, involving more than 5000 patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:17070146': {'publication date': '2006 Nov', 'sentence': 'Ivabradine is a new specific HR-reducing agent, which has been shown to have antianginal and anti-ischemic properties in patients with stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:17077980': {'publication date': '2006 Dec', 'sentence': 'While beta-blockers remain the first choice for heart rate reduction, in cases of adverse effects ivabradine may be used to treat stable angina pectoris.', 'subject score': 901, 'object score': 1000}, 'PMID:17335297': {'publication date': '2007', 'sentence': 'Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.', 'subject score': 1000, 'object score': 916}, 'PMID:17645051': {'publication date': '2007 May 30', 'sentence': 'Ivabradine is licensed in Europe for use in stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:17890862': {'publication date': '2007', 'sentence': 'Long-term safety and efficacy of ivabradine in patients with chronic stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:17999560': {'publication date': '2007', 'sentence': 'As such, ivabradine is particularly useful in patients with chronic stable angina pectoris.', 'subject score': 1000, 'object score': 1000}, 'PMID:17999562': {'publication date': '2007', 'sentence': 'Clinical evidence of the antianginal and anti-ischaemic efficacy and tolerability of ivabradine comes from the largest clinical development programme that has ever been performed in stable angina pectoris, involving more than 5000 patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:18057886': {'publication date': '2008', 'sentence': 'Since the relatively new selective IF-stream blocker ivabradine has been approved for the therapy of chronic stable angina pectoris, a new therapeutic option is available.', 'subject score': 802, 'object score': 1000}, 'PMID:18221092': {'publication date': '2006 Nov', 'sentence': 'Clinical studies proved the efficacy of ivabradine in patients with stable angina, while clinical data are awaited to verify its probable value in the treatment of atrial tachyarrhythmias and tachycardia due to ventricular dysfunction.', 'subject score': 1000, 'object score': 1000}, 'PMID:18341671': {'publication date': '2008 Jul', 'sentence': 'Ivabradine has been recently approved for the treatment of stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:18536779': {'publication date': '2008 Mar', 'sentence': 'Building on solid preclinical studies, ivabradine was shown to have anti-ischemic and antianginal efficacy in patients with stable angina pectoris in clinical trials versus placebo, beta-blockers and calcium channel blockers.', 'subject score': 1000, 'object score': 1000}, 'PMID:18575078': {'publication date': '2008 Apr', 'sentence': 'In Belgium, ivabradine is currently reimbursed in patients with stable angina and normal sinus rhythm who do not tolerate beta-blockers and non-dihydropyridine calcium antagonists or in whom these treatments are contra-indicated.', 'subject score': 1000, 'object score': 1000}, 'PMID:18806523': {'publication date': '2008 Sep-Oct', 'sentence': 'Ivabradine is a heart rate-lowering agent devoid of other direct cardiovascular effects that has been approved for treatment of patients with stable angina pectoris.', 'subject score': 1000, 'object score': 1000}, 'PMID:18987382': {'publication date': '2008 Nov', 'sentence': 'Here we consider the place of ivabradine in the management of patients with stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:19149708': {'publication date': '2009 Jan', 'sentence': 'Various experimental and clinical studies showed the efficacy of ivabradine in patients with chronic stable angina, on heart rate reduction, on ventricular remodelling after acute myocardial infarction and on coronary blood flow.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C0340288---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "12164130",
-              "object": "UMLS:C0340288",
-              "publications": [
-                "PMID:16307166",
-                "PMID:16386229",
-                "PMID:16479971",
-                "PMID:16638639",
-                "PMID:16732707",
-                "PMID:17070146",
-                "PMID:17077980",
-                "PMID:17335297",
-                "PMID:17645051",
-                "PMID:17890862",
-                "PMID:17999560",
-                "PMID:17999562",
-                "PMID:18057886",
-                "PMID:18221092",
-                "PMID:18341671",
-                "PMID:18536779",
-                "PMID:18575078",
-                "PMID:18806523",
-                "PMID:18987382",
-                "PMID:19149708"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 308937,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-          "name": "cardiovascular disorder",
-          "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "MEDDRA:10045663",
-            "MONDO:0004995",
-            "ICD9:429.2",
-            "MEDDRA:10007649",
-            "UMLS:C0243050",
-            "HP:0001626",
-            "MESH:D018376",
-            "MEDDRA:10007648",
-            "MEDDRA:10013205",
-            "SNOMEDCT:49601007",
-            "MEDDRA:10007650",
-            "MESH:D002318",
-            "DOID:1287",
-            "UMLS:C0007222",
-            "UMLS:C0728936",
-            "NCIT:C2931"
-          ],
-          "id": "MONDO:0004995",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiovascular Diseases",
-            "Cardiovascular disease, unspecified",
-            "Abnormality of the cardiovascular system",
-            "cardiovascular system disease",
-            "Disorder of circulatory system",
-            "Cardiovascular Disorder",
-            "cardiovascular disorder",
-            "Cardiovascular Abnormalities"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/circulatory_system",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308937,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-              "name": "cardiovascular disorder",
-              "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "MEDDRA:10045663",
-                "MONDO:0004995",
-                "ICD9:429.2",
-                "MEDDRA:10007649",
-                "UMLS:C0243050",
-                "HP:0001626",
-                "MESH:D018376",
-                "MEDDRA:10007648",
-                "MEDDRA:10013205",
-                "SNOMEDCT:49601007",
-                "MEDDRA:10007650",
-                "MESH:D002318",
-                "DOID:1287",
-                "UMLS:C0007222",
-                "UMLS:C0728936",
-                "NCIT:C2931"
-              ],
-              "id": "MONDO:0004995",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiovascular Diseases",
-                "Cardiovascular disease, unspecified",
-                "Abnormality of the cardiovascular system",
-                "cardiovascular system disease",
-                "Disorder of circulatory system",
-                "Cardiovascular Disorder",
-                "cardiovascular disorder",
-                "Cardiovascular Abnormalities"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/circulatory_system",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11099579,
-            "start": 557,
-            "end": 308937,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15301560': {'publication date': '2004', 'sentence': 'Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:21434947': {'publication date': '2011 Mar', 'sentence': 'The development of ivabradine represents a clear innovation in the management of cardiovascular disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:21878041': {'publication date': '2011 Aug', 'sentence': 'Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:26917820': {'publication date': '2016 06', 'sentence': 'Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:28726428': {'publication date': 'Summer 2017', 'sentence': '[A present view on ivabradine in the therapy of cardiovascular diseases].', 'subject score': 1000, 'object score': 1000}, 'PMID:30606942': {'publication date': '2019 01 25', 'sentence': 'Ivabradine for the Treatment of Cardiovascular Diseases.', 'subject score': 1000, 'object score': 1000}, 'PMID:30676481': {'publication date': '2019 Jun', 'sentence': 'In this review, we explore the effect of pharmacological heart rate lowering with a beta-blocker or ivabradine on cardiovascular outcomes in patients with cardiovascular disease and address the question as to whether pharmacological heart rate reduction is ready for prime time in the management of patients with coronary artery disease.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C0007222---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "11342280",
-              "object": "MONDO:0004995",
-              "publications": [
-                "PMID:15301560",
-                "PMID:21434947",
-                "PMID:21878041",
-                "PMID:26917820",
-                "PMID:28726428",
-                "PMID:30606942",
-                "PMID:30676481"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19131380,
-            "start": 557,
-            "end": 295849,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28262346': {'publication date': '2017 Jun 01', 'sentence': 'Effective suppression of atrial fibrillation by ivabradine: Novel target for an established drug?', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:disrupts---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "19514713",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:28262346"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:25282913': {'publication date': '2014 Sep 11', 'sentence': '[SIGNIFY study is a disappointment. Ivabradine cannot stop of the progression of coronary heart disease].', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 317775,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005010",
-          "name": "coronary artery disorder",
-          "description": "Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. [HPO:probinson]; Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. // COMMENTS: Coronary artery disease, also called atherosclerotic heart disease, is the result of atheromatous plaques within the coronary arteries leading to myocardial ischemia and infarction.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003324",
-            "ICD10:I25.10",
-            "MEDDRA:10008936",
-            "EFO:0001645",
-            "MEDDRA:10011081",
-            "HP:0001677",
-            "MEDDRA:10011106",
-            "PSY:11853",
-            "SNOMEDCT:53741008",
-            "SNOMEDCT:413844008",
-            "ICD9:414.0",
-            "MEDDRA:10003211",
-            "MEDDRA:10011079",
-            "ICD10:I20-I25",
-            "ICD9:410-414.99",
-            "MEDDRA:10013210",
-            "MEDDRA:10011076",
-            "UMLS:C0010068",
-            "MEDDRA:10011080",
-            "UMLS:C1956346",
-            "UMLS:C1533195",
-            "DOID:3393",
-            "NCIT:C26732",
-            "UMLS:C0010054",
-            "SNOMEDCT:413838009",
-            "MEDDRA:10011099",
-            "MEDDRA:10013098",
-            "MEDDRA:10008937",
-            "MEDDRA:10011078",
-            "MEDDRA:10011093",
-            "MEDDRA:10068617",
-            "ICD9:414.9",
-            "ICD10:I25",
-            "MEDDRA:10011087",
-            "MESH:D003327",
-            "MEDDRA:10049175",
-            "SNOMEDCT:414024009",
-            "MEDDRA:10011082",
-            "UMLS:C0264694",
-            "MONDO:0005010"
-          ],
-          "id": "MONDO:0005010",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic ischemic heart disease, unspecified",
-            "Coronary Artery Disease",
-            "Ischemic heart disease",
-            "Coronary atherosclerosis",
-            "Coronary artery atherosclerosis",
-            "Coronary Arteriosclerosis",
-            "Coronary Heart Disease",
-            "coronary artery disease",
-            "Coronary Disease",
-            "Chronic myocardial ischemia",
-            "Coronary heart disease",
-            "coronary artery disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:31420554",
-            "http://en.wikipedia.org/wiki/coronary_heart_disease",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317775,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005010",
-              "name": "coronary artery disorder",
-              "description": "Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. [HPO:probinson]; Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. // COMMENTS: Coronary artery disease, also called atherosclerotic heart disease, is the result of atheromatous plaques within the coronary arteries leading to myocardial ischemia and infarction.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003324",
-                "ICD10:I25.10",
-                "MEDDRA:10008936",
-                "EFO:0001645",
-                "MEDDRA:10011081",
-                "HP:0001677",
-                "MEDDRA:10011106",
-                "PSY:11853",
-                "SNOMEDCT:53741008",
-                "SNOMEDCT:413844008",
-                "ICD9:414.0",
-                "MEDDRA:10003211",
-                "MEDDRA:10011079",
-                "ICD10:I20-I25",
-                "ICD9:410-414.99",
-                "MEDDRA:10013210",
-                "MEDDRA:10011076",
-                "UMLS:C0010068",
-                "MEDDRA:10011080",
-                "UMLS:C1956346",
-                "UMLS:C1533195",
-                "DOID:3393",
-                "NCIT:C26732",
-                "UMLS:C0010054",
-                "SNOMEDCT:413838009",
-                "MEDDRA:10011099",
-                "MEDDRA:10013098",
-                "MEDDRA:10008937",
-                "MEDDRA:10011078",
-                "MEDDRA:10011093",
-                "MEDDRA:10068617",
-                "ICD9:414.9",
-                "ICD10:I25",
-                "MEDDRA:10011087",
-                "MESH:D003327",
-                "MEDDRA:10049175",
-                "SNOMEDCT:414024009",
-                "MEDDRA:10011082",
-                "UMLS:C0264694",
-                "MONDO:0005010"
-              ],
-              "id": "MONDO:0005010",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic ischemic heart disease, unspecified",
-                "Coronary Artery Disease",
-                "Ischemic heart disease",
-                "Coronary atherosclerosis",
-                "Coronary artery atherosclerosis",
-                "Coronary Arteriosclerosis",
-                "Coronary Heart Disease",
-                "coronary artery disease",
-                "Coronary Disease",
-                "Chronic myocardial ischemia",
-                "Coronary heart disease",
-                "coronary artery disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:31420554",
-                "http://en.wikipedia.org/wiki/coronary_heart_disease",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17550754,
-            "start": 557,
-            "end": 317775,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25282913': {'publication date': '2014 Sep 11', 'sentence': '[SIGNIFY study is a disappointment. Ivabradine cannot stop of the progression of coronary heart disease].', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:disrupts---None---None---None---UMLS:C0010068---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "17909104",
-              "object": "MONDO:0005010",
-              "publications": [
-                "PMID:25282913"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 295849,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:18221092': {'publication date': '2006 Nov', 'sentence': 'Clinical studies proved the efficacy of ivabradine in patients with stable angina, while clinical data are awaited to verify its probable value in the treatment of atrial tachyarrhythmias and tachycardia due to ventricular dysfunction.', 'subject score': 1000, 'object score': 1000}, 'PMID:21526046': {'publication date': '2011 Apr 26', 'sentence': 'Increased heart rate and atherosclerosis: potential implications of ivabradine therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:23719030': {'publication date': '2013 Aug', 'sentence': 'Is ivabradine suitable to control undesirable tachycardia induced by dobutamine in cardiogenic shock treatment?', 'subject score': 1000, 'object score': 861}, 'PMID:29189314': {'publication date': '2018 Nov/Dec', 'sentence': 'Ivabradine for Treatment of Refractory Tachycardia in a Patient With Hypertrophic Cardiomyopathy.', 'subject score': 1000, 'object score': 888}, 'PMID:31242382': {'publication date': '2019 06 27', 'sentence': 'More on Ivabradine in Tachycardia with Paraganglioma.', 'subject score': 1000, 'object score': 1000}, 'PMID:31242383': {'publication date': '2019 06 27', 'sentence': 'More on Ivabradine in Tachycardia with Paraganglioma.', 'subject score': 1000, 'object score': 1000}, 'PMID:31332966': {'publication date': '2019 Oct', 'sentence': 'As ivabradine does not have negative inotropic action, it may present a potential means to manage tachycardia in cardiogenic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:32612966': {'publication date': '2020', 'sentence': 'Due to its mechanism of action Ivabradine is a promising novel agent for the therapy of tachycardia due to increased automaticity.', 'subject score': 888, 'object score': 1000}, 'PMID:33018577': {'publication date': '2020 Jul', 'sentence': 'Tachycardia control in septic shock with esmolol and ivabradine: a comparison on heart function.', 'subject score': 1000, 'object score': 694}, 'PMID:35024059': {'publication date': '2022 Jan', 'sentence': 'In summary, we used ivabradine for a patient with tachycardia, low BP, a low LVEF, and severe MR.', 'subject score': 1000, 'object score': 1000}, 'PMID:35154785': {'publication date': '2022 Dec', 'sentence': 'Background: Ivabradine is used to treat tachycardia; unlike atenolol, it does not affect blood pressure or myocardial contractility.', 'subject score': 1000, 'object score': 1000}, 'PMID:35464795': {'publication date': '2022 Jun', 'sentence': 'Her tachycardia was successfully treated with ivabradine and diltiazem.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317823,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-=======
-          "iri": "http://purl.obolibrary.org/obo/HP_0001649",
-          "name": "Tachycardia",
-          "description": "A rapid heartrate that exceeds the range of the normal resting heartrate for age. [HPO:probinson]; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "MEDDRA:10019322",
-            "HP:0001649",
-            "MEDDRA:10019303",
-            "MEDDRA:10043071",
-            "MEDDRA:10037474",
-            "MEDDRA:10043086",
-            "MEDDRA:10037490",
-            "MESH:D013610",
-            "MEDDRA:10020081",
-            "SNOMEDCT:86651002",
-            "MEDDRA:10043078",
-            "UMLS:C4020868",
-            "UMLS:C0039231",
-            "SYMP:0000529",
-            "MEDDRA:10037733",
-            "SNOMEDCT:3424008",
-            "NCIT:C38029",
-            "MEDDRA:10066996",
-            "PSY:51360",
-            "MEDDRA:10019302",
-            "MEDDRA:10037484"
-          ],
-          "id": "HP:0001649",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "tachycardia",
-            "Tachycardia",
-            "Elevated heart rate"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:DiseaseOrPhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tachycardia"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 295849,
-=======
-            "identity": 317823,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-=======
-              "iri": "http://purl.obolibrary.org/obo/HP_0001649",
-              "name": "Tachycardia",
-              "description": "A rapid heartrate that exceeds the range of the normal resting heartrate for age. [HPO:probinson]; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "MEDDRA:10019322",
-                "HP:0001649",
-                "MEDDRA:10019303",
-                "MEDDRA:10043071",
-                "MEDDRA:10037474",
-                "MEDDRA:10043086",
-                "MEDDRA:10037490",
-                "MESH:D013610",
-                "MEDDRA:10020081",
-                "SNOMEDCT:86651002",
-                "MEDDRA:10043078",
-                "UMLS:C4020868",
-                "UMLS:C0039231",
-                "SYMP:0000529",
-                "MEDDRA:10037733",
-                "SNOMEDCT:3424008",
-                "NCIT:C38029",
-                "MEDDRA:10066996",
-                "PSY:51360",
-                "MEDDRA:10019302",
-                "MEDDRA:10037484"
-              ],
-              "id": "HP:0001649",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "tachycardia",
-                "Tachycardia",
-                "Elevated heart rate"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:DiseaseOrPhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tachycardia"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 17465530,
-            "start": 557,
-            "end": 295849,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25135587': {'publication date': '2014 Dec', 'sentence': 'RESULTS: Heart rate reduction and prevention of postoperative AF or tachyarrhythmia with combined therapy was more effective than with metoprolol or ivabradine alone during the immediate postoperative management of cardiac surgery patients.', 'subject score': 1000, 'object score': 901}, 'PMID:28262346': {'publication date': '2017 Jun 01', 'sentence': 'Simultaneous infusion of ivabradine (3?M) led to a significant reduction of AF (6 of 11 hearts, 63 episodes).', 'subject score': 1000, 'object score': 1000}, 'PMID:30302853': {'publication date': '2018 Oct 09', 'sentence': 'CONCLUSION: IVA reduced the incidence of AF in mice, and the antiarrhythmic effects of IVA are not limited to heart rate reduction, as they partially counteract HCN overexpression and reverse electrophysiological cardiac remodeling by attenuating If gain-of-function.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:prevents---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "17822394",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:25135587",
-                "PMID:28262346",
-                "PMID:30302853"
-=======
-            "identity": 13273899,
-            "start": 557,
-            "end": 317823,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18221092': {'publication date': '2006 Nov', 'sentence': 'Clinical studies proved the efficacy of ivabradine in patients with stable angina, while clinical data are awaited to verify its probable value in the treatment of atrial tachyarrhythmias and tachycardia due to ventricular dysfunction.', 'subject score': 1000, 'object score': 1000}, 'PMID:21526046': {'publication date': '2011 Apr 26', 'sentence': 'Increased heart rate and atherosclerosis: potential implications of ivabradine therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:23719030': {'publication date': '2013 Aug', 'sentence': 'Is ivabradine suitable to control undesirable tachycardia induced by dobutamine in cardiogenic shock treatment?', 'subject score': 1000, 'object score': 861}, 'PMID:29189314': {'publication date': '2018 Nov/Dec', 'sentence': 'Ivabradine for Treatment of Refractory Tachycardia in a Patient With Hypertrophic Cardiomyopathy.', 'subject score': 1000, 'object score': 888}, 'PMID:31242382': {'publication date': '2019 06 27', 'sentence': 'More on Ivabradine in Tachycardia with Paraganglioma.', 'subject score': 1000, 'object score': 1000}, 'PMID:31242383': {'publication date': '2019 06 27', 'sentence': 'More on Ivabradine in Tachycardia with Paraganglioma.', 'subject score': 1000, 'object score': 1000}, 'PMID:31332966': {'publication date': '2019 Oct', 'sentence': 'As ivabradine does not have negative inotropic action, it may present a potential means to manage tachycardia in cardiogenic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:32612966': {'publication date': '2020', 'sentence': 'Due to its mechanism of action Ivabradine is a promising novel agent for the therapy of tachycardia due to increased automaticity.', 'subject score': 888, 'object score': 1000}, 'PMID:33018577': {'publication date': '2020 Jul', 'sentence': 'Tachycardia control in septic shock with esmolol and ivabradine: a comparison on heart function.', 'subject score': 1000, 'object score': 694}, 'PMID:35024059': {'publication date': '2022 Jan', 'sentence': 'In summary, we used ivabradine for a patient with tachycardia, low BP, a low LVEF, and severe MR.', 'subject score': 1000, 'object score': 1000}, 'PMID:35154785': {'publication date': '2022 Dec', 'sentence': 'Background: Ivabradine is used to treat tachycardia; unlike atenolol, it does not affect blood pressure or myocardial contractility.', 'subject score': 1000, 'object score': 1000}, 'PMID:35464795': {'publication date': '2022 Jun', 'sentence': 'Her tachycardia was successfully treated with ivabradine and diltiazem.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C0039231---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "13559450",
-              "object": "HP:0001649",
-              "publications": [
-                "PMID:18221092",
-                "PMID:21526046",
-                "PMID:23719030",
-                "PMID:29189314",
-                "PMID:31242382",
-                "PMID:31242383",
-                "PMID:31332966",
-                "PMID:32612966",
-                "PMID:33018577",
-                "PMID:35024059",
-                "PMID:35154785",
-                "PMID:35464795"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:14569053': {'publication date': '2004 Jan', 'sentence': 'During exercise, ivabradine dose dependently and significantly reduced the exercise-induced tachycardia (-17, -21, and -32% at 0.25, 0.5, and 1 mg/kg, respectively, versus saline) without altering myocardial contractility nor mean ejection wall stress.', 'subject score': 790, 'object score': 901}, 'PMID:22391988': {'publication date': '2012 Aug', 'sentence': 'Lasting reduction of heart transplant tachycardia with ivabradine is effective and well tolerated: results of 48-month study.', 'subject score': 1000, 'object score': 901}, 'PMID:30653849': {'publication date': '2019 03 15', 'sentence': 'The increased EHR due to nifedipine was reduced by the ivabradine.', 'subject score': 1000, 'object score': 916}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 317823,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001649",
-          "name": "Tachycardia",
-          "description": "A rapid heartrate that exceeds the range of the normal resting heartrate for age. [HPO:probinson]; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "MEDDRA:10019322",
-            "HP:0001649",
-            "MEDDRA:10019303",
-            "MEDDRA:10043071",
-            "MEDDRA:10037474",
-            "MEDDRA:10043086",
-            "MEDDRA:10037490",
-            "MESH:D013610",
-            "MEDDRA:10020081",
-            "SNOMEDCT:86651002",
-            "MEDDRA:10043078",
-            "UMLS:C4020868",
-            "UMLS:C0039231",
-            "SYMP:0000529",
-            "MEDDRA:10037733",
-            "SNOMEDCT:3424008",
-            "NCIT:C38029",
-            "MEDDRA:10066996",
-            "PSY:51360",
-            "MEDDRA:10019302",
-            "MEDDRA:10037484"
-          ],
-          "id": "HP:0001649",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "tachycardia",
-            "Tachycardia",
-            "Elevated heart rate"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:DiseaseOrPhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tachycardia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317823,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001649",
-              "name": "Tachycardia",
-              "description": "A rapid heartrate that exceeds the range of the normal resting heartrate for age. [HPO:probinson]; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; A rapid heartrate that exceeds the range of the normal resting heartrate for age.; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "MEDDRA:10019322",
-                "HP:0001649",
-                "MEDDRA:10019303",
-                "MEDDRA:10043071",
-                "MEDDRA:10037474",
-                "MEDDRA:10043086",
-                "MEDDRA:10037490",
-                "MESH:D013610",
-                "MEDDRA:10020081",
-                "SNOMEDCT:86651002",
-                "MEDDRA:10043078",
-                "UMLS:C4020868",
-                "UMLS:C0039231",
-                "SYMP:0000529",
-                "MEDDRA:10037733",
-                "SNOMEDCT:3424008",
-                "NCIT:C38029",
-                "MEDDRA:10066996",
-                "PSY:51360",
-                "MEDDRA:10019302",
-                "MEDDRA:10037484"
-              ],
-              "id": "HP:0001649",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "tachycardia",
-                "Tachycardia",
-                "Elevated heart rate"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:DiseaseOrPhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tachycardia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10585172,
-            "start": 557,
-            "end": 317823,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14569053': {'publication date': '2004 Jan', 'sentence': 'During exercise, ivabradine dose dependently and significantly reduced the exercise-induced tachycardia (-17, -21, and -32% at 0.25, 0.5, and 1 mg/kg, respectively, versus saline) without altering myocardial contractility nor mean ejection wall stress.', 'subject score': 790, 'object score': 901}, 'PMID:22391988': {'publication date': '2012 Aug', 'sentence': 'Lasting reduction of heart transplant tachycardia with ivabradine is effective and well tolerated: results of 48-month study.', 'subject score': 1000, 'object score': 901}, 'PMID:30653849': {'publication date': '2019 03 15', 'sentence': 'The increased EHR due to nifedipine was reduced by the ivabradine.', 'subject score': 1000, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:prevents---None---None---None---UMLS:C0039231---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "10817471",
-              "object": "HP:0001649",
-              "publications": [
-                "PMID:14569053",
-                "PMID:22391988",
-                "PMID:30653849"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:26909707': {'publication date': '2016 09', 'sentence': 'If Channel Inhibition With Ivabradine Does Not Improve Cardiac and Vascular Function in Experimental Septic Shock.', 'subject score': 1000, 'object score': 901}, 'PMID:34407620': {'publication date': '2021 Aug 18', 'sentence': 'Effectiveness of enteral ivabradine for heart rate control in septic shock: A randomised controlled trial.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 528832,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-          "name": "toxic shock syndrome",
-          "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C35498",
-            "UMLS:C0600327",
-            "UMLS:CN204669",
-            "MEDDRA:10044248",
-            "MESH:D012772",
-            "MEDDRA:10044249",
-            "SNOMEDCT:18504008",
-            "DOID:14115",
-            "MEDDRA:10042852",
-            "UMLS:C0036983",
-            "ORPHANET:36234",
-            "SNOMEDCT:76571007",
-            "MEDDRA:10040580",
-            "NCIT:C35018",
-            "MEDDRA:10040070",
-            "ICD9:040.82",
-            "ICD10:A48.3",
-            "MONDO:0001881",
-            "EFO:0006834",
-            "SYMP:0000451"
-          ],
-          "id": "MONDO:0001881",
-          "category": "biolink:Disease",
-          "all_names": [
-            "toxic shock syndrome",
-            "Septic Shock",
-            "Shock, Septic",
-            "Toxic Shock Syndrome",
-            "Bacterial toxic-shock syndrome",
-            "septic shock",
-            "Toxic shock syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 528832,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-              "name": "toxic shock syndrome",
-              "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C35498",
-                "UMLS:C0600327",
-                "UMLS:CN204669",
-                "MEDDRA:10044248",
-                "MESH:D012772",
-                "MEDDRA:10044249",
-                "SNOMEDCT:18504008",
-                "DOID:14115",
-                "MEDDRA:10042852",
-                "UMLS:C0036983",
-                "ORPHANET:36234",
-                "SNOMEDCT:76571007",
-                "MEDDRA:10040580",
-                "NCIT:C35018",
-                "MEDDRA:10040070",
-                "ICD9:040.82",
-                "ICD10:A48.3",
-                "MONDO:0001881",
-                "EFO:0006834",
-                "SYMP:0000451"
-              ],
-              "id": "MONDO:0001881",
-              "category": "biolink:Disease",
-              "all_names": [
-                "toxic shock syndrome",
-                "Septic Shock",
-                "Shock, Septic",
-                "Toxic Shock Syndrome",
-                "Bacterial toxic-shock syndrome",
-                "septic shock",
-                "Toxic shock syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18468862,
-            "start": 557,
-            "end": 528832,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26909707': {'publication date': '2016 09', 'sentence': 'If Channel Inhibition With Ivabradine Does Not Improve Cardiac and Vascular Function in Experimental Septic Shock.', 'subject score': 1000, 'object score': 901}, 'PMID:34407620': {'publication date': '2021 Aug 18', 'sentence': 'Effectiveness of enteral ivabradine for heart rate control in septic shock: A randomised controlled trial.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C0036983---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "18841652",
-              "object": "MONDO:0001881",
-              "publications": [
-                "PMID:26909707",
-                "PMID:34407620"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:27659287': {'publication date': '2016 Dec', 'sentence': 'Preclinical studies of ivabradine in animal models with induced AF demonstrated a reduction in HR, with no significant worsening of QT interval or mean arterial pressure.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18849287,
-            "start": 557,
-            "end": 295849,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27659287': {'publication date': '2016 Dec', 'sentence': 'Preclinical studies of ivabradine in animal models with induced AF demonstrated a reduction in HR, with no significant worsening of QT interval or mean arterial pressure.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:causes---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "19228519",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:27659287"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:30606942': {'publication date': '2019 01 25', 'sentence': 'In this review, we summarize the current knowledge of the HCN4 channel and ivabradine, including the function of HCN4 in cardiac pacemaking, the mechanism of action of If inhibition by ivabradine, and the pharmacological and clinical effects of ivabradine in cardiac diseases as HF, coronary artery disease, and atrial fibrillation.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20382331,
-            "start": 557,
-            "end": 295849,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30606942': {'publication date': '2019 01 25', 'sentence': 'In this review, we summarize the current knowledge of the HCN4 channel and ivabradine, including the function of HCN4 in cardiac pacemaking, the mechanism of action of If inhibition by ivabradine, and the pharmacological and clinical effects of ivabradine in cardiac diseases as HF, coronary artery disease, and atrial fibrillation.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:affects---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "20784958",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:30606942"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:24765517': {'publication date': '2013 Aug 02', 'sentence': 'Ivabradine is ineffective in atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:24814540': {'publication date': '2014 Jul 15', 'sentence': 'Might ivabradine be useful in permanent atrial fibrillation?', 'subject score': 1000, 'object score': 901}, 'PMID:25464400': {'publication date': '2015 Jan 20', 'sentence': 'Ivabradine for rate control in atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:25982136': {'publication date': '2015 May 16', 'sentence': 'Effects of ivabradine on cardiac electrophysiology in dogs with age-related atrial fibrillation.', 'subject score': 1000, 'object score': 861}, 'PMID:26386926': {'publication date': '2016 01 01', 'sentence': 'Addition of ivabradine to betablockers in patients with atrial fibrillation: Effects on heart rate and exercise tolerance.', 'subject score': 1000, 'object score': 1000}, 'PMID:27511965': {'publication date': '2016 Oct', 'sentence': 'We used trial sequential analysis (TSA) to provide information on when we had reached firm evidence of new AF based on a 15% relative risk increase (RRI) in ivabradine treatment.', 'subject score': 888, 'object score': 901}, 'PMID:27589039': {'publication date': '2016 Nov 15', 'sentence': 'Need for further studies on ivabradine in patients with persistent atrial fibrillation.', 'subject score': 1000, 'object score': 901}, 'PMID:27614572': {'publication date': '2016 11 15', 'sentence': 'Corrigendum to \"Addition of ivabradine to betablockers in patients with atrial fibrillation: Effects on heart rate and exercise tolerance\" [Int. J. Cardiol. 202 (2016) 76-77].', 'subject score': 1000, 'object score': 1000}, 'PMID:27659287': {'publication date': '2016 Dec', 'sentence': 'Prospective, randomized studies are needed to determine if ivabradine has a role as a rate-control treatment in patients with AF.', 'subject score': 1000, 'object score': 1000}, 'PMID:30302853': {'publication date': '2018 Oct 09', 'sentence': 'Long-term treatment with ivabradine in transgenic atrial fibrillation mice counteracts hyperpolarization-activated cyclic nucleotide gated channel overexpression.', 'subject score': 1000, 'object score': 888}, 'PMID:30427090': {'publication date': '2018 Nov 14', 'sentence': 'Potential use of ivabradine for treatment of atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:31631048': {'publication date': '2019 Oct 17', 'sentence': 'METHODS: A multicenter, randomized, parallel, open-label, noninferiority phase III clinical trial will be conducted to compare ivabradine vs digoxin in 232 patients with uncontrolled permanent AF despite beta-blockers or calcium channel blockers.', 'subject score': 1000, 'object score': 861}, 'PMID:34983905': {'publication date': '2021 Dec 27', 'sentence': 'Furthermore, ivabradine may be effective in controlling the ventricular rate in patients with AF, although more RCTs are needed to support this conclusion.', 'subject score': 1000, 'object score': 1000}, 'PMID:35995556': {'publication date': '2022 Aug 22', 'sentence': 'PURPOSE: We conducted a retrospective observational study using Taiwanese insurance records to examine the association between beta blocker (BB)/ ivabradine (IVA) and cardiovascular (CV) outcomes in patients with atrial fibrillation (AF).', 'subject score': 901, 'object score': 1000}, 'PMID:37117042': {'publication date': '2022 Aug 22', 'sentence': 'PURPOSE: We conducted a retrospective observational study using Taiwanese insurance records to examine the association between beta blocker (BB)/ ivabradine (IVA) and cardiovascular (CV) outcomes in patients with atrial fibrillation (AF).', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17242730,
-            "start": 557,
-            "end": 295849,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24765517': {'publication date': '2013 Aug 02', 'sentence': 'Ivabradine is ineffective in atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:24814540': {'publication date': '2014 Jul 15', 'sentence': 'Might ivabradine be useful in permanent atrial fibrillation?', 'subject score': 1000, 'object score': 901}, 'PMID:25464400': {'publication date': '2015 Jan 20', 'sentence': 'Ivabradine for rate control in atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:25982136': {'publication date': '2015 May 16', 'sentence': 'Effects of ivabradine on cardiac electrophysiology in dogs with age-related atrial fibrillation.', 'subject score': 1000, 'object score': 861}, 'PMID:26386926': {'publication date': '2016 01 01', 'sentence': 'Addition of ivabradine to betablockers in patients with atrial fibrillation: Effects on heart rate and exercise tolerance.', 'subject score': 1000, 'object score': 1000}, 'PMID:27511965': {'publication date': '2016 Oct', 'sentence': 'We used trial sequential analysis (TSA) to provide information on when we had reached firm evidence of new AF based on a 15% relative risk increase (RRI) in ivabradine treatment.', 'subject score': 888, 'object score': 901}, 'PMID:27589039': {'publication date': '2016 Nov 15', 'sentence': 'Need for further studies on ivabradine in patients with persistent atrial fibrillation.', 'subject score': 1000, 'object score': 901}, 'PMID:27614572': {'publication date': '2016 11 15', 'sentence': 'Corrigendum to \"Addition of ivabradine to betablockers in patients with atrial fibrillation: Effects on heart rate and exercise tolerance\" [Int. J. Cardiol. 202 (2016) 76-77].', 'subject score': 1000, 'object score': 1000}, 'PMID:27659287': {'publication date': '2016 Dec', 'sentence': 'Prospective, randomized studies are needed to determine if ivabradine has a role as a rate-control treatment in patients with AF.', 'subject score': 1000, 'object score': 1000}, 'PMID:30302853': {'publication date': '2018 Oct 09', 'sentence': 'Long-term treatment with ivabradine in transgenic atrial fibrillation mice counteracts hyperpolarization-activated cyclic nucleotide gated channel overexpression.', 'subject score': 1000, 'object score': 888}, 'PMID:30427090': {'publication date': '2018 Nov 14', 'sentence': 'Potential use of ivabradine for treatment of atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:31631048': {'publication date': '2019 Oct 17', 'sentence': 'METHODS: A multicenter, randomized, parallel, open-label, noninferiority phase III clinical trial will be conducted to compare ivabradine vs digoxin in 232 patients with uncontrolled permanent AF despite beta-blockers or calcium channel blockers.', 'subject score': 1000, 'object score': 861}, 'PMID:34983905': {'publication date': '2021 Dec 27', 'sentence': 'Furthermore, ivabradine may be effective in controlling the ventricular rate in patients with AF, although more RCTs are needed to support this conclusion.', 'subject score': 1000, 'object score': 1000}, 'PMID:35995556': {'publication date': '2022 Aug 22', 'sentence': 'PURPOSE: We conducted a retrospective observational study using Taiwanese insurance records to examine the association between beta blocker (BB)/ ivabradine (IVA) and cardiovascular (CV) outcomes in patients with atrial fibrillation (AF).', 'subject score': 901, 'object score': 1000}, 'PMID:37117042': {'publication date': '2022 Aug 22', 'sentence': 'PURPOSE: We conducted a retrospective observational study using Taiwanese insurance records to examine the association between beta blocker (BB)/ ivabradine (IVA) and cardiovascular (CV) outcomes in patients with atrial fibrillation (AF).', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "17604342",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:24765517",
-                "PMID:24814540",
-                "PMID:25464400",
-                "PMID:25982136",
-                "PMID:26386926",
-                "PMID:27511965",
-                "PMID:27589039",
-                "PMID:27614572",
-                "PMID:27659287",
-                "PMID:30302853",
-                "PMID:30427090",
-                "PMID:31631048",
-                "PMID:34983905",
-                "PMID:35995556",
-                "PMID:37117042"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:28262346': {'publication date': '2017 Jun 01', 'sentence': 'Effective suppression of atrial fibrillation by ivabradine: Novel target for an established drug?', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19131380,
-            "start": 557,
-            "end": 295849,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28262346': {'publication date': '2017 Jun 01', 'sentence': 'Effective suppression of atrial fibrillation by ivabradine: Novel target for an established drug?', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:disrupts---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "19514713",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:28262346"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:25135587': {'publication date': '2014 Dec', 'sentence': 'RESULTS: Heart rate reduction and prevention of postoperative AF or tachyarrhythmia with combined therapy was more effective than with metoprolol or ivabradine alone during the immediate postoperative management of cardiac surgery patients.', 'subject score': 1000, 'object score': 901}, 'PMID:28262346': {'publication date': '2017 Jun 01', 'sentence': 'Simultaneous infusion of ivabradine (3?M) led to a significant reduction of AF (6 of 11 hearts, 63 episodes).', 'subject score': 1000, 'object score': 1000}, 'PMID:30302853': {'publication date': '2018 Oct 09', 'sentence': 'CONCLUSION: IVA reduced the incidence of AF in mice, and the antiarrhythmic effects of IVA are not limited to heart rate reduction, as they partially counteract HCN overexpression and reverse electrophysiological cardiac remodeling by attenuating If gain-of-function.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17465530,
-            "start": 557,
-            "end": 295849,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25135587': {'publication date': '2014 Dec', 'sentence': 'RESULTS: Heart rate reduction and prevention of postoperative AF or tachyarrhythmia with combined therapy was more effective than with metoprolol or ivabradine alone during the immediate postoperative management of cardiac surgery patients.', 'subject score': 1000, 'object score': 901}, 'PMID:28262346': {'publication date': '2017 Jun 01', 'sentence': 'Simultaneous infusion of ivabradine (3?M) led to a significant reduction of AF (6 of 11 hearts, 63 episodes).', 'subject score': 1000, 'object score': 1000}, 'PMID:30302853': {'publication date': '2018 Oct 09', 'sentence': 'CONCLUSION: IVA reduced the incidence of AF in mice, and the antiarrhythmic effects of IVA are not limited to heart rate reduction, as they partially counteract HCN overexpression and reverse electrophysiological cardiac remodeling by attenuating If gain-of-function.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:prevents---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "17822394",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:25135587",
-                "PMID:28262346",
-                "PMID:30302853"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:27511965': {'publication date': '2016 Oct', 'sentence': 'Recent trials reported that risk of atrial fibrillation (AF) is increased in patients using ivabradine compared with controls.', 'subject score': 1000, 'object score': 1000}, 'PMID:30296583': {'publication date': '2018 Nov', 'sentence': 'CONCLUSIONS: HF differentially modulates the effects of ivabradine on the electrical activities of SAN and PVs, which may increase PV arrhythmogenesis and contribute to the risk of AF in HF patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:34789473': {'publication date': '2021 Nov 17', 'sentence': 'Ivabradine seems to increase the risk of atrial fibrillation, bradycardia and non-serious adverse events.PROSPERO registration number: CRD42018112082.', 'subject score': 1000, 'object score': 1000}, 'PMID:34983905': {'publication date': '2021 Dec 27', 'sentence': 'Regarding left ventricular ejection fraction (LVEF), ivabradine increased the risk of AF in both LVEF >40% (OR, 1.42; 95% CI, 1.24 to 1.63) and LVEF <=40% subgroups (OR, 1.16; 95% CI, 0.98-1.37).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18775590,
-            "start": 557,
-            "end": 295849,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27511965': {'publication date': '2016 Oct', 'sentence': 'Recent trials reported that risk of atrial fibrillation (AF) is increased in patients using ivabradine compared with controls.', 'subject score': 1000, 'object score': 1000}, 'PMID:30296583': {'publication date': '2018 Nov', 'sentence': 'CONCLUSIONS: HF differentially modulates the effects of ivabradine on the electrical activities of SAN and PVs, which may increase PV arrhythmogenesis and contribute to the risk of AF in HF patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:34789473': {'publication date': '2021 Nov 17', 'sentence': 'Ivabradine seems to increase the risk of atrial fibrillation, bradycardia and non-serious adverse events.PROSPERO registration number: CRD42018112082.', 'subject score': 1000, 'object score': 1000}, 'PMID:34983905': {'publication date': '2021 Dec 27', 'sentence': 'Regarding left ventricular ejection fraction (LVEF), ivabradine increased the risk of AF in both LVEF >40% (OR, 1.42; 95% CI, 1.24 to 1.63) and LVEF <=40% subgroups (OR, 1.16; 95% CI, 0.98-1.37).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:predisposes---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "19153602",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:27511965",
-                "PMID:30296583",
-                "PMID:34789473",
-                "PMID:34983905"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:21638157': {'publication date': '2011 Oct', 'sentence': 'CONCLUSIONS: The MODI (f)Y trial is the first application of ivabradine as a pure heart rate reducing agent in MODS patients.', 'subject score': 1000, 'object score': 928}, 'PMID:28930912': {'publication date': '2018 Apr', 'sentence': 'CONCLUSIONS: The number of critically ill patients with MODS and a sinus rhythm of at least 90?beats/min that experienced a heart rate reduction of at least 10?beats/min after oral ivabradine treatment did not differ significantly between groups.', 'subject score': 851, 'object score': 1000}, 'PMID:30595304': {'publication date': '2018 Dec', 'sentence': 'Based on the principle of benefits of reduced HR, the ivabradine in patients with ischemic heart disease, sepsis, and multiple organ dysfunction syndrome has also been studied.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 894650,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043726",
-          "name": "multiple organ dysfunction syndrome",
-          "description": "Complete impairment of two or more organs or organ systems.; Progressive, potentially reversible physiologic dysfunction in two or more organ systems in response to severe physiologic insult. Dysregulated immunological response is the critical pathophysiologic factor in most cases.; A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0043726",
-            "SYMP:0000724",
-            "MESH:D009102",
-            "UMLS:C0026766",
-            "NCIT:C75568",
-            "SNOMEDCT:57653000",
-            "NCIT:C179648",
-            "EFO:1001373",
-            "MEDDRA:10028154",
-            "MEDDRA:10028237",
-            "MEDDRA:10028162",
-            "MEDDRA:10028151",
-            "MEDDRA:10077361"
-          ],
-          "id": "MONDO:0043726",
-          "category": "biolink:Disease",
-          "all_names": [
-            "multiple organ failure",
-            "Multiple Organ Failure",
-            "Multiple Organ Dysfunction Syndrome",
-            "multiple organ dysfunction syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/books/nbk6868/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 894650,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043726",
-              "name": "multiple organ dysfunction syndrome",
-              "description": "Complete impairment of two or more organs or organ systems.; Progressive, potentially reversible physiologic dysfunction in two or more organ systems in response to severe physiologic insult. Dysregulated immunological response is the critical pathophysiologic factor in most cases.; A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0043726",
-                "SYMP:0000724",
-                "MESH:D009102",
-                "UMLS:C0026766",
-                "NCIT:C75568",
-                "SNOMEDCT:57653000",
-                "NCIT:C179648",
-                "EFO:1001373",
-                "MEDDRA:10028154",
-                "MEDDRA:10028237",
-                "MEDDRA:10028162",
-                "MEDDRA:10028151",
-                "MEDDRA:10077361"
-              ],
-              "id": "MONDO:0043726",
-              "category": "biolink:Disease",
-              "all_names": [
-                "multiple organ failure",
-                "Multiple Organ Failure",
-                "Multiple Organ Dysfunction Syndrome",
-                "multiple organ dysfunction syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/books/nbk6868/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15359674,
-            "start": 557,
-            "end": 894650,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21638157': {'publication date': '2011 Oct', 'sentence': 'CONCLUSIONS: The MODI (f)Y trial is the first application of ivabradine as a pure heart rate reducing agent in MODS patients.', 'subject score': 1000, 'object score': 928}, 'PMID:28930912': {'publication date': '2018 Apr', 'sentence': 'CONCLUSIONS: The number of critically ill patients with MODS and a sinus rhythm of at least 90?beats/min that experienced a heart rate reduction of at least 10?beats/min after oral ivabradine treatment did not differ significantly between groups.', 'subject score': 851, 'object score': 1000}, 'PMID:30595304': {'publication date': '2018 Dec', 'sentence': 'Based on the principle of benefits of reduced HR, the ivabradine in patients with ischemic heart disease, sepsis, and multiple organ dysfunction syndrome has also been studied.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C0026766---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "15681673",
-              "object": "MONDO:0043726",
-              "publications": [
-                "PMID:21638157",
-                "PMID:28930912",
-                "PMID:30595304"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:21573990': {'publication date': '2011 Jun', 'sentence': 'Ivabradine added to guidelines-based therapy in systolic heart failure patients.', 'subject score': 1000, 'object score': 916}, 'PMID:22892123': {'publication date': '2013 Jan', 'sentence': 'AIMS: A post-hoc analysis of the SHIFT trial was performed to explore whether ivabradine is beneficial in patients with systolic heart failure, in sinus rhythm, with resting heart rate >=70 b.p.m., and whose guideline-recommended background therapy includes a mineralocorticoid receptor antagonist (MRA).', 'subject score': 1000, 'object score': 1000}, 'PMID:23549235': {'publication date': '2013 May', 'sentence': 'In addition to the nonspecific heart rate reducing drugs like beta-blockers, cardiac glycosides and Ca(2+) antagonists, ivabradine is a highly selective heart rate reducing agent without modifying ventricular contractility and atrioventricular conduction in humans and animals, and has recently been shown to improve cardiovascular outcomes in patients with systolic heart failure by lowering the heart rate only.', 'subject score': 1000, 'object score': 1000}, 'PMID:23696612': {'publication date': '2013 Sep', 'sentence': 'Heart rate reduction with ivabradine improves outcomes in patients with systolic HF.', 'subject score': 1000, 'object score': 1000}, 'PMID:23929789': {'publication date': '2013 Nov', 'sentence': 'CONCLUSIONS: In outpatients with systolic HF, the NT-proBNP reduction obtained by short-term ivabradine treatment correlates closely with the degree of HR reduction.', 'subject score': 861, 'object score': 1000}, 'PMID:24327100': {'publication date': '2014 Apr', 'sentence': 'Here we review the evidence of the prognostic role of HR in systolic HF and the potential relationship between HR lowering and the beneficial effects of beta-blockers; we will also analyze the reasons why an appropriate use of these drugs is seldom achieved in clinical practice, and review the evidence for the use of ivabradine in systolic HF in the clinical setting.', 'subject score': 1000, 'object score': 1000}, 'PMID:25733317': {'publication date': '2015', 'sentence': 'The primary aim of our study was to evaluate the short-term (6 months) effect of ivabradine on N-terminal pro B-type natriuretic peptide (NT-proBNP), CA-125, and cystatin-C values in systolic HF outpatients, and secondary aim was to determine the relationship between baseline HR and the NT-proBNP, CA-125, cystatin-C, and clinical status variation with ivabradine therapy.', 'subject score': 888, 'object score': 916}, 'PMID:25801408': {'publication date': '2015 May', 'sentence': 'CONCLUSION: Ivabradine safely and significantly lowers HR and improves HR variability in patients with systolic heart failure, without inducing significant bradycardia, ventricular arrhythmias, or supraventricular arrhythmias.', 'subject score': 861, 'object score': 1000}, 'PMID:25968495': {'publication date': '2015', 'sentence': 'CONCLUSIONS: Whatever beta-blocker was coprescribed with ivabradine, there were improvements in cardiovascular outcomes in patients with systolic heart failure, especially with the most prescribed beta-blocker--carvedilol.', 'subject score': 1000, 'object score': 1000}, 'PMID:26721645': {'publication date': '2016 07', 'sentence': 'Ivabradine was only recently approved by Food and Drug administration after the results of Systolic Heart Failure Treatment with the If Inhibitor Ivabradine (SHIFT) trial, for a reduction in rehospitalizations from chronic heart failure.', 'subject score': 1000, 'object score': 916}, 'PMID:26817946': {'publication date': '2016 Apr', 'sentence': 'We reviewed clinical evidence for the use of ivabradine in systolic heart failure (HF), in which it appears to improve symptoms, improve quality of life, prevent hospitalization, and prolong survival, thereby addressing unmet needs in the management of HF.', 'subject score': 1000, 'object score': 1000}, 'PMID:27780557': {'publication date': '2016 Dec 15', 'sentence': 'In conclusion, ivabradine improves outcomes in patients with systolic HF; rates of overall adverse events are similar to placebo.', 'subject score': 1000, 'object score': 1000}, 'PMID:27982270': {'publication date': '2016 Nov', 'sentence': 'Background:: In the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT), heart rate (HR) reduction with ivabradine was associated with improved survival and reduced hospitalizations in patients with heart failure (HF).', 'subject score': 1000, 'object score': 916}, 'PMID:28115808': {'publication date': '2017 Jan', 'sentence': 'BACKGROUND: The aim of our study was to evaluate in stable outpatients with systolic heart failure (HF) the 3 months effect of ivabradine on LV synchronization and Tei index in stable outpatients with systolic HF.', 'subject score': 1000, 'object score': 1000}, 'PMID:28289533': {'publication date': '2017 Feb 26', 'sentence': 'Ivabradine in the treatment of systolic heart failure - A systematic review and meta-analysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28316174': {'publication date': '2017 Mar 24', 'sentence': 'Objective: To evaluate the efficacy and safety of ivabradine for the treatment of Chinese patients with chronic heart failure based on the Chinese subgroup data of the systolic heart failure treatment with the I(f) inhibitor ivabradine trial (SHIFT).', 'subject score': 1000, 'object score': 916}, 'PMID:29142810': {'publication date': '2017', 'sentence': 'Background: Ivabradine (IVA) is effective in patients with coronary artery disease (CAD) or systolic heart failure in sinus rhythm.', 'subject score': 1000, 'object score': 1000}, 'PMID:29470374': {'publication date': '2018 Mar', 'sentence': 'Ivabradine for systolic heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:33956182': {'publication date': '2021 May 06', 'sentence': 'Heart rate modulation therapy using ivabradine reduces mortality and morbidity in patients with systolic heart failure, whereas too reduced heart rate seems to worsen the clinical outcome.', 'subject score': 1000, 'object score': 1000}, 'PMID:34148961': {'publication date': '2021 Jun 19', 'sentence': 'Objective Heart rate modulation therapy using ivabradine reduces both morbidity and mortality in patients with systolic heart failure.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 518250,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006993",
-          "name": "systolic heart failure",
-          "description": "Heart failure caused by abnormal myocardial contraction during systole leading to defective cardiac emptying.",
-          "equivalent_curies": [
-            "DOID:9651",
-            "EFO:1001207",
-            "ICD10:I50.20",
-            "UMLS:C1135191",
-            "SNOMEDCT:417996009",
-            "ICD9:428.2",
-            "MESH:D054143",
-            "MEDDRA:10074631",
-            "MONDO:0006993"
-          ],
-          "id": "MONDO:0006993",
-          "category": "biolink:Disease",
-          "all_names": [
-            "systolic heart failure",
-            "Systolic heart failure",
-            "Heart Failure, Systolic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 518250,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006993",
-              "name": "systolic heart failure",
-              "description": "Heart failure caused by abnormal myocardial contraction during systole leading to defective cardiac emptying.",
-              "equivalent_curies": [
-                "DOID:9651",
-                "EFO:1001207",
-                "ICD10:I50.20",
-                "UMLS:C1135191",
-                "SNOMEDCT:417996009",
-                "ICD9:428.2",
-                "MESH:D054143",
-                "MEDDRA:10074631",
-                "MONDO:0006993"
-              ],
-              "id": "MONDO:0006993",
-              "category": "biolink:Disease",
-              "all_names": [
-                "systolic heart failure",
-                "Systolic heart failure",
-                "Heart Failure, Systolic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15320099,
-            "start": 557,
-            "end": 518250,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21573990': {'publication date': '2011 Jun', 'sentence': 'Ivabradine added to guidelines-based therapy in systolic heart failure patients.', 'subject score': 1000, 'object score': 916}, 'PMID:22892123': {'publication date': '2013 Jan', 'sentence': 'AIMS: A post-hoc analysis of the SHIFT trial was performed to explore whether ivabradine is beneficial in patients with systolic heart failure, in sinus rhythm, with resting heart rate >=70 b.p.m., and whose guideline-recommended background therapy includes a mineralocorticoid receptor antagonist (MRA).', 'subject score': 1000, 'object score': 1000}, 'PMID:23549235': {'publication date': '2013 May', 'sentence': 'In addition to the nonspecific heart rate reducing drugs like beta-blockers, cardiac glycosides and Ca(2+) antagonists, ivabradine is a highly selective heart rate reducing agent without modifying ventricular contractility and atrioventricular conduction in humans and animals, and has recently been shown to improve cardiovascular outcomes in patients with systolic heart failure by lowering the heart rate only.', 'subject score': 1000, 'object score': 1000}, 'PMID:23696612': {'publication date': '2013 Sep', 'sentence': 'Heart rate reduction with ivabradine improves outcomes in patients with systolic HF.', 'subject score': 1000, 'object score': 1000}, 'PMID:23929789': {'publication date': '2013 Nov', 'sentence': 'CONCLUSIONS: In outpatients with systolic HF, the NT-proBNP reduction obtained by short-term ivabradine treatment correlates closely with the degree of HR reduction.', 'subject score': 861, 'object score': 1000}, 'PMID:24327100': {'publication date': '2014 Apr', 'sentence': 'Here we review the evidence of the prognostic role of HR in systolic HF and the potential relationship between HR lowering and the beneficial effects of beta-blockers; we will also analyze the reasons why an appropriate use of these drugs is seldom achieved in clinical practice, and review the evidence for the use of ivabradine in systolic HF in the clinical setting.', 'subject score': 1000, 'object score': 1000}, 'PMID:25733317': {'publication date': '2015', 'sentence': 'The primary aim of our study was to evaluate the short-term (6 months) effect of ivabradine on N-terminal pro B-type natriuretic peptide (NT-proBNP), CA-125, and cystatin-C values in systolic HF outpatients, and secondary aim was to determine the relationship between baseline HR and the NT-proBNP, CA-125, cystatin-C, and clinical status variation with ivabradine therapy.', 'subject score': 888, 'object score': 916}, 'PMID:25801408': {'publication date': '2015 May', 'sentence': 'CONCLUSION: Ivabradine safely and significantly lowers HR and improves HR variability in patients with systolic heart failure, without inducing significant bradycardia, ventricular arrhythmias, or supraventricular arrhythmias.', 'subject score': 861, 'object score': 1000}, 'PMID:25968495': {'publication date': '2015', 'sentence': 'CONCLUSIONS: Whatever beta-blocker was coprescribed with ivabradine, there were improvements in cardiovascular outcomes in patients with systolic heart failure, especially with the most prescribed beta-blocker--carvedilol.', 'subject score': 1000, 'object score': 1000}, 'PMID:26721645': {'publication date': '2016 07', 'sentence': 'Ivabradine was only recently approved by Food and Drug administration after the results of Systolic Heart Failure Treatment with the If Inhibitor Ivabradine (SHIFT) trial, for a reduction in rehospitalizations from chronic heart failure.', 'subject score': 1000, 'object score': 916}, 'PMID:26817946': {'publication date': '2016 Apr', 'sentence': 'We reviewed clinical evidence for the use of ivabradine in systolic heart failure (HF), in which it appears to improve symptoms, improve quality of life, prevent hospitalization, and prolong survival, thereby addressing unmet needs in the management of HF.', 'subject score': 1000, 'object score': 1000}, 'PMID:27780557': {'publication date': '2016 Dec 15', 'sentence': 'In conclusion, ivabradine improves outcomes in patients with systolic HF; rates of overall adverse events are similar to placebo.', 'subject score': 1000, 'object score': 1000}, 'PMID:27982270': {'publication date': '2016 Nov', 'sentence': 'Background:: In the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT), heart rate (HR) reduction with ivabradine was associated with improved survival and reduced hospitalizations in patients with heart failure (HF).', 'subject score': 1000, 'object score': 916}, 'PMID:28115808': {'publication date': '2017 Jan', 'sentence': 'BACKGROUND: The aim of our study was to evaluate in stable outpatients with systolic heart failure (HF) the 3 months effect of ivabradine on LV synchronization and Tei index in stable outpatients with systolic HF.', 'subject score': 1000, 'object score': 1000}, 'PMID:28289533': {'publication date': '2017 Feb 26', 'sentence': 'Ivabradine in the treatment of systolic heart failure - A systematic review and meta-analysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28316174': {'publication date': '2017 Mar 24', 'sentence': 'Objective: To evaluate the efficacy and safety of ivabradine for the treatment of Chinese patients with chronic heart failure based on the Chinese subgroup data of the systolic heart failure treatment with the I(f) inhibitor ivabradine trial (SHIFT).', 'subject score': 1000, 'object score': 916}, 'PMID:29142810': {'publication date': '2017', 'sentence': 'Background: Ivabradine (IVA) is effective in patients with coronary artery disease (CAD) or systolic heart failure in sinus rhythm.', 'subject score': 1000, 'object score': 1000}, 'PMID:29470374': {'publication date': '2018 Mar', 'sentence': 'Ivabradine for systolic heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:33956182': {'publication date': '2021 May 06', 'sentence': 'Heart rate modulation therapy using ivabradine reduces mortality and morbidity in patients with systolic heart failure, whereas too reduced heart rate seems to worsen the clinical outcome.', 'subject score': 1000, 'object score': 1000}, 'PMID:34148961': {'publication date': '2021 Jun 19', 'sentence': 'Objective Heart rate modulation therapy using ivabradine reduces both morbidity and mortality in patients with systolic heart failure.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C1135191---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "15641743",
-              "object": "MONDO:0006993",
-              "publications": [
-                "PMID:21573990",
-                "PMID:22892123",
-                "PMID:23549235",
-                "PMID:23696612",
-                "PMID:23929789",
-                "PMID:24327100",
-                "PMID:25733317",
-                "PMID:25801408",
-                "PMID:25968495",
-                "PMID:26721645",
-                "PMID:26817946",
-                "PMID:27780557",
-                "PMID:27982270",
-                "PMID:28115808",
-                "PMID:28289533",
-                "PMID:28316174",
-                "PMID:29142810",
-                "PMID:29470374",
-                "PMID:33956182",
-                "PMID:34148961"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:30116450': {'publication date': '2018 Aug', 'sentence': 'Small studies have recently investigated the role of ivabradine in MS in sinus rhythm.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317122,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005852",
-          "name": "mitral valve stenosis",
-          "description": "Narrowing of the passage through the MITRAL VALVE due to FIBROSIS, and CALCINOSIS in the leaflets and chordal areas. This elevates the left atrial pressure which, in turn, raises pulmonary venous and capillary pressure leading to bouts of DYSPNEA and TACHYCARDIA during physical exertion. RHEUMATIC FEVER is its primary cause.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D008946",
-            "UMLS:C0026269",
-            "MONDO:0005852",
-            "MEDDRA:10027733",
-            "NCIT:C50654",
-            "EFO:0007372",
-            "MEDDRA:10027719",
-            "HP:0001718",
-            "ICD9:394.0",
-            "DOID:1754",
-            "SNOMEDCT:79619009"
-          ],
-          "id": "MONDO:0005852",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Mitral stenosis",
-            "Mitral Valve Stenosis",
-            "mitral valve stenosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/mitral_valve_stenosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317122,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005852",
-              "name": "mitral valve stenosis",
-              "description": "Narrowing of the passage through the MITRAL VALVE due to FIBROSIS, and CALCINOSIS in the leaflets and chordal areas. This elevates the left atrial pressure which, in turn, raises pulmonary venous and capillary pressure leading to bouts of DYSPNEA and TACHYCARDIA during physical exertion. RHEUMATIC FEVER is its primary cause.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D008946",
-                "UMLS:C0026269",
-                "MONDO:0005852",
-                "MEDDRA:10027733",
-                "NCIT:C50654",
-                "EFO:0007372",
-                "MEDDRA:10027719",
-                "HP:0001718",
-                "ICD9:394.0",
-                "DOID:1754",
-                "SNOMEDCT:79619009"
-              ],
-              "id": "MONDO:0005852",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Mitral stenosis",
-                "Mitral Valve Stenosis",
-                "mitral valve stenosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/mitral_valve_stenosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20121566,
-            "start": 557,
-            "end": 317122,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30116450': {'publication date': '2018 Aug', 'sentence': 'Small studies have recently investigated the role of ivabradine in MS in sinus rhythm.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:affects---None---None---None---UMLS:C0026269---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "20520107",
-              "object": "MONDO:0005852",
-              "publications": [
-                "PMID:30116450"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:25636072': {'publication date': '2015 Jun', 'sentence': 'Ivabradine thus can be used effectively and safely in patients with MS in normal sinus rhythm who are intolerant or contraindicated for beta-blocker therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:27420578': {'publication date': '2016 Oct 15', 'sentence': 'Metoprolol vs ivabradine in patients with mitral stenosis in sinus rhythm.', 'subject score': 1000, 'object score': 1000}, 'PMID:27537731': {'publication date': '2016 Nov 15', 'sentence': 'Metoprolol vs ivabradine in patients with mitral stenosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:30116450': {'publication date': '2018 Aug', 'sentence': 'Ivabradine Versus Beta-Blockers in Mitral Stenosis in Sinus Rhythm: An Updated Meta-Analysis of Randomized Controlled Trials.', 'subject score': 1000, 'object score': 1000}, 'PMID:30659493': {'publication date': '2019 Feb', 'sentence': 'Aim of the review The aim of this systematic review and meta-analysis was to compare the efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317122,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005852",
-          "name": "mitral valve stenosis",
-          "description": "Narrowing of the passage through the MITRAL VALVE due to FIBROSIS, and CALCINOSIS in the leaflets and chordal areas. This elevates the left atrial pressure which, in turn, raises pulmonary venous and capillary pressure leading to bouts of DYSPNEA and TACHYCARDIA during physical exertion. RHEUMATIC FEVER is its primary cause.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D008946",
-            "UMLS:C0026269",
-            "MONDO:0005852",
-            "MEDDRA:10027733",
-            "NCIT:C50654",
-            "EFO:0007372",
-            "MEDDRA:10027719",
-            "HP:0001718",
-            "ICD9:394.0",
-            "DOID:1754",
-            "SNOMEDCT:79619009"
-          ],
-          "id": "MONDO:0005852",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Mitral stenosis",
-            "Mitral Valve Stenosis",
-            "mitral valve stenosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/mitral_valve_stenosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317122,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005852",
-              "name": "mitral valve stenosis",
-              "description": "Narrowing of the passage through the MITRAL VALVE due to FIBROSIS, and CALCINOSIS in the leaflets and chordal areas. This elevates the left atrial pressure which, in turn, raises pulmonary venous and capillary pressure leading to bouts of DYSPNEA and TACHYCARDIA during physical exertion. RHEUMATIC FEVER is its primary cause.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D008946",
-                "UMLS:C0026269",
-                "MONDO:0005852",
-                "MEDDRA:10027733",
-                "NCIT:C50654",
-                "EFO:0007372",
-                "MEDDRA:10027719",
-                "HP:0001718",
-                "ICD9:394.0",
-                "DOID:1754",
-                "SNOMEDCT:79619009"
-              ],
-              "id": "MONDO:0005852",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Mitral stenosis",
-                "Mitral Valve Stenosis",
-                "mitral valve stenosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/mitral_valve_stenosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17764958,
-            "start": 557,
-            "end": 317122,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25636072': {'publication date': '2015 Jun', 'sentence': 'Ivabradine thus can be used effectively and safely in patients with MS in normal sinus rhythm who are intolerant or contraindicated for beta-blocker therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:27420578': {'publication date': '2016 Oct 15', 'sentence': 'Metoprolol vs ivabradine in patients with mitral stenosis in sinus rhythm.', 'subject score': 1000, 'object score': 1000}, 'PMID:27537731': {'publication date': '2016 Nov 15', 'sentence': 'Metoprolol vs ivabradine in patients with mitral stenosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:30116450': {'publication date': '2018 Aug', 'sentence': 'Ivabradine Versus Beta-Blockers in Mitral Stenosis in Sinus Rhythm: An Updated Meta-Analysis of Randomized Controlled Trials.', 'subject score': 1000, 'object score': 1000}, 'PMID:30659493': {'publication date': '2019 Feb', 'sentence': 'Aim of the review The aim of this systematic review and meta-analysis was to compare the efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C0026269---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "18126606",
-              "object": "MONDO:0005852",
-              "publications": [
-                "PMID:25636072",
-                "PMID:27420578",
-                "PMID:27537731",
-                "PMID:30116450",
-                "PMID:30659493"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:16307166': {'publication date': '2005', 'sentence': 'New agent ivabradine (Procoralan) for treatment of chronic stable angina.', 'subject score': 890, 'object score': 1000}, 'PMID:16386229': {'publication date': '2006 Jan', 'sentence': 'These data were confirmed in humans, in particular the anti-ischemic efficacy of ivabradine, at least as effective as that of a b-blocker in patients with stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:16479971': {'publication date': '2006 Jan', 'sentence': 'Among the cardiovascular drugs that will soon be licensed, only ivabradine in stable angina, and remodulin in primary pulmonary arterial hypertension are new.', 'subject score': 861, 'object score': 1000}, 'PMID:16638639': {'publication date': '2006 May', 'sentence': 'These data have been confirmed in humans, and in particular, the anti-ischemic efficacy of ivabradine, at least as effective as a beta-blocker, in patients with stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:16732707': {'publication date': '2006 Jun', 'sentence': 'Clinical proof of the antianginal efficacy and tolerability of ivabradine comes from the largest clinical development programme that has ever been performed in stable angina, involving more than 5000 patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:17070146': {'publication date': '2006 Nov', 'sentence': 'Ivabradine is a new specific HR-reducing agent, which has been shown to have antianginal and anti-ischemic properties in patients with stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:17077980': {'publication date': '2006 Dec', 'sentence': 'While beta-blockers remain the first choice for heart rate reduction, in cases of adverse effects ivabradine may be used to treat stable angina pectoris.', 'subject score': 901, 'object score': 1000}, 'PMID:17335297': {'publication date': '2007', 'sentence': 'Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.', 'subject score': 1000, 'object score': 916}, 'PMID:17645051': {'publication date': '2007 May 30', 'sentence': 'Ivabradine is licensed in Europe for use in stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:17890862': {'publication date': '2007', 'sentence': 'Long-term safety and efficacy of ivabradine in patients with chronic stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:17999560': {'publication date': '2007', 'sentence': 'As such, ivabradine is particularly useful in patients with chronic stable angina pectoris.', 'subject score': 1000, 'object score': 1000}, 'PMID:17999562': {'publication date': '2007', 'sentence': 'Clinical evidence of the antianginal and anti-ischaemic efficacy and tolerability of ivabradine comes from the largest clinical development programme that has ever been performed in stable angina pectoris, involving more than 5000 patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:18057886': {'publication date': '2008', 'sentence': 'Since the relatively new selective IF-stream blocker ivabradine has been approved for the therapy of chronic stable angina pectoris, a new therapeutic option is available.', 'subject score': 802, 'object score': 1000}, 'PMID:18221092': {'publication date': '2006 Nov', 'sentence': 'Clinical studies proved the efficacy of ivabradine in patients with stable angina, while clinical data are awaited to verify its probable value in the treatment of atrial tachyarrhythmias and tachycardia due to ventricular dysfunction.', 'subject score': 1000, 'object score': 1000}, 'PMID:18341671': {'publication date': '2008 Jul', 'sentence': 'Ivabradine has been recently approved for the treatment of stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:18536779': {'publication date': '2008 Mar', 'sentence': 'Building on solid preclinical studies, ivabradine was shown to have anti-ischemic and antianginal efficacy in patients with stable angina pectoris in clinical trials versus placebo, beta-blockers and calcium channel blockers.', 'subject score': 1000, 'object score': 1000}, 'PMID:18575078': {'publication date': '2008 Apr', 'sentence': 'In Belgium, ivabradine is currently reimbursed in patients with stable angina and normal sinus rhythm who do not tolerate beta-blockers and non-dihydropyridine calcium antagonists or in whom these treatments are contra-indicated.', 'subject score': 1000, 'object score': 1000}, 'PMID:18806523': {'publication date': '2008 Sep-Oct', 'sentence': 'Ivabradine is a heart rate-lowering agent devoid of other direct cardiovascular effects that has been approved for treatment of patients with stable angina pectoris.', 'subject score': 1000, 'object score': 1000}, 'PMID:18987382': {'publication date': '2008 Nov', 'sentence': 'Here we consider the place of ivabradine in the management of patients with stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:19149708': {'publication date': '2009 Jan', 'sentence': 'Various experimental and clinical studies showed the efficacy of ivabradine in patients with chronic stable angina, on heart rate reduction, on ventricular remodelling after acute myocardial infarction and on coronary blood flow.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 973303,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C0340288",
-          "name": "Stable angina",
-          "description": "Angina pectoris which has not recently changed in frequency, duration or intensity. Stable angina pectoris is relieved by rest or administration or oral, sublingual or transdermal antianginal medications.; Persistent and reproducible chest discomfort usually precipitated by a physical exertion that dissipates upon cessation of such an activity. The symptoms are manifestations of MYOCARDIAL ISCHEMIA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:233819005",
-            "MESH:D060050",
-            "NCIT:C66914",
-            "UMLS:C0340288",
-            "MEDDRA:10049194"
-          ],
-          "id": "UMLS:C0340288",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Angina, Stable",
-            "Stable angina",
-            "Stable Angina"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 973303,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C0340288",
-              "name": "Stable angina",
-              "description": "Angina pectoris which has not recently changed in frequency, duration or intensity. Stable angina pectoris is relieved by rest or administration or oral, sublingual or transdermal antianginal medications.; Persistent and reproducible chest discomfort usually precipitated by a physical exertion that dissipates upon cessation of such an activity. The symptoms are manifestations of MYOCARDIAL ISCHEMIA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:233819005",
-                "MESH:D060050",
-                "NCIT:C66914",
-                "UMLS:C0340288",
-                "MEDDRA:10049194"
-              ],
-              "id": "UMLS:C0340288",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Angina, Stable",
-                "Stable angina",
-                "Stable Angina"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11904615,
-            "start": 557,
-            "end": 973303,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16307166': {'publication date': '2005', 'sentence': 'New agent ivabradine (Procoralan) for treatment of chronic stable angina.', 'subject score': 890, 'object score': 1000}, 'PMID:16386229': {'publication date': '2006 Jan', 'sentence': 'These data were confirmed in humans, in particular the anti-ischemic efficacy of ivabradine, at least as effective as that of a b-blocker in patients with stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:16479971': {'publication date': '2006 Jan', 'sentence': 'Among the cardiovascular drugs that will soon be licensed, only ivabradine in stable angina, and remodulin in primary pulmonary arterial hypertension are new.', 'subject score': 861, 'object score': 1000}, 'PMID:16638639': {'publication date': '2006 May', 'sentence': 'These data have been confirmed in humans, and in particular, the anti-ischemic efficacy of ivabradine, at least as effective as a beta-blocker, in patients with stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:16732707': {'publication date': '2006 Jun', 'sentence': 'Clinical proof of the antianginal efficacy and tolerability of ivabradine comes from the largest clinical development programme that has ever been performed in stable angina, involving more than 5000 patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:17070146': {'publication date': '2006 Nov', 'sentence': 'Ivabradine is a new specific HR-reducing agent, which has been shown to have antianginal and anti-ischemic properties in patients with stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:17077980': {'publication date': '2006 Dec', 'sentence': 'While beta-blockers remain the first choice for heart rate reduction, in cases of adverse effects ivabradine may be used to treat stable angina pectoris.', 'subject score': 901, 'object score': 1000}, 'PMID:17335297': {'publication date': '2007', 'sentence': 'Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.', 'subject score': 1000, 'object score': 916}, 'PMID:17645051': {'publication date': '2007 May 30', 'sentence': 'Ivabradine is licensed in Europe for use in stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:17890862': {'publication date': '2007', 'sentence': 'Long-term safety and efficacy of ivabradine in patients with chronic stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:17999560': {'publication date': '2007', 'sentence': 'As such, ivabradine is particularly useful in patients with chronic stable angina pectoris.', 'subject score': 1000, 'object score': 1000}, 'PMID:17999562': {'publication date': '2007', 'sentence': 'Clinical evidence of the antianginal and anti-ischaemic efficacy and tolerability of ivabradine comes from the largest clinical development programme that has ever been performed in stable angina pectoris, involving more than 5000 patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:18057886': {'publication date': '2008', 'sentence': 'Since the relatively new selective IF-stream blocker ivabradine has been approved for the therapy of chronic stable angina pectoris, a new therapeutic option is available.', 'subject score': 802, 'object score': 1000}, 'PMID:18221092': {'publication date': '2006 Nov', 'sentence': 'Clinical studies proved the efficacy of ivabradine in patients with stable angina, while clinical data are awaited to verify its probable value in the treatment of atrial tachyarrhythmias and tachycardia due to ventricular dysfunction.', 'subject score': 1000, 'object score': 1000}, 'PMID:18341671': {'publication date': '2008 Jul', 'sentence': 'Ivabradine has been recently approved for the treatment of stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:18536779': {'publication date': '2008 Mar', 'sentence': 'Building on solid preclinical studies, ivabradine was shown to have anti-ischemic and antianginal efficacy in patients with stable angina pectoris in clinical trials versus placebo, beta-blockers and calcium channel blockers.', 'subject score': 1000, 'object score': 1000}, 'PMID:18575078': {'publication date': '2008 Apr', 'sentence': 'In Belgium, ivabradine is currently reimbursed in patients with stable angina and normal sinus rhythm who do not tolerate beta-blockers and non-dihydropyridine calcium antagonists or in whom these treatments are contra-indicated.', 'subject score': 1000, 'object score': 1000}, 'PMID:18806523': {'publication date': '2008 Sep-Oct', 'sentence': 'Ivabradine is a heart rate-lowering agent devoid of other direct cardiovascular effects that has been approved for treatment of patients with stable angina pectoris.', 'subject score': 1000, 'object score': 1000}, 'PMID:18987382': {'publication date': '2008 Nov', 'sentence': 'Here we consider the place of ivabradine in the management of patients with stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:19149708': {'publication date': '2009 Jan', 'sentence': 'Various experimental and clinical studies showed the efficacy of ivabradine in patients with chronic stable angina, on heart rate reduction, on ventricular remodelling after acute myocardial infarction and on coronary blood flow.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C0340288---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "12164130",
-              "object": "UMLS:C0340288",
-              "publications": [
-                "PMID:16307166",
-                "PMID:16386229",
-                "PMID:16479971",
-                "PMID:16638639",
-                "PMID:16732707",
-                "PMID:17070146",
-                "PMID:17077980",
-                "PMID:17335297",
-                "PMID:17645051",
-                "PMID:17890862",
-                "PMID:17999560",
-                "PMID:17999562",
-                "PMID:18057886",
-                "PMID:18221092",
-                "PMID:18341671",
-                "PMID:18536779",
-                "PMID:18575078",
-                "PMID:18806523",
-                "PMID:18987382",
-                "PMID:19149708"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:24765517': {'publication date': '2013 Aug 02', 'sentence': 'One should be more critical about ivabradine and low-dose digoxin in diastolic heart failure.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 518244,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006727",
-          "name": "diastolic heart failure",
-          "description": "Heart failure caused by abnormal myocardial relaxation during diastole leading to defective cardiac filling.",
-          "equivalent_curies": [
-            "ICD10:I50.30",
-            "ICD9:428.3",
-            "MONDO:0006727",
-            "SNOMEDCT:418304008",
-            "EFO:1000899",
-            "MESH:D054144",
-            "DOID:9775",
-            "UMLS:C1135196",
-            "MEDDRA:10069211"
-          ],
-          "id": "MONDO:0006727",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Diastolic heart failure",
-            "Heart Failure, Diastolic",
-            "diastolic heart failure"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 518244,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006727",
-              "name": "diastolic heart failure",
-              "description": "Heart failure caused by abnormal myocardial relaxation during diastole leading to defective cardiac filling.",
-              "equivalent_curies": [
-                "ICD10:I50.30",
-                "ICD9:428.3",
-                "MONDO:0006727",
-                "SNOMEDCT:418304008",
-                "EFO:1000899",
-                "MESH:D054144",
-                "DOID:9775",
-                "UMLS:C1135196",
-                "MEDDRA:10069211"
-              ],
-              "id": "MONDO:0006727",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Diastolic heart failure",
-                "Heart Failure, Diastolic",
-                "diastolic heart failure"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17242732,
-            "start": 557,
-            "end": 518244,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24765517': {'publication date': '2013 Aug 02', 'sentence': 'One should be more critical about ivabradine and low-dose digoxin in diastolic heart failure.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:associated_with---None---None---None---UMLS:C1135196---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "17604344",
-              "object": "MONDO:0006727",
-              "publications": [
-                "PMID:24765517"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:29142810': {'publication date': '2017', 'sentence': 'The role of Ivabradine in Diastolic Heart Failure with preserved Ejection Fraction.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 518244,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006727",
-          "name": "diastolic heart failure",
-          "description": "Heart failure caused by abnormal myocardial relaxation during diastole leading to defective cardiac filling.",
-          "equivalent_curies": [
-            "ICD10:I50.30",
-            "ICD9:428.3",
-            "MONDO:0006727",
-            "SNOMEDCT:418304008",
-            "EFO:1000899",
-            "MESH:D054144",
-            "DOID:9775",
-            "UMLS:C1135196",
-            "MEDDRA:10069211"
-          ],
-          "id": "MONDO:0006727",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Diastolic heart failure",
-            "Heart Failure, Diastolic",
-            "diastolic heart failure"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 518244,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006727",
-              "name": "diastolic heart failure",
-              "description": "Heart failure caused by abnormal myocardial relaxation during diastole leading to defective cardiac filling.",
-              "equivalent_curies": [
-                "ICD10:I50.30",
-                "ICD9:428.3",
-                "MONDO:0006727",
-                "SNOMEDCT:418304008",
-                "EFO:1000899",
-                "MESH:D054144",
-                "DOID:9775",
-                "UMLS:C1135196",
-                "MEDDRA:10069211"
-              ],
-              "id": "MONDO:0006727",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Diastolic heart failure",
-                "Heart Failure, Diastolic",
-                "diastolic heart failure"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19613326,
-            "start": 557,
-            "end": 518244,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29142810': {'publication date': '2017', 'sentence': 'The role of Ivabradine in Diastolic Heart Failure with preserved Ejection Fraction.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:affects---None---None---None---UMLS:C1135196---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "20004006",
-              "object": "MONDO:0006727",
-              "publications": [
-                "PMID:29142810"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:24765517': {'publication date': '2013 Aug 02', 'sentence': 'The aim of the study was to compare the therapeutic effects of ivabradine in diastolic heart failure with preserved left ventricular systolic function.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 518244,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006727",
-          "name": "diastolic heart failure",
-          "description": "Heart failure caused by abnormal myocardial relaxation during diastole leading to defective cardiac filling.",
-          "equivalent_curies": [
-            "ICD10:I50.30",
-            "ICD9:428.3",
-            "MONDO:0006727",
-            "SNOMEDCT:418304008",
-            "EFO:1000899",
-            "MESH:D054144",
-            "DOID:9775",
-            "UMLS:C1135196",
-            "MEDDRA:10069211"
-          ],
-          "id": "MONDO:0006727",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Diastolic heart failure",
-            "Heart Failure, Diastolic",
-            "diastolic heart failure"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 518244,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006727",
-              "name": "diastolic heart failure",
-              "description": "Heart failure caused by abnormal myocardial relaxation during diastole leading to defective cardiac filling.",
-              "equivalent_curies": [
-                "ICD10:I50.30",
-                "ICD9:428.3",
-                "MONDO:0006727",
-                "SNOMEDCT:418304008",
-                "EFO:1000899",
-                "MESH:D054144",
-                "DOID:9775",
-                "UMLS:C1135196",
-                "MEDDRA:10069211"
-              ],
-              "id": "MONDO:0006727",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Diastolic heart failure",
-                "Heart Failure, Diastolic",
-                "diastolic heart failure"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17242728,
-            "start": 557,
-            "end": 518244,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24765517': {'publication date': '2013 Aug 02', 'sentence': 'The aim of the study was to compare the therapeutic effects of ivabradine in diastolic heart failure with preserved left ventricular systolic function.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C1135196---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "17604340",
-              "object": "MONDO:0006727",
-              "publications": [
-                "PMID:24765517"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:21090826': {'publication date': '2011', 'sentence': 'Other large trials are also underway to assess the effects of ivabradine on heart failure, acute coronary syndromes, CAD, and other cardiovascular disorders.', 'subject score': 1000, 'object score': 1000}, 'PMID:22547315': {'publication date': '2012 Apr 30', 'sentence': 'The biological effects of ivabradine in cardiovascular disease.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 308937,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-          "name": "cardiovascular disorder",
-          "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "MEDDRA:10045663",
-            "MONDO:0004995",
-            "ICD9:429.2",
-            "MEDDRA:10007649",
-            "UMLS:C0243050",
-            "HP:0001626",
-            "MESH:D018376",
-            "MEDDRA:10007648",
-            "MEDDRA:10013205",
-            "SNOMEDCT:49601007",
-            "MEDDRA:10007650",
-            "MESH:D002318",
-            "DOID:1287",
-            "UMLS:C0007222",
-            "UMLS:C0728936",
-            "NCIT:C2931"
-          ],
-          "id": "MONDO:0004995",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiovascular Diseases",
-            "Cardiovascular disease, unspecified",
-            "Abnormality of the cardiovascular system",
-            "cardiovascular system disease",
-            "Disorder of circulatory system",
-            "Cardiovascular Disorder",
-            "cardiovascular disorder",
-            "Cardiovascular Abnormalities"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/circulatory_system",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308937,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-              "name": "cardiovascular disorder",
-              "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "MEDDRA:10045663",
-                "MONDO:0004995",
-                "ICD9:429.2",
-                "MEDDRA:10007649",
-                "UMLS:C0243050",
-                "HP:0001626",
-                "MESH:D018376",
-                "MEDDRA:10007648",
-                "MEDDRA:10013205",
-                "SNOMEDCT:49601007",
-                "MEDDRA:10007650",
-                "MESH:D002318",
-                "DOID:1287",
-                "UMLS:C0007222",
-                "UMLS:C0728936",
-                "NCIT:C2931"
-              ],
-              "id": "MONDO:0004995",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiovascular Diseases",
-                "Cardiovascular disease, unspecified",
-                "Abnormality of the cardiovascular system",
-                "cardiovascular system disease",
-                "Disorder of circulatory system",
-                "Cardiovascular Disorder",
-                "cardiovascular disorder",
-                "Cardiovascular Abnormalities"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/circulatory_system",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15007018,
-            "start": 557,
-            "end": 308937,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21090826': {'publication date': '2011', 'sentence': 'Other large trials are also underway to assess the effects of ivabradine on heart failure, acute coronary syndromes, CAD, and other cardiovascular disorders.', 'subject score': 1000, 'object score': 1000}, 'PMID:22547315': {'publication date': '2012 Apr 30', 'sentence': 'The biological effects of ivabradine in cardiovascular disease.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:affects---None---None---None---UMLS:C0007222---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "15323309",
-              "object": "MONDO:0004995",
-              "publications": [
-                "PMID:21090826",
-                "PMID:22547315"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15301560': {'publication date': '2004', 'sentence': 'Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:21434947': {'publication date': '2011 Mar', 'sentence': 'The development of ivabradine represents a clear innovation in the management of cardiovascular disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:21878041': {'publication date': '2011 Aug', 'sentence': 'Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:26917820': {'publication date': '2016 06', 'sentence': 'Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:28726428': {'publication date': 'Summer 2017', 'sentence': '[A present view on ivabradine in the therapy of cardiovascular diseases].', 'subject score': 1000, 'object score': 1000}, 'PMID:30606942': {'publication date': '2019 01 25', 'sentence': 'Ivabradine for the Treatment of Cardiovascular Diseases.', 'subject score': 1000, 'object score': 1000}, 'PMID:30676481': {'publication date': '2019 Jun', 'sentence': 'In this review, we explore the effect of pharmacological heart rate lowering with a beta-blocker or ivabradine on cardiovascular outcomes in patients with cardiovascular disease and address the question as to whether pharmacological heart rate reduction is ready for prime time in the management of patients with coronary artery disease.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 308937,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-          "name": "cardiovascular disorder",
-          "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "MEDDRA:10045663",
-            "MONDO:0004995",
-            "ICD9:429.2",
-            "MEDDRA:10007649",
-            "UMLS:C0243050",
-            "HP:0001626",
-            "MESH:D018376",
-            "MEDDRA:10007648",
-            "MEDDRA:10013205",
-            "SNOMEDCT:49601007",
-            "MEDDRA:10007650",
-            "MESH:D002318",
-            "DOID:1287",
-            "UMLS:C0007222",
-            "UMLS:C0728936",
-            "NCIT:C2931"
-          ],
-          "id": "MONDO:0004995",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiovascular Diseases",
-            "Cardiovascular disease, unspecified",
-            "Abnormality of the cardiovascular system",
-            "cardiovascular system disease",
-            "Disorder of circulatory system",
-            "Cardiovascular Disorder",
-            "cardiovascular disorder",
-            "Cardiovascular Abnormalities"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/circulatory_system",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 557,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ivabradine",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-          "equivalent_curies": [
-            "GTOPDB:2357",
-            "RXNORM:1649480",
-            "CHEBI:85966",
-            "DRUGBANK:DB09083",
-            "UMLS:C0257190",
-            "UNII:3H48L0LPZQ",
-            "MESH:D000077550",
-            "DrugCentral:3312",
-            "NCIT:C65995",
-            "KEGG.DRUG:D07165",
-            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-            "PUBCHEM.COMPOUND:132999",
-            "ATC:C01EB17",
-            "CAS:155974-00-8",
-            "CHEMBL.COMPOUND:CHEMBL471737"
-          ],
-          "id": "PUBCHEM.COMPOUND:132999",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "corlentor",
-            "IVABRADINE",
-            "Ivabradine",
-            "ivabradine",
-            "Ivabradine (USAN/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25839989",
-            "PMID:20795648",
-            "PMID:15301560",
-            "PMID:18529044",
-            "PMID:29615340",
-            "PMID:20167941",
-            "PMID:16451297",
-            "PMID:24377458"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308937,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-              "name": "cardiovascular disorder",
-              "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "MEDDRA:10045663",
-                "MONDO:0004995",
-                "ICD9:429.2",
-                "MEDDRA:10007649",
-                "UMLS:C0243050",
-                "HP:0001626",
-                "MESH:D018376",
-                "MEDDRA:10007648",
-                "MEDDRA:10013205",
-                "SNOMEDCT:49601007",
-                "MEDDRA:10007650",
-                "MESH:D002318",
-                "DOID:1287",
-                "UMLS:C0007222",
-                "UMLS:C0728936",
-                "NCIT:C2931"
-              ],
-              "id": "MONDO:0004995",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiovascular Diseases",
-                "Cardiovascular disease, unspecified",
-                "Abnormality of the cardiovascular system",
-                "cardiovascular system disease",
-                "Disorder of circulatory system",
-                "Cardiovascular Disorder",
-                "cardiovascular disorder",
-                "Cardiovascular Abnormalities"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/circulatory_system",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11099579,
-            "start": 557,
-            "end": 308937,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15301560': {'publication date': '2004', 'sentence': 'Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:21434947': {'publication date': '2011 Mar', 'sentence': 'The development of ivabradine represents a clear innovation in the management of cardiovascular disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:21878041': {'publication date': '2011 Aug', 'sentence': 'Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:26917820': {'publication date': '2016 06', 'sentence': 'Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:28726428': {'publication date': 'Summer 2017', 'sentence': '[A present view on ivabradine in the therapy of cardiovascular diseases].', 'subject score': 1000, 'object score': 1000}, 'PMID:30606942': {'publication date': '2019 01 25', 'sentence': 'Ivabradine for the Treatment of Cardiovascular Diseases.', 'subject score': 1000, 'object score': 1000}, 'PMID:30676481': {'publication date': '2019 Jun', 'sentence': 'In this review, we explore the effect of pharmacological heart rate lowering with a beta-blocker or ivabradine on cardiovascular outcomes in patients with cardiovascular disease and address the question as to whether pharmacological heart rate reduction is ready for prime time in the management of patients with coronary artery disease.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C0007222---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:132999",
-              "id": "11342280",
-              "object": "MONDO:0004995",
-              "publications": [
-                "PMID:15301560",
-                "PMID:21434947",
-                "PMID:21878041",
-                "PMID:26917820",
-                "PMID:28726428",
-                "PMID:30606942",
-                "PMID:30676481"
-              ]
-            }
-          },
-          "end": {
-            "identity": 557,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ivabradine",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
-              "equivalent_curies": [
-                "GTOPDB:2357",
-                "RXNORM:1649480",
-                "CHEBI:85966",
-                "DRUGBANK:DB09083",
-                "UMLS:C0257190",
-                "UNII:3H48L0LPZQ",
-                "MESH:D000077550",
-                "DrugCentral:3312",
-                "NCIT:C65995",
-                "KEGG.DRUG:D07165",
-                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
-                "PUBCHEM.COMPOUND:132999",
-                "ATC:C01EB17",
-                "CAS:155974-00-8",
-                "CHEMBL.COMPOUND:CHEMBL471737"
-              ],
-              "id": "PUBCHEM.COMPOUND:132999",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "corlentor",
-                "IVABRADINE",
-                "Ivabradine",
-                "ivabradine",
-                "Ivabradine (USAN/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25839989",
-                "PMID:20795648",
-                "PMID:15301560",
-                "PMID:18529044",
-                "PMID:29615340",
-                "PMID:20167941",
-                "PMID:16451297",
-                "PMID:24377458"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:2118322': {'publication date': '1990 Jun', 'sentence': 'Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:8596127': {'publication date': '1995 Oct', 'sentence': 'Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:8618110': {'publication date': '1995 May', 'sentence': 'We have investigated the impact on normal human intestinal flora in a 10-day course with cefetamet-pivoxil (CET, 500 mg BID) in comparison to cefixime (CFX, 400 mg qD) or cefuroxime axetil (CA, 250 mg BID) in 24 patients suffering from acute exacerbation of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 321736,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005607",
-          "name": "chronic bronchitis",
-          "description": "A type of chronic obstructive pulmonary disease characterized by chronic inflammation in the bronchial tree that results in edema, mucus production, obstruction, and reduced airflow to and from the lung alveoli. The most common cause is tobacco smoking. Signs and symptoms include coughing with excessive mucus production, and shortness of breath.; A subcategory of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. The disease is characterized by hypersecretion of mucus accompanied by a chronic (more than 3 months in 2 consecutive years) productive cough. Infectious agents are a major cause of chronic bronchitis.; Chronic inflammation of the bronchi. [HPO:probinson]; What is chronic bronchitis? Chronic bronchitis is a type of COPD (chronic obstructive pulmonary disease). COPD is a group of lung diseases that make it hard to breathe and get worse over time. The other main type of COPD is emphysema. Most people with COPD have both emphysema and chronic bronchitis, but how severe each type is can be different from person to person. Chronic bronchitis is inflammation (swelling) and irritation of the bronchial tubes. These tubes are the airways that carry air to and from the air sacs in your lungs. The irritation of the tubes causes mucus to build up. This mucus and the swelling of the tubes make it harder for your lungs to move oxygen in and carbon dioxide out of your body. What causes chronic bronchitis? The cause of chronic bronchitis is usually long-term exposure to irritants that damage your lungs and airways. In the United States, cigarette smoke is the main cause. Pipe, cigar, and other types of tobacco smoke can also cause chronic bronchitis, especially if you inhale them. Exposure to other inhaled irritants can contribute to chronic bronchitis. These include secondhand smoke, air pollution, and chemical fumes or dusts from the environment or workplace. Rarely, a genetic condition called alpha-1 antitrypsin deficiency can play a role in causing chronic bronchitis. Who is at risk for chronic bronchitis? The risk factors for chronic bronchitis include: Smoking. This the main risk factor. Up to 75% of people who have chronic bronchitis smoke or used to smoke. Long-term exposure to other lung irritants, such as secondhand smoke, air pollution, and chemical fumes and dusts from the environment or workplace. Age. Most people who have chronic bronchitis are at least 40 years old when their symptoms begin. Genetics. This includes alpha-1 antitrypsin deficiency, which is a genetic condition. Also, smokers who get chronic bronchitis are more likely to get it if they have a family history of COPD.  What are the symptoms of chronic bronchitis? At first, you may have no symptoms or only mild symptoms. As the disease gets worse, your symptoms usually become more severe. They can include: Frequent coughing or a cough that produces a lot mucus Wheezing A whistling or squeaky sound when you breathe Shortness of breath, especially with physical activity Tightness in your chest  Some people with chronic bronchitis get frequent respiratory infections such as colds and the flu. In severe cases, chronic bronchitis can cause weight loss, weakness in your lower muscles, and swelling in your ankles, feet, or legs. How is chronic bronchitis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A family history Various tests, such as lung function tests, a chest x-ray or CT scan, and blood tests  What are the treatments for chronic bronchitis? There is no cure for chronic bronchitis. However, treatments can help with symptoms, slow the progress of the disease, and improve your ability to stay active. There are also treatments to prevent or treat complications of the disease. Treatments include: Lifestyle changes, such as  Quitting smoking if you are a smoker. This is the most important step you can take to treat chronic bronchitis. Avoiding secondhand smoke and places where you might breathe in other lung irritants Ask your health care provider for an eating plan that will meet your nutritional needs. Also ask about how much physical activity you can do. Physical activity can strengthen the muscles that help you breathe and improve your overall wellness.   Medicines, such as  Bronchodilators, which relax the muscles around your airways. This helps open your airways and makes breathing easier. Most bronchodilators are taken through an inhaler. In more severe cases, the inhaler may also contain steroids to reduce inflammation. Vaccines for the flu and pneumococcal pneumonia, since people with chronic bronchitis are at higher risk for serious problems from these diseases. Antibiotics if you get a bacterial or viral lung infection   Oxygen therapy, if you have severe chronic bronchitis and low levels of oxygen in your blood. Oxygen therapy can help you breathe better. You may need extra oxygen all the time or only at certain times. Pulmonary rehabilitation, which is a program that helps improve the well-being of people who have chronic breathing problems. It may include  An exercise program Disease management training Nutritional counseling Psychological counseling  A lung transplant, as a last resort for people who have severe symptoms that have not gotten better with medicines  If you have chronic bronchitis, it's important to know when and where to get help for your symptoms. You should get emergency care if you have severe symptoms, such as trouble catching your breath or talking. Call your health care provider if your symptoms are getting worse or if you have signs of an infection, such as a fever. Can chronic bronchitis be prevented? Since smoking causes most cases of chronic bronchitis, the best way to prevent it is to not smoke. It's also important to try to avoid lung irritants such as secondhand smoke, air pollution, chemical fumes, and dusts.  NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10008843",
-            "MEDDRA:10008841",
-            "NCIT:C26722",
-            "MEDDRA:10006458",
-            "MESH:D029481",
-            "MONDO:0005607",
-            "MEDDRA:10045659",
-            "EFO:0006505",
-            "UMLS:C0008677",
-            "MEDDRA:10006459",
-            "HP:0004469",
-            "SNOMEDCT:63480004"
-          ],
-          "id": "MONDO:0005607",
-          "category": "biolink:Disease",
-          "all_names": [
-            "chronic bronchitis",
-            "Bronchitis, Chronic",
-            "Chronic bronchitis",
-            "Chronic Bronchitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 558,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefixime",
-          "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "UNII:XZ7BG04GJX",
-            "DRUGBANK:DB00671",
-            "GTOPDB:10898",
-            "PDQ:CDR0000037809",
-            "NDDF:002737",
-            "CHEBI:472657",
-            "HMDB:HMDB0014809",
-            "KEGG.COMPOUND:C06881",
-            "NCIT:C1100",
-            "UMLS:C0060400",
-            "CHEMBL.COMPOUND:CHEMBL1541",
-            "ATC:J01DD08",
-            "KEGG.DRUG:D00258",
-            "MESH:D020682",
-            "DrugCentral:537",
-            "PUBCHEM.COMPOUND:5362065",
-            "RXNORM:25033",
-            "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:5362065",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "CEFIXIME",
-            "Cefixime (INN)",
-            "Cefixime",
-            "cefixime"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20070106",
-            "PMID:9379359",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23416192",
-            "PMID:19586686",
-            "PMID:21741846",
-            "PMID:21098249",
-            "PMID:24961639",
-            "PMID:8627565"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321736,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005607",
-              "name": "chronic bronchitis",
-              "description": "A type of chronic obstructive pulmonary disease characterized by chronic inflammation in the bronchial tree that results in edema, mucus production, obstruction, and reduced airflow to and from the lung alveoli. The most common cause is tobacco smoking. Signs and symptoms include coughing with excessive mucus production, and shortness of breath.; A subcategory of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. The disease is characterized by hypersecretion of mucus accompanied by a chronic (more than 3 months in 2 consecutive years) productive cough. Infectious agents are a major cause of chronic bronchitis.; Chronic inflammation of the bronchi. [HPO:probinson]; What is chronic bronchitis? Chronic bronchitis is a type of COPD (chronic obstructive pulmonary disease). COPD is a group of lung diseases that make it hard to breathe and get worse over time. The other main type of COPD is emphysema. Most people with COPD have both emphysema and chronic bronchitis, but how severe each type is can be different from person to person. Chronic bronchitis is inflammation (swelling) and irritation of the bronchial tubes. These tubes are the airways that carry air to and from the air sacs in your lungs. The irritation of the tubes causes mucus to build up. This mucus and the swelling of the tubes make it harder for your lungs to move oxygen in and carbon dioxide out of your body. What causes chronic bronchitis? The cause of chronic bronchitis is usually long-term exposure to irritants that damage your lungs and airways. In the United States, cigarette smoke is the main cause. Pipe, cigar, and other types of tobacco smoke can also cause chronic bronchitis, especially if you inhale them. Exposure to other inhaled irritants can contribute to chronic bronchitis. These include secondhand smoke, air pollution, and chemical fumes or dusts from the environment or workplace. Rarely, a genetic condition called alpha-1 antitrypsin deficiency can play a role in causing chronic bronchitis. Who is at risk for chronic bronchitis? The risk factors for chronic bronchitis include: Smoking. This the main risk factor. Up to 75% of people who have chronic bronchitis smoke or used to smoke. Long-term exposure to other lung irritants, such as secondhand smoke, air pollution, and chemical fumes and dusts from the environment or workplace. Age. Most people who have chronic bronchitis are at least 40 years old when their symptoms begin. Genetics. This includes alpha-1 antitrypsin deficiency, which is a genetic condition. Also, smokers who get chronic bronchitis are more likely to get it if they have a family history of COPD.  What are the symptoms of chronic bronchitis? At first, you may have no symptoms or only mild symptoms. As the disease gets worse, your symptoms usually become more severe. They can include: Frequent coughing or a cough that produces a lot mucus Wheezing A whistling or squeaky sound when you breathe Shortness of breath, especially with physical activity Tightness in your chest  Some people with chronic bronchitis get frequent respiratory infections such as colds and the flu. In severe cases, chronic bronchitis can cause weight loss, weakness in your lower muscles, and swelling in your ankles, feet, or legs. How is chronic bronchitis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A family history Various tests, such as lung function tests, a chest x-ray or CT scan, and blood tests  What are the treatments for chronic bronchitis? There is no cure for chronic bronchitis. However, treatments can help with symptoms, slow the progress of the disease, and improve your ability to stay active. There are also treatments to prevent or treat complications of the disease. Treatments include: Lifestyle changes, such as  Quitting smoking if you are a smoker. This is the most important step you can take to treat chronic bronchitis. Avoiding secondhand smoke and places where you might breathe in other lung irritants Ask your health care provider for an eating plan that will meet your nutritional needs. Also ask about how much physical activity you can do. Physical activity can strengthen the muscles that help you breathe and improve your overall wellness.   Medicines, such as  Bronchodilators, which relax the muscles around your airways. This helps open your airways and makes breathing easier. Most bronchodilators are taken through an inhaler. In more severe cases, the inhaler may also contain steroids to reduce inflammation. Vaccines for the flu and pneumococcal pneumonia, since people with chronic bronchitis are at higher risk for serious problems from these diseases. Antibiotics if you get a bacterial or viral lung infection   Oxygen therapy, if you have severe chronic bronchitis and low levels of oxygen in your blood. Oxygen therapy can help you breathe better. You may need extra oxygen all the time or only at certain times. Pulmonary rehabilitation, which is a program that helps improve the well-being of people who have chronic breathing problems. It may include  An exercise program Disease management training Nutritional counseling Psychological counseling  A lung transplant, as a last resort for people who have severe symptoms that have not gotten better with medicines  If you have chronic bronchitis, it's important to know when and where to get help for your symptoms. You should get emergency care if you have severe symptoms, such as trouble catching your breath or talking. Call your health care provider if your symptoms are getting worse or if you have signs of an infection, such as a fever. Can chronic bronchitis be prevented? Since smoking causes most cases of chronic bronchitis, the best way to prevent it is to not smoke. It's also important to try to avoid lung irritants such as secondhand smoke, air pollution, chemical fumes, and dusts.  NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10008843",
-                "MEDDRA:10008841",
-                "NCIT:C26722",
-                "MEDDRA:10006458",
-                "MESH:D029481",
-                "MONDO:0005607",
-                "MEDDRA:10045659",
-                "EFO:0006505",
-                "UMLS:C0008677",
-                "MEDDRA:10006459",
-                "HP:0004469",
-                "SNOMEDCT:63480004"
-              ],
-              "id": "MONDO:0005607",
-              "category": "biolink:Disease",
-              "all_names": [
-                "chronic bronchitis",
-                "Bronchitis, Chronic",
-                "Chronic bronchitis",
-                "Chronic Bronchitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15067766,
-            "start": 558,
-            "end": 321736,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2118322': {'publication date': '1990 Jun', 'sentence': 'Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:8596127': {'publication date': '1995 Oct', 'sentence': 'Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:8618110': {'publication date': '1995 May', 'sentence': 'We have investigated the impact on normal human intestinal flora in a 10-day course with cefetamet-pivoxil (CET, 500 mg BID) in comparison to cefixime (CFX, 400 mg qD) or cefuroxime axetil (CA, 250 mg BID) in 24 patients suffering from acute exacerbation of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0060400---SEMMEDDB:affects---None---None---None---UMLS:C0008677---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5362065",
-              "id": "15385004",
-              "object": "MONDO:0005607",
-              "publications": [
-                "PMID:2118322",
-                "PMID:8596127",
-                "PMID:8618110"
-              ]
-            }
-          },
-          "end": {
-            "identity": 558,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-=======
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
->>>>>>> main
-            ],
-            "properties": {
-              "name": "Cefixime",
-              "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "UNII:XZ7BG04GJX",
-                "DRUGBANK:DB00671",
-                "GTOPDB:10898",
-                "PDQ:CDR0000037809",
-                "NDDF:002737",
-                "CHEBI:472657",
-                "HMDB:HMDB0014809",
-                "KEGG.COMPOUND:C06881",
-                "NCIT:C1100",
-                "UMLS:C0060400",
-                "CHEMBL.COMPOUND:CHEMBL1541",
-                "ATC:J01DD08",
-                "KEGG.DRUG:D00258",
-                "MESH:D020682",
-                "DrugCentral:537",
-                "PUBCHEM.COMPOUND:5362065",
-                "RXNORM:25033",
-                "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:5362065",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "CEFIXIME",
-                "Cefixime (INN)",
-                "Cefixime",
-                "cefixime"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20070106",
-                "PMID:9379359",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23416192",
-                "PMID:19586686",
-                "PMID:21741846",
-                "PMID:21098249",
-                "PMID:24961639",
-                "PMID:8627565"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:20940180': {'publication date': '2010 Dec', 'sentence': 'Alterations of the pilQ gene in Neisseria gonorrhoeae are unlikely contributors to decreased susceptibility to ceftriaxone and cefixime in clinical gonococcal strains.', 'subject score': 1000, 'object score': 851}, 'PMID:28145684': {'publication date': '2017 02 28', 'sentence': 'To examine the potential of mutations at Ala501 to increase resistance to expanded-spectrum cephalosporins, we randomized codon 501 in a mosaic penA allele and transformed N. gonorrhoeae to increased cefixime resistance.', 'subject score': 623, 'object score': 773}, 'PMID:31230613': {'publication date': '2019 Jun 24', 'sentence': 'METHODS: A systematic review of all published articles in PubMed through 1 November 2018 was conducted that report findings on the molecular characteristics and potential mechanisms of resistance for gonococcal strains with decreased cefixime susceptibility.', 'subject score': 851, 'object score': 888}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 506516,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004277",
-          "name": "gonorrhea",
-          "description": "An infection that is caused by Gonococcus.; A common sexually transmitted bacterial infection caused by Neisseria gonorrhoeae. It is transmitted through vaginal, oral, or anal intercourse. Infected individuals may be asymptomatic. Symptoms in males include burning sensation during urination, discharge from the penis, and painful swelling of the testes. Symptoms in females include painful urination, vaginal discharge, and vaginal bleeding between periods. If untreated, the infection may lead to pelvic inflammatory disease.; Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, NEISSERIA GONORRHOEAE, was isolated by Neisser in 1879.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:21330",
-            "UMLS:C0018081",
-            "MEDDRA:10018612",
-            "ORPHANET:100642",
-            "MEDDRA:10018615",
-            "NCIT:C92950",
-            "MESH:D006069",
-            "DOID:7551",
-            "NCIT:C35730",
-            "ICD10:A54",
-            "SNOMEDCT:15628003",
-            "MEDDRA:10081185",
-            "MEDDRA:10051970",
-            "ICD9:098",
-            "MEDDRA:10018604",
-            "MONDO:0004277"
-          ],
-          "id": "MONDO:0004277",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Gonococcal Infection",
-            "gonorrhea",
-            "Gonorrhea",
-            "Gonococcal infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cdc.gov/std/gonorrhea/stdfact-gonorrhea.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 558,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefixime",
-          "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "UNII:XZ7BG04GJX",
-            "DRUGBANK:DB00671",
-            "GTOPDB:10898",
-            "PDQ:CDR0000037809",
-            "NDDF:002737",
-            "CHEBI:472657",
-            "HMDB:HMDB0014809",
-            "KEGG.COMPOUND:C06881",
-            "NCIT:C1100",
-            "UMLS:C0060400",
-            "CHEMBL.COMPOUND:CHEMBL1541",
-            "ATC:J01DD08",
-            "KEGG.DRUG:D00258",
-            "MESH:D020682",
-            "DrugCentral:537",
-            "PUBCHEM.COMPOUND:5362065",
-            "RXNORM:25033",
-            "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:5362065",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "CEFIXIME",
-            "Cefixime (INN)",
-            "Cefixime",
-            "cefixime"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20070106",
-            "PMID:9379359",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23416192",
-            "PMID:19586686",
-            "PMID:21741846",
-            "PMID:21098249",
-            "PMID:24961639",
-            "PMID:8627565"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 506516,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004277",
-              "name": "gonorrhea",
-              "description": "An infection that is caused by Gonococcus.; A common sexually transmitted bacterial infection caused by Neisseria gonorrhoeae. It is transmitted through vaginal, oral, or anal intercourse. Infected individuals may be asymptomatic. Symptoms in males include burning sensation during urination, discharge from the penis, and painful swelling of the testes. Symptoms in females include painful urination, vaginal discharge, and vaginal bleeding between periods. If untreated, the infection may lead to pelvic inflammatory disease.; Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, NEISSERIA GONORRHOEAE, was isolated by Neisser in 1879.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:21330",
-                "UMLS:C0018081",
-                "MEDDRA:10018612",
-                "ORPHANET:100642",
-                "MEDDRA:10018615",
-                "NCIT:C92950",
-                "MESH:D006069",
-                "DOID:7551",
-                "NCIT:C35730",
-                "ICD10:A54",
-                "SNOMEDCT:15628003",
-                "MEDDRA:10081185",
-                "MEDDRA:10051970",
-                "ICD9:098",
-                "MEDDRA:10018604",
-                "MONDO:0004277"
-              ],
-              "id": "MONDO:0004277",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Gonococcal Infection",
-                "gonorrhea",
-                "Gonorrhea",
-                "Gonococcal infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cdc.gov/std/gonorrhea/stdfact-gonorrhea.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14937781,
-            "start": 558,
-            "end": 506516,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20940180': {'publication date': '2010 Dec', 'sentence': 'Alterations of the pilQ gene in Neisseria gonorrhoeae are unlikely contributors to decreased susceptibility to ceftriaxone and cefixime in clinical gonococcal strains.', 'subject score': 1000, 'object score': 851}, 'PMID:28145684': {'publication date': '2017 02 28', 'sentence': 'To examine the potential of mutations at Ala501 to increase resistance to expanded-spectrum cephalosporins, we randomized codon 501 in a mosaic penA allele and transformed N. gonorrhoeae to increased cefixime resistance.', 'subject score': 623, 'object score': 773}, 'PMID:31230613': {'publication date': '2019 Jun 24', 'sentence': 'METHODS: A systematic review of all published articles in PubMed through 1 November 2018 was conducted that report findings on the molecular characteristics and potential mechanisms of resistance for gonococcal strains with decreased cefixime susceptibility.', 'subject score': 851, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0060400---SEMMEDDB:affects---None---None---None---UMLS:C0018081---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5362065",
-              "id": "15252860",
-              "object": "MONDO:0004277",
-              "publications": [
-                "PMID:20940180",
-                "PMID:28145684",
-                "PMID:31230613"
-              ]
-            }
-          },
-          "end": {
-            "identity": 558,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefixime",
-              "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "UNII:XZ7BG04GJX",
-                "DRUGBANK:DB00671",
-                "GTOPDB:10898",
-                "PDQ:CDR0000037809",
-                "NDDF:002737",
-                "CHEBI:472657",
-                "HMDB:HMDB0014809",
-                "KEGG.COMPOUND:C06881",
-                "NCIT:C1100",
-                "UMLS:C0060400",
-                "CHEMBL.COMPOUND:CHEMBL1541",
-                "ATC:J01DD08",
-                "KEGG.DRUG:D00258",
-                "MESH:D020682",
-                "DrugCentral:537",
-                "PUBCHEM.COMPOUND:5362065",
-                "RXNORM:25033",
-                "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:5362065",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "CEFIXIME",
-                "Cefixime (INN)",
-                "Cefixime",
-                "cefixime"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20070106",
-                "PMID:9379359",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23416192",
-                "PMID:19586686",
-                "PMID:21741846",
-                "PMID:21098249",
-                "PMID:24961639",
-                "PMID:8627565"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 317210,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001039",
-          "name": "tonsillitis",
-          "description": "Inflammation of the tonsils that has occurred repeatedly. The definition of recurrent may vary somewhat, but the criteria used recently as a measure of severity were five or more episodes of true tonsillitis per year, symptoms recurring for at least a year, and episodes that are disabling and that prevent normal functioning. In some cases recurrent tonsillitis may be related to immunosusceptibility. Evidence exists for a genetic predisposition for recurrent tonsillitis. [HPO:probinson, PMID:15897415]; Inflammation of the tonsils that has occurred repeatedly. The definition of recurrent may vary somewhat, but the criteria used recently as a measure of severity were five or more episodes of true tonsillitis per year, symptoms recurring for at least a year, and episodes that are disabling and that prevent normal functioning. In some cases recurrent tonsillitis may be related to immunosusceptibility. Evidence exists for a genetic predisposition for recurrent tonsillitis.; Inflammation of the tonsils that has occurred repeatedly. The definition of recurrent may vary somewhat, but the criteria used recently as a measure of severity were five or more episodes of true tonsillitis per year, symptoms recurring for at least a year, and episodes that are disabling and that prevent normal functioning. In some cases recurrent tonsillitis may be related to immunosusceptibility. Evidence exists for a genetic predisposition for recurrent tonsillitis.; Inflammation of the tonsils that has occurred repeatedly. The definition of recurrent may vary somewhat, but the criteria used recently as a measure of severity were five or more episodes of true tonsillitis per year, symptoms recurring for at least a year, and episodes that are disabling and that prevent normal functioning. In some cases recurrent tonsillitis may be related to immunosusceptibility. Evidence exists for a genetic predisposition for recurrent tonsillitis.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10044008",
-            "DOID:10456",
-            "MEDDRA:10009152",
-            "SNOMEDCT:90176007",
-            "MONDO:0001039",
-            "ICD10:J35.01",
-            "MEDDRA:10044010",
-            "ICD9:474.00",
-            "HP:0011110",
-            "MEDDRA:10044012",
-            "UMLS:C0149517",
-            "UMLS:C0740402",
-            "MESH:D014069",
-            "UMLS:C0040425",
-            "SNOMEDCT:90979004",
-            "MEDDRA:10044011",
-            "MEDDRA:10065169",
-            "NCIT:C116006"
-          ],
-          "id": "MONDO:0001039",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Recurrent tonsillitis",
-            "tonsillitis",
-            "Tonsillitis",
-            "Chronic tonsillitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:15897415",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tonsillitis",
-            "http://en.wikipedia.org/wiki/tonsillitis",
-            "https://orcid.org/0000-0001-5208-3432"
-          ]
-        }
-      },
-      "end": {
-        "identity": 558,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefixime",
-          "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "UNII:XZ7BG04GJX",
-            "DRUGBANK:DB00671",
-            "GTOPDB:10898",
-            "PDQ:CDR0000037809",
-            "NDDF:002737",
-            "CHEBI:472657",
-            "HMDB:HMDB0014809",
-            "KEGG.COMPOUND:C06881",
-            "NCIT:C1100",
-            "UMLS:C0060400",
-            "CHEMBL.COMPOUND:CHEMBL1541",
-            "ATC:J01DD08",
-            "KEGG.DRUG:D00258",
-            "MESH:D020682",
-            "DrugCentral:537",
-            "PUBCHEM.COMPOUND:5362065",
-            "RXNORM:25033",
-            "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:5362065",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "CEFIXIME",
-            "Cefixime (INN)",
-            "Cefixime",
-            "cefixime"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20070106",
-            "PMID:9379359",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23416192",
-            "PMID:19586686",
-            "PMID:21741846",
-            "PMID:21098249",
-            "PMID:24961639",
-            "PMID:8627565"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317210,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001039",
-              "name": "tonsillitis",
-              "description": "Inflammation of the tonsils that has occurred repeatedly. The definition of recurrent may vary somewhat, but the criteria used recently as a measure of severity were five or more episodes of true tonsillitis per year, symptoms recurring for at least a year, and episodes that are disabling and that prevent normal functioning. In some cases recurrent tonsillitis may be related to immunosusceptibility. Evidence exists for a genetic predisposition for recurrent tonsillitis. [HPO:probinson, PMID:15897415]; Inflammation of the tonsils that has occurred repeatedly. The definition of recurrent may vary somewhat, but the criteria used recently as a measure of severity were five or more episodes of true tonsillitis per year, symptoms recurring for at least a year, and episodes that are disabling and that prevent normal functioning. In some cases recurrent tonsillitis may be related to immunosusceptibility. Evidence exists for a genetic predisposition for recurrent tonsillitis.; Inflammation of the tonsils that has occurred repeatedly. The definition of recurrent may vary somewhat, but the criteria used recently as a measure of severity were five or more episodes of true tonsillitis per year, symptoms recurring for at least a year, and episodes that are disabling and that prevent normal functioning. In some cases recurrent tonsillitis may be related to immunosusceptibility. Evidence exists for a genetic predisposition for recurrent tonsillitis.; Inflammation of the tonsils that has occurred repeatedly. The definition of recurrent may vary somewhat, but the criteria used recently as a measure of severity were five or more episodes of true tonsillitis per year, symptoms recurring for at least a year, and episodes that are disabling and that prevent normal functioning. In some cases recurrent tonsillitis may be related to immunosusceptibility. Evidence exists for a genetic predisposition for recurrent tonsillitis.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10044008",
-                "DOID:10456",
-                "MEDDRA:10009152",
-                "SNOMEDCT:90176007",
-                "MONDO:0001039",
-                "ICD10:J35.01",
-                "MEDDRA:10044010",
-                "ICD9:474.00",
-                "HP:0011110",
-                "MEDDRA:10044012",
-                "UMLS:C0149517",
-                "UMLS:C0740402",
-                "MESH:D014069",
-                "UMLS:C0040425",
-                "SNOMEDCT:90979004",
-                "MEDDRA:10044011",
-                "MEDDRA:10065169",
-                "NCIT:C116006"
-              ],
-              "id": "MONDO:0001039",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Recurrent tonsillitis",
-                "tonsillitis",
-                "Tonsillitis",
-                "Chronic tonsillitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:15897415",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tonsillitis",
-                "http://en.wikipedia.org/wiki/tonsillitis",
-                "https://orcid.org/0000-0001-5208-3432"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26379045,
-            "start": 558,
-            "end": 317210,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8152203': {'publication date': '1994 Jan-Feb', 'sentence': 'These results show that cefixime once daily is at least as effective as penicillin V t.i.d. in pharyngitis and tonsillitis in children.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0060400---SEMMEDDB:treats---None---None---None---UMLS:C0040425---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5362065",
-              "id": "26843374",
-              "object": "MONDO:0001039",
-              "publications": [
-                "PMID:8152203"
-              ]
-            }
-          },
-          "end": {
-            "identity": 558,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefixime",
-              "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "UNII:XZ7BG04GJX",
-                "DRUGBANK:DB00671",
-                "GTOPDB:10898",
-                "PDQ:CDR0000037809",
-                "NDDF:002737",
-                "CHEBI:472657",
-                "HMDB:HMDB0014809",
-                "KEGG.COMPOUND:C06881",
-                "NCIT:C1100",
-                "UMLS:C0060400",
-                "CHEMBL.COMPOUND:CHEMBL1541",
-                "ATC:J01DD08",
-                "KEGG.DRUG:D00258",
-                "MESH:D020682",
-                "DrugCentral:537",
-                "PUBCHEM.COMPOUND:5362065",
-                "RXNORM:25033",
-                "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:5362065",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "CEFIXIME",
-                "Cefixime (INN)",
-                "Cefixime",
-                "cefixime"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20070106",
-                "PMID:9379359",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23416192",
-                "PMID:19586686",
-                "PMID:21741846",
-                "PMID:21098249",
-                "PMID:24961639",
-                "PMID:8627565"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 546907,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C3714514",
-          "name": "Infection",
-          "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "UMLS:C3714514",
-            "MEDDRA:10021842",
-            "NCIT:C128320",
-            "MEDDRA:10021789",
-            "MESH:D007239"
-          ],
-          "id": "UMLS:C3714514",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infection",
-            "Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 558,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefixime",
-          "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "UNII:XZ7BG04GJX",
-            "DRUGBANK:DB00671",
-            "GTOPDB:10898",
-            "PDQ:CDR0000037809",
-            "NDDF:002737",
-            "CHEBI:472657",
-            "HMDB:HMDB0014809",
-            "KEGG.COMPOUND:C06881",
-            "NCIT:C1100",
-            "UMLS:C0060400",
-            "CHEMBL.COMPOUND:CHEMBL1541",
-            "ATC:J01DD08",
-            "KEGG.DRUG:D00258",
-            "MESH:D020682",
-            "DrugCentral:537",
-            "PUBCHEM.COMPOUND:5362065",
-            "RXNORM:25033",
-            "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:5362065",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "CEFIXIME",
-            "Cefixime (INN)",
-            "Cefixime",
-            "cefixime"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20070106",
-            "PMID:9379359",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23416192",
-            "PMID:19586686",
-            "PMID:21741846",
-            "PMID:21098249",
-            "PMID:24961639",
-            "PMID:8627565"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546907,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C3714514",
-              "name": "Infection",
-              "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "UMLS:C3714514",
-                "MEDDRA:10021842",
-                "NCIT:C128320",
-                "MEDDRA:10021789",
-                "MESH:D007239"
-              ],
-              "id": "UMLS:C3714514",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infection",
-                "Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23533145,
-            "start": 558,
-            "end": 546907,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34852307': {'publication date': '2021 Nov 17', 'sentence': 'The aim of this study is to evaluate cefixime for the treatment of osteoarticular infections in pediatric SCD patients by retrospective design.', 'subject score': 1000, 'object score': 861}, 'PMID:36729626': {'publication date': '2022 Dec 14', 'sentence': 'We recommend more investigation into the effectiveness of cefixime in treating rectal infections and studying multidose therapy for the cefixime treatment of pharyngeal infection.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0060400---SEMMEDDB:treats---None---None---None---UMLS:C3714514---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5362065",
-              "id": "23970374",
-              "object": "UMLS:C3714514",
-              "publications": [
-                "PMID:34852307",
-                "PMID:36729626"
-              ]
-            }
-          },
-          "end": {
-            "identity": 558,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefixime",
-              "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "UNII:XZ7BG04GJX",
-                "DRUGBANK:DB00671",
-                "GTOPDB:10898",
-                "PDQ:CDR0000037809",
-                "NDDF:002737",
-                "CHEBI:472657",
-                "HMDB:HMDB0014809",
-                "KEGG.COMPOUND:C06881",
-                "NCIT:C1100",
-                "UMLS:C0060400",
-                "CHEMBL.COMPOUND:CHEMBL1541",
-                "ATC:J01DD08",
-                "KEGG.DRUG:D00258",
-                "MESH:D020682",
-                "DrugCentral:537",
-                "PUBCHEM.COMPOUND:5362065",
-                "RXNORM:25033",
-                "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:5362065",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "CEFIXIME",
-                "Cefixime (INN)",
-                "Cefixime",
-                "cefixime"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20070106",
-                "PMID:9379359",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23416192",
-                "PMID:19586686",
-                "PMID:21741846",
-                "PMID:21098249",
-                "PMID:24961639",
-                "PMID:8627565"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002258",
-          "name": "pharyngitis",
-          "description": "Inflammation of the throat most often caused by viral and bacterial infections. Other causes include allergens, chemical substances, and trauma.; Inflammation of the throat (PHARYNX).; Inflammation (due to infection or irritation) of the pharynx. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD9:462",
-            "UMLS:C0155824",
-            "UMLS:C0031350",
-            "NCIT:C26851",
-            "MONDO:0002258",
-            "SNOMEDCT:405737000",
-            "DOID:2275",
-            "MESH:D010612",
-            "MEDDRA:10065716",
-            "ICD9:472",
-            "HP:0025439",
-            "MEDDRA:10034838",
-            "ICD10:J02",
-            "MEDDRA:10034835",
-            "ICD9:478.20"
-          ],
-          "id": "MONDO:0002258",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pharyngitis",
-            "Unspecified disease of pharynx",
-            "Chronic pharyngitis and nasopharyngitis",
-            "pharyngitis",
-            "Acute pharyngitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=mmed&part=a5016",
-            "http://en.wikipedia.org/wiki/pharyngitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 558,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefixime",
-          "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "UNII:XZ7BG04GJX",
-            "DRUGBANK:DB00671",
-            "GTOPDB:10898",
-            "PDQ:CDR0000037809",
-            "NDDF:002737",
-            "CHEBI:472657",
-            "HMDB:HMDB0014809",
-            "KEGG.COMPOUND:C06881",
-            "NCIT:C1100",
-            "UMLS:C0060400",
-            "CHEMBL.COMPOUND:CHEMBL1541",
-            "ATC:J01DD08",
-            "KEGG.DRUG:D00258",
-            "MESH:D020682",
-            "DrugCentral:537",
-            "PUBCHEM.COMPOUND:5362065",
-            "RXNORM:25033",
-            "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:5362065",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "CEFIXIME",
-            "Cefixime (INN)",
-            "Cefixime",
-            "cefixime"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20070106",
-            "PMID:9379359",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23416192",
-            "PMID:19586686",
-            "PMID:21741846",
-            "PMID:21098249",
-            "PMID:24961639",
-            "PMID:8627565"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319104,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002258",
-              "name": "pharyngitis",
-              "description": "Inflammation of the throat most often caused by viral and bacterial infections. Other causes include allergens, chemical substances, and trauma.; Inflammation of the throat (PHARYNX).; Inflammation (due to infection or irritation) of the pharynx. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD9:462",
-                "UMLS:C0155824",
-                "UMLS:C0031350",
-                "NCIT:C26851",
-                "MONDO:0002258",
-                "SNOMEDCT:405737000",
-                "DOID:2275",
-                "MESH:D010612",
-                "MEDDRA:10065716",
-                "ICD9:472",
-                "HP:0025439",
-                "MEDDRA:10034838",
-                "ICD10:J02",
-                "MEDDRA:10034835",
-                "ICD9:478.20"
-              ],
-              "id": "MONDO:0002258",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pharyngitis",
-                "Unspecified disease of pharynx",
-                "Chronic pharyngitis and nasopharyngitis",
-                "pharyngitis",
-                "Acute pharyngitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=mmed&part=a5016",
-                "http://en.wikipedia.org/wiki/pharyngitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22116862,
-            "start": 558,
-            "end": 319104,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32984647': {'publication date': '2020 Dec', 'sentence': 'Purpose: To report a case of Acute bilateral angle closure and Myopia following oral Cefixime therapy for pharyngitis.', 'subject score': 851, 'object score': 1000}, 'PMID:3320921': {'publication date': '1987 Oct', 'sentence': 'Noncomparative, open label, multicenter trial of cefixime for treatment of bacterial pharyngitis, cystitis and pneumonia in pediatric patients.', 'subject score': 1000, 'object score': 888}, 'PMID:36729626': {'publication date': '2022 Dec 14', 'sentence': 'We recommend more investigation into the effectiveness of cefixime in treating rectal infections and studying multidose therapy for the cefixime treatment of pharyngeal infection.', 'subject score': 888, 'object score': 1000}, 'PMID:8152203': {'publication date': '1994 Jan-Feb', 'sentence': 'These results show that cefixime once daily is at least as effective as penicillin V t.i.d. in pharyngitis and tonsillitis in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:8537138': {'publication date': '1995', 'sentence': '5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillin V therapy.', 'subject score': 852, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0060400---SEMMEDDB:treats---None---None---None---UMLS:C0031350---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5362065",
-              "id": "22544340",
-              "object": "MONDO:0002258",
-              "publications": [
-                "PMID:32984647",
-                "PMID:3320921",
-                "PMID:36729626",
-                "PMID:8152203",
-                "PMID:8537138"
-              ]
-            }
-          },
-          "end": {
-            "identity": 558,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefixime",
-              "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "UNII:XZ7BG04GJX",
-                "DRUGBANK:DB00671",
-                "GTOPDB:10898",
-                "PDQ:CDR0000037809",
-                "NDDF:002737",
-                "CHEBI:472657",
-                "HMDB:HMDB0014809",
-                "KEGG.COMPOUND:C06881",
-                "NCIT:C1100",
-                "UMLS:C0060400",
-                "CHEMBL.COMPOUND:CHEMBL1541",
-                "ATC:J01DD08",
-                "KEGG.DRUG:D00258",
-                "MESH:D020682",
-                "DrugCentral:537",
-                "PUBCHEM.COMPOUND:5362065",
-                "RXNORM:25033",
-                "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:5362065",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "CEFIXIME",
-                "Cefixime (INN)",
-                "Cefixime",
-                "cefixime"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20070106",
-                "PMID:9379359",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23416192",
-                "PMID:19586686",
-                "PMID:21741846",
-                "PMID:21098249",
-                "PMID:24961639",
-                "PMID:8627565"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 533053,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005976",
-          "name": "syphilis",
-          "description": "A contagious bacterial infection caused by the spirochete Treponema pallidum. It is a sexually transmitted disorder, although it can also be transmitted from the mother to the fetus in utero. Typically, it is initially manifested with a single sore which heals without treatment. If the infection is left untreated, the initial stage is followed by skin rash and mucous membrane lesions. A late stage follows, which is characterized by damage of the internal organs, including the nervous system.; A contagious venereal disease caused by the spirochete TREPONEMA PALLIDUM.; Syphilis is a sexually transmitted disease caused by bacteria. It infects the genital area, lips, mouth, or anus of both men and women. You usually get syphilis from sexual contact with someone who has it. It can also pass from mother to baby during pregnancy. The early stage of syphilis usually causes a single, small, painless sore. Sometimes it causes swelling in nearby lymph nodes. If you do not treat it, syphilis usually causes a non-itchy skin rash, often on your hands and feet. Many people do not notice symptoms for years. Symptoms can go away and come back. The sores caused by syphilis make it easier to get or give someone HIV during sex. If you are pregnant, syphilis can cause complications, or you could lose your baby. In rare cases, syphilis causes serious health problems and even death. Syphilis is easy to cure with antibiotics if you catch it early. Correct usage of latex condoms greatly reduces, but does not completely eliminate, the risk of catching or spreading syphilis. If your or your partner is allergic to latex, you can use polyurethane condoms. The most reliable way to avoid infection is to not have anal, vaginal, or oral sex. Centers for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0039128",
-            "MEDDRA:10042896",
-            "MESH:D013587",
-            "MEDDRA:10042882",
-            "DOID:4166",
-            "EFO:0007504",
-            "MEDDRA:10044588",
-            "PSY:51240",
-            "NCIT:C35055",
-            "MEDDRA:10063034",
-            "MEDDRA:10062120",
-            "SNOMEDCT:76272004",
-            "ICD10:A51.0",
-            "MONDO:0005976"
-          ],
-          "id": "MONDO:0005976",
-          "category": "biolink:Disease",
-          "all_names": [
-            "syphilis",
-            "Syphilis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/syphilis",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=syphilis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 558,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefixime",
-          "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "UNII:XZ7BG04GJX",
-            "DRUGBANK:DB00671",
-            "GTOPDB:10898",
-            "PDQ:CDR0000037809",
-            "NDDF:002737",
-            "CHEBI:472657",
-            "HMDB:HMDB0014809",
-            "KEGG.COMPOUND:C06881",
-            "NCIT:C1100",
-            "UMLS:C0060400",
-            "CHEMBL.COMPOUND:CHEMBL1541",
-            "ATC:J01DD08",
-            "KEGG.DRUG:D00258",
-            "MESH:D020682",
-            "DrugCentral:537",
-            "PUBCHEM.COMPOUND:5362065",
-            "RXNORM:25033",
-            "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:5362065",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "CEFIXIME",
-            "Cefixime (INN)",
-            "Cefixime",
-            "cefixime"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20070106",
-            "PMID:9379359",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23416192",
-            "PMID:19586686",
-            "PMID:21741846",
-            "PMID:21098249",
-            "PMID:24961639",
-            "PMID:8627565"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 533053,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005976",
-              "name": "syphilis",
-              "description": "A contagious bacterial infection caused by the spirochete Treponema pallidum. It is a sexually transmitted disorder, although it can also be transmitted from the mother to the fetus in utero. Typically, it is initially manifested with a single sore which heals without treatment. If the infection is left untreated, the initial stage is followed by skin rash and mucous membrane lesions. A late stage follows, which is characterized by damage of the internal organs, including the nervous system.; A contagious venereal disease caused by the spirochete TREPONEMA PALLIDUM.; Syphilis is a sexually transmitted disease caused by bacteria. It infects the genital area, lips, mouth, or anus of both men and women. You usually get syphilis from sexual contact with someone who has it. It can also pass from mother to baby during pregnancy. The early stage of syphilis usually causes a single, small, painless sore. Sometimes it causes swelling in nearby lymph nodes. If you do not treat it, syphilis usually causes a non-itchy skin rash, often on your hands and feet. Many people do not notice symptoms for years. Symptoms can go away and come back. The sores caused by syphilis make it easier to get or give someone HIV during sex. If you are pregnant, syphilis can cause complications, or you could lose your baby. In rare cases, syphilis causes serious health problems and even death. Syphilis is easy to cure with antibiotics if you catch it early. Correct usage of latex condoms greatly reduces, but does not completely eliminate, the risk of catching or spreading syphilis. If your or your partner is allergic to latex, you can use polyurethane condoms. The most reliable way to avoid infection is to not have anal, vaginal, or oral sex. Centers for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0039128",
-                "MEDDRA:10042896",
-                "MESH:D013587",
-                "MEDDRA:10042882",
-                "DOID:4166",
-                "EFO:0007504",
-                "MEDDRA:10044588",
-                "PSY:51240",
-                "NCIT:C35055",
-                "MEDDRA:10063034",
-                "MEDDRA:10062120",
-                "SNOMEDCT:76272004",
-                "ICD10:A51.0",
-                "MONDO:0005976"
-              ],
-              "id": "MONDO:0005976",
-              "category": "biolink:Disease",
-              "all_names": [
-                "syphilis",
-                "Syphilis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/syphilis",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=syphilis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21718163,
-            "start": 558,
-            "end": 533053,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32522244': {'publication date': '2020 Jun 10', 'sentence': 'DISCUSSION: Demonstration of efficacy of cefixime in the treatment of active syphilis in this Phase 2 trial among non-pregnant women will inform a proposed randomized controlled trial to evaluate cefixime as an alternative treatment for pregnant women with active syphilis to evaluate prevention of congenital syphilis.', 'subject score': 1000, 'object score': 888}, 'PMID:33337615': {'publication date': '2020 Dec 15', 'sentence': 'Randomized control trials of oral cefixime for treatment of syphilis are paving the way for potential use in pregnant women.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0060400---SEMMEDDB:treats---None---None---None---UMLS:C0039128---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5362065",
-              "id": "22138225",
-              "object": "MONDO:0005976",
-              "publications": [
-                "PMID:32522244",
-                "PMID:33337615"
-              ]
-            }
-          },
-          "end": {
-            "identity": 558,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefixime",
-              "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "UNII:XZ7BG04GJX",
-                "DRUGBANK:DB00671",
-                "GTOPDB:10898",
-                "PDQ:CDR0000037809",
-                "NDDF:002737",
-                "CHEBI:472657",
-                "HMDB:HMDB0014809",
-                "KEGG.COMPOUND:C06881",
-                "NCIT:C1100",
-                "UMLS:C0060400",
-                "CHEMBL.COMPOUND:CHEMBL1541",
-                "ATC:J01DD08",
-                "KEGG.DRUG:D00258",
-                "MESH:D020682",
-                "DrugCentral:537",
-                "PUBCHEM.COMPOUND:5362065",
-                "RXNORM:25033",
-                "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:5362065",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "CEFIXIME",
-                "Cefixime (INN)",
-                "Cefixime",
-                "cefixime"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20070106",
-                "PMID:9379359",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23416192",
-                "PMID:19586686",
-                "PMID:21741846",
-                "PMID:21098249",
-                "PMID:24961639",
-                "PMID:8627565"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317030,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0003781",
-          "name": "bronchitis",
-          "description": "A bronchial disease that is an inflammation of the bronchial tubes. It is caused by bacteria and viruses. The disease has_symptom cough with mucus, has_symptom shortness of breath, has_symptom low fever and has_symptom chest tightness.",
-          "equivalent_curies": [
-            "EFO:0009661",
-            "SYMP:0000324",
-            "MEDDRA:10006461",
-            "ICD9:490",
-            "MESH:D001991",
-            "UMLS:C0006277",
-            "MEDDRA:10006451",
-            "ICD10:J42",
-            "ICD9:491",
-            "DOID:6132",
-            "NCIT:C2911",
-            "ICD10:J20",
-            "ICD9:466.0",
-            "SNOMEDCT:32398004",
-            "ICD10:J40",
-            "HP:0012387",
-            "MONDO:0003781"
-          ],
-          "id": "MONDO:0003781",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic bronchitis",
-            "Bronchitis, not specified as acute or chronic",
-            "bronchitis",
-            "Bronchitis",
-            "Acute bronchitis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=bronchitis",
-            "http://www.nlm.nih.gov/medlineplus/bronchitis.htm",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.nhlbi.nih.gov/health/dci/diseases/brnchi/brnchi_whatis.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 558,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefixime",
-          "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "UNII:XZ7BG04GJX",
-            "DRUGBANK:DB00671",
-            "GTOPDB:10898",
-            "PDQ:CDR0000037809",
-            "NDDF:002737",
-            "CHEBI:472657",
-            "HMDB:HMDB0014809",
-            "KEGG.COMPOUND:C06881",
-            "NCIT:C1100",
-            "UMLS:C0060400",
-            "CHEMBL.COMPOUND:CHEMBL1541",
-            "ATC:J01DD08",
-            "KEGG.DRUG:D00258",
-            "MESH:D020682",
-            "DrugCentral:537",
-            "PUBCHEM.COMPOUND:5362065",
-            "RXNORM:25033",
-            "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:5362065",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "CEFIXIME",
-            "Cefixime (INN)",
-            "Cefixime",
-            "cefixime"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20070106",
-            "PMID:9379359",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23416192",
-            "PMID:19586686",
-            "PMID:21741846",
-            "PMID:21098249",
-            "PMID:24961639",
-            "PMID:8627565"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317030,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0003781",
-              "name": "bronchitis",
-              "description": "A bronchial disease that is an inflammation of the bronchial tubes. It is caused by bacteria and viruses. The disease has_symptom cough with mucus, has_symptom shortness of breath, has_symptom low fever and has_symptom chest tightness.",
-              "equivalent_curies": [
-                "EFO:0009661",
-                "SYMP:0000324",
-                "MEDDRA:10006461",
-                "ICD9:490",
-                "MESH:D001991",
-                "UMLS:C0006277",
-                "MEDDRA:10006451",
-                "ICD10:J42",
-                "ICD9:491",
-                "DOID:6132",
-                "NCIT:C2911",
-                "ICD10:J20",
-                "ICD9:466.0",
-                "SNOMEDCT:32398004",
-                "ICD10:J40",
-                "HP:0012387",
-                "MONDO:0003781"
-              ],
-              "id": "MONDO:0003781",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic bronchitis",
-                "Bronchitis, not specified as acute or chronic",
-                "bronchitis",
-                "Bronchitis",
-                "Acute bronchitis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=bronchitis",
-                "http://www.nlm.nih.gov/medlineplus/bronchitis.htm",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.nhlbi.nih.gov/health/dci/diseases/brnchi/brnchi_whatis.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20219185,
-            "start": 558,
-            "end": 317030,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30290951': {'publication date': '2018 Oct', 'sentence': 'Two weeks following her return to France, the patient presented with an episode of bronchitis and received 5 days of treatment with cefixime (a third-generation cephalosporin).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0060400---SEMMEDDB:treats---None---None---None---UMLS:C0006277---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5362065",
-              "id": "20619094",
-              "object": "MONDO:0003781",
-              "publications": [
-                "PMID:30290951"
-              ]
-            }
-          },
-          "end": {
-            "identity": 558,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefixime",
-              "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "UNII:XZ7BG04GJX",
-                "DRUGBANK:DB00671",
-                "GTOPDB:10898",
-                "PDQ:CDR0000037809",
-                "NDDF:002737",
-                "CHEBI:472657",
-                "HMDB:HMDB0014809",
-                "KEGG.COMPOUND:C06881",
-                "NCIT:C1100",
-                "UMLS:C0060400",
-                "CHEMBL.COMPOUND:CHEMBL1541",
-                "ATC:J01DD08",
-                "KEGG.DRUG:D00258",
-                "MESH:D020682",
-                "DrugCentral:537",
-                "PUBCHEM.COMPOUND:5362065",
-                "RXNORM:25033",
-                "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:5362065",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "CEFIXIME",
-                "Cefixime (INN)",
-                "Cefixime",
-                "cefixime"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20070106",
-                "PMID:9379359",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23416192",
-                "PMID:19586686",
-                "PMID:21741846",
-                "PMID:21098249",
-                "PMID:24961639",
-                "PMID:8627565"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317908,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005441",
-          "name": "otitis media",
-          "description": "Inflammation of the anatomical structures of the middle ear, which is most often caused by an infectious process. Symptoms include erythema and edema of the tympanic membrane, pain, and possibly fever.; Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.; Inflammation or infection of the middle ear. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:0004992",
-            "MEDDRA:10065838",
-            "MEDDRA:10046087",
-            "MEDDRA:10056747",
-            "ICD10:H66.9",
-            "MONDO:0005441",
-            "ICD9:382.9",
-            "MESH:D010033",
-            "SNOMEDCT:65363002",
-            "DOID:10754",
-            "MEDDRA:10033084",
-            "HP:0000388",
-            "UMLS:C0029882",
-            "MEDDRA:10033078",
-            "NCIT:C34885",
-            "MEDDRA:10027585"
-          ],
-          "id": "MONDO:0005441",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Otitis media",
-            "Unspecified otitis media",
-            "Otitis Media",
-            "otitis media"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/otitis_media",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 558,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefixime",
-          "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "UNII:XZ7BG04GJX",
-            "DRUGBANK:DB00671",
-            "GTOPDB:10898",
-            "PDQ:CDR0000037809",
-            "NDDF:002737",
-            "CHEBI:472657",
-            "HMDB:HMDB0014809",
-            "KEGG.COMPOUND:C06881",
-            "NCIT:C1100",
-            "UMLS:C0060400",
-            "CHEMBL.COMPOUND:CHEMBL1541",
-            "ATC:J01DD08",
-            "KEGG.DRUG:D00258",
-            "MESH:D020682",
-            "DrugCentral:537",
-            "PUBCHEM.COMPOUND:5362065",
-            "RXNORM:25033",
-            "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:5362065",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "CEFIXIME",
-            "Cefixime (INN)",
-            "Cefixime",
-            "cefixime"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20070106",
-            "PMID:9379359",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23416192",
-            "PMID:19586686",
-            "PMID:21741846",
-            "PMID:21098249",
-            "PMID:24961639",
-            "PMID:8627565"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317908,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005441",
-              "name": "otitis media",
-              "description": "Inflammation of the anatomical structures of the middle ear, which is most often caused by an infectious process. Symptoms include erythema and edema of the tympanic membrane, pain, and possibly fever.; Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.; Inflammation or infection of the middle ear. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:0004992",
-                "MEDDRA:10065838",
-                "MEDDRA:10046087",
-                "MEDDRA:10056747",
-                "ICD10:H66.9",
-                "MONDO:0005441",
-                "ICD9:382.9",
-                "MESH:D010033",
-                "SNOMEDCT:65363002",
-                "DOID:10754",
-                "MEDDRA:10033084",
-                "HP:0000388",
-                "UMLS:C0029882",
-                "MEDDRA:10033078",
-                "NCIT:C34885",
-                "MEDDRA:10027585"
-              ],
-              "id": "MONDO:0005441",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Otitis media",
-                "Unspecified otitis media",
-                "Otitis Media",
-                "otitis media"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/otitis_media",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12667312,
-            "start": 558,
-            "end": 317908,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1725152': {'publication date': '1991', 'sentence': 'Efficacy and tolerability of cefixime in otitis media.', 'subject score': 1000, 'object score': 1000}, 'PMID:1852543': {'publication date': '1991 Jun', 'sentence': 'Pneumococcal bacteremia during oral treatment with cefixime for otitis media.', 'subject score': 1000, 'object score': 1000}, 'PMID:2405586': {'publication date': '1990 Jan', 'sentence': 'The newer agents, cefaclor, cefuroxime axetil, and cefixime, have increased in vitro activity against beta-lactamase-secreting strains of Haemophilus influenzae and Branhamella catarrhalis which has made them more popular for the treatment of otitis media and respiratory tract infections in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:2530544': {'publication date': '1989 Oct 11', 'sentence': 'Cefixime was used in the treatment of 59 patients, 44 of whom had sinusitis, 9 otitis media and 6 various ENT infections.', 'subject score': 1000, 'object score': 901}, 'PMID:30505057': {'publication date': '2018', 'sentence': 'BACKGROUND: Cefixime is a widely used third-generation cephalosporin schedule H1 drug, which is prescribed for the treatment of otitis media, respiratory tract infections, and uncomplicated urinary tract infections and is effective against infections caused by Enterobacteriaceae and Haemophilus influenzae species in India.', 'subject score': 1000, 'object score': 1000}, 'PMID:8169042': {'publication date': '1994 Mar', 'sentence': 'An experimental study of cefixime in the treatment of Streptococcus pneumoniae otitis media.', 'subject score': 1000, 'object score': 888}, 'PMID:8345993': {'publication date': '1993 Jun', 'sentence': 'Cefixime therapy for otitis media.', 'subject score': 888, 'object score': 1000}, 'PMID:8414791': {'publication date': '1993 Aug', 'sentence': 'Cefixime therapy for otitis media.', 'subject score': 888, 'object score': 1000}, 'PMID:8417430': {'publication date': '1993 Jan', 'sentence': 'Review of cefixime in the treatment of otitis media in infants and children.', 'subject score': 1000, 'object score': 1000}, 'PMID:9797419': {'publication date': '1998 Sep', 'sentence': 'Comparative studies between cefixime and conventional antibiotics for the treatment of upper respiratory tract infections and otitis media are summarized.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0060400---SEMMEDDB:treats---None---None---None---UMLS:C0029882---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5362065",
-              "id": "12941415",
-              "object": "MONDO:0005441",
-              "publications": [
-                "PMID:1725152",
-                "PMID:1852543",
-                "PMID:2405586",
-                "PMID:2530544",
-                "PMID:30505057",
-                "PMID:8169042",
-                "PMID:8345993",
-                "PMID:8414791",
-                "PMID:8417430",
-                "PMID:9797419"
-              ]
-            }
-          },
-          "end": {
-            "identity": 558,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefixime",
-              "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "UNII:XZ7BG04GJX",
-                "DRUGBANK:DB00671",
-                "GTOPDB:10898",
-                "PDQ:CDR0000037809",
-                "NDDF:002737",
-                "CHEBI:472657",
-                "HMDB:HMDB0014809",
-                "KEGG.COMPOUND:C06881",
-                "NCIT:C1100",
-                "UMLS:C0060400",
-                "CHEMBL.COMPOUND:CHEMBL1541",
-                "ATC:J01DD08",
-                "KEGG.DRUG:D00258",
-                "MESH:D020682",
-                "DrugCentral:537",
-                "PUBCHEM.COMPOUND:5362065",
-                "RXNORM:25033",
-                "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:5362065",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "CEFIXIME",
-                "Cefixime (INN)",
-                "Cefixime",
-                "cefixime"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20070106",
-                "PMID:9379359",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23416192",
-                "PMID:19586686",
-                "PMID:21741846",
-                "PMID:21098249",
-                "PMID:24961639",
-                "PMID:8627565"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11303266': {'publication date': '2001 May 01', 'sentence': 'A randomized trial of ciprofloxacin versus cefixime for treatment of gonorrhea after rapid emergence of gonococcal ciprofloxacin resistance in The Philippines.', 'subject score': 1000, 'object score': 1000}, 'PMID:11568790': {'publication date': '2001 Sep', 'sentence': 'A randomized trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhea in pregnancy.', 'subject score': 790, 'object score': 1000}, 'PMID:12291920': {'publication date': '1995 Jul', 'sentence': 'Recommended antibiotics for gonorrhea are cefixime, ceftriaxone, ciprofloxacine (contraindicated for pregnant women), spectinomycin, kanamycin, and trimethroprim/sulfamethoxazole.', 'subject score': 1000, 'object score': 1000}, 'PMID:1534422': {'publication date': '1992 Mar-Apr', 'sentence': 'Oral cefixime versus intramuscular ceftriaxone in patients with uncomplicated gonococcal infections.', 'subject score': 888, 'object score': 901}, 'PMID:1595018': {'publication date': '1992', 'sentence': 'Cefixime in the treatment of uncomplicated gonorrhea.', 'subject score': 1000, 'object score': 888}, 'PMID:17509176': {'publication date': '2007 Apr', 'sentence': 'Cefixime, therefore, seems to be effective in the treatment of pharyngeal gonorrhoea.', 'subject score': 1000, 'object score': 861}, 'PMID:17953118': {'publication date': '2007 Aug', 'sentence': 'Threat to cefixime treatment for gonorrhea.', 'subject score': 888, 'object score': 1000}, 'PMID:18367575': {'publication date': '2008 May', 'sentence': 'The emergence and spread of strains with mosaic PBP 2 could be a threat to the cefixime treatment of gonorrhea.', 'subject score': 888, 'object score': 1000}, 'PMID:18476147': {'publication date': '1997', 'sentence': 'CONCLUSIONS: A single 400 mg oral dose of cefixime was effective for the treatment of gonorrhea and was well tolerated by the pregnant women.', 'subject score': 1000, 'object score': 1000}, 'PMID:18476190': {'publication date': '1997', 'sentence': 'OBJECTIVE: To compare the efficacy and tolerance of single-dose grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in women.', 'subject score': 1000, 'object score': 888}, 'PMID:20643433': {'publication date': '2010 Sep', 'sentence': 'The emergence of N. gonorrhoeae with a mosaic penicillin-binding protein 2 associated with oral cephalosporin resistance has threatened cefixime treatment for gonorrhea.', 'subject score': 790, 'object score': 1000}, 'PMID:21571983': {'publication date': '2011 May', 'sentence': 'A 40-year-old man who has sex with men (MSM) with urethral gonorrhoea failed to respond to treatment with 400 mg cefixime orally.', 'subject score': 750, 'object score': 888}, 'PMID:22422688': {'publication date': '2012 Feb', 'sentence': 'In conclusion, this meta-analysis revealed that 250 mg ceftriaxone had a higher efficacy than 400 mg cefixime for uncomplicated gonorrhoea.', 'subject score': 790, 'object score': 888}, 'PMID:22675435': {'publication date': '2012', 'sentence': 'Cefixime, for treatment of uncomplicated anogenital gonococcal infection in woman was on 26% (23/89) of lists.', 'subject score': 1000, 'object score': 824}, 'PMID:22874837': {'publication date': '2012 Aug 10', 'sentence': \"This report, using data from CDC's Gonococcal Isolate Surveillance Project (GISP), describes laboratory evidence of declining cefixime susceptibility among urethral N. gonorrhoeae isolates collected in the United States during 2006-2011 and updates CDC's current recommendations for treatment of gonorrhea.\", 'subject score': 851, 'object score': 1000}, 'PMID:23299608': {'publication date': '2013 Jan 09', 'sentence': 'IMPORTANCE: Although cephalosporins are the cornerstone of treatment of Neisseria gonorrhoeae infections, cefixime is the only oral antimicrobial option.', 'subject score': 1000, 'object score': 983}, 'PMID:24113412': {'publication date': '2013 Nov', 'sentence': 'Dual therapy with oral cefixime and azithromycin may be a suitable alternate for the treatment of pharyngeal gonorrhea.', 'subject score': 888, 'object score': 861}, 'PMID:24498212': {'publication date': '2014', 'sentence': 'The reported lower susceptibility rate of NG isolates to cefixime and associated treatment failures, as well as the emergence of NG strains with cephalosporin resistance call for the more effective control of NG infection and the development of new antibiotics.', 'subject score': 1000, 'object score': 1000}, 'PMID:2496996': {'publication date': '1989 Mar', 'sentence': 'Efficacy and safety of a single 400 mg oral dose of cefixime in the treatment of uncomplicated gonorrhea.', 'subject score': 1000, 'object score': 888}, 'PMID:25344841': {'publication date': '2015 Feb', 'sentence': 'Neisseria gonorrhoeae infection threatens to become an untreatable sexually transmitted disease in the near future owing to the increasing emergence of N. gonorrhoeae strains with reduced susceptibility and resistance to the extended-spectrum cephalosporins (ESCs), i.e. ceftriaxone and cefixime, which are the last remaining option for first-line treatment of gonorrhea.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 506516,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004277",
-          "name": "gonorrhea",
-          "description": "An infection that is caused by Gonococcus.; A common sexually transmitted bacterial infection caused by Neisseria gonorrhoeae. It is transmitted through vaginal, oral, or anal intercourse. Infected individuals may be asymptomatic. Symptoms in males include burning sensation during urination, discharge from the penis, and painful swelling of the testes. Symptoms in females include painful urination, vaginal discharge, and vaginal bleeding between periods. If untreated, the infection may lead to pelvic inflammatory disease.; Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, NEISSERIA GONORRHOEAE, was isolated by Neisser in 1879.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:21330",
-            "UMLS:C0018081",
-            "MEDDRA:10018612",
-            "ORPHANET:100642",
-            "MEDDRA:10018615",
-            "NCIT:C92950",
-            "MESH:D006069",
-            "DOID:7551",
-            "NCIT:C35730",
-            "ICD10:A54",
-            "SNOMEDCT:15628003",
-            "MEDDRA:10081185",
-            "MEDDRA:10051970",
-            "ICD9:098",
-            "MEDDRA:10018604",
-            "MONDO:0004277"
-          ],
-          "id": "MONDO:0004277",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Gonococcal Infection",
-            "gonorrhea",
-            "Gonorrhea",
-            "Gonococcal infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cdc.gov/std/gonorrhea/stdfact-gonorrhea.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 558,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefixime",
-          "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "UNII:XZ7BG04GJX",
-            "DRUGBANK:DB00671",
-            "GTOPDB:10898",
-            "PDQ:CDR0000037809",
-            "NDDF:002737",
-            "CHEBI:472657",
-            "HMDB:HMDB0014809",
-            "KEGG.COMPOUND:C06881",
-            "NCIT:C1100",
-            "UMLS:C0060400",
-            "CHEMBL.COMPOUND:CHEMBL1541",
-            "ATC:J01DD08",
-            "KEGG.DRUG:D00258",
-            "MESH:D020682",
-            "DrugCentral:537",
-            "PUBCHEM.COMPOUND:5362065",
-            "RXNORM:25033",
-            "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:5362065",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "CEFIXIME",
-            "Cefixime (INN)",
-            "Cefixime",
-            "cefixime"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20070106",
-            "PMID:9379359",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23416192",
-            "PMID:19586686",
-            "PMID:21741846",
-            "PMID:21098249",
-            "PMID:24961639",
-            "PMID:8627565"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 506516,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004277",
-              "name": "gonorrhea",
-              "description": "An infection that is caused by Gonococcus.; A common sexually transmitted bacterial infection caused by Neisseria gonorrhoeae. It is transmitted through vaginal, oral, or anal intercourse. Infected individuals may be asymptomatic. Symptoms in males include burning sensation during urination, discharge from the penis, and painful swelling of the testes. Symptoms in females include painful urination, vaginal discharge, and vaginal bleeding between periods. If untreated, the infection may lead to pelvic inflammatory disease.; Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, NEISSERIA GONORRHOEAE, was isolated by Neisser in 1879.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:21330",
-                "UMLS:C0018081",
-                "MEDDRA:10018612",
-                "ORPHANET:100642",
-                "MEDDRA:10018615",
-                "NCIT:C92950",
-                "MESH:D006069",
-                "DOID:7551",
-                "NCIT:C35730",
-                "ICD10:A54",
-                "SNOMEDCT:15628003",
-                "MEDDRA:10081185",
-                "MEDDRA:10051970",
-                "ICD9:098",
-                "MEDDRA:10018604",
-                "MONDO:0004277"
-              ],
-              "id": "MONDO:0004277",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Gonococcal Infection",
-                "gonorrhea",
-                "Gonorrhea",
-                "Gonococcal infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cdc.gov/std/gonorrhea/stdfact-gonorrhea.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8638314,
-            "start": 558,
-            "end": 506516,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11303266': {'publication date': '2001 May 01', 'sentence': 'A randomized trial of ciprofloxacin versus cefixime for treatment of gonorrhea after rapid emergence of gonococcal ciprofloxacin resistance in The Philippines.', 'subject score': 1000, 'object score': 1000}, 'PMID:11568790': {'publication date': '2001 Sep', 'sentence': 'A randomized trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhea in pregnancy.', 'subject score': 790, 'object score': 1000}, 'PMID:12291920': {'publication date': '1995 Jul', 'sentence': 'Recommended antibiotics for gonorrhea are cefixime, ceftriaxone, ciprofloxacine (contraindicated for pregnant women), spectinomycin, kanamycin, and trimethroprim/sulfamethoxazole.', 'subject score': 1000, 'object score': 1000}, 'PMID:1534422': {'publication date': '1992 Mar-Apr', 'sentence': 'Oral cefixime versus intramuscular ceftriaxone in patients with uncomplicated gonococcal infections.', 'subject score': 888, 'object score': 901}, 'PMID:1595018': {'publication date': '1992', 'sentence': 'Cefixime in the treatment of uncomplicated gonorrhea.', 'subject score': 1000, 'object score': 888}, 'PMID:17509176': {'publication date': '2007 Apr', 'sentence': 'Cefixime, therefore, seems to be effective in the treatment of pharyngeal gonorrhoea.', 'subject score': 1000, 'object score': 861}, 'PMID:17953118': {'publication date': '2007 Aug', 'sentence': 'Threat to cefixime treatment for gonorrhea.', 'subject score': 888, 'object score': 1000}, 'PMID:18367575': {'publication date': '2008 May', 'sentence': 'The emergence and spread of strains with mosaic PBP 2 could be a threat to the cefixime treatment of gonorrhea.', 'subject score': 888, 'object score': 1000}, 'PMID:18476147': {'publication date': '1997', 'sentence': 'CONCLUSIONS: A single 400 mg oral dose of cefixime was effective for the treatment of gonorrhea and was well tolerated by the pregnant women.', 'subject score': 1000, 'object score': 1000}, 'PMID:18476190': {'publication date': '1997', 'sentence': 'OBJECTIVE: To compare the efficacy and tolerance of single-dose grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in women.', 'subject score': 1000, 'object score': 888}, 'PMID:20643433': {'publication date': '2010 Sep', 'sentence': 'The emergence of N. gonorrhoeae with a mosaic penicillin-binding protein 2 associated with oral cephalosporin resistance has threatened cefixime treatment for gonorrhea.', 'subject score': 790, 'object score': 1000}, 'PMID:21571983': {'publication date': '2011 May', 'sentence': 'A 40-year-old man who has sex with men (MSM) with urethral gonorrhoea failed to respond to treatment with 400 mg cefixime orally.', 'subject score': 750, 'object score': 888}, 'PMID:22422688': {'publication date': '2012 Feb', 'sentence': 'In conclusion, this meta-analysis revealed that 250 mg ceftriaxone had a higher efficacy than 400 mg cefixime for uncomplicated gonorrhoea.', 'subject score': 790, 'object score': 888}, 'PMID:22675435': {'publication date': '2012', 'sentence': 'Cefixime, for treatment of uncomplicated anogenital gonococcal infection in woman was on 26% (23/89) of lists.', 'subject score': 1000, 'object score': 824}, 'PMID:22874837': {'publication date': '2012 Aug 10', 'sentence': \"This report, using data from CDC's Gonococcal Isolate Surveillance Project (GISP), describes laboratory evidence of declining cefixime susceptibility among urethral N. gonorrhoeae isolates collected in the United States during 2006-2011 and updates CDC's current recommendations for treatment of gonorrhea.\", 'subject score': 851, 'object score': 1000}, 'PMID:23299608': {'publication date': '2013 Jan 09', 'sentence': 'IMPORTANCE: Although cephalosporins are the cornerstone of treatment of Neisseria gonorrhoeae infections, cefixime is the only oral antimicrobial option.', 'subject score': 1000, 'object score': 983}, 'PMID:24113412': {'publication date': '2013 Nov', 'sentence': 'Dual therapy with oral cefixime and azithromycin may be a suitable alternate for the treatment of pharyngeal gonorrhea.', 'subject score': 888, 'object score': 861}, 'PMID:24498212': {'publication date': '2014', 'sentence': 'The reported lower susceptibility rate of NG isolates to cefixime and associated treatment failures, as well as the emergence of NG strains with cephalosporin resistance call for the more effective control of NG infection and the development of new antibiotics.', 'subject score': 1000, 'object score': 1000}, 'PMID:2496996': {'publication date': '1989 Mar', 'sentence': 'Efficacy and safety of a single 400 mg oral dose of cefixime in the treatment of uncomplicated gonorrhea.', 'subject score': 1000, 'object score': 888}, 'PMID:25344841': {'publication date': '2015 Feb', 'sentence': 'Neisseria gonorrhoeae infection threatens to become an untreatable sexually transmitted disease in the near future owing to the increasing emergence of N. gonorrhoeae strains with reduced susceptibility and resistance to the extended-spectrum cephalosporins (ESCs), i.e. ceftriaxone and cefixime, which are the last remaining option for first-line treatment of gonorrhea.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0060400---SEMMEDDB:treats---None---None---None---UMLS:C0018081---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5362065",
-              "id": "8827692",
-              "object": "MONDO:0004277",
-              "publications": [
-                "PMID:11303266",
-                "PMID:11568790",
-                "PMID:12291920",
-                "PMID:1534422",
-                "PMID:1595018",
-                "PMID:17509176",
-                "PMID:17953118",
-                "PMID:18367575",
-                "PMID:18476147",
-                "PMID:18476190",
-                "PMID:20643433",
-                "PMID:21571983",
-                "PMID:22422688",
-                "PMID:22675435",
-                "PMID:22874837",
-                "PMID:23299608",
-                "PMID:24113412",
-                "PMID:24498212",
-                "PMID:2496996",
-                "PMID:25344841"
-              ]
-            }
-          },
-          "end": {
-            "identity": 558,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefixime",
-              "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "UNII:XZ7BG04GJX",
-                "DRUGBANK:DB00671",
-                "GTOPDB:10898",
-                "PDQ:CDR0000037809",
-                "NDDF:002737",
-                "CHEBI:472657",
-                "HMDB:HMDB0014809",
-                "KEGG.COMPOUND:C06881",
-                "NCIT:C1100",
-                "UMLS:C0060400",
-                "CHEMBL.COMPOUND:CHEMBL1541",
-                "ATC:J01DD08",
-                "KEGG.DRUG:D00258",
-                "MESH:D020682",
-                "DrugCentral:537",
-                "PUBCHEM.COMPOUND:5362065",
-                "RXNORM:25033",
-                "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:5362065",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "CEFIXIME",
-                "Cefixime (INN)",
-                "Cefixime",
-                "cefixime"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20070106",
-                "PMID:9379359",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23416192",
-                "PMID:19586686",
-                "PMID:21741846",
-                "PMID:21098249",
-                "PMID:24961639",
-                "PMID:8627565"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:32984647': {'publication date': '2020 Dec', 'sentence': 'Purpose: To report a case of Acute bilateral angle closure and Myopia following oral Cefixime therapy for pharyngitis.', 'subject score': 851, 'object score': 1000}, 'PMID:3320921': {'publication date': '1987 Oct', 'sentence': 'Noncomparative, open label, multicenter trial of cefixime for treatment of bacterial pharyngitis, cystitis and pneumonia in pediatric patients.', 'subject score': 1000, 'object score': 888}, 'PMID:36729626': {'publication date': '2022 Dec 14', 'sentence': 'We recommend more investigation into the effectiveness of cefixime in treating rectal infections and studying multidose therapy for the cefixime treatment of pharyngeal infection.', 'subject score': 888, 'object score': 1000}, 'PMID:8152203': {'publication date': '1994 Jan-Feb', 'sentence': 'These results show that cefixime once daily is at least as effective as penicillin V t.i.d. in pharyngitis and tonsillitis in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:8537138': {'publication date': '1995', 'sentence': '5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillin V therapy.', 'subject score': 852, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 319104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002258",
-          "name": "pharyngitis",
-          "description": "Inflammation of the throat most often caused by viral and bacterial infections. Other causes include allergens, chemical substances, and trauma.; Inflammation of the throat (PHARYNX).; Inflammation (due to infection or irritation) of the pharynx. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD9:462",
-            "UMLS:C0155824",
-            "UMLS:C0031350",
-            "NCIT:C26851",
-            "MONDO:0002258",
-            "SNOMEDCT:405737000",
-            "DOID:2275",
-            "MESH:D010612",
-            "MEDDRA:10065716",
-            "ICD9:472",
-            "HP:0025439",
-            "MEDDRA:10034838",
-            "ICD10:J02",
-            "MEDDRA:10034835",
-            "ICD9:478.20"
-          ],
-          "id": "MONDO:0002258",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pharyngitis",
-            "Unspecified disease of pharynx",
-            "Chronic pharyngitis and nasopharyngitis",
-            "pharyngitis",
-            "Acute pharyngitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=mmed&part=a5016",
-            "http://en.wikipedia.org/wiki/pharyngitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 558,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefixime",
-          "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "UNII:XZ7BG04GJX",
-            "DRUGBANK:DB00671",
-            "GTOPDB:10898",
-            "PDQ:CDR0000037809",
-            "NDDF:002737",
-            "CHEBI:472657",
-            "HMDB:HMDB0014809",
-            "KEGG.COMPOUND:C06881",
-            "NCIT:C1100",
-            "UMLS:C0060400",
-            "CHEMBL.COMPOUND:CHEMBL1541",
-            "ATC:J01DD08",
-            "KEGG.DRUG:D00258",
-            "MESH:D020682",
-            "DrugCentral:537",
-            "PUBCHEM.COMPOUND:5362065",
-            "RXNORM:25033",
-            "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:5362065",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "CEFIXIME",
-            "Cefixime (INN)",
-            "Cefixime",
-            "cefixime"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20070106",
-            "PMID:9379359",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23416192",
-            "PMID:19586686",
-            "PMID:21741846",
-            "PMID:21098249",
-            "PMID:24961639",
-            "PMID:8627565"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319104,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002258",
-              "name": "pharyngitis",
-              "description": "Inflammation of the throat most often caused by viral and bacterial infections. Other causes include allergens, chemical substances, and trauma.; Inflammation of the throat (PHARYNX).; Inflammation (due to infection or irritation) of the pharynx. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD9:462",
-                "UMLS:C0155824",
-                "UMLS:C0031350",
-                "NCIT:C26851",
-                "MONDO:0002258",
-                "SNOMEDCT:405737000",
-                "DOID:2275",
-                "MESH:D010612",
-                "MEDDRA:10065716",
-                "ICD9:472",
-                "HP:0025439",
-                "MEDDRA:10034838",
-                "ICD10:J02",
-                "MEDDRA:10034835",
-                "ICD9:478.20"
-              ],
-              "id": "MONDO:0002258",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pharyngitis",
-                "Unspecified disease of pharynx",
-                "Chronic pharyngitis and nasopharyngitis",
-                "pharyngitis",
-                "Acute pharyngitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=mmed&part=a5016",
-                "http://en.wikipedia.org/wiki/pharyngitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22116862,
-            "start": 558,
-            "end": 319104,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32984647': {'publication date': '2020 Dec', 'sentence': 'Purpose: To report a case of Acute bilateral angle closure and Myopia following oral Cefixime therapy for pharyngitis.', 'subject score': 851, 'object score': 1000}, 'PMID:3320921': {'publication date': '1987 Oct', 'sentence': 'Noncomparative, open label, multicenter trial of cefixime for treatment of bacterial pharyngitis, cystitis and pneumonia in pediatric patients.', 'subject score': 1000, 'object score': 888}, 'PMID:36729626': {'publication date': '2022 Dec 14', 'sentence': 'We recommend more investigation into the effectiveness of cefixime in treating rectal infections and studying multidose therapy for the cefixime treatment of pharyngeal infection.', 'subject score': 888, 'object score': 1000}, 'PMID:8152203': {'publication date': '1994 Jan-Feb', 'sentence': 'These results show that cefixime once daily is at least as effective as penicillin V t.i.d. in pharyngitis and tonsillitis in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:8537138': {'publication date': '1995', 'sentence': '5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillin V therapy.', 'subject score': 852, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0060400---SEMMEDDB:treats---None---None---None---UMLS:C0031350---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5362065",
-              "id": "22544340",
-              "object": "MONDO:0002258",
-              "publications": [
-                "PMID:32984647",
-                "PMID:3320921",
-                "PMID:36729626",
-                "PMID:8152203",
-                "PMID:8537138"
-              ]
-            }
-          },
-          "end": {
-            "identity": 558,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefixime",
-              "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "UNII:XZ7BG04GJX",
-                "DRUGBANK:DB00671",
-                "GTOPDB:10898",
-                "PDQ:CDR0000037809",
-                "NDDF:002737",
-                "CHEBI:472657",
-                "HMDB:HMDB0014809",
-                "KEGG.COMPOUND:C06881",
-                "NCIT:C1100",
-                "UMLS:C0060400",
-                "CHEMBL.COMPOUND:CHEMBL1541",
-                "ATC:J01DD08",
-                "KEGG.DRUG:D00258",
-                "MESH:D020682",
-                "DrugCentral:537",
-                "PUBCHEM.COMPOUND:5362065",
-                "RXNORM:25033",
-                "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:5362065",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "CEFIXIME",
-                "Cefixime (INN)",
-                "Cefixime",
-                "cefixime"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20070106",
-                "PMID:9379359",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23416192",
-                "PMID:19586686",
-                "PMID:21741846",
-                "PMID:21098249",
-                "PMID:24961639",
-                "PMID:8627565"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:30290951': {'publication date': '2018 Oct', 'sentence': 'Two weeks following her return to France, the patient presented with an episode of bronchitis and received 5 days of treatment with cefixime (a third-generation cephalosporin).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317030,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0003781",
-          "name": "bronchitis",
-          "description": "A bronchial disease that is an inflammation of the bronchial tubes. It is caused by bacteria and viruses. The disease has_symptom cough with mucus, has_symptom shortness of breath, has_symptom low fever and has_symptom chest tightness.",
-          "equivalent_curies": [
-            "EFO:0009661",
-            "SYMP:0000324",
-            "MEDDRA:10006461",
-            "ICD9:490",
-            "MESH:D001991",
-            "UMLS:C0006277",
-            "MEDDRA:10006451",
-            "ICD10:J42",
-            "ICD9:491",
-            "DOID:6132",
-            "NCIT:C2911",
-            "ICD10:J20",
-            "ICD9:466.0",
-            "SNOMEDCT:32398004",
-            "ICD10:J40",
-            "HP:0012387",
-            "MONDO:0003781"
-          ],
-          "id": "MONDO:0003781",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic bronchitis",
-            "Bronchitis, not specified as acute or chronic",
-            "bronchitis",
-            "Bronchitis",
-            "Acute bronchitis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=bronchitis",
-            "http://www.nlm.nih.gov/medlineplus/bronchitis.htm",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.nhlbi.nih.gov/health/dci/diseases/brnchi/brnchi_whatis.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 558,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefixime",
-          "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "UNII:XZ7BG04GJX",
-            "DRUGBANK:DB00671",
-            "GTOPDB:10898",
-            "PDQ:CDR0000037809",
-            "NDDF:002737",
-            "CHEBI:472657",
-            "HMDB:HMDB0014809",
-            "KEGG.COMPOUND:C06881",
-            "NCIT:C1100",
-            "UMLS:C0060400",
-            "CHEMBL.COMPOUND:CHEMBL1541",
-            "ATC:J01DD08",
-            "KEGG.DRUG:D00258",
-            "MESH:D020682",
-            "DrugCentral:537",
-            "PUBCHEM.COMPOUND:5362065",
-            "RXNORM:25033",
-            "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:5362065",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "CEFIXIME",
-            "Cefixime (INN)",
-            "Cefixime",
-            "cefixime"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20070106",
-            "PMID:9379359",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23416192",
-            "PMID:19586686",
-            "PMID:21741846",
-            "PMID:21098249",
-            "PMID:24961639",
-            "PMID:8627565"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317030,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0003781",
-              "name": "bronchitis",
-              "description": "A bronchial disease that is an inflammation of the bronchial tubes. It is caused by bacteria and viruses. The disease has_symptom cough with mucus, has_symptom shortness of breath, has_symptom low fever and has_symptom chest tightness.",
-              "equivalent_curies": [
-                "EFO:0009661",
-                "SYMP:0000324",
-                "MEDDRA:10006461",
-                "ICD9:490",
-                "MESH:D001991",
-                "UMLS:C0006277",
-                "MEDDRA:10006451",
-                "ICD10:J42",
-                "ICD9:491",
-                "DOID:6132",
-                "NCIT:C2911",
-                "ICD10:J20",
-                "ICD9:466.0",
-                "SNOMEDCT:32398004",
-                "ICD10:J40",
-                "HP:0012387",
-                "MONDO:0003781"
-              ],
-              "id": "MONDO:0003781",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic bronchitis",
-                "Bronchitis, not specified as acute or chronic",
-                "bronchitis",
-                "Bronchitis",
-                "Acute bronchitis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=bronchitis",
-                "http://www.nlm.nih.gov/medlineplus/bronchitis.htm",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.nhlbi.nih.gov/health/dci/diseases/brnchi/brnchi_whatis.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20219185,
-            "start": 558,
-            "end": 317030,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30290951': {'publication date': '2018 Oct', 'sentence': 'Two weeks following her return to France, the patient presented with an episode of bronchitis and received 5 days of treatment with cefixime (a third-generation cephalosporin).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0060400---SEMMEDDB:treats---None---None---None---UMLS:C0006277---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5362065",
-              "id": "20619094",
-              "object": "MONDO:0003781",
-              "publications": [
-                "PMID:30290951"
-              ]
-            }
-          },
-          "end": {
-            "identity": 558,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefixime",
-              "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "UNII:XZ7BG04GJX",
-                "DRUGBANK:DB00671",
-                "GTOPDB:10898",
-                "PDQ:CDR0000037809",
-                "NDDF:002737",
-                "CHEBI:472657",
-                "HMDB:HMDB0014809",
-                "KEGG.COMPOUND:C06881",
-                "NCIT:C1100",
-                "UMLS:C0060400",
-                "CHEMBL.COMPOUND:CHEMBL1541",
-                "ATC:J01DD08",
-                "KEGG.DRUG:D00258",
-                "MESH:D020682",
-                "DrugCentral:537",
-                "PUBCHEM.COMPOUND:5362065",
-                "RXNORM:25033",
-                "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:5362065",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "CEFIXIME",
-                "Cefixime (INN)",
-                "Cefixime",
-                "cefixime"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20070106",
-                "PMID:9379359",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23416192",
-                "PMID:19586686",
-                "PMID:21741846",
-                "PMID:21098249",
-                "PMID:24961639",
-                "PMID:8627565"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10436948': {'publication date': '1997 Jul', 'sentence': 'A randomized controlled clinical study of cefetamet pivoxil (CAT) compared with cefixime (CFX) was conducted to evaluate its safety and efficacy in treating bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:2079369': {'publication date': '1990', 'sentence': '[Clinical experiences with cefixime in the treatment of bacterial infections of the lower respiratory tract].', 'subject score': 1000, 'object score': 1000}, 'PMID:2079370': {'publication date': '1990', 'sentence': '[Effectiveness and tolerance of cefixime in bacterial infections in the ENT area].', 'subject score': 1000, 'object score': 1000}, 'PMID:2079376': {'publication date': '1990', 'sentence': 'The results support the assumption that cefixime is suited for the treatment of children with bacterial infections of the airways and urinary tract with sensitive pathogens.', 'subject score': 1000, 'object score': 1000}, 'PMID:2693753': {'publication date': '1989 Dec', 'sentence': 'The above results suggest that CFIX is a very useful new oral cephalosporin for the treatment of bacterial infections in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:3531565': {'publication date': '1986 Apr', 'sentence': 'In conclusion, CFIX was found to be efficacious and safe for the treatment of bacterial infections in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:3761536': {'publication date': '1986 Apr', 'sentence': 'From the above results it has been concluded that CFIX is a useful and safe antibiotic for treating various bacterial infections in children.', 'subject score': 1000, 'object score': 824}, 'PMID:3761543': {'publication date': '1986 Apr', 'sentence': 'The above results suggest that CFIX is a useful new oral cephalosporin for the treatment of bacterial infections in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:8451674': {'publication date': '1993 Mar', 'sentence': 'Cefixime was effective in the treatment of bacterial sinus infections in adults and was well tolerated.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 538307,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-          ]
-        }
-      },
-      "end": {
-        "identity": 558,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefixime",
-          "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "UNII:XZ7BG04GJX",
-            "DRUGBANK:DB00671",
-            "GTOPDB:10898",
-            "PDQ:CDR0000037809",
-            "NDDF:002737",
-            "CHEBI:472657",
-            "HMDB:HMDB0014809",
-            "KEGG.COMPOUND:C06881",
-            "NCIT:C1100",
-            "UMLS:C0060400",
-            "CHEMBL.COMPOUND:CHEMBL1541",
-            "ATC:J01DD08",
-            "KEGG.DRUG:D00258",
-            "MESH:D020682",
-            "DrugCentral:537",
-            "PUBCHEM.COMPOUND:5362065",
-            "RXNORM:25033",
-            "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:5362065",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "CEFIXIME",
-            "Cefixime (INN)",
-            "Cefixime",
-            "cefixime"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20070106",
-            "PMID:9379359",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23416192",
-            "PMID:19586686",
-            "PMID:21741846",
-            "PMID:21098249",
-            "PMID:24961639",
-            "PMID:8627565"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538307,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7439775,
-            "start": 558,
-            "end": 538307,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10436948': {'publication date': '1997 Jul', 'sentence': 'A randomized controlled clinical study of cefetamet pivoxil (CAT) compared with cefixime (CFX) was conducted to evaluate its safety and efficacy in treating bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:2079369': {'publication date': '1990', 'sentence': '[Clinical experiences with cefixime in the treatment of bacterial infections of the lower respiratory tract].', 'subject score': 1000, 'object score': 1000}, 'PMID:2079370': {'publication date': '1990', 'sentence': '[Effectiveness and tolerance of cefixime in bacterial infections in the ENT area].', 'subject score': 1000, 'object score': 1000}, 'PMID:2079376': {'publication date': '1990', 'sentence': 'The results support the assumption that cefixime is suited for the treatment of children with bacterial infections of the airways and urinary tract with sensitive pathogens.', 'subject score': 1000, 'object score': 1000}, 'PMID:2693753': {'publication date': '1989 Dec', 'sentence': 'The above results suggest that CFIX is a very useful new oral cephalosporin for the treatment of bacterial infections in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:3531565': {'publication date': '1986 Apr', 'sentence': 'In conclusion, CFIX was found to be efficacious and safe for the treatment of bacterial infections in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:3761536': {'publication date': '1986 Apr', 'sentence': 'From the above results it has been concluded that CFIX is a useful and safe antibiotic for treating various bacterial infections in children.', 'subject score': 1000, 'object score': 824}, 'PMID:3761543': {'publication date': '1986 Apr', 'sentence': 'The above results suggest that CFIX is a useful new oral cephalosporin for the treatment of bacterial infections in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:8451674': {'publication date': '1993 Mar', 'sentence': 'Cefixime was effective in the treatment of bacterial sinus infections in adults and was well tolerated.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0060400---SEMMEDDB:treats---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5362065",
-              "id": "7594422",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:10436948",
-                "PMID:2079369",
-                "PMID:2079370",
-                "PMID:2079376",
-                "PMID:2693753",
-                "PMID:3531565",
-                "PMID:3761536",
-                "PMID:3761543",
-                "PMID:8451674"
-              ]
-            }
-          },
-          "end": {
-            "identity": 558,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefixime",
-              "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "UNII:XZ7BG04GJX",
-                "DRUGBANK:DB00671",
-                "GTOPDB:10898",
-                "PDQ:CDR0000037809",
-                "NDDF:002737",
-                "CHEBI:472657",
-                "HMDB:HMDB0014809",
-                "KEGG.COMPOUND:C06881",
-                "NCIT:C1100",
-                "UMLS:C0060400",
-                "CHEMBL.COMPOUND:CHEMBL1541",
-                "ATC:J01DD08",
-                "KEGG.DRUG:D00258",
-                "MESH:D020682",
-                "DrugCentral:537",
-                "PUBCHEM.COMPOUND:5362065",
-                "RXNORM:25033",
-                "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:5362065",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "CEFIXIME",
-                "Cefixime (INN)",
-                "Cefixime",
-                "cefixime"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20070106",
-                "PMID:9379359",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23416192",
-                "PMID:19586686",
-                "PMID:21741846",
-                "PMID:21098249",
-                "PMID:24961639",
-                "PMID:8627565"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:8152203': {'publication date': '1994 Jan-Feb', 'sentence': 'These results show that cefixime once daily is at least as effective as penicillin V t.i.d. in pharyngitis and tonsillitis in children.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317210,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001039",
-          "name": "tonsillitis",
-          "description": "Inflammation of the tonsils that has occurred repeatedly. The definition of recurrent may vary somewhat, but the criteria used recently as a measure of severity were five or more episodes of true tonsillitis per year, symptoms recurring for at least a year, and episodes that are disabling and that prevent normal functioning. In some cases recurrent tonsillitis may be related to immunosusceptibility. Evidence exists for a genetic predisposition for recurrent tonsillitis. [HPO:probinson, PMID:15897415]; Inflammation of the tonsils that has occurred repeatedly. The definition of recurrent may vary somewhat, but the criteria used recently as a measure of severity were five or more episodes of true tonsillitis per year, symptoms recurring for at least a year, and episodes that are disabling and that prevent normal functioning. In some cases recurrent tonsillitis may be related to immunosusceptibility. Evidence exists for a genetic predisposition for recurrent tonsillitis.; Inflammation of the tonsils that has occurred repeatedly. The definition of recurrent may vary somewhat, but the criteria used recently as a measure of severity were five or more episodes of true tonsillitis per year, symptoms recurring for at least a year, and episodes that are disabling and that prevent normal functioning. In some cases recurrent tonsillitis may be related to immunosusceptibility. Evidence exists for a genetic predisposition for recurrent tonsillitis.; Inflammation of the tonsils that has occurred repeatedly. The definition of recurrent may vary somewhat, but the criteria used recently as a measure of severity were five or more episodes of true tonsillitis per year, symptoms recurring for at least a year, and episodes that are disabling and that prevent normal functioning. In some cases recurrent tonsillitis may be related to immunosusceptibility. Evidence exists for a genetic predisposition for recurrent tonsillitis.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10044008",
-            "DOID:10456",
-            "MEDDRA:10009152",
-            "SNOMEDCT:90176007",
-            "MONDO:0001039",
-            "ICD10:J35.01",
-            "MEDDRA:10044010",
-            "ICD9:474.00",
-            "HP:0011110",
-            "MEDDRA:10044012",
-            "UMLS:C0149517",
-            "UMLS:C0740402",
-            "MESH:D014069",
-            "UMLS:C0040425",
-            "SNOMEDCT:90979004",
-            "MEDDRA:10044011",
-            "MEDDRA:10065169",
-            "NCIT:C116006"
-          ],
-          "id": "MONDO:0001039",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Recurrent tonsillitis",
-            "tonsillitis",
-            "Tonsillitis",
-            "Chronic tonsillitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:15897415",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tonsillitis",
-            "http://en.wikipedia.org/wiki/tonsillitis",
-            "https://orcid.org/0000-0001-5208-3432"
-          ]
-        }
-      },
-      "end": {
-        "identity": 558,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefixime",
-          "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "UNII:XZ7BG04GJX",
-            "DRUGBANK:DB00671",
-            "GTOPDB:10898",
-            "PDQ:CDR0000037809",
-            "NDDF:002737",
-            "CHEBI:472657",
-            "HMDB:HMDB0014809",
-            "KEGG.COMPOUND:C06881",
-            "NCIT:C1100",
-            "UMLS:C0060400",
-            "CHEMBL.COMPOUND:CHEMBL1541",
-            "ATC:J01DD08",
-            "KEGG.DRUG:D00258",
-            "MESH:D020682",
-            "DrugCentral:537",
-            "PUBCHEM.COMPOUND:5362065",
-            "RXNORM:25033",
-            "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:5362065",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "CEFIXIME",
-            "Cefixime (INN)",
-            "Cefixime",
-            "cefixime"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20070106",
-            "PMID:9379359",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23416192",
-            "PMID:19586686",
-            "PMID:21741846",
-            "PMID:21098249",
-            "PMID:24961639",
-            "PMID:8627565"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317210,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001039",
-              "name": "tonsillitis",
-              "description": "Inflammation of the tonsils that has occurred repeatedly. The definition of recurrent may vary somewhat, but the criteria used recently as a measure of severity were five or more episodes of true tonsillitis per year, symptoms recurring for at least a year, and episodes that are disabling and that prevent normal functioning. In some cases recurrent tonsillitis may be related to immunosusceptibility. Evidence exists for a genetic predisposition for recurrent tonsillitis. [HPO:probinson, PMID:15897415]; Inflammation of the tonsils that has occurred repeatedly. The definition of recurrent may vary somewhat, but the criteria used recently as a measure of severity were five or more episodes of true tonsillitis per year, symptoms recurring for at least a year, and episodes that are disabling and that prevent normal functioning. In some cases recurrent tonsillitis may be related to immunosusceptibility. Evidence exists for a genetic predisposition for recurrent tonsillitis.; Inflammation of the tonsils that has occurred repeatedly. The definition of recurrent may vary somewhat, but the criteria used recently as a measure of severity were five or more episodes of true tonsillitis per year, symptoms recurring for at least a year, and episodes that are disabling and that prevent normal functioning. In some cases recurrent tonsillitis may be related to immunosusceptibility. Evidence exists for a genetic predisposition for recurrent tonsillitis.; Inflammation of the tonsils that has occurred repeatedly. The definition of recurrent may vary somewhat, but the criteria used recently as a measure of severity were five or more episodes of true tonsillitis per year, symptoms recurring for at least a year, and episodes that are disabling and that prevent normal functioning. In some cases recurrent tonsillitis may be related to immunosusceptibility. Evidence exists for a genetic predisposition for recurrent tonsillitis.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10044008",
-                "DOID:10456",
-                "MEDDRA:10009152",
-                "SNOMEDCT:90176007",
-                "MONDO:0001039",
-                "ICD10:J35.01",
-                "MEDDRA:10044010",
-                "ICD9:474.00",
-                "HP:0011110",
-                "MEDDRA:10044012",
-                "UMLS:C0149517",
-                "UMLS:C0740402",
-                "MESH:D014069",
-                "UMLS:C0040425",
-                "SNOMEDCT:90979004",
-                "MEDDRA:10044011",
-                "MEDDRA:10065169",
-                "NCIT:C116006"
-              ],
-              "id": "MONDO:0001039",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Recurrent tonsillitis",
-                "tonsillitis",
-                "Tonsillitis",
-                "Chronic tonsillitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:15897415",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tonsillitis",
-                "http://en.wikipedia.org/wiki/tonsillitis",
-                "https://orcid.org/0000-0001-5208-3432"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26379045,
-            "start": 558,
-            "end": 317210,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8152203': {'publication date': '1994 Jan-Feb', 'sentence': 'These results show that cefixime once daily is at least as effective as penicillin V t.i.d. in pharyngitis and tonsillitis in children.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0060400---SEMMEDDB:treats---None---None---None---UMLS:C0040425---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5362065",
-              "id": "26843374",
-              "object": "MONDO:0001039",
-              "publications": [
-                "PMID:8152203"
-              ]
-            }
-          },
-          "end": {
-            "identity": 558,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefixime",
-              "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "UNII:XZ7BG04GJX",
-                "DRUGBANK:DB00671",
-                "GTOPDB:10898",
-                "PDQ:CDR0000037809",
-                "NDDF:002737",
-                "CHEBI:472657",
-                "HMDB:HMDB0014809",
-                "KEGG.COMPOUND:C06881",
-                "NCIT:C1100",
-                "UMLS:C0060400",
-                "CHEMBL.COMPOUND:CHEMBL1541",
-                "ATC:J01DD08",
-                "KEGG.DRUG:D00258",
-                "MESH:D020682",
-                "DrugCentral:537",
-                "PUBCHEM.COMPOUND:5362065",
-                "RXNORM:25033",
-                "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:5362065",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "CEFIXIME",
-                "Cefixime (INN)",
-                "Cefixime",
-                "cefixime"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20070106",
-                "PMID:9379359",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23416192",
-                "PMID:19586686",
-                "PMID:21741846",
-                "PMID:21098249",
-                "PMID:24961639",
-                "PMID:8627565"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:32522244': {'publication date': '2020 Jun 10', 'sentence': 'DISCUSSION: Demonstration of efficacy of cefixime in the treatment of active syphilis in this Phase 2 trial among non-pregnant women will inform a proposed randomized controlled trial to evaluate cefixime as an alternative treatment for pregnant women with active syphilis to evaluate prevention of congenital syphilis.', 'subject score': 1000, 'object score': 888}, 'PMID:33337615': {'publication date': '2020 Dec 15', 'sentence': 'Randomized control trials of oral cefixime for treatment of syphilis are paving the way for potential use in pregnant women.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 533053,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005976",
-          "name": "syphilis",
-          "description": "A contagious bacterial infection caused by the spirochete Treponema pallidum. It is a sexually transmitted disorder, although it can also be transmitted from the mother to the fetus in utero. Typically, it is initially manifested with a single sore which heals without treatment. If the infection is left untreated, the initial stage is followed by skin rash and mucous membrane lesions. A late stage follows, which is characterized by damage of the internal organs, including the nervous system.; A contagious venereal disease caused by the spirochete TREPONEMA PALLIDUM.; Syphilis is a sexually transmitted disease caused by bacteria. It infects the genital area, lips, mouth, or anus of both men and women. You usually get syphilis from sexual contact with someone who has it. It can also pass from mother to baby during pregnancy. The early stage of syphilis usually causes a single, small, painless sore. Sometimes it causes swelling in nearby lymph nodes. If you do not treat it, syphilis usually causes a non-itchy skin rash, often on your hands and feet. Many people do not notice symptoms for years. Symptoms can go away and come back. The sores caused by syphilis make it easier to get or give someone HIV during sex. If you are pregnant, syphilis can cause complications, or you could lose your baby. In rare cases, syphilis causes serious health problems and even death. Syphilis is easy to cure with antibiotics if you catch it early. Correct usage of latex condoms greatly reduces, but does not completely eliminate, the risk of catching or spreading syphilis. If your or your partner is allergic to latex, you can use polyurethane condoms. The most reliable way to avoid infection is to not have anal, vaginal, or oral sex. Centers for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0039128",
-            "MEDDRA:10042896",
-            "MESH:D013587",
-            "MEDDRA:10042882",
-            "DOID:4166",
-            "EFO:0007504",
-            "MEDDRA:10044588",
-            "PSY:51240",
-            "NCIT:C35055",
-            "MEDDRA:10063034",
-            "MEDDRA:10062120",
-            "SNOMEDCT:76272004",
-            "ICD10:A51.0",
-            "MONDO:0005976"
-          ],
-          "id": "MONDO:0005976",
-          "category": "biolink:Disease",
-          "all_names": [
-            "syphilis",
-            "Syphilis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/syphilis",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=syphilis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 558,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefixime",
-          "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "UNII:XZ7BG04GJX",
-            "DRUGBANK:DB00671",
-            "GTOPDB:10898",
-            "PDQ:CDR0000037809",
-            "NDDF:002737",
-            "CHEBI:472657",
-            "HMDB:HMDB0014809",
-            "KEGG.COMPOUND:C06881",
-            "NCIT:C1100",
-            "UMLS:C0060400",
-            "CHEMBL.COMPOUND:CHEMBL1541",
-            "ATC:J01DD08",
-            "KEGG.DRUG:D00258",
-            "MESH:D020682",
-            "DrugCentral:537",
-            "PUBCHEM.COMPOUND:5362065",
-            "RXNORM:25033",
-            "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:5362065",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "CEFIXIME",
-            "Cefixime (INN)",
-            "Cefixime",
-            "cefixime"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20070106",
-            "PMID:9379359",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23416192",
-            "PMID:19586686",
-            "PMID:21741846",
-            "PMID:21098249",
-            "PMID:24961639",
-            "PMID:8627565"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 533053,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005976",
-              "name": "syphilis",
-              "description": "A contagious bacterial infection caused by the spirochete Treponema pallidum. It is a sexually transmitted disorder, although it can also be transmitted from the mother to the fetus in utero. Typically, it is initially manifested with a single sore which heals without treatment. If the infection is left untreated, the initial stage is followed by skin rash and mucous membrane lesions. A late stage follows, which is characterized by damage of the internal organs, including the nervous system.; A contagious venereal disease caused by the spirochete TREPONEMA PALLIDUM.; Syphilis is a sexually transmitted disease caused by bacteria. It infects the genital area, lips, mouth, or anus of both men and women. You usually get syphilis from sexual contact with someone who has it. It can also pass from mother to baby during pregnancy. The early stage of syphilis usually causes a single, small, painless sore. Sometimes it causes swelling in nearby lymph nodes. If you do not treat it, syphilis usually causes a non-itchy skin rash, often on your hands and feet. Many people do not notice symptoms for years. Symptoms can go away and come back. The sores caused by syphilis make it easier to get or give someone HIV during sex. If you are pregnant, syphilis can cause complications, or you could lose your baby. In rare cases, syphilis causes serious health problems and even death. Syphilis is easy to cure with antibiotics if you catch it early. Correct usage of latex condoms greatly reduces, but does not completely eliminate, the risk of catching or spreading syphilis. If your or your partner is allergic to latex, you can use polyurethane condoms. The most reliable way to avoid infection is to not have anal, vaginal, or oral sex. Centers for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0039128",
-                "MEDDRA:10042896",
-                "MESH:D013587",
-                "MEDDRA:10042882",
-                "DOID:4166",
-                "EFO:0007504",
-                "MEDDRA:10044588",
-                "PSY:51240",
-                "NCIT:C35055",
-                "MEDDRA:10063034",
-                "MEDDRA:10062120",
-                "SNOMEDCT:76272004",
-                "ICD10:A51.0",
-                "MONDO:0005976"
-              ],
-              "id": "MONDO:0005976",
-              "category": "biolink:Disease",
-              "all_names": [
-                "syphilis",
-                "Syphilis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/syphilis",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=syphilis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21718163,
-            "start": 558,
-            "end": 533053,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32522244': {'publication date': '2020 Jun 10', 'sentence': 'DISCUSSION: Demonstration of efficacy of cefixime in the treatment of active syphilis in this Phase 2 trial among non-pregnant women will inform a proposed randomized controlled trial to evaluate cefixime as an alternative treatment for pregnant women with active syphilis to evaluate prevention of congenital syphilis.', 'subject score': 1000, 'object score': 888}, 'PMID:33337615': {'publication date': '2020 Dec 15', 'sentence': 'Randomized control trials of oral cefixime for treatment of syphilis are paving the way for potential use in pregnant women.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0060400---SEMMEDDB:treats---None---None---None---UMLS:C0039128---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5362065",
-              "id": "22138225",
-              "object": "MONDO:0005976",
-              "publications": [
-                "PMID:32522244",
-                "PMID:33337615"
-              ]
-            }
-          },
-          "end": {
-            "identity": 558,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefixime",
-              "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "UNII:XZ7BG04GJX",
-                "DRUGBANK:DB00671",
-                "GTOPDB:10898",
-                "PDQ:CDR0000037809",
-                "NDDF:002737",
-                "CHEBI:472657",
-                "HMDB:HMDB0014809",
-                "KEGG.COMPOUND:C06881",
-                "NCIT:C1100",
-                "UMLS:C0060400",
-                "CHEMBL.COMPOUND:CHEMBL1541",
-                "ATC:J01DD08",
-                "KEGG.DRUG:D00258",
-                "MESH:D020682",
-                "DrugCentral:537",
-                "PUBCHEM.COMPOUND:5362065",
-                "RXNORM:25033",
-                "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:5362065",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "CEFIXIME",
-                "Cefixime (INN)",
-                "Cefixime",
-                "cefixime"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20070106",
-                "PMID:9379359",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23416192",
-                "PMID:19586686",
-                "PMID:21741846",
-                "PMID:21098249",
-                "PMID:24961639",
-                "PMID:8627565"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:34852307': {'publication date': '2021 Nov 17', 'sentence': 'The aim of this study is to evaluate cefixime for the treatment of osteoarticular infections in pediatric SCD patients by retrospective design.', 'subject score': 1000, 'object score': 861}, 'PMID:36729626': {'publication date': '2022 Dec 14', 'sentence': 'We recommend more investigation into the effectiveness of cefixime in treating rectal infections and studying multidose therapy for the cefixime treatment of pharyngeal infection.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 546907,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C3714514",
-          "name": "Infection",
-          "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "UMLS:C3714514",
-            "MEDDRA:10021842",
-            "NCIT:C128320",
-            "MEDDRA:10021789",
-            "MESH:D007239"
-          ],
-          "id": "UMLS:C3714514",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infection",
-            "Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 558,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefixime",
-          "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "UNII:XZ7BG04GJX",
-            "DRUGBANK:DB00671",
-            "GTOPDB:10898",
-            "PDQ:CDR0000037809",
-            "NDDF:002737",
-            "CHEBI:472657",
-            "HMDB:HMDB0014809",
-            "KEGG.COMPOUND:C06881",
-            "NCIT:C1100",
-            "UMLS:C0060400",
-            "CHEMBL.COMPOUND:CHEMBL1541",
-            "ATC:J01DD08",
-            "KEGG.DRUG:D00258",
-            "MESH:D020682",
-            "DrugCentral:537",
-            "PUBCHEM.COMPOUND:5362065",
-            "RXNORM:25033",
-            "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:5362065",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "CEFIXIME",
-            "Cefixime (INN)",
-            "Cefixime",
-            "cefixime"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20070106",
-            "PMID:9379359",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23416192",
-            "PMID:19586686",
-            "PMID:21741846",
-            "PMID:21098249",
-            "PMID:24961639",
-            "PMID:8627565"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546907,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C3714514",
-              "name": "Infection",
-              "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "UMLS:C3714514",
-                "MEDDRA:10021842",
-                "NCIT:C128320",
-                "MEDDRA:10021789",
-                "MESH:D007239"
-              ],
-              "id": "UMLS:C3714514",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infection",
-                "Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23533145,
-            "start": 558,
-            "end": 546907,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34852307': {'publication date': '2021 Nov 17', 'sentence': 'The aim of this study is to evaluate cefixime for the treatment of osteoarticular infections in pediatric SCD patients by retrospective design.', 'subject score': 1000, 'object score': 861}, 'PMID:36729626': {'publication date': '2022 Dec 14', 'sentence': 'We recommend more investigation into the effectiveness of cefixime in treating rectal infections and studying multidose therapy for the cefixime treatment of pharyngeal infection.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0060400---SEMMEDDB:treats---None---None---None---UMLS:C3714514---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5362065",
-              "id": "23970374",
-              "object": "UMLS:C3714514",
-              "publications": [
-                "PMID:34852307",
-                "PMID:36729626"
-              ]
-            }
-          },
-          "end": {
-            "identity": 558,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefixime",
-              "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "UNII:XZ7BG04GJX",
-                "DRUGBANK:DB00671",
-                "GTOPDB:10898",
-                "PDQ:CDR0000037809",
-                "NDDF:002737",
-                "CHEBI:472657",
-                "HMDB:HMDB0014809",
-                "KEGG.COMPOUND:C06881",
-                "NCIT:C1100",
-                "UMLS:C0060400",
-                "CHEMBL.COMPOUND:CHEMBL1541",
-                "ATC:J01DD08",
-                "KEGG.DRUG:D00258",
-                "MESH:D020682",
-                "DrugCentral:537",
-                "PUBCHEM.COMPOUND:5362065",
-                "RXNORM:25033",
-                "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:5362065",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "CEFIXIME",
-                "Cefixime (INN)",
-                "Cefixime",
-                "cefixime"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20070106",
-                "PMID:9379359",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23416192",
-                "PMID:19586686",
-                "PMID:21741846",
-                "PMID:21098249",
-                "PMID:24961639",
-                "PMID:8627565"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1725152': {'publication date': '1991', 'sentence': 'Efficacy and tolerability of cefixime in otitis media.', 'subject score': 1000, 'object score': 1000}, 'PMID:1852543': {'publication date': '1991 Jun', 'sentence': 'Pneumococcal bacteremia during oral treatment with cefixime for otitis media.', 'subject score': 1000, 'object score': 1000}, 'PMID:2405586': {'publication date': '1990 Jan', 'sentence': 'The newer agents, cefaclor, cefuroxime axetil, and cefixime, have increased in vitro activity against beta-lactamase-secreting strains of Haemophilus influenzae and Branhamella catarrhalis which has made them more popular for the treatment of otitis media and respiratory tract infections in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:2530544': {'publication date': '1989 Oct 11', 'sentence': 'Cefixime was used in the treatment of 59 patients, 44 of whom had sinusitis, 9 otitis media and 6 various ENT infections.', 'subject score': 1000, 'object score': 901}, 'PMID:30505057': {'publication date': '2018', 'sentence': 'BACKGROUND: Cefixime is a widely used third-generation cephalosporin schedule H1 drug, which is prescribed for the treatment of otitis media, respiratory tract infections, and uncomplicated urinary tract infections and is effective against infections caused by Enterobacteriaceae and Haemophilus influenzae species in India.', 'subject score': 1000, 'object score': 1000}, 'PMID:8169042': {'publication date': '1994 Mar', 'sentence': 'An experimental study of cefixime in the treatment of Streptococcus pneumoniae otitis media.', 'subject score': 1000, 'object score': 888}, 'PMID:8345993': {'publication date': '1993 Jun', 'sentence': 'Cefixime therapy for otitis media.', 'subject score': 888, 'object score': 1000}, 'PMID:8414791': {'publication date': '1993 Aug', 'sentence': 'Cefixime therapy for otitis media.', 'subject score': 888, 'object score': 1000}, 'PMID:8417430': {'publication date': '1993 Jan', 'sentence': 'Review of cefixime in the treatment of otitis media in infants and children.', 'subject score': 1000, 'object score': 1000}, 'PMID:9797419': {'publication date': '1998 Sep', 'sentence': 'Comparative studies between cefixime and conventional antibiotics for the treatment of upper respiratory tract infections and otitis media are summarized.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317908,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005441",
-          "name": "otitis media",
-          "description": "Inflammation of the anatomical structures of the middle ear, which is most often caused by an infectious process. Symptoms include erythema and edema of the tympanic membrane, pain, and possibly fever.; Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.; Inflammation or infection of the middle ear. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:0004992",
-            "MEDDRA:10065838",
-            "MEDDRA:10046087",
-            "MEDDRA:10056747",
-            "ICD10:H66.9",
-            "MONDO:0005441",
-            "ICD9:382.9",
-            "MESH:D010033",
-            "SNOMEDCT:65363002",
-            "DOID:10754",
-            "MEDDRA:10033084",
-            "HP:0000388",
-            "UMLS:C0029882",
-            "MEDDRA:10033078",
-            "NCIT:C34885",
-            "MEDDRA:10027585"
-          ],
-          "id": "MONDO:0005441",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Otitis media",
-            "Unspecified otitis media",
-            "Otitis Media",
-            "otitis media"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/otitis_media",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 558,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefixime",
-          "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "UNII:XZ7BG04GJX",
-            "DRUGBANK:DB00671",
-            "GTOPDB:10898",
-            "PDQ:CDR0000037809",
-            "NDDF:002737",
-            "CHEBI:472657",
-            "HMDB:HMDB0014809",
-            "KEGG.COMPOUND:C06881",
-            "NCIT:C1100",
-            "UMLS:C0060400",
-            "CHEMBL.COMPOUND:CHEMBL1541",
-            "ATC:J01DD08",
-            "KEGG.DRUG:D00258",
-            "MESH:D020682",
-            "DrugCentral:537",
-            "PUBCHEM.COMPOUND:5362065",
-            "RXNORM:25033",
-            "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:5362065",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "CEFIXIME",
-            "Cefixime (INN)",
-            "Cefixime",
-            "cefixime"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20070106",
-            "PMID:9379359",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23416192",
-            "PMID:19586686",
-            "PMID:21741846",
-            "PMID:21098249",
-            "PMID:24961639",
-            "PMID:8627565"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317908,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005441",
-              "name": "otitis media",
-              "description": "Inflammation of the anatomical structures of the middle ear, which is most often caused by an infectious process. Symptoms include erythema and edema of the tympanic membrane, pain, and possibly fever.; Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.; Inflammation or infection of the middle ear. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:0004992",
-                "MEDDRA:10065838",
-                "MEDDRA:10046087",
-                "MEDDRA:10056747",
-                "ICD10:H66.9",
-                "MONDO:0005441",
-                "ICD9:382.9",
-                "MESH:D010033",
-                "SNOMEDCT:65363002",
-                "DOID:10754",
-                "MEDDRA:10033084",
-                "HP:0000388",
-                "UMLS:C0029882",
-                "MEDDRA:10033078",
-                "NCIT:C34885",
-                "MEDDRA:10027585"
-              ],
-              "id": "MONDO:0005441",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Otitis media",
-                "Unspecified otitis media",
-                "Otitis Media",
-                "otitis media"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/otitis_media",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12667312,
-            "start": 558,
-            "end": 317908,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1725152': {'publication date': '1991', 'sentence': 'Efficacy and tolerability of cefixime in otitis media.', 'subject score': 1000, 'object score': 1000}, 'PMID:1852543': {'publication date': '1991 Jun', 'sentence': 'Pneumococcal bacteremia during oral treatment with cefixime for otitis media.', 'subject score': 1000, 'object score': 1000}, 'PMID:2405586': {'publication date': '1990 Jan', 'sentence': 'The newer agents, cefaclor, cefuroxime axetil, and cefixime, have increased in vitro activity against beta-lactamase-secreting strains of Haemophilus influenzae and Branhamella catarrhalis which has made them more popular for the treatment of otitis media and respiratory tract infections in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:2530544': {'publication date': '1989 Oct 11', 'sentence': 'Cefixime was used in the treatment of 59 patients, 44 of whom had sinusitis, 9 otitis media and 6 various ENT infections.', 'subject score': 1000, 'object score': 901}, 'PMID:30505057': {'publication date': '2018', 'sentence': 'BACKGROUND: Cefixime is a widely used third-generation cephalosporin schedule H1 drug, which is prescribed for the treatment of otitis media, respiratory tract infections, and uncomplicated urinary tract infections and is effective against infections caused by Enterobacteriaceae and Haemophilus influenzae species in India.', 'subject score': 1000, 'object score': 1000}, 'PMID:8169042': {'publication date': '1994 Mar', 'sentence': 'An experimental study of cefixime in the treatment of Streptococcus pneumoniae otitis media.', 'subject score': 1000, 'object score': 888}, 'PMID:8345993': {'publication date': '1993 Jun', 'sentence': 'Cefixime therapy for otitis media.', 'subject score': 888, 'object score': 1000}, 'PMID:8414791': {'publication date': '1993 Aug', 'sentence': 'Cefixime therapy for otitis media.', 'subject score': 888, 'object score': 1000}, 'PMID:8417430': {'publication date': '1993 Jan', 'sentence': 'Review of cefixime in the treatment of otitis media in infants and children.', 'subject score': 1000, 'object score': 1000}, 'PMID:9797419': {'publication date': '1998 Sep', 'sentence': 'Comparative studies between cefixime and conventional antibiotics for the treatment of upper respiratory tract infections and otitis media are summarized.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0060400---SEMMEDDB:treats---None---None---None---UMLS:C0029882---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5362065",
-              "id": "12941415",
-              "object": "MONDO:0005441",
-              "publications": [
-                "PMID:1725152",
-                "PMID:1852543",
-                "PMID:2405586",
-                "PMID:2530544",
-                "PMID:30505057",
-                "PMID:8169042",
-                "PMID:8345993",
-                "PMID:8414791",
-                "PMID:8417430",
-                "PMID:9797419"
-              ]
-            }
-          },
-          "end": {
-            "identity": 558,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefixime",
-              "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "UNII:XZ7BG04GJX",
-                "DRUGBANK:DB00671",
-                "GTOPDB:10898",
-                "PDQ:CDR0000037809",
-                "NDDF:002737",
-                "CHEBI:472657",
-                "HMDB:HMDB0014809",
-                "KEGG.COMPOUND:C06881",
-                "NCIT:C1100",
-                "UMLS:C0060400",
-                "CHEMBL.COMPOUND:CHEMBL1541",
-                "ATC:J01DD08",
-                "KEGG.DRUG:D00258",
-                "MESH:D020682",
-                "DrugCentral:537",
-                "PUBCHEM.COMPOUND:5362065",
-                "RXNORM:25033",
-                "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:5362065",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "CEFIXIME",
-                "Cefixime (INN)",
-                "Cefixime",
-                "cefixime"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20070106",
-                "PMID:9379359",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23416192",
-                "PMID:19586686",
-                "PMID:21741846",
-                "PMID:21098249",
-                "PMID:24961639",
-                "PMID:8627565"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:2685718': {'publication date': '1989 Dec', 'sentence': 'Because of the emergence of these bacteria, other antimicrobial agents, both old and new, have been advocated for treatment and prevention of otitis media; amoxicillin-clavulanate, cefuroxime axetil, and cefixime are the newer agents.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 317908,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005441",
-          "name": "otitis media",
-          "description": "Inflammation of the anatomical structures of the middle ear, which is most often caused by an infectious process. Symptoms include erythema and edema of the tympanic membrane, pain, and possibly fever.; Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.; Inflammation or infection of the middle ear. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:0004992",
-            "MEDDRA:10065838",
-            "MEDDRA:10046087",
-            "MEDDRA:10056747",
-            "ICD10:H66.9",
-            "MONDO:0005441",
-            "ICD9:382.9",
-            "MESH:D010033",
-            "SNOMEDCT:65363002",
-            "DOID:10754",
-            "MEDDRA:10033084",
-            "HP:0000388",
-            "UMLS:C0029882",
-            "MEDDRA:10033078",
-            "NCIT:C34885",
-            "MEDDRA:10027585"
-          ],
-          "id": "MONDO:0005441",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Otitis media",
-            "Unspecified otitis media",
-            "Otitis Media",
-            "otitis media"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/otitis_media",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 558,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefixime",
-          "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "UNII:XZ7BG04GJX",
-            "DRUGBANK:DB00671",
-            "GTOPDB:10898",
-            "PDQ:CDR0000037809",
-            "NDDF:002737",
-            "CHEBI:472657",
-            "HMDB:HMDB0014809",
-            "KEGG.COMPOUND:C06881",
-            "NCIT:C1100",
-            "UMLS:C0060400",
-            "CHEMBL.COMPOUND:CHEMBL1541",
-            "ATC:J01DD08",
-            "KEGG.DRUG:D00258",
-            "MESH:D020682",
-            "DrugCentral:537",
-            "PUBCHEM.COMPOUND:5362065",
-            "RXNORM:25033",
-            "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-          ],
-          "id": "PUBCHEM.COMPOUND:5362065",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "CEFIXIME",
-            "Cefixime (INN)",
-            "Cefixime",
-            "cefixime"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20070106",
-            "PMID:9379359",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23416192",
-            "PMID:19586686",
-            "PMID:21741846",
-            "PMID:21098249",
-            "PMID:24961639",
-            "PMID:8627565"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317908,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005441",
-              "name": "otitis media",
-              "description": "Inflammation of the anatomical structures of the middle ear, which is most often caused by an infectious process. Symptoms include erythema and edema of the tympanic membrane, pain, and possibly fever.; Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.; Inflammation or infection of the middle ear. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:0004992",
-                "MEDDRA:10065838",
-                "MEDDRA:10046087",
-                "MEDDRA:10056747",
-                "ICD10:H66.9",
-                "MONDO:0005441",
-                "ICD9:382.9",
-                "MESH:D010033",
-                "SNOMEDCT:65363002",
-                "DOID:10754",
-                "MEDDRA:10033084",
-                "HP:0000388",
-                "UMLS:C0029882",
-                "MEDDRA:10033078",
-                "NCIT:C34885",
-                "MEDDRA:10027585"
-              ],
-              "id": "MONDO:0005441",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Otitis media",
-                "Unspecified otitis media",
-                "Otitis Media",
-                "otitis media"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/otitis_media",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18439634,
-            "start": 558,
-            "end": 317908,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2685718': {'publication date': '1989 Dec', 'sentence': 'Because of the emergence of these bacteria, other antimicrobial agents, both old and new, have been advocated for treatment and prevention of otitis media; amoxicillin-clavulanate, cefuroxime axetil, and cefixime are the newer agents.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0060400---SEMMEDDB:prevents---None---None---None---UMLS:C0029882---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5362065",
-              "id": "18811968",
-              "object": "MONDO:0005441",
-              "publications": [
-                "PMID:2685718"
-              ]
-            }
-          },
-          "end": {
-            "identity": 558,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefixime",
-              "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "UNII:XZ7BG04GJX",
-                "DRUGBANK:DB00671",
-                "GTOPDB:10898",
-                "PDQ:CDR0000037809",
-                "NDDF:002737",
-                "CHEBI:472657",
-                "HMDB:HMDB0014809",
-                "KEGG.COMPOUND:C06881",
-                "NCIT:C1100",
-                "UMLS:C0060400",
-                "CHEMBL.COMPOUND:CHEMBL1541",
-                "ATC:J01DD08",
-                "KEGG.DRUG:D00258",
-                "MESH:D020682",
-                "DrugCentral:537",
-                "PUBCHEM.COMPOUND:5362065",
-                "RXNORM:25033",
-                "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
-              ],
-              "id": "PUBCHEM.COMPOUND:5362065",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "CEFIXIME",
-                "Cefixime (INN)",
-                "Cefixime",
-                "cefixime"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20070106",
-                "PMID:9379359",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23416192",
-                "PMID:19586686",
-                "PMID:21741846",
-                "PMID:21098249",
-                "PMID:24961639",
-                "PMID:8627565"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:6279903': {'publication date': '1982 Jan', 'sentence': 'Eighteen children with the following bacterial infections were treated with ceftizoxime; respiratory tract infection (13), acute otitis media (1), acute intervertebral chondritis and tonsillitis (1), chronic cystitis (1), subcutaneous abscess (1) and chronic bacteremia (1).', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 538307,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-          ]
-        }
-      },
-      "end": {
-        "identity": 559,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ceftizoxime",
-          "description": "A semisynthetic, broad-spectrum, beta-lactamase-resistant, third-generation cephalosporin with antibacterial activity. Ceftizoxime binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:004847",
-            "CHEBI:553473",
-            "INCHIKEY:NNULBSISHYWZJU-LLKWHZGFSA-N",
-            "GTOPDB:10785",
-            "KEGG.COMPOUND:C06890",
-            "RXNORM:2192",
-            "PUBCHEM.COMPOUND:6533629",
-            "CHEMBL.COMPOUND:CHEMBL528",
-            "KEGG.DRUG:D07658",
-            "NCIT:C61668",
-            "DRUGBANK:DB01332",
-            "DrugCentral:563",
-            "UMLS:C0007560",
-            "ATC:J01DD07",
-            "MESH:D015296",
-            "HMDB:HMDB0015427",
-            "UNII:C43C467DPE"
-          ],
-          "id": "PUBCHEM.COMPOUND:6533629",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ceftizoxime (INN)",
-            "Ceftizoxime",
-            "ceftisomin",
-            "CEFTIZOXIME",
-            "ceftizoxime"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20679504",
-            "PMID:20022146",
-            "PMID:15646539",
-            "PMID:17646416",
-            "PMID:18426954",
-            "PMID:2342058",
-            "PMID:19015345",
-            "PMID:22194678",
-            "PMID:18490507",
-            "PMID:18834112"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538307,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25622577,
-            "start": 559,
-            "end": 538307,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:6279903': {'publication date': '1982 Jan', 'sentence': 'Eighteen children with the following bacterial infections were treated with ceftizoxime; respiratory tract infection (13), acute otitis media (1), acute intervertebral chondritis and tonsillitis (1), chronic cystitis (1), subcutaneous abscess (1) and chronic bacteremia (1).', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0007560---SEMMEDDB:treats---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6533629",
-              "id": "26078551",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:6279903"
-              ]
-            }
-          },
-          "end": {
-            "identity": 559,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-=======
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
->>>>>>> main
-            ],
-            "properties": {
-              "name": "Ceftizoxime",
-              "description": "A semisynthetic, broad-spectrum, beta-lactamase-resistant, third-generation cephalosporin with antibacterial activity. Ceftizoxime binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:004847",
-                "CHEBI:553473",
-                "INCHIKEY:NNULBSISHYWZJU-LLKWHZGFSA-N",
-                "GTOPDB:10785",
-                "KEGG.COMPOUND:C06890",
-                "RXNORM:2192",
-                "PUBCHEM.COMPOUND:6533629",
-                "CHEMBL.COMPOUND:CHEMBL528",
-                "KEGG.DRUG:D07658",
-                "NCIT:C61668",
-                "DRUGBANK:DB01332",
-                "DrugCentral:563",
-                "UMLS:C0007560",
-                "ATC:J01DD07",
-                "MESH:D015296",
-                "HMDB:HMDB0015427",
-                "UNII:C43C467DPE"
-              ],
-              "id": "PUBCHEM.COMPOUND:6533629",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ceftizoxime (INN)",
-                "Ceftizoxime",
-                "ceftisomin",
-                "CEFTIZOXIME",
-                "ceftizoxime"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20679504",
-                "PMID:20022146",
-                "PMID:15646539",
-                "PMID:17646416",
-                "PMID:18426954",
-                "PMID:2342058",
-                "PMID:19015345",
-                "PMID:22194678",
-                "PMID:18490507",
-                "PMID:18834112"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:3859212': {'publication date': '1985 Jun 07', 'sentence': 'Experience with imipenem/cilastatin and that reported for cefotaxime, ceftazidime, and ceftizoxime in the treatment of biopsy-proved osteomyelitis was compared, using data from published reports from five centers.', 'subject score': 1000, 'object score': 802}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319037,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005246",
-          "name": "osteomyelitis",
-          "description": "An acute or chronic infectious process affecting the bones.; Osteomyelitis is an inflammatory process accompanied by bone destruction and caused by an infecting microorganism. [HPO:probinson, PMID:15276398]; Like other parts of the body, bones can get infected. The infections are usually bacterial, but can also be fungal. They may spread to the bone from nearby skin or muscles, or from another part of the body through the bloodstream. People who are at risk for bone infections include those with diabetes, poor circulation, or recent injury to the bone. You may also be at risk if you are having hemodialysis.  Symptoms of bone infections include: Pain in the infected area Chills and fever Swelling, warmth, and redness  A blood test or imaging test such as an x-ray can tell if you have a bone infection. Treatment includes antibiotics and often surgery.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0008707",
-            "MEDDRA:10045927",
-            "MEDDRA:10031257",
-            "MEDDRA:10046086",
-            "SNOMEDCT:111253001",
-            "SNOMEDCT:40970001",
-            "UMLS:C2242472",
-            "MEDDRA:10031252",
-            "MEDDRA:10009091",
-            "HP:0002754",
-            "DOID:1019",
-            "UMLS:C0029443",
-            "NCIT:C26839",
-            "MESH:D010019",
-            "EFO:0003102",
-            "MEDDRA:10031259",
-            "MONDO:0005246",
-            "MEDDRA:10005977",
-            "MEDDRA:10031256",
-            "SNOMEDCT:60168000",
-            "MEDDRA:10061017",
-            "MEDDRA:10045936",
-            "MEDDRA:10009081",
-            "NCIT:C27577",
-            "ICD9:730.1",
-            "MEDDRA:10046076"
-          ],
-          "id": "MONDO:0005246",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteomyelitis",
-            "Chronic osteomyelitis",
-            "osteomyelitis",
-            "Bone Infection",
-            "Infection of bone"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://my.clevelandclinic.org/disorders/osteomyelitis/hic_osteomyelitis.aspx",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://en.wikipedia.org/wiki/osteomyelitis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000437.htm",
-            "http://www.mayoclinic.com/health/osteomyelitis/ds00759",
-            "PMID:15276398",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 559,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ceftizoxime",
-          "description": "A semisynthetic, broad-spectrum, beta-lactamase-resistant, third-generation cephalosporin with antibacterial activity. Ceftizoxime binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:004847",
-            "CHEBI:553473",
-            "INCHIKEY:NNULBSISHYWZJU-LLKWHZGFSA-N",
-            "GTOPDB:10785",
-            "KEGG.COMPOUND:C06890",
-            "RXNORM:2192",
-            "PUBCHEM.COMPOUND:6533629",
-            "CHEMBL.COMPOUND:CHEMBL528",
-            "KEGG.DRUG:D07658",
-            "NCIT:C61668",
-            "DRUGBANK:DB01332",
-            "DrugCentral:563",
-            "UMLS:C0007560",
-            "ATC:J01DD07",
-            "MESH:D015296",
-            "HMDB:HMDB0015427",
-            "UNII:C43C467DPE"
-          ],
-          "id": "PUBCHEM.COMPOUND:6533629",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ceftizoxime (INN)",
-            "Ceftizoxime",
-            "ceftisomin",
-            "CEFTIZOXIME",
-            "ceftizoxime"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20679504",
-            "PMID:20022146",
-            "PMID:15646539",
-            "PMID:17646416",
-            "PMID:18426954",
-            "PMID:2342058",
-            "PMID:19015345",
-            "PMID:22194678",
-            "PMID:18490507",
-            "PMID:18834112"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319037,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005246",
-              "name": "osteomyelitis",
-              "description": "An acute or chronic infectious process affecting the bones.; Osteomyelitis is an inflammatory process accompanied by bone destruction and caused by an infecting microorganism. [HPO:probinson, PMID:15276398]; Like other parts of the body, bones can get infected. The infections are usually bacterial, but can also be fungal. They may spread to the bone from nearby skin or muscles, or from another part of the body through the bloodstream. People who are at risk for bone infections include those with diabetes, poor circulation, or recent injury to the bone. You may also be at risk if you are having hemodialysis.  Symptoms of bone infections include: Pain in the infected area Chills and fever Swelling, warmth, and redness  A blood test or imaging test such as an x-ray can tell if you have a bone infection. Treatment includes antibiotics and often surgery.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0008707",
-                "MEDDRA:10045927",
-                "MEDDRA:10031257",
-                "MEDDRA:10046086",
-                "SNOMEDCT:111253001",
-                "SNOMEDCT:40970001",
-                "UMLS:C2242472",
-                "MEDDRA:10031252",
-                "MEDDRA:10009091",
-                "HP:0002754",
-                "DOID:1019",
-                "UMLS:C0029443",
-                "NCIT:C26839",
-                "MESH:D010019",
-                "EFO:0003102",
-                "MEDDRA:10031259",
-                "MONDO:0005246",
-                "MEDDRA:10005977",
-                "MEDDRA:10031256",
-                "SNOMEDCT:60168000",
-                "MEDDRA:10061017",
-                "MEDDRA:10045936",
-                "MEDDRA:10009081",
-                "NCIT:C27577",
-                "ICD9:730.1",
-                "MEDDRA:10046076"
-              ],
-              "id": "MONDO:0005246",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteomyelitis",
-                "Chronic osteomyelitis",
-                "osteomyelitis",
-                "Bone Infection",
-                "Infection of bone"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://my.clevelandclinic.org/disorders/osteomyelitis/hic_osteomyelitis.aspx",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://en.wikipedia.org/wiki/osteomyelitis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000437.htm",
-                "http://www.mayoclinic.com/health/osteomyelitis/ds00759",
-                "PMID:15276398",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25207844,
-            "start": 559,
-            "end": 319037,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3859212': {'publication date': '1985 Jun 07', 'sentence': 'Experience with imipenem/cilastatin and that reported for cefotaxime, ceftazidime, and ceftizoxime in the treatment of biopsy-proved osteomyelitis was compared, using data from published reports from five centers.', 'subject score': 1000, 'object score': 802}}",
-              "kg2_ids": [
-                "UMLS:C0007560---SEMMEDDB:treats---None---None---None---UMLS:C0029443---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6533629",
-              "id": "25661332",
-              "object": "MONDO:0005246",
-              "publications": [
-                "PMID:3859212"
-              ]
-            }
-          },
-          "end": {
-            "identity": 559,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ceftizoxime",
-              "description": "A semisynthetic, broad-spectrum, beta-lactamase-resistant, third-generation cephalosporin with antibacterial activity. Ceftizoxime binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:004847",
-                "CHEBI:553473",
-                "INCHIKEY:NNULBSISHYWZJU-LLKWHZGFSA-N",
-                "GTOPDB:10785",
-                "KEGG.COMPOUND:C06890",
-                "RXNORM:2192",
-                "PUBCHEM.COMPOUND:6533629",
-                "CHEMBL.COMPOUND:CHEMBL528",
-                "KEGG.DRUG:D07658",
-                "NCIT:C61668",
-                "DRUGBANK:DB01332",
-                "DrugCentral:563",
-                "UMLS:C0007560",
-                "ATC:J01DD07",
-                "MESH:D015296",
-                "HMDB:HMDB0015427",
-                "UNII:C43C467DPE"
-              ],
-              "id": "PUBCHEM.COMPOUND:6533629",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ceftizoxime (INN)",
-                "Ceftizoxime",
-                "ceftisomin",
-                "CEFTIZOXIME",
-                "ceftizoxime"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20679504",
-                "PMID:20022146",
-                "PMID:15646539",
-                "PMID:17646416",
-                "PMID:18426954",
-                "PMID:2342058",
-                "PMID:19015345",
-                "PMID:22194678",
-                "PMID:18490507",
-                "PMID:18834112"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:25010195': {'publication date': '2014 Sep', 'sentence': 'Experimental comparison of protective characteristics of enalapril and trimetazidine in diabetic nephropathy.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 524326,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005016",
-          "name": "diabetic kidney disease",
-          "description": "Progressive kidney disorder caused by vascular damage to the glomerular capillaries, in patients with diabetes mellitus. It is usually manifested with nephritic syndrome and glomerulosclerosis.; KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10061835",
-            "SNOMEDCT:127013003",
-            "MEDDRA:10012678",
-            "UMLS:C0011881",
-            "EFO:0000401",
-            "MONDO:0005016",
-            "MEDDRA:10012687",
-            "MESH:D003928",
-            "MEDDRA:10084917",
-            "NCIT:C84417",
-            "MEDDRA:10012638"
-          ],
-          "id": "MONDO:0005016",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Diabetic Nephropathy",
-            "Diabetic Nephropathies",
-            "diabetic nephropathy",
-            "diabetic kidney disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 560,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Trimetazidine",
-          "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NCIT:C76590",
-            "CHEBI:94789",
-            "PUBCHEM.COMPOUND:21109",
-            "UMLS:C0041037",
-            "UNII:N9A0A0R9S8",
-            "DRUGBANK:DB09069",
-            "KEGG.DRUG:D01606",
-            "CHEMBL.COMPOUND:CHEMBL203266",
-            "ATC:C01EB15",
-            "RXNORM:10826",
-            "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-            "PDQ:CDR0000793610",
-            "MESH:D014292",
-            "DrugCentral:2750"
-          ],
-          "id": "PUBCHEM.COMPOUND:21109",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Trimetazidine",
-            "TRIMETAZIDINE",
-            "trimetazidine",
-            "Trimetazidine hydrochloride (JP18)",
-            "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-            "trimetazidine dihydrochloride"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:10350001",
-            "PMID:8868005",
-            "PMID:21504156",
-            "PMID:16509570",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:4864732",
-            "PMID:16644218",
-            "PMID:4970482",
-            "PMID:10720420"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 524326,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005016",
-              "name": "diabetic kidney disease",
-              "description": "Progressive kidney disorder caused by vascular damage to the glomerular capillaries, in patients with diabetes mellitus. It is usually manifested with nephritic syndrome and glomerulosclerosis.; KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10061835",
-                "SNOMEDCT:127013003",
-                "MEDDRA:10012678",
-                "UMLS:C0011881",
-                "EFO:0000401",
-                "MONDO:0005016",
-                "MEDDRA:10012687",
-                "MESH:D003928",
-                "MEDDRA:10084917",
-                "NCIT:C84417",
-                "MEDDRA:10012638"
-              ],
-              "id": "MONDO:0005016",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Diabetic Nephropathy",
-                "Diabetic Nephropathies",
-                "diabetic nephropathy",
-                "diabetic kidney disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17392518,
-            "start": 560,
-            "end": 524326,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25010195': {'publication date': '2014 Sep', 'sentence': 'Experimental comparison of protective characteristics of enalapril and trimetazidine in diabetic nephropathy.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0041037---SEMMEDDB:associated_with---None---None---None---UMLS:C0011881---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:21109",
-              "id": "17748395",
-              "object": "MONDO:0005016",
-              "publications": [
-                "PMID:25010195"
-              ]
-            }
-          },
-          "end": {
-            "identity": 560,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-=======
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
->>>>>>> main
-            ],
-            "properties": {
-              "name": "Trimetazidine",
-              "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NCIT:C76590",
-                "CHEBI:94789",
-                "PUBCHEM.COMPOUND:21109",
-                "UMLS:C0041037",
-                "UNII:N9A0A0R9S8",
-                "DRUGBANK:DB09069",
-                "KEGG.DRUG:D01606",
-                "CHEMBL.COMPOUND:CHEMBL203266",
-                "ATC:C01EB15",
-                "RXNORM:10826",
-                "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-                "PDQ:CDR0000793610",
-                "MESH:D014292",
-                "DrugCentral:2750"
-              ],
-              "id": "PUBCHEM.COMPOUND:21109",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Trimetazidine",
-                "TRIMETAZIDINE",
-                "trimetazidine",
-                "Trimetazidine hydrochloride (JP18)",
-                "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-                "trimetazidine dihydrochloride"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:10350001",
-                "PMID:8868005",
-                "PMID:21504156",
-                "PMID:16509570",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:4864732",
-                "PMID:16644218",
-                "PMID:4970482",
-                "PMID:10720420"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:32848753': {'publication date': '2020', 'sentence': 'This study aimed to investigate the role of TMZ in diabetic nephropathy (DN) and its potential mechanisms.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 524326,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005016",
-          "name": "diabetic kidney disease",
-          "description": "Progressive kidney disorder caused by vascular damage to the glomerular capillaries, in patients with diabetes mellitus. It is usually manifested with nephritic syndrome and glomerulosclerosis.; KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10061835",
-            "SNOMEDCT:127013003",
-            "MEDDRA:10012678",
-            "UMLS:C0011881",
-            "EFO:0000401",
-            "MONDO:0005016",
-            "MEDDRA:10012687",
-            "MESH:D003928",
-            "MEDDRA:10084917",
-            "NCIT:C84417",
-            "MEDDRA:10012638"
-          ],
-          "id": "MONDO:0005016",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Diabetic Nephropathy",
-            "Diabetic Nephropathies",
-            "diabetic nephropathy",
-            "diabetic kidney disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 560,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Trimetazidine",
-          "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NCIT:C76590",
-            "CHEBI:94789",
-            "PUBCHEM.COMPOUND:21109",
-            "UMLS:C0041037",
-            "UNII:N9A0A0R9S8",
-            "DRUGBANK:DB09069",
-            "KEGG.DRUG:D01606",
-            "CHEMBL.COMPOUND:CHEMBL203266",
-            "ATC:C01EB15",
-            "RXNORM:10826",
-            "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-            "PDQ:CDR0000793610",
-            "MESH:D014292",
-            "DrugCentral:2750"
-          ],
-          "id": "PUBCHEM.COMPOUND:21109",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Trimetazidine",
-            "TRIMETAZIDINE",
-            "trimetazidine",
-            "Trimetazidine hydrochloride (JP18)",
-            "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-            "trimetazidine dihydrochloride"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:10350001",
-            "PMID:8868005",
-            "PMID:21504156",
-            "PMID:16509570",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:4864732",
-            "PMID:16644218",
-            "PMID:4970482",
-            "PMID:10720420"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 524326,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005016",
-              "name": "diabetic kidney disease",
-              "description": "Progressive kidney disorder caused by vascular damage to the glomerular capillaries, in patients with diabetes mellitus. It is usually manifested with nephritic syndrome and glomerulosclerosis.; KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10061835",
-                "SNOMEDCT:127013003",
-                "MEDDRA:10012678",
-                "UMLS:C0011881",
-                "EFO:0000401",
-                "MONDO:0005016",
-                "MEDDRA:10012687",
-                "MESH:D003928",
-                "MEDDRA:10084917",
-                "NCIT:C84417",
-                "MEDDRA:10012638"
-              ],
-              "id": "MONDO:0005016",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Diabetic Nephropathy",
-                "Diabetic Nephropathies",
-                "diabetic nephropathy",
-                "diabetic kidney disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22003338,
-            "start": 560,
-            "end": 524326,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32848753': {'publication date': '2020', 'sentence': 'This study aimed to investigate the role of TMZ in diabetic nephropathy (DN) and its potential mechanisms.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0041037---SEMMEDDB:affects---None---None---None---UMLS:C0011881---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:21109",
-              "id": "22426756",
-              "object": "MONDO:0005016",
-              "publications": [
-                "PMID:32848753"
-              ]
-            }
-          },
-          "end": {
-            "identity": 560,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Trimetazidine",
-              "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NCIT:C76590",
-                "CHEBI:94789",
-                "PUBCHEM.COMPOUND:21109",
-                "UMLS:C0041037",
-                "UNII:N9A0A0R9S8",
-                "DRUGBANK:DB09069",
-                "KEGG.DRUG:D01606",
-                "CHEMBL.COMPOUND:CHEMBL203266",
-                "ATC:C01EB15",
-                "RXNORM:10826",
-                "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-                "PDQ:CDR0000793610",
-                "MESH:D014292",
-                "DrugCentral:2750"
-              ],
-              "id": "PUBCHEM.COMPOUND:21109",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Trimetazidine",
-                "TRIMETAZIDINE",
-                "trimetazidine",
-                "Trimetazidine hydrochloride (JP18)",
-                "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-                "trimetazidine dihydrochloride"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:10350001",
-                "PMID:8868005",
-                "PMID:21504156",
-                "PMID:16509570",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:4864732",
-                "PMID:16644218",
-                "PMID:4970482",
-                "PMID:10720420"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:34774496': {'publication date': '2021 Nov 10', 'sentence': 'In DIN and diabetic kidney diseases,TMZ treatment prevents renal injury by inactivating immune cells, attenuating renal fibrosis, inflammation, apoptosis, and histological abnormalities.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 524326,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005016",
-          "name": "diabetic kidney disease",
-          "description": "Progressive kidney disorder caused by vascular damage to the glomerular capillaries, in patients with diabetes mellitus. It is usually manifested with nephritic syndrome and glomerulosclerosis.; KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10061835",
-            "SNOMEDCT:127013003",
-            "MEDDRA:10012678",
-            "UMLS:C0011881",
-            "EFO:0000401",
-            "MONDO:0005016",
-            "MEDDRA:10012687",
-            "MESH:D003928",
-            "MEDDRA:10084917",
-            "NCIT:C84417",
-            "MEDDRA:10012638"
-          ],
-          "id": "MONDO:0005016",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Diabetic Nephropathy",
-            "Diabetic Nephropathies",
-            "diabetic nephropathy",
-            "diabetic kidney disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 560,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Trimetazidine",
-          "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NCIT:C76590",
-            "CHEBI:94789",
-            "PUBCHEM.COMPOUND:21109",
-            "UMLS:C0041037",
-            "UNII:N9A0A0R9S8",
-            "DRUGBANK:DB09069",
-            "KEGG.DRUG:D01606",
-            "CHEMBL.COMPOUND:CHEMBL203266",
-            "ATC:C01EB15",
-            "RXNORM:10826",
-            "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-            "PDQ:CDR0000793610",
-            "MESH:D014292",
-            "DrugCentral:2750"
-          ],
-          "id": "PUBCHEM.COMPOUND:21109",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Trimetazidine",
-            "TRIMETAZIDINE",
-            "trimetazidine",
-            "Trimetazidine hydrochloride (JP18)",
-            "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-            "trimetazidine dihydrochloride"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:10350001",
-            "PMID:8868005",
-            "PMID:21504156",
-            "PMID:16509570",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:4864732",
-            "PMID:16644218",
-            "PMID:4970482",
-            "PMID:10720420"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 524326,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005016",
-              "name": "diabetic kidney disease",
-              "description": "Progressive kidney disorder caused by vascular damage to the glomerular capillaries, in patients with diabetes mellitus. It is usually manifested with nephritic syndrome and glomerulosclerosis.; KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10061835",
-                "SNOMEDCT:127013003",
-                "MEDDRA:10012678",
-                "UMLS:C0011881",
-                "EFO:0000401",
-                "MONDO:0005016",
-                "MEDDRA:10012687",
-                "MESH:D003928",
-                "MEDDRA:10084917",
-                "NCIT:C84417",
-                "MEDDRA:10012638"
-              ],
-              "id": "MONDO:0005016",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Diabetic Nephropathy",
-                "Diabetic Nephropathies",
-                "diabetic nephropathy",
-                "diabetic kidney disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23474930,
-            "start": 560,
-            "end": 524326,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34774496': {'publication date': '2021 Nov 10', 'sentence': 'In DIN and diabetic kidney diseases,TMZ treatment prevents renal injury by inactivating immune cells, attenuating renal fibrosis, inflammation, apoptosis, and histological abnormalities.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0041037---SEMMEDDB:treats---None---None---None---UMLS:C0011881---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:21109",
-              "id": "23911647",
-              "object": "MONDO:0005016",
-              "publications": [
-                "PMID:34774496"
-              ]
-            }
-          },
-          "end": {
-            "identity": 560,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Trimetazidine",
-              "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NCIT:C76590",
-                "CHEBI:94789",
-                "PUBCHEM.COMPOUND:21109",
-                "UMLS:C0041037",
-                "UNII:N9A0A0R9S8",
-                "DRUGBANK:DB09069",
-                "KEGG.DRUG:D01606",
-                "CHEMBL.COMPOUND:CHEMBL203266",
-                "ATC:C01EB15",
-                "RXNORM:10826",
-                "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-                "PDQ:CDR0000793610",
-                "MESH:D014292",
-                "DrugCentral:2750"
-              ],
-              "id": "PUBCHEM.COMPOUND:21109",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Trimetazidine",
-                "TRIMETAZIDINE",
-                "trimetazidine",
-                "Trimetazidine hydrochloride (JP18)",
-                "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-                "trimetazidine dihydrochloride"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:10350001",
-                "PMID:8868005",
-                "PMID:21504156",
-                "PMID:16509570",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:4864732",
-                "PMID:16644218",
-                "PMID:4970482",
-                "PMID:10720420"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:31545912': {'publication date': '2019 Dec', 'sentence': 'Objective: This study investigates the effect of TMZ in sunitinib-induced cardiotoxicity in vivo and in vitro and molecular mechanisms.', 'subject score': 1000, 'object score': 790}, 'PMID:37115449': {'publication date': '2023 Apr 28', 'sentence': '* The combination of beta-Sitosterol and trimetazidine was the best in modulating different pathways involved in PD cardiotoxicity in rats via the interplay between NF-kappaB/AMPK/mTOR/TLR4 and HO-1/NADPH signaling pathways.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 673408,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C0876994",
-          "name": "Cardiotoxicity",
-          "description": "Toxicity that impairs or damages the heart. This condition is often caused by the administration of a pharmaceutical agent that initiates a poisonous or toxic response in cardiac tissue.; Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.",
-          "equivalent_curies": [
-            "MEDDRA:10048610",
-            "UMLS:C0876994",
-            "MESH:D066126",
-            "NCIT:C27994",
-            "SNOMEDCT:863954001",
-            "EFO:1001482"
-          ],
-          "id": "UMLS:C0876994",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiotoxicity",
-            "cardiotoxicity"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 560,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Trimetazidine",
-          "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NCIT:C76590",
-            "CHEBI:94789",
-            "PUBCHEM.COMPOUND:21109",
-            "UMLS:C0041037",
-            "UNII:N9A0A0R9S8",
-            "DRUGBANK:DB09069",
-            "KEGG.DRUG:D01606",
-            "CHEMBL.COMPOUND:CHEMBL203266",
-            "ATC:C01EB15",
-            "RXNORM:10826",
-            "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-            "PDQ:CDR0000793610",
-            "MESH:D014292",
-            "DrugCentral:2750"
-          ],
-          "id": "PUBCHEM.COMPOUND:21109",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Trimetazidine",
-            "TRIMETAZIDINE",
-            "trimetazidine",
-            "Trimetazidine hydrochloride (JP18)",
-            "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-            "trimetazidine dihydrochloride"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:10350001",
-            "PMID:8868005",
-            "PMID:21504156",
-            "PMID:16509570",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:4864732",
-            "PMID:16644218",
-            "PMID:4970482",
-            "PMID:10720420"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 673408,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C0876994",
-              "name": "Cardiotoxicity",
-              "description": "Toxicity that impairs or damages the heart. This condition is often caused by the administration of a pharmaceutical agent that initiates a poisonous or toxic response in cardiac tissue.; Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.",
-              "equivalent_curies": [
-                "MEDDRA:10048610",
-                "UMLS:C0876994",
-                "MESH:D066126",
-                "NCIT:C27994",
-                "SNOMEDCT:863954001",
-                "EFO:1001482"
-              ],
-              "id": "UMLS:C0876994",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiotoxicity",
-                "cardiotoxicity"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20886874,
-            "start": 560,
-            "end": 673408,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31545912': {'publication date': '2019 Dec', 'sentence': 'Objective: This study investigates the effect of TMZ in sunitinib-induced cardiotoxicity in vivo and in vitro and molecular mechanisms.', 'subject score': 1000, 'object score': 790}, 'PMID:37115449': {'publication date': '2023 Apr 28', 'sentence': '* The combination of beta-Sitosterol and trimetazidine was the best in modulating different pathways involved in PD cardiotoxicity in rats via the interplay between NF-kappaB/AMPK/mTOR/TLR4 and HO-1/NADPH signaling pathways.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0041037---SEMMEDDB:affects---None---None---None---UMLS:C0876994---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:21109",
-              "id": "21297588",
-              "object": "UMLS:C0876994",
-              "publications": [
-                "PMID:31545912",
-                "PMID:37115449"
-              ]
-            }
-          },
-          "end": {
-            "identity": 560,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Trimetazidine",
-              "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NCIT:C76590",
-                "CHEBI:94789",
-                "PUBCHEM.COMPOUND:21109",
-                "UMLS:C0041037",
-                "UNII:N9A0A0R9S8",
-                "DRUGBANK:DB09069",
-                "KEGG.DRUG:D01606",
-                "CHEMBL.COMPOUND:CHEMBL203266",
-                "ATC:C01EB15",
-                "RXNORM:10826",
-                "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-                "PDQ:CDR0000793610",
-                "MESH:D014292",
-                "DrugCentral:2750"
-              ],
-              "id": "PUBCHEM.COMPOUND:21109",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Trimetazidine",
-                "TRIMETAZIDINE",
-                "trimetazidine",
-                "Trimetazidine hydrochloride (JP18)",
-                "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-                "trimetazidine dihydrochloride"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:10350001",
-                "PMID:8868005",
-                "PMID:21504156",
-                "PMID:16509570",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:4864732",
-                "PMID:16644218",
-                "PMID:4970482",
-                "PMID:10720420"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:25022377': {'publication date': '2014', 'sentence': 'Concomitant administration of trimetazidine attenuates significantly the cardiotoxicity and hepatotoxity induced by doxorubicin.', 'subject score': 1000, 'object score': 1000}, 'PMID:31545912': {'publication date': '2019 Dec', 'sentence': 'Trimetazidine ameliorates sunitinib-induced cardiotoxicity in mice via the AMPK/mTOR/autophagy pathway.', 'subject score': 1000, 'object score': 790}, 'PMID:37115449': {'publication date': '2023 Apr 28', 'sentence': 'Combined beta-sitosterol and trimetazidine mitigate potassium dichromate-induced cardiotoxicity in rats through the interplay between NF-kappaB/AMPK/mTOR/TLR4 and HO-1/NADPH signaling pathways.', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 673408,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C0876994",
-          "name": "Cardiotoxicity",
-          "description": "Toxicity that impairs or damages the heart. This condition is often caused by the administration of a pharmaceutical agent that initiates a poisonous or toxic response in cardiac tissue.; Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.",
-          "equivalent_curies": [
-            "MEDDRA:10048610",
-            "UMLS:C0876994",
-            "MESH:D066126",
-            "NCIT:C27994",
-            "SNOMEDCT:863954001",
-            "EFO:1001482"
-          ],
-          "id": "UMLS:C0876994",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiotoxicity",
-            "cardiotoxicity"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 560,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Trimetazidine",
-          "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NCIT:C76590",
-            "CHEBI:94789",
-            "PUBCHEM.COMPOUND:21109",
-            "UMLS:C0041037",
-            "UNII:N9A0A0R9S8",
-            "DRUGBANK:DB09069",
-            "KEGG.DRUG:D01606",
-            "CHEMBL.COMPOUND:CHEMBL203266",
-            "ATC:C01EB15",
-            "RXNORM:10826",
-            "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-            "PDQ:CDR0000793610",
-            "MESH:D014292",
-            "DrugCentral:2750"
-          ],
-          "id": "PUBCHEM.COMPOUND:21109",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Trimetazidine",
-            "TRIMETAZIDINE",
-            "trimetazidine",
-            "Trimetazidine hydrochloride (JP18)",
-            "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-            "trimetazidine dihydrochloride"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:10350001",
-            "PMID:8868005",
-            "PMID:21504156",
-            "PMID:16509570",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:4864732",
-            "PMID:16644218",
-            "PMID:4970482",
-            "PMID:10720420"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 673408,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C0876994",
-              "name": "Cardiotoxicity",
-              "description": "Toxicity that impairs or damages the heart. This condition is often caused by the administration of a pharmaceutical agent that initiates a poisonous or toxic response in cardiac tissue.; Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.",
-              "equivalent_curies": [
-                "MEDDRA:10048610",
-                "UMLS:C0876994",
-                "MESH:D066126",
-                "NCIT:C27994",
-                "SNOMEDCT:863954001",
-                "EFO:1001482"
-              ],
-              "id": "UMLS:C0876994",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiotoxicity",
-                "cardiotoxicity"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17399192,
-            "start": 560,
-            "end": 673408,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25022377': {'publication date': '2014', 'sentence': 'Concomitant administration of trimetazidine attenuates significantly the cardiotoxicity and hepatotoxity induced by doxorubicin.', 'subject score': 1000, 'object score': 1000}, 'PMID:31545912': {'publication date': '2019 Dec', 'sentence': 'Trimetazidine ameliorates sunitinib-induced cardiotoxicity in mice via the AMPK/mTOR/autophagy pathway.', 'subject score': 1000, 'object score': 790}, 'PMID:37115449': {'publication date': '2023 Apr 28', 'sentence': 'Combined beta-sitosterol and trimetazidine mitigate potassium dichromate-induced cardiotoxicity in rats through the interplay between NF-kappaB/AMPK/mTOR/TLR4 and HO-1/NADPH signaling pathways.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0041037---SEMMEDDB:treats---None---None---None---UMLS:C0876994---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:21109",
-              "id": "17755056",
-              "object": "UMLS:C0876994",
-              "publications": [
-                "PMID:25022377",
-                "PMID:31545912",
-                "PMID:37115449"
-              ]
-            }
-          },
-          "end": {
-            "identity": 560,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Trimetazidine",
-              "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NCIT:C76590",
-                "CHEBI:94789",
-                "PUBCHEM.COMPOUND:21109",
-                "UMLS:C0041037",
-                "UNII:N9A0A0R9S8",
-                "DRUGBANK:DB09069",
-                "KEGG.DRUG:D01606",
-                "CHEMBL.COMPOUND:CHEMBL203266",
-                "ATC:C01EB15",
-                "RXNORM:10826",
-                "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-                "PDQ:CDR0000793610",
-                "MESH:D014292",
-                "DrugCentral:2750"
-              ],
-              "id": "PUBCHEM.COMPOUND:21109",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Trimetazidine",
-                "TRIMETAZIDINE",
-                "trimetazidine",
-                "Trimetazidine hydrochloride (JP18)",
-                "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-                "trimetazidine dihydrochloride"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:10350001",
-                "PMID:8868005",
-                "PMID:21504156",
-                "PMID:16509570",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:4864732",
-                "PMID:16644218",
-                "PMID:4970482",
-                "PMID:10720420"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:2636823': {'publication date': '1989', 'sentence': 'Trimetazidine, 2.5 mg/kg/day i.p. for 3 days before doxorubicin administration plus 2.5 mg/kg/day p.o. for 10 weeks, was unable to prevent the development of doxorubicin-induced long-term cardiotoxicity.', 'subject score': 1000, 'object score': 840}, 'PMID:37115449': {'publication date': '2023 Apr 28', 'sentence': 'The combination of BSS and TMZ protects against PD cardiotoxicity in rats by reducing oxidative stress and apoptotic and inflammatory biomarkers.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 673408,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C0876994",
-          "name": "Cardiotoxicity",
-          "description": "Toxicity that impairs or damages the heart. This condition is often caused by the administration of a pharmaceutical agent that initiates a poisonous or toxic response in cardiac tissue.; Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.",
-          "equivalent_curies": [
-            "MEDDRA:10048610",
-            "UMLS:C0876994",
-            "MESH:D066126",
-            "NCIT:C27994",
-            "SNOMEDCT:863954001",
-            "EFO:1001482"
-          ],
-          "id": "UMLS:C0876994",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiotoxicity",
-            "cardiotoxicity"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 560,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Trimetazidine",
-          "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NCIT:C76590",
-            "CHEBI:94789",
-            "PUBCHEM.COMPOUND:21109",
-            "UMLS:C0041037",
-            "UNII:N9A0A0R9S8",
-            "DRUGBANK:DB09069",
-            "KEGG.DRUG:D01606",
-            "CHEMBL.COMPOUND:CHEMBL203266",
-            "ATC:C01EB15",
-            "RXNORM:10826",
-            "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-            "PDQ:CDR0000793610",
-            "MESH:D014292",
-            "DrugCentral:2750"
-          ],
-          "id": "PUBCHEM.COMPOUND:21109",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Trimetazidine",
-            "TRIMETAZIDINE",
-            "trimetazidine",
-            "Trimetazidine hydrochloride (JP18)",
-            "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-            "trimetazidine dihydrochloride"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:10350001",
-            "PMID:8868005",
-            "PMID:21504156",
-            "PMID:16509570",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:4864732",
-            "PMID:16644218",
-            "PMID:4970482",
-            "PMID:10720420"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 673408,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C0876994",
-              "name": "Cardiotoxicity",
-              "description": "Toxicity that impairs or damages the heart. This condition is often caused by the administration of a pharmaceutical agent that initiates a poisonous or toxic response in cardiac tissue.; Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.",
-              "equivalent_curies": [
-                "MEDDRA:10048610",
-                "UMLS:C0876994",
-                "MESH:D066126",
-                "NCIT:C27994",
-                "SNOMEDCT:863954001",
-                "EFO:1001482"
-              ],
-              "id": "UMLS:C0876994",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiotoxicity",
-                "cardiotoxicity"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18179633,
-            "start": 560,
-            "end": 673408,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2636823': {'publication date': '1989', 'sentence': 'Trimetazidine, 2.5 mg/kg/day i.p. for 3 days before doxorubicin administration plus 2.5 mg/kg/day p.o. for 10 weeks, was unable to prevent the development of doxorubicin-induced long-term cardiotoxicity.', 'subject score': 1000, 'object score': 840}, 'PMID:37115449': {'publication date': '2023 Apr 28', 'sentence': 'The combination of BSS and TMZ protects against PD cardiotoxicity in rats by reducing oxidative stress and apoptotic and inflammatory biomarkers.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0041037---SEMMEDDB:prevents---None---None---None---UMLS:C0876994---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:21109",
-              "id": "18547788",
-              "object": "UMLS:C0876994",
-              "publications": [
-                "PMID:2636823",
-                "PMID:37115449"
-              ]
-            }
-          },
-          "end": {
-            "identity": 560,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Trimetazidine",
-              "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NCIT:C76590",
-                "CHEBI:94789",
-                "PUBCHEM.COMPOUND:21109",
-                "UMLS:C0041037",
-                "UNII:N9A0A0R9S8",
-                "DRUGBANK:DB09069",
-                "KEGG.DRUG:D01606",
-                "CHEMBL.COMPOUND:CHEMBL203266",
-                "ATC:C01EB15",
-                "RXNORM:10826",
-                "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-                "PDQ:CDR0000793610",
-                "MESH:D014292",
-                "DrugCentral:2750"
-              ],
-              "id": "PUBCHEM.COMPOUND:21109",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Trimetazidine",
-                "TRIMETAZIDINE",
-                "trimetazidine",
-                "Trimetazidine hydrochloride (JP18)",
-                "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-                "trimetazidine dihydrochloride"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:10350001",
-                "PMID:8868005",
-                "PMID:21504156",
-                "PMID:16509570",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:4864732",
-                "PMID:16644218",
-                "PMID:4970482",
-                "PMID:10720420"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:27533944': {'publication date': '2016 10', 'sentence': 'The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 308937,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-          "name": "cardiovascular disorder",
-          "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "MEDDRA:10045663",
-            "MONDO:0004995",
-            "ICD9:429.2",
-            "MEDDRA:10007649",
-            "UMLS:C0243050",
-            "HP:0001626",
-            "MESH:D018376",
-            "MEDDRA:10007648",
-            "MEDDRA:10013205",
-            "SNOMEDCT:49601007",
-            "MEDDRA:10007650",
-            "MESH:D002318",
-            "DOID:1287",
-            "UMLS:C0007222",
-            "UMLS:C0728936",
-            "NCIT:C2931"
-          ],
-          "id": "MONDO:0004995",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiovascular Diseases",
-            "Cardiovascular disease, unspecified",
-            "Abnormality of the cardiovascular system",
-            "cardiovascular system disease",
-            "Disorder of circulatory system",
-            "Cardiovascular Disorder",
-            "cardiovascular disorder",
-            "Cardiovascular Abnormalities"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/circulatory_system",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 560,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Trimetazidine",
-          "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NCIT:C76590",
-            "CHEBI:94789",
-            "PUBCHEM.COMPOUND:21109",
-            "UMLS:C0041037",
-            "UNII:N9A0A0R9S8",
-            "DRUGBANK:DB09069",
-            "KEGG.DRUG:D01606",
-            "CHEMBL.COMPOUND:CHEMBL203266",
-            "ATC:C01EB15",
-            "RXNORM:10826",
-            "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-            "PDQ:CDR0000793610",
-            "MESH:D014292",
-            "DrugCentral:2750"
-          ],
-          "id": "PUBCHEM.COMPOUND:21109",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Trimetazidine",
-            "TRIMETAZIDINE",
-            "trimetazidine",
-            "Trimetazidine hydrochloride (JP18)",
-            "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-            "trimetazidine dihydrochloride"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:10350001",
-            "PMID:8868005",
-            "PMID:21504156",
-            "PMID:16509570",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:4864732",
-            "PMID:16644218",
-            "PMID:4970482",
-            "PMID:10720420"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308937,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-              "name": "cardiovascular disorder",
-              "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "MEDDRA:10045663",
-                "MONDO:0004995",
-                "ICD9:429.2",
-                "MEDDRA:10007649",
-                "UMLS:C0243050",
-                "HP:0001626",
-                "MESH:D018376",
-                "MEDDRA:10007648",
-                "MEDDRA:10013205",
-                "SNOMEDCT:49601007",
-                "MEDDRA:10007650",
-                "MESH:D002318",
-                "DOID:1287",
-                "UMLS:C0007222",
-                "UMLS:C0728936",
-                "NCIT:C2931"
-              ],
-              "id": "MONDO:0004995",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiovascular Diseases",
-                "Cardiovascular disease, unspecified",
-                "Abnormality of the cardiovascular system",
-                "cardiovascular system disease",
-                "Disorder of circulatory system",
-                "Cardiovascular Disorder",
-                "cardiovascular disorder",
-                "Cardiovascular Abnormalities"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/circulatory_system",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18778903,
-            "start": 560,
-            "end": 308937,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27533944': {'publication date': '2016 10', 'sentence': 'The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0041037---SEMMEDDB:affects---None---None---None---UMLS:C0007222---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:21109",
-              "id": "19164679",
-              "object": "MONDO:0004995",
-              "publications": [
-                "PMID:27533944"
-              ]
-            }
-          },
-          "end": {
-            "identity": 560,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Trimetazidine",
-              "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NCIT:C76590",
-                "CHEBI:94789",
-                "PUBCHEM.COMPOUND:21109",
-                "UMLS:C0041037",
-                "UNII:N9A0A0R9S8",
-                "DRUGBANK:DB09069",
-                "KEGG.DRUG:D01606",
-                "CHEMBL.COMPOUND:CHEMBL203266",
-                "ATC:C01EB15",
-                "RXNORM:10826",
-                "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-                "PDQ:CDR0000793610",
-                "MESH:D014292",
-                "DrugCentral:2750"
-              ],
-              "id": "PUBCHEM.COMPOUND:21109",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Trimetazidine",
-                "TRIMETAZIDINE",
-                "trimetazidine",
-                "Trimetazidine hydrochloride (JP18)",
-                "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-                "trimetazidine dihydrochloride"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:10350001",
-                "PMID:8868005",
-                "PMID:21504156",
-                "PMID:16509570",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:4864732",
-                "PMID:16644218",
-                "PMID:4970482",
-                "PMID:10720420"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 524326,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005016",
-          "name": "diabetic kidney disease",
-          "description": "Progressive kidney disorder caused by vascular damage to the glomerular capillaries, in patients with diabetes mellitus. It is usually manifested with nephritic syndrome and glomerulosclerosis.; KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10061835",
-            "SNOMEDCT:127013003",
-            "MEDDRA:10012678",
-            "UMLS:C0011881",
-            "EFO:0000401",
-            "MONDO:0005016",
-            "MEDDRA:10012687",
-            "MESH:D003928",
-            "MEDDRA:10084917",
-            "NCIT:C84417",
-            "MEDDRA:10012638"
-          ],
-          "id": "MONDO:0005016",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Diabetic Nephropathy",
-            "Diabetic Nephropathies",
-            "diabetic nephropathy",
-            "diabetic kidney disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 560,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Trimetazidine",
-          "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NCIT:C76590",
-            "CHEBI:94789",
-            "PUBCHEM.COMPOUND:21109",
-            "UMLS:C0041037",
-            "UNII:N9A0A0R9S8",
-            "DRUGBANK:DB09069",
-            "KEGG.DRUG:D01606",
-            "CHEMBL.COMPOUND:CHEMBL203266",
-            "ATC:C01EB15",
-            "RXNORM:10826",
-            "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-            "PDQ:CDR0000793610",
-            "MESH:D014292",
-            "DrugCentral:2750"
-          ],
-          "id": "PUBCHEM.COMPOUND:21109",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Trimetazidine",
-            "TRIMETAZIDINE",
-            "trimetazidine",
-            "Trimetazidine hydrochloride (JP18)",
-            "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-            "trimetazidine dihydrochloride"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:10350001",
-            "PMID:8868005",
-            "PMID:21504156",
-            "PMID:16509570",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:4864732",
-            "PMID:16644218",
-            "PMID:4970482",
-            "PMID:10720420"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 524326,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005016",
-              "name": "diabetic kidney disease",
-              "description": "Progressive kidney disorder caused by vascular damage to the glomerular capillaries, in patients with diabetes mellitus. It is usually manifested with nephritic syndrome and glomerulosclerosis.; KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10061835",
-                "SNOMEDCT:127013003",
-                "MEDDRA:10012678",
-                "UMLS:C0011881",
-                "EFO:0000401",
-                "MONDO:0005016",
-                "MEDDRA:10012687",
-                "MESH:D003928",
-                "MEDDRA:10084917",
-                "NCIT:C84417",
-                "MEDDRA:10012638"
-              ],
-              "id": "MONDO:0005016",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Diabetic Nephropathy",
-                "Diabetic Nephropathies",
-                "diabetic nephropathy",
-                "diabetic kidney disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23474930,
-            "start": 560,
-            "end": 524326,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34774496': {'publication date': '2021 Nov 10', 'sentence': 'In DIN and diabetic kidney diseases,TMZ treatment prevents renal injury by inactivating immune cells, attenuating renal fibrosis, inflammation, apoptosis, and histological abnormalities.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0041037---SEMMEDDB:treats---None---None---None---UMLS:C0011881---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:21109",
-              "id": "23911647",
-              "object": "MONDO:0005016",
-              "publications": [
-                "PMID:34774496"
-              ]
-            }
-          },
-          "end": {
-            "identity": 560,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Trimetazidine",
-              "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NCIT:C76590",
-                "CHEBI:94789",
-                "PUBCHEM.COMPOUND:21109",
-                "UMLS:C0041037",
-                "UNII:N9A0A0R9S8",
-                "DRUGBANK:DB09069",
-                "KEGG.DRUG:D01606",
-                "CHEMBL.COMPOUND:CHEMBL203266",
-                "ATC:C01EB15",
-                "RXNORM:10826",
-                "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-                "PDQ:CDR0000793610",
-                "MESH:D014292",
-                "DrugCentral:2750"
-              ],
-              "id": "PUBCHEM.COMPOUND:21109",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Trimetazidine",
-                "TRIMETAZIDINE",
-                "trimetazidine",
-                "Trimetazidine hydrochloride (JP18)",
-                "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-                "trimetazidine dihydrochloride"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:10350001",
-                "PMID:8868005",
-                "PMID:21504156",
-                "PMID:16509570",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:4864732",
-                "PMID:16644218",
-                "PMID:4970482",
-                "PMID:10720420"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 673408,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C0876994",
-          "name": "Cardiotoxicity",
-          "description": "Toxicity that impairs or damages the heart. This condition is often caused by the administration of a pharmaceutical agent that initiates a poisonous or toxic response in cardiac tissue.; Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.",
-          "equivalent_curies": [
-            "MEDDRA:10048610",
-            "UMLS:C0876994",
-            "MESH:D066126",
-            "NCIT:C27994",
-            "SNOMEDCT:863954001",
-            "EFO:1001482"
-          ],
-          "id": "UMLS:C0876994",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiotoxicity",
-            "cardiotoxicity"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 560,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Trimetazidine",
-          "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NCIT:C76590",
-            "CHEBI:94789",
-            "PUBCHEM.COMPOUND:21109",
-            "UMLS:C0041037",
-            "UNII:N9A0A0R9S8",
-            "DRUGBANK:DB09069",
-            "KEGG.DRUG:D01606",
-            "CHEMBL.COMPOUND:CHEMBL203266",
-            "ATC:C01EB15",
-            "RXNORM:10826",
-            "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-            "PDQ:CDR0000793610",
-            "MESH:D014292",
-            "DrugCentral:2750"
-          ],
-          "id": "PUBCHEM.COMPOUND:21109",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Trimetazidine",
-            "TRIMETAZIDINE",
-            "trimetazidine",
-            "Trimetazidine hydrochloride (JP18)",
-            "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-            "trimetazidine dihydrochloride"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:10350001",
-            "PMID:8868005",
-            "PMID:21504156",
-            "PMID:16509570",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:4864732",
-            "PMID:16644218",
-            "PMID:4970482",
-            "PMID:10720420"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 673408,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C0876994",
-              "name": "Cardiotoxicity",
-              "description": "Toxicity that impairs or damages the heart. This condition is often caused by the administration of a pharmaceutical agent that initiates a poisonous or toxic response in cardiac tissue.; Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.",
-              "equivalent_curies": [
-                "MEDDRA:10048610",
-                "UMLS:C0876994",
-                "MESH:D066126",
-                "NCIT:C27994",
-                "SNOMEDCT:863954001",
-                "EFO:1001482"
-              ],
-              "id": "UMLS:C0876994",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiotoxicity",
-                "cardiotoxicity"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17399192,
-            "start": 560,
-            "end": 673408,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25022377': {'publication date': '2014', 'sentence': 'Concomitant administration of trimetazidine attenuates significantly the cardiotoxicity and hepatotoxity induced by doxorubicin.', 'subject score': 1000, 'object score': 1000}, 'PMID:31545912': {'publication date': '2019 Dec', 'sentence': 'Trimetazidine ameliorates sunitinib-induced cardiotoxicity in mice via the AMPK/mTOR/autophagy pathway.', 'subject score': 1000, 'object score': 790}, 'PMID:37115449': {'publication date': '2023 Apr 28', 'sentence': 'Combined beta-sitosterol and trimetazidine mitigate potassium dichromate-induced cardiotoxicity in rats through the interplay between NF-kappaB/AMPK/mTOR/TLR4 and HO-1/NADPH signaling pathways.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0041037---SEMMEDDB:treats---None---None---None---UMLS:C0876994---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:21109",
-              "id": "17755056",
-              "object": "UMLS:C0876994",
-              "publications": [
-                "PMID:25022377",
-                "PMID:31545912",
-                "PMID:37115449"
-              ]
-            }
-          },
-          "end": {
-            "identity": 560,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Trimetazidine",
-              "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NCIT:C76590",
-                "CHEBI:94789",
-                "PUBCHEM.COMPOUND:21109",
-                "UMLS:C0041037",
-                "UNII:N9A0A0R9S8",
-                "DRUGBANK:DB09069",
-                "KEGG.DRUG:D01606",
-                "CHEMBL.COMPOUND:CHEMBL203266",
-                "ATC:C01EB15",
-                "RXNORM:10826",
-                "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-                "PDQ:CDR0000793610",
-                "MESH:D014292",
-                "DrugCentral:2750"
-              ],
-              "id": "PUBCHEM.COMPOUND:21109",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Trimetazidine",
-                "TRIMETAZIDINE",
-                "trimetazidine",
-                "Trimetazidine hydrochloride (JP18)",
-                "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-                "trimetazidine dihydrochloride"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:10350001",
-                "PMID:8868005",
-                "PMID:21504156",
-                "PMID:16509570",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:4864732",
-                "PMID:16644218",
-                "PMID:4970482",
-                "PMID:10720420"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:24902800': {'publication date': '2014 Jun', 'sentence': 'Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:35713419': {'publication date': '2022 Jun 17', 'sentence': 'Trimetazidine exhibits great therapeutic potential in cardiovascular diseases and mitochondria-mediated cardioprotection by trimetazidine has been widely reported.', 'subject score': 1000, 'object score': 1000}, 'PMID:9737481': {'publication date': '1998 Sep 03', 'sentence': 'As a result, optimizing energy metabolism with agents such as trimetazidine may have considerable promise as a new approach to treating cardiovascular disease.', 'subject score': 1000, 'object score': 901}, 'PMID:9893703': {'publication date': '1998 Dec 12', 'sentence': 'Pharmacologically improving cardiac energy metabolism with drugs such as trimetazidine could be a new promising approach to the treatment of cardiovascular diseases.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 308937,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-          "name": "cardiovascular disorder",
-          "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "MEDDRA:10045663",
-            "MONDO:0004995",
-            "ICD9:429.2",
-            "MEDDRA:10007649",
-            "UMLS:C0243050",
-            "HP:0001626",
-            "MESH:D018376",
-            "MEDDRA:10007648",
-            "MEDDRA:10013205",
-            "SNOMEDCT:49601007",
-            "MEDDRA:10007650",
-            "MESH:D002318",
-            "DOID:1287",
-            "UMLS:C0007222",
-            "UMLS:C0728936",
-            "NCIT:C2931"
-          ],
-          "id": "MONDO:0004995",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiovascular Diseases",
-            "Cardiovascular disease, unspecified",
-            "Abnormality of the cardiovascular system",
-            "cardiovascular system disease",
-            "Disorder of circulatory system",
-            "Cardiovascular Disorder",
-            "cardiovascular disorder",
-            "Cardiovascular Abnormalities"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/circulatory_system",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 560,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Trimetazidine",
-          "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NCIT:C76590",
-            "CHEBI:94789",
-            "PUBCHEM.COMPOUND:21109",
-            "UMLS:C0041037",
-            "UNII:N9A0A0R9S8",
-            "DRUGBANK:DB09069",
-            "KEGG.DRUG:D01606",
-            "CHEMBL.COMPOUND:CHEMBL203266",
-            "ATC:C01EB15",
-            "RXNORM:10826",
-            "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-            "PDQ:CDR0000793610",
-            "MESH:D014292",
-            "DrugCentral:2750"
-          ],
-          "id": "PUBCHEM.COMPOUND:21109",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Trimetazidine",
-            "TRIMETAZIDINE",
-            "trimetazidine",
-            "Trimetazidine hydrochloride (JP18)",
-            "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-            "trimetazidine dihydrochloride"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:10350001",
-            "PMID:8868005",
-            "PMID:21504156",
-            "PMID:16509570",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:4864732",
-            "PMID:16644218",
-            "PMID:4970482",
-            "PMID:10720420"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308937,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-              "name": "cardiovascular disorder",
-              "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "MEDDRA:10045663",
-                "MONDO:0004995",
-                "ICD9:429.2",
-                "MEDDRA:10007649",
-                "UMLS:C0243050",
-                "HP:0001626",
-                "MESH:D018376",
-                "MEDDRA:10007648",
-                "MEDDRA:10013205",
-                "SNOMEDCT:49601007",
-                "MEDDRA:10007650",
-                "MESH:D002318",
-                "DOID:1287",
-                "UMLS:C0007222",
-                "UMLS:C0728936",
-                "NCIT:C2931"
-              ],
-              "id": "MONDO:0004995",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiovascular Diseases",
-                "Cardiovascular disease, unspecified",
-                "Abnormality of the cardiovascular system",
-                "cardiovascular system disease",
-                "Disorder of circulatory system",
-                "Cardiovascular Disorder",
-                "cardiovascular disorder",
-                "Cardiovascular Abnormalities"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/circulatory_system",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17327866,
-            "start": 560,
-            "end": 308937,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24902800': {'publication date': '2014 Jun', 'sentence': 'Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:35713419': {'publication date': '2022 Jun 17', 'sentence': 'Trimetazidine exhibits great therapeutic potential in cardiovascular diseases and mitochondria-mediated cardioprotection by trimetazidine has been widely reported.', 'subject score': 1000, 'object score': 1000}, 'PMID:9737481': {'publication date': '1998 Sep 03', 'sentence': 'As a result, optimizing energy metabolism with agents such as trimetazidine may have considerable promise as a new approach to treating cardiovascular disease.', 'subject score': 1000, 'object score': 901}, 'PMID:9893703': {'publication date': '1998 Dec 12', 'sentence': 'Pharmacologically improving cardiac energy metabolism with drugs such as trimetazidine could be a new promising approach to the treatment of cardiovascular diseases.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0041037---SEMMEDDB:treats---None---None---None---UMLS:C0007222---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:21109",
-              "id": "17682787",
-              "object": "MONDO:0004995",
-              "publications": [
-                "PMID:24902800",
-                "PMID:35713419",
-                "PMID:9737481",
-                "PMID:9893703"
-              ]
-            }
-          },
-          "end": {
-            "identity": 560,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Trimetazidine",
-              "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NCIT:C76590",
-                "CHEBI:94789",
-                "PUBCHEM.COMPOUND:21109",
-                "UMLS:C0041037",
-                "UNII:N9A0A0R9S8",
-                "DRUGBANK:DB09069",
-                "KEGG.DRUG:D01606",
-                "CHEMBL.COMPOUND:CHEMBL203266",
-                "ATC:C01EB15",
-                "RXNORM:10826",
-                "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-                "PDQ:CDR0000793610",
-                "MESH:D014292",
-                "DrugCentral:2750"
-              ],
-              "id": "PUBCHEM.COMPOUND:21109",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Trimetazidine",
-                "TRIMETAZIDINE",
-                "trimetazidine",
-                "Trimetazidine hydrochloride (JP18)",
-                "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-                "trimetazidine dihydrochloride"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:10350001",
-                "PMID:8868005",
-                "PMID:21504156",
-                "PMID:16509570",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:4864732",
-                "PMID:16644218",
-                "PMID:4970482",
-                "PMID:10720420"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 673408,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C0876994",
-          "name": "Cardiotoxicity",
-          "description": "Toxicity that impairs or damages the heart. This condition is often caused by the administration of a pharmaceutical agent that initiates a poisonous or toxic response in cardiac tissue.; Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.",
-          "equivalent_curies": [
-            "MEDDRA:10048610",
-            "UMLS:C0876994",
-            "MESH:D066126",
-            "NCIT:C27994",
-            "SNOMEDCT:863954001",
-            "EFO:1001482"
-          ],
-          "id": "UMLS:C0876994",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiotoxicity",
-            "cardiotoxicity"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 560,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Trimetazidine",
-          "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NCIT:C76590",
-            "CHEBI:94789",
-            "PUBCHEM.COMPOUND:21109",
-            "UMLS:C0041037",
-            "UNII:N9A0A0R9S8",
-            "DRUGBANK:DB09069",
-            "KEGG.DRUG:D01606",
-            "CHEMBL.COMPOUND:CHEMBL203266",
-            "ATC:C01EB15",
-            "RXNORM:10826",
-            "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-            "PDQ:CDR0000793610",
-            "MESH:D014292",
-            "DrugCentral:2750"
-          ],
-          "id": "PUBCHEM.COMPOUND:21109",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Trimetazidine",
-            "TRIMETAZIDINE",
-            "trimetazidine",
-            "Trimetazidine hydrochloride (JP18)",
-            "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-            "trimetazidine dihydrochloride"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:10350001",
-            "PMID:8868005",
-            "PMID:21504156",
-            "PMID:16509570",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:4864732",
-            "PMID:16644218",
-            "PMID:4970482",
-            "PMID:10720420"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 673408,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C0876994",
-              "name": "Cardiotoxicity",
-              "description": "Toxicity that impairs or damages the heart. This condition is often caused by the administration of a pharmaceutical agent that initiates a poisonous or toxic response in cardiac tissue.; Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.",
-              "equivalent_curies": [
-                "MEDDRA:10048610",
-                "UMLS:C0876994",
-                "MESH:D066126",
-                "NCIT:C27994",
-                "SNOMEDCT:863954001",
-                "EFO:1001482"
-              ],
-              "id": "UMLS:C0876994",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiotoxicity",
-                "cardiotoxicity"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18179633,
-            "start": 560,
-            "end": 673408,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2636823': {'publication date': '1989', 'sentence': 'Trimetazidine, 2.5 mg/kg/day i.p. for 3 days before doxorubicin administration plus 2.5 mg/kg/day p.o. for 10 weeks, was unable to prevent the development of doxorubicin-induced long-term cardiotoxicity.', 'subject score': 1000, 'object score': 840}, 'PMID:37115449': {'publication date': '2023 Apr 28', 'sentence': 'The combination of BSS and TMZ protects against PD cardiotoxicity in rats by reducing oxidative stress and apoptotic and inflammatory biomarkers.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0041037---SEMMEDDB:prevents---None---None---None---UMLS:C0876994---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:21109",
-              "id": "18547788",
-              "object": "UMLS:C0876994",
-              "publications": [
-                "PMID:2636823",
-                "PMID:37115449"
-              ]
-            }
-          },
-          "end": {
-            "identity": 560,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Trimetazidine",
-              "description": "An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76590\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76590\" NCI Thesaurus); An orally available small molecule compound with anti-ischemic, and potential immunomodulating and antineoplastic properties. Although its exact mechanism is not yet fully elucidated, it is postulated that upon administration, trimetazidine selectively inhibits long-chain 3-ketoacyl coenzyme A thiolase (LC 3-KAT), the final enzyme in the free fatty acid (FFA) beta-oxidation pathway. This stimulates glucose oxidation, which requires less oxygen usage and cellular energy than in the beta-oxidation process. This optimizes myocardial energy metabolism and cardiac functioning in an ischemic condition. In cancer cells, the inhibition of fatty acid oxidation (FAO) alters the metabolic processes needed for tumor cell function and proliferation, thereby inducing tumor cell apoptosis. In addition, inhibition of FAO may potentially block the immunosuppressive functions of myeloid-derived suppressor cells (MSDCs), which are thought to promote malignant cell proliferation and migration by inhibiting T-cell function.; A vasodilator used in angina of effort or ischemic heart disease.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NCIT:C76590",
-                "CHEBI:94789",
-                "PUBCHEM.COMPOUND:21109",
-                "UMLS:C0041037",
-                "UNII:N9A0A0R9S8",
-                "DRUGBANK:DB09069",
-                "KEGG.DRUG:D01606",
-                "CHEMBL.COMPOUND:CHEMBL203266",
-                "ATC:C01EB15",
-                "RXNORM:10826",
-                "INCHIKEY:UHWVSEOVJBQKBE-UHFFFAOYSA-N",
-                "PDQ:CDR0000793610",
-                "MESH:D014292",
-                "DrugCentral:2750"
-              ],
-              "id": "PUBCHEM.COMPOUND:21109",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Trimetazidine",
-                "TRIMETAZIDINE",
-                "trimetazidine",
-                "Trimetazidine hydrochloride (JP18)",
-                "1-[(2,3,4-trimethoxyphenyl)methyl]piperazine",
-                "trimetazidine dihydrochloride"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:10350001",
-                "PMID:8868005",
-                "PMID:21504156",
-                "PMID:16509570",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:4864732",
-                "PMID:16644218",
-                "PMID:4970482",
-                "PMID:10720420"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:2795862': {'publication date': '1989 Jun', 'sentence': '[Clinical experience with cefodizime in bacterial infection of children].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 538307,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-          ]
-        }
-      },
-      "end": {
-        "identity": 561,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefodizime",
-          "description": "A cephalosporin compound having 5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.",
-          "equivalent_curies": [
-            "MESH:C033356",
-            "HMDB:HMDB0041850",
-            "KEGG.DRUG:D07643",
-            "UMLS:C0055007",
-            "DrugCentral:541",
-            "NDDF:003947",
-            "NCIT:C98224",
-            "UNII:Z31298J4HQ",
-            "GTOPDB:12032",
-            "CHEMBL.COMPOUND:CHEMBL2303613",
-            "DRUGBANK:DB13470",
-            "INCHIKEY:XDZKBRJLTGRPSS-BGZQYGJUSA-N",
-            "RXNORM:20485",
-            "PUBCHEM.COMPOUND:5361871",
-            "ATC:J01DD09",
-            "CHEBI:63214"
-          ],
-          "id": "PUBCHEM.COMPOUND:5361871",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "cefodizime",
-            "Cefodizime (INN)",
-            "cefodizime disodium",
-            "Cefodizime",
-            "CEFODIZIME"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18426954",
-            "PMID:8510010",
-            "PMID:21112128",
-            "PMID:2795858",
-            "PMID:15646539",
-            "PMID:15567297",
-            "PMID:21741846",
-            "PMID:15920768",
-            "PMID:21425867",
-            "PMID:15974593"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538307,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18989175,
-            "start": 561,
-            "end": 538307,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2795862': {'publication date': '1989 Jun', 'sentence': '[Clinical experience with cefodizime in bacterial infection of children].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0055007---SEMMEDDB:treats---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5361871",
-              "id": "19370408",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:2795862"
-              ]
-            }
-          },
-          "end": {
-            "identity": 561,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-=======
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
->>>>>>> main
-            ],
-            "properties": {
-              "name": "Cefodizime",
-              "description": "A cephalosporin compound having 5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.",
-              "equivalent_curies": [
-                "MESH:C033356",
-                "HMDB:HMDB0041850",
-                "KEGG.DRUG:D07643",
-                "UMLS:C0055007",
-                "DrugCentral:541",
-                "NDDF:003947",
-                "NCIT:C98224",
-                "UNII:Z31298J4HQ",
-                "GTOPDB:12032",
-                "CHEMBL.COMPOUND:CHEMBL2303613",
-                "DRUGBANK:DB13470",
-                "INCHIKEY:XDZKBRJLTGRPSS-BGZQYGJUSA-N",
-                "RXNORM:20485",
-                "PUBCHEM.COMPOUND:5361871",
-                "ATC:J01DD09",
-                "CHEBI:63214"
-              ],
-              "id": "PUBCHEM.COMPOUND:5361871",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "cefodizime",
-                "Cefodizime (INN)",
-                "cefodizime disodium",
-                "Cefodizime",
-                "CEFODIZIME"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18426954",
-                "PMID:8510010",
-                "PMID:21112128",
-                "PMID:2795858",
-                "PMID:15646539",
-                "PMID:15567297",
-                "PMID:21741846",
-                "PMID:15920768",
-                "PMID:21425867",
-                "PMID:15974593"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12522004': {'publication date': '2003 May 01', 'sentence': 'These results suggest a new pathway involving AMPK in the control of apoptosis in B-CLL cells and raise the possibility of using acadesine in B-CLL treatment.', 'subject score': 1000, 'object score': 938}, 'PMID:18457469': {'publication date': '2008', 'sentence': 'Orphan drug status has been granted for acadesine in the EU for the treatment of B-cell chronic lymphocytic leukaemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:18671468': {'publication date': '2008 Aug', 'sentence': 'OBJECTIVE: This review aimed to summarise and critique available data on the mechanism of action and clinical utility of acadesine, with a focus on treatment of ischaemic reperfusion injury, B-cell chronic lymphocytic leukaemia and diabetes mellitus.', 'subject score': 1000, 'object score': 1000}, 'PMID:20367195': {'publication date': '2010 Apr', 'sentence': 'AREAS COVERED IN THIS REVIEW: The literature data show that apoptosis induced by AICA-riboside in CLL is not dependent on a functionally normal p53 pathway.', 'subject score': 1000, 'object score': 916}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 323598,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004948",
-          "name": "B-cell chronic lymphocytic leukemia",
-          "description": "The most common type of chronic lymphoid leukemia. It comprises 90% of chronic lymphoid leukemias in the United States. Morphologically, the neoplastic cells are small, round B-lymphocytes. This type of leukemia is not considered to be curable with available therapy. (WHO, 2001); A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.; A chronic lymphocytic/lymphatic/lymphoblastic leukemia (CLL) is a neoplastic disease characterized by proliferation and accumulation (blood, marrow and lymphoid organs) of morphologically mature but immunologically dysfunctional lymphocytes. A CLL is always a B-cell lymphocytic leukemia as there are no reports of cases of T-cell lymphocytic leukemias. [HPO:curators]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10051812",
-            "MEDDRA:10003908",
-            "MEDDRA:10068919",
-            "MEDDRA:10060576",
-            "MEDDRA:10068852",
-            "OMIM:151400",
-            "MEDDRA:10003909",
-            "MEDDRA:10008956",
-            "UMLS:C0855095",
-            "ICD9:204.1",
-            "MEDDRA:10060391",
-            "MEDDRA:10008976",
-            "NCIT:C7540",
-            "MEDDRA:10008957",
-            "HP:0005550",
-            "MONDO:0004948",
-            "UMLS:C0023434",
-            "MEDDRA:10024340",
-            "MEDDRA:10025306",
-            "PDQ:CDR0000038170",
-            "MEDDRA:10009310",
-            "SNOMEDCT:302841002",
-            "MEDDRA:10008960",
-            "ORPHANET:67038",
-            "SNOMEDCT:92814006",
-            "SNOMEDCT:277473004",
-            "MEDDRA:10008958",
-            "SNOMEDCT:64575004",
-            "MEDDRA:10003910",
-            "MEDDRA:10024295",
-            "ICD10:C91.10",
-            "PDQ:CDR0000037765",
-            "MEDDRA:10025302",
-            "EFO:0000095",
-            "MEDDRA:10041138",
-            "DOID:1040",
-            "SNOMEDCT:51092000",
-            "MESH:D015451",
-            "PDQ:CDR0000039824",
-            "NCIT:C3163",
-            "MEDDRA:10008993"
-          ],
-          "id": "MONDO:0004948",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic lymphatic leukemia",
-            "Lymphoid leukemia, chronic",
-            "Small Lymphocytic Lymphoma",
-            "chronic lymphocytic leukemia",
-            "Leukemia, chronic lymphocytic related phenotypic feature",
-            "Leukemia, Lymphocytic, Chronic, B-Cell",
-            "B-cell chronic lymphocytic leukemia",
-            "small lymphocytic lymphoma",
-            "Chronic Lymphocytic Leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=346545",
-            "http://en.wikipedia.org/wiki/b-cell_chronic_lymphocytic_leukemia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 562,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Acadesine",
-          "description": "A 5-aminoimidazole-4-carboxamide (AICA) riboside, a purine nucleoside analog, and a nucleotide biosynthesis precursor with B cell pro-apoptotic activity. Following cellular uptake, acadesine is phosphorylated to AICA ribotide (ZMP), which mimics 5'-adenosine monophosphate (AMP). Both AMP-activated protein kinase (AMPK) and AMPK kinase (AMPKK) are activated by ZMP, which appears to be necessary for the induction of apoptosis. Acadesine-induced apoptosis also appears to require cytochrome c release from mitochondria and caspase activation and is p53-independent. However, the exact mechanism of acadesine-induced apoptosis is unknown. T cells are significantly less susceptible than B cells to acadesine-induced apoptosis. AMPK regulates several cellular systems including the cellular uptake of glucose, the beta-oxidation of fatty acids, protein synthesis, and the biogenesis of glucose transporter 4 (GLUT4) and mitochondria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C71537\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C71537\" NCI Thesaurus); A 5-aminoimidazole-4-carboxamide (AICA) riboside, a ribnucleoside analog, and a nucleotide biosynthesis precursor with B cell pro-apoptotic activity. Following cellular uptake, acadesine is phosphorylated to AICA ribotide (ZMP), which mimics 5'-adenosine monophosphate (AMP). Both AMP-activated protein kinase (AMPK) and AMPK kinase (AMPKK) are activated by ZMP, which appears to be necessary for the induction of apoptosis. Acadesine-induced apoptosis also appears to require cytochrome c release from mitochondria and caspase activation and is p53-independent. However, the exact mechanism of acadesine-induced apoptosis is unknown. T cells are significantly less susceptible than B cells to acadesine-induced apoptosis. AMPK regulates several cellular systems including the cellular uptake of glucose, the beta-oxidation of fatty acids, protein synthesis, and the biogenesis of glucose transporter 4 (GLUT4) and mitochondria.",
-          "equivalent_curies": [
-            "KEGG.DRUG:D02742",
-            "INCHIKEY:RTRQQBHATOEIAF-UUOKFMHZSA-N",
-            "ATC:C01EB13",
-            "GTOPDB:5133",
-            "UNII:53IEF47846",
-            "DRUGBANK:DB04944",
-            "DrugCentral:37",
-            "CHEMBL.COMPOUND:CHEMBL1551724",
-            "MESH:C011651",
-            "HMDB:HMDB0062179",
-            "PDQ:CDR0000580838",
-            "CHEBI:28498",
-            "NCIT:C71537",
-            "UMLS:C0051027",
-            "PUBCHEM.COMPOUND:17513",
-            "CAS:2627-69-2"
-          ],
-          "id": "PUBCHEM.COMPOUND:17513",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "AICA-riboside",
-            "Acadesine",
-            "acadesine",
-            "Acadesine (USAN/INN)",
-            "ACADESINE",
-            "aminoimidazole carboxamide ribonucleoside"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:28325600",
-            "PMID:28094938",
-            "PMID:32163815",
-            "PMID:20014752",
-            "PMID:25299682",
-            "PMID:7660942",
-            "PMID:18798311",
-            "PMID:30336025",
-            "PMID:26088335",
-            "PMID:8227467"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323598,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004948",
-              "name": "B-cell chronic lymphocytic leukemia",
-              "description": "The most common type of chronic lymphoid leukemia. It comprises 90% of chronic lymphoid leukemias in the United States. Morphologically, the neoplastic cells are small, round B-lymphocytes. This type of leukemia is not considered to be curable with available therapy. (WHO, 2001); A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.; A chronic lymphocytic/lymphatic/lymphoblastic leukemia (CLL) is a neoplastic disease characterized by proliferation and accumulation (blood, marrow and lymphoid organs) of morphologically mature but immunologically dysfunctional lymphocytes. A CLL is always a B-cell lymphocytic leukemia as there are no reports of cases of T-cell lymphocytic leukemias. [HPO:curators]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10051812",
-                "MEDDRA:10003908",
-                "MEDDRA:10068919",
-                "MEDDRA:10060576",
-                "MEDDRA:10068852",
-                "OMIM:151400",
-                "MEDDRA:10003909",
-                "MEDDRA:10008956",
-                "UMLS:C0855095",
-                "ICD9:204.1",
-                "MEDDRA:10060391",
-                "MEDDRA:10008976",
-                "NCIT:C7540",
-                "MEDDRA:10008957",
-                "HP:0005550",
-                "MONDO:0004948",
-                "UMLS:C0023434",
-                "MEDDRA:10024340",
-                "MEDDRA:10025306",
-                "PDQ:CDR0000038170",
-                "MEDDRA:10009310",
-                "SNOMEDCT:302841002",
-                "MEDDRA:10008960",
-                "ORPHANET:67038",
-                "SNOMEDCT:92814006",
-                "SNOMEDCT:277473004",
-                "MEDDRA:10008958",
-                "SNOMEDCT:64575004",
-                "MEDDRA:10003910",
-                "MEDDRA:10024295",
-                "ICD10:C91.10",
-                "PDQ:CDR0000037765",
-                "MEDDRA:10025302",
-                "EFO:0000095",
-                "MEDDRA:10041138",
-                "DOID:1040",
-                "SNOMEDCT:51092000",
-                "MESH:D015451",
-                "PDQ:CDR0000039824",
-                "NCIT:C3163",
-                "MEDDRA:10008993"
-              ],
-              "id": "MONDO:0004948",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic lymphatic leukemia",
-                "Lymphoid leukemia, chronic",
-                "Small Lymphocytic Lymphoma",
-                "chronic lymphocytic leukemia",
-                "Leukemia, chronic lymphocytic related phenotypic feature",
-                "Leukemia, Lymphocytic, Chronic, B-Cell",
-                "B-cell chronic lymphocytic leukemia",
-                "small lymphocytic lymphoma",
-                "Chronic Lymphocytic Leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=346545",
-                "http://en.wikipedia.org/wiki/b-cell_chronic_lymphocytic_leukemia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9753372,
-            "start": 562,
-            "end": 323598,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12522004': {'publication date': '2003 May 01', 'sentence': 'These results suggest a new pathway involving AMPK in the control of apoptosis in B-CLL cells and raise the possibility of using acadesine in B-CLL treatment.', 'subject score': 1000, 'object score': 938}, 'PMID:18457469': {'publication date': '2008', 'sentence': 'Orphan drug status has been granted for acadesine in the EU for the treatment of B-cell chronic lymphocytic leukaemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:18671468': {'publication date': '2008 Aug', 'sentence': 'OBJECTIVE: This review aimed to summarise and critique available data on the mechanism of action and clinical utility of acadesine, with a focus on treatment of ischaemic reperfusion injury, B-cell chronic lymphocytic leukaemia and diabetes mellitus.', 'subject score': 1000, 'object score': 1000}, 'PMID:20367195': {'publication date': '2010 Apr', 'sentence': 'AREAS COVERED IN THIS REVIEW: The literature data show that apoptosis induced by AICA-riboside in CLL is not dependent on a functionally normal p53 pathway.', 'subject score': 1000, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0051027---SEMMEDDB:treats---None---None---None---UMLS:C0023434---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:17513",
-              "id": "9968932",
-              "object": "MONDO:0004948",
-              "publications": [
-                "PMID:12522004",
-                "PMID:18457469",
-                "PMID:18671468",
-                "PMID:20367195"
-              ]
-            }
-          },
-          "end": {
-            "identity": 562,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-=======
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
->>>>>>> main
-            ],
-            "properties": {
-              "name": "Acadesine",
-              "description": "A 5-aminoimidazole-4-carboxamide (AICA) riboside, a purine nucleoside analog, and a nucleotide biosynthesis precursor with B cell pro-apoptotic activity. Following cellular uptake, acadesine is phosphorylated to AICA ribotide (ZMP), which mimics 5'-adenosine monophosphate (AMP). Both AMP-activated protein kinase (AMPK) and AMPK kinase (AMPKK) are activated by ZMP, which appears to be necessary for the induction of apoptosis. Acadesine-induced apoptosis also appears to require cytochrome c release from mitochondria and caspase activation and is p53-independent. However, the exact mechanism of acadesine-induced apoptosis is unknown. T cells are significantly less susceptible than B cells to acadesine-induced apoptosis. AMPK regulates several cellular systems including the cellular uptake of glucose, the beta-oxidation of fatty acids, protein synthesis, and the biogenesis of glucose transporter 4 (GLUT4) and mitochondria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C71537\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C71537\" NCI Thesaurus); A 5-aminoimidazole-4-carboxamide (AICA) riboside, a ribnucleoside analog, and a nucleotide biosynthesis precursor with B cell pro-apoptotic activity. Following cellular uptake, acadesine is phosphorylated to AICA ribotide (ZMP), which mimics 5'-adenosine monophosphate (AMP). Both AMP-activated protein kinase (AMPK) and AMPK kinase (AMPKK) are activated by ZMP, which appears to be necessary for the induction of apoptosis. Acadesine-induced apoptosis also appears to require cytochrome c release from mitochondria and caspase activation and is p53-independent. However, the exact mechanism of acadesine-induced apoptosis is unknown. T cells are significantly less susceptible than B cells to acadesine-induced apoptosis. AMPK regulates several cellular systems including the cellular uptake of glucose, the beta-oxidation of fatty acids, protein synthesis, and the biogenesis of glucose transporter 4 (GLUT4) and mitochondria.",
-              "equivalent_curies": [
-                "KEGG.DRUG:D02742",
-                "INCHIKEY:RTRQQBHATOEIAF-UUOKFMHZSA-N",
-                "ATC:C01EB13",
-                "GTOPDB:5133",
-                "UNII:53IEF47846",
-                "DRUGBANK:DB04944",
-                "DrugCentral:37",
-                "CHEMBL.COMPOUND:CHEMBL1551724",
-                "MESH:C011651",
-                "HMDB:HMDB0062179",
-                "PDQ:CDR0000580838",
-                "CHEBI:28498",
-                "NCIT:C71537",
-                "UMLS:C0051027",
-                "PUBCHEM.COMPOUND:17513",
-                "CAS:2627-69-2"
-              ],
-              "id": "PUBCHEM.COMPOUND:17513",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "AICA-riboside",
-                "Acadesine",
-                "acadesine",
-                "Acadesine (USAN/INN)",
-                "ACADESINE",
-                "aminoimidazole carboxamide ribonucleoside"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:28325600",
-                "PMID:28094938",
-                "PMID:32163815",
-                "PMID:20014752",
-                "PMID:25299682",
-                "PMID:7660942",
-                "PMID:18798311",
-                "PMID:30336025",
-                "PMID:26088335",
-                "PMID:8227467"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13036849,
-            "start": 567,
-            "end": 295849,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17785620': {'publication date': '2007 Sep 25', 'sentence': 'Ranolazine was more effective than lidocaine in terminating persistent AF and in preventing the induction of AF.', 'subject score': 1000, 'object score': 1000}, 'PMID:18598958': {'publication date': '2008 Jul', 'sentence': 'Our data suggest that ranolazine may be useful in suppressing AF triggers arising from the PV sleeves.', 'subject score': 1000, 'object score': 838}, 'PMID:20201889': {'publication date': '2010 Feb', 'sentence': 'Atrial-selective sodium channel blockers, such as ranolazine and amiodarone, effectively suppress and/or prevent the induction of AF in experimental models, while producing little to no effect on ventricular myocardium.', 'subject score': 1000, 'object score': 1000}, 'PMID:23376977': {'publication date': '2013 May', 'sentence': 'The aim of the present study was to investigate whether RAN can suppress AF in an experimental rabbit whole heart model, in which acute haemodynamic changes trigger AF.', 'subject score': 1000, 'object score': 1000}, 'PMID:29068807': {'publication date': '2018 01', 'sentence': 'CONCLUSIONS: The combination of dofetilide and ranolazine showed increased antiarrhythmic effects on acutely induced AF in horses, affecting time to cardioversion, AF vulnerability, and AF duration.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:causes---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "13317799",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:17785620",
-                "PMID:18598958",
-                "PMID:20201889",
-                "PMID:23376977",
-                "PMID:29068807"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 308937,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-          "name": "cardiovascular disorder",
-          "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "MEDDRA:10045663",
-            "MONDO:0004995",
-            "ICD9:429.2",
-            "MEDDRA:10007649",
-            "UMLS:C0243050",
-            "HP:0001626",
-            "MESH:D018376",
-            "MEDDRA:10007648",
-            "MEDDRA:10013205",
-            "SNOMEDCT:49601007",
-            "MEDDRA:10007650",
-            "MESH:D002318",
-            "DOID:1287",
-            "UMLS:C0007222",
-            "UMLS:C0728936",
-            "NCIT:C2931"
-          ],
-          "id": "MONDO:0004995",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiovascular Diseases",
-            "Cardiovascular disease, unspecified",
-            "Abnormality of the cardiovascular system",
-            "cardiovascular system disease",
-            "Disorder of circulatory system",
-            "Cardiovascular Disorder",
-            "cardiovascular disorder",
-            "Cardiovascular Abnormalities"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/circulatory_system",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308937,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-              "name": "cardiovascular disorder",
-              "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "MEDDRA:10045663",
-                "MONDO:0004995",
-                "ICD9:429.2",
-                "MEDDRA:10007649",
-                "UMLS:C0243050",
-                "HP:0001626",
-                "MESH:D018376",
-                "MEDDRA:10007648",
-                "MEDDRA:10013205",
-                "SNOMEDCT:49601007",
-                "MEDDRA:10007650",
-                "MESH:D002318",
-                "DOID:1287",
-                "UMLS:C0007222",
-                "UMLS:C0728936",
-                "NCIT:C2931"
-              ],
-              "id": "MONDO:0004995",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiovascular Diseases",
-                "Cardiovascular disease, unspecified",
-                "Abnormality of the cardiovascular system",
-                "cardiovascular system disease",
-                "Disorder of circulatory system",
-                "Cardiovascular Disorder",
-                "cardiovascular disorder",
-                "Cardiovascular Abnormalities"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/circulatory_system",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18934141,
-            "start": 567,
-            "end": 308937,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27838121': {'publication date': '2017 Jan 15', 'sentence': 'Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:affects---None---None---None---UMLS:C0007222---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "19314329",
-              "object": "MONDO:0004995",
-              "publications": [
-                "PMID:27838121"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18627173,
-            "start": 567,
-            "end": 295849,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27208652': {'publication date': '2016 Jul 01', 'sentence': 'Furthermore, the activated Akt/mTOR signaling pathway induced by AF was further activated by ranolazine.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "19002641",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:27208652"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:25236919': {'publication date': '2015 Aug', 'sentence': 'Recent evidence of beneficial effects of ranolazine (RAN) in type II diabetes motivates interest in the role of the late sodium current (INaL) in glucose-stimulated insulin secretion.', 'subject score': 1000, 'object score': 1000}, 'PMID:32023991': {'publication date': '2020 Jan 31', 'sentence': 'Metabolic and Cognitive Effects of Ranolazine in Type 2 Diabetes Mellitus: Data from an in vivo Model.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 321236,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005148",
-          "name": "type 2 diabetes mellitus",
-          "description": "A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity.; A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.; A type of diabetes mellitus initially characterized by insulin resistance and hyperinsulinemia and subsequently by glucose interolerance and hyperglycemia. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C2674662",
-            "DOID:9352",
-            "UMLS:C0011860",
-            "NCIT:C26747",
-            "MEDDRA:10012611",
-            "ICD10:E11",
-            "MEDDRA:10026947",
-            "UMLS:C3149706",
-            "UMLS:C1840169",
-            "HP:0005978",
-            "OMIM:125853",
-            "UMLS:CN244395",
-            "MEDDRA:10029505",
-            "UMLS:C1852091",
-            "SNOMEDCT:44054006",
-            "KEGG.DISEASE:04930",
-            "MEDDRA:10012613",
-            "MONDO:0005148",
-            "MESH:D003924",
-            "UMLS:C2674665",
-            "MEDDRA:10045242",
-            "EFO:0001360",
-            "MEDDRA:10029402",
-            "MEDDRA:10067585",
-            "UMLS:C2674663",
-            "UMLS:C4017238"
-          ],
-          "id": "MONDO:0005148",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pon1 enzyme activity, variation in",
-            "Diabetes Mellitus, Non-Insulin-Dependent",
-            "Coronary artery disease, susceptibility to",
-            "Diabetes Mellitus, Type 2",
-            "Type 2 Diabetes Mellitus",
-            "MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 5 (finding)",
-            "obsolete_type II diabetes mellitus",
-            "Type 2 diabetes mellitus related phenotypic feature",
-            "Coronary artery spasm 2, susceptibility to",
-            "Type II diabetes mellitus",
-            "Type 2 diabetes mellitus, protection against",
-            "Organophosphate poisoning, susceptibility to",
-            "type 2 diabetes mellitus",
-            "Insulin resistance, susceptibility to"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/diabetes_mellitus_type_2",
-            "http://en.wikipedia.org/wiki/diabetes",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-5316-1399"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321236,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005148",
-              "name": "type 2 diabetes mellitus",
-              "description": "A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity.; A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.; A type of diabetes mellitus initially characterized by insulin resistance and hyperinsulinemia and subsequently by glucose interolerance and hyperglycemia. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C2674662",
-                "DOID:9352",
-                "UMLS:C0011860",
-                "NCIT:C26747",
-                "MEDDRA:10012611",
-                "ICD10:E11",
-                "MEDDRA:10026947",
-                "UMLS:C3149706",
-                "UMLS:C1840169",
-                "HP:0005978",
-                "OMIM:125853",
-                "UMLS:CN244395",
-                "MEDDRA:10029505",
-                "UMLS:C1852091",
-                "SNOMEDCT:44054006",
-                "KEGG.DISEASE:04930",
-                "MEDDRA:10012613",
-                "MONDO:0005148",
-                "MESH:D003924",
-                "UMLS:C2674665",
-                "MEDDRA:10045242",
-                "EFO:0001360",
-                "MEDDRA:10029402",
-                "MEDDRA:10067585",
-                "UMLS:C2674663",
-                "UMLS:C4017238"
-              ],
-              "id": "MONDO:0005148",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pon1 enzyme activity, variation in",
-                "Diabetes Mellitus, Non-Insulin-Dependent",
-                "Coronary artery disease, susceptibility to",
-                "Diabetes Mellitus, Type 2",
-                "Type 2 Diabetes Mellitus",
-                "MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 5 (finding)",
-                "obsolete_type II diabetes mellitus",
-                "Type 2 diabetes mellitus related phenotypic feature",
-                "Coronary artery spasm 2, susceptibility to",
-                "Type II diabetes mellitus",
-                "Type 2 diabetes mellitus, protection against",
-                "Organophosphate poisoning, susceptibility to",
-                "type 2 diabetes mellitus",
-                "Insulin resistance, susceptibility to"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/diabetes_mellitus_type_2",
-                "http://en.wikipedia.org/wiki/diabetes",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-5316-1399"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17523663,
-            "start": 567,
-            "end": 321236,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25236919': {'publication date': '2015 Aug', 'sentence': 'Recent evidence of beneficial effects of ranolazine (RAN) in type II diabetes motivates interest in the role of the late sodium current (INaL) in glucose-stimulated insulin secretion.', 'subject score': 1000, 'object score': 1000}, 'PMID:32023991': {'publication date': '2020 Jan 31', 'sentence': 'Metabolic and Cognitive Effects of Ranolazine in Type 2 Diabetes Mellitus: Data from an in vivo Model.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:affects---None---None---None---UMLS:C0011860---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "17881291",
-              "object": "MONDO:0005148",
-              "publications": [
-                "PMID:25236919",
-                "PMID:32023991"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16261983,
-            "start": 567,
-            "end": 295849,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23140547': {'publication date': '2013 Nov', 'sentence': 'Effect of ranolazine in preventing postoperative atrial fibrillation in patients undergoing coronary revascularization surgery.', 'subject score': 1000, 'object score': 808}, 'PMID:23205928': {'publication date': '2013 Oct', 'sentence': 'We could demonstrate potent effects of ranolazine on atrial fibrillation in a \"wash-in wash-out\" situation.', 'subject score': 1000, 'object score': 1000}, 'PMID:25210025': {'publication date': '2015 Jan', 'sentence': 'Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:27957034': {'publication date': '2014', 'sentence': 'Purpose of this study is to assess the effect of ranolazine on atrial fibrillation (AF), in patients with CAD, PAF and a dual-chamber pacemaker.', 'subject score': 1000, 'object score': 1000}, 'PMID:28497941': {'publication date': '2018 Jun', 'sentence': 'EVIDENCE ACQUISITION: Both methods randomized controlled trials (RCTs) and non-randomized observational studies concerning the effects of ranolazine on AF were included in the meta-analysis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:affects---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "16599546",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:23140547",
-                "PMID:23205928",
-                "PMID:25210025",
-                "PMID:27957034",
-                "PMID:28497941"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 525277,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0024644",
-          "name": "myocardial ischemia",
-          "description": "A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries, to obstruction by a thrombus, or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).; A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).",
-          "equivalent_curies": [
-            "UMLS:C0151744",
-            "MONDO:0024644",
-            "MEDDRA:10021279",
-            "MEDDRA:10007584",
-            "MEDDRA:10023024",
-            "MEDDRA:10055218",
-            "MEDDRA:10055752",
-            "SNOMEDCT:414545008",
-            "MEDDRA:10028601",
-            "NCIT:C50625",
-            "MESH:D017202",
-            "SNOMEDCT:414795007",
-            "MEDDRA:10055224",
-            "EFO:1001375",
-            "MEDDRA:10028600",
-            "MEDDRA:10023033"
-          ],
-          "id": "MONDO:0024644",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myocardial Ischemia",
-            "myocardial ischemia",
-            "Ischemic Heart Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 525277,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0024644",
-              "name": "myocardial ischemia",
-              "description": "A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries, to obstruction by a thrombus, or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).; A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).",
-              "equivalent_curies": [
-                "UMLS:C0151744",
-                "MONDO:0024644",
-                "MEDDRA:10021279",
-                "MEDDRA:10007584",
-                "MEDDRA:10023024",
-                "MEDDRA:10055218",
-                "MEDDRA:10055752",
-                "SNOMEDCT:414545008",
-                "MEDDRA:10028601",
-                "NCIT:C50625",
-                "MESH:D017202",
-                "SNOMEDCT:414795007",
-                "MEDDRA:10055224",
-                "EFO:1001375",
-                "MEDDRA:10028600",
-                "MEDDRA:10023033"
-              ],
-              "id": "MONDO:0024644",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myocardial Ischemia",
-                "myocardial ischemia",
-                "Ischemic Heart Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14884688,
-            "start": 567,
-            "end": 525277,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20828645': {'publication date': '2010 Sep 14', 'sentence': 'The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease.', 'subject score': 1000, 'object score': 923}, 'PMID:2110906': {'publication date': '1990', 'sentence': 'Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium.', 'subject score': 1000, 'object score': 928}, 'PMID:23335347': {'publication date': '2013 Feb', 'sentence': 'The inhibition of late sodium channels as well as other ion currents has a central role in the potential use of ranolazine in ischemic heart disease, arrhythmias, and heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:29938533': {'publication date': '2018 Jan 01', 'sentence': 'Effect of Ranolazine on Ischemic Myocardium IN Patients With Acute Cardiac Ischemia (RIMINI-Trial): A Randomized Controlled Pilot Trial.', 'subject score': 1000, 'object score': 928}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:affects---None---None---None---UMLS:C0151744---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "15199166",
-              "object": "MONDO:0024644",
-              "publications": [
-                "PMID:20828645",
-                "PMID:2110906",
-                "PMID:23335347",
-                "PMID:29938533"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 310237,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004976",
-          "name": "amyotrophic lateral sclerosis",
-          "description": "A neurodegenerative disorder characterized by progressive degeneration of the motor neurons of the central nervous system. It results in weakness and atrophy of the muscles which leads to an inability to initiate and control voluntary movements.; A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:0111246",
-            "NCIT:C34373",
-            "MEDDRA:10002026",
-            "OMIM:PS105400",
-            "UMLS:C0002736",
-            "DOID:332",
-            "MESH:D000690",
-            "ICD9:335.20",
-            "SNOMEDCT:86044005",
-            "MEDDRA:10052889",
-            "ORPHANET:803",
-            "HP:0007354",
-            "ICD10:G12.21",
-            "EFO:0000253",
-            "KEGG.DISEASE:05014",
-            "MONDO:0004976"
-          ],
-          "id": "MONDO:0004976",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_amyotrophic lateral sclerosis",
-            "amyotrophic lateral sclerosis-parkinsonism/dementia complex 1",
-            "Amyotrophic lateral sclerosis",
-            "amyotrophic lateral sclerosis",
-            "Amyotrophic Lateral Sclerosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/detail_als.htm",
-            "PMID:5770171",
-            "PMID:16051700",
-            "http://en.wikipedia.org/wiki/amyotrophic_lateral_sclerosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310237,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004976",
-              "name": "amyotrophic lateral sclerosis",
-              "description": "A neurodegenerative disorder characterized by progressive degeneration of the motor neurons of the central nervous system. It results in weakness and atrophy of the muscles which leads to an inability to initiate and control voluntary movements.; A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:0111246",
-                "NCIT:C34373",
-                "MEDDRA:10002026",
-                "OMIM:PS105400",
-                "UMLS:C0002736",
-                "DOID:332",
-                "MESH:D000690",
-                "ICD9:335.20",
-                "SNOMEDCT:86044005",
-                "MEDDRA:10052889",
-                "ORPHANET:803",
-                "HP:0007354",
-                "ICD10:G12.21",
-                "EFO:0000253",
-                "KEGG.DISEASE:05014",
-                "MONDO:0004976"
-              ],
-              "id": "MONDO:0004976",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_amyotrophic lateral sclerosis",
-                "amyotrophic lateral sclerosis-parkinsonism/dementia complex 1",
-                "Amyotrophic lateral sclerosis",
-                "amyotrophic lateral sclerosis",
-                "Amyotrophic Lateral Sclerosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/detail_als.htm",
-                "PMID:5770171",
-                "PMID:16051700",
-                "http://en.wikipedia.org/wiki/amyotrophic_lateral_sclerosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24000018,
-            "start": 567,
-            "end": 310237,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35466411': {'publication date': '2022 Apr 24', 'sentence': 'DISCUSSION: Ranolazine was well tolerated in ALS up to 2000 mg daily with gastrointestinal side effects being the most frequent.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:treats---None---None---None---UMLS:C0002736---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "24441273",
-              "object": "MONDO:0004976",
-              "publications": [
-                "PMID:35466411"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:23500237': {'publication date': '2013 May 21', 'sentence': 'Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).', 'subject score': 1000, 'object score': 1000}, 'PMID:24812428': {'publication date': '2014 Oct', 'sentence': 'In addition to its antianginal effects, ranolazine has been shown to reduce HbA1c levels in patients with type 2 diabetes mellitus and coronary artery disease; however, the mechanism behind its antidiabetic effect has been unclear.', 'subject score': 1000, 'object score': 1000}, 'PMID:25262254': {'publication date': '2014 Oct', 'sentence': 'Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c.', 'subject score': 1000, 'object score': 1000}, 'PMID:26049552': {'publication date': '2015 Jul', 'sentence': 'Although ranolazine is not approved for the treatment of type 2 diabetes, in post hoc analyses of pivotal angina trials, ranolazine was associated with reductions in percent glycosylated hemoglobin (HbA1c) in subjects with type 2 diabetes.', 'subject score': 1000, 'object score': 1000}, 'PMID:26386799': {'publication date': '2015 Oct', 'sentence': 'METHODS: We performed a secondary, observational analysis of the TERISA multinational trial, which evaluated the antianginal effect of ranolazine versus placebo in patients with type 2 diabetes mellitus, documented coronary disease, and a 3-month history of stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:26749407': {'publication date': '2016 May', 'sentence': 'CONCLUSIONS: Compared with placebo, addition of ranolazine in patients with type 2 diabetes treated with glimepiride, but not metformin, significantly reduced HbA1c over 24 weeks.', 'subject score': 1000, 'object score': 1000}, 'PMID:26917816': {'publication date': '2016 May', 'sentence': 'OBJECTIVE: To review the antihyperglycemic effect of ranolazine in type 2 diabetes mellitus (T2DM).', 'subject score': 1000, 'object score': 1000}, 'PMID:27128216': {'publication date': '2015 03', 'sentence': 'Co-administration of ranolazine and metformin was well tolerated in these T2DM subjects, with no serious adverse events or drug-related adverse events leading to discontinuation.', 'subject score': 1000, 'object score': 917}, 'PMID:30266352': {'publication date': '2018 Dec 15', 'sentence': 'CONCLUSION: Our model suggests the addition of ranolazine to SoC is likely cost-effective from a US societal perspective for the treatment of patients with T2D and stable, symptomatic coronary disease despite treatment with 1-2 antianginals.', 'subject score': 1000, 'object score': 1000}, 'PMID:34851748': {'publication date': '2021 Dec 01', 'sentence': 'We observed that ranolazine did not improve glycemia in mice with experimental T2D, while also having no impact on hepatic triacylglycerol content.', 'subject score': 1000, 'object score': 916}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 321236,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005148",
-          "name": "type 2 diabetes mellitus",
-          "description": "A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity.; A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.; A type of diabetes mellitus initially characterized by insulin resistance and hyperinsulinemia and subsequently by glucose interolerance and hyperglycemia. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C2674662",
-            "DOID:9352",
-            "UMLS:C0011860",
-            "NCIT:C26747",
-            "MEDDRA:10012611",
-            "ICD10:E11",
-            "MEDDRA:10026947",
-            "UMLS:C3149706",
-            "UMLS:C1840169",
-            "HP:0005978",
-            "OMIM:125853",
-            "UMLS:CN244395",
-            "MEDDRA:10029505",
-            "UMLS:C1852091",
-            "SNOMEDCT:44054006",
-            "KEGG.DISEASE:04930",
-            "MEDDRA:10012613",
-            "MONDO:0005148",
-            "MESH:D003924",
-            "UMLS:C2674665",
-            "MEDDRA:10045242",
-            "EFO:0001360",
-            "MEDDRA:10029402",
-            "MEDDRA:10067585",
-            "UMLS:C2674663",
-            "UMLS:C4017238"
-          ],
-          "id": "MONDO:0005148",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pon1 enzyme activity, variation in",
-            "Diabetes Mellitus, Non-Insulin-Dependent",
-            "Coronary artery disease, susceptibility to",
-            "Diabetes Mellitus, Type 2",
-            "Type 2 Diabetes Mellitus",
-            "MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 5 (finding)",
-            "obsolete_type II diabetes mellitus",
-            "Type 2 diabetes mellitus related phenotypic feature",
-            "Coronary artery spasm 2, susceptibility to",
-            "Type II diabetes mellitus",
-            "Type 2 diabetes mellitus, protection against",
-            "Organophosphate poisoning, susceptibility to",
-            "type 2 diabetes mellitus",
-            "Insulin resistance, susceptibility to"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/diabetes_mellitus_type_2",
-            "http://en.wikipedia.org/wiki/diabetes",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-5316-1399"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321236,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005148",
-              "name": "type 2 diabetes mellitus",
-              "description": "A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity.; A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.; A type of diabetes mellitus initially characterized by insulin resistance and hyperinsulinemia and subsequently by glucose interolerance and hyperglycemia. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C2674662",
-                "DOID:9352",
-                "UMLS:C0011860",
-                "NCIT:C26747",
-                "MEDDRA:10012611",
-                "ICD10:E11",
-                "MEDDRA:10026947",
-                "UMLS:C3149706",
-                "UMLS:C1840169",
-                "HP:0005978",
-                "OMIM:125853",
-                "UMLS:CN244395",
-                "MEDDRA:10029505",
-                "UMLS:C1852091",
-                "SNOMEDCT:44054006",
-                "KEGG.DISEASE:04930",
-                "MEDDRA:10012613",
-                "MONDO:0005148",
-                "MESH:D003924",
-                "UMLS:C2674665",
-                "MEDDRA:10045242",
-                "EFO:0001360",
-                "MEDDRA:10029402",
-                "MEDDRA:10067585",
-                "UMLS:C2674663",
-                "UMLS:C4017238"
-              ],
-              "id": "MONDO:0005148",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pon1 enzyme activity, variation in",
-                "Diabetes Mellitus, Non-Insulin-Dependent",
-                "Coronary artery disease, susceptibility to",
-                "Diabetes Mellitus, Type 2",
-                "Type 2 Diabetes Mellitus",
-                "MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 5 (finding)",
-                "obsolete_type II diabetes mellitus",
-                "Type 2 diabetes mellitus related phenotypic feature",
-                "Coronary artery spasm 2, susceptibility to",
-                "Type II diabetes mellitus",
-                "Type 2 diabetes mellitus, protection against",
-                "Organophosphate poisoning, susceptibility to",
-                "type 2 diabetes mellitus",
-                "Insulin resistance, susceptibility to"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/diabetes_mellitus_type_2",
-                "http://en.wikipedia.org/wiki/diabetes",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-5316-1399"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16480757,
-            "start": 567,
-            "end": 321236,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23500237': {'publication date': '2013 May 21', 'sentence': 'Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).', 'subject score': 1000, 'object score': 1000}, 'PMID:24812428': {'publication date': '2014 Oct', 'sentence': 'In addition to its antianginal effects, ranolazine has been shown to reduce HbA1c levels in patients with type 2 diabetes mellitus and coronary artery disease; however, the mechanism behind its antidiabetic effect has been unclear.', 'subject score': 1000, 'object score': 1000}, 'PMID:25262254': {'publication date': '2014 Oct', 'sentence': 'Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c.', 'subject score': 1000, 'object score': 1000}, 'PMID:26049552': {'publication date': '2015 Jul', 'sentence': 'Although ranolazine is not approved for the treatment of type 2 diabetes, in post hoc analyses of pivotal angina trials, ranolazine was associated with reductions in percent glycosylated hemoglobin (HbA1c) in subjects with type 2 diabetes.', 'subject score': 1000, 'object score': 1000}, 'PMID:26386799': {'publication date': '2015 Oct', 'sentence': 'METHODS: We performed a secondary, observational analysis of the TERISA multinational trial, which evaluated the antianginal effect of ranolazine versus placebo in patients with type 2 diabetes mellitus, documented coronary disease, and a 3-month history of stable angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:26749407': {'publication date': '2016 May', 'sentence': 'CONCLUSIONS: Compared with placebo, addition of ranolazine in patients with type 2 diabetes treated with glimepiride, but not metformin, significantly reduced HbA1c over 24 weeks.', 'subject score': 1000, 'object score': 1000}, 'PMID:26917816': {'publication date': '2016 May', 'sentence': 'OBJECTIVE: To review the antihyperglycemic effect of ranolazine in type 2 diabetes mellitus (T2DM).', 'subject score': 1000, 'object score': 1000}, 'PMID:27128216': {'publication date': '2015 03', 'sentence': 'Co-administration of ranolazine and metformin was well tolerated in these T2DM subjects, with no serious adverse events or drug-related adverse events leading to discontinuation.', 'subject score': 1000, 'object score': 917}, 'PMID:30266352': {'publication date': '2018 Dec 15', 'sentence': 'CONCLUSION: Our model suggests the addition of ranolazine to SoC is likely cost-effective from a US societal perspective for the treatment of patients with T2D and stable, symptomatic coronary disease despite treatment with 1-2 antianginals.', 'subject score': 1000, 'object score': 1000}, 'PMID:34851748': {'publication date': '2021 Dec 01', 'sentence': 'We observed that ranolazine did not improve glycemia in mice with experimental T2D, while also having no impact on hepatic triacylglycerol content.', 'subject score': 1000, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:treats---None---None---None---UMLS:C0011860---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "16822044",
-              "object": "MONDO:0005148",
-              "publications": [
-                "PMID:23500237",
-                "PMID:24812428",
-                "PMID:25262254",
-                "PMID:26049552",
-                "PMID:26386799",
-                "PMID:26749407",
-                "PMID:26917816",
-                "PMID:27128216",
-                "PMID:30266352",
-                "PMID:34851748"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 518244,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:35466411': {'publication date': '2022 Apr 24', 'sentence': 'DISCUSSION: Ranolazine was well tolerated in ALS up to 2000 mg daily with gastrointestinal side effects being the most frequent.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 310237,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006727",
-          "name": "diastolic heart failure",
-          "description": "Heart failure caused by abnormal myocardial relaxation during diastole leading to defective cardiac filling.",
-          "equivalent_curies": [
-            "ICD10:I50.30",
-            "ICD9:428.3",
-            "MONDO:0006727",
-            "SNOMEDCT:418304008",
-            "EFO:1000899",
-            "MESH:D054144",
-            "DOID:9775",
-            "UMLS:C1135196",
-            "MEDDRA:10069211"
-          ],
-          "id": "MONDO:0006727",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Diastolic heart failure",
-            "Heart Failure, Diastolic",
-            "diastolic heart failure"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004976",
-          "name": "amyotrophic lateral sclerosis",
-          "description": "A neurodegenerative disorder characterized by progressive degeneration of the motor neurons of the central nervous system. It results in weakness and atrophy of the muscles which leads to an inability to initiate and control voluntary movements.; A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:0111246",
-            "NCIT:C34373",
-            "MEDDRA:10002026",
-            "OMIM:PS105400",
-            "UMLS:C0002736",
-            "DOID:332",
-            "MESH:D000690",
-            "ICD9:335.20",
-            "SNOMEDCT:86044005",
-            "MEDDRA:10052889",
-            "ORPHANET:803",
-            "HP:0007354",
-            "ICD10:G12.21",
-            "EFO:0000253",
-            "KEGG.DISEASE:05014",
-            "MONDO:0004976"
-          ],
-          "id": "MONDO:0004976",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_amyotrophic lateral sclerosis",
-            "amyotrophic lateral sclerosis-parkinsonism/dementia complex 1",
-            "Amyotrophic lateral sclerosis",
-            "amyotrophic lateral sclerosis",
-            "Amyotrophic Lateral Sclerosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/detail_als.htm",
-            "PMID:5770171",
-            "PMID:16051700",
-            "http://en.wikipedia.org/wiki/amyotrophic_lateral_sclerosis"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 518244,
-=======
-            "identity": 310237,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006727",
-              "name": "diastolic heart failure",
-              "description": "Heart failure caused by abnormal myocardial relaxation during diastole leading to defective cardiac filling.",
-              "equivalent_curies": [
-                "ICD10:I50.30",
-                "ICD9:428.3",
-                "MONDO:0006727",
-                "SNOMEDCT:418304008",
-                "EFO:1000899",
-                "MESH:D054144",
-                "DOID:9775",
-                "UMLS:C1135196",
-                "MEDDRA:10069211"
-              ],
-              "id": "MONDO:0006727",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Diastolic heart failure",
-                "Heart Failure, Diastolic",
-                "diastolic heart failure"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14928066,
-            "start": 567,
-            "end": 518244,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20925013': {'publication date': '2010 Oct', 'sentence': 'Moreover, ranolazine holds potential promise to be effective in treatment of atrial fibrillation and diastolic heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:21538388': {'publication date': '2011 Jul', 'sentence': 'HYPOTHESIS: RAnoLazIne for the Treatment of Diastolic Heart Failure (RALI-DHF) is a prospective, single-center, randomized, double-blind, placebo-controlled proof-of-concept study to determine if ranolazine compared with placebo will be more effective in improving diastolic function in patients with HFpEF.', 'subject score': 1000, 'object score': 1000}, 'PMID:24621836': {'publication date': '2013 Apr', 'sentence': 'RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:treats---None---None---None---UMLS:C1135196---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "15243162",
-              "object": "MONDO:0006727",
-              "publications": [
-                "PMID:20925013",
-                "PMID:21538388",
-                "PMID:24621836"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 540883,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002442",
-          "name": "long QT syndrome",
-          "description": "A ventricular arrhythmia characterized by a long QT interval, and accompanied by syncopal episodes sometimes leading to sudden death due to paroxysmal ventricular arrhythmia. This arrhythmia is associated with a prolongation of repolarization following depolarization of the cardiac ventricles. The prolongation of the Q-T interval combined with torsades de pointes manifests as several different forms; some may be acquired or congenital; some may lead to serious arrhythmia and sudden cardiac death.; A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD9:426.82",
-            "UMLS:C0023976",
-            "MONDO:0002442",
-            "SNOMEDCT:9651007",
-            "MEDDRA:10024803",
-            "OMIM:PS192500",
-            "NCIT:C34786",
-            "MESH:D008133",
-            "DOID:2843",
-            "ICD10:I45.81"
-          ],
-          "id": "MONDO:0002442",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Long QT syndrome",
-            "long QT syndrome",
-            "Long QT Syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/long_qt_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 540883,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002442",
-              "name": "long QT syndrome",
-              "description": "A ventricular arrhythmia characterized by a long QT interval, and accompanied by syncopal episodes sometimes leading to sudden death due to paroxysmal ventricular arrhythmia. This arrhythmia is associated with a prolongation of repolarization following depolarization of the cardiac ventricles. The prolongation of the Q-T interval combined with torsades de pointes manifests as several different forms; some may be acquired or congenital; some may lead to serious arrhythmia and sudden cardiac death.; A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD9:426.82",
-                "UMLS:C0023976",
-                "MONDO:0002442",
-                "SNOMEDCT:9651007",
-                "MEDDRA:10024803",
-                "OMIM:PS192500",
-                "NCIT:C34786",
-                "MESH:D008133",
-                "DOID:2843",
-                "ICD10:I45.81"
-              ],
-              "id": "MONDO:0002442",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Long QT syndrome",
-                "long QT syndrome",
-                "Long QT Syndrome"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004976",
-              "name": "amyotrophic lateral sclerosis",
-              "description": "A neurodegenerative disorder characterized by progressive degeneration of the motor neurons of the central nervous system. It results in weakness and atrophy of the muscles which leads to an inability to initiate and control voluntary movements.; A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:0111246",
-                "NCIT:C34373",
-                "MEDDRA:10002026",
-                "OMIM:PS105400",
-                "UMLS:C0002736",
-                "DOID:332",
-                "MESH:D000690",
-                "ICD9:335.20",
-                "SNOMEDCT:86044005",
-                "MEDDRA:10052889",
-                "ORPHANET:803",
-                "HP:0007354",
-                "ICD10:G12.21",
-                "EFO:0000253",
-                "KEGG.DISEASE:05014",
-                "MONDO:0004976"
-              ],
-              "id": "MONDO:0004976",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_amyotrophic lateral sclerosis",
-                "amyotrophic lateral sclerosis-parkinsonism/dementia complex 1",
-                "Amyotrophic lateral sclerosis",
-                "amyotrophic lateral sclerosis",
-                "Amyotrophic Lateral Sclerosis"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://en.wikipedia.org/wiki/long_qt_syndrome"
-=======
-                "http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/detail_als.htm",
-                "PMID:5770171",
-                "PMID:16051700",
-                "http://en.wikipedia.org/wiki/amyotrophic_lateral_sclerosis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 14366961,
-            "start": 567,
-            "end": 540883,
-=======
-            "identity": 24000018,
-            "start": 567,
-            "end": 310237,
->>>>>>> main
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-<<<<<<< HEAD
-              "publications_info": "{'PMID:19898287': {'publication date': '2009', 'sentence': 'Small clinical trials suggest that ranolazine may have a role in the treatment of patients with non-ST-elevation acute coronary syndrome, atrial fibrillation, long QT syndromes, and sinus node dysfunction.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:treats---None---None---None---UMLS:C0023976---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "14672486",
-              "object": "MONDO:0002442",
-              "publications": [
-                "PMID:19898287"
-=======
-              "publications_info": "{'PMID:35466411': {'publication date': '2022 Apr 24', 'sentence': 'DISCUSSION: Ranolazine was well tolerated in ALS up to 2000 mg daily with gastrointestinal side effects being the most frequent.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:treats---None---None---None---UMLS:C0002736---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "24441273",
-              "object": "MONDO:0004976",
-              "publications": [
-                "PMID:35466411"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13600225,
-            "start": 567,
-            "end": 295849,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18676686': {'publication date': '2008 Oct', 'sentence': 'Recent studies have increased interest in fast-unbinding Na(+) channel blockers like vernakalant (RSD1235) and ranolazine for AF therapy, but the mechanism of efficacy is poorly understood.', 'subject score': 1000, 'object score': 901}, 'PMID:18679523': {'publication date': '2008 Aug 01', 'sentence': 'A controlled prospective trial is warranted to further investigate the efficacy of ranolazine in AF.', 'subject score': 1000, 'object score': 1000}, 'PMID:19298570': {'publication date': '2009 Jul', 'sentence': 'Potential role of ranolazine in AF management merits further investigation.', 'subject score': 1000, 'object score': 901}, 'PMID:19898287': {'publication date': '2009', 'sentence': 'Small clinical trials suggest that ranolazine may have a role in the treatment of patients with non-ST-elevation acute coronary syndrome, atrial fibrillation, long QT syndromes, and sinus node dysfunction.', 'subject score': 1000, 'object score': 1000}, 'PMID:20925013': {'publication date': '2010 Oct', 'sentence': 'Moreover, ranolazine holds potential promise to be effective in treatment of atrial fibrillation and diastolic heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:21105855': {'publication date': '2010 Dec', 'sentence': 'Further work is required in order to explore more fully the potential of ranolazine in the treatment of atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:22050058': {'publication date': '2011 Nov', 'sentence': 'If confirmed, ranolazine may be a good choice for preventing AF in patients undergoing CABG.', 'subject score': 1000, 'object score': 884}, 'PMID:22229482': {'publication date': '2012 Mar', 'sentence': 'Five of the six patients who were refractory to repeat EC despite RZ had AF of unknown duration and each is now in permanent AF.', 'subject score': 1000, 'object score': 901}, 'PMID:22767404': {'publication date': '2012 Sep', 'sentence': 'A beneficial atrial selectivity of ranolazine has been suggested that may be helpful for the treatment of atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:22916846': {'publication date': '2012 Nov', 'sentence': 'EXPERT OPINION: The combination of the antiischemic properties of ranolazine with its antiarrhythmic potency and minimal proarrhythmia provides a promising background that could expand its therapeutic role in the management of atrial fibrillation and ventricular tachyarrhythmias.', 'subject score': 1000, 'object score': 1000}, 'PMID:23205928': {'publication date': '2013 Oct', 'sentence': 'Although promising controlled studies are needed to investigate a potential role of ranolazine for the treatment of atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:23992336': {'publication date': '2014', 'sentence': 'Experimental and clinical studies have revealed an antiarrhythmic effect of ranolazine in atrial fibrillation as chronic or \"pill in the pocket\" therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:24496483': {'publication date': '2014 Mar', 'sentence': 'In this review the three recently introduced drugs dronedarone, vernakalant and ranolazine are discussed with respect to the use in atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:24523397': {'publication date': '2014 May', 'sentence': 'A third prospective trial used ranolazine in combination with amiodarone for the treatment of POAF and demonstrated a significant reduction in the time required to convert patients from atrial fibrillation to normal sinus rhythm compared with amiodarone alone.', 'subject score': 1000, 'object score': 787}, 'PMID:24581108': {'publication date': '2014 Jan-Feb', 'sentence': 'Refractory atrial fibrillation effectively treated with ranolazine.', 'subject score': 1000, 'object score': 901}, 'PMID:24662415': {'publication date': '2014 Mar', 'sentence': 'We searched PubMed and abstracts of major conferences for clinical studies using ranolazine, either alone or in combination with other antiarrhythmic agents for the prevention or treatment of atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:25138058': {'publication date': '2014 Oct', 'sentence': 'Of clinical relevance, we present growing evidence from preliminary clinical investigations indicating the safety and efficacy of RN for prevention and treatment of AF in various clinical settings including prevention of AF in patients with acute coronary syndromes, prevention and conversion of postoperative AF after surgical coronary revascularization, sinus rhythm maintenance in drug-resistant recurrent AF, and facilitating of electrical or pharmacological cardioversion in cardioversion-resistant patients.', 'subject score': 1000, 'object score': 840}, 'PMID:25602175': {'publication date': '2015 May', 'sentence': 'Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study.', 'subject score': 1000, 'object score': 1000}, 'PMID:25872749': {'publication date': '2015 Jun', 'sentence': 'Specifically, the authors review the Phase I-III trials that studied ranolazine as potential treatment for AF.', 'subject score': 861, 'object score': 1000}, 'PMID:26121051': {'publication date': '2015', 'sentence': 'Plateau phase and upstroke velocity of action potentials (APs) recorded with sharp microelectrodes in intact human trabeculae were more sensitive to ranolazine in AF than in SR preparations.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:treats---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "13891593",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:18676686",
-                "PMID:18679523",
-                "PMID:19298570",
-                "PMID:19898287",
-                "PMID:20925013",
-                "PMID:21105855",
-                "PMID:22050058",
-                "PMID:22229482",
-                "PMID:22767404",
-                "PMID:22916846",
-                "PMID:23205928",
-                "PMID:23992336",
-                "PMID:24496483",
-                "PMID:24523397",
-                "PMID:24581108",
-                "PMID:24662415",
-                "PMID:25138058",
-                "PMID:25602175",
-                "PMID:25872749",
-                "PMID:26121051"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:17296457': {'publication date': '2006 Dec', 'sentence': 'Ranolazine for the management of coronary artery disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:17714067': {'publication date': '2007 Sep', 'sentence': 'Ranolazine in patients with coronary artery disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:19389561': {'publication date': '2009 Apr 28', 'sentence': 'CONCLUSIONS: In this largest study of ranolazine in patients with established coronary artery disease, ranolazine was effective in reducing angina with favorable safety in a substantially broader group of patients with angina than previously studied.', 'subject score': 1000, 'object score': 916}, 'PMID:19444092': {'publication date': '2009 Aug', 'sentence': 'Ranolazine improves endothelial function in patients with stable coronary artery disease.', 'subject score': 1000, 'object score': 923}, 'PMID:2110906': {'publication date': '1990', 'sentence': 'This preliminary study suggests that ranolazine may significantly prolong exercise time in patients with stable coronary artery disease without altering heart rates and blood pressure.', 'subject score': 1000, 'object score': 923}, 'PMID:21228065': {'publication date': '2011 Apr', 'sentence': 'In addition to its anti-ischemic and antianginal effects, ranolazine has been shown to lower hemoglobin A(1c) (HbA(1c)) in patients with coronary artery disease and diabetes.', 'subject score': 1000, 'object score': 1000}, 'PMID:22884560': {'publication date': '2012 Nov 15', 'sentence': 'Effect of ranolazine on left ventricular dyssynchrony in patients with coronary artery disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:23500237': {'publication date': '2013 May 21', 'sentence': 'METHODS: TERISA (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina) was an international, randomized, double-blind trial of ranolazine versus placebo in patients with diabetes, CAD, and stable angina treated with 1 to 2 antianginals.', 'subject score': 1000, 'object score': 1000}, 'PMID:24812428': {'publication date': '2014 Oct', 'sentence': 'In addition to its antianginal effects, ranolazine has been shown to reduce HbA1c levels in patients with type 2 diabetes mellitus and coronary artery disease; however, the mechanism behind its antidiabetic effect has been unclear.', 'subject score': 1000, 'object score': 1000}, 'PMID:26021246': {'publication date': '2015 May-Jun', 'sentence': 'CONCLUSIONS: The use of ranolazine in patients suffering from chronic coronary artery disease has a favorable impact on diastolic function parameters.', 'subject score': 1000, 'object score': 916}, 'PMID:33438139': {'publication date': '2021 Jan 13', 'sentence': 'In two studies, exercise duration and time to myocardial ischemia were significantly increased after treatment with ranolazine.', 'subject score': 1000, 'object score': 1000}, 'PMID:33823622': {'publication date': '2021 Apr 07', 'sentence': 'In conclusion, the present study showed that treatment with ranolazine for 6 months led to a significant reduction in the activities of both serum aminotransferases in patients with stable CAD and NAFLD.', 'subject score': 1000, 'object score': 923}, 'PMID:34386127': {'publication date': '2021 Aug', 'sentence': 'Effect of ranolazine on Tp-e interval, Tp-e/QTc, and P-wave dispersion in patients with stable coronary artery disease.', 'subject score': 1000, 'object score': 923}, 'PMID:25317027': {'publication date': '2014 Sep', 'sentence': 'Angina Relief by Ranolazine Identifies False-Negative SPECT Myocardial Perfusion Scans in Patients with Coronary Disease Demonstrated by Coronary Angiography.', 'subject score': 1000, 'object score': 1000}, 'PMID:28024133': {'publication date': '2016 Dec 22', 'sentence': 'Before taking ranolazine, on the background of conventional treatment of coronary heart disease, the patient developed stable angina and persistent left bundle branch block, atrial fibrillation.', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 317775,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005010",
-          "name": "coronary artery disorder",
-          "description": "Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. [HPO:probinson]; Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. // COMMENTS: Coronary artery disease, also called atherosclerotic heart disease, is the result of atheromatous plaques within the coronary arteries leading to myocardial ischemia and infarction.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003324",
-            "ICD10:I25.10",
-            "MEDDRA:10008936",
-            "EFO:0001645",
-            "MEDDRA:10011081",
-            "HP:0001677",
-            "MEDDRA:10011106",
-            "PSY:11853",
-            "SNOMEDCT:53741008",
-            "SNOMEDCT:413844008",
-            "ICD9:414.0",
-            "MEDDRA:10003211",
-            "MEDDRA:10011079",
-            "ICD10:I20-I25",
-            "ICD9:410-414.99",
-            "MEDDRA:10013210",
-            "MEDDRA:10011076",
-            "UMLS:C0010068",
-            "MEDDRA:10011080",
-            "UMLS:C1956346",
-            "UMLS:C1533195",
-            "DOID:3393",
-            "NCIT:C26732",
-            "UMLS:C0010054",
-            "SNOMEDCT:413838009",
-            "MEDDRA:10011099",
-            "MEDDRA:10013098",
-            "MEDDRA:10008937",
-            "MEDDRA:10011078",
-            "MEDDRA:10011093",
-            "MEDDRA:10068617",
-            "ICD9:414.9",
-            "ICD10:I25",
-            "MEDDRA:10011087",
-            "MESH:D003327",
-            "MEDDRA:10049175",
-            "SNOMEDCT:414024009",
-            "MEDDRA:10011082",
-            "UMLS:C0264694",
-            "MONDO:0005010"
-          ],
-          "id": "MONDO:0005010",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic ischemic heart disease, unspecified",
-            "Coronary Artery Disease",
-            "Ischemic heart disease",
-            "Coronary atherosclerosis",
-            "Coronary artery atherosclerosis",
-            "Coronary Arteriosclerosis",
-            "Coronary Heart Disease",
-            "coronary artery disease",
-            "Coronary Disease",
-            "Chronic myocardial ischemia",
-            "Coronary heart disease",
-            "coronary artery disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:31420554",
-            "http://en.wikipedia.org/wiki/coronary_heart_disease",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317775,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005010",
-              "name": "coronary artery disorder",
-              "description": "Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. [HPO:probinson]; Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. // COMMENTS: Coronary artery disease, also called atherosclerotic heart disease, is the result of atheromatous plaques within the coronary arteries leading to myocardial ischemia and infarction.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003324",
-                "ICD10:I25.10",
-                "MEDDRA:10008936",
-                "EFO:0001645",
-                "MEDDRA:10011081",
-                "HP:0001677",
-                "MEDDRA:10011106",
-                "PSY:11853",
-                "SNOMEDCT:53741008",
-                "SNOMEDCT:413844008",
-                "ICD9:414.0",
-                "MEDDRA:10003211",
-                "MEDDRA:10011079",
-                "ICD10:I20-I25",
-                "ICD9:410-414.99",
-                "MEDDRA:10013210",
-                "MEDDRA:10011076",
-                "UMLS:C0010068",
-                "MEDDRA:10011080",
-                "UMLS:C1956346",
-                "UMLS:C1533195",
-                "DOID:3393",
-                "NCIT:C26732",
-                "UMLS:C0010054",
-                "SNOMEDCT:413838009",
-                "MEDDRA:10011099",
-                "MEDDRA:10013098",
-                "MEDDRA:10008937",
-                "MEDDRA:10011078",
-                "MEDDRA:10011093",
-                "MEDDRA:10068617",
-                "ICD9:414.9",
-                "ICD10:I25",
-                "MEDDRA:10011087",
-                "MESH:D003327",
-                "MEDDRA:10049175",
-                "SNOMEDCT:414024009",
-                "MEDDRA:10011082",
-                "UMLS:C0264694",
-                "MONDO:0005010"
-              ],
-              "id": "MONDO:0005010",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic ischemic heart disease, unspecified",
-                "Coronary Artery Disease",
-                "Ischemic heart disease",
-                "Coronary atherosclerosis",
-                "Coronary artery atherosclerosis",
-                "Coronary Arteriosclerosis",
-                "Coronary Heart Disease",
-                "coronary artery disease",
-                "Coronary Disease",
-                "Chronic myocardial ischemia",
-                "Coronary heart disease",
-                "coronary artery disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:31420554",
-                "http://en.wikipedia.org/wiki/coronary_heart_disease",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12700516,
-            "start": 567,
-            "end": 317775,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17296457': {'publication date': '2006 Dec', 'sentence': 'Ranolazine for the management of coronary artery disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:17714067': {'publication date': '2007 Sep', 'sentence': 'Ranolazine in patients with coronary artery disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:19389561': {'publication date': '2009 Apr 28', 'sentence': 'CONCLUSIONS: In this largest study of ranolazine in patients with established coronary artery disease, ranolazine was effective in reducing angina with favorable safety in a substantially broader group of patients with angina than previously studied.', 'subject score': 1000, 'object score': 916}, 'PMID:19444092': {'publication date': '2009 Aug', 'sentence': 'Ranolazine improves endothelial function in patients with stable coronary artery disease.', 'subject score': 1000, 'object score': 923}, 'PMID:2110906': {'publication date': '1990', 'sentence': 'This preliminary study suggests that ranolazine may significantly prolong exercise time in patients with stable coronary artery disease without altering heart rates and blood pressure.', 'subject score': 1000, 'object score': 923}, 'PMID:21228065': {'publication date': '2011 Apr', 'sentence': 'In addition to its anti-ischemic and antianginal effects, ranolazine has been shown to lower hemoglobin A(1c) (HbA(1c)) in patients with coronary artery disease and diabetes.', 'subject score': 1000, 'object score': 1000}, 'PMID:22884560': {'publication date': '2012 Nov 15', 'sentence': 'Effect of ranolazine on left ventricular dyssynchrony in patients with coronary artery disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:23500237': {'publication date': '2013 May 21', 'sentence': 'METHODS: TERISA (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina) was an international, randomized, double-blind trial of ranolazine versus placebo in patients with diabetes, CAD, and stable angina treated with 1 to 2 antianginals.', 'subject score': 1000, 'object score': 1000}, 'PMID:24812428': {'publication date': '2014 Oct', 'sentence': 'In addition to its antianginal effects, ranolazine has been shown to reduce HbA1c levels in patients with type 2 diabetes mellitus and coronary artery disease; however, the mechanism behind its antidiabetic effect has been unclear.', 'subject score': 1000, 'object score': 1000}, 'PMID:26021246': {'publication date': '2015 May-Jun', 'sentence': 'CONCLUSIONS: The use of ranolazine in patients suffering from chronic coronary artery disease has a favorable impact on diastolic function parameters.', 'subject score': 1000, 'object score': 916}, 'PMID:33438139': {'publication date': '2021 Jan 13', 'sentence': 'In two studies, exercise duration and time to myocardial ischemia were significantly increased after treatment with ranolazine.', 'subject score': 1000, 'object score': 1000}, 'PMID:33823622': {'publication date': '2021 Apr 07', 'sentence': 'In conclusion, the present study showed that treatment with ranolazine for 6 months led to a significant reduction in the activities of both serum aminotransferases in patients with stable CAD and NAFLD.', 'subject score': 1000, 'object score': 923}, 'PMID:34386127': {'publication date': '2021 Aug', 'sentence': 'Effect of ranolazine on Tp-e interval, Tp-e/QTc, and P-wave dispersion in patients with stable coronary artery disease.', 'subject score': 1000, 'object score': 923}, 'PMID:25317027': {'publication date': '2014 Sep', 'sentence': 'Angina Relief by Ranolazine Identifies False-Negative SPECT Myocardial Perfusion Scans in Patients with Coronary Disease Demonstrated by Coronary Angiography.', 'subject score': 1000, 'object score': 1000}, 'PMID:28024133': {'publication date': '2016 Dec 22', 'sentence': 'Before taking ranolazine, on the background of conventional treatment of coronary heart disease, the patient developed stable angina and persistent left bundle branch block, atrial fibrillation.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:treats---None---None---None---UMLS:C0010054---SEMMEDDB:",
-                "UMLS:C0073633---SEMMEDDB:treats---None---None---None---UMLS:C0010068---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "12975239",
-              "object": "MONDO:0005010",
-              "publications": [
-                "PMID:19444092",
-                "PMID:21228065",
-                "PMID:34386127",
-                "PMID:17714067",
-                "PMID:17296457",
-                "PMID:23500237",
-                "PMID:2110906",
-                "PMID:33438139",
-                "PMID:28024133",
-                "PMID:24812428",
-                "PMID:22884560",
-                "PMID:19389561",
-                "PMID:26021246",
-                "PMID:25317027",
-                "PMID:33823622"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1383622': {'publication date': '1992 Jul', 'sentence': 'Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem.', 'subject score': 1000, 'object score': 901}, 'PMID:15670536': {'publication date': '2005 Feb 01', 'sentence': 'Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.', 'subject score': 1000, 'object score': 901}, 'PMID:17196454': {'publication date': '2007 Jan 01', 'sentence': 'Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials.', 'subject score': 1000, 'object score': 901}, 'PMID:20222810': {'publication date': '2010 Mar', 'sentence': 'Ranolazine is a novel drug approved for the treatment of chronic angina pectoris.', 'subject score': 1000, 'object score': 901}, 'PMID:23472826': {'publication date': '2013 Jun', 'sentence': 'BACKGROUND AND PURPOSE: Ranolazine is an antianginal drug currently approved for treatment of angina pectoris in the United States.', 'subject score': 1000, 'object score': 1000}, 'PMID:23801963': {'publication date': '2013', 'sentence': 'Ranolazine is clinically approved for treatment of angina pectoris and is a potential candidate for antiarrhythmic, antiepileptic, and analgesic applications.', 'subject score': 1000, 'object score': 1000}, 'PMID:24122303': {'publication date': '2014 Dec', 'sentence': 'Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain.', 'subject score': 1000, 'object score': 901}, 'PMID:24574825': {'publication date': '2013 Jan 15', 'sentence': 'Safety and Efficacy of Ranolazine for the Treatment of Chronic Angina Pectoris.', 'subject score': 1000, 'object score': 901}, 'PMID:24826280': {'publication date': '2013', 'sentence': 'Resolution of angina pectoris and improvement of the coronary flow reserve after ranolazine treatment in a woman with isolated impaired coronary microcirculation.', 'subject score': 888, 'object score': 1000}, 'PMID:26532231': {'publication date': '2015 Nov', 'sentence': 'Cost-Utility Of Ranolazine For The Symptomatic Treatment Of Patients With Chronic Angina Pectoris In Greece.', 'subject score': 1000, 'object score': 901}, 'PMID:26684327': {'publication date': '2015 Dec 18', 'sentence': 'Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study.', 'subject score': 1000, 'object score': 901}, 'PMID:26994453': {'publication date': '2016 May 15', 'sentence': 'A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris.', 'subject score': 1000, 'object score': 901}, 'PMID:27201438': {'publication date': '2014 Nov', 'sentence': 'Cost-Effectiveness Of Ranolazine For The Treatment Of Angina Pectoris In Russia.', 'subject score': 1000, 'object score': 1000}, 'PMID:32540170': {'publication date': '2020 May 16', 'sentence': 'The Ranolazine Refractory Angina Registry was designed to evaluate the safety, tolerability, and effectiveness of ranolazine in RAP patients in order to expand treatment options for this challenging patient population.', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 317974,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001681",
-          "name": "Angina pectoris",
-          "description": "Paroxysms of chest pain due to reduced oxygen to the heart.; The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.; Paroxysmal chest pain that occurs with exertion or stress and is related to myocardial ischemia. [HPO:probinson]; Angina is chest pain or discomfort you feel when there is not enough blood flow to your heart muscle. Your heart muscle needs the oxygen that the blood carries. Angina may feel like pressure or a squeezing pain in your chest. It may feel like indigestion. You may also feel pain in your shoulders, arms, neck, jaw, or back.  Angina is a symptom of coronary artery disease (CAD), the most common heart disease. CAD happens when a sticky substance called plaque builds up in the arteries that supply blood to the heart, reducing blood flow. There are three types of angina:  Stable angina is the most common type. It happens when the heart is working harder than usual. Stable angina has a regular pattern. Rest and medicines usually help. Unstable angina is the most dangerous. It does not follow a pattern and can happen without physical exertion. It does not go away with rest or medicine. It is a sign that you could have a heart attack soon. Variant angina is rare. It happens when you are resting. Medicines can help.  Not all chest pain or discomfort is angina. If you have chest pain, you should see your health care provider. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "PSY:02530",
-            "MEDDRA:10002387",
-            "MEDDRA:10002393",
-            "SNOMEDCT:194828000",
-            "UMLS:C0002962",
-            "MEDDRA:10056259",
-            "MESH:D000787",
-            "ICD9:413",
-            "MEDDRA:10002383",
-            "MEDDRA:10054224",
-            "NCIT:C51221",
-            "EFO:0003913",
-            "MEDDRA:10041972",
-            "MEDDRA:10056256",
-            "SNOMEDCT:225566008",
-            "MEDDRA:10002391",
-            "HP:0001681"
-          ],
-          "id": "HP:0001681",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "angina pectoris",
-            "Angina",
-            "Angina Pectoris",
-            "Angina pectoris"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317974,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001681",
-              "name": "Angina pectoris",
-              "description": "Paroxysms of chest pain due to reduced oxygen to the heart.; The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.; Paroxysmal chest pain that occurs with exertion or stress and is related to myocardial ischemia. [HPO:probinson]; Angina is chest pain or discomfort you feel when there is not enough blood flow to your heart muscle. Your heart muscle needs the oxygen that the blood carries. Angina may feel like pressure or a squeezing pain in your chest. It may feel like indigestion. You may also feel pain in your shoulders, arms, neck, jaw, or back.  Angina is a symptom of coronary artery disease (CAD), the most common heart disease. CAD happens when a sticky substance called plaque builds up in the arteries that supply blood to the heart, reducing blood flow. There are three types of angina:  Stable angina is the most common type. It happens when the heart is working harder than usual. Stable angina has a regular pattern. Rest and medicines usually help. Unstable angina is the most dangerous. It does not follow a pattern and can happen without physical exertion. It does not go away with rest or medicine. It is a sign that you could have a heart attack soon. Variant angina is rare. It happens when you are resting. Medicines can help.  Not all chest pain or discomfort is angina. If you have chest pain, you should see your health care provider. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "PSY:02530",
-                "MEDDRA:10002387",
-                "MEDDRA:10002393",
-                "SNOMEDCT:194828000",
-                "UMLS:C0002962",
-                "MEDDRA:10056259",
-                "MESH:D000787",
-                "ICD9:413",
-                "MEDDRA:10002383",
-                "MEDDRA:10054224",
-                "NCIT:C51221",
-                "EFO:0003913",
-                "MEDDRA:10041972",
-                "MEDDRA:10056256",
-                "SNOMEDCT:225566008",
-                "MEDDRA:10002391",
-                "HP:0001681"
-              ],
-              "id": "HP:0001681",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "angina pectoris",
-                "Angina",
-                "Angina Pectoris",
-                "Angina pectoris"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10398239,
-            "start": 567,
-            "end": 317974,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1383622': {'publication date': '1992 Jul', 'sentence': 'Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem.', 'subject score': 1000, 'object score': 901}, 'PMID:15670536': {'publication date': '2005 Feb 01', 'sentence': 'Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.', 'subject score': 1000, 'object score': 901}, 'PMID:17196454': {'publication date': '2007 Jan 01', 'sentence': 'Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials.', 'subject score': 1000, 'object score': 901}, 'PMID:20222810': {'publication date': '2010 Mar', 'sentence': 'Ranolazine is a novel drug approved for the treatment of chronic angina pectoris.', 'subject score': 1000, 'object score': 901}, 'PMID:23472826': {'publication date': '2013 Jun', 'sentence': 'BACKGROUND AND PURPOSE: Ranolazine is an antianginal drug currently approved for treatment of angina pectoris in the United States.', 'subject score': 1000, 'object score': 1000}, 'PMID:23801963': {'publication date': '2013', 'sentence': 'Ranolazine is clinically approved for treatment of angina pectoris and is a potential candidate for antiarrhythmic, antiepileptic, and analgesic applications.', 'subject score': 1000, 'object score': 1000}, 'PMID:24122303': {'publication date': '2014 Dec', 'sentence': 'Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain.', 'subject score': 1000, 'object score': 901}, 'PMID:24574825': {'publication date': '2013 Jan 15', 'sentence': 'Safety and Efficacy of Ranolazine for the Treatment of Chronic Angina Pectoris.', 'subject score': 1000, 'object score': 901}, 'PMID:24826280': {'publication date': '2013', 'sentence': 'Resolution of angina pectoris and improvement of the coronary flow reserve after ranolazine treatment in a woman with isolated impaired coronary microcirculation.', 'subject score': 888, 'object score': 1000}, 'PMID:26532231': {'publication date': '2015 Nov', 'sentence': 'Cost-Utility Of Ranolazine For The Symptomatic Treatment Of Patients With Chronic Angina Pectoris In Greece.', 'subject score': 1000, 'object score': 901}, 'PMID:26684327': {'publication date': '2015 Dec 18', 'sentence': 'Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study.', 'subject score': 1000, 'object score': 901}, 'PMID:26994453': {'publication date': '2016 May 15', 'sentence': 'A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris.', 'subject score': 1000, 'object score': 901}, 'PMID:27201438': {'publication date': '2014 Nov', 'sentence': 'Cost-Effectiveness Of Ranolazine For The Treatment Of Angina Pectoris In Russia.', 'subject score': 1000, 'object score': 1000}, 'PMID:32540170': {'publication date': '2020 May 16', 'sentence': 'The Ranolazine Refractory Angina Registry was designed to evaluate the safety, tolerability, and effectiveness of ranolazine in RAP patients in order to expand treatment options for this challenging patient population.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:treats---None---None---None---UMLS:C0002962---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "10629663",
-              "object": "HP:0001681",
-              "publications": [
-                "PMID:1383622",
-                "PMID:15670536",
-                "PMID:17196454",
-                "PMID:20222810",
-                "PMID:23472826",
-                "PMID:23801963",
-                "PMID:24122303",
-                "PMID:24574825",
-                "PMID:24826280",
-                "PMID:26532231",
-                "PMID:26684327",
-                "PMID:26994453",
-                "PMID:27201438",
-                "PMID:32540170"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:24560062': {'publication date': '2014 Apr 15', 'sentence': 'Ranolazine has been shown to decrease angina pectoris frequency and nitroglycerin consumption.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 317974,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001681",
-          "name": "Angina pectoris",
-          "description": "Paroxysms of chest pain due to reduced oxygen to the heart.; The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.; Paroxysmal chest pain that occurs with exertion or stress and is related to myocardial ischemia. [HPO:probinson]; Angina is chest pain or discomfort you feel when there is not enough blood flow to your heart muscle. Your heart muscle needs the oxygen that the blood carries. Angina may feel like pressure or a squeezing pain in your chest. It may feel like indigestion. You may also feel pain in your shoulders, arms, neck, jaw, or back.  Angina is a symptom of coronary artery disease (CAD), the most common heart disease. CAD happens when a sticky substance called plaque builds up in the arteries that supply blood to the heart, reducing blood flow. There are three types of angina:  Stable angina is the most common type. It happens when the heart is working harder than usual. Stable angina has a regular pattern. Rest and medicines usually help. Unstable angina is the most dangerous. It does not follow a pattern and can happen without physical exertion. It does not go away with rest or medicine. It is a sign that you could have a heart attack soon. Variant angina is rare. It happens when you are resting. Medicines can help.  Not all chest pain or discomfort is angina. If you have chest pain, you should see your health care provider. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "PSY:02530",
-            "MEDDRA:10002387",
-            "MEDDRA:10002393",
-            "SNOMEDCT:194828000",
-            "UMLS:C0002962",
-            "MEDDRA:10056259",
-            "MESH:D000787",
-            "ICD9:413",
-            "MEDDRA:10002383",
-            "MEDDRA:10054224",
-            "NCIT:C51221",
-            "EFO:0003913",
-            "MEDDRA:10041972",
-            "MEDDRA:10056256",
-            "SNOMEDCT:225566008",
-            "MEDDRA:10002391",
-            "HP:0001681"
-          ],
-          "id": "HP:0001681",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "angina pectoris",
-            "Angina",
-            "Angina Pectoris",
-            "Angina pectoris"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317974,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001681",
-              "name": "Angina pectoris",
-              "description": "Paroxysms of chest pain due to reduced oxygen to the heart.; The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.; Paroxysmal chest pain that occurs with exertion or stress and is related to myocardial ischemia. [HPO:probinson]; Angina is chest pain or discomfort you feel when there is not enough blood flow to your heart muscle. Your heart muscle needs the oxygen that the blood carries. Angina may feel like pressure or a squeezing pain in your chest. It may feel like indigestion. You may also feel pain in your shoulders, arms, neck, jaw, or back.  Angina is a symptom of coronary artery disease (CAD), the most common heart disease. CAD happens when a sticky substance called plaque builds up in the arteries that supply blood to the heart, reducing blood flow. There are three types of angina:  Stable angina is the most common type. It happens when the heart is working harder than usual. Stable angina has a regular pattern. Rest and medicines usually help. Unstable angina is the most dangerous. It does not follow a pattern and can happen without physical exertion. It does not go away with rest or medicine. It is a sign that you could have a heart attack soon. Variant angina is rare. It happens when you are resting. Medicines can help.  Not all chest pain or discomfort is angina. If you have chest pain, you should see your health care provider. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "PSY:02530",
-                "MEDDRA:10002387",
-                "MEDDRA:10002393",
-                "SNOMEDCT:194828000",
-                "UMLS:C0002962",
-                "MEDDRA:10056259",
-                "MESH:D000787",
-                "ICD9:413",
-                "MEDDRA:10002383",
-                "MEDDRA:10054224",
-                "NCIT:C51221",
-                "EFO:0003913",
-                "MEDDRA:10041972",
-                "MEDDRA:10056256",
-                "SNOMEDCT:225566008",
-                "MEDDRA:10002391",
-                "HP:0001681"
-              ],
-              "id": "HP:0001681",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "angina pectoris",
-                "Angina",
-                "Angina Pectoris",
-                "Angina pectoris"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17123948,
-            "start": 567,
-            "end": 317974,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24560062': {'publication date': '2014 Apr 15', 'sentence': 'Ranolazine has been shown to decrease angina pectoris frequency and nitroglycerin consumption.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:prevents---None---None---None---UMLS:C0002962---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "17475563",
-              "object": "HP:0001681",
-              "publications": [
-                "PMID:24560062"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:20925013': {'publication date': '2010 Oct', 'sentence': 'Moreover, ranolazine holds potential promise to be effective in treatment of atrial fibrillation and diastolic heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:21538388': {'publication date': '2011 Jul', 'sentence': 'HYPOTHESIS: RAnoLazIne for the Treatment of Diastolic Heart Failure (RALI-DHF) is a prospective, single-center, randomized, double-blind, placebo-controlled proof-of-concept study to determine if ranolazine compared with placebo will be more effective in improving diastolic function in patients with HFpEF.', 'subject score': 1000, 'object score': 1000}, 'PMID:24621836': {'publication date': '2013 Apr', 'sentence': 'RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 518244,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006727",
-          "name": "diastolic heart failure",
-          "description": "Heart failure caused by abnormal myocardial relaxation during diastole leading to defective cardiac filling.",
-          "equivalent_curies": [
-            "ICD10:I50.30",
-            "ICD9:428.3",
-            "MONDO:0006727",
-            "SNOMEDCT:418304008",
-            "EFO:1000899",
-            "MESH:D054144",
-            "DOID:9775",
-            "UMLS:C1135196",
-            "MEDDRA:10069211"
-          ],
-          "id": "MONDO:0006727",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Diastolic heart failure",
-            "Heart Failure, Diastolic",
-            "diastolic heart failure"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 518244,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006727",
-              "name": "diastolic heart failure",
-              "description": "Heart failure caused by abnormal myocardial relaxation during diastole leading to defective cardiac filling.",
-              "equivalent_curies": [
-                "ICD10:I50.30",
-                "ICD9:428.3",
-                "MONDO:0006727",
-                "SNOMEDCT:418304008",
-                "EFO:1000899",
-                "MESH:D054144",
-                "DOID:9775",
-                "UMLS:C1135196",
-                "MEDDRA:10069211"
-              ],
-              "id": "MONDO:0006727",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Diastolic heart failure",
-                "Heart Failure, Diastolic",
-                "diastolic heart failure"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14928066,
-            "start": 567,
-            "end": 518244,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20925013': {'publication date': '2010 Oct', 'sentence': 'Moreover, ranolazine holds potential promise to be effective in treatment of atrial fibrillation and diastolic heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:21538388': {'publication date': '2011 Jul', 'sentence': 'HYPOTHESIS: RAnoLazIne for the Treatment of Diastolic Heart Failure (RALI-DHF) is a prospective, single-center, randomized, double-blind, placebo-controlled proof-of-concept study to determine if ranolazine compared with placebo will be more effective in improving diastolic function in patients with HFpEF.', 'subject score': 1000, 'object score': 1000}, 'PMID:24621836': {'publication date': '2013 Apr', 'sentence': 'RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:treats---None---None---None---UMLS:C1135196---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "15243162",
-              "object": "MONDO:0006727",
-              "publications": [
-                "PMID:20925013",
-                "PMID:21538388",
-                "PMID:24621836"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:20828645': {'publication date': '2010 Sep 14', 'sentence': 'The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease.', 'subject score': 1000, 'object score': 923}, 'PMID:2110906': {'publication date': '1990', 'sentence': 'Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium.', 'subject score': 1000, 'object score': 928}, 'PMID:23335347': {'publication date': '2013 Feb', 'sentence': 'The inhibition of late sodium channels as well as other ion currents has a central role in the potential use of ranolazine in ischemic heart disease, arrhythmias, and heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:29938533': {'publication date': '2018 Jan 01', 'sentence': 'Effect of Ranolazine on Ischemic Myocardium IN Patients With Acute Cardiac Ischemia (RIMINI-Trial): A Randomized Controlled Pilot Trial.', 'subject score': 1000, 'object score': 928}}",
-    "p2": {
-      "start": {
-        "identity": 525277,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0024644",
-          "name": "myocardial ischemia",
-          "description": "A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries, to obstruction by a thrombus, or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).; A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).",
-          "equivalent_curies": [
-            "UMLS:C0151744",
-            "MONDO:0024644",
-            "MEDDRA:10021279",
-            "MEDDRA:10007584",
-            "MEDDRA:10023024",
-            "MEDDRA:10055218",
-            "MEDDRA:10055752",
-            "SNOMEDCT:414545008",
-            "MEDDRA:10028601",
-            "NCIT:C50625",
-            "MESH:D017202",
-            "SNOMEDCT:414795007",
-            "MEDDRA:10055224",
-            "EFO:1001375",
-            "MEDDRA:10028600",
-            "MEDDRA:10023033"
-          ],
-          "id": "MONDO:0024644",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myocardial Ischemia",
-            "myocardial ischemia",
-            "Ischemic Heart Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 525277,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0024644",
-              "name": "myocardial ischemia",
-              "description": "A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries, to obstruction by a thrombus, or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).; A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).",
-              "equivalent_curies": [
-                "UMLS:C0151744",
-                "MONDO:0024644",
-                "MEDDRA:10021279",
-                "MEDDRA:10007584",
-                "MEDDRA:10023024",
-                "MEDDRA:10055218",
-                "MEDDRA:10055752",
-                "SNOMEDCT:414545008",
-                "MEDDRA:10028601",
-                "NCIT:C50625",
-                "MESH:D017202",
-                "SNOMEDCT:414795007",
-                "MEDDRA:10055224",
-                "EFO:1001375",
-                "MEDDRA:10028600",
-                "MEDDRA:10023033"
-              ],
-              "id": "MONDO:0024644",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myocardial Ischemia",
-                "myocardial ischemia",
-                "Ischemic Heart Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14884688,
-            "start": 567,
-            "end": 525277,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20828645': {'publication date': '2010 Sep 14', 'sentence': 'The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease.', 'subject score': 1000, 'object score': 923}, 'PMID:2110906': {'publication date': '1990', 'sentence': 'Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium.', 'subject score': 1000, 'object score': 928}, 'PMID:23335347': {'publication date': '2013 Feb', 'sentence': 'The inhibition of late sodium channels as well as other ion currents has a central role in the potential use of ranolazine in ischemic heart disease, arrhythmias, and heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:29938533': {'publication date': '2018 Jan 01', 'sentence': 'Effect of Ranolazine on Ischemic Myocardium IN Patients With Acute Cardiac Ischemia (RIMINI-Trial): A Randomized Controlled Pilot Trial.', 'subject score': 1000, 'object score': 928}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:affects---None---None---None---UMLS:C0151744---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "15199166",
-              "object": "MONDO:0024644",
-              "publications": [
-                "PMID:20828645",
-                "PMID:2110906",
-                "PMID:23335347",
-                "PMID:29938533"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11772326': {'publication date': '2002 Jan', 'sentence': 'Ranolazine has been shown to improve exercise-induced myocardial ischaemia and to lessen the severity of angina in the setting of chronic ischaemic heart disease.', 'subject score': 1000, 'object score': 888}, 'PMID:16382258': {'publication date': '2005 Dec', 'sentence': 'In this article, we review five novel agents (ranolazine, trimetazidine, L-carnitine, ribose, and dichloroacetate) under investigation for treatment of ischemic heart disease that work by enhancing the efficiency of the myocardium, rather than decreasing its work.', 'subject score': 1000, 'object score': 1000}, 'PMID:16620147': {'publication date': '2006', 'sentence': 'Comparative trials of ranolazine ER with other antianginal agents and trials examining its effects on long-term morbidity and mortality in patients with ischaemic heart disease are required to determine with greater certainty the place of the drug in current antianginal therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:17083271': {'publication date': '2006', 'sentence': 'Comparative trials of ranolazine ER with other antianginal agents and trials examining its effects on long-term morbidity and mortality in patients with ischemic heart disease are required to determine with greater certainty the place of the drug in current antianginal therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:21432000': {'publication date': '2011 May', 'sentence': 'BACKGROUND: We previously reported that ranolazine improved myocardial ischemia during exercise myocardial perfusion imaging (MPI).', 'subject score': 1000, 'object score': 1000}, 'PMID:22884560': {'publication date': '2012 Nov 15', 'sentence': 'Ranolazine ameliorates myocardial ischemia by augmenting myocardial blood flow; likely by a reduction in the extravascular compression of small vessels.', 'subject score': 1000, 'object score': 1000}, 'PMID:23121448': {'publication date': '2012 Dec', 'sentence': 'Should  ranolazine  be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris?', 'subject score': 1000, 'object score': 1000}, 'PMID:23121536': {'publication date': '2012 Dec', 'sentence': \"This editorial refers to 'Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal' by U Thadani also published in this issue.\", 'subject score': 1000, 'object score': 1000}, 'PMID:25041234': {'publication date': '2015 Mar', 'sentence': 'Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:26049922': {'publication date': '2015 Dec', 'sentence': 'Influence of trimetazidine and ranolazine on endothelial function in patients with ischemic heart disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:29127493': {'publication date': '2018 Mar', 'sentence': 'Selective INa,L inhibitors, exemplified by ranolazine, GS-967 and GS-458967 have little or no effect on peak sodium current and/or IKr, and carry no or minimal pro-arrhythmic risk compared to those associated with administration of classical class I or III antiarrhythmic drugs, particularly in patients with ischemic heart disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:30832963': {'publication date': '2019 May 15', 'sentence': 'In conclusion, ranolazine treatment in patients with SIHD was associated with fewer revascularization procedures and lower associated healthcare costs compared with patients initiating BB or LAN, and comparable to patients initiating CCBs.', 'subject score': 888, 'object score': 923}, 'PMID:30888919': {'publication date': '2019 May', 'sentence': 'Conclusions: Women with IHD treated with ranolazine for 4 weeks experienced less angina measured by SAQ and WISQ.', 'subject score': 1000, 'object score': 1000}, 'PMID:30922541': {'publication date': '2019 May 15', 'sentence': 'Role of Ranolazine in Reducing Angina, Subsequent Revascularization, and Healthcare Expenditures in Stable Ischemic Heart Disease.', 'subject score': 1000, 'object score': 923}, 'PMID:8044941': {'publication date': '1994 Aug', 'sentence': 'Our study does not support the published beneficial effects of similar doses of ranolazine on either myocardial ischemia or exercise performance or on anginal attacks during daily life in patients with angina pectoris.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 525277,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0024644",
-          "name": "myocardial ischemia",
-          "description": "A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries, to obstruction by a thrombus, or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).; A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).",
-          "equivalent_curies": [
-            "UMLS:C0151744",
-            "MONDO:0024644",
-            "MEDDRA:10021279",
-            "MEDDRA:10007584",
-            "MEDDRA:10023024",
-            "MEDDRA:10055218",
-            "MEDDRA:10055752",
-            "SNOMEDCT:414545008",
-            "MEDDRA:10028601",
-            "NCIT:C50625",
-            "MESH:D017202",
-            "SNOMEDCT:414795007",
-            "MEDDRA:10055224",
-            "EFO:1001375",
-            "MEDDRA:10028600",
-            "MEDDRA:10023033"
-          ],
-          "id": "MONDO:0024644",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myocardial Ischemia",
-            "myocardial ischemia",
-            "Ischemic Heart Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 525277,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0024644",
-              "name": "myocardial ischemia",
-              "description": "A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries, to obstruction by a thrombus, or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).; A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).",
-              "equivalent_curies": [
-                "UMLS:C0151744",
-                "MONDO:0024644",
-                "MEDDRA:10021279",
-                "MEDDRA:10007584",
-                "MEDDRA:10023024",
-                "MEDDRA:10055218",
-                "MEDDRA:10055752",
-                "SNOMEDCT:414545008",
-                "MEDDRA:10028601",
-                "NCIT:C50625",
-                "MESH:D017202",
-                "SNOMEDCT:414795007",
-                "MEDDRA:10055224",
-                "EFO:1001375",
-                "MEDDRA:10028600",
-                "MEDDRA:10023033"
-              ],
-              "id": "MONDO:0024644",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myocardial Ischemia",
-                "myocardial ischemia",
-                "Ischemic Heart Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9102090,
-            "start": 567,
-            "end": 525277,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11772326': {'publication date': '2002 Jan', 'sentence': 'Ranolazine has been shown to improve exercise-induced myocardial ischaemia and to lessen the severity of angina in the setting of chronic ischaemic heart disease.', 'subject score': 1000, 'object score': 888}, 'PMID:16382258': {'publication date': '2005 Dec', 'sentence': 'In this article, we review five novel agents (ranolazine, trimetazidine, L-carnitine, ribose, and dichloroacetate) under investigation for treatment of ischemic heart disease that work by enhancing the efficiency of the myocardium, rather than decreasing its work.', 'subject score': 1000, 'object score': 1000}, 'PMID:16620147': {'publication date': '2006', 'sentence': 'Comparative trials of ranolazine ER with other antianginal agents and trials examining its effects on long-term morbidity and mortality in patients with ischaemic heart disease are required to determine with greater certainty the place of the drug in current antianginal therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:17083271': {'publication date': '2006', 'sentence': 'Comparative trials of ranolazine ER with other antianginal agents and trials examining its effects on long-term morbidity and mortality in patients with ischemic heart disease are required to determine with greater certainty the place of the drug in current antianginal therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:21432000': {'publication date': '2011 May', 'sentence': 'BACKGROUND: We previously reported that ranolazine improved myocardial ischemia during exercise myocardial perfusion imaging (MPI).', 'subject score': 1000, 'object score': 1000}, 'PMID:22884560': {'publication date': '2012 Nov 15', 'sentence': 'Ranolazine ameliorates myocardial ischemia by augmenting myocardial blood flow; likely by a reduction in the extravascular compression of small vessels.', 'subject score': 1000, 'object score': 1000}, 'PMID:23121448': {'publication date': '2012 Dec', 'sentence': 'Should  ranolazine  be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris?', 'subject score': 1000, 'object score': 1000}, 'PMID:23121536': {'publication date': '2012 Dec', 'sentence': \"This editorial refers to 'Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal' by U Thadani also published in this issue.\", 'subject score': 1000, 'object score': 1000}, 'PMID:25041234': {'publication date': '2015 Mar', 'sentence': 'Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:26049922': {'publication date': '2015 Dec', 'sentence': 'Influence of trimetazidine and ranolazine on endothelial function in patients with ischemic heart disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:29127493': {'publication date': '2018 Mar', 'sentence': 'Selective INa,L inhibitors, exemplified by ranolazine, GS-967 and GS-458967 have little or no effect on peak sodium current and/or IKr, and carry no or minimal pro-arrhythmic risk compared to those associated with administration of classical class I or III antiarrhythmic drugs, particularly in patients with ischemic heart disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:30832963': {'publication date': '2019 May 15', 'sentence': 'In conclusion, ranolazine treatment in patients with SIHD was associated with fewer revascularization procedures and lower associated healthcare costs compared with patients initiating BB or LAN, and comparable to patients initiating CCBs.', 'subject score': 888, 'object score': 923}, 'PMID:30888919': {'publication date': '2019 May', 'sentence': 'Conclusions: Women with IHD treated with ranolazine for 4 weeks experienced less angina measured by SAQ and WISQ.', 'subject score': 1000, 'object score': 1000}, 'PMID:30922541': {'publication date': '2019 May 15', 'sentence': 'Role of Ranolazine in Reducing Angina, Subsequent Revascularization, and Healthcare Expenditures in Stable Ischemic Heart Disease.', 'subject score': 1000, 'object score': 923}, 'PMID:8044941': {'publication date': '1994 Aug', 'sentence': 'Our study does not support the published beneficial effects of similar doses of ranolazine on either myocardial ischemia or exercise performance or on anginal attacks during daily life in patients with angina pectoris.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:treats---None---None---None---UMLS:C0151744---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "9302562",
-              "object": "MONDO:0024644",
-              "publications": [
-                "PMID:11772326",
-                "PMID:16382258",
-                "PMID:16620147",
-                "PMID:17083271",
-                "PMID:21432000",
-                "PMID:22884560",
-                "PMID:23121448",
-                "PMID:23121536",
-                "PMID:25041234",
-                "PMID:26049922",
-                "PMID:29127493",
-                "PMID:30832963",
-                "PMID:30888919",
-                "PMID:30922541",
-                "PMID:8044941"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 308937,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:20031797': {'publication date': '2008 Nov', 'sentence': 'BACKGROUND: Ranolazine has been shown to reduce myocardial ischemia and symptom severity among selected patients with chronic angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:24902977': {'publication date': '2014 Jun 06', 'sentence': 'Ranolazine, trimetazidine, nicorandil, and ivabradine are medications that have been shown to reduce myocardial ischemia through diverse mechanisms and have been tested in limited fashion in patients with ACS.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 525277,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-          "name": "cardiovascular disorder",
-          "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "MEDDRA:10045663",
-            "MONDO:0004995",
-            "ICD9:429.2",
-            "MEDDRA:10007649",
-            "UMLS:C0243050",
-            "HP:0001626",
-            "MESH:D018376",
-            "MEDDRA:10007648",
-            "MEDDRA:10013205",
-            "SNOMEDCT:49601007",
-            "MEDDRA:10007650",
-            "MESH:D002318",
-            "DOID:1287",
-            "UMLS:C0007222",
-            "UMLS:C0728936",
-            "NCIT:C2931"
-          ],
-          "id": "MONDO:0004995",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiovascular Diseases",
-            "Cardiovascular disease, unspecified",
-            "Abnormality of the cardiovascular system",
-            "cardiovascular system disease",
-            "Disorder of circulatory system",
-            "Cardiovascular Disorder",
-            "cardiovascular disorder",
-            "Cardiovascular Abnormalities"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/circulatory_system",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0024644",
-          "name": "myocardial ischemia",
-          "description": "A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries, to obstruction by a thrombus, or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).; A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).",
-          "equivalent_curies": [
-            "UMLS:C0151744",
-            "MONDO:0024644",
-            "MEDDRA:10021279",
-            "MEDDRA:10007584",
-            "MEDDRA:10023024",
-            "MEDDRA:10055218",
-            "MEDDRA:10055752",
-            "SNOMEDCT:414545008",
-            "MEDDRA:10028601",
-            "NCIT:C50625",
-            "MESH:D017202",
-            "SNOMEDCT:414795007",
-            "MEDDRA:10055224",
-            "EFO:1001375",
-            "MEDDRA:10028600",
-            "MEDDRA:10023033"
-          ],
-          "id": "MONDO:0024644",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myocardial Ischemia",
-            "myocardial ischemia",
-            "Ischemic Heart Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 308937,
-=======
-            "identity": 525277,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-              "name": "cardiovascular disorder",
-              "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "MEDDRA:10045663",
-                "MONDO:0004995",
-                "ICD9:429.2",
-                "MEDDRA:10007649",
-                "UMLS:C0243050",
-                "HP:0001626",
-                "MESH:D018376",
-                "MEDDRA:10007648",
-                "MEDDRA:10013205",
-                "SNOMEDCT:49601007",
-                "MEDDRA:10007650",
-                "MESH:D002318",
-                "DOID:1287",
-                "UMLS:C0007222",
-                "UMLS:C0728936",
-                "NCIT:C2931"
-              ],
-              "id": "MONDO:0004995",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiovascular Diseases",
-                "Cardiovascular disease, unspecified",
-                "Abnormality of the cardiovascular system",
-                "cardiovascular system disease",
-                "Disorder of circulatory system",
-                "Cardiovascular Disorder",
-                "cardiovascular disorder",
-                "Cardiovascular Abnormalities"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/circulatory_system",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0024644",
-              "name": "myocardial ischemia",
-              "description": "A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries, to obstruction by a thrombus, or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).; A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).",
-              "equivalent_curies": [
-                "UMLS:C0151744",
-                "MONDO:0024644",
-                "MEDDRA:10021279",
-                "MEDDRA:10007584",
-                "MEDDRA:10023024",
-                "MEDDRA:10055218",
-                "MEDDRA:10055752",
-                "SNOMEDCT:414545008",
-                "MEDDRA:10028601",
-                "NCIT:C50625",
-                "MESH:D017202",
-                "SNOMEDCT:414795007",
-                "MEDDRA:10055224",
-                "EFO:1001375",
-                "MEDDRA:10028600",
-                "MEDDRA:10023033"
-              ],
-              "id": "MONDO:0024644",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myocardial Ischemia",
-                "myocardial ischemia",
-                "Ischemic Heart Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 9102088,
-            "start": 567,
-            "end": 308937,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11772326': {'publication date': '2002 Jan', 'sentence': 'Ranolazine is a novel drug that has shown promise in the treatment of cardiovascular disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:15949056': {'publication date': '2005', 'sentence': 'Ongoing clinical trials will help further establish the role of ranolazine in the treatment of cardiovascular disorders.', 'subject score': 1000, 'object score': 1000}, 'PMID:20222810': {'publication date': '2010 Mar', 'sentence': 'In this review we discuss the pharmacological profile of ranolazine and discuss the current and potential future applications in cardiovascular disease for this drug.', 'subject score': 1000, 'object score': 1000}, 'PMID:26546970': {'publication date': '2016 Jan', 'sentence': 'The use of ranolazine in non-anginal cardiovascular disorders: A review of current data and ongoing randomized clinical trials.', 'subject score': 1000, 'object score': 861}, 'PMID:26917816': {'publication date': '2016 May', 'sentence': 'For patients with T2DM and chronic stable angina, ranolazine may be of use given its utility in cardiovascular disease and benefit in A1C lowering.', 'subject score': 1000, 'object score': 1000}, 'PMID:35155576': {'publication date': '2022', 'sentence': 'Ranolazine is a piperazine derivative and is effective for the treatment of cardiovascular disease.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:treats---None---None---None---UMLS:C0007222---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "9302560",
-              "object": "MONDO:0004995",
-              "publications": [
-                "PMID:11772326",
-                "PMID:15949056",
-                "PMID:20222810",
-                "PMID:26546970",
-                "PMID:26917816",
-                "PMID:35155576"
-=======
-            "identity": 14445358,
-            "start": 567,
-            "end": 525277,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20031797': {'publication date': '2008 Nov', 'sentence': 'BACKGROUND: Ranolazine has been shown to reduce myocardial ischemia and symptom severity among selected patients with chronic angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:24902977': {'publication date': '2014 Jun 06', 'sentence': 'Ranolazine, trimetazidine, nicorandil, and ivabradine are medications that have been shown to reduce myocardial ischemia through diverse mechanisms and have been tested in limited fashion in patients with ACS.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:prevents---None---None---None---UMLS:C0151744---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "14751648",
-              "object": "MONDO:0024644",
-              "publications": [
-                "PMID:20031797",
-                "PMID:24902977"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:19898287': {'publication date': '2009', 'sentence': 'Small clinical trials suggest that ranolazine may have a role in the treatment of patients with non-ST-elevation acute coronary syndrome, atrial fibrillation, long QT syndromes, and sinus node dysfunction.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 540883,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002442",
-          "name": "long QT syndrome",
-          "description": "A ventricular arrhythmia characterized by a long QT interval, and accompanied by syncopal episodes sometimes leading to sudden death due to paroxysmal ventricular arrhythmia. This arrhythmia is associated with a prolongation of repolarization following depolarization of the cardiac ventricles. The prolongation of the Q-T interval combined with torsades de pointes manifests as several different forms; some may be acquired or congenital; some may lead to serious arrhythmia and sudden cardiac death.; A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD9:426.82",
-            "UMLS:C0023976",
-            "MONDO:0002442",
-            "SNOMEDCT:9651007",
-            "MEDDRA:10024803",
-            "OMIM:PS192500",
-            "NCIT:C34786",
-            "MESH:D008133",
-            "DOID:2843",
-            "ICD10:I45.81"
-          ],
-          "id": "MONDO:0002442",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Long QT syndrome",
-            "long QT syndrome",
-            "Long QT Syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/long_qt_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 540883,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002442",
-              "name": "long QT syndrome",
-              "description": "A ventricular arrhythmia characterized by a long QT interval, and accompanied by syncopal episodes sometimes leading to sudden death due to paroxysmal ventricular arrhythmia. This arrhythmia is associated with a prolongation of repolarization following depolarization of the cardiac ventricles. The prolongation of the Q-T interval combined with torsades de pointes manifests as several different forms; some may be acquired or congenital; some may lead to serious arrhythmia and sudden cardiac death.; A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD9:426.82",
-                "UMLS:C0023976",
-                "MONDO:0002442",
-                "SNOMEDCT:9651007",
-                "MEDDRA:10024803",
-                "OMIM:PS192500",
-                "NCIT:C34786",
-                "MESH:D008133",
-                "DOID:2843",
-                "ICD10:I45.81"
-              ],
-              "id": "MONDO:0002442",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Long QT syndrome",
-                "long QT syndrome",
-                "Long QT Syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/long_qt_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14366961,
-            "start": 567,
-            "end": 540883,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19898287': {'publication date': '2009', 'sentence': 'Small clinical trials suggest that ranolazine may have a role in the treatment of patients with non-ST-elevation acute coronary syndrome, atrial fibrillation, long QT syndromes, and sinus node dysfunction.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:treats---None---None---None---UMLS:C0023976---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "14672486",
-              "object": "MONDO:0002442",
-              "publications": [
-                "PMID:19898287"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:17785620': {'publication date': '2007 Sep 25', 'sentence': 'Ranolazine was more effective than lidocaine in terminating persistent AF and in preventing the induction of AF.', 'subject score': 1000, 'object score': 1000}, 'PMID:18598958': {'publication date': '2008 Jul', 'sentence': 'Our data suggest that ranolazine may be useful in suppressing AF triggers arising from the PV sleeves.', 'subject score': 1000, 'object score': 838}, 'PMID:20201889': {'publication date': '2010 Feb', 'sentence': 'Atrial-selective sodium channel blockers, such as ranolazine and amiodarone, effectively suppress and/or prevent the induction of AF in experimental models, while producing little to no effect on ventricular myocardium.', 'subject score': 1000, 'object score': 1000}, 'PMID:23376977': {'publication date': '2013 May', 'sentence': 'The aim of the present study was to investigate whether RAN can suppress AF in an experimental rabbit whole heart model, in which acute haemodynamic changes trigger AF.', 'subject score': 1000, 'object score': 1000}, 'PMID:29068807': {'publication date': '2018 01', 'sentence': 'CONCLUSIONS: The combination of dofetilide and ranolazine showed increased antiarrhythmic effects on acutely induced AF in horses, affecting time to cardioversion, AF vulnerability, and AF duration.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13036849,
-            "start": 567,
-            "end": 295849,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17785620': {'publication date': '2007 Sep 25', 'sentence': 'Ranolazine was more effective than lidocaine in terminating persistent AF and in preventing the induction of AF.', 'subject score': 1000, 'object score': 1000}, 'PMID:18598958': {'publication date': '2008 Jul', 'sentence': 'Our data suggest that ranolazine may be useful in suppressing AF triggers arising from the PV sleeves.', 'subject score': 1000, 'object score': 838}, 'PMID:20201889': {'publication date': '2010 Feb', 'sentence': 'Atrial-selective sodium channel blockers, such as ranolazine and amiodarone, effectively suppress and/or prevent the induction of AF in experimental models, while producing little to no effect on ventricular myocardium.', 'subject score': 1000, 'object score': 1000}, 'PMID:23376977': {'publication date': '2013 May', 'sentence': 'The aim of the present study was to investigate whether RAN can suppress AF in an experimental rabbit whole heart model, in which acute haemodynamic changes trigger AF.', 'subject score': 1000, 'object score': 1000}, 'PMID:29068807': {'publication date': '2018 01', 'sentence': 'CONCLUSIONS: The combination of dofetilide and ranolazine showed increased antiarrhythmic effects on acutely induced AF in horses, affecting time to cardioversion, AF vulnerability, and AF duration.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:causes---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "13317799",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:17785620",
-                "PMID:18598958",
-                "PMID:20201889",
-                "PMID:23376977",
-                "PMID:29068807"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:27208652': {'publication date': '2016 Jul 01', 'sentence': 'Furthermore, the activated Akt/mTOR signaling pathway induced by AF was further activated by ranolazine.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18627173,
-            "start": 567,
-            "end": 295849,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27208652': {'publication date': '2016 Jul 01', 'sentence': 'Furthermore, the activated Akt/mTOR signaling pathway induced by AF was further activated by ranolazine.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "19002641",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:27208652"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:23140547': {'publication date': '2013 Nov', 'sentence': 'Effect of ranolazine in preventing postoperative atrial fibrillation in patients undergoing coronary revascularization surgery.', 'subject score': 1000, 'object score': 808}, 'PMID:23205928': {'publication date': '2013 Oct', 'sentence': 'We could demonstrate potent effects of ranolazine on atrial fibrillation in a \"wash-in wash-out\" situation.', 'subject score': 1000, 'object score': 1000}, 'PMID:25210025': {'publication date': '2015 Jan', 'sentence': 'Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:27957034': {'publication date': '2014', 'sentence': 'Purpose of this study is to assess the effect of ranolazine on atrial fibrillation (AF), in patients with CAD, PAF and a dual-chamber pacemaker.', 'subject score': 1000, 'object score': 1000}, 'PMID:28497941': {'publication date': '2018 Jun', 'sentence': 'EVIDENCE ACQUISITION: Both methods randomized controlled trials (RCTs) and non-randomized observational studies concerning the effects of ranolazine on AF were included in the meta-analysis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16261983,
-            "start": 567,
-            "end": 295849,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23140547': {'publication date': '2013 Nov', 'sentence': 'Effect of ranolazine in preventing postoperative atrial fibrillation in patients undergoing coronary revascularization surgery.', 'subject score': 1000, 'object score': 808}, 'PMID:23205928': {'publication date': '2013 Oct', 'sentence': 'We could demonstrate potent effects of ranolazine on atrial fibrillation in a \"wash-in wash-out\" situation.', 'subject score': 1000, 'object score': 1000}, 'PMID:25210025': {'publication date': '2015 Jan', 'sentence': 'Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:27957034': {'publication date': '2014', 'sentence': 'Purpose of this study is to assess the effect of ranolazine on atrial fibrillation (AF), in patients with CAD, PAF and a dual-chamber pacemaker.', 'subject score': 1000, 'object score': 1000}, 'PMID:28497941': {'publication date': '2018 Jun', 'sentence': 'EVIDENCE ACQUISITION: Both methods randomized controlled trials (RCTs) and non-randomized observational studies concerning the effects of ranolazine on AF were included in the meta-analysis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:affects---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "16599546",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:23140547",
-                "PMID:23205928",
-                "PMID:25210025",
-                "PMID:27957034",
-                "PMID:28497941"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:18676686': {'publication date': '2008 Oct', 'sentence': 'Recent studies have increased interest in fast-unbinding Na(+) channel blockers like vernakalant (RSD1235) and ranolazine for AF therapy, but the mechanism of efficacy is poorly understood.', 'subject score': 1000, 'object score': 901}, 'PMID:18679523': {'publication date': '2008 Aug 01', 'sentence': 'A controlled prospective trial is warranted to further investigate the efficacy of ranolazine in AF.', 'subject score': 1000, 'object score': 1000}, 'PMID:19298570': {'publication date': '2009 Jul', 'sentence': 'Potential role of ranolazine in AF management merits further investigation.', 'subject score': 1000, 'object score': 901}, 'PMID:19898287': {'publication date': '2009', 'sentence': 'Small clinical trials suggest that ranolazine may have a role in the treatment of patients with non-ST-elevation acute coronary syndrome, atrial fibrillation, long QT syndromes, and sinus node dysfunction.', 'subject score': 1000, 'object score': 1000}, 'PMID:20925013': {'publication date': '2010 Oct', 'sentence': 'Moreover, ranolazine holds potential promise to be effective in treatment of atrial fibrillation and diastolic heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:21105855': {'publication date': '2010 Dec', 'sentence': 'Further work is required in order to explore more fully the potential of ranolazine in the treatment of atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:22050058': {'publication date': '2011 Nov', 'sentence': 'If confirmed, ranolazine may be a good choice for preventing AF in patients undergoing CABG.', 'subject score': 1000, 'object score': 884}, 'PMID:22229482': {'publication date': '2012 Mar', 'sentence': 'Five of the six patients who were refractory to repeat EC despite RZ had AF of unknown duration and each is now in permanent AF.', 'subject score': 1000, 'object score': 901}, 'PMID:22767404': {'publication date': '2012 Sep', 'sentence': 'A beneficial atrial selectivity of ranolazine has been suggested that may be helpful for the treatment of atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:22916846': {'publication date': '2012 Nov', 'sentence': 'EXPERT OPINION: The combination of the antiischemic properties of ranolazine with its antiarrhythmic potency and minimal proarrhythmia provides a promising background that could expand its therapeutic role in the management of atrial fibrillation and ventricular tachyarrhythmias.', 'subject score': 1000, 'object score': 1000}, 'PMID:23205928': {'publication date': '2013 Oct', 'sentence': 'Although promising controlled studies are needed to investigate a potential role of ranolazine for the treatment of atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:23992336': {'publication date': '2014', 'sentence': 'Experimental and clinical studies have revealed an antiarrhythmic effect of ranolazine in atrial fibrillation as chronic or \"pill in the pocket\" therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:24496483': {'publication date': '2014 Mar', 'sentence': 'In this review the three recently introduced drugs dronedarone, vernakalant and ranolazine are discussed with respect to the use in atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:24523397': {'publication date': '2014 May', 'sentence': 'A third prospective trial used ranolazine in combination with amiodarone for the treatment of POAF and demonstrated a significant reduction in the time required to convert patients from atrial fibrillation to normal sinus rhythm compared with amiodarone alone.', 'subject score': 1000, 'object score': 787}, 'PMID:24581108': {'publication date': '2014 Jan-Feb', 'sentence': 'Refractory atrial fibrillation effectively treated with ranolazine.', 'subject score': 1000, 'object score': 901}, 'PMID:24662415': {'publication date': '2014 Mar', 'sentence': 'We searched PubMed and abstracts of major conferences for clinical studies using ranolazine, either alone or in combination with other antiarrhythmic agents for the prevention or treatment of atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:25138058': {'publication date': '2014 Oct', 'sentence': 'Of clinical relevance, we present growing evidence from preliminary clinical investigations indicating the safety and efficacy of RN for prevention and treatment of AF in various clinical settings including prevention of AF in patients with acute coronary syndromes, prevention and conversion of postoperative AF after surgical coronary revascularization, sinus rhythm maintenance in drug-resistant recurrent AF, and facilitating of electrical or pharmacological cardioversion in cardioversion-resistant patients.', 'subject score': 1000, 'object score': 840}, 'PMID:25602175': {'publication date': '2015 May', 'sentence': 'Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study.', 'subject score': 1000, 'object score': 1000}, 'PMID:25872749': {'publication date': '2015 Jun', 'sentence': 'Specifically, the authors review the Phase I-III trials that studied ranolazine as potential treatment for AF.', 'subject score': 861, 'object score': 1000}, 'PMID:26121051': {'publication date': '2015', 'sentence': 'Plateau phase and upstroke velocity of action potentials (APs) recorded with sharp microelectrodes in intact human trabeculae were more sensitive to ranolazine in AF than in SR preparations.', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13600225,
-            "start": 567,
-            "end": 295849,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18676686': {'publication date': '2008 Oct', 'sentence': 'Recent studies have increased interest in fast-unbinding Na(+) channel blockers like vernakalant (RSD1235) and ranolazine for AF therapy, but the mechanism of efficacy is poorly understood.', 'subject score': 1000, 'object score': 901}, 'PMID:18679523': {'publication date': '2008 Aug 01', 'sentence': 'A controlled prospective trial is warranted to further investigate the efficacy of ranolazine in AF.', 'subject score': 1000, 'object score': 1000}, 'PMID:19298570': {'publication date': '2009 Jul', 'sentence': 'Potential role of ranolazine in AF management merits further investigation.', 'subject score': 1000, 'object score': 901}, 'PMID:19898287': {'publication date': '2009', 'sentence': 'Small clinical trials suggest that ranolazine may have a role in the treatment of patients with non-ST-elevation acute coronary syndrome, atrial fibrillation, long QT syndromes, and sinus node dysfunction.', 'subject score': 1000, 'object score': 1000}, 'PMID:20925013': {'publication date': '2010 Oct', 'sentence': 'Moreover, ranolazine holds potential promise to be effective in treatment of atrial fibrillation and diastolic heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:21105855': {'publication date': '2010 Dec', 'sentence': 'Further work is required in order to explore more fully the potential of ranolazine in the treatment of atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:22050058': {'publication date': '2011 Nov', 'sentence': 'If confirmed, ranolazine may be a good choice for preventing AF in patients undergoing CABG.', 'subject score': 1000, 'object score': 884}, 'PMID:22229482': {'publication date': '2012 Mar', 'sentence': 'Five of the six patients who were refractory to repeat EC despite RZ had AF of unknown duration and each is now in permanent AF.', 'subject score': 1000, 'object score': 901}, 'PMID:22767404': {'publication date': '2012 Sep', 'sentence': 'A beneficial atrial selectivity of ranolazine has been suggested that may be helpful for the treatment of atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:22916846': {'publication date': '2012 Nov', 'sentence': 'EXPERT OPINION: The combination of the antiischemic properties of ranolazine with its antiarrhythmic potency and minimal proarrhythmia provides a promising background that could expand its therapeutic role in the management of atrial fibrillation and ventricular tachyarrhythmias.', 'subject score': 1000, 'object score': 1000}, 'PMID:23205928': {'publication date': '2013 Oct', 'sentence': 'Although promising controlled studies are needed to investigate a potential role of ranolazine for the treatment of atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:23992336': {'publication date': '2014', 'sentence': 'Experimental and clinical studies have revealed an antiarrhythmic effect of ranolazine in atrial fibrillation as chronic or \"pill in the pocket\" therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:24496483': {'publication date': '2014 Mar', 'sentence': 'In this review the three recently introduced drugs dronedarone, vernakalant and ranolazine are discussed with respect to the use in atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:24523397': {'publication date': '2014 May', 'sentence': 'A third prospective trial used ranolazine in combination with amiodarone for the treatment of POAF and demonstrated a significant reduction in the time required to convert patients from atrial fibrillation to normal sinus rhythm compared with amiodarone alone.', 'subject score': 1000, 'object score': 787}, 'PMID:24581108': {'publication date': '2014 Jan-Feb', 'sentence': 'Refractory atrial fibrillation effectively treated with ranolazine.', 'subject score': 1000, 'object score': 901}, 'PMID:24662415': {'publication date': '2014 Mar', 'sentence': 'We searched PubMed and abstracts of major conferences for clinical studies using ranolazine, either alone or in combination with other antiarrhythmic agents for the prevention or treatment of atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:25138058': {'publication date': '2014 Oct', 'sentence': 'Of clinical relevance, we present growing evidence from preliminary clinical investigations indicating the safety and efficacy of RN for prevention and treatment of AF in various clinical settings including prevention of AF in patients with acute coronary syndromes, prevention and conversion of postoperative AF after surgical coronary revascularization, sinus rhythm maintenance in drug-resistant recurrent AF, and facilitating of electrical or pharmacological cardioversion in cardioversion-resistant patients.', 'subject score': 1000, 'object score': 840}, 'PMID:25602175': {'publication date': '2015 May', 'sentence': 'Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study.', 'subject score': 1000, 'object score': 1000}, 'PMID:25872749': {'publication date': '2015 Jun', 'sentence': 'Specifically, the authors review the Phase I-III trials that studied ranolazine as potential treatment for AF.', 'subject score': 861, 'object score': 1000}, 'PMID:26121051': {'publication date': '2015', 'sentence': 'Plateau phase and upstroke velocity of action potentials (APs) recorded with sharp microelectrodes in intact human trabeculae were more sensitive to ranolazine in AF than in SR preparations.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:treats---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "13891593",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:18676686",
-                "PMID:18679523",
-                "PMID:19298570",
-                "PMID:19898287",
-                "PMID:20925013",
-                "PMID:21105855",
-                "PMID:22050058",
-                "PMID:22229482",
-                "PMID:22767404",
-                "PMID:22916846",
-                "PMID:23205928",
-                "PMID:23992336",
-                "PMID:24496483",
-                "PMID:24523397",
-                "PMID:24581108",
-                "PMID:24662415",
-                "PMID:25138058",
-                "PMID:25602175",
-                "PMID:25872749",
-                "PMID:26121051"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:18670368': {'publication date': '2008 Aug', 'sentence': 'Atrial-selective/predominant sodium channel blockers such as ranolazine effectively suppress AF in experimental models of AF involving canine isolated right atrial preparations at concentrations that produce little to no effect on ventricular electrophysiologic parameters.', 'subject score': 1000, 'object score': 1000}, 'PMID:19698954': {'publication date': '2009 Nov-Dec', 'sentence': 'Atrial-selective/predominant sodium channel blockers such as ranolazine effectively suppress AF in experimental models involving canine-isolated right atrial preparations at concentrations that produce little to no effect on electrophysiological parameters in ventricular myocardium.', 'subject score': 1000, 'object score': 1000}, 'PMID:20883928': {'publication date': '2010 Oct 05', 'sentence': 'OBJECTIVES: The aim of this study was to evaluate the effectiveness of a combination of dronedarone and ranolazine in suppression of atrial fibrillation (AF).', 'subject score': 1000, 'object score': 1000}, 'PMID:21057583': {'publication date': '2008', 'sentence': 'Recent studies have proposed that an Atrial-selective depression of sodium channel-dependent parameters with agents such as ranolazine may be an alternative approach capable of effectively suppressing AF without increasing susceptibility to ventricular arrhythmias.', 'subject score': 1000, 'object score': 1000}, 'PMID:21421082': {'publication date': '2011 Aug', 'sentence': 'In atria, ranolazine effectively suppresses atrial tachyarrhythmias and atrial fibrillation (AF).', 'subject score': 1000, 'object score': 1000}, 'PMID:22005044': {'publication date': '2012 Jan', 'sentence': 'Thus, propafenone and ranolazine both suppress AF, but ranolazine, unlike propafenone, does it with minimal effects on ventricular myocardium, suggesting a reduced potential for promoting ventricular arrhythmias.', 'subject score': 1000, 'object score': 1000}, 'PMID:22621799': {'publication date': '2012 Sep 01', 'sentence': 'In experimental models, the combination of ranolazine and amiodarone has marked synergistic effects that potently suppress AF.', 'subject score': 1000, 'object score': 1000}, 'PMID:23044390': {'publication date': '2012 Dec', 'sentence': 'BACKGROUND: Ranolazine exhibits a synergistic effect in combination with class III drugs to suppress atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:23108433': {'publication date': '2013 Feb', 'sentence': 'Although the late I(Na) blocker ranolazine has been shown to be effective in suppression of AF, it is noteworthy that at concentrations at which it blocks late I(Na) in the ventricles, it also potently blocks peak I(Na) in the atria, thus causing rate-dependent prolongation of ERP due to development of post-repolarization refractoriness.', 'subject score': 861, 'object score': 1000}, 'PMID:23376977': {'publication date': '2013 May', 'sentence': 'Ranolazine suppresses stretch-induced AF by increasing interatrial conduction time and aPRR.', 'subject score': 1000, 'object score': 850}, 'PMID:24874201': {'publication date': '2014 Jul', 'sentence': 'CONCLUSIONS: Our results demonstrate more potent suppression of AF by ranolazine in the setting of HF than previously demonstrated in nonfailing hearts and absence of ventricular proarrhythmia.', 'subject score': 1000, 'object score': 1000}, 'PMID:25138058': {'publication date': '2014 Oct', 'sentence': 'While current experimental and clinical evidence points to RN as a potentially promising agent for suppression of AF, well-designed, large-scale trials will be required before RN can be considered for pharmacological treatment of AF in clinical practice.', 'subject score': 1000, 'object score': 1000}, 'PMID:28185917': {'publication date': '2017 07', 'sentence': 'Systemic application of the INa-L inhibitors ranolazine, eleclazine, and GS967 inhibited the occurrence of AF in castrated mice.', 'subject score': 816, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13596024,
-            "start": 567,
-            "end": 295849,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18670368': {'publication date': '2008 Aug', 'sentence': 'Atrial-selective/predominant sodium channel blockers such as ranolazine effectively suppress AF in experimental models of AF involving canine isolated right atrial preparations at concentrations that produce little to no effect on ventricular electrophysiologic parameters.', 'subject score': 1000, 'object score': 1000}, 'PMID:19698954': {'publication date': '2009 Nov-Dec', 'sentence': 'Atrial-selective/predominant sodium channel blockers such as ranolazine effectively suppress AF in experimental models involving canine-isolated right atrial preparations at concentrations that produce little to no effect on electrophysiological parameters in ventricular myocardium.', 'subject score': 1000, 'object score': 1000}, 'PMID:20883928': {'publication date': '2010 Oct 05', 'sentence': 'OBJECTIVES: The aim of this study was to evaluate the effectiveness of a combination of dronedarone and ranolazine in suppression of atrial fibrillation (AF).', 'subject score': 1000, 'object score': 1000}, 'PMID:21057583': {'publication date': '2008', 'sentence': 'Recent studies have proposed that an Atrial-selective depression of sodium channel-dependent parameters with agents such as ranolazine may be an alternative approach capable of effectively suppressing AF without increasing susceptibility to ventricular arrhythmias.', 'subject score': 1000, 'object score': 1000}, 'PMID:21421082': {'publication date': '2011 Aug', 'sentence': 'In atria, ranolazine effectively suppresses atrial tachyarrhythmias and atrial fibrillation (AF).', 'subject score': 1000, 'object score': 1000}, 'PMID:22005044': {'publication date': '2012 Jan', 'sentence': 'Thus, propafenone and ranolazine both suppress AF, but ranolazine, unlike propafenone, does it with minimal effects on ventricular myocardium, suggesting a reduced potential for promoting ventricular arrhythmias.', 'subject score': 1000, 'object score': 1000}, 'PMID:22621799': {'publication date': '2012 Sep 01', 'sentence': 'In experimental models, the combination of ranolazine and amiodarone has marked synergistic effects that potently suppress AF.', 'subject score': 1000, 'object score': 1000}, 'PMID:23044390': {'publication date': '2012 Dec', 'sentence': 'BACKGROUND: Ranolazine exhibits a synergistic effect in combination with class III drugs to suppress atrial fibrillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:23108433': {'publication date': '2013 Feb', 'sentence': 'Although the late I(Na) blocker ranolazine has been shown to be effective in suppression of AF, it is noteworthy that at concentrations at which it blocks late I(Na) in the ventricles, it also potently blocks peak I(Na) in the atria, thus causing rate-dependent prolongation of ERP due to development of post-repolarization refractoriness.', 'subject score': 861, 'object score': 1000}, 'PMID:23376977': {'publication date': '2013 May', 'sentence': 'Ranolazine suppresses stretch-induced AF by increasing interatrial conduction time and aPRR.', 'subject score': 1000, 'object score': 850}, 'PMID:24874201': {'publication date': '2014 Jul', 'sentence': 'CONCLUSIONS: Our results demonstrate more potent suppression of AF by ranolazine in the setting of HF than previously demonstrated in nonfailing hearts and absence of ventricular proarrhythmia.', 'subject score': 1000, 'object score': 1000}, 'PMID:25138058': {'publication date': '2014 Oct', 'sentence': 'While current experimental and clinical evidence points to RN as a potentially promising agent for suppression of AF, well-designed, large-scale trials will be required before RN can be considered for pharmacological treatment of AF in clinical practice.', 'subject score': 1000, 'object score': 1000}, 'PMID:28185917': {'publication date': '2017 07', 'sentence': 'Systemic application of the INa-L inhibitors ranolazine, eleclazine, and GS967 inhibited the occurrence of AF in castrated mice.', 'subject score': 816, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:disrupts---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "13887428",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:18670368",
-                "PMID:19698954",
-                "PMID:20883928",
-                "PMID:21057583",
-                "PMID:21421082",
-                "PMID:22005044",
-                "PMID:22621799",
-                "PMID:23044390",
-                "PMID:23108433",
-                "PMID:23376977",
-                "PMID:24874201",
-                "PMID:25138058",
-                "PMID:28185917"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 317974,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001681",
-          "name": "Angina pectoris",
-          "description": "Paroxysms of chest pain due to reduced oxygen to the heart.; The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.; Paroxysmal chest pain that occurs with exertion or stress and is related to myocardial ischemia. [HPO:probinson]; Angina is chest pain or discomfort you feel when there is not enough blood flow to your heart muscle. Your heart muscle needs the oxygen that the blood carries. Angina may feel like pressure or a squeezing pain in your chest. It may feel like indigestion. You may also feel pain in your shoulders, arms, neck, jaw, or back.  Angina is a symptom of coronary artery disease (CAD), the most common heart disease. CAD happens when a sticky substance called plaque builds up in the arteries that supply blood to the heart, reducing blood flow. There are three types of angina:  Stable angina is the most common type. It happens when the heart is working harder than usual. Stable angina has a regular pattern. Rest and medicines usually help. Unstable angina is the most dangerous. It does not follow a pattern and can happen without physical exertion. It does not go away with rest or medicine. It is a sign that you could have a heart attack soon. Variant angina is rare. It happens when you are resting. Medicines can help.  Not all chest pain or discomfort is angina. If you have chest pain, you should see your health care provider. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "PSY:02530",
-            "MEDDRA:10002387",
-            "MEDDRA:10002393",
-            "SNOMEDCT:194828000",
-            "UMLS:C0002962",
-            "MEDDRA:10056259",
-            "MESH:D000787",
-            "ICD9:413",
-            "MEDDRA:10002383",
-            "MEDDRA:10054224",
-            "NCIT:C51221",
-            "EFO:0003913",
-            "MEDDRA:10041972",
-            "MEDDRA:10056256",
-            "SNOMEDCT:225566008",
-            "MEDDRA:10002391",
-            "HP:0001681"
-          ],
-          "id": "HP:0001681",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "angina pectoris",
-            "Angina",
-            "Angina Pectoris",
-            "Angina pectoris"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317974,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001681",
-              "name": "Angina pectoris",
-              "description": "Paroxysms of chest pain due to reduced oxygen to the heart.; The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.; Paroxysmal chest pain that occurs with exertion or stress and is related to myocardial ischemia. [HPO:probinson]; Angina is chest pain or discomfort you feel when there is not enough blood flow to your heart muscle. Your heart muscle needs the oxygen that the blood carries. Angina may feel like pressure or a squeezing pain in your chest. It may feel like indigestion. You may also feel pain in your shoulders, arms, neck, jaw, or back.  Angina is a symptom of coronary artery disease (CAD), the most common heart disease. CAD happens when a sticky substance called plaque builds up in the arteries that supply blood to the heart, reducing blood flow. There are three types of angina:  Stable angina is the most common type. It happens when the heart is working harder than usual. Stable angina has a regular pattern. Rest and medicines usually help. Unstable angina is the most dangerous. It does not follow a pattern and can happen without physical exertion. It does not go away with rest or medicine. It is a sign that you could have a heart attack soon. Variant angina is rare. It happens when you are resting. Medicines can help.  Not all chest pain or discomfort is angina. If you have chest pain, you should see your health care provider. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "PSY:02530",
-                "MEDDRA:10002387",
-                "MEDDRA:10002393",
-                "SNOMEDCT:194828000",
-                "UMLS:C0002962",
-                "MEDDRA:10056259",
-                "MESH:D000787",
-                "ICD9:413",
-                "MEDDRA:10002383",
-                "MEDDRA:10054224",
-                "NCIT:C51221",
-                "EFO:0003913",
-                "MEDDRA:10041972",
-                "MEDDRA:10056256",
-                "SNOMEDCT:225566008",
-                "MEDDRA:10002391",
-                "HP:0001681"
-              ],
-              "id": "HP:0001681",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "angina pectoris",
-                "Angina",
-                "Angina Pectoris",
-                "Angina pectoris"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17123948,
-            "start": 567,
-            "end": 317974,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24560062': {'publication date': '2014 Apr 15', 'sentence': 'Ranolazine has been shown to decrease angina pectoris frequency and nitroglycerin consumption.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:prevents---None---None---None---UMLS:C0002962---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "17475563",
-              "object": "HP:0001681",
-              "publications": [
-                "PMID:24560062"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 525277,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0024644",
-          "name": "myocardial ischemia",
-          "description": "A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries, to obstruction by a thrombus, or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).; A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).",
-          "equivalent_curies": [
-            "UMLS:C0151744",
-            "MONDO:0024644",
-            "MEDDRA:10021279",
-            "MEDDRA:10007584",
-            "MEDDRA:10023024",
-            "MEDDRA:10055218",
-            "MEDDRA:10055752",
-            "SNOMEDCT:414545008",
-            "MEDDRA:10028601",
-            "NCIT:C50625",
-            "MESH:D017202",
-            "SNOMEDCT:414795007",
-            "MEDDRA:10055224",
-            "EFO:1001375",
-            "MEDDRA:10028600",
-            "MEDDRA:10023033"
-          ],
-          "id": "MONDO:0024644",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myocardial Ischemia",
-            "myocardial ischemia",
-            "Ischemic Heart Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 525277,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0024644",
-              "name": "myocardial ischemia",
-              "description": "A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries, to obstruction by a thrombus, or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).; A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).",
-              "equivalent_curies": [
-                "UMLS:C0151744",
-                "MONDO:0024644",
-                "MEDDRA:10021279",
-                "MEDDRA:10007584",
-                "MEDDRA:10023024",
-                "MEDDRA:10055218",
-                "MEDDRA:10055752",
-                "SNOMEDCT:414545008",
-                "MEDDRA:10028601",
-                "NCIT:C50625",
-                "MESH:D017202",
-                "SNOMEDCT:414795007",
-                "MEDDRA:10055224",
-                "EFO:1001375",
-                "MEDDRA:10028600",
-                "MEDDRA:10023033"
-              ],
-              "id": "MONDO:0024644",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myocardial Ischemia",
-                "myocardial ischemia",
-                "Ischemic Heart Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14445358,
-            "start": 567,
-            "end": 525277,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20031797': {'publication date': '2008 Nov', 'sentence': 'BACKGROUND: Ranolazine has been shown to reduce myocardial ischemia and symptom severity among selected patients with chronic angina.', 'subject score': 1000, 'object score': 1000}, 'PMID:24902977': {'publication date': '2014 Jun 06', 'sentence': 'Ranolazine, trimetazidine, nicorandil, and ivabradine are medications that have been shown to reduce myocardial ischemia through diverse mechanisms and have been tested in limited fashion in patients with ACS.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:prevents---None---None---None---UMLS:C0151744---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "14751648",
-              "object": "MONDO:0024644",
-              "publications": [
-                "PMID:20031797",
-                "PMID:24902977"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:19298570': {'publication date': '2009 Jul', 'sentence': 'Dominant frequency (DF) of AF was reduced by ranolazine in left atrium from 11.7 (10.7-20.5) Hz to 7.6 (2.9-8.8) Hz (P = 0.02, n = 6).', 'subject score': 1000, 'object score': 1000}, 'PMID:21063462': {'publication date': '2010 Oct 21', 'sentence': 'In a large acute coronary syndrome clinical trial, ranolazine reduced the incidence of supraventricular tachycardia, ventricular tachycardia, new-onset atrial fibrillation, and bradycardic events.', 'subject score': 1000, 'object score': 888}, 'PMID:21726841': {'publication date': '2011 Sep 01', 'sentence': 'In conclusion, ranolazine was independently associated with a significant reduction of AF compared to amiodarone after CABG, with no difference in the incidence of adverse events.', 'subject score': 1000, 'object score': 1000}, 'PMID:22050058': {'publication date': '2011 Nov', 'sentence': 'The results of this retrospective nonrandomized single-center study indicate that ranolazine may be used to effectively and safely prevent postoperative AF.', 'subject score': 1000, 'object score': 901}, 'PMID:23099358': {'publication date': '2012 Dec', 'sentence': 'Further insights into the underlying electrophysiological mechanisms for reduction of atrial fibrillation by ranolazine in an experimental model of chronic heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:23376977': {'publication date': '2013 May', 'sentence': 'These results shed further evidence on the potential role of RAN in the prevention of AF.', 'subject score': 1000, 'object score': 1000}, 'PMID:23647657': {'publication date': '2013 Dec', 'sentence': 'Dronedarone or acute infusion of sotalol did not significantly suppress AF, while additional treatment with ranolazine in these groups also reduced AF incidence.', 'subject score': 1000, 'object score': 901}, 'PMID:24523397': {'publication date': '2014 May', 'sentence': 'However, larger randomized controlled trials are needed before ranolazine should be considered for the treatment or prevention of POAF.', 'subject score': 1000, 'object score': 787}, 'PMID:25210025': {'publication date': '2015 Jan', 'sentence': 'AIMS: To determine the effect of ranolazine, an anti-ischaemic agent with anti-arrhythmic properties, on the overall burden of atrial fibrillation (AF) in acute coronary syndromes (ACS) and determine whether ranolazine reduces the long-term incidence of clinical AF after ACS.', 'subject score': 1000, 'object score': 901}, 'PMID:25416563': {'publication date': '2015 May', 'sentence': 'Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries.', 'subject score': 1000, 'object score': 901}, 'PMID:25496982': {'publication date': '2015 Feb', 'sentence': 'RESULTS: AF duration was reduced when both flecainide and ranolazine were combined with ICA in doses that did not reduce AF as monotherapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:27746384': {'publication date': '2017 01', 'sentence': 'CONCLUSION: Our meta-analysis suggests that RN may be effective in AF prevention, whereas it potentiates and accelerates the conversion effect of amiodarone of recent-onset AF.', 'subject score': 1000, 'object score': 901}, 'PMID:28497941': {'publication date': '2018 Jun', 'sentence': 'Furthermore, in patients in sinus rhythm, ranolazine proved to reduce the frequency of new onset AF as well as of its recurrences, especially in patients undergone CABG surgery, known to be at high risk of developing postoperative AF.', 'subject score': 1000, 'object score': 888}, 'PMID:28607609': {'publication date': '2017 Jun', 'sentence': 'Recent studies have demonstrated the benefit of ranolazine in preventing post-operative AF (POAF) in patients undergoing cardiac surgery.', 'subject score': 1000, 'object score': 774}, 'PMID:29982246': {'publication date': '2018', 'sentence': 'CONCLUSIONS: In this study, ranolazine seems to prevent atrial fibrillation in levosimendan-pretreated hearts.', 'subject score': 1000, 'object score': 1000}, 'PMID:30009098': {'publication date': '2018 May 06', 'sentence': 'The present study is to evaluate the effectiveness of ranolazine in preventing POAF after cardiac surgery.', 'subject score': 1000, 'object score': 808}, 'PMID:33923428': {'publication date': '2021 Apr 16', 'sentence': 'BACKGROUND: Ranolazine has the potential to prevent atrial fibrillation (AF) and plays a role in rhythm control strategy for atrial fibrillation in various clinical settings.', 'subject score': 1000, 'object score': 1000}, 'PMID:36481415': {'publication date': '2022 Dec 05', 'sentence': 'The beneficial effects of ranolazine are extended to atrial fibrillation reduction rates and better glycemic control.', 'subject score': 1000, 'object score': 850}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13982097,
-            "start": 567,
-            "end": 295849,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19298570': {'publication date': '2009 Jul', 'sentence': 'Dominant frequency (DF) of AF was reduced by ranolazine in left atrium from 11.7 (10.7-20.5) Hz to 7.6 (2.9-8.8) Hz (P = 0.02, n = 6).', 'subject score': 1000, 'object score': 1000}, 'PMID:21063462': {'publication date': '2010 Oct 21', 'sentence': 'In a large acute coronary syndrome clinical trial, ranolazine reduced the incidence of supraventricular tachycardia, ventricular tachycardia, new-onset atrial fibrillation, and bradycardic events.', 'subject score': 1000, 'object score': 888}, 'PMID:21726841': {'publication date': '2011 Sep 01', 'sentence': 'In conclusion, ranolazine was independently associated with a significant reduction of AF compared to amiodarone after CABG, with no difference in the incidence of adverse events.', 'subject score': 1000, 'object score': 1000}, 'PMID:22050058': {'publication date': '2011 Nov', 'sentence': 'The results of this retrospective nonrandomized single-center study indicate that ranolazine may be used to effectively and safely prevent postoperative AF.', 'subject score': 1000, 'object score': 901}, 'PMID:23099358': {'publication date': '2012 Dec', 'sentence': 'Further insights into the underlying electrophysiological mechanisms for reduction of atrial fibrillation by ranolazine in an experimental model of chronic heart failure.', 'subject score': 1000, 'object score': 1000}, 'PMID:23376977': {'publication date': '2013 May', 'sentence': 'These results shed further evidence on the potential role of RAN in the prevention of AF.', 'subject score': 1000, 'object score': 1000}, 'PMID:23647657': {'publication date': '2013 Dec', 'sentence': 'Dronedarone or acute infusion of sotalol did not significantly suppress AF, while additional treatment with ranolazine in these groups also reduced AF incidence.', 'subject score': 1000, 'object score': 901}, 'PMID:24523397': {'publication date': '2014 May', 'sentence': 'However, larger randomized controlled trials are needed before ranolazine should be considered for the treatment or prevention of POAF.', 'subject score': 1000, 'object score': 787}, 'PMID:25210025': {'publication date': '2015 Jan', 'sentence': 'AIMS: To determine the effect of ranolazine, an anti-ischaemic agent with anti-arrhythmic properties, on the overall burden of atrial fibrillation (AF) in acute coronary syndromes (ACS) and determine whether ranolazine reduces the long-term incidence of clinical AF after ACS.', 'subject score': 1000, 'object score': 901}, 'PMID:25416563': {'publication date': '2015 May', 'sentence': 'Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries.', 'subject score': 1000, 'object score': 901}, 'PMID:25496982': {'publication date': '2015 Feb', 'sentence': 'RESULTS: AF duration was reduced when both flecainide and ranolazine were combined with ICA in doses that did not reduce AF as monotherapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:27746384': {'publication date': '2017 01', 'sentence': 'CONCLUSION: Our meta-analysis suggests that RN may be effective in AF prevention, whereas it potentiates and accelerates the conversion effect of amiodarone of recent-onset AF.', 'subject score': 1000, 'object score': 901}, 'PMID:28497941': {'publication date': '2018 Jun', 'sentence': 'Furthermore, in patients in sinus rhythm, ranolazine proved to reduce the frequency of new onset AF as well as of its recurrences, especially in patients undergone CABG surgery, known to be at high risk of developing postoperative AF.', 'subject score': 1000, 'object score': 888}, 'PMID:28607609': {'publication date': '2017 Jun', 'sentence': 'Recent studies have demonstrated the benefit of ranolazine in preventing post-operative AF (POAF) in patients undergoing cardiac surgery.', 'subject score': 1000, 'object score': 774}, 'PMID:29982246': {'publication date': '2018', 'sentence': 'CONCLUSIONS: In this study, ranolazine seems to prevent atrial fibrillation in levosimendan-pretreated hearts.', 'subject score': 1000, 'object score': 1000}, 'PMID:30009098': {'publication date': '2018 May 06', 'sentence': 'The present study is to evaluate the effectiveness of ranolazine in preventing POAF after cardiac surgery.', 'subject score': 1000, 'object score': 808}, 'PMID:33923428': {'publication date': '2021 Apr 16', 'sentence': 'BACKGROUND: Ranolazine has the potential to prevent atrial fibrillation (AF) and plays a role in rhythm control strategy for atrial fibrillation in various clinical settings.', 'subject score': 1000, 'object score': 1000}, 'PMID:36481415': {'publication date': '2022 Dec 05', 'sentence': 'The beneficial effects of ranolazine are extended to atrial fibrillation reduction rates and better glycemic control.', 'subject score': 1000, 'object score': 850}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:prevents---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "14280230",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:19298570",
-                "PMID:21063462",
-                "PMID:21726841",
-                "PMID:22050058",
-                "PMID:23099358",
-                "PMID:23376977",
-                "PMID:23647657",
-                "PMID:24523397",
-                "PMID:25210025",
-                "PMID:25416563",
-                "PMID:25496982",
-                "PMID:27746384",
-                "PMID:28497941",
-                "PMID:28607609",
-                "PMID:29982246",
-                "PMID:30009098",
-                "PMID:33923428",
-                "PMID:36481415"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:25416563': {'publication date': '2015 May', 'sentence': 'After adjusting for potential sources of bias through propensity-score matched-pair analysis and conditional logistic regression, ranolazine was an independent predictor of preventing POAF (p < 0.0001).', 'subject score': 1000, 'object score': 808}, 'PMID:27839812': {'publication date': '2017 Jan 15', 'sentence': 'RESULTS: Ranolazine was found to be effective in reducing the risk of AF when compared to control (OR 0.47; 95% CI 0.29-0.76; p=0.003).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17629110,
-            "start": 567,
-            "end": 295849,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25416563': {'publication date': '2015 May', 'sentence': 'After adjusting for potential sources of bias through propensity-score matched-pair analysis and conditional logistic regression, ranolazine was an independent predictor of preventing POAF (p < 0.0001).', 'subject score': 1000, 'object score': 808}, 'PMID:27839812': {'publication date': '2017 Jan 15', 'sentence': 'RESULTS: Ranolazine was found to be effective in reducing the risk of AF when compared to control (OR 0.47; 95% CI 0.29-0.76; p=0.003).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:predisposes---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "17988674",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:25416563",
-                "PMID:27839812"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:27838121': {'publication date': '2017 Jan 15', 'sentence': 'Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 308937,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-          "name": "cardiovascular disorder",
-          "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "MEDDRA:10045663",
-            "MONDO:0004995",
-            "ICD9:429.2",
-            "MEDDRA:10007649",
-            "UMLS:C0243050",
-            "HP:0001626",
-            "MESH:D018376",
-            "MEDDRA:10007648",
-            "MEDDRA:10013205",
-            "SNOMEDCT:49601007",
-            "MEDDRA:10007650",
-            "MESH:D002318",
-            "DOID:1287",
-            "UMLS:C0007222",
-            "UMLS:C0728936",
-            "NCIT:C2931"
-          ],
-          "id": "MONDO:0004995",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiovascular Diseases",
-            "Cardiovascular disease, unspecified",
-            "Abnormality of the cardiovascular system",
-            "cardiovascular system disease",
-            "Disorder of circulatory system",
-            "Cardiovascular Disorder",
-            "cardiovascular disorder",
-            "Cardiovascular Abnormalities"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/circulatory_system",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308937,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-              "name": "cardiovascular disorder",
-              "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "MEDDRA:10045663",
-                "MONDO:0004995",
-                "ICD9:429.2",
-                "MEDDRA:10007649",
-                "UMLS:C0243050",
-                "HP:0001626",
-                "MESH:D018376",
-                "MEDDRA:10007648",
-                "MEDDRA:10013205",
-                "SNOMEDCT:49601007",
-                "MEDDRA:10007650",
-                "MESH:D002318",
-                "DOID:1287",
-                "UMLS:C0007222",
-                "UMLS:C0728936",
-                "NCIT:C2931"
-              ],
-              "id": "MONDO:0004995",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiovascular Diseases",
-                "Cardiovascular disease, unspecified",
-                "Abnormality of the cardiovascular system",
-                "cardiovascular system disease",
-                "Disorder of circulatory system",
-                "Cardiovascular Disorder",
-                "cardiovascular disorder",
-                "Cardiovascular Abnormalities"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/circulatory_system",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18934141,
-            "start": 567,
-            "end": 308937,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27838121': {'publication date': '2017 Jan 15', 'sentence': 'Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:affects---None---None---None---UMLS:C0007222---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "19314329",
-              "object": "MONDO:0004995",
-              "publications": [
-                "PMID:27838121"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11772326': {'publication date': '2002 Jan', 'sentence': 'Ranolazine is a novel drug that has shown promise in the treatment of cardiovascular disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:15949056': {'publication date': '2005', 'sentence': 'Ongoing clinical trials will help further establish the role of ranolazine in the treatment of cardiovascular disorders.', 'subject score': 1000, 'object score': 1000}, 'PMID:20222810': {'publication date': '2010 Mar', 'sentence': 'In this review we discuss the pharmacological profile of ranolazine and discuss the current and potential future applications in cardiovascular disease for this drug.', 'subject score': 1000, 'object score': 1000}, 'PMID:26546970': {'publication date': '2016 Jan', 'sentence': 'The use of ranolazine in non-anginal cardiovascular disorders: A review of current data and ongoing randomized clinical trials.', 'subject score': 1000, 'object score': 861}, 'PMID:26917816': {'publication date': '2016 May', 'sentence': 'For patients with T2DM and chronic stable angina, ranolazine may be of use given its utility in cardiovascular disease and benefit in A1C lowering.', 'subject score': 1000, 'object score': 1000}, 'PMID:35155576': {'publication date': '2022', 'sentence': 'Ranolazine is a piperazine derivative and is effective for the treatment of cardiovascular disease.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 308937,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-          "name": "cardiovascular disorder",
-          "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "MEDDRA:10045663",
-            "MONDO:0004995",
-            "ICD9:429.2",
-            "MEDDRA:10007649",
-            "UMLS:C0243050",
-            "HP:0001626",
-            "MESH:D018376",
-            "MEDDRA:10007648",
-            "MEDDRA:10013205",
-            "SNOMEDCT:49601007",
-            "MEDDRA:10007650",
-            "MESH:D002318",
-            "DOID:1287",
-            "UMLS:C0007222",
-            "UMLS:C0728936",
-            "NCIT:C2931"
-          ],
-          "id": "MONDO:0004995",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiovascular Diseases",
-            "Cardiovascular disease, unspecified",
-            "Abnormality of the cardiovascular system",
-            "cardiovascular system disease",
-            "Disorder of circulatory system",
-            "Cardiovascular Disorder",
-            "cardiovascular disorder",
-            "Cardiovascular Abnormalities"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/circulatory_system",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 567,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ranolazine",
-          "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-          "equivalent_curies": [
-            "MESH:D000069458",
-            "UNII:A6IEZ5M406",
-            "CHEMBL.COMPOUND:CHEMBL1404",
-            "PUBCHEM.COMPOUND:56959",
-            "MESH:C055512",
-            "DrugCentral:2359",
-            "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-            "HMDB:HMDB0014388",
-            "GTOPDB:7291",
-            "NCIT:C66507",
-            "CHEBI:87681",
-            "UMLS:C0073633",
-            "ATC:C01EB18",
-            "PDQ:CDR0000753754",
-            "KEGG.DRUG:D05700",
-            "RXNORM:35829",
-            "DRUGBANK:DB00243",
-            "NDDF:011195",
-            "CHEBI:87690"
-          ],
-          "id": "PUBCHEM.COMPOUND:56959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Ranolazine (USAN/INN)",
-            "Ranolazine",
-            "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-            "renexa",
-            "RANOLAZINE",
-            "ranolazine"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:17027025",
-            "PMID:16787254",
-            "PMID:23571415",
-            "PMID:17456819",
-            "PMID:28082152",
-            "PMID:26459200",
-            "PMID:18221101",
-            "PMID:16644218",
-            "PMID:16640453",
-            "PMID:17220471"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308937,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004995",
-              "name": "cardiovascular disorder",
-              "description": "Any abnormality of the cardiovascular system. [HPO:probinson]; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; Any abnormality of the cardiovascular system. // COMMENTS: The cardiovascular system consists of the heart, vasculature, and the lymphatic system.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "MEDDRA:10045663",
-                "MONDO:0004995",
-                "ICD9:429.2",
-                "MEDDRA:10007649",
-                "UMLS:C0243050",
-                "HP:0001626",
-                "MESH:D018376",
-                "MEDDRA:10007648",
-                "MEDDRA:10013205",
-                "SNOMEDCT:49601007",
-                "MEDDRA:10007650",
-                "MESH:D002318",
-                "DOID:1287",
-                "UMLS:C0007222",
-                "UMLS:C0728936",
-                "NCIT:C2931"
-              ],
-              "id": "MONDO:0004995",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiovascular Diseases",
-                "Cardiovascular disease, unspecified",
-                "Abnormality of the cardiovascular system",
-                "cardiovascular system disease",
-                "Disorder of circulatory system",
-                "Cardiovascular Disorder",
-                "cardiovascular disorder",
-                "Cardiovascular Abnormalities"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/circulatory_system",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9102088,
-            "start": 567,
-            "end": 308937,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11772326': {'publication date': '2002 Jan', 'sentence': 'Ranolazine is a novel drug that has shown promise in the treatment of cardiovascular disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:15949056': {'publication date': '2005', 'sentence': 'Ongoing clinical trials will help further establish the role of ranolazine in the treatment of cardiovascular disorders.', 'subject score': 1000, 'object score': 1000}, 'PMID:20222810': {'publication date': '2010 Mar', 'sentence': 'In this review we discuss the pharmacological profile of ranolazine and discuss the current and potential future applications in cardiovascular disease for this drug.', 'subject score': 1000, 'object score': 1000}, 'PMID:26546970': {'publication date': '2016 Jan', 'sentence': 'The use of ranolazine in non-anginal cardiovascular disorders: A review of current data and ongoing randomized clinical trials.', 'subject score': 1000, 'object score': 861}, 'PMID:26917816': {'publication date': '2016 May', 'sentence': 'For patients with T2DM and chronic stable angina, ranolazine may be of use given its utility in cardiovascular disease and benefit in A1C lowering.', 'subject score': 1000, 'object score': 1000}, 'PMID:35155576': {'publication date': '2022', 'sentence': 'Ranolazine is a piperazine derivative and is effective for the treatment of cardiovascular disease.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0073633---SEMMEDDB:treats---None---None---None---UMLS:C0007222---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:56959",
-              "id": "9302560",
-              "object": "MONDO:0004995",
-              "publications": [
-                "PMID:11772326",
-                "PMID:15949056",
-                "PMID:20222810",
-                "PMID:26546970",
-                "PMID:26917816",
-                "PMID:35155576"
-              ]
-            }
-          },
-          "end": {
-            "identity": 567,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ranolazine",
-              "description": "Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
-              "equivalent_curies": [
-                "MESH:D000069458",
-                "UNII:A6IEZ5M406",
-                "CHEMBL.COMPOUND:CHEMBL1404",
-                "PUBCHEM.COMPOUND:56959",
-                "MESH:C055512",
-                "DrugCentral:2359",
-                "INCHIKEY:XKLMZUWKNUAPSZ-UHFFFAOYSA-N",
-                "HMDB:HMDB0014388",
-                "GTOPDB:7291",
-                "NCIT:C66507",
-                "CHEBI:87681",
-                "UMLS:C0073633",
-                "ATC:C01EB18",
-                "PDQ:CDR0000753754",
-                "KEGG.DRUG:D05700",
-                "RXNORM:35829",
-                "DRUGBANK:DB00243",
-                "NDDF:011195",
-                "CHEBI:87690"
-              ],
-              "id": "PUBCHEM.COMPOUND:56959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Ranolazine (USAN/INN)",
-                "Ranolazine",
-                "N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide",
-                "renexa",
-                "RANOLAZINE",
-                "ranolazine"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:17027025",
-                "PMID:16787254",
-                "PMID:23571415",
-                "PMID:17456819",
-                "PMID:28082152",
-                "PMID:26459200",
-                "PMID:18221101",
-                "PMID:16644218",
-                "PMID:16640453",
-                "PMID:17220471"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:28058029': {'publication date': '2016 Dec 21', 'sentence': 'Here, we report a case of prednisolone-dependent gastric sarcoidosis that improved after additional azathioprine, and also review the literature concerning the treatment, especially for prednisolone-dependent cases.', 'subject score': 833, 'object score': 833}}",
-    "p2": {
-      "start": {
-        "identity": 516834,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019338",
-          "name": "sarcoidosis",
-          "description": "An idiopathic inflammatory disorder characterized by the formation of non-necrotizing epithelioid granulomas which contain giant cells. It usually affects the lungs, lymph nodes, liver, and skin. Cardiac involvement is also possible.; An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.; Sarcoidosis is a disease that leads to inflammation, usually in your lungs, skin, or lymph nodes. It starts as tiny, grain-like lumps, called granulomas. Sarcoidosis can affect any organ in your body.  No one is sure what causes sarcoidosis. It affects men and women of all ages and races. It occurs mostly in people ages 20 to 50, African Americans, especially women, and people of Northern European origin. Many people have no symptoms. If you have symptoms, they may include: Cough Shortness of breath Weight loss Night sweats Fatigue  Tests to diagnose sarcoidosis include chest x-rays, lung function tests, and a biopsy. Not everyone who has the disease needs treatment. If you do, prednisone, a type of steroid, is the main treatment. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D012507",
-            "MEDDRA:10039490",
-            "ICD9:135",
-            "NCIT:C34995",
-            "UMLS:C0036202",
-            "ORPHANET:797",
-            "DOID:11335",
-            "MONDO:0019338",
-            "SNOMEDCT:31541009",
-            "MEDDRA:10039485",
-            "MEDDRA:10054039",
-            "MEDDRA:10054078",
-            "ICD10:D86",
-            "MEDDRA:10054079",
-            "MEDDRA:10039486"
-          ],
-          "id": "MONDO:0019338",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_sarcoidosis",
-            "sarcoidosis",
-            "Sarcoidosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/sarcoidosis",
-            "http://www.mayoclinic.org/diseases-conditions/sarcoidosis/basics/definition/con-20022569?_ga=1.188430891.2017809229.1415219956",
-            "http://ghr.nlm.nih.gov/glossary=sarcoidosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 516834,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019338",
-              "name": "sarcoidosis",
-              "description": "An idiopathic inflammatory disorder characterized by the formation of non-necrotizing epithelioid granulomas which contain giant cells. It usually affects the lungs, lymph nodes, liver, and skin. Cardiac involvement is also possible.; An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.; Sarcoidosis is a disease that leads to inflammation, usually in your lungs, skin, or lymph nodes. It starts as tiny, grain-like lumps, called granulomas. Sarcoidosis can affect any organ in your body.  No one is sure what causes sarcoidosis. It affects men and women of all ages and races. It occurs mostly in people ages 20 to 50, African Americans, especially women, and people of Northern European origin. Many people have no symptoms. If you have symptoms, they may include: Cough Shortness of breath Weight loss Night sweats Fatigue  Tests to diagnose sarcoidosis include chest x-rays, lung function tests, and a biopsy. Not everyone who has the disease needs treatment. If you do, prednisone, a type of steroid, is the main treatment. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D012507",
-                "MEDDRA:10039490",
-                "ICD9:135",
-                "NCIT:C34995",
-                "UMLS:C0036202",
-                "ORPHANET:797",
-                "DOID:11335",
-                "MONDO:0019338",
-                "SNOMEDCT:31541009",
-                "MEDDRA:10039485",
-                "MEDDRA:10054039",
-                "MEDDRA:10054078",
-                "ICD10:D86",
-                "MEDDRA:10054079",
-                "MEDDRA:10039486"
-              ],
-              "id": "MONDO:0019338",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_sarcoidosis",
-                "sarcoidosis",
-                "Sarcoidosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/sarcoidosis",
-                "http://www.mayoclinic.org/diseases-conditions/sarcoidosis/basics/definition/con-20022569?_ga=1.188430891.2017809229.1415219956",
-                "http://ghr.nlm.nih.gov/glossary=sarcoidosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19027605,
-            "start": 568,
-            "end": 516834,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28058029': {'publication date': '2016 Dec 21', 'sentence': 'Here, we report a case of prednisolone-dependent gastric sarcoidosis that improved after additional azathioprine, and also review the literature concerning the treatment, especially for prednisolone-dependent cases.', 'subject score': 833, 'object score': 833}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0036202---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "19409335",
-              "object": "MONDO:0019338",
-              "publications": [
-                "PMID:28058029"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11573554': {'publication date': '2001 Jul', 'sentence': 'Clinical characteristics, pulmonary function abnormalities and outcome of prednisolone treatment in 106 patients with sarcoidosis.', 'subject score': 888, 'object score': 1000}, 'PMID:13456587': {'publication date': '1956 Dec', 'sentence': '[Prednisolone therapy in lymphogranulomatosis].', 'subject score': 888, 'object score': 1000}, 'PMID:14719997': {'publication date': '2003', 'sentence': 'The combination of prednisolone and azathioprine over a period of 2 years has induced long-lasting remission in patients with resistant sarcoidosis.', 'subject score': 1000, 'object score': 888}, 'PMID:16472440': {'publication date': '2006 Jan 30', 'sentence': 'We describe a 29-year-old man with histologically verified sarcoidosis and persistent, pronounced enlargement of the peripheral lymph nodes, resistant to treatment with prednisolone and methotrexate.', 'subject score': 1000, 'object score': 840}, 'PMID:16813054': {'publication date': '2006', 'sentence': 'Prednisolone exerted a significant effect on clinical manifestations, laboratory values, and radiation pattern in patients with sarcoidosis, but more commonly (28.9%) led to its relapses than alternative treatment and active follow-up.', 'subject score': 1000, 'object score': 1000}, 'PMID:1826195': {'publication date': '1991 Apr', 'sentence': 'This phenomenon, many times described but not understood, was studied in a group of 13 sarcoidosis patients, of whom 7 received prednisolone treatment.', 'subject score': 775, 'object score': 790}, 'PMID:21428758': {'publication date': '2011 Apr', 'sentence': 'Only two RCTs were indentified for the treatment of intraocular sarcoidosis, one on etanercept, and the other from 1967 on prednisolone or oxyphenbutazone vs. placebo.', 'subject score': 1000, 'object score': 888}, 'PMID:27193294': {'publication date': '2016 Oct', 'sentence': 'An 88-year-old man, receiving prednisolone for sarcoidosis, presented with a discrete keratotic lesion on the dorsum of his right hand following the placement of an intravenous cannula a month prior to its appearance.', 'subject score': 1000, 'object score': 1000}, 'PMID:2747059': {'publication date': '1989 Jan', 'sentence': 'The levels of whole immunoglobulin antibody activities to P. acnes in BALF were as follows: 412.3 +/- 443.9 O.D./albumin 1 mg (M +/- SD) in 31 untreated sarcoidosis patients, 556.6 +/- 341.8 in 10 sarcoidosis patients treated with prednisolone, and 231.5 +/- 156.8 in 16 control individuals.', 'subject score': 1000, 'object score': 790}, 'PMID:3022627': {'publication date': '1986 Nov', 'sentence': 'The use of prednisolone in patients with sarcoidosis can be safely based upon pharmacokinetic data obtained from normal volunteers.', 'subject score': 1000, 'object score': 1000}, 'PMID:33118494': {'publication date': '2020 Oct 19', 'sentence': 'We present a case story of classic WD seen in a 48-year-old man presumed to have sarcoidosis and therefore treated with prednisolone which caused WD to flare up and ultimately unmask the disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:33263945': {'publication date': '2020 Dec 02', 'sentence': 'Although in the majority of the cases (52/80, 65.0%) there was no need for systemic prednisolone for the management of sarcoidosis, a significant proportion of patients finally discontinued ICIs treatment (44/80, 55.0%).', 'subject score': 888, 'object score': 1000}, 'PMID:3576447': {'publication date': '1987 May', 'sentence': 'During the follow-up period, hypercalcemia was diagnosed in five patients and successfully treated in four: by graft excision in two patients, by excision of a fourth gland from the neck in one patient, and with prednisolone in a patient with sarcoidosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:432030': {'publication date': '1979 Jan', 'sentence': '[Combined chemotherapy with dopan + natulan + vincristine + prednisolone in children with lymphogranulomatosis].', 'subject score': 833, 'object score': 1000}, 'PMID:6893205': {'publication date': '1980 Aug', 'sentence': 'In eight patients with sarcoidosis, prednisolone treatment (50 mg/day for 8 days) produced a significant fall in serum 1,25(OH)2D [4.8 +/) 1.9 to 3.3 +/- 1.0 (SD) ng/dl; P less than 0.025], concomitant with a significant decrease in the fracitional intestinal Ca absorption (alpha) from 0.58 +/- to 0.14 to 0.46 +/- 0.13 (+/- SD; P less than 0.005).', 'subject score': 888, 'object score': 1000}, 'PMID:7702975': {'publication date': '1994 Nov', 'sentence': 'The findings ultimately led to a diagnosis of myocardial sarcoidosis, which was treated successfully with prednisolone.', 'subject score': 1000, 'object score': 888}, 'PMID:8069017': {'publication date': '1994 Apr', 'sentence': 'This is a rare case of sarcoidosis in which renal calcification remitted after treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 516834,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019338",
-          "name": "sarcoidosis",
-          "description": "An idiopathic inflammatory disorder characterized by the formation of non-necrotizing epithelioid granulomas which contain giant cells. It usually affects the lungs, lymph nodes, liver, and skin. Cardiac involvement is also possible.; An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.; Sarcoidosis is a disease that leads to inflammation, usually in your lungs, skin, or lymph nodes. It starts as tiny, grain-like lumps, called granulomas. Sarcoidosis can affect any organ in your body.  No one is sure what causes sarcoidosis. It affects men and women of all ages and races. It occurs mostly in people ages 20 to 50, African Americans, especially women, and people of Northern European origin. Many people have no symptoms. If you have symptoms, they may include: Cough Shortness of breath Weight loss Night sweats Fatigue  Tests to diagnose sarcoidosis include chest x-rays, lung function tests, and a biopsy. Not everyone who has the disease needs treatment. If you do, prednisone, a type of steroid, is the main treatment. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D012507",
-            "MEDDRA:10039490",
-            "ICD9:135",
-            "NCIT:C34995",
-            "UMLS:C0036202",
-            "ORPHANET:797",
-            "DOID:11335",
-            "MONDO:0019338",
-            "SNOMEDCT:31541009",
-            "MEDDRA:10039485",
-            "MEDDRA:10054039",
-            "MEDDRA:10054078",
-            "ICD10:D86",
-            "MEDDRA:10054079",
-            "MEDDRA:10039486"
-          ],
-          "id": "MONDO:0019338",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_sarcoidosis",
-            "sarcoidosis",
-            "Sarcoidosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/sarcoidosis",
-            "http://www.mayoclinic.org/diseases-conditions/sarcoidosis/basics/definition/con-20022569?_ga=1.188430891.2017809229.1415219956",
-            "http://ghr.nlm.nih.gov/glossary=sarcoidosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 516834,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019338",
-              "name": "sarcoidosis",
-              "description": "An idiopathic inflammatory disorder characterized by the formation of non-necrotizing epithelioid granulomas which contain giant cells. It usually affects the lungs, lymph nodes, liver, and skin. Cardiac involvement is also possible.; An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.; Sarcoidosis is a disease that leads to inflammation, usually in your lungs, skin, or lymph nodes. It starts as tiny, grain-like lumps, called granulomas. Sarcoidosis can affect any organ in your body.  No one is sure what causes sarcoidosis. It affects men and women of all ages and races. It occurs mostly in people ages 20 to 50, African Americans, especially women, and people of Northern European origin. Many people have no symptoms. If you have symptoms, they may include: Cough Shortness of breath Weight loss Night sweats Fatigue  Tests to diagnose sarcoidosis include chest x-rays, lung function tests, and a biopsy. Not everyone who has the disease needs treatment. If you do, prednisone, a type of steroid, is the main treatment. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D012507",
-                "MEDDRA:10039490",
-                "ICD9:135",
-                "NCIT:C34995",
-                "UMLS:C0036202",
-                "ORPHANET:797",
-                "DOID:11335",
-                "MONDO:0019338",
-                "SNOMEDCT:31541009",
-                "MEDDRA:10039485",
-                "MEDDRA:10054039",
-                "MEDDRA:10054078",
-                "ICD10:D86",
-                "MEDDRA:10054079",
-                "MEDDRA:10039486"
-              ],
-              "id": "MONDO:0019338",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_sarcoidosis",
-                "sarcoidosis",
-                "Sarcoidosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/sarcoidosis",
-                "http://www.mayoclinic.org/diseases-conditions/sarcoidosis/basics/definition/con-20022569?_ga=1.188430891.2017809229.1415219956",
-                "http://ghr.nlm.nih.gov/glossary=sarcoidosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8939629,
-            "start": 568,
-            "end": 516834,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11573554': {'publication date': '2001 Jul', 'sentence': 'Clinical characteristics, pulmonary function abnormalities and outcome of prednisolone treatment in 106 patients with sarcoidosis.', 'subject score': 888, 'object score': 1000}, 'PMID:13456587': {'publication date': '1956 Dec', 'sentence': '[Prednisolone therapy in lymphogranulomatosis].', 'subject score': 888, 'object score': 1000}, 'PMID:14719997': {'publication date': '2003', 'sentence': 'The combination of prednisolone and azathioprine over a period of 2 years has induced long-lasting remission in patients with resistant sarcoidosis.', 'subject score': 1000, 'object score': 888}, 'PMID:16472440': {'publication date': '2006 Jan 30', 'sentence': 'We describe a 29-year-old man with histologically verified sarcoidosis and persistent, pronounced enlargement of the peripheral lymph nodes, resistant to treatment with prednisolone and methotrexate.', 'subject score': 1000, 'object score': 840}, 'PMID:16813054': {'publication date': '2006', 'sentence': 'Prednisolone exerted a significant effect on clinical manifestations, laboratory values, and radiation pattern in patients with sarcoidosis, but more commonly (28.9%) led to its relapses than alternative treatment and active follow-up.', 'subject score': 1000, 'object score': 1000}, 'PMID:1826195': {'publication date': '1991 Apr', 'sentence': 'This phenomenon, many times described but not understood, was studied in a group of 13 sarcoidosis patients, of whom 7 received prednisolone treatment.', 'subject score': 775, 'object score': 790}, 'PMID:21428758': {'publication date': '2011 Apr', 'sentence': 'Only two RCTs were indentified for the treatment of intraocular sarcoidosis, one on etanercept, and the other from 1967 on prednisolone or oxyphenbutazone vs. placebo.', 'subject score': 1000, 'object score': 888}, 'PMID:27193294': {'publication date': '2016 Oct', 'sentence': 'An 88-year-old man, receiving prednisolone for sarcoidosis, presented with a discrete keratotic lesion on the dorsum of his right hand following the placement of an intravenous cannula a month prior to its appearance.', 'subject score': 1000, 'object score': 1000}, 'PMID:2747059': {'publication date': '1989 Jan', 'sentence': 'The levels of whole immunoglobulin antibody activities to P. acnes in BALF were as follows: 412.3 +/- 443.9 O.D./albumin 1 mg (M +/- SD) in 31 untreated sarcoidosis patients, 556.6 +/- 341.8 in 10 sarcoidosis patients treated with prednisolone, and 231.5 +/- 156.8 in 16 control individuals.', 'subject score': 1000, 'object score': 790}, 'PMID:3022627': {'publication date': '1986 Nov', 'sentence': 'The use of prednisolone in patients with sarcoidosis can be safely based upon pharmacokinetic data obtained from normal volunteers.', 'subject score': 1000, 'object score': 1000}, 'PMID:33118494': {'publication date': '2020 Oct 19', 'sentence': 'We present a case story of classic WD seen in a 48-year-old man presumed to have sarcoidosis and therefore treated with prednisolone which caused WD to flare up and ultimately unmask the disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:33263945': {'publication date': '2020 Dec 02', 'sentence': 'Although in the majority of the cases (52/80, 65.0%) there was no need for systemic prednisolone for the management of sarcoidosis, a significant proportion of patients finally discontinued ICIs treatment (44/80, 55.0%).', 'subject score': 888, 'object score': 1000}, 'PMID:3576447': {'publication date': '1987 May', 'sentence': 'During the follow-up period, hypercalcemia was diagnosed in five patients and successfully treated in four: by graft excision in two patients, by excision of a fourth gland from the neck in one patient, and with prednisolone in a patient with sarcoidosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:432030': {'publication date': '1979 Jan', 'sentence': '[Combined chemotherapy with dopan + natulan + vincristine + prednisolone in children with lymphogranulomatosis].', 'subject score': 833, 'object score': 1000}, 'PMID:6893205': {'publication date': '1980 Aug', 'sentence': 'In eight patients with sarcoidosis, prednisolone treatment (50 mg/day for 8 days) produced a significant fall in serum 1,25(OH)2D [4.8 +/) 1.9 to 3.3 +/- 1.0 (SD) ng/dl; P less than 0.025], concomitant with a significant decrease in the fracitional intestinal Ca absorption (alpha) from 0.58 +/- to 0.14 to 0.46 +/- 0.13 (+/- SD; P less than 0.005).', 'subject score': 888, 'object score': 1000}, 'PMID:7702975': {'publication date': '1994 Nov', 'sentence': 'The findings ultimately led to a diagnosis of myocardial sarcoidosis, which was treated successfully with prednisolone.', 'subject score': 1000, 'object score': 888}, 'PMID:8069017': {'publication date': '1994 Apr', 'sentence': 'This is a rare case of sarcoidosis in which renal calcification remitted after treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0036202---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9135976",
-              "object": "MONDO:0019338",
-              "publications": [
-                "PMID:11573554",
-                "PMID:13456587",
-                "PMID:14719997",
-                "PMID:16472440",
-                "PMID:16813054",
-                "PMID:1826195",
-                "PMID:21428758",
-                "PMID:27193294",
-                "PMID:2747059",
-                "PMID:3022627",
-                "PMID:33118494",
-                "PMID:33263945",
-                "PMID:3576447",
-                "PMID:432030",
-                "PMID:6893205",
-                "PMID:7702975",
-                "PMID:8069017"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:19399522': {'publication date': '2009 Sep', 'sentence': 'The second was a 6-year-old boy with acquired relapsing TTP previously managed with plasmapheresis and prednisolone, who presented with a third relapse that was treated with plasmapheresis and rituximab; he remains in remission 17 months after treatment.', 'subject score': 1000, 'object score': 875}, 'PMID:24590757': {'publication date': '2014 Oct', 'sentence': 'TTP was transiently controlled by plasma exchange, prednisolone, rituximab, and cyclophosphamide, but relapsed within a short time.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 592657,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018896",
-          "name": "thrombotic thrombocytopenic purpura",
-          "description": "An acute or subacute syndrome characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities and neurologic abnormalities such as seizures, hemiplegia, and visual disturbances. Drugs and bacteria have been implicated as etiologic factors. The introduction of plasma exchange has significantly lowered the mortality rate. If untreated, the mortality rate is high. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C78797\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C78797\" NCI Thesaurus); A coagulation disorder characterized by extensive formation of thrombi in small blood vessels throughout the body due to low levels of ADAMTS13 protein, and resulting in consumption of circulating platelets, which is characterized by thrombocytopenia, anemia, neurologic changes, and sometimes fever and renal dysfunction.; An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10037562",
-            "MONDO:0018896",
-            "UMLS:C0034155",
-            "ORPHANET:54057",
-            "ICD10:M31.19",
-            "SNOMEDCT:78129009",
-            "NCIT:C78797",
-            "MEDDRA:10073197",
-            "MESH:D011697",
-            "PDQ:CDR0000694585",
-            "MEDDRA:10043562",
-            "DOID:10772",
-            "MEDDRA:10043648",
-            "MEDDRA:10037563"
-          ],
-          "id": "MONDO:0018896",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Thrombotic Thrombocytopenic Purpura",
-            "Thrombotic thrombocytopenic purpura",
-            "thrombotic thrombocytopenic purpura",
-            "Purpura, Thrombotic Thrombocytopenic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 592657,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018896",
-              "name": "thrombotic thrombocytopenic purpura",
-              "description": "An acute or subacute syndrome characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities and neurologic abnormalities such as seizures, hemiplegia, and visual disturbances. Drugs and bacteria have been implicated as etiologic factors. The introduction of plasma exchange has significantly lowered the mortality rate. If untreated, the mortality rate is high. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C78797\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C78797\" NCI Thesaurus); A coagulation disorder characterized by extensive formation of thrombi in small blood vessels throughout the body due to low levels of ADAMTS13 protein, and resulting in consumption of circulating platelets, which is characterized by thrombocytopenia, anemia, neurologic changes, and sometimes fever and renal dysfunction.; An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10037562",
-                "MONDO:0018896",
-                "UMLS:C0034155",
-                "ORPHANET:54057",
-                "ICD10:M31.19",
-                "SNOMEDCT:78129009",
-                "NCIT:C78797",
-                "MEDDRA:10073197",
-                "MESH:D011697",
-                "PDQ:CDR0000694585",
-                "MEDDRA:10043562",
-                "DOID:10772",
-                "MEDDRA:10043648",
-                "MEDDRA:10037563"
-              ],
-              "id": "MONDO:0018896",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Thrombotic Thrombocytopenic Purpura",
-                "Thrombotic thrombocytopenic purpura",
-                "thrombotic thrombocytopenic purpura",
-                "Purpura, Thrombotic Thrombocytopenic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14046069,
-            "start": 568,
-            "end": 592657,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19399522': {'publication date': '2009 Sep', 'sentence': 'The second was a 6-year-old boy with acquired relapsing TTP previously managed with plasmapheresis and prednisolone, who presented with a third relapse that was treated with plasmapheresis and rituximab; he remains in remission 17 months after treatment.', 'subject score': 1000, 'object score': 875}, 'PMID:24590757': {'publication date': '2014 Oct', 'sentence': 'TTP was transiently controlled by plasma exchange, prednisolone, rituximab, and cyclophosphamide, but relapsed within a short time.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0034155---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "14345678",
-              "object": "MONDO:0018896",
-              "publications": [
-                "PMID:19399522",
-                "PMID:24590757"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:16183305': {'publication date': '2005 Dec', 'sentence': 'Use of ACTH and prednisolone in infantile spasms: experience from a developing country.', 'subject score': 1000, 'object score': 1000}, 'PMID:30232789': {'publication date': '2018 Sep 19', 'sentence': 'Corticotrophin-ACTH in Comparison to Prednisolone in West Syndrome - A Randomized Study.', 'subject score': 1000, 'object score': 1000}, 'PMID:31113280': {'publication date': '2019 Oct', 'sentence': 'Eleven of the 21 patients received standard therapies as first-line treatments (10 with prednisolone according to the protocol in the United Kingdom Infantile Spasms Study [UKISS] and 1 with adrenocorticotrophic hormone [ACTH]).', 'subject score': 1000, 'object score': 771}, 'PMID:33836476': {'publication date': '2021 Mar 08', 'sentence': 'Epilepsy Outcome at Four Years in a Randomized Clinical Trial Comparing Oral Prednisolone and Intramuscular ACTH in West Syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:36054157': {'publication date': '2022 Aug 24', 'sentence': 'Response to sequential treatment with prednisolone and vigabatrin in infantile spasms.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317095,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018097",
-          "name": "West syndrome",
-          "description": "A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages [HPO:jalbers, PMID:28276060]; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0011097",
-            "MONDO:0018097",
-            "MEDDRA:10021750",
-            "UMLS:C0037769",
-            "NCIT:C84788",
-            "MEDDRA:10058893",
-            "MEDDRA:10039371",
-            "SNOMEDCT:28055006",
-            "DOID:0050562",
-            "MESH:D013036",
-            "UMLS:C1527366",
-            "ORPHANET:3451"
-          ],
-          "id": "MONDO:0018097",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_West syndrome",
-            "Salaam Seizures",
-            "West Syndrome",
-            "Spasms, Infantile",
-            "West syndrome",
-            "Epileptic spasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28276060",
-            "PMID:24268986",
-            "https://rarediseases.org/rare-diseases/west-syndrome/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317095,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018097",
-              "name": "West syndrome",
-              "description": "A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages [HPO:jalbers, PMID:28276060]; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0011097",
-                "MONDO:0018097",
-                "MEDDRA:10021750",
-                "UMLS:C0037769",
-                "NCIT:C84788",
-                "MEDDRA:10058893",
-                "MEDDRA:10039371",
-                "SNOMEDCT:28055006",
-                "DOID:0050562",
-                "MESH:D013036",
-                "UMLS:C1527366",
-                "ORPHANET:3451"
-              ],
-              "id": "MONDO:0018097",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_West syndrome",
-                "Salaam Seizures",
-                "West Syndrome",
-                "Spasms, Infantile",
-                "West syndrome",
-                "Epileptic spasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28276060",
-                "PMID:24268986",
-                "https://rarediseases.org/rare-diseases/west-syndrome/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11804411,
-            "start": 568,
-            "end": 317095,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16183305': {'publication date': '2005 Dec', 'sentence': 'Use of ACTH and prednisolone in infantile spasms: experience from a developing country.', 'subject score': 1000, 'object score': 1000}, 'PMID:30232789': {'publication date': '2018 Sep 19', 'sentence': 'Corticotrophin-ACTH in Comparison to Prednisolone in West Syndrome - A Randomized Study.', 'subject score': 1000, 'object score': 1000}, 'PMID:31113280': {'publication date': '2019 Oct', 'sentence': 'Eleven of the 21 patients received standard therapies as first-line treatments (10 with prednisolone according to the protocol in the United Kingdom Infantile Spasms Study [UKISS] and 1 with adrenocorticotrophic hormone [ACTH]).', 'subject score': 1000, 'object score': 771}, 'PMID:33836476': {'publication date': '2021 Mar 08', 'sentence': 'Epilepsy Outcome at Four Years in a Randomized Clinical Trial Comparing Oral Prednisolone and Intramuscular ACTH in West Syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:36054157': {'publication date': '2022 Aug 24', 'sentence': 'Response to sequential treatment with prednisolone and vigabatrin in infantile spasms.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0037769---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "12061894",
-              "object": "MONDO:0018097",
-              "publications": [
-                "PMID:16183305",
-                "PMID:30232789",
-                "PMID:31113280",
-                "PMID:33836476",
-                "PMID:36054157"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11242620': {'publication date': '2001 Jan', 'sentence': 'BACKGROUND: The use of adrenocorticotrophic hormone (ACTH) and prednisolone in the management of infantile spasms has been well established, but is associated with significant morbidity and cannot be used as long-term medication.', 'subject score': 1000, 'object score': 1000}, 'PMID:1509814': {'publication date': '1992 Jun', 'sentence': 'A table is provided to help select the drug for each seizure type, e.g. ethosuximide for petit mal, prednisolone for infantile spasms, and carbamazepine for various types of focal and psychomotor seizures.', 'subject score': 1000, 'object score': 1000}, 'PMID:15541450': {'publication date': '2004 Nov 13-19', 'sentence': 'We aimed to compare the effects of vigabatrin with those of prednisolone and tetracosactide in the treatment of infantile spasms.', 'subject score': 1000, 'object score': 1000}, 'PMID:16183305': {'publication date': '2005 Dec', 'sentence': 'AIMS: The purpose of this retrospective data analysis was to compare the efficacy and cost of ACTH and prednisolone in the treatment of IS from the perspective of a developing country.', 'subject score': 1000, 'object score': 1000}, 'PMID:16584670': {'publication date': '2006 Apr 03', 'sentence': 'The adrenocorticotropic hormone and prednisolone are recommended for treatment of IS, although side effects are common.', 'subject score': 1000, 'object score': 1000}, 'PMID:24446954': {'publication date': '2014 Jan', 'sentence': 'High dose ACTH may be superior to very high dose prednisolone, and in lieu of a definitive clinical trial, the choice between prednisolone and ACTH for initial treatment of infantile spasms remains controversial.', 'subject score': 1000, 'object score': 1000}, 'PMID:25048310': {'publication date': '2014 Oct', 'sentence': 'OBJECTIVES: This study aimed to test the hypothesis that high-dose prednisolone (4 mg/kg/day) may be more efficacious than usual-dose (2 mg/kg/day) prednisolone for spasm resolution at 14-days in children with infantile spasms.', 'subject score': 1000, 'object score': 1000}, 'PMID:26216500': {'publication date': '2015 Sep', 'sentence': 'OBJECTIVE: A single-center, single-blind, parallel-group, randomized clinical trial was performed to test the null hypothesis that adrenocorticotropic hormone is not superior to high-dose prednisolone for treatment of newly diagnosed West syndrome.', 'subject score': 901, 'object score': 888}, 'PMID:26835388': {'publication date': '2015 Oct', 'sentence': 'Treatment of infantile spasms has little class I data, but adrenocorticotropic hormone (ACTH), prednisolone and vigabatrin have the best evidence as first-line medications.', 'subject score': 1000, 'object score': 1000}, 'PMID:28005049': {'publication date': '2016', 'sentence': 'Recent results have demonstrated the high efficacy of prednisolone in the treatment of West syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:28927673': {'publication date': '2017 Nov', 'sentence': 'OBJECTIVE: We earlier completed a single-blind, parallel-group, randomized clinical trial to test the null hypothesis that adrenocorticotropic hormone (ACTH) is not superior to high-dose prednisolone for short-term control of West syndrome.', 'subject score': 901, 'object score': 1000}, 'PMID:29547159': {'publication date': '2018 Mar-Apr', 'sentence': 'Conclusions: The combination of pyridoxine with oral prednisolone was not found to be a beneficial therapy as compared to prednisolone alone in the treatment of infantile spasms in this pilot study.', 'subject score': 1000, 'object score': 1000}, 'PMID:29966811': {'publication date': '2018 Sep', 'sentence': 'CONCLUSION: Using a treatment protocol involving vigabatrin and prednisolone for WS, 72.7% of patients showed resolution of spasms and a BASED score of <=2.', 'subject score': 1000, 'object score': 1000}, 'PMID:30233047': {'publication date': '2018', 'sentence': 'Addition of pyridoxine to prednisolone in the treatment of infantile spasms: The knowledge gaps.', 'subject score': 1000, 'object score': 1000}, 'PMID:30501886': {'publication date': '2018 Oct', 'sentence': 'High-Dose Prednisolone as a First-line Treatment for Infantile Spasms.', 'subject score': 901, 'object score': 1000}, 'PMID:31315764': {'publication date': '2019 Jul', 'sentence': 'CONCLUSIONS: The available evidence shows no difference in the clinical efficacy of prednisolone versus ACTH in the treatment of IS.', 'subject score': 1000, 'object score': 1000}, 'PMID:31331669': {'publication date': '2019 Oct', 'sentence': 'RESULTS: We identified 102 children with infantile spasms who were treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:31769329': {'publication date': '2019 Nov 26', 'sentence': 'Incidence of Hypertension Among Children Treated With Adrenocorticotropic Hormone (ACTH) or Prednisolone for Infantile Spasms.', 'subject score': 1000, 'object score': 1000}, 'PMID:33538457': {'publication date': '2021 Feb 01', 'sentence': 'High-Dose Prednisolone for Treatment of Infantile Spasms After Presumed Perinatal Stroke.', 'subject score': 901, 'object score': 1000}, 'PMID:33575989': {'publication date': '2021 Feb 11', 'sentence': 'OBJECTIVE: To compare intravenous methylprednisolone (IVMP) with oral prednisolone (OP) for the treatment of West syndrome.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317095,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018097",
-          "name": "West syndrome",
-          "description": "A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages [HPO:jalbers, PMID:28276060]; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0011097",
-            "MONDO:0018097",
-            "MEDDRA:10021750",
-            "UMLS:C0037769",
-            "NCIT:C84788",
-            "MEDDRA:10058893",
-            "MEDDRA:10039371",
-            "SNOMEDCT:28055006",
-            "DOID:0050562",
-            "MESH:D013036",
-            "UMLS:C1527366",
-            "ORPHANET:3451"
-          ],
-          "id": "MONDO:0018097",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_West syndrome",
-            "Salaam Seizures",
-            "West Syndrome",
-            "Spasms, Infantile",
-            "West syndrome",
-            "Epileptic spasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28276060",
-            "PMID:24268986",
-            "https://rarediseases.org/rare-diseases/west-syndrome/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317095,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018097",
-              "name": "West syndrome",
-              "description": "A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages [HPO:jalbers, PMID:28276060]; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0011097",
-                "MONDO:0018097",
-                "MEDDRA:10021750",
-                "UMLS:C0037769",
-                "NCIT:C84788",
-                "MEDDRA:10058893",
-                "MEDDRA:10039371",
-                "SNOMEDCT:28055006",
-                "DOID:0050562",
-                "MESH:D013036",
-                "UMLS:C1527366",
-                "ORPHANET:3451"
-              ],
-              "id": "MONDO:0018097",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_West syndrome",
-                "Salaam Seizures",
-                "West Syndrome",
-                "Spasms, Infantile",
-                "West syndrome",
-                "Epileptic spasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28276060",
-                "PMID:24268986",
-                "https://rarediseases.org/rare-diseases/west-syndrome/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8565210,
-            "start": 568,
-            "end": 317095,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11242620': {'publication date': '2001 Jan', 'sentence': 'BACKGROUND: The use of adrenocorticotrophic hormone (ACTH) and prednisolone in the management of infantile spasms has been well established, but is associated with significant morbidity and cannot be used as long-term medication.', 'subject score': 1000, 'object score': 1000}, 'PMID:1509814': {'publication date': '1992 Jun', 'sentence': 'A table is provided to help select the drug for each seizure type, e.g. ethosuximide for petit mal, prednisolone for infantile spasms, and carbamazepine for various types of focal and psychomotor seizures.', 'subject score': 1000, 'object score': 1000}, 'PMID:15541450': {'publication date': '2004 Nov 13-19', 'sentence': 'We aimed to compare the effects of vigabatrin with those of prednisolone and tetracosactide in the treatment of infantile spasms.', 'subject score': 1000, 'object score': 1000}, 'PMID:16183305': {'publication date': '2005 Dec', 'sentence': 'AIMS: The purpose of this retrospective data analysis was to compare the efficacy and cost of ACTH and prednisolone in the treatment of IS from the perspective of a developing country.', 'subject score': 1000, 'object score': 1000}, 'PMID:16584670': {'publication date': '2006 Apr 03', 'sentence': 'The adrenocorticotropic hormone and prednisolone are recommended for treatment of IS, although side effects are common.', 'subject score': 1000, 'object score': 1000}, 'PMID:24446954': {'publication date': '2014 Jan', 'sentence': 'High dose ACTH may be superior to very high dose prednisolone, and in lieu of a definitive clinical trial, the choice between prednisolone and ACTH for initial treatment of infantile spasms remains controversial.', 'subject score': 1000, 'object score': 1000}, 'PMID:25048310': {'publication date': '2014 Oct', 'sentence': 'OBJECTIVES: This study aimed to test the hypothesis that high-dose prednisolone (4 mg/kg/day) may be more efficacious than usual-dose (2 mg/kg/day) prednisolone for spasm resolution at 14-days in children with infantile spasms.', 'subject score': 1000, 'object score': 1000}, 'PMID:26216500': {'publication date': '2015 Sep', 'sentence': 'OBJECTIVE: A single-center, single-blind, parallel-group, randomized clinical trial was performed to test the null hypothesis that adrenocorticotropic hormone is not superior to high-dose prednisolone for treatment of newly diagnosed West syndrome.', 'subject score': 901, 'object score': 888}, 'PMID:26835388': {'publication date': '2015 Oct', 'sentence': 'Treatment of infantile spasms has little class I data, but adrenocorticotropic hormone (ACTH), prednisolone and vigabatrin have the best evidence as first-line medications.', 'subject score': 1000, 'object score': 1000}, 'PMID:28005049': {'publication date': '2016', 'sentence': 'Recent results have demonstrated the high efficacy of prednisolone in the treatment of West syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:28927673': {'publication date': '2017 Nov', 'sentence': 'OBJECTIVE: We earlier completed a single-blind, parallel-group, randomized clinical trial to test the null hypothesis that adrenocorticotropic hormone (ACTH) is not superior to high-dose prednisolone for short-term control of West syndrome.', 'subject score': 901, 'object score': 1000}, 'PMID:29547159': {'publication date': '2018 Mar-Apr', 'sentence': 'Conclusions: The combination of pyridoxine with oral prednisolone was not found to be a beneficial therapy as compared to prednisolone alone in the treatment of infantile spasms in this pilot study.', 'subject score': 1000, 'object score': 1000}, 'PMID:29966811': {'publication date': '2018 Sep', 'sentence': 'CONCLUSION: Using a treatment protocol involving vigabatrin and prednisolone for WS, 72.7% of patients showed resolution of spasms and a BASED score of <=2.', 'subject score': 1000, 'object score': 1000}, 'PMID:30233047': {'publication date': '2018', 'sentence': 'Addition of pyridoxine to prednisolone in the treatment of infantile spasms: The knowledge gaps.', 'subject score': 1000, 'object score': 1000}, 'PMID:30501886': {'publication date': '2018 Oct', 'sentence': 'High-Dose Prednisolone as a First-line Treatment for Infantile Spasms.', 'subject score': 901, 'object score': 1000}, 'PMID:31315764': {'publication date': '2019 Jul', 'sentence': 'CONCLUSIONS: The available evidence shows no difference in the clinical efficacy of prednisolone versus ACTH in the treatment of IS.', 'subject score': 1000, 'object score': 1000}, 'PMID:31331669': {'publication date': '2019 Oct', 'sentence': 'RESULTS: We identified 102 children with infantile spasms who were treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:31769329': {'publication date': '2019 Nov 26', 'sentence': 'Incidence of Hypertension Among Children Treated With Adrenocorticotropic Hormone (ACTH) or Prednisolone for Infantile Spasms.', 'subject score': 1000, 'object score': 1000}, 'PMID:33538457': {'publication date': '2021 Feb 01', 'sentence': 'High-Dose Prednisolone for Treatment of Infantile Spasms After Presumed Perinatal Stroke.', 'subject score': 901, 'object score': 1000}, 'PMID:33575989': {'publication date': '2021 Feb 11', 'sentence': 'OBJECTIVE: To compare intravenous methylprednisolone (IVMP) with oral prednisolone (OP) for the treatment of West syndrome.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0037769---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8752241",
-              "object": "MONDO:0018097",
-              "publications": [
-                "PMID:11242620",
-                "PMID:1509814",
-                "PMID:15541450",
-                "PMID:16183305",
-                "PMID:16584670",
-                "PMID:24446954",
-                "PMID:25048310",
-                "PMID:26216500",
-                "PMID:26835388",
-                "PMID:28005049",
-                "PMID:28927673",
-                "PMID:29547159",
-                "PMID:29966811",
-                "PMID:30233047",
-                "PMID:30501886",
-                "PMID:31315764",
-                "PMID:31331669",
-                "PMID:31769329",
-                "PMID:33538457",
-                "PMID:33575989"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:11692899': {'publication date': '2001 Apr', 'sentence': 'Prednisolone in Duchenne muscular dystrophy.', 'subject score': 1000, 'object score': 1000}, 'PMID:16786214': {'publication date': '2006 Oct', 'sentence': 'Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation.', 'subject score': 1000, 'object score': 1000}, 'PMID:268398': {'publication date': '1977', 'sentence': \"The effects of diethylstilbestrol (DES) and prednisolone (Pr), administered alone or in combination, on the serum enzyme activities in Duchenne's muscular dystrophy (DMD) have been evaluated.\", 'subject score': 1000, 'object score': 1000}, 'PMID:8186713': {'publication date': '1993 Sep-Nov', 'sentence': 'Prednisolone has been shown to improve strength in Duchenne dystrophy, the improvement starting within 10 days of treatment and reaching a maximum by 3 months, and then plateauing.', 'subject score': 1000, 'object score': 1000}, 'PMID:968173': {'publication date': '1976 Sep', 'sentence': \"We have previously shown that diethylstilbestrol (DES) almost always, and prednisolone (Pr) less frequently, lowered the high serum enzyme activities in Duchenne's muscular dystrophy (DMD).\", 'subject score': 802, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 546960,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0010679",
-          "name": "Duchenne muscular dystrophy",
-          "description": "An X-linked inherited disorder caused by mutations in the DMD gene found on the X chromosome. It is characterized by rapidly progressing muscle weakness and muscle atrophy initially involving the lower extremities and eventually affecting the whole body. It affects males whereas females can be carriers. The symptoms start before the age of six and may appear at infancy.; An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0013264",
-            "MESH:D020388",
-            "DOID:11723",
-            "OMIM:310200",
-            "NCIT:C75482",
-            "MONDO:0010679",
-            "MEDDRA:10013801",
-            "SNOMEDCT:76670001",
-            "ORPHANET:98896"
-          ],
-          "id": "MONDO:0010679",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Duchenne Muscular Dystrophy",
-            "Muscular dystrophy, duchenne type related phenotypic feature",
-            "Muscular Dystrophy, Duchenne",
-            "obsolete_Duchenne muscular dystrophy",
-            "Duchenne muscular dystrophy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/duchenne_muscular_dystrophy",
-            "http://www.genome.gov/19518854",
-            "http://omim.org/entry/300377"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546960,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0010679",
-              "name": "Duchenne muscular dystrophy",
-              "description": "An X-linked inherited disorder caused by mutations in the DMD gene found on the X chromosome. It is characterized by rapidly progressing muscle weakness and muscle atrophy initially involving the lower extremities and eventually affecting the whole body. It affects males whereas females can be carriers. The symptoms start before the age of six and may appear at infancy.; An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0013264",
-                "MESH:D020388",
-                "DOID:11723",
-                "OMIM:310200",
-                "NCIT:C75482",
-                "MONDO:0010679",
-                "MEDDRA:10013801",
-                "SNOMEDCT:76670001",
-                "ORPHANET:98896"
-              ],
-              "id": "MONDO:0010679",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Duchenne Muscular Dystrophy",
-                "Muscular dystrophy, duchenne type related phenotypic feature",
-                "Muscular Dystrophy, Duchenne",
-                "obsolete_Duchenne muscular dystrophy",
-                "Duchenne muscular dystrophy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/duchenne_muscular_dystrophy",
-                "http://www.genome.gov/19518854",
-                "http://omim.org/entry/300377"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9010072,
-            "start": 568,
-            "end": 546960,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11692899': {'publication date': '2001 Apr', 'sentence': 'Prednisolone in Duchenne muscular dystrophy.', 'subject score': 1000, 'object score': 1000}, 'PMID:16786214': {'publication date': '2006 Oct', 'sentence': 'Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation.', 'subject score': 1000, 'object score': 1000}, 'PMID:268398': {'publication date': '1977', 'sentence': \"The effects of diethylstilbestrol (DES) and prednisolone (Pr), administered alone or in combination, on the serum enzyme activities in Duchenne's muscular dystrophy (DMD) have been evaluated.\", 'subject score': 1000, 'object score': 1000}, 'PMID:8186713': {'publication date': '1993 Sep-Nov', 'sentence': 'Prednisolone has been shown to improve strength in Duchenne dystrophy, the improvement starting within 10 days of treatment and reaching a maximum by 3 months, and then plateauing.', 'subject score': 1000, 'object score': 1000}, 'PMID:968173': {'publication date': '1976 Sep', 'sentence': \"We have previously shown that diethylstilbestrol (DES) almost always, and prednisolone (Pr) less frequently, lowered the high serum enzyme activities in Duchenne's muscular dystrophy (DMD).\", 'subject score': 802, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0013264---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9208405",
-              "object": "MONDO:0010679",
-              "publications": [
-                "PMID:11692899",
-                "PMID:16786214",
-                "PMID:268398",
-                "PMID:8186713",
-                "PMID:968173"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10441862': {'publication date': '1999', 'sentence': \"A special program for long-term application of low-dose prednisolone treatment in Duchenne-Becker muscular dystrophy with complex control of the patients' state was developed.\", 'subject score': 861, 'object score': 923}, 'PMID:11249150': {'publication date': '2000 Nov', 'sentence': 'To determine the mechanism of the beneficial effects of prednisolone on Duchenne muscular dystrophy (DMD), we examined the short-term effects of prednisolone on neuromuscular transmission by using conventional microelectrode methods in the mdx mice.', 'subject score': 1000, 'object score': 1000}, 'PMID:15272899': {'publication date': '2004 Aug', 'sentence': 'Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis.', 'subject score': 888, 'object score': 1000}, 'PMID:21400928': {'publication date': '2011 Jan', 'sentence': '[Prednisolone treatment for Duchenne muscular dystrophy].', 'subject score': 888, 'object score': 1000}, 'PMID:28432191': {'publication date': '2017 Jun 01', 'sentence': 'The glucocorticoid receptor (GR) agonist prednisolone is the current standard-of-care treatment for Duchenne muscular dystrophy because it prolongs ambulation, likely due to its anti-inflammatory effects.', 'subject score': 908, 'object score': 1000}, 'PMID:30214127': {'publication date': '2018 Sep', 'sentence': 'Importance of long-term motor function evaluation after prednisolone treatment for Duchenne muscular dystrophy.', 'subject score': 888, 'object score': 1000}, 'PMID:31295065': {'publication date': '2019 Oct 01', 'sentence': 'To mimic typical pharmacology of patients with Duchenne muscular dystrophy, a group was treated with prednisolone (Pred) in combination with Q, NR, and Lis.', 'subject score': 1000, 'object score': 1000}, 'PMID:34617309': {'publication date': '2021 Oct 07', 'sentence': 'Intermittent versus Daily Regimen of Prednisolone in Ambulatory Boys with Duchenne Muscular Dystrophy: A Randomized, Open-Label Trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:34693725': {'publication date': '2021 Oct 25', 'sentence': 'Conclusion:     Deflazacort provides clinically meaningful delays in loss of physical milestones over 48 weeks compared with prednisone/prednisolone for patients with nonsense mutation Duchenne muscular dystrophy.', 'subject score': 888, 'object score': 893}, 'PMID:8482992': {'publication date': '1993', 'sentence': 'Seven patients, aged 10-17 years, with Duchenne muscular dystrophy were treated orally with prednisolone (PSL) at a dose of 0.8-1.0 mg/kg per day for 8 weeks.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 546960,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0010679",
-          "name": "Duchenne muscular dystrophy",
-          "description": "An X-linked inherited disorder caused by mutations in the DMD gene found on the X chromosome. It is characterized by rapidly progressing muscle weakness and muscle atrophy initially involving the lower extremities and eventually affecting the whole body. It affects males whereas females can be carriers. The symptoms start before the age of six and may appear at infancy.; An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0013264",
-            "MESH:D020388",
-            "DOID:11723",
-            "OMIM:310200",
-            "NCIT:C75482",
-            "MONDO:0010679",
-            "MEDDRA:10013801",
-            "SNOMEDCT:76670001",
-            "ORPHANET:98896"
-          ],
-          "id": "MONDO:0010679",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Duchenne Muscular Dystrophy",
-            "Muscular dystrophy, duchenne type related phenotypic feature",
-            "Muscular Dystrophy, Duchenne",
-            "obsolete_Duchenne muscular dystrophy",
-            "Duchenne muscular dystrophy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/duchenne_muscular_dystrophy",
-            "http://www.genome.gov/19518854",
-            "http://omim.org/entry/300377"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546960,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0010679",
-              "name": "Duchenne muscular dystrophy",
-              "description": "An X-linked inherited disorder caused by mutations in the DMD gene found on the X chromosome. It is characterized by rapidly progressing muscle weakness and muscle atrophy initially involving the lower extremities and eventually affecting the whole body. It affects males whereas females can be carriers. The symptoms start before the age of six and may appear at infancy.; An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0013264",
-                "MESH:D020388",
-                "DOID:11723",
-                "OMIM:310200",
-                "NCIT:C75482",
-                "MONDO:0010679",
-                "MEDDRA:10013801",
-                "SNOMEDCT:76670001",
-                "ORPHANET:98896"
-              ],
-              "id": "MONDO:0010679",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Duchenne Muscular Dystrophy",
-                "Muscular dystrophy, duchenne type related phenotypic feature",
-                "Muscular Dystrophy, Duchenne",
-                "obsolete_Duchenne muscular dystrophy",
-                "Duchenne muscular dystrophy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/duchenne_muscular_dystrophy",
-                "http://www.genome.gov/19518854",
-                "http://omim.org/entry/300377"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7448255,
-            "start": 568,
-            "end": 546960,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10441862': {'publication date': '1999', 'sentence': \"A special program for long-term application of low-dose prednisolone treatment in Duchenne-Becker muscular dystrophy with complex control of the patients' state was developed.\", 'subject score': 861, 'object score': 923}, 'PMID:11249150': {'publication date': '2000 Nov', 'sentence': 'To determine the mechanism of the beneficial effects of prednisolone on Duchenne muscular dystrophy (DMD), we examined the short-term effects of prednisolone on neuromuscular transmission by using conventional microelectrode methods in the mdx mice.', 'subject score': 1000, 'object score': 1000}, 'PMID:15272899': {'publication date': '2004 Aug', 'sentence': 'Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis.', 'subject score': 888, 'object score': 1000}, 'PMID:21400928': {'publication date': '2011 Jan', 'sentence': '[Prednisolone treatment for Duchenne muscular dystrophy].', 'subject score': 888, 'object score': 1000}, 'PMID:28432191': {'publication date': '2017 Jun 01', 'sentence': 'The glucocorticoid receptor (GR) agonist prednisolone is the current standard-of-care treatment for Duchenne muscular dystrophy because it prolongs ambulation, likely due to its anti-inflammatory effects.', 'subject score': 908, 'object score': 1000}, 'PMID:30214127': {'publication date': '2018 Sep', 'sentence': 'Importance of long-term motor function evaluation after prednisolone treatment for Duchenne muscular dystrophy.', 'subject score': 888, 'object score': 1000}, 'PMID:31295065': {'publication date': '2019 Oct 01', 'sentence': 'To mimic typical pharmacology of patients with Duchenne muscular dystrophy, a group was treated with prednisolone (Pred) in combination with Q, NR, and Lis.', 'subject score': 1000, 'object score': 1000}, 'PMID:34617309': {'publication date': '2021 Oct 07', 'sentence': 'Intermittent versus Daily Regimen of Prednisolone in Ambulatory Boys with Duchenne Muscular Dystrophy: A Randomized, Open-Label Trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:34693725': {'publication date': '2021 Oct 25', 'sentence': 'Conclusion:     Deflazacort provides clinically meaningful delays in loss of physical milestones over 48 weeks compared with prednisone/prednisolone for patients with nonsense mutation Duchenne muscular dystrophy.', 'subject score': 888, 'object score': 893}, 'PMID:8482992': {'publication date': '1993', 'sentence': 'Seven patients, aged 10-17 years, with Duchenne muscular dystrophy were treated orally with prednisolone (PSL) at a dose of 0.8-1.0 mg/kg per day for 8 weeks.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0013264---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7603475",
-              "object": "MONDO:0010679",
-              "publications": [
-                "PMID:10441862",
-                "PMID:11249150",
-                "PMID:15272899",
-                "PMID:21400928",
-                "PMID:28432191",
-                "PMID:30214127",
-                "PMID:31295065",
-                "PMID:34617309",
-                "PMID:34693725",
-                "PMID:8482992"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:34945055': {'publication date': '2021 Dec 09', 'sentence': 'In 2010, a study on the advantages of budesonide compared to prednisolone in autoimmune hepatitis gave rise to experimental therapy using budesonide as an adjuvant BA treatment.', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 321599,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008867",
-          "name": "biliary atresia",
-          "description": "A congenital disorder characterized by blockage or absence of the intrahepatic or extrahepatic bile ducts.; Progressive destruction or the absence of all or part of the extrahepatic BILE DUCTS, resulting in the complete obstruction of BILE flow. Usually, biliary atresia is found in infants and accounts for one third of the neonatal cholestatic JAUNDICE.; Atresia of the biliary tree. [HPO:probinson]; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "MEDDRA:10004654",
-            "HP:0005912",
-            "MEDDRA:10003650",
-            "NCIT:C34421",
-            "ICD9:751.61",
-            "MESH:D001656",
-            "UMLS:C0005411",
-            "ORPHANET:30391",
-            "MONDO:0008867",
-            "DOID:13608",
-            "MEDDRA:10004653",
-            "SNOMEDCT:77480004",
-            "ICD10:Q44.2"
-          ],
-          "id": "MONDO:0008867",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_biliary atresia",
-            "Biliary atresia",
-            "Biliary Atresia",
-            "biliary atresia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000215.htm",
-            "http://en.wikipedia.org/wiki/biliary_atresia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321599,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008867",
-              "name": "biliary atresia",
-              "description": "A congenital disorder characterized by blockage or absence of the intrahepatic or extrahepatic bile ducts.; Progressive destruction or the absence of all or part of the extrahepatic BILE DUCTS, resulting in the complete obstruction of BILE flow. Usually, biliary atresia is found in infants and accounts for one third of the neonatal cholestatic JAUNDICE.; Atresia of the biliary tree. [HPO:probinson]; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "MEDDRA:10004654",
-                "HP:0005912",
-                "MEDDRA:10003650",
-                "NCIT:C34421",
-                "ICD9:751.61",
-                "MESH:D001656",
-                "UMLS:C0005411",
-                "ORPHANET:30391",
-                "MONDO:0008867",
-                "DOID:13608",
-                "MEDDRA:10004653",
-                "SNOMEDCT:77480004",
-                "ICD10:Q44.2"
-              ],
-              "id": "MONDO:0008867",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_biliary atresia",
-                "Biliary atresia",
-                "Biliary Atresia",
-                "biliary atresia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000215.htm",
-                "http://en.wikipedia.org/wiki/biliary_atresia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23604593,
-            "start": 568,
-            "end": 321599,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34945055': {'publication date': '2021 Dec 09', 'sentence': 'In 2010, a study on the advantages of budesonide compared to prednisolone in autoimmune hepatitis gave rise to experimental therapy using budesonide as an adjuvant BA treatment.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0005411---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "24042094",
-              "object": "MONDO:0008867",
-              "publications": [
-                "PMID:34945055"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15876756': {'publication date': '2005 Apr', 'sentence': 'METHODS: Growth parameters of twelve children (8 m, 4 f) with congenital adrenal hyperplasia were retrospectively studied while on treatment with prednisolone (PR) earlier and then hydrocortisone (HC) after it became freely available in India.', 'subject score': 1000, 'object score': 1000}, 'PMID:22180995': {'publication date': '2011', 'sentence': 'CASE: We report the case of a 23-years-old female with the classic Congenital Adrenal Hyperplasia (CAH) from birth, diagnosed due to genital pigmentation, clitoromegaly and salt-wasting crisis, treated with glucocorticoid replacement (hydrocortisone, fludrocortisone and NaCI), followed by genital surgery, until the adult life when she continues treatment with fludrocortisone and prednisolone.', 'subject score': 1000, 'object score': 916}, 'PMID:29694951': {'publication date': '2018', 'sentence': 'We discuss this case based on the differential diagnosis of complete adrenal cortex failure including other genetic causes in addition to CAH, prednisolone treatment, autoimmune adrenalitis, adrenoleukodystrophy, CMV infection, and adrenal hemorrhage infarction.', 'subject score': 888, 'object score': 1000}, 'PMID:31532828': {'publication date': '2019 Sep 18', 'sentence': 'All AD patients and 42% of CAH patients were prescribed glucocorticoids, most frequently hydrocortisone in AD (82%) and prednisolone in CAH (50%).', 'subject score': 1000, 'object score': 1000}, 'PMID:33845451': {'publication date': '2021 Mar 31', 'sentence': 'We present the case of a 50-year-old man, with a classical form of congenital adrenal hyperplasia (CAH), which was well treated with prednisolone and fludrocortisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:6538545': {'publication date': '1984', 'sentence': 'Saliva 17OHP profiles provided valuable information on the efficacy of hydrocortisone, cortisone acetate, prednisolone and dexamethasone as glucocorticoid suppressive regimes in the treatment of CAH.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 312713,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-          "name": "congenital adrenal hyperplasia",
-          "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:237751000",
-            "DOID:12255",
-            "NCIT:C34360",
-            "ORPHANET:418",
-            "MONDO:0018479",
-            "MEDDRA:10010323",
-            "ICD9:255.2",
-            "DOID:0050811",
-            "HP:0008258",
-            "UMLS:C0001627",
-            "UMLS:C0701163",
-            "ICD10:E25",
-            "MESH:D000312"
-          ],
-          "id": "MONDO:0018479",
-          "category": "biolink:Disease",
-          "all_names": [
-            "congenital adrenal hyperplasia",
-            "obsolete congenital adrenal hyperplasia",
-            "Adrenogenital disorders",
-            "Adrenogenital disorder",
-            "Congenital adrenal hyperplasia",
-            "Adrenal Hyperplasia, Congenital",
-            "obsolete_congenital adrenal hyperplasia",
-            "Congenital Adrenal Hyperplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-            "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-            "http://omim.org/entry/201710",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312713,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-              "name": "congenital adrenal hyperplasia",
-              "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:237751000",
-                "DOID:12255",
-                "NCIT:C34360",
-                "ORPHANET:418",
-                "MONDO:0018479",
-                "MEDDRA:10010323",
-                "ICD9:255.2",
-                "DOID:0050811",
-                "HP:0008258",
-                "UMLS:C0001627",
-                "UMLS:C0701163",
-                "ICD10:E25",
-                "MESH:D000312"
-              ],
-              "id": "MONDO:0018479",
-              "category": "biolink:Disease",
-              "all_names": [
-                "congenital adrenal hyperplasia",
-                "obsolete congenital adrenal hyperplasia",
-                "Adrenogenital disorders",
-                "Adrenogenital disorder",
-                "Congenital adrenal hyperplasia",
-                "Adrenal Hyperplasia, Congenital",
-                "obsolete_congenital adrenal hyperplasia",
-                "Congenital Adrenal Hyperplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-                "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-                "http://omim.org/entry/201710",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11558374,
-            "start": 568,
-            "end": 312713,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15876756': {'publication date': '2005 Apr', 'sentence': 'METHODS: Growth parameters of twelve children (8 m, 4 f) with congenital adrenal hyperplasia were retrospectively studied while on treatment with prednisolone (PR) earlier and then hydrocortisone (HC) after it became freely available in India.', 'subject score': 1000, 'object score': 1000}, 'PMID:22180995': {'publication date': '2011', 'sentence': 'CASE: We report the case of a 23-years-old female with the classic Congenital Adrenal Hyperplasia (CAH) from birth, diagnosed due to genital pigmentation, clitoromegaly and salt-wasting crisis, treated with glucocorticoid replacement (hydrocortisone, fludrocortisone and NaCI), followed by genital surgery, until the adult life when she continues treatment with fludrocortisone and prednisolone.', 'subject score': 1000, 'object score': 916}, 'PMID:29694951': {'publication date': '2018', 'sentence': 'We discuss this case based on the differential diagnosis of complete adrenal cortex failure including other genetic causes in addition to CAH, prednisolone treatment, autoimmune adrenalitis, adrenoleukodystrophy, CMV infection, and adrenal hemorrhage infarction.', 'subject score': 888, 'object score': 1000}, 'PMID:31532828': {'publication date': '2019 Sep 18', 'sentence': 'All AD patients and 42% of CAH patients were prescribed glucocorticoids, most frequently hydrocortisone in AD (82%) and prednisolone in CAH (50%).', 'subject score': 1000, 'object score': 1000}, 'PMID:33845451': {'publication date': '2021 Mar 31', 'sentence': 'We present the case of a 50-year-old man, with a classical form of congenital adrenal hyperplasia (CAH), which was well treated with prednisolone and fludrocortisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:6538545': {'publication date': '1984', 'sentence': 'Saliva 17OHP profiles provided valuable information on the efficacy of hydrocortisone, cortisone acetate, prednisolone and dexamethasone as glucocorticoid suppressive regimes in the treatment of CAH.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0001627---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11810617",
-              "object": "MONDO:0018479",
-              "publications": [
-                "PMID:15876756",
-                "PMID:22180995",
-                "PMID:29694951",
-                "PMID:31532828",
-                "PMID:33845451",
-                "PMID:6538545"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:8191750': {'publication date': '1993', 'sentence': 'Prednisolone furthers T-cell immunodeficiency and also reduces the intensity of autoimmune reactions in multiple sclerosis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 522619,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005301",
-          "name": "multiple sclerosis",
-          "description": "An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D009103",
-            "NCIT:C3243",
-            "MEDDRA:10039720",
-            "EFO:0003885",
-            "ORPHANET:802",
-            "MEDDRA:10028245",
-            "PSY:32490",
-            "ICD9:340",
-            "MONDO:0005301",
-            "MEDDRA:10028053",
-            "UMLS:C0026769",
-            "MEDDRA:10013451",
-            "SNOMEDCT:24700007",
-            "ICD10:G35",
-            "PDQ:CDR0000691761",
-            "DOID:2377"
-          ],
-          "id": "MONDO:0005301",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Multiple Sclerosis",
-            "obsolete_multiple sclerosis",
-            "Multiple sclerosis",
-            "multiple sclerosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://ghr.nlm.nih.gov/condition/multiple-sclerosis",
-            "http://en.wikipedia.org/wiki/multiple_sclerosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 522619,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005301",
-              "name": "multiple sclerosis",
-              "description": "An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D009103",
-                "NCIT:C3243",
-                "MEDDRA:10039720",
-                "EFO:0003885",
-                "ORPHANET:802",
-                "MEDDRA:10028245",
-                "PSY:32490",
-                "ICD9:340",
-                "MONDO:0005301",
-                "MEDDRA:10028053",
-                "UMLS:C0026769",
-                "MEDDRA:10013451",
-                "SNOMEDCT:24700007",
-                "ICD10:G35",
-                "PDQ:CDR0000691761",
-                "DOID:2377"
-              ],
-              "id": "MONDO:0005301",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Multiple Sclerosis",
-                "obsolete_multiple sclerosis",
-                "Multiple sclerosis",
-                "multiple sclerosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://ghr.nlm.nih.gov/condition/multiple-sclerosis",
-                "http://en.wikipedia.org/wiki/multiple_sclerosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26397688,
-            "start": 568,
-            "end": 522619,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8191750': {'publication date': '1993', 'sentence': 'Prednisolone furthers T-cell immunodeficiency and also reduces the intensity of autoimmune reactions in multiple sclerosis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0026769---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "26862829",
-              "object": "MONDO:0005301",
-              "publications": [
-                "PMID:8191750"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-=======
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
->>>>>>> main
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 312686,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10440499': {'publication date': '1999 Aug', 'sentence': 'Long-term open-trial of mizoribine with prednisolone in 24 patients with multiple sclerosis: safety, clinical and magnetic resonance imaging outcome.', 'subject score': 1000, 'object score': 1000}, 'PMID:1792777': {'publication date': '1991 Dec', 'sentence': '[Changes in the clinical and immunological indices of patients with disseminated sclerosis being treated with prednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:2256298': {'publication date': '1990 Aug', 'sentence': 'Prednisolone produced an unfavourable effect on the course of the demyelinating process in patients with multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2339565': {'publication date': '1990 Feb', 'sentence': 'The authors examined 56 patients suffering of multiple sclerosis who were treated with prednisolone and Proper-Myl.', 'subject score': 1000, 'object score': 1000}, 'PMID:25392236': {'publication date': '2015 Apr', 'sentence': 'Glucocorticoids, such as prednisolone, are effective in the treatment of multiple sclerosis in large part due to their ability to inhibit pro-inflammatory pathways (e.g., NFkappaB).', 'subject score': 1000, 'object score': 1000}, 'PMID:3259769': {'publication date': '1988', 'sentence': '[The dynamics of immunological indicators in the treatment of patients with multiple sclerosis with prednisolone combined with plasmapheresis].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 522619,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-          "name": "adrenocortical insufficiency",
-          "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0405580",
-            "MEDDRA:10022460",
-            "ICD9:255.4",
-            "EFO:0009491",
-            "MEDDRA:10001367",
-            "MEDDRA:10020936",
-            "MONDO:0000004",
-            "MEDDRA:10020979",
-            "SNOMEDCT:237785004",
-            "SNOMEDCT:386584007",
-            "MEDDRA:10056485",
-            "MEDDRA:10082130",
-            "UMLS:C0001623",
-            "MEDDRA:10001344",
-            "MEDDRA:10001366",
-            "MEDDRA:10001334",
-            "DOID:10493",
-            "NCIT:C26691",
-            "HP:0000846",
-            "MEDDRA:10001335",
-            "MEDDRA:10001369",
-            "MEDDRA:10001342",
-            "MEDDRA:10001343",
-            "MESH:D000309",
-            "SNOMEDCT:111563005",
-            "MEDDRA:10011172",
-            "MEDDRA:10022461"
-          ],
-          "id": "MONDO:0000004",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortical hypofunction",
-            "Adrenocortical Insufficiency",
-            "adrenocortical insufficiency",
-            "Corticoadrenal insufficiency",
-            "Adrenal gland hypofunction",
-            "Adrenal Insufficiency",
-            "Adrenal insufficiency",
-            "Adrenal cortical hypofunction"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005301",
-          "name": "multiple sclerosis",
-          "description": "An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D009103",
-            "NCIT:C3243",
-            "MEDDRA:10039720",
-            "EFO:0003885",
-            "ORPHANET:802",
-            "MEDDRA:10028245",
-            "PSY:32490",
-            "ICD9:340",
-            "MONDO:0005301",
-            "MEDDRA:10028053",
-            "UMLS:C0026769",
-            "MEDDRA:10013451",
-            "SNOMEDCT:24700007",
-            "ICD10:G35",
-            "PDQ:CDR0000691761",
-            "DOID:2377"
-          ],
-          "id": "MONDO:0005301",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Multiple Sclerosis",
-            "obsolete_multiple sclerosis",
-            "Multiple sclerosis",
-            "multiple sclerosis"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:11443143"
-=======
-            "https://ghr.nlm.nih.gov/condition/multiple-sclerosis",
-            "http://en.wikipedia.org/wiki/multiple_sclerosis"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 312686,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-              "name": "adrenocortical insufficiency",
-              "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0405580",
-                "MEDDRA:10022460",
-                "ICD9:255.4",
-                "EFO:0009491",
-                "MEDDRA:10001367",
-                "MEDDRA:10020936",
-                "MONDO:0000004",
-                "MEDDRA:10020979",
-                "SNOMEDCT:237785004",
-                "SNOMEDCT:386584007",
-                "MEDDRA:10056485",
-                "MEDDRA:10082130",
-                "UMLS:C0001623",
-                "MEDDRA:10001344",
-                "MEDDRA:10001366",
-                "MEDDRA:10001334",
-                "DOID:10493",
-                "NCIT:C26691",
-                "HP:0000846",
-                "MEDDRA:10001335",
-                "MEDDRA:10001369",
-                "MEDDRA:10001342",
-                "MEDDRA:10001343",
-                "MESH:D000309",
-                "SNOMEDCT:111563005",
-                "MEDDRA:10011172",
-                "MEDDRA:10022461"
-              ],
-              "id": "MONDO:0000004",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortical hypofunction",
-                "Adrenocortical Insufficiency",
-                "adrenocortical insufficiency",
-                "Corticoadrenal insufficiency",
-                "Adrenal gland hypofunction",
-                "Adrenal Insufficiency",
-                "Adrenal insufficiency",
-                "Adrenal cortical hypofunction"
-=======
-            "identity": 522619,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005301",
-              "name": "multiple sclerosis",
-              "description": "An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D009103",
-                "NCIT:C3243",
-                "MEDDRA:10039720",
-                "EFO:0003885",
-                "ORPHANET:802",
-                "MEDDRA:10028245",
-                "PSY:32490",
-                "ICD9:340",
-                "MONDO:0005301",
-                "MEDDRA:10028053",
-                "UMLS:C0026769",
-                "MEDDRA:10013451",
-                "SNOMEDCT:24700007",
-                "ICD10:G35",
-                "PDQ:CDR0000691761",
-                "DOID:2377"
-              ],
-              "id": "MONDO:0005301",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Multiple Sclerosis",
-                "obsolete_multiple sclerosis",
-                "Multiple sclerosis",
-                "multiple sclerosis"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:11443143"
-=======
-                "https://ghr.nlm.nih.gov/condition/multiple-sclerosis",
-                "http://en.wikipedia.org/wiki/multiple_sclerosis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 25906576,
-            "start": 568,
-            "end": 312686,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7120877': {'publication date': '1982 Jul 01', 'sentence': '[Pharmacokinetics of prednisolone in adrenal insufficiency ].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0001623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "26365803",
-              "object": "MONDO:0000004",
-              "publications": [
-                "PMID:7120877"
-=======
-            "identity": 7442851,
-            "start": 568,
-            "end": 522619,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10440499': {'publication date': '1999 Aug', 'sentence': 'Long-term open-trial of mizoribine with prednisolone in 24 patients with multiple sclerosis: safety, clinical and magnetic resonance imaging outcome.', 'subject score': 1000, 'object score': 1000}, 'PMID:1792777': {'publication date': '1991 Dec', 'sentence': '[Changes in the clinical and immunological indices of patients with disseminated sclerosis being treated with prednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:2256298': {'publication date': '1990 Aug', 'sentence': 'Prednisolone produced an unfavourable effect on the course of the demyelinating process in patients with multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2339565': {'publication date': '1990 Feb', 'sentence': 'The authors examined 56 patients suffering of multiple sclerosis who were treated with prednisolone and Proper-Myl.', 'subject score': 1000, 'object score': 1000}, 'PMID:25392236': {'publication date': '2015 Apr', 'sentence': 'Glucocorticoids, such as prednisolone, are effective in the treatment of multiple sclerosis in large part due to their ability to inhibit pro-inflammatory pathways (e.g., NFkappaB).', 'subject score': 1000, 'object score': 1000}, 'PMID:3259769': {'publication date': '1988', 'sentence': '[The dynamics of immunological indicators in the treatment of patients with multiple sclerosis with prednisolone combined with plasmapheresis].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0026769---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7600829",
-              "object": "MONDO:0005301",
-              "publications": [
-                "PMID:10440499",
-                "PMID:1792777",
-                "PMID:2256298",
-                "PMID:2339565",
-                "PMID:25392236",
-                "PMID:3259769"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 819686,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:13442027': {'publication date': '1957 Jan', 'sentence': '[Therapeutic results of metacortandralone or prednisolone in allergy].', 'subject score': 1000, 'object score': 1000}, 'PMID:13472563': {'publication date': '1957 Nov 01', 'sentence': 'Clinical use of prednisone and prednisolone in allergic states and collagen diseases.', 'subject score': 1000, 'object score': 983}, 'PMID:23263813': {'publication date': '2012 Dec', 'sentence': 'Since prednisolone is commonly co-prescribed with anti-histamine in many hypersensitive reactions, we also examined the changes to compare the results after the prednisolone administration.', 'subject score': 1000, 'object score': 947}, 'PMID:13929849': {'publication date': '1962 Nov', 'sentence': '[Use of prednisolone in a patient with a severe temporary insulin-resistant form of diabetes mellitus associated with the development of an allergic reaction].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 130846,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004977",
-          "name": "angioimmunoblastic T-cell lymphoma",
-          "description": "A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes. It occurs in the middle aged and elderly, with an equal incidence in males and females. The clinical course is typically aggressive. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C7528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C7528\" NCI Thesaurus); A peripheral T-cell lymphoma of mature T follicular helper (TFH) cells characterized by systemic disease and a polymorphous infiltrate involving lymph nodes, with a prominent proliferation of high endothelial venules and follicular dendritic cells. EBV-positive cells are nearly always present. It is a clinically aggressive lymphoma and seen mainly in older adults. (WHO 2017); A disorder characterized by proliferation of arborizing small vessels, prominent immunoblastic proliferations and amorphous acidophilic interstitial material. Clinical manifestations include fever, sweats, weight loss, generalized lymphadenopathy and frequently hepatosplenomegaly.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:835009",
-            "EFO:1001350",
-            "MEDDRA:10002449",
-            "SNOMEDCT:52097008",
-            "MONDO:0004977",
-            "UMLS:C0020981",
-            "MEDDRA:10002451",
-            "ORPHANET:86886",
-            "MEDDRA:10079289",
-            "MEDDRA:10079282",
-            "MEDDRA:10002450",
-            "NCIT:C7528",
-            "PDQ:CDR0000042765",
-            "DOID:0111147",
-            "EFO:0000255",
-            "ICD10:C86.5",
-            "SNOMEDCT:413537009",
-            "MEDDRA:10080248",
-            "MESH:D007119"
-          ],
-          "id": "MONDO:0004977",
-          "category": "biolink:Disease",
-          "all_names": [
-            "angioimmunoblastic T-cell lymphoma",
-            "Immunoblastic Lymphadenopathy",
-            "Angioimmunoblastic T-Cell Lymphoma",
-            "Angioimmunoblastic T-cell lymphoma",
-            "Angioimmunoblastic Lymphadenopathy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:22700722",
-            "https://rarediseases.org/rare-diseases/angioimmunoblastic-t-cell-lymphoma/",
-            "https://www.lymphoma.org/aboutlymphoma/nhl/aitl/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 819686,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004977",
-              "name": "angioimmunoblastic T-cell lymphoma",
-              "description": "A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes. It occurs in the middle aged and elderly, with an equal incidence in males and females. The clinical course is typically aggressive. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C7528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C7528\" NCI Thesaurus); A peripheral T-cell lymphoma of mature T follicular helper (TFH) cells characterized by systemic disease and a polymorphous infiltrate involving lymph nodes, with a prominent proliferation of high endothelial venules and follicular dendritic cells. EBV-positive cells are nearly always present. It is a clinically aggressive lymphoma and seen mainly in older adults. (WHO 2017); A disorder characterized by proliferation of arborizing small vessels, prominent immunoblastic proliferations and amorphous acidophilic interstitial material. Clinical manifestations include fever, sweats, weight loss, generalized lymphadenopathy and frequently hepatosplenomegaly.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:835009",
-                "EFO:1001350",
-                "MEDDRA:10002449",
-                "SNOMEDCT:52097008",
-                "MONDO:0004977",
-                "UMLS:C0020981",
-                "MEDDRA:10002451",
-                "ORPHANET:86886",
-                "MEDDRA:10079289",
-                "MEDDRA:10079282",
-                "MEDDRA:10002450",
-                "NCIT:C7528",
-                "PDQ:CDR0000042765",
-                "DOID:0111147",
-                "EFO:0000255",
-                "ICD10:C86.5",
-                "SNOMEDCT:413537009",
-                "MEDDRA:10080248",
-                "MESH:D007119"
-              ],
-              "id": "MONDO:0004977",
-              "category": "biolink:Disease",
-              "all_names": [
-                "angioimmunoblastic T-cell lymphoma",
-                "Immunoblastic Lymphadenopathy",
-                "Angioimmunoblastic T-Cell Lymphoma",
-                "Angioimmunoblastic T-cell lymphoma",
-                "Angioimmunoblastic Lymphadenopathy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:22700722",
-                "https://rarediseases.org/rare-diseases/angioimmunoblastic-t-cell-lymphoma/",
-                "https://www.lymphoma.org/aboutlymphoma/nhl/aitl/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25827255,
-            "start": 568,
-            "end": 819686,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:6861268': {'publication date': '1983', 'sentence': 'It is concluded that VAP is effective therapy in AIL.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0020981---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "26295217",
-              "object": "MONDO:0004977",
-              "publications": [
-                "PMID:6861268"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320617,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002400",
-          "name": "synovitis",
-          "description": "Inflammation of a synovial membrane.; Inflammation of the SYNOVIAL MEMBRANE.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0039103",
-            "MESH:D013585",
-            "HP:0100769",
-            "SYMP:0000646",
-            "MEDDRA:10042868",
-            "MONDO:0002400",
-            "DOID:2703",
-            "EFO:0008997",
-            "NCIT:C50766",
-            "SNOMEDCT:416209007"
-          ],
-          "id": "MONDO:0002400",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Synovitis",
-            "synovitis"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-          "name": "allergic disease",
-          "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MONDO:0005271",
-            "SYMP:0000900",
-            "UMLS:C3539909",
-            "MEDDRA:10020759",
-            "MEDDRA:10020756",
-            "NCIT:C114476",
-            "SNOMEDCT:418634005",
-            "MEDDRA:10001738",
-            "HP:0012393",
-            "MESH:D006967",
-            "MEDDRA:10001719",
-            "MEDDRA:10001741",
-            "MEDDRA:10037948",
-            "SNOMEDCT:609328004",
-            "SNOMEDCT:421961002",
-            "UMLS:C1527304",
-            "ICD10:T78.40",
-            "DOID:1205",
-            "MEDDRA:10020755",
-            "MEDDRA:10020751",
-            "MEDDRA:10037932",
-            "UMLS:C0020517",
-            "MEDDRA:10020757",
-            "SNOMEDCT:419076005",
-            "MEDDRA:10001718"
-          ],
-          "id": "MONDO:0005271",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Allergic disposition",
-            "Allergic Reaction",
-            "Hypersensitivity",
-            "allergic reaction",
-            "allergic disease",
-            "Allergy"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=synovitis",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://en.wikipedia.org/wiki/synovitis"
-=======
-            "https://medlineplus.gov/ency/article/000005.htm",
-            "ISBN:0781735149",
-            "http://en.wikipedia.org/wiki/allergy",
-            "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 320617,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002400",
-              "name": "synovitis",
-              "description": "Inflammation of a synovial membrane.; Inflammation of the SYNOVIAL MEMBRANE.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0039103",
-                "MESH:D013585",
-                "HP:0100769",
-                "SYMP:0000646",
-                "MEDDRA:10042868",
-                "MONDO:0002400",
-                "DOID:2703",
-                "EFO:0008997",
-                "NCIT:C50766",
-                "SNOMEDCT:416209007"
-              ],
-              "id": "MONDO:0002400",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Synovitis",
-                "synovitis"
-=======
-            "identity": 130846,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-              "name": "allergic disease",
-              "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MONDO:0005271",
-                "SYMP:0000900",
-                "UMLS:C3539909",
-                "MEDDRA:10020759",
-                "MEDDRA:10020756",
-                "NCIT:C114476",
-                "SNOMEDCT:418634005",
-                "MEDDRA:10001738",
-                "HP:0012393",
-                "MESH:D006967",
-                "MEDDRA:10001719",
-                "MEDDRA:10001741",
-                "MEDDRA:10037948",
-                "SNOMEDCT:609328004",
-                "SNOMEDCT:421961002",
-                "UMLS:C1527304",
-                "ICD10:T78.40",
-                "DOID:1205",
-                "MEDDRA:10020755",
-                "MEDDRA:10020751",
-                "MEDDRA:10037932",
-                "UMLS:C0020517",
-                "MEDDRA:10020757",
-                "SNOMEDCT:419076005",
-                "MEDDRA:10001718"
-              ],
-              "id": "MONDO:0005271",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Allergic disposition",
-                "Allergic Reaction",
-                "Hypersensitivity",
-                "allergic reaction",
-                "allergic disease",
-                "Allergy"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=synovitis",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://en.wikipedia.org/wiki/synovitis"
-=======
-                "https://medlineplus.gov/ency/article/000005.htm",
-                "ISBN:0781735149",
-                "http://en.wikipedia.org/wiki/allergy",
-                "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 25736674,
-            "start": 568,
-            "end": 320617,
-=======
-            "identity": 10304763,
-            "start": 568,
-            "end": 130846,
->>>>>>> main
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-<<<<<<< HEAD
-              "publications_info": "{'PMID:656284': {'publication date': '1978 May', 'sentence': 'A thermographic assessment of three intra-articular prednisolone analogues given in rheumatoid synovitis.', 'subject score': 833, 'object score': 853}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0039103---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "26194122",
-              "object": "MONDO:0002400",
-              "publications": [
-                "PMID:656284"
-=======
-              "publications_info": "{'PMID:13442027': {'publication date': '1957 Jan', 'sentence': '[Therapeutic results of metacortandralone or prednisolone in allergy].', 'subject score': 1000, 'object score': 1000}, 'PMID:13472563': {'publication date': '1957 Nov 01', 'sentence': 'Clinical use of prednisone and prednisolone in allergic states and collagen diseases.', 'subject score': 1000, 'object score': 983}, 'PMID:23263813': {'publication date': '2012 Dec', 'sentence': 'Since prednisolone is commonly co-prescribed with anti-histamine in many hypersensitive reactions, we also examined the changes to compare the results after the prednisolone administration.', 'subject score': 1000, 'object score': 947}, 'PMID:13929849': {'publication date': '1962 Nov', 'sentence': '[Use of prednisolone in a patient with a severe temporary insulin-resistant form of diabetes mellitus associated with the development of an allergic reaction].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0020517---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C1527304---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10531966",
-              "object": "MONDO:0005271",
-              "publications": [
-                "PMID:13929849",
-                "PMID:23263813",
-                "PMID:13442027",
-                "PMID:13472563"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 322059,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:31924570': {'publication date': '2020 Jan 03', 'sentence': 'The behavior results showed that exposure to prednisolone resulted in decreased autonomic activity and low sensitivity to light.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 130846,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005089",
-          "name": "sarcoma",
-          "description": "A connective tissue neoplasm formed by proliferation of mesodermal cells. Bone and soft tissue sarcomas are the main types of sarcoma. Sarcoma is usually highly malignant. [HPO:sdoelken]; A connective tissue neoplasm formed by proliferation of mesodermal cells. Bone and soft tissue sarcomas are the main types of sarcoma. Sarcoma is usually highly malignant. // COMMENTS: A sarcoma (from the Greek sarx meaning flesh) is a general term describing a malignant neoplasm, or cancer, that arises from transformed connective tissue cells such as bone, cartilage and fat cells, which originate from embryonic mesoderm. This is in contrast to carcinomas, which are of epithelial origin (breast, colon, pancreas, and others). However, due to an evolving understanding of tissue origin, the term sarcoma is sometimes applied to tumors now known to arise from epithelial tissue. The term soft tissue sarcoma is used to describe tumors of soft tissue, which includes elements that are in connective tissue, but not derived from it (such as muscles and blood vessels).; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "UMLS:C0153519",
-            "ICD9:171.9",
-            "MONDO:0005089",
-            "MESH:D012509",
-            "SNOMEDCT:1187396000",
-            "SNOMEDCT:424413001",
-            "HP:0100242",
-            "EFO:0000691",
-            "DOID:1115",
-            "NCIT:C9118",
-            "UMLS:C1261473",
-            "MEDDRA:10039494",
-            "MEDDRA:10039491"
-          ],
-          "id": "MONDO:0005089",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Malignant neoplasm of connective and other soft tissue, site unspecified",
-            "Sarcoma",
-            "sarcoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/sarcoma",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://cancergenome.nih.gov/cancersselected/sarcoma",
-            "http://www.cancer.gov/dictionary?cdrid=45562",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322059,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005089",
-              "name": "sarcoma",
-              "description": "A connective tissue neoplasm formed by proliferation of mesodermal cells. Bone and soft tissue sarcomas are the main types of sarcoma. Sarcoma is usually highly malignant. [HPO:sdoelken]; A connective tissue neoplasm formed by proliferation of mesodermal cells. Bone and soft tissue sarcomas are the main types of sarcoma. Sarcoma is usually highly malignant. // COMMENTS: A sarcoma (from the Greek sarx meaning flesh) is a general term describing a malignant neoplasm, or cancer, that arises from transformed connective tissue cells such as bone, cartilage and fat cells, which originate from embryonic mesoderm. This is in contrast to carcinomas, which are of epithelial origin (breast, colon, pancreas, and others). However, due to an evolving understanding of tissue origin, the term sarcoma is sometimes applied to tumors now known to arise from epithelial tissue. The term soft tissue sarcoma is used to describe tumors of soft tissue, which includes elements that are in connective tissue, but not derived from it (such as muscles and blood vessels).; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "UMLS:C0153519",
-                "ICD9:171.9",
-                "MONDO:0005089",
-                "MESH:D012509",
-                "SNOMEDCT:1187396000",
-                "SNOMEDCT:424413001",
-                "HP:0100242",
-                "EFO:0000691",
-                "DOID:1115",
-                "NCIT:C9118",
-                "UMLS:C1261473",
-                "MEDDRA:10039494",
-                "MEDDRA:10039491"
-              ],
-              "id": "MONDO:0005089",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Malignant neoplasm of connective and other soft tissue, site unspecified",
-                "Sarcoma",
-                "sarcoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/sarcoma",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://cancergenome.nih.gov/cancersselected/sarcoma",
-                "http://www.cancer.gov/dictionary?cdrid=45562",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25504825,
-            "start": 568,
-            "end": 322059,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:5911594': {'publication date': '1966 Jul', 'sentence': 'The effect of small doses of prednisolone on the incidence of subcutaneous sarcomas induced by 3-methylcholanthrene in virgin female Swiss mice.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C1261473---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "25959730",
-              "object": "MONDO:0005089",
-              "publications": [
-                "PMID:5911594"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316847,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
-          "name": "uveitis",
-          "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:1001231",
-            "UMLS:C0042164",
-            "DOID:13141",
-            "SNOMEDCT:128473001",
-            "MEDDRA:10046851",
-            "ICD10:H20.9",
-            "MONDO:0020283",
-            "MESH:D014605",
-            "NCIT:C26909",
-            "MEDDRA:10046855",
-            "HP:0000554",
-            "ORPHANET:98715"
-          ],
-          "id": "MONDO:0020283",
-          "category": "biolink:Disease",
-          "all_names": [
-            "uveitis",
-            "Uveitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734",
-            "https://orcid.org/0000-0002-6601-2165",
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-          "name": "allergic disease",
-          "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MONDO:0005271",
-            "SYMP:0000900",
-            "UMLS:C3539909",
-            "MEDDRA:10020759",
-            "MEDDRA:10020756",
-            "NCIT:C114476",
-            "SNOMEDCT:418634005",
-            "MEDDRA:10001738",
-            "HP:0012393",
-            "MESH:D006967",
-            "MEDDRA:10001719",
-            "MEDDRA:10001741",
-            "MEDDRA:10037948",
-            "SNOMEDCT:609328004",
-            "SNOMEDCT:421961002",
-            "UMLS:C1527304",
-            "ICD10:T78.40",
-            "DOID:1205",
-            "MEDDRA:10020755",
-            "MEDDRA:10020751",
-            "MEDDRA:10037932",
-            "UMLS:C0020517",
-            "MEDDRA:10020757",
-            "SNOMEDCT:419076005",
-            "MEDDRA:10001718"
-          ],
-          "id": "MONDO:0005271",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Allergic disposition",
-            "Allergic Reaction",
-            "Hypersensitivity",
-            "allergic reaction",
-            "allergic disease",
-            "Allergy"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000005.htm",
-            "ISBN:0781735149",
-            "http://en.wikipedia.org/wiki/allergy",
->>>>>>> main
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 316847,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
-              "name": "uveitis",
-              "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:1001231",
-                "UMLS:C0042164",
-                "DOID:13141",
-                "SNOMEDCT:128473001",
-                "MEDDRA:10046851",
-                "ICD10:H20.9",
-                "MONDO:0020283",
-                "MESH:D014605",
-                "NCIT:C26909",
-                "MEDDRA:10046855",
-                "HP:0000554",
-                "ORPHANET:98715"
-              ],
-              "id": "MONDO:0020283",
-              "category": "biolink:Disease",
-              "all_names": [
-                "uveitis",
-                "Uveitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734",
-                "https://orcid.org/0000-0002-6601-2165",
-=======
-            "identity": 130846,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-              "name": "allergic disease",
-              "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MONDO:0005271",
-                "SYMP:0000900",
-                "UMLS:C3539909",
-                "MEDDRA:10020759",
-                "MEDDRA:10020756",
-                "NCIT:C114476",
-                "SNOMEDCT:418634005",
-                "MEDDRA:10001738",
-                "HP:0012393",
-                "MESH:D006967",
-                "MEDDRA:10001719",
-                "MEDDRA:10001741",
-                "MEDDRA:10037948",
-                "SNOMEDCT:609328004",
-                "SNOMEDCT:421961002",
-                "UMLS:C1527304",
-                "ICD10:T78.40",
-                "DOID:1205",
-                "MEDDRA:10020755",
-                "MEDDRA:10020751",
-                "MEDDRA:10037932",
-                "UMLS:C0020517",
-                "MEDDRA:10020757",
-                "SNOMEDCT:419076005",
-                "MEDDRA:10001718"
-              ],
-              "id": "MONDO:0005271",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Allergic disposition",
-                "Allergic Reaction",
-                "Hypersensitivity",
-                "allergic reaction",
-                "allergic disease",
-                "Allergy"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000005.htm",
-                "ISBN:0781735149",
-                "http://en.wikipedia.org/wiki/allergy",
->>>>>>> main
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 25170826,
-            "start": 568,
-            "end": 316847,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3745792': {'publication date': '1986', 'sentence': '[Effects of chromocarb diethylamine and prednisolone in experimental uveitis induced by clove oil in rabbits].', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0042164---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "25621708",
-              "object": "MONDO:0020283",
-              "publications": [
-                "PMID:3745792"
-=======
-            "identity": 21142113,
-            "start": 568,
-            "end": 130846,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31924570': {'publication date': '2020 Jan 03', 'sentence': 'The behavior results showed that exposure to prednisolone resulted in decreased autonomic activity and low sensitivity to light.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0020517---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "21556285",
-              "object": "MONDO:0005271",
-              "publications": [
-                "PMID:31924570"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 318918,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:4320276': {'publication date': '1970 Jun', 'sentence': 'A comparative study of the effects of ACTH, hydrocortisone and prednisolone in the hypersensitive reactions produced with the protein components of Hymenolepis nana in albino mice.', 'subject score': 1000, 'object score': 947}}",
-    "p2": {
-      "start": {
-        "identity": 130846,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002462",
-          "name": "glomerulonephritis",
-          "description": "A renal disorder characterized by damage in the glomeruli. It may be acute or chronic, focal or diffuse, and it may lead to renal failure. Causes include autoimmune disorders, infections, diabetes, and malignancies.; A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.; Inflammation of the renal glomeruli. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029143",
-            "UMLS:C0017658",
-            "SNOMEDCT:36171008",
-            "DOID:2921",
-            "HP:0000099",
-            "MESH:D005921",
-            "MEDDRA:10018364",
-            "MEDDRA:10018375",
-            "MONDO:0002462",
-            "ICD10:N08",
-            "NCIT:C26784"
-          ],
-          "id": "MONDO:0002462",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Glomerulonephritis",
-            "glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/wiki/glomerulonephritis",
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-          "name": "allergic disease",
-          "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MONDO:0005271",
-            "SYMP:0000900",
-            "UMLS:C3539909",
-            "MEDDRA:10020759",
-            "MEDDRA:10020756",
-            "NCIT:C114476",
-            "SNOMEDCT:418634005",
-            "MEDDRA:10001738",
-            "HP:0012393",
-            "MESH:D006967",
-            "MEDDRA:10001719",
-            "MEDDRA:10001741",
-            "MEDDRA:10037948",
-            "SNOMEDCT:609328004",
-            "SNOMEDCT:421961002",
-            "UMLS:C1527304",
-            "ICD10:T78.40",
-            "DOID:1205",
-            "MEDDRA:10020755",
-            "MEDDRA:10020751",
-            "MEDDRA:10037932",
-            "UMLS:C0020517",
-            "MEDDRA:10020757",
-            "SNOMEDCT:419076005",
-            "MEDDRA:10001718"
-          ],
-          "id": "MONDO:0005271",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Allergic disposition",
-            "Allergic Reaction",
-            "Hypersensitivity",
-            "allergic reaction",
-            "allergic disease",
-            "Allergy"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000005.htm",
-            "ISBN:0781735149",
-            "http://en.wikipedia.org/wiki/allergy",
->>>>>>> main
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 318918,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002462",
-              "name": "glomerulonephritis",
-              "description": "A renal disorder characterized by damage in the glomeruli. It may be acute or chronic, focal or diffuse, and it may lead to renal failure. Causes include autoimmune disorders, infections, diabetes, and malignancies.; A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.; Inflammation of the renal glomeruli. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029143",
-                "UMLS:C0017658",
-                "SNOMEDCT:36171008",
-                "DOID:2921",
-                "HP:0000099",
-                "MESH:D005921",
-                "MEDDRA:10018364",
-                "MEDDRA:10018375",
-                "MONDO:0002462",
-                "ICD10:N08",
-                "NCIT:C26784"
-              ],
-              "id": "MONDO:0002462",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Glomerulonephritis",
-                "glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/wiki/glomerulonephritis",
-=======
-            "identity": 130846,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-              "name": "allergic disease",
-              "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MONDO:0005271",
-                "SYMP:0000900",
-                "UMLS:C3539909",
-                "MEDDRA:10020759",
-                "MEDDRA:10020756",
-                "NCIT:C114476",
-                "SNOMEDCT:418634005",
-                "MEDDRA:10001738",
-                "HP:0012393",
-                "MESH:D006967",
-                "MEDDRA:10001719",
-                "MEDDRA:10001741",
-                "MEDDRA:10037948",
-                "SNOMEDCT:609328004",
-                "SNOMEDCT:421961002",
-                "UMLS:C1527304",
-                "ICD10:T78.40",
-                "DOID:1205",
-                "MEDDRA:10020755",
-                "MEDDRA:10020751",
-                "MEDDRA:10037932",
-                "UMLS:C0020517",
-                "MEDDRA:10020757",
-                "SNOMEDCT:419076005",
-                "MEDDRA:10001718"
-              ],
-              "id": "MONDO:0005271",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Allergic disposition",
-                "Allergic Reaction",
-                "Hypersensitivity",
-                "allergic reaction",
-                "allergic disease",
-                "Allergy"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000005.htm",
-                "ISBN:0781735149",
-                "http://en.wikipedia.org/wiki/allergy",
->>>>>>> main
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 24081562,
-            "start": 568,
-            "end": 318918,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:355719': {'publication date': '1978 Jul', 'sentence': '[Effect of prednisolone and heparin on circulating T- and B-lymphocytes in glomerulonephritis and systemic lupus erythematosus].', 'subject score': 1000, 'object score': 1000}, 'PMID:5660892': {'publication date': '1968 Feb', 'sentence': '[The effect of prednisolone on serum protein fractions in experimental glomerulonephritis].', 'subject score': 1000, 'object score': 888}, 'PMID:9420390': {'publication date': '1997 Jun', 'sentence': 'Evaluation of efficacy of methylprednisolone, prednisolone and chlorambucil in idiopathic glomerulonephritis.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0017658---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "24523226",
-              "object": "MONDO:0002462",
-              "publications": [
-                "PMID:355719",
-                "PMID:5660892",
-                "PMID:9420390"
-=======
-            "identity": 25337815,
-            "start": 568,
-            "end": 130846,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:4320276': {'publication date': '1970 Jun', 'sentence': 'A comparative study of the effects of ACTH, hydrocortisone and prednisolone in the hypersensitive reactions produced with the protein components of Hymenolepis nana in albino mice.', 'subject score': 1000, 'object score': 947}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0020517---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "25790510",
-              "object": "MONDO:0005271",
-              "publications": [
-                "PMID:4320276"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 532295,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11370712': {'publication date': '2001 May', 'sentence': 'Clinically, both prednisolone and prednisolone sodium succinate are widely used as immunosuppressive agents for the treatment of various allergic disorders.', 'subject score': 1000, 'object score': 901}, 'PMID:13475038': {'publication date': '1957 Nov 09', 'sentence': 'Principles of management of allergic disorders with prednisone and prednisolone; with emphasis on clinical and laboratory control of complications.', 'subject score': 1000, 'object score': 1000}, 'PMID:13532203': {'publication date': '1958', 'sentence': '[Various cases of allergy treated with intramuscular prednisolone].', 'subject score': 888, 'object score': 1000}, 'PMID:13606669': {'publication date': '1958', 'sentence': 'Use of a tranquilizing agent (hydroxyzine) with prednisolone in the control of allergic disorders.', 'subject score': 1000, 'object score': 1000}, 'PMID:13652829': {'publication date': '1959 Mar', 'sentence': 'A severe P.A.S. hypersensitivity reaction controlled by prednisolone.', 'subject score': 1000, 'object score': 786}, 'PMID:32270742': {'publication date': '2020 Jan-Dec', 'sentence': 'Treatment with prednisolone, in combination with theophylline, curcumin or resveratrol increases SIRT1 expression, restores steroid sensitivity, and inhibits pro-inflammatory cytokine production from these cells and may reduce systemic inflammation in COPD.', 'subject score': 1000, 'object score': 888}, 'PMID:35218445': {'publication date': '2022 Feb 26', 'sentence': 'Combination treatment with prednisolone, a component of CHOP and CVP, was found to enhance ADCC sensitivity of RL cells and resistant clones and to significantly suppress tumor growth in xenograft models.', 'subject score': 1000, 'object score': 928}}",
-    "p2": {
-      "start": {
-        "identity": 130846,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006982",
-          "name": "subacute thyroiditis",
-          "description": "Self-limited inflammation of the thyroid gland. The clinical course includes an initial phase of hyperthyroidism, followed by a phase of hypothyroidism, and eventually a return to normal thyroid function. This category includes the subacute lymphocytic thyroiditis and subacute granulomatous thyroiditis.; Self-limited inflammation of the thyroid gland characterized by the presence of multinucleated giant cells. Patients present with neck pain, often associated with fever and dysphagia. The clinical course includes an initial phase of hyperthyroidism, followed by a phase of hypothyroidism, and eventually a return to normal thyroid function.; Spontaneously remitting inflammatory condition of the THYROID GLAND, characterized by FEVER; MUSCLE WEAKNESS; SORE THROAT; severe thyroid PAIN; and an enlarged damaged gland containing GIANT CELLS. The disease frequently follows a viral infection.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10012410",
-            "SNOMEDCT:428041004",
-            "DOID:7165",
-            "MEDDRA:10042298",
-            "ICD9:245.1",
-            "SNOMEDCT:38727009",
-            "EFO:1001194",
-            "NCIT:C35828",
-            "MEDDRA:10018705",
-            "ICD10:E06.1",
-            "MEDDRA:10043784",
-            "MESH:D013968",
-            "NCIT:C35071",
-            "MONDO:0006982",
-            "UMLS:C0040149"
-          ],
-          "id": "MONDO:0006982",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Subacute Thyroiditis",
-            "Subacute thyroiditis",
-            "Subacute Granulomatous Thyroiditis",
-            "Thyroiditis, Subacute",
-            "subacute thyroiditis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 532295,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006982",
-              "name": "subacute thyroiditis",
-              "description": "Self-limited inflammation of the thyroid gland. The clinical course includes an initial phase of hyperthyroidism, followed by a phase of hypothyroidism, and eventually a return to normal thyroid function. This category includes the subacute lymphocytic thyroiditis and subacute granulomatous thyroiditis.; Self-limited inflammation of the thyroid gland characterized by the presence of multinucleated giant cells. Patients present with neck pain, often associated with fever and dysphagia. The clinical course includes an initial phase of hyperthyroidism, followed by a phase of hypothyroidism, and eventually a return to normal thyroid function.; Spontaneously remitting inflammatory condition of the THYROID GLAND, characterized by FEVER; MUSCLE WEAKNESS; SORE THROAT; severe thyroid PAIN; and an enlarged damaged gland containing GIANT CELLS. The disease frequently follows a viral infection.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10012410",
-                "SNOMEDCT:428041004",
-                "DOID:7165",
-                "MEDDRA:10042298",
-                "ICD9:245.1",
-                "SNOMEDCT:38727009",
-                "EFO:1001194",
-                "NCIT:C35828",
-                "MEDDRA:10018705",
-                "ICD10:E06.1",
-                "MEDDRA:10043784",
-                "MESH:D013968",
-                "NCIT:C35071",
-                "MONDO:0006982",
-                "UMLS:C0040149"
-              ],
-              "id": "MONDO:0006982",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Subacute Thyroiditis",
-                "Subacute thyroiditis",
-                "Subacute Granulomatous Thyroiditis",
-                "Thyroiditis, Subacute",
-                "subacute thyroiditis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23063631,
-            "start": 568,
-            "end": 532295,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3418978': {'publication date': '1988 May', 'sentence': '[Effects of prednisolone on thyroidal-123I uptake in subacute thyroiditis].', 'subject score': 1000, 'object score': 1000}, 'PMID:760253': {'publication date': '1979 Jan', 'sentence': 'Changes in thyroid hormones by treatment with aspirin and prednisolone in subacute thyroiditis with hyperthyroidism.', 'subject score': 1000, 'object score': 1000}, 'PMID:8966940': {'publication date': '1996', 'sentence': \"[Indirect endolymphatic therapy with prednisolone in de Quervain's subacute thyroiditis].\", 'subject score': 1000, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0040149---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "23496152",
-              "object": "MONDO:0006982",
-              "publications": [
-                "PMID:3418978",
-                "PMID:760253",
-                "PMID:8966940"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 303010,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004802",
-          "name": "pulmonary eosinophilia",
-          "description": "The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. [PMID:19618037, PMID:21428117]; The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. // COMMENTS: Pulmonary function testing usually reveals a restrictive process with reduced diffusion capacity for carbon monoxide. Laboratory tests typical include increased levels of eosinophils in the blood, a high erythrocyte sedimentation rate, iron deficiency anemia, and increased platelets.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "UMLS:C0034068",
-            "HP:0032071",
-            "UMLS:C5552799",
-            "DOID:9498",
-            "MESH:D011657",
-            "MEDDRA:10037412",
-            "ICD9:518.3",
-            "SNOMEDCT:367542003",
-            "MONDO:0004802",
-            "MEDDRA:10037382"
-          ],
-          "id": "MONDO:0004802",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Eosinophilic pneumonia",
-            "Pulmonary eosinophilic infiltrate",
-            "Pulmonary Eosinophilia",
-            "Pulmonary eosinophilia",
-            "pulmonary eosinophilia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:19618037",
-            "https://rarediseases.org/rare-diseases/simple-pulmonary-eosinophilia/",
-            "PMID:21428117"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 303010,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004802",
-              "name": "pulmonary eosinophilia",
-              "description": "The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. [PMID:19618037, PMID:21428117]; The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. // COMMENTS: Pulmonary function testing usually reveals a restrictive process with reduced diffusion capacity for carbon monoxide. Laboratory tests typical include increased levels of eosinophils in the blood, a high erythrocyte sedimentation rate, iron deficiency anemia, and increased platelets.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "UMLS:C0034068",
-                "HP:0032071",
-                "UMLS:C5552799",
-                "DOID:9498",
-                "MESH:D011657",
-                "MEDDRA:10037412",
-                "ICD9:518.3",
-                "SNOMEDCT:367542003",
-                "MONDO:0004802",
-                "MEDDRA:10037382"
-              ],
-              "id": "MONDO:0004802",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Eosinophilic pneumonia",
-                "Pulmonary eosinophilic infiltrate",
-                "Pulmonary Eosinophilia",
-                "Pulmonary eosinophilia",
-                "pulmonary eosinophilia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:19618037",
-                "https://rarediseases.org/rare-diseases/simple-pulmonary-eosinophilia/",
-                "PMID:21428117"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21773779,
-            "start": 568,
-            "end": 303010,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32584603': {'publication date': '2020 Jun 25', 'sentence': 'Blood Eosinophil Depletion with Mepolizumab, Benralizumab and Prednisolone in Eosinophilic Asthma.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0034068---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "22194722",
-              "object": "MONDO:0004802",
-              "publications": [
-                "PMID:32584603"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 634814,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006774",
-          "name": "habitual spontaneous abortion",
-          "description": "Three or more consecutive spontaneous abortions.",
-          "equivalent_curies": [
-            "UMLS:C0000809",
-            "MEDDRA:10038104",
-            "MEDDRA:10062935",
-            "MONDO:0006774",
-            "MESH:D000026",
-            "SNOMEDCT:102878001"
-          ],
-          "id": "MONDO:0006774",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Abortion, Habitual",
-            "habitual spontaneous abortion"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 634814,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006774",
-              "name": "habitual spontaneous abortion",
-              "description": "Three or more consecutive spontaneous abortions.",
-              "equivalent_curies": [
-                "UMLS:C0000809",
-                "MEDDRA:10038104",
-                "MEDDRA:10062935",
-                "MONDO:0006774",
-                "MESH:D000026",
-                "SNOMEDCT:102878001"
-              ],
-              "id": "MONDO:0006774",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Abortion, Habitual",
-                "habitual spontaneous abortion"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21494165,
-            "start": 568,
-            "end": 634814,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3227469': {'publication date': '1988 Oct', 'sentence': '[Prednisolone and aspirin combination therapy in habitual abortion with autoantibodies].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0000809---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "21911849",
-              "object": "MONDO:0006774",
-              "publications": [
-                "PMID:3227469"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 610975,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/DOID_0080909",
-          "name": "castration-resistant prostate carcinoma",
-          "description": "A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.",
-          "equivalent_curies": [
-            "MESH:D064129",
-            "MONDO:0850353",
-            "DOID:0080909",
-            "MEDDRA:10076506",
-            "SNOMEDCT:427492003",
-            "UMLS:C3658267",
-            "MEDDRA:10062904",
-            "NCIT:C130234",
-            "UMLS:C1328504"
-          ],
-          "id": "DOID:0080909",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Prostatic Neoplasms, Castration-Resistant",
-            "castration-resistant prostate carcinoma",
-            "Castration-Resistant Prostate Carcinoma",
-            "Hormone refractory prostate cancer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:30324351"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 610975,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/DOID_0080909",
-              "name": "castration-resistant prostate carcinoma",
-              "description": "A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.",
-              "equivalent_curies": [
-                "MESH:D064129",
-                "MONDO:0850353",
-                "DOID:0080909",
-                "MEDDRA:10076506",
-                "SNOMEDCT:427492003",
-                "UMLS:C3658267",
-                "MEDDRA:10062904",
-                "NCIT:C130234",
-                "UMLS:C1328504"
-              ],
-              "id": "DOID:0080909",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Prostatic Neoplasms, Castration-Resistant",
-                "castration-resistant prostate carcinoma",
-                "Castration-Resistant Prostate Carcinoma",
-                "Hormone refractory prostate cancer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:30324351"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20104766,
-            "start": 568,
-            "end": 610975,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30102868': {'publication date': '2018 Oct', 'sentence': 'To illustrate this, we used an example of cost-effectiveness analysis for docetaxel in combination with prednisolone in metastatic hormone-refractory prostate cancer.', 'subject score': 1000, 'object score': 937}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C1328504---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "20512112",
-              "object": "DOID:0080909",
-              "publications": [
-                "PMID:30102868"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 312684,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015129",
-          "name": "chronic primary adrenal insufficiency",
-          "description": "A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.; An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands as a result of a primary defect in the glands themselves. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0001403",
-            "MONDO:0015129",
-            "DOID:13774",
-            "SNOMEDCT:363732003",
-            "PSY:00810",
-            "MEDDRA:10052381",
-            "UMLS:C1868690",
-            "OMIM:240200",
-            "ICD10:E27.1",
-            "UMLS:C0271737",
-            "MEDDRA:10080674",
-            "SNOMEDCT:373662000",
-            "MEDDRA:10013096",
-            "MEDDRA:10001130",
-            "HP:0008207",
-            "MEDDRA:10036696",
-            "MESH:D000075262",
-            "MESH:D000224",
-            "SNOMEDCT:76715008",
-            "ORPHANET:101959",
-            "NCIT:C26689",
-            "MEDDRA:10085976"
-          ],
-          "id": "MONDO:0015129",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hypoadrenocorticism, Familial",
-            "Primary adrenal insufficiency",
-            "Addisons Disease",
-            "Chronic primary adrenal insufficiency",
-            "Addison's disease due to autoimmunity",
-            "Addison Disease",
-            "Addison's disease",
-            "chronic primary adrenal insufficiency",
-            "Hypoadrenocorticism, familial",
-            "Hypoadrenocorticism, familial related phenotypic feature",
-            "Addison's Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/addison%27s_disease",
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-          "name": "allergic disease",
-          "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MONDO:0005271",
-            "SYMP:0000900",
-            "UMLS:C3539909",
-            "MEDDRA:10020759",
-            "MEDDRA:10020756",
-            "NCIT:C114476",
-            "SNOMEDCT:418634005",
-            "MEDDRA:10001738",
-            "HP:0012393",
-            "MESH:D006967",
-            "MEDDRA:10001719",
-            "MEDDRA:10001741",
-            "MEDDRA:10037948",
-            "SNOMEDCT:609328004",
-            "SNOMEDCT:421961002",
-            "UMLS:C1527304",
-            "ICD10:T78.40",
-            "DOID:1205",
-            "MEDDRA:10020755",
-            "MEDDRA:10020751",
-            "MEDDRA:10037932",
-            "UMLS:C0020517",
-            "MEDDRA:10020757",
-            "SNOMEDCT:419076005",
-            "MEDDRA:10001718"
-          ],
-          "id": "MONDO:0005271",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Allergic disposition",
-            "Allergic Reaction",
-            "Hypersensitivity",
-            "allergic reaction",
-            "allergic disease",
-            "Allergy"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000005.htm",
-            "ISBN:0781735149",
-            "http://en.wikipedia.org/wiki/allergy",
->>>>>>> main
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 312684,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015129",
-              "name": "chronic primary adrenal insufficiency",
-              "description": "A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.; An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands as a result of a primary defect in the glands themselves. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0001403",
-                "MONDO:0015129",
-                "DOID:13774",
-                "SNOMEDCT:363732003",
-                "PSY:00810",
-                "MEDDRA:10052381",
-                "UMLS:C1868690",
-                "OMIM:240200",
-                "ICD10:E27.1",
-                "UMLS:C0271737",
-                "MEDDRA:10080674",
-                "SNOMEDCT:373662000",
-                "MEDDRA:10013096",
-                "MEDDRA:10001130",
-                "HP:0008207",
-                "MEDDRA:10036696",
-                "MESH:D000075262",
-                "MESH:D000224",
-                "SNOMEDCT:76715008",
-                "ORPHANET:101959",
-                "NCIT:C26689",
-                "MEDDRA:10085976"
-              ],
-              "id": "MONDO:0015129",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hypoadrenocorticism, Familial",
-                "Primary adrenal insufficiency",
-                "Addisons Disease",
-                "Chronic primary adrenal insufficiency",
-                "Addison's disease due to autoimmunity",
-                "Addison Disease",
-                "Addison's disease",
-                "chronic primary adrenal insufficiency",
-                "Hypoadrenocorticism, familial",
-                "Hypoadrenocorticism, familial related phenotypic feature",
-                "Addison's Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/addison%27s_disease",
-=======
-            "identity": 130846,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-              "name": "allergic disease",
-              "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MONDO:0005271",
-                "SYMP:0000900",
-                "UMLS:C3539909",
-                "MEDDRA:10020759",
-                "MEDDRA:10020756",
-                "NCIT:C114476",
-                "SNOMEDCT:418634005",
-                "MEDDRA:10001738",
-                "HP:0012393",
-                "MESH:D006967",
-                "MEDDRA:10001719",
-                "MEDDRA:10001741",
-                "MEDDRA:10037948",
-                "SNOMEDCT:609328004",
-                "SNOMEDCT:421961002",
-                "UMLS:C1527304",
-                "ICD10:T78.40",
-                "DOID:1205",
-                "MEDDRA:10020755",
-                "MEDDRA:10020751",
-                "MEDDRA:10037932",
-                "UMLS:C0020517",
-                "MEDDRA:10020757",
-                "SNOMEDCT:419076005",
-                "MEDDRA:10001718"
-              ],
-              "id": "MONDO:0005271",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Allergic disposition",
-                "Allergic Reaction",
-                "Hypersensitivity",
-                "allergic reaction",
-                "allergic disease",
-                "Allergy"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000005.htm",
-                "ISBN:0781735149",
-                "http://en.wikipedia.org/wiki/allergy",
->>>>>>> main
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 19916915,
-            "start": 568,
-            "end": 312684,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29720511': {'publication date': '2018 Jun', 'sentence': 'Prednisolone is associated with a worse bone mineral density in primary adrenal insufficiency.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0001403---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "20312000",
-              "object": "MONDO:0015129",
-              "publications": [
-                "PMID:29720511"
-=======
-            "identity": 8714917,
-            "start": 568,
-            "end": 130846,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11370712': {'publication date': '2001 May', 'sentence': 'Clinically, both prednisolone and prednisolone sodium succinate are widely used as immunosuppressive agents for the treatment of various allergic disorders.', 'subject score': 1000, 'object score': 901}, 'PMID:13475038': {'publication date': '1957 Nov 09', 'sentence': 'Principles of management of allergic disorders with prednisone and prednisolone; with emphasis on clinical and laboratory control of complications.', 'subject score': 1000, 'object score': 1000}, 'PMID:13532203': {'publication date': '1958', 'sentence': '[Various cases of allergy treated with intramuscular prednisolone].', 'subject score': 888, 'object score': 1000}, 'PMID:13606669': {'publication date': '1958', 'sentence': 'Use of a tranquilizing agent (hydroxyzine) with prednisolone in the control of allergic disorders.', 'subject score': 1000, 'object score': 1000}, 'PMID:13652829': {'publication date': '1959 Mar', 'sentence': 'A severe P.A.S. hypersensitivity reaction controlled by prednisolone.', 'subject score': 1000, 'object score': 786}, 'PMID:32270742': {'publication date': '2020 Jan-Dec', 'sentence': 'Treatment with prednisolone, in combination with theophylline, curcumin or resveratrol increases SIRT1 expression, restores steroid sensitivity, and inhibits pro-inflammatory cytokine production from these cells and may reduce systemic inflammation in COPD.', 'subject score': 1000, 'object score': 888}, 'PMID:35218445': {'publication date': '2022 Feb 26', 'sentence': 'Combination treatment with prednisolone, a component of CHOP and CVP, was found to enhance ADCC sensitivity of RL cells and resistant clones and to significantly suppress tumor growth in xenograft models.', 'subject score': 1000, 'object score': 928}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0020517---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8906209",
-              "object": "MONDO:0005271",
-              "publications": [
-                "PMID:11370712",
-                "PMID:13475038",
-                "PMID:13532203",
-                "PMID:13606669",
-                "PMID:13652829",
-                "PMID:32270742",
-                "PMID:35218445"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 520745,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:36603446': {'publication date': '2022 Dec 16', 'sentence': 'Prednisolone significantly inhibited the measurable sensitivity of IDT, while oclacitinib did not.', 'subject score': 1000, 'object score': 888}, 'PMID:4033733': {'publication date': '1985 Oct 10', 'sentence': 'Failure of prednisolone to suppress carbamazepine hypersensitivity.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 130846,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015243",
-          "name": "allergic bronchopulmonary aspergillosis",
-          "description": "An aspergillosis that involves an allergic reaction due to the spores of Aspergillus moulds (A. fumigatus), which colonizes the mucus in the airways causing inflammation. The disease has symptom cough, has symptom wheezing and has symptom fever. // COMMENTS: OMIM mapping confirmed by DO. [SN].",
-          "equivalent_curies": [
-            "ORPHANET:1164",
-            "MEDDRA:10001707",
-            "ICD9:518.6",
-            "ICD10:B44.81",
-            "UMLS:C3278302",
-            "MEDDRA:10006474",
-            "NCIT:C84547",
-            "OMIM:103920",
-            "SNOMEDCT:37981002",
-            "MESH:D001229",
-            "DOID:13166",
-            "UMLS:C0004031",
-            "EFO:0007140",
-            "MONDO:0015243"
-          ],
-          "id": "MONDO:0015243",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Aspergillosis, Allergic Bronchopulmonary",
-            "Allergic bronchopulmonary aspergillosis, familial",
-            "allergic bronchopulmonary aspergillosis",
-            "Allergic bronchopulmonary aspergillosis",
-            "Allergic Bronchopulmonary Aspergillosis",
-            "Allergic bronchopulmonary aspergillosis, familial related phenotypic feature"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000070.htm",
-            "http://www.merck.com/mmhe/sec04/ch051/ch051d.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520745,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015243",
-              "name": "allergic bronchopulmonary aspergillosis",
-              "description": "An aspergillosis that involves an allergic reaction due to the spores of Aspergillus moulds (A. fumigatus), which colonizes the mucus in the airways causing inflammation. The disease has symptom cough, has symptom wheezing and has symptom fever. // COMMENTS: OMIM mapping confirmed by DO. [SN].",
-              "equivalent_curies": [
-                "ORPHANET:1164",
-                "MEDDRA:10001707",
-                "ICD9:518.6",
-                "ICD10:B44.81",
-                "UMLS:C3278302",
-                "MEDDRA:10006474",
-                "NCIT:C84547",
-                "OMIM:103920",
-                "SNOMEDCT:37981002",
-                "MESH:D001229",
-                "DOID:13166",
-                "UMLS:C0004031",
-                "EFO:0007140",
-                "MONDO:0015243"
-              ],
-              "id": "MONDO:0015243",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Aspergillosis, Allergic Bronchopulmonary",
-                "Allergic bronchopulmonary aspergillosis, familial",
-                "allergic bronchopulmonary aspergillosis",
-                "Allergic bronchopulmonary aspergillosis",
-                "Allergic Bronchopulmonary Aspergillosis",
-                "Allergic bronchopulmonary aspergillosis, familial related phenotypic feature"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000070.htm",
-                "http://www.merck.com/mmhe/sec04/ch051/ch051d.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19713965,
-            "start": 568,
-            "end": 520745,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29331473': {'publication date': '2018 Mar', 'sentence': 'CONCLUSIONS: Prednisolone was more effective in inducing response than itraconazole in acute-stage ABPA.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0004031---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "20106181",
-              "object": "MONDO:0015243",
-              "publications": [
-                "PMID:29331473"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319679,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-          "name": "lymphoma",
-          "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:115244002",
-            "DOID:0060058",
-            "MONDO:0005062",
-            "SNOMEDCT:118600007",
-            "HP:0002665",
-            "NCIT:C7065",
-            "EFO:0000574",
-            "ORPHANET:223735",
-            "MESH:D008223",
-            "SNOMEDCT:188676008",
-            "PDQ:CDR0000041429",
-            "MEDDRA:10025316",
-            "UMLS:C0024299",
-            "NCIT:C3208",
-            "MEDDRA:10025632",
-            "MEDDRA:10025310",
-            "MEDDRA:10025633",
-            "SNOMEDCT:1163043007",
-            "ICD10:C85.9",
-            "UMLS:C1536843",
-            "UMLS:C0334621",
-            "MEDDRA:10025315"
-          ],
-          "id": "MONDO:0005062",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphocytic Neoplasm",
-            "Lymphoma",
-            "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-            "lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/lymphoma",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319679,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-              "name": "lymphoma",
-              "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:115244002",
-                "DOID:0060058",
-                "MONDO:0005062",
-                "SNOMEDCT:118600007",
-                "HP:0002665",
-                "NCIT:C7065",
-                "EFO:0000574",
-                "ORPHANET:223735",
-                "MESH:D008223",
-                "SNOMEDCT:188676008",
-                "PDQ:CDR0000041429",
-                "MEDDRA:10025316",
-                "UMLS:C0024299",
-                "NCIT:C3208",
-                "MEDDRA:10025632",
-                "MEDDRA:10025310",
-                "MEDDRA:10025633",
-                "SNOMEDCT:1163043007",
-                "ICD10:C85.9",
-                "UMLS:C1536843",
-                "UMLS:C0334621",
-                "MEDDRA:10025315"
-              ],
-              "id": "MONDO:0005062",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphocytic Neoplasm",
-                "Lymphoma",
-                "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-                "lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/lymphoma",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19363285,
-            "start": 568,
-            "end": 319679,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28675023': {'publication date': '2018 Jul', 'sentence': 'Purpose: The aim of this study was to compare asparaginase-related toxicities in two asparaginase preparations, namely native Escherichia coli L-asparaginase (L-ASP) and pegylated asparaginase (PEG-ASP) in combination with ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) in natural killer (NK)/T-cell lymphoma (NTCL).', 'subject score': 1000, 'object score': 875}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0024299---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "19750187",
-              "object": "MONDO:0005062",
-              "publications": [
-                "PMID:28675023"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 531206,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008538",
-          "name": "temporal arteritis",
-          "description": "An autoimmune, systemic, giant cell granulomatous arteritis predominantly involving the arteries that supply blood to the central nervous system, head and eyes. Superficial arteries of the scalp that are involved tend to be enlarged and tender. Signs and symptoms include headaches, myalgias, visual disturbances, and skin necrosis.; A systemic autoimmune disorder that typically affects medium and large ARTERIES, usually leading to occlusive granulomatous vasculitis with transmural infiltrate containing multinucleated GIANT CELLS. The TEMPORAL ARTERY is commonly involved. This disorder appears primarily in people over the age of 50. Symptoms include FEVER; FATIGUE; HEADACHE; visual impairment; pain in the jaw and tongue; and aggravation of pain by cold temperatures. (From Adams et al., Principles of Neurology, 6th ed); Giant cell arteritis is a disorder that causes inflammation of your arteries, usually in the scalp, neck, and arms. It narrows the arteries, which keeps blood from flowing well. Giant cell arteritis often occurs with another disorder called polymyalgia rheumatica. Both are more common in women than in men. They almost always affect people over the age of 50. Early symptoms of giant cell arteritis resemble the flu: fatigue, loss of appetite, and fever. Other symptoms include: Headaches Pain and tenderness over the temples Double vision or visual loss, dizziness Problems with coordination and balance Pain in your jaw and tongue  Your doctor will make the diagnosis based on your medical history, symptoms, and a physical exam. There is no specific test for giant cell arteritis, but you may have tests that measure inflammation. Treatment is usually with corticosteroids. Early treatment is important; otherwise there is a risk of permanent vision loss or stroke. However, when properly treated, giant cell arteritis rarely comes back. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10043207",
-            "MEDDRA:10011303",
-            "MEDDRA:10020396",
-            "MEDDRA:10020395",
-            "UMLS:C1956391",
-            "NCIT:C35065",
-            "DOID:13375",
-            "UMLS:C1956390",
-            "UMLS:C0039483",
-            "MESH:D013700",
-            "ORPHANET:397",
-            "EFO:1001209",
-            "SNOMEDCT:400130008",
-            "ICD9:446.5",
-            "MEDDRA:10018250",
-            "MONDO:0008538",
-            "OMIM:187360"
-          ],
-          "id": "MONDO:0008538",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cranial Arteritis",
-            "Giant cell arteritis",
-            "Giant Cell Arteritis",
-            "temporal arteritis",
-            "Temporal Arteritis",
-            "Temporal arteritis related phenotypic feature"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.mayoclinic.org/diseases-conditions/giant-cell-arteritis/symptoms-causes/syc-20372758",
-            "https://orcid.org/0000-0001-5208-3432"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 531206,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008538",
-              "name": "temporal arteritis",
-              "description": "An autoimmune, systemic, giant cell granulomatous arteritis predominantly involving the arteries that supply blood to the central nervous system, head and eyes. Superficial arteries of the scalp that are involved tend to be enlarged and tender. Signs and symptoms include headaches, myalgias, visual disturbances, and skin necrosis.; A systemic autoimmune disorder that typically affects medium and large ARTERIES, usually leading to occlusive granulomatous vasculitis with transmural infiltrate containing multinucleated GIANT CELLS. The TEMPORAL ARTERY is commonly involved. This disorder appears primarily in people over the age of 50. Symptoms include FEVER; FATIGUE; HEADACHE; visual impairment; pain in the jaw and tongue; and aggravation of pain by cold temperatures. (From Adams et al., Principles of Neurology, 6th ed); Giant cell arteritis is a disorder that causes inflammation of your arteries, usually in the scalp, neck, and arms. It narrows the arteries, which keeps blood from flowing well. Giant cell arteritis often occurs with another disorder called polymyalgia rheumatica. Both are more common in women than in men. They almost always affect people over the age of 50. Early symptoms of giant cell arteritis resemble the flu: fatigue, loss of appetite, and fever. Other symptoms include: Headaches Pain and tenderness over the temples Double vision or visual loss, dizziness Problems with coordination and balance Pain in your jaw and tongue  Your doctor will make the diagnosis based on your medical history, symptoms, and a physical exam. There is no specific test for giant cell arteritis, but you may have tests that measure inflammation. Treatment is usually with corticosteroids. Early treatment is important; otherwise there is a risk of permanent vision loss or stroke. However, when properly treated, giant cell arteritis rarely comes back. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10043207",
-                "MEDDRA:10011303",
-                "MEDDRA:10020396",
-                "MEDDRA:10020395",
-                "UMLS:C1956391",
-                "NCIT:C35065",
-                "DOID:13375",
-                "UMLS:C1956390",
-                "UMLS:C0039483",
-                "MESH:D013700",
-                "ORPHANET:397",
-                "EFO:1001209",
-                "SNOMEDCT:400130008",
-                "ICD9:446.5",
-                "MEDDRA:10018250",
-                "MONDO:0008538",
-                "OMIM:187360"
-              ],
-              "id": "MONDO:0008538",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cranial Arteritis",
-                "Giant cell arteritis",
-                "Giant Cell Arteritis",
-                "temporal arteritis",
-                "Temporal Arteritis",
-                "Temporal arteritis related phenotypic feature"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.mayoclinic.org/diseases-conditions/giant-cell-arteritis/symptoms-causes/syc-20372758",
-                "https://orcid.org/0000-0001-5208-3432"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16796858,
-            "start": 568,
-            "end": 531206,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24026674': {'publication date': '2014 Feb', 'sentence': 'Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:25132663': {'publication date': '2015 Mar', 'sentence': 'OBJECTIVE: To establish the incidence of giant cell arteritis (GCA), cumulative use of prednisolone, and comorbidities most associated with GCA.', 'subject score': 1000, 'object score': 1000}, 'PMID:2727585': {'publication date': '1989 Jan', 'sentence': \"[Interaction of rifampicin and prednisolone. Apropos of 2 cases occurring in Horton's disease].\", 'subject score': 1000, 'object score': 1000}, 'PMID:31034796': {'publication date': '2019 Jul', 'sentence': 'Prednisone/prednisolone at a dose of 40-60 mg/day is the cornerstone therapy in GCA.', 'subject score': 888, 'object score': 1000}, 'PMID:3511861': {'publication date': '1986 Feb', 'sentence': 'The ability of azathioprine to reduce the maintenance prednisolone requirement of 31 patients with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA), or both, was tested in a double-blind placebo controlled study over one year.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0039483---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "17143213",
-              "object": "MONDO:0008538",
-              "publications": [
-                "PMID:24026674",
-                "PMID:25132663",
-                "PMID:2727585",
-                "PMID:31034796",
-                "PMID:3511861"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318155,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004952",
-          "name": "Hodgkins lymphoma",
-          "description": "A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma has a bimodal age distribution, and involves primarily lymph nodes. Current therapy for Hodgkin lymphoma has resulted in an excellent outcome and cure for the majority of patients. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C9357\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C9357\" NCI Thesaurus); UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10020309",
-            "SNOMEDCT:1163005009",
-            "ORPHANET:98293",
-            "UMLS:C5235037",
-            "NCIT:C6914",
-            "MEDDRA:10020255",
-            "SNOMEDCT:118606001",
-            "MEDDRA:10063666",
-            "SNOMEDCT:46923007",
-            "ICD10:C81",
-            "UMLS:C0019829",
-            "ICD9:201.2",
-            "SNOMEDCT:836277009",
-            "SNOMEDCT:74189002",
-            "MEDDRA:10020206",
-            "MESH:D006689",
-            "MEDDRA:10020328",
-            "MEDDRA:10020329",
-            "HP:0012189",
-            "SNOMEDCT:118599009",
-            "NCIT:C9357",
-            "ICD9:201",
-            "NCIT:C26956",
-            "SNOMEDCT:118605002",
-            "SNOMEDCT:118602004",
-            "NCIT:C164145",
-            "PDQ:CDR0000041646",
-            "MEDDRA:10025319",
-            "MEDDRA:10020318",
-            "EFO:0000183",
-            "DOID:8567",
-            "SNOMEDCT:14537002",
-            "MONDO:0004952",
-            "SNOMEDCT:836276000",
-            "MEDDRA:10020339",
-            "SNOMEDCT:70600005"
-          ],
-          "id": "MONDO:0004952",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hodgkin Lymphoma",
-            "Hodgkin lymphoma",
-            "Hodgkin's Paragranuloma",
-            "Hodgkin's sarcoma",
-            "Hodgkin sarcoma",
-            "Hodgkin's lymphoma",
-            "Hodgkins lymphoma",
-            "Hodgkin's Granuloma",
-            "Hodgkin's Sarcoma",
-            "Hodgkin Disease",
-            "Hodgkin's disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/hodgkin%27s_lymphoma",
-            "PMID:22835602",
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-          "name": "allergic disease",
-          "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MONDO:0005271",
-            "SYMP:0000900",
-            "UMLS:C3539909",
-            "MEDDRA:10020759",
-            "MEDDRA:10020756",
-            "NCIT:C114476",
-            "SNOMEDCT:418634005",
-            "MEDDRA:10001738",
-            "HP:0012393",
-            "MESH:D006967",
-            "MEDDRA:10001719",
-            "MEDDRA:10001741",
-            "MEDDRA:10037948",
-            "SNOMEDCT:609328004",
-            "SNOMEDCT:421961002",
-            "UMLS:C1527304",
-            "ICD10:T78.40",
-            "DOID:1205",
-            "MEDDRA:10020755",
-            "MEDDRA:10020751",
-            "MEDDRA:10037932",
-            "UMLS:C0020517",
-            "MEDDRA:10020757",
-            "SNOMEDCT:419076005",
-            "MEDDRA:10001718"
-          ],
-          "id": "MONDO:0005271",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Allergic disposition",
-            "Allergic Reaction",
-            "Hypersensitivity",
-            "allergic reaction",
-            "allergic disease",
-            "Allergy"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000005.htm",
-            "ISBN:0781735149",
-            "http://en.wikipedia.org/wiki/allergy",
->>>>>>> main
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 318155,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004952",
-              "name": "Hodgkins lymphoma",
-              "description": "A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma has a bimodal age distribution, and involves primarily lymph nodes. Current therapy for Hodgkin lymphoma has resulted in an excellent outcome and cure for the majority of patients. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C9357\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C9357\" NCI Thesaurus); UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10020309",
-                "SNOMEDCT:1163005009",
-                "ORPHANET:98293",
-                "UMLS:C5235037",
-                "NCIT:C6914",
-                "MEDDRA:10020255",
-                "SNOMEDCT:118606001",
-                "MEDDRA:10063666",
-                "SNOMEDCT:46923007",
-                "ICD10:C81",
-                "UMLS:C0019829",
-                "ICD9:201.2",
-                "SNOMEDCT:836277009",
-                "SNOMEDCT:74189002",
-                "MEDDRA:10020206",
-                "MESH:D006689",
-                "MEDDRA:10020328",
-                "MEDDRA:10020329",
-                "HP:0012189",
-                "SNOMEDCT:118599009",
-                "NCIT:C9357",
-                "ICD9:201",
-                "NCIT:C26956",
-                "SNOMEDCT:118605002",
-                "SNOMEDCT:118602004",
-                "NCIT:C164145",
-                "PDQ:CDR0000041646",
-                "MEDDRA:10025319",
-                "MEDDRA:10020318",
-                "EFO:0000183",
-                "DOID:8567",
-                "SNOMEDCT:14537002",
-                "MONDO:0004952",
-                "SNOMEDCT:836276000",
-                "MEDDRA:10020339",
-                "SNOMEDCT:70600005"
-              ],
-              "id": "MONDO:0004952",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hodgkin Lymphoma",
-                "Hodgkin lymphoma",
-                "Hodgkin's Paragranuloma",
-                "Hodgkin's sarcoma",
-                "Hodgkin sarcoma",
-                "Hodgkin's lymphoma",
-                "Hodgkins lymphoma",
-                "Hodgkin's Granuloma",
-                "Hodgkin's Sarcoma",
-                "Hodgkin Disease",
-                "Hodgkin's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/hodgkin%27s_lymphoma",
-                "PMID:22835602",
-=======
-            "identity": 130846,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-              "name": "allergic disease",
-              "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MONDO:0005271",
-                "SYMP:0000900",
-                "UMLS:C3539909",
-                "MEDDRA:10020759",
-                "MEDDRA:10020756",
-                "NCIT:C114476",
-                "SNOMEDCT:418634005",
-                "MEDDRA:10001738",
-                "HP:0012393",
-                "MESH:D006967",
-                "MEDDRA:10001719",
-                "MEDDRA:10001741",
-                "MEDDRA:10037948",
-                "SNOMEDCT:609328004",
-                "SNOMEDCT:421961002",
-                "UMLS:C1527304",
-                "ICD10:T78.40",
-                "DOID:1205",
-                "MEDDRA:10020755",
-                "MEDDRA:10020751",
-                "MEDDRA:10037932",
-                "UMLS:C0020517",
-                "MEDDRA:10020757",
-                "SNOMEDCT:419076005",
-                "MEDDRA:10001718"
-              ],
-              "id": "MONDO:0005271",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Allergic disposition",
-                "Allergic Reaction",
-                "Hypersensitivity",
-                "allergic reaction",
-                "allergic disease",
-                "Allergy"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000005.htm",
-                "ISBN:0781735149",
-                "http://en.wikipedia.org/wiki/allergy",
->>>>>>> main
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 16640274,
-            "start": 568,
-            "end": 318155,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23763798': {'publication date': '2013 Jun', 'sentence': 'CONCLUSION: GVP is well-tolerated regimen with high response rate and needs to be tested in late relapsed HL.', 'subject score': 1000, 'object score': 852}, 'PMID:3383124': {'publication date': '1988 Jul 15', 'sentence': \"Nitrogen mustard, vincristine, procarbazine, and prednisolone for relapse after radiation in Hodgkin's disease.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0019829---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16983852",
-              "object": "MONDO:0004952",
-              "publications": [
-                "PMID:23763798",
-                "PMID:3383124"
-=======
-            "identity": 24785594,
-            "start": 568,
-            "end": 130846,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:36603446': {'publication date': '2022 Dec 16', 'sentence': 'Prednisolone significantly inhibited the measurable sensitivity of IDT, while oclacitinib did not.', 'subject score': 1000, 'object score': 888}, 'PMID:4033733': {'publication date': '1985 Oct 10', 'sentence': 'Failure of prednisolone to suppress carbamazepine hypersensitivity.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:disrupts---None---None---None---UMLS:C0020517---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "25233555",
-              "object": "MONDO:0005271",
-              "publications": [
-                "PMID:36603446",
-                "PMID:4033733"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 536164,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:9693425': {'publication date': '1998 May-Jun', 'sentence': '[Use of corticosteroids betamethasone and prednisolone in the prevention of allergic reactions in patients undergoing heart surgery with artificial blood circulation].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 130846,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011849",
-          "name": "psoriatic arthritis",
-          "description": "Joint inflammation associated with psoriasis.; A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people with psoriasis have psoriatic arthritis. It causes pain, stiffness, and swelling of the joints. It is often mild, but can sometimes be serious and affect many joints. The joint and skin problems don't always happen at the same time. Your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. There is no cure, but medicines can help control inflammation and pain. In rare cases, you might need surgery to repair or replace damaged joints.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10037163",
-            "EFO:0003778",
-            "UMLS:C0003872",
-            "DOID:9008",
-            "ORPHANET:40050",
-            "MEDDRA:10003377",
-            "ICD9:696.0",
-            "NCIT:C61277",
-            "MONDO:0011849",
-            "SNOMEDCT:156370009",
-            "MEDDRA:10037162",
-            "MESH:D015535",
-            "MEDDRA:10037160",
-            "ICD10:L40.5"
-          ],
-          "id": "MONDO:0011849",
-          "category": "biolink:Disease",
-          "all_names": [
-            "psoriatic arthritis",
-            "Arthritis, Psoriatic",
-            "Psoriatic arthropathy",
-            "Psoriatic Arthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/psoriatic_arthropathy",
-            "https://ghr.nlm.nih.gov/condition/psoriatic-arthritis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000413.htm",
-            "http://www.mayoclinic.com/health/psoriatic-arthritis/ds00476"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 536164,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011849",
-              "name": "psoriatic arthritis",
-              "description": "Joint inflammation associated with psoriasis.; A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people with psoriasis have psoriatic arthritis. It causes pain, stiffness, and swelling of the joints. It is often mild, but can sometimes be serious and affect many joints. The joint and skin problems don't always happen at the same time. Your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. There is no cure, but medicines can help control inflammation and pain. In rare cases, you might need surgery to repair or replace damaged joints.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10037163",
-                "EFO:0003778",
-                "UMLS:C0003872",
-                "DOID:9008",
-                "ORPHANET:40050",
-                "MEDDRA:10003377",
-                "ICD9:696.0",
-                "NCIT:C61277",
-                "MONDO:0011849",
-                "SNOMEDCT:156370009",
-                "MEDDRA:10037162",
-                "MESH:D015535",
-                "MEDDRA:10037160",
-                "ICD10:L40.5"
-              ],
-              "id": "MONDO:0011849",
-              "category": "biolink:Disease",
-              "all_names": [
-                "psoriatic arthritis",
-                "Arthritis, Psoriatic",
-                "Psoriatic arthropathy",
-                "Psoriatic Arthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/psoriatic_arthropathy",
-                "https://ghr.nlm.nih.gov/condition/psoriatic-arthritis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000413.htm",
-                "http://www.mayoclinic.com/health/psoriatic-arthritis/ds00476"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16616766,
-            "start": 568,
-            "end": 536164,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23723489': {'publication date': '2013 May', 'sentence': 'Early treatment with addition of low dose prednisolone to methotrexate improves therapeutic outcome in severe psoriatic arthritis.', 'subject score': 901, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0003872---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16960031",
-              "object": "MONDO:0011849",
-              "publications": [
-                "PMID:23723489"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 315782,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
-          "name": "aplastic anemia",
-          "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What causes aplastic anemia? The causes of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0015909",
-            "MEDDRA:10002037",
-            "HP:0001915",
-            "MEDDRA:10002967",
-            "MEDDRA:10002274",
-            "MEDDRA:10002969",
-            "MESH:D000741",
-            "SNOMEDCT:306058006",
-            "PDQ:CDR0000489004",
-            "NCIT:C2870",
-            "MEDDRA:10002968",
-            "DOID:12449",
-            "MEDDRA:10002970",
-            "ICD9:284.9",
-            "SNOMEDCT:304132006",
-            "UMLS:C0002874",
-            "ICD10:D61.9",
-            "ORPHANET:182040"
-          ],
-          "id": "MONDO:0015909",
-          "category": "biolink:Disease",
-          "all_names": [
-            "aplastic anemia",
-            "Aplastic Anemia",
-            "Aplastic anemia",
-            "Aplastic anemia, unspecified",
-            "obsolete_Medullar aplasia",
-            "Anemia, Aplastic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
-            "http://en.wikipedia.org/wiki/aplastic_anemia",
-            "PMID:21239768",
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-          "name": "allergic disease",
-          "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MONDO:0005271",
-            "SYMP:0000900",
-            "UMLS:C3539909",
-            "MEDDRA:10020759",
-            "MEDDRA:10020756",
-            "NCIT:C114476",
-            "SNOMEDCT:418634005",
-            "MEDDRA:10001738",
-            "HP:0012393",
-            "MESH:D006967",
-            "MEDDRA:10001719",
-            "MEDDRA:10001741",
-            "MEDDRA:10037948",
-            "SNOMEDCT:609328004",
-            "SNOMEDCT:421961002",
-            "UMLS:C1527304",
-            "ICD10:T78.40",
-            "DOID:1205",
-            "MEDDRA:10020755",
-            "MEDDRA:10020751",
-            "MEDDRA:10037932",
-            "UMLS:C0020517",
-            "MEDDRA:10020757",
-            "SNOMEDCT:419076005",
-            "MEDDRA:10001718"
-          ],
-          "id": "MONDO:0005271",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Allergic disposition",
-            "Allergic Reaction",
-            "Hypersensitivity",
-            "allergic reaction",
-            "allergic disease",
-            "Allergy"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000005.htm",
-            "ISBN:0781735149",
-            "http://en.wikipedia.org/wiki/allergy",
->>>>>>> main
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 315782,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
-              "name": "aplastic anemia",
-              "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What causes aplastic anemia? The causes of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0015909",
-                "MEDDRA:10002037",
-                "HP:0001915",
-                "MEDDRA:10002967",
-                "MEDDRA:10002274",
-                "MEDDRA:10002969",
-                "MESH:D000741",
-                "SNOMEDCT:306058006",
-                "PDQ:CDR0000489004",
-                "NCIT:C2870",
-                "MEDDRA:10002968",
-                "DOID:12449",
-                "MEDDRA:10002970",
-                "ICD9:284.9",
-                "SNOMEDCT:304132006",
-                "UMLS:C0002874",
-                "ICD10:D61.9",
-                "ORPHANET:182040"
-              ],
-              "id": "MONDO:0015909",
-              "category": "biolink:Disease",
-              "all_names": [
-                "aplastic anemia",
-                "Aplastic Anemia",
-                "Aplastic anemia",
-                "Aplastic anemia, unspecified",
-                "obsolete_Medullar aplasia",
-                "Anemia, Aplastic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
-                "http://en.wikipedia.org/wiki/aplastic_anemia",
-                "PMID:21239768",
-=======
-            "identity": 130846,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-              "name": "allergic disease",
-              "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MONDO:0005271",
-                "SYMP:0000900",
-                "UMLS:C3539909",
-                "MEDDRA:10020759",
-                "MEDDRA:10020756",
-                "NCIT:C114476",
-                "SNOMEDCT:418634005",
-                "MEDDRA:10001738",
-                "HP:0012393",
-                "MESH:D006967",
-                "MEDDRA:10001719",
-                "MEDDRA:10001741",
-                "MEDDRA:10037948",
-                "SNOMEDCT:609328004",
-                "SNOMEDCT:421961002",
-                "UMLS:C1527304",
-                "ICD10:T78.40",
-                "DOID:1205",
-                "MEDDRA:10020755",
-                "MEDDRA:10020751",
-                "MEDDRA:10037932",
-                "UMLS:C0020517",
-                "MEDDRA:10020757",
-                "SNOMEDCT:419076005",
-                "MEDDRA:10001718"
-              ],
-              "id": "MONDO:0005271",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Allergic disposition",
-                "Allergic Reaction",
-                "Hypersensitivity",
-                "allergic reaction",
-                "allergic disease",
-                "Allergy"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000005.htm",
-                "ISBN:0781735149",
-                "http://en.wikipedia.org/wiki/allergy",
->>>>>>> main
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 16154862,
-            "start": 568,
-            "end": 315782,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22980607': {'publication date': '2012 Sep', 'sentence': 'CONCLUSION: Flu/Cy/ATG conditioning regimen, bone marrow as stem cell source and CSA, prednisolone and short methotrexate regimen were associated with better survival in AA.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0002874---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16502712",
-              "object": "MONDO:0015909",
-              "publications": [
-                "PMID:22980607"
-=======
-            "identity": 27172588,
-            "start": 568,
-            "end": 130846,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9693425': {'publication date': '1998 May-Jun', 'sentence': '[Use of corticosteroids betamethasone and prednisolone in the prevention of allergic reactions in patients undergoing heart surgery with artificial blood circulation].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:prevents---None---None---None---UMLS:C1527304---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "27646185",
-              "object": "MONDO:0005271",
-              "publications": [
-                "PMID:9693425"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 319441,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005130",
-          "name": "celiac disease",
-          "description": "Celiac disease (CD) is an autoimmune condition affecting the small intestine, triggered by the ingestion of gluten, the protein fraction of wheat, barley, and rye. Clinical manifestations of CD are highly variable and include both gastrointestinal and non-gastrointestinal features. The hallmark of CD is an immune-mediated enteropathy. This term is included because the occurence of CD is seen as a feature of a number of other diseases. [HPO:probinson, PMID:23681421]; Celiac disease (CD) is an autoimmune condition affecting the small intestine, triggered by the ingestion of gluten, the protein fraction of wheat, barley, and rye. Clinical manifestations of CD are highly variable and include both gastrointestinal and non-gastrointestinal features. The hallmark of CD is an immune-mediated enteropathy. This term is included because the occurence of CD is seen as a feature of a number of other diseases.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10018461",
-            "MEDDRA:10058248",
-            "HP:0002608",
-            "EFO:0001060",
-            "MEDDRA:10029525",
-            "ICD9:579.0",
-            "MEDDRA:10007865",
-            "OMIM.PS:212750",
-            "MEDDRA:10007864",
-            "ORPHANET:555",
-            "UMLS:C0007570",
-            "SNOMEDCT:396331005",
-            "NCIT:C26714",
-            "MEDDRA:10009839",
-            "MEDDRA:10018458",
-            "MONDO:0005130",
-            "ICD10:K90.0",
-            "DOID:10608",
-            "MESH:D002446"
-          ],
-          "id": "MONDO:0005130",
-          "category": "biolink:Disease",
-          "all_names": [
-            "celiac disease",
-            "Celiac Disease",
-            "Celiac disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/celiac-disease/ds00319",
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:23681421",
-            "http://www.celiac.org/",
-            "http://en.wikipedia.org/wiki/coeliac_disease",
-            "https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000233.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319441,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005130",
-              "name": "celiac disease",
-              "description": "Celiac disease (CD) is an autoimmune condition affecting the small intestine, triggered by the ingestion of gluten, the protein fraction of wheat, barley, and rye. Clinical manifestations of CD are highly variable and include both gastrointestinal and non-gastrointestinal features. The hallmark of CD is an immune-mediated enteropathy. This term is included because the occurence of CD is seen as a feature of a number of other diseases. [HPO:probinson, PMID:23681421]; Celiac disease (CD) is an autoimmune condition affecting the small intestine, triggered by the ingestion of gluten, the protein fraction of wheat, barley, and rye. Clinical manifestations of CD are highly variable and include both gastrointestinal and non-gastrointestinal features. The hallmark of CD is an immune-mediated enteropathy. This term is included because the occurence of CD is seen as a feature of a number of other diseases.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10018461",
-                "MEDDRA:10058248",
-                "HP:0002608",
-                "EFO:0001060",
-                "MEDDRA:10029525",
-                "ICD9:579.0",
-                "MEDDRA:10007865",
-                "OMIM.PS:212750",
-                "MEDDRA:10007864",
-                "ORPHANET:555",
-                "UMLS:C0007570",
-                "SNOMEDCT:396331005",
-                "NCIT:C26714",
-                "MEDDRA:10009839",
-                "MEDDRA:10018458",
-                "MONDO:0005130",
-                "ICD10:K90.0",
-                "DOID:10608",
-                "MESH:D002446"
-              ],
-              "id": "MONDO:0005130",
-              "category": "biolink:Disease",
-              "all_names": [
-                "celiac disease",
-                "Celiac Disease",
-                "Celiac disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/celiac-disease/ds00319",
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:23681421",
-                "http://www.celiac.org/",
-                "http://en.wikipedia.org/wiki/coeliac_disease",
-                "https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000233.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16036943,
-            "start": 568,
-            "end": 319441,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22752636': {'publication date': '2012 Dec', 'sentence': 'Effect of addition of short course of prednisolone to gluten-free diet on mucosal epithelial cell regeneration and apoptosis in celiac disease: a pilot randomized controlled trial.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0007570---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16371065",
-              "object": "MONDO:0005130",
-              "publications": [
-                "PMID:22752636"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 530650,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016367",
-          "name": "dermatomyositis",
-          "description": "Inflammation of the skin and muscle.; A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003882",
-            "EFO:0000398",
-            "ICD10:M33",
-            "MONDO:0016367",
-            "SNOMEDCT:396230008",
-            "NCIT:C26744",
-            "DOID:10223",
-            "MEDDRA:10012503",
-            "ORPHANET:221",
-            "UMLS:C0011633",
-            "ICD9:710.3"
-          ],
-          "id": "MONDO:0016367",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatomyositis",
-            "dermatomyositis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/dermatomyositis",
-            "http://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 530650,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016367",
-              "name": "dermatomyositis",
-              "description": "Inflammation of the skin and muscle.; A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003882",
-                "EFO:0000398",
-                "ICD10:M33",
-                "MONDO:0016367",
-                "SNOMEDCT:396230008",
-                "NCIT:C26744",
-                "DOID:10223",
-                "MEDDRA:10012503",
-                "ORPHANET:221",
-                "UMLS:C0011633",
-                "ICD9:710.3"
-              ],
-              "id": "MONDO:0016367",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatomyositis",
-                "dermatomyositis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/dermatomyositis",
-                "http://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15861529,
-            "start": 568,
-            "end": 530650,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22442637': {'publication date': '2012', 'sentence': 'Coadministration of cyclosporin a with prednisolone in acute interstitial pneumonia complicating polymyositis/dermatomyositis.', 'subject score': 1000, 'object score': 864}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0011633---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16192798",
-              "object": "MONDO:0016367",
-              "publications": [
-                "PMID:22442637"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 531222,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0012727",
-          "name": "mucocutaneous lymph node syndrome",
-          "description": "A vasculitis characterized by inflammation of the arteries, particularly the coronary arteries. The vasculitis may lead to aneurysm formation and possibly, heart attacks. It affects young children who usually present with persistent high fever, redness of the mucous membranes of the mouth, redness of the palms and soles, skin rashes, lymphadenitis, and joint pain and swelling.; An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:13378",
-            "ICD9:446.1",
-            "MEDDRA:10000747",
-            "SNOMEDCT:75053002",
-            "MESH:C537014",
-            "UMLS:C0026691",
-            "UMLS:C2936917",
-            "EFO:0004246",
-            "MESH:D009080",
-            "MEDDRA:10023320",
-            "ICD10:M30.3",
-            "NCIT:C34825",
-            "MONDO:0012727",
-            "MEDDRA:10028083",
-            "OMIM:611775",
-            "ORPHANET:2331"
-          ],
-          "id": "MONDO:0012727",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infantile polyarteritis",
-            "Kawasaki disease",
-            "Kawasaki disease related phenotypic feature",
-            "Kawasaki Disease",
-            "mucocutaneous lymph node syndrome",
-            "Mucocutaneous Lymph Node Syndrome",
-            "Acute febrile mucocutaneous lymph node syndrome [MCLS]"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/kawasaki_disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 531222,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0012727",
-              "name": "mucocutaneous lymph node syndrome",
-              "description": "A vasculitis characterized by inflammation of the arteries, particularly the coronary arteries. The vasculitis may lead to aneurysm formation and possibly, heart attacks. It affects young children who usually present with persistent high fever, redness of the mucous membranes of the mouth, redness of the palms and soles, skin rashes, lymphadenitis, and joint pain and swelling.; An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:13378",
-                "ICD9:446.1",
-                "MEDDRA:10000747",
-                "SNOMEDCT:75053002",
-                "MESH:C537014",
-                "UMLS:C0026691",
-                "UMLS:C2936917",
-                "EFO:0004246",
-                "MESH:D009080",
-                "MEDDRA:10023320",
-                "ICD10:M30.3",
-                "NCIT:C34825",
-                "MONDO:0012727",
-                "MEDDRA:10028083",
-                "OMIM:611775",
-                "ORPHANET:2331"
-              ],
-              "id": "MONDO:0012727",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infantile polyarteritis",
-                "Kawasaki disease",
-                "Kawasaki disease related phenotypic feature",
-                "Kawasaki Disease",
-                "mucocutaneous lymph node syndrome",
-                "Mucocutaneous Lymph Node Syndrome",
-                "Acute febrile mucocutaneous lymph node syndrome [MCLS]"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/kawasaki_disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15839343,
-            "start": 568,
-            "end": 531222,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22405251': {'publication date': '2012 Apr 28', 'sentence': 'Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.', 'subject score': 851, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0026691---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16169223",
-              "object": "MONDO:0012727",
-              "publications": [
-                "PMID:22405251"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 323988,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009693",
-          "name": "plasma cell myeloma",
-          "description": "A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3242\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3242\" NCI Thesaurus); A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001); A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.; A malignant plasma cell tumor growing within soft tissue or within the skeleton. [HPO:sdoelken]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10074470",
-            "MEDDRA:10028569",
-            "MEDDRA:10028228",
-            "MEDDRA:10035226",
-            "EFO:0001378",
-            "SNOMEDCT:55921005",
-            "MEDDRA:10034613",
-            "MESH:D009101",
-            "MEDDRA:10028568",
-            "MONDO:0009693",
-            "ICD9:203.0",
-            "HP:0006775",
-            "OMIM:254500",
-            "MEDDRA:10028566",
-            "ORPHANET:29073",
-            "SNOMEDCT:109989006",
-            "DOID:9538",
-            "ICD10:C90.0",
-            "UMLS:C0026764",
-            "PDQ:CDR0000042947",
-            "NCIT:C3242",
-            "SNOMEDCT:1162576007"
-          ],
-          "id": "MONDO:0009693",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Multiple myeloma",
-            "Multiple Myeloma",
-            "plasma cell myeloma",
-            "multiple myeloma",
-            "Myeloma, multiple related phenotypic feature",
-            "Plasma Cell Myeloma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=411384",
-            "http://en.wikipedia.org/wiki/multiple_myeloma",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323988,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009693",
-              "name": "plasma cell myeloma",
-              "description": "A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3242\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3242\" NCI Thesaurus); A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001); A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.; A malignant plasma cell tumor growing within soft tissue or within the skeleton. [HPO:sdoelken]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10074470",
-                "MEDDRA:10028569",
-                "MEDDRA:10028228",
-                "MEDDRA:10035226",
-                "EFO:0001378",
-                "SNOMEDCT:55921005",
-                "MEDDRA:10034613",
-                "MESH:D009101",
-                "MEDDRA:10028568",
-                "MONDO:0009693",
-                "ICD9:203.0",
-                "HP:0006775",
-                "OMIM:254500",
-                "MEDDRA:10028566",
-                "ORPHANET:29073",
-                "SNOMEDCT:109989006",
-                "DOID:9538",
-                "ICD10:C90.0",
-                "UMLS:C0026764",
-                "PDQ:CDR0000042947",
-                "NCIT:C3242",
-                "SNOMEDCT:1162576007"
-              ],
-              "id": "MONDO:0009693",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Multiple myeloma",
-                "Multiple Myeloma",
-                "plasma cell myeloma",
-                "multiple myeloma",
-                "Myeloma, multiple related phenotypic feature",
-                "Plasma Cell Myeloma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=411384",
-                "http://en.wikipedia.org/wiki/multiple_myeloma",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15784333,
-            "start": 568,
-            "end": 323988,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22314465': {'publication date': '2012 Jan', 'sentence': 'Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma.', 'subject score': 1000, 'object score': 901}, 'PMID:2469398': {'publication date': '1989 Apr', 'sentence': '[Combination chemotherapy of MCNU, melphalan, procarbazine, and prednisolone (MMPP) in multiple myeloma; disappearance of M-peak on serum electrophoretic pattern].', 'subject score': 1000, 'object score': 1000}, 'PMID:28828689': {'publication date': '2017 Dec', 'sentence': 'Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).', 'subject score': 1000, 'object score': 850}, 'PMID:32583431': {'publication date': '2020 Jun 24', 'sentence': 'Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105).We conducted a randomised phase II study to determine the optimal dose and schedule of melphalan, prednisone, and bortezomib (MPB) (jRCTs031180097).', 'subject score': 1000, 'object score': 901}, 'PMID:3475485': {'publication date': '1987 Mar', 'sentence': '[Comparative studies of intermittent melphalan and prednisolone (MP) versus 5-drug regimen (QUVMP) and 3-drug regimen (QUP) in multiple myeloma].', 'subject score': 740, 'object score': 1000}, 'PMID:9025767': {'publication date': '1997', 'sentence': 'PURPOSE: To compare VMCP, a multidrug combination chemotherapy comprising vincristine (VCR), melphalan (MPH), cyclophosphamide (CPM) and prednisolone (PSL), with MMPP comprising MPH, ranimustine (MCNU), procarbazine, and PSL as induction, to elucidate the value of alternating combination chemotherapy, and to search for an appropriate maintenance therapy in multiple myeloma.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0026764---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16114172",
-              "object": "MONDO:0009693",
-              "publications": [
-                "PMID:22314465",
-                "PMID:2469398",
-                "PMID:28828689",
-                "PMID:32583431",
-                "PMID:3475485",
-                "PMID:9025767"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 323831,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-          "name": "acute lymphoblastic leukemia",
-          "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "HP:0006721",
-            "MONDO:0004967",
-            "MEDDRA:10000848",
-            "MEDDRA:10000849",
-            "MEDDRA:10025305",
-            "ORPHANET:513",
-            "MEDDRA:10025301",
-            "ICD10:C91.00",
-            "UMLS:C0023453",
-            "DOID:9952",
-            "MEDDRA:10000844",
-            "MEDDRA:10000846",
-            "MEDDRA:10000845",
-            "MEDDRA:10024338",
-            "ICD10:C91",
-            "MESH:D054198",
-            "UMLS:C1961102",
-            "MEDDRA:10060555",
-            "NCIT:C3167",
-            "PDQ:CDR0000043423",
-            "MEDDRA:10024290",
-            "MEDDRA:10000842",
-            "NCIT:C27281",
-            "ICD9:204",
-            "DOID:1037",
-            "MEDDRA:10000843",
-            "EFO:0000220",
-            "SNOMEDCT:128822004",
-            "ICD9:204.0",
-            "UMLS:C0023449",
-            "MEDDRA:10060390",
-            "SNOMEDCT:91857003"
-          ],
-          "id": "MONDO:0004967",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute lymphoblastic leukemia",
-            "lymphoid leukemia",
-            "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-            "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-            "L2 Acute Lymphoblastic Leukemia",
-            "acute lymphocytic leukemia",
-            "Lymphoid leukemia, acute",
-            "acute lymphoblastic leukemia",
-            "Acute lymphocytic leukemia",
-            "Acute Lymphoblastic Leukemia",
-            "Lymphoid leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=46332",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=616067",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323831,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-              "name": "acute lymphoblastic leukemia",
-              "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "HP:0006721",
-                "MONDO:0004967",
-                "MEDDRA:10000848",
-                "MEDDRA:10000849",
-                "MEDDRA:10025305",
-                "ORPHANET:513",
-                "MEDDRA:10025301",
-                "ICD10:C91.00",
-                "UMLS:C0023453",
-                "DOID:9952",
-                "MEDDRA:10000844",
-                "MEDDRA:10000846",
-                "MEDDRA:10000845",
-                "MEDDRA:10024338",
-                "ICD10:C91",
-                "MESH:D054198",
-                "UMLS:C1961102",
-                "MEDDRA:10060555",
-                "NCIT:C3167",
-                "PDQ:CDR0000043423",
-                "MEDDRA:10024290",
-                "MEDDRA:10000842",
-                "NCIT:C27281",
-                "ICD9:204",
-                "DOID:1037",
-                "MEDDRA:10000843",
-                "EFO:0000220",
-                "SNOMEDCT:128822004",
-                "ICD9:204.0",
-                "UMLS:C0023449",
-                "MEDDRA:10060390",
-                "SNOMEDCT:91857003"
-              ],
-              "id": "MONDO:0004967",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute lymphoblastic leukemia",
-                "lymphoid leukemia",
-                "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-                "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-                "L2 Acute Lymphoblastic Leukemia",
-                "acute lymphocytic leukemia",
-                "Lymphoid leukemia, acute",
-                "acute lymphoblastic leukemia",
-                "Acute lymphocytic leukemia",
-                "Acute Lymphoblastic Leukemia",
-                "Lymphoid leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=46332",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=616067",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14260936,
-            "start": 568,
-            "end": 323831,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19734428': {'publication date': '2009 Sep', 'sentence': 'Pyruvate kinase M2 and prednisolone resistance in acute lymphoblastic leukemia.', 'subject score': 694, 'object score': 1000}, 'PMID:19965632': {'publication date': '2010 Feb 04', 'sentence': 'To validate this observation, we determined MCL-1 expression with quantitative reverse transcription-polymerase chain reaction in a cohort of MLL-rearranged infant ALL and pediatric noninfant ALL samples and confirmed that high-level MCL-1 expression is associated with prednisolone resistance in vitro.', 'subject score': 694, 'object score': 816}, 'PMID:23128824': {'publication date': '2014 Sep', 'sentence': 'Combination of prednisolone and low dosed dexamethasone exhibits greater in vitro antileukemic activity than equiactive dose of prednisolone and overcomes prednisolone drug resistance in acute childhood lymphoblastic leukemia.', 'subject score': 1000, 'object score': 916}, 'PMID:8708730': {'publication date': '1996 Aug', 'sentence': 'PURPOSE: The relative cytotoxicity of prednisolone and dexamethasone in acute lymphoblastic leukemia (ALL) is controversial.', 'subject score': 1000, 'object score': 1000}, 'PMID:20815080': {'publication date': '2010 Oct', 'sentence': 'In our study, we also evaluate the role of DXM compared with PDN during induction or subsequent phases of therapy in adult ALL with emphasis on SR group.', 'subject score': 1000, 'object score': 1000}, 'PMID:8856090': {'publication date': '1996 Aug', 'sentence': 'This study aimed at investigating the biological and clinical significance of in vitro PDN resistance in adult ALL.', 'subject score': 658, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0023449---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0023453---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "14564343",
-              "object": "MONDO:0004967",
-              "publications": [
-                "PMID:23128824",
-                "PMID:19965632",
-                "PMID:19734428",
-                "PMID:8708730",
-                "PMID:20815080",
-                "PMID:8856090"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:18830904': {'publication date': '2008', 'sentence': 'Stimulation with prednisolone and TNFalpha reduced GDF-5 expression in OA and RA fibroblasts, whereas MTX and IL-1beta revealed minor or no relevant change.', 'subject score': 1000, 'object score': 1000}, 'PMID:29670834': {'publication date': '2018 Mar', 'sentence': 'Conclusion: It seems that this porous hybrid scaffold could be a suitable choice in cartilage regeneration as well as a controlled-release system for delivery of prednisolone in osteoarthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:5033161': {'publication date': '1972', 'sentence': '[The Tanderil + prednisolone combination in osteoarthritis: its efficacy and tolerance].', 'subject score': 851, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319030,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319030,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13695946,
-            "start": 568,
-            "end": 319030,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18830904': {'publication date': '2008', 'sentence': 'Stimulation with prednisolone and TNFalpha reduced GDF-5 expression in OA and RA fibroblasts, whereas MTX and IL-1beta revealed minor or no relevant change.', 'subject score': 1000, 'object score': 1000}, 'PMID:29670834': {'publication date': '2018 Mar', 'sentence': 'Conclusion: It seems that this porous hybrid scaffold could be a suitable choice in cartilage regeneration as well as a controlled-release system for delivery of prednisolone in osteoarthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:5033161': {'publication date': '1972', 'sentence': '[The Tanderil + prednisolone combination in osteoarthritis: its efficacy and tolerance].', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "13988965",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:18830904",
-                "PMID:29670834",
-                "PMID:5033161"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 699953,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:11826654': {'publication date': '2002 Jan', 'sentence': 'OBJECTIVE: To assess the treatment effect of sodium hyaluronate (HA) on experimental temporomandibular joint (TMJ) osteoarthritis of rabbits in comparison with prednisolone (PS).', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 319030,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018905",
-          "name": "diffuse large B-cell lymphoma",
-          "description": "A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.; Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "NCIT:C8851",
-            "UMLS:C0079744",
-            "MEDDRA:10012819",
-            "MEDDRA:10012818",
-            "MONDO:0018905",
-            "UMLS:C2699777",
-            "NCIT:C80280",
-            "SNOMEDCT:109969005",
-            "SNOMEDCT:1172695008",
-            "MESH:D016403",
-            "ORPHANET:544",
-            "MEDDRA:10012820",
-            "DOID:0050745",
-            "EFO:0000403"
-          ],
-          "id": "MONDO:0018905",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphoma, Large B-Cell, Diffuse",
-            "diffuse large B-cell lymphoma",
-            "Diffuse Large B-Cell Lymphoma",
-            "Diffuse large B-cell lymphoma",
-            "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "PMID:28487884",
-            "http://en.wikipedia.org/wiki/diffuse_large_b-cell_lymphoma",
-            "https://ncithesaurus.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&ns=ncit&code=c148392"
-=======
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 699953,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018905",
-              "name": "diffuse large B-cell lymphoma",
-              "description": "A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.; Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "NCIT:C8851",
-                "UMLS:C0079744",
-                "MEDDRA:10012819",
-                "MEDDRA:10012818",
-                "MONDO:0018905",
-                "UMLS:C2699777",
-                "NCIT:C80280",
-                "SNOMEDCT:109969005",
-                "SNOMEDCT:1172695008",
-                "MESH:D016403",
-                "ORPHANET:544",
-                "MEDDRA:10012820",
-                "DOID:0050745",
-                "EFO:0000403"
-              ],
-              "id": "MONDO:0018905",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphoma, Large B-Cell, Diffuse",
-                "diffuse large B-cell lymphoma",
-                "Diffuse Large B-Cell Lymphoma",
-                "Diffuse large B-cell lymphoma",
-                "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28487884",
-                "http://en.wikipedia.org/wiki/diffuse_large_b-cell_lymphoma",
-                "https://ncithesaurus.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&ns=ncit&code=c148392"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12874288,
-            "start": 568,
-            "end": 699953,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17530014': {'publication date': '2007 May 28', 'sentence': 'A combination of rituximab plus chemotherapy, rituximab+cyclophosphamide+doxorubicin+vincristine+prednisolone (R-CHOP), has the highest efficacy ever described with any chemotherapy in DLBCL and FL.', 'subject score': 822, 'object score': 922}, 'PMID:26085719': {'publication date': '2015 Sep', 'sentence': 'We retrospectively analyzed clinical data for 29 consecutive DLBCL patients with an initial bulky mass receiving R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy from 2004 to 2011.', 'subject score': 1000, 'object score': 806}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0079744---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "13151963",
-              "object": "MONDO:0018905",
-              "publications": [
-                "PMID:17530014",
-                "PMID:26085719"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 313140,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018906",
-          "name": "follicular lymphoma",
-          "description": "A neoplasm of follicle centre B cells which has at least a partial follicular pattern. Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)]. Histological grade correlates with prognosis. Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3209\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3209\" NCI Thesaurus); A neoplasm of follicle centre B cells which has at least a partial follicular pattern. Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)]. Histological grade correlates with prognosis. Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).; A low-grade malignant lymphoma of follicular pattern in which there is no clear preponderance of one cell type (small or large) over another. The large cells, cleaved or noncleaved, are often 2-3 times larger in diameter than normal lymphocytes.; An indolent B cell lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is characterized by diffuse lymphadenopathy, bone marrow involvement, splenomegaly and less commonly other extranodal sites of involvement. [NCIT:C3209, PMID:29314206]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10085128",
-            "ORPHANET:545",
-            "MEDDRA:10029478",
-            "MONDO:0018906",
-            "UMLS:C3887918",
-            "SNOMEDCT:277618009",
-            "SNOMEDCT:308121000",
-            "PDQ:CDR0000795359",
-            "MEDDRA:10029473",
-            "NCIT:C3209",
-            "UMLS:C0024301",
-            "HP:0033125",
-            "MESH:D008224",
-            "DOID:0050873",
-            "MEDDRA:10085262",
-            "SNOMEDCT:307637005",
-            "SNOMEDCT:55150002"
-          ],
-          "id": "MONDO:0018906",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia/lymphoma, b-cell, 2",
-            "Follicular Lymphoma",
-            "Lymphoma, Follicular",
-            "Follicular lymphoma",
-            "follicular lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/follicular_lymphoma",
-            "http://www.cancer.gov/dictionary?cdrid=428287",
-            "PMID:29314206"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313140,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018906",
-              "name": "follicular lymphoma",
-              "description": "A neoplasm of follicle centre B cells which has at least a partial follicular pattern. Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)]. Histological grade correlates with prognosis. Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3209\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3209\" NCI Thesaurus); A neoplasm of follicle centre B cells which has at least a partial follicular pattern. Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)]. Histological grade correlates with prognosis. Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).; A low-grade malignant lymphoma of follicular pattern in which there is no clear preponderance of one cell type (small or large) over another. The large cells, cleaved or noncleaved, are often 2-3 times larger in diameter than normal lymphocytes.; An indolent B cell lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is characterized by diffuse lymphadenopathy, bone marrow involvement, splenomegaly and less commonly other extranodal sites of involvement. [NCIT:C3209, PMID:29314206]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10085128",
-                "ORPHANET:545",
-                "MEDDRA:10029478",
-                "MONDO:0018906",
-                "UMLS:C3887918",
-                "SNOMEDCT:277618009",
-                "SNOMEDCT:308121000",
-                "PDQ:CDR0000795359",
-                "MEDDRA:10029473",
-                "NCIT:C3209",
-                "UMLS:C0024301",
-                "HP:0033125",
-                "MESH:D008224",
-                "DOID:0050873",
-                "MEDDRA:10085262",
-                "SNOMEDCT:307637005",
-                "SNOMEDCT:55150002"
-              ],
-              "id": "MONDO:0018906",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia/lymphoma, b-cell, 2",
-                "Follicular Lymphoma",
-                "Lymphoma, Follicular",
-                "Follicular lymphoma",
-                "follicular lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/follicular_lymphoma",
-                "http://www.cancer.gov/dictionary?cdrid=428287",
-                "PMID:29314206"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12874287,
-            "start": 568,
-            "end": 313140,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17530014': {'publication date': '2007 May 28', 'sentence': 'A combination of rituximab plus chemotherapy, rituximab+cyclophosphamide+doxorubicin+vincristine+prednisolone (R-CHOP), has the highest efficacy ever described with any chemotherapy in DLBCL and FL.', 'subject score': 822, 'object score': 1000}, 'PMID:25804839': {'publication date': '2015 Sep', 'sentence': 'Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0024301---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "13151962",
-              "object": "MONDO:0018906",
-              "publications": [
-                "PMID:17530014",
-                "PMID:25804839"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319116,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008315",
-          "name": "prostate cancer",
-          "description": "A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.; Tumors or cancer of the PROSTATE.; A cancer of the prostate. [HPO:probinson]; What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it:  Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to:  Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer.    What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include:  Problems urinating (peeing), such as:  A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen   Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm)  But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you:  Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer  What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include:  A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate.  If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options:  Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation:  Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer.   Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer.  Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include:  Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0008315",
-            "ICD10:C61",
-            "MEDDRA:10026389",
-            "MEDDRA:10007113",
-            "DOID:10283",
-            "MEDDRA:10036908",
-            "UMLS:C0376358",
-            "SNOMEDCT:399068003",
-            "ICD9:185",
-            "PDQ:CDR0000038782",
-            "MEDDRA:10036910",
-            "MEDDRA:10036946",
-            "KEGG.DISEASE:05215",
-            "NCIT:C7378",
-            "MESH:D011471",
-            "HP:0012125",
-            "MEDDRA:10060862"
-          ],
-          "id": "MONDO:0008315",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Malignant Prostate Neoplasm",
-            "prostate cancer",
-            "Prostate cancer",
-            "Prostatic Neoplasms",
-            "Malignant neoplasm of prostate"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=445079",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319116,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008315",
-              "name": "prostate cancer",
-              "description": "A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.; Tumors or cancer of the PROSTATE.; A cancer of the prostate. [HPO:probinson]; What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it:  Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to:  Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer.    What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include:  Problems urinating (peeing), such as:  A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen   Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm)  But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you:  Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer  What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include:  A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate.  If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options:  Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation:  Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer.   Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer.  Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include:  Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0008315",
-                "ICD10:C61",
-                "MEDDRA:10026389",
-                "MEDDRA:10007113",
-                "DOID:10283",
-                "MEDDRA:10036908",
-                "UMLS:C0376358",
-                "SNOMEDCT:399068003",
-                "ICD9:185",
-                "PDQ:CDR0000038782",
-                "MEDDRA:10036910",
-                "MEDDRA:10036946",
-                "KEGG.DISEASE:05215",
-                "NCIT:C7378",
-                "MESH:D011471",
-                "HP:0012125",
-                "MEDDRA:10060862"
-              ],
-              "id": "MONDO:0008315",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Malignant Prostate Neoplasm",
-                "prostate cancer",
-                "Prostate cancer",
-                "Prostatic Neoplasms",
-                "Malignant neoplasm of prostate"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=445079",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12698535,
-            "start": 568,
-            "end": 319116,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17306441': {'publication date': '2007 Dec', 'sentence': 'Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study.', 'subject score': 1000, 'object score': 861}, 'PMID:17306444': {'publication date': '2007 Dec', 'sentence': 'Editorial comment on: Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study.', 'subject score': 1000, 'object score': 861}, 'PMID:18544992': {'publication date': '2008', 'sentence': 'A randomized phase II trial comparing weekly taxotere plus prednisolone versus prednisolone alone in androgen-independent prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:25457497': {'publication date': '2015 04', 'sentence': 'A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:3157571': {'publication date': '1985', 'sentence': 'High-dose medroxyprogesterone acetate versus prednisolone in hormone-resistant prostatic cancer.', 'subject score': 1000, 'object score': 871}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0376358---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "12983495",
-              "object": "MONDO:0008315",
-              "publications": [
-                "PMID:17306441",
-                "PMID:17306444",
-                "PMID:18544992",
-                "PMID:25457497",
-                "PMID:3157571"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316993,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005376",
-          "name": "membranous glomerulonephritis",
-          "description": "A slowly progressive inflammation of the glomeruli characterized by immune complex deposits at the glomerular basement membrane, resulting in a thickened membrane, and nephrotic syndrome.; An experimental rat model of human membranous nephropathy characterized by complement activation and formation of subepithelial immune deposits in the glomerular capillary wall.; A type of glomerulonephropathy characterized by thickening of the basement membrane and deposition of immune complexes in the subepithelial space. [Eurenomics:fschaefer]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005376",
-            "HP:0012578",
-            "UMLS:C0017665",
-            "DOID:10976",
-            "MESH:D015433",
-            "SNOMEDCT:77182004",
-            "MEDDRA:10018372",
-            "MEDDRA:10027170",
-            "ICD10:N03.2",
-            "NCIT:C34645",
-            "EFO:0004254"
-          ],
-          "id": "MONDO:0005376",
-          "category": "biolink:Disease",
-          "all_names": [
-            "membranous glomerulonephritis",
-            "Glomerulonephritis, Membranous",
-            "Membranous Glomerulonephritis",
-            "Membranous nephropathy",
-            "Membranous glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316993,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005376",
-              "name": "membranous glomerulonephritis",
-              "description": "A slowly progressive inflammation of the glomeruli characterized by immune complex deposits at the glomerular basement membrane, resulting in a thickened membrane, and nephrotic syndrome.; An experimental rat model of human membranous nephropathy characterized by complement activation and formation of subepithelial immune deposits in the glomerular capillary wall.; A type of glomerulonephropathy characterized by thickening of the basement membrane and deposition of immune complexes in the subepithelial space. [Eurenomics:fschaefer]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005376",
-                "HP:0012578",
-                "UMLS:C0017665",
-                "DOID:10976",
-                "MESH:D015433",
-                "SNOMEDCT:77182004",
-                "MEDDRA:10018372",
-                "MEDDRA:10027170",
-                "ICD10:N03.2",
-                "NCIT:C34645",
-                "EFO:0004254"
-              ],
-              "id": "MONDO:0005376",
-              "category": "biolink:Disease",
-              "all_names": [
-                "membranous glomerulonephritis",
-                "Glomerulonephritis, Membranous",
-                "Membranous Glomerulonephritis",
-                "Membranous nephropathy",
-                "Membranous glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12244036,
-            "start": 568,
-            "end": 316993,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16724651': {'publication date': '2006 May', 'sentence': 'Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0017665---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "12510603",
-              "object": "MONDO:0005376",
-              "publications": [
-                "PMID:16724651"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12221971,
-            "start": 568,
-            "end": 319673,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16707187': {'publication date': '2006 Jun 12', 'sentence': 'Taken together, the present study points to a strong inhibitory effect of liposomal PLP on tumor angiogenesis by reduction of the intratumoral production of the majority of pro-angiogenic factors studied and direct inhibition of endothelial cell proliferation, which is the result of high prolonged levels of prednisolone in the tumor by liposomal delivery.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "12496746",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:16707187"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 526315,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005722",
-          "name": "croup",
-          "description": "Acute upper respiratory airways infection that results in the swelling of the larynx. It is usually caused by parainfluenza viruses. Signs include a characteristic barking cough and stridor.; Inflammation involving the GLOTTIS or VOCAL CORDS and the subglottic larynx. Croup is characterized by a barking cough, HOARSENESS, and persistent inspiratory STRIDOR (a high-pitched breathing sound). It occurs chiefly in infants and children.; Croup is an inflammation of the vocal cords (larynx) and windpipe (trachea). It causes difficulty breathing, a barking cough, and a hoarse voice. The cause is usually a virus, often parainfluenza virus. Other causes include allergies and reflux. Croup often starts out like a cold. But then the vocal cords and windpipe become swollen, causing the hoarseness and the cough. There may also be a fever and high-pitched noisy sounds when breathing. The symptoms are usually worse at night, and last for about three to five days. Children between the ages of 6 months and 3 years have the highest risk of getting croup. They may also have more severe symptoms. Croup is more common in the fall and winter. Most cases of viral croup are mild and can be treated at home. Rarely, croup can become serious and interfere with your child's breathing. If you are worried about your child's breathing, call your health care provider right away.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005722",
-            "NCIT:C26735",
-            "DOID:9395",
-            "MEDDRA:10011415",
-            "MESH:D003440",
-            "SNOMEDCT:71186008",
-            "EFO:0007227",
-            "ICD10:J05.0",
-            "UMLS:C0010380",
-            "ICD9:464.4"
-          ],
-          "id": "MONDO:0005722",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Croup",
-            "croup"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://books.google.com/books?id=g6k0tppmrsic&pg=pa254&lpg=pa254&dq#v=onepage&q=&f=false",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=croup",
-            "http://cmr.asm.org/content/16/2/242.f",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000959.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526315,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005722",
-              "name": "croup",
-              "description": "Acute upper respiratory airways infection that results in the swelling of the larynx. It is usually caused by parainfluenza viruses. Signs include a characteristic barking cough and stridor.; Inflammation involving the GLOTTIS or VOCAL CORDS and the subglottic larynx. Croup is characterized by a barking cough, HOARSENESS, and persistent inspiratory STRIDOR (a high-pitched breathing sound). It occurs chiefly in infants and children.; Croup is an inflammation of the vocal cords (larynx) and windpipe (trachea). It causes difficulty breathing, a barking cough, and a hoarse voice. The cause is usually a virus, often parainfluenza virus. Other causes include allergies and reflux. Croup often starts out like a cold. But then the vocal cords and windpipe become swollen, causing the hoarseness and the cough. There may also be a fever and high-pitched noisy sounds when breathing. The symptoms are usually worse at night, and last for about three to five days. Children between the ages of 6 months and 3 years have the highest risk of getting croup. They may also have more severe symptoms. Croup is more common in the fall and winter. Most cases of viral croup are mild and can be treated at home. Rarely, croup can become serious and interfere with your child's breathing. If you are worried about your child's breathing, call your health care provider right away.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005722",
-                "NCIT:C26735",
-                "DOID:9395",
-                "MEDDRA:10011415",
-                "MESH:D003440",
-                "SNOMEDCT:71186008",
-                "EFO:0007227",
-                "ICD10:J05.0",
-                "UMLS:C0010380",
-                "ICD9:464.4"
-              ],
-              "id": "MONDO:0005722",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Croup",
-                "croup"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://books.google.com/books?id=g6k0tppmrsic&pg=pa254&lpg=pa254&dq#v=onepage&q=&f=false",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=croup",
-                "http://cmr.asm.org/content/16/2/242.f",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000959.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12163090,
-            "start": 568,
-            "end": 526315,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16624882': {'publication date': '2006 Jul', 'sentence': 'Prednisolone versus dexamethasone in croup: a randomised equivalence trial.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0010380---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "12428137",
-              "object": "MONDO:0005722",
-              "publications": [
-                "PMID:16624882"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317095,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018097",
-          "name": "West syndrome",
-          "description": "A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages [HPO:jalbers, PMID:28276060]; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0011097",
-            "MONDO:0018097",
-            "MEDDRA:10021750",
-            "UMLS:C0037769",
-            "NCIT:C84788",
-            "MEDDRA:10058893",
-            "MEDDRA:10039371",
-            "SNOMEDCT:28055006",
-            "DOID:0050562",
-            "MESH:D013036",
-            "UMLS:C1527366",
-            "ORPHANET:3451"
-          ],
-          "id": "MONDO:0018097",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_West syndrome",
-            "Salaam Seizures",
-            "West Syndrome",
-            "Spasms, Infantile",
-            "West syndrome",
-            "Epileptic spasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28276060",
-            "PMID:24268986",
-            "https://rarediseases.org/rare-diseases/west-syndrome/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317095,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018097",
-              "name": "West syndrome",
-              "description": "A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages [HPO:jalbers, PMID:28276060]; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0011097",
-                "MONDO:0018097",
-                "MEDDRA:10021750",
-                "UMLS:C0037769",
-                "NCIT:C84788",
-                "MEDDRA:10058893",
-                "MEDDRA:10039371",
-                "SNOMEDCT:28055006",
-                "DOID:0050562",
-                "MESH:D013036",
-                "UMLS:C1527366",
-                "ORPHANET:3451"
-              ],
-              "id": "MONDO:0018097",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_West syndrome",
-                "Salaam Seizures",
-                "West Syndrome",
-                "Spasms, Infantile",
-                "West syndrome",
-                "Epileptic spasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28276060",
-                "PMID:24268986",
-                "https://rarediseases.org/rare-diseases/west-syndrome/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11804411,
-            "start": 568,
-            "end": 317095,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16183305': {'publication date': '2005 Dec', 'sentence': 'Use of ACTH and prednisolone in infantile spasms: experience from a developing country.', 'subject score': 1000, 'object score': 1000}, 'PMID:30232789': {'publication date': '2018 Sep 19', 'sentence': 'Corticotrophin-ACTH in Comparison to Prednisolone in West Syndrome - A Randomized Study.', 'subject score': 1000, 'object score': 1000}, 'PMID:31113280': {'publication date': '2019 Oct', 'sentence': 'Eleven of the 21 patients received standard therapies as first-line treatments (10 with prednisolone according to the protocol in the United Kingdom Infantile Spasms Study [UKISS] and 1 with adrenocorticotrophic hormone [ACTH]).', 'subject score': 1000, 'object score': 771}, 'PMID:33836476': {'publication date': '2021 Mar 08', 'sentence': 'Epilepsy Outcome at Four Years in a Randomized Clinical Trial Comparing Oral Prednisolone and Intramuscular ACTH in West Syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:36054157': {'publication date': '2022 Aug 24', 'sentence': 'Response to sequential treatment with prednisolone and vigabatrin in infantile spasms.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0037769---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "12061894",
-              "object": "MONDO:0018097",
-              "publications": [
-                "PMID:16183305",
-                "PMID:30232789",
-                "PMID:31113280",
-                "PMID:33836476",
-                "PMID:36054157"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322120,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-          "name": "Crohn disease",
-          "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003424",
-            "ORPHANET:206",
-            "NCIT:C37262",
-            "MEDDRA:10038281",
-            "MEDDRA:10011405",
-            "UMLS:CN043071",
-            "SNOMEDCT:50440006",
-            "MEDDRA:10057032",
-            "HP:0100280",
-            "EFO:0000384",
-            "DOID:8778",
-            "MONDO:0005011",
-            "PDQ:CDR0000714480",
-            "UMLS:C0010346",
-            "NCIT:C2965",
-            "SNOMEDCT:7620006",
-            "ICD10:K50.1",
-            "UMLS:C0156147",
-            "MEDDRA:10011398",
-            "MEDDRA:10011401",
-            "SNOMEDCT:34000006",
-            "ICD9:555.1",
-            "MEDDRA:10013099",
-            "MEDDRA:10011402",
-            "MEDDRA:10011400"
-          ],
-          "id": "MONDO:0005011",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Granulomatous Colitis",
-            "Crohn's disease of large bowel",
-            "Regional enteritis of large intestine",
-            "Crohn Disease",
-            "Crohn disease",
-            "Crohn's disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/chron%27s_disease",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322120,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-              "name": "Crohn disease",
-              "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003424",
-                "ORPHANET:206",
-                "NCIT:C37262",
-                "MEDDRA:10038281",
-                "MEDDRA:10011405",
-                "UMLS:CN043071",
-                "SNOMEDCT:50440006",
-                "MEDDRA:10057032",
-                "HP:0100280",
-                "EFO:0000384",
-                "DOID:8778",
-                "MONDO:0005011",
-                "PDQ:CDR0000714480",
-                "UMLS:C0010346",
-                "NCIT:C2965",
-                "SNOMEDCT:7620006",
-                "ICD10:K50.1",
-                "UMLS:C0156147",
-                "MEDDRA:10011398",
-                "MEDDRA:10011401",
-                "SNOMEDCT:34000006",
-                "ICD9:555.1",
-                "MEDDRA:10013099",
-                "MEDDRA:10011402",
-                "MEDDRA:10011400"
-              ],
-              "id": "MONDO:0005011",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Granulomatous Colitis",
-                "Crohn's disease of large bowel",
-                "Regional enteritis of large intestine",
-                "Crohn Disease",
-                "Crohn disease",
-                "Crohn's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/chron%27s_disease",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11413479,
-            "start": 568,
-            "end": 322120,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15704045': {'publication date': '2005 Feb', 'sentence': \"Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:16635225': {'publication date': '2006 Apr', 'sentence': 'The present study compared the efficacy of rhIL-11 versus prednisolone in remission induction in CD.', 'subject score': 1000, 'object score': 1000}, 'PMID:19160212': {'publication date': '2009 Jan 21', 'sentence': \"AUTHORS' CONCLUSIONS: Budesonide is not more effective than placebo or weaning prednisolone for maintenance of remission in Crohn's disease.\", 'subject score': 888, 'object score': 1000}, 'PMID:2452432': {'publication date': '1988 Feb', 'sentence': \"In the scope of the ECCDS, established to test the efficacy of prednisolone and/or sulfasalazine in Crohn's disease, the relationships of blood chemistry and CDAI to histology of rectal mucosa were studied in 115 patients by means of univariate and multivariate statistical analyses.\", 'subject score': 1000, 'object score': 1000}, 'PMID:2867153': {'publication date': '1985 Oct', 'sentence': \"Absorption of delayed-release prednisolone in ulcerative colitis and Crohn's disease.\", 'subject score': 851, 'object score': 1000}, 'PMID:2896346': {'publication date': '1988 Feb', 'sentence': \"In the scope of the ECCDS, testing the efficacy of prednisolone and/or sulfasalazine in Crohn's disease, the relationships between drug regime and histology of rectal mucosa were studied.\", 'subject score': 1000, 'object score': 1000}, 'PMID:3902590': {'publication date': '1985 Oct', 'sentence': \"Controlled trial comparing prednisolone with an elemental diet plus non-absorbable antibiotics in active Crohn's disease.\", 'subject score': 775, 'object score': 901}, 'PMID:7734907': {'publication date': '1995 Jan', 'sentence': \"Remission following an elemental diet or prednisolone in Crohn's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:7979514': {'publication date': '1994 Sep', 'sentence': \"Use of enteric coated prednisolone in Crohn's disease.\", 'subject score': 851, 'object score': 1000}, 'PMID:8335191': {'publication date': '1993 Aug', 'sentence': 'CONCLUSION: The combination of prednisolone and AZA was superior to the treatment with prednisolone alone in active CD.', 'subject score': 1000, 'object score': 901}, 'PMID:8608877': {'publication date': '1996 Mar', 'sentence': \"CONCLUSIONS: After a prednisolone-induces remission in Crohn's disease, mesalamine facilitates steroid withdrawal and, during the postweaning year, may reduce the relapse rate in certain patient subgroups.\", 'subject score': 1000, 'object score': 1000}, 'PMID:8652141': {'publication date': '1995 Dec', 'sentence': \"Budesonide or prednisolone in active Crohn's disease.\", 'subject score': 1000, 'object score': 901}, 'PMID:9297775': {'publication date': '1997 Aug', 'sentence': \"Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:9301500': {'publication date': '1997 Aug', 'sentence': \"CONCLUSIONS: Budesonide CIR, administered at 9 mg once daily or 4.5 mg twice daily, is comparable to prednisolone in inducing remission in active Crohn's disease.\", 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0010346---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11663099",
-              "object": "MONDO:0005011",
-              "publications": [
-                "PMID:15704045",
-                "PMID:16635225",
-                "PMID:19160212",
-                "PMID:2452432",
-                "PMID:2867153",
-                "PMID:2896346",
-                "PMID:3902590",
-                "PMID:7734907",
-                "PMID:7979514",
-                "PMID:8335191",
-                "PMID:8608877",
-                "PMID:8652141",
-                "PMID:9297775",
-                "PMID:9301500"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 538027,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015943",
-          "name": "eosinophilic granulomatosis with polyangiitis",
-          "description": "Widespread necrotizing angiitis with granulomas. Pulmonary involvement is frequent. Asthma or other respiratory infection may precede evidence of vasculitis. Eosinophilia and lung involvement differentiate this disease from POLYARTERITIS NODOSA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:82275008",
-            "ICD10:M30.1",
-            "MEDDRA:10009164",
-            "MONDO:0015943",
-            "MEDDRA:10078117",
-            "MEDDRA:10048594",
-            "UMLS:C0008728",
-            "ORPHANET:183",
-            "EFO:0007208",
-            "MEDDRA:10001713",
-            "MEDDRA:10014957",
-            "NCIT:C34481",
-            "MESH:D015267",
-            "MEDDRA:10001714",
-            "MEDDRA:10001693",
-            "DOID:3049"
-          ],
-          "id": "MONDO:0015943",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Churg-Strauss Syndrome",
-            "Churg-Strauss syndrome",
-            "Eosinophilic granulomatosis with polyangiitis",
-            "eosinophilic granulomatosis with polyangiitis",
-            "Eosinophilic Granulomatosis with Polyangiitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/churg-strauss-syndrome/ds00855",
-            "https://orcid.org/0000-0002-8719-7760",
-            "http://www.hopkinsvasculitis.org/types-vasculitis/churgstrauss-syndrome-css/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538027,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015943",
-              "name": "eosinophilic granulomatosis with polyangiitis",
-              "description": "Widespread necrotizing angiitis with granulomas. Pulmonary involvement is frequent. Asthma or other respiratory infection may precede evidence of vasculitis. Eosinophilia and lung involvement differentiate this disease from POLYARTERITIS NODOSA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:82275008",
-                "ICD10:M30.1",
-                "MEDDRA:10009164",
-                "MONDO:0015943",
-                "MEDDRA:10078117",
-                "MEDDRA:10048594",
-                "UMLS:C0008728",
-                "ORPHANET:183",
-                "EFO:0007208",
-                "MEDDRA:10001713",
-                "MEDDRA:10014957",
-                "NCIT:C34481",
-                "MESH:D015267",
-                "MEDDRA:10001714",
-                "MEDDRA:10001693",
-                "DOID:3049"
-              ],
-              "id": "MONDO:0015943",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Churg-Strauss Syndrome",
-                "Churg-Strauss syndrome",
-                "Eosinophilic granulomatosis with polyangiitis",
-                "eosinophilic granulomatosis with polyangiitis",
-                "Eosinophilic Granulomatosis with Polyangiitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/churg-strauss-syndrome/ds00855",
-                "https://orcid.org/0000-0002-8719-7760",
-                "http://www.hopkinsvasculitis.org/types-vasculitis/churgstrauss-syndrome-css/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11389101,
-            "start": 568,
-            "end": 538027,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15675136': {'publication date': '2004', 'sentence': 'OBJECTIVE: To examine the safety and efficacy of methotrexate (MTX) plus low-dose prednisolone for induction of remission in non life- or organ-threatening courses and for remission maintenance in Churg-Strauss syndrome (CSS).', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0008728---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11638013",
-              "object": "MONDO:0015943",
-              "publications": [
-                "PMID:15675136"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 517728,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005124",
-          "name": "leprosy",
-          "description": "A bacterial granulomatous infection caused by Mycobacterium leprae. It is a progressive disease affecting the skin, peripheral nerves, and limbs. If untreated, it causes permanent tissue damage leading to autoamputations.; A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10024230",
-            "NCIT:C84824",
-            "EFO:0001054",
-            "MEDDRA:10024229",
-            "ICD9:030",
-            "MEDDRA:10024232",
-            "DOID:1024",
-            "MONDO:0005124",
-            "UMLS:C0023343",
-            "SNOMEDCT:81004002",
-            "MEDDRA:10019138",
-            "ICD10:A30",
-            "MEDDRA:10024231",
-            "MESH:D007918",
-            "MEDDRA:10028451",
-            "ORPHANET:548"
-          ],
-          "id": "MONDO:0005124",
-          "category": "biolink:Disease",
-          "all_names": [
-            "leprosy",
-            "Leprosy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/leprosy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517728,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005124",
-              "name": "leprosy",
-              "description": "A bacterial granulomatous infection caused by Mycobacterium leprae. It is a progressive disease affecting the skin, peripheral nerves, and limbs. If untreated, it causes permanent tissue damage leading to autoamputations.; A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10024230",
-                "NCIT:C84824",
-                "EFO:0001054",
-                "MEDDRA:10024229",
-                "ICD9:030",
-                "MEDDRA:10024232",
-                "DOID:1024",
-                "MONDO:0005124",
-                "UMLS:C0023343",
-                "SNOMEDCT:81004002",
-                "MEDDRA:10019138",
-                "ICD10:A30",
-                "MEDDRA:10024231",
-                "MESH:D007918",
-                "MEDDRA:10028451",
-                "ORPHANET:548"
-              ],
-              "id": "MONDO:0005124",
-              "category": "biolink:Disease",
-              "all_names": [
-                "leprosy",
-                "Leprosy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/leprosy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10973702,
-            "start": 568,
-            "end": 517728,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15159285': {'publication date': '2004 Jun 19', 'sentence': 'OBJECTIVE: To determine whether addition of low dose prednisolone to multidrug treatment can prevent reaction and nerve function impairment in leprosy.', 'subject score': 901, 'object score': 1000}, 'PMID:1624226': {'publication date': '1992 Feb', 'sentence': 'Aspirin, chloroquine, and prednisolone, the drugs used in addition to multi-drug therapy to control reactions in leprosy, were in a position to inhibit the solubilization of 125I HSA--anti-HSA by normal serum only at a very high dose.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0023343---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11213963",
-              "object": "MONDO:0005124",
-              "publications": [
-                "PMID:15159285",
-                "PMID:1624226"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 526144,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001505",
-          "name": "alcoholic hepatitis",
-          "description": "Inflammation of the liver resulting from ingestion of alcohol.; INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.",
-          "equivalent_curies": [
-            "MONDO:0001505",
-            "MEDDRA:10000649",
-            "ICD9:571.1",
-            "SNOMEDCT:235875008",
-            "MEDDRA:10019728",
-            "MESH:D006519",
-            "NCIT:C34352",
-            "UMLS:C0019187",
-            "EFO:1001345",
-            "UMLS:C0001306",
-            "DOID:12351",
-            "NCIT:C34684",
-            "MEDDRA:10001624",
-            "SNOMEDCT:9953008"
-          ],
-          "id": "MONDO:0001505",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute alcoholic hepatitis",
-            "alcoholic hepatitis",
-            "Alcoholic Hepatitis",
-            "Acute Alcoholic Hepatitis",
-            "Acute alcoholic liver disease",
-            "Hepatitis, Alcoholic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526144,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001505",
-              "name": "alcoholic hepatitis",
-              "description": "Inflammation of the liver resulting from ingestion of alcohol.; INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.",
-              "equivalent_curies": [
-                "MONDO:0001505",
-                "MEDDRA:10000649",
-                "ICD9:571.1",
-                "SNOMEDCT:235875008",
-                "MEDDRA:10019728",
-                "MESH:D006519",
-                "NCIT:C34352",
-                "UMLS:C0019187",
-                "EFO:1001345",
-                "UMLS:C0001306",
-                "DOID:12351",
-                "NCIT:C34684",
-                "MEDDRA:10001624",
-                "SNOMEDCT:9953008"
-              ],
-              "id": "MONDO:0001505",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute alcoholic hepatitis",
-                "alcoholic hepatitis",
-                "Alcoholic Hepatitis",
-                "Acute Alcoholic Hepatitis",
-                "Acute alcoholic liver disease",
-                "Hepatitis, Alcoholic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10939461,
-            "start": 568,
-            "end": 526144,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15122768': {'publication date': '2004 May', 'sentence': 'A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:25328799': {'publication date': '2014 Sep', 'sentence': 'BACKGROUND: Prednisolone and pentoxifylline (PTX) have been shown to be individually useful in severe alcoholic hepatitis with Maddrey discriminant function (MDF) score >=32.', 'subject score': 1000, 'object score': 901}, 'PMID:25638854': {'publication date': '2014 Nov', 'sentence': '[Pentoxifylline against prednisolone in severe acute alcoholic hepatitis: a Korean trial].', 'subject score': 1000, 'object score': 916}, 'PMID:1614484': {'publication date': '1992 Jul 23', 'sentence': 'Prednisolone in severe alcoholic hepatitis.', 'subject score': 1000, 'object score': 901}, 'PMID:22586023': {'publication date': '2012 May 15', 'sentence': 'Adding N-acetylcysteine to prednisolone reduced early mortality in severe alcoholic hepatitis.', 'subject score': 1000, 'object score': 901}, 'PMID:24864478': {'publication date': '2014', 'sentence': 'It discusses in detail the mechanisms of liver damage within the disease in question and substantiates indications for the use of prednisolone and pentoxifylline in alcoholic hepatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28043903': {'publication date': '2017 04', 'sentence': 'We compared the effects of infection on clinical outcomes of patients treated with and without prednisolone, and identified risk factors for development of infection in SAH.', 'subject score': 1000, 'object score': 901}, 'PMID:28966126': {'publication date': '2018 Mar', 'sentence': 'While prednisolone is considered standard of care in severe AH, this recommendation remains controversial given the marginal benefits and questionable long-term safety of steroids.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0001306---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0019187---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11179224",
-              "object": "MONDO:0001505",
-              "publications": [
-                "PMID:28966126",
-                "PMID:28043903",
-                "PMID:1614484",
-                "PMID:24864478",
-                "PMID:15122768",
-                "PMID:22586023",
-                "PMID:25638854",
-                "PMID:25328799"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 309447,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005556",
-          "name": "lupus nephritis",
-          "description": "Glomerulonephritis in the context of systemic lupus erythematosus.; Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).; Lupus nephritis is a type of glomerulonephritis that constitutes one of the most severe organ manifestations of systemic lupus erythematosus. Lupus nephritis is subclassified in six distinct classes, that represent different manifestations and severities of renal involvement and guide the therapeutic management. [ORCID:0000-0002-2234-4248, PMID:31974366]",
-          "equivalent_curies": [
-            "MEDDRA:10025140",
-            "HP:0033726",
-            "MEDDRA:10029141",
-            "DOID:0080162",
-            "NCIT:C34789",
-            "UMLS:C0024143",
-            "MESH:D008181",
-            "MEDDRA:10029142",
-            "MONDO:0005556",
-            "SNOMEDCT:68815009",
-            "MEDDRA:10040970",
-            "EFO:0005761"
-          ],
-          "id": "MONDO:0005556",
-          "category": "biolink:Disease",
-          "all_names": [
-            "lupus nephritis",
-            "Lupus nephritis",
-            "Lupus Nephritis",
-            "Lupus Glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000481.htm",
-            "PMID:31974366",
-            "https://orcid.org/0000-0002-2234-4248",
-            "https://en.wikipedia.org/wiki/lupus_nephritis#cite_note-1"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 309447,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005556",
-              "name": "lupus nephritis",
-              "description": "Glomerulonephritis in the context of systemic lupus erythematosus.; Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).; Lupus nephritis is a type of glomerulonephritis that constitutes one of the most severe organ manifestations of systemic lupus erythematosus. Lupus nephritis is subclassified in six distinct classes, that represent different manifestations and severities of renal involvement and guide the therapeutic management. [ORCID:0000-0002-2234-4248, PMID:31974366]",
-              "equivalent_curies": [
-                "MEDDRA:10025140",
-                "HP:0033726",
-                "MEDDRA:10029141",
-                "DOID:0080162",
-                "NCIT:C34789",
-                "UMLS:C0024143",
-                "MESH:D008181",
-                "MEDDRA:10029142",
-                "MONDO:0005556",
-                "SNOMEDCT:68815009",
-                "MEDDRA:10040970",
-                "EFO:0005761"
-              ],
-              "id": "MONDO:0005556",
-              "category": "biolink:Disease",
-              "all_names": [
-                "lupus nephritis",
-                "Lupus nephritis",
-                "Lupus Nephritis",
-                "Lupus Glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000481.htm",
-                "PMID:31974366",
-                "https://orcid.org/0000-0002-2234-4248",
-                "https://en.wikipedia.org/wiki/lupus_nephritis#cite_note-1"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10903975,
-            "start": 568,
-            "end": 309447,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15082482': {'publication date': '2004 May', 'sentence': 'EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15824513': {'publication date': '2005', 'sentence': 'CONCLUSIONS: MMF with prednisolone was effective for remission induction in severe lupus nephritis and was well tolerated.', 'subject score': 1000, 'object score': 901}, 'PMID:24175257': {'publication date': '2012 Dec 06', 'sentence': 'Recently, a multidrug regimen of prednisolone (PDN), Tac, and mycophenolate mofetile (MMF) has been found effective and relatively safe in adult lupus nephritis.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0024143---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11142916",
-              "object": "MONDO:0005556",
-              "publications": [
-                "PMID:15082482",
-                "PMID:15824513",
-                "PMID:24175257"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 531220,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0012105",
-          "name": "granulomatosis with polyangiitis",
-          "description": "A rare, autoimmune, systemic medium and small size vasculitis. It is characterized by the formation of necrotizing granulomas in the respiratory tract, necrotizing angiitis, and glomerulonephritis.; A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10072579",
-            "DOID:12132",
-            "ICD10:M31.3",
-            "MONDO:0012105",
-            "SNOMEDCT:195353004",
-            "UMLS:C3495801",
-            "OMIM:608710",
-            "UMLS:C4050407",
-            "MEDDRA:10047889",
-            "NCIT:C3444",
-            "EFO:0005297",
-            "MESH:D014890",
-            "MEDDRA:10047888",
-            "MEDDRA:10072580",
-            "ORPHANET:900",
-            "ICD9:446.4",
-            "NCIT:C123111"
-          ],
-          "id": "MONDO:0012105",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pauci-immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-            "Granulomatosis with Polyangiitis",
-            "granulomatosis with polyangiitis",
-            "Pauci-Immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-            "Granulomatosis with polyangiitis related phenotypic feature",
-            "Granulomatosis with polyangiitis",
-            "Wegener's granulomatosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/granulomatosis_with_polyangiitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 531220,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0012105",
-              "name": "granulomatosis with polyangiitis",
-              "description": "A rare, autoimmune, systemic medium and small size vasculitis. It is characterized by the formation of necrotizing granulomas in the respiratory tract, necrotizing angiitis, and glomerulonephritis.; A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10072579",
-                "DOID:12132",
-                "ICD10:M31.3",
-                "MONDO:0012105",
-                "SNOMEDCT:195353004",
-                "UMLS:C3495801",
-                "OMIM:608710",
-                "UMLS:C4050407",
-                "MEDDRA:10047889",
-                "NCIT:C3444",
-                "EFO:0005297",
-                "MESH:D014890",
-                "MEDDRA:10047888",
-                "MEDDRA:10072580",
-                "ORPHANET:900",
-                "ICD9:446.4",
-                "NCIT:C123111"
-              ],
-              "id": "MONDO:0012105",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pauci-immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-                "Granulomatosis with Polyangiitis",
-                "granulomatosis with polyangiitis",
-                "Pauci-Immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-                "Granulomatosis with polyangiitis related phenotypic feature",
-                "Granulomatosis with polyangiitis",
-                "Wegener's granulomatosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/granulomatosis_with_polyangiitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10800774,
-            "start": 568,
-            "end": 531220,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14963200': {'publication date': '2004 Mar', 'sentence': \"OBJECTIVE: To investigate the safety and efficacy of leflunomide plus low-dose prednisolone for the maintenance of remission in Wegener's granulomatosis (WG).\", 'subject score': 901, 'object score': 1000}, 'PMID:16374738': {'publication date': '2006 Jan 05', 'sentence': 'TREATMENT AND COURSE: To achieve remission bolus therapy with cyclophosphamide and prednisolone was initiated and planned to be the first of three pulses But when the patient developed epididymitis and a neuropathy associated with Wegener\"s granulomatosis, the dose was increased and cyclophosphamide was given for a longer period.', 'subject score': 1000, 'object score': 890}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C3495801---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11037266",
-              "object": "MONDO:0012105",
-              "publications": [
-                "PMID:14963200",
-                "PMID:16374738"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 315770,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005059",
-          "name": "leukemia",
-          "description": "A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3161\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3161\" NCI Thesaurus); A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.; A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006); A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding  When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets  The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time.  The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age  What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding.  Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes  Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10045991",
-            "MEDDRA:10024329",
-            "ICD9:208",
-            "ICD10:C95.90",
-            "MEDDRA:10060430",
-            "MEDDRA:10024314",
-            "MEDDRA:10024323",
-            "MEDDRA:10024351",
-            "HP:0001909",
-            "SNOMEDCT:87163000",
-            "SNOMEDCT:1162768007",
-            "MEDDRA:10045992",
-            "MEDDRA:10060500",
-            "NCIT:C3161",
-            "EFO:0000565",
-            "MEDDRA:10045994",
-            "SNOMEDCT:93143009",
-            "MEDDRA:10024288",
-            "MEDDRA:10024352",
-            "MEDDRA:10024312",
-            "DOID:1240",
-            "UMLS:C0023418",
-            "PDQ:CDR0000041186",
-            "MESH:D007938",
-            "MONDO:0005059",
-            "MEDDRA:10024324"
-          ],
-          "id": "MONDO:0005059",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia of unspecified cell type",
-            "Leukemia",
-            "leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/leukemia",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=45343",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315770,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005059",
-              "name": "leukemia",
-              "description": "A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3161\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3161\" NCI Thesaurus); A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.; A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006); A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding  When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets  The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time.  The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age  What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding.  Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes  Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10045991",
-                "MEDDRA:10024329",
-                "ICD9:208",
-                "ICD10:C95.90",
-                "MEDDRA:10060430",
-                "MEDDRA:10024314",
-                "MEDDRA:10024323",
-                "MEDDRA:10024351",
-                "HP:0001909",
-                "SNOMEDCT:87163000",
-                "SNOMEDCT:1162768007",
-                "MEDDRA:10045992",
-                "MEDDRA:10060500",
-                "NCIT:C3161",
-                "EFO:0000565",
-                "MEDDRA:10045994",
-                "SNOMEDCT:93143009",
-                "MEDDRA:10024288",
-                "MEDDRA:10024352",
-                "MEDDRA:10024312",
-                "DOID:1240",
-                "UMLS:C0023418",
-                "PDQ:CDR0000041186",
-                "MESH:D007938",
-                "MONDO:0005059",
-                "MEDDRA:10024324"
-              ],
-              "id": "MONDO:0005059",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia of unspecified cell type",
-                "Leukemia",
-                "leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/leukemia",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=45343",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10777002,
-            "start": 568,
-            "end": 315770,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1483996': {'publication date': '1992 May', 'sentence': 'Treatment with combined therapy of adriamycin, vincristine and prednisolone produced a remission in the leukaemia with complete resolution of the breast mass.', 'subject score': 1000, 'object score': 1000}, 'PMID:23334362': {'publication date': '2013 Apr', 'sentence': 'In conclusion, we here present a novel mechanism of prednisolone resistance in MLL-rearranged leukemias, and propose that inhibition of annexin A2 phosphorylation embodies a therapeutic strategy for overcoming resistance to glucocorticoids in this highly aggressive type of leukemia.', 'subject score': 694, 'object score': 802}, 'PMID:5875818': {'publication date': '1965 Sep-Oct', 'sentence': '[The effect of pyridoxine and prednisolone on the blood picture in experimental anemia and transplantable leukemia].', 'subject score': 1000, 'object score': 853}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0023418---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11013570",
-              "object": "MONDO:0005059",
-              "publications": [
-                "PMID:1483996",
-                "PMID:23334362",
-                "PMID:5875818"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 531649,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019735",
-          "name": "polymyalgia rheumatica",
-          "description": "A syndrome characterized by pain, stiffness, and tenderness of the proximal muscle groups including the shoulder, pelvic girdle and the neck. There is no muscle atrophy and muscle biopsies do not reveal pathologic changes. Additional signs and symptoms include low grade fever, fatigue and depression.; A syndrome in the elderly characterized by proximal joint and muscle pain, high erythrocyte sedimentation rate, and a self-limiting course. Pain is usually accompanied by evidence of an inflammatory reaction. Women are affected twice as commonly as men and Caucasians more frequently than other groups. The condition is frequently associated with GIANT CELL ARTERITIS and some theories pose the possibility that the two diseases arise from a single etiology or even that they are the same entity.; Polymyalgia rheumatica is a disorder that causes muscle pain and stiffness in your neck, shoulders, and hips. It is most common in women and almost always occurs in people over 50. The main symptom is stiffness after resting. Other symptoms include fever, weakness and weight loss. In some cases, polymyalgia rheumatica develops overnight. In others, it is gradual. The cause of polymyalgia rheumatica is unknown. There is no specific test for it. Your doctor will use your medical history, symptoms, and a physical exam to make the diagnosis. Lab tests for inflammation may help confirm the diagnosis. Polymyalgia rheumatica sometimes occurs along with giant cell arteritis, a condition that causes swelling of the arteries in your head. Symptoms include headaches and blurred vision. Doctors often prescribe prednisone, a steroid medicine, for both conditions. With treatment, polymyalgia rheumatica usually disappears in a day or two. Without treatment, it usually goes away after a year or more.  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10036099",
-            "UMLS:C1527406",
-            "NCIT:C85018",
-            "DOID:853",
-            "ORPHANET:93569",
-            "MEDDRA:10068240",
-            "UMLS:C0032533",
-            "MESH:D011111",
-            "ICD9:725",
-            "SNOMEDCT:65323003",
-            "EFO:0008518",
-            "MONDO:0019735",
-            "ICD10:M35.3"
-          ],
-          "id": "MONDO:0019735",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Polymyalgia rheumatica",
-            "polymyalgia rheumatica",
-            "Rhizomelic pseudopolyarthritis",
-            "Polymyalgia Rheumatica"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/polymyalgiarheumatica.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 531649,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019735",
-              "name": "polymyalgia rheumatica",
-              "description": "A syndrome characterized by pain, stiffness, and tenderness of the proximal muscle groups including the shoulder, pelvic girdle and the neck. There is no muscle atrophy and muscle biopsies do not reveal pathologic changes. Additional signs and symptoms include low grade fever, fatigue and depression.; A syndrome in the elderly characterized by proximal joint and muscle pain, high erythrocyte sedimentation rate, and a self-limiting course. Pain is usually accompanied by evidence of an inflammatory reaction. Women are affected twice as commonly as men and Caucasians more frequently than other groups. The condition is frequently associated with GIANT CELL ARTERITIS and some theories pose the possibility that the two diseases arise from a single etiology or even that they are the same entity.; Polymyalgia rheumatica is a disorder that causes muscle pain and stiffness in your neck, shoulders, and hips. It is most common in women and almost always occurs in people over 50. The main symptom is stiffness after resting. Other symptoms include fever, weakness and weight loss. In some cases, polymyalgia rheumatica develops overnight. In others, it is gradual. The cause of polymyalgia rheumatica is unknown. There is no specific test for it. Your doctor will use your medical history, symptoms, and a physical exam to make the diagnosis. Lab tests for inflammation may help confirm the diagnosis. Polymyalgia rheumatica sometimes occurs along with giant cell arteritis, a condition that causes swelling of the arteries in your head. Symptoms include headaches and blurred vision. Doctors often prescribe prednisone, a steroid medicine, for both conditions. With treatment, polymyalgia rheumatica usually disappears in a day or two. Without treatment, it usually goes away after a year or more.  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10036099",
-                "UMLS:C1527406",
-                "NCIT:C85018",
-                "DOID:853",
-                "ORPHANET:93569",
-                "MEDDRA:10068240",
-                "UMLS:C0032533",
-                "MESH:D011111",
-                "ICD9:725",
-                "SNOMEDCT:65323003",
-                "EFO:0008518",
-                "MONDO:0019735",
-                "ICD10:M35.3"
-              ],
-              "id": "MONDO:0019735",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Polymyalgia rheumatica",
-                "polymyalgia rheumatica",
-                "Rhizomelic pseudopolyarthritis",
-                "Polymyalgia Rheumatica"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/polymyalgiarheumatica.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10714401,
-            "start": 568,
-            "end": 531649,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14713975': {'publication date': '2003 Dec 04', 'sentence': 'RESULTS: The average initial dose of prednisolone in polymyalgia rheumatica was 35 mg; 51 of 62 patients were given a starting dose exceeding 15 mg.', 'subject score': 1000, 'object score': 1000}, 'PMID:3511861': {'publication date': '1986 Feb', 'sentence': 'The ability of azathioprine to reduce the maintenance prednisolone requirement of 31 patients with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA), or both, was tested in a double-blind placebo controlled study over one year.', 'subject score': 851, 'object score': 1000}, 'PMID:3621844': {'publication date': '1987 Jun', 'sentence': 'Giant cell arteritis precipitated by a diagnostic trial of prednisolone in suspected polymyalgia rheumatica.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0032533---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10949449",
-              "object": "MONDO:0019735",
-              "publications": [
-                "PMID:14713975",
-                "PMID:3511861",
-                "PMID:3621844"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 311498,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005047",
-          "name": "infertility disorder",
-          "description": "Inability to conceive for at least one year after trying and having unprotected sex. Causes of female infertility include endometriosis, fallopian tubes obstruction, and polycystic ovary syndrome. Causes of male infertility include abnormal sperm production or function, blockage of the epididymis, blockage of the ejaculatory ducts, hypospadias, exposure to pesticides, and health related issues. // COMMENTS: Editor note: dubious as to whether this is a disease as defined, check with clingen before obsoleting",
-          "equivalent_curies": [
-            "UMLS:C4074771",
-            "MEDDRA:10021930",
-            "DOID:5223",
-            "SYMP:0000712",
-            "EFO:0000545",
-            "UMLS:C0021359",
-            "MESH:D007246",
-            "MONDO:0005047",
-            "NCIT:C3836",
-            "UMLS:C1533568",
-            "MEDDRA:10042012",
-            "HP:0000789",
-            "PSY:25210",
-            "SNOMEDCT:15296000",
-            "PDQ:CDR0000726658",
-            "SNOMEDCT:8619003",
-            "MEDDRA:10021926"
-          ],
-          "id": "MONDO:0005047",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infertility",
-            "infertility",
-            "Fertility Disorders",
-            "infertility disorder",
-            "Sterility, Reproductive"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:DiseaseOrPhenotypicFeature",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/infertility"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311498,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005047",
-              "name": "infertility disorder",
-              "description": "Inability to conceive for at least one year after trying and having unprotected sex. Causes of female infertility include endometriosis, fallopian tubes obstruction, and polycystic ovary syndrome. Causes of male infertility include abnormal sperm production or function, blockage of the epididymis, blockage of the ejaculatory ducts, hypospadias, exposure to pesticides, and health related issues. // COMMENTS: Editor note: dubious as to whether this is a disease as defined, check with clingen before obsoleting",
-              "equivalent_curies": [
-                "UMLS:C4074771",
-                "MEDDRA:10021930",
-                "DOID:5223",
-                "SYMP:0000712",
-                "EFO:0000545",
-                "UMLS:C0021359",
-                "MESH:D007246",
-                "MONDO:0005047",
-                "NCIT:C3836",
-                "UMLS:C1533568",
-                "MEDDRA:10042012",
-                "HP:0000789",
-                "PSY:25210",
-                "SNOMEDCT:15296000",
-                "PDQ:CDR0000726658",
-                "SNOMEDCT:8619003",
-                "MEDDRA:10021926"
-              ],
-              "id": "MONDO:0005047",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infertility",
-                "infertility",
-                "Fertility Disorders",
-                "infertility disorder",
-                "Sterility, Reproductive"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:DiseaseOrPhenotypicFeature",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/infertility"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10517905,
-            "start": 568,
-            "end": 311498,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14421828': {'publication date': '1959 Dec 15', 'sentence': '[Trans-utero-tubal administration of prednisolone in sterility caused by obstruction of the tubes].', 'subject score': 1000, 'object score': 1000}, 'PMID:14606767': {'publication date': '2003 Jul-Aug', 'sentence': 'The advantages of the EVAP combination are absence of pulmonary toxicity, markedly lower incidence of sterility and nausea and vomiting.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0021359---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10748640",
-              "object": "MONDO:0005047",
-              "publications": [
-                "PMID:14421828",
-                "PMID:14606767"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320151,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-          "name": "dermatitis, atopic",
-          "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MESH:C566404",
-            "MEDDRA:10012434",
-            "SNOMEDCT:24079001",
-            "MONDO:0011292",
-            "MEDDRA:10003641",
-            "MONDO:0100181",
-            "MEDDRA:10014191",
-            "OMIM:603165",
-            "HP:0001047",
-            "MEDDRA:10001711",
-            "MEDDRA:10003639",
-            "UMLS:C0011615",
-            "UMLS:C4280605",
-            "UMLS:C1864155",
-            "MEDDRA:10012438",
-            "MEDDRA:10014188",
-            "MEDDRA:10001712",
-            "MESH:D003876",
-            "SNOMEDCT:200775004"
-          ],
-          "id": "MONDO:0011292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis, Atopic, 1",
-            "dermatitis, atopic",
-            "Dermatitis, Atopic",
-            "Baby eczema",
-            "Dermatitis, atopic related phenotypic feature",
-            "Atopic dermatitis",
-            "dermatitis, atopic, 1"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:27904186",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320151,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-              "name": "dermatitis, atopic",
-              "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MESH:C566404",
-                "MEDDRA:10012434",
-                "SNOMEDCT:24079001",
-                "MONDO:0011292",
-                "MEDDRA:10003641",
-                "MONDO:0100181",
-                "MEDDRA:10014191",
-                "OMIM:603165",
-                "HP:0001047",
-                "MEDDRA:10001711",
-                "MEDDRA:10003639",
-                "UMLS:C0011615",
-                "UMLS:C4280605",
-                "UMLS:C1864155",
-                "MEDDRA:10012438",
-                "MEDDRA:10014188",
-                "MEDDRA:10001712",
-                "MESH:D003876",
-                "SNOMEDCT:200775004"
-              ],
-              "id": "MONDO:0011292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis, Atopic, 1",
-                "dermatitis, atopic",
-                "Dermatitis, Atopic",
-                "Baby eczema",
-                "Dermatitis, atopic related phenotypic feature",
-                "Atopic dermatitis",
-                "dermatitis, atopic, 1"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:27904186",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10513987,
-            "start": 568,
-            "end": 320151,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14399872': {'publication date': '1959 Nov 06', 'sentence': '[On experiences with a combination preparation from prednisolone and an antihistaminic in dermatology especially in endogenous eczema].', 'subject score': 1000, 'object score': 1000}, 'PMID:18294881': {'publication date': '2009 Apr', 'sentence': 'The objective of this study was to compare the efficacy of cyclosporine A (CsA) and prednisolone in feline atopic dermatitis (AD) in a randomised, controlled double blind study.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0011615---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10744705",
-              "object": "MONDO:0011292",
-              "publications": [
-                "PMID:14399872",
-                "PMID:18294881"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318775,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005364",
-          "name": "Graves disease",
-          "description": "Hyperthyroidism associated with diffuse hyperplasia of the thyroid gland (goiter), resulting from production of antibodies that are directed against the thyrotropin receptor complex of the follicular epithelial cells. As a result, the thyroid gland enlarges and secretes increased amounts of thyroid hormones.; A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).; An autoimmune disease where the thyroid is overactive, producing an excessive amount of thyroid hormones (a serious metabolic imbalance known as hyperthyroidism and thyrotoxicosis). This is caused by autoantibodies to the TSH-receptor (TSHR-Ab) that activate that TSH-receptor (TSHR), thereby stimulating thyroid hormone synthesis and secretion, and thyroid growth (causing a diffusely enlarged goiter). The resulting state of hyperthyroidism can cause a dramatic constellation of neuropsychological and physical signs and symptoms, which can severely compromise the patients. [HPO:sdoelken]",
-          "equivalent_curies": [
-            "MEDDRA:10018494",
-            "MEDDRA:10015679",
-            "MEDDRA:10018706",
-            "UMLS:C5546093",
-            "MEDDRA:10065624",
-            "NCIT:C3071",
-            "HP:0100647",
-            "MONDO:0005364",
-            "MEDDRA:10004161",
-            "DOID:12361",
-            "UMLS:C0018213",
-            "EFO:0004237",
-            "MESH:D006111",
-            "SNOMEDCT:55807009",
-            "MEDDRA:10074037",
-            "SNOMEDCT:353295004",
-            "MEDDRA:10015680",
-            "ICD10:E05.0",
-            "MEDDRA:10068004"
-          ],
-          "id": "MONDO:0005364",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Graves disease",
-            "Graves' disease",
-            "Graves Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/graves_disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318775,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005364",
-              "name": "Graves disease",
-              "description": "Hyperthyroidism associated with diffuse hyperplasia of the thyroid gland (goiter), resulting from production of antibodies that are directed against the thyrotropin receptor complex of the follicular epithelial cells. As a result, the thyroid gland enlarges and secretes increased amounts of thyroid hormones.; A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).; An autoimmune disease where the thyroid is overactive, producing an excessive amount of thyroid hormones (a serious metabolic imbalance known as hyperthyroidism and thyrotoxicosis). This is caused by autoantibodies to the TSH-receptor (TSHR-Ab) that activate that TSH-receptor (TSHR), thereby stimulating thyroid hormone synthesis and secretion, and thyroid growth (causing a diffusely enlarged goiter). The resulting state of hyperthyroidism can cause a dramatic constellation of neuropsychological and physical signs and symptoms, which can severely compromise the patients. [HPO:sdoelken]",
-              "equivalent_curies": [
-                "MEDDRA:10018494",
-                "MEDDRA:10015679",
-                "MEDDRA:10018706",
-                "UMLS:C5546093",
-                "MEDDRA:10065624",
-                "NCIT:C3071",
-                "HP:0100647",
-                "MONDO:0005364",
-                "MEDDRA:10004161",
-                "DOID:12361",
-                "UMLS:C0018213",
-                "EFO:0004237",
-                "MESH:D006111",
-                "SNOMEDCT:55807009",
-                "MEDDRA:10074037",
-                "SNOMEDCT:353295004",
-                "MEDDRA:10015680",
-                "ICD10:E05.0",
-                "MEDDRA:10068004"
-              ],
-              "id": "MONDO:0005364",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Graves disease",
-                "Graves' disease",
-                "Graves Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/graves_disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10505129,
-            "start": 568,
-            "end": 318775,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14346730': {'publication date': '1965 Jun', 'sentence': '[USE OF PREDNISOLONE IN SOME GRAVE FORMS OF PATHOLOGY OF THE PREMATURE INFANT].', 'subject score': 1000, 'object score': 966}, 'PMID:1497563': {'publication date': '1992 Jun', 'sentence': \"Hypokalaemic paralysis induced by bolus prednisolone in Graves' disease.\", 'subject score': 861, 'object score': 1000}, 'PMID:25603854': {'publication date': '2015 01', 'sentence': \"Accordingly, oral steroid therapy was started with 60 mg of prednisolone under the impression of AIH associated with Graves' disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:31627654': {'publication date': '2007 Oct 15', 'sentence': \"[Evaluation of methylprednisolone pulse therapy versus combined therapy with prednisolone and cyclosporine in the treatment of infiltrative ophthalmopathy in Graves' disease].\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0018213---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10736101",
-              "object": "MONDO:0005364",
-              "publications": [
-                "PMID:14346730",
-                "PMID:1497563",
-                "PMID:25603854",
-                "PMID:31627654"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319192,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-          "name": "kidney disorder",
-          "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D007674",
-            "MEDDRA:10029154",
-            "UMLS:C0022658",
-            "NCIT:C3149",
-            "MONDO:0005240",
-            "UMLS:C1408258",
-            "DOID:557",
-            "MEDDRA:10029149",
-            "HP:0000112",
-            "MEDDRA:10051051",
-            "NCIT:C34843",
-            "MEDDRA:10038428",
-            "MEDDRA:10038429",
-            "MEDDRA:10029151",
-            "MEDDRA:10051052",
-            "EFO:0003086",
-            "SNOMEDCT:90708001",
-            "MEDDRA:10013263",
-            "PSY:27347"
-          ],
-          "id": "MONDO:0005240",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Kidney damage",
-            "kidney disease",
-            "Nephropathy",
-            "Kidney Diseases",
-            "Kidney Disorder",
-            "kidney disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319192,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-              "name": "kidney disorder",
-              "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D007674",
-                "MEDDRA:10029154",
-                "UMLS:C0022658",
-                "NCIT:C3149",
-                "MONDO:0005240",
-                "UMLS:C1408258",
-                "DOID:557",
-                "MEDDRA:10029149",
-                "HP:0000112",
-                "MEDDRA:10051051",
-                "NCIT:C34843",
-                "MEDDRA:10038428",
-                "MEDDRA:10038429",
-                "MEDDRA:10029151",
-                "MEDDRA:10051052",
-                "EFO:0003086",
-                "SNOMEDCT:90708001",
-                "MEDDRA:10013263",
-                "PSY:27347"
-              ],
-              "id": "MONDO:0005240",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Kidney damage",
-                "kidney disease",
-                "Nephropathy",
-                "Kidney Diseases",
-                "Kidney Disorder",
-                "kidney disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10504714,
-            "start": 568,
-            "end": 319192,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14344800': {'publication date': '1965 Jan', 'sentence': '[EFFECT OF PREDNISOLONE ON THE CARDIAC ACTIVITY IN LIVER AND KIDNEY  DISEASES AND IN RHEUMATISM].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0022658---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10735679",
-              "object": "MONDO:0005240",
-              "publications": [
-                "PMID:14344800"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317343,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0003085",
-          "name": "keratitis",
-          "description": "A corneal disease that is characterized by inflammation of the cornea.",
-          "equivalent_curies": [
-            "DOID:4677",
-            "MEDDRA:10045988",
-            "HP:0000491",
-            "MEDDRA:10011023",
-            "MEDDRA:10023332",
-            "MESH:D007634",
-            "UMLS:C0022568",
-            "MEDDRA:10023346",
-            "SNOMEDCT:5888003",
-            "NCIT:C26805",
-            "MEDDRA:10023336",
-            "ICD10:H16",
-            "MEDDRA:10021953",
-            "SYMP:0000314",
-            "ICD9:370",
-            "MONDO:0003085",
-            "EFO:0009449"
-          ],
-          "id": "MONDO:0003085",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Keratitis",
-            "keratitis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.mayoclinic.org/diseases-conditions/keratitis/basics/definition/con-20035288",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317343,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0003085",
-              "name": "keratitis",
-              "description": "A corneal disease that is characterized by inflammation of the cornea.",
-              "equivalent_curies": [
-                "DOID:4677",
-                "MEDDRA:10045988",
-                "HP:0000491",
-                "MEDDRA:10011023",
-                "MEDDRA:10023332",
-                "MESH:D007634",
-                "UMLS:C0022568",
-                "MEDDRA:10023346",
-                "SNOMEDCT:5888003",
-                "NCIT:C26805",
-                "MEDDRA:10023336",
-                "ICD10:H16",
-                "MEDDRA:10021953",
-                "SYMP:0000314",
-                "ICD9:370",
-                "MONDO:0003085",
-                "EFO:0009449"
-              ],
-              "id": "MONDO:0003085",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Keratitis",
-                "keratitis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.mayoclinic.org/diseases-conditions/keratitis/basics/definition/con-20035288",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10485233,
-            "start": 568,
-            "end": 317343,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1424667': {'publication date': '1992 Sep', 'sentence': 'In this limited pilot study, we compared the effect on clinical outcome of treating Pseudomonas keratitis in guinea pigs with prednisolone (a corticosteroid), flurbiprofen (a cyclo-oxygenase inhibitor), nordihydroguaiaretic acid (a lipoxygenase inhibitor), and a leukotriene antagonist, SKF104353 [R-(R*, S*)]-beta-[(2-carboxyethyl) thio-alpha-hydroxy-2-(8-phenyloctyl) benzenepropanoic acid, zinc salt].', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0022568---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10715297",
-              "object": "MONDO:0003085",
-              "publications": [
-                "PMID:1424667"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10473465,
-            "start": 568,
-            "end": 322104,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14191165': {'publication date': '1964 Oct 24', 'sentence': 'URINARY EXCRETION OF PREDNISOLONE AFTER INTRARECTAL THERAPY IN ULCERATIVE COLITIS.', 'subject score': 1000, 'object score': 1000}, 'PMID:2867153': {'publication date': '1985 Oct', 'sentence': \"Absorption of delayed-release prednisolone in ulcerative colitis and Crohn's disease.\", 'subject score': 851, 'object score': 1000}, 'PMID:30863856': {'publication date': '2019 Jul 25', 'sentence': 'METHODS: This was a prospective, randomized, controlled multicentre pilot study comparing leukocyte apheresis with prednisolone in refractory UC (disease activity index [DAI] >= 4 and <=8).', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10703266",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:14191165",
-                "PMID:2867153",
-                "PMID:30863856"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319068,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007256",
-          "name": "hepatocellular carcinoma",
-          "description": "A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.; A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.; A kind of neoplasm of the liver that originates in hepatocytes and presents macroscopically as a soft and hemorrhagic tan mass in the liver. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "HP:0001402",
-            "ICD10:C22.0",
-            "ORPHANET:88673",
-            "MEDDRA:10073071",
-            "DOID:686",
-            "MESH:C567299",
-            "MEDDRA:10024658",
-            "SNOMEDCT:109841003",
-            "UMLS:C2676033",
-            "OMIM:114550",
-            "MESH:D006528",
-            "SNOMEDCT:187769009",
-            "UMLS:C1867955",
-            "SNOMEDCT:25370001",
-            "UMLS:C1862761",
-            "DOID:684",
-            "MEDDRA:10048491",
-            "SNOMEDCT:1186630006",
-            "MONDO:0007256",
-            "MEDDRA:10019838",
-            "MEDDRA:10049010",
-            "EFO:0000182",
-            "NCIT:C3099",
-            "MEDDRA:10007416",
-            "UMLS:C2239176"
-          ],
-          "id": "MONDO:0007256",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hepatocellular carcinoma",
-            "Hepatocellular Carcinoma",
-            "Increased hepatocellular carcinoma risk",
-            "Hepatocellular carcinoma related phenotypic feature",
-            "Hepatocellular carcinoma",
-            "Liver carcinoma",
-            "Carcinoma, Hepatocellular",
-            "Increased incidence of hepatocellular carcinoma",
-            "liver carcinoma",
-            "Hepatoblastoma Caused By Somatic Mutation"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/liver_cance",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/hepatocellular_carcinoma",
-            "http://en.wikipedia.org/wiki/carcinoma",
-            "http://www.omim.org/entry/114550",
-            "http://cancergenome.nih.gov/cancersselected/liverhepatocellularcarcinoma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319068,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007256",
-              "name": "hepatocellular carcinoma",
-              "description": "A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.; A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.; A kind of neoplasm of the liver that originates in hepatocytes and presents macroscopically as a soft and hemorrhagic tan mass in the liver. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "HP:0001402",
-                "ICD10:C22.0",
-                "ORPHANET:88673",
-                "MEDDRA:10073071",
-                "DOID:686",
-                "MESH:C567299",
-                "MEDDRA:10024658",
-                "SNOMEDCT:109841003",
-                "UMLS:C2676033",
-                "OMIM:114550",
-                "MESH:D006528",
-                "SNOMEDCT:187769009",
-                "UMLS:C1867955",
-                "SNOMEDCT:25370001",
-                "UMLS:C1862761",
-                "DOID:684",
-                "MEDDRA:10048491",
-                "SNOMEDCT:1186630006",
-                "MONDO:0007256",
-                "MEDDRA:10019838",
-                "MEDDRA:10049010",
-                "EFO:0000182",
-                "NCIT:C3099",
-                "MEDDRA:10007416",
-                "UMLS:C2239176"
-              ],
-              "id": "MONDO:0007256",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hepatocellular carcinoma",
-                "Hepatocellular Carcinoma",
-                "Increased hepatocellular carcinoma risk",
-                "Hepatocellular carcinoma related phenotypic feature",
-                "Hepatocellular carcinoma",
-                "Liver carcinoma",
-                "Carcinoma, Hepatocellular",
-                "Increased incidence of hepatocellular carcinoma",
-                "liver carcinoma",
-                "Hepatoblastoma Caused By Somatic Mutation"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/liver_cance",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/hepatocellular_carcinoma",
-                "http://en.wikipedia.org/wiki/carcinoma",
-                "http://www.omim.org/entry/114550",
-                "http://cancergenome.nih.gov/cancersselected/liverhepatocellularcarcinoma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10458056,
-            "start": 568,
-            "end": 319068,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1411124': {'publication date': '1992', 'sentence': 'Male rats treated with either budesonide, prednisolone, or triamcinolone acetonide in drinking water for up to 104 weeks developed slightly increased incidences of basophilic foci, and significantly increased incidences of combined hepatocellular adenomas/carcinomas as compared to controls.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C2239176---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10687782",
-              "object": "MONDO:0007256",
-              "publications": [
-                "PMID:1411124"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316685,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0003664",
-          "name": "hemolytic anemia",
-          "description": "A type of anemia caused by premature destruction of red blood cells (hemolysis). [HPO:probinson]; A type of anemia caused by premature destruction of red blood cells (hemolysis). // COMMENTS: Normally, erythrocytes survive on average about 110-120 days. With hemolysis, the erythrocyte survival is shortened, and generally increased marrow activity results in a reticulocyte count.; A type of anemia caused by premature destruction of red blood cells (hemolysis). // COMMENTS: Normally, erythrocytes survive on average about 110-120 days. With hemolysis, the erythrocyte survival is shortened, and generally increased marrow activity results in a reticulocyte count.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:0005558",
-            "UMLS:C0002878",
-            "MEDDRA:10018921",
-            "MEDDRA:10019494",
-            "SYMP:0000631",
-            "MEDDRA:10018916",
-            "ICD10:D55-D59",
-            "SNOMEDCT:61261009",
-            "MONDO:0003664",
-            "HP:0001878",
-            "MEDDRA:10019493",
-            "DOID:583",
-            "MEDDRA:10002284",
-            "MEDDRA:10055193",
-            "MEDDRA:10002045",
-            "NCIT:C34376",
-            "MESH:D000743"
-          ],
-          "id": "MONDO:0003664",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hemolytic anemia",
-            "Anemia, Hemolytic",
-            "hemolytic anemia",
-            "Hemolytic Anemia"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316685,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0003664",
-              "name": "hemolytic anemia",
-              "description": "A type of anemia caused by premature destruction of red blood cells (hemolysis). [HPO:probinson]; A type of anemia caused by premature destruction of red blood cells (hemolysis). // COMMENTS: Normally, erythrocytes survive on average about 110-120 days. With hemolysis, the erythrocyte survival is shortened, and generally increased marrow activity results in a reticulocyte count.; A type of anemia caused by premature destruction of red blood cells (hemolysis). // COMMENTS: Normally, erythrocytes survive on average about 110-120 days. With hemolysis, the erythrocyte survival is shortened, and generally increased marrow activity results in a reticulocyte count.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:0005558",
-                "UMLS:C0002878",
-                "MEDDRA:10018921",
-                "MEDDRA:10019494",
-                "SYMP:0000631",
-                "MEDDRA:10018916",
-                "ICD10:D55-D59",
-                "SNOMEDCT:61261009",
-                "MONDO:0003664",
-                "HP:0001878",
-                "MEDDRA:10019493",
-                "DOID:583",
-                "MEDDRA:10002284",
-                "MEDDRA:10055193",
-                "MEDDRA:10002045",
-                "NCIT:C34376",
-                "MESH:D000743"
-              ],
-              "id": "MONDO:0003664",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hemolytic anemia",
-                "Anemia, Hemolytic",
-                "hemolytic anemia",
-                "Hemolytic Anemia"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10395113,
-            "start": 568,
-            "end": 316685,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13814629': {'publication date': '1960 May', 'sentence': '[On the use of prednisolone in hemolytic anemia of the newborn caused by fetomaternal Rh-factor incompatibility].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0002878---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10623724",
-              "object": "MONDO:0003664",
-              "publications": [
-                "PMID:13814629"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 300724,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011429",
-          "name": "juvenile idiopathic arthritis",
-          "description": "A group of chronic, inflammatory childhood disorders of unknown etiology that primarily involve joints.; Arthritis in children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:410502007",
-            "MEDDRA:10034164",
-            "ICD9:714.33",
-            "UMLS:C0157916",
-            "ICD9:714.32",
-            "UMLS:C3714757",
-            "DOID:676",
-            "HP:0005681",
-            "EFO:0002609",
-            "ICD9:714.31",
-            "MEDDRA:10036038",
-            "MESH:D001171",
-            "MEDDRA:10027842",
-            "MEDDRA:10034165",
-            "MEDDRA:10034166",
-            "OMIM:604302",
-            "MEDDRA:10023266",
-            "MEDDRA:10023267",
-            "NCIT:C61279",
-            "ICD9:714.3",
-            "UMLS:C0157918",
-            "NCIT:C114357",
-            "SNOMEDCT:410795001",
-            "UMLS:C0157917",
-            "MONDO:0011429",
-            "MEDDRA:10059177",
-            "ORPHANET:92",
-            "MEDDRA:10059176",
-            "UMLS:C3495559",
-            "SNOMEDCT:16024431000119108",
-            "ICD10:M08.4"
-          ],
-          "id": "MONDO:0011429",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Arthritis, Juvenile",
-            "Oligoarticular Still Disease",
-            "Polyarticular juvenile rheumatoid arthritis, acute",
-            "juvenile idiopathic arthritis",
-            "Monoarticular juvenile rheumatoid arthritis",
-            "Juvenile Idiopathic Arthritis",
-            "Pauciarticular juvenile rheumatoid arthritis",
-            "juvenile rheumatoid arthritis",
-            "Acute polyarticular juvenile rheumatoid arthritis",
-            "Rheumatoid arthritis, systemic juvenile related phenotypic feature",
-            "Juvenile arthritis",
-            "Juvenile chronic polyarthritis",
-            "Juvenile idiopathic arthritis",
-            "Juvenile rheumatoid arthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000451.htm",
-            "http://www.umm.edu/ency/article/000451.htm",
-            "https://en.wikipedia.org/wiki/subtalar_joint",
-            "http://www.mayoclinic.com/health/juvenile-rheumatoid-arthritis/ds00018"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 300724,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011429",
-              "name": "juvenile idiopathic arthritis",
-              "description": "A group of chronic, inflammatory childhood disorders of unknown etiology that primarily involve joints.; Arthritis in children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:410502007",
-                "MEDDRA:10034164",
-                "ICD9:714.33",
-                "UMLS:C0157916",
-                "ICD9:714.32",
-                "UMLS:C3714757",
-                "DOID:676",
-                "HP:0005681",
-                "EFO:0002609",
-                "ICD9:714.31",
-                "MEDDRA:10036038",
-                "MESH:D001171",
-                "MEDDRA:10027842",
-                "MEDDRA:10034165",
-                "MEDDRA:10034166",
-                "OMIM:604302",
-                "MEDDRA:10023266",
-                "MEDDRA:10023267",
-                "NCIT:C61279",
-                "ICD9:714.3",
-                "UMLS:C0157918",
-                "NCIT:C114357",
-                "SNOMEDCT:410795001",
-                "UMLS:C0157917",
-                "MONDO:0011429",
-                "MEDDRA:10059177",
-                "ORPHANET:92",
-                "MEDDRA:10059176",
-                "UMLS:C3495559",
-                "SNOMEDCT:16024431000119108",
-                "ICD10:M08.4"
-              ],
-              "id": "MONDO:0011429",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Arthritis, Juvenile",
-                "Oligoarticular Still Disease",
-                "Polyarticular juvenile rheumatoid arthritis, acute",
-                "juvenile idiopathic arthritis",
-                "Monoarticular juvenile rheumatoid arthritis",
-                "Juvenile Idiopathic Arthritis",
-                "Pauciarticular juvenile rheumatoid arthritis",
-                "juvenile rheumatoid arthritis",
-                "Acute polyarticular juvenile rheumatoid arthritis",
-                "Rheumatoid arthritis, systemic juvenile related phenotypic feature",
-                "Juvenile arthritis",
-                "Juvenile chronic polyarthritis",
-                "Juvenile idiopathic arthritis",
-                "Juvenile rheumatoid arthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000451.htm",
-                "http://www.umm.edu/ency/article/000451.htm",
-                "https://en.wikipedia.org/wiki/subtalar_joint",
-                "http://www.mayoclinic.com/health/juvenile-rheumatoid-arthritis/ds00018"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10348693,
-            "start": 568,
-            "end": 300724,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13636697': {'publication date': '1959 Apr', 'sentence': 'Long-term use of prednisone and prednisolone in juvenile rheumatoid arthritis; a report of fifteen cases.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C3495559---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10576837",
-              "object": "MONDO:0011429",
-              "publications": [
-                "PMID:13636697"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319059,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005377",
-          "name": "nephrotic syndrome",
-          "description": "Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. [HPO:probinson]; Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. // COMMENTS: In adults, nephrotic syndrome is characterized by protein excretion of 3.5 g or more per day. In children, nephrotic syndrome is accompanied by protein excretion of more than 40 mg/m2/h and hypalbuminemia < 2.5 mg/dl.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10042826",
-            "MESH:D009404",
-            "HP:0000100",
-            "UMLS:C0027726",
-            "MONDO:0005377",
-            "EFO:0004255",
-            "MEDDRA:10029164",
-            "SNOMEDCT:52254009",
-            "NCIT:C34845",
-            "DOID:1184",
-            "ICD9:581"
-          ],
-          "id": "MONDO:0005377",
-          "category": "biolink:Disease",
-          "all_names": [
-            "nephrotic syndrome",
-            "Nephrotic Syndrome",
-            "Nephrotic syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://en.wikipedia.org/wiki/nephrotic_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319059,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005377",
-              "name": "nephrotic syndrome",
-              "description": "Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. [HPO:probinson]; Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. // COMMENTS: In adults, nephrotic syndrome is characterized by protein excretion of 3.5 g or more per day. In children, nephrotic syndrome is accompanied by protein excretion of more than 40 mg/m2/h and hypalbuminemia < 2.5 mg/dl.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10042826",
-                "MESH:D009404",
-                "HP:0000100",
-                "UMLS:C0027726",
-                "MONDO:0005377",
-                "EFO:0004255",
-                "MEDDRA:10029164",
-                "SNOMEDCT:52254009",
-                "NCIT:C34845",
-                "DOID:1184",
-                "ICD9:581"
-              ],
-              "id": "MONDO:0005377",
-              "category": "biolink:Disease",
-              "all_names": [
-                "nephrotic syndrome",
-                "Nephrotic Syndrome",
-                "Nephrotic syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://en.wikipedia.org/wiki/nephrotic_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10337958,
-            "start": 568,
-            "end": 319059,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13589594': {'publication date': '1958 Sep 26', 'sentence': '[Effect of prednisolone and human albumin on protein excretion in nephrotic syndrome].', 'subject score': 1000, 'object score': 1000}, 'PMID:1646675': {'publication date': '1991 Apr', 'sentence': 'All children received more than eight weeks course of prednisolone, and were in a critically ill status from their nephrotic syndrome and by steroid-toxic side effects.', 'subject score': 1000, 'object score': 1000}, 'PMID:16644478': {'publication date': '2006 Jun', 'sentence': 'We evaluated the suppressive efficacy of prednisolone, methylprednisolone, cyclosporine, and tacrolimus on the blastogenesis of PBMCs obtained from 12 ANCA-associated vasculitis patients (ANCA patients), eight patients with nephrotic syndrome, and eight healthy subjects.', 'subject score': 1000, 'object score': 1000}, 'PMID:17573408': {'publication date': '2008 Mar', 'sentence': 'Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:19562934': {'publication date': '2009 Mar', 'sentence': 'Concurrent use of cyclophosphamide and prednisolone in childhood nephrotic syndrome in South-East Nigeria; a report of 5 cases.', 'subject score': 1000, 'object score': 901}, 'PMID:26759000': {'publication date': '2016 Apr', 'sentence': 'The practice of BW-based calculations for prescribing prednisolone in NS is a reasonable approach.', 'subject score': 888, 'object score': 1000}, 'PMID:26787586': {'publication date': '2016 Jan', 'sentence': 'Use of high-dose prednisolone to overcome rifampicin-induced corticosteroid non-responsiveness in childhood nephrotic syndrome.', 'subject score': 901, 'object score': 901}, 'PMID:2751337': {'publication date': '1989 Apr', 'sentence': 'Low dose prednisolone in nephrotic syndrome.', 'subject score': 901, 'object score': 1000}, 'PMID:28341877': {'publication date': '2017 Aug', 'sentence': 'Short courses of daily prednisolone during upper respiratory tract infections reduce relapse frequency in childhood nephrotic syndrome.', 'subject score': 888, 'object score': 901}, 'PMID:7141787': {'publication date': '1982 Sep', 'sentence': 'The mean renal clearance and urinary excretion of prednisone and prednisolone in nephrotic syndrome are normal and suggest that glomerular leakage of protein bound drug is not significant.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0027726---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10565620",
-              "object": "MONDO:0005377",
-              "publications": [
-                "PMID:13589594",
-                "PMID:1646675",
-                "PMID:16644478",
-                "PMID:17573408",
-                "PMID:19562934",
-                "PMID:26759000",
-                "PMID:26787586",
-                "PMID:2751337",
-                "PMID:28341877",
-                "PMID:7141787"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 130846,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-          "name": "allergic disease",
-          "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MONDO:0005271",
-            "SYMP:0000900",
-            "UMLS:C3539909",
-            "MEDDRA:10020759",
-            "MEDDRA:10020756",
-            "NCIT:C114476",
-            "SNOMEDCT:418634005",
-            "MEDDRA:10001738",
-            "HP:0012393",
-            "MESH:D006967",
-            "MEDDRA:10001719",
-            "MEDDRA:10001741",
-            "MEDDRA:10037948",
-            "SNOMEDCT:609328004",
-            "SNOMEDCT:421961002",
-            "UMLS:C1527304",
-            "ICD10:T78.40",
-            "DOID:1205",
-            "MEDDRA:10020755",
-            "MEDDRA:10020751",
-            "MEDDRA:10037932",
-            "UMLS:C0020517",
-            "MEDDRA:10020757",
-            "SNOMEDCT:419076005",
-            "MEDDRA:10001718"
-          ],
-          "id": "MONDO:0005271",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Allergic disposition",
-            "Allergic Reaction",
-            "Hypersensitivity",
-            "allergic reaction",
-            "allergic disease",
-            "Allergy"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000005.htm",
-            "ISBN:0781735149",
-            "http://en.wikipedia.org/wiki/allergy",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 130846,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-              "name": "allergic disease",
-              "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MONDO:0005271",
-                "SYMP:0000900",
-                "UMLS:C3539909",
-                "MEDDRA:10020759",
-                "MEDDRA:10020756",
-                "NCIT:C114476",
-                "SNOMEDCT:418634005",
-                "MEDDRA:10001738",
-                "HP:0012393",
-                "MESH:D006967",
-                "MEDDRA:10001719",
-                "MEDDRA:10001741",
-                "MEDDRA:10037948",
-                "SNOMEDCT:609328004",
-                "SNOMEDCT:421961002",
-                "UMLS:C1527304",
-                "ICD10:T78.40",
-                "DOID:1205",
-                "MEDDRA:10020755",
-                "MEDDRA:10020751",
-                "MEDDRA:10037932",
-                "UMLS:C0020517",
-                "MEDDRA:10020757",
-                "SNOMEDCT:419076005",
-                "MEDDRA:10001718"
-              ],
-              "id": "MONDO:0005271",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Allergic disposition",
-                "Allergic Reaction",
-                "Hypersensitivity",
-                "allergic reaction",
-                "allergic disease",
-                "Allergy"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000005.htm",
-                "ISBN:0781735149",
-                "http://en.wikipedia.org/wiki/allergy",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10304763,
-            "start": 568,
-            "end": 130846,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13442027': {'publication date': '1957 Jan', 'sentence': '[Therapeutic results of metacortandralone or prednisolone in allergy].', 'subject score': 1000, 'object score': 1000}, 'PMID:13472563': {'publication date': '1957 Nov 01', 'sentence': 'Clinical use of prednisone and prednisolone in allergic states and collagen diseases.', 'subject score': 1000, 'object score': 983}, 'PMID:23263813': {'publication date': '2012 Dec', 'sentence': 'Since prednisolone is commonly co-prescribed with anti-histamine in many hypersensitive reactions, we also examined the changes to compare the results after the prednisolone administration.', 'subject score': 1000, 'object score': 947}, 'PMID:13929849': {'publication date': '1962 Nov', 'sentence': '[Use of prednisolone in a patient with a severe temporary insulin-resistant form of diabetes mellitus associated with the development of an allergic reaction].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0020517---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C1527304---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10531966",
-              "object": "MONDO:0005271",
-              "publications": [
-                "PMID:13929849",
-                "PMID:23263813",
-                "PMID:13442027",
-                "PMID:13472563"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321063,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018874",
-          "name": "acute myeloid leukemia",
-          "description": "A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification). (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3171\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3171\" NCI Thesaurus); Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.; A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).; Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.; A form of leukemia characterized by overproduction of an early myeloid cell. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:91861009",
-            "ICD9:205.0",
-            "MEDDRA:10024346",
-            "MEDDRA:10000801",
-            "MEDDRA:10060354",
-            "KEGG.DISEASE:05221",
-            "EFO:0000222",
-            "PDQ:CDR0000043424",
-            "MEDDRA:10000886",
-            "HP:0004808",
-            "MEDDRA:10060394",
-            "MESH:D015470",
-            "MEDDRA:10051003",
-            "MONDO:0100173",
-            "MEDDRA:10000878",
-            "MEDDRA:10060553",
-            "MEDDRA:10024291",
-            "SNOMEDCT:1162928000",
-            "MEDDRA:10054296",
-            "ORPHANET:519",
-            "MEDDRA:10000880",
-            "UMLS:C3275959",
-            "MEDDRA:10028552",
-            "MONDO:0018874",
-            "OMIM:601626",
-            "MEDDRA:10000884",
-            "DOID:9119",
-            "MEDDRA:10029549",
-            "MEDDRA:10029551",
-            "UMLS:C0023467",
-            "NCIT:C3171",
-            "MEDDRA:10060557",
-            "MEDDRA:10028557"
-          ],
-          "id": "MONDO:0018874",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia, acute myeloid related phenotypic feature",
-            "Leukemia, Myelocytic, Acute",
-            "Acute myeloid leukemia",
-            "acute myeloid leukemia",
-            "leukemia, acute myeloid, susceptibility to",
-            "Leukemia, acute myeloid, susceptibility to",
-            "Acute Myeloid Leukemia",
-            "Leukemia, Myeloid, Acute",
-            "Myeloid leukemia, acute"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=44363",
-            "http://cancergenome.nih.gov/cancersselected/acutemyeloidleukemia",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.cancer.org/cancer/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.htm",
-            "http://en.wikipedia.org/wiki/acute_myeloid_leukemia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321063,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018874",
-              "name": "acute myeloid leukemia",
-              "description": "A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification). (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3171\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3171\" NCI Thesaurus); Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.; A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).; Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.; A form of leukemia characterized by overproduction of an early myeloid cell. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:91861009",
-                "ICD9:205.0",
-                "MEDDRA:10024346",
-                "MEDDRA:10000801",
-                "MEDDRA:10060354",
-                "KEGG.DISEASE:05221",
-                "EFO:0000222",
-                "PDQ:CDR0000043424",
-                "MEDDRA:10000886",
-                "HP:0004808",
-                "MEDDRA:10060394",
-                "MESH:D015470",
-                "MEDDRA:10051003",
-                "MONDO:0100173",
-                "MEDDRA:10000878",
-                "MEDDRA:10060553",
-                "MEDDRA:10024291",
-                "SNOMEDCT:1162928000",
-                "MEDDRA:10054296",
-                "ORPHANET:519",
-                "MEDDRA:10000880",
-                "UMLS:C3275959",
-                "MEDDRA:10028552",
-                "MONDO:0018874",
-                "OMIM:601626",
-                "MEDDRA:10000884",
-                "DOID:9119",
-                "MEDDRA:10029549",
-                "MEDDRA:10029551",
-                "UMLS:C0023467",
-                "NCIT:C3171",
-                "MEDDRA:10060557",
-                "MEDDRA:10028557"
-              ],
-              "id": "MONDO:0018874",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia, acute myeloid related phenotypic feature",
-                "Leukemia, Myelocytic, Acute",
-                "Acute myeloid leukemia",
-                "acute myeloid leukemia",
-                "leukemia, acute myeloid, susceptibility to",
-                "Leukemia, acute myeloid, susceptibility to",
-                "Acute Myeloid Leukemia",
-                "Leukemia, Myeloid, Acute",
-                "Myeloid leukemia, acute"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=44363",
-                "http://cancergenome.nih.gov/cancersselected/acutemyeloidleukemia",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.cancer.org/cancer/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.htm",
-                "http://en.wikipedia.org/wiki/acute_myeloid_leukemia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10300447,
-            "start": 568,
-            "end": 321063,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1341718': {'publication date': '1992', 'sentence': \"Primary resistance to vincristine (Vcr) and prednisolone in untreated AML was observed as well as 'acquired' resistance to several other antileukemic drugs.\", 'subject score': 1000, 'object score': 923}, 'PMID:7331708': {'publication date': '1981 Jul', 'sentence': 'Combination chemotherapy with daunorubicin, cytosine arabinoside and prednisolone (DAP) in acute nonlymphocytic leukemia.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0023467---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10527508",
-              "object": "MONDO:0018874",
-              "publications": [
-                "PMID:1341718",
-                "PMID:7331708"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317004,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005324",
-          "name": "seasonal allergic rhinitis",
-          "description": "Allergic rhinitis caused by outdoor allergens.; Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS.; It is characterized by one or more symptoms including sneezing, itching, nasal congestion, and rhinorrhea. [PMID:11449200]; An allergy experienced at a particular time of year when trees or grasses pollinate and elicit an allergic reaction. [HPO:probinson]",
-          "equivalent_curies": [
-            "HP:0012395",
-            "NCIT:C92188",
-            "SNOMEDCT:300910009",
-            "PSY:22320",
-            "MEDDRA:10001726",
-            "SNOMEDCT:21719001",
-            "MEDDRA:10019170",
-            "MONDO:0005324",
-            "MEDDRA:10039776",
-            "MEDDRA:10048908",
-            "MEDDRA:10036020",
-            "SNOMEDCT:444316004",
-            "MESH:D006255",
-            "SNOMEDCT:367498001",
-            "MEDDRA:10036019",
-            "UMLS:C0018621"
-          ],
-          "id": "MONDO:0005324",
-          "category": "biolink:Disease",
-          "all_names": [
-            "seasonal allergic rhinitis",
-            "Seasonal Allergic Rhinitis",
-            "Rhinitis, Allergic, Seasonal",
-            "Seasonal allergy",
-            "Hay Fever",
-            "Hay fever"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:11449200",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317004,
-=======
-            "identity": 319030,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005324",
-              "name": "seasonal allergic rhinitis",
-              "description": "Allergic rhinitis caused by outdoor allergens.; Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS.; It is characterized by one or more symptoms including sneezing, itching, nasal congestion, and rhinorrhea. [PMID:11449200]; An allergy experienced at a particular time of year when trees or grasses pollinate and elicit an allergic reaction. [HPO:probinson]",
-              "equivalent_curies": [
-                "HP:0012395",
-                "NCIT:C92188",
-                "SNOMEDCT:300910009",
-                "PSY:22320",
-                "MEDDRA:10001726",
-                "SNOMEDCT:21719001",
-                "MEDDRA:10019170",
-                "MONDO:0005324",
-                "MEDDRA:10039776",
-                "MEDDRA:10048908",
-                "MEDDRA:10036020",
-                "SNOMEDCT:444316004",
-                "MESH:D006255",
-                "SNOMEDCT:367498001",
-                "MEDDRA:10036019",
-                "UMLS:C0018621"
-              ],
-              "id": "MONDO:0005324",
-              "category": "biolink:Disease",
-              "all_names": [
-                "seasonal allergic rhinitis",
-                "Seasonal Allergic Rhinitis",
-                "Rhinitis, Allergic, Seasonal",
-                "Seasonal allergy",
-                "Hay Fever",
-                "Hay fever"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "PMID:11449200",
-                "https://orcid.org/0000-0002-0736-9199"
-=======
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 10277145,
-            "start": 568,
-            "end": 317004,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13318863': {'publication date': '1956 May', 'sentence': 'REPORT of the Committee on New Drugs of the Research Council of the American Academy of Allergy, 1955-56; studies on prednisone and prednisolone in ragweed pollinosis.', 'subject score': 1000, 'object score': 888}, 'PMID:13346311': {'publication date': '1956 Jul', 'sentence': 'Prednisone and prednisolone in refractory pollinosis and pollen asthma.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0018621---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10503828",
-              "object": "MONDO:0005324",
-              "publications": [
-                "PMID:13318863",
-                "PMID:13346311"
-=======
-            "identity": 9160603,
-            "start": 568,
-            "end": 319030,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11826654': {'publication date': '2002 Jan', 'sentence': 'OBJECTIVE: To assess the treatment effect of sodium hyaluronate (HA) on experimental temporomandibular joint (TMJ) osteoarthritis of rabbits in comparison with prednisolone (PS).', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9361682",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:11826654"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 183319,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:13587617': {'publication date': '1958 Nov', 'sentence': 'Intra-articular injections of hydrocortisone prednisolone, and their tertiary-butylacetate derivatives in patients with rheumatoid arthritis and osteoarthritis.', 'subject score': 888, 'object score': 1000}, 'PMID:14284044': {'publication date': '1964 Nov', 'sentence': '[THE SYNOVIAL PROTEIN PICTURE IN OSTEOARTHROSES TREATED WITH INTRA-ARTICULAR PREDNISOLONE].', 'subject score': 901, 'object score': 1000}, 'PMID:31727410': {'publication date': '2019 11 30', 'sentence': 'INTERPRETATION: Treatment with 10 mg prednisolone for 6 weeks is efficacious and safe for the treatment of patients with painful hand osteoarthritis and signs of inflammation.', 'subject score': 790, 'object score': 901}, 'PMID:34264344': {'publication date': '2021 Jul 15', 'sentence': 'METHODS: Ultrasonography was performed blinded to clinical information of 30 joints of 75 patients with hand osteoarthritis, treated with prednisolone in a randomized placebo-controlled double-blind trial.', 'subject score': 1000, 'object score': 888}, 'PMID:35671123': {'publication date': '2022 Jun 07', 'sentence': 'METHODS: Data were analysed from a 6-week, randomized, double-blind, placebo-controlled trial investigating prednisolone treatment in 92 patients with painful inflammatory hand OA.', 'subject score': 827, 'object score': 861}, 'PMID:35946535': {'publication date': '2022 Aug 10', 'sentence': 'OBJECTIVES: To investigate whether biomarkers are modulated by prednisolone treatment in patients with hand osteoarthritis (OA) and whether they can predict response to prednisolone.', 'subject score': 888, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 319030,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10269883,
-            "start": 568,
-            "end": 183319,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13291449': {'publication date': '1955', 'sentence': 'Effects of prednisone and prednisolone in ocular inflammation.', 'subject score': 1000, 'object score': 888}, 'PMID:17237435': {'publication date': '2007 Feb 01', 'sentence': 'Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:27163931': {'publication date': '2016', 'sentence': 'Performance profiles were established which allowed us to identify curcumin, berberine chloride and epigallocatechin gallate as potential alternatives for prednisolone or other glucocorticoids in inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:28821031': {'publication date': '2017 Oct 15', 'sentence': 'These efficacy profiles of the NFs-CDs gel containing PD suggest that it has the potential for use in the treatment of, not only colitis, but also a variety of other disorders associated with inflammation and oxidative injuries.', 'subject score': 766, 'object score': 1000}, 'PMID:31830002': {'publication date': '2019 Dec 12', 'sentence': 'Transcriptomic analysis identified that combining Pred with dnMstn treatment affects gene expression profiles associated with inflammation, metabolism, and fibrosis.', 'subject score': 872, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10496403",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:13291449",
-                "PMID:17237435",
-                "PMID:27163931",
-                "PMID:28821031",
-                "PMID:31830002"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 4578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisone",
-          "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "HMDB:HMDB0014773",
-            "UMLS:C0032952",
-            "NCIT:C770",
-            "PUBCHEM.COMPOUND:5865",
-            "DrugCentral:2253",
-            "MESH:D011241",
-            "ATC:A07EA03",
-            "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-            "CAS:53-03-2",
-            "PDQ:CDR0000042487",
-            "PathWhiz.Compound:9120",
-            "KEGG.DRUG:D00473",
-            "DRUGBANK:DB00635",
-            "ATC:H02AB07",
-            "UNII:VB0R961HZT",
-            "NDDF:002164",
-            "CHEMBL.COMPOUND:CHEMBL635",
-            "CHEBI:8382",
-            "KEGG.COMPOUND:C07370",
-            "GTOPDB:7096",
-            "RXNORM:8640"
-          ],
-          "id": "PUBCHEM.COMPOUND:5865",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisone",
-            "Prednisone (USP)",
-            "PREDNISONE",
-            "1,2-dehydrocortisone",
-            "prednisone"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:32422522",
-            "PMID:18788725",
-            "PMID:11413487",
-            "PMID:20070106",
-            "PMID:378499",
-            "PMID:15646539",
-            "PMID:20014752",
-            "PMID:25618019",
-            "PMID:23571415",
-            "PMID:19586686"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 4578,
-            "labels": [
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-            ],
-            "properties": {
-              "name": "Prednisone",
-              "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "HMDB:HMDB0014773",
-                "UMLS:C0032952",
-                "NCIT:C770",
-                "PUBCHEM.COMPOUND:5865",
-                "DrugCentral:2253",
-                "MESH:D011241",
-                "ATC:A07EA03",
-                "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-                "CAS:53-03-2",
-                "PDQ:CDR0000042487",
-                "PathWhiz.Compound:9120",
-                "KEGG.DRUG:D00473",
-                "DRUGBANK:DB00635",
-                "ATC:H02AB07",
-                "UNII:VB0R961HZT",
-                "NDDF:002164",
-                "CHEMBL.COMPOUND:CHEMBL635",
-                "CHEBI:8382",
-                "KEGG.COMPOUND:C07370",
-                "GTOPDB:7096",
-                "RXNORM:8640"
-              ],
-              "id": "PUBCHEM.COMPOUND:5865",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisone",
-                "Prednisone (USP)",
-                "PREDNISONE",
-                "1,2-dehydrocortisone",
-                "prednisone"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:32422522",
-                "PMID:18788725",
-                "PMID:11413487",
-                "PMID:20070106",
-                "PMID:378499",
-                "PMID:15646539",
-                "PMID:20014752",
-                "PMID:25618019",
-                "PMID:23571415",
-                "PMID:19586686"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9899283,
-            "start": 568,
-            "end": 4578,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12670859': {'publication date': '2003 Apr', 'sentence': 'Prednisolone scored better than prednisone in the categories of texture, taste, and aftertaste (p < 0.05); there was no statistical difference in smell.', 'subject score': 1000, 'object score': 1000}, 'PMID:13487472': {'publication date': '1957 Nov 10', 'sentence': '[Results of asthma therapy with prednisolone in comparison with previous experience with prednisone].', 'subject score': 1000, 'object score': 1000}, 'PMID:16226134': {'publication date': '2005 Nov', 'sentence': 'Our data demonstrate unimpaired placental 11beta-HSD2 activity in patients suffering from HELLP syndrome at early gestational age as shown by both a 10-fold lower fetal prednisolone concentration as compared to the mother and a strong correlation between the last dose of prednisolone to delivery interval and the fetal prednisone concentration.', 'subject score': 1000, 'object score': 623}, 'PMID:16413504': {'publication date': '2006 Mar 14', 'sentence': 'This approach allowed the comparison of the binding ability of prednisolone and prednisone towards albumin.', 'subject score': 1000, 'object score': 1000}, 'PMID:16548096': {'publication date': '2006 Feb', 'sentence': '(3) In an open-label comparative trial involving 1006 patients, docetaxel infusion at a dose of 75 mg/m2 every 3 weeks, in combination with prednisone (or prednisolone), significantly extended the median survival time by about 2.5 months as compared with a mitoxantrone-prednisone combination (18.9 versus 16.5 months).', 'subject score': 1000, 'object score': 851}, 'PMID:2285202': {'publication date': '1990', 'sentence': 'A cross-over, double-blind, randomized trial with 8 healthy volunteers was undertaken to compare prednisolone and prednisone pharmacokinetics after a single oral dose (1 mg/kg) of prednisone (Cortancyl) and prednisolone sodium metasulfobenzoate (Solupred).', 'subject score': 1000, 'object score': 888}, 'PMID:23415134': {'publication date': '2013 Jul-Aug', 'sentence': 'Mean daily MR-prednisone dosage decreased from 8.2mg to 6.7mg between baseline and endpoint and significantly higher improvements in MS, NRS pain and GA scores were seen in patients switched from 6M-prednisolone versus IR-prednisone.', 'subject score': 861, 'object score': 851}, 'PMID:23473553': {'publication date': '2013 Aug', 'sentence': 'Although interconversion of each drug to the other was confirmed, a single 2mg/kg body weight oral dose of prednisolone produced significantly higher plasma prednisolone concentration (~4-fold higher AUC) compared to prednisone.', 'subject score': 790, 'object score': 1000}, 'PMID:27770303': {'publication date': '2017 Apr', 'sentence': 'Clinical evidence for cabazitaxel was derived from a multinational randomised open-label phase III trial (TROPIC) of cabazitaxel plus prednisone or prednisolone compared with mitoxantrone plus prednisone or prednisolone, which was assumed to represent best supportive care.', 'subject score': 1000, 'object score': 851}, 'PMID:656293': {'publication date': '1978 Jun', 'sentence': '4 It is concluded that plasma prednisolone levels will be more predictable after prednisolone than after prednisone in subjects without hepatic dysfunction.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:compared_with---None---None---None---UMLS:C0032952---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:higher_than---None---None---None---UMLS:C0032952---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10118116",
-              "object": "PUBCHEM.COMPOUND:5865",
-              "publications": [
-                "PMID:16413504",
-                "PMID:13487472",
-                "PMID:656293",
-                "PMID:27770303",
-                "PMID:12670859",
-                "PMID:16548096",
-                "PMID:23415134",
-                "PMID:16226134",
-                "PMID:2285202",
-                "PMID:23473553"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319330,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005292",
-          "name": "colitis",
-          "description": "Inflammation of the colon.; Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.; Colitis refers to an inflammation of the colon and is often used to describe an inflammation of the large intestine (colon, cecum and rectum). Colitides may be acute and self-limited or chronic, and broadly fit into the category of digestive diseases. [HPO:sdoelken]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10079511",
-            "SNOMEDCT:64226004",
-            "UMLS:C0009319",
-            "MESH:D003092",
-            "EFO:0003872",
-            "ICD10:K52.9",
-            "MEDDRA:10009889",
-            "MONDO:0005292",
-            "NCIT:C26723",
-            "MEDDRA:10009898",
-            "PSY:10220",
-            "DOID:0060180",
-            "HP:0002583",
-            "MEDDRA:10009887"
-          ],
-          "id": "MONDO:0005292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Colitis",
-            "colitis"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319330,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005292",
-              "name": "colitis",
-              "description": "Inflammation of the colon.; Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.; Colitis refers to an inflammation of the colon and is often used to describe an inflammation of the large intestine (colon, cecum and rectum). Colitides may be acute and self-limited or chronic, and broadly fit into the category of digestive diseases. [HPO:sdoelken]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10079511",
-                "SNOMEDCT:64226004",
-                "UMLS:C0009319",
-                "MESH:D003092",
-                "EFO:0003872",
-                "ICD10:K52.9",
-                "MEDDRA:10009889",
-                "MONDO:0005292",
-                "NCIT:C26723",
-                "MEDDRA:10009898",
-                "PSY:10220",
-                "DOID:0060180",
-                "HP:0002583",
-                "MEDDRA:10009887"
-              ],
-              "id": "MONDO:0005292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Colitis",
-                "colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9710006,
-            "start": 568,
-            "end": 319330,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1247769': {'publication date': '1976 Jan 24', 'sentence': 'Plasma prednisolone levels after administration of prednisolone-21-phosphate as a retention enema in colitis.', 'subject score': 851, 'object score': 1000}, 'PMID:7129207': {'publication date': '1982 Nov', 'sentence': 'Plasma prednisolone levels during intravenous therapy in acute colitis.', 'subject score': 851, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0009319---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9924521",
-              "object": "MONDO:0005292",
-              "publications": [
-                "PMID:1247769",
-                "PMID:7129207"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319015,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-          "name": "systemic lupus erythematosus",
-          "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10025133",
-            "KEGG.DISEASE:05322",
-            "MEDDRA:10042820",
-            "PDQ:CDR0000608139",
-            "MEDDRA:10040967",
-            "MEDDRA:10042800",
-            "MEDDRA:10013446",
-            "MONDO:0007915",
-            "MEDDRA:10042945",
-            "MEDDRA:10024067",
-            "ICD10:M32.9",
-            "MEDDRA:10042947",
-            "ORPHANET:536",
-            "MEDDRA:10042944",
-            "UMLS:C0024141",
-            "EFO:0002690",
-            "MESH:D008180",
-            "ICD9:710.0",
-            "DOID:9074",
-            "MEDDRA:10025139",
-            "UMLS:C1835309",
-            "MEDDRA:10024065",
-            "OMIM:152700",
-            "HP:0002725",
-            "MEDDRA:10025142",
-            "NCIT:C3201",
-            "SNOMEDCT:55464009"
-          ],
-          "id": "MONDO:0007915",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Systemic lupus erythematosus",
-            "obsolete_systemic lupus erythematosus",
-            "Systemic lupus erythematosus related phenotypic feature",
-            "Lupus Erythematosus, Systemic",
-            "Excess lmw-dna",
-            "systemic lupus erythematosus",
-            "Systemic Lupus Erythematosus"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319015,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-              "name": "systemic lupus erythematosus",
-              "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10025133",
-                "KEGG.DISEASE:05322",
-                "MEDDRA:10042820",
-                "PDQ:CDR0000608139",
-                "MEDDRA:10040967",
-                "MEDDRA:10042800",
-                "MEDDRA:10013446",
-                "MONDO:0007915",
-                "MEDDRA:10042945",
-                "MEDDRA:10024067",
-                "ICD10:M32.9",
-                "MEDDRA:10042947",
-                "ORPHANET:536",
-                "MEDDRA:10042944",
-                "UMLS:C0024141",
-                "EFO:0002690",
-                "MESH:D008180",
-                "ICD9:710.0",
-                "DOID:9074",
-                "MEDDRA:10025139",
-                "UMLS:C1835309",
-                "MEDDRA:10024065",
-                "OMIM:152700",
-                "HP:0002725",
-                "MEDDRA:10025142",
-                "NCIT:C3201",
-                "SNOMEDCT:55464009"
-              ],
-              "id": "MONDO:0007915",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Systemic lupus erythematosus",
-                "obsolete_systemic lupus erythematosus",
-                "Systemic lupus erythematosus related phenotypic feature",
-                "Lupus Erythematosus, Systemic",
-                "Excess lmw-dna",
-                "systemic lupus erythematosus",
-                "Systemic Lupus Erythematosus"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9220530,
-            "start": 568,
-            "end": 319015,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11896887': {'publication date': '2002 Apr', 'sentence': 'Mizoribine as an effective combined maintenance therapy with prednisolone in child-onset systemic lupus erythematosus.', 'subject score': 1000, 'object score': 875}, 'PMID:29320974': {'publication date': '2018 Jan 01', 'sentence': 'Conclusion Comparable intake and tapering of high dose DFZ and PDN in active SLE revealed 2-fold less weight gain, 2.5-fold less hirsutism and 1.5-fold lower cushingoid severity index as well as lower glycaemic elevation in the DFZ group as compared to PDN group.', 'subject score': 1000, 'object score': 916}, 'PMID:355719': {'publication date': '1978 Jul', 'sentence': '[Effect of prednisolone and heparin on circulating T- and B-lymphocytes in glomerulonephritis and systemic lupus erythematosus].', 'subject score': 1000, 'object score': 1000}, 'PMID:8961376': {'publication date': '1996', 'sentence': 'We concluded that suppression of production of dsDNA antibodies with high avidity is a suitable parameter to determine efficacy of treatment and long-term outcome during combined therapy with azathioprine and low-dose prednisolone in SLE.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0024141---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9437304",
-              "object": "MONDO:0007915",
-              "publications": [
-                "PMID:11896887",
-                "PMID:29320974",
-                "PMID:355719",
-                "PMID:8961376"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 311688,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005342",
-          "name": "IgA glomerulonephritis",
-          "description": "Inflammation of a specific segment of glomeruli within the kidney.; A chronic autoimmune glomerulonephritis characterized by the deposition of immunoglobulin A in the mesangium of the glomeruli. It is manifested with hematuria and mild proteinuria.; A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.; The presence of immunoglobulin A deposits in the glomerulus. [Eurenomics:ewuehl]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C34643",
-            "OMIM.PS:161950",
-            "MEDDRA:10018369",
-            "NCIT:C35280",
-            "UMLS:C0017661",
-            "MESH:D005922",
-            "EFO:0004194",
-            "UMLS:C3161650",
-            "SNOMEDCT:68779003",
-            "HP:0000794",
-            "DOID:2986",
-            "SNOMEDCT:236407003",
-            "MEDDRA:10069341",
-            "ORPHANET:34145",
-            "UMLS:C4025827",
-            "MONDO:0005342",
-            "MEDDRA:10021263"
-          ],
-          "id": "MONDO:0005342",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Glomerulonephritis, IGA",
-            "IGA Glomerulonephritis",
-            "IGA glomerulonephritis",
-            "IgA glomerulonephritis",
-            "IgA Nephropathy",
-            "Primary immunoglobulin A nephropathy (disorder)",
-            "IgA deposition in the glomerulus",
-            "Focal Glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000466.htm",
-            "http://en.wikipedia.org/wiki/iga_nephropathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311688,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005342",
-              "name": "IgA glomerulonephritis",
-              "description": "Inflammation of a specific segment of glomeruli within the kidney.; A chronic autoimmune glomerulonephritis characterized by the deposition of immunoglobulin A in the mesangium of the glomeruli. It is manifested with hematuria and mild proteinuria.; A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.; The presence of immunoglobulin A deposits in the glomerulus. [Eurenomics:ewuehl]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C34643",
-                "OMIM.PS:161950",
-                "MEDDRA:10018369",
-                "NCIT:C35280",
-                "UMLS:C0017661",
-                "MESH:D005922",
-                "EFO:0004194",
-                "UMLS:C3161650",
-                "SNOMEDCT:68779003",
-                "HP:0000794",
-                "DOID:2986",
-                "SNOMEDCT:236407003",
-                "MEDDRA:10069341",
-                "ORPHANET:34145",
-                "UMLS:C4025827",
-                "MONDO:0005342",
-                "MEDDRA:10021263"
-              ],
-              "id": "MONDO:0005342",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Glomerulonephritis, IGA",
-                "IGA Glomerulonephritis",
-                "IGA glomerulonephritis",
-                "IgA glomerulonephritis",
-                "IgA Nephropathy",
-                "Primary immunoglobulin A nephropathy (disorder)",
-                "IgA deposition in the glomerulus",
-                "Focal Glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000466.htm",
-                "http://en.wikipedia.org/wiki/iga_nephropathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9082671,
-            "start": 568,
-            "end": 311688,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11752031': {'publication date': '2002 Jan', 'sentence': 'Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy.', 'subject score': 1000, 'object score': 901}, 'PMID:12616032': {'publication date': '2003', 'sentence': 'Prednisolone and azathioprine in IgA nephropathy - a ten-year follow-up study.', 'subject score': 1000, 'object score': 1000}, 'PMID:23756850': {'publication date': '2014 Jan', 'sentence': 'Comparison of prednisolone and lamivudine combined therapy with prednisolone monotherapy on carriers of hepatitis B virus with IgA nephropathy: a prospective cohort study.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0017661---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9282196",
-              "object": "MONDO:0005342",
-              "publications": [
-                "PMID:11752031",
-                "PMID:12616032",
-                "PMID:23756850"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316866,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015691",
-          "name": "hypereosinophilic syndrome",
-          "description": "A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction. This term has often been applied to cases of chronic eosinophilic leukemia. (WHO, 2001); A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10014950",
-            "UMLS:C1636667",
-            "ICD10:D72.1",
-            "ICD9:288.3",
-            "MEDDRA:10048643",
-            "NCIT:C27038",
-            "EFO:1001467",
-            "SNOMEDCT:1156250009",
-            "SNOMEDCT:419455006",
-            "DOID:999",
-            "MESH:D004802",
-            "MESH:D017681",
-            "ORPHANET:168956",
-            "SNOMEDCT:393573009",
-            "UMLS:C0014457",
-            "HP:0001880",
-            "MONDO:0015691",
-            "UMLS:C1540912"
-          ],
-          "id": "MONDO:0015691",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Disorder characterized by eosinophilia",
-            "hypereosinophilic syndrome",
-            "Hypereosinophilic Syndrome",
-            "Hypereosinophilic syndrome",
-            "Eosinophilia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/hypereosinophilic_syndrome",
-            "https://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854",
-            "https://orcid.org/0000-0001-5208-3432",
-=======
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319030,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10337536,
-            "start": 568,
-            "end": 319030,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13587617': {'publication date': '1958 Nov', 'sentence': 'Intra-articular injections of hydrocortisone prednisolone, and their tertiary-butylacetate derivatives in patients with rheumatoid arthritis and osteoarthritis.', 'subject score': 888, 'object score': 1000}, 'PMID:14284044': {'publication date': '1964 Nov', 'sentence': '[THE SYNOVIAL PROTEIN PICTURE IN OSTEOARTHROSES TREATED WITH INTRA-ARTICULAR PREDNISOLONE].', 'subject score': 901, 'object score': 1000}, 'PMID:31727410': {'publication date': '2019 11 30', 'sentence': 'INTERPRETATION: Treatment with 10 mg prednisolone for 6 weeks is efficacious and safe for the treatment of patients with painful hand osteoarthritis and signs of inflammation.', 'subject score': 790, 'object score': 901}, 'PMID:34264344': {'publication date': '2021 Jul 15', 'sentence': 'METHODS: Ultrasonography was performed blinded to clinical information of 30 joints of 75 patients with hand osteoarthritis, treated with prednisolone in a randomized placebo-controlled double-blind trial.', 'subject score': 1000, 'object score': 888}, 'PMID:35671123': {'publication date': '2022 Jun 07', 'sentence': 'METHODS: Data were analysed from a 6-week, randomized, double-blind, placebo-controlled trial investigating prednisolone treatment in 92 patients with painful inflammatory hand OA.', 'subject score': 827, 'object score': 861}, 'PMID:35946535': {'publication date': '2022 Aug 10', 'sentence': 'OBJECTIVES: To investigate whether biomarkers are modulated by prednisolone treatment in patients with hand osteoarthritis (OA) and whether they can predict response to prednisolone.', 'subject score': 888, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10565149",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:13587617",
-                "PMID:14284044",
-                "PMID:31727410",
-                "PMID:34264344",
-                "PMID:35671123",
-                "PMID:35946535"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:24297090': {'publication date': '2014 Mar', 'sentence': 'In this study, we hypothesized that concomitant administration of the dipeptidyl peptidase-4 inhibitor sitagliptin and prednisolone in men at high risk to develop type 2 diabetes could protect against the GC-induced diabetogenic effects.', 'subject score': 1000, 'object score': 1000}, 'PMID:28348775': {'publication date': '2016 Aug', 'sentence': 'CASE PRESENTATION: A 75-year-old Chinese woman with type 2 diabetes mellitus, chronic kidney disease and rheumatoid arthritis, treated with low-dose methotrexate and prednisolone for 2.5 years, developed a Pleurostomophora richardsiae infection of her left arm.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321236,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005148",
-          "name": "type 2 diabetes mellitus",
-          "description": "A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity.; A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.; A type of diabetes mellitus initially characterized by insulin resistance and hyperinsulinemia and subsequently by glucose interolerance and hyperglycemia. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C2674662",
-            "DOID:9352",
-            "UMLS:C0011860",
-            "NCIT:C26747",
-            "MEDDRA:10012611",
-            "ICD10:E11",
-            "MEDDRA:10026947",
-            "UMLS:C3149706",
-            "UMLS:C1840169",
-            "HP:0005978",
-            "OMIM:125853",
-            "UMLS:CN244395",
-            "MEDDRA:10029505",
-            "UMLS:C1852091",
-            "SNOMEDCT:44054006",
-            "KEGG.DISEASE:04930",
-            "MEDDRA:10012613",
-            "MONDO:0005148",
-            "MESH:D003924",
-            "UMLS:C2674665",
-            "MEDDRA:10045242",
-            "EFO:0001360",
-            "MEDDRA:10029402",
-            "MEDDRA:10067585",
-            "UMLS:C2674663",
-            "UMLS:C4017238"
-          ],
-          "id": "MONDO:0005148",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pon1 enzyme activity, variation in",
-            "Diabetes Mellitus, Non-Insulin-Dependent",
-            "Coronary artery disease, susceptibility to",
-            "Diabetes Mellitus, Type 2",
-            "Type 2 Diabetes Mellitus",
-            "MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 5 (finding)",
-            "obsolete_type II diabetes mellitus",
-            "Type 2 diabetes mellitus related phenotypic feature",
-            "Coronary artery spasm 2, susceptibility to",
-            "Type II diabetes mellitus",
-            "Type 2 diabetes mellitus, protection against",
-            "Organophosphate poisoning, susceptibility to",
-            "type 2 diabetes mellitus",
-            "Insulin resistance, susceptibility to"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/diabetes_mellitus_type_2",
-            "http://en.wikipedia.org/wiki/diabetes",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-5316-1399"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321236,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005148",
-              "name": "type 2 diabetes mellitus",
-              "description": "A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity.; A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.; A type of diabetes mellitus initially characterized by insulin resistance and hyperinsulinemia and subsequently by glucose interolerance and hyperglycemia. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C2674662",
-                "DOID:9352",
-                "UMLS:C0011860",
-                "NCIT:C26747",
-                "MEDDRA:10012611",
-                "ICD10:E11",
-                "MEDDRA:10026947",
-                "UMLS:C3149706",
-                "UMLS:C1840169",
-                "HP:0005978",
-                "OMIM:125853",
-                "UMLS:CN244395",
-                "MEDDRA:10029505",
-                "UMLS:C1852091",
-                "SNOMEDCT:44054006",
-                "KEGG.DISEASE:04930",
-                "MEDDRA:10012613",
-                "MONDO:0005148",
-                "MESH:D003924",
-                "UMLS:C2674665",
-                "MEDDRA:10045242",
-                "EFO:0001360",
-                "MEDDRA:10029402",
-                "MEDDRA:10067585",
-                "UMLS:C2674663",
-                "UMLS:C4017238"
-              ],
-              "id": "MONDO:0005148",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pon1 enzyme activity, variation in",
-                "Diabetes Mellitus, Non-Insulin-Dependent",
-                "Coronary artery disease, susceptibility to",
-                "Diabetes Mellitus, Type 2",
-                "Type 2 Diabetes Mellitus",
-                "MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 5 (finding)",
-                "obsolete_type II diabetes mellitus",
-                "Type 2 diabetes mellitus related phenotypic feature",
-                "Coronary artery spasm 2, susceptibility to",
-                "Type II diabetes mellitus",
-                "Type 2 diabetes mellitus, protection against",
-                "Organophosphate poisoning, susceptibility to",
-                "type 2 diabetes mellitus",
-                "Insulin resistance, susceptibility to"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/diabetes_mellitus_type_2",
-                "http://en.wikipedia.org/wiki/diabetes",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-5316-1399"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16963152,
-            "start": 568,
-            "end": 321236,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24297090': {'publication date': '2014 Mar', 'sentence': 'In this study, we hypothesized that concomitant administration of the dipeptidyl peptidase-4 inhibitor sitagliptin and prednisolone in men at high risk to develop type 2 diabetes could protect against the GC-induced diabetogenic effects.', 'subject score': 1000, 'object score': 1000}, 'PMID:28348775': {'publication date': '2016 Aug', 'sentence': 'CASE PRESENTATION: A 75-year-old Chinese woman with type 2 diabetes mellitus, chronic kidney disease and rheumatoid arthritis, treated with low-dose methotrexate and prednisolone for 2.5 years, developed a Pleurostomophora richardsiae infection of her left arm.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0011860---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "17312178",
-              "object": "MONDO:0005148",
-              "publications": [
-                "PMID:24297090",
-                "PMID:28348775"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:11923254': {'publication date': '2002 Apr', 'sentence': 'PURPOSE: To investigate the relationship between vitamin E deficiency and prednisolone-induced cataract formation, long-term examination of lens changes was performed in rats under the condition of vitamin E deficiency or supplementation and administration of prednisolone.', 'subject score': 833, 'object score': 833}, 'PMID:12061274': {'publication date': '2002', 'sentence': 'RESULTS: When 0.25 mumol of steroids were administered to 15-day-old chick embryos, only biologically active glucocorticoids such as hydrocortisone and prednisolone could cause cataract.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316730,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005129",
-          "name": "cataract",
-          "description": "Partial or complete opacity of the crystalline lens of one or both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.); Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed); A cataract is an opacity or clouding that develops in the crystalline lens of the eye or in its capsule. [HPO:probinson]; A cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery. A cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are: Blurry vision Colors that seem faded Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights. Not being able to see well at night Double vision  Frequent prescription changes in your eye wear   Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. NIH: National Eye Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "OMIM.PS:116200",
-            "SNOMEDCT:247053007",
-            "ICD10:H26",
-            "MEDDRA:10007768",
-            "ICD9:366.8",
-            "MONDO:0005129",
-            "UMLS:C0029531",
-            "MEDDRA:10007739",
-            "MEDDRA:10045649",
-            "MEDDRA:10030347",
-            "UMLS:C0086543",
-            "SNOMEDCT:193570009",
-            "SNOMEDCT:128306009",
-            "DOID:83",
-            "OMIM:PS116200",
-            "MEDDRA:10007771",
-            "MEDDRA:10024208",
-            "UMLS:C1510497",
-            "MEDDRA:10024214",
-            "MEDDRA:10024215",
-            "ICD9:366",
-            "HP:0000518",
-            "NCIT:C26713",
-            "MESH:D002386",
-            "MEDDRA:10007757"
-          ],
-          "id": "MONDO:0005129",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Other cataract",
-            "Cataract",
-            "cataract",
-            "Lens Opacities"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:10414631",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0001-6908-9849",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://en.wikipedia.org/wiki/cataract",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316730,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005129",
-              "name": "cataract",
-              "description": "Partial or complete opacity of the crystalline lens of one or both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.); Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed); A cataract is an opacity or clouding that develops in the crystalline lens of the eye or in its capsule. [HPO:probinson]; A cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery. A cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are: Blurry vision Colors that seem faded Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights. Not being able to see well at night Double vision  Frequent prescription changes in your eye wear   Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. NIH: National Eye Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "OMIM.PS:116200",
-                "SNOMEDCT:247053007",
-                "ICD10:H26",
-                "MEDDRA:10007768",
-                "ICD9:366.8",
-                "MONDO:0005129",
-                "UMLS:C0029531",
-                "MEDDRA:10007739",
-                "MEDDRA:10045649",
-                "MEDDRA:10030347",
-                "UMLS:C0086543",
-                "SNOMEDCT:193570009",
-                "SNOMEDCT:128306009",
-                "DOID:83",
-                "OMIM:PS116200",
-                "MEDDRA:10007771",
-                "MEDDRA:10024208",
-                "UMLS:C1510497",
-                "MEDDRA:10024214",
-                "MEDDRA:10024215",
-                "ICD9:366",
-                "HP:0000518",
-                "NCIT:C26713",
-                "MESH:D002386",
-                "MEDDRA:10007757"
-              ],
-              "id": "MONDO:0005129",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Other cataract",
-                "Cataract",
-                "cataract",
-                "Lens Opacities"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:10414631",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0001-6908-9849",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://en.wikipedia.org/wiki/cataract",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9259844,
-            "start": 568,
-            "end": 316730,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11923254': {'publication date': '2002 Apr', 'sentence': 'PURPOSE: To investigate the relationship between vitamin E deficiency and prednisolone-induced cataract formation, long-term examination of lens changes was performed in rats under the condition of vitamin E deficiency or supplementation and administration of prednisolone.', 'subject score': 833, 'object score': 833}, 'PMID:12061274': {'publication date': '2002', 'sentence': 'RESULTS: When 0.25 mumol of steroids were administered to 15-day-old chick embryos, only biologically active glucocorticoids such as hydrocortisone and prednisolone could cause cataract.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0086543---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9464043",
-              "object": "MONDO:0005129",
-              "publications": [
-                "PMID:11923254",
-                "PMID:12061274"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:24765453': {'publication date': '2012 Mar 30', 'sentence': 'Her visual acuity remained stable, despite development of a cataract from prednisolone therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:30592714': {'publication date': '2018 12', 'sentence': 'However, it has been reported that prolonged treatment with prednisolone increases the risk for prednisolone-induced complications such as osteoporosis, diabetes, cataract and arteriosclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7730124': {'publication date': '1994 Dec 01', 'sentence': 'In 3 dogs scheduled for surgical removal of cataracts, systemic and topical treatment with antibiotics and topical ocular treatment with prednisolone, atropine, flurbiprofen, and phenylephrine were used to achieve maximal mydriasis, with minimal risk of pupillary constriction in response to surgery.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316730,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005129",
-          "name": "cataract",
-          "description": "Partial or complete opacity of the crystalline lens of one or both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.); Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed); A cataract is an opacity or clouding that develops in the crystalline lens of the eye or in its capsule. [HPO:probinson]; A cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery. A cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are: Blurry vision Colors that seem faded Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights. Not being able to see well at night Double vision  Frequent prescription changes in your eye wear   Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. NIH: National Eye Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "OMIM.PS:116200",
-            "SNOMEDCT:247053007",
-            "ICD10:H26",
-            "MEDDRA:10007768",
-            "ICD9:366.8",
-            "MONDO:0005129",
-            "UMLS:C0029531",
-            "MEDDRA:10007739",
-            "MEDDRA:10045649",
-            "MEDDRA:10030347",
-            "UMLS:C0086543",
-            "SNOMEDCT:193570009",
-            "SNOMEDCT:128306009",
-            "DOID:83",
-            "OMIM:PS116200",
-            "MEDDRA:10007771",
-            "MEDDRA:10024208",
-            "UMLS:C1510497",
-            "MEDDRA:10024214",
-            "MEDDRA:10024215",
-            "ICD9:366",
-            "HP:0000518",
-            "NCIT:C26713",
-            "MESH:D002386",
-            "MEDDRA:10007757"
-          ],
-          "id": "MONDO:0005129",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Other cataract",
-            "Cataract",
-            "cataract",
-            "Lens Opacities"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:10414631",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0001-6908-9849",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://en.wikipedia.org/wiki/cataract",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316730,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005129",
-              "name": "cataract",
-              "description": "Partial or complete opacity of the crystalline lens of one or both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.); Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed); A cataract is an opacity or clouding that develops in the crystalline lens of the eye or in its capsule. [HPO:probinson]; A cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery. A cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are: Blurry vision Colors that seem faded Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights. Not being able to see well at night Double vision  Frequent prescription changes in your eye wear   Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. NIH: National Eye Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "OMIM.PS:116200",
-                "SNOMEDCT:247053007",
-                "ICD10:H26",
-                "MEDDRA:10007768",
-                "ICD9:366.8",
-                "MONDO:0005129",
-                "UMLS:C0029531",
-                "MEDDRA:10007739",
-                "MEDDRA:10045649",
-                "MEDDRA:10030347",
-                "UMLS:C0086543",
-                "SNOMEDCT:193570009",
-                "SNOMEDCT:128306009",
-                "DOID:83",
-                "OMIM:PS116200",
-                "MEDDRA:10007771",
-                "MEDDRA:10024208",
-                "UMLS:C1510497",
-                "MEDDRA:10024214",
-                "MEDDRA:10024215",
-                "ICD9:366",
-                "HP:0000518",
-                "NCIT:C26713",
-                "MESH:D002386",
-                "MEDDRA:10007757"
-              ],
-              "id": "MONDO:0005129",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Other cataract",
-                "Cataract",
-                "cataract",
-                "Lens Opacities"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:10414631",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0001-6908-9849",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://en.wikipedia.org/wiki/cataract",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17242689,
-            "start": 568,
-            "end": 316730,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24765453': {'publication date': '2012 Mar 30', 'sentence': 'Her visual acuity remained stable, despite development of a cataract from prednisolone therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:30592714': {'publication date': '2018 12', 'sentence': 'However, it has been reported that prolonged treatment with prednisolone increases the risk for prednisolone-induced complications such as osteoporosis, diabetes, cataract and arteriosclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7730124': {'publication date': '1994 Dec 01', 'sentence': 'In 3 dogs scheduled for surgical removal of cataracts, systemic and topical treatment with antibiotics and topical ocular treatment with prednisolone, atropine, flurbiprofen, and phenylephrine were used to achieve maximal mydriasis, with minimal risk of pupillary constriction in response to surgery.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0086543---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "17604301",
-              "object": "MONDO:0005129",
-              "publications": [
-                "PMID:24765453",
-                "PMID:30592714",
-                "PMID:7730124"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:32513294': {'publication date': '2020 Jun 08', 'sentence': 'Therefore, the effect of prednisolone can be studied as a proof of concept for immune modulation as a treatment for schizophrenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:33711681': {'publication date': '2021 Mar 09', 'sentence': 'CONCLUSION: Adjunctive treatment with prednisolone did not improve symptom severity compared to placebo in patients with schizophrenia.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 320598,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005090",
-          "name": "schizophrenia",
-          "description": "A major psychotic disorder characterized by abnormalities in the perception or expression of reality. It affects the cognitive and psychomotor functions. Common clinical signs and symptoms include delusions, hallucinations, disorganized thinking, and retreat from reality.; A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.; A mental disorder characterized by a disintegration of thought processes and of emotional responsiveness. It most commonly manifests as auditory hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking, and it is accompanied by significant social or occupational dysfunction. The onset of symptoms typically occurs in young adulthood, with a global lifetime prevalence of about 0.3-0.7%. [HPO:sdoelken]; Schizophrenia is a serious brain illness. People who have it may hear voices that aren't there. They may think other people are trying to hurt them. Sometimes they don't make sense when they talk. The disorder makes it hard for them to keep a job or take care of themselves. Symptoms of schizophrenia usually start between ages 16 and 30. Men often develop symptoms at a younger age than women. People usually do not get schizophrenia after age 45. There are three types of symptoms:  Psychotic symptoms distort a person's thinking. These include hallucinations (hearing or seeing things that are not there), delusions (beliefs that are not true), trouble organizing thoughts, and strange movements. \"Negative\" symptoms make it difficult to show emotions and to function normally. A person may seem depressed and withdrawn. Cognitive symptoms affect the thought process. These include trouble using information, making decisions, and paying attention.  No one is sure what causes schizophrenia. Your genes, environment, and brain chemistry may play a role. There is no cure. Medicine can help control many of the symptoms. You may need to try different medicines to see which works best. You should stay on your medicine for as long as your doctor recommends. Additional treatments can help you deal with your illness from day to day. These include therapy, family education, rehabilitation, and skills training. NIH: National Institute of Mental Health; UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "MEDDRA:10039632",
-            "MEDDRA:10046150",
-            "MESH:D012559",
-            "MEDDRA:10046156",
-            "ICD9:295",
-            "MONDO:0005090",
-            "UMLS:C4538533",
-            "EFO:0000692",
-            "ORPHANET:3140",
-            "PSY:45440",
-            "MEDDRA:10012297",
-            "SNOMEDCT:58214004",
-            "SNOMEDCT:191526005",
-            "OMIM:181500",
-            "MEDDRA:10039626",
-            "DOID:5419",
-            "UMLS:C0036341",
-            "NCIT:C3362",
-            "HP:0100753",
-            "ICD10:F20"
-          ],
-          "id": "MONDO:0005090",
-          "category": "biolink:Disease",
-          "all_names": [
-            "schizophrenia",
-            "Schizophrenia with or without an affective disorder",
-            "Schizophrenia",
-            "Schizophrenic disorders",
-            "obsolete_schizophrenia",
-            "Schizophrenia related phenotypic feature"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/schizophrenia",
-            "https://orcid.org/0000-0002-6601-2165",
->>>>>>> main
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 316866,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015691",
-              "name": "hypereosinophilic syndrome",
-              "description": "A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction. This term has often been applied to cases of chronic eosinophilic leukemia. (WHO, 2001); A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10014950",
-                "UMLS:C1636667",
-                "ICD10:D72.1",
-                "ICD9:288.3",
-                "MEDDRA:10048643",
-                "NCIT:C27038",
-                "EFO:1001467",
-                "SNOMEDCT:1156250009",
-                "SNOMEDCT:419455006",
-                "DOID:999",
-                "MESH:D004802",
-                "MESH:D017681",
-                "ORPHANET:168956",
-                "SNOMEDCT:393573009",
-                "UMLS:C0014457",
-                "HP:0001880",
-                "MONDO:0015691",
-                "UMLS:C1540912"
-              ],
-              "id": "MONDO:0015691",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Disorder characterized by eosinophilia",
-                "hypereosinophilic syndrome",
-                "Hypereosinophilic Syndrome",
-                "Hypereosinophilic syndrome",
-                "Eosinophilia"
-=======
-            "identity": 320598,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005090",
-              "name": "schizophrenia",
-              "description": "A major psychotic disorder characterized by abnormalities in the perception or expression of reality. It affects the cognitive and psychomotor functions. Common clinical signs and symptoms include delusions, hallucinations, disorganized thinking, and retreat from reality.; A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.; A mental disorder characterized by a disintegration of thought processes and of emotional responsiveness. It most commonly manifests as auditory hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking, and it is accompanied by significant social or occupational dysfunction. The onset of symptoms typically occurs in young adulthood, with a global lifetime prevalence of about 0.3-0.7%. [HPO:sdoelken]; Schizophrenia is a serious brain illness. People who have it may hear voices that aren't there. They may think other people are trying to hurt them. Sometimes they don't make sense when they talk. The disorder makes it hard for them to keep a job or take care of themselves. Symptoms of schizophrenia usually start between ages 16 and 30. Men often develop symptoms at a younger age than women. People usually do not get schizophrenia after age 45. There are three types of symptoms:  Psychotic symptoms distort a person's thinking. These include hallucinations (hearing or seeing things that are not there), delusions (beliefs that are not true), trouble organizing thoughts, and strange movements. \"Negative\" symptoms make it difficult to show emotions and to function normally. A person may seem depressed and withdrawn. Cognitive symptoms affect the thought process. These include trouble using information, making decisions, and paying attention.  No one is sure what causes schizophrenia. Your genes, environment, and brain chemistry may play a role. There is no cure. Medicine can help control many of the symptoms. You may need to try different medicines to see which works best. You should stay on your medicine for as long as your doctor recommends. Additional treatments can help you deal with your illness from day to day. These include therapy, family education, rehabilitation, and skills training. NIH: National Institute of Mental Health; UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "MEDDRA:10039632",
-                "MEDDRA:10046150",
-                "MESH:D012559",
-                "MEDDRA:10046156",
-                "ICD9:295",
-                "MONDO:0005090",
-                "UMLS:C4538533",
-                "EFO:0000692",
-                "ORPHANET:3140",
-                "PSY:45440",
-                "MEDDRA:10012297",
-                "SNOMEDCT:58214004",
-                "SNOMEDCT:191526005",
-                "OMIM:181500",
-                "MEDDRA:10039626",
-                "DOID:5419",
-                "UMLS:C0036341",
-                "NCIT:C3362",
-                "HP:0100753",
-                "ICD10:F20"
-              ],
-              "id": "MONDO:0005090",
-              "category": "biolink:Disease",
-              "all_names": [
-                "schizophrenia",
-                "Schizophrenia with or without an affective disorder",
-                "Schizophrenia",
-                "Schizophrenic disorders",
-                "obsolete_schizophrenia",
-                "Schizophrenia related phenotypic feature"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://en.wikipedia.org/wiki/hypereosinophilic_syndrome",
-                "https://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854",
-                "https://orcid.org/0000-0001-5208-3432",
-=======
-                "http://en.wikipedia.org/wiki/schizophrenia",
-                "https://orcid.org/0000-0002-6601-2165",
->>>>>>> main
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 9023645,
-            "start": 568,
-            "end": 316866,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11704581': {'publication date': '2001 Oct 15', 'sentence': 'We propose that FE(NO) is associated with eosinophilic inflammation in children with difficult asthma, following prednisolone, and may help in identifying patients in whom persistent symptoms are associated with airway eosinophilia.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0014457---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9222009",
-              "object": "MONDO:0015691",
-              "publications": [
-                "PMID:11704581"
-=======
-            "identity": 21710089,
-            "start": 568,
-            "end": 320598,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32513294': {'publication date': '2020 Jun 08', 'sentence': 'Therefore, the effect of prednisolone can be studied as a proof of concept for immune modulation as a treatment for schizophrenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:33711681': {'publication date': '2021 Mar 09', 'sentence': 'CONCLUSION: Adjunctive treatment with prednisolone did not improve symptom severity compared to placebo in patients with schizophrenia.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0036341---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "22130331",
-              "object": "MONDO:0005090",
-              "publications": [
-                "PMID:32513294",
-                "PMID:33711681"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 316905,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018908",
-          "name": "non-Hodgkin lymphoma",
-          "description": "Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3211\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3211\" NCI Thesaurus); Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.; Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.; A type of lymphoma characterized microscopically by the absence of multinucleated Reed-Sternberg cells. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "UMLS:C1622254",
-            "ORPHANET:547",
-            "MESH:D008228",
-            "UMLS:C0024305",
-            "MONDO:0018908",
-            "HP:0012539",
-            "SNOMEDCT:188675007",
-            "PDQ:CDR0000038957",
-            "NCIT:C3211",
-            "SNOMEDCT:1172592001",
-            "DOID:0060060",
-            "MEDDRA:10025311",
-            "MEDDRA:10029593",
-            "SNOMEDCT:128929007",
-            "MEDDRA:10029547",
-            "UMLS:C1622813"
-          ],
-          "id": "MONDO:0018908",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Non-Hodgkin Lymphoma",
-            "Lymphoma, Non-Hodgkin",
-            "Malignant lymphoma - small cleaved cell",
-            "non-Hodgkin lymphoma",
-            "Non-Hodgkin lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/non-hodgkin_lymphoma",
-            "http://www.cancer.gov/dictionary?cdrid=45148",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316905,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018908",
-              "name": "non-Hodgkin lymphoma",
-              "description": "Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3211\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3211\" NCI Thesaurus); Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.; Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.; A type of lymphoma characterized microscopically by the absence of multinucleated Reed-Sternberg cells. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "UMLS:C1622254",
-                "ORPHANET:547",
-                "MESH:D008228",
-                "UMLS:C0024305",
-                "MONDO:0018908",
-                "HP:0012539",
-                "SNOMEDCT:188675007",
-                "PDQ:CDR0000038957",
-                "NCIT:C3211",
-                "SNOMEDCT:1172592001",
-                "DOID:0060060",
-                "MEDDRA:10025311",
-                "MEDDRA:10029593",
-                "SNOMEDCT:128929007",
-                "MEDDRA:10029547",
-                "UMLS:C1622813"
-              ],
-              "id": "MONDO:0018908",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Non-Hodgkin Lymphoma",
-                "Lymphoma, Non-Hodgkin",
-                "Malignant lymphoma - small cleaved cell",
-                "non-Hodgkin lymphoma",
-                "Non-Hodgkin lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/non-hodgkin_lymphoma",
-                "http://www.cancer.gov/dictionary?cdrid=45148",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9017579,
-            "start": 568,
-            "end": 316905,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11699226': {'publication date': '2001 Jun', 'sentence': 'Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma.', 'subject score': 1000, 'object score': 893}, 'PMID:19816010': {'publication date': '2009', 'sentence': 'Effect of L-asparaginase combined with vincristine and prednisolone on acute myeloblastic leukemia (M0) associated with non-Hodgkin lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:3293535': {'publication date': '1988 Jul', 'sentence': \"[Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, prednisolone (VEPA) in non-Hodgkin's lymphoma, with special reference to correlation of surface phenotype with response and survival].\", 'subject score': 1000, 'object score': 1000}, 'PMID:7055819': {'publication date': '1982 Feb', 'sentence': \"Phase II study of a high-dose regimen of cyclophosphamide and prednisolone in advanced non-Hodgkin's lymphoma of favorable histologic type.\", 'subject score': 1000, 'object score': 923}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0024305---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9216084",
-              "object": "MONDO:0018908",
-              "publications": [
-                "PMID:11699226",
-                "PMID:19816010",
-                "PMID:3293535",
-                "PMID:7055819"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 546960,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0010679",
-          "name": "Duchenne muscular dystrophy",
-          "description": "An X-linked inherited disorder caused by mutations in the DMD gene found on the X chromosome. It is characterized by rapidly progressing muscle weakness and muscle atrophy initially involving the lower extremities and eventually affecting the whole body. It affects males whereas females can be carriers. The symptoms start before the age of six and may appear at infancy.; An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0013264",
-            "MESH:D020388",
-            "DOID:11723",
-            "OMIM:310200",
-            "NCIT:C75482",
-            "MONDO:0010679",
-            "MEDDRA:10013801",
-            "SNOMEDCT:76670001",
-            "ORPHANET:98896"
-          ],
-          "id": "MONDO:0010679",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Duchenne Muscular Dystrophy",
-            "Muscular dystrophy, duchenne type related phenotypic feature",
-            "Muscular Dystrophy, Duchenne",
-            "obsolete_Duchenne muscular dystrophy",
-            "Duchenne muscular dystrophy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/duchenne_muscular_dystrophy",
-            "http://www.genome.gov/19518854",
-            "http://omim.org/entry/300377"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546960,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0010679",
-              "name": "Duchenne muscular dystrophy",
-              "description": "An X-linked inherited disorder caused by mutations in the DMD gene found on the X chromosome. It is characterized by rapidly progressing muscle weakness and muscle atrophy initially involving the lower extremities and eventually affecting the whole body. It affects males whereas females can be carriers. The symptoms start before the age of six and may appear at infancy.; An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0013264",
-                "MESH:D020388",
-                "DOID:11723",
-                "OMIM:310200",
-                "NCIT:C75482",
-                "MONDO:0010679",
-                "MEDDRA:10013801",
-                "SNOMEDCT:76670001",
-                "ORPHANET:98896"
-              ],
-              "id": "MONDO:0010679",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Duchenne Muscular Dystrophy",
-                "Muscular dystrophy, duchenne type related phenotypic feature",
-                "Muscular Dystrophy, Duchenne",
-                "obsolete_Duchenne muscular dystrophy",
-                "Duchenne muscular dystrophy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/duchenne_muscular_dystrophy",
-                "http://www.genome.gov/19518854",
-                "http://omim.org/entry/300377"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9010072,
-            "start": 568,
-            "end": 546960,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11692899': {'publication date': '2001 Apr', 'sentence': 'Prednisolone in Duchenne muscular dystrophy.', 'subject score': 1000, 'object score': 1000}, 'PMID:16786214': {'publication date': '2006 Oct', 'sentence': 'Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation.', 'subject score': 1000, 'object score': 1000}, 'PMID:268398': {'publication date': '1977', 'sentence': \"The effects of diethylstilbestrol (DES) and prednisolone (Pr), administered alone or in combination, on the serum enzyme activities in Duchenne's muscular dystrophy (DMD) have been evaluated.\", 'subject score': 1000, 'object score': 1000}, 'PMID:8186713': {'publication date': '1993 Sep-Nov', 'sentence': 'Prednisolone has been shown to improve strength in Duchenne dystrophy, the improvement starting within 10 days of treatment and reaching a maximum by 3 months, and then plateauing.', 'subject score': 1000, 'object score': 1000}, 'PMID:968173': {'publication date': '1976 Sep', 'sentence': \"We have previously shown that diethylstilbestrol (DES) almost always, and prednisolone (Pr) less frequently, lowered the high serum enzyme activities in Duchenne's muscular dystrophy (DMD).\", 'subject score': 802, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0013264---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9208405",
-              "object": "MONDO:0010679",
-              "publications": [
-                "PMID:11692899",
-                "PMID:16786214",
-                "PMID:268398",
-                "PMID:8186713",
-                "PMID:968173"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:1096352': {'publication date': '1975 Jun', 'sentence': 'Intravenous prednisolone in chronic bronchial asthma.', 'subject score': 888, 'object score': 901}, 'PMID:151547': {'publication date': '1978 Jul', 'sentence': 'Ipratropium bromide, salbutamol and prednisolone in bronchial asthma and chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:17045197': {'publication date': '2006', 'sentence': 'Synthetic glucocorticoids such as dexamethasone and prednisolone have for decades been the cornerstone for the clinical treatment of inflammatory diseases, such as rheumatoid arthritis and asthma, and in some lymphoid cancers, yet its prolonged use has undesirable side effects such as obesity, diabetes, immune suppression and osteoporosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:20798102': {'publication date': '2010 Sep', 'sentence': 'BET 2: dexamethasone versus prednisolone in asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:2371579': {'publication date': '1990 Apr', 'sentence': 'Inhaled budesonide was an effective long term substitute for prednisolone in chronic asthma.', 'subject score': 1000, 'object score': 888}, 'PMID:3019017': {'publication date': '1986 Jul 18', 'sentence': 'The results are discussed with respect to the reconstituting effect of prednisolone on beta-adrenergic responsiveness in bronchial asthma after therapy induced tachyphylaxis.', 'subject score': 1000, 'object score': 1000}, 'PMID:35983570': {'publication date': '2022', 'sentence': 'More than two number of trigger factors (AOR = 1.88; 95% CI: 1.09-2.01), cold weather (AOR = 2.11; 95% CI: 1.51-2.42), exacerbations of asthma in the last 12 months (AOR = 2.01; 95% CI: 1.39-2.32), moderate persistent asthma (AOR = 3.47; 95% CI: 1.75-5.13), severe persistent asthma (AOR = 2.90; 95% CI: 2.56-3.98), patients on Salbutamol puff with Beclomethasone (AOR = 2.92; 95% CI: 2.50-3.45) and patients on Salbutamol puff with Beclomethasone and Prednisolone (AOR = 5.76; 95% CI: 4.02-6.02) use were significantly associated with uncontrolled asthma.', 'subject score': 1000, 'object score': 888}, 'PMID:4376852': {'publication date': '1974', 'sentence': 'A comparative study of the efficacy of inhaled beclomethasone and systemic prednisolone in bronchial asthma.', 'subject score': 888, 'object score': 1000}, 'PMID:4607265': {'publication date': '1974 Aug', 'sentence': 'The time-course of response to prednisolone in chronic bronchial asthma.', 'subject score': 1000, 'object score': 901}, 'PMID:482191': {'publication date': '1979 Jun', 'sentence': 'Malabsorption of prednisolone administered as enteric coated tablets was suspected following therapeutic failure in an asthmatic.', 'subject score': 1000, 'object score': 1000}, 'PMID:55678': {'publication date': '1976 Feb 21', 'sentence': 'Letter: Intravenous prednisolone in asthma.', 'subject score': 888, 'object score': 1000}, 'PMID:6330924': {'publication date': '1984 May', 'sentence': 'A fall in plasma angiotensin converting enzyme levels was seen after the addition of prednisolone in asthmatics both in vivo and in vitro.', 'subject score': 1000, 'object score': 966}, 'PMID:7194101': {'publication date': '1981 Mar', 'sentence': 'Prednisolone pharmacokinetics compared between night and day in asthmatic and normal subjects.', 'subject score': 888, 'object score': 1000}, 'PMID:7326867': {'publication date': '1981 Jun', 'sentence': 'MCR and CRE in corticosteroid-responsive asthmatics receiving prednisolone were significantly lower than in corticosteroid-resistant asthmatics taking prednisolone.', 'subject score': 1000, 'object score': 840}, 'PMID:7440853': {'publication date': '1980 Nov', 'sentence': 'The apparent half-lifes of prednisolone in the asthmatics and normals were 3.33 +/- 0.71 and 3.25 +/- 0.58 hr (mean +/- SD).', 'subject score': 1000, 'object score': 966}, 'PMID:8277607': {'publication date': '1993 Nov', 'sentence': 'These findings suggest that the reduction of BMD was related to the total dose of prednisolone and the duration of therapy in asthmatics.', 'subject score': 1000, 'object score': 966}, 'PMID:9776479': {'publication date': '1998 Jul', 'sentence': 'Our results also raised the possibility that PBMC-resistance to prednisolone in asthma may correlate with an increase in IL-2R positive PBMCs.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8227046,
-            "start": 568,
-            "end": 321528,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1096352': {'publication date': '1975 Jun', 'sentence': 'Intravenous prednisolone in chronic bronchial asthma.', 'subject score': 888, 'object score': 901}, 'PMID:151547': {'publication date': '1978 Jul', 'sentence': 'Ipratropium bromide, salbutamol and prednisolone in bronchial asthma and chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:17045197': {'publication date': '2006', 'sentence': 'Synthetic glucocorticoids such as dexamethasone and prednisolone have for decades been the cornerstone for the clinical treatment of inflammatory diseases, such as rheumatoid arthritis and asthma, and in some lymphoid cancers, yet its prolonged use has undesirable side effects such as obesity, diabetes, immune suppression and osteoporosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:20798102': {'publication date': '2010 Sep', 'sentence': 'BET 2: dexamethasone versus prednisolone in asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:2371579': {'publication date': '1990 Apr', 'sentence': 'Inhaled budesonide was an effective long term substitute for prednisolone in chronic asthma.', 'subject score': 1000, 'object score': 888}, 'PMID:3019017': {'publication date': '1986 Jul 18', 'sentence': 'The results are discussed with respect to the reconstituting effect of prednisolone on beta-adrenergic responsiveness in bronchial asthma after therapy induced tachyphylaxis.', 'subject score': 1000, 'object score': 1000}, 'PMID:35983570': {'publication date': '2022', 'sentence': 'More than two number of trigger factors (AOR = 1.88; 95% CI: 1.09-2.01), cold weather (AOR = 2.11; 95% CI: 1.51-2.42), exacerbations of asthma in the last 12 months (AOR = 2.01; 95% CI: 1.39-2.32), moderate persistent asthma (AOR = 3.47; 95% CI: 1.75-5.13), severe persistent asthma (AOR = 2.90; 95% CI: 2.56-3.98), patients on Salbutamol puff with Beclomethasone (AOR = 2.92; 95% CI: 2.50-3.45) and patients on Salbutamol puff with Beclomethasone and Prednisolone (AOR = 5.76; 95% CI: 4.02-6.02) use were significantly associated with uncontrolled asthma.', 'subject score': 1000, 'object score': 888}, 'PMID:4376852': {'publication date': '1974', 'sentence': 'A comparative study of the efficacy of inhaled beclomethasone and systemic prednisolone in bronchial asthma.', 'subject score': 888, 'object score': 1000}, 'PMID:4607265': {'publication date': '1974 Aug', 'sentence': 'The time-course of response to prednisolone in chronic bronchial asthma.', 'subject score': 1000, 'object score': 901}, 'PMID:482191': {'publication date': '1979 Jun', 'sentence': 'Malabsorption of prednisolone administered as enteric coated tablets was suspected following therapeutic failure in an asthmatic.', 'subject score': 1000, 'object score': 1000}, 'PMID:55678': {'publication date': '1976 Feb 21', 'sentence': 'Letter: Intravenous prednisolone in asthma.', 'subject score': 888, 'object score': 1000}, 'PMID:6330924': {'publication date': '1984 May', 'sentence': 'A fall in plasma angiotensin converting enzyme levels was seen after the addition of prednisolone in asthmatics both in vivo and in vitro.', 'subject score': 1000, 'object score': 966}, 'PMID:7194101': {'publication date': '1981 Mar', 'sentence': 'Prednisolone pharmacokinetics compared between night and day in asthmatic and normal subjects.', 'subject score': 888, 'object score': 1000}, 'PMID:7326867': {'publication date': '1981 Jun', 'sentence': 'MCR and CRE in corticosteroid-responsive asthmatics receiving prednisolone were significantly lower than in corticosteroid-resistant asthmatics taking prednisolone.', 'subject score': 1000, 'object score': 840}, 'PMID:7440853': {'publication date': '1980 Nov', 'sentence': 'The apparent half-lifes of prednisolone in the asthmatics and normals were 3.33 +/- 0.71 and 3.25 +/- 0.58 hr (mean +/- SD).', 'subject score': 1000, 'object score': 966}, 'PMID:8277607': {'publication date': '1993 Nov', 'sentence': 'These findings suggest that the reduction of BMD was related to the total dose of prednisolone and the duration of therapy in asthmatics.', 'subject score': 1000, 'object score': 966}, 'PMID:9776479': {'publication date': '1998 Jul', 'sentence': 'Our results also raised the possibility that PBMC-resistance to prednisolone in asthma may correlate with an increase in IL-2R positive PBMCs.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8405261",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:1096352",
-                "PMID:151547",
-                "PMID:17045197",
-                "PMID:20798102",
-                "PMID:2371579",
-                "PMID:3019017",
-                "PMID:35983570",
-                "PMID:4376852",
-                "PMID:4607265",
-                "PMID:482191",
-                "PMID:55678",
-                "PMID:6330924",
-                "PMID:7194101",
-                "PMID:7326867",
-                "PMID:7440853",
-                "PMID:8277607",
-                "PMID:9776479"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 324986,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:26714414': {'publication date': '2016 06', 'sentence': 'METHODS: In 126 adults (33 healthy control subjects, 31 patients with mild asthma, 32 patients with severe asthma, and 30 patients with prednisolone-dependent asthma) parameters of inflammation (peripheral blood eosinophils and neutrophils) and markers of hemostasis (endogenous thrombin potential [ETP], thrombin-antithrombin complex, plasmin-alpha2-antiplasmin complex, plasminogen activator inhibitor type 1 [PAI-1], D-dimer, and von Willebrand factor [vWF]) were measured in plasma.', 'subject score': 851, 'object score': 851}, 'PMID:30940770': {'publication date': '2019 Aug', 'sentence': 'Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study.', 'subject score': 1000, 'object score': 809}}",
-    "p2": {
-      "start": {
-        "identity": 321528,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-          "name": "chronic obstructive pulmonary disease",
-          "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-          "equivalent_curies": [
-            "MESH:D029424",
-            "MEDDRA:10010952",
-            "MEDDRA:10009025",
-            "ICD10:J44.9",
-            "UMLS:C1527303",
-            "NCIT:C3199",
-            "UMLS:C0024117",
-            "MEDDRA:10064611",
-            "MEDDRA:10009026",
-            "MEDDRA:10029972",
-            "DOID:3083",
-            "MONDO:0005002",
-            "MEDDRA:10009032",
-            "MEDDRA:10070975",
-            "EFO:0000341",
-            "SNOMEDCT:13645005",
-            "MEDDRA:10009033",
-            "HP:0006510",
-            "MEDDRA:10008828"
-          ],
-          "id": "MONDO:0005002",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic Obstructive Pulmonary Disease",
-            "chronic obstructive pulmonary disease",
-            "Chronic pulmonary obstruction",
-            "Chronic Airflow Obstruction",
-            "Chronic Obstructive Airway Disease",
-            "Pulmonary Disease, Chronic Obstructive"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://www.nhlbi.nih.gov/health-topics/copd",
-            "PMID:32800196",
-            "PMID:28513453",
-            "PMID:25943942",
-            "PMID:32745458"
-=======
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 324986,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-              "name": "chronic obstructive pulmonary disease",
-              "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-              "equivalent_curies": [
-                "MESH:D029424",
-                "MEDDRA:10010952",
-                "MEDDRA:10009025",
-                "ICD10:J44.9",
-                "UMLS:C1527303",
-                "NCIT:C3199",
-                "UMLS:C0024117",
-                "MEDDRA:10064611",
-                "MEDDRA:10009026",
-                "MEDDRA:10029972",
-                "DOID:3083",
-                "MONDO:0005002",
-                "MEDDRA:10009032",
-                "MEDDRA:10070975",
-                "EFO:0000341",
-                "SNOMEDCT:13645005",
-                "MEDDRA:10009033",
-                "HP:0006510",
-                "MEDDRA:10008828"
-              ],
-              "id": "MONDO:0005002",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic Obstructive Pulmonary Disease",
-                "chronic obstructive pulmonary disease",
-                "Chronic pulmonary obstruction",
-                "Chronic Airflow Obstruction",
-                "Chronic Obstructive Airway Disease",
-                "Pulmonary Disease, Chronic Obstructive"
-=======
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://www.nhlbi.nih.gov/health-topics/copd",
-                "PMID:32800196",
-                "PMID:28513453",
-                "PMID:25943942",
-                "PMID:32745458"
-=======
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 7681704,
-            "start": 568,
-            "end": 324986,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10581660': {'publication date': '1999 Oct', 'sentence': 'Reversibility with prednisolone is rarely seen in COPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:11081531': {'publication date': '2000 Oct 28', 'sentence': 'Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:11247590': {'publication date': '2001 Mar 03', 'sentence': 'Response to prednisolone in COPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:24076367': {'publication date': '2014 Aug', 'sentence': 'Effects of long-acting bronchodilators and prednisolone on inspiratory lung function parameters in stable COPD.', 'subject score': 1000, 'object score': 937}, 'PMID:28684161': {'publication date': '2017 09', 'sentence': 'In comparison with prednisolone, gamma-tocotrienol demonstrated better anti-oxidative efficacy, and protection against emphysema and lung function in COPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:7621841': {'publication date': '1995', 'sentence': 'The improvements in ventilation, exercise and anxiety scores following treatment with prednisolone were not reproduced by mianserin, suggesting that the effects of prednisolone in COPD are unlikely to be due to alterations in mood.', 'subject score': 1000, 'object score': 840}, 'PMID:7292376': {'publication date': '1981 Jan', 'sentence': 'Time course of response to prednisolone in chronic airflow obstruction.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0024117---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C1527303---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7844202",
-              "object": "MONDO:0005002",
-              "publications": [
-                "PMID:11247590",
-                "PMID:7621841",
-                "PMID:7292376",
-                "PMID:28684161",
-                "PMID:24076367",
-                "PMID:10581660",
-                "PMID:11081531"
-=======
-            "identity": 18365836,
-            "start": 568,
-            "end": 321528,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26714414': {'publication date': '2016 06', 'sentence': 'METHODS: In 126 adults (33 healthy control subjects, 31 patients with mild asthma, 32 patients with severe asthma, and 30 patients with prednisolone-dependent asthma) parameters of inflammation (peripheral blood eosinophils and neutrophils) and markers of hemostasis (endogenous thrombin potential [ETP], thrombin-antithrombin complex, plasmin-alpha2-antiplasmin complex, plasminogen activator inhibitor type 1 [PAI-1], D-dimer, and von Willebrand factor [vWF]) were measured in plasma.', 'subject score': 851, 'object score': 851}, 'PMID:30940770': {'publication date': '2019 Aug', 'sentence': 'Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study.', 'subject score': 1000, 'object score': 809}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "18736907",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:26714414",
-                "PMID:30940770"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:1822832': {'publication date': '1991', 'sentence': 'Effects of prednisolone, salbutamol and theophylline on bronchial hyperreactivity and leucocyte chemokinesis in guinea pigs.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13279221,
-            "start": 568,
-            "end": 321528,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1822832': {'publication date': '1991', 'sentence': 'Effects of prednisolone, salbutamol and theophylline on bronchial hyperreactivity and leucocyte chemokinesis in guinea pigs.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0085129---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "13564625",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:1822832"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10353577': {'publication date': '1999 May', 'sentence': 'Interleukin-5 mRNA was detected in all asthmatics before prednisolone therapy; however, after prednisolone therapy, IL-5 mRNA was only detected in non-GCS-responsive BHR asthmatics.', 'subject score': 888, 'object score': 966}, 'PMID:10581660': {'publication date': '1999 Oct', 'sentence': 'In outpatients with stable COPD and no signs of asthma or atopy, 2 weeks treatment with prednisolone seems to be of no value in choosing subsequent long-term therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:10707544': {'publication date': '1999 Dec', 'sentence': 'PSL reduced the parotid mass and improved control of the asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:1105522': {'publication date': '1975', 'sentence': 'A double-blind comparison of beclomethasone dipropionate aerosol and prednisolone in asthmatic patients.', 'subject score': 1000, 'object score': 888}, 'PMID:11068988': {'publication date': '2000 Oct', 'sentence': 'These findings suggest that prednisolone is considered to be effective medicine for asthma by suppressing eosinophil activation through IL-5.', 'subject score': 1000, 'object score': 1000}, 'PMID:11180687': {'publication date': '2001 Feb', 'sentence': 'Serum levels of eosinophil cationic protein and eosinophils in asthmatic children during a course of prednisolone therapy.', 'subject score': 888, 'object score': 888}, 'PMID:12400872': {'publication date': '2002 Sep', 'sentence': 'In contrast, the expression of GRalpha and c-jun mRNAs did not correlate with the IC50 for prednisolone and methylprednisolone in asthma patients.', 'subject score': 1000, 'object score': 888}, 'PMID:12580810': {'publication date': '2003 Jan', 'sentence': 'We aimed to determine the changes of intercellular adhesion molecule-1 (ICAM-1) and L-selectin expressed on peripheral blood (PB) T lymphocytes and natural killer (NK) cells in asthmatic children with acute exacerbation and after prednisolone therapy.', 'subject score': 888, 'object score': 888}, 'PMID:1290409': {'publication date': '1992 Dec', 'sentence': 'GM-CSF production by mononuclear cells from BA patients treated with prednisolone was lower than that of mononuclear cells from untreated BA patients.', 'subject score': 1000, 'object score': 901}, 'PMID:13434625': {'publication date': '1957', 'sentence': 'Prednisolone in the treatment of bronchial asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:13487472': {'publication date': '1957 Nov 10', 'sentence': '[Results of asthma therapy with prednisolone in comparison with previous experience with prednisone].', 'subject score': 1000, 'object score': 888}, 'PMID:13499912': {'publication date': '1958 Feb 01', 'sentence': 'Prednisolone compared with cortisone in treatment of children with chronic asthma.', 'subject score': 1000, 'object score': 888}, 'PMID:13551874': {'publication date': '1958 May', 'sentence': '[The problem of protracted treatment of bronchial asthma with prednisone & prednisolone].', 'subject score': 888, 'object score': 1000}, 'PMID:13573988': {'publication date': '1958 Jul 21', 'sentence': '[Action of nebulized prednisolone in vasomotor rhinitis & its inhibitory effect on the nasobronchial reflex in asthmatic patients].', 'subject score': 861, 'object score': 888}, 'PMID:13602885': {'publication date': '1958 Sep 10', 'sentence': '[Hydrocortisone, prednisone & prednisolone; recent findings on its use in the treatment of bronchial asthma & other allergic processes].', 'subject score': 888, 'object score': 1000}, 'PMID:13612182': {'publication date': '1958 Dec 13', 'sentence': 'Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum.', 'subject score': 1000, 'object score': 888}, 'PMID:13733794': {'publication date': '1961 Feb 04', 'sentence': 'Treatment of chronic asthma with prednisolone and the newer steroids.', 'subject score': 1000, 'object score': 888}, 'PMID:13989478': {'publication date': '1963 Jun', 'sentence': 'Prolonged treatment with prednisolone in children with asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:1405085': {'publication date': '1992 Apr', 'sentence': 'To reduce the dose of prednisolone for her asthma, administration of TJ96 was started in Dec.', 'subject score': 1000, 'object score': 1000}, 'PMID:15876307': {'publication date': '2005 Jun', 'sentence': 'CONCLUSION: This study has demonstrated that serum sCTLA-4 concentrations increased after allergen inhalation in sensitized asthmatic subjects, and that serum sCTLA-4 concentrations were downregulated by prednisolone therapy.', 'subject score': 888, 'object score': 773}}",
-    "p2": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7281328,
-            "start": 568,
-            "end": 321528,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10353577': {'publication date': '1999 May', 'sentence': 'Interleukin-5 mRNA was detected in all asthmatics before prednisolone therapy; however, after prednisolone therapy, IL-5 mRNA was only detected in non-GCS-responsive BHR asthmatics.', 'subject score': 888, 'object score': 966}, 'PMID:10581660': {'publication date': '1999 Oct', 'sentence': 'In outpatients with stable COPD and no signs of asthma or atopy, 2 weeks treatment with prednisolone seems to be of no value in choosing subsequent long-term therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:10707544': {'publication date': '1999 Dec', 'sentence': 'PSL reduced the parotid mass and improved control of the asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:1105522': {'publication date': '1975', 'sentence': 'A double-blind comparison of beclomethasone dipropionate aerosol and prednisolone in asthmatic patients.', 'subject score': 1000, 'object score': 888}, 'PMID:11068988': {'publication date': '2000 Oct', 'sentence': 'These findings suggest that prednisolone is considered to be effective medicine for asthma by suppressing eosinophil activation through IL-5.', 'subject score': 1000, 'object score': 1000}, 'PMID:11180687': {'publication date': '2001 Feb', 'sentence': 'Serum levels of eosinophil cationic protein and eosinophils in asthmatic children during a course of prednisolone therapy.', 'subject score': 888, 'object score': 888}, 'PMID:12400872': {'publication date': '2002 Sep', 'sentence': 'In contrast, the expression of GRalpha and c-jun mRNAs did not correlate with the IC50 for prednisolone and methylprednisolone in asthma patients.', 'subject score': 1000, 'object score': 888}, 'PMID:12580810': {'publication date': '2003 Jan', 'sentence': 'We aimed to determine the changes of intercellular adhesion molecule-1 (ICAM-1) and L-selectin expressed on peripheral blood (PB) T lymphocytes and natural killer (NK) cells in asthmatic children with acute exacerbation and after prednisolone therapy.', 'subject score': 888, 'object score': 888}, 'PMID:1290409': {'publication date': '1992 Dec', 'sentence': 'GM-CSF production by mononuclear cells from BA patients treated with prednisolone was lower than that of mononuclear cells from untreated BA patients.', 'subject score': 1000, 'object score': 901}, 'PMID:13434625': {'publication date': '1957', 'sentence': 'Prednisolone in the treatment of bronchial asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:13487472': {'publication date': '1957 Nov 10', 'sentence': '[Results of asthma therapy with prednisolone in comparison with previous experience with prednisone].', 'subject score': 1000, 'object score': 888}, 'PMID:13499912': {'publication date': '1958 Feb 01', 'sentence': 'Prednisolone compared with cortisone in treatment of children with chronic asthma.', 'subject score': 1000, 'object score': 888}, 'PMID:13551874': {'publication date': '1958 May', 'sentence': '[The problem of protracted treatment of bronchial asthma with prednisone & prednisolone].', 'subject score': 888, 'object score': 1000}, 'PMID:13573988': {'publication date': '1958 Jul 21', 'sentence': '[Action of nebulized prednisolone in vasomotor rhinitis & its inhibitory effect on the nasobronchial reflex in asthmatic patients].', 'subject score': 861, 'object score': 888}, 'PMID:13602885': {'publication date': '1958 Sep 10', 'sentence': '[Hydrocortisone, prednisone & prednisolone; recent findings on its use in the treatment of bronchial asthma & other allergic processes].', 'subject score': 888, 'object score': 1000}, 'PMID:13612182': {'publication date': '1958 Dec 13', 'sentence': 'Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum.', 'subject score': 1000, 'object score': 888}, 'PMID:13733794': {'publication date': '1961 Feb 04', 'sentence': 'Treatment of chronic asthma with prednisolone and the newer steroids.', 'subject score': 1000, 'object score': 888}, 'PMID:13989478': {'publication date': '1963 Jun', 'sentence': 'Prolonged treatment with prednisolone in children with asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:1405085': {'publication date': '1992 Apr', 'sentence': 'To reduce the dose of prednisolone for her asthma, administration of TJ96 was started in Dec.', 'subject score': 1000, 'object score': 1000}, 'PMID:15876307': {'publication date': '2005 Jun', 'sentence': 'CONCLUSION: This study has demonstrated that serum sCTLA-4 concentrations increased after allergen inhalation in sensitized asthmatic subjects, and that serum sCTLA-4 concentrations were downregulated by prednisolone therapy.', 'subject score': 888, 'object score': 773}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7430895",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:10353577",
-                "PMID:10581660",
-                "PMID:10707544",
-                "PMID:1105522",
-                "PMID:11068988",
-                "PMID:11180687",
-                "PMID:12400872",
-                "PMID:12580810",
-                "PMID:1290409",
-                "PMID:13434625",
-                "PMID:13487472",
-                "PMID:13499912",
-                "PMID:13551874",
-                "PMID:13573988",
-                "PMID:13602885",
-                "PMID:13612182",
-                "PMID:13733794",
-                "PMID:13989478",
-                "PMID:1405085",
-                "PMID:15876307"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:13711958': {'publication date': '1961 Jan', 'sentence': 'Reduction of maintenance doses of prednisolone in bronchial asthma by the concurrent use of hydroxyzine.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10366389,
-            "start": 568,
-            "end": 321528,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13711958': {'publication date': '1961 Jan', 'sentence': 'Reduction of maintenance doses of prednisolone in bronchial asthma by the concurrent use of hydroxyzine.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:disrupts---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10594561",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:13711958"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:15929952': {'publication date': '2005 Jun', 'sentence': 'Alveolar NO concentration was increased in patients with refractory asthma (7.1 ppb) compared with mild-to-moderate asthma (3.4 ppb) and normal controls (3.4 ppb) and reduced by treatment with prednisolone.', 'subject score': 1000, 'object score': 916}}",
-    "p2": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11604490,
-            "start": 568,
-            "end": 321528,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15929952': {'publication date': '2005 Jun', 'sentence': 'Alveolar NO concentration was increased in patients with refractory asthma (7.1 ppb) compared with mild-to-moderate asthma (3.4 ppb) and normal controls (3.4 ppb) and reduced by treatment with prednisolone.', 'subject score': 1000, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:prevents---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11858005",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:15929952"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:5911594': {'publication date': '1966 Jul', 'sentence': 'The effect of small doses of prednisolone on the incidence of subcutaneous sarcomas induced by 3-methylcholanthrene in virgin female Swiss mice.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 322059,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005089",
-          "name": "sarcoma",
-          "description": "A connective tissue neoplasm formed by proliferation of mesodermal cells. Bone and soft tissue sarcomas are the main types of sarcoma. Sarcoma is usually highly malignant. [HPO:sdoelken]; A connective tissue neoplasm formed by proliferation of mesodermal cells. Bone and soft tissue sarcomas are the main types of sarcoma. Sarcoma is usually highly malignant. // COMMENTS: A sarcoma (from the Greek sarx meaning flesh) is a general term describing a malignant neoplasm, or cancer, that arises from transformed connective tissue cells such as bone, cartilage and fat cells, which originate from embryonic mesoderm. This is in contrast to carcinomas, which are of epithelial origin (breast, colon, pancreas, and others). However, due to an evolving understanding of tissue origin, the term sarcoma is sometimes applied to tumors now known to arise from epithelial tissue. The term soft tissue sarcoma is used to describe tumors of soft tissue, which includes elements that are in connective tissue, but not derived from it (such as muscles and blood vessels).; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "UMLS:C0153519",
-            "ICD9:171.9",
-            "MONDO:0005089",
-            "MESH:D012509",
-            "SNOMEDCT:1187396000",
-            "SNOMEDCT:424413001",
-            "HP:0100242",
-            "EFO:0000691",
-            "DOID:1115",
-            "NCIT:C9118",
-            "UMLS:C1261473",
-            "MEDDRA:10039494",
-            "MEDDRA:10039491"
-          ],
-          "id": "MONDO:0005089",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Malignant neoplasm of connective and other soft tissue, site unspecified",
-            "Sarcoma",
-            "sarcoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/sarcoma",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://cancergenome.nih.gov/cancersselected/sarcoma",
-            "http://www.cancer.gov/dictionary?cdrid=45562",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322059,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005089",
-              "name": "sarcoma",
-              "description": "A connective tissue neoplasm formed by proliferation of mesodermal cells. Bone and soft tissue sarcomas are the main types of sarcoma. Sarcoma is usually highly malignant. [HPO:sdoelken]; A connective tissue neoplasm formed by proliferation of mesodermal cells. Bone and soft tissue sarcomas are the main types of sarcoma. Sarcoma is usually highly malignant. // COMMENTS: A sarcoma (from the Greek sarx meaning flesh) is a general term describing a malignant neoplasm, or cancer, that arises from transformed connective tissue cells such as bone, cartilage and fat cells, which originate from embryonic mesoderm. This is in contrast to carcinomas, which are of epithelial origin (breast, colon, pancreas, and others). However, due to an evolving understanding of tissue origin, the term sarcoma is sometimes applied to tumors now known to arise from epithelial tissue. The term soft tissue sarcoma is used to describe tumors of soft tissue, which includes elements that are in connective tissue, but not derived from it (such as muscles and blood vessels).; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "UMLS:C0153519",
-                "ICD9:171.9",
-                "MONDO:0005089",
-                "MESH:D012509",
-                "SNOMEDCT:1187396000",
-                "SNOMEDCT:424413001",
-                "HP:0100242",
-                "EFO:0000691",
-                "DOID:1115",
-                "NCIT:C9118",
-                "UMLS:C1261473",
-                "MEDDRA:10039494",
-                "MEDDRA:10039491"
-              ],
-              "id": "MONDO:0005089",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Malignant neoplasm of connective and other soft tissue, site unspecified",
-                "Sarcoma",
-                "sarcoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/sarcoma",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://cancergenome.nih.gov/cancersselected/sarcoma",
-                "http://www.cancer.gov/dictionary?cdrid=45562",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25504825,
-            "start": 568,
-            "end": 322059,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:5911594': {'publication date': '1966 Jul', 'sentence': 'The effect of small doses of prednisolone on the incidence of subcutaneous sarcomas induced by 3-methylcholanthrene in virgin female Swiss mice.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C1261473---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "25959730",
-              "object": "MONDO:0005089",
-              "publications": [
-                "PMID:5911594"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:3745792': {'publication date': '1986', 'sentence': '[Effects of chromocarb diethylamine and prednisolone in experimental uveitis induced by clove oil in rabbits].', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 316847,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
-          "name": "uveitis",
-          "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:1001231",
-            "UMLS:C0042164",
-            "DOID:13141",
-            "SNOMEDCT:128473001",
-            "MEDDRA:10046851",
-            "ICD10:H20.9",
-            "MONDO:0020283",
-            "MESH:D014605",
-            "NCIT:C26909",
-            "MEDDRA:10046855",
-            "HP:0000554",
-            "ORPHANET:98715"
-          ],
-          "id": "MONDO:0020283",
-          "category": "biolink:Disease",
-          "all_names": [
-            "uveitis",
-            "Uveitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316847,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
-              "name": "uveitis",
-              "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:1001231",
-                "UMLS:C0042164",
-                "DOID:13141",
-                "SNOMEDCT:128473001",
-                "MEDDRA:10046851",
-                "ICD10:H20.9",
-                "MONDO:0020283",
-                "MESH:D014605",
-                "NCIT:C26909",
-                "MEDDRA:10046855",
-                "HP:0000554",
-                "ORPHANET:98715"
-              ],
-              "id": "MONDO:0020283",
-              "category": "biolink:Disease",
-              "all_names": [
-                "uveitis",
-                "Uveitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25170826,
-            "start": 568,
-            "end": 316847,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3745792': {'publication date': '1986', 'sentence': '[Effects of chromocarb diethylamine and prednisolone in experimental uveitis induced by clove oil in rabbits].', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0042164---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "25621708",
-              "object": "MONDO:0020283",
-              "publications": [
-                "PMID:3745792"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:7836867': {'publication date': '1994', 'sentence': 'Among 121 CK-analogs studied, CK-17, CK-101A and CK103A have been identified as promising anti-inflammatory agents as potent as prednisolone in inhibiting lens proteins-induced inflammation and twice as potent as prednisolone in inhibiting endotoxin-and IL-1-induced uveitis.', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 316847,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
-          "name": "uveitis",
-          "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:1001231",
-            "UMLS:C0042164",
-            "DOID:13141",
-            "SNOMEDCT:128473001",
-            "MEDDRA:10046851",
-            "ICD10:H20.9",
-            "MONDO:0020283",
-            "MESH:D014605",
-            "NCIT:C26909",
-            "MEDDRA:10046855",
-            "HP:0000554",
-            "ORPHANET:98715"
-          ],
-          "id": "MONDO:0020283",
-          "category": "biolink:Disease",
-          "all_names": [
-            "uveitis",
-            "Uveitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316847,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
-              "name": "uveitis",
-              "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:1001231",
-                "UMLS:C0042164",
-                "DOID:13141",
-                "SNOMEDCT:128473001",
-                "MEDDRA:10046851",
-                "ICD10:H20.9",
-                "MONDO:0020283",
-                "MESH:D014605",
-                "NCIT:C26909",
-                "MEDDRA:10046855",
-                "HP:0000554",
-                "ORPHANET:98715"
-              ],
-              "id": "MONDO:0020283",
-              "category": "biolink:Disease",
-              "all_names": [
-                "uveitis",
-                "Uveitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26214984,
-            "start": 568,
-            "end": 316847,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7836867': {'publication date': '1994', 'sentence': 'Among 121 CK-analogs studied, CK-17, CK-101A and CK103A have been identified as promising anti-inflammatory agents as potent as prednisolone in inhibiting lens proteins-induced inflammation and twice as potent as prednisolone in inhibiting endotoxin-and IL-1-induced uveitis.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0042164---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "26677891",
-              "object": "MONDO:0020283",
-              "publications": [
-                "PMID:7836867"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:9715441': {'publication date': '1998 Aug', 'sentence': 'Interleukin-1 (IL-1) blockers, CK 127 and CK 129, were found to inhibit IL-1-induced posterior uveitis very effectively at 3-10 mg/kg i.p. and were more potent than prednisolone which required at least 20 mg/kg i.p. to achieve the same level of anti-uveitis action.', 'subject score': 1000, 'object score': 660}}",
-    "p2": {
-      "start": {
-        "identity": 316847,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
-          "name": "uveitis",
-          "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:1001231",
-            "UMLS:C0042164",
-            "DOID:13141",
-            "SNOMEDCT:128473001",
-            "MEDDRA:10046851",
-            "ICD10:H20.9",
-            "MONDO:0020283",
-            "MESH:D014605",
-            "NCIT:C26909",
-            "MEDDRA:10046855",
-            "HP:0000554",
-            "ORPHANET:98715"
-          ],
-          "id": "MONDO:0020283",
-          "category": "biolink:Disease",
-          "all_names": [
-            "uveitis",
-            "Uveitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316847,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
-              "name": "uveitis",
-              "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:1001231",
-                "UMLS:C0042164",
-                "DOID:13141",
-                "SNOMEDCT:128473001",
-                "MEDDRA:10046851",
-                "ICD10:H20.9",
-                "MONDO:0020283",
-                "MESH:D014605",
-                "NCIT:C26909",
-                "MEDDRA:10046855",
-                "HP:0000554",
-                "ORPHANET:98715"
-              ],
-              "id": "MONDO:0020283",
-              "category": "biolink:Disease",
-              "all_names": [
-                "uveitis",
-                "Uveitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 27185034,
-            "start": 568,
-            "end": 316847,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9715441': {'publication date': '1998 Aug', 'sentence': 'Interleukin-1 (IL-1) blockers, CK 127 and CK 129, were found to inhibit IL-1-induced posterior uveitis very effectively at 3-10 mg/kg i.p. and were more potent than prednisolone which required at least 20 mg/kg i.p. to achieve the same level of anti-uveitis action.', 'subject score': 1000, 'object score': 660}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0042164---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "27658451",
-              "object": "MONDO:0020283",
-              "publications": [
-                "PMID:9715441"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10379613': {'publication date': '1999 Jun', 'sentence': 'DISCUSSION: Allopurinol is more effective than prednisolone in treating EAU.', 'subject score': 1000, 'object score': 833}, 'PMID:15037212': {'publication date': '2004 Mar', 'sentence': 'Allopurinol was markedly more effective than prednisolone in treating experimental autoimmune uveitis and in combination with cyclosporine suppressed the inflammatory reaction of this condition more effectively than either agent alone.', 'subject score': 1000, 'object score': 833}, 'PMID:17707134': {'publication date': '2007 Oct', 'sentence': 'In this study we investigated the effect of prednisolone on CCL2 gene expression and viral load in an HIV-1-infected patient receiving high-dose prednisolone for severe uveitis.', 'subject score': 901, 'object score': 888}, 'PMID:1867297': {'publication date': '1991 Aug 15', 'sentence': 'Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis.', 'subject score': 1000, 'object score': 888}, 'PMID:22323881': {'publication date': '2012 Feb', 'sentence': 'Data was obtained relevant to demographic characteristics, anatomic classification, and laterality of uveitis, associated systemic disorder, dosage of cyclosporine and prednisolone, usage of other immunosuppressive drugs, visual acuity (VA), control of uveitic activity, and adverse effects during the cyclosporine use.', 'subject score': 1000, 'object score': 853}, 'PMID:23363352': {'publication date': '2013 Feb', 'sentence': 'Oral administration of prednisolone or meloxicam may be an effective treatment for cats with uveitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:24179690': {'publication date': '2013 Nov', 'sentence': 'He was treated with prednisolone for chronic uveitis before being switched to sulfasalazine 3 weeks prior to admission.', 'subject score': 1000, 'object score': 888}, 'PMID:24885484': {'publication date': '2014 May 29', 'sentence': 'Systemic prednisolone and valaciclovir resulted in prompt resolution of uveitis and hyphema.', 'subject score': 888, 'object score': 1000}, 'PMID:28910554': {'publication date': '2017 Sep 14', 'sentence': 'PURPOSE: The purpose of this study was to investigate the self-microemulsifying drug delivery systems (SMEDDS) for ophthalmic delivery of Prednisolone (PDN) to treat uveitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:31182107': {'publication date': '2019 Jun 10', 'sentence': 'Both patients were treated with topical treatment and prednisolone for uveitis; however, relapses occurred during the tapering of prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:33722510': {'publication date': '2021 Mar 12', 'sentence': 'To conclude aqueous humor pharmacoproteomic revealed the anti-inflammatory activity of the dapsone comparable to the prednisolone treatment in endotoxin induced uveitis.', 'subject score': 888, 'object score': 851}, 'PMID:34632076': {'publication date': '2021', 'sentence': 'The main outcome measures were ability to reduce prednisolone dose, ability to control uveitis, final visual acuity and time to treatment failure.', 'subject score': 888, 'object score': 1000}, 'PMID:35212595': {'publication date': '2022 Feb 25', 'sentence': 'The minimum dose of PSL to control intraocular inflammation (min dose of PSL) could be reduced in all cases after the introduction of ADA (from 16.9 +/- 7.9 mg to 6.3 +/- 3.1 mg).', 'subject score': 1000, 'object score': 1000}, 'PMID:36147056': {'publication date': '2022 Sep', 'sentence': 'The medical history included a pigmentary retinopathy (PR) at age of 22 and uveitis at age of 30, which were both treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:36930111': {'publication date': '2023 Mar 17', 'sentence': 'INTERVENTIONS: We increased the existing dose of prednisolone for the treatment of uveitis and started her on oral aspirin and kallidinogenase for CRVO.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316847,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
-          "name": "uveitis",
-          "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:1001231",
-            "UMLS:C0042164",
-            "DOID:13141",
-            "SNOMEDCT:128473001",
-            "MEDDRA:10046851",
-            "ICD10:H20.9",
-            "MONDO:0020283",
-            "MESH:D014605",
-            "NCIT:C26909",
-            "MEDDRA:10046855",
-            "HP:0000554",
-            "ORPHANET:98715"
-          ],
-          "id": "MONDO:0020283",
-          "category": "biolink:Disease",
-          "all_names": [
-            "uveitis",
-            "Uveitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316847,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
-              "name": "uveitis",
-              "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:1001231",
-                "UMLS:C0042164",
-                "DOID:13141",
-                "SNOMEDCT:128473001",
-                "MEDDRA:10046851",
-                "ICD10:H20.9",
-                "MONDO:0020283",
-                "MESH:D014605",
-                "NCIT:C26909",
-                "MEDDRA:10046855",
-                "HP:0000554",
-                "ORPHANET:98715"
-              ],
-              "id": "MONDO:0020283",
-              "category": "biolink:Disease",
-              "all_names": [
-                "uveitis",
-                "Uveitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7333779,
-            "start": 568,
-            "end": 316847,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10379613': {'publication date': '1999 Jun', 'sentence': 'DISCUSSION: Allopurinol is more effective than prednisolone in treating EAU.', 'subject score': 1000, 'object score': 833}, 'PMID:15037212': {'publication date': '2004 Mar', 'sentence': 'Allopurinol was markedly more effective than prednisolone in treating experimental autoimmune uveitis and in combination with cyclosporine suppressed the inflammatory reaction of this condition more effectively than either agent alone.', 'subject score': 1000, 'object score': 833}, 'PMID:17707134': {'publication date': '2007 Oct', 'sentence': 'In this study we investigated the effect of prednisolone on CCL2 gene expression and viral load in an HIV-1-infected patient receiving high-dose prednisolone for severe uveitis.', 'subject score': 901, 'object score': 888}, 'PMID:1867297': {'publication date': '1991 Aug 15', 'sentence': 'Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis.', 'subject score': 1000, 'object score': 888}, 'PMID:22323881': {'publication date': '2012 Feb', 'sentence': 'Data was obtained relevant to demographic characteristics, anatomic classification, and laterality of uveitis, associated systemic disorder, dosage of cyclosporine and prednisolone, usage of other immunosuppressive drugs, visual acuity (VA), control of uveitic activity, and adverse effects during the cyclosporine use.', 'subject score': 1000, 'object score': 853}, 'PMID:23363352': {'publication date': '2013 Feb', 'sentence': 'Oral administration of prednisolone or meloxicam may be an effective treatment for cats with uveitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:24179690': {'publication date': '2013 Nov', 'sentence': 'He was treated with prednisolone for chronic uveitis before being switched to sulfasalazine 3 weeks prior to admission.', 'subject score': 1000, 'object score': 888}, 'PMID:24885484': {'publication date': '2014 May 29', 'sentence': 'Systemic prednisolone and valaciclovir resulted in prompt resolution of uveitis and hyphema.', 'subject score': 888, 'object score': 1000}, 'PMID:28910554': {'publication date': '2017 Sep 14', 'sentence': 'PURPOSE: The purpose of this study was to investigate the self-microemulsifying drug delivery systems (SMEDDS) for ophthalmic delivery of Prednisolone (PDN) to treat uveitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:31182107': {'publication date': '2019 Jun 10', 'sentence': 'Both patients were treated with topical treatment and prednisolone for uveitis; however, relapses occurred during the tapering of prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:33722510': {'publication date': '2021 Mar 12', 'sentence': 'To conclude aqueous humor pharmacoproteomic revealed the anti-inflammatory activity of the dapsone comparable to the prednisolone treatment in endotoxin induced uveitis.', 'subject score': 888, 'object score': 851}, 'PMID:34632076': {'publication date': '2021', 'sentence': 'The main outcome measures were ability to reduce prednisolone dose, ability to control uveitis, final visual acuity and time to treatment failure.', 'subject score': 888, 'object score': 1000}, 'PMID:35212595': {'publication date': '2022 Feb 25', 'sentence': 'The minimum dose of PSL to control intraocular inflammation (min dose of PSL) could be reduced in all cases after the introduction of ADA (from 16.9 +/- 7.9 mg to 6.3 +/- 3.1 mg).', 'subject score': 1000, 'object score': 1000}, 'PMID:36147056': {'publication date': '2022 Sep', 'sentence': 'The medical history included a pigmentary retinopathy (PR) at age of 22 and uveitis at age of 30, which were both treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:36930111': {'publication date': '2023 Mar 17', 'sentence': 'INTERVENTIONS: We increased the existing dose of prednisolone for the treatment of uveitis and started her on oral aspirin and kallidinogenase for CRVO.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0042164---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7485161",
-              "object": "MONDO:0020283",
-              "publications": [
-                "PMID:10379613",
-                "PMID:15037212",
-                "PMID:17707134",
-                "PMID:1867297",
-                "PMID:22323881",
-                "PMID:23363352",
-                "PMID:24179690",
-                "PMID:24885484",
-                "PMID:28910554",
-                "PMID:31182107",
-                "PMID:33722510",
-                "PMID:34632076",
-                "PMID:35212595",
-                "PMID:36147056",
-                "PMID:36930111"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:8846850': {'publication date': '1995 Dec', 'sentence': 'Diclofenac and prednisolone inhibit endotoxin-induced uveitis in rabbits.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 316847,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
-          "name": "uveitis",
-          "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:1001231",
-            "UMLS:C0042164",
-            "DOID:13141",
-            "SNOMEDCT:128473001",
-            "MEDDRA:10046851",
-            "ICD10:H20.9",
-            "MONDO:0020283",
-            "MESH:D014605",
-            "NCIT:C26909",
-            "MEDDRA:10046855",
-            "HP:0000554",
-            "ORPHANET:98715"
-          ],
-          "id": "MONDO:0020283",
-          "category": "biolink:Disease",
-          "all_names": [
-            "uveitis",
-            "Uveitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316847,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
-              "name": "uveitis",
-              "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:1001231",
-                "UMLS:C0042164",
-                "DOID:13141",
-                "SNOMEDCT:128473001",
-                "MEDDRA:10046851",
-                "ICD10:H20.9",
-                "MONDO:0020283",
-                "MESH:D014605",
-                "NCIT:C26909",
-                "MEDDRA:10046855",
-                "HP:0000554",
-                "ORPHANET:98715"
-              ],
-              "id": "MONDO:0020283",
-              "category": "biolink:Disease",
-              "all_names": [
-                "uveitis",
-                "Uveitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26737448,
-            "start": 568,
-            "end": 316847,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8846850': {'publication date': '1995 Dec', 'sentence': 'Diclofenac and prednisolone inhibit endotoxin-induced uveitis in rabbits.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:disrupts---None---None---None---UMLS:C0042164---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "27206106",
-              "object": "MONDO:0020283",
-              "publications": [
-                "PMID:8846850"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:10219770': {'publication date': '1999 Apr', 'sentence': 'In spite of the fact that prednisolone-based treatment of pemphigus patients has proved to be effective in controlling the disease, some undesirable effects associated with this form of treatment have prompted investigation into other therapeutic approaches.', 'subject score': 840, 'object score': 888}, 'PMID:31110731': {'publication date': '2019 May', 'sentence': 'Inadvertent treatment of hypoadrenalism with prednisolone in pemphigus: A case report.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 534914,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006594",
-          "name": "pemphigus",
-          "description": "A blistering skin disorder. Morphologically it is characterized by acantholysis and intraepidermal blister formation.; Group of chronic blistering diseases characterized histologically by ACANTHOLYSIS and blister formation within the EPIDERMIS.; Pemphigus is an autoimmune disorder. If you have it, your immune system attacks healthy cells in your skin and mouth, causing blisters and sores. No one knows the cause. Pemphigus does not spread from person to person. It does not appear to be inherited. But some people's genes put them more at risk for pemphigus. Pemphigoid is also an autoimmune skin disease. It leads to deep blisters that do not break easily. Pemphigoid is most common in older adults and may be fatal for older, sick patients. Doctors diagnose pemphigus with a physical exam, a biopsy, and blood tests. The treatment of pemphigus and pemphigoid is the same: one or more medicines to control symptoms. These may include: Steroids, which reduce inflammation Drugs that suppress the immune system response Antibiotics to treat associated infections  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:1000749",
-            "MEDDRA:10034280",
-            "NCIT:C34909",
-            "SNOMEDCT:65172003",
-            "ICD9:694.4",
-            "DOID:0080850",
-            "DOID:9182",
-            "MONDO:0006594",
-            "UMLS:C0030807",
-            "ICD10:L10",
-            "ICD10:L10.2",
-            "MESH:D010392"
-          ],
-          "id": "MONDO:0006594",
-          "category": "biolink:Disease",
-          "all_names": [
-            "pemphigus foliaceus",
-            "Pemphigus",
-            "pemphigus"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://rarediseases.info.nih.gov/diseases/7352/pemphigus",
-            "https://en.wikipedia.org/wiki/pemphigus",
-            "https://rarediseases.org/rare-diseases/pemphigus/",
-            "https://medlineplus.gov/pemphigus.htm",
-            "https://dermnetnz.org/topics/pemphigus-foliaceus/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 534914,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006594",
-              "name": "pemphigus",
-              "description": "A blistering skin disorder. Morphologically it is characterized by acantholysis and intraepidermal blister formation.; Group of chronic blistering diseases characterized histologically by ACANTHOLYSIS and blister formation within the EPIDERMIS.; Pemphigus is an autoimmune disorder. If you have it, your immune system attacks healthy cells in your skin and mouth, causing blisters and sores. No one knows the cause. Pemphigus does not spread from person to person. It does not appear to be inherited. But some people's genes put them more at risk for pemphigus. Pemphigoid is also an autoimmune skin disease. It leads to deep blisters that do not break easily. Pemphigoid is most common in older adults and may be fatal for older, sick patients. Doctors diagnose pemphigus with a physical exam, a biopsy, and blood tests. The treatment of pemphigus and pemphigoid is the same: one or more medicines to control symptoms. These may include: Steroids, which reduce inflammation Drugs that suppress the immune system response Antibiotics to treat associated infections  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:1000749",
-                "MEDDRA:10034280",
-                "NCIT:C34909",
-                "SNOMEDCT:65172003",
-                "ICD9:694.4",
-                "DOID:0080850",
-                "DOID:9182",
-                "MONDO:0006594",
-                "UMLS:C0030807",
-                "ICD10:L10",
-                "ICD10:L10.2",
-                "MESH:D010392"
-              ],
-              "id": "MONDO:0006594",
-              "category": "biolink:Disease",
-              "all_names": [
-                "pemphigus foliaceus",
-                "Pemphigus",
-                "pemphigus"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://rarediseases.info.nih.gov/diseases/7352/pemphigus",
-                "https://en.wikipedia.org/wiki/pemphigus",
-                "https://rarediseases.org/rare-diseases/pemphigus/",
-                "https://medlineplus.gov/pemphigus.htm",
-                "https://dermnetnz.org/topics/pemphigus-foliaceus/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7178200,
-            "start": 568,
-            "end": 534914,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10219770': {'publication date': '1999 Apr', 'sentence': 'In spite of the fact that prednisolone-based treatment of pemphigus patients has proved to be effective in controlling the disease, some undesirable effects associated with this form of treatment have prompted investigation into other therapeutic approaches.', 'subject score': 840, 'object score': 888}, 'PMID:31110731': {'publication date': '2019 May', 'sentence': 'Inadvertent treatment of hypoadrenalism with prednisolone in pemphigus: A case report.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0030807---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7323744",
-              "object": "MONDO:0006594",
-              "publications": [
-                "PMID:10219770",
-                "PMID:31110731"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 318890,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12890207': {'publication date': '2003 Jul', 'sentence': 'OBJECTIVES: The present study describes our experience of the addition of mycophenolate mofetil (MMF) to prednisolone in the management of severe, refractory pemphigus.', 'subject score': 1000, 'object score': 851}, 'PMID:13355751': {'publication date': '1955', 'sentence': '[Urinary steroids in pemphigus patients treated with cortisone, prednisone and prednisolone].', 'subject score': 1000, 'object score': 888}, 'PMID:19922532': {'publication date': '2010 Apr', 'sentence': 'OBJECTIVES: To report the clinical and immunological responses of 21 patients with pemphigus refractory to prednisolone and azathioprine or mycophenolate mofetil treated in our department with a standard protocol of monthly PPC.', 'subject score': 1000, 'object score': 1000}, 'PMID:22173051': {'publication date': '2012 May', 'sentence': 'A 77-year-old man treated with prednisolone for pemphigus developed severe sepsis by Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.', 'subject score': 1000, 'object score': 1000}, 'PMID:31865535': {'publication date': '2019 Dec 21', 'sentence': 'The aim of this study was to compare the efficacy and safety of each of these agents as adjuvant therapy with the corticosteroid prednisolone for the treatment of pemphigus, using standardized outcome parameters.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 534914,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-          "name": "rheumatoid arthritis",
-          "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C2884",
-            "PSY:44570",
-            "EFO:0000685",
-            "ICD9:714.0",
-            "KEGG.DISEASE:05323",
-            "MONDO:0008383",
-            "UMLS:C0003873",
-            "UMLS:C1306838",
-            "UMLS:C1833448",
-            "MEDDRA:10037740",
-            "MEDDRA:10039073",
-            "OMIM:180300",
-            "MESH:D001172",
-            "MEDDRA:10003268",
-            "HP:0001370",
-            "ORPHANET:284130",
-            "SNOMEDCT:69896004",
-            "ICD10:M06.9",
-            "DOID:7148",
-            "MEDDRA:10036856",
-            "MEDDRA:10042952"
-          ],
-          "id": "MONDO:0008383",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Proliferative arthritis",
-            "Arthritis, Rheumatoid",
-            "rheumatoid arthritis",
-            "Rheumatoid arthritis",
-            "Rheumatoid Arthritis",
-            "Rheumatoid arthritis related phenotypic feature",
-            "Rheumatoid arthritis, susceptibility to"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006594",
-          "name": "pemphigus",
-          "description": "A blistering skin disorder. Morphologically it is characterized by acantholysis and intraepidermal blister formation.; Group of chronic blistering diseases characterized histologically by ACANTHOLYSIS and blister formation within the EPIDERMIS.; Pemphigus is an autoimmune disorder. If you have it, your immune system attacks healthy cells in your skin and mouth, causing blisters and sores. No one knows the cause. Pemphigus does not spread from person to person. It does not appear to be inherited. But some people's genes put them more at risk for pemphigus. Pemphigoid is also an autoimmune skin disease. It leads to deep blisters that do not break easily. Pemphigoid is most common in older adults and may be fatal for older, sick patients. Doctors diagnose pemphigus with a physical exam, a biopsy, and blood tests. The treatment of pemphigus and pemphigoid is the same: one or more medicines to control symptoms. These may include: Steroids, which reduce inflammation Drugs that suppress the immune system response Antibiotics to treat associated infections  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:1000749",
-            "MEDDRA:10034280",
-            "NCIT:C34909",
-            "SNOMEDCT:65172003",
-            "ICD9:694.4",
-            "DOID:0080850",
-            "DOID:9182",
-            "MONDO:0006594",
-            "UMLS:C0030807",
-            "ICD10:L10",
-            "ICD10:L10.2",
-            "MESH:D010392"
-          ],
-          "id": "MONDO:0006594",
-          "category": "biolink:Disease",
-          "all_names": [
-            "pemphigus foliaceus",
-            "Pemphigus",
-            "pemphigus"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-            "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-            "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-=======
-            "https://rarediseases.info.nih.gov/diseases/7352/pemphigus",
-            "https://en.wikipedia.org/wiki/pemphigus",
-            "https://rarediseases.org/rare-diseases/pemphigus/",
-            "https://medlineplus.gov/pemphigus.htm",
-            "https://dermnetnz.org/topics/pemphigus-foliaceus/"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 318890,
-=======
-            "identity": 534914,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-              "name": "rheumatoid arthritis",
-              "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C2884",
-                "PSY:44570",
-                "EFO:0000685",
-                "ICD9:714.0",
-                "KEGG.DISEASE:05323",
-                "MONDO:0008383",
-                "UMLS:C0003873",
-                "UMLS:C1306838",
-                "UMLS:C1833448",
-                "MEDDRA:10037740",
-                "MEDDRA:10039073",
-                "OMIM:180300",
-                "MESH:D001172",
-                "MEDDRA:10003268",
-                "HP:0001370",
-                "ORPHANET:284130",
-                "SNOMEDCT:69896004",
-                "ICD10:M06.9",
-                "DOID:7148",
-                "MEDDRA:10036856",
-                "MEDDRA:10042952"
-              ],
-              "id": "MONDO:0008383",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Proliferative arthritis",
-                "Arthritis, Rheumatoid",
-                "rheumatoid arthritis",
-                "Rheumatoid arthritis",
-                "Rheumatoid Arthritis",
-                "Rheumatoid arthritis related phenotypic feature",
-                "Rheumatoid arthritis, susceptibility to"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006594",
-              "name": "pemphigus",
-              "description": "A blistering skin disorder. Morphologically it is characterized by acantholysis and intraepidermal blister formation.; Group of chronic blistering diseases characterized histologically by ACANTHOLYSIS and blister formation within the EPIDERMIS.; Pemphigus is an autoimmune disorder. If you have it, your immune system attacks healthy cells in your skin and mouth, causing blisters and sores. No one knows the cause. Pemphigus does not spread from person to person. It does not appear to be inherited. But some people's genes put them more at risk for pemphigus. Pemphigoid is also an autoimmune skin disease. It leads to deep blisters that do not break easily. Pemphigoid is most common in older adults and may be fatal for older, sick patients. Doctors diagnose pemphigus with a physical exam, a biopsy, and blood tests. The treatment of pemphigus and pemphigoid is the same: one or more medicines to control symptoms. These may include: Steroids, which reduce inflammation Drugs that suppress the immune system response Antibiotics to treat associated infections  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:1000749",
-                "MEDDRA:10034280",
-                "NCIT:C34909",
-                "SNOMEDCT:65172003",
-                "ICD9:694.4",
-                "DOID:0080850",
-                "DOID:9182",
-                "MONDO:0006594",
-                "UMLS:C0030807",
-                "ICD10:L10",
-                "ICD10:L10.2",
-                "MESH:D010392"
-              ],
-              "id": "MONDO:0006594",
-              "category": "biolink:Disease",
-              "all_names": [
-                "pemphigus foliaceus",
-                "Pemphigus",
-                "pemphigus"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-                "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-                "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-=======
-                "https://rarediseases.info.nih.gov/diseases/7352/pemphigus",
-                "https://en.wikipedia.org/wiki/pemphigus",
-                "https://rarediseases.org/rare-diseases/pemphigus/",
-                "https://medlineplus.gov/pemphigus.htm",
-                "https://dermnetnz.org/topics/pemphigus-foliaceus/"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 7118588,
-            "start": 568,
-            "end": 318890,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10193433': {'publication date': '1999 Mar', 'sentence': 'One reason for the good clinical effects of prednisolone in RA could be a down-regulation of adhesion and phagocytosis receptors on monocytes.', 'subject score': 1000, 'object score': 1000}, 'PMID:10531077': {'publication date': '1999 Nov', 'sentence': 'The data suggest that the beneficial effects of prednisolone are not as clear cut in established rheumatoid arthritis as in early disease.', 'subject score': 1000, 'object score': 901}, 'PMID:10996038': {'publication date': '2000 Sep', 'sentence': 'We compared lymphocyte-suppressive potencies of prednisolone and methylprednisolone in rheumatoid arthritis (RA).', 'subject score': 1000, 'object score': 1000}, 'PMID:111944': {'publication date': '1979 Apr', 'sentence': 'Relapses occurring in patients on a stable dose of prednisolone were commonly associated with the development of rheumatoid disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:13221414': {'publication date': '1955 Jan 22', 'sentence': 'Studies on metacortandralone and metacortandracin in rheumatoid arthritis; antirheumatic potency, metabolic effects, and hormonal properties.', 'subject score': 1000, 'object score': 1000}, 'PMID:13295650': {'publication date': '1956 Feb', 'sentence': 'Clinical and metabolic effects of prednisone and prednisolone in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:13333138': {'publication date': '1956 Jul 07', 'sentence': 'Hydrocortisone versus prednisolone in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:13407235': {'publication date': '1957 Mar', 'sentence': 'Prednisone and prednisolone in rheumatoid arthritis; an evaluation of their therapeutic efficiency.', 'subject score': 1000, 'object score': 1000}, 'PMID:13540584': {'publication date': '1958 Apr 19', 'sentence': 'Hydrocortisone and prednisolone in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:13742338': {'publication date': '1961 Jan', 'sentence': 'Prednisolone in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:14391515': {'publication date': '1955 Jul', 'sentence': 'Metacortandracin and delta 1 dehydro-hydrocortisone in rheumatoid arthritis.', 'subject score': 923, 'object score': 1000}, 'PMID:15140776': {'publication date': '2004 Jun', 'sentence': 'A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15206742': {'publication date': '2003', 'sentence': 'During 6 months of treating the RA patients with prednisolone or methotrexate, and the OP patients with raloxifene or etidronate and calcium there were significant therapeutic responses and a significant trend towards a reduction in levels of neopterin in RA patients receiving methotrexate but no changes in the profiles of tryptophan metabolites.', 'subject score': 1000, 'object score': 901}, 'PMID:15941834': {'publication date': '2006 Jan', 'sentence': 'The NPY/cortisol ratio was increased in SLE with/without prednisolone, and in RA with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:15956010': {'publication date': '2005 Jun 13', 'sentence': 'Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial.', 'subject score': 1000, 'object score': 901}, 'PMID:16255010': {'publication date': '2005 Nov', 'sentence': 'Therefore, the data support the use of low-dose prednisolone as an adjunct to DMARDs in early active RA.', 'subject score': 901, 'object score': 861}, 'PMID:16255011': {'publication date': '2005 Nov', 'sentence': 'CONCLUSION: The very low daily dose of 5 mg prednisolone given over 2 years in combination with background DMARD therapy substantially decreased radiographic progression in early RA at low risk.', 'subject score': 851, 'object score': 901}, 'PMID:16646617': {'publication date': '2006', 'sentence': 'Prednisolone plus a disease-modifying antirheumatic drug improved outcomes in early rheumatoid arthritis.', 'subject score': 1000, 'object score': 901}, 'PMID:17045197': {'publication date': '2006', 'sentence': 'Synthetic glucocorticoids such as dexamethasone and prednisolone have for decades been the cornerstone for the clinical treatment of inflammatory diseases, such as rheumatoid arthritis and asthma, and in some lymphoid cancers, yet its prolonged use has undesirable side effects such as obesity, diabetes, immune suppression and osteoporosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:17213101': {'publication date': '2006 Jun', 'sentence': 'Prednisolone plus a disease modifying antirheumatic drug improved outcomes in early rheumatoid arthritis.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0003873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7262473",
-              "object": "MONDO:0008383",
-              "publications": [
-                "PMID:10193433",
-                "PMID:10531077",
-                "PMID:10996038",
-                "PMID:111944",
-                "PMID:13221414",
-                "PMID:13295650",
-                "PMID:13333138",
-                "PMID:13407235",
-                "PMID:13540584",
-                "PMID:13742338",
-                "PMID:14391515",
-                "PMID:15140776",
-                "PMID:15206742",
-                "PMID:15941834",
-                "PMID:15956010",
-                "PMID:16255010",
-                "PMID:16255011",
-                "PMID:16646617",
-                "PMID:17045197",
-                "PMID:17213101"
-=======
-            "identity": 10112284,
-            "start": 568,
-            "end": 534914,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12890207': {'publication date': '2003 Jul', 'sentence': 'OBJECTIVES: The present study describes our experience of the addition of mycophenolate mofetil (MMF) to prednisolone in the management of severe, refractory pemphigus.', 'subject score': 1000, 'object score': 851}, 'PMID:13355751': {'publication date': '1955', 'sentence': '[Urinary steroids in pemphigus patients treated with cortisone, prednisone and prednisolone].', 'subject score': 1000, 'object score': 888}, 'PMID:19922532': {'publication date': '2010 Apr', 'sentence': 'OBJECTIVES: To report the clinical and immunological responses of 21 patients with pemphigus refractory to prednisolone and azathioprine or mycophenolate mofetil treated in our department with a standard protocol of monthly PPC.', 'subject score': 1000, 'object score': 1000}, 'PMID:22173051': {'publication date': '2012 May', 'sentence': 'A 77-year-old man treated with prednisolone for pemphigus developed severe sepsis by Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.', 'subject score': 1000, 'object score': 1000}, 'PMID:31865535': {'publication date': '2019 Dec 21', 'sentence': 'The aim of this study was to compare the efficacy and safety of each of these agents as adjuvant therapy with the corticosteroid prednisolone for the treatment of pemphigus, using standardized outcome parameters.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0030807---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10335998",
-              "object": "MONDO:0006594",
-              "publications": [
-                "PMID:12890207",
-                "PMID:13355751",
-                "PMID:19922532",
-                "PMID:22173051",
-                "PMID:31865535"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 310720,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15109274': {'publication date': '2004', 'sentence': 'It has also been used in combination with other drugs for treating a number of dermatologic disorders, e.g. in combination with cimetidine for treating recalcitrant warts, with prednisolone for treating lichen planus, erythema multiforme and aphthous ulcers of the mouth.', 'subject score': 1000, 'object score': 901}, 'PMID:9798228': {'publication date': '1998 Oct', 'sentence': 'CONCLUSIONS: The addition of levamisole to prednisolone may produce improved results in the management of erosive lichen planus, erythema multiforme, mucous membrane pemphigoid, and early pemphigus vulgaris.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 538013,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006052",
-          "name": "pulmonary tuberculosis",
-          "description": "A bacterial infection that affects the lungs and is caused by Mycobacterium tuberculosis. Most patients with tuberculosis do not have symptoms (latent tuberculosis) and are not contagious. When signs and symptoms occur (active tuberculosis), patients become contagious. The signs and symptoms include chronic cough with blood-tinged sputum, night sweats, fever, fatigue, and weight loss.; MYCOBACTERIUM infections of the lung.; A lung infection by Mycobacterium tuberculosis a slightly curved non-motile, aerobic, non-capsulated and non-spore forming strains of mycobacteria. [PMID:30345099]",
-          "equivalent_curies": [
-            "MONDO:0006052",
-            "MEDDRA:10046123",
-            "PSY:42300",
-            "ICD9:011",
-            "MEDDRA:10034980",
-            "SNOMEDCT:154283005",
-            "DOID:2957",
-            "SNOMEDCT:700272008",
-            "NCIT:C26899",
-            "EFO:1000049",
-            "MEDDRA:10037443",
-            "HP:0032262",
-            "MESH:D014397",
-            "ICD10:A15",
-            "UMLS:C0041327",
-            "MEDDRA:10037435",
-            "MEDDRA:10037440"
-          ],
-          "id": "MONDO:0006052",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Tuberculosis, Pulmonary",
-            "pulmonary tuberculosis",
-            "Pulmonary Tuberculosis",
-            "Pulmonary tuberculosis"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006572",
-          "name": "lichen planus",
-          "description": "A chronic, recurrent, pruritic inflammatory disorder of unknown etiology that affects the skin and mucus membranes. It presents with rashes and papules that tend to resolve spontaneously. It may be associated with hepatitis C. Certain drugs that contain arsenic or bismuth are associated with reactions mimicking lichen planus.; An inflammatory, pruritic disease of the skin and mucous membranes, which can be either generalized or localized. It is characterized by distinctive purplish, flat-topped papules having a predilection for the trunk and flexor surfaces. The lesions may be discrete or coalesce to form plaques. Histologically, there is a \"saw-tooth\" pattern of epidermal hyperplasia and vacuolar alteration of the basal layer of the epidermis along with an intense upper dermal inflammatory infiltrate composed predominantly of T-cells. Etiology is unknown.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10024429",
-            "ICD9:697.0",
-            "SNOMEDCT:4776004",
-            "UMLS:C0023646",
-            "MONDO:0006572",
-            "EFO:1000726",
-            "NCIT:C3189",
-            "MESH:D008010",
-            "DOID:9201",
-            "ICD10:L43"
-          ],
-          "id": "MONDO:0006572",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lichen planus",
-            "Lichen Planus",
-            "lichen planus"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "PMID:30345099",
-            "http://www.cdc.gov/tb/publications/factsheets/general/tb.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tuberculosis"
-=======
-            "http://en.wikipedia.org/wiki/lichen_planus"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 310720,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006052",
-              "name": "pulmonary tuberculosis",
-              "description": "A bacterial infection that affects the lungs and is caused by Mycobacterium tuberculosis. Most patients with tuberculosis do not have symptoms (latent tuberculosis) and are not contagious. When signs and symptoms occur (active tuberculosis), patients become contagious. The signs and symptoms include chronic cough with blood-tinged sputum, night sweats, fever, fatigue, and weight loss.; MYCOBACTERIUM infections of the lung.; A lung infection by Mycobacterium tuberculosis a slightly curved non-motile, aerobic, non-capsulated and non-spore forming strains of mycobacteria. [PMID:30345099]",
-              "equivalent_curies": [
-                "MONDO:0006052",
-                "MEDDRA:10046123",
-                "PSY:42300",
-                "ICD9:011",
-                "MEDDRA:10034980",
-                "SNOMEDCT:154283005",
-                "DOID:2957",
-                "SNOMEDCT:700272008",
-                "NCIT:C26899",
-                "EFO:1000049",
-                "MEDDRA:10037443",
-                "HP:0032262",
-                "MESH:D014397",
-                "ICD10:A15",
-                "UMLS:C0041327",
-                "MEDDRA:10037435",
-                "MEDDRA:10037440"
-              ],
-              "id": "MONDO:0006052",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Tuberculosis, Pulmonary",
-                "pulmonary tuberculosis",
-                "Pulmonary Tuberculosis",
-                "Pulmonary tuberculosis"
-=======
-            "identity": 538013,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006572",
-              "name": "lichen planus",
-              "description": "A chronic, recurrent, pruritic inflammatory disorder of unknown etiology that affects the skin and mucus membranes. It presents with rashes and papules that tend to resolve spontaneously. It may be associated with hepatitis C. Certain drugs that contain arsenic or bismuth are associated with reactions mimicking lichen planus.; An inflammatory, pruritic disease of the skin and mucous membranes, which can be either generalized or localized. It is characterized by distinctive purplish, flat-topped papules having a predilection for the trunk and flexor surfaces. The lesions may be discrete or coalesce to form plaques. Histologically, there is a \"saw-tooth\" pattern of epidermal hyperplasia and vacuolar alteration of the basal layer of the epidermis along with an intense upper dermal inflammatory infiltrate composed predominantly of T-cells. Etiology is unknown.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10024429",
-                "ICD9:697.0",
-                "SNOMEDCT:4776004",
-                "UMLS:C0023646",
-                "MONDO:0006572",
-                "EFO:1000726",
-                "NCIT:C3189",
-                "MESH:D008010",
-                "DOID:9201",
-                "ICD10:L43"
-              ],
-              "id": "MONDO:0006572",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lichen planus",
-                "Lichen Planus",
-                "lichen planus"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "PMID:30345099",
-                "http://www.cdc.gov/tb/publications/factsheets/general/tb.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tuberculosis"
-=======
-                "http://en.wikipedia.org/wiki/lichen_planus"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 7065400,
-            "start": 568,
-            "end": 310720,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10094169': {'publication date': '1999 Jan', 'sentence': 'OBJECTIVE: To appraise the adjunctive role of prednisolone (PN) in pulmonary tuberculosis (PTB) with toxic reactions.', 'subject score': 1000, 'object score': 1000}, 'PMID:13348299': {'publication date': '1956 Jun 06', 'sentence': '[Prednisone and prednisolone, anti-reactive elective drugs in pulmonary tuberculosis].', 'subject score': 1000, 'object score': 1000}, 'PMID:13672639': {'publication date': '1959 Jun', 'sentence': 'Prednisolone in pulmonary tuberculosis; case report.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0041327---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7206314",
-              "object": "MONDO:0006052",
-              "publications": [
-                "PMID:10094169",
-                "PMID:13348299",
-                "PMID:13672639"
-=======
-            "identity": 10927138,
-            "start": 568,
-            "end": 538013,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15109274': {'publication date': '2004', 'sentence': 'It has also been used in combination with other drugs for treating a number of dermatologic disorders, e.g. in combination with cimetidine for treating recalcitrant warts, with prednisolone for treating lichen planus, erythema multiforme and aphthous ulcers of the mouth.', 'subject score': 1000, 'object score': 901}, 'PMID:9798228': {'publication date': '1998 Oct', 'sentence': 'CONCLUSIONS: The addition of levamisole to prednisolone may produce improved results in the management of erosive lichen planus, erythema multiforme, mucous membrane pemphigoid, and early pemphigus vulgaris.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0023646---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11166362",
-              "object": "MONDO:0006572",
-              "publications": [
-                "PMID:15109274",
-                "PMID:9798228"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 4578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisone",
-          "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "HMDB:HMDB0014773",
-            "UMLS:C0032952",
-            "NCIT:C770",
-            "PUBCHEM.COMPOUND:5865",
-            "DrugCentral:2253",
-            "MESH:D011241",
-            "ATC:A07EA03",
-            "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-            "CAS:53-03-2",
-            "PDQ:CDR0000042487",
-            "PathWhiz.Compound:9120",
-            "KEGG.DRUG:D00473",
-            "DRUGBANK:DB00635",
-            "ATC:H02AB07",
-            "UNII:VB0R961HZT",
-            "NDDF:002164",
-            "CHEMBL.COMPOUND:CHEMBL635",
-            "CHEBI:8382",
-            "KEGG.COMPOUND:C07370",
-            "GTOPDB:7096",
-            "RXNORM:8640"
-          ],
-          "id": "PUBCHEM.COMPOUND:5865",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisone",
-            "Prednisone (USP)",
-            "PREDNISONE",
-            "1,2-dehydrocortisone",
-            "prednisone"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:32422522",
-            "PMID:18788725",
-            "PMID:11413487",
-            "PMID:20070106",
-            "PMID:378499",
-            "PMID:15646539",
-            "PMID:20014752",
-            "PMID:25618019",
-            "PMID:23571415",
-            "PMID:19586686"
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11464188': {'publication date': '2001 Aug', 'sentence': 'METHODS: Three patients with CP were treated with mycophenolate mofetil and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:14739497': {'publication date': '2004 Jan', 'sentence': 'Based on a diagnosis of anti-epiligrin cicatricial pemphigoid, he was treated with prednisolone, minocycline hydrochloride and nicotinamide.', 'subject score': 1000, 'object score': 824}, 'PMID:22727107': {'publication date': '2012 Jul', 'sentence': 'Treatment of mucous membrane pemphigoid with the combination of mycophenolate mofetil, dapsone, and prednisolone: a case series.', 'subject score': 1000, 'object score': 1000}, 'PMID:9798228': {'publication date': '1998 Oct', 'sentence': 'CONCLUSIONS: The addition of levamisole to prednisolone may produce improved results in the management of erosive lichen planus, erythema multiforme, mucous membrane pemphigoid, and early pemphigus vulgaris.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 534917,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0020548",
-          "name": "ocular pemphigoid",
-          "description": "Ocular pemphigoid is a rare inflammatory eye disease characterized by sub-epithelial blistering manifesting with bilateral, asymmetrical, chronic or recurrent conjunctivitis and aberrant tissue regeneration leading to progressive conjunctival fibrosis, secondary corneal vascularization and, in some cases, blindness. Patients typically present with conjunctival redness, increased lacrimation, burning and/or foreign body sensation, edema, limbitis and/or varying degrees of ocular pain. Ankyloblepharon may be observed in end stages of the disease.",
-          "equivalent_curies": [
-            "MONDO:0020548",
-            "MEDDRA:10057052",
-            "MEDDRA:10087064",
-            "SNOMEDCT:34250006",
-            "MEDDRA:10004294",
-            "MESH:D010390",
-            "UMLS:C0030804",
-            "ORPHANET:99922"
-          ],
-          "id": "MONDO:0020548",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Ocular cicatricial pemphigoid",
-            "Pemphigoid, Benign Mucous Membrane",
-            "ocular pemphigoid"
-          ],
-          "all_categories": [
-            "biolink:Disease"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 4578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisone",
-              "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "HMDB:HMDB0014773",
-                "UMLS:C0032952",
-                "NCIT:C770",
-                "PUBCHEM.COMPOUND:5865",
-                "DrugCentral:2253",
-                "MESH:D011241",
-                "ATC:A07EA03",
-                "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-                "CAS:53-03-2",
-                "PDQ:CDR0000042487",
-                "PathWhiz.Compound:9120",
-                "KEGG.DRUG:D00473",
-                "DRUGBANK:DB00635",
-                "ATC:H02AB07",
-                "UNII:VB0R961HZT",
-                "NDDF:002164",
-                "CHEMBL.COMPOUND:CHEMBL635",
-                "CHEBI:8382",
-                "KEGG.COMPOUND:C07370",
-                "GTOPDB:7096",
-                "RXNORM:8640"
-              ],
-              "id": "PUBCHEM.COMPOUND:5865",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisone",
-                "Prednisone (USP)",
-                "PREDNISONE",
-                "1,2-dehydrocortisone",
-                "prednisone"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:32422522",
-                "PMID:18788725",
-                "PMID:11413487",
-                "PMID:20070106",
-                "PMID:378499",
-                "PMID:15646539",
-                "PMID:20014752",
-                "PMID:25618019",
-                "PMID:23571415",
-                "PMID:19586686"
-=======
-            "identity": 534917,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0020548",
-              "name": "ocular pemphigoid",
-              "description": "Ocular pemphigoid is a rare inflammatory eye disease characterized by sub-epithelial blistering manifesting with bilateral, asymmetrical, chronic or recurrent conjunctivitis and aberrant tissue regeneration leading to progressive conjunctival fibrosis, secondary corneal vascularization and, in some cases, blindness. Patients typically present with conjunctival redness, increased lacrimation, burning and/or foreign body sensation, edema, limbitis and/or varying degrees of ocular pain. Ankyloblepharon may be observed in end stages of the disease.",
-              "equivalent_curies": [
-                "MONDO:0020548",
-                "MEDDRA:10057052",
-                "MEDDRA:10087064",
-                "SNOMEDCT:34250006",
-                "MEDDRA:10004294",
-                "MESH:D010390",
-                "UMLS:C0030804",
-                "ORPHANET:99922"
-              ],
-              "id": "MONDO:0020548",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Ocular cicatricial pemphigoid",
-                "Pemphigoid, Benign Mucous Membrane",
-                "ocular pemphigoid"
-              ],
-              "all_categories": [
-                "biolink:Disease"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 8666771,
-            "start": 4578,
-            "end": 568,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11326479': {'publication date': '2001 Mar-Apr', 'sentence': 'A significant reduction of survival was found with the presence of permanent visual loss vs absence (p = 0.04), in patients who required more than 10 mg/d of glucocorticoid (p < 0.001) at 6 months treatment and in patients treated with prednisone (vs prednisolone) (p < 0.01).', 'subject score': 1000, 'object score': 1000}, 'PMID:12428485': {'publication date': '2002 Oct', 'sentence': 'Psychiatric adverse affects appears to be more frequent with prednisone than prednisolone (P < 0.05).', 'subject score': 1000, 'object score': 1000}, 'PMID:13994945': {'publication date': '1962 Sep 15', 'sentence': '[Experimental ulcerogenic action of the prednisone. I. Comparison between prednisone and prednisolone administered orally and parenterally].', 'subject score': 1000, 'object score': 1000}, 'PMID:15635906': {'publication date': '2002 Aug', 'sentence': 'The risk of laminitis appears to be greater during treatment using some GCs (especially dexamethasone and triamcinalone) compared with others (prednisone and prednisolone).', 'subject score': 1000, 'object score': 1000}, 'PMID:16045952': {'publication date': '2005 Oct', 'sentence': 'In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.', 'subject score': 1000, 'object score': 1000}, 'PMID:22752958': {'publication date': '2013 Feb', 'sentence': 'Modified-release prednisone showed decreased complaints and fatigue compared to standard prednisolone indicating importance of glucocorticoid increase in early morning hours before waking.', 'subject score': 888, 'object score': 888}, 'PMID:23473553': {'publication date': '2013 Aug', 'sentence': 'Findings suggest low comparative bioavailability of oral prednisone compared to prednisolone in cats and consideration of lean body mass or ideal body weight for dosing practices.', 'subject score': 888, 'object score': 1000}, 'PMID:24452065': {'publication date': '2014 Aug', 'sentence': 'The objective of this study was to compare the pharmacokinetics of total and unbound prednisone and prednisolone in diabetic and nondiabetic stable kidney transplant recipients and to evaluate the factors influencing plasma protein binding of prednisolone.', 'subject score': 861, 'object score': 1000}, 'PMID:28791802': {'publication date': '2018 Jan', 'sentence': 'OBJECTIVE: A feasibility study to assess efficacy and safety of modified release (MR) prednisone (LodotraTM) compared to immediate release (IR) prednisolone in patients with newly diagnosed giant cell arteritis (GCA).', 'subject score': 851, 'object score': 851}, 'PMID:2898348': {'publication date': '1988 Mar-Apr', 'sentence': 'Compared to humans, pigs had lower concentrations of total prednisolone--assessed by HPLC--after oral prednisone (7.1 +/- 4.3 micrograms/ml x min vs. 297.9 +/- 75.6 micrograms/ml x min) and after iv prednisolone (26.8 +/- 9.5 micrograms/ml x min vs. 373.3 +/- 77.7 micrograms/ml x min).', 'subject score': 888, 'object score': 888}, 'PMID:31531960': {'publication date': '2019 Oct', 'sentence': 'CONCLUSION: Our study suggests that elevated levels of IL-6 in new GCA are better suppressed by MR prednisone compared with IR prednisolone.', 'subject score': 888, 'object score': 861}, 'PMID:3709632': {'publication date': '1986', 'sentence': 'This surprising result was observed even when prednisone concentrations were more than 35 fold greater than prednisolone concentrations.', 'subject score': 888, 'object score': 888}, 'PMID:656293': {'publication date': '1978 Jun', 'sentence': '2 In controls, values for AUC were significantly more variable after prednisone than prednisolone, and two subjects showed markedly inefficient conversion of prednisone to prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:6721988': {'publication date': '1984 Apr', 'sentence': 'Prednisone levels were lower than prednisolone levels.', 'subject score': 888, 'object score': 888}, 'PMID:7047863': {'publication date': '1982 Apr', 'sentence': 'The objective of our study was to compare the systemic bioavailability of prednisolone from oral prednisone and prednisolone.', 'subject score': 888, 'object score': 1000}, 'PMID:7141787': {'publication date': '1982 Sep', 'sentence': 'In nephrotic children the area under the curve of prednisolone (AUCPn) was higher (by 134 +/- 42%) after oral doses of prednisone when compared to the intravenous prednisolone doses.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032952---SEMMEDDB:compared_with---None---None---None---UMLS:C0032950---SEMMEDDB:",
-                "UMLS:C0032952---SEMMEDDB:higher_than---None---None---None---UMLS:C0032950---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5865",
-              "id": "8856354",
-              "object": "PUBCHEM.COMPOUND:5755",
-              "publications": [
-                "PMID:3709632",
-                "PMID:31531960",
-                "PMID:16045952",
-                "PMID:6721988",
-                "PMID:7047863",
-                "PMID:11326479",
-                "PMID:656293",
-                "PMID:28791802",
-                "PMID:7141787",
-                "PMID:13994945",
-                "PMID:12428485",
-                "PMID:24452065",
-                "PMID:2898348",
-                "PMID:15635906",
-                "PMID:23473553",
-                "PMID:22752958"
-=======
-            "identity": 8820407,
-            "start": 568,
-            "end": 534917,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11464188': {'publication date': '2001 Aug', 'sentence': 'METHODS: Three patients with CP were treated with mycophenolate mofetil and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:14739497': {'publication date': '2004 Jan', 'sentence': 'Based on a diagnosis of anti-epiligrin cicatricial pemphigoid, he was treated with prednisolone, minocycline hydrochloride and nicotinamide.', 'subject score': 1000, 'object score': 824}, 'PMID:22727107': {'publication date': '2012 Jul', 'sentence': 'Treatment of mucous membrane pemphigoid with the combination of mycophenolate mofetil, dapsone, and prednisolone: a case series.', 'subject score': 1000, 'object score': 1000}, 'PMID:9798228': {'publication date': '1998 Oct', 'sentence': 'CONCLUSIONS: The addition of levamisole to prednisolone may produce improved results in the management of erosive lichen planus, erythema multiforme, mucous membrane pemphigoid, and early pemphigus vulgaris.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0030804---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9013774",
-              "object": "MONDO:0020548",
-              "publications": [
-                "PMID:11464188",
-                "PMID:14739497",
-                "PMID:22727107",
-                "PMID:9798228"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:7120877': {'publication date': '1982 Jul 01', 'sentence': '[Pharmacokinetics of prednisolone in adrenal insufficiency ].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 312686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-          "name": "adrenocortical insufficiency",
-          "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0405580",
-            "MEDDRA:10022460",
-            "ICD9:255.4",
-            "EFO:0009491",
-            "MEDDRA:10001367",
-            "MEDDRA:10020936",
-            "MONDO:0000004",
-            "MEDDRA:10020979",
-            "SNOMEDCT:237785004",
-            "SNOMEDCT:386584007",
-            "MEDDRA:10056485",
-            "MEDDRA:10082130",
-            "UMLS:C0001623",
-            "MEDDRA:10001344",
-            "MEDDRA:10001366",
-            "MEDDRA:10001334",
-            "DOID:10493",
-            "NCIT:C26691",
-            "HP:0000846",
-            "MEDDRA:10001335",
-            "MEDDRA:10001369",
-            "MEDDRA:10001342",
-            "MEDDRA:10001343",
-            "MESH:D000309",
-            "SNOMEDCT:111563005",
-            "MEDDRA:10011172",
-            "MEDDRA:10022461"
-          ],
-          "id": "MONDO:0000004",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortical hypofunction",
-            "Adrenocortical Insufficiency",
-            "adrenocortical insufficiency",
-            "Corticoadrenal insufficiency",
-            "Adrenal gland hypofunction",
-            "Adrenal Insufficiency",
-            "Adrenal insufficiency",
-            "Adrenal cortical hypofunction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:11443143"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-              "name": "adrenocortical insufficiency",
-              "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0405580",
-                "MEDDRA:10022460",
-                "ICD9:255.4",
-                "EFO:0009491",
-                "MEDDRA:10001367",
-                "MEDDRA:10020936",
-                "MONDO:0000004",
-                "MEDDRA:10020979",
-                "SNOMEDCT:237785004",
-                "SNOMEDCT:386584007",
-                "MEDDRA:10056485",
-                "MEDDRA:10082130",
-                "UMLS:C0001623",
-                "MEDDRA:10001344",
-                "MEDDRA:10001366",
-                "MEDDRA:10001334",
-                "DOID:10493",
-                "NCIT:C26691",
-                "HP:0000846",
-                "MEDDRA:10001335",
-                "MEDDRA:10001369",
-                "MEDDRA:10001342",
-                "MEDDRA:10001343",
-                "MESH:D000309",
-                "SNOMEDCT:111563005",
-                "MEDDRA:10011172",
-                "MEDDRA:10022461"
-              ],
-              "id": "MONDO:0000004",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortical hypofunction",
-                "Adrenocortical Insufficiency",
-                "adrenocortical insufficiency",
-                "Corticoadrenal insufficiency",
-                "Adrenal gland hypofunction",
-                "Adrenal Insufficiency",
-                "Adrenal insufficiency",
-                "Adrenal cortical hypofunction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:11443143"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25906576,
-            "start": 568,
-            "end": 312686,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7120877': {'publication date': '1982 Jul 01', 'sentence': '[Pharmacokinetics of prednisolone in adrenal insufficiency ].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0001623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "26365803",
-              "object": "MONDO:0000004",
-              "publications": [
-                "PMID:7120877"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:31539081': {'publication date': '2019 Sep 20', 'sentence': 'We therefore advocate for increased clinical alertness towards prednisolone-induced adrenal insufficiency in RTx patients and thus their potential need of rescue GC supplementation during stress.', 'subject score': 861, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 312686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-          "name": "adrenocortical insufficiency",
-          "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0405580",
-            "MEDDRA:10022460",
-            "ICD9:255.4",
-            "EFO:0009491",
-            "MEDDRA:10001367",
-            "MEDDRA:10020936",
-            "MONDO:0000004",
-            "MEDDRA:10020979",
-            "SNOMEDCT:237785004",
-            "SNOMEDCT:386584007",
-            "MEDDRA:10056485",
-            "MEDDRA:10082130",
-            "UMLS:C0001623",
-            "MEDDRA:10001344",
-            "MEDDRA:10001366",
-            "MEDDRA:10001334",
-            "DOID:10493",
-            "NCIT:C26691",
-            "HP:0000846",
-            "MEDDRA:10001335",
-            "MEDDRA:10001369",
-            "MEDDRA:10001342",
-            "MEDDRA:10001343",
-            "MESH:D000309",
-            "SNOMEDCT:111563005",
-            "MEDDRA:10011172",
-            "MEDDRA:10022461"
-          ],
-          "id": "MONDO:0000004",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortical hypofunction",
-            "Adrenocortical Insufficiency",
-            "adrenocortical insufficiency",
-            "Corticoadrenal insufficiency",
-            "Adrenal gland hypofunction",
-            "Adrenal Insufficiency",
-            "Adrenal insufficiency",
-            "Adrenal cortical hypofunction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:11443143"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-              "name": "adrenocortical insufficiency",
-              "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0405580",
-                "MEDDRA:10022460",
-                "ICD9:255.4",
-                "EFO:0009491",
-                "MEDDRA:10001367",
-                "MEDDRA:10020936",
-                "MONDO:0000004",
-                "MEDDRA:10020979",
-                "SNOMEDCT:237785004",
-                "SNOMEDCT:386584007",
-                "MEDDRA:10056485",
-                "MEDDRA:10082130",
-                "UMLS:C0001623",
-                "MEDDRA:10001344",
-                "MEDDRA:10001366",
-                "MEDDRA:10001334",
-                "DOID:10493",
-                "NCIT:C26691",
-                "HP:0000846",
-                "MEDDRA:10001335",
-                "MEDDRA:10001369",
-                "MEDDRA:10001342",
-                "MEDDRA:10001343",
-                "MESH:D000309",
-                "SNOMEDCT:111563005",
-                "MEDDRA:10011172",
-                "MEDDRA:10022461"
-              ],
-              "id": "MONDO:0000004",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortical hypofunction",
-                "Adrenocortical Insufficiency",
-                "adrenocortical insufficiency",
-                "Corticoadrenal insufficiency",
-                "Adrenal gland hypofunction",
-                "Adrenal Insufficiency",
-                "Adrenal insufficiency",
-                "Adrenal cortical hypofunction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:11443143"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20883351,
-            "start": 568,
-            "end": 312686,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31539081': {'publication date': '2019 Sep 20', 'sentence': 'We therefore advocate for increased clinical alertness towards prednisolone-induced adrenal insufficiency in RTx patients and thus their potential need of rescue GC supplementation during stress.', 'subject score': 861, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0001623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "21293782",
-              "object": "MONDO:0000004",
-              "publications": [
-                "PMID:31539081"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:14517528': {'publication date': '2003 Sep', 'sentence': 'Prednisolone in the treatment of adrenal insufficiency: a re-evaluation of relative potency.', 'subject score': 1000, 'object score': 1000}, 'PMID:22071646': {'publication date': '2011', 'sentence': 'The patient was known with Adrenal insufficiency and was treated optimally with fludrocortisone and prednisolone since seven years with no history of adrenal crisis.', 'subject score': 1000, 'object score': 1000}, 'PMID:27864317': {'publication date': '2017 Jan', 'sentence': 'Data on risk factors for cardiovascular disease in patients with AI treated with prednisolone are scarce, despite this condition being the predominant cause of excess mortality.', 'subject score': 1000, 'object score': 1000}, 'PMID:28877961': {'publication date': '2017 Oct', 'sentence': 'CONCLUSION: We demonstrate a high prevalence of adrenal insufficiency during ongoing low-dose prednisolone treatment.', 'subject score': 798, 'object score': 1000}, 'PMID:29018153': {'publication date': '2017 Nov', 'sentence': 'METHODS: Data from 82 patients on hydrocortisone and 64 patients on prednisolone for AI at Imperial College Healthcare NHS Trust were analysed.', 'subject score': 1000, 'object score': 1000}, 'PMID:31110731': {'publication date': '2019 May', 'sentence': 'Inadvertent treatment of hypoadrenalism with prednisolone in pemphigus: A case report.', 'subject score': 1000, 'object score': 1000}, 'PMID:31539081': {'publication date': '2019 Sep 20', 'sentence': 'Adrenal insufficiency in kidney transplant patients during low-dose prednisolone therapy: a cross-sectional case-control study.', 'subject score': 861, 'object score': 1000}, 'PMID:33449916': {'publication date': '2021 Jan 01', 'sentence': 'The use of prednisolone versus dual-release hydrocortisone in the treatment of hypoadrenalism.', 'subject score': 1000, 'object score': 1000}, 'PMID:33626793': {'publication date': '2016 Sep 01', 'sentence': 'METHODS: Using a newly developed ultra-performance liquid chromatography MS/MS method, prednisolone profiles in healthy volunteers and patients with adrenal insufficiency already treated with prednisolone were prospectively analyzed in a tertiary center.', 'subject score': 1000, 'object score': 1000}, 'PMID:7120877': {'publication date': '1982 Jul 01', 'sentence': 'The metabolic clearance rate of prednisolone was decreased (56.0+/-7.2 1/24 h/m2) in patients with adrenal insufficiency.', 'subject score': 1000, 'object score': 1000}, 'PMID:27269282': {'publication date': '2016 Jul 23', 'sentence': 'It was concluded that dogs with hypoadrenocorticism should be continued on prednisolone therapy until they are stabilised.', 'subject score': 888, 'object score': 1000}, 'PMID:29727896': {'publication date': '2018 Apr', 'sentence': 'OBJECTIVE: To examine the prednisolone and fludrocortisone dosages in dogs with primary hypoadrenocorticism after integrating endogenous ACTH (eACTH) determination into the surveillance regimen.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 312686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-          "name": "adrenocortical insufficiency",
-          "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0405580",
-            "MEDDRA:10022460",
-            "ICD9:255.4",
-            "EFO:0009491",
-            "MEDDRA:10001367",
-            "MEDDRA:10020936",
-            "MONDO:0000004",
-            "MEDDRA:10020979",
-            "SNOMEDCT:237785004",
-            "SNOMEDCT:386584007",
-            "MEDDRA:10056485",
-            "MEDDRA:10082130",
-            "UMLS:C0001623",
-            "MEDDRA:10001344",
-            "MEDDRA:10001366",
-            "MEDDRA:10001334",
-            "DOID:10493",
-            "NCIT:C26691",
-            "HP:0000846",
-            "MEDDRA:10001335",
-            "MEDDRA:10001369",
-            "MEDDRA:10001342",
-            "MEDDRA:10001343",
-            "MESH:D000309",
-            "SNOMEDCT:111563005",
-            "MEDDRA:10011172",
-            "MEDDRA:10022461"
-          ],
-          "id": "MONDO:0000004",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortical hypofunction",
-            "Adrenocortical Insufficiency",
-            "adrenocortical insufficiency",
-            "Corticoadrenal insufficiency",
-            "Adrenal gland hypofunction",
-            "Adrenal Insufficiency",
-            "Adrenal insufficiency",
-            "Adrenal cortical hypofunction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:11443143"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-              "name": "adrenocortical insufficiency",
-              "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0405580",
-                "MEDDRA:10022460",
-                "ICD9:255.4",
-                "EFO:0009491",
-                "MEDDRA:10001367",
-                "MEDDRA:10020936",
-                "MONDO:0000004",
-                "MEDDRA:10020979",
-                "SNOMEDCT:237785004",
-                "SNOMEDCT:386584007",
-                "MEDDRA:10056485",
-                "MEDDRA:10082130",
-                "UMLS:C0001623",
-                "MEDDRA:10001344",
-                "MEDDRA:10001366",
-                "MEDDRA:10001334",
-                "DOID:10493",
-                "NCIT:C26691",
-                "HP:0000846",
-                "MEDDRA:10001335",
-                "MEDDRA:10001369",
-                "MEDDRA:10001342",
-                "MEDDRA:10001343",
-                "MESH:D000309",
-                "SNOMEDCT:111563005",
-                "MEDDRA:10011172",
-                "MEDDRA:10022461"
-              ],
-              "id": "MONDO:0000004",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortical hypofunction",
-                "Adrenocortical Insufficiency",
-                "adrenocortical insufficiency",
-                "Corticoadrenal insufficiency",
-                "Adrenal gland hypofunction",
-                "Adrenal Insufficiency",
-                "Adrenal insufficiency",
-                "Adrenal cortical hypofunction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:11443143"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10537886,
-            "start": 568,
-            "end": 312686,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14517528': {'publication date': '2003 Sep', 'sentence': 'Prednisolone in the treatment of adrenal insufficiency: a re-evaluation of relative potency.', 'subject score': 1000, 'object score': 1000}, 'PMID:22071646': {'publication date': '2011', 'sentence': 'The patient was known with Adrenal insufficiency and was treated optimally with fludrocortisone and prednisolone since seven years with no history of adrenal crisis.', 'subject score': 1000, 'object score': 1000}, 'PMID:27864317': {'publication date': '2017 Jan', 'sentence': 'Data on risk factors for cardiovascular disease in patients with AI treated with prednisolone are scarce, despite this condition being the predominant cause of excess mortality.', 'subject score': 1000, 'object score': 1000}, 'PMID:28877961': {'publication date': '2017 Oct', 'sentence': 'CONCLUSION: We demonstrate a high prevalence of adrenal insufficiency during ongoing low-dose prednisolone treatment.', 'subject score': 798, 'object score': 1000}, 'PMID:29018153': {'publication date': '2017 Nov', 'sentence': 'METHODS: Data from 82 patients on hydrocortisone and 64 patients on prednisolone for AI at Imperial College Healthcare NHS Trust were analysed.', 'subject score': 1000, 'object score': 1000}, 'PMID:31110731': {'publication date': '2019 May', 'sentence': 'Inadvertent treatment of hypoadrenalism with prednisolone in pemphigus: A case report.', 'subject score': 1000, 'object score': 1000}, 'PMID:31539081': {'publication date': '2019 Sep 20', 'sentence': 'Adrenal insufficiency in kidney transplant patients during low-dose prednisolone therapy: a cross-sectional case-control study.', 'subject score': 861, 'object score': 1000}, 'PMID:33449916': {'publication date': '2021 Jan 01', 'sentence': 'The use of prednisolone versus dual-release hydrocortisone in the treatment of hypoadrenalism.', 'subject score': 1000, 'object score': 1000}, 'PMID:33626793': {'publication date': '2016 Sep 01', 'sentence': 'METHODS: Using a newly developed ultra-performance liquid chromatography MS/MS method, prednisolone profiles in healthy volunteers and patients with adrenal insufficiency already treated with prednisolone were prospectively analyzed in a tertiary center.', 'subject score': 1000, 'object score': 1000}, 'PMID:7120877': {'publication date': '1982 Jul 01', 'sentence': 'The metabolic clearance rate of prednisolone was decreased (56.0+/-7.2 1/24 h/m2) in patients with adrenal insufficiency.', 'subject score': 1000, 'object score': 1000}, 'PMID:27269282': {'publication date': '2016 Jul 23', 'sentence': 'It was concluded that dogs with hypoadrenocorticism should be continued on prednisolone therapy until they are stabilised.', 'subject score': 888, 'object score': 1000}, 'PMID:29727896': {'publication date': '2018 Apr', 'sentence': 'OBJECTIVE: To examine the prednisolone and fludrocortisone dosages in dogs with primary hypoadrenocorticism after integrating endogenous ACTH (eACTH) determination into the surveillance regimen.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0001623---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0405580---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10782301",
-              "object": "MONDO:0000004",
-              "publications": [
-                "PMID:27269282",
-                "PMID:33626793",
-                "PMID:29018153",
-                "PMID:14517528",
-                "PMID:33449916",
-                "PMID:29727896",
-                "PMID:22071646",
-                "PMID:31110731",
-                "PMID:27864317",
-                "PMID:31539081",
-                "PMID:28877961",
-                "PMID:7120877"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:9066185': {'publication date': '1997', 'sentence': '6 cases of FSGS had poor response to any therapy; 7 cases were responsive to either triple therapy or cyclosporine A plus prednisolone.', 'subject score': 861, 'object score': 916}}",
-    "p2": {
-      "start": {
-        "identity": 318915,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005363",
-          "name": "focal segmental glomerulosclerosis",
-          "description": "A renal disorder characterized by sclerotic lesions in the glomeruli. Causes include drugs, viruses, and malignancies (lymphomas), or it may be idiopathic. It presents with asymptomatic proteinuria or nephritic syndrome and it may lead to renal failure.; A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.; Segmental accumulation of scar tissue in individual (but not all) glomeruli. [Eurenomics:fschaefer, PMID:16164633]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:236403004",
-            "HP:0000097",
-            "UMLS:C0017668",
-            "UMLS:CN043606",
-            "EFO:0004236",
-            "MESH:D005923",
-            "NCIT:C37308",
-            "DOID:1312",
-            "SNOMEDCT:25821008",
-            "OMIM.PS:603278",
-            "MONDO:0005363",
-            "MEDDRA:10067757",
-            "MEDDRA:10065581",
-            "OMIM:PS603278",
-            "MEDDRA:10016832",
-            "MONDO:0100313"
-          ],
-          "id": "MONDO:0005363",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Glomerulosclerosis, Focal Segmental",
-            "Focal Segmental Glomerulosclerosis",
-            "inherited focal segmental glomerulosclerosis",
-            "Focal glomerulosclerosis",
-            "Focal segmental glomerulosclerosis",
-            "focal segmental glomerulosclerosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:16164633"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318915,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005363",
-              "name": "focal segmental glomerulosclerosis",
-              "description": "A renal disorder characterized by sclerotic lesions in the glomeruli. Causes include drugs, viruses, and malignancies (lymphomas), or it may be idiopathic. It presents with asymptomatic proteinuria or nephritic syndrome and it may lead to renal failure.; A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.; Segmental accumulation of scar tissue in individual (but not all) glomeruli. [Eurenomics:fschaefer, PMID:16164633]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:236403004",
-                "HP:0000097",
-                "UMLS:C0017668",
-                "UMLS:CN043606",
-                "EFO:0004236",
-                "MESH:D005923",
-                "NCIT:C37308",
-                "DOID:1312",
-                "SNOMEDCT:25821008",
-                "OMIM.PS:603278",
-                "MONDO:0005363",
-                "MEDDRA:10067757",
-                "MEDDRA:10065581",
-                "OMIM:PS603278",
-                "MEDDRA:10016832",
-                "MONDO:0100313"
-              ],
-              "id": "MONDO:0005363",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Glomerulosclerosis, Focal Segmental",
-                "Focal Segmental Glomerulosclerosis",
-                "inherited focal segmental glomerulosclerosis",
-                "Focal glomerulosclerosis",
-                "Focal segmental glomerulosclerosis",
-                "focal segmental glomerulosclerosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:16164633"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26853866,
-            "start": 568,
-            "end": 318915,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9066185': {'publication date': '1997', 'sentence': '6 cases of FSGS had poor response to any therapy; 7 cases were responsive to either triple therapy or cyclosporine A plus prednisolone.', 'subject score': 861, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0017668---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "27323391",
-              "object": "MONDO:0005363",
-              "publications": [
-                "PMID:9066185"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15879445': {'publication date': '2005 Jun', 'sentence': 'RESULTS: Of 136 patients with primary FSGS and nephrotic range proteinuria, 76 (56%) were treated with prednisolone and of this group, 59% were treated with additional immunosuppression.', 'subject score': 1000, 'object score': 916}, 'PMID:16429835': {'publication date': '2006 Jan', 'sentence': 'All patients with minor glomerular abnormalities at the nephrotic stage received prednisolone for 6 months, and all FGS patients received some form of immunosuppression therapy with prednisolone, cyclophosphamide or mizoribine for 12 months.', 'subject score': 1000, 'object score': 901}, 'PMID:23461215': {'publication date': '2013', 'sentence': 'These findings were consistent with FSGS, and she was treated with mycophenolate mofetil (MMF) in combination with PSL instead of CsA, which greatly reduced her proteinuria.', 'subject score': 1000, 'object score': 1000}, 'PMID:8018488': {'publication date': '1994 Apr', 'sentence': 'They were divided into groups according to renal pathology: (1) steroid-sensitive NS (SSNS) not receiving prednisolone therapy, (2) SSNS on prednisolone, (3) focal segmental glomerulosclerosis (FSGS), (4) SSNS in remission and not receiving prednisolone therapy, (5) congenital NS (CNS).', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318915,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005363",
-          "name": "focal segmental glomerulosclerosis",
-          "description": "A renal disorder characterized by sclerotic lesions in the glomeruli. Causes include drugs, viruses, and malignancies (lymphomas), or it may be idiopathic. It presents with asymptomatic proteinuria or nephritic syndrome and it may lead to renal failure.; A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.; Segmental accumulation of scar tissue in individual (but not all) glomeruli. [Eurenomics:fschaefer, PMID:16164633]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:236403004",
-            "HP:0000097",
-            "UMLS:C0017668",
-            "UMLS:CN043606",
-            "EFO:0004236",
-            "MESH:D005923",
-            "NCIT:C37308",
-            "DOID:1312",
-            "SNOMEDCT:25821008",
-            "OMIM.PS:603278",
-            "MONDO:0005363",
-            "MEDDRA:10067757",
-            "MEDDRA:10065581",
-            "OMIM:PS603278",
-            "MEDDRA:10016832",
-            "MONDO:0100313"
-          ],
-          "id": "MONDO:0005363",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Glomerulosclerosis, Focal Segmental",
-            "Focal Segmental Glomerulosclerosis",
-            "inherited focal segmental glomerulosclerosis",
-            "Focal glomerulosclerosis",
-            "Focal segmental glomerulosclerosis",
-            "focal segmental glomerulosclerosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:16164633"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318915,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005363",
-              "name": "focal segmental glomerulosclerosis",
-              "description": "A renal disorder characterized by sclerotic lesions in the glomeruli. Causes include drugs, viruses, and malignancies (lymphomas), or it may be idiopathic. It presents with asymptomatic proteinuria or nephritic syndrome and it may lead to renal failure.; A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.; Segmental accumulation of scar tissue in individual (but not all) glomeruli. [Eurenomics:fschaefer, PMID:16164633]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:236403004",
-                "HP:0000097",
-                "UMLS:C0017668",
-                "UMLS:CN043606",
-                "EFO:0004236",
-                "MESH:D005923",
-                "NCIT:C37308",
-                "DOID:1312",
-                "SNOMEDCT:25821008",
-                "OMIM.PS:603278",
-                "MONDO:0005363",
-                "MEDDRA:10067757",
-                "MEDDRA:10065581",
-                "OMIM:PS603278",
-                "MEDDRA:10016832",
-                "MONDO:0100313"
-              ],
-              "id": "MONDO:0005363",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Glomerulosclerosis, Focal Segmental",
-                "Focal Segmental Glomerulosclerosis",
-                "inherited focal segmental glomerulosclerosis",
-                "Focal glomerulosclerosis",
-                "Focal segmental glomerulosclerosis",
-                "focal segmental glomerulosclerosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:16164633"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11561195,
-            "start": 568,
-            "end": 318915,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15879445': {'publication date': '2005 Jun', 'sentence': 'RESULTS: Of 136 patients with primary FSGS and nephrotic range proteinuria, 76 (56%) were treated with prednisolone and of this group, 59% were treated with additional immunosuppression.', 'subject score': 1000, 'object score': 916}, 'PMID:16429835': {'publication date': '2006 Jan', 'sentence': 'All patients with minor glomerular abnormalities at the nephrotic stage received prednisolone for 6 months, and all FGS patients received some form of immunosuppression therapy with prednisolone, cyclophosphamide or mizoribine for 12 months.', 'subject score': 1000, 'object score': 901}, 'PMID:23461215': {'publication date': '2013', 'sentence': 'These findings were consistent with FSGS, and she was treated with mycophenolate mofetil (MMF) in combination with PSL instead of CsA, which greatly reduced her proteinuria.', 'subject score': 1000, 'object score': 1000}, 'PMID:8018488': {'publication date': '1994 Apr', 'sentence': 'They were divided into groups according to renal pathology: (1) steroid-sensitive NS (SSNS) not receiving prednisolone therapy, (2) SSNS on prednisolone, (3) focal segmental glomerulosclerosis (FSGS), (4) SSNS in remission and not receiving prednisolone therapy, (5) congenital NS (CNS).', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0017668---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11813573",
-              "object": "MONDO:0005363",
-              "publications": [
-                "PMID:15879445",
-                "PMID:16429835",
-                "PMID:23461215",
-                "PMID:8018488"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:1247769': {'publication date': '1976 Jan 24', 'sentence': 'Plasma prednisolone levels after administration of prednisolone-21-phosphate as a retention enema in colitis.', 'subject score': 851, 'object score': 1000}, 'PMID:7129207': {'publication date': '1982 Nov', 'sentence': 'Plasma prednisolone levels during intravenous therapy in acute colitis.', 'subject score': 851, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 319330,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005292",
-          "name": "colitis",
-          "description": "Inflammation of the colon.; Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.; Colitis refers to an inflammation of the colon and is often used to describe an inflammation of the large intestine (colon, cecum and rectum). Colitides may be acute and self-limited or chronic, and broadly fit into the category of digestive diseases. [HPO:sdoelken]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10079511",
-            "SNOMEDCT:64226004",
-            "UMLS:C0009319",
-            "MESH:D003092",
-            "EFO:0003872",
-            "ICD10:K52.9",
-            "MEDDRA:10009889",
-            "MONDO:0005292",
-            "NCIT:C26723",
-            "MEDDRA:10009898",
-            "PSY:10220",
-            "DOID:0060180",
-            "HP:0002583",
-            "MEDDRA:10009887"
-          ],
-          "id": "MONDO:0005292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Colitis",
-            "colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319330,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005292",
-              "name": "colitis",
-              "description": "Inflammation of the colon.; Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.; Colitis refers to an inflammation of the colon and is often used to describe an inflammation of the large intestine (colon, cecum and rectum). Colitides may be acute and self-limited or chronic, and broadly fit into the category of digestive diseases. [HPO:sdoelken]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10079511",
-                "SNOMEDCT:64226004",
-                "UMLS:C0009319",
-                "MESH:D003092",
-                "EFO:0003872",
-                "ICD10:K52.9",
-                "MEDDRA:10009889",
-                "MONDO:0005292",
-                "NCIT:C26723",
-                "MEDDRA:10009898",
-                "PSY:10220",
-                "DOID:0060180",
-                "HP:0002583",
-                "MEDDRA:10009887"
-              ],
-              "id": "MONDO:0005292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Colitis",
-                "colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9710006,
-            "start": 568,
-            "end": 319330,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1247769': {'publication date': '1976 Jan 24', 'sentence': 'Plasma prednisolone levels after administration of prednisolone-21-phosphate as a retention enema in colitis.', 'subject score': 851, 'object score': 1000}, 'PMID:7129207': {'publication date': '1982 Nov', 'sentence': 'Plasma prednisolone levels during intravenous therapy in acute colitis.', 'subject score': 851, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0009319---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9924521",
-              "object": "MONDO:0005292",
-              "publications": [
-                "PMID:1247769",
-                "PMID:7129207"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:1337973': {'publication date': '1992', 'sentence': 'Rats were treated with a leukotriene synthesis inhibitor (PF-5901), a leukotriene B4 receptor antagonist (SC-41930), an IL-1 receptor antagonist or a corticosteroid (prednisolone) prior to induction of colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15766209': {'publication date': '2005 Feb', 'sentence': 'Prednisolone was administered orally once on the day before induction of colitis, and animals were treated twice daily thereafter.', 'subject score': 1000, 'object score': 1000}, 'PMID:9125657': {'publication date': '1997 Apr', 'sentence': 'With induction of colitis, the mucosa and lamina propria were invaded by polydendritic cells; the visual score was markedly decreased in the proximal loops treated with lidocaine, prednisolone, or sucralfate.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319330,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005292",
-          "name": "colitis",
-          "description": "Inflammation of the colon.; Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.; Colitis refers to an inflammation of the colon and is often used to describe an inflammation of the large intestine (colon, cecum and rectum). Colitides may be acute and self-limited or chronic, and broadly fit into the category of digestive diseases. [HPO:sdoelken]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10079511",
-            "SNOMEDCT:64226004",
-            "UMLS:C0009319",
-            "MESH:D003092",
-            "EFO:0003872",
-            "ICD10:K52.9",
-            "MEDDRA:10009889",
-            "MONDO:0005292",
-            "NCIT:C26723",
-            "MEDDRA:10009898",
-            "PSY:10220",
-            "DOID:0060180",
-            "HP:0002583",
-            "MEDDRA:10009887"
-          ],
-          "id": "MONDO:0005292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Colitis",
-            "colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319330,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005292",
-              "name": "colitis",
-              "description": "Inflammation of the colon.; Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.; Colitis refers to an inflammation of the colon and is often used to describe an inflammation of the large intestine (colon, cecum and rectum). Colitides may be acute and self-limited or chronic, and broadly fit into the category of digestive diseases. [HPO:sdoelken]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10079511",
-                "SNOMEDCT:64226004",
-                "UMLS:C0009319",
-                "MESH:D003092",
-                "EFO:0003872",
-                "ICD10:K52.9",
-                "MEDDRA:10009889",
-                "MONDO:0005292",
-                "NCIT:C26723",
-                "MEDDRA:10009898",
-                "PSY:10220",
-                "DOID:0060180",
-                "HP:0002583",
-                "MEDDRA:10009887"
-              ],
-              "id": "MONDO:0005292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Colitis",
-                "colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10281951,
-            "start": 568,
-            "end": 319330,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1337973': {'publication date': '1992', 'sentence': 'Rats were treated with a leukotriene synthesis inhibitor (PF-5901), a leukotriene B4 receptor antagonist (SC-41930), an IL-1 receptor antagonist or a corticosteroid (prednisolone) prior to induction of colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15766209': {'publication date': '2005 Feb', 'sentence': 'Prednisolone was administered orally once on the day before induction of colitis, and animals were treated twice daily thereafter.', 'subject score': 1000, 'object score': 1000}, 'PMID:9125657': {'publication date': '1997 Apr', 'sentence': 'With induction of colitis, the mucosa and lamina propria were invaded by polydendritic cells; the visual score was markedly decreased in the proximal loops treated with lidocaine, prednisolone, or sucralfate.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0009319---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10519611",
-              "object": "MONDO:0005292",
-              "publications": [
-                "PMID:1337973",
-                "PMID:15766209",
-                "PMID:9125657"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:2880777': {'publication date': '1986', 'sentence': 'The effect of pretreatment with topical prostaglandin E2, prednisolone and sulphasalazine in experimental colitis has been examined in the rat colon.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 319330,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005292",
-          "name": "colitis",
-          "description": "Inflammation of the colon.; Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.; Colitis refers to an inflammation of the colon and is often used to describe an inflammation of the large intestine (colon, cecum and rectum). Colitides may be acute and self-limited or chronic, and broadly fit into the category of digestive diseases. [HPO:sdoelken]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10079511",
-            "SNOMEDCT:64226004",
-            "UMLS:C0009319",
-            "MESH:D003092",
-            "EFO:0003872",
-            "ICD10:K52.9",
-            "MEDDRA:10009889",
-            "MONDO:0005292",
-            "NCIT:C26723",
-            "MEDDRA:10009898",
-            "PSY:10220",
-            "DOID:0060180",
-            "HP:0002583",
-            "MEDDRA:10009887"
-          ],
-          "id": "MONDO:0005292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Colitis",
-            "colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319330,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005292",
-              "name": "colitis",
-              "description": "Inflammation of the colon.; Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.; Colitis refers to an inflammation of the colon and is often used to describe an inflammation of the large intestine (colon, cecum and rectum). Colitides may be acute and self-limited or chronic, and broadly fit into the category of digestive diseases. [HPO:sdoelken]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10079511",
-                "SNOMEDCT:64226004",
-                "UMLS:C0009319",
-                "MESH:D003092",
-                "EFO:0003872",
-                "ICD10:K52.9",
-                "MEDDRA:10009889",
-                "MONDO:0005292",
-                "NCIT:C26723",
-                "MEDDRA:10009898",
-                "PSY:10220",
-                "DOID:0060180",
-                "HP:0002583",
-                "MEDDRA:10009887"
-              ],
-              "id": "MONDO:0005292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Colitis",
-                "colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19436712,
-            "start": 568,
-            "end": 319330,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2880777': {'publication date': '1986', 'sentence': 'The effect of pretreatment with topical prostaglandin E2, prednisolone and sulphasalazine in experimental colitis has been examined in the rat colon.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0009319---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "19824794",
-              "object": "MONDO:0005292",
-              "publications": [
-                "PMID:2880777"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10496564': {'publication date': '1999 Sep', 'sentence': 'On the other hand, prednisolone and short chain fatty acids seemed to improve only the physiologic changes of colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:12207075': {'publication date': '2002', 'sentence': 'In an inflammatory model of colitis, intrarectal honey administration is as effective as prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:20440854': {'publication date': '2010 May 07', 'sentence': 'A murine model of acute 2-4-6-trinitrobenzene sulfonic acid (TNBS)-colitis was next used to evaluate the distinct prophylactic protective capacities of three yeast strains compared with the performance of prednisolone treatment.', 'subject score': 888, 'object score': 758}, 'PMID:27424097': {'publication date': '2016 Sep', 'sentence': 'Forty male Swiss mice were assigned into five groups: control; control treated with LED therapy; colitis without treatment; colitis treated with LED therapy; colitis treated with Prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:28821031': {'publication date': '2017 Oct 15', 'sentence': 'Surface-deacetylated chitin nanofibers (SDACNFs) reinforced with a sulfobutyl ether beta-cyclodextrin (SBE-beta-CD) (NFs-CDs) gel were developed to obtain a controlled release carrier of prednisolone (PD) for the treatment of colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:31678983': {'publication date': '2019 Nov 03', 'sentence': 'After confirming that the blood culture became negative, prednisolone (PDL) was started as therapy for the colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7364320': {'publication date': '1980 Jan', 'sentence': 'Peak plasma levels were reduced after an oral dose of 40 mg prednisolone in six patients with severe acute colitis as compared with six normal subjects, though total absorption appeared to be similar; the findings suggest that prednisolone absorption was delayed in acute colitis.', 'subject score': 851, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 319330,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005292",
-          "name": "colitis",
-          "description": "Inflammation of the colon.; Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.; Colitis refers to an inflammation of the colon and is often used to describe an inflammation of the large intestine (colon, cecum and rectum). Colitides may be acute and self-limited or chronic, and broadly fit into the category of digestive diseases. [HPO:sdoelken]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10079511",
-            "SNOMEDCT:64226004",
-            "UMLS:C0009319",
-            "MESH:D003092",
-            "EFO:0003872",
-            "ICD10:K52.9",
-            "MEDDRA:10009889",
-            "MONDO:0005292",
-            "NCIT:C26723",
-            "MEDDRA:10009898",
-            "PSY:10220",
-            "DOID:0060180",
-            "HP:0002583",
-            "MEDDRA:10009887"
-          ],
-          "id": "MONDO:0005292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Colitis",
-            "colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319330,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005292",
-              "name": "colitis",
-              "description": "Inflammation of the colon.; Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.; Colitis refers to an inflammation of the colon and is often used to describe an inflammation of the large intestine (colon, cecum and rectum). Colitides may be acute and self-limited or chronic, and broadly fit into the category of digestive diseases. [HPO:sdoelken]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10079511",
-                "SNOMEDCT:64226004",
-                "UMLS:C0009319",
-                "MESH:D003092",
-                "EFO:0003872",
-                "ICD10:K52.9",
-                "MEDDRA:10009889",
-                "MONDO:0005292",
-                "NCIT:C26723",
-                "MEDDRA:10009898",
-                "PSY:10220",
-                "DOID:0060180",
-                "HP:0002583",
-                "MEDDRA:10009887"
-              ],
-              "id": "MONDO:0005292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Colitis",
-                "colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7545385,
-            "start": 568,
-            "end": 319330,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10496564': {'publication date': '1999 Sep', 'sentence': 'On the other hand, prednisolone and short chain fatty acids seemed to improve only the physiologic changes of colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:12207075': {'publication date': '2002', 'sentence': 'In an inflammatory model of colitis, intrarectal honey administration is as effective as prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:20440854': {'publication date': '2010 May 07', 'sentence': 'A murine model of acute 2-4-6-trinitrobenzene sulfonic acid (TNBS)-colitis was next used to evaluate the distinct prophylactic protective capacities of three yeast strains compared with the performance of prednisolone treatment.', 'subject score': 888, 'object score': 758}, 'PMID:27424097': {'publication date': '2016 Sep', 'sentence': 'Forty male Swiss mice were assigned into five groups: control; control treated with LED therapy; colitis without treatment; colitis treated with LED therapy; colitis treated with Prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:28821031': {'publication date': '2017 Oct 15', 'sentence': 'Surface-deacetylated chitin nanofibers (SDACNFs) reinforced with a sulfobutyl ether beta-cyclodextrin (SBE-beta-CD) (NFs-CDs) gel were developed to obtain a controlled release carrier of prednisolone (PD) for the treatment of colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:31678983': {'publication date': '2019 Nov 03', 'sentence': 'After confirming that the blood culture became negative, prednisolone (PDL) was started as therapy for the colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7364320': {'publication date': '1980 Jan', 'sentence': 'Peak plasma levels were reduced after an oral dose of 40 mg prednisolone in six patients with severe acute colitis as compared with six normal subjects, though total absorption appeared to be similar; the findings suggest that prednisolone absorption was delayed in acute colitis.', 'subject score': 851, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0009319---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7704078",
-              "object": "MONDO:0005292",
-              "publications": [
-                "PMID:10496564",
-                "PMID:12207075",
-                "PMID:20440854",
-                "PMID:27424097",
-                "PMID:28821031",
-                "PMID:31678983",
-                "PMID:7364320"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:21830095': {'publication date': '2011 Nov', 'sentence': 'Prednisolone prevented the development of colitis, but had no effect on already-developed colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:29379336': {'publication date': '2018 Jan', 'sentence': 'Only polar extract at both doses (200, 400 mg/kg) was more effective than the standard drug Prednisolone (50 mg/kg), it produced percent protection of control colitis by 63.8% and78.4% respectively, while the standard drug Prednisolone produced 54.9% protection.', 'subject score': 851, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 319330,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005292",
-          "name": "colitis",
-          "description": "Inflammation of the colon.; Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.; Colitis refers to an inflammation of the colon and is often used to describe an inflammation of the large intestine (colon, cecum and rectum). Colitides may be acute and self-limited or chronic, and broadly fit into the category of digestive diseases. [HPO:sdoelken]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10079511",
-            "SNOMEDCT:64226004",
-            "UMLS:C0009319",
-            "MESH:D003092",
-            "EFO:0003872",
-            "ICD10:K52.9",
-            "MEDDRA:10009889",
-            "MONDO:0005292",
-            "NCIT:C26723",
-            "MEDDRA:10009898",
-            "PSY:10220",
-            "DOID:0060180",
-            "HP:0002583",
-            "MEDDRA:10009887"
-          ],
-          "id": "MONDO:0005292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Colitis",
-            "colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319330,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005292",
-              "name": "colitis",
-              "description": "Inflammation of the colon.; Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.; Colitis refers to an inflammation of the colon and is often used to describe an inflammation of the large intestine (colon, cecum and rectum). Colitides may be acute and self-limited or chronic, and broadly fit into the category of digestive diseases. [HPO:sdoelken]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10079511",
-                "SNOMEDCT:64226004",
-                "UMLS:C0009319",
-                "MESH:D003092",
-                "EFO:0003872",
-                "ICD10:K52.9",
-                "MEDDRA:10009889",
-                "MONDO:0005292",
-                "NCIT:C26723",
-                "MEDDRA:10009898",
-                "PSY:10220",
-                "DOID:0060180",
-                "HP:0002583",
-                "MEDDRA:10009887"
-              ],
-              "id": "MONDO:0005292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Colitis",
-                "colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15484616,
-            "start": 568,
-            "end": 319330,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21830095': {'publication date': '2011 Nov', 'sentence': 'Prednisolone prevented the development of colitis, but had no effect on already-developed colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:29379336': {'publication date': '2018 Jan', 'sentence': 'Only polar extract at both doses (200, 400 mg/kg) was more effective than the standard drug Prednisolone (50 mg/kg), it produced percent protection of control colitis by 63.8% and78.4% respectively, while the standard drug Prednisolone produced 54.9% protection.', 'subject score': 851, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:prevents---None---None---None---UMLS:C0009319---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "15809068",
-              "object": "MONDO:0005292",
-              "publications": [
-                "PMID:21830095",
-                "PMID:29379336"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:29720511': {'publication date': '2018 Jun', 'sentence': 'Prednisolone is associated with a worse bone mineral density in primary adrenal insufficiency.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 312684,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015129",
-          "name": "chronic primary adrenal insufficiency",
-          "description": "A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.; An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands as a result of a primary defect in the glands themselves. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0001403",
-            "MONDO:0015129",
-            "DOID:13774",
-            "SNOMEDCT:363732003",
-            "PSY:00810",
-            "MEDDRA:10052381",
-            "UMLS:C1868690",
-            "OMIM:240200",
-            "ICD10:E27.1",
-            "UMLS:C0271737",
-            "MEDDRA:10080674",
-            "SNOMEDCT:373662000",
-            "MEDDRA:10013096",
-            "MEDDRA:10001130",
-            "HP:0008207",
-            "MEDDRA:10036696",
-            "MESH:D000075262",
-            "MESH:D000224",
-            "SNOMEDCT:76715008",
-            "ORPHANET:101959",
-            "NCIT:C26689",
-            "MEDDRA:10085976"
-          ],
-          "id": "MONDO:0015129",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hypoadrenocorticism, Familial",
-            "Primary adrenal insufficiency",
-            "Addisons Disease",
-            "Chronic primary adrenal insufficiency",
-            "Addison's disease due to autoimmunity",
-            "Addison Disease",
-            "Addison's disease",
-            "chronic primary adrenal insufficiency",
-            "Hypoadrenocorticism, familial",
-            "Hypoadrenocorticism, familial related phenotypic feature",
-            "Addison's Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/addison%27s_disease",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312684,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015129",
-              "name": "chronic primary adrenal insufficiency",
-              "description": "A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.; An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands as a result of a primary defect in the glands themselves. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0001403",
-                "MONDO:0015129",
-                "DOID:13774",
-                "SNOMEDCT:363732003",
-                "PSY:00810",
-                "MEDDRA:10052381",
-                "UMLS:C1868690",
-                "OMIM:240200",
-                "ICD10:E27.1",
-                "UMLS:C0271737",
-                "MEDDRA:10080674",
-                "SNOMEDCT:373662000",
-                "MEDDRA:10013096",
-                "MEDDRA:10001130",
-                "HP:0008207",
-                "MEDDRA:10036696",
-                "MESH:D000075262",
-                "MESH:D000224",
-                "SNOMEDCT:76715008",
-                "ORPHANET:101959",
-                "NCIT:C26689",
-                "MEDDRA:10085976"
-              ],
-              "id": "MONDO:0015129",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hypoadrenocorticism, Familial",
-                "Primary adrenal insufficiency",
-                "Addisons Disease",
-                "Chronic primary adrenal insufficiency",
-                "Addison's disease due to autoimmunity",
-                "Addison Disease",
-                "Addison's disease",
-                "chronic primary adrenal insufficiency",
-                "Hypoadrenocorticism, familial",
-                "Hypoadrenocorticism, familial related phenotypic feature",
-                "Addison's Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/addison%27s_disease",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19916915,
-            "start": 568,
-            "end": 312684,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29720511': {'publication date': '2018 Jun', 'sentence': 'Prednisolone is associated with a worse bone mineral density in primary adrenal insufficiency.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0001403---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "20312000",
-              "object": "MONDO:0015129",
-              "publications": [
-                "PMID:29720511"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:31994621': {'publication date': '2019 Dec', 'sentence': 'The patient started insulin therapy and treatment for AD with prednisolone and fludrocortisone with good clinical response.', 'subject score': 1000, 'object score': 1000}, 'PMID:32264857': {'publication date': '2020 Apr 07', 'sentence': \"CASE PRESENTATION: A 52-year-old woman with autoimmune hepatitis (AIH) and bronchial asthma was diagnosed with APS-2; autoimmune Addison's disease (AD), and Hashimoto's thyroiditis (HT), and she underwent prednisolone (PSL) treatment.\", 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 312684,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015129",
-          "name": "chronic primary adrenal insufficiency",
-          "description": "A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.; An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands as a result of a primary defect in the glands themselves. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0001403",
-            "MONDO:0015129",
-            "DOID:13774",
-            "SNOMEDCT:363732003",
-            "PSY:00810",
-            "MEDDRA:10052381",
-            "UMLS:C1868690",
-            "OMIM:240200",
-            "ICD10:E27.1",
-            "UMLS:C0271737",
-            "MEDDRA:10080674",
-            "SNOMEDCT:373662000",
-            "MEDDRA:10013096",
-            "MEDDRA:10001130",
-            "HP:0008207",
-            "MEDDRA:10036696",
-            "MESH:D000075262",
-            "MESH:D000224",
-            "SNOMEDCT:76715008",
-            "ORPHANET:101959",
-            "NCIT:C26689",
-            "MEDDRA:10085976"
-          ],
-          "id": "MONDO:0015129",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hypoadrenocorticism, Familial",
-            "Primary adrenal insufficiency",
-            "Addisons Disease",
-            "Chronic primary adrenal insufficiency",
-            "Addison's disease due to autoimmunity",
-            "Addison Disease",
-            "Addison's disease",
-            "chronic primary adrenal insufficiency",
-            "Hypoadrenocorticism, familial",
-            "Hypoadrenocorticism, familial related phenotypic feature",
-            "Addison's Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/addison%27s_disease",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312684,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015129",
-              "name": "chronic primary adrenal insufficiency",
-              "description": "A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.; An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands as a result of a primary defect in the glands themselves. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0001403",
-                "MONDO:0015129",
-                "DOID:13774",
-                "SNOMEDCT:363732003",
-                "PSY:00810",
-                "MEDDRA:10052381",
-                "UMLS:C1868690",
-                "OMIM:240200",
-                "ICD10:E27.1",
-                "UMLS:C0271737",
-                "MEDDRA:10080674",
-                "SNOMEDCT:373662000",
-                "MEDDRA:10013096",
-                "MEDDRA:10001130",
-                "HP:0008207",
-                "MEDDRA:10036696",
-                "MESH:D000075262",
-                "MESH:D000224",
-                "SNOMEDCT:76715008",
-                "ORPHANET:101959",
-                "NCIT:C26689",
-                "MEDDRA:10085976"
-              ],
-              "id": "MONDO:0015129",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hypoadrenocorticism, Familial",
-                "Primary adrenal insufficiency",
-                "Addisons Disease",
-                "Chronic primary adrenal insufficiency",
-                "Addison's disease due to autoimmunity",
-                "Addison Disease",
-                "Addison's disease",
-                "chronic primary adrenal insufficiency",
-                "Hypoadrenocorticism, familial",
-                "Hypoadrenocorticism, familial related phenotypic feature",
-                "Addison's Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/addison%27s_disease",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21219099,
-            "start": 568,
-            "end": 312684,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31994621': {'publication date': '2019 Dec', 'sentence': 'The patient started insulin therapy and treatment for AD with prednisolone and fludrocortisone with good clinical response.', 'subject score': 1000, 'object score': 1000}, 'PMID:32264857': {'publication date': '2020 Apr 07', 'sentence': \"CASE PRESENTATION: A 52-year-old woman with autoimmune hepatitis (AIH) and bronchial asthma was diagnosed with APS-2; autoimmune Addison's disease (AD), and Hashimoto's thyroiditis (HT), and she underwent prednisolone (PSL) treatment.\", 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0001403---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0271737---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "21634207",
-              "object": "MONDO:0015129",
-              "publications": [
-                "PMID:31994621",
-                "PMID:32264857"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:30102868': {'publication date': '2018 Oct', 'sentence': 'To illustrate this, we used an example of cost-effectiveness analysis for docetaxel in combination with prednisolone in metastatic hormone-refractory prostate cancer.', 'subject score': 1000, 'object score': 937}}",
-    "p2": {
-      "start": {
-        "identity": 610975,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/DOID_0080909",
-          "name": "castration-resistant prostate carcinoma",
-          "description": "A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.",
-          "equivalent_curies": [
-            "MESH:D064129",
-            "MONDO:0850353",
-            "DOID:0080909",
-            "MEDDRA:10076506",
-            "SNOMEDCT:427492003",
-            "UMLS:C3658267",
-            "MEDDRA:10062904",
-            "NCIT:C130234",
-            "UMLS:C1328504"
-          ],
-          "id": "DOID:0080909",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Prostatic Neoplasms, Castration-Resistant",
-            "castration-resistant prostate carcinoma",
-            "Castration-Resistant Prostate Carcinoma",
-            "Hormone refractory prostate cancer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:30324351"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 610975,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/DOID_0080909",
-              "name": "castration-resistant prostate carcinoma",
-              "description": "A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.",
-              "equivalent_curies": [
-                "MESH:D064129",
-                "MONDO:0850353",
-                "DOID:0080909",
-                "MEDDRA:10076506",
-                "SNOMEDCT:427492003",
-                "UMLS:C3658267",
-                "MEDDRA:10062904",
-                "NCIT:C130234",
-                "UMLS:C1328504"
-              ],
-              "id": "DOID:0080909",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Prostatic Neoplasms, Castration-Resistant",
-                "castration-resistant prostate carcinoma",
-                "Castration-Resistant Prostate Carcinoma",
-                "Hormone refractory prostate cancer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:30324351"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20104766,
-            "start": 568,
-            "end": 610975,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30102868': {'publication date': '2018 Oct', 'sentence': 'To illustrate this, we used an example of cost-effectiveness analysis for docetaxel in combination with prednisolone in metastatic hormone-refractory prostate cancer.', 'subject score': 1000, 'object score': 937}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C1328504---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "20512112",
-              "object": "DOID:0080909",
-              "publications": [
-                "PMID:30102868"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:9234622': {'publication date': '1997 Jun', 'sentence': '[A case of hormone-refractory prostate cancer responsive to low-dose prednisolone therapy].', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 610975,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/DOID_0080909",
-          "name": "castration-resistant prostate carcinoma",
-          "description": "A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.",
-          "equivalent_curies": [
-            "MESH:D064129",
-            "MONDO:0850353",
-            "DOID:0080909",
-            "MEDDRA:10076506",
-            "SNOMEDCT:427492003",
-            "UMLS:C3658267",
-            "MEDDRA:10062904",
-            "NCIT:C130234",
-            "UMLS:C1328504"
-          ],
-          "id": "DOID:0080909",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Prostatic Neoplasms, Castration-Resistant",
-            "castration-resistant prostate carcinoma",
-            "Castration-Resistant Prostate Carcinoma",
-            "Hormone refractory prostate cancer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:30324351"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 610975,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/DOID_0080909",
-              "name": "castration-resistant prostate carcinoma",
-              "description": "A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.",
-              "equivalent_curies": [
-                "MESH:D064129",
-                "MONDO:0850353",
-                "DOID:0080909",
-                "MEDDRA:10076506",
-                "SNOMEDCT:427492003",
-                "UMLS:C3658267",
-                "MEDDRA:10062904",
-                "NCIT:C130234",
-                "UMLS:C1328504"
-              ],
-              "id": "DOID:0080909",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Prostatic Neoplasms, Castration-Resistant",
-                "castration-resistant prostate carcinoma",
-                "Castration-Resistant Prostate Carcinoma",
-                "Hormone refractory prostate cancer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:30324351"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26939682,
-            "start": 568,
-            "end": 610975,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9234622': {'publication date': '1997 Jun', 'sentence': '[A case of hormone-refractory prostate cancer responsive to low-dose prednisolone therapy].', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C1328504---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "27410586",
-              "object": "DOID:0080909",
-              "publications": [
-                "PMID:9234622"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:16338867': {'publication date': '2006', 'sentence': 'Fifteen patients 60 to 80 years old (a mean of 72 years) with hormone-refractory prostate cancer were treated with low dose prednisolone.', 'subject score': 901, 'object score': 1000}, 'PMID:16770110': {'publication date': '2006 Jun', 'sentence': 'We have experienced a patient with tumor fever from hormone-refractory prostate cancer (HRPC) who was treated successfully using docetaxel plus prednisolone therapy.', 'subject score': 833, 'object score': 1000}, 'PMID:16880788': {'publication date': '2006 Aug 21', 'sentence': 'A systematic review was performed to evaluate the clinical effectiveness of docetaxel in combination with prednisolone (docetaxel is licensed in the UK for use in combination with prednisone or prednisolone for the treatment of patients with metastatic hormone-refractory prostate cancer. Prednisone is not used in the UK, but it is reasonable to use docetaxel plus prednisone data in this review of docetaxel plus prednisolone) for the treatment of metastatic hormone-refractory prostate cancer.', 'subject score': 1000, 'object score': 937}, 'PMID:17181985': {'publication date': '2007 Jan', 'sentence': 'OBJECTIVES: A systematic review was undertaken and an economic model constructed to evaluate the clinical effectiveness and cost-effectiveness of docetaxel (Taxotere, Sanofi-Aventis) in combination with prednisone/prednisolone for the treatment of metastatic hormone-refractory prostate cancer (mHRPC).', 'subject score': 888, 'object score': 937}, 'PMID:17352157': {'publication date': '2007 Feb', 'sentence': 'Between April 2004 and August 2005, we used docetaxel in combination with prednisolone to treat 14 patients with hormone-refractory prostate cancer (HRPC).', 'subject score': 1000, 'object score': 1000}, 'PMID:18417502': {'publication date': '2008 May', 'sentence': 'CONCLUSION: The combination of docetaxel and prednisolone was feasible and active in Japanese patients with HRPC, with a manageable adverse-event profile similar to that observed in Western patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:18657098': {'publication date': '2009', 'sentence': 'RESULTS: Depending on the cost-effectiveness threshold (lambda), we identified mitoxantrone plus prednisone/prednisolone and docetaxel plus prednisone/prednisolone (3 weekly) as the optimal treatments for mHRPC.', 'subject score': 833, 'object score': 937}, 'PMID:19409038': {'publication date': '2009 Apr', 'sentence': 'This randomized (1:1), double-blind study evaluated vandetanib (100 mg/day) or placebo in combination with docetaxel (D; 75 mg/m(2) every 3 weeks) and prednisolone (P; 2 x 5 mg/day) in 86 patients with metastatic hormone-refractory prostate cancer (mHRPC).', 'subject score': 1000, 'object score': 937}, 'PMID:19837689': {'publication date': '2010 Jan', 'sentence': 'Docetaxel in combination with prednisolone for hormone refractory prostate cancer.', 'subject score': 1000, 'object score': 1000}, 'PMID:20587613': {'publication date': '2010 Nov', 'sentence': 'METHODS: From April 2004 through August 2008, we used docetaxel plus prednisolone to treat 55 HRPC patients (median age, 72 years).', 'subject score': 851, 'object score': 876}, 'PMID:23580356': {'publication date': '2013 Jun', 'sentence': 'Clinical evidence was derived from a multinational randomized open-label phase III trial of cabazitaxel plus prednisone or prednisolone in men with mHRPC that had progressed during or following treatment with docetaxel.', 'subject score': 1000, 'object score': 937}, 'PMID:28683707': {'publication date': '2017 Jul 01', 'sentence': 'Docetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer.', 'subject score': 1000, 'object score': 924}, 'PMID:34050660': {'publication date': '2021 May 29', 'sentence': 'CONCLUSIONS: This large-scale, real-world, post-marketing surveillance study confirmed the safety and efficacy of abiraterone acetate plus prednisolone in Japanese castration-resistant prostate cancer patients with or without previous chemotherapy.', 'subject score': 861, 'object score': 876}, 'PMID:35813251': {'publication date': '2022 Jul', 'sentence': 'Background: Enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) improve survival in castration-resistant prostate cancer (CRPC).', 'subject score': 851, 'object score': 1000}, 'PMID:9186348': {'publication date': '1997 Jul', 'sentence': 'MATERIALS AND METHODS: We describe a prospective, randomized study of 40 patients comparing the second line response of flutamide to prednisolone in patients with known hormone refractory stage M1 prostate cancer.', 'subject score': 1000, 'object score': 863}}",
-    "p2": {
-      "start": {
-        "identity": 610975,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/DOID_0080909",
-          "name": "castration-resistant prostate carcinoma",
-          "description": "A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.",
-          "equivalent_curies": [
-            "MESH:D064129",
-            "MONDO:0850353",
-            "DOID:0080909",
-            "MEDDRA:10076506",
-            "SNOMEDCT:427492003",
-            "UMLS:C3658267",
-            "MEDDRA:10062904",
-            "NCIT:C130234",
-            "UMLS:C1328504"
-          ],
-          "id": "DOID:0080909",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Prostatic Neoplasms, Castration-Resistant",
-            "castration-resistant prostate carcinoma",
-            "Castration-Resistant Prostate Carcinoma",
-            "Hormone refractory prostate cancer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:30324351"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 610975,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/DOID_0080909",
-              "name": "castration-resistant prostate carcinoma",
-              "description": "A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.",
-              "equivalent_curies": [
-                "MESH:D064129",
-                "MONDO:0850353",
-                "DOID:0080909",
-                "MEDDRA:10076506",
-                "SNOMEDCT:427492003",
-                "UMLS:C3658267",
-                "MEDDRA:10062904",
-                "NCIT:C130234",
-                "UMLS:C1328504"
-              ],
-              "id": "DOID:0080909",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Prostatic Neoplasms, Castration-Resistant",
-                "castration-resistant prostate carcinoma",
-                "Castration-Resistant Prostate Carcinoma",
-                "Hormone refractory prostate cancer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:30324351"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11919963,
-            "start": 568,
-            "end": 610975,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16338867': {'publication date': '2006', 'sentence': 'Fifteen patients 60 to 80 years old (a mean of 72 years) with hormone-refractory prostate cancer were treated with low dose prednisolone.', 'subject score': 901, 'object score': 1000}, 'PMID:16770110': {'publication date': '2006 Jun', 'sentence': 'We have experienced a patient with tumor fever from hormone-refractory prostate cancer (HRPC) who was treated successfully using docetaxel plus prednisolone therapy.', 'subject score': 833, 'object score': 1000}, 'PMID:16880788': {'publication date': '2006 Aug 21', 'sentence': 'A systematic review was performed to evaluate the clinical effectiveness of docetaxel in combination with prednisolone (docetaxel is licensed in the UK for use in combination with prednisone or prednisolone for the treatment of patients with metastatic hormone-refractory prostate cancer. Prednisone is not used in the UK, but it is reasonable to use docetaxel plus prednisone data in this review of docetaxel plus prednisolone) for the treatment of metastatic hormone-refractory prostate cancer.', 'subject score': 1000, 'object score': 937}, 'PMID:17181985': {'publication date': '2007 Jan', 'sentence': 'OBJECTIVES: A systematic review was undertaken and an economic model constructed to evaluate the clinical effectiveness and cost-effectiveness of docetaxel (Taxotere, Sanofi-Aventis) in combination with prednisone/prednisolone for the treatment of metastatic hormone-refractory prostate cancer (mHRPC).', 'subject score': 888, 'object score': 937}, 'PMID:17352157': {'publication date': '2007 Feb', 'sentence': 'Between April 2004 and August 2005, we used docetaxel in combination with prednisolone to treat 14 patients with hormone-refractory prostate cancer (HRPC).', 'subject score': 1000, 'object score': 1000}, 'PMID:18417502': {'publication date': '2008 May', 'sentence': 'CONCLUSION: The combination of docetaxel and prednisolone was feasible and active in Japanese patients with HRPC, with a manageable adverse-event profile similar to that observed in Western patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:18657098': {'publication date': '2009', 'sentence': 'RESULTS: Depending on the cost-effectiveness threshold (lambda), we identified mitoxantrone plus prednisone/prednisolone and docetaxel plus prednisone/prednisolone (3 weekly) as the optimal treatments for mHRPC.', 'subject score': 833, 'object score': 937}, 'PMID:19409038': {'publication date': '2009 Apr', 'sentence': 'This randomized (1:1), double-blind study evaluated vandetanib (100 mg/day) or placebo in combination with docetaxel (D; 75 mg/m(2) every 3 weeks) and prednisolone (P; 2 x 5 mg/day) in 86 patients with metastatic hormone-refractory prostate cancer (mHRPC).', 'subject score': 1000, 'object score': 937}, 'PMID:19837689': {'publication date': '2010 Jan', 'sentence': 'Docetaxel in combination with prednisolone for hormone refractory prostate cancer.', 'subject score': 1000, 'object score': 1000}, 'PMID:20587613': {'publication date': '2010 Nov', 'sentence': 'METHODS: From April 2004 through August 2008, we used docetaxel plus prednisolone to treat 55 HRPC patients (median age, 72 years).', 'subject score': 851, 'object score': 876}, 'PMID:23580356': {'publication date': '2013 Jun', 'sentence': 'Clinical evidence was derived from a multinational randomized open-label phase III trial of cabazitaxel plus prednisone or prednisolone in men with mHRPC that had progressed during or following treatment with docetaxel.', 'subject score': 1000, 'object score': 937}, 'PMID:28683707': {'publication date': '2017 Jul 01', 'sentence': 'Docetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer.', 'subject score': 1000, 'object score': 924}, 'PMID:34050660': {'publication date': '2021 May 29', 'sentence': 'CONCLUSIONS: This large-scale, real-world, post-marketing surveillance study confirmed the safety and efficacy of abiraterone acetate plus prednisolone in Japanese castration-resistant prostate cancer patients with or without previous chemotherapy.', 'subject score': 861, 'object score': 876}, 'PMID:35813251': {'publication date': '2022 Jul', 'sentence': 'Background: Enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) improve survival in castration-resistant prostate cancer (CRPC).', 'subject score': 851, 'object score': 1000}, 'PMID:9186348': {'publication date': '1997 Jul', 'sentence': 'MATERIALS AND METHODS: We describe a prospective, randomized study of 40 patients comparing the second line response of flutamide to prednisolone in patients with known hormone refractory stage M1 prostate cancer.', 'subject score': 1000, 'object score': 863}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C1328504---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "12190701",
-              "object": "DOID:0080909",
-              "publications": [
-                "PMID:16338867",
-                "PMID:16770110",
-                "PMID:16880788",
-                "PMID:17181985",
-                "PMID:17352157",
-                "PMID:18417502",
-                "PMID:18657098",
-                "PMID:19409038",
-                "PMID:19837689",
-                "PMID:20587613",
-                "PMID:23580356",
-                "PMID:28683707",
-                "PMID:34050660",
-                "PMID:35813251",
-                "PMID:9186348"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:355719': {'publication date': '1978 Jul', 'sentence': '[Effect of prednisolone and heparin on circulating T- and B-lymphocytes in glomerulonephritis and systemic lupus erythematosus].', 'subject score': 1000, 'object score': 1000}, 'PMID:5660892': {'publication date': '1968 Feb', 'sentence': '[The effect of prednisolone on serum protein fractions in experimental glomerulonephritis].', 'subject score': 1000, 'object score': 888}, 'PMID:9420390': {'publication date': '1997 Jun', 'sentence': 'Evaluation of efficacy of methylprednisolone, prednisolone and chlorambucil in idiopathic glomerulonephritis.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 318918,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002462",
-          "name": "glomerulonephritis",
-          "description": "A renal disorder characterized by damage in the glomeruli. It may be acute or chronic, focal or diffuse, and it may lead to renal failure. Causes include autoimmune disorders, infections, diabetes, and malignancies.; A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.; Inflammation of the renal glomeruli. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029143",
-            "UMLS:C0017658",
-            "SNOMEDCT:36171008",
-            "DOID:2921",
-            "HP:0000099",
-            "MESH:D005921",
-            "MEDDRA:10018364",
-            "MEDDRA:10018375",
-            "MONDO:0002462",
-            "ICD10:N08",
-            "NCIT:C26784"
-          ],
-          "id": "MONDO:0002462",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Glomerulonephritis",
-            "glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/wiki/glomerulonephritis",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318918,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002462",
-              "name": "glomerulonephritis",
-              "description": "A renal disorder characterized by damage in the glomeruli. It may be acute or chronic, focal or diffuse, and it may lead to renal failure. Causes include autoimmune disorders, infections, diabetes, and malignancies.; A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.; Inflammation of the renal glomeruli. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029143",
-                "UMLS:C0017658",
-                "SNOMEDCT:36171008",
-                "DOID:2921",
-                "HP:0000099",
-                "MESH:D005921",
-                "MEDDRA:10018364",
-                "MEDDRA:10018375",
-                "MONDO:0002462",
-                "ICD10:N08",
-                "NCIT:C26784"
-              ],
-              "id": "MONDO:0002462",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Glomerulonephritis",
-                "glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/wiki/glomerulonephritis",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24081562,
-            "start": 568,
-            "end": 318918,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:355719': {'publication date': '1978 Jul', 'sentence': '[Effect of prednisolone and heparin on circulating T- and B-lymphocytes in glomerulonephritis and systemic lupus erythematosus].', 'subject score': 1000, 'object score': 1000}, 'PMID:5660892': {'publication date': '1968 Feb', 'sentence': '[The effect of prednisolone on serum protein fractions in experimental glomerulonephritis].', 'subject score': 1000, 'object score': 888}, 'PMID:9420390': {'publication date': '1997 Jun', 'sentence': 'Evaluation of efficacy of methylprednisolone, prednisolone and chlorambucil in idiopathic glomerulonephritis.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0017658---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "24523226",
-              "object": "MONDO:0002462",
-              "publications": [
-                "PMID:355719",
-                "PMID:5660892",
-                "PMID:9420390"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:36508113': {'publication date': '2022 Dec 12', 'sentence': 'Immunosuppressant therapy, such as prednisolone or azathioprine, is considered for exacerbations of highly active glomerulonephritis.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 318918,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002462",
-          "name": "glomerulonephritis",
-          "description": "A renal disorder characterized by damage in the glomeruli. It may be acute or chronic, focal or diffuse, and it may lead to renal failure. Causes include autoimmune disorders, infections, diabetes, and malignancies.; A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.; Inflammation of the renal glomeruli. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029143",
-            "UMLS:C0017658",
-            "SNOMEDCT:36171008",
-            "DOID:2921",
-            "HP:0000099",
-            "MESH:D005921",
-            "MEDDRA:10018364",
-            "MEDDRA:10018375",
-            "MONDO:0002462",
-            "ICD10:N08",
-            "NCIT:C26784"
-          ],
-          "id": "MONDO:0002462",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Glomerulonephritis",
-            "glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/wiki/glomerulonephritis",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318918,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002462",
-              "name": "glomerulonephritis",
-              "description": "A renal disorder characterized by damage in the glomeruli. It may be acute or chronic, focal or diffuse, and it may lead to renal failure. Causes include autoimmune disorders, infections, diabetes, and malignancies.; A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.; Inflammation of the renal glomeruli. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029143",
-                "UMLS:C0017658",
-                "SNOMEDCT:36171008",
-                "DOID:2921",
-                "HP:0000099",
-                "MESH:D005921",
-                "MEDDRA:10018364",
-                "MEDDRA:10018375",
-                "MONDO:0002462",
-                "ICD10:N08",
-                "NCIT:C26784"
-              ],
-              "id": "MONDO:0002462",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Glomerulonephritis",
-                "glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/wiki/glomerulonephritis",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24718562,
-            "start": 568,
-            "end": 318918,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:36508113': {'publication date': '2022 Dec 12', 'sentence': 'Immunosuppressant therapy, such as prednisolone or azathioprine, is considered for exacerbations of highly active glomerulonephritis.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0017658---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "25165576",
-              "object": "MONDO:0002462",
-              "publications": [
-                "PMID:36508113"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1220151': {'publication date': '1975 Nov', 'sentence': '[Comparative characteristics of the spectrum of free amino acids of blood serum and urine in children with glomerulonephritis treated with prednisolone, leukeran and anabolic steroids].', 'subject score': 1000, 'object score': 1000}, 'PMID:12890898': {'publication date': '2003 Aug', 'sentence': 'In the experimental glomerulonephritis induced in mice by anti-glomerular basement membrane antiserum, KF24345 significantly inhibited proteinuria and glomerular damage without exhibiting the side effects observed following the treatment with prednisolone and cyclophosphamide.', 'subject score': 1000, 'object score': 888}, 'PMID:18622025': {'publication date': '2008 Nov', 'sentence': 'Anti-thrombin drugs and prednisolone may be useful in treating crescentic glomerulonephritis.', 'subject score': 1000, 'object score': 828}, 'PMID:25619396': {'publication date': '2015 Feb', 'sentence': 'RESULTS: Treatment of PHN rats with SM934 or prednisolone attenuated the progression of glomerulonephritis and renal fibrosis, as evidenced by the reduced level of proteinuria and circulating antibodies, as well as by the reduced immune complex deposition, reversed podocyte injuries, and attenuated tubulointerstitial fibrosis in the kidneys.', 'subject score': 1000, 'object score': 1000}, 'PMID:30633192': {'publication date': '2019 Jan', 'sentence': 'Successful entecavir plus prednisolone treatment for hepatitis B virus-associated membranoproliferative glomerulonephritis: A case report.', 'subject score': 822, 'object score': 836}, 'PMID:35420387': {'publication date': '2022 Apr 14', 'sentence': 'Treatment with prednisolone for ANCA-associated glomerulonephritis, normalized urinalysis and decreased PR3-ANCA but MGUS persisted.', 'subject score': 1000, 'object score': 802}, 'PMID:3546234': {'publication date': '1987 Jan 01', 'sentence': 'In 5 dogs, treatment of glomerulonephritis with prednisolone (0.5 to 1.1 mg/kg) did not result in beneficial effects and in fact appeared to be detrimental, leading to azotemia and worsening proteinuria and physical condition in some of the dogs.', 'subject score': 1000, 'object score': 1000}, 'PMID:35930173': {'publication date': '2022 Aug 05', 'sentence': 'This study investigates the therapeutic effect of myrrh as a natural medicine compared to prednisolone in the treatment of immune-mediated glomerulonephritis induced by silicate.', 'subject score': 1000, 'object score': 901}, 'PMID:4000815': {'publication date': '1985 Mar', 'sentence': '[Cases of cataract during treatment of glomerulonephritis in children with prednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:4710416': {'publication date': '1973', 'sentence': '[Comparative evaluation of the effectiveness of prednisolone and indotsid in the treatment of experimental autoimmune glomerulonephritis].', 'subject score': 1000, 'object score': 851}, 'PMID:7694426': {'publication date': '1993 Jul-Aug', 'sentence': 'The employment of reaferon for treatment of GN patients was shown to increase the efficacy of GN treatment, especially in combination with immunosuppressive drugs, to prevent reactivation of hepatitis B virus when prednisolone and/or cytostatic drugs were used, and to reduce hepatitis activity.', 'subject score': 1000, 'object score': 888}, 'PMID:9697658': {'publication date': '1998 Aug', 'sentence': 'The beneficial effect of prednisolone on this GN may be partially mediated by the suppression of MAPK, followed by the suppression of AP-1.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318918,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002462",
-          "name": "glomerulonephritis",
-          "description": "A renal disorder characterized by damage in the glomeruli. It may be acute or chronic, focal or diffuse, and it may lead to renal failure. Causes include autoimmune disorders, infections, diabetes, and malignancies.; A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.; Inflammation of the renal glomeruli. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029143",
-            "UMLS:C0017658",
-            "SNOMEDCT:36171008",
-            "DOID:2921",
-            "HP:0000099",
-            "MESH:D005921",
-            "MEDDRA:10018364",
-            "MEDDRA:10018375",
-            "MONDO:0002462",
-            "ICD10:N08",
-            "NCIT:C26784"
-          ],
-          "id": "MONDO:0002462",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Glomerulonephritis",
-            "glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/wiki/glomerulonephritis",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318918,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002462",
-              "name": "glomerulonephritis",
-              "description": "A renal disorder characterized by damage in the glomeruli. It may be acute or chronic, focal or diffuse, and it may lead to renal failure. Causes include autoimmune disorders, infections, diabetes, and malignancies.; A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.; Inflammation of the renal glomeruli. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029143",
-                "UMLS:C0017658",
-                "SNOMEDCT:36171008",
-                "DOID:2921",
-                "HP:0000099",
-                "MESH:D005921",
-                "MEDDRA:10018364",
-                "MEDDRA:10018375",
-                "MONDO:0002462",
-                "ICD10:N08",
-                "NCIT:C26784"
-              ],
-              "id": "MONDO:0002462",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Glomerulonephritis",
-                "glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/wiki/glomerulonephritis",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9518721,
-            "start": 568,
-            "end": 318918,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1220151': {'publication date': '1975 Nov', 'sentence': '[Comparative characteristics of the spectrum of free amino acids of blood serum and urine in children with glomerulonephritis treated with prednisolone, leukeran and anabolic steroids].', 'subject score': 1000, 'object score': 1000}, 'PMID:12890898': {'publication date': '2003 Aug', 'sentence': 'In the experimental glomerulonephritis induced in mice by anti-glomerular basement membrane antiserum, KF24345 significantly inhibited proteinuria and glomerular damage without exhibiting the side effects observed following the treatment with prednisolone and cyclophosphamide.', 'subject score': 1000, 'object score': 888}, 'PMID:18622025': {'publication date': '2008 Nov', 'sentence': 'Anti-thrombin drugs and prednisolone may be useful in treating crescentic glomerulonephritis.', 'subject score': 1000, 'object score': 828}, 'PMID:25619396': {'publication date': '2015 Feb', 'sentence': 'RESULTS: Treatment of PHN rats with SM934 or prednisolone attenuated the progression of glomerulonephritis and renal fibrosis, as evidenced by the reduced level of proteinuria and circulating antibodies, as well as by the reduced immune complex deposition, reversed podocyte injuries, and attenuated tubulointerstitial fibrosis in the kidneys.', 'subject score': 1000, 'object score': 1000}, 'PMID:30633192': {'publication date': '2019 Jan', 'sentence': 'Successful entecavir plus prednisolone treatment for hepatitis B virus-associated membranoproliferative glomerulonephritis: A case report.', 'subject score': 822, 'object score': 836}, 'PMID:35420387': {'publication date': '2022 Apr 14', 'sentence': 'Treatment with prednisolone for ANCA-associated glomerulonephritis, normalized urinalysis and decreased PR3-ANCA but MGUS persisted.', 'subject score': 1000, 'object score': 802}, 'PMID:3546234': {'publication date': '1987 Jan 01', 'sentence': 'In 5 dogs, treatment of glomerulonephritis with prednisolone (0.5 to 1.1 mg/kg) did not result in beneficial effects and in fact appeared to be detrimental, leading to azotemia and worsening proteinuria and physical condition in some of the dogs.', 'subject score': 1000, 'object score': 1000}, 'PMID:35930173': {'publication date': '2022 Aug 05', 'sentence': 'This study investigates the therapeutic effect of myrrh as a natural medicine compared to prednisolone in the treatment of immune-mediated glomerulonephritis induced by silicate.', 'subject score': 1000, 'object score': 901}, 'PMID:4000815': {'publication date': '1985 Mar', 'sentence': '[Cases of cataract during treatment of glomerulonephritis in children with prednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:4710416': {'publication date': '1973', 'sentence': '[Comparative evaluation of the effectiveness of prednisolone and indotsid in the treatment of experimental autoimmune glomerulonephritis].', 'subject score': 1000, 'object score': 851}, 'PMID:7694426': {'publication date': '1993 Jul-Aug', 'sentence': 'The employment of reaferon for treatment of GN patients was shown to increase the efficacy of GN treatment, especially in combination with immunosuppressive drugs, to prevent reactivation of hepatitis B virus when prednisolone and/or cytostatic drugs were used, and to reduce hepatitis activity.', 'subject score': 1000, 'object score': 888}, 'PMID:9697658': {'publication date': '1998 Aug', 'sentence': 'The beneficial effect of prednisolone on this GN may be partially mediated by the suppression of MAPK, followed by the suppression of AP-1.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0017658---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9729887",
-              "object": "MONDO:0002462",
-              "publications": [
-                "PMID:1220151",
-                "PMID:12890898",
-                "PMID:18622025",
-                "PMID:25619396",
-                "PMID:30633192",
-                "PMID:35420387",
-                "PMID:3546234",
-                "PMID:35930173",
-                "PMID:4000815",
-                "PMID:4710416",
-                "PMID:7694426",
-                "PMID:9697658"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12134708': {'publication date': '2002 Jun', 'sentence': 'The PRCA and AIHA were successfully treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:12191983': {'publication date': '2002 Sep', 'sentence': 'PRCA gradually improved after treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:1753420': {'publication date': '1991 Oct', 'sentence': 'The PRCA and hemolytic anemia were successfully treated with prednisolone (60 mg/day).', 'subject score': 1000, 'object score': 1000}, 'PMID:17633099': {'publication date': '2007 Jun', 'sentence': 'The PRCA and AIHA were successfully treated with prednisolone and cyclosporine.', 'subject score': 1000, 'object score': 1000}, 'PMID:18051792': {'publication date': '2007 Nov', 'sentence': 'Prednisolone treatment (50 mg daily) resulted in dramatic regression of recurrent mediastinal and pleural tumors, as well as improvement of pure red cell aplasia.', 'subject score': 888, 'object score': 1000}, 'PMID:2128749': {'publication date': '1990 Dec', 'sentence': 'A young female with pure red cell aplasia with brisk response to prednisolone therapy is described.', 'subject score': 888, 'object score': 1000}, 'PMID:23355260': {'publication date': '2013 Feb', 'sentence': 'Successful treatment of anti-erythropoietin antibody-mediated pure red cell aplasia with low-dose prednisolone.', 'subject score': 901, 'object score': 861}, 'PMID:24042508': {'publication date': '2013', 'sentence': 'CONCLUSION: Depending on the cause of the PRCA, treatment with CSP, PSL, or Ig was found to be effective in most PRCA cases.', 'subject score': 1000, 'object score': 1000}, 'PMID:8304314': {'publication date': '1994 Feb', 'sentence': 'Pure red cell aplasia was successfully treated by prednisolone or transfusion in all patients.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317306,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001705",
-          "name": "pure red-cell aplasia",
-          "description": "A type of anemia resulting from suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production. Erythroblasts are virtually absent in bone marrow; however, leukocyte and platelet production show little or no reduction. [HPO:probinson]; A type of anemia resulting from suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production. Erythroblasts are virtually absent in bone marrow; however, leukocyte and platelet production show little or no reduction. // COMMENTS: Pure red cell aplasia results from a maturation arrest occurs in the formation of erythrocytes.; A type of anemia resulting from suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production. Erythroblasts are virtually absent in bone marrow; however, leukocyte and platelet production show little or no reduction. // COMMENTS: Pure red cell aplasia results from a maturation arrest occurs in the formation of erythrocytes.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10038184",
-            "MESH:D012010",
-            "HP:0012410",
-            "MONDO:0001705",
-            "SNOMEDCT:50715003",
-            "NCIT:C34974",
-            "MEDDRA:10002965",
-            "UMLS:C0034902",
-            "MEDDRA:10002966",
-            "DOID:1340"
-          ],
-          "id": "MONDO:0001705",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Red-Cell Aplasia, Pure",
-            "pure red-cell aplasia",
-            "Pure red cell aplasia",
-            "Pure Red-Cell Aplasia",
-            "Pure Red Cell Aplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317306,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001705",
-              "name": "pure red-cell aplasia",
-              "description": "A type of anemia resulting from suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production. Erythroblasts are virtually absent in bone marrow; however, leukocyte and platelet production show little or no reduction. [HPO:probinson]; A type of anemia resulting from suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production. Erythroblasts are virtually absent in bone marrow; however, leukocyte and platelet production show little or no reduction. // COMMENTS: Pure red cell aplasia results from a maturation arrest occurs in the formation of erythrocytes.; A type of anemia resulting from suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production. Erythroblasts are virtually absent in bone marrow; however, leukocyte and platelet production show little or no reduction. // COMMENTS: Pure red cell aplasia results from a maturation arrest occurs in the formation of erythrocytes.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10038184",
-                "MESH:D012010",
-                "HP:0012410",
-                "MONDO:0001705",
-                "SNOMEDCT:50715003",
-                "NCIT:C34974",
-                "MEDDRA:10002965",
-                "UMLS:C0034902",
-                "MEDDRA:10002966",
-                "DOID:1340"
-              ],
-              "id": "MONDO:0001705",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Red-Cell Aplasia, Pure",
-                "pure red-cell aplasia",
-                "Pure red cell aplasia",
-                "Pure Red-Cell Aplasia",
-                "Pure Red Cell Aplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9459606,
-            "start": 568,
-            "end": 317306,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12134708': {'publication date': '2002 Jun', 'sentence': 'The PRCA and AIHA were successfully treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:12191983': {'publication date': '2002 Sep', 'sentence': 'PRCA gradually improved after treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:1753420': {'publication date': '1991 Oct', 'sentence': 'The PRCA and hemolytic anemia were successfully treated with prednisolone (60 mg/day).', 'subject score': 1000, 'object score': 1000}, 'PMID:17633099': {'publication date': '2007 Jun', 'sentence': 'The PRCA and AIHA were successfully treated with prednisolone and cyclosporine.', 'subject score': 1000, 'object score': 1000}, 'PMID:18051792': {'publication date': '2007 Nov', 'sentence': 'Prednisolone treatment (50 mg daily) resulted in dramatic regression of recurrent mediastinal and pleural tumors, as well as improvement of pure red cell aplasia.', 'subject score': 888, 'object score': 1000}, 'PMID:2128749': {'publication date': '1990 Dec', 'sentence': 'A young female with pure red cell aplasia with brisk response to prednisolone therapy is described.', 'subject score': 888, 'object score': 1000}, 'PMID:23355260': {'publication date': '2013 Feb', 'sentence': 'Successful treatment of anti-erythropoietin antibody-mediated pure red cell aplasia with low-dose prednisolone.', 'subject score': 901, 'object score': 861}, 'PMID:24042508': {'publication date': '2013', 'sentence': 'CONCLUSION: Depending on the cause of the PRCA, treatment with CSP, PSL, or Ig was found to be effective in most PRCA cases.', 'subject score': 1000, 'object score': 1000}, 'PMID:8304314': {'publication date': '1994 Feb', 'sentence': 'Pure red cell aplasia was successfully treated by prednisolone or transfusion in all patients.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0034902---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9668241",
-              "object": "MONDO:0001705",
-              "publications": [
-                "PMID:12134708",
-                "PMID:12191983",
-                "PMID:1753420",
-                "PMID:17633099",
-                "PMID:18051792",
-                "PMID:2128749",
-                "PMID:23355260",
-                "PMID:24042508",
-                "PMID:8304314"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:13919503': {'publication date': '1961 Mar', 'sentence': '[On the effect of oral use of prednisolone on central chorioretinitis].', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 317278,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004674",
-          "name": "chorioretinitis",
-          "description": "An inflammation of the choroid and retina. [ORCID:0000-0001-5208-3432, PMID:16196117]; An inflammation of the choroid and retina. // COMMENTS: Chorioretinitis is a form of posterior uveitis. Note that the term Chorioretinitis suggests that the origin of the process is predominantly in the choroid while Retinitis suggests that the process is mainly in the retina.; An inflammation of the choroid and retina. // COMMENTS: Chorioretinitis is a form of posterior uveitis. Note that the term Chorioretinitis suggests that the origin of the process is predominantly in the choroid while Retinitis suggests that the process is mainly in the retina.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:8886",
-            "SNOMEDCT:46627006",
-            "ICD10:H30.9",
-            "HP:0012424",
-            "ICD9:363.20",
-            "MONDO:0004674",
-            "MESH:D002825",
-            "UMLS:C0008513",
-            "NCIT:C110923",
-            "MEDDRA:10008769",
-            "MEDDRA:10086282",
-            "MEDDRA:10008771"
-          ],
-          "id": "MONDO:0004674",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chorioretinitis",
-            "Chorioretinitis, unspecified",
-            "chorioretinitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:16196117",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0001-5208-3432"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317278,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004674",
-              "name": "chorioretinitis",
-              "description": "An inflammation of the choroid and retina. [ORCID:0000-0001-5208-3432, PMID:16196117]; An inflammation of the choroid and retina. // COMMENTS: Chorioretinitis is a form of posterior uveitis. Note that the term Chorioretinitis suggests that the origin of the process is predominantly in the choroid while Retinitis suggests that the process is mainly in the retina.; An inflammation of the choroid and retina. // COMMENTS: Chorioretinitis is a form of posterior uveitis. Note that the term Chorioretinitis suggests that the origin of the process is predominantly in the choroid while Retinitis suggests that the process is mainly in the retina.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:8886",
-                "SNOMEDCT:46627006",
-                "ICD10:H30.9",
-                "HP:0012424",
-                "ICD9:363.20",
-                "MONDO:0004674",
-                "MESH:D002825",
-                "UMLS:C0008513",
-                "NCIT:C110923",
-                "MEDDRA:10008769",
-                "MEDDRA:10086282",
-                "MEDDRA:10008771"
-              ],
-              "id": "MONDO:0004674",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chorioretinitis",
-                "Chorioretinitis, unspecified",
-                "chorioretinitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:16196117",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0001-5208-3432"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10420041,
-            "start": 568,
-            "end": 317278,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13919503': {'publication date': '1961 Mar', 'sentence': '[On the effect of oral use of prednisolone on central chorioretinitis].', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0008513---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10649036",
-              "object": "MONDO:0004674",
-              "publications": [
-                "PMID:13919503"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:13626361': {'publication date': '1959 Mar', 'sentence': 'Prednisolone (meticortelone) in treatment of epicondylitis; radiohumeral bursitis and radiohumeral synovitis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 541725,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001875",
-          "name": "epicondylitis",
-          "description": "inflammation of the lateral epicondyle.; A condition characterized by pain in or near the lateral humeral epicondyle or in the forearm extensor muscle mass as a result of unusual strain. It occurs due repetitive stresses on the elbow from activities such as tennis playing.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:1001887",
-            "SNOMEDCT:202855006",
-            "ICD9:726.32",
-            "MONDO:0001875",
-            "MESH:D013716",
-            "DOID:14087",
-            "EFO:1001896",
-            "MEDDRA:10043258",
-            "MEDDRA:10068808",
-            "NCIT:C34589",
-            "MEDDRA:10024032",
-            "NCIT:C35067",
-            "MEDDRA:10014971",
-            "SNOMEDCT:73583000",
-            "UMLS:C0039516",
-            "ICD10:M77.1",
-            "UMLS:C0014488"
-          ],
-          "id": "MONDO:0001875",
-          "category": "biolink:Disease",
-          "all_names": [
-            "epicondylitis",
-            "Lateral epicondylitis",
-            "Epicondylitis",
-            "Tennis Elbow",
-            "Lateral Epicondylitis",
-            "lateral epicondylitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/epicondylitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 541725,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001875",
-              "name": "epicondylitis",
-              "description": "inflammation of the lateral epicondyle.; A condition characterized by pain in or near the lateral humeral epicondyle or in the forearm extensor muscle mass as a result of unusual strain. It occurs due repetitive stresses on the elbow from activities such as tennis playing.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:1001887",
-                "SNOMEDCT:202855006",
-                "ICD9:726.32",
-                "MONDO:0001875",
-                "MESH:D013716",
-                "DOID:14087",
-                "EFO:1001896",
-                "MEDDRA:10043258",
-                "MEDDRA:10068808",
-                "NCIT:C34589",
-                "MEDDRA:10024032",
-                "NCIT:C35067",
-                "MEDDRA:10014971",
-                "SNOMEDCT:73583000",
-                "UMLS:C0039516",
-                "ICD10:M77.1",
-                "UMLS:C0014488"
-              ],
-              "id": "MONDO:0001875",
-              "category": "biolink:Disease",
-              "all_names": [
-                "epicondylitis",
-                "Lateral epicondylitis",
-                "Epicondylitis",
-                "Tennis Elbow",
-                "Lateral Epicondylitis",
-                "lateral epicondylitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/epicondylitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10346472,
-            "start": 568,
-            "end": 541725,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13626361': {'publication date': '1959 Mar', 'sentence': 'Prednisolone (meticortelone) in treatment of epicondylitis; radiohumeral bursitis and radiohumeral synovitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0014488---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0039516---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10574409",
-              "object": "MONDO:0001875",
-              "publications": [
-                "PMID:13626361"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:30279934': {'publication date': '2018 Oct', 'sentence': 'This is a case of EGPA relapse presenting as myocarditis despite treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:31462594': {'publication date': '2019 Aug 28', 'sentence': 'She was diagnosed with myocarditis and successfully treated using prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:9436137': {'publication date': '1997 Dec', 'sentence': 'Children with \"definite\" myocarditis comprised group I (n = 9) and were treated with cyclosporine and prednisolone.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 314697,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004496",
-          "name": "myocarditis",
-          "description": "Myocarditis is a condition that is characterized by inflammation of the heart muscle (myocardium). Some affected people have no noticeable symptoms of the condition. When present, signs and symptoms may include chest pain, abnormal heartbeat, shortness of breath, fatigue, signs of infection (i.e. fever, headache, sore throat, diarrhea), and leg swelling. Myocarditis can be caused by a variety of factors including infections (viral, bacterial, parasitic, and fungal), allergic reactions to certain medications, and exposure to certain chemicals. It can also be associated with other inflammatory conditions such as lupus, Wegener's granulomatosis, giant cell arteritis and Takayasu's arteritis. Most cases occur sporadically in people with no family history of the condition. Treatment aims to address the underlying cause of the condition. Medications and rarely, a heart transplant may be needed if the heart muscle becomes weak.",
-          "equivalent_curies": [
-            "MESH:D009205",
-            "MEDDRA:10028613",
-            "HP:0012819",
-            "DOID:820",
-            "KEGG.DISEASE:05416",
-            "UMLS:C0027059",
-            "MEDDRA:10028606",
-            "ICD9:429.0",
-            "SYMP:0000095",
-            "SNOMEDCT:50920009",
-            "EFO:0009609",
-            "NCIT:C34831",
-            "MEDDRA:10028619",
-            "MONDO:0004496",
-            "ICD10:I51.4"
-          ],
-          "id": "MONDO:0004496",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myocarditis",
-            "Myocarditis, unspecified",
-            "myocarditis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/myocarditis",
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:21304213",
-            "PMID:22361396",
-            "https://rarediseases.info.nih.gov/diseases/7137/myocarditis",
-            "PMID:22185868",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314697,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004496",
-              "name": "myocarditis",
-              "description": "Myocarditis is a condition that is characterized by inflammation of the heart muscle (myocardium). Some affected people have no noticeable symptoms of the condition. When present, signs and symptoms may include chest pain, abnormal heartbeat, shortness of breath, fatigue, signs of infection (i.e. fever, headache, sore throat, diarrhea), and leg swelling. Myocarditis can be caused by a variety of factors including infections (viral, bacterial, parasitic, and fungal), allergic reactions to certain medications, and exposure to certain chemicals. It can also be associated with other inflammatory conditions such as lupus, Wegener's granulomatosis, giant cell arteritis and Takayasu's arteritis. Most cases occur sporadically in people with no family history of the condition. Treatment aims to address the underlying cause of the condition. Medications and rarely, a heart transplant may be needed if the heart muscle becomes weak.",
-              "equivalent_curies": [
-                "MESH:D009205",
-                "MEDDRA:10028613",
-                "HP:0012819",
-                "DOID:820",
-                "KEGG.DISEASE:05416",
-                "UMLS:C0027059",
-                "MEDDRA:10028606",
-                "ICD9:429.0",
-                "SYMP:0000095",
-                "SNOMEDCT:50920009",
-                "EFO:0009609",
-                "NCIT:C34831",
-                "MEDDRA:10028619",
-                "MONDO:0004496",
-                "ICD10:I51.4"
-              ],
-              "id": "MONDO:0004496",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myocarditis",
-                "Myocarditis, unspecified",
-                "myocarditis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/myocarditis",
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:21304213",
-                "PMID:22361396",
-                "https://rarediseases.info.nih.gov/diseases/7137/myocarditis",
-                "PMID:22185868",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20212884,
-            "start": 568,
-            "end": 314697,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30279934': {'publication date': '2018 Oct', 'sentence': 'This is a case of EGPA relapse presenting as myocarditis despite treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:31462594': {'publication date': '2019 Aug 28', 'sentence': 'She was diagnosed with myocarditis and successfully treated using prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:9436137': {'publication date': '1997 Dec', 'sentence': 'Children with \"definite\" myocarditis comprised group I (n = 9) and were treated with cyclosporine and prednisolone.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0027059---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "20612701",
-              "object": "MONDO:0004496",
-              "publications": [
-                "PMID:30279934",
-                "PMID:31462594",
-                "PMID:9436137"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:19438568': {'publication date': '2009 Jul', 'sentence': 'The erythroderma improved generally as a result of systemic prednisolone treatment.', 'subject score': 851, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 320057,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043233",
-          "name": "exfoliative dermatitis",
-          "description": "An inflammatory exfoliative dermatosis involving nearly all of the surface of the skin. Erythroderma develops suddenly. A patchy erythema may generalize and spread to affect most of the skin. Scaling may appear in 2-6 days and be accompanied by hot, red, dry skin, malaise, and fever. [HPO:probinson]; An inflammatory exfoliative dermatosis involving nearly all of the surface of the skin. Erythroderma develops suddenly. A patchy erythema may generalize and spread to affect most of the skin. Scaling may appear in 2-6 days and be accompanied by hot, red, dry skin, malaise, and fever.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0011606",
-            "SNOMEDCT:400005007",
-            "MEDDRA:10012455",
-            "MEDDRA:10015665",
-            "NCIT:C39646",
-            "MEDDRA:10018082",
-            "SNOMEDCT:396349005",
-            "MEDDRA:10062416",
-            "SNOMEDCT:200948000",
-            "UMLS:C5139033",
-            "MESH:D003873",
-            "MONDO:0043233",
-            "SNOMEDCT:399992009",
-            "MEDDRA:10012456",
-            "HP:0001019",
-            "MEDDRA:10052584",
-            "MEDDRA:10062434",
-            "MEDDRA:10015277",
-            "EFO:0009456",
-            "MEDDRA:10015666",
-            "MEDDRA:10012457",
-            "SNOMEDCT:396350005"
-          ],
-          "id": "MONDO:0043233",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Red scaly skin caused by inflammatory skin disease",
-            "Erythroderma",
-            "Dermatitis, Exfoliative",
-            "Exfoliative dermatitis",
-            "exfoliative dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320057,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043233",
-              "name": "exfoliative dermatitis",
-              "description": "An inflammatory exfoliative dermatosis involving nearly all of the surface of the skin. Erythroderma develops suddenly. A patchy erythema may generalize and spread to affect most of the skin. Scaling may appear in 2-6 days and be accompanied by hot, red, dry skin, malaise, and fever. [HPO:probinson]; An inflammatory exfoliative dermatosis involving nearly all of the surface of the skin. Erythroderma develops suddenly. A patchy erythema may generalize and spread to affect most of the skin. Scaling may appear in 2-6 days and be accompanied by hot, red, dry skin, malaise, and fever.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0011606",
-                "SNOMEDCT:400005007",
-                "MEDDRA:10012455",
-                "MEDDRA:10015665",
-                "NCIT:C39646",
-                "MEDDRA:10018082",
-                "SNOMEDCT:396349005",
-                "MEDDRA:10062416",
-                "SNOMEDCT:200948000",
-                "UMLS:C5139033",
-                "MESH:D003873",
-                "MONDO:0043233",
-                "SNOMEDCT:399992009",
-                "MEDDRA:10012456",
-                "HP:0001019",
-                "MEDDRA:10052584",
-                "MEDDRA:10062434",
-                "MEDDRA:10015277",
-                "EFO:0009456",
-                "MEDDRA:10015666",
-                "MEDDRA:10012457",
-                "SNOMEDCT:396350005"
-              ],
-              "id": "MONDO:0043233",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Red scaly skin caused by inflammatory skin disease",
-                "Erythroderma",
-                "Dermatitis, Exfoliative",
-                "Exfoliative dermatitis",
-                "exfoliative dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14073675,
-            "start": 568,
-            "end": 320057,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19438568': {'publication date': '2009 Jul', 'sentence': 'The erythroderma improved generally as a result of systemic prednisolone treatment.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0011606---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "14373522",
-              "object": "MONDO:0043233",
-              "publications": [
-                "PMID:19438568"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:35273888': {'publication date': '2022 Feb', 'sentence': 'A 60-year-old Aboriginal man with underlying severe exfoliative dermatitis, treated with oral azathioprine and oral prednisolone, presented with left painful red eye for ten days.', 'subject score': 888, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 320057,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043233",
-          "name": "exfoliative dermatitis",
-          "description": "An inflammatory exfoliative dermatosis involving nearly all of the surface of the skin. Erythroderma develops suddenly. A patchy erythema may generalize and spread to affect most of the skin. Scaling may appear in 2-6 days and be accompanied by hot, red, dry skin, malaise, and fever. [HPO:probinson]; An inflammatory exfoliative dermatosis involving nearly all of the surface of the skin. Erythroderma develops suddenly. A patchy erythema may generalize and spread to affect most of the skin. Scaling may appear in 2-6 days and be accompanied by hot, red, dry skin, malaise, and fever.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0011606",
-            "SNOMEDCT:400005007",
-            "MEDDRA:10012455",
-            "MEDDRA:10015665",
-            "NCIT:C39646",
-            "MEDDRA:10018082",
-            "SNOMEDCT:396349005",
-            "MEDDRA:10062416",
-            "SNOMEDCT:200948000",
-            "UMLS:C5139033",
-            "MESH:D003873",
-            "MONDO:0043233",
-            "SNOMEDCT:399992009",
-            "MEDDRA:10012456",
-            "HP:0001019",
-            "MEDDRA:10052584",
-            "MEDDRA:10062434",
-            "MEDDRA:10015277",
-            "EFO:0009456",
-            "MEDDRA:10015666",
-            "MEDDRA:10012457",
-            "SNOMEDCT:396350005"
-          ],
-          "id": "MONDO:0043233",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Red scaly skin caused by inflammatory skin disease",
-            "Erythroderma",
-            "Dermatitis, Exfoliative",
-            "Exfoliative dermatitis",
-            "exfoliative dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320057,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043233",
-              "name": "exfoliative dermatitis",
-              "description": "An inflammatory exfoliative dermatosis involving nearly all of the surface of the skin. Erythroderma develops suddenly. A patchy erythema may generalize and spread to affect most of the skin. Scaling may appear in 2-6 days and be accompanied by hot, red, dry skin, malaise, and fever. [HPO:probinson]; An inflammatory exfoliative dermatosis involving nearly all of the surface of the skin. Erythroderma develops suddenly. A patchy erythema may generalize and spread to affect most of the skin. Scaling may appear in 2-6 days and be accompanied by hot, red, dry skin, malaise, and fever.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0011606",
-                "SNOMEDCT:400005007",
-                "MEDDRA:10012455",
-                "MEDDRA:10015665",
-                "NCIT:C39646",
-                "MEDDRA:10018082",
-                "SNOMEDCT:396349005",
-                "MEDDRA:10062416",
-                "SNOMEDCT:200948000",
-                "UMLS:C5139033",
-                "MESH:D003873",
-                "MONDO:0043233",
-                "SNOMEDCT:399992009",
-                "MEDDRA:10012456",
-                "HP:0001019",
-                "MEDDRA:10052584",
-                "MEDDRA:10062434",
-                "MEDDRA:10015277",
-                "EFO:0009456",
-                "MEDDRA:10015666",
-                "MEDDRA:10012457",
-                "SNOMEDCT:396350005"
-              ],
-              "id": "MONDO:0043233",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Red scaly skin caused by inflammatory skin disease",
-                "Erythroderma",
-                "Dermatitis, Exfoliative",
-                "Exfoliative dermatitis",
-                "exfoliative dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23854304,
-            "start": 568,
-            "end": 320057,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35273888': {'publication date': '2022 Feb', 'sentence': 'A 60-year-old Aboriginal man with underlying severe exfoliative dermatitis, treated with oral azathioprine and oral prednisolone, presented with left painful red eye for ten days.', 'subject score': 888, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0011606---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "24297743",
-              "object": "MONDO:0043233",
-              "publications": [
-                "PMID:35273888"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:1424667': {'publication date': '1992 Sep', 'sentence': 'In this limited pilot study, we compared the effect on clinical outcome of treating Pseudomonas keratitis in guinea pigs with prednisolone (a corticosteroid), flurbiprofen (a cyclo-oxygenase inhibitor), nordihydroguaiaretic acid (a lipoxygenase inhibitor), and a leukotriene antagonist, SKF104353 [R-(R*, S*)]-beta-[(2-carboxyethyl) thio-alpha-hydroxy-2-(8-phenyloctyl) benzenepropanoic acid, zinc salt].', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 317343,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0003085",
-          "name": "keratitis",
-          "description": "A corneal disease that is characterized by inflammation of the cornea.",
-          "equivalent_curies": [
-            "DOID:4677",
-            "MEDDRA:10045988",
-            "HP:0000491",
-            "MEDDRA:10011023",
-            "MEDDRA:10023332",
-            "MESH:D007634",
-            "UMLS:C0022568",
-            "MEDDRA:10023346",
-            "SNOMEDCT:5888003",
-            "NCIT:C26805",
-            "MEDDRA:10023336",
-            "ICD10:H16",
-            "MEDDRA:10021953",
-            "SYMP:0000314",
-            "ICD9:370",
-            "MONDO:0003085",
-            "EFO:0009449"
-          ],
-          "id": "MONDO:0003085",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Keratitis",
-            "keratitis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.mayoclinic.org/diseases-conditions/keratitis/basics/definition/con-20035288",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317343,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0003085",
-              "name": "keratitis",
-              "description": "A corneal disease that is characterized by inflammation of the cornea.",
-              "equivalent_curies": [
-                "DOID:4677",
-                "MEDDRA:10045988",
-                "HP:0000491",
-                "MEDDRA:10011023",
-                "MEDDRA:10023332",
-                "MESH:D007634",
-                "UMLS:C0022568",
-                "MEDDRA:10023346",
-                "SNOMEDCT:5888003",
-                "NCIT:C26805",
-                "MEDDRA:10023336",
-                "ICD10:H16",
-                "MEDDRA:10021953",
-                "SYMP:0000314",
-                "ICD9:370",
-                "MONDO:0003085",
-                "EFO:0009449"
-              ],
-              "id": "MONDO:0003085",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Keratitis",
-                "keratitis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.mayoclinic.org/diseases-conditions/keratitis/basics/definition/con-20035288",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10485233,
-            "start": 568,
-            "end": 317343,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1424667': {'publication date': '1992 Sep', 'sentence': 'In this limited pilot study, we compared the effect on clinical outcome of treating Pseudomonas keratitis in guinea pigs with prednisolone (a corticosteroid), flurbiprofen (a cyclo-oxygenase inhibitor), nordihydroguaiaretic acid (a lipoxygenase inhibitor), and a leukotriene antagonist, SKF104353 [R-(R*, S*)]-beta-[(2-carboxyethyl) thio-alpha-hydroxy-2-(8-phenyloctyl) benzenepropanoic acid, zinc salt].', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0022568---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10715297",
-              "object": "MONDO:0003085",
-              "publications": [
-                "PMID:1424667"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1587148': {'publication date': '1992 Mar', 'sentence': 'Ciprofloxacin and prednisolone therapy for experimental Pseudomonas keratitis.', 'subject score': 888, 'object score': 851}, 'PMID:7796606': {'publication date': '1995 Mar', 'sentence': 'Ciprofloxacin and prednisolone, but not an aminoglycoside and dexamethasone, were previously found to be effective in killing bacteria and reducing inflammation for the treatment of Pseudomonas keratitis.', 'subject score': 1000, 'object score': 888}, 'PMID:8239596': {'publication date': '1993 Sep', 'sentence': 'Age and therapeutic outcome of experimental Pseudomonas aeruginosa keratitis treated with ciprofloxacin, prednisolone, and flurbiprofen.', 'subject score': 1000, 'object score': 861}, 'PMID:8344070': {'publication date': '1993 May', 'sentence': 'This study was conducted to determine the therapeutic efficacy of 3.0 mg/ml ciprofloxacin administered concurrently with one of two salts of prednisolone for the treatment of experimental pseudomonal keratitis.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 317343,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0003085",
-          "name": "keratitis",
-          "description": "A corneal disease that is characterized by inflammation of the cornea.",
-          "equivalent_curies": [
-            "DOID:4677",
-            "MEDDRA:10045988",
-            "HP:0000491",
-            "MEDDRA:10011023",
-            "MEDDRA:10023332",
-            "MESH:D007634",
-            "UMLS:C0022568",
-            "MEDDRA:10023346",
-            "SNOMEDCT:5888003",
-            "NCIT:C26805",
-            "MEDDRA:10023336",
-            "ICD10:H16",
-            "MEDDRA:10021953",
-            "SYMP:0000314",
-            "ICD9:370",
-            "MONDO:0003085",
-            "EFO:0009449"
-          ],
-          "id": "MONDO:0003085",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Keratitis",
-            "keratitis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.mayoclinic.org/diseases-conditions/keratitis/basics/definition/con-20035288",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317343,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0003085",
-              "name": "keratitis",
-              "description": "A corneal disease that is characterized by inflammation of the cornea.",
-              "equivalent_curies": [
-                "DOID:4677",
-                "MEDDRA:10045988",
-                "HP:0000491",
-                "MEDDRA:10011023",
-                "MEDDRA:10023332",
-                "MESH:D007634",
-                "UMLS:C0022568",
-                "MEDDRA:10023346",
-                "SNOMEDCT:5888003",
-                "NCIT:C26805",
-                "MEDDRA:10023336",
-                "ICD10:H16",
-                "MEDDRA:10021953",
-                "SYMP:0000314",
-                "ICD9:370",
-                "MONDO:0003085",
-                "EFO:0009449"
-              ],
-              "id": "MONDO:0003085",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Keratitis",
-                "keratitis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.mayoclinic.org/diseases-conditions/keratitis/basics/definition/con-20035288",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11550789,
-            "start": 568,
-            "end": 317343,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1587148': {'publication date': '1992 Mar', 'sentence': 'Ciprofloxacin and prednisolone therapy for experimental Pseudomonas keratitis.', 'subject score': 888, 'object score': 851}, 'PMID:7796606': {'publication date': '1995 Mar', 'sentence': 'Ciprofloxacin and prednisolone, but not an aminoglycoside and dexamethasone, were previously found to be effective in killing bacteria and reducing inflammation for the treatment of Pseudomonas keratitis.', 'subject score': 1000, 'object score': 888}, 'PMID:8239596': {'publication date': '1993 Sep', 'sentence': 'Age and therapeutic outcome of experimental Pseudomonas aeruginosa keratitis treated with ciprofloxacin, prednisolone, and flurbiprofen.', 'subject score': 1000, 'object score': 861}, 'PMID:8344070': {'publication date': '1993 May', 'sentence': 'This study was conducted to determine the therapeutic efficacy of 3.0 mg/ml ciprofloxacin administered concurrently with one of two salts of prednisolone for the treatment of experimental pseudomonal keratitis.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0022568---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11808057",
-              "object": "MONDO:0003085",
-              "publications": [
-                "PMID:1587148",
-                "PMID:7796606",
-                "PMID:8239596",
-                "PMID:8344070"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:656284': {'publication date': '1978 May', 'sentence': 'A thermographic assessment of three intra-articular prednisolone analogues given in rheumatoid synovitis.', 'subject score': 833, 'object score': 853}}",
-    "p2": {
-      "start": {
-        "identity": 320617,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002400",
-          "name": "synovitis",
-          "description": "Inflammation of a synovial membrane.; Inflammation of the SYNOVIAL MEMBRANE.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0039103",
-            "MESH:D013585",
-            "HP:0100769",
-            "SYMP:0000646",
-            "MEDDRA:10042868",
-            "MONDO:0002400",
-            "DOID:2703",
-            "EFO:0008997",
-            "NCIT:C50766",
-            "SNOMEDCT:416209007"
-          ],
-          "id": "MONDO:0002400",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Synovitis",
-            "synovitis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=synovitis",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://en.wikipedia.org/wiki/synovitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320617,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002400",
-              "name": "synovitis",
-              "description": "Inflammation of a synovial membrane.; Inflammation of the SYNOVIAL MEMBRANE.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0039103",
-                "MESH:D013585",
-                "HP:0100769",
-                "SYMP:0000646",
-                "MEDDRA:10042868",
-                "MONDO:0002400",
-                "DOID:2703",
-                "EFO:0008997",
-                "NCIT:C50766",
-                "SNOMEDCT:416209007"
-              ],
-              "id": "MONDO:0002400",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Synovitis",
-                "synovitis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=synovitis",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://en.wikipedia.org/wiki/synovitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25736674,
-            "start": 568,
-            "end": 320617,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:656284': {'publication date': '1978 May', 'sentence': 'A thermographic assessment of three intra-articular prednisolone analogues given in rheumatoid synovitis.', 'subject score': 833, 'object score': 853}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0039103---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "26194122",
-              "object": "MONDO:0002400",
-              "publications": [
-                "PMID:656284"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:13626361': {'publication date': '1959 Mar', 'sentence': 'Prednisolone (meticortelone) in treatment of epicondylitis; radiohumeral bursitis and radiohumeral synovitis.', 'subject score': 1000, 'object score': 861}, 'PMID:18311044': {'publication date': '2008 Feb', 'sentence': 'Methyl-prednisolone pulse therapy followed by 30 mg/day of PSL was instituted and the bullae were diminished with gradual improvement of IP and synovitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3978363': {'publication date': '1985 Feb', 'sentence': 'Five of the 12 were noted to have synovitis on presentation which was characteristically mild, pauci-articular and cleared quickly after commencing prednisolone therapy.', 'subject score': 790, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 320617,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002400",
-          "name": "synovitis",
-          "description": "Inflammation of a synovial membrane.; Inflammation of the SYNOVIAL MEMBRANE.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0039103",
-            "MESH:D013585",
-            "HP:0100769",
-            "SYMP:0000646",
-            "MEDDRA:10042868",
-            "MONDO:0002400",
-            "DOID:2703",
-            "EFO:0008997",
-            "NCIT:C50766",
-            "SNOMEDCT:416209007"
-          ],
-          "id": "MONDO:0002400",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Synovitis",
-            "synovitis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=synovitis",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://en.wikipedia.org/wiki/synovitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320617,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002400",
-              "name": "synovitis",
-              "description": "Inflammation of a synovial membrane.; Inflammation of the SYNOVIAL MEMBRANE.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0039103",
-                "MESH:D013585",
-                "HP:0100769",
-                "SYMP:0000646",
-                "MEDDRA:10042868",
-                "MONDO:0002400",
-                "DOID:2703",
-                "EFO:0008997",
-                "NCIT:C50766",
-                "SNOMEDCT:416209007"
-              ],
-              "id": "MONDO:0002400",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Synovitis",
-                "synovitis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=synovitis",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://en.wikipedia.org/wiki/synovitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10346473,
-            "start": 568,
-            "end": 320617,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13626361': {'publication date': '1959 Mar', 'sentence': 'Prednisolone (meticortelone) in treatment of epicondylitis; radiohumeral bursitis and radiohumeral synovitis.', 'subject score': 1000, 'object score': 861}, 'PMID:18311044': {'publication date': '2008 Feb', 'sentence': 'Methyl-prednisolone pulse therapy followed by 30 mg/day of PSL was instituted and the bullae were diminished with gradual improvement of IP and synovitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3978363': {'publication date': '1985 Feb', 'sentence': 'Five of the 12 were noted to have synovitis on presentation which was characteristically mild, pauci-articular and cleared quickly after commencing prednisolone therapy.', 'subject score': 790, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0039103---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10574410",
-              "object": "MONDO:0002400",
-              "publications": [
-                "PMID:13626361",
-                "PMID:18311044",
-                "PMID:3978363"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:6675263': {'publication date': '1983 Nov', 'sentence': 'The intra-articular injection of prednisolone was shown to considerably reduce incidence of synovitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:9663476': {'publication date': '1998 Jul', 'sentence': 'The reduction in the markers of bone turnover (OC) and synovial tissue turnover (HA and PIIINP) support the general view that prednisolone reduces synovitis and suppresses bone turnover.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 320617,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002400",
-          "name": "synovitis",
-          "description": "Inflammation of a synovial membrane.; Inflammation of the SYNOVIAL MEMBRANE.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0039103",
-            "MESH:D013585",
-            "HP:0100769",
-            "SYMP:0000646",
-            "MEDDRA:10042868",
-            "MONDO:0002400",
-            "DOID:2703",
-            "EFO:0008997",
-            "NCIT:C50766",
-            "SNOMEDCT:416209007"
-          ],
-          "id": "MONDO:0002400",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Synovitis",
-            "synovitis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=synovitis",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://en.wikipedia.org/wiki/synovitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320617,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002400",
-              "name": "synovitis",
-              "description": "Inflammation of a synovial membrane.; Inflammation of the SYNOVIAL MEMBRANE.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0039103",
-                "MESH:D013585",
-                "HP:0100769",
-                "SYMP:0000646",
-                "MEDDRA:10042868",
-                "MONDO:0002400",
-                "DOID:2703",
-                "EFO:0008997",
-                "NCIT:C50766",
-                "SNOMEDCT:416209007"
-              ],
-              "id": "MONDO:0002400",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Synovitis",
-                "synovitis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=synovitis",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://en.wikipedia.org/wiki/synovitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25769857,
-            "start": 568,
-            "end": 320617,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:6675263': {'publication date': '1983 Nov', 'sentence': 'The intra-articular injection of prednisolone was shown to considerably reduce incidence of synovitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:9663476': {'publication date': '1998 Jul', 'sentence': 'The reduction in the markers of bone turnover (OC) and synovial tissue turnover (HA and PIIINP) support the general view that prednisolone reduces synovitis and suppresses bone turnover.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:prevents---None---None---None---UMLS:C0039103---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "26227245",
-              "object": "MONDO:0002400",
-              "publications": [
-                "PMID:6675263",
-                "PMID:9663476"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:14346730': {'publication date': '1965 Jun', 'sentence': '[USE OF PREDNISOLONE IN SOME GRAVE FORMS OF PATHOLOGY OF THE PREMATURE INFANT].', 'subject score': 1000, 'object score': 966}, 'PMID:1497563': {'publication date': '1992 Jun', 'sentence': \"Hypokalaemic paralysis induced by bolus prednisolone in Graves' disease.\", 'subject score': 861, 'object score': 1000}, 'PMID:25603854': {'publication date': '2015 01', 'sentence': \"Accordingly, oral steroid therapy was started with 60 mg of prednisolone under the impression of AIH associated with Graves' disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:31627654': {'publication date': '2007 Oct 15', 'sentence': \"[Evaluation of methylprednisolone pulse therapy versus combined therapy with prednisolone and cyclosporine in the treatment of infiltrative ophthalmopathy in Graves' disease].\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318775,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005364",
-          "name": "Graves disease",
-          "description": "Hyperthyroidism associated with diffuse hyperplasia of the thyroid gland (goiter), resulting from production of antibodies that are directed against the thyrotropin receptor complex of the follicular epithelial cells. As a result, the thyroid gland enlarges and secretes increased amounts of thyroid hormones.; A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).; An autoimmune disease where the thyroid is overactive, producing an excessive amount of thyroid hormones (a serious metabolic imbalance known as hyperthyroidism and thyrotoxicosis). This is caused by autoantibodies to the TSH-receptor (TSHR-Ab) that activate that TSH-receptor (TSHR), thereby stimulating thyroid hormone synthesis and secretion, and thyroid growth (causing a diffusely enlarged goiter). The resulting state of hyperthyroidism can cause a dramatic constellation of neuropsychological and physical signs and symptoms, which can severely compromise the patients. [HPO:sdoelken]",
-          "equivalent_curies": [
-            "MEDDRA:10018494",
-            "MEDDRA:10015679",
-            "MEDDRA:10018706",
-            "UMLS:C5546093",
-            "MEDDRA:10065624",
-            "NCIT:C3071",
-            "HP:0100647",
-            "MONDO:0005364",
-            "MEDDRA:10004161",
-            "DOID:12361",
-            "UMLS:C0018213",
-            "EFO:0004237",
-            "MESH:D006111",
-            "SNOMEDCT:55807009",
-            "MEDDRA:10074037",
-            "SNOMEDCT:353295004",
-            "MEDDRA:10015680",
-            "ICD10:E05.0",
-            "MEDDRA:10068004"
-          ],
-          "id": "MONDO:0005364",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Graves disease",
-            "Graves' disease",
-            "Graves Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/graves_disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318775,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005364",
-              "name": "Graves disease",
-              "description": "Hyperthyroidism associated with diffuse hyperplasia of the thyroid gland (goiter), resulting from production of antibodies that are directed against the thyrotropin receptor complex of the follicular epithelial cells. As a result, the thyroid gland enlarges and secretes increased amounts of thyroid hormones.; A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).; An autoimmune disease where the thyroid is overactive, producing an excessive amount of thyroid hormones (a serious metabolic imbalance known as hyperthyroidism and thyrotoxicosis). This is caused by autoantibodies to the TSH-receptor (TSHR-Ab) that activate that TSH-receptor (TSHR), thereby stimulating thyroid hormone synthesis and secretion, and thyroid growth (causing a diffusely enlarged goiter). The resulting state of hyperthyroidism can cause a dramatic constellation of neuropsychological and physical signs and symptoms, which can severely compromise the patients. [HPO:sdoelken]",
-              "equivalent_curies": [
-                "MEDDRA:10018494",
-                "MEDDRA:10015679",
-                "MEDDRA:10018706",
-                "UMLS:C5546093",
-                "MEDDRA:10065624",
-                "NCIT:C3071",
-                "HP:0100647",
-                "MONDO:0005364",
-                "MEDDRA:10004161",
-                "DOID:12361",
-                "UMLS:C0018213",
-                "EFO:0004237",
-                "MESH:D006111",
-                "SNOMEDCT:55807009",
-                "MEDDRA:10074037",
-                "SNOMEDCT:353295004",
-                "MEDDRA:10015680",
-                "ICD10:E05.0",
-                "MEDDRA:10068004"
-              ],
-              "id": "MONDO:0005364",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Graves disease",
-                "Graves' disease",
-                "Graves Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/graves_disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10505129,
-            "start": 568,
-            "end": 318775,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14346730': {'publication date': '1965 Jun', 'sentence': '[USE OF PREDNISOLONE IN SOME GRAVE FORMS OF PATHOLOGY OF THE PREMATURE INFANT].', 'subject score': 1000, 'object score': 966}, 'PMID:1497563': {'publication date': '1992 Jun', 'sentence': \"Hypokalaemic paralysis induced by bolus prednisolone in Graves' disease.\", 'subject score': 861, 'object score': 1000}, 'PMID:25603854': {'publication date': '2015 01', 'sentence': \"Accordingly, oral steroid therapy was started with 60 mg of prednisolone under the impression of AIH associated with Graves' disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:31627654': {'publication date': '2007 Oct 15', 'sentence': \"[Evaluation of methylprednisolone pulse therapy versus combined therapy with prednisolone and cyclosporine in the treatment of infiltrative ophthalmopathy in Graves' disease].\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0018213---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10736101",
-              "object": "MONDO:0005364",
-              "publications": [
-                "PMID:14346730",
-                "PMID:1497563",
-                "PMID:25603854",
-                "PMID:31627654"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12006721': {'publication date': '2002', 'sentence': \"She was diagnosed as having Graves' disease and was treated with propylthiouracil, and prednisolone was given for neck pain.\", 'subject score': 1000, 'object score': 1000}, 'PMID:33653401': {'publication date': '2021 Mar 02', 'sentence': 'CONCLUSIONS: The results suggested that the effect of intravenous MPT followed by oral prednisolone on TRAb level was temporary in children with GD.', 'subject score': 888, 'object score': 1000}, 'PMID:3583222': {'publication date': '1987 Apr', 'sentence': \"Significant increase (p less than .01) in clearance values and significant decreases in half-life times (p less than .01) were found for both total and unbound prednisolone in women with Graves' disease compared with the control subjects.\", 'subject score': 861, 'object score': 1000}, 'PMID:3622224': {'publication date': '1987', 'sentence': \"The ITP occurred after 8 years of well-controlled Graves' disease and IDDM with appropriate treatment, but subsided with prednisolone therapy, followed by splenectomy.\", 'subject score': 888, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 318775,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005364",
-          "name": "Graves disease",
-          "description": "Hyperthyroidism associated with diffuse hyperplasia of the thyroid gland (goiter), resulting from production of antibodies that are directed against the thyrotropin receptor complex of the follicular epithelial cells. As a result, the thyroid gland enlarges and secretes increased amounts of thyroid hormones.; A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).; An autoimmune disease where the thyroid is overactive, producing an excessive amount of thyroid hormones (a serious metabolic imbalance known as hyperthyroidism and thyrotoxicosis). This is caused by autoantibodies to the TSH-receptor (TSHR-Ab) that activate that TSH-receptor (TSHR), thereby stimulating thyroid hormone synthesis and secretion, and thyroid growth (causing a diffusely enlarged goiter). The resulting state of hyperthyroidism can cause a dramatic constellation of neuropsychological and physical signs and symptoms, which can severely compromise the patients. [HPO:sdoelken]",
-          "equivalent_curies": [
-            "MEDDRA:10018494",
-            "MEDDRA:10015679",
-            "MEDDRA:10018706",
-            "UMLS:C5546093",
-            "MEDDRA:10065624",
-            "NCIT:C3071",
-            "HP:0100647",
-            "MONDO:0005364",
-            "MEDDRA:10004161",
-            "DOID:12361",
-            "UMLS:C0018213",
-            "EFO:0004237",
-            "MESH:D006111",
-            "SNOMEDCT:55807009",
-            "MEDDRA:10074037",
-            "SNOMEDCT:353295004",
-            "MEDDRA:10015680",
-            "ICD10:E05.0",
-            "MEDDRA:10068004"
-          ],
-          "id": "MONDO:0005364",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Graves disease",
-            "Graves' disease",
-            "Graves Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/graves_disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318775,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005364",
-              "name": "Graves disease",
-              "description": "Hyperthyroidism associated with diffuse hyperplasia of the thyroid gland (goiter), resulting from production of antibodies that are directed against the thyrotropin receptor complex of the follicular epithelial cells. As a result, the thyroid gland enlarges and secretes increased amounts of thyroid hormones.; A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).; An autoimmune disease where the thyroid is overactive, producing an excessive amount of thyroid hormones (a serious metabolic imbalance known as hyperthyroidism and thyrotoxicosis). This is caused by autoantibodies to the TSH-receptor (TSHR-Ab) that activate that TSH-receptor (TSHR), thereby stimulating thyroid hormone synthesis and secretion, and thyroid growth (causing a diffusely enlarged goiter). The resulting state of hyperthyroidism can cause a dramatic constellation of neuropsychological and physical signs and symptoms, which can severely compromise the patients. [HPO:sdoelken]",
-              "equivalent_curies": [
-                "MEDDRA:10018494",
-                "MEDDRA:10015679",
-                "MEDDRA:10018706",
-                "UMLS:C5546093",
-                "MEDDRA:10065624",
-                "NCIT:C3071",
-                "HP:0100647",
-                "MONDO:0005364",
-                "MEDDRA:10004161",
-                "DOID:12361",
-                "UMLS:C0018213",
-                "EFO:0004237",
-                "MESH:D006111",
-                "SNOMEDCT:55807009",
-                "MEDDRA:10074037",
-                "SNOMEDCT:353295004",
-                "MEDDRA:10015680",
-                "ICD10:E05.0",
-                "MEDDRA:10068004"
-              ],
-              "id": "MONDO:0005364",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Graves disease",
-                "Graves' disease",
-                "Graves Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/graves_disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9333220,
-            "start": 568,
-            "end": 318775,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12006721': {'publication date': '2002', 'sentence': \"She was diagnosed as having Graves' disease and was treated with propylthiouracil, and prednisolone was given for neck pain.\", 'subject score': 1000, 'object score': 1000}, 'PMID:33653401': {'publication date': '2021 Mar 02', 'sentence': 'CONCLUSIONS: The results suggested that the effect of intravenous MPT followed by oral prednisolone on TRAb level was temporary in children with GD.', 'subject score': 888, 'object score': 1000}, 'PMID:3583222': {'publication date': '1987 Apr', 'sentence': \"Significant increase (p less than .01) in clearance values and significant decreases in half-life times (p less than .01) were found for both total and unbound prednisolone in women with Graves' disease compared with the control subjects.\", 'subject score': 861, 'object score': 1000}, 'PMID:3622224': {'publication date': '1987', 'sentence': \"The ITP occurred after 8 years of well-controlled Graves' disease and IDDM with appropriate treatment, but subsided with prednisolone therapy, followed by splenectomy.\", 'subject score': 888, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0018213---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9538921",
-              "object": "MONDO:0005364",
-              "publications": [
-                "PMID:12006721",
-                "PMID:33653401",
-                "PMID:3583222",
-                "PMID:3622224"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:32584603': {'publication date': '2020 Jun 25', 'sentence': 'Blood Eosinophil Depletion with Mepolizumab, Benralizumab and Prednisolone in Eosinophilic Asthma.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 303010,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004802",
-          "name": "pulmonary eosinophilia",
-          "description": "The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. [PMID:19618037, PMID:21428117]; The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. // COMMENTS: Pulmonary function testing usually reveals a restrictive process with reduced diffusion capacity for carbon monoxide. Laboratory tests typical include increased levels of eosinophils in the blood, a high erythrocyte sedimentation rate, iron deficiency anemia, and increased platelets.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "UMLS:C0034068",
-            "HP:0032071",
-            "UMLS:C5552799",
-            "DOID:9498",
-            "MESH:D011657",
-            "MEDDRA:10037412",
-            "ICD9:518.3",
-            "SNOMEDCT:367542003",
-            "MONDO:0004802",
-            "MEDDRA:10037382"
-          ],
-          "id": "MONDO:0004802",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Eosinophilic pneumonia",
-            "Pulmonary eosinophilic infiltrate",
-            "Pulmonary Eosinophilia",
-            "Pulmonary eosinophilia",
-            "pulmonary eosinophilia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:19618037",
-            "https://rarediseases.org/rare-diseases/simple-pulmonary-eosinophilia/",
-            "PMID:21428117"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 303010,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004802",
-              "name": "pulmonary eosinophilia",
-              "description": "The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. [PMID:19618037, PMID:21428117]; The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. // COMMENTS: Pulmonary function testing usually reveals a restrictive process with reduced diffusion capacity for carbon monoxide. Laboratory tests typical include increased levels of eosinophils in the blood, a high erythrocyte sedimentation rate, iron deficiency anemia, and increased platelets.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "UMLS:C0034068",
-                "HP:0032071",
-                "UMLS:C5552799",
-                "DOID:9498",
-                "MESH:D011657",
-                "MEDDRA:10037412",
-                "ICD9:518.3",
-                "SNOMEDCT:367542003",
-                "MONDO:0004802",
-                "MEDDRA:10037382"
-              ],
-              "id": "MONDO:0004802",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Eosinophilic pneumonia",
-                "Pulmonary eosinophilic infiltrate",
-                "Pulmonary Eosinophilia",
-                "Pulmonary eosinophilia",
-                "pulmonary eosinophilia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:19618037",
-                "https://rarediseases.org/rare-diseases/simple-pulmonary-eosinophilia/",
-                "PMID:21428117"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21773779,
-            "start": 568,
-            "end": 303010,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32584603': {'publication date': '2020 Jun 25', 'sentence': 'Blood Eosinophil Depletion with Mepolizumab, Benralizumab and Prednisolone in Eosinophilic Asthma.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0034068---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "22194722",
-              "object": "MONDO:0004802",
-              "publications": [
-                "PMID:32584603"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:8551692': {'publication date': '1995 Oct', 'sentence': 'From 1983, exacerbation of PIE was recorded three times, on which occasions prednisolone and antibiotics were quite effective.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 303010,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004802",
-          "name": "pulmonary eosinophilia",
-          "description": "The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. [PMID:19618037, PMID:21428117]; The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. // COMMENTS: Pulmonary function testing usually reveals a restrictive process with reduced diffusion capacity for carbon monoxide. Laboratory tests typical include increased levels of eosinophils in the blood, a high erythrocyte sedimentation rate, iron deficiency anemia, and increased platelets.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "UMLS:C0034068",
-            "HP:0032071",
-            "UMLS:C5552799",
-            "DOID:9498",
-            "MESH:D011657",
-            "MEDDRA:10037412",
-            "ICD9:518.3",
-            "SNOMEDCT:367542003",
-            "MONDO:0004802",
-            "MEDDRA:10037382"
-          ],
-          "id": "MONDO:0004802",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Eosinophilic pneumonia",
-            "Pulmonary eosinophilic infiltrate",
-            "Pulmonary Eosinophilia",
-            "Pulmonary eosinophilia",
-            "pulmonary eosinophilia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:19618037",
-            "https://rarediseases.org/rare-diseases/simple-pulmonary-eosinophilia/",
-            "PMID:21428117"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 303010,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004802",
-              "name": "pulmonary eosinophilia",
-              "description": "The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. [PMID:19618037, PMID:21428117]; The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. // COMMENTS: Pulmonary function testing usually reveals a restrictive process with reduced diffusion capacity for carbon monoxide. Laboratory tests typical include increased levels of eosinophils in the blood, a high erythrocyte sedimentation rate, iron deficiency anemia, and increased platelets.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "UMLS:C0034068",
-                "HP:0032071",
-                "UMLS:C5552799",
-                "DOID:9498",
-                "MESH:D011657",
-                "MEDDRA:10037412",
-                "ICD9:518.3",
-                "SNOMEDCT:367542003",
-                "MONDO:0004802",
-                "MEDDRA:10037382"
-              ],
-              "id": "MONDO:0004802",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Eosinophilic pneumonia",
-                "Pulmonary eosinophilic infiltrate",
-                "Pulmonary Eosinophilia",
-                "Pulmonary eosinophilia",
-                "pulmonary eosinophilia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:19618037",
-                "https://rarediseases.org/rare-diseases/simple-pulmonary-eosinophilia/",
-                "PMID:21428117"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26575400,
-            "start": 568,
-            "end": 303010,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8551692': {'publication date': '1995 Oct', 'sentence': 'From 1983, exacerbation of PIE was recorded three times, on which occasions prednisolone and antibiotics were quite effective.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0034068---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "27042309",
-              "object": "MONDO:0004802",
-              "publications": [
-                "PMID:8551692"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:20639010': {'publication date': '2010 Jul', 'sentence': 'Airway macrophage median percentage of red-hued area in stained sputum cytospin preparations was assessed by means of image analysis from (1) subjects with mild-to-severe asthma, subjects with nonasthmatic eosinophilic bronchitis, and healthy control subjects; (2) subjects with eosinophilic severe asthma after treatment with prednisolone; and (3) subject with noneosinophilic asthma before corticosteroid withdrawal.', 'subject score': 1000, 'object score': 901}, 'PMID:2595633': {'publication date': '1989 Nov', 'sentence': 'Of the 247 episodes of pulmonary eosinophilia that were documented during a median follow up period of 14 years, 186 were treated with prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 303010,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004802",
-          "name": "pulmonary eosinophilia",
-          "description": "The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. [PMID:19618037, PMID:21428117]; The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. // COMMENTS: Pulmonary function testing usually reveals a restrictive process with reduced diffusion capacity for carbon monoxide. Laboratory tests typical include increased levels of eosinophils in the blood, a high erythrocyte sedimentation rate, iron deficiency anemia, and increased platelets.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "UMLS:C0034068",
-            "HP:0032071",
-            "UMLS:C5552799",
-            "DOID:9498",
-            "MESH:D011657",
-            "MEDDRA:10037412",
-            "ICD9:518.3",
-            "SNOMEDCT:367542003",
-            "MONDO:0004802",
-            "MEDDRA:10037382"
-          ],
-          "id": "MONDO:0004802",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Eosinophilic pneumonia",
-            "Pulmonary eosinophilic infiltrate",
-            "Pulmonary Eosinophilia",
-            "Pulmonary eosinophilia",
-            "pulmonary eosinophilia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:19618037",
-            "https://rarediseases.org/rare-diseases/simple-pulmonary-eosinophilia/",
-            "PMID:21428117"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 303010,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004802",
-              "name": "pulmonary eosinophilia",
-              "description": "The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. [PMID:19618037, PMID:21428117]; The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. // COMMENTS: Pulmonary function testing usually reveals a restrictive process with reduced diffusion capacity for carbon monoxide. Laboratory tests typical include increased levels of eosinophils in the blood, a high erythrocyte sedimentation rate, iron deficiency anemia, and increased platelets.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "UMLS:C0034068",
-                "HP:0032071",
-                "UMLS:C5552799",
-                "DOID:9498",
-                "MESH:D011657",
-                "MEDDRA:10037412",
-                "ICD9:518.3",
-                "SNOMEDCT:367542003",
-                "MONDO:0004802",
-                "MEDDRA:10037382"
-              ],
-              "id": "MONDO:0004802",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Eosinophilic pneumonia",
-                "Pulmonary eosinophilic infiltrate",
-                "Pulmonary Eosinophilia",
-                "Pulmonary eosinophilia",
-                "pulmonary eosinophilia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:19618037",
-                "https://rarediseases.org/rare-diseases/simple-pulmonary-eosinophilia/",
-                "PMID:21428117"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14791831,
-            "start": 568,
-            "end": 303010,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20639010': {'publication date': '2010 Jul', 'sentence': 'Airway macrophage median percentage of red-hued area in stained sputum cytospin preparations was assessed by means of image analysis from (1) subjects with mild-to-severe asthma, subjects with nonasthmatic eosinophilic bronchitis, and healthy control subjects; (2) subjects with eosinophilic severe asthma after treatment with prednisolone; and (3) subject with noneosinophilic asthma before corticosteroid withdrawal.', 'subject score': 1000, 'object score': 901}, 'PMID:2595633': {'publication date': '1989 Nov', 'sentence': 'Of the 247 episodes of pulmonary eosinophilia that were documented during a median follow up period of 14 years, 186 were treated with prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0034068---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "15104714",
-              "object": "MONDO:0004802",
-              "publications": [
-                "PMID:20639010",
-                "PMID:2595633"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:24026674': {'publication date': '2014 Feb', 'sentence': 'Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:25132663': {'publication date': '2015 Mar', 'sentence': 'OBJECTIVE: To establish the incidence of giant cell arteritis (GCA), cumulative use of prednisolone, and comorbidities most associated with GCA.', 'subject score': 1000, 'object score': 1000}, 'PMID:2727585': {'publication date': '1989 Jan', 'sentence': \"[Interaction of rifampicin and prednisolone. Apropos of 2 cases occurring in Horton's disease].\", 'subject score': 1000, 'object score': 1000}, 'PMID:31034796': {'publication date': '2019 Jul', 'sentence': 'Prednisone/prednisolone at a dose of 40-60 mg/day is the cornerstone therapy in GCA.', 'subject score': 888, 'object score': 1000}, 'PMID:3511861': {'publication date': '1986 Feb', 'sentence': 'The ability of azathioprine to reduce the maintenance prednisolone requirement of 31 patients with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA), or both, was tested in a double-blind placebo controlled study over one year.', 'subject score': 851, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 531206,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008538",
-          "name": "temporal arteritis",
-          "description": "An autoimmune, systemic, giant cell granulomatous arteritis predominantly involving the arteries that supply blood to the central nervous system, head and eyes. Superficial arteries of the scalp that are involved tend to be enlarged and tender. Signs and symptoms include headaches, myalgias, visual disturbances, and skin necrosis.; A systemic autoimmune disorder that typically affects medium and large ARTERIES, usually leading to occlusive granulomatous vasculitis with transmural infiltrate containing multinucleated GIANT CELLS. The TEMPORAL ARTERY is commonly involved. This disorder appears primarily in people over the age of 50. Symptoms include FEVER; FATIGUE; HEADACHE; visual impairment; pain in the jaw and tongue; and aggravation of pain by cold temperatures. (From Adams et al., Principles of Neurology, 6th ed); Giant cell arteritis is a disorder that causes inflammation of your arteries, usually in the scalp, neck, and arms. It narrows the arteries, which keeps blood from flowing well. Giant cell arteritis often occurs with another disorder called polymyalgia rheumatica. Both are more common in women than in men. They almost always affect people over the age of 50. Early symptoms of giant cell arteritis resemble the flu: fatigue, loss of appetite, and fever. Other symptoms include: Headaches Pain and tenderness over the temples Double vision or visual loss, dizziness Problems with coordination and balance Pain in your jaw and tongue  Your doctor will make the diagnosis based on your medical history, symptoms, and a physical exam. There is no specific test for giant cell arteritis, but you may have tests that measure inflammation. Treatment is usually with corticosteroids. Early treatment is important; otherwise there is a risk of permanent vision loss or stroke. However, when properly treated, giant cell arteritis rarely comes back. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10043207",
-            "MEDDRA:10011303",
-            "MEDDRA:10020396",
-            "MEDDRA:10020395",
-            "UMLS:C1956391",
-            "NCIT:C35065",
-            "DOID:13375",
-            "UMLS:C1956390",
-            "UMLS:C0039483",
-            "MESH:D013700",
-            "ORPHANET:397",
-            "EFO:1001209",
-            "SNOMEDCT:400130008",
-            "ICD9:446.5",
-            "MEDDRA:10018250",
-            "MONDO:0008538",
-            "OMIM:187360"
-          ],
-          "id": "MONDO:0008538",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cranial Arteritis",
-            "Giant cell arteritis",
-            "Giant Cell Arteritis",
-            "temporal arteritis",
-            "Temporal Arteritis",
-            "Temporal arteritis related phenotypic feature"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.mayoclinic.org/diseases-conditions/giant-cell-arteritis/symptoms-causes/syc-20372758",
-            "https://orcid.org/0000-0001-5208-3432"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 531206,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008538",
-              "name": "temporal arteritis",
-              "description": "An autoimmune, systemic, giant cell granulomatous arteritis predominantly involving the arteries that supply blood to the central nervous system, head and eyes. Superficial arteries of the scalp that are involved tend to be enlarged and tender. Signs and symptoms include headaches, myalgias, visual disturbances, and skin necrosis.; A systemic autoimmune disorder that typically affects medium and large ARTERIES, usually leading to occlusive granulomatous vasculitis with transmural infiltrate containing multinucleated GIANT CELLS. The TEMPORAL ARTERY is commonly involved. This disorder appears primarily in people over the age of 50. Symptoms include FEVER; FATIGUE; HEADACHE; visual impairment; pain in the jaw and tongue; and aggravation of pain by cold temperatures. (From Adams et al., Principles of Neurology, 6th ed); Giant cell arteritis is a disorder that causes inflammation of your arteries, usually in the scalp, neck, and arms. It narrows the arteries, which keeps blood from flowing well. Giant cell arteritis often occurs with another disorder called polymyalgia rheumatica. Both are more common in women than in men. They almost always affect people over the age of 50. Early symptoms of giant cell arteritis resemble the flu: fatigue, loss of appetite, and fever. Other symptoms include: Headaches Pain and tenderness over the temples Double vision or visual loss, dizziness Problems with coordination and balance Pain in your jaw and tongue  Your doctor will make the diagnosis based on your medical history, symptoms, and a physical exam. There is no specific test for giant cell arteritis, but you may have tests that measure inflammation. Treatment is usually with corticosteroids. Early treatment is important; otherwise there is a risk of permanent vision loss or stroke. However, when properly treated, giant cell arteritis rarely comes back. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10043207",
-                "MEDDRA:10011303",
-                "MEDDRA:10020396",
-                "MEDDRA:10020395",
-                "UMLS:C1956391",
-                "NCIT:C35065",
-                "DOID:13375",
-                "UMLS:C1956390",
-                "UMLS:C0039483",
-                "MESH:D013700",
-                "ORPHANET:397",
-                "EFO:1001209",
-                "SNOMEDCT:400130008",
-                "ICD9:446.5",
-                "MEDDRA:10018250",
-                "MONDO:0008538",
-                "OMIM:187360"
-              ],
-              "id": "MONDO:0008538",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cranial Arteritis",
-                "Giant cell arteritis",
-                "Giant Cell Arteritis",
-                "temporal arteritis",
-                "Temporal Arteritis",
-                "Temporal arteritis related phenotypic feature"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.mayoclinic.org/diseases-conditions/giant-cell-arteritis/symptoms-causes/syc-20372758",
-                "https://orcid.org/0000-0001-5208-3432"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16796858,
-            "start": 568,
-            "end": 531206,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24026674': {'publication date': '2014 Feb', 'sentence': 'Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:25132663': {'publication date': '2015 Mar', 'sentence': 'OBJECTIVE: To establish the incidence of giant cell arteritis (GCA), cumulative use of prednisolone, and comorbidities most associated with GCA.', 'subject score': 1000, 'object score': 1000}, 'PMID:2727585': {'publication date': '1989 Jan', 'sentence': \"[Interaction of rifampicin and prednisolone. Apropos of 2 cases occurring in Horton's disease].\", 'subject score': 1000, 'object score': 1000}, 'PMID:31034796': {'publication date': '2019 Jul', 'sentence': 'Prednisone/prednisolone at a dose of 40-60 mg/day is the cornerstone therapy in GCA.', 'subject score': 888, 'object score': 1000}, 'PMID:3511861': {'publication date': '1986 Feb', 'sentence': 'The ability of azathioprine to reduce the maintenance prednisolone requirement of 31 patients with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA), or both, was tested in a double-blind placebo controlled study over one year.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0039483---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "17143213",
-              "object": "MONDO:0008538",
-              "publications": [
-                "PMID:24026674",
-                "PMID:25132663",
-                "PMID:2727585",
-                "PMID:31034796",
-                "PMID:3511861"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10616010': {'publication date': '1999 Dec', 'sentence': 'At the time of diagnosis, patients with GCA had an increased median serum level of YKL-40 (256 microg/liter; P<0.01) compared with healthy age-matched controls (median 118 microg/liter), and the serum level of YKL-40 decreased to normal levels during prednisolone treatment (-38% after 1 month; P<0.001).', 'subject score': 888, 'object score': 1000}, 'PMID:10898068': {'publication date': '2000', 'sentence': 'However, a tendency to a lower BMD was found in PMR/TA patients currently treated with prednisolone and in the prednisolone treated TA patients.', 'subject score': 1000, 'object score': 901}, 'PMID:11817115': {'publication date': '2001 Nov', 'sentence': 'PURPOSE: To assess the efficacy and tolerance of three methylprednisolone boluses (500 mg/d) followed by a standard dose of prednisolone, 20 mg/d, as the initial treatment of non-complicated giant-cell arteritis.', 'subject score': 1000, 'object score': 854}, 'PMID:13424439': {'publication date': '1957 Apr 19', 'sentence': '[Case report on temporal arteritis treated with prednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:13473393': {'publication date': '1957 Oct', 'sentence': 'Temporal arteritis treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:2254893': {'publication date': '1990 Oct', 'sentence': 'Our study indicates that most patients with PMR or TA can be treated safely with an initial prednisolone dose of 10 mg given twice daily.', 'subject score': 851, 'object score': 1000}, 'PMID:23146656': {'publication date': '2013 Jul', 'sentence': 'METHODS: Using a radioactive binding assay, the density and affinity (measured as Bmax and Kd) of 5-HT2A serotonin receptors were measured in blood samples drawn from 27 individuals diagnosed with polymyalgia rheumatica and/or giant cell arteritis before and after start of an oral treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:2351926': {'publication date': '1990 Jun', 'sentence': 'The mineral content of the heel bone, and signs of osteoporosis on X-ray of the spine, were evaluated in 26 patients (20 women and 6 men) with giant cell arteritis (GCA), treated with prednisolone for an average period of 5 years.', 'subject score': 1000, 'object score': 1000}, 'PMID:2782975': {'publication date': '1989 Aug', 'sentence': 'All but two patients with GCA were successfully treated with 40 mg/day prednisolone initially but relapsed on a reduction to 20 mg/day.', 'subject score': 822, 'object score': 1000}, 'PMID:28663795': {'publication date': '2017 Aug', 'sentence': '8 patients within the biopsies negative for GCA had their prednisolone therapy stopped.', 'subject score': 888, 'object score': 1000}, 'PMID:28791802': {'publication date': '2018 Jan', 'sentence': 'METHODS: Twelve patients with new diagnosis of GCA were initially treated with high-dose prednisolone (40-60 mg) daily for 4 weeks and then randomized to two open arms to continue tapering steroid treatment with either standard IR prednisolone or MR prednisone.', 'subject score': 901, 'object score': 1000}, 'PMID:29408476': {'publication date': '2018 Apr', 'sentence': 'The diagnosis of GCA was retained, and treatment with prednisolone was started.', 'subject score': 1000, 'object score': 1000}, 'PMID:29877748': {'publication date': '2018 Jul', 'sentence': 'Expert commentary: Prednisone/prednisolone of 40-60 mg/day is the mainstay in GCA therapy.', 'subject score': 888, 'object score': 916}, 'PMID:31431989': {'publication date': '2019', 'sentence': 'The duration of treatment with prednisolone for GCA was 22-26 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:31506102': {'publication date': '2019 Sep 11', 'sentence': 'She was diagnosed as having giant cell arteritis and started on orally administered prednisolone treatment (60 mg daily).', 'subject score': 750, 'object score': 1000}, 'PMID:31531960': {'publication date': '2019 Oct', 'sentence': 'Circulating interleukin-6 as a biomarker in a randomized controlled trial of modified-release prednisone vs immediate-release prednisolone, in newly diagnosed patients with giant cell arteritis.', 'subject score': 851, 'object score': 1000}, 'PMID:31612515': {'publication date': '2019 Dec', 'sentence': \"PATIENTS AND MEASUREMENTS: Patients with Cushing's syndrome (CS, n = 19), asthma or giant cell arteritis on chronic prednisolone treatment (PRED, n = 13), adrenal insufficiency (AI, n = 16) and healthy volunteers (HV, n = 20).\", 'subject score': 851, 'object score': 1000}, 'PMID:32031663': {'publication date': '2020 Feb 07', 'sentence': 'METHODS: We included 47 patients with PMR (n = 37), GCA (n = 1) or both (n = 9), treated with prednisolone for >=5.4 months, current dose 2.5-10 mg/day.', 'subject score': 1000, 'object score': 1000}, 'PMID:34678904': {'publication date': '2021 Oct 22', 'sentence': 'Another male patient in his 70s (patient 3) was on prednisolone therapy for polymyalgia rheumatica, giant cell arteritis, and pancreatic body tumor.', 'subject score': 888, 'object score': 1000}, 'PMID:34840228': {'publication date': '2021 Nov 27', 'sentence': 'A 79-year-old woman with GCA involving the thoracic aorta and its first branches to the posterior tibial arteries had been treated with high-dose prednisolone.', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 531206,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008538",
-          "name": "temporal arteritis",
-          "description": "An autoimmune, systemic, giant cell granulomatous arteritis predominantly involving the arteries that supply blood to the central nervous system, head and eyes. Superficial arteries of the scalp that are involved tend to be enlarged and tender. Signs and symptoms include headaches, myalgias, visual disturbances, and skin necrosis.; A systemic autoimmune disorder that typically affects medium and large ARTERIES, usually leading to occlusive granulomatous vasculitis with transmural infiltrate containing multinucleated GIANT CELLS. The TEMPORAL ARTERY is commonly involved. This disorder appears primarily in people over the age of 50. Symptoms include FEVER; FATIGUE; HEADACHE; visual impairment; pain in the jaw and tongue; and aggravation of pain by cold temperatures. (From Adams et al., Principles of Neurology, 6th ed); Giant cell arteritis is a disorder that causes inflammation of your arteries, usually in the scalp, neck, and arms. It narrows the arteries, which keeps blood from flowing well. Giant cell arteritis often occurs with another disorder called polymyalgia rheumatica. Both are more common in women than in men. They almost always affect people over the age of 50. Early symptoms of giant cell arteritis resemble the flu: fatigue, loss of appetite, and fever. Other symptoms include: Headaches Pain and tenderness over the temples Double vision or visual loss, dizziness Problems with coordination and balance Pain in your jaw and tongue  Your doctor will make the diagnosis based on your medical history, symptoms, and a physical exam. There is no specific test for giant cell arteritis, but you may have tests that measure inflammation. Treatment is usually with corticosteroids. Early treatment is important; otherwise there is a risk of permanent vision loss or stroke. However, when properly treated, giant cell arteritis rarely comes back. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10043207",
-            "MEDDRA:10011303",
-            "MEDDRA:10020396",
-            "MEDDRA:10020395",
-            "UMLS:C1956391",
-            "NCIT:C35065",
-            "DOID:13375",
-            "UMLS:C1956390",
-            "UMLS:C0039483",
-            "MESH:D013700",
-            "ORPHANET:397",
-            "EFO:1001209",
-            "SNOMEDCT:400130008",
-            "ICD9:446.5",
-            "MEDDRA:10018250",
-            "MONDO:0008538",
-            "OMIM:187360"
-          ],
-          "id": "MONDO:0008538",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cranial Arteritis",
-            "Giant cell arteritis",
-            "Giant Cell Arteritis",
-            "temporal arteritis",
-            "Temporal Arteritis",
-            "Temporal arteritis related phenotypic feature"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.mayoclinic.org/diseases-conditions/giant-cell-arteritis/symptoms-causes/syc-20372758",
-            "https://orcid.org/0000-0001-5208-3432"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 531206,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008538",
-              "name": "temporal arteritis",
-              "description": "An autoimmune, systemic, giant cell granulomatous arteritis predominantly involving the arteries that supply blood to the central nervous system, head and eyes. Superficial arteries of the scalp that are involved tend to be enlarged and tender. Signs and symptoms include headaches, myalgias, visual disturbances, and skin necrosis.; A systemic autoimmune disorder that typically affects medium and large ARTERIES, usually leading to occlusive granulomatous vasculitis with transmural infiltrate containing multinucleated GIANT CELLS. The TEMPORAL ARTERY is commonly involved. This disorder appears primarily in people over the age of 50. Symptoms include FEVER; FATIGUE; HEADACHE; visual impairment; pain in the jaw and tongue; and aggravation of pain by cold temperatures. (From Adams et al., Principles of Neurology, 6th ed); Giant cell arteritis is a disorder that causes inflammation of your arteries, usually in the scalp, neck, and arms. It narrows the arteries, which keeps blood from flowing well. Giant cell arteritis often occurs with another disorder called polymyalgia rheumatica. Both are more common in women than in men. They almost always affect people over the age of 50. Early symptoms of giant cell arteritis resemble the flu: fatigue, loss of appetite, and fever. Other symptoms include: Headaches Pain and tenderness over the temples Double vision or visual loss, dizziness Problems with coordination and balance Pain in your jaw and tongue  Your doctor will make the diagnosis based on your medical history, symptoms, and a physical exam. There is no specific test for giant cell arteritis, but you may have tests that measure inflammation. Treatment is usually with corticosteroids. Early treatment is important; otherwise there is a risk of permanent vision loss or stroke. However, when properly treated, giant cell arteritis rarely comes back. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10043207",
-                "MEDDRA:10011303",
-                "MEDDRA:10020396",
-                "MEDDRA:10020395",
-                "UMLS:C1956391",
-                "NCIT:C35065",
-                "DOID:13375",
-                "UMLS:C1956390",
-                "UMLS:C0039483",
-                "MESH:D013700",
-                "ORPHANET:397",
-                "EFO:1001209",
-                "SNOMEDCT:400130008",
-                "ICD9:446.5",
-                "MEDDRA:10018250",
-                "MONDO:0008538",
-                "OMIM:187360"
-              ],
-              "id": "MONDO:0008538",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cranial Arteritis",
-                "Giant cell arteritis",
-                "Giant Cell Arteritis",
-                "temporal arteritis",
-                "Temporal Arteritis",
-                "Temporal arteritis related phenotypic feature"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.mayoclinic.org/diseases-conditions/giant-cell-arteritis/symptoms-causes/syc-20372758",
-                "https://orcid.org/0000-0001-5208-3432"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7736659,
-            "start": 568,
-            "end": 531206,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10616010': {'publication date': '1999 Dec', 'sentence': 'At the time of diagnosis, patients with GCA had an increased median serum level of YKL-40 (256 microg/liter; P<0.01) compared with healthy age-matched controls (median 118 microg/liter), and the serum level of YKL-40 decreased to normal levels during prednisolone treatment (-38% after 1 month; P<0.001).', 'subject score': 888, 'object score': 1000}, 'PMID:10898068': {'publication date': '2000', 'sentence': 'However, a tendency to a lower BMD was found in PMR/TA patients currently treated with prednisolone and in the prednisolone treated TA patients.', 'subject score': 1000, 'object score': 901}, 'PMID:11817115': {'publication date': '2001 Nov', 'sentence': 'PURPOSE: To assess the efficacy and tolerance of three methylprednisolone boluses (500 mg/d) followed by a standard dose of prednisolone, 20 mg/d, as the initial treatment of non-complicated giant-cell arteritis.', 'subject score': 1000, 'object score': 854}, 'PMID:13424439': {'publication date': '1957 Apr 19', 'sentence': '[Case report on temporal arteritis treated with prednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:13473393': {'publication date': '1957 Oct', 'sentence': 'Temporal arteritis treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:2254893': {'publication date': '1990 Oct', 'sentence': 'Our study indicates that most patients with PMR or TA can be treated safely with an initial prednisolone dose of 10 mg given twice daily.', 'subject score': 851, 'object score': 1000}, 'PMID:23146656': {'publication date': '2013 Jul', 'sentence': 'METHODS: Using a radioactive binding assay, the density and affinity (measured as Bmax and Kd) of 5-HT2A serotonin receptors were measured in blood samples drawn from 27 individuals diagnosed with polymyalgia rheumatica and/or giant cell arteritis before and after start of an oral treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:2351926': {'publication date': '1990 Jun', 'sentence': 'The mineral content of the heel bone, and signs of osteoporosis on X-ray of the spine, were evaluated in 26 patients (20 women and 6 men) with giant cell arteritis (GCA), treated with prednisolone for an average period of 5 years.', 'subject score': 1000, 'object score': 1000}, 'PMID:2782975': {'publication date': '1989 Aug', 'sentence': 'All but two patients with GCA were successfully treated with 40 mg/day prednisolone initially but relapsed on a reduction to 20 mg/day.', 'subject score': 822, 'object score': 1000}, 'PMID:28663795': {'publication date': '2017 Aug', 'sentence': '8 patients within the biopsies negative for GCA had their prednisolone therapy stopped.', 'subject score': 888, 'object score': 1000}, 'PMID:28791802': {'publication date': '2018 Jan', 'sentence': 'METHODS: Twelve patients with new diagnosis of GCA were initially treated with high-dose prednisolone (40-60 mg) daily for 4 weeks and then randomized to two open arms to continue tapering steroid treatment with either standard IR prednisolone or MR prednisone.', 'subject score': 901, 'object score': 1000}, 'PMID:29408476': {'publication date': '2018 Apr', 'sentence': 'The diagnosis of GCA was retained, and treatment with prednisolone was started.', 'subject score': 1000, 'object score': 1000}, 'PMID:29877748': {'publication date': '2018 Jul', 'sentence': 'Expert commentary: Prednisone/prednisolone of 40-60 mg/day is the mainstay in GCA therapy.', 'subject score': 888, 'object score': 916}, 'PMID:31431989': {'publication date': '2019', 'sentence': 'The duration of treatment with prednisolone for GCA was 22-26 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:31506102': {'publication date': '2019 Sep 11', 'sentence': 'She was diagnosed as having giant cell arteritis and started on orally administered prednisolone treatment (60 mg daily).', 'subject score': 750, 'object score': 1000}, 'PMID:31531960': {'publication date': '2019 Oct', 'sentence': 'Circulating interleukin-6 as a biomarker in a randomized controlled trial of modified-release prednisone vs immediate-release prednisolone, in newly diagnosed patients with giant cell arteritis.', 'subject score': 851, 'object score': 1000}, 'PMID:31612515': {'publication date': '2019 Dec', 'sentence': \"PATIENTS AND MEASUREMENTS: Patients with Cushing's syndrome (CS, n = 19), asthma or giant cell arteritis on chronic prednisolone treatment (PRED, n = 13), adrenal insufficiency (AI, n = 16) and healthy volunteers (HV, n = 20).\", 'subject score': 851, 'object score': 1000}, 'PMID:32031663': {'publication date': '2020 Feb 07', 'sentence': 'METHODS: We included 47 patients with PMR (n = 37), GCA (n = 1) or both (n = 9), treated with prednisolone for >=5.4 months, current dose 2.5-10 mg/day.', 'subject score': 1000, 'object score': 1000}, 'PMID:34678904': {'publication date': '2021 Oct 22', 'sentence': 'Another male patient in his 70s (patient 3) was on prednisolone therapy for polymyalgia rheumatica, giant cell arteritis, and pancreatic body tumor.', 'subject score': 888, 'object score': 1000}, 'PMID:34840228': {'publication date': '2021 Nov 27', 'sentence': 'A 79-year-old woman with GCA involving the thoracic aorta and its first branches to the posterior tibial arteries had been treated with high-dose prednisolone.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0039483---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C1956391---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7900660",
-              "object": "MONDO:0008538",
-              "publications": [
-                "PMID:31612515",
-                "PMID:37026007",
-                "PMID:28791802",
-                "PMID:2254893",
-                "PMID:31506102",
-                "PMID:11817115",
-                "PMID:35169570",
-                "PMID:13473393",
-                "PMID:31531960",
-                "PMID:8257209",
-                "PMID:8203964",
-                "PMID:28663795",
-                "PMID:8116092",
-                "PMID:36631167",
-                "PMID:23146656",
-                "PMID:8205403",
-                "PMID:2351926",
-                "PMID:32031663",
-                "PMID:10898068",
-                "PMID:8094625"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:3227469': {'publication date': '1988 Oct', 'sentence': '[Prednisolone and aspirin combination therapy in habitual abortion with autoantibodies].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 634814,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006774",
-          "name": "habitual spontaneous abortion",
-          "description": "Three or more consecutive spontaneous abortions.",
-          "equivalent_curies": [
-            "UMLS:C0000809",
-            "MEDDRA:10038104",
-            "MEDDRA:10062935",
-            "MONDO:0006774",
-            "MESH:D000026",
-            "SNOMEDCT:102878001"
-          ],
-          "id": "MONDO:0006774",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Abortion, Habitual",
-            "habitual spontaneous abortion"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 634814,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006774",
-              "name": "habitual spontaneous abortion",
-              "description": "Three or more consecutive spontaneous abortions.",
-              "equivalent_curies": [
-                "UMLS:C0000809",
-                "MEDDRA:10038104",
-                "MEDDRA:10062935",
-                "MONDO:0006774",
-                "MESH:D000026",
-                "SNOMEDCT:102878001"
-              ],
-              "id": "MONDO:0006774",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Abortion, Habitual",
-                "habitual spontaneous abortion"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21494165,
-            "start": 568,
-            "end": 634814,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3227469': {'publication date': '1988 Oct', 'sentence': '[Prednisolone and aspirin combination therapy in habitual abortion with autoantibodies].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0000809---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "21911849",
-              "object": "MONDO:0006774",
-              "publications": [
-                "PMID:3227469"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:19903335': {'publication date': '2009 Nov 10', 'sentence': 'Prednisolone Trial: Study protocol for a randomised controlled trial of prednisolone for women with idiopathic recurrent miscarriage and raised levels of uterine natural killer (uNK) cells in the endometrium.', 'subject score': 1000, 'object score': 901}, 'PMID:21984529': {'publication date': '2011 Dec', 'sentence': 'CONCLUSIONS: The effect of prednisolone therapy for some women with RM may be due to altered endometrial angiogenic growth factor expression and reduced blood vessel maturation.', 'subject score': 888, 'object score': 1000}, 'PMID:24818590': {'publication date': '2014 Oct', 'sentence': 'CONCLUSION: The addition of prednisolone to heparin and low dose aspirin might be beneficial in patients with unexplained recurrent miscarriage, and this effect might be due to a suppressive effect of steroids on the peripheral CD16 NK cells concentration.', 'subject score': 1000, 'object score': 901}, 'PMID:35249235': {'publication date': '2022 Mar 06', 'sentence': 'Oral administration of cyclosporine A or prednisolone increases live birth rate (OR = 3.6, 95% CI: 2.1-6.15, p < 0.00001) and ongoing pregnancy rate (OR = 8.82, 95% CI: 2.91-26.75, p = 0.0001) in patients with idiopathic RM.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 634814,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006774",
-          "name": "habitual spontaneous abortion",
-          "description": "Three or more consecutive spontaneous abortions.",
-          "equivalent_curies": [
-            "UMLS:C0000809",
-            "MEDDRA:10038104",
-            "MEDDRA:10062935",
-            "MONDO:0006774",
-            "MESH:D000026",
-            "SNOMEDCT:102878001"
-          ],
-          "id": "MONDO:0006774",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Abortion, Habitual",
-            "habitual spontaneous abortion"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 634814,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006774",
-              "name": "habitual spontaneous abortion",
-              "description": "Three or more consecutive spontaneous abortions.",
-              "equivalent_curies": [
-                "UMLS:C0000809",
-                "MEDDRA:10038104",
-                "MEDDRA:10062935",
-                "MONDO:0006774",
-                "MESH:D000026",
-                "SNOMEDCT:102878001"
-              ],
-              "id": "MONDO:0006774",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Abortion, Habitual",
-                "habitual spontaneous abortion"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14370679,
-            "start": 568,
-            "end": 634814,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19903335': {'publication date': '2009 Nov 10', 'sentence': 'Prednisolone Trial: Study protocol for a randomised controlled trial of prednisolone for women with idiopathic recurrent miscarriage and raised levels of uterine natural killer (uNK) cells in the endometrium.', 'subject score': 1000, 'object score': 901}, 'PMID:21984529': {'publication date': '2011 Dec', 'sentence': 'CONCLUSIONS: The effect of prednisolone therapy for some women with RM may be due to altered endometrial angiogenic growth factor expression and reduced blood vessel maturation.', 'subject score': 888, 'object score': 1000}, 'PMID:24818590': {'publication date': '2014 Oct', 'sentence': 'CONCLUSION: The addition of prednisolone to heparin and low dose aspirin might be beneficial in patients with unexplained recurrent miscarriage, and this effect might be due to a suppressive effect of steroids on the peripheral CD16 NK cells concentration.', 'subject score': 1000, 'object score': 901}, 'PMID:35249235': {'publication date': '2022 Mar 06', 'sentence': 'Oral administration of cyclosporine A or prednisolone increases live birth rate (OR = 3.6, 95% CI: 2.1-6.15, p < 0.00001) and ongoing pregnancy rate (OR = 8.82, 95% CI: 2.91-26.75, p = 0.0001) in patients with idiopathic RM.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0000809---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "14676056",
-              "object": "MONDO:0006774",
-              "publications": [
-                "PMID:19903335",
-                "PMID:21984529",
-                "PMID:24818590",
-                "PMID:35249235"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:14713975': {'publication date': '2003 Dec 04', 'sentence': 'RESULTS: The average initial dose of prednisolone in polymyalgia rheumatica was 35 mg; 51 of 62 patients were given a starting dose exceeding 15 mg.', 'subject score': 1000, 'object score': 1000}, 'PMID:3511861': {'publication date': '1986 Feb', 'sentence': 'The ability of azathioprine to reduce the maintenance prednisolone requirement of 31 patients with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA), or both, was tested in a double-blind placebo controlled study over one year.', 'subject score': 851, 'object score': 1000}, 'PMID:3621844': {'publication date': '1987 Jun', 'sentence': 'Giant cell arteritis precipitated by a diagnostic trial of prednisolone in suspected polymyalgia rheumatica.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 531649,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019735",
-          "name": "polymyalgia rheumatica",
-          "description": "A syndrome characterized by pain, stiffness, and tenderness of the proximal muscle groups including the shoulder, pelvic girdle and the neck. There is no muscle atrophy and muscle biopsies do not reveal pathologic changes. Additional signs and symptoms include low grade fever, fatigue and depression.; A syndrome in the elderly characterized by proximal joint and muscle pain, high erythrocyte sedimentation rate, and a self-limiting course. Pain is usually accompanied by evidence of an inflammatory reaction. Women are affected twice as commonly as men and Caucasians more frequently than other groups. The condition is frequently associated with GIANT CELL ARTERITIS and some theories pose the possibility that the two diseases arise from a single etiology or even that they are the same entity.; Polymyalgia rheumatica is a disorder that causes muscle pain and stiffness in your neck, shoulders, and hips. It is most common in women and almost always occurs in people over 50. The main symptom is stiffness after resting. Other symptoms include fever, weakness and weight loss. In some cases, polymyalgia rheumatica develops overnight. In others, it is gradual. The cause of polymyalgia rheumatica is unknown. There is no specific test for it. Your doctor will use your medical history, symptoms, and a physical exam to make the diagnosis. Lab tests for inflammation may help confirm the diagnosis. Polymyalgia rheumatica sometimes occurs along with giant cell arteritis, a condition that causes swelling of the arteries in your head. Symptoms include headaches and blurred vision. Doctors often prescribe prednisone, a steroid medicine, for both conditions. With treatment, polymyalgia rheumatica usually disappears in a day or two. Without treatment, it usually goes away after a year or more.  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10036099",
-            "UMLS:C1527406",
-            "NCIT:C85018",
-            "DOID:853",
-            "ORPHANET:93569",
-            "MEDDRA:10068240",
-            "UMLS:C0032533",
-            "MESH:D011111",
-            "ICD9:725",
-            "SNOMEDCT:65323003",
-            "EFO:0008518",
-            "MONDO:0019735",
-            "ICD10:M35.3"
-          ],
-          "id": "MONDO:0019735",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Polymyalgia rheumatica",
-            "polymyalgia rheumatica",
-            "Rhizomelic pseudopolyarthritis",
-            "Polymyalgia Rheumatica"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/polymyalgiarheumatica.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 531649,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019735",
-              "name": "polymyalgia rheumatica",
-              "description": "A syndrome characterized by pain, stiffness, and tenderness of the proximal muscle groups including the shoulder, pelvic girdle and the neck. There is no muscle atrophy and muscle biopsies do not reveal pathologic changes. Additional signs and symptoms include low grade fever, fatigue and depression.; A syndrome in the elderly characterized by proximal joint and muscle pain, high erythrocyte sedimentation rate, and a self-limiting course. Pain is usually accompanied by evidence of an inflammatory reaction. Women are affected twice as commonly as men and Caucasians more frequently than other groups. The condition is frequently associated with GIANT CELL ARTERITIS and some theories pose the possibility that the two diseases arise from a single etiology or even that they are the same entity.; Polymyalgia rheumatica is a disorder that causes muscle pain and stiffness in your neck, shoulders, and hips. It is most common in women and almost always occurs in people over 50. The main symptom is stiffness after resting. Other symptoms include fever, weakness and weight loss. In some cases, polymyalgia rheumatica develops overnight. In others, it is gradual. The cause of polymyalgia rheumatica is unknown. There is no specific test for it. Your doctor will use your medical history, symptoms, and a physical exam to make the diagnosis. Lab tests for inflammation may help confirm the diagnosis. Polymyalgia rheumatica sometimes occurs along with giant cell arteritis, a condition that causes swelling of the arteries in your head. Symptoms include headaches and blurred vision. Doctors often prescribe prednisone, a steroid medicine, for both conditions. With treatment, polymyalgia rheumatica usually disappears in a day or two. Without treatment, it usually goes away after a year or more.  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10036099",
-                "UMLS:C1527406",
-                "NCIT:C85018",
-                "DOID:853",
-                "ORPHANET:93569",
-                "MEDDRA:10068240",
-                "UMLS:C0032533",
-                "MESH:D011111",
-                "ICD9:725",
-                "SNOMEDCT:65323003",
-                "EFO:0008518",
-                "MONDO:0019735",
-                "ICD10:M35.3"
-              ],
-              "id": "MONDO:0019735",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Polymyalgia rheumatica",
-                "polymyalgia rheumatica",
-                "Rhizomelic pseudopolyarthritis",
-                "Polymyalgia Rheumatica"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/polymyalgiarheumatica.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10714401,
-            "start": 568,
-            "end": 531649,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14713975': {'publication date': '2003 Dec 04', 'sentence': 'RESULTS: The average initial dose of prednisolone in polymyalgia rheumatica was 35 mg; 51 of 62 patients were given a starting dose exceeding 15 mg.', 'subject score': 1000, 'object score': 1000}, 'PMID:3511861': {'publication date': '1986 Feb', 'sentence': 'The ability of azathioprine to reduce the maintenance prednisolone requirement of 31 patients with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA), or both, was tested in a double-blind placebo controlled study over one year.', 'subject score': 851, 'object score': 1000}, 'PMID:3621844': {'publication date': '1987 Jun', 'sentence': 'Giant cell arteritis precipitated by a diagnostic trial of prednisolone in suspected polymyalgia rheumatica.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0032533---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10949449",
-              "object": "MONDO:0019735",
-              "publications": [
-                "PMID:14713975",
-                "PMID:3511861",
-                "PMID:3621844"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10616010': {'publication date': '1999 Dec', 'sentence': 'Most patients with PMR had normal serum YKL-40 levels (median 158 microg/liter) and had no changes in the serum YKL-40 levels during prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:10774252': {'publication date': '2000 Mar', 'sentence': 'A diagnosis of polymyalgia rheumatica was made, and low-dose prednisolone therapy (20 mg/d) was started.', 'subject score': 861, 'object score': 1000}, 'PMID:10898068': {'publication date': '2000', 'sentence': 'Similarly, no significant differences in BMD were found between current and previous users of prednisolone and between the prednisolone treated PMR and TA patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:12910963': {'publication date': '2003 Jun', 'sentence': 'SUBJECTS AND METHODS: The study included 10 patients with PMR, who could be prospectively followed up from the start of prednisolone (PSL) treatment until the CRP level decreased to 1 mg/dl or less.', 'subject score': 888, 'object score': 1000}, 'PMID:17087187': {'publication date': '2006', 'sentence': 'Polymyalgia rheumatica is treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:1768166': {'publication date': '1991 Dec', 'sentence': 'These results will be further evaluated in a controlled trial using intramuscular injections of methylprednisolone and prednisolone given by mouth for the treatment of polymyalgia rheumatica.', 'subject score': 1000, 'object score': 1000}, 'PMID:20812339': {'publication date': '2010 Dec', 'sentence': 'In the PMR patients, interstitial concentrations were normalized after prednisolone treatment.', 'subject score': 888, 'object score': 901}, 'PMID:2254893': {'publication date': '1990 Oct', 'sentence': 'Our study indicates that most patients with PMR or TA can be treated safely with an initial prednisolone dose of 10 mg given twice daily.', 'subject score': 851, 'object score': 1000}, 'PMID:28282736': {'publication date': '2018', 'sentence': 'Ocular inflammation presented as episcleritis, scleritis, or anterior uveitis, and it emerged during the tapering of low-dose prednisolone prescribed for polymyalgia rheumatica in all patients.', 'subject score': 901, 'object score': 1000}, 'PMID:28867756': {'publication date': '2017', 'sentence': 'Case 2: An 83-year-old man suffering from PMR was successfully treated with PSL and CAM.', 'subject score': 1000, 'object score': 1000}, 'PMID:32156589': {'publication date': '2020 Mar 07', 'sentence': 'He was treated with oral prednisolone for polymyalgia rheumatica.', 'subject score': 888, 'object score': 1000}, 'PMID:32996694': {'publication date': '2020 Sep 30', 'sentence': 'CONCLUSION: The normalization of CRP within 1 month from baseline predicted GC-free remission in PMR patients treated with PSL, and resulted in a lower cumulative PSL dose.', 'subject score': 1000, 'object score': 901}, 'PMID:34678904': {'publication date': '2021 Oct 22', 'sentence': 'Another male patient in his 70s (patient 3) was on prednisolone therapy for polymyalgia rheumatica, giant cell arteritis, and pancreatic body tumor.', 'subject score': 888, 'object score': 1000}, 'PMID:36152056': {'publication date': '2022 Sep 24', 'sentence': 'She was diagnosed with polymyalgia rheumatica (PMR) and treated with low-dose prednisolone (15 mg daily); however, she discontinued glucocorticoid therapy at her discretion due to the psychiatric adverse effect (cognitive dysfunction).', 'subject score': 901, 'object score': 1000}, 'PMID:3780140': {'publication date': '1986 Sep', 'sentence': 'Prednisolone pharmacokinetics in patients with rheumatoid arthritis, polymyalgia rheumatica and asthma.', 'subject score': 888, 'object score': 1000}, 'PMID:8116092': {'publication date': '1994 Feb 21', 'sentence': 'We assessed the diagnostic value of CD8+ levels in a larger group of patients with temporal arteritis and polymyalgia rheumatica before and after treatment with prednisolone and in relation to patients with other medical and rheumatic diseases.', 'subject score': 1000, 'object score': 1000}, 'PMID:8203964': {'publication date': '1994 Apr', 'sentence': 'Circulating T cell subtypes in polymyalgia rheumatica and giant cell arteritis: variation in the percentage of CD8+ cells with prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:8222521': {'publication date': '1993 Aug', 'sentence': 'However, corticosteroids, usually prednisone or prednisolone, are the class of drugs most widely used to treat PMR.', 'subject score': 1000, 'object score': 1000}, 'PMID:8257209': {'publication date': '1993 Oct', 'sentence': 'Circulating T cell subtypes in polymyalgia rheumatica and giant cell arteritis: variation in the percentage of CD8+ cells with prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:8523341': {'publication date': '1995 Sep', 'sentence': 'A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 531649,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019735",
-          "name": "polymyalgia rheumatica",
-          "description": "A syndrome characterized by pain, stiffness, and tenderness of the proximal muscle groups including the shoulder, pelvic girdle and the neck. There is no muscle atrophy and muscle biopsies do not reveal pathologic changes. Additional signs and symptoms include low grade fever, fatigue and depression.; A syndrome in the elderly characterized by proximal joint and muscle pain, high erythrocyte sedimentation rate, and a self-limiting course. Pain is usually accompanied by evidence of an inflammatory reaction. Women are affected twice as commonly as men and Caucasians more frequently than other groups. The condition is frequently associated with GIANT CELL ARTERITIS and some theories pose the possibility that the two diseases arise from a single etiology or even that they are the same entity.; Polymyalgia rheumatica is a disorder that causes muscle pain and stiffness in your neck, shoulders, and hips. It is most common in women and almost always occurs in people over 50. The main symptom is stiffness after resting. Other symptoms include fever, weakness and weight loss. In some cases, polymyalgia rheumatica develops overnight. In others, it is gradual. The cause of polymyalgia rheumatica is unknown. There is no specific test for it. Your doctor will use your medical history, symptoms, and a physical exam to make the diagnosis. Lab tests for inflammation may help confirm the diagnosis. Polymyalgia rheumatica sometimes occurs along with giant cell arteritis, a condition that causes swelling of the arteries in your head. Symptoms include headaches and blurred vision. Doctors often prescribe prednisone, a steroid medicine, for both conditions. With treatment, polymyalgia rheumatica usually disappears in a day or two. Without treatment, it usually goes away after a year or more.  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10036099",
-            "UMLS:C1527406",
-            "NCIT:C85018",
-            "DOID:853",
-            "ORPHANET:93569",
-            "MEDDRA:10068240",
-            "UMLS:C0032533",
-            "MESH:D011111",
-            "ICD9:725",
-            "SNOMEDCT:65323003",
-            "EFO:0008518",
-            "MONDO:0019735",
-            "ICD10:M35.3"
-          ],
-          "id": "MONDO:0019735",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Polymyalgia rheumatica",
-            "polymyalgia rheumatica",
-            "Rhizomelic pseudopolyarthritis",
-            "Polymyalgia Rheumatica"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/polymyalgiarheumatica.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 531649,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019735",
-              "name": "polymyalgia rheumatica",
-              "description": "A syndrome characterized by pain, stiffness, and tenderness of the proximal muscle groups including the shoulder, pelvic girdle and the neck. There is no muscle atrophy and muscle biopsies do not reveal pathologic changes. Additional signs and symptoms include low grade fever, fatigue and depression.; A syndrome in the elderly characterized by proximal joint and muscle pain, high erythrocyte sedimentation rate, and a self-limiting course. Pain is usually accompanied by evidence of an inflammatory reaction. Women are affected twice as commonly as men and Caucasians more frequently than other groups. The condition is frequently associated with GIANT CELL ARTERITIS and some theories pose the possibility that the two diseases arise from a single etiology or even that they are the same entity.; Polymyalgia rheumatica is a disorder that causes muscle pain and stiffness in your neck, shoulders, and hips. It is most common in women and almost always occurs in people over 50. The main symptom is stiffness after resting. Other symptoms include fever, weakness and weight loss. In some cases, polymyalgia rheumatica develops overnight. In others, it is gradual. The cause of polymyalgia rheumatica is unknown. There is no specific test for it. Your doctor will use your medical history, symptoms, and a physical exam to make the diagnosis. Lab tests for inflammation may help confirm the diagnosis. Polymyalgia rheumatica sometimes occurs along with giant cell arteritis, a condition that causes swelling of the arteries in your head. Symptoms include headaches and blurred vision. Doctors often prescribe prednisone, a steroid medicine, for both conditions. With treatment, polymyalgia rheumatica usually disappears in a day or two. Without treatment, it usually goes away after a year or more.  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10036099",
-                "UMLS:C1527406",
-                "NCIT:C85018",
-                "DOID:853",
-                "ORPHANET:93569",
-                "MEDDRA:10068240",
-                "UMLS:C0032533",
-                "MESH:D011111",
-                "ICD9:725",
-                "SNOMEDCT:65323003",
-                "EFO:0008518",
-                "MONDO:0019735",
-                "ICD10:M35.3"
-              ],
-              "id": "MONDO:0019735",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Polymyalgia rheumatica",
-                "polymyalgia rheumatica",
-                "Rhizomelic pseudopolyarthritis",
-                "Polymyalgia Rheumatica"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/polymyalgiarheumatica.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7736658,
-            "start": 568,
-            "end": 531649,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10616010': {'publication date': '1999 Dec', 'sentence': 'Most patients with PMR had normal serum YKL-40 levels (median 158 microg/liter) and had no changes in the serum YKL-40 levels during prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:10774252': {'publication date': '2000 Mar', 'sentence': 'A diagnosis of polymyalgia rheumatica was made, and low-dose prednisolone therapy (20 mg/d) was started.', 'subject score': 861, 'object score': 1000}, 'PMID:10898068': {'publication date': '2000', 'sentence': 'Similarly, no significant differences in BMD were found between current and previous users of prednisolone and between the prednisolone treated PMR and TA patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:12910963': {'publication date': '2003 Jun', 'sentence': 'SUBJECTS AND METHODS: The study included 10 patients with PMR, who could be prospectively followed up from the start of prednisolone (PSL) treatment until the CRP level decreased to 1 mg/dl or less.', 'subject score': 888, 'object score': 1000}, 'PMID:17087187': {'publication date': '2006', 'sentence': 'Polymyalgia rheumatica is treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:1768166': {'publication date': '1991 Dec', 'sentence': 'These results will be further evaluated in a controlled trial using intramuscular injections of methylprednisolone and prednisolone given by mouth for the treatment of polymyalgia rheumatica.', 'subject score': 1000, 'object score': 1000}, 'PMID:20812339': {'publication date': '2010 Dec', 'sentence': 'In the PMR patients, interstitial concentrations were normalized after prednisolone treatment.', 'subject score': 888, 'object score': 901}, 'PMID:2254893': {'publication date': '1990 Oct', 'sentence': 'Our study indicates that most patients with PMR or TA can be treated safely with an initial prednisolone dose of 10 mg given twice daily.', 'subject score': 851, 'object score': 1000}, 'PMID:28282736': {'publication date': '2018', 'sentence': 'Ocular inflammation presented as episcleritis, scleritis, or anterior uveitis, and it emerged during the tapering of low-dose prednisolone prescribed for polymyalgia rheumatica in all patients.', 'subject score': 901, 'object score': 1000}, 'PMID:28867756': {'publication date': '2017', 'sentence': 'Case 2: An 83-year-old man suffering from PMR was successfully treated with PSL and CAM.', 'subject score': 1000, 'object score': 1000}, 'PMID:32156589': {'publication date': '2020 Mar 07', 'sentence': 'He was treated with oral prednisolone for polymyalgia rheumatica.', 'subject score': 888, 'object score': 1000}, 'PMID:32996694': {'publication date': '2020 Sep 30', 'sentence': 'CONCLUSION: The normalization of CRP within 1 month from baseline predicted GC-free remission in PMR patients treated with PSL, and resulted in a lower cumulative PSL dose.', 'subject score': 1000, 'object score': 901}, 'PMID:34678904': {'publication date': '2021 Oct 22', 'sentence': 'Another male patient in his 70s (patient 3) was on prednisolone therapy for polymyalgia rheumatica, giant cell arteritis, and pancreatic body tumor.', 'subject score': 888, 'object score': 1000}, 'PMID:36152056': {'publication date': '2022 Sep 24', 'sentence': 'She was diagnosed with polymyalgia rheumatica (PMR) and treated with low-dose prednisolone (15 mg daily); however, she discontinued glucocorticoid therapy at her discretion due to the psychiatric adverse effect (cognitive dysfunction).', 'subject score': 901, 'object score': 1000}, 'PMID:3780140': {'publication date': '1986 Sep', 'sentence': 'Prednisolone pharmacokinetics in patients with rheumatoid arthritis, polymyalgia rheumatica and asthma.', 'subject score': 888, 'object score': 1000}, 'PMID:8116092': {'publication date': '1994 Feb 21', 'sentence': 'We assessed the diagnostic value of CD8+ levels in a larger group of patients with temporal arteritis and polymyalgia rheumatica before and after treatment with prednisolone and in relation to patients with other medical and rheumatic diseases.', 'subject score': 1000, 'object score': 1000}, 'PMID:8203964': {'publication date': '1994 Apr', 'sentence': 'Circulating T cell subtypes in polymyalgia rheumatica and giant cell arteritis: variation in the percentage of CD8+ cells with prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:8222521': {'publication date': '1993 Aug', 'sentence': 'However, corticosteroids, usually prednisone or prednisolone, are the class of drugs most widely used to treat PMR.', 'subject score': 1000, 'object score': 1000}, 'PMID:8257209': {'publication date': '1993 Oct', 'sentence': 'Circulating T cell subtypes in polymyalgia rheumatica and giant cell arteritis: variation in the percentage of CD8+ cells with prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:8523341': {'publication date': '1995 Sep', 'sentence': 'A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0032533---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7900659",
-              "object": "MONDO:0019735",
-              "publications": [
-                "PMID:10616010",
-                "PMID:10774252",
-                "PMID:10898068",
-                "PMID:12910963",
-                "PMID:17087187",
-                "PMID:1768166",
-                "PMID:20812339",
-                "PMID:2254893",
-                "PMID:28282736",
-                "PMID:28867756",
-                "PMID:32156589",
-                "PMID:32996694",
-                "PMID:34678904",
-                "PMID:36152056",
-                "PMID:3780140",
-                "PMID:8116092",
-                "PMID:8203964",
-                "PMID:8222521",
-                "PMID:8257209",
-                "PMID:8523341"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:35265413': {'publication date': '2022 Feb', 'sentence': 'These findings were consistent with a diagnosis of ANCA-associated vasculitis, and treatment with prednisolone markedly improved her condition.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 683078,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015492",
-          "name": "Anti-neutrophil cytoplasmic antibody-associated vasculitis",
-          "description": "Group of systemic vasculitis with a strong association with anca. The disorders are characterized by necrotizing inflammation of small and medium size vessels, with little or no immune-complex deposits in vessel walls.",
-          "equivalent_curies": [
-            "MONDO:0015492",
-            "UMLS:C2717865",
-            "MESH:D056648",
-            "ORPHANET:156152",
-            "SNOMEDCT:722191003",
-            "MEDDRA:10086756"
-          ],
-          "id": "MONDO:0015492",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
-            "anti-neutrophil cytoplasmic antibody-associated vasculitis",
-            "Anti-neutrophil cytoplasmic antibody-associated vasculitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 683078,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015492",
-              "name": "Anti-neutrophil cytoplasmic antibody-associated vasculitis",
-              "description": "Group of systemic vasculitis with a strong association with anca. The disorders are characterized by necrotizing inflammation of small and medium size vessels, with little or no immune-complex deposits in vessel walls.",
-              "equivalent_curies": [
-                "MONDO:0015492",
-                "UMLS:C2717865",
-                "MESH:D056648",
-                "ORPHANET:156152",
-                "SNOMEDCT:722191003",
-                "MEDDRA:10086756"
-              ],
-              "id": "MONDO:0015492",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
-                "anti-neutrophil cytoplasmic antibody-associated vasculitis",
-                "Anti-neutrophil cytoplasmic antibody-associated vasculitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23851781,
-            "start": 568,
-            "end": 683078,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35265413': {'publication date': '2022 Feb', 'sentence': 'These findings were consistent with a diagnosis of ANCA-associated vasculitis, and treatment with prednisolone markedly improved her condition.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C2717865---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "24291326",
-              "object": "MONDO:0015492",
-              "publications": [
-                "PMID:35265413"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:16724651': {'publication date': '2006 May', 'sentence': 'Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316993,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005376",
-          "name": "membranous glomerulonephritis",
-          "description": "A slowly progressive inflammation of the glomeruli characterized by immune complex deposits at the glomerular basement membrane, resulting in a thickened membrane, and nephrotic syndrome.; An experimental rat model of human membranous nephropathy characterized by complement activation and formation of subepithelial immune deposits in the glomerular capillary wall.; A type of glomerulonephropathy characterized by thickening of the basement membrane and deposition of immune complexes in the subepithelial space. [Eurenomics:fschaefer]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005376",
-            "HP:0012578",
-            "UMLS:C0017665",
-            "DOID:10976",
-            "MESH:D015433",
-            "SNOMEDCT:77182004",
-            "MEDDRA:10018372",
-            "MEDDRA:10027170",
-            "ICD10:N03.2",
-            "NCIT:C34645",
-            "EFO:0004254"
-          ],
-          "id": "MONDO:0005376",
-          "category": "biolink:Disease",
-          "all_names": [
-            "membranous glomerulonephritis",
-            "Glomerulonephritis, Membranous",
-            "Membranous Glomerulonephritis",
-            "Membranous nephropathy",
-            "Membranous glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316993,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005376",
-              "name": "membranous glomerulonephritis",
-              "description": "A slowly progressive inflammation of the glomeruli characterized by immune complex deposits at the glomerular basement membrane, resulting in a thickened membrane, and nephrotic syndrome.; An experimental rat model of human membranous nephropathy characterized by complement activation and formation of subepithelial immune deposits in the glomerular capillary wall.; A type of glomerulonephropathy characterized by thickening of the basement membrane and deposition of immune complexes in the subepithelial space. [Eurenomics:fschaefer]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005376",
-                "HP:0012578",
-                "UMLS:C0017665",
-                "DOID:10976",
-                "MESH:D015433",
-                "SNOMEDCT:77182004",
-                "MEDDRA:10018372",
-                "MEDDRA:10027170",
-                "ICD10:N03.2",
-                "NCIT:C34645",
-                "EFO:0004254"
-              ],
-              "id": "MONDO:0005376",
-              "category": "biolink:Disease",
-              "all_names": [
-                "membranous glomerulonephritis",
-                "Glomerulonephritis, Membranous",
-                "Membranous Glomerulonephritis",
-                "Membranous nephropathy",
-                "Membranous glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12244036,
-            "start": 568,
-            "end": 316993,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16724651': {'publication date': '2006 May', 'sentence': 'Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0017665---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "12510603",
-              "object": "MONDO:0005376",
-              "publications": [
-                "PMID:16724651"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11399923': {'publication date': '2001 Jun', 'sentence': 'He was diagnosed as having membranous nephropathy by renal biopsy and was treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:14964576': {'publication date': '2004 Jan', 'sentence': 'We examined outcomes of a short course of cyclophosphamide alternating with prednisolone for MN patients with nephrotic syndrome.', 'subject score': 1000, 'object score': 901}, 'PMID:1516283': {'publication date': '1992 Aug', 'sentence': 'Patients with membranous nephropathy showed a significant elevation of Leu 2a+DR+ cells after treatment with PSL.', 'subject score': 1000, 'object score': 1000}, 'PMID:16130411': {'publication date': '2005', 'sentence': 'She was diagnosed as membranous nephropathy by needle renal biopsy, and treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:16968719': {'publication date': '2006 Nov', 'sentence': 'METHODS: In the first part of the study, 51 nephrotic patients with MN were treated either with CyA and prednisolone (n=31) or CyA alone (n=20) for 12 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:17995584': {'publication date': '2007 Dec', 'sentence': 'CONCLUSION: Data from this pilot study indicate that more than 60% of patients with MN and nephrotic syndrome respond to combined MMF and prednisolone treatment, and suggest potential benefits of MMF as being steroid-sparing and having less adverse effects compared with other commonly used cytotoxic agents.', 'subject score': 888, 'object score': 1000}, 'PMID:18604487': {'publication date': '2008 Jul 15', 'sentence': 'Based on the existing evidence and experience from this case, rituximab can be recommended as a new treatment option for MN, possibly before starting any treatment with cytotoxic agents and high-dose prednisolone carrying the risk of severe side effects.', 'subject score': 901, 'object score': 1000}, 'PMID:23904308': {'publication date': '2013 Jul', 'sentence': 'Herein we report an unusual case of tonsillar Kaposi sarcoma in a patient with membranous glomerulonephritis treated with prednisolone and cyclosporine.', 'subject score': 1000, 'object score': 1000}, 'PMID:25045552': {'publication date': '2014', 'sentence': 'We report the first two cases in which the combination of prednisolone and mizoribine was effective for treating membranous nephropathy associated with IgG4-related tubulointerstitial nephritis.', 'subject score': 1000, 'object score': 901}, 'PMID:25298141': {'publication date': '2015 Jan', 'sentence': 'CONCLUSION: Elderly patients with MN who respond poorly to PSL treatment may be treated successfully with MZR.', 'subject score': 888, 'object score': 1000}, 'PMID:2565486': {'publication date': '1989 May 06', 'sentence': 'Treatment of membranous nephropathy with prednisolone and chlorambucil.', 'subject score': 1000, 'object score': 1000}, 'PMID:7507157': {'publication date': '1994 Jan', 'sentence': 'Increased FCsDex tended to normalize during prednisolone treatment in membranous nephropathy.', 'subject score': 888, 'object score': 1000}, 'PMID:7784993': {'publication date': '1994 Dec', 'sentence': 'Especially Ponticelli claims significant therapeutic success in patients with membranous glomerulonephritis treated with Prednisolone and Chlorambucil.', 'subject score': 1000, 'object score': 1000}, 'PMID:8043974': {'publication date': '1994 Mar', 'sentence': 'Because of the high rate of spontaneous remission, treatment of membranous nephropathy with prednisolone and chlorambucil is still controversial.', 'subject score': 1000, 'object score': 1000}, 'PMID:8107308': {'publication date': '1994 Jan', 'sentence': 'Prednisolone and immunosuppressive agent were most effective in these patients with membranous nephropathy.', 'subject score': 1000, 'object score': 1000}, 'PMID:9475489': {'publication date': '1998 Feb', 'sentence': 'In membranous glomerulopathy with severe NS, one month of therapy with prednisolone followed by chlorambucil for one month (all together 6 months) improves the renal outcome of the patients compared to controls.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316993,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005376",
-          "name": "membranous glomerulonephritis",
-          "description": "A slowly progressive inflammation of the glomeruli characterized by immune complex deposits at the glomerular basement membrane, resulting in a thickened membrane, and nephrotic syndrome.; An experimental rat model of human membranous nephropathy characterized by complement activation and formation of subepithelial immune deposits in the glomerular capillary wall.; A type of glomerulonephropathy characterized by thickening of the basement membrane and deposition of immune complexes in the subepithelial space. [Eurenomics:fschaefer]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005376",
-            "HP:0012578",
-            "UMLS:C0017665",
-            "DOID:10976",
-            "MESH:D015433",
-            "SNOMEDCT:77182004",
-            "MEDDRA:10018372",
-            "MEDDRA:10027170",
-            "ICD10:N03.2",
-            "NCIT:C34645",
-            "EFO:0004254"
-          ],
-          "id": "MONDO:0005376",
-          "category": "biolink:Disease",
-          "all_names": [
-            "membranous glomerulonephritis",
-            "Glomerulonephritis, Membranous",
-            "Membranous Glomerulonephritis",
-            "Membranous nephropathy",
-            "Membranous glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316993,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005376",
-              "name": "membranous glomerulonephritis",
-              "description": "A slowly progressive inflammation of the glomeruli characterized by immune complex deposits at the glomerular basement membrane, resulting in a thickened membrane, and nephrotic syndrome.; An experimental rat model of human membranous nephropathy characterized by complement activation and formation of subepithelial immune deposits in the glomerular capillary wall.; A type of glomerulonephropathy characterized by thickening of the basement membrane and deposition of immune complexes in the subepithelial space. [Eurenomics:fschaefer]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005376",
-                "HP:0012578",
-                "UMLS:C0017665",
-                "DOID:10976",
-                "MESH:D015433",
-                "SNOMEDCT:77182004",
-                "MEDDRA:10018372",
-                "MEDDRA:10027170",
-                "ICD10:N03.2",
-                "NCIT:C34645",
-                "EFO:0004254"
-              ],
-              "id": "MONDO:0005376",
-              "category": "biolink:Disease",
-              "all_names": [
-                "membranous glomerulonephritis",
-                "Glomerulonephritis, Membranous",
-                "Membranous Glomerulonephritis",
-                "Membranous nephropathy",
-                "Membranous glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8747911,
-            "start": 568,
-            "end": 316993,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11399923': {'publication date': '2001 Jun', 'sentence': 'He was diagnosed as having membranous nephropathy by renal biopsy and was treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:14964576': {'publication date': '2004 Jan', 'sentence': 'We examined outcomes of a short course of cyclophosphamide alternating with prednisolone for MN patients with nephrotic syndrome.', 'subject score': 1000, 'object score': 901}, 'PMID:1516283': {'publication date': '1992 Aug', 'sentence': 'Patients with membranous nephropathy showed a significant elevation of Leu 2a+DR+ cells after treatment with PSL.', 'subject score': 1000, 'object score': 1000}, 'PMID:16130411': {'publication date': '2005', 'sentence': 'She was diagnosed as membranous nephropathy by needle renal biopsy, and treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:16968719': {'publication date': '2006 Nov', 'sentence': 'METHODS: In the first part of the study, 51 nephrotic patients with MN were treated either with CyA and prednisolone (n=31) or CyA alone (n=20) for 12 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:17995584': {'publication date': '2007 Dec', 'sentence': 'CONCLUSION: Data from this pilot study indicate that more than 60% of patients with MN and nephrotic syndrome respond to combined MMF and prednisolone treatment, and suggest potential benefits of MMF as being steroid-sparing and having less adverse effects compared with other commonly used cytotoxic agents.', 'subject score': 888, 'object score': 1000}, 'PMID:18604487': {'publication date': '2008 Jul 15', 'sentence': 'Based on the existing evidence and experience from this case, rituximab can be recommended as a new treatment option for MN, possibly before starting any treatment with cytotoxic agents and high-dose prednisolone carrying the risk of severe side effects.', 'subject score': 901, 'object score': 1000}, 'PMID:23904308': {'publication date': '2013 Jul', 'sentence': 'Herein we report an unusual case of tonsillar Kaposi sarcoma in a patient with membranous glomerulonephritis treated with prednisolone and cyclosporine.', 'subject score': 1000, 'object score': 1000}, 'PMID:25045552': {'publication date': '2014', 'sentence': 'We report the first two cases in which the combination of prednisolone and mizoribine was effective for treating membranous nephropathy associated with IgG4-related tubulointerstitial nephritis.', 'subject score': 1000, 'object score': 901}, 'PMID:25298141': {'publication date': '2015 Jan', 'sentence': 'CONCLUSION: Elderly patients with MN who respond poorly to PSL treatment may be treated successfully with MZR.', 'subject score': 888, 'object score': 1000}, 'PMID:2565486': {'publication date': '1989 May 06', 'sentence': 'Treatment of membranous nephropathy with prednisolone and chlorambucil.', 'subject score': 1000, 'object score': 1000}, 'PMID:7507157': {'publication date': '1994 Jan', 'sentence': 'Increased FCsDex tended to normalize during prednisolone treatment in membranous nephropathy.', 'subject score': 888, 'object score': 1000}, 'PMID:7784993': {'publication date': '1994 Dec', 'sentence': 'Especially Ponticelli claims significant therapeutic success in patients with membranous glomerulonephritis treated with Prednisolone and Chlorambucil.', 'subject score': 1000, 'object score': 1000}, 'PMID:8043974': {'publication date': '1994 Mar', 'sentence': 'Because of the high rate of spontaneous remission, treatment of membranous nephropathy with prednisolone and chlorambucil is still controversial.', 'subject score': 1000, 'object score': 1000}, 'PMID:8107308': {'publication date': '1994 Jan', 'sentence': 'Prednisolone and immunosuppressive agent were most effective in these patients with membranous nephropathy.', 'subject score': 1000, 'object score': 1000}, 'PMID:9475489': {'publication date': '1998 Feb', 'sentence': 'In membranous glomerulopathy with severe NS, one month of therapy with prednisolone followed by chlorambucil for one month (all together 6 months) improves the renal outcome of the patients compared to controls.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0017665---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8939337",
-              "object": "MONDO:0005376",
-              "publications": [
-                "PMID:11399923",
-                "PMID:14964576",
-                "PMID:1516283",
-                "PMID:16130411",
-                "PMID:16968719",
-                "PMID:17995584",
-                "PMID:18604487",
-                "PMID:23904308",
-                "PMID:25045552",
-                "PMID:25298141",
-                "PMID:2565486",
-                "PMID:7507157",
-                "PMID:7784993",
-                "PMID:8043974",
-                "PMID:8107308",
-                "PMID:9475489"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11491499': {'publication date': '2001 Jul-Aug', 'sentence': 'METHODS: Resting radionuclide ventriculography with 99mTc was performed before and 20 days after the administration of prednisolone, 20 mg daily, in 32 patients with SSc without clinically evident myocardial dysfunction at rest; 13 and 19 patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), respectively, were studied in parallel as controls.', 'subject score': 1000, 'object score': 1000}, 'PMID:3280619': {'publication date': '1988 Mar', 'sentence': 'In patients with systemic scleroderma, who also suffer from additional myositis, interstitial lung diseases, or arthritis, anti-inflammatory treatment with prednisolone and azathioprine is suggested.', 'subject score': 1000, 'object score': 1000}, 'PMID:33102777': {'publication date': '2020 Oct', 'sentence': 'For RA and SSc, she was treated with prednisolone and abatacept and was taking vonoprazan as prophylaxis for steroid-induced gastric ulcers.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 530656,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005100",
-          "name": "systemic sclerosis",
-          "description": "A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.; A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:90291",
-            "EFO:0000717",
-            "UMLS:CN206012",
-            "MEDDRA:10036814",
-            "UMLS:C0036421",
-            "ICD10:M34.0",
-            "DOID:418",
-            "UMLS:C0700318",
-            "MEDDRA:10078638",
-            "SNOMEDCT:89155008",
-            "MONDO:0005100",
-            "ICD9:710.1",
-            "MEDDRA:10042953",
-            "PDQ:CDR0000587622",
-            "MESH:D012595",
-            "NCIT:C72070"
-          ],
-          "id": "MONDO:0005100",
-          "category": "biolink:Disease",
-          "all_names": [
-            "systemic sclerosis",
-            "Scleroderma, Systemic",
-            "Systemic sclerosis",
-            "Systemic Scleroderma",
-            "systemic scleroderma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://ghr.nlm.nih.gov/condition/systemic-scleroderma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 530656,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005100",
-              "name": "systemic sclerosis",
-              "description": "A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.; A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:90291",
-                "EFO:0000717",
-                "UMLS:CN206012",
-                "MEDDRA:10036814",
-                "UMLS:C0036421",
-                "ICD10:M34.0",
-                "DOID:418",
-                "UMLS:C0700318",
-                "MEDDRA:10078638",
-                "SNOMEDCT:89155008",
-                "MONDO:0005100",
-                "ICD9:710.1",
-                "MEDDRA:10042953",
-                "PDQ:CDR0000587622",
-                "MESH:D012595",
-                "NCIT:C72070"
-              ],
-              "id": "MONDO:0005100",
-              "category": "biolink:Disease",
-              "all_names": [
-                "systemic sclerosis",
-                "Scleroderma, Systemic",
-                "Systemic sclerosis",
-                "Systemic Scleroderma",
-                "systemic scleroderma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://ghr.nlm.nih.gov/condition/systemic-scleroderma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8851879,
-            "start": 568,
-            "end": 530656,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11491499': {'publication date': '2001 Jul-Aug', 'sentence': 'METHODS: Resting radionuclide ventriculography with 99mTc was performed before and 20 days after the administration of prednisolone, 20 mg daily, in 32 patients with SSc without clinically evident myocardial dysfunction at rest; 13 and 19 patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), respectively, were studied in parallel as controls.', 'subject score': 1000, 'object score': 1000}, 'PMID:3280619': {'publication date': '1988 Mar', 'sentence': 'In patients with systemic scleroderma, who also suffer from additional myositis, interstitial lung diseases, or arthritis, anti-inflammatory treatment with prednisolone and azathioprine is suggested.', 'subject score': 1000, 'object score': 1000}, 'PMID:33102777': {'publication date': '2020 Oct', 'sentence': 'For RA and SSc, she was treated with prednisolone and abatacept and was taking vonoprazan as prophylaxis for steroid-induced gastric ulcers.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0036421---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9046445",
-              "object": "MONDO:0005100",
-              "publications": [
-                "PMID:11491499",
-                "PMID:3280619",
-                "PMID:33102777"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:8575609': {'publication date': '1995 Mar', 'sentence': 'CONCLUSION: Dexamethasone or prednisolone were the easiest to induce steroid glaucoma when the patients had long-term use of steroid eyedrops.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 310037,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005041",
-          "name": "glaucoma",
-          "description": "Increased pressure in the eyeball due to obstruction of the outflow of aqueous humor.; An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed); Glaucoma refers loss of retinal ganglion cells in a characteristic pattern of optic neuropathy usually associated with increased intraocular pressure. [HPO:probinson, PMID:11815354]; Glaucoma is a group of diseases that can damage the eye's optic nerve. It is a leading cause of blindness in the United States. It usually happens when the fluid pressure inside the eyes slowly rises, damaging the optic nerve. Often there are no symptoms at first. Without treatment, people with glaucoma will slowly lose their peripheral, or side vision. They seem to be looking through a tunnel. Over time, straight-ahead vision may decrease until no vision remains. A comprehensive eye exam can tell if you have glaucoma. People at risk should get eye exams at least every two years. They include: African Americans over age 40 People over age 60, especially Mexican Americans People with a family history of glaucoma  There is no cure, but glaucoma can usually be controlled. Early treatment can help protect your eyes against vision loss. Treatments usually include prescription eyedrops and/or surgery. NIH: National Eye Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C26782",
-            "PSY:21090",
-            "MESH:D005901",
-            "ICD10:H40",
-            "SNOMEDCT:23986001",
-            "UMLS:C0017601",
-            "EFO:0000516",
-            "MEDDRA:10018304",
-            "MEDDRA:10018332",
-            "MEDDRA:10018326",
-            "MONDO:0005041",
-            "ICD9:365",
-            "MEDDRA:10045894",
-            "HP:0000501",
-            "DOID:1686"
-          ],
-          "id": "MONDO:0005041",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_glaucoma",
-            "glaucoma",
-            "Glaucoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/glaucoma",
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:11815354",
-            "https://www.aao.org/eye-health/diseases/what-is-glaucoma",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310037,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005041",
-              "name": "glaucoma",
-              "description": "Increased pressure in the eyeball due to obstruction of the outflow of aqueous humor.; An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed); Glaucoma refers loss of retinal ganglion cells in a characteristic pattern of optic neuropathy usually associated with increased intraocular pressure. [HPO:probinson, PMID:11815354]; Glaucoma is a group of diseases that can damage the eye's optic nerve. It is a leading cause of blindness in the United States. It usually happens when the fluid pressure inside the eyes slowly rises, damaging the optic nerve. Often there are no symptoms at first. Without treatment, people with glaucoma will slowly lose their peripheral, or side vision. They seem to be looking through a tunnel. Over time, straight-ahead vision may decrease until no vision remains. A comprehensive eye exam can tell if you have glaucoma. People at risk should get eye exams at least every two years. They include: African Americans over age 40 People over age 60, especially Mexican Americans People with a family history of glaucoma  There is no cure, but glaucoma can usually be controlled. Early treatment can help protect your eyes against vision loss. Treatments usually include prescription eyedrops and/or surgery. NIH: National Eye Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C26782",
-                "PSY:21090",
-                "MESH:D005901",
-                "ICD10:H40",
-                "SNOMEDCT:23986001",
-                "UMLS:C0017601",
-                "EFO:0000516",
-                "MEDDRA:10018304",
-                "MEDDRA:10018332",
-                "MEDDRA:10018326",
-                "MONDO:0005041",
-                "ICD9:365",
-                "MEDDRA:10045894",
-                "HP:0000501",
-                "DOID:1686"
-              ],
-              "id": "MONDO:0005041",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_glaucoma",
-                "glaucoma",
-                "Glaucoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/glaucoma",
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:11815354",
-                "https://www.aao.org/eye-health/diseases/what-is-glaucoma",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26584988,
-            "start": 568,
-            "end": 310037,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8575609': {'publication date': '1995 Mar', 'sentence': 'CONCLUSION: Dexamethasone or prednisolone were the easiest to induce steroid glaucoma when the patients had long-term use of steroid eyedrops.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0017601---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "27055840",
-              "object": "MONDO:0005041",
-              "publications": [
-                "PMID:8575609"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:16707187': {'publication date': '2006 Jun 12', 'sentence': 'Taken together, the present study points to a strong inhibitory effect of liposomal PLP on tumor angiogenesis by reduction of the intratumoral production of the majority of pro-angiogenic factors studied and direct inhibition of endothelial cell proliferation, which is the result of high prolonged levels of prednisolone in the tumor by liposomal delivery.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12221971,
-            "start": 568,
-            "end": 319673,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16707187': {'publication date': '2006 Jun 12', 'sentence': 'Taken together, the present study points to a strong inhibitory effect of liposomal PLP on tumor angiogenesis by reduction of the intratumoral production of the majority of pro-angiogenic factors studied and direct inhibition of endothelial cell proliferation, which is the result of high prolonged levels of prednisolone in the tumor by liposomal delivery.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "12496746",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:16707187"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:11064248': {'publication date': '2000 Nov', 'sentence': 'ETO+PSL combination treatment, however, failed to show significant enhancement of anti-tumor effects.', 'subject score': 833, 'object score': 773}, 'PMID:11393100': {'publication date': '2001 Feb', 'sentence': 'Chemotherapy, which included prednisolone, vincristine, methotrexate, and 6-mercaptopurine, had only a minimal effect on the tumor.', 'subject score': 1000, 'object score': 1000}, 'PMID:15208501': {'publication date': '2004 Jul', 'sentence': 'The levels of FDG uptake in the tumour were not significantly affected by DEX and PRE pretreatment (90% and 87% of the control value, respectively) (P=NS).', 'subject score': 888, 'object score': 1000}, 'PMID:3629691': {'publication date': '1987 Sep', 'sentence': 'Prednisolone had no effect on UVI-induced tumor development.', 'subject score': 1000, 'object score': 775}, 'PMID:7307234': {'publication date': '1981', 'sentence': 'Prednisolone had no anti-tumour effect when given alone, but increased the anti-tumour effect of melphalan significantly.', 'subject score': 1000, 'object score': 790}}",
-    "p2": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8352249,
-            "start": 568,
-            "end": 319673,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11064248': {'publication date': '2000 Nov', 'sentence': 'ETO+PSL combination treatment, however, failed to show significant enhancement of anti-tumor effects.', 'subject score': 833, 'object score': 773}, 'PMID:11393100': {'publication date': '2001 Feb', 'sentence': 'Chemotherapy, which included prednisolone, vincristine, methotrexate, and 6-mercaptopurine, had only a minimal effect on the tumor.', 'subject score': 1000, 'object score': 1000}, 'PMID:15208501': {'publication date': '2004 Jul', 'sentence': 'The levels of FDG uptake in the tumour were not significantly affected by DEX and PRE pretreatment (90% and 87% of the control value, respectively) (P=NS).', 'subject score': 888, 'object score': 1000}, 'PMID:3629691': {'publication date': '1987 Sep', 'sentence': 'Prednisolone had no effect on UVI-induced tumor development.', 'subject score': 1000, 'object score': 775}, 'PMID:7307234': {'publication date': '1981', 'sentence': 'Prednisolone had no anti-tumour effect when given alone, but increased the anti-tumour effect of melphalan significantly.', 'subject score': 1000, 'object score': 790}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8533593",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:11064248",
-                "PMID:11393100",
-                "PMID:15208501",
-                "PMID:3629691",
-                "PMID:7307234"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:17763849': {'publication date': '2007 Dec', 'sentence': 'FDG-PET was performed in rats bearing BCG granulomas or tumors before and after prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:17984697': {'publication date': '2007 Nov', 'sentence': 'The detection of type 2 somatostatin receptors on the surface of the tumor justified the introduction of treatment with somatostatin analog and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:19379301': {'publication date': '2004 Sep', 'sentence': 'Eighteen of 24 tumours (75%) decreased in size in response to prednisolone treatment.', 'subject score': 888, 'object score': 861}, 'PMID:26907854': {'publication date': '2016 Mar', 'sentence': 'A combination regimen of mitoxantrone (MTO) and prednisolone (PLP) has been ideal for tumor therapy.', 'subject score': 1000, 'object score': 888}, 'PMID:31243239': {'publication date': '2019 Oct 01', 'sentence': 'Prednisolone immediately relieved the symptoms, and the tumor was still shrinking on day 21 after eight cycles of pembrolizumab.', 'subject score': 1000, 'object score': 1000}, 'PMID:32388531': {'publication date': '2020 May 10', 'sentence': 'The lack of similar reported cases, and the aggressiveness of the tumor clinically and histopathologically, resulted in the decision to treat with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone (R-CHOP) as a case of aggressive lymphoma, with complete remission clinically and radiologically.', 'subject score': 1000, 'object score': 861}, 'PMID:35365166': {'publication date': '2022 Apr 01', 'sentence': 'One month after treatment with prednisolone (PSL), the tumor had shrunk, but a CT scan during the third month of PSL treatment revealed multiple nodular shadows in both lungs.', 'subject score': 1000, 'object score': 1000}, 'PMID:36580002': {'publication date': '2022 Dec 01', 'sentence': 'These results shed the light on the potential clinic values of ABA, and prednisolone combination in angiogenesis-dependent tumors.', 'subject score': 888, 'object score': 851}, 'PMID:5401721': {'publication date': '1969', 'sentence': '[Immunodepressive action of thalidomide and prednisolone in rats with experimentally induced neoplasms].', 'subject score': 1000, 'object score': 790}, 'PMID:6405762': {'publication date': '1983 Feb', 'sentence': 'Plasmapheresis and irradiation of the tumor were performed in conjunction with prednisolone therapy to a severe case of polyneuropathy associated with a solitary sclerotic secreting myeloma and endocrinological abnormalities.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13031072,
-            "start": 568,
-            "end": 319673,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17763849': {'publication date': '2007 Dec', 'sentence': 'FDG-PET was performed in rats bearing BCG granulomas or tumors before and after prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:17984697': {'publication date': '2007 Nov', 'sentence': 'The detection of type 2 somatostatin receptors on the surface of the tumor justified the introduction of treatment with somatostatin analog and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:19379301': {'publication date': '2004 Sep', 'sentence': 'Eighteen of 24 tumours (75%) decreased in size in response to prednisolone treatment.', 'subject score': 888, 'object score': 861}, 'PMID:26907854': {'publication date': '2016 Mar', 'sentence': 'A combination regimen of mitoxantrone (MTO) and prednisolone (PLP) has been ideal for tumor therapy.', 'subject score': 1000, 'object score': 888}, 'PMID:31243239': {'publication date': '2019 Oct 01', 'sentence': 'Prednisolone immediately relieved the symptoms, and the tumor was still shrinking on day 21 after eight cycles of pembrolizumab.', 'subject score': 1000, 'object score': 1000}, 'PMID:32388531': {'publication date': '2020 May 10', 'sentence': 'The lack of similar reported cases, and the aggressiveness of the tumor clinically and histopathologically, resulted in the decision to treat with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone (R-CHOP) as a case of aggressive lymphoma, with complete remission clinically and radiologically.', 'subject score': 1000, 'object score': 861}, 'PMID:35365166': {'publication date': '2022 Apr 01', 'sentence': 'One month after treatment with prednisolone (PSL), the tumor had shrunk, but a CT scan during the third month of PSL treatment revealed multiple nodular shadows in both lungs.', 'subject score': 1000, 'object score': 1000}, 'PMID:36580002': {'publication date': '2022 Dec 01', 'sentence': 'These results shed the light on the potential clinic values of ABA, and prednisolone combination in angiogenesis-dependent tumors.', 'subject score': 888, 'object score': 851}, 'PMID:5401721': {'publication date': '1969', 'sentence': '[Immunodepressive action of thalidomide and prednisolone in rats with experimentally induced neoplasms].', 'subject score': 1000, 'object score': 790}, 'PMID:6405762': {'publication date': '1983 Feb', 'sentence': 'Plasmapheresis and irradiation of the tumor were performed in conjunction with prednisolone therapy to a severe case of polyneuropathy associated with a solitary sclerotic secreting myeloma and endocrinological abnormalities.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "13311736",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:17763849",
-                "PMID:17984697",
-                "PMID:19379301",
-                "PMID:26907854",
-                "PMID:31243239",
-                "PMID:32388531",
-                "PMID:35365166",
-                "PMID:36580002",
-                "PMID:5401721",
-                "PMID:6405762"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:7545698': {'publication date': '1995 Sep', 'sentence': 'Although prednisolone and GH reverse hypoglycemia by different mechanisms, with only prednisolone suppressing tumor IGF-II secretion, both increase the formation of ternary IGF-IGFBP-3 complexes.', 'subject score': 1000, 'object score': 819}}",
-    "p2": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26054252,
-            "start": 568,
-            "end": 319673,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7545698': {'publication date': '1995 Sep', 'sentence': 'Although prednisolone and GH reverse hypoglycemia by different mechanisms, with only prednisolone suppressing tumor IGF-II secretion, both increase the formation of ternary IGF-IGFBP-3 complexes.', 'subject score': 1000, 'object score': 819}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:disrupts---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "26515767",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:7545698"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:23314876': {'publication date': '2013 Jan 11', 'sentence': 'The tumour was significantly reduced by prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:31499334': {'publication date': '2019 Nov - Dec', 'sentence': 'Prednisolone was administered for tumor reduction.', 'subject score': 1000, 'object score': 694}, 'PMID:33571254': {'publication date': '2021', 'sentence': 'Finally, while administration of prednisolone prevented the development of the inflammatory adverse events, it also abrogated the protective anti-tumor effect of the checkout inhibitors.', 'subject score': 1000, 'object score': 750}}",
-    "p2": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16367411,
-            "start": 568,
-            "end": 319673,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23314876': {'publication date': '2013 Jan 11', 'sentence': 'The tumour was significantly reduced by prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:31499334': {'publication date': '2019 Nov - Dec', 'sentence': 'Prednisolone was administered for tumor reduction.', 'subject score': 1000, 'object score': 694}, 'PMID:33571254': {'publication date': '2021', 'sentence': 'Finally, while administration of prednisolone prevented the development of the inflammatory adverse events, it also abrogated the protective anti-tumor effect of the checkout inhibitors.', 'subject score': 1000, 'object score': 750}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:prevents---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16706850",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:23314876",
-                "PMID:31499334",
-                "PMID:33571254"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:4083998': {'publication date': '1985', 'sentence': 'When comparing organ specific, age-adjusted expected versus observed incidences after natural death of animals an increased tumor risk was found in organ systems of all treatment modalities but prednisolone.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25291387,
-            "start": 568,
-            "end": 319673,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:4083998': {'publication date': '1985', 'sentence': 'When comparing organ specific, age-adjusted expected versus observed incidences after natural death of animals an increased tumor risk was found in organ systems of all treatment modalities but prednisolone.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:predisposes---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "25753407",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:4083998"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:13291449': {'publication date': '1955', 'sentence': 'Effects of prednisone and prednisolone in ocular inflammation.', 'subject score': 1000, 'object score': 888}, 'PMID:17237435': {'publication date': '2007 Feb 01', 'sentence': 'Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:27163931': {'publication date': '2016', 'sentence': 'Performance profiles were established which allowed us to identify curcumin, berberine chloride and epigallocatechin gallate as potential alternatives for prednisolone or other glucocorticoids in inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:28821031': {'publication date': '2017 Oct 15', 'sentence': 'These efficacy profiles of the NFs-CDs gel containing PD suggest that it has the potential for use in the treatment of, not only colitis, but also a variety of other disorders associated with inflammation and oxidative injuries.', 'subject score': 766, 'object score': 1000}, 'PMID:31830002': {'publication date': '2019 Dec 12', 'sentence': 'Transcriptomic analysis identified that combining Pred with dnMstn treatment affects gene expression profiles associated with inflammation, metabolism, and fibrosis.', 'subject score': 872, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10269883,
-            "start": 568,
-            "end": 183319,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13291449': {'publication date': '1955', 'sentence': 'Effects of prednisone and prednisolone in ocular inflammation.', 'subject score': 1000, 'object score': 888}, 'PMID:17237435': {'publication date': '2007 Feb 01', 'sentence': 'Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:27163931': {'publication date': '2016', 'sentence': 'Performance profiles were established which allowed us to identify curcumin, berberine chloride and epigallocatechin gallate as potential alternatives for prednisolone or other glucocorticoids in inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:28821031': {'publication date': '2017 Oct 15', 'sentence': 'These efficacy profiles of the NFs-CDs gel containing PD suggest that it has the potential for use in the treatment of, not only colitis, but also a variety of other disorders associated with inflammation and oxidative injuries.', 'subject score': 766, 'object score': 1000}, 'PMID:31830002': {'publication date': '2019 Dec 12', 'sentence': 'Transcriptomic analysis identified that combining Pred with dnMstn treatment affects gene expression profiles associated with inflammation, metabolism, and fibrosis.', 'subject score': 872, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10496403",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:13291449",
-                "PMID:17237435",
-                "PMID:27163931",
-                "PMID:28821031",
-                "PMID:31830002"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:12207075': {'publication date': '2002', 'sentence': 'Effects of honey, prednisolone, and disulfiram on inflammation, nitric oxide, and free radical formation.', 'subject score': 1000, 'object score': 1000}, 'PMID:15336689': {'publication date': '2004 Sep', 'sentence': 'The goal of this study was to examine the effects of prednisolone on inflammation and CAM expression in dystrophic muscle.', 'subject score': 1000, 'object score': 1000}, 'PMID:1711873': {'publication date': '1991', 'sentence': 'In a placebo-controlled double-blind study on patients undergoing cardiopulmonary bypass (CPB) we studied the inhibiting effects of dexamethasone, a high dose of methylprednisolone, and a low dose of prednisolone on the inflammatory reaction induced by CPB.', 'subject score': 1000, 'object score': 1000}, 'PMID:17237435': {'publication date': '2007 Feb 01', 'sentence': 'To determine the effects of increasing doses of prednisolone on inflammation and coagulation in humans exposed to LPS, 32 healthy males received prednisolone orally at doses of 0, 3, 10, or 30 mg (n = 8 per group) at 2 h before i.v. injection of Escherichia coli LPS (4 ng/kg).', 'subject score': 1000, 'object score': 1000}, 'PMID:18830904': {'publication date': '2008', 'sentence': 'Effects of inflammation and therapy were investigated in RA and OA fibroblasts after stimulation with interleukin (IL)-1beta, tumour necrosis factor (TNF)-alpha, methotrexate (MTX), and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:24956233': {'publication date': '2014 Jul 02', 'sentence': 'The clinically prescribed glucocorticoid prednisolone could modulate airway inflammation but was ineffective against the reversal of many HDM-induced metabolic alterations.', 'subject score': 775, 'object score': 861}, 'PMID:28152574': {'publication date': '2017 05', 'sentence': 'These effects occurred independently of the deleterious cardiometabolic effects and the impact of prednisolone on systemic inflammation.', 'subject score': 1000, 'object score': 888}, 'PMID:28904432': {'publication date': '2017 Sep-Oct', 'sentence': 'The current study was designed to analyze the influence of prednisolone treatment on the inflammatory reaction during the first 96 h after AKI induction in a rat model.', 'subject score': 888, 'object score': 1000}, 'PMID:36040807': {'publication date': '2022 Oct 10', 'sentence': 'The MRA spironolactone and glucocorticoid prednisolone were each administered for 1 week to dystrophic mdx mice during peak skeletal muscle necrosis to compare effects on inflammation.', 'subject score': 888, 'object score': 1000}, 'PMID:7146148': {'publication date': '1982 Dec', 'sentence': 'Tissue reaction to ischemia in the rabbit ear chamber: effects of prednisolone on inflammation and microvascular flow.', 'subject score': 1000, 'object score': 1000}, 'PMID:7224940': {'publication date': '1981 Apr', 'sentence': 'The results suggest that flurbiprofen and prednisolone are not different in their effect on both postoperative inflammation and postoperative wound healing.', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9525290,
-            "start": 568,
-            "end": 183319,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12207075': {'publication date': '2002', 'sentence': 'Effects of honey, prednisolone, and disulfiram on inflammation, nitric oxide, and free radical formation.', 'subject score': 1000, 'object score': 1000}, 'PMID:15336689': {'publication date': '2004 Sep', 'sentence': 'The goal of this study was to examine the effects of prednisolone on inflammation and CAM expression in dystrophic muscle.', 'subject score': 1000, 'object score': 1000}, 'PMID:1711873': {'publication date': '1991', 'sentence': 'In a placebo-controlled double-blind study on patients undergoing cardiopulmonary bypass (CPB) we studied the inhibiting effects of dexamethasone, a high dose of methylprednisolone, and a low dose of prednisolone on the inflammatory reaction induced by CPB.', 'subject score': 1000, 'object score': 1000}, 'PMID:17237435': {'publication date': '2007 Feb 01', 'sentence': 'To determine the effects of increasing doses of prednisolone on inflammation and coagulation in humans exposed to LPS, 32 healthy males received prednisolone orally at doses of 0, 3, 10, or 30 mg (n = 8 per group) at 2 h before i.v. injection of Escherichia coli LPS (4 ng/kg).', 'subject score': 1000, 'object score': 1000}, 'PMID:18830904': {'publication date': '2008', 'sentence': 'Effects of inflammation and therapy were investigated in RA and OA fibroblasts after stimulation with interleukin (IL)-1beta, tumour necrosis factor (TNF)-alpha, methotrexate (MTX), and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:24956233': {'publication date': '2014 Jul 02', 'sentence': 'The clinically prescribed glucocorticoid prednisolone could modulate airway inflammation but was ineffective against the reversal of many HDM-induced metabolic alterations.', 'subject score': 775, 'object score': 861}, 'PMID:28152574': {'publication date': '2017 05', 'sentence': 'These effects occurred independently of the deleterious cardiometabolic effects and the impact of prednisolone on systemic inflammation.', 'subject score': 1000, 'object score': 888}, 'PMID:28904432': {'publication date': '2017 Sep-Oct', 'sentence': 'The current study was designed to analyze the influence of prednisolone treatment on the inflammatory reaction during the first 96 h after AKI induction in a rat model.', 'subject score': 888, 'object score': 1000}, 'PMID:36040807': {'publication date': '2022 Oct 10', 'sentence': 'The MRA spironolactone and glucocorticoid prednisolone were each administered for 1 week to dystrophic mdx mice during peak skeletal muscle necrosis to compare effects on inflammation.', 'subject score': 888, 'object score': 1000}, 'PMID:7146148': {'publication date': '1982 Dec', 'sentence': 'Tissue reaction to ischemia in the rabbit ear chamber: effects of prednisolone on inflammation and microvascular flow.', 'subject score': 1000, 'object score': 1000}, 'PMID:7224940': {'publication date': '1981 Apr', 'sentence': 'The results suggest that flurbiprofen and prednisolone are not different in their effect on both postoperative inflammation and postoperative wound healing.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9735520",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:12207075",
-                "PMID:15336689",
-                "PMID:1711873",
-                "PMID:17237435",
-                "PMID:18830904",
-                "PMID:24956233",
-                "PMID:28152574",
-                "PMID:28904432",
-                "PMID:36040807",
-                "PMID:7146148",
-                "PMID:7224940"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12402607': {'publication date': '2002', 'sentence': 'Patients who remain high transporters with inflammatory reaction might require pharmacologic intervention, including prednisolone therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:13918410': {'publication date': '1962 Jan', 'sentence': '[Good results in the treatment of toxic inflammation with intravenous prednisolone].', 'subject score': 888, 'object score': 888}, 'PMID:18499398': {'publication date': '2008 Jul-Aug', 'sentence': 'In addition, possible effects of gender, malnutrition, inflammation, and previous prednisolone therapy were investigated.', 'subject score': 851, 'object score': 1000}, 'PMID:20080065': {'publication date': '2010 Apr', 'sentence': 'Suppression of AHI activity by prednisolone treatment decreased Treg accumulation in the liver.', 'subject score': 888, 'object score': 833}, 'PMID:21745559': {'publication date': '2011 Sep 01', 'sentence': 'CONCLUSION: Kirenol and prednisolone can upregulate nuclear annexin-1 which interacts with NF-kappaB to inhibit NF-kappaB activity, reduce cytokines expression and thereby attenuate inflammation of CIA joints.', 'subject score': 1000, 'object score': 1000}, 'PMID:22727107': {'publication date': '2012 Jul', 'sentence': 'We report safe successful treatment of 6 patients with significant MMP-related oral inflammation with the use of a previously unreported combination of mycophenolate mofetil, dapsone, and prednisolone given at relatively low doses.', 'subject score': 1000, 'object score': 836}, 'PMID:24280878': {'publication date': '2014 Jan', 'sentence': 'This is probably caused by the inflammation per se, and the treatment with prednisolone may aggravate the problem, whereas the effect of biological therapy is unknown.', 'subject score': 1000, 'object score': 1000}, 'PMID:24496321': {'publication date': '2014 Oct', 'sentence': 'Inflammation decreased more in the group treated with prednisolone, while the number of cholangiocytes, progenitor cells and fibroblasts did not differ between the treatment groups.', 'subject score': 1000, 'object score': 1000}, 'PMID:27773734': {'publication date': '2016 12 10', 'sentence': 'The only exception was the appearance of miR-146b, a known inflammation-regulating miRNA species, after liposomal prednisolone treatment.', 'subject score': 851, 'object score': 888}, 'PMID:28983403': {'publication date': '2017 Sep', 'sentence': 'Prednisolone was used as the first-line immunosuppressive agent in all cases, however steroid monotherapy failed long-term control of autoimmunity/inflammation in the majority of cases and additional immunosuppression was required.', 'subject score': 1000, 'object score': 888}, 'PMID:30279927': {'publication date': '2018 Oct', 'sentence': 'Patients with myocarditis should be carefully monitored for arrhythmia, even after ventricular function and inflammation have improved with prednisolone therapy.>.', 'subject score': 888, 'object score': 1000}, 'PMID:30593193': {'publication date': '2018 Dec', 'sentence': 'INTERVENTIONS AND OUTCOMES: The patient was started on 40 mg/day prednisolone to control the hepatic inflammation.', 'subject score': 833, 'object score': 888}, 'PMID:3127100': {'publication date': '1988 Apr', 'sentence': 'Semiquantitative histologic evaluation demonstrated less inflammation in the group treated with prednisolone than in the control group.', 'subject score': 1000, 'object score': 861}, 'PMID:32672612': {'publication date': '2020 May - Jun', 'sentence': 'Nepafenac was noninferior to prednisolone with regard to inflammation control, with 1 nepafenac-treated eye (1.3%) not meeting the primary end point because of 1+ anterior chamber cell at 2 weeks and 4 prednisolone-treated eyes (5.4%) failing to meet the primary end point because of rebound iritis (P < 0.001).', 'subject score': 1000, 'object score': 694}, 'PMID:32997729': {'publication date': '2020', 'sentence': 'In this study, we aimed to determine whether prednisolone (PD) attenuates adriamycin (ADR)-induced VSMC senescence and inflammation through the SIRT1-AMPK signaling pathway.', 'subject score': 1000, 'object score': 1000}, 'PMID:335683': {'publication date': '1977 Jul 15', 'sentence': 'Parallel to this or overlapping the rheumatic inflammatory mesenchymal tissue reactions are treated with prednisolone or derivatives, aminophenazone or salicylic acid preparations, in which cases in children prednisolone and aminophenazone are preferred.', 'subject score': 1000, 'object score': 786}, 'PMID:34622843': {'publication date': '2021 Oct 08', 'sentence': 'CONCLUSION: VKH disease is a multisystemic disorder; intravenous pulse steroid therapy and oral prednisolone can control systemic inflammation.', 'subject score': 888, 'object score': 888}, 'PMID:34725963': {'publication date': '2021 Nov 01', 'sentence': 'We could discontinue prednisolone to control his refractory inflammation of LCH after completing CLO chemotherapy in patient 2.', 'subject score': 1000, 'object score': 888}, 'PMID:35090559': {'publication date': '2022 Jan 28', 'sentence': 'Although pre-loading of the scaffolds with a combination of cells/prednisolone could not alleviate inflammation, it played an important role in regeneration and angiogenesis.', 'subject score': 888, 'object score': 1000}, 'PMID:35935398': {'publication date': '2022 Aug', 'sentence': 'One year of immunosuppressive therapy with prednisolone resolved the inflammation in the guts but not in the heart.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9635764,
-            "start": 568,
-            "end": 183319,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12402607': {'publication date': '2002', 'sentence': 'Patients who remain high transporters with inflammatory reaction might require pharmacologic intervention, including prednisolone therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:13918410': {'publication date': '1962 Jan', 'sentence': '[Good results in the treatment of toxic inflammation with intravenous prednisolone].', 'subject score': 888, 'object score': 888}, 'PMID:18499398': {'publication date': '2008 Jul-Aug', 'sentence': 'In addition, possible effects of gender, malnutrition, inflammation, and previous prednisolone therapy were investigated.', 'subject score': 851, 'object score': 1000}, 'PMID:20080065': {'publication date': '2010 Apr', 'sentence': 'Suppression of AHI activity by prednisolone treatment decreased Treg accumulation in the liver.', 'subject score': 888, 'object score': 833}, 'PMID:21745559': {'publication date': '2011 Sep 01', 'sentence': 'CONCLUSION: Kirenol and prednisolone can upregulate nuclear annexin-1 which interacts with NF-kappaB to inhibit NF-kappaB activity, reduce cytokines expression and thereby attenuate inflammation of CIA joints.', 'subject score': 1000, 'object score': 1000}, 'PMID:22727107': {'publication date': '2012 Jul', 'sentence': 'We report safe successful treatment of 6 patients with significant MMP-related oral inflammation with the use of a previously unreported combination of mycophenolate mofetil, dapsone, and prednisolone given at relatively low doses.', 'subject score': 1000, 'object score': 836}, 'PMID:24280878': {'publication date': '2014 Jan', 'sentence': 'This is probably caused by the inflammation per se, and the treatment with prednisolone may aggravate the problem, whereas the effect of biological therapy is unknown.', 'subject score': 1000, 'object score': 1000}, 'PMID:24496321': {'publication date': '2014 Oct', 'sentence': 'Inflammation decreased more in the group treated with prednisolone, while the number of cholangiocytes, progenitor cells and fibroblasts did not differ between the treatment groups.', 'subject score': 1000, 'object score': 1000}, 'PMID:27773734': {'publication date': '2016 12 10', 'sentence': 'The only exception was the appearance of miR-146b, a known inflammation-regulating miRNA species, after liposomal prednisolone treatment.', 'subject score': 851, 'object score': 888}, 'PMID:28983403': {'publication date': '2017 Sep', 'sentence': 'Prednisolone was used as the first-line immunosuppressive agent in all cases, however steroid monotherapy failed long-term control of autoimmunity/inflammation in the majority of cases and additional immunosuppression was required.', 'subject score': 1000, 'object score': 888}, 'PMID:30279927': {'publication date': '2018 Oct', 'sentence': 'Patients with myocarditis should be carefully monitored for arrhythmia, even after ventricular function and inflammation have improved with prednisolone therapy.>.', 'subject score': 888, 'object score': 1000}, 'PMID:30593193': {'publication date': '2018 Dec', 'sentence': 'INTERVENTIONS AND OUTCOMES: The patient was started on 40 mg/day prednisolone to control the hepatic inflammation.', 'subject score': 833, 'object score': 888}, 'PMID:3127100': {'publication date': '1988 Apr', 'sentence': 'Semiquantitative histologic evaluation demonstrated less inflammation in the group treated with prednisolone than in the control group.', 'subject score': 1000, 'object score': 861}, 'PMID:32672612': {'publication date': '2020 May - Jun', 'sentence': 'Nepafenac was noninferior to prednisolone with regard to inflammation control, with 1 nepafenac-treated eye (1.3%) not meeting the primary end point because of 1+ anterior chamber cell at 2 weeks and 4 prednisolone-treated eyes (5.4%) failing to meet the primary end point because of rebound iritis (P < 0.001).', 'subject score': 1000, 'object score': 694}, 'PMID:32997729': {'publication date': '2020', 'sentence': 'In this study, we aimed to determine whether prednisolone (PD) attenuates adriamycin (ADR)-induced VSMC senescence and inflammation through the SIRT1-AMPK signaling pathway.', 'subject score': 1000, 'object score': 1000}, 'PMID:335683': {'publication date': '1977 Jul 15', 'sentence': 'Parallel to this or overlapping the rheumatic inflammatory mesenchymal tissue reactions are treated with prednisolone or derivatives, aminophenazone or salicylic acid preparations, in which cases in children prednisolone and aminophenazone are preferred.', 'subject score': 1000, 'object score': 786}, 'PMID:34622843': {'publication date': '2021 Oct 08', 'sentence': 'CONCLUSION: VKH disease is a multisystemic disorder; intravenous pulse steroid therapy and oral prednisolone can control systemic inflammation.', 'subject score': 888, 'object score': 888}, 'PMID:34725963': {'publication date': '2021 Nov 01', 'sentence': 'We could discontinue prednisolone to control his refractory inflammation of LCH after completing CLO chemotherapy in patient 2.', 'subject score': 1000, 'object score': 888}, 'PMID:35090559': {'publication date': '2022 Jan 28', 'sentence': 'Although pre-loading of the scaffolds with a combination of cells/prednisolone could not alleviate inflammation, it played an important role in regeneration and angiogenesis.', 'subject score': 888, 'object score': 1000}, 'PMID:35935398': {'publication date': '2022 Aug', 'sentence': 'One year of immunosuppressive therapy with prednisolone resolved the inflammation in the guts but not in the heart.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9848677",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:12402607",
-                "PMID:13918410",
-                "PMID:18499398",
-                "PMID:20080065",
-                "PMID:21745559",
-                "PMID:22727107",
-                "PMID:24280878",
-                "PMID:24496321",
-                "PMID:27773734",
-                "PMID:28983403",
-                "PMID:30279927",
-                "PMID:30593193",
-                "PMID:3127100",
-                "PMID:32672612",
-                "PMID:32997729",
-                "PMID:335683",
-                "PMID:34622843",
-                "PMID:34725963",
-                "PMID:35090559",
-                "PMID:35935398"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:11325017': {'publication date': '2001 Mar', 'sentence': 'In contrast, cyclosporin A (CyA), FK-506 and prednisolone significantly inhibited antigen-induced airway inflammation and BHR in sensitized BN rats.', 'subject score': 1000, 'object score': 775}, 'PMID:1453084': {'publication date': '1992', 'sentence': 'Inhibition of ocular inflammation by chalcone derivatives and prednisolone.', 'subject score': 1000, 'object score': 888}, 'PMID:2201105': {'publication date': '1990 Jun', 'sentence': 'The comparative drug, prednisolone, significantly reduced inflammation in the ear to which it was applied and in the contralateral ear as well.', 'subject score': 1000, 'object score': 790}, 'PMID:22186974': {'publication date': '2012 Jun', 'sentence': 'This result suggests that prednisolone is useful in suppressing inflammation in Syrian hamster opisthorchiasis, whereas it was also beneficial for parasites by enhancing their reproductive development.', 'subject score': 1000, 'object score': 872}, 'PMID:24314325': {'publication date': '2014 May', 'sentence': 'Upon the suppression of the inflammatory reaction, prednisolone was tapered gradually.', 'subject score': 1000, 'object score': 1000}, 'PMID:3092598': {'publication date': '1986 Jun', 'sentence': 'Benoxaprofen, cyclophosphamide, indomethacin and prednisolone inhibited the paw inflammation in the developing disease whilst the anti-rheumatic compounds auranofin and D-penicillamine exacerbate the paw inflammation.', 'subject score': 1000, 'object score': 888}, 'PMID:31524075': {'publication date': '2019 Nov', 'sentence': 'Pretreatment with prednisolone increased the capacity for AIH-induced functional motor plasticity, suggesting that suppression of inflammation enhances the efficacy of AIH administration in individuals with spinal cord injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:36004044': {'publication date': '2022 Aug', 'sentence': 'We successfully monitored the inflammation activity by FDG-PET and treated recurrent CS by increasing the PSL dose and adding MTX to suppress inflammation.', 'subject score': 888, 'object score': 1000}, 'PMID:7056483': {'publication date': '1982', 'sentence': 'Oral administration of corticosteroid (less than 100 mg prednisolone daily) may be enough for suppression of the inflammation in the Harada type, while a drip infusion of the massive dosage (more than 200 mg prednisolone daily) with gradual tapering off is possible requisite in the Vogt-Koyanagi type.', 'subject score': 775, 'object score': 1000}, 'PMID:9430994': {'publication date': '1997 Sep', 'sentence': 'This inflammatory reaction might be suppressed by prednisolone to facilitate the recovery of the afferent pathway, which led to the typical clinical symptoms of HAM.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8660093,
-            "start": 568,
-            "end": 183319,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11325017': {'publication date': '2001 Mar', 'sentence': 'In contrast, cyclosporin A (CyA), FK-506 and prednisolone significantly inhibited antigen-induced airway inflammation and BHR in sensitized BN rats.', 'subject score': 1000, 'object score': 775}, 'PMID:1453084': {'publication date': '1992', 'sentence': 'Inhibition of ocular inflammation by chalcone derivatives and prednisolone.', 'subject score': 1000, 'object score': 888}, 'PMID:2201105': {'publication date': '1990 Jun', 'sentence': 'The comparative drug, prednisolone, significantly reduced inflammation in the ear to which it was applied and in the contralateral ear as well.', 'subject score': 1000, 'object score': 790}, 'PMID:22186974': {'publication date': '2012 Jun', 'sentence': 'This result suggests that prednisolone is useful in suppressing inflammation in Syrian hamster opisthorchiasis, whereas it was also beneficial for parasites by enhancing their reproductive development.', 'subject score': 1000, 'object score': 872}, 'PMID:24314325': {'publication date': '2014 May', 'sentence': 'Upon the suppression of the inflammatory reaction, prednisolone was tapered gradually.', 'subject score': 1000, 'object score': 1000}, 'PMID:3092598': {'publication date': '1986 Jun', 'sentence': 'Benoxaprofen, cyclophosphamide, indomethacin and prednisolone inhibited the paw inflammation in the developing disease whilst the anti-rheumatic compounds auranofin and D-penicillamine exacerbate the paw inflammation.', 'subject score': 1000, 'object score': 888}, 'PMID:31524075': {'publication date': '2019 Nov', 'sentence': 'Pretreatment with prednisolone increased the capacity for AIH-induced functional motor plasticity, suggesting that suppression of inflammation enhances the efficacy of AIH administration in individuals with spinal cord injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:36004044': {'publication date': '2022 Aug', 'sentence': 'We successfully monitored the inflammation activity by FDG-PET and treated recurrent CS by increasing the PSL dose and adding MTX to suppress inflammation.', 'subject score': 888, 'object score': 1000}, 'PMID:7056483': {'publication date': '1982', 'sentence': 'Oral administration of corticosteroid (less than 100 mg prednisolone daily) may be enough for suppression of the inflammation in the Harada type, while a drip infusion of the massive dosage (more than 200 mg prednisolone daily) with gradual tapering off is possible requisite in the Vogt-Koyanagi type.', 'subject score': 775, 'object score': 1000}, 'PMID:9430994': {'publication date': '1997 Sep', 'sentence': 'This inflammatory reaction might be suppressed by prednisolone to facilitate the recovery of the afferent pathway, which led to the typical clinical symptoms of HAM.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:disrupts---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8854473",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:11325017",
-                "PMID:1453084",
-                "PMID:2201105",
-                "PMID:22186974",
-                "PMID:24314325",
-                "PMID:3092598",
-                "PMID:31524075",
-                "PMID:36004044",
-                "PMID:7056483",
-                "PMID:9430994"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:12795466': {'publication date': '2003 May', 'sentence': 'CONCLUSIONS: Predocol is an oral preparation of a poorly absorbed salt of prednisolone that is effective in reducing inflammation over short treatment periods in patients with active ulcerative colitis.', 'subject score': 1000, 'object score': 762}, 'PMID:1581697': {'publication date': '1992 Feb', 'sentence': 'This assumption may be supported by the fact that a combined systemic treatment with pyrimethamine, trimethoprim, sulfamethoxazole and prednisolone reduced the retinochoroidal inflammation and periarterial infiltrates.', 'subject score': 1000, 'object score': 861}, 'PMID:16843944': {'publication date': '1995 Oct', 'sentence': 'The therapeutic enema of prednisolone reduced colonic inflammation (CMS, colon weight), improved thymic weight, %GBW and food intake, and reduced plasma IL6 concentrations (P< 0.05).', 'subject score': 1000, 'object score': 888}, 'PMID:17045826': {'publication date': '2007', 'sentence': \"Neither prednisolone nor cilomilast had protective effect on the LPS-induced airways' inflammation.\", 'subject score': 1000, 'object score': 833}, 'PMID:1776474': {'publication date': '1991 Mar', 'sentence': 'Prevention of ocular inflammation by matrine, prednisolone, and cyclooxygenase and lipoxygenase inhibitors.', 'subject score': 1000, 'object score': 888}, 'PMID:21627530': {'publication date': '2011 Jun', 'sentence': 'CONCLUSIONS AND CLINICAL RELEVANCE: Topical administration of 1% prednisolone and 0.1% diclofenac significantly reduced intraocular inflammation in cats with paracentesis-induced uveitis.', 'subject score': 861, 'object score': 888}, 'PMID:23363352': {'publication date': '2013 Feb', 'sentence': 'CONCLUSIONS AND CLINICAL RELEVANCE: Orally administered prednisolone and meloxicam significantly decreased intraocular inflammation in clinically normal cats with paracentesis-induced BAB breakdown.', 'subject score': 827, 'object score': 888}, 'PMID:24884924': {'publication date': '2014 May 02', 'sentence': 'CONCLUSIONS: This study shows that prednisolone decreases inflammation and improves renal function, whilst not reducing liver injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:26965791': {'publication date': '2016 Mar 11', 'sentence': 'Prednisolone might be more effective in reducing inflammation and it had a better safety profile.', 'subject score': 1000, 'object score': 872}, 'PMID:29293747': {'publication date': '2017 Dec', 'sentence': 'Glucocorticoids such as prednisolone reduced the transfer of blood components from blood into milk while reducing the general inflammatory reaction.', 'subject score': 1000, 'object score': 901}, 'PMID:31772757': {'publication date': '2019 Sep', 'sentence': 'A combination of prednisolone, intravenous cyclophosphamide, and plasma exchange reduced the inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:35086209': {'publication date': '2022 Feb', 'sentence': 'Conclusion: NSAIDs used in isolation are comparable to prednisolone in preventing inflammation and pain after uneventful phacoemulsification.', 'subject score': 1000, 'object score': 861}, 'PMID:36029810': {'publication date': '2022 Aug 24', 'sentence': 'Corticosteroids like Hydrocortisone, dexamethasone, Prednisolone and Methylprednisolone has been reported to be effective against SARS-CoV-2 virus in comparison to that of non-steroid drugs, by using non-genomic and genomic effects to prevent and reduce inflammation in tissues and the circulation.', 'subject score': 1000, 'object score': 1000}, 'PMID:9039486': {'publication date': '1997 Jan', 'sentence': 'These results suggest that an inflammatory reaction was induced by binding of anti-basement membrane antibody to cochlear capillaries in inner ear and that this inflammation in cochlea could be reduced by prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10018912,
-            "start": 568,
-            "end": 183319,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12795466': {'publication date': '2003 May', 'sentence': 'CONCLUSIONS: Predocol is an oral preparation of a poorly absorbed salt of prednisolone that is effective in reducing inflammation over short treatment periods in patients with active ulcerative colitis.', 'subject score': 1000, 'object score': 762}, 'PMID:1581697': {'publication date': '1992 Feb', 'sentence': 'This assumption may be supported by the fact that a combined systemic treatment with pyrimethamine, trimethoprim, sulfamethoxazole and prednisolone reduced the retinochoroidal inflammation and periarterial infiltrates.', 'subject score': 1000, 'object score': 861}, 'PMID:16843944': {'publication date': '1995 Oct', 'sentence': 'The therapeutic enema of prednisolone reduced colonic inflammation (CMS, colon weight), improved thymic weight, %GBW and food intake, and reduced plasma IL6 concentrations (P< 0.05).', 'subject score': 1000, 'object score': 888}, 'PMID:17045826': {'publication date': '2007', 'sentence': \"Neither prednisolone nor cilomilast had protective effect on the LPS-induced airways' inflammation.\", 'subject score': 1000, 'object score': 833}, 'PMID:1776474': {'publication date': '1991 Mar', 'sentence': 'Prevention of ocular inflammation by matrine, prednisolone, and cyclooxygenase and lipoxygenase inhibitors.', 'subject score': 1000, 'object score': 888}, 'PMID:21627530': {'publication date': '2011 Jun', 'sentence': 'CONCLUSIONS AND CLINICAL RELEVANCE: Topical administration of 1% prednisolone and 0.1% diclofenac significantly reduced intraocular inflammation in cats with paracentesis-induced uveitis.', 'subject score': 861, 'object score': 888}, 'PMID:23363352': {'publication date': '2013 Feb', 'sentence': 'CONCLUSIONS AND CLINICAL RELEVANCE: Orally administered prednisolone and meloxicam significantly decreased intraocular inflammation in clinically normal cats with paracentesis-induced BAB breakdown.', 'subject score': 827, 'object score': 888}, 'PMID:24884924': {'publication date': '2014 May 02', 'sentence': 'CONCLUSIONS: This study shows that prednisolone decreases inflammation and improves renal function, whilst not reducing liver injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:26965791': {'publication date': '2016 Mar 11', 'sentence': 'Prednisolone might be more effective in reducing inflammation and it had a better safety profile.', 'subject score': 1000, 'object score': 872}, 'PMID:29293747': {'publication date': '2017 Dec', 'sentence': 'Glucocorticoids such as prednisolone reduced the transfer of blood components from blood into milk while reducing the general inflammatory reaction.', 'subject score': 1000, 'object score': 901}, 'PMID:31772757': {'publication date': '2019 Sep', 'sentence': 'A combination of prednisolone, intravenous cyclophosphamide, and plasma exchange reduced the inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:35086209': {'publication date': '2022 Feb', 'sentence': 'Conclusion: NSAIDs used in isolation are comparable to prednisolone in preventing inflammation and pain after uneventful phacoemulsification.', 'subject score': 1000, 'object score': 861}, 'PMID:36029810': {'publication date': '2022 Aug 24', 'sentence': 'Corticosteroids like Hydrocortisone, dexamethasone, Prednisolone and Methylprednisolone has been reported to be effective against SARS-CoV-2 virus in comparison to that of non-steroid drugs, by using non-genomic and genomic effects to prevent and reduce inflammation in tissues and the circulation.', 'subject score': 1000, 'object score': 1000}, 'PMID:9039486': {'publication date': '1997 Jan', 'sentence': 'These results suggest that an inflammatory reaction was induced by binding of anti-basement membrane antibody to cochlear capillaries in inner ear and that this inflammation in cochlea could be reduced by prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:prevents---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10240036",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:12795466",
-                "PMID:1581697",
-                "PMID:16843944",
-                "PMID:17045826",
-                "PMID:1776474",
-                "PMID:21627530",
-                "PMID:23363352",
-                "PMID:24884924",
-                "PMID:26965791",
-                "PMID:29293747",
-                "PMID:31772757",
-                "PMID:35086209",
-                "PMID:36029810",
-                "PMID:9039486"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:24164703': {'publication date': '2014 Nov', 'sentence': 'OBJECTIVE: We want to show that an intralesional injection of prednisolone into the proximal nail fold may produce dorsal pain, dyspnoea and headaches within the 2 min following the injection and to explain the pathophysiology of his condition.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318533,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-          "name": "Headache",
-          "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10019211",
-            "PSY:22380",
-            "NCIT:C34661",
-            "MEDDRA:10019218",
-            "SNOMEDCT:25064002",
-            "UMLS:C0018681",
-            "MEDDRA:10019231",
-            "HP:0002315",
-            "MEDDRA:10033405",
-            "ICD9:784.0",
-            "MESH:D006261",
-            "SYMP:0000504",
-            "MEDDRA:10008013",
-            "MEDDRA:10019198"
-          ],
-          "id": "HP:0002315",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "headache",
-            "Headache"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-            "PMID:15304572",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318533,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-              "name": "Headache",
-              "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10019211",
-                "PSY:22380",
-                "NCIT:C34661",
-                "MEDDRA:10019218",
-                "SNOMEDCT:25064002",
-                "UMLS:C0018681",
-                "MEDDRA:10019231",
-                "HP:0002315",
-                "MEDDRA:10033405",
-                "ICD9:784.0",
-                "MESH:D006261",
-                "SYMP:0000504",
-                "MEDDRA:10008013",
-                "MEDDRA:10019198"
-              ],
-              "id": "HP:0002315",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "headache",
-                "Headache"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-                "PMID:15304572",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16882484,
-            "start": 568,
-            "end": 318533,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24164703': {'publication date': '2014 Nov', 'sentence': 'OBJECTIVE: We want to show that an intralesional injection of prednisolone into the proximal nail fold may produce dorsal pain, dyspnoea and headaches within the 2 min following the injection and to explain the pathophysiology of his condition.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0018681---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "17230021",
-              "object": "HP:0002315",
-              "publications": [
-                "PMID:24164703"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:15109361': {'publication date': '2004 Apr', 'sentence': 'Prednisolone-responsive headache in patients with solitary cysticercus granuloma and seizures.', 'subject score': 851, 'object score': 851}, 'PMID:17475943': {'publication date': '2007 Jul 03', 'sentence': 'CONCLUSION: Prednisolone has no effect on withdrawal headache in unselected patients with chronic daily headache and medication overuse.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 318533,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-          "name": "Headache",
-          "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10019211",
-            "PSY:22380",
-            "NCIT:C34661",
-            "MEDDRA:10019218",
-            "SNOMEDCT:25064002",
-            "UMLS:C0018681",
-            "MEDDRA:10019231",
-            "HP:0002315",
-            "MEDDRA:10033405",
-            "ICD9:784.0",
-            "MESH:D006261",
-            "SYMP:0000504",
-            "MEDDRA:10008013",
-            "MEDDRA:10019198"
-          ],
-          "id": "HP:0002315",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "headache",
-            "Headache"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-            "PMID:15304572",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318533,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-              "name": "Headache",
-              "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10019211",
-                "PSY:22380",
-                "NCIT:C34661",
-                "MEDDRA:10019218",
-                "SNOMEDCT:25064002",
-                "UMLS:C0018681",
-                "MEDDRA:10019231",
-                "HP:0002315",
-                "MEDDRA:10033405",
-                "ICD9:784.0",
-                "MESH:D006261",
-                "SYMP:0000504",
-                "MEDDRA:10008013",
-                "MEDDRA:10019198"
-              ],
-              "id": "HP:0002315",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "headache",
-                "Headache"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-                "PMID:15304572",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10927211,
-            "start": 568,
-            "end": 318533,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15109361': {'publication date': '2004 Apr', 'sentence': 'Prednisolone-responsive headache in patients with solitary cysticercus granuloma and seizures.', 'subject score': 851, 'object score': 851}, 'PMID:17475943': {'publication date': '2007 Jul 03', 'sentence': 'CONCLUSION: Prednisolone has no effect on withdrawal headache in unselected patients with chronic daily headache and medication overuse.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0018681---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11166436",
-              "object": "HP:0002315",
-              "publications": [
-                "PMID:15109361",
-                "PMID:17475943"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1403016': {'publication date': '1992 Aug', 'sentence': \"We report a patient with neuro-Behcet's syndrome presenting with headache and personality change in whom CT and MRI brain imaging was normal, but regional cerebral blood flow imaging using single photon emission tomography with the tracer HMPAO showed extensive perfusion deficits which partially reversed after 3 months of prednisolone therapy.\", 'subject score': 888, 'object score': 1000}, 'PMID:16324176': {'publication date': '2005', 'sentence': 'Temporal arteritis was suspected and prednisolone started with prompt resolution of the headache, chin hypoesthesia, ESR, and CRP.', 'subject score': 1000, 'object score': 1000}, 'PMID:23076953': {'publication date': '2012 Oct 17', 'sentence': 'The corticosteroid (prednisolone) showed a benefit in shortening the median time to resolution of headaches (five days in the treatment group versus 13 days in the control group, P < 0.0001).', 'subject score': 1000, 'object score': 1000}, 'PMID:25687750': {'publication date': '2015 Feb 17', 'sentence': 'The corticosteroid (prednisolone) showed a benefit in shortening the median time to resolution of headaches (five days in the treatment group versus 13 days in the control group, P value < 0.0001).', 'subject score': 1000, 'object score': 1000}, 'PMID:31506102': {'publication date': '2019 Sep 11', 'sentence': 'A dose of 20 mg of prednisolone was administered and her polymyalgia and polyarthritis improved; however, her headache and ear occlusion persisted.', 'subject score': 1000, 'object score': 1000}, 'PMID:34507542': {'publication date': '2021 Sep 10', 'sentence': 'She had fever and headache with antiviral and antibiotic treatment for 2 weeks, and she had empirical anti-tuberculosis treatment and oral prednisolone therapy.', 'subject score': 851, 'object score': 1000}, 'PMID:36384900': {'publication date': '2022 Nov 16', 'sentence': 'He received methylprednisolone pulse therapy followed by prednisolone and methotrexate, which improved his headache.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318533,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-          "name": "Headache",
-          "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10019211",
-            "PSY:22380",
-            "NCIT:C34661",
-            "MEDDRA:10019218",
-            "SNOMEDCT:25064002",
-            "UMLS:C0018681",
-            "MEDDRA:10019231",
-            "HP:0002315",
-            "MEDDRA:10033405",
-            "ICD9:784.0",
-            "MESH:D006261",
-            "SYMP:0000504",
-            "MEDDRA:10008013",
-            "MEDDRA:10019198"
-          ],
-          "id": "HP:0002315",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "headache",
-            "Headache"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-            "PMID:15304572",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318533,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-              "name": "Headache",
-              "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10019211",
-                "PSY:22380",
-                "NCIT:C34661",
-                "MEDDRA:10019218",
-                "SNOMEDCT:25064002",
-                "UMLS:C0018681",
-                "MEDDRA:10019231",
-                "HP:0002315",
-                "MEDDRA:10033405",
-                "ICD9:784.0",
-                "MESH:D006261",
-                "SYMP:0000504",
-                "MEDDRA:10008013",
-                "MEDDRA:10019198"
-              ],
-              "id": "HP:0002315",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "headache",
-                "Headache"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-                "PMID:15304572",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10442569,
-            "start": 568,
-            "end": 318533,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1403016': {'publication date': '1992 Aug', 'sentence': \"We report a patient with neuro-Behcet's syndrome presenting with headache and personality change in whom CT and MRI brain imaging was normal, but regional cerebral blood flow imaging using single photon emission tomography with the tracer HMPAO showed extensive perfusion deficits which partially reversed after 3 months of prednisolone therapy.\", 'subject score': 888, 'object score': 1000}, 'PMID:16324176': {'publication date': '2005', 'sentence': 'Temporal arteritis was suspected and prednisolone started with prompt resolution of the headache, chin hypoesthesia, ESR, and CRP.', 'subject score': 1000, 'object score': 1000}, 'PMID:23076953': {'publication date': '2012 Oct 17', 'sentence': 'The corticosteroid (prednisolone) showed a benefit in shortening the median time to resolution of headaches (five days in the treatment group versus 13 days in the control group, P < 0.0001).', 'subject score': 1000, 'object score': 1000}, 'PMID:25687750': {'publication date': '2015 Feb 17', 'sentence': 'The corticosteroid (prednisolone) showed a benefit in shortening the median time to resolution of headaches (five days in the treatment group versus 13 days in the control group, P value < 0.0001).', 'subject score': 1000, 'object score': 1000}, 'PMID:31506102': {'publication date': '2019 Sep 11', 'sentence': 'A dose of 20 mg of prednisolone was administered and her polymyalgia and polyarthritis improved; however, her headache and ear occlusion persisted.', 'subject score': 1000, 'object score': 1000}, 'PMID:34507542': {'publication date': '2021 Sep 10', 'sentence': 'She had fever and headache with antiviral and antibiotic treatment for 2 weeks, and she had empirical anti-tuberculosis treatment and oral prednisolone therapy.', 'subject score': 851, 'object score': 1000}, 'PMID:36384900': {'publication date': '2022 Nov 16', 'sentence': 'He received methylprednisolone pulse therapy followed by prednisolone and methotrexate, which improved his headache.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0018681---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10671990",
-              "object": "HP:0002315",
-              "publications": [
-                "PMID:1403016",
-                "PMID:16324176",
-                "PMID:23076953",
-                "PMID:25687750",
-                "PMID:31506102",
-                "PMID:34507542",
-                "PMID:36384900"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:14465683': {'publication date': '1962 Aug', 'sentence': '[Results of prednisolone therapy of eczemas in very young and older infants].', 'subject score': 888, 'object score': 1000}, 'PMID:19863501': {'publication date': '2010 Mar', 'sentence': 'CONCLUSIONS: Ciclosporin is significantly more efficacious than prednisolone for severe adult eczema.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 313237,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
-          "name": "atopic eczema",
-          "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SYMP:0000289",
-            "EFO:0000274",
-            "DOID:3310",
-            "HP:0000964",
-            "NCIT:C3001",
-            "UMLS:C0013595",
-            "MESH:D004485",
-            "MEDDRA:10014200",
-            "MEDDRA:10014206",
-            "MEDDRA:10012454",
-            "ICD10:L20",
-            "MEDDRA:10014184",
-            "OMIM.PS:603165",
-            "MEDDRA:10014209",
-            "PSY:15950",
-            "MONDO:0004980",
-            "OMIM:PS603165"
-          ],
-          "id": "MONDO:0004980",
-          "category": "biolink:Disease",
-          "all_names": [
-            "atopic dermatitis",
-            "atopic eczema",
-            "eczema",
-            "Eczema"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/atopic_dermatitis",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313237,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
-              "name": "atopic eczema",
-              "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SYMP:0000289",
-                "EFO:0000274",
-                "DOID:3310",
-                "HP:0000964",
-                "NCIT:C3001",
-                "UMLS:C0013595",
-                "MESH:D004485",
-                "MEDDRA:10014200",
-                "MEDDRA:10014206",
-                "MEDDRA:10012454",
-                "ICD10:L20",
-                "MEDDRA:10014184",
-                "OMIM.PS:603165",
-                "MEDDRA:10014209",
-                "PSY:15950",
-                "MONDO:0004980",
-                "OMIM:PS603165"
-              ],
-              "id": "MONDO:0004980",
-              "category": "biolink:Disease",
-              "all_names": [
-                "atopic dermatitis",
-                "atopic eczema",
-                "eczema",
-                "Eczema"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/atopic_dermatitis",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10526002,
-            "start": 568,
-            "end": 313237,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14465683': {'publication date': '1962 Aug', 'sentence': '[Results of prednisolone therapy of eczemas in very young and older infants].', 'subject score': 888, 'object score': 1000}, 'PMID:19863501': {'publication date': '2010 Mar', 'sentence': 'CONCLUSIONS: Ciclosporin is significantly more efficacious than prednisolone for severe adult eczema.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0013595---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10757066",
-              "object": "MONDO:0004980",
-              "publications": [
-                "PMID:14465683",
-                "PMID:19863501"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:11704581': {'publication date': '2001 Oct 15', 'sentence': 'We propose that FE(NO) is associated with eosinophilic inflammation in children with difficult asthma, following prednisolone, and may help in identifying patients in whom persistent symptoms are associated with airway eosinophilia.', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 316866,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015691",
-          "name": "hypereosinophilic syndrome",
-          "description": "A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction. This term has often been applied to cases of chronic eosinophilic leukemia. (WHO, 2001); A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10014950",
-            "UMLS:C1636667",
-            "ICD10:D72.1",
-            "ICD9:288.3",
-            "MEDDRA:10048643",
-            "NCIT:C27038",
-            "EFO:1001467",
-            "SNOMEDCT:1156250009",
-            "SNOMEDCT:419455006",
-            "DOID:999",
-            "MESH:D004802",
-            "MESH:D017681",
-            "ORPHANET:168956",
-            "SNOMEDCT:393573009",
-            "UMLS:C0014457",
-            "HP:0001880",
-            "MONDO:0015691",
-            "UMLS:C1540912"
-          ],
-          "id": "MONDO:0015691",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Disorder characterized by eosinophilia",
-            "hypereosinophilic syndrome",
-            "Hypereosinophilic Syndrome",
-            "Hypereosinophilic syndrome",
-            "Eosinophilia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/hypereosinophilic_syndrome",
-            "https://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316866,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015691",
-              "name": "hypereosinophilic syndrome",
-              "description": "A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction. This term has often been applied to cases of chronic eosinophilic leukemia. (WHO, 2001); A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10014950",
-                "UMLS:C1636667",
-                "ICD10:D72.1",
-                "ICD9:288.3",
-                "MEDDRA:10048643",
-                "NCIT:C27038",
-                "EFO:1001467",
-                "SNOMEDCT:1156250009",
-                "SNOMEDCT:419455006",
-                "DOID:999",
-                "MESH:D004802",
-                "MESH:D017681",
-                "ORPHANET:168956",
-                "SNOMEDCT:393573009",
-                "UMLS:C0014457",
-                "HP:0001880",
-                "MONDO:0015691",
-                "UMLS:C1540912"
-              ],
-              "id": "MONDO:0015691",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Disorder characterized by eosinophilia",
-                "hypereosinophilic syndrome",
-                "Hypereosinophilic Syndrome",
-                "Hypereosinophilic syndrome",
-                "Eosinophilia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/hypereosinophilic_syndrome",
-                "https://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9023645,
-            "start": 568,
-            "end": 316866,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11704581': {'publication date': '2001 Oct 15', 'sentence': 'We propose that FE(NO) is associated with eosinophilic inflammation in children with difficult asthma, following prednisolone, and may help in identifying patients in whom persistent symptoms are associated with airway eosinophilia.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0014457---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9222009",
-              "object": "MONDO:0015691",
-              "publications": [
-                "PMID:11704581"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:17261495': {'publication date': '2007 Jan', 'sentence': 'Of the 20 patients, 14 initially received prednisolone treatment, which resulted in rapid improvement and normalization of eosinophilia within 8 weeks; however, 2 patients with splenomegaly showed poor control of eosinophilia in response to corticosteroid treatment.', 'subject score': 771, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316866,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015691",
-          "name": "hypereosinophilic syndrome",
-          "description": "A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction. This term has often been applied to cases of chronic eosinophilic leukemia. (WHO, 2001); A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10014950",
-            "UMLS:C1636667",
-            "ICD10:D72.1",
-            "ICD9:288.3",
-            "MEDDRA:10048643",
-            "NCIT:C27038",
-            "EFO:1001467",
-            "SNOMEDCT:1156250009",
-            "SNOMEDCT:419455006",
-            "DOID:999",
-            "MESH:D004802",
-            "MESH:D017681",
-            "ORPHANET:168956",
-            "SNOMEDCT:393573009",
-            "UMLS:C0014457",
-            "HP:0001880",
-            "MONDO:0015691",
-            "UMLS:C1540912"
-          ],
-          "id": "MONDO:0015691",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Disorder characterized by eosinophilia",
-            "hypereosinophilic syndrome",
-            "Hypereosinophilic Syndrome",
-            "Hypereosinophilic syndrome",
-            "Eosinophilia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/hypereosinophilic_syndrome",
-            "https://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316866,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015691",
-              "name": "hypereosinophilic syndrome",
-              "description": "A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction. This term has often been applied to cases of chronic eosinophilic leukemia. (WHO, 2001); A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10014950",
-                "UMLS:C1636667",
-                "ICD10:D72.1",
-                "ICD9:288.3",
-                "MEDDRA:10048643",
-                "NCIT:C27038",
-                "EFO:1001467",
-                "SNOMEDCT:1156250009",
-                "SNOMEDCT:419455006",
-                "DOID:999",
-                "MESH:D004802",
-                "MESH:D017681",
-                "ORPHANET:168956",
-                "SNOMEDCT:393573009",
-                "UMLS:C0014457",
-                "HP:0001880",
-                "MONDO:0015691",
-                "UMLS:C1540912"
-              ],
-              "id": "MONDO:0015691",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Disorder characterized by eosinophilia",
-                "hypereosinophilic syndrome",
-                "Hypereosinophilic Syndrome",
-                "Hypereosinophilic syndrome",
-                "Eosinophilia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/hypereosinophilic_syndrome",
-                "https://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12675205,
-            "start": 568,
-            "end": 316866,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17261495': {'publication date': '2007 Jan', 'sentence': 'Of the 20 patients, 14 initially received prednisolone treatment, which resulted in rapid improvement and normalization of eosinophilia within 8 weeks; however, 2 patients with splenomegaly showed poor control of eosinophilia in response to corticosteroid treatment.', 'subject score': 771, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0014457---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "12949384",
-              "object": "MONDO:0015691",
-              "publications": [
-                "PMID:17261495"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11244732': {'publication date': '2000 Dec', 'sentence': 'Prednisolone (PSL) was administered, which improved the anemia, eosinophilia and the cavities.', 'subject score': 1000, 'object score': 1000}, 'PMID:14639949': {'publication date': '2003 Oct', 'sentence': 'Administration of prednisolone at 80 mg/day resulted in a marked improvement of the symptoms and the eosinophilia.', 'subject score': 1000, 'object score': 1000}, 'PMID:1578631': {'publication date': '1992 Mar', 'sentence': 'The administration of prednisolone led to clinical remission in both cases, including rapid improvement of eosinophilia, normalization of hypercoagulability and correction of platelet dysfunction.', 'subject score': 1000, 'object score': 1000}, 'PMID:1633350': {'publication date': '1992 Apr', 'sentence': 'Here we describe four young Japanese women aged 25-33 years, whose clinical findings are characterized by episodic angioedema, marked leukocytosis with eosinophilia, benign course with spontaneous remission or low-dose prednisolone treatment.', 'subject score': 861, 'object score': 1000}, 'PMID:1753511': {'publication date': '1991 Oct', 'sentence': 'Both prednisolone and aspirin were administered with improvement of eosinophilia and partial thrombolysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2241587': {'publication date': '1990 Aug', 'sentence': 'Prednisolone was given at a dose of 60 mg daily resulting in improvement of the clinical symptoms and eosinophilia.', 'subject score': 1000, 'object score': 1000}, 'PMID:22608505': {'publication date': '2012 Jun', 'sentence': 'After treatment with prednisolone, all symptoms and the eosinophilia disappeared, and there was complete remission of the RV abnormalities.', 'subject score': 1000, 'object score': 1000}, 'PMID:25318795': {'publication date': '2014', 'sentence': 'At 26 years of age, he was found to have eosinophilia and abnormal liver function parameters, for which prednisolone therapy was started.', 'subject score': 888, 'object score': 1000}, 'PMID:28263223': {'publication date': '2017 05', 'sentence': 'Prednisolone may lead to a prompt amelioration of eosinophilia and associated symptoms.', 'subject score': 1000, 'object score': 1000}, 'PMID:35135946': {'publication date': '2022', 'sentence': 'She was given prednisolone, which resulted in the resolution of eosinophilia.', 'subject score': 1000, 'object score': 1000}, 'PMID:36176718': {'publication date': '2022 Oct', 'sentence': 'A complete response had been achieved, and oral prednisolone markedly improved the rash, pruritis, and eosinophilia.', 'subject score': 888, 'object score': 1000}, 'PMID:9380224': {'publication date': '1997', 'sentence': 'Under treatment with prednisolone, the symptoms and eosinophilia improved within 3 days.', 'subject score': 1000, 'object score': 1000}, 'PMID:11808087': {'publication date': '2001 Nov', 'sentence': 'Subsequent methylPSL pulse therapy followed by PSL brought about a transient improvement of the HES and DIC, but after reduction of the PSL, the HES worsened.', 'subject score': 1000, 'object score': 1000}, 'PMID:8479090': {'publication date': '1993 Mar', 'sentence': 'Case 1 was a 45-year-old man with HES who was unresponsive to prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316866,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015691",
-          "name": "hypereosinophilic syndrome",
-          "description": "A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction. This term has often been applied to cases of chronic eosinophilic leukemia. (WHO, 2001); A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10014950",
-            "UMLS:C1636667",
-            "ICD10:D72.1",
-            "ICD9:288.3",
-            "MEDDRA:10048643",
-            "NCIT:C27038",
-            "EFO:1001467",
-            "SNOMEDCT:1156250009",
-            "SNOMEDCT:419455006",
-            "DOID:999",
-            "MESH:D004802",
-            "MESH:D017681",
-            "ORPHANET:168956",
-            "SNOMEDCT:393573009",
-            "UMLS:C0014457",
-            "HP:0001880",
-            "MONDO:0015691",
-            "UMLS:C1540912"
-          ],
-          "id": "MONDO:0015691",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Disorder characterized by eosinophilia",
-            "hypereosinophilic syndrome",
-            "Hypereosinophilic Syndrome",
-            "Hypereosinophilic syndrome",
-            "Eosinophilia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/hypereosinophilic_syndrome",
-            "https://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316866,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015691",
-              "name": "hypereosinophilic syndrome",
-              "description": "A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction. This term has often been applied to cases of chronic eosinophilic leukemia. (WHO, 2001); A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10014950",
-                "UMLS:C1636667",
-                "ICD10:D72.1",
-                "ICD9:288.3",
-                "MEDDRA:10048643",
-                "NCIT:C27038",
-                "EFO:1001467",
-                "SNOMEDCT:1156250009",
-                "SNOMEDCT:419455006",
-                "DOID:999",
-                "MESH:D004802",
-                "MESH:D017681",
-                "ORPHANET:168956",
-                "SNOMEDCT:393573009",
-                "UMLS:C0014457",
-                "HP:0001880",
-                "MONDO:0015691",
-                "UMLS:C1540912"
-              ],
-              "id": "MONDO:0015691",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Disorder characterized by eosinophilia",
-                "hypereosinophilic syndrome",
-                "Hypereosinophilic Syndrome",
-                "Hypereosinophilic syndrome",
-                "Eosinophilia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/hypereosinophilic_syndrome",
-                "https://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8568008,
-            "start": 568,
-            "end": 316866,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11244732': {'publication date': '2000 Dec', 'sentence': 'Prednisolone (PSL) was administered, which improved the anemia, eosinophilia and the cavities.', 'subject score': 1000, 'object score': 1000}, 'PMID:14639949': {'publication date': '2003 Oct', 'sentence': 'Administration of prednisolone at 80 mg/day resulted in a marked improvement of the symptoms and the eosinophilia.', 'subject score': 1000, 'object score': 1000}, 'PMID:1578631': {'publication date': '1992 Mar', 'sentence': 'The administration of prednisolone led to clinical remission in both cases, including rapid improvement of eosinophilia, normalization of hypercoagulability and correction of platelet dysfunction.', 'subject score': 1000, 'object score': 1000}, 'PMID:1633350': {'publication date': '1992 Apr', 'sentence': 'Here we describe four young Japanese women aged 25-33 years, whose clinical findings are characterized by episodic angioedema, marked leukocytosis with eosinophilia, benign course with spontaneous remission or low-dose prednisolone treatment.', 'subject score': 861, 'object score': 1000}, 'PMID:1753511': {'publication date': '1991 Oct', 'sentence': 'Both prednisolone and aspirin were administered with improvement of eosinophilia and partial thrombolysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2241587': {'publication date': '1990 Aug', 'sentence': 'Prednisolone was given at a dose of 60 mg daily resulting in improvement of the clinical symptoms and eosinophilia.', 'subject score': 1000, 'object score': 1000}, 'PMID:22608505': {'publication date': '2012 Jun', 'sentence': 'After treatment with prednisolone, all symptoms and the eosinophilia disappeared, and there was complete remission of the RV abnormalities.', 'subject score': 1000, 'object score': 1000}, 'PMID:25318795': {'publication date': '2014', 'sentence': 'At 26 years of age, he was found to have eosinophilia and abnormal liver function parameters, for which prednisolone therapy was started.', 'subject score': 888, 'object score': 1000}, 'PMID:28263223': {'publication date': '2017 05', 'sentence': 'Prednisolone may lead to a prompt amelioration of eosinophilia and associated symptoms.', 'subject score': 1000, 'object score': 1000}, 'PMID:35135946': {'publication date': '2022', 'sentence': 'She was given prednisolone, which resulted in the resolution of eosinophilia.', 'subject score': 1000, 'object score': 1000}, 'PMID:36176718': {'publication date': '2022 Oct', 'sentence': 'A complete response had been achieved, and oral prednisolone markedly improved the rash, pruritis, and eosinophilia.', 'subject score': 888, 'object score': 1000}, 'PMID:9380224': {'publication date': '1997', 'sentence': 'Under treatment with prednisolone, the symptoms and eosinophilia improved within 3 days.', 'subject score': 1000, 'object score': 1000}, 'PMID:11808087': {'publication date': '2001 Nov', 'sentence': 'Subsequent methylPSL pulse therapy followed by PSL brought about a transient improvement of the HES and DIC, but after reduction of the PSL, the HES worsened.', 'subject score': 1000, 'object score': 1000}, 'PMID:8479090': {'publication date': '1993 Mar', 'sentence': 'Case 1 was a 45-year-old man with HES who was unresponsive to prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0014457---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C1540912---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8755027",
-              "object": "MONDO:0015691",
-              "publications": [
-                "PMID:9380224",
-                "PMID:1578631",
-                "PMID:11808087",
-                "PMID:8479090",
-                "PMID:2241587",
-                "PMID:14639949",
-                "PMID:22608505",
-                "PMID:28263223",
-                "PMID:1753511",
-                "PMID:25318795",
-                "PMID:36176718",
-                "PMID:11244732",
-                "PMID:35135946",
-                "PMID:1633350"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:1937894': {'publication date': '1991', 'sentence': 'A comparison with the bronchodilator potency of the above drugs indicated that in guinea pigs salbutamol appears relatively selective as a bronchodilator, prednisolone is selective as an inhibitor of eosinophilia whilst theophylline displays a balance of both activities.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316866,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015691",
-          "name": "hypereosinophilic syndrome",
-          "description": "A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction. This term has often been applied to cases of chronic eosinophilic leukemia. (WHO, 2001); A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10014950",
-            "UMLS:C1636667",
-            "ICD10:D72.1",
-            "ICD9:288.3",
-            "MEDDRA:10048643",
-            "NCIT:C27038",
-            "EFO:1001467",
-            "SNOMEDCT:1156250009",
-            "SNOMEDCT:419455006",
-            "DOID:999",
-            "MESH:D004802",
-            "MESH:D017681",
-            "ORPHANET:168956",
-            "SNOMEDCT:393573009",
-            "UMLS:C0014457",
-            "HP:0001880",
-            "MONDO:0015691",
-            "UMLS:C1540912"
-          ],
-          "id": "MONDO:0015691",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Disorder characterized by eosinophilia",
-            "hypereosinophilic syndrome",
-            "Hypereosinophilic Syndrome",
-            "Hypereosinophilic syndrome",
-            "Eosinophilia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/hypereosinophilic_syndrome",
-            "https://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316866,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015691",
-              "name": "hypereosinophilic syndrome",
-              "description": "A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction. This term has often been applied to cases of chronic eosinophilic leukemia. (WHO, 2001); A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10014950",
-                "UMLS:C1636667",
-                "ICD10:D72.1",
-                "ICD9:288.3",
-                "MEDDRA:10048643",
-                "NCIT:C27038",
-                "EFO:1001467",
-                "SNOMEDCT:1156250009",
-                "SNOMEDCT:419455006",
-                "DOID:999",
-                "MESH:D004802",
-                "MESH:D017681",
-                "ORPHANET:168956",
-                "SNOMEDCT:393573009",
-                "UMLS:C0014457",
-                "HP:0001880",
-                "MONDO:0015691",
-                "UMLS:C1540912"
-              ],
-              "id": "MONDO:0015691",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Disorder characterized by eosinophilia",
-                "hypereosinophilic syndrome",
-                "Hypereosinophilic Syndrome",
-                "Hypereosinophilic syndrome",
-                "Eosinophilia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/hypereosinophilic_syndrome",
-                "https://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14032018,
-            "start": 568,
-            "end": 316866,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1937894': {'publication date': '1991', 'sentence': 'A comparison with the bronchodilator potency of the above drugs indicated that in guinea pigs salbutamol appears relatively selective as a bronchodilator, prednisolone is selective as an inhibitor of eosinophilia whilst theophylline displays a balance of both activities.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:disrupts---None---None---None---UMLS:C0014457---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "14331279",
-              "object": "MONDO:0015691",
-              "publications": [
-                "PMID:1937894"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:2814121': {'publication date': '1989 Nov 14', 'sentence': 'Prednisolone (100 mg/die initially, decreasing doses thereafter) led to significant reduction of infiltrates and eosinophilia.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316866,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015691",
-          "name": "hypereosinophilic syndrome",
-          "description": "A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction. This term has often been applied to cases of chronic eosinophilic leukemia. (WHO, 2001); A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10014950",
-            "UMLS:C1636667",
-            "ICD10:D72.1",
-            "ICD9:288.3",
-            "MEDDRA:10048643",
-            "NCIT:C27038",
-            "EFO:1001467",
-            "SNOMEDCT:1156250009",
-            "SNOMEDCT:419455006",
-            "DOID:999",
-            "MESH:D004802",
-            "MESH:D017681",
-            "ORPHANET:168956",
-            "SNOMEDCT:393573009",
-            "UMLS:C0014457",
-            "HP:0001880",
-            "MONDO:0015691",
-            "UMLS:C1540912"
-          ],
-          "id": "MONDO:0015691",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Disorder characterized by eosinophilia",
-            "hypereosinophilic syndrome",
-            "Hypereosinophilic Syndrome",
-            "Hypereosinophilic syndrome",
-            "Eosinophilia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/hypereosinophilic_syndrome",
-            "https://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316866,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015691",
-              "name": "hypereosinophilic syndrome",
-              "description": "A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction. This term has often been applied to cases of chronic eosinophilic leukemia. (WHO, 2001); A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10014950",
-                "UMLS:C1636667",
-                "ICD10:D72.1",
-                "ICD9:288.3",
-                "MEDDRA:10048643",
-                "NCIT:C27038",
-                "EFO:1001467",
-                "SNOMEDCT:1156250009",
-                "SNOMEDCT:419455006",
-                "DOID:999",
-                "MESH:D004802",
-                "MESH:D017681",
-                "ORPHANET:168956",
-                "SNOMEDCT:393573009",
-                "UMLS:C0014457",
-                "HP:0001880",
-                "MONDO:0015691",
-                "UMLS:C1540912"
-              ],
-              "id": "MONDO:0015691",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Disorder characterized by eosinophilia",
-                "hypereosinophilic syndrome",
-                "Hypereosinophilic Syndrome",
-                "Hypereosinophilic syndrome",
-                "Eosinophilia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/hypereosinophilic_syndrome",
-                "https://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19070820,
-            "start": 568,
-            "end": 316866,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2814121': {'publication date': '1989 Nov 14', 'sentence': 'Prednisolone (100 mg/die initially, decreasing doses thereafter) led to significant reduction of infiltrates and eosinophilia.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:prevents---None---None---None---UMLS:C0014457---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "19453072",
-              "object": "MONDO:0015691",
-              "publications": [
-                "PMID:2814121"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:31464073': {'publication date': '2019 Dec', 'sentence': 'We aimed to determine the effect of mycophenolate mofetil (MMF) and azathioprine (AZA) on lung function and prednisolone dose in cHP patients.', 'subject score': 888, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 324980,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0017853",
-          "name": "hypersensitivity pneumonitis",
-          "description": "Hypersensitivity pneumonitis involves inhalation of an antigen. This leads to an exaggerated immune response and a following inflammation of the alveoli within the lungs. The main feature of chronic hypersensitivity pneumonitis on lung biopsies is expansion of the interstitium by lymphocytes accompanied by an occasional multinucleated giant cell or loose granuloma. After exposure to the provoking antigen, following symptoms can be seen: fever, chills, malaise, cough, hemoptysis, chest tightness, dyspnea, rash, swelling and headache and can be completely reversible, based on the duration of the illness, categorized as acute (HP:0011009), subacute (HP:0011011), and chronic (HP:0011010). [LMU:mgriese, PMID:15316440, PMID:16635083, PMID:18051218]; Hypersensitivity pneumonitis involves inhalation of an antigen. This leads to an exaggerated immune response and a following inflammation of the alveoli within the lungs. The main feature of chronic hypersensitivity pneumonitis on lung biopsies is expansion of the interstitium by lymphocytes accompanied by an occasional multinucleated giant cell or loose granuloma. After exposure to the provoking antigen, following symptoms can be seen: fever, chills, malaise, cough, hemoptysis, chest tightness, dyspnea, rash, swelling and headache and can be completely reversible, based on the duration of the illness, categorized as acute (HP:0011009), subacute (HP:0011011), and chronic (HP:0011010). // COMMENTS: Hypersensitivity pneumonitis may also be called many different names, based on the provoking antigen.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0002390",
-            "MONDO:0017853",
-            "MEDDRA:10035743",
-            "EFO:1001321",
-            "MESH:D000542",
-            "HP:0006516",
-            "SNOMEDCT:37471005",
-            "NCIT:C34369",
-            "ICD10:J67.9",
-            "MEDDRA:10001890",
-            "DOID:841",
-            "MEDDRA:10035754",
-            "ICD9:495",
-            "MEDDRA:10001891",
-            "ORPHANET:31740",
-            "MEDDRA:10015887",
-            "MEDDRA:10081988"
-          ],
-          "id": "MONDO:0017853",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hypersensitivity pneumonitis",
-            "Extrinsic allergic alveolitis",
-            "Alveolitis, Extrinsic Allergic",
-            "Hypersensitivity pneumonitis",
-            "Extrinsic Allergic Alveolitis",
-            "extrinsic allergic alveolitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:15316440",
-            "https://orcid.org/0000-0003-0113-912x",
-            "PMID:16635083",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000109.htm",
-            "http://www.merck.com/mmhe/sec04/ch051/ch051b.htm",
-            "https://orcid.org/0000-0003-0113-912xf",
-            "PMID:18051218"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 324980,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0017853",
-              "name": "hypersensitivity pneumonitis",
-              "description": "Hypersensitivity pneumonitis involves inhalation of an antigen. This leads to an exaggerated immune response and a following inflammation of the alveoli within the lungs. The main feature of chronic hypersensitivity pneumonitis on lung biopsies is expansion of the interstitium by lymphocytes accompanied by an occasional multinucleated giant cell or loose granuloma. After exposure to the provoking antigen, following symptoms can be seen: fever, chills, malaise, cough, hemoptysis, chest tightness, dyspnea, rash, swelling and headache and can be completely reversible, based on the duration of the illness, categorized as acute (HP:0011009), subacute (HP:0011011), and chronic (HP:0011010). [LMU:mgriese, PMID:15316440, PMID:16635083, PMID:18051218]; Hypersensitivity pneumonitis involves inhalation of an antigen. This leads to an exaggerated immune response and a following inflammation of the alveoli within the lungs. The main feature of chronic hypersensitivity pneumonitis on lung biopsies is expansion of the interstitium by lymphocytes accompanied by an occasional multinucleated giant cell or loose granuloma. After exposure to the provoking antigen, following symptoms can be seen: fever, chills, malaise, cough, hemoptysis, chest tightness, dyspnea, rash, swelling and headache and can be completely reversible, based on the duration of the illness, categorized as acute (HP:0011009), subacute (HP:0011011), and chronic (HP:0011010). // COMMENTS: Hypersensitivity pneumonitis may also be called many different names, based on the provoking antigen.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0002390",
-                "MONDO:0017853",
-                "MEDDRA:10035743",
-                "EFO:1001321",
-                "MESH:D000542",
-                "HP:0006516",
-                "SNOMEDCT:37471005",
-                "NCIT:C34369",
-                "ICD10:J67.9",
-                "MEDDRA:10001890",
-                "DOID:841",
-                "MEDDRA:10035754",
-                "ICD9:495",
-                "MEDDRA:10001891",
-                "ORPHANET:31740",
-                "MEDDRA:10015887",
-                "MEDDRA:10081988"
-              ],
-              "id": "MONDO:0017853",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hypersensitivity pneumonitis",
-                "Extrinsic allergic alveolitis",
-                "Alveolitis, Extrinsic Allergic",
-                "Hypersensitivity pneumonitis",
-                "Extrinsic Allergic Alveolitis",
-                "extrinsic allergic alveolitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:15316440",
-                "https://orcid.org/0000-0003-0113-912x",
-                "PMID:16635083",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000109.htm",
-                "http://www.merck.com/mmhe/sec04/ch051/ch051b.htm",
-                "https://orcid.org/0000-0003-0113-912xf",
-                "PMID:18051218"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20844818,
-            "start": 568,
-            "end": 324980,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31464073': {'publication date': '2019 Dec', 'sentence': 'We aimed to determine the effect of mycophenolate mofetil (MMF) and azathioprine (AZA) on lung function and prednisolone dose in cHP patients.', 'subject score': 888, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0002390---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "21254689",
-              "object": "MONDO:0017853",
-              "publications": [
-                "PMID:31464073"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11070934': {'publication date': '2000 Sep', 'sentence': 'She had received prednisolone (PSL) therapy for autoimmune hemolytic anemia (AIHA).', 'subject score': 851, 'object score': 1000}, 'PMID:14689879': {'publication date': '2003 Nov', 'sentence': '[Hypereosinophilic syndrome developing after prednisolone therapy for autoimmune hemolytic anemia].', 'subject score': 888, 'object score': 1000}, 'PMID:15997789': {'publication date': '2005 Jun', 'sentence': 'A 52-year-old woman was taking 10 mg of prednisolone on alternate days for the treatment of autoimmune hemolytic anemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:16542723': {'publication date': '2006 Dec', 'sentence': 'Here we present a case of an 80-year-old man with B-CLL who developed autoimmune hemolytic anemia (AIHA), associated with one cycle of fludarabine treatment, and who was successfully treated with rituximab and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:20154439': {'publication date': '2010', 'sentence': 'An 88-year-old man with autoimmune hemolytic anemia (AIHA) who had been treated with low dose prednisolone developed a sudden worsening of his anemia accompanied by reactivation of Epstein-Barr virus (EBV).', 'subject score': 901, 'object score': 1000}, 'PMID:27563485': {'publication date': '2016', 'sentence': 'CASE DESCRIPTION: A 65-year-old man with a history of autoimmune hemolytic anemia treated with prednisolone presented to our hospital because of occipital headache.', 'subject score': 1000, 'object score': 1000}, 'PMID:29866698': {'publication date': '2018 Jun 04', 'sentence': 'The authors present a 70-year-old man with an autoimmune haemolytic anaemia treated with prednisolone and azathioprine.', 'subject score': 1000, 'object score': 1000}, 'PMID:30898087': {'publication date': '2019 03 21', 'sentence': 'She had initially presented with failure to thrive, proportional microcephaly as well as autoimmune hemolytic anemia (AIHA), which responded well to treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:34732625': {'publication date': '2021', 'sentence': 'She was diagnosed with autoimmune hemolytic anemia (AIHA), and oral prednisolone therapy was administered.', 'subject score': 851, 'object score': 1000}, 'PMID:34777872': {'publication date': '2021', 'sentence': 'Case presentation: A female patient with a known history of autoimmune hemolytic anemia (AIHH) for which she was treated with prednisolone was admitted for uncontrolled anemia followed by fever and elevated liver enzymes.', 'subject score': 1000, 'object score': 1000}, 'PMID:8360990': {'publication date': '1993 Jul', 'sentence': 'The patient had already been diagnosed as having autoimmune hemolytic anemia (AIHA) in February, 1982 and treated with prednisolone (PSL) until January, 1988.', 'subject score': 1000, 'object score': 1000}, 'PMID:8965407': {'publication date': '1996 Aug', 'sentence': 'Autoimmune hemolytic anemia was diagnosed, and she was treated with prednisolone (1 mg/kg).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316900,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0020108",
-          "name": "autoimmune hemolytic anemia",
-          "description": "An acquired anemia caused by destruction of the red blood cells by autoantibodies. Causes include autoimmune disorders, lymphoproliferative disorders, and infections.; Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.; An autoimmune form of hemolytic anemia. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10073785",
-            "MEDDRA:10002046",
-            "MESH:D000744",
-            "ICD9:283.0",
-            "MEDDRA:10002285",
-            "MEDDRA:10073784",
-            "HP:0001890",
-            "MEDDRA:10003822",
-            "SNOMEDCT:413603009",
-            "EFO:1001264",
-            "OMIM:205700",
-            "NCIT:C34378",
-            "MEDDRA:10003825",
-            "ORPHANET:98375",
-            "MONDO:0020108",
-            "DOID:718",
-            "UMLS:C0002880"
-          ],
-          "id": "MONDO:0020108",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Autoimmune hemolytic anemias",
-            "Anemia, autoimmune hemolytic related phenotypic feature",
-            "Anemia, Hemolytic, Autoimmune",
-            "autoimmune hemolytic anemia",
-            "Autoimmune hemolytic anemia",
-            "Autoimmune Hemolytic Anemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/autoimmune_hemolytic_anemia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316900,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0020108",
-              "name": "autoimmune hemolytic anemia",
-              "description": "An acquired anemia caused by destruction of the red blood cells by autoantibodies. Causes include autoimmune disorders, lymphoproliferative disorders, and infections.; Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.; An autoimmune form of hemolytic anemia. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10073785",
-                "MEDDRA:10002046",
-                "MESH:D000744",
-                "ICD9:283.0",
-                "MEDDRA:10002285",
-                "MEDDRA:10073784",
-                "HP:0001890",
-                "MEDDRA:10003822",
-                "SNOMEDCT:413603009",
-                "EFO:1001264",
-                "OMIM:205700",
-                "NCIT:C34378",
-                "MEDDRA:10003825",
-                "ORPHANET:98375",
-                "MONDO:0020108",
-                "DOID:718",
-                "UMLS:C0002880"
-              ],
-              "id": "MONDO:0020108",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Autoimmune hemolytic anemias",
-                "Anemia, autoimmune hemolytic related phenotypic feature",
-                "Anemia, Hemolytic, Autoimmune",
-                "autoimmune hemolytic anemia",
-                "Autoimmune hemolytic anemia",
-                "Autoimmune Hemolytic Anemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/autoimmune_hemolytic_anemia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8358698,
-            "start": 568,
-            "end": 316900,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11070934': {'publication date': '2000 Sep', 'sentence': 'She had received prednisolone (PSL) therapy for autoimmune hemolytic anemia (AIHA).', 'subject score': 851, 'object score': 1000}, 'PMID:14689879': {'publication date': '2003 Nov', 'sentence': '[Hypereosinophilic syndrome developing after prednisolone therapy for autoimmune hemolytic anemia].', 'subject score': 888, 'object score': 1000}, 'PMID:15997789': {'publication date': '2005 Jun', 'sentence': 'A 52-year-old woman was taking 10 mg of prednisolone on alternate days for the treatment of autoimmune hemolytic anemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:16542723': {'publication date': '2006 Dec', 'sentence': 'Here we present a case of an 80-year-old man with B-CLL who developed autoimmune hemolytic anemia (AIHA), associated with one cycle of fludarabine treatment, and who was successfully treated with rituximab and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:20154439': {'publication date': '2010', 'sentence': 'An 88-year-old man with autoimmune hemolytic anemia (AIHA) who had been treated with low dose prednisolone developed a sudden worsening of his anemia accompanied by reactivation of Epstein-Barr virus (EBV).', 'subject score': 901, 'object score': 1000}, 'PMID:27563485': {'publication date': '2016', 'sentence': 'CASE DESCRIPTION: A 65-year-old man with a history of autoimmune hemolytic anemia treated with prednisolone presented to our hospital because of occipital headache.', 'subject score': 1000, 'object score': 1000}, 'PMID:29866698': {'publication date': '2018 Jun 04', 'sentence': 'The authors present a 70-year-old man with an autoimmune haemolytic anaemia treated with prednisolone and azathioprine.', 'subject score': 1000, 'object score': 1000}, 'PMID:30898087': {'publication date': '2019 03 21', 'sentence': 'She had initially presented with failure to thrive, proportional microcephaly as well as autoimmune hemolytic anemia (AIHA), which responded well to treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:34732625': {'publication date': '2021', 'sentence': 'She was diagnosed with autoimmune hemolytic anemia (AIHA), and oral prednisolone therapy was administered.', 'subject score': 851, 'object score': 1000}, 'PMID:34777872': {'publication date': '2021', 'sentence': 'Case presentation: A female patient with a known history of autoimmune hemolytic anemia (AIHH) for which she was treated with prednisolone was admitted for uncontrolled anemia followed by fever and elevated liver enzymes.', 'subject score': 1000, 'object score': 1000}, 'PMID:8360990': {'publication date': '1993 Jul', 'sentence': 'The patient had already been diagnosed as having autoimmune hemolytic anemia (AIHA) in February, 1982 and treated with prednisolone (PSL) until January, 1988.', 'subject score': 1000, 'object score': 1000}, 'PMID:8965407': {'publication date': '1996 Aug', 'sentence': 'Autoimmune hemolytic anemia was diagnosed, and she was treated with prednisolone (1 mg/kg).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0002880---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8540122",
-              "object": "MONDO:0020108",
-              "publications": [
-                "PMID:11070934",
-                "PMID:14689879",
-                "PMID:15997789",
-                "PMID:16542723",
-                "PMID:20154439",
-                "PMID:27563485",
-                "PMID:29866698",
-                "PMID:30898087",
-                "PMID:34732625",
-                "PMID:34777872",
-                "PMID:8360990",
-                "PMID:8965407"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:9366170': {'publication date': '1997 Aug', 'sentence': 'Microscopic polyarteritis nodosa was diagnosed and therapy with prednisolone was begun.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 708295,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019124",
-          "name": "microscopic polyangiitis",
-          "description": "A systemic necrotizing vasculitis that typically affects the small and medium-sized muscular arteries. In some cases, however, microscopic vessels are also affected (e.g., in the kidneys), a condition that has been called microscopic polyarteritis or polyangiitis; this disorder is felt to be more closely associated with Wegener granulomatosis than to classic polyarteritis nodosa.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:1144805008",
-            "MONDO:0019124",
-            "MESH:D055953",
-            "MEDDRA:10063344",
-            "ORPHANET:727",
-            "EFO:1000784",
-            "SNOMEDCT:239928004",
-            "NCIT:C70549",
-            "UMLS:C2347126"
-          ],
-          "id": "MONDO:0019124",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Microscopic Polyangiitis",
-            "Microscopic Polyarteritis",
-            "microscopic polyangiitis",
-            "Microscopic polyangiitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 708295,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019124",
-              "name": "microscopic polyangiitis",
-              "description": "A systemic necrotizing vasculitis that typically affects the small and medium-sized muscular arteries. In some cases, however, microscopic vessels are also affected (e.g., in the kidneys), a condition that has been called microscopic polyarteritis or polyangiitis; this disorder is felt to be more closely associated with Wegener granulomatosis than to classic polyarteritis nodosa.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:1144805008",
-                "MONDO:0019124",
-                "MESH:D055953",
-                "MEDDRA:10063344",
-                "ORPHANET:727",
-                "EFO:1000784",
-                "SNOMEDCT:239928004",
-                "NCIT:C70549",
-                "UMLS:C2347126"
-              ],
-              "id": "MONDO:0019124",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Microscopic Polyangiitis",
-                "Microscopic Polyarteritis",
-                "microscopic polyangiitis",
-                "Microscopic polyangiitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 27003853,
-            "start": 568,
-            "end": 708295,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9366170': {'publication date': '1997 Aug', 'sentence': 'Microscopic polyarteritis nodosa was diagnosed and therapy with prednisolone was begun.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C2347126---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "27475554",
-              "object": "MONDO:0019124",
-              "publications": [
-                "PMID:9366170"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:16624882': {'publication date': '2006 Jul', 'sentence': 'Prednisolone versus dexamethasone in croup: a randomised equivalence trial.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 526315,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005722",
-          "name": "croup",
-          "description": "Acute upper respiratory airways infection that results in the swelling of the larynx. It is usually caused by parainfluenza viruses. Signs include a characteristic barking cough and stridor.; Inflammation involving the GLOTTIS or VOCAL CORDS and the subglottic larynx. Croup is characterized by a barking cough, HOARSENESS, and persistent inspiratory STRIDOR (a high-pitched breathing sound). It occurs chiefly in infants and children.; Croup is an inflammation of the vocal cords (larynx) and windpipe (trachea). It causes difficulty breathing, a barking cough, and a hoarse voice. The cause is usually a virus, often parainfluenza virus. Other causes include allergies and reflux. Croup often starts out like a cold. But then the vocal cords and windpipe become swollen, causing the hoarseness and the cough. There may also be a fever and high-pitched noisy sounds when breathing. The symptoms are usually worse at night, and last for about three to five days. Children between the ages of 6 months and 3 years have the highest risk of getting croup. They may also have more severe symptoms. Croup is more common in the fall and winter. Most cases of viral croup are mild and can be treated at home. Rarely, croup can become serious and interfere with your child's breathing. If you are worried about your child's breathing, call your health care provider right away.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005722",
-            "NCIT:C26735",
-            "DOID:9395",
-            "MEDDRA:10011415",
-            "MESH:D003440",
-            "SNOMEDCT:71186008",
-            "EFO:0007227",
-            "ICD10:J05.0",
-            "UMLS:C0010380",
-            "ICD9:464.4"
-          ],
-          "id": "MONDO:0005722",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Croup",
-            "croup"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://books.google.com/books?id=g6k0tppmrsic&pg=pa254&lpg=pa254&dq#v=onepage&q=&f=false",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=croup",
-            "http://cmr.asm.org/content/16/2/242.f",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000959.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526315,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005722",
-              "name": "croup",
-              "description": "Acute upper respiratory airways infection that results in the swelling of the larynx. It is usually caused by parainfluenza viruses. Signs include a characteristic barking cough and stridor.; Inflammation involving the GLOTTIS or VOCAL CORDS and the subglottic larynx. Croup is characterized by a barking cough, HOARSENESS, and persistent inspiratory STRIDOR (a high-pitched breathing sound). It occurs chiefly in infants and children.; Croup is an inflammation of the vocal cords (larynx) and windpipe (trachea). It causes difficulty breathing, a barking cough, and a hoarse voice. The cause is usually a virus, often parainfluenza virus. Other causes include allergies and reflux. Croup often starts out like a cold. But then the vocal cords and windpipe become swollen, causing the hoarseness and the cough. There may also be a fever and high-pitched noisy sounds when breathing. The symptoms are usually worse at night, and last for about three to five days. Children between the ages of 6 months and 3 years have the highest risk of getting croup. They may also have more severe symptoms. Croup is more common in the fall and winter. Most cases of viral croup are mild and can be treated at home. Rarely, croup can become serious and interfere with your child's breathing. If you are worried about your child's breathing, call your health care provider right away.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005722",
-                "NCIT:C26735",
-                "DOID:9395",
-                "MEDDRA:10011415",
-                "MESH:D003440",
-                "SNOMEDCT:71186008",
-                "EFO:0007227",
-                "ICD10:J05.0",
-                "UMLS:C0010380",
-                "ICD9:464.4"
-              ],
-              "id": "MONDO:0005722",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Croup",
-                "croup"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://books.google.com/books?id=g6k0tppmrsic&pg=pa254&lpg=pa254&dq#v=onepage&q=&f=false",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=croup",
-                "http://cmr.asm.org/content/16/2/242.f",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000959.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12163090,
-            "start": 568,
-            "end": 526315,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16624882': {'publication date': '2006 Jul', 'sentence': 'Prednisolone versus dexamethasone in croup: a randomised equivalence trial.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0010380---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "12428137",
-              "object": "MONDO:0005722",
-              "publications": [
-                "PMID:16624882"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:24092872': {'publication date': '2013 Nov', 'sentence': 'Although common practice, evidence to support treatment of croup with prednisolone is scant.', 'subject score': 1000, 'object score': 1000}, 'PMID:29290883': {'publication date': '2017', 'sentence': 'Selection Criteria: Randomised Controlled Trials, clinical trials or chart reviews which examined children with croup who were treated with prednisolone alone, or when prednisolone was compared to a dexamethasone treatment and the effectiveness of the intervention was objectively measured using croup scores and re-attendance as primary outcomes.', 'subject score': 1000, 'object score': 1000}, 'PMID:31416827': {'publication date': '2019 Sep', 'sentence': 'OBJECTIVES: The use of either prednisolone or low-dose dexamethasone in the treatment of childhood croup lacks a rigorous evidence base despite widespread use.', 'subject score': 861, 'object score': 888}, 'PMID:31843117': {'publication date': '2020 Jan', 'sentence': 'Prednisolone vs dexamethsone in croup.', 'subject score': 1000, 'object score': 1000}, 'PMID:31846157': {'publication date': '2019 Dec', 'sentence': 'Prednisolone versus dexamethasone for croup.', 'subject score': 1000, 'object score': 1000}, 'PMID:32354725': {'publication date': '2020 Apr 30', 'sentence': 'Dexamethasone or prednisolone for croup.', 'subject score': 1000, 'object score': 1000}, 'PMID:36106471': {'publication date': '2022 Sep 15', 'sentence': 'CONCLUSIONS: Hospital resource utilization did not differ significantly for children receiving dexamethasone or prednisone or prednisolone for acute croup.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 526315,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005722",
-          "name": "croup",
-          "description": "Acute upper respiratory airways infection that results in the swelling of the larynx. It is usually caused by parainfluenza viruses. Signs include a characteristic barking cough and stridor.; Inflammation involving the GLOTTIS or VOCAL CORDS and the subglottic larynx. Croup is characterized by a barking cough, HOARSENESS, and persistent inspiratory STRIDOR (a high-pitched breathing sound). It occurs chiefly in infants and children.; Croup is an inflammation of the vocal cords (larynx) and windpipe (trachea). It causes difficulty breathing, a barking cough, and a hoarse voice. The cause is usually a virus, often parainfluenza virus. Other causes include allergies and reflux. Croup often starts out like a cold. But then the vocal cords and windpipe become swollen, causing the hoarseness and the cough. There may also be a fever and high-pitched noisy sounds when breathing. The symptoms are usually worse at night, and last for about three to five days. Children between the ages of 6 months and 3 years have the highest risk of getting croup. They may also have more severe symptoms. Croup is more common in the fall and winter. Most cases of viral croup are mild and can be treated at home. Rarely, croup can become serious and interfere with your child's breathing. If you are worried about your child's breathing, call your health care provider right away.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005722",
-            "NCIT:C26735",
-            "DOID:9395",
-            "MEDDRA:10011415",
-            "MESH:D003440",
-            "SNOMEDCT:71186008",
-            "EFO:0007227",
-            "ICD10:J05.0",
-            "UMLS:C0010380",
-            "ICD9:464.4"
-          ],
-          "id": "MONDO:0005722",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Croup",
-            "croup"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://books.google.com/books?id=g6k0tppmrsic&pg=pa254&lpg=pa254&dq#v=onepage&q=&f=false",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=croup",
-            "http://cmr.asm.org/content/16/2/242.f",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000959.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526315,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005722",
-              "name": "croup",
-              "description": "Acute upper respiratory airways infection that results in the swelling of the larynx. It is usually caused by parainfluenza viruses. Signs include a characteristic barking cough and stridor.; Inflammation involving the GLOTTIS or VOCAL CORDS and the subglottic larynx. Croup is characterized by a barking cough, HOARSENESS, and persistent inspiratory STRIDOR (a high-pitched breathing sound). It occurs chiefly in infants and children.; Croup is an inflammation of the vocal cords (larynx) and windpipe (trachea). It causes difficulty breathing, a barking cough, and a hoarse voice. The cause is usually a virus, often parainfluenza virus. Other causes include allergies and reflux. Croup often starts out like a cold. But then the vocal cords and windpipe become swollen, causing the hoarseness and the cough. There may also be a fever and high-pitched noisy sounds when breathing. The symptoms are usually worse at night, and last for about three to five days. Children between the ages of 6 months and 3 years have the highest risk of getting croup. They may also have more severe symptoms. Croup is more common in the fall and winter. Most cases of viral croup are mild and can be treated at home. Rarely, croup can become serious and interfere with your child's breathing. If you are worried about your child's breathing, call your health care provider right away.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005722",
-                "NCIT:C26735",
-                "DOID:9395",
-                "MEDDRA:10011415",
-                "MESH:D003440",
-                "SNOMEDCT:71186008",
-                "EFO:0007227",
-                "ICD10:J05.0",
-                "UMLS:C0010380",
-                "ICD9:464.4"
-              ],
-              "id": "MONDO:0005722",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Croup",
-                "croup"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://books.google.com/books?id=g6k0tppmrsic&pg=pa254&lpg=pa254&dq#v=onepage&q=&f=false",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=croup",
-                "http://cmr.asm.org/content/16/2/242.f",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000959.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16837604,
-            "start": 568,
-            "end": 526315,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24092872': {'publication date': '2013 Nov', 'sentence': 'Although common practice, evidence to support treatment of croup with prednisolone is scant.', 'subject score': 1000, 'object score': 1000}, 'PMID:29290883': {'publication date': '2017', 'sentence': 'Selection Criteria: Randomised Controlled Trials, clinical trials or chart reviews which examined children with croup who were treated with prednisolone alone, or when prednisolone was compared to a dexamethasone treatment and the effectiveness of the intervention was objectively measured using croup scores and re-attendance as primary outcomes.', 'subject score': 1000, 'object score': 1000}, 'PMID:31416827': {'publication date': '2019 Sep', 'sentence': 'OBJECTIVES: The use of either prednisolone or low-dose dexamethasone in the treatment of childhood croup lacks a rigorous evidence base despite widespread use.', 'subject score': 861, 'object score': 888}, 'PMID:31843117': {'publication date': '2020 Jan', 'sentence': 'Prednisolone vs dexamethsone in croup.', 'subject score': 1000, 'object score': 1000}, 'PMID:31846157': {'publication date': '2019 Dec', 'sentence': 'Prednisolone versus dexamethasone for croup.', 'subject score': 1000, 'object score': 1000}, 'PMID:32354725': {'publication date': '2020 Apr 30', 'sentence': 'Dexamethasone or prednisolone for croup.', 'subject score': 1000, 'object score': 1000}, 'PMID:36106471': {'publication date': '2022 Sep 15', 'sentence': 'CONCLUSIONS: Hospital resource utilization did not differ significantly for children receiving dexamethasone or prednisone or prednisolone for acute croup.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0010380---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "17184322",
-              "object": "MONDO:0005722",
-              "publications": [
-                "PMID:24092872",
-                "PMID:29290883",
-                "PMID:31416827",
-                "PMID:31843117",
-                "PMID:31846157",
-                "PMID:32354725",
-                "PMID:36106471"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:15675136': {'publication date': '2004', 'sentence': 'OBJECTIVE: To examine the safety and efficacy of methotrexate (MTX) plus low-dose prednisolone for induction of remission in non life- or organ-threatening courses and for remission maintenance in Churg-Strauss syndrome (CSS).', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 538027,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015943",
-          "name": "eosinophilic granulomatosis with polyangiitis",
-          "description": "Widespread necrotizing angiitis with granulomas. Pulmonary involvement is frequent. Asthma or other respiratory infection may precede evidence of vasculitis. Eosinophilia and lung involvement differentiate this disease from POLYARTERITIS NODOSA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:82275008",
-            "ICD10:M30.1",
-            "MEDDRA:10009164",
-            "MONDO:0015943",
-            "MEDDRA:10078117",
-            "MEDDRA:10048594",
-            "UMLS:C0008728",
-            "ORPHANET:183",
-            "EFO:0007208",
-            "MEDDRA:10001713",
-            "MEDDRA:10014957",
-            "NCIT:C34481",
-            "MESH:D015267",
-            "MEDDRA:10001714",
-            "MEDDRA:10001693",
-            "DOID:3049"
-          ],
-          "id": "MONDO:0015943",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Churg-Strauss Syndrome",
-            "Churg-Strauss syndrome",
-            "Eosinophilic granulomatosis with polyangiitis",
-            "eosinophilic granulomatosis with polyangiitis",
-            "Eosinophilic Granulomatosis with Polyangiitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/churg-strauss-syndrome/ds00855",
-            "https://orcid.org/0000-0002-8719-7760",
-            "http://www.hopkinsvasculitis.org/types-vasculitis/churgstrauss-syndrome-css/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538027,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015943",
-              "name": "eosinophilic granulomatosis with polyangiitis",
-              "description": "Widespread necrotizing angiitis with granulomas. Pulmonary involvement is frequent. Asthma or other respiratory infection may precede evidence of vasculitis. Eosinophilia and lung involvement differentiate this disease from POLYARTERITIS NODOSA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:82275008",
-                "ICD10:M30.1",
-                "MEDDRA:10009164",
-                "MONDO:0015943",
-                "MEDDRA:10078117",
-                "MEDDRA:10048594",
-                "UMLS:C0008728",
-                "ORPHANET:183",
-                "EFO:0007208",
-                "MEDDRA:10001713",
-                "MEDDRA:10014957",
-                "NCIT:C34481",
-                "MESH:D015267",
-                "MEDDRA:10001714",
-                "MEDDRA:10001693",
-                "DOID:3049"
-              ],
-              "id": "MONDO:0015943",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Churg-Strauss Syndrome",
-                "Churg-Strauss syndrome",
-                "Eosinophilic granulomatosis with polyangiitis",
-                "eosinophilic granulomatosis with polyangiitis",
-                "Eosinophilic Granulomatosis with Polyangiitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/churg-strauss-syndrome/ds00855",
-                "https://orcid.org/0000-0002-8719-7760",
-                "http://www.hopkinsvasculitis.org/types-vasculitis/churgstrauss-syndrome-css/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11389101,
-            "start": 568,
-            "end": 538027,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15675136': {'publication date': '2004', 'sentence': 'OBJECTIVE: To examine the safety and efficacy of methotrexate (MTX) plus low-dose prednisolone for induction of remission in non life- or organ-threatening courses and for remission maintenance in Churg-Strauss syndrome (CSS).', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0008728---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11638013",
-              "object": "MONDO:0015943",
-              "publications": [
-                "PMID:15675136"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10555101': {'publication date': '1999 Nov', 'sentence': 'However, after administration of immunoglobulin (IVIG) (0.4 g/kg/day x 5 days), low-dose PSL (20 mg/day) alleviated the LEMS and ITP, and the diseases have remained in remission for 8 months without additional IVIG.', 'subject score': 901, 'object score': 1000}, 'PMID:10695392': {'publication date': '2000 Jan', 'sentence': '[Low-dose prednisolone therapy for idiopathic thrombocytopenic purpura].', 'subject score': 861, 'object score': 1000}, 'PMID:10910585': {'publication date': '1999', 'sentence': 'The case of a child with idiopathic thrombocytopenic purpura recovered after prednisolone treatment, but lymphoma developed four months later.', 'subject score': 888, 'object score': 1000}, 'PMID:11310493': {'publication date': '2001 Mar', 'sentence': 'A 69-year-old woman with idiopathic thrombocytopenic purpura, who was regularly followed and treated with prednisolone and danazol, was admitted to our hospital because of shortness of breath.', 'subject score': 1000, 'object score': 1000}, 'PMID:11974905': {'publication date': '2002 Mar', 'sentence': 'Idiopathic thrombocytopenic purpura (ITP) was suspected and prednisolone therapy was begun, and ultimately brought about a partial remission.', 'subject score': 888, 'object score': 1000}, 'PMID:11979754': {'publication date': '2002 Mar', 'sentence': 'A 69-year-old man was diagnosed as having idiopathic thrombocytopenic purpura (ITP) in April 2000, and treated with prednisolone (PSL) without effect.', 'subject score': 1000, 'object score': 1000}, 'PMID:12400162': {'publication date': '2002 Oct', 'sentence': 'A 47-year-old woman received combination therapy with prednisolone (PSL), danazol, cepharanthin, ascorbic acid, and cimetidine for the treatment of idiopathic thrombocytopenic purpura.', 'subject score': 1000, 'object score': 1000}, 'PMID:16019454': {'publication date': '2005 Apr', 'sentence': 'The ITP patients with HTLV-I infection were older than the patients without HTLV-I infection, and the ITP patients with HTLV-I infection had poor response to prednisolone therapy.', 'subject score': 888, 'object score': 916}, 'PMID:17309547': {'publication date': '2007 Apr', 'sentence': 'Investigations confirmed immune thrombocytopenic purpura, and she received treatment with prednisolone and intravenous immunoglobulins with no increment in the platelet count.', 'subject score': 1000, 'object score': 1000}, 'PMID:17352309': {'publication date': '2006', 'sentence': 'The aims of this study were to compare initial platelet count elevation and to determine the chance of developing persistent profound thrombocytopenia by intravenous immunoglobulin (IVIG) or prednisolone in the treatment of children with ITP.', 'subject score': 1000, 'object score': 1000}, 'PMID:17825698': {'publication date': '2007 Jul', 'sentence': 'He had been prescribed 800 mg/d of clarithromycin, 400 mg/dL of rifampicin, and 750 mg/d of ethambutol hydrochloride for pulmonary MAC infection for 2 years and 5 mg/d of prednisolone for ITP for 7 years.', 'subject score': 1000, 'object score': 1000}, 'PMID:18477219': {'publication date': '2008 Jun', 'sentence': 'A 64-year-old Japanese woman suffering from idiopathic thrombocytopenic purpura was treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:18709983': {'publication date': '2008 Jul', 'sentence': 'Administration of PSL for ITP might mask the presenting clinical picture of ADEM.', 'subject score': 1000, 'object score': 1000}, 'PMID:20009444': {'publication date': '2009 Nov', 'sentence': 'Although she was treated with prednisolone for ITP and oral iron compounds for IDA, neither ITP nor IDA showed any improvement.', 'subject score': 1000, 'object score': 1000}, 'PMID:2214183': {'publication date': '1990 Jul', 'sentence': 'A 23 year old female, born in 1957, was diagnosed as having idiopathic thrombocytopenic purpura at the age of 3 and treated with prednisolone during her childhood with no response.', 'subject score': 1000, 'object score': 1000}, 'PMID:31866629': {'publication date': '2019 Dec 20', 'sentence': 'Despite treatment with prednisolone, cyclosporin and low-density lipoprotein-apheresis, MCNS and ITP did not improve.', 'subject score': 1000, 'object score': 1000}, 'PMID:32026046': {'publication date': '2019 Jun 07', 'sentence': 'She had been diagnosed as idiopathic thrombocytopenic purpura at the age of 29 years old and treated with prednisolone at 15 mg/day.', 'subject score': 1000, 'object score': 1000}, 'PMID:32389942': {'publication date': '2020 May 08', 'sentence': 'Initially, we increased the dose of prednisolone for ITP.', 'subject score': 1000, 'object score': 1000}, 'PMID:574666': {'publication date': '1979 Sep', 'sentence': 'However the number of the patients in the study were rather small further clinical studies and treatment with 1 mg/kg and 2 mg/kg per day of prednisolone in childhood ITP are warranted.', 'subject score': 1000, 'object score': 888}, 'PMID:7197014': {'publication date': '1981 May', 'sentence': '[Effectiveness of prednisolone treatment in idiopathic thrombocytopenic purpura in children].', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316028,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008558",
-          "name": "autoimmune thrombocytopenic purpura",
-          "description": "Acquired thrombocytopenia of unknown cause, characterized by immune-mediated destruction of normal platelets. It affects both children and adults. It manifests with petechiae, purpura, and overt bleeding. Based upon the duration of the disease, it is classified as newly diagnosed (from diagnosis until 3 months), persistent (3-12 months), and chronic (lasting for more than 12 months).; Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.; The presence of thrombocytopenia in combination with detection of antiplatelet antibodies. [DDD:wouwehand]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021245",
-            "UMLS:C0398650",
-            "ORPHANET:3002",
-            "MESH:D016553",
-            "ICD9:287.31",
-            "MEDDRA:10083843",
-            "MEDDRA:10051064",
-            "MONDO:0008558",
-            "MEDDRA:10074667",
-            "OMIM:188030",
-            "DOID:8924",
-            "MEDDRA:10021243",
-            "ICD10:D69.3",
-            "EFO:0007160",
-            "NCIT:C3446"
-          ],
-          "id": "MONDO:0008558",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Purpura, Thrombocytopenic, Idiopathic",
-            "Immune thrombocytopenic purpura",
-            "Primary Immune Thrombocytopenia",
-            "Thrombocytopenic purpura, autoimmune related phenotypic feature",
-            "autoimmune thrombocytopenic purpura"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://rarediseases.org/rare-diseases/immune-thrombocytopenia/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316028,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008558",
-              "name": "autoimmune thrombocytopenic purpura",
-              "description": "Acquired thrombocytopenia of unknown cause, characterized by immune-mediated destruction of normal platelets. It affects both children and adults. It manifests with petechiae, purpura, and overt bleeding. Based upon the duration of the disease, it is classified as newly diagnosed (from diagnosis until 3 months), persistent (3-12 months), and chronic (lasting for more than 12 months).; Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.; The presence of thrombocytopenia in combination with detection of antiplatelet antibodies. [DDD:wouwehand]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021245",
-                "UMLS:C0398650",
-                "ORPHANET:3002",
-                "MESH:D016553",
-                "ICD9:287.31",
-                "MEDDRA:10083843",
-                "MEDDRA:10051064",
-                "MONDO:0008558",
-                "MEDDRA:10074667",
-                "OMIM:188030",
-                "DOID:8924",
-                "MEDDRA:10021243",
-                "ICD10:D69.3",
-                "EFO:0007160",
-                "NCIT:C3446"
-              ],
-              "id": "MONDO:0008558",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Purpura, Thrombocytopenic, Idiopathic",
-                "Immune thrombocytopenic purpura",
-                "Primary Immune Thrombocytopenia",
-                "Thrombocytopenic purpura, autoimmune related phenotypic feature",
-                "autoimmune thrombocytopenic purpura"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://rarediseases.org/rare-diseases/immune-thrombocytopenia/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7639420,
-            "start": 568,
-            "end": 316028,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10555101': {'publication date': '1999 Nov', 'sentence': 'However, after administration of immunoglobulin (IVIG) (0.4 g/kg/day x 5 days), low-dose PSL (20 mg/day) alleviated the LEMS and ITP, and the diseases have remained in remission for 8 months without additional IVIG.', 'subject score': 901, 'object score': 1000}, 'PMID:10695392': {'publication date': '2000 Jan', 'sentence': '[Low-dose prednisolone therapy for idiopathic thrombocytopenic purpura].', 'subject score': 861, 'object score': 1000}, 'PMID:10910585': {'publication date': '1999', 'sentence': 'The case of a child with idiopathic thrombocytopenic purpura recovered after prednisolone treatment, but lymphoma developed four months later.', 'subject score': 888, 'object score': 1000}, 'PMID:11310493': {'publication date': '2001 Mar', 'sentence': 'A 69-year-old woman with idiopathic thrombocytopenic purpura, who was regularly followed and treated with prednisolone and danazol, was admitted to our hospital because of shortness of breath.', 'subject score': 1000, 'object score': 1000}, 'PMID:11974905': {'publication date': '2002 Mar', 'sentence': 'Idiopathic thrombocytopenic purpura (ITP) was suspected and prednisolone therapy was begun, and ultimately brought about a partial remission.', 'subject score': 888, 'object score': 1000}, 'PMID:11979754': {'publication date': '2002 Mar', 'sentence': 'A 69-year-old man was diagnosed as having idiopathic thrombocytopenic purpura (ITP) in April 2000, and treated with prednisolone (PSL) without effect.', 'subject score': 1000, 'object score': 1000}, 'PMID:12400162': {'publication date': '2002 Oct', 'sentence': 'A 47-year-old woman received combination therapy with prednisolone (PSL), danazol, cepharanthin, ascorbic acid, and cimetidine for the treatment of idiopathic thrombocytopenic purpura.', 'subject score': 1000, 'object score': 1000}, 'PMID:16019454': {'publication date': '2005 Apr', 'sentence': 'The ITP patients with HTLV-I infection were older than the patients without HTLV-I infection, and the ITP patients with HTLV-I infection had poor response to prednisolone therapy.', 'subject score': 888, 'object score': 916}, 'PMID:17309547': {'publication date': '2007 Apr', 'sentence': 'Investigations confirmed immune thrombocytopenic purpura, and she received treatment with prednisolone and intravenous immunoglobulins with no increment in the platelet count.', 'subject score': 1000, 'object score': 1000}, 'PMID:17352309': {'publication date': '2006', 'sentence': 'The aims of this study were to compare initial platelet count elevation and to determine the chance of developing persistent profound thrombocytopenia by intravenous immunoglobulin (IVIG) or prednisolone in the treatment of children with ITP.', 'subject score': 1000, 'object score': 1000}, 'PMID:17825698': {'publication date': '2007 Jul', 'sentence': 'He had been prescribed 800 mg/d of clarithromycin, 400 mg/dL of rifampicin, and 750 mg/d of ethambutol hydrochloride for pulmonary MAC infection for 2 years and 5 mg/d of prednisolone for ITP for 7 years.', 'subject score': 1000, 'object score': 1000}, 'PMID:18477219': {'publication date': '2008 Jun', 'sentence': 'A 64-year-old Japanese woman suffering from idiopathic thrombocytopenic purpura was treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:18709983': {'publication date': '2008 Jul', 'sentence': 'Administration of PSL for ITP might mask the presenting clinical picture of ADEM.', 'subject score': 1000, 'object score': 1000}, 'PMID:20009444': {'publication date': '2009 Nov', 'sentence': 'Although she was treated with prednisolone for ITP and oral iron compounds for IDA, neither ITP nor IDA showed any improvement.', 'subject score': 1000, 'object score': 1000}, 'PMID:2214183': {'publication date': '1990 Jul', 'sentence': 'A 23 year old female, born in 1957, was diagnosed as having idiopathic thrombocytopenic purpura at the age of 3 and treated with prednisolone during her childhood with no response.', 'subject score': 1000, 'object score': 1000}, 'PMID:31866629': {'publication date': '2019 Dec 20', 'sentence': 'Despite treatment with prednisolone, cyclosporin and low-density lipoprotein-apheresis, MCNS and ITP did not improve.', 'subject score': 1000, 'object score': 1000}, 'PMID:32026046': {'publication date': '2019 Jun 07', 'sentence': 'She had been diagnosed as idiopathic thrombocytopenic purpura at the age of 29 years old and treated with prednisolone at 15 mg/day.', 'subject score': 1000, 'object score': 1000}, 'PMID:32389942': {'publication date': '2020 May 08', 'sentence': 'Initially, we increased the dose of prednisolone for ITP.', 'subject score': 1000, 'object score': 1000}, 'PMID:574666': {'publication date': '1979 Sep', 'sentence': 'However the number of the patients in the study were rather small further clinical studies and treatment with 1 mg/kg and 2 mg/kg per day of prednisolone in childhood ITP are warranted.', 'subject score': 1000, 'object score': 888}, 'PMID:7197014': {'publication date': '1981 May', 'sentence': '[Effectiveness of prednisolone treatment in idiopathic thrombocytopenic purpura in children].', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0398650---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7800931",
-              "object": "MONDO:0008558",
-              "publications": [
-                "PMID:10555101",
-                "PMID:10695392",
-                "PMID:10910585",
-                "PMID:11310493",
-                "PMID:11974905",
-                "PMID:11979754",
-                "PMID:12400162",
-                "PMID:16019454",
-                "PMID:17309547",
-                "PMID:17352309",
-                "PMID:17825698",
-                "PMID:18477219",
-                "PMID:18709983",
-                "PMID:20009444",
-                "PMID:2214183",
-                "PMID:31866629",
-                "PMID:32026046",
-                "PMID:32389942",
-                "PMID:574666",
-                "PMID:7197014"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:29331473': {'publication date': '2018 Mar', 'sentence': 'CONCLUSIONS: Prednisolone was more effective in inducing response than itraconazole in acute-stage ABPA.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 520745,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015243",
-          "name": "allergic bronchopulmonary aspergillosis",
-          "description": "An aspergillosis that involves an allergic reaction due to the spores of Aspergillus moulds (A. fumigatus), which colonizes the mucus in the airways causing inflammation. The disease has symptom cough, has symptom wheezing and has symptom fever. // COMMENTS: OMIM mapping confirmed by DO. [SN].",
-          "equivalent_curies": [
-            "ORPHANET:1164",
-            "MEDDRA:10001707",
-            "ICD9:518.6",
-            "ICD10:B44.81",
-            "UMLS:C3278302",
-            "MEDDRA:10006474",
-            "NCIT:C84547",
-            "OMIM:103920",
-            "SNOMEDCT:37981002",
-            "MESH:D001229",
-            "DOID:13166",
-            "UMLS:C0004031",
-            "EFO:0007140",
-            "MONDO:0015243"
-          ],
-          "id": "MONDO:0015243",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Aspergillosis, Allergic Bronchopulmonary",
-            "Allergic bronchopulmonary aspergillosis, familial",
-            "allergic bronchopulmonary aspergillosis",
-            "Allergic bronchopulmonary aspergillosis",
-            "Allergic Bronchopulmonary Aspergillosis",
-            "Allergic bronchopulmonary aspergillosis, familial related phenotypic feature"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000070.htm",
-            "http://www.merck.com/mmhe/sec04/ch051/ch051d.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520745,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015243",
-              "name": "allergic bronchopulmonary aspergillosis",
-              "description": "An aspergillosis that involves an allergic reaction due to the spores of Aspergillus moulds (A. fumigatus), which colonizes the mucus in the airways causing inflammation. The disease has symptom cough, has symptom wheezing and has symptom fever. // COMMENTS: OMIM mapping confirmed by DO. [SN].",
-              "equivalent_curies": [
-                "ORPHANET:1164",
-                "MEDDRA:10001707",
-                "ICD9:518.6",
-                "ICD10:B44.81",
-                "UMLS:C3278302",
-                "MEDDRA:10006474",
-                "NCIT:C84547",
-                "OMIM:103920",
-                "SNOMEDCT:37981002",
-                "MESH:D001229",
-                "DOID:13166",
-                "UMLS:C0004031",
-                "EFO:0007140",
-                "MONDO:0015243"
-              ],
-              "id": "MONDO:0015243",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Aspergillosis, Allergic Bronchopulmonary",
-                "Allergic bronchopulmonary aspergillosis, familial",
-                "allergic bronchopulmonary aspergillosis",
-                "Allergic bronchopulmonary aspergillosis",
-                "Allergic Bronchopulmonary Aspergillosis",
-                "Allergic bronchopulmonary aspergillosis, familial related phenotypic feature"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000070.htm",
-                "http://www.merck.com/mmhe/sec04/ch051/ch051d.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19713965,
-            "start": 568,
-            "end": 520745,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29331473': {'publication date': '2018 Mar', 'sentence': 'CONCLUSIONS: Prednisolone was more effective in inducing response than itraconazole in acute-stage ABPA.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0004031---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "20106181",
-              "object": "MONDO:0015243",
-              "publications": [
-                "PMID:29331473"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:3344933': {'publication date': '1988 Jan', 'sentence': 'After 14 months of treatment one of the patients developed severe, acute exacerbation of the ABPA and was treated with high-dose prednisolone and local steroid.', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 520745,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015243",
-          "name": "allergic bronchopulmonary aspergillosis",
-          "description": "An aspergillosis that involves an allergic reaction due to the spores of Aspergillus moulds (A. fumigatus), which colonizes the mucus in the airways causing inflammation. The disease has symptom cough, has symptom wheezing and has symptom fever. // COMMENTS: OMIM mapping confirmed by DO. [SN].",
-          "equivalent_curies": [
-            "ORPHANET:1164",
-            "MEDDRA:10001707",
-            "ICD9:518.6",
-            "ICD10:B44.81",
-            "UMLS:C3278302",
-            "MEDDRA:10006474",
-            "NCIT:C84547",
-            "OMIM:103920",
-            "SNOMEDCT:37981002",
-            "MESH:D001229",
-            "DOID:13166",
-            "UMLS:C0004031",
-            "EFO:0007140",
-            "MONDO:0015243"
-          ],
-          "id": "MONDO:0015243",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Aspergillosis, Allergic Bronchopulmonary",
-            "Allergic bronchopulmonary aspergillosis, familial",
-            "allergic bronchopulmonary aspergillosis",
-            "Allergic bronchopulmonary aspergillosis",
-            "Allergic Bronchopulmonary Aspergillosis",
-            "Allergic bronchopulmonary aspergillosis, familial related phenotypic feature"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000070.htm",
-            "http://www.merck.com/mmhe/sec04/ch051/ch051d.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520745,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015243",
-              "name": "allergic bronchopulmonary aspergillosis",
-              "description": "An aspergillosis that involves an allergic reaction due to the spores of Aspergillus moulds (A. fumigatus), which colonizes the mucus in the airways causing inflammation. The disease has symptom cough, has symptom wheezing and has symptom fever. // COMMENTS: OMIM mapping confirmed by DO. [SN].",
-              "equivalent_curies": [
-                "ORPHANET:1164",
-                "MEDDRA:10001707",
-                "ICD9:518.6",
-                "ICD10:B44.81",
-                "UMLS:C3278302",
-                "MEDDRA:10006474",
-                "NCIT:C84547",
-                "OMIM:103920",
-                "SNOMEDCT:37981002",
-                "MESH:D001229",
-                "DOID:13166",
-                "UMLS:C0004031",
-                "EFO:0007140",
-                "MONDO:0015243"
-              ],
-              "id": "MONDO:0015243",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Aspergillosis, Allergic Bronchopulmonary",
-                "Allergic bronchopulmonary aspergillosis, familial",
-                "allergic bronchopulmonary aspergillosis",
-                "Allergic bronchopulmonary aspergillosis",
-                "Allergic Bronchopulmonary Aspergillosis",
-                "Allergic bronchopulmonary aspergillosis, familial related phenotypic feature"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000070.htm",
-                "http://www.merck.com/mmhe/sec04/ch051/ch051d.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22494159,
-            "start": 568,
-            "end": 520745,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3344933': {'publication date': '1988 Jan', 'sentence': 'After 14 months of treatment one of the patients developed severe, acute exacerbation of the ABPA and was treated with high-dose prednisolone and local steroid.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0004031---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "22922261",
-              "object": "MONDO:0015243",
-              "publications": [
-                "PMID:3344933"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:17824467': {'publication date': '2007 Mar', 'sentence': 'Here 2 cases of allergic bronchopulmonary aspergillosis in a family (brother and sister), treated with prednisolone with complete remission are reported.', 'subject score': 1000, 'object score': 1000}, 'PMID:29331473': {'publication date': '2018 Mar', 'sentence': 'However, itraconazole was also effective in a considerable number and, with fewer side effects compared with prednisolone, remains an attractive alternative in the initial treatment of ABPA.', 'subject score': 1000, 'object score': 1000}, 'PMID:33642487': {'publication date': '2021 Mar 01', 'sentence': 'A 45-year-old man with allergic bronchopulmonary aspergillosis (ABPA) was treated with oral prednisolone (PSL) (30 mg/day), inhaled corticosteroids, and long-acting beta2-agonists.', 'subject score': 888, 'object score': 1000}, 'PMID:8767272': {'publication date': '1996', 'sentence': 'Prednisolone with an initial dose of between 0,5-1,0 mg/kg/day remains the treatment of choice for ABPA.', 'subject score': 1000, 'object score': 1000}, 'PMID:9715302': {'publication date': '1996', 'sentence': 'A 38 year old male was diagnosed to have allergic bronchopulmonary aspergillosis which responded remarkably to prednisolone therapy.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 520745,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015243",
-          "name": "allergic bronchopulmonary aspergillosis",
-          "description": "An aspergillosis that involves an allergic reaction due to the spores of Aspergillus moulds (A. fumigatus), which colonizes the mucus in the airways causing inflammation. The disease has symptom cough, has symptom wheezing and has symptom fever. // COMMENTS: OMIM mapping confirmed by DO. [SN].",
-          "equivalent_curies": [
-            "ORPHANET:1164",
-            "MEDDRA:10001707",
-            "ICD9:518.6",
-            "ICD10:B44.81",
-            "UMLS:C3278302",
-            "MEDDRA:10006474",
-            "NCIT:C84547",
-            "OMIM:103920",
-            "SNOMEDCT:37981002",
-            "MESH:D001229",
-            "DOID:13166",
-            "UMLS:C0004031",
-            "EFO:0007140",
-            "MONDO:0015243"
-          ],
-          "id": "MONDO:0015243",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Aspergillosis, Allergic Bronchopulmonary",
-            "Allergic bronchopulmonary aspergillosis, familial",
-            "allergic bronchopulmonary aspergillosis",
-            "Allergic bronchopulmonary aspergillosis",
-            "Allergic Bronchopulmonary Aspergillosis",
-            "Allergic bronchopulmonary aspergillosis, familial related phenotypic feature"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000070.htm",
-            "http://www.merck.com/mmhe/sec04/ch051/ch051d.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520745,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015243",
-              "name": "allergic bronchopulmonary aspergillosis",
-              "description": "An aspergillosis that involves an allergic reaction due to the spores of Aspergillus moulds (A. fumigatus), which colonizes the mucus in the airways causing inflammation. The disease has symptom cough, has symptom wheezing and has symptom fever. // COMMENTS: OMIM mapping confirmed by DO. [SN].",
-              "equivalent_curies": [
-                "ORPHANET:1164",
-                "MEDDRA:10001707",
-                "ICD9:518.6",
-                "ICD10:B44.81",
-                "UMLS:C3278302",
-                "MEDDRA:10006474",
-                "NCIT:C84547",
-                "OMIM:103920",
-                "SNOMEDCT:37981002",
-                "MESH:D001229",
-                "DOID:13166",
-                "UMLS:C0004031",
-                "EFO:0007140",
-                "MONDO:0015243"
-              ],
-              "id": "MONDO:0015243",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Aspergillosis, Allergic Bronchopulmonary",
-                "Allergic bronchopulmonary aspergillosis, familial",
-                "allergic bronchopulmonary aspergillosis",
-                "Allergic bronchopulmonary aspergillosis",
-                "Allergic Bronchopulmonary Aspergillosis",
-                "Allergic bronchopulmonary aspergillosis, familial related phenotypic feature"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000070.htm",
-                "http://www.merck.com/mmhe/sec04/ch051/ch051d.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13045966,
-            "start": 568,
-            "end": 520745,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17824467': {'publication date': '2007 Mar', 'sentence': 'Here 2 cases of allergic bronchopulmonary aspergillosis in a family (brother and sister), treated with prednisolone with complete remission are reported.', 'subject score': 1000, 'object score': 1000}, 'PMID:29331473': {'publication date': '2018 Mar', 'sentence': 'However, itraconazole was also effective in a considerable number and, with fewer side effects compared with prednisolone, remains an attractive alternative in the initial treatment of ABPA.', 'subject score': 1000, 'object score': 1000}, 'PMID:33642487': {'publication date': '2021 Mar 01', 'sentence': 'A 45-year-old man with allergic bronchopulmonary aspergillosis (ABPA) was treated with oral prednisolone (PSL) (30 mg/day), inhaled corticosteroids, and long-acting beta2-agonists.', 'subject score': 888, 'object score': 1000}, 'PMID:8767272': {'publication date': '1996', 'sentence': 'Prednisolone with an initial dose of between 0,5-1,0 mg/kg/day remains the treatment of choice for ABPA.', 'subject score': 1000, 'object score': 1000}, 'PMID:9715302': {'publication date': '1996', 'sentence': 'A 38 year old male was diagnosed to have allergic bronchopulmonary aspergillosis which responded remarkably to prednisolone therapy.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0004031---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "13327146",
-              "object": "MONDO:0015243",
-              "publications": [
-                "PMID:17824467",
-                "PMID:29331473",
-                "PMID:33642487",
-                "PMID:8767272",
-                "PMID:9715302"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:11699226': {'publication date': '2001 Jun', 'sentence': 'Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma.', 'subject score': 1000, 'object score': 893}, 'PMID:19816010': {'publication date': '2009', 'sentence': 'Effect of L-asparaginase combined with vincristine and prednisolone on acute myeloblastic leukemia (M0) associated with non-Hodgkin lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:3293535': {'publication date': '1988 Jul', 'sentence': \"[Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, prednisolone (VEPA) in non-Hodgkin's lymphoma, with special reference to correlation of surface phenotype with response and survival].\", 'subject score': 1000, 'object score': 1000}, 'PMID:7055819': {'publication date': '1982 Feb', 'sentence': \"Phase II study of a high-dose regimen of cyclophosphamide and prednisolone in advanced non-Hodgkin's lymphoma of favorable histologic type.\", 'subject score': 1000, 'object score': 923}}",
-    "p2": {
-      "start": {
-        "identity": 316905,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018908",
-          "name": "non-Hodgkin lymphoma",
-          "description": "Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3211\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3211\" NCI Thesaurus); Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.; Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.; A type of lymphoma characterized microscopically by the absence of multinucleated Reed-Sternberg cells. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "UMLS:C1622254",
-            "ORPHANET:547",
-            "MESH:D008228",
-            "UMLS:C0024305",
-            "MONDO:0018908",
-            "HP:0012539",
-            "SNOMEDCT:188675007",
-            "PDQ:CDR0000038957",
-            "NCIT:C3211",
-            "SNOMEDCT:1172592001",
-            "DOID:0060060",
-            "MEDDRA:10025311",
-            "MEDDRA:10029593",
-            "SNOMEDCT:128929007",
-            "MEDDRA:10029547",
-            "UMLS:C1622813"
-          ],
-          "id": "MONDO:0018908",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Non-Hodgkin Lymphoma",
-            "Lymphoma, Non-Hodgkin",
-            "Malignant lymphoma - small cleaved cell",
-            "non-Hodgkin lymphoma",
-            "Non-Hodgkin lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/non-hodgkin_lymphoma",
-            "http://www.cancer.gov/dictionary?cdrid=45148",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316905,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018908",
-              "name": "non-Hodgkin lymphoma",
-              "description": "Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3211\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3211\" NCI Thesaurus); Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.; Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.; A type of lymphoma characterized microscopically by the absence of multinucleated Reed-Sternberg cells. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "UMLS:C1622254",
-                "ORPHANET:547",
-                "MESH:D008228",
-                "UMLS:C0024305",
-                "MONDO:0018908",
-                "HP:0012539",
-                "SNOMEDCT:188675007",
-                "PDQ:CDR0000038957",
-                "NCIT:C3211",
-                "SNOMEDCT:1172592001",
-                "DOID:0060060",
-                "MEDDRA:10025311",
-                "MEDDRA:10029593",
-                "SNOMEDCT:128929007",
-                "MEDDRA:10029547",
-                "UMLS:C1622813"
-              ],
-              "id": "MONDO:0018908",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Non-Hodgkin Lymphoma",
-                "Lymphoma, Non-Hodgkin",
-                "Malignant lymphoma - small cleaved cell",
-                "non-Hodgkin lymphoma",
-                "Non-Hodgkin lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/non-hodgkin_lymphoma",
-                "http://www.cancer.gov/dictionary?cdrid=45148",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9017579,
-            "start": 568,
-            "end": 316905,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11699226': {'publication date': '2001 Jun', 'sentence': 'Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma.', 'subject score': 1000, 'object score': 893}, 'PMID:19816010': {'publication date': '2009', 'sentence': 'Effect of L-asparaginase combined with vincristine and prednisolone on acute myeloblastic leukemia (M0) associated with non-Hodgkin lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:3293535': {'publication date': '1988 Jul', 'sentence': \"[Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, prednisolone (VEPA) in non-Hodgkin's lymphoma, with special reference to correlation of surface phenotype with response and survival].\", 'subject score': 1000, 'object score': 1000}, 'PMID:7055819': {'publication date': '1982 Feb', 'sentence': \"Phase II study of a high-dose regimen of cyclophosphamide and prednisolone in advanced non-Hodgkin's lymphoma of favorable histologic type.\", 'subject score': 1000, 'object score': 923}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0024305---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9216084",
-              "object": "MONDO:0018908",
-              "publications": [
-                "PMID:11699226",
-                "PMID:19816010",
-                "PMID:3293535",
-                "PMID:7055819"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10674903': {'publication date': '2000 Jan', 'sentence': \"A regimen which incorporates cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) is the standard treatment for patients with non-Hodgkin's lymphoma (NHL), but it has not been effective in patients with aggressive NHL who are at high risk.\", 'subject score': 1000, 'object score': 1000}, 'PMID:11256023': {'publication date': '2001 Feb 23', 'sentence': '[Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma]].', 'subject score': 1000, 'object score': 840}, 'PMID:11368287': {'publication date': '2001', 'sentence': 'Substitution of bendamustine for cyclophosphamide in a standard first-line COP regimen (cyclophosphamide, vincristine and prednisolone) yielded similar response rates in patients with advanced low grade NHL.', 'subject score': 1000, 'object score': 840}, 'PMID:16247790': {'publication date': '2005 Dec 01', 'sentence': 'METHODS: Forty consecutive patients with untreated non-Hodgkin lymphoma who were scheduled to undergo standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) (mean age, 56 yrs; range, 24-70 yrs) were randomized with minimization methods to receive CHOP with or without 80 mg/day of valsartan.', 'subject score': 1000, 'object score': 923}, 'PMID:16533747': {'publication date': '2005 Dec', 'sentence': \"To facilitate more economical medical care, we carried out a prospective study of whether a THP-COP regimen (cyclophosphamide, pirarubicin, vincristine, and prednisolone) with low-dose granulocyte colony-stimulating factor (G-CSF) would effectively treat non-Hodgkin's lymphoma (NHL).\", 'subject score': 1000, 'object score': 1000}, 'PMID:18226581': {'publication date': '2008 Feb', 'sentence': 'BACKGROUND: Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is used to treat patients with non-Hodgkin lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:2298419': {'publication date': '1990', 'sentence': \"Thirty-six patients with non-Hodgkin's lymphoma (NHL) (comprising patients with refractory or relapsed disease and eight elderly, unfit patients with de novo disease) were treated with mitozantrone, chlorambucil and prednisolone on an out-patient basis.\", 'subject score': 1000, 'object score': 1000}, 'PMID:2300381': {'publication date': '1990', 'sentence': \"Combination chemotherapy with pirarubicin (THP), cyclophosphamide, vincristine, and prednisolone (VEP-THP therapy) in the treatment of non-Hodgkin's lymphoma.\", 'subject score': 1000, 'object score': 1000}, 'PMID:26370464': {'publication date': '2015 Sep 14', 'sentence': \"BACKGROUND: The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is an efficient treatment of non-Hodgkin's lymphoma (NHL).\", 'subject score': 1000, 'object score': 1000}, 'PMID:30241515': {'publication date': '2018 Sep 21', 'sentence': 'Cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), and prednisolone (CHOP) is the most common chemotherapy for non-Hodgkin lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:32884529': {'publication date': '2020 May-Aug', 'sentence': 'Sea-Blue Histiocytosis of Bone Marrow in a Patient with t(8;22) Acute Myeloid Leukemia.An 80-year-old Japanese male was treated with chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, and prednisolone, for non-Hodgkin lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:3293535': {'publication date': '1988 Jul', 'sentence': \"Thirty-seven previously untreated patients with advanced non-Hodgkin's lymphoma were treated with VEPA therapy.\", 'subject score': 888, 'object score': 923}, 'PMID:34213982': {'publication date': '2021 Jul 02', 'sentence': \"She had been treated with etoposide and prednisolone for non-Hodgkin's lymphoma.\", 'subject score': 1000, 'object score': 1000}, 'PMID:3753642': {'publication date': '1986 Jan', 'sentence': \"From these results we concluded that VEPA therapy is more effective for non-Hodgkin's lymphoma, especially large-cell type, than non-VEPA therapy.\", 'subject score': 719, 'object score': 1000}, 'PMID:3952518': {'publication date': '1986 Mar', 'sentence': \"Prednimustine v cyclophosphamide-vincristine-prednisolone in the treatment of non-Hodgkin's lymphoma with favorable histopathology: results of a national cancer care program in Sweden.\", 'subject score': 766, 'object score': 1000}, 'PMID:3975655': {'publication date': '1985 Mar', 'sentence': \"Vindesine, etoposide (VePesid), and prednisolone (VEP) have been evaluated as a second-line combination regimen in 20 patients with grade II non-Hodgkin's lymphoma (NHL) who relapsed during or after first-line intensive therapy.\", 'subject score': 1000, 'object score': 893}, 'PMID:403727': {'publication date': '1977 Mar', 'sentence': 'Peptichemio: A new oncolytic drug in combination with vincristine and prednisolone in the treatment of non-Hodgkin lymphomas.', 'subject score': 1000, 'object score': 988}, 'PMID:630211': {'publication date': '1978 Mar 04', 'sentence': \"Sixty-six untreated patients with advanced non-Hodgkin's lymphoma of favourable histological type were allocated alternately to initial treatment with cyclophosphamide, vincristine, and prednisolone or with chlorambucil.\", 'subject score': 1000, 'object score': 923}, 'PMID:6594975': {'publication date': '1984 Dec', 'sentence': \"[Clinical efficacy of a quadruple combination chemotherapy with ACNU, adriamycin, methotrexate, and prednisolone for patients with non-Hodgkin's lymphoma, who were refractory to VEPA (P) treatment].\", 'subject score': 1000, 'object score': 1000}, 'PMID:7014226': {'publication date': '1980 Nov', 'sentence': \"Intensive combination chemotherapy with vincristine, adriamycin and prednisolone (VAP) in the treatment of diffuse histology non-Hodgkin's lymphoma.\", 'subject score': 1000, 'object score': 875}}",
-    "p2": {
-      "start": {
-        "identity": 316905,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018908",
-          "name": "non-Hodgkin lymphoma",
-          "description": "Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3211\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3211\" NCI Thesaurus); Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.; Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.; A type of lymphoma characterized microscopically by the absence of multinucleated Reed-Sternberg cells. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "UMLS:C1622254",
-            "ORPHANET:547",
-            "MESH:D008228",
-            "UMLS:C0024305",
-            "MONDO:0018908",
-            "HP:0012539",
-            "SNOMEDCT:188675007",
-            "PDQ:CDR0000038957",
-            "NCIT:C3211",
-            "SNOMEDCT:1172592001",
-            "DOID:0060060",
-            "MEDDRA:10025311",
-            "MEDDRA:10029593",
-            "SNOMEDCT:128929007",
-            "MEDDRA:10029547",
-            "UMLS:C1622813"
-          ],
-          "id": "MONDO:0018908",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Non-Hodgkin Lymphoma",
-            "Lymphoma, Non-Hodgkin",
-            "Malignant lymphoma - small cleaved cell",
-            "non-Hodgkin lymphoma",
-            "Non-Hodgkin lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/non-hodgkin_lymphoma",
-            "http://www.cancer.gov/dictionary?cdrid=45148",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316905,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018908",
-              "name": "non-Hodgkin lymphoma",
-              "description": "Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3211\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3211\" NCI Thesaurus); Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.; Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.; A type of lymphoma characterized microscopically by the absence of multinucleated Reed-Sternberg cells. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "UMLS:C1622254",
-                "ORPHANET:547",
-                "MESH:D008228",
-                "UMLS:C0024305",
-                "MONDO:0018908",
-                "HP:0012539",
-                "SNOMEDCT:188675007",
-                "PDQ:CDR0000038957",
-                "NCIT:C3211",
-                "SNOMEDCT:1172592001",
-                "DOID:0060060",
-                "MEDDRA:10025311",
-                "MEDDRA:10029593",
-                "SNOMEDCT:128929007",
-                "MEDDRA:10029547",
-                "UMLS:C1622813"
-              ],
-              "id": "MONDO:0018908",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Non-Hodgkin Lymphoma",
-                "Lymphoma, Non-Hodgkin",
-                "Malignant lymphoma - small cleaved cell",
-                "non-Hodgkin lymphoma",
-                "Non-Hodgkin lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/non-hodgkin_lymphoma",
-                "http://www.cancer.gov/dictionary?cdrid=45148",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7821105,
-            "start": 568,
-            "end": 316905,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10674903': {'publication date': '2000 Jan', 'sentence': \"A regimen which incorporates cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) is the standard treatment for patients with non-Hodgkin's lymphoma (NHL), but it has not been effective in patients with aggressive NHL who are at high risk.\", 'subject score': 1000, 'object score': 1000}, 'PMID:11256023': {'publication date': '2001 Feb 23', 'sentence': '[Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma]].', 'subject score': 1000, 'object score': 840}, 'PMID:11368287': {'publication date': '2001', 'sentence': 'Substitution of bendamustine for cyclophosphamide in a standard first-line COP regimen (cyclophosphamide, vincristine and prednisolone) yielded similar response rates in patients with advanced low grade NHL.', 'subject score': 1000, 'object score': 840}, 'PMID:16247790': {'publication date': '2005 Dec 01', 'sentence': 'METHODS: Forty consecutive patients with untreated non-Hodgkin lymphoma who were scheduled to undergo standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) (mean age, 56 yrs; range, 24-70 yrs) were randomized with minimization methods to receive CHOP with or without 80 mg/day of valsartan.', 'subject score': 1000, 'object score': 923}, 'PMID:16533747': {'publication date': '2005 Dec', 'sentence': \"To facilitate more economical medical care, we carried out a prospective study of whether a THP-COP regimen (cyclophosphamide, pirarubicin, vincristine, and prednisolone) with low-dose granulocyte colony-stimulating factor (G-CSF) would effectively treat non-Hodgkin's lymphoma (NHL).\", 'subject score': 1000, 'object score': 1000}, 'PMID:18226581': {'publication date': '2008 Feb', 'sentence': 'BACKGROUND: Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is used to treat patients with non-Hodgkin lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:2298419': {'publication date': '1990', 'sentence': \"Thirty-six patients with non-Hodgkin's lymphoma (NHL) (comprising patients with refractory or relapsed disease and eight elderly, unfit patients with de novo disease) were treated with mitozantrone, chlorambucil and prednisolone on an out-patient basis.\", 'subject score': 1000, 'object score': 1000}, 'PMID:2300381': {'publication date': '1990', 'sentence': \"Combination chemotherapy with pirarubicin (THP), cyclophosphamide, vincristine, and prednisolone (VEP-THP therapy) in the treatment of non-Hodgkin's lymphoma.\", 'subject score': 1000, 'object score': 1000}, 'PMID:26370464': {'publication date': '2015 Sep 14', 'sentence': \"BACKGROUND: The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is an efficient treatment of non-Hodgkin's lymphoma (NHL).\", 'subject score': 1000, 'object score': 1000}, 'PMID:30241515': {'publication date': '2018 Sep 21', 'sentence': 'Cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), and prednisolone (CHOP) is the most common chemotherapy for non-Hodgkin lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:32884529': {'publication date': '2020 May-Aug', 'sentence': 'Sea-Blue Histiocytosis of Bone Marrow in a Patient with t(8;22) Acute Myeloid Leukemia.An 80-year-old Japanese male was treated with chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, and prednisolone, for non-Hodgkin lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:3293535': {'publication date': '1988 Jul', 'sentence': \"Thirty-seven previously untreated patients with advanced non-Hodgkin's lymphoma were treated with VEPA therapy.\", 'subject score': 888, 'object score': 923}, 'PMID:34213982': {'publication date': '2021 Jul 02', 'sentence': \"She had been treated with etoposide and prednisolone for non-Hodgkin's lymphoma.\", 'subject score': 1000, 'object score': 1000}, 'PMID:3753642': {'publication date': '1986 Jan', 'sentence': \"From these results we concluded that VEPA therapy is more effective for non-Hodgkin's lymphoma, especially large-cell type, than non-VEPA therapy.\", 'subject score': 719, 'object score': 1000}, 'PMID:3952518': {'publication date': '1986 Mar', 'sentence': \"Prednimustine v cyclophosphamide-vincristine-prednisolone in the treatment of non-Hodgkin's lymphoma with favorable histopathology: results of a national cancer care program in Sweden.\", 'subject score': 766, 'object score': 1000}, 'PMID:3975655': {'publication date': '1985 Mar', 'sentence': \"Vindesine, etoposide (VePesid), and prednisolone (VEP) have been evaluated as a second-line combination regimen in 20 patients with grade II non-Hodgkin's lymphoma (NHL) who relapsed during or after first-line intensive therapy.\", 'subject score': 1000, 'object score': 893}, 'PMID:403727': {'publication date': '1977 Mar', 'sentence': 'Peptichemio: A new oncolytic drug in combination with vincristine and prednisolone in the treatment of non-Hodgkin lymphomas.', 'subject score': 1000, 'object score': 988}, 'PMID:630211': {'publication date': '1978 Mar 04', 'sentence': \"Sixty-six untreated patients with advanced non-Hodgkin's lymphoma of favourable histological type were allocated alternately to initial treatment with cyclophosphamide, vincristine, and prednisolone or with chlorambucil.\", 'subject score': 1000, 'object score': 923}, 'PMID:6594975': {'publication date': '1984 Dec', 'sentence': \"[Clinical efficacy of a quadruple combination chemotherapy with ACNU, adriamycin, methotrexate, and prednisolone for patients with non-Hodgkin's lymphoma, who were refractory to VEPA (P) treatment].\", 'subject score': 1000, 'object score': 1000}, 'PMID:7014226': {'publication date': '1980 Nov', 'sentence': \"Intensive combination chemotherapy with vincristine, adriamycin and prednisolone (VAP) in the treatment of diffuse histology non-Hodgkin's lymphoma.\", 'subject score': 1000, 'object score': 875}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0024305---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7990669",
-              "object": "MONDO:0018908",
-              "publications": [
-                "PMID:10674903",
-                "PMID:11256023",
-                "PMID:11368287",
-                "PMID:16247790",
-                "PMID:16533747",
-                "PMID:18226581",
-                "PMID:2298419",
-                "PMID:2300381",
-                "PMID:26370464",
-                "PMID:30241515",
-                "PMID:32884529",
-                "PMID:3293535",
-                "PMID:34213982",
-                "PMID:3753642",
-                "PMID:3952518",
-                "PMID:3975655",
-                "PMID:403727",
-                "PMID:630211",
-                "PMID:6594975",
-                "PMID:7014226"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:15082482': {'publication date': '2004 May', 'sentence': 'EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15824513': {'publication date': '2005', 'sentence': 'CONCLUSIONS: MMF with prednisolone was effective for remission induction in severe lupus nephritis and was well tolerated.', 'subject score': 1000, 'object score': 901}, 'PMID:24175257': {'publication date': '2012 Dec 06', 'sentence': 'Recently, a multidrug regimen of prednisolone (PDN), Tac, and mycophenolate mofetile (MMF) has been found effective and relatively safe in adult lupus nephritis.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 309447,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005556",
-          "name": "lupus nephritis",
-          "description": "Glomerulonephritis in the context of systemic lupus erythematosus.; Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).; Lupus nephritis is a type of glomerulonephritis that constitutes one of the most severe organ manifestations of systemic lupus erythematosus. Lupus nephritis is subclassified in six distinct classes, that represent different manifestations and severities of renal involvement and guide the therapeutic management. [ORCID:0000-0002-2234-4248, PMID:31974366]",
-          "equivalent_curies": [
-            "MEDDRA:10025140",
-            "HP:0033726",
-            "MEDDRA:10029141",
-            "DOID:0080162",
-            "NCIT:C34789",
-            "UMLS:C0024143",
-            "MESH:D008181",
-            "MEDDRA:10029142",
-            "MONDO:0005556",
-            "SNOMEDCT:68815009",
-            "MEDDRA:10040970",
-            "EFO:0005761"
-          ],
-          "id": "MONDO:0005556",
-          "category": "biolink:Disease",
-          "all_names": [
-            "lupus nephritis",
-            "Lupus nephritis",
-            "Lupus Nephritis",
-            "Lupus Glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000481.htm",
-            "PMID:31974366",
-            "https://orcid.org/0000-0002-2234-4248",
-            "https://en.wikipedia.org/wiki/lupus_nephritis#cite_note-1"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 309447,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005556",
-              "name": "lupus nephritis",
-              "description": "Glomerulonephritis in the context of systemic lupus erythematosus.; Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).; Lupus nephritis is a type of glomerulonephritis that constitutes one of the most severe organ manifestations of systemic lupus erythematosus. Lupus nephritis is subclassified in six distinct classes, that represent different manifestations and severities of renal involvement and guide the therapeutic management. [ORCID:0000-0002-2234-4248, PMID:31974366]",
-              "equivalent_curies": [
-                "MEDDRA:10025140",
-                "HP:0033726",
-                "MEDDRA:10029141",
-                "DOID:0080162",
-                "NCIT:C34789",
-                "UMLS:C0024143",
-                "MESH:D008181",
-                "MEDDRA:10029142",
-                "MONDO:0005556",
-                "SNOMEDCT:68815009",
-                "MEDDRA:10040970",
-                "EFO:0005761"
-              ],
-              "id": "MONDO:0005556",
-              "category": "biolink:Disease",
-              "all_names": [
-                "lupus nephritis",
-                "Lupus nephritis",
-                "Lupus Nephritis",
-                "Lupus Glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000481.htm",
-                "PMID:31974366",
-                "https://orcid.org/0000-0002-2234-4248",
-                "https://en.wikipedia.org/wiki/lupus_nephritis#cite_note-1"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10903975,
-            "start": 568,
-            "end": 309447,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15082482': {'publication date': '2004 May', 'sentence': 'EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15824513': {'publication date': '2005', 'sentence': 'CONCLUSIONS: MMF with prednisolone was effective for remission induction in severe lupus nephritis and was well tolerated.', 'subject score': 1000, 'object score': 901}, 'PMID:24175257': {'publication date': '2012 Dec 06', 'sentence': 'Recently, a multidrug regimen of prednisolone (PDN), Tac, and mycophenolate mofetile (MMF) has been found effective and relatively safe in adult lupus nephritis.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0024143---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11142916",
-              "object": "MONDO:0005556",
-              "publications": [
-                "PMID:15082482",
-                "PMID:15824513",
-                "PMID:24175257"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11036121': {'publication date': '2000 Oct 19', 'sentence': 'CONCLUSIONS: For the treatment of diffuse proliferative lupus nephritis, the combination of mycophenolate mofetil and prednisolone is as effective as a regimen of cyclophosphamide and prednisolone followed by azathioprine and prednisolone but is less toxic.', 'subject score': 1000, 'object score': 861}, 'PMID:1301975': {'publication date': '1992 May', 'sentence': 'A secondary hyperlipidemic state, which probably related to lupus nephritis (proteinuria) and/or prednisolone treatment, increased apo H levels in SLE patients.', 'subject score': 888, 'object score': 1000}, 'PMID:15864912': {'publication date': '2005', 'sentence': 'This prospective cohort study examined the long-term renal function and disease relapse in adults with biopsy-proven DPLN, significant proteinuria, and hypoalbuminemia, who had been treated with sequential immunosuppression comprising prednisolone and oral cyclophosphamide as induction followed by low-dose prednisolone and azathioprine as maintenance.', 'subject score': 791, 'object score': 781}, 'PMID:16047642': {'publication date': '2005 Jul', 'sentence': 'METHOD: Long-term maintenance therapy with MZR and PSL was evaluated in ten patients with biopsy-proven proliferative lupus nephritis.', 'subject score': 1000, 'object score': 794}, 'PMID:16564783': {'publication date': '2006 Apr', 'sentence': 'METHODS: Patients with biopsy-proven DPLN treated with prednisolone and CYC were identified.', 'subject score': 1000, 'object score': 781}, 'PMID:16856445': {'publication date': '2005 Nov', 'sentence': 'Within the group of class-IV LN, the 5-year survival in the patients treated with intravenous CYC was significantly better than those receiving prednisolone with or without azathioprine.', 'subject score': 872, 'object score': 888}, 'PMID:1770640': {'publication date': '1991 Aug', 'sentence': 'After treatment of lupus nephritis with prednisolone, levels of plasma renin activity and plasma aldosterone concentration were elevated.', 'subject score': 1000, 'object score': 1000}, 'PMID:19004041': {'publication date': '2009 Jan', 'sentence': 'METHODS: Our retrospective single-center study compared the major healthcare costs during the first 24 months of treatment incurred by immunosuppressive medications, hospitalization, and complications in patients with severe lupus nephritis who had been treated with prednisolone and either MMF or sequential cyclophosphamide induction followed by azathioprine maintenance (CTX-AZA).', 'subject score': 1000, 'object score': 901}, 'PMID:19885661': {'publication date': '2011 Jul', 'sentence': 'Recently, we treated a patient with pulmonary and psoas muscle nocardiosis in a woman taking prednisolone for lupus nephritis; the isolated organism was Nocardia farcinica identified by polymerase chain reaction-restriction fragment length polymorphism testing.', 'subject score': 802, 'object score': 1000}, 'PMID:22590961': {'publication date': '2012', 'sentence': 'METHODS: Children with severe focal, and diffuse proliferative lupus nephritis were treated with prednisolone (initial dose; 1 mg/kg/day, maximum dose; 60 mg/day) and MMF (initial dose; 300 mg/m2/day, increased to 1 g/m2/day) for 24 months after high-dose intravenous methylprednisolone (30 mg/kg/day).', 'subject score': 1000, 'object score': 861}, 'PMID:24175257': {'publication date': '2012 Dec 06', 'sentence': 'We propose as an alternative to IVCY, a multidrug therapy with mizoribine, which acts very similarly to MMF, and Tac, which has a different mode of action, combined with PDN for pediatric-onset lupus nephritis.', 'subject score': 1000, 'object score': 861}, 'PMID:25959850': {'publication date': '2015 Nov', 'sentence': 'AIMS: The aim was to examine relationships between total and unbound mycophenolic acid (MPA) and prednisolone exposure and clinical outcomes in patients with lupus nephritis.', 'subject score': 694, 'object score': 1000}, 'PMID:34508471': {'publication date': '2021 Aug 12', 'sentence': 'Remission after Six Months of Induction Immunosuppressive Treatment with Mycofenolate Mofetil and Prednisolone in Patients with Lupus Nephritis: A Descriptive Cross-sectional Study.', 'subject score': 1000, 'object score': 1000}, 'PMID:34894070': {'publication date': '2021 Dec 11', 'sentence': 'OBJECTIVES: This study aimed to compare the efficacy of low-dose prednisolone with conventional high-dose regimen in proliferative lupus nephritis (LN) for remission.', 'subject score': 901, 'object score': 901}, 'PMID:4194493': {'publication date': '1970 May', 'sentence': 'Prednisolone treatment of lupus nephritis: Effect of high doses on course of disease, renal function, histological lesions, and immunological reactions.', 'subject score': 888, 'object score': 1000}, 'PMID:6727751': {'publication date': '1984 Jun 23', 'sentence': 'Despite overrepresentation of the more severe forms of lupus nephritis in a nephrology-unit population, there was a satisfactory outcome from therapy with either prednisolone alone or with a prenisolone /azathioprine combination.', 'subject score': 861, 'object score': 1000}, 'PMID:6971722': {'publication date': '1980 Nov', 'sentence': 'The effects of long-term treatment with azathioprine and prednisolone on T- and B-lymphocytes were studied in 52 patients with lupus nephritis (LN) and chronic glomerulonephritis (GN).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 309447,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005556",
-          "name": "lupus nephritis",
-          "description": "Glomerulonephritis in the context of systemic lupus erythematosus.; Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).; Lupus nephritis is a type of glomerulonephritis that constitutes one of the most severe organ manifestations of systemic lupus erythematosus. Lupus nephritis is subclassified in six distinct classes, that represent different manifestations and severities of renal involvement and guide the therapeutic management. [ORCID:0000-0002-2234-4248, PMID:31974366]",
-          "equivalent_curies": [
-            "MEDDRA:10025140",
-            "HP:0033726",
-            "MEDDRA:10029141",
-            "DOID:0080162",
-            "NCIT:C34789",
-            "UMLS:C0024143",
-            "MESH:D008181",
-            "MEDDRA:10029142",
-            "MONDO:0005556",
-            "SNOMEDCT:68815009",
-            "MEDDRA:10040970",
-            "EFO:0005761"
-          ],
-          "id": "MONDO:0005556",
-          "category": "biolink:Disease",
-          "all_names": [
-            "lupus nephritis",
-            "Lupus nephritis",
-            "Lupus Nephritis",
-            "Lupus Glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000481.htm",
-            "PMID:31974366",
-            "https://orcid.org/0000-0002-2234-4248",
-            "https://en.wikipedia.org/wiki/lupus_nephritis#cite_note-1"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 309447,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005556",
-              "name": "lupus nephritis",
-              "description": "Glomerulonephritis in the context of systemic lupus erythematosus.; Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).; Lupus nephritis is a type of glomerulonephritis that constitutes one of the most severe organ manifestations of systemic lupus erythematosus. Lupus nephritis is subclassified in six distinct classes, that represent different manifestations and severities of renal involvement and guide the therapeutic management. [ORCID:0000-0002-2234-4248, PMID:31974366]",
-              "equivalent_curies": [
-                "MEDDRA:10025140",
-                "HP:0033726",
-                "MEDDRA:10029141",
-                "DOID:0080162",
-                "NCIT:C34789",
-                "UMLS:C0024143",
-                "MESH:D008181",
-                "MEDDRA:10029142",
-                "MONDO:0005556",
-                "SNOMEDCT:68815009",
-                "MEDDRA:10040970",
-                "EFO:0005761"
-              ],
-              "id": "MONDO:0005556",
-              "category": "biolink:Disease",
-              "all_names": [
-                "lupus nephritis",
-                "Lupus nephritis",
-                "Lupus Nephritis",
-                "Lupus Glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000481.htm",
-                "PMID:31974366",
-                "https://orcid.org/0000-0002-2234-4248",
-                "https://en.wikipedia.org/wiki/lupus_nephritis#cite_note-1"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8318750,
-            "start": 568,
-            "end": 309447,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11036121': {'publication date': '2000 Oct 19', 'sentence': 'CONCLUSIONS: For the treatment of diffuse proliferative lupus nephritis, the combination of mycophenolate mofetil and prednisolone is as effective as a regimen of cyclophosphamide and prednisolone followed by azathioprine and prednisolone but is less toxic.', 'subject score': 1000, 'object score': 861}, 'PMID:1301975': {'publication date': '1992 May', 'sentence': 'A secondary hyperlipidemic state, which probably related to lupus nephritis (proteinuria) and/or prednisolone treatment, increased apo H levels in SLE patients.', 'subject score': 888, 'object score': 1000}, 'PMID:15864912': {'publication date': '2005', 'sentence': 'This prospective cohort study examined the long-term renal function and disease relapse in adults with biopsy-proven DPLN, significant proteinuria, and hypoalbuminemia, who had been treated with sequential immunosuppression comprising prednisolone and oral cyclophosphamide as induction followed by low-dose prednisolone and azathioprine as maintenance.', 'subject score': 791, 'object score': 781}, 'PMID:16047642': {'publication date': '2005 Jul', 'sentence': 'METHOD: Long-term maintenance therapy with MZR and PSL was evaluated in ten patients with biopsy-proven proliferative lupus nephritis.', 'subject score': 1000, 'object score': 794}, 'PMID:16564783': {'publication date': '2006 Apr', 'sentence': 'METHODS: Patients with biopsy-proven DPLN treated with prednisolone and CYC were identified.', 'subject score': 1000, 'object score': 781}, 'PMID:16856445': {'publication date': '2005 Nov', 'sentence': 'Within the group of class-IV LN, the 5-year survival in the patients treated with intravenous CYC was significantly better than those receiving prednisolone with or without azathioprine.', 'subject score': 872, 'object score': 888}, 'PMID:1770640': {'publication date': '1991 Aug', 'sentence': 'After treatment of lupus nephritis with prednisolone, levels of plasma renin activity and plasma aldosterone concentration were elevated.', 'subject score': 1000, 'object score': 1000}, 'PMID:19004041': {'publication date': '2009 Jan', 'sentence': 'METHODS: Our retrospective single-center study compared the major healthcare costs during the first 24 months of treatment incurred by immunosuppressive medications, hospitalization, and complications in patients with severe lupus nephritis who had been treated with prednisolone and either MMF or sequential cyclophosphamide induction followed by azathioprine maintenance (CTX-AZA).', 'subject score': 1000, 'object score': 901}, 'PMID:19885661': {'publication date': '2011 Jul', 'sentence': 'Recently, we treated a patient with pulmonary and psoas muscle nocardiosis in a woman taking prednisolone for lupus nephritis; the isolated organism was Nocardia farcinica identified by polymerase chain reaction-restriction fragment length polymorphism testing.', 'subject score': 802, 'object score': 1000}, 'PMID:22590961': {'publication date': '2012', 'sentence': 'METHODS: Children with severe focal, and diffuse proliferative lupus nephritis were treated with prednisolone (initial dose; 1 mg/kg/day, maximum dose; 60 mg/day) and MMF (initial dose; 300 mg/m2/day, increased to 1 g/m2/day) for 24 months after high-dose intravenous methylprednisolone (30 mg/kg/day).', 'subject score': 1000, 'object score': 861}, 'PMID:24175257': {'publication date': '2012 Dec 06', 'sentence': 'We propose as an alternative to IVCY, a multidrug therapy with mizoribine, which acts very similarly to MMF, and Tac, which has a different mode of action, combined with PDN for pediatric-onset lupus nephritis.', 'subject score': 1000, 'object score': 861}, 'PMID:25959850': {'publication date': '2015 Nov', 'sentence': 'AIMS: The aim was to examine relationships between total and unbound mycophenolic acid (MPA) and prednisolone exposure and clinical outcomes in patients with lupus nephritis.', 'subject score': 694, 'object score': 1000}, 'PMID:34508471': {'publication date': '2021 Aug 12', 'sentence': 'Remission after Six Months of Induction Immunosuppressive Treatment with Mycofenolate Mofetil and Prednisolone in Patients with Lupus Nephritis: A Descriptive Cross-sectional Study.', 'subject score': 1000, 'object score': 1000}, 'PMID:34894070': {'publication date': '2021 Dec 11', 'sentence': 'OBJECTIVES: This study aimed to compare the efficacy of low-dose prednisolone with conventional high-dose regimen in proliferative lupus nephritis (LN) for remission.', 'subject score': 901, 'object score': 901}, 'PMID:4194493': {'publication date': '1970 May', 'sentence': 'Prednisolone treatment of lupus nephritis: Effect of high doses on course of disease, renal function, histological lesions, and immunological reactions.', 'subject score': 888, 'object score': 1000}, 'PMID:6727751': {'publication date': '1984 Jun 23', 'sentence': 'Despite overrepresentation of the more severe forms of lupus nephritis in a nephrology-unit population, there was a satisfactory outcome from therapy with either prednisolone alone or with a prenisolone /azathioprine combination.', 'subject score': 861, 'object score': 1000}, 'PMID:6971722': {'publication date': '1980 Nov', 'sentence': 'The effects of long-term treatment with azathioprine and prednisolone on T- and B-lymphocytes were studied in 52 patients with lupus nephritis (LN) and chronic glomerulonephritis (GN).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0024143---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8499057",
-              "object": "MONDO:0005556",
-              "publications": [
-                "PMID:11036121",
-                "PMID:1301975",
-                "PMID:15864912",
-                "PMID:16047642",
-                "PMID:16564783",
-                "PMID:16856445",
-                "PMID:1770640",
-                "PMID:19004041",
-                "PMID:19885661",
-                "PMID:22590961",
-                "PMID:24175257",
-                "PMID:25959850",
-                "PMID:34508471",
-                "PMID:34894070",
-                "PMID:4194493",
-                "PMID:6727751",
-                "PMID:6971722"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:14963200': {'publication date': '2004 Mar', 'sentence': \"OBJECTIVE: To investigate the safety and efficacy of leflunomide plus low-dose prednisolone for the maintenance of remission in Wegener's granulomatosis (WG).\", 'subject score': 901, 'object score': 1000}, 'PMID:16374738': {'publication date': '2006 Jan 05', 'sentence': 'TREATMENT AND COURSE: To achieve remission bolus therapy with cyclophosphamide and prednisolone was initiated and planned to be the first of three pulses But when the patient developed epididymitis and a neuropathy associated with Wegener\"s granulomatosis, the dose was increased and cyclophosphamide was given for a longer period.', 'subject score': 1000, 'object score': 890}}",
-    "p2": {
-      "start": {
-        "identity": 531220,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0012105",
-          "name": "granulomatosis with polyangiitis",
-          "description": "A rare, autoimmune, systemic medium and small size vasculitis. It is characterized by the formation of necrotizing granulomas in the respiratory tract, necrotizing angiitis, and glomerulonephritis.; A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10072579",
-            "DOID:12132",
-            "ICD10:M31.3",
-            "MONDO:0012105",
-            "SNOMEDCT:195353004",
-            "UMLS:C3495801",
-            "OMIM:608710",
-            "UMLS:C4050407",
-            "MEDDRA:10047889",
-            "NCIT:C3444",
-            "EFO:0005297",
-            "MESH:D014890",
-            "MEDDRA:10047888",
-            "MEDDRA:10072580",
-            "ORPHANET:900",
-            "ICD9:446.4",
-            "NCIT:C123111"
-          ],
-          "id": "MONDO:0012105",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pauci-immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-            "Granulomatosis with Polyangiitis",
-            "granulomatosis with polyangiitis",
-            "Pauci-Immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-            "Granulomatosis with polyangiitis related phenotypic feature",
-            "Granulomatosis with polyangiitis",
-            "Wegener's granulomatosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/granulomatosis_with_polyangiitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 531220,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0012105",
-              "name": "granulomatosis with polyangiitis",
-              "description": "A rare, autoimmune, systemic medium and small size vasculitis. It is characterized by the formation of necrotizing granulomas in the respiratory tract, necrotizing angiitis, and glomerulonephritis.; A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10072579",
-                "DOID:12132",
-                "ICD10:M31.3",
-                "MONDO:0012105",
-                "SNOMEDCT:195353004",
-                "UMLS:C3495801",
-                "OMIM:608710",
-                "UMLS:C4050407",
-                "MEDDRA:10047889",
-                "NCIT:C3444",
-                "EFO:0005297",
-                "MESH:D014890",
-                "MEDDRA:10047888",
-                "MEDDRA:10072580",
-                "ORPHANET:900",
-                "ICD9:446.4",
-                "NCIT:C123111"
-              ],
-              "id": "MONDO:0012105",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pauci-immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-                "Granulomatosis with Polyangiitis",
-                "granulomatosis with polyangiitis",
-                "Pauci-Immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-                "Granulomatosis with polyangiitis related phenotypic feature",
-                "Granulomatosis with polyangiitis",
-                "Wegener's granulomatosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/granulomatosis_with_polyangiitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10800774,
-            "start": 568,
-            "end": 531220,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14963200': {'publication date': '2004 Mar', 'sentence': \"OBJECTIVE: To investigate the safety and efficacy of leflunomide plus low-dose prednisolone for the maintenance of remission in Wegener's granulomatosis (WG).\", 'subject score': 901, 'object score': 1000}, 'PMID:16374738': {'publication date': '2006 Jan 05', 'sentence': 'TREATMENT AND COURSE: To achieve remission bolus therapy with cyclophosphamide and prednisolone was initiated and planned to be the first of three pulses But when the patient developed epididymitis and a neuropathy associated with Wegener\"s granulomatosis, the dose was increased and cyclophosphamide was given for a longer period.', 'subject score': 1000, 'object score': 890}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C3495801---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11037266",
-              "object": "MONDO:0012105",
-              "publications": [
-                "PMID:14963200",
-                "PMID:16374738"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1064290': {'publication date': '1976', 'sentence': \"Two patients with Wegener's granulomatosis have been treated with chlorambucil and prednisolone continuosly for 3 and 5 years, respectively.\", 'subject score': 694, 'object score': 1000}, 'PMID:17642224': {'publication date': '2007 Jul', 'sentence': \"Finally we performed open lung biopsy of left lung, and Wegener's granulomatosis was diagnosed at last He improved immediately after treatment with prednisolone, cyclophosphamide and sulfamethoxazole-trimethoprim.\", 'subject score': 1000, 'object score': 1000}, 'PMID:1767121': {'publication date': '1991', 'sentence': \"Five cases of Wegener's granulomatosis treated with cyclophosphamide (CPM) and prednisolone are reported.\", 'subject score': 1000, 'object score': 1000}, 'PMID:20156769': {'publication date': '2009 Dec 07', 'sentence': \"GOAL AND METHODS: Prospective, randomized, placebo-controlled study of the efficacy of co-trimoxazole given 960 mg thrice weekly for 18 months in preventing relapses in patients with Wegener's granulomatosis (WG) in remission, after treatment with cyclophosphamide and prednisolone was conducted.\", 'subject score': 1000, 'object score': 1000}, 'PMID:20577017': {'publication date': '2011 Jan', 'sentence': 'METHODS: In a single-centre study from a tertiary referral centre, 32 patients with ANCA-positive WG were treated with standard immunosuppressive therapy, prednisolone and cyclophosphamide (CYC).', 'subject score': 1000, 'object score': 888}, 'PMID:5032438': {'publication date': '1972 Jan-Feb', 'sentence': \"Combined chlorambucil and prednisolone treatment of five patients with Wegener's granulomatosis.\", 'subject score': 888, 'object score': 1000}, 'PMID:7925917': {'publication date': '1994 Jul', 'sentence': 'Eight years previously, a first episode of WG involving the upper airways and kidneys, but not the lungs, had been successfully treated with prednisolone and cyclophosphamide, which could be stopped after 2 yrs.', 'subject score': 1000, 'object score': 1000}, 'PMID:7962978': {'publication date': '1994 Sep', 'sentence': \"Wegener's granulomatosis successfully treated with prednisolone and potassium iodide.\", 'subject score': 1000, 'object score': 1000}, 'PMID:8637536': {'publication date': '1996 Jul 04', 'sentence': \"METHODS: We conducted a prospective, randomized, placebo-controlled study of the efficacy of co-trimoxazole (800 mg of sulfamethoxazole and 160 mg of trimethoprim) given twice daily for 24 months in preventing relapses in patients with Wegener's granulomatosis in remission during or after treatment with cyclophosphamide and prednisolone.\", 'subject score': 1000, 'object score': 1000}, 'PMID:9566676': {'publication date': '1998 Mar', 'sentence': \"We describe a 22-yr-old woman who recovered successfully from her initial episode of Wegener's granulomatosis with a standard course of treatment with prednisolone and cyclophosphamide.\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 531220,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0012105",
-          "name": "granulomatosis with polyangiitis",
-          "description": "A rare, autoimmune, systemic medium and small size vasculitis. It is characterized by the formation of necrotizing granulomas in the respiratory tract, necrotizing angiitis, and glomerulonephritis.; A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10072579",
-            "DOID:12132",
-            "ICD10:M31.3",
-            "MONDO:0012105",
-            "SNOMEDCT:195353004",
-            "UMLS:C3495801",
-            "OMIM:608710",
-            "UMLS:C4050407",
-            "MEDDRA:10047889",
-            "NCIT:C3444",
-            "EFO:0005297",
-            "MESH:D014890",
-            "MEDDRA:10047888",
-            "MEDDRA:10072580",
-            "ORPHANET:900",
-            "ICD9:446.4",
-            "NCIT:C123111"
-          ],
-          "id": "MONDO:0012105",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pauci-immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-            "Granulomatosis with Polyangiitis",
-            "granulomatosis with polyangiitis",
-            "Pauci-Immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-            "Granulomatosis with polyangiitis related phenotypic feature",
-            "Granulomatosis with polyangiitis",
-            "Wegener's granulomatosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/granulomatosis_with_polyangiitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 531220,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0012105",
-              "name": "granulomatosis with polyangiitis",
-              "description": "A rare, autoimmune, systemic medium and small size vasculitis. It is characterized by the formation of necrotizing granulomas in the respiratory tract, necrotizing angiitis, and glomerulonephritis.; A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10072579",
-                "DOID:12132",
-                "ICD10:M31.3",
-                "MONDO:0012105",
-                "SNOMEDCT:195353004",
-                "UMLS:C3495801",
-                "OMIM:608710",
-                "UMLS:C4050407",
-                "MEDDRA:10047889",
-                "NCIT:C3444",
-                "EFO:0005297",
-                "MESH:D014890",
-                "MEDDRA:10047888",
-                "MEDDRA:10072580",
-                "ORPHANET:900",
-                "ICD9:446.4",
-                "NCIT:C123111"
-              ],
-              "id": "MONDO:0012105",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pauci-immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-                "Granulomatosis with Polyangiitis",
-                "granulomatosis with polyangiitis",
-                "Pauci-Immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-                "Granulomatosis with polyangiitis related phenotypic feature",
-                "Granulomatosis with polyangiitis",
-                "Wegener's granulomatosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/granulomatosis_with_polyangiitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7776002,
-            "start": 568,
-            "end": 531220,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1064290': {'publication date': '1976', 'sentence': \"Two patients with Wegener's granulomatosis have been treated with chlorambucil and prednisolone continuosly for 3 and 5 years, respectively.\", 'subject score': 694, 'object score': 1000}, 'PMID:17642224': {'publication date': '2007 Jul', 'sentence': \"Finally we performed open lung biopsy of left lung, and Wegener's granulomatosis was diagnosed at last He improved immediately after treatment with prednisolone, cyclophosphamide and sulfamethoxazole-trimethoprim.\", 'subject score': 1000, 'object score': 1000}, 'PMID:1767121': {'publication date': '1991', 'sentence': \"Five cases of Wegener's granulomatosis treated with cyclophosphamide (CPM) and prednisolone are reported.\", 'subject score': 1000, 'object score': 1000}, 'PMID:20156769': {'publication date': '2009 Dec 07', 'sentence': \"GOAL AND METHODS: Prospective, randomized, placebo-controlled study of the efficacy of co-trimoxazole given 960 mg thrice weekly for 18 months in preventing relapses in patients with Wegener's granulomatosis (WG) in remission, after treatment with cyclophosphamide and prednisolone was conducted.\", 'subject score': 1000, 'object score': 1000}, 'PMID:20577017': {'publication date': '2011 Jan', 'sentence': 'METHODS: In a single-centre study from a tertiary referral centre, 32 patients with ANCA-positive WG were treated with standard immunosuppressive therapy, prednisolone and cyclophosphamide (CYC).', 'subject score': 1000, 'object score': 888}, 'PMID:5032438': {'publication date': '1972 Jan-Feb', 'sentence': \"Combined chlorambucil and prednisolone treatment of five patients with Wegener's granulomatosis.\", 'subject score': 888, 'object score': 1000}, 'PMID:7925917': {'publication date': '1994 Jul', 'sentence': 'Eight years previously, a first episode of WG involving the upper airways and kidneys, but not the lungs, had been successfully treated with prednisolone and cyclophosphamide, which could be stopped after 2 yrs.', 'subject score': 1000, 'object score': 1000}, 'PMID:7962978': {'publication date': '1994 Sep', 'sentence': \"Wegener's granulomatosis successfully treated with prednisolone and potassium iodide.\", 'subject score': 1000, 'object score': 1000}, 'PMID:8637536': {'publication date': '1996 Jul 04', 'sentence': \"METHODS: We conducted a prospective, randomized, placebo-controlled study of the efficacy of co-trimoxazole (800 mg of sulfamethoxazole and 160 mg of trimethoprim) given twice daily for 24 months in preventing relapses in patients with Wegener's granulomatosis in remission during or after treatment with cyclophosphamide and prednisolone.\", 'subject score': 1000, 'object score': 1000}, 'PMID:9566676': {'publication date': '1998 Mar', 'sentence': \"We describe a 22-yr-old woman who recovered successfully from her initial episode of Wegener's granulomatosis with a standard course of treatment with prednisolone and cyclophosphamide.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C3495801---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7941298",
-              "object": "MONDO:0012105",
-              "publications": [
-                "PMID:1064290",
-                "PMID:17642224",
-                "PMID:1767121",
-                "PMID:20156769",
-                "PMID:20577017",
-                "PMID:5032438",
-                "PMID:7925917",
-                "PMID:7962978",
-                "PMID:8637536",
-                "PMID:9566676"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:22405251': {'publication date': '2012 Apr 28', 'sentence': 'Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.', 'subject score': 851, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 531222,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0012727",
-          "name": "mucocutaneous lymph node syndrome",
-          "description": "A vasculitis characterized by inflammation of the arteries, particularly the coronary arteries. The vasculitis may lead to aneurysm formation and possibly, heart attacks. It affects young children who usually present with persistent high fever, redness of the mucous membranes of the mouth, redness of the palms and soles, skin rashes, lymphadenitis, and joint pain and swelling.; An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:13378",
-            "ICD9:446.1",
-            "MEDDRA:10000747",
-            "SNOMEDCT:75053002",
-            "MESH:C537014",
-            "UMLS:C0026691",
-            "UMLS:C2936917",
-            "EFO:0004246",
-            "MESH:D009080",
-            "MEDDRA:10023320",
-            "ICD10:M30.3",
-            "NCIT:C34825",
-            "MONDO:0012727",
-            "MEDDRA:10028083",
-            "OMIM:611775",
-            "ORPHANET:2331"
-          ],
-          "id": "MONDO:0012727",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infantile polyarteritis",
-            "Kawasaki disease",
-            "Kawasaki disease related phenotypic feature",
-            "Kawasaki Disease",
-            "mucocutaneous lymph node syndrome",
-            "Mucocutaneous Lymph Node Syndrome",
-            "Acute febrile mucocutaneous lymph node syndrome [MCLS]"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/kawasaki_disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 531222,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0012727",
-              "name": "mucocutaneous lymph node syndrome",
-              "description": "A vasculitis characterized by inflammation of the arteries, particularly the coronary arteries. The vasculitis may lead to aneurysm formation and possibly, heart attacks. It affects young children who usually present with persistent high fever, redness of the mucous membranes of the mouth, redness of the palms and soles, skin rashes, lymphadenitis, and joint pain and swelling.; An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:13378",
-                "ICD9:446.1",
-                "MEDDRA:10000747",
-                "SNOMEDCT:75053002",
-                "MESH:C537014",
-                "UMLS:C0026691",
-                "UMLS:C2936917",
-                "EFO:0004246",
-                "MESH:D009080",
-                "MEDDRA:10023320",
-                "ICD10:M30.3",
-                "NCIT:C34825",
-                "MONDO:0012727",
-                "MEDDRA:10028083",
-                "OMIM:611775",
-                "ORPHANET:2331"
-              ],
-              "id": "MONDO:0012727",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infantile polyarteritis",
-                "Kawasaki disease",
-                "Kawasaki disease related phenotypic feature",
-                "Kawasaki Disease",
-                "mucocutaneous lymph node syndrome",
-                "Mucocutaneous Lymph Node Syndrome",
-                "Acute febrile mucocutaneous lymph node syndrome [MCLS]"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/kawasaki_disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15839343,
-            "start": 568,
-            "end": 531222,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22405251': {'publication date': '2012 Apr 28', 'sentence': 'Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.', 'subject score': 851, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0026691---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16169223",
-              "object": "MONDO:0012727",
-              "publications": [
-                "PMID:22405251"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15965549': {'publication date': '2005 Jun', 'sentence': 'Six patients with Kawasaki disease (KD) were treated with prednisolone (1 to 2 mg/kg/day) for 3 days (from days 10 to 12 after the onset of the illness) after apparently unsuccessful treatment with intravenous immunoglobulin (IVIG, 2 g/kg/dose and additional 1 g/kg/dose).', 'subject score': 1000, 'object score': 1000}, 'PMID:19504733': {'publication date': '2009 Jun', 'sentence': 'BACKGROUND: We reported previously that intravenous immunoglobulin (IVIG) plus prednisolone for initial therapy for Kawasaki disease (KD) prevented coronary artery abnormalities (CAA) more effectively than IVIG alone.', 'subject score': 861, 'object score': 1000}, 'PMID:25342092': {'publication date': '2015', 'sentence': 'We conclude that adrenal suppression can occur in a high proportion of children with KD treated with IVIG plus prednisolone, despite rather short duration and relatively small amounts of administered glucocorticoids.', 'subject score': 861, 'object score': 1000}, 'PMID:25518413': {'publication date': '2014 Sep', 'sentence': 'The present paper reviews the roles of prednisolone therapy for acute phase Kawasaki disease patients.', 'subject score': 888, 'object score': 857}, 'PMID:26594091': {'publication date': '2015 Jul', 'sentence': 'Single serum cortisol values at 09:00 h can be indices of adrenocortical function in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone.', 'subject score': 861, 'object score': 1000}, 'PMID:27743415': {'publication date': '2017 Apr', 'sentence': 'BACKGROUND: Prednisolone (PSL) has been suggested to be useful for the treatment of Kawasaki disease (KD) resistant to i.v. immunoglobulin (IVIG), but much remains to be elucidated regarding its use.', 'subject score': 1000, 'object score': 1000}, 'PMID:28343657': {'publication date': '2017 Jun', 'sentence': 'Bradycardia Associated with Prednisolone in Children with Severe Kawasaki Disease.', 'subject score': 1000, 'object score': 901}, 'PMID:30337183': {'publication date': '2018 Dec', 'sentence': 'BACKGROUND: The RAISE study showed that additional prednisolone improved coronary artery outcomes in patients with Kawasaki disease at high risk of intravenous immunoglobulin (IVIG) resistance.', 'subject score': 888, 'object score': 1000}, 'PMID:33341911': {'publication date': '2020 Dec 20', 'sentence': 'In this study, we compared the therapeutic effects of primary and secondary prednisolone with IVIG for KD.', 'subject score': 888, 'object score': 1000}, 'PMID:34895290': {'publication date': '2021 Dec 11', 'sentence': 'DISCUSSION: This will be the first multicenter randomized controlled trial to evaluate the efficacy of IVIG + aspirin + prednisolone in Chinese pediatric patients with KD, which may provide high-level evidence for improving the initial treatment for acute KD.', 'subject score': 861, 'object score': 1000}, 'PMID:36695415': {'publication date': '2023 Jan 25', 'sentence': 'Primary treatment with IVIG compared to prednisolone for people with KD The evidence comparing IVIG with prednisolone on incidence of CAA is very uncertain (OR 0.60, 95% CI 0.24 to 1.48; 2 studies, 140 participants; very low-certainty evidence), and there was little to no difference between groups in adverse effects (OR 4.18, 95% CI 0.19 to 89.48; 1 study; 90 participants; low-certainty evidence).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 531222,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0012727",
-          "name": "mucocutaneous lymph node syndrome",
-          "description": "A vasculitis characterized by inflammation of the arteries, particularly the coronary arteries. The vasculitis may lead to aneurysm formation and possibly, heart attacks. It affects young children who usually present with persistent high fever, redness of the mucous membranes of the mouth, redness of the palms and soles, skin rashes, lymphadenitis, and joint pain and swelling.; An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:13378",
-            "ICD9:446.1",
-            "MEDDRA:10000747",
-            "SNOMEDCT:75053002",
-            "MESH:C537014",
-            "UMLS:C0026691",
-            "UMLS:C2936917",
-            "EFO:0004246",
-            "MESH:D009080",
-            "MEDDRA:10023320",
-            "ICD10:M30.3",
-            "NCIT:C34825",
-            "MONDO:0012727",
-            "MEDDRA:10028083",
-            "OMIM:611775",
-            "ORPHANET:2331"
-          ],
-          "id": "MONDO:0012727",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infantile polyarteritis",
-            "Kawasaki disease",
-            "Kawasaki disease related phenotypic feature",
-            "Kawasaki Disease",
-            "mucocutaneous lymph node syndrome",
-            "Mucocutaneous Lymph Node Syndrome",
-            "Acute febrile mucocutaneous lymph node syndrome [MCLS]"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/kawasaki_disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 531222,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0012727",
-              "name": "mucocutaneous lymph node syndrome",
-              "description": "A vasculitis characterized by inflammation of the arteries, particularly the coronary arteries. The vasculitis may lead to aneurysm formation and possibly, heart attacks. It affects young children who usually present with persistent high fever, redness of the mucous membranes of the mouth, redness of the palms and soles, skin rashes, lymphadenitis, and joint pain and swelling.; An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:13378",
-                "ICD9:446.1",
-                "MEDDRA:10000747",
-                "SNOMEDCT:75053002",
-                "MESH:C537014",
-                "UMLS:C0026691",
-                "UMLS:C2936917",
-                "EFO:0004246",
-                "MESH:D009080",
-                "MEDDRA:10023320",
-                "ICD10:M30.3",
-                "NCIT:C34825",
-                "MONDO:0012727",
-                "MEDDRA:10028083",
-                "OMIM:611775",
-                "ORPHANET:2331"
-              ],
-              "id": "MONDO:0012727",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infantile polyarteritis",
-                "Kawasaki disease",
-                "Kawasaki disease related phenotypic feature",
-                "Kawasaki Disease",
-                "mucocutaneous lymph node syndrome",
-                "Mucocutaneous Lymph Node Syndrome",
-                "Acute febrile mucocutaneous lymph node syndrome [MCLS]"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/kawasaki_disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11635844,
-            "start": 568,
-            "end": 531222,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15965549': {'publication date': '2005 Jun', 'sentence': 'Six patients with Kawasaki disease (KD) were treated with prednisolone (1 to 2 mg/kg/day) for 3 days (from days 10 to 12 after the onset of the illness) after apparently unsuccessful treatment with intravenous immunoglobulin (IVIG, 2 g/kg/dose and additional 1 g/kg/dose).', 'subject score': 1000, 'object score': 1000}, 'PMID:19504733': {'publication date': '2009 Jun', 'sentence': 'BACKGROUND: We reported previously that intravenous immunoglobulin (IVIG) plus prednisolone for initial therapy for Kawasaki disease (KD) prevented coronary artery abnormalities (CAA) more effectively than IVIG alone.', 'subject score': 861, 'object score': 1000}, 'PMID:25342092': {'publication date': '2015', 'sentence': 'We conclude that adrenal suppression can occur in a high proportion of children with KD treated with IVIG plus prednisolone, despite rather short duration and relatively small amounts of administered glucocorticoids.', 'subject score': 861, 'object score': 1000}, 'PMID:25518413': {'publication date': '2014 Sep', 'sentence': 'The present paper reviews the roles of prednisolone therapy for acute phase Kawasaki disease patients.', 'subject score': 888, 'object score': 857}, 'PMID:26594091': {'publication date': '2015 Jul', 'sentence': 'Single serum cortisol values at 09:00 h can be indices of adrenocortical function in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone.', 'subject score': 861, 'object score': 1000}, 'PMID:27743415': {'publication date': '2017 Apr', 'sentence': 'BACKGROUND: Prednisolone (PSL) has been suggested to be useful for the treatment of Kawasaki disease (KD) resistant to i.v. immunoglobulin (IVIG), but much remains to be elucidated regarding its use.', 'subject score': 1000, 'object score': 1000}, 'PMID:28343657': {'publication date': '2017 Jun', 'sentence': 'Bradycardia Associated with Prednisolone in Children with Severe Kawasaki Disease.', 'subject score': 1000, 'object score': 901}, 'PMID:30337183': {'publication date': '2018 Dec', 'sentence': 'BACKGROUND: The RAISE study showed that additional prednisolone improved coronary artery outcomes in patients with Kawasaki disease at high risk of intravenous immunoglobulin (IVIG) resistance.', 'subject score': 888, 'object score': 1000}, 'PMID:33341911': {'publication date': '2020 Dec 20', 'sentence': 'In this study, we compared the therapeutic effects of primary and secondary prednisolone with IVIG for KD.', 'subject score': 888, 'object score': 1000}, 'PMID:34895290': {'publication date': '2021 Dec 11', 'sentence': 'DISCUSSION: This will be the first multicenter randomized controlled trial to evaluate the efficacy of IVIG + aspirin + prednisolone in Chinese pediatric patients with KD, which may provide high-level evidence for improving the initial treatment for acute KD.', 'subject score': 861, 'object score': 1000}, 'PMID:36695415': {'publication date': '2023 Jan 25', 'sentence': 'Primary treatment with IVIG compared to prednisolone for people with KD The evidence comparing IVIG with prednisolone on incidence of CAA is very uncertain (OR 0.60, 95% CI 0.24 to 1.48; 2 studies, 140 participants; very low-certainty evidence), and there was little to no difference between groups in adverse effects (OR 4.18, 95% CI 0.19 to 89.48; 1 study; 90 participants; low-certainty evidence).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0026691---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11889996",
-              "object": "MONDO:0012727",
-              "publications": [
-                "PMID:15965549",
-                "PMID:19504733",
-                "PMID:25342092",
-                "PMID:25518413",
-                "PMID:26594091",
-                "PMID:27743415",
-                "PMID:28343657",
-                "PMID:30337183",
-                "PMID:33341911",
-                "PMID:34895290",
-                "PMID:36695415"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:14344800': {'publication date': '1965 Jan', 'sentence': '[EFFECT OF PREDNISOLONE ON THE CARDIAC ACTIVITY IN LIVER AND KIDNEY  DISEASES AND IN RHEUMATISM].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319192,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-          "name": "kidney disorder",
-          "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D007674",
-            "MEDDRA:10029154",
-            "UMLS:C0022658",
-            "NCIT:C3149",
-            "MONDO:0005240",
-            "UMLS:C1408258",
-            "DOID:557",
-            "MEDDRA:10029149",
-            "HP:0000112",
-            "MEDDRA:10051051",
-            "NCIT:C34843",
-            "MEDDRA:10038428",
-            "MEDDRA:10038429",
-            "MEDDRA:10029151",
-            "MEDDRA:10051052",
-            "EFO:0003086",
-            "SNOMEDCT:90708001",
-            "MEDDRA:10013263",
-            "PSY:27347"
-          ],
-          "id": "MONDO:0005240",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Kidney damage",
-            "kidney disease",
-            "Nephropathy",
-            "Kidney Diseases",
-            "Kidney Disorder",
-            "kidney disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319192,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-              "name": "kidney disorder",
-              "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D007674",
-                "MEDDRA:10029154",
-                "UMLS:C0022658",
-                "NCIT:C3149",
-                "MONDO:0005240",
-                "UMLS:C1408258",
-                "DOID:557",
-                "MEDDRA:10029149",
-                "HP:0000112",
-                "MEDDRA:10051051",
-                "NCIT:C34843",
-                "MEDDRA:10038428",
-                "MEDDRA:10038429",
-                "MEDDRA:10029151",
-                "MEDDRA:10051052",
-                "EFO:0003086",
-                "SNOMEDCT:90708001",
-                "MEDDRA:10013263",
-                "PSY:27347"
-              ],
-              "id": "MONDO:0005240",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Kidney damage",
-                "kidney disease",
-                "Nephropathy",
-                "Kidney Diseases",
-                "Kidney Disorder",
-                "kidney disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10504714,
-            "start": 568,
-            "end": 319192,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14344800': {'publication date': '1965 Jan', 'sentence': '[EFFECT OF PREDNISOLONE ON THE CARDIAC ACTIVITY IN LIVER AND KIDNEY  DISEASES AND IN RHEUMATISM].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0022658---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10735679",
-              "object": "MONDO:0005240",
-              "publications": [
-                "PMID:14344800"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:5830625': {'publication date': '1965 Sep', 'sentence': 'Light and electron microscopy of prednisolone-induced nephropathy in rabbits.', 'subject score': 851, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 319192,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-          "name": "kidney disorder",
-          "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D007674",
-            "MEDDRA:10029154",
-            "UMLS:C0022658",
-            "NCIT:C3149",
-            "MONDO:0005240",
-            "UMLS:C1408258",
-            "DOID:557",
-            "MEDDRA:10029149",
-            "HP:0000112",
-            "MEDDRA:10051051",
-            "NCIT:C34843",
-            "MEDDRA:10038428",
-            "MEDDRA:10038429",
-            "MEDDRA:10029151",
-            "MEDDRA:10051052",
-            "EFO:0003086",
-            "SNOMEDCT:90708001",
-            "MEDDRA:10013263",
-            "PSY:27347"
-          ],
-          "id": "MONDO:0005240",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Kidney damage",
-            "kidney disease",
-            "Nephropathy",
-            "Kidney Diseases",
-            "Kidney Disorder",
-            "kidney disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319192,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-              "name": "kidney disorder",
-              "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D007674",
-                "MEDDRA:10029154",
-                "UMLS:C0022658",
-                "NCIT:C3149",
-                "MONDO:0005240",
-                "UMLS:C1408258",
-                "DOID:557",
-                "MEDDRA:10029149",
-                "HP:0000112",
-                "MEDDRA:10051051",
-                "NCIT:C34843",
-                "MEDDRA:10038428",
-                "MEDDRA:10038429",
-                "MEDDRA:10029151",
-                "MEDDRA:10051052",
-                "EFO:0003086",
-                "SNOMEDCT:90708001",
-                "MEDDRA:10013263",
-                "PSY:27347"
-              ],
-              "id": "MONDO:0005240",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Kidney damage",
-                "kidney disease",
-                "Nephropathy",
-                "Kidney Diseases",
-                "Kidney Disorder",
-                "kidney disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25498725,
-            "start": 568,
-            "end": 319192,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:5830625': {'publication date': '1965 Sep', 'sentence': 'Light and electron microscopy of prednisolone-induced nephropathy in rabbits.', 'subject score': 851, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0022658---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "25953223",
-              "object": "MONDO:0005240",
-              "publications": [
-                "PMID:5830625"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:13933655': {'publication date': '1963 Jul', 'sentence': 'Effect of prednisolone in the experimentally induced nephropathy in male albino rats.', 'subject score': 1000, 'object score': 790}, 'PMID:20175891': {'publication date': '2010 Feb 22', 'sentence': 'She was treated with relatively low dose oral mycophenolate mofetil and prednisolone which stabilised her nephropathy and neuropathy.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319192,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-          "name": "kidney disorder",
-          "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D007674",
-            "MEDDRA:10029154",
-            "UMLS:C0022658",
-            "NCIT:C3149",
-            "MONDO:0005240",
-            "UMLS:C1408258",
-            "DOID:557",
-            "MEDDRA:10029149",
-            "HP:0000112",
-            "MEDDRA:10051051",
-            "NCIT:C34843",
-            "MEDDRA:10038428",
-            "MEDDRA:10038429",
-            "MEDDRA:10029151",
-            "MEDDRA:10051052",
-            "EFO:0003086",
-            "SNOMEDCT:90708001",
-            "MEDDRA:10013263",
-            "PSY:27347"
-          ],
-          "id": "MONDO:0005240",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Kidney damage",
-            "kidney disease",
-            "Nephropathy",
-            "Kidney Diseases",
-            "Kidney Disorder",
-            "kidney disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319192,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-              "name": "kidney disorder",
-              "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D007674",
-                "MEDDRA:10029154",
-                "UMLS:C0022658",
-                "NCIT:C3149",
-                "MONDO:0005240",
-                "UMLS:C1408258",
-                "DOID:557",
-                "MEDDRA:10029149",
-                "HP:0000112",
-                "MEDDRA:10051051",
-                "NCIT:C34843",
-                "MEDDRA:10038428",
-                "MEDDRA:10038429",
-                "MEDDRA:10029151",
-                "MEDDRA:10051052",
-                "EFO:0003086",
-                "SNOMEDCT:90708001",
-                "MEDDRA:10013263",
-                "PSY:27347"
-              ],
-              "id": "MONDO:0005240",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Kidney damage",
-                "kidney disease",
-                "Nephropathy",
-                "Kidney Diseases",
-                "Kidney Disorder",
-                "kidney disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10422353,
-            "start": 568,
-            "end": 319192,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13933655': {'publication date': '1963 Jul', 'sentence': 'Effect of prednisolone in the experimentally induced nephropathy in male albino rats.', 'subject score': 1000, 'object score': 790}, 'PMID:20175891': {'publication date': '2010 Feb 22', 'sentence': 'She was treated with relatively low dose oral mycophenolate mofetil and prednisolone which stabilised her nephropathy and neuropathy.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0022658---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10651502",
-              "object": "MONDO:0005240",
-              "publications": [
-                "PMID:13933655",
-                "PMID:20175891"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15550753': {'publication date': '2004', 'sentence': 'AIM: To evaluate the efficacy of prednisolone, warfarin, and dipyridamole therapy combined with mizoribine (PWDM) in the treatment of diffuse immunoglobulin A (IgA) nephropathy in comparison with prednisolone, warfarin, and dipyridamole therapy without mizoribine (PWD) and with methylprednisolone pulse therapy (PWD pulse).', 'subject score': 1000, 'object score': 861}, 'PMID:18224343': {'publication date': '2008 May', 'sentence': 'In two previous randomized controlled trials we showed that treatment of severe childhood immunoglobulin A nephropathy (IgA-N) using prednisolone, azathioprine, heparin-warfarin, and dipyridamole prevented any increase of sclerosed glomeruli and that prednisolone alone did not prevent a further increase of sclerosed glomeruli.', 'subject score': 1000, 'object score': 840}, 'PMID:23845696': {'publication date': '2013 Oct', 'sentence': 'There is no consensus as to whether treatment with prednisolone at presentation can prevent or ameliorate the progression of nephropathy in HSP.', 'subject score': 1000, 'object score': 1000}, 'PMID:26877967': {'publication date': '2014 Sep', 'sentence': 'After renal histological examination confirmed nephropathy, treatment with prednisolone and cyclosporine was initiated, which was maintained for over 1 year.', 'subject score': 1000, 'object score': 1000}, 'PMID:27152293': {'publication date': '2016 Apr', 'sentence': 'PATIENTS AND METHODS: Seventy-five patients with IgAN and proteinuria > 1 g/day and treated with prednisolone were divided into two groups: those with low (<=20/high-power field [HPF]) urinary red blood cell (U-RBC) counts (L-RBC group, n=55) and those with high (>20/HPF) U-RBC counts (H-RBC group, n=20).', 'subject score': 1000, 'object score': 901}, 'PMID:29987456': {'publication date': '2018 Jul 09', 'sentence': 'BACKGROUND: Two previous randomized controlled trials showed that treatment of severe childhood immunoglobulin A (IgA) nephropathy using prednisolone with azathioprine, heparin-warfarin, or dipyridamole prevented the increase of sclerosed glomeruli.', 'subject score': 1000, 'object score': 840}, 'PMID:35711019': {'publication date': '2022 Jun 16', 'sentence': 'Based on these findings, she was diagnosed with IgG nephropathy and treated with prednisolone.', 'subject score': 1000, 'object score': 901}, 'PMID:7997131': {'publication date': '1994', 'sentence': 'He received prednisolone with amelioration of the renal disorder, but consulted again some months later because of fever, marked weight loss, generalized enlargement of superficial lymph nodes, autoimmune hemolytic anemia and polyclonal hypergammaglobulinemia.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319192,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-          "name": "kidney disorder",
-          "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D007674",
-            "MEDDRA:10029154",
-            "UMLS:C0022658",
-            "NCIT:C3149",
-            "MONDO:0005240",
-            "UMLS:C1408258",
-            "DOID:557",
-            "MEDDRA:10029149",
-            "HP:0000112",
-            "MEDDRA:10051051",
-            "NCIT:C34843",
-            "MEDDRA:10038428",
-            "MEDDRA:10038429",
-            "MEDDRA:10029151",
-            "MEDDRA:10051052",
-            "EFO:0003086",
-            "SNOMEDCT:90708001",
-            "MEDDRA:10013263",
-            "PSY:27347"
-          ],
-          "id": "MONDO:0005240",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Kidney damage",
-            "kidney disease",
-            "Nephropathy",
-            "Kidney Diseases",
-            "Kidney Disorder",
-            "kidney disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319192,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-              "name": "kidney disorder",
-              "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D007674",
-                "MEDDRA:10029154",
-                "UMLS:C0022658",
-                "NCIT:C3149",
-                "MONDO:0005240",
-                "UMLS:C1408258",
-                "DOID:557",
-                "MEDDRA:10029149",
-                "HP:0000112",
-                "MEDDRA:10051051",
-                "NCIT:C34843",
-                "MEDDRA:10038428",
-                "MEDDRA:10038429",
-                "MEDDRA:10029151",
-                "MEDDRA:10051052",
-                "EFO:0003086",
-                "SNOMEDCT:90708001",
-                "MEDDRA:10013263",
-                "PSY:27347"
-              ],
-              "id": "MONDO:0005240",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Kidney damage",
-                "kidney disease",
-                "Nephropathy",
-                "Kidney Diseases",
-                "Kidney Disorder",
-                "kidney disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11279559,
-            "start": 568,
-            "end": 319192,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15550753': {'publication date': '2004', 'sentence': 'AIM: To evaluate the efficacy of prednisolone, warfarin, and dipyridamole therapy combined with mizoribine (PWDM) in the treatment of diffuse immunoglobulin A (IgA) nephropathy in comparison with prednisolone, warfarin, and dipyridamole therapy without mizoribine (PWD) and with methylprednisolone pulse therapy (PWD pulse).', 'subject score': 1000, 'object score': 861}, 'PMID:18224343': {'publication date': '2008 May', 'sentence': 'In two previous randomized controlled trials we showed that treatment of severe childhood immunoglobulin A nephropathy (IgA-N) using prednisolone, azathioprine, heparin-warfarin, and dipyridamole prevented any increase of sclerosed glomeruli and that prednisolone alone did not prevent a further increase of sclerosed glomeruli.', 'subject score': 1000, 'object score': 840}, 'PMID:23845696': {'publication date': '2013 Oct', 'sentence': 'There is no consensus as to whether treatment with prednisolone at presentation can prevent or ameliorate the progression of nephropathy in HSP.', 'subject score': 1000, 'object score': 1000}, 'PMID:26877967': {'publication date': '2014 Sep', 'sentence': 'After renal histological examination confirmed nephropathy, treatment with prednisolone and cyclosporine was initiated, which was maintained for over 1 year.', 'subject score': 1000, 'object score': 1000}, 'PMID:27152293': {'publication date': '2016 Apr', 'sentence': 'PATIENTS AND METHODS: Seventy-five patients with IgAN and proteinuria > 1 g/day and treated with prednisolone were divided into two groups: those with low (<=20/high-power field [HPF]) urinary red blood cell (U-RBC) counts (L-RBC group, n=55) and those with high (>20/HPF) U-RBC counts (H-RBC group, n=20).', 'subject score': 1000, 'object score': 901}, 'PMID:29987456': {'publication date': '2018 Jul 09', 'sentence': 'BACKGROUND: Two previous randomized controlled trials showed that treatment of severe childhood immunoglobulin A (IgA) nephropathy using prednisolone with azathioprine, heparin-warfarin, or dipyridamole prevented the increase of sclerosed glomeruli.', 'subject score': 1000, 'object score': 840}, 'PMID:35711019': {'publication date': '2022 Jun 16', 'sentence': 'Based on these findings, she was diagnosed with IgG nephropathy and treated with prednisolone.', 'subject score': 1000, 'object score': 901}, 'PMID:7997131': {'publication date': '1994', 'sentence': 'He received prednisolone with amelioration of the renal disorder, but consulted again some months later because of fever, marked weight loss, generalized enlargement of superficial lymph nodes, autoimmune hemolytic anemia and polyclonal hypergammaglobulinemia.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0022658---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11526277",
-              "object": "MONDO:0005240",
-              "publications": [
-                "PMID:15550753",
-                "PMID:18224343",
-                "PMID:23845696",
-                "PMID:26877967",
-                "PMID:27152293",
-                "PMID:29987456",
-                "PMID:35711019",
-                "PMID:7997131"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:22752636': {'publication date': '2012 Dec', 'sentence': 'Effect of addition of short course of prednisolone to gluten-free diet on mucosal epithelial cell regeneration and apoptosis in celiac disease: a pilot randomized controlled trial.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319441,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005130",
-          "name": "celiac disease",
-          "description": "Celiac disease (CD) is an autoimmune condition affecting the small intestine, triggered by the ingestion of gluten, the protein fraction of wheat, barley, and rye. Clinical manifestations of CD are highly variable and include both gastrointestinal and non-gastrointestinal features. The hallmark of CD is an immune-mediated enteropathy. This term is included because the occurence of CD is seen as a feature of a number of other diseases. [HPO:probinson, PMID:23681421]; Celiac disease (CD) is an autoimmune condition affecting the small intestine, triggered by the ingestion of gluten, the protein fraction of wheat, barley, and rye. Clinical manifestations of CD are highly variable and include both gastrointestinal and non-gastrointestinal features. The hallmark of CD is an immune-mediated enteropathy. This term is included because the occurence of CD is seen as a feature of a number of other diseases.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10018461",
-            "MEDDRA:10058248",
-            "HP:0002608",
-            "EFO:0001060",
-            "MEDDRA:10029525",
-            "ICD9:579.0",
-            "MEDDRA:10007865",
-            "OMIM.PS:212750",
-            "MEDDRA:10007864",
-            "ORPHANET:555",
-            "UMLS:C0007570",
-            "SNOMEDCT:396331005",
-            "NCIT:C26714",
-            "MEDDRA:10009839",
-            "MEDDRA:10018458",
-            "MONDO:0005130",
-            "ICD10:K90.0",
-            "DOID:10608",
-            "MESH:D002446"
-          ],
-          "id": "MONDO:0005130",
-          "category": "biolink:Disease",
-          "all_names": [
-            "celiac disease",
-            "Celiac Disease",
-            "Celiac disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/celiac-disease/ds00319",
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:23681421",
-            "http://www.celiac.org/",
-            "http://en.wikipedia.org/wiki/coeliac_disease",
-            "https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000233.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319441,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005130",
-              "name": "celiac disease",
-              "description": "Celiac disease (CD) is an autoimmune condition affecting the small intestine, triggered by the ingestion of gluten, the protein fraction of wheat, barley, and rye. Clinical manifestations of CD are highly variable and include both gastrointestinal and non-gastrointestinal features. The hallmark of CD is an immune-mediated enteropathy. This term is included because the occurence of CD is seen as a feature of a number of other diseases. [HPO:probinson, PMID:23681421]; Celiac disease (CD) is an autoimmune condition affecting the small intestine, triggered by the ingestion of gluten, the protein fraction of wheat, barley, and rye. Clinical manifestations of CD are highly variable and include both gastrointestinal and non-gastrointestinal features. The hallmark of CD is an immune-mediated enteropathy. This term is included because the occurence of CD is seen as a feature of a number of other diseases.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10018461",
-                "MEDDRA:10058248",
-                "HP:0002608",
-                "EFO:0001060",
-                "MEDDRA:10029525",
-                "ICD9:579.0",
-                "MEDDRA:10007865",
-                "OMIM.PS:212750",
-                "MEDDRA:10007864",
-                "ORPHANET:555",
-                "UMLS:C0007570",
-                "SNOMEDCT:396331005",
-                "NCIT:C26714",
-                "MEDDRA:10009839",
-                "MEDDRA:10018458",
-                "MONDO:0005130",
-                "ICD10:K90.0",
-                "DOID:10608",
-                "MESH:D002446"
-              ],
-              "id": "MONDO:0005130",
-              "category": "biolink:Disease",
-              "all_names": [
-                "celiac disease",
-                "Celiac Disease",
-                "Celiac disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/celiac-disease/ds00319",
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:23681421",
-                "http://www.celiac.org/",
-                "http://en.wikipedia.org/wiki/coeliac_disease",
-                "https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000233.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16036943,
-            "start": 568,
-            "end": 319441,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22752636': {'publication date': '2012 Dec', 'sentence': 'Effect of addition of short course of prednisolone to gluten-free diet on mucosal epithelial cell regeneration and apoptosis in celiac disease: a pilot randomized controlled trial.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0007570---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16371065",
-              "object": "MONDO:0005130",
-              "publications": [
-                "PMID:22752636"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:13356997': {'publication date': '1956 Aug', 'sentence': 'The simultaneous correction of plain-water deficit and extracellular fluid volume loss in non-tropical sprue treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:6669930': {'publication date': '1983 May', 'sentence': 'The proportion of free prednisolone was 79% greater in patients with celiac disease (p less than 0.01), and the area under the time-concentration curve of free, biologically active prednisolone 53% larger (p less than 0.05).', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319441,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005130",
-          "name": "celiac disease",
-          "description": "Celiac disease (CD) is an autoimmune condition affecting the small intestine, triggered by the ingestion of gluten, the protein fraction of wheat, barley, and rye. Clinical manifestations of CD are highly variable and include both gastrointestinal and non-gastrointestinal features. The hallmark of CD is an immune-mediated enteropathy. This term is included because the occurence of CD is seen as a feature of a number of other diseases. [HPO:probinson, PMID:23681421]; Celiac disease (CD) is an autoimmune condition affecting the small intestine, triggered by the ingestion of gluten, the protein fraction of wheat, barley, and rye. Clinical manifestations of CD are highly variable and include both gastrointestinal and non-gastrointestinal features. The hallmark of CD is an immune-mediated enteropathy. This term is included because the occurence of CD is seen as a feature of a number of other diseases.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10018461",
-            "MEDDRA:10058248",
-            "HP:0002608",
-            "EFO:0001060",
-            "MEDDRA:10029525",
-            "ICD9:579.0",
-            "MEDDRA:10007865",
-            "OMIM.PS:212750",
-            "MEDDRA:10007864",
-            "ORPHANET:555",
-            "UMLS:C0007570",
-            "SNOMEDCT:396331005",
-            "NCIT:C26714",
-            "MEDDRA:10009839",
-            "MEDDRA:10018458",
-            "MONDO:0005130",
-            "ICD10:K90.0",
-            "DOID:10608",
-            "MESH:D002446"
-          ],
-          "id": "MONDO:0005130",
-          "category": "biolink:Disease",
-          "all_names": [
-            "celiac disease",
-            "Celiac Disease",
-            "Celiac disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/celiac-disease/ds00319",
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:23681421",
-            "http://www.celiac.org/",
-            "http://en.wikipedia.org/wiki/coeliac_disease",
-            "https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000233.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319441,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005130",
-              "name": "celiac disease",
-              "description": "Celiac disease (CD) is an autoimmune condition affecting the small intestine, triggered by the ingestion of gluten, the protein fraction of wheat, barley, and rye. Clinical manifestations of CD are highly variable and include both gastrointestinal and non-gastrointestinal features. The hallmark of CD is an immune-mediated enteropathy. This term is included because the occurence of CD is seen as a feature of a number of other diseases. [HPO:probinson, PMID:23681421]; Celiac disease (CD) is an autoimmune condition affecting the small intestine, triggered by the ingestion of gluten, the protein fraction of wheat, barley, and rye. Clinical manifestations of CD are highly variable and include both gastrointestinal and non-gastrointestinal features. The hallmark of CD is an immune-mediated enteropathy. This term is included because the occurence of CD is seen as a feature of a number of other diseases.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10018461",
-                "MEDDRA:10058248",
-                "HP:0002608",
-                "EFO:0001060",
-                "MEDDRA:10029525",
-                "ICD9:579.0",
-                "MEDDRA:10007865",
-                "OMIM.PS:212750",
-                "MEDDRA:10007864",
-                "ORPHANET:555",
-                "UMLS:C0007570",
-                "SNOMEDCT:396331005",
-                "NCIT:C26714",
-                "MEDDRA:10009839",
-                "MEDDRA:10018458",
-                "MONDO:0005130",
-                "ICD10:K90.0",
-                "DOID:10608",
-                "MESH:D002446"
-              ],
-              "id": "MONDO:0005130",
-              "category": "biolink:Disease",
-              "all_names": [
-                "celiac disease",
-                "Celiac Disease",
-                "Celiac disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/celiac-disease/ds00319",
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:23681421",
-                "http://www.celiac.org/",
-                "http://en.wikipedia.org/wiki/coeliac_disease",
-                "https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000233.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10287068,
-            "start": 568,
-            "end": 319441,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13356997': {'publication date': '1956 Aug', 'sentence': 'The simultaneous correction of plain-water deficit and extracellular fluid volume loss in non-tropical sprue treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:6669930': {'publication date': '1983 May', 'sentence': 'The proportion of free prednisolone was 79% greater in patients with celiac disease (p less than 0.01), and the area under the time-concentration curve of free, biologically active prednisolone 53% larger (p less than 0.05).', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0007570---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10513879",
-              "object": "MONDO:0005130",
-              "publications": [
-                "PMID:13356997",
-                "PMID:6669930"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:21272189': {'publication date': '2011 Jun', 'sentence': 'Lipomas responded with less lipolysis to isoproterenol than subcutaneous fat during microdialysis, and prednisolone treatment increased lipolysis in both lipomas and subcutaneous fat.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 307870,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005106",
-          "name": "lipoma",
-          "description": "A benign, usually painless, well-circumscribed lipomatous tumor composed of adipose tissue.; A rare benign human tumor consisting of BROWN ADIPOCYTES resembling those found in some hibernating animals.; The presence of multiple lipomas (a type of benign tissue made of fatty tissue). [HPO:sdoelken]; Benign neoplasia derived from lipoblasts or lipocytes of white or brown fat. May be angiomatous or hibernomatous. [MPATH:417]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10024615",
-            "NCIT:C3192",
-            "MESH:D008067",
-            "MEDDRA:10024623",
-            "ICD10:D17",
-            "EFO:0000759",
-            "MONDO:0005106",
-            "SNOMEDCT:134328007",
-            "ICD10:D17.9",
-            "UMLS:C0023798",
-            "DOID:3315",
-            "MEDDRA:10024612",
-            "ICD9:214",
-            "HP:0012032",
-            "SNOMEDCT:93163002"
-          ],
-          "id": "MONDO:0005106",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lipoma",
-            "lipoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/benign_tumo",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 307870,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005106",
-              "name": "lipoma",
-              "description": "A benign, usually painless, well-circumscribed lipomatous tumor composed of adipose tissue.; A rare benign human tumor consisting of BROWN ADIPOCYTES resembling those found in some hibernating animals.; The presence of multiple lipomas (a type of benign tissue made of fatty tissue). [HPO:sdoelken]; Benign neoplasia derived from lipoblasts or lipocytes of white or brown fat. May be angiomatous or hibernomatous. [MPATH:417]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10024615",
-                "NCIT:C3192",
-                "MESH:D008067",
-                "MEDDRA:10024623",
-                "ICD10:D17",
-                "EFO:0000759",
-                "MONDO:0005106",
-                "SNOMEDCT:134328007",
-                "ICD10:D17.9",
-                "UMLS:C0023798",
-                "DOID:3315",
-                "MEDDRA:10024612",
-                "ICD9:214",
-                "HP:0012032",
-                "SNOMEDCT:93163002"
-              ],
-              "id": "MONDO:0005106",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lipoma",
-                "lipoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/benign_tumo",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15123227,
-            "start": 568,
-            "end": 307870,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21272189': {'publication date': '2011 Jun', 'sentence': 'Lipomas responded with less lipolysis to isoproterenol than subcutaneous fat during microdialysis, and prednisolone treatment increased lipolysis in both lipomas and subcutaneous fat.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0023798---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "15441636",
-              "object": "MONDO:0005106",
-              "publications": [
-                "PMID:21272189"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:17306441': {'publication date': '2007 Dec', 'sentence': 'Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study.', 'subject score': 1000, 'object score': 861}, 'PMID:17306444': {'publication date': '2007 Dec', 'sentence': 'Editorial comment on: Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study.', 'subject score': 1000, 'object score': 861}, 'PMID:18544992': {'publication date': '2008', 'sentence': 'A randomized phase II trial comparing weekly taxotere plus prednisolone versus prednisolone alone in androgen-independent prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:25457497': {'publication date': '2015 04', 'sentence': 'A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:3157571': {'publication date': '1985', 'sentence': 'High-dose medroxyprogesterone acetate versus prednisolone in hormone-resistant prostatic cancer.', 'subject score': 1000, 'object score': 871}}",
-    "p2": {
-      "start": {
-        "identity": 319116,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008315",
-          "name": "prostate cancer",
-          "description": "A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.; Tumors or cancer of the PROSTATE.; A cancer of the prostate. [HPO:probinson]; What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it:  Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to:  Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer.    What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include:  Problems urinating (peeing), such as:  A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen   Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm)  But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you:  Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer  What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include:  A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate.  If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options:  Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation:  Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer.   Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer.  Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include:  Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0008315",
-            "ICD10:C61",
-            "MEDDRA:10026389",
-            "MEDDRA:10007113",
-            "DOID:10283",
-            "MEDDRA:10036908",
-            "UMLS:C0376358",
-            "SNOMEDCT:399068003",
-            "ICD9:185",
-            "PDQ:CDR0000038782",
-            "MEDDRA:10036910",
-            "MEDDRA:10036946",
-            "KEGG.DISEASE:05215",
-            "NCIT:C7378",
-            "MESH:D011471",
-            "HP:0012125",
-            "MEDDRA:10060862"
-          ],
-          "id": "MONDO:0008315",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Malignant Prostate Neoplasm",
-            "prostate cancer",
-            "Prostate cancer",
-            "Prostatic Neoplasms",
-            "Malignant neoplasm of prostate"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=445079",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319116,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008315",
-              "name": "prostate cancer",
-              "description": "A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.; Tumors or cancer of the PROSTATE.; A cancer of the prostate. [HPO:probinson]; What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it:  Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to:  Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer.    What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include:  Problems urinating (peeing), such as:  A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen   Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm)  But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you:  Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer  What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include:  A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate.  If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options:  Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation:  Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer.   Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer.  Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include:  Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0008315",
-                "ICD10:C61",
-                "MEDDRA:10026389",
-                "MEDDRA:10007113",
-                "DOID:10283",
-                "MEDDRA:10036908",
-                "UMLS:C0376358",
-                "SNOMEDCT:399068003",
-                "ICD9:185",
-                "PDQ:CDR0000038782",
-                "MEDDRA:10036910",
-                "MEDDRA:10036946",
-                "KEGG.DISEASE:05215",
-                "NCIT:C7378",
-                "MESH:D011471",
-                "HP:0012125",
-                "MEDDRA:10060862"
-              ],
-              "id": "MONDO:0008315",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Malignant Prostate Neoplasm",
-                "prostate cancer",
-                "Prostate cancer",
-                "Prostatic Neoplasms",
-                "Malignant neoplasm of prostate"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=445079",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12698535,
-            "start": 568,
-            "end": 319116,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17306441': {'publication date': '2007 Dec', 'sentence': 'Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study.', 'subject score': 1000, 'object score': 861}, 'PMID:17306444': {'publication date': '2007 Dec', 'sentence': 'Editorial comment on: Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study.', 'subject score': 1000, 'object score': 861}, 'PMID:18544992': {'publication date': '2008', 'sentence': 'A randomized phase II trial comparing weekly taxotere plus prednisolone versus prednisolone alone in androgen-independent prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:25457497': {'publication date': '2015 04', 'sentence': 'A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:3157571': {'publication date': '1985', 'sentence': 'High-dose medroxyprogesterone acetate versus prednisolone in hormone-resistant prostatic cancer.', 'subject score': 1000, 'object score': 871}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0376358---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "12983495",
-              "object": "MONDO:0008315",
-              "publications": [
-                "PMID:17306441",
-                "PMID:17306444",
-                "PMID:18544992",
-                "PMID:25457497",
-                "PMID:3157571"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15333686': {'publication date': '2004 Jun', 'sentence': 'BACKGROUND: We conducted this retrospective study to analyze a modified dose schedule of mitoxantrone and prednisolone (MP) in patients with androgen-independent prostate cancer.', 'subject score': 763, 'object score': 861}, 'PMID:18544992': {'publication date': '2008', 'sentence': 'Taxotere plus prednisolone is recommended as systemic standard treatment in androgen-independent prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:22936562': {'publication date': '2013 Oct', 'sentence': 'Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:24736579': {'publication date': '2014 May 13', 'sentence': 'Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.', 'subject score': 861, 'object score': 861}, 'PMID:25457497': {'publication date': '2015 04', 'sentence': 'BACKGROUND: Prednisolone is widely used as secondary hormonal treatment for castration-resistant prostate cancer (CRPC).', 'subject score': 1000, 'object score': 861}, 'PMID:25862824': {'publication date': '2015 Jul', 'sentence': 'In this study, we evaluated the efficacy and safety of docetaxel and prednisolone in patients with castration-resistant prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:25981653': {'publication date': '2015 May', 'sentence': '[Risk factors for predicting severe leukopenia induced by docetaxel plus prednisolone in patients with Castration-Resistant Prostate cancer].', 'subject score': 851, 'object score': 861}, 'PMID:26962246': {'publication date': '2016 Mar 08', 'sentence': 'We conducted a Phase II trial to evaluate the outcome of intermittent docetaxel and prednisolone therapy in castration-resistant prostate cancer.', 'subject score': 888, 'object score': 861}, 'PMID:30738780': {'publication date': '2019 Mar', 'sentence': 'INTERPRETATION: The addition of radium-223 to abiraterone acetate plus prednisone or prednisolone did not improve symptomatic skeletal event-free survival in patients with castration-resistant prostate cancer and bone metastases, and was associated with an increased frequency of bone fractures compared with placebo.', 'subject score': 1000, 'object score': 861}, 'PMID:31358379': {'publication date': '2019 Nov', 'sentence': 'Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial.', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 319116,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008315",
-          "name": "prostate cancer",
-          "description": "A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.; Tumors or cancer of the PROSTATE.; A cancer of the prostate. [HPO:probinson]; What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it:  Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to:  Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer.    What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include:  Problems urinating (peeing), such as:  A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen   Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm)  But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you:  Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer  What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include:  A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate.  If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options:  Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation:  Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer.   Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer.  Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include:  Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0008315",
-            "ICD10:C61",
-            "MEDDRA:10026389",
-            "MEDDRA:10007113",
-            "DOID:10283",
-            "MEDDRA:10036908",
-            "UMLS:C0376358",
-            "SNOMEDCT:399068003",
-            "ICD9:185",
-            "PDQ:CDR0000038782",
-            "MEDDRA:10036910",
-            "MEDDRA:10036946",
-            "KEGG.DISEASE:05215",
-            "NCIT:C7378",
-            "MESH:D011471",
-            "HP:0012125",
-            "MEDDRA:10060862"
-          ],
-          "id": "MONDO:0008315",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Malignant Prostate Neoplasm",
-            "prostate cancer",
-            "Prostate cancer",
-            "Prostatic Neoplasms",
-            "Malignant neoplasm of prostate"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=445079",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319116,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008315",
-              "name": "prostate cancer",
-              "description": "A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.; Tumors or cancer of the PROSTATE.; A cancer of the prostate. [HPO:probinson]; What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it:  Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to:  Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer.    What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include:  Problems urinating (peeing), such as:  A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen   Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm)  But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you:  Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer  What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include:  A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate.  If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options:  Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation:  Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer.   Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer.  Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include:  Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0008315",
-                "ICD10:C61",
-                "MEDDRA:10026389",
-                "MEDDRA:10007113",
-                "DOID:10283",
-                "MEDDRA:10036908",
-                "UMLS:C0376358",
-                "SNOMEDCT:399068003",
-                "ICD9:185",
-                "PDQ:CDR0000038782",
-                "MEDDRA:10036910",
-                "MEDDRA:10036946",
-                "KEGG.DISEASE:05215",
-                "NCIT:C7378",
-                "MESH:D011471",
-                "HP:0012125",
-                "MEDDRA:10060862"
-              ],
-              "id": "MONDO:0008315",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Malignant Prostate Neoplasm",
-                "prostate cancer",
-                "Prostate cancer",
-                "Prostatic Neoplasms",
-                "Malignant neoplasm of prostate"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=445079",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11129413,
-            "start": 568,
-            "end": 319116,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15333686': {'publication date': '2004 Jun', 'sentence': 'BACKGROUND: We conducted this retrospective study to analyze a modified dose schedule of mitoxantrone and prednisolone (MP) in patients with androgen-independent prostate cancer.', 'subject score': 763, 'object score': 861}, 'PMID:18544992': {'publication date': '2008', 'sentence': 'Taxotere plus prednisolone is recommended as systemic standard treatment in androgen-independent prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:22936562': {'publication date': '2013 Oct', 'sentence': 'Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:24736579': {'publication date': '2014 May 13', 'sentence': 'Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.', 'subject score': 861, 'object score': 861}, 'PMID:25457497': {'publication date': '2015 04', 'sentence': 'BACKGROUND: Prednisolone is widely used as secondary hormonal treatment for castration-resistant prostate cancer (CRPC).', 'subject score': 1000, 'object score': 861}, 'PMID:25862824': {'publication date': '2015 Jul', 'sentence': 'In this study, we evaluated the efficacy and safety of docetaxel and prednisolone in patients with castration-resistant prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:25981653': {'publication date': '2015 May', 'sentence': '[Risk factors for predicting severe leukopenia induced by docetaxel plus prednisolone in patients with Castration-Resistant Prostate cancer].', 'subject score': 851, 'object score': 861}, 'PMID:26962246': {'publication date': '2016 Mar 08', 'sentence': 'We conducted a Phase II trial to evaluate the outcome of intermittent docetaxel and prednisolone therapy in castration-resistant prostate cancer.', 'subject score': 888, 'object score': 861}, 'PMID:30738780': {'publication date': '2019 Mar', 'sentence': 'INTERPRETATION: The addition of radium-223 to abiraterone acetate plus prednisone or prednisolone did not improve symptomatic skeletal event-free survival in patients with castration-resistant prostate cancer and bone metastases, and was associated with an increased frequency of bone fractures compared with placebo.', 'subject score': 1000, 'object score': 861}, 'PMID:31358379': {'publication date': '2019 Nov', 'sentence': 'Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0376358---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11373326",
-              "object": "MONDO:0008315",
-              "publications": [
-                "PMID:15333686",
-                "PMID:18544992",
-                "PMID:22936562",
-                "PMID:24736579",
-                "PMID:25457497",
-                "PMID:25862824",
-                "PMID:25981653",
-                "PMID:26962246",
-                "PMID:30738780",
-                "PMID:31358379"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:14421828': {'publication date': '1959 Dec 15', 'sentence': '[Trans-utero-tubal administration of prednisolone in sterility caused by obstruction of the tubes].', 'subject score': 1000, 'object score': 1000}, 'PMID:14606767': {'publication date': '2003 Jul-Aug', 'sentence': 'The advantages of the EVAP combination are absence of pulmonary toxicity, markedly lower incidence of sterility and nausea and vomiting.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 311498,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005047",
-          "name": "infertility disorder",
-          "description": "Inability to conceive for at least one year after trying and having unprotected sex. Causes of female infertility include endometriosis, fallopian tubes obstruction, and polycystic ovary syndrome. Causes of male infertility include abnormal sperm production or function, blockage of the epididymis, blockage of the ejaculatory ducts, hypospadias, exposure to pesticides, and health related issues. // COMMENTS: Editor note: dubious as to whether this is a disease as defined, check with clingen before obsoleting",
-          "equivalent_curies": [
-            "UMLS:C4074771",
-            "MEDDRA:10021930",
-            "DOID:5223",
-            "SYMP:0000712",
-            "EFO:0000545",
-            "UMLS:C0021359",
-            "MESH:D007246",
-            "MONDO:0005047",
-            "NCIT:C3836",
-            "UMLS:C1533568",
-            "MEDDRA:10042012",
-            "HP:0000789",
-            "PSY:25210",
-            "SNOMEDCT:15296000",
-            "PDQ:CDR0000726658",
-            "SNOMEDCT:8619003",
-            "MEDDRA:10021926"
-          ],
-          "id": "MONDO:0005047",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infertility",
-            "infertility",
-            "Fertility Disorders",
-            "infertility disorder",
-            "Sterility, Reproductive"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:DiseaseOrPhenotypicFeature",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/infertility"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311498,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005047",
-              "name": "infertility disorder",
-              "description": "Inability to conceive for at least one year after trying and having unprotected sex. Causes of female infertility include endometriosis, fallopian tubes obstruction, and polycystic ovary syndrome. Causes of male infertility include abnormal sperm production or function, blockage of the epididymis, blockage of the ejaculatory ducts, hypospadias, exposure to pesticides, and health related issues. // COMMENTS: Editor note: dubious as to whether this is a disease as defined, check with clingen before obsoleting",
-              "equivalent_curies": [
-                "UMLS:C4074771",
-                "MEDDRA:10021930",
-                "DOID:5223",
-                "SYMP:0000712",
-                "EFO:0000545",
-                "UMLS:C0021359",
-                "MESH:D007246",
-                "MONDO:0005047",
-                "NCIT:C3836",
-                "UMLS:C1533568",
-                "MEDDRA:10042012",
-                "HP:0000789",
-                "PSY:25210",
-                "SNOMEDCT:15296000",
-                "PDQ:CDR0000726658",
-                "SNOMEDCT:8619003",
-                "MEDDRA:10021926"
-              ],
-              "id": "MONDO:0005047",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infertility",
-                "infertility",
-                "Fertility Disorders",
-                "infertility disorder",
-                "Sterility, Reproductive"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:DiseaseOrPhenotypicFeature",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/infertility"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10517905,
-            "start": 568,
-            "end": 311498,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14421828': {'publication date': '1959 Dec 15', 'sentence': '[Trans-utero-tubal administration of prednisolone in sterility caused by obstruction of the tubes].', 'subject score': 1000, 'object score': 1000}, 'PMID:14606767': {'publication date': '2003 Jul-Aug', 'sentence': 'The advantages of the EVAP combination are absence of pulmonary toxicity, markedly lower incidence of sterility and nausea and vomiting.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0021359---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10748640",
-              "object": "MONDO:0005047",
-              "publications": [
-                "PMID:14421828",
-                "PMID:14606767"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:2115396': {'publication date': '1990 May 01', 'sentence': \"It is concluded that six or more cycles of COPP chemotherapy for advanced Hodgkin's disease in men leads to permanent sterility.\", 'subject score': 888, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 311498,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005047",
-          "name": "infertility disorder",
-          "description": "Inability to conceive for at least one year after trying and having unprotected sex. Causes of female infertility include endometriosis, fallopian tubes obstruction, and polycystic ovary syndrome. Causes of male infertility include abnormal sperm production or function, blockage of the epididymis, blockage of the ejaculatory ducts, hypospadias, exposure to pesticides, and health related issues. // COMMENTS: Editor note: dubious as to whether this is a disease as defined, check with clingen before obsoleting",
-          "equivalent_curies": [
-            "UMLS:C4074771",
-            "MEDDRA:10021930",
-            "DOID:5223",
-            "SYMP:0000712",
-            "EFO:0000545",
-            "UMLS:C0021359",
-            "MESH:D007246",
-            "MONDO:0005047",
-            "NCIT:C3836",
-            "UMLS:C1533568",
-            "MEDDRA:10042012",
-            "HP:0000789",
-            "PSY:25210",
-            "SNOMEDCT:15296000",
-            "PDQ:CDR0000726658",
-            "SNOMEDCT:8619003",
-            "MEDDRA:10021926"
-          ],
-          "id": "MONDO:0005047",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infertility",
-            "infertility",
-            "Fertility Disorders",
-            "infertility disorder",
-            "Sterility, Reproductive"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:DiseaseOrPhenotypicFeature",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/infertility"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311498,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005047",
-              "name": "infertility disorder",
-              "description": "Inability to conceive for at least one year after trying and having unprotected sex. Causes of female infertility include endometriosis, fallopian tubes obstruction, and polycystic ovary syndrome. Causes of male infertility include abnormal sperm production or function, blockage of the epididymis, blockage of the ejaculatory ducts, hypospadias, exposure to pesticides, and health related issues. // COMMENTS: Editor note: dubious as to whether this is a disease as defined, check with clingen before obsoleting",
-              "equivalent_curies": [
-                "UMLS:C4074771",
-                "MEDDRA:10021930",
-                "DOID:5223",
-                "SYMP:0000712",
-                "EFO:0000545",
-                "UMLS:C0021359",
-                "MESH:D007246",
-                "MONDO:0005047",
-                "NCIT:C3836",
-                "UMLS:C1533568",
-                "MEDDRA:10042012",
-                "HP:0000789",
-                "PSY:25210",
-                "SNOMEDCT:15296000",
-                "PDQ:CDR0000726658",
-                "SNOMEDCT:8619003",
-                "MEDDRA:10021926"
-              ],
-              "id": "MONDO:0005047",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infertility",
-                "infertility",
-                "Fertility Disorders",
-                "infertility disorder",
-                "Sterility, Reproductive"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:DiseaseOrPhenotypicFeature",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/infertility"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15048072,
-            "start": 568,
-            "end": 311498,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2115396': {'publication date': '1990 May 01', 'sentence': \"It is concluded that six or more cycles of COPP chemotherapy for advanced Hodgkin's disease in men leads to permanent sterility.\", 'subject score': 888, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0021359---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "15365269",
-              "object": "MONDO:0005047",
-              "publications": [
-                "PMID:2115396"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1551969': {'publication date': '1992 Jan', 'sentence': \"In this double blind cross-over study, 20 infertile men, who had sperm antibodies detected by the mixed antiglobulin reaction (MAR test) in the ejaculate and by the tray agglutination test (TAT) in serum, were treated with 40 mg/day prednisolone or placebo from days 1 to 10 of the partners' menstrual cycle.\", 'subject score': 833, 'object score': 790}, 'PMID:2056224': {'publication date': '1991 May', 'sentence': 'In addition, the effect of prednisolone as a treatment of infertility caused by endometriosis was evaluated in animal experiments.', 'subject score': 1000, 'object score': 1000}, 'PMID:27591233': {'publication date': '2016 10', 'sentence': 'There is ongoing interest in immune-suppressant corticosteroid drugs such as prednisolone to treat infertility in women with repeated IVF failure and recurrent miscarriage.', 'subject score': 1000, 'object score': 1000}, 'PMID:8876264': {'publication date': '1996 Jun', 'sentence': 'Twenty infertile men, positive for antisperm antibodies by the mixed antiglobulin reaction (MAR) test, were treated with either 20 mg/day prednisolone (n = 10) or placebo (n = 10) for 3 weeks.', 'subject score': 736, 'object score': 790}}",
-    "p2": {
-      "start": {
-        "identity": 311498,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005047",
-          "name": "infertility disorder",
-          "description": "Inability to conceive for at least one year after trying and having unprotected sex. Causes of female infertility include endometriosis, fallopian tubes obstruction, and polycystic ovary syndrome. Causes of male infertility include abnormal sperm production or function, blockage of the epididymis, blockage of the ejaculatory ducts, hypospadias, exposure to pesticides, and health related issues. // COMMENTS: Editor note: dubious as to whether this is a disease as defined, check with clingen before obsoleting",
-          "equivalent_curies": [
-            "UMLS:C4074771",
-            "MEDDRA:10021930",
-            "DOID:5223",
-            "SYMP:0000712",
-            "EFO:0000545",
-            "UMLS:C0021359",
-            "MESH:D007246",
-            "MONDO:0005047",
-            "NCIT:C3836",
-            "UMLS:C1533568",
-            "MEDDRA:10042012",
-            "HP:0000789",
-            "PSY:25210",
-            "SNOMEDCT:15296000",
-            "PDQ:CDR0000726658",
-            "SNOMEDCT:8619003",
-            "MEDDRA:10021926"
-          ],
-          "id": "MONDO:0005047",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infertility",
-            "infertility",
-            "Fertility Disorders",
-            "infertility disorder",
-            "Sterility, Reproductive"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:DiseaseOrPhenotypicFeature",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/infertility"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311498,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005047",
-              "name": "infertility disorder",
-              "description": "Inability to conceive for at least one year after trying and having unprotected sex. Causes of female infertility include endometriosis, fallopian tubes obstruction, and polycystic ovary syndrome. Causes of male infertility include abnormal sperm production or function, blockage of the epididymis, blockage of the ejaculatory ducts, hypospadias, exposure to pesticides, and health related issues. // COMMENTS: Editor note: dubious as to whether this is a disease as defined, check with clingen before obsoleting",
-              "equivalent_curies": [
-                "UMLS:C4074771",
-                "MEDDRA:10021930",
-                "DOID:5223",
-                "SYMP:0000712",
-                "EFO:0000545",
-                "UMLS:C0021359",
-                "MESH:D007246",
-                "MONDO:0005047",
-                "NCIT:C3836",
-                "UMLS:C1533568",
-                "MEDDRA:10042012",
-                "HP:0000789",
-                "PSY:25210",
-                "SNOMEDCT:15296000",
-                "PDQ:CDR0000726658",
-                "SNOMEDCT:8619003",
-                "MEDDRA:10021926"
-              ],
-              "id": "MONDO:0005047",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infertility",
-                "infertility",
-                "Fertility Disorders",
-                "infertility disorder",
-                "Sterility, Reproductive"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:DiseaseOrPhenotypicFeature",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/infertility"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11251310,
-            "start": 568,
-            "end": 311498,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1551969': {'publication date': '1992 Jan', 'sentence': \"In this double blind cross-over study, 20 infertile men, who had sperm antibodies detected by the mixed antiglobulin reaction (MAR test) in the ejaculate and by the tray agglutination test (TAT) in serum, were treated with 40 mg/day prednisolone or placebo from days 1 to 10 of the partners' menstrual cycle.\", 'subject score': 833, 'object score': 790}, 'PMID:2056224': {'publication date': '1991 May', 'sentence': 'In addition, the effect of prednisolone as a treatment of infertility caused by endometriosis was evaluated in animal experiments.', 'subject score': 1000, 'object score': 1000}, 'PMID:27591233': {'publication date': '2016 10', 'sentence': 'There is ongoing interest in immune-suppressant corticosteroid drugs such as prednisolone to treat infertility in women with repeated IVF failure and recurrent miscarriage.', 'subject score': 1000, 'object score': 1000}, 'PMID:8876264': {'publication date': '1996 Jun', 'sentence': 'Twenty infertile men, positive for antisperm antibodies by the mixed antiglobulin reaction (MAR) test, were treated with either 20 mg/day prednisolone (n = 10) or placebo (n = 10) for 3 weeks.', 'subject score': 736, 'object score': 790}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0021359---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11497678",
-              "object": "MONDO:0005047",
-              "publications": [
-                "PMID:1551969",
-                "PMID:2056224",
-                "PMID:27591233",
-                "PMID:8876264"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:17530014': {'publication date': '2007 May 28', 'sentence': 'A combination of rituximab plus chemotherapy, rituximab+cyclophosphamide+doxorubicin+vincristine+prednisolone (R-CHOP), has the highest efficacy ever described with any chemotherapy in DLBCL and FL.', 'subject score': 822, 'object score': 922}, 'PMID:26085719': {'publication date': '2015 Sep', 'sentence': 'We retrospectively analyzed clinical data for 29 consecutive DLBCL patients with an initial bulky mass receiving R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy from 2004 to 2011.', 'subject score': 1000, 'object score': 806}}",
-    "p2": {
-      "start": {
-        "identity": 699953,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018905",
-          "name": "diffuse large B-cell lymphoma",
-          "description": "A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.; Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "NCIT:C8851",
-            "UMLS:C0079744",
-            "MEDDRA:10012819",
-            "MEDDRA:10012818",
-            "MONDO:0018905",
-            "UMLS:C2699777",
-            "NCIT:C80280",
-            "SNOMEDCT:109969005",
-            "SNOMEDCT:1172695008",
-            "MESH:D016403",
-            "ORPHANET:544",
-            "MEDDRA:10012820",
-            "DOID:0050745",
-            "EFO:0000403"
-          ],
-          "id": "MONDO:0018905",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphoma, Large B-Cell, Diffuse",
-            "diffuse large B-cell lymphoma",
-            "Diffuse Large B-Cell Lymphoma",
-            "Diffuse large B-cell lymphoma",
-            "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28487884",
-            "http://en.wikipedia.org/wiki/diffuse_large_b-cell_lymphoma",
-            "https://ncithesaurus.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&ns=ncit&code=c148392"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 699953,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018905",
-              "name": "diffuse large B-cell lymphoma",
-              "description": "A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.; Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "NCIT:C8851",
-                "UMLS:C0079744",
-                "MEDDRA:10012819",
-                "MEDDRA:10012818",
-                "MONDO:0018905",
-                "UMLS:C2699777",
-                "NCIT:C80280",
-                "SNOMEDCT:109969005",
-                "SNOMEDCT:1172695008",
-                "MESH:D016403",
-                "ORPHANET:544",
-                "MEDDRA:10012820",
-                "DOID:0050745",
-                "EFO:0000403"
-              ],
-              "id": "MONDO:0018905",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphoma, Large B-Cell, Diffuse",
-                "diffuse large B-cell lymphoma",
-                "Diffuse Large B-Cell Lymphoma",
-                "Diffuse large B-cell lymphoma",
-                "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28487884",
-                "http://en.wikipedia.org/wiki/diffuse_large_b-cell_lymphoma",
-                "https://ncithesaurus.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&ns=ncit&code=c148392"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12874288,
-            "start": 568,
-            "end": 699953,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17530014': {'publication date': '2007 May 28', 'sentence': 'A combination of rituximab plus chemotherapy, rituximab+cyclophosphamide+doxorubicin+vincristine+prednisolone (R-CHOP), has the highest efficacy ever described with any chemotherapy in DLBCL and FL.', 'subject score': 822, 'object score': 922}, 'PMID:26085719': {'publication date': '2015 Sep', 'sentence': 'We retrospectively analyzed clinical data for 29 consecutive DLBCL patients with an initial bulky mass receiving R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy from 2004 to 2011.', 'subject score': 1000, 'object score': 806}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0079744---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "13151963",
-              "object": "MONDO:0018905",
-              "publications": [
-                "PMID:17530014",
-                "PMID:26085719"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:16098067': {'publication date': '2005 Aug', 'sentence': 'CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) has been the standard chemotherapy regimen used for diffuse large cell lymphomas for over 30 years.', 'subject score': 1000, 'object score': 991}, 'PMID:17119328': {'publication date': '2006', 'sentence': 'The other tumors, hypoattenuating in the portal phase CT, were diagnosed histopathologically as DLBCL, and treated with cyclophosphamide, tetrahydropyranyl-Adriamycin, vincristine and prednisolone (THP-COP) in combination with rituximab.', 'subject score': 1000, 'object score': 922}, 'PMID:19590893': {'publication date': '2010 Jan', 'sentence': 'INTRODUCTION: We previously described the effectiveness of the THP-COP regimen comprising cyclophosphamide, pirarubicin (tetrahydropyranyl adriamycin; THP), vincristine and prednisolone in patients with diffuse large B-cell lymphoma (DLBCL).', 'subject score': 1000, 'object score': 922}, 'PMID:19656156': {'publication date': '2009 Oct', 'sentence': 'We evaluated the usefulness of prognostic markers in patients with diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide, vincristine, doxorubicin, and prednisolone (CHOP) +/- rituximab (R-CHOP) in Japan.', 'subject score': 1000, 'object score': 922}, 'PMID:19861288': {'publication date': '2009 Nov 01', 'sentence': 'Treatment with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been considered as the standard therapy for diffuse large B-cell lymphoma (DLBCL) for more than 20 years.', 'subject score': 1000, 'object score': 922}, 'PMID:20210673': {'publication date': '2010 Apr', 'sentence': 'CONCLUSION: These data suggest that R plus dose-reduced mitoxantrone, cyclophosphamide, vincristine, and prednisolone are feasible and highly effective in elderly patients with DLBCL of the thyroid.', 'subject score': 1000, 'object score': 922}, 'PMID:21438831': {'publication date': '2011 Apr', 'sentence': 'We previously described the benefit of the THP-COP regimen comprising cyclophosphamide, THP, vincristine, and prednisolone for elderly patients with diffuse large B-cell lymphoma (DLBCL).', 'subject score': 1000, 'object score': 922}, 'PMID:21718130': {'publication date': '2011 Oct', 'sentence': 'Patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) were evaluated with respect to clinical characteristics, treatment efficacy, and survival.', 'subject score': 1000, 'object score': 922}, 'PMID:21827339': {'publication date': '2012 Feb', 'sentence': 'We have previously described the effectiveness of the R-THP-COP regimen comprising rituximab, cyclophosphamide, pirarubicin, vincristine and prednisolone in patients with diffuse large B-cell lymphoma.', 'subject score': 1000, 'object score': 922}, 'PMID:22280534': {'publication date': '2012 Aug', 'sentence': 'Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.', 'subject score': 1000, 'object score': 922}, 'PMID:22563154': {'publication date': '2011 Oct', 'sentence': 'We report a patient with primary ovarian diffuse large B-cell lymphoma (DLBCL) and associated auto-immune hemolytic anemia (AIHA) who achieved complete remission after treatment with Rituximab-cyclophosphamide-doxorubicin-vincristine and prednisolone (R-CHOP) chemotherapy.', 'subject score': 1000, 'object score': 859}, 'PMID:22903849': {'publication date': '2012 Oct', 'sentence': 'This report concerns severe disseminated VZV infection in a diffuse large B cell lymphoma (DLBCL) patient treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP).', 'subject score': 1000, 'object score': 883}, 'PMID:22949903': {'publication date': '2012 May', 'sentence': 'The standard treatment of DLBCL patients is rituximab-based chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisolone.', 'subject score': 1000, 'object score': 877}, 'PMID:23063898': {'publication date': '2012 Oct 21', 'sentence': 'PATIENTS AND METHODS: Thirty-five diffuse large B-cell lymphoma patients were examined, who were treated with rituximab-cyclophosphamide-vincristine-doxoribicine-prednisolone (R-CHOP).', 'subject score': 766, 'object score': 819}, 'PMID:23320009': {'publication date': '2012 Dec', 'sentence': 'We report a case of diffuse large B-cell lymphoma (DLBCL) treated successfully with clarithromycin (CAM) and prednisolone (PSL).', 'subject score': 1000, 'object score': 922}, 'PMID:23452117': {'publication date': '2013 Nov', 'sentence': 'Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.', 'subject score': 888, 'object score': 922}, 'PMID:23488601': {'publication date': '2013 Nov', 'sentence': 'The purpose of this study was to investigate prognostic factors for overall survival (OS) among patients with previously untreated diffuse large B-cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP).', 'subject score': 1000, 'object score': 836}, 'PMID:24220559': {'publication date': '2014 Feb 01', 'sentence': 'De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial.', 'subject score': 1000, 'object score': 922}, 'PMID:25177375': {'publication date': '2014 Sep', 'sentence': 'CONCLUSIONS: In the current study, we identified the pre-treatment MTV measured by FDG-PET/CT as a potential predictor of survival in patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), at least in Ann Arbor stage II and III disease.', 'subject score': 1000, 'object score': 922}, 'PMID:25263825': {'publication date': '2014 Dec', 'sentence': 'The aim of the current study is to evaluate the prognostic value of anemia, an easily estimable parameter in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) immunochemotherapy.', 'subject score': 1000, 'object score': 922}}",
-    "p2": {
-      "start": {
-        "identity": 699953,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018905",
-          "name": "diffuse large B-cell lymphoma",
-          "description": "A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.; Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "NCIT:C8851",
-            "UMLS:C0079744",
-            "MEDDRA:10012819",
-            "MEDDRA:10012818",
-            "MONDO:0018905",
-            "UMLS:C2699777",
-            "NCIT:C80280",
-            "SNOMEDCT:109969005",
-            "SNOMEDCT:1172695008",
-            "MESH:D016403",
-            "ORPHANET:544",
-            "MEDDRA:10012820",
-            "DOID:0050745",
-            "EFO:0000403"
-          ],
-          "id": "MONDO:0018905",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphoma, Large B-Cell, Diffuse",
-            "diffuse large B-cell lymphoma",
-            "Diffuse Large B-Cell Lymphoma",
-            "Diffuse large B-cell lymphoma",
-            "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28487884",
-            "http://en.wikipedia.org/wiki/diffuse_large_b-cell_lymphoma",
-            "https://ncithesaurus.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&ns=ncit&code=c148392"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 699953,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018905",
-              "name": "diffuse large B-cell lymphoma",
-              "description": "A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.; Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "NCIT:C8851",
-                "UMLS:C0079744",
-                "MEDDRA:10012819",
-                "MEDDRA:10012818",
-                "MONDO:0018905",
-                "UMLS:C2699777",
-                "NCIT:C80280",
-                "SNOMEDCT:109969005",
-                "SNOMEDCT:1172695008",
-                "MESH:D016403",
-                "ORPHANET:544",
-                "MEDDRA:10012820",
-                "DOID:0050745",
-                "EFO:0000403"
-              ],
-              "id": "MONDO:0018905",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphoma, Large B-Cell, Diffuse",
-                "diffuse large B-cell lymphoma",
-                "Diffuse Large B-Cell Lymphoma",
-                "Diffuse large B-cell lymphoma",
-                "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28487884",
-                "http://en.wikipedia.org/wiki/diffuse_large_b-cell_lymphoma",
-                "https://ncithesaurus.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&ns=ncit&code=c148392"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11732152,
-            "start": 568,
-            "end": 699953,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16098067': {'publication date': '2005 Aug', 'sentence': 'CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) has been the standard chemotherapy regimen used for diffuse large cell lymphomas for over 30 years.', 'subject score': 1000, 'object score': 991}, 'PMID:17119328': {'publication date': '2006', 'sentence': 'The other tumors, hypoattenuating in the portal phase CT, were diagnosed histopathologically as DLBCL, and treated with cyclophosphamide, tetrahydropyranyl-Adriamycin, vincristine and prednisolone (THP-COP) in combination with rituximab.', 'subject score': 1000, 'object score': 922}, 'PMID:19590893': {'publication date': '2010 Jan', 'sentence': 'INTRODUCTION: We previously described the effectiveness of the THP-COP regimen comprising cyclophosphamide, pirarubicin (tetrahydropyranyl adriamycin; THP), vincristine and prednisolone in patients with diffuse large B-cell lymphoma (DLBCL).', 'subject score': 1000, 'object score': 922}, 'PMID:19656156': {'publication date': '2009 Oct', 'sentence': 'We evaluated the usefulness of prognostic markers in patients with diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide, vincristine, doxorubicin, and prednisolone (CHOP) +/- rituximab (R-CHOP) in Japan.', 'subject score': 1000, 'object score': 922}, 'PMID:19861288': {'publication date': '2009 Nov 01', 'sentence': 'Treatment with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been considered as the standard therapy for diffuse large B-cell lymphoma (DLBCL) for more than 20 years.', 'subject score': 1000, 'object score': 922}, 'PMID:20210673': {'publication date': '2010 Apr', 'sentence': 'CONCLUSION: These data suggest that R plus dose-reduced mitoxantrone, cyclophosphamide, vincristine, and prednisolone are feasible and highly effective in elderly patients with DLBCL of the thyroid.', 'subject score': 1000, 'object score': 922}, 'PMID:21438831': {'publication date': '2011 Apr', 'sentence': 'We previously described the benefit of the THP-COP regimen comprising cyclophosphamide, THP, vincristine, and prednisolone for elderly patients with diffuse large B-cell lymphoma (DLBCL).', 'subject score': 1000, 'object score': 922}, 'PMID:21718130': {'publication date': '2011 Oct', 'sentence': 'Patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) were evaluated with respect to clinical characteristics, treatment efficacy, and survival.', 'subject score': 1000, 'object score': 922}, 'PMID:21827339': {'publication date': '2012 Feb', 'sentence': 'We have previously described the effectiveness of the R-THP-COP regimen comprising rituximab, cyclophosphamide, pirarubicin, vincristine and prednisolone in patients with diffuse large B-cell lymphoma.', 'subject score': 1000, 'object score': 922}, 'PMID:22280534': {'publication date': '2012 Aug', 'sentence': 'Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.', 'subject score': 1000, 'object score': 922}, 'PMID:22563154': {'publication date': '2011 Oct', 'sentence': 'We report a patient with primary ovarian diffuse large B-cell lymphoma (DLBCL) and associated auto-immune hemolytic anemia (AIHA) who achieved complete remission after treatment with Rituximab-cyclophosphamide-doxorubicin-vincristine and prednisolone (R-CHOP) chemotherapy.', 'subject score': 1000, 'object score': 859}, 'PMID:22903849': {'publication date': '2012 Oct', 'sentence': 'This report concerns severe disseminated VZV infection in a diffuse large B cell lymphoma (DLBCL) patient treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP).', 'subject score': 1000, 'object score': 883}, 'PMID:22949903': {'publication date': '2012 May', 'sentence': 'The standard treatment of DLBCL patients is rituximab-based chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisolone.', 'subject score': 1000, 'object score': 877}, 'PMID:23063898': {'publication date': '2012 Oct 21', 'sentence': 'PATIENTS AND METHODS: Thirty-five diffuse large B-cell lymphoma patients were examined, who were treated with rituximab-cyclophosphamide-vincristine-doxoribicine-prednisolone (R-CHOP).', 'subject score': 766, 'object score': 819}, 'PMID:23320009': {'publication date': '2012 Dec', 'sentence': 'We report a case of diffuse large B-cell lymphoma (DLBCL) treated successfully with clarithromycin (CAM) and prednisolone (PSL).', 'subject score': 1000, 'object score': 922}, 'PMID:23452117': {'publication date': '2013 Nov', 'sentence': 'Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.', 'subject score': 888, 'object score': 922}, 'PMID:23488601': {'publication date': '2013 Nov', 'sentence': 'The purpose of this study was to investigate prognostic factors for overall survival (OS) among patients with previously untreated diffuse large B-cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP).', 'subject score': 1000, 'object score': 836}, 'PMID:24220559': {'publication date': '2014 Feb 01', 'sentence': 'De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial.', 'subject score': 1000, 'object score': 922}, 'PMID:25177375': {'publication date': '2014 Sep', 'sentence': 'CONCLUSIONS: In the current study, we identified the pre-treatment MTV measured by FDG-PET/CT as a potential predictor of survival in patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), at least in Ann Arbor stage II and III disease.', 'subject score': 1000, 'object score': 922}, 'PMID:25263825': {'publication date': '2014 Dec', 'sentence': 'The aim of the current study is to evaluate the prognostic value of anemia, an easily estimable parameter in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) immunochemotherapy.', 'subject score': 1000, 'object score': 922}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0079744---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11988157",
-              "object": "MONDO:0018905",
-              "publications": [
-                "PMID:16098067",
-                "PMID:17119328",
-                "PMID:19590893",
-                "PMID:19656156",
-                "PMID:19861288",
-                "PMID:20210673",
-                "PMID:21438831",
-                "PMID:21718130",
-                "PMID:21827339",
-                "PMID:22280534",
-                "PMID:22563154",
-                "PMID:22903849",
-                "PMID:22949903",
-                "PMID:23063898",
-                "PMID:23320009",
-                "PMID:23452117",
-                "PMID:23488601",
-                "PMID:24220559",
-                "PMID:25177375",
-                "PMID:25263825"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:6861268': {'publication date': '1983', 'sentence': 'It is concluded that VAP is effective therapy in AIL.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 819686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004977",
-          "name": "angioimmunoblastic T-cell lymphoma",
-          "description": "A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes. It occurs in the middle aged and elderly, with an equal incidence in males and females. The clinical course is typically aggressive. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C7528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C7528\" NCI Thesaurus); A peripheral T-cell lymphoma of mature T follicular helper (TFH) cells characterized by systemic disease and a polymorphous infiltrate involving lymph nodes, with a prominent proliferation of high endothelial venules and follicular dendritic cells. EBV-positive cells are nearly always present. It is a clinically aggressive lymphoma and seen mainly in older adults. (WHO 2017); A disorder characterized by proliferation of arborizing small vessels, prominent immunoblastic proliferations and amorphous acidophilic interstitial material. Clinical manifestations include fever, sweats, weight loss, generalized lymphadenopathy and frequently hepatosplenomegaly.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:835009",
-            "EFO:1001350",
-            "MEDDRA:10002449",
-            "SNOMEDCT:52097008",
-            "MONDO:0004977",
-            "UMLS:C0020981",
-            "MEDDRA:10002451",
-            "ORPHANET:86886",
-            "MEDDRA:10079289",
-            "MEDDRA:10079282",
-            "MEDDRA:10002450",
-            "NCIT:C7528",
-            "PDQ:CDR0000042765",
-            "DOID:0111147",
-            "EFO:0000255",
-            "ICD10:C86.5",
-            "SNOMEDCT:413537009",
-            "MEDDRA:10080248",
-            "MESH:D007119"
-          ],
-          "id": "MONDO:0004977",
-          "category": "biolink:Disease",
-          "all_names": [
-            "angioimmunoblastic T-cell lymphoma",
-            "Immunoblastic Lymphadenopathy",
-            "Angioimmunoblastic T-Cell Lymphoma",
-            "Angioimmunoblastic T-cell lymphoma",
-            "Angioimmunoblastic Lymphadenopathy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:22700722",
-            "https://rarediseases.org/rare-diseases/angioimmunoblastic-t-cell-lymphoma/",
-            "https://www.lymphoma.org/aboutlymphoma/nhl/aitl/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 819686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004977",
-              "name": "angioimmunoblastic T-cell lymphoma",
-              "description": "A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes. It occurs in the middle aged and elderly, with an equal incidence in males and females. The clinical course is typically aggressive. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C7528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C7528\" NCI Thesaurus); A peripheral T-cell lymphoma of mature T follicular helper (TFH) cells characterized by systemic disease and a polymorphous infiltrate involving lymph nodes, with a prominent proliferation of high endothelial venules and follicular dendritic cells. EBV-positive cells are nearly always present. It is a clinically aggressive lymphoma and seen mainly in older adults. (WHO 2017); A disorder characterized by proliferation of arborizing small vessels, prominent immunoblastic proliferations and amorphous acidophilic interstitial material. Clinical manifestations include fever, sweats, weight loss, generalized lymphadenopathy and frequently hepatosplenomegaly.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:835009",
-                "EFO:1001350",
-                "MEDDRA:10002449",
-                "SNOMEDCT:52097008",
-                "MONDO:0004977",
-                "UMLS:C0020981",
-                "MEDDRA:10002451",
-                "ORPHANET:86886",
-                "MEDDRA:10079289",
-                "MEDDRA:10079282",
-                "MEDDRA:10002450",
-                "NCIT:C7528",
-                "PDQ:CDR0000042765",
-                "DOID:0111147",
-                "EFO:0000255",
-                "ICD10:C86.5",
-                "SNOMEDCT:413537009",
-                "MEDDRA:10080248",
-                "MESH:D007119"
-              ],
-              "id": "MONDO:0004977",
-              "category": "biolink:Disease",
-              "all_names": [
-                "angioimmunoblastic T-cell lymphoma",
-                "Immunoblastic Lymphadenopathy",
-                "Angioimmunoblastic T-Cell Lymphoma",
-                "Angioimmunoblastic T-cell lymphoma",
-                "Angioimmunoblastic Lymphadenopathy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:22700722",
-                "https://rarediseases.org/rare-diseases/angioimmunoblastic-t-cell-lymphoma/",
-                "https://www.lymphoma.org/aboutlymphoma/nhl/aitl/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25827255,
-            "start": 568,
-            "end": 819686,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:6861268': {'publication date': '1983', 'sentence': 'It is concluded that VAP is effective therapy in AIL.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0020981---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "26295217",
-              "object": "MONDO:0004977",
-              "publications": [
-                "PMID:6861268"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1890746': {'publication date': '1991 Jun', 'sentence': 'Three months later, AILD relapsed in spite of prednisolone treatment.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 819686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004977",
-          "name": "angioimmunoblastic T-cell lymphoma",
-          "description": "A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes. It occurs in the middle aged and elderly, with an equal incidence in males and females. The clinical course is typically aggressive. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C7528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C7528\" NCI Thesaurus); A peripheral T-cell lymphoma of mature T follicular helper (TFH) cells characterized by systemic disease and a polymorphous infiltrate involving lymph nodes, with a prominent proliferation of high endothelial venules and follicular dendritic cells. EBV-positive cells are nearly always present. It is a clinically aggressive lymphoma and seen mainly in older adults. (WHO 2017); A disorder characterized by proliferation of arborizing small vessels, prominent immunoblastic proliferations and amorphous acidophilic interstitial material. Clinical manifestations include fever, sweats, weight loss, generalized lymphadenopathy and frequently hepatosplenomegaly.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:835009",
-            "EFO:1001350",
-            "MEDDRA:10002449",
-            "SNOMEDCT:52097008",
-            "MONDO:0004977",
-            "UMLS:C0020981",
-            "MEDDRA:10002451",
-            "ORPHANET:86886",
-            "MEDDRA:10079289",
-            "MEDDRA:10079282",
-            "MEDDRA:10002450",
-            "NCIT:C7528",
-            "PDQ:CDR0000042765",
-            "DOID:0111147",
-            "EFO:0000255",
-            "ICD10:C86.5",
-            "SNOMEDCT:413537009",
-            "MEDDRA:10080248",
-            "MESH:D007119"
-          ],
-          "id": "MONDO:0004977",
-          "category": "biolink:Disease",
-          "all_names": [
-            "angioimmunoblastic T-cell lymphoma",
-            "Immunoblastic Lymphadenopathy",
-            "Angioimmunoblastic T-Cell Lymphoma",
-            "Angioimmunoblastic T-cell lymphoma",
-            "Angioimmunoblastic Lymphadenopathy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:22700722",
-            "https://rarediseases.org/rare-diseases/angioimmunoblastic-t-cell-lymphoma/",
-            "https://www.lymphoma.org/aboutlymphoma/nhl/aitl/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 819686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004977",
-              "name": "angioimmunoblastic T-cell lymphoma",
-              "description": "A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes. It occurs in the middle aged and elderly, with an equal incidence in males and females. The clinical course is typically aggressive. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C7528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C7528\" NCI Thesaurus); A peripheral T-cell lymphoma of mature T follicular helper (TFH) cells characterized by systemic disease and a polymorphous infiltrate involving lymph nodes, with a prominent proliferation of high endothelial venules and follicular dendritic cells. EBV-positive cells are nearly always present. It is a clinically aggressive lymphoma and seen mainly in older adults. (WHO 2017); A disorder characterized by proliferation of arborizing small vessels, prominent immunoblastic proliferations and amorphous acidophilic interstitial material. Clinical manifestations include fever, sweats, weight loss, generalized lymphadenopathy and frequently hepatosplenomegaly.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:835009",
-                "EFO:1001350",
-                "MEDDRA:10002449",
-                "SNOMEDCT:52097008",
-                "MONDO:0004977",
-                "UMLS:C0020981",
-                "MEDDRA:10002451",
-                "ORPHANET:86886",
-                "MEDDRA:10079289",
-                "MEDDRA:10079282",
-                "MEDDRA:10002450",
-                "NCIT:C7528",
-                "PDQ:CDR0000042765",
-                "DOID:0111147",
-                "EFO:0000255",
-                "ICD10:C86.5",
-                "SNOMEDCT:413537009",
-                "MEDDRA:10080248",
-                "MESH:D007119"
-              ],
-              "id": "MONDO:0004977",
-              "category": "biolink:Disease",
-              "all_names": [
-                "angioimmunoblastic T-cell lymphoma",
-                "Immunoblastic Lymphadenopathy",
-                "Angioimmunoblastic T-Cell Lymphoma",
-                "Angioimmunoblastic T-cell lymphoma",
-                "Angioimmunoblastic Lymphadenopathy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:22700722",
-                "https://rarediseases.org/rare-diseases/angioimmunoblastic-t-cell-lymphoma/",
-                "https://www.lymphoma.org/aboutlymphoma/nhl/aitl/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13718505,
-            "start": 568,
-            "end": 819686,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1890746': {'publication date': '1991 Jun', 'sentence': 'Three months later, AILD relapsed in spite of prednisolone treatment.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0020981---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "14012190",
-              "object": "MONDO:0004977",
-              "publications": [
-                "PMID:1890746"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:1341718': {'publication date': '1992', 'sentence': \"Primary resistance to vincristine (Vcr) and prednisolone in untreated AML was observed as well as 'acquired' resistance to several other antileukemic drugs.\", 'subject score': 1000, 'object score': 923}, 'PMID:7331708': {'publication date': '1981 Jul', 'sentence': 'Combination chemotherapy with daunorubicin, cytosine arabinoside and prednisolone (DAP) in acute nonlymphocytic leukemia.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321063,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018874",
-          "name": "acute myeloid leukemia",
-          "description": "A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification). (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3171\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3171\" NCI Thesaurus); Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.; A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).; Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.; A form of leukemia characterized by overproduction of an early myeloid cell. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:91861009",
-            "ICD9:205.0",
-            "MEDDRA:10024346",
-            "MEDDRA:10000801",
-            "MEDDRA:10060354",
-            "KEGG.DISEASE:05221",
-            "EFO:0000222",
-            "PDQ:CDR0000043424",
-            "MEDDRA:10000886",
-            "HP:0004808",
-            "MEDDRA:10060394",
-            "MESH:D015470",
-            "MEDDRA:10051003",
-            "MONDO:0100173",
-            "MEDDRA:10000878",
-            "MEDDRA:10060553",
-            "MEDDRA:10024291",
-            "SNOMEDCT:1162928000",
-            "MEDDRA:10054296",
-            "ORPHANET:519",
-            "MEDDRA:10000880",
-            "UMLS:C3275959",
-            "MEDDRA:10028552",
-            "MONDO:0018874",
-            "OMIM:601626",
-            "MEDDRA:10000884",
-            "DOID:9119",
-            "MEDDRA:10029549",
-            "MEDDRA:10029551",
-            "UMLS:C0023467",
-            "NCIT:C3171",
-            "MEDDRA:10060557",
-            "MEDDRA:10028557"
-          ],
-          "id": "MONDO:0018874",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia, acute myeloid related phenotypic feature",
-            "Leukemia, Myelocytic, Acute",
-            "Acute myeloid leukemia",
-            "acute myeloid leukemia",
-            "leukemia, acute myeloid, susceptibility to",
-            "Leukemia, acute myeloid, susceptibility to",
-            "Acute Myeloid Leukemia",
-            "Leukemia, Myeloid, Acute",
-            "Myeloid leukemia, acute"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=44363",
-            "http://cancergenome.nih.gov/cancersselected/acutemyeloidleukemia",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.cancer.org/cancer/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.htm",
-            "http://en.wikipedia.org/wiki/acute_myeloid_leukemia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321063,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018874",
-              "name": "acute myeloid leukemia",
-              "description": "A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification). (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3171\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3171\" NCI Thesaurus); Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.; A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).; Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.; A form of leukemia characterized by overproduction of an early myeloid cell. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:91861009",
-                "ICD9:205.0",
-                "MEDDRA:10024346",
-                "MEDDRA:10000801",
-                "MEDDRA:10060354",
-                "KEGG.DISEASE:05221",
-                "EFO:0000222",
-                "PDQ:CDR0000043424",
-                "MEDDRA:10000886",
-                "HP:0004808",
-                "MEDDRA:10060394",
-                "MESH:D015470",
-                "MEDDRA:10051003",
-                "MONDO:0100173",
-                "MEDDRA:10000878",
-                "MEDDRA:10060553",
-                "MEDDRA:10024291",
-                "SNOMEDCT:1162928000",
-                "MEDDRA:10054296",
-                "ORPHANET:519",
-                "MEDDRA:10000880",
-                "UMLS:C3275959",
-                "MEDDRA:10028552",
-                "MONDO:0018874",
-                "OMIM:601626",
-                "MEDDRA:10000884",
-                "DOID:9119",
-                "MEDDRA:10029549",
-                "MEDDRA:10029551",
-                "UMLS:C0023467",
-                "NCIT:C3171",
-                "MEDDRA:10060557",
-                "MEDDRA:10028557"
-              ],
-              "id": "MONDO:0018874",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia, acute myeloid related phenotypic feature",
-                "Leukemia, Myelocytic, Acute",
-                "Acute myeloid leukemia",
-                "acute myeloid leukemia",
-                "leukemia, acute myeloid, susceptibility to",
-                "Leukemia, acute myeloid, susceptibility to",
-                "Acute Myeloid Leukemia",
-                "Leukemia, Myeloid, Acute",
-                "Myeloid leukemia, acute"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=44363",
-                "http://cancergenome.nih.gov/cancersselected/acutemyeloidleukemia",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.cancer.org/cancer/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.htm",
-                "http://en.wikipedia.org/wiki/acute_myeloid_leukemia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10300447,
-            "start": 568,
-            "end": 321063,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1341718': {'publication date': '1992', 'sentence': \"Primary resistance to vincristine (Vcr) and prednisolone in untreated AML was observed as well as 'acquired' resistance to several other antileukemic drugs.\", 'subject score': 1000, 'object score': 923}, 'PMID:7331708': {'publication date': '1981 Jul', 'sentence': 'Combination chemotherapy with daunorubicin, cytosine arabinoside and prednisolone (DAP) in acute nonlymphocytic leukemia.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0023467---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10527508",
-              "object": "MONDO:0018874",
-              "publications": [
-                "PMID:1341718",
-                "PMID:7331708"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1059498': {'publication date': '1975 Nov', 'sentence': 'Treatment of acute myeloid leukemia of childhood with cytosine arabinoside, daunorubicin, prednisolone, and mercaptopurine or thioguanine.', 'subject score': 1000, 'object score': 1000}, 'PMID:17071496': {'publication date': '2006 Oct', 'sentence': 'This study analysed the clinical outcome of salvage therapy consisting of aclarubicin (ACR) plus behenoyl cytarabine (BHAC) and prednisolone (PSL) for patients with acute myeloid leukemia (AML).', 'subject score': 1000, 'object score': 1000}, 'PMID:1857690': {'publication date': '1991 May', 'sentence': 'We here report a case of pulmonary infiltrates due to Mycobacterium xenopi in a patient after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission and under immunosuppressive treatment with prednisolone and Cyclosporin A.', 'subject score': 1000, 'object score': 1000}, 'PMID:4516626': {'publication date': '1973 Sep 15', 'sentence': 'A preliminary report is given of a trial of the T.R.A.P. regimen (thioguanine, rubidomycin, cytosine arabinoside, and prednisolone) for the treatment of acute myeloid leukaemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:6951069': {'publication date': '1981 Jul', 'sentence': 'Two cases of acute myelogenous leukemia with high terminal deoxynucleotidyl transferase activity responding to vincristine-prednisolone treatment with complete remission.', 'subject score': 851, 'object score': 1000}, 'PMID:7615046': {'publication date': '1995 Jul', 'sentence': 'Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:8174198': {'publication date': '1994', 'sentence': 'Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia.', 'subject score': 1000, 'object score': 884}, 'PMID:8299770': {'publication date': '1994 Jan', 'sentence': 'When patients with common acute lymphoblastic leukemia (cALL) and acute myeloblastic leukemia (AML) were treated with prednisolone (60 mg/m2/day, p.o. or i.v.) and etoposide (150 mg/m2/day, i.v.), respectively, the blast cell counts fell to below 30% and 5%, respectively, in 1 week.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321063,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018874",
-          "name": "acute myeloid leukemia",
-          "description": "A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification). (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3171\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3171\" NCI Thesaurus); Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.; A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).; Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.; A form of leukemia characterized by overproduction of an early myeloid cell. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:91861009",
-            "ICD9:205.0",
-            "MEDDRA:10024346",
-            "MEDDRA:10000801",
-            "MEDDRA:10060354",
-            "KEGG.DISEASE:05221",
-            "EFO:0000222",
-            "PDQ:CDR0000043424",
-            "MEDDRA:10000886",
-            "HP:0004808",
-            "MEDDRA:10060394",
-            "MESH:D015470",
-            "MEDDRA:10051003",
-            "MONDO:0100173",
-            "MEDDRA:10000878",
-            "MEDDRA:10060553",
-            "MEDDRA:10024291",
-            "SNOMEDCT:1162928000",
-            "MEDDRA:10054296",
-            "ORPHANET:519",
-            "MEDDRA:10000880",
-            "UMLS:C3275959",
-            "MEDDRA:10028552",
-            "MONDO:0018874",
-            "OMIM:601626",
-            "MEDDRA:10000884",
-            "DOID:9119",
-            "MEDDRA:10029549",
-            "MEDDRA:10029551",
-            "UMLS:C0023467",
-            "NCIT:C3171",
-            "MEDDRA:10060557",
-            "MEDDRA:10028557"
-          ],
-          "id": "MONDO:0018874",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia, acute myeloid related phenotypic feature",
-            "Leukemia, Myelocytic, Acute",
-            "Acute myeloid leukemia",
-            "acute myeloid leukemia",
-            "leukemia, acute myeloid, susceptibility to",
-            "Leukemia, acute myeloid, susceptibility to",
-            "Acute Myeloid Leukemia",
-            "Leukemia, Myeloid, Acute",
-            "Myeloid leukemia, acute"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=44363",
-            "http://cancergenome.nih.gov/cancersselected/acutemyeloidleukemia",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.cancer.org/cancer/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.htm",
-            "http://en.wikipedia.org/wiki/acute_myeloid_leukemia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321063,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018874",
-              "name": "acute myeloid leukemia",
-              "description": "A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification). (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3171\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3171\" NCI Thesaurus); Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.; A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).; Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.; A form of leukemia characterized by overproduction of an early myeloid cell. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:91861009",
-                "ICD9:205.0",
-                "MEDDRA:10024346",
-                "MEDDRA:10000801",
-                "MEDDRA:10060354",
-                "KEGG.DISEASE:05221",
-                "EFO:0000222",
-                "PDQ:CDR0000043424",
-                "MEDDRA:10000886",
-                "HP:0004808",
-                "MEDDRA:10060394",
-                "MESH:D015470",
-                "MEDDRA:10051003",
-                "MONDO:0100173",
-                "MEDDRA:10000878",
-                "MEDDRA:10060553",
-                "MEDDRA:10024291",
-                "SNOMEDCT:1162928000",
-                "MEDDRA:10054296",
-                "ORPHANET:519",
-                "MEDDRA:10000880",
-                "UMLS:C3275959",
-                "MEDDRA:10028552",
-                "MONDO:0018874",
-                "OMIM:601626",
-                "MEDDRA:10000884",
-                "DOID:9119",
-                "MEDDRA:10029549",
-                "MEDDRA:10029551",
-                "UMLS:C0023467",
-                "NCIT:C3171",
-                "MEDDRA:10060557",
-                "MEDDRA:10028557"
-              ],
-              "id": "MONDO:0018874",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia, acute myeloid related phenotypic feature",
-                "Leukemia, Myelocytic, Acute",
-                "Acute myeloid leukemia",
-                "acute myeloid leukemia",
-                "leukemia, acute myeloid, susceptibility to",
-                "Leukemia, acute myeloid, susceptibility to",
-                "Acute Myeloid Leukemia",
-                "Leukemia, Myeloid, Acute",
-                "Myeloid leukemia, acute"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=44363",
-                "http://cancergenome.nih.gov/cancersselected/acutemyeloidleukemia",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.cancer.org/cancer/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.htm",
-                "http://en.wikipedia.org/wiki/acute_myeloid_leukemia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7703300,
-            "start": 568,
-            "end": 321063,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1059498': {'publication date': '1975 Nov', 'sentence': 'Treatment of acute myeloid leukemia of childhood with cytosine arabinoside, daunorubicin, prednisolone, and mercaptopurine or thioguanine.', 'subject score': 1000, 'object score': 1000}, 'PMID:17071496': {'publication date': '2006 Oct', 'sentence': 'This study analysed the clinical outcome of salvage therapy consisting of aclarubicin (ACR) plus behenoyl cytarabine (BHAC) and prednisolone (PSL) for patients with acute myeloid leukemia (AML).', 'subject score': 1000, 'object score': 1000}, 'PMID:1857690': {'publication date': '1991 May', 'sentence': 'We here report a case of pulmonary infiltrates due to Mycobacterium xenopi in a patient after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission and under immunosuppressive treatment with prednisolone and Cyclosporin A.', 'subject score': 1000, 'object score': 1000}, 'PMID:4516626': {'publication date': '1973 Sep 15', 'sentence': 'A preliminary report is given of a trial of the T.R.A.P. regimen (thioguanine, rubidomycin, cytosine arabinoside, and prednisolone) for the treatment of acute myeloid leukaemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:6951069': {'publication date': '1981 Jul', 'sentence': 'Two cases of acute myelogenous leukemia with high terminal deoxynucleotidyl transferase activity responding to vincristine-prednisolone treatment with complete remission.', 'subject score': 851, 'object score': 1000}, 'PMID:7615046': {'publication date': '1995 Jul', 'sentence': 'Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:8174198': {'publication date': '1994', 'sentence': 'Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia.', 'subject score': 1000, 'object score': 884}, 'PMID:8299770': {'publication date': '1994 Jan', 'sentence': 'When patients with common acute lymphoblastic leukemia (cALL) and acute myeloblastic leukemia (AML) were treated with prednisolone (60 mg/m2/day, p.o. or i.v.) and etoposide (150 mg/m2/day, i.v.), respectively, the blast cell counts fell to below 30% and 5%, respectively, in 1 week.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0023467---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7866839",
-              "object": "MONDO:0018874",
-              "publications": [
-                "PMID:1059498",
-                "PMID:17071496",
-                "PMID:1857690",
-                "PMID:4516626",
-                "PMID:6951069",
-                "PMID:7615046",
-                "PMID:8174198",
-                "PMID:8299770"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:19734428': {'publication date': '2009 Sep', 'sentence': 'Pyruvate kinase M2 and prednisolone resistance in acute lymphoblastic leukemia.', 'subject score': 694, 'object score': 1000}, 'PMID:19965632': {'publication date': '2010 Feb 04', 'sentence': 'To validate this observation, we determined MCL-1 expression with quantitative reverse transcription-polymerase chain reaction in a cohort of MLL-rearranged infant ALL and pediatric noninfant ALL samples and confirmed that high-level MCL-1 expression is associated with prednisolone resistance in vitro.', 'subject score': 694, 'object score': 816}, 'PMID:23128824': {'publication date': '2014 Sep', 'sentence': 'Combination of prednisolone and low dosed dexamethasone exhibits greater in vitro antileukemic activity than equiactive dose of prednisolone and overcomes prednisolone drug resistance in acute childhood lymphoblastic leukemia.', 'subject score': 1000, 'object score': 916}, 'PMID:8708730': {'publication date': '1996 Aug', 'sentence': 'PURPOSE: The relative cytotoxicity of prednisolone and dexamethasone in acute lymphoblastic leukemia (ALL) is controversial.', 'subject score': 1000, 'object score': 1000}, 'PMID:20815080': {'publication date': '2010 Oct', 'sentence': 'In our study, we also evaluate the role of DXM compared with PDN during induction or subsequent phases of therapy in adult ALL with emphasis on SR group.', 'subject score': 1000, 'object score': 1000}, 'PMID:8856090': {'publication date': '1996 Aug', 'sentence': 'This study aimed at investigating the biological and clinical significance of in vitro PDN resistance in adult ALL.', 'subject score': 658, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 323831,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-          "name": "acute lymphoblastic leukemia",
-          "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "HP:0006721",
-            "MONDO:0004967",
-            "MEDDRA:10000848",
-            "MEDDRA:10000849",
-            "MEDDRA:10025305",
-            "ORPHANET:513",
-            "MEDDRA:10025301",
-            "ICD10:C91.00",
-            "UMLS:C0023453",
-            "DOID:9952",
-            "MEDDRA:10000844",
-            "MEDDRA:10000846",
-            "MEDDRA:10000845",
-            "MEDDRA:10024338",
-            "ICD10:C91",
-            "MESH:D054198",
-            "UMLS:C1961102",
-            "MEDDRA:10060555",
-            "NCIT:C3167",
-            "PDQ:CDR0000043423",
-            "MEDDRA:10024290",
-            "MEDDRA:10000842",
-            "NCIT:C27281",
-            "ICD9:204",
-            "DOID:1037",
-            "MEDDRA:10000843",
-            "EFO:0000220",
-            "SNOMEDCT:128822004",
-            "ICD9:204.0",
-            "UMLS:C0023449",
-            "MEDDRA:10060390",
-            "SNOMEDCT:91857003"
-          ],
-          "id": "MONDO:0004967",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute lymphoblastic leukemia",
-            "lymphoid leukemia",
-            "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-            "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-            "L2 Acute Lymphoblastic Leukemia",
-            "acute lymphocytic leukemia",
-            "Lymphoid leukemia, acute",
-            "acute lymphoblastic leukemia",
-            "Acute lymphocytic leukemia",
-            "Acute Lymphoblastic Leukemia",
-            "Lymphoid leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=46332",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=616067",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323831,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-              "name": "acute lymphoblastic leukemia",
-              "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "HP:0006721",
-                "MONDO:0004967",
-                "MEDDRA:10000848",
-                "MEDDRA:10000849",
-                "MEDDRA:10025305",
-                "ORPHANET:513",
-                "MEDDRA:10025301",
-                "ICD10:C91.00",
-                "UMLS:C0023453",
-                "DOID:9952",
-                "MEDDRA:10000844",
-                "MEDDRA:10000846",
-                "MEDDRA:10000845",
-                "MEDDRA:10024338",
-                "ICD10:C91",
-                "MESH:D054198",
-                "UMLS:C1961102",
-                "MEDDRA:10060555",
-                "NCIT:C3167",
-                "PDQ:CDR0000043423",
-                "MEDDRA:10024290",
-                "MEDDRA:10000842",
-                "NCIT:C27281",
-                "ICD9:204",
-                "DOID:1037",
-                "MEDDRA:10000843",
-                "EFO:0000220",
-                "SNOMEDCT:128822004",
-                "ICD9:204.0",
-                "UMLS:C0023449",
-                "MEDDRA:10060390",
-                "SNOMEDCT:91857003"
-              ],
-              "id": "MONDO:0004967",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute lymphoblastic leukemia",
-                "lymphoid leukemia",
-                "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-                "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-                "L2 Acute Lymphoblastic Leukemia",
-                "acute lymphocytic leukemia",
-                "Lymphoid leukemia, acute",
-                "acute lymphoblastic leukemia",
-                "Acute lymphocytic leukemia",
-                "Acute Lymphoblastic Leukemia",
-                "Lymphoid leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=46332",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=616067",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14260936,
-            "start": 568,
-            "end": 323831,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19734428': {'publication date': '2009 Sep', 'sentence': 'Pyruvate kinase M2 and prednisolone resistance in acute lymphoblastic leukemia.', 'subject score': 694, 'object score': 1000}, 'PMID:19965632': {'publication date': '2010 Feb 04', 'sentence': 'To validate this observation, we determined MCL-1 expression with quantitative reverse transcription-polymerase chain reaction in a cohort of MLL-rearranged infant ALL and pediatric noninfant ALL samples and confirmed that high-level MCL-1 expression is associated with prednisolone resistance in vitro.', 'subject score': 694, 'object score': 816}, 'PMID:23128824': {'publication date': '2014 Sep', 'sentence': 'Combination of prednisolone and low dosed dexamethasone exhibits greater in vitro antileukemic activity than equiactive dose of prednisolone and overcomes prednisolone drug resistance in acute childhood lymphoblastic leukemia.', 'subject score': 1000, 'object score': 916}, 'PMID:8708730': {'publication date': '1996 Aug', 'sentence': 'PURPOSE: The relative cytotoxicity of prednisolone and dexamethasone in acute lymphoblastic leukemia (ALL) is controversial.', 'subject score': 1000, 'object score': 1000}, 'PMID:20815080': {'publication date': '2010 Oct', 'sentence': 'In our study, we also evaluate the role of DXM compared with PDN during induction or subsequent phases of therapy in adult ALL with emphasis on SR group.', 'subject score': 1000, 'object score': 1000}, 'PMID:8856090': {'publication date': '1996 Aug', 'sentence': 'This study aimed at investigating the biological and clinical significance of in vitro PDN resistance in adult ALL.', 'subject score': 658, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0023449---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0023453---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "14564343",
-              "object": "MONDO:0004967",
-              "publications": [
-                "PMID:23128824",
-                "PMID:19965632",
-                "PMID:19734428",
-                "PMID:8708730",
-                "PMID:20815080",
-                "PMID:8856090"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:has_part",
-    "r2.publications_info": "{'PMID:8225380': {'publication date': '1993 Jun', 'sentence': 'Fourteen patients developed hyperglycemia during induction therapy of acute lymphoblastic leukemia with L-asparaginase, prednisolone, vincristine and daunorubicin.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 323831,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-          "name": "acute lymphoblastic leukemia",
-          "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "HP:0006721",
-            "MONDO:0004967",
-            "MEDDRA:10000848",
-            "MEDDRA:10000849",
-            "MEDDRA:10025305",
-            "ORPHANET:513",
-            "MEDDRA:10025301",
-            "ICD10:C91.00",
-            "UMLS:C0023453",
-            "DOID:9952",
-            "MEDDRA:10000844",
-            "MEDDRA:10000846",
-            "MEDDRA:10000845",
-            "MEDDRA:10024338",
-            "ICD10:C91",
-            "MESH:D054198",
-            "UMLS:C1961102",
-            "MEDDRA:10060555",
-            "NCIT:C3167",
-            "PDQ:CDR0000043423",
-            "MEDDRA:10024290",
-            "MEDDRA:10000842",
-            "NCIT:C27281",
-            "ICD9:204",
-            "DOID:1037",
-            "MEDDRA:10000843",
-            "EFO:0000220",
-            "SNOMEDCT:128822004",
-            "ICD9:204.0",
-            "UMLS:C0023449",
-            "MEDDRA:10060390",
-            "SNOMEDCT:91857003"
-          ],
-          "id": "MONDO:0004967",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute lymphoblastic leukemia",
-            "lymphoid leukemia",
-            "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-            "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-            "L2 Acute Lymphoblastic Leukemia",
-            "acute lymphocytic leukemia",
-            "Lymphoid leukemia, acute",
-            "acute lymphoblastic leukemia",
-            "Acute lymphocytic leukemia",
-            "Acute Lymphoblastic Leukemia",
-            "Lymphoid leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=46332",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=616067",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323831,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-              "name": "acute lymphoblastic leukemia",
-              "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "HP:0006721",
-                "MONDO:0004967",
-                "MEDDRA:10000848",
-                "MEDDRA:10000849",
-                "MEDDRA:10025305",
-                "ORPHANET:513",
-                "MEDDRA:10025301",
-                "ICD10:C91.00",
-                "UMLS:C0023453",
-                "DOID:9952",
-                "MEDDRA:10000844",
-                "MEDDRA:10000846",
-                "MEDDRA:10000845",
-                "MEDDRA:10024338",
-                "ICD10:C91",
-                "MESH:D054198",
-                "UMLS:C1961102",
-                "MEDDRA:10060555",
-                "NCIT:C3167",
-                "PDQ:CDR0000043423",
-                "MEDDRA:10024290",
-                "MEDDRA:10000842",
-                "NCIT:C27281",
-                "ICD9:204",
-                "DOID:1037",
-                "MEDDRA:10000843",
-                "EFO:0000220",
-                "SNOMEDCT:128822004",
-                "ICD9:204.0",
-                "UMLS:C0023449",
-                "MEDDRA:10060390",
-                "SNOMEDCT:91857003"
-              ],
-              "id": "MONDO:0004967",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute lymphoblastic leukemia",
-                "lymphoid leukemia",
-                "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-                "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-                "L2 Acute Lymphoblastic Leukemia",
-                "acute lymphocytic leukemia",
-                "Lymphoid leukemia, acute",
-                "acute lymphoblastic leukemia",
-                "Acute lymphocytic leukemia",
-                "Acute Lymphoblastic Leukemia",
-                "Lymphoid leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=46332",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=616067",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26414514,
-            "start": 323831,
-            "end": 568,
-            "type": "biolink:has_part",
-            "properties": {
-              "predicate": "biolink:has_part",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8225380': {'publication date': '1993 Jun', 'sentence': 'Fourteen patients developed hyperglycemia during induction therapy of acute lymphoblastic leukemia with L-asparaginase, prednisolone, vincristine and daunorubicin.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:part_of---None---None---None---UMLS:C0023449---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0004967",
-              "id": "26879702",
-              "object": "PUBCHEM.COMPOUND:5755",
-              "publications": [
-                "PMID:8225380"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 323988,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009693",
-          "name": "plasma cell myeloma",
-          "description": "A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3242\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3242\" NCI Thesaurus); A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001); A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.; A malignant plasma cell tumor growing within soft tissue or within the skeleton. [HPO:sdoelken]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10074470",
-            "MEDDRA:10028569",
-            "MEDDRA:10028228",
-            "MEDDRA:10035226",
-            "EFO:0001378",
-            "SNOMEDCT:55921005",
-            "MEDDRA:10034613",
-            "MESH:D009101",
-            "MEDDRA:10028568",
-            "MONDO:0009693",
-            "ICD9:203.0",
-            "HP:0006775",
-            "OMIM:254500",
-            "MEDDRA:10028566",
-            "ORPHANET:29073",
-            "SNOMEDCT:109989006",
-            "DOID:9538",
-            "ICD10:C90.0",
-            "UMLS:C0026764",
-            "PDQ:CDR0000042947",
-            "NCIT:C3242",
-            "SNOMEDCT:1162576007"
-          ],
-          "id": "MONDO:0009693",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Multiple myeloma",
-            "Multiple Myeloma",
-            "plasma cell myeloma",
-            "multiple myeloma",
-            "Myeloma, multiple related phenotypic feature",
-            "Plasma Cell Myeloma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=411384",
-            "http://en.wikipedia.org/wiki/multiple_myeloma",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323988,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009693",
-              "name": "plasma cell myeloma",
-              "description": "A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3242\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3242\" NCI Thesaurus); A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001); A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.; A malignant plasma cell tumor growing within soft tissue or within the skeleton. [HPO:sdoelken]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10074470",
-                "MEDDRA:10028569",
-                "MEDDRA:10028228",
-                "MEDDRA:10035226",
-                "EFO:0001378",
-                "SNOMEDCT:55921005",
-                "MEDDRA:10034613",
-                "MESH:D009101",
-                "MEDDRA:10028568",
-                "MONDO:0009693",
-                "ICD9:203.0",
-                "HP:0006775",
-                "OMIM:254500",
-                "MEDDRA:10028566",
-                "ORPHANET:29073",
-                "SNOMEDCT:109989006",
-                "DOID:9538",
-                "ICD10:C90.0",
-                "UMLS:C0026764",
-                "PDQ:CDR0000042947",
-                "NCIT:C3242",
-                "SNOMEDCT:1162576007"
-              ],
-              "id": "MONDO:0009693",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Multiple myeloma",
-                "Multiple Myeloma",
-                "plasma cell myeloma",
-                "multiple myeloma",
-                "Myeloma, multiple related phenotypic feature",
-                "Plasma Cell Myeloma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=411384",
-                "http://en.wikipedia.org/wiki/multiple_myeloma",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26207526,
-            "start": 323988,
-            "end": 568,
-            "type": "biolink:has_part",
-            "properties": {
-              "predicate": "biolink:has_part",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7823397': {'publication date': '1994 Nov', 'sentence': 'A 66-year-old man was treated for IgD (lambda) multiple myeloma with 2mg/day melphalan and 20mg/day prednisolone.', 'subject score': 790, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:part_of---None---None---None---UMLS:C0026764---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0009693",
-              "id": "26670577",
-              "object": "PUBCHEM.COMPOUND:5755",
-              "publications": [
-                "PMID:7823397"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 4578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisone",
-          "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "HMDB:HMDB0014773",
-            "UMLS:C0032952",
-            "NCIT:C770",
-            "PUBCHEM.COMPOUND:5865",
-            "DrugCentral:2253",
-            "MESH:D011241",
-            "ATC:A07EA03",
-            "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-            "CAS:53-03-2",
-            "PDQ:CDR0000042487",
-            "PathWhiz.Compound:9120",
-            "KEGG.DRUG:D00473",
-            "DRUGBANK:DB00635",
-            "ATC:H02AB07",
-            "UNII:VB0R961HZT",
-            "NDDF:002164",
-            "CHEMBL.COMPOUND:CHEMBL635",
-            "CHEBI:8382",
-            "KEGG.COMPOUND:C07370",
-            "GTOPDB:7096",
-            "RXNORM:8640"
-          ],
-          "id": "PUBCHEM.COMPOUND:5865",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisone",
-            "Prednisone (USP)",
-            "PREDNISONE",
-            "1,2-dehydrocortisone",
-            "prednisone"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:32422522",
-            "PMID:18788725",
-            "PMID:11413487",
-            "PMID:20070106",
-            "PMID:378499",
-            "PMID:15646539",
-            "PMID:20014752",
-            "PMID:25618019",
-            "PMID:23571415",
-            "PMID:19586686"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 4578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisone",
-              "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "HMDB:HMDB0014773",
-                "UMLS:C0032952",
-                "NCIT:C770",
-                "PUBCHEM.COMPOUND:5865",
-                "DrugCentral:2253",
-                "MESH:D011241",
-                "ATC:A07EA03",
-                "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-                "CAS:53-03-2",
-                "PDQ:CDR0000042487",
-                "PathWhiz.Compound:9120",
-                "KEGG.DRUG:D00473",
-                "DRUGBANK:DB00635",
-                "ATC:H02AB07",
-                "UNII:VB0R961HZT",
-                "NDDF:002164",
-                "CHEMBL.COMPOUND:CHEMBL635",
-                "CHEBI:8382",
-                "KEGG.COMPOUND:C07370",
-                "GTOPDB:7096",
-                "RXNORM:8640"
-              ],
-              "id": "PUBCHEM.COMPOUND:5865",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisone",
-                "Prednisone (USP)",
-                "PREDNISONE",
-                "1,2-dehydrocortisone",
-                "prednisone"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:32422522",
-                "PMID:18788725",
-                "PMID:11413487",
-                "PMID:20070106",
-                "PMID:378499",
-                "PMID:15646539",
-                "PMID:20014752",
-                "PMID:25618019",
-                "PMID:23571415",
-                "PMID:19586686"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18550702,
-            "start": 4578,
-            "end": 568,
-            "type": "biolink:coexists_with",
-            "properties": {
-              "predicate": "biolink:coexists_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27080058': {'publication date': '2017 Oct', 'sentence': 'Moreover, after recent findings regarding the presence of endogenous prednisolone in the urine of more popular breeds, particular attention was given to analysis of the presence of prednisolone and prednisone, as well.', 'subject score': 1000, 'object score': 888}, 'PMID:2931388': {'publication date': '1985', 'sentence': \"The inactivity of prednisone despite a significant conversion to its biologically active 11-hydroxyl metabolite, prednisolone, suggests the importance of the duration and timing of prednisolone's presence to immunosuppressive activity in the MLR culture.\", 'subject score': 1000, 'object score': 888}, 'PMID:356210': {'publication date': '1977', 'sentence': 'There appeared to be an increased risk of rejection during reduction of prednisone from 10 to 2.5 mg per day, but 20 out of the 23 patients in whom prednisolone has by noe been completely withdrawn have maintained stable and normal graft function over an average period of 1.6 (0.1-3.0) years on zero prednisone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032952---SEMMEDDB:coexists_with---None---None---None---UMLS:C0032950---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5865",
-              "id": "18935086",
-              "object": "PUBCHEM.COMPOUND:5755",
-              "publications": [
-                "PMID:27080058",
-                "PMID:2931388",
-                "PMID:356210"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 4578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisone",
-          "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "HMDB:HMDB0014773",
-            "UMLS:C0032952",
-            "NCIT:C770",
-            "PUBCHEM.COMPOUND:5865",
-            "DrugCentral:2253",
-            "MESH:D011241",
-            "ATC:A07EA03",
-            "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-            "CAS:53-03-2",
-            "PDQ:CDR0000042487",
-            "PathWhiz.Compound:9120",
-            "KEGG.DRUG:D00473",
-            "DRUGBANK:DB00635",
-            "ATC:H02AB07",
-            "UNII:VB0R961HZT",
-            "NDDF:002164",
-            "CHEMBL.COMPOUND:CHEMBL635",
-            "CHEBI:8382",
-            "KEGG.COMPOUND:C07370",
-            "GTOPDB:7096",
-            "RXNORM:8640"
-          ],
-          "id": "PUBCHEM.COMPOUND:5865",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisone",
-            "Prednisone (USP)",
-            "PREDNISONE",
-            "1,2-dehydrocortisone",
-            "prednisone"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:32422522",
-            "PMID:18788725",
-            "PMID:11413487",
-            "PMID:20070106",
-            "PMID:378499",
-            "PMID:15646539",
-            "PMID:20014752",
-            "PMID:25618019",
-            "PMID:23571415",
-            "PMID:19586686"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 4578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisone",
-              "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "HMDB:HMDB0014773",
-                "UMLS:C0032952",
-                "NCIT:C770",
-                "PUBCHEM.COMPOUND:5865",
-                "DrugCentral:2253",
-                "MESH:D011241",
-                "ATC:A07EA03",
-                "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-                "CAS:53-03-2",
-                "PDQ:CDR0000042487",
-                "PathWhiz.Compound:9120",
-                "KEGG.DRUG:D00473",
-                "DRUGBANK:DB00635",
-                "ATC:H02AB07",
-                "UNII:VB0R961HZT",
-                "NDDF:002164",
-                "CHEMBL.COMPOUND:CHEMBL635",
-                "CHEBI:8382",
-                "KEGG.COMPOUND:C07370",
-                "GTOPDB:7096",
-                "RXNORM:8640"
-              ],
-              "id": "PUBCHEM.COMPOUND:5865",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisone",
-                "Prednisone (USP)",
-                "PREDNISONE",
-                "1,2-dehydrocortisone",
-                "prednisone"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:32422522",
-                "PMID:18788725",
-                "PMID:11413487",
-                "PMID:20070106",
-                "PMID:378499",
-                "PMID:15646539",
-                "PMID:20014752",
-                "PMID:25618019",
-                "PMID:23571415",
-                "PMID:19586686"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9096353,
-            "start": 568,
-            "end": 4578,
-            "type": "biolink:derives_from",
-            "properties": {
-              "predicate": "biolink:derives_from",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1176582': {'publication date': '1975 Oct', 'sentence': 'Of 10 mg of prednisone given orally to 5 normal subjects, 69+/-5% was absorbed and converted to peripheral plasma prednisolone within 8 h.', 'subject score': 1000, 'object score': 851}, 'PMID:1952426': {'publication date': '1991 Nov', 'sentence': 'No differences were observed between six of the sensitive and resistant patients in the clearance of plasma prednisolone derived from orally administered prednisone.', 'subject score': 827, 'object score': 888}, 'PMID:22895925': {'publication date': '2012 Aug 15', 'sentence': 'Prednisone is converted into prednisolone in the liver so that the effect of the two drugs is usually the same.', 'subject score': 1000, 'object score': 1000}, 'PMID:25561247': {'publication date': '2015 Jan 05', 'sentence': 'Prednisone is converted into prednisolone in the liver so that the effect of the two drugs is usually the same.', 'subject score': 1000, 'object score': 1000}, 'PMID:29185258': {'publication date': '2017 11 29', 'sentence': 'Prednisone is converted into prednisolone in the liver so that the effect of the two drugs is usually the same.', 'subject score': 1000, 'object score': 1000}, 'PMID:2931388': {'publication date': '1985', 'sentence': 'Although, prednisone was inactive in the MLR, it was slowly being converted to prednisolone by 11-hydroxylation.', 'subject score': 1000, 'object score': 1000}, 'PMID:33195563': {'publication date': '2020', 'sentence': 'Oral prednisone was rapidly converted to prednisolone in dogs (<= 30 min), with plasma prednisolone reaching ~6-fold greater levels (0-656.1 ng/mL) than prednisone (0-98.8 ng/mL) overall.', 'subject score': 888, 'object score': 1000}, 'PMID:744499': {'publication date': '1978 Dec', 'sentence': 'We conclude that prednisone is effectively absorbed and converted to prednisolone in health and CALD and find no pharmacological evidence that either drug would be superior to the other for treating CALD.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032952---SEMMEDDB:converts_to---None---None---None---UMLS:C0032950---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9296680",
-              "object": "PUBCHEM.COMPOUND:5865",
-              "publications": [
-                "PMID:1176582",
-                "PMID:1952426",
-                "PMID:22895925",
-                "PMID:25561247",
-                "PMID:29185258",
-                "PMID:2931388",
-                "PMID:33195563",
-                "PMID:744499"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 4578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisone",
-          "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "HMDB:HMDB0014773",
-            "UMLS:C0032952",
-            "NCIT:C770",
-            "PUBCHEM.COMPOUND:5865",
-            "DrugCentral:2253",
-            "MESH:D011241",
-            "ATC:A07EA03",
-            "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-            "CAS:53-03-2",
-            "PDQ:CDR0000042487",
-            "PathWhiz.Compound:9120",
-            "KEGG.DRUG:D00473",
-            "DRUGBANK:DB00635",
-            "ATC:H02AB07",
-            "UNII:VB0R961HZT",
-            "NDDF:002164",
-            "CHEMBL.COMPOUND:CHEMBL635",
-            "CHEBI:8382",
-            "KEGG.COMPOUND:C07370",
-            "GTOPDB:7096",
-            "RXNORM:8640"
-          ],
-          "id": "PUBCHEM.COMPOUND:5865",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisone",
-            "Prednisone (USP)",
-            "PREDNISONE",
-            "1,2-dehydrocortisone",
-            "prednisone"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:32422522",
-            "PMID:18788725",
-            "PMID:11413487",
-            "PMID:20070106",
-            "PMID:378499",
-            "PMID:15646539",
-            "PMID:20014752",
-            "PMID:25618019",
-            "PMID:23571415",
-            "PMID:19586686"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 4578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisone",
-              "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "HMDB:HMDB0014773",
-                "UMLS:C0032952",
-                "NCIT:C770",
-                "PUBCHEM.COMPOUND:5865",
-                "DrugCentral:2253",
-                "MESH:D011241",
-                "ATC:A07EA03",
-                "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-                "CAS:53-03-2",
-                "PDQ:CDR0000042487",
-                "PathWhiz.Compound:9120",
-                "KEGG.DRUG:D00473",
-                "DRUGBANK:DB00635",
-                "ATC:H02AB07",
-                "UNII:VB0R961HZT",
-                "NDDF:002164",
-                "CHEMBL.COMPOUND:CHEMBL635",
-                "CHEBI:8382",
-                "KEGG.COMPOUND:C07370",
-                "GTOPDB:7096",
-                "RXNORM:8640"
-              ],
-              "id": "PUBCHEM.COMPOUND:5865",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisone",
-                "Prednisone (USP)",
-                "PREDNISONE",
-                "1,2-dehydrocortisone",
-                "prednisone"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:32422522",
-                "PMID:18788725",
-                "PMID:11413487",
-                "PMID:20070106",
-                "PMID:378499",
-                "PMID:15646539",
-                "PMID:20014752",
-                "PMID:25618019",
-                "PMID:23571415",
-                "PMID:19586686"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25955688,
-            "start": 4578,
-            "end": 568,
-            "type": "biolink:derives_from",
-            "properties": {
-              "predicate": "biolink:derives_from",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7299663': {'publication date': '1981 Nov', 'sentence': 'As in humans, prednisolone was partly converted to prednisone in the rabbit.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:converts_to---None---None---None---UMLS:C0032952---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5865",
-              "id": "26415442",
-              "object": "PUBCHEM.COMPOUND:5755",
-              "publications": [
-                "PMID:7299663"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 4578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisone",
-          "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "HMDB:HMDB0014773",
-            "UMLS:C0032952",
-            "NCIT:C770",
-            "PUBCHEM.COMPOUND:5865",
-            "DrugCentral:2253",
-            "MESH:D011241",
-            "ATC:A07EA03",
-            "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-            "CAS:53-03-2",
-            "PDQ:CDR0000042487",
-            "PathWhiz.Compound:9120",
-            "KEGG.DRUG:D00473",
-            "DRUGBANK:DB00635",
-            "ATC:H02AB07",
-            "UNII:VB0R961HZT",
-            "NDDF:002164",
-            "CHEMBL.COMPOUND:CHEMBL635",
-            "CHEBI:8382",
-            "KEGG.COMPOUND:C07370",
-            "GTOPDB:7096",
-            "RXNORM:8640"
-          ],
-          "id": "PUBCHEM.COMPOUND:5865",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisone",
-            "Prednisone (USP)",
-            "PREDNISONE",
-            "1,2-dehydrocortisone",
-            "prednisone"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:32422522",
-            "PMID:18788725",
-            "PMID:11413487",
-            "PMID:20070106",
-            "PMID:378499",
-            "PMID:15646539",
-            "PMID:20014752",
-            "PMID:25618019",
-            "PMID:23571415",
-            "PMID:19586686"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 4578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisone",
-              "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "HMDB:HMDB0014773",
-                "UMLS:C0032952",
-                "NCIT:C770",
-                "PUBCHEM.COMPOUND:5865",
-                "DrugCentral:2253",
-                "MESH:D011241",
-                "ATC:A07EA03",
-                "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-                "CAS:53-03-2",
-                "PDQ:CDR0000042487",
-                "PathWhiz.Compound:9120",
-                "KEGG.DRUG:D00473",
-                "DRUGBANK:DB00635",
-                "ATC:H02AB07",
-                "UNII:VB0R961HZT",
-                "NDDF:002164",
-                "CHEMBL.COMPOUND:CHEMBL635",
-                "CHEBI:8382",
-                "KEGG.COMPOUND:C07370",
-                "GTOPDB:7096",
-                "RXNORM:8640"
-              ],
-              "id": "PUBCHEM.COMPOUND:5865",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisone",
-                "Prednisone (USP)",
-                "PREDNISONE",
-                "1,2-dehydrocortisone",
-                "prednisone"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:32422522",
-                "PMID:18788725",
-                "PMID:11413487",
-                "PMID:20070106",
-                "PMID:378499",
-                "PMID:15646539",
-                "PMID:20014752",
-                "PMID:25618019",
-                "PMID:23571415",
-                "PMID:19586686"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14500325,
-            "start": 568,
-            "end": 4578,
-            "type": "biolink:physically_interacts_with",
-            "properties": {
-              "predicate": "biolink:physically_interacts_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20116390': {'publication date': '2010 Apr', 'sentence': 'Given the close resemblance of the ring A structure of prednisolone and prednisone on the one hand, and of androstadienedione on the other, the transformation of cortisol and cortisone into prednisolone and prednisone in cattle faeces was evaluated.', 'subject score': 1000, 'object score': 1000}, 'PMID:2266496': {'publication date': '1990 Oct', 'sentence': 'Further diagnostic analysis using a linear interconversion model revealed modest interconversion between the two steroids and at least two saturable clearance processes: the conversion of prednisolone to prednisone and the irreversible elimination of prednisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:2931388': {'publication date': '1985', 'sentence': 'The reverse reaction, the conversion of prednisolone to prednisone, did not occur.', 'subject score': 1000, 'object score': 1000}, 'PMID:3593903': {'publication date': '1987', 'sentence': 'The influence of prednisolone on prednisone binding in human plasma was also examined.', 'subject score': 1000, 'object score': 694}, 'PMID:3806371': {'publication date': '1986 Oct', 'sentence': 'Prednisolone was rapidly metabolized to prednisone, while corticosterone concentrations in normal rats declined rapidly and were undetectable by 1 hr.', 'subject score': 1000, 'object score': 1000}, 'PMID:3955201': {'publication date': '1986 Jan-Feb', 'sentence': 'While the non-linear conversion of prednisolone to prednisone is important in explaining the pharmacokinetics of prednisone in all three non-linear models, the same is not true for prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:6149280': {'publication date': '1984 Sep', 'sentence': 'The interaction between prednisone and prednisolone (0-500 ng ml-1) for binding sites on corticosteroid binding globulin (CBG) in rabbit plasma has been investigated.', 'subject score': 1000, 'object score': 1000}, 'PMID:7441495': {'publication date': '1980 Nov', 'sentence': 'The conversion of prednisolone to prednisone, defined by the prednisolone/prednisone ratio, exhibited saturable characteristics which, when data for all dogs was fitted to a Michaelis-Menten type equation (r2 = 0.938), gave a Km of 658 ng/ml, i.e., total prednisolone concentration at half-maximal saturation.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:interacts_with---None---None---None---UMLS:C0032952---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "14808035",
-              "object": "PUBCHEM.COMPOUND:5865",
-              "publications": [
-                "PMID:20116390",
-                "PMID:2266496",
-                "PMID:2931388",
-                "PMID:3593903",
-                "PMID:3806371",
-                "PMID:3955201",
-                "PMID:6149280",
-                "PMID:7441495"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 4578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisone",
-          "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "HMDB:HMDB0014773",
-            "UMLS:C0032952",
-            "NCIT:C770",
-            "PUBCHEM.COMPOUND:5865",
-            "DrugCentral:2253",
-            "MESH:D011241",
-            "ATC:A07EA03",
-            "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-            "CAS:53-03-2",
-            "PDQ:CDR0000042487",
-            "PathWhiz.Compound:9120",
-            "KEGG.DRUG:D00473",
-            "DRUGBANK:DB00635",
-            "ATC:H02AB07",
-            "UNII:VB0R961HZT",
-            "NDDF:002164",
-            "CHEMBL.COMPOUND:CHEMBL635",
-            "CHEBI:8382",
-            "KEGG.COMPOUND:C07370",
-            "GTOPDB:7096",
-            "RXNORM:8640"
-          ],
-          "id": "PUBCHEM.COMPOUND:5865",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisone",
-            "Prednisone (USP)",
-            "PREDNISONE",
-            "1,2-dehydrocortisone",
-            "prednisone"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:32422522",
-            "PMID:18788725",
-            "PMID:11413487",
-            "PMID:20070106",
-            "PMID:378499",
-            "PMID:15646539",
-            "PMID:20014752",
-            "PMID:25618019",
-            "PMID:23571415",
-            "PMID:19586686"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 4578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisone",
-              "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "HMDB:HMDB0014773",
-                "UMLS:C0032952",
-                "NCIT:C770",
-                "PUBCHEM.COMPOUND:5865",
-                "DrugCentral:2253",
-                "MESH:D011241",
-                "ATC:A07EA03",
-                "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-                "CAS:53-03-2",
-                "PDQ:CDR0000042487",
-                "PathWhiz.Compound:9120",
-                "KEGG.DRUG:D00473",
-                "DRUGBANK:DB00635",
-                "ATC:H02AB07",
-                "UNII:VB0R961HZT",
-                "NDDF:002164",
-                "CHEMBL.COMPOUND:CHEMBL635",
-                "CHEBI:8382",
-                "KEGG.COMPOUND:C07370",
-                "GTOPDB:7096",
-                "RXNORM:8640"
-              ],
-              "id": "PUBCHEM.COMPOUND:5865",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisone",
-                "Prednisone (USP)",
-                "PREDNISONE",
-                "1,2-dehydrocortisone",
-                "prednisone"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:32422522",
-                "PMID:18788725",
-                "PMID:11413487",
-                "PMID:20070106",
-                "PMID:378499",
-                "PMID:15646539",
-                "PMID:20014752",
-                "PMID:25618019",
-                "PMID:23571415",
-                "PMID:19586686"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9096355,
-            "start": 4578,
-            "end": 568,
-            "type": "biolink:physically_interacts_with",
-            "properties": {
-              "predicate": "biolink:physically_interacts_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1176582': {'publication date': '1975 Oct', 'sentence': 'The data indicate that prednisone is extensively metabolized to prednisolone before it clears the splanchnic circulation and the formation prednisone by oxidation of the 11-hydorxyl group of prednisolone appears to occur mainly in peripheral tissues.', 'subject score': 1000, 'object score': 1000}, 'PMID:17921190': {'publication date': '2008 Jan', 'sentence': 'PF-915275 dose-dependently inhibited 11betaHSD1-mediated conversion of prednisone to prednisolone, with a maximum of 87% inhibition at a 3-mg/kg dose.', 'subject score': 1000, 'object score': 1000}, 'PMID:20116390': {'publication date': '2010 Apr', 'sentence': 'Given the close resemblance of the ring A structure of prednisolone and prednisone on the one hand, and of androstadienedione on the other, the transformation of cortisol and cortisone into prednisolone and prednisone in cattle faeces was evaluated.', 'subject score': 1000, 'object score': 1000}, 'PMID:2242307': {'publication date': '1990 Sep', 'sentence': 'All the pharmacokinetic parameters, including the conversion of prednisone to prednisolone were similar to the data already published in children with INS.', 'subject score': 1000, 'object score': 1000}, 'PMID:35921255': {'publication date': '2022 Aug 03', 'sentence': 'Here, the urinary excretion profiles of prednisone and prednisolone were evaluated in five volunteers in therapy with glucocorticoid-based rectal formulations containing prednisone or prednisolone caproate.', 'subject score': 1000, 'object score': 1000}, 'PMID:3709632': {'publication date': '1986', 'sentence': 'Prednisone appeared to have no effect on prednisolone binding.', 'subject score': 1000, 'object score': 694}, 'PMID:3987177': {'publication date': '1985 May', 'sentence': 'Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:4639403': {'publication date': '1972 Sep', 'sentence': 'Thus, incomplete conversion of prednisone to prednisolone occurs, which is a necessary step for biological activity; on the other hand there is also impairment of prednisolone degradation.', 'subject score': 1000, 'object score': 1000}, 'PMID:656293': {'publication date': '1978 Jun', 'sentence': '2 In controls, values for AUC were significantly more variable after prednisone than prednisolone, and two subjects showed markedly inefficient conversion of prednisone to prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:7047863': {'publication date': '1982 Apr', 'sentence': 'The results from our study indicate that both of the oral preparations tested provide similar bioavailability of active prednisolone and the conversion of prednisone to prednisolone occurs rapidly.', 'subject score': 1000, 'object score': 1000}, 'PMID:7141787': {'publication date': '1982 Sep', 'sentence': 'This indicates that acute nephrotic syndrome does not produce impaired absorption and conversion of prednisone to prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:7364321': {'publication date': '1980 Jan', 'sentence': 'Impaired conversion of prednisone to prednisolone in patients with liver cirrhosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:849821': {'publication date': '1977 May', 'sentence': 'To determine the effect of impaired liver function on conversion of prednisone to prednisolone, and to investigate the relationship of this to responses to treatment with prednisone, we measured serum prednisone and prednisolone by radioimmunoassay after 10 mg of prednisone was given by vein to 10 healthy volunteers, 6 untreated patients with severe chronic active liver disease (CALD), 10 patients with prednisone-induced remission of CALD, and 3 patients with CALD deteriorating despite treatment with prednisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:994553': {'publication date': '1976 Dec', 'sentence': 'Although high levels of prednisolone appeared rapidly in normal dogs, only slight amounts were measured in dogs with hepatic vascular exclusion, which emphasized the importance of the liver in the conversion of prednisone to prednisolone, its active metabolite.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032952---SEMMEDDB:interacts_with---None---None---None---UMLS:C0032950---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5865",
-              "id": "9296682",
-              "object": "PUBCHEM.COMPOUND:5755",
-              "publications": [
-                "PMID:1176582",
-                "PMID:17921190",
-                "PMID:20116390",
-                "PMID:2242307",
-                "PMID:35921255",
-                "PMID:3709632",
-                "PMID:3987177",
-                "PMID:4639403",
-                "PMID:656293",
-                "PMID:7047863",
-                "PMID:7141787",
-                "PMID:7364321",
-                "PMID:849821",
-                "PMID:994553"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 310037,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005041",
-          "name": "glaucoma",
-          "description": "Increased pressure in the eyeball due to obstruction of the outflow of aqueous humor.; An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed); Glaucoma refers loss of retinal ganglion cells in a characteristic pattern of optic neuropathy usually associated with increased intraocular pressure. [HPO:probinson, PMID:11815354]; Glaucoma is a group of diseases that can damage the eye's optic nerve. It is a leading cause of blindness in the United States. It usually happens when the fluid pressure inside the eyes slowly rises, damaging the optic nerve. Often there are no symptoms at first. Without treatment, people with glaucoma will slowly lose their peripheral, or side vision. They seem to be looking through a tunnel. Over time, straight-ahead vision may decrease until no vision remains. A comprehensive eye exam can tell if you have glaucoma. People at risk should get eye exams at least every two years. They include: African Americans over age 40 People over age 60, especially Mexican Americans People with a family history of glaucoma  There is no cure, but glaucoma can usually be controlled. Early treatment can help protect your eyes against vision loss. Treatments usually include prescription eyedrops and/or surgery. NIH: National Eye Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C26782",
-            "PSY:21090",
-            "MESH:D005901",
-            "ICD10:H40",
-            "SNOMEDCT:23986001",
-            "UMLS:C0017601",
-            "EFO:0000516",
-            "MEDDRA:10018304",
-            "MEDDRA:10018332",
-            "MEDDRA:10018326",
-            "MONDO:0005041",
-            "ICD9:365",
-            "MEDDRA:10045894",
-            "HP:0000501",
-            "DOID:1686"
-          ],
-          "id": "MONDO:0005041",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_glaucoma",
-            "glaucoma",
-            "Glaucoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/glaucoma",
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:11815354",
-            "https://www.aao.org/eye-health/diseases/what-is-glaucoma",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310037,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005041",
-              "name": "glaucoma",
-              "description": "Increased pressure in the eyeball due to obstruction of the outflow of aqueous humor.; An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed); Glaucoma refers loss of retinal ganglion cells in a characteristic pattern of optic neuropathy usually associated with increased intraocular pressure. [HPO:probinson, PMID:11815354]; Glaucoma is a group of diseases that can damage the eye's optic nerve. It is a leading cause of blindness in the United States. It usually happens when the fluid pressure inside the eyes slowly rises, damaging the optic nerve. Often there are no symptoms at first. Without treatment, people with glaucoma will slowly lose their peripheral, or side vision. They seem to be looking through a tunnel. Over time, straight-ahead vision may decrease until no vision remains. A comprehensive eye exam can tell if you have glaucoma. People at risk should get eye exams at least every two years. They include: African Americans over age 40 People over age 60, especially Mexican Americans People with a family history of glaucoma  There is no cure, but glaucoma can usually be controlled. Early treatment can help protect your eyes against vision loss. Treatments usually include prescription eyedrops and/or surgery. NIH: National Eye Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C26782",
-                "PSY:21090",
-                "MESH:D005901",
-                "ICD10:H40",
-                "SNOMEDCT:23986001",
-                "UMLS:C0017601",
-                "EFO:0000516",
-                "MEDDRA:10018304",
-                "MEDDRA:10018332",
-                "MEDDRA:10018326",
-                "MONDO:0005041",
-                "ICD9:365",
-                "MEDDRA:10045894",
-                "HP:0000501",
-                "DOID:1686"
-              ],
-              "id": "MONDO:0005041",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_glaucoma",
-                "glaucoma",
-                "Glaucoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/glaucoma",
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:11815354",
-                "https://www.aao.org/eye-health/diseases/what-is-glaucoma",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26584988,
-            "start": 568,
-            "end": 310037,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8575609': {'publication date': '1995 Mar', 'sentence': 'CONCLUSION: Dexamethasone or prednisolone were the easiest to induce steroid glaucoma when the patients had long-term use of steroid eyedrops.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0017601---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "27055840",
-              "object": "MONDO:0005041",
-              "publications": [
-                "PMID:8575609"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316847,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
-          "name": "uveitis",
-          "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:1001231",
-            "UMLS:C0042164",
-            "DOID:13141",
-            "SNOMEDCT:128473001",
-            "MEDDRA:10046851",
-            "ICD10:H20.9",
-            "MONDO:0020283",
-            "MESH:D014605",
-            "NCIT:C26909",
-            "MEDDRA:10046855",
-            "HP:0000554",
-            "ORPHANET:98715"
-          ],
-          "id": "MONDO:0020283",
-          "category": "biolink:Disease",
-          "all_names": [
-            "uveitis",
-            "Uveitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316847,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
-              "name": "uveitis",
-              "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:1001231",
-                "UMLS:C0042164",
-                "DOID:13141",
-                "SNOMEDCT:128473001",
-                "MEDDRA:10046851",
-                "ICD10:H20.9",
-                "MONDO:0020283",
-                "MESH:D014605",
-                "NCIT:C26909",
-                "MEDDRA:10046855",
-                "HP:0000554",
-                "ORPHANET:98715"
-              ],
-              "id": "MONDO:0020283",
-              "category": "biolink:Disease",
-              "all_names": [
-                "uveitis",
-                "Uveitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26214984,
-            "start": 568,
-            "end": 316847,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7836867': {'publication date': '1994', 'sentence': 'Among 121 CK-analogs studied, CK-17, CK-101A and CK103A have been identified as promising anti-inflammatory agents as potent as prednisolone in inhibiting lens proteins-induced inflammation and twice as potent as prednisolone in inhibiting endotoxin-and IL-1-induced uveitis.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0042164---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "26677891",
-              "object": "MONDO:0020283",
-              "publications": [
-                "PMID:7836867"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319192,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-          "name": "kidney disorder",
-          "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D007674",
-            "MEDDRA:10029154",
-            "UMLS:C0022658",
-            "NCIT:C3149",
-            "MONDO:0005240",
-            "UMLS:C1408258",
-            "DOID:557",
-            "MEDDRA:10029149",
-            "HP:0000112",
-            "MEDDRA:10051051",
-            "NCIT:C34843",
-            "MEDDRA:10038428",
-            "MEDDRA:10038429",
-            "MEDDRA:10029151",
-            "MEDDRA:10051052",
-            "EFO:0003086",
-            "SNOMEDCT:90708001",
-            "MEDDRA:10013263",
-            "PSY:27347"
-          ],
-          "id": "MONDO:0005240",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Kidney damage",
-            "kidney disease",
-            "Nephropathy",
-            "Kidney Diseases",
-            "Kidney Disorder",
-            "kidney disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319192,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-              "name": "kidney disorder",
-              "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D007674",
-                "MEDDRA:10029154",
-                "UMLS:C0022658",
-                "NCIT:C3149",
-                "MONDO:0005240",
-                "UMLS:C1408258",
-                "DOID:557",
-                "MEDDRA:10029149",
-                "HP:0000112",
-                "MEDDRA:10051051",
-                "NCIT:C34843",
-                "MEDDRA:10038428",
-                "MEDDRA:10038429",
-                "MEDDRA:10029151",
-                "MEDDRA:10051052",
-                "EFO:0003086",
-                "SNOMEDCT:90708001",
-                "MEDDRA:10013263",
-                "PSY:27347"
-              ],
-              "id": "MONDO:0005240",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Kidney damage",
-                "kidney disease",
-                "Nephropathy",
-                "Kidney Diseases",
-                "Kidney Disorder",
-                "kidney disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25498725,
-            "start": 568,
-            "end": 319192,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:5830625': {'publication date': '1965 Sep', 'sentence': 'Light and electron microscopy of prednisolone-induced nephropathy in rabbits.', 'subject score': 851, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0022658---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "25953223",
-              "object": "MONDO:0005240",
-              "publications": [
-                "PMID:5830625"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 130846,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-          "name": "allergic disease",
-          "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MONDO:0005271",
-            "SYMP:0000900",
-            "UMLS:C3539909",
-            "MEDDRA:10020759",
-            "MEDDRA:10020756",
-            "NCIT:C114476",
-            "SNOMEDCT:418634005",
-            "MEDDRA:10001738",
-            "HP:0012393",
-            "MESH:D006967",
-            "MEDDRA:10001719",
-            "MEDDRA:10001741",
-            "MEDDRA:10037948",
-            "SNOMEDCT:609328004",
-            "SNOMEDCT:421961002",
-            "UMLS:C1527304",
-            "ICD10:T78.40",
-            "DOID:1205",
-            "MEDDRA:10020755",
-            "MEDDRA:10020751",
-            "MEDDRA:10037932",
-            "UMLS:C0020517",
-            "MEDDRA:10020757",
-            "SNOMEDCT:419076005",
-            "MEDDRA:10001718"
-          ],
-          "id": "MONDO:0005271",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Allergic disposition",
-            "Allergic Reaction",
-            "Hypersensitivity",
-            "allergic reaction",
-            "allergic disease",
-            "Allergy"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000005.htm",
-            "ISBN:0781735149",
-            "http://en.wikipedia.org/wiki/allergy",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 130846,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-              "name": "allergic disease",
-              "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MONDO:0005271",
-                "SYMP:0000900",
-                "UMLS:C3539909",
-                "MEDDRA:10020759",
-                "MEDDRA:10020756",
-                "NCIT:C114476",
-                "SNOMEDCT:418634005",
-                "MEDDRA:10001738",
-                "HP:0012393",
-                "MESH:D006967",
-                "MEDDRA:10001719",
-                "MEDDRA:10001741",
-                "MEDDRA:10037948",
-                "SNOMEDCT:609328004",
-                "SNOMEDCT:421961002",
-                "UMLS:C1527304",
-                "ICD10:T78.40",
-                "DOID:1205",
-                "MEDDRA:10020755",
-                "MEDDRA:10020751",
-                "MEDDRA:10037932",
-                "UMLS:C0020517",
-                "MEDDRA:10020757",
-                "SNOMEDCT:419076005",
-                "MEDDRA:10001718"
-              ],
-              "id": "MONDO:0005271",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Allergic disposition",
-                "Allergic Reaction",
-                "Hypersensitivity",
-                "allergic reaction",
-                "allergic disease",
-                "Allergy"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000005.htm",
-                "ISBN:0781735149",
-                "http://en.wikipedia.org/wiki/allergy",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21142113,
-            "start": 568,
-            "end": 130846,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31924570': {'publication date': '2020 Jan 03', 'sentence': 'The behavior results showed that exposure to prednisolone resulted in decreased autonomic activity and low sensitivity to light.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0020517---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "21556285",
-              "object": "MONDO:0005271",
-              "publications": [
-                "PMID:31924570"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 312686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-          "name": "adrenocortical insufficiency",
-          "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0405580",
-            "MEDDRA:10022460",
-            "ICD9:255.4",
-            "EFO:0009491",
-            "MEDDRA:10001367",
-            "MEDDRA:10020936",
-            "MONDO:0000004",
-            "MEDDRA:10020979",
-            "SNOMEDCT:237785004",
-            "SNOMEDCT:386584007",
-            "MEDDRA:10056485",
-            "MEDDRA:10082130",
-            "UMLS:C0001623",
-            "MEDDRA:10001344",
-            "MEDDRA:10001366",
-            "MEDDRA:10001334",
-            "DOID:10493",
-            "NCIT:C26691",
-            "HP:0000846",
-            "MEDDRA:10001335",
-            "MEDDRA:10001369",
-            "MEDDRA:10001342",
-            "MEDDRA:10001343",
-            "MESH:D000309",
-            "SNOMEDCT:111563005",
-            "MEDDRA:10011172",
-            "MEDDRA:10022461"
-          ],
-          "id": "MONDO:0000004",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortical hypofunction",
-            "Adrenocortical Insufficiency",
-            "adrenocortical insufficiency",
-            "Corticoadrenal insufficiency",
-            "Adrenal gland hypofunction",
-            "Adrenal Insufficiency",
-            "Adrenal insufficiency",
-            "Adrenal cortical hypofunction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:11443143"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-              "name": "adrenocortical insufficiency",
-              "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0405580",
-                "MEDDRA:10022460",
-                "ICD9:255.4",
-                "EFO:0009491",
-                "MEDDRA:10001367",
-                "MEDDRA:10020936",
-                "MONDO:0000004",
-                "MEDDRA:10020979",
-                "SNOMEDCT:237785004",
-                "SNOMEDCT:386584007",
-                "MEDDRA:10056485",
-                "MEDDRA:10082130",
-                "UMLS:C0001623",
-                "MEDDRA:10001344",
-                "MEDDRA:10001366",
-                "MEDDRA:10001334",
-                "DOID:10493",
-                "NCIT:C26691",
-                "HP:0000846",
-                "MEDDRA:10001335",
-                "MEDDRA:10001369",
-                "MEDDRA:10001342",
-                "MEDDRA:10001343",
-                "MESH:D000309",
-                "SNOMEDCT:111563005",
-                "MEDDRA:10011172",
-                "MEDDRA:10022461"
-              ],
-              "id": "MONDO:0000004",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortical hypofunction",
-                "Adrenocortical Insufficiency",
-                "adrenocortical insufficiency",
-                "Corticoadrenal insufficiency",
-                "Adrenal gland hypofunction",
-                "Adrenal Insufficiency",
-                "Adrenal insufficiency",
-                "Adrenal cortical hypofunction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:11443143"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20883351,
-            "start": 568,
-            "end": 312686,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31539081': {'publication date': '2019 Sep 20', 'sentence': 'We therefore advocate for increased clinical alertness towards prednisolone-induced adrenal insufficiency in RTx patients and thus their potential need of rescue GC supplementation during stress.', 'subject score': 861, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0001623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "21293782",
-              "object": "MONDO:0000004",
-              "publications": [
-                "PMID:31539081"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20386947,
-            "start": 568,
-            "end": 322104,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30616083': {'publication date': '2019 Mar', 'sentence': 'Zeaxanthin (50 mg/kg/day) or prednisolone (5 mg/kg/day) was orally administered for 14 days before induction of ulcerative colitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "20789636",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:30616083"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318533,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-          "name": "Headache",
-          "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10019211",
-            "PSY:22380",
-            "NCIT:C34661",
-            "MEDDRA:10019218",
-            "SNOMEDCT:25064002",
-            "UMLS:C0018681",
-            "MEDDRA:10019231",
-            "HP:0002315",
-            "MEDDRA:10033405",
-            "ICD9:784.0",
-            "MESH:D006261",
-            "SYMP:0000504",
-            "MEDDRA:10008013",
-            "MEDDRA:10019198"
-          ],
-          "id": "HP:0002315",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "headache",
-            "Headache"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-            "PMID:15304572",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318533,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-              "name": "Headache",
-              "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10019211",
-                "PSY:22380",
-                "NCIT:C34661",
-                "MEDDRA:10019218",
-                "SNOMEDCT:25064002",
-                "UMLS:C0018681",
-                "MEDDRA:10019231",
-                "HP:0002315",
-                "MEDDRA:10033405",
-                "ICD9:784.0",
-                "MESH:D006261",
-                "SYMP:0000504",
-                "MEDDRA:10008013",
-                "MEDDRA:10019198"
-              ],
-              "id": "HP:0002315",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "headache",
-                "Headache"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-                "PMID:15304572",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16882484,
-            "start": 568,
-            "end": 318533,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24164703': {'publication date': '2014 Nov', 'sentence': 'OBJECTIVE: We want to show that an intralesional injection of prednisolone into the proximal nail fold may produce dorsal pain, dyspnoea and headaches within the 2 min following the injection and to explain the pathophysiology of his condition.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0018681---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "17230021",
-              "object": "HP:0002315",
-              "publications": [
-                "PMID:24164703"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319059,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005377",
-          "name": "nephrotic syndrome",
-          "description": "Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. [HPO:probinson]; Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. // COMMENTS: In adults, nephrotic syndrome is characterized by protein excretion of 3.5 g or more per day. In children, nephrotic syndrome is accompanied by protein excretion of more than 40 mg/m2/h and hypalbuminemia < 2.5 mg/dl.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10042826",
-            "MESH:D009404",
-            "HP:0000100",
-            "UMLS:C0027726",
-            "MONDO:0005377",
-            "EFO:0004255",
-            "MEDDRA:10029164",
-            "SNOMEDCT:52254009",
-            "NCIT:C34845",
-            "DOID:1184",
-            "ICD9:581"
-          ],
-          "id": "MONDO:0005377",
-          "category": "biolink:Disease",
-          "all_names": [
-            "nephrotic syndrome",
-            "Nephrotic Syndrome",
-            "Nephrotic syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://en.wikipedia.org/wiki/nephrotic_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319059,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005377",
-              "name": "nephrotic syndrome",
-              "description": "Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. [HPO:probinson]; Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. // COMMENTS: In adults, nephrotic syndrome is characterized by protein excretion of 3.5 g or more per day. In children, nephrotic syndrome is accompanied by protein excretion of more than 40 mg/m2/h and hypalbuminemia < 2.5 mg/dl.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10042826",
-                "MESH:D009404",
-                "HP:0000100",
-                "UMLS:C0027726",
-                "MONDO:0005377",
-                "EFO:0004255",
-                "MEDDRA:10029164",
-                "SNOMEDCT:52254009",
-                "NCIT:C34845",
-                "DOID:1184",
-                "ICD9:581"
-              ],
-              "id": "MONDO:0005377",
-              "category": "biolink:Disease",
-              "all_names": [
-                "nephrotic syndrome",
-                "Nephrotic Syndrome",
-                "Nephrotic syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://en.wikipedia.org/wiki/nephrotic_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15971109,
-            "start": 568,
-            "end": 319059,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2262977': {'publication date': '1990 Oct', 'sentence': '[A case of nephrotic syndrome with abnormally high level of protein C induced by prednisolone].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0027726---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16304261",
-              "object": "MONDO:0005377",
-              "publications": [
-                "PMID:2262977"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 311498,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005047",
-          "name": "infertility disorder",
-          "description": "Inability to conceive for at least one year after trying and having unprotected sex. Causes of female infertility include endometriosis, fallopian tubes obstruction, and polycystic ovary syndrome. Causes of male infertility include abnormal sperm production or function, blockage of the epididymis, blockage of the ejaculatory ducts, hypospadias, exposure to pesticides, and health related issues. // COMMENTS: Editor note: dubious as to whether this is a disease as defined, check with clingen before obsoleting",
-          "equivalent_curies": [
-            "UMLS:C4074771",
-            "MEDDRA:10021930",
-            "DOID:5223",
-            "SYMP:0000712",
-            "EFO:0000545",
-            "UMLS:C0021359",
-            "MESH:D007246",
-            "MONDO:0005047",
-            "NCIT:C3836",
-            "UMLS:C1533568",
-            "MEDDRA:10042012",
-            "HP:0000789",
-            "PSY:25210",
-            "SNOMEDCT:15296000",
-            "PDQ:CDR0000726658",
-            "SNOMEDCT:8619003",
-            "MEDDRA:10021926"
-          ],
-          "id": "MONDO:0005047",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infertility",
-            "infertility",
-            "Fertility Disorders",
-            "infertility disorder",
-            "Sterility, Reproductive"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:DiseaseOrPhenotypicFeature",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/infertility"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311498,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005047",
-              "name": "infertility disorder",
-              "description": "Inability to conceive for at least one year after trying and having unprotected sex. Causes of female infertility include endometriosis, fallopian tubes obstruction, and polycystic ovary syndrome. Causes of male infertility include abnormal sperm production or function, blockage of the epididymis, blockage of the ejaculatory ducts, hypospadias, exposure to pesticides, and health related issues. // COMMENTS: Editor note: dubious as to whether this is a disease as defined, check with clingen before obsoleting",
-              "equivalent_curies": [
-                "UMLS:C4074771",
-                "MEDDRA:10021930",
-                "DOID:5223",
-                "SYMP:0000712",
-                "EFO:0000545",
-                "UMLS:C0021359",
-                "MESH:D007246",
-                "MONDO:0005047",
-                "NCIT:C3836",
-                "UMLS:C1533568",
-                "MEDDRA:10042012",
-                "HP:0000789",
-                "PSY:25210",
-                "SNOMEDCT:15296000",
-                "PDQ:CDR0000726658",
-                "SNOMEDCT:8619003",
-                "MEDDRA:10021926"
-              ],
-              "id": "MONDO:0005047",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infertility",
-                "infertility",
-                "Fertility Disorders",
-                "infertility disorder",
-                "Sterility, Reproductive"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:DiseaseOrPhenotypicFeature",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/infertility"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15048072,
-            "start": 568,
-            "end": 311498,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2115396': {'publication date': '1990 May 01', 'sentence': \"It is concluded that six or more cycles of COPP chemotherapy for advanced Hodgkin's disease in men leads to permanent sterility.\", 'subject score': 888, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0021359---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "15365269",
-              "object": "MONDO:0005047",
-              "publications": [
-                "PMID:2115396"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320057,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043233",
-          "name": "exfoliative dermatitis",
-          "description": "An inflammatory exfoliative dermatosis involving nearly all of the surface of the skin. Erythroderma develops suddenly. A patchy erythema may generalize and spread to affect most of the skin. Scaling may appear in 2-6 days and be accompanied by hot, red, dry skin, malaise, and fever. [HPO:probinson]; An inflammatory exfoliative dermatosis involving nearly all of the surface of the skin. Erythroderma develops suddenly. A patchy erythema may generalize and spread to affect most of the skin. Scaling may appear in 2-6 days and be accompanied by hot, red, dry skin, malaise, and fever.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0011606",
-            "SNOMEDCT:400005007",
-            "MEDDRA:10012455",
-            "MEDDRA:10015665",
-            "NCIT:C39646",
-            "MEDDRA:10018082",
-            "SNOMEDCT:396349005",
-            "MEDDRA:10062416",
-            "SNOMEDCT:200948000",
-            "UMLS:C5139033",
-            "MESH:D003873",
-            "MONDO:0043233",
-            "SNOMEDCT:399992009",
-            "MEDDRA:10012456",
-            "HP:0001019",
-            "MEDDRA:10052584",
-            "MEDDRA:10062434",
-            "MEDDRA:10015277",
-            "EFO:0009456",
-            "MEDDRA:10015666",
-            "MEDDRA:10012457",
-            "SNOMEDCT:396350005"
-          ],
-          "id": "MONDO:0043233",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Red scaly skin caused by inflammatory skin disease",
-            "Erythroderma",
-            "Dermatitis, Exfoliative",
-            "Exfoliative dermatitis",
-            "exfoliative dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320057,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043233",
-              "name": "exfoliative dermatitis",
-              "description": "An inflammatory exfoliative dermatosis involving nearly all of the surface of the skin. Erythroderma develops suddenly. A patchy erythema may generalize and spread to affect most of the skin. Scaling may appear in 2-6 days and be accompanied by hot, red, dry skin, malaise, and fever. [HPO:probinson]; An inflammatory exfoliative dermatosis involving nearly all of the surface of the skin. Erythroderma develops suddenly. A patchy erythema may generalize and spread to affect most of the skin. Scaling may appear in 2-6 days and be accompanied by hot, red, dry skin, malaise, and fever.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0011606",
-                "SNOMEDCT:400005007",
-                "MEDDRA:10012455",
-                "MEDDRA:10015665",
-                "NCIT:C39646",
-                "MEDDRA:10018082",
-                "SNOMEDCT:396349005",
-                "MEDDRA:10062416",
-                "SNOMEDCT:200948000",
-                "UMLS:C5139033",
-                "MESH:D003873",
-                "MONDO:0043233",
-                "SNOMEDCT:399992009",
-                "MEDDRA:10012456",
-                "HP:0001019",
-                "MEDDRA:10052584",
-                "MEDDRA:10062434",
-                "MEDDRA:10015277",
-                "EFO:0009456",
-                "MEDDRA:10015666",
-                "MEDDRA:10012457",
-                "SNOMEDCT:396350005"
-              ],
-              "id": "MONDO:0043233",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Red scaly skin caused by inflammatory skin disease",
-                "Erythroderma",
-                "Dermatitis, Exfoliative",
-                "Exfoliative dermatitis",
-                "exfoliative dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14073675,
-            "start": 568,
-            "end": 320057,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19438568': {'publication date': '2009 Jul', 'sentence': 'The erythroderma improved generally as a result of systemic prednisolone treatment.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0011606---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "14373522",
-              "object": "MONDO:0043233",
-              "publications": [
-                "PMID:19438568"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 310746,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005480",
-          "name": "contact dermatitis",
-          "description": "An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis. []; An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0011616",
-            "NCIT:C26743",
-            "EFO:0005319",
-            "ICD10:L25.9",
-            "MESH:D003877",
-            "MEDDRA:10010803",
-            "MEDDRA:10012442",
-            "MEDDRA:10058308",
-            "SNOMEDCT:40275004",
-            "DOID:2773",
-            "MONDO:0005480",
-            "MEDDRA:10010790",
-            "HP:0032282",
-            "MEDDRA:10012492"
-          ],
-          "id": "MONDO:0005480",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis, Contact",
-            "Contact dermatitis",
-            "Contact Dermatitis",
-            "contact dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310746,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005480",
-              "name": "contact dermatitis",
-              "description": "An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis. []; An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0011616",
-                "NCIT:C26743",
-                "EFO:0005319",
-                "ICD10:L25.9",
-                "MESH:D003877",
-                "MEDDRA:10010803",
-                "MEDDRA:10012442",
-                "MEDDRA:10058308",
-                "SNOMEDCT:40275004",
-                "DOID:2773",
-                "MONDO:0005480",
-                "MEDDRA:10010790",
-                "HP:0032282",
-                "MEDDRA:10012492"
-              ],
-              "id": "MONDO:0005480",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis, Contact",
-                "Contact dermatitis",
-                "Contact Dermatitis",
-                "contact dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10504892,
-            "start": 568,
-            "end": 310746,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14345404': {'publication date': '1965 Sep', 'sentence': 'CONTACT DERMATITIS DUE TO TOPICAL HYDROCORTISONE AND PREDNISOLONE.', 'subject score': 1000, 'object score': 1000}, 'PMID:18404324': {'publication date': '2008 Apr', 'sentence': 'The inhibitory activities of combinations of CU-ext (p.o.) and prednisolone (s.c.) during induction phase of PC-CD were more potent than those of CU-ext alone and prednisolone alone.', 'subject score': 1000, 'object score': 857}, 'PMID:9601904': {'publication date': '1998 Jun', 'sentence': 'OBJECTIVE: We describe a patient allergic to hydrocortisone who was given a cross-reacting corticosteroid, prednisolone, that led to a systemic contact dermatitis.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0011616---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10735861",
-              "object": "MONDO:0005480",
-              "publications": [
-                "PMID:14345404",
-                "PMID:18404324",
-                "PMID:9601904"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 310720,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006052",
-          "name": "pulmonary tuberculosis",
-          "description": "A bacterial infection that affects the lungs and is caused by Mycobacterium tuberculosis. Most patients with tuberculosis do not have symptoms (latent tuberculosis) and are not contagious. When signs and symptoms occur (active tuberculosis), patients become contagious. The signs and symptoms include chronic cough with blood-tinged sputum, night sweats, fever, fatigue, and weight loss.; MYCOBACTERIUM infections of the lung.; A lung infection by Mycobacterium tuberculosis a slightly curved non-motile, aerobic, non-capsulated and non-spore forming strains of mycobacteria. [PMID:30345099]",
-          "equivalent_curies": [
-            "MONDO:0006052",
-            "MEDDRA:10046123",
-            "PSY:42300",
-            "ICD9:011",
-            "MEDDRA:10034980",
-            "SNOMEDCT:154283005",
-            "DOID:2957",
-            "SNOMEDCT:700272008",
-            "NCIT:C26899",
-            "EFO:1000049",
-            "MEDDRA:10037443",
-            "HP:0032262",
-            "MESH:D014397",
-            "ICD10:A15",
-            "UMLS:C0041327",
-            "MEDDRA:10037435",
-            "MEDDRA:10037440"
-          ],
-          "id": "MONDO:0006052",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Tuberculosis, Pulmonary",
-            "pulmonary tuberculosis",
-            "Pulmonary Tuberculosis",
-            "Pulmonary tuberculosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:30345099",
-            "http://www.cdc.gov/tb/publications/factsheets/general/tb.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tuberculosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310720,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006052",
-              "name": "pulmonary tuberculosis",
-              "description": "A bacterial infection that affects the lungs and is caused by Mycobacterium tuberculosis. Most patients with tuberculosis do not have symptoms (latent tuberculosis) and are not contagious. When signs and symptoms occur (active tuberculosis), patients become contagious. The signs and symptoms include chronic cough with blood-tinged sputum, night sweats, fever, fatigue, and weight loss.; MYCOBACTERIUM infections of the lung.; A lung infection by Mycobacterium tuberculosis a slightly curved non-motile, aerobic, non-capsulated and non-spore forming strains of mycobacteria. [PMID:30345099]",
-              "equivalent_curies": [
-                "MONDO:0006052",
-                "MEDDRA:10046123",
-                "PSY:42300",
-                "ICD9:011",
-                "MEDDRA:10034980",
-                "SNOMEDCT:154283005",
-                "DOID:2957",
-                "SNOMEDCT:700272008",
-                "NCIT:C26899",
-                "EFO:1000049",
-                "MEDDRA:10037443",
-                "HP:0032262",
-                "MESH:D014397",
-                "ICD10:A15",
-                "UMLS:C0041327",
-                "MEDDRA:10037435",
-                "MEDDRA:10037440"
-              ],
-              "id": "MONDO:0006052",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Tuberculosis, Pulmonary",
-                "pulmonary tuberculosis",
-                "Pulmonary Tuberculosis",
-                "Pulmonary tuberculosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:30345099",
-                "http://www.cdc.gov/tb/publications/factsheets/general/tb.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tuberculosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10318497,
-            "start": 568,
-            "end": 310720,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13507005': {'publication date': '1957 Nov 22', 'sentence': '[Pulmonary tuberculosis due to prednisolone].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0041327---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10545904",
-              "object": "MONDO:0006052",
-              "publications": [
-                "PMID:13507005"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319330,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005292",
-          "name": "colitis",
-          "description": "Inflammation of the colon.; Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.; Colitis refers to an inflammation of the colon and is often used to describe an inflammation of the large intestine (colon, cecum and rectum). Colitides may be acute and self-limited or chronic, and broadly fit into the category of digestive diseases. [HPO:sdoelken]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10079511",
-            "SNOMEDCT:64226004",
-            "UMLS:C0009319",
-            "MESH:D003092",
-            "EFO:0003872",
-            "ICD10:K52.9",
-            "MEDDRA:10009889",
-            "MONDO:0005292",
-            "NCIT:C26723",
-            "MEDDRA:10009898",
-            "PSY:10220",
-            "DOID:0060180",
-            "HP:0002583",
-            "MEDDRA:10009887"
-          ],
-          "id": "MONDO:0005292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Colitis",
-            "colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319330,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005292",
-              "name": "colitis",
-              "description": "Inflammation of the colon.; Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.; Colitis refers to an inflammation of the colon and is often used to describe an inflammation of the large intestine (colon, cecum and rectum). Colitides may be acute and self-limited or chronic, and broadly fit into the category of digestive diseases. [HPO:sdoelken]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10079511",
-                "SNOMEDCT:64226004",
-                "UMLS:C0009319",
-                "MESH:D003092",
-                "EFO:0003872",
-                "ICD10:K52.9",
-                "MEDDRA:10009889",
-                "MONDO:0005292",
-                "NCIT:C26723",
-                "MEDDRA:10009898",
-                "PSY:10220",
-                "DOID:0060180",
-                "HP:0002583",
-                "MEDDRA:10009887"
-              ],
-              "id": "MONDO:0005292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Colitis",
-                "colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10281951,
-            "start": 568,
-            "end": 319330,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1337973': {'publication date': '1992', 'sentence': 'Rats were treated with a leukotriene synthesis inhibitor (PF-5901), a leukotriene B4 receptor antagonist (SC-41930), an IL-1 receptor antagonist or a corticosteroid (prednisolone) prior to induction of colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15766209': {'publication date': '2005 Feb', 'sentence': 'Prednisolone was administered orally once on the day before induction of colitis, and animals were treated twice daily thereafter.', 'subject score': 1000, 'object score': 1000}, 'PMID:9125657': {'publication date': '1997 Apr', 'sentence': 'With induction of colitis, the mucosa and lamina propria were invaded by polydendritic cells; the visual score was markedly decreased in the proximal loops treated with lidocaine, prednisolone, or sucralfate.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0009319---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10519611",
-              "object": "MONDO:0005292",
-              "publications": [
-                "PMID:1337973",
-                "PMID:15766209",
-                "PMID:9125657"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316730,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005129",
-          "name": "cataract",
-          "description": "Partial or complete opacity of the crystalline lens of one or both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.); Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed); A cataract is an opacity or clouding that develops in the crystalline lens of the eye or in its capsule. [HPO:probinson]; A cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery. A cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are: Blurry vision Colors that seem faded Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights. Not being able to see well at night Double vision  Frequent prescription changes in your eye wear   Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. NIH: National Eye Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "OMIM.PS:116200",
-            "SNOMEDCT:247053007",
-            "ICD10:H26",
-            "MEDDRA:10007768",
-            "ICD9:366.8",
-            "MONDO:0005129",
-            "UMLS:C0029531",
-            "MEDDRA:10007739",
-            "MEDDRA:10045649",
-            "MEDDRA:10030347",
-            "UMLS:C0086543",
-            "SNOMEDCT:193570009",
-            "SNOMEDCT:128306009",
-            "DOID:83",
-            "OMIM:PS116200",
-            "MEDDRA:10007771",
-            "MEDDRA:10024208",
-            "UMLS:C1510497",
-            "MEDDRA:10024214",
-            "MEDDRA:10024215",
-            "ICD9:366",
-            "HP:0000518",
-            "NCIT:C26713",
-            "MESH:D002386",
-            "MEDDRA:10007757"
-          ],
-          "id": "MONDO:0005129",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Other cataract",
-            "Cataract",
-            "cataract",
-            "Lens Opacities"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:10414631",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0001-6908-9849",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://en.wikipedia.org/wiki/cataract",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316730,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005129",
-              "name": "cataract",
-              "description": "Partial or complete opacity of the crystalline lens of one or both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.); Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed); A cataract is an opacity or clouding that develops in the crystalline lens of the eye or in its capsule. [HPO:probinson]; A cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery. A cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are: Blurry vision Colors that seem faded Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights. Not being able to see well at night Double vision  Frequent prescription changes in your eye wear   Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. NIH: National Eye Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "OMIM.PS:116200",
-                "SNOMEDCT:247053007",
-                "ICD10:H26",
-                "MEDDRA:10007768",
-                "ICD9:366.8",
-                "MONDO:0005129",
-                "UMLS:C0029531",
-                "MEDDRA:10007739",
-                "MEDDRA:10045649",
-                "MEDDRA:10030347",
-                "UMLS:C0086543",
-                "SNOMEDCT:193570009",
-                "SNOMEDCT:128306009",
-                "DOID:83",
-                "OMIM:PS116200",
-                "MEDDRA:10007771",
-                "MEDDRA:10024208",
-                "UMLS:C1510497",
-                "MEDDRA:10024214",
-                "MEDDRA:10024215",
-                "ICD9:366",
-                "HP:0000518",
-                "NCIT:C26713",
-                "MESH:D002386",
-                "MEDDRA:10007757"
-              ],
-              "id": "MONDO:0005129",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Other cataract",
-                "Cataract",
-                "cataract",
-                "Lens Opacities"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:10414631",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0001-6908-9849",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://en.wikipedia.org/wiki/cataract",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9259844,
-            "start": 568,
-            "end": 316730,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11923254': {'publication date': '2002 Apr', 'sentence': 'PURPOSE: To investigate the relationship between vitamin E deficiency and prednisolone-induced cataract formation, long-term examination of lens changes was performed in rats under the condition of vitamin E deficiency or supplementation and administration of prednisolone.', 'subject score': 833, 'object score': 833}, 'PMID:12061274': {'publication date': '2002', 'sentence': 'RESULTS: When 0.25 mumol of steroids were administered to 15-day-old chick embryos, only biologically active glucocorticoids such as hydrocortisone and prednisolone could cause cataract.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0086543---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9464043",
-              "object": "MONDO:0005129",
-              "publications": [
-                "PMID:11923254",
-                "PMID:12061274"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319015,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-          "name": "systemic lupus erythematosus",
-          "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10025133",
-            "KEGG.DISEASE:05322",
-            "MEDDRA:10042820",
-            "PDQ:CDR0000608139",
-            "MEDDRA:10040967",
-            "MEDDRA:10042800",
-            "MEDDRA:10013446",
-            "MONDO:0007915",
-            "MEDDRA:10042945",
-            "MEDDRA:10024067",
-            "ICD10:M32.9",
-            "MEDDRA:10042947",
-            "ORPHANET:536",
-            "MEDDRA:10042944",
-            "UMLS:C0024141",
-            "EFO:0002690",
-            "MESH:D008180",
-            "ICD9:710.0",
-            "DOID:9074",
-            "MEDDRA:10025139",
-            "UMLS:C1835309",
-            "MEDDRA:10024065",
-            "OMIM:152700",
-            "HP:0002725",
-            "MEDDRA:10025142",
-            "NCIT:C3201",
-            "SNOMEDCT:55464009"
-          ],
-          "id": "MONDO:0007915",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Systemic lupus erythematosus",
-            "obsolete_systemic lupus erythematosus",
-            "Systemic lupus erythematosus related phenotypic feature",
-            "Lupus Erythematosus, Systemic",
-            "Excess lmw-dna",
-            "systemic lupus erythematosus",
-            "Systemic Lupus Erythematosus"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319015,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-              "name": "systemic lupus erythematosus",
-              "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10025133",
-                "KEGG.DISEASE:05322",
-                "MEDDRA:10042820",
-                "PDQ:CDR0000608139",
-                "MEDDRA:10040967",
-                "MEDDRA:10042800",
-                "MEDDRA:10013446",
-                "MONDO:0007915",
-                "MEDDRA:10042945",
-                "MEDDRA:10024067",
-                "ICD10:M32.9",
-                "MEDDRA:10042947",
-                "ORPHANET:536",
-                "MEDDRA:10042944",
-                "UMLS:C0024141",
-                "EFO:0002690",
-                "MESH:D008180",
-                "ICD9:710.0",
-                "DOID:9074",
-                "MEDDRA:10025139",
-                "UMLS:C1835309",
-                "MEDDRA:10024065",
-                "OMIM:152700",
-                "HP:0002725",
-                "MEDDRA:10025142",
-                "NCIT:C3201",
-                "SNOMEDCT:55464009"
-              ],
-              "id": "MONDO:0007915",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Systemic lupus erythematosus",
-                "obsolete_systemic lupus erythematosus",
-                "Systemic lupus erythematosus related phenotypic feature",
-                "Lupus Erythematosus, Systemic",
-                "Excess lmw-dna",
-                "systemic lupus erythematosus",
-                "Systemic Lupus Erythematosus"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8570880,
-            "start": 568,
-            "end": 319015,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11246661': {'publication date': '2001 Feb', 'sentence': 'In inactive SLE induced by prednisolone therapy, the invariant Valpha24JalphaQ TCR could be detected in DN Valpha24+ T cells from all the patients and dominated in most of the patients.', 'subject score': 888, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0024141---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8757881",
-              "object": "MONDO:0007915",
-              "publications": [
-                "PMID:11246661"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316847,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
-          "name": "uveitis",
-          "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:1001231",
-            "UMLS:C0042164",
-            "DOID:13141",
-            "SNOMEDCT:128473001",
-            "MEDDRA:10046851",
-            "ICD10:H20.9",
-            "MONDO:0020283",
-            "MESH:D014605",
-            "NCIT:C26909",
-            "MEDDRA:10046855",
-            "HP:0000554",
-            "ORPHANET:98715"
-          ],
-          "id": "MONDO:0020283",
-          "category": "biolink:Disease",
-          "all_names": [
-            "uveitis",
-            "Uveitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316847,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
-              "name": "uveitis",
-              "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:1001231",
-                "UMLS:C0042164",
-                "DOID:13141",
-                "SNOMEDCT:128473001",
-                "MEDDRA:10046851",
-                "ICD10:H20.9",
-                "MONDO:0020283",
-                "MESH:D014605",
-                "NCIT:C26909",
-                "MEDDRA:10046855",
-                "HP:0000554",
-                "ORPHANET:98715"
-              ],
-              "id": "MONDO:0020283",
-              "category": "biolink:Disease",
-              "all_names": [
-                "uveitis",
-                "Uveitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 27185034,
-            "start": 568,
-            "end": 316847,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9715441': {'publication date': '1998 Aug', 'sentence': 'Interleukin-1 (IL-1) blockers, CK 127 and CK 129, were found to inhibit IL-1-induced posterior uveitis very effectively at 3-10 mg/kg i.p. and were more potent than prednisolone which required at least 20 mg/kg i.p. to achieve the same level of anti-uveitis action.', 'subject score': 1000, 'object score': 660}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0042164---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "27658451",
-              "object": "MONDO:0020283",
-              "publications": [
-                "PMID:9715441"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 610975,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/DOID_0080909",
-          "name": "castration-resistant prostate carcinoma",
-          "description": "A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.",
-          "equivalent_curies": [
-            "MESH:D064129",
-            "MONDO:0850353",
-            "DOID:0080909",
-            "MEDDRA:10076506",
-            "SNOMEDCT:427492003",
-            "UMLS:C3658267",
-            "MEDDRA:10062904",
-            "NCIT:C130234",
-            "UMLS:C1328504"
-          ],
-          "id": "DOID:0080909",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Prostatic Neoplasms, Castration-Resistant",
-            "castration-resistant prostate carcinoma",
-            "Castration-Resistant Prostate Carcinoma",
-            "Hormone refractory prostate cancer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:30324351"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 610975,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/DOID_0080909",
-              "name": "castration-resistant prostate carcinoma",
-              "description": "A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.",
-              "equivalent_curies": [
-                "MESH:D064129",
-                "MONDO:0850353",
-                "DOID:0080909",
-                "MEDDRA:10076506",
-                "SNOMEDCT:427492003",
-                "UMLS:C3658267",
-                "MEDDRA:10062904",
-                "NCIT:C130234",
-                "UMLS:C1328504"
-              ],
-              "id": "DOID:0080909",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Prostatic Neoplasms, Castration-Resistant",
-                "castration-resistant prostate carcinoma",
-                "Castration-Resistant Prostate Carcinoma",
-                "Hormone refractory prostate cancer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:30324351"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26939682,
-            "start": 568,
-            "end": 610975,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9234622': {'publication date': '1997 Jun', 'sentence': '[A case of hormone-refractory prostate cancer responsive to low-dose prednisolone therapy].', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C1328504---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "27410586",
-              "object": "DOID:0080909",
-              "publications": [
-                "PMID:9234622"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318915,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005363",
-          "name": "focal segmental glomerulosclerosis",
-          "description": "A renal disorder characterized by sclerotic lesions in the glomeruli. Causes include drugs, viruses, and malignancies (lymphomas), or it may be idiopathic. It presents with asymptomatic proteinuria or nephritic syndrome and it may lead to renal failure.; A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.; Segmental accumulation of scar tissue in individual (but not all) glomeruli. [Eurenomics:fschaefer, PMID:16164633]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:236403004",
-            "HP:0000097",
-            "UMLS:C0017668",
-            "UMLS:CN043606",
-            "EFO:0004236",
-            "MESH:D005923",
-            "NCIT:C37308",
-            "DOID:1312",
-            "SNOMEDCT:25821008",
-            "OMIM.PS:603278",
-            "MONDO:0005363",
-            "MEDDRA:10067757",
-            "MEDDRA:10065581",
-            "OMIM:PS603278",
-            "MEDDRA:10016832",
-            "MONDO:0100313"
-          ],
-          "id": "MONDO:0005363",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Glomerulosclerosis, Focal Segmental",
-            "Focal Segmental Glomerulosclerosis",
-            "inherited focal segmental glomerulosclerosis",
-            "Focal glomerulosclerosis",
-            "Focal segmental glomerulosclerosis",
-            "focal segmental glomerulosclerosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:16164633"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318915,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005363",
-              "name": "focal segmental glomerulosclerosis",
-              "description": "A renal disorder characterized by sclerotic lesions in the glomeruli. Causes include drugs, viruses, and malignancies (lymphomas), or it may be idiopathic. It presents with asymptomatic proteinuria or nephritic syndrome and it may lead to renal failure.; A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.; Segmental accumulation of scar tissue in individual (but not all) glomeruli. [Eurenomics:fschaefer, PMID:16164633]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:236403004",
-                "HP:0000097",
-                "UMLS:C0017668",
-                "UMLS:CN043606",
-                "EFO:0004236",
-                "MESH:D005923",
-                "NCIT:C37308",
-                "DOID:1312",
-                "SNOMEDCT:25821008",
-                "OMIM.PS:603278",
-                "MONDO:0005363",
-                "MEDDRA:10067757",
-                "MEDDRA:10065581",
-                "OMIM:PS603278",
-                "MEDDRA:10016832",
-                "MONDO:0100313"
-              ],
-              "id": "MONDO:0005363",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Glomerulosclerosis, Focal Segmental",
-                "Focal Segmental Glomerulosclerosis",
-                "inherited focal segmental glomerulosclerosis",
-                "Focal glomerulosclerosis",
-                "Focal segmental glomerulosclerosis",
-                "focal segmental glomerulosclerosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:16164633"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26853866,
-            "start": 568,
-            "end": 318915,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9066185': {'publication date': '1997', 'sentence': '6 cases of FSGS had poor response to any therapy; 7 cases were responsive to either triple therapy or cyclosporine A plus prednisolone.', 'subject score': 861, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0017668---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "27323391",
-              "object": "MONDO:0005363",
-              "publications": [
-                "PMID:9066185"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 303010,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004802",
-          "name": "pulmonary eosinophilia",
-          "description": "The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. [PMID:19618037, PMID:21428117]; The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. // COMMENTS: Pulmonary function testing usually reveals a restrictive process with reduced diffusion capacity for carbon monoxide. Laboratory tests typical include increased levels of eosinophils in the blood, a high erythrocyte sedimentation rate, iron deficiency anemia, and increased platelets.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "UMLS:C0034068",
-            "HP:0032071",
-            "UMLS:C5552799",
-            "DOID:9498",
-            "MESH:D011657",
-            "MEDDRA:10037412",
-            "ICD9:518.3",
-            "SNOMEDCT:367542003",
-            "MONDO:0004802",
-            "MEDDRA:10037382"
-          ],
-          "id": "MONDO:0004802",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Eosinophilic pneumonia",
-            "Pulmonary eosinophilic infiltrate",
-            "Pulmonary Eosinophilia",
-            "Pulmonary eosinophilia",
-            "pulmonary eosinophilia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:19618037",
-            "https://rarediseases.org/rare-diseases/simple-pulmonary-eosinophilia/",
-            "PMID:21428117"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 303010,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004802",
-              "name": "pulmonary eosinophilia",
-              "description": "The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. [PMID:19618037, PMID:21428117]; The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. // COMMENTS: Pulmonary function testing usually reveals a restrictive process with reduced diffusion capacity for carbon monoxide. Laboratory tests typical include increased levels of eosinophils in the blood, a high erythrocyte sedimentation rate, iron deficiency anemia, and increased platelets.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "UMLS:C0034068",
-                "HP:0032071",
-                "UMLS:C5552799",
-                "DOID:9498",
-                "MESH:D011657",
-                "MEDDRA:10037412",
-                "ICD9:518.3",
-                "SNOMEDCT:367542003",
-                "MONDO:0004802",
-                "MEDDRA:10037382"
-              ],
-              "id": "MONDO:0004802",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Eosinophilic pneumonia",
-                "Pulmonary eosinophilic infiltrate",
-                "Pulmonary Eosinophilia",
-                "Pulmonary eosinophilia",
-                "pulmonary eosinophilia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:19618037",
-                "https://rarediseases.org/rare-diseases/simple-pulmonary-eosinophilia/",
-                "PMID:21428117"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26575400,
-            "start": 568,
-            "end": 303010,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8551692': {'publication date': '1995 Oct', 'sentence': 'From 1983, exacerbation of PIE was recorded three times, on which occasions prednisolone and antibiotics were quite effective.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0034068---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "27042309",
-              "object": "MONDO:0004802",
-              "publications": [
-                "PMID:8551692"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 130846,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-          "name": "allergic disease",
-          "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MONDO:0005271",
-            "SYMP:0000900",
-            "UMLS:C3539909",
-            "MEDDRA:10020759",
-            "MEDDRA:10020756",
-            "NCIT:C114476",
-            "SNOMEDCT:418634005",
-            "MEDDRA:10001738",
-            "HP:0012393",
-            "MESH:D006967",
-            "MEDDRA:10001719",
-            "MEDDRA:10001741",
-            "MEDDRA:10037948",
-            "SNOMEDCT:609328004",
-            "SNOMEDCT:421961002",
-            "UMLS:C1527304",
-            "ICD10:T78.40",
-            "DOID:1205",
-            "MEDDRA:10020755",
-            "MEDDRA:10020751",
-            "MEDDRA:10037932",
-            "UMLS:C0020517",
-            "MEDDRA:10020757",
-            "SNOMEDCT:419076005",
-            "MEDDRA:10001718"
-          ],
-          "id": "MONDO:0005271",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Allergic disposition",
-            "Allergic Reaction",
-            "Hypersensitivity",
-            "allergic reaction",
-            "allergic disease",
-            "Allergy"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000005.htm",
-            "ISBN:0781735149",
-            "http://en.wikipedia.org/wiki/allergy",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 130846,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-              "name": "allergic disease",
-              "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MONDO:0005271",
-                "SYMP:0000900",
-                "UMLS:C3539909",
-                "MEDDRA:10020759",
-                "MEDDRA:10020756",
-                "NCIT:C114476",
-                "SNOMEDCT:418634005",
-                "MEDDRA:10001738",
-                "HP:0012393",
-                "MESH:D006967",
-                "MEDDRA:10001719",
-                "MEDDRA:10001741",
-                "MEDDRA:10037948",
-                "SNOMEDCT:609328004",
-                "SNOMEDCT:421961002",
-                "UMLS:C1527304",
-                "ICD10:T78.40",
-                "DOID:1205",
-                "MEDDRA:10020755",
-                "MEDDRA:10020751",
-                "MEDDRA:10037932",
-                "UMLS:C0020517",
-                "MEDDRA:10020757",
-                "SNOMEDCT:419076005",
-                "MEDDRA:10001718"
-              ],
-              "id": "MONDO:0005271",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Allergic disposition",
-                "Allergic Reaction",
-                "Hypersensitivity",
-                "allergic reaction",
-                "allergic disease",
-                "Allergy"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000005.htm",
-                "ISBN:0781735149",
-                "http://en.wikipedia.org/wiki/allergy",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25337815,
-            "start": 568,
-            "end": 130846,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:4320276': {'publication date': '1970 Jun', 'sentence': 'A comparative study of the effects of ACTH, hydrocortisone and prednisolone in the hypersensitive reactions produced with the protein components of Hymenolepis nana in albino mice.', 'subject score': 1000, 'object score': 947}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0020517---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "25790510",
-              "object": "MONDO:0005271",
-              "publications": [
-                "PMID:4320276"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318918,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002462",
-          "name": "glomerulonephritis",
-          "description": "A renal disorder characterized by damage in the glomeruli. It may be acute or chronic, focal or diffuse, and it may lead to renal failure. Causes include autoimmune disorders, infections, diabetes, and malignancies.; A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.; Inflammation of the renal glomeruli. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029143",
-            "UMLS:C0017658",
-            "SNOMEDCT:36171008",
-            "DOID:2921",
-            "HP:0000099",
-            "MESH:D005921",
-            "MEDDRA:10018364",
-            "MEDDRA:10018375",
-            "MONDO:0002462",
-            "ICD10:N08",
-            "NCIT:C26784"
-          ],
-          "id": "MONDO:0002462",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Glomerulonephritis",
-            "glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/wiki/glomerulonephritis",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318918,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002462",
-              "name": "glomerulonephritis",
-              "description": "A renal disorder characterized by damage in the glomeruli. It may be acute or chronic, focal or diffuse, and it may lead to renal failure. Causes include autoimmune disorders, infections, diabetes, and malignancies.; A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.; Inflammation of the renal glomeruli. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029143",
-                "UMLS:C0017658",
-                "SNOMEDCT:36171008",
-                "DOID:2921",
-                "HP:0000099",
-                "MESH:D005921",
-                "MEDDRA:10018364",
-                "MEDDRA:10018375",
-                "MONDO:0002462",
-                "ICD10:N08",
-                "NCIT:C26784"
-              ],
-              "id": "MONDO:0002462",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Glomerulonephritis",
-                "glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/wiki/glomerulonephritis",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24718562,
-            "start": 568,
-            "end": 318918,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:36508113': {'publication date': '2022 Dec 12', 'sentence': 'Immunosuppressant therapy, such as prednisolone or azathioprine, is considered for exacerbations of highly active glomerulonephritis.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0017658---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "25165576",
-              "object": "MONDO:0002462",
-              "publications": [
-                "PMID:36508113"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 530650,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016367",
-          "name": "dermatomyositis",
-          "description": "Inflammation of the skin and muscle.; A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003882",
-            "EFO:0000398",
-            "ICD10:M33",
-            "MONDO:0016367",
-            "SNOMEDCT:396230008",
-            "NCIT:C26744",
-            "DOID:10223",
-            "MEDDRA:10012503",
-            "ORPHANET:221",
-            "UMLS:C0011633",
-            "ICD9:710.3"
-          ],
-          "id": "MONDO:0016367",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatomyositis",
-            "dermatomyositis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/dermatomyositis",
-            "http://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 530650,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016367",
-              "name": "dermatomyositis",
-              "description": "Inflammation of the skin and muscle.; A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003882",
-                "EFO:0000398",
-                "ICD10:M33",
-                "MONDO:0016367",
-                "SNOMEDCT:396230008",
-                "NCIT:C26744",
-                "DOID:10223",
-                "MEDDRA:10012503",
-                "ORPHANET:221",
-                "UMLS:C0011633",
-                "ICD9:710.3"
-              ],
-              "id": "MONDO:0016367",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatomyositis",
-                "dermatomyositis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/dermatomyositis",
-                "http://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23830892,
-            "start": 568,
-            "end": 530650,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35238770': {'publication date': '2022 Feb 10', 'sentence': 'We describe a 57-year-old Caucasian male with anti-MDA5 positive dermatomyositis, that had a 4-month history of progressive dyspnoea requiring oxygen-therapy, scarcely responsive to prednisolone.', 'subject score': 1000, 'object score': 784}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0011633---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "24270725",
-              "object": "MONDO:0016367",
-              "publications": [
-                "PMID:35238770"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 520745,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015243",
-          "name": "allergic bronchopulmonary aspergillosis",
-          "description": "An aspergillosis that involves an allergic reaction due to the spores of Aspergillus moulds (A. fumigatus), which colonizes the mucus in the airways causing inflammation. The disease has symptom cough, has symptom wheezing and has symptom fever. // COMMENTS: OMIM mapping confirmed by DO. [SN].",
-          "equivalent_curies": [
-            "ORPHANET:1164",
-            "MEDDRA:10001707",
-            "ICD9:518.6",
-            "ICD10:B44.81",
-            "UMLS:C3278302",
-            "MEDDRA:10006474",
-            "NCIT:C84547",
-            "OMIM:103920",
-            "SNOMEDCT:37981002",
-            "MESH:D001229",
-            "DOID:13166",
-            "UMLS:C0004031",
-            "EFO:0007140",
-            "MONDO:0015243"
-          ],
-          "id": "MONDO:0015243",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Aspergillosis, Allergic Bronchopulmonary",
-            "Allergic bronchopulmonary aspergillosis, familial",
-            "allergic bronchopulmonary aspergillosis",
-            "Allergic bronchopulmonary aspergillosis",
-            "Allergic Bronchopulmonary Aspergillosis",
-            "Allergic bronchopulmonary aspergillosis, familial related phenotypic feature"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000070.htm",
-            "http://www.merck.com/mmhe/sec04/ch051/ch051d.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520745,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015243",
-              "name": "allergic bronchopulmonary aspergillosis",
-              "description": "An aspergillosis that involves an allergic reaction due to the spores of Aspergillus moulds (A. fumigatus), which colonizes the mucus in the airways causing inflammation. The disease has symptom cough, has symptom wheezing and has symptom fever. // COMMENTS: OMIM mapping confirmed by DO. [SN].",
-              "equivalent_curies": [
-                "ORPHANET:1164",
-                "MEDDRA:10001707",
-                "ICD9:518.6",
-                "ICD10:B44.81",
-                "UMLS:C3278302",
-                "MEDDRA:10006474",
-                "NCIT:C84547",
-                "OMIM:103920",
-                "SNOMEDCT:37981002",
-                "MESH:D001229",
-                "DOID:13166",
-                "UMLS:C0004031",
-                "EFO:0007140",
-                "MONDO:0015243"
-              ],
-              "id": "MONDO:0015243",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Aspergillosis, Allergic Bronchopulmonary",
-                "Allergic bronchopulmonary aspergillosis, familial",
-                "allergic bronchopulmonary aspergillosis",
-                "Allergic bronchopulmonary aspergillosis",
-                "Allergic Bronchopulmonary Aspergillosis",
-                "Allergic bronchopulmonary aspergillosis, familial related phenotypic feature"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000070.htm",
-                "http://www.merck.com/mmhe/sec04/ch051/ch051d.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22494159,
-            "start": 568,
-            "end": 520745,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3344933': {'publication date': '1988 Jan', 'sentence': 'After 14 months of treatment one of the patients developed severe, acute exacerbation of the ABPA and was treated with high-dose prednisolone and local steroid.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0004031---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "22922261",
-              "object": "MONDO:0015243",
-              "publications": [
-                "PMID:3344933"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319330,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005292",
-          "name": "colitis",
-          "description": "Inflammation of the colon.; Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.; Colitis refers to an inflammation of the colon and is often used to describe an inflammation of the large intestine (colon, cecum and rectum). Colitides may be acute and self-limited or chronic, and broadly fit into the category of digestive diseases. [HPO:sdoelken]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10079511",
-            "SNOMEDCT:64226004",
-            "UMLS:C0009319",
-            "MESH:D003092",
-            "EFO:0003872",
-            "ICD10:K52.9",
-            "MEDDRA:10009889",
-            "MONDO:0005292",
-            "NCIT:C26723",
-            "MEDDRA:10009898",
-            "PSY:10220",
-            "DOID:0060180",
-            "HP:0002583",
-            "MEDDRA:10009887"
-          ],
-          "id": "MONDO:0005292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Colitis",
-            "colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319330,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005292",
-              "name": "colitis",
-              "description": "Inflammation of the colon.; Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.; Colitis refers to an inflammation of the colon and is often used to describe an inflammation of the large intestine (colon, cecum and rectum). Colitides may be acute and self-limited or chronic, and broadly fit into the category of digestive diseases. [HPO:sdoelken]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10079511",
-                "SNOMEDCT:64226004",
-                "UMLS:C0009319",
-                "MESH:D003092",
-                "EFO:0003872",
-                "ICD10:K52.9",
-                "MEDDRA:10009889",
-                "MONDO:0005292",
-                "NCIT:C26723",
-                "MEDDRA:10009898",
-                "PSY:10220",
-                "DOID:0060180",
-                "HP:0002583",
-                "MEDDRA:10009887"
-              ],
-              "id": "MONDO:0005292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Colitis",
-                "colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19436712,
-            "start": 568,
-            "end": 319330,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2880777': {'publication date': '1986', 'sentence': 'The effect of pretreatment with topical prostaglandin E2, prednisolone and sulphasalazine in experimental colitis has been examined in the rat colon.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0009319---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "19824794",
-              "object": "MONDO:0005292",
-              "publications": [
-                "PMID:2880777"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 516834,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019338",
-          "name": "sarcoidosis",
-          "description": "An idiopathic inflammatory disorder characterized by the formation of non-necrotizing epithelioid granulomas which contain giant cells. It usually affects the lungs, lymph nodes, liver, and skin. Cardiac involvement is also possible.; An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.; Sarcoidosis is a disease that leads to inflammation, usually in your lungs, skin, or lymph nodes. It starts as tiny, grain-like lumps, called granulomas. Sarcoidosis can affect any organ in your body.  No one is sure what causes sarcoidosis. It affects men and women of all ages and races. It occurs mostly in people ages 20 to 50, African Americans, especially women, and people of Northern European origin. Many people have no symptoms. If you have symptoms, they may include: Cough Shortness of breath Weight loss Night sweats Fatigue  Tests to diagnose sarcoidosis include chest x-rays, lung function tests, and a biopsy. Not everyone who has the disease needs treatment. If you do, prednisone, a type of steroid, is the main treatment. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D012507",
-            "MEDDRA:10039490",
-            "ICD9:135",
-            "NCIT:C34995",
-            "UMLS:C0036202",
-            "ORPHANET:797",
-            "DOID:11335",
-            "MONDO:0019338",
-            "SNOMEDCT:31541009",
-            "MEDDRA:10039485",
-            "MEDDRA:10054039",
-            "MEDDRA:10054078",
-            "ICD10:D86",
-            "MEDDRA:10054079",
-            "MEDDRA:10039486"
-          ],
-          "id": "MONDO:0019338",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_sarcoidosis",
-            "sarcoidosis",
-            "Sarcoidosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/sarcoidosis",
-            "http://www.mayoclinic.org/diseases-conditions/sarcoidosis/basics/definition/con-20022569?_ga=1.188430891.2017809229.1415219956",
-            "http://ghr.nlm.nih.gov/glossary=sarcoidosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 516834,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019338",
-              "name": "sarcoidosis",
-              "description": "An idiopathic inflammatory disorder characterized by the formation of non-necrotizing epithelioid granulomas which contain giant cells. It usually affects the lungs, lymph nodes, liver, and skin. Cardiac involvement is also possible.; An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.; Sarcoidosis is a disease that leads to inflammation, usually in your lungs, skin, or lymph nodes. It starts as tiny, grain-like lumps, called granulomas. Sarcoidosis can affect any organ in your body.  No one is sure what causes sarcoidosis. It affects men and women of all ages and races. It occurs mostly in people ages 20 to 50, African Americans, especially women, and people of Northern European origin. Many people have no symptoms. If you have symptoms, they may include: Cough Shortness of breath Weight loss Night sweats Fatigue  Tests to diagnose sarcoidosis include chest x-rays, lung function tests, and a biopsy. Not everyone who has the disease needs treatment. If you do, prednisone, a type of steroid, is the main treatment. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D012507",
-                "MEDDRA:10039490",
-                "ICD9:135",
-                "NCIT:C34995",
-                "UMLS:C0036202",
-                "ORPHANET:797",
-                "DOID:11335",
-                "MONDO:0019338",
-                "SNOMEDCT:31541009",
-                "MEDDRA:10039485",
-                "MEDDRA:10054039",
-                "MEDDRA:10054078",
-                "ICD10:D86",
-                "MEDDRA:10054079",
-                "MEDDRA:10039486"
-              ],
-              "id": "MONDO:0019338",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_sarcoidosis",
-                "sarcoidosis",
-                "Sarcoidosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/sarcoidosis",
-                "http://www.mayoclinic.org/diseases-conditions/sarcoidosis/basics/definition/con-20022569?_ga=1.188430891.2017809229.1415219956",
-                "http://ghr.nlm.nih.gov/glossary=sarcoidosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19027605,
-            "start": 568,
-            "end": 516834,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28058029': {'publication date': '2016 Dec 21', 'sentence': 'Here, we report a case of prednisolone-dependent gastric sarcoidosis that improved after additional azathioprine, and also review the literature concerning the treatment, especially for prednisolone-dependent cases.', 'subject score': 833, 'object score': 833}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0036202---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "19409335",
-              "object": "MONDO:0019338",
-              "publications": [
-                "PMID:28058029"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18365836,
-            "start": 568,
-            "end": 321528,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26714414': {'publication date': '2016 06', 'sentence': 'METHODS: In 126 adults (33 healthy control subjects, 31 patients with mild asthma, 32 patients with severe asthma, and 30 patients with prednisolone-dependent asthma) parameters of inflammation (peripheral blood eosinophils and neutrophils) and markers of hemostasis (endogenous thrombin potential [ETP], thrombin-antithrombin complex, plasmin-alpha2-antiplasmin complex, plasminogen activator inhibitor type 1 [PAI-1], D-dimer, and von Willebrand factor [vWF]) were measured in plasma.', 'subject score': 851, 'object score': 851}, 'PMID:30940770': {'publication date': '2019 Aug', 'sentence': 'Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study.', 'subject score': 1000, 'object score': 809}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "18736907",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:26714414",
-                "PMID:30940770"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 4578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisone",
-          "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "HMDB:HMDB0014773",
-            "UMLS:C0032952",
-            "NCIT:C770",
-            "PUBCHEM.COMPOUND:5865",
-            "DrugCentral:2253",
-            "MESH:D011241",
-            "ATC:A07EA03",
-            "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-            "CAS:53-03-2",
-            "PDQ:CDR0000042487",
-            "PathWhiz.Compound:9120",
-            "KEGG.DRUG:D00473",
-            "DRUGBANK:DB00635",
-            "ATC:H02AB07",
-            "UNII:VB0R961HZT",
-            "NDDF:002164",
-            "CHEMBL.COMPOUND:CHEMBL635",
-            "CHEBI:8382",
-            "KEGG.COMPOUND:C07370",
-            "GTOPDB:7096",
-            "RXNORM:8640"
-          ],
-          "id": "PUBCHEM.COMPOUND:5865",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisone",
-            "Prednisone (USP)",
-            "PREDNISONE",
-            "1,2-dehydrocortisone",
-            "prednisone"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:32422522",
-            "PMID:18788725",
-            "PMID:11413487",
-            "PMID:20070106",
-            "PMID:378499",
-            "PMID:15646539",
-            "PMID:20014752",
-            "PMID:25618019",
-            "PMID:23571415",
-            "PMID:19586686"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 4578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisone",
-              "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "HMDB:HMDB0014773",
-                "UMLS:C0032952",
-                "NCIT:C770",
-                "PUBCHEM.COMPOUND:5865",
-                "DrugCentral:2253",
-                "MESH:D011241",
-                "ATC:A07EA03",
-                "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-                "CAS:53-03-2",
-                "PDQ:CDR0000042487",
-                "PathWhiz.Compound:9120",
-                "KEGG.DRUG:D00473",
-                "DRUGBANK:DB00635",
-                "ATC:H02AB07",
-                "UNII:VB0R961HZT",
-                "NDDF:002164",
-                "CHEMBL.COMPOUND:CHEMBL635",
-                "CHEBI:8382",
-                "KEGG.COMPOUND:C07370",
-                "GTOPDB:7096",
-                "RXNORM:8640"
-              ],
-              "id": "PUBCHEM.COMPOUND:5865",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisone",
-                "Prednisone (USP)",
-                "PREDNISONE",
-                "1,2-dehydrocortisone",
-                "prednisone"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:32422522",
-                "PMID:18788725",
-                "PMID:11413487",
-                "PMID:20070106",
-                "PMID:378499",
-                "PMID:15646539",
-                "PMID:20014752",
-                "PMID:25618019",
-                "PMID:23571415",
-                "PMID:19586686"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17314023,
-            "start": 568,
-            "end": 4578,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24876875': {'publication date': '2014', 'sentence': 'Previous studies from our laboratory revealed that coadministration of EP significantly increased the plasma concentration of prednisolone while decreased the level of cotreated prednisone in rats.', 'subject score': 1000, 'object score': 861}, 'PMID:3207856': {'publication date': '1988 Jul-Aug', 'sentence': 'In a pilot study using one rabbit, prednisone and prednisolone clearance values increased with increase in either prednisone or prednisolone infusion rates.', 'subject score': 851, 'object score': 861}, 'PMID:7107818': {'publication date': '1982 Oct', 'sentence': 'Although there is an increase in the apparent clearance of unbound prednisolone with increasing concentrations, these results are confounded by the interconversion process between prednisone and prednisolone.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:inhibits---biolink:causes---activity---None---UMLS:C0032952---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:stimulates---biolink:causes---activity---None---UMLS:C0032952---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "17668631",
-              "object": "PUBCHEM.COMPOUND:5865",
-              "publications": [
-                "PMID:7107818",
-                "PMID:3207856",
-                "PMID:24876875"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318890,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-          "name": "rheumatoid arthritis",
-          "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C2884",
-            "PSY:44570",
-            "EFO:0000685",
-            "ICD9:714.0",
-            "KEGG.DISEASE:05323",
-            "MONDO:0008383",
-            "UMLS:C0003873",
-            "UMLS:C1306838",
-            "UMLS:C1833448",
-            "MEDDRA:10037740",
-            "MEDDRA:10039073",
-            "OMIM:180300",
-            "MESH:D001172",
-            "MEDDRA:10003268",
-            "HP:0001370",
-            "ORPHANET:284130",
-            "SNOMEDCT:69896004",
-            "ICD10:M06.9",
-            "DOID:7148",
-            "MEDDRA:10036856",
-            "MEDDRA:10042952"
-          ],
-          "id": "MONDO:0008383",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Proliferative arthritis",
-            "Arthritis, Rheumatoid",
-            "rheumatoid arthritis",
-            "Rheumatoid arthritis",
-            "Rheumatoid Arthritis",
-            "Rheumatoid arthritis related phenotypic feature",
-            "Rheumatoid arthritis, susceptibility to"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-            "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-            "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318890,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-              "name": "rheumatoid arthritis",
-              "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C2884",
-                "PSY:44570",
-                "EFO:0000685",
-                "ICD9:714.0",
-                "KEGG.DISEASE:05323",
-                "MONDO:0008383",
-                "UMLS:C0003873",
-                "UMLS:C1306838",
-                "UMLS:C1833448",
-                "MEDDRA:10037740",
-                "MEDDRA:10039073",
-                "OMIM:180300",
-                "MESH:D001172",
-                "MEDDRA:10003268",
-                "HP:0001370",
-                "ORPHANET:284130",
-                "SNOMEDCT:69896004",
-                "ICD10:M06.9",
-                "DOID:7148",
-                "MEDDRA:10036856",
-                "MEDDRA:10042952"
-              ],
-              "id": "MONDO:0008383",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Proliferative arthritis",
-                "Arthritis, Rheumatoid",
-                "rheumatoid arthritis",
-                "Rheumatoid arthritis",
-                "Rheumatoid Arthritis",
-                "Rheumatoid arthritis related phenotypic feature",
-                "Rheumatoid arthritis, susceptibility to"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-                "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-                "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15562682,
-            "start": 568,
-            "end": 318890,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21953589': {'publication date': '2012 Mar', 'sentence': 'Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction.', 'subject score': 861, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0003873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "15888410",
-              "object": "MONDO:0008383",
-              "publications": [
-                "PMID:21953589"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13279221,
-            "start": 568,
-            "end": 321528,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1822832': {'publication date': '1991', 'sentence': 'Effects of prednisolone, salbutamol and theophylline on bronchial hyperreactivity and leucocyte chemokinesis in guinea pigs.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0085129---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "13564625",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:1822832"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317106,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005904",
-          "name": "pericarditis",
-          "description": "An inflammatory process affecting the pericardium.; Inflammation of both the PERICARDIUM and the PLEURA.; Inflammation of the sac-like covering around the heart (pericardium). [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:1787",
-            "MEDDRA:10034484",
-            "ORPHANET:58208",
-            "HP:0001701",
-            "MESH:D010493",
-            "UMLS:C0031046",
-            "MEDDRA:10034495",
-            "NCIT:C34915",
-            "SNOMEDCT:3238004",
-            "EFO:0007427",
-            "MONDO:0005904"
-          ],
-          "id": "MONDO:0005904",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pericarditis",
-            "pericarditis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/wiki/pericarditis",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317106,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005904",
-              "name": "pericarditis",
-              "description": "An inflammatory process affecting the pericardium.; Inflammation of both the PERICARDIUM and the PLEURA.; Inflammation of the sac-like covering around the heart (pericardium). [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:1787",
-                "MEDDRA:10034484",
-                "ORPHANET:58208",
-                "HP:0001701",
-                "MESH:D010493",
-                "UMLS:C0031046",
-                "MEDDRA:10034495",
-                "NCIT:C34915",
-                "SNOMEDCT:3238004",
-                "EFO:0007427",
-                "MONDO:0005904"
-              ],
-              "id": "MONDO:0005904",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pericarditis",
-                "pericarditis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/wiki/pericarditis",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12954798,
-            "start": 568,
-            "end": 317106,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17634717': {'publication date': '2007', 'sentence': 'This is the first case to support the beneficial effect of prednisolone in pericarditis with pSS, and illustrates its safety during pregnancy.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0031046---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "13234063",
-              "object": "MONDO:0005904",
-              "publications": [
-                "PMID:17634717"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 324986,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-          "name": "chronic obstructive pulmonary disease",
-          "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-          "equivalent_curies": [
-            "MESH:D029424",
-            "MEDDRA:10010952",
-            "MEDDRA:10009025",
-            "ICD10:J44.9",
-            "UMLS:C1527303",
-            "NCIT:C3199",
-            "UMLS:C0024117",
-            "MEDDRA:10064611",
-            "MEDDRA:10009026",
-            "MEDDRA:10029972",
-            "DOID:3083",
-            "MONDO:0005002",
-            "MEDDRA:10009032",
-            "MEDDRA:10070975",
-            "EFO:0000341",
-            "SNOMEDCT:13645005",
-            "MEDDRA:10009033",
-            "HP:0006510",
-            "MEDDRA:10008828"
-          ],
-          "id": "MONDO:0005002",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic Obstructive Pulmonary Disease",
-            "chronic obstructive pulmonary disease",
-            "Chronic pulmonary obstruction",
-            "Chronic Airflow Obstruction",
-            "Chronic Obstructive Airway Disease",
-            "Pulmonary Disease, Chronic Obstructive"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health-topics/copd",
-            "PMID:32800196",
-            "PMID:28513453",
-            "PMID:25943942",
-            "PMID:32745458"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 324986,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-              "name": "chronic obstructive pulmonary disease",
-              "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-              "equivalent_curies": [
-                "MESH:D029424",
-                "MEDDRA:10010952",
-                "MEDDRA:10009025",
-                "ICD10:J44.9",
-                "UMLS:C1527303",
-                "NCIT:C3199",
-                "UMLS:C0024117",
-                "MEDDRA:10064611",
-                "MEDDRA:10009026",
-                "MEDDRA:10029972",
-                "DOID:3083",
-                "MONDO:0005002",
-                "MEDDRA:10009032",
-                "MEDDRA:10070975",
-                "EFO:0000341",
-                "SNOMEDCT:13645005",
-                "MEDDRA:10009033",
-                "HP:0006510",
-                "MEDDRA:10008828"
-              ],
-              "id": "MONDO:0005002",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic Obstructive Pulmonary Disease",
-                "chronic obstructive pulmonary disease",
-                "Chronic pulmonary obstruction",
-                "Chronic Airflow Obstruction",
-                "Chronic Obstructive Airway Disease",
-                "Pulmonary Disease, Chronic Obstructive"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health-topics/copd",
-                "PMID:32800196",
-                "PMID:28513453",
-                "PMID:25943942",
-                "PMID:32745458"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12752857,
-            "start": 568,
-            "end": 324986,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17363304': {'publication date': '2008 Feb', 'sentence': 'When combined with environmental control, prednisolone and dexamethasone treatments had similar effects on heaves score, blood gases and endoscopic scores.', 'subject score': 1000, 'object score': 1000}, 'PMID:18836113': {'publication date': '2008 Oct', 'sentence': 'Oral prednisolone was not inferior to intravenous prednisolone for treatment failure in chronic obstructive pulmonary disease exacerbation.', 'subject score': 888, 'object score': 771}, 'PMID:18972276': {'publication date': '2008 Oct', 'sentence': 'Forty-five patients not using steroids (37 male, 21/24 current/ex smoker, median packyears 38, age 65 years, FEV(1) 61% predicted), experiencing a COPD exacerbation, were treated at home with budesonide/formoterol (320/9 microg 4 times daily), prednisolone (30 mg daily), or placebo for 14 days.', 'subject score': 1000, 'object score': 771}, 'PMID:24925917': {'publication date': '2014 Sep', 'sentence': 'Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis.', 'subject score': 888, 'object score': 1000}, 'PMID:25562034': {'publication date': '2014', 'sentence': 'CONCLUSIONS: We detected no evidence for the effectiveness of addition of antibiotics to prednisolone for COPD exacerbations of moderate severity and with intermediate probability of bacterial infection in this underpowered study.', 'subject score': 1000, 'object score': 771}, 'PMID:30565022': {'publication date': '2019 05', 'sentence': 'Doxycycline Added to Prednisolone in Outpatient-Treated Acute Exacerbations of COPD: A Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:6146752': {'publication date': '1984 Jul 28', 'sentence': 'Effects of prednisolone in chronic airflow limitation.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0024117---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "13029310",
-              "object": "MONDO:0005002",
-              "publications": [
-                "PMID:17363304",
-                "PMID:18836113",
-                "PMID:18972276",
-                "PMID:24925917",
-                "PMID:25562034",
-                "PMID:30565022",
-                "PMID:6146752"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316866,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015691",
-          "name": "hypereosinophilic syndrome",
-          "description": "A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction. This term has often been applied to cases of chronic eosinophilic leukemia. (WHO, 2001); A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10014950",
-            "UMLS:C1636667",
-            "ICD10:D72.1",
-            "ICD9:288.3",
-            "MEDDRA:10048643",
-            "NCIT:C27038",
-            "EFO:1001467",
-            "SNOMEDCT:1156250009",
-            "SNOMEDCT:419455006",
-            "DOID:999",
-            "MESH:D004802",
-            "MESH:D017681",
-            "ORPHANET:168956",
-            "SNOMEDCT:393573009",
-            "UMLS:C0014457",
-            "HP:0001880",
-            "MONDO:0015691",
-            "UMLS:C1540912"
-          ],
-          "id": "MONDO:0015691",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Disorder characterized by eosinophilia",
-            "hypereosinophilic syndrome",
-            "Hypereosinophilic Syndrome",
-            "Hypereosinophilic syndrome",
-            "Eosinophilia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/hypereosinophilic_syndrome",
-            "https://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316866,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015691",
-              "name": "hypereosinophilic syndrome",
-              "description": "A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction. This term has often been applied to cases of chronic eosinophilic leukemia. (WHO, 2001); A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10014950",
-                "UMLS:C1636667",
-                "ICD10:D72.1",
-                "ICD9:288.3",
-                "MEDDRA:10048643",
-                "NCIT:C27038",
-                "EFO:1001467",
-                "SNOMEDCT:1156250009",
-                "SNOMEDCT:419455006",
-                "DOID:999",
-                "MESH:D004802",
-                "MESH:D017681",
-                "ORPHANET:168956",
-                "SNOMEDCT:393573009",
-                "UMLS:C0014457",
-                "HP:0001880",
-                "MONDO:0015691",
-                "UMLS:C1540912"
-              ],
-              "id": "MONDO:0015691",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Disorder characterized by eosinophilia",
-                "hypereosinophilic syndrome",
-                "Hypereosinophilic Syndrome",
-                "Hypereosinophilic syndrome",
-                "Eosinophilia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/hypereosinophilic_syndrome",
-                "https://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12675205,
-            "start": 568,
-            "end": 316866,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17261495': {'publication date': '2007 Jan', 'sentence': 'Of the 20 patients, 14 initially received prednisolone treatment, which resulted in rapid improvement and normalization of eosinophilia within 8 weeks; however, 2 patients with splenomegaly showed poor control of eosinophilia in response to corticosteroid treatment.', 'subject score': 771, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0014457---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "12949384",
-              "object": "MONDO:0015691",
-              "publications": [
-                "PMID:17261495"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322120,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-          "name": "Crohn disease",
-          "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003424",
-            "ORPHANET:206",
-            "NCIT:C37262",
-            "MEDDRA:10038281",
-            "MEDDRA:10011405",
-            "UMLS:CN043071",
-            "SNOMEDCT:50440006",
-            "MEDDRA:10057032",
-            "HP:0100280",
-            "EFO:0000384",
-            "DOID:8778",
-            "MONDO:0005011",
-            "PDQ:CDR0000714480",
-            "UMLS:C0010346",
-            "NCIT:C2965",
-            "SNOMEDCT:7620006",
-            "ICD10:K50.1",
-            "UMLS:C0156147",
-            "MEDDRA:10011398",
-            "MEDDRA:10011401",
-            "SNOMEDCT:34000006",
-            "ICD9:555.1",
-            "MEDDRA:10013099",
-            "MEDDRA:10011402",
-            "MEDDRA:10011400"
-          ],
-          "id": "MONDO:0005011",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Granulomatous Colitis",
-            "Crohn's disease of large bowel",
-            "Regional enteritis of large intestine",
-            "Crohn Disease",
-            "Crohn disease",
-            "Crohn's disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/chron%27s_disease",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322120,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-              "name": "Crohn disease",
-              "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003424",
-                "ORPHANET:206",
-                "NCIT:C37262",
-                "MEDDRA:10038281",
-                "MEDDRA:10011405",
-                "UMLS:CN043071",
-                "SNOMEDCT:50440006",
-                "MEDDRA:10057032",
-                "HP:0100280",
-                "EFO:0000384",
-                "DOID:8778",
-                "MONDO:0005011",
-                "PDQ:CDR0000714480",
-                "UMLS:C0010346",
-                "NCIT:C2965",
-                "SNOMEDCT:7620006",
-                "ICD10:K50.1",
-                "UMLS:C0156147",
-                "MEDDRA:10011398",
-                "MEDDRA:10011401",
-                "SNOMEDCT:34000006",
-                "ICD9:555.1",
-                "MEDDRA:10013099",
-                "MEDDRA:10011402",
-                "MEDDRA:10011400"
-              ],
-              "id": "MONDO:0005011",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Granulomatous Colitis",
-                "Crohn's disease of large bowel",
-                "Regional enteritis of large intestine",
-                "Crohn Disease",
-                "Crohn disease",
-                "Crohn's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/chron%27s_disease",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11800576,
-            "start": 568,
-            "end": 322120,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16179087': {'publication date': '2005 Sep 22', 'sentence': \"Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis.\", 'subject score': 861, 'object score': 1000}, 'PMID:6428577': {'publication date': '1984 Jun 23', 'sentence': \"Acute exacerbations of Crohn's disease are usually treated with prednisolone or potentially more toxic immunosuppressive drugs or by surgery.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0010346---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "12057849",
-              "object": "MONDO:0005011",
-              "publications": [
-                "PMID:16179087",
-                "PMID:6428577"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318533,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-          "name": "Headache",
-          "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10019211",
-            "PSY:22380",
-            "NCIT:C34661",
-            "MEDDRA:10019218",
-            "SNOMEDCT:25064002",
-            "UMLS:C0018681",
-            "MEDDRA:10019231",
-            "HP:0002315",
-            "MEDDRA:10033405",
-            "ICD9:784.0",
-            "MESH:D006261",
-            "SYMP:0000504",
-            "MEDDRA:10008013",
-            "MEDDRA:10019198"
-          ],
-          "id": "HP:0002315",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "headache",
-            "Headache"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-            "PMID:15304572",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318533,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-              "name": "Headache",
-              "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10019211",
-                "PSY:22380",
-                "NCIT:C34661",
-                "MEDDRA:10019218",
-                "SNOMEDCT:25064002",
-                "UMLS:C0018681",
-                "MEDDRA:10019231",
-                "HP:0002315",
-                "MEDDRA:10033405",
-                "ICD9:784.0",
-                "MESH:D006261",
-                "SYMP:0000504",
-                "MEDDRA:10008013",
-                "MEDDRA:10019198"
-              ],
-              "id": "HP:0002315",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "headache",
-                "Headache"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-                "PMID:15304572",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10927211,
-            "start": 568,
-            "end": 318533,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15109361': {'publication date': '2004 Apr', 'sentence': 'Prednisolone-responsive headache in patients with solitary cysticercus granuloma and seizures.', 'subject score': 851, 'object score': 851}, 'PMID:17475943': {'publication date': '2007 Jul 03', 'sentence': 'CONCLUSION: Prednisolone has no effect on withdrawal headache in unselected patients with chronic daily headache and medication overuse.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0018681---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11166436",
-              "object": "HP:0002315",
-              "publications": [
-                "PMID:15109361",
-                "PMID:17475943"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319679,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-          "name": "lymphoma",
-          "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:115244002",
-            "DOID:0060058",
-            "MONDO:0005062",
-            "SNOMEDCT:118600007",
-            "HP:0002665",
-            "NCIT:C7065",
-            "EFO:0000574",
-            "ORPHANET:223735",
-            "MESH:D008223",
-            "SNOMEDCT:188676008",
-            "PDQ:CDR0000041429",
-            "MEDDRA:10025316",
-            "UMLS:C0024299",
-            "NCIT:C3208",
-            "MEDDRA:10025632",
-            "MEDDRA:10025310",
-            "MEDDRA:10025633",
-            "SNOMEDCT:1163043007",
-            "ICD10:C85.9",
-            "UMLS:C1536843",
-            "UMLS:C0334621",
-            "MEDDRA:10025315"
-          ],
-          "id": "MONDO:0005062",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphocytic Neoplasm",
-            "Lymphoma",
-            "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-            "lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/lymphoma",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319679,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-              "name": "lymphoma",
-              "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:115244002",
-                "DOID:0060058",
-                "MONDO:0005062",
-                "SNOMEDCT:118600007",
-                "HP:0002665",
-                "NCIT:C7065",
-                "EFO:0000574",
-                "ORPHANET:223735",
-                "MESH:D008223",
-                "SNOMEDCT:188676008",
-                "PDQ:CDR0000041429",
-                "MEDDRA:10025316",
-                "UMLS:C0024299",
-                "NCIT:C3208",
-                "MEDDRA:10025632",
-                "MEDDRA:10025310",
-                "MEDDRA:10025633",
-                "SNOMEDCT:1163043007",
-                "ICD10:C85.9",
-                "UMLS:C1536843",
-                "UMLS:C0334621",
-                "MEDDRA:10025315"
-              ],
-              "id": "MONDO:0005062",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphocytic Neoplasm",
-                "Lymphoma",
-                "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-                "lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/lymphoma",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10827742,
-            "start": 568,
-            "end": 319679,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15005254': {'publication date': '2004 Feb', 'sentence': 'The patient was treated with chemotherapy by cyclophosphamide, hydroxydoxorubicin, vincristine and prednisolone (CHOP), however, it was ineffective, and the patient died of hemorrhage from the lymphoma involvement of the intestine 5 months after the onset of disease.', 'subject score': 1000, 'object score': 694}, 'PMID:15326651': {'publication date': '2004 Jul 17', 'sentence': 'The lymphoma was refractory to cyclophosphamide-doxorubicin-vincristine-prednisolone (CHOP); this was followed by intensive chemotherapy and autologous stem-cell transplantation, resulting finally in a complete remission.', 'subject score': 833, 'object score': 1000}, 'PMID:21253433': {'publication date': '2010 Dec', 'sentence': 'Diffuse large B-cell lymphoma was diagnosed through a cardiac catheterization-assisted percutaneous endomyocardial biopsy, and there was no evidence of extracardiac involvement of the lymphoma.The patient had a complete clinical response after systemic chemotherapy with a rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) regimen and additional post-chemotherapeutic radiation therapy.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0024299---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11074135",
-              "object": "MONDO:0005062",
-              "publications": [
-                "PMID:15005254",
-                "PMID:15326651",
-                "PMID:21253433"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319192,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-          "name": "kidney disorder",
-          "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D007674",
-            "MEDDRA:10029154",
-            "UMLS:C0022658",
-            "NCIT:C3149",
-            "MONDO:0005240",
-            "UMLS:C1408258",
-            "DOID:557",
-            "MEDDRA:10029149",
-            "HP:0000112",
-            "MEDDRA:10051051",
-            "NCIT:C34843",
-            "MEDDRA:10038428",
-            "MEDDRA:10038429",
-            "MEDDRA:10029151",
-            "MEDDRA:10051052",
-            "EFO:0003086",
-            "SNOMEDCT:90708001",
-            "MEDDRA:10013263",
-            "PSY:27347"
-          ],
-          "id": "MONDO:0005240",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Kidney damage",
-            "kidney disease",
-            "Nephropathy",
-            "Kidney Diseases",
-            "Kidney Disorder",
-            "kidney disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319192,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-              "name": "kidney disorder",
-              "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D007674",
-                "MEDDRA:10029154",
-                "UMLS:C0022658",
-                "NCIT:C3149",
-                "MONDO:0005240",
-                "UMLS:C1408258",
-                "DOID:557",
-                "MEDDRA:10029149",
-                "HP:0000112",
-                "MEDDRA:10051051",
-                "NCIT:C34843",
-                "MEDDRA:10038428",
-                "MEDDRA:10038429",
-                "MEDDRA:10029151",
-                "MEDDRA:10051052",
-                "EFO:0003086",
-                "SNOMEDCT:90708001",
-                "MEDDRA:10013263",
-                "PSY:27347"
-              ],
-              "id": "MONDO:0005240",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Kidney damage",
-                "kidney disease",
-                "Nephropathy",
-                "Kidney Diseases",
-                "Kidney Disorder",
-                "kidney disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10422353,
-            "start": 568,
-            "end": 319192,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13933655': {'publication date': '1963 Jul', 'sentence': 'Effect of prednisolone in the experimentally induced nephropathy in male albino rats.', 'subject score': 1000, 'object score': 790}, 'PMID:20175891': {'publication date': '2010 Feb 22', 'sentence': 'She was treated with relatively low dose oral mycophenolate mofetil and prednisolone which stabilised her nephropathy and neuropathy.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0022658---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10651502",
-              "object": "MONDO:0005240",
-              "publications": [
-                "PMID:13933655",
-                "PMID:20175891"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317278,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004674",
-          "name": "chorioretinitis",
-          "description": "An inflammation of the choroid and retina. [ORCID:0000-0001-5208-3432, PMID:16196117]; An inflammation of the choroid and retina. // COMMENTS: Chorioretinitis is a form of posterior uveitis. Note that the term Chorioretinitis suggests that the origin of the process is predominantly in the choroid while Retinitis suggests that the process is mainly in the retina.; An inflammation of the choroid and retina. // COMMENTS: Chorioretinitis is a form of posterior uveitis. Note that the term Chorioretinitis suggests that the origin of the process is predominantly in the choroid while Retinitis suggests that the process is mainly in the retina.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:8886",
-            "SNOMEDCT:46627006",
-            "ICD10:H30.9",
-            "HP:0012424",
-            "ICD9:363.20",
-            "MONDO:0004674",
-            "MESH:D002825",
-            "UMLS:C0008513",
-            "NCIT:C110923",
-            "MEDDRA:10008769",
-            "MEDDRA:10086282",
-            "MEDDRA:10008771"
-          ],
-          "id": "MONDO:0004674",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chorioretinitis",
-            "Chorioretinitis, unspecified",
-            "chorioretinitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:16196117",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0001-5208-3432"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317278,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004674",
-              "name": "chorioretinitis",
-              "description": "An inflammation of the choroid and retina. [ORCID:0000-0001-5208-3432, PMID:16196117]; An inflammation of the choroid and retina. // COMMENTS: Chorioretinitis is a form of posterior uveitis. Note that the term Chorioretinitis suggests that the origin of the process is predominantly in the choroid while Retinitis suggests that the process is mainly in the retina.; An inflammation of the choroid and retina. // COMMENTS: Chorioretinitis is a form of posterior uveitis. Note that the term Chorioretinitis suggests that the origin of the process is predominantly in the choroid while Retinitis suggests that the process is mainly in the retina.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:8886",
-                "SNOMEDCT:46627006",
-                "ICD10:H30.9",
-                "HP:0012424",
-                "ICD9:363.20",
-                "MONDO:0004674",
-                "MESH:D002825",
-                "UMLS:C0008513",
-                "NCIT:C110923",
-                "MEDDRA:10008769",
-                "MEDDRA:10086282",
-                "MEDDRA:10008771"
-              ],
-              "id": "MONDO:0004674",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chorioretinitis",
-                "Chorioretinitis, unspecified",
-                "chorioretinitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:16196117",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0001-5208-3432"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10420041,
-            "start": 568,
-            "end": 317278,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13919503': {'publication date': '1961 Mar', 'sentence': '[On the effect of oral use of prednisolone on central chorioretinitis].', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0008513---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10649036",
-              "object": "MONDO:0004674",
-              "publications": [
-                "PMID:13919503"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316638,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-          "name": "peptic ulcer disease",
-          "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10018053",
-            "MEDDRA:10045305",
-            "MESH:D010437",
-            "MONDO:0004247",
-            "DOID:750",
-            "UMLS:C0030920",
-            "MEDDRA:10017886",
-            "MEDDRA:10045342",
-            "ICD9:533",
-            "ICD10:K27",
-            "HP:0004398",
-            "MEDDRA:10034343",
-            "MEDDRA:10034360",
-            "MEDDRA:10045328",
-            "MEDDRA:10042834",
-            "MEDDRA:10034341",
-            "MEDDRA:10034367",
-            "MEDDRA:10037287",
-            "NCIT:C3318",
-            "SNOMEDCT:13200003",
-            "MEDDRA:10034369"
-          ],
-          "id": "MONDO:0004247",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peptic ulcer, site unspecified",
-            "Peptic Ulcer",
-            "peptic ulcer disease",
-            "Peptic ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28242110",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316638,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-              "name": "peptic ulcer disease",
-              "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10018053",
-                "MEDDRA:10045305",
-                "MESH:D010437",
-                "MONDO:0004247",
-                "DOID:750",
-                "UMLS:C0030920",
-                "MEDDRA:10017886",
-                "MEDDRA:10045342",
-                "ICD9:533",
-                "ICD10:K27",
-                "HP:0004398",
-                "MEDDRA:10034343",
-                "MEDDRA:10034360",
-                "MEDDRA:10045328",
-                "MEDDRA:10042834",
-                "MEDDRA:10034341",
-                "MEDDRA:10034367",
-                "MEDDRA:10037287",
-                "NCIT:C3318",
-                "SNOMEDCT:13200003",
-                "MEDDRA:10034369"
-              ],
-              "id": "MONDO:0004247",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peptic ulcer, site unspecified",
-                "Peptic Ulcer",
-                "peptic ulcer disease",
-                "Peptic ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28242110",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10327816,
-            "start": 568,
-            "end": 316638,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13546582': {'publication date': '1958 Jun', 'sentence': 'Peptic ulceration associated with prednisolone therapy.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0030920---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10555139",
-              "object": "MONDO:0004247",
-              "publications": [
-                "PMID:13546582"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9963081,
-            "start": 568,
-            "end": 322104,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12737443': {'publication date': '2003 Mar', 'sentence': 'Glucocorticoids (e.g. prednisolone) are cornerstones in the treatment of acute exacerbations of ulcerative colitis (UC), and influence of the leucocyte/endothelial interaction appears to be part of their mode of action.', 'subject score': 1000, 'object score': 1000}, 'PMID:16179087': {'publication date': '2005 Sep 22', 'sentence': \"Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis.\", 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10183156",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:12737443",
-                "PMID:16179087"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9525290,
-            "start": 568,
-            "end": 183319,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12207075': {'publication date': '2002', 'sentence': 'Effects of honey, prednisolone, and disulfiram on inflammation, nitric oxide, and free radical formation.', 'subject score': 1000, 'object score': 1000}, 'PMID:15336689': {'publication date': '2004 Sep', 'sentence': 'The goal of this study was to examine the effects of prednisolone on inflammation and CAM expression in dystrophic muscle.', 'subject score': 1000, 'object score': 1000}, 'PMID:1711873': {'publication date': '1991', 'sentence': 'In a placebo-controlled double-blind study on patients undergoing cardiopulmonary bypass (CPB) we studied the inhibiting effects of dexamethasone, a high dose of methylprednisolone, and a low dose of prednisolone on the inflammatory reaction induced by CPB.', 'subject score': 1000, 'object score': 1000}, 'PMID:17237435': {'publication date': '2007 Feb 01', 'sentence': 'To determine the effects of increasing doses of prednisolone on inflammation and coagulation in humans exposed to LPS, 32 healthy males received prednisolone orally at doses of 0, 3, 10, or 30 mg (n = 8 per group) at 2 h before i.v. injection of Escherichia coli LPS (4 ng/kg).', 'subject score': 1000, 'object score': 1000}, 'PMID:18830904': {'publication date': '2008', 'sentence': 'Effects of inflammation and therapy were investigated in RA and OA fibroblasts after stimulation with interleukin (IL)-1beta, tumour necrosis factor (TNF)-alpha, methotrexate (MTX), and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:24956233': {'publication date': '2014 Jul 02', 'sentence': 'The clinically prescribed glucocorticoid prednisolone could modulate airway inflammation but was ineffective against the reversal of many HDM-induced metabolic alterations.', 'subject score': 775, 'object score': 861}, 'PMID:28152574': {'publication date': '2017 05', 'sentence': 'These effects occurred independently of the deleterious cardiometabolic effects and the impact of prednisolone on systemic inflammation.', 'subject score': 1000, 'object score': 888}, 'PMID:28904432': {'publication date': '2017 Sep-Oct', 'sentence': 'The current study was designed to analyze the influence of prednisolone treatment on the inflammatory reaction during the first 96 h after AKI induction in a rat model.', 'subject score': 888, 'object score': 1000}, 'PMID:36040807': {'publication date': '2022 Oct 10', 'sentence': 'The MRA spironolactone and glucocorticoid prednisolone were each administered for 1 week to dystrophic mdx mice during peak skeletal muscle necrosis to compare effects on inflammation.', 'subject score': 888, 'object score': 1000}, 'PMID:7146148': {'publication date': '1982 Dec', 'sentence': 'Tissue reaction to ischemia in the rabbit ear chamber: effects of prednisolone on inflammation and microvascular flow.', 'subject score': 1000, 'object score': 1000}, 'PMID:7224940': {'publication date': '1981 Apr', 'sentence': 'The results suggest that flurbiprofen and prednisolone are not different in their effect on both postoperative inflammation and postoperative wound healing.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9735520",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:12207075",
-                "PMID:15336689",
-                "PMID:1711873",
-                "PMID:17237435",
-                "PMID:18830904",
-                "PMID:24956233",
-                "PMID:28152574",
-                "PMID:28904432",
-                "PMID:36040807",
-                "PMID:7146148",
-                "PMID:7224940"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319030,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319030,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9160603,
-            "start": 568,
-            "end": 319030,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11826654': {'publication date': '2002 Jan', 'sentence': 'OBJECTIVE: To assess the treatment effect of sodium hyaluronate (HA) on experimental temporomandibular joint (TMJ) osteoarthritis of rabbits in comparison with prednisolone (PS).', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9361682",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:11826654"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8352249,
-            "start": 568,
-            "end": 319673,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11064248': {'publication date': '2000 Nov', 'sentence': 'ETO+PSL combination treatment, however, failed to show significant enhancement of anti-tumor effects.', 'subject score': 833, 'object score': 773}, 'PMID:11393100': {'publication date': '2001 Feb', 'sentence': 'Chemotherapy, which included prednisolone, vincristine, methotrexate, and 6-mercaptopurine, had only a minimal effect on the tumor.', 'subject score': 1000, 'object score': 1000}, 'PMID:15208501': {'publication date': '2004 Jul', 'sentence': 'The levels of FDG uptake in the tumour were not significantly affected by DEX and PRE pretreatment (90% and 87% of the control value, respectively) (P=NS).', 'subject score': 888, 'object score': 1000}, 'PMID:3629691': {'publication date': '1987 Sep', 'sentence': 'Prednisolone had no effect on UVI-induced tumor development.', 'subject score': 1000, 'object score': 775}, 'PMID:7307234': {'publication date': '1981', 'sentence': 'Prednisolone had no anti-tumour effect when given alone, but increased the anti-tumour effect of melphalan significantly.', 'subject score': 1000, 'object score': 790}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8533593",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:11064248",
-                "PMID:11393100",
-                "PMID:15208501",
-                "PMID:3629691",
-                "PMID:7307234"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:10554796': {'publication date': '1999 Jun', 'sentence': 'My- and My+ ALL did not significantly differ in sensitivity to prednisolone, dexamethasone, L-asparaginase and cytarabine.', 'subject score': 1000, 'object score': 1000}, 'PMID:19066270': {'publication date': '2008 Dec 17', 'sentence': 'METHODS: Gene expression and in vitro sensitivity to prednisolone and dexamethasone were assessed in a training set of primary ALL cells from 177 children with newly diagnosed ALL and a validation set of cells from an independent cohort of 95 ALL patients.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 323831,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-          "name": "acute lymphoblastic leukemia",
-          "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "HP:0006721",
-            "MONDO:0004967",
-            "MEDDRA:10000848",
-            "MEDDRA:10000849",
-            "MEDDRA:10025305",
-            "ORPHANET:513",
-            "MEDDRA:10025301",
-            "ICD10:C91.00",
-            "UMLS:C0023453",
-            "DOID:9952",
-            "MEDDRA:10000844",
-            "MEDDRA:10000846",
-            "MEDDRA:10000845",
-            "MEDDRA:10024338",
-            "ICD10:C91",
-            "MESH:D054198",
-            "UMLS:C1961102",
-            "MEDDRA:10060555",
-            "NCIT:C3167",
-            "PDQ:CDR0000043423",
-            "MEDDRA:10024290",
-            "MEDDRA:10000842",
-            "NCIT:C27281",
-            "ICD9:204",
-            "DOID:1037",
-            "MEDDRA:10000843",
-            "EFO:0000220",
-            "SNOMEDCT:128822004",
-            "ICD9:204.0",
-            "UMLS:C0023449",
-            "MEDDRA:10060390",
-            "SNOMEDCT:91857003"
-          ],
-          "id": "MONDO:0004967",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute lymphoblastic leukemia",
-            "lymphoid leukemia",
-            "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-            "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-            "L2 Acute Lymphoblastic Leukemia",
-            "acute lymphocytic leukemia",
-            "Lymphoid leukemia, acute",
-            "acute lymphoblastic leukemia",
-            "Acute lymphocytic leukemia",
-            "Acute Lymphoblastic Leukemia",
-            "Lymphoid leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=46332",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=616067",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323831,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-              "name": "acute lymphoblastic leukemia",
-              "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "HP:0006721",
-                "MONDO:0004967",
-                "MEDDRA:10000848",
-                "MEDDRA:10000849",
-                "MEDDRA:10025305",
-                "ORPHANET:513",
-                "MEDDRA:10025301",
-                "ICD10:C91.00",
-                "UMLS:C0023453",
-                "DOID:9952",
-                "MEDDRA:10000844",
-                "MEDDRA:10000846",
-                "MEDDRA:10000845",
-                "MEDDRA:10024338",
-                "ICD10:C91",
-                "MESH:D054198",
-                "UMLS:C1961102",
-                "MEDDRA:10060555",
-                "NCIT:C3167",
-                "PDQ:CDR0000043423",
-                "MEDDRA:10024290",
-                "MEDDRA:10000842",
-                "NCIT:C27281",
-                "ICD9:204",
-                "DOID:1037",
-                "MEDDRA:10000843",
-                "EFO:0000220",
-                "SNOMEDCT:128822004",
-                "ICD9:204.0",
-                "UMLS:C0023449",
-                "MEDDRA:10060390",
-                "SNOMEDCT:91857003"
-              ],
-              "id": "MONDO:0004967",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute lymphoblastic leukemia",
-                "lymphoid leukemia",
-                "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-                "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-                "L2 Acute Lymphoblastic Leukemia",
-                "acute lymphocytic leukemia",
-                "Lymphoid leukemia, acute",
-                "acute lymphoblastic leukemia",
-                "Acute lymphocytic leukemia",
-                "Acute Lymphoblastic Leukemia",
-                "Lymphoid leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=46332",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=616067",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7638932,
-            "start": 568,
-            "end": 323831,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10554796': {'publication date': '1999 Jun', 'sentence': 'My- and My+ ALL did not significantly differ in sensitivity to prednisolone, dexamethasone, L-asparaginase and cytarabine.', 'subject score': 1000, 'object score': 1000}, 'PMID:19066270': {'publication date': '2008 Dec 17', 'sentence': 'METHODS: Gene expression and in vitro sensitivity to prednisolone and dexamethasone were assessed in a training set of primary ALL cells from 177 children with newly diagnosed ALL and a validation set of cells from an independent cohort of 95 ALL patients.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0023449---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7800426",
-              "object": "MONDO:0004967",
-              "publications": [
-                "PMID:10554796",
-                "PMID:19066270"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 319015,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-          "name": "systemic lupus erythematosus",
-          "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10025133",
-            "KEGG.DISEASE:05322",
-            "MEDDRA:10042820",
-            "PDQ:CDR0000608139",
-            "MEDDRA:10040967",
-            "MEDDRA:10042800",
-            "MEDDRA:10013446",
-            "MONDO:0007915",
-            "MEDDRA:10042945",
-            "MEDDRA:10024067",
-            "ICD10:M32.9",
-            "MEDDRA:10042947",
-            "ORPHANET:536",
-            "MEDDRA:10042944",
-            "UMLS:C0024141",
-            "EFO:0002690",
-            "MESH:D008180",
-            "ICD9:710.0",
-            "DOID:9074",
-            "MEDDRA:10025139",
-            "UMLS:C1835309",
-            "MEDDRA:10024065",
-            "OMIM:152700",
-            "HP:0002725",
-            "MEDDRA:10025142",
-            "NCIT:C3201",
-            "SNOMEDCT:55464009"
-          ],
-          "id": "MONDO:0007915",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Systemic lupus erythematosus",
-            "obsolete_systemic lupus erythematosus",
-            "Systemic lupus erythematosus related phenotypic feature",
-            "Lupus Erythematosus, Systemic",
-            "Excess lmw-dna",
-            "systemic lupus erythematosus",
-            "Systemic Lupus Erythematosus"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319015,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-              "name": "systemic lupus erythematosus",
-              "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10025133",
-                "KEGG.DISEASE:05322",
-                "MEDDRA:10042820",
-                "PDQ:CDR0000608139",
-                "MEDDRA:10040967",
-                "MEDDRA:10042800",
-                "MEDDRA:10013446",
-                "MONDO:0007915",
-                "MEDDRA:10042945",
-                "MEDDRA:10024067",
-                "ICD10:M32.9",
-                "MEDDRA:10042947",
-                "ORPHANET:536",
-                "MEDDRA:10042944",
-                "UMLS:C0024141",
-                "EFO:0002690",
-                "MESH:D008180",
-                "ICD9:710.0",
-                "DOID:9074",
-                "MEDDRA:10025139",
-                "UMLS:C1835309",
-                "MEDDRA:10024065",
-                "OMIM:152700",
-                "HP:0002725",
-                "MEDDRA:10025142",
-                "NCIT:C3201",
-                "SNOMEDCT:55464009"
-              ],
-              "id": "MONDO:0007915",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Systemic lupus erythematosus",
-                "obsolete_systemic lupus erythematosus",
-                "Systemic lupus erythematosus related phenotypic feature",
-                "Lupus Erythematosus, Systemic",
-                "Excess lmw-dna",
-                "systemic lupus erythematosus",
-                "Systemic Lupus Erythematosus"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7246960,
-            "start": 568,
-            "end": 319015,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10332213': {'publication date': '1999 Feb', 'sentence': 'The dose of prednisolone was increased considering he was exacerbated of SLE, however, the convulsion as CNS lupus occurred to him.', 'subject score': 1000, 'object score': 1000}, 'PMID:2137939': {'publication date': '1990 Feb', 'sentence': 'Increased circulating HLA-DR+ CD4+ T cells in systemic lupus erythematosus: alterations associated with prednisolone therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:30078223': {'publication date': '2018 Jan', 'sentence': 'We observed that probiotics and prednisolone could delay SLE in pretreatment and treatment mice groups, with a reduction in ANA, anti-dsDNA, anti-RNP, and mass of lipogranuloma.', 'subject score': 1000, 'object score': 1000}, 'PMID:3686432': {'publication date': '1987', 'sentence': 'A study was made of the sensitivity to prednisolone (PS) of peripheral blood mononuclear cells (MS) of patients with systemic lupus erythematosus (SLE) with renal lesion showing resistance to glucocorticoids (GC).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0024141---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7395227",
-              "object": "MONDO:0007915",
-              "publications": [
-                "PMID:10332213",
-                "PMID:2137939",
-                "PMID:30078223",
-                "PMID:3686432"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 4578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisone",
-          "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "HMDB:HMDB0014773",
-            "UMLS:C0032952",
-            "NCIT:C770",
-            "PUBCHEM.COMPOUND:5865",
-            "DrugCentral:2253",
-            "MESH:D011241",
-            "ATC:A07EA03",
-            "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-            "CAS:53-03-2",
-            "PDQ:CDR0000042487",
-            "PathWhiz.Compound:9120",
-            "KEGG.DRUG:D00473",
-            "DRUGBANK:DB00635",
-            "ATC:H02AB07",
-            "UNII:VB0R961HZT",
-            "NDDF:002164",
-            "CHEMBL.COMPOUND:CHEMBL635",
-            "CHEBI:8382",
-            "KEGG.COMPOUND:C07370",
-            "GTOPDB:7096",
-            "RXNORM:8640"
-          ],
-          "id": "PUBCHEM.COMPOUND:5865",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisone",
-            "Prednisone (USP)",
-            "PREDNISONE",
-            "1,2-dehydrocortisone",
-            "prednisone"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:32422522",
-            "PMID:18788725",
-            "PMID:11413487",
-            "PMID:20070106",
-            "PMID:378499",
-            "PMID:15646539",
-            "PMID:20014752",
-            "PMID:25618019",
-            "PMID:23571415",
-            "PMID:19586686"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 4578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisone",
-              "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "HMDB:HMDB0014773",
-                "UMLS:C0032952",
-                "NCIT:C770",
-                "PUBCHEM.COMPOUND:5865",
-                "DrugCentral:2253",
-                "MESH:D011241",
-                "ATC:A07EA03",
-                "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-                "CAS:53-03-2",
-                "PDQ:CDR0000042487",
-                "PathWhiz.Compound:9120",
-                "KEGG.DRUG:D00473",
-                "DRUGBANK:DB00635",
-                "ATC:H02AB07",
-                "UNII:VB0R961HZT",
-                "NDDF:002164",
-                "CHEMBL.COMPOUND:CHEMBL635",
-                "CHEBI:8382",
-                "KEGG.COMPOUND:C07370",
-                "GTOPDB:7096",
-                "RXNORM:8640"
-              ],
-              "id": "PUBCHEM.COMPOUND:5865",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisone",
-                "Prednisone (USP)",
-                "PREDNISONE",
-                "1,2-dehydrocortisone",
-                "prednisone"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:32422522",
-                "PMID:18788725",
-                "PMID:11413487",
-                "PMID:20070106",
-                "PMID:378499",
-                "PMID:15646539",
-                "PMID:20014752",
-                "PMID:25618019",
-                "PMID:23571415",
-                "PMID:19586686"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21306599,
-            "start": 4578,
-            "end": 568,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3207856': {'publication date': '1988 Jul-Aug', 'sentence': 'In a pilot study using one rabbit, prednisone and prednisolone clearance values increased with increase in either prednisone or prednisolone infusion rates.', 'subject score': 1000, 'object score': 840}, 'PMID:656293': {'publication date': '1978 Jun', 'sentence': '3 Patients with biochemical and histological evidence of active hepatocellular necrosis showed evidence of impaired activation of prednisone, but this was compensated for by a decreased rate of elimination of prednisolone from the plasma.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032952---SEMMEDDB:stimulates---biolink:causes---activity---None---UMLS:C0032950---SEMMEDDB:",
-                "UMLS:C0032952---SEMMEDDB:inhibits---biolink:causes---activity---None---UMLS:C0032950---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5865",
-              "id": "21722189",
-              "object": "PUBCHEM.COMPOUND:5755",
-              "publications": [
-                "PMID:656293",
-                "PMID:3207856"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 708295,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019124",
-          "name": "microscopic polyangiitis",
-          "description": "A systemic necrotizing vasculitis that typically affects the small and medium-sized muscular arteries. In some cases, however, microscopic vessels are also affected (e.g., in the kidneys), a condition that has been called microscopic polyarteritis or polyangiitis; this disorder is felt to be more closely associated with Wegener granulomatosis than to classic polyarteritis nodosa.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:1144805008",
-            "MONDO:0019124",
-            "MESH:D055953",
-            "MEDDRA:10063344",
-            "ORPHANET:727",
-            "EFO:1000784",
-            "SNOMEDCT:239928004",
-            "NCIT:C70549",
-            "UMLS:C2347126"
-          ],
-          "id": "MONDO:0019124",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Microscopic Polyangiitis",
-            "Microscopic Polyarteritis",
-            "microscopic polyangiitis",
-            "Microscopic polyangiitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 708295,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019124",
-              "name": "microscopic polyangiitis",
-              "description": "A systemic necrotizing vasculitis that typically affects the small and medium-sized muscular arteries. In some cases, however, microscopic vessels are also affected (e.g., in the kidneys), a condition that has been called microscopic polyarteritis or polyangiitis; this disorder is felt to be more closely associated with Wegener granulomatosis than to classic polyarteritis nodosa.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:1144805008",
-                "MONDO:0019124",
-                "MESH:D055953",
-                "MEDDRA:10063344",
-                "ORPHANET:727",
-                "EFO:1000784",
-                "SNOMEDCT:239928004",
-                "NCIT:C70549",
-                "UMLS:C2347126"
-              ],
-              "id": "MONDO:0019124",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Microscopic Polyangiitis",
-                "Microscopic Polyarteritis",
-                "microscopic polyangiitis",
-                "Microscopic polyangiitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 27003853,
-            "start": 568,
-            "end": 708295,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9366170': {'publication date': '1997 Aug', 'sentence': 'Microscopic polyarteritis nodosa was diagnosed and therapy with prednisolone was begun.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C2347126---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "27475554",
-              "object": "MONDO:0019124",
-              "publications": [
-                "PMID:9366170"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 308745,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005328",
-          "name": "eye disorder",
-          "description": "Diseases or defects of the eye. Use VISION DISORDERS for other pathology involving visual neural pathways.; A non-neoplastic or neoplastic disorder that affects the eye. Representative examples include conjunctivitis, glaucoma, cataract, conjunctival squamous cell carcinoma, uveal melanoma, and retinoblastoma.; Diseases affecting the eye.; Any abnormality of the eye, including location, spacing, and intraocular abnormalities. [HPO:probinson]; Some eye problems are minor and don't last long. But some can lead to a permanent loss of vision. Common eye problems include: Refractive errors Cataracts - clouded lenses Optic nerve disorders, including glaucoma Retinal disorders - problems with the nerve layer at the back of the eye Macular degeneration - a disease that destroys sharp, central vision Diabetic eye problems Conjunctivitis - an infection also known as pink eye  Your best defense is to have regular checkups, because eye diseases do not always have symptoms. Early detection and treatment could prevent vision loss. See an eye care professional right away if you have a sudden change in vision, if everything looks dim, or if you see flashes of light. Other symptoms that need quick attention are pain, double vision, fluid coming from the eye, and inflammation. NIH: National Eye Institute ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0015397",
-            "NCIT:C26767",
-            "MEDDRA:10045783",
-            "MEDDRA:10013221",
-            "MEDDRA:10015919",
-            "MEDDRA:10054716",
-            "ICD9:360.29",
-            "MESH:D005128",
-            "EFO:0003966",
-            "MEDDRA:10015916",
-            "MEDDRA:10059159",
-            "UMLS:C0015393",
-            "ICD10:H44",
-            "MEDDRA:10045790",
-            "HP:0000478",
-            "SNOMEDCT:19416009",
-            "MEDDRA:10015913",
-            "MEDDRA:10030874",
-            "NCIT:C98887",
-            "MEDDRA:10010435",
-            "MEDDRA:10010462",
-            "MEDDRA:10015949",
-            "UMLS:C4316870",
-            "MEDDRA:10015904",
-            "MESH:D005124",
-            "MEDDRA:10015920",
-            "MEDDRA:10015903",
-            "MEDDRA:10015918",
-            "MONDO:0005328",
-            "SNOMEDCT:371405004",
-            "ICD9:379.90",
-            "DOID:5614",
-            "UMLS:C0154780",
-            "DOID:1242",
-            "MEDDRA:10045628",
-            "ICD10:H44.39"
-          ],
-          "id": "MONDO:0005328",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Disorder of eye, unspecified",
-            "Eye Abnormalities",
-            "Other degenerative disorders of globe",
-            "eye disease",
-            "Congenital Eye Disorder",
-            "globe disease",
-            "Disorder of eye",
-            "Abnormality of the eye",
-            "eye disorder",
-            "Eye Diseases",
-            "Eye Disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/eye_disease",
-            "https://en.wikipedia.org/wiki/globe_(human_eye)",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-5316-1399"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308745,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005328",
-              "name": "eye disorder",
-              "description": "Diseases or defects of the eye. Use VISION DISORDERS for other pathology involving visual neural pathways.; A non-neoplastic or neoplastic disorder that affects the eye. Representative examples include conjunctivitis, glaucoma, cataract, conjunctival squamous cell carcinoma, uveal melanoma, and retinoblastoma.; Diseases affecting the eye.; Any abnormality of the eye, including location, spacing, and intraocular abnormalities. [HPO:probinson]; Some eye problems are minor and don't last long. But some can lead to a permanent loss of vision. Common eye problems include: Refractive errors Cataracts - clouded lenses Optic nerve disorders, including glaucoma Retinal disorders - problems with the nerve layer at the back of the eye Macular degeneration - a disease that destroys sharp, central vision Diabetic eye problems Conjunctivitis - an infection also known as pink eye  Your best defense is to have regular checkups, because eye diseases do not always have symptoms. Early detection and treatment could prevent vision loss. See an eye care professional right away if you have a sudden change in vision, if everything looks dim, or if you see flashes of light. Other symptoms that need quick attention are pain, double vision, fluid coming from the eye, and inflammation. NIH: National Eye Institute ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0015397",
-                "NCIT:C26767",
-                "MEDDRA:10045783",
-                "MEDDRA:10013221",
-                "MEDDRA:10015919",
-                "MEDDRA:10054716",
-                "ICD9:360.29",
-                "MESH:D005128",
-                "EFO:0003966",
-                "MEDDRA:10015916",
-                "MEDDRA:10059159",
-                "UMLS:C0015393",
-                "ICD10:H44",
-                "MEDDRA:10045790",
-                "HP:0000478",
-                "SNOMEDCT:19416009",
-                "MEDDRA:10015913",
-                "MEDDRA:10030874",
-                "NCIT:C98887",
-                "MEDDRA:10010435",
-                "MEDDRA:10010462",
-                "MEDDRA:10015949",
-                "UMLS:C4316870",
-                "MEDDRA:10015904",
-                "MESH:D005124",
-                "MEDDRA:10015920",
-                "MEDDRA:10015903",
-                "MEDDRA:10015918",
-                "MONDO:0005328",
-                "SNOMEDCT:371405004",
-                "ICD9:379.90",
-                "DOID:5614",
-                "UMLS:C0154780",
-                "DOID:1242",
-                "MEDDRA:10045628",
-                "ICD10:H44.39"
-              ],
-              "id": "MONDO:0005328",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Disorder of eye, unspecified",
-                "Eye Abnormalities",
-                "Other degenerative disorders of globe",
-                "eye disease",
-                "Congenital Eye Disorder",
-                "globe disease",
-                "Disorder of eye",
-                "Abnormality of the eye",
-                "eye disorder",
-                "Eye Diseases",
-                "Eye Disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/eye_disease",
-                "https://en.wikipedia.org/wiki/globe_(human_eye)",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-5316-1399"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25849016,
-            "start": 568,
-            "end": 308745,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:6896620': {'publication date': '1981 Dec', 'sentence': 'A short trial with high doses of prednisolone to treat a 62 year-old woman with malignant ophthalmopathy due to Graves disease yielded an unsatisfactory improvement after 5-6 days.', 'subject score': 1000, 'object score': 861}, 'PMID:8000111': {'publication date': '1994 Sep', 'sentence': 'Ophthalmopathy was aggravated in spite of prednisolone therapy and euthyroidism being maintained by thyroxine replacement.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0015397---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "26307899",
-              "object": "MONDO:0005328",
-              "publications": [
-                "PMID:6896620",
-                "PMID:8000111"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 529246,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019198",
-          "name": "sympathetic ophthalmia",
-          "description": "Granulomatous uveitis which follows in one eye after a penetrating injury to the other eye; the secondarily affected eye is called the sympathizing eye, and the injured eye is called the exciting or activating eye.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD9:360.11",
-            "UMLS:C0029077",
-            "MONDO:0019198",
-            "MESH:D009879",
-            "ORPHANET:79098",
-            "DOID:12029",
-            "MEDDRA:10042745",
-            "ICD10:H44.13",
-            "MEDDRA:10042743",
-            "EFO:1001205",
-            "MEDDRA:10042742",
-            "SNOMEDCT:75315001"
-          ],
-          "id": "MONDO:0019198",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Sympathetic ophthalmia",
-            "Sympathetic uveitis",
-            "sympathetic ophthalmia",
-            "Ophthalmia, Sympathetic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3277011/",
-            "http://eyewiki.aao.org/sympathetic_ophthalmia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 529246,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019198",
-              "name": "sympathetic ophthalmia",
-              "description": "Granulomatous uveitis which follows in one eye after a penetrating injury to the other eye; the secondarily affected eye is called the sympathizing eye, and the injured eye is called the exciting or activating eye.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD9:360.11",
-                "UMLS:C0029077",
-                "MONDO:0019198",
-                "MESH:D009879",
-                "ORPHANET:79098",
-                "DOID:12029",
-                "MEDDRA:10042745",
-                "ICD10:H44.13",
-                "MEDDRA:10042743",
-                "EFO:1001205",
-                "MEDDRA:10042742",
-                "SNOMEDCT:75315001"
-              ],
-              "id": "MONDO:0019198",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Sympathetic ophthalmia",
-                "Sympathetic uveitis",
-                "sympathetic ophthalmia",
-                "Ophthalmia, Sympathetic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3277011/",
-                "http://eyewiki.aao.org/sympathetic_ophthalmia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25488064,
-            "start": 568,
-            "end": 529246,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:5738852': {'publication date': '1968 Mar', 'sentence': '[\"Abolishment\" syndrome in prednisolone treatment of patients with sympathetic ophthalmia].', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0029077---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "25942811",
-              "object": "MONDO:0019198",
-              "publications": [
-                "PMID:5738852"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320057,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043233",
-          "name": "exfoliative dermatitis",
-          "description": "An inflammatory exfoliative dermatosis involving nearly all of the surface of the skin. Erythroderma develops suddenly. A patchy erythema may generalize and spread to affect most of the skin. Scaling may appear in 2-6 days and be accompanied by hot, red, dry skin, malaise, and fever. [HPO:probinson]; An inflammatory exfoliative dermatosis involving nearly all of the surface of the skin. Erythroderma develops suddenly. A patchy erythema may generalize and spread to affect most of the skin. Scaling may appear in 2-6 days and be accompanied by hot, red, dry skin, malaise, and fever.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0011606",
-            "SNOMEDCT:400005007",
-            "MEDDRA:10012455",
-            "MEDDRA:10015665",
-            "NCIT:C39646",
-            "MEDDRA:10018082",
-            "SNOMEDCT:396349005",
-            "MEDDRA:10062416",
-            "SNOMEDCT:200948000",
-            "UMLS:C5139033",
-            "MESH:D003873",
-            "MONDO:0043233",
-            "SNOMEDCT:399992009",
-            "MEDDRA:10012456",
-            "HP:0001019",
-            "MEDDRA:10052584",
-            "MEDDRA:10062434",
-            "MEDDRA:10015277",
-            "EFO:0009456",
-            "MEDDRA:10015666",
-            "MEDDRA:10012457",
-            "SNOMEDCT:396350005"
-          ],
-          "id": "MONDO:0043233",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Red scaly skin caused by inflammatory skin disease",
-            "Erythroderma",
-            "Dermatitis, Exfoliative",
-            "Exfoliative dermatitis",
-            "exfoliative dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320057,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043233",
-              "name": "exfoliative dermatitis",
-              "description": "An inflammatory exfoliative dermatosis involving nearly all of the surface of the skin. Erythroderma develops suddenly. A patchy erythema may generalize and spread to affect most of the skin. Scaling may appear in 2-6 days and be accompanied by hot, red, dry skin, malaise, and fever. [HPO:probinson]; An inflammatory exfoliative dermatosis involving nearly all of the surface of the skin. Erythroderma develops suddenly. A patchy erythema may generalize and spread to affect most of the skin. Scaling may appear in 2-6 days and be accompanied by hot, red, dry skin, malaise, and fever.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0011606",
-                "SNOMEDCT:400005007",
-                "MEDDRA:10012455",
-                "MEDDRA:10015665",
-                "NCIT:C39646",
-                "MEDDRA:10018082",
-                "SNOMEDCT:396349005",
-                "MEDDRA:10062416",
-                "SNOMEDCT:200948000",
-                "UMLS:C5139033",
-                "MESH:D003873",
-                "MONDO:0043233",
-                "SNOMEDCT:399992009",
-                "MEDDRA:10012456",
-                "HP:0001019",
-                "MEDDRA:10052584",
-                "MEDDRA:10062434",
-                "MEDDRA:10015277",
-                "EFO:0009456",
-                "MEDDRA:10015666",
-                "MEDDRA:10012457",
-                "SNOMEDCT:396350005"
-              ],
-              "id": "MONDO:0043233",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Red scaly skin caused by inflammatory skin disease",
-                "Erythroderma",
-                "Dermatitis, Exfoliative",
-                "Exfoliative dermatitis",
-                "exfoliative dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23854304,
-            "start": 568,
-            "end": 320057,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35273888': {'publication date': '2022 Feb', 'sentence': 'A 60-year-old Aboriginal man with underlying severe exfoliative dermatitis, treated with oral azathioprine and oral prednisolone, presented with left painful red eye for ten days.', 'subject score': 888, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0011606---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "24297743",
-              "object": "MONDO:0043233",
-              "publications": [
-                "PMID:35273888"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 683078,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015492",
-          "name": "Anti-neutrophil cytoplasmic antibody-associated vasculitis",
-          "description": "Group of systemic vasculitis with a strong association with anca. The disorders are characterized by necrotizing inflammation of small and medium size vessels, with little or no immune-complex deposits in vessel walls.",
-          "equivalent_curies": [
-            "MONDO:0015492",
-            "UMLS:C2717865",
-            "MESH:D056648",
-            "ORPHANET:156152",
-            "SNOMEDCT:722191003",
-            "MEDDRA:10086756"
-          ],
-          "id": "MONDO:0015492",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
-            "anti-neutrophil cytoplasmic antibody-associated vasculitis",
-            "Anti-neutrophil cytoplasmic antibody-associated vasculitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 683078,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015492",
-              "name": "Anti-neutrophil cytoplasmic antibody-associated vasculitis",
-              "description": "Group of systemic vasculitis with a strong association with anca. The disorders are characterized by necrotizing inflammation of small and medium size vessels, with little or no immune-complex deposits in vessel walls.",
-              "equivalent_curies": [
-                "MONDO:0015492",
-                "UMLS:C2717865",
-                "MESH:D056648",
-                "ORPHANET:156152",
-                "SNOMEDCT:722191003",
-                "MEDDRA:10086756"
-              ],
-              "id": "MONDO:0015492",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
-                "anti-neutrophil cytoplasmic antibody-associated vasculitis",
-                "Anti-neutrophil cytoplasmic antibody-associated vasculitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23851781,
-            "start": 568,
-            "end": 683078,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35265413': {'publication date': '2022 Feb', 'sentence': 'These findings were consistent with a diagnosis of ANCA-associated vasculitis, and treatment with prednisolone markedly improved her condition.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C2717865---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "24291326",
-              "object": "MONDO:0015492",
-              "publications": [
-                "PMID:35265413"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321599,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008867",
-          "name": "biliary atresia",
-          "description": "A congenital disorder characterized by blockage or absence of the intrahepatic or extrahepatic bile ducts.; Progressive destruction or the absence of all or part of the extrahepatic BILE DUCTS, resulting in the complete obstruction of BILE flow. Usually, biliary atresia is found in infants and accounts for one third of the neonatal cholestatic JAUNDICE.; Atresia of the biliary tree. [HPO:probinson]; UMLS Semantic Type: STY:T019",
-          "equivalent_curies": [
-            "MEDDRA:10004654",
-            "HP:0005912",
-            "MEDDRA:10003650",
-            "NCIT:C34421",
-            "ICD9:751.61",
-            "MESH:D001656",
-            "UMLS:C0005411",
-            "ORPHANET:30391",
-            "MONDO:0008867",
-            "DOID:13608",
-            "MEDDRA:10004653",
-            "SNOMEDCT:77480004",
-            "ICD10:Q44.2"
-          ],
-          "id": "MONDO:0008867",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_biliary atresia",
-            "Biliary atresia",
-            "Biliary Atresia",
-            "biliary atresia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000215.htm",
-            "http://en.wikipedia.org/wiki/biliary_atresia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321599,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008867",
-              "name": "biliary atresia",
-              "description": "A congenital disorder characterized by blockage or absence of the intrahepatic or extrahepatic bile ducts.; Progressive destruction or the absence of all or part of the extrahepatic BILE DUCTS, resulting in the complete obstruction of BILE flow. Usually, biliary atresia is found in infants and accounts for one third of the neonatal cholestatic JAUNDICE.; Atresia of the biliary tree. [HPO:probinson]; UMLS Semantic Type: STY:T019",
-              "equivalent_curies": [
-                "MEDDRA:10004654",
-                "HP:0005912",
-                "MEDDRA:10003650",
-                "NCIT:C34421",
-                "ICD9:751.61",
-                "MESH:D001656",
-                "UMLS:C0005411",
-                "ORPHANET:30391",
-                "MONDO:0008867",
-                "DOID:13608",
-                "MEDDRA:10004653",
-                "SNOMEDCT:77480004",
-                "ICD10:Q44.2"
-              ],
-              "id": "MONDO:0008867",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_biliary atresia",
-                "Biliary atresia",
-                "Biliary Atresia",
-                "biliary atresia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000215.htm",
-                "http://en.wikipedia.org/wiki/biliary_atresia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23604593,
-            "start": 568,
-            "end": 321599,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34945055': {'publication date': '2021 Dec 09', 'sentence': 'In 2010, a study on the advantages of budesonide compared to prednisolone in autoimmune hepatitis gave rise to experimental therapy using budesonide as an adjuvant BA treatment.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0005411---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "24042094",
-              "object": "MONDO:0008867",
-              "publications": [
-                "PMID:34945055"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 535036,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009691",
-          "name": "mycosis fungoides",
-          "description": "A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei. Patients with limited disease generally have an excellent prognosis. In the more advanced stages, the prognosis is poor. (WHO, 2001); A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MESH:D009182",
-            "MEDDRA:10028483",
-            "MONDO:0009691",
-            "UMLS:C0026948",
-            "SNOMEDCT:90120004",
-            "NCIT:C3246",
-            "ICD9:202.1",
-            "OMIM:254400",
-            "ORPHANET:2584",
-            "MEDDRA:10028484",
-            "ICD10:C84.0",
-            "DOID:8691",
-            "EFO:1001051",
-            "MEDDRA:10028500",
-            "SNOMEDCT:118618005"
-          ],
-          "id": "MONDO:0009691",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Mycosis fungoides",
-            "Mycosis fungoides related phenotypic feature",
-            "Classic mycosis fungoides",
-            "mycosis fungoides",
-            "Mycosis Fungoides"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 535036,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009691",
-              "name": "mycosis fungoides",
-              "description": "A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei. Patients with limited disease generally have an excellent prognosis. In the more advanced stages, the prognosis is poor. (WHO, 2001); A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MESH:D009182",
-                "MEDDRA:10028483",
-                "MONDO:0009691",
-                "UMLS:C0026948",
-                "SNOMEDCT:90120004",
-                "NCIT:C3246",
-                "ICD9:202.1",
-                "OMIM:254400",
-                "ORPHANET:2584",
-                "MEDDRA:10028484",
-                "ICD10:C84.0",
-                "DOID:8691",
-                "EFO:1001051",
-                "MEDDRA:10028500",
-                "SNOMEDCT:118618005"
-              ],
-              "id": "MONDO:0009691",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Mycosis fungoides",
-                "Mycosis fungoides related phenotypic feature",
-                "Classic mycosis fungoides",
-                "mycosis fungoides",
-                "Mycosis Fungoides"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23543736,
-            "start": 568,
-            "end": 535036,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34866072': {'publication date': '2021 Dec 06', 'sentence': 'Prednisolone was initially used alone as an alternative treatment for CEL.', 'subject score': 1000, 'object score': 1000}, 'PMID:3658820': {'publication date': '1987 Apr', 'sentence': 'Treatment of light-sensitive mycosis fungoides with PUVA and prednisolone.', 'subject score': 1000, 'object score': 865}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0026948---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "23981131",
-              "object": "MONDO:0009691",
-              "publications": [
-                "PMID:34866072",
-                "PMID:3658820"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 508253,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019444",
-          "name": "trichinellosis",
-          "description": "A parasitic infection caused by larvae of worms of the genus Trichinella. It is transmitted to humans by ingesting raw or undercooked meat from infected animals. Signs and symptoms include abdominal discomfort, nausea, vomiting, fever, diarrhea, headache, coughing, myalgias, arthralgias, and eye swelling.; An infection with TRICHINELLA. It is caused by eating raw or undercooked meat that is infected with larvae of nematode worms TRICHINELLA genus. All members of the TRICHINELLA genus can infect human in addition to TRICHINELLA SPIRALIS, the traditional etiological agent. It is distributed throughout much of the world and is re-emerging in some parts as a public health hazard and a food safety problem.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0040896",
-            "EFO:0007520",
-            "SNOMEDCT:709018004",
-            "DOID:9784",
-            "MONDO:0019444",
-            "NCIT:C85199",
-            "ORPHANET:863",
-            "ICD9:124",
-            "MESH:D014235",
-            "MEDDRA:10044608",
-            "ICD10:B75",
-            "MEDDRA:10044609"
-          ],
-          "id": "MONDO:0019444",
-          "category": "biolink:Disease",
-          "all_names": [
-            "trichinellosis",
-            "Trichinosis",
-            "Trichinellosis",
-            "trichinosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.dpd.cdc.gov/dpdx/html/trichinellosis.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 508253,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019444",
-              "name": "trichinellosis",
-              "description": "A parasitic infection caused by larvae of worms of the genus Trichinella. It is transmitted to humans by ingesting raw or undercooked meat from infected animals. Signs and symptoms include abdominal discomfort, nausea, vomiting, fever, diarrhea, headache, coughing, myalgias, arthralgias, and eye swelling.; An infection with TRICHINELLA. It is caused by eating raw or undercooked meat that is infected with larvae of nematode worms TRICHINELLA genus. All members of the TRICHINELLA genus can infect human in addition to TRICHINELLA SPIRALIS, the traditional etiological agent. It is distributed throughout much of the world and is re-emerging in some parts as a public health hazard and a food safety problem.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0040896",
-                "EFO:0007520",
-                "SNOMEDCT:709018004",
-                "DOID:9784",
-                "MONDO:0019444",
-                "NCIT:C85199",
-                "ORPHANET:863",
-                "ICD9:124",
-                "MESH:D014235",
-                "MEDDRA:10044608",
-                "ICD10:B75",
-                "MEDDRA:10044609"
-              ],
-              "id": "MONDO:0019444",
-              "category": "biolink:Disease",
-              "all_names": [
-                "trichinellosis",
-                "Trichinosis",
-                "Trichinellosis",
-                "trichinosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.dpd.cdc.gov/dpdx/html/trichinellosis.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22942849,
-            "start": 568,
-            "end": 508253,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34030751': {'publication date': '2021 May 25', 'sentence': 'This study assessed the antiparasitic and anti-inflammatory effects of Citrus limon and Capsicum frutescens on murine trichinellosis and compared them with those of albendazole and prednisolone, which are conventionally used to treat trichinellosis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0040896---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "23374627",
-              "object": "MONDO:0019444",
-              "publications": [
-                "PMID:34030751"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316306,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0800029",
-          "name": "interstitial lung disease 2",
-          "description": "Interstitial pneumonia characterized by the presence of fibrosis in the interstitial lung tissue. The pathologic diagnosis is based on the identification of fibrotic lesions at different stages of development within a lung biopsy specimen. Typically there are foci of normal lung parenchyma alternating with interstitial inflammation and honeycombing. The term usual interstitial pneumonia sometimes is used interchangeably with idiopathic interstitial fibrosis. The two terms are not entirely synonymous. Usual interstitial pneumonia may be associated with other conditions such as connective tissue disorders and asbestosis. The diagnosis of idiopathic interstitial fibrosis requires the exclusion of such conditions. Patients with usual interstitial pneumonia present with progressive dyspnea, cough, and restrictive pulmonary function abnormalities. The prognosis is usually poor.; A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.; Temporal and spatial heterogeneity in lungs based on presence of fibrosis and honeycombing. [PMID:26666486, PMID:8697837]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:2032",
-            "MEDDRA:10001892",
-            "MEDDRA:10016641",
-            "NCIT:C35715",
-            "UMLS:C4721952",
-            "ICD9:516.31",
-            "UMLS:C1800706",
-            "UMLS:C5561926",
-            "SNOMEDCT:196125002",
-            "NCIT:C35716",
-            "MEDDRA:10011495",
-            "HP:0031950",
-            "MESH:D054990",
-            "OMIM:178500",
-            "UMLS:C4721508",
-            "MEDDRA:10021240",
-            "MEDDRA:10016640",
-            "SNOMEDCT:700250006",
-            "UMLS:C4721509",
-            "MONDO:0800029",
-            "SNOMEDCT:426437004",
-            "ICD10:J84.112",
-            "DOID:0050156",
-            "EFO:0000768"
-          ],
-          "id": "MONDO:0800029",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Familial Idiopathic Pulmonary Fibrosis",
-            "Idiopathic pulmonary fibrosis",
-            "Interstitial lung disease 2 related phenotypic feature",
-            "Interstitial lung disease 2",
-            "idiopathic pulmonary fibrosis",
-            "interstitial lung disease 2",
-            "Idiopathic Pulmonary Fibrosis",
-            "Hamman-Rich Disease",
-            "Usual Interstitial Pneumonia",
-            "Usual interstitial pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:26666486",
-            "https://www.pulmonaryfibrosis.org/life-with-pf/about-ipf",
-            "https://orcid.org/0000-0001-5208-3432",
-            "PMID:8697837"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316306,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0800029",
-              "name": "interstitial lung disease 2",
-              "description": "Interstitial pneumonia characterized by the presence of fibrosis in the interstitial lung tissue. The pathologic diagnosis is based on the identification of fibrotic lesions at different stages of development within a lung biopsy specimen. Typically there are foci of normal lung parenchyma alternating with interstitial inflammation and honeycombing. The term usual interstitial pneumonia sometimes is used interchangeably with idiopathic interstitial fibrosis. The two terms are not entirely synonymous. Usual interstitial pneumonia may be associated with other conditions such as connective tissue disorders and asbestosis. The diagnosis of idiopathic interstitial fibrosis requires the exclusion of such conditions. Patients with usual interstitial pneumonia present with progressive dyspnea, cough, and restrictive pulmonary function abnormalities. The prognosis is usually poor.; A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.; Temporal and spatial heterogeneity in lungs based on presence of fibrosis and honeycombing. [PMID:26666486, PMID:8697837]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:2032",
-                "MEDDRA:10001892",
-                "MEDDRA:10016641",
-                "NCIT:C35715",
-                "UMLS:C4721952",
-                "ICD9:516.31",
-                "UMLS:C1800706",
-                "UMLS:C5561926",
-                "SNOMEDCT:196125002",
-                "NCIT:C35716",
-                "MEDDRA:10011495",
-                "HP:0031950",
-                "MESH:D054990",
-                "OMIM:178500",
-                "UMLS:C4721508",
-                "MEDDRA:10021240",
-                "MEDDRA:10016640",
-                "SNOMEDCT:700250006",
-                "UMLS:C4721509",
-                "MONDO:0800029",
-                "SNOMEDCT:426437004",
-                "ICD10:J84.112",
-                "DOID:0050156",
-                "EFO:0000768"
-              ],
-              "id": "MONDO:0800029",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Familial Idiopathic Pulmonary Fibrosis",
-                "Idiopathic pulmonary fibrosis",
-                "Interstitial lung disease 2 related phenotypic feature",
-                "Interstitial lung disease 2",
-                "idiopathic pulmonary fibrosis",
-                "interstitial lung disease 2",
-                "Idiopathic Pulmonary Fibrosis",
-                "Hamman-Rich Disease",
-                "Usual Interstitial Pneumonia",
-                "Usual interstitial pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:26666486",
-                "https://www.pulmonaryfibrosis.org/life-with-pf/about-ipf",
-                "https://orcid.org/0000-0001-5208-3432",
-                "PMID:8697837"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22155421,
-            "start": 568,
-            "end": 316306,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:33028767': {'publication date': '2020 Oct 07', 'sentence': 'Regression of Lung Squamous Cell Carcinoma after the Withdrawal of Cyclosporin A Combined With Pirfenidone Treatment in a Patient with Idiopathic Pulmonary Fibrosis.A 72-year-old man was treated with prednisolone and cyclosporine A for idiopathic pulmonary fibrosis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C1800706---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "22580782",
-              "object": "MONDO:0800029",
-              "publications": [
-                "PMID:33028767"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 517695,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005109",
-          "name": "HIV infectious disease",
-          "description": "A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.",
-          "equivalent_curies": [
-            "UMLS:C0019693",
-            "ICD9:042-042.99",
-            "SNOMEDCT:86406008",
-            "NCIT:C3108",
-            "MEDDRA:10020161",
-            "PDQ:CDR0000585059",
-            "MEDDRA:10020443",
-            "MEDDRA:10020160",
-            "MONDO:0005109",
-            "EFO:0000764",
-            "MEDDRA:10020172",
-            "MESH:D015658",
-            "DOID:526"
-          ],
-          "id": "MONDO:0005109",
-          "category": "biolink:Disease",
-          "all_names": [
-            "human immunodeficiency virus infectious disease",
-            "HIV infection",
-            "HIV infectious disease",
-            "HIV Infection",
-            "Human immunodeficiency virus [hiv] infection",
-            "HIV Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/hiv",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000602.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517695,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005109",
-              "name": "HIV infectious disease",
-              "description": "A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.",
-              "equivalent_curies": [
-                "UMLS:C0019693",
-                "ICD9:042-042.99",
-                "SNOMEDCT:86406008",
-                "NCIT:C3108",
-                "MEDDRA:10020161",
-                "PDQ:CDR0000585059",
-                "MEDDRA:10020443",
-                "MEDDRA:10020160",
-                "MONDO:0005109",
-                "EFO:0000764",
-                "MEDDRA:10020172",
-                "MESH:D015658",
-                "DOID:526"
-              ],
-              "id": "MONDO:0005109",
-              "category": "biolink:Disease",
-              "all_names": [
-                "human immunodeficiency virus infectious disease",
-                "HIV infection",
-                "HIV infectious disease",
-                "HIV Infection",
-                "Human immunodeficiency virus [hiv] infection",
-                "HIV Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/hiv",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000602.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22075896,
-            "start": 568,
-            "end": 517695,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32933857': {'publication date': '2020 Sep 12', 'sentence': 'The most common coexisting conditions were HIV infection (30%), prednisolone therapy (16.9%), and diabetes mellitus (15.7%).', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0019693---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "22500116",
-              "object": "MONDO:0005109",
-              "publications": [
-                "PMID:32933857"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320598,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005090",
-          "name": "schizophrenia",
-          "description": "A major psychotic disorder characterized by abnormalities in the perception or expression of reality. It affects the cognitive and psychomotor functions. Common clinical signs and symptoms include delusions, hallucinations, disorganized thinking, and retreat from reality.; A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.; A mental disorder characterized by a disintegration of thought processes and of emotional responsiveness. It most commonly manifests as auditory hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking, and it is accompanied by significant social or occupational dysfunction. The onset of symptoms typically occurs in young adulthood, with a global lifetime prevalence of about 0.3-0.7%. [HPO:sdoelken]; Schizophrenia is a serious brain illness. People who have it may hear voices that aren't there. They may think other people are trying to hurt them. Sometimes they don't make sense when they talk. The disorder makes it hard for them to keep a job or take care of themselves. Symptoms of schizophrenia usually start between ages 16 and 30. Men often develop symptoms at a younger age than women. People usually do not get schizophrenia after age 45. There are three types of symptoms:  Psychotic symptoms distort a person's thinking. These include hallucinations (hearing or seeing things that are not there), delusions (beliefs that are not true), trouble organizing thoughts, and strange movements. \"Negative\" symptoms make it difficult to show emotions and to function normally. A person may seem depressed and withdrawn. Cognitive symptoms affect the thought process. These include trouble using information, making decisions, and paying attention.  No one is sure what causes schizophrenia. Your genes, environment, and brain chemistry may play a role. There is no cure. Medicine can help control many of the symptoms. You may need to try different medicines to see which works best. You should stay on your medicine for as long as your doctor recommends. Additional treatments can help you deal with your illness from day to day. These include therapy, family education, rehabilitation, and skills training. NIH: National Institute of Mental Health; UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "MEDDRA:10039632",
-            "MEDDRA:10046150",
-            "MESH:D012559",
-            "MEDDRA:10046156",
-            "ICD9:295",
-            "MONDO:0005090",
-            "UMLS:C4538533",
-            "EFO:0000692",
-            "ORPHANET:3140",
-            "PSY:45440",
-            "MEDDRA:10012297",
-            "SNOMEDCT:58214004",
-            "SNOMEDCT:191526005",
-            "OMIM:181500",
-            "MEDDRA:10039626",
-            "DOID:5419",
-            "UMLS:C0036341",
-            "NCIT:C3362",
-            "HP:0100753",
-            "ICD10:F20"
-          ],
-          "id": "MONDO:0005090",
-          "category": "biolink:Disease",
-          "all_names": [
-            "schizophrenia",
-            "Schizophrenia with or without an affective disorder",
-            "Schizophrenia",
-            "Schizophrenic disorders",
-            "obsolete_schizophrenia",
-            "Schizophrenia related phenotypic feature"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/schizophrenia",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320598,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005090",
-              "name": "schizophrenia",
-              "description": "A major psychotic disorder characterized by abnormalities in the perception or expression of reality. It affects the cognitive and psychomotor functions. Common clinical signs and symptoms include delusions, hallucinations, disorganized thinking, and retreat from reality.; A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.; A mental disorder characterized by a disintegration of thought processes and of emotional responsiveness. It most commonly manifests as auditory hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking, and it is accompanied by significant social or occupational dysfunction. The onset of symptoms typically occurs in young adulthood, with a global lifetime prevalence of about 0.3-0.7%. [HPO:sdoelken]; Schizophrenia is a serious brain illness. People who have it may hear voices that aren't there. They may think other people are trying to hurt them. Sometimes they don't make sense when they talk. The disorder makes it hard for them to keep a job or take care of themselves. Symptoms of schizophrenia usually start between ages 16 and 30. Men often develop symptoms at a younger age than women. People usually do not get schizophrenia after age 45. There are three types of symptoms:  Psychotic symptoms distort a person's thinking. These include hallucinations (hearing or seeing things that are not there), delusions (beliefs that are not true), trouble organizing thoughts, and strange movements. \"Negative\" symptoms make it difficult to show emotions and to function normally. A person may seem depressed and withdrawn. Cognitive symptoms affect the thought process. These include trouble using information, making decisions, and paying attention.  No one is sure what causes schizophrenia. Your genes, environment, and brain chemistry may play a role. There is no cure. Medicine can help control many of the symptoms. You may need to try different medicines to see which works best. You should stay on your medicine for as long as your doctor recommends. Additional treatments can help you deal with your illness from day to day. These include therapy, family education, rehabilitation, and skills training. NIH: National Institute of Mental Health; UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "MEDDRA:10039632",
-                "MEDDRA:10046150",
-                "MESH:D012559",
-                "MEDDRA:10046156",
-                "ICD9:295",
-                "MONDO:0005090",
-                "UMLS:C4538533",
-                "EFO:0000692",
-                "ORPHANET:3140",
-                "PSY:45440",
-                "MEDDRA:10012297",
-                "SNOMEDCT:58214004",
-                "SNOMEDCT:191526005",
-                "OMIM:181500",
-                "MEDDRA:10039626",
-                "DOID:5419",
-                "UMLS:C0036341",
-                "NCIT:C3362",
-                "HP:0100753",
-                "ICD10:F20"
-              ],
-              "id": "MONDO:0005090",
-              "category": "biolink:Disease",
-              "all_names": [
-                "schizophrenia",
-                "Schizophrenia with or without an affective disorder",
-                "Schizophrenia",
-                "Schizophrenic disorders",
-                "obsolete_schizophrenia",
-                "Schizophrenia related phenotypic feature"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/schizophrenia",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21710089,
-            "start": 568,
-            "end": 320598,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32513294': {'publication date': '2020 Jun 08', 'sentence': 'Therefore, the effect of prednisolone can be studied as a proof of concept for immune modulation as a treatment for schizophrenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:33711681': {'publication date': '2021 Mar 09', 'sentence': 'CONCLUSION: Adjunctive treatment with prednisolone did not improve symptom severity compared to placebo in patients with schizophrenia.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0036341---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "22130331",
-              "object": "MONDO:0005090",
-              "publications": [
-                "PMID:32513294",
-                "PMID:33711681"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 312684,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015129",
-          "name": "chronic primary adrenal insufficiency",
-          "description": "A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.; An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands as a result of a primary defect in the glands themselves. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0001403",
-            "MONDO:0015129",
-            "DOID:13774",
-            "SNOMEDCT:363732003",
-            "PSY:00810",
-            "MEDDRA:10052381",
-            "UMLS:C1868690",
-            "OMIM:240200",
-            "ICD10:E27.1",
-            "UMLS:C0271737",
-            "MEDDRA:10080674",
-            "SNOMEDCT:373662000",
-            "MEDDRA:10013096",
-            "MEDDRA:10001130",
-            "HP:0008207",
-            "MEDDRA:10036696",
-            "MESH:D000075262",
-            "MESH:D000224",
-            "SNOMEDCT:76715008",
-            "ORPHANET:101959",
-            "NCIT:C26689",
-            "MEDDRA:10085976"
-          ],
-          "id": "MONDO:0015129",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hypoadrenocorticism, Familial",
-            "Primary adrenal insufficiency",
-            "Addisons Disease",
-            "Chronic primary adrenal insufficiency",
-            "Addison's disease due to autoimmunity",
-            "Addison Disease",
-            "Addison's disease",
-            "chronic primary adrenal insufficiency",
-            "Hypoadrenocorticism, familial",
-            "Hypoadrenocorticism, familial related phenotypic feature",
-            "Addison's Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/addison%27s_disease",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312684,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015129",
-              "name": "chronic primary adrenal insufficiency",
-              "description": "A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.; An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands as a result of a primary defect in the glands themselves. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0001403",
-                "MONDO:0015129",
-                "DOID:13774",
-                "SNOMEDCT:363732003",
-                "PSY:00810",
-                "MEDDRA:10052381",
-                "UMLS:C1868690",
-                "OMIM:240200",
-                "ICD10:E27.1",
-                "UMLS:C0271737",
-                "MEDDRA:10080674",
-                "SNOMEDCT:373662000",
-                "MEDDRA:10013096",
-                "MEDDRA:10001130",
-                "HP:0008207",
-                "MEDDRA:10036696",
-                "MESH:D000075262",
-                "MESH:D000224",
-                "SNOMEDCT:76715008",
-                "ORPHANET:101959",
-                "NCIT:C26689",
-                "MEDDRA:10085976"
-              ],
-              "id": "MONDO:0015129",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hypoadrenocorticism, Familial",
-                "Primary adrenal insufficiency",
-                "Addisons Disease",
-                "Chronic primary adrenal insufficiency",
-                "Addison's disease due to autoimmunity",
-                "Addison Disease",
-                "Addison's disease",
-                "chronic primary adrenal insufficiency",
-                "Hypoadrenocorticism, familial",
-                "Hypoadrenocorticism, familial related phenotypic feature",
-                "Addison's Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/addison%27s_disease",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21219099,
-            "start": 568,
-            "end": 312684,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31994621': {'publication date': '2019 Dec', 'sentence': 'The patient started insulin therapy and treatment for AD with prednisolone and fludrocortisone with good clinical response.', 'subject score': 1000, 'object score': 1000}, 'PMID:32264857': {'publication date': '2020 Apr 07', 'sentence': \"CASE PRESENTATION: A 52-year-old woman with autoimmune hepatitis (AIH) and bronchial asthma was diagnosed with APS-2; autoimmune Addison's disease (AD), and Hashimoto's thyroiditis (HT), and she underwent prednisolone (PSL) treatment.\", 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0001403---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0271737---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "21634207",
-              "object": "MONDO:0015129",
-              "publications": [
-                "PMID:31994621",
-                "PMID:32264857"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 324980,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0017853",
-          "name": "hypersensitivity pneumonitis",
-          "description": "Hypersensitivity pneumonitis involves inhalation of an antigen. This leads to an exaggerated immune response and a following inflammation of the alveoli within the lungs. The main feature of chronic hypersensitivity pneumonitis on lung biopsies is expansion of the interstitium by lymphocytes accompanied by an occasional multinucleated giant cell or loose granuloma. After exposure to the provoking antigen, following symptoms can be seen: fever, chills, malaise, cough, hemoptysis, chest tightness, dyspnea, rash, swelling and headache and can be completely reversible, based on the duration of the illness, categorized as acute (HP:0011009), subacute (HP:0011011), and chronic (HP:0011010). [LMU:mgriese, PMID:15316440, PMID:16635083, PMID:18051218]; Hypersensitivity pneumonitis involves inhalation of an antigen. This leads to an exaggerated immune response and a following inflammation of the alveoli within the lungs. The main feature of chronic hypersensitivity pneumonitis on lung biopsies is expansion of the interstitium by lymphocytes accompanied by an occasional multinucleated giant cell or loose granuloma. After exposure to the provoking antigen, following symptoms can be seen: fever, chills, malaise, cough, hemoptysis, chest tightness, dyspnea, rash, swelling and headache and can be completely reversible, based on the duration of the illness, categorized as acute (HP:0011009), subacute (HP:0011011), and chronic (HP:0011010). // COMMENTS: Hypersensitivity pneumonitis may also be called many different names, based on the provoking antigen.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0002390",
-            "MONDO:0017853",
-            "MEDDRA:10035743",
-            "EFO:1001321",
-            "MESH:D000542",
-            "HP:0006516",
-            "SNOMEDCT:37471005",
-            "NCIT:C34369",
-            "ICD10:J67.9",
-            "MEDDRA:10001890",
-            "DOID:841",
-            "MEDDRA:10035754",
-            "ICD9:495",
-            "MEDDRA:10001891",
-            "ORPHANET:31740",
-            "MEDDRA:10015887",
-            "MEDDRA:10081988"
-          ],
-          "id": "MONDO:0017853",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hypersensitivity pneumonitis",
-            "Extrinsic allergic alveolitis",
-            "Alveolitis, Extrinsic Allergic",
-            "Hypersensitivity pneumonitis",
-            "Extrinsic Allergic Alveolitis",
-            "extrinsic allergic alveolitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:15316440",
-            "https://orcid.org/0000-0003-0113-912x",
-            "PMID:16635083",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000109.htm",
-            "http://www.merck.com/mmhe/sec04/ch051/ch051b.htm",
-            "https://orcid.org/0000-0003-0113-912xf",
-            "PMID:18051218"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 324980,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0017853",
-              "name": "hypersensitivity pneumonitis",
-              "description": "Hypersensitivity pneumonitis involves inhalation of an antigen. This leads to an exaggerated immune response and a following inflammation of the alveoli within the lungs. The main feature of chronic hypersensitivity pneumonitis on lung biopsies is expansion of the interstitium by lymphocytes accompanied by an occasional multinucleated giant cell or loose granuloma. After exposure to the provoking antigen, following symptoms can be seen: fever, chills, malaise, cough, hemoptysis, chest tightness, dyspnea, rash, swelling and headache and can be completely reversible, based on the duration of the illness, categorized as acute (HP:0011009), subacute (HP:0011011), and chronic (HP:0011010). [LMU:mgriese, PMID:15316440, PMID:16635083, PMID:18051218]; Hypersensitivity pneumonitis involves inhalation of an antigen. This leads to an exaggerated immune response and a following inflammation of the alveoli within the lungs. The main feature of chronic hypersensitivity pneumonitis on lung biopsies is expansion of the interstitium by lymphocytes accompanied by an occasional multinucleated giant cell or loose granuloma. After exposure to the provoking antigen, following symptoms can be seen: fever, chills, malaise, cough, hemoptysis, chest tightness, dyspnea, rash, swelling and headache and can be completely reversible, based on the duration of the illness, categorized as acute (HP:0011009), subacute (HP:0011011), and chronic (HP:0011010). // COMMENTS: Hypersensitivity pneumonitis may also be called many different names, based on the provoking antigen.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0002390",
-                "MONDO:0017853",
-                "MEDDRA:10035743",
-                "EFO:1001321",
-                "MESH:D000542",
-                "HP:0006516",
-                "SNOMEDCT:37471005",
-                "NCIT:C34369",
-                "ICD10:J67.9",
-                "MEDDRA:10001890",
-                "DOID:841",
-                "MEDDRA:10035754",
-                "ICD9:495",
-                "MEDDRA:10001891",
-                "ORPHANET:31740",
-                "MEDDRA:10015887",
-                "MEDDRA:10081988"
-              ],
-              "id": "MONDO:0017853",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hypersensitivity pneumonitis",
-                "Extrinsic allergic alveolitis",
-                "Alveolitis, Extrinsic Allergic",
-                "Hypersensitivity pneumonitis",
-                "Extrinsic Allergic Alveolitis",
-                "extrinsic allergic alveolitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:15316440",
-                "https://orcid.org/0000-0003-0113-912x",
-                "PMID:16635083",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000109.htm",
-                "http://www.merck.com/mmhe/sec04/ch051/ch051b.htm",
-                "https://orcid.org/0000-0003-0113-912xf",
-                "PMID:18051218"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20844818,
-            "start": 568,
-            "end": 324980,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31464073': {'publication date': '2019 Dec', 'sentence': 'We aimed to determine the effect of mycophenolate mofetil (MMF) and azathioprine (AZA) on lung function and prednisolone dose in cHP patients.', 'subject score': 888, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0002390---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "21254689",
-              "object": "MONDO:0017853",
-              "publications": [
-                "PMID:31464073"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 300724,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011429",
-          "name": "juvenile idiopathic arthritis",
-          "description": "A group of chronic, inflammatory childhood disorders of unknown etiology that primarily involve joints.; Arthritis in children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:410502007",
-            "MEDDRA:10034164",
-            "ICD9:714.33",
-            "UMLS:C0157916",
-            "ICD9:714.32",
-            "UMLS:C3714757",
-            "DOID:676",
-            "HP:0005681",
-            "EFO:0002609",
-            "ICD9:714.31",
-            "MEDDRA:10036038",
-            "MESH:D001171",
-            "MEDDRA:10027842",
-            "MEDDRA:10034165",
-            "MEDDRA:10034166",
-            "OMIM:604302",
-            "MEDDRA:10023266",
-            "MEDDRA:10023267",
-            "NCIT:C61279",
-            "ICD9:714.3",
-            "UMLS:C0157918",
-            "NCIT:C114357",
-            "SNOMEDCT:410795001",
-            "UMLS:C0157917",
-            "MONDO:0011429",
-            "MEDDRA:10059177",
-            "ORPHANET:92",
-            "MEDDRA:10059176",
-            "UMLS:C3495559",
-            "SNOMEDCT:16024431000119108",
-            "ICD10:M08.4"
-          ],
-          "id": "MONDO:0011429",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Arthritis, Juvenile",
-            "Oligoarticular Still Disease",
-            "Polyarticular juvenile rheumatoid arthritis, acute",
-            "juvenile idiopathic arthritis",
-            "Monoarticular juvenile rheumatoid arthritis",
-            "Juvenile Idiopathic Arthritis",
-            "Pauciarticular juvenile rheumatoid arthritis",
-            "juvenile rheumatoid arthritis",
-            "Acute polyarticular juvenile rheumatoid arthritis",
-            "Rheumatoid arthritis, systemic juvenile related phenotypic feature",
-            "Juvenile arthritis",
-            "Juvenile chronic polyarthritis",
-            "Juvenile idiopathic arthritis",
-            "Juvenile rheumatoid arthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000451.htm",
-            "http://www.umm.edu/ency/article/000451.htm",
-            "https://en.wikipedia.org/wiki/subtalar_joint",
-            "http://www.mayoclinic.com/health/juvenile-rheumatoid-arthritis/ds00018"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 300724,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011429",
-              "name": "juvenile idiopathic arthritis",
-              "description": "A group of chronic, inflammatory childhood disorders of unknown etiology that primarily involve joints.; Arthritis in children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:410502007",
-                "MEDDRA:10034164",
-                "ICD9:714.33",
-                "UMLS:C0157916",
-                "ICD9:714.32",
-                "UMLS:C3714757",
-                "DOID:676",
-                "HP:0005681",
-                "EFO:0002609",
-                "ICD9:714.31",
-                "MEDDRA:10036038",
-                "MESH:D001171",
-                "MEDDRA:10027842",
-                "MEDDRA:10034165",
-                "MEDDRA:10034166",
-                "OMIM:604302",
-                "MEDDRA:10023266",
-                "MEDDRA:10023267",
-                "NCIT:C61279",
-                "ICD9:714.3",
-                "UMLS:C0157918",
-                "NCIT:C114357",
-                "SNOMEDCT:410795001",
-                "UMLS:C0157917",
-                "MONDO:0011429",
-                "MEDDRA:10059177",
-                "ORPHANET:92",
-                "MEDDRA:10059176",
-                "UMLS:C3495559",
-                "SNOMEDCT:16024431000119108",
-                "ICD10:M08.4"
-              ],
-              "id": "MONDO:0011429",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Arthritis, Juvenile",
-                "Oligoarticular Still Disease",
-                "Polyarticular juvenile rheumatoid arthritis, acute",
-                "juvenile idiopathic arthritis",
-                "Monoarticular juvenile rheumatoid arthritis",
-                "Juvenile Idiopathic Arthritis",
-                "Pauciarticular juvenile rheumatoid arthritis",
-                "juvenile rheumatoid arthritis",
-                "Acute polyarticular juvenile rheumatoid arthritis",
-                "Rheumatoid arthritis, systemic juvenile related phenotypic feature",
-                "Juvenile arthritis",
-                "Juvenile chronic polyarthritis",
-                "Juvenile idiopathic arthritis",
-                "Juvenile rheumatoid arthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000451.htm",
-                "http://www.umm.edu/ency/article/000451.htm",
-                "https://en.wikipedia.org/wiki/subtalar_joint",
-                "http://www.mayoclinic.com/health/juvenile-rheumatoid-arthritis/ds00018"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20433389,
-            "start": 568,
-            "end": 300724,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30701571': {'publication date': '2019 Apr', 'sentence': 'Here, we report the case of an 8-year-old girl with a 5-year history of multiple subcutaneous nodules on her extremities and a right wrist joint contracture who had been previously diagnosed with juvenile idiopathic arthritis and treated with salazosulfapyridine, low-dose prednisolone (PSL) and methotrexate.', 'subject score': 901, 'object score': 1000}, 'PMID:7165998': {'publication date': '1982 Dec', 'sentence': \"These studies suggest that not only is a still wider range of culture conditions required to assess fully the differences in lymphocyte function related to disease activity and prednisolone treatment in JCA or Behcet's, but also that the use of a narrow set of 'optimized' conditions may be misleading.\", 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C3495559---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "20836940",
-              "object": "MONDO:0011429",
-              "publications": [
-                "PMID:30701571",
-                "PMID:7165998"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 314697,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004496",
-          "name": "myocarditis",
-          "description": "Myocarditis is a condition that is characterized by inflammation of the heart muscle (myocardium). Some affected people have no noticeable symptoms of the condition. When present, signs and symptoms may include chest pain, abnormal heartbeat, shortness of breath, fatigue, signs of infection (i.e. fever, headache, sore throat, diarrhea), and leg swelling. Myocarditis can be caused by a variety of factors including infections (viral, bacterial, parasitic, and fungal), allergic reactions to certain medications, and exposure to certain chemicals. It can also be associated with other inflammatory conditions such as lupus, Wegener's granulomatosis, giant cell arteritis and Takayasu's arteritis. Most cases occur sporadically in people with no family history of the condition. Treatment aims to address the underlying cause of the condition. Medications and rarely, a heart transplant may be needed if the heart muscle becomes weak.",
-          "equivalent_curies": [
-            "MESH:D009205",
-            "MEDDRA:10028613",
-            "HP:0012819",
-            "DOID:820",
-            "KEGG.DISEASE:05416",
-            "UMLS:C0027059",
-            "MEDDRA:10028606",
-            "ICD9:429.0",
-            "SYMP:0000095",
-            "SNOMEDCT:50920009",
-            "EFO:0009609",
-            "NCIT:C34831",
-            "MEDDRA:10028619",
-            "MONDO:0004496",
-            "ICD10:I51.4"
-          ],
-          "id": "MONDO:0004496",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myocarditis",
-            "Myocarditis, unspecified",
-            "myocarditis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/myocarditis",
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:21304213",
-            "PMID:22361396",
-            "https://rarediseases.info.nih.gov/diseases/7137/myocarditis",
-            "PMID:22185868",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314697,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004496",
-              "name": "myocarditis",
-              "description": "Myocarditis is a condition that is characterized by inflammation of the heart muscle (myocardium). Some affected people have no noticeable symptoms of the condition. When present, signs and symptoms may include chest pain, abnormal heartbeat, shortness of breath, fatigue, signs of infection (i.e. fever, headache, sore throat, diarrhea), and leg swelling. Myocarditis can be caused by a variety of factors including infections (viral, bacterial, parasitic, and fungal), allergic reactions to certain medications, and exposure to certain chemicals. It can also be associated with other inflammatory conditions such as lupus, Wegener's granulomatosis, giant cell arteritis and Takayasu's arteritis. Most cases occur sporadically in people with no family history of the condition. Treatment aims to address the underlying cause of the condition. Medications and rarely, a heart transplant may be needed if the heart muscle becomes weak.",
-              "equivalent_curies": [
-                "MESH:D009205",
-                "MEDDRA:10028613",
-                "HP:0012819",
-                "DOID:820",
-                "KEGG.DISEASE:05416",
-                "UMLS:C0027059",
-                "MEDDRA:10028606",
-                "ICD9:429.0",
-                "SYMP:0000095",
-                "SNOMEDCT:50920009",
-                "EFO:0009609",
-                "NCIT:C34831",
-                "MEDDRA:10028619",
-                "MONDO:0004496",
-                "ICD10:I51.4"
-              ],
-              "id": "MONDO:0004496",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myocarditis",
-                "Myocarditis, unspecified",
-                "myocarditis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/myocarditis",
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:21304213",
-                "PMID:22361396",
-                "https://rarediseases.info.nih.gov/diseases/7137/myocarditis",
-                "PMID:22185868",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20212884,
-            "start": 568,
-            "end": 314697,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30279934': {'publication date': '2018 Oct', 'sentence': 'This is a case of EGPA relapse presenting as myocarditis despite treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:31462594': {'publication date': '2019 Aug 28', 'sentence': 'She was diagnosed with myocarditis and successfully treated using prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:9436137': {'publication date': '1997 Dec', 'sentence': 'Children with \"definite\" myocarditis comprised group I (n = 9) and were treated with cyclosporine and prednisolone.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0027059---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "20612701",
-              "object": "MONDO:0004496",
-              "publications": [
-                "PMID:30279934",
-                "PMID:31462594",
-                "PMID:9436137"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316730,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005129",
-          "name": "cataract",
-          "description": "Partial or complete opacity of the crystalline lens of one or both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.); Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed); A cataract is an opacity or clouding that develops in the crystalline lens of the eye or in its capsule. [HPO:probinson]; A cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery. A cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are: Blurry vision Colors that seem faded Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights. Not being able to see well at night Double vision  Frequent prescription changes in your eye wear   Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. NIH: National Eye Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "OMIM.PS:116200",
-            "SNOMEDCT:247053007",
-            "ICD10:H26",
-            "MEDDRA:10007768",
-            "ICD9:366.8",
-            "MONDO:0005129",
-            "UMLS:C0029531",
-            "MEDDRA:10007739",
-            "MEDDRA:10045649",
-            "MEDDRA:10030347",
-            "UMLS:C0086543",
-            "SNOMEDCT:193570009",
-            "SNOMEDCT:128306009",
-            "DOID:83",
-            "OMIM:PS116200",
-            "MEDDRA:10007771",
-            "MEDDRA:10024208",
-            "UMLS:C1510497",
-            "MEDDRA:10024214",
-            "MEDDRA:10024215",
-            "ICD9:366",
-            "HP:0000518",
-            "NCIT:C26713",
-            "MESH:D002386",
-            "MEDDRA:10007757"
-          ],
-          "id": "MONDO:0005129",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Other cataract",
-            "Cataract",
-            "cataract",
-            "Lens Opacities"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:10414631",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0001-6908-9849",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://en.wikipedia.org/wiki/cataract",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316730,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005129",
-              "name": "cataract",
-              "description": "Partial or complete opacity of the crystalline lens of one or both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.); Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed); A cataract is an opacity or clouding that develops in the crystalline lens of the eye or in its capsule. [HPO:probinson]; A cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery. A cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are: Blurry vision Colors that seem faded Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights. Not being able to see well at night Double vision  Frequent prescription changes in your eye wear   Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. NIH: National Eye Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "OMIM.PS:116200",
-                "SNOMEDCT:247053007",
-                "ICD10:H26",
-                "MEDDRA:10007768",
-                "ICD9:366.8",
-                "MONDO:0005129",
-                "UMLS:C0029531",
-                "MEDDRA:10007739",
-                "MEDDRA:10045649",
-                "MEDDRA:10030347",
-                "UMLS:C0086543",
-                "SNOMEDCT:193570009",
-                "SNOMEDCT:128306009",
-                "DOID:83",
-                "OMIM:PS116200",
-                "MEDDRA:10007771",
-                "MEDDRA:10024208",
-                "UMLS:C1510497",
-                "MEDDRA:10024214",
-                "MEDDRA:10024215",
-                "ICD9:366",
-                "HP:0000518",
-                "NCIT:C26713",
-                "MESH:D002386",
-                "MEDDRA:10007757"
-              ],
-              "id": "MONDO:0005129",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Other cataract",
-                "Cataract",
-                "cataract",
-                "Lens Opacities"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:10414631",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0001-6908-9849",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://en.wikipedia.org/wiki/cataract",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17242689,
-            "start": 568,
-            "end": 316730,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24765453': {'publication date': '2012 Mar 30', 'sentence': 'Her visual acuity remained stable, despite development of a cataract from prednisolone therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:30592714': {'publication date': '2018 12', 'sentence': 'However, it has been reported that prolonged treatment with prednisolone increases the risk for prednisolone-induced complications such as osteoporosis, diabetes, cataract and arteriosclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7730124': {'publication date': '1994 Dec 01', 'sentence': 'In 3 dogs scheduled for surgical removal of cataracts, systemic and topical treatment with antibiotics and topical ocular treatment with prednisolone, atropine, flurbiprofen, and phenylephrine were used to achieve maximal mydriasis, with minimal risk of pupillary constriction in response to surgery.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0086543---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "17604301",
-              "object": "MONDO:0005129",
-              "publications": [
-                "PMID:24765453",
-                "PMID:30592714",
-                "PMID:7730124"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321236,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005148",
-          "name": "type 2 diabetes mellitus",
-          "description": "A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity.; A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.; A type of diabetes mellitus initially characterized by insulin resistance and hyperinsulinemia and subsequently by glucose interolerance and hyperglycemia. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C2674662",
-            "DOID:9352",
-            "UMLS:C0011860",
-            "NCIT:C26747",
-            "MEDDRA:10012611",
-            "ICD10:E11",
-            "MEDDRA:10026947",
-            "UMLS:C3149706",
-            "UMLS:C1840169",
-            "HP:0005978",
-            "OMIM:125853",
-            "UMLS:CN244395",
-            "MEDDRA:10029505",
-            "UMLS:C1852091",
-            "SNOMEDCT:44054006",
-            "KEGG.DISEASE:04930",
-            "MEDDRA:10012613",
-            "MONDO:0005148",
-            "MESH:D003924",
-            "UMLS:C2674665",
-            "MEDDRA:10045242",
-            "EFO:0001360",
-            "MEDDRA:10029402",
-            "MEDDRA:10067585",
-            "UMLS:C2674663",
-            "UMLS:C4017238"
-          ],
-          "id": "MONDO:0005148",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pon1 enzyme activity, variation in",
-            "Diabetes Mellitus, Non-Insulin-Dependent",
-            "Coronary artery disease, susceptibility to",
-            "Diabetes Mellitus, Type 2",
-            "Type 2 Diabetes Mellitus",
-            "MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 5 (finding)",
-            "obsolete_type II diabetes mellitus",
-            "Type 2 diabetes mellitus related phenotypic feature",
-            "Coronary artery spasm 2, susceptibility to",
-            "Type II diabetes mellitus",
-            "Type 2 diabetes mellitus, protection against",
-            "Organophosphate poisoning, susceptibility to",
-            "type 2 diabetes mellitus",
-            "Insulin resistance, susceptibility to"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/diabetes_mellitus_type_2",
-            "http://en.wikipedia.org/wiki/diabetes",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-5316-1399"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321236,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005148",
-              "name": "type 2 diabetes mellitus",
-              "description": "A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity.; A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.; A type of diabetes mellitus initially characterized by insulin resistance and hyperinsulinemia and subsequently by glucose interolerance and hyperglycemia. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C2674662",
-                "DOID:9352",
-                "UMLS:C0011860",
-                "NCIT:C26747",
-                "MEDDRA:10012611",
-                "ICD10:E11",
-                "MEDDRA:10026947",
-                "UMLS:C3149706",
-                "UMLS:C1840169",
-                "HP:0005978",
-                "OMIM:125853",
-                "UMLS:CN244395",
-                "MEDDRA:10029505",
-                "UMLS:C1852091",
-                "SNOMEDCT:44054006",
-                "KEGG.DISEASE:04930",
-                "MEDDRA:10012613",
-                "MONDO:0005148",
-                "MESH:D003924",
-                "UMLS:C2674665",
-                "MEDDRA:10045242",
-                "EFO:0001360",
-                "MEDDRA:10029402",
-                "MEDDRA:10067585",
-                "UMLS:C2674663",
-                "UMLS:C4017238"
-              ],
-              "id": "MONDO:0005148",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pon1 enzyme activity, variation in",
-                "Diabetes Mellitus, Non-Insulin-Dependent",
-                "Coronary artery disease, susceptibility to",
-                "Diabetes Mellitus, Type 2",
-                "Type 2 Diabetes Mellitus",
-                "MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 5 (finding)",
-                "obsolete_type II diabetes mellitus",
-                "Type 2 diabetes mellitus related phenotypic feature",
-                "Coronary artery spasm 2, susceptibility to",
-                "Type II diabetes mellitus",
-                "Type 2 diabetes mellitus, protection against",
-                "Organophosphate poisoning, susceptibility to",
-                "type 2 diabetes mellitus",
-                "Insulin resistance, susceptibility to"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/diabetes_mellitus_type_2",
-                "http://en.wikipedia.org/wiki/diabetes",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-5316-1399"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16963152,
-            "start": 568,
-            "end": 321236,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24297090': {'publication date': '2014 Mar', 'sentence': 'In this study, we hypothesized that concomitant administration of the dipeptidyl peptidase-4 inhibitor sitagliptin and prednisolone in men at high risk to develop type 2 diabetes could protect against the GC-induced diabetogenic effects.', 'subject score': 1000, 'object score': 1000}, 'PMID:28348775': {'publication date': '2016 Aug', 'sentence': 'CASE PRESENTATION: A 75-year-old Chinese woman with type 2 diabetes mellitus, chronic kidney disease and rheumatoid arthritis, treated with low-dose methotrexate and prednisolone for 2.5 years, developed a Pleurostomophora richardsiae infection of her left arm.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0011860---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "17312178",
-              "object": "MONDO:0005148",
-              "publications": [
-                "PMID:24297090",
-                "PMID:28348775"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 526315,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005722",
-          "name": "croup",
-          "description": "Acute upper respiratory airways infection that results in the swelling of the larynx. It is usually caused by parainfluenza viruses. Signs include a characteristic barking cough and stridor.; Inflammation involving the GLOTTIS or VOCAL CORDS and the subglottic larynx. Croup is characterized by a barking cough, HOARSENESS, and persistent inspiratory STRIDOR (a high-pitched breathing sound). It occurs chiefly in infants and children.; Croup is an inflammation of the vocal cords (larynx) and windpipe (trachea). It causes difficulty breathing, a barking cough, and a hoarse voice. The cause is usually a virus, often parainfluenza virus. Other causes include allergies and reflux. Croup often starts out like a cold. But then the vocal cords and windpipe become swollen, causing the hoarseness and the cough. There may also be a fever and high-pitched noisy sounds when breathing. The symptoms are usually worse at night, and last for about three to five days. Children between the ages of 6 months and 3 years have the highest risk of getting croup. They may also have more severe symptoms. Croup is more common in the fall and winter. Most cases of viral croup are mild and can be treated at home. Rarely, croup can become serious and interfere with your child's breathing. If you are worried about your child's breathing, call your health care provider right away.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005722",
-            "NCIT:C26735",
-            "DOID:9395",
-            "MEDDRA:10011415",
-            "MESH:D003440",
-            "SNOMEDCT:71186008",
-            "EFO:0007227",
-            "ICD10:J05.0",
-            "UMLS:C0010380",
-            "ICD9:464.4"
-          ],
-          "id": "MONDO:0005722",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Croup",
-            "croup"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://books.google.com/books?id=g6k0tppmrsic&pg=pa254&lpg=pa254&dq#v=onepage&q=&f=false",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=croup",
-            "http://cmr.asm.org/content/16/2/242.f",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000959.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526315,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005722",
-              "name": "croup",
-              "description": "Acute upper respiratory airways infection that results in the swelling of the larynx. It is usually caused by parainfluenza viruses. Signs include a characteristic barking cough and stridor.; Inflammation involving the GLOTTIS or VOCAL CORDS and the subglottic larynx. Croup is characterized by a barking cough, HOARSENESS, and persistent inspiratory STRIDOR (a high-pitched breathing sound). It occurs chiefly in infants and children.; Croup is an inflammation of the vocal cords (larynx) and windpipe (trachea). It causes difficulty breathing, a barking cough, and a hoarse voice. The cause is usually a virus, often parainfluenza virus. Other causes include allergies and reflux. Croup often starts out like a cold. But then the vocal cords and windpipe become swollen, causing the hoarseness and the cough. There may also be a fever and high-pitched noisy sounds when breathing. The symptoms are usually worse at night, and last for about three to five days. Children between the ages of 6 months and 3 years have the highest risk of getting croup. They may also have more severe symptoms. Croup is more common in the fall and winter. Most cases of viral croup are mild and can be treated at home. Rarely, croup can become serious and interfere with your child's breathing. If you are worried about your child's breathing, call your health care provider right away.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005722",
-                "NCIT:C26735",
-                "DOID:9395",
-                "MEDDRA:10011415",
-                "MESH:D003440",
-                "SNOMEDCT:71186008",
-                "EFO:0007227",
-                "ICD10:J05.0",
-                "UMLS:C0010380",
-                "ICD9:464.4"
-              ],
-              "id": "MONDO:0005722",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Croup",
-                "croup"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://books.google.com/books?id=g6k0tppmrsic&pg=pa254&lpg=pa254&dq#v=onepage&q=&f=false",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=croup",
-                "http://cmr.asm.org/content/16/2/242.f",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000959.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16837604,
-            "start": 568,
-            "end": 526315,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24092872': {'publication date': '2013 Nov', 'sentence': 'Although common practice, evidence to support treatment of croup with prednisolone is scant.', 'subject score': 1000, 'object score': 1000}, 'PMID:29290883': {'publication date': '2017', 'sentence': 'Selection Criteria: Randomised Controlled Trials, clinical trials or chart reviews which examined children with croup who were treated with prednisolone alone, or when prednisolone was compared to a dexamethasone treatment and the effectiveness of the intervention was objectively measured using croup scores and re-attendance as primary outcomes.', 'subject score': 1000, 'object score': 1000}, 'PMID:31416827': {'publication date': '2019 Sep', 'sentence': 'OBJECTIVES: The use of either prednisolone or low-dose dexamethasone in the treatment of childhood croup lacks a rigorous evidence base despite widespread use.', 'subject score': 861, 'object score': 888}, 'PMID:31843117': {'publication date': '2020 Jan', 'sentence': 'Prednisolone vs dexamethsone in croup.', 'subject score': 1000, 'object score': 1000}, 'PMID:31846157': {'publication date': '2019 Dec', 'sentence': 'Prednisolone versus dexamethasone for croup.', 'subject score': 1000, 'object score': 1000}, 'PMID:32354725': {'publication date': '2020 Apr 30', 'sentence': 'Dexamethasone or prednisolone for croup.', 'subject score': 1000, 'object score': 1000}, 'PMID:36106471': {'publication date': '2022 Sep 15', 'sentence': 'CONCLUSIONS: Hospital resource utilization did not differ significantly for children receiving dexamethasone or prednisone or prednisolone for acute croup.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0010380---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "17184322",
-              "object": "MONDO:0005722",
-              "publications": [
-                "PMID:24092872",
-                "PMID:29290883",
-                "PMID:31416827",
-                "PMID:31843117",
-                "PMID:31846157",
-                "PMID:32354725",
-                "PMID:36106471"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 535028,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000430",
-          "name": "mature T-cell and NK-cell non-Hodgkin lymphoma",
-          "description": "A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10034624",
-            "MONDO:0000430",
-            "MEDDRA:10034623",
-            "UMLS:C1337073",
-            "MESH:D016411",
-            "UMLS:C1337074",
-            "NCIT:C27352",
-            "UMLS:C0079774",
-            "UMLS:C5551485",
-            "UMLS:C1337079",
-            "DOID:0050743",
-            "NCIT:C7204",
-            "UMLS:C0334655",
-            "NCIT:C3468",
-            "DOID:0050749",
-            "SNOMEDCT:109977009",
-            "ICD9:202.7",
-            "SNOMEDCT:1163404000",
-            "SNOMEDCT:109975001"
-          ],
-          "id": "MONDO:0000430",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peripheral T-Cell Lymphoma, Large Cell",
-            "T-Zone Variant Peripheral T-Cell Lymphoma",
-            "mature T-cell and NK-cell non-Hodgkin lymphoma",
-            "peripheral T-cell lymphoma",
-            "T-zone lymphoma (clinical)",
-            "Lymphoma, T-Cell, Peripheral",
-            "mature T-cell and NK-cell lymphoma",
-            "Peripheral T-Cell Lymphoma",
-            "Peripheral T-cell lymphoma",
-            "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:21919697",
-            "http://www.cancer.gov/dictionary?cdrid=393800",
-            "http://www.cancer.gov/dictionary?cdrid=44062",
-            "http://en.wikipedia.org/wiki/peripheral_t-cell_lymphoma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 535028,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000430",
-              "name": "mature T-cell and NK-cell non-Hodgkin lymphoma",
-              "description": "A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10034624",
-                "MONDO:0000430",
-                "MEDDRA:10034623",
-                "UMLS:C1337073",
-                "MESH:D016411",
-                "UMLS:C1337074",
-                "NCIT:C27352",
-                "UMLS:C0079774",
-                "UMLS:C5551485",
-                "UMLS:C1337079",
-                "DOID:0050743",
-                "NCIT:C7204",
-                "UMLS:C0334655",
-                "NCIT:C3468",
-                "DOID:0050749",
-                "SNOMEDCT:109977009",
-                "ICD9:202.7",
-                "SNOMEDCT:1163404000",
-                "SNOMEDCT:109975001"
-              ],
-              "id": "MONDO:0000430",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peripheral T-Cell Lymphoma, Large Cell",
-                "T-Zone Variant Peripheral T-Cell Lymphoma",
-                "mature T-cell and NK-cell non-Hodgkin lymphoma",
-                "peripheral T-cell lymphoma",
-                "T-zone lymphoma (clinical)",
-                "Lymphoma, T-Cell, Peripheral",
-                "mature T-cell and NK-cell lymphoma",
-                "Peripheral T-Cell Lymphoma",
-                "Peripheral T-cell lymphoma",
-                "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:21919697",
-                "http://www.cancer.gov/dictionary?cdrid=393800",
-                "http://www.cancer.gov/dictionary?cdrid=44062",
-                "http://en.wikipedia.org/wiki/peripheral_t-cell_lymphoma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16510643,
-            "start": 568,
-            "end": 535028,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23550277': {'publication date': '2013 Jun', 'sentence': 'Treatment of peripheral T cell lymphoma with an intensive protocol ACEP (adriamycin, cyclophosphamide, etoposide and prednisolone) and ifosfamide showing an important response and overall survival rates.', 'subject score': 1000, 'object score': 1000}, 'PMID:30511217': {'publication date': '2018 Dec 03', 'sentence': 'We designed a CHOPE/G regimen (cyclophosphamide, pirarubicin, vincristine, prednisolone, and etoposide alternating with a gemcitabine-based regimen) as the first-line treatment of PTCLs and compared with CHOP (cyclophosphamide, pirarubicin, vincristine, and prednisolone) and CHOPE (CHOP plus etoposide) regimen to evaluate the optimal chemotherapy regimen.', 'subject score': 1000, 'object score': 1000}, 'PMID:36990775': {'publication date': '2023', 'sentence': 'Benefit of prednisolone alone in nodal peripheral T-cell lymphoma with T follicular helper phenotype.', 'subject score': 1000, 'object score': 928}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0079774---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16852549",
-              "object": "MONDO:0000430",
-              "publications": [
-                "PMID:23550277",
-                "PMID:30511217",
-                "PMID:36990775"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 533929,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005883",
-          "name": "ophthalmic herpes zoster",
-          "description": "Virus infection of the Gasserian ganglion and its nerve branches characterized by pain and vesicular eruptions with much swelling. Ocular involvement is usually heralded by a vesicle on the tip of the nose. This area is innervated by the nasociliary nerve.",
-          "equivalent_curies": [
-            "MESH:D006563",
-            "SNOMEDCT:186524006",
-            "MEDDRA:10019983",
-            "UMLS:C0019364",
-            "MEDDRA:10019984",
-            "MEDDRA:10030865",
-            "SNOMEDCT:87513003",
-            "MEDDRA:10030868",
-            "MONDO:0005883",
-            "EFO:0007403"
-          ],
-          "id": "MONDO:0005883",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Herpes Zoster Ophthalmicus",
-            "ophthalmic herpes zoster"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 533929,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005883",
-              "name": "ophthalmic herpes zoster",
-              "description": "Virus infection of the Gasserian ganglion and its nerve branches characterized by pain and vesicular eruptions with much swelling. Ocular involvement is usually heralded by a vesicle on the tip of the nose. This area is innervated by the nasociliary nerve.",
-              "equivalent_curies": [
-                "MESH:D006563",
-                "SNOMEDCT:186524006",
-                "MEDDRA:10019983",
-                "UMLS:C0019364",
-                "MEDDRA:10019984",
-                "MEDDRA:10030865",
-                "SNOMEDCT:87513003",
-                "MEDDRA:10030868",
-                "MONDO:0005883",
-                "EFO:0007403"
-              ],
-              "id": "MONDO:0005883",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Herpes Zoster Ophthalmicus",
-                "ophthalmic herpes zoster"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16027396,
-            "start": 568,
-            "end": 533929,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22735124': {'publication date': '2012 Jun 25', 'sentence': 'Herpes zoster ophthalmicus was suspected and treatment with i.v. acyclovir and prednisolone was commenced, which led to a gradual improvement of the clinical condition.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0019364---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16360878",
-              "object": "MONDO:0005883",
-              "publications": [
-                "PMID:22735124"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 307870,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005106",
-          "name": "lipoma",
-          "description": "A benign, usually painless, well-circumscribed lipomatous tumor composed of adipose tissue.; A rare benign human tumor consisting of BROWN ADIPOCYTES resembling those found in some hibernating animals.; The presence of multiple lipomas (a type of benign tissue made of fatty tissue). [HPO:sdoelken]; Benign neoplasia derived from lipoblasts or lipocytes of white or brown fat. May be angiomatous or hibernomatous. [MPATH:417]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10024615",
-            "NCIT:C3192",
-            "MESH:D008067",
-            "MEDDRA:10024623",
-            "ICD10:D17",
-            "EFO:0000759",
-            "MONDO:0005106",
-            "SNOMEDCT:134328007",
-            "ICD10:D17.9",
-            "UMLS:C0023798",
-            "DOID:3315",
-            "MEDDRA:10024612",
-            "ICD9:214",
-            "HP:0012032",
-            "SNOMEDCT:93163002"
-          ],
-          "id": "MONDO:0005106",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lipoma",
-            "lipoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/benign_tumo",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 307870,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005106",
-              "name": "lipoma",
-              "description": "A benign, usually painless, well-circumscribed lipomatous tumor composed of adipose tissue.; A rare benign human tumor consisting of BROWN ADIPOCYTES resembling those found in some hibernating animals.; The presence of multiple lipomas (a type of benign tissue made of fatty tissue). [HPO:sdoelken]; Benign neoplasia derived from lipoblasts or lipocytes of white or brown fat. May be angiomatous or hibernomatous. [MPATH:417]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10024615",
-                "NCIT:C3192",
-                "MESH:D008067",
-                "MEDDRA:10024623",
-                "ICD10:D17",
-                "EFO:0000759",
-                "MONDO:0005106",
-                "SNOMEDCT:134328007",
-                "ICD10:D17.9",
-                "UMLS:C0023798",
-                "DOID:3315",
-                "MEDDRA:10024612",
-                "ICD9:214",
-                "HP:0012032",
-                "SNOMEDCT:93163002"
-              ],
-              "id": "MONDO:0005106",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lipoma",
-                "lipoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/benign_tumo",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15123227,
-            "start": 568,
-            "end": 307870,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21272189': {'publication date': '2011 Jun', 'sentence': 'Lipomas responded with less lipolysis to isoproterenol than subcutaneous fat during microdialysis, and prednisolone treatment increased lipolysis in both lipomas and subcutaneous fat.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0023798---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "15441636",
-              "object": "MONDO:0005106",
-              "publications": [
-                "PMID:21272189"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317106,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005904",
-          "name": "pericarditis",
-          "description": "An inflammatory process affecting the pericardium.; Inflammation of both the PERICARDIUM and the PLEURA.; Inflammation of the sac-like covering around the heart (pericardium). [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:1787",
-            "MEDDRA:10034484",
-            "ORPHANET:58208",
-            "HP:0001701",
-            "MESH:D010493",
-            "UMLS:C0031046",
-            "MEDDRA:10034495",
-            "NCIT:C34915",
-            "SNOMEDCT:3238004",
-            "EFO:0007427",
-            "MONDO:0005904"
-          ],
-          "id": "MONDO:0005904",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pericarditis",
-            "pericarditis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/wiki/pericarditis",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317106,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005904",
-              "name": "pericarditis",
-              "description": "An inflammatory process affecting the pericardium.; Inflammation of both the PERICARDIUM and the PLEURA.; Inflammation of the sac-like covering around the heart (pericardium). [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:1787",
-                "MEDDRA:10034484",
-                "ORPHANET:58208",
-                "HP:0001701",
-                "MESH:D010493",
-                "UMLS:C0031046",
-                "MEDDRA:10034495",
-                "NCIT:C34915",
-                "SNOMEDCT:3238004",
-                "EFO:0007427",
-                "MONDO:0005904"
-              ],
-              "id": "MONDO:0005904",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pericarditis",
-                "pericarditis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/wiki/pericarditis",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15044546,
-            "start": 568,
-            "end": 317106,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21161021': {'publication date': '2010 Sep 27', 'sentence': 'Treatment with prednisolone improved the pericarditis and motor nerve disturbance and the treatment with intravenous immunoglobulin improved the sensory nerve disturbance.', 'subject score': 1000, 'object score': 1000}, 'PMID:35283383': {'publication date': '2022 Mar 12', 'sentence': 'We herein report a case of systemic sclerosis (SSc)-related pericarditis successfully treated with mycophenolate mofetil (MMF) and low-dose prednisolone (PSL).', 'subject score': 901, 'object score': 861}, 'PMID:35927545': {'publication date': '2022 Aug 04', 'sentence': 'Treatment with anti-inflammatory medications and prednisolone resolved the pericarditis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0031046---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "15369817",
-              "object": "MONDO:0005904",
-              "publications": [
-                "PMID:21161021",
-                "PMID:35283383",
-                "PMID:35927545"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 303010,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004802",
-          "name": "pulmonary eosinophilia",
-          "description": "The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. [PMID:19618037, PMID:21428117]; The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. // COMMENTS: Pulmonary function testing usually reveals a restrictive process with reduced diffusion capacity for carbon monoxide. Laboratory tests typical include increased levels of eosinophils in the blood, a high erythrocyte sedimentation rate, iron deficiency anemia, and increased platelets.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "UMLS:C0034068",
-            "HP:0032071",
-            "UMLS:C5552799",
-            "DOID:9498",
-            "MESH:D011657",
-            "MEDDRA:10037412",
-            "ICD9:518.3",
-            "SNOMEDCT:367542003",
-            "MONDO:0004802",
-            "MEDDRA:10037382"
-          ],
-          "id": "MONDO:0004802",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Eosinophilic pneumonia",
-            "Pulmonary eosinophilic infiltrate",
-            "Pulmonary Eosinophilia",
-            "Pulmonary eosinophilia",
-            "pulmonary eosinophilia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:19618037",
-            "https://rarediseases.org/rare-diseases/simple-pulmonary-eosinophilia/",
-            "PMID:21428117"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 303010,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004802",
-              "name": "pulmonary eosinophilia",
-              "description": "The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. [PMID:19618037, PMID:21428117]; The presence of eosinophils in lung tissue, generally as detected by tissue biopsy, with or without blood eosinophilia. // COMMENTS: Pulmonary function testing usually reveals a restrictive process with reduced diffusion capacity for carbon monoxide. Laboratory tests typical include increased levels of eosinophils in the blood, a high erythrocyte sedimentation rate, iron deficiency anemia, and increased platelets.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "UMLS:C0034068",
-                "HP:0032071",
-                "UMLS:C5552799",
-                "DOID:9498",
-                "MESH:D011657",
-                "MEDDRA:10037412",
-                "ICD9:518.3",
-                "SNOMEDCT:367542003",
-                "MONDO:0004802",
-                "MEDDRA:10037382"
-              ],
-              "id": "MONDO:0004802",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Eosinophilic pneumonia",
-                "Pulmonary eosinophilic infiltrate",
-                "Pulmonary Eosinophilia",
-                "Pulmonary eosinophilia",
-                "pulmonary eosinophilia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:19618037",
-                "https://rarediseases.org/rare-diseases/simple-pulmonary-eosinophilia/",
-                "PMID:21428117"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14791831,
-            "start": 568,
-            "end": 303010,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20639010': {'publication date': '2010 Jul', 'sentence': 'Airway macrophage median percentage of red-hued area in stained sputum cytospin preparations was assessed by means of image analysis from (1) subjects with mild-to-severe asthma, subjects with nonasthmatic eosinophilic bronchitis, and healthy control subjects; (2) subjects with eosinophilic severe asthma after treatment with prednisolone; and (3) subject with noneosinophilic asthma before corticosteroid withdrawal.', 'subject score': 1000, 'object score': 901}, 'PMID:2595633': {'publication date': '1989 Nov', 'sentence': 'Of the 247 episodes of pulmonary eosinophilia that were documented during a median follow up period of 14 years, 186 were treated with prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0034068---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "15104714",
-              "object": "MONDO:0004802",
-              "publications": [
-                "PMID:20639010",
-                "PMID:2595633"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 315782,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
-          "name": "aplastic anemia",
-          "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What causes aplastic anemia? The causes of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0015909",
-            "MEDDRA:10002037",
-            "HP:0001915",
-            "MEDDRA:10002967",
-            "MEDDRA:10002274",
-            "MEDDRA:10002969",
-            "MESH:D000741",
-            "SNOMEDCT:306058006",
-            "PDQ:CDR0000489004",
-            "NCIT:C2870",
-            "MEDDRA:10002968",
-            "DOID:12449",
-            "MEDDRA:10002970",
-            "ICD9:284.9",
-            "SNOMEDCT:304132006",
-            "UMLS:C0002874",
-            "ICD10:D61.9",
-            "ORPHANET:182040"
-          ],
-          "id": "MONDO:0015909",
-          "category": "biolink:Disease",
-          "all_names": [
-            "aplastic anemia",
-            "Aplastic Anemia",
-            "Aplastic anemia",
-            "Aplastic anemia, unspecified",
-            "obsolete_Medullar aplasia",
-            "Anemia, Aplastic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
-            "http://en.wikipedia.org/wiki/aplastic_anemia",
-            "PMID:21239768",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315782,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
-              "name": "aplastic anemia",
-              "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What causes aplastic anemia? The causes of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0015909",
-                "MEDDRA:10002037",
-                "HP:0001915",
-                "MEDDRA:10002967",
-                "MEDDRA:10002274",
-                "MEDDRA:10002969",
-                "MESH:D000741",
-                "SNOMEDCT:306058006",
-                "PDQ:CDR0000489004",
-                "NCIT:C2870",
-                "MEDDRA:10002968",
-                "DOID:12449",
-                "MEDDRA:10002970",
-                "ICD9:284.9",
-                "SNOMEDCT:304132006",
-                "UMLS:C0002874",
-                "ICD10:D61.9",
-                "ORPHANET:182040"
-              ],
-              "id": "MONDO:0015909",
-              "category": "biolink:Disease",
-              "all_names": [
-                "aplastic anemia",
-                "Aplastic Anemia",
-                "Aplastic anemia",
-                "Aplastic anemia, unspecified",
-                "obsolete_Medullar aplasia",
-                "Anemia, Aplastic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
-                "http://en.wikipedia.org/wiki/aplastic_anemia",
-                "PMID:21239768",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14682208,
-            "start": 568,
-            "end": 315782,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20467197': {'publication date': '2010', 'sentence': 'We report a case of subcutaneous abscess caused by Nocardia farcinica in a 44-year-old man, who had been treated with systemic prednisolone and cyclosporin for aplastic anemia.', 'subject score': 888, 'object score': 1000}, 'PMID:2634465': {'publication date': '1989 Oct', 'sentence': 'Here we report a 11-year-old boy who was initially diagnosed as aplastic anemia and treated with prednisolone and androgen with prompt response terminated into overt acute lymphoblastic leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:2724733': {'publication date': '1989 Jan', 'sentence': 'Aplastic anemia was effectively managed with prednisolone and mepitiostane pre-operatively.', 'subject score': 1000, 'object score': 1000}, 'PMID:4054169': {'publication date': '1985 Sep', 'sentence': 'During an episode of aplastic anaemia she was treated with prednisolone, with a subsequent dramatic fall of serum calcium despite 1 alpha D3 treatment and serum 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in the high-normal range.', 'subject score': 1000, 'object score': 1000}, 'PMID:6810992': {'publication date': '1982 Sep 18', 'sentence': 'The aplastic anaemia worsened despite treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0002874---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "14992803",
-              "object": "MONDO:0015909",
-              "publications": [
-                "PMID:20467197",
-                "PMID:2634465",
-                "PMID:2724733",
-                "PMID:4054169",
-                "PMID:6810992"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320360,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005083",
-          "name": "psoriasis",
-          "description": "An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.; A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.; A skin abnormality characterized by redness and irritation, with thick, red skin that displays flaky, silver-white patches (scales). [HPO:probinson]; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have psoriasis also get a form of arthritis called psoriatic arthritis. A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast.  Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope. Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include: Infections Stress Dry skin Certain medicines  Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases ; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D011565",
-            "SNOMEDCT:9014002",
-            "ICD10:L40",
-            "MEDDRA:10058675",
-            "MONDO:0005083",
-            "DOID:8893",
-            "UMLS:C0033860",
-            "EFO:0000676",
-            "UMLS:C0262985",
-            "NCIT:C3346",
-            "NCIT:C27724",
-            "OMIM.PS:177900",
-            "OMIM:PS177900",
-            "SNOMEDCT:52230004",
-            "HP:0003765",
-            "MEDDRA:10037153",
-            "SNOMEDCT:238564003"
-          ],
-          "id": "MONDO:0005083",
-          "category": "biolink:Disease",
-          "all_names": [
-            "psoriasis",
-            "Psoriasiform eczema",
-            "Psoriasis",
-            "Psoriasiform dermatitis",
-            "Psoriasiform Dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.cdc.gov/psoriasis/index.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320360,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005083",
-              "name": "psoriasis",
-              "description": "An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.; A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.; A skin abnormality characterized by redness and irritation, with thick, red skin that displays flaky, silver-white patches (scales). [HPO:probinson]; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have psoriasis also get a form of arthritis called psoriatic arthritis. A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast.  Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope. Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include: Infections Stress Dry skin Certain medicines  Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases ; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D011565",
-                "SNOMEDCT:9014002",
-                "ICD10:L40",
-                "MEDDRA:10058675",
-                "MONDO:0005083",
-                "DOID:8893",
-                "UMLS:C0033860",
-                "EFO:0000676",
-                "UMLS:C0262985",
-                "NCIT:C3346",
-                "NCIT:C27724",
-                "OMIM.PS:177900",
-                "OMIM:PS177900",
-                "SNOMEDCT:52230004",
-                "HP:0003765",
-                "MEDDRA:10037153",
-                "SNOMEDCT:238564003"
-              ],
-              "id": "MONDO:0005083",
-              "category": "biolink:Disease",
-              "all_names": [
-                "psoriasis",
-                "Psoriasiform eczema",
-                "Psoriasis",
-                "Psoriasiform dermatitis",
-                "Psoriasiform Dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.cdc.gov/psoriasis/index.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14436218,
-            "start": 568,
-            "end": 320360,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2001900': {'publication date': '1991 Feb', 'sentence': 'Genetically determined coincidence of Kaposi sarcoma and psoriasis in an HIV-negative patient after prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:23064668': {'publication date': '2012 Dec', 'sentence': \"The patient's past history revealed a 10-year history of psoriasis and chronic obstructive pulmonary disease treated with methotrexate and prednisolone.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0033860---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "14742554",
-              "object": "MONDO:0005083",
-              "publications": [
-                "PMID:2001900",
-                "PMID:23064668"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 634814,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006774",
-          "name": "habitual spontaneous abortion",
-          "description": "Three or more consecutive spontaneous abortions.",
-          "equivalent_curies": [
-            "UMLS:C0000809",
-            "MEDDRA:10038104",
-            "MEDDRA:10062935",
-            "MONDO:0006774",
-            "MESH:D000026",
-            "SNOMEDCT:102878001"
-          ],
-          "id": "MONDO:0006774",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Abortion, Habitual",
-            "habitual spontaneous abortion"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 634814,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006774",
-              "name": "habitual spontaneous abortion",
-              "description": "Three or more consecutive spontaneous abortions.",
-              "equivalent_curies": [
-                "UMLS:C0000809",
-                "MEDDRA:10038104",
-                "MEDDRA:10062935",
-                "MONDO:0006774",
-                "MESH:D000026",
-                "SNOMEDCT:102878001"
-              ],
-              "id": "MONDO:0006774",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Abortion, Habitual",
-                "habitual spontaneous abortion"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14370679,
-            "start": 568,
-            "end": 634814,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19903335': {'publication date': '2009 Nov 10', 'sentence': 'Prednisolone Trial: Study protocol for a randomised controlled trial of prednisolone for women with idiopathic recurrent miscarriage and raised levels of uterine natural killer (uNK) cells in the endometrium.', 'subject score': 1000, 'object score': 901}, 'PMID:21984529': {'publication date': '2011 Dec', 'sentence': 'CONCLUSIONS: The effect of prednisolone therapy for some women with RM may be due to altered endometrial angiogenic growth factor expression and reduced blood vessel maturation.', 'subject score': 888, 'object score': 1000}, 'PMID:24818590': {'publication date': '2014 Oct', 'sentence': 'CONCLUSION: The addition of prednisolone to heparin and low dose aspirin might be beneficial in patients with unexplained recurrent miscarriage, and this effect might be due to a suppressive effect of steroids on the peripheral CD16 NK cells concentration.', 'subject score': 1000, 'object score': 901}, 'PMID:35249235': {'publication date': '2022 Mar 06', 'sentence': 'Oral administration of cyclosporine A or prednisolone increases live birth rate (OR = 3.6, 95% CI: 2.1-6.15, p < 0.00001) and ongoing pregnancy rate (OR = 8.82, 95% CI: 2.91-26.75, p = 0.0001) in patients with idiopathic RM.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0000809---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "14676056",
-              "object": "MONDO:0006774",
-              "publications": [
-                "PMID:19903335",
-                "PMID:21984529",
-                "PMID:24818590",
-                "PMID:35249235"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 592657,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018896",
-          "name": "thrombotic thrombocytopenic purpura",
-          "description": "An acute or subacute syndrome characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities and neurologic abnormalities such as seizures, hemiplegia, and visual disturbances. Drugs and bacteria have been implicated as etiologic factors. The introduction of plasma exchange has significantly lowered the mortality rate. If untreated, the mortality rate is high. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C78797\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C78797\" NCI Thesaurus); A coagulation disorder characterized by extensive formation of thrombi in small blood vessels throughout the body due to low levels of ADAMTS13 protein, and resulting in consumption of circulating platelets, which is characterized by thrombocytopenia, anemia, neurologic changes, and sometimes fever and renal dysfunction.; An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10037562",
-            "MONDO:0018896",
-            "UMLS:C0034155",
-            "ORPHANET:54057",
-            "ICD10:M31.19",
-            "SNOMEDCT:78129009",
-            "NCIT:C78797",
-            "MEDDRA:10073197",
-            "MESH:D011697",
-            "PDQ:CDR0000694585",
-            "MEDDRA:10043562",
-            "DOID:10772",
-            "MEDDRA:10043648",
-            "MEDDRA:10037563"
-          ],
-          "id": "MONDO:0018896",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Thrombotic Thrombocytopenic Purpura",
-            "Thrombotic thrombocytopenic purpura",
-            "thrombotic thrombocytopenic purpura",
-            "Purpura, Thrombotic Thrombocytopenic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 592657,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018896",
-              "name": "thrombotic thrombocytopenic purpura",
-              "description": "An acute or subacute syndrome characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities and neurologic abnormalities such as seizures, hemiplegia, and visual disturbances. Drugs and bacteria have been implicated as etiologic factors. The introduction of plasma exchange has significantly lowered the mortality rate. If untreated, the mortality rate is high. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C78797\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C78797\" NCI Thesaurus); A coagulation disorder characterized by extensive formation of thrombi in small blood vessels throughout the body due to low levels of ADAMTS13 protein, and resulting in consumption of circulating platelets, which is characterized by thrombocytopenia, anemia, neurologic changes, and sometimes fever and renal dysfunction.; An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10037562",
-                "MONDO:0018896",
-                "UMLS:C0034155",
-                "ORPHANET:54057",
-                "ICD10:M31.19",
-                "SNOMEDCT:78129009",
-                "NCIT:C78797",
-                "MEDDRA:10073197",
-                "MESH:D011697",
-                "PDQ:CDR0000694585",
-                "MEDDRA:10043562",
-                "DOID:10772",
-                "MEDDRA:10043648",
-                "MEDDRA:10037563"
-              ],
-              "id": "MONDO:0018896",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Thrombotic Thrombocytopenic Purpura",
-                "Thrombotic thrombocytopenic purpura",
-                "thrombotic thrombocytopenic purpura",
-                "Purpura, Thrombotic Thrombocytopenic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14046069,
-            "start": 568,
-            "end": 592657,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19399522': {'publication date': '2009 Sep', 'sentence': 'The second was a 6-year-old boy with acquired relapsing TTP previously managed with plasmapheresis and prednisolone, who presented with a third relapse that was treated with plasmapheresis and rituximab; he remains in remission 17 months after treatment.', 'subject score': 1000, 'object score': 875}, 'PMID:24590757': {'publication date': '2014 Oct', 'sentence': 'TTP was transiently controlled by plasma exchange, prednisolone, rituximab, and cyclophosphamide, but relapsed within a short time.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0034155---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "14345678",
-              "object": "MONDO:0018896",
-              "publications": [
-                "PMID:19399522",
-                "PMID:24590757"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 819686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004977",
-          "name": "angioimmunoblastic T-cell lymphoma",
-          "description": "A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes. It occurs in the middle aged and elderly, with an equal incidence in males and females. The clinical course is typically aggressive. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C7528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C7528\" NCI Thesaurus); A peripheral T-cell lymphoma of mature T follicular helper (TFH) cells characterized by systemic disease and a polymorphous infiltrate involving lymph nodes, with a prominent proliferation of high endothelial venules and follicular dendritic cells. EBV-positive cells are nearly always present. It is a clinically aggressive lymphoma and seen mainly in older adults. (WHO 2017); A disorder characterized by proliferation of arborizing small vessels, prominent immunoblastic proliferations and amorphous acidophilic interstitial material. Clinical manifestations include fever, sweats, weight loss, generalized lymphadenopathy and frequently hepatosplenomegaly.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:835009",
-            "EFO:1001350",
-            "MEDDRA:10002449",
-            "SNOMEDCT:52097008",
-            "MONDO:0004977",
-            "UMLS:C0020981",
-            "MEDDRA:10002451",
-            "ORPHANET:86886",
-            "MEDDRA:10079289",
-            "MEDDRA:10079282",
-            "MEDDRA:10002450",
-            "NCIT:C7528",
-            "PDQ:CDR0000042765",
-            "DOID:0111147",
-            "EFO:0000255",
-            "ICD10:C86.5",
-            "SNOMEDCT:413537009",
-            "MEDDRA:10080248",
-            "MESH:D007119"
-          ],
-          "id": "MONDO:0004977",
-          "category": "biolink:Disease",
-          "all_names": [
-            "angioimmunoblastic T-cell lymphoma",
-            "Immunoblastic Lymphadenopathy",
-            "Angioimmunoblastic T-Cell Lymphoma",
-            "Angioimmunoblastic T-cell lymphoma",
-            "Angioimmunoblastic Lymphadenopathy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:22700722",
-            "https://rarediseases.org/rare-diseases/angioimmunoblastic-t-cell-lymphoma/",
-            "https://www.lymphoma.org/aboutlymphoma/nhl/aitl/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 819686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004977",
-              "name": "angioimmunoblastic T-cell lymphoma",
-              "description": "A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes. It occurs in the middle aged and elderly, with an equal incidence in males and females. The clinical course is typically aggressive. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C7528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C7528\" NCI Thesaurus); A peripheral T-cell lymphoma of mature T follicular helper (TFH) cells characterized by systemic disease and a polymorphous infiltrate involving lymph nodes, with a prominent proliferation of high endothelial venules and follicular dendritic cells. EBV-positive cells are nearly always present. It is a clinically aggressive lymphoma and seen mainly in older adults. (WHO 2017); A disorder characterized by proliferation of arborizing small vessels, prominent immunoblastic proliferations and amorphous acidophilic interstitial material. Clinical manifestations include fever, sweats, weight loss, generalized lymphadenopathy and frequently hepatosplenomegaly.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:835009",
-                "EFO:1001350",
-                "MEDDRA:10002449",
-                "SNOMEDCT:52097008",
-                "MONDO:0004977",
-                "UMLS:C0020981",
-                "MEDDRA:10002451",
-                "ORPHANET:86886",
-                "MEDDRA:10079289",
-                "MEDDRA:10079282",
-                "MEDDRA:10002450",
-                "NCIT:C7528",
-                "PDQ:CDR0000042765",
-                "DOID:0111147",
-                "EFO:0000255",
-                "ICD10:C86.5",
-                "SNOMEDCT:413537009",
-                "MEDDRA:10080248",
-                "MESH:D007119"
-              ],
-              "id": "MONDO:0004977",
-              "category": "biolink:Disease",
-              "all_names": [
-                "angioimmunoblastic T-cell lymphoma",
-                "Immunoblastic Lymphadenopathy",
-                "Angioimmunoblastic T-Cell Lymphoma",
-                "Angioimmunoblastic T-cell lymphoma",
-                "Angioimmunoblastic Lymphadenopathy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:22700722",
-                "https://rarediseases.org/rare-diseases/angioimmunoblastic-t-cell-lymphoma/",
-                "https://www.lymphoma.org/aboutlymphoma/nhl/aitl/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13718505,
-            "start": 568,
-            "end": 819686,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1890746': {'publication date': '1991 Jun', 'sentence': 'Three months later, AILD relapsed in spite of prednisolone treatment.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0020981---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "14012190",
-              "object": "MONDO:0004977",
-              "publications": [
-                "PMID:1890746"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318789,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005885",
-          "name": "optic neuritis",
-          "description": "A disorder characterized by inflammation of the optic nerve. Causes include autoimmune disorders, infections, toxins, drugs, and multiple sclerosis. It may manifest with acute loss of vision and pain.; Inflammation of the optic nerve. Commonly associated conditions include autoimmune disorders such as MULTIPLE SCLEROSIS, infections, and granulomatous diseases. Clinical features include retro-orbital pain that is aggravated by eye movement, loss of color vision, and contrast sensitivity that may progress to severe visual loss, an afferent pupillary defect (Marcus-Gunn pupil), and in some instances optic disc hyperemia and swelling. Inflammation may occur in the portion of the nerve within the globe (neuropapillitis or anterior optic neuritis) or the portion behind the globe (retrobulbar neuritis or posterior optic neuritis).; Inflammation of the optic nerve. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D009902",
-            "NCIT:C84950",
-            "DOID:1210",
-            "HP:0100653",
-            "ICD10:H46",
-            "MEDDRA:10030942",
-            "MONDO:0005885",
-            "UMLS:C0029134",
-            "EFO:0007405",
-            "MEDDRA:10030946",
-            "ICD9:377.3",
-            "MEDDRA:10029247",
-            "MEDDRA:10030944",
-            "SNOMEDCT:66760008"
-          ],
-          "id": "MONDO:0005885",
-          "category": "biolink:Disease",
-          "all_names": [
-            "optic neuritis",
-            "Optic neuritis",
-            "Optic Neuritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.mayoclinic.org/diseases-conditions/optic-neuritis/symptoms-causes/syc-20354953",
-            "https://rarediseases.info.nih.gov/diseases/7320/optic-neuritis",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318789,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005885",
-              "name": "optic neuritis",
-              "description": "A disorder characterized by inflammation of the optic nerve. Causes include autoimmune disorders, infections, toxins, drugs, and multiple sclerosis. It may manifest with acute loss of vision and pain.; Inflammation of the optic nerve. Commonly associated conditions include autoimmune disorders such as MULTIPLE SCLEROSIS, infections, and granulomatous diseases. Clinical features include retro-orbital pain that is aggravated by eye movement, loss of color vision, and contrast sensitivity that may progress to severe visual loss, an afferent pupillary defect (Marcus-Gunn pupil), and in some instances optic disc hyperemia and swelling. Inflammation may occur in the portion of the nerve within the globe (neuropapillitis or anterior optic neuritis) or the portion behind the globe (retrobulbar neuritis or posterior optic neuritis).; Inflammation of the optic nerve. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D009902",
-                "NCIT:C84950",
-                "DOID:1210",
-                "HP:0100653",
-                "ICD10:H46",
-                "MEDDRA:10030942",
-                "MONDO:0005885",
-                "UMLS:C0029134",
-                "EFO:0007405",
-                "MEDDRA:10030946",
-                "ICD9:377.3",
-                "MEDDRA:10029247",
-                "MEDDRA:10030944",
-                "SNOMEDCT:66760008"
-              ],
-              "id": "MONDO:0005885",
-              "category": "biolink:Disease",
-              "all_names": [
-                "optic neuritis",
-                "Optic neuritis",
-                "Optic Neuritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.mayoclinic.org/diseases-conditions/optic-neuritis/symptoms-causes/syc-20354953",
-                "https://rarediseases.info.nih.gov/diseases/7320/optic-neuritis",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13469270,
-            "start": 568,
-            "end": 318789,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18489605': {'publication date': '2008 Jul', 'sentence': 'Acute generalized exanthematous pustulosis induced by high-dose prednisolone in a young woman with optic neuritis owing to disseminated encephalomyelitis.', 'subject score': 901, 'object score': 1000}, 'PMID:18575879': {'publication date': '2008 Oct', 'sentence': 'BACKGROUND: In this study, patients with optic neuritis were treated with high-dose prednisolone.', 'subject score': 901, 'object score': 1000}, 'PMID:18805845': {'publication date': '2009 Feb', 'sentence': 'CASE PRESENTATION: In this study, we report on the exceptional case of a young female treated with intravenous high-dose prednisolone for optic neuritis who developed acute generalized exanthematous pustulosis (AGEP).', 'subject score': 861, 'object score': 1000}, 'PMID:30577778': {'publication date': '2018 Dec 21', 'sentence': 'CASE PRESENTATION: We describe the case of a 45-year-old man with MOG-IgG1-positive highly relapsing optic neuritis who had experienced 5 attacks over 21 months and had monocular blindness despite prednisolone and azathioprine therapy.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0029134---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "13758030",
-              "object": "MONDO:0005885",
-              "publications": [
-                "PMID:18489605",
-                "PMID:18575879",
-                "PMID:18805845",
-                "PMID:30577778"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 313140,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018906",
-          "name": "follicular lymphoma",
-          "description": "A neoplasm of follicle centre B cells which has at least a partial follicular pattern. Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)]. Histological grade correlates with prognosis. Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3209\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3209\" NCI Thesaurus); A neoplasm of follicle centre B cells which has at least a partial follicular pattern. Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)]. Histological grade correlates with prognosis. Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).; A low-grade malignant lymphoma of follicular pattern in which there is no clear preponderance of one cell type (small or large) over another. The large cells, cleaved or noncleaved, are often 2-3 times larger in diameter than normal lymphocytes.; An indolent B cell lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is characterized by diffuse lymphadenopathy, bone marrow involvement, splenomegaly and less commonly other extranodal sites of involvement. [NCIT:C3209, PMID:29314206]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10085128",
-            "ORPHANET:545",
-            "MEDDRA:10029478",
-            "MONDO:0018906",
-            "UMLS:C3887918",
-            "SNOMEDCT:277618009",
-            "SNOMEDCT:308121000",
-            "PDQ:CDR0000795359",
-            "MEDDRA:10029473",
-            "NCIT:C3209",
-            "UMLS:C0024301",
-            "HP:0033125",
-            "MESH:D008224",
-            "DOID:0050873",
-            "MEDDRA:10085262",
-            "SNOMEDCT:307637005",
-            "SNOMEDCT:55150002"
-          ],
-          "id": "MONDO:0018906",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia/lymphoma, b-cell, 2",
-            "Follicular Lymphoma",
-            "Lymphoma, Follicular",
-            "Follicular lymphoma",
-            "follicular lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/follicular_lymphoma",
-            "http://www.cancer.gov/dictionary?cdrid=428287",
-            "PMID:29314206"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313140,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018906",
-              "name": "follicular lymphoma",
-              "description": "A neoplasm of follicle centre B cells which has at least a partial follicular pattern. Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)]. Histological grade correlates with prognosis. Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3209\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3209\" NCI Thesaurus); A neoplasm of follicle centre B cells which has at least a partial follicular pattern. Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)]. Histological grade correlates with prognosis. Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).; A low-grade malignant lymphoma of follicular pattern in which there is no clear preponderance of one cell type (small or large) over another. The large cells, cleaved or noncleaved, are often 2-3 times larger in diameter than normal lymphocytes.; An indolent B cell lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is characterized by diffuse lymphadenopathy, bone marrow involvement, splenomegaly and less commonly other extranodal sites of involvement. [NCIT:C3209, PMID:29314206]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10085128",
-                "ORPHANET:545",
-                "MEDDRA:10029478",
-                "MONDO:0018906",
-                "UMLS:C3887918",
-                "SNOMEDCT:277618009",
-                "SNOMEDCT:308121000",
-                "PDQ:CDR0000795359",
-                "MEDDRA:10029473",
-                "NCIT:C3209",
-                "UMLS:C0024301",
-                "HP:0033125",
-                "MESH:D008224",
-                "DOID:0050873",
-                "MEDDRA:10085262",
-                "SNOMEDCT:307637005",
-                "SNOMEDCT:55150002"
-              ],
-              "id": "MONDO:0018906",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia/lymphoma, b-cell, 2",
-                "Follicular Lymphoma",
-                "Lymphoma, Follicular",
-                "Follicular lymphoma",
-                "follicular lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/follicular_lymphoma",
-                "http://www.cancer.gov/dictionary?cdrid=428287",
-                "PMID:29314206"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13280763,
-            "start": 568,
-            "end": 313140,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18231908': {'publication date': '2008 Feb', 'sentence': 'The addition of rituximab to cyclophosphamide, vincristine and prednisolone (CVP) for advanced follicular lymphoma increases median time to progression by 17 months.', 'subject score': 1000, 'object score': 901}, 'PMID:21592582': {'publication date': '2011 Jun', 'sentence': 'We present a rare case of chronic Pneumocystis jiroveci infection presenting as multiple persistent granulomatous pulmonary nodules over a 12 month period in a patient with follicular lymphoma undergoing treatment with Rituximab, Cyclophosphamide, Vincristine, and Prednisolone chemotherapy.', 'subject score': 888, 'object score': 1000}, 'PMID:21627880': {'publication date': '2010 Nov-Dec', 'sentence': '[Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal].', 'subject score': 1000, 'object score': 901}, 'PMID:24471908': {'publication date': '2014 Oct', 'sentence': 'Patients received six or eight cycles of rituximab plus cyclophosphamide, vincristine, doxorubicin and prednisone for DLBCL or plus cyclophosphamide, vincristine and prednisolone for FL.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0024301---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "13566191",
-              "object": "MONDO:0018906",
-              "publications": [
-                "PMID:18231908",
-                "PMID:21592582",
-                "PMID:21627880",
-                "PMID:24471908"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 520745,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015243",
-          "name": "allergic bronchopulmonary aspergillosis",
-          "description": "An aspergillosis that involves an allergic reaction due to the spores of Aspergillus moulds (A. fumigatus), which colonizes the mucus in the airways causing inflammation. The disease has symptom cough, has symptom wheezing and has symptom fever. // COMMENTS: OMIM mapping confirmed by DO. [SN].",
-          "equivalent_curies": [
-            "ORPHANET:1164",
-            "MEDDRA:10001707",
-            "ICD9:518.6",
-            "ICD10:B44.81",
-            "UMLS:C3278302",
-            "MEDDRA:10006474",
-            "NCIT:C84547",
-            "OMIM:103920",
-            "SNOMEDCT:37981002",
-            "MESH:D001229",
-            "DOID:13166",
-            "UMLS:C0004031",
-            "EFO:0007140",
-            "MONDO:0015243"
-          ],
-          "id": "MONDO:0015243",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Aspergillosis, Allergic Bronchopulmonary",
-            "Allergic bronchopulmonary aspergillosis, familial",
-            "allergic bronchopulmonary aspergillosis",
-            "Allergic bronchopulmonary aspergillosis",
-            "Allergic Bronchopulmonary Aspergillosis",
-            "Allergic bronchopulmonary aspergillosis, familial related phenotypic feature"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000070.htm",
-            "http://www.merck.com/mmhe/sec04/ch051/ch051d.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520745,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015243",
-              "name": "allergic bronchopulmonary aspergillosis",
-              "description": "An aspergillosis that involves an allergic reaction due to the spores of Aspergillus moulds (A. fumigatus), which colonizes the mucus in the airways causing inflammation. The disease has symptom cough, has symptom wheezing and has symptom fever. // COMMENTS: OMIM mapping confirmed by DO. [SN].",
-              "equivalent_curies": [
-                "ORPHANET:1164",
-                "MEDDRA:10001707",
-                "ICD9:518.6",
-                "ICD10:B44.81",
-                "UMLS:C3278302",
-                "MEDDRA:10006474",
-                "NCIT:C84547",
-                "OMIM:103920",
-                "SNOMEDCT:37981002",
-                "MESH:D001229",
-                "DOID:13166",
-                "UMLS:C0004031",
-                "EFO:0007140",
-                "MONDO:0015243"
-              ],
-              "id": "MONDO:0015243",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Aspergillosis, Allergic Bronchopulmonary",
-                "Allergic bronchopulmonary aspergillosis, familial",
-                "allergic bronchopulmonary aspergillosis",
-                "Allergic bronchopulmonary aspergillosis",
-                "Allergic Bronchopulmonary Aspergillosis",
-                "Allergic bronchopulmonary aspergillosis, familial related phenotypic feature"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000070.htm",
-                "http://www.merck.com/mmhe/sec04/ch051/ch051d.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13045966,
-            "start": 568,
-            "end": 520745,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17824467': {'publication date': '2007 Mar', 'sentence': 'Here 2 cases of allergic bronchopulmonary aspergillosis in a family (brother and sister), treated with prednisolone with complete remission are reported.', 'subject score': 1000, 'object score': 1000}, 'PMID:29331473': {'publication date': '2018 Mar', 'sentence': 'However, itraconazole was also effective in a considerable number and, with fewer side effects compared with prednisolone, remains an attractive alternative in the initial treatment of ABPA.', 'subject score': 1000, 'object score': 1000}, 'PMID:33642487': {'publication date': '2021 Mar 01', 'sentence': 'A 45-year-old man with allergic bronchopulmonary aspergillosis (ABPA) was treated with oral prednisolone (PSL) (30 mg/day), inhaled corticosteroids, and long-acting beta2-agonists.', 'subject score': 888, 'object score': 1000}, 'PMID:8767272': {'publication date': '1996', 'sentence': 'Prednisolone with an initial dose of between 0,5-1,0 mg/kg/day remains the treatment of choice for ABPA.', 'subject score': 1000, 'object score': 1000}, 'PMID:9715302': {'publication date': '1996', 'sentence': 'A 38 year old male was diagnosed to have allergic bronchopulmonary aspergillosis which responded remarkably to prednisolone therapy.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0004031---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "13327146",
-              "object": "MONDO:0015243",
-              "publications": [
-                "PMID:17824467",
-                "PMID:29331473",
-                "PMID:33642487",
-                "PMID:8767272",
-                "PMID:9715302"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13031072,
-            "start": 568,
-            "end": 319673,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17763849': {'publication date': '2007 Dec', 'sentence': 'FDG-PET was performed in rats bearing BCG granulomas or tumors before and after prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:17984697': {'publication date': '2007 Nov', 'sentence': 'The detection of type 2 somatostatin receptors on the surface of the tumor justified the introduction of treatment with somatostatin analog and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:19379301': {'publication date': '2004 Sep', 'sentence': 'Eighteen of 24 tumours (75%) decreased in size in response to prednisolone treatment.', 'subject score': 888, 'object score': 861}, 'PMID:26907854': {'publication date': '2016 Mar', 'sentence': 'A combination regimen of mitoxantrone (MTO) and prednisolone (PLP) has been ideal for tumor therapy.', 'subject score': 1000, 'object score': 888}, 'PMID:31243239': {'publication date': '2019 Oct 01', 'sentence': 'Prednisolone immediately relieved the symptoms, and the tumor was still shrinking on day 21 after eight cycles of pembrolizumab.', 'subject score': 1000, 'object score': 1000}, 'PMID:32388531': {'publication date': '2020 May 10', 'sentence': 'The lack of similar reported cases, and the aggressiveness of the tumor clinically and histopathologically, resulted in the decision to treat with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone (R-CHOP) as a case of aggressive lymphoma, with complete remission clinically and radiologically.', 'subject score': 1000, 'object score': 861}, 'PMID:35365166': {'publication date': '2022 Apr 01', 'sentence': 'One month after treatment with prednisolone (PSL), the tumor had shrunk, but a CT scan during the third month of PSL treatment revealed multiple nodular shadows in both lungs.', 'subject score': 1000, 'object score': 1000}, 'PMID:36580002': {'publication date': '2022 Dec 01', 'sentence': 'These results shed the light on the potential clinic values of ABA, and prednisolone combination in angiogenesis-dependent tumors.', 'subject score': 888, 'object score': 851}, 'PMID:5401721': {'publication date': '1969', 'sentence': '[Immunodepressive action of thalidomide and prednisolone in rats with experimentally induced neoplasms].', 'subject score': 1000, 'object score': 790}, 'PMID:6405762': {'publication date': '1983 Feb', 'sentence': 'Plasmapheresis and irradiation of the tumor were performed in conjunction with prednisolone therapy to a severe case of polyneuropathy associated with a solitary sclerotic secreting myeloma and endocrinological abnormalities.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "13311736",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:17763849",
-                "PMID:17984697",
-                "PMID:19379301",
-                "PMID:26907854",
-                "PMID:31243239",
-                "PMID:32388531",
-                "PMID:35365166",
-                "PMID:36580002",
-                "PMID:5401721",
-                "PMID:6405762"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12497118,
-            "start": 568,
-            "end": 321523,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17041382': {'publication date': '2002 Oct', 'sentence': 'After recovering from pneumonia, she was treated initially with prednisolone, 30 mg/day, and remained well until she developed hemoptysis at age 34 years.', 'subject score': 1000, 'object score': 1000}, 'PMID:17144587': {'publication date': '2006 Nov', 'sentence': 'We report a case of SELAPINA-induced pneumonia successfully treated with glucocorticoid pulse therapy followed by orally administered prednisolone.', 'subject score': 827, 'object score': 790}, 'PMID:20133929': {'publication date': '2010 May 01', 'sentence': 'CONCLUSIONS: Prednisolone (at 40 mg) once daily for a week does not improve outcome in hospitalized patients with CAP.', 'subject score': 1000, 'object score': 851}, 'PMID:23423809': {'publication date': '2013 May', 'sentence': 'The pneumonitis progressed rapidly and the patient developed respiratory failure, so we performed bronchoalveolar lavage to make a definitive diagnosis, and simultaneously started treatment with prednisolone and trimethoprim-sulfamethoxazole to cover both interstitial lung disease and pneumocystis pneumonia.', 'subject score': 1000, 'object score': 1000}, 'PMID:2860710': {'publication date': '1985', 'sentence': 'The pneumonia resolved following discontinuation of the drug and the start of treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:30671549': {'publication date': '2019 Feb', 'sentence': 'Re-staging showed a para-mediastinal, radiotherapy-induced pneumonitis, which was treated by prednisolone due to clinical symptoms.', 'subject score': 1000, 'object score': 822}, 'PMID:31438923': {'publication date': '2019 Aug 22', 'sentence': 'The re-escalated dosage of PSL improved the pneumonitis, and then nintedanib was started as additional therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:34121010': {'publication date': '2021 Jun 12', 'sentence': 'After 12 cycles, immune-related pneumonitis developed and was treated with prednisolone.', 'subject score': 1000, 'object score': 851}, 'PMID:36451154': {'publication date': '2022 Nov 30', 'sentence': 'CASE PRESENTATION: A 68-year-old woman complained of floaters and blurred vision in her right eye as she was receiving systemic prednisolone for COVID-19 pneumonia under isolation in our hospital.', 'subject score': 888, 'object score': 916}, 'PMID:4404939': {'publication date': '1972 Dec 09', 'sentence': 'Ampicillin dosage and use of prednisolone in treatment of pneumonia: co-operative controlled trial.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "12767794",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:17041382",
-                "PMID:17144587",
-                "PMID:20133929",
-                "PMID:23423809",
-                "PMID:2860710",
-                "PMID:30671549",
-                "PMID:31438923",
-                "PMID:34121010",
-                "PMID:36451154",
-                "PMID:4404939"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 610975,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/DOID_0080909",
-          "name": "castration-resistant prostate carcinoma",
-          "description": "A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.",
-          "equivalent_curies": [
-            "MESH:D064129",
-            "MONDO:0850353",
-            "DOID:0080909",
-            "MEDDRA:10076506",
-            "SNOMEDCT:427492003",
-            "UMLS:C3658267",
-            "MEDDRA:10062904",
-            "NCIT:C130234",
-            "UMLS:C1328504"
-          ],
-          "id": "DOID:0080909",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Prostatic Neoplasms, Castration-Resistant",
-            "castration-resistant prostate carcinoma",
-            "Castration-Resistant Prostate Carcinoma",
-            "Hormone refractory prostate cancer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:30324351"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 610975,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/DOID_0080909",
-              "name": "castration-resistant prostate carcinoma",
-              "description": "A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.",
-              "equivalent_curies": [
-                "MESH:D064129",
-                "MONDO:0850353",
-                "DOID:0080909",
-                "MEDDRA:10076506",
-                "SNOMEDCT:427492003",
-                "UMLS:C3658267",
-                "MEDDRA:10062904",
-                "NCIT:C130234",
-                "UMLS:C1328504"
-              ],
-              "id": "DOID:0080909",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Prostatic Neoplasms, Castration-Resistant",
-                "castration-resistant prostate carcinoma",
-                "Castration-Resistant Prostate Carcinoma",
-                "Hormone refractory prostate cancer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:30324351"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11919963,
-            "start": 568,
-            "end": 610975,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16338867': {'publication date': '2006', 'sentence': 'Fifteen patients 60 to 80 years old (a mean of 72 years) with hormone-refractory prostate cancer were treated with low dose prednisolone.', 'subject score': 901, 'object score': 1000}, 'PMID:16770110': {'publication date': '2006 Jun', 'sentence': 'We have experienced a patient with tumor fever from hormone-refractory prostate cancer (HRPC) who was treated successfully using docetaxel plus prednisolone therapy.', 'subject score': 833, 'object score': 1000}, 'PMID:16880788': {'publication date': '2006 Aug 21', 'sentence': 'A systematic review was performed to evaluate the clinical effectiveness of docetaxel in combination with prednisolone (docetaxel is licensed in the UK for use in combination with prednisone or prednisolone for the treatment of patients with metastatic hormone-refractory prostate cancer. Prednisone is not used in the UK, but it is reasonable to use docetaxel plus prednisone data in this review of docetaxel plus prednisolone) for the treatment of metastatic hormone-refractory prostate cancer.', 'subject score': 1000, 'object score': 937}, 'PMID:17181985': {'publication date': '2007 Jan', 'sentence': 'OBJECTIVES: A systematic review was undertaken and an economic model constructed to evaluate the clinical effectiveness and cost-effectiveness of docetaxel (Taxotere, Sanofi-Aventis) in combination with prednisone/prednisolone for the treatment of metastatic hormone-refractory prostate cancer (mHRPC).', 'subject score': 888, 'object score': 937}, 'PMID:17352157': {'publication date': '2007 Feb', 'sentence': 'Between April 2004 and August 2005, we used docetaxel in combination with prednisolone to treat 14 patients with hormone-refractory prostate cancer (HRPC).', 'subject score': 1000, 'object score': 1000}, 'PMID:18417502': {'publication date': '2008 May', 'sentence': 'CONCLUSION: The combination of docetaxel and prednisolone was feasible and active in Japanese patients with HRPC, with a manageable adverse-event profile similar to that observed in Western patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:18657098': {'publication date': '2009', 'sentence': 'RESULTS: Depending on the cost-effectiveness threshold (lambda), we identified mitoxantrone plus prednisone/prednisolone and docetaxel plus prednisone/prednisolone (3 weekly) as the optimal treatments for mHRPC.', 'subject score': 833, 'object score': 937}, 'PMID:19409038': {'publication date': '2009 Apr', 'sentence': 'This randomized (1:1), double-blind study evaluated vandetanib (100 mg/day) or placebo in combination with docetaxel (D; 75 mg/m(2) every 3 weeks) and prednisolone (P; 2 x 5 mg/day) in 86 patients with metastatic hormone-refractory prostate cancer (mHRPC).', 'subject score': 1000, 'object score': 937}, 'PMID:19837689': {'publication date': '2010 Jan', 'sentence': 'Docetaxel in combination with prednisolone for hormone refractory prostate cancer.', 'subject score': 1000, 'object score': 1000}, 'PMID:20587613': {'publication date': '2010 Nov', 'sentence': 'METHODS: From April 2004 through August 2008, we used docetaxel plus prednisolone to treat 55 HRPC patients (median age, 72 years).', 'subject score': 851, 'object score': 876}, 'PMID:23580356': {'publication date': '2013 Jun', 'sentence': 'Clinical evidence was derived from a multinational randomized open-label phase III trial of cabazitaxel plus prednisone or prednisolone in men with mHRPC that had progressed during or following treatment with docetaxel.', 'subject score': 1000, 'object score': 937}, 'PMID:28683707': {'publication date': '2017 Jul 01', 'sentence': 'Docetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer.', 'subject score': 1000, 'object score': 924}, 'PMID:34050660': {'publication date': '2021 May 29', 'sentence': 'CONCLUSIONS: This large-scale, real-world, post-marketing surveillance study confirmed the safety and efficacy of abiraterone acetate plus prednisolone in Japanese castration-resistant prostate cancer patients with or without previous chemotherapy.', 'subject score': 861, 'object score': 876}, 'PMID:35813251': {'publication date': '2022 Jul', 'sentence': 'Background: Enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) improve survival in castration-resistant prostate cancer (CRPC).', 'subject score': 851, 'object score': 1000}, 'PMID:9186348': {'publication date': '1997 Jul', 'sentence': 'MATERIALS AND METHODS: We describe a prospective, randomized study of 40 patients comparing the second line response of flutamide to prednisolone in patients with known hormone refractory stage M1 prostate cancer.', 'subject score': 1000, 'object score': 863}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C1328504---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "12190701",
-              "object": "DOID:0080909",
-              "publications": [
-                "PMID:16338867",
-                "PMID:16770110",
-                "PMID:16880788",
-                "PMID:17181985",
-                "PMID:17352157",
-                "PMID:18417502",
-                "PMID:18657098",
-                "PMID:19409038",
-                "PMID:19837689",
-                "PMID:20587613",
-                "PMID:23580356",
-                "PMID:28683707",
-                "PMID:34050660",
-                "PMID:35813251",
-                "PMID:9186348"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 699953,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018905",
-          "name": "diffuse large B-cell lymphoma",
-          "description": "A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.; Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "NCIT:C8851",
-            "UMLS:C0079744",
-            "MEDDRA:10012819",
-            "MEDDRA:10012818",
-            "MONDO:0018905",
-            "UMLS:C2699777",
-            "NCIT:C80280",
-            "SNOMEDCT:109969005",
-            "SNOMEDCT:1172695008",
-            "MESH:D016403",
-            "ORPHANET:544",
-            "MEDDRA:10012820",
-            "DOID:0050745",
-            "EFO:0000403"
-          ],
-          "id": "MONDO:0018905",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphoma, Large B-Cell, Diffuse",
-            "diffuse large B-cell lymphoma",
-            "Diffuse Large B-Cell Lymphoma",
-            "Diffuse large B-cell lymphoma",
-            "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28487884",
-            "http://en.wikipedia.org/wiki/diffuse_large_b-cell_lymphoma",
-            "https://ncithesaurus.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&ns=ncit&code=c148392"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 699953,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018905",
-              "name": "diffuse large B-cell lymphoma",
-              "description": "A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.; Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "NCIT:C8851",
-                "UMLS:C0079744",
-                "MEDDRA:10012819",
-                "MEDDRA:10012818",
-                "MONDO:0018905",
-                "UMLS:C2699777",
-                "NCIT:C80280",
-                "SNOMEDCT:109969005",
-                "SNOMEDCT:1172695008",
-                "MESH:D016403",
-                "ORPHANET:544",
-                "MEDDRA:10012820",
-                "DOID:0050745",
-                "EFO:0000403"
-              ],
-              "id": "MONDO:0018905",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphoma, Large B-Cell, Diffuse",
-                "diffuse large B-cell lymphoma",
-                "Diffuse Large B-Cell Lymphoma",
-                "Diffuse large B-cell lymphoma",
-                "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28487884",
-                "http://en.wikipedia.org/wiki/diffuse_large_b-cell_lymphoma",
-                "https://ncithesaurus.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&ns=ncit&code=c148392"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11732152,
-            "start": 568,
-            "end": 699953,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16098067': {'publication date': '2005 Aug', 'sentence': 'CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) has been the standard chemotherapy regimen used for diffuse large cell lymphomas for over 30 years.', 'subject score': 1000, 'object score': 991}, 'PMID:17119328': {'publication date': '2006', 'sentence': 'The other tumors, hypoattenuating in the portal phase CT, were diagnosed histopathologically as DLBCL, and treated with cyclophosphamide, tetrahydropyranyl-Adriamycin, vincristine and prednisolone (THP-COP) in combination with rituximab.', 'subject score': 1000, 'object score': 922}, 'PMID:19590893': {'publication date': '2010 Jan', 'sentence': 'INTRODUCTION: We previously described the effectiveness of the THP-COP regimen comprising cyclophosphamide, pirarubicin (tetrahydropyranyl adriamycin; THP), vincristine and prednisolone in patients with diffuse large B-cell lymphoma (DLBCL).', 'subject score': 1000, 'object score': 922}, 'PMID:19656156': {'publication date': '2009 Oct', 'sentence': 'We evaluated the usefulness of prognostic markers in patients with diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide, vincristine, doxorubicin, and prednisolone (CHOP) +/- rituximab (R-CHOP) in Japan.', 'subject score': 1000, 'object score': 922}, 'PMID:19861288': {'publication date': '2009 Nov 01', 'sentence': 'Treatment with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been considered as the standard therapy for diffuse large B-cell lymphoma (DLBCL) for more than 20 years.', 'subject score': 1000, 'object score': 922}, 'PMID:20210673': {'publication date': '2010 Apr', 'sentence': 'CONCLUSION: These data suggest that R plus dose-reduced mitoxantrone, cyclophosphamide, vincristine, and prednisolone are feasible and highly effective in elderly patients with DLBCL of the thyroid.', 'subject score': 1000, 'object score': 922}, 'PMID:21438831': {'publication date': '2011 Apr', 'sentence': 'We previously described the benefit of the THP-COP regimen comprising cyclophosphamide, THP, vincristine, and prednisolone for elderly patients with diffuse large B-cell lymphoma (DLBCL).', 'subject score': 1000, 'object score': 922}, 'PMID:21718130': {'publication date': '2011 Oct', 'sentence': 'Patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) were evaluated with respect to clinical characteristics, treatment efficacy, and survival.', 'subject score': 1000, 'object score': 922}, 'PMID:21827339': {'publication date': '2012 Feb', 'sentence': 'We have previously described the effectiveness of the R-THP-COP regimen comprising rituximab, cyclophosphamide, pirarubicin, vincristine and prednisolone in patients with diffuse large B-cell lymphoma.', 'subject score': 1000, 'object score': 922}, 'PMID:22280534': {'publication date': '2012 Aug', 'sentence': 'Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.', 'subject score': 1000, 'object score': 922}, 'PMID:22563154': {'publication date': '2011 Oct', 'sentence': 'We report a patient with primary ovarian diffuse large B-cell lymphoma (DLBCL) and associated auto-immune hemolytic anemia (AIHA) who achieved complete remission after treatment with Rituximab-cyclophosphamide-doxorubicin-vincristine and prednisolone (R-CHOP) chemotherapy.', 'subject score': 1000, 'object score': 859}, 'PMID:22903849': {'publication date': '2012 Oct', 'sentence': 'This report concerns severe disseminated VZV infection in a diffuse large B cell lymphoma (DLBCL) patient treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP).', 'subject score': 1000, 'object score': 883}, 'PMID:22949903': {'publication date': '2012 May', 'sentence': 'The standard treatment of DLBCL patients is rituximab-based chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisolone.', 'subject score': 1000, 'object score': 877}, 'PMID:23063898': {'publication date': '2012 Oct 21', 'sentence': 'PATIENTS AND METHODS: Thirty-five diffuse large B-cell lymphoma patients were examined, who were treated with rituximab-cyclophosphamide-vincristine-doxoribicine-prednisolone (R-CHOP).', 'subject score': 766, 'object score': 819}, 'PMID:23320009': {'publication date': '2012 Dec', 'sentence': 'We report a case of diffuse large B-cell lymphoma (DLBCL) treated successfully with clarithromycin (CAM) and prednisolone (PSL).', 'subject score': 1000, 'object score': 922}, 'PMID:23452117': {'publication date': '2013 Nov', 'sentence': 'Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.', 'subject score': 888, 'object score': 922}, 'PMID:23488601': {'publication date': '2013 Nov', 'sentence': 'The purpose of this study was to investigate prognostic factors for overall survival (OS) among patients with previously untreated diffuse large B-cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP).', 'subject score': 1000, 'object score': 836}, 'PMID:24220559': {'publication date': '2014 Feb 01', 'sentence': 'De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial.', 'subject score': 1000, 'object score': 922}, 'PMID:25177375': {'publication date': '2014 Sep', 'sentence': 'CONCLUSIONS: In the current study, we identified the pre-treatment MTV measured by FDG-PET/CT as a potential predictor of survival in patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), at least in Ann Arbor stage II and III disease.', 'subject score': 1000, 'object score': 922}, 'PMID:25263825': {'publication date': '2014 Dec', 'sentence': 'The aim of the current study is to evaluate the prognostic value of anemia, an easily estimable parameter in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) immunochemotherapy.', 'subject score': 1000, 'object score': 922}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0079744---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11988157",
-              "object": "MONDO:0018905",
-              "publications": [
-                "PMID:16098067",
-                "PMID:17119328",
-                "PMID:19590893",
-                "PMID:19656156",
-                "PMID:19861288",
-                "PMID:20210673",
-                "PMID:21438831",
-                "PMID:21718130",
-                "PMID:21827339",
-                "PMID:22280534",
-                "PMID:22563154",
-                "PMID:22903849",
-                "PMID:22949903",
-                "PMID:23063898",
-                "PMID:23320009",
-                "PMID:23452117",
-                "PMID:23488601",
-                "PMID:24220559",
-                "PMID:25177375",
-                "PMID:25263825"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 531222,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0012727",
-          "name": "mucocutaneous lymph node syndrome",
-          "description": "A vasculitis characterized by inflammation of the arteries, particularly the coronary arteries. The vasculitis may lead to aneurysm formation and possibly, heart attacks. It affects young children who usually present with persistent high fever, redness of the mucous membranes of the mouth, redness of the palms and soles, skin rashes, lymphadenitis, and joint pain and swelling.; An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:13378",
-            "ICD9:446.1",
-            "MEDDRA:10000747",
-            "SNOMEDCT:75053002",
-            "MESH:C537014",
-            "UMLS:C0026691",
-            "UMLS:C2936917",
-            "EFO:0004246",
-            "MESH:D009080",
-            "MEDDRA:10023320",
-            "ICD10:M30.3",
-            "NCIT:C34825",
-            "MONDO:0012727",
-            "MEDDRA:10028083",
-            "OMIM:611775",
-            "ORPHANET:2331"
-          ],
-          "id": "MONDO:0012727",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infantile polyarteritis",
-            "Kawasaki disease",
-            "Kawasaki disease related phenotypic feature",
-            "Kawasaki Disease",
-            "mucocutaneous lymph node syndrome",
-            "Mucocutaneous Lymph Node Syndrome",
-            "Acute febrile mucocutaneous lymph node syndrome [MCLS]"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/kawasaki_disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 531222,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0012727",
-              "name": "mucocutaneous lymph node syndrome",
-              "description": "A vasculitis characterized by inflammation of the arteries, particularly the coronary arteries. The vasculitis may lead to aneurysm formation and possibly, heart attacks. It affects young children who usually present with persistent high fever, redness of the mucous membranes of the mouth, redness of the palms and soles, skin rashes, lymphadenitis, and joint pain and swelling.; An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:13378",
-                "ICD9:446.1",
-                "MEDDRA:10000747",
-                "SNOMEDCT:75053002",
-                "MESH:C537014",
-                "UMLS:C0026691",
-                "UMLS:C2936917",
-                "EFO:0004246",
-                "MESH:D009080",
-                "MEDDRA:10023320",
-                "ICD10:M30.3",
-                "NCIT:C34825",
-                "MONDO:0012727",
-                "MEDDRA:10028083",
-                "OMIM:611775",
-                "ORPHANET:2331"
-              ],
-              "id": "MONDO:0012727",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infantile polyarteritis",
-                "Kawasaki disease",
-                "Kawasaki disease related phenotypic feature",
-                "Kawasaki Disease",
-                "mucocutaneous lymph node syndrome",
-                "Mucocutaneous Lymph Node Syndrome",
-                "Acute febrile mucocutaneous lymph node syndrome [MCLS]"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/kawasaki_disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11635844,
-            "start": 568,
-            "end": 531222,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15965549': {'publication date': '2005 Jun', 'sentence': 'Six patients with Kawasaki disease (KD) were treated with prednisolone (1 to 2 mg/kg/day) for 3 days (from days 10 to 12 after the onset of the illness) after apparently unsuccessful treatment with intravenous immunoglobulin (IVIG, 2 g/kg/dose and additional 1 g/kg/dose).', 'subject score': 1000, 'object score': 1000}, 'PMID:19504733': {'publication date': '2009 Jun', 'sentence': 'BACKGROUND: We reported previously that intravenous immunoglobulin (IVIG) plus prednisolone for initial therapy for Kawasaki disease (KD) prevented coronary artery abnormalities (CAA) more effectively than IVIG alone.', 'subject score': 861, 'object score': 1000}, 'PMID:25342092': {'publication date': '2015', 'sentence': 'We conclude that adrenal suppression can occur in a high proportion of children with KD treated with IVIG plus prednisolone, despite rather short duration and relatively small amounts of administered glucocorticoids.', 'subject score': 861, 'object score': 1000}, 'PMID:25518413': {'publication date': '2014 Sep', 'sentence': 'The present paper reviews the roles of prednisolone therapy for acute phase Kawasaki disease patients.', 'subject score': 888, 'object score': 857}, 'PMID:26594091': {'publication date': '2015 Jul', 'sentence': 'Single serum cortisol values at 09:00 h can be indices of adrenocortical function in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone.', 'subject score': 861, 'object score': 1000}, 'PMID:27743415': {'publication date': '2017 Apr', 'sentence': 'BACKGROUND: Prednisolone (PSL) has been suggested to be useful for the treatment of Kawasaki disease (KD) resistant to i.v. immunoglobulin (IVIG), but much remains to be elucidated regarding its use.', 'subject score': 1000, 'object score': 1000}, 'PMID:28343657': {'publication date': '2017 Jun', 'sentence': 'Bradycardia Associated with Prednisolone in Children with Severe Kawasaki Disease.', 'subject score': 1000, 'object score': 901}, 'PMID:30337183': {'publication date': '2018 Dec', 'sentence': 'BACKGROUND: The RAISE study showed that additional prednisolone improved coronary artery outcomes in patients with Kawasaki disease at high risk of intravenous immunoglobulin (IVIG) resistance.', 'subject score': 888, 'object score': 1000}, 'PMID:33341911': {'publication date': '2020 Dec 20', 'sentence': 'In this study, we compared the therapeutic effects of primary and secondary prednisolone with IVIG for KD.', 'subject score': 888, 'object score': 1000}, 'PMID:34895290': {'publication date': '2021 Dec 11', 'sentence': 'DISCUSSION: This will be the first multicenter randomized controlled trial to evaluate the efficacy of IVIG + aspirin + prednisolone in Chinese pediatric patients with KD, which may provide high-level evidence for improving the initial treatment for acute KD.', 'subject score': 861, 'object score': 1000}, 'PMID:36695415': {'publication date': '2023 Jan 25', 'sentence': 'Primary treatment with IVIG compared to prednisolone for people with KD The evidence comparing IVIG with prednisolone on incidence of CAA is very uncertain (OR 0.60, 95% CI 0.24 to 1.48; 2 studies, 140 participants; very low-certainty evidence), and there was little to no difference between groups in adverse effects (OR 4.18, 95% CI 0.19 to 89.48; 1 study; 90 participants; low-certainty evidence).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0026691---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11889996",
-              "object": "MONDO:0012727",
-              "publications": [
-                "PMID:15965549",
-                "PMID:19504733",
-                "PMID:25342092",
-                "PMID:25518413",
-                "PMID:26594091",
-                "PMID:27743415",
-                "PMID:28343657",
-                "PMID:30337183",
-                "PMID:33341911",
-                "PMID:34895290",
-                "PMID:36695415"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318915,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005363",
-          "name": "focal segmental glomerulosclerosis",
-          "description": "A renal disorder characterized by sclerotic lesions in the glomeruli. Causes include drugs, viruses, and malignancies (lymphomas), or it may be idiopathic. It presents with asymptomatic proteinuria or nephritic syndrome and it may lead to renal failure.; A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.; Segmental accumulation of scar tissue in individual (but not all) glomeruli. [Eurenomics:fschaefer, PMID:16164633]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:236403004",
-            "HP:0000097",
-            "UMLS:C0017668",
-            "UMLS:CN043606",
-            "EFO:0004236",
-            "MESH:D005923",
-            "NCIT:C37308",
-            "DOID:1312",
-            "SNOMEDCT:25821008",
-            "OMIM.PS:603278",
-            "MONDO:0005363",
-            "MEDDRA:10067757",
-            "MEDDRA:10065581",
-            "OMIM:PS603278",
-            "MEDDRA:10016832",
-            "MONDO:0100313"
-          ],
-          "id": "MONDO:0005363",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Glomerulosclerosis, Focal Segmental",
-            "Focal Segmental Glomerulosclerosis",
-            "inherited focal segmental glomerulosclerosis",
-            "Focal glomerulosclerosis",
-            "Focal segmental glomerulosclerosis",
-            "focal segmental glomerulosclerosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:16164633"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318915,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005363",
-              "name": "focal segmental glomerulosclerosis",
-              "description": "A renal disorder characterized by sclerotic lesions in the glomeruli. Causes include drugs, viruses, and malignancies (lymphomas), or it may be idiopathic. It presents with asymptomatic proteinuria or nephritic syndrome and it may lead to renal failure.; A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.; Segmental accumulation of scar tissue in individual (but not all) glomeruli. [Eurenomics:fschaefer, PMID:16164633]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:236403004",
-                "HP:0000097",
-                "UMLS:C0017668",
-                "UMLS:CN043606",
-                "EFO:0004236",
-                "MESH:D005923",
-                "NCIT:C37308",
-                "DOID:1312",
-                "SNOMEDCT:25821008",
-                "OMIM.PS:603278",
-                "MONDO:0005363",
-                "MEDDRA:10067757",
-                "MEDDRA:10065581",
-                "OMIM:PS603278",
-                "MEDDRA:10016832",
-                "MONDO:0100313"
-              ],
-              "id": "MONDO:0005363",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Glomerulosclerosis, Focal Segmental",
-                "Focal Segmental Glomerulosclerosis",
-                "inherited focal segmental glomerulosclerosis",
-                "Focal glomerulosclerosis",
-                "Focal segmental glomerulosclerosis",
-                "focal segmental glomerulosclerosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:16164633"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11561195,
-            "start": 568,
-            "end": 318915,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15879445': {'publication date': '2005 Jun', 'sentence': 'RESULTS: Of 136 patients with primary FSGS and nephrotic range proteinuria, 76 (56%) were treated with prednisolone and of this group, 59% were treated with additional immunosuppression.', 'subject score': 1000, 'object score': 916}, 'PMID:16429835': {'publication date': '2006 Jan', 'sentence': 'All patients with minor glomerular abnormalities at the nephrotic stage received prednisolone for 6 months, and all FGS patients received some form of immunosuppression therapy with prednisolone, cyclophosphamide or mizoribine for 12 months.', 'subject score': 1000, 'object score': 901}, 'PMID:23461215': {'publication date': '2013', 'sentence': 'These findings were consistent with FSGS, and she was treated with mycophenolate mofetil (MMF) in combination with PSL instead of CsA, which greatly reduced her proteinuria.', 'subject score': 1000, 'object score': 1000}, 'PMID:8018488': {'publication date': '1994 Apr', 'sentence': 'They were divided into groups according to renal pathology: (1) steroid-sensitive NS (SSNS) not receiving prednisolone therapy, (2) SSNS on prednisolone, (3) focal segmental glomerulosclerosis (FSGS), (4) SSNS in remission and not receiving prednisolone therapy, (5) congenital NS (CNS).', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0017668---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11813573",
-              "object": "MONDO:0005363",
-              "publications": [
-                "PMID:15879445",
-                "PMID:16429835",
-                "PMID:23461215",
-                "PMID:8018488"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 312713,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-          "name": "congenital adrenal hyperplasia",
-          "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:237751000",
-            "DOID:12255",
-            "NCIT:C34360",
-            "ORPHANET:418",
-            "MONDO:0018479",
-            "MEDDRA:10010323",
-            "ICD9:255.2",
-            "DOID:0050811",
-            "HP:0008258",
-            "UMLS:C0001627",
-            "UMLS:C0701163",
-            "ICD10:E25",
-            "MESH:D000312"
-          ],
-          "id": "MONDO:0018479",
-          "category": "biolink:Disease",
-          "all_names": [
-            "congenital adrenal hyperplasia",
-            "obsolete congenital adrenal hyperplasia",
-            "Adrenogenital disorders",
-            "Adrenogenital disorder",
-            "Congenital adrenal hyperplasia",
-            "Adrenal Hyperplasia, Congenital",
-            "obsolete_congenital adrenal hyperplasia",
-            "Congenital Adrenal Hyperplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-            "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-            "http://omim.org/entry/201710",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312713,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-              "name": "congenital adrenal hyperplasia",
-              "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:237751000",
-                "DOID:12255",
-                "NCIT:C34360",
-                "ORPHANET:418",
-                "MONDO:0018479",
-                "MEDDRA:10010323",
-                "ICD9:255.2",
-                "DOID:0050811",
-                "HP:0008258",
-                "UMLS:C0001627",
-                "UMLS:C0701163",
-                "ICD10:E25",
-                "MESH:D000312"
-              ],
-              "id": "MONDO:0018479",
-              "category": "biolink:Disease",
-              "all_names": [
-                "congenital adrenal hyperplasia",
-                "obsolete congenital adrenal hyperplasia",
-                "Adrenogenital disorders",
-                "Adrenogenital disorder",
-                "Congenital adrenal hyperplasia",
-                "Adrenal Hyperplasia, Congenital",
-                "obsolete_congenital adrenal hyperplasia",
-                "Congenital Adrenal Hyperplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-                "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-                "http://omim.org/entry/201710",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11558374,
-            "start": 568,
-            "end": 312713,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15876756': {'publication date': '2005 Apr', 'sentence': 'METHODS: Growth parameters of twelve children (8 m, 4 f) with congenital adrenal hyperplasia were retrospectively studied while on treatment with prednisolone (PR) earlier and then hydrocortisone (HC) after it became freely available in India.', 'subject score': 1000, 'object score': 1000}, 'PMID:22180995': {'publication date': '2011', 'sentence': 'CASE: We report the case of a 23-years-old female with the classic Congenital Adrenal Hyperplasia (CAH) from birth, diagnosed due to genital pigmentation, clitoromegaly and salt-wasting crisis, treated with glucocorticoid replacement (hydrocortisone, fludrocortisone and NaCI), followed by genital surgery, until the adult life when she continues treatment with fludrocortisone and prednisolone.', 'subject score': 1000, 'object score': 916}, 'PMID:29694951': {'publication date': '2018', 'sentence': 'We discuss this case based on the differential diagnosis of complete adrenal cortex failure including other genetic causes in addition to CAH, prednisolone treatment, autoimmune adrenalitis, adrenoleukodystrophy, CMV infection, and adrenal hemorrhage infarction.', 'subject score': 888, 'object score': 1000}, 'PMID:31532828': {'publication date': '2019 Sep 18', 'sentence': 'All AD patients and 42% of CAH patients were prescribed glucocorticoids, most frequently hydrocortisone in AD (82%) and prednisolone in CAH (50%).', 'subject score': 1000, 'object score': 1000}, 'PMID:33845451': {'publication date': '2021 Mar 31', 'sentence': 'We present the case of a 50-year-old man, with a classical form of congenital adrenal hyperplasia (CAH), which was well treated with prednisolone and fludrocortisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:6538545': {'publication date': '1984', 'sentence': 'Saliva 17OHP profiles provided valuable information on the efficacy of hydrocortisone, cortisone acetate, prednisolone and dexamethasone as glucocorticoid suppressive regimes in the treatment of CAH.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0001627---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11810617",
-              "object": "MONDO:0018479",
-              "publications": [
-                "PMID:15876756",
-                "PMID:22180995",
-                "PMID:29694951",
-                "PMID:31532828",
-                "PMID:33845451",
-                "PMID:6538545"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317343,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0003085",
-          "name": "keratitis",
-          "description": "A corneal disease that is characterized by inflammation of the cornea.",
-          "equivalent_curies": [
-            "DOID:4677",
-            "MEDDRA:10045988",
-            "HP:0000491",
-            "MEDDRA:10011023",
-            "MEDDRA:10023332",
-            "MESH:D007634",
-            "UMLS:C0022568",
-            "MEDDRA:10023346",
-            "SNOMEDCT:5888003",
-            "NCIT:C26805",
-            "MEDDRA:10023336",
-            "ICD10:H16",
-            "MEDDRA:10021953",
-            "SYMP:0000314",
-            "ICD9:370",
-            "MONDO:0003085",
-            "EFO:0009449"
-          ],
-          "id": "MONDO:0003085",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Keratitis",
-            "keratitis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.mayoclinic.org/diseases-conditions/keratitis/basics/definition/con-20035288",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317343,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0003085",
-              "name": "keratitis",
-              "description": "A corneal disease that is characterized by inflammation of the cornea.",
-              "equivalent_curies": [
-                "DOID:4677",
-                "MEDDRA:10045988",
-                "HP:0000491",
-                "MEDDRA:10011023",
-                "MEDDRA:10023332",
-                "MESH:D007634",
-                "UMLS:C0022568",
-                "MEDDRA:10023346",
-                "SNOMEDCT:5888003",
-                "NCIT:C26805",
-                "MEDDRA:10023336",
-                "ICD10:H16",
-                "MEDDRA:10021953",
-                "SYMP:0000314",
-                "ICD9:370",
-                "MONDO:0003085",
-                "EFO:0009449"
-              ],
-              "id": "MONDO:0003085",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Keratitis",
-                "keratitis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.mayoclinic.org/diseases-conditions/keratitis/basics/definition/con-20035288",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11550789,
-            "start": 568,
-            "end": 317343,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1587148': {'publication date': '1992 Mar', 'sentence': 'Ciprofloxacin and prednisolone therapy for experimental Pseudomonas keratitis.', 'subject score': 888, 'object score': 851}, 'PMID:7796606': {'publication date': '1995 Mar', 'sentence': 'Ciprofloxacin and prednisolone, but not an aminoglycoside and dexamethasone, were previously found to be effective in killing bacteria and reducing inflammation for the treatment of Pseudomonas keratitis.', 'subject score': 1000, 'object score': 888}, 'PMID:8239596': {'publication date': '1993 Sep', 'sentence': 'Age and therapeutic outcome of experimental Pseudomonas aeruginosa keratitis treated with ciprofloxacin, prednisolone, and flurbiprofen.', 'subject score': 1000, 'object score': 861}, 'PMID:8344070': {'publication date': '1993 May', 'sentence': 'This study was conducted to determine the therapeutic efficacy of 3.0 mg/ml ciprofloxacin administered concurrently with one of two salts of prednisolone for the treatment of experimental pseudomonal keratitis.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0022568---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11808057",
-              "object": "MONDO:0003085",
-              "publications": [
-                "PMID:1587148",
-                "PMID:7796606",
-                "PMID:8239596",
-                "PMID:8344070"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320151,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-          "name": "dermatitis, atopic",
-          "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MESH:C566404",
-            "MEDDRA:10012434",
-            "SNOMEDCT:24079001",
-            "MONDO:0011292",
-            "MEDDRA:10003641",
-            "MONDO:0100181",
-            "MEDDRA:10014191",
-            "OMIM:603165",
-            "HP:0001047",
-            "MEDDRA:10001711",
-            "MEDDRA:10003639",
-            "UMLS:C0011615",
-            "UMLS:C4280605",
-            "UMLS:C1864155",
-            "MEDDRA:10012438",
-            "MEDDRA:10014188",
-            "MEDDRA:10001712",
-            "MESH:D003876",
-            "SNOMEDCT:200775004"
-          ],
-          "id": "MONDO:0011292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis, Atopic, 1",
-            "dermatitis, atopic",
-            "Dermatitis, Atopic",
-            "Baby eczema",
-            "Dermatitis, atopic related phenotypic feature",
-            "Atopic dermatitis",
-            "dermatitis, atopic, 1"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:27904186",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320151,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-              "name": "dermatitis, atopic",
-              "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MESH:C566404",
-                "MEDDRA:10012434",
-                "SNOMEDCT:24079001",
-                "MONDO:0011292",
-                "MEDDRA:10003641",
-                "MONDO:0100181",
-                "MEDDRA:10014191",
-                "OMIM:603165",
-                "HP:0001047",
-                "MEDDRA:10001711",
-                "MEDDRA:10003639",
-                "UMLS:C0011615",
-                "UMLS:C4280605",
-                "UMLS:C1864155",
-                "MEDDRA:10012438",
-                "MEDDRA:10014188",
-                "MEDDRA:10001712",
-                "MESH:D003876",
-                "SNOMEDCT:200775004"
-              ],
-              "id": "MONDO:0011292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis, Atopic, 1",
-                "dermatitis, atopic",
-                "Dermatitis, Atopic",
-                "Baby eczema",
-                "Dermatitis, atopic related phenotypic feature",
-                "Atopic dermatitis",
-                "dermatitis, atopic, 1"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:27904186",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11280531,
-            "start": 568,
-            "end": 320151,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15552608': {'publication date': '2004 Sep-Oct', 'sentence': 'Prednicarbate is a non-halogenated, double-ester derivative of prednisolone that has become of interest for the treatment of inflammatory skin diseases, for example atopic dermatitis.', 'subject score': 1000, 'object score': 901}, 'PMID:22141403': {'publication date': '2012 Apr', 'sentence': 'Additional studies are required to establish whether vitamin D has a synergistic therapeutic effect with prednisolone in dogs with atopic dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:22143560': {'publication date': '2011', 'sentence': 'OBJECTIVE: Prednisolone and antihistamines are highly potent drugs in the treatment of atopic dermatitis and widely used in humans and dogs.', 'subject score': 1000, 'object score': 1000}, 'PMID:24004561': {'publication date': '2013 Sep 03', 'sentence': 'BACKGROUND: A randomized, unmasked, multicenter study was conducted to evaluate the rate of pruritus reduction and improvement in clinical scoring by cyclosporine A (5 mg/kg orally, once daily for 28 days) either alone (n = 25 dogs) or with concurrent prednisolone (1 mg/kg once daily for 7 days, followed by alternate dosing for 14 days; n = 23 dogs) for the treatment of atopic dermatitis in dogs.', 'subject score': 888, 'object score': 1000}, 'PMID:26711698': {'publication date': '2016 Jan-Feb', 'sentence': 'In severe atopic dermatitis the increased expression of GRbeta mRNA is not connected to insensitivity against prednisolone treatment.', 'subject score': 888, 'object score': 901}, 'PMID:30633387': {'publication date': '2019 Jun', 'sentence': 'The use of prednisolone and other systemic anti-inflammatory therapy was substantially higher in adults with AD than in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:31339769': {'publication date': '2019 Aug', 'sentence': 'CONCLUSIONS AND CLINICAL RELEVANCE: Results indicated short-term oral administration of anti-inflammatory dosages of prednisolone did not cause relevant hemodynamic, echocardiographic, or diabetogenic effects in systemically normal cats with allergic dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:32945018': {'publication date': '2020 Sep 17', 'sentence': 'Serum TARC concentrations also were measured in 20 dogs with cAD treated with prednisolone or oclacitinib for four weeks.', 'subject score': 1000, 'object score': 901}, 'PMID:36330780': {'publication date': '2022 Nov 04', 'sentence': 'A randomised controlled trial testing the rebound-preventing benefit of four days of prednisolone during the induction of oclacitinib therapy in dogs with atopic dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:5454467': {'publication date': '1970 Jul 05', 'sentence': '[Steroid-induced peptic ulcer following prednisolone therapy of allergic dermatitis].', 'subject score': 888, 'object score': 1000}, 'PMID:8135003': {'publication date': '1994 Jan 08', 'sentence': 'Combined treatment with concentrated essential fatty acids and prednisolone in the management of canine atopy.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0011615---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11527350",
-              "object": "MONDO:0011292",
-              "publications": [
-                "PMID:15552608",
-                "PMID:22141403",
-                "PMID:22143560",
-                "PMID:24004561",
-                "PMID:26711698",
-                "PMID:30633387",
-                "PMID:31339769",
-                "PMID:32945018",
-                "PMID:36330780",
-                "PMID:5454467",
-                "PMID:8135003"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319192,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-          "name": "kidney disorder",
-          "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D007674",
-            "MEDDRA:10029154",
-            "UMLS:C0022658",
-            "NCIT:C3149",
-            "MONDO:0005240",
-            "UMLS:C1408258",
-            "DOID:557",
-            "MEDDRA:10029149",
-            "HP:0000112",
-            "MEDDRA:10051051",
-            "NCIT:C34843",
-            "MEDDRA:10038428",
-            "MEDDRA:10038429",
-            "MEDDRA:10029151",
-            "MEDDRA:10051052",
-            "EFO:0003086",
-            "SNOMEDCT:90708001",
-            "MEDDRA:10013263",
-            "PSY:27347"
-          ],
-          "id": "MONDO:0005240",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Kidney damage",
-            "kidney disease",
-            "Nephropathy",
-            "Kidney Diseases",
-            "Kidney Disorder",
-            "kidney disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319192,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-              "name": "kidney disorder",
-              "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D007674",
-                "MEDDRA:10029154",
-                "UMLS:C0022658",
-                "NCIT:C3149",
-                "MONDO:0005240",
-                "UMLS:C1408258",
-                "DOID:557",
-                "MEDDRA:10029149",
-                "HP:0000112",
-                "MEDDRA:10051051",
-                "NCIT:C34843",
-                "MEDDRA:10038428",
-                "MEDDRA:10038429",
-                "MEDDRA:10029151",
-                "MEDDRA:10051052",
-                "EFO:0003086",
-                "SNOMEDCT:90708001",
-                "MEDDRA:10013263",
-                "PSY:27347"
-              ],
-              "id": "MONDO:0005240",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Kidney damage",
-                "kidney disease",
-                "Nephropathy",
-                "Kidney Diseases",
-                "Kidney Disorder",
-                "kidney disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11279559,
-            "start": 568,
-            "end": 319192,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15550753': {'publication date': '2004', 'sentence': 'AIM: To evaluate the efficacy of prednisolone, warfarin, and dipyridamole therapy combined with mizoribine (PWDM) in the treatment of diffuse immunoglobulin A (IgA) nephropathy in comparison with prednisolone, warfarin, and dipyridamole therapy without mizoribine (PWD) and with methylprednisolone pulse therapy (PWD pulse).', 'subject score': 1000, 'object score': 861}, 'PMID:18224343': {'publication date': '2008 May', 'sentence': 'In two previous randomized controlled trials we showed that treatment of severe childhood immunoglobulin A nephropathy (IgA-N) using prednisolone, azathioprine, heparin-warfarin, and dipyridamole prevented any increase of sclerosed glomeruli and that prednisolone alone did not prevent a further increase of sclerosed glomeruli.', 'subject score': 1000, 'object score': 840}, 'PMID:23845696': {'publication date': '2013 Oct', 'sentence': 'There is no consensus as to whether treatment with prednisolone at presentation can prevent or ameliorate the progression of nephropathy in HSP.', 'subject score': 1000, 'object score': 1000}, 'PMID:26877967': {'publication date': '2014 Sep', 'sentence': 'After renal histological examination confirmed nephropathy, treatment with prednisolone and cyclosporine was initiated, which was maintained for over 1 year.', 'subject score': 1000, 'object score': 1000}, 'PMID:27152293': {'publication date': '2016 Apr', 'sentence': 'PATIENTS AND METHODS: Seventy-five patients with IgAN and proteinuria > 1 g/day and treated with prednisolone were divided into two groups: those with low (<=20/high-power field [HPF]) urinary red blood cell (U-RBC) counts (L-RBC group, n=55) and those with high (>20/HPF) U-RBC counts (H-RBC group, n=20).', 'subject score': 1000, 'object score': 901}, 'PMID:29987456': {'publication date': '2018 Jul 09', 'sentence': 'BACKGROUND: Two previous randomized controlled trials showed that treatment of severe childhood immunoglobulin A (IgA) nephropathy using prednisolone with azathioprine, heparin-warfarin, or dipyridamole prevented the increase of sclerosed glomeruli.', 'subject score': 1000, 'object score': 840}, 'PMID:35711019': {'publication date': '2022 Jun 16', 'sentence': 'Based on these findings, she was diagnosed with IgG nephropathy and treated with prednisolone.', 'subject score': 1000, 'object score': 901}, 'PMID:7997131': {'publication date': '1994', 'sentence': 'He received prednisolone with amelioration of the renal disorder, but consulted again some months later because of fever, marked weight loss, generalized enlargement of superficial lymph nodes, autoimmune hemolytic anemia and polyclonal hypergammaglobulinemia.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0022658---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11526277",
-              "object": "MONDO:0005240",
-              "publications": [
-                "PMID:15550753",
-                "PMID:18224343",
-                "PMID:23845696",
-                "PMID:26877967",
-                "PMID:27152293",
-                "PMID:29987456",
-                "PMID:35711019",
-                "PMID:7997131"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 311498,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005047",
-          "name": "infertility disorder",
-          "description": "Inability to conceive for at least one year after trying and having unprotected sex. Causes of female infertility include endometriosis, fallopian tubes obstruction, and polycystic ovary syndrome. Causes of male infertility include abnormal sperm production or function, blockage of the epididymis, blockage of the ejaculatory ducts, hypospadias, exposure to pesticides, and health related issues. // COMMENTS: Editor note: dubious as to whether this is a disease as defined, check with clingen before obsoleting",
-          "equivalent_curies": [
-            "UMLS:C4074771",
-            "MEDDRA:10021930",
-            "DOID:5223",
-            "SYMP:0000712",
-            "EFO:0000545",
-            "UMLS:C0021359",
-            "MESH:D007246",
-            "MONDO:0005047",
-            "NCIT:C3836",
-            "UMLS:C1533568",
-            "MEDDRA:10042012",
-            "HP:0000789",
-            "PSY:25210",
-            "SNOMEDCT:15296000",
-            "PDQ:CDR0000726658",
-            "SNOMEDCT:8619003",
-            "MEDDRA:10021926"
-          ],
-          "id": "MONDO:0005047",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infertility",
-            "infertility",
-            "Fertility Disorders",
-            "infertility disorder",
-            "Sterility, Reproductive"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:DiseaseOrPhenotypicFeature",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/infertility"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311498,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005047",
-              "name": "infertility disorder",
-              "description": "Inability to conceive for at least one year after trying and having unprotected sex. Causes of female infertility include endometriosis, fallopian tubes obstruction, and polycystic ovary syndrome. Causes of male infertility include abnormal sperm production or function, blockage of the epididymis, blockage of the ejaculatory ducts, hypospadias, exposure to pesticides, and health related issues. // COMMENTS: Editor note: dubious as to whether this is a disease as defined, check with clingen before obsoleting",
-              "equivalent_curies": [
-                "UMLS:C4074771",
-                "MEDDRA:10021930",
-                "DOID:5223",
-                "SYMP:0000712",
-                "EFO:0000545",
-                "UMLS:C0021359",
-                "MESH:D007246",
-                "MONDO:0005047",
-                "NCIT:C3836",
-                "UMLS:C1533568",
-                "MEDDRA:10042012",
-                "HP:0000789",
-                "PSY:25210",
-                "SNOMEDCT:15296000",
-                "PDQ:CDR0000726658",
-                "SNOMEDCT:8619003",
-                "MEDDRA:10021926"
-              ],
-              "id": "MONDO:0005047",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infertility",
-                "infertility",
-                "Fertility Disorders",
-                "infertility disorder",
-                "Sterility, Reproductive"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:DiseaseOrPhenotypicFeature",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/infertility"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11251310,
-            "start": 568,
-            "end": 311498,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1551969': {'publication date': '1992 Jan', 'sentence': \"In this double blind cross-over study, 20 infertile men, who had sperm antibodies detected by the mixed antiglobulin reaction (MAR test) in the ejaculate and by the tray agglutination test (TAT) in serum, were treated with 40 mg/day prednisolone or placebo from days 1 to 10 of the partners' menstrual cycle.\", 'subject score': 833, 'object score': 790}, 'PMID:2056224': {'publication date': '1991 May', 'sentence': 'In addition, the effect of prednisolone as a treatment of infertility caused by endometriosis was evaluated in animal experiments.', 'subject score': 1000, 'object score': 1000}, 'PMID:27591233': {'publication date': '2016 10', 'sentence': 'There is ongoing interest in immune-suppressant corticosteroid drugs such as prednisolone to treat infertility in women with repeated IVF failure and recurrent miscarriage.', 'subject score': 1000, 'object score': 1000}, 'PMID:8876264': {'publication date': '1996 Jun', 'sentence': 'Twenty infertile men, positive for antisperm antibodies by the mixed antiglobulin reaction (MAR) test, were treated with either 20 mg/day prednisolone (n = 10) or placebo (n = 10) for 3 weeks.', 'subject score': 736, 'object score': 790}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0021359---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11497678",
-              "object": "MONDO:0005047",
-              "publications": [
-                "PMID:1551969",
-                "PMID:2056224",
-                "PMID:27591233",
-                "PMID:8876264"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319116,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008315",
-          "name": "prostate cancer",
-          "description": "A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.; Tumors or cancer of the PROSTATE.; A cancer of the prostate. [HPO:probinson]; What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it:  Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to:  Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer.    What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include:  Problems urinating (peeing), such as:  A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen   Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm)  But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you:  Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer  What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include:  A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate.  If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options:  Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation:  Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer.   Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer.  Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include:  Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0008315",
-            "ICD10:C61",
-            "MEDDRA:10026389",
-            "MEDDRA:10007113",
-            "DOID:10283",
-            "MEDDRA:10036908",
-            "UMLS:C0376358",
-            "SNOMEDCT:399068003",
-            "ICD9:185",
-            "PDQ:CDR0000038782",
-            "MEDDRA:10036910",
-            "MEDDRA:10036946",
-            "KEGG.DISEASE:05215",
-            "NCIT:C7378",
-            "MESH:D011471",
-            "HP:0012125",
-            "MEDDRA:10060862"
-          ],
-          "id": "MONDO:0008315",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Malignant Prostate Neoplasm",
-            "prostate cancer",
-            "Prostate cancer",
-            "Prostatic Neoplasms",
-            "Malignant neoplasm of prostate"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=445079",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319116,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008315",
-              "name": "prostate cancer",
-              "description": "A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.; Tumors or cancer of the PROSTATE.; A cancer of the prostate. [HPO:probinson]; What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it:  Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to:  Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer.    What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include:  Problems urinating (peeing), such as:  A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen   Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm)  But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you:  Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer  What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include:  A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate.  If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options:  Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation:  Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer.   Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer.  Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include:  Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0008315",
-                "ICD10:C61",
-                "MEDDRA:10026389",
-                "MEDDRA:10007113",
-                "DOID:10283",
-                "MEDDRA:10036908",
-                "UMLS:C0376358",
-                "SNOMEDCT:399068003",
-                "ICD9:185",
-                "PDQ:CDR0000038782",
-                "MEDDRA:10036910",
-                "MEDDRA:10036946",
-                "KEGG.DISEASE:05215",
-                "NCIT:C7378",
-                "MESH:D011471",
-                "HP:0012125",
-                "MEDDRA:10060862"
-              ],
-              "id": "MONDO:0008315",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Malignant Prostate Neoplasm",
-                "prostate cancer",
-                "Prostate cancer",
-                "Prostatic Neoplasms",
-                "Malignant neoplasm of prostate"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=445079",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11129413,
-            "start": 568,
-            "end": 319116,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15333686': {'publication date': '2004 Jun', 'sentence': 'BACKGROUND: We conducted this retrospective study to analyze a modified dose schedule of mitoxantrone and prednisolone (MP) in patients with androgen-independent prostate cancer.', 'subject score': 763, 'object score': 861}, 'PMID:18544992': {'publication date': '2008', 'sentence': 'Taxotere plus prednisolone is recommended as systemic standard treatment in androgen-independent prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:22936562': {'publication date': '2013 Oct', 'sentence': 'Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:24736579': {'publication date': '2014 May 13', 'sentence': 'Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.', 'subject score': 861, 'object score': 861}, 'PMID:25457497': {'publication date': '2015 04', 'sentence': 'BACKGROUND: Prednisolone is widely used as secondary hormonal treatment for castration-resistant prostate cancer (CRPC).', 'subject score': 1000, 'object score': 861}, 'PMID:25862824': {'publication date': '2015 Jul', 'sentence': 'In this study, we evaluated the efficacy and safety of docetaxel and prednisolone in patients with castration-resistant prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:25981653': {'publication date': '2015 May', 'sentence': '[Risk factors for predicting severe leukopenia induced by docetaxel plus prednisolone in patients with Castration-Resistant Prostate cancer].', 'subject score': 851, 'object score': 861}, 'PMID:26962246': {'publication date': '2016 Mar 08', 'sentence': 'We conducted a Phase II trial to evaluate the outcome of intermittent docetaxel and prednisolone therapy in castration-resistant prostate cancer.', 'subject score': 888, 'object score': 861}, 'PMID:30738780': {'publication date': '2019 Mar', 'sentence': 'INTERPRETATION: The addition of radium-223 to abiraterone acetate plus prednisone or prednisolone did not improve symptomatic skeletal event-free survival in patients with castration-resistant prostate cancer and bone metastases, and was associated with an increased frequency of bone fractures compared with placebo.', 'subject score': 1000, 'object score': 861}, 'PMID:31358379': {'publication date': '2019 Nov', 'sentence': 'Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0376358---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11373326",
-              "object": "MONDO:0008315",
-              "publications": [
-                "PMID:15333686",
-                "PMID:18544992",
-                "PMID:22936562",
-                "PMID:24736579",
-                "PMID:25457497",
-                "PMID:25862824",
-                "PMID:25981653",
-                "PMID:26962246",
-                "PMID:30738780",
-                "PMID:31358379"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 311935,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005318",
-          "name": "canker sore",
-          "description": "A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval, lasting for 7-14 days and healing without scarring.; A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval. Two to eight crops of lesions occur per year, lasting for 7 to 14 days and then heal without scarring. (From Jablonski's Dictionary of Dentistry, 1992, p742); Recurrent episodes of ulceration of the oral mucosa, typically presenting as painful, sharply circumscribed fibrin-covered mucosal defects with a hyperemic border. [HPO:probinson]; Oral aphthous ulcers typically present as painful, sharply circumscribed fibrin-covered mucosal defects with a hyperemic border. [PMID:25346356]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:722781002",
-            "MEDDRA:10042131",
-            "MEDDRA:10002959",
-            "UMLS:C2937365",
-            "SNOMEDCT:426965005",
-            "SNOMEDCT:427617000",
-            "UMLS:C1959869",
-            "NCIT:C62546",
-            "MONDO:0005318",
-            "SNOMEDCT:398870000",
-            "MEDDRA:10007166",
-            "MEDDRA:10045287",
-            "MEDDRA:10002958",
-            "MESH:D013281",
-            "UMLS:C0038363",
-            "MEDDRA:10066577",
-            "MEDDRA:10030960",
-            "SNOMEDCT:110426005",
-            "MEDDRA:10067589",
-            "MEDDRA:10084265",
-            "HP:0011107",
-            "MEDDRA:10045372",
-            "MEDDRA:10045288"
-          ],
-          "id": "MONDO:0005318",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Stomatitis, Aphthous",
-            "canker sore",
-            "Canker Sore",
-            "Aphthous ulceration of skin and/or mucous membrane (disorder)",
-            "Recurrent aphthous stomatitis",
-            "Aphthous Stomatitis",
-            "Recurrent aphthous ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:25346356",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311935,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005318",
-              "name": "canker sore",
-              "description": "A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval, lasting for 7-14 days and healing without scarring.; A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval. Two to eight crops of lesions occur per year, lasting for 7 to 14 days and then heal without scarring. (From Jablonski's Dictionary of Dentistry, 1992, p742); Recurrent episodes of ulceration of the oral mucosa, typically presenting as painful, sharply circumscribed fibrin-covered mucosal defects with a hyperemic border. [HPO:probinson]; Oral aphthous ulcers typically present as painful, sharply circumscribed fibrin-covered mucosal defects with a hyperemic border. [PMID:25346356]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:722781002",
-                "MEDDRA:10042131",
-                "MEDDRA:10002959",
-                "UMLS:C2937365",
-                "SNOMEDCT:426965005",
-                "SNOMEDCT:427617000",
-                "UMLS:C1959869",
-                "NCIT:C62546",
-                "MONDO:0005318",
-                "SNOMEDCT:398870000",
-                "MEDDRA:10007166",
-                "MEDDRA:10045287",
-                "MEDDRA:10002958",
-                "MESH:D013281",
-                "UMLS:C0038363",
-                "MEDDRA:10066577",
-                "MEDDRA:10030960",
-                "SNOMEDCT:110426005",
-                "MEDDRA:10067589",
-                "MEDDRA:10084265",
-                "HP:0011107",
-                "MEDDRA:10045372",
-                "MEDDRA:10045288"
-              ],
-              "id": "MONDO:0005318",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Stomatitis, Aphthous",
-                "canker sore",
-                "Canker Sore",
-                "Aphthous ulceration of skin and/or mucous membrane (disorder)",
-                "Recurrent aphthous stomatitis",
-                "Aphthous Stomatitis",
-                "Recurrent aphthous ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:25346356",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10927139,
-            "start": 568,
-            "end": 311935,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15109274': {'publication date': '2004', 'sentence': 'It has also been used in combination with other drugs for treating a number of dermatologic disorders, e.g. in combination with cimetidine for treating recalcitrant warts, with prednisolone for treating lichen planus, erythema multiforme and aphthous ulcers of the mouth.', 'subject score': 1000, 'object score': 1000}, 'PMID:24822268': {'publication date': '2014 Apr', 'sentence': 'Levamisole and low-dose prednisolone in the treatment of   reccurent aphthous stomatitis.', 'subject score': 901, 'object score': 901}, 'PMID:6883599': {'publication date': '1983 Mar', 'sentence': 'Ointment-type oral mucosal dosage form of Carbopol containing prednisolone for treatment of aphtha.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0038363---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11166363",
-              "object": "MONDO:0005318",
-              "publications": [
-                "PMID:15109274",
-                "PMID:24822268",
-                "PMID:6883599"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 538013,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006572",
-          "name": "lichen planus",
-          "description": "A chronic, recurrent, pruritic inflammatory disorder of unknown etiology that affects the skin and mucus membranes. It presents with rashes and papules that tend to resolve spontaneously. It may be associated with hepatitis C. Certain drugs that contain arsenic or bismuth are associated with reactions mimicking lichen planus.; An inflammatory, pruritic disease of the skin and mucous membranes, which can be either generalized or localized. It is characterized by distinctive purplish, flat-topped papules having a predilection for the trunk and flexor surfaces. The lesions may be discrete or coalesce to form plaques. Histologically, there is a \"saw-tooth\" pattern of epidermal hyperplasia and vacuolar alteration of the basal layer of the epidermis along with an intense upper dermal inflammatory infiltrate composed predominantly of T-cells. Etiology is unknown.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10024429",
-            "ICD9:697.0",
-            "SNOMEDCT:4776004",
-            "UMLS:C0023646",
-            "MONDO:0006572",
-            "EFO:1000726",
-            "NCIT:C3189",
-            "MESH:D008010",
-            "DOID:9201",
-            "ICD10:L43"
-          ],
-          "id": "MONDO:0006572",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lichen planus",
-            "Lichen Planus",
-            "lichen planus"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/lichen_planus"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538013,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006572",
-              "name": "lichen planus",
-              "description": "A chronic, recurrent, pruritic inflammatory disorder of unknown etiology that affects the skin and mucus membranes. It presents with rashes and papules that tend to resolve spontaneously. It may be associated with hepatitis C. Certain drugs that contain arsenic or bismuth are associated with reactions mimicking lichen planus.; An inflammatory, pruritic disease of the skin and mucous membranes, which can be either generalized or localized. It is characterized by distinctive purplish, flat-topped papules having a predilection for the trunk and flexor surfaces. The lesions may be discrete or coalesce to form plaques. Histologically, there is a \"saw-tooth\" pattern of epidermal hyperplasia and vacuolar alteration of the basal layer of the epidermis along with an intense upper dermal inflammatory infiltrate composed predominantly of T-cells. Etiology is unknown.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10024429",
-                "ICD9:697.0",
-                "SNOMEDCT:4776004",
-                "UMLS:C0023646",
-                "MONDO:0006572",
-                "EFO:1000726",
-                "NCIT:C3189",
-                "MESH:D008010",
-                "DOID:9201",
-                "ICD10:L43"
-              ],
-              "id": "MONDO:0006572",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lichen planus",
-                "Lichen Planus",
-                "lichen planus"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/lichen_planus"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10927138,
-            "start": 568,
-            "end": 538013,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15109274': {'publication date': '2004', 'sentence': 'It has also been used in combination with other drugs for treating a number of dermatologic disorders, e.g. in combination with cimetidine for treating recalcitrant warts, with prednisolone for treating lichen planus, erythema multiforme and aphthous ulcers of the mouth.', 'subject score': 1000, 'object score': 901}, 'PMID:9798228': {'publication date': '1998 Oct', 'sentence': 'CONCLUSIONS: The addition of levamisole to prednisolone may produce improved results in the management of erosive lichen planus, erythema multiforme, mucous membrane pemphigoid, and early pemphigus vulgaris.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0023646---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11166362",
-              "object": "MONDO:0006572",
-              "publications": [
-                "PMID:15109274",
-                "PMID:9798228"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 524787,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006545",
-          "name": "erythema multiforme",
-          "description": "A hypersensitivity reaction characterized by the sudden appearance of symmetrical cutaneous and mucocutaneous macular or papular lesions which evolve into lesions with bright red borders (target lesions). The lesions usually appear in the hands, feet, extremities, and face. Symptoms include fever, malaise, sore throat, cough, vomiting, diarrhea, arthralgia, and myalgia. Causes include infections (most commonly herpes simplex virus), drugs (e.g., sulfonamides, anticonvulsants, and antibiotics), malignancies, and collagen vascular disorders.; A skin and mucous membrane disease characterized by an eruption of macules, papules, nodules, vesicles, and/or bullae with characteristic \"bull's-eye\" lesions usually occurring on the dorsal aspect of the hands and forearms.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:1000694",
-            "NCIT:C3024",
-            "MESH:D004892",
-            "SNOMEDCT:36715001",
-            "UMLS:C0014742",
-            "ICD9:695.1",
-            "DOID:0050185",
-            "MEDDRA:10057866",
-            "MEDDRA:10015218",
-            "MEDDRA:10057783",
-            "MONDO:0006545"
-          ],
-          "id": "MONDO:0006545",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Erythema multiforme",
-            "erythema multiforme",
-            "Erythema Multiforme"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000851.htm",
-            "https://rarediseases.info.nih.gov/diseases/6372/erythema-multiforme"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 524787,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006545",
-              "name": "erythema multiforme",
-              "description": "A hypersensitivity reaction characterized by the sudden appearance of symmetrical cutaneous and mucocutaneous macular or papular lesions which evolve into lesions with bright red borders (target lesions). The lesions usually appear in the hands, feet, extremities, and face. Symptoms include fever, malaise, sore throat, cough, vomiting, diarrhea, arthralgia, and myalgia. Causes include infections (most commonly herpes simplex virus), drugs (e.g., sulfonamides, anticonvulsants, and antibiotics), malignancies, and collagen vascular disorders.; A skin and mucous membrane disease characterized by an eruption of macules, papules, nodules, vesicles, and/or bullae with characteristic \"bull's-eye\" lesions usually occurring on the dorsal aspect of the hands and forearms.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:1000694",
-                "NCIT:C3024",
-                "MESH:D004892",
-                "SNOMEDCT:36715001",
-                "UMLS:C0014742",
-                "ICD9:695.1",
-                "DOID:0050185",
-                "MEDDRA:10057866",
-                "MEDDRA:10015218",
-                "MEDDRA:10057783",
-                "MONDO:0006545"
-              ],
-              "id": "MONDO:0006545",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Erythema multiforme",
-                "erythema multiforme",
-                "Erythema Multiforme"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000851.htm",
-                "https://rarediseases.info.nih.gov/diseases/6372/erythema-multiforme"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10927137,
-            "start": 568,
-            "end": 524787,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15109274': {'publication date': '2004', 'sentence': 'It has also been used in combination with other drugs for treating a number of dermatologic disorders, e.g. in combination with cimetidine for treating recalcitrant warts, with prednisolone for treating lichen planus, erythema multiforme and aphthous ulcers of the mouth.', 'subject score': 1000, 'object score': 1000}, 'PMID:9798228': {'publication date': '1998 Oct', 'sentence': 'CONCLUSIONS: The addition of levamisole to prednisolone may produce improved results in the management of erosive lichen planus, erythema multiforme, mucous membrane pemphigoid, and early pemphigus vulgaris.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0014742---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11166361",
-              "object": "MONDO:0006545",
-              "publications": [
-                "PMID:15109274",
-                "PMID:9798228"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 312686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-          "name": "adrenocortical insufficiency",
-          "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0405580",
-            "MEDDRA:10022460",
-            "ICD9:255.4",
-            "EFO:0009491",
-            "MEDDRA:10001367",
-            "MEDDRA:10020936",
-            "MONDO:0000004",
-            "MEDDRA:10020979",
-            "SNOMEDCT:237785004",
-            "SNOMEDCT:386584007",
-            "MEDDRA:10056485",
-            "MEDDRA:10082130",
-            "UMLS:C0001623",
-            "MEDDRA:10001344",
-            "MEDDRA:10001366",
-            "MEDDRA:10001334",
-            "DOID:10493",
-            "NCIT:C26691",
-            "HP:0000846",
-            "MEDDRA:10001335",
-            "MEDDRA:10001369",
-            "MEDDRA:10001342",
-            "MEDDRA:10001343",
-            "MESH:D000309",
-            "SNOMEDCT:111563005",
-            "MEDDRA:10011172",
-            "MEDDRA:10022461"
-          ],
-          "id": "MONDO:0000004",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortical hypofunction",
-            "Adrenocortical Insufficiency",
-            "adrenocortical insufficiency",
-            "Corticoadrenal insufficiency",
-            "Adrenal gland hypofunction",
-            "Adrenal Insufficiency",
-            "Adrenal insufficiency",
-            "Adrenal cortical hypofunction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:11443143"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-              "name": "adrenocortical insufficiency",
-              "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0405580",
-                "MEDDRA:10022460",
-                "ICD9:255.4",
-                "EFO:0009491",
-                "MEDDRA:10001367",
-                "MEDDRA:10020936",
-                "MONDO:0000004",
-                "MEDDRA:10020979",
-                "SNOMEDCT:237785004",
-                "SNOMEDCT:386584007",
-                "MEDDRA:10056485",
-                "MEDDRA:10082130",
-                "UMLS:C0001623",
-                "MEDDRA:10001344",
-                "MEDDRA:10001366",
-                "MEDDRA:10001334",
-                "DOID:10493",
-                "NCIT:C26691",
-                "HP:0000846",
-                "MEDDRA:10001335",
-                "MEDDRA:10001369",
-                "MEDDRA:10001342",
-                "MEDDRA:10001343",
-                "MESH:D000309",
-                "SNOMEDCT:111563005",
-                "MEDDRA:10011172",
-                "MEDDRA:10022461"
-              ],
-              "id": "MONDO:0000004",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortical hypofunction",
-                "Adrenocortical Insufficiency",
-                "adrenocortical insufficiency",
-                "Corticoadrenal insufficiency",
-                "Adrenal gland hypofunction",
-                "Adrenal Insufficiency",
-                "Adrenal insufficiency",
-                "Adrenal cortical hypofunction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:11443143"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10537886,
-            "start": 568,
-            "end": 312686,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14517528': {'publication date': '2003 Sep', 'sentence': 'Prednisolone in the treatment of adrenal insufficiency: a re-evaluation of relative potency.', 'subject score': 1000, 'object score': 1000}, 'PMID:22071646': {'publication date': '2011', 'sentence': 'The patient was known with Adrenal insufficiency and was treated optimally with fludrocortisone and prednisolone since seven years with no history of adrenal crisis.', 'subject score': 1000, 'object score': 1000}, 'PMID:27864317': {'publication date': '2017 Jan', 'sentence': 'Data on risk factors for cardiovascular disease in patients with AI treated with prednisolone are scarce, despite this condition being the predominant cause of excess mortality.', 'subject score': 1000, 'object score': 1000}, 'PMID:28877961': {'publication date': '2017 Oct', 'sentence': 'CONCLUSION: We demonstrate a high prevalence of adrenal insufficiency during ongoing low-dose prednisolone treatment.', 'subject score': 798, 'object score': 1000}, 'PMID:29018153': {'publication date': '2017 Nov', 'sentence': 'METHODS: Data from 82 patients on hydrocortisone and 64 patients on prednisolone for AI at Imperial College Healthcare NHS Trust were analysed.', 'subject score': 1000, 'object score': 1000}, 'PMID:31110731': {'publication date': '2019 May', 'sentence': 'Inadvertent treatment of hypoadrenalism with prednisolone in pemphigus: A case report.', 'subject score': 1000, 'object score': 1000}, 'PMID:31539081': {'publication date': '2019 Sep 20', 'sentence': 'Adrenal insufficiency in kidney transplant patients during low-dose prednisolone therapy: a cross-sectional case-control study.', 'subject score': 861, 'object score': 1000}, 'PMID:33449916': {'publication date': '2021 Jan 01', 'sentence': 'The use of prednisolone versus dual-release hydrocortisone in the treatment of hypoadrenalism.', 'subject score': 1000, 'object score': 1000}, 'PMID:33626793': {'publication date': '2016 Sep 01', 'sentence': 'METHODS: Using a newly developed ultra-performance liquid chromatography MS/MS method, prednisolone profiles in healthy volunteers and patients with adrenal insufficiency already treated with prednisolone were prospectively analyzed in a tertiary center.', 'subject score': 1000, 'object score': 1000}, 'PMID:7120877': {'publication date': '1982 Jul 01', 'sentence': 'The metabolic clearance rate of prednisolone was decreased (56.0+/-7.2 1/24 h/m2) in patients with adrenal insufficiency.', 'subject score': 1000, 'object score': 1000}, 'PMID:27269282': {'publication date': '2016 Jul 23', 'sentence': 'It was concluded that dogs with hypoadrenocorticism should be continued on prednisolone therapy until they are stabilised.', 'subject score': 888, 'object score': 1000}, 'PMID:29727896': {'publication date': '2018 Apr', 'sentence': 'OBJECTIVE: To examine the prednisolone and fludrocortisone dosages in dogs with primary hypoadrenocorticism after integrating endogenous ACTH (eACTH) determination into the surveillance regimen.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0001623---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0405580---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10782301",
-              "object": "MONDO:0000004",
-              "publications": [
-                "PMID:27269282",
-                "PMID:33626793",
-                "PMID:29018153",
-                "PMID:14517528",
-                "PMID:33449916",
-                "PMID:29727896",
-                "PMID:22071646",
-                "PMID:31110731",
-                "PMID:27864317",
-                "PMID:31539081",
-                "PMID:28877961",
-                "PMID:7120877"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 313237,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
-          "name": "atopic eczema",
-          "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SYMP:0000289",
-            "EFO:0000274",
-            "DOID:3310",
-            "HP:0000964",
-            "NCIT:C3001",
-            "UMLS:C0013595",
-            "MESH:D004485",
-            "MEDDRA:10014200",
-            "MEDDRA:10014206",
-            "MEDDRA:10012454",
-            "ICD10:L20",
-            "MEDDRA:10014184",
-            "OMIM.PS:603165",
-            "MEDDRA:10014209",
-            "PSY:15950",
-            "MONDO:0004980",
-            "OMIM:PS603165"
-          ],
-          "id": "MONDO:0004980",
-          "category": "biolink:Disease",
-          "all_names": [
-            "atopic dermatitis",
-            "atopic eczema",
-            "eczema",
-            "Eczema"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/atopic_dermatitis",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313237,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
-              "name": "atopic eczema",
-              "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SYMP:0000289",
-                "EFO:0000274",
-                "DOID:3310",
-                "HP:0000964",
-                "NCIT:C3001",
-                "UMLS:C0013595",
-                "MESH:D004485",
-                "MEDDRA:10014200",
-                "MEDDRA:10014206",
-                "MEDDRA:10012454",
-                "ICD10:L20",
-                "MEDDRA:10014184",
-                "OMIM.PS:603165",
-                "MEDDRA:10014209",
-                "PSY:15950",
-                "MONDO:0004980",
-                "OMIM:PS603165"
-              ],
-              "id": "MONDO:0004980",
-              "category": "biolink:Disease",
-              "all_names": [
-                "atopic dermatitis",
-                "atopic eczema",
-                "eczema",
-                "Eczema"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/atopic_dermatitis",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10526002,
-            "start": 568,
-            "end": 313237,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14465683': {'publication date': '1962 Aug', 'sentence': '[Results of prednisolone therapy of eczemas in very young and older infants].', 'subject score': 888, 'object score': 1000}, 'PMID:19863501': {'publication date': '2010 Mar', 'sentence': 'CONCLUSIONS: Ciclosporin is significantly more efficacious than prednisolone for severe adult eczema.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0013595---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10757066",
-              "object": "MONDO:0004980",
-              "publications": [
-                "PMID:14465683",
-                "PMID:19863501"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318533,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-          "name": "Headache",
-          "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10019211",
-            "PSY:22380",
-            "NCIT:C34661",
-            "MEDDRA:10019218",
-            "SNOMEDCT:25064002",
-            "UMLS:C0018681",
-            "MEDDRA:10019231",
-            "HP:0002315",
-            "MEDDRA:10033405",
-            "ICD9:784.0",
-            "MESH:D006261",
-            "SYMP:0000504",
-            "MEDDRA:10008013",
-            "MEDDRA:10019198"
-          ],
-          "id": "HP:0002315",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "headache",
-            "Headache"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-            "PMID:15304572",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318533,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002315",
-              "name": "Headache",
-              "description": "Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. [HPO:probinson, PMID:15304572]; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumor or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. // COMMENTS: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10019211",
-                "PSY:22380",
-                "NCIT:C34661",
-                "MEDDRA:10019218",
-                "SNOMEDCT:25064002",
-                "UMLS:C0018681",
-                "MEDDRA:10019231",
-                "HP:0002315",
-                "MEDDRA:10033405",
-                "ICD9:784.0",
-                "MESH:D006261",
-                "SYMP:0000504",
-                "MEDDRA:10008013",
-                "MEDDRA:10019198"
-              ],
-              "id": "HP:0002315",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "headache",
-                "Headache"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=headache",
-                "PMID:15304572",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10442569,
-            "start": 568,
-            "end": 318533,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1403016': {'publication date': '1992 Aug', 'sentence': \"We report a patient with neuro-Behcet's syndrome presenting with headache and personality change in whom CT and MRI brain imaging was normal, but regional cerebral blood flow imaging using single photon emission tomography with the tracer HMPAO showed extensive perfusion deficits which partially reversed after 3 months of prednisolone therapy.\", 'subject score': 888, 'object score': 1000}, 'PMID:16324176': {'publication date': '2005', 'sentence': 'Temporal arteritis was suspected and prednisolone started with prompt resolution of the headache, chin hypoesthesia, ESR, and CRP.', 'subject score': 1000, 'object score': 1000}, 'PMID:23076953': {'publication date': '2012 Oct 17', 'sentence': 'The corticosteroid (prednisolone) showed a benefit in shortening the median time to resolution of headaches (five days in the treatment group versus 13 days in the control group, P < 0.0001).', 'subject score': 1000, 'object score': 1000}, 'PMID:25687750': {'publication date': '2015 Feb 17', 'sentence': 'The corticosteroid (prednisolone) showed a benefit in shortening the median time to resolution of headaches (five days in the treatment group versus 13 days in the control group, P value < 0.0001).', 'subject score': 1000, 'object score': 1000}, 'PMID:31506102': {'publication date': '2019 Sep 11', 'sentence': 'A dose of 20 mg of prednisolone was administered and her polymyalgia and polyarthritis improved; however, her headache and ear occlusion persisted.', 'subject score': 1000, 'object score': 1000}, 'PMID:34507542': {'publication date': '2021 Sep 10', 'sentence': 'She had fever and headache with antiviral and antibiotic treatment for 2 weeks, and she had empirical anti-tuberculosis treatment and oral prednisolone therapy.', 'subject score': 851, 'object score': 1000}, 'PMID:36384900': {'publication date': '2022 Nov 16', 'sentence': 'He received methylprednisolone pulse therapy followed by prednisolone and methotrexate, which improved his headache.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0018681---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10671990",
-              "object": "HP:0002315",
-              "publications": [
-                "PMID:1403016",
-                "PMID:16324176",
-                "PMID:23076953",
-                "PMID:25687750",
-                "PMID:31506102",
-                "PMID:34507542",
-                "PMID:36384900"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320617,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002400",
-          "name": "synovitis",
-          "description": "Inflammation of a synovial membrane.; Inflammation of the SYNOVIAL MEMBRANE.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0039103",
-            "MESH:D013585",
-            "HP:0100769",
-            "SYMP:0000646",
-            "MEDDRA:10042868",
-            "MONDO:0002400",
-            "DOID:2703",
-            "EFO:0008997",
-            "NCIT:C50766",
-            "SNOMEDCT:416209007"
-          ],
-          "id": "MONDO:0002400",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Synovitis",
-            "synovitis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=synovitis",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://en.wikipedia.org/wiki/synovitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320617,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002400",
-              "name": "synovitis",
-              "description": "Inflammation of a synovial membrane.; Inflammation of the SYNOVIAL MEMBRANE.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0039103",
-                "MESH:D013585",
-                "HP:0100769",
-                "SYMP:0000646",
-                "MEDDRA:10042868",
-                "MONDO:0002400",
-                "DOID:2703",
-                "EFO:0008997",
-                "NCIT:C50766",
-                "SNOMEDCT:416209007"
-              ],
-              "id": "MONDO:0002400",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Synovitis",
-                "synovitis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=synovitis",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://en.wikipedia.org/wiki/synovitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10346473,
-            "start": 568,
-            "end": 320617,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13626361': {'publication date': '1959 Mar', 'sentence': 'Prednisolone (meticortelone) in treatment of epicondylitis; radiohumeral bursitis and radiohumeral synovitis.', 'subject score': 1000, 'object score': 861}, 'PMID:18311044': {'publication date': '2008 Feb', 'sentence': 'Methyl-prednisolone pulse therapy followed by 30 mg/day of PSL was instituted and the bullae were diminished with gradual improvement of IP and synovitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3978363': {'publication date': '1985 Feb', 'sentence': 'Five of the 12 were noted to have synovitis on presentation which was characteristically mild, pauci-articular and cleared quickly after commencing prednisolone therapy.', 'subject score': 790, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0039103---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10574410",
-              "object": "MONDO:0002400",
-              "publications": [
-                "PMID:13626361",
-                "PMID:18311044",
-                "PMID:3978363"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 541725,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001875",
-          "name": "epicondylitis",
-          "description": "inflammation of the lateral epicondyle.; A condition characterized by pain in or near the lateral humeral epicondyle or in the forearm extensor muscle mass as a result of unusual strain. It occurs due repetitive stresses on the elbow from activities such as tennis playing.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:1001887",
-            "SNOMEDCT:202855006",
-            "ICD9:726.32",
-            "MONDO:0001875",
-            "MESH:D013716",
-            "DOID:14087",
-            "EFO:1001896",
-            "MEDDRA:10043258",
-            "MEDDRA:10068808",
-            "NCIT:C34589",
-            "MEDDRA:10024032",
-            "NCIT:C35067",
-            "MEDDRA:10014971",
-            "SNOMEDCT:73583000",
-            "UMLS:C0039516",
-            "ICD10:M77.1",
-            "UMLS:C0014488"
-          ],
-          "id": "MONDO:0001875",
-          "category": "biolink:Disease",
-          "all_names": [
-            "epicondylitis",
-            "Lateral epicondylitis",
-            "Epicondylitis",
-            "Tennis Elbow",
-            "Lateral Epicondylitis",
-            "lateral epicondylitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/epicondylitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 541725,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001875",
-              "name": "epicondylitis",
-              "description": "inflammation of the lateral epicondyle.; A condition characterized by pain in or near the lateral humeral epicondyle or in the forearm extensor muscle mass as a result of unusual strain. It occurs due repetitive stresses on the elbow from activities such as tennis playing.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:1001887",
-                "SNOMEDCT:202855006",
-                "ICD9:726.32",
-                "MONDO:0001875",
-                "MESH:D013716",
-                "DOID:14087",
-                "EFO:1001896",
-                "MEDDRA:10043258",
-                "MEDDRA:10068808",
-                "NCIT:C34589",
-                "MEDDRA:10024032",
-                "NCIT:C35067",
-                "MEDDRA:10014971",
-                "SNOMEDCT:73583000",
-                "UMLS:C0039516",
-                "ICD10:M77.1",
-                "UMLS:C0014488"
-              ],
-              "id": "MONDO:0001875",
-              "category": "biolink:Disease",
-              "all_names": [
-                "epicondylitis",
-                "Lateral epicondylitis",
-                "Epicondylitis",
-                "Tennis Elbow",
-                "Lateral Epicondylitis",
-                "lateral epicondylitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/epicondylitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10346472,
-            "start": 568,
-            "end": 541725,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13626361': {'publication date': '1959 Mar', 'sentence': 'Prednisolone (meticortelone) in treatment of epicondylitis; radiohumeral bursitis and radiohumeral synovitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0014488---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0039516---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10574409",
-              "object": "MONDO:0001875",
-              "publications": [
-                "PMID:13626361"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319030,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319030,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10337536,
-            "start": 568,
-            "end": 319030,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13587617': {'publication date': '1958 Nov', 'sentence': 'Intra-articular injections of hydrocortisone prednisolone, and their tertiary-butylacetate derivatives in patients with rheumatoid arthritis and osteoarthritis.', 'subject score': 888, 'object score': 1000}, 'PMID:14284044': {'publication date': '1964 Nov', 'sentence': '[THE SYNOVIAL PROTEIN PICTURE IN OSTEOARTHROSES TREATED WITH INTRA-ARTICULAR PREDNISOLONE].', 'subject score': 901, 'object score': 1000}, 'PMID:31727410': {'publication date': '2019 11 30', 'sentence': 'INTERPRETATION: Treatment with 10 mg prednisolone for 6 weeks is efficacious and safe for the treatment of patients with painful hand osteoarthritis and signs of inflammation.', 'subject score': 790, 'object score': 901}, 'PMID:34264344': {'publication date': '2021 Jul 15', 'sentence': 'METHODS: Ultrasonography was performed blinded to clinical information of 30 joints of 75 patients with hand osteoarthritis, treated with prednisolone in a randomized placebo-controlled double-blind trial.', 'subject score': 1000, 'object score': 888}, 'PMID:35671123': {'publication date': '2022 Jun 07', 'sentence': 'METHODS: Data were analysed from a 6-week, randomized, double-blind, placebo-controlled trial investigating prednisolone treatment in 92 patients with painful inflammatory hand OA.', 'subject score': 827, 'object score': 861}, 'PMID:35946535': {'publication date': '2022 Aug 10', 'sentence': 'OBJECTIVES: To investigate whether biomarkers are modulated by prednisolone treatment in patients with hand osteoarthritis (OA) and whether they can predict response to prednisolone.', 'subject score': 888, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10565149",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:13587617",
-                "PMID:14284044",
-                "PMID:31727410",
-                "PMID:34264344",
-                "PMID:35671123",
-                "PMID:35946535"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316638,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-          "name": "peptic ulcer disease",
-          "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10018053",
-            "MEDDRA:10045305",
-            "MESH:D010437",
-            "MONDO:0004247",
-            "DOID:750",
-            "UMLS:C0030920",
-            "MEDDRA:10017886",
-            "MEDDRA:10045342",
-            "ICD9:533",
-            "ICD10:K27",
-            "HP:0004398",
-            "MEDDRA:10034343",
-            "MEDDRA:10034360",
-            "MEDDRA:10045328",
-            "MEDDRA:10042834",
-            "MEDDRA:10034341",
-            "MEDDRA:10034367",
-            "MEDDRA:10037287",
-            "NCIT:C3318",
-            "SNOMEDCT:13200003",
-            "MEDDRA:10034369"
-          ],
-          "id": "MONDO:0004247",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peptic ulcer, site unspecified",
-            "Peptic Ulcer",
-            "peptic ulcer disease",
-            "Peptic ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28242110",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316638,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-              "name": "peptic ulcer disease",
-              "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10018053",
-                "MEDDRA:10045305",
-                "MESH:D010437",
-                "MONDO:0004247",
-                "DOID:750",
-                "UMLS:C0030920",
-                "MEDDRA:10017886",
-                "MEDDRA:10045342",
-                "ICD9:533",
-                "ICD10:K27",
-                "HP:0004398",
-                "MEDDRA:10034343",
-                "MEDDRA:10034360",
-                "MEDDRA:10045328",
-                "MEDDRA:10042834",
-                "MEDDRA:10034341",
-                "MEDDRA:10034367",
-                "MEDDRA:10037287",
-                "NCIT:C3318",
-                "SNOMEDCT:13200003",
-                "MEDDRA:10034369"
-              ],
-              "id": "MONDO:0004247",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peptic ulcer, site unspecified",
-                "Peptic Ulcer",
-                "peptic ulcer disease",
-                "Peptic ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28242110",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10329865,
-            "start": 568,
-            "end": 316638,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13555798': {'publication date': '1958', 'sentence': 'On the development of peptic ulcers in patients treated with prednisone or prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:14487928': {'publication date': '1962 Jul', 'sentence': '[The pathogenesis of peptic ulcer of the duodenum during prednisolone therapy].', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0030920---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10557390",
-              "object": "MONDO:0004247",
-              "publications": [
-                "PMID:13555798",
-                "PMID:14487928"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319441,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005130",
-          "name": "celiac disease",
-          "description": "Celiac disease (CD) is an autoimmune condition affecting the small intestine, triggered by the ingestion of gluten, the protein fraction of wheat, barley, and rye. Clinical manifestations of CD are highly variable and include both gastrointestinal and non-gastrointestinal features. The hallmark of CD is an immune-mediated enteropathy. This term is included because the occurence of CD is seen as a feature of a number of other diseases. [HPO:probinson, PMID:23681421]; Celiac disease (CD) is an autoimmune condition affecting the small intestine, triggered by the ingestion of gluten, the protein fraction of wheat, barley, and rye. Clinical manifestations of CD are highly variable and include both gastrointestinal and non-gastrointestinal features. The hallmark of CD is an immune-mediated enteropathy. This term is included because the occurence of CD is seen as a feature of a number of other diseases.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10018461",
-            "MEDDRA:10058248",
-            "HP:0002608",
-            "EFO:0001060",
-            "MEDDRA:10029525",
-            "ICD9:579.0",
-            "MEDDRA:10007865",
-            "OMIM.PS:212750",
-            "MEDDRA:10007864",
-            "ORPHANET:555",
-            "UMLS:C0007570",
-            "SNOMEDCT:396331005",
-            "NCIT:C26714",
-            "MEDDRA:10009839",
-            "MEDDRA:10018458",
-            "MONDO:0005130",
-            "ICD10:K90.0",
-            "DOID:10608",
-            "MESH:D002446"
-          ],
-          "id": "MONDO:0005130",
-          "category": "biolink:Disease",
-          "all_names": [
-            "celiac disease",
-            "Celiac Disease",
-            "Celiac disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/celiac-disease/ds00319",
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:23681421",
-            "http://www.celiac.org/",
-            "http://en.wikipedia.org/wiki/coeliac_disease",
-            "https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000233.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319441,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005130",
-              "name": "celiac disease",
-              "description": "Celiac disease (CD) is an autoimmune condition affecting the small intestine, triggered by the ingestion of gluten, the protein fraction of wheat, barley, and rye. Clinical manifestations of CD are highly variable and include both gastrointestinal and non-gastrointestinal features. The hallmark of CD is an immune-mediated enteropathy. This term is included because the occurence of CD is seen as a feature of a number of other diseases. [HPO:probinson, PMID:23681421]; Celiac disease (CD) is an autoimmune condition affecting the small intestine, triggered by the ingestion of gluten, the protein fraction of wheat, barley, and rye. Clinical manifestations of CD are highly variable and include both gastrointestinal and non-gastrointestinal features. The hallmark of CD is an immune-mediated enteropathy. This term is included because the occurence of CD is seen as a feature of a number of other diseases.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10018461",
-                "MEDDRA:10058248",
-                "HP:0002608",
-                "EFO:0001060",
-                "MEDDRA:10029525",
-                "ICD9:579.0",
-                "MEDDRA:10007865",
-                "OMIM.PS:212750",
-                "MEDDRA:10007864",
-                "ORPHANET:555",
-                "UMLS:C0007570",
-                "SNOMEDCT:396331005",
-                "NCIT:C26714",
-                "MEDDRA:10009839",
-                "MEDDRA:10018458",
-                "MONDO:0005130",
-                "ICD10:K90.0",
-                "DOID:10608",
-                "MESH:D002446"
-              ],
-              "id": "MONDO:0005130",
-              "category": "biolink:Disease",
-              "all_names": [
-                "celiac disease",
-                "Celiac Disease",
-                "Celiac disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/celiac-disease/ds00319",
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:23681421",
-                "http://www.celiac.org/",
-                "http://en.wikipedia.org/wiki/coeliac_disease",
-                "https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000233.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10287068,
-            "start": 568,
-            "end": 319441,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13356997': {'publication date': '1956 Aug', 'sentence': 'The simultaneous correction of plain-water deficit and extracellular fluid volume loss in non-tropical sprue treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:6669930': {'publication date': '1983 May', 'sentence': 'The proportion of free prednisolone was 79% greater in patients with celiac disease (p less than 0.01), and the area under the time-concentration curve of free, biologically active prednisolone 53% larger (p less than 0.05).', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0007570---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10513879",
-              "object": "MONDO:0005130",
-              "publications": [
-                "PMID:13356997",
-                "PMID:6669930"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319068,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007256",
-          "name": "hepatocellular carcinoma",
-          "description": "A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.; A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.; A kind of neoplasm of the liver that originates in hepatocytes and presents macroscopically as a soft and hemorrhagic tan mass in the liver. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "HP:0001402",
-            "ICD10:C22.0",
-            "ORPHANET:88673",
-            "MEDDRA:10073071",
-            "DOID:686",
-            "MESH:C567299",
-            "MEDDRA:10024658",
-            "SNOMEDCT:109841003",
-            "UMLS:C2676033",
-            "OMIM:114550",
-            "MESH:D006528",
-            "SNOMEDCT:187769009",
-            "UMLS:C1867955",
-            "SNOMEDCT:25370001",
-            "UMLS:C1862761",
-            "DOID:684",
-            "MEDDRA:10048491",
-            "SNOMEDCT:1186630006",
-            "MONDO:0007256",
-            "MEDDRA:10019838",
-            "MEDDRA:10049010",
-            "EFO:0000182",
-            "NCIT:C3099",
-            "MEDDRA:10007416",
-            "UMLS:C2239176"
-          ],
-          "id": "MONDO:0007256",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hepatocellular carcinoma",
-            "Hepatocellular Carcinoma",
-            "Increased hepatocellular carcinoma risk",
-            "Hepatocellular carcinoma related phenotypic feature",
-            "Hepatocellular carcinoma",
-            "Liver carcinoma",
-            "Carcinoma, Hepatocellular",
-            "Increased incidence of hepatocellular carcinoma",
-            "liver carcinoma",
-            "Hepatoblastoma Caused By Somatic Mutation"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/liver_cance",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/hepatocellular_carcinoma",
-            "http://en.wikipedia.org/wiki/carcinoma",
-            "http://www.omim.org/entry/114550",
-            "http://cancergenome.nih.gov/cancersselected/liverhepatocellularcarcinoma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319068,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007256",
-              "name": "hepatocellular carcinoma",
-              "description": "A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.; A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.; A kind of neoplasm of the liver that originates in hepatocytes and presents macroscopically as a soft and hemorrhagic tan mass in the liver. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "HP:0001402",
-                "ICD10:C22.0",
-                "ORPHANET:88673",
-                "MEDDRA:10073071",
-                "DOID:686",
-                "MESH:C567299",
-                "MEDDRA:10024658",
-                "SNOMEDCT:109841003",
-                "UMLS:C2676033",
-                "OMIM:114550",
-                "MESH:D006528",
-                "SNOMEDCT:187769009",
-                "UMLS:C1867955",
-                "SNOMEDCT:25370001",
-                "UMLS:C1862761",
-                "DOID:684",
-                "MEDDRA:10048491",
-                "SNOMEDCT:1186630006",
-                "MONDO:0007256",
-                "MEDDRA:10019838",
-                "MEDDRA:10049010",
-                "EFO:0000182",
-                "NCIT:C3099",
-                "MEDDRA:10007416",
-                "UMLS:C2239176"
-              ],
-              "id": "MONDO:0007256",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hepatocellular carcinoma",
-                "Hepatocellular Carcinoma",
-                "Increased hepatocellular carcinoma risk",
-                "Hepatocellular carcinoma related phenotypic feature",
-                "Hepatocellular carcinoma",
-                "Liver carcinoma",
-                "Carcinoma, Hepatocellular",
-                "Increased incidence of hepatocellular carcinoma",
-                "liver carcinoma",
-                "Hepatoblastoma Caused By Somatic Mutation"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/liver_cance",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/hepatocellular_carcinoma",
-                "http://en.wikipedia.org/wiki/carcinoma",
-                "http://www.omim.org/entry/114550",
-                "http://cancergenome.nih.gov/cancersselected/liverhepatocellularcarcinoma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10282470,
-            "start": 568,
-            "end": 319068,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1333900': {'publication date': '1992', 'sentence': 'One had received four weekly cycles of prednisolone, Adriamycin, vincristine and 5-fluorouracil for an inoperable HCC with a 10-cm diameter, and the other had received localised synchronised hepatic irradiation and Adriamycin.', 'subject score': 1000, 'object score': 901}, 'PMID:23673446': {'publication date': '2013 Jul', 'sentence': 'Here, we report a pharmacokinetic interaction between sorafenib and the CYP3A4 inducer prednisolone in a patient with hepatocellular carcinoma (HCC).', 'subject score': 802, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C2239176---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10509017",
-              "object": "MONDO:0007256",
-              "publications": [
-                "PMID:1333900",
-                "PMID:23673446"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316685,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0003664",
-          "name": "hemolytic anemia",
-          "description": "A type of anemia caused by premature destruction of red blood cells (hemolysis). [HPO:probinson]; A type of anemia caused by premature destruction of red blood cells (hemolysis). // COMMENTS: Normally, erythrocytes survive on average about 110-120 days. With hemolysis, the erythrocyte survival is shortened, and generally increased marrow activity results in a reticulocyte count.; A type of anemia caused by premature destruction of red blood cells (hemolysis). // COMMENTS: Normally, erythrocytes survive on average about 110-120 days. With hemolysis, the erythrocyte survival is shortened, and generally increased marrow activity results in a reticulocyte count.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:0005558",
-            "UMLS:C0002878",
-            "MEDDRA:10018921",
-            "MEDDRA:10019494",
-            "SYMP:0000631",
-            "MEDDRA:10018916",
-            "ICD10:D55-D59",
-            "SNOMEDCT:61261009",
-            "MONDO:0003664",
-            "HP:0001878",
-            "MEDDRA:10019493",
-            "DOID:583",
-            "MEDDRA:10002284",
-            "MEDDRA:10055193",
-            "MEDDRA:10002045",
-            "NCIT:C34376",
-            "MESH:D000743"
-          ],
-          "id": "MONDO:0003664",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hemolytic anemia",
-            "Anemia, Hemolytic",
-            "hemolytic anemia",
-            "Hemolytic Anemia"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316685,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0003664",
-              "name": "hemolytic anemia",
-              "description": "A type of anemia caused by premature destruction of red blood cells (hemolysis). [HPO:probinson]; A type of anemia caused by premature destruction of red blood cells (hemolysis). // COMMENTS: Normally, erythrocytes survive on average about 110-120 days. With hemolysis, the erythrocyte survival is shortened, and generally increased marrow activity results in a reticulocyte count.; A type of anemia caused by premature destruction of red blood cells (hemolysis). // COMMENTS: Normally, erythrocytes survive on average about 110-120 days. With hemolysis, the erythrocyte survival is shortened, and generally increased marrow activity results in a reticulocyte count.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:0005558",
-                "UMLS:C0002878",
-                "MEDDRA:10018921",
-                "MEDDRA:10019494",
-                "SYMP:0000631",
-                "MEDDRA:10018916",
-                "ICD10:D55-D59",
-                "SNOMEDCT:61261009",
-                "MONDO:0003664",
-                "HP:0001878",
-                "MEDDRA:10019493",
-                "DOID:583",
-                "MEDDRA:10002284",
-                "MEDDRA:10055193",
-                "MEDDRA:10002045",
-                "NCIT:C34376",
-                "MESH:D000743"
-              ],
-              "id": "MONDO:0003664",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hemolytic anemia",
-                "Anemia, Hemolytic",
-                "hemolytic anemia",
-                "Hemolytic Anemia"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10276186,
-            "start": 568,
-            "end": 316685,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13314848': {'publication date': '1955 Dec', 'sentence': '[A case of hemolytic anemia with generalized agglutination, treated with ACTH, cortisone, and prednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:13355536': {'publication date': '1956 Apr', 'sentence': '[Immune hemolytic anemia treated with prednisone and prednisolone].', 'subject score': 1000, 'object score': 901}, 'PMID:17156326': {'publication date': '2006 Dec', 'sentence': 'A 7-year-old castrated male Whippet developed deep ulcerative skin lesions whilst receiving immunosuppressive doses of prednisolone and cyclosporine for the treatment of immune-mediated haemolytic anaemia.', 'subject score': 1000, 'object score': 850}, 'PMID:17329922': {'publication date': '2007', 'sentence': 'High-dose prednisolone therapy improved the hemolytic anemia and thrombocytopenia, but not the CD16(+) CD56(-) NK lymphocytosis completely.', 'subject score': 861, 'object score': 1000}, 'PMID:1753420': {'publication date': '1991 Oct', 'sentence': 'The PRCA and hemolytic anemia were successfully treated with prednisolone (60 mg/day).', 'subject score': 1000, 'object score': 1000}, 'PMID:22563154': {'publication date': '2011 Oct', 'sentence': 'We report a patient with primary ovarian diffuse large B-cell lymphoma (DLBCL) and associated auto-immune hemolytic anemia (AIHA) who achieved complete remission after treatment with Rituximab-cyclophosphamide-doxorubicin-vincristine and prednisolone (R-CHOP) chemotherapy.', 'subject score': 1000, 'object score': 798}, 'PMID:2280484': {'publication date': '1990 Oct', 'sentence': \"A canine case of Coombs' test positive and antinuclear antibody-negative hemolytic anemia was examined because of the development of skin lesions after 18 months treatment with prednisolone.\", 'subject score': 1000, 'object score': 893}, 'PMID:24490015': {'publication date': '2014', 'sentence': 'CASE PRESENTATION: A- 46 year old woman who was a known case of hemolytic anemia has been treated by prednisolone (with different doses from 7.5 to 75 mg/day), calcium-D 500 mg/day and alendronate 70 mg/week for 3 years.', 'subject score': 1000, 'object score': 1000}, 'PMID:29509140': {'publication date': '2018 Mar', 'sentence': 'The addition of MMF to prednisolone for the treatment of dogs with acute IMHA was well tolerated and seemed to positively affect the course of the disease.', 'subject score': 1000, 'object score': 820}, 'PMID:7997131': {'publication date': '1994', 'sentence': 'The hemolytic anemia was treated with prednisolone without success and KS cutaneous lesions extended to both legs and ulcerated even after a short course of bleomycin and radiotherapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:9785987': {'publication date': '1998 Aug', 'sentence': 'Further administration of 60 mg of prednisolone and plasmapheresis ameliorated the hemolytic anemia and cured the jaundice.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0002878---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10502737",
-              "object": "MONDO:0003664",
-              "publications": [
-                "PMID:13314848",
-                "PMID:13355536",
-                "PMID:17156326",
-                "PMID:17329922",
-                "PMID:1753420",
-                "PMID:22563154",
-                "PMID:2280484",
-                "PMID:24490015",
-                "PMID:29509140",
-                "PMID:7997131",
-                "PMID:9785987"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 534914,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006594",
-          "name": "pemphigus",
-          "description": "A blistering skin disorder. Morphologically it is characterized by acantholysis and intraepidermal blister formation.; Group of chronic blistering diseases characterized histologically by ACANTHOLYSIS and blister formation within the EPIDERMIS.; Pemphigus is an autoimmune disorder. If you have it, your immune system attacks healthy cells in your skin and mouth, causing blisters and sores. No one knows the cause. Pemphigus does not spread from person to person. It does not appear to be inherited. But some people's genes put them more at risk for pemphigus. Pemphigoid is also an autoimmune skin disease. It leads to deep blisters that do not break easily. Pemphigoid is most common in older adults and may be fatal for older, sick patients. Doctors diagnose pemphigus with a physical exam, a biopsy, and blood tests. The treatment of pemphigus and pemphigoid is the same: one or more medicines to control symptoms. These may include: Steroids, which reduce inflammation Drugs that suppress the immune system response Antibiotics to treat associated infections  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:1000749",
-            "MEDDRA:10034280",
-            "NCIT:C34909",
-            "SNOMEDCT:65172003",
-            "ICD9:694.4",
-            "DOID:0080850",
-            "DOID:9182",
-            "MONDO:0006594",
-            "UMLS:C0030807",
-            "ICD10:L10",
-            "ICD10:L10.2",
-            "MESH:D010392"
-          ],
-          "id": "MONDO:0006594",
-          "category": "biolink:Disease",
-          "all_names": [
-            "pemphigus foliaceus",
-            "Pemphigus",
-            "pemphigus"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://rarediseases.info.nih.gov/diseases/7352/pemphigus",
-            "https://en.wikipedia.org/wiki/pemphigus",
-            "https://rarediseases.org/rare-diseases/pemphigus/",
-            "https://medlineplus.gov/pemphigus.htm",
-            "https://dermnetnz.org/topics/pemphigus-foliaceus/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 534914,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006594",
-              "name": "pemphigus",
-              "description": "A blistering skin disorder. Morphologically it is characterized by acantholysis and intraepidermal blister formation.; Group of chronic blistering diseases characterized histologically by ACANTHOLYSIS and blister formation within the EPIDERMIS.; Pemphigus is an autoimmune disorder. If you have it, your immune system attacks healthy cells in your skin and mouth, causing blisters and sores. No one knows the cause. Pemphigus does not spread from person to person. It does not appear to be inherited. But some people's genes put them more at risk for pemphigus. Pemphigoid is also an autoimmune skin disease. It leads to deep blisters that do not break easily. Pemphigoid is most common in older adults and may be fatal for older, sick patients. Doctors diagnose pemphigus with a physical exam, a biopsy, and blood tests. The treatment of pemphigus and pemphigoid is the same: one or more medicines to control symptoms. These may include: Steroids, which reduce inflammation Drugs that suppress the immune system response Antibiotics to treat associated infections  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:1000749",
-                "MEDDRA:10034280",
-                "NCIT:C34909",
-                "SNOMEDCT:65172003",
-                "ICD9:694.4",
-                "DOID:0080850",
-                "DOID:9182",
-                "MONDO:0006594",
-                "UMLS:C0030807",
-                "ICD10:L10",
-                "ICD10:L10.2",
-                "MESH:D010392"
-              ],
-              "id": "MONDO:0006594",
-              "category": "biolink:Disease",
-              "all_names": [
-                "pemphigus foliaceus",
-                "Pemphigus",
-                "pemphigus"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://rarediseases.info.nih.gov/diseases/7352/pemphigus",
-                "https://en.wikipedia.org/wiki/pemphigus",
-                "https://rarediseases.org/rare-diseases/pemphigus/",
-                "https://medlineplus.gov/pemphigus.htm",
-                "https://dermnetnz.org/topics/pemphigus-foliaceus/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10112284,
-            "start": 568,
-            "end": 534914,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12890207': {'publication date': '2003 Jul', 'sentence': 'OBJECTIVES: The present study describes our experience of the addition of mycophenolate mofetil (MMF) to prednisolone in the management of severe, refractory pemphigus.', 'subject score': 1000, 'object score': 851}, 'PMID:13355751': {'publication date': '1955', 'sentence': '[Urinary steroids in pemphigus patients treated with cortisone, prednisone and prednisolone].', 'subject score': 1000, 'object score': 888}, 'PMID:19922532': {'publication date': '2010 Apr', 'sentence': 'OBJECTIVES: To report the clinical and immunological responses of 21 patients with pemphigus refractory to prednisolone and azathioprine or mycophenolate mofetil treated in our department with a standard protocol of monthly PPC.', 'subject score': 1000, 'object score': 1000}, 'PMID:22173051': {'publication date': '2012 May', 'sentence': 'A 77-year-old man treated with prednisolone for pemphigus developed severe sepsis by Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.', 'subject score': 1000, 'object score': 1000}, 'PMID:31865535': {'publication date': '2019 Dec 21', 'sentence': 'The aim of this study was to compare the efficacy and safety of each of these agents as adjuvant therapy with the corticosteroid prednisolone for the treatment of pemphigus, using standardized outcome parameters.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0030807---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10335998",
-              "object": "MONDO:0006594",
-              "publications": [
-                "PMID:12890207",
-                "PMID:13355751",
-                "PMID:19922532",
-                "PMID:22173051",
-                "PMID:31865535"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318155,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004952",
-          "name": "Hodgkins lymphoma",
-          "description": "A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma has a bimodal age distribution, and involves primarily lymph nodes. Current therapy for Hodgkin lymphoma has resulted in an excellent outcome and cure for the majority of patients. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C9357\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C9357\" NCI Thesaurus); UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10020309",
-            "SNOMEDCT:1163005009",
-            "ORPHANET:98293",
-            "UMLS:C5235037",
-            "NCIT:C6914",
-            "MEDDRA:10020255",
-            "SNOMEDCT:118606001",
-            "MEDDRA:10063666",
-            "SNOMEDCT:46923007",
-            "ICD10:C81",
-            "UMLS:C0019829",
-            "ICD9:201.2",
-            "SNOMEDCT:836277009",
-            "SNOMEDCT:74189002",
-            "MEDDRA:10020206",
-            "MESH:D006689",
-            "MEDDRA:10020328",
-            "MEDDRA:10020329",
-            "HP:0012189",
-            "SNOMEDCT:118599009",
-            "NCIT:C9357",
-            "ICD9:201",
-            "NCIT:C26956",
-            "SNOMEDCT:118605002",
-            "SNOMEDCT:118602004",
-            "NCIT:C164145",
-            "PDQ:CDR0000041646",
-            "MEDDRA:10025319",
-            "MEDDRA:10020318",
-            "EFO:0000183",
-            "DOID:8567",
-            "SNOMEDCT:14537002",
-            "MONDO:0004952",
-            "SNOMEDCT:836276000",
-            "MEDDRA:10020339",
-            "SNOMEDCT:70600005"
-          ],
-          "id": "MONDO:0004952",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hodgkin Lymphoma",
-            "Hodgkin lymphoma",
-            "Hodgkin's Paragranuloma",
-            "Hodgkin's sarcoma",
-            "Hodgkin sarcoma",
-            "Hodgkin's lymphoma",
-            "Hodgkins lymphoma",
-            "Hodgkin's Granuloma",
-            "Hodgkin's Sarcoma",
-            "Hodgkin Disease",
-            "Hodgkin's disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/hodgkin%27s_lymphoma",
-            "PMID:22835602",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318155,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004952",
-              "name": "Hodgkins lymphoma",
-              "description": "A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma has a bimodal age distribution, and involves primarily lymph nodes. Current therapy for Hodgkin lymphoma has resulted in an excellent outcome and cure for the majority of patients. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C9357\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C9357\" NCI Thesaurus); UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10020309",
-                "SNOMEDCT:1163005009",
-                "ORPHANET:98293",
-                "UMLS:C5235037",
-                "NCIT:C6914",
-                "MEDDRA:10020255",
-                "SNOMEDCT:118606001",
-                "MEDDRA:10063666",
-                "SNOMEDCT:46923007",
-                "ICD10:C81",
-                "UMLS:C0019829",
-                "ICD9:201.2",
-                "SNOMEDCT:836277009",
-                "SNOMEDCT:74189002",
-                "MEDDRA:10020206",
-                "MESH:D006689",
-                "MEDDRA:10020328",
-                "MEDDRA:10020329",
-                "HP:0012189",
-                "SNOMEDCT:118599009",
-                "NCIT:C9357",
-                "ICD9:201",
-                "NCIT:C26956",
-                "SNOMEDCT:118605002",
-                "SNOMEDCT:118602004",
-                "NCIT:C164145",
-                "PDQ:CDR0000041646",
-                "MEDDRA:10025319",
-                "MEDDRA:10020318",
-                "EFO:0000183",
-                "DOID:8567",
-                "SNOMEDCT:14537002",
-                "MONDO:0004952",
-                "SNOMEDCT:836276000",
-                "MEDDRA:10020339",
-                "SNOMEDCT:70600005"
-              ],
-              "id": "MONDO:0004952",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hodgkin Lymphoma",
-                "Hodgkin lymphoma",
-                "Hodgkin's Paragranuloma",
-                "Hodgkin's sarcoma",
-                "Hodgkin sarcoma",
-                "Hodgkin's lymphoma",
-                "Hodgkins lymphoma",
-                "Hodgkin's Granuloma",
-                "Hodgkin's Sarcoma",
-                "Hodgkin Disease",
-                "Hodgkin's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/hodgkin%27s_lymphoma",
-                "PMID:22835602",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9803579,
-            "start": 568,
-            "end": 318155,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12574967': {'publication date': '2003 Jan', 'sentence': \"Under the diagnosis of Hodgkin's disease, she was treated with combination chemotherapy containing pirarubicin, cyclophosphamide, vincristine, and prednisolone.\", 'subject score': 1000, 'object score': 1000}, 'PMID:1748400': {'publication date': '1991', 'sentence': \"Fourteen patients with Hodgkin's disease (two previously untreated, 12 following relapse or with refractory disease) were treated with a combination chemotherapy regimen comprising chlorambucil, vinblastine, procarbazine, prednisolone, etoposide, vincristine and adriamycin administered on days 1-8.\", 'subject score': 1000, 'object score': 1000}, 'PMID:1832882': {'publication date': '1991', 'sentence': \"Between January 1972 and October 1985, 60 patients with advanced Hodgkin's disease were treated with mechlorethamine/vinblastine/procarbazine/prednisolone (MVPP).\", 'subject score': 833, 'object score': 901}, 'PMID:2115396': {'publication date': '1990 May 01', 'sentence': \"It is concluded that six or more cycles of COPP chemotherapy for advanced Hodgkin's disease in men leads to permanent sterility.\", 'subject score': 888, 'object score': 901}, 'PMID:2193118': {'publication date': '1990 Jul', 'sentence': 'These results strongly suggest that extended high-dose irradiation and MOPP chemotherapy should not be combined for the treatment of HD.', 'subject score': 888, 'object score': 1000}, 'PMID:2207371': {'publication date': '1990', 'sentence': \"This study deals with the effectiveness of nitrosourea derivatives (nitrosomethylurea and CCNU) used as single agents or in combination with vinca alkaloids, procarbazine and prednisolone in 23 patients suffering from Hodgkin's disease with spinal cord or intracranial involvement.\", 'subject score': 1000, 'object score': 1000}, 'PMID:2386744': {'publication date': '1990 Aug', 'sentence': \"Two hundred and eighty-four patients with advanced Hodgkin's disease (HD) (stage II with poor prognostic features and stage III/IV) have been treated with the ChlVPP combination chemotherapy regimen (chlorambucil, vinblastine, procarbazine and prednisolone) in a single-centre unselected series.\", 'subject score': 1000, 'object score': 901}, 'PMID:2703008': {'publication date': '1989 Mar', 'sentence': \"ChlVPP is effective first-line treatment for Hodgkin's disease with results which may be comparable to those achieved for MOPP but with significantly less toxicity.\", 'subject score': 713, 'object score': 1000}, 'PMID:2769976': {'publication date': '1989 Apr', 'sentence': \"She was treated by the combination chemotherapy consisting of mitoxantrone, cyclophosphamide, vincristine and prednisolone for Hodgkin's disease in November 1986.\", 'subject score': 1000, 'object score': 1000}, 'PMID:3381494': {'publication date': '1988', 'sentence': \"The study deals with the effectiveness of nitrosourea derivatives (nitrosomethylurea and CCNU) used for monochemotherapy or polychemotherapy in combination with vinca alkaloids, natulan and prednisolone in 22 patients suffering Hodgkin's disease with spinal cord and intracranial involvement.\", 'subject score': 1000, 'object score': 1000}, 'PMID:435366': {'publication date': '1979 Feb', 'sentence': \"Three years' experience with Ch1VPP (a combination of drugs of low toxicity) for the treatment of Hodgkin's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:911666': {'publication date': '1977 Aug', 'sentence': \"A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0019829---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10020250",
-              "object": "MONDO:0004952",
-              "publications": [
-                "PMID:12574967",
-                "PMID:1748400",
-                "PMID:1832882",
-                "PMID:2115396",
-                "PMID:2193118",
-                "PMID:2207371",
-                "PMID:2386744",
-                "PMID:2703008",
-                "PMID:2769976",
-                "PMID:3381494",
-                "PMID:435366",
-                "PMID:911666"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9635764,
-            "start": 568,
-            "end": 183319,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12402607': {'publication date': '2002', 'sentence': 'Patients who remain high transporters with inflammatory reaction might require pharmacologic intervention, including prednisolone therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:13918410': {'publication date': '1962 Jan', 'sentence': '[Good results in the treatment of toxic inflammation with intravenous prednisolone].', 'subject score': 888, 'object score': 888}, 'PMID:18499398': {'publication date': '2008 Jul-Aug', 'sentence': 'In addition, possible effects of gender, malnutrition, inflammation, and previous prednisolone therapy were investigated.', 'subject score': 851, 'object score': 1000}, 'PMID:20080065': {'publication date': '2010 Apr', 'sentence': 'Suppression of AHI activity by prednisolone treatment decreased Treg accumulation in the liver.', 'subject score': 888, 'object score': 833}, 'PMID:21745559': {'publication date': '2011 Sep 01', 'sentence': 'CONCLUSION: Kirenol and prednisolone can upregulate nuclear annexin-1 which interacts with NF-kappaB to inhibit NF-kappaB activity, reduce cytokines expression and thereby attenuate inflammation of CIA joints.', 'subject score': 1000, 'object score': 1000}, 'PMID:22727107': {'publication date': '2012 Jul', 'sentence': 'We report safe successful treatment of 6 patients with significant MMP-related oral inflammation with the use of a previously unreported combination of mycophenolate mofetil, dapsone, and prednisolone given at relatively low doses.', 'subject score': 1000, 'object score': 836}, 'PMID:24280878': {'publication date': '2014 Jan', 'sentence': 'This is probably caused by the inflammation per se, and the treatment with prednisolone may aggravate the problem, whereas the effect of biological therapy is unknown.', 'subject score': 1000, 'object score': 1000}, 'PMID:24496321': {'publication date': '2014 Oct', 'sentence': 'Inflammation decreased more in the group treated with prednisolone, while the number of cholangiocytes, progenitor cells and fibroblasts did not differ between the treatment groups.', 'subject score': 1000, 'object score': 1000}, 'PMID:27773734': {'publication date': '2016 12 10', 'sentence': 'The only exception was the appearance of miR-146b, a known inflammation-regulating miRNA species, after liposomal prednisolone treatment.', 'subject score': 851, 'object score': 888}, 'PMID:28983403': {'publication date': '2017 Sep', 'sentence': 'Prednisolone was used as the first-line immunosuppressive agent in all cases, however steroid monotherapy failed long-term control of autoimmunity/inflammation in the majority of cases and additional immunosuppression was required.', 'subject score': 1000, 'object score': 888}, 'PMID:30279927': {'publication date': '2018 Oct', 'sentence': 'Patients with myocarditis should be carefully monitored for arrhythmia, even after ventricular function and inflammation have improved with prednisolone therapy.>.', 'subject score': 888, 'object score': 1000}, 'PMID:30593193': {'publication date': '2018 Dec', 'sentence': 'INTERVENTIONS AND OUTCOMES: The patient was started on 40 mg/day prednisolone to control the hepatic inflammation.', 'subject score': 833, 'object score': 888}, 'PMID:3127100': {'publication date': '1988 Apr', 'sentence': 'Semiquantitative histologic evaluation demonstrated less inflammation in the group treated with prednisolone than in the control group.', 'subject score': 1000, 'object score': 861}, 'PMID:32672612': {'publication date': '2020 May - Jun', 'sentence': 'Nepafenac was noninferior to prednisolone with regard to inflammation control, with 1 nepafenac-treated eye (1.3%) not meeting the primary end point because of 1+ anterior chamber cell at 2 weeks and 4 prednisolone-treated eyes (5.4%) failing to meet the primary end point because of rebound iritis (P < 0.001).', 'subject score': 1000, 'object score': 694}, 'PMID:32997729': {'publication date': '2020', 'sentence': 'In this study, we aimed to determine whether prednisolone (PD) attenuates adriamycin (ADR)-induced VSMC senescence and inflammation through the SIRT1-AMPK signaling pathway.', 'subject score': 1000, 'object score': 1000}, 'PMID:335683': {'publication date': '1977 Jul 15', 'sentence': 'Parallel to this or overlapping the rheumatic inflammatory mesenchymal tissue reactions are treated with prednisolone or derivatives, aminophenazone or salicylic acid preparations, in which cases in children prednisolone and aminophenazone are preferred.', 'subject score': 1000, 'object score': 786}, 'PMID:34622843': {'publication date': '2021 Oct 08', 'sentence': 'CONCLUSION: VKH disease is a multisystemic disorder; intravenous pulse steroid therapy and oral prednisolone can control systemic inflammation.', 'subject score': 888, 'object score': 888}, 'PMID:34725963': {'publication date': '2021 Nov 01', 'sentence': 'We could discontinue prednisolone to control his refractory inflammation of LCH after completing CLO chemotherapy in patient 2.', 'subject score': 1000, 'object score': 888}, 'PMID:35090559': {'publication date': '2022 Jan 28', 'sentence': 'Although pre-loading of the scaffolds with a combination of cells/prednisolone could not alleviate inflammation, it played an important role in regeneration and angiogenesis.', 'subject score': 888, 'object score': 1000}, 'PMID:35935398': {'publication date': '2022 Aug', 'sentence': 'One year of immunosuppressive therapy with prednisolone resolved the inflammation in the guts but not in the heart.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9848677",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:12402607",
-                "PMID:13918410",
-                "PMID:18499398",
-                "PMID:20080065",
-                "PMID:21745559",
-                "PMID:22727107",
-                "PMID:24280878",
-                "PMID:24496321",
-                "PMID:27773734",
-                "PMID:28983403",
-                "PMID:30279927",
-                "PMID:30593193",
-                "PMID:3127100",
-                "PMID:32672612",
-                "PMID:32997729",
-                "PMID:335683",
-                "PMID:34622843",
-                "PMID:34725963",
-                "PMID:35090559",
-                "PMID:35935398"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318918,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002462",
-          "name": "glomerulonephritis",
-          "description": "A renal disorder characterized by damage in the glomeruli. It may be acute or chronic, focal or diffuse, and it may lead to renal failure. Causes include autoimmune disorders, infections, diabetes, and malignancies.; A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.; Inflammation of the renal glomeruli. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029143",
-            "UMLS:C0017658",
-            "SNOMEDCT:36171008",
-            "DOID:2921",
-            "HP:0000099",
-            "MESH:D005921",
-            "MEDDRA:10018364",
-            "MEDDRA:10018375",
-            "MONDO:0002462",
-            "ICD10:N08",
-            "NCIT:C26784"
-          ],
-          "id": "MONDO:0002462",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Glomerulonephritis",
-            "glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/wiki/glomerulonephritis",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318918,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002462",
-              "name": "glomerulonephritis",
-              "description": "A renal disorder characterized by damage in the glomeruli. It may be acute or chronic, focal or diffuse, and it may lead to renal failure. Causes include autoimmune disorders, infections, diabetes, and malignancies.; A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.; Inflammation of the renal glomeruli. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029143",
-                "UMLS:C0017658",
-                "SNOMEDCT:36171008",
-                "DOID:2921",
-                "HP:0000099",
-                "MESH:D005921",
-                "MEDDRA:10018364",
-                "MEDDRA:10018375",
-                "MONDO:0002462",
-                "ICD10:N08",
-                "NCIT:C26784"
-              ],
-              "id": "MONDO:0002462",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Glomerulonephritis",
-                "glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/wiki/glomerulonephritis",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9518721,
-            "start": 568,
-            "end": 318918,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1220151': {'publication date': '1975 Nov', 'sentence': '[Comparative characteristics of the spectrum of free amino acids of blood serum and urine in children with glomerulonephritis treated with prednisolone, leukeran and anabolic steroids].', 'subject score': 1000, 'object score': 1000}, 'PMID:12890898': {'publication date': '2003 Aug', 'sentence': 'In the experimental glomerulonephritis induced in mice by anti-glomerular basement membrane antiserum, KF24345 significantly inhibited proteinuria and glomerular damage without exhibiting the side effects observed following the treatment with prednisolone and cyclophosphamide.', 'subject score': 1000, 'object score': 888}, 'PMID:18622025': {'publication date': '2008 Nov', 'sentence': 'Anti-thrombin drugs and prednisolone may be useful in treating crescentic glomerulonephritis.', 'subject score': 1000, 'object score': 828}, 'PMID:25619396': {'publication date': '2015 Feb', 'sentence': 'RESULTS: Treatment of PHN rats with SM934 or prednisolone attenuated the progression of glomerulonephritis and renal fibrosis, as evidenced by the reduced level of proteinuria and circulating antibodies, as well as by the reduced immune complex deposition, reversed podocyte injuries, and attenuated tubulointerstitial fibrosis in the kidneys.', 'subject score': 1000, 'object score': 1000}, 'PMID:30633192': {'publication date': '2019 Jan', 'sentence': 'Successful entecavir plus prednisolone treatment for hepatitis B virus-associated membranoproliferative glomerulonephritis: A case report.', 'subject score': 822, 'object score': 836}, 'PMID:35420387': {'publication date': '2022 Apr 14', 'sentence': 'Treatment with prednisolone for ANCA-associated glomerulonephritis, normalized urinalysis and decreased PR3-ANCA but MGUS persisted.', 'subject score': 1000, 'object score': 802}, 'PMID:3546234': {'publication date': '1987 Jan 01', 'sentence': 'In 5 dogs, treatment of glomerulonephritis with prednisolone (0.5 to 1.1 mg/kg) did not result in beneficial effects and in fact appeared to be detrimental, leading to azotemia and worsening proteinuria and physical condition in some of the dogs.', 'subject score': 1000, 'object score': 1000}, 'PMID:35930173': {'publication date': '2022 Aug 05', 'sentence': 'This study investigates the therapeutic effect of myrrh as a natural medicine compared to prednisolone in the treatment of immune-mediated glomerulonephritis induced by silicate.', 'subject score': 1000, 'object score': 901}, 'PMID:4000815': {'publication date': '1985 Mar', 'sentence': '[Cases of cataract during treatment of glomerulonephritis in children with prednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:4710416': {'publication date': '1973', 'sentence': '[Comparative evaluation of the effectiveness of prednisolone and indotsid in the treatment of experimental autoimmune glomerulonephritis].', 'subject score': 1000, 'object score': 851}, 'PMID:7694426': {'publication date': '1993 Jul-Aug', 'sentence': 'The employment of reaferon for treatment of GN patients was shown to increase the efficacy of GN treatment, especially in combination with immunosuppressive drugs, to prevent reactivation of hepatitis B virus when prednisolone and/or cytostatic drugs were used, and to reduce hepatitis activity.', 'subject score': 1000, 'object score': 888}, 'PMID:9697658': {'publication date': '1998 Aug', 'sentence': 'The beneficial effect of prednisolone on this GN may be partially mediated by the suppression of MAPK, followed by the suppression of AP-1.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0017658---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9729887",
-              "object": "MONDO:0002462",
-              "publications": [
-                "PMID:1220151",
-                "PMID:12890898",
-                "PMID:18622025",
-                "PMID:25619396",
-                "PMID:30633192",
-                "PMID:35420387",
-                "PMID:3546234",
-                "PMID:35930173",
-                "PMID:4000815",
-                "PMID:4710416",
-                "PMID:7694426",
-                "PMID:9697658"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319991,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006500",
-          "name": "hemangioma",
-          "description": "A benign localized vascular neoplasm usually occurring in infancy and childhood. It is characterized by the formation of capillary-sized or cavernous vascular channels. The majority of cases are congenital. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3085\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3085\" NCI Thesaurus); A benign vascular lesion characterized by the formation of capillary-sized or cavernous vascular channels.; A vascular anomaly due to proliferation of blood or lymphatic vessels that forms a tumor-like mass. Vessels in the angioma may or may not be dilated.; A hemangioma is a benign tumor characterized by blood-filled spaces lined by benign endothelial cells. A hemangioma characterized by large endothelial spaces (caverns) is called a cavernous hemangioma (in contrast to a hemangioma with small endothelial spaces, which is called capillary hemangioma). [HPO:probinson]; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10018814",
-            "PDQ:CDR0000665618",
-            "ICD9:228.00",
-            "MEDDRA:10019401",
-            "SNOMEDCT:253053003",
-            "NCIT:C3085",
-            "DOID:255",
-            "UMLS:C0018916",
-            "SNOMEDCT:400210000",
-            "MEDDRA:10055903",
-            "MESH:D006391",
-            "EFO:1000635",
-            "MEDDRA:10019386",
-            "HP:0001028",
-            "MEDDRA:10019393",
-            "MEDDRA:10018819",
-            "ICD10:D18.0",
-            "MONDO:0006500"
-          ],
-          "id": "MONDO:0006500",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hemangioma",
-            "Hemangioma of unspecified site",
-            "hemangioma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-6908-9849",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/hemangioma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319991,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006500",
-              "name": "hemangioma",
-              "description": "A benign localized vascular neoplasm usually occurring in infancy and childhood. It is characterized by the formation of capillary-sized or cavernous vascular channels. The majority of cases are congenital. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3085\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3085\" NCI Thesaurus); A benign vascular lesion characterized by the formation of capillary-sized or cavernous vascular channels.; A vascular anomaly due to proliferation of blood or lymphatic vessels that forms a tumor-like mass. Vessels in the angioma may or may not be dilated.; A hemangioma is a benign tumor characterized by blood-filled spaces lined by benign endothelial cells. A hemangioma characterized by large endothelial spaces (caverns) is called a cavernous hemangioma (in contrast to a hemangioma with small endothelial spaces, which is called capillary hemangioma). [HPO:probinson]; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10018814",
-                "PDQ:CDR0000665618",
-                "ICD9:228.00",
-                "MEDDRA:10019401",
-                "SNOMEDCT:253053003",
-                "NCIT:C3085",
-                "DOID:255",
-                "UMLS:C0018916",
-                "SNOMEDCT:400210000",
-                "MEDDRA:10055903",
-                "MESH:D006391",
-                "EFO:1000635",
-                "MEDDRA:10019386",
-                "HP:0001028",
-                "MEDDRA:10019393",
-                "MEDDRA:10018819",
-                "ICD10:D18.0",
-                "MONDO:0006500"
-              ],
-              "id": "MONDO:0006500",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hemangioma",
-                "Hemangioma of unspecified site",
-                "hemangioma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-6908-9849",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/hemangioma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9507430,
-            "start": 568,
-            "end": 319991,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12188424': {'publication date': '2002 Jun', 'sentence': 'Management of hemangioma included observation, prednisolone, flashlamp-pumped pulsed-dye laser, topical therapy and excision in 68 per cent, 8.6 per cent, 10.7 per cent, 9.6 per cent, and 2.5 per cent, respectively.', 'subject score': 1000, 'object score': 1000}, 'PMID:25639889': {'publication date': '2015 Jul', 'sentence': 'Prior to propranolol the systemic treatment for haemangiomas was prednisolone and then the concern was the opposite, namely hypertension.', 'subject score': 1000, 'object score': 1000}, 'PMID:28488296': {'publication date': '2017 Jul', 'sentence': 'The hemangioma responded rapidly to systemic propranolol and prednisolone, and we believe that describing her atypical clinical course would be helpful for others managing complicated scalp hemangiomas.', 'subject score': 1000, 'object score': 851}, 'PMID:965873': {'publication date': '1976 Aug', 'sentence': 'Treatment of hemangiomas in pediatric patients with prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0018916---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9717382",
-              "object": "MONDO:0006500",
-              "publications": [
-                "PMID:12188424",
-                "PMID:25639889",
-                "PMID:28488296",
-                "PMID:965873"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317306,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001705",
-          "name": "pure red-cell aplasia",
-          "description": "A type of anemia resulting from suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production. Erythroblasts are virtually absent in bone marrow; however, leukocyte and platelet production show little or no reduction. [HPO:probinson]; A type of anemia resulting from suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production. Erythroblasts are virtually absent in bone marrow; however, leukocyte and platelet production show little or no reduction. // COMMENTS: Pure red cell aplasia results from a maturation arrest occurs in the formation of erythrocytes.; A type of anemia resulting from suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production. Erythroblasts are virtually absent in bone marrow; however, leukocyte and platelet production show little or no reduction. // COMMENTS: Pure red cell aplasia results from a maturation arrest occurs in the formation of erythrocytes.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10038184",
-            "MESH:D012010",
-            "HP:0012410",
-            "MONDO:0001705",
-            "SNOMEDCT:50715003",
-            "NCIT:C34974",
-            "MEDDRA:10002965",
-            "UMLS:C0034902",
-            "MEDDRA:10002966",
-            "DOID:1340"
-          ],
-          "id": "MONDO:0001705",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Red-Cell Aplasia, Pure",
-            "pure red-cell aplasia",
-            "Pure red cell aplasia",
-            "Pure Red-Cell Aplasia",
-            "Pure Red Cell Aplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317306,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001705",
-              "name": "pure red-cell aplasia",
-              "description": "A type of anemia resulting from suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production. Erythroblasts are virtually absent in bone marrow; however, leukocyte and platelet production show little or no reduction. [HPO:probinson]; A type of anemia resulting from suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production. Erythroblasts are virtually absent in bone marrow; however, leukocyte and platelet production show little or no reduction. // COMMENTS: Pure red cell aplasia results from a maturation arrest occurs in the formation of erythrocytes.; A type of anemia resulting from suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production. Erythroblasts are virtually absent in bone marrow; however, leukocyte and platelet production show little or no reduction. // COMMENTS: Pure red cell aplasia results from a maturation arrest occurs in the formation of erythrocytes.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10038184",
-                "MESH:D012010",
-                "HP:0012410",
-                "MONDO:0001705",
-                "SNOMEDCT:50715003",
-                "NCIT:C34974",
-                "MEDDRA:10002965",
-                "UMLS:C0034902",
-                "MEDDRA:10002966",
-                "DOID:1340"
-              ],
-              "id": "MONDO:0001705",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Red-Cell Aplasia, Pure",
-                "pure red-cell aplasia",
-                "Pure red cell aplasia",
-                "Pure Red-Cell Aplasia",
-                "Pure Red Cell Aplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9459606,
-            "start": 568,
-            "end": 317306,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12134708': {'publication date': '2002 Jun', 'sentence': 'The PRCA and AIHA were successfully treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:12191983': {'publication date': '2002 Sep', 'sentence': 'PRCA gradually improved after treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:1753420': {'publication date': '1991 Oct', 'sentence': 'The PRCA and hemolytic anemia were successfully treated with prednisolone (60 mg/day).', 'subject score': 1000, 'object score': 1000}, 'PMID:17633099': {'publication date': '2007 Jun', 'sentence': 'The PRCA and AIHA were successfully treated with prednisolone and cyclosporine.', 'subject score': 1000, 'object score': 1000}, 'PMID:18051792': {'publication date': '2007 Nov', 'sentence': 'Prednisolone treatment (50 mg daily) resulted in dramatic regression of recurrent mediastinal and pleural tumors, as well as improvement of pure red cell aplasia.', 'subject score': 888, 'object score': 1000}, 'PMID:2128749': {'publication date': '1990 Dec', 'sentence': 'A young female with pure red cell aplasia with brisk response to prednisolone therapy is described.', 'subject score': 888, 'object score': 1000}, 'PMID:23355260': {'publication date': '2013 Feb', 'sentence': 'Successful treatment of anti-erythropoietin antibody-mediated pure red cell aplasia with low-dose prednisolone.', 'subject score': 901, 'object score': 861}, 'PMID:24042508': {'publication date': '2013', 'sentence': 'CONCLUSION: Depending on the cause of the PRCA, treatment with CSP, PSL, or Ig was found to be effective in most PRCA cases.', 'subject score': 1000, 'object score': 1000}, 'PMID:8304314': {'publication date': '1994 Feb', 'sentence': 'Pure red cell aplasia was successfully treated by prednisolone or transfusion in all patients.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0034902---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9668241",
-              "object": "MONDO:0001705",
-              "publications": [
-                "PMID:12134708",
-                "PMID:12191983",
-                "PMID:1753420",
-                "PMID:17633099",
-                "PMID:18051792",
-                "PMID:2128749",
-                "PMID:23355260",
-                "PMID:24042508",
-                "PMID:8304314"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318775,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005364",
-          "name": "Graves disease",
-          "description": "Hyperthyroidism associated with diffuse hyperplasia of the thyroid gland (goiter), resulting from production of antibodies that are directed against the thyrotropin receptor complex of the follicular epithelial cells. As a result, the thyroid gland enlarges and secretes increased amounts of thyroid hormones.; A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).; An autoimmune disease where the thyroid is overactive, producing an excessive amount of thyroid hormones (a serious metabolic imbalance known as hyperthyroidism and thyrotoxicosis). This is caused by autoantibodies to the TSH-receptor (TSHR-Ab) that activate that TSH-receptor (TSHR), thereby stimulating thyroid hormone synthesis and secretion, and thyroid growth (causing a diffusely enlarged goiter). The resulting state of hyperthyroidism can cause a dramatic constellation of neuropsychological and physical signs and symptoms, which can severely compromise the patients. [HPO:sdoelken]",
-          "equivalent_curies": [
-            "MEDDRA:10018494",
-            "MEDDRA:10015679",
-            "MEDDRA:10018706",
-            "UMLS:C5546093",
-            "MEDDRA:10065624",
-            "NCIT:C3071",
-            "HP:0100647",
-            "MONDO:0005364",
-            "MEDDRA:10004161",
-            "DOID:12361",
-            "UMLS:C0018213",
-            "EFO:0004237",
-            "MESH:D006111",
-            "SNOMEDCT:55807009",
-            "MEDDRA:10074037",
-            "SNOMEDCT:353295004",
-            "MEDDRA:10015680",
-            "ICD10:E05.0",
-            "MEDDRA:10068004"
-          ],
-          "id": "MONDO:0005364",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Graves disease",
-            "Graves' disease",
-            "Graves Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/graves_disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318775,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005364",
-              "name": "Graves disease",
-              "description": "Hyperthyroidism associated with diffuse hyperplasia of the thyroid gland (goiter), resulting from production of antibodies that are directed against the thyrotropin receptor complex of the follicular epithelial cells. As a result, the thyroid gland enlarges and secretes increased amounts of thyroid hormones.; A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).; An autoimmune disease where the thyroid is overactive, producing an excessive amount of thyroid hormones (a serious metabolic imbalance known as hyperthyroidism and thyrotoxicosis). This is caused by autoantibodies to the TSH-receptor (TSHR-Ab) that activate that TSH-receptor (TSHR), thereby stimulating thyroid hormone synthesis and secretion, and thyroid growth (causing a diffusely enlarged goiter). The resulting state of hyperthyroidism can cause a dramatic constellation of neuropsychological and physical signs and symptoms, which can severely compromise the patients. [HPO:sdoelken]",
-              "equivalent_curies": [
-                "MEDDRA:10018494",
-                "MEDDRA:10015679",
-                "MEDDRA:10018706",
-                "UMLS:C5546093",
-                "MEDDRA:10065624",
-                "NCIT:C3071",
-                "HP:0100647",
-                "MONDO:0005364",
-                "MEDDRA:10004161",
-                "DOID:12361",
-                "UMLS:C0018213",
-                "EFO:0004237",
-                "MESH:D006111",
-                "SNOMEDCT:55807009",
-                "MEDDRA:10074037",
-                "SNOMEDCT:353295004",
-                "MEDDRA:10015680",
-                "ICD10:E05.0",
-                "MEDDRA:10068004"
-              ],
-              "id": "MONDO:0005364",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Graves disease",
-                "Graves' disease",
-                "Graves Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/graves_disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9333220,
-            "start": 568,
-            "end": 318775,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12006721': {'publication date': '2002', 'sentence': \"She was diagnosed as having Graves' disease and was treated with propylthiouracil, and prednisolone was given for neck pain.\", 'subject score': 1000, 'object score': 1000}, 'PMID:33653401': {'publication date': '2021 Mar 02', 'sentence': 'CONCLUSIONS: The results suggested that the effect of intravenous MPT followed by oral prednisolone on TRAb level was temporary in children with GD.', 'subject score': 888, 'object score': 1000}, 'PMID:3583222': {'publication date': '1987 Apr', 'sentence': \"Significant increase (p less than .01) in clearance values and significant decreases in half-life times (p less than .01) were found for both total and unbound prednisolone in women with Graves' disease compared with the control subjects.\", 'subject score': 861, 'object score': 1000}, 'PMID:3622224': {'publication date': '1987', 'sentence': \"The ITP occurred after 8 years of well-controlled Graves' disease and IDDM with appropriate treatment, but subsided with prednisolone therapy, followed by splenectomy.\", 'subject score': 888, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0018213---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9538921",
-              "object": "MONDO:0005364",
-              "publications": [
-                "PMID:12006721",
-                "PMID:33653401",
-                "PMID:3583222",
-                "PMID:3622224"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 516834,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019338",
-          "name": "sarcoidosis",
-          "description": "An idiopathic inflammatory disorder characterized by the formation of non-necrotizing epithelioid granulomas which contain giant cells. It usually affects the lungs, lymph nodes, liver, and skin. Cardiac involvement is also possible.; An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.; Sarcoidosis is a disease that leads to inflammation, usually in your lungs, skin, or lymph nodes. It starts as tiny, grain-like lumps, called granulomas. Sarcoidosis can affect any organ in your body.  No one is sure what causes sarcoidosis. It affects men and women of all ages and races. It occurs mostly in people ages 20 to 50, African Americans, especially women, and people of Northern European origin. Many people have no symptoms. If you have symptoms, they may include: Cough Shortness of breath Weight loss Night sweats Fatigue  Tests to diagnose sarcoidosis include chest x-rays, lung function tests, and a biopsy. Not everyone who has the disease needs treatment. If you do, prednisone, a type of steroid, is the main treatment. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D012507",
-            "MEDDRA:10039490",
-            "ICD9:135",
-            "NCIT:C34995",
-            "UMLS:C0036202",
-            "ORPHANET:797",
-            "DOID:11335",
-            "MONDO:0019338",
-            "SNOMEDCT:31541009",
-            "MEDDRA:10039485",
-            "MEDDRA:10054039",
-            "MEDDRA:10054078",
-            "ICD10:D86",
-            "MEDDRA:10054079",
-            "MEDDRA:10039486"
-          ],
-          "id": "MONDO:0019338",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_sarcoidosis",
-            "sarcoidosis",
-            "Sarcoidosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/sarcoidosis",
-            "http://www.mayoclinic.org/diseases-conditions/sarcoidosis/basics/definition/con-20022569?_ga=1.188430891.2017809229.1415219956",
-            "http://ghr.nlm.nih.gov/glossary=sarcoidosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 516834,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019338",
-              "name": "sarcoidosis",
-              "description": "An idiopathic inflammatory disorder characterized by the formation of non-necrotizing epithelioid granulomas which contain giant cells. It usually affects the lungs, lymph nodes, liver, and skin. Cardiac involvement is also possible.; An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.; Sarcoidosis is a disease that leads to inflammation, usually in your lungs, skin, or lymph nodes. It starts as tiny, grain-like lumps, called granulomas. Sarcoidosis can affect any organ in your body.  No one is sure what causes sarcoidosis. It affects men and women of all ages and races. It occurs mostly in people ages 20 to 50, African Americans, especially women, and people of Northern European origin. Many people have no symptoms. If you have symptoms, they may include: Cough Shortness of breath Weight loss Night sweats Fatigue  Tests to diagnose sarcoidosis include chest x-rays, lung function tests, and a biopsy. Not everyone who has the disease needs treatment. If you do, prednisone, a type of steroid, is the main treatment. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D012507",
-                "MEDDRA:10039490",
-                "ICD9:135",
-                "NCIT:C34995",
-                "UMLS:C0036202",
-                "ORPHANET:797",
-                "DOID:11335",
-                "MONDO:0019338",
-                "SNOMEDCT:31541009",
-                "MEDDRA:10039485",
-                "MEDDRA:10054039",
-                "MEDDRA:10054078",
-                "ICD10:D86",
-                "MEDDRA:10054079",
-                "MEDDRA:10039486"
-              ],
-              "id": "MONDO:0019338",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_sarcoidosis",
-                "sarcoidosis",
-                "Sarcoidosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/sarcoidosis",
-                "http://www.mayoclinic.org/diseases-conditions/sarcoidosis/basics/definition/con-20022569?_ga=1.188430891.2017809229.1415219956",
-                "http://ghr.nlm.nih.gov/glossary=sarcoidosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8939629,
-            "start": 568,
-            "end": 516834,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11573554': {'publication date': '2001 Jul', 'sentence': 'Clinical characteristics, pulmonary function abnormalities and outcome of prednisolone treatment in 106 patients with sarcoidosis.', 'subject score': 888, 'object score': 1000}, 'PMID:13456587': {'publication date': '1956 Dec', 'sentence': '[Prednisolone therapy in lymphogranulomatosis].', 'subject score': 888, 'object score': 1000}, 'PMID:14719997': {'publication date': '2003', 'sentence': 'The combination of prednisolone and azathioprine over a period of 2 years has induced long-lasting remission in patients with resistant sarcoidosis.', 'subject score': 1000, 'object score': 888}, 'PMID:16472440': {'publication date': '2006 Jan 30', 'sentence': 'We describe a 29-year-old man with histologically verified sarcoidosis and persistent, pronounced enlargement of the peripheral lymph nodes, resistant to treatment with prednisolone and methotrexate.', 'subject score': 1000, 'object score': 840}, 'PMID:16813054': {'publication date': '2006', 'sentence': 'Prednisolone exerted a significant effect on clinical manifestations, laboratory values, and radiation pattern in patients with sarcoidosis, but more commonly (28.9%) led to its relapses than alternative treatment and active follow-up.', 'subject score': 1000, 'object score': 1000}, 'PMID:1826195': {'publication date': '1991 Apr', 'sentence': 'This phenomenon, many times described but not understood, was studied in a group of 13 sarcoidosis patients, of whom 7 received prednisolone treatment.', 'subject score': 775, 'object score': 790}, 'PMID:21428758': {'publication date': '2011 Apr', 'sentence': 'Only two RCTs were indentified for the treatment of intraocular sarcoidosis, one on etanercept, and the other from 1967 on prednisolone or oxyphenbutazone vs. placebo.', 'subject score': 1000, 'object score': 888}, 'PMID:27193294': {'publication date': '2016 Oct', 'sentence': 'An 88-year-old man, receiving prednisolone for sarcoidosis, presented with a discrete keratotic lesion on the dorsum of his right hand following the placement of an intravenous cannula a month prior to its appearance.', 'subject score': 1000, 'object score': 1000}, 'PMID:2747059': {'publication date': '1989 Jan', 'sentence': 'The levels of whole immunoglobulin antibody activities to P. acnes in BALF were as follows: 412.3 +/- 443.9 O.D./albumin 1 mg (M +/- SD) in 31 untreated sarcoidosis patients, 556.6 +/- 341.8 in 10 sarcoidosis patients treated with prednisolone, and 231.5 +/- 156.8 in 16 control individuals.', 'subject score': 1000, 'object score': 790}, 'PMID:3022627': {'publication date': '1986 Nov', 'sentence': 'The use of prednisolone in patients with sarcoidosis can be safely based upon pharmacokinetic data obtained from normal volunteers.', 'subject score': 1000, 'object score': 1000}, 'PMID:33118494': {'publication date': '2020 Oct 19', 'sentence': 'We present a case story of classic WD seen in a 48-year-old man presumed to have sarcoidosis and therefore treated with prednisolone which caused WD to flare up and ultimately unmask the disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:33263945': {'publication date': '2020 Dec 02', 'sentence': 'Although in the majority of the cases (52/80, 65.0%) there was no need for systemic prednisolone for the management of sarcoidosis, a significant proportion of patients finally discontinued ICIs treatment (44/80, 55.0%).', 'subject score': 888, 'object score': 1000}, 'PMID:3576447': {'publication date': '1987 May', 'sentence': 'During the follow-up period, hypercalcemia was diagnosed in five patients and successfully treated in four: by graft excision in two patients, by excision of a fourth gland from the neck in one patient, and with prednisolone in a patient with sarcoidosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:432030': {'publication date': '1979 Jan', 'sentence': '[Combined chemotherapy with dopan + natulan + vincristine + prednisolone in children with lymphogranulomatosis].', 'subject score': 833, 'object score': 1000}, 'PMID:6893205': {'publication date': '1980 Aug', 'sentence': 'In eight patients with sarcoidosis, prednisolone treatment (50 mg/day for 8 days) produced a significant fall in serum 1,25(OH)2D [4.8 +/) 1.9 to 3.3 +/- 1.0 (SD) ng/dl; P less than 0.025], concomitant with a significant decrease in the fracitional intestinal Ca absorption (alpha) from 0.58 +/- to 0.14 to 0.46 +/- 0.13 (+/- SD; P less than 0.005).', 'subject score': 888, 'object score': 1000}, 'PMID:7702975': {'publication date': '1994 Nov', 'sentence': 'The findings ultimately led to a diagnosis of myocardial sarcoidosis, which was treated successfully with prednisolone.', 'subject score': 1000, 'object score': 888}, 'PMID:8069017': {'publication date': '1994 Apr', 'sentence': 'This is a rare case of sarcoidosis in which renal calcification remitted after treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0036202---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9135976",
-              "object": "MONDO:0019338",
-              "publications": [
-                "PMID:11573554",
-                "PMID:13456587",
-                "PMID:14719997",
-                "PMID:16472440",
-                "PMID:16813054",
-                "PMID:1826195",
-                "PMID:21428758",
-                "PMID:27193294",
-                "PMID:2747059",
-                "PMID:3022627",
-                "PMID:33118494",
-                "PMID:33263945",
-                "PMID:3576447",
-                "PMID:432030",
-                "PMID:6893205",
-                "PMID:7702975",
-                "PMID:8069017"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 536164,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011849",
-          "name": "psoriatic arthritis",
-          "description": "Joint inflammation associated with psoriasis.; A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people with psoriasis have psoriatic arthritis. It causes pain, stiffness, and swelling of the joints. It is often mild, but can sometimes be serious and affect many joints. The joint and skin problems don't always happen at the same time. Your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. There is no cure, but medicines can help control inflammation and pain. In rare cases, you might need surgery to repair or replace damaged joints.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10037163",
-            "EFO:0003778",
-            "UMLS:C0003872",
-            "DOID:9008",
-            "ORPHANET:40050",
-            "MEDDRA:10003377",
-            "ICD9:696.0",
-            "NCIT:C61277",
-            "MONDO:0011849",
-            "SNOMEDCT:156370009",
-            "MEDDRA:10037162",
-            "MESH:D015535",
-            "MEDDRA:10037160",
-            "ICD10:L40.5"
-          ],
-          "id": "MONDO:0011849",
-          "category": "biolink:Disease",
-          "all_names": [
-            "psoriatic arthritis",
-            "Arthritis, Psoriatic",
-            "Psoriatic arthropathy",
-            "Psoriatic Arthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/psoriatic_arthropathy",
-            "https://ghr.nlm.nih.gov/condition/psoriatic-arthritis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000413.htm",
-            "http://www.mayoclinic.com/health/psoriatic-arthritis/ds00476"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 536164,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011849",
-              "name": "psoriatic arthritis",
-              "description": "Joint inflammation associated with psoriasis.; A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people with psoriasis have psoriatic arthritis. It causes pain, stiffness, and swelling of the joints. It is often mild, but can sometimes be serious and affect many joints. The joint and skin problems don't always happen at the same time. Your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. There is no cure, but medicines can help control inflammation and pain. In rare cases, you might need surgery to repair or replace damaged joints.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10037163",
-                "EFO:0003778",
-                "UMLS:C0003872",
-                "DOID:9008",
-                "ORPHANET:40050",
-                "MEDDRA:10003377",
-                "ICD9:696.0",
-                "NCIT:C61277",
-                "MONDO:0011849",
-                "SNOMEDCT:156370009",
-                "MEDDRA:10037162",
-                "MESH:D015535",
-                "MEDDRA:10037160",
-                "ICD10:L40.5"
-              ],
-              "id": "MONDO:0011849",
-              "category": "biolink:Disease",
-              "all_names": [
-                "psoriatic arthritis",
-                "Arthritis, Psoriatic",
-                "Psoriatic arthropathy",
-                "Psoriatic Arthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/psoriatic_arthropathy",
-                "https://ghr.nlm.nih.gov/condition/psoriatic-arthritis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000413.htm",
-                "http://www.mayoclinic.com/health/psoriatic-arthritis/ds00476"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8912988,
-            "start": 568,
-            "end": 536164,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1155088': {'publication date': '1975 Jul', 'sentence': 'Methotrexate and prednisolone treatment of a child with psoriatic arthritis.', 'subject score': 888, 'object score': 1000}, 'PMID:1275584': {'publication date': '1976 Feb', 'sentence': 'Thirteen patients with rheumatoid or psoriatic arthritis who had not previously received corticosteroids were treated with prednisolone in a single-dose each morning.', 'subject score': 1000, 'object score': 1000}, 'PMID:34544940': {'publication date': '2021 Sep 21', 'sentence': 'A Japanese man in his 80s with psoriatic arthritis that was being treated with prednisolone was admitted for dyspnea.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0003872---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9109448",
-              "object": "MONDO:0011849",
-              "publications": [
-                "PMID:1155088",
-                "PMID:1275584",
-                "PMID:34544940"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319679,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-          "name": "lymphoma",
-          "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:115244002",
-            "DOID:0060058",
-            "MONDO:0005062",
-            "SNOMEDCT:118600007",
-            "HP:0002665",
-            "NCIT:C7065",
-            "EFO:0000574",
-            "ORPHANET:223735",
-            "MESH:D008223",
-            "SNOMEDCT:188676008",
-            "PDQ:CDR0000041429",
-            "MEDDRA:10025316",
-            "UMLS:C0024299",
-            "NCIT:C3208",
-            "MEDDRA:10025632",
-            "MEDDRA:10025310",
-            "MEDDRA:10025633",
-            "SNOMEDCT:1163043007",
-            "ICD10:C85.9",
-            "UMLS:C1536843",
-            "UMLS:C0334621",
-            "MEDDRA:10025315"
-          ],
-          "id": "MONDO:0005062",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphocytic Neoplasm",
-            "Lymphoma",
-            "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-            "lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/lymphoma",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319679,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-              "name": "lymphoma",
-              "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:115244002",
-                "DOID:0060058",
-                "MONDO:0005062",
-                "SNOMEDCT:118600007",
-                "HP:0002665",
-                "NCIT:C7065",
-                "EFO:0000574",
-                "ORPHANET:223735",
-                "MESH:D008223",
-                "SNOMEDCT:188676008",
-                "PDQ:CDR0000041429",
-                "MEDDRA:10025316",
-                "UMLS:C0024299",
-                "NCIT:C3208",
-                "MEDDRA:10025632",
-                "MEDDRA:10025310",
-                "MEDDRA:10025633",
-                "SNOMEDCT:1163043007",
-                "ICD10:C85.9",
-                "UMLS:C1536843",
-                "UMLS:C0334621",
-                "MEDDRA:10025315"
-              ],
-              "id": "MONDO:0005062",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphocytic Neoplasm",
-                "Lymphoma",
-                "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-                "lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/lymphoma",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8882138,
-            "start": 568,
-            "end": 319679,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11518416': {'publication date': '2001 Aug', 'sentence': 'This paper presents the results of a prospective study to investigate the prognostic value of clinical staging, histological grading, immunophenotype, mitotic count and average numbers of argyrophilic nucleolar organiser region counts in dogs with multicentric lymphosarcoma treated with a standard chemotherapy protocol comprising vincristine, cyclophosphamide and prednisolone.', 'subject score': 1000, 'object score': 888}, 'PMID:11837901': {'publication date': '2001 Dec', 'sentence': 'PROCEDURE: An accepted chemotherapy protocol utilising l-asparaginase, vincristine, cyclophosphamide, doxorubicin, methotrexate and prednisolone was modified and used to treat 60 cats with lymphosarcoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:11899035': {'publication date': '2002', 'sentence': 'Chemotherapy with cyclophosphamide, vincristine, and prednisolone (COP) in cats with malignant lymphoma: new results with an old protocol.', 'subject score': 1000, 'object score': 1000}, 'PMID:14432695': {'publication date': '1959 May-Jun', 'sentence': '[Apropos of a case of lymphosarcoma treated with prednisolone and roentgenotherapy].', 'subject score': 1000, 'object score': 1000}, 'PMID:17993883': {'publication date': '2007 Nov', 'sentence': 'Eight patients were treated surgically with adjuvant postoperative radiotherapy, whereas eight patients with lymphoma treated with combination chemotherapy (vincristine, Adriamycin, cyclophosphamide, methotrexate, and prednisolone), the survival rate was very poor.', 'subject score': 1000, 'object score': 1000}, 'PMID:18762565': {'publication date': '2008', 'sentence': 'An 8-year-old, mixed-breed dog with preputial epitheliotropic lymphoma was initially treated with cyclophosphamide, vincristine, and prednisolone.', 'subject score': 1000, 'object score': 766}, 'PMID:1923457': {'publication date': '1991 Jun', 'sentence': 'Thirty-seven patients with malignant lymphoma were treated with mitoxantrone, ifosfamide, vindesine, and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:19620817': {'publication date': '2009 Jul', 'sentence': 'After a diagnosis of HHV-8-negative PEL-like lymphoma, she was treated with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisolone).', 'subject score': 1000, 'object score': 1000}, 'PMID:20059527': {'publication date': '2010 May', 'sentence': 'OBJECTIVE: The efficacy of pirarubicin (THP)-COP was previously compared with cyclophophamide + doxorubicin + vincristine + prednisolone (CHOP) in elderly patients with lymphoma.', 'subject score': 775, 'object score': 1000}, 'PMID:22489828': {'publication date': '2014 Mar', 'sentence': 'In this retrospective study, the efficacy and safety were examined for an intraperitoneal chemotherapy protocol-cyclophosphamide, vincristine and prednisolone (IP-COP) in 26 cats with malignant lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:22997596': {'publication date': '2012', 'sentence': 'We present the results of a long-term followup of two patients who were diagnosed with PRL and treated with cyclophosphamide, adriamycin, vincristine, prednisolone and rituximab (CHOP + R) regimen.', 'subject score': 1000, 'object score': 851}, 'PMID:23267908': {'publication date': '2012 Nov', 'sentence': 'The malignant lymphoma patient was treated by cyclophosphamide+doxorubicin+vincristine+prednisolone(CHOP) with rituximab.', 'subject score': 833, 'object score': 901}, 'PMID:24721419': {'publication date': '2014 Apr 11', 'sentence': 'The lymphoma went into complete remission after 6 courses of rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone/prednisolone therapy.', 'subject score': 851, 'object score': 1000}, 'PMID:26933263': {'publication date': '2016 Mar', 'sentence': 'Forty-four dogs with multicentric lymphoma were treated using a cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) induction protocol or treated using a cyclophosphamide, mitoxantrone, vincristine, and prednisolone (CMOP) induction protocol.', 'subject score': 1000, 'object score': 888}, 'PMID:27240922': {'publication date': '2016 Jul', 'sentence': 'Combination chemotherapy, using cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone (CHOP), is the most commonly used treatment for canine lymphoma.', 'subject score': 1000, 'object score': 888}, 'PMID:27777431': {'publication date': '2016 Oct', 'sentence': 'Malignant lymphoma was suspected as a possible underlying disease, but the histology of the lymph nodes led to a final diagnosis of KFD and treatment with prednisolone (1 mg/kg/day), resulting in clinical improvement.', 'subject score': 1000, 'object score': 1000}, 'PMID:2785612': {'publication date': '1989 Jan', 'sentence': 'Lymphoma was treated with cyclophosphamide, doxorubicin, vinblastine and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:29380942': {'publication date': '2018 Sep', 'sentence': 'The standard of care treatment for canine lymphoma is multi-agent chemotherapy containing prednisolone, cyclophosphamide, vincristine and an anthracycline such as doxorubicin (CHOP) or epirubicin (CEOP).', 'subject score': 822, 'object score': 888}, 'PMID:29958524': {'publication date': '2018 06', 'sentence': 'Permeability glycoprotein (P-glycoprotein, Pgp) immunohistochemistry (IHC) was evaluated in dogs with multicentric lymphoma treated with cyclophosphamide- doxorubicin-vincristine-prednisolone with or without L-Asparaginase.', 'subject score': 833, 'object score': 888}, 'PMID:30117253': {'publication date': '2018 Dec', 'sentence': 'The cyclophosphamide, doxorubicin, vincristine, and prednisolone protocol is widely accepted as a first line treatment for canine lymphoma.', 'subject score': 888, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0024299---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9077262",
-              "object": "MONDO:0005062",
-              "publications": [
-                "PMID:11518416",
-                "PMID:11837901",
-                "PMID:11899035",
-                "PMID:14432695",
-                "PMID:17993883",
-                "PMID:18762565",
-                "PMID:1923457",
-                "PMID:19620817",
-                "PMID:20059527",
-                "PMID:22489828",
-                "PMID:22997596",
-                "PMID:23267908",
-                "PMID:24721419",
-                "PMID:26933263",
-                "PMID:27240922",
-                "PMID:27777431",
-                "PMID:2785612",
-                "PMID:29380942",
-                "PMID:29958524",
-                "PMID:30117253"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 530650,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016367",
-          "name": "dermatomyositis",
-          "description": "Inflammation of the skin and muscle.; A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003882",
-            "EFO:0000398",
-            "ICD10:M33",
-            "MONDO:0016367",
-            "SNOMEDCT:396230008",
-            "NCIT:C26744",
-            "DOID:10223",
-            "MEDDRA:10012503",
-            "ORPHANET:221",
-            "UMLS:C0011633",
-            "ICD9:710.3"
-          ],
-          "id": "MONDO:0016367",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatomyositis",
-            "dermatomyositis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/dermatomyositis",
-            "http://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 530650,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016367",
-              "name": "dermatomyositis",
-              "description": "Inflammation of the skin and muscle.; A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003882",
-                "EFO:0000398",
-                "ICD10:M33",
-                "MONDO:0016367",
-                "SNOMEDCT:396230008",
-                "NCIT:C26744",
-                "DOID:10223",
-                "MEDDRA:10012503",
-                "ORPHANET:221",
-                "UMLS:C0011633",
-                "ICD9:710.3"
-              ],
-              "id": "MONDO:0016367",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatomyositis",
-                "dermatomyositis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/dermatomyositis",
-                "http://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8867076,
-            "start": 568,
-            "end": 530650,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11505515': {'publication date': '2001 Jun', 'sentence': 'The administration of prednisolone (60 mg/day) was initiated, which resulted in improvement of DM.', 'subject score': 1000, 'object score': 1000}, 'PMID:15101164': {'publication date': '2004 Feb', 'sentence': 'The patient was treated by administration of diethylstilbestrol phosphate and prednisolone for prostatic carcinoma and dermatomyositis, respectively, but he died of multiple metastasis of the tumor 1 year and 5 months later.', 'subject score': 1000, 'object score': 1000}, 'PMID:15146429': {'publication date': '2004 May', 'sentence': 'METHODS: Muscle biopsy specimens from 5 patients with PM and 4 patients with DM, obtained before and 3-6 months after initiation of prednisolone therapy, were assessed by conventional microscopic evaluation and computerized image analysis, and HMGB-1 expression was investigated by immunohistochemical staining.', 'subject score': 888, 'object score': 1000}, 'PMID:15197005': {'publication date': '2004', 'sentence': 'A 69-year-old Japanese man treated with prednisolone for dermatomyositis developed erythema and bilateral swelling of arms and forearms.', 'subject score': 1000, 'object score': 1000}, 'PMID:17389171': {'publication date': '2007 Mar', 'sentence': 'A 56-year-old woman with dermatomyositis who had been treated with prednisolone, cyclophosphamide, and azathioprine for 2 months presented with fever, hematuria, and abdominal pain for 2 days.', 'subject score': 1000, 'object score': 1000}, 'PMID:17878679': {'publication date': '2007 Aug', 'sentence': 'Twenty-one patients (91%) with PM/DM received high dose of prednisolone therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:18387858': {'publication date': '2008 Jul 15', 'sentence': 'The unbound concentrations of prednisolone were measured in 10 patients with nephrotic syndrome, two patients with systemic lupus erythematosus, and one patient with dermatomyositis by examining protein bindings of prednisolone on one or more occasions during prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:19209021': {'publication date': '2009 Feb', 'sentence': 'The dermatomyositis responded well to treatment with prednisolone and azathioprin although sorafenib did not lead to a response in the underlying HCC.', 'subject score': 1000, 'object score': 1000}, 'PMID:21340495': {'publication date': '2011 Aug', 'sentence': 'DM patients (n=14) with A/SIP were treated with 1 mg/kg/day prednisolone and 4 mg/kg/day CSA within 4.4 days (range, 1-12 days) from diagnosis.', 'subject score': 840, 'object score': 888}, 'PMID:23173570': {'publication date': '2012 Nov 22', 'sentence': 'BACKGROUND: To investigate whether or not coadministration of tacrolimus (TAC) with prednisolone (PSL) can produce a beneficial effect in the treatment of polymyositis/ dermatomyositis (PM/DM).', 'subject score': 1000, 'object score': 1000}, 'PMID:24090894': {'publication date': '2013 Oct', 'sentence': 'A diagnosis of DM was suspected in patients treated with prednisolone, 1.5 mg/kg/d.', 'subject score': 1000, 'object score': 1000}, 'PMID:24387253': {'publication date': '2003 Dec', 'sentence': 'PM/DM was defined as steroid-resistant when the muscle strength of a patient did not improve despite the administration of more than 50 mg prednisolone per day for more than 4 weeks.', 'subject score': 790, 'object score': 1000}, 'PMID:25943378': {'publication date': '2015 May 06', 'sentence': 'Her history revealed that she had been taking prednisolone to treat dermatomyositis and interstitial pneumonia for approximately 15 years.', 'subject score': 1000, 'object score': 1000}, 'PMID:26668568': {'publication date': '2015 Sep-Dec', 'sentence': 'She immediately underwent cancer chemotherapy with prednisolone therapy for DM.', 'subject score': 888, 'object score': 1000}, 'PMID:28133335': {'publication date': '2016 Nov', 'sentence': 'He was diagnosed with dermatomyositis and treated with prednisolone after gastrectomy.', 'subject score': 1000, 'object score': 1000}, 'PMID:28224486': {'publication date': '2017 06', 'sentence': 'We report a case of severe anterograde amnesia caused by HHV-6 encephalitis in a young female patient on rituximab, azathioprine and prednisolone for dermatomyositis (DM).', 'subject score': 1000, 'object score': 1000}, 'PMID:29567897': {'publication date': '2018', 'sentence': 'She had a 10-year history of chronic immunosuppressive therapy including methotrexate and prednisolone for dermatomyositis.', 'subject score': 1000, 'object score': 1000}, 'PMID:30483040': {'publication date': '2018', 'sentence': 'She was diagnosed with DM, and combination treatment with prednisolone and tacrolimus was started.', 'subject score': 1000, 'object score': 1000}, 'PMID:30690762': {'publication date': '2019 07', 'sentence': 'A case of dermatomyositis with the anti-signal recognition particle antibody that was successfully treated with prednisolone and intravenous immunoglobulin therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:32830178': {'publication date': '2020 Aug 22', 'sentence': 'A Case of Mycophenolate Mofetil-induced Diffuse Large B-cell Lymphoma in Which a Solitary Lung Nodule Remitted Spontaneously.A 76-year-old woman with dermatomyositis was being treated with prednisolone, tacrolimus, and mycophenolate mofetil.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0011633---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9061500",
-              "object": "MONDO:0016367",
-              "publications": [
-                "PMID:11505515",
-                "PMID:15101164",
-                "PMID:15146429",
-                "PMID:15197005",
-                "PMID:17389171",
-                "PMID:17878679",
-                "PMID:18387858",
-                "PMID:19209021",
-                "PMID:21340495",
-                "PMID:23173570",
-                "PMID:24090894",
-                "PMID:24387253",
-                "PMID:25943378",
-                "PMID:26668568",
-                "PMID:28133335",
-                "PMID:28224486",
-                "PMID:29567897",
-                "PMID:30483040",
-                "PMID:30690762",
-                "PMID:32830178"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 530656,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005100",
-          "name": "systemic sclerosis",
-          "description": "A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.; A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:90291",
-            "EFO:0000717",
-            "UMLS:CN206012",
-            "MEDDRA:10036814",
-            "UMLS:C0036421",
-            "ICD10:M34.0",
-            "DOID:418",
-            "UMLS:C0700318",
-            "MEDDRA:10078638",
-            "SNOMEDCT:89155008",
-            "MONDO:0005100",
-            "ICD9:710.1",
-            "MEDDRA:10042953",
-            "PDQ:CDR0000587622",
-            "MESH:D012595",
-            "NCIT:C72070"
-          ],
-          "id": "MONDO:0005100",
-          "category": "biolink:Disease",
-          "all_names": [
-            "systemic sclerosis",
-            "Scleroderma, Systemic",
-            "Systemic sclerosis",
-            "Systemic Scleroderma",
-            "systemic scleroderma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://ghr.nlm.nih.gov/condition/systemic-scleroderma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 530656,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005100",
-              "name": "systemic sclerosis",
-              "description": "A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.; A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:90291",
-                "EFO:0000717",
-                "UMLS:CN206012",
-                "MEDDRA:10036814",
-                "UMLS:C0036421",
-                "ICD10:M34.0",
-                "DOID:418",
-                "UMLS:C0700318",
-                "MEDDRA:10078638",
-                "SNOMEDCT:89155008",
-                "MONDO:0005100",
-                "ICD9:710.1",
-                "MEDDRA:10042953",
-                "PDQ:CDR0000587622",
-                "MESH:D012595",
-                "NCIT:C72070"
-              ],
-              "id": "MONDO:0005100",
-              "category": "biolink:Disease",
-              "all_names": [
-                "systemic sclerosis",
-                "Scleroderma, Systemic",
-                "Systemic sclerosis",
-                "Systemic Scleroderma",
-                "systemic scleroderma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://ghr.nlm.nih.gov/condition/systemic-scleroderma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8851879,
-            "start": 568,
-            "end": 530656,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11491499': {'publication date': '2001 Jul-Aug', 'sentence': 'METHODS: Resting radionuclide ventriculography with 99mTc was performed before and 20 days after the administration of prednisolone, 20 mg daily, in 32 patients with SSc without clinically evident myocardial dysfunction at rest; 13 and 19 patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), respectively, were studied in parallel as controls.', 'subject score': 1000, 'object score': 1000}, 'PMID:3280619': {'publication date': '1988 Mar', 'sentence': 'In patients with systemic scleroderma, who also suffer from additional myositis, interstitial lung diseases, or arthritis, anti-inflammatory treatment with prednisolone and azathioprine is suggested.', 'subject score': 1000, 'object score': 1000}, 'PMID:33102777': {'publication date': '2020 Oct', 'sentence': 'For RA and SSc, she was treated with prednisolone and abatacept and was taking vonoprazan as prophylaxis for steroid-induced gastric ulcers.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0036421---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9046445",
-              "object": "MONDO:0005100",
-              "publications": [
-                "PMID:11491499",
-                "PMID:3280619",
-                "PMID:33102777"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 534917,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0020548",
-          "name": "ocular pemphigoid",
-          "description": "Ocular pemphigoid is a rare inflammatory eye disease characterized by sub-epithelial blistering manifesting with bilateral, asymmetrical, chronic or recurrent conjunctivitis and aberrant tissue regeneration leading to progressive conjunctival fibrosis, secondary corneal vascularization and, in some cases, blindness. Patients typically present with conjunctival redness, increased lacrimation, burning and/or foreign body sensation, edema, limbitis and/or varying degrees of ocular pain. Ankyloblepharon may be observed in end stages of the disease.",
-          "equivalent_curies": [
-            "MONDO:0020548",
-            "MEDDRA:10057052",
-            "MEDDRA:10087064",
-            "SNOMEDCT:34250006",
-            "MEDDRA:10004294",
-            "MESH:D010390",
-            "UMLS:C0030804",
-            "ORPHANET:99922"
-          ],
-          "id": "MONDO:0020548",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Ocular cicatricial pemphigoid",
-            "Pemphigoid, Benign Mucous Membrane",
-            "ocular pemphigoid"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 534917,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0020548",
-              "name": "ocular pemphigoid",
-              "description": "Ocular pemphigoid is a rare inflammatory eye disease characterized by sub-epithelial blistering manifesting with bilateral, asymmetrical, chronic or recurrent conjunctivitis and aberrant tissue regeneration leading to progressive conjunctival fibrosis, secondary corneal vascularization and, in some cases, blindness. Patients typically present with conjunctival redness, increased lacrimation, burning and/or foreign body sensation, edema, limbitis and/or varying degrees of ocular pain. Ankyloblepharon may be observed in end stages of the disease.",
-              "equivalent_curies": [
-                "MONDO:0020548",
-                "MEDDRA:10057052",
-                "MEDDRA:10087064",
-                "SNOMEDCT:34250006",
-                "MEDDRA:10004294",
-                "MESH:D010390",
-                "UMLS:C0030804",
-                "ORPHANET:99922"
-              ],
-              "id": "MONDO:0020548",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Ocular cicatricial pemphigoid",
-                "Pemphigoid, Benign Mucous Membrane",
-                "ocular pemphigoid"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8820407,
-            "start": 568,
-            "end": 534917,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11464188': {'publication date': '2001 Aug', 'sentence': 'METHODS: Three patients with CP were treated with mycophenolate mofetil and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:14739497': {'publication date': '2004 Jan', 'sentence': 'Based on a diagnosis of anti-epiligrin cicatricial pemphigoid, he was treated with prednisolone, minocycline hydrochloride and nicotinamide.', 'subject score': 1000, 'object score': 824}, 'PMID:22727107': {'publication date': '2012 Jul', 'sentence': 'Treatment of mucous membrane pemphigoid with the combination of mycophenolate mofetil, dapsone, and prednisolone: a case series.', 'subject score': 1000, 'object score': 1000}, 'PMID:9798228': {'publication date': '1998 Oct', 'sentence': 'CONCLUSIONS: The addition of levamisole to prednisolone may produce improved results in the management of erosive lichen planus, erythema multiforme, mucous membrane pemphigoid, and early pemphigus vulgaris.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0030804---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9013774",
-              "object": "MONDO:0020548",
-              "publications": [
-                "PMID:11464188",
-                "PMID:14739497",
-                "PMID:22727107",
-                "PMID:9798228"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316993,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005376",
-          "name": "membranous glomerulonephritis",
-          "description": "A slowly progressive inflammation of the glomeruli characterized by immune complex deposits at the glomerular basement membrane, resulting in a thickened membrane, and nephrotic syndrome.; An experimental rat model of human membranous nephropathy characterized by complement activation and formation of subepithelial immune deposits in the glomerular capillary wall.; A type of glomerulonephropathy characterized by thickening of the basement membrane and deposition of immune complexes in the subepithelial space. [Eurenomics:fschaefer]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005376",
-            "HP:0012578",
-            "UMLS:C0017665",
-            "DOID:10976",
-            "MESH:D015433",
-            "SNOMEDCT:77182004",
-            "MEDDRA:10018372",
-            "MEDDRA:10027170",
-            "ICD10:N03.2",
-            "NCIT:C34645",
-            "EFO:0004254"
-          ],
-          "id": "MONDO:0005376",
-          "category": "biolink:Disease",
-          "all_names": [
-            "membranous glomerulonephritis",
-            "Glomerulonephritis, Membranous",
-            "Membranous Glomerulonephritis",
-            "Membranous nephropathy",
-            "Membranous glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316993,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005376",
-              "name": "membranous glomerulonephritis",
-              "description": "A slowly progressive inflammation of the glomeruli characterized by immune complex deposits at the glomerular basement membrane, resulting in a thickened membrane, and nephrotic syndrome.; An experimental rat model of human membranous nephropathy characterized by complement activation and formation of subepithelial immune deposits in the glomerular capillary wall.; A type of glomerulonephropathy characterized by thickening of the basement membrane and deposition of immune complexes in the subepithelial space. [Eurenomics:fschaefer]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005376",
-                "HP:0012578",
-                "UMLS:C0017665",
-                "DOID:10976",
-                "MESH:D015433",
-                "SNOMEDCT:77182004",
-                "MEDDRA:10018372",
-                "MEDDRA:10027170",
-                "ICD10:N03.2",
-                "NCIT:C34645",
-                "EFO:0004254"
-              ],
-              "id": "MONDO:0005376",
-              "category": "biolink:Disease",
-              "all_names": [
-                "membranous glomerulonephritis",
-                "Glomerulonephritis, Membranous",
-                "Membranous Glomerulonephritis",
-                "Membranous nephropathy",
-                "Membranous glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8747911,
-            "start": 568,
-            "end": 316993,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11399923': {'publication date': '2001 Jun', 'sentence': 'He was diagnosed as having membranous nephropathy by renal biopsy and was treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:14964576': {'publication date': '2004 Jan', 'sentence': 'We examined outcomes of a short course of cyclophosphamide alternating with prednisolone for MN patients with nephrotic syndrome.', 'subject score': 1000, 'object score': 901}, 'PMID:1516283': {'publication date': '1992 Aug', 'sentence': 'Patients with membranous nephropathy showed a significant elevation of Leu 2a+DR+ cells after treatment with PSL.', 'subject score': 1000, 'object score': 1000}, 'PMID:16130411': {'publication date': '2005', 'sentence': 'She was diagnosed as membranous nephropathy by needle renal biopsy, and treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:16968719': {'publication date': '2006 Nov', 'sentence': 'METHODS: In the first part of the study, 51 nephrotic patients with MN were treated either with CyA and prednisolone (n=31) or CyA alone (n=20) for 12 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:17995584': {'publication date': '2007 Dec', 'sentence': 'CONCLUSION: Data from this pilot study indicate that more than 60% of patients with MN and nephrotic syndrome respond to combined MMF and prednisolone treatment, and suggest potential benefits of MMF as being steroid-sparing and having less adverse effects compared with other commonly used cytotoxic agents.', 'subject score': 888, 'object score': 1000}, 'PMID:18604487': {'publication date': '2008 Jul 15', 'sentence': 'Based on the existing evidence and experience from this case, rituximab can be recommended as a new treatment option for MN, possibly before starting any treatment with cytotoxic agents and high-dose prednisolone carrying the risk of severe side effects.', 'subject score': 901, 'object score': 1000}, 'PMID:23904308': {'publication date': '2013 Jul', 'sentence': 'Herein we report an unusual case of tonsillar Kaposi sarcoma in a patient with membranous glomerulonephritis treated with prednisolone and cyclosporine.', 'subject score': 1000, 'object score': 1000}, 'PMID:25045552': {'publication date': '2014', 'sentence': 'We report the first two cases in which the combination of prednisolone and mizoribine was effective for treating membranous nephropathy associated with IgG4-related tubulointerstitial nephritis.', 'subject score': 1000, 'object score': 901}, 'PMID:25298141': {'publication date': '2015 Jan', 'sentence': 'CONCLUSION: Elderly patients with MN who respond poorly to PSL treatment may be treated successfully with MZR.', 'subject score': 888, 'object score': 1000}, 'PMID:2565486': {'publication date': '1989 May 06', 'sentence': 'Treatment of membranous nephropathy with prednisolone and chlorambucil.', 'subject score': 1000, 'object score': 1000}, 'PMID:7507157': {'publication date': '1994 Jan', 'sentence': 'Increased FCsDex tended to normalize during prednisolone treatment in membranous nephropathy.', 'subject score': 888, 'object score': 1000}, 'PMID:7784993': {'publication date': '1994 Dec', 'sentence': 'Especially Ponticelli claims significant therapeutic success in patients with membranous glomerulonephritis treated with Prednisolone and Chlorambucil.', 'subject score': 1000, 'object score': 1000}, 'PMID:8043974': {'publication date': '1994 Mar', 'sentence': 'Because of the high rate of spontaneous remission, treatment of membranous nephropathy with prednisolone and chlorambucil is still controversial.', 'subject score': 1000, 'object score': 1000}, 'PMID:8107308': {'publication date': '1994 Jan', 'sentence': 'Prednisolone and immunosuppressive agent were most effective in these patients with membranous nephropathy.', 'subject score': 1000, 'object score': 1000}, 'PMID:9475489': {'publication date': '1998 Feb', 'sentence': 'In membranous glomerulopathy with severe NS, one month of therapy with prednisolone followed by chlorambucil for one month (all together 6 months) improves the renal outcome of the patients compared to controls.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0017665---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8939337",
-              "object": "MONDO:0005376",
-              "publications": [
-                "PMID:11399923",
-                "PMID:14964576",
-                "PMID:1516283",
-                "PMID:16130411",
-                "PMID:16968719",
-                "PMID:17995584",
-                "PMID:18604487",
-                "PMID:23904308",
-                "PMID:25045552",
-                "PMID:25298141",
-                "PMID:2565486",
-                "PMID:7507157",
-                "PMID:7784993",
-                "PMID:8043974",
-                "PMID:8107308",
-                "PMID:9475489"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 130846,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-          "name": "allergic disease",
-          "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MONDO:0005271",
-            "SYMP:0000900",
-            "UMLS:C3539909",
-            "MEDDRA:10020759",
-            "MEDDRA:10020756",
-            "NCIT:C114476",
-            "SNOMEDCT:418634005",
-            "MEDDRA:10001738",
-            "HP:0012393",
-            "MESH:D006967",
-            "MEDDRA:10001719",
-            "MEDDRA:10001741",
-            "MEDDRA:10037948",
-            "SNOMEDCT:609328004",
-            "SNOMEDCT:421961002",
-            "UMLS:C1527304",
-            "ICD10:T78.40",
-            "DOID:1205",
-            "MEDDRA:10020755",
-            "MEDDRA:10020751",
-            "MEDDRA:10037932",
-            "UMLS:C0020517",
-            "MEDDRA:10020757",
-            "SNOMEDCT:419076005",
-            "MEDDRA:10001718"
-          ],
-          "id": "MONDO:0005271",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Allergic disposition",
-            "Allergic Reaction",
-            "Hypersensitivity",
-            "allergic reaction",
-            "allergic disease",
-            "Allergy"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000005.htm",
-            "ISBN:0781735149",
-            "http://en.wikipedia.org/wiki/allergy",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 130846,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-              "name": "allergic disease",
-              "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MONDO:0005271",
-                "SYMP:0000900",
-                "UMLS:C3539909",
-                "MEDDRA:10020759",
-                "MEDDRA:10020756",
-                "NCIT:C114476",
-                "SNOMEDCT:418634005",
-                "MEDDRA:10001738",
-                "HP:0012393",
-                "MESH:D006967",
-                "MEDDRA:10001719",
-                "MEDDRA:10001741",
-                "MEDDRA:10037948",
-                "SNOMEDCT:609328004",
-                "SNOMEDCT:421961002",
-                "UMLS:C1527304",
-                "ICD10:T78.40",
-                "DOID:1205",
-                "MEDDRA:10020755",
-                "MEDDRA:10020751",
-                "MEDDRA:10037932",
-                "UMLS:C0020517",
-                "MEDDRA:10020757",
-                "SNOMEDCT:419076005",
-                "MEDDRA:10001718"
-              ],
-              "id": "MONDO:0005271",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Allergic disposition",
-                "Allergic Reaction",
-                "Hypersensitivity",
-                "allergic reaction",
-                "allergic disease",
-                "Allergy"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000005.htm",
-                "ISBN:0781735149",
-                "http://en.wikipedia.org/wiki/allergy",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8714917,
-            "start": 568,
-            "end": 130846,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11370712': {'publication date': '2001 May', 'sentence': 'Clinically, both prednisolone and prednisolone sodium succinate are widely used as immunosuppressive agents for the treatment of various allergic disorders.', 'subject score': 1000, 'object score': 901}, 'PMID:13475038': {'publication date': '1957 Nov 09', 'sentence': 'Principles of management of allergic disorders with prednisone and prednisolone; with emphasis on clinical and laboratory control of complications.', 'subject score': 1000, 'object score': 1000}, 'PMID:13532203': {'publication date': '1958', 'sentence': '[Various cases of allergy treated with intramuscular prednisolone].', 'subject score': 888, 'object score': 1000}, 'PMID:13606669': {'publication date': '1958', 'sentence': 'Use of a tranquilizing agent (hydroxyzine) with prednisolone in the control of allergic disorders.', 'subject score': 1000, 'object score': 1000}, 'PMID:13652829': {'publication date': '1959 Mar', 'sentence': 'A severe P.A.S. hypersensitivity reaction controlled by prednisolone.', 'subject score': 1000, 'object score': 786}, 'PMID:32270742': {'publication date': '2020 Jan-Dec', 'sentence': 'Treatment with prednisolone, in combination with theophylline, curcumin or resveratrol increases SIRT1 expression, restores steroid sensitivity, and inhibits pro-inflammatory cytokine production from these cells and may reduce systemic inflammation in COPD.', 'subject score': 1000, 'object score': 888}, 'PMID:35218445': {'publication date': '2022 Feb 26', 'sentence': 'Combination treatment with prednisolone, a component of CHOP and CVP, was found to enhance ADCC sensitivity of RL cells and resistant clones and to significantly suppress tumor growth in xenograft models.', 'subject score': 1000, 'object score': 928}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0020517---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8906209",
-              "object": "MONDO:0005271",
-              "publications": [
-                "PMID:11370712",
-                "PMID:13475038",
-                "PMID:13532203",
-                "PMID:13606669",
-                "PMID:13652829",
-                "PMID:32270742",
-                "PMID:35218445"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 532295,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006982",
-          "name": "subacute thyroiditis",
-          "description": "Self-limited inflammation of the thyroid gland. The clinical course includes an initial phase of hyperthyroidism, followed by a phase of hypothyroidism, and eventually a return to normal thyroid function. This category includes the subacute lymphocytic thyroiditis and subacute granulomatous thyroiditis.; Self-limited inflammation of the thyroid gland characterized by the presence of multinucleated giant cells. Patients present with neck pain, often associated with fever and dysphagia. The clinical course includes an initial phase of hyperthyroidism, followed by a phase of hypothyroidism, and eventually a return to normal thyroid function.; Spontaneously remitting inflammatory condition of the THYROID GLAND, characterized by FEVER; MUSCLE WEAKNESS; SORE THROAT; severe thyroid PAIN; and an enlarged damaged gland containing GIANT CELLS. The disease frequently follows a viral infection.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10012410",
-            "SNOMEDCT:428041004",
-            "DOID:7165",
-            "MEDDRA:10042298",
-            "ICD9:245.1",
-            "SNOMEDCT:38727009",
-            "EFO:1001194",
-            "NCIT:C35828",
-            "MEDDRA:10018705",
-            "ICD10:E06.1",
-            "MEDDRA:10043784",
-            "MESH:D013968",
-            "NCIT:C35071",
-            "MONDO:0006982",
-            "UMLS:C0040149"
-          ],
-          "id": "MONDO:0006982",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Subacute Thyroiditis",
-            "Subacute thyroiditis",
-            "Subacute Granulomatous Thyroiditis",
-            "Thyroiditis, Subacute",
-            "subacute thyroiditis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 532295,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006982",
-              "name": "subacute thyroiditis",
-              "description": "Self-limited inflammation of the thyroid gland. The clinical course includes an initial phase of hyperthyroidism, followed by a phase of hypothyroidism, and eventually a return to normal thyroid function. This category includes the subacute lymphocytic thyroiditis and subacute granulomatous thyroiditis.; Self-limited inflammation of the thyroid gland characterized by the presence of multinucleated giant cells. Patients present with neck pain, often associated with fever and dysphagia. The clinical course includes an initial phase of hyperthyroidism, followed by a phase of hypothyroidism, and eventually a return to normal thyroid function.; Spontaneously remitting inflammatory condition of the THYROID GLAND, characterized by FEVER; MUSCLE WEAKNESS; SORE THROAT; severe thyroid PAIN; and an enlarged damaged gland containing GIANT CELLS. The disease frequently follows a viral infection.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10012410",
-                "SNOMEDCT:428041004",
-                "DOID:7165",
-                "MEDDRA:10042298",
-                "ICD9:245.1",
-                "SNOMEDCT:38727009",
-                "EFO:1001194",
-                "NCIT:C35828",
-                "MEDDRA:10018705",
-                "ICD10:E06.1",
-                "MEDDRA:10043784",
-                "MESH:D013968",
-                "NCIT:C35071",
-                "MONDO:0006982",
-                "UMLS:C0040149"
-              ],
-              "id": "MONDO:0006982",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Subacute Thyroiditis",
-                "Subacute thyroiditis",
-                "Subacute Granulomatous Thyroiditis",
-                "Thyroiditis, Subacute",
-                "subacute thyroiditis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8662989,
-            "start": 568,
-            "end": 532295,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11334386': {'publication date': '2001 Apr', 'sentence': 'CONCLUSIONS: The recurrence rate of SAT with treated PSL is about 20%.', 'subject score': 872, 'object score': 1000}, 'PMID:21245641': {'publication date': '2011', 'sentence': 'A 46-year-old female with a past history of ulcerative colitis (UC) was diagnosed with subacute thyroiditis (SAT), which improved with prednisolone (PSL) treatment (60 mg/day).', 'subject score': 888, 'object score': 1000}, 'PMID:23227861': {'publication date': '2013 Mar', 'sentence': 'CONCLUSIONS: The treatment protocol that we employed had 15 mg/day of PSL as the initial dosage for the treatment of SAT, with tapering by 5 mg every 2 weeks, and was effective and safe for Japanese patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:25969738': {'publication date': '2015', 'sentence': 'When the thyroid remains swollen after improvement of thyrotoxicosis following treatment with prednisolone, it should be assessed to differentiate between an amyloid goiter and common subacute thyroiditis.', 'subject score': 1000, 'object score': 901}, 'PMID:26073499': {'publication date': '2015 Jun 01', 'sentence': 'This study was a medical record-based retrospective study and involved 26 patients (3 men, 23 women) who received PSL therapy for SAT.', 'subject score': 888, 'object score': 1000}, 'PMID:26500930': {'publication date': '2015 Sep', 'sentence': 'CONCLUSION: Twenty mg of prednisolone daily tapered over 4 weeks is an adequate treatment of subacute thyroiditis.', 'subject score': 1000, 'object score': 1000}, 'PMID:27688010': {'publication date': '2017 Jan', 'sentence': 'Prednisolone treatment of patients with subacute thyroiditis was superior to nonsteroidal anti-inflammation drugs with regard to resolution of symptoms.', 'subject score': 888, 'object score': 1000}, 'PMID:30906749': {'publication date': '2019 Feb', 'sentence': 'Conclusions: The combination of low-dose PSL as a treatment choice for SAT was both effective and safe.', 'subject score': 901, 'object score': 1000}, 'PMID:32448401': {'publication date': '2020 May 24', 'sentence': 'Comparison of the therapeutic effects of 15 mg and 30 mg initial dosage of prednisolone daily in patients with subacute thyroiditis: protocol for a multicenter, randomized, open, parallel control study.BACKGROUND: Subacute thyroiditis (SAT) is the most common cause of thyroid pain.', 'subject score': 888, 'object score': 1000}, 'PMID:3427792': {'publication date': '1987 Sep', 'sentence': 'Twelve patients with subacute thyroiditis were divided into two groups and treated with prednisolone or salicylate.', 'subject score': 1000, 'object score': 1000}, 'PMID:34636318': {'publication date': '2021 Oct 11', 'sentence': 'CONCLUSION: According to the results of this meta-analysis, 15 to 20 mg/day of prednisolone is the most effective dosage with the lowest recurrence rate in the treatment of subacute Granulomatous thyroiditis.', 'subject score': 1000, 'object score': 1000}, 'PMID:35975250': {'publication date': '2022 Jan-Mar', 'sentence': 'THE USE OF LOW DOSE PREDNISOLONE IN PATIENTS WITH SUBACUTE THYROIDITIS AND ITS EFFECT ON IMPAIRED LIFE AND SLEEP QUALITY.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0040149---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8865745",
-              "object": "MONDO:0006982",
-              "publications": [
-                "PMID:11334386",
-                "PMID:21245641",
-                "PMID:23227861",
-                "PMID:25969738",
-                "PMID:26073499",
-                "PMID:26500930",
-                "PMID:27688010",
-                "PMID:30906749",
-                "PMID:32448401",
-                "PMID:3427792",
-                "PMID:34636318",
-                "PMID:35975250"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 520323,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006042",
-          "name": "meningeal tuberculosis",
-          "description": "A bacterial infection of the membranes covering the brain and the spinal cord caused by Mycobacterium tuberculosis.; A form of bacterial meningitis caused by MYCOBACTERIUM TUBERCULOSIS or rarely MYCOBACTERIUM BOVIS. The organism seeds the meninges and forms microtuberculomas which subsequently rupture. The clinical course tends to be subacute, with progressions occurring over a period of several days or longer. Headache and meningeal irritation may be followed by SEIZURES, cranial neuropathies, focal neurologic deficits, somnolence, and eventually COMA. The illness may occur in immunocompetent individuals or as an OPPORTUNISTIC INFECTION in the ACQUIRED IMMUNODEFICIENCY SYNDROME and other immunodeficiency syndromes. (From Adams et al., Principles of Neurology, 6th ed, pp717-9); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C84888",
-            "ORPHANET:499004",
-            "EFO:1000039",
-            "UMLS:C0041318",
-            "MEDDRA:10027190",
-            "SNOMEDCT:58437007",
-            "MESH:D014390",
-            "MEDDRA:10027259",
-            "MONDO:0006042",
-            "ICD9:013.0",
-            "MEDDRA:10045080",
-            "MEDDRA:10043155"
-          ],
-          "id": "MONDO:0006042",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Meningeal Tuberculosis",
-            "Tuberculous meningitis",
-            "meningeal tuberculosis",
-            "Tuberculosis, Meningeal"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520323,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006042",
-              "name": "meningeal tuberculosis",
-              "description": "A bacterial infection of the membranes covering the brain and the spinal cord caused by Mycobacterium tuberculosis.; A form of bacterial meningitis caused by MYCOBACTERIUM TUBERCULOSIS or rarely MYCOBACTERIUM BOVIS. The organism seeds the meninges and forms microtuberculomas which subsequently rupture. The clinical course tends to be subacute, with progressions occurring over a period of several days or longer. Headache and meningeal irritation may be followed by SEIZURES, cranial neuropathies, focal neurologic deficits, somnolence, and eventually COMA. The illness may occur in immunocompetent individuals or as an OPPORTUNISTIC INFECTION in the ACQUIRED IMMUNODEFICIENCY SYNDROME and other immunodeficiency syndromes. (From Adams et al., Principles of Neurology, 6th ed, pp717-9); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C84888",
-                "ORPHANET:499004",
-                "EFO:1000039",
-                "UMLS:C0041318",
-                "MEDDRA:10027190",
-                "SNOMEDCT:58437007",
-                "MESH:D014390",
-                "MEDDRA:10027259",
-                "MONDO:0006042",
-                "ICD9:013.0",
-                "MEDDRA:10045080",
-                "MEDDRA:10043155"
-              ],
-              "id": "MONDO:0006042",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Meningeal Tuberculosis",
-                "Tuberculous meningitis",
-                "meningeal tuberculosis",
-                "Tuberculosis, Meningeal"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8630174,
-            "start": 568,
-            "end": 520323,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11296366': {'publication date': '2000 Oct', 'sentence': 'In this case, prednisolone was indispensable for treating tuberculous meningitis in combination with appropriate antituberculosis drugs, though the role of corticosteroids has remained controversial over the years.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0041318---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8819323",
-              "object": "MONDO:0006042",
-              "publications": [
-                "PMID:11296366"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316866,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015691",
-          "name": "hypereosinophilic syndrome",
-          "description": "A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction. This term has often been applied to cases of chronic eosinophilic leukemia. (WHO, 2001); A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10014950",
-            "UMLS:C1636667",
-            "ICD10:D72.1",
-            "ICD9:288.3",
-            "MEDDRA:10048643",
-            "NCIT:C27038",
-            "EFO:1001467",
-            "SNOMEDCT:1156250009",
-            "SNOMEDCT:419455006",
-            "DOID:999",
-            "MESH:D004802",
-            "MESH:D017681",
-            "ORPHANET:168956",
-            "SNOMEDCT:393573009",
-            "UMLS:C0014457",
-            "HP:0001880",
-            "MONDO:0015691",
-            "UMLS:C1540912"
-          ],
-          "id": "MONDO:0015691",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Disorder characterized by eosinophilia",
-            "hypereosinophilic syndrome",
-            "Hypereosinophilic Syndrome",
-            "Hypereosinophilic syndrome",
-            "Eosinophilia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/hypereosinophilic_syndrome",
-            "https://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316866,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015691",
-              "name": "hypereosinophilic syndrome",
-              "description": "A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction. This term has often been applied to cases of chronic eosinophilic leukemia. (WHO, 2001); A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10014950",
-                "UMLS:C1636667",
-                "ICD10:D72.1",
-                "ICD9:288.3",
-                "MEDDRA:10048643",
-                "NCIT:C27038",
-                "EFO:1001467",
-                "SNOMEDCT:1156250009",
-                "SNOMEDCT:419455006",
-                "DOID:999",
-                "MESH:D004802",
-                "MESH:D017681",
-                "ORPHANET:168956",
-                "SNOMEDCT:393573009",
-                "UMLS:C0014457",
-                "HP:0001880",
-                "MONDO:0015691",
-                "UMLS:C1540912"
-              ],
-              "id": "MONDO:0015691",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Disorder characterized by eosinophilia",
-                "hypereosinophilic syndrome",
-                "Hypereosinophilic Syndrome",
-                "Hypereosinophilic syndrome",
-                "Eosinophilia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/hypereosinophilic_syndrome",
-                "https://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8568008,
-            "start": 568,
-            "end": 316866,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11244732': {'publication date': '2000 Dec', 'sentence': 'Prednisolone (PSL) was administered, which improved the anemia, eosinophilia and the cavities.', 'subject score': 1000, 'object score': 1000}, 'PMID:14639949': {'publication date': '2003 Oct', 'sentence': 'Administration of prednisolone at 80 mg/day resulted in a marked improvement of the symptoms and the eosinophilia.', 'subject score': 1000, 'object score': 1000}, 'PMID:1578631': {'publication date': '1992 Mar', 'sentence': 'The administration of prednisolone led to clinical remission in both cases, including rapid improvement of eosinophilia, normalization of hypercoagulability and correction of platelet dysfunction.', 'subject score': 1000, 'object score': 1000}, 'PMID:1633350': {'publication date': '1992 Apr', 'sentence': 'Here we describe four young Japanese women aged 25-33 years, whose clinical findings are characterized by episodic angioedema, marked leukocytosis with eosinophilia, benign course with spontaneous remission or low-dose prednisolone treatment.', 'subject score': 861, 'object score': 1000}, 'PMID:1753511': {'publication date': '1991 Oct', 'sentence': 'Both prednisolone and aspirin were administered with improvement of eosinophilia and partial thrombolysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2241587': {'publication date': '1990 Aug', 'sentence': 'Prednisolone was given at a dose of 60 mg daily resulting in improvement of the clinical symptoms and eosinophilia.', 'subject score': 1000, 'object score': 1000}, 'PMID:22608505': {'publication date': '2012 Jun', 'sentence': 'After treatment with prednisolone, all symptoms and the eosinophilia disappeared, and there was complete remission of the RV abnormalities.', 'subject score': 1000, 'object score': 1000}, 'PMID:25318795': {'publication date': '2014', 'sentence': 'At 26 years of age, he was found to have eosinophilia and abnormal liver function parameters, for which prednisolone therapy was started.', 'subject score': 888, 'object score': 1000}, 'PMID:28263223': {'publication date': '2017 05', 'sentence': 'Prednisolone may lead to a prompt amelioration of eosinophilia and associated symptoms.', 'subject score': 1000, 'object score': 1000}, 'PMID:35135946': {'publication date': '2022', 'sentence': 'She was given prednisolone, which resulted in the resolution of eosinophilia.', 'subject score': 1000, 'object score': 1000}, 'PMID:36176718': {'publication date': '2022 Oct', 'sentence': 'A complete response had been achieved, and oral prednisolone markedly improved the rash, pruritis, and eosinophilia.', 'subject score': 888, 'object score': 1000}, 'PMID:9380224': {'publication date': '1997', 'sentence': 'Under treatment with prednisolone, the symptoms and eosinophilia improved within 3 days.', 'subject score': 1000, 'object score': 1000}, 'PMID:11808087': {'publication date': '2001 Nov', 'sentence': 'Subsequent methylPSL pulse therapy followed by PSL brought about a transient improvement of the HES and DIC, but after reduction of the PSL, the HES worsened.', 'subject score': 1000, 'object score': 1000}, 'PMID:8479090': {'publication date': '1993 Mar', 'sentence': 'Case 1 was a 45-year-old man with HES who was unresponsive to prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0014457---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C1540912---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8755027",
-              "object": "MONDO:0015691",
-              "publications": [
-                "PMID:9380224",
-                "PMID:1578631",
-                "PMID:11808087",
-                "PMID:8479090",
-                "PMID:2241587",
-                "PMID:14639949",
-                "PMID:22608505",
-                "PMID:28263223",
-                "PMID:1753511",
-                "PMID:25318795",
-                "PMID:36176718",
-                "PMID:11244732",
-                "PMID:35135946",
-                "PMID:1633350"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317095,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018097",
-          "name": "West syndrome",
-          "description": "A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages [HPO:jalbers, PMID:28276060]; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0011097",
-            "MONDO:0018097",
-            "MEDDRA:10021750",
-            "UMLS:C0037769",
-            "NCIT:C84788",
-            "MEDDRA:10058893",
-            "MEDDRA:10039371",
-            "SNOMEDCT:28055006",
-            "DOID:0050562",
-            "MESH:D013036",
-            "UMLS:C1527366",
-            "ORPHANET:3451"
-          ],
-          "id": "MONDO:0018097",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_West syndrome",
-            "Salaam Seizures",
-            "West Syndrome",
-            "Spasms, Infantile",
-            "West syndrome",
-            "Epileptic spasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28276060",
-            "PMID:24268986",
-            "https://rarediseases.org/rare-diseases/west-syndrome/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317095,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018097",
-              "name": "West syndrome",
-              "description": "A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages [HPO:jalbers, PMID:28276060]; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0011097",
-                "MONDO:0018097",
-                "MEDDRA:10021750",
-                "UMLS:C0037769",
-                "NCIT:C84788",
-                "MEDDRA:10058893",
-                "MEDDRA:10039371",
-                "SNOMEDCT:28055006",
-                "DOID:0050562",
-                "MESH:D013036",
-                "UMLS:C1527366",
-                "ORPHANET:3451"
-              ],
-              "id": "MONDO:0018097",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_West syndrome",
-                "Salaam Seizures",
-                "West Syndrome",
-                "Spasms, Infantile",
-                "West syndrome",
-                "Epileptic spasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28276060",
-                "PMID:24268986",
-                "https://rarediseases.org/rare-diseases/west-syndrome/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8565210,
-            "start": 568,
-            "end": 317095,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11242620': {'publication date': '2001 Jan', 'sentence': 'BACKGROUND: The use of adrenocorticotrophic hormone (ACTH) and prednisolone in the management of infantile spasms has been well established, but is associated with significant morbidity and cannot be used as long-term medication.', 'subject score': 1000, 'object score': 1000}, 'PMID:1509814': {'publication date': '1992 Jun', 'sentence': 'A table is provided to help select the drug for each seizure type, e.g. ethosuximide for petit mal, prednisolone for infantile spasms, and carbamazepine for various types of focal and psychomotor seizures.', 'subject score': 1000, 'object score': 1000}, 'PMID:15541450': {'publication date': '2004 Nov 13-19', 'sentence': 'We aimed to compare the effects of vigabatrin with those of prednisolone and tetracosactide in the treatment of infantile spasms.', 'subject score': 1000, 'object score': 1000}, 'PMID:16183305': {'publication date': '2005 Dec', 'sentence': 'AIMS: The purpose of this retrospective data analysis was to compare the efficacy and cost of ACTH and prednisolone in the treatment of IS from the perspective of a developing country.', 'subject score': 1000, 'object score': 1000}, 'PMID:16584670': {'publication date': '2006 Apr 03', 'sentence': 'The adrenocorticotropic hormone and prednisolone are recommended for treatment of IS, although side effects are common.', 'subject score': 1000, 'object score': 1000}, 'PMID:24446954': {'publication date': '2014 Jan', 'sentence': 'High dose ACTH may be superior to very high dose prednisolone, and in lieu of a definitive clinical trial, the choice between prednisolone and ACTH for initial treatment of infantile spasms remains controversial.', 'subject score': 1000, 'object score': 1000}, 'PMID:25048310': {'publication date': '2014 Oct', 'sentence': 'OBJECTIVES: This study aimed to test the hypothesis that high-dose prednisolone (4 mg/kg/day) may be more efficacious than usual-dose (2 mg/kg/day) prednisolone for spasm resolution at 14-days in children with infantile spasms.', 'subject score': 1000, 'object score': 1000}, 'PMID:26216500': {'publication date': '2015 Sep', 'sentence': 'OBJECTIVE: A single-center, single-blind, parallel-group, randomized clinical trial was performed to test the null hypothesis that adrenocorticotropic hormone is not superior to high-dose prednisolone for treatment of newly diagnosed West syndrome.', 'subject score': 901, 'object score': 888}, 'PMID:26835388': {'publication date': '2015 Oct', 'sentence': 'Treatment of infantile spasms has little class I data, but adrenocorticotropic hormone (ACTH), prednisolone and vigabatrin have the best evidence as first-line medications.', 'subject score': 1000, 'object score': 1000}, 'PMID:28005049': {'publication date': '2016', 'sentence': 'Recent results have demonstrated the high efficacy of prednisolone in the treatment of West syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:28927673': {'publication date': '2017 Nov', 'sentence': 'OBJECTIVE: We earlier completed a single-blind, parallel-group, randomized clinical trial to test the null hypothesis that adrenocorticotropic hormone (ACTH) is not superior to high-dose prednisolone for short-term control of West syndrome.', 'subject score': 901, 'object score': 1000}, 'PMID:29547159': {'publication date': '2018 Mar-Apr', 'sentence': 'Conclusions: The combination of pyridoxine with oral prednisolone was not found to be a beneficial therapy as compared to prednisolone alone in the treatment of infantile spasms in this pilot study.', 'subject score': 1000, 'object score': 1000}, 'PMID:29966811': {'publication date': '2018 Sep', 'sentence': 'CONCLUSION: Using a treatment protocol involving vigabatrin and prednisolone for WS, 72.7% of patients showed resolution of spasms and a BASED score of <=2.', 'subject score': 1000, 'object score': 1000}, 'PMID:30233047': {'publication date': '2018', 'sentence': 'Addition of pyridoxine to prednisolone in the treatment of infantile spasms: The knowledge gaps.', 'subject score': 1000, 'object score': 1000}, 'PMID:30501886': {'publication date': '2018 Oct', 'sentence': 'High-Dose Prednisolone as a First-line Treatment for Infantile Spasms.', 'subject score': 901, 'object score': 1000}, 'PMID:31315764': {'publication date': '2019 Jul', 'sentence': 'CONCLUSIONS: The available evidence shows no difference in the clinical efficacy of prednisolone versus ACTH in the treatment of IS.', 'subject score': 1000, 'object score': 1000}, 'PMID:31331669': {'publication date': '2019 Oct', 'sentence': 'RESULTS: We identified 102 children with infantile spasms who were treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:31769329': {'publication date': '2019 Nov 26', 'sentence': 'Incidence of Hypertension Among Children Treated With Adrenocorticotropic Hormone (ACTH) or Prednisolone for Infantile Spasms.', 'subject score': 1000, 'object score': 1000}, 'PMID:33538457': {'publication date': '2021 Feb 01', 'sentence': 'High-Dose Prednisolone for Treatment of Infantile Spasms After Presumed Perinatal Stroke.', 'subject score': 901, 'object score': 1000}, 'PMID:33575989': {'publication date': '2021 Feb 11', 'sentence': 'OBJECTIVE: To compare intravenous methylprednisolone (IVMP) with oral prednisolone (OP) for the treatment of West syndrome.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0037769---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8752241",
-              "object": "MONDO:0018097",
-              "publications": [
-                "PMID:11242620",
-                "PMID:1509814",
-                "PMID:15541450",
-                "PMID:16183305",
-                "PMID:16584670",
-                "PMID:24446954",
-                "PMID:25048310",
-                "PMID:26216500",
-                "PMID:26835388",
-                "PMID:28005049",
-                "PMID:28927673",
-                "PMID:29547159",
-                "PMID:29966811",
-                "PMID:30233047",
-                "PMID:30501886",
-                "PMID:31315764",
-                "PMID:31331669",
-                "PMID:31769329",
-                "PMID:33538457",
-                "PMID:33575989"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 310720,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006052",
-          "name": "pulmonary tuberculosis",
-          "description": "A bacterial infection that affects the lungs and is caused by Mycobacterium tuberculosis. Most patients with tuberculosis do not have symptoms (latent tuberculosis) and are not contagious. When signs and symptoms occur (active tuberculosis), patients become contagious. The signs and symptoms include chronic cough with blood-tinged sputum, night sweats, fever, fatigue, and weight loss.; MYCOBACTERIUM infections of the lung.; A lung infection by Mycobacterium tuberculosis a slightly curved non-motile, aerobic, non-capsulated and non-spore forming strains of mycobacteria. [PMID:30345099]",
-          "equivalent_curies": [
-            "MONDO:0006052",
-            "MEDDRA:10046123",
-            "PSY:42300",
-            "ICD9:011",
-            "MEDDRA:10034980",
-            "SNOMEDCT:154283005",
-            "DOID:2957",
-            "SNOMEDCT:700272008",
-            "NCIT:C26899",
-            "EFO:1000049",
-            "MEDDRA:10037443",
-            "HP:0032262",
-            "MESH:D014397",
-            "ICD10:A15",
-            "UMLS:C0041327",
-            "MEDDRA:10037435",
-            "MEDDRA:10037440"
-          ],
-          "id": "MONDO:0006052",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Tuberculosis, Pulmonary",
-            "pulmonary tuberculosis",
-            "Pulmonary Tuberculosis",
-            "Pulmonary tuberculosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:30345099",
-            "http://www.cdc.gov/tb/publications/factsheets/general/tb.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tuberculosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310720,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006052",
-              "name": "pulmonary tuberculosis",
-              "description": "A bacterial infection that affects the lungs and is caused by Mycobacterium tuberculosis. Most patients with tuberculosis do not have symptoms (latent tuberculosis) and are not contagious. When signs and symptoms occur (active tuberculosis), patients become contagious. The signs and symptoms include chronic cough with blood-tinged sputum, night sweats, fever, fatigue, and weight loss.; MYCOBACTERIUM infections of the lung.; A lung infection by Mycobacterium tuberculosis a slightly curved non-motile, aerobic, non-capsulated and non-spore forming strains of mycobacteria. [PMID:30345099]",
-              "equivalent_curies": [
-                "MONDO:0006052",
-                "MEDDRA:10046123",
-                "PSY:42300",
-                "ICD9:011",
-                "MEDDRA:10034980",
-                "SNOMEDCT:154283005",
-                "DOID:2957",
-                "SNOMEDCT:700272008",
-                "NCIT:C26899",
-                "EFO:1000049",
-                "MEDDRA:10037443",
-                "HP:0032262",
-                "MESH:D014397",
-                "ICD10:A15",
-                "UMLS:C0041327",
-                "MEDDRA:10037435",
-                "MEDDRA:10037440"
-              ],
-              "id": "MONDO:0006052",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Tuberculosis, Pulmonary",
-                "pulmonary tuberculosis",
-                "Pulmonary Tuberculosis",
-                "Pulmonary tuberculosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:30345099",
-                "http://www.cdc.gov/tb/publications/factsheets/general/tb.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tuberculosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8462413,
-            "start": 568,
-            "end": 310720,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11155703': {'publication date': '2000 Oct', 'sentence': 'However, he died because of lung tuberculosis and acute tuberculous pericarditis during treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:13402557': {'publication date': '1956 Dec', 'sentence': '[Comparative study of the results of tuberculostatic agents with and without prednisolone in therapy of common phthisis].', 'subject score': 1000, 'object score': 888}, 'PMID:13468536': {'publication date': '1957 Jul', 'sentence': '[Supportive use of cortisone and prednisolone during tuberculostatic therapy of pulmonary tuberculosis].', 'subject score': 1000, 'object score': 1000}, 'PMID:13472066': {'publication date': '1957 Nov 16', 'sentence': 'PREDNISOLONE in the treatment of pulmonary tuberculosis: a controlled trial; a preliminary report by the Research Committee of the Tuberculosis Society of Scotland.', 'subject score': 1000, 'object score': 1000}, 'PMID:13715890': {'publication date': '1960 Dec 17', 'sentence': 'Prednisolone in treatment of pulmonary tuberculosis: a controlled trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:13856608': {'publication date': '1960 Apr', 'sentence': 'PRELIMINARY observations from a controlled trail of prednisolone in the treatment of pulmonary tuberculosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:14264779': {'publication date': '1965 Mar', 'sentence': 'PREDNISOLONE IN THE TREATMENT OF PULMONARY TUBERCULOSIS; A UNITED STATES PUBLIC HEALTH SERVICE TUBERCULOSIS THERAPY TRIAL.', 'subject score': 1000, 'object score': 1000}, 'PMID:3265334': {'publication date': '1988 Dec', 'sentence': 'A generally similar pattern is seen in healthy controls and in patients with untreated pulmonary tuberculosis, treated leprosy, haemophilia A and chronic obstructive lung disease (COLD) patients treated with prednisolone, but the gradient of increasing CD4:CD8 ratio with depth into the dermis is significantly less steep in patients with tuberculosis, haemophilia and prednisolone-treated COLD than in the healthy controls.', 'subject score': 1000, 'object score': 901}, 'PMID:4648215': {'publication date': '1972 Nov', 'sentence': '[Characteristics of the postoperative period in patients with pulmonary tuberculosis treated with prednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:5380208': {'publication date': '1969', 'sentence': '[Radiographic observation of changes in foci in patients with pulmonary tuberculosis treated with antibacterial preparations in combination with prednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:5432970': {'publication date': '1970', 'sentence': '[PASA metabolism and the functional state of the adrenal cortex during chemotherapy combined with prednisolone in patients with pulmonary tuberculosis].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0041327---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8647269",
-              "object": "MONDO:0006052",
-              "publications": [
-                "PMID:11155703",
-                "PMID:13402557",
-                "PMID:13468536",
-                "PMID:13472066",
-                "PMID:13715890",
-                "PMID:13856608",
-                "PMID:14264779",
-                "PMID:3265334",
-                "PMID:4648215",
-                "PMID:5380208",
-                "PMID:5432970"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 517728,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005124",
-          "name": "leprosy",
-          "description": "A bacterial granulomatous infection caused by Mycobacterium leprae. It is a progressive disease affecting the skin, peripheral nerves, and limbs. If untreated, it causes permanent tissue damage leading to autoamputations.; A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10024230",
-            "NCIT:C84824",
-            "EFO:0001054",
-            "MEDDRA:10024229",
-            "ICD9:030",
-            "MEDDRA:10024232",
-            "DOID:1024",
-            "MONDO:0005124",
-            "UMLS:C0023343",
-            "SNOMEDCT:81004002",
-            "MEDDRA:10019138",
-            "ICD10:A30",
-            "MEDDRA:10024231",
-            "MESH:D007918",
-            "MEDDRA:10028451",
-            "ORPHANET:548"
-          ],
-          "id": "MONDO:0005124",
-          "category": "biolink:Disease",
-          "all_names": [
-            "leprosy",
-            "Leprosy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/leprosy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517728,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005124",
-              "name": "leprosy",
-              "description": "A bacterial granulomatous infection caused by Mycobacterium leprae. It is a progressive disease affecting the skin, peripheral nerves, and limbs. If untreated, it causes permanent tissue damage leading to autoamputations.; A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10024230",
-                "NCIT:C84824",
-                "EFO:0001054",
-                "MEDDRA:10024229",
-                "ICD9:030",
-                "MEDDRA:10024232",
-                "DOID:1024",
-                "MONDO:0005124",
-                "UMLS:C0023343",
-                "SNOMEDCT:81004002",
-                "MEDDRA:10019138",
-                "ICD10:A30",
-                "MEDDRA:10024231",
-                "MESH:D007918",
-                "MEDDRA:10028451",
-                "ORPHANET:548"
-              ],
-              "id": "MONDO:0005124",
-              "category": "biolink:Disease",
-              "all_names": [
-                "leprosy",
-                "Leprosy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/leprosy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8400823,
-            "start": 568,
-            "end": 517728,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11105495': {'publication date': '2000 Sep', 'sentence': 'In untreated reactional leprosy patients, the levels of urinary NO metabolites (1645 +/- 454 microM, n = 9, ENL = 4, RR = 5) decreased significantly 2 weeks after high dose prednisolone treatment (1075 +/- 414 microM, P < 0.05), and remained stable 4 (895 +/- 385 microM, P < 0.02) and 6 weeks following treatment initiation (1048 +/- 452 microM, P < 0.02).', 'subject score': 861, 'object score': 751}, 'PMID:14750578': {'publication date': '2003 Dec', 'sentence': \"Based on those data and supported by the literature and the author's own observations, it can be concluded that type I leprosy reaction should be treated with prednisolone for a longer period than the 12 weeks, advised by the WHO.\", 'subject score': 1000, 'object score': 888}, 'PMID:15159285': {'publication date': '2004 Jun 19', 'sentence': 'CONCLUSIONS: The use of low dose prophylactic prednisolone during the first four months of multidrug treatment for leprosy reduces the incidence of new reactions and nerve function impairment in the short term, but the effect is not sustained at one year.', 'subject score': 861, 'object score': 1000}, 'PMID:17320974': {'publication date': '2007 Mar 15', 'sentence': 'Gene expression of the shuttle enzymes were quantified in skin biopsies from 15 leprosy patients with new T1R before and during prednisolone treatment and compared with levels in skin biopsies from 10 borderline leprosy patients without reactions.', 'subject score': 888, 'object score': 790}, 'PMID:19803379': {'publication date': '2009 Sep', 'sentence': '[Prevalence of disability among leprosy patients and effectiveness of leprosy reaction services with standard prednisolone treatment at field level in an endemic country--some data from joint leprosy research collaboration in Myanmar].', 'subject score': 851, 'object score': 851}, 'PMID:20509340': {'publication date': '2009', 'sentence': 'Steroid induced diabetes is a serious complication among leprosy patients treated with prednisolone for reactions requiring careful monitoring for detection and appropriate clinical management.', 'subject score': 1000, 'object score': 888}, 'PMID:23249098': {'publication date': '2012 Dec 18', 'sentence': \"Within the 'Treatment of Early Neuropathy in LEProsy' (TENLEP) study two double blind randomized controlled trials (RCT) will be carried out: a trial to establish whether prednisolone treatment of 32 weeks duration is more effective than 20 weeks in restoring nerve function in leprosy patients with clinical NFI (Clinical trial) and a trial to determine whether prednisolone treatment of early sub-clinical NFI can prevent clinical NFI (Subclinical trial).\", 'subject score': 888, 'object score': 704}, 'PMID:27046330': {'publication date': '2016 Apr', 'sentence': 'A Randomized Controlled Double Blind Trial of Ciclosporin versus Prednisolone in the Management of Leprosy Patients with New Type 1 Reaction, in Ethiopia.', 'subject score': 1000, 'object score': 888}, 'PMID:28976976': {'publication date': '2017 Oct', 'sentence': 'CONCLUSION: In our study, a 20-week course of prednisolone was as effective as a 32-week course in improving and restoring recent clinical NFI in leprosy patients.', 'subject score': 1000, 'object score': 888}, 'PMID:3265334': {'publication date': '1988 Dec', 'sentence': 'A generally similar pattern is seen in healthy controls and in patients with untreated pulmonary tuberculosis, treated leprosy, haemophilia A and chronic obstructive lung disease (COLD) patients treated with prednisolone, but the gradient of increasing CD4:CD8 ratio with depth into the dermis is significantly less steep in patients with tuberculosis, haemophilia and prednisolone-treated COLD than in the healthy controls.', 'subject score': 1000, 'object score': 872}, 'PMID:34336901': {'publication date': '2021', 'sentence': 'Although the diagnosis of ENL is not difficult to make for physicians involved in the care of leprosy patients, its management continues to be a most challenging aspect of the leprosy eradication program: the chronic and recurrent painful skin lesions, neuritis, and organ involvement necessitates prolonged treatment with prednisolone, thalidomide, and anti-inflammatory and immunosuppressive drugs, which further adds to the existing morbidity.', 'subject score': 1000, 'object score': 802}, 'PMID:9503867': {'publication date': '1997 Dec', 'sentence': \"In this study, a fixed regimen of prednisolone for the treatment of acute nerve function impairment (NFI) in leprosy patients was developed and introduced at field level in one area (Thakurgaon) of the Danish-Bangladesh Leprosy Mission's field in NW Bangladesh.\", 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0023343---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8583398",
-              "object": "MONDO:0005124",
-              "publications": [
-                "PMID:11105495",
-                "PMID:14750578",
-                "PMID:15159285",
-                "PMID:17320974",
-                "PMID:19803379",
-                "PMID:20509340",
-                "PMID:23249098",
-                "PMID:27046330",
-                "PMID:28976976",
-                "PMID:3265334",
-                "PMID:34336901",
-                "PMID:9503867"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 526144,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001505",
-          "name": "alcoholic hepatitis",
-          "description": "Inflammation of the liver resulting from ingestion of alcohol.; INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.",
-          "equivalent_curies": [
-            "MONDO:0001505",
-            "MEDDRA:10000649",
-            "ICD9:571.1",
-            "SNOMEDCT:235875008",
-            "MEDDRA:10019728",
-            "MESH:D006519",
-            "NCIT:C34352",
-            "UMLS:C0019187",
-            "EFO:1001345",
-            "UMLS:C0001306",
-            "DOID:12351",
-            "NCIT:C34684",
-            "MEDDRA:10001624",
-            "SNOMEDCT:9953008"
-          ],
-          "id": "MONDO:0001505",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute alcoholic hepatitis",
-            "alcoholic hepatitis",
-            "Alcoholic Hepatitis",
-            "Acute Alcoholic Hepatitis",
-            "Acute alcoholic liver disease",
-            "Hepatitis, Alcoholic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526144,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001505",
-              "name": "alcoholic hepatitis",
-              "description": "Inflammation of the liver resulting from ingestion of alcohol.; INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.",
-              "equivalent_curies": [
-                "MONDO:0001505",
-                "MEDDRA:10000649",
-                "ICD9:571.1",
-                "SNOMEDCT:235875008",
-                "MEDDRA:10019728",
-                "MESH:D006519",
-                "NCIT:C34352",
-                "UMLS:C0019187",
-                "EFO:1001345",
-                "UMLS:C0001306",
-                "DOID:12351",
-                "NCIT:C34684",
-                "MEDDRA:10001624",
-                "SNOMEDCT:9953008"
-              ],
-              "id": "MONDO:0001505",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute alcoholic hepatitis",
-                "alcoholic hepatitis",
-                "Alcoholic Hepatitis",
-                "Acute Alcoholic Hepatitis",
-                "Acute alcoholic liver disease",
-                "Hepatitis, Alcoholic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8390714,
-            "start": 568,
-            "end": 526144,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11096576': {'publication date': '1999 Feb', 'sentence': 'Prednisolone improves survival in patients with alcoholic hepatitis who have either spontaneous hepatic encephalopathy or a high \"discriminant function.\"', 'subject score': 1000, 'object score': 1000}, 'PMID:14647046': {'publication date': '2003 Dec', 'sentence': 'Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone.', 'subject score': 1000, 'object score': 901}, 'PMID:1531090': {'publication date': '1992 Feb 20', 'sentence': 'A randomized trial of prednisolone in patients with severe alcoholic hepatitis.', 'subject score': 1000, 'object score': 901}, 'PMID:19340904': {'publication date': '2009 Apr 07', 'sentence': 'CONCLUSION: Reduced mortality, improved risk-benefit profile and renoprotective effects of pentoxifylline compared with prednisolone suggest that pentoxifylline is superior to prednisolone for treatment of severe alcoholic hepatitis.', 'subject score': 1000, 'object score': 901}, 'PMID:24026598': {'publication date': '2013 Sep 11', 'sentence': 'CONCLUSION AND RELEVANCE: In patients with alcoholic hepatitis, 4-week treatment with pentoxifylline and prednisolone, compared with prednisolone alone, did not result in improved 6-month survival.', 'subject score': 1000, 'object score': 1000}, 'PMID:24845609': {'publication date': '2014 Oct', 'sentence': 'CONCLUSIONS: The findings demonstrate that the efficacy of the pentoxifylline is not statistically equivalent to the efficacy of prednisolone, supporting the use of prednisolone as a preferred treatment option in patients with severe alcoholic hepatitis.', 'subject score': 1000, 'object score': 901}, 'PMID:25328799': {'publication date': '2014 Sep', 'sentence': 'However the efficacy of PTX and prednisolone combination over PTX alone in the management of acute alcoholic hepatitis (MDF score >=32) is yet unrevealed.', 'subject score': 775, 'object score': 1000}, 'PMID:25901427': {'publication date': '2015 Apr 23', 'sentence': 'Prednisolone and pentoxifylline are both recommended for the treatment of severe alcoholic hepatitis, but uncertainty about their benefit persists.', 'subject score': 1000, 'object score': 901}, 'PMID:26176387': {'publication date': '2015 07 16', 'sentence': 'Prednisolone or Pentoxifylline for Alcoholic Hepatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:26176388': {'publication date': '2015 07 16', 'sentence': 'Prednisolone or Pentoxifylline for Alcoholic Hepatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:26176389': {'publication date': '2015 07 16', 'sentence': 'Prednisolone or Pentoxifylline for Alcoholic Hepatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:26279269': {'publication date': '2016 05', 'sentence': 'BACKGROUND & AIMS: Prednisolone is the first-line therapy for severe alcoholic hepatitis (AH).', 'subject score': 1000, 'object score': 901}, 'PMID:26691209': {'publication date': '2015 Dec', 'sentence': 'Prednisolone and pentoxifylline (PTX) are recommended in guidelines for treatment of severe AH, but trials supporting their use have given heterogeneous results and controversy persists about their benefit.', 'subject score': 1000, 'object score': 901}, 'PMID:26948886': {'publication date': '2016 Jun', 'sentence': 'The optimal treatment for patients with severe AH is prednisolone, possibly in combination with N-acetyl cysteine.', 'subject score': 1000, 'object score': 901}, 'PMID:27337960': {'publication date': '2016 Nov', 'sentence': 'CONCLUSIONS: Management of severe alcoholic hepatitis with prednisolone plus SAMe was associated with better therapy response (p = 0.044) and less frequent HRS occurrence (p = 0.035).', 'subject score': 1000, 'object score': 901}, 'PMID:28043903': {'publication date': '2017 04', 'sentence': 'Development of infection was associated with increased 90-day mortality in patients with SAH treated with prednisolone, independent of model for end-stage liver disease or Lille score (OR, 2.46; 95% CI, 1.41-4.30; P = .002).', 'subject score': 1000, 'object score': 901}, 'PMID:29113530': {'publication date': '2018 05', 'sentence': 'Thus, metabolic liver failure in AH seems to be prognostically important, is potentially reversible, and may recover more rapidly following treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:2954078': {'publication date': '1987 May 02', 'sentence': 'Whether or not prednisolone (or prednisone) should be used to treat alcoholic hepatitis remains controversial.', 'subject score': 888, 'object score': 1000}, 'PMID:29663389': {'publication date': '2018 Mar', 'sentence': 'We assessed serum cholesterol, cholesterol precursors, cholestanol, phytosterols, and biochemical markers in 24 patients with severe AH treated with prednisolone and randomized to ciprofloxacin in the ratio 1:1.', 'subject score': 1000, 'object score': 901}, 'PMID:29753761': {'publication date': '2018 Aug', 'sentence': 'He was diagnosed with severe alcoholic hepatitis (Maddrey discriminant function score of 50) and treated with prednisolone for 28 days with symptomatic and biochemical improvement.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0019187---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0001306---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8573433",
-              "object": "MONDO:0001505",
-              "publications": [
-                "PMID:36051363",
-                "PMID:28043903",
-                "PMID:8964410",
-                "PMID:35042254",
-                "PMID:19340904",
-                "PMID:2954078",
-                "PMID:26176387",
-                "PMID:36278756",
-                "PMID:29663389",
-                "PMID:26176389",
-                "PMID:14647046",
-                "PMID:15864177",
-                "PMID:24845609",
-                "PMID:26691209",
-                "PMID:24026598",
-                "PMID:6390194",
-                "PMID:26948886",
-                "PMID:27337960",
-                "PMID:1531090",
-                "PMID:37159035"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316900,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0020108",
-          "name": "autoimmune hemolytic anemia",
-          "description": "An acquired anemia caused by destruction of the red blood cells by autoantibodies. Causes include autoimmune disorders, lymphoproliferative disorders, and infections.; Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.; An autoimmune form of hemolytic anemia. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10073785",
-            "MEDDRA:10002046",
-            "MESH:D000744",
-            "ICD9:283.0",
-            "MEDDRA:10002285",
-            "MEDDRA:10073784",
-            "HP:0001890",
-            "MEDDRA:10003822",
-            "SNOMEDCT:413603009",
-            "EFO:1001264",
-            "OMIM:205700",
-            "NCIT:C34378",
-            "MEDDRA:10003825",
-            "ORPHANET:98375",
-            "MONDO:0020108",
-            "DOID:718",
-            "UMLS:C0002880"
-          ],
-          "id": "MONDO:0020108",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Autoimmune hemolytic anemias",
-            "Anemia, autoimmune hemolytic related phenotypic feature",
-            "Anemia, Hemolytic, Autoimmune",
-            "autoimmune hemolytic anemia",
-            "Autoimmune hemolytic anemia",
-            "Autoimmune Hemolytic Anemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/autoimmune_hemolytic_anemia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316900,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0020108",
-              "name": "autoimmune hemolytic anemia",
-              "description": "An acquired anemia caused by destruction of the red blood cells by autoantibodies. Causes include autoimmune disorders, lymphoproliferative disorders, and infections.; Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.; An autoimmune form of hemolytic anemia. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10073785",
-                "MEDDRA:10002046",
-                "MESH:D000744",
-                "ICD9:283.0",
-                "MEDDRA:10002285",
-                "MEDDRA:10073784",
-                "HP:0001890",
-                "MEDDRA:10003822",
-                "SNOMEDCT:413603009",
-                "EFO:1001264",
-                "OMIM:205700",
-                "NCIT:C34378",
-                "MEDDRA:10003825",
-                "ORPHANET:98375",
-                "MONDO:0020108",
-                "DOID:718",
-                "UMLS:C0002880"
-              ],
-              "id": "MONDO:0020108",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Autoimmune hemolytic anemias",
-                "Anemia, autoimmune hemolytic related phenotypic feature",
-                "Anemia, Hemolytic, Autoimmune",
-                "autoimmune hemolytic anemia",
-                "Autoimmune hemolytic anemia",
-                "Autoimmune Hemolytic Anemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/autoimmune_hemolytic_anemia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8358698,
-            "start": 568,
-            "end": 316900,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11070934': {'publication date': '2000 Sep', 'sentence': 'She had received prednisolone (PSL) therapy for autoimmune hemolytic anemia (AIHA).', 'subject score': 851, 'object score': 1000}, 'PMID:14689879': {'publication date': '2003 Nov', 'sentence': '[Hypereosinophilic syndrome developing after prednisolone therapy for autoimmune hemolytic anemia].', 'subject score': 888, 'object score': 1000}, 'PMID:15997789': {'publication date': '2005 Jun', 'sentence': 'A 52-year-old woman was taking 10 mg of prednisolone on alternate days for the treatment of autoimmune hemolytic anemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:16542723': {'publication date': '2006 Dec', 'sentence': 'Here we present a case of an 80-year-old man with B-CLL who developed autoimmune hemolytic anemia (AIHA), associated with one cycle of fludarabine treatment, and who was successfully treated with rituximab and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:20154439': {'publication date': '2010', 'sentence': 'An 88-year-old man with autoimmune hemolytic anemia (AIHA) who had been treated with low dose prednisolone developed a sudden worsening of his anemia accompanied by reactivation of Epstein-Barr virus (EBV).', 'subject score': 901, 'object score': 1000}, 'PMID:27563485': {'publication date': '2016', 'sentence': 'CASE DESCRIPTION: A 65-year-old man with a history of autoimmune hemolytic anemia treated with prednisolone presented to our hospital because of occipital headache.', 'subject score': 1000, 'object score': 1000}, 'PMID:29866698': {'publication date': '2018 Jun 04', 'sentence': 'The authors present a 70-year-old man with an autoimmune haemolytic anaemia treated with prednisolone and azathioprine.', 'subject score': 1000, 'object score': 1000}, 'PMID:30898087': {'publication date': '2019 03 21', 'sentence': 'She had initially presented with failure to thrive, proportional microcephaly as well as autoimmune hemolytic anemia (AIHA), which responded well to treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:34732625': {'publication date': '2021', 'sentence': 'She was diagnosed with autoimmune hemolytic anemia (AIHA), and oral prednisolone therapy was administered.', 'subject score': 851, 'object score': 1000}, 'PMID:34777872': {'publication date': '2021', 'sentence': 'Case presentation: A female patient with a known history of autoimmune hemolytic anemia (AIHH) for which she was treated with prednisolone was admitted for uncontrolled anemia followed by fever and elevated liver enzymes.', 'subject score': 1000, 'object score': 1000}, 'PMID:8360990': {'publication date': '1993 Jul', 'sentence': 'The patient had already been diagnosed as having autoimmune hemolytic anemia (AIHA) in February, 1982 and treated with prednisolone (PSL) until January, 1988.', 'subject score': 1000, 'object score': 1000}, 'PMID:8965407': {'publication date': '1996 Aug', 'sentence': 'Autoimmune hemolytic anemia was diagnosed, and she was treated with prednisolone (1 mg/kg).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0002880---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8540122",
-              "object": "MONDO:0020108",
-              "publications": [
-                "PMID:11070934",
-                "PMID:14689879",
-                "PMID:15997789",
-                "PMID:16542723",
-                "PMID:20154439",
-                "PMID:27563485",
-                "PMID:29866698",
-                "PMID:30898087",
-                "PMID:34732625",
-                "PMID:34777872",
-                "PMID:8360990",
-                "PMID:8965407"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 309447,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005556",
-          "name": "lupus nephritis",
-          "description": "Glomerulonephritis in the context of systemic lupus erythematosus.; Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).; Lupus nephritis is a type of glomerulonephritis that constitutes one of the most severe organ manifestations of systemic lupus erythematosus. Lupus nephritis is subclassified in six distinct classes, that represent different manifestations and severities of renal involvement and guide the therapeutic management. [ORCID:0000-0002-2234-4248, PMID:31974366]",
-          "equivalent_curies": [
-            "MEDDRA:10025140",
-            "HP:0033726",
-            "MEDDRA:10029141",
-            "DOID:0080162",
-            "NCIT:C34789",
-            "UMLS:C0024143",
-            "MESH:D008181",
-            "MEDDRA:10029142",
-            "MONDO:0005556",
-            "SNOMEDCT:68815009",
-            "MEDDRA:10040970",
-            "EFO:0005761"
-          ],
-          "id": "MONDO:0005556",
-          "category": "biolink:Disease",
-          "all_names": [
-            "lupus nephritis",
-            "Lupus nephritis",
-            "Lupus Nephritis",
-            "Lupus Glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000481.htm",
-            "PMID:31974366",
-            "https://orcid.org/0000-0002-2234-4248",
-            "https://en.wikipedia.org/wiki/lupus_nephritis#cite_note-1"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 309447,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005556",
-              "name": "lupus nephritis",
-              "description": "Glomerulonephritis in the context of systemic lupus erythematosus.; Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).; Lupus nephritis is a type of glomerulonephritis that constitutes one of the most severe organ manifestations of systemic lupus erythematosus. Lupus nephritis is subclassified in six distinct classes, that represent different manifestations and severities of renal involvement and guide the therapeutic management. [ORCID:0000-0002-2234-4248, PMID:31974366]",
-              "equivalent_curies": [
-                "MEDDRA:10025140",
-                "HP:0033726",
-                "MEDDRA:10029141",
-                "DOID:0080162",
-                "NCIT:C34789",
-                "UMLS:C0024143",
-                "MESH:D008181",
-                "MEDDRA:10029142",
-                "MONDO:0005556",
-                "SNOMEDCT:68815009",
-                "MEDDRA:10040970",
-                "EFO:0005761"
-              ],
-              "id": "MONDO:0005556",
-              "category": "biolink:Disease",
-              "all_names": [
-                "lupus nephritis",
-                "Lupus nephritis",
-                "Lupus Nephritis",
-                "Lupus Glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000481.htm",
-                "PMID:31974366",
-                "https://orcid.org/0000-0002-2234-4248",
-                "https://en.wikipedia.org/wiki/lupus_nephritis#cite_note-1"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8318750,
-            "start": 568,
-            "end": 309447,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11036121': {'publication date': '2000 Oct 19', 'sentence': 'CONCLUSIONS: For the treatment of diffuse proliferative lupus nephritis, the combination of mycophenolate mofetil and prednisolone is as effective as a regimen of cyclophosphamide and prednisolone followed by azathioprine and prednisolone but is less toxic.', 'subject score': 1000, 'object score': 861}, 'PMID:1301975': {'publication date': '1992 May', 'sentence': 'A secondary hyperlipidemic state, which probably related to lupus nephritis (proteinuria) and/or prednisolone treatment, increased apo H levels in SLE patients.', 'subject score': 888, 'object score': 1000}, 'PMID:15864912': {'publication date': '2005', 'sentence': 'This prospective cohort study examined the long-term renal function and disease relapse in adults with biopsy-proven DPLN, significant proteinuria, and hypoalbuminemia, who had been treated with sequential immunosuppression comprising prednisolone and oral cyclophosphamide as induction followed by low-dose prednisolone and azathioprine as maintenance.', 'subject score': 791, 'object score': 781}, 'PMID:16047642': {'publication date': '2005 Jul', 'sentence': 'METHOD: Long-term maintenance therapy with MZR and PSL was evaluated in ten patients with biopsy-proven proliferative lupus nephritis.', 'subject score': 1000, 'object score': 794}, 'PMID:16564783': {'publication date': '2006 Apr', 'sentence': 'METHODS: Patients with biopsy-proven DPLN treated with prednisolone and CYC were identified.', 'subject score': 1000, 'object score': 781}, 'PMID:16856445': {'publication date': '2005 Nov', 'sentence': 'Within the group of class-IV LN, the 5-year survival in the patients treated with intravenous CYC was significantly better than those receiving prednisolone with or without azathioprine.', 'subject score': 872, 'object score': 888}, 'PMID:1770640': {'publication date': '1991 Aug', 'sentence': 'After treatment of lupus nephritis with prednisolone, levels of plasma renin activity and plasma aldosterone concentration were elevated.', 'subject score': 1000, 'object score': 1000}, 'PMID:19004041': {'publication date': '2009 Jan', 'sentence': 'METHODS: Our retrospective single-center study compared the major healthcare costs during the first 24 months of treatment incurred by immunosuppressive medications, hospitalization, and complications in patients with severe lupus nephritis who had been treated with prednisolone and either MMF or sequential cyclophosphamide induction followed by azathioprine maintenance (CTX-AZA).', 'subject score': 1000, 'object score': 901}, 'PMID:19885661': {'publication date': '2011 Jul', 'sentence': 'Recently, we treated a patient with pulmonary and psoas muscle nocardiosis in a woman taking prednisolone for lupus nephritis; the isolated organism was Nocardia farcinica identified by polymerase chain reaction-restriction fragment length polymorphism testing.', 'subject score': 802, 'object score': 1000}, 'PMID:22590961': {'publication date': '2012', 'sentence': 'METHODS: Children with severe focal, and diffuse proliferative lupus nephritis were treated with prednisolone (initial dose; 1 mg/kg/day, maximum dose; 60 mg/day) and MMF (initial dose; 300 mg/m2/day, increased to 1 g/m2/day) for 24 months after high-dose intravenous methylprednisolone (30 mg/kg/day).', 'subject score': 1000, 'object score': 861}, 'PMID:24175257': {'publication date': '2012 Dec 06', 'sentence': 'We propose as an alternative to IVCY, a multidrug therapy with mizoribine, which acts very similarly to MMF, and Tac, which has a different mode of action, combined with PDN for pediatric-onset lupus nephritis.', 'subject score': 1000, 'object score': 861}, 'PMID:25959850': {'publication date': '2015 Nov', 'sentence': 'AIMS: The aim was to examine relationships between total and unbound mycophenolic acid (MPA) and prednisolone exposure and clinical outcomes in patients with lupus nephritis.', 'subject score': 694, 'object score': 1000}, 'PMID:34508471': {'publication date': '2021 Aug 12', 'sentence': 'Remission after Six Months of Induction Immunosuppressive Treatment with Mycofenolate Mofetil and Prednisolone in Patients with Lupus Nephritis: A Descriptive Cross-sectional Study.', 'subject score': 1000, 'object score': 1000}, 'PMID:34894070': {'publication date': '2021 Dec 11', 'sentence': 'OBJECTIVES: This study aimed to compare the efficacy of low-dose prednisolone with conventional high-dose regimen in proliferative lupus nephritis (LN) for remission.', 'subject score': 901, 'object score': 901}, 'PMID:4194493': {'publication date': '1970 May', 'sentence': 'Prednisolone treatment of lupus nephritis: Effect of high doses on course of disease, renal function, histological lesions, and immunological reactions.', 'subject score': 888, 'object score': 1000}, 'PMID:6727751': {'publication date': '1984 Jun 23', 'sentence': 'Despite overrepresentation of the more severe forms of lupus nephritis in a nephrology-unit population, there was a satisfactory outcome from therapy with either prednisolone alone or with a prenisolone /azathioprine combination.', 'subject score': 861, 'object score': 1000}, 'PMID:6971722': {'publication date': '1980 Nov', 'sentence': 'The effects of long-term treatment with azathioprine and prednisolone on T- and B-lymphocytes were studied in 52 patients with lupus nephritis (LN) and chronic glomerulonephritis (GN).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0024143---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8499057",
-              "object": "MONDO:0005556",
-              "publications": [
-                "PMID:11036121",
-                "PMID:1301975",
-                "PMID:15864912",
-                "PMID:16047642",
-                "PMID:16564783",
-                "PMID:16856445",
-                "PMID:1770640",
-                "PMID:19004041",
-                "PMID:19885661",
-                "PMID:22590961",
-                "PMID:24175257",
-                "PMID:25959850",
-                "PMID:34508471",
-                "PMID:34894070",
-                "PMID:4194493",
-                "PMID:6727751",
-                "PMID:6971722"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 324986,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-          "name": "chronic obstructive pulmonary disease",
-          "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-          "equivalent_curies": [
-            "MESH:D029424",
-            "MEDDRA:10010952",
-            "MEDDRA:10009025",
-            "ICD10:J44.9",
-            "UMLS:C1527303",
-            "NCIT:C3199",
-            "UMLS:C0024117",
-            "MEDDRA:10064611",
-            "MEDDRA:10009026",
-            "MEDDRA:10029972",
-            "DOID:3083",
-            "MONDO:0005002",
-            "MEDDRA:10009032",
-            "MEDDRA:10070975",
-            "EFO:0000341",
-            "SNOMEDCT:13645005",
-            "MEDDRA:10009033",
-            "HP:0006510",
-            "MEDDRA:10008828"
-          ],
-          "id": "MONDO:0005002",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic Obstructive Pulmonary Disease",
-            "chronic obstructive pulmonary disease",
-            "Chronic pulmonary obstruction",
-            "Chronic Airflow Obstruction",
-            "Chronic Obstructive Airway Disease",
-            "Pulmonary Disease, Chronic Obstructive"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health-topics/copd",
-            "PMID:32800196",
-            "PMID:28513453",
-            "PMID:25943942",
-            "PMID:32745458"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 324986,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-              "name": "chronic obstructive pulmonary disease",
-              "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-              "equivalent_curies": [
-                "MESH:D029424",
-                "MEDDRA:10010952",
-                "MEDDRA:10009025",
-                "ICD10:J44.9",
-                "UMLS:C1527303",
-                "NCIT:C3199",
-                "UMLS:C0024117",
-                "MEDDRA:10064611",
-                "MEDDRA:10009026",
-                "MEDDRA:10029972",
-                "DOID:3083",
-                "MONDO:0005002",
-                "MEDDRA:10009032",
-                "MEDDRA:10070975",
-                "EFO:0000341",
-                "SNOMEDCT:13645005",
-                "MEDDRA:10009033",
-                "HP:0006510",
-                "MEDDRA:10008828"
-              ],
-              "id": "MONDO:0005002",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic Obstructive Pulmonary Disease",
-                "chronic obstructive pulmonary disease",
-                "Chronic pulmonary obstruction",
-                "Chronic Airflow Obstruction",
-                "Chronic Obstructive Airway Disease",
-                "Pulmonary Disease, Chronic Obstructive"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health-topics/copd",
-                "PMID:32800196",
-                "PMID:28513453",
-                "PMID:25943942",
-                "PMID:32745458"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8276205,
-            "start": 568,
-            "end": 324986,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11001866': {'publication date': '2000', 'sentence': 'Additive effects of prednisolone and beclomethasone dipropionate in patients with stable chronic obstructive pulmonary disease.', 'subject score': 1000, 'object score': 937}, 'PMID:11874817': {'publication date': '2002 Mar 01', 'sentence': 'Both budesonide and prednisolone improved airflow in COPD patients with acute exacerbations when compared with placebo.', 'subject score': 1000, 'object score': 928}, 'PMID:136811': {'publication date': '1976 Sep 03', 'sentence': 'The acute bronchodilator effect of chinoxaline, prednisolone and ipratropium bromide was tested by whole-body plethysmography in 18 patients with chronic obstructive airway disease over a period of 60 min.', 'subject score': 1000, 'object score': 1000}, 'PMID:1496499': {'publication date': '1992 Jun', 'sentence': 'Bone turnover during short course prednisolone treatment in patients with chronic obstructive airways disease.', 'subject score': 833, 'object score': 1000}, 'PMID:15741434': {'publication date': '2005 Mar', 'sentence': 'BACKGROUND: An association between the sputum eosinophil count and the response to a 2 week course of prednisolone has previously been reported in patients with chronic obstructive pulmonary disease (COPD).', 'subject score': 1000, 'object score': 1000}, 'PMID:15765929': {'publication date': '2004', 'sentence': 'Sputum cells were harvested from mild asthmatics and stable COPD patients and treated with piclamilast, theophylline or prednisolone.', 'subject score': 1000, 'object score': 790}, 'PMID:17646228': {'publication date': '2007 Dec', 'sentence': 'METHODS: Patients hospitalized for an exacerbation of COPD were randomized to receive 5 days of therapy with prednisolone, 60 mg IV or orally.', 'subject score': 1000, 'object score': 1000}, 'PMID:20298414': {'publication date': '2010 Jan', 'sentence': 'RESULTS: COPD patients who had filled a prescription for prednisolone (P-COPD) were DXA-scanned more frequently (17%) than those who had not (non-P-COPD) (9%) and were prescribed antiresorptive medicine more often (27%) than non-P-COPD (16%).', 'subject score': 1000, 'object score': 876}, 'PMID:21411550': {'publication date': '2011 Jun', 'sentence': 'PARTICIPANTS: Participants included 60 consecutive consenting subjects with chronic obstructive pulmonary disease admitted to hospital: 13 without known diabetes admitted for other indications and not treated with glucocorticoids (group 1), 40 without known diabetes admitted with an exacerbation of chronic obstructive pulmonary disease and treated with prednisolone (group 2, prednisolone = 30 +/- 6 mg/d), and seven with known diabetes treated with prednisolone (group 3, prednisolone = 26 +/- 9 mg/d).', 'subject score': 1000, 'object score': 1000}, 'PMID:23064668': {'publication date': '2012 Dec', 'sentence': \"The patient's past history revealed a 10-year history of psoriasis and chronic obstructive pulmonary disease treated with methotrexate and prednisolone.\", 'subject score': 1000, 'object score': 1000}, 'PMID:23991645': {'publication date': '2014 Nov', 'sentence': 'An 82-year-old woman on long-term prednisolone for chronic obstructive airways disease presented with a 2-month history of nodules on her left forearm.', 'subject score': 901, 'object score': 1000}, 'PMID:28183273': {'publication date': '2017 02 10', 'sentence': 'He had been suffering from rheumatoid arthritis for 18 years and chronic obstructive pulmonary disease for 20 years, for which he was being treated with 5 mg/day prednisolone and 8 mg/week methotrexate.', 'subject score': 852, 'object score': 1000}, 'PMID:2868289': {'publication date': '1986 Feb 01', 'sentence': 'Clinical improvement after treatment with prednisolone in chronic airways obstruction in absence of change in lung function tests.', 'subject score': 1000, 'object score': 988}, 'PMID:31761896': {'publication date': '2019 Nov 25', 'sentence': 'The patient had no known history of well-established immunocompromised state except for a short course of prednisolone for chronic obstructive pulmonary disease management.', 'subject score': 1000, 'object score': 928}, 'PMID:3265334': {'publication date': '1988 Dec', 'sentence': 'A generally similar pattern is seen in healthy controls and in patients with untreated pulmonary tuberculosis, treated leprosy, haemophilia A and chronic obstructive lung disease (COLD) patients treated with prednisolone, but the gradient of increasing CD4:CD8 ratio with depth into the dermis is significantly less steep in patients with tuberculosis, haemophilia and prednisolone-treated COLD than in the healthy controls.', 'subject score': 1000, 'object score': 928}, 'PMID:34079652': {'publication date': '2021 Apr 13', 'sentence': 'History revealed that he was taking prednisolone daily for his hyperactive airway disease.', 'subject score': 840, 'object score': 1000}, 'PMID:3538487': {'publication date': '1986 Aug', 'sentence': 'A double blind, randomised, placebo controlled, crossover trial of prednisolone (40 mg/day for 14 days) was carried out in 33 patients with chronic airflow limitation (mean age 62 years, mean FEV1 1.01 litres, mean FEV1/FVC ratio 44%), to assess the value of serial peak expiratory flow (PEF) measurements, taken five times daily in evaluating treatment response by comparison with other objective measurements and with measurements of symptoms.', 'subject score': 1000, 'object score': 1000}, 'PMID:6146752': {'publication date': '1984 Jul 28', 'sentence': 'A double-blind, randomised, placebo-controlled, crossover trial of prednisolone (40 mg daily for 14 days) was carried out in 43 patients with chronic airflow limitation (mean age 60 years, mean FEV1 1.02 litres, FEV1/FVC ratio 43.7%).', 'subject score': 1000, 'object score': 1000}, 'PMID:9089801': {'publication date': '1997 Mar', 'sentence': 'The mean leukotriene E4 level in patients with COPD during remission, during acute exacerbation before and after prednisolone treatment were 16.8[4.02], 41.7[21.9], and 19.5[3.78] pg/ml (mean[SD]), respectively.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0024117---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8455402",
-              "object": "MONDO:0005002",
-              "publications": [
-                "PMID:11001866",
-                "PMID:11874817",
-                "PMID:136811",
-                "PMID:1496499",
-                "PMID:15741434",
-                "PMID:15765929",
-                "PMID:17646228",
-                "PMID:20298414",
-                "PMID:21411550",
-                "PMID:23064668",
-                "PMID:23991645",
-                "PMID:28183273",
-                "PMID:2868289",
-                "PMID:31761896",
-                "PMID:3265334",
-                "PMID:34079652",
-                "PMID:3538487",
-                "PMID:6146752",
-                "PMID:9089801"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002049",
-          "name": "thrombocytopenia",
-          "description": "A reduction in the number of circulating thrombocytes. [HPO:probinson]; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T034",
-          "equivalent_curies": [
-            "UMLS:C0392386",
-            "SNOMEDCT:302215000",
-            "MEDDRA:10035545",
-            "MEDDRA:10043555",
-            "PDQ:CDR0000041408",
-            "MEDDRA:10024922",
-            "ICD10:D69.6",
-            "HP:0001873",
-            "NCIT:C3408",
-            "NCIT:C162108",
-            "MEDDRA:10035528",
-            "UMLS:C5201036",
-            "MEDDRA:10043560",
-            "DOID:1588",
-            "UMLS:CN130080",
-            "SYMP:0000114",
-            "MEDDRA:10038213",
-            "MEDDRA:10043546",
-            "MESH:D013921",
-            "MEDDRA:10035529",
-            "MEDDRA:10043569",
-            "UMLS:C0040034",
-            "MEDDRA:10043554",
-            "ICD9:287.5",
-            "MONDO:0002049",
-            "SNOMEDCT:415116008"
-          ],
-          "id": "MONDO:0002049",
-          "category": "biolink:Disease",
-          "all_names": [
-            "thrombocytopenia",
-            "Thrombocytopenia, unspecified",
-            "Low Platelet Count",
-            "Thrombocytopenia",
-            "Decreased platelet count"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/thrombocytopenia",
-            "http://www.merckmanuals.com/professional/hematology_and_oncology/thrombocytopenia_and_platelet_dysfunction/overview_of_platelet_disorders.htm",
-            "http://ghr.nlm.nih.gov/glossary=thrombocytopenia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316686,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002049",
-              "name": "thrombocytopenia",
-              "description": "A reduction in the number of circulating thrombocytes. [HPO:probinson]; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T034",
-              "equivalent_curies": [
-                "UMLS:C0392386",
-                "SNOMEDCT:302215000",
-                "MEDDRA:10035545",
-                "MEDDRA:10043555",
-                "PDQ:CDR0000041408",
-                "MEDDRA:10024922",
-                "ICD10:D69.6",
-                "HP:0001873",
-                "NCIT:C3408",
-                "NCIT:C162108",
-                "MEDDRA:10035528",
-                "UMLS:C5201036",
-                "MEDDRA:10043560",
-                "DOID:1588",
-                "UMLS:CN130080",
-                "SYMP:0000114",
-                "MEDDRA:10038213",
-                "MEDDRA:10043546",
-                "MESH:D013921",
-                "MEDDRA:10035529",
-                "MEDDRA:10043569",
-                "UMLS:C0040034",
-                "MEDDRA:10043554",
-                "ICD9:287.5",
-                "MONDO:0002049",
-                "SNOMEDCT:415116008"
-              ],
-              "id": "MONDO:0002049",
-              "category": "biolink:Disease",
-              "all_names": [
-                "thrombocytopenia",
-                "Thrombocytopenia, unspecified",
-                "Low Platelet Count",
-                "Thrombocytopenia",
-                "Decreased platelet count"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/thrombocytopenia",
-                "http://www.merckmanuals.com/professional/hematology_and_oncology/thrombocytopenia_and_platelet_dysfunction/overview_of_platelet_disorders.htm",
-                "http://ghr.nlm.nih.gov/glossary=thrombocytopenia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8094215,
-            "start": 568,
-            "end": 316686,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10863327': {'publication date': '2000 Apr', 'sentence': 'Three out of 8 patients with thrombocytopenia were treated with prednisolone according to the protocol for idiopathic thrombocytopenic purpura.', 'subject score': 1000, 'object score': 1000}, 'PMID:11235133': {'publication date': '2001 Jan', 'sentence': \"After amelioration of the thrombocytopenia by prednisolone therapy, open renal biopsy was performed and a diagnosis of diffuse large B-cell non-Hodgkin's lymphoma was made.\", 'subject score': 888, 'object score': 1000}, 'PMID:12613003': {'publication date': '2003 Mar', 'sentence': 'Although renal dysfunction progressed to dialysis-dependent renal failure in one patient despite treatment with prednisolone and plasmapheresis but not in other, withdrawal of the treatment resulted in a prompt resolution of thrombocytopenia and microangiopathic hemolytic anemia in both patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:14211529': {'publication date': '1964', 'sentence': '[LEUKEMIC RETICULO-SARCOMATOSIS FOLLOWING METHYLTESTOSTERONE AND PREDNISOLONE TREATED PANMYELOPATHY AND THROMBOCYTOPENIA].', 'subject score': 1000, 'object score': 1000}, 'PMID:17329922': {'publication date': '2007', 'sentence': 'High-dose prednisolone therapy improved the hemolytic anemia and thrombocytopenia, but not the CD16(+) CD56(-) NK lymphocytosis completely.', 'subject score': 861, 'object score': 1000}, 'PMID:21372465': {'publication date': '2011', 'sentence': 'After treatment with prednisolone and fresh frozen plasma, ADAMTS-13 activity was normalized, the ADAMTS-13 inhibitor had disappeared and the thrombocytopenia with a bleeding tendency was improved.', 'subject score': 1000, 'object score': 1000}, 'PMID:21772119': {'publication date': '2011 Jul', 'sentence': 'Immune pathogenesis was suspected since platelet-associated immunoglobulin G (PAIGg) was increased and the administration of prednisolone (PSL) quickly ameliorated the thrombocytopenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:2243038': {'publication date': '1990 Oct 15', 'sentence': 'Prednisolone and danazol for treatment of immune-mediated anemia, thrombocytopenia, and ineffective erythroid regeneration in a dog.', 'subject score': 1000, 'object score': 1000}, 'PMID:2381060': {'publication date': '1990 Apr', 'sentence': 'The treatment with prednisolone resulted in a decrease in the severity of the lymphadenopathy, thrombocytopenia and polyclonal hypergammopathy.', 'subject score': 1000, 'object score': 1000}, 'PMID:2390633': {'publication date': '1990 Jul', 'sentence': 'On day 556 post-graft severe thrombocytopenia was resistant to prednisolone, cyclophosphamide and high dose immunoglobulin.', 'subject score': 1000, 'object score': 888}, 'PMID:26387855': {'publication date': '2015 Oct', 'sentence': 'Thrombocytopenia took a chronic course and platelet count fluctuated in the range 18 000-46 000/MUL, not responding to i.v. immunoglobulin or prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:26664400': {'publication date': '2015', 'sentence': 'The patient had a normal bone marrow aspiration and biopsy, the thrombocytopenia was resistant to platelet transfusion which successfully was treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:28535135': {'publication date': '2017 Jul/Aug', 'sentence': 'A second episode of thrombocytopenia (day +51) was managed with vincristine, prednisolone, and melatonin.', 'subject score': 1000, 'object score': 1000}, 'PMID:30567252': {'publication date': '2018 Dec 13', 'sentence': 'The patient subsequently developed pulmonary cysts and thrombocytopaenia due to autoimmune pathology and was successfully treated using prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:3184476': {'publication date': '1988 Jul', 'sentence': '[Normalization of platelet count following prednisolone and splenectomy in a patient with splenic hamartoma and thrombocytopenia].', 'subject score': 1000, 'object score': 1000}, 'PMID:31866622': {'publication date': '2019', 'sentence': 'The thrombocytopenia and neutropenia were successfully treated by prednisolone and romiplostim with negative conversion of antineutrophil antibody.', 'subject score': 1000, 'object score': 1000}, 'PMID:32258416': {'publication date': '2020', 'sentence': 'Streptococcus Pneumoniae    -associated Thrombotic Microangiopathy in an Immunosuppressed Adult.A 62-year-old male who was receiving prednisolone and methotrexate for scleroderma and rheumatoid arthritis complained of diarrhea and vomiting, and was transferred to our hospital for detailed examination and treatment of renal dysfunction and thrombocytopenia.', 'subject score': 888, 'object score': 1000}, 'PMID:3441913': {'publication date': '1987', 'sentence': 'The striking recurrent thrombocytopenia was successfully treated with prednisolone.', 'subject score': 1000, 'object score': 790}, 'PMID:35700350': {'publication date': '2022 Jun 07', 'sentence': 'We describe a case of infantile MLT that did not respond to treatment with propranolol, prednisolone, or vincristine.', 'subject score': 1000, 'object score': 753}, 'PMID:37123554': {'publication date': '2023 Jan-Jun', 'sentence': 'Case summary: A 3-year-old neutered domestic shorthair cat with a long history of idiopathic immune-mediated haemolytic anaemia and thrombocytopenia treated with ciclosporin and prednisolone was referred 2 months after the appearance of nodular dermatitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0040034---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8268574",
-              "object": "MONDO:0002049",
-              "publications": [
-                "PMID:10863327",
-                "PMID:11235133",
-                "PMID:12613003",
-                "PMID:14211529",
-                "PMID:17329922",
-                "PMID:21372465",
-                "PMID:21772119",
-                "PMID:2243038",
-                "PMID:2381060",
-                "PMID:2390633",
-                "PMID:26387855",
-                "PMID:26664400",
-                "PMID:28535135",
-                "PMID:30567252",
-                "PMID:3184476",
-                "PMID:31866622",
-                "PMID:32258416",
-                "PMID:3441913",
-                "PMID:35700350",
-                "PMID:37123554"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316905,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018908",
-          "name": "non-Hodgkin lymphoma",
-          "description": "Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3211\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3211\" NCI Thesaurus); Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.; Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.; A type of lymphoma characterized microscopically by the absence of multinucleated Reed-Sternberg cells. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "UMLS:C1622254",
-            "ORPHANET:547",
-            "MESH:D008228",
-            "UMLS:C0024305",
-            "MONDO:0018908",
-            "HP:0012539",
-            "SNOMEDCT:188675007",
-            "PDQ:CDR0000038957",
-            "NCIT:C3211",
-            "SNOMEDCT:1172592001",
-            "DOID:0060060",
-            "MEDDRA:10025311",
-            "MEDDRA:10029593",
-            "SNOMEDCT:128929007",
-            "MEDDRA:10029547",
-            "UMLS:C1622813"
-          ],
-          "id": "MONDO:0018908",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Non-Hodgkin Lymphoma",
-            "Lymphoma, Non-Hodgkin",
-            "Malignant lymphoma - small cleaved cell",
-            "non-Hodgkin lymphoma",
-            "Non-Hodgkin lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/non-hodgkin_lymphoma",
-            "http://www.cancer.gov/dictionary?cdrid=45148",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316905,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018908",
-              "name": "non-Hodgkin lymphoma",
-              "description": "Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3211\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3211\" NCI Thesaurus); Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.; Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.; A type of lymphoma characterized microscopically by the absence of multinucleated Reed-Sternberg cells. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "UMLS:C1622254",
-                "ORPHANET:547",
-                "MESH:D008228",
-                "UMLS:C0024305",
-                "MONDO:0018908",
-                "HP:0012539",
-                "SNOMEDCT:188675007",
-                "PDQ:CDR0000038957",
-                "NCIT:C3211",
-                "SNOMEDCT:1172592001",
-                "DOID:0060060",
-                "MEDDRA:10025311",
-                "MEDDRA:10029593",
-                "SNOMEDCT:128929007",
-                "MEDDRA:10029547",
-                "UMLS:C1622813"
-              ],
-              "id": "MONDO:0018908",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Non-Hodgkin Lymphoma",
-                "Lymphoma, Non-Hodgkin",
-                "Malignant lymphoma - small cleaved cell",
-                "non-Hodgkin lymphoma",
-                "Non-Hodgkin lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/non-hodgkin_lymphoma",
-                "http://www.cancer.gov/dictionary?cdrid=45148",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7821105,
-            "start": 568,
-            "end": 316905,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10674903': {'publication date': '2000 Jan', 'sentence': \"A regimen which incorporates cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) is the standard treatment for patients with non-Hodgkin's lymphoma (NHL), but it has not been effective in patients with aggressive NHL who are at high risk.\", 'subject score': 1000, 'object score': 1000}, 'PMID:11256023': {'publication date': '2001 Feb 23', 'sentence': '[Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma]].', 'subject score': 1000, 'object score': 840}, 'PMID:11368287': {'publication date': '2001', 'sentence': 'Substitution of bendamustine for cyclophosphamide in a standard first-line COP regimen (cyclophosphamide, vincristine and prednisolone) yielded similar response rates in patients with advanced low grade NHL.', 'subject score': 1000, 'object score': 840}, 'PMID:16247790': {'publication date': '2005 Dec 01', 'sentence': 'METHODS: Forty consecutive patients with untreated non-Hodgkin lymphoma who were scheduled to undergo standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) (mean age, 56 yrs; range, 24-70 yrs) were randomized with minimization methods to receive CHOP with or without 80 mg/day of valsartan.', 'subject score': 1000, 'object score': 923}, 'PMID:16533747': {'publication date': '2005 Dec', 'sentence': \"To facilitate more economical medical care, we carried out a prospective study of whether a THP-COP regimen (cyclophosphamide, pirarubicin, vincristine, and prednisolone) with low-dose granulocyte colony-stimulating factor (G-CSF) would effectively treat non-Hodgkin's lymphoma (NHL).\", 'subject score': 1000, 'object score': 1000}, 'PMID:18226581': {'publication date': '2008 Feb', 'sentence': 'BACKGROUND: Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is used to treat patients with non-Hodgkin lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:2298419': {'publication date': '1990', 'sentence': \"Thirty-six patients with non-Hodgkin's lymphoma (NHL) (comprising patients with refractory or relapsed disease and eight elderly, unfit patients with de novo disease) were treated with mitozantrone, chlorambucil and prednisolone on an out-patient basis.\", 'subject score': 1000, 'object score': 1000}, 'PMID:2300381': {'publication date': '1990', 'sentence': \"Combination chemotherapy with pirarubicin (THP), cyclophosphamide, vincristine, and prednisolone (VEP-THP therapy) in the treatment of non-Hodgkin's lymphoma.\", 'subject score': 1000, 'object score': 1000}, 'PMID:26370464': {'publication date': '2015 Sep 14', 'sentence': \"BACKGROUND: The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is an efficient treatment of non-Hodgkin's lymphoma (NHL).\", 'subject score': 1000, 'object score': 1000}, 'PMID:30241515': {'publication date': '2018 Sep 21', 'sentence': 'Cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), and prednisolone (CHOP) is the most common chemotherapy for non-Hodgkin lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:32884529': {'publication date': '2020 May-Aug', 'sentence': 'Sea-Blue Histiocytosis of Bone Marrow in a Patient with t(8;22) Acute Myeloid Leukemia.An 80-year-old Japanese male was treated with chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, and prednisolone, for non-Hodgkin lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:3293535': {'publication date': '1988 Jul', 'sentence': \"Thirty-seven previously untreated patients with advanced non-Hodgkin's lymphoma were treated with VEPA therapy.\", 'subject score': 888, 'object score': 923}, 'PMID:34213982': {'publication date': '2021 Jul 02', 'sentence': \"She had been treated with etoposide and prednisolone for non-Hodgkin's lymphoma.\", 'subject score': 1000, 'object score': 1000}, 'PMID:3753642': {'publication date': '1986 Jan', 'sentence': \"From these results we concluded that VEPA therapy is more effective for non-Hodgkin's lymphoma, especially large-cell type, than non-VEPA therapy.\", 'subject score': 719, 'object score': 1000}, 'PMID:3952518': {'publication date': '1986 Mar', 'sentence': \"Prednimustine v cyclophosphamide-vincristine-prednisolone in the treatment of non-Hodgkin's lymphoma with favorable histopathology: results of a national cancer care program in Sweden.\", 'subject score': 766, 'object score': 1000}, 'PMID:3975655': {'publication date': '1985 Mar', 'sentence': \"Vindesine, etoposide (VePesid), and prednisolone (VEP) have been evaluated as a second-line combination regimen in 20 patients with grade II non-Hodgkin's lymphoma (NHL) who relapsed during or after first-line intensive therapy.\", 'subject score': 1000, 'object score': 893}, 'PMID:403727': {'publication date': '1977 Mar', 'sentence': 'Peptichemio: A new oncolytic drug in combination with vincristine and prednisolone in the treatment of non-Hodgkin lymphomas.', 'subject score': 1000, 'object score': 988}, 'PMID:630211': {'publication date': '1978 Mar 04', 'sentence': \"Sixty-six untreated patients with advanced non-Hodgkin's lymphoma of favourable histological type were allocated alternately to initial treatment with cyclophosphamide, vincristine, and prednisolone or with chlorambucil.\", 'subject score': 1000, 'object score': 923}, 'PMID:6594975': {'publication date': '1984 Dec', 'sentence': \"[Clinical efficacy of a quadruple combination chemotherapy with ACNU, adriamycin, methotrexate, and prednisolone for patients with non-Hodgkin's lymphoma, who were refractory to VEPA (P) treatment].\", 'subject score': 1000, 'object score': 1000}, 'PMID:7014226': {'publication date': '1980 Nov', 'sentence': \"Intensive combination chemotherapy with vincristine, adriamycin and prednisolone (VAP) in the treatment of diffuse histology non-Hodgkin's lymphoma.\", 'subject score': 1000, 'object score': 875}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0024305---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7990669",
-              "object": "MONDO:0018908",
-              "publications": [
-                "PMID:10674903",
-                "PMID:11256023",
-                "PMID:11368287",
-                "PMID:16247790",
-                "PMID:16533747",
-                "PMID:18226581",
-                "PMID:2298419",
-                "PMID:2300381",
-                "PMID:26370464",
-                "PMID:30241515",
-                "PMID:32884529",
-                "PMID:3293535",
-                "PMID:34213982",
-                "PMID:3753642",
-                "PMID:3952518",
-                "PMID:3975655",
-                "PMID:403727",
-                "PMID:630211",
-                "PMID:6594975",
-                "PMID:7014226"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322120,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-          "name": "Crohn disease",
-          "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003424",
-            "ORPHANET:206",
-            "NCIT:C37262",
-            "MEDDRA:10038281",
-            "MEDDRA:10011405",
-            "UMLS:CN043071",
-            "SNOMEDCT:50440006",
-            "MEDDRA:10057032",
-            "HP:0100280",
-            "EFO:0000384",
-            "DOID:8778",
-            "MONDO:0005011",
-            "PDQ:CDR0000714480",
-            "UMLS:C0010346",
-            "NCIT:C2965",
-            "SNOMEDCT:7620006",
-            "ICD10:K50.1",
-            "UMLS:C0156147",
-            "MEDDRA:10011398",
-            "MEDDRA:10011401",
-            "SNOMEDCT:34000006",
-            "ICD9:555.1",
-            "MEDDRA:10013099",
-            "MEDDRA:10011402",
-            "MEDDRA:10011400"
-          ],
-          "id": "MONDO:0005011",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Granulomatous Colitis",
-            "Crohn's disease of large bowel",
-            "Regional enteritis of large intestine",
-            "Crohn Disease",
-            "Crohn disease",
-            "Crohn's disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/chron%27s_disease",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322120,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-              "name": "Crohn disease",
-              "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003424",
-                "ORPHANET:206",
-                "NCIT:C37262",
-                "MEDDRA:10038281",
-                "MEDDRA:10011405",
-                "UMLS:CN043071",
-                "SNOMEDCT:50440006",
-                "MEDDRA:10057032",
-                "HP:0100280",
-                "EFO:0000384",
-                "DOID:8778",
-                "MONDO:0005011",
-                "PDQ:CDR0000714480",
-                "UMLS:C0010346",
-                "NCIT:C2965",
-                "SNOMEDCT:7620006",
-                "ICD10:K50.1",
-                "UMLS:C0156147",
-                "MEDDRA:10011398",
-                "MEDDRA:10011401",
-                "SNOMEDCT:34000006",
-                "ICD9:555.1",
-                "MEDDRA:10013099",
-                "MEDDRA:10011402",
-                "MEDDRA:10011400"
-              ],
-              "id": "MONDO:0005011",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Granulomatous Colitis",
-                "Crohn's disease of large bowel",
-                "Regional enteritis of large intestine",
-                "Crohn Disease",
-                "Crohn disease",
-                "Crohn's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/chron%27s_disease",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7819928,
-            "start": 568,
-            "end": 322120,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10672132': {'publication date': '2000 Jan', 'sentence': 'In a stepwise regression that included age, sex, disease duration and cumulative prednisolone dose as independent variables, the femur T score was significantly inversely related to disease duration (r2 = 0.125, F = 6.06) in CD patients.', 'subject score': 851, 'object score': 901}, 'PMID:11181269': {'publication date': '2001 Jan 20', 'sentence': 'CONCLUSIONS: Budesonide is as useful as prednisolone in treatment of active CD and it has a lower impact in serum cortisol levels.', 'subject score': 1000, 'object score': 901}, 'PMID:12012225': {'publication date': '2002 May', 'sentence': 'UNLABELLED: In an 11-year old boy with Crohn disease, long-term therapy with prednisolone was decided to be augmented by infliximab, a monoclonal antibody to tumour necrosis factor alpha.', 'subject score': 1000, 'object score': 1000}, 'PMID:12120182': {'publication date': '2001', 'sentence': \"Budesonide is equal to less effective than prednisolone or prednisone therapy in the treatment of active Crohn's disease, but is associated with fewer glucocorticoids adverse reactions.\", 'subject score': 1000, 'object score': 901}, 'PMID:12381231': {'publication date': '2002', 'sentence': \"CONCLUSION: Oral budesonide 9 mg/day offers efficacy that is superior to mesalazine slow release and placebo, and similar to prednisolone in the treatment of patients with active mild to moderate Crohn's disease involving the ileum and/or ascending colon.\", 'subject score': 1000, 'object score': 864}, 'PMID:12673090': {'publication date': '2003', 'sentence': 'The patient improved promptly after initiating oral treatment for CD with mesalazine and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:14572572': {'publication date': '2003 Oct', 'sentence': 'The aim of the present work was to investigate serum ASCA levels during the courses of prednisolone and mesalamine therapy in CD patients.', 'subject score': 1000, 'object score': 901}, 'PMID:15095852': {'publication date': '2004 Jan', 'sentence': \"Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial.\", 'subject score': 1000, 'object score': 901}, 'PMID:15555744': {'publication date': '2005 Jan 06', 'sentence': \"The drug's effectiveness in this disease has been proven in multiple, placebo-controlled trials, where it has been shown to be superior to mesalamine and placebo, and equivalent to prednisolone for the control of mild to moderately active right-sided Crohn's disease.\", 'subject score': 1000, 'object score': 773}, 'PMID:15704045': {'publication date': '2005 Feb', 'sentence': \"METHODS: In 34 international centers, 272 patients with Crohn's disease involving ileum and/or colon ascendens were randomized to once daily treatment with budesonide or prednisolone for 2 years at doses adapted to disease activity.\", 'subject score': 1000, 'object score': 1000}, 'PMID:16179087': {'publication date': '2005 Sep 22', 'sentence': 'METHODS: Plasma from patients with exacerbations of UC (n = 18) or CD (n = 18) were collected before and during high dose prednisolone treatment (1 mg/kg body weight) and tapering.', 'subject score': 861, 'object score': 1000}, 'PMID:17068395': {'publication date': '2006', 'sentence': 'Additionally, serum TFF concentrations were determined in patients with severe activity in colon IBD (4 UC and 6 CD) before and during prednisolone treatment with 7 healthy subjects as controls.', 'subject score': 888, 'object score': 901}, 'PMID:17429201': {'publication date': '2007', 'sentence': \"Impact of enteral supplements enriched with omega-3 fatty acids and/or omega-6 fatty acids, arginine and ribonucleic acid compounds on leptin levels and nutritional status in active Crohn's disease treated with prednisolone.\", 'subject score': 1000, 'object score': 901}, 'PMID:1790809': {'publication date': '1991', 'sentence': \"Patients with nonspecific ulcerative colitis and Crohn's disease were treated with drug therapy (prednisolone, sulphasalazine, metronidazole per os and hydrocortisone per rectum) and subjected to 12 sessions of HBO.\", 'subject score': 1000, 'object score': 1000}, 'PMID:21355357': {'publication date': '2010 Nov 25-Dec 8', 'sentence': \"Prednisolone in the management of patients with Crohn's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:2179093': {'publication date': '1990 Feb', 'sentence': \"Controlled trial comparing an elemental diet with prednisolone in the treatment of active Crohn's disease.\", 'subject score': 1000, 'object score': 901}, 'PMID:23185152': {'publication date': '2012 Sep', 'sentence': 'Both patients were released on a prednisolone-based treatment for suspected CD.', 'subject score': 840, 'object score': 901}, 'PMID:2323598': {'publication date': '1990 Mar', 'sentence': \"The effect of prednisolone (20-30 mg daily for six to nine weeks) was studied in eight patients with Crohn's disease and recurrent, preanastomotic ileal inflammation, in respect of symptoms, endoscopic findings and phospholipase A2 activity in the ileal mucosa.\", 'subject score': 1000, 'object score': 1000}, 'PMID:26019475': {'publication date': '2015 May 21', 'sentence': \"Following commencement of prednisolone for her Crohn's disease, the patient developed widespread Hodgkin lymphoma which ultimately presented as a life-threatening lower GIT bleed requiring emergency colectomy.\", 'subject score': 1000, 'object score': 1000}, 'PMID:2709273': {'publication date': '1989 Apr', 'sentence': \"Measurement of plasma prednisolone level to evaluate a prednisone treatment failure in an adolescent with Crohn's disease.\", 'subject score': 623, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0010346---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7986379",
-              "object": "MONDO:0005011",
-              "publications": [
-                "PMID:10672132",
-                "PMID:11181269",
-                "PMID:12012225",
-                "PMID:12120182",
-                "PMID:12381231",
-                "PMID:12673090",
-                "PMID:14572572",
-                "PMID:15095852",
-                "PMID:15555744",
-                "PMID:15704045",
-                "PMID:16179087",
-                "PMID:17068395",
-                "PMID:17429201",
-                "PMID:1790809",
-                "PMID:21355357",
-                "PMID:2179093",
-                "PMID:23185152",
-                "PMID:2323598",
-                "PMID:26019475",
-                "PMID:2709273"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1067159': {'publication date': '1976', 'sentence': 'A regime of treatment of acute non-lymphoblastic leukemia in adult, employing DMCP protocol, especially two step method consisting of daunorubicin, cytosine arabinoside, 6-mercaptopurine and prednisolone is described.', 'subject score': 1000, 'object score': 923}, 'PMID:11984797': {'publication date': '2002 Jun', 'sentence': 'Adult Ph+ (n = 12) ALL was more resistant to prednisolone (> 270-fold, P = 0.030), and displayed an overall tendency to resistance when compared to matched cases of Ph- (n = 15) adult precursor B-cell ALL.', 'subject score': 1000, 'object score': 1000}, 'PMID:11999561': {'publication date': '2002 Feb', 'sentence': 'It seems that in vitro resistance to prednisolone with respect to the age might be a continuous variable in ALL patients, except infants.', 'subject score': 1000, 'object score': 916}, 'PMID:12698270': {'publication date': '2003 Jun', 'sentence': 'Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:12774931': {'publication date': '2003 May', 'sentence': 'A 69-year-old man with relapsed acute lymphoid leukemia was treated with adriamycin, vincristine, and prednisolone.', 'subject score': 1000, 'object score': 905}, 'PMID:12780755': {'publication date': '2003 Jun', 'sentence': 'Short-term effects of prednisolone and dexamethasone on circulating concentrations of leptin and sex hormone-binding globulin in children being treated for acute lymphoblastic leukaemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:12807155': {'publication date': '2002 Dec', 'sentence': 'We studied the association between the presence of bcr-abl fusion gene and in vitro prednisolone resistance in children with B-lineage acute lymphoblastic leukaemia at diagnosis.', 'subject score': 658, 'object score': 884}, 'PMID:12825213': {'publication date': '2003 Aug', 'sentence': 'The purpose of this study was to assess the incidence of adrenal insufficiency and the time for children with ALL to recover after treatment with the glucorticoids prednisolone or dexamethasone.', 'subject score': 861, 'object score': 1000}, 'PMID:12920041': {'publication date': '2003 Dec 15', 'sentence': 'To investigate the underlying mechanisms of cellular drug resistance, the activation of various apoptotic parameters in leukemic cells from 50 children with ALL was studied after in vitro exposure with 4 important drugs in ALL therapy (prednisolone, vincristine, l-asparaginase, and daunorubicin).', 'subject score': 1000, 'object score': 916}, 'PMID:1488756': {'publication date': '1992 Sep', 'sentence': 'On the other hand, the median survival was only 13 months for the 5 patients with ALL treated with PSL.', 'subject score': 1000, 'object score': 1000}, 'PMID:15192618': {'publication date': '2004 Jun', 'sentence': 'Study design Children with ALL (N=24) were treated with prednisolone (40 mg/m(2) per day) for 28 days during the induction phase followed by 1 week of oral dexamethasone every 4 weeks.', 'subject score': 1000, 'object score': 1000}, 'PMID:15295046': {'publication date': '2004 Aug 05', 'sentence': 'RESULTS: We identified sets of differentially expressed genes in B-lineage ALL that were sensitive or resistant to prednisolone (33 genes), vincristine (40 genes), asparaginase (35 genes), or daunorubicin (20 genes).', 'subject score': 1000, 'object score': 884}, 'PMID:15952999': {'publication date': '2005 Jun', 'sentence': 'Substitution of dexamethasone for prednisolone in the treatment of ALL might, therefore, result in improved event-free and overall survival.', 'subject score': 1000, 'object score': 1000}, 'PMID:17190987': {'publication date': '2007', 'sentence': 'CASE DESCRIPTION: A 3-year-old boy with ALL was successfully treated with chemotherapy (vincristine, prednisolone, mercaptopurine and methotrexate) and prophylactic cranial irradiation (total 18 Gy).', 'subject score': 1000, 'object score': 1000}, 'PMID:18519521': {'publication date': '2008 Aug', 'sentence': \"Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.\", 'subject score': 888, 'object score': 1000}, 'PMID:19352661': {'publication date': '2009 Dec', 'sentence': 'Multidrug resistance 1 (MDR1) gene expression determined by real-time polymerase chain reaction and results of rhodamine assay were analyzed at diagnosis and after 3 days of ex vivo therapy with prednisolone in 36 pediatric patients with acute lymphoblastic leukemia (ALL).', 'subject score': 1000, 'object score': 1000}, 'PMID:20378563': {'publication date': '2010 Sep', 'sentence': 'CONCLUSIONS: In the ALL-4 trial in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma, treatment with dexamethasone did not show any advantage over treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:20494936': {'publication date': '2010 Oct', 'sentence': 'Although patients with MLL-rearranged acute lymphoblastic leukemia are highly resistant to prednisolone and L-asparaginase, this resistance was not attributed to miR-196b expression.', 'subject score': 1000, 'object score': 850}, 'PMID:20815080': {'publication date': '2010 Oct', 'sentence': '[2] reported their first investigation in comparison of the antileukemic activity and toxicity between DXM and PDN for adult patients with ALL and lymphoblastic lymphoma (LBL) through a randomized clinical trial (the ALL-4 trial of the EORTC Leukemia Group), and the author concluded that DXM as a steroid therapy for adult patients with ALL/LBL did not show any benefit compared with PDN, which did not support the experience from several other pediatric studies.', 'subject score': 1000, 'object score': 933}, 'PMID:20979663': {'publication date': '2010 Oct 28', 'sentence': 'In silico analysis of published data demonstrated that reduced levels of MLL mRNA are associated with relapse and prednisolone resistance in T-ALL patients and adverse clinical outcome in children with MLL-rearranged ALL.', 'subject score': 694, 'object score': 823}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 323831,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-          "name": "acute lymphoblastic leukemia",
-          "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "HP:0006721",
-            "MONDO:0004967",
-            "MEDDRA:10000848",
-            "MEDDRA:10000849",
-            "MEDDRA:10025305",
-            "ORPHANET:513",
-            "MEDDRA:10025301",
-            "ICD10:C91.00",
-            "UMLS:C0023453",
-            "DOID:9952",
-            "MEDDRA:10000844",
-            "MEDDRA:10000846",
-            "MEDDRA:10000845",
-            "MEDDRA:10024338",
-            "ICD10:C91",
-            "MESH:D054198",
-            "UMLS:C1961102",
-            "MEDDRA:10060555",
-            "NCIT:C3167",
-            "PDQ:CDR0000043423",
-            "MEDDRA:10024290",
-            "MEDDRA:10000842",
-            "NCIT:C27281",
-            "ICD9:204",
-            "DOID:1037",
-            "MEDDRA:10000843",
-            "EFO:0000220",
-            "SNOMEDCT:128822004",
-            "ICD9:204.0",
-            "UMLS:C0023449",
-            "MEDDRA:10060390",
-            "SNOMEDCT:91857003"
-          ],
-          "id": "MONDO:0004967",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute lymphoblastic leukemia",
-            "lymphoid leukemia",
-            "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-            "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-            "L2 Acute Lymphoblastic Leukemia",
-            "acute lymphocytic leukemia",
-            "Lymphoid leukemia, acute",
-            "acute lymphoblastic leukemia",
-            "Acute lymphocytic leukemia",
-            "Acute Lymphoblastic Leukemia",
-            "Lymphoid leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=46332",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=616067",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323831,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-              "name": "acute lymphoblastic leukemia",
-              "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "HP:0006721",
-                "MONDO:0004967",
-                "MEDDRA:10000848",
-                "MEDDRA:10000849",
-                "MEDDRA:10025305",
-                "ORPHANET:513",
-                "MEDDRA:10025301",
-                "ICD10:C91.00",
-                "UMLS:C0023453",
-                "DOID:9952",
-                "MEDDRA:10000844",
-                "MEDDRA:10000846",
-                "MEDDRA:10000845",
-                "MEDDRA:10024338",
-                "ICD10:C91",
-                "MESH:D054198",
-                "UMLS:C1961102",
-                "MEDDRA:10060555",
-                "NCIT:C3167",
-                "PDQ:CDR0000043423",
-                "MEDDRA:10024290",
-                "MEDDRA:10000842",
-                "NCIT:C27281",
-                "ICD9:204",
-                "DOID:1037",
-                "MEDDRA:10000843",
-                "EFO:0000220",
-                "SNOMEDCT:128822004",
-                "ICD9:204.0",
-                "UMLS:C0023449",
-                "MEDDRA:10060390",
-                "SNOMEDCT:91857003"
-              ],
-              "id": "MONDO:0004967",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute lymphoblastic leukemia",
-                "lymphoid leukemia",
-                "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-                "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-                "L2 Acute Lymphoblastic Leukemia",
-                "acute lymphocytic leukemia",
-                "Lymphoid leukemia, acute",
-                "acute lymphoblastic leukemia",
-                "Acute lymphocytic leukemia",
-                "Acute Lymphoblastic Leukemia",
-                "Lymphoid leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=46332",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=616067",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7811916,
-            "start": 568,
-            "end": 323831,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1067159': {'publication date': '1976', 'sentence': 'A regime of treatment of acute non-lymphoblastic leukemia in adult, employing DMCP protocol, especially two step method consisting of daunorubicin, cytosine arabinoside, 6-mercaptopurine and prednisolone is described.', 'subject score': 1000, 'object score': 923}, 'PMID:11984797': {'publication date': '2002 Jun', 'sentence': 'Adult Ph+ (n = 12) ALL was more resistant to prednisolone (> 270-fold, P = 0.030), and displayed an overall tendency to resistance when compared to matched cases of Ph- (n = 15) adult precursor B-cell ALL.', 'subject score': 1000, 'object score': 1000}, 'PMID:11999561': {'publication date': '2002 Feb', 'sentence': 'It seems that in vitro resistance to prednisolone with respect to the age might be a continuous variable in ALL patients, except infants.', 'subject score': 1000, 'object score': 916}, 'PMID:12698270': {'publication date': '2003 Jun', 'sentence': 'Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:12774931': {'publication date': '2003 May', 'sentence': 'A 69-year-old man with relapsed acute lymphoid leukemia was treated with adriamycin, vincristine, and prednisolone.', 'subject score': 1000, 'object score': 905}, 'PMID:12780755': {'publication date': '2003 Jun', 'sentence': 'Short-term effects of prednisolone and dexamethasone on circulating concentrations of leptin and sex hormone-binding globulin in children being treated for acute lymphoblastic leukaemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:12807155': {'publication date': '2002 Dec', 'sentence': 'We studied the association between the presence of bcr-abl fusion gene and in vitro prednisolone resistance in children with B-lineage acute lymphoblastic leukaemia at diagnosis.', 'subject score': 658, 'object score': 884}, 'PMID:12825213': {'publication date': '2003 Aug', 'sentence': 'The purpose of this study was to assess the incidence of adrenal insufficiency and the time for children with ALL to recover after treatment with the glucorticoids prednisolone or dexamethasone.', 'subject score': 861, 'object score': 1000}, 'PMID:12920041': {'publication date': '2003 Dec 15', 'sentence': 'To investigate the underlying mechanisms of cellular drug resistance, the activation of various apoptotic parameters in leukemic cells from 50 children with ALL was studied after in vitro exposure with 4 important drugs in ALL therapy (prednisolone, vincristine, l-asparaginase, and daunorubicin).', 'subject score': 1000, 'object score': 916}, 'PMID:1488756': {'publication date': '1992 Sep', 'sentence': 'On the other hand, the median survival was only 13 months for the 5 patients with ALL treated with PSL.', 'subject score': 1000, 'object score': 1000}, 'PMID:15192618': {'publication date': '2004 Jun', 'sentence': 'Study design Children with ALL (N=24) were treated with prednisolone (40 mg/m(2) per day) for 28 days during the induction phase followed by 1 week of oral dexamethasone every 4 weeks.', 'subject score': 1000, 'object score': 1000}, 'PMID:15295046': {'publication date': '2004 Aug 05', 'sentence': 'RESULTS: We identified sets of differentially expressed genes in B-lineage ALL that were sensitive or resistant to prednisolone (33 genes), vincristine (40 genes), asparaginase (35 genes), or daunorubicin (20 genes).', 'subject score': 1000, 'object score': 884}, 'PMID:15952999': {'publication date': '2005 Jun', 'sentence': 'Substitution of dexamethasone for prednisolone in the treatment of ALL might, therefore, result in improved event-free and overall survival.', 'subject score': 1000, 'object score': 1000}, 'PMID:17190987': {'publication date': '2007', 'sentence': 'CASE DESCRIPTION: A 3-year-old boy with ALL was successfully treated with chemotherapy (vincristine, prednisolone, mercaptopurine and methotrexate) and prophylactic cranial irradiation (total 18 Gy).', 'subject score': 1000, 'object score': 1000}, 'PMID:18519521': {'publication date': '2008 Aug', 'sentence': \"Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.\", 'subject score': 888, 'object score': 1000}, 'PMID:19352661': {'publication date': '2009 Dec', 'sentence': 'Multidrug resistance 1 (MDR1) gene expression determined by real-time polymerase chain reaction and results of rhodamine assay were analyzed at diagnosis and after 3 days of ex vivo therapy with prednisolone in 36 pediatric patients with acute lymphoblastic leukemia (ALL).', 'subject score': 1000, 'object score': 1000}, 'PMID:20378563': {'publication date': '2010 Sep', 'sentence': 'CONCLUSIONS: In the ALL-4 trial in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma, treatment with dexamethasone did not show any advantage over treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:20494936': {'publication date': '2010 Oct', 'sentence': 'Although patients with MLL-rearranged acute lymphoblastic leukemia are highly resistant to prednisolone and L-asparaginase, this resistance was not attributed to miR-196b expression.', 'subject score': 1000, 'object score': 850}, 'PMID:20815080': {'publication date': '2010 Oct', 'sentence': '[2] reported their first investigation in comparison of the antileukemic activity and toxicity between DXM and PDN for adult patients with ALL and lymphoblastic lymphoma (LBL) through a randomized clinical trial (the ALL-4 trial of the EORTC Leukemia Group), and the author concluded that DXM as a steroid therapy for adult patients with ALL/LBL did not show any benefit compared with PDN, which did not support the experience from several other pediatric studies.', 'subject score': 1000, 'object score': 933}, 'PMID:20979663': {'publication date': '2010 Oct 28', 'sentence': 'In silico analysis of published data demonstrated that reduced levels of MLL mRNA are associated with relapse and prednisolone resistance in T-ALL patients and adverse clinical outcome in children with MLL-rearranged ALL.', 'subject score': 694, 'object score': 823}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0023449---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7985554",
-              "object": "MONDO:0004967",
-              "publications": [
-                "PMID:1067159",
-                "PMID:11984797",
-                "PMID:11999561",
-                "PMID:12698270",
-                "PMID:12774931",
-                "PMID:12780755",
-                "PMID:12807155",
-                "PMID:12825213",
-                "PMID:12920041",
-                "PMID:1488756",
-                "PMID:15192618",
-                "PMID:15295046",
-                "PMID:15952999",
-                "PMID:17190987",
-                "PMID:18519521",
-                "PMID:19352661",
-                "PMID:20378563",
-                "PMID:20494936",
-                "PMID:20815080",
-                "PMID:20979663"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 531220,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:23550277': {'publication date': '2013 Jun', 'sentence': 'Treatment of peripheral T cell lymphoma with an intensive protocol ACEP (adriamycin, cyclophosphamide, etoposide and prednisolone) and ifosfamide showing an important response and overall survival rates.', 'subject score': 1000, 'object score': 1000}, 'PMID:30511217': {'publication date': '2018 Dec 03', 'sentence': 'We designed a CHOPE/G regimen (cyclophosphamide, pirarubicin, vincristine, prednisolone, and etoposide alternating with a gemcitabine-based regimen) as the first-line treatment of PTCLs and compared with CHOP (cyclophosphamide, pirarubicin, vincristine, and prednisolone) and CHOPE (CHOP plus etoposide) regimen to evaluate the optimal chemotherapy regimen.', 'subject score': 1000, 'object score': 1000}, 'PMID:36990775': {'publication date': '2023', 'sentence': 'Benefit of prednisolone alone in nodal peripheral T-cell lymphoma with T follicular helper phenotype.', 'subject score': 1000, 'object score': 928}}",
-    "p2": {
-      "start": {
-        "identity": 535028,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0012105",
-          "name": "granulomatosis with polyangiitis",
-          "description": "A rare, autoimmune, systemic medium and small size vasculitis. It is characterized by the formation of necrotizing granulomas in the respiratory tract, necrotizing angiitis, and glomerulonephritis.; A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10072579",
-            "DOID:12132",
-            "ICD10:M31.3",
-            "MONDO:0012105",
-            "SNOMEDCT:195353004",
-            "UMLS:C3495801",
-            "OMIM:608710",
-            "UMLS:C4050407",
-            "MEDDRA:10047889",
-            "NCIT:C3444",
-            "EFO:0005297",
-            "MESH:D014890",
-            "MEDDRA:10047888",
-            "MEDDRA:10072580",
-            "ORPHANET:900",
-            "ICD9:446.4",
-            "NCIT:C123111"
-          ],
-          "id": "MONDO:0012105",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pauci-immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-            "Granulomatosis with Polyangiitis",
-            "granulomatosis with polyangiitis",
-            "Pauci-Immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-            "Granulomatosis with polyangiitis related phenotypic feature",
-            "Granulomatosis with polyangiitis",
-            "Wegener's granulomatosis"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000430",
-          "name": "mature T-cell and NK-cell non-Hodgkin lymphoma",
-          "description": "A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10034624",
-            "MONDO:0000430",
-            "MEDDRA:10034623",
-            "UMLS:C1337073",
-            "MESH:D016411",
-            "UMLS:C1337074",
-            "NCIT:C27352",
-            "UMLS:C0079774",
-            "UMLS:C5551485",
-            "UMLS:C1337079",
-            "DOID:0050743",
-            "NCIT:C7204",
-            "UMLS:C0334655",
-            "NCIT:C3468",
-            "DOID:0050749",
-            "SNOMEDCT:109977009",
-            "ICD9:202.7",
-            "SNOMEDCT:1163404000",
-            "SNOMEDCT:109975001"
-          ],
-          "id": "MONDO:0000430",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peripheral T-Cell Lymphoma, Large Cell",
-            "T-Zone Variant Peripheral T-Cell Lymphoma",
-            "mature T-cell and NK-cell non-Hodgkin lymphoma",
-            "peripheral T-cell lymphoma",
-            "T-zone lymphoma (clinical)",
-            "Lymphoma, T-Cell, Peripheral",
-            "mature T-cell and NK-cell lymphoma",
-            "Peripheral T-Cell Lymphoma",
-            "Peripheral T-cell lymphoma",
-            "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://en.wikipedia.org/wiki/granulomatosis_with_polyangiitis"
-=======
-            "PMID:21919697",
-            "http://www.cancer.gov/dictionary?cdrid=393800",
-            "http://www.cancer.gov/dictionary?cdrid=44062",
-            "http://en.wikipedia.org/wiki/peripheral_t-cell_lymphoma"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 531220,
-=======
-            "identity": 535028,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0012105",
-              "name": "granulomatosis with polyangiitis",
-              "description": "A rare, autoimmune, systemic medium and small size vasculitis. It is characterized by the formation of necrotizing granulomas in the respiratory tract, necrotizing angiitis, and glomerulonephritis.; A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10072579",
-                "DOID:12132",
-                "ICD10:M31.3",
-                "MONDO:0012105",
-                "SNOMEDCT:195353004",
-                "UMLS:C3495801",
-                "OMIM:608710",
-                "UMLS:C4050407",
-                "MEDDRA:10047889",
-                "NCIT:C3444",
-                "EFO:0005297",
-                "MESH:D014890",
-                "MEDDRA:10047888",
-                "MEDDRA:10072580",
-                "ORPHANET:900",
-                "ICD9:446.4",
-                "NCIT:C123111"
-              ],
-              "id": "MONDO:0012105",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pauci-immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-                "Granulomatosis with Polyangiitis",
-                "granulomatosis with polyangiitis",
-                "Pauci-Immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-                "Granulomatosis with polyangiitis related phenotypic feature",
-                "Granulomatosis with polyangiitis",
-                "Wegener's granulomatosis"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000430",
-              "name": "mature T-cell and NK-cell non-Hodgkin lymphoma",
-              "description": "A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10034624",
-                "MONDO:0000430",
-                "MEDDRA:10034623",
-                "UMLS:C1337073",
-                "MESH:D016411",
-                "UMLS:C1337074",
-                "NCIT:C27352",
-                "UMLS:C0079774",
-                "UMLS:C5551485",
-                "UMLS:C1337079",
-                "DOID:0050743",
-                "NCIT:C7204",
-                "UMLS:C0334655",
-                "NCIT:C3468",
-                "DOID:0050749",
-                "SNOMEDCT:109977009",
-                "ICD9:202.7",
-                "SNOMEDCT:1163404000",
-                "SNOMEDCT:109975001"
-              ],
-              "id": "MONDO:0000430",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peripheral T-Cell Lymphoma, Large Cell",
-                "T-Zone Variant Peripheral T-Cell Lymphoma",
-                "mature T-cell and NK-cell non-Hodgkin lymphoma",
-                "peripheral T-cell lymphoma",
-                "T-zone lymphoma (clinical)",
-                "Lymphoma, T-Cell, Peripheral",
-                "mature T-cell and NK-cell lymphoma",
-                "Peripheral T-Cell Lymphoma",
-                "Peripheral T-cell lymphoma",
-                "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://en.wikipedia.org/wiki/granulomatosis_with_polyangiitis"
-=======
-                "PMID:21919697",
-                "http://www.cancer.gov/dictionary?cdrid=393800",
-                "http://www.cancer.gov/dictionary?cdrid=44062",
-                "http://en.wikipedia.org/wiki/peripheral_t-cell_lymphoma"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 7776002,
-            "start": 568,
-            "end": 531220,
-=======
-            "identity": 16510643,
-            "start": 568,
-            "end": 535028,
->>>>>>> main
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-<<<<<<< HEAD
-              "publications_info": "{'PMID:1064290': {'publication date': '1976', 'sentence': \"Two patients with Wegener's granulomatosis have been treated with chlorambucil and prednisolone continuosly for 3 and 5 years, respectively.\", 'subject score': 694, 'object score': 1000}, 'PMID:17642224': {'publication date': '2007 Jul', 'sentence': \"Finally we performed open lung biopsy of left lung, and Wegener's granulomatosis was diagnosed at last He improved immediately after treatment with prednisolone, cyclophosphamide and sulfamethoxazole-trimethoprim.\", 'subject score': 1000, 'object score': 1000}, 'PMID:1767121': {'publication date': '1991', 'sentence': \"Five cases of Wegener's granulomatosis treated with cyclophosphamide (CPM) and prednisolone are reported.\", 'subject score': 1000, 'object score': 1000}, 'PMID:20156769': {'publication date': '2009 Dec 07', 'sentence': \"GOAL AND METHODS: Prospective, randomized, placebo-controlled study of the efficacy of co-trimoxazole given 960 mg thrice weekly for 18 months in preventing relapses in patients with Wegener's granulomatosis (WG) in remission, after treatment with cyclophosphamide and prednisolone was conducted.\", 'subject score': 1000, 'object score': 1000}, 'PMID:20577017': {'publication date': '2011 Jan', 'sentence': 'METHODS: In a single-centre study from a tertiary referral centre, 32 patients with ANCA-positive WG were treated with standard immunosuppressive therapy, prednisolone and cyclophosphamide (CYC).', 'subject score': 1000, 'object score': 888}, 'PMID:5032438': {'publication date': '1972 Jan-Feb', 'sentence': \"Combined chlorambucil and prednisolone treatment of five patients with Wegener's granulomatosis.\", 'subject score': 888, 'object score': 1000}, 'PMID:7925917': {'publication date': '1994 Jul', 'sentence': 'Eight years previously, a first episode of WG involving the upper airways and kidneys, but not the lungs, had been successfully treated with prednisolone and cyclophosphamide, which could be stopped after 2 yrs.', 'subject score': 1000, 'object score': 1000}, 'PMID:7962978': {'publication date': '1994 Sep', 'sentence': \"Wegener's granulomatosis successfully treated with prednisolone and potassium iodide.\", 'subject score': 1000, 'object score': 1000}, 'PMID:8637536': {'publication date': '1996 Jul 04', 'sentence': \"METHODS: We conducted a prospective, randomized, placebo-controlled study of the efficacy of co-trimoxazole (800 mg of sulfamethoxazole and 160 mg of trimethoprim) given twice daily for 24 months in preventing relapses in patients with Wegener's granulomatosis in remission during or after treatment with cyclophosphamide and prednisolone.\", 'subject score': 1000, 'object score': 1000}, 'PMID:9566676': {'publication date': '1998 Mar', 'sentence': \"We describe a 22-yr-old woman who recovered successfully from her initial episode of Wegener's granulomatosis with a standard course of treatment with prednisolone and cyclophosphamide.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C3495801---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7941298",
-              "object": "MONDO:0012105",
-              "publications": [
-                "PMID:1064290",
-                "PMID:17642224",
-                "PMID:1767121",
-                "PMID:20156769",
-                "PMID:20577017",
-                "PMID:5032438",
-                "PMID:7925917",
-                "PMID:7962978",
-                "PMID:8637536",
-                "PMID:9566676"
-=======
-              "publications_info": "{'PMID:23550277': {'publication date': '2013 Jun', 'sentence': 'Treatment of peripheral T cell lymphoma with an intensive protocol ACEP (adriamycin, cyclophosphamide, etoposide and prednisolone) and ifosfamide showing an important response and overall survival rates.', 'subject score': 1000, 'object score': 1000}, 'PMID:30511217': {'publication date': '2018 Dec 03', 'sentence': 'We designed a CHOPE/G regimen (cyclophosphamide, pirarubicin, vincristine, prednisolone, and etoposide alternating with a gemcitabine-based regimen) as the first-line treatment of PTCLs and compared with CHOP (cyclophosphamide, pirarubicin, vincristine, and prednisolone) and CHOPE (CHOP plus etoposide) regimen to evaluate the optimal chemotherapy regimen.', 'subject score': 1000, 'object score': 1000}, 'PMID:36990775': {'publication date': '2023', 'sentence': 'Benefit of prednisolone alone in nodal peripheral T-cell lymphoma with T follicular helper phenotype.', 'subject score': 1000, 'object score': 928}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0079774---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16852549",
-              "object": "MONDO:0000430",
-              "publications": [
-                "PMID:23550277",
-                "PMID:30511217",
-                "PMID:36990775"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 319059,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:23763798': {'publication date': '2013 Jun', 'sentence': 'CONCLUSION: GVP is well-tolerated regimen with high response rate and needs to be tested in late relapsed HL.', 'subject score': 1000, 'object score': 852}, 'PMID:3383124': {'publication date': '1988 Jul 15', 'sentence': \"Nitrogen mustard, vincristine, procarbazine, and prednisolone for relapse after radiation in Hodgkin's disease.\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318155,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005377",
-          "name": "nephrotic syndrome",
-          "description": "Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. [HPO:probinson]; Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. // COMMENTS: In adults, nephrotic syndrome is characterized by protein excretion of 3.5 g or more per day. In children, nephrotic syndrome is accompanied by protein excretion of more than 40 mg/m2/h and hypalbuminemia < 2.5 mg/dl.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10042826",
-            "MESH:D009404",
-            "HP:0000100",
-            "UMLS:C0027726",
-            "MONDO:0005377",
-            "EFO:0004255",
-            "MEDDRA:10029164",
-            "SNOMEDCT:52254009",
-            "NCIT:C34845",
-            "DOID:1184",
-            "ICD9:581"
-          ],
-          "id": "MONDO:0005377",
-          "category": "biolink:Disease",
-          "all_names": [
-            "nephrotic syndrome",
-            "Nephrotic Syndrome",
-            "Nephrotic syndrome"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004952",
-          "name": "Hodgkins lymphoma",
-          "description": "A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma has a bimodal age distribution, and involves primarily lymph nodes. Current therapy for Hodgkin lymphoma has resulted in an excellent outcome and cure for the majority of patients. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C9357\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C9357\" NCI Thesaurus); UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10020309",
-            "SNOMEDCT:1163005009",
-            "ORPHANET:98293",
-            "UMLS:C5235037",
-            "NCIT:C6914",
-            "MEDDRA:10020255",
-            "SNOMEDCT:118606001",
-            "MEDDRA:10063666",
-            "SNOMEDCT:46923007",
-            "ICD10:C81",
-            "UMLS:C0019829",
-            "ICD9:201.2",
-            "SNOMEDCT:836277009",
-            "SNOMEDCT:74189002",
-            "MEDDRA:10020206",
-            "MESH:D006689",
-            "MEDDRA:10020328",
-            "MEDDRA:10020329",
-            "HP:0012189",
-            "SNOMEDCT:118599009",
-            "NCIT:C9357",
-            "ICD9:201",
-            "NCIT:C26956",
-            "SNOMEDCT:118605002",
-            "SNOMEDCT:118602004",
-            "NCIT:C164145",
-            "PDQ:CDR0000041646",
-            "MEDDRA:10025319",
-            "MEDDRA:10020318",
-            "EFO:0000183",
-            "DOID:8567",
-            "SNOMEDCT:14537002",
-            "MONDO:0004952",
-            "SNOMEDCT:836276000",
-            "MEDDRA:10020339",
-            "SNOMEDCT:70600005"
-          ],
-          "id": "MONDO:0004952",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hodgkin Lymphoma",
-            "Hodgkin lymphoma",
-            "Hodgkin's Paragranuloma",
-            "Hodgkin's sarcoma",
-            "Hodgkin sarcoma",
-            "Hodgkin's lymphoma",
-            "Hodgkins lymphoma",
-            "Hodgkin's Granuloma",
-            "Hodgkin's Sarcoma",
-            "Hodgkin Disease",
-            "Hodgkin's disease"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://en.wikipedia.org/wiki/nephrotic_syndrome"
-=======
-            "https://en.wikipedia.org/wiki/hodgkin%27s_lymphoma",
-            "PMID:22835602",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318155,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004952",
-              "name": "Hodgkins lymphoma",
-              "description": "A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma has a bimodal age distribution, and involves primarily lymph nodes. Current therapy for Hodgkin lymphoma has resulted in an excellent outcome and cure for the majority of patients. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C9357\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C9357\" NCI Thesaurus); UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10020309",
-                "SNOMEDCT:1163005009",
-                "ORPHANET:98293",
-                "UMLS:C5235037",
-                "NCIT:C6914",
-                "MEDDRA:10020255",
-                "SNOMEDCT:118606001",
-                "MEDDRA:10063666",
-                "SNOMEDCT:46923007",
-                "ICD10:C81",
-                "UMLS:C0019829",
-                "ICD9:201.2",
-                "SNOMEDCT:836277009",
-                "SNOMEDCT:74189002",
-                "MEDDRA:10020206",
-                "MESH:D006689",
-                "MEDDRA:10020328",
-                "MEDDRA:10020329",
-                "HP:0012189",
-                "SNOMEDCT:118599009",
-                "NCIT:C9357",
-                "ICD9:201",
-                "NCIT:C26956",
-                "SNOMEDCT:118605002",
-                "SNOMEDCT:118602004",
-                "NCIT:C164145",
-                "PDQ:CDR0000041646",
-                "MEDDRA:10025319",
-                "MEDDRA:10020318",
-                "EFO:0000183",
-                "DOID:8567",
-                "SNOMEDCT:14537002",
-                "MONDO:0004952",
-                "SNOMEDCT:836276000",
-                "MEDDRA:10020339",
-                "SNOMEDCT:70600005"
-              ],
-              "id": "MONDO:0004952",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hodgkin Lymphoma",
-                "Hodgkin lymphoma",
-                "Hodgkin's Paragranuloma",
-                "Hodgkin's sarcoma",
-                "Hodgkin sarcoma",
-                "Hodgkin's lymphoma",
-                "Hodgkins lymphoma",
-                "Hodgkin's Granuloma",
-                "Hodgkin's Sarcoma",
-                "Hodgkin Disease",
-                "Hodgkin's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/hodgkin%27s_lymphoma",
-                "PMID:22835602",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16640274,
-            "start": 568,
-            "end": 318155,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23763798': {'publication date': '2013 Jun', 'sentence': 'CONCLUSION: GVP is well-tolerated regimen with high response rate and needs to be tested in late relapsed HL.', 'subject score': 1000, 'object score': 852}, 'PMID:3383124': {'publication date': '1988 Jul 15', 'sentence': \"Nitrogen mustard, vincristine, procarbazine, and prednisolone for relapse after radiation in Hodgkin's disease.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0019829---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16983852",
-              "object": "MONDO:0004952",
-              "publications": [
-                "PMID:23763798",
-                "PMID:3383124"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12574967': {'publication date': '2003 Jan', 'sentence': \"Under the diagnosis of Hodgkin's disease, she was treated with combination chemotherapy containing pirarubicin, cyclophosphamide, vincristine, and prednisolone.\", 'subject score': 1000, 'object score': 1000}, 'PMID:1748400': {'publication date': '1991', 'sentence': \"Fourteen patients with Hodgkin's disease (two previously untreated, 12 following relapse or with refractory disease) were treated with a combination chemotherapy regimen comprising chlorambucil, vinblastine, procarbazine, prednisolone, etoposide, vincristine and adriamycin administered on days 1-8.\", 'subject score': 1000, 'object score': 1000}, 'PMID:1832882': {'publication date': '1991', 'sentence': \"Between January 1972 and October 1985, 60 patients with advanced Hodgkin's disease were treated with mechlorethamine/vinblastine/procarbazine/prednisolone (MVPP).\", 'subject score': 833, 'object score': 901}, 'PMID:2115396': {'publication date': '1990 May 01', 'sentence': \"It is concluded that six or more cycles of COPP chemotherapy for advanced Hodgkin's disease in men leads to permanent sterility.\", 'subject score': 888, 'object score': 901}, 'PMID:2193118': {'publication date': '1990 Jul', 'sentence': 'These results strongly suggest that extended high-dose irradiation and MOPP chemotherapy should not be combined for the treatment of HD.', 'subject score': 888, 'object score': 1000}, 'PMID:2207371': {'publication date': '1990', 'sentence': \"This study deals with the effectiveness of nitrosourea derivatives (nitrosomethylurea and CCNU) used as single agents or in combination with vinca alkaloids, procarbazine and prednisolone in 23 patients suffering from Hodgkin's disease with spinal cord or intracranial involvement.\", 'subject score': 1000, 'object score': 1000}, 'PMID:2386744': {'publication date': '1990 Aug', 'sentence': \"Two hundred and eighty-four patients with advanced Hodgkin's disease (HD) (stage II with poor prognostic features and stage III/IV) have been treated with the ChlVPP combination chemotherapy regimen (chlorambucil, vinblastine, procarbazine and prednisolone) in a single-centre unselected series.\", 'subject score': 1000, 'object score': 901}, 'PMID:2703008': {'publication date': '1989 Mar', 'sentence': \"ChlVPP is effective first-line treatment for Hodgkin's disease with results which may be comparable to those achieved for MOPP but with significantly less toxicity.\", 'subject score': 713, 'object score': 1000}, 'PMID:2769976': {'publication date': '1989 Apr', 'sentence': \"She was treated by the combination chemotherapy consisting of mitoxantrone, cyclophosphamide, vincristine and prednisolone for Hodgkin's disease in November 1986.\", 'subject score': 1000, 'object score': 1000}, 'PMID:3381494': {'publication date': '1988', 'sentence': \"The study deals with the effectiveness of nitrosourea derivatives (nitrosomethylurea and CCNU) used for monochemotherapy or polychemotherapy in combination with vinca alkaloids, natulan and prednisolone in 22 patients suffering Hodgkin's disease with spinal cord and intracranial involvement.\", 'subject score': 1000, 'object score': 1000}, 'PMID:435366': {'publication date': '1979 Feb', 'sentence': \"Three years' experience with Ch1VPP (a combination of drugs of low toxicity) for the treatment of Hodgkin's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:911666': {'publication date': '1977 Aug', 'sentence': \"A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease.\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318155,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004952",
-          "name": "Hodgkins lymphoma",
-          "description": "A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma has a bimodal age distribution, and involves primarily lymph nodes. Current therapy for Hodgkin lymphoma has resulted in an excellent outcome and cure for the majority of patients. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C9357\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C9357\" NCI Thesaurus); UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10020309",
-            "SNOMEDCT:1163005009",
-            "ORPHANET:98293",
-            "UMLS:C5235037",
-            "NCIT:C6914",
-            "MEDDRA:10020255",
-            "SNOMEDCT:118606001",
-            "MEDDRA:10063666",
-            "SNOMEDCT:46923007",
-            "ICD10:C81",
-            "UMLS:C0019829",
-            "ICD9:201.2",
-            "SNOMEDCT:836277009",
-            "SNOMEDCT:74189002",
-            "MEDDRA:10020206",
-            "MESH:D006689",
-            "MEDDRA:10020328",
-            "MEDDRA:10020329",
-            "HP:0012189",
-            "SNOMEDCT:118599009",
-            "NCIT:C9357",
-            "ICD9:201",
-            "NCIT:C26956",
-            "SNOMEDCT:118605002",
-            "SNOMEDCT:118602004",
-            "NCIT:C164145",
-            "PDQ:CDR0000041646",
-            "MEDDRA:10025319",
-            "MEDDRA:10020318",
-            "EFO:0000183",
-            "DOID:8567",
-            "SNOMEDCT:14537002",
-            "MONDO:0004952",
-            "SNOMEDCT:836276000",
-            "MEDDRA:10020339",
-            "SNOMEDCT:70600005"
-          ],
-          "id": "MONDO:0004952",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hodgkin Lymphoma",
-            "Hodgkin lymphoma",
-            "Hodgkin's Paragranuloma",
-            "Hodgkin's sarcoma",
-            "Hodgkin sarcoma",
-            "Hodgkin's lymphoma",
-            "Hodgkins lymphoma",
-            "Hodgkin's Granuloma",
-            "Hodgkin's Sarcoma",
-            "Hodgkin Disease",
-            "Hodgkin's disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/hodgkin%27s_lymphoma",
-            "PMID:22835602",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318155,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004952",
-              "name": "Hodgkins lymphoma",
-              "description": "A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma has a bimodal age distribution, and involves primarily lymph nodes. Current therapy for Hodgkin lymphoma has resulted in an excellent outcome and cure for the majority of patients. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C9357\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C9357\" NCI Thesaurus); UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10020309",
-                "SNOMEDCT:1163005009",
-                "ORPHANET:98293",
-                "UMLS:C5235037",
-                "NCIT:C6914",
-                "MEDDRA:10020255",
-                "SNOMEDCT:118606001",
-                "MEDDRA:10063666",
-                "SNOMEDCT:46923007",
-                "ICD10:C81",
-                "UMLS:C0019829",
-                "ICD9:201.2",
-                "SNOMEDCT:836277009",
-                "SNOMEDCT:74189002",
-                "MEDDRA:10020206",
-                "MESH:D006689",
-                "MEDDRA:10020328",
-                "MEDDRA:10020329",
-                "HP:0012189",
-                "SNOMEDCT:118599009",
-                "NCIT:C9357",
-                "ICD9:201",
-                "NCIT:C26956",
-                "SNOMEDCT:118605002",
-                "SNOMEDCT:118602004",
-                "NCIT:C164145",
-                "PDQ:CDR0000041646",
-                "MEDDRA:10025319",
-                "MEDDRA:10020318",
-                "EFO:0000183",
-                "DOID:8567",
-                "SNOMEDCT:14537002",
-                "MONDO:0004952",
-                "SNOMEDCT:836276000",
-                "MEDDRA:10020339",
-                "SNOMEDCT:70600005"
-              ],
-              "id": "MONDO:0004952",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hodgkin Lymphoma",
-                "Hodgkin lymphoma",
-                "Hodgkin's Paragranuloma",
-                "Hodgkin's sarcoma",
-                "Hodgkin sarcoma",
-                "Hodgkin's lymphoma",
-                "Hodgkins lymphoma",
-                "Hodgkin's Granuloma",
-                "Hodgkin's Sarcoma",
-                "Hodgkin Disease",
-                "Hodgkin's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/hodgkin%27s_lymphoma",
-                "PMID:22835602",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9803579,
-            "start": 568,
-            "end": 318155,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12574967': {'publication date': '2003 Jan', 'sentence': \"Under the diagnosis of Hodgkin's disease, she was treated with combination chemotherapy containing pirarubicin, cyclophosphamide, vincristine, and prednisolone.\", 'subject score': 1000, 'object score': 1000}, 'PMID:1748400': {'publication date': '1991', 'sentence': \"Fourteen patients with Hodgkin's disease (two previously untreated, 12 following relapse or with refractory disease) were treated with a combination chemotherapy regimen comprising chlorambucil, vinblastine, procarbazine, prednisolone, etoposide, vincristine and adriamycin administered on days 1-8.\", 'subject score': 1000, 'object score': 1000}, 'PMID:1832882': {'publication date': '1991', 'sentence': \"Between January 1972 and October 1985, 60 patients with advanced Hodgkin's disease were treated with mechlorethamine/vinblastine/procarbazine/prednisolone (MVPP).\", 'subject score': 833, 'object score': 901}, 'PMID:2115396': {'publication date': '1990 May 01', 'sentence': \"It is concluded that six or more cycles of COPP chemotherapy for advanced Hodgkin's disease in men leads to permanent sterility.\", 'subject score': 888, 'object score': 901}, 'PMID:2193118': {'publication date': '1990 Jul', 'sentence': 'These results strongly suggest that extended high-dose irradiation and MOPP chemotherapy should not be combined for the treatment of HD.', 'subject score': 888, 'object score': 1000}, 'PMID:2207371': {'publication date': '1990', 'sentence': \"This study deals with the effectiveness of nitrosourea derivatives (nitrosomethylurea and CCNU) used as single agents or in combination with vinca alkaloids, procarbazine and prednisolone in 23 patients suffering from Hodgkin's disease with spinal cord or intracranial involvement.\", 'subject score': 1000, 'object score': 1000}, 'PMID:2386744': {'publication date': '1990 Aug', 'sentence': \"Two hundred and eighty-four patients with advanced Hodgkin's disease (HD) (stage II with poor prognostic features and stage III/IV) have been treated with the ChlVPP combination chemotherapy regimen (chlorambucil, vinblastine, procarbazine and prednisolone) in a single-centre unselected series.\", 'subject score': 1000, 'object score': 901}, 'PMID:2703008': {'publication date': '1989 Mar', 'sentence': \"ChlVPP is effective first-line treatment for Hodgkin's disease with results which may be comparable to those achieved for MOPP but with significantly less toxicity.\", 'subject score': 713, 'object score': 1000}, 'PMID:2769976': {'publication date': '1989 Apr', 'sentence': \"She was treated by the combination chemotherapy consisting of mitoxantrone, cyclophosphamide, vincristine and prednisolone for Hodgkin's disease in November 1986.\", 'subject score': 1000, 'object score': 1000}, 'PMID:3381494': {'publication date': '1988', 'sentence': \"The study deals with the effectiveness of nitrosourea derivatives (nitrosomethylurea and CCNU) used for monochemotherapy or polychemotherapy in combination with vinca alkaloids, natulan and prednisolone in 22 patients suffering Hodgkin's disease with spinal cord and intracranial involvement.\", 'subject score': 1000, 'object score': 1000}, 'PMID:435366': {'publication date': '1979 Feb', 'sentence': \"Three years' experience with Ch1VPP (a combination of drugs of low toxicity) for the treatment of Hodgkin's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:911666': {'publication date': '1977 Aug', 'sentence': \"A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0019829---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10020250",
-              "object": "MONDO:0004952",
-              "publications": [
-                "PMID:12574967",
-                "PMID:1748400",
-                "PMID:1832882",
-                "PMID:2115396",
-                "PMID:2193118",
-                "PMID:2207371",
-                "PMID:2386744",
-                "PMID:2703008",
-                "PMID:2769976",
-                "PMID:3381494",
-                "PMID:435366",
-                "PMID:911666"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:1411124': {'publication date': '1992', 'sentence': 'Male rats treated with either budesonide, prednisolone, or triamcinolone acetonide in drinking water for up to 104 weeks developed slightly increased incidences of basophilic foci, and significantly increased incidences of combined hepatocellular adenomas/carcinomas as compared to controls.', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 319068,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007256",
-          "name": "hepatocellular carcinoma",
-          "description": "A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.; A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.; A kind of neoplasm of the liver that originates in hepatocytes and presents macroscopically as a soft and hemorrhagic tan mass in the liver. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "HP:0001402",
-            "ICD10:C22.0",
-            "ORPHANET:88673",
-            "MEDDRA:10073071",
-            "DOID:686",
-            "MESH:C567299",
-            "MEDDRA:10024658",
-            "SNOMEDCT:109841003",
-            "UMLS:C2676033",
-            "OMIM:114550",
-            "MESH:D006528",
-            "SNOMEDCT:187769009",
-            "UMLS:C1867955",
-            "SNOMEDCT:25370001",
-            "UMLS:C1862761",
-            "DOID:684",
-            "MEDDRA:10048491",
-            "SNOMEDCT:1186630006",
-            "MONDO:0007256",
-            "MEDDRA:10019838",
-            "MEDDRA:10049010",
-            "EFO:0000182",
-            "NCIT:C3099",
-            "MEDDRA:10007416",
-            "UMLS:C2239176"
-          ],
-          "id": "MONDO:0007256",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hepatocellular carcinoma",
-            "Hepatocellular Carcinoma",
-            "Increased hepatocellular carcinoma risk",
-            "Hepatocellular carcinoma related phenotypic feature",
-            "Hepatocellular carcinoma",
-            "Liver carcinoma",
-            "Carcinoma, Hepatocellular",
-            "Increased incidence of hepatocellular carcinoma",
-            "liver carcinoma",
-            "Hepatoblastoma Caused By Somatic Mutation"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/liver_cance",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/hepatocellular_carcinoma",
-            "http://en.wikipedia.org/wiki/carcinoma",
-            "http://www.omim.org/entry/114550",
-            "http://cancergenome.nih.gov/cancersselected/liverhepatocellularcarcinoma"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 319059,
-=======
-            "identity": 319068,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005377",
-              "name": "nephrotic syndrome",
-              "description": "Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. [HPO:probinson]; Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. // COMMENTS: In adults, nephrotic syndrome is characterized by protein excretion of 3.5 g or more per day. In children, nephrotic syndrome is accompanied by protein excretion of more than 40 mg/m2/h and hypalbuminemia < 2.5 mg/dl.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10042826",
-                "MESH:D009404",
-                "HP:0000100",
-                "UMLS:C0027726",
-                "MONDO:0005377",
-                "EFO:0004255",
-                "MEDDRA:10029164",
-                "SNOMEDCT:52254009",
-                "NCIT:C34845",
-                "DOID:1184",
-                "ICD9:581"
-              ],
-              "id": "MONDO:0005377",
-              "category": "biolink:Disease",
-              "all_names": [
-                "nephrotic syndrome",
-                "Nephrotic Syndrome",
-                "Nephrotic syndrome"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007256",
-              "name": "hepatocellular carcinoma",
-              "description": "A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.; A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.; A kind of neoplasm of the liver that originates in hepatocytes and presents macroscopically as a soft and hemorrhagic tan mass in the liver. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "HP:0001402",
-                "ICD10:C22.0",
-                "ORPHANET:88673",
-                "MEDDRA:10073071",
-                "DOID:686",
-                "MESH:C567299",
-                "MEDDRA:10024658",
-                "SNOMEDCT:109841003",
-                "UMLS:C2676033",
-                "OMIM:114550",
-                "MESH:D006528",
-                "SNOMEDCT:187769009",
-                "UMLS:C1867955",
-                "SNOMEDCT:25370001",
-                "UMLS:C1862761",
-                "DOID:684",
-                "MEDDRA:10048491",
-                "SNOMEDCT:1186630006",
-                "MONDO:0007256",
-                "MEDDRA:10019838",
-                "MEDDRA:10049010",
-                "EFO:0000182",
-                "NCIT:C3099",
-                "MEDDRA:10007416",
-                "UMLS:C2239176"
-              ],
-              "id": "MONDO:0007256",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hepatocellular carcinoma",
-                "Hepatocellular Carcinoma",
-                "Increased hepatocellular carcinoma risk",
-                "Hepatocellular carcinoma related phenotypic feature",
-                "Hepatocellular carcinoma",
-                "Liver carcinoma",
-                "Carcinoma, Hepatocellular",
-                "Increased incidence of hepatocellular carcinoma",
-                "liver carcinoma",
-                "Hepatoblastoma Caused By Somatic Mutation"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://en.wikipedia.org/wiki/nephrotic_syndrome"
-=======
-                "http://en.wikipedia.org/wiki/liver_cance",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/hepatocellular_carcinoma",
-                "http://en.wikipedia.org/wiki/carcinoma",
-                "http://www.omim.org/entry/114550",
-                "http://cancergenome.nih.gov/cancersselected/liverhepatocellularcarcinoma"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 7762935,
-            "start": 568,
-            "end": 319059,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10634026': {'publication date': '1999 Dec', 'sentence': 'The second patient, a 73-year-old man receiving prednisolone therapy for nephrotic syndrome, developed right leg cellulitis that evolved to NF.', 'subject score': 763, 'object score': 1000}, 'PMID:10972687': {'publication date': '2000 Sep', 'sentence': 'There has been no study on prednisolone dosage for the effective treatment of nephrotic syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:11503553': {'publication date': '2001 Jul', 'sentence': 'The second patient had his relapses of nephrotic syndrome over a period of 10 years when treated with prednisolone and cyclophosphamide.', 'subject score': 1000, 'object score': 1000}, 'PMID:11510096': {'publication date': '2001 May', 'sentence': 'A 70-year-old man treated for 6 months with prednisolone for nephrotic syndrome, was referred to our pulmonary division because of a nodule in the right lower lung field.', 'subject score': 1000, 'object score': 1000}, 'PMID:11867955': {'publication date': '2002 Mar', 'sentence': 'After 5 courses of therapy with melphalan and prednisolone which failed to improve the nephrotic syndrome or her general clinical condition, and 1 year after the diagnosis of renal amyloidosis, surgical excision of the abdominal mass was performed.', 'subject score': 1000, 'object score': 1000}, 'PMID:12428401': {'publication date': '2002 Aug', 'sentence': 'The patient was a 56-year-old man who had received diagnoses of psoriasis vulgaris at the age of thirty-three and of nephrotic syndrome at forty-five, and had been treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:14700154': {'publication date': '2003 Aug', 'sentence': 'Resection of the ileum and appendectomy were performed while the relapsing nephrotic syndrome was treated by prednisolone.', 'subject score': 1000, 'object score': 901}, 'PMID:14964453': {'publication date': '2004 Jan', 'sentence': 'PATIENTS AND METHODS: Sixteen patients, with nephrotic syndrome due to IMN and well-preserved renal function, were treated with prednisolone (starting dose: 0.5 mg/kg bw/day) and CsA (starting dose: 3 mg/kg bw/day) for 24 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:14964576': {'publication date': '2004 Jan', 'sentence': 'We examined outcomes of a short course of cyclophosphamide alternating with prednisolone for MN patients with nephrotic syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:1600282': {'publication date': '1992 Feb', 'sentence': 'NS responded to prednisolone therapy initially and at the time of the relapse.', 'subject score': 851, 'object score': 1000}, 'PMID:16848751': {'publication date': '2006 Jul', 'sentence': 'Small doses of CsA with prednisolone are effective in the treatment of nephrotic syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:17009081': {'publication date': '2006 Sep', 'sentence': 'The nephrotic syndrome was treated successfully with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:17284479': {'publication date': '2007 Jul', 'sentence': 'OBJECTIVE: Children with nephrotic syndrome (NS) are usually treated with long-term low dose alternate day prednisolone with or without glucocorticoid sparing therapy, such as levamisole or ciclosporin, to maintain remission.', 'subject score': 830, 'object score': 1000}, 'PMID:17995584': {'publication date': '2007 Dec', 'sentence': 'CONCLUSION: Data from this pilot study indicate that more than 60% of patients with MN and nephrotic syndrome respond to combined MMF and prednisolone treatment, and suggest potential benefits of MMF as being steroid-sparing and having less adverse effects compared with other commonly used cytotoxic agents.', 'subject score': 888, 'object score': 1000}, 'PMID:18186228': {'publication date': '2007', 'sentence': 'Administration of prednisolone or cyclosporine improved the nephrotic syndrome, leading all patients to a complete or almost complete remission.', 'subject score': 1000, 'object score': 1000}, 'PMID:18367765': {'publication date': '2008 Mar', 'sentence': 'It is proposed that patients with frequently relapsing nephrotic syndrome should, at the first instance, be treated with long-term, alternate-day prednisolone.', 'subject score': 849, 'object score': 1000}, 'PMID:18387858': {'publication date': '2008 Jul 15', 'sentence': 'The unbound concentrations of prednisolone were measured in 10 patients with nephrotic syndrome, two patients with systemic lupus erythematosus, and one patient with dermatomyositis by examining protein bindings of prednisolone on one or more occasions during prednisolone treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:19212916': {'publication date': '2009', 'sentence': \"She was completely recovered from nephrotic syndrome after two years' treatment with prednisolone, aspirin, and dimethyl sulfoxide.\", 'subject score': 1000, 'object score': 1000}, 'PMID:21426894': {'publication date': '2011 Apr', 'sentence': 'Cyclosporin A in combination with prednisolone was given in 3 patients with HSP nephritis and nephrotic syndrome after a course of other immunosuppressive drugs and in 2 patients as initial treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:21454171': {'publication date': '2011 Apr', 'sentence': 'It is concluded that rational use of steroid (prednisolone) has a very effective role in the prevention and control of nephrotic syndrome either at initial stage or in complicated cases.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0027726---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7927983",
-              "object": "MONDO:0005377",
-              "publications": [
-                "PMID:10634026",
-                "PMID:10972687",
-                "PMID:11503553",
-                "PMID:11510096",
-                "PMID:11867955",
-                "PMID:12428401",
-                "PMID:14700154",
-                "PMID:14964453",
-                "PMID:14964576",
-                "PMID:1600282",
-                "PMID:16848751",
-                "PMID:17009081",
-                "PMID:17284479",
-                "PMID:17995584",
-                "PMID:18186228",
-                "PMID:18367765",
-                "PMID:18387858",
-                "PMID:19212916",
-                "PMID:21426894",
-                "PMID:21454171"
-=======
-            "identity": 10458056,
-            "start": 568,
-            "end": 319068,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1411124': {'publication date': '1992', 'sentence': 'Male rats treated with either budesonide, prednisolone, or triamcinolone acetonide in drinking water for up to 104 weeks developed slightly increased incidences of basophilic foci, and significantly increased incidences of combined hepatocellular adenomas/carcinomas as compared to controls.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C2239176---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10687782",
-              "object": "MONDO:0007256",
-              "publications": [
-                "PMID:1411124"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 531206,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1333900': {'publication date': '1992', 'sentence': 'One had received four weekly cycles of prednisolone, Adriamycin, vincristine and 5-fluorouracil for an inoperable HCC with a 10-cm diameter, and the other had received localised synchronised hepatic irradiation and Adriamycin.', 'subject score': 1000, 'object score': 901}, 'PMID:23673446': {'publication date': '2013 Jul', 'sentence': 'Here, we report a pharmacokinetic interaction between sorafenib and the CYP3A4 inducer prednisolone in a patient with hepatocellular carcinoma (HCC).', 'subject score': 802, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319068,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008538",
-          "name": "temporal arteritis",
-          "description": "An autoimmune, systemic, giant cell granulomatous arteritis predominantly involving the arteries that supply blood to the central nervous system, head and eyes. Superficial arteries of the scalp that are involved tend to be enlarged and tender. Signs and symptoms include headaches, myalgias, visual disturbances, and skin necrosis.; A systemic autoimmune disorder that typically affects medium and large ARTERIES, usually leading to occlusive granulomatous vasculitis with transmural infiltrate containing multinucleated GIANT CELLS. The TEMPORAL ARTERY is commonly involved. This disorder appears primarily in people over the age of 50. Symptoms include FEVER; FATIGUE; HEADACHE; visual impairment; pain in the jaw and tongue; and aggravation of pain by cold temperatures. (From Adams et al., Principles of Neurology, 6th ed); Giant cell arteritis is a disorder that causes inflammation of your arteries, usually in the scalp, neck, and arms. It narrows the arteries, which keeps blood from flowing well. Giant cell arteritis often occurs with another disorder called polymyalgia rheumatica. Both are more common in women than in men. They almost always affect people over the age of 50. Early symptoms of giant cell arteritis resemble the flu: fatigue, loss of appetite, and fever. Other symptoms include: Headaches Pain and tenderness over the temples Double vision or visual loss, dizziness Problems with coordination and balance Pain in your jaw and tongue  Your doctor will make the diagnosis based on your medical history, symptoms, and a physical exam. There is no specific test for giant cell arteritis, but you may have tests that measure inflammation. Treatment is usually with corticosteroids. Early treatment is important; otherwise there is a risk of permanent vision loss or stroke. However, when properly treated, giant cell arteritis rarely comes back. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10043207",
-            "MEDDRA:10011303",
-            "MEDDRA:10020396",
-            "MEDDRA:10020395",
-            "UMLS:C1956391",
-            "NCIT:C35065",
-            "DOID:13375",
-            "UMLS:C1956390",
-            "UMLS:C0039483",
-            "MESH:D013700",
-            "ORPHANET:397",
-            "EFO:1001209",
-            "SNOMEDCT:400130008",
-            "ICD9:446.5",
-            "MEDDRA:10018250",
-            "MONDO:0008538",
-            "OMIM:187360"
-          ],
-          "id": "MONDO:0008538",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cranial Arteritis",
-            "Giant cell arteritis",
-            "Giant Cell Arteritis",
-            "temporal arteritis",
-            "Temporal Arteritis",
-            "Temporal arteritis related phenotypic feature"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007256",
-          "name": "hepatocellular carcinoma",
-          "description": "A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.; A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.; A kind of neoplasm of the liver that originates in hepatocytes and presents macroscopically as a soft and hemorrhagic tan mass in the liver. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "HP:0001402",
-            "ICD10:C22.0",
-            "ORPHANET:88673",
-            "MEDDRA:10073071",
-            "DOID:686",
-            "MESH:C567299",
-            "MEDDRA:10024658",
-            "SNOMEDCT:109841003",
-            "UMLS:C2676033",
-            "OMIM:114550",
-            "MESH:D006528",
-            "SNOMEDCT:187769009",
-            "UMLS:C1867955",
-            "SNOMEDCT:25370001",
-            "UMLS:C1862761",
-            "DOID:684",
-            "MEDDRA:10048491",
-            "SNOMEDCT:1186630006",
-            "MONDO:0007256",
-            "MEDDRA:10019838",
-            "MEDDRA:10049010",
-            "EFO:0000182",
-            "NCIT:C3099",
-            "MEDDRA:10007416",
-            "UMLS:C2239176"
-          ],
-          "id": "MONDO:0007256",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hepatocellular carcinoma",
-            "Hepatocellular Carcinoma",
-            "Increased hepatocellular carcinoma risk",
-            "Hepatocellular carcinoma related phenotypic feature",
-            "Hepatocellular carcinoma",
-            "Liver carcinoma",
-            "Carcinoma, Hepatocellular",
-            "Increased incidence of hepatocellular carcinoma",
-            "liver carcinoma",
-            "Hepatoblastoma Caused By Somatic Mutation"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://www.mayoclinic.org/diseases-conditions/giant-cell-arteritis/symptoms-causes/syc-20372758",
-            "https://orcid.org/0000-0001-5208-3432"
-=======
-            "http://en.wikipedia.org/wiki/liver_cance",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/hepatocellular_carcinoma",
-            "http://en.wikipedia.org/wiki/carcinoma",
-            "http://www.omim.org/entry/114550",
-            "http://cancergenome.nih.gov/cancersselected/liverhepatocellularcarcinoma"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 531206,
-=======
-            "identity": 319068,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008538",
-              "name": "temporal arteritis",
-              "description": "An autoimmune, systemic, giant cell granulomatous arteritis predominantly involving the arteries that supply blood to the central nervous system, head and eyes. Superficial arteries of the scalp that are involved tend to be enlarged and tender. Signs and symptoms include headaches, myalgias, visual disturbances, and skin necrosis.; A systemic autoimmune disorder that typically affects medium and large ARTERIES, usually leading to occlusive granulomatous vasculitis with transmural infiltrate containing multinucleated GIANT CELLS. The TEMPORAL ARTERY is commonly involved. This disorder appears primarily in people over the age of 50. Symptoms include FEVER; FATIGUE; HEADACHE; visual impairment; pain in the jaw and tongue; and aggravation of pain by cold temperatures. (From Adams et al., Principles of Neurology, 6th ed); Giant cell arteritis is a disorder that causes inflammation of your arteries, usually in the scalp, neck, and arms. It narrows the arteries, which keeps blood from flowing well. Giant cell arteritis often occurs with another disorder called polymyalgia rheumatica. Both are more common in women than in men. They almost always affect people over the age of 50. Early symptoms of giant cell arteritis resemble the flu: fatigue, loss of appetite, and fever. Other symptoms include: Headaches Pain and tenderness over the temples Double vision or visual loss, dizziness Problems with coordination and balance Pain in your jaw and tongue  Your doctor will make the diagnosis based on your medical history, symptoms, and a physical exam. There is no specific test for giant cell arteritis, but you may have tests that measure inflammation. Treatment is usually with corticosteroids. Early treatment is important; otherwise there is a risk of permanent vision loss or stroke. However, when properly treated, giant cell arteritis rarely comes back. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10043207",
-                "MEDDRA:10011303",
-                "MEDDRA:10020396",
-                "MEDDRA:10020395",
-                "UMLS:C1956391",
-                "NCIT:C35065",
-                "DOID:13375",
-                "UMLS:C1956390",
-                "UMLS:C0039483",
-                "MESH:D013700",
-                "ORPHANET:397",
-                "EFO:1001209",
-                "SNOMEDCT:400130008",
-                "ICD9:446.5",
-                "MEDDRA:10018250",
-                "MONDO:0008538",
-                "OMIM:187360"
-              ],
-              "id": "MONDO:0008538",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cranial Arteritis",
-                "Giant cell arteritis",
-                "Giant Cell Arteritis",
-                "temporal arteritis",
-                "Temporal Arteritis",
-                "Temporal arteritis related phenotypic feature"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007256",
-              "name": "hepatocellular carcinoma",
-              "description": "A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.; A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.; A kind of neoplasm of the liver that originates in hepatocytes and presents macroscopically as a soft and hemorrhagic tan mass in the liver. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "HP:0001402",
-                "ICD10:C22.0",
-                "ORPHANET:88673",
-                "MEDDRA:10073071",
-                "DOID:686",
-                "MESH:C567299",
-                "MEDDRA:10024658",
-                "SNOMEDCT:109841003",
-                "UMLS:C2676033",
-                "OMIM:114550",
-                "MESH:D006528",
-                "SNOMEDCT:187769009",
-                "UMLS:C1867955",
-                "SNOMEDCT:25370001",
-                "UMLS:C1862761",
-                "DOID:684",
-                "MEDDRA:10048491",
-                "SNOMEDCT:1186630006",
-                "MONDO:0007256",
-                "MEDDRA:10019838",
-                "MEDDRA:10049010",
-                "EFO:0000182",
-                "NCIT:C3099",
-                "MEDDRA:10007416",
-                "UMLS:C2239176"
-              ],
-              "id": "MONDO:0007256",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hepatocellular carcinoma",
-                "Hepatocellular Carcinoma",
-                "Increased hepatocellular carcinoma risk",
-                "Hepatocellular carcinoma related phenotypic feature",
-                "Hepatocellular carcinoma",
-                "Liver carcinoma",
-                "Carcinoma, Hepatocellular",
-                "Increased incidence of hepatocellular carcinoma",
-                "liver carcinoma",
-                "Hepatoblastoma Caused By Somatic Mutation"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://www.mayoclinic.org/diseases-conditions/giant-cell-arteritis/symptoms-causes/syc-20372758",
-                "https://orcid.org/0000-0001-5208-3432"
-=======
-                "http://en.wikipedia.org/wiki/liver_cance",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/hepatocellular_carcinoma",
-                "http://en.wikipedia.org/wiki/carcinoma",
-                "http://www.omim.org/entry/114550",
-                "http://cancergenome.nih.gov/cancersselected/liverhepatocellularcarcinoma"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 7736659,
-            "start": 568,
-            "end": 531206,
-=======
-            "identity": 10282470,
-            "start": 568,
-            "end": 319068,
->>>>>>> main
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-<<<<<<< HEAD
-              "publications_info": "{'PMID:10616010': {'publication date': '1999 Dec', 'sentence': 'At the time of diagnosis, patients with GCA had an increased median serum level of YKL-40 (256 microg/liter; P<0.01) compared with healthy age-matched controls (median 118 microg/liter), and the serum level of YKL-40 decreased to normal levels during prednisolone treatment (-38% after 1 month; P<0.001).', 'subject score': 888, 'object score': 1000}, 'PMID:10898068': {'publication date': '2000', 'sentence': 'However, a tendency to a lower BMD was found in PMR/TA patients currently treated with prednisolone and in the prednisolone treated TA patients.', 'subject score': 1000, 'object score': 901}, 'PMID:11817115': {'publication date': '2001 Nov', 'sentence': 'PURPOSE: To assess the efficacy and tolerance of three methylprednisolone boluses (500 mg/d) followed by a standard dose of prednisolone, 20 mg/d, as the initial treatment of non-complicated giant-cell arteritis.', 'subject score': 1000, 'object score': 854}, 'PMID:13424439': {'publication date': '1957 Apr 19', 'sentence': '[Case report on temporal arteritis treated with prednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:13473393': {'publication date': '1957 Oct', 'sentence': 'Temporal arteritis treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:2254893': {'publication date': '1990 Oct', 'sentence': 'Our study indicates that most patients with PMR or TA can be treated safely with an initial prednisolone dose of 10 mg given twice daily.', 'subject score': 851, 'object score': 1000}, 'PMID:23146656': {'publication date': '2013 Jul', 'sentence': 'METHODS: Using a radioactive binding assay, the density and affinity (measured as Bmax and Kd) of 5-HT2A serotonin receptors were measured in blood samples drawn from 27 individuals diagnosed with polymyalgia rheumatica and/or giant cell arteritis before and after start of an oral treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:2351926': {'publication date': '1990 Jun', 'sentence': 'The mineral content of the heel bone, and signs of osteoporosis on X-ray of the spine, were evaluated in 26 patients (20 women and 6 men) with giant cell arteritis (GCA), treated with prednisolone for an average period of 5 years.', 'subject score': 1000, 'object score': 1000}, 'PMID:2782975': {'publication date': '1989 Aug', 'sentence': 'All but two patients with GCA were successfully treated with 40 mg/day prednisolone initially but relapsed on a reduction to 20 mg/day.', 'subject score': 822, 'object score': 1000}, 'PMID:28663795': {'publication date': '2017 Aug', 'sentence': '8 patients within the biopsies negative for GCA had their prednisolone therapy stopped.', 'subject score': 888, 'object score': 1000}, 'PMID:28791802': {'publication date': '2018 Jan', 'sentence': 'METHODS: Twelve patients with new diagnosis of GCA were initially treated with high-dose prednisolone (40-60 mg) daily for 4 weeks and then randomized to two open arms to continue tapering steroid treatment with either standard IR prednisolone or MR prednisone.', 'subject score': 901, 'object score': 1000}, 'PMID:29408476': {'publication date': '2018 Apr', 'sentence': 'The diagnosis of GCA was retained, and treatment with prednisolone was started.', 'subject score': 1000, 'object score': 1000}, 'PMID:29877748': {'publication date': '2018 Jul', 'sentence': 'Expert commentary: Prednisone/prednisolone of 40-60 mg/day is the mainstay in GCA therapy.', 'subject score': 888, 'object score': 916}, 'PMID:31431989': {'publication date': '2019', 'sentence': 'The duration of treatment with prednisolone for GCA was 22-26 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:31506102': {'publication date': '2019 Sep 11', 'sentence': 'She was diagnosed as having giant cell arteritis and started on orally administered prednisolone treatment (60 mg daily).', 'subject score': 750, 'object score': 1000}, 'PMID:31531960': {'publication date': '2019 Oct', 'sentence': 'Circulating interleukin-6 as a biomarker in a randomized controlled trial of modified-release prednisone vs immediate-release prednisolone, in newly diagnosed patients with giant cell arteritis.', 'subject score': 851, 'object score': 1000}, 'PMID:31612515': {'publication date': '2019 Dec', 'sentence': \"PATIENTS AND MEASUREMENTS: Patients with Cushing's syndrome (CS, n = 19), asthma or giant cell arteritis on chronic prednisolone treatment (PRED, n = 13), adrenal insufficiency (AI, n = 16) and healthy volunteers (HV, n = 20).\", 'subject score': 851, 'object score': 1000}, 'PMID:32031663': {'publication date': '2020 Feb 07', 'sentence': 'METHODS: We included 47 patients with PMR (n = 37), GCA (n = 1) or both (n = 9), treated with prednisolone for >=5.4 months, current dose 2.5-10 mg/day.', 'subject score': 1000, 'object score': 1000}, 'PMID:34678904': {'publication date': '2021 Oct 22', 'sentence': 'Another male patient in his 70s (patient 3) was on prednisolone therapy for polymyalgia rheumatica, giant cell arteritis, and pancreatic body tumor.', 'subject score': 888, 'object score': 1000}, 'PMID:34840228': {'publication date': '2021 Nov 27', 'sentence': 'A 79-year-old woman with GCA involving the thoracic aorta and its first branches to the posterior tibial arteries had been treated with high-dose prednisolone.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0039483---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C1956391---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7900660",
-              "object": "MONDO:0008538",
-              "publications": [
-                "PMID:31612515",
-                "PMID:37026007",
-                "PMID:28791802",
-                "PMID:2254893",
-                "PMID:31506102",
-                "PMID:11817115",
-                "PMID:35169570",
-                "PMID:13473393",
-                "PMID:31531960",
-                "PMID:8257209",
-                "PMID:8203964",
-                "PMID:28663795",
-                "PMID:8116092",
-                "PMID:36631167",
-                "PMID:23146656",
-                "PMID:8205403",
-                "PMID:2351926",
-                "PMID:32031663",
-                "PMID:10898068",
-                "PMID:8094625"
-=======
-              "publications_info": "{'PMID:1333900': {'publication date': '1992', 'sentence': 'One had received four weekly cycles of prednisolone, Adriamycin, vincristine and 5-fluorouracil for an inoperable HCC with a 10-cm diameter, and the other had received localised synchronised hepatic irradiation and Adriamycin.', 'subject score': 1000, 'object score': 901}, 'PMID:23673446': {'publication date': '2013 Jul', 'sentence': 'Here, we report a pharmacokinetic interaction between sorafenib and the CYP3A4 inducer prednisolone in a patient with hepatocellular carcinoma (HCC).', 'subject score': 802, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C2239176---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10509017",
-              "object": "MONDO:0007256",
-              "publications": [
-                "PMID:1333900",
-                "PMID:23673446"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 531649,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:17530014': {'publication date': '2007 May 28', 'sentence': 'A combination of rituximab plus chemotherapy, rituximab+cyclophosphamide+doxorubicin+vincristine+prednisolone (R-CHOP), has the highest efficacy ever described with any chemotherapy in DLBCL and FL.', 'subject score': 822, 'object score': 1000}, 'PMID:25804839': {'publication date': '2015 Sep', 'sentence': 'Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 313140,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019735",
-          "name": "polymyalgia rheumatica",
-          "description": "A syndrome characterized by pain, stiffness, and tenderness of the proximal muscle groups including the shoulder, pelvic girdle and the neck. There is no muscle atrophy and muscle biopsies do not reveal pathologic changes. Additional signs and symptoms include low grade fever, fatigue and depression.; A syndrome in the elderly characterized by proximal joint and muscle pain, high erythrocyte sedimentation rate, and a self-limiting course. Pain is usually accompanied by evidence of an inflammatory reaction. Women are affected twice as commonly as men and Caucasians more frequently than other groups. The condition is frequently associated with GIANT CELL ARTERITIS and some theories pose the possibility that the two diseases arise from a single etiology or even that they are the same entity.; Polymyalgia rheumatica is a disorder that causes muscle pain and stiffness in your neck, shoulders, and hips. It is most common in women and almost always occurs in people over 50. The main symptom is stiffness after resting. Other symptoms include fever, weakness and weight loss. In some cases, polymyalgia rheumatica develops overnight. In others, it is gradual. The cause of polymyalgia rheumatica is unknown. There is no specific test for it. Your doctor will use your medical history, symptoms, and a physical exam to make the diagnosis. Lab tests for inflammation may help confirm the diagnosis. Polymyalgia rheumatica sometimes occurs along with giant cell arteritis, a condition that causes swelling of the arteries in your head. Symptoms include headaches and blurred vision. Doctors often prescribe prednisone, a steroid medicine, for both conditions. With treatment, polymyalgia rheumatica usually disappears in a day or two. Without treatment, it usually goes away after a year or more.  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10036099",
-            "UMLS:C1527406",
-            "NCIT:C85018",
-            "DOID:853",
-            "ORPHANET:93569",
-            "MEDDRA:10068240",
-            "UMLS:C0032533",
-            "MESH:D011111",
-            "ICD9:725",
-            "SNOMEDCT:65323003",
-            "EFO:0008518",
-            "MONDO:0019735",
-            "ICD10:M35.3"
-          ],
-          "id": "MONDO:0019735",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Polymyalgia rheumatica",
-            "polymyalgia rheumatica",
-            "Rhizomelic pseudopolyarthritis",
-            "Polymyalgia Rheumatica"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018906",
-          "name": "follicular lymphoma",
-          "description": "A neoplasm of follicle centre B cells which has at least a partial follicular pattern. Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)]. Histological grade correlates with prognosis. Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3209\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3209\" NCI Thesaurus); A neoplasm of follicle centre B cells which has at least a partial follicular pattern. Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)]. Histological grade correlates with prognosis. Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).; A low-grade malignant lymphoma of follicular pattern in which there is no clear preponderance of one cell type (small or large) over another. The large cells, cleaved or noncleaved, are often 2-3 times larger in diameter than normal lymphocytes.; An indolent B cell lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is characterized by diffuse lymphadenopathy, bone marrow involvement, splenomegaly and less commonly other extranodal sites of involvement. [NCIT:C3209, PMID:29314206]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10085128",
-            "ORPHANET:545",
-            "MEDDRA:10029478",
-            "MONDO:0018906",
-            "UMLS:C3887918",
-            "SNOMEDCT:277618009",
-            "SNOMEDCT:308121000",
-            "PDQ:CDR0000795359",
-            "MEDDRA:10029473",
-            "NCIT:C3209",
-            "UMLS:C0024301",
-            "HP:0033125",
-            "MESH:D008224",
-            "DOID:0050873",
-            "MEDDRA:10085262",
-            "SNOMEDCT:307637005",
-            "SNOMEDCT:55150002"
-          ],
-          "id": "MONDO:0018906",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia/lymphoma, b-cell, 2",
-            "Follicular Lymphoma",
-            "Lymphoma, Follicular",
-            "Follicular lymphoma",
-            "follicular lymphoma"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://medlineplus.gov/polymyalgiarheumatica.htm"
-=======
-            "http://en.wikipedia.org/wiki/follicular_lymphoma",
-            "http://www.cancer.gov/dictionary?cdrid=428287",
-            "PMID:29314206"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 531649,
-=======
-            "identity": 313140,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019735",
-              "name": "polymyalgia rheumatica",
-              "description": "A syndrome characterized by pain, stiffness, and tenderness of the proximal muscle groups including the shoulder, pelvic girdle and the neck. There is no muscle atrophy and muscle biopsies do not reveal pathologic changes. Additional signs and symptoms include low grade fever, fatigue and depression.; A syndrome in the elderly characterized by proximal joint and muscle pain, high erythrocyte sedimentation rate, and a self-limiting course. Pain is usually accompanied by evidence of an inflammatory reaction. Women are affected twice as commonly as men and Caucasians more frequently than other groups. The condition is frequently associated with GIANT CELL ARTERITIS and some theories pose the possibility that the two diseases arise from a single etiology or even that they are the same entity.; Polymyalgia rheumatica is a disorder that causes muscle pain and stiffness in your neck, shoulders, and hips. It is most common in women and almost always occurs in people over 50. The main symptom is stiffness after resting. Other symptoms include fever, weakness and weight loss. In some cases, polymyalgia rheumatica develops overnight. In others, it is gradual. The cause of polymyalgia rheumatica is unknown. There is no specific test for it. Your doctor will use your medical history, symptoms, and a physical exam to make the diagnosis. Lab tests for inflammation may help confirm the diagnosis. Polymyalgia rheumatica sometimes occurs along with giant cell arteritis, a condition that causes swelling of the arteries in your head. Symptoms include headaches and blurred vision. Doctors often prescribe prednisone, a steroid medicine, for both conditions. With treatment, polymyalgia rheumatica usually disappears in a day or two. Without treatment, it usually goes away after a year or more.  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10036099",
-                "UMLS:C1527406",
-                "NCIT:C85018",
-                "DOID:853",
-                "ORPHANET:93569",
-                "MEDDRA:10068240",
-                "UMLS:C0032533",
-                "MESH:D011111",
-                "ICD9:725",
-                "SNOMEDCT:65323003",
-                "EFO:0008518",
-                "MONDO:0019735",
-                "ICD10:M35.3"
-              ],
-              "id": "MONDO:0019735",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Polymyalgia rheumatica",
-                "polymyalgia rheumatica",
-                "Rhizomelic pseudopolyarthritis",
-                "Polymyalgia Rheumatica"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018906",
-              "name": "follicular lymphoma",
-              "description": "A neoplasm of follicle centre B cells which has at least a partial follicular pattern. Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)]. Histological grade correlates with prognosis. Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3209\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3209\" NCI Thesaurus); A neoplasm of follicle centre B cells which has at least a partial follicular pattern. Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)]. Histological grade correlates with prognosis. Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).; A low-grade malignant lymphoma of follicular pattern in which there is no clear preponderance of one cell type (small or large) over another. The large cells, cleaved or noncleaved, are often 2-3 times larger in diameter than normal lymphocytes.; An indolent B cell lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is characterized by diffuse lymphadenopathy, bone marrow involvement, splenomegaly and less commonly other extranodal sites of involvement. [NCIT:C3209, PMID:29314206]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10085128",
-                "ORPHANET:545",
-                "MEDDRA:10029478",
-                "MONDO:0018906",
-                "UMLS:C3887918",
-                "SNOMEDCT:277618009",
-                "SNOMEDCT:308121000",
-                "PDQ:CDR0000795359",
-                "MEDDRA:10029473",
-                "NCIT:C3209",
-                "UMLS:C0024301",
-                "HP:0033125",
-                "MESH:D008224",
-                "DOID:0050873",
-                "MEDDRA:10085262",
-                "SNOMEDCT:307637005",
-                "SNOMEDCT:55150002"
-              ],
-              "id": "MONDO:0018906",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia/lymphoma, b-cell, 2",
-                "Follicular Lymphoma",
-                "Lymphoma, Follicular",
-                "Follicular lymphoma",
-                "follicular lymphoma"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://medlineplus.gov/polymyalgiarheumatica.htm"
-=======
-                "http://en.wikipedia.org/wiki/follicular_lymphoma",
-                "http://www.cancer.gov/dictionary?cdrid=428287",
-                "PMID:29314206"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 7736658,
-            "start": 568,
-            "end": 531649,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10616010': {'publication date': '1999 Dec', 'sentence': 'Most patients with PMR had normal serum YKL-40 levels (median 158 microg/liter) and had no changes in the serum YKL-40 levels during prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:10774252': {'publication date': '2000 Mar', 'sentence': 'A diagnosis of polymyalgia rheumatica was made, and low-dose prednisolone therapy (20 mg/d) was started.', 'subject score': 861, 'object score': 1000}, 'PMID:10898068': {'publication date': '2000', 'sentence': 'Similarly, no significant differences in BMD were found between current and previous users of prednisolone and between the prednisolone treated PMR and TA patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:12910963': {'publication date': '2003 Jun', 'sentence': 'SUBJECTS AND METHODS: The study included 10 patients with PMR, who could be prospectively followed up from the start of prednisolone (PSL) treatment until the CRP level decreased to 1 mg/dl or less.', 'subject score': 888, 'object score': 1000}, 'PMID:17087187': {'publication date': '2006', 'sentence': 'Polymyalgia rheumatica is treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:1768166': {'publication date': '1991 Dec', 'sentence': 'These results will be further evaluated in a controlled trial using intramuscular injections of methylprednisolone and prednisolone given by mouth for the treatment of polymyalgia rheumatica.', 'subject score': 1000, 'object score': 1000}, 'PMID:20812339': {'publication date': '2010 Dec', 'sentence': 'In the PMR patients, interstitial concentrations were normalized after prednisolone treatment.', 'subject score': 888, 'object score': 901}, 'PMID:2254893': {'publication date': '1990 Oct', 'sentence': 'Our study indicates that most patients with PMR or TA can be treated safely with an initial prednisolone dose of 10 mg given twice daily.', 'subject score': 851, 'object score': 1000}, 'PMID:28282736': {'publication date': '2018', 'sentence': 'Ocular inflammation presented as episcleritis, scleritis, or anterior uveitis, and it emerged during the tapering of low-dose prednisolone prescribed for polymyalgia rheumatica in all patients.', 'subject score': 901, 'object score': 1000}, 'PMID:28867756': {'publication date': '2017', 'sentence': 'Case 2: An 83-year-old man suffering from PMR was successfully treated with PSL and CAM.', 'subject score': 1000, 'object score': 1000}, 'PMID:32156589': {'publication date': '2020 Mar 07', 'sentence': 'He was treated with oral prednisolone for polymyalgia rheumatica.', 'subject score': 888, 'object score': 1000}, 'PMID:32996694': {'publication date': '2020 Sep 30', 'sentence': 'CONCLUSION: The normalization of CRP within 1 month from baseline predicted GC-free remission in PMR patients treated with PSL, and resulted in a lower cumulative PSL dose.', 'subject score': 1000, 'object score': 901}, 'PMID:34678904': {'publication date': '2021 Oct 22', 'sentence': 'Another male patient in his 70s (patient 3) was on prednisolone therapy for polymyalgia rheumatica, giant cell arteritis, and pancreatic body tumor.', 'subject score': 888, 'object score': 1000}, 'PMID:36152056': {'publication date': '2022 Sep 24', 'sentence': 'She was diagnosed with polymyalgia rheumatica (PMR) and treated with low-dose prednisolone (15 mg daily); however, she discontinued glucocorticoid therapy at her discretion due to the psychiatric adverse effect (cognitive dysfunction).', 'subject score': 901, 'object score': 1000}, 'PMID:3780140': {'publication date': '1986 Sep', 'sentence': 'Prednisolone pharmacokinetics in patients with rheumatoid arthritis, polymyalgia rheumatica and asthma.', 'subject score': 888, 'object score': 1000}, 'PMID:8116092': {'publication date': '1994 Feb 21', 'sentence': 'We assessed the diagnostic value of CD8+ levels in a larger group of patients with temporal arteritis and polymyalgia rheumatica before and after treatment with prednisolone and in relation to patients with other medical and rheumatic diseases.', 'subject score': 1000, 'object score': 1000}, 'PMID:8203964': {'publication date': '1994 Apr', 'sentence': 'Circulating T cell subtypes in polymyalgia rheumatica and giant cell arteritis: variation in the percentage of CD8+ cells with prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:8222521': {'publication date': '1993 Aug', 'sentence': 'However, corticosteroids, usually prednisone or prednisolone, are the class of drugs most widely used to treat PMR.', 'subject score': 1000, 'object score': 1000}, 'PMID:8257209': {'publication date': '1993 Oct', 'sentence': 'Circulating T cell subtypes in polymyalgia rheumatica and giant cell arteritis: variation in the percentage of CD8+ cells with prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:8523341': {'publication date': '1995 Sep', 'sentence': 'A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0032533---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7900659",
-              "object": "MONDO:0019735",
-              "publications": [
-                "PMID:10616010",
-                "PMID:10774252",
-                "PMID:10898068",
-                "PMID:12910963",
-                "PMID:17087187",
-                "PMID:1768166",
-                "PMID:20812339",
-                "PMID:2254893",
-                "PMID:28282736",
-                "PMID:28867756",
-                "PMID:32156589",
-                "PMID:32996694",
-                "PMID:34678904",
-                "PMID:36152056",
-                "PMID:3780140",
-                "PMID:8116092",
-                "PMID:8203964",
-                "PMID:8222521",
-                "PMID:8257209",
-                "PMID:8523341"
-=======
-            "identity": 12874287,
-            "start": 568,
-            "end": 313140,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17530014': {'publication date': '2007 May 28', 'sentence': 'A combination of rituximab plus chemotherapy, rituximab+cyclophosphamide+doxorubicin+vincristine+prednisolone (R-CHOP), has the highest efficacy ever described with any chemotherapy in DLBCL and FL.', 'subject score': 822, 'object score': 1000}, 'PMID:25804839': {'publication date': '2015 Sep', 'sentence': 'Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0024301---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "13151962",
-              "object": "MONDO:0018906",
-              "publications": [
-                "PMID:17530014",
-                "PMID:25804839"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 321063,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:18231908': {'publication date': '2008 Feb', 'sentence': 'The addition of rituximab to cyclophosphamide, vincristine and prednisolone (CVP) for advanced follicular lymphoma increases median time to progression by 17 months.', 'subject score': 1000, 'object score': 901}, 'PMID:21592582': {'publication date': '2011 Jun', 'sentence': 'We present a rare case of chronic Pneumocystis jiroveci infection presenting as multiple persistent granulomatous pulmonary nodules over a 12 month period in a patient with follicular lymphoma undergoing treatment with Rituximab, Cyclophosphamide, Vincristine, and Prednisolone chemotherapy.', 'subject score': 888, 'object score': 1000}, 'PMID:21627880': {'publication date': '2010 Nov-Dec', 'sentence': '[Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal].', 'subject score': 1000, 'object score': 901}, 'PMID:24471908': {'publication date': '2014 Oct', 'sentence': 'Patients received six or eight cycles of rituximab plus cyclophosphamide, vincristine, doxorubicin and prednisone for DLBCL or plus cyclophosphamide, vincristine and prednisolone for FL.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 313140,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018874",
-          "name": "acute myeloid leukemia",
-          "description": "A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification). (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3171\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3171\" NCI Thesaurus); Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.; A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).; Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.; A form of leukemia characterized by overproduction of an early myeloid cell. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:91861009",
-            "ICD9:205.0",
-            "MEDDRA:10024346",
-            "MEDDRA:10000801",
-            "MEDDRA:10060354",
-            "KEGG.DISEASE:05221",
-            "EFO:0000222",
-            "PDQ:CDR0000043424",
-            "MEDDRA:10000886",
-            "HP:0004808",
-            "MEDDRA:10060394",
-            "MESH:D015470",
-            "MEDDRA:10051003",
-            "MONDO:0100173",
-            "MEDDRA:10000878",
-            "MEDDRA:10060553",
-            "MEDDRA:10024291",
-            "SNOMEDCT:1162928000",
-            "MEDDRA:10054296",
-            "ORPHANET:519",
-            "MEDDRA:10000880",
-            "UMLS:C3275959",
-            "MEDDRA:10028552",
-            "MONDO:0018874",
-            "OMIM:601626",
-            "MEDDRA:10000884",
-            "DOID:9119",
-            "MEDDRA:10029549",
-            "MEDDRA:10029551",
-            "UMLS:C0023467",
-            "NCIT:C3171",
-            "MEDDRA:10060557",
-            "MEDDRA:10028557"
-          ],
-          "id": "MONDO:0018874",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia, acute myeloid related phenotypic feature",
-            "Leukemia, Myelocytic, Acute",
-            "Acute myeloid leukemia",
-            "acute myeloid leukemia",
-            "leukemia, acute myeloid, susceptibility to",
-            "Leukemia, acute myeloid, susceptibility to",
-            "Acute Myeloid Leukemia",
-            "Leukemia, Myeloid, Acute",
-            "Myeloid leukemia, acute"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018906",
-          "name": "follicular lymphoma",
-          "description": "A neoplasm of follicle centre B cells which has at least a partial follicular pattern. Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)]. Histological grade correlates with prognosis. Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3209\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3209\" NCI Thesaurus); A neoplasm of follicle centre B cells which has at least a partial follicular pattern. Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)]. Histological grade correlates with prognosis. Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).; A low-grade malignant lymphoma of follicular pattern in which there is no clear preponderance of one cell type (small or large) over another. The large cells, cleaved or noncleaved, are often 2-3 times larger in diameter than normal lymphocytes.; An indolent B cell lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is characterized by diffuse lymphadenopathy, bone marrow involvement, splenomegaly and less commonly other extranodal sites of involvement. [NCIT:C3209, PMID:29314206]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10085128",
-            "ORPHANET:545",
-            "MEDDRA:10029478",
-            "MONDO:0018906",
-            "UMLS:C3887918",
-            "SNOMEDCT:277618009",
-            "SNOMEDCT:308121000",
-            "PDQ:CDR0000795359",
-            "MEDDRA:10029473",
-            "NCIT:C3209",
-            "UMLS:C0024301",
-            "HP:0033125",
-            "MESH:D008224",
-            "DOID:0050873",
-            "MEDDRA:10085262",
-            "SNOMEDCT:307637005",
-            "SNOMEDCT:55150002"
-          ],
-          "id": "MONDO:0018906",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia/lymphoma, b-cell, 2",
-            "Follicular Lymphoma",
-            "Lymphoma, Follicular",
-            "Follicular lymphoma",
-            "follicular lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/follicular_lymphoma",
-            "http://www.cancer.gov/dictionary?cdrid=428287",
-            "PMID:29314206"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313140,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018906",
-              "name": "follicular lymphoma",
-              "description": "A neoplasm of follicle centre B cells which has at least a partial follicular pattern. Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)]. Histological grade correlates with prognosis. Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3209\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3209\" NCI Thesaurus); A neoplasm of follicle centre B cells which has at least a partial follicular pattern. Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)]. Histological grade correlates with prognosis. Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).; A low-grade malignant lymphoma of follicular pattern in which there is no clear preponderance of one cell type (small or large) over another. The large cells, cleaved or noncleaved, are often 2-3 times larger in diameter than normal lymphocytes.; An indolent B cell lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is characterized by diffuse lymphadenopathy, bone marrow involvement, splenomegaly and less commonly other extranodal sites of involvement. [NCIT:C3209, PMID:29314206]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10085128",
-                "ORPHANET:545",
-                "MEDDRA:10029478",
-                "MONDO:0018906",
-                "UMLS:C3887918",
-                "SNOMEDCT:277618009",
-                "SNOMEDCT:308121000",
-                "PDQ:CDR0000795359",
-                "MEDDRA:10029473",
-                "NCIT:C3209",
-                "UMLS:C0024301",
-                "HP:0033125",
-                "MESH:D008224",
-                "DOID:0050873",
-                "MEDDRA:10085262",
-                "SNOMEDCT:307637005",
-                "SNOMEDCT:55150002"
-              ],
-              "id": "MONDO:0018906",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia/lymphoma, b-cell, 2",
-                "Follicular Lymphoma",
-                "Lymphoma, Follicular",
-                "Follicular lymphoma",
-                "follicular lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/follicular_lymphoma",
-                "http://www.cancer.gov/dictionary?cdrid=428287",
-                "PMID:29314206"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13280763,
-            "start": 568,
-            "end": 313140,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18231908': {'publication date': '2008 Feb', 'sentence': 'The addition of rituximab to cyclophosphamide, vincristine and prednisolone (CVP) for advanced follicular lymphoma increases median time to progression by 17 months.', 'subject score': 1000, 'object score': 901}, 'PMID:21592582': {'publication date': '2011 Jun', 'sentence': 'We present a rare case of chronic Pneumocystis jiroveci infection presenting as multiple persistent granulomatous pulmonary nodules over a 12 month period in a patient with follicular lymphoma undergoing treatment with Rituximab, Cyclophosphamide, Vincristine, and Prednisolone chemotherapy.', 'subject score': 888, 'object score': 1000}, 'PMID:21627880': {'publication date': '2010 Nov-Dec', 'sentence': '[Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal].', 'subject score': 1000, 'object score': 901}, 'PMID:24471908': {'publication date': '2014 Oct', 'sentence': 'Patients received six or eight cycles of rituximab plus cyclophosphamide, vincristine, doxorubicin and prednisone for DLBCL or plus cyclophosphamide, vincristine and prednisolone for FL.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0024301---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "13566191",
-              "object": "MONDO:0018906",
-              "publications": [
-                "PMID:18231908",
-                "PMID:21592582",
-                "PMID:21627880",
-                "PMID:24471908"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:15122768': {'publication date': '2004 May', 'sentence': 'A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:25328799': {'publication date': '2014 Sep', 'sentence': 'BACKGROUND: Prednisolone and pentoxifylline (PTX) have been shown to be individually useful in severe alcoholic hepatitis with Maddrey discriminant function (MDF) score >=32.', 'subject score': 1000, 'object score': 901}, 'PMID:25638854': {'publication date': '2014 Nov', 'sentence': '[Pentoxifylline against prednisolone in severe acute alcoholic hepatitis: a Korean trial].', 'subject score': 1000, 'object score': 916}, 'PMID:1614484': {'publication date': '1992 Jul 23', 'sentence': 'Prednisolone in severe alcoholic hepatitis.', 'subject score': 1000, 'object score': 901}, 'PMID:22586023': {'publication date': '2012 May 15', 'sentence': 'Adding N-acetylcysteine to prednisolone reduced early mortality in severe alcoholic hepatitis.', 'subject score': 1000, 'object score': 901}, 'PMID:24864478': {'publication date': '2014', 'sentence': 'It discusses in detail the mechanisms of liver damage within the disease in question and substantiates indications for the use of prednisolone and pentoxifylline in alcoholic hepatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28043903': {'publication date': '2017 04', 'sentence': 'We compared the effects of infection on clinical outcomes of patients treated with and without prednisolone, and identified risk factors for development of infection in SAH.', 'subject score': 1000, 'object score': 901}, 'PMID:28966126': {'publication date': '2018 Mar', 'sentence': 'While prednisolone is considered standard of care in severe AH, this recommendation remains controversial given the marginal benefits and questionable long-term safety of steroids.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 526144,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001505",
-          "name": "alcoholic hepatitis",
-          "description": "Inflammation of the liver resulting from ingestion of alcohol.; INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.",
-          "equivalent_curies": [
-            "MONDO:0001505",
-            "MEDDRA:10000649",
-            "ICD9:571.1",
-            "SNOMEDCT:235875008",
-            "MEDDRA:10019728",
-            "MESH:D006519",
-            "NCIT:C34352",
-            "UMLS:C0019187",
-            "EFO:1001345",
-            "UMLS:C0001306",
-            "DOID:12351",
-            "NCIT:C34684",
-            "MEDDRA:10001624",
-            "SNOMEDCT:9953008"
-          ],
-          "id": "MONDO:0001505",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute alcoholic hepatitis",
-            "alcoholic hepatitis",
-            "Alcoholic Hepatitis",
-            "Acute Alcoholic Hepatitis",
-            "Acute alcoholic liver disease",
-            "Hepatitis, Alcoholic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526144,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001505",
-              "name": "alcoholic hepatitis",
-              "description": "Inflammation of the liver resulting from ingestion of alcohol.; INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.",
-              "equivalent_curies": [
-                "MONDO:0001505",
-                "MEDDRA:10000649",
-                "ICD9:571.1",
-                "SNOMEDCT:235875008",
-                "MEDDRA:10019728",
-                "MESH:D006519",
-                "NCIT:C34352",
-                "UMLS:C0019187",
-                "EFO:1001345",
-                "UMLS:C0001306",
-                "DOID:12351",
-                "NCIT:C34684",
-                "MEDDRA:10001624",
-                "SNOMEDCT:9953008"
-              ],
-              "id": "MONDO:0001505",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute alcoholic hepatitis",
-                "alcoholic hepatitis",
-                "Alcoholic Hepatitis",
-                "Acute Alcoholic Hepatitis",
-                "Acute alcoholic liver disease",
-                "Hepatitis, Alcoholic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10939461,
-            "start": 568,
-            "end": 526144,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15122768': {'publication date': '2004 May', 'sentence': 'A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:25328799': {'publication date': '2014 Sep', 'sentence': 'BACKGROUND: Prednisolone and pentoxifylline (PTX) have been shown to be individually useful in severe alcoholic hepatitis with Maddrey discriminant function (MDF) score >=32.', 'subject score': 1000, 'object score': 901}, 'PMID:25638854': {'publication date': '2014 Nov', 'sentence': '[Pentoxifylline against prednisolone in severe acute alcoholic hepatitis: a Korean trial].', 'subject score': 1000, 'object score': 916}, 'PMID:1614484': {'publication date': '1992 Jul 23', 'sentence': 'Prednisolone in severe alcoholic hepatitis.', 'subject score': 1000, 'object score': 901}, 'PMID:22586023': {'publication date': '2012 May 15', 'sentence': 'Adding N-acetylcysteine to prednisolone reduced early mortality in severe alcoholic hepatitis.', 'subject score': 1000, 'object score': 901}, 'PMID:24864478': {'publication date': '2014', 'sentence': 'It discusses in detail the mechanisms of liver damage within the disease in question and substantiates indications for the use of prednisolone and pentoxifylline in alcoholic hepatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28043903': {'publication date': '2017 04', 'sentence': 'We compared the effects of infection on clinical outcomes of patients treated with and without prednisolone, and identified risk factors for development of infection in SAH.', 'subject score': 1000, 'object score': 901}, 'PMID:28966126': {'publication date': '2018 Mar', 'sentence': 'While prednisolone is considered standard of care in severe AH, this recommendation remains controversial given the marginal benefits and questionable long-term safety of steroids.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0001306---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0019187---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11179224",
-              "object": "MONDO:0001505",
-              "publications": [
-                "PMID:28966126",
-                "PMID:28043903",
-                "PMID:1614484",
-                "PMID:24864478",
-                "PMID:15122768",
-                "PMID:22586023",
-                "PMID:25638854",
-                "PMID:25328799"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11096576': {'publication date': '1999 Feb', 'sentence': 'Prednisolone improves survival in patients with alcoholic hepatitis who have either spontaneous hepatic encephalopathy or a high \"discriminant function.\"', 'subject score': 1000, 'object score': 1000}, 'PMID:14647046': {'publication date': '2003 Dec', 'sentence': 'Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone.', 'subject score': 1000, 'object score': 901}, 'PMID:1531090': {'publication date': '1992 Feb 20', 'sentence': 'A randomized trial of prednisolone in patients with severe alcoholic hepatitis.', 'subject score': 1000, 'object score': 901}, 'PMID:19340904': {'publication date': '2009 Apr 07', 'sentence': 'CONCLUSION: Reduced mortality, improved risk-benefit profile and renoprotective effects of pentoxifylline compared with prednisolone suggest that pentoxifylline is superior to prednisolone for treatment of severe alcoholic hepatitis.', 'subject score': 1000, 'object score': 901}, 'PMID:24026598': {'publication date': '2013 Sep 11', 'sentence': 'CONCLUSION AND RELEVANCE: In patients with alcoholic hepatitis, 4-week treatment with pentoxifylline and prednisolone, compared with prednisolone alone, did not result in improved 6-month survival.', 'subject score': 1000, 'object score': 1000}, 'PMID:24845609': {'publication date': '2014 Oct', 'sentence': 'CONCLUSIONS: The findings demonstrate that the efficacy of the pentoxifylline is not statistically equivalent to the efficacy of prednisolone, supporting the use of prednisolone as a preferred treatment option in patients with severe alcoholic hepatitis.', 'subject score': 1000, 'object score': 901}, 'PMID:25328799': {'publication date': '2014 Sep', 'sentence': 'However the efficacy of PTX and prednisolone combination over PTX alone in the management of acute alcoholic hepatitis (MDF score >=32) is yet unrevealed.', 'subject score': 775, 'object score': 1000}, 'PMID:25901427': {'publication date': '2015 Apr 23', 'sentence': 'Prednisolone and pentoxifylline are both recommended for the treatment of severe alcoholic hepatitis, but uncertainty about their benefit persists.', 'subject score': 1000, 'object score': 901}, 'PMID:26176387': {'publication date': '2015 07 16', 'sentence': 'Prednisolone or Pentoxifylline for Alcoholic Hepatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:26176388': {'publication date': '2015 07 16', 'sentence': 'Prednisolone or Pentoxifylline for Alcoholic Hepatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:26176389': {'publication date': '2015 07 16', 'sentence': 'Prednisolone or Pentoxifylline for Alcoholic Hepatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:26279269': {'publication date': '2016 05', 'sentence': 'BACKGROUND & AIMS: Prednisolone is the first-line therapy for severe alcoholic hepatitis (AH).', 'subject score': 1000, 'object score': 901}, 'PMID:26691209': {'publication date': '2015 Dec', 'sentence': 'Prednisolone and pentoxifylline (PTX) are recommended in guidelines for treatment of severe AH, but trials supporting their use have given heterogeneous results and controversy persists about their benefit.', 'subject score': 1000, 'object score': 901}, 'PMID:26948886': {'publication date': '2016 Jun', 'sentence': 'The optimal treatment for patients with severe AH is prednisolone, possibly in combination with N-acetyl cysteine.', 'subject score': 1000, 'object score': 901}, 'PMID:27337960': {'publication date': '2016 Nov', 'sentence': 'CONCLUSIONS: Management of severe alcoholic hepatitis with prednisolone plus SAMe was associated with better therapy response (p = 0.044) and less frequent HRS occurrence (p = 0.035).', 'subject score': 1000, 'object score': 901}, 'PMID:28043903': {'publication date': '2017 04', 'sentence': 'Development of infection was associated with increased 90-day mortality in patients with SAH treated with prednisolone, independent of model for end-stage liver disease or Lille score (OR, 2.46; 95% CI, 1.41-4.30; P = .002).', 'subject score': 1000, 'object score': 901}, 'PMID:29113530': {'publication date': '2018 05', 'sentence': 'Thus, metabolic liver failure in AH seems to be prognostically important, is potentially reversible, and may recover more rapidly following treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:2954078': {'publication date': '1987 May 02', 'sentence': 'Whether or not prednisolone (or prednisone) should be used to treat alcoholic hepatitis remains controversial.', 'subject score': 888, 'object score': 1000}, 'PMID:29663389': {'publication date': '2018 Mar', 'sentence': 'We assessed serum cholesterol, cholesterol precursors, cholestanol, phytosterols, and biochemical markers in 24 patients with severe AH treated with prednisolone and randomized to ciprofloxacin in the ratio 1:1.', 'subject score': 1000, 'object score': 901}, 'PMID:29753761': {'publication date': '2018 Aug', 'sentence': 'He was diagnosed with severe alcoholic hepatitis (Maddrey discriminant function score of 50) and treated with prednisolone for 28 days with symptomatic and biochemical improvement.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 526144,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001505",
-          "name": "alcoholic hepatitis",
-          "description": "Inflammation of the liver resulting from ingestion of alcohol.; INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.",
-          "equivalent_curies": [
-            "MONDO:0001505",
-            "MEDDRA:10000649",
-            "ICD9:571.1",
-            "SNOMEDCT:235875008",
-            "MEDDRA:10019728",
-            "MESH:D006519",
-            "NCIT:C34352",
-            "UMLS:C0019187",
-            "EFO:1001345",
-            "UMLS:C0001306",
-            "DOID:12351",
-            "NCIT:C34684",
-            "MEDDRA:10001624",
-            "SNOMEDCT:9953008"
-          ],
-          "id": "MONDO:0001505",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute alcoholic hepatitis",
-            "alcoholic hepatitis",
-            "Alcoholic Hepatitis",
-            "Acute Alcoholic Hepatitis",
-            "Acute alcoholic liver disease",
-            "Hepatitis, Alcoholic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526144,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001505",
-              "name": "alcoholic hepatitis",
-              "description": "Inflammation of the liver resulting from ingestion of alcohol.; INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.",
-              "equivalent_curies": [
-                "MONDO:0001505",
-                "MEDDRA:10000649",
-                "ICD9:571.1",
-                "SNOMEDCT:235875008",
-                "MEDDRA:10019728",
-                "MESH:D006519",
-                "NCIT:C34352",
-                "UMLS:C0019187",
-                "EFO:1001345",
-                "UMLS:C0001306",
-                "DOID:12351",
-                "NCIT:C34684",
-                "MEDDRA:10001624",
-                "SNOMEDCT:9953008"
-              ],
-              "id": "MONDO:0001505",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute alcoholic hepatitis",
-                "alcoholic hepatitis",
-                "Alcoholic Hepatitis",
-                "Acute Alcoholic Hepatitis",
-                "Acute alcoholic liver disease",
-                "Hepatitis, Alcoholic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8390714,
-            "start": 568,
-            "end": 526144,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11096576': {'publication date': '1999 Feb', 'sentence': 'Prednisolone improves survival in patients with alcoholic hepatitis who have either spontaneous hepatic encephalopathy or a high \"discriminant function.\"', 'subject score': 1000, 'object score': 1000}, 'PMID:14647046': {'publication date': '2003 Dec', 'sentence': 'Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone.', 'subject score': 1000, 'object score': 901}, 'PMID:1531090': {'publication date': '1992 Feb 20', 'sentence': 'A randomized trial of prednisolone in patients with severe alcoholic hepatitis.', 'subject score': 1000, 'object score': 901}, 'PMID:19340904': {'publication date': '2009 Apr 07', 'sentence': 'CONCLUSION: Reduced mortality, improved risk-benefit profile and renoprotective effects of pentoxifylline compared with prednisolone suggest that pentoxifylline is superior to prednisolone for treatment of severe alcoholic hepatitis.', 'subject score': 1000, 'object score': 901}, 'PMID:24026598': {'publication date': '2013 Sep 11', 'sentence': 'CONCLUSION AND RELEVANCE: In patients with alcoholic hepatitis, 4-week treatment with pentoxifylline and prednisolone, compared with prednisolone alone, did not result in improved 6-month survival.', 'subject score': 1000, 'object score': 1000}, 'PMID:24845609': {'publication date': '2014 Oct', 'sentence': 'CONCLUSIONS: The findings demonstrate that the efficacy of the pentoxifylline is not statistically equivalent to the efficacy of prednisolone, supporting the use of prednisolone as a preferred treatment option in patients with severe alcoholic hepatitis.', 'subject score': 1000, 'object score': 901}, 'PMID:25328799': {'publication date': '2014 Sep', 'sentence': 'However the efficacy of PTX and prednisolone combination over PTX alone in the management of acute alcoholic hepatitis (MDF score >=32) is yet unrevealed.', 'subject score': 775, 'object score': 1000}, 'PMID:25901427': {'publication date': '2015 Apr 23', 'sentence': 'Prednisolone and pentoxifylline are both recommended for the treatment of severe alcoholic hepatitis, but uncertainty about their benefit persists.', 'subject score': 1000, 'object score': 901}, 'PMID:26176387': {'publication date': '2015 07 16', 'sentence': 'Prednisolone or Pentoxifylline for Alcoholic Hepatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:26176388': {'publication date': '2015 07 16', 'sentence': 'Prednisolone or Pentoxifylline for Alcoholic Hepatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:26176389': {'publication date': '2015 07 16', 'sentence': 'Prednisolone or Pentoxifylline for Alcoholic Hepatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:26279269': {'publication date': '2016 05', 'sentence': 'BACKGROUND & AIMS: Prednisolone is the first-line therapy for severe alcoholic hepatitis (AH).', 'subject score': 1000, 'object score': 901}, 'PMID:26691209': {'publication date': '2015 Dec', 'sentence': 'Prednisolone and pentoxifylline (PTX) are recommended in guidelines for treatment of severe AH, but trials supporting their use have given heterogeneous results and controversy persists about their benefit.', 'subject score': 1000, 'object score': 901}, 'PMID:26948886': {'publication date': '2016 Jun', 'sentence': 'The optimal treatment for patients with severe AH is prednisolone, possibly in combination with N-acetyl cysteine.', 'subject score': 1000, 'object score': 901}, 'PMID:27337960': {'publication date': '2016 Nov', 'sentence': 'CONCLUSIONS: Management of severe alcoholic hepatitis with prednisolone plus SAMe was associated with better therapy response (p = 0.044) and less frequent HRS occurrence (p = 0.035).', 'subject score': 1000, 'object score': 901}, 'PMID:28043903': {'publication date': '2017 04', 'sentence': 'Development of infection was associated with increased 90-day mortality in patients with SAH treated with prednisolone, independent of model for end-stage liver disease or Lille score (OR, 2.46; 95% CI, 1.41-4.30; P = .002).', 'subject score': 1000, 'object score': 901}, 'PMID:29113530': {'publication date': '2018 05', 'sentence': 'Thus, metabolic liver failure in AH seems to be prognostically important, is potentially reversible, and may recover more rapidly following treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:2954078': {'publication date': '1987 May 02', 'sentence': 'Whether or not prednisolone (or prednisone) should be used to treat alcoholic hepatitis remains controversial.', 'subject score': 888, 'object score': 1000}, 'PMID:29663389': {'publication date': '2018 Mar', 'sentence': 'We assessed serum cholesterol, cholesterol precursors, cholestanol, phytosterols, and biochemical markers in 24 patients with severe AH treated with prednisolone and randomized to ciprofloxacin in the ratio 1:1.', 'subject score': 1000, 'object score': 901}, 'PMID:29753761': {'publication date': '2018 Aug', 'sentence': 'He was diagnosed with severe alcoholic hepatitis (Maddrey discriminant function score of 50) and treated with prednisolone for 28 days with symptomatic and biochemical improvement.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0019187---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0001306---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8573433",
-              "object": "MONDO:0001505",
-              "publications": [
-                "PMID:36051363",
-                "PMID:28043903",
-                "PMID:8964410",
-                "PMID:35042254",
-                "PMID:19340904",
-                "PMID:2954078",
-                "PMID:26176387",
-                "PMID:36278756",
-                "PMID:29663389",
-                "PMID:26176389",
-                "PMID:14647046",
-                "PMID:15864177",
-                "PMID:24845609",
-                "PMID:26691209",
-                "PMID:24026598",
-                "PMID:6390194",
-                "PMID:26948886",
-                "PMID:27337960",
-                "PMID:1531090",
-                "PMID:37159035"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:33028767': {'publication date': '2020 Oct 07', 'sentence': 'Regression of Lung Squamous Cell Carcinoma after the Withdrawal of Cyclosporin A Combined With Pirfenidone Treatment in a Patient with Idiopathic Pulmonary Fibrosis.A 72-year-old man was treated with prednisolone and cyclosporine A for idiopathic pulmonary fibrosis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316306,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0800029",
-          "name": "interstitial lung disease 2",
-          "description": "Interstitial pneumonia characterized by the presence of fibrosis in the interstitial lung tissue. The pathologic diagnosis is based on the identification of fibrotic lesions at different stages of development within a lung biopsy specimen. Typically there are foci of normal lung parenchyma alternating with interstitial inflammation and honeycombing. The term usual interstitial pneumonia sometimes is used interchangeably with idiopathic interstitial fibrosis. The two terms are not entirely synonymous. Usual interstitial pneumonia may be associated with other conditions such as connective tissue disorders and asbestosis. The diagnosis of idiopathic interstitial fibrosis requires the exclusion of such conditions. Patients with usual interstitial pneumonia present with progressive dyspnea, cough, and restrictive pulmonary function abnormalities. The prognosis is usually poor.; A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.; Temporal and spatial heterogeneity in lungs based on presence of fibrosis and honeycombing. [PMID:26666486, PMID:8697837]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:2032",
-            "MEDDRA:10001892",
-            "MEDDRA:10016641",
-            "NCIT:C35715",
-            "UMLS:C4721952",
-            "ICD9:516.31",
-            "UMLS:C1800706",
-            "UMLS:C5561926",
-            "SNOMEDCT:196125002",
-            "NCIT:C35716",
-            "MEDDRA:10011495",
-            "HP:0031950",
-            "MESH:D054990",
-            "OMIM:178500",
-            "UMLS:C4721508",
-            "MEDDRA:10021240",
-            "MEDDRA:10016640",
-            "SNOMEDCT:700250006",
-            "UMLS:C4721509",
-            "MONDO:0800029",
-            "SNOMEDCT:426437004",
-            "ICD10:J84.112",
-            "DOID:0050156",
-            "EFO:0000768"
-          ],
-          "id": "MONDO:0800029",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Familial Idiopathic Pulmonary Fibrosis",
-            "Idiopathic pulmonary fibrosis",
-            "Interstitial lung disease 2 related phenotypic feature",
-            "Interstitial lung disease 2",
-            "idiopathic pulmonary fibrosis",
-            "interstitial lung disease 2",
-            "Idiopathic Pulmonary Fibrosis",
-            "Hamman-Rich Disease",
-            "Usual Interstitial Pneumonia",
-            "Usual interstitial pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:26666486",
-            "https://www.pulmonaryfibrosis.org/life-with-pf/about-ipf",
-            "https://orcid.org/0000-0001-5208-3432",
-            "PMID:8697837"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316306,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0800029",
-              "name": "interstitial lung disease 2",
-              "description": "Interstitial pneumonia characterized by the presence of fibrosis in the interstitial lung tissue. The pathologic diagnosis is based on the identification of fibrotic lesions at different stages of development within a lung biopsy specimen. Typically there are foci of normal lung parenchyma alternating with interstitial inflammation and honeycombing. The term usual interstitial pneumonia sometimes is used interchangeably with idiopathic interstitial fibrosis. The two terms are not entirely synonymous. Usual interstitial pneumonia may be associated with other conditions such as connective tissue disorders and asbestosis. The diagnosis of idiopathic interstitial fibrosis requires the exclusion of such conditions. Patients with usual interstitial pneumonia present with progressive dyspnea, cough, and restrictive pulmonary function abnormalities. The prognosis is usually poor.; A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.; Temporal and spatial heterogeneity in lungs based on presence of fibrosis and honeycombing. [PMID:26666486, PMID:8697837]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:2032",
-                "MEDDRA:10001892",
-                "MEDDRA:10016641",
-                "NCIT:C35715",
-                "UMLS:C4721952",
-                "ICD9:516.31",
-                "UMLS:C1800706",
-                "UMLS:C5561926",
-                "SNOMEDCT:196125002",
-                "NCIT:C35716",
-                "MEDDRA:10011495",
-                "HP:0031950",
-                "MESH:D054990",
-                "OMIM:178500",
-                "UMLS:C4721508",
-                "MEDDRA:10021240",
-                "MEDDRA:10016640",
-                "SNOMEDCT:700250006",
-                "UMLS:C4721509",
-                "MONDO:0800029",
-                "SNOMEDCT:426437004",
-                "ICD10:J84.112",
-                "DOID:0050156",
-                "EFO:0000768"
-              ],
-              "id": "MONDO:0800029",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Familial Idiopathic Pulmonary Fibrosis",
-                "Idiopathic pulmonary fibrosis",
-                "Interstitial lung disease 2 related phenotypic feature",
-                "Interstitial lung disease 2",
-                "idiopathic pulmonary fibrosis",
-                "interstitial lung disease 2",
-                "Idiopathic Pulmonary Fibrosis",
-                "Hamman-Rich Disease",
-                "Usual Interstitial Pneumonia",
-                "Usual interstitial pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:26666486",
-                "https://www.pulmonaryfibrosis.org/life-with-pf/about-ipf",
-                "https://orcid.org/0000-0001-5208-3432",
-                "PMID:8697837"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22155421,
-            "start": 568,
-            "end": 316306,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:33028767': {'publication date': '2020 Oct 07', 'sentence': 'Regression of Lung Squamous Cell Carcinoma after the Withdrawal of Cyclosporin A Combined With Pirfenidone Treatment in a Patient with Idiopathic Pulmonary Fibrosis.A 72-year-old man was treated with prednisolone and cyclosporine A for idiopathic pulmonary fibrosis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C1800706---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "22580782",
-              "object": "MONDO:0800029",
-              "publications": [
-                "PMID:33028767"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:17634717': {'publication date': '2007', 'sentence': 'This is the first case to support the beneficial effect of prednisolone in pericarditis with pSS, and illustrates its safety during pregnancy.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317106,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005904",
-          "name": "pericarditis",
-          "description": "An inflammatory process affecting the pericardium.; Inflammation of both the PERICARDIUM and the PLEURA.; Inflammation of the sac-like covering around the heart (pericardium). [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:1787",
-            "MEDDRA:10034484",
-            "ORPHANET:58208",
-            "HP:0001701",
-            "MESH:D010493",
-            "UMLS:C0031046",
-            "MEDDRA:10034495",
-            "NCIT:C34915",
-            "SNOMEDCT:3238004",
-            "EFO:0007427",
-            "MONDO:0005904"
-          ],
-          "id": "MONDO:0005904",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pericarditis",
-            "pericarditis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/wiki/pericarditis",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317106,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005904",
-              "name": "pericarditis",
-              "description": "An inflammatory process affecting the pericardium.; Inflammation of both the PERICARDIUM and the PLEURA.; Inflammation of the sac-like covering around the heart (pericardium). [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:1787",
-                "MEDDRA:10034484",
-                "ORPHANET:58208",
-                "HP:0001701",
-                "MESH:D010493",
-                "UMLS:C0031046",
-                "MEDDRA:10034495",
-                "NCIT:C34915",
-                "SNOMEDCT:3238004",
-                "EFO:0007427",
-                "MONDO:0005904"
-              ],
-              "id": "MONDO:0005904",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pericarditis",
-                "pericarditis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/wiki/pericarditis",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12954798,
-            "start": 568,
-            "end": 317106,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17634717': {'publication date': '2007', 'sentence': 'This is the first case to support the beneficial effect of prednisolone in pericarditis with pSS, and illustrates its safety during pregnancy.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0031046---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "13234063",
-              "object": "MONDO:0005904",
-              "publications": [
-                "PMID:17634717"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:21161021': {'publication date': '2010 Sep 27', 'sentence': 'Treatment with prednisolone improved the pericarditis and motor nerve disturbance and the treatment with intravenous immunoglobulin improved the sensory nerve disturbance.', 'subject score': 1000, 'object score': 1000}, 'PMID:35283383': {'publication date': '2022 Mar 12', 'sentence': 'We herein report a case of systemic sclerosis (SSc)-related pericarditis successfully treated with mycophenolate mofetil (MMF) and low-dose prednisolone (PSL).', 'subject score': 901, 'object score': 861}, 'PMID:35927545': {'publication date': '2022 Aug 04', 'sentence': 'Treatment with anti-inflammatory medications and prednisolone resolved the pericarditis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317106,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005904",
-          "name": "pericarditis",
-          "description": "An inflammatory process affecting the pericardium.; Inflammation of both the PERICARDIUM and the PLEURA.; Inflammation of the sac-like covering around the heart (pericardium). [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:1787",
-            "MEDDRA:10034484",
-            "ORPHANET:58208",
-            "HP:0001701",
-            "MESH:D010493",
-            "UMLS:C0031046",
-            "MEDDRA:10034495",
-            "NCIT:C34915",
-            "SNOMEDCT:3238004",
-            "EFO:0007427",
-            "MONDO:0005904"
-          ],
-          "id": "MONDO:0005904",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pericarditis",
-            "pericarditis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/wiki/pericarditis",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317106,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005904",
-              "name": "pericarditis",
-              "description": "An inflammatory process affecting the pericardium.; Inflammation of both the PERICARDIUM and the PLEURA.; Inflammation of the sac-like covering around the heart (pericardium). [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:1787",
-                "MEDDRA:10034484",
-                "ORPHANET:58208",
-                "HP:0001701",
-                "MESH:D010493",
-                "UMLS:C0031046",
-                "MEDDRA:10034495",
-                "NCIT:C34915",
-                "SNOMEDCT:3238004",
-                "EFO:0007427",
-                "MONDO:0005904"
-              ],
-              "id": "MONDO:0005904",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pericarditis",
-                "pericarditis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/wiki/pericarditis",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15044546,
-            "start": 568,
-            "end": 317106,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21161021': {'publication date': '2010 Sep 27', 'sentence': 'Treatment with prednisolone improved the pericarditis and motor nerve disturbance and the treatment with intravenous immunoglobulin improved the sensory nerve disturbance.', 'subject score': 1000, 'object score': 1000}, 'PMID:35283383': {'publication date': '2022 Mar 12', 'sentence': 'We herein report a case of systemic sclerosis (SSc)-related pericarditis successfully treated with mycophenolate mofetil (MMF) and low-dose prednisolone (PSL).', 'subject score': 901, 'object score': 861}, 'PMID:35927545': {'publication date': '2022 Aug 04', 'sentence': 'Treatment with anti-inflammatory medications and prednisolone resolved the pericarditis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0031046---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "15369817",
-              "object": "MONDO:0005904",
-              "publications": [
-                "PMID:21161021",
-                "PMID:35283383",
-                "PMID:35927545"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10481465': {'publication date': '1999 Jul', 'sentence': 'Treatment with extracorporeal shock wave lithotripsy, transurethral lithotomy, saline infusion, and prednisolone (30 mg/day) alleviated the urolithiasis, renal insufficiency, and hypercalcemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:11488718': {'publication date': '2001 Aug', 'sentence': 'Asymptomatic hypercalcaemia was noted on periodic testing at 7 weeks and treated by rehydration, diuretics, prednisolone, etidronate and a low-calcium and -vitamin D diet.', 'subject score': 1000, 'object score': 888}, 'PMID:16573764': {'publication date': '2006 Apr', 'sentence': 'The clinical signs, hypercalcaemia and elevated serum concentrations of 1,25 dihydroxyvitamin D resolved following prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:2534486': {'publication date': '1989 Nov-Dec', 'sentence': 'Medical therapy with normal saline, furosemide, indomethacin, prednisolone, and calcitonin failed to ameliorate hypercalcemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:26597827': {'publication date': '2017 Jan', 'sentence': 'Prednisolone treatment improved the hypercalcemia and decreased the levels of 1,25(OH)2D and IL-6.', 'subject score': 888, 'object score': 1000}, 'PMID:28976049': {'publication date': '2018 Jun', 'sentence': 'The patients discussed experienced a significant and rapid improvement in both renal function and hypercalcaemia in response to therapy with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:30396880': {'publication date': '2018 Nov 05', 'sentence': 'Prednisolone is less effective in the treatment of children with severe hypercalcaemia secondary to vitamin D intoxication and timely implementation of other treatment regimens would be considered.', 'subject score': 1000, 'object score': 888}, 'PMID:6361747': {'publication date': '1983', 'sentence': 'Hypercalcaemia due to overdosage with vitamin D2 during simultaneous prednisolone therapy was usually mild and returned to normal in a few days by dose reduction.', 'subject score': 851, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316662,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001566",
-          "name": "hypercalcemia disease",
-          "description": "An abnormally increased calcium concentration in the blood. [HPO:curators]; An abnormally increased calcium concentration in the blood.; An abnormally increased calcium concentration in the blood.; An abnormally increased calcium concentration in the blood.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0001566",
-            "MEDDRA:10020583",
-            "MEDDRA:10020587",
-            "NCIT:C3112",
-            "MESH:D006934",
-            "MEDDRA:10006952",
-            "ICD10:E83.52",
-            "DOID:12678",
-            "MEDDRA:10005396",
-            "SNOMEDCT:166702002",
-            "SNOMEDCT:66931009",
-            "PDQ:CDR0000662921",
-            "ICD9:275.42",
-            "UMLS:C0020437",
-            "HP:0003072"
-          ],
-          "id": "MONDO:0001566",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hypercalcemia",
-            "hypercalcemia",
-            "hypercalcemia disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316662,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001566",
-              "name": "hypercalcemia disease",
-              "description": "An abnormally increased calcium concentration in the blood. [HPO:curators]; An abnormally increased calcium concentration in the blood.; An abnormally increased calcium concentration in the blood.; An abnormally increased calcium concentration in the blood.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0001566",
-                "MEDDRA:10020583",
-                "MEDDRA:10020587",
-                "NCIT:C3112",
-                "MESH:D006934",
-                "MEDDRA:10006952",
-                "ICD10:E83.52",
-                "DOID:12678",
-                "MEDDRA:10005396",
-                "SNOMEDCT:166702002",
-                "SNOMEDCT:66931009",
-                "PDQ:CDR0000662921",
-                "ICD9:275.42",
-                "UMLS:C0020437",
-                "HP:0003072"
-              ],
-              "id": "MONDO:0001566",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hypercalcemia",
-                "hypercalcemia",
-                "hypercalcemia disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7509645,
-            "start": 568,
-            "end": 316662,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10481465': {'publication date': '1999 Jul', 'sentence': 'Treatment with extracorporeal shock wave lithotripsy, transurethral lithotomy, saline infusion, and prednisolone (30 mg/day) alleviated the urolithiasis, renal insufficiency, and hypercalcemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:11488718': {'publication date': '2001 Aug', 'sentence': 'Asymptomatic hypercalcaemia was noted on periodic testing at 7 weeks and treated by rehydration, diuretics, prednisolone, etidronate and a low-calcium and -vitamin D diet.', 'subject score': 1000, 'object score': 888}, 'PMID:16573764': {'publication date': '2006 Apr', 'sentence': 'The clinical signs, hypercalcaemia and elevated serum concentrations of 1,25 dihydroxyvitamin D resolved following prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:2534486': {'publication date': '1989 Nov-Dec', 'sentence': 'Medical therapy with normal saline, furosemide, indomethacin, prednisolone, and calcitonin failed to ameliorate hypercalcemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:26597827': {'publication date': '2017 Jan', 'sentence': 'Prednisolone treatment improved the hypercalcemia and decreased the levels of 1,25(OH)2D and IL-6.', 'subject score': 888, 'object score': 1000}, 'PMID:28976049': {'publication date': '2018 Jun', 'sentence': 'The patients discussed experienced a significant and rapid improvement in both renal function and hypercalcaemia in response to therapy with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:30396880': {'publication date': '2018 Nov 05', 'sentence': 'Prednisolone is less effective in the treatment of children with severe hypercalcaemia secondary to vitamin D intoxication and timely implementation of other treatment regimens would be considered.', 'subject score': 1000, 'object score': 888}, 'PMID:6361747': {'publication date': '1983', 'sentence': 'Hypercalcaemia due to overdosage with vitamin D2 during simultaneous prednisolone therapy was usually mild and returned to normal in a few days by dose reduction.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0020437---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7676165",
-              "object": "MONDO:0001566",
-              "publications": [
-                "PMID:10481465",
-                "PMID:11488718",
-                "PMID:16573764",
-                "PMID:2534486",
-                "PMID:26597827",
-                "PMID:28976049",
-                "PMID:30396880",
-                "PMID:6361747"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:11752031': {'publication date': '2002 Jan', 'sentence': 'Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy.', 'subject score': 1000, 'object score': 901}, 'PMID:12616032': {'publication date': '2003', 'sentence': 'Prednisolone and azathioprine in IgA nephropathy - a ten-year follow-up study.', 'subject score': 1000, 'object score': 1000}, 'PMID:23756850': {'publication date': '2014 Jan', 'sentence': 'Comparison of prednisolone and lamivudine combined therapy with prednisolone monotherapy on carriers of hepatitis B virus with IgA nephropathy: a prospective cohort study.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 311688,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005342",
-          "name": "IgA glomerulonephritis",
-          "description": "Inflammation of a specific segment of glomeruli within the kidney.; A chronic autoimmune glomerulonephritis characterized by the deposition of immunoglobulin A in the mesangium of the glomeruli. It is manifested with hematuria and mild proteinuria.; A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.; The presence of immunoglobulin A deposits in the glomerulus. [Eurenomics:ewuehl]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C34643",
-            "OMIM.PS:161950",
-            "MEDDRA:10018369",
-            "NCIT:C35280",
-            "UMLS:C0017661",
-            "MESH:D005922",
-            "EFO:0004194",
-            "UMLS:C3161650",
-            "SNOMEDCT:68779003",
-            "HP:0000794",
-            "DOID:2986",
-            "SNOMEDCT:236407003",
-            "MEDDRA:10069341",
-            "ORPHANET:34145",
-            "UMLS:C4025827",
-            "MONDO:0005342",
-            "MEDDRA:10021263"
-          ],
-          "id": "MONDO:0005342",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Glomerulonephritis, IGA",
-            "IGA Glomerulonephritis",
-            "IGA glomerulonephritis",
-            "IgA glomerulonephritis",
-            "IgA Nephropathy",
-            "Primary immunoglobulin A nephropathy (disorder)",
-            "IgA deposition in the glomerulus",
-            "Focal Glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000466.htm",
-            "http://en.wikipedia.org/wiki/iga_nephropathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311688,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005342",
-              "name": "IgA glomerulonephritis",
-              "description": "Inflammation of a specific segment of glomeruli within the kidney.; A chronic autoimmune glomerulonephritis characterized by the deposition of immunoglobulin A in the mesangium of the glomeruli. It is manifested with hematuria and mild proteinuria.; A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.; The presence of immunoglobulin A deposits in the glomerulus. [Eurenomics:ewuehl]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C34643",
-                "OMIM.PS:161950",
-                "MEDDRA:10018369",
-                "NCIT:C35280",
-                "UMLS:C0017661",
-                "MESH:D005922",
-                "EFO:0004194",
-                "UMLS:C3161650",
-                "SNOMEDCT:68779003",
-                "HP:0000794",
-                "DOID:2986",
-                "SNOMEDCT:236407003",
-                "MEDDRA:10069341",
-                "ORPHANET:34145",
-                "UMLS:C4025827",
-                "MONDO:0005342",
-                "MEDDRA:10021263"
-              ],
-              "id": "MONDO:0005342",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Glomerulonephritis, IGA",
-                "IGA Glomerulonephritis",
-                "IGA glomerulonephritis",
-                "IgA glomerulonephritis",
-                "IgA Nephropathy",
-                "Primary immunoglobulin A nephropathy (disorder)",
-                "IgA deposition in the glomerulus",
-                "Focal Glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000466.htm",
-                "http://en.wikipedia.org/wiki/iga_nephropathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9082671,
-            "start": 568,
-            "end": 311688,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11752031': {'publication date': '2002 Jan', 'sentence': 'Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy.', 'subject score': 1000, 'object score': 901}, 'PMID:12616032': {'publication date': '2003', 'sentence': 'Prednisolone and azathioprine in IgA nephropathy - a ten-year follow-up study.', 'subject score': 1000, 'object score': 1000}, 'PMID:23756850': {'publication date': '2014 Jan', 'sentence': 'Comparison of prednisolone and lamivudine combined therapy with prednisolone monotherapy on carriers of hepatitis B virus with IgA nephropathy: a prospective cohort study.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0017661---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9282196",
-              "object": "MONDO:0005342",
-              "publications": [
-                "PMID:11752031",
-                "PMID:12616032",
-                "PMID:23756850"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10344344': {'publication date': '1999 May', 'sentence': 'Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy--is it relevant for adult patients?', 'subject score': 1000, 'object score': 901}, 'PMID:15571177': {'publication date': '2004 Nov', 'sentence': 'Ten of the 30 children with IgAN were treated with combination therapy comprising prednisolone, warfarin and dipyridamole and urine samples were collected weekly during the period of treatment.', 'subject score': 824, 'object score': 1000}, 'PMID:17699253': {'publication date': '2006 May', 'sentence': 'It is concluded that combination treatment may be better for severe IgAN than treatment with prednisolone alone.', 'subject score': 1000, 'object score': 901}, 'PMID:18085391': {'publication date': '2007 Dec', 'sentence': 'Histologically advanced IgA nephropathy treated successfully with prednisolone and cyclophosphamide.', 'subject score': 1000, 'object score': 824}, 'PMID:18324350': {'publication date': '2008 Aug', 'sentence': 'Long-term follow-up of patients with IgA nephropathy treated with prednisolone and cyclophosphamide therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:19398873': {'publication date': '2009 May', 'sentence': 'We collected data on 25 IgAN children who had been treated with prednisolone and divided these patients into two groups: Favorable group, consisting of 11 patients with normal urine and 6 with minor urinary abnormalities at 4.3 +/- 1.3 years after initial treatment; and Unfavorable group, consisting of 8 patients with persistent nephropathy.', 'subject score': 1000, 'object score': 824}, 'PMID:19418967': {'publication date': '2008 Dec', 'sentence': 'As to the treatment of IgAN, we evaluated the efficacy of tonsillectomy plus prednisolone, warfarin, and dipyridamole including methylprednisolone pulse therapy (tonsillectomy plus pulse therapy) and prednisolone, warfarin, and dipyridamole including mizoribine (PWDM) for the treatment of diffuse IgAN in children.', 'subject score': 851, 'object score': 1000}, 'PMID:19901893': {'publication date': '2009 Oct', 'sentence': 'He had been treated with prednisolone for IgA nephropathy and undergone surgical closure of an isolated ventricular septal defect (VSD).', 'subject score': 1000, 'object score': 1000}, 'PMID:19918307': {'publication date': '2009 Jul', 'sentence': 'A case of crescentic IgA nephropathy treated with prednisolone and cyclophosphamide.', 'subject score': 1000, 'object score': 865}, 'PMID:27714465': {'publication date': '2017 03', 'sentence': 'Twenty children with NS-IgAN were treated with prednisolone alone, or prednisolone and immunosuppressant.', 'subject score': 1000, 'object score': 888}, 'PMID:29520517': {'publication date': '2018 Oct', 'sentence': 'Initial treatment with pulse methylprednisolone followed by short-term prednisolone and tonsillectomy for childhood IgA nephropathy.', 'subject score': 901, 'object score': 901}, 'PMID:31033860': {'publication date': '2019 08', 'sentence': 'Is Dose Adjustment of Prednisolone Required in Patients With IgA Nephropathy During Rifampicin Treatment for Mycobacterium avium Complex Lung Disease?', 'subject score': 1000, 'object score': 1000}, 'PMID:31993782': {'publication date': '2020 Jan 28', 'sentence': 'The 16 children with C-IgAN were treated with prednisolone and immunosuppressant.', 'subject score': 1000, 'object score': 865}, 'PMID:35119558': {'publication date': '2022 Feb 04', 'sentence': 'For severe IgA nephropathy, in particular, multidrug therapy with prednisolone, immunosuppressants, and angiotensin enzyme synthesis inhibitors and tonsillectomy methylprednisolone pulse therapy are now performed- and, as a result, the number of renal deaths has decreased and the long-term prognosis has improved.', 'subject score': 1000, 'object score': 901}, 'PMID:36357635': {'publication date': '2022 Nov 10', 'sentence': 'METHODS: A retrospective cohort of 90 children with IgAN were divided into groups treated with prednisolone (PSL) alone (P group; n = 42) or PSL plus Miz (PM group; n = 48) for a 2-year period.', 'subject score': 1000, 'object score': 1000}, 'PMID:9890315': {'publication date': '1999 Jan', 'sentence': 'In conclusion, the present study shows that treatment of children with severe IgA nephropathy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for 2 yr early in the course of disease reduces immunologic renal injury and prevents increase of sclerosed glomeruli.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 311688,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005342",
-          "name": "IgA glomerulonephritis",
-          "description": "Inflammation of a specific segment of glomeruli within the kidney.; A chronic autoimmune glomerulonephritis characterized by the deposition of immunoglobulin A in the mesangium of the glomeruli. It is manifested with hematuria and mild proteinuria.; A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.; The presence of immunoglobulin A deposits in the glomerulus. [Eurenomics:ewuehl]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C34643",
-            "OMIM.PS:161950",
-            "MEDDRA:10018369",
-            "NCIT:C35280",
-            "UMLS:C0017661",
-            "MESH:D005922",
-            "EFO:0004194",
-            "UMLS:C3161650",
-            "SNOMEDCT:68779003",
-            "HP:0000794",
-            "DOID:2986",
-            "SNOMEDCT:236407003",
-            "MEDDRA:10069341",
-            "ORPHANET:34145",
-            "UMLS:C4025827",
-            "MONDO:0005342",
-            "MEDDRA:10021263"
-          ],
-          "id": "MONDO:0005342",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Glomerulonephritis, IGA",
-            "IGA Glomerulonephritis",
-            "IGA glomerulonephritis",
-            "IgA glomerulonephritis",
-            "IgA Nephropathy",
-            "Primary immunoglobulin A nephropathy (disorder)",
-            "IgA deposition in the glomerulus",
-            "Focal Glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000466.htm",
-            "http://en.wikipedia.org/wiki/iga_nephropathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311688,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005342",
-              "name": "IgA glomerulonephritis",
-              "description": "Inflammation of a specific segment of glomeruli within the kidney.; A chronic autoimmune glomerulonephritis characterized by the deposition of immunoglobulin A in the mesangium of the glomeruli. It is manifested with hematuria and mild proteinuria.; A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.; The presence of immunoglobulin A deposits in the glomerulus. [Eurenomics:ewuehl]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C34643",
-                "OMIM.PS:161950",
-                "MEDDRA:10018369",
-                "NCIT:C35280",
-                "UMLS:C0017661",
-                "MESH:D005922",
-                "EFO:0004194",
-                "UMLS:C3161650",
-                "SNOMEDCT:68779003",
-                "HP:0000794",
-                "DOID:2986",
-                "SNOMEDCT:236407003",
-                "MEDDRA:10069341",
-                "ORPHANET:34145",
-                "UMLS:C4025827",
-                "MONDO:0005342",
-                "MEDDRA:10021263"
-              ],
-              "id": "MONDO:0005342",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Glomerulonephritis, IGA",
-                "IGA Glomerulonephritis",
-                "IGA glomerulonephritis",
-                "IgA glomerulonephritis",
-                "IgA Nephropathy",
-                "Primary immunoglobulin A nephropathy (disorder)",
-                "IgA deposition in the glomerulus",
-                "Focal Glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000466.htm",
-                "http://en.wikipedia.org/wiki/iga_nephropathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7269347,
-            "start": 568,
-            "end": 311688,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10344344': {'publication date': '1999 May', 'sentence': 'Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy--is it relevant for adult patients?', 'subject score': 1000, 'object score': 901}, 'PMID:15571177': {'publication date': '2004 Nov', 'sentence': 'Ten of the 30 children with IgAN were treated with combination therapy comprising prednisolone, warfarin and dipyridamole and urine samples were collected weekly during the period of treatment.', 'subject score': 824, 'object score': 1000}, 'PMID:17699253': {'publication date': '2006 May', 'sentence': 'It is concluded that combination treatment may be better for severe IgAN than treatment with prednisolone alone.', 'subject score': 1000, 'object score': 901}, 'PMID:18085391': {'publication date': '2007 Dec', 'sentence': 'Histologically advanced IgA nephropathy treated successfully with prednisolone and cyclophosphamide.', 'subject score': 1000, 'object score': 824}, 'PMID:18324350': {'publication date': '2008 Aug', 'sentence': 'Long-term follow-up of patients with IgA nephropathy treated with prednisolone and cyclophosphamide therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:19398873': {'publication date': '2009 May', 'sentence': 'We collected data on 25 IgAN children who had been treated with prednisolone and divided these patients into two groups: Favorable group, consisting of 11 patients with normal urine and 6 with minor urinary abnormalities at 4.3 +/- 1.3 years after initial treatment; and Unfavorable group, consisting of 8 patients with persistent nephropathy.', 'subject score': 1000, 'object score': 824}, 'PMID:19418967': {'publication date': '2008 Dec', 'sentence': 'As to the treatment of IgAN, we evaluated the efficacy of tonsillectomy plus prednisolone, warfarin, and dipyridamole including methylprednisolone pulse therapy (tonsillectomy plus pulse therapy) and prednisolone, warfarin, and dipyridamole including mizoribine (PWDM) for the treatment of diffuse IgAN in children.', 'subject score': 851, 'object score': 1000}, 'PMID:19901893': {'publication date': '2009 Oct', 'sentence': 'He had been treated with prednisolone for IgA nephropathy and undergone surgical closure of an isolated ventricular septal defect (VSD).', 'subject score': 1000, 'object score': 1000}, 'PMID:19918307': {'publication date': '2009 Jul', 'sentence': 'A case of crescentic IgA nephropathy treated with prednisolone and cyclophosphamide.', 'subject score': 1000, 'object score': 865}, 'PMID:27714465': {'publication date': '2017 03', 'sentence': 'Twenty children with NS-IgAN were treated with prednisolone alone, or prednisolone and immunosuppressant.', 'subject score': 1000, 'object score': 888}, 'PMID:29520517': {'publication date': '2018 Oct', 'sentence': 'Initial treatment with pulse methylprednisolone followed by short-term prednisolone and tonsillectomy for childhood IgA nephropathy.', 'subject score': 901, 'object score': 901}, 'PMID:31033860': {'publication date': '2019 08', 'sentence': 'Is Dose Adjustment of Prednisolone Required in Patients With IgA Nephropathy During Rifampicin Treatment for Mycobacterium avium Complex Lung Disease?', 'subject score': 1000, 'object score': 1000}, 'PMID:31993782': {'publication date': '2020 Jan 28', 'sentence': 'The 16 children with C-IgAN were treated with prednisolone and immunosuppressant.', 'subject score': 1000, 'object score': 865}, 'PMID:35119558': {'publication date': '2022 Feb 04', 'sentence': 'For severe IgA nephropathy, in particular, multidrug therapy with prednisolone, immunosuppressants, and angiotensin enzyme synthesis inhibitors and tonsillectomy methylprednisolone pulse therapy are now performed- and, as a result, the number of renal deaths has decreased and the long-term prognosis has improved.', 'subject score': 1000, 'object score': 901}, 'PMID:36357635': {'publication date': '2022 Nov 10', 'sentence': 'METHODS: A retrospective cohort of 90 children with IgAN were divided into groups treated with prednisolone (PSL) alone (P group; n = 42) or PSL plus Miz (PM group; n = 48) for a 2-year period.', 'subject score': 1000, 'object score': 1000}, 'PMID:9890315': {'publication date': '1999 Jan', 'sentence': 'In conclusion, the present study shows that treatment of children with severe IgA nephropathy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for 2 yr early in the course of disease reduces immunologic renal injury and prevents increase of sclerosed glomeruli.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0017661---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7417999",
-              "object": "MONDO:0005342",
-              "publications": [
-                "PMID:10344344",
-                "PMID:15571177",
-                "PMID:17699253",
-                "PMID:18085391",
-                "PMID:18324350",
-                "PMID:19398873",
-                "PMID:19418967",
-                "PMID:19901893",
-                "PMID:19918307",
-                "PMID:27714465",
-                "PMID:29520517",
-                "PMID:31033860",
-                "PMID:31993782",
-                "PMID:35119558",
-                "PMID:36357635",
-                "PMID:9890315"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10863327': {'publication date': '2000 Apr', 'sentence': 'Three out of 8 patients with thrombocytopenia were treated with prednisolone according to the protocol for idiopathic thrombocytopenic purpura.', 'subject score': 1000, 'object score': 1000}, 'PMID:11235133': {'publication date': '2001 Jan', 'sentence': \"After amelioration of the thrombocytopenia by prednisolone therapy, open renal biopsy was performed and a diagnosis of diffuse large B-cell non-Hodgkin's lymphoma was made.\", 'subject score': 888, 'object score': 1000}, 'PMID:12613003': {'publication date': '2003 Mar', 'sentence': 'Although renal dysfunction progressed to dialysis-dependent renal failure in one patient despite treatment with prednisolone and plasmapheresis but not in other, withdrawal of the treatment resulted in a prompt resolution of thrombocytopenia and microangiopathic hemolytic anemia in both patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:14211529': {'publication date': '1964', 'sentence': '[LEUKEMIC RETICULO-SARCOMATOSIS FOLLOWING METHYLTESTOSTERONE AND PREDNISOLONE TREATED PANMYELOPATHY AND THROMBOCYTOPENIA].', 'subject score': 1000, 'object score': 1000}, 'PMID:17329922': {'publication date': '2007', 'sentence': 'High-dose prednisolone therapy improved the hemolytic anemia and thrombocytopenia, but not the CD16(+) CD56(-) NK lymphocytosis completely.', 'subject score': 861, 'object score': 1000}, 'PMID:21372465': {'publication date': '2011', 'sentence': 'After treatment with prednisolone and fresh frozen plasma, ADAMTS-13 activity was normalized, the ADAMTS-13 inhibitor had disappeared and the thrombocytopenia with a bleeding tendency was improved.', 'subject score': 1000, 'object score': 1000}, 'PMID:21772119': {'publication date': '2011 Jul', 'sentence': 'Immune pathogenesis was suspected since platelet-associated immunoglobulin G (PAIGg) was increased and the administration of prednisolone (PSL) quickly ameliorated the thrombocytopenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:2243038': {'publication date': '1990 Oct 15', 'sentence': 'Prednisolone and danazol for treatment of immune-mediated anemia, thrombocytopenia, and ineffective erythroid regeneration in a dog.', 'subject score': 1000, 'object score': 1000}, 'PMID:2381060': {'publication date': '1990 Apr', 'sentence': 'The treatment with prednisolone resulted in a decrease in the severity of the lymphadenopathy, thrombocytopenia and polyclonal hypergammopathy.', 'subject score': 1000, 'object score': 1000}, 'PMID:2390633': {'publication date': '1990 Jul', 'sentence': 'On day 556 post-graft severe thrombocytopenia was resistant to prednisolone, cyclophosphamide and high dose immunoglobulin.', 'subject score': 1000, 'object score': 888}, 'PMID:26387855': {'publication date': '2015 Oct', 'sentence': 'Thrombocytopenia took a chronic course and platelet count fluctuated in the range 18 000-46 000/MUL, not responding to i.v. immunoglobulin or prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:26664400': {'publication date': '2015', 'sentence': 'The patient had a normal bone marrow aspiration and biopsy, the thrombocytopenia was resistant to platelet transfusion which successfully was treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:28535135': {'publication date': '2017 Jul/Aug', 'sentence': 'A second episode of thrombocytopenia (day +51) was managed with vincristine, prednisolone, and melatonin.', 'subject score': 1000, 'object score': 1000}, 'PMID:30567252': {'publication date': '2018 Dec 13', 'sentence': 'The patient subsequently developed pulmonary cysts and thrombocytopaenia due to autoimmune pathology and was successfully treated using prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:3184476': {'publication date': '1988 Jul', 'sentence': '[Normalization of platelet count following prednisolone and splenectomy in a patient with splenic hamartoma and thrombocytopenia].', 'subject score': 1000, 'object score': 1000}, 'PMID:31866622': {'publication date': '2019', 'sentence': 'The thrombocytopenia and neutropenia were successfully treated by prednisolone and romiplostim with negative conversion of antineutrophil antibody.', 'subject score': 1000, 'object score': 1000}, 'PMID:32258416': {'publication date': '2020', 'sentence': 'Streptococcus Pneumoniae    -associated Thrombotic Microangiopathy in an Immunosuppressed Adult.A 62-year-old male who was receiving prednisolone and methotrexate for scleroderma and rheumatoid arthritis complained of diarrhea and vomiting, and was transferred to our hospital for detailed examination and treatment of renal dysfunction and thrombocytopenia.', 'subject score': 888, 'object score': 1000}, 'PMID:3441913': {'publication date': '1987', 'sentence': 'The striking recurrent thrombocytopenia was successfully treated with prednisolone.', 'subject score': 1000, 'object score': 790}, 'PMID:35700350': {'publication date': '2022 Jun 07', 'sentence': 'We describe a case of infantile MLT that did not respond to treatment with propranolol, prednisolone, or vincristine.', 'subject score': 1000, 'object score': 753}, 'PMID:37123554': {'publication date': '2023 Jan-Jun', 'sentence': 'Case summary: A 3-year-old neutered domestic shorthair cat with a long history of idiopathic immune-mediated haemolytic anaemia and thrombocytopenia treated with ciclosporin and prednisolone was referred 2 months after the appearance of nodular dermatitis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002049",
-          "name": "thrombocytopenia",
-          "description": "A reduction in the number of circulating thrombocytes. [HPO:probinson]; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T034",
-          "equivalent_curies": [
-            "UMLS:C0392386",
-            "SNOMEDCT:302215000",
-            "MEDDRA:10035545",
-            "MEDDRA:10043555",
-            "PDQ:CDR0000041408",
-            "MEDDRA:10024922",
-            "ICD10:D69.6",
-            "HP:0001873",
-            "NCIT:C3408",
-            "NCIT:C162108",
-            "MEDDRA:10035528",
-            "UMLS:C5201036",
-            "MEDDRA:10043560",
-            "DOID:1588",
-            "UMLS:CN130080",
-            "SYMP:0000114",
-            "MEDDRA:10038213",
-            "MEDDRA:10043546",
-            "MESH:D013921",
-            "MEDDRA:10035529",
-            "MEDDRA:10043569",
-            "UMLS:C0040034",
-            "MEDDRA:10043554",
-            "ICD9:287.5",
-            "MONDO:0002049",
-            "SNOMEDCT:415116008"
-          ],
-          "id": "MONDO:0002049",
-          "category": "biolink:Disease",
-          "all_names": [
-            "thrombocytopenia",
-            "Thrombocytopenia, unspecified",
-            "Low Platelet Count",
-            "Thrombocytopenia",
-            "Decreased platelet count"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://www.cancer.gov/dictionary?cdrid=44363",
-            "http://cancergenome.nih.gov/cancersselected/acutemyeloidleukemia",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.cancer.org/cancer/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.htm",
-            "http://en.wikipedia.org/wiki/acute_myeloid_leukemia"
-=======
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/thrombocytopenia",
-            "http://www.merckmanuals.com/professional/hematology_and_oncology/thrombocytopenia_and_platelet_dysfunction/overview_of_platelet_disorders.htm",
-            "http://ghr.nlm.nih.gov/glossary=thrombocytopenia"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 321063,
-=======
-            "identity": 316686,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018874",
-              "name": "acute myeloid leukemia",
-              "description": "A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification). (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3171\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3171\" NCI Thesaurus); Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.; A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).; Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.; A form of leukemia characterized by overproduction of an early myeloid cell. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:91861009",
-                "ICD9:205.0",
-                "MEDDRA:10024346",
-                "MEDDRA:10000801",
-                "MEDDRA:10060354",
-                "KEGG.DISEASE:05221",
-                "EFO:0000222",
-                "PDQ:CDR0000043424",
-                "MEDDRA:10000886",
-                "HP:0004808",
-                "MEDDRA:10060394",
-                "MESH:D015470",
-                "MEDDRA:10051003",
-                "MONDO:0100173",
-                "MEDDRA:10000878",
-                "MEDDRA:10060553",
-                "MEDDRA:10024291",
-                "SNOMEDCT:1162928000",
-                "MEDDRA:10054296",
-                "ORPHANET:519",
-                "MEDDRA:10000880",
-                "UMLS:C3275959",
-                "MEDDRA:10028552",
-                "MONDO:0018874",
-                "OMIM:601626",
-                "MEDDRA:10000884",
-                "DOID:9119",
-                "MEDDRA:10029549",
-                "MEDDRA:10029551",
-                "UMLS:C0023467",
-                "NCIT:C3171",
-                "MEDDRA:10060557",
-                "MEDDRA:10028557"
-              ],
-              "id": "MONDO:0018874",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia, acute myeloid related phenotypic feature",
-                "Leukemia, Myelocytic, Acute",
-                "Acute myeloid leukemia",
-                "acute myeloid leukemia",
-                "leukemia, acute myeloid, susceptibility to",
-                "Leukemia, acute myeloid, susceptibility to",
-                "Acute Myeloid Leukemia",
-                "Leukemia, Myeloid, Acute",
-                "Myeloid leukemia, acute"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002049",
-              "name": "thrombocytopenia",
-              "description": "A reduction in the number of circulating thrombocytes. [HPO:probinson]; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T034",
-              "equivalent_curies": [
-                "UMLS:C0392386",
-                "SNOMEDCT:302215000",
-                "MEDDRA:10035545",
-                "MEDDRA:10043555",
-                "PDQ:CDR0000041408",
-                "MEDDRA:10024922",
-                "ICD10:D69.6",
-                "HP:0001873",
-                "NCIT:C3408",
-                "NCIT:C162108",
-                "MEDDRA:10035528",
-                "UMLS:C5201036",
-                "MEDDRA:10043560",
-                "DOID:1588",
-                "UMLS:CN130080",
-                "SYMP:0000114",
-                "MEDDRA:10038213",
-                "MEDDRA:10043546",
-                "MESH:D013921",
-                "MEDDRA:10035529",
-                "MEDDRA:10043569",
-                "UMLS:C0040034",
-                "MEDDRA:10043554",
-                "ICD9:287.5",
-                "MONDO:0002049",
-                "SNOMEDCT:415116008"
-              ],
-              "id": "MONDO:0002049",
-              "category": "biolink:Disease",
-              "all_names": [
-                "thrombocytopenia",
-                "Thrombocytopenia, unspecified",
-                "Low Platelet Count",
-                "Thrombocytopenia",
-                "Decreased platelet count"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://www.cancer.gov/dictionary?cdrid=44363",
-                "http://cancergenome.nih.gov/cancersselected/acutemyeloidleukemia",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.cancer.org/cancer/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.htm",
-                "http://en.wikipedia.org/wiki/acute_myeloid_leukemia"
-=======
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/thrombocytopenia",
-                "http://www.merckmanuals.com/professional/hematology_and_oncology/thrombocytopenia_and_platelet_dysfunction/overview_of_platelet_disorders.htm",
-                "http://ghr.nlm.nih.gov/glossary=thrombocytopenia"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 7703300,
-            "start": 568,
-            "end": 321063,
-=======
-            "identity": 8094215,
-            "start": 568,
-            "end": 316686,
->>>>>>> main
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-<<<<<<< HEAD
-              "publications_info": "{'PMID:1059498': {'publication date': '1975 Nov', 'sentence': 'Treatment of acute myeloid leukemia of childhood with cytosine arabinoside, daunorubicin, prednisolone, and mercaptopurine or thioguanine.', 'subject score': 1000, 'object score': 1000}, 'PMID:17071496': {'publication date': '2006 Oct', 'sentence': 'This study analysed the clinical outcome of salvage therapy consisting of aclarubicin (ACR) plus behenoyl cytarabine (BHAC) and prednisolone (PSL) for patients with acute myeloid leukemia (AML).', 'subject score': 1000, 'object score': 1000}, 'PMID:1857690': {'publication date': '1991 May', 'sentence': 'We here report a case of pulmonary infiltrates due to Mycobacterium xenopi in a patient after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission and under immunosuppressive treatment with prednisolone and Cyclosporin A.', 'subject score': 1000, 'object score': 1000}, 'PMID:4516626': {'publication date': '1973 Sep 15', 'sentence': 'A preliminary report is given of a trial of the T.R.A.P. regimen (thioguanine, rubidomycin, cytosine arabinoside, and prednisolone) for the treatment of acute myeloid leukaemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:6951069': {'publication date': '1981 Jul', 'sentence': 'Two cases of acute myelogenous leukemia with high terminal deoxynucleotidyl transferase activity responding to vincristine-prednisolone treatment with complete remission.', 'subject score': 851, 'object score': 1000}, 'PMID:7615046': {'publication date': '1995 Jul', 'sentence': 'Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:8174198': {'publication date': '1994', 'sentence': 'Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia.', 'subject score': 1000, 'object score': 884}, 'PMID:8299770': {'publication date': '1994 Jan', 'sentence': 'When patients with common acute lymphoblastic leukemia (cALL) and acute myeloblastic leukemia (AML) were treated with prednisolone (60 mg/m2/day, p.o. or i.v.) and etoposide (150 mg/m2/day, i.v.), respectively, the blast cell counts fell to below 30% and 5%, respectively, in 1 week.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0023467---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7866839",
-              "object": "MONDO:0018874",
-              "publications": [
-                "PMID:1059498",
-                "PMID:17071496",
-                "PMID:1857690",
-                "PMID:4516626",
-                "PMID:6951069",
-                "PMID:7615046",
-                "PMID:8174198",
-                "PMID:8299770"
-=======
-              "publications_info": "{'PMID:10863327': {'publication date': '2000 Apr', 'sentence': 'Three out of 8 patients with thrombocytopenia were treated with prednisolone according to the protocol for idiopathic thrombocytopenic purpura.', 'subject score': 1000, 'object score': 1000}, 'PMID:11235133': {'publication date': '2001 Jan', 'sentence': \"After amelioration of the thrombocytopenia by prednisolone therapy, open renal biopsy was performed and a diagnosis of diffuse large B-cell non-Hodgkin's lymphoma was made.\", 'subject score': 888, 'object score': 1000}, 'PMID:12613003': {'publication date': '2003 Mar', 'sentence': 'Although renal dysfunction progressed to dialysis-dependent renal failure in one patient despite treatment with prednisolone and plasmapheresis but not in other, withdrawal of the treatment resulted in a prompt resolution of thrombocytopenia and microangiopathic hemolytic anemia in both patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:14211529': {'publication date': '1964', 'sentence': '[LEUKEMIC RETICULO-SARCOMATOSIS FOLLOWING METHYLTESTOSTERONE AND PREDNISOLONE TREATED PANMYELOPATHY AND THROMBOCYTOPENIA].', 'subject score': 1000, 'object score': 1000}, 'PMID:17329922': {'publication date': '2007', 'sentence': 'High-dose prednisolone therapy improved the hemolytic anemia and thrombocytopenia, but not the CD16(+) CD56(-) NK lymphocytosis completely.', 'subject score': 861, 'object score': 1000}, 'PMID:21372465': {'publication date': '2011', 'sentence': 'After treatment with prednisolone and fresh frozen plasma, ADAMTS-13 activity was normalized, the ADAMTS-13 inhibitor had disappeared and the thrombocytopenia with a bleeding tendency was improved.', 'subject score': 1000, 'object score': 1000}, 'PMID:21772119': {'publication date': '2011 Jul', 'sentence': 'Immune pathogenesis was suspected since platelet-associated immunoglobulin G (PAIGg) was increased and the administration of prednisolone (PSL) quickly ameliorated the thrombocytopenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:2243038': {'publication date': '1990 Oct 15', 'sentence': 'Prednisolone and danazol for treatment of immune-mediated anemia, thrombocytopenia, and ineffective erythroid regeneration in a dog.', 'subject score': 1000, 'object score': 1000}, 'PMID:2381060': {'publication date': '1990 Apr', 'sentence': 'The treatment with prednisolone resulted in a decrease in the severity of the lymphadenopathy, thrombocytopenia and polyclonal hypergammopathy.', 'subject score': 1000, 'object score': 1000}, 'PMID:2390633': {'publication date': '1990 Jul', 'sentence': 'On day 556 post-graft severe thrombocytopenia was resistant to prednisolone, cyclophosphamide and high dose immunoglobulin.', 'subject score': 1000, 'object score': 888}, 'PMID:26387855': {'publication date': '2015 Oct', 'sentence': 'Thrombocytopenia took a chronic course and platelet count fluctuated in the range 18 000-46 000/MUL, not responding to i.v. immunoglobulin or prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:26664400': {'publication date': '2015', 'sentence': 'The patient had a normal bone marrow aspiration and biopsy, the thrombocytopenia was resistant to platelet transfusion which successfully was treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:28535135': {'publication date': '2017 Jul/Aug', 'sentence': 'A second episode of thrombocytopenia (day +51) was managed with vincristine, prednisolone, and melatonin.', 'subject score': 1000, 'object score': 1000}, 'PMID:30567252': {'publication date': '2018 Dec 13', 'sentence': 'The patient subsequently developed pulmonary cysts and thrombocytopaenia due to autoimmune pathology and was successfully treated using prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:3184476': {'publication date': '1988 Jul', 'sentence': '[Normalization of platelet count following prednisolone and splenectomy in a patient with splenic hamartoma and thrombocytopenia].', 'subject score': 1000, 'object score': 1000}, 'PMID:31866622': {'publication date': '2019', 'sentence': 'The thrombocytopenia and neutropenia were successfully treated by prednisolone and romiplostim with negative conversion of antineutrophil antibody.', 'subject score': 1000, 'object score': 1000}, 'PMID:32258416': {'publication date': '2020', 'sentence': 'Streptococcus Pneumoniae    -associated Thrombotic Microangiopathy in an Immunosuppressed Adult.A 62-year-old male who was receiving prednisolone and methotrexate for scleroderma and rheumatoid arthritis complained of diarrhea and vomiting, and was transferred to our hospital for detailed examination and treatment of renal dysfunction and thrombocytopenia.', 'subject score': 888, 'object score': 1000}, 'PMID:3441913': {'publication date': '1987', 'sentence': 'The striking recurrent thrombocytopenia was successfully treated with prednisolone.', 'subject score': 1000, 'object score': 790}, 'PMID:35700350': {'publication date': '2022 Jun 07', 'sentence': 'We describe a case of infantile MLT that did not respond to treatment with propranolol, prednisolone, or vincristine.', 'subject score': 1000, 'object score': 753}, 'PMID:37123554': {'publication date': '2023 Jan-Jun', 'sentence': 'Case summary: A 3-year-old neutered domestic shorthair cat with a long history of idiopathic immune-mediated haemolytic anaemia and thrombocytopenia treated with ciclosporin and prednisolone was referred 2 months after the appearance of nodular dermatitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0040034---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8268574",
-              "object": "MONDO:0002049",
-              "publications": [
-                "PMID:10863327",
-                "PMID:11235133",
-                "PMID:12613003",
-                "PMID:14211529",
-                "PMID:17329922",
-                "PMID:21372465",
-                "PMID:21772119",
-                "PMID:2243038",
-                "PMID:2381060",
-                "PMID:2390633",
-                "PMID:26387855",
-                "PMID:26664400",
-                "PMID:28535135",
-                "PMID:30567252",
-                "PMID:3184476",
-                "PMID:31866622",
-                "PMID:32258416",
-                "PMID:3441913",
-                "PMID:35700350",
-                "PMID:37123554"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12188424': {'publication date': '2002 Jun', 'sentence': 'Management of hemangioma included observation, prednisolone, flashlamp-pumped pulsed-dye laser, topical therapy and excision in 68 per cent, 8.6 per cent, 10.7 per cent, 9.6 per cent, and 2.5 per cent, respectively.', 'subject score': 1000, 'object score': 1000}, 'PMID:25639889': {'publication date': '2015 Jul', 'sentence': 'Prior to propranolol the systemic treatment for haemangiomas was prednisolone and then the concern was the opposite, namely hypertension.', 'subject score': 1000, 'object score': 1000}, 'PMID:28488296': {'publication date': '2017 Jul', 'sentence': 'The hemangioma responded rapidly to systemic propranolol and prednisolone, and we believe that describing her atypical clinical course would be helpful for others managing complicated scalp hemangiomas.', 'subject score': 1000, 'object score': 851}, 'PMID:965873': {'publication date': '1976 Aug', 'sentence': 'Treatment of hemangiomas in pediatric patients with prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319991,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006500",
-          "name": "hemangioma",
-          "description": "A benign localized vascular neoplasm usually occurring in infancy and childhood. It is characterized by the formation of capillary-sized or cavernous vascular channels. The majority of cases are congenital. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3085\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3085\" NCI Thesaurus); A benign vascular lesion characterized by the formation of capillary-sized or cavernous vascular channels.; A vascular anomaly due to proliferation of blood or lymphatic vessels that forms a tumor-like mass. Vessels in the angioma may or may not be dilated.; A hemangioma is a benign tumor characterized by blood-filled spaces lined by benign endothelial cells. A hemangioma characterized by large endothelial spaces (caverns) is called a cavernous hemangioma (in contrast to a hemangioma with small endothelial spaces, which is called capillary hemangioma). [HPO:probinson]; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10018814",
-            "PDQ:CDR0000665618",
-            "ICD9:228.00",
-            "MEDDRA:10019401",
-            "SNOMEDCT:253053003",
-            "NCIT:C3085",
-            "DOID:255",
-            "UMLS:C0018916",
-            "SNOMEDCT:400210000",
-            "MEDDRA:10055903",
-            "MESH:D006391",
-            "EFO:1000635",
-            "MEDDRA:10019386",
-            "HP:0001028",
-            "MEDDRA:10019393",
-            "MEDDRA:10018819",
-            "ICD10:D18.0",
-            "MONDO:0006500"
-          ],
-          "id": "MONDO:0006500",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hemangioma",
-            "Hemangioma of unspecified site",
-            "hemangioma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-6908-9849",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/hemangioma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319991,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006500",
-              "name": "hemangioma",
-              "description": "A benign localized vascular neoplasm usually occurring in infancy and childhood. It is characterized by the formation of capillary-sized or cavernous vascular channels. The majority of cases are congenital. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3085\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3085\" NCI Thesaurus); A benign vascular lesion characterized by the formation of capillary-sized or cavernous vascular channels.; A vascular anomaly due to proliferation of blood or lymphatic vessels that forms a tumor-like mass. Vessels in the angioma may or may not be dilated.; A hemangioma is a benign tumor characterized by blood-filled spaces lined by benign endothelial cells. A hemangioma characterized by large endothelial spaces (caverns) is called a cavernous hemangioma (in contrast to a hemangioma with small endothelial spaces, which is called capillary hemangioma). [HPO:probinson]; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10018814",
-                "PDQ:CDR0000665618",
-                "ICD9:228.00",
-                "MEDDRA:10019401",
-                "SNOMEDCT:253053003",
-                "NCIT:C3085",
-                "DOID:255",
-                "UMLS:C0018916",
-                "SNOMEDCT:400210000",
-                "MEDDRA:10055903",
-                "MESH:D006391",
-                "EFO:1000635",
-                "MEDDRA:10019386",
-                "HP:0001028",
-                "MEDDRA:10019393",
-                "MEDDRA:10018819",
-                "ICD10:D18.0",
-                "MONDO:0006500"
-              ],
-              "id": "MONDO:0006500",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hemangioma",
-                "Hemangioma of unspecified site",
-                "hemangioma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-6908-9849",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/hemangioma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9507430,
-            "start": 568,
-            "end": 319991,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12188424': {'publication date': '2002 Jun', 'sentence': 'Management of hemangioma included observation, prednisolone, flashlamp-pumped pulsed-dye laser, topical therapy and excision in 68 per cent, 8.6 per cent, 10.7 per cent, 9.6 per cent, and 2.5 per cent, respectively.', 'subject score': 1000, 'object score': 1000}, 'PMID:25639889': {'publication date': '2015 Jul', 'sentence': 'Prior to propranolol the systemic treatment for haemangiomas was prednisolone and then the concern was the opposite, namely hypertension.', 'subject score': 1000, 'object score': 1000}, 'PMID:28488296': {'publication date': '2017 Jul', 'sentence': 'The hemangioma responded rapidly to systemic propranolol and prednisolone, and we believe that describing her atypical clinical course would be helpful for others managing complicated scalp hemangiomas.', 'subject score': 1000, 'object score': 851}, 'PMID:965873': {'publication date': '1976 Aug', 'sentence': 'Treatment of hemangiomas in pediatric patients with prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0018916---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9717382",
-              "object": "MONDO:0006500",
-              "publications": [
-                "PMID:12188424",
-                "PMID:25639889",
-                "PMID:28488296",
-                "PMID:965873"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:3418978': {'publication date': '1988 May', 'sentence': '[Effects of prednisolone on thyroidal-123I uptake in subacute thyroiditis].', 'subject score': 1000, 'object score': 1000}, 'PMID:760253': {'publication date': '1979 Jan', 'sentence': 'Changes in thyroid hormones by treatment with aspirin and prednisolone in subacute thyroiditis with hyperthyroidism.', 'subject score': 1000, 'object score': 1000}, 'PMID:8966940': {'publication date': '1996', 'sentence': \"[Indirect endolymphatic therapy with prednisolone in de Quervain's subacute thyroiditis].\", 'subject score': 1000, 'object score': 916}}",
-    "p2": {
-      "start": {
-        "identity": 532295,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006982",
-          "name": "subacute thyroiditis",
-          "description": "Self-limited inflammation of the thyroid gland. The clinical course includes an initial phase of hyperthyroidism, followed by a phase of hypothyroidism, and eventually a return to normal thyroid function. This category includes the subacute lymphocytic thyroiditis and subacute granulomatous thyroiditis.; Self-limited inflammation of the thyroid gland characterized by the presence of multinucleated giant cells. Patients present with neck pain, often associated with fever and dysphagia. The clinical course includes an initial phase of hyperthyroidism, followed by a phase of hypothyroidism, and eventually a return to normal thyroid function.; Spontaneously remitting inflammatory condition of the THYROID GLAND, characterized by FEVER; MUSCLE WEAKNESS; SORE THROAT; severe thyroid PAIN; and an enlarged damaged gland containing GIANT CELLS. The disease frequently follows a viral infection.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10012410",
-            "SNOMEDCT:428041004",
-            "DOID:7165",
-            "MEDDRA:10042298",
-            "ICD9:245.1",
-            "SNOMEDCT:38727009",
-            "EFO:1001194",
-            "NCIT:C35828",
-            "MEDDRA:10018705",
-            "ICD10:E06.1",
-            "MEDDRA:10043784",
-            "MESH:D013968",
-            "NCIT:C35071",
-            "MONDO:0006982",
-            "UMLS:C0040149"
-          ],
-          "id": "MONDO:0006982",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Subacute Thyroiditis",
-            "Subacute thyroiditis",
-            "Subacute Granulomatous Thyroiditis",
-            "Thyroiditis, Subacute",
-            "subacute thyroiditis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 532295,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006982",
-              "name": "subacute thyroiditis",
-              "description": "Self-limited inflammation of the thyroid gland. The clinical course includes an initial phase of hyperthyroidism, followed by a phase of hypothyroidism, and eventually a return to normal thyroid function. This category includes the subacute lymphocytic thyroiditis and subacute granulomatous thyroiditis.; Self-limited inflammation of the thyroid gland characterized by the presence of multinucleated giant cells. Patients present with neck pain, often associated with fever and dysphagia. The clinical course includes an initial phase of hyperthyroidism, followed by a phase of hypothyroidism, and eventually a return to normal thyroid function.; Spontaneously remitting inflammatory condition of the THYROID GLAND, characterized by FEVER; MUSCLE WEAKNESS; SORE THROAT; severe thyroid PAIN; and an enlarged damaged gland containing GIANT CELLS. The disease frequently follows a viral infection.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10012410",
-                "SNOMEDCT:428041004",
-                "DOID:7165",
-                "MEDDRA:10042298",
-                "ICD9:245.1",
-                "SNOMEDCT:38727009",
-                "EFO:1001194",
-                "NCIT:C35828",
-                "MEDDRA:10018705",
-                "ICD10:E06.1",
-                "MEDDRA:10043784",
-                "MESH:D013968",
-                "NCIT:C35071",
-                "MONDO:0006982",
-                "UMLS:C0040149"
-              ],
-              "id": "MONDO:0006982",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Subacute Thyroiditis",
-                "Subacute thyroiditis",
-                "Subacute Granulomatous Thyroiditis",
-                "Thyroiditis, Subacute",
-                "subacute thyroiditis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23063631,
-            "start": 568,
-            "end": 532295,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3418978': {'publication date': '1988 May', 'sentence': '[Effects of prednisolone on thyroidal-123I uptake in subacute thyroiditis].', 'subject score': 1000, 'object score': 1000}, 'PMID:760253': {'publication date': '1979 Jan', 'sentence': 'Changes in thyroid hormones by treatment with aspirin and prednisolone in subacute thyroiditis with hyperthyroidism.', 'subject score': 1000, 'object score': 1000}, 'PMID:8966940': {'publication date': '1996', 'sentence': \"[Indirect endolymphatic therapy with prednisolone in de Quervain's subacute thyroiditis].\", 'subject score': 1000, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0040149---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "23496152",
-              "object": "MONDO:0006982",
-              "publications": [
-                "PMID:3418978",
-                "PMID:760253",
-                "PMID:8966940"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11334386': {'publication date': '2001 Apr', 'sentence': 'CONCLUSIONS: The recurrence rate of SAT with treated PSL is about 20%.', 'subject score': 872, 'object score': 1000}, 'PMID:21245641': {'publication date': '2011', 'sentence': 'A 46-year-old female with a past history of ulcerative colitis (UC) was diagnosed with subacute thyroiditis (SAT), which improved with prednisolone (PSL) treatment (60 mg/day).', 'subject score': 888, 'object score': 1000}, 'PMID:23227861': {'publication date': '2013 Mar', 'sentence': 'CONCLUSIONS: The treatment protocol that we employed had 15 mg/day of PSL as the initial dosage for the treatment of SAT, with tapering by 5 mg every 2 weeks, and was effective and safe for Japanese patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:25969738': {'publication date': '2015', 'sentence': 'When the thyroid remains swollen after improvement of thyrotoxicosis following treatment with prednisolone, it should be assessed to differentiate between an amyloid goiter and common subacute thyroiditis.', 'subject score': 1000, 'object score': 901}, 'PMID:26073499': {'publication date': '2015 Jun 01', 'sentence': 'This study was a medical record-based retrospective study and involved 26 patients (3 men, 23 women) who received PSL therapy for SAT.', 'subject score': 888, 'object score': 1000}, 'PMID:26500930': {'publication date': '2015 Sep', 'sentence': 'CONCLUSION: Twenty mg of prednisolone daily tapered over 4 weeks is an adequate treatment of subacute thyroiditis.', 'subject score': 1000, 'object score': 1000}, 'PMID:27688010': {'publication date': '2017 Jan', 'sentence': 'Prednisolone treatment of patients with subacute thyroiditis was superior to nonsteroidal anti-inflammation drugs with regard to resolution of symptoms.', 'subject score': 888, 'object score': 1000}, 'PMID:30906749': {'publication date': '2019 Feb', 'sentence': 'Conclusions: The combination of low-dose PSL as a treatment choice for SAT was both effective and safe.', 'subject score': 901, 'object score': 1000}, 'PMID:32448401': {'publication date': '2020 May 24', 'sentence': 'Comparison of the therapeutic effects of 15 mg and 30 mg initial dosage of prednisolone daily in patients with subacute thyroiditis: protocol for a multicenter, randomized, open, parallel control study.BACKGROUND: Subacute thyroiditis (SAT) is the most common cause of thyroid pain.', 'subject score': 888, 'object score': 1000}, 'PMID:3427792': {'publication date': '1987 Sep', 'sentence': 'Twelve patients with subacute thyroiditis were divided into two groups and treated with prednisolone or salicylate.', 'subject score': 1000, 'object score': 1000}, 'PMID:34636318': {'publication date': '2021 Oct 11', 'sentence': 'CONCLUSION: According to the results of this meta-analysis, 15 to 20 mg/day of prednisolone is the most effective dosage with the lowest recurrence rate in the treatment of subacute Granulomatous thyroiditis.', 'subject score': 1000, 'object score': 1000}, 'PMID:35975250': {'publication date': '2022 Jan-Mar', 'sentence': 'THE USE OF LOW DOSE PREDNISOLONE IN PATIENTS WITH SUBACUTE THYROIDITIS AND ITS EFFECT ON IMPAIRED LIFE AND SLEEP QUALITY.', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 532295,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006982",
-          "name": "subacute thyroiditis",
-          "description": "Self-limited inflammation of the thyroid gland. The clinical course includes an initial phase of hyperthyroidism, followed by a phase of hypothyroidism, and eventually a return to normal thyroid function. This category includes the subacute lymphocytic thyroiditis and subacute granulomatous thyroiditis.; Self-limited inflammation of the thyroid gland characterized by the presence of multinucleated giant cells. Patients present with neck pain, often associated with fever and dysphagia. The clinical course includes an initial phase of hyperthyroidism, followed by a phase of hypothyroidism, and eventually a return to normal thyroid function.; Spontaneously remitting inflammatory condition of the THYROID GLAND, characterized by FEVER; MUSCLE WEAKNESS; SORE THROAT; severe thyroid PAIN; and an enlarged damaged gland containing GIANT CELLS. The disease frequently follows a viral infection.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10012410",
-            "SNOMEDCT:428041004",
-            "DOID:7165",
-            "MEDDRA:10042298",
-            "ICD9:245.1",
-            "SNOMEDCT:38727009",
-            "EFO:1001194",
-            "NCIT:C35828",
-            "MEDDRA:10018705",
-            "ICD10:E06.1",
-            "MEDDRA:10043784",
-            "MESH:D013968",
-            "NCIT:C35071",
-            "MONDO:0006982",
-            "UMLS:C0040149"
-          ],
-          "id": "MONDO:0006982",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Subacute Thyroiditis",
-            "Subacute thyroiditis",
-            "Subacute Granulomatous Thyroiditis",
-            "Thyroiditis, Subacute",
-            "subacute thyroiditis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 532295,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006982",
-              "name": "subacute thyroiditis",
-              "description": "Self-limited inflammation of the thyroid gland. The clinical course includes an initial phase of hyperthyroidism, followed by a phase of hypothyroidism, and eventually a return to normal thyroid function. This category includes the subacute lymphocytic thyroiditis and subacute granulomatous thyroiditis.; Self-limited inflammation of the thyroid gland characterized by the presence of multinucleated giant cells. Patients present with neck pain, often associated with fever and dysphagia. The clinical course includes an initial phase of hyperthyroidism, followed by a phase of hypothyroidism, and eventually a return to normal thyroid function.; Spontaneously remitting inflammatory condition of the THYROID GLAND, characterized by FEVER; MUSCLE WEAKNESS; SORE THROAT; severe thyroid PAIN; and an enlarged damaged gland containing GIANT CELLS. The disease frequently follows a viral infection.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10012410",
-                "SNOMEDCT:428041004",
-                "DOID:7165",
-                "MEDDRA:10042298",
-                "ICD9:245.1",
-                "SNOMEDCT:38727009",
-                "EFO:1001194",
-                "NCIT:C35828",
-                "MEDDRA:10018705",
-                "ICD10:E06.1",
-                "MEDDRA:10043784",
-                "MESH:D013968",
-                "NCIT:C35071",
-                "MONDO:0006982",
-                "UMLS:C0040149"
-              ],
-              "id": "MONDO:0006982",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Subacute Thyroiditis",
-                "Subacute thyroiditis",
-                "Subacute Granulomatous Thyroiditis",
-                "Thyroiditis, Subacute",
-                "subacute thyroiditis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8662989,
-            "start": 568,
-            "end": 532295,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11334386': {'publication date': '2001 Apr', 'sentence': 'CONCLUSIONS: The recurrence rate of SAT with treated PSL is about 20%.', 'subject score': 872, 'object score': 1000}, 'PMID:21245641': {'publication date': '2011', 'sentence': 'A 46-year-old female with a past history of ulcerative colitis (UC) was diagnosed with subacute thyroiditis (SAT), which improved with prednisolone (PSL) treatment (60 mg/day).', 'subject score': 888, 'object score': 1000}, 'PMID:23227861': {'publication date': '2013 Mar', 'sentence': 'CONCLUSIONS: The treatment protocol that we employed had 15 mg/day of PSL as the initial dosage for the treatment of SAT, with tapering by 5 mg every 2 weeks, and was effective and safe for Japanese patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:25969738': {'publication date': '2015', 'sentence': 'When the thyroid remains swollen after improvement of thyrotoxicosis following treatment with prednisolone, it should be assessed to differentiate between an amyloid goiter and common subacute thyroiditis.', 'subject score': 1000, 'object score': 901}, 'PMID:26073499': {'publication date': '2015 Jun 01', 'sentence': 'This study was a medical record-based retrospective study and involved 26 patients (3 men, 23 women) who received PSL therapy for SAT.', 'subject score': 888, 'object score': 1000}, 'PMID:26500930': {'publication date': '2015 Sep', 'sentence': 'CONCLUSION: Twenty mg of prednisolone daily tapered over 4 weeks is an adequate treatment of subacute thyroiditis.', 'subject score': 1000, 'object score': 1000}, 'PMID:27688010': {'publication date': '2017 Jan', 'sentence': 'Prednisolone treatment of patients with subacute thyroiditis was superior to nonsteroidal anti-inflammation drugs with regard to resolution of symptoms.', 'subject score': 888, 'object score': 1000}, 'PMID:30906749': {'publication date': '2019 Feb', 'sentence': 'Conclusions: The combination of low-dose PSL as a treatment choice for SAT was both effective and safe.', 'subject score': 901, 'object score': 1000}, 'PMID:32448401': {'publication date': '2020 May 24', 'sentence': 'Comparison of the therapeutic effects of 15 mg and 30 mg initial dosage of prednisolone daily in patients with subacute thyroiditis: protocol for a multicenter, randomized, open, parallel control study.BACKGROUND: Subacute thyroiditis (SAT) is the most common cause of thyroid pain.', 'subject score': 888, 'object score': 1000}, 'PMID:3427792': {'publication date': '1987 Sep', 'sentence': 'Twelve patients with subacute thyroiditis were divided into two groups and treated with prednisolone or salicylate.', 'subject score': 1000, 'object score': 1000}, 'PMID:34636318': {'publication date': '2021 Oct 11', 'sentence': 'CONCLUSION: According to the results of this meta-analysis, 15 to 20 mg/day of prednisolone is the most effective dosage with the lowest recurrence rate in the treatment of subacute Granulomatous thyroiditis.', 'subject score': 1000, 'object score': 1000}, 'PMID:35975250': {'publication date': '2022 Jan-Mar', 'sentence': 'THE USE OF LOW DOSE PREDNISOLONE IN PATIENTS WITH SUBACUTE THYROIDITIS AND ITS EFFECT ON IMPAIRED LIFE AND SLEEP QUALITY.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0040149---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8865745",
-              "object": "MONDO:0006982",
-              "publications": [
-                "PMID:11334386",
-                "PMID:21245641",
-                "PMID:23227861",
-                "PMID:25969738",
-                "PMID:26073499",
-                "PMID:26500930",
-                "PMID:27688010",
-                "PMID:30906749",
-                "PMID:32448401",
-                "PMID:3427792",
-                "PMID:34636318",
-                "PMID:35975250"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11296366': {'publication date': '2000 Oct', 'sentence': 'In this case, prednisolone was indispensable for treating tuberculous meningitis in combination with appropriate antituberculosis drugs, though the role of corticosteroids has remained controversial over the years.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 520323,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006042",
-          "name": "meningeal tuberculosis",
-          "description": "A bacterial infection of the membranes covering the brain and the spinal cord caused by Mycobacterium tuberculosis.; A form of bacterial meningitis caused by MYCOBACTERIUM TUBERCULOSIS or rarely MYCOBACTERIUM BOVIS. The organism seeds the meninges and forms microtuberculomas which subsequently rupture. The clinical course tends to be subacute, with progressions occurring over a period of several days or longer. Headache and meningeal irritation may be followed by SEIZURES, cranial neuropathies, focal neurologic deficits, somnolence, and eventually COMA. The illness may occur in immunocompetent individuals or as an OPPORTUNISTIC INFECTION in the ACQUIRED IMMUNODEFICIENCY SYNDROME and other immunodeficiency syndromes. (From Adams et al., Principles of Neurology, 6th ed, pp717-9); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C84888",
-            "ORPHANET:499004",
-            "EFO:1000039",
-            "UMLS:C0041318",
-            "MEDDRA:10027190",
-            "SNOMEDCT:58437007",
-            "MESH:D014390",
-            "MEDDRA:10027259",
-            "MONDO:0006042",
-            "ICD9:013.0",
-            "MEDDRA:10045080",
-            "MEDDRA:10043155"
-          ],
-          "id": "MONDO:0006042",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Meningeal Tuberculosis",
-            "Tuberculous meningitis",
-            "meningeal tuberculosis",
-            "Tuberculosis, Meningeal"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520323,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006042",
-              "name": "meningeal tuberculosis",
-              "description": "A bacterial infection of the membranes covering the brain and the spinal cord caused by Mycobacterium tuberculosis.; A form of bacterial meningitis caused by MYCOBACTERIUM TUBERCULOSIS or rarely MYCOBACTERIUM BOVIS. The organism seeds the meninges and forms microtuberculomas which subsequently rupture. The clinical course tends to be subacute, with progressions occurring over a period of several days or longer. Headache and meningeal irritation may be followed by SEIZURES, cranial neuropathies, focal neurologic deficits, somnolence, and eventually COMA. The illness may occur in immunocompetent individuals or as an OPPORTUNISTIC INFECTION in the ACQUIRED IMMUNODEFICIENCY SYNDROME and other immunodeficiency syndromes. (From Adams et al., Principles of Neurology, 6th ed, pp717-9); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C84888",
-                "ORPHANET:499004",
-                "EFO:1000039",
-                "UMLS:C0041318",
-                "MEDDRA:10027190",
-                "SNOMEDCT:58437007",
-                "MESH:D014390",
-                "MEDDRA:10027259",
-                "MONDO:0006042",
-                "ICD9:013.0",
-                "MEDDRA:10045080",
-                "MEDDRA:10043155"
-              ],
-              "id": "MONDO:0006042",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Meningeal Tuberculosis",
-                "Tuberculous meningitis",
-                "meningeal tuberculosis",
-                "Tuberculosis, Meningeal"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8630174,
-            "start": 568,
-            "end": 520323,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11296366': {'publication date': '2000 Oct', 'sentence': 'In this case, prednisolone was indispensable for treating tuberculous meningitis in combination with appropriate antituberculosis drugs, though the role of corticosteroids has remained controversial over the years.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0041318---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8819323",
-              "object": "MONDO:0006042",
-              "publications": [
-                "PMID:11296366"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:17041382': {'publication date': '2002 Oct', 'sentence': 'After recovering from pneumonia, she was treated initially with prednisolone, 30 mg/day, and remained well until she developed hemoptysis at age 34 years.', 'subject score': 1000, 'object score': 1000}, 'PMID:17144587': {'publication date': '2006 Nov', 'sentence': 'We report a case of SELAPINA-induced pneumonia successfully treated with glucocorticoid pulse therapy followed by orally administered prednisolone.', 'subject score': 827, 'object score': 790}, 'PMID:20133929': {'publication date': '2010 May 01', 'sentence': 'CONCLUSIONS: Prednisolone (at 40 mg) once daily for a week does not improve outcome in hospitalized patients with CAP.', 'subject score': 1000, 'object score': 851}, 'PMID:23423809': {'publication date': '2013 May', 'sentence': 'The pneumonitis progressed rapidly and the patient developed respiratory failure, so we performed bronchoalveolar lavage to make a definitive diagnosis, and simultaneously started treatment with prednisolone and trimethoprim-sulfamethoxazole to cover both interstitial lung disease and pneumocystis pneumonia.', 'subject score': 1000, 'object score': 1000}, 'PMID:2860710': {'publication date': '1985', 'sentence': 'The pneumonia resolved following discontinuation of the drug and the start of treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:30671549': {'publication date': '2019 Feb', 'sentence': 'Re-staging showed a para-mediastinal, radiotherapy-induced pneumonitis, which was treated by prednisolone due to clinical symptoms.', 'subject score': 1000, 'object score': 822}, 'PMID:31438923': {'publication date': '2019 Aug 22', 'sentence': 'The re-escalated dosage of PSL improved the pneumonitis, and then nintedanib was started as additional therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:34121010': {'publication date': '2021 Jun 12', 'sentence': 'After 12 cycles, immune-related pneumonitis developed and was treated with prednisolone.', 'subject score': 1000, 'object score': 851}, 'PMID:36451154': {'publication date': '2022 Nov 30', 'sentence': 'CASE PRESENTATION: A 68-year-old woman complained of floaters and blurred vision in her right eye as she was receiving systemic prednisolone for COVID-19 pneumonia under isolation in our hospital.', 'subject score': 888, 'object score': 916}, 'PMID:4404939': {'publication date': '1972 Dec 09', 'sentence': 'Ampicillin dosage and use of prednisolone in treatment of pneumonia: co-operative controlled trial.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12497118,
-            "start": 568,
-            "end": 321523,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17041382': {'publication date': '2002 Oct', 'sentence': 'After recovering from pneumonia, she was treated initially with prednisolone, 30 mg/day, and remained well until she developed hemoptysis at age 34 years.', 'subject score': 1000, 'object score': 1000}, 'PMID:17144587': {'publication date': '2006 Nov', 'sentence': 'We report a case of SELAPINA-induced pneumonia successfully treated with glucocorticoid pulse therapy followed by orally administered prednisolone.', 'subject score': 827, 'object score': 790}, 'PMID:20133929': {'publication date': '2010 May 01', 'sentence': 'CONCLUSIONS: Prednisolone (at 40 mg) once daily for a week does not improve outcome in hospitalized patients with CAP.', 'subject score': 1000, 'object score': 851}, 'PMID:23423809': {'publication date': '2013 May', 'sentence': 'The pneumonitis progressed rapidly and the patient developed respiratory failure, so we performed bronchoalveolar lavage to make a definitive diagnosis, and simultaneously started treatment with prednisolone and trimethoprim-sulfamethoxazole to cover both interstitial lung disease and pneumocystis pneumonia.', 'subject score': 1000, 'object score': 1000}, 'PMID:2860710': {'publication date': '1985', 'sentence': 'The pneumonia resolved following discontinuation of the drug and the start of treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:30671549': {'publication date': '2019 Feb', 'sentence': 'Re-staging showed a para-mediastinal, radiotherapy-induced pneumonitis, which was treated by prednisolone due to clinical symptoms.', 'subject score': 1000, 'object score': 822}, 'PMID:31438923': {'publication date': '2019 Aug 22', 'sentence': 'The re-escalated dosage of PSL improved the pneumonitis, and then nintedanib was started as additional therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:34121010': {'publication date': '2021 Jun 12', 'sentence': 'After 12 cycles, immune-related pneumonitis developed and was treated with prednisolone.', 'subject score': 1000, 'object score': 851}, 'PMID:36451154': {'publication date': '2022 Nov 30', 'sentence': 'CASE PRESENTATION: A 68-year-old woman complained of floaters and blurred vision in her right eye as she was receiving systemic prednisolone for COVID-19 pneumonia under isolation in our hospital.', 'subject score': 888, 'object score': 916}, 'PMID:4404939': {'publication date': '1972 Dec 09', 'sentence': 'Ampicillin dosage and use of prednisolone in treatment of pneumonia: co-operative controlled trial.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "12767794",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:17041382",
-                "PMID:17144587",
-                "PMID:20133929",
-                "PMID:23423809",
-                "PMID:2860710",
-                "PMID:30671549",
-                "PMID:31438923",
-                "PMID:34121010",
-                "PMID:36451154",
-                "PMID:4404939"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:413820': {'publication date': '1977 Dec', 'sentence': 'Only hydrocortisone and prednisolone suppressed LPS pneumonia.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25310462,
-            "start": 568,
-            "end": 321523,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:413820': {'publication date': '1977 Dec', 'sentence': 'Only hydrocortisone and prednisolone suppressed LPS pneumonia.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:disrupts---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "25763558",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:413820"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:23053189': {'publication date': '2013 Jan', 'sentence': 'R-CHOP chemotherapy composed of rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone which might increase the risk of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma.', 'subject score': 1000, 'object score': 888}, 'PMID:33262125': {'publication date': '2020 Dec 01', 'sentence': 'The study also suggests that exposure to oral prednisolone increases the risk of cellulitis, pneumonia, and upper respiratory infection.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16209955,
-            "start": 568,
-            "end": 321523,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23053189': {'publication date': '2013 Jan', 'sentence': 'R-CHOP chemotherapy composed of rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone which might increase the risk of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma.', 'subject score': 1000, 'object score': 888}, 'PMID:33262125': {'publication date': '2020 Dec 01', 'sentence': 'The study also suggests that exposure to oral prednisolone increases the risk of cellulitis, pneumonia, and upper respiratory infection.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:predisposes---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16546227",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:23053189",
-                "PMID:33262125"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:1483996': {'publication date': '1992 May', 'sentence': 'Treatment with combined therapy of adriamycin, vincristine and prednisolone produced a remission in the leukaemia with complete resolution of the breast mass.', 'subject score': 1000, 'object score': 1000}, 'PMID:23334362': {'publication date': '2013 Apr', 'sentence': 'In conclusion, we here present a novel mechanism of prednisolone resistance in MLL-rearranged leukemias, and propose that inhibition of annexin A2 phosphorylation embodies a therapeutic strategy for overcoming resistance to glucocorticoids in this highly aggressive type of leukemia.', 'subject score': 694, 'object score': 802}, 'PMID:5875818': {'publication date': '1965 Sep-Oct', 'sentence': '[The effect of pyridoxine and prednisolone on the blood picture in experimental anemia and transplantable leukemia].', 'subject score': 1000, 'object score': 853}}",
-    "p2": {
-      "start": {
-        "identity": 315770,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005059",
-          "name": "leukemia",
-          "description": "A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3161\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3161\" NCI Thesaurus); A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.; A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006); A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding  When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets  The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time.  The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age  What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding.  Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes  Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10045991",
-            "MEDDRA:10024329",
-            "ICD9:208",
-            "ICD10:C95.90",
-            "MEDDRA:10060430",
-            "MEDDRA:10024314",
-            "MEDDRA:10024323",
-            "MEDDRA:10024351",
-            "HP:0001909",
-            "SNOMEDCT:87163000",
-            "SNOMEDCT:1162768007",
-            "MEDDRA:10045992",
-            "MEDDRA:10060500",
-            "NCIT:C3161",
-            "EFO:0000565",
-            "MEDDRA:10045994",
-            "SNOMEDCT:93143009",
-            "MEDDRA:10024288",
-            "MEDDRA:10024352",
-            "MEDDRA:10024312",
-            "DOID:1240",
-            "UMLS:C0023418",
-            "PDQ:CDR0000041186",
-            "MESH:D007938",
-            "MONDO:0005059",
-            "MEDDRA:10024324"
-          ],
-          "id": "MONDO:0005059",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia of unspecified cell type",
-            "Leukemia",
-            "leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/leukemia",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=45343",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315770,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005059",
-              "name": "leukemia",
-              "description": "A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3161\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3161\" NCI Thesaurus); A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.; A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006); A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding  When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets  The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time.  The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age  What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding.  Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes  Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10045991",
-                "MEDDRA:10024329",
-                "ICD9:208",
-                "ICD10:C95.90",
-                "MEDDRA:10060430",
-                "MEDDRA:10024314",
-                "MEDDRA:10024323",
-                "MEDDRA:10024351",
-                "HP:0001909",
-                "SNOMEDCT:87163000",
-                "SNOMEDCT:1162768007",
-                "MEDDRA:10045992",
-                "MEDDRA:10060500",
-                "NCIT:C3161",
-                "EFO:0000565",
-                "MEDDRA:10045994",
-                "SNOMEDCT:93143009",
-                "MEDDRA:10024288",
-                "MEDDRA:10024352",
-                "MEDDRA:10024312",
-                "DOID:1240",
-                "UMLS:C0023418",
-                "PDQ:CDR0000041186",
-                "MESH:D007938",
-                "MONDO:0005059",
-                "MEDDRA:10024324"
-              ],
-              "id": "MONDO:0005059",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia of unspecified cell type",
-                "Leukemia",
-                "leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/leukemia",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=45343",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10777002,
-            "start": 568,
-            "end": 315770,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1483996': {'publication date': '1992 May', 'sentence': 'Treatment with combined therapy of adriamycin, vincristine and prednisolone produced a remission in the leukaemia with complete resolution of the breast mass.', 'subject score': 1000, 'object score': 1000}, 'PMID:23334362': {'publication date': '2013 Apr', 'sentence': 'In conclusion, we here present a novel mechanism of prednisolone resistance in MLL-rearranged leukemias, and propose that inhibition of annexin A2 phosphorylation embodies a therapeutic strategy for overcoming resistance to glucocorticoids in this highly aggressive type of leukemia.', 'subject score': 694, 'object score': 802}, 'PMID:5875818': {'publication date': '1965 Sep-Oct', 'sentence': '[The effect of pyridoxine and prednisolone on the blood picture in experimental anemia and transplantable leukemia].', 'subject score': 1000, 'object score': 853}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0023418---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11013570",
-              "object": "MONDO:0005059",
-              "publications": [
-                "PMID:1483996",
-                "PMID:23334362",
-                "PMID:5875818"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:13814629': {'publication date': '1960 May', 'sentence': '[On the use of prednisolone in hemolytic anemia of the newborn caused by fetomaternal Rh-factor incompatibility].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316685,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0003664",
-          "name": "hemolytic anemia",
-          "description": "A type of anemia caused by premature destruction of red blood cells (hemolysis). [HPO:probinson]; A type of anemia caused by premature destruction of red blood cells (hemolysis). // COMMENTS: Normally, erythrocytes survive on average about 110-120 days. With hemolysis, the erythrocyte survival is shortened, and generally increased marrow activity results in a reticulocyte count.; A type of anemia caused by premature destruction of red blood cells (hemolysis). // COMMENTS: Normally, erythrocytes survive on average about 110-120 days. With hemolysis, the erythrocyte survival is shortened, and generally increased marrow activity results in a reticulocyte count.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:0005558",
-            "UMLS:C0002878",
-            "MEDDRA:10018921",
-            "MEDDRA:10019494",
-            "SYMP:0000631",
-            "MEDDRA:10018916",
-            "ICD10:D55-D59",
-            "SNOMEDCT:61261009",
-            "MONDO:0003664",
-            "HP:0001878",
-            "MEDDRA:10019493",
-            "DOID:583",
-            "MEDDRA:10002284",
-            "MEDDRA:10055193",
-            "MEDDRA:10002045",
-            "NCIT:C34376",
-            "MESH:D000743"
-          ],
-          "id": "MONDO:0003664",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hemolytic anemia",
-            "Anemia, Hemolytic",
-            "hemolytic anemia",
-            "Hemolytic Anemia"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316685,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0003664",
-              "name": "hemolytic anemia",
-              "description": "A type of anemia caused by premature destruction of red blood cells (hemolysis). [HPO:probinson]; A type of anemia caused by premature destruction of red blood cells (hemolysis). // COMMENTS: Normally, erythrocytes survive on average about 110-120 days. With hemolysis, the erythrocyte survival is shortened, and generally increased marrow activity results in a reticulocyte count.; A type of anemia caused by premature destruction of red blood cells (hemolysis). // COMMENTS: Normally, erythrocytes survive on average about 110-120 days. With hemolysis, the erythrocyte survival is shortened, and generally increased marrow activity results in a reticulocyte count.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:0005558",
-                "UMLS:C0002878",
-                "MEDDRA:10018921",
-                "MEDDRA:10019494",
-                "SYMP:0000631",
-                "MEDDRA:10018916",
-                "ICD10:D55-D59",
-                "SNOMEDCT:61261009",
-                "MONDO:0003664",
-                "HP:0001878",
-                "MEDDRA:10019493",
-                "DOID:583",
-                "MEDDRA:10002284",
-                "MEDDRA:10055193",
-                "MEDDRA:10002045",
-                "NCIT:C34376",
-                "MESH:D000743"
-              ],
-              "id": "MONDO:0003664",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hemolytic anemia",
-                "Anemia, Hemolytic",
-                "hemolytic anemia",
-                "Hemolytic Anemia"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10395113,
-            "start": 568,
-            "end": 316685,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13814629': {'publication date': '1960 May', 'sentence': '[On the use of prednisolone in hemolytic anemia of the newborn caused by fetomaternal Rh-factor incompatibility].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0002878---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10623724",
-              "object": "MONDO:0003664",
-              "publications": [
-                "PMID:13814629"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:13314848': {'publication date': '1955 Dec', 'sentence': '[A case of hemolytic anemia with generalized agglutination, treated with ACTH, cortisone, and prednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:13355536': {'publication date': '1956 Apr', 'sentence': '[Immune hemolytic anemia treated with prednisone and prednisolone].', 'subject score': 1000, 'object score': 901}, 'PMID:17156326': {'publication date': '2006 Dec', 'sentence': 'A 7-year-old castrated male Whippet developed deep ulcerative skin lesions whilst receiving immunosuppressive doses of prednisolone and cyclosporine for the treatment of immune-mediated haemolytic anaemia.', 'subject score': 1000, 'object score': 850}, 'PMID:17329922': {'publication date': '2007', 'sentence': 'High-dose prednisolone therapy improved the hemolytic anemia and thrombocytopenia, but not the CD16(+) CD56(-) NK lymphocytosis completely.', 'subject score': 861, 'object score': 1000}, 'PMID:1753420': {'publication date': '1991 Oct', 'sentence': 'The PRCA and hemolytic anemia were successfully treated with prednisolone (60 mg/day).', 'subject score': 1000, 'object score': 1000}, 'PMID:22563154': {'publication date': '2011 Oct', 'sentence': 'We report a patient with primary ovarian diffuse large B-cell lymphoma (DLBCL) and associated auto-immune hemolytic anemia (AIHA) who achieved complete remission after treatment with Rituximab-cyclophosphamide-doxorubicin-vincristine and prednisolone (R-CHOP) chemotherapy.', 'subject score': 1000, 'object score': 798}, 'PMID:2280484': {'publication date': '1990 Oct', 'sentence': \"A canine case of Coombs' test positive and antinuclear antibody-negative hemolytic anemia was examined because of the development of skin lesions after 18 months treatment with prednisolone.\", 'subject score': 1000, 'object score': 893}, 'PMID:24490015': {'publication date': '2014', 'sentence': 'CASE PRESENTATION: A- 46 year old woman who was a known case of hemolytic anemia has been treated by prednisolone (with different doses from 7.5 to 75 mg/day), calcium-D 500 mg/day and alendronate 70 mg/week for 3 years.', 'subject score': 1000, 'object score': 1000}, 'PMID:29509140': {'publication date': '2018 Mar', 'sentence': 'The addition of MMF to prednisolone for the treatment of dogs with acute IMHA was well tolerated and seemed to positively affect the course of the disease.', 'subject score': 1000, 'object score': 820}, 'PMID:7997131': {'publication date': '1994', 'sentence': 'The hemolytic anemia was treated with prednisolone without success and KS cutaneous lesions extended to both legs and ulcerated even after a short course of bleomycin and radiotherapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:9785987': {'publication date': '1998 Aug', 'sentence': 'Further administration of 60 mg of prednisolone and plasmapheresis ameliorated the hemolytic anemia and cured the jaundice.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316685,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0003664",
-          "name": "hemolytic anemia",
-          "description": "A type of anemia caused by premature destruction of red blood cells (hemolysis). [HPO:probinson]; A type of anemia caused by premature destruction of red blood cells (hemolysis). // COMMENTS: Normally, erythrocytes survive on average about 110-120 days. With hemolysis, the erythrocyte survival is shortened, and generally increased marrow activity results in a reticulocyte count.; A type of anemia caused by premature destruction of red blood cells (hemolysis). // COMMENTS: Normally, erythrocytes survive on average about 110-120 days. With hemolysis, the erythrocyte survival is shortened, and generally increased marrow activity results in a reticulocyte count.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:0005558",
-            "UMLS:C0002878",
-            "MEDDRA:10018921",
-            "MEDDRA:10019494",
-            "SYMP:0000631",
-            "MEDDRA:10018916",
-            "ICD10:D55-D59",
-            "SNOMEDCT:61261009",
-            "MONDO:0003664",
-            "HP:0001878",
-            "MEDDRA:10019493",
-            "DOID:583",
-            "MEDDRA:10002284",
-            "MEDDRA:10055193",
-            "MEDDRA:10002045",
-            "NCIT:C34376",
-            "MESH:D000743"
-          ],
-          "id": "MONDO:0003664",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hemolytic anemia",
-            "Anemia, Hemolytic",
-            "hemolytic anemia",
-            "Hemolytic Anemia"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316685,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0003664",
-              "name": "hemolytic anemia",
-              "description": "A type of anemia caused by premature destruction of red blood cells (hemolysis). [HPO:probinson]; A type of anemia caused by premature destruction of red blood cells (hemolysis). // COMMENTS: Normally, erythrocytes survive on average about 110-120 days. With hemolysis, the erythrocyte survival is shortened, and generally increased marrow activity results in a reticulocyte count.; A type of anemia caused by premature destruction of red blood cells (hemolysis). // COMMENTS: Normally, erythrocytes survive on average about 110-120 days. With hemolysis, the erythrocyte survival is shortened, and generally increased marrow activity results in a reticulocyte count.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:0005558",
-                "UMLS:C0002878",
-                "MEDDRA:10018921",
-                "MEDDRA:10019494",
-                "SYMP:0000631",
-                "MEDDRA:10018916",
-                "ICD10:D55-D59",
-                "SNOMEDCT:61261009",
-                "MONDO:0003664",
-                "HP:0001878",
-                "MEDDRA:10019493",
-                "DOID:583",
-                "MEDDRA:10002284",
-                "MEDDRA:10055193",
-                "MEDDRA:10002045",
-                "NCIT:C34376",
-                "MESH:D000743"
-              ],
-              "id": "MONDO:0003664",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hemolytic anemia",
-                "Anemia, Hemolytic",
-                "hemolytic anemia",
-                "Hemolytic Anemia"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10276186,
-            "start": 568,
-            "end": 316685,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13314848': {'publication date': '1955 Dec', 'sentence': '[A case of hemolytic anemia with generalized agglutination, treated with ACTH, cortisone, and prednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:13355536': {'publication date': '1956 Apr', 'sentence': '[Immune hemolytic anemia treated with prednisone and prednisolone].', 'subject score': 1000, 'object score': 901}, 'PMID:17156326': {'publication date': '2006 Dec', 'sentence': 'A 7-year-old castrated male Whippet developed deep ulcerative skin lesions whilst receiving immunosuppressive doses of prednisolone and cyclosporine for the treatment of immune-mediated haemolytic anaemia.', 'subject score': 1000, 'object score': 850}, 'PMID:17329922': {'publication date': '2007', 'sentence': 'High-dose prednisolone therapy improved the hemolytic anemia and thrombocytopenia, but not the CD16(+) CD56(-) NK lymphocytosis completely.', 'subject score': 861, 'object score': 1000}, 'PMID:1753420': {'publication date': '1991 Oct', 'sentence': 'The PRCA and hemolytic anemia were successfully treated with prednisolone (60 mg/day).', 'subject score': 1000, 'object score': 1000}, 'PMID:22563154': {'publication date': '2011 Oct', 'sentence': 'We report a patient with primary ovarian diffuse large B-cell lymphoma (DLBCL) and associated auto-immune hemolytic anemia (AIHA) who achieved complete remission after treatment with Rituximab-cyclophosphamide-doxorubicin-vincristine and prednisolone (R-CHOP) chemotherapy.', 'subject score': 1000, 'object score': 798}, 'PMID:2280484': {'publication date': '1990 Oct', 'sentence': \"A canine case of Coombs' test positive and antinuclear antibody-negative hemolytic anemia was examined because of the development of skin lesions after 18 months treatment with prednisolone.\", 'subject score': 1000, 'object score': 893}, 'PMID:24490015': {'publication date': '2014', 'sentence': 'CASE PRESENTATION: A- 46 year old woman who was a known case of hemolytic anemia has been treated by prednisolone (with different doses from 7.5 to 75 mg/day), calcium-D 500 mg/day and alendronate 70 mg/week for 3 years.', 'subject score': 1000, 'object score': 1000}, 'PMID:29509140': {'publication date': '2018 Mar', 'sentence': 'The addition of MMF to prednisolone for the treatment of dogs with acute IMHA was well tolerated and seemed to positively affect the course of the disease.', 'subject score': 1000, 'object score': 820}, 'PMID:7997131': {'publication date': '1994', 'sentence': 'The hemolytic anemia was treated with prednisolone without success and KS cutaneous lesions extended to both legs and ulcerated even after a short course of bleomycin and radiotherapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:9785987': {'publication date': '1998 Aug', 'sentence': 'Further administration of 60 mg of prednisolone and plasmapheresis ameliorated the hemolytic anemia and cured the jaundice.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0002878---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10502737",
-              "object": "MONDO:0003664",
-              "publications": [
-                "PMID:13314848",
-                "PMID:13355536",
-                "PMID:17156326",
-                "PMID:17329922",
-                "PMID:1753420",
-                "PMID:22563154",
-                "PMID:2280484",
-                "PMID:24490015",
-                "PMID:29509140",
-                "PMID:7997131",
-                "PMID:9785987"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:23723489': {'publication date': '2013 May', 'sentence': 'Early treatment with addition of low dose prednisolone to methotrexate improves therapeutic outcome in severe psoriatic arthritis.', 'subject score': 901, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 536164,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011849",
-          "name": "psoriatic arthritis",
-          "description": "Joint inflammation associated with psoriasis.; A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people with psoriasis have psoriatic arthritis. It causes pain, stiffness, and swelling of the joints. It is often mild, but can sometimes be serious and affect many joints. The joint and skin problems don't always happen at the same time. Your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. There is no cure, but medicines can help control inflammation and pain. In rare cases, you might need surgery to repair or replace damaged joints.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10037163",
-            "EFO:0003778",
-            "UMLS:C0003872",
-            "DOID:9008",
-            "ORPHANET:40050",
-            "MEDDRA:10003377",
-            "ICD9:696.0",
-            "NCIT:C61277",
-            "MONDO:0011849",
-            "SNOMEDCT:156370009",
-            "MEDDRA:10037162",
-            "MESH:D015535",
-            "MEDDRA:10037160",
-            "ICD10:L40.5"
-          ],
-          "id": "MONDO:0011849",
-          "category": "biolink:Disease",
-          "all_names": [
-            "psoriatic arthritis",
-            "Arthritis, Psoriatic",
-            "Psoriatic arthropathy",
-            "Psoriatic Arthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/psoriatic_arthropathy",
-            "https://ghr.nlm.nih.gov/condition/psoriatic-arthritis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000413.htm",
-            "http://www.mayoclinic.com/health/psoriatic-arthritis/ds00476"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 536164,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011849",
-              "name": "psoriatic arthritis",
-              "description": "Joint inflammation associated with psoriasis.; A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people with psoriasis have psoriatic arthritis. It causes pain, stiffness, and swelling of the joints. It is often mild, but can sometimes be serious and affect many joints. The joint and skin problems don't always happen at the same time. Your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. There is no cure, but medicines can help control inflammation and pain. In rare cases, you might need surgery to repair or replace damaged joints.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10037163",
-                "EFO:0003778",
-                "UMLS:C0003872",
-                "DOID:9008",
-                "ORPHANET:40050",
-                "MEDDRA:10003377",
-                "ICD9:696.0",
-                "NCIT:C61277",
-                "MONDO:0011849",
-                "SNOMEDCT:156370009",
-                "MEDDRA:10037162",
-                "MESH:D015535",
-                "MEDDRA:10037160",
-                "ICD10:L40.5"
-              ],
-              "id": "MONDO:0011849",
-              "category": "biolink:Disease",
-              "all_names": [
-                "psoriatic arthritis",
-                "Arthritis, Psoriatic",
-                "Psoriatic arthropathy",
-                "Psoriatic Arthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/psoriatic_arthropathy",
-                "https://ghr.nlm.nih.gov/condition/psoriatic-arthritis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000413.htm",
-                "http://www.mayoclinic.com/health/psoriatic-arthritis/ds00476"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16616766,
-            "start": 568,
-            "end": 536164,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23723489': {'publication date': '2013 May', 'sentence': 'Early treatment with addition of low dose prednisolone to methotrexate improves therapeutic outcome in severe psoriatic arthritis.', 'subject score': 901, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0003872---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16960031",
-              "object": "MONDO:0011849",
-              "publications": [
-                "PMID:23723489"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1155088': {'publication date': '1975 Jul', 'sentence': 'Methotrexate and prednisolone treatment of a child with psoriatic arthritis.', 'subject score': 888, 'object score': 1000}, 'PMID:1275584': {'publication date': '1976 Feb', 'sentence': 'Thirteen patients with rheumatoid or psoriatic arthritis who had not previously received corticosteroids were treated with prednisolone in a single-dose each morning.', 'subject score': 1000, 'object score': 1000}, 'PMID:34544940': {'publication date': '2021 Sep 21', 'sentence': 'A Japanese man in his 80s with psoriatic arthritis that was being treated with prednisolone was admitted for dyspnea.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 536164,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011849",
-          "name": "psoriatic arthritis",
-          "description": "Joint inflammation associated with psoriasis.; A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people with psoriasis have psoriatic arthritis. It causes pain, stiffness, and swelling of the joints. It is often mild, but can sometimes be serious and affect many joints. The joint and skin problems don't always happen at the same time. Your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. There is no cure, but medicines can help control inflammation and pain. In rare cases, you might need surgery to repair or replace damaged joints.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10037163",
-            "EFO:0003778",
-            "UMLS:C0003872",
-            "DOID:9008",
-            "ORPHANET:40050",
-            "MEDDRA:10003377",
-            "ICD9:696.0",
-            "NCIT:C61277",
-            "MONDO:0011849",
-            "SNOMEDCT:156370009",
-            "MEDDRA:10037162",
-            "MESH:D015535",
-            "MEDDRA:10037160",
-            "ICD10:L40.5"
-          ],
-          "id": "MONDO:0011849",
-          "category": "biolink:Disease",
-          "all_names": [
-            "psoriatic arthritis",
-            "Arthritis, Psoriatic",
-            "Psoriatic arthropathy",
-            "Psoriatic Arthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/psoriatic_arthropathy",
-            "https://ghr.nlm.nih.gov/condition/psoriatic-arthritis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000413.htm",
-            "http://www.mayoclinic.com/health/psoriatic-arthritis/ds00476"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 536164,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011849",
-              "name": "psoriatic arthritis",
-              "description": "Joint inflammation associated with psoriasis.; A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people with psoriasis have psoriatic arthritis. It causes pain, stiffness, and swelling of the joints. It is often mild, but can sometimes be serious and affect many joints. The joint and skin problems don't always happen at the same time. Your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. There is no cure, but medicines can help control inflammation and pain. In rare cases, you might need surgery to repair or replace damaged joints.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10037163",
-                "EFO:0003778",
-                "UMLS:C0003872",
-                "DOID:9008",
-                "ORPHANET:40050",
-                "MEDDRA:10003377",
-                "ICD9:696.0",
-                "NCIT:C61277",
-                "MONDO:0011849",
-                "SNOMEDCT:156370009",
-                "MEDDRA:10037162",
-                "MESH:D015535",
-                "MEDDRA:10037160",
-                "ICD10:L40.5"
-              ],
-              "id": "MONDO:0011849",
-              "category": "biolink:Disease",
-              "all_names": [
-                "psoriatic arthritis",
-                "Arthritis, Psoriatic",
-                "Psoriatic arthropathy",
-                "Psoriatic Arthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/psoriatic_arthropathy",
-                "https://ghr.nlm.nih.gov/condition/psoriatic-arthritis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000413.htm",
-                "http://www.mayoclinic.com/health/psoriatic-arthritis/ds00476"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8912988,
-            "start": 568,
-            "end": 536164,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1155088': {'publication date': '1975 Jul', 'sentence': 'Methotrexate and prednisolone treatment of a child with psoriatic arthritis.', 'subject score': 888, 'object score': 1000}, 'PMID:1275584': {'publication date': '1976 Feb', 'sentence': 'Thirteen patients with rheumatoid or psoriatic arthritis who had not previously received corticosteroids were treated with prednisolone in a single-dose each morning.', 'subject score': 1000, 'object score': 1000}, 'PMID:34544940': {'publication date': '2021 Sep 21', 'sentence': 'A Japanese man in his 80s with psoriatic arthritis that was being treated with prednisolone was admitted for dyspnea.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0003872---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9109448",
-              "object": "MONDO:0011849",
-              "publications": [
-                "PMID:1155088",
-                "PMID:1275584",
-                "PMID:34544940"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:2001900': {'publication date': '1991 Feb', 'sentence': 'Genetically determined coincidence of Kaposi sarcoma and psoriasis in an HIV-negative patient after prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:23064668': {'publication date': '2012 Dec', 'sentence': \"The patient's past history revealed a 10-year history of psoriasis and chronic obstructive pulmonary disease treated with methotrexate and prednisolone.\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 320360,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005083",
-          "name": "psoriasis",
-          "description": "An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.; A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.; A skin abnormality characterized by redness and irritation, with thick, red skin that displays flaky, silver-white patches (scales). [HPO:probinson]; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have psoriasis also get a form of arthritis called psoriatic arthritis. A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast.  Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope. Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include: Infections Stress Dry skin Certain medicines  Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases ; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D011565",
-            "SNOMEDCT:9014002",
-            "ICD10:L40",
-            "MEDDRA:10058675",
-            "MONDO:0005083",
-            "DOID:8893",
-            "UMLS:C0033860",
-            "EFO:0000676",
-            "UMLS:C0262985",
-            "NCIT:C3346",
-            "NCIT:C27724",
-            "OMIM.PS:177900",
-            "OMIM:PS177900",
-            "SNOMEDCT:52230004",
-            "HP:0003765",
-            "MEDDRA:10037153",
-            "SNOMEDCT:238564003"
-          ],
-          "id": "MONDO:0005083",
-          "category": "biolink:Disease",
-          "all_names": [
-            "psoriasis",
-            "Psoriasiform eczema",
-            "Psoriasis",
-            "Psoriasiform dermatitis",
-            "Psoriasiform Dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.cdc.gov/psoriasis/index.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320360,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005083",
-              "name": "psoriasis",
-              "description": "An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.; A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.; A skin abnormality characterized by redness and irritation, with thick, red skin that displays flaky, silver-white patches (scales). [HPO:probinson]; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have psoriasis also get a form of arthritis called psoriatic arthritis. A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast.  Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope. Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include: Infections Stress Dry skin Certain medicines  Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases ; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D011565",
-                "SNOMEDCT:9014002",
-                "ICD10:L40",
-                "MEDDRA:10058675",
-                "MONDO:0005083",
-                "DOID:8893",
-                "UMLS:C0033860",
-                "EFO:0000676",
-                "UMLS:C0262985",
-                "NCIT:C3346",
-                "NCIT:C27724",
-                "OMIM.PS:177900",
-                "OMIM:PS177900",
-                "SNOMEDCT:52230004",
-                "HP:0003765",
-                "MEDDRA:10037153",
-                "SNOMEDCT:238564003"
-              ],
-              "id": "MONDO:0005083",
-              "category": "biolink:Disease",
-              "all_names": [
-                "psoriasis",
-                "Psoriasiform eczema",
-                "Psoriasis",
-                "Psoriasiform dermatitis",
-                "Psoriasiform Dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.cdc.gov/psoriasis/index.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14436218,
-            "start": 568,
-            "end": 320360,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2001900': {'publication date': '1991 Feb', 'sentence': 'Genetically determined coincidence of Kaposi sarcoma and psoriasis in an HIV-negative patient after prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:23064668': {'publication date': '2012 Dec', 'sentence': \"The patient's past history revealed a 10-year history of psoriasis and chronic obstructive pulmonary disease treated with methotrexate and prednisolone.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0033860---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "14742554",
-              "object": "MONDO:0005083",
-              "publications": [
-                "PMID:2001900",
-                "PMID:23064668"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:32933857': {'publication date': '2020 Sep 12', 'sentence': 'The most common coexisting conditions were HIV infection (30%), prednisolone therapy (16.9%), and diabetes mellitus (15.7%).', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 517695,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005109",
-          "name": "HIV infectious disease",
-          "description": "A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.",
-          "equivalent_curies": [
-            "UMLS:C0019693",
-            "ICD9:042-042.99",
-            "SNOMEDCT:86406008",
-            "NCIT:C3108",
-            "MEDDRA:10020161",
-            "PDQ:CDR0000585059",
-            "MEDDRA:10020443",
-            "MEDDRA:10020160",
-            "MONDO:0005109",
-            "EFO:0000764",
-            "MEDDRA:10020172",
-            "MESH:D015658",
-            "DOID:526"
-          ],
-          "id": "MONDO:0005109",
-          "category": "biolink:Disease",
-          "all_names": [
-            "human immunodeficiency virus infectious disease",
-            "HIV infection",
-            "HIV infectious disease",
-            "HIV Infection",
-            "Human immunodeficiency virus [hiv] infection",
-            "HIV Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/hiv",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000602.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517695,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005109",
-              "name": "HIV infectious disease",
-              "description": "A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.",
-              "equivalent_curies": [
-                "UMLS:C0019693",
-                "ICD9:042-042.99",
-                "SNOMEDCT:86406008",
-                "NCIT:C3108",
-                "MEDDRA:10020161",
-                "PDQ:CDR0000585059",
-                "MEDDRA:10020443",
-                "MEDDRA:10020160",
-                "MONDO:0005109",
-                "EFO:0000764",
-                "MEDDRA:10020172",
-                "MESH:D015658",
-                "DOID:526"
-              ],
-              "id": "MONDO:0005109",
-              "category": "biolink:Disease",
-              "all_names": [
-                "human immunodeficiency virus infectious disease",
-                "HIV infection",
-                "HIV infectious disease",
-                "HIV Infection",
-                "Human immunodeficiency virus [hiv] infection",
-                "HIV Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/hiv",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000602.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22075896,
-            "start": 568,
-            "end": 517695,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32933857': {'publication date': '2020 Sep 12', 'sentence': 'The most common coexisting conditions were HIV infection (30%), prednisolone therapy (16.9%), and diabetes mellitus (15.7%).', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0019693---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "22500116",
-              "object": "MONDO:0005109",
-              "publications": [
-                "PMID:32933857"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:34030751': {'publication date': '2021 May 25', 'sentence': 'This study assessed the antiparasitic and anti-inflammatory effects of Citrus limon and Capsicum frutescens on murine trichinellosis and compared them with those of albendazole and prednisolone, which are conventionally used to treat trichinellosis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 508253,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019444",
-          "name": "trichinellosis",
-          "description": "A parasitic infection caused by larvae of worms of the genus Trichinella. It is transmitted to humans by ingesting raw or undercooked meat from infected animals. Signs and symptoms include abdominal discomfort, nausea, vomiting, fever, diarrhea, headache, coughing, myalgias, arthralgias, and eye swelling.; An infection with TRICHINELLA. It is caused by eating raw or undercooked meat that is infected with larvae of nematode worms TRICHINELLA genus. All members of the TRICHINELLA genus can infect human in addition to TRICHINELLA SPIRALIS, the traditional etiological agent. It is distributed throughout much of the world and is re-emerging in some parts as a public health hazard and a food safety problem.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0040896",
-            "EFO:0007520",
-            "SNOMEDCT:709018004",
-            "DOID:9784",
-            "MONDO:0019444",
-            "NCIT:C85199",
-            "ORPHANET:863",
-            "ICD9:124",
-            "MESH:D014235",
-            "MEDDRA:10044608",
-            "ICD10:B75",
-            "MEDDRA:10044609"
-          ],
-          "id": "MONDO:0019444",
-          "category": "biolink:Disease",
-          "all_names": [
-            "trichinellosis",
-            "Trichinosis",
-            "Trichinellosis",
-            "trichinosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.dpd.cdc.gov/dpdx/html/trichinellosis.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 508253,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019444",
-              "name": "trichinellosis",
-              "description": "A parasitic infection caused by larvae of worms of the genus Trichinella. It is transmitted to humans by ingesting raw or undercooked meat from infected animals. Signs and symptoms include abdominal discomfort, nausea, vomiting, fever, diarrhea, headache, coughing, myalgias, arthralgias, and eye swelling.; An infection with TRICHINELLA. It is caused by eating raw or undercooked meat that is infected with larvae of nematode worms TRICHINELLA genus. All members of the TRICHINELLA genus can infect human in addition to TRICHINELLA SPIRALIS, the traditional etiological agent. It is distributed throughout much of the world and is re-emerging in some parts as a public health hazard and a food safety problem.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0040896",
-                "EFO:0007520",
-                "SNOMEDCT:709018004",
-                "DOID:9784",
-                "MONDO:0019444",
-                "NCIT:C85199",
-                "ORPHANET:863",
-                "ICD9:124",
-                "MESH:D014235",
-                "MEDDRA:10044608",
-                "ICD10:B75",
-                "MEDDRA:10044609"
-              ],
-              "id": "MONDO:0019444",
-              "category": "biolink:Disease",
-              "all_names": [
-                "trichinellosis",
-                "Trichinosis",
-                "Trichinellosis",
-                "trichinosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.dpd.cdc.gov/dpdx/html/trichinellosis.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22942849,
-            "start": 568,
-            "end": 508253,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34030751': {'publication date': '2021 May 25', 'sentence': 'This study assessed the antiparasitic and anti-inflammatory effects of Citrus limon and Capsicum frutescens on murine trichinellosis and compared them with those of albendazole and prednisolone, which are conventionally used to treat trichinellosis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0040896---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "23374627",
-              "object": "MONDO:0019444",
-              "publications": [
-                "PMID:34030751"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:18489605': {'publication date': '2008 Jul', 'sentence': 'Acute generalized exanthematous pustulosis induced by high-dose prednisolone in a young woman with optic neuritis owing to disseminated encephalomyelitis.', 'subject score': 901, 'object score': 1000}, 'PMID:18575879': {'publication date': '2008 Oct', 'sentence': 'BACKGROUND: In this study, patients with optic neuritis were treated with high-dose prednisolone.', 'subject score': 901, 'object score': 1000}, 'PMID:18805845': {'publication date': '2009 Feb', 'sentence': 'CASE PRESENTATION: In this study, we report on the exceptional case of a young female treated with intravenous high-dose prednisolone for optic neuritis who developed acute generalized exanthematous pustulosis (AGEP).', 'subject score': 861, 'object score': 1000}, 'PMID:30577778': {'publication date': '2018 Dec 21', 'sentence': 'CASE PRESENTATION: We describe the case of a 45-year-old man with MOG-IgG1-positive highly relapsing optic neuritis who had experienced 5 attacks over 21 months and had monocular blindness despite prednisolone and azathioprine therapy.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318789,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005885",
-          "name": "optic neuritis",
-          "description": "A disorder characterized by inflammation of the optic nerve. Causes include autoimmune disorders, infections, toxins, drugs, and multiple sclerosis. It may manifest with acute loss of vision and pain.; Inflammation of the optic nerve. Commonly associated conditions include autoimmune disorders such as MULTIPLE SCLEROSIS, infections, and granulomatous diseases. Clinical features include retro-orbital pain that is aggravated by eye movement, loss of color vision, and contrast sensitivity that may progress to severe visual loss, an afferent pupillary defect (Marcus-Gunn pupil), and in some instances optic disc hyperemia and swelling. Inflammation may occur in the portion of the nerve within the globe (neuropapillitis or anterior optic neuritis) or the portion behind the globe (retrobulbar neuritis or posterior optic neuritis).; Inflammation of the optic nerve. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D009902",
-            "NCIT:C84950",
-            "DOID:1210",
-            "HP:0100653",
-            "ICD10:H46",
-            "MEDDRA:10030942",
-            "MONDO:0005885",
-            "UMLS:C0029134",
-            "EFO:0007405",
-            "MEDDRA:10030946",
-            "ICD9:377.3",
-            "MEDDRA:10029247",
-            "MEDDRA:10030944",
-            "SNOMEDCT:66760008"
-          ],
-          "id": "MONDO:0005885",
-          "category": "biolink:Disease",
-          "all_names": [
-            "optic neuritis",
-            "Optic neuritis",
-            "Optic Neuritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.mayoclinic.org/diseases-conditions/optic-neuritis/symptoms-causes/syc-20354953",
-            "https://rarediseases.info.nih.gov/diseases/7320/optic-neuritis",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318789,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005885",
-              "name": "optic neuritis",
-              "description": "A disorder characterized by inflammation of the optic nerve. Causes include autoimmune disorders, infections, toxins, drugs, and multiple sclerosis. It may manifest with acute loss of vision and pain.; Inflammation of the optic nerve. Commonly associated conditions include autoimmune disorders such as MULTIPLE SCLEROSIS, infections, and granulomatous diseases. Clinical features include retro-orbital pain that is aggravated by eye movement, loss of color vision, and contrast sensitivity that may progress to severe visual loss, an afferent pupillary defect (Marcus-Gunn pupil), and in some instances optic disc hyperemia and swelling. Inflammation may occur in the portion of the nerve within the globe (neuropapillitis or anterior optic neuritis) or the portion behind the globe (retrobulbar neuritis or posterior optic neuritis).; Inflammation of the optic nerve. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D009902",
-                "NCIT:C84950",
-                "DOID:1210",
-                "HP:0100653",
-                "ICD10:H46",
-                "MEDDRA:10030942",
-                "MONDO:0005885",
-                "UMLS:C0029134",
-                "EFO:0007405",
-                "MEDDRA:10030946",
-                "ICD9:377.3",
-                "MEDDRA:10029247",
-                "MEDDRA:10030944",
-                "SNOMEDCT:66760008"
-              ],
-              "id": "MONDO:0005885",
-              "category": "biolink:Disease",
-              "all_names": [
-                "optic neuritis",
-                "Optic neuritis",
-                "Optic Neuritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.mayoclinic.org/diseases-conditions/optic-neuritis/symptoms-causes/syc-20354953",
-                "https://rarediseases.info.nih.gov/diseases/7320/optic-neuritis",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13469270,
-            "start": 568,
-            "end": 318789,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18489605': {'publication date': '2008 Jul', 'sentence': 'Acute generalized exanthematous pustulosis induced by high-dose prednisolone in a young woman with optic neuritis owing to disseminated encephalomyelitis.', 'subject score': 901, 'object score': 1000}, 'PMID:18575879': {'publication date': '2008 Oct', 'sentence': 'BACKGROUND: In this study, patients with optic neuritis were treated with high-dose prednisolone.', 'subject score': 901, 'object score': 1000}, 'PMID:18805845': {'publication date': '2009 Feb', 'sentence': 'CASE PRESENTATION: In this study, we report on the exceptional case of a young female treated with intravenous high-dose prednisolone for optic neuritis who developed acute generalized exanthematous pustulosis (AGEP).', 'subject score': 861, 'object score': 1000}, 'PMID:30577778': {'publication date': '2018 Dec 21', 'sentence': 'CASE PRESENTATION: We describe the case of a 45-year-old man with MOG-IgG1-positive highly relapsing optic neuritis who had experienced 5 attacks over 21 months and had monocular blindness despite prednisolone and azathioprine therapy.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0029134---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "13758030",
-              "object": "MONDO:0005885",
-              "publications": [
-                "PMID:18489605",
-                "PMID:18575879",
-                "PMID:18805845",
-                "PMID:30577778"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:13318863': {'publication date': '1956 May', 'sentence': 'REPORT of the Committee on New Drugs of the Research Council of the American Academy of Allergy, 1955-56; studies on prednisone and prednisolone in ragweed pollinosis.', 'subject score': 1000, 'object score': 888}, 'PMID:13346311': {'publication date': '1956 Jul', 'sentence': 'Prednisone and prednisolone in refractory pollinosis and pollen asthma.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 317004,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005324",
-          "name": "seasonal allergic rhinitis",
-          "description": "Allergic rhinitis caused by outdoor allergens.; Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS.; It is characterized by one or more symptoms including sneezing, itching, nasal congestion, and rhinorrhea. [PMID:11449200]; An allergy experienced at a particular time of year when trees or grasses pollinate and elicit an allergic reaction. [HPO:probinson]",
-          "equivalent_curies": [
-            "HP:0012395",
-            "NCIT:C92188",
-            "SNOMEDCT:300910009",
-            "PSY:22320",
-            "MEDDRA:10001726",
-            "SNOMEDCT:21719001",
-            "MEDDRA:10019170",
-            "MONDO:0005324",
-            "MEDDRA:10039776",
-            "MEDDRA:10048908",
-            "MEDDRA:10036020",
-            "SNOMEDCT:444316004",
-            "MESH:D006255",
-            "SNOMEDCT:367498001",
-            "MEDDRA:10036019",
-            "UMLS:C0018621"
-          ],
-          "id": "MONDO:0005324",
-          "category": "biolink:Disease",
-          "all_names": [
-            "seasonal allergic rhinitis",
-            "Seasonal Allergic Rhinitis",
-            "Rhinitis, Allergic, Seasonal",
-            "Seasonal allergy",
-            "Hay Fever",
-            "Hay fever"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:11449200",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317004,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005324",
-              "name": "seasonal allergic rhinitis",
-              "description": "Allergic rhinitis caused by outdoor allergens.; Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS.; It is characterized by one or more symptoms including sneezing, itching, nasal congestion, and rhinorrhea. [PMID:11449200]; An allergy experienced at a particular time of year when trees or grasses pollinate and elicit an allergic reaction. [HPO:probinson]",
-              "equivalent_curies": [
-                "HP:0012395",
-                "NCIT:C92188",
-                "SNOMEDCT:300910009",
-                "PSY:22320",
-                "MEDDRA:10001726",
-                "SNOMEDCT:21719001",
-                "MEDDRA:10019170",
-                "MONDO:0005324",
-                "MEDDRA:10039776",
-                "MEDDRA:10048908",
-                "MEDDRA:10036020",
-                "SNOMEDCT:444316004",
-                "MESH:D006255",
-                "SNOMEDCT:367498001",
-                "MEDDRA:10036019",
-                "UMLS:C0018621"
-              ],
-              "id": "MONDO:0005324",
-              "category": "biolink:Disease",
-              "all_names": [
-                "seasonal allergic rhinitis",
-                "Seasonal Allergic Rhinitis",
-                "Rhinitis, Allergic, Seasonal",
-                "Seasonal allergy",
-                "Hay Fever",
-                "Hay fever"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:11449200",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10277145,
-            "start": 568,
-            "end": 317004,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13318863': {'publication date': '1956 May', 'sentence': 'REPORT of the Committee on New Drugs of the Research Council of the American Academy of Allergy, 1955-56; studies on prednisone and prednisolone in ragweed pollinosis.', 'subject score': 1000, 'object score': 888}, 'PMID:13346311': {'publication date': '1956 Jul', 'sentence': 'Prednisone and prednisolone in refractory pollinosis and pollen asthma.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0018621---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10503828",
-              "object": "MONDO:0005324",
-              "publications": [
-                "PMID:13318863",
-                "PMID:13346311"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:22980607': {'publication date': '2012 Sep', 'sentence': 'CONCLUSION: Flu/Cy/ATG conditioning regimen, bone marrow as stem cell source and CSA, prednisolone and short methotrexate regimen were associated with better survival in AA.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 315782,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
-          "name": "aplastic anemia",
-          "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What causes aplastic anemia? The causes of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0015909",
-            "MEDDRA:10002037",
-            "HP:0001915",
-            "MEDDRA:10002967",
-            "MEDDRA:10002274",
-            "MEDDRA:10002969",
-            "MESH:D000741",
-            "SNOMEDCT:306058006",
-            "PDQ:CDR0000489004",
-            "NCIT:C2870",
-            "MEDDRA:10002968",
-            "DOID:12449",
-            "MEDDRA:10002970",
-            "ICD9:284.9",
-            "SNOMEDCT:304132006",
-            "UMLS:C0002874",
-            "ICD10:D61.9",
-            "ORPHANET:182040"
-          ],
-          "id": "MONDO:0015909",
-          "category": "biolink:Disease",
-          "all_names": [
-            "aplastic anemia",
-            "Aplastic Anemia",
-            "Aplastic anemia",
-            "Aplastic anemia, unspecified",
-            "obsolete_Medullar aplasia",
-            "Anemia, Aplastic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
-            "http://en.wikipedia.org/wiki/aplastic_anemia",
-            "PMID:21239768",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315782,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
-              "name": "aplastic anemia",
-              "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What causes aplastic anemia? The causes of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0015909",
-                "MEDDRA:10002037",
-                "HP:0001915",
-                "MEDDRA:10002967",
-                "MEDDRA:10002274",
-                "MEDDRA:10002969",
-                "MESH:D000741",
-                "SNOMEDCT:306058006",
-                "PDQ:CDR0000489004",
-                "NCIT:C2870",
-                "MEDDRA:10002968",
-                "DOID:12449",
-                "MEDDRA:10002970",
-                "ICD9:284.9",
-                "SNOMEDCT:304132006",
-                "UMLS:C0002874",
-                "ICD10:D61.9",
-                "ORPHANET:182040"
-              ],
-              "id": "MONDO:0015909",
-              "category": "biolink:Disease",
-              "all_names": [
-                "aplastic anemia",
-                "Aplastic Anemia",
-                "Aplastic anemia",
-                "Aplastic anemia, unspecified",
-                "obsolete_Medullar aplasia",
-                "Anemia, Aplastic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
-                "http://en.wikipedia.org/wiki/aplastic_anemia",
-                "PMID:21239768",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16154862,
-            "start": 568,
-            "end": 315782,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22980607': {'publication date': '2012 Sep', 'sentence': 'CONCLUSION: Flu/Cy/ATG conditioning regimen, bone marrow as stem cell source and CSA, prednisolone and short methotrexate regimen were associated with better survival in AA.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0002874---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16502712",
-              "object": "MONDO:0015909",
-              "publications": [
-                "PMID:22980607"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:20467197': {'publication date': '2010', 'sentence': 'We report a case of subcutaneous abscess caused by Nocardia farcinica in a 44-year-old man, who had been treated with systemic prednisolone and cyclosporin for aplastic anemia.', 'subject score': 888, 'object score': 1000}, 'PMID:2634465': {'publication date': '1989 Oct', 'sentence': 'Here we report a 11-year-old boy who was initially diagnosed as aplastic anemia and treated with prednisolone and androgen with prompt response terminated into overt acute lymphoblastic leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:2724733': {'publication date': '1989 Jan', 'sentence': 'Aplastic anemia was effectively managed with prednisolone and mepitiostane pre-operatively.', 'subject score': 1000, 'object score': 1000}, 'PMID:4054169': {'publication date': '1985 Sep', 'sentence': 'During an episode of aplastic anaemia she was treated with prednisolone, with a subsequent dramatic fall of serum calcium despite 1 alpha D3 treatment and serum 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in the high-normal range.', 'subject score': 1000, 'object score': 1000}, 'PMID:6810992': {'publication date': '1982 Sep 18', 'sentence': 'The aplastic anaemia worsened despite treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 315782,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
-          "name": "aplastic anemia",
-          "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What causes aplastic anemia? The causes of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0015909",
-            "MEDDRA:10002037",
-            "HP:0001915",
-            "MEDDRA:10002967",
-            "MEDDRA:10002274",
-            "MEDDRA:10002969",
-            "MESH:D000741",
-            "SNOMEDCT:306058006",
-            "PDQ:CDR0000489004",
-            "NCIT:C2870",
-            "MEDDRA:10002968",
-            "DOID:12449",
-            "MEDDRA:10002970",
-            "ICD9:284.9",
-            "SNOMEDCT:304132006",
-            "UMLS:C0002874",
-            "ICD10:D61.9",
-            "ORPHANET:182040"
-          ],
-          "id": "MONDO:0015909",
-          "category": "biolink:Disease",
-          "all_names": [
-            "aplastic anemia",
-            "Aplastic Anemia",
-            "Aplastic anemia",
-            "Aplastic anemia, unspecified",
-            "obsolete_Medullar aplasia",
-            "Anemia, Aplastic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
-            "http://en.wikipedia.org/wiki/aplastic_anemia",
-            "PMID:21239768",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315782,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
-              "name": "aplastic anemia",
-              "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What causes aplastic anemia? The causes of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0015909",
-                "MEDDRA:10002037",
-                "HP:0001915",
-                "MEDDRA:10002967",
-                "MEDDRA:10002274",
-                "MEDDRA:10002969",
-                "MESH:D000741",
-                "SNOMEDCT:306058006",
-                "PDQ:CDR0000489004",
-                "NCIT:C2870",
-                "MEDDRA:10002968",
-                "DOID:12449",
-                "MEDDRA:10002970",
-                "ICD9:284.9",
-                "SNOMEDCT:304132006",
-                "UMLS:C0002874",
-                "ICD10:D61.9",
-                "ORPHANET:182040"
-              ],
-              "id": "MONDO:0015909",
-              "category": "biolink:Disease",
-              "all_names": [
-                "aplastic anemia",
-                "Aplastic Anemia",
-                "Aplastic anemia",
-                "Aplastic anemia, unspecified",
-                "obsolete_Medullar aplasia",
-                "Anemia, Aplastic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
-                "http://en.wikipedia.org/wiki/aplastic_anemia",
-                "PMID:21239768",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14682208,
-            "start": 568,
-            "end": 315782,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20467197': {'publication date': '2010', 'sentence': 'We report a case of subcutaneous abscess caused by Nocardia farcinica in a 44-year-old man, who had been treated with systemic prednisolone and cyclosporin for aplastic anemia.', 'subject score': 888, 'object score': 1000}, 'PMID:2634465': {'publication date': '1989 Oct', 'sentence': 'Here we report a 11-year-old boy who was initially diagnosed as aplastic anemia and treated with prednisolone and androgen with prompt response terminated into overt acute lymphoblastic leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:2724733': {'publication date': '1989 Jan', 'sentence': 'Aplastic anemia was effectively managed with prednisolone and mepitiostane pre-operatively.', 'subject score': 1000, 'object score': 1000}, 'PMID:4054169': {'publication date': '1985 Sep', 'sentence': 'During an episode of aplastic anaemia she was treated with prednisolone, with a subsequent dramatic fall of serum calcium despite 1 alpha D3 treatment and serum 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in the high-normal range.', 'subject score': 1000, 'object score': 1000}, 'PMID:6810992': {'publication date': '1982 Sep 18', 'sentence': 'The aplastic anaemia worsened despite treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0002874---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "14992803",
-              "object": "MONDO:0015909",
-              "publications": [
-                "PMID:20467197",
-                "PMID:2634465",
-                "PMID:2724733",
-                "PMID:4054169",
-                "PMID:6810992"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:13636697': {'publication date': '1959 Apr', 'sentence': 'Long-term use of prednisone and prednisolone in juvenile rheumatoid arthritis; a report of fifteen cases.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 300724,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011429",
-          "name": "juvenile idiopathic arthritis",
-          "description": "A group of chronic, inflammatory childhood disorders of unknown etiology that primarily involve joints.; Arthritis in children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:410502007",
-            "MEDDRA:10034164",
-            "ICD9:714.33",
-            "UMLS:C0157916",
-            "ICD9:714.32",
-            "UMLS:C3714757",
-            "DOID:676",
-            "HP:0005681",
-            "EFO:0002609",
-            "ICD9:714.31",
-            "MEDDRA:10036038",
-            "MESH:D001171",
-            "MEDDRA:10027842",
-            "MEDDRA:10034165",
-            "MEDDRA:10034166",
-            "OMIM:604302",
-            "MEDDRA:10023266",
-            "MEDDRA:10023267",
-            "NCIT:C61279",
-            "ICD9:714.3",
-            "UMLS:C0157918",
-            "NCIT:C114357",
-            "SNOMEDCT:410795001",
-            "UMLS:C0157917",
-            "MONDO:0011429",
-            "MEDDRA:10059177",
-            "ORPHANET:92",
-            "MEDDRA:10059176",
-            "UMLS:C3495559",
-            "SNOMEDCT:16024431000119108",
-            "ICD10:M08.4"
-          ],
-          "id": "MONDO:0011429",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Arthritis, Juvenile",
-            "Oligoarticular Still Disease",
-            "Polyarticular juvenile rheumatoid arthritis, acute",
-            "juvenile idiopathic arthritis",
-            "Monoarticular juvenile rheumatoid arthritis",
-            "Juvenile Idiopathic Arthritis",
-            "Pauciarticular juvenile rheumatoid arthritis",
-            "juvenile rheumatoid arthritis",
-            "Acute polyarticular juvenile rheumatoid arthritis",
-            "Rheumatoid arthritis, systemic juvenile related phenotypic feature",
-            "Juvenile arthritis",
-            "Juvenile chronic polyarthritis",
-            "Juvenile idiopathic arthritis",
-            "Juvenile rheumatoid arthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000451.htm",
-            "http://www.umm.edu/ency/article/000451.htm",
-            "https://en.wikipedia.org/wiki/subtalar_joint",
-            "http://www.mayoclinic.com/health/juvenile-rheumatoid-arthritis/ds00018"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 300724,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011429",
-              "name": "juvenile idiopathic arthritis",
-              "description": "A group of chronic, inflammatory childhood disorders of unknown etiology that primarily involve joints.; Arthritis in children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:410502007",
-                "MEDDRA:10034164",
-                "ICD9:714.33",
-                "UMLS:C0157916",
-                "ICD9:714.32",
-                "UMLS:C3714757",
-                "DOID:676",
-                "HP:0005681",
-                "EFO:0002609",
-                "ICD9:714.31",
-                "MEDDRA:10036038",
-                "MESH:D001171",
-                "MEDDRA:10027842",
-                "MEDDRA:10034165",
-                "MEDDRA:10034166",
-                "OMIM:604302",
-                "MEDDRA:10023266",
-                "MEDDRA:10023267",
-                "NCIT:C61279",
-                "ICD9:714.3",
-                "UMLS:C0157918",
-                "NCIT:C114357",
-                "SNOMEDCT:410795001",
-                "UMLS:C0157917",
-                "MONDO:0011429",
-                "MEDDRA:10059177",
-                "ORPHANET:92",
-                "MEDDRA:10059176",
-                "UMLS:C3495559",
-                "SNOMEDCT:16024431000119108",
-                "ICD10:M08.4"
-              ],
-              "id": "MONDO:0011429",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Arthritis, Juvenile",
-                "Oligoarticular Still Disease",
-                "Polyarticular juvenile rheumatoid arthritis, acute",
-                "juvenile idiopathic arthritis",
-                "Monoarticular juvenile rheumatoid arthritis",
-                "Juvenile Idiopathic Arthritis",
-                "Pauciarticular juvenile rheumatoid arthritis",
-                "juvenile rheumatoid arthritis",
-                "Acute polyarticular juvenile rheumatoid arthritis",
-                "Rheumatoid arthritis, systemic juvenile related phenotypic feature",
-                "Juvenile arthritis",
-                "Juvenile chronic polyarthritis",
-                "Juvenile idiopathic arthritis",
-                "Juvenile rheumatoid arthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000451.htm",
-                "http://www.umm.edu/ency/article/000451.htm",
-                "https://en.wikipedia.org/wiki/subtalar_joint",
-                "http://www.mayoclinic.com/health/juvenile-rheumatoid-arthritis/ds00018"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10348693,
-            "start": 568,
-            "end": 300724,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13636697': {'publication date': '1959 Apr', 'sentence': 'Long-term use of prednisone and prednisolone in juvenile rheumatoid arthritis; a report of fifteen cases.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C3495559---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10576837",
-              "object": "MONDO:0011429",
-              "publications": [
-                "PMID:13636697"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:30701571': {'publication date': '2019 Apr', 'sentence': 'Here, we report the case of an 8-year-old girl with a 5-year history of multiple subcutaneous nodules on her extremities and a right wrist joint contracture who had been previously diagnosed with juvenile idiopathic arthritis and treated with salazosulfapyridine, low-dose prednisolone (PSL) and methotrexate.', 'subject score': 901, 'object score': 1000}, 'PMID:7165998': {'publication date': '1982 Dec', 'sentence': \"These studies suggest that not only is a still wider range of culture conditions required to assess fully the differences in lymphocyte function related to disease activity and prednisolone treatment in JCA or Behcet's, but also that the use of a narrow set of 'optimized' conditions may be misleading.\", 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 300724,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011429",
-          "name": "juvenile idiopathic arthritis",
-          "description": "A group of chronic, inflammatory childhood disorders of unknown etiology that primarily involve joints.; Arthritis in children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:410502007",
-            "MEDDRA:10034164",
-            "ICD9:714.33",
-            "UMLS:C0157916",
-            "ICD9:714.32",
-            "UMLS:C3714757",
-            "DOID:676",
-            "HP:0005681",
-            "EFO:0002609",
-            "ICD9:714.31",
-            "MEDDRA:10036038",
-            "MESH:D001171",
-            "MEDDRA:10027842",
-            "MEDDRA:10034165",
-            "MEDDRA:10034166",
-            "OMIM:604302",
-            "MEDDRA:10023266",
-            "MEDDRA:10023267",
-            "NCIT:C61279",
-            "ICD9:714.3",
-            "UMLS:C0157918",
-            "NCIT:C114357",
-            "SNOMEDCT:410795001",
-            "UMLS:C0157917",
-            "MONDO:0011429",
-            "MEDDRA:10059177",
-            "ORPHANET:92",
-            "MEDDRA:10059176",
-            "UMLS:C3495559",
-            "SNOMEDCT:16024431000119108",
-            "ICD10:M08.4"
-          ],
-          "id": "MONDO:0011429",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Arthritis, Juvenile",
-            "Oligoarticular Still Disease",
-            "Polyarticular juvenile rheumatoid arthritis, acute",
-            "juvenile idiopathic arthritis",
-            "Monoarticular juvenile rheumatoid arthritis",
-            "Juvenile Idiopathic Arthritis",
-            "Pauciarticular juvenile rheumatoid arthritis",
-            "juvenile rheumatoid arthritis",
-            "Acute polyarticular juvenile rheumatoid arthritis",
-            "Rheumatoid arthritis, systemic juvenile related phenotypic feature",
-            "Juvenile arthritis",
-            "Juvenile chronic polyarthritis",
-            "Juvenile idiopathic arthritis",
-            "Juvenile rheumatoid arthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000451.htm",
-            "http://www.umm.edu/ency/article/000451.htm",
-            "https://en.wikipedia.org/wiki/subtalar_joint",
-            "http://www.mayoclinic.com/health/juvenile-rheumatoid-arthritis/ds00018"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 300724,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011429",
-              "name": "juvenile idiopathic arthritis",
-              "description": "A group of chronic, inflammatory childhood disorders of unknown etiology that primarily involve joints.; Arthritis in children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:410502007",
-                "MEDDRA:10034164",
-                "ICD9:714.33",
-                "UMLS:C0157916",
-                "ICD9:714.32",
-                "UMLS:C3714757",
-                "DOID:676",
-                "HP:0005681",
-                "EFO:0002609",
-                "ICD9:714.31",
-                "MEDDRA:10036038",
-                "MESH:D001171",
-                "MEDDRA:10027842",
-                "MEDDRA:10034165",
-                "MEDDRA:10034166",
-                "OMIM:604302",
-                "MEDDRA:10023266",
-                "MEDDRA:10023267",
-                "NCIT:C61279",
-                "ICD9:714.3",
-                "UMLS:C0157918",
-                "NCIT:C114357",
-                "SNOMEDCT:410795001",
-                "UMLS:C0157917",
-                "MONDO:0011429",
-                "MEDDRA:10059177",
-                "ORPHANET:92",
-                "MEDDRA:10059176",
-                "UMLS:C3495559",
-                "SNOMEDCT:16024431000119108",
-                "ICD10:M08.4"
-              ],
-              "id": "MONDO:0011429",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Arthritis, Juvenile",
-                "Oligoarticular Still Disease",
-                "Polyarticular juvenile rheumatoid arthritis, acute",
-                "juvenile idiopathic arthritis",
-                "Monoarticular juvenile rheumatoid arthritis",
-                "Juvenile Idiopathic Arthritis",
-                "Pauciarticular juvenile rheumatoid arthritis",
-                "juvenile rheumatoid arthritis",
-                "Acute polyarticular juvenile rheumatoid arthritis",
-                "Rheumatoid arthritis, systemic juvenile related phenotypic feature",
-                "Juvenile arthritis",
-                "Juvenile chronic polyarthritis",
-                "Juvenile idiopathic arthritis",
-                "Juvenile rheumatoid arthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000451.htm",
-                "http://www.umm.edu/ency/article/000451.htm",
-                "https://en.wikipedia.org/wiki/subtalar_joint",
-                "http://www.mayoclinic.com/health/juvenile-rheumatoid-arthritis/ds00018"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20433389,
-            "start": 568,
-            "end": 300724,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30701571': {'publication date': '2019 Apr', 'sentence': 'Here, we report the case of an 8-year-old girl with a 5-year history of multiple subcutaneous nodules on her extremities and a right wrist joint contracture who had been previously diagnosed with juvenile idiopathic arthritis and treated with salazosulfapyridine, low-dose prednisolone (PSL) and methotrexate.', 'subject score': 901, 'object score': 1000}, 'PMID:7165998': {'publication date': '1982 Dec', 'sentence': \"These studies suggest that not only is a still wider range of culture conditions required to assess fully the differences in lymphocyte function related to disease activity and prednisolone treatment in JCA or Behcet's, but also that the use of a narrow set of 'optimized' conditions may be misleading.\", 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C3495559---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "20836940",
-              "object": "MONDO:0011429",
-              "publications": [
-                "PMID:30701571",
-                "PMID:7165998"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:28675023': {'publication date': '2018 Jul', 'sentence': 'Purpose: The aim of this study was to compare asparaginase-related toxicities in two asparaginase preparations, namely native Escherichia coli L-asparaginase (L-ASP) and pegylated asparaginase (PEG-ASP) in combination with ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) in natural killer (NK)/T-cell lymphoma (NTCL).', 'subject score': 1000, 'object score': 875}}",
-    "p2": {
-      "start": {
-        "identity": 319679,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-          "name": "lymphoma",
-          "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:115244002",
-            "DOID:0060058",
-            "MONDO:0005062",
-            "SNOMEDCT:118600007",
-            "HP:0002665",
-            "NCIT:C7065",
-            "EFO:0000574",
-            "ORPHANET:223735",
-            "MESH:D008223",
-            "SNOMEDCT:188676008",
-            "PDQ:CDR0000041429",
-            "MEDDRA:10025316",
-            "UMLS:C0024299",
-            "NCIT:C3208",
-            "MEDDRA:10025632",
-            "MEDDRA:10025310",
-            "MEDDRA:10025633",
-            "SNOMEDCT:1163043007",
-            "ICD10:C85.9",
-            "UMLS:C1536843",
-            "UMLS:C0334621",
-            "MEDDRA:10025315"
-          ],
-          "id": "MONDO:0005062",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphocytic Neoplasm",
-            "Lymphoma",
-            "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-            "lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/lymphoma",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319679,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-              "name": "lymphoma",
-              "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:115244002",
-                "DOID:0060058",
-                "MONDO:0005062",
-                "SNOMEDCT:118600007",
-                "HP:0002665",
-                "NCIT:C7065",
-                "EFO:0000574",
-                "ORPHANET:223735",
-                "MESH:D008223",
-                "SNOMEDCT:188676008",
-                "PDQ:CDR0000041429",
-                "MEDDRA:10025316",
-                "UMLS:C0024299",
-                "NCIT:C3208",
-                "MEDDRA:10025632",
-                "MEDDRA:10025310",
-                "MEDDRA:10025633",
-                "SNOMEDCT:1163043007",
-                "ICD10:C85.9",
-                "UMLS:C1536843",
-                "UMLS:C0334621",
-                "MEDDRA:10025315"
-              ],
-              "id": "MONDO:0005062",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphocytic Neoplasm",
-                "Lymphoma",
-                "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-                "lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/lymphoma",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19363285,
-            "start": 568,
-            "end": 319679,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28675023': {'publication date': '2018 Jul', 'sentence': 'Purpose: The aim of this study was to compare asparaginase-related toxicities in two asparaginase preparations, namely native Escherichia coli L-asparaginase (L-ASP) and pegylated asparaginase (PEG-ASP) in combination with ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) in natural killer (NK)/T-cell lymphoma (NTCL).', 'subject score': 1000, 'object score': 875}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0024299---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "19750187",
-              "object": "MONDO:0005062",
-              "publications": [
-                "PMID:28675023"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:15005254': {'publication date': '2004 Feb', 'sentence': 'The patient was treated with chemotherapy by cyclophosphamide, hydroxydoxorubicin, vincristine and prednisolone (CHOP), however, it was ineffective, and the patient died of hemorrhage from the lymphoma involvement of the intestine 5 months after the onset of disease.', 'subject score': 1000, 'object score': 694}, 'PMID:15326651': {'publication date': '2004 Jul 17', 'sentence': 'The lymphoma was refractory to cyclophosphamide-doxorubicin-vincristine-prednisolone (CHOP); this was followed by intensive chemotherapy and autologous stem-cell transplantation, resulting finally in a complete remission.', 'subject score': 833, 'object score': 1000}, 'PMID:21253433': {'publication date': '2010 Dec', 'sentence': 'Diffuse large B-cell lymphoma was diagnosed through a cardiac catheterization-assisted percutaneous endomyocardial biopsy, and there was no evidence of extracardiac involvement of the lymphoma.The patient had a complete clinical response after systemic chemotherapy with a rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) regimen and additional post-chemotherapeutic radiation therapy.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319679,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-          "name": "lymphoma",
-          "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:115244002",
-            "DOID:0060058",
-            "MONDO:0005062",
-            "SNOMEDCT:118600007",
-            "HP:0002665",
-            "NCIT:C7065",
-            "EFO:0000574",
-            "ORPHANET:223735",
-            "MESH:D008223",
-            "SNOMEDCT:188676008",
-            "PDQ:CDR0000041429",
-            "MEDDRA:10025316",
-            "UMLS:C0024299",
-            "NCIT:C3208",
-            "MEDDRA:10025632",
-            "MEDDRA:10025310",
-            "MEDDRA:10025633",
-            "SNOMEDCT:1163043007",
-            "ICD10:C85.9",
-            "UMLS:C1536843",
-            "UMLS:C0334621",
-            "MEDDRA:10025315"
-          ],
-          "id": "MONDO:0005062",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphocytic Neoplasm",
-            "Lymphoma",
-            "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-            "lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/lymphoma",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319679,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-              "name": "lymphoma",
-              "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:115244002",
-                "DOID:0060058",
-                "MONDO:0005062",
-                "SNOMEDCT:118600007",
-                "HP:0002665",
-                "NCIT:C7065",
-                "EFO:0000574",
-                "ORPHANET:223735",
-                "MESH:D008223",
-                "SNOMEDCT:188676008",
-                "PDQ:CDR0000041429",
-                "MEDDRA:10025316",
-                "UMLS:C0024299",
-                "NCIT:C3208",
-                "MEDDRA:10025632",
-                "MEDDRA:10025310",
-                "MEDDRA:10025633",
-                "SNOMEDCT:1163043007",
-                "ICD10:C85.9",
-                "UMLS:C1536843",
-                "UMLS:C0334621",
-                "MEDDRA:10025315"
-              ],
-              "id": "MONDO:0005062",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphocytic Neoplasm",
-                "Lymphoma",
-                "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-                "lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/lymphoma",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10827742,
-            "start": 568,
-            "end": 319679,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15005254': {'publication date': '2004 Feb', 'sentence': 'The patient was treated with chemotherapy by cyclophosphamide, hydroxydoxorubicin, vincristine and prednisolone (CHOP), however, it was ineffective, and the patient died of hemorrhage from the lymphoma involvement of the intestine 5 months after the onset of disease.', 'subject score': 1000, 'object score': 694}, 'PMID:15326651': {'publication date': '2004 Jul 17', 'sentence': 'The lymphoma was refractory to cyclophosphamide-doxorubicin-vincristine-prednisolone (CHOP); this was followed by intensive chemotherapy and autologous stem-cell transplantation, resulting finally in a complete remission.', 'subject score': 833, 'object score': 1000}, 'PMID:21253433': {'publication date': '2010 Dec', 'sentence': 'Diffuse large B-cell lymphoma was diagnosed through a cardiac catheterization-assisted percutaneous endomyocardial biopsy, and there was no evidence of extracardiac involvement of the lymphoma.The patient had a complete clinical response after systemic chemotherapy with a rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) regimen and additional post-chemotherapeutic radiation therapy.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0024299---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11074135",
-              "object": "MONDO:0005062",
-              "publications": [
-                "PMID:15005254",
-                "PMID:15326651",
-                "PMID:21253433"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11518416': {'publication date': '2001 Aug', 'sentence': 'This paper presents the results of a prospective study to investigate the prognostic value of clinical staging, histological grading, immunophenotype, mitotic count and average numbers of argyrophilic nucleolar organiser region counts in dogs with multicentric lymphosarcoma treated with a standard chemotherapy protocol comprising vincristine, cyclophosphamide and prednisolone.', 'subject score': 1000, 'object score': 888}, 'PMID:11837901': {'publication date': '2001 Dec', 'sentence': 'PROCEDURE: An accepted chemotherapy protocol utilising l-asparaginase, vincristine, cyclophosphamide, doxorubicin, methotrexate and prednisolone was modified and used to treat 60 cats with lymphosarcoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:11899035': {'publication date': '2002', 'sentence': 'Chemotherapy with cyclophosphamide, vincristine, and prednisolone (COP) in cats with malignant lymphoma: new results with an old protocol.', 'subject score': 1000, 'object score': 1000}, 'PMID:14432695': {'publication date': '1959 May-Jun', 'sentence': '[Apropos of a case of lymphosarcoma treated with prednisolone and roentgenotherapy].', 'subject score': 1000, 'object score': 1000}, 'PMID:17993883': {'publication date': '2007 Nov', 'sentence': 'Eight patients were treated surgically with adjuvant postoperative radiotherapy, whereas eight patients with lymphoma treated with combination chemotherapy (vincristine, Adriamycin, cyclophosphamide, methotrexate, and prednisolone), the survival rate was very poor.', 'subject score': 1000, 'object score': 1000}, 'PMID:18762565': {'publication date': '2008', 'sentence': 'An 8-year-old, mixed-breed dog with preputial epitheliotropic lymphoma was initially treated with cyclophosphamide, vincristine, and prednisolone.', 'subject score': 1000, 'object score': 766}, 'PMID:1923457': {'publication date': '1991 Jun', 'sentence': 'Thirty-seven patients with malignant lymphoma were treated with mitoxantrone, ifosfamide, vindesine, and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:19620817': {'publication date': '2009 Jul', 'sentence': 'After a diagnosis of HHV-8-negative PEL-like lymphoma, she was treated with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisolone).', 'subject score': 1000, 'object score': 1000}, 'PMID:20059527': {'publication date': '2010 May', 'sentence': 'OBJECTIVE: The efficacy of pirarubicin (THP)-COP was previously compared with cyclophophamide + doxorubicin + vincristine + prednisolone (CHOP) in elderly patients with lymphoma.', 'subject score': 775, 'object score': 1000}, 'PMID:22489828': {'publication date': '2014 Mar', 'sentence': 'In this retrospective study, the efficacy and safety were examined for an intraperitoneal chemotherapy protocol-cyclophosphamide, vincristine and prednisolone (IP-COP) in 26 cats with malignant lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:22997596': {'publication date': '2012', 'sentence': 'We present the results of a long-term followup of two patients who were diagnosed with PRL and treated with cyclophosphamide, adriamycin, vincristine, prednisolone and rituximab (CHOP + R) regimen.', 'subject score': 1000, 'object score': 851}, 'PMID:23267908': {'publication date': '2012 Nov', 'sentence': 'The malignant lymphoma patient was treated by cyclophosphamide+doxorubicin+vincristine+prednisolone(CHOP) with rituximab.', 'subject score': 833, 'object score': 901}, 'PMID:24721419': {'publication date': '2014 Apr 11', 'sentence': 'The lymphoma went into complete remission after 6 courses of rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone/prednisolone therapy.', 'subject score': 851, 'object score': 1000}, 'PMID:26933263': {'publication date': '2016 Mar', 'sentence': 'Forty-four dogs with multicentric lymphoma were treated using a cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) induction protocol or treated using a cyclophosphamide, mitoxantrone, vincristine, and prednisolone (CMOP) induction protocol.', 'subject score': 1000, 'object score': 888}, 'PMID:27240922': {'publication date': '2016 Jul', 'sentence': 'Combination chemotherapy, using cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone (CHOP), is the most commonly used treatment for canine lymphoma.', 'subject score': 1000, 'object score': 888}, 'PMID:27777431': {'publication date': '2016 Oct', 'sentence': 'Malignant lymphoma was suspected as a possible underlying disease, but the histology of the lymph nodes led to a final diagnosis of KFD and treatment with prednisolone (1 mg/kg/day), resulting in clinical improvement.', 'subject score': 1000, 'object score': 1000}, 'PMID:2785612': {'publication date': '1989 Jan', 'sentence': 'Lymphoma was treated with cyclophosphamide, doxorubicin, vinblastine and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:29380942': {'publication date': '2018 Sep', 'sentence': 'The standard of care treatment for canine lymphoma is multi-agent chemotherapy containing prednisolone, cyclophosphamide, vincristine and an anthracycline such as doxorubicin (CHOP) or epirubicin (CEOP).', 'subject score': 822, 'object score': 888}, 'PMID:29958524': {'publication date': '2018 06', 'sentence': 'Permeability glycoprotein (P-glycoprotein, Pgp) immunohistochemistry (IHC) was evaluated in dogs with multicentric lymphoma treated with cyclophosphamide- doxorubicin-vincristine-prednisolone with or without L-Asparaginase.', 'subject score': 833, 'object score': 888}, 'PMID:30117253': {'publication date': '2018 Dec', 'sentence': 'The cyclophosphamide, doxorubicin, vincristine, and prednisolone protocol is widely accepted as a first line treatment for canine lymphoma.', 'subject score': 888, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 319679,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-          "name": "lymphoma",
-          "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:115244002",
-            "DOID:0060058",
-            "MONDO:0005062",
-            "SNOMEDCT:118600007",
-            "HP:0002665",
-            "NCIT:C7065",
-            "EFO:0000574",
-            "ORPHANET:223735",
-            "MESH:D008223",
-            "SNOMEDCT:188676008",
-            "PDQ:CDR0000041429",
-            "MEDDRA:10025316",
-            "UMLS:C0024299",
-            "NCIT:C3208",
-            "MEDDRA:10025632",
-            "MEDDRA:10025310",
-            "MEDDRA:10025633",
-            "SNOMEDCT:1163043007",
-            "ICD10:C85.9",
-            "UMLS:C1536843",
-            "UMLS:C0334621",
-            "MEDDRA:10025315"
-          ],
-          "id": "MONDO:0005062",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphocytic Neoplasm",
-            "Lymphoma",
-            "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-            "lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/lymphoma",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319679,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-              "name": "lymphoma",
-              "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:115244002",
-                "DOID:0060058",
-                "MONDO:0005062",
-                "SNOMEDCT:118600007",
-                "HP:0002665",
-                "NCIT:C7065",
-                "EFO:0000574",
-                "ORPHANET:223735",
-                "MESH:D008223",
-                "SNOMEDCT:188676008",
-                "PDQ:CDR0000041429",
-                "MEDDRA:10025316",
-                "UMLS:C0024299",
-                "NCIT:C3208",
-                "MEDDRA:10025632",
-                "MEDDRA:10025310",
-                "MEDDRA:10025633",
-                "SNOMEDCT:1163043007",
-                "ICD10:C85.9",
-                "UMLS:C1536843",
-                "UMLS:C0334621",
-                "MEDDRA:10025315"
-              ],
-              "id": "MONDO:0005062",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphocytic Neoplasm",
-                "Lymphoma",
-                "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-                "lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/lymphoma",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8882138,
-            "start": 568,
-            "end": 319679,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11518416': {'publication date': '2001 Aug', 'sentence': 'This paper presents the results of a prospective study to investigate the prognostic value of clinical staging, histological grading, immunophenotype, mitotic count and average numbers of argyrophilic nucleolar organiser region counts in dogs with multicentric lymphosarcoma treated with a standard chemotherapy protocol comprising vincristine, cyclophosphamide and prednisolone.', 'subject score': 1000, 'object score': 888}, 'PMID:11837901': {'publication date': '2001 Dec', 'sentence': 'PROCEDURE: An accepted chemotherapy protocol utilising l-asparaginase, vincristine, cyclophosphamide, doxorubicin, methotrexate and prednisolone was modified and used to treat 60 cats with lymphosarcoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:11899035': {'publication date': '2002', 'sentence': 'Chemotherapy with cyclophosphamide, vincristine, and prednisolone (COP) in cats with malignant lymphoma: new results with an old protocol.', 'subject score': 1000, 'object score': 1000}, 'PMID:14432695': {'publication date': '1959 May-Jun', 'sentence': '[Apropos of a case of lymphosarcoma treated with prednisolone and roentgenotherapy].', 'subject score': 1000, 'object score': 1000}, 'PMID:17993883': {'publication date': '2007 Nov', 'sentence': 'Eight patients were treated surgically with adjuvant postoperative radiotherapy, whereas eight patients with lymphoma treated with combination chemotherapy (vincristine, Adriamycin, cyclophosphamide, methotrexate, and prednisolone), the survival rate was very poor.', 'subject score': 1000, 'object score': 1000}, 'PMID:18762565': {'publication date': '2008', 'sentence': 'An 8-year-old, mixed-breed dog with preputial epitheliotropic lymphoma was initially treated with cyclophosphamide, vincristine, and prednisolone.', 'subject score': 1000, 'object score': 766}, 'PMID:1923457': {'publication date': '1991 Jun', 'sentence': 'Thirty-seven patients with malignant lymphoma were treated with mitoxantrone, ifosfamide, vindesine, and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:19620817': {'publication date': '2009 Jul', 'sentence': 'After a diagnosis of HHV-8-negative PEL-like lymphoma, she was treated with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisolone).', 'subject score': 1000, 'object score': 1000}, 'PMID:20059527': {'publication date': '2010 May', 'sentence': 'OBJECTIVE: The efficacy of pirarubicin (THP)-COP was previously compared with cyclophophamide + doxorubicin + vincristine + prednisolone (CHOP) in elderly patients with lymphoma.', 'subject score': 775, 'object score': 1000}, 'PMID:22489828': {'publication date': '2014 Mar', 'sentence': 'In this retrospective study, the efficacy and safety were examined for an intraperitoneal chemotherapy protocol-cyclophosphamide, vincristine and prednisolone (IP-COP) in 26 cats with malignant lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:22997596': {'publication date': '2012', 'sentence': 'We present the results of a long-term followup of two patients who were diagnosed with PRL and treated with cyclophosphamide, adriamycin, vincristine, prednisolone and rituximab (CHOP + R) regimen.', 'subject score': 1000, 'object score': 851}, 'PMID:23267908': {'publication date': '2012 Nov', 'sentence': 'The malignant lymphoma patient was treated by cyclophosphamide+doxorubicin+vincristine+prednisolone(CHOP) with rituximab.', 'subject score': 833, 'object score': 901}, 'PMID:24721419': {'publication date': '2014 Apr 11', 'sentence': 'The lymphoma went into complete remission after 6 courses of rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone/prednisolone therapy.', 'subject score': 851, 'object score': 1000}, 'PMID:26933263': {'publication date': '2016 Mar', 'sentence': 'Forty-four dogs with multicentric lymphoma were treated using a cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) induction protocol or treated using a cyclophosphamide, mitoxantrone, vincristine, and prednisolone (CMOP) induction protocol.', 'subject score': 1000, 'object score': 888}, 'PMID:27240922': {'publication date': '2016 Jul', 'sentence': 'Combination chemotherapy, using cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone (CHOP), is the most commonly used treatment for canine lymphoma.', 'subject score': 1000, 'object score': 888}, 'PMID:27777431': {'publication date': '2016 Oct', 'sentence': 'Malignant lymphoma was suspected as a possible underlying disease, but the histology of the lymph nodes led to a final diagnosis of KFD and treatment with prednisolone (1 mg/kg/day), resulting in clinical improvement.', 'subject score': 1000, 'object score': 1000}, 'PMID:2785612': {'publication date': '1989 Jan', 'sentence': 'Lymphoma was treated with cyclophosphamide, doxorubicin, vinblastine and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:29380942': {'publication date': '2018 Sep', 'sentence': 'The standard of care treatment for canine lymphoma is multi-agent chemotherapy containing prednisolone, cyclophosphamide, vincristine and an anthracycline such as doxorubicin (CHOP) or epirubicin (CEOP).', 'subject score': 822, 'object score': 888}, 'PMID:29958524': {'publication date': '2018 06', 'sentence': 'Permeability glycoprotein (P-glycoprotein, Pgp) immunohistochemistry (IHC) was evaluated in dogs with multicentric lymphoma treated with cyclophosphamide- doxorubicin-vincristine-prednisolone with or without L-Asparaginase.', 'subject score': 833, 'object score': 888}, 'PMID:30117253': {'publication date': '2018 Dec', 'sentence': 'The cyclophosphamide, doxorubicin, vincristine, and prednisolone protocol is widely accepted as a first line treatment for canine lymphoma.', 'subject score': 888, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0024299---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9077262",
-              "object": "MONDO:0005062",
-              "publications": [
-                "PMID:11518416",
-                "PMID:11837901",
-                "PMID:11899035",
-                "PMID:14432695",
-                "PMID:17993883",
-                "PMID:18762565",
-                "PMID:1923457",
-                "PMID:19620817",
-                "PMID:20059527",
-                "PMID:22489828",
-                "PMID:22997596",
-                "PMID:23267908",
-                "PMID:24721419",
-                "PMID:26933263",
-                "PMID:27240922",
-                "PMID:27777431",
-                "PMID:2785612",
-                "PMID:29380942",
-                "PMID:29958524",
-                "PMID:30117253"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:22442637': {'publication date': '2012', 'sentence': 'Coadministration of cyclosporin a with prednisolone in acute interstitial pneumonia complicating polymyositis/dermatomyositis.', 'subject score': 1000, 'object score': 864}}",
-    "p2": {
-      "start": {
-        "identity": 530650,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016367",
-          "name": "dermatomyositis",
-          "description": "Inflammation of the skin and muscle.; A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003882",
-            "EFO:0000398",
-            "ICD10:M33",
-            "MONDO:0016367",
-            "SNOMEDCT:396230008",
-            "NCIT:C26744",
-            "DOID:10223",
-            "MEDDRA:10012503",
-            "ORPHANET:221",
-            "UMLS:C0011633",
-            "ICD9:710.3"
-          ],
-          "id": "MONDO:0016367",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatomyositis",
-            "dermatomyositis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/dermatomyositis",
-            "http://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 530650,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016367",
-              "name": "dermatomyositis",
-              "description": "Inflammation of the skin and muscle.; A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003882",
-                "EFO:0000398",
-                "ICD10:M33",
-                "MONDO:0016367",
-                "SNOMEDCT:396230008",
-                "NCIT:C26744",
-                "DOID:10223",
-                "MEDDRA:10012503",
-                "ORPHANET:221",
-                "UMLS:C0011633",
-                "ICD9:710.3"
-              ],
-              "id": "MONDO:0016367",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatomyositis",
-                "dermatomyositis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/dermatomyositis",
-                "http://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15861529,
-            "start": 568,
-            "end": 530650,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22442637': {'publication date': '2012', 'sentence': 'Coadministration of cyclosporin a with prednisolone in acute interstitial pneumonia complicating polymyositis/dermatomyositis.', 'subject score': 1000, 'object score': 864}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0011633---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16192798",
-              "object": "MONDO:0016367",
-              "publications": [
-                "PMID:22442637"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:35238770': {'publication date': '2022 Feb 10', 'sentence': 'We describe a 57-year-old Caucasian male with anti-MDA5 positive dermatomyositis, that had a 4-month history of progressive dyspnoea requiring oxygen-therapy, scarcely responsive to prednisolone.', 'subject score': 1000, 'object score': 784}}",
-    "p2": {
-      "start": {
-        "identity": 530650,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016367",
-          "name": "dermatomyositis",
-          "description": "Inflammation of the skin and muscle.; A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003882",
-            "EFO:0000398",
-            "ICD10:M33",
-            "MONDO:0016367",
-            "SNOMEDCT:396230008",
-            "NCIT:C26744",
-            "DOID:10223",
-            "MEDDRA:10012503",
-            "ORPHANET:221",
-            "UMLS:C0011633",
-            "ICD9:710.3"
-          ],
-          "id": "MONDO:0016367",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatomyositis",
-            "dermatomyositis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/dermatomyositis",
-            "http://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 530650,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016367",
-              "name": "dermatomyositis",
-              "description": "Inflammation of the skin and muscle.; A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003882",
-                "EFO:0000398",
-                "ICD10:M33",
-                "MONDO:0016367",
-                "SNOMEDCT:396230008",
-                "NCIT:C26744",
-                "DOID:10223",
-                "MEDDRA:10012503",
-                "ORPHANET:221",
-                "UMLS:C0011633",
-                "ICD9:710.3"
-              ],
-              "id": "MONDO:0016367",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatomyositis",
-                "dermatomyositis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/dermatomyositis",
-                "http://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23830892,
-            "start": 568,
-            "end": 530650,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35238770': {'publication date': '2022 Feb 10', 'sentence': 'We describe a 57-year-old Caucasian male with anti-MDA5 positive dermatomyositis, that had a 4-month history of progressive dyspnoea requiring oxygen-therapy, scarcely responsive to prednisolone.', 'subject score': 1000, 'object score': 784}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0011633---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "24270725",
-              "object": "MONDO:0016367",
-              "publications": [
-                "PMID:35238770"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11505515': {'publication date': '2001 Jun', 'sentence': 'The administration of prednisolone (60 mg/day) was initiated, which resulted in improvement of DM.', 'subject score': 1000, 'object score': 1000}, 'PMID:15101164': {'publication date': '2004 Feb', 'sentence': 'The patient was treated by administration of diethylstilbestrol phosphate and prednisolone for prostatic carcinoma and dermatomyositis, respectively, but he died of multiple metastasis of the tumor 1 year and 5 months later.', 'subject score': 1000, 'object score': 1000}, 'PMID:15146429': {'publication date': '2004 May', 'sentence': 'METHODS: Muscle biopsy specimens from 5 patients with PM and 4 patients with DM, obtained before and 3-6 months after initiation of prednisolone therapy, were assessed by conventional microscopic evaluation and computerized image analysis, and HMGB-1 expression was investigated by immunohistochemical staining.', 'subject score': 888, 'object score': 1000}, 'PMID:15197005': {'publication date': '2004', 'sentence': 'A 69-year-old Japanese man treated with prednisolone for dermatomyositis developed erythema and bilateral swelling of arms and forearms.', 'subject score': 1000, 'object score': 1000}, 'PMID:17389171': {'publication date': '2007 Mar', 'sentence': 'A 56-year-old woman with dermatomyositis who had been treated with prednisolone, cyclophosphamide, and azathioprine for 2 months presented with fever, hematuria, and abdominal pain for 2 days.', 'subject score': 1000, 'object score': 1000}, 'PMID:17878679': {'publication date': '2007 Aug', 'sentence': 'Twenty-one patients (91%) with PM/DM received high dose of prednisolone therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:18387858': {'publication date': '2008 Jul 15', 'sentence': 'The unbound concentrations of prednisolone were measured in 10 patients with nephrotic syndrome, two patients with systemic lupus erythematosus, and one patient with dermatomyositis by examining protein bindings of prednisolone on one or more occasions during prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:19209021': {'publication date': '2009 Feb', 'sentence': 'The dermatomyositis responded well to treatment with prednisolone and azathioprin although sorafenib did not lead to a response in the underlying HCC.', 'subject score': 1000, 'object score': 1000}, 'PMID:21340495': {'publication date': '2011 Aug', 'sentence': 'DM patients (n=14) with A/SIP were treated with 1 mg/kg/day prednisolone and 4 mg/kg/day CSA within 4.4 days (range, 1-12 days) from diagnosis.', 'subject score': 840, 'object score': 888}, 'PMID:23173570': {'publication date': '2012 Nov 22', 'sentence': 'BACKGROUND: To investigate whether or not coadministration of tacrolimus (TAC) with prednisolone (PSL) can produce a beneficial effect in the treatment of polymyositis/ dermatomyositis (PM/DM).', 'subject score': 1000, 'object score': 1000}, 'PMID:24090894': {'publication date': '2013 Oct', 'sentence': 'A diagnosis of DM was suspected in patients treated with prednisolone, 1.5 mg/kg/d.', 'subject score': 1000, 'object score': 1000}, 'PMID:24387253': {'publication date': '2003 Dec', 'sentence': 'PM/DM was defined as steroid-resistant when the muscle strength of a patient did not improve despite the administration of more than 50 mg prednisolone per day for more than 4 weeks.', 'subject score': 790, 'object score': 1000}, 'PMID:25943378': {'publication date': '2015 May 06', 'sentence': 'Her history revealed that she had been taking prednisolone to treat dermatomyositis and interstitial pneumonia for approximately 15 years.', 'subject score': 1000, 'object score': 1000}, 'PMID:26668568': {'publication date': '2015 Sep-Dec', 'sentence': 'She immediately underwent cancer chemotherapy with prednisolone therapy for DM.', 'subject score': 888, 'object score': 1000}, 'PMID:28133335': {'publication date': '2016 Nov', 'sentence': 'He was diagnosed with dermatomyositis and treated with prednisolone after gastrectomy.', 'subject score': 1000, 'object score': 1000}, 'PMID:28224486': {'publication date': '2017 06', 'sentence': 'We report a case of severe anterograde amnesia caused by HHV-6 encephalitis in a young female patient on rituximab, azathioprine and prednisolone for dermatomyositis (DM).', 'subject score': 1000, 'object score': 1000}, 'PMID:29567897': {'publication date': '2018', 'sentence': 'She had a 10-year history of chronic immunosuppressive therapy including methotrexate and prednisolone for dermatomyositis.', 'subject score': 1000, 'object score': 1000}, 'PMID:30483040': {'publication date': '2018', 'sentence': 'She was diagnosed with DM, and combination treatment with prednisolone and tacrolimus was started.', 'subject score': 1000, 'object score': 1000}, 'PMID:30690762': {'publication date': '2019 07', 'sentence': 'A case of dermatomyositis with the anti-signal recognition particle antibody that was successfully treated with prednisolone and intravenous immunoglobulin therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:32830178': {'publication date': '2020 Aug 22', 'sentence': 'A Case of Mycophenolate Mofetil-induced Diffuse Large B-cell Lymphoma in Which a Solitary Lung Nodule Remitted Spontaneously.A 76-year-old woman with dermatomyositis was being treated with prednisolone, tacrolimus, and mycophenolate mofetil.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 530650,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016367",
-          "name": "dermatomyositis",
-          "description": "Inflammation of the skin and muscle.; A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003882",
-            "EFO:0000398",
-            "ICD10:M33",
-            "MONDO:0016367",
-            "SNOMEDCT:396230008",
-            "NCIT:C26744",
-            "DOID:10223",
-            "MEDDRA:10012503",
-            "ORPHANET:221",
-            "UMLS:C0011633",
-            "ICD9:710.3"
-          ],
-          "id": "MONDO:0016367",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatomyositis",
-            "dermatomyositis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/dermatomyositis",
-            "http://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 530650,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016367",
-              "name": "dermatomyositis",
-              "description": "Inflammation of the skin and muscle.; A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003882",
-                "EFO:0000398",
-                "ICD10:M33",
-                "MONDO:0016367",
-                "SNOMEDCT:396230008",
-                "NCIT:C26744",
-                "DOID:10223",
-                "MEDDRA:10012503",
-                "ORPHANET:221",
-                "UMLS:C0011633",
-                "ICD9:710.3"
-              ],
-              "id": "MONDO:0016367",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatomyositis",
-                "dermatomyositis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/dermatomyositis",
-                "http://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8867076,
-            "start": 568,
-            "end": 530650,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11505515': {'publication date': '2001 Jun', 'sentence': 'The administration of prednisolone (60 mg/day) was initiated, which resulted in improvement of DM.', 'subject score': 1000, 'object score': 1000}, 'PMID:15101164': {'publication date': '2004 Feb', 'sentence': 'The patient was treated by administration of diethylstilbestrol phosphate and prednisolone for prostatic carcinoma and dermatomyositis, respectively, but he died of multiple metastasis of the tumor 1 year and 5 months later.', 'subject score': 1000, 'object score': 1000}, 'PMID:15146429': {'publication date': '2004 May', 'sentence': 'METHODS: Muscle biopsy specimens from 5 patients with PM and 4 patients with DM, obtained before and 3-6 months after initiation of prednisolone therapy, were assessed by conventional microscopic evaluation and computerized image analysis, and HMGB-1 expression was investigated by immunohistochemical staining.', 'subject score': 888, 'object score': 1000}, 'PMID:15197005': {'publication date': '2004', 'sentence': 'A 69-year-old Japanese man treated with prednisolone for dermatomyositis developed erythema and bilateral swelling of arms and forearms.', 'subject score': 1000, 'object score': 1000}, 'PMID:17389171': {'publication date': '2007 Mar', 'sentence': 'A 56-year-old woman with dermatomyositis who had been treated with prednisolone, cyclophosphamide, and azathioprine for 2 months presented with fever, hematuria, and abdominal pain for 2 days.', 'subject score': 1000, 'object score': 1000}, 'PMID:17878679': {'publication date': '2007 Aug', 'sentence': 'Twenty-one patients (91%) with PM/DM received high dose of prednisolone therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:18387858': {'publication date': '2008 Jul 15', 'sentence': 'The unbound concentrations of prednisolone were measured in 10 patients with nephrotic syndrome, two patients with systemic lupus erythematosus, and one patient with dermatomyositis by examining protein bindings of prednisolone on one or more occasions during prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:19209021': {'publication date': '2009 Feb', 'sentence': 'The dermatomyositis responded well to treatment with prednisolone and azathioprin although sorafenib did not lead to a response in the underlying HCC.', 'subject score': 1000, 'object score': 1000}, 'PMID:21340495': {'publication date': '2011 Aug', 'sentence': 'DM patients (n=14) with A/SIP were treated with 1 mg/kg/day prednisolone and 4 mg/kg/day CSA within 4.4 days (range, 1-12 days) from diagnosis.', 'subject score': 840, 'object score': 888}, 'PMID:23173570': {'publication date': '2012 Nov 22', 'sentence': 'BACKGROUND: To investigate whether or not coadministration of tacrolimus (TAC) with prednisolone (PSL) can produce a beneficial effect in the treatment of polymyositis/ dermatomyositis (PM/DM).', 'subject score': 1000, 'object score': 1000}, 'PMID:24090894': {'publication date': '2013 Oct', 'sentence': 'A diagnosis of DM was suspected in patients treated with prednisolone, 1.5 mg/kg/d.', 'subject score': 1000, 'object score': 1000}, 'PMID:24387253': {'publication date': '2003 Dec', 'sentence': 'PM/DM was defined as steroid-resistant when the muscle strength of a patient did not improve despite the administration of more than 50 mg prednisolone per day for more than 4 weeks.', 'subject score': 790, 'object score': 1000}, 'PMID:25943378': {'publication date': '2015 May 06', 'sentence': 'Her history revealed that she had been taking prednisolone to treat dermatomyositis and interstitial pneumonia for approximately 15 years.', 'subject score': 1000, 'object score': 1000}, 'PMID:26668568': {'publication date': '2015 Sep-Dec', 'sentence': 'She immediately underwent cancer chemotherapy with prednisolone therapy for DM.', 'subject score': 888, 'object score': 1000}, 'PMID:28133335': {'publication date': '2016 Nov', 'sentence': 'He was diagnosed with dermatomyositis and treated with prednisolone after gastrectomy.', 'subject score': 1000, 'object score': 1000}, 'PMID:28224486': {'publication date': '2017 06', 'sentence': 'We report a case of severe anterograde amnesia caused by HHV-6 encephalitis in a young female patient on rituximab, azathioprine and prednisolone for dermatomyositis (DM).', 'subject score': 1000, 'object score': 1000}, 'PMID:29567897': {'publication date': '2018', 'sentence': 'She had a 10-year history of chronic immunosuppressive therapy including methotrexate and prednisolone for dermatomyositis.', 'subject score': 1000, 'object score': 1000}, 'PMID:30483040': {'publication date': '2018', 'sentence': 'She was diagnosed with DM, and combination treatment with prednisolone and tacrolimus was started.', 'subject score': 1000, 'object score': 1000}, 'PMID:30690762': {'publication date': '2019 07', 'sentence': 'A case of dermatomyositis with the anti-signal recognition particle antibody that was successfully treated with prednisolone and intravenous immunoglobulin therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:32830178': {'publication date': '2020 Aug 22', 'sentence': 'A Case of Mycophenolate Mofetil-induced Diffuse Large B-cell Lymphoma in Which a Solitary Lung Nodule Remitted Spontaneously.A 76-year-old woman with dermatomyositis was being treated with prednisolone, tacrolimus, and mycophenolate mofetil.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0011633---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9061500",
-              "object": "MONDO:0016367",
-              "publications": [
-                "PMID:11505515",
-                "PMID:15101164",
-                "PMID:15146429",
-                "PMID:15197005",
-                "PMID:17389171",
-                "PMID:17878679",
-                "PMID:18387858",
-                "PMID:19209021",
-                "PMID:21340495",
-                "PMID:23173570",
-                "PMID:24090894",
-                "PMID:24387253",
-                "PMID:25943378",
-                "PMID:26668568",
-                "PMID:28133335",
-                "PMID:28224486",
-                "PMID:29567897",
-                "PMID:30483040",
-                "PMID:30690762",
-                "PMID:32830178"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:15704045': {'publication date': '2005 Feb', 'sentence': \"Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:16635225': {'publication date': '2006 Apr', 'sentence': 'The present study compared the efficacy of rhIL-11 versus prednisolone in remission induction in CD.', 'subject score': 1000, 'object score': 1000}, 'PMID:19160212': {'publication date': '2009 Jan 21', 'sentence': \"AUTHORS' CONCLUSIONS: Budesonide is not more effective than placebo or weaning prednisolone for maintenance of remission in Crohn's disease.\", 'subject score': 888, 'object score': 1000}, 'PMID:2452432': {'publication date': '1988 Feb', 'sentence': \"In the scope of the ECCDS, established to test the efficacy of prednisolone and/or sulfasalazine in Crohn's disease, the relationships of blood chemistry and CDAI to histology of rectal mucosa were studied in 115 patients by means of univariate and multivariate statistical analyses.\", 'subject score': 1000, 'object score': 1000}, 'PMID:2867153': {'publication date': '1985 Oct', 'sentence': \"Absorption of delayed-release prednisolone in ulcerative colitis and Crohn's disease.\", 'subject score': 851, 'object score': 1000}, 'PMID:2896346': {'publication date': '1988 Feb', 'sentence': \"In the scope of the ECCDS, testing the efficacy of prednisolone and/or sulfasalazine in Crohn's disease, the relationships between drug regime and histology of rectal mucosa were studied.\", 'subject score': 1000, 'object score': 1000}, 'PMID:3902590': {'publication date': '1985 Oct', 'sentence': \"Controlled trial comparing prednisolone with an elemental diet plus non-absorbable antibiotics in active Crohn's disease.\", 'subject score': 775, 'object score': 901}, 'PMID:7734907': {'publication date': '1995 Jan', 'sentence': \"Remission following an elemental diet or prednisolone in Crohn's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:7979514': {'publication date': '1994 Sep', 'sentence': \"Use of enteric coated prednisolone in Crohn's disease.\", 'subject score': 851, 'object score': 1000}, 'PMID:8335191': {'publication date': '1993 Aug', 'sentence': 'CONCLUSION: The combination of prednisolone and AZA was superior to the treatment with prednisolone alone in active CD.', 'subject score': 1000, 'object score': 901}, 'PMID:8608877': {'publication date': '1996 Mar', 'sentence': \"CONCLUSIONS: After a prednisolone-induces remission in Crohn's disease, mesalamine facilitates steroid withdrawal and, during the postweaning year, may reduce the relapse rate in certain patient subgroups.\", 'subject score': 1000, 'object score': 1000}, 'PMID:8652141': {'publication date': '1995 Dec', 'sentence': \"Budesonide or prednisolone in active Crohn's disease.\", 'subject score': 1000, 'object score': 901}, 'PMID:9297775': {'publication date': '1997 Aug', 'sentence': \"Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:9301500': {'publication date': '1997 Aug', 'sentence': \"CONCLUSIONS: Budesonide CIR, administered at 9 mg once daily or 4.5 mg twice daily, is comparable to prednisolone in inducing remission in active Crohn's disease.\", 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 322120,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-          "name": "Crohn disease",
-          "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003424",
-            "ORPHANET:206",
-            "NCIT:C37262",
-            "MEDDRA:10038281",
-            "MEDDRA:10011405",
-            "UMLS:CN043071",
-            "SNOMEDCT:50440006",
-            "MEDDRA:10057032",
-            "HP:0100280",
-            "EFO:0000384",
-            "DOID:8778",
-            "MONDO:0005011",
-            "PDQ:CDR0000714480",
-            "UMLS:C0010346",
-            "NCIT:C2965",
-            "SNOMEDCT:7620006",
-            "ICD10:K50.1",
-            "UMLS:C0156147",
-            "MEDDRA:10011398",
-            "MEDDRA:10011401",
-            "SNOMEDCT:34000006",
-            "ICD9:555.1",
-            "MEDDRA:10013099",
-            "MEDDRA:10011402",
-            "MEDDRA:10011400"
-          ],
-          "id": "MONDO:0005011",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Granulomatous Colitis",
-            "Crohn's disease of large bowel",
-            "Regional enteritis of large intestine",
-            "Crohn Disease",
-            "Crohn disease",
-            "Crohn's disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/chron%27s_disease",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322120,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-              "name": "Crohn disease",
-              "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003424",
-                "ORPHANET:206",
-                "NCIT:C37262",
-                "MEDDRA:10038281",
-                "MEDDRA:10011405",
-                "UMLS:CN043071",
-                "SNOMEDCT:50440006",
-                "MEDDRA:10057032",
-                "HP:0100280",
-                "EFO:0000384",
-                "DOID:8778",
-                "MONDO:0005011",
-                "PDQ:CDR0000714480",
-                "UMLS:C0010346",
-                "NCIT:C2965",
-                "SNOMEDCT:7620006",
-                "ICD10:K50.1",
-                "UMLS:C0156147",
-                "MEDDRA:10011398",
-                "MEDDRA:10011401",
-                "SNOMEDCT:34000006",
-                "ICD9:555.1",
-                "MEDDRA:10013099",
-                "MEDDRA:10011402",
-                "MEDDRA:10011400"
-              ],
-              "id": "MONDO:0005011",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Granulomatous Colitis",
-                "Crohn's disease of large bowel",
-                "Regional enteritis of large intestine",
-                "Crohn Disease",
-                "Crohn disease",
-                "Crohn's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/chron%27s_disease",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11413479,
-            "start": 568,
-            "end": 322120,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15704045': {'publication date': '2005 Feb', 'sentence': \"Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:16635225': {'publication date': '2006 Apr', 'sentence': 'The present study compared the efficacy of rhIL-11 versus prednisolone in remission induction in CD.', 'subject score': 1000, 'object score': 1000}, 'PMID:19160212': {'publication date': '2009 Jan 21', 'sentence': \"AUTHORS' CONCLUSIONS: Budesonide is not more effective than placebo or weaning prednisolone for maintenance of remission in Crohn's disease.\", 'subject score': 888, 'object score': 1000}, 'PMID:2452432': {'publication date': '1988 Feb', 'sentence': \"In the scope of the ECCDS, established to test the efficacy of prednisolone and/or sulfasalazine in Crohn's disease, the relationships of blood chemistry and CDAI to histology of rectal mucosa were studied in 115 patients by means of univariate and multivariate statistical analyses.\", 'subject score': 1000, 'object score': 1000}, 'PMID:2867153': {'publication date': '1985 Oct', 'sentence': \"Absorption of delayed-release prednisolone in ulcerative colitis and Crohn's disease.\", 'subject score': 851, 'object score': 1000}, 'PMID:2896346': {'publication date': '1988 Feb', 'sentence': \"In the scope of the ECCDS, testing the efficacy of prednisolone and/or sulfasalazine in Crohn's disease, the relationships between drug regime and histology of rectal mucosa were studied.\", 'subject score': 1000, 'object score': 1000}, 'PMID:3902590': {'publication date': '1985 Oct', 'sentence': \"Controlled trial comparing prednisolone with an elemental diet plus non-absorbable antibiotics in active Crohn's disease.\", 'subject score': 775, 'object score': 901}, 'PMID:7734907': {'publication date': '1995 Jan', 'sentence': \"Remission following an elemental diet or prednisolone in Crohn's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:7979514': {'publication date': '1994 Sep', 'sentence': \"Use of enteric coated prednisolone in Crohn's disease.\", 'subject score': 851, 'object score': 1000}, 'PMID:8335191': {'publication date': '1993 Aug', 'sentence': 'CONCLUSION: The combination of prednisolone and AZA was superior to the treatment with prednisolone alone in active CD.', 'subject score': 1000, 'object score': 901}, 'PMID:8608877': {'publication date': '1996 Mar', 'sentence': \"CONCLUSIONS: After a prednisolone-induces remission in Crohn's disease, mesalamine facilitates steroid withdrawal and, during the postweaning year, may reduce the relapse rate in certain patient subgroups.\", 'subject score': 1000, 'object score': 1000}, 'PMID:8652141': {'publication date': '1995 Dec', 'sentence': \"Budesonide or prednisolone in active Crohn's disease.\", 'subject score': 1000, 'object score': 901}, 'PMID:9297775': {'publication date': '1997 Aug', 'sentence': \"Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:9301500': {'publication date': '1997 Aug', 'sentence': \"CONCLUSIONS: Budesonide CIR, administered at 9 mg once daily or 4.5 mg twice daily, is comparable to prednisolone in inducing remission in active Crohn's disease.\", 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0010346---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11663099",
-              "object": "MONDO:0005011",
-              "publications": [
-                "PMID:15704045",
-                "PMID:16635225",
-                "PMID:19160212",
-                "PMID:2452432",
-                "PMID:2867153",
-                "PMID:2896346",
-                "PMID:3902590",
-                "PMID:7734907",
-                "PMID:7979514",
-                "PMID:8335191",
-                "PMID:8608877",
-                "PMID:8652141",
-                "PMID:9297775",
-                "PMID:9301500"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:16179087': {'publication date': '2005 Sep 22', 'sentence': \"Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis.\", 'subject score': 861, 'object score': 1000}, 'PMID:6428577': {'publication date': '1984 Jun 23', 'sentence': \"Acute exacerbations of Crohn's disease are usually treated with prednisolone or potentially more toxic immunosuppressive drugs or by surgery.\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 322120,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-          "name": "Crohn disease",
-          "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003424",
-            "ORPHANET:206",
-            "NCIT:C37262",
-            "MEDDRA:10038281",
-            "MEDDRA:10011405",
-            "UMLS:CN043071",
-            "SNOMEDCT:50440006",
-            "MEDDRA:10057032",
-            "HP:0100280",
-            "EFO:0000384",
-            "DOID:8778",
-            "MONDO:0005011",
-            "PDQ:CDR0000714480",
-            "UMLS:C0010346",
-            "NCIT:C2965",
-            "SNOMEDCT:7620006",
-            "ICD10:K50.1",
-            "UMLS:C0156147",
-            "MEDDRA:10011398",
-            "MEDDRA:10011401",
-            "SNOMEDCT:34000006",
-            "ICD9:555.1",
-            "MEDDRA:10013099",
-            "MEDDRA:10011402",
-            "MEDDRA:10011400"
-          ],
-          "id": "MONDO:0005011",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Granulomatous Colitis",
-            "Crohn's disease of large bowel",
-            "Regional enteritis of large intestine",
-            "Crohn Disease",
-            "Crohn disease",
-            "Crohn's disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/chron%27s_disease",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322120,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-              "name": "Crohn disease",
-              "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003424",
-                "ORPHANET:206",
-                "NCIT:C37262",
-                "MEDDRA:10038281",
-                "MEDDRA:10011405",
-                "UMLS:CN043071",
-                "SNOMEDCT:50440006",
-                "MEDDRA:10057032",
-                "HP:0100280",
-                "EFO:0000384",
-                "DOID:8778",
-                "MONDO:0005011",
-                "PDQ:CDR0000714480",
-                "UMLS:C0010346",
-                "NCIT:C2965",
-                "SNOMEDCT:7620006",
-                "ICD10:K50.1",
-                "UMLS:C0156147",
-                "MEDDRA:10011398",
-                "MEDDRA:10011401",
-                "SNOMEDCT:34000006",
-                "ICD9:555.1",
-                "MEDDRA:10013099",
-                "MEDDRA:10011402",
-                "MEDDRA:10011400"
-              ],
-              "id": "MONDO:0005011",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Granulomatous Colitis",
-                "Crohn's disease of large bowel",
-                "Regional enteritis of large intestine",
-                "Crohn Disease",
-                "Crohn disease",
-                "Crohn's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/chron%27s_disease",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11800576,
-            "start": 568,
-            "end": 322120,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16179087': {'publication date': '2005 Sep 22', 'sentence': \"Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis.\", 'subject score': 861, 'object score': 1000}, 'PMID:6428577': {'publication date': '1984 Jun 23', 'sentence': \"Acute exacerbations of Crohn's disease are usually treated with prednisolone or potentially more toxic immunosuppressive drugs or by surgery.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0010346---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "12057849",
-              "object": "MONDO:0005011",
-              "publications": [
-                "PMID:16179087",
-                "PMID:6428577"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10672132': {'publication date': '2000 Jan', 'sentence': 'In a stepwise regression that included age, sex, disease duration and cumulative prednisolone dose as independent variables, the femur T score was significantly inversely related to disease duration (r2 = 0.125, F = 6.06) in CD patients.', 'subject score': 851, 'object score': 901}, 'PMID:11181269': {'publication date': '2001 Jan 20', 'sentence': 'CONCLUSIONS: Budesonide is as useful as prednisolone in treatment of active CD and it has a lower impact in serum cortisol levels.', 'subject score': 1000, 'object score': 901}, 'PMID:12012225': {'publication date': '2002 May', 'sentence': 'UNLABELLED: In an 11-year old boy with Crohn disease, long-term therapy with prednisolone was decided to be augmented by infliximab, a monoclonal antibody to tumour necrosis factor alpha.', 'subject score': 1000, 'object score': 1000}, 'PMID:12120182': {'publication date': '2001', 'sentence': \"Budesonide is equal to less effective than prednisolone or prednisone therapy in the treatment of active Crohn's disease, but is associated with fewer glucocorticoids adverse reactions.\", 'subject score': 1000, 'object score': 901}, 'PMID:12381231': {'publication date': '2002', 'sentence': \"CONCLUSION: Oral budesonide 9 mg/day offers efficacy that is superior to mesalazine slow release and placebo, and similar to prednisolone in the treatment of patients with active mild to moderate Crohn's disease involving the ileum and/or ascending colon.\", 'subject score': 1000, 'object score': 864}, 'PMID:12673090': {'publication date': '2003', 'sentence': 'The patient improved promptly after initiating oral treatment for CD with mesalazine and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:14572572': {'publication date': '2003 Oct', 'sentence': 'The aim of the present work was to investigate serum ASCA levels during the courses of prednisolone and mesalamine therapy in CD patients.', 'subject score': 1000, 'object score': 901}, 'PMID:15095852': {'publication date': '2004 Jan', 'sentence': \"Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial.\", 'subject score': 1000, 'object score': 901}, 'PMID:15555744': {'publication date': '2005 Jan 06', 'sentence': \"The drug's effectiveness in this disease has been proven in multiple, placebo-controlled trials, where it has been shown to be superior to mesalamine and placebo, and equivalent to prednisolone for the control of mild to moderately active right-sided Crohn's disease.\", 'subject score': 1000, 'object score': 773}, 'PMID:15704045': {'publication date': '2005 Feb', 'sentence': \"METHODS: In 34 international centers, 272 patients with Crohn's disease involving ileum and/or colon ascendens were randomized to once daily treatment with budesonide or prednisolone for 2 years at doses adapted to disease activity.\", 'subject score': 1000, 'object score': 1000}, 'PMID:16179087': {'publication date': '2005 Sep 22', 'sentence': 'METHODS: Plasma from patients with exacerbations of UC (n = 18) or CD (n = 18) were collected before and during high dose prednisolone treatment (1 mg/kg body weight) and tapering.', 'subject score': 861, 'object score': 1000}, 'PMID:17068395': {'publication date': '2006', 'sentence': 'Additionally, serum TFF concentrations were determined in patients with severe activity in colon IBD (4 UC and 6 CD) before and during prednisolone treatment with 7 healthy subjects as controls.', 'subject score': 888, 'object score': 901}, 'PMID:17429201': {'publication date': '2007', 'sentence': \"Impact of enteral supplements enriched with omega-3 fatty acids and/or omega-6 fatty acids, arginine and ribonucleic acid compounds on leptin levels and nutritional status in active Crohn's disease treated with prednisolone.\", 'subject score': 1000, 'object score': 901}, 'PMID:1790809': {'publication date': '1991', 'sentence': \"Patients with nonspecific ulcerative colitis and Crohn's disease were treated with drug therapy (prednisolone, sulphasalazine, metronidazole per os and hydrocortisone per rectum) and subjected to 12 sessions of HBO.\", 'subject score': 1000, 'object score': 1000}, 'PMID:21355357': {'publication date': '2010 Nov 25-Dec 8', 'sentence': \"Prednisolone in the management of patients with Crohn's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:2179093': {'publication date': '1990 Feb', 'sentence': \"Controlled trial comparing an elemental diet with prednisolone in the treatment of active Crohn's disease.\", 'subject score': 1000, 'object score': 901}, 'PMID:23185152': {'publication date': '2012 Sep', 'sentence': 'Both patients were released on a prednisolone-based treatment for suspected CD.', 'subject score': 840, 'object score': 901}, 'PMID:2323598': {'publication date': '1990 Mar', 'sentence': \"The effect of prednisolone (20-30 mg daily for six to nine weeks) was studied in eight patients with Crohn's disease and recurrent, preanastomotic ileal inflammation, in respect of symptoms, endoscopic findings and phospholipase A2 activity in the ileal mucosa.\", 'subject score': 1000, 'object score': 1000}, 'PMID:26019475': {'publication date': '2015 May 21', 'sentence': \"Following commencement of prednisolone for her Crohn's disease, the patient developed widespread Hodgkin lymphoma which ultimately presented as a life-threatening lower GIT bleed requiring emergency colectomy.\", 'subject score': 1000, 'object score': 1000}, 'PMID:2709273': {'publication date': '1989 Apr', 'sentence': \"Measurement of plasma prednisolone level to evaluate a prednisone treatment failure in an adolescent with Crohn's disease.\", 'subject score': 623, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 322120,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-          "name": "Crohn disease",
-          "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003424",
-            "ORPHANET:206",
-            "NCIT:C37262",
-            "MEDDRA:10038281",
-            "MEDDRA:10011405",
-            "UMLS:CN043071",
-            "SNOMEDCT:50440006",
-            "MEDDRA:10057032",
-            "HP:0100280",
-            "EFO:0000384",
-            "DOID:8778",
-            "MONDO:0005011",
-            "PDQ:CDR0000714480",
-            "UMLS:C0010346",
-            "NCIT:C2965",
-            "SNOMEDCT:7620006",
-            "ICD10:K50.1",
-            "UMLS:C0156147",
-            "MEDDRA:10011398",
-            "MEDDRA:10011401",
-            "SNOMEDCT:34000006",
-            "ICD9:555.1",
-            "MEDDRA:10013099",
-            "MEDDRA:10011402",
-            "MEDDRA:10011400"
-          ],
-          "id": "MONDO:0005011",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Granulomatous Colitis",
-            "Crohn's disease of large bowel",
-            "Regional enteritis of large intestine",
-            "Crohn Disease",
-            "Crohn disease",
-            "Crohn's disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/chron%27s_disease",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322120,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-              "name": "Crohn disease",
-              "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003424",
-                "ORPHANET:206",
-                "NCIT:C37262",
-                "MEDDRA:10038281",
-                "MEDDRA:10011405",
-                "UMLS:CN043071",
-                "SNOMEDCT:50440006",
-                "MEDDRA:10057032",
-                "HP:0100280",
-                "EFO:0000384",
-                "DOID:8778",
-                "MONDO:0005011",
-                "PDQ:CDR0000714480",
-                "UMLS:C0010346",
-                "NCIT:C2965",
-                "SNOMEDCT:7620006",
-                "ICD10:K50.1",
-                "UMLS:C0156147",
-                "MEDDRA:10011398",
-                "MEDDRA:10011401",
-                "SNOMEDCT:34000006",
-                "ICD9:555.1",
-                "MEDDRA:10013099",
-                "MEDDRA:10011402",
-                "MEDDRA:10011400"
-              ],
-              "id": "MONDO:0005011",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Granulomatous Colitis",
-                "Crohn's disease of large bowel",
-                "Regional enteritis of large intestine",
-                "Crohn Disease",
-                "Crohn disease",
-                "Crohn's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/chron%27s_disease",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7819928,
-            "start": 568,
-            "end": 322120,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10672132': {'publication date': '2000 Jan', 'sentence': 'In a stepwise regression that included age, sex, disease duration and cumulative prednisolone dose as independent variables, the femur T score was significantly inversely related to disease duration (r2 = 0.125, F = 6.06) in CD patients.', 'subject score': 851, 'object score': 901}, 'PMID:11181269': {'publication date': '2001 Jan 20', 'sentence': 'CONCLUSIONS: Budesonide is as useful as prednisolone in treatment of active CD and it has a lower impact in serum cortisol levels.', 'subject score': 1000, 'object score': 901}, 'PMID:12012225': {'publication date': '2002 May', 'sentence': 'UNLABELLED: In an 11-year old boy with Crohn disease, long-term therapy with prednisolone was decided to be augmented by infliximab, a monoclonal antibody to tumour necrosis factor alpha.', 'subject score': 1000, 'object score': 1000}, 'PMID:12120182': {'publication date': '2001', 'sentence': \"Budesonide is equal to less effective than prednisolone or prednisone therapy in the treatment of active Crohn's disease, but is associated with fewer glucocorticoids adverse reactions.\", 'subject score': 1000, 'object score': 901}, 'PMID:12381231': {'publication date': '2002', 'sentence': \"CONCLUSION: Oral budesonide 9 mg/day offers efficacy that is superior to mesalazine slow release and placebo, and similar to prednisolone in the treatment of patients with active mild to moderate Crohn's disease involving the ileum and/or ascending colon.\", 'subject score': 1000, 'object score': 864}, 'PMID:12673090': {'publication date': '2003', 'sentence': 'The patient improved promptly after initiating oral treatment for CD with mesalazine and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:14572572': {'publication date': '2003 Oct', 'sentence': 'The aim of the present work was to investigate serum ASCA levels during the courses of prednisolone and mesalamine therapy in CD patients.', 'subject score': 1000, 'object score': 901}, 'PMID:15095852': {'publication date': '2004 Jan', 'sentence': \"Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial.\", 'subject score': 1000, 'object score': 901}, 'PMID:15555744': {'publication date': '2005 Jan 06', 'sentence': \"The drug's effectiveness in this disease has been proven in multiple, placebo-controlled trials, where it has been shown to be superior to mesalamine and placebo, and equivalent to prednisolone for the control of mild to moderately active right-sided Crohn's disease.\", 'subject score': 1000, 'object score': 773}, 'PMID:15704045': {'publication date': '2005 Feb', 'sentence': \"METHODS: In 34 international centers, 272 patients with Crohn's disease involving ileum and/or colon ascendens were randomized to once daily treatment with budesonide or prednisolone for 2 years at doses adapted to disease activity.\", 'subject score': 1000, 'object score': 1000}, 'PMID:16179087': {'publication date': '2005 Sep 22', 'sentence': 'METHODS: Plasma from patients with exacerbations of UC (n = 18) or CD (n = 18) were collected before and during high dose prednisolone treatment (1 mg/kg body weight) and tapering.', 'subject score': 861, 'object score': 1000}, 'PMID:17068395': {'publication date': '2006', 'sentence': 'Additionally, serum TFF concentrations were determined in patients with severe activity in colon IBD (4 UC and 6 CD) before and during prednisolone treatment with 7 healthy subjects as controls.', 'subject score': 888, 'object score': 901}, 'PMID:17429201': {'publication date': '2007', 'sentence': \"Impact of enteral supplements enriched with omega-3 fatty acids and/or omega-6 fatty acids, arginine and ribonucleic acid compounds on leptin levels and nutritional status in active Crohn's disease treated with prednisolone.\", 'subject score': 1000, 'object score': 901}, 'PMID:1790809': {'publication date': '1991', 'sentence': \"Patients with nonspecific ulcerative colitis and Crohn's disease were treated with drug therapy (prednisolone, sulphasalazine, metronidazole per os and hydrocortisone per rectum) and subjected to 12 sessions of HBO.\", 'subject score': 1000, 'object score': 1000}, 'PMID:21355357': {'publication date': '2010 Nov 25-Dec 8', 'sentence': \"Prednisolone in the management of patients with Crohn's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:2179093': {'publication date': '1990 Feb', 'sentence': \"Controlled trial comparing an elemental diet with prednisolone in the treatment of active Crohn's disease.\", 'subject score': 1000, 'object score': 901}, 'PMID:23185152': {'publication date': '2012 Sep', 'sentence': 'Both patients were released on a prednisolone-based treatment for suspected CD.', 'subject score': 840, 'object score': 901}, 'PMID:2323598': {'publication date': '1990 Mar', 'sentence': \"The effect of prednisolone (20-30 mg daily for six to nine weeks) was studied in eight patients with Crohn's disease and recurrent, preanastomotic ileal inflammation, in respect of symptoms, endoscopic findings and phospholipase A2 activity in the ileal mucosa.\", 'subject score': 1000, 'object score': 1000}, 'PMID:26019475': {'publication date': '2015 May 21', 'sentence': \"Following commencement of prednisolone for her Crohn's disease, the patient developed widespread Hodgkin lymphoma which ultimately presented as a life-threatening lower GIT bleed requiring emergency colectomy.\", 'subject score': 1000, 'object score': 1000}, 'PMID:2709273': {'publication date': '1989 Apr', 'sentence': \"Measurement of plasma prednisolone level to evaluate a prednisone treatment failure in an adolescent with Crohn's disease.\", 'subject score': 623, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0010346---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7986379",
-              "object": "MONDO:0005011",
-              "publications": [
-                "PMID:10672132",
-                "PMID:11181269",
-                "PMID:12012225",
-                "PMID:12120182",
-                "PMID:12381231",
-                "PMID:12673090",
-                "PMID:14572572",
-                "PMID:15095852",
-                "PMID:15555744",
-                "PMID:15704045",
-                "PMID:16179087",
-                "PMID:17068395",
-                "PMID:17429201",
-                "PMID:1790809",
-                "PMID:21355357",
-                "PMID:2179093",
-                "PMID:23185152",
-                "PMID:2323598",
-                "PMID:26019475",
-                "PMID:2709273"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:14191165': {'publication date': '1964 Oct 24', 'sentence': 'URINARY EXCRETION OF PREDNISOLONE AFTER INTRARECTAL THERAPY IN ULCERATIVE COLITIS.', 'subject score': 1000, 'object score': 1000}, 'PMID:2867153': {'publication date': '1985 Oct', 'sentence': \"Absorption of delayed-release prednisolone in ulcerative colitis and Crohn's disease.\", 'subject score': 851, 'object score': 1000}, 'PMID:30863856': {'publication date': '2019 Jul 25', 'sentence': 'METHODS: This was a prospective, randomized, controlled multicentre pilot study comparing leukocyte apheresis with prednisolone in refractory UC (disease activity index [DAI] >= 4 and <=8).', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10473465,
-            "start": 568,
-            "end": 322104,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14191165': {'publication date': '1964 Oct 24', 'sentence': 'URINARY EXCRETION OF PREDNISOLONE AFTER INTRARECTAL THERAPY IN ULCERATIVE COLITIS.', 'subject score': 1000, 'object score': 1000}, 'PMID:2867153': {'publication date': '1985 Oct', 'sentence': \"Absorption of delayed-release prednisolone in ulcerative colitis and Crohn's disease.\", 'subject score': 851, 'object score': 1000}, 'PMID:30863856': {'publication date': '2019 Jul 25', 'sentence': 'METHODS: This was a prospective, randomized, controlled multicentre pilot study comparing leukocyte apheresis with prednisolone in refractory UC (disease activity index [DAI] >= 4 and <=8).', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10703266",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:14191165",
-                "PMID:2867153",
-                "PMID:30863856"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:30616083': {'publication date': '2019 Mar', 'sentence': 'Zeaxanthin (50 mg/kg/day) or prednisolone (5 mg/kg/day) was orally administered for 14 days before induction of ulcerative colitis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20386947,
-            "start": 568,
-            "end": 322104,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30616083': {'publication date': '2019 Mar', 'sentence': 'Zeaxanthin (50 mg/kg/day) or prednisolone (5 mg/kg/day) was orally administered for 14 days before induction of ulcerative colitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "20789636",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:30616083"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:12737443': {'publication date': '2003 Mar', 'sentence': 'Glucocorticoids (e.g. prednisolone) are cornerstones in the treatment of acute exacerbations of ulcerative colitis (UC), and influence of the leucocyte/endothelial interaction appears to be part of their mode of action.', 'subject score': 1000, 'object score': 1000}, 'PMID:16179087': {'publication date': '2005 Sep 22', 'sentence': \"Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis.\", 'subject score': 861, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9963081,
-            "start": 568,
-            "end": 322104,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12737443': {'publication date': '2003 Mar', 'sentence': 'Glucocorticoids (e.g. prednisolone) are cornerstones in the treatment of acute exacerbations of ulcerative colitis (UC), and influence of the leucocyte/endothelial interaction appears to be part of their mode of action.', 'subject score': 1000, 'object score': 1000}, 'PMID:16179087': {'publication date': '2005 Sep 22', 'sentence': \"Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis.\", 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10183156",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:12737443",
-                "PMID:16179087"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10433019': {'publication date': '1999 Jun', 'sentence': 'A 25-year-old man had been treated with high-dose prednisolone for UC.', 'subject score': 901, 'object score': 1000}, 'PMID:10811328': {'publication date': '2000 May', 'sentence': 'CONCLUSIONS: Treatment with AZA/prednisolone appears to be more effective and safe compared to MMF/prednisolone in patients with chronic active UC.', 'subject score': 824, 'object score': 916}, 'PMID:11868601': {'publication date': '2002 Feb', 'sentence': 'The first case had been treated initially with 60 mg prednisolone for ulcerative colitis, and L. pneumophila serogroup 1 was isolated from sputum samples after cavitation of the lung lesion.', 'subject score': 790, 'object score': 1000}, 'PMID:12349943': {'publication date': '2002 Jul', 'sentence': 'In 14 UC patients, there was a significant correlation between amounts of prednisolone (p < 0.05) or period of prednisolone administration (p < 0.05) for UC treatment and prednisolone IC50.', 'subject score': 1000, 'object score': 901}, 'PMID:12737443': {'publication date': '2003 Mar', 'sentence': 'The aim of the present study was therefore to evaluate the ICAM-1-shedding through measurements of sICAM-1 concentrations during prednisolone treatment of UC patients.', 'subject score': 888, 'object score': 901}, 'PMID:13474175': {'publication date': '1957 Sep', 'sentence': 'The longterm treatment of ulcerative colitis with hydrocortisone, prednisone and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:13850068': {'publication date': '1959 Dec', 'sentence': 'Continuous use of prednisolone in the treatment of ulcerative colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:14530652': {'publication date': '2003 Oct', 'sentence': 'METHODS: From 1998 to 2002, 35 patients with moderate-to-severe recurrence of ulcerative colitis were treated by intravenous prednisolone only or prednisolone plus leukocytapheresis once per week.', 'subject score': 790, 'object score': 1000}, 'PMID:1543815': {'publication date': '1992 Feb', 'sentence': 'An Eudragit-coated prednisolone preparation for ulcerative colitis: pharmacokinetics and preliminary therapeutic use.', 'subject score': 861, 'object score': 1000}, 'PMID:15449684': {'publication date': '2004 Jul-Aug', 'sentence': '[Endocrine cells of rectal epithelium in health, in nonspecific ulcerative colitis and irritable colon syndrome in the treatment with prednisolone and salofalk and in the absence of treatment].', 'subject score': 1000, 'object score': 901}, 'PMID:15843756': {'publication date': '2005 Apr', 'sentence': 'We used prednisolone and sulfasalazine for the treatment of ulcerative colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:16378006': {'publication date': '2006 Jan', 'sentence': 'An unblinded randomized controlled trial of a different selective apheresis device (Cellsorba) versus high-dose prednisolone in patients with active UC showed a greater therapeutic effect (74%) than high-dose prednisolone (38%) and lower frequency of adverse effects (24% versus 68%).', 'subject score': 901, 'object score': 901}, 'PMID:16937542': {'publication date': '2006 Aug 28', 'sentence': 'Being diagnosed as having severe active left-side UC, she was successfully treated with intravenous methylprednisolone followed by prednisolone and leukocytapheresis.', 'subject score': 1000, 'object score': 839}, 'PMID:17068395': {'publication date': '2006', 'sentence': 'Additionally, serum TFF concentrations were determined in patients with severe activity in colon IBD (4 UC and 6 CD) before and during prednisolone treatment with 7 healthy subjects as controls.', 'subject score': 888, 'object score': 901}, 'PMID:17497998': {'publication date': '2007 Jun', 'sentence': 'Patient 2 was a 29-year-old woman who had been suffering from pyoderma gangrenosum with severe pain for two weeks, associated with an 11-year history of ulcerative colitis treated with prednisolone and salazosulfapyridine.', 'subject score': 1000, 'object score': 1000}, 'PMID:1790809': {'publication date': '1991', 'sentence': \"Patients with nonspecific ulcerative colitis and Crohn's disease were treated with drug therapy (prednisolone, sulphasalazine, metronidazole per os and hydrocortisone per rectum) and subjected to 12 sessions of HBO.\", 'subject score': 1000, 'object score': 901}, 'PMID:18296130': {'publication date': '2008 Jun', 'sentence': 'This study was to compare the efficacy and safety of intensive GMA with intensive intravenous prednisolone in patients with severe ulcerative colitis.', 'subject score': 790, 'object score': 901}, 'PMID:19721403': {'publication date': '2009 Sep', 'sentence': 'CASE REPORT: A 50-year-old man who had been treated with prednisolone for left-sided ulcerative colitis (UC) underwent follow-up colonoscopy.', 'subject score': 1000, 'object score': 888}, 'PMID:20651970': {'publication date': '2009 Apr 15', 'sentence': 'Although he was under treatment with prednisolone and ursodeoxycholic acid, exacerbation of UC and PSC-associated cholestasis were seen.', 'subject score': 1000, 'object score': 1000}, 'PMID:21591873': {'publication date': '2011 Aug', 'sentence': 'DISCUSSION AND CONCLUSION: Results showed that ethanol extract of V. negundo root is effective in the treatment of UC and results are comparable with the standard drug, prednisolone, and thus possessing a great potential in the treatment of UC.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7432241,
-            "start": 568,
-            "end": 322104,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10433019': {'publication date': '1999 Jun', 'sentence': 'A 25-year-old man had been treated with high-dose prednisolone for UC.', 'subject score': 901, 'object score': 1000}, 'PMID:10811328': {'publication date': '2000 May', 'sentence': 'CONCLUSIONS: Treatment with AZA/prednisolone appears to be more effective and safe compared to MMF/prednisolone in patients with chronic active UC.', 'subject score': 824, 'object score': 916}, 'PMID:11868601': {'publication date': '2002 Feb', 'sentence': 'The first case had been treated initially with 60 mg prednisolone for ulcerative colitis, and L. pneumophila serogroup 1 was isolated from sputum samples after cavitation of the lung lesion.', 'subject score': 790, 'object score': 1000}, 'PMID:12349943': {'publication date': '2002 Jul', 'sentence': 'In 14 UC patients, there was a significant correlation between amounts of prednisolone (p < 0.05) or period of prednisolone administration (p < 0.05) for UC treatment and prednisolone IC50.', 'subject score': 1000, 'object score': 901}, 'PMID:12737443': {'publication date': '2003 Mar', 'sentence': 'The aim of the present study was therefore to evaluate the ICAM-1-shedding through measurements of sICAM-1 concentrations during prednisolone treatment of UC patients.', 'subject score': 888, 'object score': 901}, 'PMID:13474175': {'publication date': '1957 Sep', 'sentence': 'The longterm treatment of ulcerative colitis with hydrocortisone, prednisone and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:13850068': {'publication date': '1959 Dec', 'sentence': 'Continuous use of prednisolone in the treatment of ulcerative colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:14530652': {'publication date': '2003 Oct', 'sentence': 'METHODS: From 1998 to 2002, 35 patients with moderate-to-severe recurrence of ulcerative colitis were treated by intravenous prednisolone only or prednisolone plus leukocytapheresis once per week.', 'subject score': 790, 'object score': 1000}, 'PMID:1543815': {'publication date': '1992 Feb', 'sentence': 'An Eudragit-coated prednisolone preparation for ulcerative colitis: pharmacokinetics and preliminary therapeutic use.', 'subject score': 861, 'object score': 1000}, 'PMID:15449684': {'publication date': '2004 Jul-Aug', 'sentence': '[Endocrine cells of rectal epithelium in health, in nonspecific ulcerative colitis and irritable colon syndrome in the treatment with prednisolone and salofalk and in the absence of treatment].', 'subject score': 1000, 'object score': 901}, 'PMID:15843756': {'publication date': '2005 Apr', 'sentence': 'We used prednisolone and sulfasalazine for the treatment of ulcerative colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:16378006': {'publication date': '2006 Jan', 'sentence': 'An unblinded randomized controlled trial of a different selective apheresis device (Cellsorba) versus high-dose prednisolone in patients with active UC showed a greater therapeutic effect (74%) than high-dose prednisolone (38%) and lower frequency of adverse effects (24% versus 68%).', 'subject score': 901, 'object score': 901}, 'PMID:16937542': {'publication date': '2006 Aug 28', 'sentence': 'Being diagnosed as having severe active left-side UC, she was successfully treated with intravenous methylprednisolone followed by prednisolone and leukocytapheresis.', 'subject score': 1000, 'object score': 839}, 'PMID:17068395': {'publication date': '2006', 'sentence': 'Additionally, serum TFF concentrations were determined in patients with severe activity in colon IBD (4 UC and 6 CD) before and during prednisolone treatment with 7 healthy subjects as controls.', 'subject score': 888, 'object score': 901}, 'PMID:17497998': {'publication date': '2007 Jun', 'sentence': 'Patient 2 was a 29-year-old woman who had been suffering from pyoderma gangrenosum with severe pain for two weeks, associated with an 11-year history of ulcerative colitis treated with prednisolone and salazosulfapyridine.', 'subject score': 1000, 'object score': 1000}, 'PMID:1790809': {'publication date': '1991', 'sentence': \"Patients with nonspecific ulcerative colitis and Crohn's disease were treated with drug therapy (prednisolone, sulphasalazine, metronidazole per os and hydrocortisone per rectum) and subjected to 12 sessions of HBO.\", 'subject score': 1000, 'object score': 901}, 'PMID:18296130': {'publication date': '2008 Jun', 'sentence': 'This study was to compare the efficacy and safety of intensive GMA with intensive intravenous prednisolone in patients with severe ulcerative colitis.', 'subject score': 790, 'object score': 901}, 'PMID:19721403': {'publication date': '2009 Sep', 'sentence': 'CASE REPORT: A 50-year-old man who had been treated with prednisolone for left-sided ulcerative colitis (UC) underwent follow-up colonoscopy.', 'subject score': 1000, 'object score': 888}, 'PMID:20651970': {'publication date': '2009 Apr 15', 'sentence': 'Although he was under treatment with prednisolone and ursodeoxycholic acid, exacerbation of UC and PSC-associated cholestasis were seen.', 'subject score': 1000, 'object score': 1000}, 'PMID:21591873': {'publication date': '2011 Aug', 'sentence': 'DISCUSSION AND CONCLUSION: Results showed that ethanol extract of V. negundo root is effective in the treatment of UC and results are comparable with the standard drug, prednisolone, and thus possessing a great potential in the treatment of UC.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7586864",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:10433019",
-                "PMID:10811328",
-                "PMID:11868601",
-                "PMID:12349943",
-                "PMID:12737443",
-                "PMID:13474175",
-                "PMID:13850068",
-                "PMID:14530652",
-                "PMID:1543815",
-                "PMID:15449684",
-                "PMID:15843756",
-                "PMID:16378006",
-                "PMID:16937542",
-                "PMID:17068395",
-                "PMID:17497998",
-                "PMID:1790809",
-                "PMID:18296130",
-                "PMID:19721403",
-                "PMID:20651970",
-                "PMID:21591873"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:exacerbates",
-    "r2.publications_info": "{'PMID:26193651': {'publication date': '2008 Oct', 'sentence': 'Six weeks prior to his symptoms, prednisolone (PSL) and SASP had been started because of UC aggravation.', 'subject score': 1000, 'object score': 734}}",
-    "p2": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18085320,
-            "start": 568,
-            "end": 322104,
-            "type": "biolink:exacerbates",
-            "properties": {
-              "predicate": "biolink:exacerbates",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26193651': {'publication date': '2008 Oct', 'sentence': 'Six weeks prior to his symptoms, prednisolone (PSL) and SASP had been started because of UC aggravation.', 'subject score': 1000, 'object score': 734}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:complicates---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "18452194",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:26193651"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:10581660': {'publication date': '1999 Oct', 'sentence': 'Reversibility with prednisolone is rarely seen in COPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:11081531': {'publication date': '2000 Oct 28', 'sentence': 'Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:11247590': {'publication date': '2001 Mar 03', 'sentence': 'Response to prednisolone in COPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:24076367': {'publication date': '2014 Aug', 'sentence': 'Effects of long-acting bronchodilators and prednisolone on inspiratory lung function parameters in stable COPD.', 'subject score': 1000, 'object score': 937}, 'PMID:28684161': {'publication date': '2017 09', 'sentence': 'In comparison with prednisolone, gamma-tocotrienol demonstrated better anti-oxidative efficacy, and protection against emphysema and lung function in COPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:7621841': {'publication date': '1995', 'sentence': 'The improvements in ventilation, exercise and anxiety scores following treatment with prednisolone were not reproduced by mianserin, suggesting that the effects of prednisolone in COPD are unlikely to be due to alterations in mood.', 'subject score': 1000, 'object score': 840}, 'PMID:7292376': {'publication date': '1981 Jan', 'sentence': 'Time course of response to prednisolone in chronic airflow obstruction.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 324986,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-          "name": "chronic obstructive pulmonary disease",
-          "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-          "equivalent_curies": [
-            "MESH:D029424",
-            "MEDDRA:10010952",
-            "MEDDRA:10009025",
-            "ICD10:J44.9",
-            "UMLS:C1527303",
-            "NCIT:C3199",
-            "UMLS:C0024117",
-            "MEDDRA:10064611",
-            "MEDDRA:10009026",
-            "MEDDRA:10029972",
-            "DOID:3083",
-            "MONDO:0005002",
-            "MEDDRA:10009032",
-            "MEDDRA:10070975",
-            "EFO:0000341",
-            "SNOMEDCT:13645005",
-            "MEDDRA:10009033",
-            "HP:0006510",
-            "MEDDRA:10008828"
-          ],
-          "id": "MONDO:0005002",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic Obstructive Pulmonary Disease",
-            "chronic obstructive pulmonary disease",
-            "Chronic pulmonary obstruction",
-            "Chronic Airflow Obstruction",
-            "Chronic Obstructive Airway Disease",
-            "Pulmonary Disease, Chronic Obstructive"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health-topics/copd",
-            "PMID:32800196",
-            "PMID:28513453",
-            "PMID:25943942",
-            "PMID:32745458"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 324986,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-              "name": "chronic obstructive pulmonary disease",
-              "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-              "equivalent_curies": [
-                "MESH:D029424",
-                "MEDDRA:10010952",
-                "MEDDRA:10009025",
-                "ICD10:J44.9",
-                "UMLS:C1527303",
-                "NCIT:C3199",
-                "UMLS:C0024117",
-                "MEDDRA:10064611",
-                "MEDDRA:10009026",
-                "MEDDRA:10029972",
-                "DOID:3083",
-                "MONDO:0005002",
-                "MEDDRA:10009032",
-                "MEDDRA:10070975",
-                "EFO:0000341",
-                "SNOMEDCT:13645005",
-                "MEDDRA:10009033",
-                "HP:0006510",
-                "MEDDRA:10008828"
-              ],
-              "id": "MONDO:0005002",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic Obstructive Pulmonary Disease",
-                "chronic obstructive pulmonary disease",
-                "Chronic pulmonary obstruction",
-                "Chronic Airflow Obstruction",
-                "Chronic Obstructive Airway Disease",
-                "Pulmonary Disease, Chronic Obstructive"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health-topics/copd",
-                "PMID:32800196",
-                "PMID:28513453",
-                "PMID:25943942",
-                "PMID:32745458"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7681704,
-            "start": 568,
-            "end": 324986,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10581660': {'publication date': '1999 Oct', 'sentence': 'Reversibility with prednisolone is rarely seen in COPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:11081531': {'publication date': '2000 Oct 28', 'sentence': 'Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:11247590': {'publication date': '2001 Mar 03', 'sentence': 'Response to prednisolone in COPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:24076367': {'publication date': '2014 Aug', 'sentence': 'Effects of long-acting bronchodilators and prednisolone on inspiratory lung function parameters in stable COPD.', 'subject score': 1000, 'object score': 937}, 'PMID:28684161': {'publication date': '2017 09', 'sentence': 'In comparison with prednisolone, gamma-tocotrienol demonstrated better anti-oxidative efficacy, and protection against emphysema and lung function in COPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:7621841': {'publication date': '1995', 'sentence': 'The improvements in ventilation, exercise and anxiety scores following treatment with prednisolone were not reproduced by mianserin, suggesting that the effects of prednisolone in COPD are unlikely to be due to alterations in mood.', 'subject score': 1000, 'object score': 840}, 'PMID:7292376': {'publication date': '1981 Jan', 'sentence': 'Time course of response to prednisolone in chronic airflow obstruction.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0024117---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C1527303---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7844202",
-              "object": "MONDO:0005002",
-              "publications": [
-                "PMID:11247590",
-                "PMID:7621841",
-                "PMID:7292376",
-                "PMID:28684161",
-                "PMID:24076367",
-                "PMID:10581660",
-                "PMID:11081531"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:17363304': {'publication date': '2008 Feb', 'sentence': 'When combined with environmental control, prednisolone and dexamethasone treatments had similar effects on heaves score, blood gases and endoscopic scores.', 'subject score': 1000, 'object score': 1000}, 'PMID:18836113': {'publication date': '2008 Oct', 'sentence': 'Oral prednisolone was not inferior to intravenous prednisolone for treatment failure in chronic obstructive pulmonary disease exacerbation.', 'subject score': 888, 'object score': 771}, 'PMID:18972276': {'publication date': '2008 Oct', 'sentence': 'Forty-five patients not using steroids (37 male, 21/24 current/ex smoker, median packyears 38, age 65 years, FEV(1) 61% predicted), experiencing a COPD exacerbation, were treated at home with budesonide/formoterol (320/9 microg 4 times daily), prednisolone (30 mg daily), or placebo for 14 days.', 'subject score': 1000, 'object score': 771}, 'PMID:24925917': {'publication date': '2014 Sep', 'sentence': 'Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis.', 'subject score': 888, 'object score': 1000}, 'PMID:25562034': {'publication date': '2014', 'sentence': 'CONCLUSIONS: We detected no evidence for the effectiveness of addition of antibiotics to prednisolone for COPD exacerbations of moderate severity and with intermediate probability of bacterial infection in this underpowered study.', 'subject score': 1000, 'object score': 771}, 'PMID:30565022': {'publication date': '2019 05', 'sentence': 'Doxycycline Added to Prednisolone in Outpatient-Treated Acute Exacerbations of COPD: A Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:6146752': {'publication date': '1984 Jul 28', 'sentence': 'Effects of prednisolone in chronic airflow limitation.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 324986,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-          "name": "chronic obstructive pulmonary disease",
-          "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-          "equivalent_curies": [
-            "MESH:D029424",
-            "MEDDRA:10010952",
-            "MEDDRA:10009025",
-            "ICD10:J44.9",
-            "UMLS:C1527303",
-            "NCIT:C3199",
-            "UMLS:C0024117",
-            "MEDDRA:10064611",
-            "MEDDRA:10009026",
-            "MEDDRA:10029972",
-            "DOID:3083",
-            "MONDO:0005002",
-            "MEDDRA:10009032",
-            "MEDDRA:10070975",
-            "EFO:0000341",
-            "SNOMEDCT:13645005",
-            "MEDDRA:10009033",
-            "HP:0006510",
-            "MEDDRA:10008828"
-          ],
-          "id": "MONDO:0005002",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic Obstructive Pulmonary Disease",
-            "chronic obstructive pulmonary disease",
-            "Chronic pulmonary obstruction",
-            "Chronic Airflow Obstruction",
-            "Chronic Obstructive Airway Disease",
-            "Pulmonary Disease, Chronic Obstructive"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health-topics/copd",
-            "PMID:32800196",
-            "PMID:28513453",
-            "PMID:25943942",
-            "PMID:32745458"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 324986,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-              "name": "chronic obstructive pulmonary disease",
-              "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-              "equivalent_curies": [
-                "MESH:D029424",
-                "MEDDRA:10010952",
-                "MEDDRA:10009025",
-                "ICD10:J44.9",
-                "UMLS:C1527303",
-                "NCIT:C3199",
-                "UMLS:C0024117",
-                "MEDDRA:10064611",
-                "MEDDRA:10009026",
-                "MEDDRA:10029972",
-                "DOID:3083",
-                "MONDO:0005002",
-                "MEDDRA:10009032",
-                "MEDDRA:10070975",
-                "EFO:0000341",
-                "SNOMEDCT:13645005",
-                "MEDDRA:10009033",
-                "HP:0006510",
-                "MEDDRA:10008828"
-              ],
-              "id": "MONDO:0005002",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic Obstructive Pulmonary Disease",
-                "chronic obstructive pulmonary disease",
-                "Chronic pulmonary obstruction",
-                "Chronic Airflow Obstruction",
-                "Chronic Obstructive Airway Disease",
-                "Pulmonary Disease, Chronic Obstructive"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health-topics/copd",
-                "PMID:32800196",
-                "PMID:28513453",
-                "PMID:25943942",
-                "PMID:32745458"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12752857,
-            "start": 568,
-            "end": 324986,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17363304': {'publication date': '2008 Feb', 'sentence': 'When combined with environmental control, prednisolone and dexamethasone treatments had similar effects on heaves score, blood gases and endoscopic scores.', 'subject score': 1000, 'object score': 1000}, 'PMID:18836113': {'publication date': '2008 Oct', 'sentence': 'Oral prednisolone was not inferior to intravenous prednisolone for treatment failure in chronic obstructive pulmonary disease exacerbation.', 'subject score': 888, 'object score': 771}, 'PMID:18972276': {'publication date': '2008 Oct', 'sentence': 'Forty-five patients not using steroids (37 male, 21/24 current/ex smoker, median packyears 38, age 65 years, FEV(1) 61% predicted), experiencing a COPD exacerbation, were treated at home with budesonide/formoterol (320/9 microg 4 times daily), prednisolone (30 mg daily), or placebo for 14 days.', 'subject score': 1000, 'object score': 771}, 'PMID:24925917': {'publication date': '2014 Sep', 'sentence': 'Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis.', 'subject score': 888, 'object score': 1000}, 'PMID:25562034': {'publication date': '2014', 'sentence': 'CONCLUSIONS: We detected no evidence for the effectiveness of addition of antibiotics to prednisolone for COPD exacerbations of moderate severity and with intermediate probability of bacterial infection in this underpowered study.', 'subject score': 1000, 'object score': 771}, 'PMID:30565022': {'publication date': '2019 05', 'sentence': 'Doxycycline Added to Prednisolone in Outpatient-Treated Acute Exacerbations of COPD: A Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:6146752': {'publication date': '1984 Jul 28', 'sentence': 'Effects of prednisolone in chronic airflow limitation.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0024117---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "13029310",
-              "object": "MONDO:0005002",
-              "publications": [
-                "PMID:17363304",
-                "PMID:18836113",
-                "PMID:18972276",
-                "PMID:24925917",
-                "PMID:25562034",
-                "PMID:30565022",
-                "PMID:6146752"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11001866': {'publication date': '2000', 'sentence': 'Additive effects of prednisolone and beclomethasone dipropionate in patients with stable chronic obstructive pulmonary disease.', 'subject score': 1000, 'object score': 937}, 'PMID:11874817': {'publication date': '2002 Mar 01', 'sentence': 'Both budesonide and prednisolone improved airflow in COPD patients with acute exacerbations when compared with placebo.', 'subject score': 1000, 'object score': 928}, 'PMID:136811': {'publication date': '1976 Sep 03', 'sentence': 'The acute bronchodilator effect of chinoxaline, prednisolone and ipratropium bromide was tested by whole-body plethysmography in 18 patients with chronic obstructive airway disease over a period of 60 min.', 'subject score': 1000, 'object score': 1000}, 'PMID:1496499': {'publication date': '1992 Jun', 'sentence': 'Bone turnover during short course prednisolone treatment in patients with chronic obstructive airways disease.', 'subject score': 833, 'object score': 1000}, 'PMID:15741434': {'publication date': '2005 Mar', 'sentence': 'BACKGROUND: An association between the sputum eosinophil count and the response to a 2 week course of prednisolone has previously been reported in patients with chronic obstructive pulmonary disease (COPD).', 'subject score': 1000, 'object score': 1000}, 'PMID:15765929': {'publication date': '2004', 'sentence': 'Sputum cells were harvested from mild asthmatics and stable COPD patients and treated with piclamilast, theophylline or prednisolone.', 'subject score': 1000, 'object score': 790}, 'PMID:17646228': {'publication date': '2007 Dec', 'sentence': 'METHODS: Patients hospitalized for an exacerbation of COPD were randomized to receive 5 days of therapy with prednisolone, 60 mg IV or orally.', 'subject score': 1000, 'object score': 1000}, 'PMID:20298414': {'publication date': '2010 Jan', 'sentence': 'RESULTS: COPD patients who had filled a prescription for prednisolone (P-COPD) were DXA-scanned more frequently (17%) than those who had not (non-P-COPD) (9%) and were prescribed antiresorptive medicine more often (27%) than non-P-COPD (16%).', 'subject score': 1000, 'object score': 876}, 'PMID:21411550': {'publication date': '2011 Jun', 'sentence': 'PARTICIPANTS: Participants included 60 consecutive consenting subjects with chronic obstructive pulmonary disease admitted to hospital: 13 without known diabetes admitted for other indications and not treated with glucocorticoids (group 1), 40 without known diabetes admitted with an exacerbation of chronic obstructive pulmonary disease and treated with prednisolone (group 2, prednisolone = 30 +/- 6 mg/d), and seven with known diabetes treated with prednisolone (group 3, prednisolone = 26 +/- 9 mg/d).', 'subject score': 1000, 'object score': 1000}, 'PMID:23064668': {'publication date': '2012 Dec', 'sentence': \"The patient's past history revealed a 10-year history of psoriasis and chronic obstructive pulmonary disease treated with methotrexate and prednisolone.\", 'subject score': 1000, 'object score': 1000}, 'PMID:23991645': {'publication date': '2014 Nov', 'sentence': 'An 82-year-old woman on long-term prednisolone for chronic obstructive airways disease presented with a 2-month history of nodules on her left forearm.', 'subject score': 901, 'object score': 1000}, 'PMID:28183273': {'publication date': '2017 02 10', 'sentence': 'He had been suffering from rheumatoid arthritis for 18 years and chronic obstructive pulmonary disease for 20 years, for which he was being treated with 5 mg/day prednisolone and 8 mg/week methotrexate.', 'subject score': 852, 'object score': 1000}, 'PMID:2868289': {'publication date': '1986 Feb 01', 'sentence': 'Clinical improvement after treatment with prednisolone in chronic airways obstruction in absence of change in lung function tests.', 'subject score': 1000, 'object score': 988}, 'PMID:31761896': {'publication date': '2019 Nov 25', 'sentence': 'The patient had no known history of well-established immunocompromised state except for a short course of prednisolone for chronic obstructive pulmonary disease management.', 'subject score': 1000, 'object score': 928}, 'PMID:3265334': {'publication date': '1988 Dec', 'sentence': 'A generally similar pattern is seen in healthy controls and in patients with untreated pulmonary tuberculosis, treated leprosy, haemophilia A and chronic obstructive lung disease (COLD) patients treated with prednisolone, but the gradient of increasing CD4:CD8 ratio with depth into the dermis is significantly less steep in patients with tuberculosis, haemophilia and prednisolone-treated COLD than in the healthy controls.', 'subject score': 1000, 'object score': 928}, 'PMID:34079652': {'publication date': '2021 Apr 13', 'sentence': 'History revealed that he was taking prednisolone daily for his hyperactive airway disease.', 'subject score': 840, 'object score': 1000}, 'PMID:3538487': {'publication date': '1986 Aug', 'sentence': 'A double blind, randomised, placebo controlled, crossover trial of prednisolone (40 mg/day for 14 days) was carried out in 33 patients with chronic airflow limitation (mean age 62 years, mean FEV1 1.01 litres, mean FEV1/FVC ratio 44%), to assess the value of serial peak expiratory flow (PEF) measurements, taken five times daily in evaluating treatment response by comparison with other objective measurements and with measurements of symptoms.', 'subject score': 1000, 'object score': 1000}, 'PMID:6146752': {'publication date': '1984 Jul 28', 'sentence': 'A double-blind, randomised, placebo-controlled, crossover trial of prednisolone (40 mg daily for 14 days) was carried out in 43 patients with chronic airflow limitation (mean age 60 years, mean FEV1 1.02 litres, FEV1/FVC ratio 43.7%).', 'subject score': 1000, 'object score': 1000}, 'PMID:9089801': {'publication date': '1997 Mar', 'sentence': 'The mean leukotriene E4 level in patients with COPD during remission, during acute exacerbation before and after prednisolone treatment were 16.8[4.02], 41.7[21.9], and 19.5[3.78] pg/ml (mean[SD]), respectively.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 324986,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-          "name": "chronic obstructive pulmonary disease",
-          "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-          "equivalent_curies": [
-            "MESH:D029424",
-            "MEDDRA:10010952",
-            "MEDDRA:10009025",
-            "ICD10:J44.9",
-            "UMLS:C1527303",
-            "NCIT:C3199",
-            "UMLS:C0024117",
-            "MEDDRA:10064611",
-            "MEDDRA:10009026",
-            "MEDDRA:10029972",
-            "DOID:3083",
-            "MONDO:0005002",
-            "MEDDRA:10009032",
-            "MEDDRA:10070975",
-            "EFO:0000341",
-            "SNOMEDCT:13645005",
-            "MEDDRA:10009033",
-            "HP:0006510",
-            "MEDDRA:10008828"
-          ],
-          "id": "MONDO:0005002",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic Obstructive Pulmonary Disease",
-            "chronic obstructive pulmonary disease",
-            "Chronic pulmonary obstruction",
-            "Chronic Airflow Obstruction",
-            "Chronic Obstructive Airway Disease",
-            "Pulmonary Disease, Chronic Obstructive"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health-topics/copd",
-            "PMID:32800196",
-            "PMID:28513453",
-            "PMID:25943942",
-            "PMID:32745458"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 324986,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-              "name": "chronic obstructive pulmonary disease",
-              "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-              "equivalent_curies": [
-                "MESH:D029424",
-                "MEDDRA:10010952",
-                "MEDDRA:10009025",
-                "ICD10:J44.9",
-                "UMLS:C1527303",
-                "NCIT:C3199",
-                "UMLS:C0024117",
-                "MEDDRA:10064611",
-                "MEDDRA:10009026",
-                "MEDDRA:10029972",
-                "DOID:3083",
-                "MONDO:0005002",
-                "MEDDRA:10009032",
-                "MEDDRA:10070975",
-                "EFO:0000341",
-                "SNOMEDCT:13645005",
-                "MEDDRA:10009033",
-                "HP:0006510",
-                "MEDDRA:10008828"
-              ],
-              "id": "MONDO:0005002",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic Obstructive Pulmonary Disease",
-                "chronic obstructive pulmonary disease",
-                "Chronic pulmonary obstruction",
-                "Chronic Airflow Obstruction",
-                "Chronic Obstructive Airway Disease",
-                "Pulmonary Disease, Chronic Obstructive"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health-topics/copd",
-                "PMID:32800196",
-                "PMID:28513453",
-                "PMID:25943942",
-                "PMID:32745458"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8276205,
-            "start": 568,
-            "end": 324986,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11001866': {'publication date': '2000', 'sentence': 'Additive effects of prednisolone and beclomethasone dipropionate in patients with stable chronic obstructive pulmonary disease.', 'subject score': 1000, 'object score': 937}, 'PMID:11874817': {'publication date': '2002 Mar 01', 'sentence': 'Both budesonide and prednisolone improved airflow in COPD patients with acute exacerbations when compared with placebo.', 'subject score': 1000, 'object score': 928}, 'PMID:136811': {'publication date': '1976 Sep 03', 'sentence': 'The acute bronchodilator effect of chinoxaline, prednisolone and ipratropium bromide was tested by whole-body plethysmography in 18 patients with chronic obstructive airway disease over a period of 60 min.', 'subject score': 1000, 'object score': 1000}, 'PMID:1496499': {'publication date': '1992 Jun', 'sentence': 'Bone turnover during short course prednisolone treatment in patients with chronic obstructive airways disease.', 'subject score': 833, 'object score': 1000}, 'PMID:15741434': {'publication date': '2005 Mar', 'sentence': 'BACKGROUND: An association between the sputum eosinophil count and the response to a 2 week course of prednisolone has previously been reported in patients with chronic obstructive pulmonary disease (COPD).', 'subject score': 1000, 'object score': 1000}, 'PMID:15765929': {'publication date': '2004', 'sentence': 'Sputum cells were harvested from mild asthmatics and stable COPD patients and treated with piclamilast, theophylline or prednisolone.', 'subject score': 1000, 'object score': 790}, 'PMID:17646228': {'publication date': '2007 Dec', 'sentence': 'METHODS: Patients hospitalized for an exacerbation of COPD were randomized to receive 5 days of therapy with prednisolone, 60 mg IV or orally.', 'subject score': 1000, 'object score': 1000}, 'PMID:20298414': {'publication date': '2010 Jan', 'sentence': 'RESULTS: COPD patients who had filled a prescription for prednisolone (P-COPD) were DXA-scanned more frequently (17%) than those who had not (non-P-COPD) (9%) and were prescribed antiresorptive medicine more often (27%) than non-P-COPD (16%).', 'subject score': 1000, 'object score': 876}, 'PMID:21411550': {'publication date': '2011 Jun', 'sentence': 'PARTICIPANTS: Participants included 60 consecutive consenting subjects with chronic obstructive pulmonary disease admitted to hospital: 13 without known diabetes admitted for other indications and not treated with glucocorticoids (group 1), 40 without known diabetes admitted with an exacerbation of chronic obstructive pulmonary disease and treated with prednisolone (group 2, prednisolone = 30 +/- 6 mg/d), and seven with known diabetes treated with prednisolone (group 3, prednisolone = 26 +/- 9 mg/d).', 'subject score': 1000, 'object score': 1000}, 'PMID:23064668': {'publication date': '2012 Dec', 'sentence': \"The patient's past history revealed a 10-year history of psoriasis and chronic obstructive pulmonary disease treated with methotrexate and prednisolone.\", 'subject score': 1000, 'object score': 1000}, 'PMID:23991645': {'publication date': '2014 Nov', 'sentence': 'An 82-year-old woman on long-term prednisolone for chronic obstructive airways disease presented with a 2-month history of nodules on her left forearm.', 'subject score': 901, 'object score': 1000}, 'PMID:28183273': {'publication date': '2017 02 10', 'sentence': 'He had been suffering from rheumatoid arthritis for 18 years and chronic obstructive pulmonary disease for 20 years, for which he was being treated with 5 mg/day prednisolone and 8 mg/week methotrexate.', 'subject score': 852, 'object score': 1000}, 'PMID:2868289': {'publication date': '1986 Feb 01', 'sentence': 'Clinical improvement after treatment with prednisolone in chronic airways obstruction in absence of change in lung function tests.', 'subject score': 1000, 'object score': 988}, 'PMID:31761896': {'publication date': '2019 Nov 25', 'sentence': 'The patient had no known history of well-established immunocompromised state except for a short course of prednisolone for chronic obstructive pulmonary disease management.', 'subject score': 1000, 'object score': 928}, 'PMID:3265334': {'publication date': '1988 Dec', 'sentence': 'A generally similar pattern is seen in healthy controls and in patients with untreated pulmonary tuberculosis, treated leprosy, haemophilia A and chronic obstructive lung disease (COLD) patients treated with prednisolone, but the gradient of increasing CD4:CD8 ratio with depth into the dermis is significantly less steep in patients with tuberculosis, haemophilia and prednisolone-treated COLD than in the healthy controls.', 'subject score': 1000, 'object score': 928}, 'PMID:34079652': {'publication date': '2021 Apr 13', 'sentence': 'History revealed that he was taking prednisolone daily for his hyperactive airway disease.', 'subject score': 840, 'object score': 1000}, 'PMID:3538487': {'publication date': '1986 Aug', 'sentence': 'A double blind, randomised, placebo controlled, crossover trial of prednisolone (40 mg/day for 14 days) was carried out in 33 patients with chronic airflow limitation (mean age 62 years, mean FEV1 1.01 litres, mean FEV1/FVC ratio 44%), to assess the value of serial peak expiratory flow (PEF) measurements, taken five times daily in evaluating treatment response by comparison with other objective measurements and with measurements of symptoms.', 'subject score': 1000, 'object score': 1000}, 'PMID:6146752': {'publication date': '1984 Jul 28', 'sentence': 'A double-blind, randomised, placebo-controlled, crossover trial of prednisolone (40 mg daily for 14 days) was carried out in 43 patients with chronic airflow limitation (mean age 60 years, mean FEV1 1.02 litres, FEV1/FVC ratio 43.7%).', 'subject score': 1000, 'object score': 1000}, 'PMID:9089801': {'publication date': '1997 Mar', 'sentence': 'The mean leukotriene E4 level in patients with COPD during remission, during acute exacerbation before and after prednisolone treatment were 16.8[4.02], 41.7[21.9], and 19.5[3.78] pg/ml (mean[SD]), respectively.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0024117---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8455402",
-              "object": "MONDO:0005002",
-              "publications": [
-                "PMID:11001866",
-                "PMID:11874817",
-                "PMID:136811",
-                "PMID:1496499",
-                "PMID:15741434",
-                "PMID:15765929",
-                "PMID:17646228",
-                "PMID:20298414",
-                "PMID:21411550",
-                "PMID:23064668",
-                "PMID:23991645",
-                "PMID:28183273",
-                "PMID:2868289",
-                "PMID:31761896",
-                "PMID:3265334",
-                "PMID:34079652",
-                "PMID:3538487",
-                "PMID:6146752",
-                "PMID:9089801"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:22735124': {'publication date': '2012 Jun 25', 'sentence': 'Herpes zoster ophthalmicus was suspected and treatment with i.v. acyclovir and prednisolone was commenced, which led to a gradual improvement of the clinical condition.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 533929,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005883",
-          "name": "ophthalmic herpes zoster",
-          "description": "Virus infection of the Gasserian ganglion and its nerve branches characterized by pain and vesicular eruptions with much swelling. Ocular involvement is usually heralded by a vesicle on the tip of the nose. This area is innervated by the nasociliary nerve.",
-          "equivalent_curies": [
-            "MESH:D006563",
-            "SNOMEDCT:186524006",
-            "MEDDRA:10019983",
-            "UMLS:C0019364",
-            "MEDDRA:10019984",
-            "MEDDRA:10030865",
-            "SNOMEDCT:87513003",
-            "MEDDRA:10030868",
-            "MONDO:0005883",
-            "EFO:0007403"
-          ],
-          "id": "MONDO:0005883",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Herpes Zoster Ophthalmicus",
-            "ophthalmic herpes zoster"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 533929,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005883",
-              "name": "ophthalmic herpes zoster",
-              "description": "Virus infection of the Gasserian ganglion and its nerve branches characterized by pain and vesicular eruptions with much swelling. Ocular involvement is usually heralded by a vesicle on the tip of the nose. This area is innervated by the nasociliary nerve.",
-              "equivalent_curies": [
-                "MESH:D006563",
-                "SNOMEDCT:186524006",
-                "MEDDRA:10019983",
-                "UMLS:C0019364",
-                "MEDDRA:10019984",
-                "MEDDRA:10030865",
-                "SNOMEDCT:87513003",
-                "MEDDRA:10030868",
-                "MONDO:0005883",
-                "EFO:0007403"
-              ],
-              "id": "MONDO:0005883",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Herpes Zoster Ophthalmicus",
-                "ophthalmic herpes zoster"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16027396,
-            "start": 568,
-            "end": 533929,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22735124': {'publication date': '2012 Jun 25', 'sentence': 'Herpes zoster ophthalmicus was suspected and treatment with i.v. acyclovir and prednisolone was commenced, which led to a gradual improvement of the clinical condition.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0019364---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16360878",
-              "object": "MONDO:0005883",
-              "publications": [
-                "PMID:22735124"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:14345404': {'publication date': '1965 Sep', 'sentence': 'CONTACT DERMATITIS DUE TO TOPICAL HYDROCORTISONE AND PREDNISOLONE.', 'subject score': 1000, 'object score': 1000}, 'PMID:18404324': {'publication date': '2008 Apr', 'sentence': 'The inhibitory activities of combinations of CU-ext (p.o.) and prednisolone (s.c.) during induction phase of PC-CD were more potent than those of CU-ext alone and prednisolone alone.', 'subject score': 1000, 'object score': 857}, 'PMID:9601904': {'publication date': '1998 Jun', 'sentence': 'OBJECTIVE: We describe a patient allergic to hydrocortisone who was given a cross-reacting corticosteroid, prednisolone, that led to a systemic contact dermatitis.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 310746,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005480",
-          "name": "contact dermatitis",
-          "description": "An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis. []; An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0011616",
-            "NCIT:C26743",
-            "EFO:0005319",
-            "ICD10:L25.9",
-            "MESH:D003877",
-            "MEDDRA:10010803",
-            "MEDDRA:10012442",
-            "MEDDRA:10058308",
-            "SNOMEDCT:40275004",
-            "DOID:2773",
-            "MONDO:0005480",
-            "MEDDRA:10010790",
-            "HP:0032282",
-            "MEDDRA:10012492"
-          ],
-          "id": "MONDO:0005480",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis, Contact",
-            "Contact dermatitis",
-            "Contact Dermatitis",
-            "contact dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310746,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005480",
-              "name": "contact dermatitis",
-              "description": "An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis. []; An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0011616",
-                "NCIT:C26743",
-                "EFO:0005319",
-                "ICD10:L25.9",
-                "MESH:D003877",
-                "MEDDRA:10010803",
-                "MEDDRA:10012442",
-                "MEDDRA:10058308",
-                "SNOMEDCT:40275004",
-                "DOID:2773",
-                "MONDO:0005480",
-                "MEDDRA:10010790",
-                "HP:0032282",
-                "MEDDRA:10012492"
-              ],
-              "id": "MONDO:0005480",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis, Contact",
-                "Contact dermatitis",
-                "Contact Dermatitis",
-                "contact dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10504892,
-            "start": 568,
-            "end": 310746,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14345404': {'publication date': '1965 Sep', 'sentence': 'CONTACT DERMATITIS DUE TO TOPICAL HYDROCORTISONE AND PREDNISOLONE.', 'subject score': 1000, 'object score': 1000}, 'PMID:18404324': {'publication date': '2008 Apr', 'sentence': 'The inhibitory activities of combinations of CU-ext (p.o.) and prednisolone (s.c.) during induction phase of PC-CD were more potent than those of CU-ext alone and prednisolone alone.', 'subject score': 1000, 'object score': 857}, 'PMID:9601904': {'publication date': '1998 Jun', 'sentence': 'OBJECTIVE: We describe a patient allergic to hydrocortisone who was given a cross-reacting corticosteroid, prednisolone, that led to a systemic contact dermatitis.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0011616---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10735861",
-              "object": "MONDO:0005480",
-              "publications": [
-                "PMID:14345404",
-                "PMID:18404324",
-                "PMID:9601904"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:7173732': {'publication date': '1982 Jul', 'sentence': 'The aqueous extract of Saiboku-to also showed an inhibition of the contact dermatitis, and it significantly potentiated the inhibition of contact dermatitis by prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:9441732': {'publication date': '1997 Nov', 'sentence': 'RSG or CD also enhanced the activity of prednisolone in suppressing PCl-induced ear contact sensitivity.', 'subject score': 1000, 'object score': 821}}",
-    "p2": {
-      "start": {
-        "identity": 310746,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005480",
-          "name": "contact dermatitis",
-          "description": "An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis. []; An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0011616",
-            "NCIT:C26743",
-            "EFO:0005319",
-            "ICD10:L25.9",
-            "MESH:D003877",
-            "MEDDRA:10010803",
-            "MEDDRA:10012442",
-            "MEDDRA:10058308",
-            "SNOMEDCT:40275004",
-            "DOID:2773",
-            "MONDO:0005480",
-            "MEDDRA:10010790",
-            "HP:0032282",
-            "MEDDRA:10012492"
-          ],
-          "id": "MONDO:0005480",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis, Contact",
-            "Contact dermatitis",
-            "Contact Dermatitis",
-            "contact dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310746,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005480",
-              "name": "contact dermatitis",
-              "description": "An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis. []; An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0011616",
-                "NCIT:C26743",
-                "EFO:0005319",
-                "ICD10:L25.9",
-                "MESH:D003877",
-                "MEDDRA:10010803",
-                "MEDDRA:10012442",
-                "MEDDRA:10058308",
-                "SNOMEDCT:40275004",
-                "DOID:2773",
-                "MONDO:0005480",
-                "MEDDRA:10010790",
-                "HP:0032282",
-                "MEDDRA:10012492"
-              ],
-              "id": "MONDO:0005480",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis, Contact",
-                "Contact dermatitis",
-                "Contact Dermatitis",
-                "contact dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25920021,
-            "start": 568,
-            "end": 310746,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7173732': {'publication date': '1982 Jul', 'sentence': 'The aqueous extract of Saiboku-to also showed an inhibition of the contact dermatitis, and it significantly potentiated the inhibition of contact dermatitis by prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:9441732': {'publication date': '1997 Nov', 'sentence': 'RSG or CD also enhanced the activity of prednisolone in suppressing PCl-induced ear contact sensitivity.', 'subject score': 1000, 'object score': 821}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:disrupts---None---None---None---UMLS:C0011616---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "26379811",
-              "object": "MONDO:0005480",
-              "publications": [
-                "PMID:7173732",
-                "PMID:9441732"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:14399872': {'publication date': '1959 Nov 06', 'sentence': '[On experiences with a combination preparation from prednisolone and an antihistaminic in dermatology especially in endogenous eczema].', 'subject score': 1000, 'object score': 1000}, 'PMID:18294881': {'publication date': '2009 Apr', 'sentence': 'The objective of this study was to compare the efficacy of cyclosporine A (CsA) and prednisolone in feline atopic dermatitis (AD) in a randomised, controlled double blind study.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 320151,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-          "name": "dermatitis, atopic",
-          "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MESH:C566404",
-            "MEDDRA:10012434",
-            "SNOMEDCT:24079001",
-            "MONDO:0011292",
-            "MEDDRA:10003641",
-            "MONDO:0100181",
-            "MEDDRA:10014191",
-            "OMIM:603165",
-            "HP:0001047",
-            "MEDDRA:10001711",
-            "MEDDRA:10003639",
-            "UMLS:C0011615",
-            "UMLS:C4280605",
-            "UMLS:C1864155",
-            "MEDDRA:10012438",
-            "MEDDRA:10014188",
-            "MEDDRA:10001712",
-            "MESH:D003876",
-            "SNOMEDCT:200775004"
-          ],
-          "id": "MONDO:0011292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis, Atopic, 1",
-            "dermatitis, atopic",
-            "Dermatitis, Atopic",
-            "Baby eczema",
-            "Dermatitis, atopic related phenotypic feature",
-            "Atopic dermatitis",
-            "dermatitis, atopic, 1"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:27904186",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320151,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-              "name": "dermatitis, atopic",
-              "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MESH:C566404",
-                "MEDDRA:10012434",
-                "SNOMEDCT:24079001",
-                "MONDO:0011292",
-                "MEDDRA:10003641",
-                "MONDO:0100181",
-                "MEDDRA:10014191",
-                "OMIM:603165",
-                "HP:0001047",
-                "MEDDRA:10001711",
-                "MEDDRA:10003639",
-                "UMLS:C0011615",
-                "UMLS:C4280605",
-                "UMLS:C1864155",
-                "MEDDRA:10012438",
-                "MEDDRA:10014188",
-                "MEDDRA:10001712",
-                "MESH:D003876",
-                "SNOMEDCT:200775004"
-              ],
-              "id": "MONDO:0011292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis, Atopic, 1",
-                "dermatitis, atopic",
-                "Dermatitis, Atopic",
-                "Baby eczema",
-                "Dermatitis, atopic related phenotypic feature",
-                "Atopic dermatitis",
-                "dermatitis, atopic, 1"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:27904186",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10513987,
-            "start": 568,
-            "end": 320151,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14399872': {'publication date': '1959 Nov 06', 'sentence': '[On experiences with a combination preparation from prednisolone and an antihistaminic in dermatology especially in endogenous eczema].', 'subject score': 1000, 'object score': 1000}, 'PMID:18294881': {'publication date': '2009 Apr', 'sentence': 'The objective of this study was to compare the efficacy of cyclosporine A (CsA) and prednisolone in feline atopic dermatitis (AD) in a randomised, controlled double blind study.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0011615---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10744705",
-              "object": "MONDO:0011292",
-              "publications": [
-                "PMID:14399872",
-                "PMID:18294881"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15552608': {'publication date': '2004 Sep-Oct', 'sentence': 'Prednicarbate is a non-halogenated, double-ester derivative of prednisolone that has become of interest for the treatment of inflammatory skin diseases, for example atopic dermatitis.', 'subject score': 1000, 'object score': 901}, 'PMID:22141403': {'publication date': '2012 Apr', 'sentence': 'Additional studies are required to establish whether vitamin D has a synergistic therapeutic effect with prednisolone in dogs with atopic dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:22143560': {'publication date': '2011', 'sentence': 'OBJECTIVE: Prednisolone and antihistamines are highly potent drugs in the treatment of atopic dermatitis and widely used in humans and dogs.', 'subject score': 1000, 'object score': 1000}, 'PMID:24004561': {'publication date': '2013 Sep 03', 'sentence': 'BACKGROUND: A randomized, unmasked, multicenter study was conducted to evaluate the rate of pruritus reduction and improvement in clinical scoring by cyclosporine A (5 mg/kg orally, once daily for 28 days) either alone (n = 25 dogs) or with concurrent prednisolone (1 mg/kg once daily for 7 days, followed by alternate dosing for 14 days; n = 23 dogs) for the treatment of atopic dermatitis in dogs.', 'subject score': 888, 'object score': 1000}, 'PMID:26711698': {'publication date': '2016 Jan-Feb', 'sentence': 'In severe atopic dermatitis the increased expression of GRbeta mRNA is not connected to insensitivity against prednisolone treatment.', 'subject score': 888, 'object score': 901}, 'PMID:30633387': {'publication date': '2019 Jun', 'sentence': 'The use of prednisolone and other systemic anti-inflammatory therapy was substantially higher in adults with AD than in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:31339769': {'publication date': '2019 Aug', 'sentence': 'CONCLUSIONS AND CLINICAL RELEVANCE: Results indicated short-term oral administration of anti-inflammatory dosages of prednisolone did not cause relevant hemodynamic, echocardiographic, or diabetogenic effects in systemically normal cats with allergic dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:32945018': {'publication date': '2020 Sep 17', 'sentence': 'Serum TARC concentrations also were measured in 20 dogs with cAD treated with prednisolone or oclacitinib for four weeks.', 'subject score': 1000, 'object score': 901}, 'PMID:36330780': {'publication date': '2022 Nov 04', 'sentence': 'A randomised controlled trial testing the rebound-preventing benefit of four days of prednisolone during the induction of oclacitinib therapy in dogs with atopic dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:5454467': {'publication date': '1970 Jul 05', 'sentence': '[Steroid-induced peptic ulcer following prednisolone therapy of allergic dermatitis].', 'subject score': 888, 'object score': 1000}, 'PMID:8135003': {'publication date': '1994 Jan 08', 'sentence': 'Combined treatment with concentrated essential fatty acids and prednisolone in the management of canine atopy.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 320151,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-          "name": "dermatitis, atopic",
-          "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MESH:C566404",
-            "MEDDRA:10012434",
-            "SNOMEDCT:24079001",
-            "MONDO:0011292",
-            "MEDDRA:10003641",
-            "MONDO:0100181",
-            "MEDDRA:10014191",
-            "OMIM:603165",
-            "HP:0001047",
-            "MEDDRA:10001711",
-            "MEDDRA:10003639",
-            "UMLS:C0011615",
-            "UMLS:C4280605",
-            "UMLS:C1864155",
-            "MEDDRA:10012438",
-            "MEDDRA:10014188",
-            "MEDDRA:10001712",
-            "MESH:D003876",
-            "SNOMEDCT:200775004"
-          ],
-          "id": "MONDO:0011292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis, Atopic, 1",
-            "dermatitis, atopic",
-            "Dermatitis, Atopic",
-            "Baby eczema",
-            "Dermatitis, atopic related phenotypic feature",
-            "Atopic dermatitis",
-            "dermatitis, atopic, 1"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:27904186",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320151,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-              "name": "dermatitis, atopic",
-              "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MESH:C566404",
-                "MEDDRA:10012434",
-                "SNOMEDCT:24079001",
-                "MONDO:0011292",
-                "MEDDRA:10003641",
-                "MONDO:0100181",
-                "MEDDRA:10014191",
-                "OMIM:603165",
-                "HP:0001047",
-                "MEDDRA:10001711",
-                "MEDDRA:10003639",
-                "UMLS:C0011615",
-                "UMLS:C4280605",
-                "UMLS:C1864155",
-                "MEDDRA:10012438",
-                "MEDDRA:10014188",
-                "MEDDRA:10001712",
-                "MESH:D003876",
-                "SNOMEDCT:200775004"
-              ],
-              "id": "MONDO:0011292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis, Atopic, 1",
-                "dermatitis, atopic",
-                "Dermatitis, Atopic",
-                "Baby eczema",
-                "Dermatitis, atopic related phenotypic feature",
-                "Atopic dermatitis",
-                "dermatitis, atopic, 1"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:27904186",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11280531,
-            "start": 568,
-            "end": 320151,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15552608': {'publication date': '2004 Sep-Oct', 'sentence': 'Prednicarbate is a non-halogenated, double-ester derivative of prednisolone that has become of interest for the treatment of inflammatory skin diseases, for example atopic dermatitis.', 'subject score': 1000, 'object score': 901}, 'PMID:22141403': {'publication date': '2012 Apr', 'sentence': 'Additional studies are required to establish whether vitamin D has a synergistic therapeutic effect with prednisolone in dogs with atopic dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:22143560': {'publication date': '2011', 'sentence': 'OBJECTIVE: Prednisolone and antihistamines are highly potent drugs in the treatment of atopic dermatitis and widely used in humans and dogs.', 'subject score': 1000, 'object score': 1000}, 'PMID:24004561': {'publication date': '2013 Sep 03', 'sentence': 'BACKGROUND: A randomized, unmasked, multicenter study was conducted to evaluate the rate of pruritus reduction and improvement in clinical scoring by cyclosporine A (5 mg/kg orally, once daily for 28 days) either alone (n = 25 dogs) or with concurrent prednisolone (1 mg/kg once daily for 7 days, followed by alternate dosing for 14 days; n = 23 dogs) for the treatment of atopic dermatitis in dogs.', 'subject score': 888, 'object score': 1000}, 'PMID:26711698': {'publication date': '2016 Jan-Feb', 'sentence': 'In severe atopic dermatitis the increased expression of GRbeta mRNA is not connected to insensitivity against prednisolone treatment.', 'subject score': 888, 'object score': 901}, 'PMID:30633387': {'publication date': '2019 Jun', 'sentence': 'The use of prednisolone and other systemic anti-inflammatory therapy was substantially higher in adults with AD than in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:31339769': {'publication date': '2019 Aug', 'sentence': 'CONCLUSIONS AND CLINICAL RELEVANCE: Results indicated short-term oral administration of anti-inflammatory dosages of prednisolone did not cause relevant hemodynamic, echocardiographic, or diabetogenic effects in systemically normal cats with allergic dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:32945018': {'publication date': '2020 Sep 17', 'sentence': 'Serum TARC concentrations also were measured in 20 dogs with cAD treated with prednisolone or oclacitinib for four weeks.', 'subject score': 1000, 'object score': 901}, 'PMID:36330780': {'publication date': '2022 Nov 04', 'sentence': 'A randomised controlled trial testing the rebound-preventing benefit of four days of prednisolone during the induction of oclacitinib therapy in dogs with atopic dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:5454467': {'publication date': '1970 Jul 05', 'sentence': '[Steroid-induced peptic ulcer following prednisolone therapy of allergic dermatitis].', 'subject score': 888, 'object score': 1000}, 'PMID:8135003': {'publication date': '1994 Jan 08', 'sentence': 'Combined treatment with concentrated essential fatty acids and prednisolone in the management of canine atopy.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0011615---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11527350",
-              "object": "MONDO:0011292",
-              "publications": [
-                "PMID:15552608",
-                "PMID:22141403",
-                "PMID:22143560",
-                "PMID:24004561",
-                "PMID:26711698",
-                "PMID:30633387",
-                "PMID:31339769",
-                "PMID:32945018",
-                "PMID:36330780",
-                "PMID:5454467",
-                "PMID:8135003"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:11896887': {'publication date': '2002 Apr', 'sentence': 'Mizoribine as an effective combined maintenance therapy with prednisolone in child-onset systemic lupus erythematosus.', 'subject score': 1000, 'object score': 875}, 'PMID:29320974': {'publication date': '2018 Jan 01', 'sentence': 'Conclusion Comparable intake and tapering of high dose DFZ and PDN in active SLE revealed 2-fold less weight gain, 2.5-fold less hirsutism and 1.5-fold lower cushingoid severity index as well as lower glycaemic elevation in the DFZ group as compared to PDN group.', 'subject score': 1000, 'object score': 916}, 'PMID:355719': {'publication date': '1978 Jul', 'sentence': '[Effect of prednisolone and heparin on circulating T- and B-lymphocytes in glomerulonephritis and systemic lupus erythematosus].', 'subject score': 1000, 'object score': 1000}, 'PMID:8961376': {'publication date': '1996', 'sentence': 'We concluded that suppression of production of dsDNA antibodies with high avidity is a suitable parameter to determine efficacy of treatment and long-term outcome during combined therapy with azathioprine and low-dose prednisolone in SLE.', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319015,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-          "name": "systemic lupus erythematosus",
-          "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10025133",
-            "KEGG.DISEASE:05322",
-            "MEDDRA:10042820",
-            "PDQ:CDR0000608139",
-            "MEDDRA:10040967",
-            "MEDDRA:10042800",
-            "MEDDRA:10013446",
-            "MONDO:0007915",
-            "MEDDRA:10042945",
-            "MEDDRA:10024067",
-            "ICD10:M32.9",
-            "MEDDRA:10042947",
-            "ORPHANET:536",
-            "MEDDRA:10042944",
-            "UMLS:C0024141",
-            "EFO:0002690",
-            "MESH:D008180",
-            "ICD9:710.0",
-            "DOID:9074",
-            "MEDDRA:10025139",
-            "UMLS:C1835309",
-            "MEDDRA:10024065",
-            "OMIM:152700",
-            "HP:0002725",
-            "MEDDRA:10025142",
-            "NCIT:C3201",
-            "SNOMEDCT:55464009"
-          ],
-          "id": "MONDO:0007915",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Systemic lupus erythematosus",
-            "obsolete_systemic lupus erythematosus",
-            "Systemic lupus erythematosus related phenotypic feature",
-            "Lupus Erythematosus, Systemic",
-            "Excess lmw-dna",
-            "systemic lupus erythematosus",
-            "Systemic Lupus Erythematosus"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319015,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-              "name": "systemic lupus erythematosus",
-              "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10025133",
-                "KEGG.DISEASE:05322",
-                "MEDDRA:10042820",
-                "PDQ:CDR0000608139",
-                "MEDDRA:10040967",
-                "MEDDRA:10042800",
-                "MEDDRA:10013446",
-                "MONDO:0007915",
-                "MEDDRA:10042945",
-                "MEDDRA:10024067",
-                "ICD10:M32.9",
-                "MEDDRA:10042947",
-                "ORPHANET:536",
-                "MEDDRA:10042944",
-                "UMLS:C0024141",
-                "EFO:0002690",
-                "MESH:D008180",
-                "ICD9:710.0",
-                "DOID:9074",
-                "MEDDRA:10025139",
-                "UMLS:C1835309",
-                "MEDDRA:10024065",
-                "OMIM:152700",
-                "HP:0002725",
-                "MEDDRA:10025142",
-                "NCIT:C3201",
-                "SNOMEDCT:55464009"
-              ],
-              "id": "MONDO:0007915",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Systemic lupus erythematosus",
-                "obsolete_systemic lupus erythematosus",
-                "Systemic lupus erythematosus related phenotypic feature",
-                "Lupus Erythematosus, Systemic",
-                "Excess lmw-dna",
-                "systemic lupus erythematosus",
-                "Systemic Lupus Erythematosus"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9220530,
-            "start": 568,
-            "end": 319015,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11896887': {'publication date': '2002 Apr', 'sentence': 'Mizoribine as an effective combined maintenance therapy with prednisolone in child-onset systemic lupus erythematosus.', 'subject score': 1000, 'object score': 875}, 'PMID:29320974': {'publication date': '2018 Jan 01', 'sentence': 'Conclusion Comparable intake and tapering of high dose DFZ and PDN in active SLE revealed 2-fold less weight gain, 2.5-fold less hirsutism and 1.5-fold lower cushingoid severity index as well as lower glycaemic elevation in the DFZ group as compared to PDN group.', 'subject score': 1000, 'object score': 916}, 'PMID:355719': {'publication date': '1978 Jul', 'sentence': '[Effect of prednisolone and heparin on circulating T- and B-lymphocytes in glomerulonephritis and systemic lupus erythematosus].', 'subject score': 1000, 'object score': 1000}, 'PMID:8961376': {'publication date': '1996', 'sentence': 'We concluded that suppression of production of dsDNA antibodies with high avidity is a suitable parameter to determine efficacy of treatment and long-term outcome during combined therapy with azathioprine and low-dose prednisolone in SLE.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0024141---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9437304",
-              "object": "MONDO:0007915",
-              "publications": [
-                "PMID:11896887",
-                "PMID:29320974",
-                "PMID:355719",
-                "PMID:8961376"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:11246661': {'publication date': '2001 Feb', 'sentence': 'In inactive SLE induced by prednisolone therapy, the invariant Valpha24JalphaQ TCR could be detected in DN Valpha24+ T cells from all the patients and dominated in most of the patients.', 'subject score': 888, 'object score': 916}}",
-    "p2": {
-      "start": {
-        "identity": 319015,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-          "name": "systemic lupus erythematosus",
-          "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10025133",
-            "KEGG.DISEASE:05322",
-            "MEDDRA:10042820",
-            "PDQ:CDR0000608139",
-            "MEDDRA:10040967",
-            "MEDDRA:10042800",
-            "MEDDRA:10013446",
-            "MONDO:0007915",
-            "MEDDRA:10042945",
-            "MEDDRA:10024067",
-            "ICD10:M32.9",
-            "MEDDRA:10042947",
-            "ORPHANET:536",
-            "MEDDRA:10042944",
-            "UMLS:C0024141",
-            "EFO:0002690",
-            "MESH:D008180",
-            "ICD9:710.0",
-            "DOID:9074",
-            "MEDDRA:10025139",
-            "UMLS:C1835309",
-            "MEDDRA:10024065",
-            "OMIM:152700",
-            "HP:0002725",
-            "MEDDRA:10025142",
-            "NCIT:C3201",
-            "SNOMEDCT:55464009"
-          ],
-          "id": "MONDO:0007915",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Systemic lupus erythematosus",
-            "obsolete_systemic lupus erythematosus",
-            "Systemic lupus erythematosus related phenotypic feature",
-            "Lupus Erythematosus, Systemic",
-            "Excess lmw-dna",
-            "systemic lupus erythematosus",
-            "Systemic Lupus Erythematosus"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319015,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-              "name": "systemic lupus erythematosus",
-              "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10025133",
-                "KEGG.DISEASE:05322",
-                "MEDDRA:10042820",
-                "PDQ:CDR0000608139",
-                "MEDDRA:10040967",
-                "MEDDRA:10042800",
-                "MEDDRA:10013446",
-                "MONDO:0007915",
-                "MEDDRA:10042945",
-                "MEDDRA:10024067",
-                "ICD10:M32.9",
-                "MEDDRA:10042947",
-                "ORPHANET:536",
-                "MEDDRA:10042944",
-                "UMLS:C0024141",
-                "EFO:0002690",
-                "MESH:D008180",
-                "ICD9:710.0",
-                "DOID:9074",
-                "MEDDRA:10025139",
-                "UMLS:C1835309",
-                "MEDDRA:10024065",
-                "OMIM:152700",
-                "HP:0002725",
-                "MEDDRA:10025142",
-                "NCIT:C3201",
-                "SNOMEDCT:55464009"
-              ],
-              "id": "MONDO:0007915",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Systemic lupus erythematosus",
-                "obsolete_systemic lupus erythematosus",
-                "Systemic lupus erythematosus related phenotypic feature",
-                "Lupus Erythematosus, Systemic",
-                "Excess lmw-dna",
-                "systemic lupus erythematosus",
-                "Systemic Lupus Erythematosus"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8570880,
-            "start": 568,
-            "end": 319015,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11246661': {'publication date': '2001 Feb', 'sentence': 'In inactive SLE induced by prednisolone therapy, the invariant Valpha24JalphaQ TCR could be detected in DN Valpha24+ T cells from all the patients and dominated in most of the patients.', 'subject score': 888, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0024141---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8757881",
-              "object": "MONDO:0007915",
-              "publications": [
-                "PMID:11246661"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:10332213': {'publication date': '1999 Feb', 'sentence': 'The dose of prednisolone was increased considering he was exacerbated of SLE, however, the convulsion as CNS lupus occurred to him.', 'subject score': 1000, 'object score': 1000}, 'PMID:2137939': {'publication date': '1990 Feb', 'sentence': 'Increased circulating HLA-DR+ CD4+ T cells in systemic lupus erythematosus: alterations associated with prednisolone therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:30078223': {'publication date': '2018 Jan', 'sentence': 'We observed that probiotics and prednisolone could delay SLE in pretreatment and treatment mice groups, with a reduction in ANA, anti-dsDNA, anti-RNP, and mass of lipogranuloma.', 'subject score': 1000, 'object score': 1000}, 'PMID:3686432': {'publication date': '1987', 'sentence': 'A study was made of the sensitivity to prednisolone (PS) of peripheral blood mononuclear cells (MS) of patients with systemic lupus erythematosus (SLE) with renal lesion showing resistance to glucocorticoids (GC).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319015,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-          "name": "systemic lupus erythematosus",
-          "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10025133",
-            "KEGG.DISEASE:05322",
-            "MEDDRA:10042820",
-            "PDQ:CDR0000608139",
-            "MEDDRA:10040967",
-            "MEDDRA:10042800",
-            "MEDDRA:10013446",
-            "MONDO:0007915",
-            "MEDDRA:10042945",
-            "MEDDRA:10024067",
-            "ICD10:M32.9",
-            "MEDDRA:10042947",
-            "ORPHANET:536",
-            "MEDDRA:10042944",
-            "UMLS:C0024141",
-            "EFO:0002690",
-            "MESH:D008180",
-            "ICD9:710.0",
-            "DOID:9074",
-            "MEDDRA:10025139",
-            "UMLS:C1835309",
-            "MEDDRA:10024065",
-            "OMIM:152700",
-            "HP:0002725",
-            "MEDDRA:10025142",
-            "NCIT:C3201",
-            "SNOMEDCT:55464009"
-          ],
-          "id": "MONDO:0007915",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Systemic lupus erythematosus",
-            "obsolete_systemic lupus erythematosus",
-            "Systemic lupus erythematosus related phenotypic feature",
-            "Lupus Erythematosus, Systemic",
-            "Excess lmw-dna",
-            "systemic lupus erythematosus",
-            "Systemic Lupus Erythematosus"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319015,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-              "name": "systemic lupus erythematosus",
-              "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10025133",
-                "KEGG.DISEASE:05322",
-                "MEDDRA:10042820",
-                "PDQ:CDR0000608139",
-                "MEDDRA:10040967",
-                "MEDDRA:10042800",
-                "MEDDRA:10013446",
-                "MONDO:0007915",
-                "MEDDRA:10042945",
-                "MEDDRA:10024067",
-                "ICD10:M32.9",
-                "MEDDRA:10042947",
-                "ORPHANET:536",
-                "MEDDRA:10042944",
-                "UMLS:C0024141",
-                "EFO:0002690",
-                "MESH:D008180",
-                "ICD9:710.0",
-                "DOID:9074",
-                "MEDDRA:10025139",
-                "UMLS:C1835309",
-                "MEDDRA:10024065",
-                "OMIM:152700",
-                "HP:0002725",
-                "MEDDRA:10025142",
-                "NCIT:C3201",
-                "SNOMEDCT:55464009"
-              ],
-              "id": "MONDO:0007915",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Systemic lupus erythematosus",
-                "obsolete_systemic lupus erythematosus",
-                "Systemic lupus erythematosus related phenotypic feature",
-                "Lupus Erythematosus, Systemic",
-                "Excess lmw-dna",
-                "systemic lupus erythematosus",
-                "Systemic Lupus Erythematosus"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7246960,
-            "start": 568,
-            "end": 319015,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10332213': {'publication date': '1999 Feb', 'sentence': 'The dose of prednisolone was increased considering he was exacerbated of SLE, however, the convulsion as CNS lupus occurred to him.', 'subject score': 1000, 'object score': 1000}, 'PMID:2137939': {'publication date': '1990 Feb', 'sentence': 'Increased circulating HLA-DR+ CD4+ T cells in systemic lupus erythematosus: alterations associated with prednisolone therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:30078223': {'publication date': '2018 Jan', 'sentence': 'We observed that probiotics and prednisolone could delay SLE in pretreatment and treatment mice groups, with a reduction in ANA, anti-dsDNA, anti-RNP, and mass of lipogranuloma.', 'subject score': 1000, 'object score': 1000}, 'PMID:3686432': {'publication date': '1987', 'sentence': 'A study was made of the sensitivity to prednisolone (PS) of peripheral blood mononuclear cells (MS) of patients with systemic lupus erythematosus (SLE) with renal lesion showing resistance to glucocorticoids (GC).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0024141---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7395227",
-              "object": "MONDO:0007915",
-              "publications": [
-                "PMID:10332213",
-                "PMID:2137939",
-                "PMID:30078223",
-                "PMID:3686432"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10566758': {'publication date': '1999 Nov', 'sentence': 'Subacute severe steatohepatitis during prednisolone therapy for systemic lupus erythematosis.', 'subject score': 888, 'object score': 1000}, 'PMID:10634026': {'publication date': '1999 Dec', 'sentence': 'The first patient, a 40-year-old man with systemic lupus erythematosus and uremia on prednisolone therapy, developed fulminant cellulitis and septic shock 1 month after a skin biopsy for cutaneous vasculitis of the left foot.', 'subject score': 888, 'object score': 1000}, 'PMID:10713652': {'publication date': '2000', 'sentence': 'We report on a 23-year-old Japanese female with a 13-year history of systemic lupus erythematosus (SLE), and two episodes of deterioration followed by treatment with high dose prednisolone.', 'subject score': 901, 'object score': 1000}, 'PMID:11246661': {'publication date': '2001 Feb', 'sentence': 'METHODS: We carried out a 2 step frequency analysis of DN Valpha24JalphaQ T cells in patients with SLE before and after prednisolone therapy; the frequency of DN Valpha24+ T cells was determined by 3 color FACS analysis and subsequently the frequency of Valpha24JalphaQ rearrangement among DN Valpha24+ T cells was determined by sequencing.', 'subject score': 888, 'object score': 1000}, 'PMID:11517569': {'publication date': '2001 Jul', 'sentence': 'SLE has been treated with prednisolone and mizoribine for 4 years.', 'subject score': 1000, 'object score': 1000}, 'PMID:11896887': {'publication date': '2002 Apr', 'sentence': 'METHODS: We have proposed and tested a new type of combination therapy using prednisolone (PSL) and mizoribine (MZR) in pediatric patients with SLE for maintenance therapy after the induction of remission.', 'subject score': 1000, 'object score': 1000}, 'PMID:12563679': {'publication date': '2003 Feb', 'sentence': 'In SLE patients without prior prednisolone treatment, serum levels of 17OHPreg and cortisol were similar, and serum levels of P, 17OHP, ASD, DHEA, and DHEAS were significantly lower as compared to controls.', 'subject score': 851, 'object score': 916}, 'PMID:13271100': {'publication date': '1955 Dec 17', 'sentence': 'Treatment of systemic lupus erythematosus with prednisone and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:13573187': {'publication date': '1958 Sep', 'sentence': 'Twenty-nine patients with systemic lupus erythematosus were treated with a new synthetic unsaturated prednisolone derivative, triamcinolone, for as long as 11 months.', 'subject score': 766, 'object score': 1000}, 'PMID:14747618': {'publication date': '2004 May', 'sentence': 'ICAM-1 expression was reduced on monocytes from patients with SLE (P = 0.002), although high-dose prednisolone therapy was associated with the lowest level of surface ICAM-1 on monocytes.', 'subject score': 861, 'object score': 1000}, 'PMID:14994392': {'publication date': '2004 Mar', 'sentence': 'RESULTS: Urinary concentration and total urinary loss of 2-hydroxyestrogens was 10 times higher in healthy subjects compared to patients with either SLE or RA irrespective of prior prednisolone treatment or sex.', 'subject score': 851, 'object score': 923}, 'PMID:15317831': {'publication date': '2004 Sep', 'sentence': 'These studies help rationalize actual or potential use of other drugs with prednisolone in the treatment of systemic lupus erythematosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:1570066': {'publication date': '1992 Apr', 'sentence': 'She had been treated with prednisolone for systemic lupus erythematosus (SLE) for one and a half year before admission.', 'subject score': 1000, 'object score': 1000}, 'PMID:15825716': {'publication date': '2004 Nov', 'sentence': 'These findings suggest that low dose prednisolone may not be detrimental to bone in premenopausal women with SLE during longterm treatment.', 'subject score': 901, 'object score': 1000}, 'PMID:15941834': {'publication date': '2006 Jan', 'sentence': 'The NPY/ACTH ratio was increased in SLE and RA, irrespective of prior prednisolone treatment.', 'subject score': 851, 'object score': 1000}, 'PMID:16234272': {'publication date': '2006 Apr', 'sentence': 'Outcome of protein-losing gastroenteropathy in systemic lupus erythematosus treated with prednisolone and azathioprine.', 'subject score': 1000, 'object score': 1000}, 'PMID:16763400': {'publication date': '2006', 'sentence': 'CLINICAL PRESENTATION AND INTERVENTION: A 56-year-old man, a known case of systemic lupus erythematosus on azathioprine and prednisolone therapy, developed urinary tract infection followed by bacteremia and epididymo-orchitis.', 'subject score': 888, 'object score': 1000}, 'PMID:17381807': {'publication date': '2007 Apr', 'sentence': 'She had systemic lupus erythematosus and interstitial pneumonia for 17 years, treated with prednisolone and azathioprine.', 'subject score': 1000, 'object score': 1000}, 'PMID:17483980': {'publication date': '2008 Jan', 'sentence': 'We believe that the MZR pulse protocol combined with PDN for induction therapy may be the treatment of choice in selected young patients with SLE.', 'subject score': 1000, 'object score': 1000}, 'PMID:17537533': {'publication date': '2007 Jul 31', 'sentence': 'We treated a patient whose initial manifestation of SLE was pericardial effusion causing CHF, which improved following prednisolone therapy that led to a dramatic decrease in pericardial effusion and improvement in left ventricular diastolic dysfunction as shown in Doppler echocardiography findings.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319015,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-          "name": "systemic lupus erythematosus",
-          "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10025133",
-            "KEGG.DISEASE:05322",
-            "MEDDRA:10042820",
-            "PDQ:CDR0000608139",
-            "MEDDRA:10040967",
-            "MEDDRA:10042800",
-            "MEDDRA:10013446",
-            "MONDO:0007915",
-            "MEDDRA:10042945",
-            "MEDDRA:10024067",
-            "ICD10:M32.9",
-            "MEDDRA:10042947",
-            "ORPHANET:536",
-            "MEDDRA:10042944",
-            "UMLS:C0024141",
-            "EFO:0002690",
-            "MESH:D008180",
-            "ICD9:710.0",
-            "DOID:9074",
-            "MEDDRA:10025139",
-            "UMLS:C1835309",
-            "MEDDRA:10024065",
-            "OMIM:152700",
-            "HP:0002725",
-            "MEDDRA:10025142",
-            "NCIT:C3201",
-            "SNOMEDCT:55464009"
-          ],
-          "id": "MONDO:0007915",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Systemic lupus erythematosus",
-            "obsolete_systemic lupus erythematosus",
-            "Systemic lupus erythematosus related phenotypic feature",
-            "Lupus Erythematosus, Systemic",
-            "Excess lmw-dna",
-            "systemic lupus erythematosus",
-            "Systemic Lupus Erythematosus"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319015,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-              "name": "systemic lupus erythematosus",
-              "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10025133",
-                "KEGG.DISEASE:05322",
-                "MEDDRA:10042820",
-                "PDQ:CDR0000608139",
-                "MEDDRA:10040967",
-                "MEDDRA:10042800",
-                "MEDDRA:10013446",
-                "MONDO:0007915",
-                "MEDDRA:10042945",
-                "MEDDRA:10024067",
-                "ICD10:M32.9",
-                "MEDDRA:10042947",
-                "ORPHANET:536",
-                "MEDDRA:10042944",
-                "UMLS:C0024141",
-                "EFO:0002690",
-                "MESH:D008180",
-                "ICD9:710.0",
-                "DOID:9074",
-                "MEDDRA:10025139",
-                "UMLS:C1835309",
-                "MEDDRA:10024065",
-                "OMIM:152700",
-                "HP:0002725",
-                "MEDDRA:10025142",
-                "NCIT:C3201",
-                "SNOMEDCT:55464009"
-              ],
-              "id": "MONDO:0007915",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Systemic lupus erythematosus",
-                "obsolete_systemic lupus erythematosus",
-                "Systemic lupus erythematosus related phenotypic feature",
-                "Lupus Erythematosus, Systemic",
-                "Excess lmw-dna",
-                "systemic lupus erythematosus",
-                "Systemic Lupus Erythematosus"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7657370,
-            "start": 568,
-            "end": 319015,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10566758': {'publication date': '1999 Nov', 'sentence': 'Subacute severe steatohepatitis during prednisolone therapy for systemic lupus erythematosis.', 'subject score': 888, 'object score': 1000}, 'PMID:10634026': {'publication date': '1999 Dec', 'sentence': 'The first patient, a 40-year-old man with systemic lupus erythematosus and uremia on prednisolone therapy, developed fulminant cellulitis and septic shock 1 month after a skin biopsy for cutaneous vasculitis of the left foot.', 'subject score': 888, 'object score': 1000}, 'PMID:10713652': {'publication date': '2000', 'sentence': 'We report on a 23-year-old Japanese female with a 13-year history of systemic lupus erythematosus (SLE), and two episodes of deterioration followed by treatment with high dose prednisolone.', 'subject score': 901, 'object score': 1000}, 'PMID:11246661': {'publication date': '2001 Feb', 'sentence': 'METHODS: We carried out a 2 step frequency analysis of DN Valpha24JalphaQ T cells in patients with SLE before and after prednisolone therapy; the frequency of DN Valpha24+ T cells was determined by 3 color FACS analysis and subsequently the frequency of Valpha24JalphaQ rearrangement among DN Valpha24+ T cells was determined by sequencing.', 'subject score': 888, 'object score': 1000}, 'PMID:11517569': {'publication date': '2001 Jul', 'sentence': 'SLE has been treated with prednisolone and mizoribine for 4 years.', 'subject score': 1000, 'object score': 1000}, 'PMID:11896887': {'publication date': '2002 Apr', 'sentence': 'METHODS: We have proposed and tested a new type of combination therapy using prednisolone (PSL) and mizoribine (MZR) in pediatric patients with SLE for maintenance therapy after the induction of remission.', 'subject score': 1000, 'object score': 1000}, 'PMID:12563679': {'publication date': '2003 Feb', 'sentence': 'In SLE patients without prior prednisolone treatment, serum levels of 17OHPreg and cortisol were similar, and serum levels of P, 17OHP, ASD, DHEA, and DHEAS were significantly lower as compared to controls.', 'subject score': 851, 'object score': 916}, 'PMID:13271100': {'publication date': '1955 Dec 17', 'sentence': 'Treatment of systemic lupus erythematosus with prednisone and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:13573187': {'publication date': '1958 Sep', 'sentence': 'Twenty-nine patients with systemic lupus erythematosus were treated with a new synthetic unsaturated prednisolone derivative, triamcinolone, for as long as 11 months.', 'subject score': 766, 'object score': 1000}, 'PMID:14747618': {'publication date': '2004 May', 'sentence': 'ICAM-1 expression was reduced on monocytes from patients with SLE (P = 0.002), although high-dose prednisolone therapy was associated with the lowest level of surface ICAM-1 on monocytes.', 'subject score': 861, 'object score': 1000}, 'PMID:14994392': {'publication date': '2004 Mar', 'sentence': 'RESULTS: Urinary concentration and total urinary loss of 2-hydroxyestrogens was 10 times higher in healthy subjects compared to patients with either SLE or RA irrespective of prior prednisolone treatment or sex.', 'subject score': 851, 'object score': 923}, 'PMID:15317831': {'publication date': '2004 Sep', 'sentence': 'These studies help rationalize actual or potential use of other drugs with prednisolone in the treatment of systemic lupus erythematosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:1570066': {'publication date': '1992 Apr', 'sentence': 'She had been treated with prednisolone for systemic lupus erythematosus (SLE) for one and a half year before admission.', 'subject score': 1000, 'object score': 1000}, 'PMID:15825716': {'publication date': '2004 Nov', 'sentence': 'These findings suggest that low dose prednisolone may not be detrimental to bone in premenopausal women with SLE during longterm treatment.', 'subject score': 901, 'object score': 1000}, 'PMID:15941834': {'publication date': '2006 Jan', 'sentence': 'The NPY/ACTH ratio was increased in SLE and RA, irrespective of prior prednisolone treatment.', 'subject score': 851, 'object score': 1000}, 'PMID:16234272': {'publication date': '2006 Apr', 'sentence': 'Outcome of protein-losing gastroenteropathy in systemic lupus erythematosus treated with prednisolone and azathioprine.', 'subject score': 1000, 'object score': 1000}, 'PMID:16763400': {'publication date': '2006', 'sentence': 'CLINICAL PRESENTATION AND INTERVENTION: A 56-year-old man, a known case of systemic lupus erythematosus on azathioprine and prednisolone therapy, developed urinary tract infection followed by bacteremia and epididymo-orchitis.', 'subject score': 888, 'object score': 1000}, 'PMID:17381807': {'publication date': '2007 Apr', 'sentence': 'She had systemic lupus erythematosus and interstitial pneumonia for 17 years, treated with prednisolone and azathioprine.', 'subject score': 1000, 'object score': 1000}, 'PMID:17483980': {'publication date': '2008 Jan', 'sentence': 'We believe that the MZR pulse protocol combined with PDN for induction therapy may be the treatment of choice in selected young patients with SLE.', 'subject score': 1000, 'object score': 1000}, 'PMID:17537533': {'publication date': '2007 Jul 31', 'sentence': 'We treated a patient whose initial manifestation of SLE was pericardial effusion causing CHF, which improved following prednisolone therapy that led to a dramatic decrease in pericardial effusion and improvement in left ventricular diastolic dysfunction as shown in Doppler echocardiography findings.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0024141---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7819165",
-              "object": "MONDO:0007915",
-              "publications": [
-                "PMID:10566758",
-                "PMID:10634026",
-                "PMID:10713652",
-                "PMID:11246661",
-                "PMID:11517569",
-                "PMID:11896887",
-                "PMID:12563679",
-                "PMID:13271100",
-                "PMID:13573187",
-                "PMID:14747618",
-                "PMID:14994392",
-                "PMID:15317831",
-                "PMID:1570066",
-                "PMID:15825716",
-                "PMID:15941834",
-                "PMID:16234272",
-                "PMID:16763400",
-                "PMID:17381807",
-                "PMID:17483980",
-                "PMID:17537533"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 316028,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:22314465': {'publication date': '2012 Jan', 'sentence': 'Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma.', 'subject score': 1000, 'object score': 901}, 'PMID:2469398': {'publication date': '1989 Apr', 'sentence': '[Combination chemotherapy of MCNU, melphalan, procarbazine, and prednisolone (MMPP) in multiple myeloma; disappearance of M-peak on serum electrophoretic pattern].', 'subject score': 1000, 'object score': 1000}, 'PMID:28828689': {'publication date': '2017 Dec', 'sentence': 'Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).', 'subject score': 1000, 'object score': 850}, 'PMID:32583431': {'publication date': '2020 Jun 24', 'sentence': 'Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105).We conducted a randomised phase II study to determine the optimal dose and schedule of melphalan, prednisone, and bortezomib (MPB) (jRCTs031180097).', 'subject score': 1000, 'object score': 901}, 'PMID:3475485': {'publication date': '1987 Mar', 'sentence': '[Comparative studies of intermittent melphalan and prednisolone (MP) versus 5-drug regimen (QUVMP) and 3-drug regimen (QUP) in multiple myeloma].', 'subject score': 740, 'object score': 1000}, 'PMID:9025767': {'publication date': '1997', 'sentence': 'PURPOSE: To compare VMCP, a multidrug combination chemotherapy comprising vincristine (VCR), melphalan (MPH), cyclophosphamide (CPM) and prednisolone (PSL), with MMPP comprising MPH, ranimustine (MCNU), procarbazine, and PSL as induction, to elucidate the value of alternating combination chemotherapy, and to search for an appropriate maintenance therapy in multiple myeloma.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 323988,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008558",
-          "name": "autoimmune thrombocytopenic purpura",
-          "description": "Acquired thrombocytopenia of unknown cause, characterized by immune-mediated destruction of normal platelets. It affects both children and adults. It manifests with petechiae, purpura, and overt bleeding. Based upon the duration of the disease, it is classified as newly diagnosed (from diagnosis until 3 months), persistent (3-12 months), and chronic (lasting for more than 12 months).; Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.; The presence of thrombocytopenia in combination with detection of antiplatelet antibodies. [DDD:wouwehand]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021245",
-            "UMLS:C0398650",
-            "ORPHANET:3002",
-            "MESH:D016553",
-            "ICD9:287.31",
-            "MEDDRA:10083843",
-            "MEDDRA:10051064",
-            "MONDO:0008558",
-            "MEDDRA:10074667",
-            "OMIM:188030",
-            "DOID:8924",
-            "MEDDRA:10021243",
-            "ICD10:D69.3",
-            "EFO:0007160",
-            "NCIT:C3446"
-          ],
-          "id": "MONDO:0008558",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Purpura, Thrombocytopenic, Idiopathic",
-            "Immune thrombocytopenic purpura",
-            "Primary Immune Thrombocytopenia",
-            "Thrombocytopenic purpura, autoimmune related phenotypic feature",
-            "autoimmune thrombocytopenic purpura"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009693",
-          "name": "plasma cell myeloma",
-          "description": "A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3242\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3242\" NCI Thesaurus); A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001); A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.; A malignant plasma cell tumor growing within soft tissue or within the skeleton. [HPO:sdoelken]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10074470",
-            "MEDDRA:10028569",
-            "MEDDRA:10028228",
-            "MEDDRA:10035226",
-            "EFO:0001378",
-            "SNOMEDCT:55921005",
-            "MEDDRA:10034613",
-            "MESH:D009101",
-            "MEDDRA:10028568",
-            "MONDO:0009693",
-            "ICD9:203.0",
-            "HP:0006775",
-            "OMIM:254500",
-            "MEDDRA:10028566",
-            "ORPHANET:29073",
-            "SNOMEDCT:109989006",
-            "DOID:9538",
-            "ICD10:C90.0",
-            "UMLS:C0026764",
-            "PDQ:CDR0000042947",
-            "NCIT:C3242",
-            "SNOMEDCT:1162576007"
-          ],
-          "id": "MONDO:0009693",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Multiple myeloma",
-            "Multiple Myeloma",
-            "plasma cell myeloma",
-            "multiple myeloma",
-            "Myeloma, multiple related phenotypic feature",
-            "Plasma Cell Myeloma"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://rarediseases.org/rare-diseases/immune-thrombocytopenia/"
-=======
-            "http://www.cancer.gov/dictionary?cdrid=411384",
-            "http://en.wikipedia.org/wiki/multiple_myeloma",
-            "https://orcid.org/0009-0006-4530-3154"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 316028,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008558",
-              "name": "autoimmune thrombocytopenic purpura",
-              "description": "Acquired thrombocytopenia of unknown cause, characterized by immune-mediated destruction of normal platelets. It affects both children and adults. It manifests with petechiae, purpura, and overt bleeding. Based upon the duration of the disease, it is classified as newly diagnosed (from diagnosis until 3 months), persistent (3-12 months), and chronic (lasting for more than 12 months).; Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.; The presence of thrombocytopenia in combination with detection of antiplatelet antibodies. [DDD:wouwehand]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021245",
-                "UMLS:C0398650",
-                "ORPHANET:3002",
-                "MESH:D016553",
-                "ICD9:287.31",
-                "MEDDRA:10083843",
-                "MEDDRA:10051064",
-                "MONDO:0008558",
-                "MEDDRA:10074667",
-                "OMIM:188030",
-                "DOID:8924",
-                "MEDDRA:10021243",
-                "ICD10:D69.3",
-                "EFO:0007160",
-                "NCIT:C3446"
-              ],
-              "id": "MONDO:0008558",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Purpura, Thrombocytopenic, Idiopathic",
-                "Immune thrombocytopenic purpura",
-                "Primary Immune Thrombocytopenia",
-                "Thrombocytopenic purpura, autoimmune related phenotypic feature",
-                "autoimmune thrombocytopenic purpura"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://rarediseases.org/rare-diseases/immune-thrombocytopenia/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7639420,
-            "start": 568,
-            "end": 316028,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10555101': {'publication date': '1999 Nov', 'sentence': 'However, after administration of immunoglobulin (IVIG) (0.4 g/kg/day x 5 days), low-dose PSL (20 mg/day) alleviated the LEMS and ITP, and the diseases have remained in remission for 8 months without additional IVIG.', 'subject score': 901, 'object score': 1000}, 'PMID:10695392': {'publication date': '2000 Jan', 'sentence': '[Low-dose prednisolone therapy for idiopathic thrombocytopenic purpura].', 'subject score': 861, 'object score': 1000}, 'PMID:10910585': {'publication date': '1999', 'sentence': 'The case of a child with idiopathic thrombocytopenic purpura recovered after prednisolone treatment, but lymphoma developed four months later.', 'subject score': 888, 'object score': 1000}, 'PMID:11310493': {'publication date': '2001 Mar', 'sentence': 'A 69-year-old woman with idiopathic thrombocytopenic purpura, who was regularly followed and treated with prednisolone and danazol, was admitted to our hospital because of shortness of breath.', 'subject score': 1000, 'object score': 1000}, 'PMID:11974905': {'publication date': '2002 Mar', 'sentence': 'Idiopathic thrombocytopenic purpura (ITP) was suspected and prednisolone therapy was begun, and ultimately brought about a partial remission.', 'subject score': 888, 'object score': 1000}, 'PMID:11979754': {'publication date': '2002 Mar', 'sentence': 'A 69-year-old man was diagnosed as having idiopathic thrombocytopenic purpura (ITP) in April 2000, and treated with prednisolone (PSL) without effect.', 'subject score': 1000, 'object score': 1000}, 'PMID:12400162': {'publication date': '2002 Oct', 'sentence': 'A 47-year-old woman received combination therapy with prednisolone (PSL), danazol, cepharanthin, ascorbic acid, and cimetidine for the treatment of idiopathic thrombocytopenic purpura.', 'subject score': 1000, 'object score': 1000}, 'PMID:16019454': {'publication date': '2005 Apr', 'sentence': 'The ITP patients with HTLV-I infection were older than the patients without HTLV-I infection, and the ITP patients with HTLV-I infection had poor response to prednisolone therapy.', 'subject score': 888, 'object score': 916}, 'PMID:17309547': {'publication date': '2007 Apr', 'sentence': 'Investigations confirmed immune thrombocytopenic purpura, and she received treatment with prednisolone and intravenous immunoglobulins with no increment in the platelet count.', 'subject score': 1000, 'object score': 1000}, 'PMID:17352309': {'publication date': '2006', 'sentence': 'The aims of this study were to compare initial platelet count elevation and to determine the chance of developing persistent profound thrombocytopenia by intravenous immunoglobulin (IVIG) or prednisolone in the treatment of children with ITP.', 'subject score': 1000, 'object score': 1000}, 'PMID:17825698': {'publication date': '2007 Jul', 'sentence': 'He had been prescribed 800 mg/d of clarithromycin, 400 mg/dL of rifampicin, and 750 mg/d of ethambutol hydrochloride for pulmonary MAC infection for 2 years and 5 mg/d of prednisolone for ITP for 7 years.', 'subject score': 1000, 'object score': 1000}, 'PMID:18477219': {'publication date': '2008 Jun', 'sentence': 'A 64-year-old Japanese woman suffering from idiopathic thrombocytopenic purpura was treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:18709983': {'publication date': '2008 Jul', 'sentence': 'Administration of PSL for ITP might mask the presenting clinical picture of ADEM.', 'subject score': 1000, 'object score': 1000}, 'PMID:20009444': {'publication date': '2009 Nov', 'sentence': 'Although she was treated with prednisolone for ITP and oral iron compounds for IDA, neither ITP nor IDA showed any improvement.', 'subject score': 1000, 'object score': 1000}, 'PMID:2214183': {'publication date': '1990 Jul', 'sentence': 'A 23 year old female, born in 1957, was diagnosed as having idiopathic thrombocytopenic purpura at the age of 3 and treated with prednisolone during her childhood with no response.', 'subject score': 1000, 'object score': 1000}, 'PMID:31866629': {'publication date': '2019 Dec 20', 'sentence': 'Despite treatment with prednisolone, cyclosporin and low-density lipoprotein-apheresis, MCNS and ITP did not improve.', 'subject score': 1000, 'object score': 1000}, 'PMID:32026046': {'publication date': '2019 Jun 07', 'sentence': 'She had been diagnosed as idiopathic thrombocytopenic purpura at the age of 29 years old and treated with prednisolone at 15 mg/day.', 'subject score': 1000, 'object score': 1000}, 'PMID:32389942': {'publication date': '2020 May 08', 'sentence': 'Initially, we increased the dose of prednisolone for ITP.', 'subject score': 1000, 'object score': 1000}, 'PMID:574666': {'publication date': '1979 Sep', 'sentence': 'However the number of the patients in the study were rather small further clinical studies and treatment with 1 mg/kg and 2 mg/kg per day of prednisolone in childhood ITP are warranted.', 'subject score': 1000, 'object score': 888}, 'PMID:7197014': {'publication date': '1981 May', 'sentence': '[Effectiveness of prednisolone treatment in idiopathic thrombocytopenic purpura in children].', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0398650---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7800931",
-              "object": "MONDO:0008558",
-              "publications": [
-                "PMID:10555101",
-                "PMID:10695392",
-                "PMID:10910585",
-                "PMID:11310493",
-                "PMID:11974905",
-                "PMID:11979754",
-                "PMID:12400162",
-                "PMID:16019454",
-                "PMID:17309547",
-                "PMID:17352309",
-                "PMID:17825698",
-                "PMID:18477219",
-                "PMID:18709983",
-                "PMID:20009444",
-                "PMID:2214183",
-                "PMID:31866629",
-                "PMID:32026046",
-                "PMID:32389942",
-                "PMID:574666",
-                "PMID:7197014"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319330,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005292",
-          "name": "colitis",
-          "description": "Inflammation of the colon.; Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.; Colitis refers to an inflammation of the colon and is often used to describe an inflammation of the large intestine (colon, cecum and rectum). Colitides may be acute and self-limited or chronic, and broadly fit into the category of digestive diseases. [HPO:sdoelken]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10079511",
-            "SNOMEDCT:64226004",
-            "UMLS:C0009319",
-            "MESH:D003092",
-            "EFO:0003872",
-            "ICD10:K52.9",
-            "MEDDRA:10009889",
-            "MONDO:0005292",
-            "NCIT:C26723",
-            "MEDDRA:10009898",
-            "PSY:10220",
-            "DOID:0060180",
-            "HP:0002583",
-            "MEDDRA:10009887"
-          ],
-          "id": "MONDO:0005292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Colitis",
-            "colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319330,
-=======
-            "identity": 323988,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005292",
-              "name": "colitis",
-              "description": "Inflammation of the colon.; Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.; Colitis refers to an inflammation of the colon and is often used to describe an inflammation of the large intestine (colon, cecum and rectum). Colitides may be acute and self-limited or chronic, and broadly fit into the category of digestive diseases. [HPO:sdoelken]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10079511",
-                "SNOMEDCT:64226004",
-                "UMLS:C0009319",
-                "MESH:D003092",
-                "EFO:0003872",
-                "ICD10:K52.9",
-                "MEDDRA:10009889",
-                "MONDO:0005292",
-                "NCIT:C26723",
-                "MEDDRA:10009898",
-                "PSY:10220",
-                "DOID:0060180",
-                "HP:0002583",
-                "MEDDRA:10009887"
-              ],
-              "id": "MONDO:0005292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Colitis",
-                "colitis"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009693",
-              "name": "plasma cell myeloma",
-              "description": "A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3242\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3242\" NCI Thesaurus); A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001); A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.; A malignant plasma cell tumor growing within soft tissue or within the skeleton. [HPO:sdoelken]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10074470",
-                "MEDDRA:10028569",
-                "MEDDRA:10028228",
-                "MEDDRA:10035226",
-                "EFO:0001378",
-                "SNOMEDCT:55921005",
-                "MEDDRA:10034613",
-                "MESH:D009101",
-                "MEDDRA:10028568",
-                "MONDO:0009693",
-                "ICD9:203.0",
-                "HP:0006775",
-                "OMIM:254500",
-                "MEDDRA:10028566",
-                "ORPHANET:29073",
-                "SNOMEDCT:109989006",
-                "DOID:9538",
-                "ICD10:C90.0",
-                "UMLS:C0026764",
-                "PDQ:CDR0000042947",
-                "NCIT:C3242",
-                "SNOMEDCT:1162576007"
-              ],
-              "id": "MONDO:0009693",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Multiple myeloma",
-                "Multiple Myeloma",
-                "plasma cell myeloma",
-                "multiple myeloma",
-                "Myeloma, multiple related phenotypic feature",
-                "Plasma Cell Myeloma"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/colitis"
-=======
-                "http://www.cancer.gov/dictionary?cdrid=411384",
-                "http://en.wikipedia.org/wiki/multiple_myeloma",
-                "https://orcid.org/0009-0006-4530-3154"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 7545385,
-            "start": 568,
-            "end": 319330,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10496564': {'publication date': '1999 Sep', 'sentence': 'On the other hand, prednisolone and short chain fatty acids seemed to improve only the physiologic changes of colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:12207075': {'publication date': '2002', 'sentence': 'In an inflammatory model of colitis, intrarectal honey administration is as effective as prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:20440854': {'publication date': '2010 May 07', 'sentence': 'A murine model of acute 2-4-6-trinitrobenzene sulfonic acid (TNBS)-colitis was next used to evaluate the distinct prophylactic protective capacities of three yeast strains compared with the performance of prednisolone treatment.', 'subject score': 888, 'object score': 758}, 'PMID:27424097': {'publication date': '2016 Sep', 'sentence': 'Forty male Swiss mice were assigned into five groups: control; control treated with LED therapy; colitis without treatment; colitis treated with LED therapy; colitis treated with Prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:28821031': {'publication date': '2017 Oct 15', 'sentence': 'Surface-deacetylated chitin nanofibers (SDACNFs) reinforced with a sulfobutyl ether beta-cyclodextrin (SBE-beta-CD) (NFs-CDs) gel were developed to obtain a controlled release carrier of prednisolone (PD) for the treatment of colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:31678983': {'publication date': '2019 Nov 03', 'sentence': 'After confirming that the blood culture became negative, prednisolone (PDL) was started as therapy for the colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7364320': {'publication date': '1980 Jan', 'sentence': 'Peak plasma levels were reduced after an oral dose of 40 mg prednisolone in six patients with severe acute colitis as compared with six normal subjects, though total absorption appeared to be similar; the findings suggest that prednisolone absorption was delayed in acute colitis.', 'subject score': 851, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0009319---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7704078",
-              "object": "MONDO:0005292",
-              "publications": [
-                "PMID:10496564",
-                "PMID:12207075",
-                "PMID:20440854",
-                "PMID:27424097",
-                "PMID:28821031",
-                "PMID:31678983",
-                "PMID:7364320"
-=======
-            "identity": 15784333,
-            "start": 568,
-            "end": 323988,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22314465': {'publication date': '2012 Jan', 'sentence': 'Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma.', 'subject score': 1000, 'object score': 901}, 'PMID:2469398': {'publication date': '1989 Apr', 'sentence': '[Combination chemotherapy of MCNU, melphalan, procarbazine, and prednisolone (MMPP) in multiple myeloma; disappearance of M-peak on serum electrophoretic pattern].', 'subject score': 1000, 'object score': 1000}, 'PMID:28828689': {'publication date': '2017 Dec', 'sentence': 'Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).', 'subject score': 1000, 'object score': 850}, 'PMID:32583431': {'publication date': '2020 Jun 24', 'sentence': 'Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105).We conducted a randomised phase II study to determine the optimal dose and schedule of melphalan, prednisone, and bortezomib (MPB) (jRCTs031180097).', 'subject score': 1000, 'object score': 901}, 'PMID:3475485': {'publication date': '1987 Mar', 'sentence': '[Comparative studies of intermittent melphalan and prednisolone (MP) versus 5-drug regimen (QUVMP) and 3-drug regimen (QUP) in multiple myeloma].', 'subject score': 740, 'object score': 1000}, 'PMID:9025767': {'publication date': '1997', 'sentence': 'PURPOSE: To compare VMCP, a multidrug combination chemotherapy comprising vincristine (VCR), melphalan (MPH), cyclophosphamide (CPM) and prednisolone (PSL), with MMPP comprising MPH, ranimustine (MCNU), procarbazine, and PSL as induction, to elucidate the value of alternating combination chemotherapy, and to search for an appropriate maintenance therapy in multiple myeloma.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0026764---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16114172",
-              "object": "MONDO:0009693",
-              "publications": [
-                "PMID:22314465",
-                "PMID:2469398",
-                "PMID:28828689",
-                "PMID:32583431",
-                "PMID:3475485",
-                "PMID:9025767"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 316662,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:has_part",
-    "r2.publications_info": "{'PMID:7823397': {'publication date': '1994 Nov', 'sentence': 'A 66-year-old man was treated for IgD (lambda) multiple myeloma with 2mg/day melphalan and 20mg/day prednisolone.', 'subject score': 790, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 323988,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001566",
-          "name": "hypercalcemia disease",
-          "description": "An abnormally increased calcium concentration in the blood. [HPO:curators]; An abnormally increased calcium concentration in the blood.; An abnormally increased calcium concentration in the blood.; An abnormally increased calcium concentration in the blood.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0001566",
-            "MEDDRA:10020583",
-            "MEDDRA:10020587",
-            "NCIT:C3112",
-            "MESH:D006934",
-            "MEDDRA:10006952",
-            "ICD10:E83.52",
-            "DOID:12678",
-            "MEDDRA:10005396",
-            "SNOMEDCT:166702002",
-            "SNOMEDCT:66931009",
-            "PDQ:CDR0000662921",
-            "ICD9:275.42",
-            "UMLS:C0020437",
-            "HP:0003072"
-          ],
-          "id": "MONDO:0001566",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hypercalcemia",
-            "hypercalcemia",
-            "hypercalcemia disease"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009693",
-          "name": "plasma cell myeloma",
-          "description": "A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3242\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3242\" NCI Thesaurus); A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001); A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.; A malignant plasma cell tumor growing within soft tissue or within the skeleton. [HPO:sdoelken]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10074470",
-            "MEDDRA:10028569",
-            "MEDDRA:10028228",
-            "MEDDRA:10035226",
-            "EFO:0001378",
-            "SNOMEDCT:55921005",
-            "MEDDRA:10034613",
-            "MESH:D009101",
-            "MEDDRA:10028568",
-            "MONDO:0009693",
-            "ICD9:203.0",
-            "HP:0006775",
-            "OMIM:254500",
-            "MEDDRA:10028566",
-            "ORPHANET:29073",
-            "SNOMEDCT:109989006",
-            "DOID:9538",
-            "ICD10:C90.0",
-            "UMLS:C0026764",
-            "PDQ:CDR0000042947",
-            "NCIT:C3242",
-            "SNOMEDCT:1162576007"
-          ],
-          "id": "MONDO:0009693",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Multiple myeloma",
-            "Multiple Myeloma",
-            "plasma cell myeloma",
-            "multiple myeloma",
-            "Myeloma, multiple related phenotypic feature",
-            "Plasma Cell Myeloma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=411384",
-            "http://en.wikipedia.org/wiki/multiple_myeloma",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323988,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009693",
-              "name": "plasma cell myeloma",
-              "description": "A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3242\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3242\" NCI Thesaurus); A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001); A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.; A malignant plasma cell tumor growing within soft tissue or within the skeleton. [HPO:sdoelken]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10074470",
-                "MEDDRA:10028569",
-                "MEDDRA:10028228",
-                "MEDDRA:10035226",
-                "EFO:0001378",
-                "SNOMEDCT:55921005",
-                "MEDDRA:10034613",
-                "MESH:D009101",
-                "MEDDRA:10028568",
-                "MONDO:0009693",
-                "ICD9:203.0",
-                "HP:0006775",
-                "OMIM:254500",
-                "MEDDRA:10028566",
-                "ORPHANET:29073",
-                "SNOMEDCT:109989006",
-                "DOID:9538",
-                "ICD10:C90.0",
-                "UMLS:C0026764",
-                "PDQ:CDR0000042947",
-                "NCIT:C3242",
-                "SNOMEDCT:1162576007"
-              ],
-              "id": "MONDO:0009693",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Multiple myeloma",
-                "Multiple Myeloma",
-                "plasma cell myeloma",
-                "multiple myeloma",
-                "Myeloma, multiple related phenotypic feature",
-                "Plasma Cell Myeloma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=411384",
-                "http://en.wikipedia.org/wiki/multiple_myeloma",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26207526,
-            "start": 323988,
-            "end": 568,
-            "type": "biolink:has_part",
-            "properties": {
-              "predicate": "biolink:has_part",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7823397': {'publication date': '1994 Nov', 'sentence': 'A 66-year-old man was treated for IgD (lambda) multiple myeloma with 2mg/day melphalan and 20mg/day prednisolone.', 'subject score': 790, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:part_of---None---None---None---UMLS:C0026764---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0009693",
-              "id": "26670577",
-              "object": "PUBCHEM.COMPOUND:5755",
-              "publications": [
-                "PMID:7823397"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:15159285': {'publication date': '2004 Jun 19', 'sentence': 'OBJECTIVE: To determine whether addition of low dose prednisolone to multidrug treatment can prevent reaction and nerve function impairment in leprosy.', 'subject score': 901, 'object score': 1000}, 'PMID:1624226': {'publication date': '1992 Feb', 'sentence': 'Aspirin, chloroquine, and prednisolone, the drugs used in addition to multi-drug therapy to control reactions in leprosy, were in a position to inhibit the solubilization of 125I HSA--anti-HSA by normal serum only at a very high dose.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 517728,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005124",
-          "name": "leprosy",
-          "description": "A bacterial granulomatous infection caused by Mycobacterium leprae. It is a progressive disease affecting the skin, peripheral nerves, and limbs. If untreated, it causes permanent tissue damage leading to autoamputations.; A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10024230",
-            "NCIT:C84824",
-            "EFO:0001054",
-            "MEDDRA:10024229",
-            "ICD9:030",
-            "MEDDRA:10024232",
-            "DOID:1024",
-            "MONDO:0005124",
-            "UMLS:C0023343",
-            "SNOMEDCT:81004002",
-            "MEDDRA:10019138",
-            "ICD10:A30",
-            "MEDDRA:10024231",
-            "MESH:D007918",
-            "MEDDRA:10028451",
-            "ORPHANET:548"
-          ],
-          "id": "MONDO:0005124",
-          "category": "biolink:Disease",
-          "all_names": [
-            "leprosy",
-            "Leprosy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/leprosy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517728,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005124",
-              "name": "leprosy",
-              "description": "A bacterial granulomatous infection caused by Mycobacterium leprae. It is a progressive disease affecting the skin, peripheral nerves, and limbs. If untreated, it causes permanent tissue damage leading to autoamputations.; A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10024230",
-                "NCIT:C84824",
-                "EFO:0001054",
-                "MEDDRA:10024229",
-                "ICD9:030",
-                "MEDDRA:10024232",
-                "DOID:1024",
-                "MONDO:0005124",
-                "UMLS:C0023343",
-                "SNOMEDCT:81004002",
-                "MEDDRA:10019138",
-                "ICD10:A30",
-                "MEDDRA:10024231",
-                "MESH:D007918",
-                "MEDDRA:10028451",
-                "ORPHANET:548"
-              ],
-              "id": "MONDO:0005124",
-              "category": "biolink:Disease",
-              "all_names": [
-                "leprosy",
-                "Leprosy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/leprosy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10973702,
-            "start": 568,
-            "end": 517728,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15159285': {'publication date': '2004 Jun 19', 'sentence': 'OBJECTIVE: To determine whether addition of low dose prednisolone to multidrug treatment can prevent reaction and nerve function impairment in leprosy.', 'subject score': 901, 'object score': 1000}, 'PMID:1624226': {'publication date': '1992 Feb', 'sentence': 'Aspirin, chloroquine, and prednisolone, the drugs used in addition to multi-drug therapy to control reactions in leprosy, were in a position to inhibit the solubilization of 125I HSA--anti-HSA by normal serum only at a very high dose.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0023343---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11213963",
-              "object": "MONDO:0005124",
-              "publications": [
-                "PMID:15159285",
-                "PMID:1624226"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11105495': {'publication date': '2000 Sep', 'sentence': 'In untreated reactional leprosy patients, the levels of urinary NO metabolites (1645 +/- 454 microM, n = 9, ENL = 4, RR = 5) decreased significantly 2 weeks after high dose prednisolone treatment (1075 +/- 414 microM, P < 0.05), and remained stable 4 (895 +/- 385 microM, P < 0.02) and 6 weeks following treatment initiation (1048 +/- 452 microM, P < 0.02).', 'subject score': 861, 'object score': 751}, 'PMID:14750578': {'publication date': '2003 Dec', 'sentence': \"Based on those data and supported by the literature and the author's own observations, it can be concluded that type I leprosy reaction should be treated with prednisolone for a longer period than the 12 weeks, advised by the WHO.\", 'subject score': 1000, 'object score': 888}, 'PMID:15159285': {'publication date': '2004 Jun 19', 'sentence': 'CONCLUSIONS: The use of low dose prophylactic prednisolone during the first four months of multidrug treatment for leprosy reduces the incidence of new reactions and nerve function impairment in the short term, but the effect is not sustained at one year.', 'subject score': 861, 'object score': 1000}, 'PMID:17320974': {'publication date': '2007 Mar 15', 'sentence': 'Gene expression of the shuttle enzymes were quantified in skin biopsies from 15 leprosy patients with new T1R before and during prednisolone treatment and compared with levels in skin biopsies from 10 borderline leprosy patients without reactions.', 'subject score': 888, 'object score': 790}, 'PMID:19803379': {'publication date': '2009 Sep', 'sentence': '[Prevalence of disability among leprosy patients and effectiveness of leprosy reaction services with standard prednisolone treatment at field level in an endemic country--some data from joint leprosy research collaboration in Myanmar].', 'subject score': 851, 'object score': 851}, 'PMID:20509340': {'publication date': '2009', 'sentence': 'Steroid induced diabetes is a serious complication among leprosy patients treated with prednisolone for reactions requiring careful monitoring for detection and appropriate clinical management.', 'subject score': 1000, 'object score': 888}, 'PMID:23249098': {'publication date': '2012 Dec 18', 'sentence': \"Within the 'Treatment of Early Neuropathy in LEProsy' (TENLEP) study two double blind randomized controlled trials (RCT) will be carried out: a trial to establish whether prednisolone treatment of 32 weeks duration is more effective than 20 weeks in restoring nerve function in leprosy patients with clinical NFI (Clinical trial) and a trial to determine whether prednisolone treatment of early sub-clinical NFI can prevent clinical NFI (Subclinical trial).\", 'subject score': 888, 'object score': 704}, 'PMID:27046330': {'publication date': '2016 Apr', 'sentence': 'A Randomized Controlled Double Blind Trial of Ciclosporin versus Prednisolone in the Management of Leprosy Patients with New Type 1 Reaction, in Ethiopia.', 'subject score': 1000, 'object score': 888}, 'PMID:28976976': {'publication date': '2017 Oct', 'sentence': 'CONCLUSION: In our study, a 20-week course of prednisolone was as effective as a 32-week course in improving and restoring recent clinical NFI in leprosy patients.', 'subject score': 1000, 'object score': 888}, 'PMID:3265334': {'publication date': '1988 Dec', 'sentence': 'A generally similar pattern is seen in healthy controls and in patients with untreated pulmonary tuberculosis, treated leprosy, haemophilia A and chronic obstructive lung disease (COLD) patients treated with prednisolone, but the gradient of increasing CD4:CD8 ratio with depth into the dermis is significantly less steep in patients with tuberculosis, haemophilia and prednisolone-treated COLD than in the healthy controls.', 'subject score': 1000, 'object score': 872}, 'PMID:34336901': {'publication date': '2021', 'sentence': 'Although the diagnosis of ENL is not difficult to make for physicians involved in the care of leprosy patients, its management continues to be a most challenging aspect of the leprosy eradication program: the chronic and recurrent painful skin lesions, neuritis, and organ involvement necessitates prolonged treatment with prednisolone, thalidomide, and anti-inflammatory and immunosuppressive drugs, which further adds to the existing morbidity.', 'subject score': 1000, 'object score': 802}, 'PMID:9503867': {'publication date': '1997 Dec', 'sentence': \"In this study, a fixed regimen of prednisolone for the treatment of acute nerve function impairment (NFI) in leprosy patients was developed and introduced at field level in one area (Thakurgaon) of the Danish-Bangladesh Leprosy Mission's field in NW Bangladesh.\", 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 517728,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005124",
-          "name": "leprosy",
-          "description": "A bacterial granulomatous infection caused by Mycobacterium leprae. It is a progressive disease affecting the skin, peripheral nerves, and limbs. If untreated, it causes permanent tissue damage leading to autoamputations.; A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10024230",
-            "NCIT:C84824",
-            "EFO:0001054",
-            "MEDDRA:10024229",
-            "ICD9:030",
-            "MEDDRA:10024232",
-            "DOID:1024",
-            "MONDO:0005124",
-            "UMLS:C0023343",
-            "SNOMEDCT:81004002",
-            "MEDDRA:10019138",
-            "ICD10:A30",
-            "MEDDRA:10024231",
-            "MESH:D007918",
-            "MEDDRA:10028451",
-            "ORPHANET:548"
-          ],
-          "id": "MONDO:0005124",
-          "category": "biolink:Disease",
-          "all_names": [
-            "leprosy",
-            "Leprosy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/leprosy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517728,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005124",
-              "name": "leprosy",
-              "description": "A bacterial granulomatous infection caused by Mycobacterium leprae. It is a progressive disease affecting the skin, peripheral nerves, and limbs. If untreated, it causes permanent tissue damage leading to autoamputations.; A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10024230",
-                "NCIT:C84824",
-                "EFO:0001054",
-                "MEDDRA:10024229",
-                "ICD9:030",
-                "MEDDRA:10024232",
-                "DOID:1024",
-                "MONDO:0005124",
-                "UMLS:C0023343",
-                "SNOMEDCT:81004002",
-                "MEDDRA:10019138",
-                "ICD10:A30",
-                "MEDDRA:10024231",
-                "MESH:D007918",
-                "MEDDRA:10028451",
-                "ORPHANET:548"
-              ],
-              "id": "MONDO:0005124",
-              "category": "biolink:Disease",
-              "all_names": [
-                "leprosy",
-                "Leprosy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/leprosy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8400823,
-            "start": 568,
-            "end": 517728,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11105495': {'publication date': '2000 Sep', 'sentence': 'In untreated reactional leprosy patients, the levels of urinary NO metabolites (1645 +/- 454 microM, n = 9, ENL = 4, RR = 5) decreased significantly 2 weeks after high dose prednisolone treatment (1075 +/- 414 microM, P < 0.05), and remained stable 4 (895 +/- 385 microM, P < 0.02) and 6 weeks following treatment initiation (1048 +/- 452 microM, P < 0.02).', 'subject score': 861, 'object score': 751}, 'PMID:14750578': {'publication date': '2003 Dec', 'sentence': \"Based on those data and supported by the literature and the author's own observations, it can be concluded that type I leprosy reaction should be treated with prednisolone for a longer period than the 12 weeks, advised by the WHO.\", 'subject score': 1000, 'object score': 888}, 'PMID:15159285': {'publication date': '2004 Jun 19', 'sentence': 'CONCLUSIONS: The use of low dose prophylactic prednisolone during the first four months of multidrug treatment for leprosy reduces the incidence of new reactions and nerve function impairment in the short term, but the effect is not sustained at one year.', 'subject score': 861, 'object score': 1000}, 'PMID:17320974': {'publication date': '2007 Mar 15', 'sentence': 'Gene expression of the shuttle enzymes were quantified in skin biopsies from 15 leprosy patients with new T1R before and during prednisolone treatment and compared with levels in skin biopsies from 10 borderline leprosy patients without reactions.', 'subject score': 888, 'object score': 790}, 'PMID:19803379': {'publication date': '2009 Sep', 'sentence': '[Prevalence of disability among leprosy patients and effectiveness of leprosy reaction services with standard prednisolone treatment at field level in an endemic country--some data from joint leprosy research collaboration in Myanmar].', 'subject score': 851, 'object score': 851}, 'PMID:20509340': {'publication date': '2009', 'sentence': 'Steroid induced diabetes is a serious complication among leprosy patients treated with prednisolone for reactions requiring careful monitoring for detection and appropriate clinical management.', 'subject score': 1000, 'object score': 888}, 'PMID:23249098': {'publication date': '2012 Dec 18', 'sentence': \"Within the 'Treatment of Early Neuropathy in LEProsy' (TENLEP) study two double blind randomized controlled trials (RCT) will be carried out: a trial to establish whether prednisolone treatment of 32 weeks duration is more effective than 20 weeks in restoring nerve function in leprosy patients with clinical NFI (Clinical trial) and a trial to determine whether prednisolone treatment of early sub-clinical NFI can prevent clinical NFI (Subclinical trial).\", 'subject score': 888, 'object score': 704}, 'PMID:27046330': {'publication date': '2016 Apr', 'sentence': 'A Randomized Controlled Double Blind Trial of Ciclosporin versus Prednisolone in the Management of Leprosy Patients with New Type 1 Reaction, in Ethiopia.', 'subject score': 1000, 'object score': 888}, 'PMID:28976976': {'publication date': '2017 Oct', 'sentence': 'CONCLUSION: In our study, a 20-week course of prednisolone was as effective as a 32-week course in improving and restoring recent clinical NFI in leprosy patients.', 'subject score': 1000, 'object score': 888}, 'PMID:3265334': {'publication date': '1988 Dec', 'sentence': 'A generally similar pattern is seen in healthy controls and in patients with untreated pulmonary tuberculosis, treated leprosy, haemophilia A and chronic obstructive lung disease (COLD) patients treated with prednisolone, but the gradient of increasing CD4:CD8 ratio with depth into the dermis is significantly less steep in patients with tuberculosis, haemophilia and prednisolone-treated COLD than in the healthy controls.', 'subject score': 1000, 'object score': 872}, 'PMID:34336901': {'publication date': '2021', 'sentence': 'Although the diagnosis of ENL is not difficult to make for physicians involved in the care of leprosy patients, its management continues to be a most challenging aspect of the leprosy eradication program: the chronic and recurrent painful skin lesions, neuritis, and organ involvement necessitates prolonged treatment with prednisolone, thalidomide, and anti-inflammatory and immunosuppressive drugs, which further adds to the existing morbidity.', 'subject score': 1000, 'object score': 802}, 'PMID:9503867': {'publication date': '1997 Dec', 'sentence': \"In this study, a fixed regimen of prednisolone for the treatment of acute nerve function impairment (NFI) in leprosy patients was developed and introduced at field level in one area (Thakurgaon) of the Danish-Bangladesh Leprosy Mission's field in NW Bangladesh.\", 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0023343---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8583398",
-              "object": "MONDO:0005124",
-              "publications": [
-                "PMID:11105495",
-                "PMID:14750578",
-                "PMID:15159285",
-                "PMID:17320974",
-                "PMID:19803379",
-                "PMID:20509340",
-                "PMID:23249098",
-                "PMID:27046330",
-                "PMID:28976976",
-                "PMID:3265334",
-                "PMID:34336901",
-                "PMID:9503867"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:14750575': {'publication date': '2003 Dec', 'sentence': 'Prednisolone treatment of sensory impairment of the ulnar and posterior tibial nerves detectable with the monofilament test, but not with the ballpen test, did not improve the long-term outcome in terms of recovery of touch sensibility, not did it reduce the risk of leprosy reactions or nerve function impairment beyond the initial 4-month treatment phase.', 'subject score': 888, 'object score': 872}}",
-    "p2": {
-      "start": {
-        "identity": 517728,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005124",
-          "name": "leprosy",
-          "description": "A bacterial granulomatous infection caused by Mycobacterium leprae. It is a progressive disease affecting the skin, peripheral nerves, and limbs. If untreated, it causes permanent tissue damage leading to autoamputations.; A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10024230",
-            "NCIT:C84824",
-            "EFO:0001054",
-            "MEDDRA:10024229",
-            "ICD9:030",
-            "MEDDRA:10024232",
-            "DOID:1024",
-            "MONDO:0005124",
-            "UMLS:C0023343",
-            "SNOMEDCT:81004002",
-            "MEDDRA:10019138",
-            "ICD10:A30",
-            "MEDDRA:10024231",
-            "MESH:D007918",
-            "MEDDRA:10028451",
-            "ORPHANET:548"
-          ],
-          "id": "MONDO:0005124",
-          "category": "biolink:Disease",
-          "all_names": [
-            "leprosy",
-            "Leprosy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/leprosy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517728,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005124",
-              "name": "leprosy",
-              "description": "A bacterial granulomatous infection caused by Mycobacterium leprae. It is a progressive disease affecting the skin, peripheral nerves, and limbs. If untreated, it causes permanent tissue damage leading to autoamputations.; A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10024230",
-                "NCIT:C84824",
-                "EFO:0001054",
-                "MEDDRA:10024229",
-                "ICD9:030",
-                "MEDDRA:10024232",
-                "DOID:1024",
-                "MONDO:0005124",
-                "UMLS:C0023343",
-                "SNOMEDCT:81004002",
-                "MEDDRA:10019138",
-                "ICD10:A30",
-                "MEDDRA:10024231",
-                "MESH:D007918",
-                "MEDDRA:10028451",
-                "ORPHANET:548"
-              ],
-              "id": "MONDO:0005124",
-              "category": "biolink:Disease",
-              "all_names": [
-                "leprosy",
-                "Leprosy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/leprosy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10748269,
-            "start": 568,
-            "end": 517728,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14750575': {'publication date': '2003 Dec', 'sentence': 'Prednisolone treatment of sensory impairment of the ulnar and posterior tibial nerves detectable with the monofilament test, but not with the ballpen test, did not improve the long-term outcome in terms of recovery of touch sensibility, not did it reduce the risk of leprosy reactions or nerve function impairment beyond the initial 4-month treatment phase.', 'subject score': 888, 'object score': 872}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:prevents---None---None---None---UMLS:C0023343---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10983909",
-              "object": "MONDO:0005124",
-              "publications": [
-                "PMID:14750575"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:10193433': {'publication date': '1999 Mar', 'sentence': 'One reason for the good clinical effects of prednisolone in RA could be a down-regulation of adhesion and phagocytosis receptors on monocytes.', 'subject score': 1000, 'object score': 1000}, 'PMID:10531077': {'publication date': '1999 Nov', 'sentence': 'The data suggest that the beneficial effects of prednisolone are not as clear cut in established rheumatoid arthritis as in early disease.', 'subject score': 1000, 'object score': 901}, 'PMID:10996038': {'publication date': '2000 Sep', 'sentence': 'We compared lymphocyte-suppressive potencies of prednisolone and methylprednisolone in rheumatoid arthritis (RA).', 'subject score': 1000, 'object score': 1000}, 'PMID:111944': {'publication date': '1979 Apr', 'sentence': 'Relapses occurring in patients on a stable dose of prednisolone were commonly associated with the development of rheumatoid disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:13221414': {'publication date': '1955 Jan 22', 'sentence': 'Studies on metacortandralone and metacortandracin in rheumatoid arthritis; antirheumatic potency, metabolic effects, and hormonal properties.', 'subject score': 1000, 'object score': 1000}, 'PMID:13295650': {'publication date': '1956 Feb', 'sentence': 'Clinical and metabolic effects of prednisone and prednisolone in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:13333138': {'publication date': '1956 Jul 07', 'sentence': 'Hydrocortisone versus prednisolone in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:13407235': {'publication date': '1957 Mar', 'sentence': 'Prednisone and prednisolone in rheumatoid arthritis; an evaluation of their therapeutic efficiency.', 'subject score': 1000, 'object score': 1000}, 'PMID:13540584': {'publication date': '1958 Apr 19', 'sentence': 'Hydrocortisone and prednisolone in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:13742338': {'publication date': '1961 Jan', 'sentence': 'Prednisolone in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:14391515': {'publication date': '1955 Jul', 'sentence': 'Metacortandracin and delta 1 dehydro-hydrocortisone in rheumatoid arthritis.', 'subject score': 923, 'object score': 1000}, 'PMID:15140776': {'publication date': '2004 Jun', 'sentence': 'A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15206742': {'publication date': '2003', 'sentence': 'During 6 months of treating the RA patients with prednisolone or methotrexate, and the OP patients with raloxifene or etidronate and calcium there were significant therapeutic responses and a significant trend towards a reduction in levels of neopterin in RA patients receiving methotrexate but no changes in the profiles of tryptophan metabolites.', 'subject score': 1000, 'object score': 901}, 'PMID:15941834': {'publication date': '2006 Jan', 'sentence': 'The NPY/cortisol ratio was increased in SLE with/without prednisolone, and in RA with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:15956010': {'publication date': '2005 Jun 13', 'sentence': 'Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial.', 'subject score': 1000, 'object score': 901}, 'PMID:16255010': {'publication date': '2005 Nov', 'sentence': 'Therefore, the data support the use of low-dose prednisolone as an adjunct to DMARDs in early active RA.', 'subject score': 901, 'object score': 861}, 'PMID:16255011': {'publication date': '2005 Nov', 'sentence': 'CONCLUSION: The very low daily dose of 5 mg prednisolone given over 2 years in combination with background DMARD therapy substantially decreased radiographic progression in early RA at low risk.', 'subject score': 851, 'object score': 901}, 'PMID:16646617': {'publication date': '2006', 'sentence': 'Prednisolone plus a disease-modifying antirheumatic drug improved outcomes in early rheumatoid arthritis.', 'subject score': 1000, 'object score': 901}, 'PMID:17045197': {'publication date': '2006', 'sentence': 'Synthetic glucocorticoids such as dexamethasone and prednisolone have for decades been the cornerstone for the clinical treatment of inflammatory diseases, such as rheumatoid arthritis and asthma, and in some lymphoid cancers, yet its prolonged use has undesirable side effects such as obesity, diabetes, immune suppression and osteoporosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:17213101': {'publication date': '2006 Jun', 'sentence': 'Prednisolone plus a disease modifying antirheumatic drug improved outcomes in early rheumatoid arthritis.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 318890,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-          "name": "rheumatoid arthritis",
-          "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C2884",
-            "PSY:44570",
-            "EFO:0000685",
-            "ICD9:714.0",
-            "KEGG.DISEASE:05323",
-            "MONDO:0008383",
-            "UMLS:C0003873",
-            "UMLS:C1306838",
-            "UMLS:C1833448",
-            "MEDDRA:10037740",
-            "MEDDRA:10039073",
-            "OMIM:180300",
-            "MESH:D001172",
-            "MEDDRA:10003268",
-            "HP:0001370",
-            "ORPHANET:284130",
-            "SNOMEDCT:69896004",
-            "ICD10:M06.9",
-            "DOID:7148",
-            "MEDDRA:10036856",
-            "MEDDRA:10042952"
-          ],
-          "id": "MONDO:0008383",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Proliferative arthritis",
-            "Arthritis, Rheumatoid",
-            "rheumatoid arthritis",
-            "Rheumatoid arthritis",
-            "Rheumatoid Arthritis",
-            "Rheumatoid arthritis related phenotypic feature",
-            "Rheumatoid arthritis, susceptibility to"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-<<<<<<< HEAD
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0001-6908-9849"
-=======
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-            "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-            "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 316662,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001566",
-              "name": "hypercalcemia disease",
-              "description": "An abnormally increased calcium concentration in the blood. [HPO:curators]; An abnormally increased calcium concentration in the blood.; An abnormally increased calcium concentration in the blood.; An abnormally increased calcium concentration in the blood.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0001566",
-                "MEDDRA:10020583",
-                "MEDDRA:10020587",
-                "NCIT:C3112",
-                "MESH:D006934",
-                "MEDDRA:10006952",
-                "ICD10:E83.52",
-                "DOID:12678",
-                "MEDDRA:10005396",
-                "SNOMEDCT:166702002",
-                "SNOMEDCT:66931009",
-                "PDQ:CDR0000662921",
-                "ICD9:275.42",
-                "UMLS:C0020437",
-                "HP:0003072"
-              ],
-              "id": "MONDO:0001566",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hypercalcemia",
-                "hypercalcemia",
-                "hypercalcemia disease"
-=======
-            "identity": 318890,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-              "name": "rheumatoid arthritis",
-              "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C2884",
-                "PSY:44570",
-                "EFO:0000685",
-                "ICD9:714.0",
-                "KEGG.DISEASE:05323",
-                "MONDO:0008383",
-                "UMLS:C0003873",
-                "UMLS:C1306838",
-                "UMLS:C1833448",
-                "MEDDRA:10037740",
-                "MEDDRA:10039073",
-                "OMIM:180300",
-                "MESH:D001172",
-                "MEDDRA:10003268",
-                "HP:0001370",
-                "ORPHANET:284130",
-                "SNOMEDCT:69896004",
-                "ICD10:M06.9",
-                "DOID:7148",
-                "MEDDRA:10036856",
-                "MEDDRA:10042952"
-              ],
-              "id": "MONDO:0008383",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Proliferative arthritis",
-                "Arthritis, Rheumatoid",
-                "rheumatoid arthritis",
-                "Rheumatoid arthritis",
-                "Rheumatoid Arthritis",
-                "Rheumatoid arthritis related phenotypic feature",
-                "Rheumatoid arthritis, susceptibility to"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-<<<<<<< HEAD
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0001-6908-9849"
-=======
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-                "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-                "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 7509645,
-            "start": 568,
-            "end": 316662,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10481465': {'publication date': '1999 Jul', 'sentence': 'Treatment with extracorporeal shock wave lithotripsy, transurethral lithotomy, saline infusion, and prednisolone (30 mg/day) alleviated the urolithiasis, renal insufficiency, and hypercalcemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:11488718': {'publication date': '2001 Aug', 'sentence': 'Asymptomatic hypercalcaemia was noted on periodic testing at 7 weeks and treated by rehydration, diuretics, prednisolone, etidronate and a low-calcium and -vitamin D diet.', 'subject score': 1000, 'object score': 888}, 'PMID:16573764': {'publication date': '2006 Apr', 'sentence': 'The clinical signs, hypercalcaemia and elevated serum concentrations of 1,25 dihydroxyvitamin D resolved following prednisolone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:2534486': {'publication date': '1989 Nov-Dec', 'sentence': 'Medical therapy with normal saline, furosemide, indomethacin, prednisolone, and calcitonin failed to ameliorate hypercalcemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:26597827': {'publication date': '2017 Jan', 'sentence': 'Prednisolone treatment improved the hypercalcemia and decreased the levels of 1,25(OH)2D and IL-6.', 'subject score': 888, 'object score': 1000}, 'PMID:28976049': {'publication date': '2018 Jun', 'sentence': 'The patients discussed experienced a significant and rapid improvement in both renal function and hypercalcaemia in response to therapy with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:30396880': {'publication date': '2018 Nov 05', 'sentence': 'Prednisolone is less effective in the treatment of children with severe hypercalcaemia secondary to vitamin D intoxication and timely implementation of other treatment regimens would be considered.', 'subject score': 1000, 'object score': 888}, 'PMID:6361747': {'publication date': '1983', 'sentence': 'Hypercalcaemia due to overdosage with vitamin D2 during simultaneous prednisolone therapy was usually mild and returned to normal in a few days by dose reduction.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0020437---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7676165",
-              "object": "MONDO:0001566",
-              "publications": [
-                "PMID:10481465",
-                "PMID:11488718",
-                "PMID:16573764",
-                "PMID:2534486",
-                "PMID:26597827",
-                "PMID:28976049",
-                "PMID:30396880",
-                "PMID:6361747"
-=======
-            "identity": 7118588,
-            "start": 568,
-            "end": 318890,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10193433': {'publication date': '1999 Mar', 'sentence': 'One reason for the good clinical effects of prednisolone in RA could be a down-regulation of adhesion and phagocytosis receptors on monocytes.', 'subject score': 1000, 'object score': 1000}, 'PMID:10531077': {'publication date': '1999 Nov', 'sentence': 'The data suggest that the beneficial effects of prednisolone are not as clear cut in established rheumatoid arthritis as in early disease.', 'subject score': 1000, 'object score': 901}, 'PMID:10996038': {'publication date': '2000 Sep', 'sentence': 'We compared lymphocyte-suppressive potencies of prednisolone and methylprednisolone in rheumatoid arthritis (RA).', 'subject score': 1000, 'object score': 1000}, 'PMID:111944': {'publication date': '1979 Apr', 'sentence': 'Relapses occurring in patients on a stable dose of prednisolone were commonly associated with the development of rheumatoid disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:13221414': {'publication date': '1955 Jan 22', 'sentence': 'Studies on metacortandralone and metacortandracin in rheumatoid arthritis; antirheumatic potency, metabolic effects, and hormonal properties.', 'subject score': 1000, 'object score': 1000}, 'PMID:13295650': {'publication date': '1956 Feb', 'sentence': 'Clinical and metabolic effects of prednisone and prednisolone in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:13333138': {'publication date': '1956 Jul 07', 'sentence': 'Hydrocortisone versus prednisolone in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:13407235': {'publication date': '1957 Mar', 'sentence': 'Prednisone and prednisolone in rheumatoid arthritis; an evaluation of their therapeutic efficiency.', 'subject score': 1000, 'object score': 1000}, 'PMID:13540584': {'publication date': '1958 Apr 19', 'sentence': 'Hydrocortisone and prednisolone in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:13742338': {'publication date': '1961 Jan', 'sentence': 'Prednisolone in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:14391515': {'publication date': '1955 Jul', 'sentence': 'Metacortandracin and delta 1 dehydro-hydrocortisone in rheumatoid arthritis.', 'subject score': 923, 'object score': 1000}, 'PMID:15140776': {'publication date': '2004 Jun', 'sentence': 'A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15206742': {'publication date': '2003', 'sentence': 'During 6 months of treating the RA patients with prednisolone or methotrexate, and the OP patients with raloxifene or etidronate and calcium there were significant therapeutic responses and a significant trend towards a reduction in levels of neopterin in RA patients receiving methotrexate but no changes in the profiles of tryptophan metabolites.', 'subject score': 1000, 'object score': 901}, 'PMID:15941834': {'publication date': '2006 Jan', 'sentence': 'The NPY/cortisol ratio was increased in SLE with/without prednisolone, and in RA with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:15956010': {'publication date': '2005 Jun 13', 'sentence': 'Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial.', 'subject score': 1000, 'object score': 901}, 'PMID:16255010': {'publication date': '2005 Nov', 'sentence': 'Therefore, the data support the use of low-dose prednisolone as an adjunct to DMARDs in early active RA.', 'subject score': 901, 'object score': 861}, 'PMID:16255011': {'publication date': '2005 Nov', 'sentence': 'CONCLUSION: The very low daily dose of 5 mg prednisolone given over 2 years in combination with background DMARD therapy substantially decreased radiographic progression in early RA at low risk.', 'subject score': 851, 'object score': 901}, 'PMID:16646617': {'publication date': '2006', 'sentence': 'Prednisolone plus a disease-modifying antirheumatic drug improved outcomes in early rheumatoid arthritis.', 'subject score': 1000, 'object score': 901}, 'PMID:17045197': {'publication date': '2006', 'sentence': 'Synthetic glucocorticoids such as dexamethasone and prednisolone have for decades been the cornerstone for the clinical treatment of inflammatory diseases, such as rheumatoid arthritis and asthma, and in some lymphoid cancers, yet its prolonged use has undesirable side effects such as obesity, diabetes, immune suppression and osteoporosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:17213101': {'publication date': '2006 Jun', 'sentence': 'Prednisolone plus a disease modifying antirheumatic drug improved outcomes in early rheumatoid arthritis.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0003873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7262473",
-              "object": "MONDO:0008383",
-              "publications": [
-                "PMID:10193433",
-                "PMID:10531077",
-                "PMID:10996038",
-                "PMID:111944",
-                "PMID:13221414",
-                "PMID:13295650",
-                "PMID:13333138",
-                "PMID:13407235",
-                "PMID:13540584",
-                "PMID:13742338",
-                "PMID:14391515",
-                "PMID:15140776",
-                "PMID:15206742",
-                "PMID:15941834",
-                "PMID:15956010",
-                "PMID:16255010",
-                "PMID:16255011",
-                "PMID:16646617",
-                "PMID:17045197",
-                "PMID:17213101"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 546960,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:21953589': {'publication date': '2012 Mar', 'sentence': 'Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction.', 'subject score': 861, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 318890,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0010679",
-          "name": "Duchenne muscular dystrophy",
-          "description": "An X-linked inherited disorder caused by mutations in the DMD gene found on the X chromosome. It is characterized by rapidly progressing muscle weakness and muscle atrophy initially involving the lower extremities and eventually affecting the whole body. It affects males whereas females can be carriers. The symptoms start before the age of six and may appear at infancy.; An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0013264",
-            "MESH:D020388",
-            "DOID:11723",
-            "OMIM:310200",
-            "NCIT:C75482",
-            "MONDO:0010679",
-            "MEDDRA:10013801",
-            "SNOMEDCT:76670001",
-            "ORPHANET:98896"
-          ],
-          "id": "MONDO:0010679",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Duchenne Muscular Dystrophy",
-            "Muscular dystrophy, duchenne type related phenotypic feature",
-            "Muscular Dystrophy, Duchenne",
-            "obsolete_Duchenne muscular dystrophy",
-            "Duchenne muscular dystrophy"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-          "name": "rheumatoid arthritis",
-          "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C2884",
-            "PSY:44570",
-            "EFO:0000685",
-            "ICD9:714.0",
-            "KEGG.DISEASE:05323",
-            "MONDO:0008383",
-            "UMLS:C0003873",
-            "UMLS:C1306838",
-            "UMLS:C1833448",
-            "MEDDRA:10037740",
-            "MEDDRA:10039073",
-            "OMIM:180300",
-            "MESH:D001172",
-            "MEDDRA:10003268",
-            "HP:0001370",
-            "ORPHANET:284130",
-            "SNOMEDCT:69896004",
-            "ICD10:M06.9",
-            "DOID:7148",
-            "MEDDRA:10036856",
-            "MEDDRA:10042952"
-          ],
-          "id": "MONDO:0008383",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Proliferative arthritis",
-            "Arthritis, Rheumatoid",
-            "rheumatoid arthritis",
-            "Rheumatoid arthritis",
-            "Rheumatoid Arthritis",
-            "Rheumatoid arthritis related phenotypic feature",
-            "Rheumatoid arthritis, susceptibility to"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://en.wikipedia.org/wiki/duchenne_muscular_dystrophy",
-            "http://www.genome.gov/19518854",
-            "http://omim.org/entry/300377"
-=======
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-            "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-            "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 546960,
-=======
-            "identity": 318890,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0010679",
-              "name": "Duchenne muscular dystrophy",
-              "description": "An X-linked inherited disorder caused by mutations in the DMD gene found on the X chromosome. It is characterized by rapidly progressing muscle weakness and muscle atrophy initially involving the lower extremities and eventually affecting the whole body. It affects males whereas females can be carriers. The symptoms start before the age of six and may appear at infancy.; An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0013264",
-                "MESH:D020388",
-                "DOID:11723",
-                "OMIM:310200",
-                "NCIT:C75482",
-                "MONDO:0010679",
-                "MEDDRA:10013801",
-                "SNOMEDCT:76670001",
-                "ORPHANET:98896"
-              ],
-              "id": "MONDO:0010679",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Duchenne Muscular Dystrophy",
-                "Muscular dystrophy, duchenne type related phenotypic feature",
-                "Muscular Dystrophy, Duchenne",
-                "obsolete_Duchenne muscular dystrophy",
-                "Duchenne muscular dystrophy"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-              "name": "rheumatoid arthritis",
-              "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C2884",
-                "PSY:44570",
-                "EFO:0000685",
-                "ICD9:714.0",
-                "KEGG.DISEASE:05323",
-                "MONDO:0008383",
-                "UMLS:C0003873",
-                "UMLS:C1306838",
-                "UMLS:C1833448",
-                "MEDDRA:10037740",
-                "MEDDRA:10039073",
-                "OMIM:180300",
-                "MESH:D001172",
-                "MEDDRA:10003268",
-                "HP:0001370",
-                "ORPHANET:284130",
-                "SNOMEDCT:69896004",
-                "ICD10:M06.9",
-                "DOID:7148",
-                "MEDDRA:10036856",
-                "MEDDRA:10042952"
-              ],
-              "id": "MONDO:0008383",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Proliferative arthritis",
-                "Arthritis, Rheumatoid",
-                "rheumatoid arthritis",
-                "Rheumatoid arthritis",
-                "Rheumatoid Arthritis",
-                "Rheumatoid arthritis related phenotypic feature",
-                "Rheumatoid arthritis, susceptibility to"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://en.wikipedia.org/wiki/duchenne_muscular_dystrophy",
-                "http://www.genome.gov/19518854",
-                "http://omim.org/entry/300377"
-=======
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-                "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-                "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 7448255,
-            "start": 568,
-            "end": 546960,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10441862': {'publication date': '1999', 'sentence': \"A special program for long-term application of low-dose prednisolone treatment in Duchenne-Becker muscular dystrophy with complex control of the patients' state was developed.\", 'subject score': 861, 'object score': 923}, 'PMID:11249150': {'publication date': '2000 Nov', 'sentence': 'To determine the mechanism of the beneficial effects of prednisolone on Duchenne muscular dystrophy (DMD), we examined the short-term effects of prednisolone on neuromuscular transmission by using conventional microelectrode methods in the mdx mice.', 'subject score': 1000, 'object score': 1000}, 'PMID:15272899': {'publication date': '2004 Aug', 'sentence': 'Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis.', 'subject score': 888, 'object score': 1000}, 'PMID:21400928': {'publication date': '2011 Jan', 'sentence': '[Prednisolone treatment for Duchenne muscular dystrophy].', 'subject score': 888, 'object score': 1000}, 'PMID:28432191': {'publication date': '2017 Jun 01', 'sentence': 'The glucocorticoid receptor (GR) agonist prednisolone is the current standard-of-care treatment for Duchenne muscular dystrophy because it prolongs ambulation, likely due to its anti-inflammatory effects.', 'subject score': 908, 'object score': 1000}, 'PMID:30214127': {'publication date': '2018 Sep', 'sentence': 'Importance of long-term motor function evaluation after prednisolone treatment for Duchenne muscular dystrophy.', 'subject score': 888, 'object score': 1000}, 'PMID:31295065': {'publication date': '2019 Oct 01', 'sentence': 'To mimic typical pharmacology of patients with Duchenne muscular dystrophy, a group was treated with prednisolone (Pred) in combination with Q, NR, and Lis.', 'subject score': 1000, 'object score': 1000}, 'PMID:34617309': {'publication date': '2021 Oct 07', 'sentence': 'Intermittent versus Daily Regimen of Prednisolone in Ambulatory Boys with Duchenne Muscular Dystrophy: A Randomized, Open-Label Trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:34693725': {'publication date': '2021 Oct 25', 'sentence': 'Conclusion:     Deflazacort provides clinically meaningful delays in loss of physical milestones over 48 weeks compared with prednisone/prednisolone for patients with nonsense mutation Duchenne muscular dystrophy.', 'subject score': 888, 'object score': 893}, 'PMID:8482992': {'publication date': '1993', 'sentence': 'Seven patients, aged 10-17 years, with Duchenne muscular dystrophy were treated orally with prednisolone (PSL) at a dose of 0.8-1.0 mg/kg per day for 8 weeks.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0013264---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7603475",
-              "object": "MONDO:0010679",
-              "publications": [
-                "PMID:10441862",
-                "PMID:11249150",
-                "PMID:15272899",
-                "PMID:21400928",
-                "PMID:28432191",
-                "PMID:30214127",
-                "PMID:31295065",
-                "PMID:34617309",
-                "PMID:34693725",
-                "PMID:8482992"
-=======
-            "identity": 15562682,
-            "start": 568,
-            "end": 318890,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21953589': {'publication date': '2012 Mar', 'sentence': 'Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction.', 'subject score': 861, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0003873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "15888410",
-              "object": "MONDO:0008383",
-              "publications": [
-                "PMID:21953589"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 522619,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005301",
-          "name": "multiple sclerosis",
-          "description": "An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D009103",
-            "NCIT:C3243",
-            "MEDDRA:10039720",
-            "EFO:0003885",
-            "ORPHANET:802",
-            "MEDDRA:10028245",
-            "PSY:32490",
-            "ICD9:340",
-            "MONDO:0005301",
-            "MEDDRA:10028053",
-            "UMLS:C0026769",
-            "MEDDRA:10013451",
-            "SNOMEDCT:24700007",
-            "ICD10:G35",
-            "PDQ:CDR0000691761",
-            "DOID:2377"
-          ],
-          "id": "MONDO:0005301",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Multiple Sclerosis",
-            "obsolete_multiple sclerosis",
-            "Multiple sclerosis",
-            "multiple sclerosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://ghr.nlm.nih.gov/condition/multiple-sclerosis",
-            "http://en.wikipedia.org/wiki/multiple_sclerosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 522619,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005301",
-              "name": "multiple sclerosis",
-              "description": "An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D009103",
-                "NCIT:C3243",
-                "MEDDRA:10039720",
-                "EFO:0003885",
-                "ORPHANET:802",
-                "MEDDRA:10028245",
-                "PSY:32490",
-                "ICD9:340",
-                "MONDO:0005301",
-                "MEDDRA:10028053",
-                "UMLS:C0026769",
-                "MEDDRA:10013451",
-                "SNOMEDCT:24700007",
-                "ICD10:G35",
-                "PDQ:CDR0000691761",
-                "DOID:2377"
-              ],
-              "id": "MONDO:0005301",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Multiple Sclerosis",
-                "obsolete_multiple sclerosis",
-                "Multiple sclerosis",
-                "multiple sclerosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://ghr.nlm.nih.gov/condition/multiple-sclerosis",
-                "http://en.wikipedia.org/wiki/multiple_sclerosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7442851,
-            "start": 568,
-            "end": 522619,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10440499': {'publication date': '1999 Aug', 'sentence': 'Long-term open-trial of mizoribine with prednisolone in 24 patients with multiple sclerosis: safety, clinical and magnetic resonance imaging outcome.', 'subject score': 1000, 'object score': 1000}, 'PMID:1792777': {'publication date': '1991 Dec', 'sentence': '[Changes in the clinical and immunological indices of patients with disseminated sclerosis being treated with prednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:2256298': {'publication date': '1990 Aug', 'sentence': 'Prednisolone produced an unfavourable effect on the course of the demyelinating process in patients with multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2339565': {'publication date': '1990 Feb', 'sentence': 'The authors examined 56 patients suffering of multiple sclerosis who were treated with prednisolone and Proper-Myl.', 'subject score': 1000, 'object score': 1000}, 'PMID:25392236': {'publication date': '2015 Apr', 'sentence': 'Glucocorticoids, such as prednisolone, are effective in the treatment of multiple sclerosis in large part due to their ability to inhibit pro-inflammatory pathways (e.g., NFkappaB).', 'subject score': 1000, 'object score': 1000}, 'PMID:3259769': {'publication date': '1988', 'sentence': '[The dynamics of immunological indicators in the treatment of patients with multiple sclerosis with prednisolone combined with plasmapheresis].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0026769---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7600829",
-              "object": "MONDO:0005301",
-              "publications": [
-                "PMID:10440499",
-                "PMID:1792777",
-                "PMID:2256298",
-                "PMID:2339565",
-                "PMID:25392236",
-                "PMID:3259769"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7432241,
-            "start": 568,
-            "end": 322104,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10433019': {'publication date': '1999 Jun', 'sentence': 'A 25-year-old man had been treated with high-dose prednisolone for UC.', 'subject score': 901, 'object score': 1000}, 'PMID:10811328': {'publication date': '2000 May', 'sentence': 'CONCLUSIONS: Treatment with AZA/prednisolone appears to be more effective and safe compared to MMF/prednisolone in patients with chronic active UC.', 'subject score': 824, 'object score': 916}, 'PMID:11868601': {'publication date': '2002 Feb', 'sentence': 'The first case had been treated initially with 60 mg prednisolone for ulcerative colitis, and L. pneumophila serogroup 1 was isolated from sputum samples after cavitation of the lung lesion.', 'subject score': 790, 'object score': 1000}, 'PMID:12349943': {'publication date': '2002 Jul', 'sentence': 'In 14 UC patients, there was a significant correlation between amounts of prednisolone (p < 0.05) or period of prednisolone administration (p < 0.05) for UC treatment and prednisolone IC50.', 'subject score': 1000, 'object score': 901}, 'PMID:12737443': {'publication date': '2003 Mar', 'sentence': 'The aim of the present study was therefore to evaluate the ICAM-1-shedding through measurements of sICAM-1 concentrations during prednisolone treatment of UC patients.', 'subject score': 888, 'object score': 901}, 'PMID:13474175': {'publication date': '1957 Sep', 'sentence': 'The longterm treatment of ulcerative colitis with hydrocortisone, prednisone and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:13850068': {'publication date': '1959 Dec', 'sentence': 'Continuous use of prednisolone in the treatment of ulcerative colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:14530652': {'publication date': '2003 Oct', 'sentence': 'METHODS: From 1998 to 2002, 35 patients with moderate-to-severe recurrence of ulcerative colitis were treated by intravenous prednisolone only or prednisolone plus leukocytapheresis once per week.', 'subject score': 790, 'object score': 1000}, 'PMID:1543815': {'publication date': '1992 Feb', 'sentence': 'An Eudragit-coated prednisolone preparation for ulcerative colitis: pharmacokinetics and preliminary therapeutic use.', 'subject score': 861, 'object score': 1000}, 'PMID:15449684': {'publication date': '2004 Jul-Aug', 'sentence': '[Endocrine cells of rectal epithelium in health, in nonspecific ulcerative colitis and irritable colon syndrome in the treatment with prednisolone and salofalk and in the absence of treatment].', 'subject score': 1000, 'object score': 901}, 'PMID:15843756': {'publication date': '2005 Apr', 'sentence': 'We used prednisolone and sulfasalazine for the treatment of ulcerative colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:16378006': {'publication date': '2006 Jan', 'sentence': 'An unblinded randomized controlled trial of a different selective apheresis device (Cellsorba) versus high-dose prednisolone in patients with active UC showed a greater therapeutic effect (74%) than high-dose prednisolone (38%) and lower frequency of adverse effects (24% versus 68%).', 'subject score': 901, 'object score': 901}, 'PMID:16937542': {'publication date': '2006 Aug 28', 'sentence': 'Being diagnosed as having severe active left-side UC, she was successfully treated with intravenous methylprednisolone followed by prednisolone and leukocytapheresis.', 'subject score': 1000, 'object score': 839}, 'PMID:17068395': {'publication date': '2006', 'sentence': 'Additionally, serum TFF concentrations were determined in patients with severe activity in colon IBD (4 UC and 6 CD) before and during prednisolone treatment with 7 healthy subjects as controls.', 'subject score': 888, 'object score': 901}, 'PMID:17497998': {'publication date': '2007 Jun', 'sentence': 'Patient 2 was a 29-year-old woman who had been suffering from pyoderma gangrenosum with severe pain for two weeks, associated with an 11-year history of ulcerative colitis treated with prednisolone and salazosulfapyridine.', 'subject score': 1000, 'object score': 1000}, 'PMID:1790809': {'publication date': '1991', 'sentence': \"Patients with nonspecific ulcerative colitis and Crohn's disease were treated with drug therapy (prednisolone, sulphasalazine, metronidazole per os and hydrocortisone per rectum) and subjected to 12 sessions of HBO.\", 'subject score': 1000, 'object score': 901}, 'PMID:18296130': {'publication date': '2008 Jun', 'sentence': 'This study was to compare the efficacy and safety of intensive GMA with intensive intravenous prednisolone in patients with severe ulcerative colitis.', 'subject score': 790, 'object score': 901}, 'PMID:19721403': {'publication date': '2009 Sep', 'sentence': 'CASE REPORT: A 50-year-old man who had been treated with prednisolone for left-sided ulcerative colitis (UC) underwent follow-up colonoscopy.', 'subject score': 1000, 'object score': 888}, 'PMID:20651970': {'publication date': '2009 Apr 15', 'sentence': 'Although he was under treatment with prednisolone and ursodeoxycholic acid, exacerbation of UC and PSC-associated cholestasis were seen.', 'subject score': 1000, 'object score': 1000}, 'PMID:21591873': {'publication date': '2011 Aug', 'sentence': 'DISCUSSION AND CONCLUSION: Results showed that ethanol extract of V. negundo root is effective in the treatment of UC and results are comparable with the standard drug, prednisolone, and thus possessing a great potential in the treatment of UC.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7586864",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:10433019",
-                "PMID:10811328",
-                "PMID:11868601",
-                "PMID:12349943",
-                "PMID:12737443",
-                "PMID:13474175",
-                "PMID:13850068",
-                "PMID:14530652",
-                "PMID:1543815",
-                "PMID:15449684",
-                "PMID:15843756",
-                "PMID:16378006",
-                "PMID:16937542",
-                "PMID:17068395",
-                "PMID:17497998",
-                "PMID:1790809",
-                "PMID:18296130",
-                "PMID:19721403",
-                "PMID:20651970",
-                "PMID:21591873"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316847,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
-          "name": "uveitis",
-          "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:1001231",
-            "UMLS:C0042164",
-            "DOID:13141",
-            "SNOMEDCT:128473001",
-            "MEDDRA:10046851",
-            "ICD10:H20.9",
-            "MONDO:0020283",
-            "MESH:D014605",
-            "NCIT:C26909",
-            "MEDDRA:10046855",
-            "HP:0000554",
-            "ORPHANET:98715"
-          ],
-          "id": "MONDO:0020283",
-          "category": "biolink:Disease",
-          "all_names": [
-            "uveitis",
-            "Uveitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316847,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
-              "name": "uveitis",
-              "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:1001231",
-                "UMLS:C0042164",
-                "DOID:13141",
-                "SNOMEDCT:128473001",
-                "MEDDRA:10046851",
-                "ICD10:H20.9",
-                "MONDO:0020283",
-                "MESH:D014605",
-                "NCIT:C26909",
-                "MEDDRA:10046855",
-                "HP:0000554",
-                "ORPHANET:98715"
-              ],
-              "id": "MONDO:0020283",
-              "category": "biolink:Disease",
-              "all_names": [
-                "uveitis",
-                "Uveitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7333779,
-            "start": 568,
-            "end": 316847,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10379613': {'publication date': '1999 Jun', 'sentence': 'DISCUSSION: Allopurinol is more effective than prednisolone in treating EAU.', 'subject score': 1000, 'object score': 833}, 'PMID:15037212': {'publication date': '2004 Mar', 'sentence': 'Allopurinol was markedly more effective than prednisolone in treating experimental autoimmune uveitis and in combination with cyclosporine suppressed the inflammatory reaction of this condition more effectively than either agent alone.', 'subject score': 1000, 'object score': 833}, 'PMID:17707134': {'publication date': '2007 Oct', 'sentence': 'In this study we investigated the effect of prednisolone on CCL2 gene expression and viral load in an HIV-1-infected patient receiving high-dose prednisolone for severe uveitis.', 'subject score': 901, 'object score': 888}, 'PMID:1867297': {'publication date': '1991 Aug 15', 'sentence': 'Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis.', 'subject score': 1000, 'object score': 888}, 'PMID:22323881': {'publication date': '2012 Feb', 'sentence': 'Data was obtained relevant to demographic characteristics, anatomic classification, and laterality of uveitis, associated systemic disorder, dosage of cyclosporine and prednisolone, usage of other immunosuppressive drugs, visual acuity (VA), control of uveitic activity, and adverse effects during the cyclosporine use.', 'subject score': 1000, 'object score': 853}, 'PMID:23363352': {'publication date': '2013 Feb', 'sentence': 'Oral administration of prednisolone or meloxicam may be an effective treatment for cats with uveitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:24179690': {'publication date': '2013 Nov', 'sentence': 'He was treated with prednisolone for chronic uveitis before being switched to sulfasalazine 3 weeks prior to admission.', 'subject score': 1000, 'object score': 888}, 'PMID:24885484': {'publication date': '2014 May 29', 'sentence': 'Systemic prednisolone and valaciclovir resulted in prompt resolution of uveitis and hyphema.', 'subject score': 888, 'object score': 1000}, 'PMID:28910554': {'publication date': '2017 Sep 14', 'sentence': 'PURPOSE: The purpose of this study was to investigate the self-microemulsifying drug delivery systems (SMEDDS) for ophthalmic delivery of Prednisolone (PDN) to treat uveitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:31182107': {'publication date': '2019 Jun 10', 'sentence': 'Both patients were treated with topical treatment and prednisolone for uveitis; however, relapses occurred during the tapering of prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:33722510': {'publication date': '2021 Mar 12', 'sentence': 'To conclude aqueous humor pharmacoproteomic revealed the anti-inflammatory activity of the dapsone comparable to the prednisolone treatment in endotoxin induced uveitis.', 'subject score': 888, 'object score': 851}, 'PMID:34632076': {'publication date': '2021', 'sentence': 'The main outcome measures were ability to reduce prednisolone dose, ability to control uveitis, final visual acuity and time to treatment failure.', 'subject score': 888, 'object score': 1000}, 'PMID:35212595': {'publication date': '2022 Feb 25', 'sentence': 'The minimum dose of PSL to control intraocular inflammation (min dose of PSL) could be reduced in all cases after the introduction of ADA (from 16.9 +/- 7.9 mg to 6.3 +/- 3.1 mg).', 'subject score': 1000, 'object score': 1000}, 'PMID:36147056': {'publication date': '2022 Sep', 'sentence': 'The medical history included a pigmentary retinopathy (PR) at age of 22 and uveitis at age of 30, which were both treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:36930111': {'publication date': '2023 Mar 17', 'sentence': 'INTERVENTIONS: We increased the existing dose of prednisolone for the treatment of uveitis and started her on oral aspirin and kallidinogenase for CRVO.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0042164---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7485161",
-              "object": "MONDO:0020283",
-              "publications": [
-                "PMID:10379613",
-                "PMID:15037212",
-                "PMID:17707134",
-                "PMID:1867297",
-                "PMID:22323881",
-                "PMID:23363352",
-                "PMID:24179690",
-                "PMID:24885484",
-                "PMID:28910554",
-                "PMID:31182107",
-                "PMID:33722510",
-                "PMID:34632076",
-                "PMID:35212595",
-                "PMID:36147056",
-                "PMID:36930111"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7281328,
-            "start": 568,
-            "end": 321528,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10353577': {'publication date': '1999 May', 'sentence': 'Interleukin-5 mRNA was detected in all asthmatics before prednisolone therapy; however, after prednisolone therapy, IL-5 mRNA was only detected in non-GCS-responsive BHR asthmatics.', 'subject score': 888, 'object score': 966}, 'PMID:10581660': {'publication date': '1999 Oct', 'sentence': 'In outpatients with stable COPD and no signs of asthma or atopy, 2 weeks treatment with prednisolone seems to be of no value in choosing subsequent long-term therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:10707544': {'publication date': '1999 Dec', 'sentence': 'PSL reduced the parotid mass and improved control of the asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:1105522': {'publication date': '1975', 'sentence': 'A double-blind comparison of beclomethasone dipropionate aerosol and prednisolone in asthmatic patients.', 'subject score': 1000, 'object score': 888}, 'PMID:11068988': {'publication date': '2000 Oct', 'sentence': 'These findings suggest that prednisolone is considered to be effective medicine for asthma by suppressing eosinophil activation through IL-5.', 'subject score': 1000, 'object score': 1000}, 'PMID:11180687': {'publication date': '2001 Feb', 'sentence': 'Serum levels of eosinophil cationic protein and eosinophils in asthmatic children during a course of prednisolone therapy.', 'subject score': 888, 'object score': 888}, 'PMID:12400872': {'publication date': '2002 Sep', 'sentence': 'In contrast, the expression of GRalpha and c-jun mRNAs did not correlate with the IC50 for prednisolone and methylprednisolone in asthma patients.', 'subject score': 1000, 'object score': 888}, 'PMID:12580810': {'publication date': '2003 Jan', 'sentence': 'We aimed to determine the changes of intercellular adhesion molecule-1 (ICAM-1) and L-selectin expressed on peripheral blood (PB) T lymphocytes and natural killer (NK) cells in asthmatic children with acute exacerbation and after prednisolone therapy.', 'subject score': 888, 'object score': 888}, 'PMID:1290409': {'publication date': '1992 Dec', 'sentence': 'GM-CSF production by mononuclear cells from BA patients treated with prednisolone was lower than that of mononuclear cells from untreated BA patients.', 'subject score': 1000, 'object score': 901}, 'PMID:13434625': {'publication date': '1957', 'sentence': 'Prednisolone in the treatment of bronchial asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:13487472': {'publication date': '1957 Nov 10', 'sentence': '[Results of asthma therapy with prednisolone in comparison with previous experience with prednisone].', 'subject score': 1000, 'object score': 888}, 'PMID:13499912': {'publication date': '1958 Feb 01', 'sentence': 'Prednisolone compared with cortisone in treatment of children with chronic asthma.', 'subject score': 1000, 'object score': 888}, 'PMID:13551874': {'publication date': '1958 May', 'sentence': '[The problem of protracted treatment of bronchial asthma with prednisone & prednisolone].', 'subject score': 888, 'object score': 1000}, 'PMID:13573988': {'publication date': '1958 Jul 21', 'sentence': '[Action of nebulized prednisolone in vasomotor rhinitis & its inhibitory effect on the nasobronchial reflex in asthmatic patients].', 'subject score': 861, 'object score': 888}, 'PMID:13602885': {'publication date': '1958 Sep 10', 'sentence': '[Hydrocortisone, prednisone & prednisolone; recent findings on its use in the treatment of bronchial asthma & other allergic processes].', 'subject score': 888, 'object score': 1000}, 'PMID:13612182': {'publication date': '1958 Dec 13', 'sentence': 'Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum.', 'subject score': 1000, 'object score': 888}, 'PMID:13733794': {'publication date': '1961 Feb 04', 'sentence': 'Treatment of chronic asthma with prednisolone and the newer steroids.', 'subject score': 1000, 'object score': 888}, 'PMID:13989478': {'publication date': '1963 Jun', 'sentence': 'Prolonged treatment with prednisolone in children with asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:1405085': {'publication date': '1992 Apr', 'sentence': 'To reduce the dose of prednisolone for her asthma, administration of TJ96 was started in Dec.', 'subject score': 1000, 'object score': 1000}, 'PMID:15876307': {'publication date': '2005 Jun', 'sentence': 'CONCLUSION: This study has demonstrated that serum sCTLA-4 concentrations increased after allergen inhalation in sensitized asthmatic subjects, and that serum sCTLA-4 concentrations were downregulated by prednisolone therapy.', 'subject score': 888, 'object score': 773}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7430895",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:10353577",
-                "PMID:10581660",
-                "PMID:10707544",
-                "PMID:1105522",
-                "PMID:11068988",
-                "PMID:11180687",
-                "PMID:12400872",
-                "PMID:12580810",
-                "PMID:1290409",
-                "PMID:13434625",
-                "PMID:13487472",
-                "PMID:13499912",
-                "PMID:13551874",
-                "PMID:13573988",
-                "PMID:13602885",
-                "PMID:13612182",
-                "PMID:13733794",
-                "PMID:13989478",
-                "PMID:1405085",
-                "PMID:15876307"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 311688,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005342",
-          "name": "IgA glomerulonephritis",
-          "description": "Inflammation of a specific segment of glomeruli within the kidney.; A chronic autoimmune glomerulonephritis characterized by the deposition of immunoglobulin A in the mesangium of the glomeruli. It is manifested with hematuria and mild proteinuria.; A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.; The presence of immunoglobulin A deposits in the glomerulus. [Eurenomics:ewuehl]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C34643",
-            "OMIM.PS:161950",
-            "MEDDRA:10018369",
-            "NCIT:C35280",
-            "UMLS:C0017661",
-            "MESH:D005922",
-            "EFO:0004194",
-            "UMLS:C3161650",
-            "SNOMEDCT:68779003",
-            "HP:0000794",
-            "DOID:2986",
-            "SNOMEDCT:236407003",
-            "MEDDRA:10069341",
-            "ORPHANET:34145",
-            "UMLS:C4025827",
-            "MONDO:0005342",
-            "MEDDRA:10021263"
-          ],
-          "id": "MONDO:0005342",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Glomerulonephritis, IGA",
-            "IGA Glomerulonephritis",
-            "IGA glomerulonephritis",
-            "IgA glomerulonephritis",
-            "IgA Nephropathy",
-            "Primary immunoglobulin A nephropathy (disorder)",
-            "IgA deposition in the glomerulus",
-            "Focal Glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000466.htm",
-            "http://en.wikipedia.org/wiki/iga_nephropathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311688,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005342",
-              "name": "IgA glomerulonephritis",
-              "description": "Inflammation of a specific segment of glomeruli within the kidney.; A chronic autoimmune glomerulonephritis characterized by the deposition of immunoglobulin A in the mesangium of the glomeruli. It is manifested with hematuria and mild proteinuria.; A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.; The presence of immunoglobulin A deposits in the glomerulus. [Eurenomics:ewuehl]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C34643",
-                "OMIM.PS:161950",
-                "MEDDRA:10018369",
-                "NCIT:C35280",
-                "UMLS:C0017661",
-                "MESH:D005922",
-                "EFO:0004194",
-                "UMLS:C3161650",
-                "SNOMEDCT:68779003",
-                "HP:0000794",
-                "DOID:2986",
-                "SNOMEDCT:236407003",
-                "MEDDRA:10069341",
-                "ORPHANET:34145",
-                "UMLS:C4025827",
-                "MONDO:0005342",
-                "MEDDRA:10021263"
-              ],
-              "id": "MONDO:0005342",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Glomerulonephritis, IGA",
-                "IGA Glomerulonephritis",
-                "IGA glomerulonephritis",
-                "IgA glomerulonephritis",
-                "IgA Nephropathy",
-                "Primary immunoglobulin A nephropathy (disorder)",
-                "IgA deposition in the glomerulus",
-                "Focal Glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000466.htm",
-                "http://en.wikipedia.org/wiki/iga_nephropathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7269347,
-            "start": 568,
-            "end": 311688,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10344344': {'publication date': '1999 May', 'sentence': 'Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy--is it relevant for adult patients?', 'subject score': 1000, 'object score': 901}, 'PMID:15571177': {'publication date': '2004 Nov', 'sentence': 'Ten of the 30 children with IgAN were treated with combination therapy comprising prednisolone, warfarin and dipyridamole and urine samples were collected weekly during the period of treatment.', 'subject score': 824, 'object score': 1000}, 'PMID:17699253': {'publication date': '2006 May', 'sentence': 'It is concluded that combination treatment may be better for severe IgAN than treatment with prednisolone alone.', 'subject score': 1000, 'object score': 901}, 'PMID:18085391': {'publication date': '2007 Dec', 'sentence': 'Histologically advanced IgA nephropathy treated successfully with prednisolone and cyclophosphamide.', 'subject score': 1000, 'object score': 824}, 'PMID:18324350': {'publication date': '2008 Aug', 'sentence': 'Long-term follow-up of patients with IgA nephropathy treated with prednisolone and cyclophosphamide therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:19398873': {'publication date': '2009 May', 'sentence': 'We collected data on 25 IgAN children who had been treated with prednisolone and divided these patients into two groups: Favorable group, consisting of 11 patients with normal urine and 6 with minor urinary abnormalities at 4.3 +/- 1.3 years after initial treatment; and Unfavorable group, consisting of 8 patients with persistent nephropathy.', 'subject score': 1000, 'object score': 824}, 'PMID:19418967': {'publication date': '2008 Dec', 'sentence': 'As to the treatment of IgAN, we evaluated the efficacy of tonsillectomy plus prednisolone, warfarin, and dipyridamole including methylprednisolone pulse therapy (tonsillectomy plus pulse therapy) and prednisolone, warfarin, and dipyridamole including mizoribine (PWDM) for the treatment of diffuse IgAN in children.', 'subject score': 851, 'object score': 1000}, 'PMID:19901893': {'publication date': '2009 Oct', 'sentence': 'He had been treated with prednisolone for IgA nephropathy and undergone surgical closure of an isolated ventricular septal defect (VSD).', 'subject score': 1000, 'object score': 1000}, 'PMID:19918307': {'publication date': '2009 Jul', 'sentence': 'A case of crescentic IgA nephropathy treated with prednisolone and cyclophosphamide.', 'subject score': 1000, 'object score': 865}, 'PMID:27714465': {'publication date': '2017 03', 'sentence': 'Twenty children with NS-IgAN were treated with prednisolone alone, or prednisolone and immunosuppressant.', 'subject score': 1000, 'object score': 888}, 'PMID:29520517': {'publication date': '2018 Oct', 'sentence': 'Initial treatment with pulse methylprednisolone followed by short-term prednisolone and tonsillectomy for childhood IgA nephropathy.', 'subject score': 901, 'object score': 901}, 'PMID:31033860': {'publication date': '2019 08', 'sentence': 'Is Dose Adjustment of Prednisolone Required in Patients With IgA Nephropathy During Rifampicin Treatment for Mycobacterium avium Complex Lung Disease?', 'subject score': 1000, 'object score': 1000}, 'PMID:31993782': {'publication date': '2020 Jan 28', 'sentence': 'The 16 children with C-IgAN were treated with prednisolone and immunosuppressant.', 'subject score': 1000, 'object score': 865}, 'PMID:35119558': {'publication date': '2022 Feb 04', 'sentence': 'For severe IgA nephropathy, in particular, multidrug therapy with prednisolone, immunosuppressants, and angiotensin enzyme synthesis inhibitors and tonsillectomy methylprednisolone pulse therapy are now performed- and, as a result, the number of renal deaths has decreased and the long-term prognosis has improved.', 'subject score': 1000, 'object score': 901}, 'PMID:36357635': {'publication date': '2022 Nov 10', 'sentence': 'METHODS: A retrospective cohort of 90 children with IgAN were divided into groups treated with prednisolone (PSL) alone (P group; n = 42) or PSL plus Miz (PM group; n = 48) for a 2-year period.', 'subject score': 1000, 'object score': 1000}, 'PMID:9890315': {'publication date': '1999 Jan', 'sentence': 'In conclusion, the present study shows that treatment of children with severe IgA nephropathy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for 2 yr early in the course of disease reduces immunologic renal injury and prevents increase of sclerosed glomeruli.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0017661---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7417999",
-              "object": "MONDO:0005342",
-              "publications": [
-                "PMID:10344344",
-                "PMID:15571177",
-                "PMID:17699253",
-                "PMID:18085391",
-                "PMID:18324350",
-                "PMID:19398873",
-                "PMID:19418967",
-                "PMID:19901893",
-                "PMID:19918307",
-                "PMID:27714465",
-                "PMID:29520517",
-                "PMID:31033860",
-                "PMID:31993782",
-                "PMID:35119558",
-                "PMID:36357635",
-                "PMID:9890315"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10074595': {'publication date': '1998 Nov', 'sentence': 'Remission of the nephrotic syndrome in a patient with renal amyloidosis due to rheumatoid arthritis treated with prednisolone and methotrexate.', 'subject score': 1000, 'object score': 1000}, 'PMID:10328573': {'publication date': '1999 May', 'sentence': 'The combination of sulfasalazine, methotrexate with reducing high-dose prednisolone, is demonstrated to be cost-effective in patients with rheumatoid arthritis, but although several other combinations have been reported effective in patients with rheumatoid arthritis, most trials do not have the power to provide a definitive answer as to the best combination available, if one exists.', 'subject score': 850, 'object score': 1000}, 'PMID:10334255': {'publication date': '1999 May 08', 'sentence': 'This multicentre, randomised trial with 2-year follow-up sought evidence on the efficacy and tolerability of combination therapy (sulphasalazine, methotrexate, hydroxychloroquine, and prednisolone) compared with treatment with a single disease-modifying antirheumatic drug, with or without prednisolone, in the treatment of early rheumatoid arthritis.', 'subject score': 1000, 'object score': 901}, 'PMID:10520307': {'publication date': '1999 Sep 17', 'sentence': 'HISTORY AND ADMISSION FINDINGS: A 78-year-old woman had a 30-year history of rheumatoid arthritis, of late treated with prednisolone and methotrexate.', 'subject score': 1000, 'object score': 1000}, 'PMID:10531077': {'publication date': '1999 Nov', 'sentence': 'CONCLUSIONS: This study does not allow any firm conclusions for or against the treatment of rheumatoid arthritis with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:10689949': {'publication date': '2000 Feb 07', 'sentence': 'CONCLUSIONS: Prednisolone in low doses (not exceeding 15 mg daily) may be used intermittently in patients with rheumatoid arthritis, particularly if the disease cannot be controlled by other means.', 'subject score': 1000, 'object score': 1000}, 'PMID:10796316': {'publication date': '2000', 'sentence': \"REVIEWER'S CONCLUSIONS: Prednisolone in low doses (not exceeding 15 mg daily) may be used intermittently in patients with rheumatoid arthritis, particularly if the disease cannot be controlled by other means.\", 'subject score': 1000, 'object score': 1000}, 'PMID:10808674': {'publication date': '2000 Mar', 'sentence': 'OBJECTIVE: To compare patterns and time trends of initial disease-modifying antirheumatic drugs (DMARDs) and prednisolone prescriptions for patients with rheumatoid arthritis (RA) by the rheumatologists at King Chulalongkorn Memorial Hospital, Bangkok, Thailand over a 15-year period, as well as their side effects.', 'subject score': 888, 'object score': 1000}, 'PMID:11155812': {'publication date': '2000', 'sentence': 'Low dose prednisolone therapy (LDPT) retards radiographically detectable destruction in early rheumatoid arthritis--preliminary results of a multicenter, randomized, parallel, double blind study.', 'subject score': 861, 'object score': 901}, 'PMID:11247319': {'publication date': '2001 Jan-Feb', 'sentence': 'Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate.', 'subject score': 901, 'object score': 1000}, 'PMID:11269535': {'publication date': '2001 Feb', 'sentence': 'In this study, we investigated the effects of oral alendronate in RA patients treated with MTX and prednisolone by comparing the effects of \"alendronate+calcium\" and \"only calcium\" on bone mineral density (BMD).', 'subject score': 1000, 'object score': 901}, 'PMID:11296970': {'publication date': '2001 Mar', 'sentence': 'She had had RA for 12 years, which had been controlled well with prednisolone (3 mg/day) at the orthopedic clinic.', 'subject score': 1000, 'object score': 1000}, 'PMID:11333345': {'publication date': '2001 May', 'sentence': 'During the last 2 years, the combination of methotrexate, sulfasalazine, hydroxychloroquine, and prednisolone has been demonstrated to be more beneficial than monotherapy in patients with early rheumatoid arthritis.', 'subject score': 1000, 'object score': 901}, 'PMID:11405954': {'publication date': '2001', 'sentence': \"REVIEWER'S CONCLUSIONS: Prednisolone in low doses (not exceeding 15 mg daily) may be used intermittently in patients with rheumatoid arthritis, particularly if the disease cannot be controlled by other means.\", 'subject score': 1000, 'object score': 1000}, 'PMID:11642646': {'publication date': '2001 Oct', 'sentence': 'It is known and has been repeatedly demonstrated that low doses of prednisone or prednisolone (10 mg daily or 5 mg bid) will control most of the inflammatory features of early polyarticular rheumatoid arthritis (Table 2).', 'subject score': 1000, 'object score': 861}, 'PMID:11792891': {'publication date': '2002 Jan', 'sentence': 'Effective treatment of early rheumatoid arthritis with a combination of methotrexate, prednisolone and cyclosporin.', 'subject score': 1000, 'object score': 901}, 'PMID:11908553': {'publication date': '2002 Mar', 'sentence': 'Prior prednisolone treatment of RA patients was related to decreased spontaneous cytokine secretion, a lower density of T cells, CD163+ macrophages and TH+ cells, a lower degree of inflammation, and reduced synovial NE secretion.', 'subject score': 851, 'object score': 901}, 'PMID:11915862': {'publication date': '2002 Mar', 'sentence': 'The patient received prednisolone for rheumatoid arthritis and antibiotics for his fever and pneumonia in another hospital, but the response to the therapy was poor.', 'subject score': 1000, 'object score': 1000}, 'PMID:11980132': {'publication date': '2002', 'sentence': 'CONCLUSION: Pharmacokinetic indices of prednisolone in RA patients provide more reliable information for design of treatment scheme for each patient individually.', 'subject score': 1000, 'object score': 901}, 'PMID:12030042': {'publication date': '2002 Apr', 'sentence': '[A case of multiple bone and joint tuberculosis which had been misdiagnosed as the rheumatoid arthritis and treated with prednisolone for eleven months].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 318890,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-          "name": "rheumatoid arthritis",
-          "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C2884",
-            "PSY:44570",
-            "EFO:0000685",
-            "ICD9:714.0",
-            "KEGG.DISEASE:05323",
-            "MONDO:0008383",
-            "UMLS:C0003873",
-            "UMLS:C1306838",
-            "UMLS:C1833448",
-            "MEDDRA:10037740",
-            "MEDDRA:10039073",
-            "OMIM:180300",
-            "MESH:D001172",
-            "MEDDRA:10003268",
-            "HP:0001370",
-            "ORPHANET:284130",
-            "SNOMEDCT:69896004",
-            "ICD10:M06.9",
-            "DOID:7148",
-            "MEDDRA:10036856",
-            "MEDDRA:10042952"
-          ],
-          "id": "MONDO:0008383",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Proliferative arthritis",
-            "Arthritis, Rheumatoid",
-            "rheumatoid arthritis",
-            "Rheumatoid arthritis",
-            "Rheumatoid Arthritis",
-            "Rheumatoid arthritis related phenotypic feature",
-            "Rheumatoid arthritis, susceptibility to"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-            "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-            "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318890,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-              "name": "rheumatoid arthritis",
-              "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C2884",
-                "PSY:44570",
-                "EFO:0000685",
-                "ICD9:714.0",
-                "KEGG.DISEASE:05323",
-                "MONDO:0008383",
-                "UMLS:C0003873",
-                "UMLS:C1306838",
-                "UMLS:C1833448",
-                "MEDDRA:10037740",
-                "MEDDRA:10039073",
-                "OMIM:180300",
-                "MESH:D001172",
-                "MEDDRA:10003268",
-                "HP:0001370",
-                "ORPHANET:284130",
-                "SNOMEDCT:69896004",
-                "ICD10:M06.9",
-                "DOID:7148",
-                "MEDDRA:10036856",
-                "MEDDRA:10042952"
-              ],
-              "id": "MONDO:0008383",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Proliferative arthritis",
-                "Arthritis, Rheumatoid",
-                "rheumatoid arthritis",
-                "Rheumatoid arthritis",
-                "Rheumatoid Arthritis",
-                "Rheumatoid arthritis related phenotypic feature",
-                "Rheumatoid arthritis, susceptibility to"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-                "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-                "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7015896,
-            "start": 568,
-            "end": 318890,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10074595': {'publication date': '1998 Nov', 'sentence': 'Remission of the nephrotic syndrome in a patient with renal amyloidosis due to rheumatoid arthritis treated with prednisolone and methotrexate.', 'subject score': 1000, 'object score': 1000}, 'PMID:10328573': {'publication date': '1999 May', 'sentence': 'The combination of sulfasalazine, methotrexate with reducing high-dose prednisolone, is demonstrated to be cost-effective in patients with rheumatoid arthritis, but although several other combinations have been reported effective in patients with rheumatoid arthritis, most trials do not have the power to provide a definitive answer as to the best combination available, if one exists.', 'subject score': 850, 'object score': 1000}, 'PMID:10334255': {'publication date': '1999 May 08', 'sentence': 'This multicentre, randomised trial with 2-year follow-up sought evidence on the efficacy and tolerability of combination therapy (sulphasalazine, methotrexate, hydroxychloroquine, and prednisolone) compared with treatment with a single disease-modifying antirheumatic drug, with or without prednisolone, in the treatment of early rheumatoid arthritis.', 'subject score': 1000, 'object score': 901}, 'PMID:10520307': {'publication date': '1999 Sep 17', 'sentence': 'HISTORY AND ADMISSION FINDINGS: A 78-year-old woman had a 30-year history of rheumatoid arthritis, of late treated with prednisolone and methotrexate.', 'subject score': 1000, 'object score': 1000}, 'PMID:10531077': {'publication date': '1999 Nov', 'sentence': 'CONCLUSIONS: This study does not allow any firm conclusions for or against the treatment of rheumatoid arthritis with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:10689949': {'publication date': '2000 Feb 07', 'sentence': 'CONCLUSIONS: Prednisolone in low doses (not exceeding 15 mg daily) may be used intermittently in patients with rheumatoid arthritis, particularly if the disease cannot be controlled by other means.', 'subject score': 1000, 'object score': 1000}, 'PMID:10796316': {'publication date': '2000', 'sentence': \"REVIEWER'S CONCLUSIONS: Prednisolone in low doses (not exceeding 15 mg daily) may be used intermittently in patients with rheumatoid arthritis, particularly if the disease cannot be controlled by other means.\", 'subject score': 1000, 'object score': 1000}, 'PMID:10808674': {'publication date': '2000 Mar', 'sentence': 'OBJECTIVE: To compare patterns and time trends of initial disease-modifying antirheumatic drugs (DMARDs) and prednisolone prescriptions for patients with rheumatoid arthritis (RA) by the rheumatologists at King Chulalongkorn Memorial Hospital, Bangkok, Thailand over a 15-year period, as well as their side effects.', 'subject score': 888, 'object score': 1000}, 'PMID:11155812': {'publication date': '2000', 'sentence': 'Low dose prednisolone therapy (LDPT) retards radiographically detectable destruction in early rheumatoid arthritis--preliminary results of a multicenter, randomized, parallel, double blind study.', 'subject score': 861, 'object score': 901}, 'PMID:11247319': {'publication date': '2001 Jan-Feb', 'sentence': 'Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate.', 'subject score': 901, 'object score': 1000}, 'PMID:11269535': {'publication date': '2001 Feb', 'sentence': 'In this study, we investigated the effects of oral alendronate in RA patients treated with MTX and prednisolone by comparing the effects of \"alendronate+calcium\" and \"only calcium\" on bone mineral density (BMD).', 'subject score': 1000, 'object score': 901}, 'PMID:11296970': {'publication date': '2001 Mar', 'sentence': 'She had had RA for 12 years, which had been controlled well with prednisolone (3 mg/day) at the orthopedic clinic.', 'subject score': 1000, 'object score': 1000}, 'PMID:11333345': {'publication date': '2001 May', 'sentence': 'During the last 2 years, the combination of methotrexate, sulfasalazine, hydroxychloroquine, and prednisolone has been demonstrated to be more beneficial than monotherapy in patients with early rheumatoid arthritis.', 'subject score': 1000, 'object score': 901}, 'PMID:11405954': {'publication date': '2001', 'sentence': \"REVIEWER'S CONCLUSIONS: Prednisolone in low doses (not exceeding 15 mg daily) may be used intermittently in patients with rheumatoid arthritis, particularly if the disease cannot be controlled by other means.\", 'subject score': 1000, 'object score': 1000}, 'PMID:11642646': {'publication date': '2001 Oct', 'sentence': 'It is known and has been repeatedly demonstrated that low doses of prednisone or prednisolone (10 mg daily or 5 mg bid) will control most of the inflammatory features of early polyarticular rheumatoid arthritis (Table 2).', 'subject score': 1000, 'object score': 861}, 'PMID:11792891': {'publication date': '2002 Jan', 'sentence': 'Effective treatment of early rheumatoid arthritis with a combination of methotrexate, prednisolone and cyclosporin.', 'subject score': 1000, 'object score': 901}, 'PMID:11908553': {'publication date': '2002 Mar', 'sentence': 'Prior prednisolone treatment of RA patients was related to decreased spontaneous cytokine secretion, a lower density of T cells, CD163+ macrophages and TH+ cells, a lower degree of inflammation, and reduced synovial NE secretion.', 'subject score': 851, 'object score': 901}, 'PMID:11915862': {'publication date': '2002 Mar', 'sentence': 'The patient received prednisolone for rheumatoid arthritis and antibiotics for his fever and pneumonia in another hospital, but the response to the therapy was poor.', 'subject score': 1000, 'object score': 1000}, 'PMID:11980132': {'publication date': '2002', 'sentence': 'CONCLUSION: Pharmacokinetic indices of prednisolone in RA patients provide more reliable information for design of treatment scheme for each patient individually.', 'subject score': 1000, 'object score': 901}, 'PMID:12030042': {'publication date': '2002 Apr', 'sentence': '[A case of multiple bone and joint tuberculosis which had been misdiagnosed as the rheumatoid arthritis and treated with prednisolone for eleven months].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0003873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7158230",
-              "object": "MONDO:0008383",
-              "publications": [
-                "PMID:10074595",
-                "PMID:10328573",
-                "PMID:10334255",
-                "PMID:10520307",
-                "PMID:10531077",
-                "PMID:10689949",
-                "PMID:10796316",
-                "PMID:10808674",
-                "PMID:11155812",
-                "PMID:11247319",
-                "PMID:11269535",
-                "PMID:11296970",
-                "PMID:11333345",
-                "PMID:11405954",
-                "PMID:11642646",
-                "PMID:11792891",
-                "PMID:11908553",
-                "PMID:11915862",
-                "PMID:11980132",
-                "PMID:12030042"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:13589594': {'publication date': '1958 Sep 26', 'sentence': '[Effect of prednisolone and human albumin on protein excretion in nephrotic syndrome].', 'subject score': 1000, 'object score': 1000}, 'PMID:1646675': {'publication date': '1991 Apr', 'sentence': 'All children received more than eight weeks course of prednisolone, and were in a critically ill status from their nephrotic syndrome and by steroid-toxic side effects.', 'subject score': 1000, 'object score': 1000}, 'PMID:16644478': {'publication date': '2006 Jun', 'sentence': 'We evaluated the suppressive efficacy of prednisolone, methylprednisolone, cyclosporine, and tacrolimus on the blastogenesis of PBMCs obtained from 12 ANCA-associated vasculitis patients (ANCA patients), eight patients with nephrotic syndrome, and eight healthy subjects.', 'subject score': 1000, 'object score': 1000}, 'PMID:17573408': {'publication date': '2008 Mar', 'sentence': 'Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:19562934': {'publication date': '2009 Mar', 'sentence': 'Concurrent use of cyclophosphamide and prednisolone in childhood nephrotic syndrome in South-East Nigeria; a report of 5 cases.', 'subject score': 1000, 'object score': 901}, 'PMID:26759000': {'publication date': '2016 Apr', 'sentence': 'The practice of BW-based calculations for prescribing prednisolone in NS is a reasonable approach.', 'subject score': 888, 'object score': 1000}, 'PMID:26787586': {'publication date': '2016 Jan', 'sentence': 'Use of high-dose prednisolone to overcome rifampicin-induced corticosteroid non-responsiveness in childhood nephrotic syndrome.', 'subject score': 901, 'object score': 901}, 'PMID:2751337': {'publication date': '1989 Apr', 'sentence': 'Low dose prednisolone in nephrotic syndrome.', 'subject score': 901, 'object score': 1000}, 'PMID:28341877': {'publication date': '2017 Aug', 'sentence': 'Short courses of daily prednisolone during upper respiratory tract infections reduce relapse frequency in childhood nephrotic syndrome.', 'subject score': 888, 'object score': 901}, 'PMID:7141787': {'publication date': '1982 Sep', 'sentence': 'The mean renal clearance and urinary excretion of prednisone and prednisolone in nephrotic syndrome are normal and suggest that glomerular leakage of protein bound drug is not significant.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319059,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005377",
-          "name": "nephrotic syndrome",
-          "description": "Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. [HPO:probinson]; Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. // COMMENTS: In adults, nephrotic syndrome is characterized by protein excretion of 3.5 g or more per day. In children, nephrotic syndrome is accompanied by protein excretion of more than 40 mg/m2/h and hypalbuminemia < 2.5 mg/dl.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10042826",
-            "MESH:D009404",
-            "HP:0000100",
-            "UMLS:C0027726",
-            "MONDO:0005377",
-            "EFO:0004255",
-            "MEDDRA:10029164",
-            "SNOMEDCT:52254009",
-            "NCIT:C34845",
-            "DOID:1184",
-            "ICD9:581"
-          ],
-          "id": "MONDO:0005377",
-          "category": "biolink:Disease",
-          "all_names": [
-            "nephrotic syndrome",
-            "Nephrotic Syndrome",
-            "Nephrotic syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://en.wikipedia.org/wiki/nephrotic_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319059,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005377",
-              "name": "nephrotic syndrome",
-              "description": "Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. [HPO:probinson]; Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. // COMMENTS: In adults, nephrotic syndrome is characterized by protein excretion of 3.5 g or more per day. In children, nephrotic syndrome is accompanied by protein excretion of more than 40 mg/m2/h and hypalbuminemia < 2.5 mg/dl.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10042826",
-                "MESH:D009404",
-                "HP:0000100",
-                "UMLS:C0027726",
-                "MONDO:0005377",
-                "EFO:0004255",
-                "MEDDRA:10029164",
-                "SNOMEDCT:52254009",
-                "NCIT:C34845",
-                "DOID:1184",
-                "ICD9:581"
-              ],
-              "id": "MONDO:0005377",
-              "category": "biolink:Disease",
-              "all_names": [
-                "nephrotic syndrome",
-                "Nephrotic Syndrome",
-                "Nephrotic syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://en.wikipedia.org/wiki/nephrotic_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10337958,
-            "start": 568,
-            "end": 319059,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13589594': {'publication date': '1958 Sep 26', 'sentence': '[Effect of prednisolone and human albumin on protein excretion in nephrotic syndrome].', 'subject score': 1000, 'object score': 1000}, 'PMID:1646675': {'publication date': '1991 Apr', 'sentence': 'All children received more than eight weeks course of prednisolone, and were in a critically ill status from their nephrotic syndrome and by steroid-toxic side effects.', 'subject score': 1000, 'object score': 1000}, 'PMID:16644478': {'publication date': '2006 Jun', 'sentence': 'We evaluated the suppressive efficacy of prednisolone, methylprednisolone, cyclosporine, and tacrolimus on the blastogenesis of PBMCs obtained from 12 ANCA-associated vasculitis patients (ANCA patients), eight patients with nephrotic syndrome, and eight healthy subjects.', 'subject score': 1000, 'object score': 1000}, 'PMID:17573408': {'publication date': '2008 Mar', 'sentence': 'Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:19562934': {'publication date': '2009 Mar', 'sentence': 'Concurrent use of cyclophosphamide and prednisolone in childhood nephrotic syndrome in South-East Nigeria; a report of 5 cases.', 'subject score': 1000, 'object score': 901}, 'PMID:26759000': {'publication date': '2016 Apr', 'sentence': 'The practice of BW-based calculations for prescribing prednisolone in NS is a reasonable approach.', 'subject score': 888, 'object score': 1000}, 'PMID:26787586': {'publication date': '2016 Jan', 'sentence': 'Use of high-dose prednisolone to overcome rifampicin-induced corticosteroid non-responsiveness in childhood nephrotic syndrome.', 'subject score': 901, 'object score': 901}, 'PMID:2751337': {'publication date': '1989 Apr', 'sentence': 'Low dose prednisolone in nephrotic syndrome.', 'subject score': 901, 'object score': 1000}, 'PMID:28341877': {'publication date': '2017 Aug', 'sentence': 'Short courses of daily prednisolone during upper respiratory tract infections reduce relapse frequency in childhood nephrotic syndrome.', 'subject score': 888, 'object score': 901}, 'PMID:7141787': {'publication date': '1982 Sep', 'sentence': 'The mean renal clearance and urinary excretion of prednisone and prednisolone in nephrotic syndrome are normal and suggest that glomerular leakage of protein bound drug is not significant.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0027726---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10565620",
-              "object": "MONDO:0005377",
-              "publications": [
-                "PMID:13589594",
-                "PMID:1646675",
-                "PMID:16644478",
-                "PMID:17573408",
-                "PMID:19562934",
-                "PMID:26759000",
-                "PMID:26787586",
-                "PMID:2751337",
-                "PMID:28341877",
-                "PMID:7141787"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:2262977': {'publication date': '1990 Oct', 'sentence': '[A case of nephrotic syndrome with abnormally high level of protein C induced by prednisolone].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319059,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005377",
-          "name": "nephrotic syndrome",
-          "description": "Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. [HPO:probinson]; Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. // COMMENTS: In adults, nephrotic syndrome is characterized by protein excretion of 3.5 g or more per day. In children, nephrotic syndrome is accompanied by protein excretion of more than 40 mg/m2/h and hypalbuminemia < 2.5 mg/dl.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10042826",
-            "MESH:D009404",
-            "HP:0000100",
-            "UMLS:C0027726",
-            "MONDO:0005377",
-            "EFO:0004255",
-            "MEDDRA:10029164",
-            "SNOMEDCT:52254009",
-            "NCIT:C34845",
-            "DOID:1184",
-            "ICD9:581"
-          ],
-          "id": "MONDO:0005377",
-          "category": "biolink:Disease",
-          "all_names": [
-            "nephrotic syndrome",
-            "Nephrotic Syndrome",
-            "Nephrotic syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://en.wikipedia.org/wiki/nephrotic_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319059,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005377",
-              "name": "nephrotic syndrome",
-              "description": "Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. [HPO:probinson]; Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. // COMMENTS: In adults, nephrotic syndrome is characterized by protein excretion of 3.5 g or more per day. In children, nephrotic syndrome is accompanied by protein excretion of more than 40 mg/m2/h and hypalbuminemia < 2.5 mg/dl.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10042826",
-                "MESH:D009404",
-                "HP:0000100",
-                "UMLS:C0027726",
-                "MONDO:0005377",
-                "EFO:0004255",
-                "MEDDRA:10029164",
-                "SNOMEDCT:52254009",
-                "NCIT:C34845",
-                "DOID:1184",
-                "ICD9:581"
-              ],
-              "id": "MONDO:0005377",
-              "category": "biolink:Disease",
-              "all_names": [
-                "nephrotic syndrome",
-                "Nephrotic Syndrome",
-                "Nephrotic syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://en.wikipedia.org/wiki/nephrotic_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15971109,
-            "start": 568,
-            "end": 319059,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2262977': {'publication date': '1990 Oct', 'sentence': '[A case of nephrotic syndrome with abnormally high level of protein C induced by prednisolone].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0027726---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16304261",
-              "object": "MONDO:0005377",
-              "publications": [
-                "PMID:2262977"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10634026': {'publication date': '1999 Dec', 'sentence': 'The second patient, a 73-year-old man receiving prednisolone therapy for nephrotic syndrome, developed right leg cellulitis that evolved to NF.', 'subject score': 763, 'object score': 1000}, 'PMID:10972687': {'publication date': '2000 Sep', 'sentence': 'There has been no study on prednisolone dosage for the effective treatment of nephrotic syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:11503553': {'publication date': '2001 Jul', 'sentence': 'The second patient had his relapses of nephrotic syndrome over a period of 10 years when treated with prednisolone and cyclophosphamide.', 'subject score': 1000, 'object score': 1000}, 'PMID:11510096': {'publication date': '2001 May', 'sentence': 'A 70-year-old man treated for 6 months with prednisolone for nephrotic syndrome, was referred to our pulmonary division because of a nodule in the right lower lung field.', 'subject score': 1000, 'object score': 1000}, 'PMID:11867955': {'publication date': '2002 Mar', 'sentence': 'After 5 courses of therapy with melphalan and prednisolone which failed to improve the nephrotic syndrome or her general clinical condition, and 1 year after the diagnosis of renal amyloidosis, surgical excision of the abdominal mass was performed.', 'subject score': 1000, 'object score': 1000}, 'PMID:12428401': {'publication date': '2002 Aug', 'sentence': 'The patient was a 56-year-old man who had received diagnoses of psoriasis vulgaris at the age of thirty-three and of nephrotic syndrome at forty-five, and had been treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:14700154': {'publication date': '2003 Aug', 'sentence': 'Resection of the ileum and appendectomy were performed while the relapsing nephrotic syndrome was treated by prednisolone.', 'subject score': 1000, 'object score': 901}, 'PMID:14964453': {'publication date': '2004 Jan', 'sentence': 'PATIENTS AND METHODS: Sixteen patients, with nephrotic syndrome due to IMN and well-preserved renal function, were treated with prednisolone (starting dose: 0.5 mg/kg bw/day) and CsA (starting dose: 3 mg/kg bw/day) for 24 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:14964576': {'publication date': '2004 Jan', 'sentence': 'We examined outcomes of a short course of cyclophosphamide alternating with prednisolone for MN patients with nephrotic syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:1600282': {'publication date': '1992 Feb', 'sentence': 'NS responded to prednisolone therapy initially and at the time of the relapse.', 'subject score': 851, 'object score': 1000}, 'PMID:16848751': {'publication date': '2006 Jul', 'sentence': 'Small doses of CsA with prednisolone are effective in the treatment of nephrotic syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:17009081': {'publication date': '2006 Sep', 'sentence': 'The nephrotic syndrome was treated successfully with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:17284479': {'publication date': '2007 Jul', 'sentence': 'OBJECTIVE: Children with nephrotic syndrome (NS) are usually treated with long-term low dose alternate day prednisolone with or without glucocorticoid sparing therapy, such as levamisole or ciclosporin, to maintain remission.', 'subject score': 830, 'object score': 1000}, 'PMID:17995584': {'publication date': '2007 Dec', 'sentence': 'CONCLUSION: Data from this pilot study indicate that more than 60% of patients with MN and nephrotic syndrome respond to combined MMF and prednisolone treatment, and suggest potential benefits of MMF as being steroid-sparing and having less adverse effects compared with other commonly used cytotoxic agents.', 'subject score': 888, 'object score': 1000}, 'PMID:18186228': {'publication date': '2007', 'sentence': 'Administration of prednisolone or cyclosporine improved the nephrotic syndrome, leading all patients to a complete or almost complete remission.', 'subject score': 1000, 'object score': 1000}, 'PMID:18367765': {'publication date': '2008 Mar', 'sentence': 'It is proposed that patients with frequently relapsing nephrotic syndrome should, at the first instance, be treated with long-term, alternate-day prednisolone.', 'subject score': 849, 'object score': 1000}, 'PMID:18387858': {'publication date': '2008 Jul 15', 'sentence': 'The unbound concentrations of prednisolone were measured in 10 patients with nephrotic syndrome, two patients with systemic lupus erythematosus, and one patient with dermatomyositis by examining protein bindings of prednisolone on one or more occasions during prednisolone treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:19212916': {'publication date': '2009', 'sentence': \"She was completely recovered from nephrotic syndrome after two years' treatment with prednisolone, aspirin, and dimethyl sulfoxide.\", 'subject score': 1000, 'object score': 1000}, 'PMID:21426894': {'publication date': '2011 Apr', 'sentence': 'Cyclosporin A in combination with prednisolone was given in 3 patients with HSP nephritis and nephrotic syndrome after a course of other immunosuppressive drugs and in 2 patients as initial treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:21454171': {'publication date': '2011 Apr', 'sentence': 'It is concluded that rational use of steroid (prednisolone) has a very effective role in the prevention and control of nephrotic syndrome either at initial stage or in complicated cases.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 319059,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005377",
-          "name": "nephrotic syndrome",
-          "description": "Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. [HPO:probinson]; Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. // COMMENTS: In adults, nephrotic syndrome is characterized by protein excretion of 3.5 g or more per day. In children, nephrotic syndrome is accompanied by protein excretion of more than 40 mg/m2/h and hypalbuminemia < 2.5 mg/dl.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10042826",
-            "MESH:D009404",
-            "HP:0000100",
-            "UMLS:C0027726",
-            "MONDO:0005377",
-            "EFO:0004255",
-            "MEDDRA:10029164",
-            "SNOMEDCT:52254009",
-            "NCIT:C34845",
-            "DOID:1184",
-            "ICD9:581"
-          ],
-          "id": "MONDO:0005377",
-          "category": "biolink:Disease",
-          "all_names": [
-            "nephrotic syndrome",
-            "Nephrotic Syndrome",
-            "Nephrotic syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://en.wikipedia.org/wiki/nephrotic_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319059,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005377",
-              "name": "nephrotic syndrome",
-              "description": "Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. [HPO:probinson]; Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. // COMMENTS: In adults, nephrotic syndrome is characterized by protein excretion of 3.5 g or more per day. In children, nephrotic syndrome is accompanied by protein excretion of more than 40 mg/m2/h and hypalbuminemia < 2.5 mg/dl.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10042826",
-                "MESH:D009404",
-                "HP:0000100",
-                "UMLS:C0027726",
-                "MONDO:0005377",
-                "EFO:0004255",
-                "MEDDRA:10029164",
-                "SNOMEDCT:52254009",
-                "NCIT:C34845",
-                "DOID:1184",
-                "ICD9:581"
-              ],
-              "id": "MONDO:0005377",
-              "category": "biolink:Disease",
-              "all_names": [
-                "nephrotic syndrome",
-                "Nephrotic Syndrome",
-                "Nephrotic syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://en.wikipedia.org/wiki/nephrotic_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7762935,
-            "start": 568,
-            "end": 319059,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10634026': {'publication date': '1999 Dec', 'sentence': 'The second patient, a 73-year-old man receiving prednisolone therapy for nephrotic syndrome, developed right leg cellulitis that evolved to NF.', 'subject score': 763, 'object score': 1000}, 'PMID:10972687': {'publication date': '2000 Sep', 'sentence': 'There has been no study on prednisolone dosage for the effective treatment of nephrotic syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:11503553': {'publication date': '2001 Jul', 'sentence': 'The second patient had his relapses of nephrotic syndrome over a period of 10 years when treated with prednisolone and cyclophosphamide.', 'subject score': 1000, 'object score': 1000}, 'PMID:11510096': {'publication date': '2001 May', 'sentence': 'A 70-year-old man treated for 6 months with prednisolone for nephrotic syndrome, was referred to our pulmonary division because of a nodule in the right lower lung field.', 'subject score': 1000, 'object score': 1000}, 'PMID:11867955': {'publication date': '2002 Mar', 'sentence': 'After 5 courses of therapy with melphalan and prednisolone which failed to improve the nephrotic syndrome or her general clinical condition, and 1 year after the diagnosis of renal amyloidosis, surgical excision of the abdominal mass was performed.', 'subject score': 1000, 'object score': 1000}, 'PMID:12428401': {'publication date': '2002 Aug', 'sentence': 'The patient was a 56-year-old man who had received diagnoses of psoriasis vulgaris at the age of thirty-three and of nephrotic syndrome at forty-five, and had been treated with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:14700154': {'publication date': '2003 Aug', 'sentence': 'Resection of the ileum and appendectomy were performed while the relapsing nephrotic syndrome was treated by prednisolone.', 'subject score': 1000, 'object score': 901}, 'PMID:14964453': {'publication date': '2004 Jan', 'sentence': 'PATIENTS AND METHODS: Sixteen patients, with nephrotic syndrome due to IMN and well-preserved renal function, were treated with prednisolone (starting dose: 0.5 mg/kg bw/day) and CsA (starting dose: 3 mg/kg bw/day) for 24 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:14964576': {'publication date': '2004 Jan', 'sentence': 'We examined outcomes of a short course of cyclophosphamide alternating with prednisolone for MN patients with nephrotic syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:1600282': {'publication date': '1992 Feb', 'sentence': 'NS responded to prednisolone therapy initially and at the time of the relapse.', 'subject score': 851, 'object score': 1000}, 'PMID:16848751': {'publication date': '2006 Jul', 'sentence': 'Small doses of CsA with prednisolone are effective in the treatment of nephrotic syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:17009081': {'publication date': '2006 Sep', 'sentence': 'The nephrotic syndrome was treated successfully with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:17284479': {'publication date': '2007 Jul', 'sentence': 'OBJECTIVE: Children with nephrotic syndrome (NS) are usually treated with long-term low dose alternate day prednisolone with or without glucocorticoid sparing therapy, such as levamisole or ciclosporin, to maintain remission.', 'subject score': 830, 'object score': 1000}, 'PMID:17995584': {'publication date': '2007 Dec', 'sentence': 'CONCLUSION: Data from this pilot study indicate that more than 60% of patients with MN and nephrotic syndrome respond to combined MMF and prednisolone treatment, and suggest potential benefits of MMF as being steroid-sparing and having less adverse effects compared with other commonly used cytotoxic agents.', 'subject score': 888, 'object score': 1000}, 'PMID:18186228': {'publication date': '2007', 'sentence': 'Administration of prednisolone or cyclosporine improved the nephrotic syndrome, leading all patients to a complete or almost complete remission.', 'subject score': 1000, 'object score': 1000}, 'PMID:18367765': {'publication date': '2008 Mar', 'sentence': 'It is proposed that patients with frequently relapsing nephrotic syndrome should, at the first instance, be treated with long-term, alternate-day prednisolone.', 'subject score': 849, 'object score': 1000}, 'PMID:18387858': {'publication date': '2008 Jul 15', 'sentence': 'The unbound concentrations of prednisolone were measured in 10 patients with nephrotic syndrome, two patients with systemic lupus erythematosus, and one patient with dermatomyositis by examining protein bindings of prednisolone on one or more occasions during prednisolone treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:19212916': {'publication date': '2009', 'sentence': \"She was completely recovered from nephrotic syndrome after two years' treatment with prednisolone, aspirin, and dimethyl sulfoxide.\", 'subject score': 1000, 'object score': 1000}, 'PMID:21426894': {'publication date': '2011 Apr', 'sentence': 'Cyclosporin A in combination with prednisolone was given in 3 patients with HSP nephritis and nephrotic syndrome after a course of other immunosuppressive drugs and in 2 patients as initial treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:21454171': {'publication date': '2011 Apr', 'sentence': 'It is concluded that rational use of steroid (prednisolone) has a very effective role in the prevention and control of nephrotic syndrome either at initial stage or in complicated cases.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0027726---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7927983",
-              "object": "MONDO:0005377",
-              "publications": [
-                "PMID:10634026",
-                "PMID:10972687",
-                "PMID:11503553",
-                "PMID:11510096",
-                "PMID:11867955",
-                "PMID:12428401",
-                "PMID:14700154",
-                "PMID:14964453",
-                "PMID:14964576",
-                "PMID:1600282",
-                "PMID:16848751",
-                "PMID:17009081",
-                "PMID:17284479",
-                "PMID:17995584",
-                "PMID:18186228",
-                "PMID:18367765",
-                "PMID:18387858",
-                "PMID:19212916",
-                "PMID:21426894",
-                "PMID:21454171"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:6896620': {'publication date': '1981 Dec', 'sentence': 'A short trial with high doses of prednisolone to treat a 62 year-old woman with malignant ophthalmopathy due to Graves disease yielded an unsatisfactory improvement after 5-6 days.', 'subject score': 1000, 'object score': 861}, 'PMID:8000111': {'publication date': '1994 Sep', 'sentence': 'Ophthalmopathy was aggravated in spite of prednisolone therapy and euthyroidism being maintained by thyroxine replacement.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 308745,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005328",
-          "name": "eye disorder",
-          "description": "Diseases or defects of the eye. Use VISION DISORDERS for other pathology involving visual neural pathways.; A non-neoplastic or neoplastic disorder that affects the eye. Representative examples include conjunctivitis, glaucoma, cataract, conjunctival squamous cell carcinoma, uveal melanoma, and retinoblastoma.; Diseases affecting the eye.; Any abnormality of the eye, including location, spacing, and intraocular abnormalities. [HPO:probinson]; Some eye problems are minor and don't last long. But some can lead to a permanent loss of vision. Common eye problems include: Refractive errors Cataracts - clouded lenses Optic nerve disorders, including glaucoma Retinal disorders - problems with the nerve layer at the back of the eye Macular degeneration - a disease that destroys sharp, central vision Diabetic eye problems Conjunctivitis - an infection also known as pink eye  Your best defense is to have regular checkups, because eye diseases do not always have symptoms. Early detection and treatment could prevent vision loss. See an eye care professional right away if you have a sudden change in vision, if everything looks dim, or if you see flashes of light. Other symptoms that need quick attention are pain, double vision, fluid coming from the eye, and inflammation. NIH: National Eye Institute ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0015397",
-            "NCIT:C26767",
-            "MEDDRA:10045783",
-            "MEDDRA:10013221",
-            "MEDDRA:10015919",
-            "MEDDRA:10054716",
-            "ICD9:360.29",
-            "MESH:D005128",
-            "EFO:0003966",
-            "MEDDRA:10015916",
-            "MEDDRA:10059159",
-            "UMLS:C0015393",
-            "ICD10:H44",
-            "MEDDRA:10045790",
-            "HP:0000478",
-            "SNOMEDCT:19416009",
-            "MEDDRA:10015913",
-            "MEDDRA:10030874",
-            "NCIT:C98887",
-            "MEDDRA:10010435",
-            "MEDDRA:10010462",
-            "MEDDRA:10015949",
-            "UMLS:C4316870",
-            "MEDDRA:10015904",
-            "MESH:D005124",
-            "MEDDRA:10015920",
-            "MEDDRA:10015903",
-            "MEDDRA:10015918",
-            "MONDO:0005328",
-            "SNOMEDCT:371405004",
-            "ICD9:379.90",
-            "DOID:5614",
-            "UMLS:C0154780",
-            "DOID:1242",
-            "MEDDRA:10045628",
-            "ICD10:H44.39"
-          ],
-          "id": "MONDO:0005328",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Disorder of eye, unspecified",
-            "Eye Abnormalities",
-            "Other degenerative disorders of globe",
-            "eye disease",
-            "Congenital Eye Disorder",
-            "globe disease",
-            "Disorder of eye",
-            "Abnormality of the eye",
-            "eye disorder",
-            "Eye Diseases",
-            "Eye Disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/eye_disease",
-            "https://en.wikipedia.org/wiki/globe_(human_eye)",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-5316-1399"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308745,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005328",
-              "name": "eye disorder",
-              "description": "Diseases or defects of the eye. Use VISION DISORDERS for other pathology involving visual neural pathways.; A non-neoplastic or neoplastic disorder that affects the eye. Representative examples include conjunctivitis, glaucoma, cataract, conjunctival squamous cell carcinoma, uveal melanoma, and retinoblastoma.; Diseases affecting the eye.; Any abnormality of the eye, including location, spacing, and intraocular abnormalities. [HPO:probinson]; Some eye problems are minor and don't last long. But some can lead to a permanent loss of vision. Common eye problems include: Refractive errors Cataracts - clouded lenses Optic nerve disorders, including glaucoma Retinal disorders - problems with the nerve layer at the back of the eye Macular degeneration - a disease that destroys sharp, central vision Diabetic eye problems Conjunctivitis - an infection also known as pink eye  Your best defense is to have regular checkups, because eye diseases do not always have symptoms. Early detection and treatment could prevent vision loss. See an eye care professional right away if you have a sudden change in vision, if everything looks dim, or if you see flashes of light. Other symptoms that need quick attention are pain, double vision, fluid coming from the eye, and inflammation. NIH: National Eye Institute ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0015397",
-                "NCIT:C26767",
-                "MEDDRA:10045783",
-                "MEDDRA:10013221",
-                "MEDDRA:10015919",
-                "MEDDRA:10054716",
-                "ICD9:360.29",
-                "MESH:D005128",
-                "EFO:0003966",
-                "MEDDRA:10015916",
-                "MEDDRA:10059159",
-                "UMLS:C0015393",
-                "ICD10:H44",
-                "MEDDRA:10045790",
-                "HP:0000478",
-                "SNOMEDCT:19416009",
-                "MEDDRA:10015913",
-                "MEDDRA:10030874",
-                "NCIT:C98887",
-                "MEDDRA:10010435",
-                "MEDDRA:10010462",
-                "MEDDRA:10015949",
-                "UMLS:C4316870",
-                "MEDDRA:10015904",
-                "MESH:D005124",
-                "MEDDRA:10015920",
-                "MEDDRA:10015903",
-                "MEDDRA:10015918",
-                "MONDO:0005328",
-                "SNOMEDCT:371405004",
-                "ICD9:379.90",
-                "DOID:5614",
-                "UMLS:C0154780",
-                "DOID:1242",
-                "MEDDRA:10045628",
-                "ICD10:H44.39"
-              ],
-              "id": "MONDO:0005328",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Disorder of eye, unspecified",
-                "Eye Abnormalities",
-                "Other degenerative disorders of globe",
-                "eye disease",
-                "Congenital Eye Disorder",
-                "globe disease",
-                "Disorder of eye",
-                "Abnormality of the eye",
-                "eye disorder",
-                "Eye Diseases",
-                "Eye Disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/eye_disease",
-                "https://en.wikipedia.org/wiki/globe_(human_eye)",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-5316-1399"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25849016,
-            "start": 568,
-            "end": 308745,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:6896620': {'publication date': '1981 Dec', 'sentence': 'A short trial with high doses of prednisolone to treat a 62 year-old woman with malignant ophthalmopathy due to Graves disease yielded an unsatisfactory improvement after 5-6 days.', 'subject score': 1000, 'object score': 861}, 'PMID:8000111': {'publication date': '1994 Sep', 'sentence': 'Ophthalmopathy was aggravated in spite of prednisolone therapy and euthyroidism being maintained by thyroxine replacement.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0015397---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "26307899",
-              "object": "MONDO:0005328",
-              "publications": [
-                "PMID:6896620",
-                "PMID:8000111"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:34866072': {'publication date': '2021 Dec 06', 'sentence': 'Prednisolone was initially used alone as an alternative treatment for CEL.', 'subject score': 1000, 'object score': 1000}, 'PMID:3658820': {'publication date': '1987 Apr', 'sentence': 'Treatment of light-sensitive mycosis fungoides with PUVA and prednisolone.', 'subject score': 1000, 'object score': 865}}",
-    "p2": {
-      "start": {
-        "identity": 535036,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009691",
-          "name": "mycosis fungoides",
-          "description": "A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei. Patients with limited disease generally have an excellent prognosis. In the more advanced stages, the prognosis is poor. (WHO, 2001); A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MESH:D009182",
-            "MEDDRA:10028483",
-            "MONDO:0009691",
-            "UMLS:C0026948",
-            "SNOMEDCT:90120004",
-            "NCIT:C3246",
-            "ICD9:202.1",
-            "OMIM:254400",
-            "ORPHANET:2584",
-            "MEDDRA:10028484",
-            "ICD10:C84.0",
-            "DOID:8691",
-            "EFO:1001051",
-            "MEDDRA:10028500",
-            "SNOMEDCT:118618005"
-          ],
-          "id": "MONDO:0009691",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Mycosis fungoides",
-            "Mycosis fungoides related phenotypic feature",
-            "Classic mycosis fungoides",
-            "mycosis fungoides",
-            "Mycosis Fungoides"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 535036,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009691",
-              "name": "mycosis fungoides",
-              "description": "A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei. Patients with limited disease generally have an excellent prognosis. In the more advanced stages, the prognosis is poor. (WHO, 2001); A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MESH:D009182",
-                "MEDDRA:10028483",
-                "MONDO:0009691",
-                "UMLS:C0026948",
-                "SNOMEDCT:90120004",
-                "NCIT:C3246",
-                "ICD9:202.1",
-                "OMIM:254400",
-                "ORPHANET:2584",
-                "MEDDRA:10028484",
-                "ICD10:C84.0",
-                "DOID:8691",
-                "EFO:1001051",
-                "MEDDRA:10028500",
-                "SNOMEDCT:118618005"
-              ],
-              "id": "MONDO:0009691",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Mycosis fungoides",
-                "Mycosis fungoides related phenotypic feature",
-                "Classic mycosis fungoides",
-                "mycosis fungoides",
-                "Mycosis Fungoides"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23543736,
-            "start": 568,
-            "end": 535036,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34866072': {'publication date': '2021 Dec 06', 'sentence': 'Prednisolone was initially used alone as an alternative treatment for CEL.', 'subject score': 1000, 'object score': 1000}, 'PMID:3658820': {'publication date': '1987 Apr', 'sentence': 'Treatment of light-sensitive mycosis fungoides with PUVA and prednisolone.', 'subject score': 1000, 'object score': 865}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0026948---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "23981131",
-              "object": "MONDO:0009691",
-              "publications": [
-                "PMID:34866072",
-                "PMID:3658820"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15109274': {'publication date': '2004', 'sentence': 'It has also been used in combination with other drugs for treating a number of dermatologic disorders, e.g. in combination with cimetidine for treating recalcitrant warts, with prednisolone for treating lichen planus, erythema multiforme and aphthous ulcers of the mouth.', 'subject score': 1000, 'object score': 1000}, 'PMID:9798228': {'publication date': '1998 Oct', 'sentence': 'CONCLUSIONS: The addition of levamisole to prednisolone may produce improved results in the management of erosive lichen planus, erythema multiforme, mucous membrane pemphigoid, and early pemphigus vulgaris.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 524787,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006545",
-          "name": "erythema multiforme",
-          "description": "A hypersensitivity reaction characterized by the sudden appearance of symmetrical cutaneous and mucocutaneous macular or papular lesions which evolve into lesions with bright red borders (target lesions). The lesions usually appear in the hands, feet, extremities, and face. Symptoms include fever, malaise, sore throat, cough, vomiting, diarrhea, arthralgia, and myalgia. Causes include infections (most commonly herpes simplex virus), drugs (e.g., sulfonamides, anticonvulsants, and antibiotics), malignancies, and collagen vascular disorders.; A skin and mucous membrane disease characterized by an eruption of macules, papules, nodules, vesicles, and/or bullae with characteristic \"bull's-eye\" lesions usually occurring on the dorsal aspect of the hands and forearms.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:1000694",
-            "NCIT:C3024",
-            "MESH:D004892",
-            "SNOMEDCT:36715001",
-            "UMLS:C0014742",
-            "ICD9:695.1",
-            "DOID:0050185",
-            "MEDDRA:10057866",
-            "MEDDRA:10015218",
-            "MEDDRA:10057783",
-            "MONDO:0006545"
-          ],
-          "id": "MONDO:0006545",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Erythema multiforme",
-            "erythema multiforme",
-            "Erythema Multiforme"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000851.htm",
-            "https://rarediseases.info.nih.gov/diseases/6372/erythema-multiforme"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 524787,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006545",
-              "name": "erythema multiforme",
-              "description": "A hypersensitivity reaction characterized by the sudden appearance of symmetrical cutaneous and mucocutaneous macular or papular lesions which evolve into lesions with bright red borders (target lesions). The lesions usually appear in the hands, feet, extremities, and face. Symptoms include fever, malaise, sore throat, cough, vomiting, diarrhea, arthralgia, and myalgia. Causes include infections (most commonly herpes simplex virus), drugs (e.g., sulfonamides, anticonvulsants, and antibiotics), malignancies, and collagen vascular disorders.; A skin and mucous membrane disease characterized by an eruption of macules, papules, nodules, vesicles, and/or bullae with characteristic \"bull's-eye\" lesions usually occurring on the dorsal aspect of the hands and forearms.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:1000694",
-                "NCIT:C3024",
-                "MESH:D004892",
-                "SNOMEDCT:36715001",
-                "UMLS:C0014742",
-                "ICD9:695.1",
-                "DOID:0050185",
-                "MEDDRA:10057866",
-                "MEDDRA:10015218",
-                "MEDDRA:10057783",
-                "MONDO:0006545"
-              ],
-              "id": "MONDO:0006545",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Erythema multiforme",
-                "erythema multiforme",
-                "Erythema Multiforme"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000851.htm",
-                "https://rarediseases.info.nih.gov/diseases/6372/erythema-multiforme"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10927137,
-            "start": 568,
-            "end": 524787,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15109274': {'publication date': '2004', 'sentence': 'It has also been used in combination with other drugs for treating a number of dermatologic disorders, e.g. in combination with cimetidine for treating recalcitrant warts, with prednisolone for treating lichen planus, erythema multiforme and aphthous ulcers of the mouth.', 'subject score': 1000, 'object score': 1000}, 'PMID:9798228': {'publication date': '1998 Oct', 'sentence': 'CONCLUSIONS: The addition of levamisole to prednisolone may produce improved results in the management of erosive lichen planus, erythema multiforme, mucous membrane pemphigoid, and early pemphigus vulgaris.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0014742---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11166361",
-              "object": "MONDO:0006545",
-              "publications": [
-                "PMID:15109274",
-                "PMID:9798228"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:13546582': {'publication date': '1958 Jun', 'sentence': 'Peptic ulceration associated with prednisolone therapy.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316638,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-          "name": "peptic ulcer disease",
-          "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10018053",
-            "MEDDRA:10045305",
-            "MESH:D010437",
-            "MONDO:0004247",
-            "DOID:750",
-            "UMLS:C0030920",
-            "MEDDRA:10017886",
-            "MEDDRA:10045342",
-            "ICD9:533",
-            "ICD10:K27",
-            "HP:0004398",
-            "MEDDRA:10034343",
-            "MEDDRA:10034360",
-            "MEDDRA:10045328",
-            "MEDDRA:10042834",
-            "MEDDRA:10034341",
-            "MEDDRA:10034367",
-            "MEDDRA:10037287",
-            "NCIT:C3318",
-            "SNOMEDCT:13200003",
-            "MEDDRA:10034369"
-          ],
-          "id": "MONDO:0004247",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peptic ulcer, site unspecified",
-            "Peptic Ulcer",
-            "peptic ulcer disease",
-            "Peptic ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28242110",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316638,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-              "name": "peptic ulcer disease",
-              "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10018053",
-                "MEDDRA:10045305",
-                "MESH:D010437",
-                "MONDO:0004247",
-                "DOID:750",
-                "UMLS:C0030920",
-                "MEDDRA:10017886",
-                "MEDDRA:10045342",
-                "ICD9:533",
-                "ICD10:K27",
-                "HP:0004398",
-                "MEDDRA:10034343",
-                "MEDDRA:10034360",
-                "MEDDRA:10045328",
-                "MEDDRA:10042834",
-                "MEDDRA:10034341",
-                "MEDDRA:10034367",
-                "MEDDRA:10037287",
-                "NCIT:C3318",
-                "SNOMEDCT:13200003",
-                "MEDDRA:10034369"
-              ],
-              "id": "MONDO:0004247",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peptic ulcer, site unspecified",
-                "Peptic Ulcer",
-                "peptic ulcer disease",
-                "Peptic ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28242110",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10327816,
-            "start": 568,
-            "end": 316638,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13546582': {'publication date': '1958 Jun', 'sentence': 'Peptic ulceration associated with prednisolone therapy.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:affects---None---None---None---UMLS:C0030920---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10555139",
-              "object": "MONDO:0004247",
-              "publications": [
-                "PMID:13546582"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:13555798': {'publication date': '1958', 'sentence': 'On the development of peptic ulcers in patients treated with prednisone or prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:14487928': {'publication date': '1962 Jul', 'sentence': '[The pathogenesis of peptic ulcer of the duodenum during prednisolone therapy].', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316638,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-          "name": "peptic ulcer disease",
-          "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10018053",
-            "MEDDRA:10045305",
-            "MESH:D010437",
-            "MONDO:0004247",
-            "DOID:750",
-            "UMLS:C0030920",
-            "MEDDRA:10017886",
-            "MEDDRA:10045342",
-            "ICD9:533",
-            "ICD10:K27",
-            "HP:0004398",
-            "MEDDRA:10034343",
-            "MEDDRA:10034360",
-            "MEDDRA:10045328",
-            "MEDDRA:10042834",
-            "MEDDRA:10034341",
-            "MEDDRA:10034367",
-            "MEDDRA:10037287",
-            "NCIT:C3318",
-            "SNOMEDCT:13200003",
-            "MEDDRA:10034369"
-          ],
-          "id": "MONDO:0004247",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peptic ulcer, site unspecified",
-            "Peptic Ulcer",
-            "peptic ulcer disease",
-            "Peptic ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28242110",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316638,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-              "name": "peptic ulcer disease",
-              "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10018053",
-                "MEDDRA:10045305",
-                "MESH:D010437",
-                "MONDO:0004247",
-                "DOID:750",
-                "UMLS:C0030920",
-                "MEDDRA:10017886",
-                "MEDDRA:10045342",
-                "ICD9:533",
-                "ICD10:K27",
-                "HP:0004398",
-                "MEDDRA:10034343",
-                "MEDDRA:10034360",
-                "MEDDRA:10045328",
-                "MEDDRA:10042834",
-                "MEDDRA:10034341",
-                "MEDDRA:10034367",
-                "MEDDRA:10037287",
-                "NCIT:C3318",
-                "SNOMEDCT:13200003",
-                "MEDDRA:10034369"
-              ],
-              "id": "MONDO:0004247",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peptic ulcer, site unspecified",
-                "Peptic Ulcer",
-                "peptic ulcer disease",
-                "Peptic ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28242110",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10329865,
-            "start": 568,
-            "end": 316638,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13555798': {'publication date': '1958', 'sentence': 'On the development of peptic ulcers in patients treated with prednisone or prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:14487928': {'publication date': '1962 Jul', 'sentence': '[The pathogenesis of peptic ulcer of the duodenum during prednisolone therapy].', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0030920---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10557390",
-              "object": "MONDO:0004247",
-              "publications": [
-                "PMID:13555798",
-                "PMID:14487928"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:5738852': {'publication date': '1968 Mar', 'sentence': '[\"Abolishment\" syndrome in prednisolone treatment of patients with sympathetic ophthalmia].', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 529246,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019198",
-          "name": "sympathetic ophthalmia",
-          "description": "Granulomatous uveitis which follows in one eye after a penetrating injury to the other eye; the secondarily affected eye is called the sympathizing eye, and the injured eye is called the exciting or activating eye.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD9:360.11",
-            "UMLS:C0029077",
-            "MONDO:0019198",
-            "MESH:D009879",
-            "ORPHANET:79098",
-            "DOID:12029",
-            "MEDDRA:10042745",
-            "ICD10:H44.13",
-            "MEDDRA:10042743",
-            "EFO:1001205",
-            "MEDDRA:10042742",
-            "SNOMEDCT:75315001"
-          ],
-          "id": "MONDO:0019198",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Sympathetic ophthalmia",
-            "Sympathetic uveitis",
-            "sympathetic ophthalmia",
-            "Ophthalmia, Sympathetic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3277011/",
-            "http://eyewiki.aao.org/sympathetic_ophthalmia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 529246,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019198",
-              "name": "sympathetic ophthalmia",
-              "description": "Granulomatous uveitis which follows in one eye after a penetrating injury to the other eye; the secondarily affected eye is called the sympathizing eye, and the injured eye is called the exciting or activating eye.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD9:360.11",
-                "UMLS:C0029077",
-                "MONDO:0019198",
-                "MESH:D009879",
-                "ORPHANET:79098",
-                "DOID:12029",
-                "MEDDRA:10042745",
-                "ICD10:H44.13",
-                "MEDDRA:10042743",
-                "EFO:1001205",
-                "MEDDRA:10042742",
-                "SNOMEDCT:75315001"
-              ],
-              "id": "MONDO:0019198",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Sympathetic ophthalmia",
-                "Sympathetic uveitis",
-                "sympathetic ophthalmia",
-                "Ophthalmia, Sympathetic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3277011/",
-                "http://eyewiki.aao.org/sympathetic_ophthalmia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25488064,
-            "start": 568,
-            "end": 529246,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:5738852': {'publication date': '1968 Mar', 'sentence': '[\"Abolishment\" syndrome in prednisolone treatment of patients with sympathetic ophthalmia].', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0029077---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "25942811",
-              "object": "MONDO:0019198",
-              "publications": [
-                "PMID:5738852"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:10094169': {'publication date': '1999 Jan', 'sentence': 'OBJECTIVE: To appraise the adjunctive role of prednisolone (PN) in pulmonary tuberculosis (PTB) with toxic reactions.', 'subject score': 1000, 'object score': 1000}, 'PMID:13348299': {'publication date': '1956 Jun 06', 'sentence': '[Prednisone and prednisolone, anti-reactive elective drugs in pulmonary tuberculosis].', 'subject score': 1000, 'object score': 1000}, 'PMID:13672639': {'publication date': '1959 Jun', 'sentence': 'Prednisolone in pulmonary tuberculosis; case report.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 310720,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006052",
-          "name": "pulmonary tuberculosis",
-          "description": "A bacterial infection that affects the lungs and is caused by Mycobacterium tuberculosis. Most patients with tuberculosis do not have symptoms (latent tuberculosis) and are not contagious. When signs and symptoms occur (active tuberculosis), patients become contagious. The signs and symptoms include chronic cough with blood-tinged sputum, night sweats, fever, fatigue, and weight loss.; MYCOBACTERIUM infections of the lung.; A lung infection by Mycobacterium tuberculosis a slightly curved non-motile, aerobic, non-capsulated and non-spore forming strains of mycobacteria. [PMID:30345099]",
-          "equivalent_curies": [
-            "MONDO:0006052",
-            "MEDDRA:10046123",
-            "PSY:42300",
-            "ICD9:011",
-            "MEDDRA:10034980",
-            "SNOMEDCT:154283005",
-            "DOID:2957",
-            "SNOMEDCT:700272008",
-            "NCIT:C26899",
-            "EFO:1000049",
-            "MEDDRA:10037443",
-            "HP:0032262",
-            "MESH:D014397",
-            "ICD10:A15",
-            "UMLS:C0041327",
-            "MEDDRA:10037435",
-            "MEDDRA:10037440"
-          ],
-          "id": "MONDO:0006052",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Tuberculosis, Pulmonary",
-            "pulmonary tuberculosis",
-            "Pulmonary Tuberculosis",
-            "Pulmonary tuberculosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:30345099",
-            "http://www.cdc.gov/tb/publications/factsheets/general/tb.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tuberculosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310720,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006052",
-              "name": "pulmonary tuberculosis",
-              "description": "A bacterial infection that affects the lungs and is caused by Mycobacterium tuberculosis. Most patients with tuberculosis do not have symptoms (latent tuberculosis) and are not contagious. When signs and symptoms occur (active tuberculosis), patients become contagious. The signs and symptoms include chronic cough with blood-tinged sputum, night sweats, fever, fatigue, and weight loss.; MYCOBACTERIUM infections of the lung.; A lung infection by Mycobacterium tuberculosis a slightly curved non-motile, aerobic, non-capsulated and non-spore forming strains of mycobacteria. [PMID:30345099]",
-              "equivalent_curies": [
-                "MONDO:0006052",
-                "MEDDRA:10046123",
-                "PSY:42300",
-                "ICD9:011",
-                "MEDDRA:10034980",
-                "SNOMEDCT:154283005",
-                "DOID:2957",
-                "SNOMEDCT:700272008",
-                "NCIT:C26899",
-                "EFO:1000049",
-                "MEDDRA:10037443",
-                "HP:0032262",
-                "MESH:D014397",
-                "ICD10:A15",
-                "UMLS:C0041327",
-                "MEDDRA:10037435",
-                "MEDDRA:10037440"
-              ],
-              "id": "MONDO:0006052",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Tuberculosis, Pulmonary",
-                "pulmonary tuberculosis",
-                "Pulmonary Tuberculosis",
-                "Pulmonary tuberculosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:30345099",
-                "http://www.cdc.gov/tb/publications/factsheets/general/tb.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tuberculosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7065400,
-            "start": 568,
-            "end": 310720,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10094169': {'publication date': '1999 Jan', 'sentence': 'OBJECTIVE: To appraise the adjunctive role of prednisolone (PN) in pulmonary tuberculosis (PTB) with toxic reactions.', 'subject score': 1000, 'object score': 1000}, 'PMID:13348299': {'publication date': '1956 Jun 06', 'sentence': '[Prednisone and prednisolone, anti-reactive elective drugs in pulmonary tuberculosis].', 'subject score': 1000, 'object score': 1000}, 'PMID:13672639': {'publication date': '1959 Jun', 'sentence': 'Prednisolone in pulmonary tuberculosis; case report.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:associated_with---None---None---None---UMLS:C0041327---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "7206314",
-              "object": "MONDO:0006052",
-              "publications": [
-                "PMID:10094169",
-                "PMID:13348299",
-                "PMID:13672639"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:13507005': {'publication date': '1957 Nov 22', 'sentence': '[Pulmonary tuberculosis due to prednisolone].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 310720,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006052",
-          "name": "pulmonary tuberculosis",
-          "description": "A bacterial infection that affects the lungs and is caused by Mycobacterium tuberculosis. Most patients with tuberculosis do not have symptoms (latent tuberculosis) and are not contagious. When signs and symptoms occur (active tuberculosis), patients become contagious. The signs and symptoms include chronic cough with blood-tinged sputum, night sweats, fever, fatigue, and weight loss.; MYCOBACTERIUM infections of the lung.; A lung infection by Mycobacterium tuberculosis a slightly curved non-motile, aerobic, non-capsulated and non-spore forming strains of mycobacteria. [PMID:30345099]",
-          "equivalent_curies": [
-            "MONDO:0006052",
-            "MEDDRA:10046123",
-            "PSY:42300",
-            "ICD9:011",
-            "MEDDRA:10034980",
-            "SNOMEDCT:154283005",
-            "DOID:2957",
-            "SNOMEDCT:700272008",
-            "NCIT:C26899",
-            "EFO:1000049",
-            "MEDDRA:10037443",
-            "HP:0032262",
-            "MESH:D014397",
-            "ICD10:A15",
-            "UMLS:C0041327",
-            "MEDDRA:10037435",
-            "MEDDRA:10037440"
-          ],
-          "id": "MONDO:0006052",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Tuberculosis, Pulmonary",
-            "pulmonary tuberculosis",
-            "Pulmonary Tuberculosis",
-            "Pulmonary tuberculosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:30345099",
-            "http://www.cdc.gov/tb/publications/factsheets/general/tb.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tuberculosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310720,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006052",
-              "name": "pulmonary tuberculosis",
-              "description": "A bacterial infection that affects the lungs and is caused by Mycobacterium tuberculosis. Most patients with tuberculosis do not have symptoms (latent tuberculosis) and are not contagious. When signs and symptoms occur (active tuberculosis), patients become contagious. The signs and symptoms include chronic cough with blood-tinged sputum, night sweats, fever, fatigue, and weight loss.; MYCOBACTERIUM infections of the lung.; A lung infection by Mycobacterium tuberculosis a slightly curved non-motile, aerobic, non-capsulated and non-spore forming strains of mycobacteria. [PMID:30345099]",
-              "equivalent_curies": [
-                "MONDO:0006052",
-                "MEDDRA:10046123",
-                "PSY:42300",
-                "ICD9:011",
-                "MEDDRA:10034980",
-                "SNOMEDCT:154283005",
-                "DOID:2957",
-                "SNOMEDCT:700272008",
-                "NCIT:C26899",
-                "EFO:1000049",
-                "MEDDRA:10037443",
-                "HP:0032262",
-                "MESH:D014397",
-                "ICD10:A15",
-                "UMLS:C0041327",
-                "MEDDRA:10037435",
-                "MEDDRA:10037440"
-              ],
-              "id": "MONDO:0006052",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Tuberculosis, Pulmonary",
-                "pulmonary tuberculosis",
-                "Pulmonary Tuberculosis",
-                "Pulmonary tuberculosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:30345099",
-                "http://www.cdc.gov/tb/publications/factsheets/general/tb.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tuberculosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10318497,
-            "start": 568,
-            "end": 310720,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13507005': {'publication date': '1957 Nov 22', 'sentence': '[Pulmonary tuberculosis due to prednisolone].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:causes---None---None---None---UMLS:C0041327---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10545904",
-              "object": "MONDO:0006052",
-              "publications": [
-                "PMID:13507005"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11155703': {'publication date': '2000 Oct', 'sentence': 'However, he died because of lung tuberculosis and acute tuberculous pericarditis during treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:13402557': {'publication date': '1956 Dec', 'sentence': '[Comparative study of the results of tuberculostatic agents with and without prednisolone in therapy of common phthisis].', 'subject score': 1000, 'object score': 888}, 'PMID:13468536': {'publication date': '1957 Jul', 'sentence': '[Supportive use of cortisone and prednisolone during tuberculostatic therapy of pulmonary tuberculosis].', 'subject score': 1000, 'object score': 1000}, 'PMID:13472066': {'publication date': '1957 Nov 16', 'sentence': 'PREDNISOLONE in the treatment of pulmonary tuberculosis: a controlled trial; a preliminary report by the Research Committee of the Tuberculosis Society of Scotland.', 'subject score': 1000, 'object score': 1000}, 'PMID:13715890': {'publication date': '1960 Dec 17', 'sentence': 'Prednisolone in treatment of pulmonary tuberculosis: a controlled trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:13856608': {'publication date': '1960 Apr', 'sentence': 'PRELIMINARY observations from a controlled trail of prednisolone in the treatment of pulmonary tuberculosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:14264779': {'publication date': '1965 Mar', 'sentence': 'PREDNISOLONE IN THE TREATMENT OF PULMONARY TUBERCULOSIS; A UNITED STATES PUBLIC HEALTH SERVICE TUBERCULOSIS THERAPY TRIAL.', 'subject score': 1000, 'object score': 1000}, 'PMID:3265334': {'publication date': '1988 Dec', 'sentence': 'A generally similar pattern is seen in healthy controls and in patients with untreated pulmonary tuberculosis, treated leprosy, haemophilia A and chronic obstructive lung disease (COLD) patients treated with prednisolone, but the gradient of increasing CD4:CD8 ratio with depth into the dermis is significantly less steep in patients with tuberculosis, haemophilia and prednisolone-treated COLD than in the healthy controls.', 'subject score': 1000, 'object score': 901}, 'PMID:4648215': {'publication date': '1972 Nov', 'sentence': '[Characteristics of the postoperative period in patients with pulmonary tuberculosis treated with prednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:5380208': {'publication date': '1969', 'sentence': '[Radiographic observation of changes in foci in patients with pulmonary tuberculosis treated with antibacterial preparations in combination with prednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:5432970': {'publication date': '1970', 'sentence': '[PASA metabolism and the functional state of the adrenal cortex during chemotherapy combined with prednisolone in patients with pulmonary tuberculosis].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 310720,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006052",
-          "name": "pulmonary tuberculosis",
-          "description": "A bacterial infection that affects the lungs and is caused by Mycobacterium tuberculosis. Most patients with tuberculosis do not have symptoms (latent tuberculosis) and are not contagious. When signs and symptoms occur (active tuberculosis), patients become contagious. The signs and symptoms include chronic cough with blood-tinged sputum, night sweats, fever, fatigue, and weight loss.; MYCOBACTERIUM infections of the lung.; A lung infection by Mycobacterium tuberculosis a slightly curved non-motile, aerobic, non-capsulated and non-spore forming strains of mycobacteria. [PMID:30345099]",
-          "equivalent_curies": [
-            "MONDO:0006052",
-            "MEDDRA:10046123",
-            "PSY:42300",
-            "ICD9:011",
-            "MEDDRA:10034980",
-            "SNOMEDCT:154283005",
-            "DOID:2957",
-            "SNOMEDCT:700272008",
-            "NCIT:C26899",
-            "EFO:1000049",
-            "MEDDRA:10037443",
-            "HP:0032262",
-            "MESH:D014397",
-            "ICD10:A15",
-            "UMLS:C0041327",
-            "MEDDRA:10037435",
-            "MEDDRA:10037440"
-          ],
-          "id": "MONDO:0006052",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Tuberculosis, Pulmonary",
-            "pulmonary tuberculosis",
-            "Pulmonary Tuberculosis",
-            "Pulmonary tuberculosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:30345099",
-            "http://www.cdc.gov/tb/publications/factsheets/general/tb.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tuberculosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310720,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006052",
-              "name": "pulmonary tuberculosis",
-              "description": "A bacterial infection that affects the lungs and is caused by Mycobacterium tuberculosis. Most patients with tuberculosis do not have symptoms (latent tuberculosis) and are not contagious. When signs and symptoms occur (active tuberculosis), patients become contagious. The signs and symptoms include chronic cough with blood-tinged sputum, night sweats, fever, fatigue, and weight loss.; MYCOBACTERIUM infections of the lung.; A lung infection by Mycobacterium tuberculosis a slightly curved non-motile, aerobic, non-capsulated and non-spore forming strains of mycobacteria. [PMID:30345099]",
-              "equivalent_curies": [
-                "MONDO:0006052",
-                "MEDDRA:10046123",
-                "PSY:42300",
-                "ICD9:011",
-                "MEDDRA:10034980",
-                "SNOMEDCT:154283005",
-                "DOID:2957",
-                "SNOMEDCT:700272008",
-                "NCIT:C26899",
-                "EFO:1000049",
-                "MEDDRA:10037443",
-                "HP:0032262",
-                "MESH:D014397",
-                "ICD10:A15",
-                "UMLS:C0041327",
-                "MEDDRA:10037435",
-                "MEDDRA:10037440"
-              ],
-              "id": "MONDO:0006052",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Tuberculosis, Pulmonary",
-                "pulmonary tuberculosis",
-                "Pulmonary Tuberculosis",
-                "Pulmonary tuberculosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:30345099",
-                "http://www.cdc.gov/tb/publications/factsheets/general/tb.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=tuberculosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8462413,
-            "start": 568,
-            "end": 310720,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11155703': {'publication date': '2000 Oct', 'sentence': 'However, he died because of lung tuberculosis and acute tuberculous pericarditis during treatment with prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:13402557': {'publication date': '1956 Dec', 'sentence': '[Comparative study of the results of tuberculostatic agents with and without prednisolone in therapy of common phthisis].', 'subject score': 1000, 'object score': 888}, 'PMID:13468536': {'publication date': '1957 Jul', 'sentence': '[Supportive use of cortisone and prednisolone during tuberculostatic therapy of pulmonary tuberculosis].', 'subject score': 1000, 'object score': 1000}, 'PMID:13472066': {'publication date': '1957 Nov 16', 'sentence': 'PREDNISOLONE in the treatment of pulmonary tuberculosis: a controlled trial; a preliminary report by the Research Committee of the Tuberculosis Society of Scotland.', 'subject score': 1000, 'object score': 1000}, 'PMID:13715890': {'publication date': '1960 Dec 17', 'sentence': 'Prednisolone in treatment of pulmonary tuberculosis: a controlled trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:13856608': {'publication date': '1960 Apr', 'sentence': 'PRELIMINARY observations from a controlled trail of prednisolone in the treatment of pulmonary tuberculosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:14264779': {'publication date': '1965 Mar', 'sentence': 'PREDNISOLONE IN THE TREATMENT OF PULMONARY TUBERCULOSIS; A UNITED STATES PUBLIC HEALTH SERVICE TUBERCULOSIS THERAPY TRIAL.', 'subject score': 1000, 'object score': 1000}, 'PMID:3265334': {'publication date': '1988 Dec', 'sentence': 'A generally similar pattern is seen in healthy controls and in patients with untreated pulmonary tuberculosis, treated leprosy, haemophilia A and chronic obstructive lung disease (COLD) patients treated with prednisolone, but the gradient of increasing CD4:CD8 ratio with depth into the dermis is significantly less steep in patients with tuberculosis, haemophilia and prednisolone-treated COLD than in the healthy controls.', 'subject score': 1000, 'object score': 901}, 'PMID:4648215': {'publication date': '1972 Nov', 'sentence': '[Characteristics of the postoperative period in patients with pulmonary tuberculosis treated with prednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:5380208': {'publication date': '1969', 'sentence': '[Radiographic observation of changes in foci in patients with pulmonary tuberculosis treated with antibacterial preparations in combination with prednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:5432970': {'publication date': '1970', 'sentence': '[PASA metabolism and the functional state of the adrenal cortex during chemotherapy combined with prednisolone in patients with pulmonary tuberculosis].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0041327---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8647269",
-              "object": "MONDO:0006052",
-              "publications": [
-                "PMID:11155703",
-                "PMID:13402557",
-                "PMID:13468536",
-                "PMID:13472066",
-                "PMID:13715890",
-                "PMID:13856608",
-                "PMID:14264779",
-                "PMID:3265334",
-                "PMID:4648215",
-                "PMID:5380208",
-                "PMID:5432970"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15109274': {'publication date': '2004', 'sentence': 'It has also been used in combination with other drugs for treating a number of dermatologic disorders, e.g. in combination with cimetidine for treating recalcitrant warts, with prednisolone for treating lichen planus, erythema multiforme and aphthous ulcers of the mouth.', 'subject score': 1000, 'object score': 1000}, 'PMID:24822268': {'publication date': '2014 Apr', 'sentence': 'Levamisole and low-dose prednisolone in the treatment of   reccurent aphthous stomatitis.', 'subject score': 901, 'object score': 901}, 'PMID:6883599': {'publication date': '1983 Mar', 'sentence': 'Ointment-type oral mucosal dosage form of Carbopol containing prednisolone for treatment of aphtha.', 'subject score': 851, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 311935,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005318",
-          "name": "canker sore",
-          "description": "A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval, lasting for 7-14 days and healing without scarring.; A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval. Two to eight crops of lesions occur per year, lasting for 7 to 14 days and then heal without scarring. (From Jablonski's Dictionary of Dentistry, 1992, p742); Recurrent episodes of ulceration of the oral mucosa, typically presenting as painful, sharply circumscribed fibrin-covered mucosal defects with a hyperemic border. [HPO:probinson]; Oral aphthous ulcers typically present as painful, sharply circumscribed fibrin-covered mucosal defects with a hyperemic border. [PMID:25346356]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:722781002",
-            "MEDDRA:10042131",
-            "MEDDRA:10002959",
-            "UMLS:C2937365",
-            "SNOMEDCT:426965005",
-            "SNOMEDCT:427617000",
-            "UMLS:C1959869",
-            "NCIT:C62546",
-            "MONDO:0005318",
-            "SNOMEDCT:398870000",
-            "MEDDRA:10007166",
-            "MEDDRA:10045287",
-            "MEDDRA:10002958",
-            "MESH:D013281",
-            "UMLS:C0038363",
-            "MEDDRA:10066577",
-            "MEDDRA:10030960",
-            "SNOMEDCT:110426005",
-            "MEDDRA:10067589",
-            "MEDDRA:10084265",
-            "HP:0011107",
-            "MEDDRA:10045372",
-            "MEDDRA:10045288"
-          ],
-          "id": "MONDO:0005318",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Stomatitis, Aphthous",
-            "canker sore",
-            "Canker Sore",
-            "Aphthous ulceration of skin and/or mucous membrane (disorder)",
-            "Recurrent aphthous stomatitis",
-            "Aphthous Stomatitis",
-            "Recurrent aphthous ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:25346356",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311935,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005318",
-              "name": "canker sore",
-              "description": "A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval, lasting for 7-14 days and healing without scarring.; A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval. Two to eight crops of lesions occur per year, lasting for 7 to 14 days and then heal without scarring. (From Jablonski's Dictionary of Dentistry, 1992, p742); Recurrent episodes of ulceration of the oral mucosa, typically presenting as painful, sharply circumscribed fibrin-covered mucosal defects with a hyperemic border. [HPO:probinson]; Oral aphthous ulcers typically present as painful, sharply circumscribed fibrin-covered mucosal defects with a hyperemic border. [PMID:25346356]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:722781002",
-                "MEDDRA:10042131",
-                "MEDDRA:10002959",
-                "UMLS:C2937365",
-                "SNOMEDCT:426965005",
-                "SNOMEDCT:427617000",
-                "UMLS:C1959869",
-                "NCIT:C62546",
-                "MONDO:0005318",
-                "SNOMEDCT:398870000",
-                "MEDDRA:10007166",
-                "MEDDRA:10045287",
-                "MEDDRA:10002958",
-                "MESH:D013281",
-                "UMLS:C0038363",
-                "MEDDRA:10066577",
-                "MEDDRA:10030960",
-                "SNOMEDCT:110426005",
-                "MEDDRA:10067589",
-                "MEDDRA:10084265",
-                "HP:0011107",
-                "MEDDRA:10045372",
-                "MEDDRA:10045288"
-              ],
-              "id": "MONDO:0005318",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Stomatitis, Aphthous",
-                "canker sore",
-                "Canker Sore",
-                "Aphthous ulceration of skin and/or mucous membrane (disorder)",
-                "Recurrent aphthous stomatitis",
-                "Aphthous Stomatitis",
-                "Recurrent aphthous ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:25346356",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10927139,
-            "start": 568,
-            "end": 311935,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15109274': {'publication date': '2004', 'sentence': 'It has also been used in combination with other drugs for treating a number of dermatologic disorders, e.g. in combination with cimetidine for treating recalcitrant warts, with prednisolone for treating lichen planus, erythema multiforme and aphthous ulcers of the mouth.', 'subject score': 1000, 'object score': 1000}, 'PMID:24822268': {'publication date': '2014 Apr', 'sentence': 'Levamisole and low-dose prednisolone in the treatment of   reccurent aphthous stomatitis.', 'subject score': 901, 'object score': 901}, 'PMID:6883599': {'publication date': '1983 Mar', 'sentence': 'Ointment-type oral mucosal dosage form of Carbopol containing prednisolone for treatment of aphtha.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0038363---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11166363",
-              "object": "MONDO:0005318",
-              "publications": [
-                "PMID:15109274",
-                "PMID:24822268",
-                "PMID:6883599"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:has_metabolite",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:12670859': {'publication date': '2003 Apr', 'sentence': 'Prednisolone scored better than prednisone in the categories of texture, taste, and aftertaste (p < 0.05); there was no statistical difference in smell.', 'subject score': 1000, 'object score': 1000}, 'PMID:13487472': {'publication date': '1957 Nov 10', 'sentence': '[Results of asthma therapy with prednisolone in comparison with previous experience with prednisone].', 'subject score': 1000, 'object score': 1000}, 'PMID:16226134': {'publication date': '2005 Nov', 'sentence': 'Our data demonstrate unimpaired placental 11beta-HSD2 activity in patients suffering from HELLP syndrome at early gestational age as shown by both a 10-fold lower fetal prednisolone concentration as compared to the mother and a strong correlation between the last dose of prednisolone to delivery interval and the fetal prednisone concentration.', 'subject score': 1000, 'object score': 623}, 'PMID:16413504': {'publication date': '2006 Mar 14', 'sentence': 'This approach allowed the comparison of the binding ability of prednisolone and prednisone towards albumin.', 'subject score': 1000, 'object score': 1000}, 'PMID:16548096': {'publication date': '2006 Feb', 'sentence': '(3) In an open-label comparative trial involving 1006 patients, docetaxel infusion at a dose of 75 mg/m2 every 3 weeks, in combination with prednisone (or prednisolone), significantly extended the median survival time by about 2.5 months as compared with a mitoxantrone-prednisone combination (18.9 versus 16.5 months).', 'subject score': 1000, 'object score': 851}, 'PMID:2285202': {'publication date': '1990', 'sentence': 'A cross-over, double-blind, randomized trial with 8 healthy volunteers was undertaken to compare prednisolone and prednisone pharmacokinetics after a single oral dose (1 mg/kg) of prednisone (Cortancyl) and prednisolone sodium metasulfobenzoate (Solupred).', 'subject score': 1000, 'object score': 888}, 'PMID:23415134': {'publication date': '2013 Jul-Aug', 'sentence': 'Mean daily MR-prednisone dosage decreased from 8.2mg to 6.7mg between baseline and endpoint and significantly higher improvements in MS, NRS pain and GA scores were seen in patients switched from 6M-prednisolone versus IR-prednisone.', 'subject score': 861, 'object score': 851}, 'PMID:23473553': {'publication date': '2013 Aug', 'sentence': 'Although interconversion of each drug to the other was confirmed, a single 2mg/kg body weight oral dose of prednisolone produced significantly higher plasma prednisolone concentration (~4-fold higher AUC) compared to prednisone.', 'subject score': 790, 'object score': 1000}, 'PMID:27770303': {'publication date': '2017 Apr', 'sentence': 'Clinical evidence for cabazitaxel was derived from a multinational randomised open-label phase III trial (TROPIC) of cabazitaxel plus prednisone or prednisolone compared with mitoxantrone plus prednisone or prednisolone, which was assumed to represent best supportive care.', 'subject score': 1000, 'object score': 851}, 'PMID:656293': {'publication date': '1978 Jun', 'sentence': '4 It is concluded that plasma prednisolone levels will be more predictable after prednisolone than after prednisone in subjects without hepatic dysfunction.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 4578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisone",
-          "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "HMDB:HMDB0014773",
-            "UMLS:C0032952",
-            "NCIT:C770",
-            "PUBCHEM.COMPOUND:5865",
-            "DrugCentral:2253",
-            "MESH:D011241",
-            "ATC:A07EA03",
-            "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-            "CAS:53-03-2",
-            "PDQ:CDR0000042487",
-            "PathWhiz.Compound:9120",
-            "KEGG.DRUG:D00473",
-            "DRUGBANK:DB00635",
-            "ATC:H02AB07",
-            "UNII:VB0R961HZT",
-            "NDDF:002164",
-            "CHEMBL.COMPOUND:CHEMBL635",
-            "CHEBI:8382",
-            "KEGG.COMPOUND:C07370",
-            "GTOPDB:7096",
-            "RXNORM:8640"
-          ],
-          "id": "PUBCHEM.COMPOUND:5865",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisone",
-            "Prednisone (USP)",
-            "PREDNISONE",
-            "1,2-dehydrocortisone",
-            "prednisone"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:32422522",
-            "PMID:18788725",
-            "PMID:11413487",
-            "PMID:20070106",
-            "PMID:378499",
-            "PMID:15646539",
-            "PMID:20014752",
-            "PMID:25618019",
-            "PMID:23571415",
-            "PMID:19586686"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 4578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisone",
-              "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "HMDB:HMDB0014773",
-                "UMLS:C0032952",
-                "NCIT:C770",
-                "PUBCHEM.COMPOUND:5865",
-                "DrugCentral:2253",
-                "MESH:D011241",
-                "ATC:A07EA03",
-                "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-                "CAS:53-03-2",
-                "PDQ:CDR0000042487",
-                "PathWhiz.Compound:9120",
-                "KEGG.DRUG:D00473",
-                "DRUGBANK:DB00635",
-                "ATC:H02AB07",
-                "UNII:VB0R961HZT",
-                "NDDF:002164",
-                "CHEMBL.COMPOUND:CHEMBL635",
-                "CHEBI:8382",
-                "KEGG.COMPOUND:C07370",
-                "GTOPDB:7096",
-                "RXNORM:8640"
-              ],
-              "id": "PUBCHEM.COMPOUND:5865",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisone",
-                "Prednisone (USP)",
-                "PREDNISONE",
-                "1,2-dehydrocortisone",
-                "prednisone"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:32422522",
-                "PMID:18788725",
-                "PMID:11413487",
-                "PMID:20070106",
-                "PMID:378499",
-                "PMID:15646539",
-                "PMID:20014752",
-                "PMID:25618019",
-                "PMID:23571415",
-                "PMID:19586686"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9899283,
-            "start": 568,
-            "end": 4578,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12670859': {'publication date': '2003 Apr', 'sentence': 'Prednisolone scored better than prednisone in the categories of texture, taste, and aftertaste (p < 0.05); there was no statistical difference in smell.', 'subject score': 1000, 'object score': 1000}, 'PMID:13487472': {'publication date': '1957 Nov 10', 'sentence': '[Results of asthma therapy with prednisolone in comparison with previous experience with prednisone].', 'subject score': 1000, 'object score': 1000}, 'PMID:16226134': {'publication date': '2005 Nov', 'sentence': 'Our data demonstrate unimpaired placental 11beta-HSD2 activity in patients suffering from HELLP syndrome at early gestational age as shown by both a 10-fold lower fetal prednisolone concentration as compared to the mother and a strong correlation between the last dose of prednisolone to delivery interval and the fetal prednisone concentration.', 'subject score': 1000, 'object score': 623}, 'PMID:16413504': {'publication date': '2006 Mar 14', 'sentence': 'This approach allowed the comparison of the binding ability of prednisolone and prednisone towards albumin.', 'subject score': 1000, 'object score': 1000}, 'PMID:16548096': {'publication date': '2006 Feb', 'sentence': '(3) In an open-label comparative trial involving 1006 patients, docetaxel infusion at a dose of 75 mg/m2 every 3 weeks, in combination with prednisone (or prednisolone), significantly extended the median survival time by about 2.5 months as compared with a mitoxantrone-prednisone combination (18.9 versus 16.5 months).', 'subject score': 1000, 'object score': 851}, 'PMID:2285202': {'publication date': '1990', 'sentence': 'A cross-over, double-blind, randomized trial with 8 healthy volunteers was undertaken to compare prednisolone and prednisone pharmacokinetics after a single oral dose (1 mg/kg) of prednisone (Cortancyl) and prednisolone sodium metasulfobenzoate (Solupred).', 'subject score': 1000, 'object score': 888}, 'PMID:23415134': {'publication date': '2013 Jul-Aug', 'sentence': 'Mean daily MR-prednisone dosage decreased from 8.2mg to 6.7mg between baseline and endpoint and significantly higher improvements in MS, NRS pain and GA scores were seen in patients switched from 6M-prednisolone versus IR-prednisone.', 'subject score': 861, 'object score': 851}, 'PMID:23473553': {'publication date': '2013 Aug', 'sentence': 'Although interconversion of each drug to the other was confirmed, a single 2mg/kg body weight oral dose of prednisolone produced significantly higher plasma prednisolone concentration (~4-fold higher AUC) compared to prednisone.', 'subject score': 790, 'object score': 1000}, 'PMID:27770303': {'publication date': '2017 Apr', 'sentence': 'Clinical evidence for cabazitaxel was derived from a multinational randomised open-label phase III trial (TROPIC) of cabazitaxel plus prednisone or prednisolone compared with mitoxantrone plus prednisone or prednisolone, which was assumed to represent best supportive care.', 'subject score': 1000, 'object score': 851}, 'PMID:656293': {'publication date': '1978 Jun', 'sentence': '4 It is concluded that plasma prednisolone levels will be more predictable after prednisolone than after prednisone in subjects without hepatic dysfunction.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:compared_with---None---None---None---UMLS:C0032952---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:higher_than---None---None---None---UMLS:C0032952---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10118116",
-              "object": "PUBCHEM.COMPOUND:5865",
-              "publications": [
-                "PMID:16413504",
-                "PMID:13487472",
-                "PMID:656293",
-                "PMID:27770303",
-                "PMID:12670859",
-                "PMID:16548096",
-                "PMID:23415134",
-                "PMID:16226134",
-                "PMID:2285202",
-                "PMID:23473553"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:has_metabolite",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:11326479': {'publication date': '2001 Mar-Apr', 'sentence': 'A significant reduction of survival was found with the presence of permanent visual loss vs absence (p = 0.04), in patients who required more than 10 mg/d of glucocorticoid (p < 0.001) at 6 months treatment and in patients treated with prednisone (vs prednisolone) (p < 0.01).', 'subject score': 1000, 'object score': 1000}, 'PMID:12428485': {'publication date': '2002 Oct', 'sentence': 'Psychiatric adverse affects appears to be more frequent with prednisone than prednisolone (P < 0.05).', 'subject score': 1000, 'object score': 1000}, 'PMID:13994945': {'publication date': '1962 Sep 15', 'sentence': '[Experimental ulcerogenic action of the prednisone. I. Comparison between prednisone and prednisolone administered orally and parenterally].', 'subject score': 1000, 'object score': 1000}, 'PMID:15635906': {'publication date': '2002 Aug', 'sentence': 'The risk of laminitis appears to be greater during treatment using some GCs (especially dexamethasone and triamcinalone) compared with others (prednisone and prednisolone).', 'subject score': 1000, 'object score': 1000}, 'PMID:16045952': {'publication date': '2005 Oct', 'sentence': 'In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.', 'subject score': 1000, 'object score': 1000}, 'PMID:22752958': {'publication date': '2013 Feb', 'sentence': 'Modified-release prednisone showed decreased complaints and fatigue compared to standard prednisolone indicating importance of glucocorticoid increase in early morning hours before waking.', 'subject score': 888, 'object score': 888}, 'PMID:23473553': {'publication date': '2013 Aug', 'sentence': 'Findings suggest low comparative bioavailability of oral prednisone compared to prednisolone in cats and consideration of lean body mass or ideal body weight for dosing practices.', 'subject score': 888, 'object score': 1000}, 'PMID:24452065': {'publication date': '2014 Aug', 'sentence': 'The objective of this study was to compare the pharmacokinetics of total and unbound prednisone and prednisolone in diabetic and nondiabetic stable kidney transplant recipients and to evaluate the factors influencing plasma protein binding of prednisolone.', 'subject score': 861, 'object score': 1000}, 'PMID:28791802': {'publication date': '2018 Jan', 'sentence': 'OBJECTIVE: A feasibility study to assess efficacy and safety of modified release (MR) prednisone (LodotraTM) compared to immediate release (IR) prednisolone in patients with newly diagnosed giant cell arteritis (GCA).', 'subject score': 851, 'object score': 851}, 'PMID:2898348': {'publication date': '1988 Mar-Apr', 'sentence': 'Compared to humans, pigs had lower concentrations of total prednisolone--assessed by HPLC--after oral prednisone (7.1 +/- 4.3 micrograms/ml x min vs. 297.9 +/- 75.6 micrograms/ml x min) and after iv prednisolone (26.8 +/- 9.5 micrograms/ml x min vs. 373.3 +/- 77.7 micrograms/ml x min).', 'subject score': 888, 'object score': 888}, 'PMID:31531960': {'publication date': '2019 Oct', 'sentence': 'CONCLUSION: Our study suggests that elevated levels of IL-6 in new GCA are better suppressed by MR prednisone compared with IR prednisolone.', 'subject score': 888, 'object score': 861}, 'PMID:3709632': {'publication date': '1986', 'sentence': 'This surprising result was observed even when prednisone concentrations were more than 35 fold greater than prednisolone concentrations.', 'subject score': 888, 'object score': 888}, 'PMID:656293': {'publication date': '1978 Jun', 'sentence': '2 In controls, values for AUC were significantly more variable after prednisone than prednisolone, and two subjects showed markedly inefficient conversion of prednisone to prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:6721988': {'publication date': '1984 Apr', 'sentence': 'Prednisone levels were lower than prednisolone levels.', 'subject score': 888, 'object score': 888}, 'PMID:7047863': {'publication date': '1982 Apr', 'sentence': 'The objective of our study was to compare the systemic bioavailability of prednisolone from oral prednisone and prednisolone.', 'subject score': 888, 'object score': 1000}, 'PMID:7141787': {'publication date': '1982 Sep', 'sentence': 'In nephrotic children the area under the curve of prednisolone (AUCPn) was higher (by 134 +/- 42%) after oral doses of prednisone when compared to the intravenous prednisolone doses.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 4578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisone",
-          "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "HMDB:HMDB0014773",
-            "UMLS:C0032952",
-            "NCIT:C770",
-            "PUBCHEM.COMPOUND:5865",
-            "DrugCentral:2253",
-            "MESH:D011241",
-            "ATC:A07EA03",
-            "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-            "CAS:53-03-2",
-            "PDQ:CDR0000042487",
-            "PathWhiz.Compound:9120",
-            "KEGG.DRUG:D00473",
-            "DRUGBANK:DB00635",
-            "ATC:H02AB07",
-            "UNII:VB0R961HZT",
-            "NDDF:002164",
-            "CHEMBL.COMPOUND:CHEMBL635",
-            "CHEBI:8382",
-            "KEGG.COMPOUND:C07370",
-            "GTOPDB:7096",
-            "RXNORM:8640"
-          ],
-          "id": "PUBCHEM.COMPOUND:5865",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisone",
-            "Prednisone (USP)",
-            "PREDNISONE",
-            "1,2-dehydrocortisone",
-            "prednisone"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:32422522",
-            "PMID:18788725",
-            "PMID:11413487",
-            "PMID:20070106",
-            "PMID:378499",
-            "PMID:15646539",
-            "PMID:20014752",
-            "PMID:25618019",
-            "PMID:23571415",
-            "PMID:19586686"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 4578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisone",
-              "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "HMDB:HMDB0014773",
-                "UMLS:C0032952",
-                "NCIT:C770",
-                "PUBCHEM.COMPOUND:5865",
-                "DrugCentral:2253",
-                "MESH:D011241",
-                "ATC:A07EA03",
-                "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-                "CAS:53-03-2",
-                "PDQ:CDR0000042487",
-                "PathWhiz.Compound:9120",
-                "KEGG.DRUG:D00473",
-                "DRUGBANK:DB00635",
-                "ATC:H02AB07",
-                "UNII:VB0R961HZT",
-                "NDDF:002164",
-                "CHEMBL.COMPOUND:CHEMBL635",
-                "CHEBI:8382",
-                "KEGG.COMPOUND:C07370",
-                "GTOPDB:7096",
-                "RXNORM:8640"
-              ],
-              "id": "PUBCHEM.COMPOUND:5865",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisone",
-                "Prednisone (USP)",
-                "PREDNISONE",
-                "1,2-dehydrocortisone",
-                "prednisone"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:32422522",
-                "PMID:18788725",
-                "PMID:11413487",
-                "PMID:20070106",
-                "PMID:378499",
-                "PMID:15646539",
-                "PMID:20014752",
-                "PMID:25618019",
-                "PMID:23571415",
-                "PMID:19586686"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8666771,
-            "start": 4578,
-            "end": 568,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11326479': {'publication date': '2001 Mar-Apr', 'sentence': 'A significant reduction of survival was found with the presence of permanent visual loss vs absence (p = 0.04), in patients who required more than 10 mg/d of glucocorticoid (p < 0.001) at 6 months treatment and in patients treated with prednisone (vs prednisolone) (p < 0.01).', 'subject score': 1000, 'object score': 1000}, 'PMID:12428485': {'publication date': '2002 Oct', 'sentence': 'Psychiatric adverse affects appears to be more frequent with prednisone than prednisolone (P < 0.05).', 'subject score': 1000, 'object score': 1000}, 'PMID:13994945': {'publication date': '1962 Sep 15', 'sentence': '[Experimental ulcerogenic action of the prednisone. I. Comparison between prednisone and prednisolone administered orally and parenterally].', 'subject score': 1000, 'object score': 1000}, 'PMID:15635906': {'publication date': '2002 Aug', 'sentence': 'The risk of laminitis appears to be greater during treatment using some GCs (especially dexamethasone and triamcinalone) compared with others (prednisone and prednisolone).', 'subject score': 1000, 'object score': 1000}, 'PMID:16045952': {'publication date': '2005 Oct', 'sentence': 'In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.', 'subject score': 1000, 'object score': 1000}, 'PMID:22752958': {'publication date': '2013 Feb', 'sentence': 'Modified-release prednisone showed decreased complaints and fatigue compared to standard prednisolone indicating importance of glucocorticoid increase in early morning hours before waking.', 'subject score': 888, 'object score': 888}, 'PMID:23473553': {'publication date': '2013 Aug', 'sentence': 'Findings suggest low comparative bioavailability of oral prednisone compared to prednisolone in cats and consideration of lean body mass or ideal body weight for dosing practices.', 'subject score': 888, 'object score': 1000}, 'PMID:24452065': {'publication date': '2014 Aug', 'sentence': 'The objective of this study was to compare the pharmacokinetics of total and unbound prednisone and prednisolone in diabetic and nondiabetic stable kidney transplant recipients and to evaluate the factors influencing plasma protein binding of prednisolone.', 'subject score': 861, 'object score': 1000}, 'PMID:28791802': {'publication date': '2018 Jan', 'sentence': 'OBJECTIVE: A feasibility study to assess efficacy and safety of modified release (MR) prednisone (LodotraTM) compared to immediate release (IR) prednisolone in patients with newly diagnosed giant cell arteritis (GCA).', 'subject score': 851, 'object score': 851}, 'PMID:2898348': {'publication date': '1988 Mar-Apr', 'sentence': 'Compared to humans, pigs had lower concentrations of total prednisolone--assessed by HPLC--after oral prednisone (7.1 +/- 4.3 micrograms/ml x min vs. 297.9 +/- 75.6 micrograms/ml x min) and after iv prednisolone (26.8 +/- 9.5 micrograms/ml x min vs. 373.3 +/- 77.7 micrograms/ml x min).', 'subject score': 888, 'object score': 888}, 'PMID:31531960': {'publication date': '2019 Oct', 'sentence': 'CONCLUSION: Our study suggests that elevated levels of IL-6 in new GCA are better suppressed by MR prednisone compared with IR prednisolone.', 'subject score': 888, 'object score': 861}, 'PMID:3709632': {'publication date': '1986', 'sentence': 'This surprising result was observed even when prednisone concentrations were more than 35 fold greater than prednisolone concentrations.', 'subject score': 888, 'object score': 888}, 'PMID:656293': {'publication date': '1978 Jun', 'sentence': '2 In controls, values for AUC were significantly more variable after prednisone than prednisolone, and two subjects showed markedly inefficient conversion of prednisone to prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:6721988': {'publication date': '1984 Apr', 'sentence': 'Prednisone levels were lower than prednisolone levels.', 'subject score': 888, 'object score': 888}, 'PMID:7047863': {'publication date': '1982 Apr', 'sentence': 'The objective of our study was to compare the systemic bioavailability of prednisolone from oral prednisone and prednisolone.', 'subject score': 888, 'object score': 1000}, 'PMID:7141787': {'publication date': '1982 Sep', 'sentence': 'In nephrotic children the area under the curve of prednisolone (AUCPn) was higher (by 134 +/- 42%) after oral doses of prednisone when compared to the intravenous prednisolone doses.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032952---SEMMEDDB:compared_with---None---None---None---UMLS:C0032950---SEMMEDDB:",
-                "UMLS:C0032952---SEMMEDDB:higher_than---None---None---None---UMLS:C0032950---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5865",
-              "id": "8856354",
-              "object": "PUBCHEM.COMPOUND:5755",
-              "publications": [
-                "PMID:3709632",
-                "PMID:31531960",
-                "PMID:16045952",
-                "PMID:6721988",
-                "PMID:7047863",
-                "PMID:11326479",
-                "PMID:656293",
-                "PMID:28791802",
-                "PMID:7141787",
-                "PMID:13994945",
-                "PMID:12428485",
-                "PMID:24452065",
-                "PMID:2898348",
-                "PMID:15635906",
-                "PMID:23473553",
-                "PMID:22752958"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:has_metabolite",
-    "type(r2)": "biolink:coexists_with",
-    "r2.publications_info": "{'PMID:27080058': {'publication date': '2017 Oct', 'sentence': 'Moreover, after recent findings regarding the presence of endogenous prednisolone in the urine of more popular breeds, particular attention was given to analysis of the presence of prednisolone and prednisone, as well.', 'subject score': 1000, 'object score': 888}, 'PMID:2931388': {'publication date': '1985', 'sentence': \"The inactivity of prednisone despite a significant conversion to its biologically active 11-hydroxyl metabolite, prednisolone, suggests the importance of the duration and timing of prednisolone's presence to immunosuppressive activity in the MLR culture.\", 'subject score': 1000, 'object score': 888}, 'PMID:356210': {'publication date': '1977', 'sentence': 'There appeared to be an increased risk of rejection during reduction of prednisone from 10 to 2.5 mg per day, but 20 out of the 23 patients in whom prednisolone has by noe been completely withdrawn have maintained stable and normal graft function over an average period of 1.6 (0.1-3.0) years on zero prednisone.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 4578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisone",
-          "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "HMDB:HMDB0014773",
-            "UMLS:C0032952",
-            "NCIT:C770",
-            "PUBCHEM.COMPOUND:5865",
-            "DrugCentral:2253",
-            "MESH:D011241",
-            "ATC:A07EA03",
-            "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-            "CAS:53-03-2",
-            "PDQ:CDR0000042487",
-            "PathWhiz.Compound:9120",
-            "KEGG.DRUG:D00473",
-            "DRUGBANK:DB00635",
-            "ATC:H02AB07",
-            "UNII:VB0R961HZT",
-            "NDDF:002164",
-            "CHEMBL.COMPOUND:CHEMBL635",
-            "CHEBI:8382",
-            "KEGG.COMPOUND:C07370",
-            "GTOPDB:7096",
-            "RXNORM:8640"
-          ],
-          "id": "PUBCHEM.COMPOUND:5865",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisone",
-            "Prednisone (USP)",
-            "PREDNISONE",
-            "1,2-dehydrocortisone",
-            "prednisone"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:32422522",
-            "PMID:18788725",
-            "PMID:11413487",
-            "PMID:20070106",
-            "PMID:378499",
-            "PMID:15646539",
-            "PMID:20014752",
-            "PMID:25618019",
-            "PMID:23571415",
-            "PMID:19586686"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 4578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisone",
-              "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "HMDB:HMDB0014773",
-                "UMLS:C0032952",
-                "NCIT:C770",
-                "PUBCHEM.COMPOUND:5865",
-                "DrugCentral:2253",
-                "MESH:D011241",
-                "ATC:A07EA03",
-                "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-                "CAS:53-03-2",
-                "PDQ:CDR0000042487",
-                "PathWhiz.Compound:9120",
-                "KEGG.DRUG:D00473",
-                "DRUGBANK:DB00635",
-                "ATC:H02AB07",
-                "UNII:VB0R961HZT",
-                "NDDF:002164",
-                "CHEMBL.COMPOUND:CHEMBL635",
-                "CHEBI:8382",
-                "KEGG.COMPOUND:C07370",
-                "GTOPDB:7096",
-                "RXNORM:8640"
-              ],
-              "id": "PUBCHEM.COMPOUND:5865",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisone",
-                "Prednisone (USP)",
-                "PREDNISONE",
-                "1,2-dehydrocortisone",
-                "prednisone"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:32422522",
-                "PMID:18788725",
-                "PMID:11413487",
-                "PMID:20070106",
-                "PMID:378499",
-                "PMID:15646539",
-                "PMID:20014752",
-                "PMID:25618019",
-                "PMID:23571415",
-                "PMID:19586686"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18550702,
-            "start": 4578,
-            "end": 568,
-            "type": "biolink:coexists_with",
-            "properties": {
-              "predicate": "biolink:coexists_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27080058': {'publication date': '2017 Oct', 'sentence': 'Moreover, after recent findings regarding the presence of endogenous prednisolone in the urine of more popular breeds, particular attention was given to analysis of the presence of prednisolone and prednisone, as well.', 'subject score': 1000, 'object score': 888}, 'PMID:2931388': {'publication date': '1985', 'sentence': \"The inactivity of prednisone despite a significant conversion to its biologically active 11-hydroxyl metabolite, prednisolone, suggests the importance of the duration and timing of prednisolone's presence to immunosuppressive activity in the MLR culture.\", 'subject score': 1000, 'object score': 888}, 'PMID:356210': {'publication date': '1977', 'sentence': 'There appeared to be an increased risk of rejection during reduction of prednisone from 10 to 2.5 mg per day, but 20 out of the 23 patients in whom prednisolone has by noe been completely withdrawn have maintained stable and normal graft function over an average period of 1.6 (0.1-3.0) years on zero prednisone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032952---SEMMEDDB:coexists_with---None---None---None---UMLS:C0032950---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5865",
-              "id": "18935086",
-              "object": "PUBCHEM.COMPOUND:5755",
-              "publications": [
-                "PMID:27080058",
-                "PMID:2931388",
-                "PMID:356210"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:has_metabolite",
-    "type(r2)": "biolink:derives_from",
-    "r2.publications_info": "{'PMID:1176582': {'publication date': '1975 Oct', 'sentence': 'Of 10 mg of prednisone given orally to 5 normal subjects, 69+/-5% was absorbed and converted to peripheral plasma prednisolone within 8 h.', 'subject score': 1000, 'object score': 851}, 'PMID:1952426': {'publication date': '1991 Nov', 'sentence': 'No differences were observed between six of the sensitive and resistant patients in the clearance of plasma prednisolone derived from orally administered prednisone.', 'subject score': 827, 'object score': 888}, 'PMID:22895925': {'publication date': '2012 Aug 15', 'sentence': 'Prednisone is converted into prednisolone in the liver so that the effect of the two drugs is usually the same.', 'subject score': 1000, 'object score': 1000}, 'PMID:25561247': {'publication date': '2015 Jan 05', 'sentence': 'Prednisone is converted into prednisolone in the liver so that the effect of the two drugs is usually the same.', 'subject score': 1000, 'object score': 1000}, 'PMID:29185258': {'publication date': '2017 11 29', 'sentence': 'Prednisone is converted into prednisolone in the liver so that the effect of the two drugs is usually the same.', 'subject score': 1000, 'object score': 1000}, 'PMID:2931388': {'publication date': '1985', 'sentence': 'Although, prednisone was inactive in the MLR, it was slowly being converted to prednisolone by 11-hydroxylation.', 'subject score': 1000, 'object score': 1000}, 'PMID:33195563': {'publication date': '2020', 'sentence': 'Oral prednisone was rapidly converted to prednisolone in dogs (<= 30 min), with plasma prednisolone reaching ~6-fold greater levels (0-656.1 ng/mL) than prednisone (0-98.8 ng/mL) overall.', 'subject score': 888, 'object score': 1000}, 'PMID:744499': {'publication date': '1978 Dec', 'sentence': 'We conclude that prednisone is effectively absorbed and converted to prednisolone in health and CALD and find no pharmacological evidence that either drug would be superior to the other for treating CALD.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 4578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisone",
-          "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "HMDB:HMDB0014773",
-            "UMLS:C0032952",
-            "NCIT:C770",
-            "PUBCHEM.COMPOUND:5865",
-            "DrugCentral:2253",
-            "MESH:D011241",
-            "ATC:A07EA03",
-            "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-            "CAS:53-03-2",
-            "PDQ:CDR0000042487",
-            "PathWhiz.Compound:9120",
-            "KEGG.DRUG:D00473",
-            "DRUGBANK:DB00635",
-            "ATC:H02AB07",
-            "UNII:VB0R961HZT",
-            "NDDF:002164",
-            "CHEMBL.COMPOUND:CHEMBL635",
-            "CHEBI:8382",
-            "KEGG.COMPOUND:C07370",
-            "GTOPDB:7096",
-            "RXNORM:8640"
-          ],
-          "id": "PUBCHEM.COMPOUND:5865",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisone",
-            "Prednisone (USP)",
-            "PREDNISONE",
-            "1,2-dehydrocortisone",
-            "prednisone"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:32422522",
-            "PMID:18788725",
-            "PMID:11413487",
-            "PMID:20070106",
-            "PMID:378499",
-            "PMID:15646539",
-            "PMID:20014752",
-            "PMID:25618019",
-            "PMID:23571415",
-            "PMID:19586686"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 4578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisone",
-              "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "HMDB:HMDB0014773",
-                "UMLS:C0032952",
-                "NCIT:C770",
-                "PUBCHEM.COMPOUND:5865",
-                "DrugCentral:2253",
-                "MESH:D011241",
-                "ATC:A07EA03",
-                "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-                "CAS:53-03-2",
-                "PDQ:CDR0000042487",
-                "PathWhiz.Compound:9120",
-                "KEGG.DRUG:D00473",
-                "DRUGBANK:DB00635",
-                "ATC:H02AB07",
-                "UNII:VB0R961HZT",
-                "NDDF:002164",
-                "CHEMBL.COMPOUND:CHEMBL635",
-                "CHEBI:8382",
-                "KEGG.COMPOUND:C07370",
-                "GTOPDB:7096",
-                "RXNORM:8640"
-              ],
-              "id": "PUBCHEM.COMPOUND:5865",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisone",
-                "Prednisone (USP)",
-                "PREDNISONE",
-                "1,2-dehydrocortisone",
-                "prednisone"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:32422522",
-                "PMID:18788725",
-                "PMID:11413487",
-                "PMID:20070106",
-                "PMID:378499",
-                "PMID:15646539",
-                "PMID:20014752",
-                "PMID:25618019",
-                "PMID:23571415",
-                "PMID:19586686"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9096353,
-            "start": 568,
-            "end": 4578,
-            "type": "biolink:derives_from",
-            "properties": {
-              "predicate": "biolink:derives_from",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1176582': {'publication date': '1975 Oct', 'sentence': 'Of 10 mg of prednisone given orally to 5 normal subjects, 69+/-5% was absorbed and converted to peripheral plasma prednisolone within 8 h.', 'subject score': 1000, 'object score': 851}, 'PMID:1952426': {'publication date': '1991 Nov', 'sentence': 'No differences were observed between six of the sensitive and resistant patients in the clearance of plasma prednisolone derived from orally administered prednisone.', 'subject score': 827, 'object score': 888}, 'PMID:22895925': {'publication date': '2012 Aug 15', 'sentence': 'Prednisone is converted into prednisolone in the liver so that the effect of the two drugs is usually the same.', 'subject score': 1000, 'object score': 1000}, 'PMID:25561247': {'publication date': '2015 Jan 05', 'sentence': 'Prednisone is converted into prednisolone in the liver so that the effect of the two drugs is usually the same.', 'subject score': 1000, 'object score': 1000}, 'PMID:29185258': {'publication date': '2017 11 29', 'sentence': 'Prednisone is converted into prednisolone in the liver so that the effect of the two drugs is usually the same.', 'subject score': 1000, 'object score': 1000}, 'PMID:2931388': {'publication date': '1985', 'sentence': 'Although, prednisone was inactive in the MLR, it was slowly being converted to prednisolone by 11-hydroxylation.', 'subject score': 1000, 'object score': 1000}, 'PMID:33195563': {'publication date': '2020', 'sentence': 'Oral prednisone was rapidly converted to prednisolone in dogs (<= 30 min), with plasma prednisolone reaching ~6-fold greater levels (0-656.1 ng/mL) than prednisone (0-98.8 ng/mL) overall.', 'subject score': 888, 'object score': 1000}, 'PMID:744499': {'publication date': '1978 Dec', 'sentence': 'We conclude that prednisone is effectively absorbed and converted to prednisolone in health and CALD and find no pharmacological evidence that either drug would be superior to the other for treating CALD.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032952---SEMMEDDB:converts_to---None---None---None---UMLS:C0032950---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9296680",
-              "object": "PUBCHEM.COMPOUND:5865",
-              "publications": [
-                "PMID:1176582",
-                "PMID:1952426",
-                "PMID:22895925",
-                "PMID:25561247",
-                "PMID:29185258",
-                "PMID:2931388",
-                "PMID:33195563",
-                "PMID:744499"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:has_metabolite",
-    "type(r2)": "biolink:derives_from",
-    "r2.publications_info": "{'PMID:7299663': {'publication date': '1981 Nov', 'sentence': 'As in humans, prednisolone was partly converted to prednisone in the rabbit.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 4578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisone",
-          "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "HMDB:HMDB0014773",
-            "UMLS:C0032952",
-            "NCIT:C770",
-            "PUBCHEM.COMPOUND:5865",
-            "DrugCentral:2253",
-            "MESH:D011241",
-            "ATC:A07EA03",
-            "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-            "CAS:53-03-2",
-            "PDQ:CDR0000042487",
-            "PathWhiz.Compound:9120",
-            "KEGG.DRUG:D00473",
-            "DRUGBANK:DB00635",
-            "ATC:H02AB07",
-            "UNII:VB0R961HZT",
-            "NDDF:002164",
-            "CHEMBL.COMPOUND:CHEMBL635",
-            "CHEBI:8382",
-            "KEGG.COMPOUND:C07370",
-            "GTOPDB:7096",
-            "RXNORM:8640"
-          ],
-          "id": "PUBCHEM.COMPOUND:5865",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisone",
-            "Prednisone (USP)",
-            "PREDNISONE",
-            "1,2-dehydrocortisone",
-            "prednisone"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:32422522",
-            "PMID:18788725",
-            "PMID:11413487",
-            "PMID:20070106",
-            "PMID:378499",
-            "PMID:15646539",
-            "PMID:20014752",
-            "PMID:25618019",
-            "PMID:23571415",
-            "PMID:19586686"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 4578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisone",
-              "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "HMDB:HMDB0014773",
-                "UMLS:C0032952",
-                "NCIT:C770",
-                "PUBCHEM.COMPOUND:5865",
-                "DrugCentral:2253",
-                "MESH:D011241",
-                "ATC:A07EA03",
-                "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-                "CAS:53-03-2",
-                "PDQ:CDR0000042487",
-                "PathWhiz.Compound:9120",
-                "KEGG.DRUG:D00473",
-                "DRUGBANK:DB00635",
-                "ATC:H02AB07",
-                "UNII:VB0R961HZT",
-                "NDDF:002164",
-                "CHEMBL.COMPOUND:CHEMBL635",
-                "CHEBI:8382",
-                "KEGG.COMPOUND:C07370",
-                "GTOPDB:7096",
-                "RXNORM:8640"
-              ],
-              "id": "PUBCHEM.COMPOUND:5865",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisone",
-                "Prednisone (USP)",
-                "PREDNISONE",
-                "1,2-dehydrocortisone",
-                "prednisone"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:32422522",
-                "PMID:18788725",
-                "PMID:11413487",
-                "PMID:20070106",
-                "PMID:378499",
-                "PMID:15646539",
-                "PMID:20014752",
-                "PMID:25618019",
-                "PMID:23571415",
-                "PMID:19586686"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25955688,
-            "start": 4578,
-            "end": 568,
-            "type": "biolink:derives_from",
-            "properties": {
-              "predicate": "biolink:derives_from",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7299663': {'publication date': '1981 Nov', 'sentence': 'As in humans, prednisolone was partly converted to prednisone in the rabbit.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:converts_to---None---None---None---UMLS:C0032952---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5865",
-              "id": "26415442",
-              "object": "PUBCHEM.COMPOUND:5755",
-              "publications": [
-                "PMID:7299663"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:has_metabolite",
-    "type(r2)": "biolink:physically_interacts_with",
-    "r2.publications_info": "{'PMID:20116390': {'publication date': '2010 Apr', 'sentence': 'Given the close resemblance of the ring A structure of prednisolone and prednisone on the one hand, and of androstadienedione on the other, the transformation of cortisol and cortisone into prednisolone and prednisone in cattle faeces was evaluated.', 'subject score': 1000, 'object score': 1000}, 'PMID:2266496': {'publication date': '1990 Oct', 'sentence': 'Further diagnostic analysis using a linear interconversion model revealed modest interconversion between the two steroids and at least two saturable clearance processes: the conversion of prednisolone to prednisone and the irreversible elimination of prednisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:2931388': {'publication date': '1985', 'sentence': 'The reverse reaction, the conversion of prednisolone to prednisone, did not occur.', 'subject score': 1000, 'object score': 1000}, 'PMID:3593903': {'publication date': '1987', 'sentence': 'The influence of prednisolone on prednisone binding in human plasma was also examined.', 'subject score': 1000, 'object score': 694}, 'PMID:3806371': {'publication date': '1986 Oct', 'sentence': 'Prednisolone was rapidly metabolized to prednisone, while corticosterone concentrations in normal rats declined rapidly and were undetectable by 1 hr.', 'subject score': 1000, 'object score': 1000}, 'PMID:3955201': {'publication date': '1986 Jan-Feb', 'sentence': 'While the non-linear conversion of prednisolone to prednisone is important in explaining the pharmacokinetics of prednisone in all three non-linear models, the same is not true for prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:6149280': {'publication date': '1984 Sep', 'sentence': 'The interaction between prednisone and prednisolone (0-500 ng ml-1) for binding sites on corticosteroid binding globulin (CBG) in rabbit plasma has been investigated.', 'subject score': 1000, 'object score': 1000}, 'PMID:7441495': {'publication date': '1980 Nov', 'sentence': 'The conversion of prednisolone to prednisone, defined by the prednisolone/prednisone ratio, exhibited saturable characteristics which, when data for all dogs was fitted to a Michaelis-Menten type equation (r2 = 0.938), gave a Km of 658 ng/ml, i.e., total prednisolone concentration at half-maximal saturation.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 4578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisone",
-          "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "HMDB:HMDB0014773",
-            "UMLS:C0032952",
-            "NCIT:C770",
-            "PUBCHEM.COMPOUND:5865",
-            "DrugCentral:2253",
-            "MESH:D011241",
-            "ATC:A07EA03",
-            "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-            "CAS:53-03-2",
-            "PDQ:CDR0000042487",
-            "PathWhiz.Compound:9120",
-            "KEGG.DRUG:D00473",
-            "DRUGBANK:DB00635",
-            "ATC:H02AB07",
-            "UNII:VB0R961HZT",
-            "NDDF:002164",
-            "CHEMBL.COMPOUND:CHEMBL635",
-            "CHEBI:8382",
-            "KEGG.COMPOUND:C07370",
-            "GTOPDB:7096",
-            "RXNORM:8640"
-          ],
-          "id": "PUBCHEM.COMPOUND:5865",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisone",
-            "Prednisone (USP)",
-            "PREDNISONE",
-            "1,2-dehydrocortisone",
-            "prednisone"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:32422522",
-            "PMID:18788725",
-            "PMID:11413487",
-            "PMID:20070106",
-            "PMID:378499",
-            "PMID:15646539",
-            "PMID:20014752",
-            "PMID:25618019",
-            "PMID:23571415",
-            "PMID:19586686"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 4578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisone",
-              "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "HMDB:HMDB0014773",
-                "UMLS:C0032952",
-                "NCIT:C770",
-                "PUBCHEM.COMPOUND:5865",
-                "DrugCentral:2253",
-                "MESH:D011241",
-                "ATC:A07EA03",
-                "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-                "CAS:53-03-2",
-                "PDQ:CDR0000042487",
-                "PathWhiz.Compound:9120",
-                "KEGG.DRUG:D00473",
-                "DRUGBANK:DB00635",
-                "ATC:H02AB07",
-                "UNII:VB0R961HZT",
-                "NDDF:002164",
-                "CHEMBL.COMPOUND:CHEMBL635",
-                "CHEBI:8382",
-                "KEGG.COMPOUND:C07370",
-                "GTOPDB:7096",
-                "RXNORM:8640"
-              ],
-              "id": "PUBCHEM.COMPOUND:5865",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisone",
-                "Prednisone (USP)",
-                "PREDNISONE",
-                "1,2-dehydrocortisone",
-                "prednisone"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:32422522",
-                "PMID:18788725",
-                "PMID:11413487",
-                "PMID:20070106",
-                "PMID:378499",
-                "PMID:15646539",
-                "PMID:20014752",
-                "PMID:25618019",
-                "PMID:23571415",
-                "PMID:19586686"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14500325,
-            "start": 568,
-            "end": 4578,
-            "type": "biolink:physically_interacts_with",
-            "properties": {
-              "predicate": "biolink:physically_interacts_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20116390': {'publication date': '2010 Apr', 'sentence': 'Given the close resemblance of the ring A structure of prednisolone and prednisone on the one hand, and of androstadienedione on the other, the transformation of cortisol and cortisone into prednisolone and prednisone in cattle faeces was evaluated.', 'subject score': 1000, 'object score': 1000}, 'PMID:2266496': {'publication date': '1990 Oct', 'sentence': 'Further diagnostic analysis using a linear interconversion model revealed modest interconversion between the two steroids and at least two saturable clearance processes: the conversion of prednisolone to prednisone and the irreversible elimination of prednisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:2931388': {'publication date': '1985', 'sentence': 'The reverse reaction, the conversion of prednisolone to prednisone, did not occur.', 'subject score': 1000, 'object score': 1000}, 'PMID:3593903': {'publication date': '1987', 'sentence': 'The influence of prednisolone on prednisone binding in human plasma was also examined.', 'subject score': 1000, 'object score': 694}, 'PMID:3806371': {'publication date': '1986 Oct', 'sentence': 'Prednisolone was rapidly metabolized to prednisone, while corticosterone concentrations in normal rats declined rapidly and were undetectable by 1 hr.', 'subject score': 1000, 'object score': 1000}, 'PMID:3955201': {'publication date': '1986 Jan-Feb', 'sentence': 'While the non-linear conversion of prednisolone to prednisone is important in explaining the pharmacokinetics of prednisone in all three non-linear models, the same is not true for prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:6149280': {'publication date': '1984 Sep', 'sentence': 'The interaction between prednisone and prednisolone (0-500 ng ml-1) for binding sites on corticosteroid binding globulin (CBG) in rabbit plasma has been investigated.', 'subject score': 1000, 'object score': 1000}, 'PMID:7441495': {'publication date': '1980 Nov', 'sentence': 'The conversion of prednisolone to prednisone, defined by the prednisolone/prednisone ratio, exhibited saturable characteristics which, when data for all dogs was fitted to a Michaelis-Menten type equation (r2 = 0.938), gave a Km of 658 ng/ml, i.e., total prednisolone concentration at half-maximal saturation.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:interacts_with---None---None---None---UMLS:C0032952---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "14808035",
-              "object": "PUBCHEM.COMPOUND:5865",
-              "publications": [
-                "PMID:20116390",
-                "PMID:2266496",
-                "PMID:2931388",
-                "PMID:3593903",
-                "PMID:3806371",
-                "PMID:3955201",
-                "PMID:6149280",
-                "PMID:7441495"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:has_metabolite",
-    "type(r2)": "biolink:physically_interacts_with",
-    "r2.publications_info": "{'PMID:1176582': {'publication date': '1975 Oct', 'sentence': 'The data indicate that prednisone is extensively metabolized to prednisolone before it clears the splanchnic circulation and the formation prednisone by oxidation of the 11-hydorxyl group of prednisolone appears to occur mainly in peripheral tissues.', 'subject score': 1000, 'object score': 1000}, 'PMID:17921190': {'publication date': '2008 Jan', 'sentence': 'PF-915275 dose-dependently inhibited 11betaHSD1-mediated conversion of prednisone to prednisolone, with a maximum of 87% inhibition at a 3-mg/kg dose.', 'subject score': 1000, 'object score': 1000}, 'PMID:20116390': {'publication date': '2010 Apr', 'sentence': 'Given the close resemblance of the ring A structure of prednisolone and prednisone on the one hand, and of androstadienedione on the other, the transformation of cortisol and cortisone into prednisolone and prednisone in cattle faeces was evaluated.', 'subject score': 1000, 'object score': 1000}, 'PMID:2242307': {'publication date': '1990 Sep', 'sentence': 'All the pharmacokinetic parameters, including the conversion of prednisone to prednisolone were similar to the data already published in children with INS.', 'subject score': 1000, 'object score': 1000}, 'PMID:35921255': {'publication date': '2022 Aug 03', 'sentence': 'Here, the urinary excretion profiles of prednisone and prednisolone were evaluated in five volunteers in therapy with glucocorticoid-based rectal formulations containing prednisone or prednisolone caproate.', 'subject score': 1000, 'object score': 1000}, 'PMID:3709632': {'publication date': '1986', 'sentence': 'Prednisone appeared to have no effect on prednisolone binding.', 'subject score': 1000, 'object score': 694}, 'PMID:3987177': {'publication date': '1985 May', 'sentence': 'Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:4639403': {'publication date': '1972 Sep', 'sentence': 'Thus, incomplete conversion of prednisone to prednisolone occurs, which is a necessary step for biological activity; on the other hand there is also impairment of prednisolone degradation.', 'subject score': 1000, 'object score': 1000}, 'PMID:656293': {'publication date': '1978 Jun', 'sentence': '2 In controls, values for AUC were significantly more variable after prednisone than prednisolone, and two subjects showed markedly inefficient conversion of prednisone to prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:7047863': {'publication date': '1982 Apr', 'sentence': 'The results from our study indicate that both of the oral preparations tested provide similar bioavailability of active prednisolone and the conversion of prednisone to prednisolone occurs rapidly.', 'subject score': 1000, 'object score': 1000}, 'PMID:7141787': {'publication date': '1982 Sep', 'sentence': 'This indicates that acute nephrotic syndrome does not produce impaired absorption and conversion of prednisone to prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:7364321': {'publication date': '1980 Jan', 'sentence': 'Impaired conversion of prednisone to prednisolone in patients with liver cirrhosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:849821': {'publication date': '1977 May', 'sentence': 'To determine the effect of impaired liver function on conversion of prednisone to prednisolone, and to investigate the relationship of this to responses to treatment with prednisone, we measured serum prednisone and prednisolone by radioimmunoassay after 10 mg of prednisone was given by vein to 10 healthy volunteers, 6 untreated patients with severe chronic active liver disease (CALD), 10 patients with prednisone-induced remission of CALD, and 3 patients with CALD deteriorating despite treatment with prednisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:994553': {'publication date': '1976 Dec', 'sentence': 'Although high levels of prednisolone appeared rapidly in normal dogs, only slight amounts were measured in dogs with hepatic vascular exclusion, which emphasized the importance of the liver in the conversion of prednisone to prednisolone, its active metabolite.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 4578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisone",
-          "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "HMDB:HMDB0014773",
-            "UMLS:C0032952",
-            "NCIT:C770",
-            "PUBCHEM.COMPOUND:5865",
-            "DrugCentral:2253",
-            "MESH:D011241",
-            "ATC:A07EA03",
-            "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-            "CAS:53-03-2",
-            "PDQ:CDR0000042487",
-            "PathWhiz.Compound:9120",
-            "KEGG.DRUG:D00473",
-            "DRUGBANK:DB00635",
-            "ATC:H02AB07",
-            "UNII:VB0R961HZT",
-            "NDDF:002164",
-            "CHEMBL.COMPOUND:CHEMBL635",
-            "CHEBI:8382",
-            "KEGG.COMPOUND:C07370",
-            "GTOPDB:7096",
-            "RXNORM:8640"
-          ],
-          "id": "PUBCHEM.COMPOUND:5865",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisone",
-            "Prednisone (USP)",
-            "PREDNISONE",
-            "1,2-dehydrocortisone",
-            "prednisone"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:32422522",
-            "PMID:18788725",
-            "PMID:11413487",
-            "PMID:20070106",
-            "PMID:378499",
-            "PMID:15646539",
-            "PMID:20014752",
-            "PMID:25618019",
-            "PMID:23571415",
-            "PMID:19586686"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 4578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisone",
-              "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "HMDB:HMDB0014773",
-                "UMLS:C0032952",
-                "NCIT:C770",
-                "PUBCHEM.COMPOUND:5865",
-                "DrugCentral:2253",
-                "MESH:D011241",
-                "ATC:A07EA03",
-                "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-                "CAS:53-03-2",
-                "PDQ:CDR0000042487",
-                "PathWhiz.Compound:9120",
-                "KEGG.DRUG:D00473",
-                "DRUGBANK:DB00635",
-                "ATC:H02AB07",
-                "UNII:VB0R961HZT",
-                "NDDF:002164",
-                "CHEMBL.COMPOUND:CHEMBL635",
-                "CHEBI:8382",
-                "KEGG.COMPOUND:C07370",
-                "GTOPDB:7096",
-                "RXNORM:8640"
-              ],
-              "id": "PUBCHEM.COMPOUND:5865",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisone",
-                "Prednisone (USP)",
-                "PREDNISONE",
-                "1,2-dehydrocortisone",
-                "prednisone"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:32422522",
-                "PMID:18788725",
-                "PMID:11413487",
-                "PMID:20070106",
-                "PMID:378499",
-                "PMID:15646539",
-                "PMID:20014752",
-                "PMID:25618019",
-                "PMID:23571415",
-                "PMID:19586686"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9096355,
-            "start": 4578,
-            "end": 568,
-            "type": "biolink:physically_interacts_with",
-            "properties": {
-              "predicate": "biolink:physically_interacts_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1176582': {'publication date': '1975 Oct', 'sentence': 'The data indicate that prednisone is extensively metabolized to prednisolone before it clears the splanchnic circulation and the formation prednisone by oxidation of the 11-hydorxyl group of prednisolone appears to occur mainly in peripheral tissues.', 'subject score': 1000, 'object score': 1000}, 'PMID:17921190': {'publication date': '2008 Jan', 'sentence': 'PF-915275 dose-dependently inhibited 11betaHSD1-mediated conversion of prednisone to prednisolone, with a maximum of 87% inhibition at a 3-mg/kg dose.', 'subject score': 1000, 'object score': 1000}, 'PMID:20116390': {'publication date': '2010 Apr', 'sentence': 'Given the close resemblance of the ring A structure of prednisolone and prednisone on the one hand, and of androstadienedione on the other, the transformation of cortisol and cortisone into prednisolone and prednisone in cattle faeces was evaluated.', 'subject score': 1000, 'object score': 1000}, 'PMID:2242307': {'publication date': '1990 Sep', 'sentence': 'All the pharmacokinetic parameters, including the conversion of prednisone to prednisolone were similar to the data already published in children with INS.', 'subject score': 1000, 'object score': 1000}, 'PMID:35921255': {'publication date': '2022 Aug 03', 'sentence': 'Here, the urinary excretion profiles of prednisone and prednisolone were evaluated in five volunteers in therapy with glucocorticoid-based rectal formulations containing prednisone or prednisolone caproate.', 'subject score': 1000, 'object score': 1000}, 'PMID:3709632': {'publication date': '1986', 'sentence': 'Prednisone appeared to have no effect on prednisolone binding.', 'subject score': 1000, 'object score': 694}, 'PMID:3987177': {'publication date': '1985 May', 'sentence': 'Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:4639403': {'publication date': '1972 Sep', 'sentence': 'Thus, incomplete conversion of prednisone to prednisolone occurs, which is a necessary step for biological activity; on the other hand there is also impairment of prednisolone degradation.', 'subject score': 1000, 'object score': 1000}, 'PMID:656293': {'publication date': '1978 Jun', 'sentence': '2 In controls, values for AUC were significantly more variable after prednisone than prednisolone, and two subjects showed markedly inefficient conversion of prednisone to prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:7047863': {'publication date': '1982 Apr', 'sentence': 'The results from our study indicate that both of the oral preparations tested provide similar bioavailability of active prednisolone and the conversion of prednisone to prednisolone occurs rapidly.', 'subject score': 1000, 'object score': 1000}, 'PMID:7141787': {'publication date': '1982 Sep', 'sentence': 'This indicates that acute nephrotic syndrome does not produce impaired absorption and conversion of prednisone to prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:7364321': {'publication date': '1980 Jan', 'sentence': 'Impaired conversion of prednisone to prednisolone in patients with liver cirrhosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:849821': {'publication date': '1977 May', 'sentence': 'To determine the effect of impaired liver function on conversion of prednisone to prednisolone, and to investigate the relationship of this to responses to treatment with prednisone, we measured serum prednisone and prednisolone by radioimmunoassay after 10 mg of prednisone was given by vein to 10 healthy volunteers, 6 untreated patients with severe chronic active liver disease (CALD), 10 patients with prednisone-induced remission of CALD, and 3 patients with CALD deteriorating despite treatment with prednisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:994553': {'publication date': '1976 Dec', 'sentence': 'Although high levels of prednisolone appeared rapidly in normal dogs, only slight amounts were measured in dogs with hepatic vascular exclusion, which emphasized the importance of the liver in the conversion of prednisone to prednisolone, its active metabolite.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032952---SEMMEDDB:interacts_with---None---None---None---UMLS:C0032950---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5865",
-              "id": "9296682",
-              "object": "PUBCHEM.COMPOUND:5755",
-              "publications": [
-                "PMID:1176582",
-                "PMID:17921190",
-                "PMID:20116390",
-                "PMID:2242307",
-                "PMID:35921255",
-                "PMID:3709632",
-                "PMID:3987177",
-                "PMID:4639403",
-                "PMID:656293",
-                "PMID:7047863",
-                "PMID:7141787",
-                "PMID:7364321",
-                "PMID:849821",
-                "PMID:994553"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:has_metabolite",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:24876875': {'publication date': '2014', 'sentence': 'Previous studies from our laboratory revealed that coadministration of EP significantly increased the plasma concentration of prednisolone while decreased the level of cotreated prednisone in rats.', 'subject score': 1000, 'object score': 861}, 'PMID:3207856': {'publication date': '1988 Jul-Aug', 'sentence': 'In a pilot study using one rabbit, prednisone and prednisolone clearance values increased with increase in either prednisone or prednisolone infusion rates.', 'subject score': 851, 'object score': 861}, 'PMID:7107818': {'publication date': '1982 Oct', 'sentence': 'Although there is an increase in the apparent clearance of unbound prednisolone with increasing concentrations, these results are confounded by the interconversion process between prednisone and prednisolone.', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 4578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisone",
-          "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "HMDB:HMDB0014773",
-            "UMLS:C0032952",
-            "NCIT:C770",
-            "PUBCHEM.COMPOUND:5865",
-            "DrugCentral:2253",
-            "MESH:D011241",
-            "ATC:A07EA03",
-            "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-            "CAS:53-03-2",
-            "PDQ:CDR0000042487",
-            "PathWhiz.Compound:9120",
-            "KEGG.DRUG:D00473",
-            "DRUGBANK:DB00635",
-            "ATC:H02AB07",
-            "UNII:VB0R961HZT",
-            "NDDF:002164",
-            "CHEMBL.COMPOUND:CHEMBL635",
-            "CHEBI:8382",
-            "KEGG.COMPOUND:C07370",
-            "GTOPDB:7096",
-            "RXNORM:8640"
-          ],
-          "id": "PUBCHEM.COMPOUND:5865",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisone",
-            "Prednisone (USP)",
-            "PREDNISONE",
-            "1,2-dehydrocortisone",
-            "prednisone"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:32422522",
-            "PMID:18788725",
-            "PMID:11413487",
-            "PMID:20070106",
-            "PMID:378499",
-            "PMID:15646539",
-            "PMID:20014752",
-            "PMID:25618019",
-            "PMID:23571415",
-            "PMID:19586686"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 4578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisone",
-              "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "HMDB:HMDB0014773",
-                "UMLS:C0032952",
-                "NCIT:C770",
-                "PUBCHEM.COMPOUND:5865",
-                "DrugCentral:2253",
-                "MESH:D011241",
-                "ATC:A07EA03",
-                "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-                "CAS:53-03-2",
-                "PDQ:CDR0000042487",
-                "PathWhiz.Compound:9120",
-                "KEGG.DRUG:D00473",
-                "DRUGBANK:DB00635",
-                "ATC:H02AB07",
-                "UNII:VB0R961HZT",
-                "NDDF:002164",
-                "CHEMBL.COMPOUND:CHEMBL635",
-                "CHEBI:8382",
-                "KEGG.COMPOUND:C07370",
-                "GTOPDB:7096",
-                "RXNORM:8640"
-              ],
-              "id": "PUBCHEM.COMPOUND:5865",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisone",
-                "Prednisone (USP)",
-                "PREDNISONE",
-                "1,2-dehydrocortisone",
-                "prednisone"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:32422522",
-                "PMID:18788725",
-                "PMID:11413487",
-                "PMID:20070106",
-                "PMID:378499",
-                "PMID:15646539",
-                "PMID:20014752",
-                "PMID:25618019",
-                "PMID:23571415",
-                "PMID:19586686"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17314023,
-            "start": 568,
-            "end": 4578,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24876875': {'publication date': '2014', 'sentence': 'Previous studies from our laboratory revealed that coadministration of EP significantly increased the plasma concentration of prednisolone while decreased the level of cotreated prednisone in rats.', 'subject score': 1000, 'object score': 861}, 'PMID:3207856': {'publication date': '1988 Jul-Aug', 'sentence': 'In a pilot study using one rabbit, prednisone and prednisolone clearance values increased with increase in either prednisone or prednisolone infusion rates.', 'subject score': 851, 'object score': 861}, 'PMID:7107818': {'publication date': '1982 Oct', 'sentence': 'Although there is an increase in the apparent clearance of unbound prednisolone with increasing concentrations, these results are confounded by the interconversion process between prednisone and prednisolone.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:inhibits---biolink:causes---activity---None---UMLS:C0032952---SEMMEDDB:",
-                "UMLS:C0032950---SEMMEDDB:stimulates---biolink:causes---activity---None---UMLS:C0032952---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "17668631",
-              "object": "PUBCHEM.COMPOUND:5865",
-              "publications": [
-                "PMID:7107818",
-                "PMID:3207856",
-                "PMID:24876875"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:has_metabolite",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:3207856': {'publication date': '1988 Jul-Aug', 'sentence': 'In a pilot study using one rabbit, prednisone and prednisolone clearance values increased with increase in either prednisone or prednisolone infusion rates.', 'subject score': 1000, 'object score': 840}, 'PMID:656293': {'publication date': '1978 Jun', 'sentence': '3 Patients with biochemical and histological evidence of active hepatocellular necrosis showed evidence of impaired activation of prednisone, but this was compensated for by a decreased rate of elimination of prednisolone from the plasma.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 4578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisone",
-          "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "HMDB:HMDB0014773",
-            "UMLS:C0032952",
-            "NCIT:C770",
-            "PUBCHEM.COMPOUND:5865",
-            "DrugCentral:2253",
-            "MESH:D011241",
-            "ATC:A07EA03",
-            "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-            "CAS:53-03-2",
-            "PDQ:CDR0000042487",
-            "PathWhiz.Compound:9120",
-            "KEGG.DRUG:D00473",
-            "DRUGBANK:DB00635",
-            "ATC:H02AB07",
-            "UNII:VB0R961HZT",
-            "NDDF:002164",
-            "CHEMBL.COMPOUND:CHEMBL635",
-            "CHEBI:8382",
-            "KEGG.COMPOUND:C07370",
-            "GTOPDB:7096",
-            "RXNORM:8640"
-          ],
-          "id": "PUBCHEM.COMPOUND:5865",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisone",
-            "Prednisone (USP)",
-            "PREDNISONE",
-            "1,2-dehydrocortisone",
-            "prednisone"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:32422522",
-            "PMID:18788725",
-            "PMID:11413487",
-            "PMID:20070106",
-            "PMID:378499",
-            "PMID:15646539",
-            "PMID:20014752",
-            "PMID:25618019",
-            "PMID:23571415",
-            "PMID:19586686"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 4578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisone",
-              "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "HMDB:HMDB0014773",
-                "UMLS:C0032952",
-                "NCIT:C770",
-                "PUBCHEM.COMPOUND:5865",
-                "DrugCentral:2253",
-                "MESH:D011241",
-                "ATC:A07EA03",
-                "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-                "CAS:53-03-2",
-                "PDQ:CDR0000042487",
-                "PathWhiz.Compound:9120",
-                "KEGG.DRUG:D00473",
-                "DRUGBANK:DB00635",
-                "ATC:H02AB07",
-                "UNII:VB0R961HZT",
-                "NDDF:002164",
-                "CHEMBL.COMPOUND:CHEMBL635",
-                "CHEBI:8382",
-                "KEGG.COMPOUND:C07370",
-                "GTOPDB:7096",
-                "RXNORM:8640"
-              ],
-              "id": "PUBCHEM.COMPOUND:5865",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisone",
-                "Prednisone (USP)",
-                "PREDNISONE",
-                "1,2-dehydrocortisone",
-                "prednisone"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:32422522",
-                "PMID:18788725",
-                "PMID:11413487",
-                "PMID:20070106",
-                "PMID:378499",
-                "PMID:15646539",
-                "PMID:20014752",
-                "PMID:25618019",
-                "PMID:23571415",
-                "PMID:19586686"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21306599,
-            "start": 4578,
-            "end": 568,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3207856': {'publication date': '1988 Jul-Aug', 'sentence': 'In a pilot study using one rabbit, prednisone and prednisolone clearance values increased with increase in either prednisone or prednisolone infusion rates.', 'subject score': 1000, 'object score': 840}, 'PMID:656293': {'publication date': '1978 Jun', 'sentence': '3 Patients with biochemical and histological evidence of active hepatocellular necrosis showed evidence of impaired activation of prednisone, but this was compensated for by a decreased rate of elimination of prednisolone from the plasma.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032952---SEMMEDDB:stimulates---biolink:causes---activity---None---UMLS:C0032950---SEMMEDDB:",
-                "UMLS:C0032952---SEMMEDDB:inhibits---biolink:causes---activity---None---UMLS:C0032950---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5865",
-              "id": "21722189",
-              "object": "PUBCHEM.COMPOUND:5755",
-              "publications": [
-                "PMID:656293",
-                "PMID:3207856"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:has_metabolite",
-    "type(r2)": "biolink:has_input",
-    "r2.publications_info": "{'PMID:12120182': {'publication date': '2001', 'sentence': \"Budesonide is equal to less effective than prednisolone or prednisone therapy in the treatment of active Crohn's disease, but is associated with fewer glucocorticoids adverse reactions.\", 'subject score': 1000, 'object score': 888}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 4578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisone",
-          "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "HMDB:HMDB0014773",
-            "UMLS:C0032952",
-            "NCIT:C770",
-            "PUBCHEM.COMPOUND:5865",
-            "DrugCentral:2253",
-            "MESH:D011241",
-            "ATC:A07EA03",
-            "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-            "CAS:53-03-2",
-            "PDQ:CDR0000042487",
-            "PathWhiz.Compound:9120",
-            "KEGG.DRUG:D00473",
-            "DRUGBANK:DB00635",
-            "ATC:H02AB07",
-            "UNII:VB0R961HZT",
-            "NDDF:002164",
-            "CHEMBL.COMPOUND:CHEMBL635",
-            "CHEBI:8382",
-            "KEGG.COMPOUND:C07370",
-            "GTOPDB:7096",
-            "RXNORM:8640"
-          ],
-          "id": "PUBCHEM.COMPOUND:5865",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisone",
-            "Prednisone (USP)",
-            "PREDNISONE",
-            "1,2-dehydrocortisone",
-            "prednisone"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:32422522",
-            "PMID:18788725",
-            "PMID:11413487",
-            "PMID:20070106",
-            "PMID:378499",
-            "PMID:15646539",
-            "PMID:20014752",
-            "PMID:25618019",
-            "PMID:23571415",
-            "PMID:19586686"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 4578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisone",
-              "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C770\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C770\" NCI Thesaurus); A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.; A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T125; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "HMDB:HMDB0014773",
-                "UMLS:C0032952",
-                "NCIT:C770",
-                "PUBCHEM.COMPOUND:5865",
-                "DrugCentral:2253",
-                "MESH:D011241",
-                "ATC:A07EA03",
-                "INCHIKEY:XOFYZVNMUHMLCC-ZPOLXVRWSA-N",
-                "CAS:53-03-2",
-                "PDQ:CDR0000042487",
-                "PathWhiz.Compound:9120",
-                "KEGG.DRUG:D00473",
-                "DRUGBANK:DB00635",
-                "ATC:H02AB07",
-                "UNII:VB0R961HZT",
-                "NDDF:002164",
-                "CHEMBL.COMPOUND:CHEMBL635",
-                "CHEBI:8382",
-                "KEGG.COMPOUND:C07370",
-                "GTOPDB:7096",
-                "RXNORM:8640"
-              ],
-              "id": "PUBCHEM.COMPOUND:5865",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisone",
-                "Prednisone (USP)",
-                "PREDNISONE",
-                "1,2-dehydrocortisone",
-                "prednisone"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:32422522",
-                "PMID:18788725",
-                "PMID:11413487",
-                "PMID:20070106",
-                "PMID:378499",
-                "PMID:15646539",
-                "PMID:20014752",
-                "PMID:25618019",
-                "PMID:23571415",
-                "PMID:19586686"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9446662,
-            "start": 568,
-            "end": 4578,
-            "type": "biolink:has_input",
-            "properties": {
-              "predicate": "biolink:has_input",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:12120182': {'publication date': '2001', 'sentence': \"Budesonide is equal to less effective than prednisolone or prednisone therapy in the treatment of active Crohn's disease, but is associated with fewer glucocorticoids adverse reactions.\", 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:uses---None---None---None---UMLS:C0032952---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "9655099",
-              "object": "PUBCHEM.COMPOUND:5865",
-              "publications": [
-                "PMID:12120182"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 316847,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
-          "name": "uveitis",
-          "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:1001231",
-            "UMLS:C0042164",
-            "DOID:13141",
-            "SNOMEDCT:128473001",
-            "MEDDRA:10046851",
-            "ICD10:H20.9",
-            "MONDO:0020283",
-            "MESH:D014605",
-            "NCIT:C26909",
-            "MEDDRA:10046855",
-            "HP:0000554",
-            "ORPHANET:98715"
-          ],
-          "id": "MONDO:0020283",
-          "category": "biolink:Disease",
-          "all_names": [
-            "uveitis",
-            "Uveitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316847,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
-              "name": "uveitis",
-              "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:1001231",
-                "UMLS:C0042164",
-                "DOID:13141",
-                "SNOMEDCT:128473001",
-                "MEDDRA:10046851",
-                "ICD10:H20.9",
-                "MONDO:0020283",
-                "MESH:D014605",
-                "NCIT:C26909",
-                "MEDDRA:10046855",
-                "HP:0000554",
-                "ORPHANET:98715"
-              ],
-              "id": "MONDO:0020283",
-              "category": "biolink:Disease",
-              "all_names": [
-                "uveitis",
-                "Uveitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26737448,
-            "start": 568,
-            "end": 316847,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8846850': {'publication date': '1995 Dec', 'sentence': 'Diclofenac and prednisolone inhibit endotoxin-induced uveitis in rabbits.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:disrupts---None---None---None---UMLS:C0042164---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "27206106",
-              "object": "MONDO:0020283",
-              "publications": [
-                "PMID:8846850"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26054252,
-            "start": 568,
-            "end": 319673,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7545698': {'publication date': '1995 Sep', 'sentence': 'Although prednisolone and GH reverse hypoglycemia by different mechanisms, with only prednisolone suppressing tumor IGF-II secretion, both increase the formation of ternary IGF-IGFBP-3 complexes.', 'subject score': 1000, 'object score': 819}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:disrupts---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "26515767",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:7545698"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 310746,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005480",
-          "name": "contact dermatitis",
-          "description": "An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis. []; An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0011616",
-            "NCIT:C26743",
-            "EFO:0005319",
-            "ICD10:L25.9",
-            "MESH:D003877",
-            "MEDDRA:10010803",
-            "MEDDRA:10012442",
-            "MEDDRA:10058308",
-            "SNOMEDCT:40275004",
-            "DOID:2773",
-            "MONDO:0005480",
-            "MEDDRA:10010790",
-            "HP:0032282",
-            "MEDDRA:10012492"
-          ],
-          "id": "MONDO:0005480",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis, Contact",
-            "Contact dermatitis",
-            "Contact Dermatitis",
-            "contact dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310746,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005480",
-              "name": "contact dermatitis",
-              "description": "An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis. []; An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0011616",
-                "NCIT:C26743",
-                "EFO:0005319",
-                "ICD10:L25.9",
-                "MESH:D003877",
-                "MEDDRA:10010803",
-                "MEDDRA:10012442",
-                "MEDDRA:10058308",
-                "SNOMEDCT:40275004",
-                "DOID:2773",
-                "MONDO:0005480",
-                "MEDDRA:10010790",
-                "HP:0032282",
-                "MEDDRA:10012492"
-              ],
-              "id": "MONDO:0005480",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis, Contact",
-                "Contact dermatitis",
-                "Contact Dermatitis",
-                "contact dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25920021,
-            "start": 568,
-            "end": 310746,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7173732': {'publication date': '1982 Jul', 'sentence': 'The aqueous extract of Saiboku-to also showed an inhibition of the contact dermatitis, and it significantly potentiated the inhibition of contact dermatitis by prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:9441732': {'publication date': '1997 Nov', 'sentence': 'RSG or CD also enhanced the activity of prednisolone in suppressing PCl-induced ear contact sensitivity.', 'subject score': 1000, 'object score': 821}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:disrupts---None---None---None---UMLS:C0011616---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "26379811",
-              "object": "MONDO:0005480",
-              "publications": [
-                "PMID:7173732",
-                "PMID:9441732"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25310462,
-            "start": 568,
-            "end": 321523,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:413820': {'publication date': '1977 Dec', 'sentence': 'Only hydrocortisone and prednisolone suppressed LPS pneumonia.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:disrupts---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "25763558",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:413820"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 130846,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-          "name": "allergic disease",
-          "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MONDO:0005271",
-            "SYMP:0000900",
-            "UMLS:C3539909",
-            "MEDDRA:10020759",
-            "MEDDRA:10020756",
-            "NCIT:C114476",
-            "SNOMEDCT:418634005",
-            "MEDDRA:10001738",
-            "HP:0012393",
-            "MESH:D006967",
-            "MEDDRA:10001719",
-            "MEDDRA:10001741",
-            "MEDDRA:10037948",
-            "SNOMEDCT:609328004",
-            "SNOMEDCT:421961002",
-            "UMLS:C1527304",
-            "ICD10:T78.40",
-            "DOID:1205",
-            "MEDDRA:10020755",
-            "MEDDRA:10020751",
-            "MEDDRA:10037932",
-            "UMLS:C0020517",
-            "MEDDRA:10020757",
-            "SNOMEDCT:419076005",
-            "MEDDRA:10001718"
-          ],
-          "id": "MONDO:0005271",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Allergic disposition",
-            "Allergic Reaction",
-            "Hypersensitivity",
-            "allergic reaction",
-            "allergic disease",
-            "Allergy"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000005.htm",
-            "ISBN:0781735149",
-            "http://en.wikipedia.org/wiki/allergy",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 130846,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-              "name": "allergic disease",
-              "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MONDO:0005271",
-                "SYMP:0000900",
-                "UMLS:C3539909",
-                "MEDDRA:10020759",
-                "MEDDRA:10020756",
-                "NCIT:C114476",
-                "SNOMEDCT:418634005",
-                "MEDDRA:10001738",
-                "HP:0012393",
-                "MESH:D006967",
-                "MEDDRA:10001719",
-                "MEDDRA:10001741",
-                "MEDDRA:10037948",
-                "SNOMEDCT:609328004",
-                "SNOMEDCT:421961002",
-                "UMLS:C1527304",
-                "ICD10:T78.40",
-                "DOID:1205",
-                "MEDDRA:10020755",
-                "MEDDRA:10020751",
-                "MEDDRA:10037932",
-                "UMLS:C0020517",
-                "MEDDRA:10020757",
-                "SNOMEDCT:419076005",
-                "MEDDRA:10001718"
-              ],
-              "id": "MONDO:0005271",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Allergic disposition",
-                "Allergic Reaction",
-                "Hypersensitivity",
-                "allergic reaction",
-                "allergic disease",
-                "Allergy"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000005.htm",
-                "ISBN:0781735149",
-                "http://en.wikipedia.org/wiki/allergy",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24785594,
-            "start": 568,
-            "end": 130846,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:36603446': {'publication date': '2022 Dec 16', 'sentence': 'Prednisolone significantly inhibited the measurable sensitivity of IDT, while oclacitinib did not.', 'subject score': 1000, 'object score': 888}, 'PMID:4033733': {'publication date': '1985 Oct 10', 'sentence': 'Failure of prednisolone to suppress carbamazepine hypersensitivity.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:disrupts---None---None---None---UMLS:C0020517---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "25233555",
-              "object": "MONDO:0005271",
-              "publications": [
-                "PMID:36603446",
-                "PMID:4033733"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316866,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015691",
-          "name": "hypereosinophilic syndrome",
-          "description": "A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction. This term has often been applied to cases of chronic eosinophilic leukemia. (WHO, 2001); A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10014950",
-            "UMLS:C1636667",
-            "ICD10:D72.1",
-            "ICD9:288.3",
-            "MEDDRA:10048643",
-            "NCIT:C27038",
-            "EFO:1001467",
-            "SNOMEDCT:1156250009",
-            "SNOMEDCT:419455006",
-            "DOID:999",
-            "MESH:D004802",
-            "MESH:D017681",
-            "ORPHANET:168956",
-            "SNOMEDCT:393573009",
-            "UMLS:C0014457",
-            "HP:0001880",
-            "MONDO:0015691",
-            "UMLS:C1540912"
-          ],
-          "id": "MONDO:0015691",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Disorder characterized by eosinophilia",
-            "hypereosinophilic syndrome",
-            "Hypereosinophilic Syndrome",
-            "Hypereosinophilic syndrome",
-            "Eosinophilia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/hypereosinophilic_syndrome",
-            "https://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316866,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015691",
-              "name": "hypereosinophilic syndrome",
-              "description": "A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction. This term has often been applied to cases of chronic eosinophilic leukemia. (WHO, 2001); A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10014950",
-                "UMLS:C1636667",
-                "ICD10:D72.1",
-                "ICD9:288.3",
-                "MEDDRA:10048643",
-                "NCIT:C27038",
-                "EFO:1001467",
-                "SNOMEDCT:1156250009",
-                "SNOMEDCT:419455006",
-                "DOID:999",
-                "MESH:D004802",
-                "MESH:D017681",
-                "ORPHANET:168956",
-                "SNOMEDCT:393573009",
-                "UMLS:C0014457",
-                "HP:0001880",
-                "MONDO:0015691",
-                "UMLS:C1540912"
-              ],
-              "id": "MONDO:0015691",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Disorder characterized by eosinophilia",
-                "hypereosinophilic syndrome",
-                "Hypereosinophilic Syndrome",
-                "Hypereosinophilic syndrome",
-                "Eosinophilia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/hypereosinophilic_syndrome",
-                "https://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14032018,
-            "start": 568,
-            "end": 316866,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1937894': {'publication date': '1991', 'sentence': 'A comparison with the bronchodilator potency of the above drugs indicated that in guinea pigs salbutamol appears relatively selective as a bronchodilator, prednisolone is selective as an inhibitor of eosinophilia whilst theophylline displays a balance of both activities.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:disrupts---None---None---None---UMLS:C0014457---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "14331279",
-              "object": "MONDO:0015691",
-              "publications": [
-                "PMID:1937894"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10366389,
-            "start": 568,
-            "end": 321528,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13711958': {'publication date': '1961 Jan', 'sentence': 'Reduction of maintenance doses of prednisolone in bronchial asthma by the concurrent use of hydroxyzine.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:disrupts---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10594561",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:13711958"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8660093,
-            "start": 568,
-            "end": 183319,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11325017': {'publication date': '2001 Mar', 'sentence': 'In contrast, cyclosporin A (CyA), FK-506 and prednisolone significantly inhibited antigen-induced airway inflammation and BHR in sensitized BN rats.', 'subject score': 1000, 'object score': 775}, 'PMID:1453084': {'publication date': '1992', 'sentence': 'Inhibition of ocular inflammation by chalcone derivatives and prednisolone.', 'subject score': 1000, 'object score': 888}, 'PMID:2201105': {'publication date': '1990 Jun', 'sentence': 'The comparative drug, prednisolone, significantly reduced inflammation in the ear to which it was applied and in the contralateral ear as well.', 'subject score': 1000, 'object score': 790}, 'PMID:22186974': {'publication date': '2012 Jun', 'sentence': 'This result suggests that prednisolone is useful in suppressing inflammation in Syrian hamster opisthorchiasis, whereas it was also beneficial for parasites by enhancing their reproductive development.', 'subject score': 1000, 'object score': 872}, 'PMID:24314325': {'publication date': '2014 May', 'sentence': 'Upon the suppression of the inflammatory reaction, prednisolone was tapered gradually.', 'subject score': 1000, 'object score': 1000}, 'PMID:3092598': {'publication date': '1986 Jun', 'sentence': 'Benoxaprofen, cyclophosphamide, indomethacin and prednisolone inhibited the paw inflammation in the developing disease whilst the anti-rheumatic compounds auranofin and D-penicillamine exacerbate the paw inflammation.', 'subject score': 1000, 'object score': 888}, 'PMID:31524075': {'publication date': '2019 Nov', 'sentence': 'Pretreatment with prednisolone increased the capacity for AIH-induced functional motor plasticity, suggesting that suppression of inflammation enhances the efficacy of AIH administration in individuals with spinal cord injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:36004044': {'publication date': '2022 Aug', 'sentence': 'We successfully monitored the inflammation activity by FDG-PET and treated recurrent CS by increasing the PSL dose and adding MTX to suppress inflammation.', 'subject score': 888, 'object score': 1000}, 'PMID:7056483': {'publication date': '1982', 'sentence': 'Oral administration of corticosteroid (less than 100 mg prednisolone daily) may be enough for suppression of the inflammation in the Harada type, while a drip infusion of the massive dosage (more than 200 mg prednisolone daily) with gradual tapering off is possible requisite in the Vogt-Koyanagi type.', 'subject score': 775, 'object score': 1000}, 'PMID:9430994': {'publication date': '1997 Sep', 'sentence': 'This inflammatory reaction might be suppressed by prednisolone to facilitate the recovery of the afferent pathway, which led to the typical clinical symptoms of HAM.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:disrupts---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "8854473",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:11325017",
-                "PMID:1453084",
-                "PMID:2201105",
-                "PMID:22186974",
-                "PMID:24314325",
-                "PMID:3092598",
-                "PMID:31524075",
-                "PMID:36004044",
-                "PMID:7056483",
-                "PMID:9430994"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 130846,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-          "name": "allergic disease",
-          "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MONDO:0005271",
-            "SYMP:0000900",
-            "UMLS:C3539909",
-            "MEDDRA:10020759",
-            "MEDDRA:10020756",
-            "NCIT:C114476",
-            "SNOMEDCT:418634005",
-            "MEDDRA:10001738",
-            "HP:0012393",
-            "MESH:D006967",
-            "MEDDRA:10001719",
-            "MEDDRA:10001741",
-            "MEDDRA:10037948",
-            "SNOMEDCT:609328004",
-            "SNOMEDCT:421961002",
-            "UMLS:C1527304",
-            "ICD10:T78.40",
-            "DOID:1205",
-            "MEDDRA:10020755",
-            "MEDDRA:10020751",
-            "MEDDRA:10037932",
-            "UMLS:C0020517",
-            "MEDDRA:10020757",
-            "SNOMEDCT:419076005",
-            "MEDDRA:10001718"
-          ],
-          "id": "MONDO:0005271",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Allergic disposition",
-            "Allergic Reaction",
-            "Hypersensitivity",
-            "allergic reaction",
-            "allergic disease",
-            "Allergy"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000005.htm",
-            "ISBN:0781735149",
-            "http://en.wikipedia.org/wiki/allergy",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 130846,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005271",
-              "name": "allergic disease",
-              "description": "An allergy is an immune response or reaction to substances that are usually not harmful. [HPO:probinson]; An allergy is an immune response or reaction to substances that are usually not harmful.; An allergy is an immune response or reaction to substances that are usually not harmful.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MONDO:0005271",
-                "SYMP:0000900",
-                "UMLS:C3539909",
-                "MEDDRA:10020759",
-                "MEDDRA:10020756",
-                "NCIT:C114476",
-                "SNOMEDCT:418634005",
-                "MEDDRA:10001738",
-                "HP:0012393",
-                "MESH:D006967",
-                "MEDDRA:10001719",
-                "MEDDRA:10001741",
-                "MEDDRA:10037948",
-                "SNOMEDCT:609328004",
-                "SNOMEDCT:421961002",
-                "UMLS:C1527304",
-                "ICD10:T78.40",
-                "DOID:1205",
-                "MEDDRA:10020755",
-                "MEDDRA:10020751",
-                "MEDDRA:10037932",
-                "UMLS:C0020517",
-                "MEDDRA:10020757",
-                "SNOMEDCT:419076005",
-                "MEDDRA:10001718"
-              ],
-              "id": "MONDO:0005271",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Allergic disposition",
-                "Allergic Reaction",
-                "Hypersensitivity",
-                "allergic reaction",
-                "allergic disease",
-                "Allergy"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000005.htm",
-                "ISBN:0781735149",
-                "http://en.wikipedia.org/wiki/allergy",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 27172588,
-            "start": 568,
-            "end": 130846,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9693425': {'publication date': '1998 May-Jun', 'sentence': '[Use of corticosteroids betamethasone and prednisolone in the prevention of allergic reactions in patients undergoing heart surgery with artificial blood circulation].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:prevents---None---None---None---UMLS:C1527304---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "27646185",
-              "object": "MONDO:0005271",
-              "publications": [
-                "PMID:9693425"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320617,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002400",
-          "name": "synovitis",
-          "description": "Inflammation of a synovial membrane.; Inflammation of the SYNOVIAL MEMBRANE.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0039103",
-            "MESH:D013585",
-            "HP:0100769",
-            "SYMP:0000646",
-            "MEDDRA:10042868",
-            "MONDO:0002400",
-            "DOID:2703",
-            "EFO:0008997",
-            "NCIT:C50766",
-            "SNOMEDCT:416209007"
-          ],
-          "id": "MONDO:0002400",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Synovitis",
-            "synovitis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=synovitis",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://en.wikipedia.org/wiki/synovitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320617,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002400",
-              "name": "synovitis",
-              "description": "Inflammation of a synovial membrane.; Inflammation of the SYNOVIAL MEMBRANE.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0039103",
-                "MESH:D013585",
-                "HP:0100769",
-                "SYMP:0000646",
-                "MEDDRA:10042868",
-                "MONDO:0002400",
-                "DOID:2703",
-                "EFO:0008997",
-                "NCIT:C50766",
-                "SNOMEDCT:416209007"
-              ],
-              "id": "MONDO:0002400",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Synovitis",
-                "synovitis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=synovitis",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://en.wikipedia.org/wiki/synovitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25769857,
-            "start": 568,
-            "end": 320617,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:6675263': {'publication date': '1983 Nov', 'sentence': 'The intra-articular injection of prednisolone was shown to considerably reduce incidence of synovitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:9663476': {'publication date': '1998 Jul', 'sentence': 'The reduction in the markers of bone turnover (OC) and synovial tissue turnover (HA and PIIINP) support the general view that prednisolone reduces synovitis and suppresses bone turnover.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:prevents---None---None---None---UMLS:C0039103---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "26227245",
-              "object": "MONDO:0002400",
-              "publications": [
-                "PMID:6675263",
-                "PMID:9663476"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316866,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015691",
-          "name": "hypereosinophilic syndrome",
-          "description": "A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction. This term has often been applied to cases of chronic eosinophilic leukemia. (WHO, 2001); A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10014950",
-            "UMLS:C1636667",
-            "ICD10:D72.1",
-            "ICD9:288.3",
-            "MEDDRA:10048643",
-            "NCIT:C27038",
-            "EFO:1001467",
-            "SNOMEDCT:1156250009",
-            "SNOMEDCT:419455006",
-            "DOID:999",
-            "MESH:D004802",
-            "MESH:D017681",
-            "ORPHANET:168956",
-            "SNOMEDCT:393573009",
-            "UMLS:C0014457",
-            "HP:0001880",
-            "MONDO:0015691",
-            "UMLS:C1540912"
-          ],
-          "id": "MONDO:0015691",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Disorder characterized by eosinophilia",
-            "hypereosinophilic syndrome",
-            "Hypereosinophilic Syndrome",
-            "Hypereosinophilic syndrome",
-            "Eosinophilia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/hypereosinophilic_syndrome",
-            "https://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316866,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015691",
-              "name": "hypereosinophilic syndrome",
-              "description": "A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction. This term has often been applied to cases of chronic eosinophilic leukemia. (WHO, 2001); A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10014950",
-                "UMLS:C1636667",
-                "ICD10:D72.1",
-                "ICD9:288.3",
-                "MEDDRA:10048643",
-                "NCIT:C27038",
-                "EFO:1001467",
-                "SNOMEDCT:1156250009",
-                "SNOMEDCT:419455006",
-                "DOID:999",
-                "MESH:D004802",
-                "MESH:D017681",
-                "ORPHANET:168956",
-                "SNOMEDCT:393573009",
-                "UMLS:C0014457",
-                "HP:0001880",
-                "MONDO:0015691",
-                "UMLS:C1540912"
-              ],
-              "id": "MONDO:0015691",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Disorder characterized by eosinophilia",
-                "hypereosinophilic syndrome",
-                "Hypereosinophilic Syndrome",
-                "Hypereosinophilic syndrome",
-                "Eosinophilia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/hypereosinophilic_syndrome",
-                "https://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19070820,
-            "start": 568,
-            "end": 316866,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2814121': {'publication date': '1989 Nov 14', 'sentence': 'Prednisolone (100 mg/die initially, decreasing doses thereafter) led to significant reduction of infiltrates and eosinophilia.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:prevents---None---None---None---UMLS:C0014457---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "19453072",
-              "object": "MONDO:0015691",
-              "publications": [
-                "PMID:2814121"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16367411,
-            "start": 568,
-            "end": 319673,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23314876': {'publication date': '2013 Jan 11', 'sentence': 'The tumour was significantly reduced by prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:31499334': {'publication date': '2019 Nov - Dec', 'sentence': 'Prednisolone was administered for tumor reduction.', 'subject score': 1000, 'object score': 694}, 'PMID:33571254': {'publication date': '2021', 'sentence': 'Finally, while administration of prednisolone prevented the development of the inflammatory adverse events, it also abrogated the protective anti-tumor effect of the checkout inhibitors.', 'subject score': 1000, 'object score': 750}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:prevents---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16706850",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:23314876",
-                "PMID:31499334",
-                "PMID:33571254"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319330,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005292",
-          "name": "colitis",
-          "description": "Inflammation of the colon.; Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.; Colitis refers to an inflammation of the colon and is often used to describe an inflammation of the large intestine (colon, cecum and rectum). Colitides may be acute and self-limited or chronic, and broadly fit into the category of digestive diseases. [HPO:sdoelken]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10079511",
-            "SNOMEDCT:64226004",
-            "UMLS:C0009319",
-            "MESH:D003092",
-            "EFO:0003872",
-            "ICD10:K52.9",
-            "MEDDRA:10009889",
-            "MONDO:0005292",
-            "NCIT:C26723",
-            "MEDDRA:10009898",
-            "PSY:10220",
-            "DOID:0060180",
-            "HP:0002583",
-            "MEDDRA:10009887"
-          ],
-          "id": "MONDO:0005292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Colitis",
-            "colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319330,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005292",
-              "name": "colitis",
-              "description": "Inflammation of the colon.; Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.; Colitis refers to an inflammation of the colon and is often used to describe an inflammation of the large intestine (colon, cecum and rectum). Colitides may be acute and self-limited or chronic, and broadly fit into the category of digestive diseases. [HPO:sdoelken]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10079511",
-                "SNOMEDCT:64226004",
-                "UMLS:C0009319",
-                "MESH:D003092",
-                "EFO:0003872",
-                "ICD10:K52.9",
-                "MEDDRA:10009889",
-                "MONDO:0005292",
-                "NCIT:C26723",
-                "MEDDRA:10009898",
-                "PSY:10220",
-                "DOID:0060180",
-                "HP:0002583",
-                "MEDDRA:10009887"
-              ],
-              "id": "MONDO:0005292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Colitis",
-                "colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15484616,
-            "start": 568,
-            "end": 319330,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21830095': {'publication date': '2011 Nov', 'sentence': 'Prednisolone prevented the development of colitis, but had no effect on already-developed colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:29379336': {'publication date': '2018 Jan', 'sentence': 'Only polar extract at both doses (200, 400 mg/kg) was more effective than the standard drug Prednisolone (50 mg/kg), it produced percent protection of control colitis by 63.8% and78.4% respectively, while the standard drug Prednisolone produced 54.9% protection.', 'subject score': 851, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:prevents---None---None---None---UMLS:C0009319---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "15809068",
-              "object": "MONDO:0005292",
-              "publications": [
-                "PMID:21830095",
-                "PMID:29379336"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11604490,
-            "start": 568,
-            "end": 321528,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15929952': {'publication date': '2005 Jun', 'sentence': 'Alveolar NO concentration was increased in patients with refractory asthma (7.1 ppb) compared with mild-to-moderate asthma (3.4 ppb) and normal controls (3.4 ppb) and reduced by treatment with prednisolone.', 'subject score': 1000, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:prevents---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "11858005",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:15929952"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 517728,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005124",
-          "name": "leprosy",
-          "description": "A bacterial granulomatous infection caused by Mycobacterium leprae. It is a progressive disease affecting the skin, peripheral nerves, and limbs. If untreated, it causes permanent tissue damage leading to autoamputations.; A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10024230",
-            "NCIT:C84824",
-            "EFO:0001054",
-            "MEDDRA:10024229",
-            "ICD9:030",
-            "MEDDRA:10024232",
-            "DOID:1024",
-            "MONDO:0005124",
-            "UMLS:C0023343",
-            "SNOMEDCT:81004002",
-            "MEDDRA:10019138",
-            "ICD10:A30",
-            "MEDDRA:10024231",
-            "MESH:D007918",
-            "MEDDRA:10028451",
-            "ORPHANET:548"
-          ],
-          "id": "MONDO:0005124",
-          "category": "biolink:Disease",
-          "all_names": [
-            "leprosy",
-            "Leprosy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/leprosy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517728,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005124",
-              "name": "leprosy",
-              "description": "A bacterial granulomatous infection caused by Mycobacterium leprae. It is a progressive disease affecting the skin, peripheral nerves, and limbs. If untreated, it causes permanent tissue damage leading to autoamputations.; A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10024230",
-                "NCIT:C84824",
-                "EFO:0001054",
-                "MEDDRA:10024229",
-                "ICD9:030",
-                "MEDDRA:10024232",
-                "DOID:1024",
-                "MONDO:0005124",
-                "UMLS:C0023343",
-                "SNOMEDCT:81004002",
-                "MEDDRA:10019138",
-                "ICD10:A30",
-                "MEDDRA:10024231",
-                "MESH:D007918",
-                "MEDDRA:10028451",
-                "ORPHANET:548"
-              ],
-              "id": "MONDO:0005124",
-              "category": "biolink:Disease",
-              "all_names": [
-                "leprosy",
-                "Leprosy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/leprosy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10748269,
-            "start": 568,
-            "end": 517728,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14750575': {'publication date': '2003 Dec', 'sentence': 'Prednisolone treatment of sensory impairment of the ulnar and posterior tibial nerves detectable with the monofilament test, but not with the ballpen test, did not improve the long-term outcome in terms of recovery of touch sensibility, not did it reduce the risk of leprosy reactions or nerve function impairment beyond the initial 4-month treatment phase.', 'subject score': 888, 'object score': 872}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:prevents---None---None---None---UMLS:C0023343---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10983909",
-              "object": "MONDO:0005124",
-              "publications": [
-                "PMID:14750575"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10018912,
-            "start": 568,
-            "end": 183319,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12795466': {'publication date': '2003 May', 'sentence': 'CONCLUSIONS: Predocol is an oral preparation of a poorly absorbed salt of prednisolone that is effective in reducing inflammation over short treatment periods in patients with active ulcerative colitis.', 'subject score': 1000, 'object score': 762}, 'PMID:1581697': {'publication date': '1992 Feb', 'sentence': 'This assumption may be supported by the fact that a combined systemic treatment with pyrimethamine, trimethoprim, sulfamethoxazole and prednisolone reduced the retinochoroidal inflammation and periarterial infiltrates.', 'subject score': 1000, 'object score': 861}, 'PMID:16843944': {'publication date': '1995 Oct', 'sentence': 'The therapeutic enema of prednisolone reduced colonic inflammation (CMS, colon weight), improved thymic weight, %GBW and food intake, and reduced plasma IL6 concentrations (P< 0.05).', 'subject score': 1000, 'object score': 888}, 'PMID:17045826': {'publication date': '2007', 'sentence': \"Neither prednisolone nor cilomilast had protective effect on the LPS-induced airways' inflammation.\", 'subject score': 1000, 'object score': 833}, 'PMID:1776474': {'publication date': '1991 Mar', 'sentence': 'Prevention of ocular inflammation by matrine, prednisolone, and cyclooxygenase and lipoxygenase inhibitors.', 'subject score': 1000, 'object score': 888}, 'PMID:21627530': {'publication date': '2011 Jun', 'sentence': 'CONCLUSIONS AND CLINICAL RELEVANCE: Topical administration of 1% prednisolone and 0.1% diclofenac significantly reduced intraocular inflammation in cats with paracentesis-induced uveitis.', 'subject score': 861, 'object score': 888}, 'PMID:23363352': {'publication date': '2013 Feb', 'sentence': 'CONCLUSIONS AND CLINICAL RELEVANCE: Orally administered prednisolone and meloxicam significantly decreased intraocular inflammation in clinically normal cats with paracentesis-induced BAB breakdown.', 'subject score': 827, 'object score': 888}, 'PMID:24884924': {'publication date': '2014 May 02', 'sentence': 'CONCLUSIONS: This study shows that prednisolone decreases inflammation and improves renal function, whilst not reducing liver injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:26965791': {'publication date': '2016 Mar 11', 'sentence': 'Prednisolone might be more effective in reducing inflammation and it had a better safety profile.', 'subject score': 1000, 'object score': 872}, 'PMID:29293747': {'publication date': '2017 Dec', 'sentence': 'Glucocorticoids such as prednisolone reduced the transfer of blood components from blood into milk while reducing the general inflammatory reaction.', 'subject score': 1000, 'object score': 901}, 'PMID:31772757': {'publication date': '2019 Sep', 'sentence': 'A combination of prednisolone, intravenous cyclophosphamide, and plasma exchange reduced the inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:35086209': {'publication date': '2022 Feb', 'sentence': 'Conclusion: NSAIDs used in isolation are comparable to prednisolone in preventing inflammation and pain after uneventful phacoemulsification.', 'subject score': 1000, 'object score': 861}, 'PMID:36029810': {'publication date': '2022 Aug 24', 'sentence': 'Corticosteroids like Hydrocortisone, dexamethasone, Prednisolone and Methylprednisolone has been reported to be effective against SARS-CoV-2 virus in comparison to that of non-steroid drugs, by using non-genomic and genomic effects to prevent and reduce inflammation in tissues and the circulation.', 'subject score': 1000, 'object score': 1000}, 'PMID:9039486': {'publication date': '1997 Jan', 'sentence': 'These results suggest that an inflammatory reaction was induced by binding of anti-basement membrane antibody to cochlear capillaries in inner ear and that this inflammation in cochlea could be reduced by prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:prevents---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "10240036",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:12795466",
-                "PMID:1581697",
-                "PMID:16843944",
-                "PMID:17045826",
-                "PMID:1776474",
-                "PMID:21627530",
-                "PMID:23363352",
-                "PMID:24884924",
-                "PMID:26965791",
-                "PMID:29293747",
-                "PMID:31772757",
-                "PMID:35086209",
-                "PMID:36029810",
-                "PMID:9039486"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18085320,
-            "start": 568,
-            "end": 322104,
-            "type": "biolink:exacerbates",
-            "properties": {
-              "predicate": "biolink:exacerbates",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26193651': {'publication date': '2008 Oct', 'sentence': 'Six weeks prior to his symptoms, prednisolone (PSL) and SASP had been started because of UC aggravation.', 'subject score': 1000, 'object score': 734}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:complicates---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "18452194",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:26193651"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25291387,
-            "start": 568,
-            "end": 319673,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:4083998': {'publication date': '1985', 'sentence': 'When comparing organ specific, age-adjusted expected versus observed incidences after natural death of animals an increased tumor risk was found in organ systems of all treatment modalities but prednisolone.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:predisposes---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "25753407",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:4083998"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 568,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Prednisolone",
-          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-          "equivalent_curies": [
-            "RXNORM:8638",
-            "ATC:A07EA01",
-            "ATC:C05AA04",
-            "ATC:S03BA02",
-            "PDQ:CDR0000043296",
-            "CAS:50-24-8",
-            "ATC:D07XA02",
-            "KEGG.DRUG:D00472",
-            "MESH:D011239",
-            "ATC:S01BA04",
-            "ATC:S02BA03",
-            "CHEBI:8378",
-            "ATC:H02AB06",
-            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-            "ATC:R01AD02",
-            "PUBCHEM.COMPOUND:5755",
-            "PSY:39980",
-            "DrugCentral:2245",
-            "KEGG.COMPOUND:C07369",
-            "ATC:D07AA03",
-            "CAS:8056-11-9",
-            "GTOPDB:2866",
-            "UMLS:C0032950",
-            "UNII:9PHQ9Y1OLM",
-            "CHEMBL.COMPOUND:CHEMBL131",
-            "DRUGBANK:DB00860",
-            "HMDB:HMDB0014998",
-            "NCIT:C769",
-            "PathWhiz.Compound:9315",
-            "NDDF:002155",
-            "ATC:S01CB02"
-          ],
-          "id": "PUBCHEM.COMPOUND:5755",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Prednisolone",
-            "prednisolone",
-            "PREDNISOLONE",
-            "Prednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:24656565",
-            "PMID:20022146",
-            "PMID:19397323",
-            "PMID:12932140",
-            "PMID:17181172",
-            "PMID:22465636",
-            "PMID:14971904",
-            "PMID:6827553",
-            "PMID:19682771"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16209955,
-            "start": 568,
-            "end": 321523,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23053189': {'publication date': '2013 Jan', 'sentence': 'R-CHOP chemotherapy composed of rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone which might increase the risk of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma.', 'subject score': 1000, 'object score': 888}, 'PMID:33262125': {'publication date': '2020 Dec 01', 'sentence': 'The study also suggests that exposure to oral prednisolone increases the risk of cellulitis, pneumonia, and upper respiratory infection.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0032950---SEMMEDDB:predisposes---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5755",
-              "id": "16546227",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:23053189",
-                "PMID:33262125"
-              ]
-            }
-          },
-          "end": {
-            "identity": 568,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Prednisolone",
-              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
-              "equivalent_curies": [
-                "RXNORM:8638",
-                "ATC:A07EA01",
-                "ATC:C05AA04",
-                "ATC:S03BA02",
-                "PDQ:CDR0000043296",
-                "CAS:50-24-8",
-                "ATC:D07XA02",
-                "KEGG.DRUG:D00472",
-                "MESH:D011239",
-                "ATC:S01BA04",
-                "ATC:S02BA03",
-                "CHEBI:8378",
-                "ATC:H02AB06",
-                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
-                "ATC:R01AD02",
-                "PUBCHEM.COMPOUND:5755",
-                "PSY:39980",
-                "DrugCentral:2245",
-                "KEGG.COMPOUND:C07369",
-                "ATC:D07AA03",
-                "CAS:8056-11-9",
-                "GTOPDB:2866",
-                "UMLS:C0032950",
-                "UNII:9PHQ9Y1OLM",
-                "CHEMBL.COMPOUND:CHEMBL131",
-                "DRUGBANK:DB00860",
-                "HMDB:HMDB0014998",
-                "NCIT:C769",
-                "PathWhiz.Compound:9315",
-                "NDDF:002155",
-                "ATC:S01CB02"
-              ],
-              "id": "PUBCHEM.COMPOUND:5755",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Prednisolone",
-                "prednisolone",
-                "PREDNISOLONE",
-                "Prednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:24656565",
-                "PMID:20022146",
-                "PMID:19397323",
-                "PMID:12932140",
-                "PMID:17181172",
-                "PMID:22465636",
-                "PMID:14971904",
-                "PMID:6827553",
-                "PMID:19682771"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 517695,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005109",
-          "name": "HIV infectious disease",
-          "description": "A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.",
-          "equivalent_curies": [
-            "UMLS:C0019693",
-            "ICD9:042-042.99",
-            "SNOMEDCT:86406008",
-            "NCIT:C3108",
-            "MEDDRA:10020161",
-            "PDQ:CDR0000585059",
-            "MEDDRA:10020443",
-            "MEDDRA:10020160",
-            "MONDO:0005109",
-            "EFO:0000764",
-            "MEDDRA:10020172",
-            "MESH:D015658",
-            "DOID:526"
-          ],
-          "id": "MONDO:0005109",
-          "category": "biolink:Disease",
-          "all_names": [
-            "human immunodeficiency virus infectious disease",
-            "HIV infection",
-            "HIV infectious disease",
-            "HIV Infection",
-            "Human immunodeficiency virus [hiv] infection",
-            "HIV Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/hiv",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000602.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517695,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005109",
-              "name": "HIV infectious disease",
-              "description": "A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.",
-              "equivalent_curies": [
-                "UMLS:C0019693",
-                "ICD9:042-042.99",
-                "SNOMEDCT:86406008",
-                "NCIT:C3108",
-                "MEDDRA:10020161",
-                "PDQ:CDR0000585059",
-                "MEDDRA:10020443",
-                "MEDDRA:10020160",
-                "MONDO:0005109",
-                "EFO:0000764",
-                "MEDDRA:10020172",
-                "MESH:D015658",
-                "DOID:526"
-              ],
-              "id": "MONDO:0005109",
-              "category": "biolink:Disease",
-              "all_names": [
-                "human immunodeficiency virus infectious disease",
-                "HIV infection",
-                "HIV infectious disease",
-                "HIV Infection",
-                "Human immunodeficiency virus [hiv] infection",
-                "HIV Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/hiv",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000602.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26552751,
-            "start": 569,
-            "end": 517695,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8522825': {'publication date': '1995 Jul', 'sentence': 'Cortisol deficiency is common in late stage HIV disease, but symptoms of fatigue and postural hypotension, as well as biochemical findings, are poor predictors of cortisol deficiency.', 'subject score': 888, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0019693---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "27027571",
-              "object": "MONDO:0005109",
-              "publications": [
-                "PMID:8522825"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318021,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000745",
-          "name": "cardiac arrest",
-          "description": "The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.; Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.; An abrupt loss of heart function. []; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:0060319",
-            "ICD10:I46",
-            "MEDDRA:10003109",
-            "UMLS:C0018790",
-            "HP:0001695",
-            "SNOMEDCT:410429000",
-            "MEDDRA:10082515",
-            "UMLS:C0444720",
-            "SNOMEDCT:397829000",
-            "MEDDRA:10003589",
-            "NCIT:C50479",
-            "PSY:07595",
-            "MEDDRA:10019249",
-            "SNOMEDCT:261195002",
-            "MEDDRA:10003587",
-            "MEDDRA:10047284",
-            "MESH:D006323",
-            "MONDO:0000745",
-            "MEDDRA:10041914",
-            "EFO:0009492",
-            "MEDDRA:10003586",
-            "MEDDRA:10007515",
-            "ICD9:427.5",
-            "MEDDRA:10047285"
-          ],
-          "id": "MONDO:0000745",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiac Arrest",
-            "cardiac arrest",
-            "Cardiac arrest",
-            "Heart Arrest"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/cardiacarrest.htm",
-            "http://en.wikipedia.org/wiki/cardiac_arrest",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318021,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000745",
-              "name": "cardiac arrest",
-              "description": "The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.; Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.; An abrupt loss of heart function. []; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:0060319",
-                "ICD10:I46",
-                "MEDDRA:10003109",
-                "UMLS:C0018790",
-                "HP:0001695",
-                "SNOMEDCT:410429000",
-                "MEDDRA:10082515",
-                "UMLS:C0444720",
-                "SNOMEDCT:397829000",
-                "MEDDRA:10003589",
-                "NCIT:C50479",
-                "PSY:07595",
-                "MEDDRA:10019249",
-                "SNOMEDCT:261195002",
-                "MEDDRA:10003587",
-                "MEDDRA:10047284",
-                "MESH:D006323",
-                "MONDO:0000745",
-                "MEDDRA:10041914",
-                "EFO:0009492",
-                "MEDDRA:10003586",
-                "MEDDRA:10007515",
-                "ICD9:427.5",
-                "MEDDRA:10047285"
-              ],
-              "id": "MONDO:0000745",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiac Arrest",
-                "cardiac arrest",
-                "Cardiac arrest",
-                "Heart Arrest"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/cardiacarrest.htm",
-                "http://en.wikipedia.org/wiki/cardiac_arrest",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25473097,
-            "start": 569,
-            "end": 318021,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:5597676': {'publication date': '1967 Jun 08', 'sentence': '[Plasma cortisol and 17-ketosteroids in urine in relation to cardiac arrest].', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0018790---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "25927636",
-              "object": "MONDO:0000745",
-              "publications": [
-                "PMID:5597676"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319679,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-          "name": "lymphoma",
-          "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:115244002",
-            "DOID:0060058",
-            "MONDO:0005062",
-            "SNOMEDCT:118600007",
-            "HP:0002665",
-            "NCIT:C7065",
-            "EFO:0000574",
-            "ORPHANET:223735",
-            "MESH:D008223",
-            "SNOMEDCT:188676008",
-            "PDQ:CDR0000041429",
-            "MEDDRA:10025316",
-            "UMLS:C0024299",
-            "NCIT:C3208",
-            "MEDDRA:10025632",
-            "MEDDRA:10025310",
-            "MEDDRA:10025633",
-            "SNOMEDCT:1163043007",
-            "ICD10:C85.9",
-            "UMLS:C1536843",
-            "UMLS:C0334621",
-            "MEDDRA:10025315"
-          ],
-          "id": "MONDO:0005062",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphocytic Neoplasm",
-            "Lymphoma",
-            "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-            "lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/lymphoma",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319679,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-              "name": "lymphoma",
-              "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:115244002",
-                "DOID:0060058",
-                "MONDO:0005062",
-                "SNOMEDCT:118600007",
-                "HP:0002665",
-                "NCIT:C7065",
-                "EFO:0000574",
-                "ORPHANET:223735",
-                "MESH:D008223",
-                "SNOMEDCT:188676008",
-                "PDQ:CDR0000041429",
-                "MEDDRA:10025316",
-                "UMLS:C0024299",
-                "NCIT:C3208",
-                "MEDDRA:10025632",
-                "MEDDRA:10025310",
-                "MEDDRA:10025633",
-                "SNOMEDCT:1163043007",
-                "ICD10:C85.9",
-                "UMLS:C1536843",
-                "UMLS:C0334621",
-                "MEDDRA:10025315"
-              ],
-              "id": "MONDO:0005062",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphocytic Neoplasm",
-                "Lymphoma",
-                "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-                "lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/lymphoma",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25344361,
-            "start": 569,
-            "end": 319679,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:4358928': {'publication date': '1973 Dec 19', 'sentence': 'Independence of theta and TL surface antigens and killing by thymidine, cortisol, phytohemagglutinin, and cyclic AMP in a murine lymphoma.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0024299---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "25797574",
-              "object": "MONDO:0005062",
-              "publications": [
-                "PMID:4358928"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322120,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-          "name": "Crohn disease",
-          "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003424",
-            "ORPHANET:206",
-            "NCIT:C37262",
-            "MEDDRA:10038281",
-            "MEDDRA:10011405",
-            "UMLS:CN043071",
-            "SNOMEDCT:50440006",
-            "MEDDRA:10057032",
-            "HP:0100280",
-            "EFO:0000384",
-            "DOID:8778",
-            "MONDO:0005011",
-            "PDQ:CDR0000714480",
-            "UMLS:C0010346",
-            "NCIT:C2965",
-            "SNOMEDCT:7620006",
-            "ICD10:K50.1",
-            "UMLS:C0156147",
-            "MEDDRA:10011398",
-            "MEDDRA:10011401",
-            "SNOMEDCT:34000006",
-            "ICD9:555.1",
-            "MEDDRA:10013099",
-            "MEDDRA:10011402",
-            "MEDDRA:10011400"
-          ],
-          "id": "MONDO:0005011",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Granulomatous Colitis",
-            "Crohn's disease of large bowel",
-            "Regional enteritis of large intestine",
-            "Crohn Disease",
-            "Crohn disease",
-            "Crohn's disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/chron%27s_disease",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322120,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-              "name": "Crohn disease",
-              "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003424",
-                "ORPHANET:206",
-                "NCIT:C37262",
-                "MEDDRA:10038281",
-                "MEDDRA:10011405",
-                "UMLS:CN043071",
-                "SNOMEDCT:50440006",
-                "MEDDRA:10057032",
-                "HP:0100280",
-                "EFO:0000384",
-                "DOID:8778",
-                "MONDO:0005011",
-                "PDQ:CDR0000714480",
-                "UMLS:C0010346",
-                "NCIT:C2965",
-                "SNOMEDCT:7620006",
-                "ICD10:K50.1",
-                "UMLS:C0156147",
-                "MEDDRA:10011398",
-                "MEDDRA:10011401",
-                "SNOMEDCT:34000006",
-                "ICD9:555.1",
-                "MEDDRA:10013099",
-                "MEDDRA:10011402",
-                "MEDDRA:10011400"
-              ],
-              "id": "MONDO:0005011",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Granulomatous Colitis",
-                "Crohn's disease of large bowel",
-                "Regional enteritis of large intestine",
-                "Crohn Disease",
-                "Crohn disease",
-                "Crohn's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/chron%27s_disease",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24684607,
-            "start": 569,
-            "end": 322120,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:36450464': {'publication date': '2022 Nov 30', 'sentence': 'Furthermore, this treatment process demonstrated the superior anti-inflammatory effect of prednisolone over that of hydrocortisone and supported the assumption of inflammation related to CD.', 'subject score': 1000, 'object score': 1000}, 'PMID:9741018': {'publication date': '1998 Aug', 'sentence': \"The effectiveness of intravenous corticotrophin versus hydrocortisone in ulcerative colitis has been determined including whether previous steroid therapy influenced the better response to one rather than the other, but no such studies have ever been done in Crohn's disease.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0010346---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "25131277",
-              "object": "MONDO:0005011",
-              "publications": [
-                "PMID:36450464",
-                "PMID:9741018"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 540309,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002046",
-          "name": "alcohol abuse",
-          "description": "The use of alcoholic beverages to excess, either on individual occasions (\"binge drinking\") or as a regular practice.; A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4); UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "MEDDRA:10001584",
-            "UMLS:C0085762",
-            "MONDO:0002046",
-            "MESH:D000437",
-            "PSY:01660",
-            "DOID:1574",
-            "NCIT:C20701",
-            "MEDDRA:10063501",
-            "MEDDRA:10001589",
-            "ICD9:305.0",
-            "ICD10:F10.1",
-            "SNOMEDCT:15167005"
-          ],
-          "id": "MONDO:0002046",
-          "category": "biolink:Disease",
-          "all_names": [
-            "alcohol use disorder",
-            "alcohol abuse",
-            "Alcoholism",
-            "Alcohol Abuse",
-            "Alcohol abuse"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/alcohol-use-disorders",
-            "http://en.wikipedia.org/wiki/alcohol_abuse"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 540309,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002046",
-              "name": "alcohol abuse",
-              "description": "The use of alcoholic beverages to excess, either on individual occasions (\"binge drinking\") or as a regular practice.; A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4); UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "MEDDRA:10001584",
-                "UMLS:C0085762",
-                "MONDO:0002046",
-                "MESH:D000437",
-                "PSY:01660",
-                "DOID:1574",
-                "NCIT:C20701",
-                "MEDDRA:10063501",
-                "MEDDRA:10001589",
-                "ICD9:305.0",
-                "ICD10:F10.1",
-                "SNOMEDCT:15167005"
-              ],
-              "id": "MONDO:0002046",
-              "category": "biolink:Disease",
-              "all_names": [
-                "alcohol use disorder",
-                "alcohol abuse",
-                "Alcoholism",
-                "Alcohol Abuse",
-                "Alcohol abuse"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/alcohol-use-disorders",
-                "http://en.wikipedia.org/wiki/alcohol_abuse"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19406436,
-            "start": 569,
-            "end": 540309,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28751021': {'publication date': '2017 Nov', 'sentence': 'Ordinary least squared (OLS) regression was used to evaluate whether race moderated the associations between alcohol abuse and four biomarkers-urinary cortisol and serum dehydroepiandrosterone sulfate (DHEA-S), epinephrine and norepinephrine-and two composite summary scores, each consisting of two components that characterize the hypothalamic pituitary adrenal (HPA)-axis and sympathetic nervous systems (SNS), respectively.', 'subject score': 833, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0085762---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "19793698",
-              "object": "MONDO:0002046",
-              "publications": [
-                "PMID:28751021"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19148229,
-            "start": 569,
-            "end": 295849,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28292220': {'publication date': '2017 Jan 01', 'sentence': 'CONCLUSION: In patients with septic shock, low-dose hydrocortisone was associated with a lower risk of developing AF during the acute phase.', 'subject score': 901, 'object score': 901}, 'PMID:33822969': {'publication date': '2021 Apr 05', 'sentence': 'RESULTS: One standard deviation increase in genetically predicted plasma cortisol was associated with greater risk of AF (OR 1.20, 95% CI 1.06-1.35).', 'subject score': 775, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "19531872",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:28292220",
-                "PMID:33822969"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 526488,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0003699",
-          "name": "phobic disorder",
-          "description": "Disorders characterized by persistent, unrealistic, intense fear of an object, activity, or situation.; An anxiety disorder characterized by an intense, irrational fear of an object, activity, or situation. The individual seeks to avoid the object, activity, or situation. In adults, the individual recognizes that the fear is excessive or unreasonable.; Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid. The individual recognizes the fear as excessive or unreasonable.; A phobia is a type of anxiety disorder. It is a strong, irrational fear of something that poses little or no real danger. There are many specific phobias. Acrophobia is a fear of heights. Agoraphobia is a fear of public places, and claustrophobia is a fear of closed-in places. If you become anxious and extremely self-conscious in everyday social situations, you could have a social phobia. Other common phobias involve tunnels, highway driving, water, flying, animals and blood.  People with phobias try to avoid what they are afraid of. If they cannot, they may experience: Panic and fear Rapid heartbeat Shortness of breath Trembling A strong desire to get away  Phobias usually start in children or teens, and continue into adulthood. The causes of specific phobias are not known, but they sometimes run in families.  Treatment helps most people with phobias. Options include medicines, therapy or both. NIH: National Institute of Mental Health; UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "NCIT:C35420",
-            "SNOMEDCT:386808001",
-            "NBO:0000246",
-            "ICD9:300.2",
-            "MONDO:0003699",
-            "ICD10:F40",
-            "MEDDRA:10034919",
-            "MESH:D010698",
-            "UMLS:C0349231",
-            "MEDDRA:10034922",
-            "SNOMEDCT:386810004",
-            "ICD9:300.20",
-            "MEDDRA:10034912",
-            "MEDDRA:10034917",
-            "EFO:1001908",
-            "DOID:591",
-            "MEDDRA:10034915"
-          ],
-          "id": "MONDO:0003699",
-          "category": "biolink:Disease",
-          "all_names": [
-            "phobic disorder",
-            "Phobia",
-            "phobia",
-            "Phobic anxiety disorder",
-            "Phobic Disorders",
-            "Phobia, unspecified",
-            "Phobic disorders"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/anxiety_disorde"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526488,
-            "labels": [
-              "biolink:BehavioralFeature",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0003699",
-              "name": "phobic disorder",
-              "description": "Disorders characterized by persistent, unrealistic, intense fear of an object, activity, or situation.; An anxiety disorder characterized by an intense, irrational fear of an object, activity, or situation. The individual seeks to avoid the object, activity, or situation. In adults, the individual recognizes that the fear is excessive or unreasonable.; Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid. The individual recognizes the fear as excessive or unreasonable.; A phobia is a type of anxiety disorder. It is a strong, irrational fear of something that poses little or no real danger. There are many specific phobias. Acrophobia is a fear of heights. Agoraphobia is a fear of public places, and claustrophobia is a fear of closed-in places. If you become anxious and extremely self-conscious in everyday social situations, you could have a social phobia. Other common phobias involve tunnels, highway driving, water, flying, animals and blood.  People with phobias try to avoid what they are afraid of. If they cannot, they may experience: Panic and fear Rapid heartbeat Shortness of breath Trembling A strong desire to get away  Phobias usually start in children or teens, and continue into adulthood. The causes of specific phobias are not known, but they sometimes run in families.  Treatment helps most people with phobias. Options include medicines, therapy or both. NIH: National Institute of Mental Health; UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "NCIT:C35420",
-                "SNOMEDCT:386808001",
-                "NBO:0000246",
-                "ICD9:300.2",
-                "MONDO:0003699",
-                "ICD10:F40",
-                "MEDDRA:10034919",
-                "MESH:D010698",
-                "UMLS:C0349231",
-                "MEDDRA:10034922",
-                "SNOMEDCT:386810004",
-                "ICD9:300.20",
-                "MEDDRA:10034912",
-                "MEDDRA:10034917",
-                "EFO:1001908",
-                "DOID:591",
-                "MEDDRA:10034915"
-              ],
-              "id": "MONDO:0003699",
-              "category": "biolink:Disease",
-              "all_names": [
-                "phobic disorder",
-                "Phobia",
-                "phobia",
-                "Phobic anxiety disorder",
-                "Phobic Disorders",
-                "Phobia, unspecified",
-                "Phobic disorders"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/anxiety_disorde"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18335343,
-            "start": 569,
-            "end": 526488,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26657985': {'publication date': '2015 Dec', 'sentence': 'The incidence of psychological symptoms as somatization, obsessive-compulsive symptoms, depression, anxiety, phobia, and nonspecific symptoms is statistically increased in pregnant women with elevated morning cortisol, but in women with elevated afternoon cortisol also occurring aggressiveness and paranoia.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0349231---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "18705900",
-              "object": "MONDO:0003699",
-              "publications": [
-                "PMID:26657985"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320360,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005083",
-          "name": "psoriasis",
-          "description": "An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.; A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.; A skin abnormality characterized by redness and irritation, with thick, red skin that displays flaky, silver-white patches (scales). [HPO:probinson]; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have psoriasis also get a form of arthritis called psoriatic arthritis. A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast.  Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope. Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include: Infections Stress Dry skin Certain medicines  Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases ; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D011565",
-            "SNOMEDCT:9014002",
-            "ICD10:L40",
-            "MEDDRA:10058675",
-            "MONDO:0005083",
-            "DOID:8893",
-            "UMLS:C0033860",
-            "EFO:0000676",
-            "UMLS:C0262985",
-            "NCIT:C3346",
-            "NCIT:C27724",
-            "OMIM.PS:177900",
-            "OMIM:PS177900",
-            "SNOMEDCT:52230004",
-            "HP:0003765",
-            "MEDDRA:10037153",
-            "SNOMEDCT:238564003"
-          ],
-          "id": "MONDO:0005083",
-          "category": "biolink:Disease",
-          "all_names": [
-            "psoriasis",
-            "Psoriasiform eczema",
-            "Psoriasis",
-            "Psoriasiform dermatitis",
-            "Psoriasiform Dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.cdc.gov/psoriasis/index.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320360,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005083",
-              "name": "psoriasis",
-              "description": "An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.; A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.; A skin abnormality characterized by redness and irritation, with thick, red skin that displays flaky, silver-white patches (scales). [HPO:probinson]; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have psoriasis also get a form of arthritis called psoriatic arthritis. A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast.  Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope. Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include: Infections Stress Dry skin Certain medicines  Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases ; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D011565",
-                "SNOMEDCT:9014002",
-                "ICD10:L40",
-                "MEDDRA:10058675",
-                "MONDO:0005083",
-                "DOID:8893",
-                "UMLS:C0033860",
-                "EFO:0000676",
-                "UMLS:C0262985",
-                "NCIT:C3346",
-                "NCIT:C27724",
-                "OMIM.PS:177900",
-                "OMIM:PS177900",
-                "SNOMEDCT:52230004",
-                "HP:0003765",
-                "MEDDRA:10037153",
-                "SNOMEDCT:238564003"
-              ],
-              "id": "MONDO:0005083",
-              "category": "biolink:Disease",
-              "all_names": [
-                "psoriasis",
-                "Psoriasiform eczema",
-                "Psoriasis",
-                "Psoriasiform dermatitis",
-                "Psoriasiform Dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.cdc.gov/psoriasis/index.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14842179,
-            "start": 569,
-            "end": 320360,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20716227': {'publication date': '2010 Nov', 'sentence': 'How stress gets under the skin: cortisol and stress reactivity in psoriasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:21094146': {'publication date': '2011 Jan 07', 'sentence': 'Collectively these data show that PHK are capable of extra-adrenal cortisol synthesis, which could be a fundamental pathway in skin biology with implications in psoriasis and atopic dermatitis.', 'subject score': 775, 'object score': 1000}, 'PMID:24288511': {'publication date': '2013', 'sentence': 'Association of psoriasis severity with serum prolactin, thyroid hormones, and cortisol before and after treatment.', 'subject score': 1000, 'object score': 888}, 'PMID:25387679': {'publication date': '2014 Dec', 'sentence': 'The findings indicated that HPA dysfunction may be present in psoriasis, as bedtime cortisol was correlated with psoriasis severity.', 'subject score': 888, 'object score': 888}, 'PMID:28735612': {'publication date': '2017 08', 'sentence': 'Cutaneous Glucocorticoidogenesis and Cortisol Signaling Are Defective in Psoriasis.', 'subject score': 888, 'object score': 1000}, 'PMID:5122563': {'publication date': '1971 May', 'sentence': '[Use of ultrasonics and phonophoresis with hydrocortisone in chronic psoriasis].', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0033860---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "15155784",
-              "object": "MONDO:0005083",
-              "publications": [
-                "PMID:20716227",
-                "PMID:21094146",
-                "PMID:24288511",
-                "PMID:25387679",
-                "PMID:28735612",
-                "PMID:5122563"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320151,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-          "name": "dermatitis, atopic",
-          "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MESH:C566404",
-            "MEDDRA:10012434",
-            "SNOMEDCT:24079001",
-            "MONDO:0011292",
-            "MEDDRA:10003641",
-            "MONDO:0100181",
-            "MEDDRA:10014191",
-            "OMIM:603165",
-            "HP:0001047",
-            "MEDDRA:10001711",
-            "MEDDRA:10003639",
-            "UMLS:C0011615",
-            "UMLS:C4280605",
-            "UMLS:C1864155",
-            "MEDDRA:10012438",
-            "MEDDRA:10014188",
-            "MEDDRA:10001712",
-            "MESH:D003876",
-            "SNOMEDCT:200775004"
-          ],
-          "id": "MONDO:0011292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis, Atopic, 1",
-            "dermatitis, atopic",
-            "Dermatitis, Atopic",
-            "Baby eczema",
-            "Dermatitis, atopic related phenotypic feature",
-            "Atopic dermatitis",
-            "dermatitis, atopic, 1"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:27904186",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320151,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-              "name": "dermatitis, atopic",
-              "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MESH:C566404",
-                "MEDDRA:10012434",
-                "SNOMEDCT:24079001",
-                "MONDO:0011292",
-                "MEDDRA:10003641",
-                "MONDO:0100181",
-                "MEDDRA:10014191",
-                "OMIM:603165",
-                "HP:0001047",
-                "MEDDRA:10001711",
-                "MEDDRA:10003639",
-                "UMLS:C0011615",
-                "UMLS:C4280605",
-                "UMLS:C1864155",
-                "MEDDRA:10012438",
-                "MEDDRA:10014188",
-                "MEDDRA:10001712",
-                "MESH:D003876",
-                "SNOMEDCT:200775004"
-              ],
-              "id": "MONDO:0011292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis, Atopic, 1",
-                "dermatitis, atopic",
-                "Dermatitis, Atopic",
-                "Baby eczema",
-                "Dermatitis, atopic related phenotypic feature",
-                "Atopic dermatitis",
-                "dermatitis, atopic, 1"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:27904186",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14582341,
-            "start": 569,
-            "end": 320151,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2025556': {'publication date': '1991 Apr', 'sentence': 'Absorption of hydrocortisone from the skin reservoir in atopic dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:21094146': {'publication date': '2011 Jan 07', 'sentence': 'Collectively these data show that PHK are capable of extra-adrenal cortisol synthesis, which could be a fundamental pathway in skin biology with implications in psoriasis and atopic dermatitis.', 'subject score': 775, 'object score': 1000}, 'PMID:25396426': {'publication date': '2014', 'sentence': 'Thus, NP-mediated transcutaneous co-delivery of HC and HT can be considered as a promising therapy for managing immunological and histological spectra associated with AD.', 'subject score': 1000, 'object score': 1000}, 'PMID:27506086': {'publication date': '2016 May', 'sentence': 'The correlation between CAD severity and hair cortisol concentration was evaluated.', 'subject score': 623, 'object score': 861}, 'PMID:3890401': {'publication date': '1985 Apr', 'sentence': '[Comparative characteristics of the changes in the concentrations of sugar, insulin, glucagon and cortisol of the blood in atopic dermatitis and eczema patients].', 'subject score': 1000, 'object score': 1000}, 'PMID:8949461': {'publication date': '1996 Sep', 'sentence': 'Transepidermal water loss predicts systemic absorption of topical hydrocortisone in atopic dermatitis.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0011615---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14891361",
-              "object": "MONDO:0011292",
-              "publications": [
-                "PMID:2025556",
-                "PMID:21094146",
-                "PMID:25396426",
-                "PMID:27506086",
-                "PMID:3890401",
-                "PMID:8949461"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:19620192': {'publication date': '2009 Aug', 'sentence': \"OBJECTIVE: To assess dexamethasone (DEX) and hydrocortisone (HC) use in premature infants over time and the association of steroid use with the incidence of bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age.\", 'subject score': 888, 'object score': 1000}, 'PMID:27239054': {'publication date': '2016 Sep', 'sentence': 'CONCLUSION: Using hydrocortisone after 14 days on ventilated extremely preterm infants was associated with decreased BPD, with no apparent effects on neurodevelopment at two years of corrected age.', 'subject score': 1000, 'object score': 901}, 'PMID:35226067': {'publication date': '2022 Feb 28', 'sentence': \"High certainty of evidence from high-quality systematic reviews indicated that delivery room continuous positive airway pressure compared with intubation with or without routine surfactant (relative risk [RR], 0.80 [95% CI, 0.68-0.94]), early selective surfactant compared with delayed selective surfactant (RR, 0.83 [95% CI, 0.75-0.91]), early inhaled corticosteroids (RR, 0.86 [95% CI, 0.75-0.99]), early systemic hydrocortisone (RR, 0.90 [95% CI, 0.82-0.99]), avoiding endotracheal tube placement with delivery room continuous positive airway pressure and use of less invasive surfactant administration (RR, 0.90 [95% CI, 0.82-0.99]), and volume-targeted compared with pressure-limited ventilation (RR, 0.73 [95% CI, 0.59-0.89]) were associated with decreased risk of BPD or mortality at 36 weeks' PMA.\", 'subject score': 851, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 722907,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-          "name": "bronchopulmonary dysplasia",
-          "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:70589",
-            "MESH:D001997",
-            "MONDO:0019091",
-            "SNOMEDCT:67569000",
-            "MEDDRA:10066204",
-            "UMLS:C0006287",
-            "NCIT:C90599",
-            "DOID:11650",
-            "MEDDRA:10006475"
-          ],
-          "id": "MONDO:0019091",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bronchopulmonary Dysplasia",
-            "obsolete_bronchopulmonary dysplasia",
-            "bronchopulmonary dysplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 722907,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-              "name": "bronchopulmonary dysplasia",
-              "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:70589",
-                "MESH:D001997",
-                "MONDO:0019091",
-                "SNOMEDCT:67569000",
-                "MEDDRA:10066204",
-                "UMLS:C0006287",
-                "NCIT:C90599",
-                "DOID:11650",
-                "MEDDRA:10006475"
-              ],
-              "id": "MONDO:0019091",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bronchopulmonary Dysplasia",
-                "obsolete_bronchopulmonary dysplasia",
-                "bronchopulmonary dysplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14181494,
-            "start": 569,
-            "end": 722907,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19620192': {'publication date': '2009 Aug', 'sentence': \"OBJECTIVE: To assess dexamethasone (DEX) and hydrocortisone (HC) use in premature infants over time and the association of steroid use with the incidence of bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age.\", 'subject score': 888, 'object score': 1000}, 'PMID:27239054': {'publication date': '2016 Sep', 'sentence': 'CONCLUSION: Using hydrocortisone after 14 days on ventilated extremely preterm infants was associated with decreased BPD, with no apparent effects on neurodevelopment at two years of corrected age.', 'subject score': 1000, 'object score': 901}, 'PMID:35226067': {'publication date': '2022 Feb 28', 'sentence': \"High certainty of evidence from high-quality systematic reviews indicated that delivery room continuous positive airway pressure compared with intubation with or without routine surfactant (relative risk [RR], 0.80 [95% CI, 0.68-0.94]), early selective surfactant compared with delayed selective surfactant (RR, 0.83 [95% CI, 0.75-0.91]), early inhaled corticosteroids (RR, 0.86 [95% CI, 0.75-0.99]), early systemic hydrocortisone (RR, 0.90 [95% CI, 0.82-0.99]), avoiding endotracheal tube placement with delivery room continuous positive airway pressure and use of less invasive surfactant administration (RR, 0.90 [95% CI, 0.82-0.99]), and volume-targeted compared with pressure-limited ventilation (RR, 0.73 [95% CI, 0.59-0.89]) were associated with decreased risk of BPD or mortality at 36 weeks' PMA.\", 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0006287---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14483328",
-              "object": "MONDO:0019091",
-              "publications": [
-                "PMID:19620192",
-                "PMID:27239054",
-                "PMID:35226067"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 318773,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11144310': {'publication date': '2000', 'sentence': 'To study a possible relation between the use of postnatal glucocorticoids and the incidence and severity of retinopathy of prematurity (ROP), we conducted a retrospective study over a 4-year period that compared data of 161 preterm infants treated with hydrocortisone for bronchopulmonary dysplasia (BPD) with the data of 253 controls.', 'subject score': 1000, 'object score': 1000}, 'PMID:16439598': {'publication date': '2006 Feb', 'sentence': 'Eighteen children were treated with hydrocortisone for BPD (starting dose 5 mg/kg/d tapered over a minimum period of 22 d, median duration 28 d) and 19 never received corticosteroids during the perinatal period.', 'subject score': 1000, 'object score': 1000}, 'PMID:17382109': {'publication date': '2007 Apr', 'sentence': 'CONCLUSIONS: Neonatal hydrocortisone treatment for BPD had no long-term effects on neurodevelopment.', 'subject score': 851, 'object score': 1000}, 'PMID:19240295': {'publication date': '2009 Mar', 'sentence': 'Hydrocortisone treatment for severe evolving bronchopulmonary dysplasia and cerebral haemodynamics.', 'subject score': 888, 'object score': 861}, 'PMID:20150750': {'publication date': '2010', 'sentence': 'METHODS: Randomised controlled trials (RCTs) of postnatal hydrocortisone therapy to prevent or treat BPD were sought.', 'subject score': 851, 'object score': 1000}, 'PMID:23706359': {'publication date': '2013 Sep', 'sentence': 'CONCLUSIONS: In the absence of associated parenchymal brain injury, no reduction in brain tissue or cerebellar volumes could be found at term-equivalent age between infants with or without treatment with HC for BPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:24142604': {'publication date': '2013 Oct', 'sentence': 'CONCLUSIONS: The treatment with hydrocortisone, which is used for BPD, improves anti-oxidant system and reduces oxidative stress in infants with BPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:24298974': {'publication date': '2013', 'sentence': 'INTRODUCTION: The aim of our study was to determine whether hydrocortisone even at low dose could be an effective and safe alternative treatment for bronchopulmonary dysplasia.', 'subject score': 861, 'object score': 1000}, 'PMID:31508250': {'publication date': '2019 Mar 01', 'sentence': 'In addition, blood samples were obtained at the time of diagnosis of BPD and after the end of hydrocortisone (HC) treatment to measure IL-33 values in the serum.', 'subject score': 888, 'object score': 1000}, 'PMID:32883333': {'publication date': '2020 Sep 03', 'sentence': 'METHODS: This study protocol is for a multicenter double-blind randomized controlled trial of low-dose HC in the treatment of early BPD.', 'subject score': 901, 'object score': 901}, 'PMID:34012057': {'publication date': '2021 May 19', 'sentence': 'Corticosteroids, such as dexamethasone and hydrocortisone, have proven beneficial for the prevention and management of BPD postnatally due to their anti-inflammatory characteristics.', 'subject score': 1000, 'object score': 901}, 'PMID:35831259': {'publication date': '2022 Jan', 'sentence': 'CONCLUSIONS: Although the postnatal hydrocortisone treatment provided for respiratory deterioration did not prevent the BPD development, hydrocortisone treatment might suppress IL-6 overproduction in extremely preterm infants.', 'subject score': 888, 'object score': 901}, 'PMID:35907315': {'publication date': '2022 Jul 15', 'sentence': \"CONCLUSION: Prophylactic administration of low-dose hydrocortisone for BPD to infants born below 28 weeks' gestation was not associated with an increase in serious adverse outcomes in our population.\", 'subject score': 901, 'object score': 1000}, 'PMID:9973669': {'publication date': '1998', 'sentence': 'The aim of the present study was to test the practicability of sequential cortisol determinations in saliva of low birth weight neonates and to evaluate the impact of systemic and inhaled glucocorticoid therapy on saliva concentrations of cortisol in preterm neonates with bronchopulmonary dysplasia (BPD).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 722907,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0036591",
-          "name": "adrenal cortex neoplasm",
-          "description": "The presence of a neoplasm of the adrenal cortex. [HPO:probinson]; The presence of a neoplasm of the adrenal cortex.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0036591",
-            "MESH:D000306",
-            "UMLS:C0001618",
-            "HP:0100641",
-            "NCIT:C2858",
-            "SNOMEDCT:127022002"
-          ],
-          "id": "MONDO:0036591",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortex neoplasm",
-            "Adrenal Cortical Neoplasm",
-            "Neoplasm of the adrenal cortex",
-            "Adrenal Cortex Neoplasms"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-          "name": "bronchopulmonary dysplasia",
-          "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:70589",
-            "MESH:D001997",
-            "MONDO:0019091",
-            "SNOMEDCT:67569000",
-            "MEDDRA:10066204",
-            "UMLS:C0006287",
-            "NCIT:C90599",
-            "DOID:11650",
-            "MEDDRA:10006475"
-          ],
-          "id": "MONDO:0019091",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bronchopulmonary Dysplasia",
-            "obsolete_bronchopulmonary dysplasia",
-            "bronchopulmonary dysplasia"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://orcid.org/0000-0002-0736-9199"
-=======
-            "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 318773,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0036591",
-              "name": "adrenal cortex neoplasm",
-              "description": "The presence of a neoplasm of the adrenal cortex. [HPO:probinson]; The presence of a neoplasm of the adrenal cortex.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0036591",
-                "MESH:D000306",
-                "UMLS:C0001618",
-                "HP:0100641",
-                "NCIT:C2858",
-                "SNOMEDCT:127022002"
-              ],
-              "id": "MONDO:0036591",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortex neoplasm",
-                "Adrenal Cortical Neoplasm",
-                "Neoplasm of the adrenal cortex",
-                "Adrenal Cortex Neoplasms"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14149120,
-            "start": 569,
-            "end": 318773,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19564722': {'publication date': '2009 Nov', 'sentence': 'Increased ratio of mRNA expression of the genes CYP17 and CYP11B1 indicates autonomous cortisol production in adrenocortical tumors.', 'subject score': 828, 'object score': 983}, 'PMID:23055545': {'publication date': '2012 Dec', 'sentence': 'CONCLUSION: Low SGK1 expression is related to ACTH-independent cortisol secretion in adrenocortical tumors and is a new prognostic factor in adrenocortical carcinoma.', 'subject score': 833, 'object score': 983}, 'PMID:27085553': {'publication date': '2016 08', 'sentence': 'Adrenal Cushing syndrome (CS) is caused by the overproduction of cortisol in adrenocortical tumors including adrenal cortisol-producing adenoma (CPA).', 'subject score': 1000, 'object score': 983}, 'PMID:28248753': {'publication date': '2017 Jun', 'sentence': 'This review summarizes the most recent evidence showing the potential risks related to adrenocortical tumors classified as nonfunctioning adrenal incidentalomas (NFAIs) or associated with clinically autonomous cortisol secretion (ACS).', 'subject score': 751, 'object score': 983}, 'PMID:3563638': {'publication date': '1987', 'sentence': '[Cortisol clearance in hormonally-active adrenal cortex tumors].', 'subject score': 888, 'object score': 843}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0001618---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14450267",
-              "object": "MONDO:0036591",
-              "publications": [
-                "PMID:19564722",
-                "PMID:23055545",
-                "PMID:27085553",
-                "PMID:28248753",
-                "PMID:3563638"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 307894,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005155",
-          "name": "cirrhosis of liver",
-          "description": "A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.; Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.; A chronic disorder of the liver in which liver tissue becomes scarred and is partially replaced by regenerative nodules and fibrotic tissue resulting in loss of liver function. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10024667",
-            "ICD10:K74.60",
-            "NCIT:C2951",
-            "MESH:D008103",
-            "HP:0001394",
-            "MEDDRA:10019642",
-            "MONDO:0005155",
-            "EFO:0001422",
-            "UMLS:C0023890",
-            "MEDDRA:10009211",
-            "MEDDRA:10009213",
-            "MEDDRA:10019641",
-            "SNOMEDCT:19943007",
-            "DOID:5082"
-          ],
-          "id": "MONDO:0005155",
-          "category": "biolink:Disease",
-          "all_names": [
-            "liver cirrhosis",
-            "Cirrhosis",
-            "cirrhosis of liver",
-            "Liver Cirrhosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 307894,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005155",
-              "name": "cirrhosis of liver",
-              "description": "A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.; Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.; A chronic disorder of the liver in which liver tissue becomes scarred and is partially replaced by regenerative nodules and fibrotic tissue resulting in loss of liver function. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10024667",
-                "ICD10:K74.60",
-                "NCIT:C2951",
-                "MESH:D008103",
-                "HP:0001394",
-                "MEDDRA:10019642",
-                "MONDO:0005155",
-                "EFO:0001422",
-                "UMLS:C0023890",
-                "MEDDRA:10009211",
-                "MEDDRA:10009213",
-                "MEDDRA:10019641",
-                "SNOMEDCT:19943007",
-                "DOID:5082"
-              ],
-              "id": "MONDO:0005155",
-              "category": "biolink:Disease",
-              "all_names": [
-                "liver cirrhosis",
-                "Cirrhosis",
-                "cirrhosis of liver",
-                "Liver Cirrhosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14087042,
-            "start": 569,
-            "end": 307894,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1945747': {'publication date': '1991 Jul', 'sentence': 'It is concluded that bile acids are potent endogenous inhibitors of 11 beta-HSD and, therefore, could participate in abnormalities of cortisol metabolism observed in liver cirrhosis and extrahepatic biliary obstruction and, possibly, after ingestion of bile acids.', 'subject score': 888, 'object score': 1000}, 'PMID:4480665': {'publication date': '1974 Dec', 'sentence': 'Cortisol metabolism in liver cirrhosis.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0023890---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14387016",
-              "object": "MONDO:0005155",
-              "publications": [
-                "PMID:1945747",
-                "PMID:4480665"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 308784,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002406",
-          "name": "dermatitis",
-          "description": "The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes. [HPO:probinson]; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0011123",
-            "MEDDRA:10062249",
-            "MEDDRA:10012431",
-            "MP:0004947",
-            "MESH:D003872",
-            "SNOMEDCT:43116000",
-            "MONDO:0002406",
-            "MEDDRA:10012478",
-            "MEDDRA:10040876",
-            "ICD10:L30.9",
-            "DOID:2723",
-            "NCIT:C2983",
-            "SNOMEDCT:703938007",
-            "UMLS:C3875321",
-            "PSY:13710",
-            "UMLS:C0011603"
-          ],
-          "id": "MONDO:0002406",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis",
-            "Inflammatory abnormality of the skin",
-            "Inflammatory dermatosis",
-            "dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/eczema.htm",
-            "http://en.wikipedia.org/wiki/dermatitis",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308784,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002406",
-              "name": "dermatitis",
-              "description": "The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes. [HPO:probinson]; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0011123",
-                "MEDDRA:10062249",
-                "MEDDRA:10012431",
-                "MP:0004947",
-                "MESH:D003872",
-                "SNOMEDCT:43116000",
-                "MONDO:0002406",
-                "MEDDRA:10012478",
-                "MEDDRA:10040876",
-                "ICD10:L30.9",
-                "DOID:2723",
-                "NCIT:C2983",
-                "SNOMEDCT:703938007",
-                "UMLS:C3875321",
-                "PSY:13710",
-                "UMLS:C0011603"
-              ],
-              "id": "MONDO:0002406",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis",
-                "Inflammatory abnormality of the skin",
-                "Inflammatory dermatosis",
-                "dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/eczema.htm",
-                "http://en.wikipedia.org/wiki/dermatitis",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14060981,
-            "start": 569,
-            "end": 308784,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19420839': {'publication date': '2009 Apr', 'sentence': 'The plasma cortisol concentration was significantly higher in both DD groups before treatment than in the control group, and it decreased significantly after hoof trimming in the trimmed group.', 'subject score': 901, 'object score': 861}, 'PMID:8338747': {'publication date': '1993 Jun', 'sentence': 'Transepidermal water loss and absorption of hydrocortisone in widespread dermatitis.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0011603---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14360687",
-              "object": "MONDO:0002406",
-              "publications": [
-                "PMID:19420839",
-                "PMID:8338747"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321063,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018874",
-          "name": "acute myeloid leukemia",
-          "description": "A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification). (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3171\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3171\" NCI Thesaurus); Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.; A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).; Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.; A form of leukemia characterized by overproduction of an early myeloid cell. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:91861009",
-            "ICD9:205.0",
-            "MEDDRA:10024346",
-            "MEDDRA:10000801",
-            "MEDDRA:10060354",
-            "KEGG.DISEASE:05221",
-            "EFO:0000222",
-            "PDQ:CDR0000043424",
-            "MEDDRA:10000886",
-            "HP:0004808",
-            "MEDDRA:10060394",
-            "MESH:D015470",
-            "MEDDRA:10051003",
-            "MONDO:0100173",
-            "MEDDRA:10000878",
-            "MEDDRA:10060553",
-            "MEDDRA:10024291",
-            "SNOMEDCT:1162928000",
-            "MEDDRA:10054296",
-            "ORPHANET:519",
-            "MEDDRA:10000880",
-            "UMLS:C3275959",
-            "MEDDRA:10028552",
-            "MONDO:0018874",
-            "OMIM:601626",
-            "MEDDRA:10000884",
-            "DOID:9119",
-            "MEDDRA:10029549",
-            "MEDDRA:10029551",
-            "UMLS:C0023467",
-            "NCIT:C3171",
-            "MEDDRA:10060557",
-            "MEDDRA:10028557"
-          ],
-          "id": "MONDO:0018874",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia, acute myeloid related phenotypic feature",
-            "Leukemia, Myelocytic, Acute",
-            "Acute myeloid leukemia",
-            "acute myeloid leukemia",
-            "leukemia, acute myeloid, susceptibility to",
-            "Leukemia, acute myeloid, susceptibility to",
-            "Acute Myeloid Leukemia",
-            "Leukemia, Myeloid, Acute",
-            "Myeloid leukemia, acute"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=44363",
-            "http://cancergenome.nih.gov/cancersselected/acutemyeloidleukemia",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.cancer.org/cancer/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.htm",
-            "http://en.wikipedia.org/wiki/acute_myeloid_leukemia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321063,
-=======
-            "identity": 722907,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018874",
-              "name": "acute myeloid leukemia",
-              "description": "A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification). (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3171\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3171\" NCI Thesaurus); Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.; A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).; Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.; A form of leukemia characterized by overproduction of an early myeloid cell. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:91861009",
-                "ICD9:205.0",
-                "MEDDRA:10024346",
-                "MEDDRA:10000801",
-                "MEDDRA:10060354",
-                "KEGG.DISEASE:05221",
-                "EFO:0000222",
-                "PDQ:CDR0000043424",
-                "MEDDRA:10000886",
-                "HP:0004808",
-                "MEDDRA:10060394",
-                "MESH:D015470",
-                "MEDDRA:10051003",
-                "MONDO:0100173",
-                "MEDDRA:10000878",
-                "MEDDRA:10060553",
-                "MEDDRA:10024291",
-                "SNOMEDCT:1162928000",
-                "MEDDRA:10054296",
-                "ORPHANET:519",
-                "MEDDRA:10000880",
-                "UMLS:C3275959",
-                "MEDDRA:10028552",
-                "MONDO:0018874",
-                "OMIM:601626",
-                "MEDDRA:10000884",
-                "DOID:9119",
-                "MEDDRA:10029549",
-                "MEDDRA:10029551",
-                "UMLS:C0023467",
-                "NCIT:C3171",
-                "MEDDRA:10060557",
-                "MEDDRA:10028557"
-              ],
-              "id": "MONDO:0018874",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia, acute myeloid related phenotypic feature",
-                "Leukemia, Myelocytic, Acute",
-                "Acute myeloid leukemia",
-                "acute myeloid leukemia",
-                "leukemia, acute myeloid, susceptibility to",
-                "Leukemia, acute myeloid, susceptibility to",
-                "Acute Myeloid Leukemia",
-                "Leukemia, Myeloid, Acute",
-                "Myeloid leukemia, acute"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=44363",
-                "http://cancergenome.nih.gov/cancersselected/acutemyeloidleukemia",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.cancer.org/cancer/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.htm",
-                "http://en.wikipedia.org/wiki/acute_myeloid_leukemia"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-              "name": "bronchopulmonary dysplasia",
-              "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:70589",
-                "MESH:D001997",
-                "MONDO:0019091",
-                "SNOMEDCT:67569000",
-                "MEDDRA:10066204",
-                "UMLS:C0006287",
-                "NCIT:C90599",
-                "DOID:11650",
-                "MEDDRA:10006475"
-              ],
-              "id": "MONDO:0019091",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bronchopulmonary Dysplasia",
-                "obsolete_bronchopulmonary dysplasia",
-                "bronchopulmonary dysplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 13553984,
-            "start": 569,
-            "end": 321063,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1860896': {'publication date': '1991 Jul', 'sentence': 'Hydrocortisone in culture protects the blast cells in acute myeloblastic leukemia from the lethal effects of cytosine arabinoside.', 'subject score': 1000, 'object score': 1000}, 'PMID:3878438': {'publication date': '1985', 'sentence': 'Response to hydrocortisone of blast progenitors in acute myeloblastic leukemia: an aspect of lineage infidelity.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0023467---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13844584",
-              "object": "MONDO:0018874",
-              "publications": [
-                "PMID:1860896",
-                "PMID:3878438"
-=======
-            "identity": 8441874,
-            "start": 569,
-            "end": 722907,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11144310': {'publication date': '2000', 'sentence': 'To study a possible relation between the use of postnatal glucocorticoids and the incidence and severity of retinopathy of prematurity (ROP), we conducted a retrospective study over a 4-year period that compared data of 161 preterm infants treated with hydrocortisone for bronchopulmonary dysplasia (BPD) with the data of 253 controls.', 'subject score': 1000, 'object score': 1000}, 'PMID:16439598': {'publication date': '2006 Feb', 'sentence': 'Eighteen children were treated with hydrocortisone for BPD (starting dose 5 mg/kg/d tapered over a minimum period of 22 d, median duration 28 d) and 19 never received corticosteroids during the perinatal period.', 'subject score': 1000, 'object score': 1000}, 'PMID:17382109': {'publication date': '2007 Apr', 'sentence': 'CONCLUSIONS: Neonatal hydrocortisone treatment for BPD had no long-term effects on neurodevelopment.', 'subject score': 851, 'object score': 1000}, 'PMID:19240295': {'publication date': '2009 Mar', 'sentence': 'Hydrocortisone treatment for severe evolving bronchopulmonary dysplasia and cerebral haemodynamics.', 'subject score': 888, 'object score': 861}, 'PMID:20150750': {'publication date': '2010', 'sentence': 'METHODS: Randomised controlled trials (RCTs) of postnatal hydrocortisone therapy to prevent or treat BPD were sought.', 'subject score': 851, 'object score': 1000}, 'PMID:23706359': {'publication date': '2013 Sep', 'sentence': 'CONCLUSIONS: In the absence of associated parenchymal brain injury, no reduction in brain tissue or cerebellar volumes could be found at term-equivalent age between infants with or without treatment with HC for BPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:24142604': {'publication date': '2013 Oct', 'sentence': 'CONCLUSIONS: The treatment with hydrocortisone, which is used for BPD, improves anti-oxidant system and reduces oxidative stress in infants with BPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:24298974': {'publication date': '2013', 'sentence': 'INTRODUCTION: The aim of our study was to determine whether hydrocortisone even at low dose could be an effective and safe alternative treatment for bronchopulmonary dysplasia.', 'subject score': 861, 'object score': 1000}, 'PMID:31508250': {'publication date': '2019 Mar 01', 'sentence': 'In addition, blood samples were obtained at the time of diagnosis of BPD and after the end of hydrocortisone (HC) treatment to measure IL-33 values in the serum.', 'subject score': 888, 'object score': 1000}, 'PMID:32883333': {'publication date': '2020 Sep 03', 'sentence': 'METHODS: This study protocol is for a multicenter double-blind randomized controlled trial of low-dose HC in the treatment of early BPD.', 'subject score': 901, 'object score': 901}, 'PMID:34012057': {'publication date': '2021 May 19', 'sentence': 'Corticosteroids, such as dexamethasone and hydrocortisone, have proven beneficial for the prevention and management of BPD postnatally due to their anti-inflammatory characteristics.', 'subject score': 1000, 'object score': 901}, 'PMID:35831259': {'publication date': '2022 Jan', 'sentence': 'CONCLUSIONS: Although the postnatal hydrocortisone treatment provided for respiratory deterioration did not prevent the BPD development, hydrocortisone treatment might suppress IL-6 overproduction in extremely preterm infants.', 'subject score': 888, 'object score': 901}, 'PMID:35907315': {'publication date': '2022 Jul 15', 'sentence': \"CONCLUSION: Prophylactic administration of low-dose hydrocortisone for BPD to infants born below 28 weeks' gestation was not associated with an increase in serious adverse outcomes in our population.\", 'subject score': 901, 'object score': 1000}, 'PMID:9973669': {'publication date': '1998', 'sentence': 'The aim of the present study was to test the practicability of sequential cortisol determinations in saliva of low birth weight neonates and to evaluate the impact of systemic and inhaled glucocorticoid therapy on saliva concentrations of cortisol in preterm neonates with bronchopulmonary dysplasia (BPD).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0006287---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8632826",
-              "object": "MONDO:0019091",
-              "publications": [
-                "PMID:11144310",
-                "PMID:16439598",
-                "PMID:17382109",
-                "PMID:19240295",
-                "PMID:20150750",
-                "PMID:23706359",
-                "PMID:24142604",
-                "PMID:24298974",
-                "PMID:31508250",
-                "PMID:32883333",
-                "PMID:34012057",
-                "PMID:35831259",
-                "PMID:35907315",
-                "PMID:9973669"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 312684,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:18931525': {'publication date': '2009', 'sentence': 'Early hydrocortisone (HC) treatment may decrease the incidence of bronchopulmonary dysplasia; however, the long-term effects are still under evaluation.', 'subject score': 851, 'object score': 1000}, 'PMID:20864322': {'publication date': '2010 Oct', 'sentence': 'Intravenous hydrocortisone administered at an early stage for the prevention of BPD is being evaluated and should not be administered in this indication, except within clinical trials approved by the ethics committee.', 'subject score': 888, 'object score': 1000}, 'PMID:22070744': {'publication date': '2011 Nov 09', 'sentence': 'Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial.', 'subject score': 888, 'object score': 1000}, 'PMID:26058477': {'publication date': '2016 Feb', 'sentence': 'AIM: We evaluated the neurodevelopment and growth of five- to seven-year-old children who had participated in a randomised trial of early low-dose hydrocortisone treatment to prevent bronchopulmonary dysplasia.', 'subject score': 840, 'object score': 1000}, 'PMID:29348196': {'publication date': '2018 Feb', 'sentence': 'OBJECTIVES: To investigate the relationship between histologic findings of the placenta and response to early postnatal hydrocortisone treatment used to prevent bronchopulmonary dysplasia (BPD) in extremely preterm infants.', 'subject score': 833, 'object score': 1000}, 'PMID:29363502': {'publication date': '2018 May', 'sentence': \"Low-dose hydrocortisone for the first 10 days prevents BPD, but was associated with almost twice as many cases of late-onset sepsis in infants born at 24-25 weeks' gestation.\", 'subject score': 901, 'object score': 1000}, 'PMID:29523175': {'publication date': '2018 Mar 09', 'sentence': 'The aim of the Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (SToP-BPD) trial is to assess the efficacy and safety of postnatal hydrocortisone administration for the reduction of death or BPD in ventilator-dependent preterm infants.', 'subject score': 888, 'object score': 1000}, 'PMID:31043325': {'publication date': '2019 06', 'sentence': 'Based on four randomised clinical trials enrolling almost 1000 extremely preterm infants, prophylaxis of early adrenal insufficiency with low-dose hydrocortisone significantly decreased BPD and mortality, as well as medical treatment for a patent ductus arteriosus.', 'subject score': 901, 'object score': 1000}, 'PMID:31144162': {'publication date': '2019 Aug', 'sentence': 'Conclusion: Early systemic hydrocortisone is a modestly effective therapy for the prevention of BPD in preterm infants, although some safety concerns remain.', 'subject score': 851, 'object score': 1000}, 'PMID:31471578': {'publication date': '2019 Dec', 'sentence': 'Is prophylaxis with early low-dose hydrocortisone in very preterm infants effective in preventing bronchopulmonary dysplasia?', 'subject score': 861, 'object score': 884}, 'PMID:31899929': {'publication date': '2020 Jan 03', 'sentence': 'CONCLUSION:  Early application of low-dose hydrocortisone could potentially prevent BPD or death in infants weighing less than 1,000 g with exposure to chorioamnionitis.', 'subject score': 901, 'object score': 1000}, 'PMID:35320649': {'publication date': '2022 Mar 24', 'sentence': 'Hydrocortisone to Prevent Bronchopulmonary Dysplasia - Not a Silver Bullet.', 'subject score': 1000, 'object score': 1000}, 'PMID:35661314': {'publication date': '2022 Jul', 'sentence': 'Late hydrocortisone does not prevent bronchopulmonary dysplasia.', 'subject score': 888, 'object score': 1000}, 'PMID:36593110': {'publication date': '2023 Jan 02', 'sentence': \"OBJECTIVE: To report the parent-reported behavioural outcomes of infants included in the Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants study at 2 years' corrected age (CA).\", 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 722907,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015129",
-          "name": "chronic primary adrenal insufficiency",
-          "description": "A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.; An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands as a result of a primary defect in the glands themselves. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0001403",
-            "MONDO:0015129",
-            "DOID:13774",
-            "SNOMEDCT:363732003",
-            "PSY:00810",
-            "MEDDRA:10052381",
-            "UMLS:C1868690",
-            "OMIM:240200",
-            "ICD10:E27.1",
-            "UMLS:C0271737",
-            "MEDDRA:10080674",
-            "SNOMEDCT:373662000",
-            "MEDDRA:10013096",
-            "MEDDRA:10001130",
-            "HP:0008207",
-            "MEDDRA:10036696",
-            "MESH:D000075262",
-            "MESH:D000224",
-            "SNOMEDCT:76715008",
-            "ORPHANET:101959",
-            "NCIT:C26689",
-            "MEDDRA:10085976"
-          ],
-          "id": "MONDO:0015129",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hypoadrenocorticism, Familial",
-            "Primary adrenal insufficiency",
-            "Addisons Disease",
-            "Chronic primary adrenal insufficiency",
-            "Addison's disease due to autoimmunity",
-            "Addison Disease",
-            "Addison's disease",
-            "chronic primary adrenal insufficiency",
-            "Hypoadrenocorticism, familial",
-            "Hypoadrenocorticism, familial related phenotypic feature",
-            "Addison's Disease"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-          "name": "bronchopulmonary dysplasia",
-          "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:70589",
-            "MESH:D001997",
-            "MONDO:0019091",
-            "SNOMEDCT:67569000",
-            "MEDDRA:10066204",
-            "UMLS:C0006287",
-            "NCIT:C90599",
-            "DOID:11650",
-            "MEDDRA:10006475"
-          ],
-          "id": "MONDO:0019091",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bronchopulmonary Dysplasia",
-            "obsolete_bronchopulmonary dysplasia",
-            "bronchopulmonary dysplasia"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://en.wikipedia.org/wiki/addison%27s_disease",
-            "https://orcid.org/0000-0002-0736-9199"
-=======
-            "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 312684,
-=======
-            "identity": 722907,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015129",
-              "name": "chronic primary adrenal insufficiency",
-              "description": "A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.; An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands as a result of a primary defect in the glands themselves. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0001403",
-                "MONDO:0015129",
-                "DOID:13774",
-                "SNOMEDCT:363732003",
-                "PSY:00810",
-                "MEDDRA:10052381",
-                "UMLS:C1868690",
-                "OMIM:240200",
-                "ICD10:E27.1",
-                "UMLS:C0271737",
-                "MEDDRA:10080674",
-                "SNOMEDCT:373662000",
-                "MEDDRA:10013096",
-                "MEDDRA:10001130",
-                "HP:0008207",
-                "MEDDRA:10036696",
-                "MESH:D000075262",
-                "MESH:D000224",
-                "SNOMEDCT:76715008",
-                "ORPHANET:101959",
-                "NCIT:C26689",
-                "MEDDRA:10085976"
-              ],
-              "id": "MONDO:0015129",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hypoadrenocorticism, Familial",
-                "Primary adrenal insufficiency",
-                "Addisons Disease",
-                "Chronic primary adrenal insufficiency",
-                "Addison's disease due to autoimmunity",
-                "Addison Disease",
-                "Addison's disease",
-                "chronic primary adrenal insufficiency",
-                "Hypoadrenocorticism, familial",
-                "Hypoadrenocorticism, familial related phenotypic feature",
-                "Addison's Disease"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-              "name": "bronchopulmonary dysplasia",
-              "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:70589",
-                "MESH:D001997",
-                "MONDO:0019091",
-                "SNOMEDCT:67569000",
-                "MEDDRA:10066204",
-                "UMLS:C0006287",
-                "NCIT:C90599",
-                "DOID:11650",
-                "MEDDRA:10006475"
-              ],
-              "id": "MONDO:0019091",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bronchopulmonary Dysplasia",
-                "obsolete_bronchopulmonary dysplasia",
-                "bronchopulmonary dysplasia"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://en.wikipedia.org/wiki/addison%27s_disease",
-                "https://orcid.org/0000-0002-0736-9199"
-=======
-                "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 12934219,
-            "start": 569,
-            "end": 312684,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17609409': {'publication date': '2007 Jul', 'sentence': \"Continuous subcutaneous hydrocortisone infusion in Addison's disease.\", 'subject score': 861, 'object score': 1000}, 'PMID:18280810': {'publication date': '2008 Jun', 'sentence': \"Morning serum and saliva cortisol in Addison's disease were lower than in controls (6.74+/-1.69 vs 22.58+/-1.78 microg/dL, and 0.15+/-0.25 vs 0.67+/-0.12 microg/dL) (p<0.001).\", 'subject score': 888, 'object score': 1000}, 'PMID:18611115': {'publication date': '2008 Jun', 'sentence': 'METHODS: A literature search was performed with the aim of covering the field of gastrointestinal drug absorption of hydrocortisone in AD.', 'subject score': 1000, 'object score': 1000}, 'PMID:20674414': {'publication date': '2010 Sep', 'sentence': 'Primary adrenal insufficiency is an endocrine disorder characterized by cortisol and aldosterone deficiency caused by destruction of the adrenal cortex.', 'subject score': 1000, 'object score': 1000}, 'PMID:2209230': {'publication date': '1990 Feb', 'sentence': \"We conclude that the increase of metabolism of cortisol after simultaneous taking of rifampicin may induce adrenal crisis in Addison's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:22288685': {'publication date': '2012 Jul', 'sentence': 'A randomized, double-blind, crossover study comparing two- and four-dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency.', 'subject score': 1000, 'object score': 817}, 'PMID:24275191': {'publication date': '2013 Dec', 'sentence': \"The main reason to measure cortisol is to diagnose human diseases characterised by deficiency of adrenal steroid excretion in Addison's disease or overproduction in Cushing's syndrome (CS).\", 'subject score': 1000, 'object score': 1000}, 'PMID:25127090': {'publication date': '2014 Nov', 'sentence': \"Continuous subcutaneous hydrocortisone infusion therapy in Addison's disease: a randomized, placebo-controlled clinical trial.\", 'subject score': 840, 'object score': 1000}, 'PMID:26811406': {'publication date': '2016 Apr', 'sentence': 'Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency.', 'subject score': 851, 'object score': 1000}, 'PMID:27813051': {'publication date': '2016 Dec', 'sentence': \"Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease.\", 'subject score': 888, 'object score': 1000}, 'PMID:29872468': {'publication date': '2014 Feb', 'sentence': \"Dual-release Hydrocortisone in Addison's Disease - A Review of the Literature.\", 'subject score': 790, 'object score': 1000}, 'PMID:3019857': {'publication date': '1986 Aug', 'sentence': \"Response to low-dose pulsatile cortisol in Addison's disease with suspected corticotropinoma.\", 'subject score': 861, 'object score': 1000}, 'PMID:31532828': {'publication date': '2019 Sep 18', 'sentence': 'All AD patients and 42% of CAH patients were prescribed glucocorticoids, most frequently hydrocortisone in AD (82%) and prednisolone in CAH (50%).', 'subject score': 851, 'object score': 1000}, 'PMID:34512546': {'publication date': '2021', 'sentence': \"Sleep, Cognition and Cortisol in Addison's Disease: A Mechanistic Relationship.\", 'subject score': 1000, 'object score': 1000}, 'PMID:35918399': {'publication date': '2022 Aug 02', 'sentence': 'The study aims to compare dual-release hydrocortisone (DR-HC) and conventional steroids on bone metabolism in patients with primary adrenal insufficiency (PAI).', 'subject score': 851, 'object score': 804}, 'PMID:4312783': {'publication date': '1970 Jan', 'sentence': \"[Passage of cortisol in unaltered and unconjugated form into the urine in central type of Cushing's syndrome and in Addison's disease at different levels of ACTH in the organism].\", 'subject score': 1000, 'object score': 1000}, 'PMID:5040535': {'publication date': '1972 Jul 12', 'sentence': \"[Effect of hydrocortisone on gastric secretion and histology in Addison's disease].\", 'subject score': 1000, 'object score': 1000}, 'PMID:7375407': {'publication date': '1980 May', 'sentence': 'Primary adrenal insufficiency is characterized by cortisol and aldosterone deficiency; in the secondary form, cortisol alone is decreased.', 'subject score': 1000, 'object score': 1000}, 'PMID:8388783': {'publication date': '1993 Apr', 'sentence': \"A chronobiological approach to circulating levels of renin, angiotensin-converting enzyme, aldosterone, ACTH, and cortisol in Addison's disease.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0001403---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13213365",
-              "object": "MONDO:0015129",
-              "publications": [
-                "PMID:17609409",
-                "PMID:18280810",
-                "PMID:18611115",
-                "PMID:20674414",
-                "PMID:2209230",
-                "PMID:22288685",
-                "PMID:24275191",
-                "PMID:25127090",
-                "PMID:26811406",
-                "PMID:27813051",
-                "PMID:29872468",
-                "PMID:3019857",
-                "PMID:31532828",
-                "PMID:34512546",
-                "PMID:35918399",
-                "PMID:4312783",
-                "PMID:5040535",
-                "PMID:7375407",
-                "PMID:8388783"
-=======
-            "identity": 13726700,
-            "start": 569,
-            "end": 722907,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18931525': {'publication date': '2009', 'sentence': 'Early hydrocortisone (HC) treatment may decrease the incidence of bronchopulmonary dysplasia; however, the long-term effects are still under evaluation.', 'subject score': 851, 'object score': 1000}, 'PMID:20864322': {'publication date': '2010 Oct', 'sentence': 'Intravenous hydrocortisone administered at an early stage for the prevention of BPD is being evaluated and should not be administered in this indication, except within clinical trials approved by the ethics committee.', 'subject score': 888, 'object score': 1000}, 'PMID:22070744': {'publication date': '2011 Nov 09', 'sentence': 'Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial.', 'subject score': 888, 'object score': 1000}, 'PMID:26058477': {'publication date': '2016 Feb', 'sentence': 'AIM: We evaluated the neurodevelopment and growth of five- to seven-year-old children who had participated in a randomised trial of early low-dose hydrocortisone treatment to prevent bronchopulmonary dysplasia.', 'subject score': 840, 'object score': 1000}, 'PMID:29348196': {'publication date': '2018 Feb', 'sentence': 'OBJECTIVES: To investigate the relationship between histologic findings of the placenta and response to early postnatal hydrocortisone treatment used to prevent bronchopulmonary dysplasia (BPD) in extremely preterm infants.', 'subject score': 833, 'object score': 1000}, 'PMID:29363502': {'publication date': '2018 May', 'sentence': \"Low-dose hydrocortisone for the first 10 days prevents BPD, but was associated with almost twice as many cases of late-onset sepsis in infants born at 24-25 weeks' gestation.\", 'subject score': 901, 'object score': 1000}, 'PMID:29523175': {'publication date': '2018 Mar 09', 'sentence': 'The aim of the Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (SToP-BPD) trial is to assess the efficacy and safety of postnatal hydrocortisone administration for the reduction of death or BPD in ventilator-dependent preterm infants.', 'subject score': 888, 'object score': 1000}, 'PMID:31043325': {'publication date': '2019 06', 'sentence': 'Based on four randomised clinical trials enrolling almost 1000 extremely preterm infants, prophylaxis of early adrenal insufficiency with low-dose hydrocortisone significantly decreased BPD and mortality, as well as medical treatment for a patent ductus arteriosus.', 'subject score': 901, 'object score': 1000}, 'PMID:31144162': {'publication date': '2019 Aug', 'sentence': 'Conclusion: Early systemic hydrocortisone is a modestly effective therapy for the prevention of BPD in preterm infants, although some safety concerns remain.', 'subject score': 851, 'object score': 1000}, 'PMID:31471578': {'publication date': '2019 Dec', 'sentence': 'Is prophylaxis with early low-dose hydrocortisone in very preterm infants effective in preventing bronchopulmonary dysplasia?', 'subject score': 861, 'object score': 884}, 'PMID:31899929': {'publication date': '2020 Jan 03', 'sentence': 'CONCLUSION:  Early application of low-dose hydrocortisone could potentially prevent BPD or death in infants weighing less than 1,000 g with exposure to chorioamnionitis.', 'subject score': 901, 'object score': 1000}, 'PMID:35320649': {'publication date': '2022 Mar 24', 'sentence': 'Hydrocortisone to Prevent Bronchopulmonary Dysplasia - Not a Silver Bullet.', 'subject score': 1000, 'object score': 1000}, 'PMID:35661314': {'publication date': '2022 Jul', 'sentence': 'Late hydrocortisone does not prevent bronchopulmonary dysplasia.', 'subject score': 888, 'object score': 1000}, 'PMID:36593110': {'publication date': '2023 Jan 02', 'sentence': \"OBJECTIVE: To report the parent-reported behavioural outcomes of infants included in the Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants study at 2 years' corrected age (CA).\", 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0006287---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14020540",
-              "object": "MONDO:0019091",
-              "publications": [
-                "PMID:18931525",
-                "PMID:20864322",
-                "PMID:22070744",
-                "PMID:26058477",
-                "PMID:29348196",
-                "PMID:29363502",
-                "PMID:29523175",
-                "PMID:31043325",
-                "PMID:31144162",
-                "PMID:31471578",
-                "PMID:31899929",
-                "PMID:35320649",
-                "PMID:35661314",
-                "PMID:36593110"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 318927,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001156",
-          "name": "borderline personality disorder",
-          "description": "A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions. [HPO:probinson]; A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions.; A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions.; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "SNOMEDCT:20010003",
-            "ICD10:F60.3",
-            "MEDDRA:10006034",
-            "PSY:06622",
-            "MESH:D001883",
-            "HP:0012076",
-            "DOID:10930",
-            "MONDO:0001156",
-            "NCIT:C92633",
-            "UMLS:C0006012",
-            "ICD9:301.83",
-            "MEDDRA:10006033"
-          ],
-          "id": "MONDO:0001156",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Borderline Personality Disorder",
-            "borderline personality disorder",
-            "Borderline personality disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/borderline_personality_disorde",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318927,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001156",
-              "name": "borderline personality disorder",
-              "description": "A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions. [HPO:probinson]; A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions.; A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions.; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "SNOMEDCT:20010003",
-                "ICD10:F60.3",
-                "MEDDRA:10006034",
-                "PSY:06622",
-                "MESH:D001883",
-                "HP:0012076",
-                "DOID:10930",
-                "MONDO:0001156",
-                "NCIT:C92633",
-                "UMLS:C0006012",
-                "ICD9:301.83",
-                "MEDDRA:10006033"
-              ],
-              "id": "MONDO:0001156",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Borderline Personality Disorder",
-                "borderline personality disorder",
-                "Borderline personality disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/borderline_personality_disorde",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12486073,
-            "start": 569,
-            "end": 318927,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17028025': {'publication date': '2007 Dec', 'sentence': 'The current findings underline the relevance of cortisol and DHEA assessments and the need for further scrutiny of their interplay to foster our understanding of the biological basis of stress regulation in BPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:17169436': {'publication date': '2007 Jan 15', 'sentence': 'A preliminary study of cortisol and norepinephrine reactivity to psychosocial stress in borderline personality disorder with high and low dissociation.', 'subject score': 1000, 'object score': 1000}, 'PMID:25462901': {'publication date': '2015 Jan', 'sentence': 'Effects of cortisol on cognition in major depressive disorder, posttraumatic stress disorder and borderline personality disorder - 2014 Curt Richter Award Winner.', 'subject score': 1000, 'object score': 642}, 'PMID:29702176': {'publication date': '2018 Apr 24', 'sentence': 'The single cortisol sample showed a significant and opposite correlations in the sexual abuse diagnosis-related groups, being a negative correlation in BD and positive in BPD.', 'subject score': 623, 'object score': 1000}, 'PMID:35709662': {'publication date': '2022 Jun 03', 'sentence': 'CONCLUSIONS: These findings suggest that alterations in oxytocin, cortisol, and testosterone contribute to disruptions in mother-child interaction in BPD.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0006012---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "12756660",
-              "object": "MONDO:0001156",
-              "publications": [
-                "PMID:17028025",
-                "PMID:17169436",
-                "PMID:25462901",
-                "PMID:29702176",
-                "PMID:35709662"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317312,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-          "name": "Hypoxemia",
-          "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "NCIT:C93047",
-            "MEDDRA:10021142",
-            "UMLS:C0242184",
-            "ICD9:799.02",
-            "HP:0012418",
-            "EFO:0009444",
-            "MEDDRA:10021143",
-            "EFO:0009447",
-            "MEDDRA:10021141",
-            "UMLS:C0700292",
-            "SNOMEDCT:389086002",
-            "PDQ:CDR0000773145",
-            "SYMP:0000303",
-            "MEDDRA:10021144",
-            "MESH:D000860",
-            "NCIT:C3890",
-            "SNOMEDCT:389087006"
-          ],
-          "id": "HP:0012418",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hypoxia",
-            "Hypoxemia",
-            "hypoxemia",
-            "Hypoxia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:DiseaseOrPhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317312,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-              "name": "Hypoxemia",
-              "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "NCIT:C93047",
-                "MEDDRA:10021142",
-                "UMLS:C0242184",
-                "ICD9:799.02",
-                "HP:0012418",
-                "EFO:0009444",
-                "MEDDRA:10021143",
-                "EFO:0009447",
-                "MEDDRA:10021141",
-                "UMLS:C0700292",
-                "SNOMEDCT:389086002",
-                "PDQ:CDR0000773145",
-                "SYMP:0000303",
-                "MEDDRA:10021144",
-                "MESH:D000860",
-                "NCIT:C3890",
-                "SNOMEDCT:389087006"
-              ],
-              "id": "HP:0012418",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hypoxia",
-                "Hypoxemia",
-                "hypoxemia",
-                "Hypoxia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:DiseaseOrPhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12309621,
-            "start": 569,
-            "end": 317312,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1680955': {'publication date': '1991 Jul', 'sentence': 'This hypoxia-specific increase in surface beta-adrenoreceptors was significantly enhanced in the cortisol-treated erythrocytes, showing that cortisol had a significant impact on erythrocyte beta-adrenoreceptor dynamics in addition to the direct influence of hypoxia.', 'subject score': 1000, 'object score': 1000}, 'PMID:28468567': {'publication date': '2018 02', 'sentence': 'Cortisol was higher in the LTH versus control ( P < .05).', 'subject score': 1000, 'object score': 901}, 'PMID:7155642': {'publication date': '1982', 'sentence': '[Effect of adrenalectomy and hydrocortisone on carbohydrate metabolism in the lungs and myocardium in chronic hypoxia].', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0242184---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "12576998",
-              "object": "HP:0012418",
-              "publications": [
-                "PMID:1680955",
-                "PMID:28468567",
-                "PMID:7155642"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:15964450': {'publication date': '2005 Jun 18-24', 'sentence': 'Congenital adrenal hyperplasia (CAH) due to deficiency of 21-hydroxylase is a disorder of the adrenal cortex characterised by cortisol deficiency, with or without aldosterone deficiency, and androgen excess.', 'subject score': 888, 'object score': 1000}, 'PMID:1979594': {'publication date': '1990 Jul', 'sentence': 'Congenital adrenal hyperplasia (CAH) is a heterogeneous group of hereditary diseases characterized by deficient adrenal cortisol synthesis.', 'subject score': 833, 'object score': 1000}, 'PMID:25913739': {'publication date': '2015 Jul 10', 'sentence': 'Congenital adrenal hyperplasia (CAH) is an autosomal recessive disease which is characterized by a deficiency of one of the enzymes involved in the synthesis of cortisol from cholesterol by the adrenal cortex.', 'subject score': 1000, 'object score': 1000}, 'PMID:27634643': {'publication date': '2017 01', 'sentence': 'Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a disorder characterized by impaired cortisol synthesis leading to excessive production of adrenal androgens.', 'subject score': 851, 'object score': 1000}, 'PMID:32652643': {'publication date': '2020 Jul 11', 'sentence': 'An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia.AIM: To characterize the pharmacokinetic/pharmacodynamic relationships of cortisol and the adrenal biomarkers 17-hydroxyprogesterone and androstenedione in children with congenital adrenal hyperplasia (CAH).', 'subject score': 1000, 'object score': 804}, 'PMID:33527139': {'publication date': '2021 Feb 02', 'sentence': 'Modified-release Hydrocortisone in Congenital Adrenal Hyperplasia.', 'subject score': 901, 'object score': 1000}, 'PMID:34697763': {'publication date': '2021 Oct 26', 'sentence': 'BACKGROUND: Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder caused by pathogenic variants in seven genes involved in the cortisol and aldosterone biosynthetic pathway.', 'subject score': 1000, 'object score': 1000}, 'PMID:36589847': {'publication date': '2022', 'sentence': '17alpha-hydroxylase/17,20-lyase deficiency (17-OHD), caused by mutations in the gene of the cytochrome P450 family 17 subfamily A member 1 (CYP17A1), is a rare type of congenital adrenal hyperplasia (CAH), usually characterized by cortisol and sex steroid deficiency combined with excessive mineralocorticoid.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 312713,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-          "name": "congenital adrenal hyperplasia",
-          "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:237751000",
-            "DOID:12255",
-            "NCIT:C34360",
-            "ORPHANET:418",
-            "MONDO:0018479",
-            "MEDDRA:10010323",
-            "ICD9:255.2",
-            "DOID:0050811",
-            "HP:0008258",
-            "UMLS:C0001627",
-            "UMLS:C0701163",
-            "ICD10:E25",
-            "MESH:D000312"
-          ],
-          "id": "MONDO:0018479",
-          "category": "biolink:Disease",
-          "all_names": [
-            "congenital adrenal hyperplasia",
-            "obsolete congenital adrenal hyperplasia",
-            "Adrenogenital disorders",
-            "Adrenogenital disorder",
-            "Congenital adrenal hyperplasia",
-            "Adrenal Hyperplasia, Congenital",
-            "obsolete_congenital adrenal hyperplasia",
-            "Congenital Adrenal Hyperplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-            "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-            "http://omim.org/entry/201710",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312713,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-              "name": "congenital adrenal hyperplasia",
-              "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:237751000",
-                "DOID:12255",
-                "NCIT:C34360",
-                "ORPHANET:418",
-                "MONDO:0018479",
-                "MEDDRA:10010323",
-                "ICD9:255.2",
-                "DOID:0050811",
-                "HP:0008258",
-                "UMLS:C0001627",
-                "UMLS:C0701163",
-                "ICD10:E25",
-                "MESH:D000312"
-              ],
-              "id": "MONDO:0018479",
-              "category": "biolink:Disease",
-              "all_names": [
-                "congenital adrenal hyperplasia",
-                "obsolete congenital adrenal hyperplasia",
-                "Adrenogenital disorders",
-                "Adrenogenital disorder",
-                "Congenital adrenal hyperplasia",
-                "Adrenal Hyperplasia, Congenital",
-                "obsolete_congenital adrenal hyperplasia",
-                "Congenital Adrenal Hyperplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-                "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-                "http://omim.org/entry/201710",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11629725,
-            "start": 569,
-            "end": 312713,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15964450': {'publication date': '2005 Jun 18-24', 'sentence': 'Congenital adrenal hyperplasia (CAH) due to deficiency of 21-hydroxylase is a disorder of the adrenal cortex characterised by cortisol deficiency, with or without aldosterone deficiency, and androgen excess.', 'subject score': 888, 'object score': 1000}, 'PMID:1979594': {'publication date': '1990 Jul', 'sentence': 'Congenital adrenal hyperplasia (CAH) is a heterogeneous group of hereditary diseases characterized by deficient adrenal cortisol synthesis.', 'subject score': 833, 'object score': 1000}, 'PMID:25913739': {'publication date': '2015 Jul 10', 'sentence': 'Congenital adrenal hyperplasia (CAH) is an autosomal recessive disease which is characterized by a deficiency of one of the enzymes involved in the synthesis of cortisol from cholesterol by the adrenal cortex.', 'subject score': 1000, 'object score': 1000}, 'PMID:27634643': {'publication date': '2017 01', 'sentence': 'Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a disorder characterized by impaired cortisol synthesis leading to excessive production of adrenal androgens.', 'subject score': 851, 'object score': 1000}, 'PMID:32652643': {'publication date': '2020 Jul 11', 'sentence': 'An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia.AIM: To characterize the pharmacokinetic/pharmacodynamic relationships of cortisol and the adrenal biomarkers 17-hydroxyprogesterone and androstenedione in children with congenital adrenal hyperplasia (CAH).', 'subject score': 1000, 'object score': 804}, 'PMID:33527139': {'publication date': '2021 Feb 02', 'sentence': 'Modified-release Hydrocortisone in Congenital Adrenal Hyperplasia.', 'subject score': 901, 'object score': 1000}, 'PMID:34697763': {'publication date': '2021 Oct 26', 'sentence': 'BACKGROUND: Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder caused by pathogenic variants in seven genes involved in the cortisol and aldosterone biosynthetic pathway.', 'subject score': 1000, 'object score': 1000}, 'PMID:36589847': {'publication date': '2022', 'sentence': '17alpha-hydroxylase/17,20-lyase deficiency (17-OHD), caused by mutations in the gene of the cytochrome P450 family 17 subfamily A member 1 (CYP17A1), is a rare type of congenital adrenal hyperplasia (CAH), usually characterized by cortisol and sex steroid deficiency combined with excessive mineralocorticoid.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0001627---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "11888652",
-              "object": "MONDO:0018479",
-              "publications": [
-                "PMID:15964450",
-                "PMID:1979594",
-                "PMID:25913739",
-                "PMID:27634643",
-                "PMID:32652643",
-                "PMID:33527139",
-                "PMID:34697763",
-                "PMID:36589847"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 310664,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:26184920': {'publication date': '2015 Oct', 'sentence': 'Congenital adrenal hyperplasia (CAH) is a chronic condition and individuals are exposed to elevated androgen levels in utero as a result of the endogenous cortisol deficiency.', 'subject score': 851, 'object score': 1000}, 'PMID:3487786': {'publication date': '1986 Jul', 'sentence': 'If this cytochrome P-450 enzyme is defective, cortisol cannot be synthesized, resulting in congenital adrenal hyperplasia.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 312713,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008575",
-          "name": "nicotine dependence",
-          "description": "Any disease or disorder that is caused by the use of tobacco.; Tobacco used to the detriment of a person's health or social functioning. Tobacco dependence is included.",
-          "equivalent_curies": [
-            "PDQ:CDR0000482224",
-            "SNOMEDCT:56294008",
-            "MEDDRA:10083286",
-            "UMLS:C0040332",
-            "NCIT:C54203",
-            "EFO:0003768",
-            "MEDDRA:10043903",
-            "MEDDRA:10057852",
-            "NCIT:C35074",
-            "MESH:D014029",
-            "DOID:0050742",
-            "SNOMEDCT:89765005",
-            "MEDDRA:10056478",
-            "UMLS:C0028043",
-            "ICD9:305.1",
-            "UMLS:C1306274",
-            "ICD10:F17",
-            "MEDDRA:10043906",
-            "MONDO:0008575",
-            "UMLS:C0040336",
-            "HP:0033543"
-          ],
-          "id": "MONDO:0008575",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Tobacco use disorder",
-            "Tabagism",
-            "Nicotine Dependence",
-            "Nicotine addiction",
-            "tobacco use disorder",
-            "nicotine dependence",
-            "Tobacco Use Disorder",
-            "Tobacco Dependence"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-          "name": "congenital adrenal hyperplasia",
-          "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:237751000",
-            "DOID:12255",
-            "NCIT:C34360",
-            "ORPHANET:418",
-            "MONDO:0018479",
-            "MEDDRA:10010323",
-            "ICD9:255.2",
-            "DOID:0050811",
-            "HP:0008258",
-            "UMLS:C0001627",
-            "UMLS:C0701163",
-            "ICD10:E25",
-            "MESH:D000312"
-          ],
-          "id": "MONDO:0018479",
-          "category": "biolink:Disease",
-          "all_names": [
-            "congenital adrenal hyperplasia",
-            "obsolete congenital adrenal hyperplasia",
-            "Adrenogenital disorders",
-            "Adrenogenital disorder",
-            "Congenital adrenal hyperplasia",
-            "Adrenal Hyperplasia, Congenital",
-            "obsolete_congenital adrenal hyperplasia",
-            "Congenital Adrenal Hyperplasia"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://en.wikipedia.org/wiki/nicotine_dependence"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310664,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008575",
-              "name": "nicotine dependence",
-              "description": "Any disease or disorder that is caused by the use of tobacco.; Tobacco used to the detriment of a person's health or social functioning. Tobacco dependence is included.",
-              "equivalent_curies": [
-                "PDQ:CDR0000482224",
-                "SNOMEDCT:56294008",
-                "MEDDRA:10083286",
-                "UMLS:C0040332",
-                "NCIT:C54203",
-                "EFO:0003768",
-                "MEDDRA:10043903",
-                "MEDDRA:10057852",
-                "NCIT:C35074",
-                "MESH:D014029",
-                "DOID:0050742",
-                "SNOMEDCT:89765005",
-                "MEDDRA:10056478",
-                "UMLS:C0028043",
-                "ICD9:305.1",
-                "UMLS:C1306274",
-                "ICD10:F17",
-                "MEDDRA:10043906",
-                "MONDO:0008575",
-                "UMLS:C0040336",
-                "HP:0033543"
-              ],
-              "id": "MONDO:0008575",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Tobacco use disorder",
-                "Tabagism",
-                "Nicotine Dependence",
-                "Nicotine addiction",
-                "tobacco use disorder",
-                "nicotine dependence",
-                "Tobacco Use Disorder",
-                "Tobacco Dependence"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/nicotine_dependence"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11611077,
-            "start": 569,
-            "end": 310664,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15939519': {'publication date': '2005 Jun', 'sentence': 'Changes of smoking behavior and serum adrenocorticotropic hormone, cortisol, prolactin, and endogenous opioids levels in nicotine dependence after naltrexone treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:24034414': {'publication date': '2014 Jan 01', 'sentence': 'However, cortisol did not mediate the MSDP-lifetime ND relation.', 'subject score': 1000, 'object score': 717}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0028043---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "11866289",
-              "object": "MONDO:0008575",
-              "publications": [
-                "PMID:15939519",
-                "PMID:24034414"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-=======
-            "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-            "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-            "http://omim.org/entry/201710",
->>>>>>> main
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 321523,
-=======
-            "identity": 312713,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-              "name": "congenital adrenal hyperplasia",
-              "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:237751000",
-                "DOID:12255",
-                "NCIT:C34360",
-                "ORPHANET:418",
-                "MONDO:0018479",
-                "MEDDRA:10010323",
-                "ICD9:255.2",
-                "DOID:0050811",
-                "HP:0008258",
-                "UMLS:C0001627",
-                "UMLS:C0701163",
-                "ICD10:E25",
-                "MESH:D000312"
-              ],
-              "id": "MONDO:0018479",
-              "category": "biolink:Disease",
-              "all_names": [
-                "congenital adrenal hyperplasia",
-                "obsolete congenital adrenal hyperplasia",
-                "Adrenogenital disorders",
-                "Adrenogenital disorder",
-                "Congenital adrenal hyperplasia",
-                "Adrenal Hyperplasia, Congenital",
-                "obsolete_congenital adrenal hyperplasia",
-                "Congenital Adrenal Hyperplasia"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://en.wikipedia.org/wiki/pneumonia",
-=======
-                "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-                "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-                "http://omim.org/entry/201710",
->>>>>>> main
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 11283939,
-            "start": 569,
-            "end": 321523,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15557131': {'publication date': '2005 Feb 01', 'sentence': 'We hypothesize that hydrocortisone infusion in severe community-acquired pneumonia attenuates systemic inflammation and leads to earlier resolution of pneumonia and a reduction in sepsis-related complications.', 'subject score': 888, 'object score': 833}, 'PMID:17698896': {'publication date': '2007 Sep', 'sentence': 'Finally, a pilot study has found that hydrocortisone lowers morbidity and mortality in SCAP.', 'subject score': 1000, 'object score': 833}, 'PMID:17702966': {'publication date': '2007 Nov 01', 'sentence': 'OBJECTIVES: To investigate the predictive value of TC and FC in community-acquired pneumonia (CAP).', 'subject score': 888, 'object score': 851}, 'PMID:18753464': {'publication date': '2008 Nov', 'sentence': 'However, the predictive value of total cortisol and of the presence of critical illness-related corticosteroid insufficiency (CIRCI) in severe community-acquired pneumonia (CAP) remains to be thoroughly evaluated.', 'subject score': 888, 'object score': 833}, 'PMID:20236471': {'publication date': '2010', 'sentence': 'Elevated levels of pro-adrenomedullin, copeptin (which is produced in equimolar amounts to vasopressin), natriuretic peptides and cortisol are significantly related to mortality in community-acquired pneumonia, as are other prohormones such as pro-atrial natriuretic peptide, coagulation markers, and other combinations of inflammatory cytokine profiles.', 'subject score': 1000, 'object score': 851}, 'PMID:20723107': {'publication date': '2010 Jun', 'sentence': 'Continuous hydrocortisone infusion in severe pediatric community-acquired pneumonia (CAP).', 'subject score': 901, 'object score': 822}, 'PMID:22402329': {'publication date': '2012 Jun', 'sentence': 'Delta-cortisol could be another meaningful biomarker in CAP.', 'subject score': 861, 'object score': 851}, 'PMID:23018905': {'publication date': '2013 Apr', 'sentence': 'New cardiovascular or stress-related biomarkers like copeptin, midregional proadrenomedullin and cortisol have been repeatedly linked with outcome and disease course in CAP and improved clinical scoring in observational studies.', 'subject score': 1000, 'object score': 851}, 'PMID:24910975': {'publication date': '2014', 'sentence': 'CONCLUSION: Cortisol, DHEAS and their ratios correlate with CAP severity, and cortisol and DHEA predict mortality.', 'subject score': 1000, 'object score': 833}, 'PMID:30485501': {'publication date': '2018 Nov 28', 'sentence': 'CONCLUSIONS: Neither baseline nor stimulated cortisol after low-dose cosyntropin testing at a dose of 1 ug predicted glucocorticoid responsiveness in mild to moderate CAP.', 'subject score': 861, 'object score': 851}, 'PMID:35881034': {'publication date': '2022 Aug 01', 'sentence': 'CONCLUSION: Hydrocortisone, ascorbic acid, and thiamine therapy has minimal benefits in pneumonia.', 'subject score': 1000, 'object score': 1000}, 'PMID:8339624': {'publication date': '1993 Aug', 'sentence': 'Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia.', 'subject score': 1000, 'object score': 833}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "11530989",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:15557131",
-                "PMID:17698896",
-                "PMID:17702966",
-                "PMID:18753464",
-                "PMID:20236471",
-                "PMID:20723107",
-                "PMID:22402329",
-                "PMID:23018905",
-                "PMID:24910975",
-                "PMID:30485501",
-                "PMID:35881034",
-                "PMID:8339624"
-=======
-            "identity": 18080355,
-            "start": 569,
-            "end": 312713,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26184920': {'publication date': '2015 Oct', 'sentence': 'Congenital adrenal hyperplasia (CAH) is a chronic condition and individuals are exposed to elevated androgen levels in utero as a result of the endogenous cortisol deficiency.', 'subject score': 851, 'object score': 1000}, 'PMID:3487786': {'publication date': '1986 Jul', 'sentence': 'If this cytochrome P-450 enzyme is defective, cortisol cannot be synthesized, resulting in congenital adrenal hyperplasia.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0001627---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "18446972",
-              "object": "MONDO:0018479",
-              "publications": [
-                "PMID:26184920",
-                "PMID:3487786"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 319116,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:845476': {'publication date': '1977 Apr', 'sentence': 'False elevation of plasma cortisol in congenital adrenal hyperplasia.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 312713,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008315",
-          "name": "prostate cancer",
-          "description": "A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.; Tumors or cancer of the PROSTATE.; A cancer of the prostate. [HPO:probinson]; What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it:  Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to:  Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer.    What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include:  Problems urinating (peeing), such as:  A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen   Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm)  But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you:  Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer  What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include:  A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate.  If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options:  Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation:  Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer.   Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer.  Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include:  Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0008315",
-            "ICD10:C61",
-            "MEDDRA:10026389",
-            "MEDDRA:10007113",
-            "DOID:10283",
-            "MEDDRA:10036908",
-            "UMLS:C0376358",
-            "SNOMEDCT:399068003",
-            "ICD9:185",
-            "PDQ:CDR0000038782",
-            "MEDDRA:10036910",
-            "MEDDRA:10036946",
-            "KEGG.DISEASE:05215",
-            "NCIT:C7378",
-            "MESH:D011471",
-            "HP:0012125",
-            "MEDDRA:10060862"
-          ],
-          "id": "MONDO:0008315",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Malignant Prostate Neoplasm",
-            "prostate cancer",
-            "Prostate cancer",
-            "Prostatic Neoplasms",
-            "Malignant neoplasm of prostate"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-          "name": "congenital adrenal hyperplasia",
-          "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:237751000",
-            "DOID:12255",
-            "NCIT:C34360",
-            "ORPHANET:418",
-            "MONDO:0018479",
-            "MEDDRA:10010323",
-            "ICD9:255.2",
-            "DOID:0050811",
-            "HP:0008258",
-            "UMLS:C0001627",
-            "UMLS:C0701163",
-            "ICD10:E25",
-            "MESH:D000312"
-          ],
-          "id": "MONDO:0018479",
-          "category": "biolink:Disease",
-          "all_names": [
-            "congenital adrenal hyperplasia",
-            "obsolete congenital adrenal hyperplasia",
-            "Adrenogenital disorders",
-            "Adrenogenital disorder",
-            "Congenital adrenal hyperplasia",
-            "Adrenal Hyperplasia, Congenital",
-            "obsolete_congenital adrenal hyperplasia",
-            "Congenital Adrenal Hyperplasia"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://www.cancer.gov/dictionary?cdrid=445079",
-=======
-            "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-            "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-            "http://omim.org/entry/201710",
->>>>>>> main
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 319116,
-=======
-            "identity": 312713,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008315",
-              "name": "prostate cancer",
-              "description": "A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.; Tumors or cancer of the PROSTATE.; A cancer of the prostate. [HPO:probinson]; What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it:  Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to:  Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer.    What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include:  Problems urinating (peeing), such as:  A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen   Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm)  But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you:  Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer  What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include:  A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate.  If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options:  Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation:  Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer.   Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer.  Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include:  Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0008315",
-                "ICD10:C61",
-                "MEDDRA:10026389",
-                "MEDDRA:10007113",
-                "DOID:10283",
-                "MEDDRA:10036908",
-                "UMLS:C0376358",
-                "SNOMEDCT:399068003",
-                "ICD9:185",
-                "PDQ:CDR0000038782",
-                "MEDDRA:10036910",
-                "MEDDRA:10036946",
-                "KEGG.DISEASE:05215",
-                "NCIT:C7378",
-                "MESH:D011471",
-                "HP:0012125",
-                "MEDDRA:10060862"
-              ],
-              "id": "MONDO:0008315",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Malignant Prostate Neoplasm",
-                "prostate cancer",
-                "Prostate cancer",
-                "Prostatic Neoplasms",
-                "Malignant neoplasm of prostate"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-              "name": "congenital adrenal hyperplasia",
-              "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:237751000",
-                "DOID:12255",
-                "NCIT:C34360",
-                "ORPHANET:418",
-                "MONDO:0018479",
-                "MEDDRA:10010323",
-                "ICD9:255.2",
-                "DOID:0050811",
-                "HP:0008258",
-                "UMLS:C0001627",
-                "UMLS:C0701163",
-                "ICD10:E25",
-                "MESH:D000312"
-              ],
-              "id": "MONDO:0018479",
-              "category": "biolink:Disease",
-              "all_names": [
-                "congenital adrenal hyperplasia",
-                "obsolete congenital adrenal hyperplasia",
-                "Adrenogenital disorders",
-                "Adrenogenital disorder",
-                "Congenital adrenal hyperplasia",
-                "Adrenal Hyperplasia, Congenital",
-                "obsolete_congenital adrenal hyperplasia",
-                "Congenital Adrenal Hyperplasia"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://www.cancer.gov/dictionary?cdrid=445079",
-=======
-                "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-                "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-                "http://omim.org/entry/201710",
->>>>>>> main
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 11198021,
-            "start": 569,
-            "end": 319116,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15457124': {'publication date': '2004 Oct', 'sentence': 'A prospective study was performed to investigate the combination of the aromatase inhibitor aminoglutethimide and hydrocortisone in androgen-independent prostate cancer with changes in prostate-specific antigen (PSA) level as main determinant for response.', 'subject score': 1000, 'object score': 861}, 'PMID:19887483': {'publication date': '2009 Nov 15', 'sentence': 'Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.', 'subject score': 1000, 'object score': 840}, 'PMID:28692205': {'publication date': '2018 Jan', 'sentence': 'OBJECTIVE: To investigate the effect of chronic stress as measured in cortisol concentrations upon the association between psychological resilience (PR) and depression in prostate cancer (PCa) patients.', 'subject score': 888, 'object score': 1000}, 'PMID:7666079': {'publication date': '1995 Sep', 'sentence': 'Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0376358---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "11442939",
-              "object": "MONDO:0008315",
-              "publications": [
-                "PMID:15457124",
-                "PMID:19887483",
-                "PMID:28692205",
-                "PMID:7666079"
-=======
-            "identity": 26531049,
-            "start": 569,
-            "end": 312713,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:845476': {'publication date': '1977 Apr', 'sentence': 'False elevation of plasma cortisol in congenital adrenal hyperplasia.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0001627---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "26997315",
-              "object": "MONDO:0018479",
-              "publications": [
-                "PMID:845476"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 317183,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:18844712': {'publication date': '2008', 'sentence': 'Several types of the congenital adrenal hyperplasias are associated with decreased cortisol production and excessive adrenal sex steroid secretion.', 'subject score': 851, 'object score': 1000}, 'PMID:3871229': {'publication date': '1985 Jan', 'sentence': 'To explore the potential effect of dose schedule on the adrenal suppressive action of hydrocortisone in congenital adrenal hyperplasia, eight patients (six with 21-hydroxylase deficiency and two with 11-hydroxylase deficiency) were given five different dose schedules.', 'subject score': 1000, 'object score': 1000}, 'PMID:9370898': {'publication date': '1997 Sep', 'sentence': 'Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia.', 'subject score': 1000, 'object score': 1000}, 'PMID:9516061': {'publication date': '1998', 'sentence': \"The effects of hypercortisolemia and ACTH on the metabolism of cortisol in congenital adrenal hyperplasia, Cushing's syndrome, and exogenous ACTH and cortisol administration were investigated by analysis of the respective urinary tetrahydro-metabolites of cortisol (THF and aTHF) and cortisone (THE) by capillary gas chromatography.\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 312713,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004982",
-          "name": "pancreatitis",
-          "description": "Inflammation of the pancreas.; INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.; The presence of inflammation in the pancreas. [HPO:probinson]; The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0004982",
-            "MEDDRA:10076039",
-            "MEDDRA:10033656",
-            "DOID:4989",
-            "SNOMEDCT:75694006",
-            "ICD10:K85.9",
-            "MEDDRA:10033645",
-            "NCIT:C3306",
-            "EFO:0000278",
-            "HP:0001733",
-            "MESH:D010195",
-            "UMLS:C0030305"
-          ],
-          "id": "MONDO:0004982",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pancreatitis",
-            "pancreatitis"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-          "name": "congenital adrenal hyperplasia",
-          "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:237751000",
-            "DOID:12255",
-            "NCIT:C34360",
-            "ORPHANET:418",
-            "MONDO:0018479",
-            "MEDDRA:10010323",
-            "ICD9:255.2",
-            "DOID:0050811",
-            "HP:0008258",
-            "UMLS:C0001627",
-            "UMLS:C0701163",
-            "ICD10:E25",
-            "MESH:D000312"
-          ],
-          "id": "MONDO:0018479",
-          "category": "biolink:Disease",
-          "all_names": [
-            "congenital adrenal hyperplasia",
-            "obsolete congenital adrenal hyperplasia",
-            "Adrenogenital disorders",
-            "Adrenogenital disorder",
-            "Congenital adrenal hyperplasia",
-            "Adrenal Hyperplasia, Congenital",
-            "obsolete_congenital adrenal hyperplasia",
-            "Congenital Adrenal Hyperplasia"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://medlineplus.gov/pancreatitis.htm",
-            "https://orcid.org/0000-0001-5208-3432",
-=======
-            "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-            "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-            "http://omim.org/entry/201710",
->>>>>>> main
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 317183,
-=======
-            "identity": 312713,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004982",
-              "name": "pancreatitis",
-              "description": "Inflammation of the pancreas.; INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.; The presence of inflammation in the pancreas. [HPO:probinson]; The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0004982",
-                "MEDDRA:10076039",
-                "MEDDRA:10033656",
-                "DOID:4989",
-                "SNOMEDCT:75694006",
-                "ICD10:K85.9",
-                "MEDDRA:10033645",
-                "NCIT:C3306",
-                "EFO:0000278",
-                "HP:0001733",
-                "MESH:D010195",
-                "UMLS:C0030305"
-              ],
-              "id": "MONDO:0004982",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pancreatitis",
-                "pancreatitis"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-              "name": "congenital adrenal hyperplasia",
-              "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:237751000",
-                "DOID:12255",
-                "NCIT:C34360",
-                "ORPHANET:418",
-                "MONDO:0018479",
-                "MEDDRA:10010323",
-                "ICD9:255.2",
-                "DOID:0050811",
-                "HP:0008258",
-                "UMLS:C0001627",
-                "UMLS:C0701163",
-                "ICD10:E25",
-                "MESH:D000312"
-              ],
-              "id": "MONDO:0018479",
-              "category": "biolink:Disease",
-              "all_names": [
-                "congenital adrenal hyperplasia",
-                "obsolete congenital adrenal hyperplasia",
-                "Adrenogenital disorders",
-                "Adrenogenital disorder",
-                "Congenital adrenal hyperplasia",
-                "Adrenal Hyperplasia, Congenital",
-                "obsolete_congenital adrenal hyperplasia",
-                "Congenital Adrenal Hyperplasia"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://medlineplus.gov/pancreatitis.htm",
-                "https://orcid.org/0000-0001-5208-3432",
-=======
-                "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-                "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-                "http://omim.org/entry/201710",
->>>>>>> main
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 10851408,
-            "start": 569,
-            "end": 317183,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15022622': {'publication date': '2003 Oct', 'sentence': 'To investigate the time courses of the effects of the exogenous glucocorticoid agonists dexamethasone (DEX) and hydrocortisone (HYD) and a glucocorticoid antagonist (RU-38486), and to characterize the local and systemic responses in experimental AP.', 'subject score': 1000, 'object score': 851}, 'PMID:15211115': {'publication date': '2004 Jul', 'sentence': 'The aim of this study was to investigate the time courses of the effects of the exogenous glucocorticoid agonists dexamethasone (DEX) and hydrocortisone (HYD) and a glucocorticoid antagonist (RU-38486) and to characterize the local and systemic responses in AP in rats.', 'subject score': 1000, 'object score': 888}, 'PMID:29215538': {'publication date': '2018 01', 'sentence': 'Cortisol Outperforms Novel Cardiovascular, Inflammatory, and Neurohumoral Biomarkers in the Prediction of Outcome in Acute Pancreatitis.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0030305---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "11089023",
-              "object": "MONDO:0004982",
-              "publications": [
-                "PMID:15022622",
-                "PMID:15211115",
-                "PMID:29215538"
-=======
-            "identity": 13705766,
-            "start": 569,
-            "end": 312713,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18844712': {'publication date': '2008', 'sentence': 'Several types of the congenital adrenal hyperplasias are associated with decreased cortisol production and excessive adrenal sex steroid secretion.', 'subject score': 851, 'object score': 1000}, 'PMID:3871229': {'publication date': '1985 Jan', 'sentence': 'To explore the potential effect of dose schedule on the adrenal suppressive action of hydrocortisone in congenital adrenal hyperplasia, eight patients (six with 21-hydroxylase deficiency and two with 11-hydroxylase deficiency) were given five different dose schedules.', 'subject score': 1000, 'object score': 1000}, 'PMID:9370898': {'publication date': '1997 Sep', 'sentence': 'Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia.', 'subject score': 1000, 'object score': 1000}, 'PMID:9516061': {'publication date': '1998', 'sentence': \"The effects of hypercortisolemia and ACTH on the metabolism of cortisol in congenital adrenal hyperplasia, Cushing's syndrome, and exogenous ACTH and cortisol administration were investigated by analysis of the respective urinary tetrahydro-metabolites of cortisol (THF and aTHF) and cortisone (THE) by capillary gas chromatography.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0001627---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13999195",
-              "object": "MONDO:0018479",
-              "publications": [
-                "PMID:18844712",
-                "PMID:3871229",
-                "PMID:9370898",
-                "PMID:9516061"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 317845,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10720048': {'publication date': '2000 Mar', 'sentence': 'We conclude that the regimen of flutamide, testolactone, reduced hydrocortisone dose, and fludrocortisone provides effective control of congenital adrenal hyperplasia with reduced risk of glucocorticoid excess.', 'subject score': 851, 'object score': 1000}, 'PMID:11057552': {'publication date': '2000', 'sentence': 'Nine are still being treated medically by the pediatric endocrine team with hydrocortisone for CAH.', 'subject score': 1000, 'object score': 1000}, 'PMID:12174243': {'publication date': '2002 Jul', 'sentence': 'We report a case, which was misdiagnosed as a case of congenital adrenal hyperplasia and treated inappropriately with hydrocortisone and fludrocortisone for 12-months before he had a urinary tract infection and was discovered to have obstructive uropathy on ultrasound.', 'subject score': 1000, 'object score': 1000}, 'PMID:16607925': {'publication date': '2006 Mar', 'sentence': 'CONCLUSION: We demonstrated that a hydrocortisone dose of 17.64 +/- 3.60 mg/m2/day in classical CAH had a negative influence on height development for genetic height potential in 8.5 years of follow-up and that it is necessary to use the lowest possible steroid dosage by individualizing the dose.', 'subject score': 888, 'object score': 916}, 'PMID:18647821': {'publication date': '2008 Oct', 'sentence': 'CASE REPORT: The patient was known with CAH due to 3beta-HSD deficiency and treated with hydrocortisone and fludrocortisone since the neonatal period.', 'subject score': 1000, 'object score': 1000}, 'PMID:19486026': {'publication date': '2010 Apr', 'sentence': 'A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia.', 'subject score': 888, 'object score': 1000}, 'PMID:19622620': {'publication date': '2009 Oct', 'sentence': 'OBJECTIVE: The aim of the study was to determine an optimal range for hydrocortisone dosing during puberty in children with classical CAH who were exclusively treated with hydrocortisone.', 'subject score': 1000, 'object score': 916}, 'PMID:20379352': {'publication date': '2010', 'sentence': 'Hydrocortisone has long been the treatment of choice for congenital adrenal hyperplasia (CAH).', 'subject score': 1000, 'object score': 861}, 'PMID:20857846': {'publication date': '2010 Jul', 'sentence': '11beta-hydroxylase deficient congenital adrenal hyperplasia was diagnosed and hydrocortisone treatment was started.', 'subject score': 888, 'object score': 823}, 'PMID:2303071': {'publication date': '1990 Jan', 'sentence': 'Daily profiles of salivary cortisol were determined in 14 cortisol-treated children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, and in 5 healthy sibs.', 'subject score': 888, 'object score': 777}, 'PMID:24170965': {'publication date': '2013 Oct', 'sentence': 'He was diagnosed as having salt-wasting CAH with a high 17-OHP level at neonatal screening and was initially treated with hydrocortisone at 8 days of age.', 'subject score': 1000, 'object score': 1000}, 'PMID:24560184': {'publication date': '2014 May', 'sentence': 'OBJECTIVE: To estimate the impact of the average daily dose of hydrocortisone (HC) on the amount of growth attained in children with congenital adrenal hyperplasia (CAH).', 'subject score': 1000, 'object score': 817}, 'PMID:24655023': {'publication date': '2014 Jul', 'sentence': 'The child with difficult to control Congenital Adrenal Hyperplasia: is there a place for continuous subcutaneous hydrocortisone therapy.', 'subject score': 833, 'object score': 1000}, 'PMID:25364676': {'publication date': '2014 Nov', 'sentence': 'BACKGROUND: There are recommendations regarding the total dose of hydrocortisone to be administered in the treatment of classical congenital adrenal hyperplasia (CAH) to achieve the twin objectives of glucocorticoid replacement and control of hyperandrogenism.', 'subject score': 1000, 'object score': 916}, 'PMID:25494662': {'publication date': '2015 Mar', 'sentence': 'MAIN OUTCOME MEASURES: The primary outcome was cortisol pharmacokinetics of Chronocort and secondary outcomes included biomarkers of CAH control (androstenedione and 17-OHP).', 'subject score': 888, 'object score': 756}, 'PMID:26107677': {'publication date': '2015 Jun', 'sentence': 'No germline p53 gene mutation including R337H was detected.The patient was first misdiagnosed as CAH and treated with hydrocortisone for 3 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:26108325': {'publication date': '2015 Jun', 'sentence': 'After treatment with hydrocortisone and/or 9-alpha fluorohydrocortisone, cortical hormone levels improved in all the children, and the levels of cortisol, testosterone, estradiol, and electrolytes improved significantly after treatment in children with salt-losing CAH (P<0.05).', 'subject score': 1000, 'object score': 1000}, 'PMID:27680873': {'publication date': '2016 12', 'sentence': 'OBJECTIVE: This study sought to approximate physiologic cortisol secretion via continuous subcutaneous hydrocortisone infusion (CSHI) and evaluate the safety and efficacy of CSHI in patients with difficult-to-treat CAH.', 'subject score': 861, 'object score': 916}, 'PMID:27688786': {'publication date': '2016', 'sentence': 'Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia.', 'subject score': 1000, 'object score': 817}, 'PMID:28100629': {'publication date': '2017 Apr', 'sentence': 'Impact of food, alcohol and pH on modified-release hydrocortisone developed to treat congenital adrenal hyperplasia.', 'subject score': 851, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 312713,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005068",
-          "name": "myocardial infarction",
-          "description": "Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin. [HPO:probinson]; Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021758",
-            "EFO:0000612",
-            "MEDDRA:10019250",
-            "MEDDRA:10028595",
-            "MONDO:0005068",
-            "SNOMEDCT:22298006",
-            "HP:0001658",
-            "NCIT:C27996",
-            "MEDDRA:10003723",
-            "ICD10:I21",
-            "MEDDRA:10003724",
-            "MESH:D009203",
-            "DOID:5844",
-            "UMLS:C0027051",
-            "MEDDRA:10028596"
-          ],
-          "id": "MONDO:0005068",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myocardial Infarction",
-            "Myocardial infarction",
-            "myocardial infarction"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-          "name": "congenital adrenal hyperplasia",
-          "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:237751000",
-            "DOID:12255",
-            "NCIT:C34360",
-            "ORPHANET:418",
-            "MONDO:0018479",
-            "MEDDRA:10010323",
-            "ICD9:255.2",
-            "DOID:0050811",
-            "HP:0008258",
-            "UMLS:C0001627",
-            "UMLS:C0701163",
-            "ICD10:E25",
-            "MESH:D000312"
-          ],
-          "id": "MONDO:0018479",
-          "category": "biolink:Disease",
-          "all_names": [
-            "congenital adrenal hyperplasia",
-            "obsolete congenital adrenal hyperplasia",
-            "Adrenogenital disorders",
-            "Adrenogenital disorder",
-            "Congenital adrenal hyperplasia",
-            "Adrenal Hyperplasia, Congenital",
-            "obsolete_congenital adrenal hyperplasia",
-            "Congenital Adrenal Hyperplasia"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0001-5208-3432",
-            "PMID:17951287",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://en.wikipedia.org/wiki/myocardial_infarction"
-=======
-            "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-            "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-            "http://omim.org/entry/201710",
-            "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 317845,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005068",
-              "name": "myocardial infarction",
-              "description": "Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin. [HPO:probinson]; Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021758",
-                "EFO:0000612",
-                "MEDDRA:10019250",
-                "MEDDRA:10028595",
-                "MONDO:0005068",
-                "SNOMEDCT:22298006",
-                "HP:0001658",
-                "NCIT:C27996",
-                "MEDDRA:10003723",
-                "ICD10:I21",
-                "MEDDRA:10003724",
-                "MESH:D009203",
-                "DOID:5844",
-                "UMLS:C0027051",
-                "MEDDRA:10028596"
-              ],
-              "id": "MONDO:0005068",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myocardial Infarction",
-                "Myocardial infarction",
-                "myocardial infarction"
-=======
-            "identity": 312713,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-              "name": "congenital adrenal hyperplasia",
-              "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:237751000",
-                "DOID:12255",
-                "NCIT:C34360",
-                "ORPHANET:418",
-                "MONDO:0018479",
-                "MEDDRA:10010323",
-                "ICD9:255.2",
-                "DOID:0050811",
-                "HP:0008258",
-                "UMLS:C0001627",
-                "UMLS:C0701163",
-                "ICD10:E25",
-                "MESH:D000312"
-              ],
-              "id": "MONDO:0018479",
-              "category": "biolink:Disease",
-              "all_names": [
-                "congenital adrenal hyperplasia",
-                "obsolete congenital adrenal hyperplasia",
-                "Adrenogenital disorders",
-                "Adrenogenital disorder",
-                "Congenital adrenal hyperplasia",
-                "Adrenal Hyperplasia, Congenital",
-                "obsolete_congenital adrenal hyperplasia",
-                "Congenital Adrenal Hyperplasia"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0001-5208-3432",
-                "PMID:17951287",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://en.wikipedia.org/wiki/myocardial_infarction"
-=======
-                "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-                "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-                "http://omim.org/entry/201710",
-                "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 10416618,
-            "start": 569,
-            "end": 317845,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13924001': {'publication date': '1962 May-Jun', 'sentence': '[The adrenal cortex and hydrocortisone metabolism in experimental myocardial infarct].', 'subject score': 888, 'object score': 901}, 'PMID:14033341': {'publication date': '1963 Mar', 'sentence': 'Plasma cortisol in myocardial infarction.', 'subject score': 888, 'object score': 1000}, 'PMID:14187467': {'publication date': '1964 Oct 10', 'sentence': 'HYDROCORTISONE IN SEVERE MYOCARDIAL INFARCTION.', 'subject score': 1000, 'object score': 901}, 'PMID:14255194': {'publication date': '1964 Jul-Aug', 'sentence': '[THERAPEUTIC USE OF HYDROCORTISONE AND THE FUNCTIONAL STATE OF THE ADRENAL CORTEX IN MYOCARDIAL INFARCT, COMPLICATED BY COLLAPSE].', 'subject score': 1000, 'object score': 1000}, 'PMID:30691725': {'publication date': '2019 Apr', 'sentence': 'Stress hyperglycemia: A prospective study examining the relationship between glucose, cortisol and diabetes in myocardial infarction.', 'subject score': 1000, 'object score': 1000}, 'PMID:369021': {'publication date': '1978', 'sentence': '[Changes in the level and metabolism of a number of hormones (insulin, somatotropin, thyrotropin, thyroid hormones, ACTH and cortisol) in myocardial infarct in vitro and in vivo according to the radioisotope dilution tests].', 'subject score': 1000, 'object score': 1000}, 'PMID:6670263': {'publication date': '1983 Oct 15', 'sentence': '[Use of large doses of hydrocortisone in the treatment of shock in myocardial infarct].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0027051---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10649902",
-              "object": "MONDO:0005068",
-              "publications": [
-                "PMID:13924001",
-                "PMID:14033341",
-                "PMID:14187467",
-                "PMID:14255194",
-                "PMID:30691725",
-                "PMID:369021",
-                "PMID:6670263"
-=======
-            "identity": 7892658,
-            "start": 569,
-            "end": 312713,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10720048': {'publication date': '2000 Mar', 'sentence': 'We conclude that the regimen of flutamide, testolactone, reduced hydrocortisone dose, and fludrocortisone provides effective control of congenital adrenal hyperplasia with reduced risk of glucocorticoid excess.', 'subject score': 851, 'object score': 1000}, 'PMID:11057552': {'publication date': '2000', 'sentence': 'Nine are still being treated medically by the pediatric endocrine team with hydrocortisone for CAH.', 'subject score': 1000, 'object score': 1000}, 'PMID:12174243': {'publication date': '2002 Jul', 'sentence': 'We report a case, which was misdiagnosed as a case of congenital adrenal hyperplasia and treated inappropriately with hydrocortisone and fludrocortisone for 12-months before he had a urinary tract infection and was discovered to have obstructive uropathy on ultrasound.', 'subject score': 1000, 'object score': 1000}, 'PMID:16607925': {'publication date': '2006 Mar', 'sentence': 'CONCLUSION: We demonstrated that a hydrocortisone dose of 17.64 +/- 3.60 mg/m2/day in classical CAH had a negative influence on height development for genetic height potential in 8.5 years of follow-up and that it is necessary to use the lowest possible steroid dosage by individualizing the dose.', 'subject score': 888, 'object score': 916}, 'PMID:18647821': {'publication date': '2008 Oct', 'sentence': 'CASE REPORT: The patient was known with CAH due to 3beta-HSD deficiency and treated with hydrocortisone and fludrocortisone since the neonatal period.', 'subject score': 1000, 'object score': 1000}, 'PMID:19486026': {'publication date': '2010 Apr', 'sentence': 'A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia.', 'subject score': 888, 'object score': 1000}, 'PMID:19622620': {'publication date': '2009 Oct', 'sentence': 'OBJECTIVE: The aim of the study was to determine an optimal range for hydrocortisone dosing during puberty in children with classical CAH who were exclusively treated with hydrocortisone.', 'subject score': 1000, 'object score': 916}, 'PMID:20379352': {'publication date': '2010', 'sentence': 'Hydrocortisone has long been the treatment of choice for congenital adrenal hyperplasia (CAH).', 'subject score': 1000, 'object score': 861}, 'PMID:20857846': {'publication date': '2010 Jul', 'sentence': '11beta-hydroxylase deficient congenital adrenal hyperplasia was diagnosed and hydrocortisone treatment was started.', 'subject score': 888, 'object score': 823}, 'PMID:2303071': {'publication date': '1990 Jan', 'sentence': 'Daily profiles of salivary cortisol were determined in 14 cortisol-treated children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, and in 5 healthy sibs.', 'subject score': 888, 'object score': 777}, 'PMID:24170965': {'publication date': '2013 Oct', 'sentence': 'He was diagnosed as having salt-wasting CAH with a high 17-OHP level at neonatal screening and was initially treated with hydrocortisone at 8 days of age.', 'subject score': 1000, 'object score': 1000}, 'PMID:24560184': {'publication date': '2014 May', 'sentence': 'OBJECTIVE: To estimate the impact of the average daily dose of hydrocortisone (HC) on the amount of growth attained in children with congenital adrenal hyperplasia (CAH).', 'subject score': 1000, 'object score': 817}, 'PMID:24655023': {'publication date': '2014 Jul', 'sentence': 'The child with difficult to control Congenital Adrenal Hyperplasia: is there a place for continuous subcutaneous hydrocortisone therapy.', 'subject score': 833, 'object score': 1000}, 'PMID:25364676': {'publication date': '2014 Nov', 'sentence': 'BACKGROUND: There are recommendations regarding the total dose of hydrocortisone to be administered in the treatment of classical congenital adrenal hyperplasia (CAH) to achieve the twin objectives of glucocorticoid replacement and control of hyperandrogenism.', 'subject score': 1000, 'object score': 916}, 'PMID:25494662': {'publication date': '2015 Mar', 'sentence': 'MAIN OUTCOME MEASURES: The primary outcome was cortisol pharmacokinetics of Chronocort and secondary outcomes included biomarkers of CAH control (androstenedione and 17-OHP).', 'subject score': 888, 'object score': 756}, 'PMID:26107677': {'publication date': '2015 Jun', 'sentence': 'No germline p53 gene mutation including R337H was detected.The patient was first misdiagnosed as CAH and treated with hydrocortisone for 3 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:26108325': {'publication date': '2015 Jun', 'sentence': 'After treatment with hydrocortisone and/or 9-alpha fluorohydrocortisone, cortical hormone levels improved in all the children, and the levels of cortisol, testosterone, estradiol, and electrolytes improved significantly after treatment in children with salt-losing CAH (P<0.05).', 'subject score': 1000, 'object score': 1000}, 'PMID:27680873': {'publication date': '2016 12', 'sentence': 'OBJECTIVE: This study sought to approximate physiologic cortisol secretion via continuous subcutaneous hydrocortisone infusion (CSHI) and evaluate the safety and efficacy of CSHI in patients with difficult-to-treat CAH.', 'subject score': 861, 'object score': 916}, 'PMID:27688786': {'publication date': '2016', 'sentence': 'Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia.', 'subject score': 1000, 'object score': 817}, 'PMID:28100629': {'publication date': '2017 Apr', 'sentence': 'Impact of food, alcohol and pH on modified-release hydrocortisone developed to treat congenital adrenal hyperplasia.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0001627---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8061437",
-              "object": "MONDO:0018479",
-              "publications": [
-                "PMID:10720048",
-                "PMID:11057552",
-                "PMID:12174243",
-                "PMID:16607925",
-                "PMID:18647821",
-                "PMID:19486026",
-                "PMID:19622620",
-                "PMID:20379352",
-                "PMID:20857846",
-                "PMID:2303071",
-                "PMID:24170965",
-                "PMID:24560184",
-                "PMID:24655023",
-                "PMID:25364676",
-                "PMID:25494662",
-                "PMID:26107677",
-                "PMID:26108325",
-                "PMID:27680873",
-                "PMID:27688786",
-                "PMID:28100629"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:produces",
-    "r2.publications_info": "{'PMID:34518380': {'publication date': '2021 Aug 01', 'sentence': 'Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder that leads to the partial or complete deficiency of cortisol and aldosterone production from the adrenal glands.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 312713,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-          "name": "congenital adrenal hyperplasia",
-          "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:237751000",
-            "DOID:12255",
-            "NCIT:C34360",
-            "ORPHANET:418",
-            "MONDO:0018479",
-            "MEDDRA:10010323",
-            "ICD9:255.2",
-            "DOID:0050811",
-            "HP:0008258",
-            "UMLS:C0001627",
-            "UMLS:C0701163",
-            "ICD10:E25",
-            "MESH:D000312"
-          ],
-          "id": "MONDO:0018479",
-          "category": "biolink:Disease",
-          "all_names": [
-            "congenital adrenal hyperplasia",
-            "obsolete congenital adrenal hyperplasia",
-            "Adrenogenital disorders",
-            "Adrenogenital disorder",
-            "Congenital adrenal hyperplasia",
-            "Adrenal Hyperplasia, Congenital",
-            "obsolete_congenital adrenal hyperplasia",
-            "Congenital Adrenal Hyperplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-            "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-            "http://omim.org/entry/201710",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312713,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-              "name": "congenital adrenal hyperplasia",
-              "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:237751000",
-                "DOID:12255",
-                "NCIT:C34360",
-                "ORPHANET:418",
-                "MONDO:0018479",
-                "MEDDRA:10010323",
-                "ICD9:255.2",
-                "DOID:0050811",
-                "HP:0008258",
-                "UMLS:C0001627",
-                "UMLS:C0701163",
-                "ICD10:E25",
-                "MESH:D000312"
-              ],
-              "id": "MONDO:0018479",
-              "category": "biolink:Disease",
-              "all_names": [
-                "congenital adrenal hyperplasia",
-                "obsolete congenital adrenal hyperplasia",
-                "Adrenogenital disorders",
-                "Adrenogenital disorder",
-                "Congenital adrenal hyperplasia",
-                "Adrenal Hyperplasia, Congenital",
-                "obsolete_congenital adrenal hyperplasia",
-                "Congenital Adrenal Hyperplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-                "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-                "http://omim.org/entry/201710",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23304107,
-            "start": 312713,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:34518380': {'publication date': '2021 Aug 01', 'sentence': 'Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder that leads to the partial or complete deficiency of cortisol and aldosterone production from the adrenal glands.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0001627---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0018479",
-              "id": "23738730",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:34518380"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:28751021': {'publication date': '2017 Nov', 'sentence': 'Ordinary least squared (OLS) regression was used to evaluate whether race moderated the associations between alcohol abuse and four biomarkers-urinary cortisol and serum dehydroepiandrosterone sulfate (DHEA-S), epinephrine and norepinephrine-and two composite summary scores, each consisting of two components that characterize the hypothalamic pituitary adrenal (HPA)-axis and sympathetic nervous systems (SNS), respectively.', 'subject score': 833, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 540309,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002046",
-          "name": "alcohol abuse",
-          "description": "The use of alcoholic beverages to excess, either on individual occasions (\"binge drinking\") or as a regular practice.; A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4); UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "MEDDRA:10001584",
-            "UMLS:C0085762",
-            "MONDO:0002046",
-            "MESH:D000437",
-            "PSY:01660",
-            "DOID:1574",
-            "NCIT:C20701",
-            "MEDDRA:10063501",
-            "MEDDRA:10001589",
-            "ICD9:305.0",
-            "ICD10:F10.1",
-            "SNOMEDCT:15167005"
-          ],
-          "id": "MONDO:0002046",
-          "category": "biolink:Disease",
-          "all_names": [
-            "alcohol use disorder",
-            "alcohol abuse",
-            "Alcoholism",
-            "Alcohol Abuse",
-            "Alcohol abuse"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/alcohol-use-disorders",
-            "http://en.wikipedia.org/wiki/alcohol_abuse"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 540309,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002046",
-              "name": "alcohol abuse",
-              "description": "The use of alcoholic beverages to excess, either on individual occasions (\"binge drinking\") or as a regular practice.; A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4); UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "MEDDRA:10001584",
-                "UMLS:C0085762",
-                "MONDO:0002046",
-                "MESH:D000437",
-                "PSY:01660",
-                "DOID:1574",
-                "NCIT:C20701",
-                "MEDDRA:10063501",
-                "MEDDRA:10001589",
-                "ICD9:305.0",
-                "ICD10:F10.1",
-                "SNOMEDCT:15167005"
-              ],
-              "id": "MONDO:0002046",
-              "category": "biolink:Disease",
-              "all_names": [
-                "alcohol use disorder",
-                "alcohol abuse",
-                "Alcoholism",
-                "Alcohol Abuse",
-                "Alcohol abuse"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/alcohol-use-disorders",
-                "http://en.wikipedia.org/wiki/alcohol_abuse"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19406436,
-            "start": 569,
-            "end": 540309,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28751021': {'publication date': '2017 Nov', 'sentence': 'Ordinary least squared (OLS) regression was used to evaluate whether race moderated the associations between alcohol abuse and four biomarkers-urinary cortisol and serum dehydroepiandrosterone sulfate (DHEA-S), epinephrine and norepinephrine-and two composite summary scores, each consisting of two components that characterize the hypothalamic pituitary adrenal (HPA)-axis and sympathetic nervous systems (SNS), respectively.', 'subject score': 833, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0085762---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "19793698",
-              "object": "MONDO:0002046",
-              "publications": [
-                "PMID:28751021"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:13389946': {'publication date': '1956 Aug 31', 'sentence': '[Intraarticular hydrocortisone (cortril) in arthritis and osteoarthritis].', 'subject score': 888, 'object score': 1000}, 'PMID:20467005': {'publication date': '2010 Jun', 'sentence': 'Fibromyalgia and osteoarthritis groups showed similar secretory patterns, and maltreatment was associated with elevated cortisol in both.', 'subject score': 888, 'object score': 888}, 'PMID:9825759': {'publication date': '1998 Oct', 'sentence': 'Similar response of adrenocorticotrophic hormone, cortisol and prolactin to surgery in rheumatoid arthritis and osteoarthritis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319030,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319030,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10295239,
-            "start": 569,
-            "end": 319030,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13389946': {'publication date': '1956 Aug 31', 'sentence': '[Intraarticular hydrocortisone (cortril) in arthritis and osteoarthritis].', 'subject score': 888, 'object score': 1000}, 'PMID:20467005': {'publication date': '2010 Jun', 'sentence': 'Fibromyalgia and osteoarthritis groups showed similar secretory patterns, and maltreatment was associated with elevated cortisol in both.', 'subject score': 888, 'object score': 888}, 'PMID:9825759': {'publication date': '1998 Oct', 'sentence': 'Similar response of adrenocorticotrophic hormone, cortisol and prolactin to surgery in rheumatoid arthritis and osteoarthritis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10522181",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:13389946",
-                "PMID:20467005",
-                "PMID:9825759"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 308745,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:31500387': {'publication date': '2019 Sep 08', 'sentence': 'In this review, we summarize the effects of circadian melatonin, TSH, and cortisol on OA, focusing on how different levels of these hormones affect OA pathogenesis and recovery with respect to the circadian clock.', 'subject score': 1000, 'object score': 1000}, 'PMID:32392916': {'publication date': '2020 May 01', 'sentence': 'These data indicate that 25-HC may act as a metabolic pathophysiological factor in osteoarthritis that is mediated by progressive chondrocyte death in the articular cartilage with inflammatory condition.', 'subject score': 861, 'object score': 1000}, 'PMID:32395076': {'publication date': '2020 May 01', 'sentence': 'These data indicate that 25-HC may act as a metabolic pathophysiological factor in osteoarthritis that is mediated by progressive chondrocyte death in the articular cartilage with inflammatory condition.', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319030,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005328",
-          "name": "eye disorder",
-          "description": "Diseases or defects of the eye. Use VISION DISORDERS for other pathology involving visual neural pathways.; A non-neoplastic or neoplastic disorder that affects the eye. Representative examples include conjunctivitis, glaucoma, cataract, conjunctival squamous cell carcinoma, uveal melanoma, and retinoblastoma.; Diseases affecting the eye.; Any abnormality of the eye, including location, spacing, and intraocular abnormalities. [HPO:probinson]; Some eye problems are minor and don't last long. But some can lead to a permanent loss of vision. Common eye problems include: Refractive errors Cataracts - clouded lenses Optic nerve disorders, including glaucoma Retinal disorders - problems with the nerve layer at the back of the eye Macular degeneration - a disease that destroys sharp, central vision Diabetic eye problems Conjunctivitis - an infection also known as pink eye  Your best defense is to have regular checkups, because eye diseases do not always have symptoms. Early detection and treatment could prevent vision loss. See an eye care professional right away if you have a sudden change in vision, if everything looks dim, or if you see flashes of light. Other symptoms that need quick attention are pain, double vision, fluid coming from the eye, and inflammation. NIH: National Eye Institute ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0015397",
-            "NCIT:C26767",
-            "MEDDRA:10045783",
-            "MEDDRA:10013221",
-            "MEDDRA:10015919",
-            "MEDDRA:10054716",
-            "ICD9:360.29",
-            "MESH:D005128",
-            "EFO:0003966",
-            "MEDDRA:10015916",
-            "MEDDRA:10059159",
-            "UMLS:C0015393",
-            "ICD10:H44",
-            "MEDDRA:10045790",
-            "HP:0000478",
-            "SNOMEDCT:19416009",
-            "MEDDRA:10015913",
-            "MEDDRA:10030874",
-            "NCIT:C98887",
-            "MEDDRA:10010435",
-            "MEDDRA:10010462",
-            "MEDDRA:10015949",
-            "UMLS:C4316870",
-            "MEDDRA:10015904",
-            "MESH:D005124",
-            "MEDDRA:10015920",
-            "MEDDRA:10015903",
-            "MEDDRA:10015918",
-            "MONDO:0005328",
-            "SNOMEDCT:371405004",
-            "ICD9:379.90",
-            "DOID:5614",
-            "UMLS:C0154780",
-            "DOID:1242",
-            "MEDDRA:10045628",
-            "ICD10:H44.39"
-          ],
-          "id": "MONDO:0005328",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Disorder of eye, unspecified",
-            "Eye Abnormalities",
-            "Other degenerative disorders of globe",
-            "eye disease",
-            "Congenital Eye Disorder",
-            "globe disease",
-            "Disorder of eye",
-            "Abnormality of the eye",
-            "eye disorder",
-            "Eye Diseases",
-            "Eye Disorder"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://en.wikipedia.org/wiki/eye_disease",
-            "https://en.wikipedia.org/wiki/globe_(human_eye)",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-5316-1399"
-=======
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 308745,
-=======
-            "identity": 319030,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005328",
-              "name": "eye disorder",
-              "description": "Diseases or defects of the eye. Use VISION DISORDERS for other pathology involving visual neural pathways.; A non-neoplastic or neoplastic disorder that affects the eye. Representative examples include conjunctivitis, glaucoma, cataract, conjunctival squamous cell carcinoma, uveal melanoma, and retinoblastoma.; Diseases affecting the eye.; Any abnormality of the eye, including location, spacing, and intraocular abnormalities. [HPO:probinson]; Some eye problems are minor and don't last long. But some can lead to a permanent loss of vision. Common eye problems include: Refractive errors Cataracts - clouded lenses Optic nerve disorders, including glaucoma Retinal disorders - problems with the nerve layer at the back of the eye Macular degeneration - a disease that destroys sharp, central vision Diabetic eye problems Conjunctivitis - an infection also known as pink eye  Your best defense is to have regular checkups, because eye diseases do not always have symptoms. Early detection and treatment could prevent vision loss. See an eye care professional right away if you have a sudden change in vision, if everything looks dim, or if you see flashes of light. Other symptoms that need quick attention are pain, double vision, fluid coming from the eye, and inflammation. NIH: National Eye Institute ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0015397",
-                "NCIT:C26767",
-                "MEDDRA:10045783",
-                "MEDDRA:10013221",
-                "MEDDRA:10015919",
-                "MEDDRA:10054716",
-                "ICD9:360.29",
-                "MESH:D005128",
-                "EFO:0003966",
-                "MEDDRA:10015916",
-                "MEDDRA:10059159",
-                "UMLS:C0015393",
-                "ICD10:H44",
-                "MEDDRA:10045790",
-                "HP:0000478",
-                "SNOMEDCT:19416009",
-                "MEDDRA:10015913",
-                "MEDDRA:10030874",
-                "NCIT:C98887",
-                "MEDDRA:10010435",
-                "MEDDRA:10010462",
-                "MEDDRA:10015949",
-                "UMLS:C4316870",
-                "MEDDRA:10015904",
-                "MESH:D005124",
-                "MEDDRA:10015920",
-                "MEDDRA:10015903",
-                "MEDDRA:10015918",
-                "MONDO:0005328",
-                "SNOMEDCT:371405004",
-                "ICD9:379.90",
-                "DOID:5614",
-                "UMLS:C0154780",
-                "DOID:1242",
-                "MEDDRA:10045628",
-                "ICD10:H44.39"
-              ],
-              "id": "MONDO:0005328",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Disorder of eye, unspecified",
-                "Eye Abnormalities",
-                "Other degenerative disorders of globe",
-                "eye disease",
-                "Congenital Eye Disorder",
-                "globe disease",
-                "Disorder of eye",
-                "Abnormality of the eye",
-                "eye disorder",
-                "Eye Diseases",
-                "Eye Disorder"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://en.wikipedia.org/wiki/eye_disease",
-                "https://en.wikipedia.org/wiki/globe_(human_eye)",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-5316-1399"
-=======
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 10294481,
-            "start": 569,
-            "end": 308745,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13386145': {'publication date': '1956', 'sentence': '[Use of cortisone and hydrocortisone in eye diseases].', 'subject score': 1000, 'object score': 1000}, 'PMID:14373050': {'publication date': '1955', 'sentence': 'Hydrocortisone and ACTH in eye disease.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0015397---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10521296",
-              "object": "MONDO:0005328",
-              "publications": [
-                "PMID:13386145",
-                "PMID:14373050"
-=======
-            "identity": 20863965,
-            "start": 569,
-            "end": 319030,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31500387': {'publication date': '2019 Sep 08', 'sentence': 'In this review, we summarize the effects of circadian melatonin, TSH, and cortisol on OA, focusing on how different levels of these hormones affect OA pathogenesis and recovery with respect to the circadian clock.', 'subject score': 1000, 'object score': 1000}, 'PMID:32392916': {'publication date': '2020 May 01', 'sentence': 'These data indicate that 25-HC may act as a metabolic pathophysiological factor in osteoarthritis that is mediated by progressive chondrocyte death in the articular cartilage with inflammatory condition.', 'subject score': 861, 'object score': 1000}, 'PMID:32395076': {'publication date': '2020 May 01', 'sentence': 'These data indicate that 25-HC may act as a metabolic pathophysiological factor in osteoarthritis that is mediated by progressive chondrocyte death in the articular cartilage with inflammatory condition.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "21274202",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:31500387",
-                "PMID:32392916",
-                "PMID:32395076"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 314857,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:13276616': {'publication date': '1956 Jan', 'sentence': 'Phenylbutazone and compound F for osteoarthritis of the hip; a survey and clinical report.', 'subject score': 1000, 'object score': 1000}, 'PMID:13524937': {'publication date': '1958 May', 'sentence': 'Hydrocortisone ionization; a study to determine the effects of a new method of utilizing hydrocortisone in the treatment of rheumatoid and osteoarthritis.', 'subject score': 861, 'object score': 1000}, 'PMID:13649406': {'publication date': '1959', 'sentence': 'The effect of intra-articular hydrocortisone therapy upon the joint temperature in osteoarthritis and rheumatoid arthritis.', 'subject score': 861, 'object score': 1000}, 'PMID:20525314': {'publication date': '2010', 'sentence': 'Cortisol inhibited HNP1-3 levels only in OA patients.', 'subject score': 1000, 'object score': 888}, 'PMID:37072059': {'publication date': '2023 Apr 16', 'sentence': 'Ultrasound-responsive hyaluronic acid hydrogel of hydrocortisone to treat osteoarthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:5669141': {'publication date': '1968 Apr 08', 'sentence': '[Results of hydrocortisone injections into small joints in rheumatoid arthritis and osteoarthritis].', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319030,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004795",
-          "name": "otitis externa",
-          "description": "Inflammation of the anatomical structures of the outer ear and ear canal, which is most often caused by an infectious process. Symptoms include erythema, edema, and pain.; Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.; Inflammation or infection of the external auditory canal (EAC), the auricle, or both. [http://search.medscape.com/search/?q=otitis%20externa, ORCID:0000-0001-5208-3432]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021919",
-            "NCIT:C79601",
-            "MESH:D010032",
-            "SNOMEDCT:3135009",
-            "MEDDRA:10052558",
-            "NCIT:C3299",
-            "MEDDRA:10021920",
-            "UMLS:C0029878",
-            "UMLS:C0021355",
-            "MEDDRA:10065837",
-            "HP:0410017",
-            "MEDDRA:10033072",
-            "MEDDRA:10082612",
-            "EFO:0009560",
-            "DOID:9463",
-            "ICD9:380.1",
-            "SNOMEDCT:86981007",
-            "MONDO:0004795"
-          ],
-          "id": "MONDO:0004795",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infective otitis externa",
-            "Otitis Externa",
-            "Otitis externa",
-            "otitis externa",
-            "Infectious Otitis Externa"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://en.wikipedia.org/wiki/otitis_externa",
-            "http://search.medscape.com/search/?q=otitis%20externa",
-            "https://orcid.org/0000-0001-5208-3432"
-=======
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 314857,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004795",
-              "name": "otitis externa",
-              "description": "Inflammation of the anatomical structures of the outer ear and ear canal, which is most often caused by an infectious process. Symptoms include erythema, edema, and pain.; Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.; Inflammation or infection of the external auditory canal (EAC), the auricle, or both. [http://search.medscape.com/search/?q=otitis%20externa, ORCID:0000-0001-5208-3432]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021919",
-                "NCIT:C79601",
-                "MESH:D010032",
-                "SNOMEDCT:3135009",
-                "MEDDRA:10052558",
-                "NCIT:C3299",
-                "MEDDRA:10021920",
-                "UMLS:C0029878",
-                "UMLS:C0021355",
-                "MEDDRA:10065837",
-                "HP:0410017",
-                "MEDDRA:10033072",
-                "MEDDRA:10082612",
-                "EFO:0009560",
-                "DOID:9463",
-                "ICD9:380.1",
-                "SNOMEDCT:86981007",
-                "MONDO:0004795"
-              ],
-              "id": "MONDO:0004795",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infective otitis externa",
-                "Otitis Externa",
-                "Otitis externa",
-                "otitis externa",
-                "Infectious Otitis Externa"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/otitis_externa",
-                "http://search.medscape.com/search/?q=otitis%20externa",
-                "https://orcid.org/0000-0001-5208-3432"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10291447,
-            "start": 569,
-            "end": 314857,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13373990': {'publication date': '1956 Jul-Aug', 'sentence': '[Topical use of hydrocortisone in otitis externa].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0029878---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10518203",
-              "object": "MONDO:0004795",
-              "publications": [
-                "PMID:13373990"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-=======
-            "identity": 319030,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-=======
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 10258383,
-            "start": 569,
-            "end": 322104,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13249258': {'publication date': '1955 May 27', 'sentence': 'The use of hydrocortisone in ulcerative colitis:  preliminary observations.', 'subject score': 1000, 'object score': 1000}, 'PMID:13518363': {'publication date': '1958 Mar', 'sentence': 'Absorption of cortisol from the colon in ulcerative colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:6307809': {'publication date': '1983 Sep', 'sentence': 'ACTH vs. hydrocortisone in ulcerative colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7199714': {'publication date': '1981 Sep 28', 'sentence': '[Diurnal rhythm of plasma cortisol in ulcerative colitis].', 'subject score': 888, 'object score': 1000}, 'PMID:9741018': {'publication date': '1998 Aug', 'sentence': \"The effectiveness of intravenous corticotrophin versus hydrocortisone in ulcerative colitis has been determined including whether previous steroid therapy influenced the better response to one rather than the other, but no such studies have ever been done in Crohn's disease.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10484611",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:13249258",
-                "PMID:13518363",
-                "PMID:6307809",
-                "PMID:7199714",
-                "PMID:9741018"
-=======
-            "identity": 10264547,
-            "start": 569,
-            "end": 319030,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13276616': {'publication date': '1956 Jan', 'sentence': 'Phenylbutazone and compound F for osteoarthritis of the hip; a survey and clinical report.', 'subject score': 1000, 'object score': 1000}, 'PMID:13524937': {'publication date': '1958 May', 'sentence': 'Hydrocortisone ionization; a study to determine the effects of a new method of utilizing hydrocortisone in the treatment of rheumatoid and osteoarthritis.', 'subject score': 861, 'object score': 1000}, 'PMID:13649406': {'publication date': '1959', 'sentence': 'The effect of intra-articular hydrocortisone therapy upon the joint temperature in osteoarthritis and rheumatoid arthritis.', 'subject score': 861, 'object score': 1000}, 'PMID:20525314': {'publication date': '2010', 'sentence': 'Cortisol inhibited HNP1-3 levels only in OA patients.', 'subject score': 1000, 'object score': 888}, 'PMID:37072059': {'publication date': '2023 Apr 16', 'sentence': 'Ultrasound-responsive hyaluronic acid hydrogel of hydrocortisone to treat osteoarthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:5669141': {'publication date': '1968 Apr 08', 'sentence': '[Results of hydrocortisone injections into small joints in rheumatoid arthritis and osteoarthritis].', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10492262",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:13276616",
-                "PMID:13524937",
-                "PMID:13649406",
-                "PMID:20525314",
-                "PMID:37072059",
-                "PMID:5669141"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 313237,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
-          "name": "atopic eczema",
-          "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SYMP:0000289",
-            "EFO:0000274",
-            "DOID:3310",
-            "HP:0000964",
-            "NCIT:C3001",
-            "UMLS:C0013595",
-            "MESH:D004485",
-            "MEDDRA:10014200",
-            "MEDDRA:10014206",
-            "MEDDRA:10012454",
-            "ICD10:L20",
-            "MEDDRA:10014184",
-            "OMIM.PS:603165",
-            "MEDDRA:10014209",
-            "PSY:15950",
-            "MONDO:0004980",
-            "OMIM:PS603165"
-          ],
-          "id": "MONDO:0004980",
-          "category": "biolink:Disease",
-          "all_names": [
-            "atopic dermatitis",
-            "atopic eczema",
-            "eczema",
-            "Eczema"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/atopic_dermatitis",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313237,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
-              "name": "atopic eczema",
-              "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SYMP:0000289",
-                "EFO:0000274",
-                "DOID:3310",
-                "HP:0000964",
-                "NCIT:C3001",
-                "UMLS:C0013595",
-                "MESH:D004485",
-                "MEDDRA:10014200",
-                "MEDDRA:10014206",
-                "MEDDRA:10012454",
-                "ICD10:L20",
-                "MEDDRA:10014184",
-                "OMIM.PS:603165",
-                "MEDDRA:10014209",
-                "PSY:15950",
-                "MONDO:0004980",
-                "OMIM:PS603165"
-              ],
-              "id": "MONDO:0004980",
-              "category": "biolink:Disease",
-              "all_names": [
-                "atopic dermatitis",
-                "atopic eczema",
-                "eczema",
-                "Eczema"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/atopic_dermatitis",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9501810,
-            "start": 569,
-            "end": 313237,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12189774': {'publication date': '2002', 'sentence': 'It can therefore be concluded that ointments containing either only E. coli BCS or a combination of BCS and hydrocortisone provide significant relief in perianal eczema as well as in early stages of hemorrhoidal disease.', 'subject score': 1000, 'object score': 888}, 'PMID:13116093': {'publication date': '1954 Jan', 'sentence': 'Hydrocortisone (compound F) acetate ointment in eczema of infants and children.', 'subject score': 1000, 'object score': 1000}, 'PMID:17376223': {'publication date': '2007 Mar 21', 'sentence': 'CONCLUSION: The anti-inflammatory activity demonstrated in the ACD model suggests that the mechanism of action of the MPM is different than that of hydrocortisone and could become a relevant product for people suffering from dermatological manifestations associated with immune dysfunctions such as allergies, eczema, dermatitis, and autoimmune diseases.', 'subject score': 1000, 'object score': 1000}, 'PMID:3890401': {'publication date': '1985 Apr', 'sentence': '[Comparative characteristics of the changes in the concentrations of sugar, insulin, glucagon and cortisol of the blood in atopic dermatitis and eczema patients].', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0013595---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9718673",
-              "object": "MONDO:0004980",
-              "publications": [
-                "PMID:12189774",
-                "PMID:13116093",
-                "PMID:17376223",
-                "PMID:3890401"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 303504,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005530",
-          "name": "opiate dependence",
-          "description": "Disorders related to or resulting from abuse or misuse of OPIOIDS.; Addiction to opioids. [ORCID:0000-0002-4095-8489, PMID:27508068]; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "MESH:D009293",
-            "MEDDRA:10030896",
-            "MEDDRA:10030892",
-            "SNOMEDCT:75544000",
-            "ICD9:304.00",
-            "UMLS:C0027412",
-            "HP:0033515",
-            "MONDO:0005530",
-            "MEDDRA:10012346",
-            "ICD10:F11.2",
-            "DOID:2559",
-            "UMLS:C0524662"
-          ],
-          "id": "MONDO:0005530",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Opioid type dependence, unspecified",
-            "Opiate Addiction",
-            "opiate dependence",
-            "Opioid addiction",
-            "Opioid-Related Disorders"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/opiate_dependency",
-            "https://orcid.org/0000-0002-4095-8489",
-            "PMID:27508068"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 303504,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005530",
-              "name": "opiate dependence",
-              "description": "Disorders related to or resulting from abuse or misuse of OPIOIDS.; Addiction to opioids. [ORCID:0000-0002-4095-8489, PMID:27508068]; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "MESH:D009293",
-                "MEDDRA:10030896",
-                "MEDDRA:10030892",
-                "SNOMEDCT:75544000",
-                "ICD9:304.00",
-                "UMLS:C0027412",
-                "HP:0033515",
-                "MONDO:0005530",
-                "MEDDRA:10012346",
-                "ICD10:F11.2",
-                "DOID:2559",
-                "UMLS:C0524662"
-              ],
-              "id": "MONDO:0005530",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Opioid type dependence, unspecified",
-                "Opiate Addiction",
-                "opiate dependence",
-                "Opioid addiction",
-                "Opioid-Related Disorders"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/opiate_dependency",
-                "https://orcid.org/0000-0002-4095-8489",
-                "PMID:27508068"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9288120,
-            "start": 569,
-            "end": 303504,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11955464': {'publication date': '2002 Apr 15', 'sentence': 'The effect on cortisol supports the above conclusion and is consistent with HPA axis perturbation in opioid dependence as reported in other studies and extends these observations to stable methadone-maintained patients.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0524662---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9492934",
-              "object": "MONDO:0005530",
-              "publications": [
-                "PMID:11955464"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9039473,
-            "start": 569,
-            "end": 320039,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11717587': {'publication date': '2001', 'sentence': 'Several randomized controlled trials have evaluated the efficacy of a replacement therapy with hydrocortisone in severe sepsis.', 'subject score': 1000, 'object score': 888}, 'PMID:11800521': {'publication date': '2001 Dec', 'sentence': 'Recent studies with stress doses of hydrocortisone in sepsis and septic shock have shown a marked haemodynamic improvement, but whether patients with relative adrenal dysfunction benefit most from this treatment and whether there is definitely an effect on outcome is still undecided.', 'subject score': 1000, 'object score': 1000}, 'PMID:12120695': {'publication date': '2002 May', 'sentence': 'The relationship between cortisol and IL-6 in sepsis is discussed.', 'subject score': 1000, 'object score': 1000}, 'PMID:17021536': {'publication date': '2004 Apr', 'sentence': 'Together with new findings on low-dose hydrocortisone, this stresses the relevance of adjunctive therapy in severe sepsis and septic shock.', 'subject score': 901, 'object score': 888}, 'PMID:17558491': {'publication date': '2007 Oct', 'sentence': 'There were no significant correlations observed between total plasma cortisol or cortisone and sickness severity in the sepsis and trauma cohorts.', 'subject score': 851, 'object score': 1000}, 'PMID:18597063': {'publication date': '2008 Aug', 'sentence': '[Hydrocortisone in sepsis. A physiological concept without effect?].', 'subject score': 1000, 'object score': 1000}, 'PMID:18708964': {'publication date': '2008 Sep', 'sentence': 'Hydrocortisone in severe sepsis: time to accept the null hypothesis?', 'subject score': 1000, 'object score': 888}, 'PMID:21600230': {'publication date': '2011', 'sentence': 'In conclusion, the combined effect of inflammatory cytokines at the adrenal level in acute or chronic inflammatory states could significantly stimulate glucocorticoid production, and thus explain the observed discrepancy between the cortisol and ACTH concentrations sometimes seen in sepsis and chronic inflammatory states.', 'subject score': 1000, 'object score': 1000}, 'PMID:21850531': {'publication date': '2011 Dec', 'sentence': 'The areas under the receiver operating characteristic curve for predicting increases in free from total cortisol were 0.93-0.97 in sepsis and 0.79-0.85 in non-sepsis (P = 0.044 or lower for sepsis vs. non-sepsis).', 'subject score': 888, 'object score': 1000}, 'PMID:21991143': {'publication date': '2009 Mar 31', 'sentence': 'Our results suggest that increased cortisol and decreased immunoglobulin levels could be related to severe sepsis and clinical outcome.', 'subject score': 888, 'object score': 888}, 'PMID:22781364': {'publication date': '2012 Jul 10', 'sentence': 'Baseline cortisol directly related to sepsis and endogenous ACTH, independent of etomidate use.', 'subject score': 888, 'object score': 1000}, 'PMID:24373796': {'publication date': '2014 May', 'sentence': 'We found no significant difference in the estimated affinity of CBG and albumin for cortisol in normal, sepsis and septic shock groups, although free cortisol was higher in sepsis and septic shock groups.', 'subject score': 1000, 'object score': 888}, 'PMID:24910975': {'publication date': '2014', 'sentence': 'Cortisol to dehydroepiandrosterone (DHEA) ratio was put forward as a prognostic marker in sepsis.', 'subject score': 1000, 'object score': 1000}, 'PMID:25243181': {'publication date': '2014', 'sentence': 'CONCLUSION: Prolactin, apart from cortisol, may have a role in the acute stress response in severe sepsis.', 'subject score': 1000, 'object score': 888}, 'PMID:25560635': {'publication date': '2015 Jan 06', 'sentence': 'A low Delta cortisol in time was associated with more-severe disease, culture-positive sepsis, and prolonged activated prothrombin time.', 'subject score': 802, 'object score': 851}, 'PMID:26753096': {'publication date': '2016', 'sentence': 'CONCLUSIONS: SS is associated with increased SaC, but decreased cFC levels when baseline STC is assumed to be sufficient.', 'subject score': 851, 'object score': 888}, 'PMID:28224564': {'publication date': '2017 Dec', 'sentence': 'CONCLUSIONS: Acute-phase sepsis is associated with increased hGR expression and cortisol concentrations, possibly implying no need for exogenous steroids.', 'subject score': 888, 'object score': 901}, 'PMID:28974331': {'publication date': '2018 Feb', 'sentence': 'The primary literature summaries evaluate the following: dexmedetomidine for delirium prevention in post-cardiac surgery, dexmedetomidine for delirium management in mechanically ventilated patients, high-dose epoetin alfa after out-of-hospital cardiac arrest, ideal blood pressure targets in ICH, hydrocortisone in severe sepsis, procalcitonin-guided antibiotic de-escalation, and empiric micafungin therapy.', 'subject score': 1000, 'object score': 888}, 'PMID:31679383': {'publication date': '2019 Jul 01', 'sentence': 'CONCLUSION: Hydrocortisone, when used in sepsis or septic shock, in critically ill adult patients showed a statistically insignificant trend towards decreasing 28 day all-cause mortality.', 'subject score': 1000, 'object score': 1000}, 'PMID:31990246': {'publication date': '2020 Jan 28', 'sentence': 'Background:     Combination of vitamin C, hydrocortisone and thiamine have recently been used in sepsis but data of efficacy are conflicting and no data are available from developing countries.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0036690---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9238280",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:11717587",
-                "PMID:11800521",
-                "PMID:12120695",
-                "PMID:17021536",
-                "PMID:17558491",
-                "PMID:18597063",
-                "PMID:18708964",
-                "PMID:21600230",
-                "PMID:21850531",
-                "PMID:21991143",
-                "PMID:22781364",
-                "PMID:24373796",
-                "PMID:24910975",
-                "PMID:25243181",
-                "PMID:25560635",
-                "PMID:26753096",
-                "PMID:28224564",
-                "PMID:28974331",
-                "PMID:31679383",
-                "PMID:31990246"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:1171545': {'publication date': '1975 Aug 25', 'sentence': '[Diurnal variations in blood glucose and plasma cortisol in juvenile diabetes mellitus without ketoacidosis].', 'subject score': 888, 'object score': 1000}, 'PMID:1388312': {'publication date': '1992 Aug', 'sentence': 'Dissociation of cortisol and adrenal androgen secretion in poorly controlled insulin-dependent diabetes mellitus.', 'subject score': 1000, 'object score': 888}, 'PMID:19509020': {'publication date': '2009 Sep', 'sentence': 'These data suggest that prior elevations of cortisol may play a role in the development of exercise-related counterregulatory failure in those with type 1 diabetes.', 'subject score': 1000, 'object score': 923}, 'PMID:2200623': {'publication date': '1990 Jun', 'sentence': 'The effects of improved blood glucose on growth hormone and cortisol secretion in insulin-dependent diabetes mellitus.', 'subject score': 888, 'object score': 1000}, 'PMID:25224993': {'publication date': '2014 Sep 16', 'sentence': 'Depression, smoking, physical inactivity and season independently associated with midnight salivary cortisol in type 1 diabetes.', 'subject score': 851, 'object score': 1000}, 'PMID:2884179': {'publication date': '1987 Apr', 'sentence': 'Diabetogenic action of GH and cortisol in insulin-dependent diabetes mellitus.', 'subject score': 1000, 'object score': 1000}, 'PMID:30922491': {'publication date': '2019 Apr', 'sentence': '50 Years Ago in The Journal of Pediatrics: Cortisol Secretion in Acidotic and Nonacidotic Juvenile Diabetes Mellitus.', 'subject score': 888, 'object score': 923}, 'PMID:395097': {'publication date': '1979', 'sentence': 'Glucagon, growth hormone, and cortisol secretion was studied in seven male insulin-dependent diabetics under conventional subcutaneous insulin therapy and after three days of blood glucose normalization attained by the artificial endocrine pancreas (Biostator-GCIIS).', 'subject score': 888, 'object score': 838}, 'PMID:49515': {'publication date': '1975 Jun 14', 'sentence': 'Blood concentrations of pancreatic glucagon, cortisol, noradrenaline, adrenaline, and growth hormone have been measured during the first 41 hours of insulin deprivation in six insulin-dependent diabetics to assess the importance of these hormones in the pathogenesis of diabetic ketoacidosis.', 'subject score': 1000, 'object score': 905}, 'PMID:5767340': {'publication date': '1969 Apr', 'sentence': 'Cortisol secretion in acidotic and nonacidotic juvenile diabetes mellitus.', 'subject score': 888, 'object score': 923}, 'PMID:6361439': {'publication date': '1983', 'sentence': 'The levels of cortisol and ketone bodies in the IDDM subjects were significantly (P less than 0.05) elevated above the values obtained in the healthy subjects irrespective of the type of exercise.', 'subject score': 1000, 'object score': 912}, 'PMID:7005532': {'publication date': '1980 Nov 03', 'sentence': \"[Glucagon, growth hormone, and cortisol response to insulin-induced hypoglycemia in insulin-dependent diabetics (IDD) without autonomic neuropathy (author's transl)].\", 'subject score': 888, 'object score': 983}, 'PMID:719944': {'publication date': '1978 Sep', 'sentence': '[Insulin therapy and behaviors of insulin antagonist hormones, with special reference to the reactions of growth hormone and cortisol during the hypoglycemic stage in juvenile diabetes].', 'subject score': 1000, 'object score': 1000}, 'PMID:7559888': {'publication date': '1995 Oct', 'sentence': 'Alterations in cortisol metabolism in insulin-dependent diabetes mellitus: relationship with metabolic control and estimated blood volume and effect of angiotensin-converting enzyme inhibition.', 'subject score': 888, 'object score': 1000}, 'PMID:8636289': {'publication date': '1996 Feb', 'sentence': 'At the nadir glucose level (2.2 mmol/L), ACTH, cortisol, and epinephrine levels were significantly lower in well controlled IDDM compared to healthy controls, and the glucose levels required for significant secretion of ACTH, cortisol, and epinephrine also were lower in well controlled IDDM compared to those in both poorly controlled IDDM and healthy volunteers (P < 0.05).', 'subject score': 1000, 'object score': 888}, 'PMID:976635': {'publication date': '1976 Oct', 'sentence': 'The study investigated the respective influences of nicotinic acid and somatostatin on plasma concentrations of blood glucose, free fatty acids, glucagon, growth hormone and cortisol in insulin-dependent diabetic subjects.', 'subject score': 1000, 'object score': 905}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 318783,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005147",
-          "name": "type 1 diabetes mellitus",
-          "description": "A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. [HPO:probinson]; A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. // COMMENTS: The onset of type 1 diabetes is typically during adolescence, but it can develop at any age.; A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. // COMMENTS: The onset of type 1 diabetes is typically during adolescence, but it can develop at any age.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10045228",
-            "MEDDRA:10012608",
-            "MESH:D003922",
-            "DOID:9744",
-            "MEDDRA:10022482",
-            "MEDDRA:10067584",
-            "MEDDRA:10022497",
-            "ORPHANET:243377",
-            "KEGG.DISEASE:04940",
-            "UMLS:C0011854",
-            "MEDDRA:10085412",
-            "MEDDRA:10012609",
-            "SNOMEDCT:46635009",
-            "OMIM:222100",
-            "UMLS:C5435660",
-            "MONDO:0005147",
-            "MEDDRA:10023253",
-            "HP:0100651",
-            "EFO:0001359",
-            "NCIT:C2986",
-            "MEDDRA:10021211"
-          ],
-          "id": "MONDO:0005147",
-          "category": "biolink:Disease",
-          "all_names": [
-            "type 1 diabetes mellitus",
-            "Type I diabetes mellitus",
-            "Type 1 diabetes mellitus 1",
-            "obsolete_type I diabetes mellitus",
-            "Type 1 Diabetes Mellitus",
-            "Type 1 diabetes mellitus related phenotypic feature",
-            "Diabetes Mellitus, Insulin-Dependent",
-            "Diabetes Mellitus, Type 1"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/diabetes_mellitus_type_1",
-            "http://en.wikipedia.org/wiki/diabetes",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318783,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005147",
-              "name": "type 1 diabetes mellitus",
-              "description": "A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. [HPO:probinson]; A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. // COMMENTS: The onset of type 1 diabetes is typically during adolescence, but it can develop at any age.; A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. // COMMENTS: The onset of type 1 diabetes is typically during adolescence, but it can develop at any age.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10045228",
-                "MEDDRA:10012608",
-                "MESH:D003922",
-                "DOID:9744",
-                "MEDDRA:10022482",
-                "MEDDRA:10067584",
-                "MEDDRA:10022497",
-                "ORPHANET:243377",
-                "KEGG.DISEASE:04940",
-                "UMLS:C0011854",
-                "MEDDRA:10085412",
-                "MEDDRA:10012609",
-                "SNOMEDCT:46635009",
-                "OMIM:222100",
-                "UMLS:C5435660",
-                "MONDO:0005147",
-                "MEDDRA:10023253",
-                "HP:0100651",
-                "EFO:0001359",
-                "NCIT:C2986",
-                "MEDDRA:10021211"
-              ],
-              "id": "MONDO:0005147",
-              "category": "biolink:Disease",
-              "all_names": [
-                "type 1 diabetes mellitus",
-                "Type I diabetes mellitus",
-                "Type 1 diabetes mellitus 1",
-                "obsolete_type I diabetes mellitus",
-                "Type 1 Diabetes Mellitus",
-                "Type 1 diabetes mellitus related phenotypic feature",
-                "Diabetes Mellitus, Insulin-Dependent",
-                "Diabetes Mellitus, Type 1"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/diabetes_mellitus_type_1",
-                "http://en.wikipedia.org/wiki/diabetes",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9025846,
-            "start": 569,
-            "end": 318783,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1171545': {'publication date': '1975 Aug 25', 'sentence': '[Diurnal variations in blood glucose and plasma cortisol in juvenile diabetes mellitus without ketoacidosis].', 'subject score': 888, 'object score': 1000}, 'PMID:1388312': {'publication date': '1992 Aug', 'sentence': 'Dissociation of cortisol and adrenal androgen secretion in poorly controlled insulin-dependent diabetes mellitus.', 'subject score': 1000, 'object score': 888}, 'PMID:19509020': {'publication date': '2009 Sep', 'sentence': 'These data suggest that prior elevations of cortisol may play a role in the development of exercise-related counterregulatory failure in those with type 1 diabetes.', 'subject score': 1000, 'object score': 923}, 'PMID:2200623': {'publication date': '1990 Jun', 'sentence': 'The effects of improved blood glucose on growth hormone and cortisol secretion in insulin-dependent diabetes mellitus.', 'subject score': 888, 'object score': 1000}, 'PMID:25224993': {'publication date': '2014 Sep 16', 'sentence': 'Depression, smoking, physical inactivity and season independently associated with midnight salivary cortisol in type 1 diabetes.', 'subject score': 851, 'object score': 1000}, 'PMID:2884179': {'publication date': '1987 Apr', 'sentence': 'Diabetogenic action of GH and cortisol in insulin-dependent diabetes mellitus.', 'subject score': 1000, 'object score': 1000}, 'PMID:30922491': {'publication date': '2019 Apr', 'sentence': '50 Years Ago in The Journal of Pediatrics: Cortisol Secretion in Acidotic and Nonacidotic Juvenile Diabetes Mellitus.', 'subject score': 888, 'object score': 923}, 'PMID:395097': {'publication date': '1979', 'sentence': 'Glucagon, growth hormone, and cortisol secretion was studied in seven male insulin-dependent diabetics under conventional subcutaneous insulin therapy and after three days of blood glucose normalization attained by the artificial endocrine pancreas (Biostator-GCIIS).', 'subject score': 888, 'object score': 838}, 'PMID:49515': {'publication date': '1975 Jun 14', 'sentence': 'Blood concentrations of pancreatic glucagon, cortisol, noradrenaline, adrenaline, and growth hormone have been measured during the first 41 hours of insulin deprivation in six insulin-dependent diabetics to assess the importance of these hormones in the pathogenesis of diabetic ketoacidosis.', 'subject score': 1000, 'object score': 905}, 'PMID:5767340': {'publication date': '1969 Apr', 'sentence': 'Cortisol secretion in acidotic and nonacidotic juvenile diabetes mellitus.', 'subject score': 888, 'object score': 923}, 'PMID:6361439': {'publication date': '1983', 'sentence': 'The levels of cortisol and ketone bodies in the IDDM subjects were significantly (P less than 0.05) elevated above the values obtained in the healthy subjects irrespective of the type of exercise.', 'subject score': 1000, 'object score': 912}, 'PMID:7005532': {'publication date': '1980 Nov 03', 'sentence': \"[Glucagon, growth hormone, and cortisol response to insulin-induced hypoglycemia in insulin-dependent diabetics (IDD) without autonomic neuropathy (author's transl)].\", 'subject score': 888, 'object score': 983}, 'PMID:719944': {'publication date': '1978 Sep', 'sentence': '[Insulin therapy and behaviors of insulin antagonist hormones, with special reference to the reactions of growth hormone and cortisol during the hypoglycemic stage in juvenile diabetes].', 'subject score': 1000, 'object score': 1000}, 'PMID:7559888': {'publication date': '1995 Oct', 'sentence': 'Alterations in cortisol metabolism in insulin-dependent diabetes mellitus: relationship with metabolic control and estimated blood volume and effect of angiotensin-converting enzyme inhibition.', 'subject score': 888, 'object score': 1000}, 'PMID:8636289': {'publication date': '1996 Feb', 'sentence': 'At the nadir glucose level (2.2 mmol/L), ACTH, cortisol, and epinephrine levels were significantly lower in well controlled IDDM compared to healthy controls, and the glucose levels required for significant secretion of ACTH, cortisol, and epinephrine also were lower in well controlled IDDM compared to those in both poorly controlled IDDM and healthy volunteers (P < 0.05).', 'subject score': 1000, 'object score': 888}, 'PMID:976635': {'publication date': '1976 Oct', 'sentence': 'The study investigated the respective influences of nicotinic acid and somatostatin on plasma concentrations of blood glucose, free fatty acids, glucagon, growth hormone and cortisol in insulin-dependent diabetic subjects.', 'subject score': 1000, 'object score': 905}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0011854---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9235597",
-              "object": "MONDO:0005147",
-              "publications": [
-                "PMID:1171545",
-                "PMID:1388312",
-                "PMID:19509020",
-                "PMID:2200623",
-                "PMID:25224993",
-                "PMID:2884179",
-                "PMID:30922491",
-                "PMID:395097",
-                "PMID:49515",
-                "PMID:5767340",
-                "PMID:6361439",
-                "PMID:7005532",
-                "PMID:719944",
-                "PMID:7559888",
-                "PMID:8636289",
-                "PMID:976635"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 546804,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1161341': {'publication date': '1975 Jun', 'sentence': 'Interaction of endogenous growth hormone, cortisol, and catecholamines with blood glucose in children with brittle diabetes mellitus.', 'subject score': 1000, 'object score': 1000}, 'PMID:15239023': {'publication date': '2004 Jul', 'sentence': 'METHODS: hs-CRP, soluble interleukin-2 receptor (sIL-2R), C-peptide, insulin, cortisol, vitamin B12, folic acid, leptin, and homocysteine were determined in 148 patients with juvenile type 1 diabetes, 86 obese children and 142 normal weighted age-matched healthy controls.', 'subject score': 1000, 'object score': 916}, 'PMID:16616286': {'publication date': '2006 Jul', 'sentence': 'The aim of this study was to non-invasively examine the cortisol metabolism in children with Type 1 diabetes mellitus (T1DM) in detail and to test the hypothesis that adrenarche is affected under conventional intensive insulin therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:20189610': {'publication date': '2010 Oct', 'sentence': 'We therefore studied GH, ACTH, and cortisol responses to ghrelin and GHRP-6 in 9 patients with T1DM and 9 control subjects.', 'subject score': 888, 'object score': 1000}, 'PMID:21114371': {'publication date': '2011', 'sentence': 'The examination of peripheral metabolism of cortisol using cortisone acetate test in patients with diabetes mellitus type 1 showed adaptive changes of 11beta-hydroxysteroid dehydrogenace activity associated with altered cortisol tissue supply.', 'subject score': 1000, 'object score': 1000}, 'PMID:2200623': {'publication date': '1990 Jun', 'sentence': 'Growth hormone and cortisol secretion were studied in 25 patients with insulin-dependent diabetes before (Study 1) and 2 weeks after improved glucoregulation (Study 2).', 'subject score': 888, 'object score': 1000}, 'PMID:24350820': {'publication date': '2014 Sep', 'sentence': 'OBJECTIVE: To test the hypothesis that endogenous adrenocorticotropic hormone (ACTH)-cortisol dose-responsive drive, estimated analytically, is significantly accentuated in adolescents and young adults with T1DM compared with healthy individuals.', 'subject score': 615, 'object score': 1000}, 'PMID:34027090': {'publication date': '2021 May', 'sentence': 'In this review, a range of analytes, including glucose, insulin, glucagon, cortisol, lactate, epinephrine, and alcohol, as well as ketones such as beta-hydroxybutyrate, will be evaluated to determine the current status and research direction of those analytes specifically relevant to T1D management, using both in-vitro and on-body detection.', 'subject score': 1000, 'object score': 916}, 'PMID:8816035': {'publication date': '1996 08', 'sentence': 'Growth parameters, growth hormone (GH) response to clonidine and circulating insulin-like growth factor-I (IGF-I), free thyroxine (FT4) and cortisol concentrations in relation to glycaemic control in children with insulin-dependent diabetes mellitus.', 'subject score': 888, 'object score': 1000}, 'PMID:8911878': {'publication date': '1996', 'sentence': 'OBJECTIVE: The role of the dose and route of administration of octreotide in addition to insulin on daily blood glucose, growth hormone, glucagon, cortisol and adrenaline profiles in 7 insulin-dependent diabetic patients have been studied.', 'subject score': 1000, 'object score': 854}}",
-    "p2": {
-      "start": {
-        "identity": 318783,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005147",
-          "name": "type 1 diabetes mellitus",
-          "description": "A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. [HPO:probinson]; A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. // COMMENTS: The onset of type 1 diabetes is typically during adolescence, but it can develop at any age.; A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. // COMMENTS: The onset of type 1 diabetes is typically during adolescence, but it can develop at any age.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10045228",
-            "MEDDRA:10012608",
-            "MESH:D003922",
-            "DOID:9744",
-            "MEDDRA:10022482",
-            "MEDDRA:10067584",
-            "MEDDRA:10022497",
-            "ORPHANET:243377",
-            "KEGG.DISEASE:04940",
-            "UMLS:C0011854",
-            "MEDDRA:10085412",
-            "MEDDRA:10012609",
-            "SNOMEDCT:46635009",
-            "OMIM:222100",
-            "UMLS:C5435660",
-            "MONDO:0005147",
-            "MEDDRA:10023253",
-            "HP:0100651",
-            "EFO:0001359",
-            "NCIT:C2986",
-            "MEDDRA:10021211"
-          ],
-          "id": "MONDO:0005147",
-          "category": "biolink:Disease",
-          "all_names": [
-            "type 1 diabetes mellitus",
-            "Type I diabetes mellitus",
-            "Type 1 diabetes mellitus 1",
-            "obsolete_type I diabetes mellitus",
-            "Type 1 Diabetes Mellitus",
-            "Type 1 diabetes mellitus related phenotypic feature",
-            "Diabetes Mellitus, Insulin-Dependent",
-            "Diabetes Mellitus, Type 1"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/diabetes_mellitus_type_1",
-            "http://en.wikipedia.org/wiki/diabetes",
-            "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 546804,
-=======
-            "identity": 318783,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005147",
-              "name": "type 1 diabetes mellitus",
-              "description": "A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. [HPO:probinson]; A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. // COMMENTS: The onset of type 1 diabetes is typically during adolescence, but it can develop at any age.; A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. // COMMENTS: The onset of type 1 diabetes is typically during adolescence, but it can develop at any age.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10045228",
-                "MEDDRA:10012608",
-                "MESH:D003922",
-                "DOID:9744",
-                "MEDDRA:10022482",
-                "MEDDRA:10067584",
-                "MEDDRA:10022497",
-                "ORPHANET:243377",
-                "KEGG.DISEASE:04940",
-                "UMLS:C0011854",
-                "MEDDRA:10085412",
-                "MEDDRA:10012609",
-                "SNOMEDCT:46635009",
-                "OMIM:222100",
-                "UMLS:C5435660",
-                "MONDO:0005147",
-                "MEDDRA:10023253",
-                "HP:0100651",
-                "EFO:0001359",
-                "NCIT:C2986",
-                "MEDDRA:10021211"
-              ],
-              "id": "MONDO:0005147",
-              "category": "biolink:Disease",
-              "all_names": [
-                "type 1 diabetes mellitus",
-                "Type I diabetes mellitus",
-                "Type 1 diabetes mellitus 1",
-                "obsolete_type I diabetes mellitus",
-                "Type 1 Diabetes Mellitus",
-                "Type 1 diabetes mellitus related phenotypic feature",
-                "Diabetes Mellitus, Insulin-Dependent",
-                "Diabetes Mellitus, Type 1"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/diabetes_mellitus_type_1",
-                "http://en.wikipedia.org/wiki/diabetes",
-                "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 8785487,
-            "start": 569,
-            "end": 546804,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11433135': {'publication date': '2001', 'sentence': 'OBJECTIVES: Elderly women with proximal femur fracture show abnormal persistence of increased cortisol concentrations, which could contribute to the high morbidity associated with this injury.', 'subject score': 851, 'object score': 1000}, 'PMID:20003512': {'publication date': '2009 Dec 15', 'sentence': 'Postnatal dexamethasone or cortisol, at the doses tested, did not have important effects on lung function or injury, suggesting that corticosteroids given at birth will not decrease resuscitation mediated injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:2082258': {'publication date': '1990 Nov-Dec', 'sentence': '[Sensitivity of phagocytes in the blood and bronchoalveolar tract to hydrocortisone in acute injury of the respiratory organs].', 'subject score': 1000, 'object score': 888}, 'PMID:23218665': {'publication date': '2013 Feb', 'sentence': 'The role of cortisol in chronic binge alcohol-induced cerebellar injury: Ovine model.', 'subject score': 1000, 'object score': 809}, 'PMID:27604139': {'publication date': '2016 Oct 31', 'sentence': 'Effects of hydrocortisone on activation of inflammation via interleukin-33 in ventilator-induced lung injury.', 'subject score': 1000, 'object score': 861}, 'PMID:30590339': {'publication date': '2019 04', 'sentence': 'Follow-up analyses suggested the possibility that this pattern of lower cortisol for those who engage in NSSI was present in females and males, and was more pronounced in those with repeated NSSI (but not subthreshold NSSI) and those with a history of NSSI and suicide attempts.', 'subject score': 888, 'object score': 734}, 'PMID:31388512': {'publication date': '2019', 'sentence': 'The balance of these steroids after injury appears to influence outcomes in injured humans, with high cortisol: DHEAS ratio associated with increased morbidity and mortality.', 'subject score': 888, 'object score': 1000}, 'PMID:3913164': {'publication date': '1985 Dec', 'sentence': 'This symptom is connected with high blood levels of cortisol, which are probably also involved in the injuries to connective tissue known in scurvy.', 'subject score': 1000, 'object score': 1000}, 'PMID:4570817': {'publication date': '1973 Mar 01', 'sentence': '[Complications following administration of hydrocortisone in injuries of the locomotor system].', 'subject score': 1000, 'object score': 1000}, 'PMID:5863706': {'publication date': '1965', 'sentence': '[Effect of hydrocortisone on the extinction in injuries of the shock-absorbing apparatus of the knee joint].', 'subject score': 1000, 'object score': 1000}, 'PMID:6887289': {'publication date': '1983 Aug', 'sentence': 'Similar elevations in glucose and cortisol have been found to correlate with both injury severity and survival.', 'subject score': 1000, 'object score': 888}, 'PMID:7986163': {'publication date': '1994 Dec', 'sentence': 'INTERVENTIONS: The catabolic hormones epinephrine, cortisol, and glucagon were infused simultaneously into the femoral artery of five healthy volunteers, thus acutely simulating the hormonal milieu associated with a severe injury.', 'subject score': 1000, 'object score': 888}, 'PMID:13782584': {'publication date': '1960 Dec', 'sentence': '[The metabolism of cortisol in trauma].', 'subject score': 1000, 'object score': 1000}, 'PMID:17558491': {'publication date': '2007 Oct', 'sentence': 'There were no significant correlations observed between total plasma cortisol or cortisone and sickness severity in the sepsis and trauma cohorts.', 'subject score': 851, 'object score': 872}, 'PMID:19389455': {'publication date': '2009 Aug 01', 'sentence': 'Significantly blunted plasma cortisol and ACTH responses in response to dex/CRH administration were found in the trauma exposed compared to the non-exposed women (F(1,20)=5.08, p=0.04 and F(1,20)=5.23, p=0.03 respectively).', 'subject score': 750, 'object score': 1000}, 'PMID:20419739': {'publication date': '2010 Apr', 'sentence': 'This study explores the associations between morning cortisol, trauma, and suicide attempts or ideation among young people.', 'subject score': 888, 'object score': 1000}, 'PMID:21641725': {'publication date': '2012 Jan', 'sentence': 'CONCLUSION: Childhood trauma in adults with personality disorder is associated with blunted cortisol and ACTH secretion following DEX/CRH challenge.', 'subject score': 861, 'object score': 888}, 'PMID:23726317': {'publication date': '2013 Nov 01', 'sentence': 'Association between childhood trauma and low hair cortisol in depressed patients and healthy control subjects.', 'subject score': 851, 'object score': 888}, 'PMID:23907073': {'publication date': '2014 Jan', 'sentence': 'Association of DHEA, DHEAS, and cortisol with childhood trauma exposure and post-traumatic stress disorder.', 'subject score': 1000, 'object score': 623}, 'PMID:25459889': {'publication date': '2015 Feb', 'sentence': 'RESULTS: There was no association between early childhood trauma and cortisol as measured over the 7-day period.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C3263723---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0043251---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8977987",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:21641725",
-                "PMID:4570817",
-                "PMID:25705799",
-                "PMID:30248494",
-                "PMID:8222688",
-                "PMID:11433135",
-                "PMID:7986163",
-                "PMID:36921662",
-                "PMID:2082258",
-                "PMID:23726317",
-                "PMID:20003512",
-                "PMID:32072017",
-                "PMID:33192700",
-                "PMID:13782584",
-                "PMID:5863706",
-                "PMID:19389455",
-                "PMID:30844606",
-                "PMID:6887289",
-                "PMID:23218665",
-                "PMID:3223434"
-=======
-            "identity": 8977950,
-            "start": 569,
-            "end": 318783,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1161341': {'publication date': '1975 Jun', 'sentence': 'Interaction of endogenous growth hormone, cortisol, and catecholamines with blood glucose in children with brittle diabetes mellitus.', 'subject score': 1000, 'object score': 1000}, 'PMID:15239023': {'publication date': '2004 Jul', 'sentence': 'METHODS: hs-CRP, soluble interleukin-2 receptor (sIL-2R), C-peptide, insulin, cortisol, vitamin B12, folic acid, leptin, and homocysteine were determined in 148 patients with juvenile type 1 diabetes, 86 obese children and 142 normal weighted age-matched healthy controls.', 'subject score': 1000, 'object score': 916}, 'PMID:16616286': {'publication date': '2006 Jul', 'sentence': 'The aim of this study was to non-invasively examine the cortisol metabolism in children with Type 1 diabetes mellitus (T1DM) in detail and to test the hypothesis that adrenarche is affected under conventional intensive insulin therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:20189610': {'publication date': '2010 Oct', 'sentence': 'We therefore studied GH, ACTH, and cortisol responses to ghrelin and GHRP-6 in 9 patients with T1DM and 9 control subjects.', 'subject score': 888, 'object score': 1000}, 'PMID:21114371': {'publication date': '2011', 'sentence': 'The examination of peripheral metabolism of cortisol using cortisone acetate test in patients with diabetes mellitus type 1 showed adaptive changes of 11beta-hydroxysteroid dehydrogenace activity associated with altered cortisol tissue supply.', 'subject score': 1000, 'object score': 1000}, 'PMID:2200623': {'publication date': '1990 Jun', 'sentence': 'Growth hormone and cortisol secretion were studied in 25 patients with insulin-dependent diabetes before (Study 1) and 2 weeks after improved glucoregulation (Study 2).', 'subject score': 888, 'object score': 1000}, 'PMID:24350820': {'publication date': '2014 Sep', 'sentence': 'OBJECTIVE: To test the hypothesis that endogenous adrenocorticotropic hormone (ACTH)-cortisol dose-responsive drive, estimated analytically, is significantly accentuated in adolescents and young adults with T1DM compared with healthy individuals.', 'subject score': 615, 'object score': 1000}, 'PMID:34027090': {'publication date': '2021 May', 'sentence': 'In this review, a range of analytes, including glucose, insulin, glucagon, cortisol, lactate, epinephrine, and alcohol, as well as ketones such as beta-hydroxybutyrate, will be evaluated to determine the current status and research direction of those analytes specifically relevant to T1D management, using both in-vitro and on-body detection.', 'subject score': 1000, 'object score': 916}, 'PMID:8816035': {'publication date': '1996 08', 'sentence': 'Growth parameters, growth hormone (GH) response to clonidine and circulating insulin-like growth factor-I (IGF-I), free thyroxine (FT4) and cortisol concentrations in relation to glycaemic control in children with insulin-dependent diabetes mellitus.', 'subject score': 888, 'object score': 1000}, 'PMID:8911878': {'publication date': '1996', 'sentence': 'OBJECTIVE: The role of the dose and route of administration of octreotide in addition to insulin on daily blood glucose, growth hormone, glucagon, cortisol and adrenaline profiles in 7 insulin-dependent diabetic patients have been studied.', 'subject score': 1000, 'object score': 854}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0011854---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9175521",
-              "object": "MONDO:0005147",
-              "publications": [
-                "PMID:1161341",
-                "PMID:15239023",
-                "PMID:16616286",
-                "PMID:20189610",
-                "PMID:21114371",
-                "PMID:2200623",
-                "PMID:24350820",
-                "PMID:34027090",
-                "PMID:8816035",
-                "PMID:8911878"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 183319,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:produces",
-    "r2.publications_info": "{'PMID:22934546': {'publication date': '2012 Nov', 'sentence': 'The propensity to develop type 1 diabetes or type 2 diabetes/metabolic syndrome depends on the propensity to release of cortisol which correlates with race.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318783,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005147",
-          "name": "type 1 diabetes mellitus",
-          "description": "A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. [HPO:probinson]; A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. // COMMENTS: The onset of type 1 diabetes is typically during adolescence, but it can develop at any age.; A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. // COMMENTS: The onset of type 1 diabetes is typically during adolescence, but it can develop at any age.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10045228",
-            "MEDDRA:10012608",
-            "MESH:D003922",
-            "DOID:9744",
-            "MEDDRA:10022482",
-            "MEDDRA:10067584",
-            "MEDDRA:10022497",
-            "ORPHANET:243377",
-            "KEGG.DISEASE:04940",
-            "UMLS:C0011854",
-            "MEDDRA:10085412",
-            "MEDDRA:10012609",
-            "SNOMEDCT:46635009",
-            "OMIM:222100",
-            "UMLS:C5435660",
-            "MONDO:0005147",
-            "MEDDRA:10023253",
-            "HP:0100651",
-            "EFO:0001359",
-            "NCIT:C2986",
-            "MEDDRA:10021211"
-          ],
-          "id": "MONDO:0005147",
-          "category": "biolink:Disease",
-          "all_names": [
-            "type 1 diabetes mellitus",
-            "Type I diabetes mellitus",
-            "Type 1 diabetes mellitus 1",
-            "obsolete_type I diabetes mellitus",
-            "Type 1 Diabetes Mellitus",
-            "Type 1 diabetes mellitus related phenotypic feature",
-            "Diabetes Mellitus, Insulin-Dependent",
-            "Diabetes Mellitus, Type 1"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/diabetes_mellitus_type_1",
-            "http://en.wikipedia.org/wiki/diabetes",
-            "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 183319,
-=======
-            "identity": 318783,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8590480,
-            "start": 569,
-            "end": 183319,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11263762': {'publication date': '2001 Mar', 'sentence': 'From the compendium presented above, the following statements become evident: 1) Inappropriately low secretion of cortisol in relation to inflammation is a typical feature of the inflammatory disease in patients with RA.', 'subject score': 1000, 'object score': 1000}, 'PMID:13443347': {'publication date': '1957 May 25', 'sentence': '[Hydrocortisone in inflammation of the anterior section of the eye; report on experiences with terracortril & cortril].', 'subject score': 1000, 'object score': 1000}, 'PMID:18047442': {'publication date': '2007 Nov', 'sentence': 'A relationship between cortisol and inflammation was established in the pioneering work of H.', 'subject score': 1000, 'object score': 1000}, 'PMID:18455685': {'publication date': '2008 Apr', 'sentence': 'Such alterations are observed as decreased responsiveness of the hypothalamic-pituitary-adrenal axis, an inadequate production of cortisol in relation to inflammation, and - consequently - elevated sympathetic activity, alterations of sex hormone metabolism (loss of androgens), psychological alterations (with chronic fatigue and symptoms of depression due to elevated circulating cytokines), local reduction of synovial sympathetic innervation, altered metabolism of estrogens in the synovium, and high expression of estrogen receptors in synovial cells.', 'subject score': 1000, 'object score': 1000}, 'PMID:18559919': {'publication date': '2008 Sep', 'sentence': 'Amniotic fluid and umbilical cord plasma corticotropin-releasing factor (CRF), CRF-binding protein, adrenocorticotropin, and cortisol concentrations in intraamniotic infection and inflammation at term.', 'subject score': 888, 'object score': 1000}, 'PMID:19591636': {'publication date': '2009', 'sentence': 'Among other mechanisms, the loss of sympathetic nerve fibers in inflamed tissue and inadequate cortisol secretion in relation to inflammation lead to an enhanced proinflammatory load in RA.', 'subject score': 851, 'object score': 1000}, 'PMID:20204984': {'publication date': '2009 Dec', 'sentence': 'Increased cortisol and inflammation have been related to psychological stress while separate studies have found an inverse relation between cortisol and inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:25218898': {'publication date': '2015 Mar', 'sentence': 'The purpose of this study was to characterize relationships between cerebrospinal fluid (CSF) cortisol and inflammation after TBI, and to determine how these relationships differ by outcome.', 'subject score': 901, 'object score': 1000}, 'PMID:25502945': {'publication date': '2015 Jun', 'sentence': 'Inadequate production of cortisol related to inflammation and decrease in adrenal androgen production are hallmarks of hypothalamic-pituitary-adrenal (HPA)-related endocrine findings in rheumatoid arthritis (RA).', 'subject score': 1000, 'object score': 1000}, 'PMID:28043038': {'publication date': '2017 03', 'sentence': 'OBJECTIVE: This study examined the associations between intra-individual variability in, and inter-individual levels of, diurnal cortisol secretion with a marker of low-grade inflammation (i.e., C-Reactive Protein; CRP).', 'subject score': 851, 'object score': 901}, 'PMID:30304079': {'publication date': '2018 Oct 10', 'sentence': 'AIMS: To investigate whether acute dental pain due to pulpal or periapical inflammation is associated with increased expression of cortisol and inflammatory markers and mediators in the saliva, as well as changes in salivary flow rate.', 'subject score': 1000, 'object score': 888}, 'PMID:30445703': {'publication date': '2018 Nov 15', 'sentence': 'We tested whether (1) cortisol is associated to inflammation, (2) cortisol is associated to the adolescent Mediterranean diet score (aMDS), (3) aMDS lessens inflammation, (4) aMDS associates with cortisol levels and inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:35462473': {'publication date': '2022 Mar 25', 'sentence': 'In this study, we use knockout mice, hepatic cells and liver biopsies to explore the role of Ch25h and 25-HC in lipid metabolism and accumulation in liver, determine the molecular mechanism of lipid accumulation and inflammation influenced by Ch25h and 25-HC, and assess the regulatory effects of Ch25h and 25-HC on human NAFLD.', 'subject score': 861, 'object score': 1000}, 'PMID:35634363': {'publication date': '2022 Jun', 'sentence': 'Understanding the role of cortisol in the increased inflammation observed in depression.', 'subject score': 1000, 'object score': 888}, 'PMID:36865036': {'publication date': '2023 Mar', 'sentence': 'However, the role of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), which catalyzes the conversion of inactive cortisone into active cortisol, in inflammation remains unclear.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8778414",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:11263762",
-                "PMID:13443347",
-                "PMID:18047442",
-                "PMID:18455685",
-                "PMID:18559919",
-                "PMID:19591636",
-                "PMID:20204984",
-                "PMID:25218898",
-                "PMID:25502945",
-                "PMID:28043038",
-                "PMID:30304079",
-                "PMID:30445703",
-                "PMID:35462473",
-                "PMID:35634363",
-                "PMID:36865036"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 528832,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-          "name": "toxic shock syndrome",
-          "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C35498",
-            "UMLS:C0600327",
-            "UMLS:CN204669",
-            "MEDDRA:10044248",
-            "MESH:D012772",
-            "MEDDRA:10044249",
-            "SNOMEDCT:18504008",
-            "DOID:14115",
-            "MEDDRA:10042852",
-            "UMLS:C0036983",
-            "ORPHANET:36234",
-            "SNOMEDCT:76571007",
-            "MEDDRA:10040580",
-            "NCIT:C35018",
-            "MEDDRA:10040070",
-            "ICD9:040.82",
-            "ICD10:A48.3",
-            "MONDO:0001881",
-            "EFO:0006834",
-            "SYMP:0000451"
-          ],
-          "id": "MONDO:0001881",
-          "category": "biolink:Disease",
-          "all_names": [
-            "toxic shock syndrome",
-            "Septic Shock",
-            "Shock, Septic",
-            "Toxic Shock Syndrome",
-            "Bacterial toxic-shock syndrome",
-            "septic shock",
-            "Toxic shock syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 528832,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-              "name": "toxic shock syndrome",
-              "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C35498",
-                "UMLS:C0600327",
-                "UMLS:CN204669",
-                "MEDDRA:10044248",
-                "MESH:D012772",
-                "MEDDRA:10044249",
-                "SNOMEDCT:18504008",
-                "DOID:14115",
-                "MEDDRA:10042852",
-                "UMLS:C0036983",
-                "ORPHANET:36234",
-                "SNOMEDCT:76571007",
-                "MEDDRA:10040580",
-                "NCIT:C35018",
-                "MEDDRA:10040070",
-                "ICD9:040.82",
-                "ICD10:A48.3",
-                "MONDO:0001881",
-                "EFO:0006834",
-                "SYMP:0000451"
-              ],
-              "id": "MONDO:0001881",
-              "category": "biolink:Disease",
-              "all_names": [
-                "toxic shock syndrome",
-                "Septic Shock",
-                "Shock, Septic",
-                "Toxic Shock Syndrome",
-                "Bacterial toxic-shock syndrome",
-                "septic shock",
-                "Toxic shock syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005147",
-              "name": "type 1 diabetes mellitus",
-              "description": "A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. [HPO:probinson]; A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. // COMMENTS: The onset of type 1 diabetes is typically during adolescence, but it can develop at any age.; A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. // COMMENTS: The onset of type 1 diabetes is typically during adolescence, but it can develop at any age.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10045228",
-                "MEDDRA:10012608",
-                "MESH:D003922",
-                "DOID:9744",
-                "MEDDRA:10022482",
-                "MEDDRA:10067584",
-                "MEDDRA:10022497",
-                "ORPHANET:243377",
-                "KEGG.DISEASE:04940",
-                "UMLS:C0011854",
-                "MEDDRA:10085412",
-                "MEDDRA:10012609",
-                "SNOMEDCT:46635009",
-                "OMIM:222100",
-                "UMLS:C5435660",
-                "MONDO:0005147",
-                "MEDDRA:10023253",
-                "HP:0100651",
-                "EFO:0001359",
-                "NCIT:C2986",
-                "MEDDRA:10021211"
-              ],
-              "id": "MONDO:0005147",
-              "category": "biolink:Disease",
-              "all_names": [
-                "type 1 diabetes mellitus",
-                "Type I diabetes mellitus",
-                "Type 1 diabetes mellitus 1",
-                "obsolete_type I diabetes mellitus",
-                "Type 1 Diabetes Mellitus",
-                "Type 1 diabetes mellitus related phenotypic feature",
-                "Diabetes Mellitus, Insulin-Dependent",
-                "Diabetes Mellitus, Type 1"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/diabetes_mellitus_type_1",
-                "http://en.wikipedia.org/wiki/diabetes",
-                "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 8566750,
-            "start": 569,
-            "end": 528832,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11251036': {'publication date': '2001 Feb', 'sentence': 'Hydrocortisone infusion in septic shock differentially regulated the cytokine responses.', 'subject score': 888, 'object score': 1000}, 'PMID:11271077': {'publication date': '2000 Dec', 'sentence': 'Hydrocortisone and the reduction of vasopressors in septic shock: therapy or only chart cosmetics?', 'subject score': 1000, 'object score': 1000}, 'PMID:11800521': {'publication date': '2001 Dec', 'sentence': 'Recent studies with stress doses of hydrocortisone in sepsis and septic shock have shown a marked haemodynamic improvement, but whether patients with relative adrenal dysfunction benefit most from this treatment and whether there is definitely an effect on outcome is still undecided.', 'subject score': 1000, 'object score': 1000}, 'PMID:11868733': {'publication date': '2001 Aug', 'sentence': 'More recently, work by Annane et al. using lower doses closer to those that might constitute a stress dose of hydrocortisone have shown encouraging results with a 30% decrease in mortality in septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:12614129': {'publication date': '2003', 'sentence': 'Hydrocortisone and fludrocortisone improved 28-day survival in septic shock and adrenal insufficiency.', 'subject score': 1000, 'object score': 1000}, 'PMID:16263835': {'publication date': '2006 Jan', 'sentence': 'Recently, low total cortisol increments after tetracosactrin have been associated with increased mortality and hemodynamic responsiveness to exogenous hydrocortisone in septic shock (SS), a phenomenon termed by some investigators as relative adrenal insufficiency (RAI).', 'subject score': 888, 'object score': 1000}, 'PMID:16608898': {'publication date': '2006 Jul', 'sentence': 'However, most severe disease and mortality is associated with an increased cortisol to DHEA ratio, which may represent a novel prognostic marker in septic shock.', 'subject score': 888, 'object score': 1000}, 'PMID:1669084': {'publication date': '1991', 'sentence': 'An effect of hydrocortisone and dopamine on beta-glucuronidase activity in the lung tissue in experimental septic shock was analysed.', 'subject score': 1000, 'object score': 901}, 'PMID:17021536': {'publication date': '2004 Apr', 'sentence': 'Together with new findings on low-dose hydrocortisone, this stresses the relevance of adjunctive therapy in severe sepsis and septic shock.', 'subject score': 901, 'object score': 1000}, 'PMID:17316466': {'publication date': '2007', 'sentence': \"A good example of this is the conflict between intensive insulin therapy and 'low dose' hydrocortisone in septic shock.\", 'subject score': 901, 'object score': 1000}, 'PMID:17658222': {'publication date': '2008', 'sentence': 'Mineralocorticoid effects due to cortisol inactivation overload explain the beneficial use of hydrocortisone in septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:17906853': {'publication date': '2008 Feb', 'sentence': 'Stress doses of hydrocortisone in septic shock: beneficial effects on opsonization-dependent neutrophil functions.', 'subject score': 1000, 'object score': 1000}, 'PMID:19004144': {'publication date': '2008 May-Jun', 'sentence': 'Does low dose hydrocortisone reduce mortality in septic shock?', 'subject score': 901, 'object score': 1000}, 'PMID:19057445': {'publication date': '2009 Jan', 'sentence': 'CONCLUSIONS: Our data, although, inconclusive favor the need for a study with a larger sample size to clearly define role of low-dose hydrocortisone in pediatric septic shock in developing countries, while taking in consideration effect of malnutrition, delayed presentations, and their interactions with the hypothalamic-pituitary-adrenocortical axis.', 'subject score': 901, 'object score': 901}, 'PMID:19326575': {'publication date': '2009 Apr', 'sentence': 'CONCLUSIONS: The administration of moderate doses of hydrocortisone in septic shock results in a modest but consistent improvement in capillary perfusion, independent of the response to the ACTH test.', 'subject score': 1000, 'object score': 1000}, 'PMID:19652948': {'publication date': '2009 Nov', 'sentence': 'METHODS: An a-priori sub-study of the CORTICUS multi-centre, randomised, double-blind, placebo-controlled trial of hydrocortisone in septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:21479650': {'publication date': '2011 Apr', 'sentence': 'Concomitant hydrocortisone and arginine vasopressin therapy increases arginine vasopressin plasma levels and may improve survival in septic shock.', 'subject score': 888, 'object score': 1000}, 'PMID:21993448': {'publication date': '2012 Jan', 'sentence': 'The aim of this prospective observational study was to investigate serial changes in plasma total and free cortisol and tissue cortisol activity in septic shock.', 'subject score': 790, 'object score': 1000}, 'PMID:22269144': {'publication date': '2012 Apr', 'sentence': 'The consensus statement from the international task force of the American College of Critical Care medicine recommends 100 mg of intravenous hydrocortisone for patients with adrenal insufficiency in septic shock, but in patients undergoing surgery, especially with extracorporeal circulation, the dosage may even be higher.', 'subject score': 888, 'object score': 1000}, 'PMID:22584796': {'publication date': '2012 Aug', 'sentence': 'Gluco- and mineralocorticoid biological effects of a 7-day treatment with low doses of hydrocortisone and fludrocortisone in septic shock.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0036983---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8763179",
-              "object": "MONDO:0001881",
-              "publications": [
-                "PMID:11251036",
-                "PMID:11271077",
-                "PMID:11800521",
-                "PMID:11868733",
-                "PMID:12614129",
-                "PMID:16263835",
-                "PMID:16608898",
-                "PMID:1669084",
-                "PMID:17021536",
-                "PMID:17316466",
-                "PMID:17658222",
-                "PMID:17906853",
-                "PMID:19004144",
-                "PMID:19057445",
-                "PMID:19326575",
-                "PMID:19652948",
-                "PMID:21479650",
-                "PMID:21993448",
-                "PMID:22269144",
-                "PMID:22584796"
-=======
-            "identity": 16136113,
-            "start": 318783,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:22934546': {'publication date': '2012 Nov', 'sentence': 'The propensity to develop type 1 diabetes or type 2 diabetes/metabolic syndrome depends on the propensity to release of cortisol which correlates with race.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0011854---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0005147",
-              "id": "16473285",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:22934546"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 319995,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001185",
-          "name": "dissociative amnesia",
-          "description": "Partial or complete loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories. Compare FORGETTING and MEMORY DECAY.; Systematic and extensive loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories.; Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7); UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "NCIT:C78444",
-            "SYMP:0000543",
-            "MONDO:0001185",
-            "MEDDRA:10027178",
-            "ICD9:300.12",
-            "ICD9:780.93",
-            "SNOMEDCT:55533009",
-            "MESH:D000647",
-            "SNOMEDCT:48167000",
-            "MEDDRA:10001949",
-            "NBO:0000253",
-            "PSY:30590",
-            "ICD10:F44.0",
-            "UMLS:C3887551",
-            "MEDDRA:10013461",
-            "MESH:D008569",
-            "DOID:11037",
-            "MEDDRA:10027172",
-            "MEDDRA:10027174",
-            "MEDDRA:10027176",
-            "MEDDRA:10017060",
-            "UMLS:C0236795",
-            "UMLS:C0542476",
-            "NCIT:C2867",
-            "UMLS:C0025261",
-            "MEDDRA:10027175",
-            "UMLS:C0751295",
-            "SNOMEDCT:386807006",
-            "MEDDRA:10027171",
-            "EFO:1001454",
-            "NCIT:C94328",
-            "PSY:02120",
-            "UMLS:C0002622",
-            "NCIT:C46084",
-            "UMLS:C0233794",
-            "SYMP:0000719",
-            "EFO:0001072",
-            "MEDDRA:10024871",
-            "HP:0002354",
-            "SNOMEDCT:84209002",
-            "MEDDRA:10037186"
-          ],
-          "id": "MONDO:0001185",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Memory Disorders",
-            "dissociative amnesia",
-            "Memory Loss",
-            "Dissociative Amnesia",
-            "memory impairment",
-            "memory loss",
-            "Forgetful",
-            "Memory Impairment",
-            "Amnesia",
-            "Dissociative amnesia",
-            "Memory impairment",
-            "amnesia",
-            "Memory dysfunction",
-            "Memory loss",
-            "Memory Dysfunction"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://www.merckmanuals.com/professional/psychiatric-disorders/dissociative-disorders/dissociative-amnesia",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.merriam-webster.com/dictionary/impairment",
-            "https://medlineplus.gov/ency/article/003257.htm",
-            "https://www.merckmanuals.com/professional/neurologic-disorders/symptoms-of-neurologic-disorders/memory-loss"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319995,
-            "labels": [
-              "biolink:BehavioralFeature",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001185",
-              "name": "dissociative amnesia",
-              "description": "Partial or complete loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories. Compare FORGETTING and MEMORY DECAY.; Systematic and extensive loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories.; Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7); UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "NCIT:C78444",
-                "SYMP:0000543",
-                "MONDO:0001185",
-                "MEDDRA:10027178",
-                "ICD9:300.12",
-                "ICD9:780.93",
-                "SNOMEDCT:55533009",
-                "MESH:D000647",
-                "SNOMEDCT:48167000",
-                "MEDDRA:10001949",
-                "NBO:0000253",
-                "PSY:30590",
-                "ICD10:F44.0",
-                "UMLS:C3887551",
-                "MEDDRA:10013461",
-                "MESH:D008569",
-                "DOID:11037",
-                "MEDDRA:10027172",
-                "MEDDRA:10027174",
-                "MEDDRA:10027176",
-                "MEDDRA:10017060",
-                "UMLS:C0236795",
-                "UMLS:C0542476",
-                "NCIT:C2867",
-                "UMLS:C0025261",
-                "MEDDRA:10027175",
-                "UMLS:C0751295",
-                "SNOMEDCT:386807006",
-                "MEDDRA:10027171",
-                "EFO:1001454",
-                "NCIT:C94328",
-                "PSY:02120",
-                "UMLS:C0002622",
-                "NCIT:C46084",
-                "UMLS:C0233794",
-                "SYMP:0000719",
-                "EFO:0001072",
-                "MEDDRA:10024871",
-                "HP:0002354",
-                "SNOMEDCT:84209002",
-                "MEDDRA:10037186"
-              ],
-              "id": "MONDO:0001185",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Memory Disorders",
-                "dissociative amnesia",
-                "Memory Loss",
-                "Dissociative Amnesia",
-                "memory impairment",
-                "memory loss",
-                "Forgetful",
-                "Memory Impairment",
-                "Amnesia",
-                "Dissociative amnesia",
-                "Memory impairment",
-                "amnesia",
-                "Memory dysfunction",
-                "Memory loss",
-                "Memory Dysfunction"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://www.merckmanuals.com/professional/psychiatric-disorders/dissociative-disorders/dissociative-amnesia",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.merriam-webster.com/dictionary/impairment",
-                "https://medlineplus.gov/ency/article/003257.htm",
-                "https://www.merckmanuals.com/professional/neurologic-disorders/symptoms-of-neurologic-disorders/memory-loss"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8441764,
-            "start": 569,
-            "end": 319995,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11137052': {'publication date': '2000 Dec 15', 'sentence': 'BACKGROUND: There is substantial evidence of dysregulation of cortisol secretion, hippocampal abnormalities, and memory deficits in schizophrenia and other psychotic disorders.', 'subject score': 888, 'object score': 1000}, 'PMID:16151537': {'publication date': '2005 Sep', 'sentence': 'We have found that long-term exposure to high endogenous levels of cortisol is associated with both memory impairments and a 14; smaller volume of the hippocampus.', 'subject score': 1000, 'object score': 983}, 'PMID:16274857': {'publication date': '2006 Nov', 'sentence': 'CONCLUSION: These results partially confirm previous findings that high cortisol is associated with impaired declarative memory function in non-demented older persons.', 'subject score': 888, 'object score': 824}, 'PMID:18702680': {'publication date': '2009 Feb', 'sentence': 'RESULTS: Our data show that chronic exposure to elevated levels of cortisol is clinically associated with significant working memory deficits, which included less shot-term memory volume, slow learning rate, memory contamination and no accurate perception of own performance.', 'subject score': 1000, 'object score': 861}, 'PMID:19375236': {'publication date': '2009 Sep', 'sentence': 'CONCLUSIONS: These findings are the first to demonstrate that learning and memory deficits in CD individuals are associated with enhanced cortisol and with cocaine use outcomes after inpatient treatment.', 'subject score': 861, 'object score': 1000}, 'PMID:22946487': {'publication date': '2013 Feb', 'sentence': 'CONCLUSION: We therefore conclude that MDMA-induced increments in cortisol concentrations are not related to MDMA-induced memory impairments.', 'subject score': 888, 'object score': 813}, 'PMID:26569538': {'publication date': '2016', 'sentence': 'RESULTS: In multilevel models, persistently but not phasically higher cortisol was associated with worse verbal memory in both learning (t(181) = 2.99, p = .003) and recall (t(280) = 3.10, p = .002).', 'subject score': 764, 'object score': 890}, 'PMID:26984331': {'publication date': '2002 Aug', 'sentence': 'OBJECTIVES: In the present paper the association of stress-induced cortisol with memory impairment is discussed Methods: An experiment is described in which an attempt is made to block stress-induced cortisol by lowering 5-HT neurotransmission by means of acute tryptophan depletion (ATD).', 'subject score': 851, 'object score': 1000}, 'PMID:17544378': {'publication date': '2007 Sep 01', 'sentence': 'BACKGROUND: Chronic elevations in cortisol associated with prolonged stress have been associated with memory loss, as has the apolipoprotein E gene (APOE-epsilon4) genotype.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0233794---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0751295---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8625521",
-              "object": "MONDO:0001185",
-              "publications": [
-                "PMID:26984331",
-                "PMID:26569538",
-                "PMID:16151537",
-                "PMID:19375236",
-                "PMID:17544378",
-                "PMID:18702680",
-                "PMID:16274857",
-                "PMID:11137052",
-                "PMID:22946487"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:1112950': {'publication date': '1975 Mar', 'sentence': '(2) One of the mechanisms of therapeutic effect of cortisol in asthma might be its inhibitory effect on CA uptake.', 'subject score': 1000, 'object score': 1000}, 'PMID:1144179': {'publication date': '1975 Jun 16', 'sentence': '[Disorders of cortisol metabolism and functions of the hypothalamo-hypophyseo-adrenal axis in bronchial asthma].', 'subject score': 888, 'object score': 1000}, 'PMID:13160904': {'publication date': '1954 Jun', 'sentence': 'The use of oral compound F (17-hydroxycorticosterone) in asthma.', 'subject score': 901, 'object score': 1000}, 'PMID:13249267': {'publication date': '1955 May 27', 'sentence': 'The use of intravenous hydrocortisone in asthma.', 'subject score': 888, 'object score': 1000}, 'PMID:1846332': {'publication date': '1991 Jan', 'sentence': 'Plasma histamine, epinephrine, cortisol, and leukocyte beta-adrenergic receptors in nocturnal asthma.', 'subject score': 1000, 'object score': 888}, 'PMID:18679556': {'publication date': '2008 Jul-Aug', 'sentence': 'OBJECTIVES: To evaluate basal plasma cortisol in persistent asthmatics on inhaled fluticasone propionate 200 mcg/day and 300 mcg/day.', 'subject score': 851, 'object score': 872}, 'PMID:20627904': {'publication date': '2010 Aug', 'sentence': 'With maternal asthma, female birth weight centiles were inversely associated with cortisol (r=-0.286, p=0.017) and, despite a decrease in placental GR mRNA (p=0.003), placental GRalpha protein levels were unchanged.', 'subject score': 1000, 'object score': 888}, 'PMID:20709818': {'publication date': '2011 Jan 01', 'sentence': 'Furthermore, although studies have demonstrated lower levels or reactivity of endogenous cortisol in asthma, the association with airway inflammatory activity in stress remains unexplored.', 'subject score': 888, 'object score': 1000}, 'PMID:22049323': {'publication date': '2001 Mar', 'sentence': 'This study suggests that relaxation training can influence cortisol secretion in asthmatics, but that these effects differ from those observed in healthy individuals and may be influenced by corticosteroid medication use.', 'subject score': 888, 'object score': 966}, 'PMID:22790914': {'publication date': '2013 Apr', 'sentence': 'We found no evidence supporting a role for cortisol in asthma and asthma development.', 'subject score': 1000, 'object score': 1000}, 'PMID:23323569': {'publication date': '2013 Apr', 'sentence': 'Twenty-four-hour urinary cortisol, salivary cortisol at 8 a.m. and 4 p.m. were lower in asthmatics with depression compared to other groups (p < .05).', 'subject score': 888, 'object score': 966}, 'PMID:2457747': {'publication date': '1988', 'sentence': '[Antibody (autoantibody) to cortisol in bronchial asthma, detectable by enzyme immunoassay].', 'subject score': 1000, 'object score': 1000}, 'PMID:26348209': {'publication date': '2015 Nov', 'sentence': 'Negative affect and cortisol increased during final exams, but these increases were smaller in asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:2799535': {'publication date': '1989', 'sentence': '[Secretion of endogenous cortisol in bronchial asthma effected by short courses of glucocorticoid therapy].', 'subject score': 888, 'object score': 1000}, 'PMID:30937140': {'publication date': '2019', 'sentence': 'It is unknown whether or not GLCCI1 rs37973 is associated with circulation epinephrine and cortisol concentrations in asthma.', 'subject score': 888, 'object score': 1000}, 'PMID:31651095': {'publication date': '2019 Oct 25', 'sentence': 'CONCLUSION: We observed a significantly lower HCC in asthmatics than in healthy controls and a nonsignificant trend of lower HCC with increasing ICS dose.', 'subject score': 569, 'object score': 966}, 'PMID:31738144': {'publication date': '2019 Oct 25', 'sentence': 'Mostly, studies on the relationship between asthma and cortisol have focused on side effects of treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:3228046': {'publication date': '1988', 'sentence': 'The purpose of this work was to study the concentrations of the sex steroids estradiol and progesterone as well as those of cortisol, and the relationships between them in asthmatic and normal women.', 'subject score': 1000, 'object score': 1000}, 'PMID:4023443': {'publication date': '1985', 'sentence': 'Plasma cortisol concentrations have been measured in 14 asthmatics previously treated with oral steroids in addition to conventional doses of beclomethasone dipropionate.', 'subject score': 890, 'object score': 827}, 'PMID:4349947': {'publication date': '1973 Jun', 'sentence': 'Glucocorticoids (prednisolone succinate, hydrocortisone, hydrocortisone phosphate, and hydrocortisone succinate) stimulated cyclic AMP accumulation in asthma and normal control lymphocytes, increases occurring within the first 2 min of incubation.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8431435,
-            "start": 569,
-            "end": 321528,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1112950': {'publication date': '1975 Mar', 'sentence': '(2) One of the mechanisms of therapeutic effect of cortisol in asthma might be its inhibitory effect on CA uptake.', 'subject score': 1000, 'object score': 1000}, 'PMID:1144179': {'publication date': '1975 Jun 16', 'sentence': '[Disorders of cortisol metabolism and functions of the hypothalamo-hypophyseo-adrenal axis in bronchial asthma].', 'subject score': 888, 'object score': 1000}, 'PMID:13160904': {'publication date': '1954 Jun', 'sentence': 'The use of oral compound F (17-hydroxycorticosterone) in asthma.', 'subject score': 901, 'object score': 1000}, 'PMID:13249267': {'publication date': '1955 May 27', 'sentence': 'The use of intravenous hydrocortisone in asthma.', 'subject score': 888, 'object score': 1000}, 'PMID:1846332': {'publication date': '1991 Jan', 'sentence': 'Plasma histamine, epinephrine, cortisol, and leukocyte beta-adrenergic receptors in nocturnal asthma.', 'subject score': 1000, 'object score': 888}, 'PMID:18679556': {'publication date': '2008 Jul-Aug', 'sentence': 'OBJECTIVES: To evaluate basal plasma cortisol in persistent asthmatics on inhaled fluticasone propionate 200 mcg/day and 300 mcg/day.', 'subject score': 851, 'object score': 872}, 'PMID:20627904': {'publication date': '2010 Aug', 'sentence': 'With maternal asthma, female birth weight centiles were inversely associated with cortisol (r=-0.286, p=0.017) and, despite a decrease in placental GR mRNA (p=0.003), placental GRalpha protein levels were unchanged.', 'subject score': 1000, 'object score': 888}, 'PMID:20709818': {'publication date': '2011 Jan 01', 'sentence': 'Furthermore, although studies have demonstrated lower levels or reactivity of endogenous cortisol in asthma, the association with airway inflammatory activity in stress remains unexplored.', 'subject score': 888, 'object score': 1000}, 'PMID:22049323': {'publication date': '2001 Mar', 'sentence': 'This study suggests that relaxation training can influence cortisol secretion in asthmatics, but that these effects differ from those observed in healthy individuals and may be influenced by corticosteroid medication use.', 'subject score': 888, 'object score': 966}, 'PMID:22790914': {'publication date': '2013 Apr', 'sentence': 'We found no evidence supporting a role for cortisol in asthma and asthma development.', 'subject score': 1000, 'object score': 1000}, 'PMID:23323569': {'publication date': '2013 Apr', 'sentence': 'Twenty-four-hour urinary cortisol, salivary cortisol at 8 a.m. and 4 p.m. were lower in asthmatics with depression compared to other groups (p < .05).', 'subject score': 888, 'object score': 966}, 'PMID:2457747': {'publication date': '1988', 'sentence': '[Antibody (autoantibody) to cortisol in bronchial asthma, detectable by enzyme immunoassay].', 'subject score': 1000, 'object score': 1000}, 'PMID:26348209': {'publication date': '2015 Nov', 'sentence': 'Negative affect and cortisol increased during final exams, but these increases were smaller in asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:2799535': {'publication date': '1989', 'sentence': '[Secretion of endogenous cortisol in bronchial asthma effected by short courses of glucocorticoid therapy].', 'subject score': 888, 'object score': 1000}, 'PMID:30937140': {'publication date': '2019', 'sentence': 'It is unknown whether or not GLCCI1 rs37973 is associated with circulation epinephrine and cortisol concentrations in asthma.', 'subject score': 888, 'object score': 1000}, 'PMID:31651095': {'publication date': '2019 Oct 25', 'sentence': 'CONCLUSION: We observed a significantly lower HCC in asthmatics than in healthy controls and a nonsignificant trend of lower HCC with increasing ICS dose.', 'subject score': 569, 'object score': 966}, 'PMID:31738144': {'publication date': '2019 Oct 25', 'sentence': 'Mostly, studies on the relationship between asthma and cortisol have focused on side effects of treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:3228046': {'publication date': '1988', 'sentence': 'The purpose of this work was to study the concentrations of the sex steroids estradiol and progesterone as well as those of cortisol, and the relationships between them in asthmatic and normal women.', 'subject score': 1000, 'object score': 1000}, 'PMID:4023443': {'publication date': '1985', 'sentence': 'Plasma cortisol concentrations have been measured in 14 asthmatics previously treated with oral steroids in addition to conventional doses of beclomethasone dipropionate.', 'subject score': 890, 'object score': 827}, 'PMID:4349947': {'publication date': '1973 Jun', 'sentence': 'Glucocorticoids (prednisolone succinate, hydrocortisone, hydrocortisone phosphate, and hydrocortisone succinate) stimulated cyclic AMP accumulation in asthma and normal control lymphocytes, increases occurring within the first 2 min of incubation.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8615164",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:1112950",
-                "PMID:1144179",
-                "PMID:13160904",
-                "PMID:13249267",
-                "PMID:1846332",
-                "PMID:18679556",
-                "PMID:20627904",
-                "PMID:20709818",
-                "PMID:22049323",
-                "PMID:22790914",
-                "PMID:23323569",
-                "PMID:2457747",
-                "PMID:26348209",
-                "PMID:2799535",
-                "PMID:30937140",
-                "PMID:31651095",
-                "PMID:31738144",
-                "PMID:3228046",
-                "PMID:4023443",
-                "PMID:4349947"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 547810,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:1787683': {'publication date': '1991 Dec', 'sentence': '[Use of cryo-apheresis in the treatment of patients with cortisol-dependent bronchial asthma].', 'subject score': 861, 'object score': 861}, 'PMID:2283805': {'publication date': '1990 Nov', 'sentence': 'Following discontinuation of glucocorticoid drugs GCR count in cortisol-dependent BA tends to rise.', 'subject score': 861, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 321528,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005546",
-          "name": "fibromyalgia",
-          "description": "A common nonarticular rheumatic condition that is characterized by muscle pain, tenderness, and stiffness.; A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.; Inflammation and fibrous degeneration of a muscle.; A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10016631",
-            "MEDDRA:10048439",
-            "MEDDRA:10028363",
-            "PSY:19685",
-            "SNOMEDCT:56557000",
-            "SNOMEDCT:726531007",
-            "NCIT:C50566",
-            "ORPHANET:41842",
-            "SNOMEDCT:203082005",
-            "MEDDRA:10063041",
-            "MONDO:0005546",
-            "SNOMEDCT:203102006",
-            "MEDDRA:10016663",
-            "DOID:631",
-            "EFO:0005687",
-            "MESH:D005356",
-            "ICD10:M79.7",
-            "NCIT:C87497",
-            "MEDDRA:10079197",
-            "UMLS:C0016053"
-          ],
-          "id": "MONDO:0005546",
-          "category": "biolink:Disease",
-          "all_names": [
-            "fibromyalgia",
-            "Fibromyalgia",
-            "Fibromyositis"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "PMID:33024295",
-            "https://www.ncbi.nlm.nih.gov/labs/pmc/articles/pmc7660651/",
-            "PMID:30486733",
-            "PMID:32120395"
-=======
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 547810,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005546",
-              "name": "fibromyalgia",
-              "description": "A common nonarticular rheumatic condition that is characterized by muscle pain, tenderness, and stiffness.; A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.; Inflammation and fibrous degeneration of a muscle.; A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10016631",
-                "MEDDRA:10048439",
-                "MEDDRA:10028363",
-                "PSY:19685",
-                "SNOMEDCT:56557000",
-                "SNOMEDCT:726531007",
-                "NCIT:C50566",
-                "ORPHANET:41842",
-                "SNOMEDCT:203082005",
-                "MEDDRA:10063041",
-                "MONDO:0005546",
-                "SNOMEDCT:203102006",
-                "MEDDRA:10016663",
-                "DOID:631",
-                "EFO:0005687",
-                "MESH:D005356",
-                "ICD10:M79.7",
-                "NCIT:C87497",
-                "MEDDRA:10079197",
-                "UMLS:C0016053"
-              ],
-              "id": "MONDO:0005546",
-              "category": "biolink:Disease",
-              "all_names": [
-                "fibromyalgia",
-                "Fibromyalgia",
-                "Fibromyositis"
-=======
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "PMID:33024295",
-                "https://www.ncbi.nlm.nih.gov/labs/pmc/articles/pmc7660651/",
-                "PMID:30486733",
-                "PMID:32120395"
-=======
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 8388036,
-            "start": 569,
-            "end": 547810,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11094926': {'publication date': '2000 Feb', 'sentence': 'OBJECTIVE: To compare cortisol levels, diurnal cycles of cortisol, and reactivity of cortisol to psychological stress in fibromyalgia (FM) and rheumatoid arthritis (RA) patients in their natural environment, and to examine the effect on results of accounting for differences among the groups in psychological stress and other lifestyle and psychosocial variables.', 'subject score': 1000, 'object score': 1000}, 'PMID:16884460': {'publication date': '2006 Aug', 'sentence': 'Counterbalance between leptin and cortisol may be associated with fibromyalgia.', 'subject score': 1000, 'object score': 1000}, 'PMID:17188125': {'publication date': '2007 Jan', 'sentence': 'OBJECTIVE: Fibromyalgia syndrome (FMS) has been associated with decreased cortisol secretion.', 'subject score': 851, 'object score': 1000}, 'PMID:19120140': {'publication date': '2008 Dec', 'sentence': 'A lack of cortisol, potentially due to an adrenocortical deficit is postulated in FMS.', 'subject score': 1000, 'object score': 1000}, 'PMID:19457504': {'publication date': '2009 Jul 18', 'sentence': 'RESULTS: Urinary cortisol in FM was 65.0 microg/l (median), which was significantly lower than that of the healthy group (80.0 microg/l), p<0.001.', 'subject score': 888, 'object score': 1000}, 'PMID:20467005': {'publication date': '2010 Jun', 'sentence': 'Fibromyalgia and osteoarthritis groups showed similar secretory patterns, and maltreatment was associated with elevated cortisol in both.', 'subject score': 888, 'object score': 1000}, 'PMID:21887116': {'publication date': '2011', 'sentence': 'To date, published studies have not investigated the effects of yoga on cortisol in FM.', 'subject score': 1000, 'object score': 1000}, 'PMID:24478898': {'publication date': '2014 Jan', 'sentence': 'Evaluation of salivary cortisol and anxiety levels in myofascial pain dysfunction syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:2607509': {'publication date': '1989 Nov', 'sentence': 'These data suggest alteration in the pituitary hypothalamic axis with respect to cortisol secretion in fibromyalgia syndrome, perhaps as a consequence of chronic pain.', 'subject score': 888, 'object score': 1000}, 'PMID:34437747': {'publication date': '2021 Aug 26', 'sentence': 'CONCLUSIONS: This study indicates elevated salivary cortisol in FM and those at high risk, and identifies anxiety, depression and sleep problems as potential contributing factors.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0016053---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8570630",
-              "object": "MONDO:0005546",
-              "publications": [
-                "PMID:11094926",
-                "PMID:16884460",
-                "PMID:17188125",
-                "PMID:19120140",
-                "PMID:19457504",
-                "PMID:20467005",
-                "PMID:21887116",
-                "PMID:24478898",
-                "PMID:2607509",
-                "PMID:34437747"
-=======
-            "identity": 13066269,
-            "start": 569,
-            "end": 321528,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1787683': {'publication date': '1991 Dec', 'sentence': '[Use of cryo-apheresis in the treatment of patients with cortisol-dependent bronchial asthma].', 'subject score': 861, 'object score': 861}, 'PMID:2283805': {'publication date': '1990 Nov', 'sentence': 'Following discontinuation of glucocorticoid drugs GCR count in cortisol-dependent BA tends to rise.', 'subject score': 861, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13347553",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:1787683",
-                "PMID:2283805"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 314596,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:11560105': {'publication date': '2001 Aug', 'sentence': 'In conclusion, HRT in postmenopausal asthmatic women has a favorable influence on the course of asthma, reduces daily use of glucocorticosteroids and frequency of asthma exacerbations and normalizes serum concentrations of estradiol, cortisol and DHEAS, which were decreased before HRT.', 'subject score': 1000, 'object score': 694}, 'PMID:14366902': {'publication date': '1955 May', 'sentence': 'Metacortandracin (prednisone) in bronchial asthma: comparative effects of metacortandracin, hydrocortisone, and cortisone in bronchial asthma with diabetes mellitus and bronchial asthma with nasal polyps; preliminary report.', 'subject score': 1000, 'object score': 1000}, 'PMID:1773552': {'publication date': '1991 Nov', 'sentence': 'After unsuccessful therapy with salbutamol syrup and inhaled terbutaline a 3-year-old boy with an acute exacerbation of asthma was treated with nebulised salbutamol (albuterol), intravenous aminophylline and hydrocortisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:30788950': {'publication date': '2018 Apr 08', 'sentence': 'CONCLUSIONS: Combined administration of RASI and hydrocortisone have obvious anti-asthma effects and one of the mechanisms is to inhibit protein synthetization of HMGB1, TLR4 and NF-kappaB.The combined administration of RASI and hydrocortisone has stronger improvement of lung function than that of RASI and hydrocortisone alone, and it may be related to the inhibition of TLR4 and NF-kappaB synthetization.', 'subject score': 1000, 'object score': 733}, 'PMID:35152259': {'publication date': '2022 Feb 13', 'sentence': 'An additional course of hydrocortisone was given due to asthma exacerbation, gradually liberating her from the HFNC.', 'subject score': 1000, 'object score': 888}, 'PMID:6853932': {'publication date': '1983 Jul', 'sentence': 'We conclude that cortisol had no short-term effect on airway caliber in normals, at best a slowly evolving effect in asymptomatic unmedicated asthmatics, and no interaction with the bronchodilator effects of a maximal dose of isoproterenol in these groups.', 'subject score': 1000, 'object score': 785}}",
-    "p2": {
-      "start": {
-        "identity": 321528,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-          "name": "Insulin resistance",
-          "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "NCIT:C113101",
-            "UMLS:C0021655",
-            "MEDDRA:10022489",
-            "SNOMEDCT:48606007",
-            "MESH:D007333",
-            "EFO:0002614",
-            "HP:0000855",
-            "SNOMEDCT:763325000"
-          ],
-          "id": "HP:0000855",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Insulin resistance",
-            "insulin resistance",
-            "Insulin Resistance"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 314596,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-              "name": "Insulin resistance",
-              "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "NCIT:C113101",
-                "UMLS:C0021655",
-                "MEDDRA:10022489",
-                "SNOMEDCT:48606007",
-                "MESH:D007333",
-                "EFO:0002614",
-                "HP:0000855",
-                "SNOMEDCT:763325000"
-              ],
-              "id": "HP:0000855",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Insulin resistance",
-                "insulin resistance",
-                "Insulin Resistance"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-=======
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 7849951,
-            "start": 569,
-            "end": 314596,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10692082': {'publication date': '2000 Feb', 'sentence': \"OBJECTIVES: Recent data suggest that higher plasma cortisol may be associated with hypertension and insulin resistance in otherwise healthy men, as it is in Cushing's syndrome.\", 'subject score': 840, 'object score': 1000}, 'PMID:11916927': {'publication date': '2002 Apr', 'sentence': 'In common with the GR, 11beta-HSD1 expression in myoblasts incubated with physiological concentrations of cortisol in vitro was positively associated with levels of insulin resistance (r(2) = 0.68, P < 0.001), BMI (r(2) = 0.63, P < 0.005), and blood pressure (r(2) = 0.27, P < 0.05).', 'subject score': 1000, 'object score': 1000}, 'PMID:14557475': {'publication date': '2003 Oct', 'sentence': 'Higher excretion of 5beta-reduced cortisol metabolites was independently associated with insulin resistance and hypertriglyceridemia.', 'subject score': 775, 'object score': 1000}, 'PMID:15026790': {'publication date': '2004 Mar 22', 'sentence': 'Therefore, it would appear that low leptin concentrations, increased fat oxidation and insulin resistance are associated with increased concentrations of cortisol and interleukin-6 in weight-losing patients with pancreatic cancer.', 'subject score': 1000, 'object score': 1000}, 'PMID:15142652': {'publication date': '2004', 'sentence': 'Prolonged exposure to high levels of cortisol is associated with insulin resistance, as exemplified by the metabolic syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:15256820': {'publication date': '2004', 'sentence': 'These facts point to an association between cortisol and insulin resistance in obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:16009799': {'publication date': '2005 Jul 19', 'sentence': 'CONCLUSIONS: This is the first population-based prospective study that has found a specific association between cortisol:testosterone ratio and incident ischemic heart disease, apparently mediated through the insulin resistance syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:19050176': {'publication date': '2009 Feb', 'sentence': 'Controversy exists as to whether endogenous cortisol production is associated with visceral obesity and insulin resistance in humans.', 'subject score': 851, 'object score': 1000}, 'PMID:19342030': {'publication date': '2010 Mar 01', 'sentence': 'CONCLUSION(S): Obesity and insulin resistance are associated with lower morning cortisol and DHEAS but increased cortisol and DHEA responses after glucose ingestion.', 'subject score': 851, 'object score': 1000}, 'PMID:20354921': {'publication date': '2010 Apr', 'sentence': 'However, the aetiological role of CBG and cortisol in insulin resistance is uncertain, although in males, cortisol and CBG could be subtly related to the degree of insulin resistance.', 'subject score': 1000, 'object score': 1000}, 'PMID:21475800': {'publication date': '2009', 'sentence': 'Though vasopressin responders with subclinical CS had lower autonomous cortisol secretion, they had a high prevalence of hypertension, in which insulin resistance was closely correlated with cortisol response to vasopressin.', 'subject score': 815, 'object score': 1000}, 'PMID:22283617': {'publication date': '2012 Apr', 'sentence': 'Higher levels of cortisol correlated with increased insulin resistance after the jump.', 'subject score': 1000, 'object score': 901}, 'PMID:23577182': {'publication date': '2013', 'sentence': \"10% of the elderly population has an 'adrenal incidentaloma', up to 20% of these show low-grade autonomous cortisol secretion and 60% of patients with autonomous cortisol secretion have insulin resistance.\", 'subject score': 828, 'object score': 1000}, 'PMID:24926956': {'publication date': '2014 Sep', 'sentence': 'CONTEXT: Adult-onset GH deficiency (GHD) increases visceral adiposity and the activity of the enzyme 11beta-hydroxysteroid dehydrogenase, which converts cortisone (E) to cortisol (F), both linked to insulin resistance and increased cardiovascular risk.', 'subject score': 1000, 'object score': 1000}, 'PMID:2647890': {'publication date': '1989 Mar', 'sentence': 'These results demonstrate that timed daily injections of cortisol and prolactin in specific temporal relationships can produce marked reductions in obesity, hyperinsulinaemia and insulin resistance in the Syrian hamster that persist long after the termination of treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:26934392': {'publication date': '2016 05', 'sentence': 'DESIGN: Follicular fluid and granulosa cells were collected from non-PCOS and PCOS patients with and without IR to measure cortisol concentration and the amounts of 11beta-HSD1 and -2, which were then correlated with IR status.', 'subject score': 694, 'object score': 901}, 'PMID:29223281': {'publication date': '2017 10', 'sentence': \"Higher nocturnal cortisol exposure is observed in patients with Cushing's syndrome and adrenal incidentalomas with autonomous cortisol secretion and is associated with insulin resistance, and increased cardiovascular risk and mortality.\", 'subject score': 828, 'object score': 1000}, 'PMID:29618067': {'publication date': '2018 Jul 01', 'sentence': 'Objective: To investigate whether the abundance of 11?-hydroxysteroid dehydrogenases (11?-HSDs) 1 and 2 and cortisol as well as the insulin signaling pathway are altered in PCOS endometrium and to clarify the relationship between endometrial IR and local cortisol.', 'subject score': 888, 'object score': 901}, 'PMID:31176299': {'publication date': '2019 Jun 01', 'sentence': 'CONCLUSION: In the CoLaus study of healthy adults, basal salivary cortisol was not associated with incident IR or T2DM.', 'subject score': 851, 'object score': 901}, 'PMID:31664610': {'publication date': '2019 Oct 29', 'sentence': 'The inhibition of 11beta-HSD1 has been shown to attenuate the development of type 2 diabetes mellitus, insulin resistance, metabolic syndrome and other diseases mediated by excessive cortisol production.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0021655---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8017438",
-              "object": "HP:0000855",
-              "publications": [
-                "PMID:10692082",
-                "PMID:11916927",
-                "PMID:14557475",
-                "PMID:15026790",
-                "PMID:15142652",
-                "PMID:15256820",
-                "PMID:16009799",
-                "PMID:19050176",
-                "PMID:19342030",
-                "PMID:20354921",
-                "PMID:21475800",
-                "PMID:22283617",
-                "PMID:23577182",
-                "PMID:24926956",
-                "PMID:2647890",
-                "PMID:26934392",
-                "PMID:29223281",
-                "PMID:29618067",
-                "PMID:31176299",
-                "PMID:31664610"
-=======
-            "identity": 8924464,
-            "start": 569,
-            "end": 321528,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11560105': {'publication date': '2001 Aug', 'sentence': 'In conclusion, HRT in postmenopausal asthmatic women has a favorable influence on the course of asthma, reduces daily use of glucocorticosteroids and frequency of asthma exacerbations and normalizes serum concentrations of estradiol, cortisol and DHEAS, which were decreased before HRT.', 'subject score': 1000, 'object score': 694}, 'PMID:14366902': {'publication date': '1955 May', 'sentence': 'Metacortandracin (prednisone) in bronchial asthma: comparative effects of metacortandracin, hydrocortisone, and cortisone in bronchial asthma with diabetes mellitus and bronchial asthma with nasal polyps; preliminary report.', 'subject score': 1000, 'object score': 1000}, 'PMID:1773552': {'publication date': '1991 Nov', 'sentence': 'After unsuccessful therapy with salbutamol syrup and inhaled terbutaline a 3-year-old boy with an acute exacerbation of asthma was treated with nebulised salbutamol (albuterol), intravenous aminophylline and hydrocortisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:30788950': {'publication date': '2018 Apr 08', 'sentence': 'CONCLUSIONS: Combined administration of RASI and hydrocortisone have obvious anti-asthma effects and one of the mechanisms is to inhibit protein synthetization of HMGB1, TLR4 and NF-kappaB.The combined administration of RASI and hydrocortisone has stronger improvement of lung function than that of RASI and hydrocortisone alone, and it may be related to the inhibition of TLR4 and NF-kappaB synthetization.', 'subject score': 1000, 'object score': 733}, 'PMID:35152259': {'publication date': '2022 Feb 13', 'sentence': 'An additional course of hydrocortisone was given due to asthma exacerbation, gradually liberating her from the HFNC.', 'subject score': 1000, 'object score': 888}, 'PMID:6853932': {'publication date': '1983 Jul', 'sentence': 'We conclude that cortisol had no short-term effect on airway caliber in normals, at best a slowly evolving effect in asymptomatic unmedicated asthmatics, and no interaction with the bronchodilator effects of a maximal dose of isoproterenol in these groups.', 'subject score': 1000, 'object score': 785}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9120606",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:11560105",
-                "PMID:14366902",
-                "PMID:1773552",
-                "PMID:30788950",
-                "PMID:35152259",
-                "PMID:6853932"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1027272': {'publication date': '1976 Dec', 'sentence': '[Dynamics of the cortisol content in the blood plasma in specific hyposensibilization in children with bronchial asthma].', 'subject score': 694, 'object score': 1000}, 'PMID:10531155': {'publication date': '1999 Oct', 'sentence': 'Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate.', 'subject score': 851, 'object score': 888}, 'PMID:10900296': {'publication date': '2000 Sep', 'sentence': 'Serum concentrations of cortisol, cortisone, and cortisol precursors were measured in the morning and in the afternoon in asthmatic patients by reversed-phase high-performance liquid chromatography.', 'subject score': 1000, 'object score': 888}, 'PMID:11112113': {'publication date': '2000 Dec', 'sentence': 'This study aimed to compare the relative effect of fluticasone propionate (FP) and budesonide (BUD) on bronchial responsiveness and endogenous cortisol secretion in adults with asthma.', 'subject score': 851, 'object score': 1000}, 'PMID:11560105': {'publication date': '2001 Aug', 'sentence': 'A reduction in mean 24-hour serum estradiol levels in asthmatic women was noted, whereas cortisol and DHEAS serum concentrations were decreased in asthmatic patients treated with glucocorticosteroids compared with the control group, before HRT.', 'subject score': 1000, 'object score': 888}, 'PMID:11874819': {'publication date': '2002 Mar 01', 'sentence': 'We investigated whether endogenous cortisol levels are lower, and also whether the 24-h cortisol variation is greater, in children with asthma than in control subjects and assessed the relationship between serum cortisol and nocturnal airflow limitation in children with asthma.', 'subject score': 861, 'object score': 1000}, 'PMID:12161504': {'publication date': '2002 Aug', 'sentence': 'We measured serum GBA (bioassay) and cortisol (RIA) levels in 34 asthmatic children (age range, 5.7-14.2 yr) at baseline and after treatment with either inhaled budesonide (800 microg/d, n = 14), fluticasone propionate (500 microg/d, n = 14), or cromones (control group, n = 6).', 'subject score': 1000, 'object score': 790}, 'PMID:12360594': {'publication date': '2002', 'sentence': '[Clinico-experimental aspects of liposomal therapy of bronchial asthma patients with hydrocortisone therapy].', 'subject score': 888, 'object score': 901}, 'PMID:12785222': {'publication date': '2003', 'sentence': '[Glucocorticoid adrenal function and clinical implications of hydrocortisone metabolism tests in patients with bronchial asthma].', 'subject score': 888, 'object score': 1000}, 'PMID:13132667': {'publication date': '1953 Dec 08', 'sentence': '[Remarks on the hydrocortisone therapy of hay-fever and bronchial asthma].', 'subject score': 888, 'object score': 1000}, 'PMID:1315017': {'publication date': '1992 Feb', 'sentence': 'We assessed the effect of long-term therapy with inhaled beclomethasone dipropionate (BDP) on the pituitary-adrenal axis, by measuring the integrated concentration (IC) of plasma cortisol in eight children with asthma (age, 6-16 years) who regularly used inhaled BDP in doses ranging from 8 to 26.5 micrograms/kg (200-450 micrograms/day) for 6 months to 4 years.', 'subject score': 888, 'object score': 1000}, 'PMID:13174318': {'publication date': '1954 Jul', 'sentence': 'Comparative results of the use of ACTH, cortisone, and hydrocortisone in the treatment of intractable bronchial asthma and pulmonary emphysema.', 'subject score': 1000, 'object score': 901}, 'PMID:13234340': {'publication date': '1955 Jan 29', 'sentence': 'Hydrocortisone in treatment of allergic conjunctivitis, allergic rhinitis, and bronchial asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:13240504': {'publication date': '1955 Aug', 'sentence': 'At present combined antibiotic and cortisone or hydrocortisone therapy of asthma seems to be the most rational method of preventing the disease from becoming chronic and intractable.', 'subject score': 888, 'object score': 1000}, 'PMID:13249257': {'publication date': '1955 May 27', 'sentence': 'Hydrocortisone in the therapy of asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:13368523': {'publication date': '1956 Oct 20', 'sentence': 'Chronic asthma treated with aerosol hydrocortisone.', 'subject score': 888, 'object score': 888}, 'PMID:14387393': {'publication date': '1955', 'sentence': 'Ambulatory treatment of bronchial asthma with ACTH, cortisone and hydrocortisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:14626432': {'publication date': '2003', 'sentence': 'We sought to evaluate the effect of short-term and chronic GC therapy on GCR number in peripheral blood lymphocytes, the relationship between GCR number and cortisol concentrations in asthma patients treated with GCs as well as the response to GC therapy in various pictures of this disease.', 'subject score': 888, 'object score': 888}, 'PMID:1477359': {'publication date': '1992 Sep', 'sentence': '[Effects of cortisol on calcium contents of lymphocytes in patients with bronchial asthma].', 'subject score': 1000, 'object score': 1000}, 'PMID:15090754': {'publication date': '2004 Mar', 'sentence': 'Life-threatening hypokalemia in an asthmatic patient treated with high-dose hydrocortisone.', 'subject score': 901, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7216091,
-            "start": 569,
-            "end": 321528,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1027272': {'publication date': '1976 Dec', 'sentence': '[Dynamics of the cortisol content in the blood plasma in specific hyposensibilization in children with bronchial asthma].', 'subject score': 694, 'object score': 1000}, 'PMID:10531155': {'publication date': '1999 Oct', 'sentence': 'Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate.', 'subject score': 851, 'object score': 888}, 'PMID:10900296': {'publication date': '2000 Sep', 'sentence': 'Serum concentrations of cortisol, cortisone, and cortisol precursors were measured in the morning and in the afternoon in asthmatic patients by reversed-phase high-performance liquid chromatography.', 'subject score': 1000, 'object score': 888}, 'PMID:11112113': {'publication date': '2000 Dec', 'sentence': 'This study aimed to compare the relative effect of fluticasone propionate (FP) and budesonide (BUD) on bronchial responsiveness and endogenous cortisol secretion in adults with asthma.', 'subject score': 851, 'object score': 1000}, 'PMID:11560105': {'publication date': '2001 Aug', 'sentence': 'A reduction in mean 24-hour serum estradiol levels in asthmatic women was noted, whereas cortisol and DHEAS serum concentrations were decreased in asthmatic patients treated with glucocorticosteroids compared with the control group, before HRT.', 'subject score': 1000, 'object score': 888}, 'PMID:11874819': {'publication date': '2002 Mar 01', 'sentence': 'We investigated whether endogenous cortisol levels are lower, and also whether the 24-h cortisol variation is greater, in children with asthma than in control subjects and assessed the relationship between serum cortisol and nocturnal airflow limitation in children with asthma.', 'subject score': 861, 'object score': 1000}, 'PMID:12161504': {'publication date': '2002 Aug', 'sentence': 'We measured serum GBA (bioassay) and cortisol (RIA) levels in 34 asthmatic children (age range, 5.7-14.2 yr) at baseline and after treatment with either inhaled budesonide (800 microg/d, n = 14), fluticasone propionate (500 microg/d, n = 14), or cromones (control group, n = 6).', 'subject score': 1000, 'object score': 790}, 'PMID:12360594': {'publication date': '2002', 'sentence': '[Clinico-experimental aspects of liposomal therapy of bronchial asthma patients with hydrocortisone therapy].', 'subject score': 888, 'object score': 901}, 'PMID:12785222': {'publication date': '2003', 'sentence': '[Glucocorticoid adrenal function and clinical implications of hydrocortisone metabolism tests in patients with bronchial asthma].', 'subject score': 888, 'object score': 1000}, 'PMID:13132667': {'publication date': '1953 Dec 08', 'sentence': '[Remarks on the hydrocortisone therapy of hay-fever and bronchial asthma].', 'subject score': 888, 'object score': 1000}, 'PMID:1315017': {'publication date': '1992 Feb', 'sentence': 'We assessed the effect of long-term therapy with inhaled beclomethasone dipropionate (BDP) on the pituitary-adrenal axis, by measuring the integrated concentration (IC) of plasma cortisol in eight children with asthma (age, 6-16 years) who regularly used inhaled BDP in doses ranging from 8 to 26.5 micrograms/kg (200-450 micrograms/day) for 6 months to 4 years.', 'subject score': 888, 'object score': 1000}, 'PMID:13174318': {'publication date': '1954 Jul', 'sentence': 'Comparative results of the use of ACTH, cortisone, and hydrocortisone in the treatment of intractable bronchial asthma and pulmonary emphysema.', 'subject score': 1000, 'object score': 901}, 'PMID:13234340': {'publication date': '1955 Jan 29', 'sentence': 'Hydrocortisone in treatment of allergic conjunctivitis, allergic rhinitis, and bronchial asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:13240504': {'publication date': '1955 Aug', 'sentence': 'At present combined antibiotic and cortisone or hydrocortisone therapy of asthma seems to be the most rational method of preventing the disease from becoming chronic and intractable.', 'subject score': 888, 'object score': 1000}, 'PMID:13249257': {'publication date': '1955 May 27', 'sentence': 'Hydrocortisone in the therapy of asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:13368523': {'publication date': '1956 Oct 20', 'sentence': 'Chronic asthma treated with aerosol hydrocortisone.', 'subject score': 888, 'object score': 888}, 'PMID:14387393': {'publication date': '1955', 'sentence': 'Ambulatory treatment of bronchial asthma with ACTH, cortisone and hydrocortisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:14626432': {'publication date': '2003', 'sentence': 'We sought to evaluate the effect of short-term and chronic GC therapy on GCR number in peripheral blood lymphocytes, the relationship between GCR number and cortisol concentrations in asthma patients treated with GCs as well as the response to GC therapy in various pictures of this disease.', 'subject score': 888, 'object score': 888}, 'PMID:1477359': {'publication date': '1992 Sep', 'sentence': '[Effects of cortisol on calcium contents of lymphocytes in patients with bronchial asthma].', 'subject score': 1000, 'object score': 1000}, 'PMID:15090754': {'publication date': '2004 Mar', 'sentence': 'Life-threatening hypokalemia in an asthmatic patient treated with high-dose hydrocortisone.', 'subject score': 901, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7363431",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:1027272",
-                "PMID:10531155",
-                "PMID:10900296",
-                "PMID:11112113",
-                "PMID:11560105",
-                "PMID:11874819",
-                "PMID:12161504",
-                "PMID:12360594",
-                "PMID:12785222",
-                "PMID:13132667",
-                "PMID:1315017",
-                "PMID:13174318",
-                "PMID:13234340",
-                "PMID:13240504",
-                "PMID:13249257",
-                "PMID:13368523",
-                "PMID:14387393",
-                "PMID:14626432",
-                "PMID:1477359",
-                "PMID:15090754"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:produces",
-    "r2.publications_info": "{'PMID:18373959': {'publication date': '2008 Apr', 'sentence': 'Ironically, despite our understanding of the various stressors that promote chronic adult-onset asthma, most of which are known to elevate cortisol production via the hypothalamic-pituitary-adrenal (HPA) axis, inhaled and systemic corticosteroids are the mainstay for the treatment of chronic asthma.', 'subject score': 833, 'object score': 623}, 'PMID:6230596': {'publication date': '1983', 'sentence': 'The results suggest that bronchial asthma is associated with hypoadrenia due to an impaired production not only of cortisol, but also of adrenocortical androgens resulting in an insufficient hormone supply of the target organs.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13382406,
-            "start": 321528,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:18373959': {'publication date': '2008 Apr', 'sentence': 'Ironically, despite our understanding of the various stressors that promote chronic adult-onset asthma, most of which are known to elevate cortisol production via the hypothalamic-pituitary-adrenal (HPA) axis, inhaled and systemic corticosteroids are the mainstay for the treatment of chronic asthma.', 'subject score': 833, 'object score': 623}, 'PMID:6230596': {'publication date': '1983', 'sentence': 'The results suggest that bronchial asthma is associated with hypoadrenia due to an impaired production not only of cortisol, but also of adrenocortical androgens resulting in an insufficient hormone supply of the target organs.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0004096---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0004979",
-              "id": "13669597",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:18373959",
-                "PMID:6230596"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:11080743': {'publication date': '2000 Nov', 'sentence': 'A growing body of evidence now suggests that endogenous cortisol, which is produced in significant quantities by the body in a diurnal rhythm, is an important regulator of allergic disease expression and allergic inflammatory responses: lung function varies along with plasma cortisol levels; the number of circulating inflammatory cells varies with plasma cortisol levels; and low levels of endogenous cortisol may be associated with risk for asthma.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8370797,
-            "start": 569,
-            "end": 321528,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11080743': {'publication date': '2000 Nov', 'sentence': 'A growing body of evidence now suggests that endogenous cortisol, which is produced in significant quantities by the body in a diurnal rhythm, is an important regulator of allergic disease expression and allergic inflammatory responses: lung function varies along with plasma cortisol levels; the number of circulating inflammatory cells varies with plasma cortisol levels; and low levels of endogenous cortisol may be associated with risk for asthma.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:predisposes---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8552834",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:11080743"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:15022622': {'publication date': '2003 Oct', 'sentence': 'To investigate the time courses of the effects of the exogenous glucocorticoid agonists dexamethasone (DEX) and hydrocortisone (HYD) and a glucocorticoid antagonist (RU-38486), and to characterize the local and systemic responses in experimental AP.', 'subject score': 1000, 'object score': 851}, 'PMID:15211115': {'publication date': '2004 Jul', 'sentence': 'The aim of this study was to investigate the time courses of the effects of the exogenous glucocorticoid agonists dexamethasone (DEX) and hydrocortisone (HYD) and a glucocorticoid antagonist (RU-38486) and to characterize the local and systemic responses in AP in rats.', 'subject score': 1000, 'object score': 888}, 'PMID:29215538': {'publication date': '2018 01', 'sentence': 'Cortisol Outperforms Novel Cardiovascular, Inflammatory, and Neurohumoral Biomarkers in the Prediction of Outcome in Acute Pancreatitis.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 317183,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004982",
-          "name": "pancreatitis",
-          "description": "Inflammation of the pancreas.; INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.; The presence of inflammation in the pancreas. [HPO:probinson]; The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0004982",
-            "MEDDRA:10076039",
-            "MEDDRA:10033656",
-            "DOID:4989",
-            "SNOMEDCT:75694006",
-            "ICD10:K85.9",
-            "MEDDRA:10033645",
-            "NCIT:C3306",
-            "EFO:0000278",
-            "HP:0001733",
-            "MESH:D010195",
-            "UMLS:C0030305"
-          ],
-          "id": "MONDO:0004982",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pancreatitis",
-            "pancreatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/pancreatitis.htm",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317183,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004982",
-              "name": "pancreatitis",
-              "description": "Inflammation of the pancreas.; INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.; The presence of inflammation in the pancreas. [HPO:probinson]; The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0004982",
-                "MEDDRA:10076039",
-                "MEDDRA:10033656",
-                "DOID:4989",
-                "SNOMEDCT:75694006",
-                "ICD10:K85.9",
-                "MEDDRA:10033645",
-                "NCIT:C3306",
-                "EFO:0000278",
-                "HP:0001733",
-                "MESH:D010195",
-                "UMLS:C0030305"
-              ],
-              "id": "MONDO:0004982",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pancreatitis",
-                "pancreatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/pancreatitis.htm",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10851408,
-            "start": 569,
-            "end": 317183,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15022622': {'publication date': '2003 Oct', 'sentence': 'To investigate the time courses of the effects of the exogenous glucocorticoid agonists dexamethasone (DEX) and hydrocortisone (HYD) and a glucocorticoid antagonist (RU-38486), and to characterize the local and systemic responses in experimental AP.', 'subject score': 1000, 'object score': 851}, 'PMID:15211115': {'publication date': '2004 Jul', 'sentence': 'The aim of this study was to investigate the time courses of the effects of the exogenous glucocorticoid agonists dexamethasone (DEX) and hydrocortisone (HYD) and a glucocorticoid antagonist (RU-38486) and to characterize the local and systemic responses in AP in rats.', 'subject score': 1000, 'object score': 888}, 'PMID:29215538': {'publication date': '2018 01', 'sentence': 'Cortisol Outperforms Novel Cardiovascular, Inflammatory, and Neurohumoral Biomarkers in the Prediction of Outcome in Acute Pancreatitis.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0030305---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "11089023",
-              "object": "MONDO:0004982",
-              "publications": [
-                "PMID:15022622",
-                "PMID:15211115",
-                "PMID:29215538"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:10354211': {'publication date': '1999 Jun', 'sentence': 'The amount of N-acetyl D-glucosamine in the zymogen granule membrane was not altered by caerulein acute pancreatitis induced under continuous hydrocortisone treatment, but it was decreased by the administration of L-364,718 over 7 days after pancreatitis induction.', 'subject score': 851, 'object score': 888}, 'PMID:10436370': {'publication date': '1999', 'sentence': 'Hydrocortisone should be tested experimentally after the induction of AP and clinically as a prophylactic measure to avoid severe AP induced by endoscopic retrograde cholangiopancreaticography.', 'subject score': 1000, 'object score': 888}, 'PMID:11680590': {'publication date': '2001 Oct', 'sentence': 'Hydrocortisone (10 mg/kg) was administered intravenously 10 minutes after induction of acute pancreatitis.', 'subject score': 1000, 'object score': 888}, 'PMID:12911675': {'publication date': '2003 Sep', 'sentence': 'Acute pancreatitis due to hydrocortisone in a patient with ulcerative colitis.', 'subject score': 1000, 'object score': 888}, 'PMID:12924636': {'publication date': '2003 Aug', 'sentence': 'According to the dose and time of administration, hydrocortisone therapy was effective and beneficial at a dose of 4 mg/kg give 30 min before inducing acute pancreatitis.', 'subject score': 888, 'object score': 888}, 'PMID:8530830': {'publication date': '1995 Oct', 'sentence': 'In groups II-V, rats were treated with the anti-inflammatory drugs indomethacine, hydrocortisone, cimetidine, and acetylsalicylic acid (ASS) before induction of AP.', 'subject score': 1000, 'object score': 888}, 'PMID:9408342': {'publication date': '1997', 'sentence': 'In animal experiments, dexamethasone and hydrocortisone significantly decreased the serum amylase activities 8 hours after the induction of pancreatitis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317183,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004982",
-          "name": "pancreatitis",
-          "description": "Inflammation of the pancreas.; INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.; The presence of inflammation in the pancreas. [HPO:probinson]; The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0004982",
-            "MEDDRA:10076039",
-            "MEDDRA:10033656",
-            "DOID:4989",
-            "SNOMEDCT:75694006",
-            "ICD10:K85.9",
-            "MEDDRA:10033645",
-            "NCIT:C3306",
-            "EFO:0000278",
-            "HP:0001733",
-            "MESH:D010195",
-            "UMLS:C0030305"
-          ],
-          "id": "MONDO:0004982",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pancreatitis",
-            "pancreatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/pancreatitis.htm",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317183,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004982",
-              "name": "pancreatitis",
-              "description": "Inflammation of the pancreas.; INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.; The presence of inflammation in the pancreas. [HPO:probinson]; The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0004982",
-                "MEDDRA:10076039",
-                "MEDDRA:10033656",
-                "DOID:4989",
-                "SNOMEDCT:75694006",
-                "ICD10:K85.9",
-                "MEDDRA:10033645",
-                "NCIT:C3306",
-                "EFO:0000278",
-                "HP:0001733",
-                "MESH:D010195",
-                "UMLS:C0030305"
-              ],
-              "id": "MONDO:0004982",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pancreatitis",
-                "pancreatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/pancreatitis.htm",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7282813,
-            "start": 569,
-            "end": 317183,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10354211': {'publication date': '1999 Jun', 'sentence': 'The amount of N-acetyl D-glucosamine in the zymogen granule membrane was not altered by caerulein acute pancreatitis induced under continuous hydrocortisone treatment, but it was decreased by the administration of L-364,718 over 7 days after pancreatitis induction.', 'subject score': 851, 'object score': 888}, 'PMID:10436370': {'publication date': '1999', 'sentence': 'Hydrocortisone should be tested experimentally after the induction of AP and clinically as a prophylactic measure to avoid severe AP induced by endoscopic retrograde cholangiopancreaticography.', 'subject score': 1000, 'object score': 888}, 'PMID:11680590': {'publication date': '2001 Oct', 'sentence': 'Hydrocortisone (10 mg/kg) was administered intravenously 10 minutes after induction of acute pancreatitis.', 'subject score': 1000, 'object score': 888}, 'PMID:12911675': {'publication date': '2003 Sep', 'sentence': 'Acute pancreatitis due to hydrocortisone in a patient with ulcerative colitis.', 'subject score': 1000, 'object score': 888}, 'PMID:12924636': {'publication date': '2003 Aug', 'sentence': 'According to the dose and time of administration, hydrocortisone therapy was effective and beneficial at a dose of 4 mg/kg give 30 min before inducing acute pancreatitis.', 'subject score': 888, 'object score': 888}, 'PMID:8530830': {'publication date': '1995 Oct', 'sentence': 'In groups II-V, rats were treated with the anti-inflammatory drugs indomethacine, hydrocortisone, cimetidine, and acetylsalicylic acid (ASS) before induction of AP.', 'subject score': 1000, 'object score': 888}, 'PMID:9408342': {'publication date': '1997', 'sentence': 'In animal experiments, dexamethasone and hydrocortisone significantly decreased the serum amylase activities 8 hours after the induction of pancreatitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0030305---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7432490",
-              "object": "MONDO:0004982",
-              "publications": [
-                "PMID:10354211",
-                "PMID:10436370",
-                "PMID:11680590",
-                "PMID:12911675",
-                "PMID:12924636",
-                "PMID:8530830",
-                "PMID:9408342"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10354211': {'publication date': '1999 Jun', 'sentence': 'The amount of N-acetyl D-glucosamine in the zymogen granule membrane was not altered by caerulein acute pancreatitis induced under continuous hydrocortisone treatment, but it was decreased by the administration of L-364,718 over 7 days after pancreatitis induction.', 'subject score': 851, 'object score': 851}, 'PMID:10436370': {'publication date': '1999', 'sentence': 'OBJECTIVE: To investigate the effects of pretreatment with hydrocortisone on the production of cytokines and the occurrence of acute lung injury in rabbits with AP.', 'subject score': 1000, 'object score': 888}, 'PMID:17805969': {'publication date': '2007 Dec', 'sentence': 'Successful treatment of acute pancreatitis with hydrocortisone in a patient postadrenalectomy.', 'subject score': 1000, 'object score': 888}, 'PMID:29215538': {'publication date': '2018 01', 'sentence': 'OBJECTIVES: The aims of this study were to assess whether copeptin, pro-atrial natriuretic peptide, proadrenomedullin, and cortisol are associated with disease severity in patients with acute pancreatitis (AP) and to compare their ability in predicting organ failure or death.', 'subject score': 1000, 'object score': 888}, 'PMID:6280355': {'publication date': '1981 Dec', 'sentence': '[Concentration of blood adrenocorticotropic hormone and cortisol in patients with acute pancreatitis].', 'subject score': 1000, 'object score': 888}, 'PMID:8521247': {'publication date': '1995 Jun', 'sentence': \"Administration of the cholecystokinin octapeptide (CCK-8) (10 micrograms/kg/day) during the development of acute pancreatitis in animals pretreated with hydrocortisone substantially improved the general state of the animals' pancreases.\", 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 317183,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004982",
-          "name": "pancreatitis",
-          "description": "Inflammation of the pancreas.; INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.; The presence of inflammation in the pancreas. [HPO:probinson]; The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0004982",
-            "MEDDRA:10076039",
-            "MEDDRA:10033656",
-            "DOID:4989",
-            "SNOMEDCT:75694006",
-            "ICD10:K85.9",
-            "MEDDRA:10033645",
-            "NCIT:C3306",
-            "EFO:0000278",
-            "HP:0001733",
-            "MESH:D010195",
-            "UMLS:C0030305"
-          ],
-          "id": "MONDO:0004982",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pancreatitis",
-            "pancreatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/pancreatitis.htm",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317183,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004982",
-              "name": "pancreatitis",
-              "description": "Inflammation of the pancreas.; INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.; The presence of inflammation in the pancreas. [HPO:probinson]; The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0004982",
-                "MEDDRA:10076039",
-                "MEDDRA:10033656",
-                "DOID:4989",
-                "SNOMEDCT:75694006",
-                "ICD10:K85.9",
-                "MEDDRA:10033645",
-                "NCIT:C3306",
-                "EFO:0000278",
-                "HP:0001733",
-                "MESH:D010195",
-                "UMLS:C0030305"
-              ],
-              "id": "MONDO:0004982",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pancreatitis",
-                "pancreatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/pancreatitis.htm",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7282805,
-            "start": 569,
-            "end": 317183,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10354211': {'publication date': '1999 Jun', 'sentence': 'The amount of N-acetyl D-glucosamine in the zymogen granule membrane was not altered by caerulein acute pancreatitis induced under continuous hydrocortisone treatment, but it was decreased by the administration of L-364,718 over 7 days after pancreatitis induction.', 'subject score': 851, 'object score': 851}, 'PMID:10436370': {'publication date': '1999', 'sentence': 'OBJECTIVE: To investigate the effects of pretreatment with hydrocortisone on the production of cytokines and the occurrence of acute lung injury in rabbits with AP.', 'subject score': 1000, 'object score': 888}, 'PMID:17805969': {'publication date': '2007 Dec', 'sentence': 'Successful treatment of acute pancreatitis with hydrocortisone in a patient postadrenalectomy.', 'subject score': 1000, 'object score': 888}, 'PMID:29215538': {'publication date': '2018 01', 'sentence': 'OBJECTIVES: The aims of this study were to assess whether copeptin, pro-atrial natriuretic peptide, proadrenomedullin, and cortisol are associated with disease severity in patients with acute pancreatitis (AP) and to compare their ability in predicting organ failure or death.', 'subject score': 1000, 'object score': 888}, 'PMID:6280355': {'publication date': '1981 Dec', 'sentence': '[Concentration of blood adrenocorticotropic hormone and cortisol in patients with acute pancreatitis].', 'subject score': 1000, 'object score': 888}, 'PMID:8521247': {'publication date': '1995 Jun', 'sentence': \"Administration of the cholecystokinin octapeptide (CCK-8) (10 micrograms/kg/day) during the development of acute pancreatitis in animals pretreated with hydrocortisone substantially improved the general state of the animals' pancreases.\", 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0030305---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7432481",
-              "object": "MONDO:0004982",
-              "publications": [
-                "PMID:10354211",
-                "PMID:10436370",
-                "PMID:17805969",
-                "PMID:29215538",
-                "PMID:6280355",
-                "PMID:8521247"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:18448259': {'publication date': '2008 Aug', 'sentence': 'Cortisol levels are elevated in patients with RSV and Ebola, and cortisol was higher in SARS patients with lymphopenia before any steroid therapy.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 523855,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005091",
-          "name": "severe acute respiratory syndrome",
-          "description": "A viral respiratory infection caused by the SARS coronavirus. It is transmitted through close person-to-person contact. It is manifested with high fever, headache, dry cough and myalgias. It may progress to pneumonia and cause death.; A viral disorder characterized by high FEVER, dry COUGH, shortness of breath (DYSPNEA) or breathing difficulties, and atypical PNEUMONIA. A virus in the genus CORONAVIRUS is the suspected agent.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10061986",
-            "UMLS:C1175175",
-            "NCIT:C85064",
-            "ICD9:079.82",
-            "ICD10:J12.81",
-            "MONDO:0005091",
-            "MEDDRA:10084784",
-            "SNOMEDCT:398447004",
-            "MESH:D045169",
-            "DOID:2945",
-            "ORPHANET:140896",
-            "EFO:0000694",
-            "MEDDRA:10061982"
-          ],
-          "id": "MONDO:0005091",
-          "category": "biolink:Disease",
-          "all_names": [
-            "SARS-associated coronavirus",
-            "Acute respiratory coronavirus infection",
-            "severe acute respiratory syndrome",
-            "Severe Acute Respiratory Syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/severe_acute_respiratory_syndrome",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=sars"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 523855,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005091",
-              "name": "severe acute respiratory syndrome",
-              "description": "A viral respiratory infection caused by the SARS coronavirus. It is transmitted through close person-to-person contact. It is manifested with high fever, headache, dry cough and myalgias. It may progress to pneumonia and cause death.; A viral disorder characterized by high FEVER, dry COUGH, shortness of breath (DYSPNEA) or breathing difficulties, and atypical PNEUMONIA. A virus in the genus CORONAVIRUS is the suspected agent.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10061986",
-                "UMLS:C1175175",
-                "NCIT:C85064",
-                "ICD9:079.82",
-                "ICD10:J12.81",
-                "MONDO:0005091",
-                "MEDDRA:10084784",
-                "SNOMEDCT:398447004",
-                "MESH:D045169",
-                "DOID:2945",
-                "ORPHANET:140896",
-                "EFO:0000694",
-                "MEDDRA:10061982"
-              ],
-              "id": "MONDO:0005091",
-              "category": "biolink:Disease",
-              "all_names": [
-                "SARS-associated coronavirus",
-                "Acute respiratory coronavirus infection",
-                "severe acute respiratory syndrome",
-                "Severe Acute Respiratory Syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/severe_acute_respiratory_syndrome",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=sars"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13436331,
-            "start": 569,
-            "end": 523855,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18448259': {'publication date': '2008 Aug', 'sentence': 'Cortisol levels are elevated in patients with RSV and Ebola, and cortisol was higher in SARS patients with lymphopenia before any steroid therapy.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C1175175---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13724762",
-              "object": "MONDO:0005091",
-              "publications": [
-                "PMID:18448259"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:1062871': {'publication date': '1975', 'sentence': 'These findings demonstrate 2 types of adrenal insufficiency with different clinical pictures: Type 1 is characterized by cortisol deficiency with hypoglycaemia, low corticoid levels and a low cortisol secretion rate; Type 2 shows aldosterone deficiency with prominent salt loss.', 'subject score': 888, 'object score': 1000}, 'PMID:12614129': {'publication date': '2003', 'sentence': 'Hydrocortisone and fludrocortisone improved 28-day survival in septic shock and adrenal insufficiency.', 'subject score': 1000, 'object score': 1000}, 'PMID:13475458': {'publication date': '1957 Oct', 'sentence': 'Urinary metabolites of cortisol in adrenal insufficiency and in pituitary eunuchoidism.', 'subject score': 1000, 'object score': 1000}, 'PMID:15942340': {'publication date': '2005 Jun', 'sentence': 'In those patients receiving vasopressor agents at the time of adrenal testing, the baseline cortisol was 10.0 +/- 4.8 microg/dL in those with adrenal insufficiency compared with 35.6 +/- 21.2 microg/dL in those with normal adrenal function.', 'subject score': 888, 'object score': 901}, 'PMID:1921930': {'publication date': '1991 Aug', 'sentence': 'Two patients with subclinical cortisol secretion developed adrenal insufficiency after removal of benign adenomas.', 'subject score': 851, 'object score': 1000}, 'PMID:22812714': {'publication date': '2012 Nov', 'sentence': 'There are emerging roles for the use of salivary cortisol in diagnosing adrenal insufficiency, particularly in conditions associated with low cortisol-binding globulin levels, and in the monitoring of glucocorticoid replacement.', 'subject score': 888, 'object score': 884}, 'PMID:22914231': {'publication date': '2012 Aug 21', 'sentence': 'Serum adrenocorticotropic hormone and cortisol concentrations were compatible with adrenal insufficiency.', 'subject score': 888, 'object score': 1000}, 'PMID:25702760': {'publication date': '2015 Mar', 'sentence': 'BACKGROUND: Measurements of total plasma cortisol (TPC) in the acute phase of aneurysmal subarachnoid haemorrhage (aSAH) have suggested a high incidence of adrenal insufficiency (AI).', 'subject score': 851, 'object score': 1000}, 'PMID:28614010': {'publication date': '2017 Aug', 'sentence': 'If cortisol was ?100 nmol/L (n = 69/804, 8.6%) the positive predictive value was 93.2% to rule in AI.', 'subject score': 1000, 'object score': 1000}, 'PMID:30058902': {'publication date': '2018 May', 'sentence': 'Alkindi(r) is a novel paediatric formulation of immediate release hydrocortisone licensed for use in paediatric adrenal insufficiency.', 'subject score': 851, 'object score': 901}, 'PMID:30656706': {'publication date': '2019 Apr', 'sentence': 'Of the eight patients with normal cortisol at diagnosis, two developed adrenal insufficiency on follow-up.', 'subject score': 888, 'object score': 1000}, 'PMID:31252397': {'publication date': '2019 Jul 01', 'sentence': 'Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency.', 'subject score': 790, 'object score': 1000}, 'PMID:31808753': {'publication date': '2019 11 06', 'sentence': 'Morning cortisol <=6.51 MUg/dL (179.6 nmol/L) gave 100% positive predictive value (PPV) to rule-in AI.', 'subject score': 888, 'object score': 1000}, 'PMID:33290598': {'publication date': '2020 Dec 08', 'sentence': 'Morning serum cortisol is superior to salivary cortisone and cortisol in predicting normal adrenal function in suspected adrenal insufficiency.', 'subject score': 1000, 'object score': 901}, 'PMID:33776936': {'publication date': '2021', 'sentence': 'Early Metabolic Benefits of Switching Hydrocortisone to Modified Release Hydrocortisone in Adult Adrenal Insufficiency.', 'subject score': 901, 'object score': 901}, 'PMID:33993277': {'publication date': '2021 May 16', 'sentence': 'CONTEXT: Prednisolone has been recommended rather than hydrocortisone for glucocorticoid replacement in adrenal insufficiency due its longer duration of action and lower cost.', 'subject score': 1000, 'object score': 1000}, 'PMID:34225184': {'publication date': '2021 Jun 20', 'sentence': 'Our data suggest that children with HCC < 2.5th percentile and (repeatedly) negative CAR might possibly have adrenal insufficiency or delayed HPA-axis responsiveness.', 'subject score': 851, 'object score': 1000}, 'PMID:34243144': {'publication date': '2021 Jul 01', 'sentence': 'Use of dual-release hydrocortisone in adrenal insufficiency.', 'subject score': 851, 'object score': 1000}, 'PMID:35341087': {'publication date': '2021', 'sentence': 'Patients with basal cortisol < 10 MUg/dl or those with ? cortisol < 9 MUg/dl after the cosyntropin test were considered as having AI.', 'subject score': 888, 'object score': 1000}, 'PMID:35982612': {'publication date': '2022 Aug 19', 'sentence': 'Accurate measurement of cortisol is critical in adrenal insufficiency as it reduces the risk associated with misdiagnosis and supports the optimization of stress dose.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 312686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-          "name": "adrenocortical insufficiency",
-          "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0405580",
-            "MEDDRA:10022460",
-            "ICD9:255.4",
-            "EFO:0009491",
-            "MEDDRA:10001367",
-            "MEDDRA:10020936",
-            "MONDO:0000004",
-            "MEDDRA:10020979",
-            "SNOMEDCT:237785004",
-            "SNOMEDCT:386584007",
-            "MEDDRA:10056485",
-            "MEDDRA:10082130",
-            "UMLS:C0001623",
-            "MEDDRA:10001344",
-            "MEDDRA:10001366",
-            "MEDDRA:10001334",
-            "DOID:10493",
-            "NCIT:C26691",
-            "HP:0000846",
-            "MEDDRA:10001335",
-            "MEDDRA:10001369",
-            "MEDDRA:10001342",
-            "MEDDRA:10001343",
-            "MESH:D000309",
-            "SNOMEDCT:111563005",
-            "MEDDRA:10011172",
-            "MEDDRA:10022461"
-          ],
-          "id": "MONDO:0000004",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortical hypofunction",
-            "Adrenocortical Insufficiency",
-            "adrenocortical insufficiency",
-            "Corticoadrenal insufficiency",
-            "Adrenal gland hypofunction",
-            "Adrenal Insufficiency",
-            "Adrenal insufficiency",
-            "Adrenal cortical hypofunction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:11443143"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-              "name": "adrenocortical insufficiency",
-              "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0405580",
-                "MEDDRA:10022460",
-                "ICD9:255.4",
-                "EFO:0009491",
-                "MEDDRA:10001367",
-                "MEDDRA:10020936",
-                "MONDO:0000004",
-                "MEDDRA:10020979",
-                "SNOMEDCT:237785004",
-                "SNOMEDCT:386584007",
-                "MEDDRA:10056485",
-                "MEDDRA:10082130",
-                "UMLS:C0001623",
-                "MEDDRA:10001344",
-                "MEDDRA:10001366",
-                "MEDDRA:10001334",
-                "DOID:10493",
-                "NCIT:C26691",
-                "HP:0000846",
-                "MEDDRA:10001335",
-                "MEDDRA:10001369",
-                "MEDDRA:10001342",
-                "MEDDRA:10001343",
-                "MESH:D000309",
-                "SNOMEDCT:111563005",
-                "MEDDRA:10011172",
-                "MEDDRA:10022461"
-              ],
-              "id": "MONDO:0000004",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortical hypofunction",
-                "Adrenocortical Insufficiency",
-                "adrenocortical insufficiency",
-                "Corticoadrenal insufficiency",
-                "Adrenal gland hypofunction",
-                "Adrenal Insufficiency",
-                "Adrenal insufficiency",
-                "Adrenal cortical hypofunction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:11443143"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7754458,
-            "start": 569,
-            "end": 312686,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1062871': {'publication date': '1975', 'sentence': 'These findings demonstrate 2 types of adrenal insufficiency with different clinical pictures: Type 1 is characterized by cortisol deficiency with hypoglycaemia, low corticoid levels and a low cortisol secretion rate; Type 2 shows aldosterone deficiency with prominent salt loss.', 'subject score': 888, 'object score': 1000}, 'PMID:12614129': {'publication date': '2003', 'sentence': 'Hydrocortisone and fludrocortisone improved 28-day survival in septic shock and adrenal insufficiency.', 'subject score': 1000, 'object score': 1000}, 'PMID:13475458': {'publication date': '1957 Oct', 'sentence': 'Urinary metabolites of cortisol in adrenal insufficiency and in pituitary eunuchoidism.', 'subject score': 1000, 'object score': 1000}, 'PMID:15942340': {'publication date': '2005 Jun', 'sentence': 'In those patients receiving vasopressor agents at the time of adrenal testing, the baseline cortisol was 10.0 +/- 4.8 microg/dL in those with adrenal insufficiency compared with 35.6 +/- 21.2 microg/dL in those with normal adrenal function.', 'subject score': 888, 'object score': 901}, 'PMID:1921930': {'publication date': '1991 Aug', 'sentence': 'Two patients with subclinical cortisol secretion developed adrenal insufficiency after removal of benign adenomas.', 'subject score': 851, 'object score': 1000}, 'PMID:22812714': {'publication date': '2012 Nov', 'sentence': 'There are emerging roles for the use of salivary cortisol in diagnosing adrenal insufficiency, particularly in conditions associated with low cortisol-binding globulin levels, and in the monitoring of glucocorticoid replacement.', 'subject score': 888, 'object score': 884}, 'PMID:22914231': {'publication date': '2012 Aug 21', 'sentence': 'Serum adrenocorticotropic hormone and cortisol concentrations were compatible with adrenal insufficiency.', 'subject score': 888, 'object score': 1000}, 'PMID:25702760': {'publication date': '2015 Mar', 'sentence': 'BACKGROUND: Measurements of total plasma cortisol (TPC) in the acute phase of aneurysmal subarachnoid haemorrhage (aSAH) have suggested a high incidence of adrenal insufficiency (AI).', 'subject score': 851, 'object score': 1000}, 'PMID:28614010': {'publication date': '2017 Aug', 'sentence': 'If cortisol was ?100 nmol/L (n = 69/804, 8.6%) the positive predictive value was 93.2% to rule in AI.', 'subject score': 1000, 'object score': 1000}, 'PMID:30058902': {'publication date': '2018 May', 'sentence': 'Alkindi(r) is a novel paediatric formulation of immediate release hydrocortisone licensed for use in paediatric adrenal insufficiency.', 'subject score': 851, 'object score': 901}, 'PMID:30656706': {'publication date': '2019 Apr', 'sentence': 'Of the eight patients with normal cortisol at diagnosis, two developed adrenal insufficiency on follow-up.', 'subject score': 888, 'object score': 1000}, 'PMID:31252397': {'publication date': '2019 Jul 01', 'sentence': 'Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency.', 'subject score': 790, 'object score': 1000}, 'PMID:31808753': {'publication date': '2019 11 06', 'sentence': 'Morning cortisol <=6.51 MUg/dL (179.6 nmol/L) gave 100% positive predictive value (PPV) to rule-in AI.', 'subject score': 888, 'object score': 1000}, 'PMID:33290598': {'publication date': '2020 Dec 08', 'sentence': 'Morning serum cortisol is superior to salivary cortisone and cortisol in predicting normal adrenal function in suspected adrenal insufficiency.', 'subject score': 1000, 'object score': 901}, 'PMID:33776936': {'publication date': '2021', 'sentence': 'Early Metabolic Benefits of Switching Hydrocortisone to Modified Release Hydrocortisone in Adult Adrenal Insufficiency.', 'subject score': 901, 'object score': 901}, 'PMID:33993277': {'publication date': '2021 May 16', 'sentence': 'CONTEXT: Prednisolone has been recommended rather than hydrocortisone for glucocorticoid replacement in adrenal insufficiency due its longer duration of action and lower cost.', 'subject score': 1000, 'object score': 1000}, 'PMID:34225184': {'publication date': '2021 Jun 20', 'sentence': 'Our data suggest that children with HCC < 2.5th percentile and (repeatedly) negative CAR might possibly have adrenal insufficiency or delayed HPA-axis responsiveness.', 'subject score': 851, 'object score': 1000}, 'PMID:34243144': {'publication date': '2021 Jul 01', 'sentence': 'Use of dual-release hydrocortisone in adrenal insufficiency.', 'subject score': 851, 'object score': 1000}, 'PMID:35341087': {'publication date': '2021', 'sentence': 'Patients with basal cortisol < 10 MUg/dl or those with ? cortisol < 9 MUg/dl after the cosyntropin test were considered as having AI.', 'subject score': 888, 'object score': 1000}, 'PMID:35982612': {'publication date': '2022 Aug 19', 'sentence': 'Accurate measurement of cortisol is critical in adrenal insufficiency as it reduces the risk associated with misdiagnosis and supports the optimization of stress dose.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0001623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7919367",
-              "object": "MONDO:0000004",
-              "publications": [
-                "PMID:1062871",
-                "PMID:12614129",
-                "PMID:13475458",
-                "PMID:15942340",
-                "PMID:1921930",
-                "PMID:22812714",
-                "PMID:22914231",
-                "PMID:25702760",
-                "PMID:28614010",
-                "PMID:30058902",
-                "PMID:30656706",
-                "PMID:31252397",
-                "PMID:31808753",
-                "PMID:33290598",
-                "PMID:33776936",
-                "PMID:33993277",
-                "PMID:34225184",
-                "PMID:34243144",
-                "PMID:35341087",
-                "PMID:35982612"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:11786677': {'publication date': '2001', 'sentence': 'Firstly, the GH-mediated increase in cortisol metabolism (mediated via reduced E to F conversion) may precipitate adrenal insufficiency in hypopituitary patients with partial adrenocorticotropic hormone deficiency commencing GH therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:17157339': {'publication date': '2007 Jan', 'sentence': 'It is proposed that a steroid profile measuring cortisol, aldosterone, 11-deoxycortisol, and dehydroepiandrosterone would potentially improve the ability to determine the cause of adrenal insufficiency.', 'subject score': 852, 'object score': 1000}, 'PMID:18430777': {'publication date': '2008 Jul', 'sentence': 'METHODS: Diagnosis of FGD was based on clinical features, high ACTH, and low cortisol concentrations with normal renin and aldosterone concentrations and exclusion of other causes of adrenal failure.', 'subject score': 851, 'object score': 1000}, 'PMID:19225029': {'publication date': '2009 Mar', 'sentence': 'Clinically, it was doubted whether she had true adrenal insufficiency and it was thought that the cortisol results might be artefactually low due to assay interference.', 'subject score': 872, 'object score': 901}, 'PMID:24424183': {'publication date': '2014 Apr-May', 'sentence': 'The diagnosis depends on demonstrating inappropriately low cortisol production and the presence of high titers of adrenal cortex autoantibodies (ACAs), along with excluding other causes of adrenal failure using other tests as necessary.', 'subject score': 775, 'object score': 1000}, 'PMID:30670349': {'publication date': '2019 Oct', 'sentence': 'BACKGROUND: Immature adrenocortical function in preterm infants may cause inadequate production of cortisol under stress, resulting in adrenal insufficiency of prematurity (AOP).', 'subject score': 1000, 'object score': 1000}, 'PMID:34582361': {'publication date': '2021 Sep 01', 'sentence': 'The use of combined chemotherapy and atezolizumab in the ectopic ACTH syndrome secondary to small-cell lung cancer may cause a precipitous fall in circulating ACTH/cortisol, resulting in symptomatic adrenal insufficiency The advances in cancer therapy and treatment for endocrine paraneoplastic syndrome need to be adapted.', 'subject score': 851, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 312686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-          "name": "adrenocortical insufficiency",
-          "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0405580",
-            "MEDDRA:10022460",
-            "ICD9:255.4",
-            "EFO:0009491",
-            "MEDDRA:10001367",
-            "MEDDRA:10020936",
-            "MONDO:0000004",
-            "MEDDRA:10020979",
-            "SNOMEDCT:237785004",
-            "SNOMEDCT:386584007",
-            "MEDDRA:10056485",
-            "MEDDRA:10082130",
-            "UMLS:C0001623",
-            "MEDDRA:10001344",
-            "MEDDRA:10001366",
-            "MEDDRA:10001334",
-            "DOID:10493",
-            "NCIT:C26691",
-            "HP:0000846",
-            "MEDDRA:10001335",
-            "MEDDRA:10001369",
-            "MEDDRA:10001342",
-            "MEDDRA:10001343",
-            "MESH:D000309",
-            "SNOMEDCT:111563005",
-            "MEDDRA:10011172",
-            "MEDDRA:10022461"
-          ],
-          "id": "MONDO:0000004",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortical hypofunction",
-            "Adrenocortical Insufficiency",
-            "adrenocortical insufficiency",
-            "Corticoadrenal insufficiency",
-            "Adrenal gland hypofunction",
-            "Adrenal Insufficiency",
-            "Adrenal insufficiency",
-            "Adrenal cortical hypofunction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:11443143"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-              "name": "adrenocortical insufficiency",
-              "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0405580",
-                "MEDDRA:10022460",
-                "ICD9:255.4",
-                "EFO:0009491",
-                "MEDDRA:10001367",
-                "MEDDRA:10020936",
-                "MONDO:0000004",
-                "MEDDRA:10020979",
-                "SNOMEDCT:237785004",
-                "SNOMEDCT:386584007",
-                "MEDDRA:10056485",
-                "MEDDRA:10082130",
-                "UMLS:C0001623",
-                "MEDDRA:10001344",
-                "MEDDRA:10001366",
-                "MEDDRA:10001334",
-                "DOID:10493",
-                "NCIT:C26691",
-                "HP:0000846",
-                "MEDDRA:10001335",
-                "MEDDRA:10001369",
-                "MEDDRA:10001342",
-                "MEDDRA:10001343",
-                "MESH:D000309",
-                "SNOMEDCT:111563005",
-                "MEDDRA:10011172",
-                "MEDDRA:10022461"
-              ],
-              "id": "MONDO:0000004",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortical hypofunction",
-                "Adrenocortical Insufficiency",
-                "adrenocortical insufficiency",
-                "Corticoadrenal insufficiency",
-                "Adrenal gland hypofunction",
-                "Adrenal Insufficiency",
-                "Adrenal insufficiency",
-                "Adrenal cortical hypofunction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:11443143"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9118394,
-            "start": 569,
-            "end": 312686,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11786677': {'publication date': '2001', 'sentence': 'Firstly, the GH-mediated increase in cortisol metabolism (mediated via reduced E to F conversion) may precipitate adrenal insufficiency in hypopituitary patients with partial adrenocorticotropic hormone deficiency commencing GH therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:17157339': {'publication date': '2007 Jan', 'sentence': 'It is proposed that a steroid profile measuring cortisol, aldosterone, 11-deoxycortisol, and dehydroepiandrosterone would potentially improve the ability to determine the cause of adrenal insufficiency.', 'subject score': 852, 'object score': 1000}, 'PMID:18430777': {'publication date': '2008 Jul', 'sentence': 'METHODS: Diagnosis of FGD was based on clinical features, high ACTH, and low cortisol concentrations with normal renin and aldosterone concentrations and exclusion of other causes of adrenal failure.', 'subject score': 851, 'object score': 1000}, 'PMID:19225029': {'publication date': '2009 Mar', 'sentence': 'Clinically, it was doubted whether she had true adrenal insufficiency and it was thought that the cortisol results might be artefactually low due to assay interference.', 'subject score': 872, 'object score': 901}, 'PMID:24424183': {'publication date': '2014 Apr-May', 'sentence': 'The diagnosis depends on demonstrating inappropriately low cortisol production and the presence of high titers of adrenal cortex autoantibodies (ACAs), along with excluding other causes of adrenal failure using other tests as necessary.', 'subject score': 775, 'object score': 1000}, 'PMID:30670349': {'publication date': '2019 Oct', 'sentence': 'BACKGROUND: Immature adrenocortical function in preterm infants may cause inadequate production of cortisol under stress, resulting in adrenal insufficiency of prematurity (AOP).', 'subject score': 1000, 'object score': 1000}, 'PMID:34582361': {'publication date': '2021 Sep 01', 'sentence': 'The use of combined chemotherapy and atezolizumab in the ectopic ACTH syndrome secondary to small-cell lung cancer may cause a precipitous fall in circulating ACTH/cortisol, resulting in symptomatic adrenal insufficiency The advances in cancer therapy and treatment for endocrine paraneoplastic syndrome need to be adapted.', 'subject score': 851, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0001623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9318796",
-              "object": "MONDO:0000004",
-              "publications": [
-                "PMID:11786677",
-                "PMID:17157339",
-                "PMID:18430777",
-                "PMID:19225029",
-                "PMID:24424183",
-                "PMID:30670349",
-                "PMID:34582361"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12003388': {'publication date': '2002 Apr', 'sentence': 'Long term hydrocortisone therapy for his adrenal insufficiency may have prevented a faster course of the liver disease, whereas the heterozygous alpha1-antitrypsin deficiency and moderate alcohol consumption constituted additional risk factors ultimately leading to the development of cirrhosis.', 'subject score': 861, 'object score': 1000}, 'PMID:13203378': {'publication date': '1954 Sep', 'sentence': 'Problems arising in the treatment of adrenal insufficiency with cortisone and hydrocortisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:15355454': {'publication date': '2004 Sep', 'sentence': 'OBJECTIVE: The objective of this study was to examine the variables determining hydrocortisone (HC) disposition in patients with adrenal insufficiency and to develop practical protocols for individualized prescribing and monitoring of HC treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:15857523': {'publication date': '2005 May', 'sentence': 'Recent studies in septic adults have shown decreased mortality with the use of hydrocortisone in patients with relative adrenal insufficiency.', 'subject score': 1000, 'object score': 901}, 'PMID:15942340': {'publication date': '2005 Jun', 'sentence': 'In vasopressor-dependent patients without adrenal insufficiency, treatment with hydrocortisone did not affect vasopressor dose at 24 hrs.', 'subject score': 1000, 'object score': 1000}, 'PMID:16093597': {'publication date': '2005 Jul', 'sentence': 'Interestingly, the parkinsonism fully disappeared after the replacement therapy of hydrocortisone for adrenal insufficiency due to hypopituitarism, and MRI 5 months later showed complete disappearance of the lesions, indicating the patient had ameliorated from the EPM.', 'subject score': 1000, 'object score': 1000}, 'PMID:16817818': {'publication date': '2006 Jul', 'sentence': 'OBJECTIVE: Conventional hydrocortisone therapy in adrenal insufficiency cannot provide physiological replacement.', 'subject score': 851, 'object score': 1000}, 'PMID:16886035': {'publication date': '2006 Jul', 'sentence': 'Practitioners need to recognize immediately this potentially lethal disorder in patients with known or suspected adrenal insufficiency and treat with intravenous hydrocortisone.', 'subject score': 888, 'object score': 901}, 'PMID:17003064': {'publication date': '2007 Feb', 'sentence': 'What is the rationale for hydrocortisone treatment in children with infection-related adrenal insufficiency and septic shock?', 'subject score': 888, 'object score': 861}, 'PMID:17058239': {'publication date': '2006 Nov', 'sentence': 'Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival.', 'subject score': 1000, 'object score': 1000}, 'PMID:17255644': {'publication date': '2006 Dec', 'sentence': 'Early recognition of severe hyponatremia due to hypopituitarism with adrenal insufficiency is critical, and treatment with hydrocortisone results in safe and improved quality of life.', 'subject score': 1000, 'object score': 1000}, 'PMID:17606560': {'publication date': '2007 Jul', 'sentence': 'Together with the short-term benefit previously reported, these data support additional studies of hydrocortisone treatment of adrenal insufficiency in extremely premature infants.', 'subject score': 888, 'object score': 1000}, 'PMID:18401570': {'publication date': '2008 May', 'sentence': 'Innovations comprise the development of new delayed release glucocorticoid preparations that allow to better mimic the circadian cortisol secretion and may have the potential to improve the treatment of patients with adrenal insufficiency.', 'subject score': 790, 'object score': 1000}, 'PMID:19168600': {'publication date': '2009 May', 'sentence': 'Recently, proof-of-concept studies have shown that more physiological circadian glucocorticoid therapy using HC infusions and newly developed oral formulations of HC have the potential for better biochemical control in patients with adrenal insufficiency.', 'subject score': 1000, 'object score': 1000}, 'PMID:19325359': {'publication date': '2009 Feb', 'sentence': 'The updated 2007 guidelines continue to recognize an increased likelihood that children with septic shock, compared with adults, require 1) proportionally larger quantities of fluid, 2) inotrope and vasodilator therapies, 3) hydrocortisone for absolute adrenal insufficiency, and 4) ECMO for refractory shock.', 'subject score': 1000, 'object score': 901}, 'PMID:19387826': {'publication date': '2009 Jun', 'sentence': 'Hydrocortisone infusion during night time might improve adrenomedullary reserve in patients with adrenal insufficiency.', 'subject score': 888, 'object score': 1000}, 'PMID:19500761': {'publication date': '2009 Apr', 'sentence': 'Further innovations comprise the development of delayed-release glucocorticoid preparations that better allow mimicking of circadian cortisol secretion and may have the potential to significantly improve the treatment of patients with adrenal insufficiency.', 'subject score': 790, 'object score': 1000}, 'PMID:19508599': {'publication date': '2010 Mar', 'sentence': 'Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency.', 'subject score': 851, 'object score': 1000}, 'PMID:20528006': {'publication date': '2010 Jul', 'sentence': 'CONCLUSIONS: Most patients with adrenal insufficiency are imperfectly treated with hydrocortisone relative to their plasma cortisol concentrations.', 'subject score': 1000, 'object score': 1000}, 'PMID:21521272': {'publication date': '2011 Jun', 'sentence': 'CONCLUSIONS: Hair cortisol content correlates with hydrocortisone (HC) dose in patients with AI.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 312686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-          "name": "adrenocortical insufficiency",
-          "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0405580",
-            "MEDDRA:10022460",
-            "ICD9:255.4",
-            "EFO:0009491",
-            "MEDDRA:10001367",
-            "MEDDRA:10020936",
-            "MONDO:0000004",
-            "MEDDRA:10020979",
-            "SNOMEDCT:237785004",
-            "SNOMEDCT:386584007",
-            "MEDDRA:10056485",
-            "MEDDRA:10082130",
-            "UMLS:C0001623",
-            "MEDDRA:10001344",
-            "MEDDRA:10001366",
-            "MEDDRA:10001334",
-            "DOID:10493",
-            "NCIT:C26691",
-            "HP:0000846",
-            "MEDDRA:10001335",
-            "MEDDRA:10001369",
-            "MEDDRA:10001342",
-            "MEDDRA:10001343",
-            "MESH:D000309",
-            "SNOMEDCT:111563005",
-            "MEDDRA:10011172",
-            "MEDDRA:10022461"
-          ],
-          "id": "MONDO:0000004",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortical hypofunction",
-            "Adrenocortical Insufficiency",
-            "adrenocortical insufficiency",
-            "Corticoadrenal insufficiency",
-            "Adrenal gland hypofunction",
-            "Adrenal Insufficiency",
-            "Adrenal insufficiency",
-            "Adrenal cortical hypofunction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:11443143"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-              "name": "adrenocortical insufficiency",
-              "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0405580",
-                "MEDDRA:10022460",
-                "ICD9:255.4",
-                "EFO:0009491",
-                "MEDDRA:10001367",
-                "MEDDRA:10020936",
-                "MONDO:0000004",
-                "MEDDRA:10020979",
-                "SNOMEDCT:237785004",
-                "SNOMEDCT:386584007",
-                "MEDDRA:10056485",
-                "MEDDRA:10082130",
-                "UMLS:C0001623",
-                "MEDDRA:10001344",
-                "MEDDRA:10001366",
-                "MEDDRA:10001334",
-                "DOID:10493",
-                "NCIT:C26691",
-                "HP:0000846",
-                "MEDDRA:10001335",
-                "MEDDRA:10001369",
-                "MEDDRA:10001342",
-                "MEDDRA:10001343",
-                "MESH:D000309",
-                "SNOMEDCT:111563005",
-                "MEDDRA:10011172",
-                "MEDDRA:10022461"
-              ],
-              "id": "MONDO:0000004",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortical hypofunction",
-                "Adrenocortical Insufficiency",
-                "adrenocortical insufficiency",
-                "Corticoadrenal insufficiency",
-                "Adrenal gland hypofunction",
-                "Adrenal Insufficiency",
-                "Adrenal insufficiency",
-                "Adrenal cortical hypofunction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:11443143"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9330184,
-            "start": 569,
-            "end": 312686,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12003388': {'publication date': '2002 Apr', 'sentence': 'Long term hydrocortisone therapy for his adrenal insufficiency may have prevented a faster course of the liver disease, whereas the heterozygous alpha1-antitrypsin deficiency and moderate alcohol consumption constituted additional risk factors ultimately leading to the development of cirrhosis.', 'subject score': 861, 'object score': 1000}, 'PMID:13203378': {'publication date': '1954 Sep', 'sentence': 'Problems arising in the treatment of adrenal insufficiency with cortisone and hydrocortisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:15355454': {'publication date': '2004 Sep', 'sentence': 'OBJECTIVE: The objective of this study was to examine the variables determining hydrocortisone (HC) disposition in patients with adrenal insufficiency and to develop practical protocols for individualized prescribing and monitoring of HC treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:15857523': {'publication date': '2005 May', 'sentence': 'Recent studies in septic adults have shown decreased mortality with the use of hydrocortisone in patients with relative adrenal insufficiency.', 'subject score': 1000, 'object score': 901}, 'PMID:15942340': {'publication date': '2005 Jun', 'sentence': 'In vasopressor-dependent patients without adrenal insufficiency, treatment with hydrocortisone did not affect vasopressor dose at 24 hrs.', 'subject score': 1000, 'object score': 1000}, 'PMID:16093597': {'publication date': '2005 Jul', 'sentence': 'Interestingly, the parkinsonism fully disappeared after the replacement therapy of hydrocortisone for adrenal insufficiency due to hypopituitarism, and MRI 5 months later showed complete disappearance of the lesions, indicating the patient had ameliorated from the EPM.', 'subject score': 1000, 'object score': 1000}, 'PMID:16817818': {'publication date': '2006 Jul', 'sentence': 'OBJECTIVE: Conventional hydrocortisone therapy in adrenal insufficiency cannot provide physiological replacement.', 'subject score': 851, 'object score': 1000}, 'PMID:16886035': {'publication date': '2006 Jul', 'sentence': 'Practitioners need to recognize immediately this potentially lethal disorder in patients with known or suspected adrenal insufficiency and treat with intravenous hydrocortisone.', 'subject score': 888, 'object score': 901}, 'PMID:17003064': {'publication date': '2007 Feb', 'sentence': 'What is the rationale for hydrocortisone treatment in children with infection-related adrenal insufficiency and septic shock?', 'subject score': 888, 'object score': 861}, 'PMID:17058239': {'publication date': '2006 Nov', 'sentence': 'Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival.', 'subject score': 1000, 'object score': 1000}, 'PMID:17255644': {'publication date': '2006 Dec', 'sentence': 'Early recognition of severe hyponatremia due to hypopituitarism with adrenal insufficiency is critical, and treatment with hydrocortisone results in safe and improved quality of life.', 'subject score': 1000, 'object score': 1000}, 'PMID:17606560': {'publication date': '2007 Jul', 'sentence': 'Together with the short-term benefit previously reported, these data support additional studies of hydrocortisone treatment of adrenal insufficiency in extremely premature infants.', 'subject score': 888, 'object score': 1000}, 'PMID:18401570': {'publication date': '2008 May', 'sentence': 'Innovations comprise the development of new delayed release glucocorticoid preparations that allow to better mimic the circadian cortisol secretion and may have the potential to improve the treatment of patients with adrenal insufficiency.', 'subject score': 790, 'object score': 1000}, 'PMID:19168600': {'publication date': '2009 May', 'sentence': 'Recently, proof-of-concept studies have shown that more physiological circadian glucocorticoid therapy using HC infusions and newly developed oral formulations of HC have the potential for better biochemical control in patients with adrenal insufficiency.', 'subject score': 1000, 'object score': 1000}, 'PMID:19325359': {'publication date': '2009 Feb', 'sentence': 'The updated 2007 guidelines continue to recognize an increased likelihood that children with septic shock, compared with adults, require 1) proportionally larger quantities of fluid, 2) inotrope and vasodilator therapies, 3) hydrocortisone for absolute adrenal insufficiency, and 4) ECMO for refractory shock.', 'subject score': 1000, 'object score': 901}, 'PMID:19387826': {'publication date': '2009 Jun', 'sentence': 'Hydrocortisone infusion during night time might improve adrenomedullary reserve in patients with adrenal insufficiency.', 'subject score': 888, 'object score': 1000}, 'PMID:19500761': {'publication date': '2009 Apr', 'sentence': 'Further innovations comprise the development of delayed-release glucocorticoid preparations that better allow mimicking of circadian cortisol secretion and may have the potential to significantly improve the treatment of patients with adrenal insufficiency.', 'subject score': 790, 'object score': 1000}, 'PMID:19508599': {'publication date': '2010 Mar', 'sentence': 'Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency.', 'subject score': 851, 'object score': 1000}, 'PMID:20528006': {'publication date': '2010 Jul', 'sentence': 'CONCLUSIONS: Most patients with adrenal insufficiency are imperfectly treated with hydrocortisone relative to their plasma cortisol concentrations.', 'subject score': 1000, 'object score': 1000}, 'PMID:21521272': {'publication date': '2011 Jun', 'sentence': 'CONCLUSIONS: Hair cortisol content correlates with hydrocortisone (HC) dose in patients with AI.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0001623---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0405580---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9535781",
-              "object": "MONDO:0000004",
-              "publications": [
-                "PMID:18401570",
-                "PMID:28292927",
-                "PMID:2561439",
-                "PMID:17003064",
-                "PMID:27864317",
-                "PMID:30385421",
-                "PMID:36476353",
-                "PMID:36447826",
-                "PMID:28815660",
-                "PMID:33278125",
-                "PMID:12003388",
-                "PMID:2922232",
-                "PMID:32431136",
-                "PMID:35987847",
-                "PMID:25646792",
-                "PMID:25039686",
-                "PMID:31927751",
-                "PMID:36986325",
-                "PMID:31102070",
-                "PMID:8578311"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:produces",
-    "r2.publications_info": "{'PMID:18520332': {'publication date': '2008 Jun', 'sentence': 'We conclude that the clinical picture of late-onset adrenal insufficiency in preterm infants is not a result of an absolute deficiency of cortisol production, but may be a result of a limited ability to synthesize sufficient cortisol for the degree of clinical stress.', 'subject score': 861, 'object score': 888}, 'PMID:36674647': {'publication date': '2023 Jan 06', 'sentence': 'This review aimed to clarify the association between mitochondrial diseases and adrenal insufficiency to produce cortisol.', 'subject score': 1000, 'object score': 1000}, 'PMID:9627368': {'publication date': '1998 Jun', 'sentence': 'We hypothesized that patients with AIDS and symptoms of adrenal insufficiency who produce normal amounts of cortisol in response to administration of 0.25 mg cosyntropin may nevertheless produce lower amounts of cortisol in a course of 24 hours than comparably sick AIDS patients without symptoms of adrenal insufficiency or comparably sick patients without AIDS.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 312686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-          "name": "adrenocortical insufficiency",
-          "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0405580",
-            "MEDDRA:10022460",
-            "ICD9:255.4",
-            "EFO:0009491",
-            "MEDDRA:10001367",
-            "MEDDRA:10020936",
-            "MONDO:0000004",
-            "MEDDRA:10020979",
-            "SNOMEDCT:237785004",
-            "SNOMEDCT:386584007",
-            "MEDDRA:10056485",
-            "MEDDRA:10082130",
-            "UMLS:C0001623",
-            "MEDDRA:10001344",
-            "MEDDRA:10001366",
-            "MEDDRA:10001334",
-            "DOID:10493",
-            "NCIT:C26691",
-            "HP:0000846",
-            "MEDDRA:10001335",
-            "MEDDRA:10001369",
-            "MEDDRA:10001342",
-            "MEDDRA:10001343",
-            "MESH:D000309",
-            "SNOMEDCT:111563005",
-            "MEDDRA:10011172",
-            "MEDDRA:10022461"
-          ],
-          "id": "MONDO:0000004",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortical hypofunction",
-            "Adrenocortical Insufficiency",
-            "adrenocortical insufficiency",
-            "Corticoadrenal insufficiency",
-            "Adrenal gland hypofunction",
-            "Adrenal Insufficiency",
-            "Adrenal insufficiency",
-            "Adrenal cortical hypofunction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:11443143"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-              "name": "adrenocortical insufficiency",
-              "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0405580",
-                "MEDDRA:10022460",
-                "ICD9:255.4",
-                "EFO:0009491",
-                "MEDDRA:10001367",
-                "MEDDRA:10020936",
-                "MONDO:0000004",
-                "MEDDRA:10020979",
-                "SNOMEDCT:237785004",
-                "SNOMEDCT:386584007",
-                "MEDDRA:10056485",
-                "MEDDRA:10082130",
-                "UMLS:C0001623",
-                "MEDDRA:10001344",
-                "MEDDRA:10001366",
-                "MEDDRA:10001334",
-                "DOID:10493",
-                "NCIT:C26691",
-                "HP:0000846",
-                "MEDDRA:10001335",
-                "MEDDRA:10001369",
-                "MEDDRA:10001342",
-                "MEDDRA:10001343",
-                "MESH:D000309",
-                "SNOMEDCT:111563005",
-                "MEDDRA:10011172",
-                "MEDDRA:10022461"
-              ],
-              "id": "MONDO:0000004",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortical hypofunction",
-                "Adrenocortical Insufficiency",
-                "adrenocortical insufficiency",
-                "Corticoadrenal insufficiency",
-                "Adrenal gland hypofunction",
-                "Adrenal Insufficiency",
-                "Adrenal insufficiency",
-                "Adrenal cortical hypofunction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:11443143"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13494770,
-            "start": 312686,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:18520332': {'publication date': '2008 Jun', 'sentence': 'We conclude that the clinical picture of late-onset adrenal insufficiency in preterm infants is not a result of an absolute deficiency of cortisol production, but may be a result of a limited ability to synthesize sufficient cortisol for the degree of clinical stress.', 'subject score': 861, 'object score': 888}, 'PMID:36674647': {'publication date': '2023 Jan 06', 'sentence': 'This review aimed to clarify the association between mitochondrial diseases and adrenal insufficiency to produce cortisol.', 'subject score': 1000, 'object score': 1000}, 'PMID:9627368': {'publication date': '1998 Jun', 'sentence': 'We hypothesized that patients with AIDS and symptoms of adrenal insufficiency who produce normal amounts of cortisol in response to administration of 0.25 mg cosyntropin may nevertheless produce lower amounts of cortisol in a course of 24 hours than comparably sick AIDS patients without symptoms of adrenal insufficiency or comparably sick patients without AIDS.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0001623---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0000004",
-              "id": "13783969",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:18520332",
-                "PMID:36674647",
-                "PMID:9627368"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:9815636': {'publication date': '1997 Dec', 'sentence': 'Replacement doses of hydrocortisone were administered throughout treatment to counteract potential adrenal insufficiency secondary to the ketoconazole.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 312686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-          "name": "adrenocortical insufficiency",
-          "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0405580",
-            "MEDDRA:10022460",
-            "ICD9:255.4",
-            "EFO:0009491",
-            "MEDDRA:10001367",
-            "MEDDRA:10020936",
-            "MONDO:0000004",
-            "MEDDRA:10020979",
-            "SNOMEDCT:237785004",
-            "SNOMEDCT:386584007",
-            "MEDDRA:10056485",
-            "MEDDRA:10082130",
-            "UMLS:C0001623",
-            "MEDDRA:10001344",
-            "MEDDRA:10001366",
-            "MEDDRA:10001334",
-            "DOID:10493",
-            "NCIT:C26691",
-            "HP:0000846",
-            "MEDDRA:10001335",
-            "MEDDRA:10001369",
-            "MEDDRA:10001342",
-            "MEDDRA:10001343",
-            "MESH:D000309",
-            "SNOMEDCT:111563005",
-            "MEDDRA:10011172",
-            "MEDDRA:10022461"
-          ],
-          "id": "MONDO:0000004",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortical hypofunction",
-            "Adrenocortical Insufficiency",
-            "adrenocortical insufficiency",
-            "Corticoadrenal insufficiency",
-            "Adrenal gland hypofunction",
-            "Adrenal Insufficiency",
-            "Adrenal insufficiency",
-            "Adrenal cortical hypofunction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:11443143"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-              "name": "adrenocortical insufficiency",
-              "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0405580",
-                "MEDDRA:10022460",
-                "ICD9:255.4",
-                "EFO:0009491",
-                "MEDDRA:10001367",
-                "MEDDRA:10020936",
-                "MONDO:0000004",
-                "MEDDRA:10020979",
-                "SNOMEDCT:237785004",
-                "SNOMEDCT:386584007",
-                "MEDDRA:10056485",
-                "MEDDRA:10082130",
-                "UMLS:C0001623",
-                "MEDDRA:10001344",
-                "MEDDRA:10001366",
-                "MEDDRA:10001334",
-                "DOID:10493",
-                "NCIT:C26691",
-                "HP:0000846",
-                "MEDDRA:10001335",
-                "MEDDRA:10001369",
-                "MEDDRA:10001342",
-                "MEDDRA:10001343",
-                "MESH:D000309",
-                "SNOMEDCT:111563005",
-                "MEDDRA:10011172",
-                "MEDDRA:10022461"
-              ],
-              "id": "MONDO:0000004",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortical hypofunction",
-                "Adrenocortical Insufficiency",
-                "adrenocortical insufficiency",
-                "Corticoadrenal insufficiency",
-                "Adrenal gland hypofunction",
-                "Adrenal Insufficiency",
-                "Adrenal insufficiency",
-                "Adrenal cortical hypofunction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:11443143"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 27237612,
-            "start": 569,
-            "end": 312686,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9815636': {'publication date': '1997 Dec', 'sentence': 'Replacement doses of hydrocortisone were administered throughout treatment to counteract potential adrenal insufficiency secondary to the ketoconazole.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:disrupts---None---None---None---UMLS:C0001623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "27711985",
-              "object": "MONDO:0000004",
-              "publications": [
-                "PMID:9815636"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:23729712': {'publication date': '2013 May 31', 'sentence': 'Hydrocortisone therapy was started to prevent adrenal insufficiency before laboratory findings for ACTH (adrenocorticotropic hormone) and cortisol levels.', 'subject score': 888, 'object score': 1000}, 'PMID:32942788': {'publication date': '2020 Aug', 'sentence': 'However, there was no difference in the extent of reduction in SC concentration after ESI, the occurrence of AI, and pain reduction.', 'subject score': 851, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 312686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-          "name": "adrenocortical insufficiency",
-          "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0405580",
-            "MEDDRA:10022460",
-            "ICD9:255.4",
-            "EFO:0009491",
-            "MEDDRA:10001367",
-            "MEDDRA:10020936",
-            "MONDO:0000004",
-            "MEDDRA:10020979",
-            "SNOMEDCT:237785004",
-            "SNOMEDCT:386584007",
-            "MEDDRA:10056485",
-            "MEDDRA:10082130",
-            "UMLS:C0001623",
-            "MEDDRA:10001344",
-            "MEDDRA:10001366",
-            "MEDDRA:10001334",
-            "DOID:10493",
-            "NCIT:C26691",
-            "HP:0000846",
-            "MEDDRA:10001335",
-            "MEDDRA:10001369",
-            "MEDDRA:10001342",
-            "MEDDRA:10001343",
-            "MESH:D000309",
-            "SNOMEDCT:111563005",
-            "MEDDRA:10011172",
-            "MEDDRA:10022461"
-          ],
-          "id": "MONDO:0000004",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortical hypofunction",
-            "Adrenocortical Insufficiency",
-            "adrenocortical insufficiency",
-            "Corticoadrenal insufficiency",
-            "Adrenal gland hypofunction",
-            "Adrenal Insufficiency",
-            "Adrenal insufficiency",
-            "Adrenal cortical hypofunction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:11443143"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-              "name": "adrenocortical insufficiency",
-              "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0405580",
-                "MEDDRA:10022460",
-                "ICD9:255.4",
-                "EFO:0009491",
-                "MEDDRA:10001367",
-                "MEDDRA:10020936",
-                "MONDO:0000004",
-                "MEDDRA:10020979",
-                "SNOMEDCT:237785004",
-                "SNOMEDCT:386584007",
-                "MEDDRA:10056485",
-                "MEDDRA:10082130",
-                "UMLS:C0001623",
-                "MEDDRA:10001344",
-                "MEDDRA:10001366",
-                "MEDDRA:10001334",
-                "DOID:10493",
-                "NCIT:C26691",
-                "HP:0000846",
-                "MEDDRA:10001335",
-                "MEDDRA:10001369",
-                "MEDDRA:10001342",
-                "MEDDRA:10001343",
-                "MESH:D000309",
-                "SNOMEDCT:111563005",
-                "MEDDRA:10011172",
-                "MEDDRA:10022461"
-              ],
-              "id": "MONDO:0000004",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortical hypofunction",
-                "Adrenocortical Insufficiency",
-                "adrenocortical insufficiency",
-                "Corticoadrenal insufficiency",
-                "Adrenal gland hypofunction",
-                "Adrenal Insufficiency",
-                "Adrenal insufficiency",
-                "Adrenal cortical hypofunction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:11443143"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16620721,
-            "start": 569,
-            "end": 312686,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23729712': {'publication date': '2013 May 31', 'sentence': 'Hydrocortisone therapy was started to prevent adrenal insufficiency before laboratory findings for ACTH (adrenocorticotropic hormone) and cortisol levels.', 'subject score': 888, 'object score': 1000}, 'PMID:32942788': {'publication date': '2020 Aug', 'sentence': 'However, there was no difference in the extent of reduction in SC concentration after ESI, the occurrence of AI, and pain reduction.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0001623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "16963888",
-              "object": "MONDO:0000004",
-              "publications": [
-                "PMID:23729712",
-                "PMID:32942788"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:10425468': {'publication date': '1999 Aug', 'sentence': 'November, a period of reproductive quiescence in the southern hemisphere, with new antler growth and rapid weight gain, is associated with higher mean plasma cortisol concentrations and a greater responsiveness to exogenous ACTH.', 'subject score': 777, 'object score': 901}, 'PMID:12168818': {'publication date': '2002 May-Jun', 'sentence': 'The incidence of ML-3 tumor in the hydrocortisone group was significantly higher than that of the saline, RU486, or hydrocortisone plus RU486 groups.', 'subject score': 833, 'object score': 802}, 'PMID:1580560': {'publication date': '1992 Mar-Apr', 'sentence': 'Inverse relationship between tumor susceptibility and salt-hydrocortisone conditioned acceleration of water turnover in rodents.', 'subject score': 888, 'object score': 888}, 'PMID:2157992': {'publication date': '1990 Mar', 'sentence': 'There was no consistent change in CVD of endoplasmic reticulum, Golgi apparatus or secretory granules in adenoma cells incubated with cortisol, but in all tumors there were marked filament accumulations indicating a direct effect of cortisol on adenomatous corticotrophs.', 'subject score': 1000, 'object score': 1000}, 'PMID:27824928': {'publication date': '2016', 'sentence': 'In some animal species, including dogs, the aberrant expression of 11beta-hydroxysteroid dehydrogenase (11HSD), a cortisol metabolic enzyme, is observed in corticotroph tumors.', 'subject score': 851, 'object score': 861}, 'PMID:3000651': {'publication date': '1985 Sep', 'sentence': 'Cortisol and oCRF have been shown in one tumour to have antagonistic actions at the pituitary level.', 'subject score': 1000, 'object score': 888}, 'PMID:32413902': {'publication date': '2020 May 15', 'sentence': 'ACS showed a higher risk of incident AF than NST (HR 2.95; 95%CI 1.27-6.86; P=0.012), which was associated with post-dexamethasone cortisol (HR 1.15; 95%CI 1.07-1.24; P<0.001), independently of known contributing factors.', 'subject score': 851, 'object score': 851}, 'PMID:33221858': {'publication date': '2020 Nov 21', 'sentence': 'CONTEXT: Pituitary corticotroph adenomas are rare tumors that can be associated with excess adrenocorticotropic hormone (ACTH) and adrenal cortisol production, resulting in the clinically debilitating endocrine condition Cushing disease.', 'subject score': 790, 'object score': 888}, 'PMID:34076197': {'publication date': '2021', 'sentence': 'Salivary cortisol concentrations in hematogy/oncology nurses on working days and days off.', 'subject score': 851, 'object score': 861}, 'PMID:35451730': {'publication date': '2022 Apr 22', 'sentence': 'Indeed, the ACTH and cortisol responsiveness to DDAVP was greater in USP8 mutation positive tumors than that in USP8 wild type tumors (3.0-fold vs. 1.3-fold, 1.6-fold vs. 1.1-fold, respectively).', 'subject score': 853, 'object score': 851}, 'PMID:5520844': {'publication date': '1970', 'sentence': 'Facilitated metastatic distribution of the Walker 256 tumor in Sprague-Dawley rats with hydrocortisone and-or cyclophosphamide.', 'subject score': 1000, 'object score': 802}, 'PMID:6145833': {'publication date': '1984 Jun 23', 'sentence': \"Dissociation between plasma adrenal androgens and cortisol in Cushing's disease and ectopic ACTH-producing tumour: relation to adrenarche.\", 'subject score': 1000, 'object score': 824}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7419674,
-            "start": 569,
-            "end": 319673,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10425468': {'publication date': '1999 Aug', 'sentence': 'November, a period of reproductive quiescence in the southern hemisphere, with new antler growth and rapid weight gain, is associated with higher mean plasma cortisol concentrations and a greater responsiveness to exogenous ACTH.', 'subject score': 777, 'object score': 901}, 'PMID:12168818': {'publication date': '2002 May-Jun', 'sentence': 'The incidence of ML-3 tumor in the hydrocortisone group was significantly higher than that of the saline, RU486, or hydrocortisone plus RU486 groups.', 'subject score': 833, 'object score': 802}, 'PMID:1580560': {'publication date': '1992 Mar-Apr', 'sentence': 'Inverse relationship between tumor susceptibility and salt-hydrocortisone conditioned acceleration of water turnover in rodents.', 'subject score': 888, 'object score': 888}, 'PMID:2157992': {'publication date': '1990 Mar', 'sentence': 'There was no consistent change in CVD of endoplasmic reticulum, Golgi apparatus or secretory granules in adenoma cells incubated with cortisol, but in all tumors there were marked filament accumulations indicating a direct effect of cortisol on adenomatous corticotrophs.', 'subject score': 1000, 'object score': 1000}, 'PMID:27824928': {'publication date': '2016', 'sentence': 'In some animal species, including dogs, the aberrant expression of 11beta-hydroxysteroid dehydrogenase (11HSD), a cortisol metabolic enzyme, is observed in corticotroph tumors.', 'subject score': 851, 'object score': 861}, 'PMID:3000651': {'publication date': '1985 Sep', 'sentence': 'Cortisol and oCRF have been shown in one tumour to have antagonistic actions at the pituitary level.', 'subject score': 1000, 'object score': 888}, 'PMID:32413902': {'publication date': '2020 May 15', 'sentence': 'ACS showed a higher risk of incident AF than NST (HR 2.95; 95%CI 1.27-6.86; P=0.012), which was associated with post-dexamethasone cortisol (HR 1.15; 95%CI 1.07-1.24; P<0.001), independently of known contributing factors.', 'subject score': 851, 'object score': 851}, 'PMID:33221858': {'publication date': '2020 Nov 21', 'sentence': 'CONTEXT: Pituitary corticotroph adenomas are rare tumors that can be associated with excess adrenocorticotropic hormone (ACTH) and adrenal cortisol production, resulting in the clinically debilitating endocrine condition Cushing disease.', 'subject score': 790, 'object score': 888}, 'PMID:34076197': {'publication date': '2021', 'sentence': 'Salivary cortisol concentrations in hematogy/oncology nurses on working days and days off.', 'subject score': 851, 'object score': 861}, 'PMID:35451730': {'publication date': '2022 Apr 22', 'sentence': 'Indeed, the ACTH and cortisol responsiveness to DDAVP was greater in USP8 mutation positive tumors than that in USP8 wild type tumors (3.0-fold vs. 1.3-fold, 1.6-fold vs. 1.1-fold, respectively).', 'subject score': 853, 'object score': 851}, 'PMID:5520844': {'publication date': '1970', 'sentence': 'Facilitated metastatic distribution of the Walker 256 tumor in Sprague-Dawley rats with hydrocortisone and-or cyclophosphamide.', 'subject score': 1000, 'object score': 802}, 'PMID:6145833': {'publication date': '1984 Jun 23', 'sentence': \"Dissociation between plasma adrenal androgens and cortisol in Cushing's disease and ectopic ACTH-producing tumour: relation to adrenarche.\", 'subject score': 1000, 'object score': 824}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7573954",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:10425468",
-                "PMID:12168818",
-                "PMID:1580560",
-                "PMID:2157992",
-                "PMID:27824928",
-                "PMID:3000651",
-                "PMID:32413902",
-                "PMID:33221858",
-                "PMID:34076197",
-                "PMID:35451730",
-                "PMID:5520844",
-                "PMID:6145833"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 318216,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318216,
-            "labels": [
-              "biolink:BehavioralFeature",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7042224,
-            "start": 569,
-            "end": 318216,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10084590': {'publication date': '1999 Mar', 'sentence': 'Cortisol metabolism in human obesity: impaired cortisone-->cortisol conversion in subjects with central adiposity.', 'subject score': 888, 'object score': 888}, 'PMID:10678256': {'publication date': '2000 Jan', 'sentence': 'RESEARCH METHODS AND PROCEDURES: Body composition (DXA), visceral obesity (computed tomography), leptin, cortisol, insulin, and sex hormone-binding globulin (SHBG) concentrations were measured in 54 obese (body mass index [BMI] = 32.0+/-4.5 kg/m2; mean +/- SD), women (60+/-6 years) before and after a 6-month hypocaloric diet (250 to 350 kcal/day deficit).', 'subject score': 1000, 'object score': 861}, 'PMID:10692082': {'publication date': '2000 Feb', 'sentence': 'RESULTS: Plasma cortisol was lower in relatively obese subjects: in men, this was observed only in the 2 h sample (r = -0.23, P = 0.02) and in women only in the fasting sample (r = -0.26, P < 0.01).', 'subject score': 888, 'object score': 773}, 'PMID:10997615': {'publication date': '2000 Jun', 'sentence': 'Indeed, obesity, mostly visceral type, is associated with an increased cortisol clearance and 11-beta hydroxysteroid dehydrogenase activity in the omental fat.', 'subject score': 851, 'object score': 1000}, 'PMID:11050809': {'publication date': '2000', 'sentence': 'In DM (47/48) total urinary cortisol (UF) levels were similar to those found in Ob and N.', 'subject score': 851, 'object score': 1000}, 'PMID:11054598': {'publication date': '2000 Oct', 'sentence': 'Cortisol in obesity is a much-studied problem.', 'subject score': 1000, 'object score': 1000}, 'PMID:11095438': {'publication date': '2000 Nov', 'sentence': 'Anxiety and depression may be associated with oversecretion of cortisol and could represent a confounding factor in the evaluation of the HPA axis in different obesity phenotypes.', 'subject score': 1000, 'object score': 828}, 'PMID:11238541': {'publication date': '2001 Mar', 'sentence': 'This study addressed whether the same tissue-specific disruption of cortisol metabolism occurs in human obesity.', 'subject score': 888, 'object score': 888}, 'PMID:11316764': {'publication date': '2001 May', 'sentence': 'This autocrine and/or paracrine regulation is tissue specific and explains recent clinical data and animal studies evaluating cortisol metabolism in obesity.', 'subject score': 888, 'object score': 1000}, 'PMID:115194': {'publication date': '1979 Aug', 'sentence': \"Results before fasting: T4, T3, TBG, cortisol, CBG, alpha 2-haptoglobin and complement C'3 of the obese patients were elevated when compared with healthy normal weight controls, whereas rT3, T4/TBG ratio, T3/TBG ratio, TSH, coritsol/cbg ratio, growth hormone, prolactin, parathyrin and transferrin of the obese group were normal.\", 'subject score': 1000, 'object score': 888}, 'PMID:11527096': {'publication date': '2001 Jun', 'sentence': 'Most intriguingly, the changes in 11beta-HSD1 are tissue-specific, and generation of cortisol from inactive cortisone appears to be increased in adipose tissue in obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:12055988': {'publication date': '2002 Mar', 'sentence': \"The increase in cortisol secretion in obesity needs to be distinguished from Cushing's syndrome, the decrease in thyroid hormone levels in anorexia nervosa needs to be distinguished from secondary hypothyroidism, and the increase in cortisol secretion observed in anorexia nervosa requires a differential diagnosis with primary depressive disorder.\", 'subject score': 888, 'object score': 1000}, 'PMID:12105278': {'publication date': '2002 Jul', 'sentence': 'OBJECTIVE: There is considerable evidence that cortisol secretion is associated with obesity.', 'subject score': 888, 'object score': 1000}, 'PMID:12161549': {'publication date': '2002 Aug', 'sentence': 'Because hypothalamic lesions may explain daytime sleepiness in craniopharyngioma patients, salivary melatonin and cortisol concentrations were examined in obese and nonobese craniopharyngioma patients (n = 79), patients with hypothalamic pilocytic astrocytoma (n = 19), and control subjects (n = 30).', 'subject score': 888, 'object score': 1000}, 'PMID:1231837': {'publication date': '1975 Nov 15', 'sentence': '[Biorhythm of plasma cortisol in obesity].', 'subject score': 888, 'object score': 1000}, 'PMID:12788882': {'publication date': '2003 Jun', 'sentence': 'Our data support the hypothesis that increased regeneration of cortisol in adipose tissue influences metabolic sequelae of human obesity.', 'subject score': 1000, 'object score': 888}, 'PMID:1298871': {'publication date': '1992 Jul-Sep', 'sentence': '[Effect of 5-hydroxytryptophan on the secretion of PRL, GH, TSH and cortisol in obesity].', 'subject score': 1000, 'object score': 1000}, 'PMID:1319389': {'publication date': '1992 Jan', 'sentence': 'Effects of naloxone on adrenocorticotrophin (ACTH) and cortisol in obese subjects.', 'subject score': 1000, 'object score': 872}, 'PMID:14216471': {'publication date': '1964 Sep', 'sentence': 'CORTISOL METABOLISM IN OBESITY.', 'subject score': 888, 'object score': 1000}, 'PMID:14474905': {'publication date': '1962 Jun', 'sentence': 'Cortisol production rates in obesity.', 'subject score': 840, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0028754---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7182905",
-              "object": "MONDO:0011122",
-              "publications": [
-                "PMID:10084590",
-                "PMID:10678256",
-                "PMID:10692082",
-                "PMID:10997615",
-                "PMID:11050809",
-                "PMID:11054598",
-                "PMID:11095438",
-                "PMID:11238541",
-                "PMID:11316764",
-                "PMID:115194",
-                "PMID:11527096",
-                "PMID:12055988",
-                "PMID:12105278",
-                "PMID:12161549",
-                "PMID:1231837",
-                "PMID:12788882",
-                "PMID:1298871",
-                "PMID:1319389",
-                "PMID:14216471",
-                "PMID:14474905"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 183319,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:1116140': {'publication date': '1975 Apr', 'sentence': 'The administration of hydrocortisone before tumor inoculation resulted in increased tumor take, reduced mean survival time of mice, and concentration of tumor metastasis in a specific organ (i.e., lung metastasis for Ehrlich hypotetraploid clone 1 tumor, and liver metastasis for Ehrlich hypotetraploid stock and Ehrlich hyperdiploid stock tumors).', 'subject score': 1000, 'object score': 888}, 'PMID:18034306': {'publication date': '2008', 'sentence': 'CS can be ACTH-dependent, caused by ACTH-secreting pituitary or ectopic tumours, or ACTH-independent, caused by cortisol-secreting adrenal tumours.', 'subject score': 1000, 'object score': 888}, 'PMID:2017766': {'publication date': '1991 Mar 25', 'sentence': 'MB, CORT, IND, or the injection vehicle (water) alone did not produce tumors.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319673,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 183319,
-=======
-            "identity": 319673,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 24003863,
-            "start": 183319,
-            "end": 569,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35472267': {'publication date': '2022 Apr', 'sentence': 'The hypothalamic-pituitary-adrenal (HPA) axis is one of the key physiological systems that counterbalances this systemic inflammation through changes in adrenocorticotrophic hormone (ACTH) and cortisol.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0021368---SEMMEDDB:associated_with---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "NCIT:C3137",
-              "id": "24445107",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:35472267"
-=======
-            "identity": 8472799,
-            "start": 569,
-            "end": 319673,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1116140': {'publication date': '1975 Apr', 'sentence': 'The administration of hydrocortisone before tumor inoculation resulted in increased tumor take, reduced mean survival time of mice, and concentration of tumor metastasis in a specific organ (i.e., lung metastasis for Ehrlich hypotetraploid clone 1 tumor, and liver metastasis for Ehrlich hypotetraploid stock and Ehrlich hyperdiploid stock tumors).', 'subject score': 1000, 'object score': 888}, 'PMID:18034306': {'publication date': '2008', 'sentence': 'CS can be ACTH-dependent, caused by ACTH-secreting pituitary or ectopic tumours, or ACTH-independent, caused by cortisol-secreting adrenal tumours.', 'subject score': 1000, 'object score': 888}, 'PMID:2017766': {'publication date': '1991 Mar 25', 'sentence': 'MB, CORT, IND, or the injection vehicle (water) alone did not produce tumors.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8657746",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:1116140",
-                "PMID:18034306",
-                "PMID:2017766"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:12076698': {'publication date': '2002 Jun', 'sentence': 'To prolong the anti-tumor effect some mice were also given cyclophosphamide, hydrocortisone, or a second injection of virus.', 'subject score': 1000, 'object score': 790}, 'PMID:13600766': {'publication date': '1958', 'sentence': 'Topical effects of cortisol upon Walker tumors.', 'subject score': 1000, 'object score': 888}, 'PMID:2017766': {'publication date': '1991 Mar 25', 'sentence': 'Although local treatment with CORT or IND had no significant effect on the final tumor incidence by Ni3S2, it shortened the latency of tumors to 17 weeks compared with 23 weeks for Ni3S2 alone.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9403336,
-            "start": 569,
-            "end": 319673,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12076698': {'publication date': '2002 Jun', 'sentence': 'To prolong the anti-tumor effect some mice were also given cyclophosphamide, hydrocortisone, or a second injection of virus.', 'subject score': 1000, 'object score': 790}, 'PMID:13600766': {'publication date': '1958', 'sentence': 'Topical effects of cortisol upon Walker tumors.', 'subject score': 1000, 'object score': 888}, 'PMID:2017766': {'publication date': '1991 Mar 25', 'sentence': 'Although local treatment with CORT or IND had no significant effect on the final tumor incidence by Ni3S2, it shortened the latency of tumors to 17 weeks compared with 23 weeks for Ni3S2 alone.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9610203",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:12076698",
-                "PMID:13600766",
-                "PMID:2017766"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:16740975': {'publication date': '2006 Sep', 'sentence': 'Retinoic acid treatment controls ACTH and cortisol hyperactivity and tumor size in dogs with ACTH-secreting tumors, leading to resolution of the clinical phenotype.', 'subject score': 888, 'object score': 802}, 'PMID:2417679': {'publication date': '1986 Feb 01', 'sentence': 'Extracts of tumors from control animals as well as from animals treated with HHS plus HC were prepared for quantitative testing in vitro by endothelial cell migration assay.', 'subject score': 875, 'object score': 1000}, 'PMID:2548970': {'publication date': '1989 May-Jun', 'sentence': 'We investigated plasma levels of cortisol and ACTH in 9 patients with advanced metastatic tumors before and during treatment with interferon-gamma (IFN-gamma), 2-4 h after administration of IFN-gamma there was a sharp rise in plasma cortisol levels.', 'subject score': 1000, 'object score': 827}, 'PMID:2773484': {'publication date': '1989 Jul 14', 'sentence': 'On the basis of approximately 3000 assays of HGH, prolactin, thyroglobulin, calcitonin, CEA, insulin, gastrin, cortisol and aldosterone (in part with suppression and/or stimulation techniques), it is shown that these mostly indirect tumour marker assays are very important in follow-up programmes after therapy of neoplasms of the endocrine system.', 'subject score': 1000, 'object score': 1000}, 'PMID:32686618': {'publication date': '2020 Jul 19', 'sentence': 'Effect of hydrocortisone versus methylprednisolone on clinical outcomes in oncology patients with septic shock.BACKGROUND: Corticosteroids are used as adjunctive treatment of critical illness-related corticosteroid insufficiency in patients with septic shock.', 'subject score': 1000, 'object score': 888}, 'PMID:468890': {'publication date': '1979 Apr 12', 'sentence': 'The first detectable increase of cortisol occurred in patients with tumors classified T 2 according to the TNM scheme (+27% above the control).', 'subject score': 1000, 'object score': 1000}, 'PMID:6405459': {'publication date': '1983', 'sentence': 'In the type III lactating tumors, the total tRNA methyltransferases were inhibited by 35% after cortisol treatment.', 'subject score': 888, 'object score': 852}, 'PMID:6931263': {'publication date': '1980 Aug', 'sentence': 'These data indicate that tumors of lymphosarcoma P1798 became resistant to cortisol in a size-dependent manner.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12257628,
-            "start": 569,
-            "end": 319673,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16740975': {'publication date': '2006 Sep', 'sentence': 'Retinoic acid treatment controls ACTH and cortisol hyperactivity and tumor size in dogs with ACTH-secreting tumors, leading to resolution of the clinical phenotype.', 'subject score': 888, 'object score': 802}, 'PMID:2417679': {'publication date': '1986 Feb 01', 'sentence': 'Extracts of tumors from control animals as well as from animals treated with HHS plus HC were prepared for quantitative testing in vitro by endothelial cell migration assay.', 'subject score': 875, 'object score': 1000}, 'PMID:2548970': {'publication date': '1989 May-Jun', 'sentence': 'We investigated plasma levels of cortisol and ACTH in 9 patients with advanced metastatic tumors before and during treatment with interferon-gamma (IFN-gamma), 2-4 h after administration of IFN-gamma there was a sharp rise in plasma cortisol levels.', 'subject score': 1000, 'object score': 827}, 'PMID:2773484': {'publication date': '1989 Jul 14', 'sentence': 'On the basis of approximately 3000 assays of HGH, prolactin, thyroglobulin, calcitonin, CEA, insulin, gastrin, cortisol and aldosterone (in part with suppression and/or stimulation techniques), it is shown that these mostly indirect tumour marker assays are very important in follow-up programmes after therapy of neoplasms of the endocrine system.', 'subject score': 1000, 'object score': 1000}, 'PMID:32686618': {'publication date': '2020 Jul 19', 'sentence': 'Effect of hydrocortisone versus methylprednisolone on clinical outcomes in oncology patients with septic shock.BACKGROUND: Corticosteroids are used as adjunctive treatment of critical illness-related corticosteroid insufficiency in patients with septic shock.', 'subject score': 1000, 'object score': 888}, 'PMID:468890': {'publication date': '1979 Apr 12', 'sentence': 'The first detectable increase of cortisol occurred in patients with tumors classified T 2 according to the TNM scheme (+27% above the control).', 'subject score': 1000, 'object score': 1000}, 'PMID:6405459': {'publication date': '1983', 'sentence': 'In the type III lactating tumors, the total tRNA methyltransferases were inhibited by 35% after cortisol treatment.', 'subject score': 888, 'object score': 852}, 'PMID:6931263': {'publication date': '1980 Aug', 'sentence': 'These data indicate that tumors of lymphosarcoma P1798 became resistant to cortisol in a size-dependent manner.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "12524121",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:16740975",
-                "PMID:2417679",
-                "PMID:2548970",
-                "PMID:2773484",
-                "PMID:32686618",
-                "PMID:468890",
-                "PMID:6405459",
-                "PMID:6931263"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:produces",
-    "r2.publications_info": "{'PMID:10730906': {'publication date': '1999 Dec', 'sentence': 'The tumour secreted excessive cortisol and dehydroepiandrosterone-sulphate (DHEA-S), and had invaded the right hepatic lobe and vena cava.', 'subject score': 1000, 'object score': 888}, 'PMID:11281375': {'publication date': '2000 Dec', 'sentence': \"However, in 5%-12% of the patients a preclinical Cushing's syndrome (PCS) with autonomous cortisol production by the tumour is present.\", 'subject score': 1000, 'object score': 828}, 'PMID:11456263': {'publication date': '2001 Apr', 'sentence': \"Dehydroepiandrosterone-sulfotransferase (DHEA-ST) immunoreactivity in nonneoplastic regions was suppressed in one case in which the tumor secreted cortisol similar to preclinical and/or overt Cushing's syndrome.\", 'subject score': 1000, 'object score': 1000}, 'PMID:11588777': {'publication date': '2001', 'sentence': 'ACE and GR II were detected in the tissues of the adrenal cortex and cortisol-producing tumors.', 'subject score': 802, 'object score': 802}, 'PMID:14567506': {'publication date': '2003 Aug', 'sentence': 'The clear cells in the tumor were admixed with small numbers of compact cells that expressed 17alpha-hydroxylase, suggesting that the tumor was able to produce and secrete cortisol.', 'subject score': 1000, 'object score': 1000}, 'PMID:15012620': {'publication date': '2004 Mar', 'sentence': 'The cortisol-producing tumours appear to have increased angiogenic potential.', 'subject score': 802, 'object score': 802}, 'PMID:15069374': {'publication date': '2004 Feb 26', 'sentence': 'These tumors most commonly produce cortisol (30%), then androgens (20%), estrogens (10%) or aldosterone (2%).', 'subject score': 861, 'object score': 1000}, 'PMID:15145240': {'publication date': '2004 Jun', 'sentence': \"Although these tumors do not secrete enough cortisol to lead to the development of overt Cushing's syndrome, they are likely playing a contributory role in the development of hypertension, diabetes, osteoporosis, and obesity.\", 'subject score': 1000, 'object score': 1000}, 'PMID:1580324': {'publication date': '1992 May', 'sentence': \"This finding suggests that cortisol production by tumor is a determinant factor in hypertension in Cushing's syndrome.\", 'subject score': 1000, 'object score': 888}, 'PMID:15805423': {'publication date': '2005 Apr', 'sentence': 'In cortisol-producing tumors, non-tumor parts of the cortex, which were generally atrophic due to low ACTH, had less B1 protein than normal adrenals.', 'subject score': 802, 'object score': 802}, 'PMID:1606918': {'publication date': '1992 Feb', 'sentence': \"It is suggested that the tumor autonomously produced a small amount of cortisol not only insufficient to provide clinical Cushing's syndrome, but also to provide typical suppression of hypothalamo-pituitary corticotroph-adrenal system.\", 'subject score': 1000, 'object score': 1000}, 'PMID:16791399': {'publication date': '2006 Jun', 'sentence': 'Immunohistochemical staining for the enzymes involved in cortisol biosynthesis suggested that the upper tumor secreted aldosterone, whereas either or both of the two other tumors secreted cortisol.', 'subject score': 1000, 'object score': 1000}, 'PMID:16927063': {'publication date': '2006 Sep', 'sentence': 'METHODS: An autonomous cortisol-producing tumor was detected in 11 of 94 patients with adrenal incidentaloma between 1995 and 2005.', 'subject score': 751, 'object score': 751}, 'PMID:17408424': {'publication date': '2007 Jun', 'sentence': 'Immunohistochemical analysis confirmed CYP17, HSD3B2, SULT2A1 and CYB5 expression by all cortisol-producing tumours.', 'subject score': 802, 'object score': 802}, 'PMID:1745970': {'publication date': '1991 Dec', 'sentence': 'Studies to evaluate biochemical hyperfunction were performed in 172 patients (50%), 2 of whom were found to have cortisol-producing tumors and 5 pheochromocytomas.', 'subject score': 802, 'object score': 802}, 'PMID:18406701': {'publication date': '1995 Aug', 'sentence': 'Recent studies of the function of adrenal \"incidentalomas\" have revealed that a proportion of those tumors secrete cortisol insufficiently to produce overt clinical Cushing s syndrome, but that their autonomous cortisol production can suppress the hypothalamo-pituitaryadrenal (HPA) axis to various degrees; this needs to be recognized to avoid acute adrenal insufficiency after adrenalectomy.', 'subject score': 1000, 'object score': 861}, 'PMID:18543063': {'publication date': '2008 Oct', 'sentence': 'The results of a subsequent adrenal venous catheterization study were consistent with the presence of a left cortisol-producing tumor and a right aldosterone-producing tumor.', 'subject score': 775, 'object score': 775}, 'PMID:18926198': {'publication date': '2008 Oct', 'sentence': 'Some of these tumors secrete abnormally high levels of cortisol, suppressing function of the contralateral adrenal gland and, thus, leading to life-threatening postoperative adrenal insufficiency.', 'subject score': 1000, 'object score': 1000}, 'PMID:2232630': {'publication date': '1990 Oct 03', 'sentence': 'The tumor appeared to produce autonomously cortisol as well as corticosterone, 18-hydroxycorticosterone and aldosterone.', 'subject score': 1000, 'object score': 861}, 'PMID:22328110': {'publication date': '2012 Apr', 'sentence': 'CONCLUSION: We demonstrated that subtle cortisol-producing tumors, such as SH as well as SubCS, were an independent risk factor for hypertension.', 'subject score': 763, 'object score': 763}}",
-    "p2": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7908233,
-            "start": 319673,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10730906': {'publication date': '1999 Dec', 'sentence': 'The tumour secreted excessive cortisol and dehydroepiandrosterone-sulphate (DHEA-S), and had invaded the right hepatic lobe and vena cava.', 'subject score': 1000, 'object score': 888}, 'PMID:11281375': {'publication date': '2000 Dec', 'sentence': \"However, in 5%-12% of the patients a preclinical Cushing's syndrome (PCS) with autonomous cortisol production by the tumour is present.\", 'subject score': 1000, 'object score': 828}, 'PMID:11456263': {'publication date': '2001 Apr', 'sentence': \"Dehydroepiandrosterone-sulfotransferase (DHEA-ST) immunoreactivity in nonneoplastic regions was suppressed in one case in which the tumor secreted cortisol similar to preclinical and/or overt Cushing's syndrome.\", 'subject score': 1000, 'object score': 1000}, 'PMID:11588777': {'publication date': '2001', 'sentence': 'ACE and GR II were detected in the tissues of the adrenal cortex and cortisol-producing tumors.', 'subject score': 802, 'object score': 802}, 'PMID:14567506': {'publication date': '2003 Aug', 'sentence': 'The clear cells in the tumor were admixed with small numbers of compact cells that expressed 17alpha-hydroxylase, suggesting that the tumor was able to produce and secrete cortisol.', 'subject score': 1000, 'object score': 1000}, 'PMID:15012620': {'publication date': '2004 Mar', 'sentence': 'The cortisol-producing tumours appear to have increased angiogenic potential.', 'subject score': 802, 'object score': 802}, 'PMID:15069374': {'publication date': '2004 Feb 26', 'sentence': 'These tumors most commonly produce cortisol (30%), then androgens (20%), estrogens (10%) or aldosterone (2%).', 'subject score': 861, 'object score': 1000}, 'PMID:15145240': {'publication date': '2004 Jun', 'sentence': \"Although these tumors do not secrete enough cortisol to lead to the development of overt Cushing's syndrome, they are likely playing a contributory role in the development of hypertension, diabetes, osteoporosis, and obesity.\", 'subject score': 1000, 'object score': 1000}, 'PMID:1580324': {'publication date': '1992 May', 'sentence': \"This finding suggests that cortisol production by tumor is a determinant factor in hypertension in Cushing's syndrome.\", 'subject score': 1000, 'object score': 888}, 'PMID:15805423': {'publication date': '2005 Apr', 'sentence': 'In cortisol-producing tumors, non-tumor parts of the cortex, which were generally atrophic due to low ACTH, had less B1 protein than normal adrenals.', 'subject score': 802, 'object score': 802}, 'PMID:1606918': {'publication date': '1992 Feb', 'sentence': \"It is suggested that the tumor autonomously produced a small amount of cortisol not only insufficient to provide clinical Cushing's syndrome, but also to provide typical suppression of hypothalamo-pituitary corticotroph-adrenal system.\", 'subject score': 1000, 'object score': 1000}, 'PMID:16791399': {'publication date': '2006 Jun', 'sentence': 'Immunohistochemical staining for the enzymes involved in cortisol biosynthesis suggested that the upper tumor secreted aldosterone, whereas either or both of the two other tumors secreted cortisol.', 'subject score': 1000, 'object score': 1000}, 'PMID:16927063': {'publication date': '2006 Sep', 'sentence': 'METHODS: An autonomous cortisol-producing tumor was detected in 11 of 94 patients with adrenal incidentaloma between 1995 and 2005.', 'subject score': 751, 'object score': 751}, 'PMID:17408424': {'publication date': '2007 Jun', 'sentence': 'Immunohistochemical analysis confirmed CYP17, HSD3B2, SULT2A1 and CYB5 expression by all cortisol-producing tumours.', 'subject score': 802, 'object score': 802}, 'PMID:1745970': {'publication date': '1991 Dec', 'sentence': 'Studies to evaluate biochemical hyperfunction were performed in 172 patients (50%), 2 of whom were found to have cortisol-producing tumors and 5 pheochromocytomas.', 'subject score': 802, 'object score': 802}, 'PMID:18406701': {'publication date': '1995 Aug', 'sentence': 'Recent studies of the function of adrenal \"incidentalomas\" have revealed that a proportion of those tumors secrete cortisol insufficiently to produce overt clinical Cushing s syndrome, but that their autonomous cortisol production can suppress the hypothalamo-pituitaryadrenal (HPA) axis to various degrees; this needs to be recognized to avoid acute adrenal insufficiency after adrenalectomy.', 'subject score': 1000, 'object score': 861}, 'PMID:18543063': {'publication date': '2008 Oct', 'sentence': 'The results of a subsequent adrenal venous catheterization study were consistent with the presence of a left cortisol-producing tumor and a right aldosterone-producing tumor.', 'subject score': 775, 'object score': 775}, 'PMID:18926198': {'publication date': '2008 Oct', 'sentence': 'Some of these tumors secrete abnormally high levels of cortisol, suppressing function of the contralateral adrenal gland and, thus, leading to life-threatening postoperative adrenal insufficiency.', 'subject score': 1000, 'object score': 1000}, 'PMID:2232630': {'publication date': '1990 Oct 03', 'sentence': 'The tumor appeared to produce autonomously cortisol as well as corticosterone, 18-hydroxycorticosterone and aldosterone.', 'subject score': 1000, 'object score': 861}, 'PMID:22328110': {'publication date': '2012 Apr', 'sentence': 'CONCLUSION: We demonstrated that subtle cortisol-producing tumors, such as SH as well as SubCS, were an independent risk factor for hypertension.', 'subject score': 763, 'object score': 763}}",
-              "kg2_ids": [
-                "UMLS:C0027651---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0005070",
-              "id": "8077250",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:10730906",
-                "PMID:11281375",
-                "PMID:11456263",
-                "PMID:11588777",
-                "PMID:14567506",
-                "PMID:15012620",
-                "PMID:15069374",
-                "PMID:15145240",
-                "PMID:1580324",
-                "PMID:15805423",
-                "PMID:1606918",
-                "PMID:16791399",
-                "PMID:16927063",
-                "PMID:17408424",
-                "PMID:1745970",
-                "PMID:18406701",
-                "PMID:18543063",
-                "PMID:18926198",
-                "PMID:2232630",
-                "PMID:22328110"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:7202921': {'publication date': '1980 Apr', 'sentence': 'The results demonstrated that the intrarectal dose of indomethacin and hydrocortisone inhibited the development of tumors from microscopic carcinoma lesions in the large bowel and growing further.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25929898,
-            "start": 569,
-            "end": 319673,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7202921': {'publication date': '1980 Apr', 'sentence': 'The results demonstrated that the intrarectal dose of indomethacin and hydrocortisone inhibited the development of tumors from microscopic carcinoma lesions in the large bowel and growing further.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:disrupts---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "26389045",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:7202921"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:6607223': {'publication date': '1984 Jan 15', 'sentence': 'Hydrocortisone (HC) reduced the macrophage content of four murine tumors to less than half of control values.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25748238,
-            "start": 569,
-            "end": 319673,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:6607223': {'publication date': '1984 Jan 15', 'sentence': 'Hydrocortisone (HC) reduced the macrophage content of four murine tumors to less than half of control values.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "26205555",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:6607223"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:17609409': {'publication date': '2007 Jul', 'sentence': \"Continuous subcutaneous hydrocortisone infusion in Addison's disease.\", 'subject score': 861, 'object score': 1000}, 'PMID:18280810': {'publication date': '2008 Jun', 'sentence': \"Morning serum and saliva cortisol in Addison's disease were lower than in controls (6.74+/-1.69 vs 22.58+/-1.78 microg/dL, and 0.15+/-0.25 vs 0.67+/-0.12 microg/dL) (p<0.001).\", 'subject score': 888, 'object score': 1000}, 'PMID:18611115': {'publication date': '2008 Jun', 'sentence': 'METHODS: A literature search was performed with the aim of covering the field of gastrointestinal drug absorption of hydrocortisone in AD.', 'subject score': 1000, 'object score': 1000}, 'PMID:20674414': {'publication date': '2010 Sep', 'sentence': 'Primary adrenal insufficiency is an endocrine disorder characterized by cortisol and aldosterone deficiency caused by destruction of the adrenal cortex.', 'subject score': 1000, 'object score': 1000}, 'PMID:2209230': {'publication date': '1990 Feb', 'sentence': \"We conclude that the increase of metabolism of cortisol after simultaneous taking of rifampicin may induce adrenal crisis in Addison's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:22288685': {'publication date': '2012 Jul', 'sentence': 'A randomized, double-blind, crossover study comparing two- and four-dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency.', 'subject score': 1000, 'object score': 817}, 'PMID:24275191': {'publication date': '2013 Dec', 'sentence': \"The main reason to measure cortisol is to diagnose human diseases characterised by deficiency of adrenal steroid excretion in Addison's disease or overproduction in Cushing's syndrome (CS).\", 'subject score': 1000, 'object score': 1000}, 'PMID:25127090': {'publication date': '2014 Nov', 'sentence': \"Continuous subcutaneous hydrocortisone infusion therapy in Addison's disease: a randomized, placebo-controlled clinical trial.\", 'subject score': 840, 'object score': 1000}, 'PMID:26811406': {'publication date': '2016 Apr', 'sentence': 'Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency.', 'subject score': 851, 'object score': 1000}, 'PMID:27813051': {'publication date': '2016 Dec', 'sentence': \"Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease.\", 'subject score': 888, 'object score': 1000}, 'PMID:29872468': {'publication date': '2014 Feb', 'sentence': \"Dual-release Hydrocortisone in Addison's Disease - A Review of the Literature.\", 'subject score': 790, 'object score': 1000}, 'PMID:3019857': {'publication date': '1986 Aug', 'sentence': \"Response to low-dose pulsatile cortisol in Addison's disease with suspected corticotropinoma.\", 'subject score': 861, 'object score': 1000}, 'PMID:31532828': {'publication date': '2019 Sep 18', 'sentence': 'All AD patients and 42% of CAH patients were prescribed glucocorticoids, most frequently hydrocortisone in AD (82%) and prednisolone in CAH (50%).', 'subject score': 851, 'object score': 1000}, 'PMID:34512546': {'publication date': '2021', 'sentence': \"Sleep, Cognition and Cortisol in Addison's Disease: A Mechanistic Relationship.\", 'subject score': 1000, 'object score': 1000}, 'PMID:35918399': {'publication date': '2022 Aug 02', 'sentence': 'The study aims to compare dual-release hydrocortisone (DR-HC) and conventional steroids on bone metabolism in patients with primary adrenal insufficiency (PAI).', 'subject score': 851, 'object score': 804}, 'PMID:4312783': {'publication date': '1970 Jan', 'sentence': \"[Passage of cortisol in unaltered and unconjugated form into the urine in central type of Cushing's syndrome and in Addison's disease at different levels of ACTH in the organism].\", 'subject score': 1000, 'object score': 1000}, 'PMID:5040535': {'publication date': '1972 Jul 12', 'sentence': \"[Effect of hydrocortisone on gastric secretion and histology in Addison's disease].\", 'subject score': 1000, 'object score': 1000}, 'PMID:7375407': {'publication date': '1980 May', 'sentence': 'Primary adrenal insufficiency is characterized by cortisol and aldosterone deficiency; in the secondary form, cortisol alone is decreased.', 'subject score': 1000, 'object score': 1000}, 'PMID:8388783': {'publication date': '1993 Apr', 'sentence': \"A chronobiological approach to circulating levels of renin, angiotensin-converting enzyme, aldosterone, ACTH, and cortisol in Addison's disease.\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 312684,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015129",
-          "name": "chronic primary adrenal insufficiency",
-          "description": "A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.; An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands as a result of a primary defect in the glands themselves. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0001403",
-            "MONDO:0015129",
-            "DOID:13774",
-            "SNOMEDCT:363732003",
-            "PSY:00810",
-            "MEDDRA:10052381",
-            "UMLS:C1868690",
-            "OMIM:240200",
-            "ICD10:E27.1",
-            "UMLS:C0271737",
-            "MEDDRA:10080674",
-            "SNOMEDCT:373662000",
-            "MEDDRA:10013096",
-            "MEDDRA:10001130",
-            "HP:0008207",
-            "MEDDRA:10036696",
-            "MESH:D000075262",
-            "MESH:D000224",
-            "SNOMEDCT:76715008",
-            "ORPHANET:101959",
-            "NCIT:C26689",
-            "MEDDRA:10085976"
-          ],
-          "id": "MONDO:0015129",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hypoadrenocorticism, Familial",
-            "Primary adrenal insufficiency",
-            "Addisons Disease",
-            "Chronic primary adrenal insufficiency",
-            "Addison's disease due to autoimmunity",
-            "Addison Disease",
-            "Addison's disease",
-            "chronic primary adrenal insufficiency",
-            "Hypoadrenocorticism, familial",
-            "Hypoadrenocorticism, familial related phenotypic feature",
-            "Addison's Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/addison%27s_disease",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312684,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015129",
-              "name": "chronic primary adrenal insufficiency",
-              "description": "A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.; An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands as a result of a primary defect in the glands themselves. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0001403",
-                "MONDO:0015129",
-                "DOID:13774",
-                "SNOMEDCT:363732003",
-                "PSY:00810",
-                "MEDDRA:10052381",
-                "UMLS:C1868690",
-                "OMIM:240200",
-                "ICD10:E27.1",
-                "UMLS:C0271737",
-                "MEDDRA:10080674",
-                "SNOMEDCT:373662000",
-                "MEDDRA:10013096",
-                "MEDDRA:10001130",
-                "HP:0008207",
-                "MEDDRA:10036696",
-                "MESH:D000075262",
-                "MESH:D000224",
-                "SNOMEDCT:76715008",
-                "ORPHANET:101959",
-                "NCIT:C26689",
-                "MEDDRA:10085976"
-              ],
-              "id": "MONDO:0015129",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hypoadrenocorticism, Familial",
-                "Primary adrenal insufficiency",
-                "Addisons Disease",
-                "Chronic primary adrenal insufficiency",
-                "Addison's disease due to autoimmunity",
-                "Addison Disease",
-                "Addison's disease",
-                "chronic primary adrenal insufficiency",
-                "Hypoadrenocorticism, familial",
-                "Hypoadrenocorticism, familial related phenotypic feature",
-                "Addison's Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/addison%27s_disease",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12934219,
-            "start": 569,
-            "end": 312684,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17609409': {'publication date': '2007 Jul', 'sentence': \"Continuous subcutaneous hydrocortisone infusion in Addison's disease.\", 'subject score': 861, 'object score': 1000}, 'PMID:18280810': {'publication date': '2008 Jun', 'sentence': \"Morning serum and saliva cortisol in Addison's disease were lower than in controls (6.74+/-1.69 vs 22.58+/-1.78 microg/dL, and 0.15+/-0.25 vs 0.67+/-0.12 microg/dL) (p<0.001).\", 'subject score': 888, 'object score': 1000}, 'PMID:18611115': {'publication date': '2008 Jun', 'sentence': 'METHODS: A literature search was performed with the aim of covering the field of gastrointestinal drug absorption of hydrocortisone in AD.', 'subject score': 1000, 'object score': 1000}, 'PMID:20674414': {'publication date': '2010 Sep', 'sentence': 'Primary adrenal insufficiency is an endocrine disorder characterized by cortisol and aldosterone deficiency caused by destruction of the adrenal cortex.', 'subject score': 1000, 'object score': 1000}, 'PMID:2209230': {'publication date': '1990 Feb', 'sentence': \"We conclude that the increase of metabolism of cortisol after simultaneous taking of rifampicin may induce adrenal crisis in Addison's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:22288685': {'publication date': '2012 Jul', 'sentence': 'A randomized, double-blind, crossover study comparing two- and four-dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency.', 'subject score': 1000, 'object score': 817}, 'PMID:24275191': {'publication date': '2013 Dec', 'sentence': \"The main reason to measure cortisol is to diagnose human diseases characterised by deficiency of adrenal steroid excretion in Addison's disease or overproduction in Cushing's syndrome (CS).\", 'subject score': 1000, 'object score': 1000}, 'PMID:25127090': {'publication date': '2014 Nov', 'sentence': \"Continuous subcutaneous hydrocortisone infusion therapy in Addison's disease: a randomized, placebo-controlled clinical trial.\", 'subject score': 840, 'object score': 1000}, 'PMID:26811406': {'publication date': '2016 Apr', 'sentence': 'Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency.', 'subject score': 851, 'object score': 1000}, 'PMID:27813051': {'publication date': '2016 Dec', 'sentence': \"Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease.\", 'subject score': 888, 'object score': 1000}, 'PMID:29872468': {'publication date': '2014 Feb', 'sentence': \"Dual-release Hydrocortisone in Addison's Disease - A Review of the Literature.\", 'subject score': 790, 'object score': 1000}, 'PMID:3019857': {'publication date': '1986 Aug', 'sentence': \"Response to low-dose pulsatile cortisol in Addison's disease with suspected corticotropinoma.\", 'subject score': 861, 'object score': 1000}, 'PMID:31532828': {'publication date': '2019 Sep 18', 'sentence': 'All AD patients and 42% of CAH patients were prescribed glucocorticoids, most frequently hydrocortisone in AD (82%) and prednisolone in CAH (50%).', 'subject score': 851, 'object score': 1000}, 'PMID:34512546': {'publication date': '2021', 'sentence': \"Sleep, Cognition and Cortisol in Addison's Disease: A Mechanistic Relationship.\", 'subject score': 1000, 'object score': 1000}, 'PMID:35918399': {'publication date': '2022 Aug 02', 'sentence': 'The study aims to compare dual-release hydrocortisone (DR-HC) and conventional steroids on bone metabolism in patients with primary adrenal insufficiency (PAI).', 'subject score': 851, 'object score': 804}, 'PMID:4312783': {'publication date': '1970 Jan', 'sentence': \"[Passage of cortisol in unaltered and unconjugated form into the urine in central type of Cushing's syndrome and in Addison's disease at different levels of ACTH in the organism].\", 'subject score': 1000, 'object score': 1000}, 'PMID:5040535': {'publication date': '1972 Jul 12', 'sentence': \"[Effect of hydrocortisone on gastric secretion and histology in Addison's disease].\", 'subject score': 1000, 'object score': 1000}, 'PMID:7375407': {'publication date': '1980 May', 'sentence': 'Primary adrenal insufficiency is characterized by cortisol and aldosterone deficiency; in the secondary form, cortisol alone is decreased.', 'subject score': 1000, 'object score': 1000}, 'PMID:8388783': {'publication date': '1993 Apr', 'sentence': \"A chronobiological approach to circulating levels of renin, angiotensin-converting enzyme, aldosterone, ACTH, and cortisol in Addison's disease.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0001403---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13213365",
-              "object": "MONDO:0015129",
-              "publications": [
-                "PMID:17609409",
-                "PMID:18280810",
-                "PMID:18611115",
-                "PMID:20674414",
-                "PMID:2209230",
-                "PMID:22288685",
-                "PMID:24275191",
-                "PMID:25127090",
-                "PMID:26811406",
-                "PMID:27813051",
-                "PMID:29872468",
-                "PMID:3019857",
-                "PMID:31532828",
-                "PMID:34512546",
-                "PMID:35918399",
-                "PMID:4312783",
-                "PMID:5040535",
-                "PMID:7375407",
-                "PMID:8388783"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10323386': {'publication date': '1999 May', 'sentence': \"The effects of endogenous opioids and cortisol on thyrotropin and prolactin secretion in patients with Addison's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:13481096': {'publication date': '1957 Dec', 'sentence': \"Lack of plasma cortisol and urinary aldosterone in a pregnant woman with Addison's disease.\", 'subject score': 888, 'object score': 1000}, 'PMID:16580396': {'publication date': '2006 Apr', 'sentence': \"His Addison's disease was managed with hydrocortisone and fludrocortisone, and his hyperthyroidism, with methimazole.\", 'subject score': 1000, 'object score': 1000}, 'PMID:168433': {'publication date': '1975 Feb', 'sentence': \"Effect of natural and synthetic Beta-1 minus 24-and Beta-1 minus 18-corticotrophins on the extra-adrenal metabolism of cortisol and aldosterone in patients with addison's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:17609409': {'publication date': '2007 Jul', 'sentence': 'CONCLUSIONS: CSHI is technically feasible and safe in patients with AD.', 'subject score': 790, 'object score': 1000}, 'PMID:186258': {'publication date': '1976 Jun', 'sentence': \"The plasma ACTH responses to hydrocortisone infusion were compared in patients with Cushing's disease and primary adrenocortical insufficiency.\", 'subject score': 888, 'object score': 1000}, 'PMID:19273569': {'publication date': '2009 Jun', 'sentence': 'OBJECTIVE: Current glucocorticoid replacement regimens fail to fully mimic physiologic cortisol secretion in patients with primary adrenal insufficiency.', 'subject score': 851, 'object score': 1000}, 'PMID:20925018': {'publication date': '2010 Dec', 'sentence': \"Our aim was to investigate the usefulness of circulating levels of adrenocorticotropic hormone (ACTH) and also salivary cortisol to monitor cortisone substitution in patients with Addison's disease.\", 'subject score': 790, 'object score': 1000}, 'PMID:216821': {'publication date': '1979 Mar 23', 'sentence': 'Basal plasma adrenocorticotrophic hormone (ACTH) and cortisol concentrations as well as plasma ACTH and 11-deoxycortisol responses to the administration of a single dose of metyrapone were evaluated in 104 patients with intact pituitary-adrenal axis, in 20 patients with secondary adrenal insufficiency, and in seven patients with primary adrenal insufficiency.', 'subject score': 888, 'object score': 1000}, 'PMID:22893258': {'publication date': '2013 Jan', 'sentence': \"Cortisol pharmacokinetics was assessed in 31 patients with Addison's disease on replacement hydrocortisone doses (median daily dose 20 mg; range 5-50 mg) and 30 healthy control subjects.\", 'subject score': 888, 'object score': 1000}, 'PMID:22907517': {'publication date': '2012 Sep', 'sentence': \"Hydrocortisone and fludrocortisone are the preferred therapy for Addison's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:233701': {'publication date': '1978 Jun', 'sentence': 'In order first to establish the disappearance t 1/2 of endogenous immunoreactive human beta-MSH (RIA-h beta MSH), which is now known to represent the lipotropins, human beta-LPH and human gamma-LPH, the plasma concentrations of RIA-h beta MSH, RIA-hACTH, and fluorogenic corticosteroids (cortisol) were measured before and during infusion of cortisol in three patients with primary adrenocortical insufficiency from whom steroid replacement had been withdrawn.', 'subject score': 1000, 'object score': 1000}, 'PMID:24466047': {'publication date': '2014', 'sentence': 'CONCLUSIONS: This study did not identify any associations between the 9beta polymorphism and cardiovascular risk factors or hydrocortisone dose and determination of this polymorphism is therefore unlikely to be of clinical benefit in the management of patients with AD.', 'subject score': 888, 'object score': 1000}, 'PMID:24517155': {'publication date': '2014 May', 'sentence': \"Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of addison's disease: a randomized clinical trial.\", 'subject score': 861, 'object score': 1000}, 'PMID:24944332': {'publication date': '2014 Sep', 'sentence': 'CONCLUSIONS: This long-term prospective trial is the first to document the safety of DR-HC in patients with primary AI and demonstrates that such treatment is well tolerated during 24 consecutive months of therapy.', 'subject score': 790, 'object score': 1000}, 'PMID:25400085': {'publication date': '2015 Jul', 'sentence': 'OBJECTIVE: The aim of this study was to compare circadian hormone rhythms and insulin sensitivity in conventional thrice-daily regimen of glucocorticoid replacement therapy with CSHI treatment in patients with AD.', 'subject score': 840, 'object score': 1000}, 'PMID:2557986': {'publication date': '1989 May', 'sentence': \"Plasma ACTH responses to cortisol infusion are similar in patients with primary hypoadrenalism and patients studied some years after bilateral adrenalectomy for Cushing's syndrome.\", 'subject score': 888, 'object score': 1000}, 'PMID:25781534': {'publication date': '2015 Jul', 'sentence': 'We report the use of continuous subcutaneous hydrocortisone infusion in an adolescent patient with primary adrenal insufficiency.', 'subject score': 861, 'object score': 1000}, 'PMID:26184416': {'publication date': '2016 Feb', 'sentence': 'This study aimed to assess variations of anthropometric, metabolic, and hormonal parameters in patients with AD after switching from conventional hydrocortisone (HC) treatment to PLEN.', 'subject score': 851, 'object score': 1000}, 'PMID:26684152': {'publication date': '2016 Apr', 'sentence': 'OBJECTIVE: In primary adrenal insufficiency (PAI), replacement with prednisolone may result in lower bone mineral density (BMD) compared with hydrocortisone therapy.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 312684,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015129",
-          "name": "chronic primary adrenal insufficiency",
-          "description": "A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.; An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands as a result of a primary defect in the glands themselves. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0001403",
-            "MONDO:0015129",
-            "DOID:13774",
-            "SNOMEDCT:363732003",
-            "PSY:00810",
-            "MEDDRA:10052381",
-            "UMLS:C1868690",
-            "OMIM:240200",
-            "ICD10:E27.1",
-            "UMLS:C0271737",
-            "MEDDRA:10080674",
-            "SNOMEDCT:373662000",
-            "MEDDRA:10013096",
-            "MEDDRA:10001130",
-            "HP:0008207",
-            "MEDDRA:10036696",
-            "MESH:D000075262",
-            "MESH:D000224",
-            "SNOMEDCT:76715008",
-            "ORPHANET:101959",
-            "NCIT:C26689",
-            "MEDDRA:10085976"
-          ],
-          "id": "MONDO:0015129",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hypoadrenocorticism, Familial",
-            "Primary adrenal insufficiency",
-            "Addisons Disease",
-            "Chronic primary adrenal insufficiency",
-            "Addison's disease due to autoimmunity",
-            "Addison Disease",
-            "Addison's disease",
-            "chronic primary adrenal insufficiency",
-            "Hypoadrenocorticism, familial",
-            "Hypoadrenocorticism, familial related phenotypic feature",
-            "Addison's Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/addison%27s_disease",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312684,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015129",
-              "name": "chronic primary adrenal insufficiency",
-              "description": "A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.; An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands as a result of a primary defect in the glands themselves. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0001403",
-                "MONDO:0015129",
-                "DOID:13774",
-                "SNOMEDCT:363732003",
-                "PSY:00810",
-                "MEDDRA:10052381",
-                "UMLS:C1868690",
-                "OMIM:240200",
-                "ICD10:E27.1",
-                "UMLS:C0271737",
-                "MEDDRA:10080674",
-                "SNOMEDCT:373662000",
-                "MEDDRA:10013096",
-                "MEDDRA:10001130",
-                "HP:0008207",
-                "MEDDRA:10036696",
-                "MESH:D000075262",
-                "MESH:D000224",
-                "SNOMEDCT:76715008",
-                "ORPHANET:101959",
-                "NCIT:C26689",
-                "MEDDRA:10085976"
-              ],
-              "id": "MONDO:0015129",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hypoadrenocorticism, Familial",
-                "Primary adrenal insufficiency",
-                "Addisons Disease",
-                "Chronic primary adrenal insufficiency",
-                "Addison's disease due to autoimmunity",
-                "Addison Disease",
-                "Addison's disease",
-                "chronic primary adrenal insufficiency",
-                "Hypoadrenocorticism, familial",
-                "Hypoadrenocorticism, familial related phenotypic feature",
-                "Addison's Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/addison%27s_disease",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7223915,
-            "start": 569,
-            "end": 312684,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10323386': {'publication date': '1999 May', 'sentence': \"The effects of endogenous opioids and cortisol on thyrotropin and prolactin secretion in patients with Addison's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:13481096': {'publication date': '1957 Dec', 'sentence': \"Lack of plasma cortisol and urinary aldosterone in a pregnant woman with Addison's disease.\", 'subject score': 888, 'object score': 1000}, 'PMID:16580396': {'publication date': '2006 Apr', 'sentence': \"His Addison's disease was managed with hydrocortisone and fludrocortisone, and his hyperthyroidism, with methimazole.\", 'subject score': 1000, 'object score': 1000}, 'PMID:168433': {'publication date': '1975 Feb', 'sentence': \"Effect of natural and synthetic Beta-1 minus 24-and Beta-1 minus 18-corticotrophins on the extra-adrenal metabolism of cortisol and aldosterone in patients with addison's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:17609409': {'publication date': '2007 Jul', 'sentence': 'CONCLUSIONS: CSHI is technically feasible and safe in patients with AD.', 'subject score': 790, 'object score': 1000}, 'PMID:186258': {'publication date': '1976 Jun', 'sentence': \"The plasma ACTH responses to hydrocortisone infusion were compared in patients with Cushing's disease and primary adrenocortical insufficiency.\", 'subject score': 888, 'object score': 1000}, 'PMID:19273569': {'publication date': '2009 Jun', 'sentence': 'OBJECTIVE: Current glucocorticoid replacement regimens fail to fully mimic physiologic cortisol secretion in patients with primary adrenal insufficiency.', 'subject score': 851, 'object score': 1000}, 'PMID:20925018': {'publication date': '2010 Dec', 'sentence': \"Our aim was to investigate the usefulness of circulating levels of adrenocorticotropic hormone (ACTH) and also salivary cortisol to monitor cortisone substitution in patients with Addison's disease.\", 'subject score': 790, 'object score': 1000}, 'PMID:216821': {'publication date': '1979 Mar 23', 'sentence': 'Basal plasma adrenocorticotrophic hormone (ACTH) and cortisol concentrations as well as plasma ACTH and 11-deoxycortisol responses to the administration of a single dose of metyrapone were evaluated in 104 patients with intact pituitary-adrenal axis, in 20 patients with secondary adrenal insufficiency, and in seven patients with primary adrenal insufficiency.', 'subject score': 888, 'object score': 1000}, 'PMID:22893258': {'publication date': '2013 Jan', 'sentence': \"Cortisol pharmacokinetics was assessed in 31 patients with Addison's disease on replacement hydrocortisone doses (median daily dose 20 mg; range 5-50 mg) and 30 healthy control subjects.\", 'subject score': 888, 'object score': 1000}, 'PMID:22907517': {'publication date': '2012 Sep', 'sentence': \"Hydrocortisone and fludrocortisone are the preferred therapy for Addison's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:233701': {'publication date': '1978 Jun', 'sentence': 'In order first to establish the disappearance t 1/2 of endogenous immunoreactive human beta-MSH (RIA-h beta MSH), which is now known to represent the lipotropins, human beta-LPH and human gamma-LPH, the plasma concentrations of RIA-h beta MSH, RIA-hACTH, and fluorogenic corticosteroids (cortisol) were measured before and during infusion of cortisol in three patients with primary adrenocortical insufficiency from whom steroid replacement had been withdrawn.', 'subject score': 1000, 'object score': 1000}, 'PMID:24466047': {'publication date': '2014', 'sentence': 'CONCLUSIONS: This study did not identify any associations between the 9beta polymorphism and cardiovascular risk factors or hydrocortisone dose and determination of this polymorphism is therefore unlikely to be of clinical benefit in the management of patients with AD.', 'subject score': 888, 'object score': 1000}, 'PMID:24517155': {'publication date': '2014 May', 'sentence': \"Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of addison's disease: a randomized clinical trial.\", 'subject score': 861, 'object score': 1000}, 'PMID:24944332': {'publication date': '2014 Sep', 'sentence': 'CONCLUSIONS: This long-term prospective trial is the first to document the safety of DR-HC in patients with primary AI and demonstrates that such treatment is well tolerated during 24 consecutive months of therapy.', 'subject score': 790, 'object score': 1000}, 'PMID:25400085': {'publication date': '2015 Jul', 'sentence': 'OBJECTIVE: The aim of this study was to compare circadian hormone rhythms and insulin sensitivity in conventional thrice-daily regimen of glucocorticoid replacement therapy with CSHI treatment in patients with AD.', 'subject score': 840, 'object score': 1000}, 'PMID:2557986': {'publication date': '1989 May', 'sentence': \"Plasma ACTH responses to cortisol infusion are similar in patients with primary hypoadrenalism and patients studied some years after bilateral adrenalectomy for Cushing's syndrome.\", 'subject score': 888, 'object score': 1000}, 'PMID:25781534': {'publication date': '2015 Jul', 'sentence': 'We report the use of continuous subcutaneous hydrocortisone infusion in an adolescent patient with primary adrenal insufficiency.', 'subject score': 861, 'object score': 1000}, 'PMID:26184416': {'publication date': '2016 Feb', 'sentence': 'This study aimed to assess variations of anthropometric, metabolic, and hormonal parameters in patients with AD after switching from conventional hydrocortisone (HC) treatment to PLEN.', 'subject score': 851, 'object score': 1000}, 'PMID:26684152': {'publication date': '2016 Apr', 'sentence': 'OBJECTIVE: In primary adrenal insufficiency (PAI), replacement with prednisolone may result in lower bone mineral density (BMD) compared with hydrocortisone therapy.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0001403---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0271737---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7378370",
-              "object": "MONDO:0015129",
-              "publications": [
-                "PMID:186258",
-                "PMID:24517155",
-                "PMID:33553982",
-                "PMID:31059146",
-                "PMID:3115635",
-                "PMID:16580396",
-                "PMID:13481096",
-                "PMID:8013139",
-                "PMID:4819287",
-                "PMID:22907517",
-                "PMID:216821",
-                "PMID:22893258",
-                "PMID:741991",
-                "PMID:31744021",
-                "PMID:27813051",
-                "PMID:31611225",
-                "PMID:25781534",
-                "PMID:3015556",
-                "PMID:6090183",
-                "PMID:168433"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:produces",
-    "r2.publications_info": "{'PMID:21103194': {'publication date': '2010 Jun 01', 'sentence': \"Synacthen test diagnosed Addison's disease with a clear deficiency of cortisol production.\", 'subject score': 901, 'object score': 888}, 'PMID:29280740': {'publication date': '2017 Dec 30', 'sentence': 'Primary adrenal insufficiency (PAI) is a heterogeneous group of disorders characterized by an impaired production of cortisol and other steroid hormones by the adrenal cortex.', 'subject score': 1000, 'object score': 1000}, 'PMID:34660134': {'publication date': '2021 Sep', 'sentence': 'Primary adrenal insufficiency leads to the decreased production of cortisol and aldosterone.', 'subject score': 1000, 'object score': 1000}, 'PMID:36611246': {'publication date': '2023 Jan 06', 'sentence': 'This review describes advances in adrenal cell transplants and gene therapy that may allow physiological cortisol production for children and adults with primary adrenal insufficiency.', 'subject score': 1000, 'object score': 851}, 'PMID:7000877': {'publication date': '1980 Jul-Sep', 'sentence': \"Plasma immunoreactive glucagon (IRG), insulin (IRI) and blood glucose (BG) were evaluated in the fasting state and during an arginine test (ATT) in 6 subjects with untreated hypopituitarism (H), in 2 hypopituitary subjects with normal cortisol production (H + C), in 3 subjects with Addison's disease (A) and in 14 normal volunteers (N).\", 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 312684,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015129",
-          "name": "chronic primary adrenal insufficiency",
-          "description": "A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.; An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands as a result of a primary defect in the glands themselves. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0001403",
-            "MONDO:0015129",
-            "DOID:13774",
-            "SNOMEDCT:363732003",
-            "PSY:00810",
-            "MEDDRA:10052381",
-            "UMLS:C1868690",
-            "OMIM:240200",
-            "ICD10:E27.1",
-            "UMLS:C0271737",
-            "MEDDRA:10080674",
-            "SNOMEDCT:373662000",
-            "MEDDRA:10013096",
-            "MEDDRA:10001130",
-            "HP:0008207",
-            "MEDDRA:10036696",
-            "MESH:D000075262",
-            "MESH:D000224",
-            "SNOMEDCT:76715008",
-            "ORPHANET:101959",
-            "NCIT:C26689",
-            "MEDDRA:10085976"
-          ],
-          "id": "MONDO:0015129",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hypoadrenocorticism, Familial",
-            "Primary adrenal insufficiency",
-            "Addisons Disease",
-            "Chronic primary adrenal insufficiency",
-            "Addison's disease due to autoimmunity",
-            "Addison Disease",
-            "Addison's disease",
-            "chronic primary adrenal insufficiency",
-            "Hypoadrenocorticism, familial",
-            "Hypoadrenocorticism, familial related phenotypic feature",
-            "Addison's Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/addison%27s_disease",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312684,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015129",
-              "name": "chronic primary adrenal insufficiency",
-              "description": "A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.; An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands as a result of a primary defect in the glands themselves. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0001403",
-                "MONDO:0015129",
-                "DOID:13774",
-                "SNOMEDCT:363732003",
-                "PSY:00810",
-                "MEDDRA:10052381",
-                "UMLS:C1868690",
-                "OMIM:240200",
-                "ICD10:E27.1",
-                "UMLS:C0271737",
-                "MEDDRA:10080674",
-                "SNOMEDCT:373662000",
-                "MEDDRA:10013096",
-                "MEDDRA:10001130",
-                "HP:0008207",
-                "MEDDRA:10036696",
-                "MESH:D000075262",
-                "MESH:D000224",
-                "SNOMEDCT:76715008",
-                "ORPHANET:101959",
-                "NCIT:C26689",
-                "MEDDRA:10085976"
-              ],
-              "id": "MONDO:0015129",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hypoadrenocorticism, Familial",
-                "Primary adrenal insufficiency",
-                "Addisons Disease",
-                "Chronic primary adrenal insufficiency",
-                "Addison's disease due to autoimmunity",
-                "Addison Disease",
-                "Addison's disease",
-                "chronic primary adrenal insufficiency",
-                "Hypoadrenocorticism, familial",
-                "Hypoadrenocorticism, familial related phenotypic feature",
-                "Addison's Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/addison%27s_disease",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15008006,
-            "start": 312684,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:21103194': {'publication date': '2010 Jun 01', 'sentence': \"Synacthen test diagnosed Addison's disease with a clear deficiency of cortisol production.\", 'subject score': 901, 'object score': 888}, 'PMID:29280740': {'publication date': '2017 Dec 30', 'sentence': 'Primary adrenal insufficiency (PAI) is a heterogeneous group of disorders characterized by an impaired production of cortisol and other steroid hormones by the adrenal cortex.', 'subject score': 1000, 'object score': 1000}, 'PMID:34660134': {'publication date': '2021 Sep', 'sentence': 'Primary adrenal insufficiency leads to the decreased production of cortisol and aldosterone.', 'subject score': 1000, 'object score': 1000}, 'PMID:36611246': {'publication date': '2023 Jan 06', 'sentence': 'This review describes advances in adrenal cell transplants and gene therapy that may allow physiological cortisol production for children and adults with primary adrenal insufficiency.', 'subject score': 1000, 'object score': 851}, 'PMID:7000877': {'publication date': '1980 Jul-Sep', 'sentence': \"Plasma immunoreactive glucagon (IRG), insulin (IRI) and blood glucose (BG) were evaluated in the fasting state and during an arginine test (ATT) in 6 subjects with untreated hypopituitarism (H), in 2 hypopituitary subjects with normal cortisol production (H + C), in 3 subjects with Addison's disease (A) and in 14 normal volunteers (N).\", 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0001403---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0015129",
-              "id": "15330155",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:21103194",
-                "PMID:29280740",
-                "PMID:34660134",
-                "PMID:36611246",
-                "PMID:7000877"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10604268': {'publication date': '1999 Oct', 'sentence': 'We have studied intravenous docetaxel 70 mg/m2, oral estramustine, and low-dose daily hydrocortisone in men with HRPC who demonstrated progression after initial hormone therapy.', 'subject score': 861, 'object score': 1000}, 'PMID:11331330': {'publication date': '2001 May 01', 'sentence': 'We studied intravenous administration of docetaxel 70 mg/m(2), oral estramustine, and low-dose daily hydrocortisone in men with HRPC who demonstrated progression after initial hormone therapy.', 'subject score': 861, 'object score': 1000}, 'PMID:20438593': {'publication date': '2010 Jul', 'sentence': 'OBJECTIVE: To assess the combination of docetaxel (DTX), estramustine phosphate (EMP) and hydrocortisone for patients with hormone-refractory prostate cancer (HRPC).', 'subject score': 1000, 'object score': 1000}, 'PMID:7506794': {'publication date': '1994 Feb 02', 'sentence': 'BACKGROUND: The best treatment for patients with \"hormone-refractory\" metastatic prostate cancer is unclear, particularly in patients for whom suramin and hydrocortisone have failed.', 'subject score': 1000, 'object score': 924}}",
-    "p2": {
-      "start": {
-        "identity": 610975,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/DOID_0080909",
-          "name": "castration-resistant prostate carcinoma",
-          "description": "A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.",
-          "equivalent_curies": [
-            "MESH:D064129",
-            "MONDO:0850353",
-            "DOID:0080909",
-            "MEDDRA:10076506",
-            "SNOMEDCT:427492003",
-            "UMLS:C3658267",
-            "MEDDRA:10062904",
-            "NCIT:C130234",
-            "UMLS:C1328504"
-          ],
-          "id": "DOID:0080909",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Prostatic Neoplasms, Castration-Resistant",
-            "castration-resistant prostate carcinoma",
-            "Castration-Resistant Prostate Carcinoma",
-            "Hormone refractory prostate cancer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:30324351"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 610975,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/DOID_0080909",
-              "name": "castration-resistant prostate carcinoma",
-              "description": "A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.",
-              "equivalent_curies": [
-                "MESH:D064129",
-                "MONDO:0850353",
-                "DOID:0080909",
-                "MEDDRA:10076506",
-                "SNOMEDCT:427492003",
-                "UMLS:C3658267",
-                "MEDDRA:10062904",
-                "NCIT:C130234",
-                "UMLS:C1328504"
-              ],
-              "id": "DOID:0080909",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Prostatic Neoplasms, Castration-Resistant",
-                "castration-resistant prostate carcinoma",
-                "Castration-Resistant Prostate Carcinoma",
-                "Hormone refractory prostate cancer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:30324351"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7718626,
-            "start": 569,
-            "end": 610975,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10604268': {'publication date': '1999 Oct', 'sentence': 'We have studied intravenous docetaxel 70 mg/m2, oral estramustine, and low-dose daily hydrocortisone in men with HRPC who demonstrated progression after initial hormone therapy.', 'subject score': 861, 'object score': 1000}, 'PMID:11331330': {'publication date': '2001 May 01', 'sentence': 'We studied intravenous administration of docetaxel 70 mg/m(2), oral estramustine, and low-dose daily hydrocortisone in men with HRPC who demonstrated progression after initial hormone therapy.', 'subject score': 861, 'object score': 1000}, 'PMID:20438593': {'publication date': '2010 Jul', 'sentence': 'OBJECTIVE: To assess the combination of docetaxel (DTX), estramustine phosphate (EMP) and hydrocortisone for patients with hormone-refractory prostate cancer (HRPC).', 'subject score': 1000, 'object score': 1000}, 'PMID:7506794': {'publication date': '1994 Feb 02', 'sentence': 'BACKGROUND: The best treatment for patients with \"hormone-refractory\" metastatic prostate cancer is unclear, particularly in patients for whom suramin and hydrocortisone have failed.', 'subject score': 1000, 'object score': 924}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C1328504---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7882717",
-              "object": "DOID:0080909",
-              "publications": [
-                "PMID:10604268",
-                "PMID:11331330",
-                "PMID:20438593",
-                "PMID:7506794"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:19420839': {'publication date': '2009 Apr', 'sentence': 'The plasma cortisol concentration was significantly higher in both DD groups before treatment than in the control group, and it decreased significantly after hoof trimming in the trimmed group.', 'subject score': 901, 'object score': 861}, 'PMID:8338747': {'publication date': '1993 Jun', 'sentence': 'Transepidermal water loss and absorption of hydrocortisone in widespread dermatitis.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 308784,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002406",
-          "name": "dermatitis",
-          "description": "The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes. [HPO:probinson]; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0011123",
-            "MEDDRA:10062249",
-            "MEDDRA:10012431",
-            "MP:0004947",
-            "MESH:D003872",
-            "SNOMEDCT:43116000",
-            "MONDO:0002406",
-            "MEDDRA:10012478",
-            "MEDDRA:10040876",
-            "ICD10:L30.9",
-            "DOID:2723",
-            "NCIT:C2983",
-            "SNOMEDCT:703938007",
-            "UMLS:C3875321",
-            "PSY:13710",
-            "UMLS:C0011603"
-          ],
-          "id": "MONDO:0002406",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis",
-            "Inflammatory abnormality of the skin",
-            "Inflammatory dermatosis",
-            "dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/eczema.htm",
-            "http://en.wikipedia.org/wiki/dermatitis",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308784,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002406",
-              "name": "dermatitis",
-              "description": "The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes. [HPO:probinson]; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0011123",
-                "MEDDRA:10062249",
-                "MEDDRA:10012431",
-                "MP:0004947",
-                "MESH:D003872",
-                "SNOMEDCT:43116000",
-                "MONDO:0002406",
-                "MEDDRA:10012478",
-                "MEDDRA:10040876",
-                "ICD10:L30.9",
-                "DOID:2723",
-                "NCIT:C2983",
-                "SNOMEDCT:703938007",
-                "UMLS:C3875321",
-                "PSY:13710",
-                "UMLS:C0011603"
-              ],
-              "id": "MONDO:0002406",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis",
-                "Inflammatory abnormality of the skin",
-                "Inflammatory dermatosis",
-                "dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/eczema.htm",
-                "http://en.wikipedia.org/wiki/dermatitis",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14060981,
-            "start": 569,
-            "end": 308784,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19420839': {'publication date': '2009 Apr', 'sentence': 'The plasma cortisol concentration was significantly higher in both DD groups before treatment than in the control group, and it decreased significantly after hoof trimming in the trimmed group.', 'subject score': 901, 'object score': 861}, 'PMID:8338747': {'publication date': '1993 Jun', 'sentence': 'Transepidermal water loss and absorption of hydrocortisone in widespread dermatitis.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0011603---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14360687",
-              "object": "MONDO:0002406",
-              "publications": [
-                "PMID:19420839",
-                "PMID:8338747"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:2976496': {'publication date': '1988 Nov', 'sentence': 'In addition to local effect, topical hydrocortisone therapy of childhood dermatitis is accompanied by a systemic effect that may be pronounced in the acute phase of disease.', 'subject score': 790, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 308784,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002406",
-          "name": "dermatitis",
-          "description": "The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes. [HPO:probinson]; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0011123",
-            "MEDDRA:10062249",
-            "MEDDRA:10012431",
-            "MP:0004947",
-            "MESH:D003872",
-            "SNOMEDCT:43116000",
-            "MONDO:0002406",
-            "MEDDRA:10012478",
-            "MEDDRA:10040876",
-            "ICD10:L30.9",
-            "DOID:2723",
-            "NCIT:C2983",
-            "SNOMEDCT:703938007",
-            "UMLS:C3875321",
-            "PSY:13710",
-            "UMLS:C0011603"
-          ],
-          "id": "MONDO:0002406",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis",
-            "Inflammatory abnormality of the skin",
-            "Inflammatory dermatosis",
-            "dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/eczema.htm",
-            "http://en.wikipedia.org/wiki/dermatitis",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308784,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002406",
-              "name": "dermatitis",
-              "description": "The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes. [HPO:probinson]; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0011123",
-                "MEDDRA:10062249",
-                "MEDDRA:10012431",
-                "MP:0004947",
-                "MESH:D003872",
-                "SNOMEDCT:43116000",
-                "MONDO:0002406",
-                "MEDDRA:10012478",
-                "MEDDRA:10040876",
-                "ICD10:L30.9",
-                "DOID:2723",
-                "NCIT:C2983",
-                "SNOMEDCT:703938007",
-                "UMLS:C3875321",
-                "PSY:13710",
-                "UMLS:C0011603"
-              ],
-              "id": "MONDO:0002406",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis",
-                "Inflammatory abnormality of the skin",
-                "Inflammatory dermatosis",
-                "dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/eczema.htm",
-                "http://en.wikipedia.org/wiki/dermatitis",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19938658,
-            "start": 569,
-            "end": 308784,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2976496': {'publication date': '1988 Nov', 'sentence': 'In addition to local effect, topical hydrocortisone therapy of childhood dermatitis is accompanied by a systemic effect that may be pronounced in the acute phase of disease.', 'subject score': 790, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0011603---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "20336537",
-              "object": "MONDO:0002406",
-              "publications": [
-                "PMID:2976496"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:2459879': {'publication date': '1988', 'sentence': 'In the acute phase of dermatitis, topical hydrocortisone treatment has both a local and a systemic effect, due to percutaneous absorption.', 'subject score': 790, 'object score': 1000}, 'PMID:25395851': {'publication date': '2014', 'sentence': 'CONCLUSION: The current investigation suggests that NP-mediated transcutaneous delivery of HC could be considered an effective therapeutic approach to manage dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2792121': {'publication date': '1989 Aug', 'sentence': 'To evaluate the effect of topical hydrocortisone therapy on cortisol secretion, the plasma cortisol response to a 2 h adrenocorticotropic hormone (ACTH) test was determined in 17 children with dermatitis.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 308784,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002406",
-          "name": "dermatitis",
-          "description": "The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes. [HPO:probinson]; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0011123",
-            "MEDDRA:10062249",
-            "MEDDRA:10012431",
-            "MP:0004947",
-            "MESH:D003872",
-            "SNOMEDCT:43116000",
-            "MONDO:0002406",
-            "MEDDRA:10012478",
-            "MEDDRA:10040876",
-            "ICD10:L30.9",
-            "DOID:2723",
-            "NCIT:C2983",
-            "SNOMEDCT:703938007",
-            "UMLS:C3875321",
-            "PSY:13710",
-            "UMLS:C0011603"
-          ],
-          "id": "MONDO:0002406",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis",
-            "Inflammatory abnormality of the skin",
-            "Inflammatory dermatosis",
-            "dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/eczema.htm",
-            "http://en.wikipedia.org/wiki/dermatitis",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308784,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002406",
-              "name": "dermatitis",
-              "description": "The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes. [HPO:probinson]; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0011123",
-                "MEDDRA:10062249",
-                "MEDDRA:10012431",
-                "MP:0004947",
-                "MESH:D003872",
-                "SNOMEDCT:43116000",
-                "MONDO:0002406",
-                "MEDDRA:10012478",
-                "MEDDRA:10040876",
-                "ICD10:L30.9",
-                "DOID:2723",
-                "NCIT:C2983",
-                "SNOMEDCT:703938007",
-                "UMLS:C3875321",
-                "PSY:13710",
-                "UMLS:C0011603"
-              ],
-              "id": "MONDO:0002406",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis",
-                "Inflammatory abnormality of the skin",
-                "Inflammatory dermatosis",
-                "dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/eczema.htm",
-                "http://en.wikipedia.org/wiki/dermatitis",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17147821,
-            "start": 569,
-            "end": 308784,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2459879': {'publication date': '1988', 'sentence': 'In the acute phase of dermatitis, topical hydrocortisone treatment has both a local and a systemic effect, due to percutaneous absorption.', 'subject score': 790, 'object score': 1000}, 'PMID:25395851': {'publication date': '2014', 'sentence': 'CONCLUSION: The current investigation suggests that NP-mediated transcutaneous delivery of HC could be considered an effective therapeutic approach to manage dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2792121': {'publication date': '1989 Aug', 'sentence': 'To evaluate the effect of topical hydrocortisone therapy on cortisol secretion, the plasma cortisol response to a 2 h adrenocorticotropic hormone (ACTH) test was determined in 17 children with dermatitis.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0011603---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "17499762",
-              "object": "MONDO:0002406",
-              "publications": [
-                "PMID:2459879",
-                "PMID:25395851",
-                "PMID:2792121"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:1680955': {'publication date': '1991 Jul', 'sentence': 'This hypoxia-specific increase in surface beta-adrenoreceptors was significantly enhanced in the cortisol-treated erythrocytes, showing that cortisol had a significant impact on erythrocyte beta-adrenoreceptor dynamics in addition to the direct influence of hypoxia.', 'subject score': 1000, 'object score': 1000}, 'PMID:28468567': {'publication date': '2018 02', 'sentence': 'Cortisol was higher in the LTH versus control ( P < .05).', 'subject score': 1000, 'object score': 901}, 'PMID:7155642': {'publication date': '1982', 'sentence': '[Effect of adrenalectomy and hydrocortisone on carbohydrate metabolism in the lungs and myocardium in chronic hypoxia].', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 317312,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-          "name": "Hypoxemia",
-          "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "NCIT:C93047",
-            "MEDDRA:10021142",
-            "UMLS:C0242184",
-            "ICD9:799.02",
-            "HP:0012418",
-            "EFO:0009444",
-            "MEDDRA:10021143",
-            "EFO:0009447",
-            "MEDDRA:10021141",
-            "UMLS:C0700292",
-            "SNOMEDCT:389086002",
-            "PDQ:CDR0000773145",
-            "SYMP:0000303",
-            "MEDDRA:10021144",
-            "MESH:D000860",
-            "NCIT:C3890",
-            "SNOMEDCT:389087006"
-          ],
-          "id": "HP:0012418",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hypoxia",
-            "Hypoxemia",
-            "hypoxemia",
-            "Hypoxia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:DiseaseOrPhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317312,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-              "name": "Hypoxemia",
-              "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "NCIT:C93047",
-                "MEDDRA:10021142",
-                "UMLS:C0242184",
-                "ICD9:799.02",
-                "HP:0012418",
-                "EFO:0009444",
-                "MEDDRA:10021143",
-                "EFO:0009447",
-                "MEDDRA:10021141",
-                "UMLS:C0700292",
-                "SNOMEDCT:389086002",
-                "PDQ:CDR0000773145",
-                "SYMP:0000303",
-                "MEDDRA:10021144",
-                "MESH:D000860",
-                "NCIT:C3890",
-                "SNOMEDCT:389087006"
-              ],
-              "id": "HP:0012418",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hypoxia",
-                "Hypoxemia",
-                "hypoxemia",
-                "Hypoxia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:DiseaseOrPhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12309621,
-            "start": 569,
-            "end": 317312,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1680955': {'publication date': '1991 Jul', 'sentence': 'This hypoxia-specific increase in surface beta-adrenoreceptors was significantly enhanced in the cortisol-treated erythrocytes, showing that cortisol had a significant impact on erythrocyte beta-adrenoreceptor dynamics in addition to the direct influence of hypoxia.', 'subject score': 1000, 'object score': 1000}, 'PMID:28468567': {'publication date': '2018 02', 'sentence': 'Cortisol was higher in the LTH versus control ( P < .05).', 'subject score': 1000, 'object score': 901}, 'PMID:7155642': {'publication date': '1982', 'sentence': '[Effect of adrenalectomy and hydrocortisone on carbohydrate metabolism in the lungs and myocardium in chronic hypoxia].', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0242184---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "12576998",
-              "object": "HP:0012418",
-              "publications": [
-                "PMID:1680955",
-                "PMID:28468567",
-                "PMID:7155642"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:34931659': {'publication date': '2021 Dec 21', 'sentence': 'The 5 dpf hypoxic exposure also elicited transient increases in whole body cortisol and in crf, uts1, and hsd20b2 expression, key regulators of the endocrine stress response.', 'subject score': 620, 'object score': 901}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 317312,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-          "name": "Hypoxemia",
-          "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "NCIT:C93047",
-            "MEDDRA:10021142",
-            "UMLS:C0242184",
-            "ICD9:799.02",
-            "HP:0012418",
-            "EFO:0009444",
-            "MEDDRA:10021143",
-            "EFO:0009447",
-            "MEDDRA:10021141",
-            "UMLS:C0700292",
-            "SNOMEDCT:389086002",
-            "PDQ:CDR0000773145",
-            "SYMP:0000303",
-            "MEDDRA:10021144",
-            "MESH:D000860",
-            "NCIT:C3890",
-            "SNOMEDCT:389087006"
-          ],
-          "id": "HP:0012418",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hypoxia",
-            "Hypoxemia",
-            "hypoxemia",
-            "Hypoxia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:DiseaseOrPhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317312,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-              "name": "Hypoxemia",
-              "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "NCIT:C93047",
-                "MEDDRA:10021142",
-                "UMLS:C0242184",
-                "ICD9:799.02",
-                "HP:0012418",
-                "EFO:0009444",
-                "MEDDRA:10021143",
-                "EFO:0009447",
-                "MEDDRA:10021141",
-                "UMLS:C0700292",
-                "SNOMEDCT:389086002",
-                "PDQ:CDR0000773145",
-                "SYMP:0000303",
-                "MEDDRA:10021144",
-                "MESH:D000860",
-                "NCIT:C3890",
-                "SNOMEDCT:389087006"
-              ],
-              "id": "HP:0012418",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hypoxia",
-                "Hypoxemia",
-                "hypoxemia",
-                "Hypoxia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:DiseaseOrPhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23593121,
-            "start": 317312,
-            "end": 569,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34931659': {'publication date': '2021 Dec 21', 'sentence': 'The 5 dpf hypoxic exposure also elicited transient increases in whole body cortisol and in crf, uts1, and hsd20b2 expression, key regulators of the endocrine stress response.', 'subject score': 620, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0242184---SEMMEDDB:associated_with---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "HP:0012418",
-              "id": "24030854",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:34931659"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 314596,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-          "name": "Insulin resistance",
-          "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "NCIT:C113101",
-            "UMLS:C0021655",
-            "MEDDRA:10022489",
-            "SNOMEDCT:48606007",
-            "MESH:D007333",
-            "EFO:0002614",
-            "HP:0000855",
-            "SNOMEDCT:763325000"
-          ],
-          "id": "HP:0000855",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Insulin resistance",
-            "insulin resistance",
-            "Insulin Resistance"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314596,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-              "name": "Insulin resistance",
-              "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "NCIT:C113101",
-                "UMLS:C0021655",
-                "MEDDRA:10022489",
-                "SNOMEDCT:48606007",
-                "MESH:D007333",
-                "EFO:0002614",
-                "HP:0000855",
-                "SNOMEDCT:763325000"
-              ],
-              "id": "HP:0000855",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Insulin resistance",
-                "insulin resistance",
-                "Insulin Resistance"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12266984,
-            "start": 314596,
-            "end": 569,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16757401': {'publication date': '2006 Apr-Jun', 'sentence': 'At multiple regression analyses, HOMA-IR on admission in the IR group significantly correlated with thyroid-stimulating hormone, glucagon, and cortisol.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0021655---SEMMEDDB:associated_with---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "HP:0000855",
-              "id": "12533519",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:16757401"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 528832,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-          "name": "toxic shock syndrome",
-          "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C35498",
-            "UMLS:C0600327",
-            "UMLS:CN204669",
-            "MEDDRA:10044248",
-            "MESH:D012772",
-            "MEDDRA:10044249",
-            "SNOMEDCT:18504008",
-            "DOID:14115",
-            "MEDDRA:10042852",
-            "UMLS:C0036983",
-            "ORPHANET:36234",
-            "SNOMEDCT:76571007",
-            "MEDDRA:10040580",
-            "NCIT:C35018",
-            "MEDDRA:10040070",
-            "ICD9:040.82",
-            "ICD10:A48.3",
-            "MONDO:0001881",
-            "EFO:0006834",
-            "SYMP:0000451"
-          ],
-          "id": "MONDO:0001881",
-          "category": "biolink:Disease",
-          "all_names": [
-            "toxic shock syndrome",
-            "Septic Shock",
-            "Shock, Septic",
-            "Toxic Shock Syndrome",
-            "Bacterial toxic-shock syndrome",
-            "septic shock",
-            "Toxic shock syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 528832,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-              "name": "toxic shock syndrome",
-              "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C35498",
-                "UMLS:C0600327",
-                "UMLS:CN204669",
-                "MEDDRA:10044248",
-                "MESH:D012772",
-                "MEDDRA:10044249",
-                "SNOMEDCT:18504008",
-                "DOID:14115",
-                "MEDDRA:10042852",
-                "UMLS:C0036983",
-                "ORPHANET:36234",
-                "SNOMEDCT:76571007",
-                "MEDDRA:10040580",
-                "NCIT:C35018",
-                "MEDDRA:10040070",
-                "ICD9:040.82",
-                "ICD10:A48.3",
-                "MONDO:0001881",
-                "EFO:0006834",
-                "SYMP:0000451"
-              ],
-              "id": "MONDO:0001881",
-              "category": "biolink:Disease",
-              "all_names": [
-                "toxic shock syndrome",
-                "Septic Shock",
-                "Shock, Septic",
-                "Toxic Shock Syndrome",
-                "Bacterial toxic-shock syndrome",
-                "septic shock",
-                "Toxic shock syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 27272384,
-            "start": 569,
-            "end": 528832,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9881838': {'publication date': '1998 Jul', 'sentence': 'The suppression of the anti-inflammatory effects of cortisol as a result of states of excessive stress leads to hypercatabolic diseases such as AIDS, sepsis and toxic shock syndrome and protein calorie malnutrition (NAIDS).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0600327---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "27747116",
-              "object": "MONDO:0001881",
-              "publications": [
-                "PMID:9881838"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 27272383,
-            "start": 569,
-            "end": 320039,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9881838': {'publication date': '1998 Jul', 'sentence': 'The suppression of the anti-inflammatory effects of cortisol as a result of states of excessive stress leads to hypercatabolic diseases such as AIDS, sepsis and toxic shock syndrome and protein calorie malnutrition (NAIDS).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0036690---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "27747115",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:9881838"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 313237,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
-          "name": "atopic eczema",
-          "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SYMP:0000289",
-            "EFO:0000274",
-            "DOID:3310",
-            "HP:0000964",
-            "NCIT:C3001",
-            "UMLS:C0013595",
-            "MESH:D004485",
-            "MEDDRA:10014200",
-            "MEDDRA:10014206",
-            "MEDDRA:10012454",
-            "ICD10:L20",
-            "MEDDRA:10014184",
-            "OMIM.PS:603165",
-            "MEDDRA:10014209",
-            "PSY:15950",
-            "MONDO:0004980",
-            "OMIM:PS603165"
-          ],
-          "id": "MONDO:0004980",
-          "category": "biolink:Disease",
-          "all_names": [
-            "atopic dermatitis",
-            "atopic eczema",
-            "eczema",
-            "Eczema"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/atopic_dermatitis",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313237,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
-              "name": "atopic eczema",
-              "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SYMP:0000289",
-                "EFO:0000274",
-                "DOID:3310",
-                "HP:0000964",
-                "NCIT:C3001",
-                "UMLS:C0013595",
-                "MESH:D004485",
-                "MEDDRA:10014200",
-                "MEDDRA:10014206",
-                "MEDDRA:10012454",
-                "ICD10:L20",
-                "MEDDRA:10014184",
-                "OMIM.PS:603165",
-                "MEDDRA:10014209",
-                "PSY:15950",
-                "MONDO:0004980",
-                "OMIM:PS603165"
-              ],
-              "id": "MONDO:0004980",
-              "category": "biolink:Disease",
-              "all_names": [
-                "atopic dermatitis",
-                "atopic eczema",
-                "eczema",
-                "Eczema"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/atopic_dermatitis",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26606828,
-            "start": 569,
-            "end": 313237,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8607567': {'publication date': '1995 Oct', 'sentence': 'We report the case of a 41-year-old nonatopic women with a previous history of eczematous reaction due to hydrocortisone who suffered worsening of her perennial rhinitis in association with perinasal dermatitis from the use of budesonide in nasal spray form, and stomatitis and pharyngitis due to budesonide in a bronchial inhaler.', 'subject score': 1000, 'object score': 853}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0013595---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "27073884",
-              "object": "MONDO:0004980",
-              "publications": [
-                "PMID:8607567"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 547810,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005546",
-          "name": "fibromyalgia",
-          "description": "A common nonarticular rheumatic condition that is characterized by muscle pain, tenderness, and stiffness.; A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.; Inflammation and fibrous degeneration of a muscle.; A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10016631",
-            "MEDDRA:10048439",
-            "MEDDRA:10028363",
-            "PSY:19685",
-            "SNOMEDCT:56557000",
-            "SNOMEDCT:726531007",
-            "NCIT:C50566",
-            "ORPHANET:41842",
-            "SNOMEDCT:203082005",
-            "MEDDRA:10063041",
-            "MONDO:0005546",
-            "SNOMEDCT:203102006",
-            "MEDDRA:10016663",
-            "DOID:631",
-            "EFO:0005687",
-            "MESH:D005356",
-            "ICD10:M79.7",
-            "NCIT:C87497",
-            "MEDDRA:10079197",
-            "UMLS:C0016053"
-          ],
-          "id": "MONDO:0005546",
-          "category": "biolink:Disease",
-          "all_names": [
-            "fibromyalgia",
-            "Fibromyalgia",
-            "Fibromyositis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:33024295",
-            "https://www.ncbi.nlm.nih.gov/labs/pmc/articles/pmc7660651/",
-            "PMID:30486733",
-            "PMID:32120395"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 547810,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005546",
-              "name": "fibromyalgia",
-              "description": "A common nonarticular rheumatic condition that is characterized by muscle pain, tenderness, and stiffness.; A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.; Inflammation and fibrous degeneration of a muscle.; A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10016631",
-                "MEDDRA:10048439",
-                "MEDDRA:10028363",
-                "PSY:19685",
-                "SNOMEDCT:56557000",
-                "SNOMEDCT:726531007",
-                "NCIT:C50566",
-                "ORPHANET:41842",
-                "SNOMEDCT:203082005",
-                "MEDDRA:10063041",
-                "MONDO:0005546",
-                "SNOMEDCT:203102006",
-                "MEDDRA:10016663",
-                "DOID:631",
-                "EFO:0005687",
-                "MESH:D005356",
-                "ICD10:M79.7",
-                "NCIT:C87497",
-                "MEDDRA:10079197",
-                "UMLS:C0016053"
-              ],
-              "id": "MONDO:0005546",
-              "category": "biolink:Disease",
-              "all_names": [
-                "fibromyalgia",
-                "Fibromyalgia",
-                "Fibromyositis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:33024295",
-                "https://www.ncbi.nlm.nih.gov/labs/pmc/articles/pmc7660651/",
-                "PMID:30486733",
-                "PMID:32120395"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24934283,
-            "start": 569,
-            "end": 547810,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:36831148': {'publication date': '2023 Feb 18', 'sentence': 'In this perspective paper, we focus on the neuro-endocrine interactions that occur between progesterone, allopregnanolone, and cortisol during pregnancy, and propose that they align with our previously proposed model of FM pathogenesis based on GABAergic \"weakening\" in a thalamocortical neural loop system.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0016053---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "25383174",
-              "object": "MONDO:0005546",
-              "publications": [
-                "PMID:36831148"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319508,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005468",
-          "name": "hypotensive disorder",
-          "description": "Blood pressure that is abnormally low.; Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.; Low Blood Pressure, vascular hypotension. [HPO:probinson]; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "MEDDRA:10036638",
-            "PDQ:CDR0000041785",
-            "MEDDRA:10021099",
-            "MEDDRA:10024896",
-            "MEDDRA:10024895",
-            "MEDDRA:10003146",
-            "MEDDRA:10024982",
-            "MEDDRA:10021106",
-            "EFO:0005251",
-            "SYMP:0000059",
-            "SNOMEDCT:45007003",
-            "NCIT:C3128",
-            "MEDDRA:10016174",
-            "PSY:24060",
-            "MEDDRA:10005744",
-            "MEDDRA:10066331",
-            "HP:0002615",
-            "ICD9:458",
-            "MEDDRA:10005753",
-            "MEDDRA:10005734",
-            "MEDDRA:10021097",
-            "MEDDRA:10013645",
-            "MEDDRA:10013644",
-            "MEDDRA:10006065",
-            "MONDO:0005468",
-            "MEDDRA:10003169",
-            "MEDDRA:10005743",
-            "MEDDRA:10006064",
-            "UMLS:C0020649",
-            "MESH:D007022"
-          ],
-          "id": "MONDO:0005468",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hypotensive disorder",
-            "hypotension",
-            "Hypotension"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:DiseaseOrPhenotypicFeature",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://github.com/monarch-initiative/mondo/issues/1030"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319508,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005468",
-              "name": "hypotensive disorder",
-              "description": "Blood pressure that is abnormally low.; Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.; Low Blood Pressure, vascular hypotension. [HPO:probinson]; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "MEDDRA:10036638",
-                "PDQ:CDR0000041785",
-                "MEDDRA:10021099",
-                "MEDDRA:10024896",
-                "MEDDRA:10024895",
-                "MEDDRA:10003146",
-                "MEDDRA:10024982",
-                "MEDDRA:10021106",
-                "EFO:0005251",
-                "SYMP:0000059",
-                "SNOMEDCT:45007003",
-                "NCIT:C3128",
-                "MEDDRA:10016174",
-                "PSY:24060",
-                "MEDDRA:10005744",
-                "MEDDRA:10066331",
-                "HP:0002615",
-                "ICD9:458",
-                "MEDDRA:10005753",
-                "MEDDRA:10005734",
-                "MEDDRA:10021097",
-                "MEDDRA:10013645",
-                "MEDDRA:10013644",
-                "MEDDRA:10006065",
-                "MONDO:0005468",
-                "MEDDRA:10003169",
-                "MEDDRA:10005743",
-                "MEDDRA:10006064",
-                "UMLS:C0020649",
-                "MESH:D007022"
-              ],
-              "id": "MONDO:0005468",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hypotensive disorder",
-                "hypotension",
-                "Hypotension"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:DiseaseOrPhenotypicFeature",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://github.com/monarch-initiative/mondo/issues/1030"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24758053,
-            "start": 569,
-            "end": 319508,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:36564159': {'publication date': '2022 Dec 23', 'sentence': 'The present study reported a case of hydrocortisone-induced blood pressure reduction in a patient with anterior pituitary hypofunction due to allergic reaction.', 'subject score': 875, 'object score': 875}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0020649---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "25205462",
-              "object": "MONDO:0005468",
-              "publications": [
-                "PMID:36564159"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:3024490': {'publication date': '1986 Dec', 'sentence': 'Fetal adrenocorticotropic hormone and cortisol increased to peak values within 2.8 hours of induced hypoxia but by 7.2 hours had begun to fall to values that were not significantly different from those at 1.4 hours.', 'subject score': 1000, 'object score': 888}, 'PMID:37120097': {'publication date': '2023 Apr 27', 'sentence': 'By contrast, individuals of the two solitary species had a reduced plasma cortisol response to acute hypoxia, possibly due to increased plasma cortisol under normoxia.', 'subject score': 851, 'object score': 888}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 317312,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-          "name": "Hypoxemia",
-          "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "NCIT:C93047",
-            "MEDDRA:10021142",
-            "UMLS:C0242184",
-            "ICD9:799.02",
-            "HP:0012418",
-            "EFO:0009444",
-            "MEDDRA:10021143",
-            "EFO:0009447",
-            "MEDDRA:10021141",
-            "UMLS:C0700292",
-            "SNOMEDCT:389086002",
-            "PDQ:CDR0000773145",
-            "SYMP:0000303",
-            "MEDDRA:10021144",
-            "MESH:D000860",
-            "NCIT:C3890",
-            "SNOMEDCT:389087006"
-          ],
-          "id": "HP:0012418",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hypoxia",
-            "Hypoxemia",
-            "hypoxemia",
-            "Hypoxia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:DiseaseOrPhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317312,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-              "name": "Hypoxemia",
-              "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "NCIT:C93047",
-                "MEDDRA:10021142",
-                "UMLS:C0242184",
-                "ICD9:799.02",
-                "HP:0012418",
-                "EFO:0009444",
-                "MEDDRA:10021143",
-                "EFO:0009447",
-                "MEDDRA:10021141",
-                "UMLS:C0700292",
-                "SNOMEDCT:389086002",
-                "PDQ:CDR0000773145",
-                "SYMP:0000303",
-                "MEDDRA:10021144",
-                "MESH:D000860",
-                "NCIT:C3890",
-                "SNOMEDCT:389087006"
-              ],
-              "id": "HP:0012418",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hypoxia",
-                "Hypoxemia",
-                "hypoxemia",
-                "Hypoxia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:DiseaseOrPhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20192340,
-            "start": 569,
-            "end": 317312,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3024490': {'publication date': '1986 Dec', 'sentence': 'Fetal adrenocorticotropic hormone and cortisol increased to peak values within 2.8 hours of induced hypoxia but by 7.2 hours had begun to fall to values that were not significantly different from those at 1.4 hours.', 'subject score': 1000, 'object score': 888}, 'PMID:37120097': {'publication date': '2023 Apr 27', 'sentence': 'By contrast, individuals of the two solitary species had a reduced plasma cortisol response to acute hypoxia, possibly due to increased plasma cortisol under normoxia.', 'subject score': 851, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0242184---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "20591759",
-              "object": "HP:0012418",
-              "publications": [
-                "PMID:3024490",
-                "PMID:37120097"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 312713,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:15740685': {'publication date': '2004', 'sentence': 'Fetal plasma cortisol concentrations were increased ( P < 0.05) during all levels of hypoxia.', 'subject score': 852, 'object score': 1000}, 'PMID:21042829': {'publication date': '2011 Feb', 'sentence': 'Hydrocortisone (HC) and DXA increased hypoxia- or TGF-beta-stimulated production of PAI-1 mRNA and protein.', 'subject score': 1000, 'object score': 1000}, 'PMID:8071889': {'publication date': '1994 May 15', 'sentence': 'Whilst plasma cortisol increased in early (after 15 min) and late (after 45 min) hypoxia in intact fetuses, the rise in cortisol in denervated fetuses was delayed, increasing significantly only by late hypoxia.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 317312,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-          "name": "congenital adrenal hyperplasia",
-          "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:237751000",
-            "DOID:12255",
-            "NCIT:C34360",
-            "ORPHANET:418",
-            "MONDO:0018479",
-            "MEDDRA:10010323",
-            "ICD9:255.2",
-            "DOID:0050811",
-            "HP:0008258",
-            "UMLS:C0001627",
-            "UMLS:C0701163",
-            "ICD10:E25",
-            "MESH:D000312"
-          ],
-          "id": "MONDO:0018479",
-          "category": "biolink:Disease",
-          "all_names": [
-            "congenital adrenal hyperplasia",
-            "obsolete congenital adrenal hyperplasia",
-            "Adrenogenital disorders",
-            "Adrenogenital disorder",
-            "Congenital adrenal hyperplasia",
-            "Adrenal Hyperplasia, Congenital",
-            "obsolete_congenital adrenal hyperplasia",
-            "Congenital Adrenal Hyperplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-            "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-            "http://omim.org/entry/201710",
-=======
-          "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-          "name": "Hypoxemia",
-          "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "NCIT:C93047",
-            "MEDDRA:10021142",
-            "UMLS:C0242184",
-            "ICD9:799.02",
-            "HP:0012418",
-            "EFO:0009444",
-            "MEDDRA:10021143",
-            "EFO:0009447",
-            "MEDDRA:10021141",
-            "UMLS:C0700292",
-            "SNOMEDCT:389086002",
-            "PDQ:CDR0000773145",
-            "SYMP:0000303",
-            "MEDDRA:10021144",
-            "MESH:D000860",
-            "NCIT:C3890",
-            "SNOMEDCT:389087006"
-          ],
-          "id": "HP:0012418",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hypoxia",
-            "Hypoxemia",
-            "hypoxemia",
-            "Hypoxia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:DiseaseOrPhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
->>>>>>> main
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 312713,
-=======
-            "identity": 317312,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-              "name": "congenital adrenal hyperplasia",
-              "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:237751000",
-                "DOID:12255",
-                "NCIT:C34360",
-                "ORPHANET:418",
-                "MONDO:0018479",
-                "MEDDRA:10010323",
-                "ICD9:255.2",
-                "DOID:0050811",
-                "HP:0008258",
-                "UMLS:C0001627",
-                "UMLS:C0701163",
-                "ICD10:E25",
-                "MESH:D000312"
-              ],
-              "id": "MONDO:0018479",
-              "category": "biolink:Disease",
-              "all_names": [
-                "congenital adrenal hyperplasia",
-                "obsolete congenital adrenal hyperplasia",
-                "Adrenogenital disorders",
-                "Adrenogenital disorder",
-                "Congenital adrenal hyperplasia",
-                "Adrenal Hyperplasia, Congenital",
-                "obsolete_congenital adrenal hyperplasia",
-                "Congenital Adrenal Hyperplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-                "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-                "http://omim.org/entry/201710",
-=======
-              "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-              "name": "Hypoxemia",
-              "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "NCIT:C93047",
-                "MEDDRA:10021142",
-                "UMLS:C0242184",
-                "ICD9:799.02",
-                "HP:0012418",
-                "EFO:0009444",
-                "MEDDRA:10021143",
-                "EFO:0009447",
-                "MEDDRA:10021141",
-                "UMLS:C0700292",
-                "SNOMEDCT:389086002",
-                "PDQ:CDR0000773145",
-                "SYMP:0000303",
-                "MEDDRA:10021144",
-                "MESH:D000860",
-                "NCIT:C3890",
-                "SNOMEDCT:389087006"
-              ],
-              "id": "HP:0012418",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hypoxia",
-                "Hypoxemia",
-                "hypoxemia",
-                "Hypoxia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:DiseaseOrPhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
->>>>>>> main
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 18080355,
-            "start": 569,
-            "end": 312713,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26184920': {'publication date': '2015 Oct', 'sentence': 'Congenital adrenal hyperplasia (CAH) is a chronic condition and individuals are exposed to elevated androgen levels in utero as a result of the endogenous cortisol deficiency.', 'subject score': 851, 'object score': 1000}, 'PMID:3487786': {'publication date': '1986 Jul', 'sentence': 'If this cytochrome P-450 enzyme is defective, cortisol cannot be synthesized, resulting in congenital adrenal hyperplasia.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0001627---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "18446972",
-              "object": "MONDO:0018479",
-              "publications": [
-                "PMID:26184920",
-                "PMID:3487786"
-=======
-            "identity": 11445217,
-            "start": 569,
-            "end": 317312,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15740685': {'publication date': '2004', 'sentence': 'Fetal plasma cortisol concentrations were increased ( P < 0.05) during all levels of hypoxia.', 'subject score': 852, 'object score': 1000}, 'PMID:21042829': {'publication date': '2011 Feb', 'sentence': 'Hydrocortisone (HC) and DXA increased hypoxia- or TGF-beta-stimulated production of PAI-1 mRNA and protein.', 'subject score': 1000, 'object score': 1000}, 'PMID:8071889': {'publication date': '1994 May 15', 'sentence': 'Whilst plasma cortisol increased in early (after 15 min) and late (after 45 min) hypoxia in intact fetuses, the rise in cortisol in denervated fetuses was delayed, increasing significantly only by late hypoxia.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0242184---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "11695335",
-              "object": "HP:0012418",
-              "publications": [
-                "PMID:15740685",
-                "PMID:21042829",
-                "PMID:8071889"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 546804,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:1030880': {'publication date': '1976 Jan-Feb', 'sentence': 'Pretreatment of rats with hydrocortisone or protamin-Zn-insulin within 4 days altered in subsequent acute hypoxia (3 hrs, \"height\" 10 000 m) the isoenzyme spectrum of LDH in lungs, liver tissue and kidney cortex.', 'subject score': 1000, 'object score': 851}, 'PMID:29956573': {'publication date': '2018 Apr-Jun', 'sentence': 'A pilot investigation into the effects of acute normobaric hypoxia, high altitude exposure and exercise on serum angiotensin-converting enzyme, aldosterone and cortisol.', 'subject score': 1000, 'object score': 802}, 'PMID:5401027': {'publication date': '1969', 'sentence': '[The adaptive effect of hydrocortisone in hypoxia].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317312,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-=======
-          "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-          "name": "Hypoxemia",
-          "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "NCIT:C93047",
-            "MEDDRA:10021142",
-            "UMLS:C0242184",
-            "ICD9:799.02",
-            "HP:0012418",
-            "EFO:0009444",
-            "MEDDRA:10021143",
-            "EFO:0009447",
-            "MEDDRA:10021141",
-            "UMLS:C0700292",
-            "SNOMEDCT:389086002",
-            "PDQ:CDR0000773145",
-            "SYMP:0000303",
-            "MEDDRA:10021144",
-            "MESH:D000860",
-            "NCIT:C3890",
-            "SNOMEDCT:389087006"
-          ],
-          "id": "HP:0012418",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hypoxia",
-            "Hypoxemia",
-            "hypoxemia",
-            "Hypoxia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:DiseaseOrPhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 546804,
-=======
-            "identity": 317312,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-=======
-              "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-              "name": "Hypoxemia",
-              "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "NCIT:C93047",
-                "MEDDRA:10021142",
-                "UMLS:C0242184",
-                "ICD9:799.02",
-                "HP:0012418",
-                "EFO:0009444",
-                "MEDDRA:10021143",
-                "EFO:0009447",
-                "MEDDRA:10021141",
-                "UMLS:C0700292",
-                "SNOMEDCT:389086002",
-                "PDQ:CDR0000773145",
-                "SYMP:0000303",
-                "MEDDRA:10021144",
-                "MESH:D000860",
-                "NCIT:C3890",
-                "SNOMEDCT:389087006"
-              ],
-              "id": "HP:0012418",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hypoxia",
-                "Hypoxemia",
-                "hypoxemia",
-                "Hypoxia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:DiseaseOrPhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 17865024,
-            "start": 569,
-            "end": 546804,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25821896': {'publication date': '2015 Aug', 'sentence': 'The results of our study confirm that thymol has strong ameliorative effect against hydrocortisone-induced oxidative stress injury in hepatic tissues.', 'subject score': 840, 'object score': 840}, 'PMID:30672332': {'publication date': '2019', 'sentence': 'Vitamin C Prevents Hydrocortisone-Induced Injury in HMEC-1 through Promoting Bestrophin-3 Expression.', 'subject score': 851, 'object score': 851}, 'PMID:31547969': {'publication date': '2019 11', 'sentence': 'Basic science studies suggest that high circulating levels of cortisol may directly cause organ injury.', 'subject score': 1000, 'object score': 888}, 'PMID:9151238': {'publication date': '1997 Feb', 'sentence': 'These compounds prevented injury during in vivo experiments, such as hydrocortisone-induced cataracts, endotoxin shock and CCl4-induced liver injury (isolated hepatocytes and rats).', 'subject score': 851, 'object score': 833}, 'PMID:25982069': {'publication date': '2015 Aug', 'sentence': 'This is the first report on the effects of cortisol and BDNF induced trauma in child and adolescent victims of sexual abuse.', 'subject score': 1000, 'object score': 1000}, 'PMID:3495144': {'publication date': '1987 Jun', 'sentence': 'Technetium-99m imaging of bone trauma: reduced sensitivity caused by hydrocortisone in rabbits.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C3263723---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0043251---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "18240145",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:3495144",
-                "PMID:9151238",
-                "PMID:30672332",
-                "PMID:25821896",
-                "PMID:25982069",
-                "PMID:31547969"
-=======
-            "identity": 7219825,
-            "start": 569,
-            "end": 317312,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1030880': {'publication date': '1976 Jan-Feb', 'sentence': 'Pretreatment of rats with hydrocortisone or protamin-Zn-insulin within 4 days altered in subsequent acute hypoxia (3 hrs, \"height\" 10 000 m) the isoenzyme spectrum of LDH in lungs, liver tissue and kidney cortex.', 'subject score': 1000, 'object score': 851}, 'PMID:29956573': {'publication date': '2018 Apr-Jun', 'sentence': 'A pilot investigation into the effects of acute normobaric hypoxia, high altitude exposure and exercise on serum angiotensin-converting enzyme, aldosterone and cortisol.', 'subject score': 1000, 'object score': 802}, 'PMID:5401027': {'publication date': '1969', 'sentence': '[The adaptive effect of hydrocortisone in hypoxia].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0242184---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7366981",
-              "object": "HP:0012418",
-              "publications": [
-                "PMID:1030880",
-                "PMID:29956573",
-                "PMID:5401027"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:2152': {'publication date': '1975 Nov', 'sentence': 'All inhibitors prevented the rise in cortisol secretion usually observed in hypoxic dogs.', 'subject score': 888, 'object score': 888}, 'PMID:32779728': {'publication date': '2020 Jul 21', 'sentence': 'Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-Protocol and statistical analysis plan.', 'subject score': 901, 'object score': 888}, 'PMID:34138478': {'publication date': '2021 Jun 17', 'sentence': 'In the COVID STEROID trial, we aimed to assess the effects of low-dose hydrocortisone on patient-centred outcomes in adults with COVID-19 and severe hypoxia.', 'subject score': 901, 'object score': 888}, 'PMID:9776848': {'publication date': '1998 Jan-Feb', 'sentence': 'Keloid fibroblasts displayed enhanced apoptosis rates in response to hydrocortisone, gamma interferon, and hypoxia treatment as compared with normal adult fibroblasts.', 'subject score': 1000, 'object score': 888}, 'PMID:3024490': {'publication date': '1986 Dec', 'sentence': 'We conclude that the changes in fetal adrenocorticotropic hormone, cortisol, and adrenal blood flow seen in short-term hypoxemia are reproduced during sustained hypoxemia with acidemia.', 'subject score': 1000, 'object score': 901}, 'PMID:9564872': {'publication date': '1998 May', 'sentence': 'Despite this, the increase in plasma cortisol in hypoxemia in intact fetuses was absent in carotid-denervated fetuses.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317312,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-          "name": "Hypoxemia",
-          "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "NCIT:C93047",
-            "MEDDRA:10021142",
-            "UMLS:C0242184",
-            "ICD9:799.02",
-            "HP:0012418",
-            "EFO:0009444",
-            "MEDDRA:10021143",
-            "EFO:0009447",
-            "MEDDRA:10021141",
-            "UMLS:C0700292",
-            "SNOMEDCT:389086002",
-            "PDQ:CDR0000773145",
-            "SYMP:0000303",
-            "MEDDRA:10021144",
-            "MESH:D000860",
-            "NCIT:C3890",
-            "SNOMEDCT:389087006"
-          ],
-          "id": "HP:0012418",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hypoxia",
-            "Hypoxemia",
-            "hypoxemia",
-            "Hypoxia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:DiseaseOrPhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317312,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-              "name": "Hypoxemia",
-              "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "NCIT:C93047",
-                "MEDDRA:10021142",
-                "UMLS:C0242184",
-                "ICD9:799.02",
-                "HP:0012418",
-                "EFO:0009444",
-                "MEDDRA:10021143",
-                "EFO:0009447",
-                "MEDDRA:10021141",
-                "UMLS:C0700292",
-                "SNOMEDCT:389086002",
-                "PDQ:CDR0000773145",
-                "SYMP:0000303",
-                "MEDDRA:10021144",
-                "MESH:D000860",
-                "NCIT:C3890",
-                "SNOMEDCT:389087006"
-              ],
-              "id": "HP:0012418",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hypoxia",
-                "Hypoxemia",
-                "hypoxemia",
-                "Hypoxia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:DiseaseOrPhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15281540,
-            "start": 569,
-            "end": 317312,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2152': {'publication date': '1975 Nov', 'sentence': 'All inhibitors prevented the rise in cortisol secretion usually observed in hypoxic dogs.', 'subject score': 888, 'object score': 888}, 'PMID:32779728': {'publication date': '2020 Jul 21', 'sentence': 'Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-Protocol and statistical analysis plan.', 'subject score': 901, 'object score': 888}, 'PMID:34138478': {'publication date': '2021 Jun 17', 'sentence': 'In the COVID STEROID trial, we aimed to assess the effects of low-dose hydrocortisone on patient-centred outcomes in adults with COVID-19 and severe hypoxia.', 'subject score': 901, 'object score': 888}, 'PMID:9776848': {'publication date': '1998 Jan-Feb', 'sentence': 'Keloid fibroblasts displayed enhanced apoptosis rates in response to hydrocortisone, gamma interferon, and hypoxia treatment as compared with normal adult fibroblasts.', 'subject score': 1000, 'object score': 888}, 'PMID:3024490': {'publication date': '1986 Dec', 'sentence': 'We conclude that the changes in fetal adrenocorticotropic hormone, cortisol, and adrenal blood flow seen in short-term hypoxemia are reproduced during sustained hypoxemia with acidemia.', 'subject score': 1000, 'object score': 901}, 'PMID:9564872': {'publication date': '1998 May', 'sentence': 'Despite this, the increase in plasma cortisol in hypoxemia in intact fetuses was absent in carotid-denervated fetuses.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0242184---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0700292---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "15602187",
-              "object": "HP:0012418",
-              "publications": [
-                "PMID:34138478",
-                "PMID:3024490",
-                "PMID:9776848",
-                "PMID:9564872",
-                "PMID:2152",
-                "PMID:32779728"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:produces",
-    "r2.publications_info": "{'PMID:16099825': {'publication date': '2005 Dec', 'sentence': 'This likely represents an adaptive response to LTH, to prevent excessive cortisol production that would restrict fetal growth and potentially induce preterm delivery.', 'subject score': 901, 'object score': 851}, 'PMID:20713972': {'publication date': '2010 Oct', 'sentence': 'These data indicate that LTH enhances adrenal cortical sensitivity to the inhibitory effects of NO on cortisol production.', 'subject score': 901, 'object score': 790}}",
-    "p2": {
-      "start": {
-        "identity": 317312,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-          "name": "Hypoxemia",
-          "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "NCIT:C93047",
-            "MEDDRA:10021142",
-            "UMLS:C0242184",
-            "ICD9:799.02",
-            "HP:0012418",
-            "EFO:0009444",
-            "MEDDRA:10021143",
-            "EFO:0009447",
-            "MEDDRA:10021141",
-            "UMLS:C0700292",
-            "SNOMEDCT:389086002",
-            "PDQ:CDR0000773145",
-            "SYMP:0000303",
-            "MEDDRA:10021144",
-            "MESH:D000860",
-            "NCIT:C3890",
-            "SNOMEDCT:389087006"
-          ],
-          "id": "HP:0012418",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hypoxia",
-            "Hypoxemia",
-            "hypoxemia",
-            "Hypoxia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:DiseaseOrPhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317312,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-              "name": "Hypoxemia",
-              "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "NCIT:C93047",
-                "MEDDRA:10021142",
-                "UMLS:C0242184",
-                "ICD9:799.02",
-                "HP:0012418",
-                "EFO:0009444",
-                "MEDDRA:10021143",
-                "EFO:0009447",
-                "MEDDRA:10021141",
-                "UMLS:C0700292",
-                "SNOMEDCT:389086002",
-                "PDQ:CDR0000773145",
-                "SYMP:0000303",
-                "MEDDRA:10021144",
-                "MESH:D000860",
-                "NCIT:C3890",
-                "SNOMEDCT:389087006"
-              ],
-              "id": "HP:0012418",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hypoxia",
-                "Hypoxemia",
-                "hypoxemia",
-                "Hypoxia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:DiseaseOrPhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11733776,
-            "start": 317312,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16099825': {'publication date': '2005 Dec', 'sentence': 'This likely represents an adaptive response to LTH, to prevent excessive cortisol production that would restrict fetal growth and potentially induce preterm delivery.', 'subject score': 901, 'object score': 851}, 'PMID:20713972': {'publication date': '2010 Oct', 'sentence': 'These data indicate that LTH enhances adrenal cortical sensitivity to the inhibitory effects of NO on cortisol production.', 'subject score': 901, 'object score': 790}}",
-              "kg2_ids": [
-                "UMLS:C0242184---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "HP:0012418",
-              "id": "11989948",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:16099825",
-                "PMID:20713972"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:2437075': {'publication date': '1987 Feb', 'sentence': 'The effects of 8-bromo-cyclic AMP and cyclic AMP agonists (cholera toxin plus hydrocortisone and prostaglandin E2 plus 3-isobutyl-1-methylxanthine) on the cytotoxic activity of T cells generated during murine influenza virus infection have been examined.', 'subject score': 861, 'object score': 861}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 521264,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005812",
-          "name": "influenza",
-          "description": "An acute viral infection of the respiratory tract, occurring in isolated cases, in epidemics, or in pandemics; it is caused by serologically different strains of viruses (influenzaviruses) designated A, B, and C, has a 3-day incubation period, and usually lasts for 3 to 10 days. It is marked by inflammation of the nasal mucosa, pharynx, and conjunctiva; headache; myalgia; often fever, chills, and prostration; and occasionally involvement of the myocardium or central nervous system.; An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD9:487",
-            "SNOMEDCT:61700007",
-            "MESH:D007251",
-            "MESH:D009976",
-            "UMLS:C0029342",
-            "DOID:8469",
-            "ICD10:J11.1",
-            "UMLS:C0021400",
-            "MONDO:0005812",
-            "NCIT:C53482",
-            "PSY:25260",
-            "SNOMEDCT:6142004",
-            "EFO:0007328",
-            "MEDDRA:10016793",
-            "MEDDRA:10022000",
-            "MEDDRA:10016790",
-            "MEDDRA:10042807",
-            "SNOMEDCT:65093003",
-            "UMLS:C0155871"
-          ],
-          "id": "MONDO:0005812",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Influenza, Human",
-            "Influenza with non-respiratory manifestation",
-            "Influenza",
-            "Orthomyxoviridae Infections",
-            "influenza"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.merck.com/mmhe/sec17/ch198/ch198d.htm",
-            "http://www.who.int/mediacentre/factsheets/2003/fs211/en/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 521264,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005812",
-              "name": "influenza",
-              "description": "An acute viral infection of the respiratory tract, occurring in isolated cases, in epidemics, or in pandemics; it is caused by serologically different strains of viruses (influenzaviruses) designated A, B, and C, has a 3-day incubation period, and usually lasts for 3 to 10 days. It is marked by inflammation of the nasal mucosa, pharynx, and conjunctiva; headache; myalgia; often fever, chills, and prostration; and occasionally involvement of the myocardium or central nervous system.; An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD9:487",
-                "SNOMEDCT:61700007",
-                "MESH:D007251",
-                "MESH:D009976",
-                "UMLS:C0029342",
-                "DOID:8469",
-                "ICD10:J11.1",
-                "UMLS:C0021400",
-                "MONDO:0005812",
-                "NCIT:C53482",
-                "PSY:25260",
-                "SNOMEDCT:6142004",
-                "EFO:0007328",
-                "MEDDRA:10016793",
-                "MEDDRA:10022000",
-                "MEDDRA:10016790",
-                "MEDDRA:10042807",
-                "SNOMEDCT:65093003",
-                "UMLS:C0155871"
-              ],
-              "id": "MONDO:0005812",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Influenza, Human",
-                "Influenza with non-respiratory manifestation",
-                "Influenza",
-                "Orthomyxoviridae Infections",
-                "influenza"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.merck.com/mmhe/sec17/ch198/ch198d.htm",
-                "http://www.who.int/mediacentre/factsheets/2003/fs211/en/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17009646,
-            "start": 569,
-            "end": 521264,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2437075': {'publication date': '1987 Feb', 'sentence': 'The effects of 8-bromo-cyclic AMP and cyclic AMP agonists (cholera toxin plus hydrocortisone and prostaglandin E2 plus 3-isobutyl-1-methylxanthine) on the cytotoxic activity of T cells generated during murine influenza virus infection have been examined.', 'subject score': 861, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0021400---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "17359303",
-              "object": "MONDO:0005812",
-              "publications": [
-                "PMID:2437075"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 320151,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:20716227': {'publication date': '2010 Nov', 'sentence': 'How stress gets under the skin: cortisol and stress reactivity in psoriasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:21094146': {'publication date': '2011 Jan 07', 'sentence': 'Collectively these data show that PHK are capable of extra-adrenal cortisol synthesis, which could be a fundamental pathway in skin biology with implications in psoriasis and atopic dermatitis.', 'subject score': 775, 'object score': 1000}, 'PMID:24288511': {'publication date': '2013', 'sentence': 'Association of psoriasis severity with serum prolactin, thyroid hormones, and cortisol before and after treatment.', 'subject score': 1000, 'object score': 888}, 'PMID:25387679': {'publication date': '2014 Dec', 'sentence': 'The findings indicated that HPA dysfunction may be present in psoriasis, as bedtime cortisol was correlated with psoriasis severity.', 'subject score': 888, 'object score': 888}, 'PMID:28735612': {'publication date': '2017 08', 'sentence': 'Cutaneous Glucocorticoidogenesis and Cortisol Signaling Are Defective in Psoriasis.', 'subject score': 888, 'object score': 1000}, 'PMID:5122563': {'publication date': '1971 May', 'sentence': '[Use of ultrasonics and phonophoresis with hydrocortisone in chronic psoriasis].', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 320360,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-          "name": "dermatitis, atopic",
-          "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MESH:C566404",
-            "MEDDRA:10012434",
-            "SNOMEDCT:24079001",
-            "MONDO:0011292",
-            "MEDDRA:10003641",
-            "MONDO:0100181",
-            "MEDDRA:10014191",
-            "OMIM:603165",
-            "HP:0001047",
-            "MEDDRA:10001711",
-            "MEDDRA:10003639",
-            "UMLS:C0011615",
-            "UMLS:C4280605",
-            "UMLS:C1864155",
-            "MEDDRA:10012438",
-            "MEDDRA:10014188",
-            "MEDDRA:10001712",
-            "MESH:D003876",
-            "SNOMEDCT:200775004"
-          ],
-          "id": "MONDO:0011292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis, Atopic, 1",
-            "dermatitis, atopic",
-            "Dermatitis, Atopic",
-            "Baby eczema",
-            "Dermatitis, atopic related phenotypic feature",
-            "Atopic dermatitis",
-            "dermatitis, atopic, 1"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:27904186",
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005083",
-          "name": "psoriasis",
-          "description": "An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.; A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.; A skin abnormality characterized by redness and irritation, with thick, red skin that displays flaky, silver-white patches (scales). [HPO:probinson]; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have psoriasis also get a form of arthritis called psoriatic arthritis. A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast.  Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope. Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include: Infections Stress Dry skin Certain medicines  Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases ; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D011565",
-            "SNOMEDCT:9014002",
-            "ICD10:L40",
-            "MEDDRA:10058675",
-            "MONDO:0005083",
-            "DOID:8893",
-            "UMLS:C0033860",
-            "EFO:0000676",
-            "UMLS:C0262985",
-            "NCIT:C3346",
-            "NCIT:C27724",
-            "OMIM.PS:177900",
-            "OMIM:PS177900",
-            "SNOMEDCT:52230004",
-            "HP:0003765",
-            "MEDDRA:10037153",
-            "SNOMEDCT:238564003"
-          ],
-          "id": "MONDO:0005083",
-          "category": "biolink:Disease",
-          "all_names": [
-            "psoriasis",
-            "Psoriasiform eczema",
-            "Psoriasis",
-            "Psoriasiform dermatitis",
-            "Psoriasiform Dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.cdc.gov/psoriasis/index.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320360,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005083",
-              "name": "psoriasis",
-              "description": "An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.; A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.; A skin abnormality characterized by redness and irritation, with thick, red skin that displays flaky, silver-white patches (scales). [HPO:probinson]; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have psoriasis also get a form of arthritis called psoriatic arthritis. A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast.  Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope. Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include: Infections Stress Dry skin Certain medicines  Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases ; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D011565",
-                "SNOMEDCT:9014002",
-                "ICD10:L40",
-                "MEDDRA:10058675",
-                "MONDO:0005083",
-                "DOID:8893",
-                "UMLS:C0033860",
-                "EFO:0000676",
-                "UMLS:C0262985",
-                "NCIT:C3346",
-                "NCIT:C27724",
-                "OMIM.PS:177900",
-                "OMIM:PS177900",
-                "SNOMEDCT:52230004",
-                "HP:0003765",
-                "MEDDRA:10037153",
-                "SNOMEDCT:238564003"
-              ],
-              "id": "MONDO:0005083",
-              "category": "biolink:Disease",
-              "all_names": [
-                "psoriasis",
-                "Psoriasiform eczema",
-                "Psoriasis",
-                "Psoriasiform dermatitis",
-                "Psoriasiform Dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.cdc.gov/psoriasis/index.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14842179,
-            "start": 569,
-            "end": 320360,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20716227': {'publication date': '2010 Nov', 'sentence': 'How stress gets under the skin: cortisol and stress reactivity in psoriasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:21094146': {'publication date': '2011 Jan 07', 'sentence': 'Collectively these data show that PHK are capable of extra-adrenal cortisol synthesis, which could be a fundamental pathway in skin biology with implications in psoriasis and atopic dermatitis.', 'subject score': 775, 'object score': 1000}, 'PMID:24288511': {'publication date': '2013', 'sentence': 'Association of psoriasis severity with serum prolactin, thyroid hormones, and cortisol before and after treatment.', 'subject score': 1000, 'object score': 888}, 'PMID:25387679': {'publication date': '2014 Dec', 'sentence': 'The findings indicated that HPA dysfunction may be present in psoriasis, as bedtime cortisol was correlated with psoriasis severity.', 'subject score': 888, 'object score': 888}, 'PMID:28735612': {'publication date': '2017 08', 'sentence': 'Cutaneous Glucocorticoidogenesis and Cortisol Signaling Are Defective in Psoriasis.', 'subject score': 888, 'object score': 1000}, 'PMID:5122563': {'publication date': '1971 May', 'sentence': '[Use of ultrasonics and phonophoresis with hydrocortisone in chronic psoriasis].', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0033860---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "15155784",
-              "object": "MONDO:0005083",
-              "publications": [
-                "PMID:20716227",
-                "PMID:21094146",
-                "PMID:24288511",
-                "PMID:25387679",
-                "PMID:28735612",
-                "PMID:5122563"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:30446190': {'publication date': '2018 Nov - Dec', 'sentence': 'There may be a subset of patients unable to elicit an appropriate immunosuppressive response to stress through upregulation of cortisol, with resultant exacerbation of their psoriasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:36065538': {'publication date': '2022 05 01', 'sentence': 'Also, blunted salivary cortisol diurnal rhythm in psoriatic patients and a positive correlation of salivary cortisol concentration with state anxiety and psoriasis severity were revealed.', 'subject score': 851, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 320360,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005083",
-          "name": "psoriasis",
-          "description": "An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.; A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.; A skin abnormality characterized by redness and irritation, with thick, red skin that displays flaky, silver-white patches (scales). [HPO:probinson]; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have psoriasis also get a form of arthritis called psoriatic arthritis. A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast.  Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope. Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include: Infections Stress Dry skin Certain medicines  Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases ; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D011565",
-            "SNOMEDCT:9014002",
-            "ICD10:L40",
-            "MEDDRA:10058675",
-            "MONDO:0005083",
-            "DOID:8893",
-            "UMLS:C0033860",
-            "EFO:0000676",
-            "UMLS:C0262985",
-            "NCIT:C3346",
-            "NCIT:C27724",
-            "OMIM.PS:177900",
-            "OMIM:PS177900",
-            "SNOMEDCT:52230004",
-            "HP:0003765",
-            "MEDDRA:10037153",
-            "SNOMEDCT:238564003"
-          ],
-          "id": "MONDO:0005083",
-          "category": "biolink:Disease",
-          "all_names": [
-            "psoriasis",
-            "Psoriasiform eczema",
-            "Psoriasis",
-            "Psoriasiform dermatitis",
-            "Psoriasiform Dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.cdc.gov/psoriasis/index.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320360,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005083",
-              "name": "psoriasis",
-              "description": "An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.; A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.; A skin abnormality characterized by redness and irritation, with thick, red skin that displays flaky, silver-white patches (scales). [HPO:probinson]; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have psoriasis also get a form of arthritis called psoriatic arthritis. A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast.  Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope. Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include: Infections Stress Dry skin Certain medicines  Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases ; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D011565",
-                "SNOMEDCT:9014002",
-                "ICD10:L40",
-                "MEDDRA:10058675",
-                "MONDO:0005083",
-                "DOID:8893",
-                "UMLS:C0033860",
-                "EFO:0000676",
-                "UMLS:C0262985",
-                "NCIT:C3346",
-                "NCIT:C27724",
-                "OMIM.PS:177900",
-                "OMIM:PS177900",
-                "SNOMEDCT:52230004",
-                "HP:0003765",
-                "MEDDRA:10037153",
-                "SNOMEDCT:238564003"
-              ],
-              "id": "MONDO:0005083",
-              "category": "biolink:Disease",
-              "all_names": [
-                "psoriasis",
-                "Psoriasiform eczema",
-                "Psoriasis",
-                "Psoriasiform dermatitis",
-                "Psoriasiform Dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.cdc.gov/psoriasis/index.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20299961,
-            "start": 569,
-            "end": 320360,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30446190': {'publication date': '2018 Nov - Dec', 'sentence': 'There may be a subset of patients unable to elicit an appropriate immunosuppressive response to stress through upregulation of cortisol, with resultant exacerbation of their psoriasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:36065538': {'publication date': '2022 05 01', 'sentence': 'Also, blunted salivary cortisol diurnal rhythm in psoriatic patients and a positive correlation of salivary cortisol concentration with state anxiety and psoriasis severity were revealed.', 'subject score': 851, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0033860---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "20701310",
-              "object": "MONDO:0005083",
-              "publications": [
-                "PMID:30446190",
-                "PMID:36065538"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:21094146': {'publication date': '2011 Jan 07', 'sentence': 'The expression of StAR and MLN64 was aberrant in two skin disorders, psoriasis and atopic dermatitis, that are commonly treated with cortisol, suggesting dysregulation of epidermal steroid synthesis in these patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:27824222': {'publication date': '2016 Dec', 'sentence': 'This study aimed to determine serum levels of basal cortisol and adrenocorticotropic hormone (ACTH) and circulating levels of various cytokines and chemokines and their association with psychological measures in psoriasis patients.', 'subject score': 888, 'object score': 888}, 'PMID:36065538': {'publication date': '2022 05 01', 'sentence': 'Circadian cortisol profiles and hair cortisol concentration in patients with psoriasis: associations with anxiety, depressive symptomatology and disease severity', 'subject score': 851, 'object score': 1000}, 'PMID:36249714': {'publication date': '2022', 'sentence': 'Conclusion: Oral administration of Lactocare(r) probiotic (two times daily) associated with administration of topical hydrocortisone resulted in the improvement of PASI, DLQI, and VAS scores in the patients with psoriasis after 12 weeks of treatment.', 'subject score': 861, 'object score': 1000}, 'PMID:6832467': {'publication date': '1983', 'sentence': 'Plasma cortisol studies with 0.05% halometasone cream and ointment in patients with psoriasis.', 'subject score': 888, 'object score': 1000}, 'PMID:881090': {'publication date': '1977', 'sentence': 'Triamcinolone acetonide, hydrocortisone and methotrexate, all known to be useful clinically in the treatment of psoriasis, were examined for their ability to antagonize the development of retinoic-acid-induced scaling.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 320360,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005083",
-          "name": "psoriasis",
-          "description": "An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.; A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.; A skin abnormality characterized by redness and irritation, with thick, red skin that displays flaky, silver-white patches (scales). [HPO:probinson]; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have psoriasis also get a form of arthritis called psoriatic arthritis. A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast.  Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope. Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include: Infections Stress Dry skin Certain medicines  Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases ; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D011565",
-            "SNOMEDCT:9014002",
-            "ICD10:L40",
-            "MEDDRA:10058675",
-            "MONDO:0005083",
-            "DOID:8893",
-            "UMLS:C0033860",
-            "EFO:0000676",
-            "UMLS:C0262985",
-            "NCIT:C3346",
-            "NCIT:C27724",
-            "OMIM.PS:177900",
-            "OMIM:PS177900",
-            "SNOMEDCT:52230004",
-            "HP:0003765",
-            "MEDDRA:10037153",
-            "SNOMEDCT:238564003"
-          ],
-          "id": "MONDO:0005083",
-          "category": "biolink:Disease",
-          "all_names": [
-            "psoriasis",
-            "Psoriasiform eczema",
-            "Psoriasis",
-            "Psoriasiform dermatitis",
-            "Psoriasiform Dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.cdc.gov/psoriasis/index.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320360,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005083",
-              "name": "psoriasis",
-              "description": "An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.; A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.; A skin abnormality characterized by redness and irritation, with thick, red skin that displays flaky, silver-white patches (scales). [HPO:probinson]; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have psoriasis also get a form of arthritis called psoriatic arthritis. A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast.  Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope. Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include: Infections Stress Dry skin Certain medicines  Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases ; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D011565",
-                "SNOMEDCT:9014002",
-                "ICD10:L40",
-                "MEDDRA:10058675",
-                "MONDO:0005083",
-                "DOID:8893",
-                "UMLS:C0033860",
-                "EFO:0000676",
-                "UMLS:C0262985",
-                "NCIT:C3346",
-                "NCIT:C27724",
-                "OMIM.PS:177900",
-                "OMIM:PS177900",
-                "SNOMEDCT:52230004",
-                "HP:0003765",
-                "MEDDRA:10037153",
-                "SNOMEDCT:238564003"
-              ],
-              "id": "MONDO:0005083",
-              "category": "biolink:Disease",
-              "all_names": [
-                "psoriasis",
-                "Psoriasiform eczema",
-                "Psoriasis",
-                "Psoriasiform dermatitis",
-                "Psoriasiform Dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.cdc.gov/psoriasis/index.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15009495,
-            "start": 569,
-            "end": 320360,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21094146': {'publication date': '2011 Jan 07', 'sentence': 'The expression of StAR and MLN64 was aberrant in two skin disorders, psoriasis and atopic dermatitis, that are commonly treated with cortisol, suggesting dysregulation of epidermal steroid synthesis in these patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:27824222': {'publication date': '2016 Dec', 'sentence': 'This study aimed to determine serum levels of basal cortisol and adrenocorticotropic hormone (ACTH) and circulating levels of various cytokines and chemokines and their association with psychological measures in psoriasis patients.', 'subject score': 888, 'object score': 888}, 'PMID:36065538': {'publication date': '2022 05 01', 'sentence': 'Circadian cortisol profiles and hair cortisol concentration in patients with psoriasis: associations with anxiety, depressive symptomatology and disease severity', 'subject score': 851, 'object score': 1000}, 'PMID:36249714': {'publication date': '2022', 'sentence': 'Conclusion: Oral administration of Lactocare(r) probiotic (two times daily) associated with administration of topical hydrocortisone resulted in the improvement of PASI, DLQI, and VAS scores in the patients with psoriasis after 12 weeks of treatment.', 'subject score': 861, 'object score': 1000}, 'PMID:6832467': {'publication date': '1983', 'sentence': 'Plasma cortisol studies with 0.05% halometasone cream and ointment in patients with psoriasis.', 'subject score': 888, 'object score': 1000}, 'PMID:881090': {'publication date': '1977', 'sentence': 'Triamcinolone acetonide, hydrocortisone and methotrexate, all known to be useful clinically in the treatment of psoriasis, were examined for their ability to antagonize the development of retinoic-acid-induced scaling.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0033860---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "15325707",
-              "object": "MONDO:0005083",
-              "publications": [
-                "PMID:21094146",
-                "PMID:27824222",
-                "PMID:36065538",
-                "PMID:36249714",
-                "PMID:6832467",
-                "PMID:881090"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:19564722': {'publication date': '2009 Nov', 'sentence': 'Increased ratio of mRNA expression of the genes CYP17 and CYP11B1 indicates autonomous cortisol production in adrenocortical tumors.', 'subject score': 828, 'object score': 983}, 'PMID:23055545': {'publication date': '2012 Dec', 'sentence': 'CONCLUSION: Low SGK1 expression is related to ACTH-independent cortisol secretion in adrenocortical tumors and is a new prognostic factor in adrenocortical carcinoma.', 'subject score': 833, 'object score': 983}, 'PMID:27085553': {'publication date': '2016 08', 'sentence': 'Adrenal Cushing syndrome (CS) is caused by the overproduction of cortisol in adrenocortical tumors including adrenal cortisol-producing adenoma (CPA).', 'subject score': 1000, 'object score': 983}, 'PMID:28248753': {'publication date': '2017 Jun', 'sentence': 'This review summarizes the most recent evidence showing the potential risks related to adrenocortical tumors classified as nonfunctioning adrenal incidentalomas (NFAIs) or associated with clinically autonomous cortisol secretion (ACS).', 'subject score': 751, 'object score': 983}, 'PMID:3563638': {'publication date': '1987', 'sentence': '[Cortisol clearance in hormonally-active adrenal cortex tumors].', 'subject score': 888, 'object score': 843}}",
-    "p2": {
-      "start": {
-        "identity": 318773,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0036591",
-          "name": "adrenal cortex neoplasm",
-          "description": "The presence of a neoplasm of the adrenal cortex. [HPO:probinson]; The presence of a neoplasm of the adrenal cortex.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0036591",
-            "MESH:D000306",
-            "UMLS:C0001618",
-            "HP:0100641",
-            "NCIT:C2858",
-            "SNOMEDCT:127022002"
-          ],
-          "id": "MONDO:0036591",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortex neoplasm",
-            "Adrenal Cortical Neoplasm",
-            "Neoplasm of the adrenal cortex",
-            "Adrenal Cortex Neoplasms"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
->>>>>>> main
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 320151,
-=======
-            "identity": 318773,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-              "name": "dermatitis, atopic",
-              "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MESH:C566404",
-                "MEDDRA:10012434",
-                "SNOMEDCT:24079001",
-                "MONDO:0011292",
-                "MEDDRA:10003641",
-                "MONDO:0100181",
-                "MEDDRA:10014191",
-                "OMIM:603165",
-                "HP:0001047",
-                "MEDDRA:10001711",
-                "MEDDRA:10003639",
-                "UMLS:C0011615",
-                "UMLS:C4280605",
-                "UMLS:C1864155",
-                "MEDDRA:10012438",
-                "MEDDRA:10014188",
-                "MEDDRA:10001712",
-                "MESH:D003876",
-                "SNOMEDCT:200775004"
-              ],
-              "id": "MONDO:0011292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis, Atopic, 1",
-                "dermatitis, atopic",
-                "Dermatitis, Atopic",
-                "Baby eczema",
-                "Dermatitis, atopic related phenotypic feature",
-                "Atopic dermatitis",
-                "dermatitis, atopic, 1"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:27904186",
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0036591",
-              "name": "adrenal cortex neoplasm",
-              "description": "The presence of a neoplasm of the adrenal cortex. [HPO:probinson]; The presence of a neoplasm of the adrenal cortex.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0036591",
-                "MESH:D000306",
-                "UMLS:C0001618",
-                "HP:0100641",
-                "NCIT:C2858",
-                "SNOMEDCT:127022002"
-              ],
-              "id": "MONDO:0036591",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortex neoplasm",
-                "Adrenal Cortical Neoplasm",
-                "Neoplasm of the adrenal cortex",
-                "Adrenal Cortex Neoplasms"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
->>>>>>> main
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 13299976,
-            "start": 569,
-            "end": 320151,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1826110': {'publication date': '1991 Feb', 'sentence': 'Open oral provocation with 100 or 250 mg hydrocortisone in patients with hydrocortisone contact hypersensitivity elicited cutaneous reactions at sites of previous allergic dermatitis caused by hydrocortisone in two patients and at sites of earlier allergic patch test reactions caused by hydrocortisone in the other two patients.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0011615---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13585273",
-              "object": "MONDO:0011292",
-              "publications": [
-                "PMID:1826110"
-=======
-            "identity": 14149120,
-            "start": 569,
-            "end": 318773,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19564722': {'publication date': '2009 Nov', 'sentence': 'Increased ratio of mRNA expression of the genes CYP17 and CYP11B1 indicates autonomous cortisol production in adrenocortical tumors.', 'subject score': 828, 'object score': 983}, 'PMID:23055545': {'publication date': '2012 Dec', 'sentence': 'CONCLUSION: Low SGK1 expression is related to ACTH-independent cortisol secretion in adrenocortical tumors and is a new prognostic factor in adrenocortical carcinoma.', 'subject score': 833, 'object score': 983}, 'PMID:27085553': {'publication date': '2016 08', 'sentence': 'Adrenal Cushing syndrome (CS) is caused by the overproduction of cortisol in adrenocortical tumors including adrenal cortisol-producing adenoma (CPA).', 'subject score': 1000, 'object score': 983}, 'PMID:28248753': {'publication date': '2017 Jun', 'sentence': 'This review summarizes the most recent evidence showing the potential risks related to adrenocortical tumors classified as nonfunctioning adrenal incidentalomas (NFAIs) or associated with clinically autonomous cortisol secretion (ACS).', 'subject score': 751, 'object score': 983}, 'PMID:3563638': {'publication date': '1987', 'sentence': '[Cortisol clearance in hormonally-active adrenal cortex tumors].', 'subject score': 888, 'object score': 843}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0001618---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14450267",
-              "object": "MONDO:0036591",
-              "publications": [
-                "PMID:19564722",
-                "PMID:23055545",
-                "PMID:27085553",
-                "PMID:28248753",
-                "PMID:3563638"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 318216,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:11196414': {'publication date': '2000 Nov', 'sentence': 'In conclusion, the reciprocal expression of CYP17 and the transcriptional repressors COUP-TF and DAX-1 indicates that these orphan receptors have a pathophysiologic role in the excessive hormone production in cortisol- and deoxycorticosterone-producing adrenocortical tumors.', 'subject score': 1000, 'object score': 983}, 'PMID:16449345': {'publication date': '2006 Apr', 'sentence': 'CONTEXT: Arginine vasopressin (AVP) stimulates steroid secretion from the normal human adrenal gland and some cortisol-producing adrenocortical tumors or hyperplasia through activation of the V(1a) receptor.', 'subject score': 1000, 'object score': 983}, 'PMID:17980016': {'publication date': '2008 May', 'sentence': 'OBJECTIVE: Abnormal responsiveness to arginine vasopressin (AVP) was previously observed in cortisol-producing adrenocortical tumours but the mechanism remains unclear.', 'subject score': 1000, 'object score': 983}, 'PMID:204155': {'publication date': '1977 Nov', 'sentence': 'Correlation of alkaline phosphatase staining of cortisol-producing adrenocortical tumors with dexamethasone suppression and ACTH stimulation.', 'subject score': 1000, 'object score': 983}, 'PMID:29299796': {'publication date': '2018 02', 'sentence': 'CONCLUSIONS: EV-associated miRNAs are differentially expressed in different non-functioning and cortisol-producing adrenocortical tumors.', 'subject score': 1000, 'object score': 983}, 'PMID:29642186': {'publication date': '2018 Apr', 'sentence': 'LESSIONS: An understanding of RTH after adrenalectomy as a treatment for cortisol-producing adrenocortical tumors is important for the prevention of unnecessary surgical intervention and therapy.', 'subject score': 1000, 'object score': 983}, 'PMID:32507359': {'publication date': '2020 May 23', 'sentence': 'Genetic alterations in GNAS, PRKAR1A, PRKACA, PRKACB, PDE11A, and PDE8B, that lead to aberrant cyclic adenosine monophosphate-protein (cAMP) kinase A signaling, were found to play a major role in the development of benign cortisol-producing adrenocortical tumors and/or hyperplasias, whereas genetic defects in KCNJ5, ATP1A1, ATP2B3, CACNA1D, CACNA1H, and CLCN2 were implicated in the development of benign aldosterone-producing tumors and/or hyperplasias through modification of intracellular calcium signaling.', 'subject score': 888, 'object score': 1000}, 'PMID:33776926': {'publication date': '2021', 'sentence': 'This review describes the genetic causes of benign cortisol- and aldosterone-producing adrenocortical tumors.', 'subject score': 888, 'object score': 1000}, 'PMID:9694577': {'publication date': '1998', 'sentence': 'However, recent work by our group and others have shown that these cortisol-producing adrenocortical tumors may be under the control of inappropriate, illicit or ectopic hormone receptors.', 'subject score': 1000, 'object score': 983}}",
-    "p2": {
-      "start": {
-        "identity": 318773,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0036591",
-          "name": "adrenal cortex neoplasm",
-          "description": "The presence of a neoplasm of the adrenal cortex. [HPO:probinson]; The presence of a neoplasm of the adrenal cortex.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0036591",
-            "MESH:D000306",
-            "UMLS:C0001618",
-            "HP:0100641",
-            "NCIT:C2858",
-            "SNOMEDCT:127022002"
-          ],
-          "id": "MONDO:0036591",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortex neoplasm",
-            "Adrenal Cortical Neoplasm",
-            "Neoplasm of the adrenal cortex",
-            "Adrenal Cortex Neoplasms"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318773,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0036591",
-              "name": "adrenal cortex neoplasm",
-              "description": "The presence of a neoplasm of the adrenal cortex. [HPO:probinson]; The presence of a neoplasm of the adrenal cortex.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0036591",
-                "MESH:D000306",
-                "UMLS:C0001618",
-                "HP:0100641",
-                "NCIT:C2858",
-                "SNOMEDCT:127022002"
-              ],
-              "id": "MONDO:0036591",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortex neoplasm",
-                "Adrenal Cortical Neoplasm",
-                "Neoplasm of the adrenal cortex",
-                "Adrenal Cortex Neoplasms"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8502652,
-            "start": 569,
-            "end": 318773,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11196414': {'publication date': '2000 Nov', 'sentence': 'In conclusion, the reciprocal expression of CYP17 and the transcriptional repressors COUP-TF and DAX-1 indicates that these orphan receptors have a pathophysiologic role in the excessive hormone production in cortisol- and deoxycorticosterone-producing adrenocortical tumors.', 'subject score': 1000, 'object score': 983}, 'PMID:16449345': {'publication date': '2006 Apr', 'sentence': 'CONTEXT: Arginine vasopressin (AVP) stimulates steroid secretion from the normal human adrenal gland and some cortisol-producing adrenocortical tumors or hyperplasia through activation of the V(1a) receptor.', 'subject score': 1000, 'object score': 983}, 'PMID:17980016': {'publication date': '2008 May', 'sentence': 'OBJECTIVE: Abnormal responsiveness to arginine vasopressin (AVP) was previously observed in cortisol-producing adrenocortical tumours but the mechanism remains unclear.', 'subject score': 1000, 'object score': 983}, 'PMID:204155': {'publication date': '1977 Nov', 'sentence': 'Correlation of alkaline phosphatase staining of cortisol-producing adrenocortical tumors with dexamethasone suppression and ACTH stimulation.', 'subject score': 1000, 'object score': 983}, 'PMID:29299796': {'publication date': '2018 02', 'sentence': 'CONCLUSIONS: EV-associated miRNAs are differentially expressed in different non-functioning and cortisol-producing adrenocortical tumors.', 'subject score': 1000, 'object score': 983}, 'PMID:29642186': {'publication date': '2018 Apr', 'sentence': 'LESSIONS: An understanding of RTH after adrenalectomy as a treatment for cortisol-producing adrenocortical tumors is important for the prevention of unnecessary surgical intervention and therapy.', 'subject score': 1000, 'object score': 983}, 'PMID:32507359': {'publication date': '2020 May 23', 'sentence': 'Genetic alterations in GNAS, PRKAR1A, PRKACA, PRKACB, PDE11A, and PDE8B, that lead to aberrant cyclic adenosine monophosphate-protein (cAMP) kinase A signaling, were found to play a major role in the development of benign cortisol-producing adrenocortical tumors and/or hyperplasias, whereas genetic defects in KCNJ5, ATP1A1, ATP2B3, CACNA1D, CACNA1H, and CLCN2 were implicated in the development of benign aldosterone-producing tumors and/or hyperplasias through modification of intracellular calcium signaling.', 'subject score': 888, 'object score': 1000}, 'PMID:33776926': {'publication date': '2021', 'sentence': 'This review describes the genetic causes of benign cortisol- and aldosterone-producing adrenocortical tumors.', 'subject score': 888, 'object score': 1000}, 'PMID:9694577': {'publication date': '1998', 'sentence': 'However, recent work by our group and others have shown that these cortisol-producing adrenocortical tumors may be under the control of inappropriate, illicit or ectopic hormone receptors.', 'subject score': 1000, 'object score': 983}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0001618---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8699464",
-              "object": "MONDO:0036591",
-              "publications": [
-                "PMID:11196414",
-                "PMID:16449345",
-                "PMID:17980016",
-                "PMID:204155",
-                "PMID:29299796",
-                "PMID:29642186",
-                "PMID:32507359",
-                "PMID:33776926",
-                "PMID:9694577"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:2370223': {'publication date': '1990 Jul 01', 'sentence': 'The mean (+/- SD) plasma cortisol concentration for the initial 8-hour testing period was highest in 18 dogs with adrenocortical tumor (5.3 +/- 1.6 micrograms/dl), lowest in 15 control dogs (1.3 +/- 0.5 micrograms/dl), and intermediate in 31 dogs with pituitary-dependent hyperadrenocorticism (PDH; 3.4 +/- 1.2 micrograms/dl).', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318773,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0036591",
-          "name": "adrenal cortex neoplasm",
-          "description": "The presence of a neoplasm of the adrenal cortex. [HPO:probinson]; The presence of a neoplasm of the adrenal cortex.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0036591",
-            "MESH:D000306",
-            "UMLS:C0001618",
-            "HP:0100641",
-            "NCIT:C2858",
-            "SNOMEDCT:127022002"
-          ],
-          "id": "MONDO:0036591",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortex neoplasm",
-            "Adrenal Cortical Neoplasm",
-            "Neoplasm of the adrenal cortex",
-            "Adrenal Cortex Neoplasms"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318773,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0036591",
-              "name": "adrenal cortex neoplasm",
-              "description": "The presence of a neoplasm of the adrenal cortex. [HPO:probinson]; The presence of a neoplasm of the adrenal cortex.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0036591",
-                "MESH:D000306",
-                "UMLS:C0001618",
-                "HP:0100641",
-                "NCIT:C2858",
-                "SNOMEDCT:127022002"
-              ],
-              "id": "MONDO:0036591",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortex neoplasm",
-                "Adrenal Cortical Neoplasm",
-                "Neoplasm of the adrenal cortex",
-                "Adrenal Cortex Neoplasms"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16595638,
-            "start": 569,
-            "end": 318773,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2370223': {'publication date': '1990 Jul 01', 'sentence': 'The mean (+/- SD) plasma cortisol concentration for the initial 8-hour testing period was highest in 18 dogs with adrenocortical tumor (5.3 +/- 1.6 micrograms/dl), lowest in 15 control dogs (1.3 +/- 0.5 micrograms/dl), and intermediate in 31 dogs with pituitary-dependent hyperadrenocorticism (PDH; 3.4 +/- 1.2 micrograms/dl).', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0001618---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "16946872",
-              "object": "MONDO:0036591",
-              "publications": [
-                "PMID:2370223"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:produces",
-    "r2.publications_info": "{'PMID:18543063': {'publication date': '2008 Oct', 'sentence': 'This is an extremely rare case of bilateral adrenal tumors, in which the left adrenocortical tumor produced and secreted cortisol or both cortisol and aldosterone and the right one produced and secreted both aldosterone and cortisol, as confirmed by clinical findings and pathological studies using immunohistochemical analysis.', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318773,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0036591",
-          "name": "adrenal cortex neoplasm",
-          "description": "The presence of a neoplasm of the adrenal cortex. [HPO:probinson]; The presence of a neoplasm of the adrenal cortex.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0036591",
-            "MESH:D000306",
-            "UMLS:C0001618",
-            "HP:0100641",
-            "NCIT:C2858",
-            "SNOMEDCT:127022002"
-          ],
-          "id": "MONDO:0036591",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortex neoplasm",
-            "Adrenal Cortical Neoplasm",
-            "Neoplasm of the adrenal cortex",
-            "Adrenal Cortex Neoplasms"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318773,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0036591",
-              "name": "adrenal cortex neoplasm",
-              "description": "The presence of a neoplasm of the adrenal cortex. [HPO:probinson]; The presence of a neoplasm of the adrenal cortex.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0036591",
-                "MESH:D000306",
-                "UMLS:C0001618",
-                "HP:0100641",
-                "NCIT:C2858",
-                "SNOMEDCT:127022002"
-              ],
-              "id": "MONDO:0036591",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortex neoplasm",
-                "Adrenal Cortical Neoplasm",
-                "Neoplasm of the adrenal cortex",
-                "Adrenal Cortex Neoplasms"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13506439,
-            "start": 318773,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18543063': {'publication date': '2008 Oct', 'sentence': 'This is an extremely rare case of bilateral adrenal tumors, in which the left adrenocortical tumor produced and secreted cortisol or both cortisol and aldosterone and the right one produced and secreted both aldosterone and cortisol, as confirmed by clinical findings and pathological studies using immunohistochemical analysis.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0001618---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0036591",
-              "id": "13796050",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:18543063"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:13373990': {'publication date': '1956 Jul-Aug', 'sentence': '[Topical use of hydrocortisone in otitis externa].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 314857,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004795",
-          "name": "otitis externa",
-          "description": "Inflammation of the anatomical structures of the outer ear and ear canal, which is most often caused by an infectious process. Symptoms include erythema, edema, and pain.; Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.; Inflammation or infection of the external auditory canal (EAC), the auricle, or both. [http://search.medscape.com/search/?q=otitis%20externa, ORCID:0000-0001-5208-3432]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021919",
-            "NCIT:C79601",
-            "MESH:D010032",
-            "SNOMEDCT:3135009",
-            "MEDDRA:10052558",
-            "NCIT:C3299",
-            "MEDDRA:10021920",
-            "UMLS:C0029878",
-            "UMLS:C0021355",
-            "MEDDRA:10065837",
-            "HP:0410017",
-            "MEDDRA:10033072",
-            "MEDDRA:10082612",
-            "EFO:0009560",
-            "DOID:9463",
-            "ICD9:380.1",
-            "SNOMEDCT:86981007",
-            "MONDO:0004795"
-          ],
-          "id": "MONDO:0004795",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infective otitis externa",
-            "Otitis Externa",
-            "Otitis externa",
-            "otitis externa",
-            "Infectious Otitis Externa"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/otitis_externa",
-            "http://search.medscape.com/search/?q=otitis%20externa",
-            "https://orcid.org/0000-0001-5208-3432"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314857,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004795",
-              "name": "otitis externa",
-              "description": "Inflammation of the anatomical structures of the outer ear and ear canal, which is most often caused by an infectious process. Symptoms include erythema, edema, and pain.; Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.; Inflammation or infection of the external auditory canal (EAC), the auricle, or both. [http://search.medscape.com/search/?q=otitis%20externa, ORCID:0000-0001-5208-3432]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021919",
-                "NCIT:C79601",
-                "MESH:D010032",
-                "SNOMEDCT:3135009",
-                "MEDDRA:10052558",
-                "NCIT:C3299",
-                "MEDDRA:10021920",
-                "UMLS:C0029878",
-                "UMLS:C0021355",
-                "MEDDRA:10065837",
-                "HP:0410017",
-                "MEDDRA:10033072",
-                "MEDDRA:10082612",
-                "EFO:0009560",
-                "DOID:9463",
-                "ICD9:380.1",
-                "SNOMEDCT:86981007",
-                "MONDO:0004795"
-              ],
-              "id": "MONDO:0004795",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infective otitis externa",
-                "Otitis Externa",
-                "Otitis externa",
-                "otitis externa",
-                "Infectious Otitis Externa"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/otitis_externa",
-                "http://search.medscape.com/search/?q=otitis%20externa",
-                "https://orcid.org/0000-0001-5208-3432"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10291447,
-            "start": 569,
-            "end": 314857,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13373990': {'publication date': '1956 Jul-Aug', 'sentence': '[Topical use of hydrocortisone in otitis externa].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0029878---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10518203",
-              "object": "MONDO:0004795",
-              "publications": [
-                "PMID:13373990"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:11583468': {'publication date': '2001 Aug', 'sentence': 'From this study it is inferred that the group III steroid betamethasone dipropionate alone heals experimentally induced external otitis more rapidly than hydrocortisone with oxytetracycline, with or without polymyxin B.', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 314857,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004795",
-          "name": "otitis externa",
-          "description": "Inflammation of the anatomical structures of the outer ear and ear canal, which is most often caused by an infectious process. Symptoms include erythema, edema, and pain.; Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.; Inflammation or infection of the external auditory canal (EAC), the auricle, or both. [http://search.medscape.com/search/?q=otitis%20externa, ORCID:0000-0001-5208-3432]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021919",
-            "NCIT:C79601",
-            "MESH:D010032",
-            "SNOMEDCT:3135009",
-            "MEDDRA:10052558",
-            "NCIT:C3299",
-            "MEDDRA:10021920",
-            "UMLS:C0029878",
-            "UMLS:C0021355",
-            "MEDDRA:10065837",
-            "HP:0410017",
-            "MEDDRA:10033072",
-            "MEDDRA:10082612",
-            "EFO:0009560",
-            "DOID:9463",
-            "ICD9:380.1",
-            "SNOMEDCT:86981007",
-            "MONDO:0004795"
-          ],
-          "id": "MONDO:0004795",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infective otitis externa",
-            "Otitis Externa",
-            "Otitis externa",
-            "otitis externa",
-            "Infectious Otitis Externa"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/otitis_externa",
-            "http://search.medscape.com/search/?q=otitis%20externa",
-            "https://orcid.org/0000-0001-5208-3432"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314857,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004795",
-              "name": "otitis externa",
-              "description": "Inflammation of the anatomical structures of the outer ear and ear canal, which is most often caused by an infectious process. Symptoms include erythema, edema, and pain.; Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.; Inflammation or infection of the external auditory canal (EAC), the auricle, or both. [http://search.medscape.com/search/?q=otitis%20externa, ORCID:0000-0001-5208-3432]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021919",
-                "NCIT:C79601",
-                "MESH:D010032",
-                "SNOMEDCT:3135009",
-                "MEDDRA:10052558",
-                "NCIT:C3299",
-                "MEDDRA:10021920",
-                "UMLS:C0029878",
-                "UMLS:C0021355",
-                "MEDDRA:10065837",
-                "HP:0410017",
-                "MEDDRA:10033072",
-                "MEDDRA:10082612",
-                "EFO:0009560",
-                "DOID:9463",
-                "ICD9:380.1",
-                "SNOMEDCT:86981007",
-                "MONDO:0004795"
-              ],
-              "id": "MONDO:0004795",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infective otitis externa",
-                "Otitis Externa",
-                "Otitis externa",
-                "otitis externa",
-                "Infectious Otitis Externa"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/otitis_externa",
-                "http://search.medscape.com/search/?q=otitis%20externa",
-                "https://orcid.org/0000-0001-5208-3432"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8949519,
-            "start": 569,
-            "end": 314857,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11583468': {'publication date': '2001 Aug', 'sentence': 'From this study it is inferred that the group III steroid betamethasone dipropionate alone heals experimentally induced external otitis more rapidly than hydrocortisone with oxytetracycline, with or without polymyxin B.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0029878---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9145908",
-              "object": "MONDO:0004795",
-              "publications": [
-                "PMID:11583468"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10493278': {'publication date': '1999 Sep', 'sentence': 'Results of clinical trials indicate that ofloxacin otic solution 0.3% is as effective as topical neomycin/polymixin B/hydrocortisone preparations in the treatment of otitis externa (clinical cure rate >80% in adults and >95% in children for both treatments) and oral amoxicillin/clavulanic acid in the treatment of otitis media in the presence of tympanostomy tubes in children (clinical cure rates 76 and 69% for ofloxacin and amoxicillin/clavulanic acid, respectively).', 'subject score': 858, 'object score': 1000}, 'PMID:13219726': {'publication date': '1955 Jan', 'sentence': 'The use of neomycin and hydrocortisone in the treatment of external otitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15180022': {'publication date': '2004 May', 'sentence': 'BACKGROUND: Otitis externa is usually treated empirically with topical neomycin/polymyxin B/hydrocortisone.', 'subject score': 857, 'object score': 1000}, 'PMID:15324520': {'publication date': '2004 Aug', 'sentence': 'Efficacy and safety of topical ciprofloxacin/dexamethasone versus neomycin/polymyxin B/hydrocortisone for otitis externa.', 'subject score': 916, 'object score': 1000}, 'PMID:17660178': {'publication date': '2007 May-Jun', 'sentence': 'A comparison of ciprofloxacin/dexamethasone with neomycin/polymyxin/hydrocortisone for otitis externa pain.', 'subject score': 851, 'object score': 901}, 'PMID:2155756': {'publication date': '1990', 'sentence': \"An open, multi-centre study was carried out in general practice to compare the efficacy, tolerability and acceptability of a neomycin/dexamethasone preparation administered by spray ('Otomize') and neomycin/polymyxin B/hydrocortisone administered as drops ('Otosporin') in the treatment of 187 patients with otitis externa.\", 'subject score': 916, 'object score': 1000}, 'PMID:2156538': {'publication date': '1990', 'sentence': 'In a single blind, randomized study, 46 patients with acute external otitis were treated with either oxytetracycline/hydrocortisone with polymyxin B (TPB) or hydrocortisone-17-alpha-butyrate eardrops for 7 days.', 'subject score': 790, 'object score': 901}, 'PMID:2415098': {'publication date': '1985', 'sentence': 'A randomized clinical trial of two topical preparations (framycitin/gramicidin and oxytetracycline/hydrocortisone with polymyxin B) in the treatment of external otitis.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 314857,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004795",
-          "name": "otitis externa",
-          "description": "Inflammation of the anatomical structures of the outer ear and ear canal, which is most often caused by an infectious process. Symptoms include erythema, edema, and pain.; Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.; Inflammation or infection of the external auditory canal (EAC), the auricle, or both. [http://search.medscape.com/search/?q=otitis%20externa, ORCID:0000-0001-5208-3432]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021919",
-            "NCIT:C79601",
-            "MESH:D010032",
-            "SNOMEDCT:3135009",
-            "MEDDRA:10052558",
-            "NCIT:C3299",
-            "MEDDRA:10021920",
-            "UMLS:C0029878",
-            "UMLS:C0021355",
-            "MEDDRA:10065837",
-            "HP:0410017",
-            "MEDDRA:10033072",
-            "MEDDRA:10082612",
-            "EFO:0009560",
-            "DOID:9463",
-            "ICD9:380.1",
-            "SNOMEDCT:86981007",
-            "MONDO:0004795"
-          ],
-          "id": "MONDO:0004795",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infective otitis externa",
-            "Otitis Externa",
-            "Otitis externa",
-            "otitis externa",
-            "Infectious Otitis Externa"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/otitis_externa",
-            "http://search.medscape.com/search/?q=otitis%20externa",
-            "https://orcid.org/0000-0001-5208-3432"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314857,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004795",
-              "name": "otitis externa",
-              "description": "Inflammation of the anatomical structures of the outer ear and ear canal, which is most often caused by an infectious process. Symptoms include erythema, edema, and pain.; Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.; Inflammation or infection of the external auditory canal (EAC), the auricle, or both. [http://search.medscape.com/search/?q=otitis%20externa, ORCID:0000-0001-5208-3432]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021919",
-                "NCIT:C79601",
-                "MESH:D010032",
-                "SNOMEDCT:3135009",
-                "MEDDRA:10052558",
-                "NCIT:C3299",
-                "MEDDRA:10021920",
-                "UMLS:C0029878",
-                "UMLS:C0021355",
-                "MEDDRA:10065837",
-                "HP:0410017",
-                "MEDDRA:10033072",
-                "MEDDRA:10082612",
-                "EFO:0009560",
-                "DOID:9463",
-                "ICD9:380.1",
-                "SNOMEDCT:86981007",
-                "MONDO:0004795"
-              ],
-              "id": "MONDO:0004795",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infective otitis externa",
-                "Otitis Externa",
-                "Otitis externa",
-                "otitis externa",
-                "Infectious Otitis Externa"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/otitis_externa",
-                "http://search.medscape.com/search/?q=otitis%20externa",
-                "https://orcid.org/0000-0001-5208-3432"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7539713,
-            "start": 569,
-            "end": 314857,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10493278': {'publication date': '1999 Sep', 'sentence': 'Results of clinical trials indicate that ofloxacin otic solution 0.3% is as effective as topical neomycin/polymixin B/hydrocortisone preparations in the treatment of otitis externa (clinical cure rate >80% in adults and >95% in children for both treatments) and oral amoxicillin/clavulanic acid in the treatment of otitis media in the presence of tympanostomy tubes in children (clinical cure rates 76 and 69% for ofloxacin and amoxicillin/clavulanic acid, respectively).', 'subject score': 858, 'object score': 1000}, 'PMID:13219726': {'publication date': '1955 Jan', 'sentence': 'The use of neomycin and hydrocortisone in the treatment of external otitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15180022': {'publication date': '2004 May', 'sentence': 'BACKGROUND: Otitis externa is usually treated empirically with topical neomycin/polymyxin B/hydrocortisone.', 'subject score': 857, 'object score': 1000}, 'PMID:15324520': {'publication date': '2004 Aug', 'sentence': 'Efficacy and safety of topical ciprofloxacin/dexamethasone versus neomycin/polymyxin B/hydrocortisone for otitis externa.', 'subject score': 916, 'object score': 1000}, 'PMID:17660178': {'publication date': '2007 May-Jun', 'sentence': 'A comparison of ciprofloxacin/dexamethasone with neomycin/polymyxin/hydrocortisone for otitis externa pain.', 'subject score': 851, 'object score': 901}, 'PMID:2155756': {'publication date': '1990', 'sentence': \"An open, multi-centre study was carried out in general practice to compare the efficacy, tolerability and acceptability of a neomycin/dexamethasone preparation administered by spray ('Otomize') and neomycin/polymyxin B/hydrocortisone administered as drops ('Otosporin') in the treatment of 187 patients with otitis externa.\", 'subject score': 916, 'object score': 1000}, 'PMID:2156538': {'publication date': '1990', 'sentence': 'In a single blind, randomized study, 46 patients with acute external otitis were treated with either oxytetracycline/hydrocortisone with polymyxin B (TPB) or hydrocortisone-17-alpha-butyrate eardrops for 7 days.', 'subject score': 790, 'object score': 901}, 'PMID:2415098': {'publication date': '1985', 'sentence': 'A randomized clinical trial of two topical preparations (framycitin/gramicidin and oxytetracycline/hydrocortisone with polymyxin B) in the treatment of external otitis.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0029878---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7698304",
-              "object": "MONDO:0004795",
-              "publications": [
-                "PMID:10493278",
-                "PMID:13219726",
-                "PMID:15180022",
-                "PMID:15324520",
-                "PMID:17660178",
-                "PMID:2155756",
-                "PMID:2156538",
-                "PMID:2415098"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:5597676': {'publication date': '1967 Jun 08', 'sentence': '[Plasma cortisol and 17-ketosteroids in urine in relation to cardiac arrest].', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318021,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000745",
-          "name": "cardiac arrest",
-          "description": "The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.; Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.; An abrupt loss of heart function. []; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:0060319",
-            "ICD10:I46",
-            "MEDDRA:10003109",
-            "UMLS:C0018790",
-            "HP:0001695",
-            "SNOMEDCT:410429000",
-            "MEDDRA:10082515",
-            "UMLS:C0444720",
-            "SNOMEDCT:397829000",
-            "MEDDRA:10003589",
-            "NCIT:C50479",
-            "PSY:07595",
-            "MEDDRA:10019249",
-            "SNOMEDCT:261195002",
-            "MEDDRA:10003587",
-            "MEDDRA:10047284",
-            "MESH:D006323",
-            "MONDO:0000745",
-            "MEDDRA:10041914",
-            "EFO:0009492",
-            "MEDDRA:10003586",
-            "MEDDRA:10007515",
-            "ICD9:427.5",
-            "MEDDRA:10047285"
-          ],
-          "id": "MONDO:0000745",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiac Arrest",
-            "cardiac arrest",
-            "Cardiac arrest",
-            "Heart Arrest"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/cardiacarrest.htm",
-            "http://en.wikipedia.org/wiki/cardiac_arrest",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318021,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000745",
-              "name": "cardiac arrest",
-              "description": "The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.; Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.; An abrupt loss of heart function. []; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:0060319",
-                "ICD10:I46",
-                "MEDDRA:10003109",
-                "UMLS:C0018790",
-                "HP:0001695",
-                "SNOMEDCT:410429000",
-                "MEDDRA:10082515",
-                "UMLS:C0444720",
-                "SNOMEDCT:397829000",
-                "MEDDRA:10003589",
-                "NCIT:C50479",
-                "PSY:07595",
-                "MEDDRA:10019249",
-                "SNOMEDCT:261195002",
-                "MEDDRA:10003587",
-                "MEDDRA:10047284",
-                "MESH:D006323",
-                "MONDO:0000745",
-                "MEDDRA:10041914",
-                "EFO:0009492",
-                "MEDDRA:10003586",
-                "MEDDRA:10007515",
-                "ICD9:427.5",
-                "MEDDRA:10047285"
-              ],
-              "id": "MONDO:0000745",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiac Arrest",
-                "cardiac arrest",
-                "Cardiac arrest",
-                "Heart Arrest"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/cardiacarrest.htm",
-                "http://en.wikipedia.org/wiki/cardiac_arrest",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25473097,
-            "start": 569,
-            "end": 318021,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:5597676': {'publication date': '1967 Jun 08', 'sentence': '[Plasma cortisol and 17-ketosteroids in urine in relation to cardiac arrest].', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0018790---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "25927636",
-              "object": "MONDO:0000745",
-              "publications": [
-                "PMID:5597676"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:8351423': {'publication date': '1993 Jun', 'sentence': 'Further studies evaluating the mechanism of action and long term effects of hydrocortisone in cardiac arrest need to be conducted.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318021,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000745",
-          "name": "cardiac arrest",
-          "description": "The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.; Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.; An abrupt loss of heart function. []; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:0060319",
-            "ICD10:I46",
-            "MEDDRA:10003109",
-            "UMLS:C0018790",
-            "HP:0001695",
-            "SNOMEDCT:410429000",
-            "MEDDRA:10082515",
-            "UMLS:C0444720",
-            "SNOMEDCT:397829000",
-            "MEDDRA:10003589",
-            "NCIT:C50479",
-            "PSY:07595",
-            "MEDDRA:10019249",
-            "SNOMEDCT:261195002",
-            "MEDDRA:10003587",
-            "MEDDRA:10047284",
-            "MESH:D006323",
-            "MONDO:0000745",
-            "MEDDRA:10041914",
-            "EFO:0009492",
-            "MEDDRA:10003586",
-            "MEDDRA:10007515",
-            "ICD9:427.5",
-            "MEDDRA:10047285"
-          ],
-          "id": "MONDO:0000745",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiac Arrest",
-            "cardiac arrest",
-            "Cardiac arrest",
-            "Heart Arrest"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/cardiacarrest.htm",
-            "http://en.wikipedia.org/wiki/cardiac_arrest",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318021,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000745",
-              "name": "cardiac arrest",
-              "description": "The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.; Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.; An abrupt loss of heart function. []; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:0060319",
-                "ICD10:I46",
-                "MEDDRA:10003109",
-                "UMLS:C0018790",
-                "HP:0001695",
-                "SNOMEDCT:410429000",
-                "MEDDRA:10082515",
-                "UMLS:C0444720",
-                "SNOMEDCT:397829000",
-                "MEDDRA:10003589",
-                "NCIT:C50479",
-                "PSY:07595",
-                "MEDDRA:10019249",
-                "SNOMEDCT:261195002",
-                "MEDDRA:10003587",
-                "MEDDRA:10047284",
-                "MESH:D006323",
-                "MONDO:0000745",
-                "MEDDRA:10041914",
-                "EFO:0009492",
-                "MEDDRA:10003586",
-                "MEDDRA:10007515",
-                "ICD9:427.5",
-                "MEDDRA:10047285"
-              ],
-              "id": "MONDO:0000745",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiac Arrest",
-                "cardiac arrest",
-                "Cardiac arrest",
-                "Heart Arrest"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/cardiacarrest.htm",
-                "http://en.wikipedia.org/wiki/cardiac_arrest",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26474619,
-            "start": 569,
-            "end": 318021,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8351423': {'publication date': '1993 Jun', 'sentence': 'Further studies evaluating the mechanism of action and long term effects of hydrocortisone in cardiac arrest need to be conducted.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0018790---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "26940919",
-              "object": "MONDO:0000745",
-              "publications": [
-                "PMID:8351423"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:28825336': {'publication date': '2018 Nov', 'sentence': 'Compared to controls, glycocalyx was mildly injured by CA, severely disrupted by hyaluronidase (HAase) with CA, and mitigated by hydrocortisone (HC) with CA.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318021,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000745",
-          "name": "cardiac arrest",
-          "description": "The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.; Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.; An abrupt loss of heart function. []; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:0060319",
-            "ICD10:I46",
-            "MEDDRA:10003109",
-            "UMLS:C0018790",
-            "HP:0001695",
-            "SNOMEDCT:410429000",
-            "MEDDRA:10082515",
-            "UMLS:C0444720",
-            "SNOMEDCT:397829000",
-            "MEDDRA:10003589",
-            "NCIT:C50479",
-            "PSY:07595",
-            "MEDDRA:10019249",
-            "SNOMEDCT:261195002",
-            "MEDDRA:10003587",
-            "MEDDRA:10047284",
-            "MESH:D006323",
-            "MONDO:0000745",
-            "MEDDRA:10041914",
-            "EFO:0009492",
-            "MEDDRA:10003586",
-            "MEDDRA:10007515",
-            "ICD9:427.5",
-            "MEDDRA:10047285"
-          ],
-          "id": "MONDO:0000745",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiac Arrest",
-            "cardiac arrest",
-            "Cardiac arrest",
-            "Heart Arrest"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/cardiacarrest.htm",
-            "http://en.wikipedia.org/wiki/cardiac_arrest",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318021,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000745",
-              "name": "cardiac arrest",
-              "description": "The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.; Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.; An abrupt loss of heart function. []; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:0060319",
-                "ICD10:I46",
-                "MEDDRA:10003109",
-                "UMLS:C0018790",
-                "HP:0001695",
-                "SNOMEDCT:410429000",
-                "MEDDRA:10082515",
-                "UMLS:C0444720",
-                "SNOMEDCT:397829000",
-                "MEDDRA:10003589",
-                "NCIT:C50479",
-                "PSY:07595",
-                "MEDDRA:10019249",
-                "SNOMEDCT:261195002",
-                "MEDDRA:10003587",
-                "MEDDRA:10047284",
-                "MESH:D006323",
-                "MONDO:0000745",
-                "MEDDRA:10041914",
-                "EFO:0009492",
-                "MEDDRA:10003586",
-                "MEDDRA:10007515",
-                "ICD9:427.5",
-                "MEDDRA:10047285"
-              ],
-              "id": "MONDO:0000745",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiac Arrest",
-                "cardiac arrest",
-                "Cardiac arrest",
-                "Heart Arrest"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/cardiacarrest.htm",
-                "http://en.wikipedia.org/wiki/cardiac_arrest",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19446877,
-            "start": 569,
-            "end": 318021,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28825336': {'publication date': '2018 Nov', 'sentence': 'Compared to controls, glycocalyx was mildly injured by CA, severely disrupted by hyaluronidase (HAase) with CA, and mitigated by hydrocortisone (HC) with CA.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0018790---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "19834754",
-              "object": "MONDO:0000745",
-              "publications": [
-                "PMID:28825336"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:15939519': {'publication date': '2005 Jun', 'sentence': 'Changes of smoking behavior and serum adrenocorticotropic hormone, cortisol, prolactin, and endogenous opioids levels in nicotine dependence after naltrexone treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:24034414': {'publication date': '2014 Jan 01', 'sentence': 'However, cortisol did not mediate the MSDP-lifetime ND relation.', 'subject score': 1000, 'object score': 717}}",
-    "p2": {
-      "start": {
-        "identity": 310664,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008575",
-          "name": "nicotine dependence",
-          "description": "Any disease or disorder that is caused by the use of tobacco.; Tobacco used to the detriment of a person's health or social functioning. Tobacco dependence is included.",
-          "equivalent_curies": [
-            "PDQ:CDR0000482224",
-            "SNOMEDCT:56294008",
-            "MEDDRA:10083286",
-            "UMLS:C0040332",
-            "NCIT:C54203",
-            "EFO:0003768",
-            "MEDDRA:10043903",
-            "MEDDRA:10057852",
-            "NCIT:C35074",
-            "MESH:D014029",
-            "DOID:0050742",
-            "SNOMEDCT:89765005",
-            "MEDDRA:10056478",
-            "UMLS:C0028043",
-            "ICD9:305.1",
-            "UMLS:C1306274",
-            "ICD10:F17",
-            "MEDDRA:10043906",
-            "MONDO:0008575",
-            "UMLS:C0040336",
-            "HP:0033543"
-          ],
-          "id": "MONDO:0008575",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Tobacco use disorder",
-            "Tabagism",
-            "Nicotine Dependence",
-            "Nicotine addiction",
-            "tobacco use disorder",
-            "nicotine dependence",
-            "Tobacco Use Disorder",
-            "Tobacco Dependence"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/nicotine_dependence"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310664,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008575",
-              "name": "nicotine dependence",
-              "description": "Any disease or disorder that is caused by the use of tobacco.; Tobacco used to the detriment of a person's health or social functioning. Tobacco dependence is included.",
-              "equivalent_curies": [
-                "PDQ:CDR0000482224",
-                "SNOMEDCT:56294008",
-                "MEDDRA:10083286",
-                "UMLS:C0040332",
-                "NCIT:C54203",
-                "EFO:0003768",
-                "MEDDRA:10043903",
-                "MEDDRA:10057852",
-                "NCIT:C35074",
-                "MESH:D014029",
-                "DOID:0050742",
-                "SNOMEDCT:89765005",
-                "MEDDRA:10056478",
-                "UMLS:C0028043",
-                "ICD9:305.1",
-                "UMLS:C1306274",
-                "ICD10:F17",
-                "MEDDRA:10043906",
-                "MONDO:0008575",
-                "UMLS:C0040336",
-                "HP:0033543"
-              ],
-              "id": "MONDO:0008575",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Tobacco use disorder",
-                "Tabagism",
-                "Nicotine Dependence",
-                "Nicotine addiction",
-                "tobacco use disorder",
-                "nicotine dependence",
-                "Tobacco Use Disorder",
-                "Tobacco Dependence"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/nicotine_dependence"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11611077,
-            "start": 569,
-            "end": 310664,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15939519': {'publication date': '2005 Jun', 'sentence': 'Changes of smoking behavior and serum adrenocorticotropic hormone, cortisol, prolactin, and endogenous opioids levels in nicotine dependence after naltrexone treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:24034414': {'publication date': '2014 Jan 01', 'sentence': 'However, cortisol did not mediate the MSDP-lifetime ND relation.', 'subject score': 1000, 'object score': 717}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0028043---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "11866289",
-              "object": "MONDO:0008575",
-              "publications": [
-                "PMID:15939519",
-                "PMID:24034414"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:11137052': {'publication date': '2000 Dec 15', 'sentence': 'BACKGROUND: There is substantial evidence of dysregulation of cortisol secretion, hippocampal abnormalities, and memory deficits in schizophrenia and other psychotic disorders.', 'subject score': 888, 'object score': 1000}, 'PMID:16151537': {'publication date': '2005 Sep', 'sentence': 'We have found that long-term exposure to high endogenous levels of cortisol is associated with both memory impairments and a 14; smaller volume of the hippocampus.', 'subject score': 1000, 'object score': 983}, 'PMID:16274857': {'publication date': '2006 Nov', 'sentence': 'CONCLUSION: These results partially confirm previous findings that high cortisol is associated with impaired declarative memory function in non-demented older persons.', 'subject score': 888, 'object score': 824}, 'PMID:18702680': {'publication date': '2009 Feb', 'sentence': 'RESULTS: Our data show that chronic exposure to elevated levels of cortisol is clinically associated with significant working memory deficits, which included less shot-term memory volume, slow learning rate, memory contamination and no accurate perception of own performance.', 'subject score': 1000, 'object score': 861}, 'PMID:19375236': {'publication date': '2009 Sep', 'sentence': 'CONCLUSIONS: These findings are the first to demonstrate that learning and memory deficits in CD individuals are associated with enhanced cortisol and with cocaine use outcomes after inpatient treatment.', 'subject score': 861, 'object score': 1000}, 'PMID:22946487': {'publication date': '2013 Feb', 'sentence': 'CONCLUSION: We therefore conclude that MDMA-induced increments in cortisol concentrations are not related to MDMA-induced memory impairments.', 'subject score': 888, 'object score': 813}, 'PMID:26569538': {'publication date': '2016', 'sentence': 'RESULTS: In multilevel models, persistently but not phasically higher cortisol was associated with worse verbal memory in both learning (t(181) = 2.99, p = .003) and recall (t(280) = 3.10, p = .002).', 'subject score': 764, 'object score': 890}, 'PMID:26984331': {'publication date': '2002 Aug', 'sentence': 'OBJECTIVES: In the present paper the association of stress-induced cortisol with memory impairment is discussed Methods: An experiment is described in which an attempt is made to block stress-induced cortisol by lowering 5-HT neurotransmission by means of acute tryptophan depletion (ATD).', 'subject score': 851, 'object score': 1000}, 'PMID:17544378': {'publication date': '2007 Sep 01', 'sentence': 'BACKGROUND: Chronic elevations in cortisol associated with prolonged stress have been associated with memory loss, as has the apolipoprotein E gene (APOE-epsilon4) genotype.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319995,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001185",
-          "name": "dissociative amnesia",
-          "description": "Partial or complete loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories. Compare FORGETTING and MEMORY DECAY.; Systematic and extensive loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories.; Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7); UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "NCIT:C78444",
-            "SYMP:0000543",
-            "MONDO:0001185",
-            "MEDDRA:10027178",
-            "ICD9:300.12",
-            "ICD9:780.93",
-            "SNOMEDCT:55533009",
-            "MESH:D000647",
-            "SNOMEDCT:48167000",
-            "MEDDRA:10001949",
-            "NBO:0000253",
-            "PSY:30590",
-            "ICD10:F44.0",
-            "UMLS:C3887551",
-            "MEDDRA:10013461",
-            "MESH:D008569",
-            "DOID:11037",
-            "MEDDRA:10027172",
-            "MEDDRA:10027174",
-            "MEDDRA:10027176",
-            "MEDDRA:10017060",
-            "UMLS:C0236795",
-            "UMLS:C0542476",
-            "NCIT:C2867",
-            "UMLS:C0025261",
-            "MEDDRA:10027175",
-            "UMLS:C0751295",
-            "SNOMEDCT:386807006",
-            "MEDDRA:10027171",
-            "EFO:1001454",
-            "NCIT:C94328",
-            "PSY:02120",
-            "UMLS:C0002622",
-            "NCIT:C46084",
-            "UMLS:C0233794",
-            "SYMP:0000719",
-            "EFO:0001072",
-            "MEDDRA:10024871",
-            "HP:0002354",
-            "SNOMEDCT:84209002",
-            "MEDDRA:10037186"
-          ],
-          "id": "MONDO:0001185",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Memory Disorders",
-            "dissociative amnesia",
-            "Memory Loss",
-            "Dissociative Amnesia",
-            "memory impairment",
-            "memory loss",
-            "Forgetful",
-            "Memory Impairment",
-            "Amnesia",
-            "Dissociative amnesia",
-            "Memory impairment",
-            "amnesia",
-            "Memory dysfunction",
-            "Memory loss",
-            "Memory Dysfunction"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://www.merckmanuals.com/professional/psychiatric-disorders/dissociative-disorders/dissociative-amnesia",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.merriam-webster.com/dictionary/impairment",
-            "https://medlineplus.gov/ency/article/003257.htm",
-            "https://www.merckmanuals.com/professional/neurologic-disorders/symptoms-of-neurologic-disorders/memory-loss"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 318216,
-=======
-            "identity": 319995,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001185",
-              "name": "dissociative amnesia",
-              "description": "Partial or complete loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories. Compare FORGETTING and MEMORY DECAY.; Systematic and extensive loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories.; Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7); UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "NCIT:C78444",
-                "SYMP:0000543",
-                "MONDO:0001185",
-                "MEDDRA:10027178",
-                "ICD9:300.12",
-                "ICD9:780.93",
-                "SNOMEDCT:55533009",
-                "MESH:D000647",
-                "SNOMEDCT:48167000",
-                "MEDDRA:10001949",
-                "NBO:0000253",
-                "PSY:30590",
-                "ICD10:F44.0",
-                "UMLS:C3887551",
-                "MEDDRA:10013461",
-                "MESH:D008569",
-                "DOID:11037",
-                "MEDDRA:10027172",
-                "MEDDRA:10027174",
-                "MEDDRA:10027176",
-                "MEDDRA:10017060",
-                "UMLS:C0236795",
-                "UMLS:C0542476",
-                "NCIT:C2867",
-                "UMLS:C0025261",
-                "MEDDRA:10027175",
-                "UMLS:C0751295",
-                "SNOMEDCT:386807006",
-                "MEDDRA:10027171",
-                "EFO:1001454",
-                "NCIT:C94328",
-                "PSY:02120",
-                "UMLS:C0002622",
-                "NCIT:C46084",
-                "UMLS:C0233794",
-                "SYMP:0000719",
-                "EFO:0001072",
-                "MEDDRA:10024871",
-                "HP:0002354",
-                "SNOMEDCT:84209002",
-                "MEDDRA:10037186"
-              ],
-              "id": "MONDO:0001185",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Memory Disorders",
-                "dissociative amnesia",
-                "Memory Loss",
-                "Dissociative Amnesia",
-                "memory impairment",
-                "memory loss",
-                "Forgetful",
-                "Memory Impairment",
-                "Amnesia",
-                "Dissociative amnesia",
-                "Memory impairment",
-                "amnesia",
-                "Memory dysfunction",
-                "Memory loss",
-                "Memory Dysfunction"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://www.merckmanuals.com/professional/psychiatric-disorders/dissociative-disorders/dissociative-amnesia",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.merriam-webster.com/dictionary/impairment",
-                "https://medlineplus.gov/ency/article/003257.htm",
-                "https://www.merckmanuals.com/professional/neurologic-disorders/symptoms-of-neurologic-disorders/memory-loss"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 12377074,
-            "start": 569,
-            "end": 318216,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16893715': {'publication date': '2006 Aug 15', 'sentence': 'Although initial studies in transgenic mice and humans are encouraging, more data are required to conclusively prove the hypothesis that the adipose-tissue-specific overexpression of HSD1 and the resultant increase in tissue-specific cortisol concentrations result in human obesity, insulin resistance, high blood pressure, and metabolic syndrome.', 'subject score': 750, 'object score': 888}, 'PMID:17558491': {'publication date': '2007 Oct', 'sentence': 'CONTEXT: Changes in cortisol metabolism due to altered activity of the enzyme 11beta-hydroxysteroid dehydrogenase (11beta-HSD) have been implicated in the pathogenesis of hypertension, obesity and the metabolic syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:22146091': {'publication date': '2012 May', 'sentence': 'Moreover, chronic alterations in cortisol secretion in children may affect the timing of puberty, final stature, and body composition, as well as cause early-onset obesity, metabolic syndrome, and type 2 diabetes mellitus.', 'subject score': 888, 'object score': 851}, 'PMID:23505190': {'publication date': '2013 Jan', 'sentence': 'OBJECTIVE: Circulating cortisol and psychosocial stress may contribute to the pathogenesis of obesity and metabolic syndrome (MS).', 'subject score': 1000, 'object score': 1000}, 'PMID:24384019': {'publication date': '2014 Jan', 'sentence': 'CONTEXT: Pathologically increased cortisol exposure induces obesity, but it is not known whether relatively high cortisol within the physiological range is related to childhood obesity.', 'subject score': 583, 'object score': 1000}, 'PMID:28567298': {'publication date': '2017', 'sentence': 'He was initially misdiagnosed as having an adrenal insufficiency and developed cushingoid features and obesity secondary to hydrocortisone treatment and excessive sugar intake.', 'subject score': 888, 'object score': 1000}, 'PMID:36446324': {'publication date': '2022', 'sentence': 'Proponents of the \"Energy Storage\" hypothesis point to data implicating monogenetic disorders, the ventromedial hypothalamus, insulin, cortisol, and the adipocyte itself in the pathogenesis of obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:7550541': {'publication date': '1995 May', 'sentence': 'Cortisol in the presence of relatively high insulin concentrations can promote the deposition of energy and lead to obesity.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0028754---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "12645476",
-              "object": "MONDO:0011122",
-              "publications": [
-                "PMID:16893715",
-                "PMID:17558491",
-                "PMID:22146091",
-                "PMID:23505190",
-                "PMID:24384019",
-                "PMID:28567298",
-                "PMID:36446324",
-                "PMID:7550541"
-=======
-            "identity": 8441764,
-            "start": 569,
-            "end": 319995,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11137052': {'publication date': '2000 Dec 15', 'sentence': 'BACKGROUND: There is substantial evidence of dysregulation of cortisol secretion, hippocampal abnormalities, and memory deficits in schizophrenia and other psychotic disorders.', 'subject score': 888, 'object score': 1000}, 'PMID:16151537': {'publication date': '2005 Sep', 'sentence': 'We have found that long-term exposure to high endogenous levels of cortisol is associated with both memory impairments and a 14; smaller volume of the hippocampus.', 'subject score': 1000, 'object score': 983}, 'PMID:16274857': {'publication date': '2006 Nov', 'sentence': 'CONCLUSION: These results partially confirm previous findings that high cortisol is associated with impaired declarative memory function in non-demented older persons.', 'subject score': 888, 'object score': 824}, 'PMID:18702680': {'publication date': '2009 Feb', 'sentence': 'RESULTS: Our data show that chronic exposure to elevated levels of cortisol is clinically associated with significant working memory deficits, which included less shot-term memory volume, slow learning rate, memory contamination and no accurate perception of own performance.', 'subject score': 1000, 'object score': 861}, 'PMID:19375236': {'publication date': '2009 Sep', 'sentence': 'CONCLUSIONS: These findings are the first to demonstrate that learning and memory deficits in CD individuals are associated with enhanced cortisol and with cocaine use outcomes after inpatient treatment.', 'subject score': 861, 'object score': 1000}, 'PMID:22946487': {'publication date': '2013 Feb', 'sentence': 'CONCLUSION: We therefore conclude that MDMA-induced increments in cortisol concentrations are not related to MDMA-induced memory impairments.', 'subject score': 888, 'object score': 813}, 'PMID:26569538': {'publication date': '2016', 'sentence': 'RESULTS: In multilevel models, persistently but not phasically higher cortisol was associated with worse verbal memory in both learning (t(181) = 2.99, p = .003) and recall (t(280) = 3.10, p = .002).', 'subject score': 764, 'object score': 890}, 'PMID:26984331': {'publication date': '2002 Aug', 'sentence': 'OBJECTIVES: In the present paper the association of stress-induced cortisol with memory impairment is discussed Methods: An experiment is described in which an attempt is made to block stress-induced cortisol by lowering 5-HT neurotransmission by means of acute tryptophan depletion (ATD).', 'subject score': 851, 'object score': 1000}, 'PMID:17544378': {'publication date': '2007 Sep 01', 'sentence': 'BACKGROUND: Chronic elevations in cortisol associated with prolonged stress have been associated with memory loss, as has the apolipoprotein E gene (APOE-epsilon4) genotype.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0233794---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0751295---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8625521",
-              "object": "MONDO:0001185",
-              "publications": [
-                "PMID:26984331",
-                "PMID:26569538",
-                "PMID:16151537",
-                "PMID:19375236",
-                "PMID:17544378",
-                "PMID:18702680",
-                "PMID:16274857",
-                "PMID:11137052",
-                "PMID:22946487"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9850761,
-            "start": 569,
-            "end": 183319,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12621354': {'publication date': '2003 Mar', 'sentence': 'CONCLUSION: Although hydrocortisone has anti-inflammatory properties, it seems to provoke inflammation in the round window membrane after topical instillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:18182463': {'publication date': '2007', 'sentence': 'In contrast to the influence of cortisol on the above parameters of systemic inflammation, the significant endotoxin-induced decreases in HRV time and frequency domains were not influenced by prior hydrocortisone treatment.', 'subject score': 851, 'object score': 888}, 'PMID:29269321': {'publication date': '2018 Mar', 'sentence': 'However, in the context of chronic stress, it is hypothesized that glucocorticoid receptors within immune cells become less sensitive to the anti-inflammatory effects of cortisol, resulting in increased systemic inflammation.', 'subject score': 1000, 'object score': 851}, 'PMID:31260749': {'publication date': '2019 Oct', 'sentence': 'Here, we measured 53 oxylipins using LC-MS/MS in an in vitro model of endothelial cell inflammation, and compared the changes induced by DHA to hydrocortisone, a well-established anti-inflammatory drug.', 'subject score': 1000, 'object score': 901}, 'PMID:35634363': {'publication date': '2022 Jun', 'sentence': 'However, opposing evidence has accumulated that supports a more recent model, which instead proposes that cortisol possesses immune potentiating properties and may thus directly cause the increased inflammation seen in depression.', 'subject score': 1000, 'object score': 888}, 'PMID:36869869': {'publication date': '2023 Mar 06', 'sentence': 'In addition, lowering interleukin-6 and cortisol leads to reduced inflammation, faster recovery, and increased immunity.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10068843",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:12621354",
-                "PMID:18182463",
-                "PMID:29269321",
-                "PMID:31260749",
-                "PMID:35634363",
-                "PMID:36869869"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:12404564': {'publication date': '2001 Jun', 'sentence': 'Type 2 glucocorticoid receptors (GRs), which are occupied by cortisol in humans in times of stress, are thought to be responsible for the glucocorticoid-induced memory impairment.', 'subject score': 1000, 'object score': 861}, 'PMID:17702612': {'publication date': '2008 Feb', 'sentence': 'The results provide further evidence that cortisol is a primary effector in the stress-induced memory retrieval deficit.', 'subject score': 1000, 'object score': 840}, 'PMID:18761097': {'publication date': '2009 Jan', 'sentence': 'The memory impairment due to cortisol remained, even after a washout period of 1 week.', 'subject score': 1000, 'object score': 1000}, 'PMID:26098727': {'publication date': '2015 Dec', 'sentence': 'Combined, the findings from this study suggest that cortisol enhances the impact of mind wandering on working memory, that state anxiety may not always result in stress-related working memory impairments, and that high working memory performance can protect against mind wandering.', 'subject score': 1000, 'object score': 833}, 'PMID:36118093': {'publication date': '2022', 'sentence': 'This study aimed to investigate the effect of noni on brain memory impairment induced by hydrocortisone and its protective mechanism in mice.', 'subject score': 1000, 'object score': 901}, 'PMID:32133575': {'publication date': '2020 Mar 04', 'sentence': \"Prolonged excess cortisol leads to visceral adiposity, insulin resistance, hyperglycemia, memory dysfunction, cognitive impairment, and more severe Alzheimer's disease phenotypes.\", 'subject score': 851, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319995,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001185",
-          "name": "dissociative amnesia",
-          "description": "Partial or complete loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories. Compare FORGETTING and MEMORY DECAY.; Systematic and extensive loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories.; Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7); UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "NCIT:C78444",
-            "SYMP:0000543",
-            "MONDO:0001185",
-            "MEDDRA:10027178",
-            "ICD9:300.12",
-            "ICD9:780.93",
-            "SNOMEDCT:55533009",
-            "MESH:D000647",
-            "SNOMEDCT:48167000",
-            "MEDDRA:10001949",
-            "NBO:0000253",
-            "PSY:30590",
-            "ICD10:F44.0",
-            "UMLS:C3887551",
-            "MEDDRA:10013461",
-            "MESH:D008569",
-            "DOID:11037",
-            "MEDDRA:10027172",
-            "MEDDRA:10027174",
-            "MEDDRA:10027176",
-            "MEDDRA:10017060",
-            "UMLS:C0236795",
-            "UMLS:C0542476",
-            "NCIT:C2867",
-            "UMLS:C0025261",
-            "MEDDRA:10027175",
-            "UMLS:C0751295",
-            "SNOMEDCT:386807006",
-            "MEDDRA:10027171",
-            "EFO:1001454",
-            "NCIT:C94328",
-            "PSY:02120",
-            "UMLS:C0002622",
-            "NCIT:C46084",
-            "UMLS:C0233794",
-            "SYMP:0000719",
-            "EFO:0001072",
-            "MEDDRA:10024871",
-            "HP:0002354",
-            "SNOMEDCT:84209002",
-            "MEDDRA:10037186"
-          ],
-          "id": "MONDO:0001185",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Memory Disorders",
-            "dissociative amnesia",
-            "Memory Loss",
-            "Dissociative Amnesia",
-            "memory impairment",
-            "memory loss",
-            "Forgetful",
-            "Memory Impairment",
-            "Amnesia",
-            "Dissociative amnesia",
-            "Memory impairment",
-            "amnesia",
-            "Memory dysfunction",
-            "Memory loss",
-            "Memory Dysfunction"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://www.merckmanuals.com/professional/psychiatric-disorders/dissociative-disorders/dissociative-amnesia",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.merriam-webster.com/dictionary/impairment",
-            "https://medlineplus.gov/ency/article/003257.htm",
-            "https://www.merckmanuals.com/professional/neurologic-disorders/symptoms-of-neurologic-disorders/memory-loss"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319995,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001185",
-              "name": "dissociative amnesia",
-              "description": "Partial or complete loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories. Compare FORGETTING and MEMORY DECAY.; Systematic and extensive loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories.; Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7); UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "NCIT:C78444",
-                "SYMP:0000543",
-                "MONDO:0001185",
-                "MEDDRA:10027178",
-                "ICD9:300.12",
-                "ICD9:780.93",
-                "SNOMEDCT:55533009",
-                "MESH:D000647",
-                "SNOMEDCT:48167000",
-                "MEDDRA:10001949",
-                "NBO:0000253",
-                "PSY:30590",
-                "ICD10:F44.0",
-                "UMLS:C3887551",
-                "MEDDRA:10013461",
-                "MESH:D008569",
-                "DOID:11037",
-                "MEDDRA:10027172",
-                "MEDDRA:10027174",
-                "MEDDRA:10027176",
-                "MEDDRA:10017060",
-                "UMLS:C0236795",
-                "UMLS:C0542476",
-                "NCIT:C2867",
-                "UMLS:C0025261",
-                "MEDDRA:10027175",
-                "UMLS:C0751295",
-                "SNOMEDCT:386807006",
-                "MEDDRA:10027171",
-                "EFO:1001454",
-                "NCIT:C94328",
-                "PSY:02120",
-                "UMLS:C0002622",
-                "NCIT:C46084",
-                "UMLS:C0233794",
-                "SYMP:0000719",
-                "EFO:0001072",
-                "MEDDRA:10024871",
-                "HP:0002354",
-                "SNOMEDCT:84209002",
-                "MEDDRA:10037186"
-              ],
-              "id": "MONDO:0001185",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Memory Disorders",
-                "dissociative amnesia",
-                "Memory Loss",
-                "Dissociative Amnesia",
-                "memory impairment",
-                "memory loss",
-                "Forgetful",
-                "Memory Impairment",
-                "Amnesia",
-                "Dissociative amnesia",
-                "Memory impairment",
-                "amnesia",
-                "Memory dysfunction",
-                "Memory loss",
-                "Memory Dysfunction"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://www.merckmanuals.com/professional/psychiatric-disorders/dissociative-disorders/dissociative-amnesia",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.merriam-webster.com/dictionary/impairment",
-                "https://medlineplus.gov/ency/article/003257.htm",
-                "https://www.merckmanuals.com/professional/neurologic-disorders/symptoms-of-neurologic-disorders/memory-loss"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9637207,
-            "start": 569,
-            "end": 319995,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12404564': {'publication date': '2001 Jun', 'sentence': 'Type 2 glucocorticoid receptors (GRs), which are occupied by cortisol in humans in times of stress, are thought to be responsible for the glucocorticoid-induced memory impairment.', 'subject score': 1000, 'object score': 861}, 'PMID:17702612': {'publication date': '2008 Feb', 'sentence': 'The results provide further evidence that cortisol is a primary effector in the stress-induced memory retrieval deficit.', 'subject score': 1000, 'object score': 840}, 'PMID:18761097': {'publication date': '2009 Jan', 'sentence': 'The memory impairment due to cortisol remained, even after a washout period of 1 week.', 'subject score': 1000, 'object score': 1000}, 'PMID:26098727': {'publication date': '2015 Dec', 'sentence': 'Combined, the findings from this study suggest that cortisol enhances the impact of mind wandering on working memory, that state anxiety may not always result in stress-related working memory impairments, and that high working memory performance can protect against mind wandering.', 'subject score': 1000, 'object score': 833}, 'PMID:36118093': {'publication date': '2022', 'sentence': 'This study aimed to investigate the effect of noni on brain memory impairment induced by hydrocortisone and its protective mechanism in mice.', 'subject score': 1000, 'object score': 901}, 'PMID:32133575': {'publication date': '2020 Mar 04', 'sentence': \"Prolonged excess cortisol leads to visceral adiposity, insulin resistance, hyperglycemia, memory dysfunction, cognitive impairment, and more severe Alzheimer's disease phenotypes.\", 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0233794---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C3887551---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9850315",
-              "object": "MONDO:0001185",
-              "publications": [
-                "PMID:18761097",
-                "PMID:12404564",
-                "PMID:36118093",
-                "PMID:32133575",
-                "PMID:17702612",
-                "PMID:26098727"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 312686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-          "name": "adrenocortical insufficiency",
-          "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0405580",
-            "MEDDRA:10022460",
-            "ICD9:255.4",
-            "EFO:0009491",
-            "MEDDRA:10001367",
-            "MEDDRA:10020936",
-            "MONDO:0000004",
-            "MEDDRA:10020979",
-            "SNOMEDCT:237785004",
-            "SNOMEDCT:386584007",
-            "MEDDRA:10056485",
-            "MEDDRA:10082130",
-            "UMLS:C0001623",
-            "MEDDRA:10001344",
-            "MEDDRA:10001366",
-            "MEDDRA:10001334",
-            "DOID:10493",
-            "NCIT:C26691",
-            "HP:0000846",
-            "MEDDRA:10001335",
-            "MEDDRA:10001369",
-            "MEDDRA:10001342",
-            "MEDDRA:10001343",
-            "MESH:D000309",
-            "SNOMEDCT:111563005",
-            "MEDDRA:10011172",
-            "MEDDRA:10022461"
-          ],
-          "id": "MONDO:0000004",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortical hypofunction",
-            "Adrenocortical Insufficiency",
-            "adrenocortical insufficiency",
-            "Corticoadrenal insufficiency",
-            "Adrenal gland hypofunction",
-            "Adrenal Insufficiency",
-            "Adrenal insufficiency",
-            "Adrenal cortical hypofunction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:11443143"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-              "name": "adrenocortical insufficiency",
-              "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0405580",
-                "MEDDRA:10022460",
-                "ICD9:255.4",
-                "EFO:0009491",
-                "MEDDRA:10001367",
-                "MEDDRA:10020936",
-                "MONDO:0000004",
-                "MEDDRA:10020979",
-                "SNOMEDCT:237785004",
-                "SNOMEDCT:386584007",
-                "MEDDRA:10056485",
-                "MEDDRA:10082130",
-                "UMLS:C0001623",
-                "MEDDRA:10001344",
-                "MEDDRA:10001366",
-                "MEDDRA:10001334",
-                "DOID:10493",
-                "NCIT:C26691",
-                "HP:0000846",
-                "MEDDRA:10001335",
-                "MEDDRA:10001369",
-                "MEDDRA:10001342",
-                "MEDDRA:10001343",
-                "MESH:D000309",
-                "SNOMEDCT:111563005",
-                "MEDDRA:10011172",
-                "MEDDRA:10022461"
-              ],
-              "id": "MONDO:0000004",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortical hypofunction",
-                "Adrenocortical Insufficiency",
-                "adrenocortical insufficiency",
-                "Corticoadrenal insufficiency",
-                "Adrenal gland hypofunction",
-                "Adrenal Insufficiency",
-                "Adrenal insufficiency",
-                "Adrenal cortical hypofunction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:11443143"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9118394,
-            "start": 569,
-            "end": 312686,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11786677': {'publication date': '2001', 'sentence': 'Firstly, the GH-mediated increase in cortisol metabolism (mediated via reduced E to F conversion) may precipitate adrenal insufficiency in hypopituitary patients with partial adrenocorticotropic hormone deficiency commencing GH therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:17157339': {'publication date': '2007 Jan', 'sentence': 'It is proposed that a steroid profile measuring cortisol, aldosterone, 11-deoxycortisol, and dehydroepiandrosterone would potentially improve the ability to determine the cause of adrenal insufficiency.', 'subject score': 852, 'object score': 1000}, 'PMID:18430777': {'publication date': '2008 Jul', 'sentence': 'METHODS: Diagnosis of FGD was based on clinical features, high ACTH, and low cortisol concentrations with normal renin and aldosterone concentrations and exclusion of other causes of adrenal failure.', 'subject score': 851, 'object score': 1000}, 'PMID:19225029': {'publication date': '2009 Mar', 'sentence': 'Clinically, it was doubted whether she had true adrenal insufficiency and it was thought that the cortisol results might be artefactually low due to assay interference.', 'subject score': 872, 'object score': 901}, 'PMID:24424183': {'publication date': '2014 Apr-May', 'sentence': 'The diagnosis depends on demonstrating inappropriately low cortisol production and the presence of high titers of adrenal cortex autoantibodies (ACAs), along with excluding other causes of adrenal failure using other tests as necessary.', 'subject score': 775, 'object score': 1000}, 'PMID:30670349': {'publication date': '2019 Oct', 'sentence': 'BACKGROUND: Immature adrenocortical function in preterm infants may cause inadequate production of cortisol under stress, resulting in adrenal insufficiency of prematurity (AOP).', 'subject score': 1000, 'object score': 1000}, 'PMID:34582361': {'publication date': '2021 Sep 01', 'sentence': 'The use of combined chemotherapy and atezolizumab in the ectopic ACTH syndrome secondary to small-cell lung cancer may cause a precipitous fall in circulating ACTH/cortisol, resulting in symptomatic adrenal insufficiency The advances in cancer therapy and treatment for endocrine paraneoplastic syndrome need to be adapted.', 'subject score': 851, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0001623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9318796",
-              "object": "MONDO:0000004",
-              "publications": [
-                "PMID:11786677",
-                "PMID:17157339",
-                "PMID:18430777",
-                "PMID:19225029",
-                "PMID:24424183",
-                "PMID:30670349",
-                "PMID:34582361"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 314857,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004795",
-          "name": "otitis externa",
-          "description": "Inflammation of the anatomical structures of the outer ear and ear canal, which is most often caused by an infectious process. Symptoms include erythema, edema, and pain.; Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.; Inflammation or infection of the external auditory canal (EAC), the auricle, or both. [http://search.medscape.com/search/?q=otitis%20externa, ORCID:0000-0001-5208-3432]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021919",
-            "NCIT:C79601",
-            "MESH:D010032",
-            "SNOMEDCT:3135009",
-            "MEDDRA:10052558",
-            "NCIT:C3299",
-            "MEDDRA:10021920",
-            "UMLS:C0029878",
-            "UMLS:C0021355",
-            "MEDDRA:10065837",
-            "HP:0410017",
-            "MEDDRA:10033072",
-            "MEDDRA:10082612",
-            "EFO:0009560",
-            "DOID:9463",
-            "ICD9:380.1",
-            "SNOMEDCT:86981007",
-            "MONDO:0004795"
-          ],
-          "id": "MONDO:0004795",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infective otitis externa",
-            "Otitis Externa",
-            "Otitis externa",
-            "otitis externa",
-            "Infectious Otitis Externa"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/otitis_externa",
-            "http://search.medscape.com/search/?q=otitis%20externa",
-            "https://orcid.org/0000-0001-5208-3432"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314857,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004795",
-              "name": "otitis externa",
-              "description": "Inflammation of the anatomical structures of the outer ear and ear canal, which is most often caused by an infectious process. Symptoms include erythema, edema, and pain.; Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.; Inflammation or infection of the external auditory canal (EAC), the auricle, or both. [http://search.medscape.com/search/?q=otitis%20externa, ORCID:0000-0001-5208-3432]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021919",
-                "NCIT:C79601",
-                "MESH:D010032",
-                "SNOMEDCT:3135009",
-                "MEDDRA:10052558",
-                "NCIT:C3299",
-                "MEDDRA:10021920",
-                "UMLS:C0029878",
-                "UMLS:C0021355",
-                "MEDDRA:10065837",
-                "HP:0410017",
-                "MEDDRA:10033072",
-                "MEDDRA:10082612",
-                "EFO:0009560",
-                "DOID:9463",
-                "ICD9:380.1",
-                "SNOMEDCT:86981007",
-                "MONDO:0004795"
-              ],
-              "id": "MONDO:0004795",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infective otitis externa",
-                "Otitis Externa",
-                "Otitis externa",
-                "otitis externa",
-                "Infectious Otitis Externa"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/otitis_externa",
-                "http://search.medscape.com/search/?q=otitis%20externa",
-                "https://orcid.org/0000-0001-5208-3432"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8949519,
-            "start": 569,
-            "end": 314857,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11583468': {'publication date': '2001 Aug', 'sentence': 'From this study it is inferred that the group III steroid betamethasone dipropionate alone heals experimentally induced external otitis more rapidly than hydrocortisone with oxytetracycline, with or without polymyxin B.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0029878---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9145908",
-              "object": "MONDO:0004795",
-              "publications": [
-                "PMID:11583468"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318773,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0036591",
-          "name": "adrenal cortex neoplasm",
-          "description": "The presence of a neoplasm of the adrenal cortex. [HPO:probinson]; The presence of a neoplasm of the adrenal cortex.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0036591",
-            "MESH:D000306",
-            "UMLS:C0001618",
-            "HP:0100641",
-            "NCIT:C2858",
-            "SNOMEDCT:127022002"
-          ],
-          "id": "MONDO:0036591",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortex neoplasm",
-            "Adrenal Cortical Neoplasm",
-            "Neoplasm of the adrenal cortex",
-            "Adrenal Cortex Neoplasms"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318773,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0036591",
-              "name": "adrenal cortex neoplasm",
-              "description": "The presence of a neoplasm of the adrenal cortex. [HPO:probinson]; The presence of a neoplasm of the adrenal cortex.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0036591",
-                "MESH:D000306",
-                "UMLS:C0001618",
-                "HP:0100641",
-                "NCIT:C2858",
-                "SNOMEDCT:127022002"
-              ],
-              "id": "MONDO:0036591",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortex neoplasm",
-                "Adrenal Cortical Neoplasm",
-                "Neoplasm of the adrenal cortex",
-                "Adrenal Cortex Neoplasms"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8502652,
-            "start": 569,
-            "end": 318773,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11196414': {'publication date': '2000 Nov', 'sentence': 'In conclusion, the reciprocal expression of CYP17 and the transcriptional repressors COUP-TF and DAX-1 indicates that these orphan receptors have a pathophysiologic role in the excessive hormone production in cortisol- and deoxycorticosterone-producing adrenocortical tumors.', 'subject score': 1000, 'object score': 983}, 'PMID:16449345': {'publication date': '2006 Apr', 'sentence': 'CONTEXT: Arginine vasopressin (AVP) stimulates steroid secretion from the normal human adrenal gland and some cortisol-producing adrenocortical tumors or hyperplasia through activation of the V(1a) receptor.', 'subject score': 1000, 'object score': 983}, 'PMID:17980016': {'publication date': '2008 May', 'sentence': 'OBJECTIVE: Abnormal responsiveness to arginine vasopressin (AVP) was previously observed in cortisol-producing adrenocortical tumours but the mechanism remains unclear.', 'subject score': 1000, 'object score': 983}, 'PMID:204155': {'publication date': '1977 Nov', 'sentence': 'Correlation of alkaline phosphatase staining of cortisol-producing adrenocortical tumors with dexamethasone suppression and ACTH stimulation.', 'subject score': 1000, 'object score': 983}, 'PMID:29299796': {'publication date': '2018 02', 'sentence': 'CONCLUSIONS: EV-associated miRNAs are differentially expressed in different non-functioning and cortisol-producing adrenocortical tumors.', 'subject score': 1000, 'object score': 983}, 'PMID:29642186': {'publication date': '2018 Apr', 'sentence': 'LESSIONS: An understanding of RTH after adrenalectomy as a treatment for cortisol-producing adrenocortical tumors is important for the prevention of unnecessary surgical intervention and therapy.', 'subject score': 1000, 'object score': 983}, 'PMID:32507359': {'publication date': '2020 May 23', 'sentence': 'Genetic alterations in GNAS, PRKAR1A, PRKACA, PRKACB, PDE11A, and PDE8B, that lead to aberrant cyclic adenosine monophosphate-protein (cAMP) kinase A signaling, were found to play a major role in the development of benign cortisol-producing adrenocortical tumors and/or hyperplasias, whereas genetic defects in KCNJ5, ATP1A1, ATP2B3, CACNA1D, CACNA1H, and CLCN2 were implicated in the development of benign aldosterone-producing tumors and/or hyperplasias through modification of intracellular calcium signaling.', 'subject score': 888, 'object score': 1000}, 'PMID:33776926': {'publication date': '2021', 'sentence': 'This review describes the genetic causes of benign cortisol- and aldosterone-producing adrenocortical tumors.', 'subject score': 888, 'object score': 1000}, 'PMID:9694577': {'publication date': '1998', 'sentence': 'However, recent work by our group and others have shown that these cortisol-producing adrenocortical tumors may be under the control of inappropriate, illicit or ectopic hormone receptors.', 'subject score': 1000, 'object score': 983}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0001618---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8699464",
-              "object": "MONDO:0036591",
-              "publications": [
-                "PMID:11196414",
-                "PMID:16449345",
-                "PMID:17980016",
-                "PMID:204155",
-                "PMID:29299796",
-                "PMID:29642186",
-                "PMID:32507359",
-                "PMID:33776926",
-                "PMID:9694577"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8472799,
-            "start": 569,
-            "end": 319673,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1116140': {'publication date': '1975 Apr', 'sentence': 'The administration of hydrocortisone before tumor inoculation resulted in increased tumor take, reduced mean survival time of mice, and concentration of tumor metastasis in a specific organ (i.e., lung metastasis for Ehrlich hypotetraploid clone 1 tumor, and liver metastasis for Ehrlich hypotetraploid stock and Ehrlich hyperdiploid stock tumors).', 'subject score': 1000, 'object score': 888}, 'PMID:18034306': {'publication date': '2008', 'sentence': 'CS can be ACTH-dependent, caused by ACTH-secreting pituitary or ectopic tumours, or ACTH-independent, caused by cortisol-secreting adrenal tumours.', 'subject score': 1000, 'object score': 888}, 'PMID:2017766': {'publication date': '1991 Mar 25', 'sentence': 'MB, CORT, IND, or the injection vehicle (water) alone did not produce tumors.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8657746",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:1116140",
-                "PMID:18034306",
-                "PMID:2017766"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 314596,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-          "name": "Insulin resistance",
-          "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "NCIT:C113101",
-            "UMLS:C0021655",
-            "MEDDRA:10022489",
-            "SNOMEDCT:48606007",
-            "MESH:D007333",
-            "EFO:0002614",
-            "HP:0000855",
-            "SNOMEDCT:763325000"
-          ],
-          "id": "HP:0000855",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Insulin resistance",
-            "insulin resistance",
-            "Insulin Resistance"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314596,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-              "name": "Insulin resistance",
-              "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "NCIT:C113101",
-                "UMLS:C0021655",
-                "MEDDRA:10022489",
-                "SNOMEDCT:48606007",
-                "MESH:D007333",
-                "EFO:0002614",
-                "HP:0000855",
-                "SNOMEDCT:763325000"
-              ],
-              "id": "HP:0000855",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Insulin resistance",
-                "insulin resistance",
-                "Insulin Resistance"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7764698,
-            "start": 569,
-            "end": 314596,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10634968': {'publication date': '1999', 'sentence': 'Cortisol counteracts the insulin activation of glycogen synthase in muscle, the insulin inhibition of hepatic glucose production and the insulin inhibition of lipolysis in adipose tissue, leading to the well-established systemic insulin resistance caused by excess cortisol.', 'subject score': 853, 'object score': 840}, 'PMID:12397528': {'publication date': '2002 Oct', 'sentence': 'Evidence is presented, that by the action of 11 beta-hydroxysteroid dehydrogenase 1 (11 beta HSD1) higher intracellular cortisol concentration may be created that may be relevant to induce insulin resistance and metabolic disturbances.', 'subject score': 597, 'object score': 1000}, 'PMID:15823722': {'publication date': '2005', 'sentence': 'Chromium picolinate may favorably influence the vascular risk associated with smoking by combating cortisol-induced insulin resistance.', 'subject score': 798, 'object score': 798}, 'PMID:1605044': {'publication date': '1992 Apr', 'sentence': 'These results suggest that the insulin resistance caused by cortisol is elicited in a stepwise manner, starting with an inhibition in the glycogen synthesis system in insulin-sensitive muscles, later including all muscles as well as 2-deoxyglucose uptake.', 'subject score': 1000, 'object score': 1000}, 'PMID:16772320': {'publication date': '2006 Nov', 'sentence': 'Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:16893715': {'publication date': '2006 Aug 15', 'sentence': 'Although initial studies in transgenic mice and humans are encouraging, more data are required to conclusively prove the hypothesis that the adipose-tissue-specific overexpression of HSD1 and the resultant increase in tissue-specific cortisol concentrations result in human obesity, insulin resistance, high blood pressure, and metabolic syndrome.', 'subject score': 750, 'object score': 1000}, 'PMID:1773700': {'publication date': '1991 Dec', 'sentence': 'Cortisol and testosterone have \"permissive\" effect on adipose lipolysis and therefore amplify lipolytic stimulation; FFA, cortisol, and testosterone thus have powerful combined effects, resulting in insulin resistance and increased hepatic gluconeogenesis.', 'subject score': 1000, 'object score': 1000}, 'PMID:18789704': {'publication date': '2008 Oct 01', 'sentence': 'Excess 11beta-HSD1 or cortisol leads to insulin resistance and metabolic syndrome in animal models and in humans.', 'subject score': 1000, 'object score': 1000}, 'PMID:19131173': {'publication date': '2009 Jun', 'sentence': 'In conclusion olanzapine OST and ODT equally elevated the prolactin concentration and significantly shifted its acrophase, thus dissociating PRL and cortisol, while both formulations induced similar insulin resistance as evidenced by the elevated HOMA-IR.', 'subject score': 1000, 'object score': 865}, 'PMID:21510838': {'publication date': '2011', 'sentence': 'Excess cortisol or 11beta-HSD1 leads to insulin resistance and metabolic syndrome.', 'subject score': 853, 'object score': 1000}, 'PMID:23389468': {'publication date': '2014 Apr', 'sentence': 'Excess cortisol and GH induce insulin resistance, a central feature of type 2 diabetes (T2D).', 'subject score': 853, 'object score': 1000}, 'PMID:23426618': {'publication date': '2013 Apr', 'sentence': 'RESULTS: Hydrocortisone induced systemic insulin resistance but failed to cause sc adipose tissue insulin resistance as measured by suppression of adipose tissue lipolysis and enhanced insulin-stimulated pyruvate generation.', 'subject score': 1000, 'object score': 901}, 'PMID:23577182': {'publication date': '2013', 'sentence': 'Cortisol excess is known to cause insulin resistance, an independent cardiovascular risk marker, however in patients with adrenal incidentalomas it is unknown whether their insulin resistance is secondary to the excess cortisol and therefore potentially reversible.', 'subject score': 853, 'object score': 1000}, 'PMID:24967820': {'publication date': '2014', 'sentence': 'In contrast, both groups of mice lacking functional incretin receptors displayed substantially impaired islet adaptations to insulin resistance induced by hydrocortisone, including marked curtailment of expansion of islet area, beta cell mass and islet number.', 'subject score': 1000, 'object score': 1000}, 'PMID:27465830': {'publication date': '2016 11 15', 'sentence': 'In contrast, hydrocortisone-induced insulin resistance increased islet number (p < 0.01) and beta-cell mass (p < 0.001).', 'subject score': 861, 'object score': 861}, 'PMID:29225114': {'publication date': '2018 May - Jun', 'sentence': 'Furthermore, fructose in the brain, either from fructose uptake via the blood brain barrier or endogenous formation from glucose via the polyol pathway stimulates an increased release of cortisol causing hepatic gluconeogenesis leading to overall insulin resistance and further body fattening.', 'subject score': 1000, 'object score': 901}, 'PMID:32133575': {'publication date': '2020 Mar 04', 'sentence': \"Prolonged excess cortisol leads to visceral adiposity, insulin resistance, hyperglycemia, memory dysfunction, cognitive impairment, and more severe Alzheimer's disease phenotypes.\", 'subject score': 851, 'object score': 1000}, 'PMID:33419065': {'publication date': '2021 Jan 06', 'sentence': 'During sleep at night, the gradual development of insulin resistance, due to growth hormone and cortisol surges, ensures that blood glucose levels will be maintained within normal levels by: (a) switching from glucose to NEFA oxidation in muscle; (b) modulating glucose production from the liver/kidneys.', 'subject score': 694, 'object score': 1000}, 'PMID:3517554': {'publication date': '1986 May', 'sentence': \"The data demonstrate that acute elevation of plasma cortisol to levels near those observed in severe stress results in insulin resistance of peripheral and hepatic glucose metabolism but in unimpaired insulin effects on plasma FFA and branched chain amino acids, suggesting that cortisol's lipolytic and proteolytic effects are antagonized by elevated plasma insulin levels.\", 'subject score': 888, 'object score': 1000}, 'PMID:6348064': {'publication date': '1983 Sep', 'sentence': 'These results, particularly the marked decrease in MGD, a typical feature of postreceptor defects, indicate that cortisol-induced insulin resistance in man is due to an impairment of peripheral insulin action located beyond the hormone-receptor binding step.', 'subject score': 861, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0021655---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7929803",
-              "object": "HP:0000855",
-              "publications": [
-                "PMID:10634968",
-                "PMID:12397528",
-                "PMID:15823722",
-                "PMID:1605044",
-                "PMID:16772320",
-                "PMID:16893715",
-                "PMID:1773700",
-                "PMID:18789704",
-                "PMID:19131173",
-                "PMID:21510838",
-                "PMID:23389468",
-                "PMID:23426618",
-                "PMID:23577182",
-                "PMID:24967820",
-                "PMID:27465830",
-                "PMID:29225114",
-                "PMID:32133575",
-                "PMID:33419065",
-                "PMID:3517554",
-                "PMID:6348064"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317183,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004982",
-          "name": "pancreatitis",
-          "description": "Inflammation of the pancreas.; INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.; The presence of inflammation in the pancreas. [HPO:probinson]; The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0004982",
-            "MEDDRA:10076039",
-            "MEDDRA:10033656",
-            "DOID:4989",
-            "SNOMEDCT:75694006",
-            "ICD10:K85.9",
-            "MEDDRA:10033645",
-            "NCIT:C3306",
-            "EFO:0000278",
-            "HP:0001733",
-            "MESH:D010195",
-            "UMLS:C0030305"
-          ],
-          "id": "MONDO:0004982",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pancreatitis",
-            "pancreatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/pancreatitis.htm",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317183,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004982",
-              "name": "pancreatitis",
-              "description": "Inflammation of the pancreas.; INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.; The presence of inflammation in the pancreas. [HPO:probinson]; The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0004982",
-                "MEDDRA:10076039",
-                "MEDDRA:10033656",
-                "DOID:4989",
-                "SNOMEDCT:75694006",
-                "ICD10:K85.9",
-                "MEDDRA:10033645",
-                "NCIT:C3306",
-                "EFO:0000278",
-                "HP:0001733",
-                "MESH:D010195",
-                "UMLS:C0030305"
-              ],
-              "id": "MONDO:0004982",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pancreatitis",
-                "pancreatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/pancreatitis.htm",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7282813,
-            "start": 569,
-            "end": 317183,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10354211': {'publication date': '1999 Jun', 'sentence': 'The amount of N-acetyl D-glucosamine in the zymogen granule membrane was not altered by caerulein acute pancreatitis induced under continuous hydrocortisone treatment, but it was decreased by the administration of L-364,718 over 7 days after pancreatitis induction.', 'subject score': 851, 'object score': 888}, 'PMID:10436370': {'publication date': '1999', 'sentence': 'Hydrocortisone should be tested experimentally after the induction of AP and clinically as a prophylactic measure to avoid severe AP induced by endoscopic retrograde cholangiopancreaticography.', 'subject score': 1000, 'object score': 888}, 'PMID:11680590': {'publication date': '2001 Oct', 'sentence': 'Hydrocortisone (10 mg/kg) was administered intravenously 10 minutes after induction of acute pancreatitis.', 'subject score': 1000, 'object score': 888}, 'PMID:12911675': {'publication date': '2003 Sep', 'sentence': 'Acute pancreatitis due to hydrocortisone in a patient with ulcerative colitis.', 'subject score': 1000, 'object score': 888}, 'PMID:12924636': {'publication date': '2003 Aug', 'sentence': 'According to the dose and time of administration, hydrocortisone therapy was effective and beneficial at a dose of 4 mg/kg give 30 min before inducing acute pancreatitis.', 'subject score': 888, 'object score': 888}, 'PMID:8530830': {'publication date': '1995 Oct', 'sentence': 'In groups II-V, rats were treated with the anti-inflammatory drugs indomethacine, hydrocortisone, cimetidine, and acetylsalicylic acid (ASS) before induction of AP.', 'subject score': 1000, 'object score': 888}, 'PMID:9408342': {'publication date': '1997', 'sentence': 'In animal experiments, dexamethasone and hydrocortisone significantly decreased the serum amylase activities 8 hours after the induction of pancreatitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0030305---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7432490",
-              "object": "MONDO:0004982",
-              "publications": [
-                "PMID:10354211",
-                "PMID:10436370",
-                "PMID:11680590",
-                "PMID:12911675",
-                "PMID:12924636",
-                "PMID:8530830",
-                "PMID:9408342"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 312713,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-          "name": "congenital adrenal hyperplasia",
-          "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:237751000",
-            "DOID:12255",
-            "NCIT:C34360",
-            "ORPHANET:418",
-            "MONDO:0018479",
-            "MEDDRA:10010323",
-            "ICD9:255.2",
-            "DOID:0050811",
-            "HP:0008258",
-            "UMLS:C0001627",
-            "UMLS:C0701163",
-            "ICD10:E25",
-            "MESH:D000312"
-          ],
-          "id": "MONDO:0018479",
-          "category": "biolink:Disease",
-          "all_names": [
-            "congenital adrenal hyperplasia",
-            "obsolete congenital adrenal hyperplasia",
-            "Adrenogenital disorders",
-            "Adrenogenital disorder",
-            "Congenital adrenal hyperplasia",
-            "Adrenal Hyperplasia, Congenital",
-            "obsolete_congenital adrenal hyperplasia",
-            "Congenital Adrenal Hyperplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-            "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-            "http://omim.org/entry/201710",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312713,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-              "name": "congenital adrenal hyperplasia",
-              "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:237751000",
-                "DOID:12255",
-                "NCIT:C34360",
-                "ORPHANET:418",
-                "MONDO:0018479",
-                "MEDDRA:10010323",
-                "ICD9:255.2",
-                "DOID:0050811",
-                "HP:0008258",
-                "UMLS:C0001627",
-                "UMLS:C0701163",
-                "ICD10:E25",
-                "MESH:D000312"
-              ],
-              "id": "MONDO:0018479",
-              "category": "biolink:Disease",
-              "all_names": [
-                "congenital adrenal hyperplasia",
-                "obsolete congenital adrenal hyperplasia",
-                "Adrenogenital disorders",
-                "Adrenogenital disorder",
-                "Congenital adrenal hyperplasia",
-                "Adrenal Hyperplasia, Congenital",
-                "obsolete_congenital adrenal hyperplasia",
-                "Congenital Adrenal Hyperplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-                "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-                "http://omim.org/entry/201710",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26531049,
-            "start": 569,
-            "end": 312713,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:845476': {'publication date': '1977 Apr', 'sentence': 'False elevation of plasma cortisol in congenital adrenal hyperplasia.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0001627---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "26997315",
-              "object": "MONDO:0018479",
-              "publications": [
-                "PMID:845476"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318021,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000745",
-          "name": "cardiac arrest",
-          "description": "The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.; Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.; An abrupt loss of heart function. []; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:0060319",
-            "ICD10:I46",
-            "MEDDRA:10003109",
-            "UMLS:C0018790",
-            "HP:0001695",
-            "SNOMEDCT:410429000",
-            "MEDDRA:10082515",
-            "UMLS:C0444720",
-            "SNOMEDCT:397829000",
-            "MEDDRA:10003589",
-            "NCIT:C50479",
-            "PSY:07595",
-            "MEDDRA:10019249",
-            "SNOMEDCT:261195002",
-            "MEDDRA:10003587",
-            "MEDDRA:10047284",
-            "MESH:D006323",
-            "MONDO:0000745",
-            "MEDDRA:10041914",
-            "EFO:0009492",
-            "MEDDRA:10003586",
-            "MEDDRA:10007515",
-            "ICD9:427.5",
-            "MEDDRA:10047285"
-          ],
-          "id": "MONDO:0000745",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiac Arrest",
-            "cardiac arrest",
-            "Cardiac arrest",
-            "Heart Arrest"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/cardiacarrest.htm",
-            "http://en.wikipedia.org/wiki/cardiac_arrest",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318021,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000745",
-              "name": "cardiac arrest",
-              "description": "The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.; Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.; An abrupt loss of heart function. []; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:0060319",
-                "ICD10:I46",
-                "MEDDRA:10003109",
-                "UMLS:C0018790",
-                "HP:0001695",
-                "SNOMEDCT:410429000",
-                "MEDDRA:10082515",
-                "UMLS:C0444720",
-                "SNOMEDCT:397829000",
-                "MEDDRA:10003589",
-                "NCIT:C50479",
-                "PSY:07595",
-                "MEDDRA:10019249",
-                "SNOMEDCT:261195002",
-                "MEDDRA:10003587",
-                "MEDDRA:10047284",
-                "MESH:D006323",
-                "MONDO:0000745",
-                "MEDDRA:10041914",
-                "EFO:0009492",
-                "MEDDRA:10003586",
-                "MEDDRA:10007515",
-                "ICD9:427.5",
-                "MEDDRA:10047285"
-              ],
-              "id": "MONDO:0000745",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiac Arrest",
-                "cardiac arrest",
-                "Cardiac arrest",
-                "Heart Arrest"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/cardiacarrest.htm",
-                "http://en.wikipedia.org/wiki/cardiac_arrest",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26474619,
-            "start": 569,
-            "end": 318021,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8351423': {'publication date': '1993 Jun', 'sentence': 'Further studies evaluating the mechanism of action and long term effects of hydrocortisone in cardiac arrest need to be conducted.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0018790---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "26940919",
-              "object": "MONDO:0000745",
-              "publications": [
-                "PMID:8351423"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317845,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005068",
-          "name": "myocardial infarction",
-          "description": "Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin. [HPO:probinson]; Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021758",
-            "EFO:0000612",
-            "MEDDRA:10019250",
-            "MEDDRA:10028595",
-            "MONDO:0005068",
-            "SNOMEDCT:22298006",
-            "HP:0001658",
-            "NCIT:C27996",
-            "MEDDRA:10003723",
-            "ICD10:I21",
-            "MEDDRA:10003724",
-            "MESH:D009203",
-            "DOID:5844",
-            "UMLS:C0027051",
-            "MEDDRA:10028596"
-          ],
-          "id": "MONDO:0005068",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myocardial Infarction",
-            "Myocardial infarction",
-            "myocardial infarction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0001-5208-3432",
-            "PMID:17951287",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://en.wikipedia.org/wiki/myocardial_infarction"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317845,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005068",
-              "name": "myocardial infarction",
-              "description": "Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin. [HPO:probinson]; Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021758",
-                "EFO:0000612",
-                "MEDDRA:10019250",
-                "MEDDRA:10028595",
-                "MONDO:0005068",
-                "SNOMEDCT:22298006",
-                "HP:0001658",
-                "NCIT:C27996",
-                "MEDDRA:10003723",
-                "ICD10:I21",
-                "MEDDRA:10003724",
-                "MESH:D009203",
-                "DOID:5844",
-                "UMLS:C0027051",
-                "MEDDRA:10028596"
-              ],
-              "id": "MONDO:0005068",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myocardial Infarction",
-                "Myocardial infarction",
-                "myocardial infarction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0001-5208-3432",
-                "PMID:17951287",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://en.wikipedia.org/wiki/myocardial_infarction"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26363920,
-            "start": 569,
-            "end": 317845,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8145427': {'publication date': '1993', 'sentence': 'In acute MI, there were elevated plasma levels of cortisol depending on the MI severity with a small repeated peak of its increase on day 14 and its subsequent decrease, except deaths.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0027051---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "26840479",
-              "object": "MONDO:0005068",
-              "publications": [
-                "PMID:8145427"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24257842,
-            "start": 569,
-            "end": 320039,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35813323': {'publication date': '2022 Jun', 'sentence': 'Aldosterone levels, like cortisol, have been shown to be increased in sepsis and hemorrhagic shock.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0036690---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "24701128",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:35813323"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319030,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319030,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20863965,
-            "start": 569,
-            "end": 319030,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31500387': {'publication date': '2019 Sep 08', 'sentence': 'In this review, we summarize the effects of circadian melatonin, TSH, and cortisol on OA, focusing on how different levels of these hormones affect OA pathogenesis and recovery with respect to the circadian clock.', 'subject score': 1000, 'object score': 1000}, 'PMID:32392916': {'publication date': '2020 May 01', 'sentence': 'These data indicate that 25-HC may act as a metabolic pathophysiological factor in osteoarthritis that is mediated by progressive chondrocyte death in the articular cartilage with inflammatory condition.', 'subject score': 861, 'object score': 1000}, 'PMID:32395076': {'publication date': '2020 May 01', 'sentence': 'These data indicate that 25-HC may act as a metabolic pathophysiological factor in osteoarthritis that is mediated by progressive chondrocyte death in the articular cartilage with inflammatory condition.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "21274202",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:31500387",
-                "PMID:32392916",
-                "PMID:32395076"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320360,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005083",
-          "name": "psoriasis",
-          "description": "An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.; A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.; A skin abnormality characterized by redness and irritation, with thick, red skin that displays flaky, silver-white patches (scales). [HPO:probinson]; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have psoriasis also get a form of arthritis called psoriatic arthritis. A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast.  Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope. Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include: Infections Stress Dry skin Certain medicines  Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases ; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D011565",
-            "SNOMEDCT:9014002",
-            "ICD10:L40",
-            "MEDDRA:10058675",
-            "MONDO:0005083",
-            "DOID:8893",
-            "UMLS:C0033860",
-            "EFO:0000676",
-            "UMLS:C0262985",
-            "NCIT:C3346",
-            "NCIT:C27724",
-            "OMIM.PS:177900",
-            "OMIM:PS177900",
-            "SNOMEDCT:52230004",
-            "HP:0003765",
-            "MEDDRA:10037153",
-            "SNOMEDCT:238564003"
-          ],
-          "id": "MONDO:0005083",
-          "category": "biolink:Disease",
-          "all_names": [
-            "psoriasis",
-            "Psoriasiform eczema",
-            "Psoriasis",
-            "Psoriasiform dermatitis",
-            "Psoriasiform Dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.cdc.gov/psoriasis/index.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320360,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005083",
-              "name": "psoriasis",
-              "description": "An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.; A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.; A skin abnormality characterized by redness and irritation, with thick, red skin that displays flaky, silver-white patches (scales). [HPO:probinson]; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have psoriasis also get a form of arthritis called psoriatic arthritis. A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast.  Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope. Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include: Infections Stress Dry skin Certain medicines  Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases ; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D011565",
-                "SNOMEDCT:9014002",
-                "ICD10:L40",
-                "MEDDRA:10058675",
-                "MONDO:0005083",
-                "DOID:8893",
-                "UMLS:C0033860",
-                "EFO:0000676",
-                "UMLS:C0262985",
-                "NCIT:C3346",
-                "NCIT:C27724",
-                "OMIM.PS:177900",
-                "OMIM:PS177900",
-                "SNOMEDCT:52230004",
-                "HP:0003765",
-                "MEDDRA:10037153",
-                "SNOMEDCT:238564003"
-              ],
-              "id": "MONDO:0005083",
-              "category": "biolink:Disease",
-              "all_names": [
-                "psoriasis",
-                "Psoriasiform eczema",
-                "Psoriasis",
-                "Psoriasiform dermatitis",
-                "Psoriasiform Dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.cdc.gov/psoriasis/index.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20299961,
-            "start": 569,
-            "end": 320360,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30446190': {'publication date': '2018 Nov - Dec', 'sentence': 'There may be a subset of patients unable to elicit an appropriate immunosuppressive response to stress through upregulation of cortisol, with resultant exacerbation of their psoriasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:36065538': {'publication date': '2022 05 01', 'sentence': 'Also, blunted salivary cortisol diurnal rhythm in psoriatic patients and a positive correlation of salivary cortisol concentration with state anxiety and psoriasis severity were revealed.', 'subject score': 851, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0033860---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "20701310",
-              "object": "MONDO:0005083",
-              "publications": [
-                "PMID:30446190",
-                "PMID:36065538"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 308784,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002406",
-          "name": "dermatitis",
-          "description": "The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes. [HPO:probinson]; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0011123",
-            "MEDDRA:10062249",
-            "MEDDRA:10012431",
-            "MP:0004947",
-            "MESH:D003872",
-            "SNOMEDCT:43116000",
-            "MONDO:0002406",
-            "MEDDRA:10012478",
-            "MEDDRA:10040876",
-            "ICD10:L30.9",
-            "DOID:2723",
-            "NCIT:C2983",
-            "SNOMEDCT:703938007",
-            "UMLS:C3875321",
-            "PSY:13710",
-            "UMLS:C0011603"
-          ],
-          "id": "MONDO:0002406",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis",
-            "Inflammatory abnormality of the skin",
-            "Inflammatory dermatosis",
-            "dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/eczema.htm",
-            "http://en.wikipedia.org/wiki/dermatitis",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308784,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002406",
-              "name": "dermatitis",
-              "description": "The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes. [HPO:probinson]; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0011123",
-                "MEDDRA:10062249",
-                "MEDDRA:10012431",
-                "MP:0004947",
-                "MESH:D003872",
-                "SNOMEDCT:43116000",
-                "MONDO:0002406",
-                "MEDDRA:10012478",
-                "MEDDRA:10040876",
-                "ICD10:L30.9",
-                "DOID:2723",
-                "NCIT:C2983",
-                "SNOMEDCT:703938007",
-                "UMLS:C3875321",
-                "PSY:13710",
-                "UMLS:C0011603"
-              ],
-              "id": "MONDO:0002406",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis",
-                "Inflammatory abnormality of the skin",
-                "Inflammatory dermatosis",
-                "dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/eczema.htm",
-                "http://en.wikipedia.org/wiki/dermatitis",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19938658,
-            "start": 569,
-            "end": 308784,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2976496': {'publication date': '1988 Nov', 'sentence': 'In addition to local effect, topical hydrocortisone therapy of childhood dermatitis is accompanied by a systemic effect that may be pronounced in the acute phase of disease.', 'subject score': 790, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0011603---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "20336537",
-              "object": "MONDO:0002406",
-              "publications": [
-                "PMID:2976496"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 547810,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005546",
-          "name": "fibromyalgia",
-          "description": "A common nonarticular rheumatic condition that is characterized by muscle pain, tenderness, and stiffness.; A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.; Inflammation and fibrous degeneration of a muscle.; A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10016631",
-            "MEDDRA:10048439",
-            "MEDDRA:10028363",
-            "PSY:19685",
-            "SNOMEDCT:56557000",
-            "SNOMEDCT:726531007",
-            "NCIT:C50566",
-            "ORPHANET:41842",
-            "SNOMEDCT:203082005",
-            "MEDDRA:10063041",
-            "MONDO:0005546",
-            "SNOMEDCT:203102006",
-            "MEDDRA:10016663",
-            "DOID:631",
-            "EFO:0005687",
-            "MESH:D005356",
-            "ICD10:M79.7",
-            "NCIT:C87497",
-            "MEDDRA:10079197",
-            "UMLS:C0016053"
-          ],
-          "id": "MONDO:0005546",
-          "category": "biolink:Disease",
-          "all_names": [
-            "fibromyalgia",
-            "Fibromyalgia",
-            "Fibromyositis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:33024295",
-            "https://www.ncbi.nlm.nih.gov/labs/pmc/articles/pmc7660651/",
-            "PMID:30486733",
-            "PMID:32120395"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 547810,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005546",
-              "name": "fibromyalgia",
-              "description": "A common nonarticular rheumatic condition that is characterized by muscle pain, tenderness, and stiffness.; A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.; Inflammation and fibrous degeneration of a muscle.; A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10016631",
-                "MEDDRA:10048439",
-                "MEDDRA:10028363",
-                "PSY:19685",
-                "SNOMEDCT:56557000",
-                "SNOMEDCT:726531007",
-                "NCIT:C50566",
-                "ORPHANET:41842",
-                "SNOMEDCT:203082005",
-                "MEDDRA:10063041",
-                "MONDO:0005546",
-                "SNOMEDCT:203102006",
-                "MEDDRA:10016663",
-                "DOID:631",
-                "EFO:0005687",
-                "MESH:D005356",
-                "ICD10:M79.7",
-                "NCIT:C87497",
-                "MEDDRA:10079197",
-                "UMLS:C0016053"
-              ],
-              "id": "MONDO:0005546",
-              "category": "biolink:Disease",
-              "all_names": [
-                "fibromyalgia",
-                "Fibromyalgia",
-                "Fibromyositis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:33024295",
-                "https://www.ncbi.nlm.nih.gov/labs/pmc/articles/pmc7660651/",
-                "PMID:30486733",
-                "PMID:32120395"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19745219,
-            "start": 569,
-            "end": 547810,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29389485': {'publication date': '2018 Feb', 'sentence': 'They answered the Fibromyalgia Impact Questionnaire (FIQ), Perceived Stress Questionnaire (PSQ) and McGill Pain Questionnaire (MPQ-Br), and collected saliva to evaluate CC before and after the end of each month.', 'subject score': 694, 'object score': 851}, 'PMID:36728497': {'publication date': '2023 Jan 05', 'sentence': 'No main effect of FMS was found on altered levels of blood cortisol, ACTH, CRH, and epinephrine.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0016053---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "20137862",
-              "object": "MONDO:0005546",
-              "publications": [
-                "PMID:29389485",
-                "PMID:36728497"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19171098,
-            "start": 569,
-            "end": 321523,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28335807': {'publication date': '2017 03 24', 'sentence': 'BACKGROUND: The hypothalamic-pituitary-adrenal stress axis plays a crucial role in community-acquired pneumonia (CAP), with high cortisol being associated with disease severity and corticosteroid treatment resulting in earlier time to recovery.', 'subject score': 888, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "19555227",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:28335807"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19148228,
-            "start": 569,
-            "end": 295849,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28292220': {'publication date': '2017 Jan 01', 'sentence': 'The incidence of AF was compared among patients who received hydrocortisone, and the effect of low-dose hydrocortisone on AF was estimated using the inverse probability treatment weighting method based on propensity scores.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "19531871",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:28292220"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319679,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-          "name": "lymphoma",
-          "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:115244002",
-            "DOID:0060058",
-            "MONDO:0005062",
-            "SNOMEDCT:118600007",
-            "HP:0002665",
-            "NCIT:C7065",
-            "EFO:0000574",
-            "ORPHANET:223735",
-            "MESH:D008223",
-            "SNOMEDCT:188676008",
-            "PDQ:CDR0000041429",
-            "MEDDRA:10025316",
-            "UMLS:C0024299",
-            "NCIT:C3208",
-            "MEDDRA:10025632",
-            "MEDDRA:10025310",
-            "MEDDRA:10025633",
-            "SNOMEDCT:1163043007",
-            "ICD10:C85.9",
-            "UMLS:C1536843",
-            "UMLS:C0334621",
-            "MEDDRA:10025315"
-          ],
-          "id": "MONDO:0005062",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphocytic Neoplasm",
-            "Lymphoma",
-            "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-            "lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/lymphoma",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319679,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-              "name": "lymphoma",
-              "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:115244002",
-                "DOID:0060058",
-                "MONDO:0005062",
-                "SNOMEDCT:118600007",
-                "HP:0002665",
-                "NCIT:C7065",
-                "EFO:0000574",
-                "ORPHANET:223735",
-                "MESH:D008223",
-                "SNOMEDCT:188676008",
-                "PDQ:CDR0000041429",
-                "MEDDRA:10025316",
-                "UMLS:C0024299",
-                "NCIT:C3208",
-                "MEDDRA:10025632",
-                "MEDDRA:10025310",
-                "MEDDRA:10025633",
-                "SNOMEDCT:1163043007",
-                "ICD10:C85.9",
-                "UMLS:C1536843",
-                "UMLS:C0334621",
-                "MEDDRA:10025315"
-              ],
-              "id": "MONDO:0005062",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphocytic Neoplasm",
-                "Lymphoma",
-                "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-                "lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/lymphoma",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18127861,
-            "start": 569,
-            "end": 319679,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26271105': {'publication date': '2016 Oct', 'sentence': 'INTRODUCTION: Intrathecal administration of methotrexate, cytarabine, and hydrocortisone is commonly used to treat and prevent central nervous system involvement in leukemias and lymphomas.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0024299---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "18495054",
-              "object": "MONDO:0005062",
-              "publications": [
-                "PMID:26271105"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 315770,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005059",
-          "name": "leukemia",
-          "description": "A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3161\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3161\" NCI Thesaurus); A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.; A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006); A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding  When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets  The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time.  The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age  What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding.  Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes  Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10045991",
-            "MEDDRA:10024329",
-            "ICD9:208",
-            "ICD10:C95.90",
-            "MEDDRA:10060430",
-            "MEDDRA:10024314",
-            "MEDDRA:10024323",
-            "MEDDRA:10024351",
-            "HP:0001909",
-            "SNOMEDCT:87163000",
-            "SNOMEDCT:1162768007",
-            "MEDDRA:10045992",
-            "MEDDRA:10060500",
-            "NCIT:C3161",
-            "EFO:0000565",
-            "MEDDRA:10045994",
-            "SNOMEDCT:93143009",
-            "MEDDRA:10024288",
-            "MEDDRA:10024352",
-            "MEDDRA:10024312",
-            "DOID:1240",
-            "UMLS:C0023418",
-            "PDQ:CDR0000041186",
-            "MESH:D007938",
-            "MONDO:0005059",
-            "MEDDRA:10024324"
-          ],
-          "id": "MONDO:0005059",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia of unspecified cell type",
-            "Leukemia",
-            "leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/leukemia",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=45343",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315770,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005059",
-              "name": "leukemia",
-              "description": "A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3161\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3161\" NCI Thesaurus); A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.; A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006); A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding  When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets  The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time.  The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age  What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding.  Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes  Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10045991",
-                "MEDDRA:10024329",
-                "ICD9:208",
-                "ICD10:C95.90",
-                "MEDDRA:10060430",
-                "MEDDRA:10024314",
-                "MEDDRA:10024323",
-                "MEDDRA:10024351",
-                "HP:0001909",
-                "SNOMEDCT:87163000",
-                "SNOMEDCT:1162768007",
-                "MEDDRA:10045992",
-                "MEDDRA:10060500",
-                "NCIT:C3161",
-                "EFO:0000565",
-                "MEDDRA:10045994",
-                "SNOMEDCT:93143009",
-                "MEDDRA:10024288",
-                "MEDDRA:10024352",
-                "MEDDRA:10024312",
-                "DOID:1240",
-                "UMLS:C0023418",
-                "PDQ:CDR0000041186",
-                "MESH:D007938",
-                "MONDO:0005059",
-                "MEDDRA:10024324"
-              ],
-              "id": "MONDO:0005059",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia of unspecified cell type",
-                "Leukemia",
-                "leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/leukemia",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=45343",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18127860,
-            "start": 569,
-            "end": 315770,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26271105': {'publication date': '2016 Oct', 'sentence': 'INTRODUCTION: Intrathecal administration of methotrexate, cytarabine, and hydrocortisone is commonly used to treat and prevent central nervous system involvement in leukemias and lymphomas.', 'subject score': 1000, 'object score': 1000}, 'PMID:3736113': {'publication date': '1986', 'sentence': 'The investigations included also mice submitted to non-leukemogenic irradiation (1 X 1.5 and 1 X 4.5 Gy) and mice submitted to an additional treatment with hydrocortisone, which delays leukemia development after methylnitrosourea.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0023418---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "18495053",
-              "object": "MONDO:0005059",
-              "publications": [
-                "PMID:26271105",
-                "PMID:3736113"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 528832,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-          "name": "toxic shock syndrome",
-          "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C35498",
-            "UMLS:C0600327",
-            "UMLS:CN204669",
-            "MEDDRA:10044248",
-            "MESH:D012772",
-            "MEDDRA:10044249",
-            "SNOMEDCT:18504008",
-            "DOID:14115",
-            "MEDDRA:10042852",
-            "UMLS:C0036983",
-            "ORPHANET:36234",
-            "SNOMEDCT:76571007",
-            "MEDDRA:10040580",
-            "NCIT:C35018",
-            "MEDDRA:10040070",
-            "ICD9:040.82",
-            "ICD10:A48.3",
-            "MONDO:0001881",
-            "EFO:0006834",
-            "SYMP:0000451"
-          ],
-          "id": "MONDO:0001881",
-          "category": "biolink:Disease",
-          "all_names": [
-            "toxic shock syndrome",
-            "Septic Shock",
-            "Shock, Septic",
-            "Toxic Shock Syndrome",
-            "Bacterial toxic-shock syndrome",
-            "septic shock",
-            "Toxic shock syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 528832,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-              "name": "toxic shock syndrome",
-              "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C35498",
-                "UMLS:C0600327",
-                "UMLS:CN204669",
-                "MEDDRA:10044248",
-                "MESH:D012772",
-                "MEDDRA:10044249",
-                "SNOMEDCT:18504008",
-                "DOID:14115",
-                "MEDDRA:10042852",
-                "UMLS:C0036983",
-                "ORPHANET:36234",
-                "SNOMEDCT:76571007",
-                "MEDDRA:10040580",
-                "NCIT:C35018",
-                "MEDDRA:10040070",
-                "ICD9:040.82",
-                "ICD10:A48.3",
-                "MONDO:0001881",
-                "EFO:0006834",
-                "SYMP:0000451"
-              ],
-              "id": "MONDO:0001881",
-              "category": "biolink:Disease",
-              "all_names": [
-                "toxic shock syndrome",
-                "Septic Shock",
-                "Shock, Septic",
-                "Toxic Shock Syndrome",
-                "Bacterial toxic-shock syndrome",
-                "septic shock",
-                "Toxic shock syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17946115,
-            "start": 569,
-            "end": 528832,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25942482': {'publication date': '2015 Jul', 'sentence': 'CONCLUSIONS: Early PN did not affect plasma concentrations of ACTH and (free) cortisol, but increased the incidence of septic shock, which statistically explained why more patients on early PN received corticosteroids.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0036983---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "18310128",
-              "object": "MONDO:0001881",
-              "publications": [
-                "PMID:25942482"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 313237,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
-          "name": "atopic eczema",
-          "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SYMP:0000289",
-            "EFO:0000274",
-            "DOID:3310",
-            "HP:0000964",
-            "NCIT:C3001",
-            "UMLS:C0013595",
-            "MESH:D004485",
-            "MEDDRA:10014200",
-            "MEDDRA:10014206",
-            "MEDDRA:10012454",
-            "ICD10:L20",
-            "MEDDRA:10014184",
-            "OMIM.PS:603165",
-            "MEDDRA:10014209",
-            "PSY:15950",
-            "MONDO:0004980",
-            "OMIM:PS603165"
-          ],
-          "id": "MONDO:0004980",
-          "category": "biolink:Disease",
-          "all_names": [
-            "atopic dermatitis",
-            "atopic eczema",
-            "eczema",
-            "Eczema"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/atopic_dermatitis",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313237,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
-              "name": "atopic eczema",
-              "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SYMP:0000289",
-                "EFO:0000274",
-                "DOID:3310",
-                "HP:0000964",
-                "NCIT:C3001",
-                "UMLS:C0013595",
-                "MESH:D004485",
-                "MEDDRA:10014200",
-                "MEDDRA:10014206",
-                "MEDDRA:10012454",
-                "ICD10:L20",
-                "MEDDRA:10014184",
-                "OMIM.PS:603165",
-                "MEDDRA:10014209",
-                "PSY:15950",
-                "MONDO:0004980",
-                "OMIM:PS603165"
-              ],
-              "id": "MONDO:0004980",
-              "category": "biolink:Disease",
-              "all_names": [
-                "atopic dermatitis",
-                "atopic eczema",
-                "eczema",
-                "Eczema"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/atopic_dermatitis",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17552230,
-            "start": 569,
-            "end": 313237,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2528573': {'publication date': '1989 Sep', 'sentence': 'Sixteen reacted to tixocortol pivalate and also to other corticosteroids, particularly to hydrocortisone, which could explain exacerbations of eczema in these cases.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0013595---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "17910566",
-              "object": "MONDO:0004980",
-              "publications": [
-                "PMID:2528573"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15599319,
-            "start": 569,
-            "end": 183319,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22013396': {'publication date': '2011', 'sentence': 'Finally, transient pre-treatment of healthy humans with cortisol induces a bi-phasic response during a later, delayed systemic inflammatory response: an intermediate cortisol concentration augments inflammation while a high cortisol concentration is neither pro- nor anti-inflammatory.', 'subject score': 623, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "15925719",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:22013396"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 314596,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-          "name": "Insulin resistance",
-          "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "NCIT:C113101",
-            "UMLS:C0021655",
-            "MEDDRA:10022489",
-            "SNOMEDCT:48606007",
-            "MESH:D007333",
-            "EFO:0002614",
-            "HP:0000855",
-            "SNOMEDCT:763325000"
-          ],
-          "id": "HP:0000855",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Insulin resistance",
-            "insulin resistance",
-            "Insulin Resistance"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314596,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-              "name": "Insulin resistance",
-              "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "NCIT:C113101",
-                "UMLS:C0021655",
-                "MEDDRA:10022489",
-                "SNOMEDCT:48606007",
-                "MESH:D007333",
-                "EFO:0002614",
-                "HP:0000855",
-                "SNOMEDCT:763325000"
-              ],
-              "id": "HP:0000855",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Insulin resistance",
-                "insulin resistance",
-                "Insulin Resistance"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14654843,
-            "start": 569,
-            "end": 314596,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2043222': {'publication date': '1991', 'sentence': 'Adrenaline induces the early posthypoglycaemic insulin resistance, whereas cortisol and growth hormone are important for the insulin resistance that is observed later following hypoglycaemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:32670417': {'publication date': '2020', 'sentence': 'In the subjects exposed to frequent/chronic psychological stressors, cortisol and oxidative stress marker affected IR incidence, being statistically attenuated, though, following adjustment for metabolic syndrome, or its components.', 'subject score': 1000, 'object score': 901}, 'PMID:8708543': {'publication date': '1996 May', 'sentence': 'The results of this study in elderly subjects suggest that in women cortisol may be implicated in the age-associated insulin resistance.', 'subject score': 888, 'object score': 824}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0021655---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14970164",
-              "object": "HP:0000855",
-              "publications": [
-                "PMID:2043222",
-                "PMID:32670417",
-                "PMID:8708543"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14486782,
-            "start": 569,
-            "end": 546804,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20109364': {'publication date': '2010 Feb', 'sentence': 'RESULTS: Within 24 hours following TBI, the concentrations of total cortisol, ACTH and gastrin increased proportionally to the severity of injury, especially significant in the experimental group (P less than 0.05).', 'subject score': 888, 'object score': 1000}, 'PMID:3339690': {'publication date': '1988 Jan', 'sentence': 'When the dogs were considered as one group the mean plasma cortisol concentration increased promptly 10 min after injury (p less than 0.05) and reached its peak at 1 hour and then decreased.', 'subject score': 824, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C3263723---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14804311",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:20109364",
-                "PMID:3339690"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319508,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005468",
-          "name": "hypotensive disorder",
-          "description": "Blood pressure that is abnormally low.; Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.; Low Blood Pressure, vascular hypotension. [HPO:probinson]; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "MEDDRA:10036638",
-            "PDQ:CDR0000041785",
-            "MEDDRA:10021099",
-            "MEDDRA:10024896",
-            "MEDDRA:10024895",
-            "MEDDRA:10003146",
-            "MEDDRA:10024982",
-            "MEDDRA:10021106",
-            "EFO:0005251",
-            "SYMP:0000059",
-            "SNOMEDCT:45007003",
-            "NCIT:C3128",
-            "MEDDRA:10016174",
-            "PSY:24060",
-            "MEDDRA:10005744",
-            "MEDDRA:10066331",
-            "HP:0002615",
-            "ICD9:458",
-            "MEDDRA:10005753",
-            "MEDDRA:10005734",
-            "MEDDRA:10021097",
-            "MEDDRA:10013645",
-            "MEDDRA:10013644",
-            "MEDDRA:10006065",
-            "MONDO:0005468",
-            "MEDDRA:10003169",
-            "MEDDRA:10005743",
-            "MEDDRA:10006064",
-            "UMLS:C0020649",
-            "MESH:D007022"
-          ],
-          "id": "MONDO:0005468",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hypotensive disorder",
-            "hypotension",
-            "Hypotension"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:DiseaseOrPhenotypicFeature",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://github.com/monarch-initiative/mondo/issues/1030"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319508,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005468",
-              "name": "hypotensive disorder",
-              "description": "Blood pressure that is abnormally low.; Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.; Low Blood Pressure, vascular hypotension. [HPO:probinson]; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "MEDDRA:10036638",
-                "PDQ:CDR0000041785",
-                "MEDDRA:10021099",
-                "MEDDRA:10024896",
-                "MEDDRA:10024895",
-                "MEDDRA:10003146",
-                "MEDDRA:10024982",
-                "MEDDRA:10021106",
-                "EFO:0005251",
-                "SYMP:0000059",
-                "SNOMEDCT:45007003",
-                "NCIT:C3128",
-                "MEDDRA:10016174",
-                "PSY:24060",
-                "MEDDRA:10005744",
-                "MEDDRA:10066331",
-                "HP:0002615",
-                "ICD9:458",
-                "MEDDRA:10005753",
-                "MEDDRA:10005734",
-                "MEDDRA:10021097",
-                "MEDDRA:10013645",
-                "MEDDRA:10013644",
-                "MEDDRA:10006065",
-                "MONDO:0005468",
-                "MEDDRA:10003169",
-                "MEDDRA:10005743",
-                "MEDDRA:10006064",
-                "UMLS:C0020649",
-                "MESH:D007022"
-              ],
-              "id": "MONDO:0005468",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hypotensive disorder",
-                "hypotension",
-                "Hypotension"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:DiseaseOrPhenotypicFeature",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://github.com/monarch-initiative/mondo/issues/1030"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14230402,
-            "start": 569,
-            "end": 319508,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19691511': {'publication date': '2009 Jun', 'sentence': 'NEW OR UNIQUE INFORMATION PROVIDED: This case is the first published report of hydrocortisone-responsive hypotension and transient CIRCI associated with naturally occurring septic shock in a dog.', 'subject score': 851, 'object score': 851}, 'PMID:22721515': {'publication date': '2012 May', 'sentence': 'Starting during normothermic cardiopulmonary bypass (CPB), hypotension occurred, refractory to phenylephrine, noradrenaline, terlipressin, hydrocortisone and dexchlorpheniramine.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0020649---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14533429",
-              "object": "MONDO:0005468",
-              "publications": [
-                "PMID:19691511",
-                "PMID:22721515"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 312713,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-          "name": "congenital adrenal hyperplasia",
-          "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:237751000",
-            "DOID:12255",
-            "NCIT:C34360",
-            "ORPHANET:418",
-            "MONDO:0018479",
-            "MEDDRA:10010323",
-            "ICD9:255.2",
-            "DOID:0050811",
-            "HP:0008258",
-            "UMLS:C0001627",
-            "UMLS:C0701163",
-            "ICD10:E25",
-            "MESH:D000312"
-          ],
-          "id": "MONDO:0018479",
-          "category": "biolink:Disease",
-          "all_names": [
-            "congenital adrenal hyperplasia",
-            "obsolete congenital adrenal hyperplasia",
-            "Adrenogenital disorders",
-            "Adrenogenital disorder",
-            "Congenital adrenal hyperplasia",
-            "Adrenal Hyperplasia, Congenital",
-            "obsolete_congenital adrenal hyperplasia",
-            "Congenital Adrenal Hyperplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-            "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-            "http://omim.org/entry/201710",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312713,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-              "name": "congenital adrenal hyperplasia",
-              "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:237751000",
-                "DOID:12255",
-                "NCIT:C34360",
-                "ORPHANET:418",
-                "MONDO:0018479",
-                "MEDDRA:10010323",
-                "ICD9:255.2",
-                "DOID:0050811",
-                "HP:0008258",
-                "UMLS:C0001627",
-                "UMLS:C0701163",
-                "ICD10:E25",
-                "MESH:D000312"
-              ],
-              "id": "MONDO:0018479",
-              "category": "biolink:Disease",
-              "all_names": [
-                "congenital adrenal hyperplasia",
-                "obsolete congenital adrenal hyperplasia",
-                "Adrenogenital disorders",
-                "Adrenogenital disorder",
-                "Congenital adrenal hyperplasia",
-                "Adrenal Hyperplasia, Congenital",
-                "obsolete_congenital adrenal hyperplasia",
-                "Congenital Adrenal Hyperplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-                "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-                "http://omim.org/entry/201710",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13705766,
-            "start": 569,
-            "end": 312713,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18844712': {'publication date': '2008', 'sentence': 'Several types of the congenital adrenal hyperplasias are associated with decreased cortisol production and excessive adrenal sex steroid secretion.', 'subject score': 851, 'object score': 1000}, 'PMID:3871229': {'publication date': '1985 Jan', 'sentence': 'To explore the potential effect of dose schedule on the adrenal suppressive action of hydrocortisone in congenital adrenal hyperplasia, eight patients (six with 21-hydroxylase deficiency and two with 11-hydroxylase deficiency) were given five different dose schedules.', 'subject score': 1000, 'object score': 1000}, 'PMID:9370898': {'publication date': '1997 Sep', 'sentence': 'Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia.', 'subject score': 1000, 'object score': 1000}, 'PMID:9516061': {'publication date': '1998', 'sentence': \"The effects of hypercortisolemia and ACTH on the metabolism of cortisol in congenital adrenal hyperplasia, Cushing's syndrome, and exogenous ACTH and cortisol administration were investigated by analysis of the respective urinary tetrahydro-metabolites of cortisol (THF and aTHF) and cortisone (THE) by capillary gas chromatography.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0001627---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13999195",
-              "object": "MONDO:0018479",
-              "publications": [
-                "PMID:18844712",
-                "PMID:3871229",
-                "PMID:9370898",
-                "PMID:9516061"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13066269,
-            "start": 569,
-            "end": 321528,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1787683': {'publication date': '1991 Dec', 'sentence': '[Use of cryo-apheresis in the treatment of patients with cortisol-dependent bronchial asthma].', 'subject score': 861, 'object score': 861}, 'PMID:2283805': {'publication date': '1990 Nov', 'sentence': 'Following discontinuation of glucocorticoid drugs GCR count in cortisol-dependent BA tends to rise.', 'subject score': 861, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13347553",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:1787683",
-                "PMID:2283805"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319508,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005468",
-          "name": "hypotensive disorder",
-          "description": "Blood pressure that is abnormally low.; Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.; Low Blood Pressure, vascular hypotension. [HPO:probinson]; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "MEDDRA:10036638",
-            "PDQ:CDR0000041785",
-            "MEDDRA:10021099",
-            "MEDDRA:10024896",
-            "MEDDRA:10024895",
-            "MEDDRA:10003146",
-            "MEDDRA:10024982",
-            "MEDDRA:10021106",
-            "EFO:0005251",
-            "SYMP:0000059",
-            "SNOMEDCT:45007003",
-            "NCIT:C3128",
-            "MEDDRA:10016174",
-            "PSY:24060",
-            "MEDDRA:10005744",
-            "MEDDRA:10066331",
-            "HP:0002615",
-            "ICD9:458",
-            "MEDDRA:10005753",
-            "MEDDRA:10005734",
-            "MEDDRA:10021097",
-            "MEDDRA:10013645",
-            "MEDDRA:10013644",
-            "MEDDRA:10006065",
-            "MONDO:0005468",
-            "MEDDRA:10003169",
-            "MEDDRA:10005743",
-            "MEDDRA:10006064",
-            "UMLS:C0020649",
-            "MESH:D007022"
-          ],
-          "id": "MONDO:0005468",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hypotensive disorder",
-            "hypotension",
-            "Hypotension"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:DiseaseOrPhenotypicFeature",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://github.com/monarch-initiative/mondo/issues/1030"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319508,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005468",
-              "name": "hypotensive disorder",
-              "description": "Blood pressure that is abnormally low.; Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.; Low Blood Pressure, vascular hypotension. [HPO:probinson]; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "MEDDRA:10036638",
-                "PDQ:CDR0000041785",
-                "MEDDRA:10021099",
-                "MEDDRA:10024896",
-                "MEDDRA:10024895",
-                "MEDDRA:10003146",
-                "MEDDRA:10024982",
-                "MEDDRA:10021106",
-                "EFO:0005251",
-                "SYMP:0000059",
-                "SNOMEDCT:45007003",
-                "NCIT:C3128",
-                "MEDDRA:10016174",
-                "PSY:24060",
-                "MEDDRA:10005744",
-                "MEDDRA:10066331",
-                "HP:0002615",
-                "ICD9:458",
-                "MEDDRA:10005753",
-                "MEDDRA:10005734",
-                "MEDDRA:10021097",
-                "MEDDRA:10013645",
-                "MEDDRA:10013644",
-                "MEDDRA:10006065",
-                "MONDO:0005468",
-                "MEDDRA:10003169",
-                "MEDDRA:10005743",
-                "MEDDRA:10006064",
-                "UMLS:C0020649",
-                "MESH:D007022"
-              ],
-              "id": "MONDO:0005468",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hypotensive disorder",
-                "hypotension",
-                "Hypotension"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:DiseaseOrPhenotypicFeature",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://github.com/monarch-initiative/mondo/issues/1030"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12902220,
-            "start": 569,
-            "end": 319508,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17568152': {'publication date': '2007', 'sentence': 'Hypotension after recruitment was reduced by HC (0 vs. 30%).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:inhibits---biolink:causes---activity---None---UMLS:C0020649---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13180935",
-              "object": "MONDO:0005468",
-              "publications": [
-                "PMID:17568152"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317312,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-          "name": "Hypoxemia",
-          "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "NCIT:C93047",
-            "MEDDRA:10021142",
-            "UMLS:C0242184",
-            "ICD9:799.02",
-            "HP:0012418",
-            "EFO:0009444",
-            "MEDDRA:10021143",
-            "EFO:0009447",
-            "MEDDRA:10021141",
-            "UMLS:C0700292",
-            "SNOMEDCT:389086002",
-            "PDQ:CDR0000773145",
-            "SYMP:0000303",
-            "MEDDRA:10021144",
-            "MESH:D000860",
-            "NCIT:C3890",
-            "SNOMEDCT:389087006"
-          ],
-          "id": "HP:0012418",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hypoxia",
-            "Hypoxemia",
-            "hypoxemia",
-            "Hypoxia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:DiseaseOrPhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317312,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-              "name": "Hypoxemia",
-              "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "NCIT:C93047",
-                "MEDDRA:10021142",
-                "UMLS:C0242184",
-                "ICD9:799.02",
-                "HP:0012418",
-                "EFO:0009444",
-                "MEDDRA:10021143",
-                "EFO:0009447",
-                "MEDDRA:10021141",
-                "UMLS:C0700292",
-                "SNOMEDCT:389086002",
-                "PDQ:CDR0000773145",
-                "SYMP:0000303",
-                "MEDDRA:10021144",
-                "MESH:D000860",
-                "NCIT:C3890",
-                "SNOMEDCT:389087006"
-              ],
-              "id": "HP:0012418",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hypoxia",
-                "Hypoxemia",
-                "hypoxemia",
-                "Hypoxia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:DiseaseOrPhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11445217,
-            "start": 569,
-            "end": 317312,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15740685': {'publication date': '2004', 'sentence': 'Fetal plasma cortisol concentrations were increased ( P < 0.05) during all levels of hypoxia.', 'subject score': 852, 'object score': 1000}, 'PMID:21042829': {'publication date': '2011 Feb', 'sentence': 'Hydrocortisone (HC) and DXA increased hypoxia- or TGF-beta-stimulated production of PAI-1 mRNA and protein.', 'subject score': 1000, 'object score': 1000}, 'PMID:8071889': {'publication date': '1994 May 15', 'sentence': 'Whilst plasma cortisol increased in early (after 15 min) and late (after 45 min) hypoxia in intact fetuses, the rise in cortisol in denervated fetuses was delayed, increasing significantly only by late hypoxia.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0242184---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "11695335",
-              "object": "HP:0012418",
-              "publications": [
-                "PMID:15740685",
-                "PMID:21042829",
-                "PMID:8071889"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318216,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318216,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11061930,
-            "start": 569,
-            "end": 318216,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15257241': {'publication date': '2004 Jun 05', 'sentence': 'INTRA-CELL CORTISOL: Attention is also focused on the potential implication of cortisol in the genesis of metabolic syndrome, because cortisol is a potent antagonist of the effect of insulin and its presence in excess enhances visceral obesity and insulin resistance.', 'subject score': 1000, 'object score': 888}, 'PMID:20109546': {'publication date': '2010 Aug', 'sentence': 'Cortisol secretion and glucocorticoid excretion rates are regularly increased in obesity and associate with indices of body size and visceral adiposity.', 'subject score': 888, 'object score': 1000}, 'PMID:28771488': {'publication date': '2017', 'sentence': 'Plasma cortisol concentrations were increased (P<0.05) in MO vs.', 'subject score': 890, 'object score': 888}, 'PMID:9039335': {'publication date': '1996 Dec', 'sentence': 'CONCLUSION: Our results suggest that DHEA may vary independently of circulating cortisol, and that the cortisol response to food is enhanced in obese subjects, particularly in those with central obesity.', 'subject score': 888, 'object score': 872}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0028754---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "11304252",
-              "object": "MONDO:0011122",
-              "publications": [
-                "PMID:15257241",
-                "PMID:20109546",
-                "PMID:28771488",
-                "PMID:9039335"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10296638,
-            "start": 569,
-            "end": 546804,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13396133': {'publication date': '1957 Jan', 'sentence': 'The effect of hydrocortisone on standardized skin-surface trauma.', 'subject score': 1000, 'object score': 775}, 'PMID:2305936': {'publication date': '1990 Mar', 'sentence': 'Increased plasma levels of the catabolic hormones glucagon, epinephrine, and cortisol have been implicated in mediating various metabolic alterations in trauma and sepsis.', 'subject score': 1000, 'object score': 1000}, 'PMID:25982069': {'publication date': '2015 Aug', 'sentence': 'CONCLUSIONS: The results of the present study suggest that cortisol and BDNF could be biological molecular mediators of the effects of trauma on biological and psychological systems.', 'subject score': 1000, 'object score': 1000}, 'PMID:30197200': {'publication date': '2018 Dec', 'sentence': 'CONCLUSIONS: These findings underscore the need to consider complex interactions among maternal trauma, disrupted in utero cortisol production, and fetal sex to fully elucidate intergenerational effects of maternal lifetime trauma.', 'subject score': 775, 'object score': 802}, 'PMID:6516244': {'publication date': '1984', 'sentence': '[The effect of trauma, exogenous hydrocortisone and adrenalectomy on the histological structure of the thymus in mice].', 'subject score': 888, 'object score': 1000}, 'PMID:6887289': {'publication date': '1983 Aug', 'sentence': 'The lack of correlation of increased cortisol with injury severity suggests an interaction of multiple hormones resulting in the increase in osmolality and glucose.', 'subject score': 888, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0043251---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C3263723---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10523644",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:6516244",
-                "PMID:30197200",
-                "PMID:2305936",
-                "PMID:25982069",
-                "PMID:13396133",
-                "PMID:6887289"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10206018,
-            "start": 569,
-            "end": 183319,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13052711': {'publication date': '1953 Jun', 'sentence': 'The action of hydrocortisone in synovial inflammation.', 'subject score': 1000, 'object score': 888}, 'PMID:14437778': {'publication date': '1959 Oct', 'sentence': 'Effect of cortisol on an experimental inflammation already established.', 'subject score': 1000, 'object score': 888}, 'PMID:16535928': {'publication date': '2006 Jan', 'sentence': 'Hydrocortisone and other glucorticoid agents have a powerful modulating effect on inflammation and balance between pro- and anti-inflammatory factors.', 'subject score': 1000, 'object score': 1000}, 'PMID:16857225': {'publication date': '2006 Oct', 'sentence': 'Endogenous and synthetic glucocorticoids (GCs), such as cortisol and dexamethasone (Dex), modulate airway inflammation, regulate the production of surfactant by lung epithelial cells, and influence fetal lung maturation.', 'subject score': 1000, 'object score': 861}, 'PMID:22013396': {'publication date': '2011', 'sentence': 'Based on these findings and the work of others, we propose a new paradigm that identifies cortisol regulation of human inflammation as both dualistic-it is pro- and anti-inflammatory-and dynamic, it evolves over time.', 'subject score': 888, 'object score': 888}, 'PMID:26829709': {'publication date': '2016 Apr', 'sentence': 'Cortisol sensitivity was determined by the difference in monocytic TNF production between the conditions of 1 and 0 MUM cortisol incubation (\"cortisol-mediated inflammation regulation, CoMIR\").', 'subject score': 825, 'object score': 825}, 'PMID:28063472': {'publication date': '2017 Jan', 'sentence': 'Only unbound cortisol was believed to be biologically active, but recent evidence suggests that CBG-bound cortisol also regulates inflammation.', 'subject score': 827, 'object score': 1000}, 'PMID:28953797': {'publication date': '2017 Sep', 'sentence': \"RESULTS: The reduction of the cytokine's levels by participation and psycho-education inside the Group Psychotherapeutic Treatment, could lead to a regulation of IL-1, to the reduction of CRP, to the amelioration of the levels of cortisol thus regulating the inflammation of the bain.\", 'subject score': 1000, 'object score': 1000}, 'PMID:29845974': {'publication date': '2018 May 30', 'sentence': 'However, the effect of hydrocortisone on regulating inflammation, hemodynamic stability, and preventing shock is still unclear in Chinese patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:3004514': {'publication date': '1986 Jan', 'sentence': 'Effect of high-dose hydrocortisone treatment on inflammation and intraarticular calcium hydroxyapatite deposits.', 'subject score': 861, 'object score': 1000}, 'PMID:30445703': {'publication date': '2018 Nov 15', 'sentence': 'We tested whether (1) cortisol is associated to inflammation, (2) cortisol is associated to the adolescent Mediterranean diet score (aMDS), (3) aMDS lessens inflammation, (4) aMDS associates with cortisol levels and inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:31043325': {'publication date': '2019 06', 'sentence': 'Inflammation is a key contributor to the pathogenesis of bronchopulmonary dysplasia (BPD) in preterm infants, and cortisol plays a central role in controlling inflammation.', 'subject score': 1000, 'object score': 861}, 'PMID:36415926': {'publication date': '2022 Nov 22', 'sentence': 'A steroid, cortisol, is the most important glucocorticoid, and dexamethasone (Dex), a synthetic glucocorticoid, is widely used for suppressing inflammation in clinics.', 'subject score': 1000, 'object score': 888}, 'PMID:4272037': {'publication date': '1972', 'sentence': 'The effect of estrogen, progesterone and cortisol on gingival inflammation.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10431364",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:13052711",
-                "PMID:14437778",
-                "PMID:16535928",
-                "PMID:16857225",
-                "PMID:22013396",
-                "PMID:26829709",
-                "PMID:28063472",
-                "PMID:28953797",
-                "PMID:29845974",
-                "PMID:3004514",
-                "PMID:30445703",
-                "PMID:31043325",
-                "PMID:36415926",
-                "PMID:4272037"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 517695,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005109",
-          "name": "HIV infectious disease",
-          "description": "A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.",
-          "equivalent_curies": [
-            "UMLS:C0019693",
-            "ICD9:042-042.99",
-            "SNOMEDCT:86406008",
-            "NCIT:C3108",
-            "MEDDRA:10020161",
-            "PDQ:CDR0000585059",
-            "MEDDRA:10020443",
-            "MEDDRA:10020160",
-            "MONDO:0005109",
-            "EFO:0000764",
-            "MEDDRA:10020172",
-            "MESH:D015658",
-            "DOID:526"
-          ],
-          "id": "MONDO:0005109",
-          "category": "biolink:Disease",
-          "all_names": [
-            "human immunodeficiency virus infectious disease",
-            "HIV infection",
-            "HIV infectious disease",
-            "HIV Infection",
-            "Human immunodeficiency virus [hiv] infection",
-            "HIV Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/hiv",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000602.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517695,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005109",
-              "name": "HIV infectious disease",
-              "description": "A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.",
-              "equivalent_curies": [
-                "UMLS:C0019693",
-                "ICD9:042-042.99",
-                "SNOMEDCT:86406008",
-                "NCIT:C3108",
-                "MEDDRA:10020161",
-                "PDQ:CDR0000585059",
-                "MEDDRA:10020443",
-                "MEDDRA:10020160",
-                "MONDO:0005109",
-                "EFO:0000764",
-                "MEDDRA:10020172",
-                "MESH:D015658",
-                "DOID:526"
-              ],
-              "id": "MONDO:0005109",
-              "category": "biolink:Disease",
-              "all_names": [
-                "human immunodeficiency virus infectious disease",
-                "HIV infection",
-                "HIV infectious disease",
-                "HIV Infection",
-                "Human immunodeficiency virus [hiv] infection",
-                "HIV Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/hiv",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000602.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9851332,
-            "start": 569,
-            "end": 517695,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12627047': {'publication date': '2003 Jan', 'sentence': 'The effects of stressful life events, coping, and cortisol on HIV infection.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0019693---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10074536",
-              "object": "MONDO:0005109",
-              "publications": [
-                "PMID:12627047"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 528832,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-          "name": "toxic shock syndrome",
-          "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C35498",
-            "UMLS:C0600327",
-            "UMLS:CN204669",
-            "MEDDRA:10044248",
-            "MESH:D012772",
-            "MEDDRA:10044249",
-            "SNOMEDCT:18504008",
-            "DOID:14115",
-            "MEDDRA:10042852",
-            "UMLS:C0036983",
-            "ORPHANET:36234",
-            "SNOMEDCT:76571007",
-            "MEDDRA:10040580",
-            "NCIT:C35018",
-            "MEDDRA:10040070",
-            "ICD9:040.82",
-            "ICD10:A48.3",
-            "MONDO:0001881",
-            "EFO:0006834",
-            "SYMP:0000451"
-          ],
-          "id": "MONDO:0001881",
-          "category": "biolink:Disease",
-          "all_names": [
-            "toxic shock syndrome",
-            "Septic Shock",
-            "Shock, Septic",
-            "Toxic Shock Syndrome",
-            "Bacterial toxic-shock syndrome",
-            "septic shock",
-            "Toxic shock syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 528832,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-              "name": "toxic shock syndrome",
-              "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C35498",
-                "UMLS:C0600327",
-                "UMLS:CN204669",
-                "MEDDRA:10044248",
-                "MESH:D012772",
-                "MEDDRA:10044249",
-                "SNOMEDCT:18504008",
-                "DOID:14115",
-                "MEDDRA:10042852",
-                "UMLS:C0036983",
-                "ORPHANET:36234",
-                "SNOMEDCT:76571007",
-                "MEDDRA:10040580",
-                "NCIT:C35018",
-                "MEDDRA:10040070",
-                "ICD9:040.82",
-                "ICD10:A48.3",
-                "MONDO:0001881",
-                "EFO:0006834",
-                "SYMP:0000451"
-              ],
-              "id": "MONDO:0001881",
-              "category": "biolink:Disease",
-              "all_names": [
-                "toxic shock syndrome",
-                "Septic Shock",
-                "Shock, Septic",
-                "Toxic Shock Syndrome",
-                "Bacterial toxic-shock syndrome",
-                "septic shock",
-                "Toxic shock syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9659155,
-            "start": 569,
-            "end": 528832,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12426230': {'publication date': '2003 Feb 15', 'sentence': 'Immunologic and hemodynamic effects of \"low-dose\" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study.', 'subject score': 901, 'object score': 1000}, 'PMID:17509634': {'publication date': '2007 Jun', 'sentence': 'Recently, it was demonstrated that hydrocortisone has immunologic effects in septic shock and therefore may affect cell adhesion molecules.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0036983---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9872405",
-              "object": "MONDO:0001881",
-              "publications": [
-                "PMID:12426230",
-                "PMID:17509634"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9403336,
-            "start": 569,
-            "end": 319673,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12076698': {'publication date': '2002 Jun', 'sentence': 'To prolong the anti-tumor effect some mice were also given cyclophosphamide, hydrocortisone, or a second injection of virus.', 'subject score': 1000, 'object score': 790}, 'PMID:13600766': {'publication date': '1958', 'sentence': 'Topical effects of cortisol upon Walker tumors.', 'subject score': 1000, 'object score': 888}, 'PMID:2017766': {'publication date': '1991 Mar 25', 'sentence': 'Although local treatment with CORT or IND had no significant effect on the final tumor incidence by Ni3S2, it shortened the latency of tumors to 17 weeks compared with 23 weeks for Ni3S2 alone.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9610203",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:12076698",
-                "PMID:13600766",
-                "PMID:2017766"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8924464,
-            "start": 569,
-            "end": 321528,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11560105': {'publication date': '2001 Aug', 'sentence': 'In conclusion, HRT in postmenopausal asthmatic women has a favorable influence on the course of asthma, reduces daily use of glucocorticosteroids and frequency of asthma exacerbations and normalizes serum concentrations of estradiol, cortisol and DHEAS, which were decreased before HRT.', 'subject score': 1000, 'object score': 694}, 'PMID:14366902': {'publication date': '1955 May', 'sentence': 'Metacortandracin (prednisone) in bronchial asthma: comparative effects of metacortandracin, hydrocortisone, and cortisone in bronchial asthma with diabetes mellitus and bronchial asthma with nasal polyps; preliminary report.', 'subject score': 1000, 'object score': 1000}, 'PMID:1773552': {'publication date': '1991 Nov', 'sentence': 'After unsuccessful therapy with salbutamol syrup and inhaled terbutaline a 3-year-old boy with an acute exacerbation of asthma was treated with nebulised salbutamol (albuterol), intravenous aminophylline and hydrocortisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:30788950': {'publication date': '2018 Apr 08', 'sentence': 'CONCLUSIONS: Combined administration of RASI and hydrocortisone have obvious anti-asthma effects and one of the mechanisms is to inhibit protein synthetization of HMGB1, TLR4 and NF-kappaB.The combined administration of RASI and hydrocortisone has stronger improvement of lung function than that of RASI and hydrocortisone alone, and it may be related to the inhibition of TLR4 and NF-kappaB synthetization.', 'subject score': 1000, 'object score': 733}, 'PMID:35152259': {'publication date': '2022 Feb 13', 'sentence': 'An additional course of hydrocortisone was given due to asthma exacerbation, gradually liberating her from the HFNC.', 'subject score': 1000, 'object score': 888}, 'PMID:6853932': {'publication date': '1983 Jul', 'sentence': 'We conclude that cortisol had no short-term effect on airway caliber in normals, at best a slowly evolving effect in asymptomatic unmedicated asthmatics, and no interaction with the bronchodilator effects of a maximal dose of isoproterenol in these groups.', 'subject score': 1000, 'object score': 785}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9120606",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:11560105",
-                "PMID:14366902",
-                "PMID:1773552",
-                "PMID:30788950",
-                "PMID:35152259",
-                "PMID:6853932"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318216,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318216,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7849953,
-            "start": 569,
-            "end": 318216,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10692082': {'publication date': '2000 Feb', 'sentence': 'However, after adjusting for the effect of obesity by multiple regression, higher plasma cortisol was independently associated with higher diastolic blood pressure in men (r = 0.21, P = 0.04) but not in women, and higher fasting serum triglyceride levels in women (r = 0.28, P < 0. 001) but not in men.', 'subject score': 840, 'object score': 1000}, 'PMID:11238541': {'publication date': '2001 Mar', 'sentence': 'However, changes in 11beta-HSD1 are tissue-specific: strikingly enhanced reactivation of cortisone to cortisol in subcutaneous adipose tissue may exacerbate obesity; and it may be beneficial to inhibit this enzyme in adipose tissue in obese patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:1158040': {'publication date': '1975 Aug', 'sentence': 'Effect of physical exercise on secretion of growth hormone, glucagon, and cortisol in obese and diabetic children.', 'subject score': 1000, 'object score': 1000}, 'PMID:12055988': {'publication date': '2002 Mar', 'sentence': 'The effects of obesity and starvation on thyroid hormone, GH, and cortisol secretion are summarized in Table 1.', 'subject score': 888, 'object score': 1000}, 'PMID:15356083': {'publication date': '2004 Sep', 'sentence': 'These data suggest that salivary cortisol and lipolytic responses are not necessarily linked, but are altered in obesity.', 'subject score': 888, 'object score': 1000}, 'PMID:1666898': {'publication date': '1991 Dec', 'sentence': 'The effects of glucose ingestion and fasting on plasma immunoreactive beta-endorphin, adrenocorticotropic hormone and cortisol in obese subjects.', 'subject score': 1000, 'object score': 872}, 'PMID:16958791': {'publication date': '2006 Oct', 'sentence': 'In the present study, we investigated the effect of naturally acquired obesity on cortisol, insulin-like growth factor (IGF)-1 and prolactin secretion in dogs.', 'subject score': 1000, 'object score': 790}, 'PMID:24983396': {'publication date': '2014 Aug', 'sentence': 'PURPOSE OF REVIEW: To review recent progress in the field of cortisol exposure and sensitivity, and its implications for research concerning obesity and related metabolic disturbances.', 'subject score': 694, 'object score': 802}, 'PMID:25618798': {'publication date': '2015 Apr', 'sentence': 'The effect of body temperature, melatonin and cortisol on obesity in women: A biochemical evaluation?', 'subject score': 1000, 'object score': 1000}, 'PMID:2847928': {'publication date': '1988', 'sentence': 'Effect of clonidine on beta-endorphin, ACTH and cortisol secretion in essential hypertension and obesity.', 'subject score': 888, 'object score': 1000}, 'PMID:29262485': {'publication date': '2017 Dec 06', 'sentence': 'Conclusion: Hair cortisol had a significant relation with overweight and obesity in 6-9 years old childhood especially among girls.', 'subject score': 888, 'object score': 1000}, 'PMID:30118922': {'publication date': '2018 Dec', 'sentence': 'Perceived weight discrimination significantly mediated associations between obesity and hair cortisol (beta = 0.021, SE = 0.007, 95% CI 0.007-0.036) and BMI and hair cortisol (beta = 0.001, SE = 0.0004, 95% CI 0.0004-0.002), accounting for 19% of the total effect of obesity and 23% of the total effect of BMI on hair cortisol.', 'subject score': 888, 'object score': 1000}, 'PMID:3155995': {'publication date': '1985 Feb 15', 'sentence': '[The effect of physical activity in obese subjects on the levels of cortisol, glucagon and beta-endorphins in the blood].', 'subject score': 1000, 'object score': 872}, 'PMID:31863690': {'publication date': '2019 Dec 01', 'sentence': 'Cortisol and IGF-I SDS were divided in quartiles and then crossed to explore the reciprocal influence of high/high, low/low, and high/low levels of each one on the metabolic alterations of obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:32546861': {'publication date': '2020 Jun 16', 'sentence': 'Amygdala networks, cumulative cortisol, and weight loss in adolescents with excess weight.OBJECTIVE: The amygdala is importantly involved in stress and obesity, but its role on weight change and diet-related stress remains unexplored among adolescents with excess weight.', 'subject score': 888, 'object score': 1000}, 'PMID:36714602': {'publication date': '2022', 'sentence': 'Conclusions: Although women with obesity reported higher perceived stress, they had lower urinary cortisol than women with normal BMI, and gestation-related increases in cortisol were similar across weight groups and unrelated to perceived stress, suggesting that physiological factors that drive increases in cortisol as pregnancy may outweigh effects of stress and adiposity.', 'subject score': 1000, 'object score': 1000}, 'PMID:679499': {'publication date': '1978 Jul', 'sentence': 'The circadian rhythm of cortisol was not altered in obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:9589697': {'publication date': '1998 May', 'sentence': 'These observations suggest that cortisol clearance is altered in obesity, and this may account for activation of the hypothalamic-pituitary-adrenal axis.', 'subject score': 888, 'object score': 1000}, 'PMID:9760012': {'publication date': '1998 Sep', 'sentence': 'Effect of fat distribution on the pharmacokinetics of cortisol in obesity.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0028754---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8017440",
-              "object": "MONDO:0011122",
-              "publications": [
-                "PMID:10692082",
-                "PMID:11238541",
-                "PMID:1158040",
-                "PMID:12055988",
-                "PMID:15356083",
-                "PMID:1666898",
-                "PMID:16958791",
-                "PMID:24983396",
-                "PMID:25618798",
-                "PMID:2847928",
-                "PMID:29262485",
-                "PMID:30118922",
-                "PMID:3155995",
-                "PMID:31863690",
-                "PMID:32546861",
-                "PMID:36714602",
-                "PMID:679499",
-                "PMID:9589697",
-                "PMID:9760012"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 314596,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-          "name": "Insulin resistance",
-          "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "NCIT:C113101",
-            "UMLS:C0021655",
-            "MEDDRA:10022489",
-            "SNOMEDCT:48606007",
-            "MESH:D007333",
-            "EFO:0002614",
-            "HP:0000855",
-            "SNOMEDCT:763325000"
-          ],
-          "id": "HP:0000855",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Insulin resistance",
-            "insulin resistance",
-            "Insulin Resistance"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314596,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-              "name": "Insulin resistance",
-              "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "NCIT:C113101",
-                "UMLS:C0021655",
-                "MEDDRA:10022489",
-                "SNOMEDCT:48606007",
-                "MESH:D007333",
-                "EFO:0002614",
-                "HP:0000855",
-                "SNOMEDCT:763325000"
-              ],
-              "id": "HP:0000855",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Insulin resistance",
-                "insulin resistance",
-                "Insulin Resistance"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7807812,
-            "start": 569,
-            "end": 314596,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10664531': {'publication date': '2000 Feb', 'sentence': 'ii) Reduction of cortisone to cortisol in the liver may increase insulin resistance in type 2 diabetes mellitus, and inhibition of the enzyme may lead to a decrease in gluconeogenesis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15257241': {'publication date': '2004 Jun 05', 'sentence': 'INTRA-CELL CORTISOL: Attention is also focused on the potential implication of cortisol in the genesis of metabolic syndrome, because cortisol is a potent antagonist of the effect of insulin and its presence in excess enhances visceral obesity and insulin resistance.', 'subject score': 1000, 'object score': 1000}, 'PMID:21249616': {'publication date': '2011 Apr', 'sentence': 'In obesity, adipose tissue 11betaHSD1 is upregulated, leading to the generation of higher tissue levels of cortisol, which may increase insulin resistance.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0021655---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7974249",
-              "object": "HP:0000855",
-              "publications": [
-                "PMID:10664531",
-                "PMID:15257241",
-                "PMID:21249616"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317312,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-          "name": "Hypoxemia",
-          "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "NCIT:C93047",
-            "MEDDRA:10021142",
-            "UMLS:C0242184",
-            "ICD9:799.02",
-            "HP:0012418",
-            "EFO:0009444",
-            "MEDDRA:10021143",
-            "EFO:0009447",
-            "MEDDRA:10021141",
-            "UMLS:C0700292",
-            "SNOMEDCT:389086002",
-            "PDQ:CDR0000773145",
-            "SYMP:0000303",
-            "MEDDRA:10021144",
-            "MESH:D000860",
-            "NCIT:C3890",
-            "SNOMEDCT:389087006"
-          ],
-          "id": "HP:0012418",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hypoxia",
-            "Hypoxemia",
-            "hypoxemia",
-            "Hypoxia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:DiseaseOrPhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317312,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-              "name": "Hypoxemia",
-              "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "NCIT:C93047",
-                "MEDDRA:10021142",
-                "UMLS:C0242184",
-                "ICD9:799.02",
-                "HP:0012418",
-                "EFO:0009444",
-                "MEDDRA:10021143",
-                "EFO:0009447",
-                "MEDDRA:10021141",
-                "UMLS:C0700292",
-                "SNOMEDCT:389086002",
-                "PDQ:CDR0000773145",
-                "SYMP:0000303",
-                "MEDDRA:10021144",
-                "MESH:D000860",
-                "NCIT:C3890",
-                "SNOMEDCT:389087006"
-              ],
-              "id": "HP:0012418",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hypoxia",
-                "Hypoxemia",
-                "hypoxemia",
-                "Hypoxia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:DiseaseOrPhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7219825,
-            "start": 569,
-            "end": 317312,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1030880': {'publication date': '1976 Jan-Feb', 'sentence': 'Pretreatment of rats with hydrocortisone or protamin-Zn-insulin within 4 days altered in subsequent acute hypoxia (3 hrs, \"height\" 10 000 m) the isoenzyme spectrum of LDH in lungs, liver tissue and kidney cortex.', 'subject score': 1000, 'object score': 851}, 'PMID:29956573': {'publication date': '2018 Apr-Jun', 'sentence': 'A pilot investigation into the effects of acute normobaric hypoxia, high altitude exposure and exercise on serum angiotensin-converting enzyme, aldosterone and cortisol.', 'subject score': 1000, 'object score': 802}, 'PMID:5401027': {'publication date': '1969', 'sentence': '[The adaptive effect of hydrocortisone in hypoxia].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0242184---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7366981",
-              "object": "HP:0012418",
-              "publications": [
-                "PMID:1030880",
-                "PMID:29956573",
-                "PMID:5401027"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:10195112': {'publication date': '1998 May', 'sentence': 'Previously we related persistent cortisol increases to memory impairments in elderly humans studied over five years.', 'subject score': 888, 'object score': 983}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319995,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001185",
-          "name": "dissociative amnesia",
-          "description": "Partial or complete loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories. Compare FORGETTING and MEMORY DECAY.; Systematic and extensive loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories.; Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7); UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "NCIT:C78444",
-            "SYMP:0000543",
-            "MONDO:0001185",
-            "MEDDRA:10027178",
-            "ICD9:300.12",
-            "ICD9:780.93",
-            "SNOMEDCT:55533009",
-            "MESH:D000647",
-            "SNOMEDCT:48167000",
-            "MEDDRA:10001949",
-            "NBO:0000253",
-            "PSY:30590",
-            "ICD10:F44.0",
-            "UMLS:C3887551",
-            "MEDDRA:10013461",
-            "MESH:D008569",
-            "DOID:11037",
-            "MEDDRA:10027172",
-            "MEDDRA:10027174",
-            "MEDDRA:10027176",
-            "MEDDRA:10017060",
-            "UMLS:C0236795",
-            "UMLS:C0542476",
-            "NCIT:C2867",
-            "UMLS:C0025261",
-            "MEDDRA:10027175",
-            "UMLS:C0751295",
-            "SNOMEDCT:386807006",
-            "MEDDRA:10027171",
-            "EFO:1001454",
-            "NCIT:C94328",
-            "PSY:02120",
-            "UMLS:C0002622",
-            "NCIT:C46084",
-            "UMLS:C0233794",
-            "SYMP:0000719",
-            "EFO:0001072",
-            "MEDDRA:10024871",
-            "HP:0002354",
-            "SNOMEDCT:84209002",
-            "MEDDRA:10037186"
-          ],
-          "id": "MONDO:0001185",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Memory Disorders",
-            "dissociative amnesia",
-            "Memory Loss",
-            "Dissociative Amnesia",
-            "memory impairment",
-            "memory loss",
-            "Forgetful",
-            "Memory Impairment",
-            "Amnesia",
-            "Dissociative amnesia",
-            "Memory impairment",
-            "amnesia",
-            "Memory dysfunction",
-            "Memory loss",
-            "Memory Dysfunction"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://www.merckmanuals.com/professional/psychiatric-disorders/dissociative-disorders/dissociative-amnesia",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.merriam-webster.com/dictionary/impairment",
-            "https://medlineplus.gov/ency/article/003257.htm",
-            "https://www.merckmanuals.com/professional/neurologic-disorders/symptoms-of-neurologic-disorders/memory-loss"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319995,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001185",
-              "name": "dissociative amnesia",
-              "description": "Partial or complete loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories. Compare FORGETTING and MEMORY DECAY.; Systematic and extensive loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories.; Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7); UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "NCIT:C78444",
-                "SYMP:0000543",
-                "MONDO:0001185",
-                "MEDDRA:10027178",
-                "ICD9:300.12",
-                "ICD9:780.93",
-                "SNOMEDCT:55533009",
-                "MESH:D000647",
-                "SNOMEDCT:48167000",
-                "MEDDRA:10001949",
-                "NBO:0000253",
-                "PSY:30590",
-                "ICD10:F44.0",
-                "UMLS:C3887551",
-                "MEDDRA:10013461",
-                "MESH:D008569",
-                "DOID:11037",
-                "MEDDRA:10027172",
-                "MEDDRA:10027174",
-                "MEDDRA:10027176",
-                "MEDDRA:10017060",
-                "UMLS:C0236795",
-                "UMLS:C0542476",
-                "NCIT:C2867",
-                "UMLS:C0025261",
-                "MEDDRA:10027175",
-                "UMLS:C0751295",
-                "SNOMEDCT:386807006",
-                "MEDDRA:10027171",
-                "EFO:1001454",
-                "NCIT:C94328",
-                "PSY:02120",
-                "UMLS:C0002622",
-                "NCIT:C46084",
-                "UMLS:C0233794",
-                "SYMP:0000719",
-                "EFO:0001072",
-                "MEDDRA:10024871",
-                "HP:0002354",
-                "SNOMEDCT:84209002",
-                "MEDDRA:10037186"
-              ],
-              "id": "MONDO:0001185",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Memory Disorders",
-                "dissociative amnesia",
-                "Memory Loss",
-                "Dissociative Amnesia",
-                "memory impairment",
-                "memory loss",
-                "Forgetful",
-                "Memory Impairment",
-                "Amnesia",
-                "Dissociative amnesia",
-                "Memory impairment",
-                "amnesia",
-                "Memory dysfunction",
-                "Memory loss",
-                "Memory Dysfunction"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://www.merckmanuals.com/professional/psychiatric-disorders/dissociative-disorders/dissociative-amnesia",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.merriam-webster.com/dictionary/impairment",
-                "https://medlineplus.gov/ency/article/003257.htm",
-                "https://www.merckmanuals.com/professional/neurologic-disorders/symptoms-of-neurologic-disorders/memory-loss"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7122662,
-            "start": 569,
-            "end": 319995,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10195112': {'publication date': '1998 May', 'sentence': 'Previously we related persistent cortisol increases to memory impairments in elderly humans studied over five years.', 'subject score': 888, 'object score': 983}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0233794---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7266667",
-              "object": "MONDO:0001185",
-              "publications": [
-                "PMID:10195112"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 315770,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005059",
-          "name": "leukemia",
-          "description": "A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3161\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3161\" NCI Thesaurus); A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.; A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006); A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding  When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets  The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time.  The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age  What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding.  Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes  Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10045991",
-            "MEDDRA:10024329",
-            "ICD9:208",
-            "ICD10:C95.90",
-            "MEDDRA:10060430",
-            "MEDDRA:10024314",
-            "MEDDRA:10024323",
-            "MEDDRA:10024351",
-            "HP:0001909",
-            "SNOMEDCT:87163000",
-            "SNOMEDCT:1162768007",
-            "MEDDRA:10045992",
-            "MEDDRA:10060500",
-            "NCIT:C3161",
-            "EFO:0000565",
-            "MEDDRA:10045994",
-            "SNOMEDCT:93143009",
-            "MEDDRA:10024288",
-            "MEDDRA:10024352",
-            "MEDDRA:10024312",
-            "DOID:1240",
-            "UMLS:C0023418",
-            "PDQ:CDR0000041186",
-            "MESH:D007938",
-            "MONDO:0005059",
-            "MEDDRA:10024324"
-          ],
-          "id": "MONDO:0005059",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia of unspecified cell type",
-            "Leukemia",
-            "leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/leukemia",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=45343",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315770,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005059",
-              "name": "leukemia",
-              "description": "A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3161\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3161\" NCI Thesaurus); A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.; A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006); A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding  When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets  The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time.  The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age  What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding.  Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes  Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10045991",
-                "MEDDRA:10024329",
-                "ICD9:208",
-                "ICD10:C95.90",
-                "MEDDRA:10060430",
-                "MEDDRA:10024314",
-                "MEDDRA:10024323",
-                "MEDDRA:10024351",
-                "HP:0001909",
-                "SNOMEDCT:87163000",
-                "SNOMEDCT:1162768007",
-                "MEDDRA:10045992",
-                "MEDDRA:10060500",
-                "NCIT:C3161",
-                "EFO:0000565",
-                "MEDDRA:10045994",
-                "SNOMEDCT:93143009",
-                "MEDDRA:10024288",
-                "MEDDRA:10024352",
-                "MEDDRA:10024312",
-                "DOID:1240",
-                "UMLS:C0023418",
-                "PDQ:CDR0000041186",
-                "MESH:D007938",
-                "MONDO:0005059",
-                "MEDDRA:10024324"
-              ],
-              "id": "MONDO:0005059",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia of unspecified cell type",
-                "Leukemia",
-                "leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/leukemia",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=45343",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23333501,
-            "start": 569,
-            "end": 315770,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34579671': {'publication date': '2021 Sep 27', 'sentence': 'Study protocol: DexaDays-2, hydrocortisone for treatment of dexamethasone-induced neurobehavioral side effects in pediatric leukemia patients: a double-blind placebo controlled randomized intervention study with cross-over design.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0023418---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "23769275",
-              "object": "MONDO:0005059",
-              "publications": [
-                "PMID:34579671"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 521389,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018166",
-          "name": "oral submucous fibrosis",
-          "description": "Oral submucous fibrosis (OSMF) is a chronic, progressive disease that alters the fibroelasticity of the oral submucosa, prevalent in India and Southeast Asia but rare elsewhere, and characterized by burning and pain in the oral cavity, loss of gustatory sensation, the presence of blanched fibrous bands and stiffening of the oral mucosa and oro-pharynx (leading to trismus and a progressive reduction in mouth opening) and an increased risk of developing oral squamous cell cancer (3-19%). It is usually associated with the chewing of the areca nut (an ingredient in betel quid) but the exact etiology is unknown and there is currently no effective treatment.",
-          "equivalent_curies": [
-            "MONDO:0018166",
-            "ICD10:K13.5",
-            "UMLS:C0029171",
-            "UMLS:C0029172",
-            "MESH:D009914",
-            "MEDDRA:10031023",
-            "EFO:1001818",
-            "MEDDRA:10031025",
-            "MEDDRA:10056775",
-            "ICD9:528.8",
-            "SNOMEDCT:32883009",
-            "NCIT:C34866",
-            "DOID:5773",
-            "ORPHANET:357154"
-          ],
-          "id": "MONDO:0018166",
-          "category": "biolink:Disease",
-          "all_names": [
-            "oral submucous fibrosis",
-            "Oral Submucous Fibrosis",
-            "Oral submucosal fibrosis, including of tongue",
-            "Oral submucous fibrosis",
-            "Oral Cavity Submucous Fibrosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/oral_submucous_fibrosis",
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6627879/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 521389,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018166",
-              "name": "oral submucous fibrosis",
-              "description": "Oral submucous fibrosis (OSMF) is a chronic, progressive disease that alters the fibroelasticity of the oral submucosa, prevalent in India and Southeast Asia but rare elsewhere, and characterized by burning and pain in the oral cavity, loss of gustatory sensation, the presence of blanched fibrous bands and stiffening of the oral mucosa and oro-pharynx (leading to trismus and a progressive reduction in mouth opening) and an increased risk of developing oral squamous cell cancer (3-19%). It is usually associated with the chewing of the areca nut (an ingredient in betel quid) but the exact etiology is unknown and there is currently no effective treatment.",
-              "equivalent_curies": [
-                "MONDO:0018166",
-                "ICD10:K13.5",
-                "UMLS:C0029171",
-                "UMLS:C0029172",
-                "MESH:D009914",
-                "MEDDRA:10031023",
-                "EFO:1001818",
-                "MEDDRA:10031025",
-                "MEDDRA:10056775",
-                "ICD9:528.8",
-                "SNOMEDCT:32883009",
-                "NCIT:C34866",
-                "DOID:5773",
-                "ORPHANET:357154"
-              ],
-              "id": "MONDO:0018166",
-              "category": "biolink:Disease",
-              "all_names": [
-                "oral submucous fibrosis",
-                "Oral Submucous Fibrosis",
-                "Oral submucosal fibrosis, including of tongue",
-                "Oral submucous fibrosis",
-                "Oral Cavity Submucous Fibrosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/oral_submucous_fibrosis",
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6627879/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21922849,
-            "start": 569,
-            "end": 521389,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32754522': {'publication date': '2020 May', 'sentence': 'Aims and Objective: To evaluate the efficacy of injection placentrex and injection hydrocortisone in oral submucous fibrosis patients in increasing mouth opening, burning sensation, and improve the mucosal lining.', 'subject score': 888, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0029172---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "22345112",
-              "object": "MONDO:0018166",
-              "publications": [
-                "PMID:32754522"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 546907,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C3714514",
-          "name": "Infection",
-          "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "UMLS:C3714514",
-            "MEDDRA:10021842",
-            "NCIT:C128320",
-            "MEDDRA:10021789",
-            "MESH:D007239"
-          ],
-          "id": "UMLS:C3714514",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infection",
-            "Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546907,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C3714514",
-              "name": "Infection",
-              "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "UMLS:C3714514",
-                "MEDDRA:10021842",
-                "NCIT:C128320",
-                "MEDDRA:10021789",
-                "MESH:D007239"
-              ],
-              "id": "UMLS:C3714514",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infection",
-                "Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21860162,
-            "start": 569,
-            "end": 546907,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32682157': {'publication date': '2020 Jul 06', 'sentence': 'The results presented herein imply that the three families of cyanine dyes, in particular compounds 5a-f, show high potential as selective scaffolds to treat C. albicans infections.', 'subject score': 813, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C3714514---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "22282269",
-              "object": "UMLS:C3714514",
-              "publications": [
-                "PMID:32682157"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319679,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-          "name": "lymphoma",
-          "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:115244002",
-            "DOID:0060058",
-            "MONDO:0005062",
-            "SNOMEDCT:118600007",
-            "HP:0002665",
-            "NCIT:C7065",
-            "EFO:0000574",
-            "ORPHANET:223735",
-            "MESH:D008223",
-            "SNOMEDCT:188676008",
-            "PDQ:CDR0000041429",
-            "MEDDRA:10025316",
-            "UMLS:C0024299",
-            "NCIT:C3208",
-            "MEDDRA:10025632",
-            "MEDDRA:10025310",
-            "MEDDRA:10025633",
-            "SNOMEDCT:1163043007",
-            "ICD10:C85.9",
-            "UMLS:C1536843",
-            "UMLS:C0334621",
-            "MEDDRA:10025315"
-          ],
-          "id": "MONDO:0005062",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphocytic Neoplasm",
-            "Lymphoma",
-            "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-            "lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/lymphoma",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319679,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-              "name": "lymphoma",
-              "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:115244002",
-                "DOID:0060058",
-                "MONDO:0005062",
-                "SNOMEDCT:118600007",
-                "HP:0002665",
-                "NCIT:C7065",
-                "EFO:0000574",
-                "ORPHANET:223735",
-                "MESH:D008223",
-                "SNOMEDCT:188676008",
-                "PDQ:CDR0000041429",
-                "MEDDRA:10025316",
-                "UMLS:C0024299",
-                "NCIT:C3208",
-                "MEDDRA:10025632",
-                "MEDDRA:10025310",
-                "MEDDRA:10025633",
-                "SNOMEDCT:1163043007",
-                "ICD10:C85.9",
-                "UMLS:C1536843",
-                "UMLS:C0334621",
-                "MEDDRA:10025315"
-              ],
-              "id": "MONDO:0005062",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphocytic Neoplasm",
-                "Lymphoma",
-                "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-                "lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/lymphoma",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20956434,
-            "start": 569,
-            "end": 319679,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3167775': {'publication date': '1988 Oct 15', 'sentence': 'The serum cortisol concentration in the LYMPH patients was 285 +/- 74 nmol/l.', 'subject score': 901, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0024299---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "21368080",
-              "object": "MONDO:0005062",
-              "publications": [
-                "PMID:3167775"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318021,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000745",
-          "name": "cardiac arrest",
-          "description": "The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.; Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.; An abrupt loss of heart function. []; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:0060319",
-            "ICD10:I46",
-            "MEDDRA:10003109",
-            "UMLS:C0018790",
-            "HP:0001695",
-            "SNOMEDCT:410429000",
-            "MEDDRA:10082515",
-            "UMLS:C0444720",
-            "SNOMEDCT:397829000",
-            "MEDDRA:10003589",
-            "NCIT:C50479",
-            "PSY:07595",
-            "MEDDRA:10019249",
-            "SNOMEDCT:261195002",
-            "MEDDRA:10003587",
-            "MEDDRA:10047284",
-            "MESH:D006323",
-            "MONDO:0000745",
-            "MEDDRA:10041914",
-            "EFO:0009492",
-            "MEDDRA:10003586",
-            "MEDDRA:10007515",
-            "ICD9:427.5",
-            "MEDDRA:10047285"
-          ],
-          "id": "MONDO:0000745",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiac Arrest",
-            "cardiac arrest",
-            "Cardiac arrest",
-            "Heart Arrest"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/cardiacarrest.htm",
-            "http://en.wikipedia.org/wiki/cardiac_arrest",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318021,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000745",
-              "name": "cardiac arrest",
-              "description": "The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.; Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.; An abrupt loss of heart function. []; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:0060319",
-                "ICD10:I46",
-                "MEDDRA:10003109",
-                "UMLS:C0018790",
-                "HP:0001695",
-                "SNOMEDCT:410429000",
-                "MEDDRA:10082515",
-                "UMLS:C0444720",
-                "SNOMEDCT:397829000",
-                "MEDDRA:10003589",
-                "NCIT:C50479",
-                "PSY:07595",
-                "MEDDRA:10019249",
-                "SNOMEDCT:261195002",
-                "MEDDRA:10003587",
-                "MEDDRA:10047284",
-                "MESH:D006323",
-                "MONDO:0000745",
-                "MEDDRA:10041914",
-                "EFO:0009492",
-                "MEDDRA:10003586",
-                "MEDDRA:10007515",
-                "ICD9:427.5",
-                "MEDDRA:10047285"
-              ],
-              "id": "MONDO:0000745",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiac Arrest",
-                "cardiac arrest",
-                "Cardiac arrest",
-                "Heart Arrest"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/cardiacarrest.htm",
-                "http://en.wikipedia.org/wiki/cardiac_arrest",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19446877,
-            "start": 569,
-            "end": 318021,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28825336': {'publication date': '2018 Nov', 'sentence': 'Compared to controls, glycocalyx was mildly injured by CA, severely disrupted by hyaluronidase (HAase) with CA, and mitigated by hydrocortisone (HC) with CA.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0018790---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "19834754",
-              "object": "MONDO:0000745",
-              "publications": [
-                "PMID:28825336"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 308784,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002406",
-          "name": "dermatitis",
-          "description": "The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes. [HPO:probinson]; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0011123",
-            "MEDDRA:10062249",
-            "MEDDRA:10012431",
-            "MP:0004947",
-            "MESH:D003872",
-            "SNOMEDCT:43116000",
-            "MONDO:0002406",
-            "MEDDRA:10012478",
-            "MEDDRA:10040876",
-            "ICD10:L30.9",
-            "DOID:2723",
-            "NCIT:C2983",
-            "SNOMEDCT:703938007",
-            "UMLS:C3875321",
-            "PSY:13710",
-            "UMLS:C0011603"
-          ],
-          "id": "MONDO:0002406",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis",
-            "Inflammatory abnormality of the skin",
-            "Inflammatory dermatosis",
-            "dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/eczema.htm",
-            "http://en.wikipedia.org/wiki/dermatitis",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308784,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002406",
-              "name": "dermatitis",
-              "description": "The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes. [HPO:probinson]; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0011123",
-                "MEDDRA:10062249",
-                "MEDDRA:10012431",
-                "MP:0004947",
-                "MESH:D003872",
-                "SNOMEDCT:43116000",
-                "MONDO:0002406",
-                "MEDDRA:10012478",
-                "MEDDRA:10040876",
-                "ICD10:L30.9",
-                "DOID:2723",
-                "NCIT:C2983",
-                "SNOMEDCT:703938007",
-                "UMLS:C3875321",
-                "PSY:13710",
-                "UMLS:C0011603"
-              ],
-              "id": "MONDO:0002406",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis",
-                "Inflammatory abnormality of the skin",
-                "Inflammatory dermatosis",
-                "dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/eczema.htm",
-                "http://en.wikipedia.org/wiki/dermatitis",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17147821,
-            "start": 569,
-            "end": 308784,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2459879': {'publication date': '1988', 'sentence': 'In the acute phase of dermatitis, topical hydrocortisone treatment has both a local and a systemic effect, due to percutaneous absorption.', 'subject score': 790, 'object score': 1000}, 'PMID:25395851': {'publication date': '2014', 'sentence': 'CONCLUSION: The current investigation suggests that NP-mediated transcutaneous delivery of HC could be considered an effective therapeutic approach to manage dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2792121': {'publication date': '1989 Aug', 'sentence': 'To evaluate the effect of topical hydrocortisone therapy on cortisol secretion, the plasma cortisol response to a 2 h adrenocorticotropic hormone (ACTH) test was determined in 17 children with dermatitis.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0011603---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "17499762",
-              "object": "MONDO:0002406",
-              "publications": [
-                "PMID:2459879",
-                "PMID:25395851",
-                "PMID:2792121"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318773,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0036591",
-          "name": "adrenal cortex neoplasm",
-          "description": "The presence of a neoplasm of the adrenal cortex. [HPO:probinson]; The presence of a neoplasm of the adrenal cortex.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0036591",
-            "MESH:D000306",
-            "UMLS:C0001618",
-            "HP:0100641",
-            "NCIT:C2858",
-            "SNOMEDCT:127022002"
-          ],
-          "id": "MONDO:0036591",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortex neoplasm",
-            "Adrenal Cortical Neoplasm",
-            "Neoplasm of the adrenal cortex",
-            "Adrenal Cortex Neoplasms"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318773,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0036591",
-              "name": "adrenal cortex neoplasm",
-              "description": "The presence of a neoplasm of the adrenal cortex. [HPO:probinson]; The presence of a neoplasm of the adrenal cortex.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0036591",
-                "MESH:D000306",
-                "UMLS:C0001618",
-                "HP:0100641",
-                "NCIT:C2858",
-                "SNOMEDCT:127022002"
-              ],
-              "id": "MONDO:0036591",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortex neoplasm",
-                "Adrenal Cortical Neoplasm",
-                "Neoplasm of the adrenal cortex",
-                "Adrenal Cortex Neoplasms"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16595638,
-            "start": 569,
-            "end": 318773,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2370223': {'publication date': '1990 Jul 01', 'sentence': 'The mean (+/- SD) plasma cortisol concentration for the initial 8-hour testing period was highest in 18 dogs with adrenocortical tumor (5.3 +/- 1.6 micrograms/dl), lowest in 15 control dogs (1.3 +/- 0.5 micrograms/dl), and intermediate in 31 dogs with pituitary-dependent hyperadrenocorticism (PDH; 3.4 +/- 1.2 micrograms/dl).', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0001618---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "16946872",
-              "object": "MONDO:0036591",
-              "publications": [
-                "PMID:2370223"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:21745622': {'publication date': '2011 Jun', 'sentence': 'Our results suggest that PL may increase the availability of cortisol in chronically stressed men and may attenuate stress-induced memory impairments.', 'subject score': 1000, 'object score': 852}, 'PMID:567357': {'publication date': '1978 May', 'sentence': 'Attenuation of amnesia by hydrocortisone in the mouse.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319995,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001185",
-          "name": "dissociative amnesia",
-          "description": "Partial or complete loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories. Compare FORGETTING and MEMORY DECAY.; Systematic and extensive loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories.; Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7); UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "NCIT:C78444",
-            "SYMP:0000543",
-            "MONDO:0001185",
-            "MEDDRA:10027178",
-            "ICD9:300.12",
-            "ICD9:780.93",
-            "SNOMEDCT:55533009",
-            "MESH:D000647",
-            "SNOMEDCT:48167000",
-            "MEDDRA:10001949",
-            "NBO:0000253",
-            "PSY:30590",
-            "ICD10:F44.0",
-            "UMLS:C3887551",
-            "MEDDRA:10013461",
-            "MESH:D008569",
-            "DOID:11037",
-            "MEDDRA:10027172",
-            "MEDDRA:10027174",
-            "MEDDRA:10027176",
-            "MEDDRA:10017060",
-            "UMLS:C0236795",
-            "UMLS:C0542476",
-            "NCIT:C2867",
-            "UMLS:C0025261",
-            "MEDDRA:10027175",
-            "UMLS:C0751295",
-            "SNOMEDCT:386807006",
-            "MEDDRA:10027171",
-            "EFO:1001454",
-            "NCIT:C94328",
-            "PSY:02120",
-            "UMLS:C0002622",
-            "NCIT:C46084",
-            "UMLS:C0233794",
-            "SYMP:0000719",
-            "EFO:0001072",
-            "MEDDRA:10024871",
-            "HP:0002354",
-            "SNOMEDCT:84209002",
-            "MEDDRA:10037186"
-          ],
-          "id": "MONDO:0001185",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Memory Disorders",
-            "dissociative amnesia",
-            "Memory Loss",
-            "Dissociative Amnesia",
-            "memory impairment",
-            "memory loss",
-            "Forgetful",
-            "Memory Impairment",
-            "Amnesia",
-            "Dissociative amnesia",
-            "Memory impairment",
-            "amnesia",
-            "Memory dysfunction",
-            "Memory loss",
-            "Memory Dysfunction"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://www.merckmanuals.com/professional/psychiatric-disorders/dissociative-disorders/dissociative-amnesia",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.merriam-webster.com/dictionary/impairment",
-            "https://medlineplus.gov/ency/article/003257.htm",
-            "https://www.merckmanuals.com/professional/neurologic-disorders/symptoms-of-neurologic-disorders/memory-loss"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319995,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001185",
-              "name": "dissociative amnesia",
-              "description": "Partial or complete loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories. Compare FORGETTING and MEMORY DECAY.; Systematic and extensive loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories.; Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7); UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "NCIT:C78444",
-                "SYMP:0000543",
-                "MONDO:0001185",
-                "MEDDRA:10027178",
-                "ICD9:300.12",
-                "ICD9:780.93",
-                "SNOMEDCT:55533009",
-                "MESH:D000647",
-                "SNOMEDCT:48167000",
-                "MEDDRA:10001949",
-                "NBO:0000253",
-                "PSY:30590",
-                "ICD10:F44.0",
-                "UMLS:C3887551",
-                "MEDDRA:10013461",
-                "MESH:D008569",
-                "DOID:11037",
-                "MEDDRA:10027172",
-                "MEDDRA:10027174",
-                "MEDDRA:10027176",
-                "MEDDRA:10017060",
-                "UMLS:C0236795",
-                "UMLS:C0542476",
-                "NCIT:C2867",
-                "UMLS:C0025261",
-                "MEDDRA:10027175",
-                "UMLS:C0751295",
-                "SNOMEDCT:386807006",
-                "MEDDRA:10027171",
-                "EFO:1001454",
-                "NCIT:C94328",
-                "PSY:02120",
-                "UMLS:C0002622",
-                "NCIT:C46084",
-                "UMLS:C0233794",
-                "SYMP:0000719",
-                "EFO:0001072",
-                "MEDDRA:10024871",
-                "HP:0002354",
-                "SNOMEDCT:84209002",
-                "MEDDRA:10037186"
-              ],
-              "id": "MONDO:0001185",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Memory Disorders",
-                "dissociative amnesia",
-                "Memory Loss",
-                "Dissociative Amnesia",
-                "memory impairment",
-                "memory loss",
-                "Forgetful",
-                "Memory Impairment",
-                "Amnesia",
-                "Dissociative amnesia",
-                "Memory impairment",
-                "amnesia",
-                "Memory dysfunction",
-                "Memory loss",
-                "Memory Dysfunction"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://www.merckmanuals.com/professional/psychiatric-disorders/dissociative-disorders/dissociative-amnesia",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.merriam-webster.com/dictionary/impairment",
-                "https://medlineplus.gov/ency/article/003257.htm",
-                "https://www.merckmanuals.com/professional/neurologic-disorders/symptoms-of-neurologic-disorders/memory-loss"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15429960,
-            "start": 569,
-            "end": 319995,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21745622': {'publication date': '2011 Jun', 'sentence': 'Our results suggest that PL may increase the availability of cortisol in chronically stressed men and may attenuate stress-induced memory impairments.', 'subject score': 1000, 'object score': 852}, 'PMID:567357': {'publication date': '1978 May', 'sentence': 'Attenuation of amnesia by hydrocortisone in the mouse.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0233794---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0002622---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "15753359",
-              "object": "MONDO:0001185",
-              "publications": [
-                "PMID:567357",
-                "PMID:21745622"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 317312,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-          "name": "Hypoxemia",
-          "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "NCIT:C93047",
-            "MEDDRA:10021142",
-            "UMLS:C0242184",
-            "ICD9:799.02",
-            "HP:0012418",
-            "EFO:0009444",
-            "MEDDRA:10021143",
-            "EFO:0009447",
-            "MEDDRA:10021141",
-            "UMLS:C0700292",
-            "SNOMEDCT:389086002",
-            "PDQ:CDR0000773145",
-            "SYMP:0000303",
-            "MEDDRA:10021144",
-            "MESH:D000860",
-            "NCIT:C3890",
-            "SNOMEDCT:389087006"
-          ],
-          "id": "HP:0012418",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hypoxia",
-            "Hypoxemia",
-            "hypoxemia",
-            "Hypoxia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:DiseaseOrPhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317312,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-              "name": "Hypoxemia",
-              "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "NCIT:C93047",
-                "MEDDRA:10021142",
-                "UMLS:C0242184",
-                "ICD9:799.02",
-                "HP:0012418",
-                "EFO:0009444",
-                "MEDDRA:10021143",
-                "EFO:0009447",
-                "MEDDRA:10021141",
-                "UMLS:C0700292",
-                "SNOMEDCT:389086002",
-                "PDQ:CDR0000773145",
-                "SYMP:0000303",
-                "MEDDRA:10021144",
-                "MESH:D000860",
-                "NCIT:C3890",
-                "SNOMEDCT:389087006"
-              ],
-              "id": "HP:0012418",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hypoxia",
-                "Hypoxemia",
-                "hypoxemia",
-                "Hypoxia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:DiseaseOrPhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15281540,
-            "start": 569,
-            "end": 317312,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2152': {'publication date': '1975 Nov', 'sentence': 'All inhibitors prevented the rise in cortisol secretion usually observed in hypoxic dogs.', 'subject score': 888, 'object score': 888}, 'PMID:32779728': {'publication date': '2020 Jul 21', 'sentence': 'Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-Protocol and statistical analysis plan.', 'subject score': 901, 'object score': 888}, 'PMID:34138478': {'publication date': '2021 Jun 17', 'sentence': 'In the COVID STEROID trial, we aimed to assess the effects of low-dose hydrocortisone on patient-centred outcomes in adults with COVID-19 and severe hypoxia.', 'subject score': 901, 'object score': 888}, 'PMID:9776848': {'publication date': '1998 Jan-Feb', 'sentence': 'Keloid fibroblasts displayed enhanced apoptosis rates in response to hydrocortisone, gamma interferon, and hypoxia treatment as compared with normal adult fibroblasts.', 'subject score': 1000, 'object score': 888}, 'PMID:3024490': {'publication date': '1986 Dec', 'sentence': 'We conclude that the changes in fetal adrenocorticotropic hormone, cortisol, and adrenal blood flow seen in short-term hypoxemia are reproduced during sustained hypoxemia with acidemia.', 'subject score': 1000, 'object score': 901}, 'PMID:9564872': {'publication date': '1998 May', 'sentence': 'Despite this, the increase in plasma cortisol in hypoxemia in intact fetuses was absent in carotid-denervated fetuses.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0242184---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0700292---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "15602187",
-              "object": "HP:0012418",
-              "publications": [
-                "PMID:34138478",
-                "PMID:3024490",
-                "PMID:9776848",
-                "PMID:9564872",
-                "PMID:2152",
-                "PMID:32779728"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320360,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005083",
-          "name": "psoriasis",
-          "description": "An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.; A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.; A skin abnormality characterized by redness and irritation, with thick, red skin that displays flaky, silver-white patches (scales). [HPO:probinson]; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have psoriasis also get a form of arthritis called psoriatic arthritis. A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast.  Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope. Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include: Infections Stress Dry skin Certain medicines  Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases ; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D011565",
-            "SNOMEDCT:9014002",
-            "ICD10:L40",
-            "MEDDRA:10058675",
-            "MONDO:0005083",
-            "DOID:8893",
-            "UMLS:C0033860",
-            "EFO:0000676",
-            "UMLS:C0262985",
-            "NCIT:C3346",
-            "NCIT:C27724",
-            "OMIM.PS:177900",
-            "OMIM:PS177900",
-            "SNOMEDCT:52230004",
-            "HP:0003765",
-            "MEDDRA:10037153",
-            "SNOMEDCT:238564003"
-          ],
-          "id": "MONDO:0005083",
-          "category": "biolink:Disease",
-          "all_names": [
-            "psoriasis",
-            "Psoriasiform eczema",
-            "Psoriasis",
-            "Psoriasiform dermatitis",
-            "Psoriasiform Dermatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.cdc.gov/psoriasis/index.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320360,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005083",
-              "name": "psoriasis",
-              "description": "An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.; A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.; A skin abnormality characterized by redness and irritation, with thick, red skin that displays flaky, silver-white patches (scales). [HPO:probinson]; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have psoriasis also get a form of arthritis called psoriatic arthritis. A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast.  Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope. Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include: Infections Stress Dry skin Certain medicines  Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases ; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D011565",
-                "SNOMEDCT:9014002",
-                "ICD10:L40",
-                "MEDDRA:10058675",
-                "MONDO:0005083",
-                "DOID:8893",
-                "UMLS:C0033860",
-                "EFO:0000676",
-                "UMLS:C0262985",
-                "NCIT:C3346",
-                "NCIT:C27724",
-                "OMIM.PS:177900",
-                "OMIM:PS177900",
-                "SNOMEDCT:52230004",
-                "HP:0003765",
-                "MEDDRA:10037153",
-                "SNOMEDCT:238564003"
-              ],
-              "id": "MONDO:0005083",
-              "category": "biolink:Disease",
-              "all_names": [
-                "psoriasis",
-                "Psoriasiform eczema",
-                "Psoriasis",
-                "Psoriasiform dermatitis",
-                "Psoriasiform Dermatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.cdc.gov/psoriasis/index.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15009495,
-            "start": 569,
-            "end": 320360,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21094146': {'publication date': '2011 Jan 07', 'sentence': 'The expression of StAR and MLN64 was aberrant in two skin disorders, psoriasis and atopic dermatitis, that are commonly treated with cortisol, suggesting dysregulation of epidermal steroid synthesis in these patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:27824222': {'publication date': '2016 Dec', 'sentence': 'This study aimed to determine serum levels of basal cortisol and adrenocorticotropic hormone (ACTH) and circulating levels of various cytokines and chemokines and their association with psychological measures in psoriasis patients.', 'subject score': 888, 'object score': 888}, 'PMID:36065538': {'publication date': '2022 05 01', 'sentence': 'Circadian cortisol profiles and hair cortisol concentration in patients with psoriasis: associations with anxiety, depressive symptomatology and disease severity', 'subject score': 851, 'object score': 1000}, 'PMID:36249714': {'publication date': '2022', 'sentence': 'Conclusion: Oral administration of Lactocare(r) probiotic (two times daily) associated with administration of topical hydrocortisone resulted in the improvement of PASI, DLQI, and VAS scores in the patients with psoriasis after 12 weeks of treatment.', 'subject score': 861, 'object score': 1000}, 'PMID:6832467': {'publication date': '1983', 'sentence': 'Plasma cortisol studies with 0.05% halometasone cream and ointment in patients with psoriasis.', 'subject score': 888, 'object score': 1000}, 'PMID:881090': {'publication date': '1977', 'sentence': 'Triamcinolone acetonide, hydrocortisone and methotrexate, all known to be useful clinically in the treatment of psoriasis, were examined for their ability to antagonize the development of retinoic-acid-induced scaling.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0033860---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "15325707",
-              "object": "MONDO:0005083",
-              "publications": [
-                "PMID:21094146",
-                "PMID:27824222",
-                "PMID:36065538",
-                "PMID:36249714",
-                "PMID:6832467",
-                "PMID:881090"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 547959,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043653",
-          "name": "herpes labialis",
-          "description": "Herpes simplex, caused by type 1 virus, primarily spread by oral secretions and usually occurring as a concomitant of fever. It may also develop in the absence of fever or prior illness. It commonly involves the facial region, especially the lips and the nares. (Dorland, 27th ed.); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10019942",
-            "MEDDRA:10049352",
-            "MEDDRA:10049362",
-            "UMLS:C0019345",
-            "MEDDRA:10082141",
-            "MEDDRA:10009865",
-            "SNOMEDCT:1475003",
-            "MEDDRA:10009864",
-            "MEDDRA:10016564",
-            "EFO:1001347",
-            "MEDDRA:10019946",
-            "NCIT:C34695",
-            "MESH:D006560",
-            "MONDO:0043653"
-          ],
-          "id": "MONDO:0043653",
-          "category": "biolink:Disease",
-          "all_names": [
-            "herpes labialis",
-            "Cold Sore",
-            "Herpes Labialis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 547959,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043653",
-              "name": "herpes labialis",
-              "description": "Herpes simplex, caused by type 1 virus, primarily spread by oral secretions and usually occurring as a concomitant of fever. It may also develop in the absence of fever or prior illness. It commonly involves the facial region, especially the lips and the nares. (Dorland, 27th ed.); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10019942",
-                "MEDDRA:10049352",
-                "MEDDRA:10049362",
-                "UMLS:C0019345",
-                "MEDDRA:10082141",
-                "MEDDRA:10009865",
-                "SNOMEDCT:1475003",
-                "MEDDRA:10009864",
-                "MEDDRA:10016564",
-                "EFO:1001347",
-                "MEDDRA:10019946",
-                "NCIT:C34695",
-                "MESH:D006560",
-                "MONDO:0043653"
-              ],
-              "id": "MONDO:0043653",
-              "category": "biolink:Disease",
-              "all_names": [
-                "herpes labialis",
-                "Cold Sore",
-                "Herpes Labialis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14894857,
-            "start": 569,
-            "end": 547959,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20851499': {'publication date': '2011 Apr', 'sentence': 'ME-609 (Xerese, Xerclear) is a combination of 5% acyclovir and 1% hydrocortisone developed for the topical treatment of HSL.', 'subject score': 861, 'object score': 923}, 'PMID:21954513': {'publication date': '2011 Sep', 'sentence': 'A cream containing 5% aciclovir and 1% hydrocortisone has been authorised in France for symptomatic treatment of herpes labialis in adults and adolescents 12 years of age and older.', 'subject score': 861, 'object score': 1000}, 'PMID:28971780': {'publication date': '2017', 'sentence': 'Topical antiviral agents such as 5% acyclovir cream/ointment (Zovirax) +/- hydrocortisone (Xerese), 1% penciclovir (Denavir) cream, and 50 mg Buccal Adhesive Tablet (ABT-50 mg) can also be used for episodic treatment of herpes labialis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0019345---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "15213238",
-              "object": "MONDO:0043653",
-              "publications": [
-                "PMID:20851499",
-                "PMID:21954513",
-                "PMID:28971780"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 307894,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005155",
-          "name": "cirrhosis of liver",
-          "description": "A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.; Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.; A chronic disorder of the liver in which liver tissue becomes scarred and is partially replaced by regenerative nodules and fibrotic tissue resulting in loss of liver function. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10024667",
-            "ICD10:K74.60",
-            "NCIT:C2951",
-            "MESH:D008103",
-            "HP:0001394",
-            "MEDDRA:10019642",
-            "MONDO:0005155",
-            "EFO:0001422",
-            "UMLS:C0023890",
-            "MEDDRA:10009211",
-            "MEDDRA:10009213",
-            "MEDDRA:10019641",
-            "SNOMEDCT:19943007",
-            "DOID:5082"
-          ],
-          "id": "MONDO:0005155",
-          "category": "biolink:Disease",
-          "all_names": [
-            "liver cirrhosis",
-            "Cirrhosis",
-            "cirrhosis of liver",
-            "Liver Cirrhosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 307894,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005155",
-              "name": "cirrhosis of liver",
-              "description": "A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.; Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.; A chronic disorder of the liver in which liver tissue becomes scarred and is partially replaced by regenerative nodules and fibrotic tissue resulting in loss of liver function. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10024667",
-                "ICD10:K74.60",
-                "NCIT:C2951",
-                "MESH:D008103",
-                "HP:0001394",
-                "MEDDRA:10019642",
-                "MONDO:0005155",
-                "EFO:0001422",
-                "UMLS:C0023890",
-                "MEDDRA:10009211",
-                "MEDDRA:10009213",
-                "MEDDRA:10019641",
-                "SNOMEDCT:19943007",
-                "DOID:5082"
-              ],
-              "id": "MONDO:0005155",
-              "category": "biolink:Disease",
-              "all_names": [
-                "liver cirrhosis",
-                "Cirrhosis",
-                "cirrhosis of liver",
-                "Liver Cirrhosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14229887,
-            "start": 569,
-            "end": 307894,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19690646': {'publication date': '2007 Feb 07', 'sentence': 'The urinary ratio of 6 beta-hydroxycortisol/cortisol (6 beta-OHC/C) as a biomarker of CYP3A4 metabolizing activity has been studied in Egyptian patients with chronic liver cirrhosis associated with previous hepatic Schistosomiasis infection to determine any possible alteration in enzyme activity.', 'subject score': 916, 'object score': 901}, 'PMID:35449323': {'publication date': '2022 Apr 22', 'sentence': 'Urinary free cortisol constitutes an index of adrenal cortisol production; however, it has never been used in assessing adrenal function in patients with liver cirrhosis.', 'subject score': 790, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0023890---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14532907",
-              "object": "MONDO:0005155",
-              "publications": [
-                "PMID:19690646",
-                "PMID:35449323"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 323831,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-          "name": "acute lymphoblastic leukemia",
-          "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "HP:0006721",
-            "MONDO:0004967",
-            "MEDDRA:10000848",
-            "MEDDRA:10000849",
-            "MEDDRA:10025305",
-            "ORPHANET:513",
-            "MEDDRA:10025301",
-            "ICD10:C91.00",
-            "UMLS:C0023453",
-            "DOID:9952",
-            "MEDDRA:10000844",
-            "MEDDRA:10000846",
-            "MEDDRA:10000845",
-            "MEDDRA:10024338",
-            "ICD10:C91",
-            "MESH:D054198",
-            "UMLS:C1961102",
-            "MEDDRA:10060555",
-            "NCIT:C3167",
-            "PDQ:CDR0000043423",
-            "MEDDRA:10024290",
-            "MEDDRA:10000842",
-            "NCIT:C27281",
-            "ICD9:204",
-            "DOID:1037",
-            "MEDDRA:10000843",
-            "EFO:0000220",
-            "SNOMEDCT:128822004",
-            "ICD9:204.0",
-            "UMLS:C0023449",
-            "MEDDRA:10060390",
-            "SNOMEDCT:91857003"
-          ],
-          "id": "MONDO:0004967",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute lymphoblastic leukemia",
-            "lymphoid leukemia",
-            "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-            "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-            "L2 Acute Lymphoblastic Leukemia",
-            "acute lymphocytic leukemia",
-            "Lymphoid leukemia, acute",
-            "acute lymphoblastic leukemia",
-            "Acute lymphocytic leukemia",
-            "Acute Lymphoblastic Leukemia",
-            "Lymphoid leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=46332",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=616067",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323831,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-              "name": "acute lymphoblastic leukemia",
-              "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "HP:0006721",
-                "MONDO:0004967",
-                "MEDDRA:10000848",
-                "MEDDRA:10000849",
-                "MEDDRA:10025305",
-                "ORPHANET:513",
-                "MEDDRA:10025301",
-                "ICD10:C91.00",
-                "UMLS:C0023453",
-                "DOID:9952",
-                "MEDDRA:10000844",
-                "MEDDRA:10000846",
-                "MEDDRA:10000845",
-                "MEDDRA:10024338",
-                "ICD10:C91",
-                "MESH:D054198",
-                "UMLS:C1961102",
-                "MEDDRA:10060555",
-                "NCIT:C3167",
-                "PDQ:CDR0000043423",
-                "MEDDRA:10024290",
-                "MEDDRA:10000842",
-                "NCIT:C27281",
-                "ICD9:204",
-                "DOID:1037",
-                "MEDDRA:10000843",
-                "EFO:0000220",
-                "SNOMEDCT:128822004",
-                "ICD9:204.0",
-                "UMLS:C0023449",
-                "MEDDRA:10060390",
-                "SNOMEDCT:91857003"
-              ],
-              "id": "MONDO:0004967",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute lymphoblastic leukemia",
-                "lymphoid leukemia",
-                "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-                "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-                "L2 Acute Lymphoblastic Leukemia",
-                "acute lymphocytic leukemia",
-                "Lymphoid leukemia, acute",
-                "acute lymphoblastic leukemia",
-                "Acute lymphocytic leukemia",
-                "Acute Lymphoblastic Leukemia",
-                "Lymphoid leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=46332",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=616067",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13781035,
-            "start": 569,
-            "end": 323831,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19015613': {'publication date': '2008', 'sentence': 'Here, we report a case of fatal ATLS complicating intrathecal injections of methotrexate, cytarabine and hydrocortisone for acute lymphoblastic leukemia which relapsed with meningeal involvement after allogeneic stem cell transplantation.', 'subject score': 1000, 'object score': 1000}, 'PMID:27161966': {'publication date': '2016 07 01', 'sentence': 'CONCLUSION: Our results suggest that adding a physiologic dose of hydrocortisone to dexamethasone treatment can reduce the occurrence of serious neuropsychological adverse effects and sleep-related difficulties in pediatric patients with ALL.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0023449---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14075841",
-              "object": "MONDO:0004967",
-              "publications": [
-                "PMID:19015613",
-                "PMID:27161966"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 517695,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005109",
-          "name": "HIV infectious disease",
-          "description": "A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.",
-          "equivalent_curies": [
-            "UMLS:C0019693",
-            "ICD9:042-042.99",
-            "SNOMEDCT:86406008",
-            "NCIT:C3108",
-            "MEDDRA:10020161",
-            "PDQ:CDR0000585059",
-            "MEDDRA:10020443",
-            "MEDDRA:10020160",
-            "MONDO:0005109",
-            "EFO:0000764",
-            "MEDDRA:10020172",
-            "MESH:D015658",
-            "DOID:526"
-          ],
-          "id": "MONDO:0005109",
-          "category": "biolink:Disease",
-          "all_names": [
-            "human immunodeficiency virus infectious disease",
-            "HIV infection",
-            "HIV infectious disease",
-            "HIV Infection",
-            "Human immunodeficiency virus [hiv] infection",
-            "HIV Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/hiv",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000602.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517695,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005109",
-              "name": "HIV infectious disease",
-              "description": "A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.",
-              "equivalent_curies": [
-                "UMLS:C0019693",
-                "ICD9:042-042.99",
-                "SNOMEDCT:86406008",
-                "NCIT:C3108",
-                "MEDDRA:10020161",
-                "PDQ:CDR0000585059",
-                "MEDDRA:10020443",
-                "MEDDRA:10020160",
-                "MONDO:0005109",
-                "EFO:0000764",
-                "MEDDRA:10020172",
-                "MESH:D015658",
-                "DOID:526"
-              ],
-              "id": "MONDO:0005109",
-              "category": "biolink:Disease",
-              "all_names": [
-                "human immunodeficiency virus infectious disease",
-                "HIV infection",
-                "HIV infectious disease",
-                "HIV Infection",
-                "Human immunodeficiency virus [hiv] infection",
-                "HIV Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/hiv",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000602.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13658519,
-            "start": 569,
-            "end": 517695,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18778540': {'publication date': '2008', 'sentence': 'Except in one patient with HIV infection, all the signs and symptoms improved after antituberculous and hydrocortisone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:7620208': {'publication date': '1995 Mar', 'sentence': 'The synergistic inhibitory effect of cortisol- and HIV-derived soluble products in patients with HIV infections are consistent with a model that proposes that stress and circulating HIV-1-derived products may be involved in the progression of HIV infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:8543334': {'publication date': '1995 Aug', 'sentence': 'The selective inhibitory effects of cortisol and ACTH in patients with HIV infections are consistent with a model which proposes that stress related neurohormones and/or neuropeptides may be involved in the progression of HIV infections.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0019693---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13951019",
-              "object": "MONDO:0005109",
-              "publications": [
-                "PMID:18778540",
-                "PMID:7620208",
-                "PMID:8543334"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 523855,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005091",
-          "name": "severe acute respiratory syndrome",
-          "description": "A viral respiratory infection caused by the SARS coronavirus. It is transmitted through close person-to-person contact. It is manifested with high fever, headache, dry cough and myalgias. It may progress to pneumonia and cause death.; A viral disorder characterized by high FEVER, dry COUGH, shortness of breath (DYSPNEA) or breathing difficulties, and atypical PNEUMONIA. A virus in the genus CORONAVIRUS is the suspected agent.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10061986",
-            "UMLS:C1175175",
-            "NCIT:C85064",
-            "ICD9:079.82",
-            "ICD10:J12.81",
-            "MONDO:0005091",
-            "MEDDRA:10084784",
-            "SNOMEDCT:398447004",
-            "MESH:D045169",
-            "DOID:2945",
-            "ORPHANET:140896",
-            "EFO:0000694",
-            "MEDDRA:10061982"
-          ],
-          "id": "MONDO:0005091",
-          "category": "biolink:Disease",
-          "all_names": [
-            "SARS-associated coronavirus",
-            "Acute respiratory coronavirus infection",
-            "severe acute respiratory syndrome",
-            "Severe Acute Respiratory Syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/severe_acute_respiratory_syndrome",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=sars"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 523855,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005091",
-              "name": "severe acute respiratory syndrome",
-              "description": "A viral respiratory infection caused by the SARS coronavirus. It is transmitted through close person-to-person contact. It is manifested with high fever, headache, dry cough and myalgias. It may progress to pneumonia and cause death.; A viral disorder characterized by high FEVER, dry COUGH, shortness of breath (DYSPNEA) or breathing difficulties, and atypical PNEUMONIA. A virus in the genus CORONAVIRUS is the suspected agent.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10061986",
-                "UMLS:C1175175",
-                "NCIT:C85064",
-                "ICD9:079.82",
-                "ICD10:J12.81",
-                "MONDO:0005091",
-                "MEDDRA:10084784",
-                "SNOMEDCT:398447004",
-                "MESH:D045169",
-                "DOID:2945",
-                "ORPHANET:140896",
-                "EFO:0000694",
-                "MEDDRA:10061982"
-              ],
-              "id": "MONDO:0005091",
-              "category": "biolink:Disease",
-              "all_names": [
-                "SARS-associated coronavirus",
-                "Acute respiratory coronavirus infection",
-                "severe acute respiratory syndrome",
-                "Severe Acute Respiratory Syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/severe_acute_respiratory_syndrome",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=sars"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13436331,
-            "start": 569,
-            "end": 523855,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18448259': {'publication date': '2008 Aug', 'sentence': 'Cortisol levels are elevated in patients with RSV and Ebola, and cortisol was higher in SARS patients with lymphopenia before any steroid therapy.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C1175175---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13724762",
-              "object": "MONDO:0005091",
-              "publications": [
-                "PMID:18448259"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 314596,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-          "name": "Insulin resistance",
-          "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "NCIT:C113101",
-            "UMLS:C0021655",
-            "MEDDRA:10022489",
-            "SNOMEDCT:48606007",
-            "MESH:D007333",
-            "EFO:0002614",
-            "HP:0000855",
-            "SNOMEDCT:763325000"
-          ],
-          "id": "HP:0000855",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Insulin resistance",
-            "insulin resistance",
-            "Insulin Resistance"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314596,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-              "name": "Insulin resistance",
-              "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "NCIT:C113101",
-                "UMLS:C0021655",
-                "MEDDRA:10022489",
-                "SNOMEDCT:48606007",
-                "MESH:D007333",
-                "EFO:0002614",
-                "HP:0000855",
-                "SNOMEDCT:763325000"
-              ],
-              "id": "HP:0000855",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Insulin resistance",
-                "insulin resistance",
-                "Insulin Resistance"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13403715,
-            "start": 569,
-            "end": 314596,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18402944': {'publication date': '2009 Mar', 'sentence': 'OBJECTIVE: To investigate possible effects of insulin-sensitizing treatment on cortisol metabolism in insulin-resistant patients with polycystic ovary syndrome (PCOS).', 'subject score': 888, 'object score': 877}, 'PMID:34043794': {'publication date': '2021 May 27', 'sentence': 'Clamping cortisol and testosterone alleviated the development of overall insulin resistance (p=0.046) and hyperinsulinemia (p=0.014) by 50%.', 'subject score': 888, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0021655---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13691671",
-              "object": "HP:0000855",
-              "publications": [
-                "PMID:18402944",
-                "PMID:34043794"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317845,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005068",
-          "name": "myocardial infarction",
-          "description": "Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin. [HPO:probinson]; Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021758",
-            "EFO:0000612",
-            "MEDDRA:10019250",
-            "MEDDRA:10028595",
-            "MONDO:0005068",
-            "SNOMEDCT:22298006",
-            "HP:0001658",
-            "NCIT:C27996",
-            "MEDDRA:10003723",
-            "ICD10:I21",
-            "MEDDRA:10003724",
-            "MESH:D009203",
-            "DOID:5844",
-            "UMLS:C0027051",
-            "MEDDRA:10028596"
-          ],
-          "id": "MONDO:0005068",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myocardial Infarction",
-            "Myocardial infarction",
-            "myocardial infarction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0001-5208-3432",
-            "PMID:17951287",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://en.wikipedia.org/wiki/myocardial_infarction"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317845,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005068",
-              "name": "myocardial infarction",
-              "description": "Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin. [HPO:probinson]; Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021758",
-                "EFO:0000612",
-                "MEDDRA:10019250",
-                "MEDDRA:10028595",
-                "MONDO:0005068",
-                "SNOMEDCT:22298006",
-                "HP:0001658",
-                "NCIT:C27996",
-                "MEDDRA:10003723",
-                "ICD10:I21",
-                "MEDDRA:10003724",
-                "MESH:D009203",
-                "DOID:5844",
-                "UMLS:C0027051",
-                "MEDDRA:10028596"
-              ],
-              "id": "MONDO:0005068",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myocardial Infarction",
-                "Myocardial infarction",
-                "myocardial infarction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0001-5208-3432",
-                "PMID:17951287",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://en.wikipedia.org/wiki/myocardial_infarction"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12608498,
-            "start": 569,
-            "end": 317845,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1717735': {'publication date': '1991 Jun', 'sentence': 'The paper yields the results of the study into the elimination of exogenous cortisol from the blood bed in 26 patients with myocardial infarction.', 'subject score': 888, 'object score': 1000}, 'PMID:21537104': {'publication date': '2011', 'sentence': 'The outcomes under study include morning saliva cortisol, treatment for hypertension, self-reported hypertension, and myocardial infarction.', 'subject score': 851, 'object score': 1000}, 'PMID:24656116': {'publication date': '2014 Jun', 'sentence': 'CONCLUSIONS: A high baseline plasma TC was associated with a trend toward increased mortality in patients with cardiogenic shock post-AMI.', 'subject score': 822, 'object score': 864}, 'PMID:4459728': {'publication date': '1974 Dec', 'sentence': '[Clinical considerations on the use of hydrocortisone in the treatment of myocardial infarct].', 'subject score': 1000, 'object score': 1000}, 'PMID:5096585': {'publication date': '1971', 'sentence': '[Free and transcortin-bound hydrocortisone in patients with myocardial infarct complicated by cardiogenic shock].', 'subject score': 802, 'object score': 1000}, 'PMID:5504121': {'publication date': '1970 Oct', 'sentence': '[Urinary levels of hydrocortisone, cortisone and their metabolites in patients with myocardial infarct in the acute period of the disease].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0027051---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "12881395",
-              "object": "MONDO:0005068",
-              "publications": [
-                "PMID:1717735",
-                "PMID:21537104",
-                "PMID:24656116",
-                "PMID:4459728",
-                "PMID:5096585",
-                "PMID:5504121"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12257628,
-            "start": 569,
-            "end": 319673,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16740975': {'publication date': '2006 Sep', 'sentence': 'Retinoic acid treatment controls ACTH and cortisol hyperactivity and tumor size in dogs with ACTH-secreting tumors, leading to resolution of the clinical phenotype.', 'subject score': 888, 'object score': 802}, 'PMID:2417679': {'publication date': '1986 Feb 01', 'sentence': 'Extracts of tumors from control animals as well as from animals treated with HHS plus HC were prepared for quantitative testing in vitro by endothelial cell migration assay.', 'subject score': 875, 'object score': 1000}, 'PMID:2548970': {'publication date': '1989 May-Jun', 'sentence': 'We investigated plasma levels of cortisol and ACTH in 9 patients with advanced metastatic tumors before and during treatment with interferon-gamma (IFN-gamma), 2-4 h after administration of IFN-gamma there was a sharp rise in plasma cortisol levels.', 'subject score': 1000, 'object score': 827}, 'PMID:2773484': {'publication date': '1989 Jul 14', 'sentence': 'On the basis of approximately 3000 assays of HGH, prolactin, thyroglobulin, calcitonin, CEA, insulin, gastrin, cortisol and aldosterone (in part with suppression and/or stimulation techniques), it is shown that these mostly indirect tumour marker assays are very important in follow-up programmes after therapy of neoplasms of the endocrine system.', 'subject score': 1000, 'object score': 1000}, 'PMID:32686618': {'publication date': '2020 Jul 19', 'sentence': 'Effect of hydrocortisone versus methylprednisolone on clinical outcomes in oncology patients with septic shock.BACKGROUND: Corticosteroids are used as adjunctive treatment of critical illness-related corticosteroid insufficiency in patients with septic shock.', 'subject score': 1000, 'object score': 888}, 'PMID:468890': {'publication date': '1979 Apr 12', 'sentence': 'The first detectable increase of cortisol occurred in patients with tumors classified T 2 according to the TNM scheme (+27% above the control).', 'subject score': 1000, 'object score': 1000}, 'PMID:6405459': {'publication date': '1983', 'sentence': 'In the type III lactating tumors, the total tRNA methyltransferases were inhibited by 35% after cortisol treatment.', 'subject score': 888, 'object score': 852}, 'PMID:6931263': {'publication date': '1980 Aug', 'sentence': 'These data indicate that tumors of lymphosarcoma P1798 became resistant to cortisol in a size-dependent manner.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "12524121",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:16740975",
-                "PMID:2417679",
-                "PMID:2548970",
-                "PMID:2773484",
-                "PMID:32686618",
-                "PMID:468890",
-                "PMID:6405459",
-                "PMID:6931263"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11710389,
-            "start": 569,
-            "end": 546804,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16055307': {'publication date': '2005 Nov 15', 'sentence': 'Diurnal cortisol in schizophrenia patients with childhood trauma.', 'subject score': 888, 'object score': 888}, 'PMID:16352953': {'publication date': '2005 Dec', 'sentence': 'OBJECTIVE: To assess the pressor response to phenylephrine infusion before and after hydrocortisone in severe trauma patients and to correlate this response with their adrenal reserve.', 'subject score': 1000, 'object score': 851}, 'PMID:17296270': {'publication date': '2007 Apr', 'sentence': 'Salivary cortisol, plasma cortisol and ACTH suppression as well as CBG levels did not differ between PTSD patients and trauma controls.', 'subject score': 888, 'object score': 872}, 'PMID:22777514': {'publication date': '2012 Oct', 'sentence': 'METHODS: This was a sub-study of the HYPOLYTE multi-centre, randomized, double-blind, placebo-controlled trial of hydrocortisone in trauma patients (NCT00563303).', 'subject score': 1000, 'object score': 888}, 'PMID:23126006': {'publication date': '2012 Sep', 'sentence': '[Effects of hydrocortisone in trauma patients].', 'subject score': 1000, 'object score': 888}, 'PMID:25808607': {'publication date': '2017 08', 'sentence': 'METHODS: Early trauma and current perceived stress were assessed in 28 treated schizophrenia cases, along with salivary cortisol, brain volumes, cognition and symptoms.', 'subject score': 888, 'object score': 888}, 'PMID:4002110': {'publication date': '1985 Jun', 'sentence': 'Plasma beta-endorphin, cortisol and total opioid-like activities were measured upon arrival at the hospital in ten patients with extensive trauma and in a state of shock and 11 patients with minor injury.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0043251---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "11965490",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:16055307",
-                "PMID:16352953",
-                "PMID:17296270",
-                "PMID:22777514",
-                "PMID:23126006",
-                "PMID:25808607",
-                "PMID:4002110"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 308745,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005328",
-          "name": "eye disorder",
-          "description": "Diseases or defects of the eye. Use VISION DISORDERS for other pathology involving visual neural pathways.; A non-neoplastic or neoplastic disorder that affects the eye. Representative examples include conjunctivitis, glaucoma, cataract, conjunctival squamous cell carcinoma, uveal melanoma, and retinoblastoma.; Diseases affecting the eye.; Any abnormality of the eye, including location, spacing, and intraocular abnormalities. [HPO:probinson]; Some eye problems are minor and don't last long. But some can lead to a permanent loss of vision. Common eye problems include: Refractive errors Cataracts - clouded lenses Optic nerve disorders, including glaucoma Retinal disorders - problems with the nerve layer at the back of the eye Macular degeneration - a disease that destroys sharp, central vision Diabetic eye problems Conjunctivitis - an infection also known as pink eye  Your best defense is to have regular checkups, because eye diseases do not always have symptoms. Early detection and treatment could prevent vision loss. See an eye care professional right away if you have a sudden change in vision, if everything looks dim, or if you see flashes of light. Other symptoms that need quick attention are pain, double vision, fluid coming from the eye, and inflammation. NIH: National Eye Institute ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0015397",
-            "NCIT:C26767",
-            "MEDDRA:10045783",
-            "MEDDRA:10013221",
-            "MEDDRA:10015919",
-            "MEDDRA:10054716",
-            "ICD9:360.29",
-            "MESH:D005128",
-            "EFO:0003966",
-            "MEDDRA:10015916",
-            "MEDDRA:10059159",
-            "UMLS:C0015393",
-            "ICD10:H44",
-            "MEDDRA:10045790",
-            "HP:0000478",
-            "SNOMEDCT:19416009",
-            "MEDDRA:10015913",
-            "MEDDRA:10030874",
-            "NCIT:C98887",
-            "MEDDRA:10010435",
-            "MEDDRA:10010462",
-            "MEDDRA:10015949",
-            "UMLS:C4316870",
-            "MEDDRA:10015904",
-            "MESH:D005124",
-            "MEDDRA:10015920",
-            "MEDDRA:10015903",
-            "MEDDRA:10015918",
-            "MONDO:0005328",
-            "SNOMEDCT:371405004",
-            "ICD9:379.90",
-            "DOID:5614",
-            "UMLS:C0154780",
-            "DOID:1242",
-            "MEDDRA:10045628",
-            "ICD10:H44.39"
-          ],
-          "id": "MONDO:0005328",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Disorder of eye, unspecified",
-            "Eye Abnormalities",
-            "Other degenerative disorders of globe",
-            "eye disease",
-            "Congenital Eye Disorder",
-            "globe disease",
-            "Disorder of eye",
-            "Abnormality of the eye",
-            "eye disorder",
-            "Eye Diseases",
-            "Eye Disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/eye_disease",
-            "https://en.wikipedia.org/wiki/globe_(human_eye)",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-5316-1399"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308745,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005328",
-              "name": "eye disorder",
-              "description": "Diseases or defects of the eye. Use VISION DISORDERS for other pathology involving visual neural pathways.; A non-neoplastic or neoplastic disorder that affects the eye. Representative examples include conjunctivitis, glaucoma, cataract, conjunctival squamous cell carcinoma, uveal melanoma, and retinoblastoma.; Diseases affecting the eye.; Any abnormality of the eye, including location, spacing, and intraocular abnormalities. [HPO:probinson]; Some eye problems are minor and don't last long. But some can lead to a permanent loss of vision. Common eye problems include: Refractive errors Cataracts - clouded lenses Optic nerve disorders, including glaucoma Retinal disorders - problems with the nerve layer at the back of the eye Macular degeneration - a disease that destroys sharp, central vision Diabetic eye problems Conjunctivitis - an infection also known as pink eye  Your best defense is to have regular checkups, because eye diseases do not always have symptoms. Early detection and treatment could prevent vision loss. See an eye care professional right away if you have a sudden change in vision, if everything looks dim, or if you see flashes of light. Other symptoms that need quick attention are pain, double vision, fluid coming from the eye, and inflammation. NIH: National Eye Institute ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0015397",
-                "NCIT:C26767",
-                "MEDDRA:10045783",
-                "MEDDRA:10013221",
-                "MEDDRA:10015919",
-                "MEDDRA:10054716",
-                "ICD9:360.29",
-                "MESH:D005128",
-                "EFO:0003966",
-                "MEDDRA:10015916",
-                "MEDDRA:10059159",
-                "UMLS:C0015393",
-                "ICD10:H44",
-                "MEDDRA:10045790",
-                "HP:0000478",
-                "SNOMEDCT:19416009",
-                "MEDDRA:10015913",
-                "MEDDRA:10030874",
-                "NCIT:C98887",
-                "MEDDRA:10010435",
-                "MEDDRA:10010462",
-                "MEDDRA:10015949",
-                "UMLS:C4316870",
-                "MEDDRA:10015904",
-                "MESH:D005124",
-                "MEDDRA:10015920",
-                "MEDDRA:10015903",
-                "MEDDRA:10015918",
-                "MONDO:0005328",
-                "SNOMEDCT:371405004",
-                "ICD9:379.90",
-                "DOID:5614",
-                "UMLS:C0154780",
-                "DOID:1242",
-                "MEDDRA:10045628",
-                "ICD10:H44.39"
-              ],
-              "id": "MONDO:0005328",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Disorder of eye, unspecified",
-                "Eye Abnormalities",
-                "Other degenerative disorders of globe",
-                "eye disease",
-                "Congenital Eye Disorder",
-                "globe disease",
-                "Disorder of eye",
-                "Abnormality of the eye",
-                "eye disorder",
-                "Eye Diseases",
-                "Eye Disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/eye_disease",
-                "https://en.wikipedia.org/wiki/globe_(human_eye)",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-5316-1399"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10793554,
-            "start": 569,
-            "end": 308745,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14933543': {'publication date': '1952 Jul', 'sentence': 'Topical compound F in the treatment of anterior segment eye disease; a preliminary report.', 'subject score': 901, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0015397---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "11029944",
-              "object": "MONDO:0005328",
-              "publications": [
-                "PMID:14933543"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10291551,
-            "start": 569,
-            "end": 322104,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13374319': {'publication date': '1956 Dec 01', 'sentence': 'Treatment of ulcerative colitis with local hydrocortisone.', 'subject score': 888, 'object score': 1000}, 'PMID:13402775': {'publication date': '1957 Feb', 'sentence': 'The use of ACTH, cortisone, hydrocortisone and related compounds in the management of ulcerative colitis; experience in 180 patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:13474175': {'publication date': '1957 Sep', 'sentence': 'The longterm treatment of ulcerative colitis with hydrocortisone, prednisone and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:13567689': {'publication date': '1958 Jun', 'sentence': 'Treatment of ulcerative colitis with local hydrocortisone.', 'subject score': 888, 'object score': 1000}, 'PMID:13669781': {'publication date': '1959 Aug', 'sentence': 'Rectal cortisol in the therapy of ulcerative colitis.', 'subject score': 888, 'object score': 1000}, 'PMID:13689058': {'publication date': '1960 Nov', 'sentence': '[Local application of hydrocortisone in the treatment of ulcerative colitis].', 'subject score': 1000, 'object score': 1000}, 'PMID:13713786': {'publication date': '1961 Jun', 'sentence': 'Rectal hydrocortisone for ulcerative colitis refractory to oral corticosteroids.', 'subject score': 888, 'object score': 1000}, 'PMID:13963047': {'publication date': '1962 Oct 26', 'sentence': '[Ulcerative colitis and proctosigmoiditis treated locally with hydrocortisone].', 'subject score': 1000, 'object score': 1000}, 'PMID:15507500': {'publication date': '2004 Dec', 'sentence': 'CASE SUMMARY: A 28-year-old man previously diagnosed with ulcerative colitis was admitted to the internal medicine department due to exacerbation of the condition and treated with intravenous hydrocortisone, followed by treatment with intravenous cyclosporine.', 'subject score': 888, 'object score': 1000}, 'PMID:1790809': {'publication date': '1991', 'sentence': \"Patients with nonspecific ulcerative colitis and Crohn's disease were treated with drug therapy (prednisolone, sulphasalazine, metronidazole per os and hydrocortisone per rectum) and subjected to 12 sessions of HBO.\", 'subject score': 901, 'object score': 901}, 'PMID:18442203': {'publication date': '2008 Apr 28', 'sentence': 'RESULTS: Fifteen patients were included, 7 with UC unresponsive or intolerant to i.v. hydrocortisone, and 8 with active disease despite oral steroids (all but one with therapeutic dosage and duration of immunomodulation).', 'subject score': 827, 'object score': 1000}, 'PMID:19005257': {'publication date': '2008', 'sentence': 'METHODS: 10 severe ulcerative colitis patients refractory to intravenous hydrocortisone administered for at least 7 days and candidate for colectomy were selected to receive a single infusion of infliximab (5 mg/kg).', 'subject score': 888, 'object score': 798}, 'PMID:3031150': {'publication date': '1987 Feb', 'sentence': 'We looked for factors predicting the therapeutic outcome in 66 patients with severe ulcerative colitis treated with intravenous hydrocortisone or corticotropin (ACTH) for 10 days.', 'subject score': 888, 'object score': 901}, 'PMID:6305758': {'publication date': '1983 Aug', 'sentence': 'Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7733079': {'publication date': '1995 May', 'sentence': 'Low Pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative colitis: a randomized, double-blind study.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10518308",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:13374319",
-                "PMID:13402775",
-                "PMID:13474175",
-                "PMID:13567689",
-                "PMID:13669781",
-                "PMID:13689058",
-                "PMID:13713786",
-                "PMID:13963047",
-                "PMID:15507500",
-                "PMID:1790809",
-                "PMID:18442203",
-                "PMID:19005257",
-                "PMID:3031150",
-                "PMID:6305758",
-                "PMID:7733079"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320422,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000687",
-          "name": "diffuse alopecia areata",
-          "description": "Transient, non-scarring hair loss and preservation of the hair follicle located in in well-defined patches. []; Transient, non-scarring hair loss and preservation of the hair follicle located in in well-defined patches.; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "SNOMEDCT:201138007",
-            "MESH:C531609",
-            "SNOMEDCT:68225006",
-            "DOID:0060157",
-            "UMLS:C0002171",
-            "HP:0002232",
-            "UMLS:C0406458",
-            "MEDDRA:10001761",
-            "SNOMEDCT:46586006",
-            "UMLS:C0263479",
-            "MEDDRA:10073736",
-            "MONDO:0000687",
-            "UMLS:C1862862",
-            "MESH:D000506"
-          ],
-          "id": "MONDO:0000687",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Diffuse alopecia",
-            "Alopecia Areata",
-            "diffuse alopecia areata",
-            "Patchy alopecia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/alopecia_areata"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320422,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000687",
-              "name": "diffuse alopecia areata",
-              "description": "Transient, non-scarring hair loss and preservation of the hair follicle located in in well-defined patches. []; Transient, non-scarring hair loss and preservation of the hair follicle located in in well-defined patches.; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "SNOMEDCT:201138007",
-                "MESH:C531609",
-                "SNOMEDCT:68225006",
-                "DOID:0060157",
-                "UMLS:C0002171",
-                "HP:0002232",
-                "UMLS:C0406458",
-                "MEDDRA:10001761",
-                "SNOMEDCT:46586006",
-                "UMLS:C0263479",
-                "MEDDRA:10073736",
-                "MONDO:0000687",
-                "UMLS:C1862862",
-                "MESH:D000506"
-              ],
-              "id": "MONDO:0000687",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Diffuse alopecia",
-                "Alopecia Areata",
-                "diffuse alopecia areata",
-                "Patchy alopecia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/alopecia_areata"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10290270,
-            "start": 569,
-            "end": 320422,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13368875': {'publication date': '1956 Oct', 'sentence': 'Alopecia areata, partialis, and totalis; treatment with cortisone, hydrocortisone and their analogs, prednisone and prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0002171---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10516843",
-              "object": "MONDO:0000687",
-              "publications": [
-                "PMID:13368875"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319030,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319030,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10264547,
-            "start": 569,
-            "end": 319030,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13276616': {'publication date': '1956 Jan', 'sentence': 'Phenylbutazone and compound F for osteoarthritis of the hip; a survey and clinical report.', 'subject score': 1000, 'object score': 1000}, 'PMID:13524937': {'publication date': '1958 May', 'sentence': 'Hydrocortisone ionization; a study to determine the effects of a new method of utilizing hydrocortisone in the treatment of rheumatoid and osteoarthritis.', 'subject score': 861, 'object score': 1000}, 'PMID:13649406': {'publication date': '1959', 'sentence': 'The effect of intra-articular hydrocortisone therapy upon the joint temperature in osteoarthritis and rheumatoid arthritis.', 'subject score': 861, 'object score': 1000}, 'PMID:20525314': {'publication date': '2010', 'sentence': 'Cortisol inhibited HNP1-3 levels only in OA patients.', 'subject score': 1000, 'object score': 888}, 'PMID:37072059': {'publication date': '2023 Apr 16', 'sentence': 'Ultrasound-responsive hyaluronic acid hydrogel of hydrocortisone to treat osteoarthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:5669141': {'publication date': '1968 Apr 08', 'sentence': '[Results of hydrocortisone injections into small joints in rheumatoid arthritis and osteoarthritis].', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10492262",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:13276616",
-                "PMID:13524937",
-                "PMID:13649406",
-                "PMID:20525314",
-                "PMID:37072059",
-                "PMID:5669141"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 325169,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005642",
-          "name": "atopic conjunctivitis",
-          "description": "A chronic conjunctivitis that is an inflammation of the conjunctiva involing red, itchy, and watery eyes a resulting from an exposure to an allergen or an irritant.",
-          "equivalent_curies": [
-            "MONDO:0005642",
-            "UMLS:C0009766",
-            "MEDDRA:10010744",
-            "EFO:0007141",
-            "MEDDRA:10080573",
-            "SNOMEDCT:231854006",
-            "NCIT:C34506",
-            "MEDDRA:10001709",
-            "MESH:D003233",
-            "HP:0007879",
-            "DOID:11204",
-            "SNOMEDCT:473460002"
-          ],
-          "id": "MONDO:0005642",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Allergic conjunctivitis",
-            "Allergic Conjunctivitis",
-            "Conjunctivitis, Allergic",
-            "allergic conjunctivitis",
-            "atopic conjunctivitis",
-            "Atopic Conjunctivitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/allergic_conjunctivitis",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 325169,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005642",
-              "name": "atopic conjunctivitis",
-              "description": "A chronic conjunctivitis that is an inflammation of the conjunctiva involing red, itchy, and watery eyes a resulting from an exposure to an allergen or an irritant.",
-              "equivalent_curies": [
-                "MONDO:0005642",
-                "UMLS:C0009766",
-                "MEDDRA:10010744",
-                "EFO:0007141",
-                "MEDDRA:10080573",
-                "SNOMEDCT:231854006",
-                "NCIT:C34506",
-                "MEDDRA:10001709",
-                "MESH:D003233",
-                "HP:0007879",
-                "DOID:11204",
-                "SNOMEDCT:473460002"
-              ],
-              "id": "MONDO:0005642",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Allergic conjunctivitis",
-                "Allergic Conjunctivitis",
-                "Conjunctivitis, Allergic",
-                "allergic conjunctivitis",
-                "atopic conjunctivitis",
-                "Atopic Conjunctivitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/allergic_conjunctivitis",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10254325,
-            "start": 569,
-            "end": 325169,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13234340': {'publication date': '1955 Jan 29', 'sentence': 'Hydrocortisone in treatment of allergic conjunctivitis, allergic rhinitis, and bronchial asthma.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0009766---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10480635",
-              "object": "MONDO:0005642",
-              "publications": [
-                "PMID:13234340"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318348,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005105",
-          "name": "melanoma",
-          "description": "A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.; A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445); The presence of a melanoma, a malignant cancer originating from pigment producing melanocytes. Melanoma can originate from the skin or the pigmented layers of the eye (the uvea). [HPO:probinson]; Melanoma is the most serious type of skin cancer. Often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. Most melanomas have a black or black-blue area. Melanoma may also appear as a new mole. It may be black, abnormal, or \"ugly looking.\" Thinking of \"ABCDE\" can help you remember what to watch for:   Asymmetry - the shape of one half does not match the other  Border - the edges are ragged, blurred or irregular  Color - the color is uneven and may include shades of black, brown and tan  Diameter - there is a change in size, usually an increase Evolving - the mole has changed over the past few weeks or months  Surgery is the first treatment of all stages of melanoma. Other treatments include chemotherapy and radiation, biologic, and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "UMLS:C0025202",
-            "EFO:0000756",
-            "PDQ:CDR0000038833",
-            "NCIT:C3224",
-            "SNOMEDCT:372244006",
-            "MEDDRA:10053571",
-            "HP:0002861",
-            "MEDDRA:10025650",
-            "UMLS:CN971653",
-            "MONDO:0005105",
-            "MESH:D008545",
-            "ORPHANET:411533",
-            "MEDDRA:10027150",
-            "SNOMEDCT:1162635006",
-            "KEGG.DISEASE:05218",
-            "DOID:1909"
-          ],
-          "id": "MONDO:0005105",
-          "category": "biolink:Disease",
-          "all_names": [
-            "melanoma",
-            "Melanoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/melanoma",
-            "PMID:22123420",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318348,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005105",
-              "name": "melanoma",
-              "description": "A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.; A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445); The presence of a melanoma, a malignant cancer originating from pigment producing melanocytes. Melanoma can originate from the skin or the pigmented layers of the eye (the uvea). [HPO:probinson]; Melanoma is the most serious type of skin cancer. Often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. Most melanomas have a black or black-blue area. Melanoma may also appear as a new mole. It may be black, abnormal, or \"ugly looking.\" Thinking of \"ABCDE\" can help you remember what to watch for:   Asymmetry - the shape of one half does not match the other  Border - the edges are ragged, blurred or irregular  Color - the color is uneven and may include shades of black, brown and tan  Diameter - there is a change in size, usually an increase Evolving - the mole has changed over the past few weeks or months  Surgery is the first treatment of all stages of melanoma. Other treatments include chemotherapy and radiation, biologic, and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "UMLS:C0025202",
-                "EFO:0000756",
-                "PDQ:CDR0000038833",
-                "NCIT:C3224",
-                "SNOMEDCT:372244006",
-                "MEDDRA:10053571",
-                "HP:0002861",
-                "MEDDRA:10025650",
-                "UMLS:CN971653",
-                "MONDO:0005105",
-                "MESH:D008545",
-                "ORPHANET:411533",
-                "MEDDRA:10027150",
-                "SNOMEDCT:1162635006",
-                "KEGG.DISEASE:05218",
-                "DOID:1909"
-              ],
-              "id": "MONDO:0005105",
-              "category": "biolink:Disease",
-              "all_names": [
-                "melanoma",
-                "Melanoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/melanoma",
-                "PMID:22123420",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10057979,
-            "start": 569,
-            "end": 318348,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12832253': {'publication date': '2003 Jul', 'sentence': 'METHOD: Adrenocorticotropic hormone (ACTH), cortisol, and interleukin-6 (IL-6) plasma concentrations were measured in 14 patients with malignant melanoma at regular intervals during the first 12 weeks of IFN-alpha therapy, both immediately before and 1, 2, and 3 hours after IFN-alpha administration.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0025202---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10280121",
-              "object": "MONDO:0005105",
-              "publications": [
-                "PMID:12832253"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 313237,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
-          "name": "atopic eczema",
-          "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SYMP:0000289",
-            "EFO:0000274",
-            "DOID:3310",
-            "HP:0000964",
-            "NCIT:C3001",
-            "UMLS:C0013595",
-            "MESH:D004485",
-            "MEDDRA:10014200",
-            "MEDDRA:10014206",
-            "MEDDRA:10012454",
-            "ICD10:L20",
-            "MEDDRA:10014184",
-            "OMIM.PS:603165",
-            "MEDDRA:10014209",
-            "PSY:15950",
-            "MONDO:0004980",
-            "OMIM:PS603165"
-          ],
-          "id": "MONDO:0004980",
-          "category": "biolink:Disease",
-          "all_names": [
-            "atopic dermatitis",
-            "atopic eczema",
-            "eczema",
-            "Eczema"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/atopic_dermatitis",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313237,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
-              "name": "atopic eczema",
-              "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SYMP:0000289",
-                "EFO:0000274",
-                "DOID:3310",
-                "HP:0000964",
-                "NCIT:C3001",
-                "UMLS:C0013595",
-                "MESH:D004485",
-                "MEDDRA:10014200",
-                "MEDDRA:10014206",
-                "MEDDRA:10012454",
-                "ICD10:L20",
-                "MEDDRA:10014184",
-                "OMIM.PS:603165",
-                "MEDDRA:10014209",
-                "PSY:15950",
-                "MONDO:0004980",
-                "OMIM:PS603165"
-              ],
-              "id": "MONDO:0004980",
-              "category": "biolink:Disease",
-              "all_names": [
-                "atopic dermatitis",
-                "atopic eczema",
-                "eczema",
-                "Eczema"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/atopic_dermatitis",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10000196,
-            "start": 569,
-            "end": 313237,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12775314': {'publication date': '2003 Jun', 'sentence': 'These data show clobetasone butyrate 0.05% is more effective than 1.0% hydrocortisone in the treatment of eczema and more effective than flurandrenolone 0.0125% (p=0.01%) and a potent topical steroid hydrocortisone butyrate (p<0.05), in the treatment of psoriasis.', 'subject score': 827, 'object score': 1000}, 'PMID:13676318': {'publication date': '1959 Aug', 'sentence': 'Aureomycin, chloramphenicol and hydrocortisone in ointments and pastes as a treatment for eczema.', 'subject score': 1000, 'object score': 1000}, 'PMID:29244413': {'publication date': '1965 Jan-Feb', 'sentence': 'The Management of Pyodermas and Eczematous Dermatoses with Varied Combinations of Neomycin, Bacitracin, Sulphacetamide and Hydrocortisone in an Ointment Base.', 'subject score': 1000, 'object score': 853}, 'PMID:6244198': {'publication date': '1980', 'sentence': 'Study of the effects of hydrocortisone and hydrocortisone 17-butyrate ointments on plasma ACTH levels and Synacthen responses in children with eczema.', 'subject score': 1000, 'object score': 1000}, 'PMID:82309': {'publication date': '1978 Nov 01', 'sentence': 'Administering sexual hormons the physician takes advantage of the sebosuppressive effect of female sexual hormons as he does of the antiallergic activity of the hormon cortisol (and related compounds) in the treatment of eczemas.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0013595---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10221382",
-              "object": "MONDO:0004980",
-              "publications": [
-                "PMID:12775314",
-                "PMID:13676318",
-                "PMID:29244413",
-                "PMID:6244198",
-                "PMID:82309"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9756082,
-            "start": 569,
-            "end": 321523,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12524982': {'publication date': '2002', 'sentence': 'The use of extracorporeal immunopharmacotherapy with diucifon in 53 patients and the retrosternal injection of isoniazid in combination with hydrocortisone in 43 patients have shown their efficiencies in the treatment of patients with caseous pneumonia.', 'subject score': 1000, 'object score': 861}, 'PMID:15557131': {'publication date': '2005 Feb 01', 'sentence': 'Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study.', 'subject score': 888, 'object score': 833}, 'PMID:15719662': {'publication date': '2004', 'sentence': 'The use of extracorporeal immune pharmacotherapy with diucifon in 53 patients and the retrosternal administration of isoniazid with hydrocortisone in 43 patients showed the efficiency of these methods in the treatment of patients with caseous pneumonia.', 'subject score': 1000, 'object score': 861}, 'PMID:16148196': {'publication date': '2005 Sep 15', 'sentence': 'Hydrocortisone infusion for severe community-acquired pneumonia: the role of relative adrenal insufficiency.', 'subject score': 888, 'object score': 833}, 'PMID:30029205': {'publication date': '2018 Oct', 'sentence': 'PURPOSE: To evaluate the efficacy of combined vitamin C, hydrocortisone, and thiamine in patients with severe pneumonia.', 'subject score': 1000, 'object score': 888}, 'PMID:32513653': {'publication date': '2020 Jun 08', 'sentence': 'As per BSG guidance, intravenous hydrocortisone was considered appropriate as initial management; only in patients with COVID-19 pneumonia was its use deemed uncertain.', 'subject score': 888, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9971730",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:12524982",
-                "PMID:15557131",
-                "PMID:15719662",
-                "PMID:16148196",
-                "PMID:30029205",
-                "PMID:32513653"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319116,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008315",
-          "name": "prostate cancer",
-          "description": "A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.; Tumors or cancer of the PROSTATE.; A cancer of the prostate. [HPO:probinson]; What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it:  Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to:  Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer.    What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include:  Problems urinating (peeing), such as:  A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen   Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm)  But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you:  Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer  What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include:  A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate.  If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options:  Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation:  Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer.   Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer.  Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include:  Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0008315",
-            "ICD10:C61",
-            "MEDDRA:10026389",
-            "MEDDRA:10007113",
-            "DOID:10283",
-            "MEDDRA:10036908",
-            "UMLS:C0376358",
-            "SNOMEDCT:399068003",
-            "ICD9:185",
-            "PDQ:CDR0000038782",
-            "MEDDRA:10036910",
-            "MEDDRA:10036946",
-            "KEGG.DISEASE:05215",
-            "NCIT:C7378",
-            "MESH:D011471",
-            "HP:0012125",
-            "MEDDRA:10060862"
-          ],
-          "id": "MONDO:0008315",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Malignant Prostate Neoplasm",
-            "prostate cancer",
-            "Prostate cancer",
-            "Prostatic Neoplasms",
-            "Malignant neoplasm of prostate"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=445079",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319116,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008315",
-              "name": "prostate cancer",
-              "description": "A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.; Tumors or cancer of the PROSTATE.; A cancer of the prostate. [HPO:probinson]; What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it:  Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to:  Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer.    What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include:  Problems urinating (peeing), such as:  A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen   Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm)  But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you:  Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer  What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include:  A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate.  If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options:  Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation:  Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer.   Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer.  Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include:  Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0008315",
-                "ICD10:C61",
-                "MEDDRA:10026389",
-                "MEDDRA:10007113",
-                "DOID:10283",
-                "MEDDRA:10036908",
-                "UMLS:C0376358",
-                "SNOMEDCT:399068003",
-                "ICD9:185",
-                "PDQ:CDR0000038782",
-                "MEDDRA:10036910",
-                "MEDDRA:10036946",
-                "KEGG.DISEASE:05215",
-                "NCIT:C7378",
-                "MESH:D011471",
-                "HP:0012125",
-                "MEDDRA:10060862"
-              ],
-              "id": "MONDO:0008315",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Malignant Prostate Neoplasm",
-                "prostate cancer",
-                "Prostate cancer",
-                "Prostatic Neoplasms",
-                "Malignant neoplasm of prostate"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=445079",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9456491,
-            "start": 569,
-            "end": 319116,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12131305': {'publication date': '2002 Aug', 'sentence': 'Therefore, a prospective phase II study was conducted to assess the efficacy and safety of a regimen of low dose (200 mg.) oral ketoconazole 3 times daily with replacement doses of hydrocortisone in men with androgen independent prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:1384013': {'publication date': '1992', 'sentence': 'Natural killer (NK) cell activity was studied together with tumor marker serotests (PSA, PAP) and blood testosterone, estradiol, cortisol, and prolactin concentrations in treated prostate cancer patients.', 'subject score': 1000, 'object score': 850}, 'PMID:14598689': {'publication date': '2003 Sep', 'sentence': 'We measured serum concentrations of testosterone (T), 4-androstene-3, 17-dione (A-dione), dehydroepiandrosterone (DHEA), LH, follicle-stimulating hormone (FSH), adrenocorticotropic hormone (ACTH) and cortisol before and after 3-12 months of the first hormonal treatment in 17 prostatic cancer patients who had received ORX (8 cases) or LHRH (9 cases).', 'subject score': 1000, 'object score': 824}, 'PMID:15879788': {'publication date': '2005 Jun', 'sentence': 'Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.', 'subject score': 1000, 'object score': 861}, 'PMID:20029646': {'publication date': '2009', 'sentence': 'A 59-year-old man treated with warfarin for aortic valve replacement was prescribed high-dose ketoconazole and hydrocortisone for the treatment of prostate cancer.', 'subject score': 1000, 'object score': 1000}, 'PMID:2161578': {'publication date': '1990', 'sentence': \"Basal serum levels and ACTH-induced increments ('delta-values') of dehydroepiandrosterone (DHA) and its sulfate (DHAS), 4-androstene-3,17-dione (A-4), 17 alpha-hydroxyprogesterone (17-OHP), cortisol and testosterone and serum albumin levels were studied in patients with prostatic cancer before treatment and after orchidectomy or during estrogen treatment (intramuscular polyestradiol phosphate during the first 3 months, followed by another 3 months with additional oral ethinyl estradiol).\", 'subject score': 1000, 'object score': 1000}, 'PMID:2734983': {'publication date': '1989', 'sentence': 'Serum levels of testosterone (T), 17 alpha-hydroxyprogesterone (17OHP), 4-androstene-3,17-dione (A-4), dehydroepiandrosterone (DHA), dehydroepiandrosterone sulfate (DHAS) and cortisol were measured before and after 6 months of treatment in prostatic cancer patients treated by orchidectomy (ORX) or with oral + parenteral estrogens (OE), single parenteral estrogens (PE; 160 or 320 mg polyestradiol phosphate i.m. every fourth week), estramustine phosphate (ECYT) or LHRH agonist without (LHRH) or with (LHRH-F) flutamide.', 'subject score': 1000, 'object score': 901}, 'PMID:2752257': {'publication date': '1989 Jun', 'sentence': 'The effect of further adrenal androgen blockade with aminoglutethimide (AG) plus low dose hydrocortisone (HC) was studied in 119 patients with clinical stage D2 prostate cancer who previously progressed after standard hormone therapy and were under progression while receiving the combination therapy with Flutamide and castration.', 'subject score': 901, 'object score': 857}, 'PMID:2958420': {'publication date': '1987 Aug', 'sentence': 'Peripheral serum levels of dehydroepiandrosterone (DHA) and its sulphate (DHAS), 4-androstene-3, 17-dione (A-4), 17 alpha-hydroxyprogesterone (17-OHP), cortisol and albumin were measured in patients with prostatic cancer before treatment and after orchidectomy or during combined oral and intramuscular oestrogen treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:29696999': {'publication date': '2018 Apr 01', 'sentence': 'Sexual well-being and diurnal cortisol after prostate cancer treatment.', 'subject score': 888, 'object score': 901}, 'PMID:7545218': {'publication date': '1995 Sep', 'sentence': 'Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:7666079': {'publication date': '1995 Sep', 'sentence': 'PURPOSE: The combination of suramin and hydrocortisone has shown clinical benefit in patients with androgen-independent prostate cancer.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0376358---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9665107",
-              "object": "MONDO:0008315",
-              "publications": [
-                "PMID:12131305",
-                "PMID:1384013",
-                "PMID:14598689",
-                "PMID:15879788",
-                "PMID:20029646",
-                "PMID:2161578",
-                "PMID:2734983",
-                "PMID:2752257",
-                "PMID:2958420",
-                "PMID:29696999",
-                "PMID:7545218",
-                "PMID:7666079"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 312686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-          "name": "adrenocortical insufficiency",
-          "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0405580",
-            "MEDDRA:10022460",
-            "ICD9:255.4",
-            "EFO:0009491",
-            "MEDDRA:10001367",
-            "MEDDRA:10020936",
-            "MONDO:0000004",
-            "MEDDRA:10020979",
-            "SNOMEDCT:237785004",
-            "SNOMEDCT:386584007",
-            "MEDDRA:10056485",
-            "MEDDRA:10082130",
-            "UMLS:C0001623",
-            "MEDDRA:10001344",
-            "MEDDRA:10001366",
-            "MEDDRA:10001334",
-            "DOID:10493",
-            "NCIT:C26691",
-            "HP:0000846",
-            "MEDDRA:10001335",
-            "MEDDRA:10001369",
-            "MEDDRA:10001342",
-            "MEDDRA:10001343",
-            "MESH:D000309",
-            "SNOMEDCT:111563005",
-            "MEDDRA:10011172",
-            "MEDDRA:10022461"
-          ],
-          "id": "MONDO:0000004",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortical hypofunction",
-            "Adrenocortical Insufficiency",
-            "adrenocortical insufficiency",
-            "Corticoadrenal insufficiency",
-            "Adrenal gland hypofunction",
-            "Adrenal Insufficiency",
-            "Adrenal insufficiency",
-            "Adrenal cortical hypofunction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:11443143"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-              "name": "adrenocortical insufficiency",
-              "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0405580",
-                "MEDDRA:10022460",
-                "ICD9:255.4",
-                "EFO:0009491",
-                "MEDDRA:10001367",
-                "MEDDRA:10020936",
-                "MONDO:0000004",
-                "MEDDRA:10020979",
-                "SNOMEDCT:237785004",
-                "SNOMEDCT:386584007",
-                "MEDDRA:10056485",
-                "MEDDRA:10082130",
-                "UMLS:C0001623",
-                "MEDDRA:10001344",
-                "MEDDRA:10001366",
-                "MEDDRA:10001334",
-                "DOID:10493",
-                "NCIT:C26691",
-                "HP:0000846",
-                "MEDDRA:10001335",
-                "MEDDRA:10001369",
-                "MEDDRA:10001342",
-                "MEDDRA:10001343",
-                "MESH:D000309",
-                "SNOMEDCT:111563005",
-                "MEDDRA:10011172",
-                "MEDDRA:10022461"
-              ],
-              "id": "MONDO:0000004",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortical hypofunction",
-                "Adrenocortical Insufficiency",
-                "adrenocortical insufficiency",
-                "Corticoadrenal insufficiency",
-                "Adrenal gland hypofunction",
-                "Adrenal Insufficiency",
-                "Adrenal insufficiency",
-                "Adrenal cortical hypofunction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:11443143"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9330184,
-            "start": 569,
-            "end": 312686,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12003388': {'publication date': '2002 Apr', 'sentence': 'Long term hydrocortisone therapy for his adrenal insufficiency may have prevented a faster course of the liver disease, whereas the heterozygous alpha1-antitrypsin deficiency and moderate alcohol consumption constituted additional risk factors ultimately leading to the development of cirrhosis.', 'subject score': 861, 'object score': 1000}, 'PMID:13203378': {'publication date': '1954 Sep', 'sentence': 'Problems arising in the treatment of adrenal insufficiency with cortisone and hydrocortisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:15355454': {'publication date': '2004 Sep', 'sentence': 'OBJECTIVE: The objective of this study was to examine the variables determining hydrocortisone (HC) disposition in patients with adrenal insufficiency and to develop practical protocols for individualized prescribing and monitoring of HC treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:15857523': {'publication date': '2005 May', 'sentence': 'Recent studies in septic adults have shown decreased mortality with the use of hydrocortisone in patients with relative adrenal insufficiency.', 'subject score': 1000, 'object score': 901}, 'PMID:15942340': {'publication date': '2005 Jun', 'sentence': 'In vasopressor-dependent patients without adrenal insufficiency, treatment with hydrocortisone did not affect vasopressor dose at 24 hrs.', 'subject score': 1000, 'object score': 1000}, 'PMID:16093597': {'publication date': '2005 Jul', 'sentence': 'Interestingly, the parkinsonism fully disappeared after the replacement therapy of hydrocortisone for adrenal insufficiency due to hypopituitarism, and MRI 5 months later showed complete disappearance of the lesions, indicating the patient had ameliorated from the EPM.', 'subject score': 1000, 'object score': 1000}, 'PMID:16817818': {'publication date': '2006 Jul', 'sentence': 'OBJECTIVE: Conventional hydrocortisone therapy in adrenal insufficiency cannot provide physiological replacement.', 'subject score': 851, 'object score': 1000}, 'PMID:16886035': {'publication date': '2006 Jul', 'sentence': 'Practitioners need to recognize immediately this potentially lethal disorder in patients with known or suspected adrenal insufficiency and treat with intravenous hydrocortisone.', 'subject score': 888, 'object score': 901}, 'PMID:17003064': {'publication date': '2007 Feb', 'sentence': 'What is the rationale for hydrocortisone treatment in children with infection-related adrenal insufficiency and septic shock?', 'subject score': 888, 'object score': 861}, 'PMID:17058239': {'publication date': '2006 Nov', 'sentence': 'Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival.', 'subject score': 1000, 'object score': 1000}, 'PMID:17255644': {'publication date': '2006 Dec', 'sentence': 'Early recognition of severe hyponatremia due to hypopituitarism with adrenal insufficiency is critical, and treatment with hydrocortisone results in safe and improved quality of life.', 'subject score': 1000, 'object score': 1000}, 'PMID:17606560': {'publication date': '2007 Jul', 'sentence': 'Together with the short-term benefit previously reported, these data support additional studies of hydrocortisone treatment of adrenal insufficiency in extremely premature infants.', 'subject score': 888, 'object score': 1000}, 'PMID:18401570': {'publication date': '2008 May', 'sentence': 'Innovations comprise the development of new delayed release glucocorticoid preparations that allow to better mimic the circadian cortisol secretion and may have the potential to improve the treatment of patients with adrenal insufficiency.', 'subject score': 790, 'object score': 1000}, 'PMID:19168600': {'publication date': '2009 May', 'sentence': 'Recently, proof-of-concept studies have shown that more physiological circadian glucocorticoid therapy using HC infusions and newly developed oral formulations of HC have the potential for better biochemical control in patients with adrenal insufficiency.', 'subject score': 1000, 'object score': 1000}, 'PMID:19325359': {'publication date': '2009 Feb', 'sentence': 'The updated 2007 guidelines continue to recognize an increased likelihood that children with septic shock, compared with adults, require 1) proportionally larger quantities of fluid, 2) inotrope and vasodilator therapies, 3) hydrocortisone for absolute adrenal insufficiency, and 4) ECMO for refractory shock.', 'subject score': 1000, 'object score': 901}, 'PMID:19387826': {'publication date': '2009 Jun', 'sentence': 'Hydrocortisone infusion during night time might improve adrenomedullary reserve in patients with adrenal insufficiency.', 'subject score': 888, 'object score': 1000}, 'PMID:19500761': {'publication date': '2009 Apr', 'sentence': 'Further innovations comprise the development of delayed-release glucocorticoid preparations that better allow mimicking of circadian cortisol secretion and may have the potential to significantly improve the treatment of patients with adrenal insufficiency.', 'subject score': 790, 'object score': 1000}, 'PMID:19508599': {'publication date': '2010 Mar', 'sentence': 'Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency.', 'subject score': 851, 'object score': 1000}, 'PMID:20528006': {'publication date': '2010 Jul', 'sentence': 'CONCLUSIONS: Most patients with adrenal insufficiency are imperfectly treated with hydrocortisone relative to their plasma cortisol concentrations.', 'subject score': 1000, 'object score': 1000}, 'PMID:21521272': {'publication date': '2011 Jun', 'sentence': 'CONCLUSIONS: Hair cortisol content correlates with hydrocortisone (HC) dose in patients with AI.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0001623---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0405580---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9535781",
-              "object": "MONDO:0000004",
-              "publications": [
-                "PMID:18401570",
-                "PMID:28292927",
-                "PMID:2561439",
-                "PMID:17003064",
-                "PMID:27864317",
-                "PMID:30385421",
-                "PMID:36476353",
-                "PMID:36447826",
-                "PMID:28815660",
-                "PMID:33278125",
-                "PMID:12003388",
-                "PMID:2922232",
-                "PMID:32431136",
-                "PMID:35987847",
-                "PMID:25646792",
-                "PMID:25039686",
-                "PMID:31927751",
-                "PMID:36986325",
-                "PMID:31102070",
-                "PMID:8578311"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319508,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005468",
-          "name": "hypotensive disorder",
-          "description": "Blood pressure that is abnormally low.; Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.; Low Blood Pressure, vascular hypotension. [HPO:probinson]; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "MEDDRA:10036638",
-            "PDQ:CDR0000041785",
-            "MEDDRA:10021099",
-            "MEDDRA:10024896",
-            "MEDDRA:10024895",
-            "MEDDRA:10003146",
-            "MEDDRA:10024982",
-            "MEDDRA:10021106",
-            "EFO:0005251",
-            "SYMP:0000059",
-            "SNOMEDCT:45007003",
-            "NCIT:C3128",
-            "MEDDRA:10016174",
-            "PSY:24060",
-            "MEDDRA:10005744",
-            "MEDDRA:10066331",
-            "HP:0002615",
-            "ICD9:458",
-            "MEDDRA:10005753",
-            "MEDDRA:10005734",
-            "MEDDRA:10021097",
-            "MEDDRA:10013645",
-            "MEDDRA:10013644",
-            "MEDDRA:10006065",
-            "MONDO:0005468",
-            "MEDDRA:10003169",
-            "MEDDRA:10005743",
-            "MEDDRA:10006064",
-            "UMLS:C0020649",
-            "MESH:D007022"
-          ],
-          "id": "MONDO:0005468",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hypotensive disorder",
-            "hypotension",
-            "Hypotension"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:DiseaseOrPhenotypicFeature",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://github.com/monarch-initiative/mondo/issues/1030"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319508,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005468",
-              "name": "hypotensive disorder",
-              "description": "Blood pressure that is abnormally low.; Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.; Low Blood Pressure, vascular hypotension. [HPO:probinson]; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "MEDDRA:10036638",
-                "PDQ:CDR0000041785",
-                "MEDDRA:10021099",
-                "MEDDRA:10024896",
-                "MEDDRA:10024895",
-                "MEDDRA:10003146",
-                "MEDDRA:10024982",
-                "MEDDRA:10021106",
-                "EFO:0005251",
-                "SYMP:0000059",
-                "SNOMEDCT:45007003",
-                "NCIT:C3128",
-                "MEDDRA:10016174",
-                "PSY:24060",
-                "MEDDRA:10005744",
-                "MEDDRA:10066331",
-                "HP:0002615",
-                "ICD9:458",
-                "MEDDRA:10005753",
-                "MEDDRA:10005734",
-                "MEDDRA:10021097",
-                "MEDDRA:10013645",
-                "MEDDRA:10013644",
-                "MEDDRA:10006065",
-                "MONDO:0005468",
-                "MEDDRA:10003169",
-                "MEDDRA:10005743",
-                "MEDDRA:10006064",
-                "UMLS:C0020649",
-                "MESH:D007022"
-              ],
-              "id": "MONDO:0005468",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hypotensive disorder",
-                "hypotension",
-                "Hypotension"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:DiseaseOrPhenotypicFeature",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://github.com/monarch-initiative/mondo/issues/1030"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9256009,
-            "start": 569,
-            "end": 319508,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:11919326': {'publication date': '2002 Apr', 'sentence': 'After 24-h age, a subgroup (n = 8) received up to four doses (0.5-1.0 mg/kg each) of hydrocortisone for refractory hypotension.', 'subject score': 1000, 'object score': 888}, 'PMID:15162902': {'publication date': '2004 May', 'sentence': 'Initial symptoms of oral angioedema and laryngopharyngeal constriction progressed to dyspnea, tachypnea, hypotension, and tachycardia, all of which quickly resolved after immediate treatment with hydrocortisone, diphenhydramine, and epinephrine.', 'subject score': 1000, 'object score': 1000}, 'PMID:15329742': {'publication date': '2005 Feb', 'sentence': 'We conducted a randomized-controlled trial to determine the potential role on adrenal insufficiency in early neonatal hypotension and to determine the effectiveness of prophylactic HC in reducing treatment of hypotension in ELBW infants.', 'subject score': 888, 'object score': 1000}, 'PMID:16452355': {'publication date': '2006 Feb', 'sentence': 'CONCLUSIONS: A stress dose of hydrocortisone was effective in treating refractory hypotension in VLBW infants.', 'subject score': 1000, 'object score': 851}, 'PMID:16510650': {'publication date': '2006 Mar', 'sentence': 'CONCLUSIONS: The common early use of hydrocortisone for hypotension and the high morbidity and mortality in children receiving such treatment has not been recognized previously and prospective trials evaluating the short- and long-term risk/benefit of such treatment are urgently required.', 'subject score': 1000, 'object score': 1000}, 'PMID:16572567': {'publication date': '2006', 'sentence': \"During 2 infectious episodes, this patient's dosage of hydrocortisone had to be doubled to control symptomatic hypotension, lethargy, diffuse weakness, and anorexia.\", 'subject score': 1000, 'object score': 888}, 'PMID:17319465': {'publication date': '2006', 'sentence': 'Replacement doses of hydrocortisone and vasopressin may reduce mortality and improve hypotension, respectively, in a subgroup of patients with catecholamine-refractory septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:1811442': {'publication date': '1991 Dec', 'sentence': 'Frusemide for raised central venous pressure and pulmonary oedema, crystalloid infusion for reduced central venous pressure, and hydrocortisone and dopamine for hypotension were used as standard therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:18337742': {'publication date': '2008 Jun', 'sentence': 'OBJECTIVE: The purpose of this observation was to evaluate the safety and efficacy of hydrocortisone (HC) for the treatment of refractory hypotension in term and preterm infants.', 'subject score': 1000, 'object score': 888}, 'PMID:19160190': {'publication date': '2009 Jan 21', 'sentence': 'Most studies evaluated the use of dexamethasone but we also included studies that assessed hydrocortisone, even if it was used to manage hypotension.', 'subject score': 888, 'object score': 1000}, 'PMID:19693023': {'publication date': '2010 Jun', 'sentence': 'OBJECTIVE: To examine the efficacy of hydrocortisone for treatment of hypotension and reduction of vasopressor requirements in preterm infants.', 'subject score': 1000, 'object score': 1000}, 'PMID:20091516': {'publication date': '2010 Jan 20', 'sentence': 'Most studies evaluated the use of dexamethasone but we also included studies that assessed hydrocortisone, even if it was used to manage hypotension.', 'subject score': 888, 'object score': 1000}, 'PMID:21292456': {'publication date': '2011 Mar', 'sentence': 'The incidence of hypotension (61% vs 33%; P<0.05), patent ductus arteriosus (50% vs 17%; P<0.05), dopamine treatment (39% vs 16%; P<0.05), and hydrocortisone treatment (25% vs 6%; p<0.05) was higher in the HTOP group.', 'subject score': 888, 'object score': 1000}, 'PMID:21429058': {'publication date': '2011 Dec', 'sentence': 'Twelve infants (10%) were treated with HC for refractory hypotension (HC group).', 'subject score': 1000, 'object score': 888}, 'PMID:2154137': {'publication date': '1990 Jan', 'sentence': 'In contrast, the large vasopressin response to severe hypotension in the control experiments (from 3.1 +/- 0.3 to 270 +/- 113 pg/ml) was significantly attenuated by cortisol infusion in a dose-dependent manner.', 'subject score': 888, 'object score': 888}, 'PMID:22012173': {'publication date': '2012 Feb', 'sentence': 'Hydrocortisone for refractory hypotension of very low birth weight infant with patent ductus arteriosus: a case report.', 'subject score': 1000, 'object score': 888}, 'PMID:22341536': {'publication date': '2012 Mar', 'sentence': 'Hydrocortisone therapy is increasingly used to treat hypotension in critically ill newborns; however, the outcomes of this therapy must be evaluated in randomized trials.', 'subject score': 888, 'object score': 1000}, 'PMID:23904065': {'publication date': '2014 Aug', 'sentence': 'In this pilot study the authors demonstrate the feasibility, effectiveness and safety of the combined early treatment with hydrocortisone and dopamine for refractory hypotension in preterm newborns.', 'subject score': 1000, 'object score': 888}, 'PMID:24139558': {'publication date': '2014 Jun', 'sentence': 'There are a small number of reports on the use of hydrocortisone (HC) for the treatment of refractory hypotension in infants.', 'subject score': 1000, 'object score': 888}, 'PMID:24190402': {'publication date': '2014 Sep', 'sentence': \"Adding hydrocortisone as 1st line of inotropic treatment for hypotension in very low birth weight infants: authors' reply.\", 'subject score': 872, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0020649---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9459897",
-              "object": "MONDO:0005468",
-              "publications": [
-                "PMID:11919326",
-                "PMID:15162902",
-                "PMID:15329742",
-                "PMID:16452355",
-                "PMID:16510650",
-                "PMID:16572567",
-                "PMID:17319465",
-                "PMID:1811442",
-                "PMID:18337742",
-                "PMID:19160190",
-                "PMID:19693023",
-                "PMID:20091516",
-                "PMID:21292456",
-                "PMID:21429058",
-                "PMID:2154137",
-                "PMID:22012173",
-                "PMID:22341536",
-                "PMID:23904065",
-                "PMID:24139558",
-                "PMID:24190402"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318783,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005147",
-          "name": "type 1 diabetes mellitus",
-          "description": "A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. [HPO:probinson]; A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. // COMMENTS: The onset of type 1 diabetes is typically during adolescence, but it can develop at any age.; A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. // COMMENTS: The onset of type 1 diabetes is typically during adolescence, but it can develop at any age.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10045228",
-            "MEDDRA:10012608",
-            "MESH:D003922",
-            "DOID:9744",
-            "MEDDRA:10022482",
-            "MEDDRA:10067584",
-            "MEDDRA:10022497",
-            "ORPHANET:243377",
-            "KEGG.DISEASE:04940",
-            "UMLS:C0011854",
-            "MEDDRA:10085412",
-            "MEDDRA:10012609",
-            "SNOMEDCT:46635009",
-            "OMIM:222100",
-            "UMLS:C5435660",
-            "MONDO:0005147",
-            "MEDDRA:10023253",
-            "HP:0100651",
-            "EFO:0001359",
-            "NCIT:C2986",
-            "MEDDRA:10021211"
-          ],
-          "id": "MONDO:0005147",
-          "category": "biolink:Disease",
-          "all_names": [
-            "type 1 diabetes mellitus",
-            "Type I diabetes mellitus",
-            "Type 1 diabetes mellitus 1",
-            "obsolete_type I diabetes mellitus",
-            "Type 1 Diabetes Mellitus",
-            "Type 1 diabetes mellitus related phenotypic feature",
-            "Diabetes Mellitus, Insulin-Dependent",
-            "Diabetes Mellitus, Type 1"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/diabetes_mellitus_type_1",
-            "http://en.wikipedia.org/wiki/diabetes",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318783,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005147",
-              "name": "type 1 diabetes mellitus",
-              "description": "A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. [HPO:probinson]; A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. // COMMENTS: The onset of type 1 diabetes is typically during adolescence, but it can develop at any age.; A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. // COMMENTS: The onset of type 1 diabetes is typically during adolescence, but it can develop at any age.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10045228",
-                "MEDDRA:10012608",
-                "MESH:D003922",
-                "DOID:9744",
-                "MEDDRA:10022482",
-                "MEDDRA:10067584",
-                "MEDDRA:10022497",
-                "ORPHANET:243377",
-                "KEGG.DISEASE:04940",
-                "UMLS:C0011854",
-                "MEDDRA:10085412",
-                "MEDDRA:10012609",
-                "SNOMEDCT:46635009",
-                "OMIM:222100",
-                "UMLS:C5435660",
-                "MONDO:0005147",
-                "MEDDRA:10023253",
-                "HP:0100651",
-                "EFO:0001359",
-                "NCIT:C2986",
-                "MEDDRA:10021211"
-              ],
-              "id": "MONDO:0005147",
-              "category": "biolink:Disease",
-              "all_names": [
-                "type 1 diabetes mellitus",
-                "Type I diabetes mellitus",
-                "Type 1 diabetes mellitus 1",
-                "obsolete_type I diabetes mellitus",
-                "Type 1 Diabetes Mellitus",
-                "Type 1 diabetes mellitus related phenotypic feature",
-                "Diabetes Mellitus, Insulin-Dependent",
-                "Diabetes Mellitus, Type 1"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/diabetes_mellitus_type_1",
-                "http://en.wikipedia.org/wiki/diabetes",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8977950,
-            "start": 569,
-            "end": 318783,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1161341': {'publication date': '1975 Jun', 'sentence': 'Interaction of endogenous growth hormone, cortisol, and catecholamines with blood glucose in children with brittle diabetes mellitus.', 'subject score': 1000, 'object score': 1000}, 'PMID:15239023': {'publication date': '2004 Jul', 'sentence': 'METHODS: hs-CRP, soluble interleukin-2 receptor (sIL-2R), C-peptide, insulin, cortisol, vitamin B12, folic acid, leptin, and homocysteine were determined in 148 patients with juvenile type 1 diabetes, 86 obese children and 142 normal weighted age-matched healthy controls.', 'subject score': 1000, 'object score': 916}, 'PMID:16616286': {'publication date': '2006 Jul', 'sentence': 'The aim of this study was to non-invasively examine the cortisol metabolism in children with Type 1 diabetes mellitus (T1DM) in detail and to test the hypothesis that adrenarche is affected under conventional intensive insulin therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:20189610': {'publication date': '2010 Oct', 'sentence': 'We therefore studied GH, ACTH, and cortisol responses to ghrelin and GHRP-6 in 9 patients with T1DM and 9 control subjects.', 'subject score': 888, 'object score': 1000}, 'PMID:21114371': {'publication date': '2011', 'sentence': 'The examination of peripheral metabolism of cortisol using cortisone acetate test in patients with diabetes mellitus type 1 showed adaptive changes of 11beta-hydroxysteroid dehydrogenace activity associated with altered cortisol tissue supply.', 'subject score': 1000, 'object score': 1000}, 'PMID:2200623': {'publication date': '1990 Jun', 'sentence': 'Growth hormone and cortisol secretion were studied in 25 patients with insulin-dependent diabetes before (Study 1) and 2 weeks after improved glucoregulation (Study 2).', 'subject score': 888, 'object score': 1000}, 'PMID:24350820': {'publication date': '2014 Sep', 'sentence': 'OBJECTIVE: To test the hypothesis that endogenous adrenocorticotropic hormone (ACTH)-cortisol dose-responsive drive, estimated analytically, is significantly accentuated in adolescents and young adults with T1DM compared with healthy individuals.', 'subject score': 615, 'object score': 1000}, 'PMID:34027090': {'publication date': '2021 May', 'sentence': 'In this review, a range of analytes, including glucose, insulin, glucagon, cortisol, lactate, epinephrine, and alcohol, as well as ketones such as beta-hydroxybutyrate, will be evaluated to determine the current status and research direction of those analytes specifically relevant to T1D management, using both in-vitro and on-body detection.', 'subject score': 1000, 'object score': 916}, 'PMID:8816035': {'publication date': '1996 08', 'sentence': 'Growth parameters, growth hormone (GH) response to clonidine and circulating insulin-like growth factor-I (IGF-I), free thyroxine (FT4) and cortisol concentrations in relation to glycaemic control in children with insulin-dependent diabetes mellitus.', 'subject score': 888, 'object score': 1000}, 'PMID:8911878': {'publication date': '1996', 'sentence': 'OBJECTIVE: The role of the dose and route of administration of octreotide in addition to insulin on daily blood glucose, growth hormone, glucagon, cortisol and adrenaline profiles in 7 insulin-dependent diabetic patients have been studied.', 'subject score': 1000, 'object score': 854}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0011854---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9175521",
-              "object": "MONDO:0005147",
-              "publications": [
-                "PMID:1161341",
-                "PMID:15239023",
-                "PMID:16616286",
-                "PMID:20189610",
-                "PMID:21114371",
-                "PMID:2200623",
-                "PMID:24350820",
-                "PMID:34027090",
-                "PMID:8816035",
-                "PMID:8911878"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8588542,
-            "start": 569,
-            "end": 183319,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11261868': {'publication date': '2001 Mar 01', 'sentence': 'Acidification with a topical solution of 2 percent acetic acid combined with hydrocortisone for inflammation is effective treatment in most cases and, when used after exposure to moisture, is an excellent prophylactic.', 'subject score': 1000, 'object score': 1000}, 'PMID:1266622': {'publication date': '1976 Feb', 'sentence': 'The impaired differentiation of monocytes is suggested as an additional explanation of the reduced number of macrophages appearing at the site of inflammation during cortisol treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:12682474': {'publication date': '2003 Apr', 'sentence': 'CONCLUSIONS: Although we acknowledge the limitations of a nonblinded interventional trial, stress doses of hydrocortisone seem to attenuate systemic inflammation in a predefined risk group of patients after cardiac surgery with cardiopulmonary bypass and improve early outcome.', 'subject score': 1000, 'object score': 888}, 'PMID:15525570': {'publication date': '2004 Oct', 'sentence': 'IL-1alpha co-ordinately induces 11betaHSD1 and a panel of glucocorticoid-regulated, inflammation-associated genes in HOSE cells, providing further evidence that cortisol generated by 11betaHSD1 could participate in the local resolution of inflammation associated with ovulation.', 'subject score': 1000, 'object score': 1000}, 'PMID:15557131': {'publication date': '2005 Feb 01', 'sentence': 'We hypothesize that hydrocortisone infusion in severe community-acquired pneumonia attenuates systemic inflammation and leads to earlier resolution of pneumonia and a reduction in sepsis-related complications.', 'subject score': 888, 'object score': 888}, 'PMID:16088513': {'publication date': '2004 Dec', 'sentence': 'Assuming relative adrenal insufficiency (RAI) and peripheral cortisol resistance, treatment with low-dose hydrocortisone improved shock reversal, reduced inflammation, and improved outcome.', 'subject score': 901, 'object score': 888}, 'PMID:17195247': {'publication date': '2007 Jan', 'sentence': 'Cortisol metabolism by 11 beta-hydroxysteroid dehydrogenase as a novel target in the treatment of inflammation- or immune-mediated bone loss: comment on the article by Makrygiannakis et al.', 'subject score': 888, 'object score': 1000}, 'PMID:19022342': {'publication date': '2009 Mar 25', 'sentence': 'On the other hand, endogenous cortisol is regarded as physiological compound to combat inflammation.', 'subject score': 888, 'object score': 1000}, 'PMID:20634656': {'publication date': '2010 Aug', 'sentence': 'Preconditioning with either hydrocortisone or antithrombin should, thus, alleviate vascular leakage, tissue edema, and inflammation.', 'subject score': 861, 'object score': 1000}, 'PMID:20965252': {'publication date': '2011 Jan', 'sentence': 'In contrast, cortisol in combination with the pro-inflammatory agents has a synergistic effect on IL-10 expression, an anti-inflammatory molecule, suggesting that the activation of certain macrophage functions that lead to the resolution of inflammation occurs in fish macrophages in response to cortisol treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:23817641': {'publication date': '2013 Sep', 'sentence': 'Cortisol is one of the most potent immunomodulatory hormones involved in control of inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:23831090': {'publication date': '2013 Sep', 'sentence': 'The lower increase in cortisol after the ACTH challenge in cows with greater inflammation (LO quartile) seems a consequence of the lower availability of cortisol-binding globulin synthetized by the liver, but other mechanisms can be involved (e.g., rate of cortisol production, secretion, and metabolic clearance).', 'subject score': 1000, 'object score': 888}, 'PMID:28101752': {'publication date': '2017 Dec', 'sentence': 'In this experimental model of systemic inflammation, we sought to investigate whether septic neutrophil activation, evaluated by the plasma levels of neutrophil gelatinase-associated protein (NGAL), is modulated by the timing of hydrocortisone treatment.', 'subject score': 888, 'object score': 888}, 'PMID:3004514': {'publication date': '1986 Jan', 'sentence': 'Since inhibition of inflammation by hydrocortisone treatment did not block apatite accumulation, intraarticular deposition of hydroxyapatite occurs independent of inflammation in progressive ankylosis.', 'subject score': 888, 'object score': 1000}, 'PMID:31572556': {'publication date': '2019 Oct', 'sentence': 'Rats were divided into control (Control), high-inflammation treated with hydrocortisone (HT), high-inflammation non-treatment (HNT), low-inflammation treated with hydrocortisone (LT) and low-inflammation non-treatment (LNT) groups according to the levels of serum C-reactive protein (CRP), interleukin (IL)-6 and interferon (IFN)-gamma.', 'subject score': 1000, 'object score': 888}, 'PMID:34816666': {'publication date': '2021 Sep', 'sentence': 'Conclusion:     Tangeretin supplementation can significantly alleviate the cortisol stress response induced by high-intensity resistance exercise, inhibit the excessive secretion of cortisol, enhance antioxidant capacity, accelerate the elimination of inflammation in the body, and promote the recovery of body functions.', 'subject score': 1000, 'object score': 1000}, 'PMID:9229827': {'publication date': '1997', 'sentence': 'A positive therapeutic effect consisting in elimination of inflammation in the tracheobronchial tree and normalizing the indices of cellular and humoral immunity was observed earlier in patients receiving therapeutic fiber bronchoscopy with liposome and hydrocortisone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8776300",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:11261868",
-                "PMID:1266622",
-                "PMID:12682474",
-                "PMID:15525570",
-                "PMID:15557131",
-                "PMID:16088513",
-                "PMID:17195247",
-                "PMID:19022342",
-                "PMID:20634656",
-                "PMID:20965252",
-                "PMID:23817641",
-                "PMID:23831090",
-                "PMID:28101752",
-                "PMID:3004514",
-                "PMID:31572556",
-                "PMID:34816666",
-                "PMID:9229827"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 722907,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-          "name": "bronchopulmonary dysplasia",
-          "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:70589",
-            "MESH:D001997",
-            "MONDO:0019091",
-            "SNOMEDCT:67569000",
-            "MEDDRA:10066204",
-            "UMLS:C0006287",
-            "NCIT:C90599",
-            "DOID:11650",
-            "MEDDRA:10006475"
-          ],
-          "id": "MONDO:0019091",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bronchopulmonary Dysplasia",
-            "obsolete_bronchopulmonary dysplasia",
-            "bronchopulmonary dysplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 722907,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-              "name": "bronchopulmonary dysplasia",
-              "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:70589",
-                "MESH:D001997",
-                "MONDO:0019091",
-                "SNOMEDCT:67569000",
-                "MEDDRA:10066204",
-                "UMLS:C0006287",
-                "NCIT:C90599",
-                "DOID:11650",
-                "MEDDRA:10006475"
-              ],
-              "id": "MONDO:0019091",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bronchopulmonary Dysplasia",
-                "obsolete_bronchopulmonary dysplasia",
-                "bronchopulmonary dysplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8441874,
-            "start": 569,
-            "end": 722907,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11144310': {'publication date': '2000', 'sentence': 'To study a possible relation between the use of postnatal glucocorticoids and the incidence and severity of retinopathy of prematurity (ROP), we conducted a retrospective study over a 4-year period that compared data of 161 preterm infants treated with hydrocortisone for bronchopulmonary dysplasia (BPD) with the data of 253 controls.', 'subject score': 1000, 'object score': 1000}, 'PMID:16439598': {'publication date': '2006 Feb', 'sentence': 'Eighteen children were treated with hydrocortisone for BPD (starting dose 5 mg/kg/d tapered over a minimum period of 22 d, median duration 28 d) and 19 never received corticosteroids during the perinatal period.', 'subject score': 1000, 'object score': 1000}, 'PMID:17382109': {'publication date': '2007 Apr', 'sentence': 'CONCLUSIONS: Neonatal hydrocortisone treatment for BPD had no long-term effects on neurodevelopment.', 'subject score': 851, 'object score': 1000}, 'PMID:19240295': {'publication date': '2009 Mar', 'sentence': 'Hydrocortisone treatment for severe evolving bronchopulmonary dysplasia and cerebral haemodynamics.', 'subject score': 888, 'object score': 861}, 'PMID:20150750': {'publication date': '2010', 'sentence': 'METHODS: Randomised controlled trials (RCTs) of postnatal hydrocortisone therapy to prevent or treat BPD were sought.', 'subject score': 851, 'object score': 1000}, 'PMID:23706359': {'publication date': '2013 Sep', 'sentence': 'CONCLUSIONS: In the absence of associated parenchymal brain injury, no reduction in brain tissue or cerebellar volumes could be found at term-equivalent age between infants with or without treatment with HC for BPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:24142604': {'publication date': '2013 Oct', 'sentence': 'CONCLUSIONS: The treatment with hydrocortisone, which is used for BPD, improves anti-oxidant system and reduces oxidative stress in infants with BPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:24298974': {'publication date': '2013', 'sentence': 'INTRODUCTION: The aim of our study was to determine whether hydrocortisone even at low dose could be an effective and safe alternative treatment for bronchopulmonary dysplasia.', 'subject score': 861, 'object score': 1000}, 'PMID:31508250': {'publication date': '2019 Mar 01', 'sentence': 'In addition, blood samples were obtained at the time of diagnosis of BPD and after the end of hydrocortisone (HC) treatment to measure IL-33 values in the serum.', 'subject score': 888, 'object score': 1000}, 'PMID:32883333': {'publication date': '2020 Sep 03', 'sentence': 'METHODS: This study protocol is for a multicenter double-blind randomized controlled trial of low-dose HC in the treatment of early BPD.', 'subject score': 901, 'object score': 901}, 'PMID:34012057': {'publication date': '2021 May 19', 'sentence': 'Corticosteroids, such as dexamethasone and hydrocortisone, have proven beneficial for the prevention and management of BPD postnatally due to their anti-inflammatory characteristics.', 'subject score': 1000, 'object score': 901}, 'PMID:35831259': {'publication date': '2022 Jan', 'sentence': 'CONCLUSIONS: Although the postnatal hydrocortisone treatment provided for respiratory deterioration did not prevent the BPD development, hydrocortisone treatment might suppress IL-6 overproduction in extremely preterm infants.', 'subject score': 888, 'object score': 901}, 'PMID:35907315': {'publication date': '2022 Jul 15', 'sentence': \"CONCLUSION: Prophylactic administration of low-dose hydrocortisone for BPD to infants born below 28 weeks' gestation was not associated with an increase in serious adverse outcomes in our population.\", 'subject score': 901, 'object score': 1000}, 'PMID:9973669': {'publication date': '1998', 'sentence': 'The aim of the present study was to test the practicability of sequential cortisol determinations in saliva of low birth weight neonates and to evaluate the impact of systemic and inhaled glucocorticoid therapy on saliva concentrations of cortisol in preterm neonates with bronchopulmonary dysplasia (BPD).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0006287---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8632826",
-              "object": "MONDO:0019091",
-              "publications": [
-                "PMID:11144310",
-                "PMID:16439598",
-                "PMID:17382109",
-                "PMID:19240295",
-                "PMID:20150750",
-                "PMID:23706359",
-                "PMID:24142604",
-                "PMID:24298974",
-                "PMID:31508250",
-                "PMID:32883333",
-                "PMID:34012057",
-                "PMID:35831259",
-                "PMID:35907315",
-                "PMID:9973669"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320151,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-          "name": "dermatitis, atopic",
-          "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MESH:C566404",
-            "MEDDRA:10012434",
-            "SNOMEDCT:24079001",
-            "MONDO:0011292",
-            "MEDDRA:10003641",
-            "MONDO:0100181",
-            "MEDDRA:10014191",
-            "OMIM:603165",
-            "HP:0001047",
-            "MEDDRA:10001711",
-            "MEDDRA:10003639",
-            "UMLS:C0011615",
-            "UMLS:C4280605",
-            "UMLS:C1864155",
-            "MEDDRA:10012438",
-            "MEDDRA:10014188",
-            "MEDDRA:10001712",
-            "MESH:D003876",
-            "SNOMEDCT:200775004"
-          ],
-          "id": "MONDO:0011292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis, Atopic, 1",
-            "dermatitis, atopic",
-            "Dermatitis, Atopic",
-            "Baby eczema",
-            "Dermatitis, atopic related phenotypic feature",
-            "Atopic dermatitis",
-            "dermatitis, atopic, 1"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:27904186",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320151,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-              "name": "dermatitis, atopic",
-              "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MESH:C566404",
-                "MEDDRA:10012434",
-                "SNOMEDCT:24079001",
-                "MONDO:0011292",
-                "MEDDRA:10003641",
-                "MONDO:0100181",
-                "MEDDRA:10014191",
-                "OMIM:603165",
-                "HP:0001047",
-                "MEDDRA:10001711",
-                "MEDDRA:10003639",
-                "UMLS:C0011615",
-                "UMLS:C4280605",
-                "UMLS:C1864155",
-                "MEDDRA:10012438",
-                "MEDDRA:10014188",
-                "MEDDRA:10001712",
-                "MESH:D003876",
-                "SNOMEDCT:200775004"
-              ],
-              "id": "MONDO:0011292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis, Atopic, 1",
-                "dermatitis, atopic",
-                "Dermatitis, Atopic",
-                "Baby eczema",
-                "Dermatitis, atopic related phenotypic feature",
-                "Atopic dermatitis",
-                "dermatitis, atopic, 1"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:27904186",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8358666,
-            "start": 569,
-            "end": 320151,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1107090': {'publication date': '1975', 'sentence': 'Topical treatment with urea-hydrocortisone in atopic dermatitis.', 'subject score': 888, 'object score': 1000}, 'PMID:15245526': {'publication date': '2004 Jul', 'sentence': 'We compared the efficacy of WWT with a standard regime of hydrocortisone, to control moderate AD in children.', 'subject score': 1000, 'object score': 901}, 'PMID:16874433': {'publication date': '2006', 'sentence': 'Treatment of atopic dermatitis with 1% hydrocortisone and 25% pentane-1,5-diol: effect on Staphylococcus aureus.', 'subject score': 861, 'object score': 1000}, 'PMID:20337610': {'publication date': '2010 Sep', 'sentence': 'METHODS: Sixteen patients with AD were treated topically with miltefosine and hydrocortisone localized on representative AD target lesions for 3 weeks.', 'subject score': 1000, 'object score': 1000}, 'PMID:21094146': {'publication date': '2011 Jan 07', 'sentence': 'The expression of StAR and MLN64 was aberrant in two skin disorders, psoriasis and atopic dermatitis, that are commonly treated with cortisol, suggesting dysregulation of epidermal steroid synthesis in these patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:30657034': {'publication date': '2018', 'sentence': 'Due to these beneficial properties, GA and its derivatives (e.g. lipid-soluble phenols such as synthetic gallic esters aka gallates) have been extensively used as an adjuvant in a number of therapeutic formulations, as a substitute of hydrocortisone in children with atopic dermatitis (AD) and other skin conditions (hyperpigmentation, wound healing), and as a cosmetic ingredient.', 'subject score': 1000, 'object score': 1000}, 'PMID:32993977': {'publication date': '2020 Sep', 'sentence': 'Biopolymeric films as delivery vehicles for controlled release of hydrocortisone: Promising devices to treat chronic skin diseases.Atopic dermatitis (AD) is the most common chronic inflammatory skin disease with nasty effects on the psychosocial wellbeing of patients.', 'subject score': 1000, 'object score': 893}, 'PMID:33689537': {'publication date': '2021 Mar 09', 'sentence': 'This could support the proposed hypothesis of clinical dermatological treatment of hydrocortisone to local skin inflammations should the epidermis be found to be a key target for atopic dermatitis therapy.', 'subject score': 1000, 'object score': 901}, 'PMID:339846': {'publication date': '1978 Jan', 'sentence': 'Topical use of caffeine with hydrocortisone in the treatment of atopic dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:36365170': {'publication date': '2022 Oct 31', 'sentence': 'However, the nano-based film containing silibinin modulated the inflammatory and oxidative parameters in a similar or more pronounced way than silibinin solution and vehicle film, as well as than hydrocortisone, a classical treatment of AD.', 'subject score': 1000, 'object score': 1000}, 'PMID:37165693': {'publication date': '2023 May 11', 'sentence': 'BACKGROUND: There are no studies which evaluate hair cortisol as a biological marker of stress and anxiety in pruritic dogs during atopic dermatitis therapy.', 'subject score': 888, 'object score': 901}, 'PMID:6389217': {'publication date': '1984', 'sentence': 'Hydrocortisone 17-butyrate (Locoid) 0.1% cream versus hydrocortisone (Uniderm) 1% cream in the treatment of children suffering from atopic dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7490367': {'publication date': '1995 Dec', 'sentence': 'CONCLUSION: TEWL reflects changes in the systemic absorption of topical hydrocortisone during treatment of atopic dermatitis.', 'subject score': 861, 'object score': 1000}, 'PMID:7662574': {'publication date': '1995 Jun', 'sentence': 'However, the peak in plasma cortisol occurred earlier in children with atopic dermatitis (median 17.5 min) than in controls (median 25 min) (P = 0.02).', 'subject score': 888, 'object score': 1000}, 'PMID:7813169': {'publication date': '1994 Sep', 'sentence': 'In case of a history of untoward drug effects, oral antibiotics should be preferred (erythromycin or micamycin); for atopic dermatitis the preference is for topical treatment with hydrocortisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:9990411': {'publication date': '1998 Dec', 'sentence': 'The topical combinations of fusidic acid with either betamethasone or hydrocortisone are extremely useful in the treatment of atopic dermatitis/eczema whenever staphylococcal/secondary infection is suspected, and in more persistent cases of eczema where staphylococcal superantigen may be playing an important exacerbating role.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0011615---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8540090",
-              "object": "MONDO:0011292",
-              "publications": [
-                "PMID:1107090",
-                "PMID:15245526",
-                "PMID:16874433",
-                "PMID:20337610",
-                "PMID:21094146",
-                "PMID:30657034",
-                "PMID:32993977",
-                "PMID:33689537",
-                "PMID:339846",
-                "PMID:36365170",
-                "PMID:37165693",
-                "PMID:6389217",
-                "PMID:7490367",
-                "PMID:7662574",
-                "PMID:7813169",
-                "PMID:9990411"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318216,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318216,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8234463,
-            "start": 569,
-            "end": 318216,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10968480': {'publication date': '2000 Jul-Aug', 'sentence': 'We studied the interactions of leptin, insulin and cortisol in obese children and adolescents at different stages of maturation.', 'subject score': 1000, 'object score': 888}, 'PMID:10997634': {'publication date': '2000 Jun', 'sentence': 'Increased response of cortisol and ACTH to corticotrophin releasing hormone in centrally obese men, but not in post-menopausal women.', 'subject score': 1000, 'object score': 790}, 'PMID:11428718': {'publication date': '2001 Feb-May', 'sentence': 'The results presented are consistent with a lower overall cortisol secretion in the morbid obese women, which also show a narrower margin of variation in cortisol secretion than non-obese controls.', 'subject score': 888, 'object score': 773}, 'PMID:11454512': {'publication date': '2001 Aug', 'sentence': 'OBJECTIVE: To compare salivary, plasma and urinary free cortisol (UFC) measurements in patients with anorexia nervosa, in whom an overdrive of the hypothalamic-pituitary-adrenal (HPA) axis is well established but information on salivary cortisol is lacking, in viscerally obese patients in whom subtle abnormalities of cortisol secretion and metabolism are postulated, and in normal-weight healthy women.', 'subject score': 888, 'object score': 790}, 'PMID:11889189': {'publication date': '2002 Mar', 'sentence': \"As exemplified in patients with Cushing's syndrome, glucocorticoids play an important role in regulating adipose tissue distribution and function, but circulating cortisol concentrations are normal in most patients with obesity.\", 'subject score': 851, 'object score': 1000}, 'PMID:12107245': {'publication date': '2002 Jul', 'sentence': 'Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity.', 'subject score': 851, 'object score': 888}, 'PMID:12530648': {'publication date': '2002 Nov', 'sentence': 'In humans, glucocorticoids are important regulators of adipose tissue distribution and function but circulating cortisol concentrations are normal in most patients with obesity.', 'subject score': 851, 'object score': 1000}, 'PMID:12688161': {'publication date': '2002', 'sentence': 'Fasting plasma levels of both cortisol and sex hormone binding globulin (SHBG) in obese women were significantly inversely related to anthropometric characteristics of body fat distribution.', 'subject score': 1000, 'object score': 888}, 'PMID:14711067': {'publication date': '2003 Dec', 'sentence': 'Cortisol, ACTH, and urine free cortisol levels are usually normal; however, a hyperresponsiveness of the HPA axis with increased cortisol and ACTH response to stimulatory tests is observed in centrally obese individuals.', 'subject score': 888, 'object score': 790}, 'PMID:14763916': {'publication date': '2004 Feb', 'sentence': 'We suggest that activation of cortisol secretion is not an irreversible intrinsic abnormality in obese patients, and speculate that dietary content has an important influence on the neuroendocrine response to weight loss.', 'subject score': 888, 'object score': 888}, 'PMID:15256820': {'publication date': '2004', 'sentence': 'CONCLUSIONS: Cortisol was moderately increased in insulin-resistant, obese children and related to insulin resistance.', 'subject score': 1000, 'object score': 843}, 'PMID:15481772': {'publication date': '1997 Aug', 'sentence': 'MEASUREMENTS: Evaluation of TGF-beta1, insulin, prolactin, sex-hormone binding globulin, androstenedione, free triiodothyronine, free tetraiodothyronine, thyroid-stimulating hormone, dehydroepiandrosterone-sulfate, testosterone, insulin-like growth factor 1, cortisol and adrenocorticotropic hormone plasma concentrations in obese women.', 'subject score': 1000, 'object score': 888}, 'PMID:15481773': {'publication date': '1997 Aug', 'sentence': 'Incremental areas of ACTH and cortisol were significantly higher in women with visceral obesity than in those with subcutaneous obesity and controls.', 'subject score': 1000, 'object score': 888}, 'PMID:15537170': {'publication date': '2004', 'sentence': 'The aim of this study was to investigate the response of cortisol, insulin and lipid parameters [serum Lipoprotein Lipase activity, choleseryl-ester transfer protein, triglycerides, total Cholesterol, High Density Lipoprotein, Free Fatty Acids] during the perioperative period in obese patients undergoing laparoscopic cholecystectomy.', 'subject score': 1000, 'object score': 888}, 'PMID:15985478': {'publication date': '2005 Sep', 'sentence': 'Inhibition of cortisol biosynthesis decreases circulating leptin levels in obese humans.', 'subject score': 840, 'object score': 888}, 'PMID:16332937': {'publication date': '2006 Feb', 'sentence': 'Lower excess postexercise oxygen consumption and altered growth hormone and cortisol responses to exercise in obese men.', 'subject score': 888, 'object score': 888}, 'PMID:163455': {'publication date': '1975 Jan 24', 'sentence': 'Changes in plasma cortisol during the tolbutamide test were evaluated in normal subjects and in obese patients with a normal (D = 60,1 plus or minus 8,3) or reduced (D = 23,2 plus or minus 9,5) blood sugar decrease coefficient.', 'subject score': 888, 'object score': 888}, 'PMID:16353581': {'publication date': '1994 Jul', 'sentence': 'There was no difference in baseline values of prolactin (PRL), corticotropin (ACTH) and cortisol in non-obese controls, obese before and obese after weight loss.', 'subject score': 1000, 'object score': 773}, 'PMID:16772320': {'publication date': '2006 Nov', 'sentence': 'The increase of PAI-1 between time(180) and time(240) after HC was higher in obese women (+25%) than in controls (+12%) (P < 0.05), whereas no differential effect between groups was observed for free fatty acids or adiponectin.', 'subject score': 1000, 'object score': 888}, 'PMID:17505053': {'publication date': '2007 Aug', 'sentence': 'We compared the circadian profiles of cortisol in obese men with [obSAS+; apnea-hypopnea index (AHI) >or= 20/h] and without SAS (obSAS-; AHI <or= 5/h).', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0028754---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8412499",
-              "object": "MONDO:0011122",
-              "publications": [
-                "PMID:10968480",
-                "PMID:10997634",
-                "PMID:11428718",
-                "PMID:11454512",
-                "PMID:11889189",
-                "PMID:12107245",
-                "PMID:12530648",
-                "PMID:12688161",
-                "PMID:14711067",
-                "PMID:14763916",
-                "PMID:15256820",
-                "PMID:15481772",
-                "PMID:15481773",
-                "PMID:15537170",
-                "PMID:15985478",
-                "PMID:16332937",
-                "PMID:163455",
-                "PMID:16353581",
-                "PMID:16772320",
-                "PMID:17505053"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8074608,
-            "start": 569,
-            "end": 320039,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10849939': {'publication date': '2000 Apr 21', 'sentence': '[Cortisol in critically ill patients with sepsis: physiologic functions and therapeutic implications].', 'subject score': 1000, 'object score': 1000}, 'PMID:11246311': {'publication date': '2001 Feb', 'sentence': 'However, the change in plasma cortisol, expressed as mean +/- sem and calculated by subtracting the basal cortisol from the peak cortisol after CRH stimulation, was not significantly different in survivors with severe sepsis (243.5 +/- 36.1, range 111.0-524.0 nmol/L, n = 15) compared with nonsurvivors (161.0 +/- 38.9, range 42.0-245.0 nmol/L, n = 5; p >.05).', 'subject score': 861, 'object score': 888}, 'PMID:11333472': {'publication date': '2001 May', 'sentence': 'CONCLUSIONS: Plasma cortisol and ACTH levels were increased in children with sepsis and septic shock.', 'subject score': 888, 'object score': 1000}, 'PMID:11471384': {'publication date': '2000', 'sentence': 'Several high quality randomised controlled trials have evaluated the efficacy and safety of a prolonged treatment with low dose hydrocortisone in severe sepsis.', 'subject score': 901, 'object score': 888}, 'PMID:11885413': {'publication date': '2002 Feb 15', 'sentence': 'Recent small studies have shown benefits with low-dose hydrocortisone in patients with refractory sepsis.', 'subject score': 901, 'object score': 888}, 'PMID:12120695': {'publication date': '2002 May', 'sentence': 'There was a positive correlation between cortisol and IL-6 only in control patients with sepsis (r=0.89, p=0.019), but not within the MS patents with sepsis or MS and control groups without sepsis.', 'subject score': 1000, 'object score': 1000}, 'PMID:12558137': {'publication date': '2003 Jan', 'sentence': 'The prognostic value of basal and corticotropin-stimulated cortisol concentration in patients with sepsis remains a controversial issue.', 'subject score': 597, 'object score': 1000}, 'PMID:14767873': {'publication date': '2004 Feb', 'sentence': 'The mean basal circulating cortisol concentration and peak cortisol responses to low-dose and standard-dose ACTH tests were higher in stressed infants with sepsis and RD compared to normal.', 'subject score': 569, 'object score': 1000}, 'PMID:15503552': {'publication date': '2002', 'sentence': '[Cortisol in critically ill patients with sepsis--physiological functions and therapeutic implications].', 'subject score': 1000, 'object score': 1000}, 'PMID:15752405': {'publication date': '2005 Mar', 'sentence': 'Vasodilatory shock in severe acute pancreatitis without sepsis: is there any place for hydrocortisone treatment?', 'subject score': 888, 'object score': 1000}, 'PMID:15947898': {'publication date': '2005 Jul', 'sentence': 'Clinical and experimental evidence suggests, however, that even glucocorticoid-treated patients undergoing surgery do not require maximum stress doses of hydrocortisone, which should be reserved for the treatment of sepsis.', 'subject score': 1000, 'object score': 1000}, 'PMID:16850006': {'publication date': '2006 Sep', 'sentence': 'CONCLUSIONS: Low-dose hydrocortisone seems to reduce MACR and serum C-reactive protein but not procalcitonin in patients with severe sepsis.', 'subject score': 901, 'object score': 888}, 'PMID:18499615': {'publication date': '2008 Jun', 'sentence': 'There was no difference in the total cortisol concentrations in patients with sepsis and septic shock (728 +/- 386 nmol/L vs 793 +/- 439 nmol/L, P = 0.44).', 'subject score': 851, 'object score': 1000}, 'PMID:20358501': {'publication date': '2010 Apr', 'sentence': 'In the last years, two topics received a lot of attention since a single intervention led to a mortality benefit: the intensive blood glucose control in surgical intensive care patients and the low dose hydrocortisone therapy in sepsis.', 'subject score': 861, 'object score': 1000}, 'PMID:20455885': {'publication date': '2010 Sep', 'sentence': 'Demonstration of a relation between NOx, cortisol and vasopressor requirement may provide an impetus towards the study of hydrocortisone-mediated NOx suppression as a tool in sepsis management.', 'subject score': 1000, 'object score': 888}, 'PMID:21308518': {'publication date': '2010 Sep', 'sentence': 'Activated protein C and hydrocortisone are the only two available adjunct therapies for sepsis.', 'subject score': 1000, 'object score': 1000}, 'PMID:24621333': {'publication date': '2014 02 28', 'sentence': 'The aim of this study was to investigate: [1] serial changes over time in the plasma levels of AnxA1 and cortisol in sepsis patients; and [2] prognostic value of AnxA1 level in the survival of sepsis patients.', 'subject score': 1000, 'object score': 888}, 'PMID:25223852': {'publication date': '2014 Oct', 'sentence': 'Furthermore, measurements of copeptin level and serum baseline cortisol concentration are promising independent prognostic markers for mortality in patients with severe sepsis or septic shock.', 'subject score': 861, 'object score': 888}, 'PMID:26753096': {'publication date': '2016', 'sentence': 'BACKGROUND: The purposes of the study were to compare serum total cortisol (STC), salivary cortisol (SaC) and calculated free cortisol (cFC) levels at baseline and after the adrenocorticotrophic hormone (ACTH) stimulation test in patients with severe sepsis (SS) and determine the suitability of use of SaC and cFC levels instead of STC for the diagnosis of adrenal insufficiency (AI) in patients with SS.', 'subject score': 888, 'object score': 888}, 'PMID:27695824': {'publication date': '2016 Nov 01', 'sentence': 'The efficacy of hydrocortisone in patients with severe sepsis without shock remains controversial.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0036690---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8248241",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:10849939",
-                "PMID:11246311",
-                "PMID:11333472",
-                "PMID:11471384",
-                "PMID:11885413",
-                "PMID:12120695",
-                "PMID:12558137",
-                "PMID:14767873",
-                "PMID:15503552",
-                "PMID:15752405",
-                "PMID:15947898",
-                "PMID:16850006",
-                "PMID:18499615",
-                "PMID:20358501",
-                "PMID:20455885",
-                "PMID:21308518",
-                "PMID:24621333",
-                "PMID:25223852",
-                "PMID:26753096",
-                "PMID:27695824"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 312713,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-          "name": "congenital adrenal hyperplasia",
-          "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:237751000",
-            "DOID:12255",
-            "NCIT:C34360",
-            "ORPHANET:418",
-            "MONDO:0018479",
-            "MEDDRA:10010323",
-            "ICD9:255.2",
-            "DOID:0050811",
-            "HP:0008258",
-            "UMLS:C0001627",
-            "UMLS:C0701163",
-            "ICD10:E25",
-            "MESH:D000312"
-          ],
-          "id": "MONDO:0018479",
-          "category": "biolink:Disease",
-          "all_names": [
-            "congenital adrenal hyperplasia",
-            "obsolete congenital adrenal hyperplasia",
-            "Adrenogenital disorders",
-            "Adrenogenital disorder",
-            "Congenital adrenal hyperplasia",
-            "Adrenal Hyperplasia, Congenital",
-            "obsolete_congenital adrenal hyperplasia",
-            "Congenital Adrenal Hyperplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-            "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-            "http://omim.org/entry/201710",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312713,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-              "name": "congenital adrenal hyperplasia",
-              "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:237751000",
-                "DOID:12255",
-                "NCIT:C34360",
-                "ORPHANET:418",
-                "MONDO:0018479",
-                "MEDDRA:10010323",
-                "ICD9:255.2",
-                "DOID:0050811",
-                "HP:0008258",
-                "UMLS:C0001627",
-                "UMLS:C0701163",
-                "ICD10:E25",
-                "MESH:D000312"
-              ],
-              "id": "MONDO:0018479",
-              "category": "biolink:Disease",
-              "all_names": [
-                "congenital adrenal hyperplasia",
-                "obsolete congenital adrenal hyperplasia",
-                "Adrenogenital disorders",
-                "Adrenogenital disorder",
-                "Congenital adrenal hyperplasia",
-                "Adrenal Hyperplasia, Congenital",
-                "obsolete_congenital adrenal hyperplasia",
-                "Congenital Adrenal Hyperplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-                "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-                "http://omim.org/entry/201710",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7892658,
-            "start": 569,
-            "end": 312713,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10720048': {'publication date': '2000 Mar', 'sentence': 'We conclude that the regimen of flutamide, testolactone, reduced hydrocortisone dose, and fludrocortisone provides effective control of congenital adrenal hyperplasia with reduced risk of glucocorticoid excess.', 'subject score': 851, 'object score': 1000}, 'PMID:11057552': {'publication date': '2000', 'sentence': 'Nine are still being treated medically by the pediatric endocrine team with hydrocortisone for CAH.', 'subject score': 1000, 'object score': 1000}, 'PMID:12174243': {'publication date': '2002 Jul', 'sentence': 'We report a case, which was misdiagnosed as a case of congenital adrenal hyperplasia and treated inappropriately with hydrocortisone and fludrocortisone for 12-months before he had a urinary tract infection and was discovered to have obstructive uropathy on ultrasound.', 'subject score': 1000, 'object score': 1000}, 'PMID:16607925': {'publication date': '2006 Mar', 'sentence': 'CONCLUSION: We demonstrated that a hydrocortisone dose of 17.64 +/- 3.60 mg/m2/day in classical CAH had a negative influence on height development for genetic height potential in 8.5 years of follow-up and that it is necessary to use the lowest possible steroid dosage by individualizing the dose.', 'subject score': 888, 'object score': 916}, 'PMID:18647821': {'publication date': '2008 Oct', 'sentence': 'CASE REPORT: The patient was known with CAH due to 3beta-HSD deficiency and treated with hydrocortisone and fludrocortisone since the neonatal period.', 'subject score': 1000, 'object score': 1000}, 'PMID:19486026': {'publication date': '2010 Apr', 'sentence': 'A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia.', 'subject score': 888, 'object score': 1000}, 'PMID:19622620': {'publication date': '2009 Oct', 'sentence': 'OBJECTIVE: The aim of the study was to determine an optimal range for hydrocortisone dosing during puberty in children with classical CAH who were exclusively treated with hydrocortisone.', 'subject score': 1000, 'object score': 916}, 'PMID:20379352': {'publication date': '2010', 'sentence': 'Hydrocortisone has long been the treatment of choice for congenital adrenal hyperplasia (CAH).', 'subject score': 1000, 'object score': 861}, 'PMID:20857846': {'publication date': '2010 Jul', 'sentence': '11beta-hydroxylase deficient congenital adrenal hyperplasia was diagnosed and hydrocortisone treatment was started.', 'subject score': 888, 'object score': 823}, 'PMID:2303071': {'publication date': '1990 Jan', 'sentence': 'Daily profiles of salivary cortisol were determined in 14 cortisol-treated children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, and in 5 healthy sibs.', 'subject score': 888, 'object score': 777}, 'PMID:24170965': {'publication date': '2013 Oct', 'sentence': 'He was diagnosed as having salt-wasting CAH with a high 17-OHP level at neonatal screening and was initially treated with hydrocortisone at 8 days of age.', 'subject score': 1000, 'object score': 1000}, 'PMID:24560184': {'publication date': '2014 May', 'sentence': 'OBJECTIVE: To estimate the impact of the average daily dose of hydrocortisone (HC) on the amount of growth attained in children with congenital adrenal hyperplasia (CAH).', 'subject score': 1000, 'object score': 817}, 'PMID:24655023': {'publication date': '2014 Jul', 'sentence': 'The child with difficult to control Congenital Adrenal Hyperplasia: is there a place for continuous subcutaneous hydrocortisone therapy.', 'subject score': 833, 'object score': 1000}, 'PMID:25364676': {'publication date': '2014 Nov', 'sentence': 'BACKGROUND: There are recommendations regarding the total dose of hydrocortisone to be administered in the treatment of classical congenital adrenal hyperplasia (CAH) to achieve the twin objectives of glucocorticoid replacement and control of hyperandrogenism.', 'subject score': 1000, 'object score': 916}, 'PMID:25494662': {'publication date': '2015 Mar', 'sentence': 'MAIN OUTCOME MEASURES: The primary outcome was cortisol pharmacokinetics of Chronocort and secondary outcomes included biomarkers of CAH control (androstenedione and 17-OHP).', 'subject score': 888, 'object score': 756}, 'PMID:26107677': {'publication date': '2015 Jun', 'sentence': 'No germline p53 gene mutation including R337H was detected.The patient was first misdiagnosed as CAH and treated with hydrocortisone for 3 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:26108325': {'publication date': '2015 Jun', 'sentence': 'After treatment with hydrocortisone and/or 9-alpha fluorohydrocortisone, cortical hormone levels improved in all the children, and the levels of cortisol, testosterone, estradiol, and electrolytes improved significantly after treatment in children with salt-losing CAH (P<0.05).', 'subject score': 1000, 'object score': 1000}, 'PMID:27680873': {'publication date': '2016 12', 'sentence': 'OBJECTIVE: This study sought to approximate physiologic cortisol secretion via continuous subcutaneous hydrocortisone infusion (CSHI) and evaluate the safety and efficacy of CSHI in patients with difficult-to-treat CAH.', 'subject score': 861, 'object score': 916}, 'PMID:27688786': {'publication date': '2016', 'sentence': 'Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia.', 'subject score': 1000, 'object score': 817}, 'PMID:28100629': {'publication date': '2017 Apr', 'sentence': 'Impact of food, alcohol and pH on modified-release hydrocortisone developed to treat congenital adrenal hyperplasia.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0001627---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8061437",
-              "object": "MONDO:0018479",
-              "publications": [
-                "PMID:10720048",
-                "PMID:11057552",
-                "PMID:12174243",
-                "PMID:16607925",
-                "PMID:18647821",
-                "PMID:19486026",
-                "PMID:19622620",
-                "PMID:20379352",
-                "PMID:20857846",
-                "PMID:2303071",
-                "PMID:24170965",
-                "PMID:24560184",
-                "PMID:24655023",
-                "PMID:25364676",
-                "PMID:25494662",
-                "PMID:26107677",
-                "PMID:26108325",
-                "PMID:27680873",
-                "PMID:27688786",
-                "PMID:28100629"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318927,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001156",
-          "name": "borderline personality disorder",
-          "description": "A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions. [HPO:probinson]; A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions.; A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions.; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "SNOMEDCT:20010003",
-            "ICD10:F60.3",
-            "MEDDRA:10006034",
-            "PSY:06622",
-            "MESH:D001883",
-            "HP:0012076",
-            "DOID:10930",
-            "MONDO:0001156",
-            "NCIT:C92633",
-            "UMLS:C0006012",
-            "ICD9:301.83",
-            "MEDDRA:10006033"
-          ],
-          "id": "MONDO:0001156",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Borderline Personality Disorder",
-            "borderline personality disorder",
-            "Borderline personality disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/borderline_personality_disorde",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318927,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001156",
-              "name": "borderline personality disorder",
-              "description": "A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions. [HPO:probinson]; A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions.; A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions.; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "SNOMEDCT:20010003",
-                "ICD10:F60.3",
-                "MEDDRA:10006034",
-                "PSY:06622",
-                "MESH:D001883",
-                "HP:0012076",
-                "DOID:10930",
-                "MONDO:0001156",
-                "NCIT:C92633",
-                "UMLS:C0006012",
-                "ICD9:301.83",
-                "MEDDRA:10006033"
-              ],
-              "id": "MONDO:0001156",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Borderline Personality Disorder",
-                "borderline personality disorder",
-                "Borderline personality disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/borderline_personality_disorde",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7885542,
-            "start": 569,
-            "end": 318927,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10715361': {'publication date': '2000 Mar 15', 'sentence': 'RESULTS: The cortisol and prolactin responses to the m-CPP challenge in BPD patients were significantly lower compared to those in controls.', 'subject score': 1000, 'object score': 916}, 'PMID:12695738': {'publication date': '2003 Apr', 'sentence': 'Twenty-four-hour urine cortisol in combat veterans with PTSD and comorbid borderline personality disorder.', 'subject score': 771, 'object score': 880}, 'PMID:12772042': {'publication date': '2003', 'sentence': 'Baseline cortisol concentrations, although lower in BPD patients, were not significantly different among groups.', 'subject score': 851, 'object score': 916}, 'PMID:15458851': {'publication date': '2004', 'sentence': 'The ambulatory assessment of saliva cortisol is a suitable approach to study basic parameters of the HPA-axis in patients with BPD.', 'subject score': 888, 'object score': 1000}, 'PMID:16199015': {'publication date': '2006 Apr 01', 'sentence': 'Therefore, our study aimed at examining serum profiles of cortisol, cytokines, and the cortisol/dehydroepiandrosterone (cortisol/DHEA) ratio in MDD/BPD patients and a healthy comparison group.', 'subject score': 1000, 'object score': 854}, 'PMID:17028025': {'publication date': '2007 Dec', 'sentence': 'Hence, the present pilot study investigates the basic levels of cortisol and DHEA and the ratio (CDR) between the two hormones in BPD patients.', 'subject score': 1000, 'object score': 916}, 'PMID:24134123': {'publication date': '2014 Jul', 'sentence': 'METHODS: Serum CRP levels and salivary cortisol before and after the dexamethasone suppression test (DST) were assessed in 50 inpatients with main diagnoses PTSD, major depressive disorder or borderline personality disorder.', 'subject score': 888, 'object score': 1000}, 'PMID:24401326': {'publication date': '2014', 'sentence': 'METHODS: The aim of this work consisted in assessing, by ELISA, fasting plasma levels of DBI and dehydroepiandrosterone sulphate (DHEA-S), including cortisol and the cortisol-to-DHEA-S molar ratio (CDR), in 17 BPD adolescents versus 13 healthy controls, testing the possibility that clinical scales related to depressive or anxious traits (CDI, STAI-Y) or to disease severity (BPDCL) might be associated with a selective dysregulation of these parameters.', 'subject score': 1000, 'object score': 854}, 'PMID:29702176': {'publication date': '2018 Apr 24', 'sentence': 'Cortisol measured in patients with BPD was significantly lower compared to HC in the presence of emotional neglect and physical neglect.', 'subject score': 1000, 'object score': 1000}, 'PMID:35709662': {'publication date': '2022 Jun 03', 'sentence': 'RESULTS: Oxytocin decreased and cortisol remained unchanged in mothers with BPD while healthy mothers showed stable oxytocin and decreased cortisol after interaction.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0006012---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8054429",
-              "object": "MONDO:0001156",
-              "publications": [
-                "PMID:10715361",
-                "PMID:12695738",
-                "PMID:12772042",
-                "PMID:15458851",
-                "PMID:16199015",
-                "PMID:17028025",
-                "PMID:24134123",
-                "PMID:24401326",
-                "PMID:29702176",
-                "PMID:35709662"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 528832,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-          "name": "toxic shock syndrome",
-          "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C35498",
-            "UMLS:C0600327",
-            "UMLS:CN204669",
-            "MEDDRA:10044248",
-            "MESH:D012772",
-            "MEDDRA:10044249",
-            "SNOMEDCT:18504008",
-            "DOID:14115",
-            "MEDDRA:10042852",
-            "UMLS:C0036983",
-            "ORPHANET:36234",
-            "SNOMEDCT:76571007",
-            "MEDDRA:10040580",
-            "NCIT:C35018",
-            "MEDDRA:10040070",
-            "ICD9:040.82",
-            "ICD10:A48.3",
-            "MONDO:0001881",
-            "EFO:0006834",
-            "SYMP:0000451"
-          ],
-          "id": "MONDO:0001881",
-          "category": "biolink:Disease",
-          "all_names": [
-            "toxic shock syndrome",
-            "Septic Shock",
-            "Shock, Septic",
-            "Toxic Shock Syndrome",
-            "Bacterial toxic-shock syndrome",
-            "septic shock",
-            "Toxic shock syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 528832,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-              "name": "toxic shock syndrome",
-              "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C35498",
-                "UMLS:C0600327",
-                "UMLS:CN204669",
-                "MEDDRA:10044248",
-                "MESH:D012772",
-                "MEDDRA:10044249",
-                "SNOMEDCT:18504008",
-                "DOID:14115",
-                "MEDDRA:10042852",
-                "UMLS:C0036983",
-                "ORPHANET:36234",
-                "SNOMEDCT:76571007",
-                "MEDDRA:10040580",
-                "NCIT:C35018",
-                "MEDDRA:10040070",
-                "ICD9:040.82",
-                "ICD10:A48.3",
-                "MONDO:0001881",
-                "EFO:0006834",
-                "SYMP:0000451"
-              ],
-              "id": "MONDO:0001881",
-              "category": "biolink:Disease",
-              "all_names": [
-                "toxic shock syndrome",
-                "Septic Shock",
-                "Shock, Septic",
-                "Toxic Shock Syndrome",
-                "Bacterial toxic-shock syndrome",
-                "septic shock",
-                "Toxic shock syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7829565,
-            "start": 569,
-            "end": 528832,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10678798': {'publication date': '1999 Dec', 'sentence': 'Two recent small randomized trials evaluating a 5- to 12-day course of low dose hydrocortisone in patients with septic shock have reported a significant clinical improvement and a reduction in mortality.', 'subject score': 901, 'object score': 1000}, 'PMID:11271081': {'publication date': '2000 Dec', 'sentence': 'PATIENTS: Twenty consecutive patients with septic shock and a cardiac index of 3.5 l/min or higher, started on \"low-dose\" hydrocortisone therapy (100 mg bolus, 10 mg/h for 7 days and subsequent tapering) within 72 h of the onset of shock.', 'subject score': 861, 'object score': 1000}, 'PMID:11333472': {'publication date': '2001 May', 'sentence': 'CONCLUSIONS: Plasma cortisol and ACTH levels were increased in children with sepsis and septic shock.', 'subject score': 888, 'object score': 1000}, 'PMID:11445745': {'publication date': '2001 Jul', 'sentence': 'OBJECTIVE: To gather the data to provide a rationale for using replacement therapy with hydrocortisone in septic shock patients.', 'subject score': 1000, 'object score': 901}, 'PMID:12186604': {'publication date': '2002 Aug 21', 'sentence': 'Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:12426230': {'publication date': '2003 Feb 15', 'sentence': 'Within the last few years, increasing evidence of relative adrenal insufficiency in septic shock evoked a reassessment of hydrocortisone therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:12545007': {'publication date': '2003 Jan', 'sentence': 'OBJECTIVE: To determine whether a baseline (random) cortisol concentration <25 microg/dL in patients with septic shock was a better discriminator of adrenal insufficiency than the standard (250 microg) and the low-dose (1 microg) corticotropin stimulation tests as assessed by the hemodynamic response to steroid replacement.', 'subject score': 694, 'object score': 1000}, 'PMID:12592960': {'publication date': '2003 Jan', 'sentence': 'Recently, a new concept has emerged with more promising results--low dose, long-term hydrocortisone therapy- and this approach is now being evaluated in the treatment of septic shock.', 'subject score': 861, 'object score': 1000}, 'PMID:12766716': {'publication date': '2003 Apr', 'sentence': 'There is no concordance in literature about the role of replacement therapy with hydrocortisone on survival in patients with septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:13678564': {'publication date': '2003 Oct', 'sentence': 'Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:14714106': {'publication date': '2004 Feb', 'sentence': 'PATIENTS: Septic shock patients (n=300) included in a placebo-controlled randomized double-blind study on the efficacy and safety of a 7-day treatment with 50 mg hydrocortisone every 6 h intravenously and 50 microg fludrocortisone every 24 h orally.', 'subject score': 790, 'object score': 901}, 'PMID:15179130': {'publication date': '2004 Apr', 'sentence': 'The aim of the present study was to investigate whether the plasma levels of soluble CAMs, reflecting in vivo endothelial activation, could be modulated in patients with septic shock treated by hydrocortisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:15482661': {'publication date': '2004 Sep', 'sentence': '[Effects of different doses of hydrocortisone on acute lung injury in rats with early septic shock induced by Escherichia coli].', 'subject score': 1000, 'object score': 901}, 'PMID:16276166': {'publication date': '2005 Nov', 'sentence': 'OBJECTIVES: To investigate the effect of low-dose hydrocortisone on time to shock reversal, the cytokine profile, and its relation to adrenal function in patients with early septic shock.', 'subject score': 901, 'object score': 901}, 'PMID:1669084': {'publication date': '1991', 'sentence': 'It was found, that hydrocortisone and dopamine given together increase the stability of the pulmonary lysosomes indicating a value of such management of the septic shock in man.', 'subject score': 1000, 'object score': 1000}, 'PMID:17003064': {'publication date': '2007 Feb', 'sentence': 'What is the rationale for hydrocortisone treatment in children with infection-related adrenal insufficiency and septic shock?', 'subject score': 888, 'object score': 1000}, 'PMID:17325831': {'publication date': '2007 Apr', 'sentence': 'CONCLUSIONS: Bolus injections of hydrocortisone may induce significant increases of blood glucose in patients with septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:17509634': {'publication date': '2007 Jun', 'sentence': 'CONCLUSIONS: Hydrocortisone mediates immunmodulating effects in therapy of patients suffering of septic shock without involvement of specific platelet receptors in vitro.', 'subject score': 1000, 'object score': 1000}, 'PMID:17551886': {'publication date': '2007 Jun 15', 'sentence': 'TREATMENT AND COURSE: The patient was admitted to the intensive care unit and initially treated with intravenous piperacillin/tazobactam and hydrocortisone for septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:17596656': {'publication date': '2007 Jun', 'sentence': 'Because high levels of cortisol are frequently observed in patients with septic shock, low levels of serum cortisol are considered indicative of relative adrenal insufficiency (RAI).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0036983---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7996696",
-              "object": "MONDO:0001881",
-              "publications": [
-                "PMID:10678798",
-                "PMID:11271081",
-                "PMID:11333472",
-                "PMID:11445745",
-                "PMID:12186604",
-                "PMID:12426230",
-                "PMID:12545007",
-                "PMID:12592960",
-                "PMID:12766716",
-                "PMID:13678564",
-                "PMID:14714106",
-                "PMID:15179130",
-                "PMID:15482661",
-                "PMID:16276166",
-                "PMID:1669084",
-                "PMID:17003064",
-                "PMID:17325831",
-                "PMID:17509634",
-                "PMID:17551886",
-                "PMID:17596656"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 610975,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/DOID_0080909",
-          "name": "castration-resistant prostate carcinoma",
-          "description": "A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.",
-          "equivalent_curies": [
-            "MESH:D064129",
-            "MONDO:0850353",
-            "DOID:0080909",
-            "MEDDRA:10076506",
-            "SNOMEDCT:427492003",
-            "UMLS:C3658267",
-            "MEDDRA:10062904",
-            "NCIT:C130234",
-            "UMLS:C1328504"
-          ],
-          "id": "DOID:0080909",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Prostatic Neoplasms, Castration-Resistant",
-            "castration-resistant prostate carcinoma",
-            "Castration-Resistant Prostate Carcinoma",
-            "Hormone refractory prostate cancer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:30324351"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 610975,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/DOID_0080909",
-              "name": "castration-resistant prostate carcinoma",
-              "description": "A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.",
-              "equivalent_curies": [
-                "MESH:D064129",
-                "MONDO:0850353",
-                "DOID:0080909",
-                "MEDDRA:10076506",
-                "SNOMEDCT:427492003",
-                "UMLS:C3658267",
-                "MEDDRA:10062904",
-                "NCIT:C130234",
-                "UMLS:C1328504"
-              ],
-              "id": "DOID:0080909",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Prostatic Neoplasms, Castration-Resistant",
-                "castration-resistant prostate carcinoma",
-                "Castration-Resistant Prostate Carcinoma",
-                "Hormone refractory prostate cancer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:30324351"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7718626,
-            "start": 569,
-            "end": 610975,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10604268': {'publication date': '1999 Oct', 'sentence': 'We have studied intravenous docetaxel 70 mg/m2, oral estramustine, and low-dose daily hydrocortisone in men with HRPC who demonstrated progression after initial hormone therapy.', 'subject score': 861, 'object score': 1000}, 'PMID:11331330': {'publication date': '2001 May 01', 'sentence': 'We studied intravenous administration of docetaxel 70 mg/m(2), oral estramustine, and low-dose daily hydrocortisone in men with HRPC who demonstrated progression after initial hormone therapy.', 'subject score': 861, 'object score': 1000}, 'PMID:20438593': {'publication date': '2010 Jul', 'sentence': 'OBJECTIVE: To assess the combination of docetaxel (DTX), estramustine phosphate (EMP) and hydrocortisone for patients with hormone-refractory prostate cancer (HRPC).', 'subject score': 1000, 'object score': 1000}, 'PMID:7506794': {'publication date': '1994 Feb 02', 'sentence': 'BACKGROUND: The best treatment for patients with \"hormone-refractory\" metastatic prostate cancer is unclear, particularly in patients for whom suramin and hydrocortisone have failed.', 'subject score': 1000, 'object score': 924}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C1328504---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7882717",
-              "object": "DOID:0080909",
-              "publications": [
-                "PMID:10604268",
-                "PMID:11331330",
-                "PMID:20438593",
-                "PMID:7506794"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 314857,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004795",
-          "name": "otitis externa",
-          "description": "Inflammation of the anatomical structures of the outer ear and ear canal, which is most often caused by an infectious process. Symptoms include erythema, edema, and pain.; Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.; Inflammation or infection of the external auditory canal (EAC), the auricle, or both. [http://search.medscape.com/search/?q=otitis%20externa, ORCID:0000-0001-5208-3432]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021919",
-            "NCIT:C79601",
-            "MESH:D010032",
-            "SNOMEDCT:3135009",
-            "MEDDRA:10052558",
-            "NCIT:C3299",
-            "MEDDRA:10021920",
-            "UMLS:C0029878",
-            "UMLS:C0021355",
-            "MEDDRA:10065837",
-            "HP:0410017",
-            "MEDDRA:10033072",
-            "MEDDRA:10082612",
-            "EFO:0009560",
-            "DOID:9463",
-            "ICD9:380.1",
-            "SNOMEDCT:86981007",
-            "MONDO:0004795"
-          ],
-          "id": "MONDO:0004795",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infective otitis externa",
-            "Otitis Externa",
-            "Otitis externa",
-            "otitis externa",
-            "Infectious Otitis Externa"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/otitis_externa",
-            "http://search.medscape.com/search/?q=otitis%20externa",
-            "https://orcid.org/0000-0001-5208-3432"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314857,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004795",
-              "name": "otitis externa",
-              "description": "Inflammation of the anatomical structures of the outer ear and ear canal, which is most often caused by an infectious process. Symptoms include erythema, edema, and pain.; Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.; Inflammation or infection of the external auditory canal (EAC), the auricle, or both. [http://search.medscape.com/search/?q=otitis%20externa, ORCID:0000-0001-5208-3432]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021919",
-                "NCIT:C79601",
-                "MESH:D010032",
-                "SNOMEDCT:3135009",
-                "MEDDRA:10052558",
-                "NCIT:C3299",
-                "MEDDRA:10021920",
-                "UMLS:C0029878",
-                "UMLS:C0021355",
-                "MEDDRA:10065837",
-                "HP:0410017",
-                "MEDDRA:10033072",
-                "MEDDRA:10082612",
-                "EFO:0009560",
-                "DOID:9463",
-                "ICD9:380.1",
-                "SNOMEDCT:86981007",
-                "MONDO:0004795"
-              ],
-              "id": "MONDO:0004795",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infective otitis externa",
-                "Otitis Externa",
-                "Otitis externa",
-                "otitis externa",
-                "Infectious Otitis Externa"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/otitis_externa",
-                "http://search.medscape.com/search/?q=otitis%20externa",
-                "https://orcid.org/0000-0001-5208-3432"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7539713,
-            "start": 569,
-            "end": 314857,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10493278': {'publication date': '1999 Sep', 'sentence': 'Results of clinical trials indicate that ofloxacin otic solution 0.3% is as effective as topical neomycin/polymixin B/hydrocortisone preparations in the treatment of otitis externa (clinical cure rate >80% in adults and >95% in children for both treatments) and oral amoxicillin/clavulanic acid in the treatment of otitis media in the presence of tympanostomy tubes in children (clinical cure rates 76 and 69% for ofloxacin and amoxicillin/clavulanic acid, respectively).', 'subject score': 858, 'object score': 1000}, 'PMID:13219726': {'publication date': '1955 Jan', 'sentence': 'The use of neomycin and hydrocortisone in the treatment of external otitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15180022': {'publication date': '2004 May', 'sentence': 'BACKGROUND: Otitis externa is usually treated empirically with topical neomycin/polymyxin B/hydrocortisone.', 'subject score': 857, 'object score': 1000}, 'PMID:15324520': {'publication date': '2004 Aug', 'sentence': 'Efficacy and safety of topical ciprofloxacin/dexamethasone versus neomycin/polymyxin B/hydrocortisone for otitis externa.', 'subject score': 916, 'object score': 1000}, 'PMID:17660178': {'publication date': '2007 May-Jun', 'sentence': 'A comparison of ciprofloxacin/dexamethasone with neomycin/polymyxin/hydrocortisone for otitis externa pain.', 'subject score': 851, 'object score': 901}, 'PMID:2155756': {'publication date': '1990', 'sentence': \"An open, multi-centre study was carried out in general practice to compare the efficacy, tolerability and acceptability of a neomycin/dexamethasone preparation administered by spray ('Otomize') and neomycin/polymyxin B/hydrocortisone administered as drops ('Otosporin') in the treatment of 187 patients with otitis externa.\", 'subject score': 916, 'object score': 1000}, 'PMID:2156538': {'publication date': '1990', 'sentence': 'In a single blind, randomized study, 46 patients with acute external otitis were treated with either oxytetracycline/hydrocortisone with polymyxin B (TPB) or hydrocortisone-17-alpha-butyrate eardrops for 7 days.', 'subject score': 790, 'object score': 901}, 'PMID:2415098': {'publication date': '1985', 'sentence': 'A randomized clinical trial of two topical preparations (framycitin/gramicidin and oxytetracycline/hydrocortisone with polymyxin B) in the treatment of external otitis.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0029878---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7698304",
-              "object": "MONDO:0004795",
-              "publications": [
-                "PMID:10493278",
-                "PMID:13219726",
-                "PMID:15180022",
-                "PMID:15324520",
-                "PMID:17660178",
-                "PMID:2155756",
-                "PMID:2156538",
-                "PMID:2415098"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322120,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-          "name": "Crohn disease",
-          "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003424",
-            "ORPHANET:206",
-            "NCIT:C37262",
-            "MEDDRA:10038281",
-            "MEDDRA:10011405",
-            "UMLS:CN043071",
-            "SNOMEDCT:50440006",
-            "MEDDRA:10057032",
-            "HP:0100280",
-            "EFO:0000384",
-            "DOID:8778",
-            "MONDO:0005011",
-            "PDQ:CDR0000714480",
-            "UMLS:C0010346",
-            "NCIT:C2965",
-            "SNOMEDCT:7620006",
-            "ICD10:K50.1",
-            "UMLS:C0156147",
-            "MEDDRA:10011398",
-            "MEDDRA:10011401",
-            "SNOMEDCT:34000006",
-            "ICD9:555.1",
-            "MEDDRA:10013099",
-            "MEDDRA:10011402",
-            "MEDDRA:10011400"
-          ],
-          "id": "MONDO:0005011",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Granulomatous Colitis",
-            "Crohn's disease of large bowel",
-            "Regional enteritis of large intestine",
-            "Crohn Disease",
-            "Crohn disease",
-            "Crohn's disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/chron%27s_disease",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322120,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-              "name": "Crohn disease",
-              "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003424",
-                "ORPHANET:206",
-                "NCIT:C37262",
-                "MEDDRA:10038281",
-                "MEDDRA:10011405",
-                "UMLS:CN043071",
-                "SNOMEDCT:50440006",
-                "MEDDRA:10057032",
-                "HP:0100280",
-                "EFO:0000384",
-                "DOID:8778",
-                "MONDO:0005011",
-                "PDQ:CDR0000714480",
-                "UMLS:C0010346",
-                "NCIT:C2965",
-                "SNOMEDCT:7620006",
-                "ICD10:K50.1",
-                "UMLS:C0156147",
-                "MEDDRA:10011398",
-                "MEDDRA:10011401",
-                "SNOMEDCT:34000006",
-                "ICD9:555.1",
-                "MEDDRA:10013099",
-                "MEDDRA:10011402",
-                "MEDDRA:10011400"
-              ],
-              "id": "MONDO:0005011",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Granulomatous Colitis",
-                "Crohn's disease of large bowel",
-                "Regional enteritis of large intestine",
-                "Crohn Disease",
-                "Crohn disease",
-                "Crohn's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/chron%27s_disease",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7430038,
-            "start": 569,
-            "end": 322120,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10431487': {'publication date': '1999 Jul', 'sentence': \"CONCLUSIONS: The observed increase in albumin binding might limit the bioactivity of cortisol in patients with Crohn's disease and contribute to the decreased effectiveness and weaker side effects of glucocorticoid therapy in these patients.\", 'subject score': 1000, 'object score': 1000}, 'PMID:1790809': {'publication date': '1991', 'sentence': \"Patients with nonspecific ulcerative colitis and Crohn's disease were treated with drug therapy (prednisolone, sulphasalazine, metronidazole per os and hydrocortisone per rectum) and subjected to 12 sessions of HBO.\", 'subject score': 901, 'object score': 1000}, 'PMID:30797955': {'publication date': '2019', 'sentence': \"Synthetic glucocorticoids are important pharmacological agents that augment the anti-inflammatory and immunosuppressive properties of endogenous cortisol and are widely used for the treatment of asthma, Crohn's disease, and rheumatoid arthritis, amongst other chronic conditions.\", 'subject score': 888, 'object score': 1000}, 'PMID:9741018': {'publication date': '1998 Aug', 'sentence': \"Intravenous ACTH and hydrocortisone are equally effective in achieving therapeutic goals in patients with Crohn's disease who have not achieved results with oral medications.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0010346---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7584436",
-              "object": "MONDO:0005011",
-              "publications": [
-                "PMID:10431487",
-                "PMID:1790809",
-                "PMID:30797955",
-                "PMID:9741018"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317183,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004982",
-          "name": "pancreatitis",
-          "description": "Inflammation of the pancreas.; INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.; The presence of inflammation in the pancreas. [HPO:probinson]; The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0004982",
-            "MEDDRA:10076039",
-            "MEDDRA:10033656",
-            "DOID:4989",
-            "SNOMEDCT:75694006",
-            "ICD10:K85.9",
-            "MEDDRA:10033645",
-            "NCIT:C3306",
-            "EFO:0000278",
-            "HP:0001733",
-            "MESH:D010195",
-            "UMLS:C0030305"
-          ],
-          "id": "MONDO:0004982",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pancreatitis",
-            "pancreatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/pancreatitis.htm",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317183,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004982",
-              "name": "pancreatitis",
-              "description": "Inflammation of the pancreas.; INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.; The presence of inflammation in the pancreas. [HPO:probinson]; The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0004982",
-                "MEDDRA:10076039",
-                "MEDDRA:10033656",
-                "DOID:4989",
-                "SNOMEDCT:75694006",
-                "ICD10:K85.9",
-                "MEDDRA:10033645",
-                "NCIT:C3306",
-                "EFO:0000278",
-                "HP:0001733",
-                "MESH:D010195",
-                "UMLS:C0030305"
-              ],
-              "id": "MONDO:0004982",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pancreatitis",
-                "pancreatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/pancreatitis.htm",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7282805,
-            "start": 569,
-            "end": 317183,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10354211': {'publication date': '1999 Jun', 'sentence': 'The amount of N-acetyl D-glucosamine in the zymogen granule membrane was not altered by caerulein acute pancreatitis induced under continuous hydrocortisone treatment, but it was decreased by the administration of L-364,718 over 7 days after pancreatitis induction.', 'subject score': 851, 'object score': 851}, 'PMID:10436370': {'publication date': '1999', 'sentence': 'OBJECTIVE: To investigate the effects of pretreatment with hydrocortisone on the production of cytokines and the occurrence of acute lung injury in rabbits with AP.', 'subject score': 1000, 'object score': 888}, 'PMID:17805969': {'publication date': '2007 Dec', 'sentence': 'Successful treatment of acute pancreatitis with hydrocortisone in a patient postadrenalectomy.', 'subject score': 1000, 'object score': 888}, 'PMID:29215538': {'publication date': '2018 01', 'sentence': 'OBJECTIVES: The aims of this study were to assess whether copeptin, pro-atrial natriuretic peptide, proadrenomedullin, and cortisol are associated with disease severity in patients with acute pancreatitis (AP) and to compare their ability in predicting organ failure or death.', 'subject score': 1000, 'object score': 888}, 'PMID:6280355': {'publication date': '1981 Dec', 'sentence': '[Concentration of blood adrenocorticotropic hormone and cortisol in patients with acute pancreatitis].', 'subject score': 1000, 'object score': 888}, 'PMID:8521247': {'publication date': '1995 Jun', 'sentence': \"Administration of the cholecystokinin octapeptide (CCK-8) (10 micrograms/kg/day) during the development of acute pancreatitis in animals pretreated with hydrocortisone substantially improved the general state of the animals' pancreases.\", 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0030305---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7432481",
-              "object": "MONDO:0004982",
-              "publications": [
-                "PMID:10354211",
-                "PMID:10436370",
-                "PMID:17805969",
-                "PMID:29215538",
-                "PMID:6280355",
-                "PMID:8521247"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 547810,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005546",
-          "name": "fibromyalgia",
-          "description": "A common nonarticular rheumatic condition that is characterized by muscle pain, tenderness, and stiffness.; A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.; Inflammation and fibrous degeneration of a muscle.; A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10016631",
-            "MEDDRA:10048439",
-            "MEDDRA:10028363",
-            "PSY:19685",
-            "SNOMEDCT:56557000",
-            "SNOMEDCT:726531007",
-            "NCIT:C50566",
-            "ORPHANET:41842",
-            "SNOMEDCT:203082005",
-            "MEDDRA:10063041",
-            "MONDO:0005546",
-            "SNOMEDCT:203102006",
-            "MEDDRA:10016663",
-            "DOID:631",
-            "EFO:0005687",
-            "MESH:D005356",
-            "ICD10:M79.7",
-            "NCIT:C87497",
-            "MEDDRA:10079197",
-            "UMLS:C0016053"
-          ],
-          "id": "MONDO:0005546",
-          "category": "biolink:Disease",
-          "all_names": [
-            "fibromyalgia",
-            "Fibromyalgia",
-            "Fibromyositis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:33024295",
-            "https://www.ncbi.nlm.nih.gov/labs/pmc/articles/pmc7660651/",
-            "PMID:30486733",
-            "PMID:32120395"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 547810,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005546",
-              "name": "fibromyalgia",
-              "description": "A common nonarticular rheumatic condition that is characterized by muscle pain, tenderness, and stiffness.; A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.; Inflammation and fibrous degeneration of a muscle.; A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10016631",
-                "MEDDRA:10048439",
-                "MEDDRA:10028363",
-                "PSY:19685",
-                "SNOMEDCT:56557000",
-                "SNOMEDCT:726531007",
-                "NCIT:C50566",
-                "ORPHANET:41842",
-                "SNOMEDCT:203082005",
-                "MEDDRA:10063041",
-                "MONDO:0005546",
-                "SNOMEDCT:203102006",
-                "MEDDRA:10016663",
-                "DOID:631",
-                "EFO:0005687",
-                "MESH:D005356",
-                "ICD10:M79.7",
-                "NCIT:C87497",
-                "MEDDRA:10079197",
-                "UMLS:C0016053"
-              ],
-              "id": "MONDO:0005546",
-              "category": "biolink:Disease",
-              "all_names": [
-                "fibromyalgia",
-                "Fibromyalgia",
-                "Fibromyositis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:33024295",
-                "https://www.ncbi.nlm.nih.gov/labs/pmc/articles/pmc7660651/",
-                "PMID:30486733",
-                "PMID:32120395"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7253757,
-            "start": 569,
-            "end": 547810,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10335725': {'publication date': '1999 May', 'sentence': 'Graded ACTH infusion revealed similar increases in cortisol in women with fibromyalgia and healthy controls.', 'subject score': 1000, 'object score': 1000}, 'PMID:11094926': {'publication date': '2000 Feb', 'sentence': 'A naturalistic evaluation of cortisol secretion in persons with fibromyalgia and rheumatoid arthritis.', 'subject score': 888, 'object score': 1000}, 'PMID:15142269': {'publication date': '2004', 'sentence': 'We investigated abnormalities of the hypothalamic-pituitary-gonadal axis and cortisol concentrations in women with fibromyalgia and chronic fatigue syndrome (CFS) who were in the follicular phase of their menstrual cycle, and whether their scores for depressive symptoms were related to levels of these hormones.', 'subject score': 888, 'object score': 1000}, 'PMID:15157948': {'publication date': '2004 Jul', 'sentence': 'Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:15479904': {'publication date': '2004 Nov', 'sentence': 'CONCLUSION: Despite low cortisol concentrations in young women with FM, there is no abnormality in HPG axis hormones.', 'subject score': 851, 'object score': 1000}, 'PMID:19102778': {'publication date': '2008 Dec 22', 'sentence': 'Our aim was to demonstrate that urinary cortisol was lower in patients with FM than in healthy subjects.', 'subject score': 888, 'object score': 1000}, 'PMID:21682138': {'publication date': '2011 Apr', 'sentence': 'Moreover, there are reports of deficiency of serotonin, melatonin, cortisol and cytokines in FMS patients, which are fully regulated by circadian rhythm.', 'subject score': 1000, 'object score': 901}, 'PMID:22000300': {'publication date': '2012 May', 'sentence': 'PPT measurement did induce three times higher cortisol and four times higher IL-6 levels in FMS patients, but no change in their ACTH levels.', 'subject score': 816, 'object score': 901}, 'PMID:24426206': {'publication date': '2013 Apr', 'sentence': 'It could be concluded that there is an abnormality in circadian secretion of cortisol in female FMS patients.', 'subject score': 1000, 'object score': 861}, 'PMID:30209437': {'publication date': '2018 Sep 11', 'sentence': 'This study aims to evaluate the probable relationship between intestinal dysbiosis and altered secretion of hormones and vitamins such as cortisol, serotonin, Vitamin D and thyroid hormones in a patient with fibromyalgia.', 'subject score': 1000, 'object score': 1000}, 'PMID:30785911': {'publication date': '2019', 'sentence': 'The objective of this study was to verify the effects of aerobic exercise associated with tryptophan (TRP) supplementation on hyperalgesia, as well as on cortisol, IL-6 and TNF concentrations in female rats with experimental fibromyalgia (FM).', 'subject score': 1000, 'object score': 888}, 'PMID:32149617': {'publication date': '2020 Mar 05', 'sentence': 'RESULTS: Our results show that the clearance rate of cortisol is lower in FMS patients as compared to their matched healthy individuals based on a simplified cortisol secretion model.', 'subject score': 1000, 'object score': 901}, 'PMID:5245506': {'publication date': '1967 Jan', 'sentence': '[The use of hydrocortisone in the treatment of tendovaginitis and fibromyositis].', 'subject score': 1000, 'object score': 1000}, 'PMID:7980669': {'publication date': '1994 Nov', 'sentence': 'OBJECTIVE: To examine basal and stimulated hypothalamic-pituitary-adrenal (HPA) axis and related hormone levels, including adrenocorticotropin (ACTH), cortisol, arginine vasopressin (AVP), and neuropeptide Y (NPY), in patients with fibromyalgia (FM).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0016053---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7402054",
-              "object": "MONDO:0005546",
-              "publications": [
-                "PMID:10335725",
-                "PMID:11094926",
-                "PMID:15142269",
-                "PMID:15157948",
-                "PMID:15479904",
-                "PMID:19102778",
-                "PMID:21682138",
-                "PMID:22000300",
-                "PMID:24426206",
-                "PMID:30209437",
-                "PMID:30785911",
-                "PMID:32149617",
-                "PMID:5245506",
-                "PMID:7980669"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 312684,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015129",
-          "name": "chronic primary adrenal insufficiency",
-          "description": "A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.; An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands as a result of a primary defect in the glands themselves. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0001403",
-            "MONDO:0015129",
-            "DOID:13774",
-            "SNOMEDCT:363732003",
-            "PSY:00810",
-            "MEDDRA:10052381",
-            "UMLS:C1868690",
-            "OMIM:240200",
-            "ICD10:E27.1",
-            "UMLS:C0271737",
-            "MEDDRA:10080674",
-            "SNOMEDCT:373662000",
-            "MEDDRA:10013096",
-            "MEDDRA:10001130",
-            "HP:0008207",
-            "MEDDRA:10036696",
-            "MESH:D000075262",
-            "MESH:D000224",
-            "SNOMEDCT:76715008",
-            "ORPHANET:101959",
-            "NCIT:C26689",
-            "MEDDRA:10085976"
-          ],
-          "id": "MONDO:0015129",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hypoadrenocorticism, Familial",
-            "Primary adrenal insufficiency",
-            "Addisons Disease",
-            "Chronic primary adrenal insufficiency",
-            "Addison's disease due to autoimmunity",
-            "Addison Disease",
-            "Addison's disease",
-            "chronic primary adrenal insufficiency",
-            "Hypoadrenocorticism, familial",
-            "Hypoadrenocorticism, familial related phenotypic feature",
-            "Addison's Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/addison%27s_disease",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312684,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015129",
-              "name": "chronic primary adrenal insufficiency",
-              "description": "A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.; An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands as a result of a primary defect in the glands themselves. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0001403",
-                "MONDO:0015129",
-                "DOID:13774",
-                "SNOMEDCT:363732003",
-                "PSY:00810",
-                "MEDDRA:10052381",
-                "UMLS:C1868690",
-                "OMIM:240200",
-                "ICD10:E27.1",
-                "UMLS:C0271737",
-                "MEDDRA:10080674",
-                "SNOMEDCT:373662000",
-                "MEDDRA:10013096",
-                "MEDDRA:10001130",
-                "HP:0008207",
-                "MEDDRA:10036696",
-                "MESH:D000075262",
-                "MESH:D000224",
-                "SNOMEDCT:76715008",
-                "ORPHANET:101959",
-                "NCIT:C26689",
-                "MEDDRA:10085976"
-              ],
-              "id": "MONDO:0015129",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hypoadrenocorticism, Familial",
-                "Primary adrenal insufficiency",
-                "Addisons Disease",
-                "Chronic primary adrenal insufficiency",
-                "Addison's disease due to autoimmunity",
-                "Addison Disease",
-                "Addison's disease",
-                "chronic primary adrenal insufficiency",
-                "Hypoadrenocorticism, familial",
-                "Hypoadrenocorticism, familial related phenotypic feature",
-                "Addison's Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/addison%27s_disease",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7223915,
-            "start": 569,
-            "end": 312684,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10323386': {'publication date': '1999 May', 'sentence': \"The effects of endogenous opioids and cortisol on thyrotropin and prolactin secretion in patients with Addison's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:13481096': {'publication date': '1957 Dec', 'sentence': \"Lack of plasma cortisol and urinary aldosterone in a pregnant woman with Addison's disease.\", 'subject score': 888, 'object score': 1000}, 'PMID:16580396': {'publication date': '2006 Apr', 'sentence': \"His Addison's disease was managed with hydrocortisone and fludrocortisone, and his hyperthyroidism, with methimazole.\", 'subject score': 1000, 'object score': 1000}, 'PMID:168433': {'publication date': '1975 Feb', 'sentence': \"Effect of natural and synthetic Beta-1 minus 24-and Beta-1 minus 18-corticotrophins on the extra-adrenal metabolism of cortisol and aldosterone in patients with addison's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:17609409': {'publication date': '2007 Jul', 'sentence': 'CONCLUSIONS: CSHI is technically feasible and safe in patients with AD.', 'subject score': 790, 'object score': 1000}, 'PMID:186258': {'publication date': '1976 Jun', 'sentence': \"The plasma ACTH responses to hydrocortisone infusion were compared in patients with Cushing's disease and primary adrenocortical insufficiency.\", 'subject score': 888, 'object score': 1000}, 'PMID:19273569': {'publication date': '2009 Jun', 'sentence': 'OBJECTIVE: Current glucocorticoid replacement regimens fail to fully mimic physiologic cortisol secretion in patients with primary adrenal insufficiency.', 'subject score': 851, 'object score': 1000}, 'PMID:20925018': {'publication date': '2010 Dec', 'sentence': \"Our aim was to investigate the usefulness of circulating levels of adrenocorticotropic hormone (ACTH) and also salivary cortisol to monitor cortisone substitution in patients with Addison's disease.\", 'subject score': 790, 'object score': 1000}, 'PMID:216821': {'publication date': '1979 Mar 23', 'sentence': 'Basal plasma adrenocorticotrophic hormone (ACTH) and cortisol concentrations as well as plasma ACTH and 11-deoxycortisol responses to the administration of a single dose of metyrapone were evaluated in 104 patients with intact pituitary-adrenal axis, in 20 patients with secondary adrenal insufficiency, and in seven patients with primary adrenal insufficiency.', 'subject score': 888, 'object score': 1000}, 'PMID:22893258': {'publication date': '2013 Jan', 'sentence': \"Cortisol pharmacokinetics was assessed in 31 patients with Addison's disease on replacement hydrocortisone doses (median daily dose 20 mg; range 5-50 mg) and 30 healthy control subjects.\", 'subject score': 888, 'object score': 1000}, 'PMID:22907517': {'publication date': '2012 Sep', 'sentence': \"Hydrocortisone and fludrocortisone are the preferred therapy for Addison's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:233701': {'publication date': '1978 Jun', 'sentence': 'In order first to establish the disappearance t 1/2 of endogenous immunoreactive human beta-MSH (RIA-h beta MSH), which is now known to represent the lipotropins, human beta-LPH and human gamma-LPH, the plasma concentrations of RIA-h beta MSH, RIA-hACTH, and fluorogenic corticosteroids (cortisol) were measured before and during infusion of cortisol in three patients with primary adrenocortical insufficiency from whom steroid replacement had been withdrawn.', 'subject score': 1000, 'object score': 1000}, 'PMID:24466047': {'publication date': '2014', 'sentence': 'CONCLUSIONS: This study did not identify any associations between the 9beta polymorphism and cardiovascular risk factors or hydrocortisone dose and determination of this polymorphism is therefore unlikely to be of clinical benefit in the management of patients with AD.', 'subject score': 888, 'object score': 1000}, 'PMID:24517155': {'publication date': '2014 May', 'sentence': \"Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of addison's disease: a randomized clinical trial.\", 'subject score': 861, 'object score': 1000}, 'PMID:24944332': {'publication date': '2014 Sep', 'sentence': 'CONCLUSIONS: This long-term prospective trial is the first to document the safety of DR-HC in patients with primary AI and demonstrates that such treatment is well tolerated during 24 consecutive months of therapy.', 'subject score': 790, 'object score': 1000}, 'PMID:25400085': {'publication date': '2015 Jul', 'sentence': 'OBJECTIVE: The aim of this study was to compare circadian hormone rhythms and insulin sensitivity in conventional thrice-daily regimen of glucocorticoid replacement therapy with CSHI treatment in patients with AD.', 'subject score': 840, 'object score': 1000}, 'PMID:2557986': {'publication date': '1989 May', 'sentence': \"Plasma ACTH responses to cortisol infusion are similar in patients with primary hypoadrenalism and patients studied some years after bilateral adrenalectomy for Cushing's syndrome.\", 'subject score': 888, 'object score': 1000}, 'PMID:25781534': {'publication date': '2015 Jul', 'sentence': 'We report the use of continuous subcutaneous hydrocortisone infusion in an adolescent patient with primary adrenal insufficiency.', 'subject score': 861, 'object score': 1000}, 'PMID:26184416': {'publication date': '2016 Feb', 'sentence': 'This study aimed to assess variations of anthropometric, metabolic, and hormonal parameters in patients with AD after switching from conventional hydrocortisone (HC) treatment to PLEN.', 'subject score': 851, 'object score': 1000}, 'PMID:26684152': {'publication date': '2016 Apr', 'sentence': 'OBJECTIVE: In primary adrenal insufficiency (PAI), replacement with prednisolone may result in lower bone mineral density (BMD) compared with hydrocortisone therapy.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0001403---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0271737---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7378370",
-              "object": "MONDO:0015129",
-              "publications": [
-                "PMID:186258",
-                "PMID:24517155",
-                "PMID:33553982",
-                "PMID:31059146",
-                "PMID:3115635",
-                "PMID:16580396",
-                "PMID:13481096",
-                "PMID:8013139",
-                "PMID:4819287",
-                "PMID:22907517",
-                "PMID:216821",
-                "PMID:22893258",
-                "PMID:741991",
-                "PMID:31744021",
-                "PMID:27813051",
-                "PMID:31611225",
-                "PMID:25781534",
-                "PMID:3015556",
-                "PMID:6090183",
-                "PMID:168433"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7216091,
-            "start": 569,
-            "end": 321528,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1027272': {'publication date': '1976 Dec', 'sentence': '[Dynamics of the cortisol content in the blood plasma in specific hyposensibilization in children with bronchial asthma].', 'subject score': 694, 'object score': 1000}, 'PMID:10531155': {'publication date': '1999 Oct', 'sentence': 'Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate.', 'subject score': 851, 'object score': 888}, 'PMID:10900296': {'publication date': '2000 Sep', 'sentence': 'Serum concentrations of cortisol, cortisone, and cortisol precursors were measured in the morning and in the afternoon in asthmatic patients by reversed-phase high-performance liquid chromatography.', 'subject score': 1000, 'object score': 888}, 'PMID:11112113': {'publication date': '2000 Dec', 'sentence': 'This study aimed to compare the relative effect of fluticasone propionate (FP) and budesonide (BUD) on bronchial responsiveness and endogenous cortisol secretion in adults with asthma.', 'subject score': 851, 'object score': 1000}, 'PMID:11560105': {'publication date': '2001 Aug', 'sentence': 'A reduction in mean 24-hour serum estradiol levels in asthmatic women was noted, whereas cortisol and DHEAS serum concentrations were decreased in asthmatic patients treated with glucocorticosteroids compared with the control group, before HRT.', 'subject score': 1000, 'object score': 888}, 'PMID:11874819': {'publication date': '2002 Mar 01', 'sentence': 'We investigated whether endogenous cortisol levels are lower, and also whether the 24-h cortisol variation is greater, in children with asthma than in control subjects and assessed the relationship between serum cortisol and nocturnal airflow limitation in children with asthma.', 'subject score': 861, 'object score': 1000}, 'PMID:12161504': {'publication date': '2002 Aug', 'sentence': 'We measured serum GBA (bioassay) and cortisol (RIA) levels in 34 asthmatic children (age range, 5.7-14.2 yr) at baseline and after treatment with either inhaled budesonide (800 microg/d, n = 14), fluticasone propionate (500 microg/d, n = 14), or cromones (control group, n = 6).', 'subject score': 1000, 'object score': 790}, 'PMID:12360594': {'publication date': '2002', 'sentence': '[Clinico-experimental aspects of liposomal therapy of bronchial asthma patients with hydrocortisone therapy].', 'subject score': 888, 'object score': 901}, 'PMID:12785222': {'publication date': '2003', 'sentence': '[Glucocorticoid adrenal function and clinical implications of hydrocortisone metabolism tests in patients with bronchial asthma].', 'subject score': 888, 'object score': 1000}, 'PMID:13132667': {'publication date': '1953 Dec 08', 'sentence': '[Remarks on the hydrocortisone therapy of hay-fever and bronchial asthma].', 'subject score': 888, 'object score': 1000}, 'PMID:1315017': {'publication date': '1992 Feb', 'sentence': 'We assessed the effect of long-term therapy with inhaled beclomethasone dipropionate (BDP) on the pituitary-adrenal axis, by measuring the integrated concentration (IC) of plasma cortisol in eight children with asthma (age, 6-16 years) who regularly used inhaled BDP in doses ranging from 8 to 26.5 micrograms/kg (200-450 micrograms/day) for 6 months to 4 years.', 'subject score': 888, 'object score': 1000}, 'PMID:13174318': {'publication date': '1954 Jul', 'sentence': 'Comparative results of the use of ACTH, cortisone, and hydrocortisone in the treatment of intractable bronchial asthma and pulmonary emphysema.', 'subject score': 1000, 'object score': 901}, 'PMID:13234340': {'publication date': '1955 Jan 29', 'sentence': 'Hydrocortisone in treatment of allergic conjunctivitis, allergic rhinitis, and bronchial asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:13240504': {'publication date': '1955 Aug', 'sentence': 'At present combined antibiotic and cortisone or hydrocortisone therapy of asthma seems to be the most rational method of preventing the disease from becoming chronic and intractable.', 'subject score': 888, 'object score': 1000}, 'PMID:13249257': {'publication date': '1955 May 27', 'sentence': 'Hydrocortisone in the therapy of asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:13368523': {'publication date': '1956 Oct 20', 'sentence': 'Chronic asthma treated with aerosol hydrocortisone.', 'subject score': 888, 'object score': 888}, 'PMID:14387393': {'publication date': '1955', 'sentence': 'Ambulatory treatment of bronchial asthma with ACTH, cortisone and hydrocortisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:14626432': {'publication date': '2003', 'sentence': 'We sought to evaluate the effect of short-term and chronic GC therapy on GCR number in peripheral blood lymphocytes, the relationship between GCR number and cortisol concentrations in asthma patients treated with GCs as well as the response to GC therapy in various pictures of this disease.', 'subject score': 888, 'object score': 888}, 'PMID:1477359': {'publication date': '1992 Sep', 'sentence': '[Effects of cortisol on calcium contents of lymphocytes in patients with bronchial asthma].', 'subject score': 1000, 'object score': 1000}, 'PMID:15090754': {'publication date': '2004 Mar', 'sentence': 'Life-threatening hypokalemia in an asthmatic patient treated with high-dose hydrocortisone.', 'subject score': 901, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7363431",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:1027272",
-                "PMID:10531155",
-                "PMID:10900296",
-                "PMID:11112113",
-                "PMID:11560105",
-                "PMID:11874819",
-                "PMID:12161504",
-                "PMID:12360594",
-                "PMID:12785222",
-                "PMID:13132667",
-                "PMID:1315017",
-                "PMID:13174318",
-                "PMID:13234340",
-                "PMID:13240504",
-                "PMID:13249257",
-                "PMID:13368523",
-                "PMID:14387393",
-                "PMID:14626432",
-                "PMID:1477359",
-                "PMID:15090754"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 517695,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005109",
-          "name": "HIV infectious disease",
-          "description": "A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.",
-          "equivalent_curies": [
-            "UMLS:C0019693",
-            "ICD9:042-042.99",
-            "SNOMEDCT:86406008",
-            "NCIT:C3108",
-            "MEDDRA:10020161",
-            "PDQ:CDR0000585059",
-            "MEDDRA:10020443",
-            "MEDDRA:10020160",
-            "MONDO:0005109",
-            "EFO:0000764",
-            "MEDDRA:10020172",
-            "MESH:D015658",
-            "DOID:526"
-          ],
-          "id": "MONDO:0005109",
-          "category": "biolink:Disease",
-          "all_names": [
-            "human immunodeficiency virus infectious disease",
-            "HIV infection",
-            "HIV infectious disease",
-            "HIV Infection",
-            "Human immunodeficiency virus [hiv] infection",
-            "HIV Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/hiv",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000602.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517695,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005109",
-              "name": "HIV infectious disease",
-              "description": "A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.",
-              "equivalent_curies": [
-                "UMLS:C0019693",
-                "ICD9:042-042.99",
-                "SNOMEDCT:86406008",
-                "NCIT:C3108",
-                "MEDDRA:10020161",
-                "PDQ:CDR0000585059",
-                "MEDDRA:10020443",
-                "MEDDRA:10020160",
-                "MONDO:0005109",
-                "EFO:0000764",
-                "MEDDRA:10020172",
-                "MESH:D015658",
-                "DOID:526"
-              ],
-              "id": "MONDO:0005109",
-              "category": "biolink:Disease",
-              "all_names": [
-                "human immunodeficiency virus infectious disease",
-                "HIV infection",
-                "HIV infectious disease",
-                "HIV Infection",
-                "Human immunodeficiency virus [hiv] infection",
-                "HIV Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/hiv",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000602.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26954921,
-            "start": 517695,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:9264144': {'publication date': '1997', 'sentence': 'It was suggested that the progressive shift from type 1 to type 2 cytokine production characteristic of HIV infection could be at least partially provoked by the increase in the production of cortisol and the reduction of DHEA.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0019693---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0005109",
-              "id": "27426083",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:9264144"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 307894,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005155",
-          "name": "cirrhosis of liver",
-          "description": "A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.; Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.; A chronic disorder of the liver in which liver tissue becomes scarred and is partially replaced by regenerative nodules and fibrotic tissue resulting in loss of liver function. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10024667",
-            "ICD10:K74.60",
-            "NCIT:C2951",
-            "MESH:D008103",
-            "HP:0001394",
-            "MEDDRA:10019642",
-            "MONDO:0005155",
-            "EFO:0001422",
-            "UMLS:C0023890",
-            "MEDDRA:10009211",
-            "MEDDRA:10009213",
-            "MEDDRA:10019641",
-            "SNOMEDCT:19943007",
-            "DOID:5082"
-          ],
-          "id": "MONDO:0005155",
-          "category": "biolink:Disease",
-          "all_names": [
-            "liver cirrhosis",
-            "Cirrhosis",
-            "cirrhosis of liver",
-            "Liver Cirrhosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 307894,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005155",
-              "name": "cirrhosis of liver",
-              "description": "A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.; Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.; A chronic disorder of the liver in which liver tissue becomes scarred and is partially replaced by regenerative nodules and fibrotic tissue resulting in loss of liver function. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10024667",
-                "ICD10:K74.60",
-                "NCIT:C2951",
-                "MESH:D008103",
-                "HP:0001394",
-                "MEDDRA:10019642",
-                "MONDO:0005155",
-                "EFO:0001422",
-                "UMLS:C0023890",
-                "MEDDRA:10009211",
-                "MEDDRA:10009213",
-                "MEDDRA:10019641",
-                "SNOMEDCT:19943007",
-                "DOID:5082"
-              ],
-              "id": "MONDO:0005155",
-              "category": "biolink:Disease",
-              "all_names": [
-                "liver cirrhosis",
-                "Cirrhosis",
-                "cirrhosis of liver",
-                "Liver Cirrhosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23986403,
-            "start": 307894,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:35449323': {'publication date': '2022 Apr 22', 'sentence': 'CONCLUSIONS: This study suggests that 24 h urinary free cortisol could be considered as a potential index of adrenal cortisol production in patients with liver cirrhosis and it potentially detects patients with a high mortality risk.', 'subject score': 1000, 'object score': 790}}",
-              "kg2_ids": [
-                "UMLS:C0023890---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0005155",
-              "id": "24427531",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:35449323"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 312713,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-          "name": "congenital adrenal hyperplasia",
-          "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:237751000",
-            "DOID:12255",
-            "NCIT:C34360",
-            "ORPHANET:418",
-            "MONDO:0018479",
-            "MEDDRA:10010323",
-            "ICD9:255.2",
-            "DOID:0050811",
-            "HP:0008258",
-            "UMLS:C0001627",
-            "UMLS:C0701163",
-            "ICD10:E25",
-            "MESH:D000312"
-          ],
-          "id": "MONDO:0018479",
-          "category": "biolink:Disease",
-          "all_names": [
-            "congenital adrenal hyperplasia",
-            "obsolete congenital adrenal hyperplasia",
-            "Adrenogenital disorders",
-            "Adrenogenital disorder",
-            "Congenital adrenal hyperplasia",
-            "Adrenal Hyperplasia, Congenital",
-            "obsolete_congenital adrenal hyperplasia",
-            "Congenital Adrenal Hyperplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-            "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-            "http://omim.org/entry/201710",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312713,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
-              "name": "congenital adrenal hyperplasia",
-              "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:237751000",
-                "DOID:12255",
-                "NCIT:C34360",
-                "ORPHANET:418",
-                "MONDO:0018479",
-                "MEDDRA:10010323",
-                "ICD9:255.2",
-                "DOID:0050811",
-                "HP:0008258",
-                "UMLS:C0001627",
-                "UMLS:C0701163",
-                "ICD10:E25",
-                "MESH:D000312"
-              ],
-              "id": "MONDO:0018479",
-              "category": "biolink:Disease",
-              "all_names": [
-                "congenital adrenal hyperplasia",
-                "obsolete congenital adrenal hyperplasia",
-                "Adrenogenital disorders",
-                "Adrenogenital disorder",
-                "Congenital adrenal hyperplasia",
-                "Adrenal Hyperplasia, Congenital",
-                "obsolete_congenital adrenal hyperplasia",
-                "Congenital Adrenal Hyperplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
-                "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
-                "http://omim.org/entry/201710",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23304107,
-            "start": 312713,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:34518380': {'publication date': '2021 Aug 01', 'sentence': 'Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder that leads to the partial or complete deficiency of cortisol and aldosterone production from the adrenal glands.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0001627---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0018479",
-              "id": "23738730",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:34518380"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320151,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-          "name": "dermatitis, atopic",
-          "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MESH:C566404",
-            "MEDDRA:10012434",
-            "SNOMEDCT:24079001",
-            "MONDO:0011292",
-            "MEDDRA:10003641",
-            "MONDO:0100181",
-            "MEDDRA:10014191",
-            "OMIM:603165",
-            "HP:0001047",
-            "MEDDRA:10001711",
-            "MEDDRA:10003639",
-            "UMLS:C0011615",
-            "UMLS:C4280605",
-            "UMLS:C1864155",
-            "MEDDRA:10012438",
-            "MEDDRA:10014188",
-            "MEDDRA:10001712",
-            "MESH:D003876",
-            "SNOMEDCT:200775004"
-          ],
-          "id": "MONDO:0011292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis, Atopic, 1",
-            "dermatitis, atopic",
-            "Dermatitis, Atopic",
-            "Baby eczema",
-            "Dermatitis, atopic related phenotypic feature",
-            "Atopic dermatitis",
-            "dermatitis, atopic, 1"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:27904186",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320151,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-              "name": "dermatitis, atopic",
-              "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MESH:C566404",
-                "MEDDRA:10012434",
-                "SNOMEDCT:24079001",
-                "MONDO:0011292",
-                "MEDDRA:10003641",
-                "MONDO:0100181",
-                "MEDDRA:10014191",
-                "OMIM:603165",
-                "HP:0001047",
-                "MEDDRA:10001711",
-                "MEDDRA:10003639",
-                "UMLS:C0011615",
-                "UMLS:C4280605",
-                "UMLS:C1864155",
-                "MEDDRA:10012438",
-                "MEDDRA:10014188",
-                "MEDDRA:10001712",
-                "MESH:D003876",
-                "SNOMEDCT:200775004"
-              ],
-              "id": "MONDO:0011292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis, Atopic, 1",
-                "dermatitis, atopic",
-                "Dermatitis, Atopic",
-                "Baby eczema",
-                "Dermatitis, atopic related phenotypic feature",
-                "Atopic dermatitis",
-                "dermatitis, atopic, 1"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:27904186",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20115875,
-            "start": 320151,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:3010589': {'publication date': '1986', 'sentence': '[Reaction of autogenous cortisol production in patients with extensive psoriasis vulgaris or atopic dermatitis following external administration of a 0.25% prednicarbate salve (W/O emulsion)].', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0011615---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0011292",
-              "id": "20514012",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:3010589"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18550439,
-            "start": 183319,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27061835': {'publication date': '2016 09', 'sentence': 'OBJECTIVE: Corticosteroid-binding globulin (CBG), the cortisol transport protein, is cleaved from high-affinity (haCBG) to low-affinity (laCBG) CBG at sites of inflammation releasing bioavailable, anti-inflammatory cortisol.', 'subject score': 1000, 'object score': 861}, 'PMID:28043038': {'publication date': '2017 03', 'sentence': 'CONCLUSION: Variability in cortisol secretion across days forecasts low-grade inflammation, and this association is paramount among older adults who secrete high levels of diurnal cortisol.', 'subject score': 901, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0021368---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "NCIT:C3137",
-              "id": "18924640",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:27061835",
-                "PMID:28043038"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318783,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005147",
-          "name": "type 1 diabetes mellitus",
-          "description": "A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. [HPO:probinson]; A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. // COMMENTS: The onset of type 1 diabetes is typically during adolescence, but it can develop at any age.; A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. // COMMENTS: The onset of type 1 diabetes is typically during adolescence, but it can develop at any age.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10045228",
-            "MEDDRA:10012608",
-            "MESH:D003922",
-            "DOID:9744",
-            "MEDDRA:10022482",
-            "MEDDRA:10067584",
-            "MEDDRA:10022497",
-            "ORPHANET:243377",
-            "KEGG.DISEASE:04940",
-            "UMLS:C0011854",
-            "MEDDRA:10085412",
-            "MEDDRA:10012609",
-            "SNOMEDCT:46635009",
-            "OMIM:222100",
-            "UMLS:C5435660",
-            "MONDO:0005147",
-            "MEDDRA:10023253",
-            "HP:0100651",
-            "EFO:0001359",
-            "NCIT:C2986",
-            "MEDDRA:10021211"
-          ],
-          "id": "MONDO:0005147",
-          "category": "biolink:Disease",
-          "all_names": [
-            "type 1 diabetes mellitus",
-            "Type I diabetes mellitus",
-            "Type 1 diabetes mellitus 1",
-            "obsolete_type I diabetes mellitus",
-            "Type 1 Diabetes Mellitus",
-            "Type 1 diabetes mellitus related phenotypic feature",
-            "Diabetes Mellitus, Insulin-Dependent",
-            "Diabetes Mellitus, Type 1"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/diabetes_mellitus_type_1",
-            "http://en.wikipedia.org/wiki/diabetes",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318783,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005147",
-              "name": "type 1 diabetes mellitus",
-              "description": "A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. [HPO:probinson]; A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. // COMMENTS: The onset of type 1 diabetes is typically during adolescence, but it can develop at any age.; A chronic condition in which the pancreas produces little or no insulin. Type I diabetes mellitus is manifested by the sudden onset of severe hyperglycemia with rapid progression to diabetic ketoacidosis unless treated with insulin. // COMMENTS: The onset of type 1 diabetes is typically during adolescence, but it can develop at any age.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10045228",
-                "MEDDRA:10012608",
-                "MESH:D003922",
-                "DOID:9744",
-                "MEDDRA:10022482",
-                "MEDDRA:10067584",
-                "MEDDRA:10022497",
-                "ORPHANET:243377",
-                "KEGG.DISEASE:04940",
-                "UMLS:C0011854",
-                "MEDDRA:10085412",
-                "MEDDRA:10012609",
-                "SNOMEDCT:46635009",
-                "OMIM:222100",
-                "UMLS:C5435660",
-                "MONDO:0005147",
-                "MEDDRA:10023253",
-                "HP:0100651",
-                "EFO:0001359",
-                "NCIT:C2986",
-                "MEDDRA:10021211"
-              ],
-              "id": "MONDO:0005147",
-              "category": "biolink:Disease",
-              "all_names": [
-                "type 1 diabetes mellitus",
-                "Type I diabetes mellitus",
-                "Type 1 diabetes mellitus 1",
-                "obsolete_type I diabetes mellitus",
-                "Type 1 Diabetes Mellitus",
-                "Type 1 diabetes mellitus related phenotypic feature",
-                "Diabetes Mellitus, Insulin-Dependent",
-                "Diabetes Mellitus, Type 1"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/diabetes_mellitus_type_1",
-                "http://en.wikipedia.org/wiki/diabetes",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16136113,
-            "start": 318783,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:22934546': {'publication date': '2012 Nov', 'sentence': 'The propensity to develop type 1 diabetes or type 2 diabetes/metabolic syndrome depends on the propensity to release of cortisol which correlates with race.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0011854---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0005147",
-              "id": "16473285",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:22934546"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 528832,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-          "name": "toxic shock syndrome",
-          "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C35498",
-            "UMLS:C0600327",
-            "UMLS:CN204669",
-            "MEDDRA:10044248",
-            "MESH:D012772",
-            "MEDDRA:10044249",
-            "SNOMEDCT:18504008",
-            "DOID:14115",
-            "MEDDRA:10042852",
-            "UMLS:C0036983",
-            "ORPHANET:36234",
-            "SNOMEDCT:76571007",
-            "MEDDRA:10040580",
-            "NCIT:C35018",
-            "MEDDRA:10040070",
-            "ICD9:040.82",
-            "ICD10:A48.3",
-            "MONDO:0001881",
-            "EFO:0006834",
-            "SYMP:0000451"
-          ],
-          "id": "MONDO:0001881",
-          "category": "biolink:Disease",
-          "all_names": [
-            "toxic shock syndrome",
-            "Septic Shock",
-            "Shock, Septic",
-            "Toxic Shock Syndrome",
-            "Bacterial toxic-shock syndrome",
-            "septic shock",
-            "Toxic shock syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 528832,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-              "name": "toxic shock syndrome",
-              "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C35498",
-                "UMLS:C0600327",
-                "UMLS:CN204669",
-                "MEDDRA:10044248",
-                "MESH:D012772",
-                "MEDDRA:10044249",
-                "SNOMEDCT:18504008",
-                "DOID:14115",
-                "MEDDRA:10042852",
-                "UMLS:C0036983",
-                "ORPHANET:36234",
-                "SNOMEDCT:76571007",
-                "MEDDRA:10040580",
-                "NCIT:C35018",
-                "MEDDRA:10040070",
-                "ICD9:040.82",
-                "ICD10:A48.3",
-                "MONDO:0001881",
-                "EFO:0006834",
-                "SYMP:0000451"
-              ],
-              "id": "MONDO:0001881",
-              "category": "biolink:Disease",
-              "all_names": [
-                "toxic shock syndrome",
-                "Septic Shock",
-                "Shock, Septic",
-                "Toxic Shock Syndrome",
-                "Bacterial toxic-shock syndrome",
-                "septic shock",
-                "Toxic shock syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15437053,
-            "start": 528832,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21757092': {'publication date': '2011 Jul', 'sentence': 'CIRCI is characterized by an inadequate production of cortisol in relation to an increased demand during periods of severe stress, particularly in critical illnesses such as sepsis or septic shock.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0036983---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0001881",
-              "id": "15760263",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:21757092"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 312684,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015129",
-          "name": "chronic primary adrenal insufficiency",
-          "description": "A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.; An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands as a result of a primary defect in the glands themselves. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0001403",
-            "MONDO:0015129",
-            "DOID:13774",
-            "SNOMEDCT:363732003",
-            "PSY:00810",
-            "MEDDRA:10052381",
-            "UMLS:C1868690",
-            "OMIM:240200",
-            "ICD10:E27.1",
-            "UMLS:C0271737",
-            "MEDDRA:10080674",
-            "SNOMEDCT:373662000",
-            "MEDDRA:10013096",
-            "MEDDRA:10001130",
-            "HP:0008207",
-            "MEDDRA:10036696",
-            "MESH:D000075262",
-            "MESH:D000224",
-            "SNOMEDCT:76715008",
-            "ORPHANET:101959",
-            "NCIT:C26689",
-            "MEDDRA:10085976"
-          ],
-          "id": "MONDO:0015129",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hypoadrenocorticism, Familial",
-            "Primary adrenal insufficiency",
-            "Addisons Disease",
-            "Chronic primary adrenal insufficiency",
-            "Addison's disease due to autoimmunity",
-            "Addison Disease",
-            "Addison's disease",
-            "chronic primary adrenal insufficiency",
-            "Hypoadrenocorticism, familial",
-            "Hypoadrenocorticism, familial related phenotypic feature",
-            "Addison's Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/addison%27s_disease",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312684,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015129",
-              "name": "chronic primary adrenal insufficiency",
-              "description": "A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.; An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands as a result of a primary defect in the glands themselves. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0001403",
-                "MONDO:0015129",
-                "DOID:13774",
-                "SNOMEDCT:363732003",
-                "PSY:00810",
-                "MEDDRA:10052381",
-                "UMLS:C1868690",
-                "OMIM:240200",
-                "ICD10:E27.1",
-                "UMLS:C0271737",
-                "MEDDRA:10080674",
-                "SNOMEDCT:373662000",
-                "MEDDRA:10013096",
-                "MEDDRA:10001130",
-                "HP:0008207",
-                "MEDDRA:10036696",
-                "MESH:D000075262",
-                "MESH:D000224",
-                "SNOMEDCT:76715008",
-                "ORPHANET:101959",
-                "NCIT:C26689",
-                "MEDDRA:10085976"
-              ],
-              "id": "MONDO:0015129",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hypoadrenocorticism, Familial",
-                "Primary adrenal insufficiency",
-                "Addisons Disease",
-                "Chronic primary adrenal insufficiency",
-                "Addison's disease due to autoimmunity",
-                "Addison Disease",
-                "Addison's disease",
-                "chronic primary adrenal insufficiency",
-                "Hypoadrenocorticism, familial",
-                "Hypoadrenocorticism, familial related phenotypic feature",
-                "Addison's Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/addison%27s_disease",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15008006,
-            "start": 312684,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:21103194': {'publication date': '2010 Jun 01', 'sentence': \"Synacthen test diagnosed Addison's disease with a clear deficiency of cortisol production.\", 'subject score': 901, 'object score': 888}, 'PMID:29280740': {'publication date': '2017 Dec 30', 'sentence': 'Primary adrenal insufficiency (PAI) is a heterogeneous group of disorders characterized by an impaired production of cortisol and other steroid hormones by the adrenal cortex.', 'subject score': 1000, 'object score': 1000}, 'PMID:34660134': {'publication date': '2021 Sep', 'sentence': 'Primary adrenal insufficiency leads to the decreased production of cortisol and aldosterone.', 'subject score': 1000, 'object score': 1000}, 'PMID:36611246': {'publication date': '2023 Jan 06', 'sentence': 'This review describes advances in adrenal cell transplants and gene therapy that may allow physiological cortisol production for children and adults with primary adrenal insufficiency.', 'subject score': 1000, 'object score': 851}, 'PMID:7000877': {'publication date': '1980 Jul-Sep', 'sentence': \"Plasma immunoreactive glucagon (IRG), insulin (IRI) and blood glucose (BG) were evaluated in the fasting state and during an arginine test (ATT) in 6 subjects with untreated hypopituitarism (H), in 2 hypopituitary subjects with normal cortisol production (H + C), in 3 subjects with Addison's disease (A) and in 14 normal volunteers (N).\", 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0001403---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0015129",
-              "id": "15330155",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:21103194",
-                "PMID:29280740",
-                "PMID:34660134",
-                "PMID:36611246",
-                "PMID:7000877"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 314596,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-          "name": "Insulin resistance",
-          "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "NCIT:C113101",
-            "UMLS:C0021655",
-            "MEDDRA:10022489",
-            "SNOMEDCT:48606007",
-            "MESH:D007333",
-            "EFO:0002614",
-            "HP:0000855",
-            "SNOMEDCT:763325000"
-          ],
-          "id": "HP:0000855",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Insulin resistance",
-            "insulin resistance",
-            "Insulin Resistance"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314596,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-              "name": "Insulin resistance",
-              "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "NCIT:C113101",
-                "UMLS:C0021655",
-                "MEDDRA:10022489",
-                "SNOMEDCT:48606007",
-                "MESH:D007333",
-                "EFO:0002614",
-                "HP:0000855",
-                "SNOMEDCT:763325000"
-              ],
-              "id": "HP:0000855",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Insulin resistance",
-                "insulin resistance",
-                "Insulin Resistance"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13806069,
-            "start": 314596,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19050176': {'publication date': '2009 Feb', 'sentence': 'Enhanced cortisol production rates, free cortisol, and 11beta-HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss.', 'subject score': 1000, 'object score': 764}, 'PMID:3328721': {'publication date': '1987 Nov', 'sentence': 'This prolonged insulin resistance is largely related to release of growth hormone and cortisol.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0021655---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "HP:0000855",
-              "id": "14100936",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:19050176",
-                "PMID:3328721"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318216,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318216,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13589642,
-            "start": 318216,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:18676028': {'publication date': '2008 Sep 15', 'sentence': 'Obesity is also related to dysregulation of cortisol production by the pre-receptor enzyme, 11beta-hydroxysteroid dehydrogenase, and we speculate that this may have a role in the pathogenesis of obesity and raised ICP seen in IIH.', 'subject score': 1000, 'object score': 888}, 'PMID:22934546': {'publication date': '2012 Nov', 'sentence': 'Further studies indicate the inverse relationship between type 1 diabetes and type 2 diabetes/obesity is due to cortisol production.', 'subject score': 916, 'object score': 888}, 'PMID:23455734': {'publication date': '2013', 'sentence': 'OBJECTIVES: Visceral obesity may be due to the dysregulation of cortisol production or metabolism that lead to metabolic disease.', 'subject score': 888, 'object score': 888}, 'PMID:2682149': {'publication date': '1989 Oct', 'sentence': 'In humans, studies have reported that some obese subjects hypersecrete cortisol and have an increase in the cortisol production rate.', 'subject score': 872, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0028754---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0011122",
-              "id": "13891079",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:18676028",
-                "PMID:22934546",
-                "PMID:23455734",
-                "PMID:2682149"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318773,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0036591",
-          "name": "adrenal cortex neoplasm",
-          "description": "The presence of a neoplasm of the adrenal cortex. [HPO:probinson]; The presence of a neoplasm of the adrenal cortex.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0036591",
-            "MESH:D000306",
-            "UMLS:C0001618",
-            "HP:0100641",
-            "NCIT:C2858",
-            "SNOMEDCT:127022002"
-          ],
-          "id": "MONDO:0036591",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortex neoplasm",
-            "Adrenal Cortical Neoplasm",
-            "Neoplasm of the adrenal cortex",
-            "Adrenal Cortex Neoplasms"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318773,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0036591",
-              "name": "adrenal cortex neoplasm",
-              "description": "The presence of a neoplasm of the adrenal cortex. [HPO:probinson]; The presence of a neoplasm of the adrenal cortex.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0036591",
-                "MESH:D000306",
-                "UMLS:C0001618",
-                "HP:0100641",
-                "NCIT:C2858",
-                "SNOMEDCT:127022002"
-              ],
-              "id": "MONDO:0036591",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortex neoplasm",
-                "Adrenal Cortical Neoplasm",
-                "Neoplasm of the adrenal cortex",
-                "Adrenal Cortex Neoplasms"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13506439,
-            "start": 318773,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18543063': {'publication date': '2008 Oct', 'sentence': 'This is an extremely rare case of bilateral adrenal tumors, in which the left adrenocortical tumor produced and secreted cortisol or both cortisol and aldosterone and the right one produced and secreted both aldosterone and cortisol, as confirmed by clinical findings and pathological studies using immunohistochemical analysis.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0001618---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0036591",
-              "id": "13796050",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:18543063"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 312686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-          "name": "adrenocortical insufficiency",
-          "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0405580",
-            "MEDDRA:10022460",
-            "ICD9:255.4",
-            "EFO:0009491",
-            "MEDDRA:10001367",
-            "MEDDRA:10020936",
-            "MONDO:0000004",
-            "MEDDRA:10020979",
-            "SNOMEDCT:237785004",
-            "SNOMEDCT:386584007",
-            "MEDDRA:10056485",
-            "MEDDRA:10082130",
-            "UMLS:C0001623",
-            "MEDDRA:10001344",
-            "MEDDRA:10001366",
-            "MEDDRA:10001334",
-            "DOID:10493",
-            "NCIT:C26691",
-            "HP:0000846",
-            "MEDDRA:10001335",
-            "MEDDRA:10001369",
-            "MEDDRA:10001342",
-            "MEDDRA:10001343",
-            "MESH:D000309",
-            "SNOMEDCT:111563005",
-            "MEDDRA:10011172",
-            "MEDDRA:10022461"
-          ],
-          "id": "MONDO:0000004",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortical hypofunction",
-            "Adrenocortical Insufficiency",
-            "adrenocortical insufficiency",
-            "Corticoadrenal insufficiency",
-            "Adrenal gland hypofunction",
-            "Adrenal Insufficiency",
-            "Adrenal insufficiency",
-            "Adrenal cortical hypofunction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:11443143"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-              "name": "adrenocortical insufficiency",
-              "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0405580",
-                "MEDDRA:10022460",
-                "ICD9:255.4",
-                "EFO:0009491",
-                "MEDDRA:10001367",
-                "MEDDRA:10020936",
-                "MONDO:0000004",
-                "MEDDRA:10020979",
-                "SNOMEDCT:237785004",
-                "SNOMEDCT:386584007",
-                "MEDDRA:10056485",
-                "MEDDRA:10082130",
-                "UMLS:C0001623",
-                "MEDDRA:10001344",
-                "MEDDRA:10001366",
-                "MEDDRA:10001334",
-                "DOID:10493",
-                "NCIT:C26691",
-                "HP:0000846",
-                "MEDDRA:10001335",
-                "MEDDRA:10001369",
-                "MEDDRA:10001342",
-                "MEDDRA:10001343",
-                "MESH:D000309",
-                "SNOMEDCT:111563005",
-                "MEDDRA:10011172",
-                "MEDDRA:10022461"
-              ],
-              "id": "MONDO:0000004",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortical hypofunction",
-                "Adrenocortical Insufficiency",
-                "adrenocortical insufficiency",
-                "Corticoadrenal insufficiency",
-                "Adrenal gland hypofunction",
-                "Adrenal Insufficiency",
-                "Adrenal insufficiency",
-                "Adrenal cortical hypofunction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:11443143"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13494770,
-            "start": 312686,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:18520332': {'publication date': '2008 Jun', 'sentence': 'We conclude that the clinical picture of late-onset adrenal insufficiency in preterm infants is not a result of an absolute deficiency of cortisol production, but may be a result of a limited ability to synthesize sufficient cortisol for the degree of clinical stress.', 'subject score': 861, 'object score': 888}, 'PMID:36674647': {'publication date': '2023 Jan 06', 'sentence': 'This review aimed to clarify the association between mitochondrial diseases and adrenal insufficiency to produce cortisol.', 'subject score': 1000, 'object score': 1000}, 'PMID:9627368': {'publication date': '1998 Jun', 'sentence': 'We hypothesized that patients with AIDS and symptoms of adrenal insufficiency who produce normal amounts of cortisol in response to administration of 0.25 mg cosyntropin may nevertheless produce lower amounts of cortisol in a course of 24 hours than comparably sick AIDS patients without symptoms of adrenal insufficiency or comparably sick patients without AIDS.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0001623---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0000004",
-              "id": "13783969",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:18520332",
-                "PMID:36674647",
-                "PMID:9627368"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13382406,
-            "start": 321528,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:18373959': {'publication date': '2008 Apr', 'sentence': 'Ironically, despite our understanding of the various stressors that promote chronic adult-onset asthma, most of which are known to elevate cortisol production via the hypothalamic-pituitary-adrenal (HPA) axis, inhaled and systemic corticosteroids are the mainstay for the treatment of chronic asthma.', 'subject score': 833, 'object score': 623}, 'PMID:6230596': {'publication date': '1983', 'sentence': 'The results suggest that bronchial asthma is associated with hypoadrenia due to an impaired production not only of cortisol, but also of adrenocortical androgens resulting in an insufficient hormone supply of the target organs.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0004096---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0004979",
-              "id": "13669597",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:18373959",
-                "PMID:6230596"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11888702,
-            "start": 320039,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:16288183': {'publication date': '2005 Dec', 'sentence': 'Glucocorticoid insufficiency is common during sepsis and may result from insufficient production of cortisol or peripheral tissues resistance.', 'subject score': 1000, 'object score': 1000}, 'PMID:18499615': {'publication date': '2008 Jun', 'sentence': 'BACKGROUND: Severe sepsis activates the hypothalamopituitary axis, increasing cortisol production.', 'subject score': 888, 'object score': 888}, 'PMID:21586102': {'publication date': '2011', 'sentence': 'Severe sepsis is, however, associated with complex alterations of the HPA axis, which may result in decreased production of cortisol as well as glucocorticoid tissue resistance.', 'subject score': 888, 'object score': 1000}, 'PMID:21757092': {'publication date': '2011 Jul', 'sentence': 'CIRCI is characterized by an inadequate production of cortisol in relation to an increased demand during periods of severe stress, particularly in critical illnesses such as sepsis or septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:34516312': {'publication date': '2021 Sep 13', 'sentence': 'This small study suggests that an inability to increase endogenous cortisol production in patients with sepsis who are then provided steroid treatment could improve survival.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0036690---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "HP:0100806",
-              "id": "12147996",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:16288183",
-                "PMID:18499615",
-                "PMID:21586102",
-                "PMID:21757092",
-                "PMID:34516312"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317312,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-          "name": "Hypoxemia",
-          "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "NCIT:C93047",
-            "MEDDRA:10021142",
-            "UMLS:C0242184",
-            "ICD9:799.02",
-            "HP:0012418",
-            "EFO:0009444",
-            "MEDDRA:10021143",
-            "EFO:0009447",
-            "MEDDRA:10021141",
-            "UMLS:C0700292",
-            "SNOMEDCT:389086002",
-            "PDQ:CDR0000773145",
-            "SYMP:0000303",
-            "MEDDRA:10021144",
-            "MESH:D000860",
-            "NCIT:C3890",
-            "SNOMEDCT:389087006"
-          ],
-          "id": "HP:0012418",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "hypoxia",
-            "Hypoxemia",
-            "hypoxemia",
-            "Hypoxia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:DiseaseOrPhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317312,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012418",
-              "name": "Hypoxemia",
-              "description": "An abnormally low level of blood oxygen. [HPO:probinson]; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; An abnormally low level of blood oxygen. // COMMENTS: Note that hypoxemia is defined as a condition where arterial oxygen tension is below normal (80-100mmHg). Hypoxia is defined as the failure of oxygenation at the tissue level. Hypoxia is not measured directly by a standard laboratory value.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "NCIT:C93047",
-                "MEDDRA:10021142",
-                "UMLS:C0242184",
-                "ICD9:799.02",
-                "HP:0012418",
-                "EFO:0009444",
-                "MEDDRA:10021143",
-                "EFO:0009447",
-                "MEDDRA:10021141",
-                "UMLS:C0700292",
-                "SNOMEDCT:389086002",
-                "PDQ:CDR0000773145",
-                "SYMP:0000303",
-                "MEDDRA:10021144",
-                "MESH:D000860",
-                "NCIT:C3890",
-                "SNOMEDCT:389087006"
-              ],
-              "id": "HP:0012418",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "hypoxia",
-                "Hypoxemia",
-                "hypoxemia",
-                "Hypoxia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:DiseaseOrPhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11733776,
-            "start": 317312,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16099825': {'publication date': '2005 Dec', 'sentence': 'This likely represents an adaptive response to LTH, to prevent excessive cortisol production that would restrict fetal growth and potentially induce preterm delivery.', 'subject score': 901, 'object score': 851}, 'PMID:20713972': {'publication date': '2010 Oct', 'sentence': 'These data indicate that LTH enhances adrenal cortical sensitivity to the inhibitory effects of NO on cortisol production.', 'subject score': 901, 'object score': 790}}",
-              "kg2_ids": [
-                "UMLS:C0242184---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "HP:0012418",
-              "id": "11989948",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:16099825",
-                "PMID:20713972"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11479184,
-            "start": 321523,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:15780497': {'publication date': '2005', 'sentence': 'The reduction in local cortisol production which diminishes the endogenous anti-inflammatory effects, also allows for the progression of both vascular and pulmonary inflammation.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032285---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0005249",
-              "id": "11730055",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:15780497"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319116,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008315",
-          "name": "prostate cancer",
-          "description": "A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.; Tumors or cancer of the PROSTATE.; A cancer of the prostate. [HPO:probinson]; What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it:  Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to:  Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer.    What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include:  Problems urinating (peeing), such as:  A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen   Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm)  But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you:  Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer  What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include:  A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate.  If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options:  Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation:  Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer.   Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer.  Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include:  Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0008315",
-            "ICD10:C61",
-            "MEDDRA:10026389",
-            "MEDDRA:10007113",
-            "DOID:10283",
-            "MEDDRA:10036908",
-            "UMLS:C0376358",
-            "SNOMEDCT:399068003",
-            "ICD9:185",
-            "PDQ:CDR0000038782",
-            "MEDDRA:10036910",
-            "MEDDRA:10036946",
-            "KEGG.DISEASE:05215",
-            "NCIT:C7378",
-            "MESH:D011471",
-            "HP:0012125",
-            "MEDDRA:10060862"
-          ],
-          "id": "MONDO:0008315",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Malignant Prostate Neoplasm",
-            "prostate cancer",
-            "Prostate cancer",
-            "Prostatic Neoplasms",
-            "Malignant neoplasm of prostate"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=445079",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319116,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008315",
-              "name": "prostate cancer",
-              "description": "A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.; Tumors or cancer of the PROSTATE.; A cancer of the prostate. [HPO:probinson]; What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it:  Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to:  Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer.    What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include:  Problems urinating (peeing), such as:  A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen   Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm)  But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you:  Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer  What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include:  A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate.  If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options:  Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation:  Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer.   Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer.  Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include:  Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0008315",
-                "ICD10:C61",
-                "MEDDRA:10026389",
-                "MEDDRA:10007113",
-                "DOID:10283",
-                "MEDDRA:10036908",
-                "UMLS:C0376358",
-                "SNOMEDCT:399068003",
-                "ICD9:185",
-                "PDQ:CDR0000038782",
-                "MEDDRA:10036910",
-                "MEDDRA:10036946",
-                "KEGG.DISEASE:05215",
-                "NCIT:C7378",
-                "MESH:D011471",
-                "HP:0012125",
-                "MEDDRA:10060862"
-              ],
-              "id": "MONDO:0008315",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Malignant Prostate Neoplasm",
-                "prostate cancer",
-                "Prostate cancer",
-                "Prostatic Neoplasms",
-                "Malignant neoplasm of prostate"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=445079",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8153060,
-            "start": 319116,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10906738': {'publication date': '2000 Aug 01', 'sentence': 'CONCLUSIONS: Patients with newly diagnosed, untreated PC yielded significantly higher cortisol and lower estradiol serum concentrations than controls.', 'subject score': 901, 'object score': 773}}",
-              "kg2_ids": [
-                "UMLS:C0376358---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0008315",
-              "id": "8328567",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:10906738"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7908233,
-            "start": 319673,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10730906': {'publication date': '1999 Dec', 'sentence': 'The tumour secreted excessive cortisol and dehydroepiandrosterone-sulphate (DHEA-S), and had invaded the right hepatic lobe and vena cava.', 'subject score': 1000, 'object score': 888}, 'PMID:11281375': {'publication date': '2000 Dec', 'sentence': \"However, in 5%-12% of the patients a preclinical Cushing's syndrome (PCS) with autonomous cortisol production by the tumour is present.\", 'subject score': 1000, 'object score': 828}, 'PMID:11456263': {'publication date': '2001 Apr', 'sentence': \"Dehydroepiandrosterone-sulfotransferase (DHEA-ST) immunoreactivity in nonneoplastic regions was suppressed in one case in which the tumor secreted cortisol similar to preclinical and/or overt Cushing's syndrome.\", 'subject score': 1000, 'object score': 1000}, 'PMID:11588777': {'publication date': '2001', 'sentence': 'ACE and GR II were detected in the tissues of the adrenal cortex and cortisol-producing tumors.', 'subject score': 802, 'object score': 802}, 'PMID:14567506': {'publication date': '2003 Aug', 'sentence': 'The clear cells in the tumor were admixed with small numbers of compact cells that expressed 17alpha-hydroxylase, suggesting that the tumor was able to produce and secrete cortisol.', 'subject score': 1000, 'object score': 1000}, 'PMID:15012620': {'publication date': '2004 Mar', 'sentence': 'The cortisol-producing tumours appear to have increased angiogenic potential.', 'subject score': 802, 'object score': 802}, 'PMID:15069374': {'publication date': '2004 Feb 26', 'sentence': 'These tumors most commonly produce cortisol (30%), then androgens (20%), estrogens (10%) or aldosterone (2%).', 'subject score': 861, 'object score': 1000}, 'PMID:15145240': {'publication date': '2004 Jun', 'sentence': \"Although these tumors do not secrete enough cortisol to lead to the development of overt Cushing's syndrome, they are likely playing a contributory role in the development of hypertension, diabetes, osteoporosis, and obesity.\", 'subject score': 1000, 'object score': 1000}, 'PMID:1580324': {'publication date': '1992 May', 'sentence': \"This finding suggests that cortisol production by tumor is a determinant factor in hypertension in Cushing's syndrome.\", 'subject score': 1000, 'object score': 888}, 'PMID:15805423': {'publication date': '2005 Apr', 'sentence': 'In cortisol-producing tumors, non-tumor parts of the cortex, which were generally atrophic due to low ACTH, had less B1 protein than normal adrenals.', 'subject score': 802, 'object score': 802}, 'PMID:1606918': {'publication date': '1992 Feb', 'sentence': \"It is suggested that the tumor autonomously produced a small amount of cortisol not only insufficient to provide clinical Cushing's syndrome, but also to provide typical suppression of hypothalamo-pituitary corticotroph-adrenal system.\", 'subject score': 1000, 'object score': 1000}, 'PMID:16791399': {'publication date': '2006 Jun', 'sentence': 'Immunohistochemical staining for the enzymes involved in cortisol biosynthesis suggested that the upper tumor secreted aldosterone, whereas either or both of the two other tumors secreted cortisol.', 'subject score': 1000, 'object score': 1000}, 'PMID:16927063': {'publication date': '2006 Sep', 'sentence': 'METHODS: An autonomous cortisol-producing tumor was detected in 11 of 94 patients with adrenal incidentaloma between 1995 and 2005.', 'subject score': 751, 'object score': 751}, 'PMID:17408424': {'publication date': '2007 Jun', 'sentence': 'Immunohistochemical analysis confirmed CYP17, HSD3B2, SULT2A1 and CYB5 expression by all cortisol-producing tumours.', 'subject score': 802, 'object score': 802}, 'PMID:1745970': {'publication date': '1991 Dec', 'sentence': 'Studies to evaluate biochemical hyperfunction were performed in 172 patients (50%), 2 of whom were found to have cortisol-producing tumors and 5 pheochromocytomas.', 'subject score': 802, 'object score': 802}, 'PMID:18406701': {'publication date': '1995 Aug', 'sentence': 'Recent studies of the function of adrenal \"incidentalomas\" have revealed that a proportion of those tumors secrete cortisol insufficiently to produce overt clinical Cushing s syndrome, but that their autonomous cortisol production can suppress the hypothalamo-pituitaryadrenal (HPA) axis to various degrees; this needs to be recognized to avoid acute adrenal insufficiency after adrenalectomy.', 'subject score': 1000, 'object score': 861}, 'PMID:18543063': {'publication date': '2008 Oct', 'sentence': 'The results of a subsequent adrenal venous catheterization study were consistent with the presence of a left cortisol-producing tumor and a right aldosterone-producing tumor.', 'subject score': 775, 'object score': 775}, 'PMID:18926198': {'publication date': '2008 Oct', 'sentence': 'Some of these tumors secrete abnormally high levels of cortisol, suppressing function of the contralateral adrenal gland and, thus, leading to life-threatening postoperative adrenal insufficiency.', 'subject score': 1000, 'object score': 1000}, 'PMID:2232630': {'publication date': '1990 Oct 03', 'sentence': 'The tumor appeared to produce autonomously cortisol as well as corticosterone, 18-hydroxycorticosterone and aldosterone.', 'subject score': 1000, 'object score': 861}, 'PMID:22328110': {'publication date': '2012 Apr', 'sentence': 'CONCLUSION: We demonstrated that subtle cortisol-producing tumors, such as SH as well as SubCS, were an independent risk factor for hypertension.', 'subject score': 763, 'object score': 763}}",
-              "kg2_ids": [
-                "UMLS:C0027651---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0005070",
-              "id": "8077250",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:10730906",
-                "PMID:11281375",
-                "PMID:11456263",
-                "PMID:11588777",
-                "PMID:14567506",
-                "PMID:15012620",
-                "PMID:15069374",
-                "PMID:15145240",
-                "PMID:1580324",
-                "PMID:15805423",
-                "PMID:1606918",
-                "PMID:16791399",
-                "PMID:16927063",
-                "PMID:17408424",
-                "PMID:1745970",
-                "PMID:18406701",
-                "PMID:18543063",
-                "PMID:18926198",
-                "PMID:2232630",
-                "PMID:22328110"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 312686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-          "name": "adrenocortical insufficiency",
-          "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0405580",
-            "MEDDRA:10022460",
-            "ICD9:255.4",
-            "EFO:0009491",
-            "MEDDRA:10001367",
-            "MEDDRA:10020936",
-            "MONDO:0000004",
-            "MEDDRA:10020979",
-            "SNOMEDCT:237785004",
-            "SNOMEDCT:386584007",
-            "MEDDRA:10056485",
-            "MEDDRA:10082130",
-            "UMLS:C0001623",
-            "MEDDRA:10001344",
-            "MEDDRA:10001366",
-            "MEDDRA:10001334",
-            "DOID:10493",
-            "NCIT:C26691",
-            "HP:0000846",
-            "MEDDRA:10001335",
-            "MEDDRA:10001369",
-            "MEDDRA:10001342",
-            "MEDDRA:10001343",
-            "MESH:D000309",
-            "SNOMEDCT:111563005",
-            "MEDDRA:10011172",
-            "MEDDRA:10022461"
-          ],
-          "id": "MONDO:0000004",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortical hypofunction",
-            "Adrenocortical Insufficiency",
-            "adrenocortical insufficiency",
-            "Corticoadrenal insufficiency",
-            "Adrenal gland hypofunction",
-            "Adrenal Insufficiency",
-            "Adrenal insufficiency",
-            "Adrenal cortical hypofunction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:11443143"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-              "name": "adrenocortical insufficiency",
-              "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0405580",
-                "MEDDRA:10022460",
-                "ICD9:255.4",
-                "EFO:0009491",
-                "MEDDRA:10001367",
-                "MEDDRA:10020936",
-                "MONDO:0000004",
-                "MEDDRA:10020979",
-                "SNOMEDCT:237785004",
-                "SNOMEDCT:386584007",
-                "MEDDRA:10056485",
-                "MEDDRA:10082130",
-                "UMLS:C0001623",
-                "MEDDRA:10001344",
-                "MEDDRA:10001366",
-                "MEDDRA:10001334",
-                "DOID:10493",
-                "NCIT:C26691",
-                "HP:0000846",
-                "MEDDRA:10001335",
-                "MEDDRA:10001369",
-                "MEDDRA:10001342",
-                "MEDDRA:10001343",
-                "MESH:D000309",
-                "SNOMEDCT:111563005",
-                "MEDDRA:10011172",
-                "MEDDRA:10022461"
-              ],
-              "id": "MONDO:0000004",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortical hypofunction",
-                "Adrenocortical Insufficiency",
-                "adrenocortical insufficiency",
-                "Corticoadrenal insufficiency",
-                "Adrenal gland hypofunction",
-                "Adrenal Insufficiency",
-                "Adrenal insufficiency",
-                "Adrenal cortical hypofunction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:11443143"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 27237612,
-            "start": 569,
-            "end": 312686,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9815636': {'publication date': '1997 Dec', 'sentence': 'Replacement doses of hydrocortisone were administered throughout treatment to counteract potential adrenal insufficiency secondary to the ketoconazole.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:disrupts---None---None---None---UMLS:C0001623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "27711985",
-              "object": "MONDO:0000004",
-              "publications": [
-                "PMID:9815636"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 315770,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005059",
-          "name": "leukemia",
-          "description": "A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3161\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3161\" NCI Thesaurus); A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.; A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006); A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding  When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets  The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time.  The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age  What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding.  Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes  Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10045991",
-            "MEDDRA:10024329",
-            "ICD9:208",
-            "ICD10:C95.90",
-            "MEDDRA:10060430",
-            "MEDDRA:10024314",
-            "MEDDRA:10024323",
-            "MEDDRA:10024351",
-            "HP:0001909",
-            "SNOMEDCT:87163000",
-            "SNOMEDCT:1162768007",
-            "MEDDRA:10045992",
-            "MEDDRA:10060500",
-            "NCIT:C3161",
-            "EFO:0000565",
-            "MEDDRA:10045994",
-            "SNOMEDCT:93143009",
-            "MEDDRA:10024288",
-            "MEDDRA:10024352",
-            "MEDDRA:10024312",
-            "DOID:1240",
-            "UMLS:C0023418",
-            "PDQ:CDR0000041186",
-            "MESH:D007938",
-            "MONDO:0005059",
-            "MEDDRA:10024324"
-          ],
-          "id": "MONDO:0005059",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia of unspecified cell type",
-            "Leukemia",
-            "leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/leukemia",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=45343",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315770,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005059",
-              "name": "leukemia",
-              "description": "A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3161\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3161\" NCI Thesaurus); A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.; A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006); A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding  When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets  The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time.  The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age  What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding.  Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes  Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10045991",
-                "MEDDRA:10024329",
-                "ICD9:208",
-                "ICD10:C95.90",
-                "MEDDRA:10060430",
-                "MEDDRA:10024314",
-                "MEDDRA:10024323",
-                "MEDDRA:10024351",
-                "HP:0001909",
-                "SNOMEDCT:87163000",
-                "SNOMEDCT:1162768007",
-                "MEDDRA:10045992",
-                "MEDDRA:10060500",
-                "NCIT:C3161",
-                "EFO:0000565",
-                "MEDDRA:10045994",
-                "SNOMEDCT:93143009",
-                "MEDDRA:10024288",
-                "MEDDRA:10024352",
-                "MEDDRA:10024312",
-                "DOID:1240",
-                "UMLS:C0023418",
-                "PDQ:CDR0000041186",
-                "MESH:D007938",
-                "MONDO:0005059",
-                "MEDDRA:10024324"
-              ],
-              "id": "MONDO:0005059",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia of unspecified cell type",
-                "Leukemia",
-                "leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/leukemia",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=45343",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25968747,
-            "start": 569,
-            "end": 315770,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7355482': {'publication date': '1980 Feb', 'sentence': 'Amplication by hydrocortisone of the induction of cytotoxic response in vitro to syngeneic murine leukemias.', 'subject score': 1000, 'object score': 790}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:disrupts---None---None---None---UMLS:C0023418---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "26428860",
-              "object": "MONDO:0005059",
-              "publications": [
-                "PMID:7355482"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25929898,
-            "start": 569,
-            "end": 319673,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7202921': {'publication date': '1980 Apr', 'sentence': 'The results demonstrated that the intrarectal dose of indomethacin and hydrocortisone inhibited the development of tumors from microscopic carcinoma lesions in the large bowel and growing further.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:disrupts---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "26389045",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:7202921"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318348,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005105",
-          "name": "melanoma",
-          "description": "A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.; A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445); The presence of a melanoma, a malignant cancer originating from pigment producing melanocytes. Melanoma can originate from the skin or the pigmented layers of the eye (the uvea). [HPO:probinson]; Melanoma is the most serious type of skin cancer. Often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. Most melanomas have a black or black-blue area. Melanoma may also appear as a new mole. It may be black, abnormal, or \"ugly looking.\" Thinking of \"ABCDE\" can help you remember what to watch for:   Asymmetry - the shape of one half does not match the other  Border - the edges are ragged, blurred or irregular  Color - the color is uneven and may include shades of black, brown and tan  Diameter - there is a change in size, usually an increase Evolving - the mole has changed over the past few weeks or months  Surgery is the first treatment of all stages of melanoma. Other treatments include chemotherapy and radiation, biologic, and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "UMLS:C0025202",
-            "EFO:0000756",
-            "PDQ:CDR0000038833",
-            "NCIT:C3224",
-            "SNOMEDCT:372244006",
-            "MEDDRA:10053571",
-            "HP:0002861",
-            "MEDDRA:10025650",
-            "UMLS:CN971653",
-            "MONDO:0005105",
-            "MESH:D008545",
-            "ORPHANET:411533",
-            "MEDDRA:10027150",
-            "SNOMEDCT:1162635006",
-            "KEGG.DISEASE:05218",
-            "DOID:1909"
-          ],
-          "id": "MONDO:0005105",
-          "category": "biolink:Disease",
-          "all_names": [
-            "melanoma",
-            "Melanoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/melanoma",
-            "PMID:22123420",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318348,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005105",
-              "name": "melanoma",
-              "description": "A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.; A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445); The presence of a melanoma, a malignant cancer originating from pigment producing melanocytes. Melanoma can originate from the skin or the pigmented layers of the eye (the uvea). [HPO:probinson]; Melanoma is the most serious type of skin cancer. Often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. Most melanomas have a black or black-blue area. Melanoma may also appear as a new mole. It may be black, abnormal, or \"ugly looking.\" Thinking of \"ABCDE\" can help you remember what to watch for:   Asymmetry - the shape of one half does not match the other  Border - the edges are ragged, blurred or irregular  Color - the color is uneven and may include shades of black, brown and tan  Diameter - there is a change in size, usually an increase Evolving - the mole has changed over the past few weeks or months  Surgery is the first treatment of all stages of melanoma. Other treatments include chemotherapy and radiation, biologic, and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "UMLS:C0025202",
-                "EFO:0000756",
-                "PDQ:CDR0000038833",
-                "NCIT:C3224",
-                "SNOMEDCT:372244006",
-                "MEDDRA:10053571",
-                "HP:0002861",
-                "MEDDRA:10025650",
-                "UMLS:CN971653",
-                "MONDO:0005105",
-                "MESH:D008545",
-                "ORPHANET:411533",
-                "MEDDRA:10027150",
-                "SNOMEDCT:1162635006",
-                "KEGG.DISEASE:05218",
-                "DOID:1909"
-              ],
-              "id": "MONDO:0005105",
-              "category": "biolink:Disease",
-              "all_names": [
-                "melanoma",
-                "Melanoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/melanoma",
-                "PMID:22123420",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25671416,
-            "start": 569,
-            "end": 318348,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:6376378': {'publication date': '1984 Jun 15', 'sentence': 'Growth of ovarian, lung, breast, and kidney carcinomas was increased by 136%, 126%, 78% and 69%, respectively, whereas melanomas, sarcomas, and colon tumors were inhibited by hydrocortisone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:disrupts---None---None---None---UMLS:C0025202---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "26128287",
-              "object": "MONDO:0005105",
-              "publications": [
-                "PMID:6376378"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20614302,
-            "start": 569,
-            "end": 321523,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31043325': {'publication date': '2019 06', 'sentence': 'Insufficient cortisol limits the ability of the sick newborn to handle stress and inhibit pulmonary inflammation.', 'subject score': 888, 'object score': 1000}, 'PMID:413820': {'publication date': '1977 Dec', 'sentence': 'Only hydrocortisone and prednisolone suppressed LPS pneumonia.', 'subject score': 861, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:disrupts---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "21020907",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:31043325",
-                "PMID:413820"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318216,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318216,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15569401,
-            "start": 569,
-            "end": 318216,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21964795': {'publication date': '2012 Mar', 'sentence': 'BACKGROUND: Hepatic 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) activity, which converts cortisone (inactive) to cortisol, is downregulated in obesity.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:disrupts---None---None---None---UMLS:C0028754---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "15895489",
-              "object": "MONDO:0011122",
-              "publications": [
-                "PMID:21964795"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15427277,
-            "start": 569,
-            "end": 546804,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21741804': {'publication date': '2011 Nov', 'sentence': 'High-dose hydrocortisone treatment given in the first few hours after a traumatic experience was associated with significant favorable changes in the trajectory of exposure to trauma, as expressed by the reduced risk of the development of PTSD post-trauma.', 'subject score': 861, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:disrupts---None---None---None---UMLS:C0043251---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "15750557",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:21741804"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8675913,
-            "start": 569,
-            "end": 183319,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11334460': {'publication date': '2001 May', 'sentence': 'Under normal conditions, stress induces increased cortisol secretion that counteracts inflammatory reactions.', 'subject score': 851, 'object score': 983}, 'PMID:13529445': {'publication date': '1958 Feb', 'sentence': 'Local anti-inflammatory effect of hydrocortisone, Ro 2-5383/2 and histamine; suppression of inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:19212128': {'publication date': '2009', 'sentence': 'Similar to hydrocortisone, they suppress inflammation, but without immune suppression, and have a role in the maintenance of the Th1/Th2 balance and immune homeostasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:21529303': {'publication date': '2011', 'sentence': 'In RA, the increase in nocturnal anti-inflammatory cortisol secretion is insufficient to suppress ongoing inflammation, resulting in the morning symptoms characteristic of RA.', 'subject score': 840, 'object score': 861}, 'PMID:25227591': {'publication date': '2015', 'sentence': 'Under long-standing chronic stress of disease, insufficient cortisol is available to inhibit an ongoing nocturnal immune/inflammatory reaction.', 'subject score': 888, 'object score': 798}, 'PMID:27403034': {'publication date': '2016', 'sentence': 'The adrenal glands are able to modulate immune responses through neuroimmunoendocrine interactions and cortisol secretion that could suppress exacerbated inflammation such as in inflammatory bowel disease (IBD).', 'subject score': 888, 'object score': 888}, 'PMID:30028389': {'publication date': '2018 Aug', 'sentence': 'Glucocorticoids (GCs) such as cortisol are widely understood to suppress inflammation and immunity.', 'subject score': 1000, 'object score': 1000}, 'PMID:31807025': {'publication date': '2019', 'sentence': 'Hydrocortisone Suppresses Early Paraneoplastic Inflammation And Angiogenesis To Attenuate Early Hepatocellular Carcinoma Progression In Rats.', 'subject score': 1000, 'object score': 851}, 'PMID:35635075': {'publication date': '2022 May 30', 'sentence': 'Ascorbic acid and hydrocortisone synergistically inhibit septic organ injury via improving oxidative stress and inhibiting inflammation.', 'subject score': 1000, 'object score': 888}, 'PMID:6446523': {'publication date': '1980 Jun', 'sentence': 'The antihistamine metiamide, an H2-blocker; the antiserotonin drug, p-chlorophenylalanine; and the antiinflammatory drugs, aspirin, hydrocortisone, and ibuprofen failed to antagonize adriamycin-induced inflammation at 2 h or 5 days after adriamycin injection.', 'subject score': 1000, 'object score': 851}, 'PMID:9257297': {'publication date': '1997 Jul', 'sentence': 'In the periphery, hydrocortisone inhibits inflammation, downregulates the immune system and produces many other crucial physiological and metabolic changes.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:disrupts---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8865955",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:11334460",
-                "PMID:13529445",
-                "PMID:19212128",
-                "PMID:21529303",
-                "PMID:25227591",
-                "PMID:27403034",
-                "PMID:30028389",
-                "PMID:31807025",
-                "PMID:35635075",
-                "PMID:6446523",
-                "PMID:9257297"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25748238,
-            "start": 569,
-            "end": 319673,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:6607223': {'publication date': '1984 Jan 15', 'sentence': 'Hydrocortisone (HC) reduced the macrophage content of four murine tumors to less than half of control values.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "26205555",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:6607223"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318216,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318216,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18961170,
-            "start": 569,
-            "end": 318216,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27891832': {'publication date': '2016 Dec', 'sentence': 'Further, because infant formula contains only trace amounts of glucocorticoids, these findings suggest that cortisol in milk is a novel biological pathway through which breastfeeding may protect against later obesity.', 'subject score': 1000, 'object score': 872}, 'PMID:2844443': {'publication date': '1988 Jan', 'sentence': 'The peak ACTH response to CRF was less in the obese but this was not significant (obese ACTH +/- SEM, 31 +/- 4 ng/l, controls 39 +/- 4 ng/l) whereas the peak cortisol was significantly reduced in the obese (obese cortisol, 456 +/- 21 nmol/l, controls 638 +/- 50 nmol/l).', 'subject score': 861, 'object score': 1000}, 'PMID:873764': {'publication date': '1977 May', 'sentence': 'The responses of cortisol and GH were reduced in the obese subjects as compared with the normal-weight subjects.', 'subject score': 1000, 'object score': 872}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0028754---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "19342068",
-              "object": "MONDO:0011122",
-              "publications": [
-                "PMID:27891832",
-                "PMID:2844443",
-                "PMID:873764"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 528832,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-          "name": "toxic shock syndrome",
-          "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C35498",
-            "UMLS:C0600327",
-            "UMLS:CN204669",
-            "MEDDRA:10044248",
-            "MESH:D012772",
-            "MEDDRA:10044249",
-            "SNOMEDCT:18504008",
-            "DOID:14115",
-            "MEDDRA:10042852",
-            "UMLS:C0036983",
-            "ORPHANET:36234",
-            "SNOMEDCT:76571007",
-            "MEDDRA:10040580",
-            "NCIT:C35018",
-            "MEDDRA:10040070",
-            "ICD9:040.82",
-            "ICD10:A48.3",
-            "MONDO:0001881",
-            "EFO:0006834",
-            "SYMP:0000451"
-          ],
-          "id": "MONDO:0001881",
-          "category": "biolink:Disease",
-          "all_names": [
-            "toxic shock syndrome",
-            "Septic Shock",
-            "Shock, Septic",
-            "Toxic Shock Syndrome",
-            "Bacterial toxic-shock syndrome",
-            "septic shock",
-            "Toxic shock syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 528832,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-              "name": "toxic shock syndrome",
-              "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C35498",
-                "UMLS:C0600327",
-                "UMLS:CN204669",
-                "MEDDRA:10044248",
-                "MESH:D012772",
-                "MEDDRA:10044249",
-                "SNOMEDCT:18504008",
-                "DOID:14115",
-                "MEDDRA:10042852",
-                "UMLS:C0036983",
-                "ORPHANET:36234",
-                "SNOMEDCT:76571007",
-                "MEDDRA:10040580",
-                "NCIT:C35018",
-                "MEDDRA:10040070",
-                "ICD9:040.82",
-                "ICD10:A48.3",
-                "MONDO:0001881",
-                "EFO:0006834",
-                "SYMP:0000451"
-              ],
-              "id": "MONDO:0001881",
-              "category": "biolink:Disease",
-              "all_names": [
-                "toxic shock syndrome",
-                "Septic Shock",
-                "Shock, Septic",
-                "Toxic Shock Syndrome",
-                "Bacterial toxic-shock syndrome",
-                "septic shock",
-                "Toxic shock syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18866296,
-            "start": 569,
-            "end": 528832,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27695824': {'publication date': '2016 Nov 01', 'sentence': 'Conclusions and Relevance: Among adults with severe sepsis not in septic shock, use of hydrocortisone compared with placebo did not reduce the risk of septic shock within 14 days.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0036983---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "19245686",
-              "object": "MONDO:0001881",
-              "publications": [
-                "PMID:27695824"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18386662,
-            "start": 569,
-            "end": 546804,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26756781': {'publication date': '2016 05', 'sentence': 'These findings suggest that HC may protect against hyperoxic injury in the developing pulmonary vasculature.', 'subject score': 1000, 'object score': 853}, 'PMID:4085992': {'publication date': '1985 Dec', 'sentence': 'Testosterone, estradiol, and cortisol were tested using an immersion technique to minimize trauma, and we also examined metyrapone, a blocker of cortisol biosynthesis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C3263723---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0043251---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "18758297",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:26756781",
-                "PMID:4085992"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17598011,
-            "start": 569,
-            "end": 320039,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25365720': {'publication date': '2015 Mar', 'sentence': 'OBJECTIVE: Cortisol clearance is reduced in sepsis and may contribute to the development of impaired adrenocortical function that is thought to contribute to the pathophysiology of critical illness-related corticosteroid insufficiency.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0036690---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "17956690",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:25365720"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 312686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-          "name": "adrenocortical insufficiency",
-          "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0405580",
-            "MEDDRA:10022460",
-            "ICD9:255.4",
-            "EFO:0009491",
-            "MEDDRA:10001367",
-            "MEDDRA:10020936",
-            "MONDO:0000004",
-            "MEDDRA:10020979",
-            "SNOMEDCT:237785004",
-            "SNOMEDCT:386584007",
-            "MEDDRA:10056485",
-            "MEDDRA:10082130",
-            "UMLS:C0001623",
-            "MEDDRA:10001344",
-            "MEDDRA:10001366",
-            "MEDDRA:10001334",
-            "DOID:10493",
-            "NCIT:C26691",
-            "HP:0000846",
-            "MEDDRA:10001335",
-            "MEDDRA:10001369",
-            "MEDDRA:10001342",
-            "MEDDRA:10001343",
-            "MESH:D000309",
-            "SNOMEDCT:111563005",
-            "MEDDRA:10011172",
-            "MEDDRA:10022461"
-          ],
-          "id": "MONDO:0000004",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adrenal cortical hypofunction",
-            "Adrenocortical Insufficiency",
-            "adrenocortical insufficiency",
-            "Corticoadrenal insufficiency",
-            "Adrenal gland hypofunction",
-            "Adrenal Insufficiency",
-            "Adrenal insufficiency",
-            "Adrenal cortical hypofunction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:11443143"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
-              "name": "adrenocortical insufficiency",
-              "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0405580",
-                "MEDDRA:10022460",
-                "ICD9:255.4",
-                "EFO:0009491",
-                "MEDDRA:10001367",
-                "MEDDRA:10020936",
-                "MONDO:0000004",
-                "MEDDRA:10020979",
-                "SNOMEDCT:237785004",
-                "SNOMEDCT:386584007",
-                "MEDDRA:10056485",
-                "MEDDRA:10082130",
-                "UMLS:C0001623",
-                "MEDDRA:10001344",
-                "MEDDRA:10001366",
-                "MEDDRA:10001334",
-                "DOID:10493",
-                "NCIT:C26691",
-                "HP:0000846",
-                "MEDDRA:10001335",
-                "MEDDRA:10001369",
-                "MEDDRA:10001342",
-                "MEDDRA:10001343",
-                "MESH:D000309",
-                "SNOMEDCT:111563005",
-                "MEDDRA:10011172",
-                "MEDDRA:10022461"
-              ],
-              "id": "MONDO:0000004",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adrenal cortical hypofunction",
-                "Adrenocortical Insufficiency",
-                "adrenocortical insufficiency",
-                "Corticoadrenal insufficiency",
-                "Adrenal gland hypofunction",
-                "Adrenal Insufficiency",
-                "Adrenal insufficiency",
-                "Adrenal cortical hypofunction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:11443143"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16620721,
-            "start": 569,
-            "end": 312686,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23729712': {'publication date': '2013 May 31', 'sentence': 'Hydrocortisone therapy was started to prevent adrenal insufficiency before laboratory findings for ACTH (adrenocorticotropic hormone) and cortisol levels.', 'subject score': 888, 'object score': 1000}, 'PMID:32942788': {'publication date': '2020 Aug', 'sentence': 'However, there was no difference in the extent of reduction in SC concentration after ESI, the occurrence of AI, and pain reduction.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0001623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "16963888",
-              "object": "MONDO:0000004",
-              "publications": [
-                "PMID:23729712",
-                "PMID:32942788"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15229757,
-            "start": 569,
-            "end": 183319,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21441882': {'publication date': '2011 Mar', 'sentence': 'CONCLUSION: We conclude that intravenous stress doses of hydrocortisone lead to a reduction of systemic inflammation and to a potential improvement in the early outcome of patients undergoing off-pump CABG.', 'subject score': 1000, 'object score': 888}, 'PMID:24269961': {'publication date': '2014 Jan', 'sentence': 'It was found that cortisol reduces inflammation in differentiated monocytes.', 'subject score': 1000, 'object score': 1000}, 'PMID:27187933': {'publication date': '2016 07', 'sentence': 'RESULTS: Ours results showed that cortisol and cortisone decreased significantly the inflammation promoted by OxLDL, and also diminished the expression of genes involved in influx and efflux of cholesterol resulting in a reduced lipid accumulation.', 'subject score': 1000, 'object score': 1000}, 'PMID:28986096': {'publication date': '2017 Dec 15', 'sentence': 'KEY FINDINGS: We found that HCT reduced hepatic necrosis and inflammatory infiltration after hepatic I/R injury in mice that received high fat diet treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:31328119': {'publication date': '2019 Jun', 'sentence': 'Supplementation with SHP 450 mg/kg can be used as an alternative source of functional food for overcoming oxidative stress, as indicated by its ability to improve levels of blood glucose, triacylglycerol, total cholesterol, and cortisol, and to improve liver histology by decreasing severity of liver inflammation.', 'subject score': 1000, 'object score': 888}, 'PMID:36029810': {'publication date': '2022 Aug 24', 'sentence': 'Corticosteroids like Hydrocortisone, dexamethasone, Prednisolone and Methylprednisolone has been reported to be effective against SARS-CoV-2 virus in comparison to that of non-steroid drugs, by using non-genomic and genomic effects to prevent and reduce inflammation in tissues and the circulation.', 'subject score': 1000, 'object score': 1000}, 'PMID:3618038': {'publication date': '1987', 'sentence': 'In the first 7 days of the experiment HC decreased the inflammatory reaction and metabolic disorders in the cerebral tissue, activated HPNS and reduced the mortality rate.', 'subject score': 888, 'object score': 1000}, 'PMID:8751764': {'publication date': '1996 Sep', 'sentence': 'Hydrocortisone, as expected, showed significant detrimental effects on bursting strength, as well as decreasing systemic inflammation.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "15550113",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:21441882",
-                "PMID:24269961",
-                "PMID:27187933",
-                "PMID:28986096",
-                "PMID:31328119",
-                "PMID:36029810",
-                "PMID:3618038",
-                "PMID:8751764"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15220892,
-            "start": 569,
-            "end": 321523,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21427372': {'publication date': '2011 Mar 23', 'sentence': 'CONCLUSION: In intubated trauma patients, the use of an intravenous stress-dose of hydrocortisone, compared with placebo, resulted in a decreased risk of hospital-acquired pneumonia.', 'subject score': 1000, 'object score': 901}, 'PMID:25066331': {'publication date': '2014 Sep', 'sentence': 'Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trial.', 'subject score': 1000, 'object score': 901}, 'PMID:25289930': {'publication date': '2014 Dec', 'sentence': 'Hydrocortisone reduces the rate of pneumonia in patients with trauma.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "15540854",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:21427372",
-                "PMID:25066331",
-                "PMID:25289930"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 722907,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-          "name": "bronchopulmonary dysplasia",
-          "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:70589",
-            "MESH:D001997",
-            "MONDO:0019091",
-            "SNOMEDCT:67569000",
-            "MEDDRA:10066204",
-            "UMLS:C0006287",
-            "NCIT:C90599",
-            "DOID:11650",
-            "MEDDRA:10006475"
-          ],
-          "id": "MONDO:0019091",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bronchopulmonary Dysplasia",
-            "obsolete_bronchopulmonary dysplasia",
-            "bronchopulmonary dysplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 722907,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-              "name": "bronchopulmonary dysplasia",
-              "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:70589",
-                "MESH:D001997",
-                "MONDO:0019091",
-                "SNOMEDCT:67569000",
-                "MEDDRA:10066204",
-                "UMLS:C0006287",
-                "NCIT:C90599",
-                "DOID:11650",
-                "MEDDRA:10006475"
-              ],
-              "id": "MONDO:0019091",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bronchopulmonary Dysplasia",
-                "obsolete_bronchopulmonary dysplasia",
-                "bronchopulmonary dysplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13726700,
-            "start": 569,
-            "end": 722907,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18931525': {'publication date': '2009', 'sentence': 'Early hydrocortisone (HC) treatment may decrease the incidence of bronchopulmonary dysplasia; however, the long-term effects are still under evaluation.', 'subject score': 851, 'object score': 1000}, 'PMID:20864322': {'publication date': '2010 Oct', 'sentence': 'Intravenous hydrocortisone administered at an early stage for the prevention of BPD is being evaluated and should not be administered in this indication, except within clinical trials approved by the ethics committee.', 'subject score': 888, 'object score': 1000}, 'PMID:22070744': {'publication date': '2011 Nov 09', 'sentence': 'Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial.', 'subject score': 888, 'object score': 1000}, 'PMID:26058477': {'publication date': '2016 Feb', 'sentence': 'AIM: We evaluated the neurodevelopment and growth of five- to seven-year-old children who had participated in a randomised trial of early low-dose hydrocortisone treatment to prevent bronchopulmonary dysplasia.', 'subject score': 840, 'object score': 1000}, 'PMID:29348196': {'publication date': '2018 Feb', 'sentence': 'OBJECTIVES: To investigate the relationship between histologic findings of the placenta and response to early postnatal hydrocortisone treatment used to prevent bronchopulmonary dysplasia (BPD) in extremely preterm infants.', 'subject score': 833, 'object score': 1000}, 'PMID:29363502': {'publication date': '2018 May', 'sentence': \"Low-dose hydrocortisone for the first 10 days prevents BPD, but was associated with almost twice as many cases of late-onset sepsis in infants born at 24-25 weeks' gestation.\", 'subject score': 901, 'object score': 1000}, 'PMID:29523175': {'publication date': '2018 Mar 09', 'sentence': 'The aim of the Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (SToP-BPD) trial is to assess the efficacy and safety of postnatal hydrocortisone administration for the reduction of death or BPD in ventilator-dependent preterm infants.', 'subject score': 888, 'object score': 1000}, 'PMID:31043325': {'publication date': '2019 06', 'sentence': 'Based on four randomised clinical trials enrolling almost 1000 extremely preterm infants, prophylaxis of early adrenal insufficiency with low-dose hydrocortisone significantly decreased BPD and mortality, as well as medical treatment for a patent ductus arteriosus.', 'subject score': 901, 'object score': 1000}, 'PMID:31144162': {'publication date': '2019 Aug', 'sentence': 'Conclusion: Early systemic hydrocortisone is a modestly effective therapy for the prevention of BPD in preterm infants, although some safety concerns remain.', 'subject score': 851, 'object score': 1000}, 'PMID:31471578': {'publication date': '2019 Dec', 'sentence': 'Is prophylaxis with early low-dose hydrocortisone in very preterm infants effective in preventing bronchopulmonary dysplasia?', 'subject score': 861, 'object score': 884}, 'PMID:31899929': {'publication date': '2020 Jan 03', 'sentence': 'CONCLUSION:  Early application of low-dose hydrocortisone could potentially prevent BPD or death in infants weighing less than 1,000 g with exposure to chorioamnionitis.', 'subject score': 901, 'object score': 1000}, 'PMID:35320649': {'publication date': '2022 Mar 24', 'sentence': 'Hydrocortisone to Prevent Bronchopulmonary Dysplasia - Not a Silver Bullet.', 'subject score': 1000, 'object score': 1000}, 'PMID:35661314': {'publication date': '2022 Jul', 'sentence': 'Late hydrocortisone does not prevent bronchopulmonary dysplasia.', 'subject score': 888, 'object score': 1000}, 'PMID:36593110': {'publication date': '2023 Jan 02', 'sentence': \"OBJECTIVE: To report the parent-reported behavioural outcomes of infants included in the Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants study at 2 years' corrected age (CA).\", 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0006287---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14020540",
-              "object": "MONDO:0019091",
-              "publications": [
-                "PMID:18931525",
-                "PMID:20864322",
-                "PMID:22070744",
-                "PMID:26058477",
-                "PMID:29348196",
-                "PMID:29363502",
-                "PMID:29523175",
-                "PMID:31043325",
-                "PMID:31144162",
-                "PMID:31471578",
-                "PMID:31899929",
-                "PMID:35320649",
-                "PMID:35661314",
-                "PMID:36593110"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12797169,
-            "start": 569,
-            "end": 295849,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17426275': {'publication date': '2007 Apr 11', 'sentence': 'CONCLUSION: Intravenous hydrocortisone reduced the incidence of AF after cardiac surgery.', 'subject score': 888, 'object score': 1000}, 'PMID:24254538': {'publication date': '2014 Feb', 'sentence': 'Literature search showed that the prophylactic use of hydrocortisone (100 mg/day, 4 days) can reduce the incidence of POAF to 30%, compared with 48% in the control group (P = 0.004).', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13075196",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:17426275",
-                "PMID:24254538"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 314596,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-          "name": "Insulin resistance",
-          "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "NCIT:C113101",
-            "UMLS:C0021655",
-            "MEDDRA:10022489",
-            "SNOMEDCT:48606007",
-            "MESH:D007333",
-            "EFO:0002614",
-            "HP:0000855",
-            "SNOMEDCT:763325000"
-          ],
-          "id": "HP:0000855",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Insulin resistance",
-            "insulin resistance",
-            "Insulin Resistance"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314596,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-              "name": "Insulin resistance",
-              "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "NCIT:C113101",
-                "UMLS:C0021655",
-                "MEDDRA:10022489",
-                "SNOMEDCT:48606007",
-                "MESH:D007333",
-                "EFO:0002614",
-                "HP:0000855",
-                "SNOMEDCT:763325000"
-              ],
-              "id": "HP:0000855",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Insulin resistance",
-                "insulin resistance",
-                "Insulin Resistance"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11927457,
-            "start": 569,
-            "end": 314596,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16334949': {'publication date': '2005 Nov', 'sentence': 'Assuming a single dose of hydrocortisone improves sensitivity of peripheral tissues to insulin, it may be an interesting candidate for use in reducing insulin resistance in peripheral tissues of horses with several disease states.', 'subject score': 1000, 'object score': 884}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0021655---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "12187318",
-              "object": "HP:0000855",
-              "publications": [
-                "PMID:16334949"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14338928,
-            "start": 569,
-            "end": 320039,
-            "type": "biolink:exacerbates",
-            "properties": {
-              "predicate": "biolink:exacerbates",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1985540': {'publication date': '1991 Jan', 'sentence': 'Plasma cortisol and glucagon concentrations were not increased markedly except in a case complicated other systemic bacterial infection.', 'subject score': 888, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:complicates---None---None---None---UMLS:C0243026---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14643692",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:1985540"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318216,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318216,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7952217,
-            "start": 569,
-            "end": 318216,
-            "type": "biolink:exacerbates",
-            "properties": {
-              "predicate": "biolink:exacerbates",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10762282': {'publication date': '2000 Apr', 'sentence': 'In view of the stimulatory effects of insulin and cortisol on adipogenesis, long-term stimulation of 11betaHSD reductase activity by insulin could aggravate visceral obesity.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:complicates---None---None---None---UMLS:C0028754---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8122784",
-              "object": "MONDO:0011122",
-              "publications": [
-                "PMID:10762282"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24962364,
-            "start": 569,
-            "end": 295849,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:36874560': {'publication date': '2023 Feb', 'sentence': 'For this purpose, this review article contends that plasma cortisol is linked to a greater risk of AF.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:predisposes---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "25411585",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:36874560"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19368995,
-            "start": 569,
-            "end": 320039,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28685301': {'publication date': '2017 Sep', 'sentence': 'After multivariate analysis, duration of HC stress dose administration was associated with increased risk of mortality (OR 1.11, 95% CI 1.02-1.2, p = 0.021), and total duration of HC treatment was associated with increased risk of sepsis (OR 1.04, 95% CI 1.005-1.075, p = 0.026).', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:predisposes---None---None---None---UMLS:C0036690---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "19755964",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:28685301"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13424533,
-            "start": 569,
-            "end": 546804,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18431270': {'publication date': '2008 Mar', 'sentence': 'Plasma leptin and ghrelin levels in endotoxin-treated dogs were correlated with serum nitric oxide (r = .955 and r = .890; p < .001), procalcitonin (r = .825 and r = .716; p < .001), cortisol (r = .823 and r = .786; p < .001), and hepatorenal injury markers (r = .580 to .745 and r = .393 to .574; p < .05 to .01).', 'subject score': 1000, 'object score': 660}, 'PMID:21684014': {'publication date': '2011 Oct 30', 'sentence': 'To address gaps in the literature related to the contribution of childhood trauma on aggression, we evaluated salivary cortisol and heart rate changes to psychological challenge in aggressive children with various degrees of trauma.', 'subject score': 888, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:predisposes---None---None---None---UMLS:C3263723---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:predisposes---None---None---None---UMLS:C0043251---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13712588",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:18431270",
-                "PMID:21684014"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 528832,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-          "name": "toxic shock syndrome",
-          "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C35498",
-            "UMLS:C0600327",
-            "UMLS:CN204669",
-            "MEDDRA:10044248",
-            "MESH:D012772",
-            "MEDDRA:10044249",
-            "SNOMEDCT:18504008",
-            "DOID:14115",
-            "MEDDRA:10042852",
-            "UMLS:C0036983",
-            "ORPHANET:36234",
-            "SNOMEDCT:76571007",
-            "MEDDRA:10040580",
-            "NCIT:C35018",
-            "MEDDRA:10040070",
-            "ICD9:040.82",
-            "ICD10:A48.3",
-            "MONDO:0001881",
-            "EFO:0006834",
-            "SYMP:0000451"
-          ],
-          "id": "MONDO:0001881",
-          "category": "biolink:Disease",
-          "all_names": [
-            "toxic shock syndrome",
-            "Septic Shock",
-            "Shock, Septic",
-            "Toxic Shock Syndrome",
-            "Bacterial toxic-shock syndrome",
-            "septic shock",
-            "Toxic shock syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 528832,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-              "name": "toxic shock syndrome",
-              "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C35498",
-                "UMLS:C0600327",
-                "UMLS:CN204669",
-                "MEDDRA:10044248",
-                "MESH:D012772",
-                "MEDDRA:10044249",
-                "SNOMEDCT:18504008",
-                "DOID:14115",
-                "MEDDRA:10042852",
-                "UMLS:C0036983",
-                "ORPHANET:36234",
-                "SNOMEDCT:76571007",
-                "MEDDRA:10040580",
-                "NCIT:C35018",
-                "MEDDRA:10040070",
-                "ICD9:040.82",
-                "ICD10:A48.3",
-                "MONDO:0001881",
-                "EFO:0006834",
-                "SYMP:0000451"
-              ],
-              "id": "MONDO:0001881",
-              "category": "biolink:Disease",
-              "all_names": [
-                "toxic shock syndrome",
-                "Septic Shock",
-                "Shock, Septic",
-                "Toxic Shock Syndrome",
-                "Bacterial toxic-shock syndrome",
-                "septic shock",
-                "Toxic shock syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12288777,
-            "start": 569,
-            "end": 528832,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1678460': {'publication date': '1991 Aug 24', 'sentence': 'Contribution of cortisol deficiency to septic shock.', 'subject score': 888, 'object score': 1000}, 'PMID:20455885': {'publication date': '2010 Sep', 'sentence': 'Free cortisol, and to a lesser extent total cortisol, but not NOx concentrations, predicted septic shock.', 'subject score': 833, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:predisposes---None---None---None---UMLS:C0036983---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "12555774",
-              "object": "MONDO:0001881",
-              "publications": [
-                "PMID:1678460",
-                "PMID:20455885"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11530888,
-            "start": 569,
-            "end": 183319,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15843228': {'publication date': '2005', 'sentence': 'The objective of this study was to demonstrate the effect of stress doses of hydrocortisone during the initial phase of human septic shock on the serum values of the neurospecific protein S-100B in comparison to the inflammation markers interleukin (IL)-8 in serum and polymorphonuclear (PMN) elastase in plasma.', 'subject score': 1000, 'object score': 824}, 'PMID:27832762': {'publication date': '2016 11 10', 'sentence': 'Serum samples were analysed by Liquid Chromatography coupled to Mass Spectrometry, for tryptophan, ten of its metabolites, the inflammation marker neopterin and the hypothalamic-pituitary-adrenal (HPA) axis marker cortisol.', 'subject score': 888, 'object score': 851}, 'PMID:29899546': {'publication date': '2018 Jun 13', 'sentence': 'The present study combined neuroimaging, salivary cortisol, and blood markers of inflammation and metabolism collected prior to scanning.', 'subject score': 888, 'object score': 1000}, 'PMID:30200906': {'publication date': '2018 Sep 10', 'sentence': 'Secondary outcomes include sleep quality, depression, anxiety, quality of life, cognitive complaints, cancer worries, fatigue catastrophizing, self-efficacy to handle fatigue, biological circadian rhythms of melatonin, cortisol and activity, and biomarkers of inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:30935010': {'publication date': '2019 Mar 30', 'sentence': 'Serum glucose (n = 35), serum insulin (n = 35), serum creatine kinase (n = 15) and myoglobin (n = 15), hematologic parameters, cortisol (n = 35), inflammation markers (n = 27) and leg strength (n = 15) as a functional marker were measured.', 'subject score': 1000, 'object score': 694}, 'PMID:31374824': {'publication date': '2019 Aug 01', 'sentence': 'In this work, we investigate the effects of thoracic (T6-7) and cervical (C6-7) moderate-severe contusion SCIs on the spleen by characterizing splenic norepinephrine (NE) and cortisol (CORT), caspase-3, and multiple inflammation markers at 3- and 7-days post-SCI.', 'subject score': 1000, 'object score': 623}, 'PMID:32098947': {'publication date': '2020 Feb 25', 'sentence': 'Raised levels of cortisol, and markers of inflammation such as Interleukin (IL-6) and C-reactive protein (CRP), have been linked to both early life stress and MDD.', 'subject score': 1000, 'object score': 1000}, 'PMID:32153900': {'publication date': '2018', 'sentence': 'Secondary outcomes include mid-upper-arm circumference, neuro-behavioral development, hair cortisol concentrations, markers of intestinal inflammation and parasite burden.', 'subject score': 851, 'object score': 888}, 'PMID:34669995': {'publication date': '2021 Oct 20', 'sentence': 'CONCLUSIONS: Compared with plasma cortisol and inflammation biomarkers, HRV is more sensitive to detect surgical stress and autonomic nervous dysfunction induced by radical gastrectomy in patients with gastric cancer.', 'subject score': 888, 'object score': 888}, 'PMID:37138028': {'publication date': '2023 May 03', 'sentence': 'The findings indicate a dose-dependency of hydrocortisone for metabolomic and anti-inflammatory effects, that prolonged therapy may lower the supply of many nutrients, and that monitoring concentrations of cortisol and inflammation markers may be a useful clinical approach during corticosteroid therapy.', 'subject score': 1000, 'object score': 872}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:predisposes---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "11782928",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:15843228",
-                "PMID:27832762",
-                "PMID:29899546",
-                "PMID:30200906",
-                "PMID:30935010",
-                "PMID:31374824",
-                "PMID:32098947",
-                "PMID:32153900",
-                "PMID:34669995",
-                "PMID:37138028"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318216,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318216,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10293634,
-            "start": 569,
-            "end": 318216,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1338326': {'publication date': '1992 Dec', 'sentence': 'The synergism between insulin and cortisol in stimulating energy deposition, associated with a decreased effect of corticotropin-releasing factor in stimulating energy expenditure, is likely to contribute to the development of obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:15607573': {'publication date': '2005', 'sentence': 'Since cortisol promotes development of visceral obesity, and has a direct negative impact on insulin function throughout the body, even a modest sustained up-regulation of cortisol production may have the potential to increase risk for insulin resistance syndrome and type 2 diabetes.', 'subject score': 1000, 'object score': 888}, 'PMID:23512832': {'publication date': '2013 Dec', 'sentence': 'OBJECTIVES: Increased intra-adipose cortisol is thought to promote obesity, but few human studies have investigated intra-adipose glucocorticoid hormones and none have demonstrated prospective changes with fat loss.', 'subject score': 775, 'object score': 1000}, 'PMID:28229550': {'publication date': '2017 03', 'sentence': 'OBJECTIVE: Chronic cortisol exposure is hypothesized to contribute to obesity.', 'subject score': 623, 'object score': 1000}, 'PMID:30849107': {'publication date': '2019', 'sentence': 'Association between hair cortisol concentration and dietary intake among normal weight preschool children predisposed to overweight and obesity.', 'subject score': 623, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:predisposes---None---None---None---UMLS:C0028754---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10520517",
-              "object": "MONDO:0011122",
-              "publications": [
-                "PMID:1338326",
-                "PMID:15607573",
-                "PMID:23512832",
-                "PMID:28229550",
-                "PMID:30849107"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:11129757': {'publication date': '2000 Dec', 'sentence': 'Higher basal cortisol predicts verbal memory loss in postmenopausal women: Rancho Bernardo Study.', 'subject score': 840, 'object score': 901}, 'PMID:21855200': {'publication date': '2011 Nov', 'sentence': 'Peer victimization, depressive symptoms, and high salivary cortisol predict poorer memory in children.', 'subject score': 851, 'object score': 983}, 'PMID:26569538': {'publication date': '2016', 'sentence': 'CONCLUSIONS: Higher secretion of cortisol may, over time, contribute to memory dysfunction in older adults.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319995,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001185",
-          "name": "dissociative amnesia",
-          "description": "Partial or complete loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories. Compare FORGETTING and MEMORY DECAY.; Systematic and extensive loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories.; Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7); UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "NCIT:C78444",
-            "SYMP:0000543",
-            "MONDO:0001185",
-            "MEDDRA:10027178",
-            "ICD9:300.12",
-            "ICD9:780.93",
-            "SNOMEDCT:55533009",
-            "MESH:D000647",
-            "SNOMEDCT:48167000",
-            "MEDDRA:10001949",
-            "NBO:0000253",
-            "PSY:30590",
-            "ICD10:F44.0",
-            "UMLS:C3887551",
-            "MEDDRA:10013461",
-            "MESH:D008569",
-            "DOID:11037",
-            "MEDDRA:10027172",
-            "MEDDRA:10027174",
-            "MEDDRA:10027176",
-            "MEDDRA:10017060",
-            "UMLS:C0236795",
-            "UMLS:C0542476",
-            "NCIT:C2867",
-            "UMLS:C0025261",
-            "MEDDRA:10027175",
-            "UMLS:C0751295",
-            "SNOMEDCT:386807006",
-            "MEDDRA:10027171",
-            "EFO:1001454",
-            "NCIT:C94328",
-            "PSY:02120",
-            "UMLS:C0002622",
-            "NCIT:C46084",
-            "UMLS:C0233794",
-            "SYMP:0000719",
-            "EFO:0001072",
-            "MEDDRA:10024871",
-            "HP:0002354",
-            "SNOMEDCT:84209002",
-            "MEDDRA:10037186"
-          ],
-          "id": "MONDO:0001185",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Memory Disorders",
-            "dissociative amnesia",
-            "Memory Loss",
-            "Dissociative Amnesia",
-            "memory impairment",
-            "memory loss",
-            "Forgetful",
-            "Memory Impairment",
-            "Amnesia",
-            "Dissociative amnesia",
-            "Memory impairment",
-            "amnesia",
-            "Memory dysfunction",
-            "Memory loss",
-            "Memory Dysfunction"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://www.merckmanuals.com/professional/psychiatric-disorders/dissociative-disorders/dissociative-amnesia",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.merriam-webster.com/dictionary/impairment",
-            "https://medlineplus.gov/ency/article/003257.htm",
-            "https://www.merckmanuals.com/professional/neurologic-disorders/symptoms-of-neurologic-disorders/memory-loss"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319995,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001185",
-              "name": "dissociative amnesia",
-              "description": "Partial or complete loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories. Compare FORGETTING and MEMORY DECAY.; Systematic and extensive loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories.; Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7); UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "NCIT:C78444",
-                "SYMP:0000543",
-                "MONDO:0001185",
-                "MEDDRA:10027178",
-                "ICD9:300.12",
-                "ICD9:780.93",
-                "SNOMEDCT:55533009",
-                "MESH:D000647",
-                "SNOMEDCT:48167000",
-                "MEDDRA:10001949",
-                "NBO:0000253",
-                "PSY:30590",
-                "ICD10:F44.0",
-                "UMLS:C3887551",
-                "MEDDRA:10013461",
-                "MESH:D008569",
-                "DOID:11037",
-                "MEDDRA:10027172",
-                "MEDDRA:10027174",
-                "MEDDRA:10027176",
-                "MEDDRA:10017060",
-                "UMLS:C0236795",
-                "UMLS:C0542476",
-                "NCIT:C2867",
-                "UMLS:C0025261",
-                "MEDDRA:10027175",
-                "UMLS:C0751295",
-                "SNOMEDCT:386807006",
-                "MEDDRA:10027171",
-                "EFO:1001454",
-                "NCIT:C94328",
-                "PSY:02120",
-                "UMLS:C0002622",
-                "NCIT:C46084",
-                "UMLS:C0233794",
-                "SYMP:0000719",
-                "EFO:0001072",
-                "MEDDRA:10024871",
-                "HP:0002354",
-                "SNOMEDCT:84209002",
-                "MEDDRA:10037186"
-              ],
-              "id": "MONDO:0001185",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Memory Disorders",
-                "dissociative amnesia",
-                "Memory Loss",
-                "Dissociative Amnesia",
-                "memory impairment",
-                "memory loss",
-                "Forgetful",
-                "Memory Impairment",
-                "Amnesia",
-                "Dissociative amnesia",
-                "Memory impairment",
-                "amnesia",
-                "Memory dysfunction",
-                "Memory loss",
-                "Memory Dysfunction"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://www.merckmanuals.com/professional/psychiatric-disorders/dissociative-disorders/dissociative-amnesia",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.merriam-webster.com/dictionary/impairment",
-                "https://medlineplus.gov/ency/article/003257.htm",
-                "https://www.merckmanuals.com/professional/neurologic-disorders/symptoms-of-neurologic-disorders/memory-loss"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8431902,
-            "start": 569,
-            "end": 319995,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11129757': {'publication date': '2000 Dec', 'sentence': 'Higher basal cortisol predicts verbal memory loss in postmenopausal women: Rancho Bernardo Study.', 'subject score': 840, 'object score': 901}, 'PMID:21855200': {'publication date': '2011 Nov', 'sentence': 'Peer victimization, depressive symptoms, and high salivary cortisol predict poorer memory in children.', 'subject score': 851, 'object score': 983}, 'PMID:26569538': {'publication date': '2016', 'sentence': 'CONCLUSIONS: Higher secretion of cortisol may, over time, contribute to memory dysfunction in older adults.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:predisposes---None---None---None---UMLS:C0002622---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:predisposes---None---None---None---UMLS:C0233794---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8615556",
-              "object": "MONDO:0001185",
-              "publications": [
-                "PMID:11129757",
-                "PMID:21855200",
-                "PMID:26569538"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 321528,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:36450464': {'publication date': '2022 Nov 30', 'sentence': 'Furthermore, this treatment process demonstrated the superior anti-inflammatory effect of prednisolone over that of hydrocortisone and supported the assumption of inflammation related to CD.', 'subject score': 1000, 'object score': 1000}, 'PMID:9741018': {'publication date': '1998 Aug', 'sentence': \"The effectiveness of intravenous corticotrophin versus hydrocortisone in ulcerative colitis has been determined including whether previous steroid therapy influenced the better response to one rather than the other, but no such studies have ever been done in Crohn's disease.\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 322120,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-          "name": "Crohn disease",
-          "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003424",
-            "ORPHANET:206",
-            "NCIT:C37262",
-            "MEDDRA:10038281",
-            "MEDDRA:10011405",
-            "UMLS:CN043071",
-            "SNOMEDCT:50440006",
-            "MEDDRA:10057032",
-            "HP:0100280",
-            "EFO:0000384",
-            "DOID:8778",
-            "MONDO:0005011",
-            "PDQ:CDR0000714480",
-            "UMLS:C0010346",
-            "NCIT:C2965",
-            "SNOMEDCT:7620006",
-            "ICD10:K50.1",
-            "UMLS:C0156147",
-            "MEDDRA:10011398",
-            "MEDDRA:10011401",
-            "SNOMEDCT:34000006",
-            "ICD9:555.1",
-            "MEDDRA:10013099",
-            "MEDDRA:10011402",
-            "MEDDRA:10011400"
-          ],
-          "id": "MONDO:0005011",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Granulomatous Colitis",
-            "Crohn's disease of large bowel",
-            "Regional enteritis of large intestine",
-            "Crohn Disease",
-            "Crohn disease",
-            "Crohn's disease"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-=======
-            "http://en.wikipedia.org/wiki/chron%27s_disease",
-            "https://orcid.org/0009-0006-4530-3154"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 321528,
-=======
-            "identity": 322120,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-              "name": "Crohn disease",
-              "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003424",
-                "ORPHANET:206",
-                "NCIT:C37262",
-                "MEDDRA:10038281",
-                "MEDDRA:10011405",
-                "UMLS:CN043071",
-                "SNOMEDCT:50440006",
-                "MEDDRA:10057032",
-                "HP:0100280",
-                "EFO:0000384",
-                "DOID:8778",
-                "MONDO:0005011",
-                "PDQ:CDR0000714480",
-                "UMLS:C0010346",
-                "NCIT:C2965",
-                "SNOMEDCT:7620006",
-                "ICD10:K50.1",
-                "UMLS:C0156147",
-                "MEDDRA:10011398",
-                "MEDDRA:10011401",
-                "SNOMEDCT:34000006",
-                "ICD9:555.1",
-                "MEDDRA:10013099",
-                "MEDDRA:10011402",
-                "MEDDRA:10011400"
-              ],
-              "id": "MONDO:0005011",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Granulomatous Colitis",
-                "Crohn's disease of large bowel",
-                "Regional enteritis of large intestine",
-                "Crohn Disease",
-                "Crohn disease",
-                "Crohn's disease"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-=======
-                "http://en.wikipedia.org/wiki/chron%27s_disease",
-                "https://orcid.org/0009-0006-4530-3154"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 8370797,
-            "start": 569,
-            "end": 321528,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11080743': {'publication date': '2000 Nov', 'sentence': 'A growing body of evidence now suggests that endogenous cortisol, which is produced in significant quantities by the body in a diurnal rhythm, is an important regulator of allergic disease expression and allergic inflammatory responses: lung function varies along with plasma cortisol levels; the number of circulating inflammatory cells varies with plasma cortisol levels; and low levels of endogenous cortisol may be associated with risk for asthma.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:predisposes---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8552834",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:11080743"
-=======
-            "identity": 24684607,
-            "start": 569,
-            "end": 322120,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:36450464': {'publication date': '2022 Nov 30', 'sentence': 'Furthermore, this treatment process demonstrated the superior anti-inflammatory effect of prednisolone over that of hydrocortisone and supported the assumption of inflammation related to CD.', 'subject score': 1000, 'object score': 1000}, 'PMID:9741018': {'publication date': '1998 Aug', 'sentence': \"The effectiveness of intravenous corticotrophin versus hydrocortisone in ulcerative colitis has been determined including whether previous steroid therapy influenced the better response to one rather than the other, but no such studies have ever been done in Crohn's disease.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0010346---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "25131277",
-              "object": "MONDO:0005011",
-              "publications": [
-                "PMID:36450464",
-                "PMID:9741018"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10431487': {'publication date': '1999 Jul', 'sentence': \"CONCLUSIONS: The observed increase in albumin binding might limit the bioactivity of cortisol in patients with Crohn's disease and contribute to the decreased effectiveness and weaker side effects of glucocorticoid therapy in these patients.\", 'subject score': 1000, 'object score': 1000}, 'PMID:1790809': {'publication date': '1991', 'sentence': \"Patients with nonspecific ulcerative colitis and Crohn's disease were treated with drug therapy (prednisolone, sulphasalazine, metronidazole per os and hydrocortisone per rectum) and subjected to 12 sessions of HBO.\", 'subject score': 901, 'object score': 1000}, 'PMID:30797955': {'publication date': '2019', 'sentence': \"Synthetic glucocorticoids are important pharmacological agents that augment the anti-inflammatory and immunosuppressive properties of endogenous cortisol and are widely used for the treatment of asthma, Crohn's disease, and rheumatoid arthritis, amongst other chronic conditions.\", 'subject score': 888, 'object score': 1000}, 'PMID:9741018': {'publication date': '1998 Aug', 'sentence': \"Intravenous ACTH and hydrocortisone are equally effective in achieving therapeutic goals in patients with Crohn's disease who have not achieved results with oral medications.\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 322120,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-          "name": "Crohn disease",
-          "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003424",
-            "ORPHANET:206",
-            "NCIT:C37262",
-            "MEDDRA:10038281",
-            "MEDDRA:10011405",
-            "UMLS:CN043071",
-            "SNOMEDCT:50440006",
-            "MEDDRA:10057032",
-            "HP:0100280",
-            "EFO:0000384",
-            "DOID:8778",
-            "MONDO:0005011",
-            "PDQ:CDR0000714480",
-            "UMLS:C0010346",
-            "NCIT:C2965",
-            "SNOMEDCT:7620006",
-            "ICD10:K50.1",
-            "UMLS:C0156147",
-            "MEDDRA:10011398",
-            "MEDDRA:10011401",
-            "SNOMEDCT:34000006",
-            "ICD9:555.1",
-            "MEDDRA:10013099",
-            "MEDDRA:10011402",
-            "MEDDRA:10011400"
-          ],
-          "id": "MONDO:0005011",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Granulomatous Colitis",
-            "Crohn's disease of large bowel",
-            "Regional enteritis of large intestine",
-            "Crohn Disease",
-            "Crohn disease",
-            "Crohn's disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/chron%27s_disease",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322120,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-              "name": "Crohn disease",
-              "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003424",
-                "ORPHANET:206",
-                "NCIT:C37262",
-                "MEDDRA:10038281",
-                "MEDDRA:10011405",
-                "UMLS:CN043071",
-                "SNOMEDCT:50440006",
-                "MEDDRA:10057032",
-                "HP:0100280",
-                "EFO:0000384",
-                "DOID:8778",
-                "MONDO:0005011",
-                "PDQ:CDR0000714480",
-                "UMLS:C0010346",
-                "NCIT:C2965",
-                "SNOMEDCT:7620006",
-                "ICD10:K50.1",
-                "UMLS:C0156147",
-                "MEDDRA:10011398",
-                "MEDDRA:10011401",
-                "SNOMEDCT:34000006",
-                "ICD9:555.1",
-                "MEDDRA:10013099",
-                "MEDDRA:10011402",
-                "MEDDRA:10011400"
-              ],
-              "id": "MONDO:0005011",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Granulomatous Colitis",
-                "Crohn's disease of large bowel",
-                "Regional enteritis of large intestine",
-                "Crohn Disease",
-                "Crohn disease",
-                "Crohn's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/chron%27s_disease",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7430038,
-            "start": 569,
-            "end": 322120,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10431487': {'publication date': '1999 Jul', 'sentence': \"CONCLUSIONS: The observed increase in albumin binding might limit the bioactivity of cortisol in patients with Crohn's disease and contribute to the decreased effectiveness and weaker side effects of glucocorticoid therapy in these patients.\", 'subject score': 1000, 'object score': 1000}, 'PMID:1790809': {'publication date': '1991', 'sentence': \"Patients with nonspecific ulcerative colitis and Crohn's disease were treated with drug therapy (prednisolone, sulphasalazine, metronidazole per os and hydrocortisone per rectum) and subjected to 12 sessions of HBO.\", 'subject score': 901, 'object score': 1000}, 'PMID:30797955': {'publication date': '2019', 'sentence': \"Synthetic glucocorticoids are important pharmacological agents that augment the anti-inflammatory and immunosuppressive properties of endogenous cortisol and are widely used for the treatment of asthma, Crohn's disease, and rheumatoid arthritis, amongst other chronic conditions.\", 'subject score': 888, 'object score': 1000}, 'PMID:9741018': {'publication date': '1998 Aug', 'sentence': \"Intravenous ACTH and hydrocortisone are equally effective in achieving therapeutic goals in patients with Crohn's disease who have not achieved results with oral medications.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0010346---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7584436",
-              "object": "MONDO:0005011",
-              "publications": [
-                "PMID:10431487",
-                "PMID:1790809",
-                "PMID:30797955",
-                "PMID:9741018"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:28292220': {'publication date': '2017 Jan 01', 'sentence': 'CONCLUSION: In patients with septic shock, low-dose hydrocortisone was associated with a lower risk of developing AF during the acute phase.', 'subject score': 901, 'object score': 901}, 'PMID:33822969': {'publication date': '2021 Apr 05', 'sentence': 'RESULTS: One standard deviation increase in genetically predicted plasma cortisol was associated with greater risk of AF (OR 1.20, 95% CI 1.06-1.35).', 'subject score': 775, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19148229,
-            "start": 569,
-            "end": 295849,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28292220': {'publication date': '2017 Jan 01', 'sentence': 'CONCLUSION: In patients with septic shock, low-dose hydrocortisone was associated with a lower risk of developing AF during the acute phase.', 'subject score': 901, 'object score': 901}, 'PMID:33822969': {'publication date': '2021 Apr 05', 'sentence': 'RESULTS: One standard deviation increase in genetically predicted plasma cortisol was associated with greater risk of AF (OR 1.20, 95% CI 1.06-1.35).', 'subject score': 775, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "19531872",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:28292220",
-                "PMID:33822969"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:28292220': {'publication date': '2017 Jan 01', 'sentence': 'The incidence of AF was compared among patients who received hydrocortisone, and the effect of low-dose hydrocortisone on AF was estimated using the inverse probability treatment weighting method based on propensity scores.', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19148228,
-            "start": 569,
-            "end": 295849,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28292220': {'publication date': '2017 Jan 01', 'sentence': 'The incidence of AF was compared among patients who received hydrocortisone, and the effect of low-dose hydrocortisone on AF was estimated using the inverse probability treatment weighting method based on propensity scores.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "19531871",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:28292220"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:17426275': {'publication date': '2007 Apr 11', 'sentence': 'CONCLUSION: Intravenous hydrocortisone reduced the incidence of AF after cardiac surgery.', 'subject score': 888, 'object score': 1000}, 'PMID:24254538': {'publication date': '2014 Feb', 'sentence': 'Literature search showed that the prophylactic use of hydrocortisone (100 mg/day, 4 days) can reduce the incidence of POAF to 30%, compared with 48% in the control group (P = 0.004).', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12797169,
-            "start": 569,
-            "end": 295849,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17426275': {'publication date': '2007 Apr 11', 'sentence': 'CONCLUSION: Intravenous hydrocortisone reduced the incidence of AF after cardiac surgery.', 'subject score': 888, 'object score': 1000}, 'PMID:24254538': {'publication date': '2014 Feb', 'sentence': 'Literature search showed that the prophylactic use of hydrocortisone (100 mg/day, 4 days) can reduce the incidence of POAF to 30%, compared with 48% in the control group (P = 0.004).', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13075196",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:17426275",
-                "PMID:24254538"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:36874560': {'publication date': '2023 Feb', 'sentence': 'For this purpose, this review article contends that plasma cortisol is linked to a greater risk of AF.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 295849,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-          "name": "atrial fibrillation",
-          "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:04333",
-            "MEDDRA:10001452",
-            "ICD9:427.31",
-            "HP:0005110",
-            "MONDO:0004981",
-            "MEDDRA:10003658",
-            "MEDDRA:10016566",
-            "NCIT:C50466",
-            "SNOMEDCT:49436004",
-            "UMLS:C0004238",
-            "MESH:D001281",
-            "EFO:0000275",
-            "MEDDRA:10003796",
-            "SYMP:0000226",
-            "DOID:0060224"
-          ],
-          "id": "MONDO:0004981",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Atrial fibrillation",
-            "atrial fibrillation",
-            "Atrial Fibrillation"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-            "http://en.wikipedia.org/wiki/atrial_fibrillation",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 295849,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004981",
-              "name": "atrial fibrillation",
-              "description": "An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. [HPO:probinson]; An atrial arrhythmia characterized by disorganized atrial activity without discrete P waves on the surface EKG, but instead by an undulating baseline or more sharply circumscribed atrial deflections of varying amplitude an frequency ranging from 350 to 600 per minute. // COMMENTS: The ventricular response to atrial fibrillation is irregularly irregular because of the large number of atrial impulses that transit the atrioventricular node, making the ventricle partially refractory to further impulses. Atrial fibrillation can cause a number of manifestations including excessive ventricular response with angina pectoris or hypotension in susceptible individuals, syncope, systemic embolization, fatigue, or anxiety. These features should be coded separately.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:04333",
-                "MEDDRA:10001452",
-                "ICD9:427.31",
-                "HP:0005110",
-                "MONDO:0004981",
-                "MEDDRA:10003658",
-                "MEDDRA:10016566",
-                "NCIT:C50466",
-                "SNOMEDCT:49436004",
-                "UMLS:C0004238",
-                "MESH:D001281",
-                "EFO:0000275",
-                "MEDDRA:10003796",
-                "SYMP:0000226",
-                "DOID:0060224"
-              ],
-              "id": "MONDO:0004981",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Atrial fibrillation",
-                "atrial fibrillation",
-                "Atrial Fibrillation"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=atrial%20fibrillation",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/basics/definition/con-20027014",
-                "http://en.wikipedia.org/wiki/atrial_fibrillation",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/af",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24962364,
-            "start": 569,
-            "end": 295849,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:36874560': {'publication date': '2023 Feb', 'sentence': 'For this purpose, this review article contends that plasma cortisol is linked to a greater risk of AF.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:predisposes---None---None---None---UMLS:C0004238---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "25411585",
-              "object": "MONDO:0004981",
-              "publications": [
-                "PMID:36874560"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:2025556': {'publication date': '1991 Apr', 'sentence': 'Absorption of hydrocortisone from the skin reservoir in atopic dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:21094146': {'publication date': '2011 Jan 07', 'sentence': 'Collectively these data show that PHK are capable of extra-adrenal cortisol synthesis, which could be a fundamental pathway in skin biology with implications in psoriasis and atopic dermatitis.', 'subject score': 775, 'object score': 1000}, 'PMID:25396426': {'publication date': '2014', 'sentence': 'Thus, NP-mediated transcutaneous co-delivery of HC and HT can be considered as a promising therapy for managing immunological and histological spectra associated with AD.', 'subject score': 1000, 'object score': 1000}, 'PMID:27506086': {'publication date': '2016 May', 'sentence': 'The correlation between CAD severity and hair cortisol concentration was evaluated.', 'subject score': 623, 'object score': 861}, 'PMID:3890401': {'publication date': '1985 Apr', 'sentence': '[Comparative characteristics of the changes in the concentrations of sugar, insulin, glucagon and cortisol of the blood in atopic dermatitis and eczema patients].', 'subject score': 1000, 'object score': 1000}, 'PMID:8949461': {'publication date': '1996 Sep', 'sentence': 'Transepidermal water loss predicts systemic absorption of topical hydrocortisone in atopic dermatitis.', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 320151,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-          "name": "dermatitis, atopic",
-          "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MESH:C566404",
-            "MEDDRA:10012434",
-            "SNOMEDCT:24079001",
-            "MONDO:0011292",
-            "MEDDRA:10003641",
-            "MONDO:0100181",
-            "MEDDRA:10014191",
-            "OMIM:603165",
-            "HP:0001047",
-            "MEDDRA:10001711",
-            "MEDDRA:10003639",
-            "UMLS:C0011615",
-            "UMLS:C4280605",
-            "UMLS:C1864155",
-            "MEDDRA:10012438",
-            "MEDDRA:10014188",
-            "MEDDRA:10001712",
-            "MESH:D003876",
-            "SNOMEDCT:200775004"
-          ],
-          "id": "MONDO:0011292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis, Atopic, 1",
-            "dermatitis, atopic",
-            "Dermatitis, Atopic",
-            "Baby eczema",
-            "Dermatitis, atopic related phenotypic feature",
-            "Atopic dermatitis",
-            "dermatitis, atopic, 1"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:27904186",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320151,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-              "name": "dermatitis, atopic",
-              "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MESH:C566404",
-                "MEDDRA:10012434",
-                "SNOMEDCT:24079001",
-                "MONDO:0011292",
-                "MEDDRA:10003641",
-                "MONDO:0100181",
-                "MEDDRA:10014191",
-                "OMIM:603165",
-                "HP:0001047",
-                "MEDDRA:10001711",
-                "MEDDRA:10003639",
-                "UMLS:C0011615",
-                "UMLS:C4280605",
-                "UMLS:C1864155",
-                "MEDDRA:10012438",
-                "MEDDRA:10014188",
-                "MEDDRA:10001712",
-                "MESH:D003876",
-                "SNOMEDCT:200775004"
-              ],
-              "id": "MONDO:0011292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis, Atopic, 1",
-                "dermatitis, atopic",
-                "Dermatitis, Atopic",
-                "Baby eczema",
-                "Dermatitis, atopic related phenotypic feature",
-                "Atopic dermatitis",
-                "dermatitis, atopic, 1"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:27904186",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14582341,
-            "start": 569,
-            "end": 320151,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2025556': {'publication date': '1991 Apr', 'sentence': 'Absorption of hydrocortisone from the skin reservoir in atopic dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:21094146': {'publication date': '2011 Jan 07', 'sentence': 'Collectively these data show that PHK are capable of extra-adrenal cortisol synthesis, which could be a fundamental pathway in skin biology with implications in psoriasis and atopic dermatitis.', 'subject score': 775, 'object score': 1000}, 'PMID:25396426': {'publication date': '2014', 'sentence': 'Thus, NP-mediated transcutaneous co-delivery of HC and HT can be considered as a promising therapy for managing immunological and histological spectra associated with AD.', 'subject score': 1000, 'object score': 1000}, 'PMID:27506086': {'publication date': '2016 May', 'sentence': 'The correlation between CAD severity and hair cortisol concentration was evaluated.', 'subject score': 623, 'object score': 861}, 'PMID:3890401': {'publication date': '1985 Apr', 'sentence': '[Comparative characteristics of the changes in the concentrations of sugar, insulin, glucagon and cortisol of the blood in atopic dermatitis and eczema patients].', 'subject score': 1000, 'object score': 1000}, 'PMID:8949461': {'publication date': '1996 Sep', 'sentence': 'Transepidermal water loss predicts systemic absorption of topical hydrocortisone in atopic dermatitis.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0011615---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14891361",
-              "object": "MONDO:0011292",
-              "publications": [
-                "PMID:2025556",
-                "PMID:21094146",
-                "PMID:25396426",
-                "PMID:27506086",
-                "PMID:3890401",
-                "PMID:8949461"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:1826110': {'publication date': '1991 Feb', 'sentence': 'Open oral provocation with 100 or 250 mg hydrocortisone in patients with hydrocortisone contact hypersensitivity elicited cutaneous reactions at sites of previous allergic dermatitis caused by hydrocortisone in two patients and at sites of earlier allergic patch test reactions caused by hydrocortisone in the other two patients.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 320151,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-          "name": "dermatitis, atopic",
-          "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MESH:C566404",
-            "MEDDRA:10012434",
-            "SNOMEDCT:24079001",
-            "MONDO:0011292",
-            "MEDDRA:10003641",
-            "MONDO:0100181",
-            "MEDDRA:10014191",
-            "OMIM:603165",
-            "HP:0001047",
-            "MEDDRA:10001711",
-            "MEDDRA:10003639",
-            "UMLS:C0011615",
-            "UMLS:C4280605",
-            "UMLS:C1864155",
-            "MEDDRA:10012438",
-            "MEDDRA:10014188",
-            "MEDDRA:10001712",
-            "MESH:D003876",
-            "SNOMEDCT:200775004"
-          ],
-          "id": "MONDO:0011292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis, Atopic, 1",
-            "dermatitis, atopic",
-            "Dermatitis, Atopic",
-            "Baby eczema",
-            "Dermatitis, atopic related phenotypic feature",
-            "Atopic dermatitis",
-            "dermatitis, atopic, 1"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:27904186",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320151,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-              "name": "dermatitis, atopic",
-              "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MESH:C566404",
-                "MEDDRA:10012434",
-                "SNOMEDCT:24079001",
-                "MONDO:0011292",
-                "MEDDRA:10003641",
-                "MONDO:0100181",
-                "MEDDRA:10014191",
-                "OMIM:603165",
-                "HP:0001047",
-                "MEDDRA:10001711",
-                "MEDDRA:10003639",
-                "UMLS:C0011615",
-                "UMLS:C4280605",
-                "UMLS:C1864155",
-                "MEDDRA:10012438",
-                "MEDDRA:10014188",
-                "MEDDRA:10001712",
-                "MESH:D003876",
-                "SNOMEDCT:200775004"
-              ],
-              "id": "MONDO:0011292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis, Atopic, 1",
-                "dermatitis, atopic",
-                "Dermatitis, Atopic",
-                "Baby eczema",
-                "Dermatitis, atopic related phenotypic feature",
-                "Atopic dermatitis",
-                "dermatitis, atopic, 1"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:27904186",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13299976,
-            "start": 569,
-            "end": 320151,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1826110': {'publication date': '1991 Feb', 'sentence': 'Open oral provocation with 100 or 250 mg hydrocortisone in patients with hydrocortisone contact hypersensitivity elicited cutaneous reactions at sites of previous allergic dermatitis caused by hydrocortisone in two patients and at sites of earlier allergic patch test reactions caused by hydrocortisone in the other two patients.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0011615---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13585273",
-              "object": "MONDO:0011292",
-              "publications": [
-                "PMID:1826110"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1107090': {'publication date': '1975', 'sentence': 'Topical treatment with urea-hydrocortisone in atopic dermatitis.', 'subject score': 888, 'object score': 1000}, 'PMID:15245526': {'publication date': '2004 Jul', 'sentence': 'We compared the efficacy of WWT with a standard regime of hydrocortisone, to control moderate AD in children.', 'subject score': 1000, 'object score': 901}, 'PMID:16874433': {'publication date': '2006', 'sentence': 'Treatment of atopic dermatitis with 1% hydrocortisone and 25% pentane-1,5-diol: effect on Staphylococcus aureus.', 'subject score': 861, 'object score': 1000}, 'PMID:20337610': {'publication date': '2010 Sep', 'sentence': 'METHODS: Sixteen patients with AD were treated topically with miltefosine and hydrocortisone localized on representative AD target lesions for 3 weeks.', 'subject score': 1000, 'object score': 1000}, 'PMID:21094146': {'publication date': '2011 Jan 07', 'sentence': 'The expression of StAR and MLN64 was aberrant in two skin disorders, psoriasis and atopic dermatitis, that are commonly treated with cortisol, suggesting dysregulation of epidermal steroid synthesis in these patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:30657034': {'publication date': '2018', 'sentence': 'Due to these beneficial properties, GA and its derivatives (e.g. lipid-soluble phenols such as synthetic gallic esters aka gallates) have been extensively used as an adjuvant in a number of therapeutic formulations, as a substitute of hydrocortisone in children with atopic dermatitis (AD) and other skin conditions (hyperpigmentation, wound healing), and as a cosmetic ingredient.', 'subject score': 1000, 'object score': 1000}, 'PMID:32993977': {'publication date': '2020 Sep', 'sentence': 'Biopolymeric films as delivery vehicles for controlled release of hydrocortisone: Promising devices to treat chronic skin diseases.Atopic dermatitis (AD) is the most common chronic inflammatory skin disease with nasty effects on the psychosocial wellbeing of patients.', 'subject score': 1000, 'object score': 893}, 'PMID:33689537': {'publication date': '2021 Mar 09', 'sentence': 'This could support the proposed hypothesis of clinical dermatological treatment of hydrocortisone to local skin inflammations should the epidermis be found to be a key target for atopic dermatitis therapy.', 'subject score': 1000, 'object score': 901}, 'PMID:339846': {'publication date': '1978 Jan', 'sentence': 'Topical use of caffeine with hydrocortisone in the treatment of atopic dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:36365170': {'publication date': '2022 Oct 31', 'sentence': 'However, the nano-based film containing silibinin modulated the inflammatory and oxidative parameters in a similar or more pronounced way than silibinin solution and vehicle film, as well as than hydrocortisone, a classical treatment of AD.', 'subject score': 1000, 'object score': 1000}, 'PMID:37165693': {'publication date': '2023 May 11', 'sentence': 'BACKGROUND: There are no studies which evaluate hair cortisol as a biological marker of stress and anxiety in pruritic dogs during atopic dermatitis therapy.', 'subject score': 888, 'object score': 901}, 'PMID:6389217': {'publication date': '1984', 'sentence': 'Hydrocortisone 17-butyrate (Locoid) 0.1% cream versus hydrocortisone (Uniderm) 1% cream in the treatment of children suffering from atopic dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7490367': {'publication date': '1995 Dec', 'sentence': 'CONCLUSION: TEWL reflects changes in the systemic absorption of topical hydrocortisone during treatment of atopic dermatitis.', 'subject score': 861, 'object score': 1000}, 'PMID:7662574': {'publication date': '1995 Jun', 'sentence': 'However, the peak in plasma cortisol occurred earlier in children with atopic dermatitis (median 17.5 min) than in controls (median 25 min) (P = 0.02).', 'subject score': 888, 'object score': 1000}, 'PMID:7813169': {'publication date': '1994 Sep', 'sentence': 'In case of a history of untoward drug effects, oral antibiotics should be preferred (erythromycin or micamycin); for atopic dermatitis the preference is for topical treatment with hydrocortisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:9990411': {'publication date': '1998 Dec', 'sentence': 'The topical combinations of fusidic acid with either betamethasone or hydrocortisone are extremely useful in the treatment of atopic dermatitis/eczema whenever staphylococcal/secondary infection is suspected, and in more persistent cases of eczema where staphylococcal superantigen may be playing an important exacerbating role.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 320151,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-          "name": "dermatitis, atopic",
-          "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MESH:C566404",
-            "MEDDRA:10012434",
-            "SNOMEDCT:24079001",
-            "MONDO:0011292",
-            "MEDDRA:10003641",
-            "MONDO:0100181",
-            "MEDDRA:10014191",
-            "OMIM:603165",
-            "HP:0001047",
-            "MEDDRA:10001711",
-            "MEDDRA:10003639",
-            "UMLS:C0011615",
-            "UMLS:C4280605",
-            "UMLS:C1864155",
-            "MEDDRA:10012438",
-            "MEDDRA:10014188",
-            "MEDDRA:10001712",
-            "MESH:D003876",
-            "SNOMEDCT:200775004"
-          ],
-          "id": "MONDO:0011292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis, Atopic, 1",
-            "dermatitis, atopic",
-            "Dermatitis, Atopic",
-            "Baby eczema",
-            "Dermatitis, atopic related phenotypic feature",
-            "Atopic dermatitis",
-            "dermatitis, atopic, 1"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:27904186",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320151,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-              "name": "dermatitis, atopic",
-              "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MESH:C566404",
-                "MEDDRA:10012434",
-                "SNOMEDCT:24079001",
-                "MONDO:0011292",
-                "MEDDRA:10003641",
-                "MONDO:0100181",
-                "MEDDRA:10014191",
-                "OMIM:603165",
-                "HP:0001047",
-                "MEDDRA:10001711",
-                "MEDDRA:10003639",
-                "UMLS:C0011615",
-                "UMLS:C4280605",
-                "UMLS:C1864155",
-                "MEDDRA:10012438",
-                "MEDDRA:10014188",
-                "MEDDRA:10001712",
-                "MESH:D003876",
-                "SNOMEDCT:200775004"
-              ],
-              "id": "MONDO:0011292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis, Atopic, 1",
-                "dermatitis, atopic",
-                "Dermatitis, Atopic",
-                "Baby eczema",
-                "Dermatitis, atopic related phenotypic feature",
-                "Atopic dermatitis",
-                "dermatitis, atopic, 1"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:27904186",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8358666,
-            "start": 569,
-            "end": 320151,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1107090': {'publication date': '1975', 'sentence': 'Topical treatment with urea-hydrocortisone in atopic dermatitis.', 'subject score': 888, 'object score': 1000}, 'PMID:15245526': {'publication date': '2004 Jul', 'sentence': 'We compared the efficacy of WWT with a standard regime of hydrocortisone, to control moderate AD in children.', 'subject score': 1000, 'object score': 901}, 'PMID:16874433': {'publication date': '2006', 'sentence': 'Treatment of atopic dermatitis with 1% hydrocortisone and 25% pentane-1,5-diol: effect on Staphylococcus aureus.', 'subject score': 861, 'object score': 1000}, 'PMID:20337610': {'publication date': '2010 Sep', 'sentence': 'METHODS: Sixteen patients with AD were treated topically with miltefosine and hydrocortisone localized on representative AD target lesions for 3 weeks.', 'subject score': 1000, 'object score': 1000}, 'PMID:21094146': {'publication date': '2011 Jan 07', 'sentence': 'The expression of StAR and MLN64 was aberrant in two skin disorders, psoriasis and atopic dermatitis, that are commonly treated with cortisol, suggesting dysregulation of epidermal steroid synthesis in these patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:30657034': {'publication date': '2018', 'sentence': 'Due to these beneficial properties, GA and its derivatives (e.g. lipid-soluble phenols such as synthetic gallic esters aka gallates) have been extensively used as an adjuvant in a number of therapeutic formulations, as a substitute of hydrocortisone in children with atopic dermatitis (AD) and other skin conditions (hyperpigmentation, wound healing), and as a cosmetic ingredient.', 'subject score': 1000, 'object score': 1000}, 'PMID:32993977': {'publication date': '2020 Sep', 'sentence': 'Biopolymeric films as delivery vehicles for controlled release of hydrocortisone: Promising devices to treat chronic skin diseases.Atopic dermatitis (AD) is the most common chronic inflammatory skin disease with nasty effects on the psychosocial wellbeing of patients.', 'subject score': 1000, 'object score': 893}, 'PMID:33689537': {'publication date': '2021 Mar 09', 'sentence': 'This could support the proposed hypothesis of clinical dermatological treatment of hydrocortisone to local skin inflammations should the epidermis be found to be a key target for atopic dermatitis therapy.', 'subject score': 1000, 'object score': 901}, 'PMID:339846': {'publication date': '1978 Jan', 'sentence': 'Topical use of caffeine with hydrocortisone in the treatment of atopic dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:36365170': {'publication date': '2022 Oct 31', 'sentence': 'However, the nano-based film containing silibinin modulated the inflammatory and oxidative parameters in a similar or more pronounced way than silibinin solution and vehicle film, as well as than hydrocortisone, a classical treatment of AD.', 'subject score': 1000, 'object score': 1000}, 'PMID:37165693': {'publication date': '2023 May 11', 'sentence': 'BACKGROUND: There are no studies which evaluate hair cortisol as a biological marker of stress and anxiety in pruritic dogs during atopic dermatitis therapy.', 'subject score': 888, 'object score': 901}, 'PMID:6389217': {'publication date': '1984', 'sentence': 'Hydrocortisone 17-butyrate (Locoid) 0.1% cream versus hydrocortisone (Uniderm) 1% cream in the treatment of children suffering from atopic dermatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7490367': {'publication date': '1995 Dec', 'sentence': 'CONCLUSION: TEWL reflects changes in the systemic absorption of topical hydrocortisone during treatment of atopic dermatitis.', 'subject score': 861, 'object score': 1000}, 'PMID:7662574': {'publication date': '1995 Jun', 'sentence': 'However, the peak in plasma cortisol occurred earlier in children with atopic dermatitis (median 17.5 min) than in controls (median 25 min) (P = 0.02).', 'subject score': 888, 'object score': 1000}, 'PMID:7813169': {'publication date': '1994 Sep', 'sentence': 'In case of a history of untoward drug effects, oral antibiotics should be preferred (erythromycin or micamycin); for atopic dermatitis the preference is for topical treatment with hydrocortisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:9990411': {'publication date': '1998 Dec', 'sentence': 'The topical combinations of fusidic acid with either betamethasone or hydrocortisone are extremely useful in the treatment of atopic dermatitis/eczema whenever staphylococcal/secondary infection is suspected, and in more persistent cases of eczema where staphylococcal superantigen may be playing an important exacerbating role.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0011615---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8540090",
-              "object": "MONDO:0011292",
-              "publications": [
-                "PMID:1107090",
-                "PMID:15245526",
-                "PMID:16874433",
-                "PMID:20337610",
-                "PMID:21094146",
-                "PMID:30657034",
-                "PMID:32993977",
-                "PMID:33689537",
-                "PMID:339846",
-                "PMID:36365170",
-                "PMID:37165693",
-                "PMID:6389217",
-                "PMID:7490367",
-                "PMID:7662574",
-                "PMID:7813169",
-                "PMID:9990411"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:produces",
-    "r2.publications_info": "{'PMID:3010589': {'publication date': '1986', 'sentence': '[Reaction of autogenous cortisol production in patients with extensive psoriasis vulgaris or atopic dermatitis following external administration of a 0.25% prednicarbate salve (W/O emulsion)].', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 320151,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-          "name": "dermatitis, atopic",
-          "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MESH:C566404",
-            "MEDDRA:10012434",
-            "SNOMEDCT:24079001",
-            "MONDO:0011292",
-            "MEDDRA:10003641",
-            "MONDO:0100181",
-            "MEDDRA:10014191",
-            "OMIM:603165",
-            "HP:0001047",
-            "MEDDRA:10001711",
-            "MEDDRA:10003639",
-            "UMLS:C0011615",
-            "UMLS:C4280605",
-            "UMLS:C1864155",
-            "MEDDRA:10012438",
-            "MEDDRA:10014188",
-            "MEDDRA:10001712",
-            "MESH:D003876",
-            "SNOMEDCT:200775004"
-          ],
-          "id": "MONDO:0011292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis, Atopic, 1",
-            "dermatitis, atopic",
-            "Dermatitis, Atopic",
-            "Baby eczema",
-            "Dermatitis, atopic related phenotypic feature",
-            "Atopic dermatitis",
-            "dermatitis, atopic, 1"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:27904186",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320151,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-              "name": "dermatitis, atopic",
-              "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MESH:C566404",
-                "MEDDRA:10012434",
-                "SNOMEDCT:24079001",
-                "MONDO:0011292",
-                "MEDDRA:10003641",
-                "MONDO:0100181",
-                "MEDDRA:10014191",
-                "OMIM:603165",
-                "HP:0001047",
-                "MEDDRA:10001711",
-                "MEDDRA:10003639",
-                "UMLS:C0011615",
-                "UMLS:C4280605",
-                "UMLS:C1864155",
-                "MEDDRA:10012438",
-                "MEDDRA:10014188",
-                "MEDDRA:10001712",
-                "MESH:D003876",
-                "SNOMEDCT:200775004"
-              ],
-              "id": "MONDO:0011292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis, Atopic, 1",
-                "dermatitis, atopic",
-                "Dermatitis, Atopic",
-                "Baby eczema",
-                "Dermatitis, atopic related phenotypic feature",
-                "Atopic dermatitis",
-                "dermatitis, atopic, 1"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:27904186",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20115875,
-            "start": 320151,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:3010589': {'publication date': '1986', 'sentence': '[Reaction of autogenous cortisol production in patients with extensive psoriasis vulgaris or atopic dermatitis following external administration of a 0.25% prednicarbate salve (W/O emulsion)].', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0011615---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0011292",
-              "id": "20514012",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:3010589"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:11263762': {'publication date': '2001 Mar', 'sentence': 'From the compendium presented above, the following statements become evident: 1) Inappropriately low secretion of cortisol in relation to inflammation is a typical feature of the inflammatory disease in patients with RA.', 'subject score': 1000, 'object score': 1000}, 'PMID:13443347': {'publication date': '1957 May 25', 'sentence': '[Hydrocortisone in inflammation of the anterior section of the eye; report on experiences with terracortril & cortril].', 'subject score': 1000, 'object score': 1000}, 'PMID:18047442': {'publication date': '2007 Nov', 'sentence': 'A relationship between cortisol and inflammation was established in the pioneering work of H.', 'subject score': 1000, 'object score': 1000}, 'PMID:18455685': {'publication date': '2008 Apr', 'sentence': 'Such alterations are observed as decreased responsiveness of the hypothalamic-pituitary-adrenal axis, an inadequate production of cortisol in relation to inflammation, and - consequently - elevated sympathetic activity, alterations of sex hormone metabolism (loss of androgens), psychological alterations (with chronic fatigue and symptoms of depression due to elevated circulating cytokines), local reduction of synovial sympathetic innervation, altered metabolism of estrogens in the synovium, and high expression of estrogen receptors in synovial cells.', 'subject score': 1000, 'object score': 1000}, 'PMID:18559919': {'publication date': '2008 Sep', 'sentence': 'Amniotic fluid and umbilical cord plasma corticotropin-releasing factor (CRF), CRF-binding protein, adrenocorticotropin, and cortisol concentrations in intraamniotic infection and inflammation at term.', 'subject score': 888, 'object score': 1000}, 'PMID:19591636': {'publication date': '2009', 'sentence': 'Among other mechanisms, the loss of sympathetic nerve fibers in inflamed tissue and inadequate cortisol secretion in relation to inflammation lead to an enhanced proinflammatory load in RA.', 'subject score': 851, 'object score': 1000}, 'PMID:20204984': {'publication date': '2009 Dec', 'sentence': 'Increased cortisol and inflammation have been related to psychological stress while separate studies have found an inverse relation between cortisol and inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:25218898': {'publication date': '2015 Mar', 'sentence': 'The purpose of this study was to characterize relationships between cerebrospinal fluid (CSF) cortisol and inflammation after TBI, and to determine how these relationships differ by outcome.', 'subject score': 901, 'object score': 1000}, 'PMID:25502945': {'publication date': '2015 Jun', 'sentence': 'Inadequate production of cortisol related to inflammation and decrease in adrenal androgen production are hallmarks of hypothalamic-pituitary-adrenal (HPA)-related endocrine findings in rheumatoid arthritis (RA).', 'subject score': 1000, 'object score': 1000}, 'PMID:28043038': {'publication date': '2017 03', 'sentence': 'OBJECTIVE: This study examined the associations between intra-individual variability in, and inter-individual levels of, diurnal cortisol secretion with a marker of low-grade inflammation (i.e., C-Reactive Protein; CRP).', 'subject score': 851, 'object score': 901}, 'PMID:30304079': {'publication date': '2018 Oct 10', 'sentence': 'AIMS: To investigate whether acute dental pain due to pulpal or periapical inflammation is associated with increased expression of cortisol and inflammatory markers and mediators in the saliva, as well as changes in salivary flow rate.', 'subject score': 1000, 'object score': 888}, 'PMID:30445703': {'publication date': '2018 Nov 15', 'sentence': 'We tested whether (1) cortisol is associated to inflammation, (2) cortisol is associated to the adolescent Mediterranean diet score (aMDS), (3) aMDS lessens inflammation, (4) aMDS associates with cortisol levels and inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:35462473': {'publication date': '2022 Mar 25', 'sentence': 'In this study, we use knockout mice, hepatic cells and liver biopsies to explore the role of Ch25h and 25-HC in lipid metabolism and accumulation in liver, determine the molecular mechanism of lipid accumulation and inflammation influenced by Ch25h and 25-HC, and assess the regulatory effects of Ch25h and 25-HC on human NAFLD.', 'subject score': 861, 'object score': 1000}, 'PMID:35634363': {'publication date': '2022 Jun', 'sentence': 'Understanding the role of cortisol in the increased inflammation observed in depression.', 'subject score': 1000, 'object score': 888}, 'PMID:36865036': {'publication date': '2023 Mar', 'sentence': 'However, the role of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), which catalyzes the conversion of inactive cortisone into active cortisol, in inflammation remains unclear.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8590480,
-            "start": 569,
-            "end": 183319,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11263762': {'publication date': '2001 Mar', 'sentence': 'From the compendium presented above, the following statements become evident: 1) Inappropriately low secretion of cortisol in relation to inflammation is a typical feature of the inflammatory disease in patients with RA.', 'subject score': 1000, 'object score': 1000}, 'PMID:13443347': {'publication date': '1957 May 25', 'sentence': '[Hydrocortisone in inflammation of the anterior section of the eye; report on experiences with terracortril & cortril].', 'subject score': 1000, 'object score': 1000}, 'PMID:18047442': {'publication date': '2007 Nov', 'sentence': 'A relationship between cortisol and inflammation was established in the pioneering work of H.', 'subject score': 1000, 'object score': 1000}, 'PMID:18455685': {'publication date': '2008 Apr', 'sentence': 'Such alterations are observed as decreased responsiveness of the hypothalamic-pituitary-adrenal axis, an inadequate production of cortisol in relation to inflammation, and - consequently - elevated sympathetic activity, alterations of sex hormone metabolism (loss of androgens), psychological alterations (with chronic fatigue and symptoms of depression due to elevated circulating cytokines), local reduction of synovial sympathetic innervation, altered metabolism of estrogens in the synovium, and high expression of estrogen receptors in synovial cells.', 'subject score': 1000, 'object score': 1000}, 'PMID:18559919': {'publication date': '2008 Sep', 'sentence': 'Amniotic fluid and umbilical cord plasma corticotropin-releasing factor (CRF), CRF-binding protein, adrenocorticotropin, and cortisol concentrations in intraamniotic infection and inflammation at term.', 'subject score': 888, 'object score': 1000}, 'PMID:19591636': {'publication date': '2009', 'sentence': 'Among other mechanisms, the loss of sympathetic nerve fibers in inflamed tissue and inadequate cortisol secretion in relation to inflammation lead to an enhanced proinflammatory load in RA.', 'subject score': 851, 'object score': 1000}, 'PMID:20204984': {'publication date': '2009 Dec', 'sentence': 'Increased cortisol and inflammation have been related to psychological stress while separate studies have found an inverse relation between cortisol and inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:25218898': {'publication date': '2015 Mar', 'sentence': 'The purpose of this study was to characterize relationships between cerebrospinal fluid (CSF) cortisol and inflammation after TBI, and to determine how these relationships differ by outcome.', 'subject score': 901, 'object score': 1000}, 'PMID:25502945': {'publication date': '2015 Jun', 'sentence': 'Inadequate production of cortisol related to inflammation and decrease in adrenal androgen production are hallmarks of hypothalamic-pituitary-adrenal (HPA)-related endocrine findings in rheumatoid arthritis (RA).', 'subject score': 1000, 'object score': 1000}, 'PMID:28043038': {'publication date': '2017 03', 'sentence': 'OBJECTIVE: This study examined the associations between intra-individual variability in, and inter-individual levels of, diurnal cortisol secretion with a marker of low-grade inflammation (i.e., C-Reactive Protein; CRP).', 'subject score': 851, 'object score': 901}, 'PMID:30304079': {'publication date': '2018 Oct 10', 'sentence': 'AIMS: To investigate whether acute dental pain due to pulpal or periapical inflammation is associated with increased expression of cortisol and inflammatory markers and mediators in the saliva, as well as changes in salivary flow rate.', 'subject score': 1000, 'object score': 888}, 'PMID:30445703': {'publication date': '2018 Nov 15', 'sentence': 'We tested whether (1) cortisol is associated to inflammation, (2) cortisol is associated to the adolescent Mediterranean diet score (aMDS), (3) aMDS lessens inflammation, (4) aMDS associates with cortisol levels and inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:35462473': {'publication date': '2022 Mar 25', 'sentence': 'In this study, we use knockout mice, hepatic cells and liver biopsies to explore the role of Ch25h and 25-HC in lipid metabolism and accumulation in liver, determine the molecular mechanism of lipid accumulation and inflammation influenced by Ch25h and 25-HC, and assess the regulatory effects of Ch25h and 25-HC on human NAFLD.', 'subject score': 861, 'object score': 1000}, 'PMID:35634363': {'publication date': '2022 Jun', 'sentence': 'Understanding the role of cortisol in the increased inflammation observed in depression.', 'subject score': 1000, 'object score': 888}, 'PMID:36865036': {'publication date': '2023 Mar', 'sentence': 'However, the role of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), which catalyzes the conversion of inactive cortisone into active cortisol, in inflammation remains unclear.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8778414",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:11263762",
-                "PMID:13443347",
-                "PMID:18047442",
-                "PMID:18455685",
-                "PMID:18559919",
-                "PMID:19591636",
-                "PMID:20204984",
-                "PMID:25218898",
-                "PMID:25502945",
-                "PMID:28043038",
-                "PMID:30304079",
-                "PMID:30445703",
-                "PMID:35462473",
-                "PMID:35634363",
-                "PMID:36865036"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:35472267': {'publication date': '2022 Apr', 'sentence': 'The hypothalamic-pituitary-adrenal (HPA) axis is one of the key physiological systems that counterbalances this systemic inflammation through changes in adrenocorticotrophic hormone (ACTH) and cortisol.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24003863,
-            "start": 183319,
-            "end": 569,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35472267': {'publication date': '2022 Apr', 'sentence': 'The hypothalamic-pituitary-adrenal (HPA) axis is one of the key physiological systems that counterbalances this systemic inflammation through changes in adrenocorticotrophic hormone (ACTH) and cortisol.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0021368---SEMMEDDB:associated_with---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "NCIT:C3137",
-              "id": "24445107",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:35472267"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:12621354': {'publication date': '2003 Mar', 'sentence': 'CONCLUSION: Although hydrocortisone has anti-inflammatory properties, it seems to provoke inflammation in the round window membrane after topical instillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:18182463': {'publication date': '2007', 'sentence': 'In contrast to the influence of cortisol on the above parameters of systemic inflammation, the significant endotoxin-induced decreases in HRV time and frequency domains were not influenced by prior hydrocortisone treatment.', 'subject score': 851, 'object score': 888}, 'PMID:29269321': {'publication date': '2018 Mar', 'sentence': 'However, in the context of chronic stress, it is hypothesized that glucocorticoid receptors within immune cells become less sensitive to the anti-inflammatory effects of cortisol, resulting in increased systemic inflammation.', 'subject score': 1000, 'object score': 851}, 'PMID:31260749': {'publication date': '2019 Oct', 'sentence': 'Here, we measured 53 oxylipins using LC-MS/MS in an in vitro model of endothelial cell inflammation, and compared the changes induced by DHA to hydrocortisone, a well-established anti-inflammatory drug.', 'subject score': 1000, 'object score': 901}, 'PMID:35634363': {'publication date': '2022 Jun', 'sentence': 'However, opposing evidence has accumulated that supports a more recent model, which instead proposes that cortisol possesses immune potentiating properties and may thus directly cause the increased inflammation seen in depression.', 'subject score': 1000, 'object score': 888}, 'PMID:36869869': {'publication date': '2023 Mar 06', 'sentence': 'In addition, lowering interleukin-6 and cortisol leads to reduced inflammation, faster recovery, and increased immunity.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9850761,
-            "start": 569,
-            "end": 183319,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12621354': {'publication date': '2003 Mar', 'sentence': 'CONCLUSION: Although hydrocortisone has anti-inflammatory properties, it seems to provoke inflammation in the round window membrane after topical instillation.', 'subject score': 1000, 'object score': 1000}, 'PMID:18182463': {'publication date': '2007', 'sentence': 'In contrast to the influence of cortisol on the above parameters of systemic inflammation, the significant endotoxin-induced decreases in HRV time and frequency domains were not influenced by prior hydrocortisone treatment.', 'subject score': 851, 'object score': 888}, 'PMID:29269321': {'publication date': '2018 Mar', 'sentence': 'However, in the context of chronic stress, it is hypothesized that glucocorticoid receptors within immune cells become less sensitive to the anti-inflammatory effects of cortisol, resulting in increased systemic inflammation.', 'subject score': 1000, 'object score': 851}, 'PMID:31260749': {'publication date': '2019 Oct', 'sentence': 'Here, we measured 53 oxylipins using LC-MS/MS in an in vitro model of endothelial cell inflammation, and compared the changes induced by DHA to hydrocortisone, a well-established anti-inflammatory drug.', 'subject score': 1000, 'object score': 901}, 'PMID:35634363': {'publication date': '2022 Jun', 'sentence': 'However, opposing evidence has accumulated that supports a more recent model, which instead proposes that cortisol possesses immune potentiating properties and may thus directly cause the increased inflammation seen in depression.', 'subject score': 1000, 'object score': 888}, 'PMID:36869869': {'publication date': '2023 Mar 06', 'sentence': 'In addition, lowering interleukin-6 and cortisol leads to reduced inflammation, faster recovery, and increased immunity.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10068843",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:12621354",
-                "PMID:18182463",
-                "PMID:29269321",
-                "PMID:31260749",
-                "PMID:35634363",
-                "PMID:36869869"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:22013396': {'publication date': '2011', 'sentence': 'Finally, transient pre-treatment of healthy humans with cortisol induces a bi-phasic response during a later, delayed systemic inflammatory response: an intermediate cortisol concentration augments inflammation while a high cortisol concentration is neither pro- nor anti-inflammatory.', 'subject score': 623, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15599319,
-            "start": 569,
-            "end": 183319,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22013396': {'publication date': '2011', 'sentence': 'Finally, transient pre-treatment of healthy humans with cortisol induces a bi-phasic response during a later, delayed systemic inflammatory response: an intermediate cortisol concentration augments inflammation while a high cortisol concentration is neither pro- nor anti-inflammatory.', 'subject score': 623, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "15925719",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:22013396"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:13052711': {'publication date': '1953 Jun', 'sentence': 'The action of hydrocortisone in synovial inflammation.', 'subject score': 1000, 'object score': 888}, 'PMID:14437778': {'publication date': '1959 Oct', 'sentence': 'Effect of cortisol on an experimental inflammation already established.', 'subject score': 1000, 'object score': 888}, 'PMID:16535928': {'publication date': '2006 Jan', 'sentence': 'Hydrocortisone and other glucorticoid agents have a powerful modulating effect on inflammation and balance between pro- and anti-inflammatory factors.', 'subject score': 1000, 'object score': 1000}, 'PMID:16857225': {'publication date': '2006 Oct', 'sentence': 'Endogenous and synthetic glucocorticoids (GCs), such as cortisol and dexamethasone (Dex), modulate airway inflammation, regulate the production of surfactant by lung epithelial cells, and influence fetal lung maturation.', 'subject score': 1000, 'object score': 861}, 'PMID:22013396': {'publication date': '2011', 'sentence': 'Based on these findings and the work of others, we propose a new paradigm that identifies cortisol regulation of human inflammation as both dualistic-it is pro- and anti-inflammatory-and dynamic, it evolves over time.', 'subject score': 888, 'object score': 888}, 'PMID:26829709': {'publication date': '2016 Apr', 'sentence': 'Cortisol sensitivity was determined by the difference in monocytic TNF production between the conditions of 1 and 0 MUM cortisol incubation (\"cortisol-mediated inflammation regulation, CoMIR\").', 'subject score': 825, 'object score': 825}, 'PMID:28063472': {'publication date': '2017 Jan', 'sentence': 'Only unbound cortisol was believed to be biologically active, but recent evidence suggests that CBG-bound cortisol also regulates inflammation.', 'subject score': 827, 'object score': 1000}, 'PMID:28953797': {'publication date': '2017 Sep', 'sentence': \"RESULTS: The reduction of the cytokine's levels by participation and psycho-education inside the Group Psychotherapeutic Treatment, could lead to a regulation of IL-1, to the reduction of CRP, to the amelioration of the levels of cortisol thus regulating the inflammation of the bain.\", 'subject score': 1000, 'object score': 1000}, 'PMID:29845974': {'publication date': '2018 May 30', 'sentence': 'However, the effect of hydrocortisone on regulating inflammation, hemodynamic stability, and preventing shock is still unclear in Chinese patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:3004514': {'publication date': '1986 Jan', 'sentence': 'Effect of high-dose hydrocortisone treatment on inflammation and intraarticular calcium hydroxyapatite deposits.', 'subject score': 861, 'object score': 1000}, 'PMID:30445703': {'publication date': '2018 Nov 15', 'sentence': 'We tested whether (1) cortisol is associated to inflammation, (2) cortisol is associated to the adolescent Mediterranean diet score (aMDS), (3) aMDS lessens inflammation, (4) aMDS associates with cortisol levels and inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:31043325': {'publication date': '2019 06', 'sentence': 'Inflammation is a key contributor to the pathogenesis of bronchopulmonary dysplasia (BPD) in preterm infants, and cortisol plays a central role in controlling inflammation.', 'subject score': 1000, 'object score': 861}, 'PMID:36415926': {'publication date': '2022 Nov 22', 'sentence': 'A steroid, cortisol, is the most important glucocorticoid, and dexamethasone (Dex), a synthetic glucocorticoid, is widely used for suppressing inflammation in clinics.', 'subject score': 1000, 'object score': 888}, 'PMID:4272037': {'publication date': '1972', 'sentence': 'The effect of estrogen, progesterone and cortisol on gingival inflammation.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10206018,
-            "start": 569,
-            "end": 183319,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13052711': {'publication date': '1953 Jun', 'sentence': 'The action of hydrocortisone in synovial inflammation.', 'subject score': 1000, 'object score': 888}, 'PMID:14437778': {'publication date': '1959 Oct', 'sentence': 'Effect of cortisol on an experimental inflammation already established.', 'subject score': 1000, 'object score': 888}, 'PMID:16535928': {'publication date': '2006 Jan', 'sentence': 'Hydrocortisone and other glucorticoid agents have a powerful modulating effect on inflammation and balance between pro- and anti-inflammatory factors.', 'subject score': 1000, 'object score': 1000}, 'PMID:16857225': {'publication date': '2006 Oct', 'sentence': 'Endogenous and synthetic glucocorticoids (GCs), such as cortisol and dexamethasone (Dex), modulate airway inflammation, regulate the production of surfactant by lung epithelial cells, and influence fetal lung maturation.', 'subject score': 1000, 'object score': 861}, 'PMID:22013396': {'publication date': '2011', 'sentence': 'Based on these findings and the work of others, we propose a new paradigm that identifies cortisol regulation of human inflammation as both dualistic-it is pro- and anti-inflammatory-and dynamic, it evolves over time.', 'subject score': 888, 'object score': 888}, 'PMID:26829709': {'publication date': '2016 Apr', 'sentence': 'Cortisol sensitivity was determined by the difference in monocytic TNF production between the conditions of 1 and 0 MUM cortisol incubation (\"cortisol-mediated inflammation regulation, CoMIR\").', 'subject score': 825, 'object score': 825}, 'PMID:28063472': {'publication date': '2017 Jan', 'sentence': 'Only unbound cortisol was believed to be biologically active, but recent evidence suggests that CBG-bound cortisol also regulates inflammation.', 'subject score': 827, 'object score': 1000}, 'PMID:28953797': {'publication date': '2017 Sep', 'sentence': \"RESULTS: The reduction of the cytokine's levels by participation and psycho-education inside the Group Psychotherapeutic Treatment, could lead to a regulation of IL-1, to the reduction of CRP, to the amelioration of the levels of cortisol thus regulating the inflammation of the bain.\", 'subject score': 1000, 'object score': 1000}, 'PMID:29845974': {'publication date': '2018 May 30', 'sentence': 'However, the effect of hydrocortisone on regulating inflammation, hemodynamic stability, and preventing shock is still unclear in Chinese patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:3004514': {'publication date': '1986 Jan', 'sentence': 'Effect of high-dose hydrocortisone treatment on inflammation and intraarticular calcium hydroxyapatite deposits.', 'subject score': 861, 'object score': 1000}, 'PMID:30445703': {'publication date': '2018 Nov 15', 'sentence': 'We tested whether (1) cortisol is associated to inflammation, (2) cortisol is associated to the adolescent Mediterranean diet score (aMDS), (3) aMDS lessens inflammation, (4) aMDS associates with cortisol levels and inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:31043325': {'publication date': '2019 06', 'sentence': 'Inflammation is a key contributor to the pathogenesis of bronchopulmonary dysplasia (BPD) in preterm infants, and cortisol plays a central role in controlling inflammation.', 'subject score': 1000, 'object score': 861}, 'PMID:36415926': {'publication date': '2022 Nov 22', 'sentence': 'A steroid, cortisol, is the most important glucocorticoid, and dexamethasone (Dex), a synthetic glucocorticoid, is widely used for suppressing inflammation in clinics.', 'subject score': 1000, 'object score': 888}, 'PMID:4272037': {'publication date': '1972', 'sentence': 'The effect of estrogen, progesterone and cortisol on gingival inflammation.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10431364",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:13052711",
-                "PMID:14437778",
-                "PMID:16535928",
-                "PMID:16857225",
-                "PMID:22013396",
-                "PMID:26829709",
-                "PMID:28063472",
-                "PMID:28953797",
-                "PMID:29845974",
-                "PMID:3004514",
-                "PMID:30445703",
-                "PMID:31043325",
-                "PMID:36415926",
-                "PMID:4272037"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11261868': {'publication date': '2001 Mar 01', 'sentence': 'Acidification with a topical solution of 2 percent acetic acid combined with hydrocortisone for inflammation is effective treatment in most cases and, when used after exposure to moisture, is an excellent prophylactic.', 'subject score': 1000, 'object score': 1000}, 'PMID:1266622': {'publication date': '1976 Feb', 'sentence': 'The impaired differentiation of monocytes is suggested as an additional explanation of the reduced number of macrophages appearing at the site of inflammation during cortisol treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:12682474': {'publication date': '2003 Apr', 'sentence': 'CONCLUSIONS: Although we acknowledge the limitations of a nonblinded interventional trial, stress doses of hydrocortisone seem to attenuate systemic inflammation in a predefined risk group of patients after cardiac surgery with cardiopulmonary bypass and improve early outcome.', 'subject score': 1000, 'object score': 888}, 'PMID:15525570': {'publication date': '2004 Oct', 'sentence': 'IL-1alpha co-ordinately induces 11betaHSD1 and a panel of glucocorticoid-regulated, inflammation-associated genes in HOSE cells, providing further evidence that cortisol generated by 11betaHSD1 could participate in the local resolution of inflammation associated with ovulation.', 'subject score': 1000, 'object score': 1000}, 'PMID:15557131': {'publication date': '2005 Feb 01', 'sentence': 'We hypothesize that hydrocortisone infusion in severe community-acquired pneumonia attenuates systemic inflammation and leads to earlier resolution of pneumonia and a reduction in sepsis-related complications.', 'subject score': 888, 'object score': 888}, 'PMID:16088513': {'publication date': '2004 Dec', 'sentence': 'Assuming relative adrenal insufficiency (RAI) and peripheral cortisol resistance, treatment with low-dose hydrocortisone improved shock reversal, reduced inflammation, and improved outcome.', 'subject score': 901, 'object score': 888}, 'PMID:17195247': {'publication date': '2007 Jan', 'sentence': 'Cortisol metabolism by 11 beta-hydroxysteroid dehydrogenase as a novel target in the treatment of inflammation- or immune-mediated bone loss: comment on the article by Makrygiannakis et al.', 'subject score': 888, 'object score': 1000}, 'PMID:19022342': {'publication date': '2009 Mar 25', 'sentence': 'On the other hand, endogenous cortisol is regarded as physiological compound to combat inflammation.', 'subject score': 888, 'object score': 1000}, 'PMID:20634656': {'publication date': '2010 Aug', 'sentence': 'Preconditioning with either hydrocortisone or antithrombin should, thus, alleviate vascular leakage, tissue edema, and inflammation.', 'subject score': 861, 'object score': 1000}, 'PMID:20965252': {'publication date': '2011 Jan', 'sentence': 'In contrast, cortisol in combination with the pro-inflammatory agents has a synergistic effect on IL-10 expression, an anti-inflammatory molecule, suggesting that the activation of certain macrophage functions that lead to the resolution of inflammation occurs in fish macrophages in response to cortisol treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:23817641': {'publication date': '2013 Sep', 'sentence': 'Cortisol is one of the most potent immunomodulatory hormones involved in control of inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:23831090': {'publication date': '2013 Sep', 'sentence': 'The lower increase in cortisol after the ACTH challenge in cows with greater inflammation (LO quartile) seems a consequence of the lower availability of cortisol-binding globulin synthetized by the liver, but other mechanisms can be involved (e.g., rate of cortisol production, secretion, and metabolic clearance).', 'subject score': 1000, 'object score': 888}, 'PMID:28101752': {'publication date': '2017 Dec', 'sentence': 'In this experimental model of systemic inflammation, we sought to investigate whether septic neutrophil activation, evaluated by the plasma levels of neutrophil gelatinase-associated protein (NGAL), is modulated by the timing of hydrocortisone treatment.', 'subject score': 888, 'object score': 888}, 'PMID:3004514': {'publication date': '1986 Jan', 'sentence': 'Since inhibition of inflammation by hydrocortisone treatment did not block apatite accumulation, intraarticular deposition of hydroxyapatite occurs independent of inflammation in progressive ankylosis.', 'subject score': 888, 'object score': 1000}, 'PMID:31572556': {'publication date': '2019 Oct', 'sentence': 'Rats were divided into control (Control), high-inflammation treated with hydrocortisone (HT), high-inflammation non-treatment (HNT), low-inflammation treated with hydrocortisone (LT) and low-inflammation non-treatment (LNT) groups according to the levels of serum C-reactive protein (CRP), interleukin (IL)-6 and interferon (IFN)-gamma.', 'subject score': 1000, 'object score': 888}, 'PMID:34816666': {'publication date': '2021 Sep', 'sentence': 'Conclusion:     Tangeretin supplementation can significantly alleviate the cortisol stress response induced by high-intensity resistance exercise, inhibit the excessive secretion of cortisol, enhance antioxidant capacity, accelerate the elimination of inflammation in the body, and promote the recovery of body functions.', 'subject score': 1000, 'object score': 1000}, 'PMID:9229827': {'publication date': '1997', 'sentence': 'A positive therapeutic effect consisting in elimination of inflammation in the tracheobronchial tree and normalizing the indices of cellular and humoral immunity was observed earlier in patients receiving therapeutic fiber bronchoscopy with liposome and hydrocortisone.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8588542,
-            "start": 569,
-            "end": 183319,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11261868': {'publication date': '2001 Mar 01', 'sentence': 'Acidification with a topical solution of 2 percent acetic acid combined with hydrocortisone for inflammation is effective treatment in most cases and, when used after exposure to moisture, is an excellent prophylactic.', 'subject score': 1000, 'object score': 1000}, 'PMID:1266622': {'publication date': '1976 Feb', 'sentence': 'The impaired differentiation of monocytes is suggested as an additional explanation of the reduced number of macrophages appearing at the site of inflammation during cortisol treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:12682474': {'publication date': '2003 Apr', 'sentence': 'CONCLUSIONS: Although we acknowledge the limitations of a nonblinded interventional trial, stress doses of hydrocortisone seem to attenuate systemic inflammation in a predefined risk group of patients after cardiac surgery with cardiopulmonary bypass and improve early outcome.', 'subject score': 1000, 'object score': 888}, 'PMID:15525570': {'publication date': '2004 Oct', 'sentence': 'IL-1alpha co-ordinately induces 11betaHSD1 and a panel of glucocorticoid-regulated, inflammation-associated genes in HOSE cells, providing further evidence that cortisol generated by 11betaHSD1 could participate in the local resolution of inflammation associated with ovulation.', 'subject score': 1000, 'object score': 1000}, 'PMID:15557131': {'publication date': '2005 Feb 01', 'sentence': 'We hypothesize that hydrocortisone infusion in severe community-acquired pneumonia attenuates systemic inflammation and leads to earlier resolution of pneumonia and a reduction in sepsis-related complications.', 'subject score': 888, 'object score': 888}, 'PMID:16088513': {'publication date': '2004 Dec', 'sentence': 'Assuming relative adrenal insufficiency (RAI) and peripheral cortisol resistance, treatment with low-dose hydrocortisone improved shock reversal, reduced inflammation, and improved outcome.', 'subject score': 901, 'object score': 888}, 'PMID:17195247': {'publication date': '2007 Jan', 'sentence': 'Cortisol metabolism by 11 beta-hydroxysteroid dehydrogenase as a novel target in the treatment of inflammation- or immune-mediated bone loss: comment on the article by Makrygiannakis et al.', 'subject score': 888, 'object score': 1000}, 'PMID:19022342': {'publication date': '2009 Mar 25', 'sentence': 'On the other hand, endogenous cortisol is regarded as physiological compound to combat inflammation.', 'subject score': 888, 'object score': 1000}, 'PMID:20634656': {'publication date': '2010 Aug', 'sentence': 'Preconditioning with either hydrocortisone or antithrombin should, thus, alleviate vascular leakage, tissue edema, and inflammation.', 'subject score': 861, 'object score': 1000}, 'PMID:20965252': {'publication date': '2011 Jan', 'sentence': 'In contrast, cortisol in combination with the pro-inflammatory agents has a synergistic effect on IL-10 expression, an anti-inflammatory molecule, suggesting that the activation of certain macrophage functions that lead to the resolution of inflammation occurs in fish macrophages in response to cortisol treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:23817641': {'publication date': '2013 Sep', 'sentence': 'Cortisol is one of the most potent immunomodulatory hormones involved in control of inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:23831090': {'publication date': '2013 Sep', 'sentence': 'The lower increase in cortisol after the ACTH challenge in cows with greater inflammation (LO quartile) seems a consequence of the lower availability of cortisol-binding globulin synthetized by the liver, but other mechanisms can be involved (e.g., rate of cortisol production, secretion, and metabolic clearance).', 'subject score': 1000, 'object score': 888}, 'PMID:28101752': {'publication date': '2017 Dec', 'sentence': 'In this experimental model of systemic inflammation, we sought to investigate whether septic neutrophil activation, evaluated by the plasma levels of neutrophil gelatinase-associated protein (NGAL), is modulated by the timing of hydrocortisone treatment.', 'subject score': 888, 'object score': 888}, 'PMID:3004514': {'publication date': '1986 Jan', 'sentence': 'Since inhibition of inflammation by hydrocortisone treatment did not block apatite accumulation, intraarticular deposition of hydroxyapatite occurs independent of inflammation in progressive ankylosis.', 'subject score': 888, 'object score': 1000}, 'PMID:31572556': {'publication date': '2019 Oct', 'sentence': 'Rats were divided into control (Control), high-inflammation treated with hydrocortisone (HT), high-inflammation non-treatment (HNT), low-inflammation treated with hydrocortisone (LT) and low-inflammation non-treatment (LNT) groups according to the levels of serum C-reactive protein (CRP), interleukin (IL)-6 and interferon (IFN)-gamma.', 'subject score': 1000, 'object score': 888}, 'PMID:34816666': {'publication date': '2021 Sep', 'sentence': 'Conclusion:     Tangeretin supplementation can significantly alleviate the cortisol stress response induced by high-intensity resistance exercise, inhibit the excessive secretion of cortisol, enhance antioxidant capacity, accelerate the elimination of inflammation in the body, and promote the recovery of body functions.', 'subject score': 1000, 'object score': 1000}, 'PMID:9229827': {'publication date': '1997', 'sentence': 'A positive therapeutic effect consisting in elimination of inflammation in the tracheobronchial tree and normalizing the indices of cellular and humoral immunity was observed earlier in patients receiving therapeutic fiber bronchoscopy with liposome and hydrocortisone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8776300",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:11261868",
-                "PMID:1266622",
-                "PMID:12682474",
-                "PMID:15525570",
-                "PMID:15557131",
-                "PMID:16088513",
-                "PMID:17195247",
-                "PMID:19022342",
-                "PMID:20634656",
-                "PMID:20965252",
-                "PMID:23817641",
-                "PMID:23831090",
-                "PMID:28101752",
-                "PMID:3004514",
-                "PMID:31572556",
-                "PMID:34816666",
-                "PMID:9229827"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:produces",
-    "r2.publications_info": "{'PMID:27061835': {'publication date': '2016 09', 'sentence': 'OBJECTIVE: Corticosteroid-binding globulin (CBG), the cortisol transport protein, is cleaved from high-affinity (haCBG) to low-affinity (laCBG) CBG at sites of inflammation releasing bioavailable, anti-inflammatory cortisol.', 'subject score': 1000, 'object score': 861}, 'PMID:28043038': {'publication date': '2017 03', 'sentence': 'CONCLUSION: Variability in cortisol secretion across days forecasts low-grade inflammation, and this association is paramount among older adults who secrete high levels of diurnal cortisol.', 'subject score': 901, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18550439,
-            "start": 183319,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27061835': {'publication date': '2016 09', 'sentence': 'OBJECTIVE: Corticosteroid-binding globulin (CBG), the cortisol transport protein, is cleaved from high-affinity (haCBG) to low-affinity (laCBG) CBG at sites of inflammation releasing bioavailable, anti-inflammatory cortisol.', 'subject score': 1000, 'object score': 861}, 'PMID:28043038': {'publication date': '2017 03', 'sentence': 'CONCLUSION: Variability in cortisol secretion across days forecasts low-grade inflammation, and this association is paramount among older adults who secrete high levels of diurnal cortisol.', 'subject score': 901, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0021368---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "NCIT:C3137",
-              "id": "18924640",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:27061835",
-                "PMID:28043038"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:11334460': {'publication date': '2001 May', 'sentence': 'Under normal conditions, stress induces increased cortisol secretion that counteracts inflammatory reactions.', 'subject score': 851, 'object score': 983}, 'PMID:13529445': {'publication date': '1958 Feb', 'sentence': 'Local anti-inflammatory effect of hydrocortisone, Ro 2-5383/2 and histamine; suppression of inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:19212128': {'publication date': '2009', 'sentence': 'Similar to hydrocortisone, they suppress inflammation, but without immune suppression, and have a role in the maintenance of the Th1/Th2 balance and immune homeostasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:21529303': {'publication date': '2011', 'sentence': 'In RA, the increase in nocturnal anti-inflammatory cortisol secretion is insufficient to suppress ongoing inflammation, resulting in the morning symptoms characteristic of RA.', 'subject score': 840, 'object score': 861}, 'PMID:25227591': {'publication date': '2015', 'sentence': 'Under long-standing chronic stress of disease, insufficient cortisol is available to inhibit an ongoing nocturnal immune/inflammatory reaction.', 'subject score': 888, 'object score': 798}, 'PMID:27403034': {'publication date': '2016', 'sentence': 'The adrenal glands are able to modulate immune responses through neuroimmunoendocrine interactions and cortisol secretion that could suppress exacerbated inflammation such as in inflammatory bowel disease (IBD).', 'subject score': 888, 'object score': 888}, 'PMID:30028389': {'publication date': '2018 Aug', 'sentence': 'Glucocorticoids (GCs) such as cortisol are widely understood to suppress inflammation and immunity.', 'subject score': 1000, 'object score': 1000}, 'PMID:31807025': {'publication date': '2019', 'sentence': 'Hydrocortisone Suppresses Early Paraneoplastic Inflammation And Angiogenesis To Attenuate Early Hepatocellular Carcinoma Progression In Rats.', 'subject score': 1000, 'object score': 851}, 'PMID:35635075': {'publication date': '2022 May 30', 'sentence': 'Ascorbic acid and hydrocortisone synergistically inhibit septic organ injury via improving oxidative stress and inhibiting inflammation.', 'subject score': 1000, 'object score': 888}, 'PMID:6446523': {'publication date': '1980 Jun', 'sentence': 'The antihistamine metiamide, an H2-blocker; the antiserotonin drug, p-chlorophenylalanine; and the antiinflammatory drugs, aspirin, hydrocortisone, and ibuprofen failed to antagonize adriamycin-induced inflammation at 2 h or 5 days after adriamycin injection.', 'subject score': 1000, 'object score': 851}, 'PMID:9257297': {'publication date': '1997 Jul', 'sentence': 'In the periphery, hydrocortisone inhibits inflammation, downregulates the immune system and produces many other crucial physiological and metabolic changes.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8675913,
-            "start": 569,
-            "end": 183319,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11334460': {'publication date': '2001 May', 'sentence': 'Under normal conditions, stress induces increased cortisol secretion that counteracts inflammatory reactions.', 'subject score': 851, 'object score': 983}, 'PMID:13529445': {'publication date': '1958 Feb', 'sentence': 'Local anti-inflammatory effect of hydrocortisone, Ro 2-5383/2 and histamine; suppression of inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:19212128': {'publication date': '2009', 'sentence': 'Similar to hydrocortisone, they suppress inflammation, but without immune suppression, and have a role in the maintenance of the Th1/Th2 balance and immune homeostasis.', 'subject score': 1000, 'object score': 1000}, 'PMID:21529303': {'publication date': '2011', 'sentence': 'In RA, the increase in nocturnal anti-inflammatory cortisol secretion is insufficient to suppress ongoing inflammation, resulting in the morning symptoms characteristic of RA.', 'subject score': 840, 'object score': 861}, 'PMID:25227591': {'publication date': '2015', 'sentence': 'Under long-standing chronic stress of disease, insufficient cortisol is available to inhibit an ongoing nocturnal immune/inflammatory reaction.', 'subject score': 888, 'object score': 798}, 'PMID:27403034': {'publication date': '2016', 'sentence': 'The adrenal glands are able to modulate immune responses through neuroimmunoendocrine interactions and cortisol secretion that could suppress exacerbated inflammation such as in inflammatory bowel disease (IBD).', 'subject score': 888, 'object score': 888}, 'PMID:30028389': {'publication date': '2018 Aug', 'sentence': 'Glucocorticoids (GCs) such as cortisol are widely understood to suppress inflammation and immunity.', 'subject score': 1000, 'object score': 1000}, 'PMID:31807025': {'publication date': '2019', 'sentence': 'Hydrocortisone Suppresses Early Paraneoplastic Inflammation And Angiogenesis To Attenuate Early Hepatocellular Carcinoma Progression In Rats.', 'subject score': 1000, 'object score': 851}, 'PMID:35635075': {'publication date': '2022 May 30', 'sentence': 'Ascorbic acid and hydrocortisone synergistically inhibit septic organ injury via improving oxidative stress and inhibiting inflammation.', 'subject score': 1000, 'object score': 888}, 'PMID:6446523': {'publication date': '1980 Jun', 'sentence': 'The antihistamine metiamide, an H2-blocker; the antiserotonin drug, p-chlorophenylalanine; and the antiinflammatory drugs, aspirin, hydrocortisone, and ibuprofen failed to antagonize adriamycin-induced inflammation at 2 h or 5 days after adriamycin injection.', 'subject score': 1000, 'object score': 851}, 'PMID:9257297': {'publication date': '1997 Jul', 'sentence': 'In the periphery, hydrocortisone inhibits inflammation, downregulates the immune system and produces many other crucial physiological and metabolic changes.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:disrupts---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8865955",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:11334460",
-                "PMID:13529445",
-                "PMID:19212128",
-                "PMID:21529303",
-                "PMID:25227591",
-                "PMID:27403034",
-                "PMID:30028389",
-                "PMID:31807025",
-                "PMID:35635075",
-                "PMID:6446523",
-                "PMID:9257297"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:21441882': {'publication date': '2011 Mar', 'sentence': 'CONCLUSION: We conclude that intravenous stress doses of hydrocortisone lead to a reduction of systemic inflammation and to a potential improvement in the early outcome of patients undergoing off-pump CABG.', 'subject score': 1000, 'object score': 888}, 'PMID:24269961': {'publication date': '2014 Jan', 'sentence': 'It was found that cortisol reduces inflammation in differentiated monocytes.', 'subject score': 1000, 'object score': 1000}, 'PMID:27187933': {'publication date': '2016 07', 'sentence': 'RESULTS: Ours results showed that cortisol and cortisone decreased significantly the inflammation promoted by OxLDL, and also diminished the expression of genes involved in influx and efflux of cholesterol resulting in a reduced lipid accumulation.', 'subject score': 1000, 'object score': 1000}, 'PMID:28986096': {'publication date': '2017 Dec 15', 'sentence': 'KEY FINDINGS: We found that HCT reduced hepatic necrosis and inflammatory infiltration after hepatic I/R injury in mice that received high fat diet treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:31328119': {'publication date': '2019 Jun', 'sentence': 'Supplementation with SHP 450 mg/kg can be used as an alternative source of functional food for overcoming oxidative stress, as indicated by its ability to improve levels of blood glucose, triacylglycerol, total cholesterol, and cortisol, and to improve liver histology by decreasing severity of liver inflammation.', 'subject score': 1000, 'object score': 888}, 'PMID:36029810': {'publication date': '2022 Aug 24', 'sentence': 'Corticosteroids like Hydrocortisone, dexamethasone, Prednisolone and Methylprednisolone has been reported to be effective against SARS-CoV-2 virus in comparison to that of non-steroid drugs, by using non-genomic and genomic effects to prevent and reduce inflammation in tissues and the circulation.', 'subject score': 1000, 'object score': 1000}, 'PMID:3618038': {'publication date': '1987', 'sentence': 'In the first 7 days of the experiment HC decreased the inflammatory reaction and metabolic disorders in the cerebral tissue, activated HPNS and reduced the mortality rate.', 'subject score': 888, 'object score': 1000}, 'PMID:8751764': {'publication date': '1996 Sep', 'sentence': 'Hydrocortisone, as expected, showed significant detrimental effects on bursting strength, as well as decreasing systemic inflammation.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15229757,
-            "start": 569,
-            "end": 183319,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21441882': {'publication date': '2011 Mar', 'sentence': 'CONCLUSION: We conclude that intravenous stress doses of hydrocortisone lead to a reduction of systemic inflammation and to a potential improvement in the early outcome of patients undergoing off-pump CABG.', 'subject score': 1000, 'object score': 888}, 'PMID:24269961': {'publication date': '2014 Jan', 'sentence': 'It was found that cortisol reduces inflammation in differentiated monocytes.', 'subject score': 1000, 'object score': 1000}, 'PMID:27187933': {'publication date': '2016 07', 'sentence': 'RESULTS: Ours results showed that cortisol and cortisone decreased significantly the inflammation promoted by OxLDL, and also diminished the expression of genes involved in influx and efflux of cholesterol resulting in a reduced lipid accumulation.', 'subject score': 1000, 'object score': 1000}, 'PMID:28986096': {'publication date': '2017 Dec 15', 'sentence': 'KEY FINDINGS: We found that HCT reduced hepatic necrosis and inflammatory infiltration after hepatic I/R injury in mice that received high fat diet treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:31328119': {'publication date': '2019 Jun', 'sentence': 'Supplementation with SHP 450 mg/kg can be used as an alternative source of functional food for overcoming oxidative stress, as indicated by its ability to improve levels of blood glucose, triacylglycerol, total cholesterol, and cortisol, and to improve liver histology by decreasing severity of liver inflammation.', 'subject score': 1000, 'object score': 888}, 'PMID:36029810': {'publication date': '2022 Aug 24', 'sentence': 'Corticosteroids like Hydrocortisone, dexamethasone, Prednisolone and Methylprednisolone has been reported to be effective against SARS-CoV-2 virus in comparison to that of non-steroid drugs, by using non-genomic and genomic effects to prevent and reduce inflammation in tissues and the circulation.', 'subject score': 1000, 'object score': 1000}, 'PMID:3618038': {'publication date': '1987', 'sentence': 'In the first 7 days of the experiment HC decreased the inflammatory reaction and metabolic disorders in the cerebral tissue, activated HPNS and reduced the mortality rate.', 'subject score': 888, 'object score': 1000}, 'PMID:8751764': {'publication date': '1996 Sep', 'sentence': 'Hydrocortisone, as expected, showed significant detrimental effects on bursting strength, as well as decreasing systemic inflammation.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "15550113",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:21441882",
-                "PMID:24269961",
-                "PMID:27187933",
-                "PMID:28986096",
-                "PMID:31328119",
-                "PMID:36029810",
-                "PMID:3618038",
-                "PMID:8751764"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:15843228': {'publication date': '2005', 'sentence': 'The objective of this study was to demonstrate the effect of stress doses of hydrocortisone during the initial phase of human septic shock on the serum values of the neurospecific protein S-100B in comparison to the inflammation markers interleukin (IL)-8 in serum and polymorphonuclear (PMN) elastase in plasma.', 'subject score': 1000, 'object score': 824}, 'PMID:27832762': {'publication date': '2016 11 10', 'sentence': 'Serum samples were analysed by Liquid Chromatography coupled to Mass Spectrometry, for tryptophan, ten of its metabolites, the inflammation marker neopterin and the hypothalamic-pituitary-adrenal (HPA) axis marker cortisol.', 'subject score': 888, 'object score': 851}, 'PMID:29899546': {'publication date': '2018 Jun 13', 'sentence': 'The present study combined neuroimaging, salivary cortisol, and blood markers of inflammation and metabolism collected prior to scanning.', 'subject score': 888, 'object score': 1000}, 'PMID:30200906': {'publication date': '2018 Sep 10', 'sentence': 'Secondary outcomes include sleep quality, depression, anxiety, quality of life, cognitive complaints, cancer worries, fatigue catastrophizing, self-efficacy to handle fatigue, biological circadian rhythms of melatonin, cortisol and activity, and biomarkers of inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:30935010': {'publication date': '2019 Mar 30', 'sentence': 'Serum glucose (n = 35), serum insulin (n = 35), serum creatine kinase (n = 15) and myoglobin (n = 15), hematologic parameters, cortisol (n = 35), inflammation markers (n = 27) and leg strength (n = 15) as a functional marker were measured.', 'subject score': 1000, 'object score': 694}, 'PMID:31374824': {'publication date': '2019 Aug 01', 'sentence': 'In this work, we investigate the effects of thoracic (T6-7) and cervical (C6-7) moderate-severe contusion SCIs on the spleen by characterizing splenic norepinephrine (NE) and cortisol (CORT), caspase-3, and multiple inflammation markers at 3- and 7-days post-SCI.', 'subject score': 1000, 'object score': 623}, 'PMID:32098947': {'publication date': '2020 Feb 25', 'sentence': 'Raised levels of cortisol, and markers of inflammation such as Interleukin (IL-6) and C-reactive protein (CRP), have been linked to both early life stress and MDD.', 'subject score': 1000, 'object score': 1000}, 'PMID:32153900': {'publication date': '2018', 'sentence': 'Secondary outcomes include mid-upper-arm circumference, neuro-behavioral development, hair cortisol concentrations, markers of intestinal inflammation and parasite burden.', 'subject score': 851, 'object score': 888}, 'PMID:34669995': {'publication date': '2021 Oct 20', 'sentence': 'CONCLUSIONS: Compared with plasma cortisol and inflammation biomarkers, HRV is more sensitive to detect surgical stress and autonomic nervous dysfunction induced by radical gastrectomy in patients with gastric cancer.', 'subject score': 888, 'object score': 888}, 'PMID:37138028': {'publication date': '2023 May 03', 'sentence': 'The findings indicate a dose-dependency of hydrocortisone for metabolomic and anti-inflammatory effects, that prolonged therapy may lower the supply of many nutrients, and that monitoring concentrations of cortisol and inflammation markers may be a useful clinical approach during corticosteroid therapy.', 'subject score': 1000, 'object score': 872}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11530888,
-            "start": 569,
-            "end": 183319,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15843228': {'publication date': '2005', 'sentence': 'The objective of this study was to demonstrate the effect of stress doses of hydrocortisone during the initial phase of human septic shock on the serum values of the neurospecific protein S-100B in comparison to the inflammation markers interleukin (IL)-8 in serum and polymorphonuclear (PMN) elastase in plasma.', 'subject score': 1000, 'object score': 824}, 'PMID:27832762': {'publication date': '2016 11 10', 'sentence': 'Serum samples were analysed by Liquid Chromatography coupled to Mass Spectrometry, for tryptophan, ten of its metabolites, the inflammation marker neopterin and the hypothalamic-pituitary-adrenal (HPA) axis marker cortisol.', 'subject score': 888, 'object score': 851}, 'PMID:29899546': {'publication date': '2018 Jun 13', 'sentence': 'The present study combined neuroimaging, salivary cortisol, and blood markers of inflammation and metabolism collected prior to scanning.', 'subject score': 888, 'object score': 1000}, 'PMID:30200906': {'publication date': '2018 Sep 10', 'sentence': 'Secondary outcomes include sleep quality, depression, anxiety, quality of life, cognitive complaints, cancer worries, fatigue catastrophizing, self-efficacy to handle fatigue, biological circadian rhythms of melatonin, cortisol and activity, and biomarkers of inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:30935010': {'publication date': '2019 Mar 30', 'sentence': 'Serum glucose (n = 35), serum insulin (n = 35), serum creatine kinase (n = 15) and myoglobin (n = 15), hematologic parameters, cortisol (n = 35), inflammation markers (n = 27) and leg strength (n = 15) as a functional marker were measured.', 'subject score': 1000, 'object score': 694}, 'PMID:31374824': {'publication date': '2019 Aug 01', 'sentence': 'In this work, we investigate the effects of thoracic (T6-7) and cervical (C6-7) moderate-severe contusion SCIs on the spleen by characterizing splenic norepinephrine (NE) and cortisol (CORT), caspase-3, and multiple inflammation markers at 3- and 7-days post-SCI.', 'subject score': 1000, 'object score': 623}, 'PMID:32098947': {'publication date': '2020 Feb 25', 'sentence': 'Raised levels of cortisol, and markers of inflammation such as Interleukin (IL-6) and C-reactive protein (CRP), have been linked to both early life stress and MDD.', 'subject score': 1000, 'object score': 1000}, 'PMID:32153900': {'publication date': '2018', 'sentence': 'Secondary outcomes include mid-upper-arm circumference, neuro-behavioral development, hair cortisol concentrations, markers of intestinal inflammation and parasite burden.', 'subject score': 851, 'object score': 888}, 'PMID:34669995': {'publication date': '2021 Oct 20', 'sentence': 'CONCLUSIONS: Compared with plasma cortisol and inflammation biomarkers, HRV is more sensitive to detect surgical stress and autonomic nervous dysfunction induced by radical gastrectomy in patients with gastric cancer.', 'subject score': 888, 'object score': 888}, 'PMID:37138028': {'publication date': '2023 May 03', 'sentence': 'The findings indicate a dose-dependency of hydrocortisone for metabolomic and anti-inflammatory effects, that prolonged therapy may lower the supply of many nutrients, and that monitoring concentrations of cortisol and inflammation markers may be a useful clinical approach during corticosteroid therapy.', 'subject score': 1000, 'object score': 872}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:predisposes---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "11782928",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:15843228",
-                "PMID:27832762",
-                "PMID:29899546",
-                "PMID:30200906",
-                "PMID:30935010",
-                "PMID:31374824",
-                "PMID:32098947",
-                "PMID:32153900",
-                "PMID:34669995",
-                "PMID:37138028"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:11717587': {'publication date': '2001', 'sentence': 'Several randomized controlled trials have evaluated the efficacy of a replacement therapy with hydrocortisone in severe sepsis.', 'subject score': 1000, 'object score': 888}, 'PMID:11800521': {'publication date': '2001 Dec', 'sentence': 'Recent studies with stress doses of hydrocortisone in sepsis and septic shock have shown a marked haemodynamic improvement, but whether patients with relative adrenal dysfunction benefit most from this treatment and whether there is definitely an effect on outcome is still undecided.', 'subject score': 1000, 'object score': 1000}, 'PMID:12120695': {'publication date': '2002 May', 'sentence': 'The relationship between cortisol and IL-6 in sepsis is discussed.', 'subject score': 1000, 'object score': 1000}, 'PMID:17021536': {'publication date': '2004 Apr', 'sentence': 'Together with new findings on low-dose hydrocortisone, this stresses the relevance of adjunctive therapy in severe sepsis and septic shock.', 'subject score': 901, 'object score': 888}, 'PMID:17558491': {'publication date': '2007 Oct', 'sentence': 'There were no significant correlations observed between total plasma cortisol or cortisone and sickness severity in the sepsis and trauma cohorts.', 'subject score': 851, 'object score': 1000}, 'PMID:18597063': {'publication date': '2008 Aug', 'sentence': '[Hydrocortisone in sepsis. A physiological concept without effect?].', 'subject score': 1000, 'object score': 1000}, 'PMID:18708964': {'publication date': '2008 Sep', 'sentence': 'Hydrocortisone in severe sepsis: time to accept the null hypothesis?', 'subject score': 1000, 'object score': 888}, 'PMID:21600230': {'publication date': '2011', 'sentence': 'In conclusion, the combined effect of inflammatory cytokines at the adrenal level in acute or chronic inflammatory states could significantly stimulate glucocorticoid production, and thus explain the observed discrepancy between the cortisol and ACTH concentrations sometimes seen in sepsis and chronic inflammatory states.', 'subject score': 1000, 'object score': 1000}, 'PMID:21850531': {'publication date': '2011 Dec', 'sentence': 'The areas under the receiver operating characteristic curve for predicting increases in free from total cortisol were 0.93-0.97 in sepsis and 0.79-0.85 in non-sepsis (P = 0.044 or lower for sepsis vs. non-sepsis).', 'subject score': 888, 'object score': 1000}, 'PMID:21991143': {'publication date': '2009 Mar 31', 'sentence': 'Our results suggest that increased cortisol and decreased immunoglobulin levels could be related to severe sepsis and clinical outcome.', 'subject score': 888, 'object score': 888}, 'PMID:22781364': {'publication date': '2012 Jul 10', 'sentence': 'Baseline cortisol directly related to sepsis and endogenous ACTH, independent of etomidate use.', 'subject score': 888, 'object score': 1000}, 'PMID:24373796': {'publication date': '2014 May', 'sentence': 'We found no significant difference in the estimated affinity of CBG and albumin for cortisol in normal, sepsis and septic shock groups, although free cortisol was higher in sepsis and septic shock groups.', 'subject score': 1000, 'object score': 888}, 'PMID:24910975': {'publication date': '2014', 'sentence': 'Cortisol to dehydroepiandrosterone (DHEA) ratio was put forward as a prognostic marker in sepsis.', 'subject score': 1000, 'object score': 1000}, 'PMID:25243181': {'publication date': '2014', 'sentence': 'CONCLUSION: Prolactin, apart from cortisol, may have a role in the acute stress response in severe sepsis.', 'subject score': 1000, 'object score': 888}, 'PMID:25560635': {'publication date': '2015 Jan 06', 'sentence': 'A low Delta cortisol in time was associated with more-severe disease, culture-positive sepsis, and prolonged activated prothrombin time.', 'subject score': 802, 'object score': 851}, 'PMID:26753096': {'publication date': '2016', 'sentence': 'CONCLUSIONS: SS is associated with increased SaC, but decreased cFC levels when baseline STC is assumed to be sufficient.', 'subject score': 851, 'object score': 888}, 'PMID:28224564': {'publication date': '2017 Dec', 'sentence': 'CONCLUSIONS: Acute-phase sepsis is associated with increased hGR expression and cortisol concentrations, possibly implying no need for exogenous steroids.', 'subject score': 888, 'object score': 901}, 'PMID:28974331': {'publication date': '2018 Feb', 'sentence': 'The primary literature summaries evaluate the following: dexmedetomidine for delirium prevention in post-cardiac surgery, dexmedetomidine for delirium management in mechanically ventilated patients, high-dose epoetin alfa after out-of-hospital cardiac arrest, ideal blood pressure targets in ICH, hydrocortisone in severe sepsis, procalcitonin-guided antibiotic de-escalation, and empiric micafungin therapy.', 'subject score': 1000, 'object score': 888}, 'PMID:31679383': {'publication date': '2019 Jul 01', 'sentence': 'CONCLUSION: Hydrocortisone, when used in sepsis or septic shock, in critically ill adult patients showed a statistically insignificant trend towards decreasing 28 day all-cause mortality.', 'subject score': 1000, 'object score': 1000}, 'PMID:31990246': {'publication date': '2020 Jan 28', 'sentence': 'Background:     Combination of vitamin C, hydrocortisone and thiamine have recently been used in sepsis but data of efficacy are conflicting and no data are available from developing countries.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9039473,
-            "start": 569,
-            "end": 320039,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11717587': {'publication date': '2001', 'sentence': 'Several randomized controlled trials have evaluated the efficacy of a replacement therapy with hydrocortisone in severe sepsis.', 'subject score': 1000, 'object score': 888}, 'PMID:11800521': {'publication date': '2001 Dec', 'sentence': 'Recent studies with stress doses of hydrocortisone in sepsis and septic shock have shown a marked haemodynamic improvement, but whether patients with relative adrenal dysfunction benefit most from this treatment and whether there is definitely an effect on outcome is still undecided.', 'subject score': 1000, 'object score': 1000}, 'PMID:12120695': {'publication date': '2002 May', 'sentence': 'The relationship between cortisol and IL-6 in sepsis is discussed.', 'subject score': 1000, 'object score': 1000}, 'PMID:17021536': {'publication date': '2004 Apr', 'sentence': 'Together with new findings on low-dose hydrocortisone, this stresses the relevance of adjunctive therapy in severe sepsis and septic shock.', 'subject score': 901, 'object score': 888}, 'PMID:17558491': {'publication date': '2007 Oct', 'sentence': 'There were no significant correlations observed between total plasma cortisol or cortisone and sickness severity in the sepsis and trauma cohorts.', 'subject score': 851, 'object score': 1000}, 'PMID:18597063': {'publication date': '2008 Aug', 'sentence': '[Hydrocortisone in sepsis. A physiological concept without effect?].', 'subject score': 1000, 'object score': 1000}, 'PMID:18708964': {'publication date': '2008 Sep', 'sentence': 'Hydrocortisone in severe sepsis: time to accept the null hypothesis?', 'subject score': 1000, 'object score': 888}, 'PMID:21600230': {'publication date': '2011', 'sentence': 'In conclusion, the combined effect of inflammatory cytokines at the adrenal level in acute or chronic inflammatory states could significantly stimulate glucocorticoid production, and thus explain the observed discrepancy between the cortisol and ACTH concentrations sometimes seen in sepsis and chronic inflammatory states.', 'subject score': 1000, 'object score': 1000}, 'PMID:21850531': {'publication date': '2011 Dec', 'sentence': 'The areas under the receiver operating characteristic curve for predicting increases in free from total cortisol were 0.93-0.97 in sepsis and 0.79-0.85 in non-sepsis (P = 0.044 or lower for sepsis vs. non-sepsis).', 'subject score': 888, 'object score': 1000}, 'PMID:21991143': {'publication date': '2009 Mar 31', 'sentence': 'Our results suggest that increased cortisol and decreased immunoglobulin levels could be related to severe sepsis and clinical outcome.', 'subject score': 888, 'object score': 888}, 'PMID:22781364': {'publication date': '2012 Jul 10', 'sentence': 'Baseline cortisol directly related to sepsis and endogenous ACTH, independent of etomidate use.', 'subject score': 888, 'object score': 1000}, 'PMID:24373796': {'publication date': '2014 May', 'sentence': 'We found no significant difference in the estimated affinity of CBG and albumin for cortisol in normal, sepsis and septic shock groups, although free cortisol was higher in sepsis and septic shock groups.', 'subject score': 1000, 'object score': 888}, 'PMID:24910975': {'publication date': '2014', 'sentence': 'Cortisol to dehydroepiandrosterone (DHEA) ratio was put forward as a prognostic marker in sepsis.', 'subject score': 1000, 'object score': 1000}, 'PMID:25243181': {'publication date': '2014', 'sentence': 'CONCLUSION: Prolactin, apart from cortisol, may have a role in the acute stress response in severe sepsis.', 'subject score': 1000, 'object score': 888}, 'PMID:25560635': {'publication date': '2015 Jan 06', 'sentence': 'A low Delta cortisol in time was associated with more-severe disease, culture-positive sepsis, and prolonged activated prothrombin time.', 'subject score': 802, 'object score': 851}, 'PMID:26753096': {'publication date': '2016', 'sentence': 'CONCLUSIONS: SS is associated with increased SaC, but decreased cFC levels when baseline STC is assumed to be sufficient.', 'subject score': 851, 'object score': 888}, 'PMID:28224564': {'publication date': '2017 Dec', 'sentence': 'CONCLUSIONS: Acute-phase sepsis is associated with increased hGR expression and cortisol concentrations, possibly implying no need for exogenous steroids.', 'subject score': 888, 'object score': 901}, 'PMID:28974331': {'publication date': '2018 Feb', 'sentence': 'The primary literature summaries evaluate the following: dexmedetomidine for delirium prevention in post-cardiac surgery, dexmedetomidine for delirium management in mechanically ventilated patients, high-dose epoetin alfa after out-of-hospital cardiac arrest, ideal blood pressure targets in ICH, hydrocortisone in severe sepsis, procalcitonin-guided antibiotic de-escalation, and empiric micafungin therapy.', 'subject score': 1000, 'object score': 888}, 'PMID:31679383': {'publication date': '2019 Jul 01', 'sentence': 'CONCLUSION: Hydrocortisone, when used in sepsis or septic shock, in critically ill adult patients showed a statistically insignificant trend towards decreasing 28 day all-cause mortality.', 'subject score': 1000, 'object score': 1000}, 'PMID:31990246': {'publication date': '2020 Jan 28', 'sentence': 'Background:     Combination of vitamin C, hydrocortisone and thiamine have recently been used in sepsis but data of efficacy are conflicting and no data are available from developing countries.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0036690---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9238280",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:11717587",
-                "PMID:11800521",
-                "PMID:12120695",
-                "PMID:17021536",
-                "PMID:17558491",
-                "PMID:18597063",
-                "PMID:18708964",
-                "PMID:21600230",
-                "PMID:21850531",
-                "PMID:21991143",
-                "PMID:22781364",
-                "PMID:24373796",
-                "PMID:24910975",
-                "PMID:25243181",
-                "PMID:25560635",
-                "PMID:26753096",
-                "PMID:28224564",
-                "PMID:28974331",
-                "PMID:31679383",
-                "PMID:31990246"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:9881838': {'publication date': '1998 Jul', 'sentence': 'The suppression of the anti-inflammatory effects of cortisol as a result of states of excessive stress leads to hypercatabolic diseases such as AIDS, sepsis and toxic shock syndrome and protein calorie malnutrition (NAIDS).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 27272383,
-            "start": 569,
-            "end": 320039,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9881838': {'publication date': '1998 Jul', 'sentence': 'The suppression of the anti-inflammatory effects of cortisol as a result of states of excessive stress leads to hypercatabolic diseases such as AIDS, sepsis and toxic shock syndrome and protein calorie malnutrition (NAIDS).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0036690---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "27747115",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:9881838"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:35813323': {'publication date': '2022 Jun', 'sentence': 'Aldosterone levels, like cortisol, have been shown to be increased in sepsis and hemorrhagic shock.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24257842,
-            "start": 569,
-            "end": 320039,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35813323': {'publication date': '2022 Jun', 'sentence': 'Aldosterone levels, like cortisol, have been shown to be increased in sepsis and hemorrhagic shock.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0036690---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "24701128",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:35813323"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10849939': {'publication date': '2000 Apr 21', 'sentence': '[Cortisol in critically ill patients with sepsis: physiologic functions and therapeutic implications].', 'subject score': 1000, 'object score': 1000}, 'PMID:11246311': {'publication date': '2001 Feb', 'sentence': 'However, the change in plasma cortisol, expressed as mean +/- sem and calculated by subtracting the basal cortisol from the peak cortisol after CRH stimulation, was not significantly different in survivors with severe sepsis (243.5 +/- 36.1, range 111.0-524.0 nmol/L, n = 15) compared with nonsurvivors (161.0 +/- 38.9, range 42.0-245.0 nmol/L, n = 5; p >.05).', 'subject score': 861, 'object score': 888}, 'PMID:11333472': {'publication date': '2001 May', 'sentence': 'CONCLUSIONS: Plasma cortisol and ACTH levels were increased in children with sepsis and septic shock.', 'subject score': 888, 'object score': 1000}, 'PMID:11471384': {'publication date': '2000', 'sentence': 'Several high quality randomised controlled trials have evaluated the efficacy and safety of a prolonged treatment with low dose hydrocortisone in severe sepsis.', 'subject score': 901, 'object score': 888}, 'PMID:11885413': {'publication date': '2002 Feb 15', 'sentence': 'Recent small studies have shown benefits with low-dose hydrocortisone in patients with refractory sepsis.', 'subject score': 901, 'object score': 888}, 'PMID:12120695': {'publication date': '2002 May', 'sentence': 'There was a positive correlation between cortisol and IL-6 only in control patients with sepsis (r=0.89, p=0.019), but not within the MS patents with sepsis or MS and control groups without sepsis.', 'subject score': 1000, 'object score': 1000}, 'PMID:12558137': {'publication date': '2003 Jan', 'sentence': 'The prognostic value of basal and corticotropin-stimulated cortisol concentration in patients with sepsis remains a controversial issue.', 'subject score': 597, 'object score': 1000}, 'PMID:14767873': {'publication date': '2004 Feb', 'sentence': 'The mean basal circulating cortisol concentration and peak cortisol responses to low-dose and standard-dose ACTH tests were higher in stressed infants with sepsis and RD compared to normal.', 'subject score': 569, 'object score': 1000}, 'PMID:15503552': {'publication date': '2002', 'sentence': '[Cortisol in critically ill patients with sepsis--physiological functions and therapeutic implications].', 'subject score': 1000, 'object score': 1000}, 'PMID:15752405': {'publication date': '2005 Mar', 'sentence': 'Vasodilatory shock in severe acute pancreatitis without sepsis: is there any place for hydrocortisone treatment?', 'subject score': 888, 'object score': 1000}, 'PMID:15947898': {'publication date': '2005 Jul', 'sentence': 'Clinical and experimental evidence suggests, however, that even glucocorticoid-treated patients undergoing surgery do not require maximum stress doses of hydrocortisone, which should be reserved for the treatment of sepsis.', 'subject score': 1000, 'object score': 1000}, 'PMID:16850006': {'publication date': '2006 Sep', 'sentence': 'CONCLUSIONS: Low-dose hydrocortisone seems to reduce MACR and serum C-reactive protein but not procalcitonin in patients with severe sepsis.', 'subject score': 901, 'object score': 888}, 'PMID:18499615': {'publication date': '2008 Jun', 'sentence': 'There was no difference in the total cortisol concentrations in patients with sepsis and septic shock (728 +/- 386 nmol/L vs 793 +/- 439 nmol/L, P = 0.44).', 'subject score': 851, 'object score': 1000}, 'PMID:20358501': {'publication date': '2010 Apr', 'sentence': 'In the last years, two topics received a lot of attention since a single intervention led to a mortality benefit: the intensive blood glucose control in surgical intensive care patients and the low dose hydrocortisone therapy in sepsis.', 'subject score': 861, 'object score': 1000}, 'PMID:20455885': {'publication date': '2010 Sep', 'sentence': 'Demonstration of a relation between NOx, cortisol and vasopressor requirement may provide an impetus towards the study of hydrocortisone-mediated NOx suppression as a tool in sepsis management.', 'subject score': 1000, 'object score': 888}, 'PMID:21308518': {'publication date': '2010 Sep', 'sentence': 'Activated protein C and hydrocortisone are the only two available adjunct therapies for sepsis.', 'subject score': 1000, 'object score': 1000}, 'PMID:24621333': {'publication date': '2014 02 28', 'sentence': 'The aim of this study was to investigate: [1] serial changes over time in the plasma levels of AnxA1 and cortisol in sepsis patients; and [2] prognostic value of AnxA1 level in the survival of sepsis patients.', 'subject score': 1000, 'object score': 888}, 'PMID:25223852': {'publication date': '2014 Oct', 'sentence': 'Furthermore, measurements of copeptin level and serum baseline cortisol concentration are promising independent prognostic markers for mortality in patients with severe sepsis or septic shock.', 'subject score': 861, 'object score': 888}, 'PMID:26753096': {'publication date': '2016', 'sentence': 'BACKGROUND: The purposes of the study were to compare serum total cortisol (STC), salivary cortisol (SaC) and calculated free cortisol (cFC) levels at baseline and after the adrenocorticotrophic hormone (ACTH) stimulation test in patients with severe sepsis (SS) and determine the suitability of use of SaC and cFC levels instead of STC for the diagnosis of adrenal insufficiency (AI) in patients with SS.', 'subject score': 888, 'object score': 888}, 'PMID:27695824': {'publication date': '2016 Nov 01', 'sentence': 'The efficacy of hydrocortisone in patients with severe sepsis without shock remains controversial.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8074608,
-            "start": 569,
-            "end": 320039,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10849939': {'publication date': '2000 Apr 21', 'sentence': '[Cortisol in critically ill patients with sepsis: physiologic functions and therapeutic implications].', 'subject score': 1000, 'object score': 1000}, 'PMID:11246311': {'publication date': '2001 Feb', 'sentence': 'However, the change in plasma cortisol, expressed as mean +/- sem and calculated by subtracting the basal cortisol from the peak cortisol after CRH stimulation, was not significantly different in survivors with severe sepsis (243.5 +/- 36.1, range 111.0-524.0 nmol/L, n = 15) compared with nonsurvivors (161.0 +/- 38.9, range 42.0-245.0 nmol/L, n = 5; p >.05).', 'subject score': 861, 'object score': 888}, 'PMID:11333472': {'publication date': '2001 May', 'sentence': 'CONCLUSIONS: Plasma cortisol and ACTH levels were increased in children with sepsis and septic shock.', 'subject score': 888, 'object score': 1000}, 'PMID:11471384': {'publication date': '2000', 'sentence': 'Several high quality randomised controlled trials have evaluated the efficacy and safety of a prolonged treatment with low dose hydrocortisone in severe sepsis.', 'subject score': 901, 'object score': 888}, 'PMID:11885413': {'publication date': '2002 Feb 15', 'sentence': 'Recent small studies have shown benefits with low-dose hydrocortisone in patients with refractory sepsis.', 'subject score': 901, 'object score': 888}, 'PMID:12120695': {'publication date': '2002 May', 'sentence': 'There was a positive correlation between cortisol and IL-6 only in control patients with sepsis (r=0.89, p=0.019), but not within the MS patents with sepsis or MS and control groups without sepsis.', 'subject score': 1000, 'object score': 1000}, 'PMID:12558137': {'publication date': '2003 Jan', 'sentence': 'The prognostic value of basal and corticotropin-stimulated cortisol concentration in patients with sepsis remains a controversial issue.', 'subject score': 597, 'object score': 1000}, 'PMID:14767873': {'publication date': '2004 Feb', 'sentence': 'The mean basal circulating cortisol concentration and peak cortisol responses to low-dose and standard-dose ACTH tests were higher in stressed infants with sepsis and RD compared to normal.', 'subject score': 569, 'object score': 1000}, 'PMID:15503552': {'publication date': '2002', 'sentence': '[Cortisol in critically ill patients with sepsis--physiological functions and therapeutic implications].', 'subject score': 1000, 'object score': 1000}, 'PMID:15752405': {'publication date': '2005 Mar', 'sentence': 'Vasodilatory shock in severe acute pancreatitis without sepsis: is there any place for hydrocortisone treatment?', 'subject score': 888, 'object score': 1000}, 'PMID:15947898': {'publication date': '2005 Jul', 'sentence': 'Clinical and experimental evidence suggests, however, that even glucocorticoid-treated patients undergoing surgery do not require maximum stress doses of hydrocortisone, which should be reserved for the treatment of sepsis.', 'subject score': 1000, 'object score': 1000}, 'PMID:16850006': {'publication date': '2006 Sep', 'sentence': 'CONCLUSIONS: Low-dose hydrocortisone seems to reduce MACR and serum C-reactive protein but not procalcitonin in patients with severe sepsis.', 'subject score': 901, 'object score': 888}, 'PMID:18499615': {'publication date': '2008 Jun', 'sentence': 'There was no difference in the total cortisol concentrations in patients with sepsis and septic shock (728 +/- 386 nmol/L vs 793 +/- 439 nmol/L, P = 0.44).', 'subject score': 851, 'object score': 1000}, 'PMID:20358501': {'publication date': '2010 Apr', 'sentence': 'In the last years, two topics received a lot of attention since a single intervention led to a mortality benefit: the intensive blood glucose control in surgical intensive care patients and the low dose hydrocortisone therapy in sepsis.', 'subject score': 861, 'object score': 1000}, 'PMID:20455885': {'publication date': '2010 Sep', 'sentence': 'Demonstration of a relation between NOx, cortisol and vasopressor requirement may provide an impetus towards the study of hydrocortisone-mediated NOx suppression as a tool in sepsis management.', 'subject score': 1000, 'object score': 888}, 'PMID:21308518': {'publication date': '2010 Sep', 'sentence': 'Activated protein C and hydrocortisone are the only two available adjunct therapies for sepsis.', 'subject score': 1000, 'object score': 1000}, 'PMID:24621333': {'publication date': '2014 02 28', 'sentence': 'The aim of this study was to investigate: [1] serial changes over time in the plasma levels of AnxA1 and cortisol in sepsis patients; and [2] prognostic value of AnxA1 level in the survival of sepsis patients.', 'subject score': 1000, 'object score': 888}, 'PMID:25223852': {'publication date': '2014 Oct', 'sentence': 'Furthermore, measurements of copeptin level and serum baseline cortisol concentration are promising independent prognostic markers for mortality in patients with severe sepsis or septic shock.', 'subject score': 861, 'object score': 888}, 'PMID:26753096': {'publication date': '2016', 'sentence': 'BACKGROUND: The purposes of the study were to compare serum total cortisol (STC), salivary cortisol (SaC) and calculated free cortisol (cFC) levels at baseline and after the adrenocorticotrophic hormone (ACTH) stimulation test in patients with severe sepsis (SS) and determine the suitability of use of SaC and cFC levels instead of STC for the diagnosis of adrenal insufficiency (AI) in patients with SS.', 'subject score': 888, 'object score': 888}, 'PMID:27695824': {'publication date': '2016 Nov 01', 'sentence': 'The efficacy of hydrocortisone in patients with severe sepsis without shock remains controversial.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0036690---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8248241",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:10849939",
-                "PMID:11246311",
-                "PMID:11333472",
-                "PMID:11471384",
-                "PMID:11885413",
-                "PMID:12120695",
-                "PMID:12558137",
-                "PMID:14767873",
-                "PMID:15503552",
-                "PMID:15752405",
-                "PMID:15947898",
-                "PMID:16850006",
-                "PMID:18499615",
-                "PMID:20358501",
-                "PMID:20455885",
-                "PMID:21308518",
-                "PMID:24621333",
-                "PMID:25223852",
-                "PMID:26753096",
-                "PMID:27695824"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:produces",
-    "r2.publications_info": "{'PMID:16288183': {'publication date': '2005 Dec', 'sentence': 'Glucocorticoid insufficiency is common during sepsis and may result from insufficient production of cortisol or peripheral tissues resistance.', 'subject score': 1000, 'object score': 1000}, 'PMID:18499615': {'publication date': '2008 Jun', 'sentence': 'BACKGROUND: Severe sepsis activates the hypothalamopituitary axis, increasing cortisol production.', 'subject score': 888, 'object score': 888}, 'PMID:21586102': {'publication date': '2011', 'sentence': 'Severe sepsis is, however, associated with complex alterations of the HPA axis, which may result in decreased production of cortisol as well as glucocorticoid tissue resistance.', 'subject score': 888, 'object score': 1000}, 'PMID:21757092': {'publication date': '2011 Jul', 'sentence': 'CIRCI is characterized by an inadequate production of cortisol in relation to an increased demand during periods of severe stress, particularly in critical illnesses such as sepsis or septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:34516312': {'publication date': '2021 Sep 13', 'sentence': 'This small study suggests that an inability to increase endogenous cortisol production in patients with sepsis who are then provided steroid treatment could improve survival.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11888702,
-            "start": 320039,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:16288183': {'publication date': '2005 Dec', 'sentence': 'Glucocorticoid insufficiency is common during sepsis and may result from insufficient production of cortisol or peripheral tissues resistance.', 'subject score': 1000, 'object score': 1000}, 'PMID:18499615': {'publication date': '2008 Jun', 'sentence': 'BACKGROUND: Severe sepsis activates the hypothalamopituitary axis, increasing cortisol production.', 'subject score': 888, 'object score': 888}, 'PMID:21586102': {'publication date': '2011', 'sentence': 'Severe sepsis is, however, associated with complex alterations of the HPA axis, which may result in decreased production of cortisol as well as glucocorticoid tissue resistance.', 'subject score': 888, 'object score': 1000}, 'PMID:21757092': {'publication date': '2011 Jul', 'sentence': 'CIRCI is characterized by an inadequate production of cortisol in relation to an increased demand during periods of severe stress, particularly in critical illnesses such as sepsis or septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:34516312': {'publication date': '2021 Sep 13', 'sentence': 'This small study suggests that an inability to increase endogenous cortisol production in patients with sepsis who are then provided steroid treatment could improve survival.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0036690---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "HP:0100806",
-              "id": "12147996",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:16288183",
-                "PMID:18499615",
-                "PMID:21586102",
-                "PMID:21757092",
-                "PMID:34516312"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:25365720': {'publication date': '2015 Mar', 'sentence': 'OBJECTIVE: Cortisol clearance is reduced in sepsis and may contribute to the development of impaired adrenocortical function that is thought to contribute to the pathophysiology of critical illness-related corticosteroid insufficiency.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17598011,
-            "start": 569,
-            "end": 320039,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25365720': {'publication date': '2015 Mar', 'sentence': 'OBJECTIVE: Cortisol clearance is reduced in sepsis and may contribute to the development of impaired adrenocortical function that is thought to contribute to the pathophysiology of critical illness-related corticosteroid insufficiency.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0036690---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "17956690",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:25365720"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:exacerbates",
-    "r2.publications_info": "{'PMID:1985540': {'publication date': '1991 Jan', 'sentence': 'Plasma cortisol and glucagon concentrations were not increased markedly except in a case complicated other systemic bacterial infection.', 'subject score': 888, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14338928,
-            "start": 569,
-            "end": 320039,
-            "type": "biolink:exacerbates",
-            "properties": {
-              "predicate": "biolink:exacerbates",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1985540': {'publication date': '1991 Jan', 'sentence': 'Plasma cortisol and glucagon concentrations were not increased markedly except in a case complicated other systemic bacterial infection.', 'subject score': 888, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:complicates---None---None---None---UMLS:C0243026---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14643692",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:1985540"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:28685301': {'publication date': '2017 Sep', 'sentence': 'After multivariate analysis, duration of HC stress dose administration was associated with increased risk of mortality (OR 1.11, 95% CI 1.02-1.2, p = 0.021), and total duration of HC treatment was associated with increased risk of sepsis (OR 1.04, 95% CI 1.005-1.075, p = 0.026).', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19368995,
-            "start": 569,
-            "end": 320039,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28685301': {'publication date': '2017 Sep', 'sentence': 'After multivariate analysis, duration of HC stress dose administration was associated with increased risk of mortality (OR 1.11, 95% CI 1.02-1.2, p = 0.021), and total duration of HC treatment was associated with increased risk of sepsis (OR 1.04, 95% CI 1.005-1.075, p = 0.026).', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:predisposes---None---None---None---UMLS:C0036690---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "19755964",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:28685301"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:17028025': {'publication date': '2007 Dec', 'sentence': 'The current findings underline the relevance of cortisol and DHEA assessments and the need for further scrutiny of their interplay to foster our understanding of the biological basis of stress regulation in BPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:17169436': {'publication date': '2007 Jan 15', 'sentence': 'A preliminary study of cortisol and norepinephrine reactivity to psychosocial stress in borderline personality disorder with high and low dissociation.', 'subject score': 1000, 'object score': 1000}, 'PMID:25462901': {'publication date': '2015 Jan', 'sentence': 'Effects of cortisol on cognition in major depressive disorder, posttraumatic stress disorder and borderline personality disorder - 2014 Curt Richter Award Winner.', 'subject score': 1000, 'object score': 642}, 'PMID:29702176': {'publication date': '2018 Apr 24', 'sentence': 'The single cortisol sample showed a significant and opposite correlations in the sexual abuse diagnosis-related groups, being a negative correlation in BD and positive in BPD.', 'subject score': 623, 'object score': 1000}, 'PMID:35709662': {'publication date': '2022 Jun 03', 'sentence': 'CONCLUSIONS: These findings suggest that alterations in oxytocin, cortisol, and testosterone contribute to disruptions in mother-child interaction in BPD.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318927,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001156",
-          "name": "borderline personality disorder",
-          "description": "A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions. [HPO:probinson]; A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions.; A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions.; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "SNOMEDCT:20010003",
-            "ICD10:F60.3",
-            "MEDDRA:10006034",
-            "PSY:06622",
-            "MESH:D001883",
-            "HP:0012076",
-            "DOID:10930",
-            "MONDO:0001156",
-            "NCIT:C92633",
-            "UMLS:C0006012",
-            "ICD9:301.83",
-            "MEDDRA:10006033"
-          ],
-          "id": "MONDO:0001156",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Borderline Personality Disorder",
-            "borderline personality disorder",
-            "Borderline personality disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/borderline_personality_disorde",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318927,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001156",
-              "name": "borderline personality disorder",
-              "description": "A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions. [HPO:probinson]; A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions.; A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions.; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "SNOMEDCT:20010003",
-                "ICD10:F60.3",
-                "MEDDRA:10006034",
-                "PSY:06622",
-                "MESH:D001883",
-                "HP:0012076",
-                "DOID:10930",
-                "MONDO:0001156",
-                "NCIT:C92633",
-                "UMLS:C0006012",
-                "ICD9:301.83",
-                "MEDDRA:10006033"
-              ],
-              "id": "MONDO:0001156",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Borderline Personality Disorder",
-                "borderline personality disorder",
-                "Borderline personality disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/borderline_personality_disorde",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12486073,
-            "start": 569,
-            "end": 318927,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17028025': {'publication date': '2007 Dec', 'sentence': 'The current findings underline the relevance of cortisol and DHEA assessments and the need for further scrutiny of their interplay to foster our understanding of the biological basis of stress regulation in BPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:17169436': {'publication date': '2007 Jan 15', 'sentence': 'A preliminary study of cortisol and norepinephrine reactivity to psychosocial stress in borderline personality disorder with high and low dissociation.', 'subject score': 1000, 'object score': 1000}, 'PMID:25462901': {'publication date': '2015 Jan', 'sentence': 'Effects of cortisol on cognition in major depressive disorder, posttraumatic stress disorder and borderline personality disorder - 2014 Curt Richter Award Winner.', 'subject score': 1000, 'object score': 642}, 'PMID:29702176': {'publication date': '2018 Apr 24', 'sentence': 'The single cortisol sample showed a significant and opposite correlations in the sexual abuse diagnosis-related groups, being a negative correlation in BD and positive in BPD.', 'subject score': 623, 'object score': 1000}, 'PMID:35709662': {'publication date': '2022 Jun 03', 'sentence': 'CONCLUSIONS: These findings suggest that alterations in oxytocin, cortisol, and testosterone contribute to disruptions in mother-child interaction in BPD.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0006012---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "12756660",
-              "object": "MONDO:0001156",
-              "publications": [
-                "PMID:17028025",
-                "PMID:17169436",
-                "PMID:25462901",
-                "PMID:29702176",
-                "PMID:35709662"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10715361': {'publication date': '2000 Mar 15', 'sentence': 'RESULTS: The cortisol and prolactin responses to the m-CPP challenge in BPD patients were significantly lower compared to those in controls.', 'subject score': 1000, 'object score': 916}, 'PMID:12695738': {'publication date': '2003 Apr', 'sentence': 'Twenty-four-hour urine cortisol in combat veterans with PTSD and comorbid borderline personality disorder.', 'subject score': 771, 'object score': 880}, 'PMID:12772042': {'publication date': '2003', 'sentence': 'Baseline cortisol concentrations, although lower in BPD patients, were not significantly different among groups.', 'subject score': 851, 'object score': 916}, 'PMID:15458851': {'publication date': '2004', 'sentence': 'The ambulatory assessment of saliva cortisol is a suitable approach to study basic parameters of the HPA-axis in patients with BPD.', 'subject score': 888, 'object score': 1000}, 'PMID:16199015': {'publication date': '2006 Apr 01', 'sentence': 'Therefore, our study aimed at examining serum profiles of cortisol, cytokines, and the cortisol/dehydroepiandrosterone (cortisol/DHEA) ratio in MDD/BPD patients and a healthy comparison group.', 'subject score': 1000, 'object score': 854}, 'PMID:17028025': {'publication date': '2007 Dec', 'sentence': 'Hence, the present pilot study investigates the basic levels of cortisol and DHEA and the ratio (CDR) between the two hormones in BPD patients.', 'subject score': 1000, 'object score': 916}, 'PMID:24134123': {'publication date': '2014 Jul', 'sentence': 'METHODS: Serum CRP levels and salivary cortisol before and after the dexamethasone suppression test (DST) were assessed in 50 inpatients with main diagnoses PTSD, major depressive disorder or borderline personality disorder.', 'subject score': 888, 'object score': 1000}, 'PMID:24401326': {'publication date': '2014', 'sentence': 'METHODS: The aim of this work consisted in assessing, by ELISA, fasting plasma levels of DBI and dehydroepiandrosterone sulphate (DHEA-S), including cortisol and the cortisol-to-DHEA-S molar ratio (CDR), in 17 BPD adolescents versus 13 healthy controls, testing the possibility that clinical scales related to depressive or anxious traits (CDI, STAI-Y) or to disease severity (BPDCL) might be associated with a selective dysregulation of these parameters.', 'subject score': 1000, 'object score': 854}, 'PMID:29702176': {'publication date': '2018 Apr 24', 'sentence': 'Cortisol measured in patients with BPD was significantly lower compared to HC in the presence of emotional neglect and physical neglect.', 'subject score': 1000, 'object score': 1000}, 'PMID:35709662': {'publication date': '2022 Jun 03', 'sentence': 'RESULTS: Oxytocin decreased and cortisol remained unchanged in mothers with BPD while healthy mothers showed stable oxytocin and decreased cortisol after interaction.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318927,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001156",
-          "name": "borderline personality disorder",
-          "description": "A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions. [HPO:probinson]; A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions.; A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions.; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "SNOMEDCT:20010003",
-            "ICD10:F60.3",
-            "MEDDRA:10006034",
-            "PSY:06622",
-            "MESH:D001883",
-            "HP:0012076",
-            "DOID:10930",
-            "MONDO:0001156",
-            "NCIT:C92633",
-            "UMLS:C0006012",
-            "ICD9:301.83",
-            "MEDDRA:10006033"
-          ],
-          "id": "MONDO:0001156",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Borderline Personality Disorder",
-            "borderline personality disorder",
-            "Borderline personality disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/borderline_personality_disorde",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318927,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001156",
-              "name": "borderline personality disorder",
-              "description": "A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions. [HPO:probinson]; A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions.; A personality disorder characterized by impulsive behavior and unpredictable and capricious mood. Affected individuals show a liability to outbursts of emotion and an incapacity to control the behavioural explosions.; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "SNOMEDCT:20010003",
-                "ICD10:F60.3",
-                "MEDDRA:10006034",
-                "PSY:06622",
-                "MESH:D001883",
-                "HP:0012076",
-                "DOID:10930",
-                "MONDO:0001156",
-                "NCIT:C92633",
-                "UMLS:C0006012",
-                "ICD9:301.83",
-                "MEDDRA:10006033"
-              ],
-              "id": "MONDO:0001156",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Borderline Personality Disorder",
-                "borderline personality disorder",
-                "Borderline personality disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/borderline_personality_disorde",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7885542,
-            "start": 569,
-            "end": 318927,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10715361': {'publication date': '2000 Mar 15', 'sentence': 'RESULTS: The cortisol and prolactin responses to the m-CPP challenge in BPD patients were significantly lower compared to those in controls.', 'subject score': 1000, 'object score': 916}, 'PMID:12695738': {'publication date': '2003 Apr', 'sentence': 'Twenty-four-hour urine cortisol in combat veterans with PTSD and comorbid borderline personality disorder.', 'subject score': 771, 'object score': 880}, 'PMID:12772042': {'publication date': '2003', 'sentence': 'Baseline cortisol concentrations, although lower in BPD patients, were not significantly different among groups.', 'subject score': 851, 'object score': 916}, 'PMID:15458851': {'publication date': '2004', 'sentence': 'The ambulatory assessment of saliva cortisol is a suitable approach to study basic parameters of the HPA-axis in patients with BPD.', 'subject score': 888, 'object score': 1000}, 'PMID:16199015': {'publication date': '2006 Apr 01', 'sentence': 'Therefore, our study aimed at examining serum profiles of cortisol, cytokines, and the cortisol/dehydroepiandrosterone (cortisol/DHEA) ratio in MDD/BPD patients and a healthy comparison group.', 'subject score': 1000, 'object score': 854}, 'PMID:17028025': {'publication date': '2007 Dec', 'sentence': 'Hence, the present pilot study investigates the basic levels of cortisol and DHEA and the ratio (CDR) between the two hormones in BPD patients.', 'subject score': 1000, 'object score': 916}, 'PMID:24134123': {'publication date': '2014 Jul', 'sentence': 'METHODS: Serum CRP levels and salivary cortisol before and after the dexamethasone suppression test (DST) were assessed in 50 inpatients with main diagnoses PTSD, major depressive disorder or borderline personality disorder.', 'subject score': 888, 'object score': 1000}, 'PMID:24401326': {'publication date': '2014', 'sentence': 'METHODS: The aim of this work consisted in assessing, by ELISA, fasting plasma levels of DBI and dehydroepiandrosterone sulphate (DHEA-S), including cortisol and the cortisol-to-DHEA-S molar ratio (CDR), in 17 BPD adolescents versus 13 healthy controls, testing the possibility that clinical scales related to depressive or anxious traits (CDI, STAI-Y) or to disease severity (BPDCL) might be associated with a selective dysregulation of these parameters.', 'subject score': 1000, 'object score': 854}, 'PMID:29702176': {'publication date': '2018 Apr 24', 'sentence': 'Cortisol measured in patients with BPD was significantly lower compared to HC in the presence of emotional neglect and physical neglect.', 'subject score': 1000, 'object score': 1000}, 'PMID:35709662': {'publication date': '2022 Jun 03', 'sentence': 'RESULTS: Oxytocin decreased and cortisol remained unchanged in mothers with BPD while healthy mothers showed stable oxytocin and decreased cortisol after interaction.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0006012---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8054429",
-              "object": "MONDO:0001156",
-              "publications": [
-                "PMID:10715361",
-                "PMID:12695738",
-                "PMID:12772042",
-                "PMID:15458851",
-                "PMID:16199015",
-                "PMID:17028025",
-                "PMID:24134123",
-                "PMID:24401326",
-                "PMID:29702176",
-                "PMID:35709662"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:12189774': {'publication date': '2002', 'sentence': 'It can therefore be concluded that ointments containing either only E. coli BCS or a combination of BCS and hydrocortisone provide significant relief in perianal eczema as well as in early stages of hemorrhoidal disease.', 'subject score': 1000, 'object score': 888}, 'PMID:13116093': {'publication date': '1954 Jan', 'sentence': 'Hydrocortisone (compound F) acetate ointment in eczema of infants and children.', 'subject score': 1000, 'object score': 1000}, 'PMID:17376223': {'publication date': '2007 Mar 21', 'sentence': 'CONCLUSION: The anti-inflammatory activity demonstrated in the ACD model suggests that the mechanism of action of the MPM is different than that of hydrocortisone and could become a relevant product for people suffering from dermatological manifestations associated with immune dysfunctions such as allergies, eczema, dermatitis, and autoimmune diseases.', 'subject score': 1000, 'object score': 1000}, 'PMID:3890401': {'publication date': '1985 Apr', 'sentence': '[Comparative characteristics of the changes in the concentrations of sugar, insulin, glucagon and cortisol of the blood in atopic dermatitis and eczema patients].', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 313237,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
-          "name": "atopic eczema",
-          "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SYMP:0000289",
-            "EFO:0000274",
-            "DOID:3310",
-            "HP:0000964",
-            "NCIT:C3001",
-            "UMLS:C0013595",
-            "MESH:D004485",
-            "MEDDRA:10014200",
-            "MEDDRA:10014206",
-            "MEDDRA:10012454",
-            "ICD10:L20",
-            "MEDDRA:10014184",
-            "OMIM.PS:603165",
-            "MEDDRA:10014209",
-            "PSY:15950",
-            "MONDO:0004980",
-            "OMIM:PS603165"
-          ],
-          "id": "MONDO:0004980",
-          "category": "biolink:Disease",
-          "all_names": [
-            "atopic dermatitis",
-            "atopic eczema",
-            "eczema",
-            "Eczema"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/atopic_dermatitis",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313237,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
-              "name": "atopic eczema",
-              "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SYMP:0000289",
-                "EFO:0000274",
-                "DOID:3310",
-                "HP:0000964",
-                "NCIT:C3001",
-                "UMLS:C0013595",
-                "MESH:D004485",
-                "MEDDRA:10014200",
-                "MEDDRA:10014206",
-                "MEDDRA:10012454",
-                "ICD10:L20",
-                "MEDDRA:10014184",
-                "OMIM.PS:603165",
-                "MEDDRA:10014209",
-                "PSY:15950",
-                "MONDO:0004980",
-                "OMIM:PS603165"
-              ],
-              "id": "MONDO:0004980",
-              "category": "biolink:Disease",
-              "all_names": [
-                "atopic dermatitis",
-                "atopic eczema",
-                "eczema",
-                "Eczema"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/atopic_dermatitis",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9501810,
-            "start": 569,
-            "end": 313237,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12189774': {'publication date': '2002', 'sentence': 'It can therefore be concluded that ointments containing either only E. coli BCS or a combination of BCS and hydrocortisone provide significant relief in perianal eczema as well as in early stages of hemorrhoidal disease.', 'subject score': 1000, 'object score': 888}, 'PMID:13116093': {'publication date': '1954 Jan', 'sentence': 'Hydrocortisone (compound F) acetate ointment in eczema of infants and children.', 'subject score': 1000, 'object score': 1000}, 'PMID:17376223': {'publication date': '2007 Mar 21', 'sentence': 'CONCLUSION: The anti-inflammatory activity demonstrated in the ACD model suggests that the mechanism of action of the MPM is different than that of hydrocortisone and could become a relevant product for people suffering from dermatological manifestations associated with immune dysfunctions such as allergies, eczema, dermatitis, and autoimmune diseases.', 'subject score': 1000, 'object score': 1000}, 'PMID:3890401': {'publication date': '1985 Apr', 'sentence': '[Comparative characteristics of the changes in the concentrations of sugar, insulin, glucagon and cortisol of the blood in atopic dermatitis and eczema patients].', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0013595---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9718673",
-              "object": "MONDO:0004980",
-              "publications": [
-                "PMID:12189774",
-                "PMID:13116093",
-                "PMID:17376223",
-                "PMID:3890401"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:8607567': {'publication date': '1995 Oct', 'sentence': 'We report the case of a 41-year-old nonatopic women with a previous history of eczematous reaction due to hydrocortisone who suffered worsening of her perennial rhinitis in association with perinasal dermatitis from the use of budesonide in nasal spray form, and stomatitis and pharyngitis due to budesonide in a bronchial inhaler.', 'subject score': 1000, 'object score': 853}}",
-    "p2": {
-      "start": {
-        "identity": 313237,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
-          "name": "atopic eczema",
-          "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SYMP:0000289",
-            "EFO:0000274",
-            "DOID:3310",
-            "HP:0000964",
-            "NCIT:C3001",
-            "UMLS:C0013595",
-            "MESH:D004485",
-            "MEDDRA:10014200",
-            "MEDDRA:10014206",
-            "MEDDRA:10012454",
-            "ICD10:L20",
-            "MEDDRA:10014184",
-            "OMIM.PS:603165",
-            "MEDDRA:10014209",
-            "PSY:15950",
-            "MONDO:0004980",
-            "OMIM:PS603165"
-          ],
-          "id": "MONDO:0004980",
-          "category": "biolink:Disease",
-          "all_names": [
-            "atopic dermatitis",
-            "atopic eczema",
-            "eczema",
-            "Eczema"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/atopic_dermatitis",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313237,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
-              "name": "atopic eczema",
-              "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SYMP:0000289",
-                "EFO:0000274",
-                "DOID:3310",
-                "HP:0000964",
-                "NCIT:C3001",
-                "UMLS:C0013595",
-                "MESH:D004485",
-                "MEDDRA:10014200",
-                "MEDDRA:10014206",
-                "MEDDRA:10012454",
-                "ICD10:L20",
-                "MEDDRA:10014184",
-                "OMIM.PS:603165",
-                "MEDDRA:10014209",
-                "PSY:15950",
-                "MONDO:0004980",
-                "OMIM:PS603165"
-              ],
-              "id": "MONDO:0004980",
-              "category": "biolink:Disease",
-              "all_names": [
-                "atopic dermatitis",
-                "atopic eczema",
-                "eczema",
-                "Eczema"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/atopic_dermatitis",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26606828,
-            "start": 569,
-            "end": 313237,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8607567': {'publication date': '1995 Oct', 'sentence': 'We report the case of a 41-year-old nonatopic women with a previous history of eczematous reaction due to hydrocortisone who suffered worsening of her perennial rhinitis in association with perinasal dermatitis from the use of budesonide in nasal spray form, and stomatitis and pharyngitis due to budesonide in a bronchial inhaler.', 'subject score': 1000, 'object score': 853}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0013595---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "27073884",
-              "object": "MONDO:0004980",
-              "publications": [
-                "PMID:8607567"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:2528573': {'publication date': '1989 Sep', 'sentence': 'Sixteen reacted to tixocortol pivalate and also to other corticosteroids, particularly to hydrocortisone, which could explain exacerbations of eczema in these cases.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 313237,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
-          "name": "atopic eczema",
-          "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SYMP:0000289",
-            "EFO:0000274",
-            "DOID:3310",
-            "HP:0000964",
-            "NCIT:C3001",
-            "UMLS:C0013595",
-            "MESH:D004485",
-            "MEDDRA:10014200",
-            "MEDDRA:10014206",
-            "MEDDRA:10012454",
-            "ICD10:L20",
-            "MEDDRA:10014184",
-            "OMIM.PS:603165",
-            "MEDDRA:10014209",
-            "PSY:15950",
-            "MONDO:0004980",
-            "OMIM:PS603165"
-          ],
-          "id": "MONDO:0004980",
-          "category": "biolink:Disease",
-          "all_names": [
-            "atopic dermatitis",
-            "atopic eczema",
-            "eczema",
-            "Eczema"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/atopic_dermatitis",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313237,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
-              "name": "atopic eczema",
-              "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SYMP:0000289",
-                "EFO:0000274",
-                "DOID:3310",
-                "HP:0000964",
-                "NCIT:C3001",
-                "UMLS:C0013595",
-                "MESH:D004485",
-                "MEDDRA:10014200",
-                "MEDDRA:10014206",
-                "MEDDRA:10012454",
-                "ICD10:L20",
-                "MEDDRA:10014184",
-                "OMIM.PS:603165",
-                "MEDDRA:10014209",
-                "PSY:15950",
-                "MONDO:0004980",
-                "OMIM:PS603165"
-              ],
-              "id": "MONDO:0004980",
-              "category": "biolink:Disease",
-              "all_names": [
-                "atopic dermatitis",
-                "atopic eczema",
-                "eczema",
-                "Eczema"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/atopic_dermatitis",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17552230,
-            "start": 569,
-            "end": 313237,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2528573': {'publication date': '1989 Sep', 'sentence': 'Sixteen reacted to tixocortol pivalate and also to other corticosteroids, particularly to hydrocortisone, which could explain exacerbations of eczema in these cases.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0013595---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "17910566",
-              "object": "MONDO:0004980",
-              "publications": [
-                "PMID:2528573"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12775314': {'publication date': '2003 Jun', 'sentence': 'These data show clobetasone butyrate 0.05% is more effective than 1.0% hydrocortisone in the treatment of eczema and more effective than flurandrenolone 0.0125% (p=0.01%) and a potent topical steroid hydrocortisone butyrate (p<0.05), in the treatment of psoriasis.', 'subject score': 827, 'object score': 1000}, 'PMID:13676318': {'publication date': '1959 Aug', 'sentence': 'Aureomycin, chloramphenicol and hydrocortisone in ointments and pastes as a treatment for eczema.', 'subject score': 1000, 'object score': 1000}, 'PMID:29244413': {'publication date': '1965 Jan-Feb', 'sentence': 'The Management of Pyodermas and Eczematous Dermatoses with Varied Combinations of Neomycin, Bacitracin, Sulphacetamide and Hydrocortisone in an Ointment Base.', 'subject score': 1000, 'object score': 853}, 'PMID:6244198': {'publication date': '1980', 'sentence': 'Study of the effects of hydrocortisone and hydrocortisone 17-butyrate ointments on plasma ACTH levels and Synacthen responses in children with eczema.', 'subject score': 1000, 'object score': 1000}, 'PMID:82309': {'publication date': '1978 Nov 01', 'sentence': 'Administering sexual hormons the physician takes advantage of the sebosuppressive effect of female sexual hormons as he does of the antiallergic activity of the hormon cortisol (and related compounds) in the treatment of eczemas.', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 313237,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
-          "name": "atopic eczema",
-          "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SYMP:0000289",
-            "EFO:0000274",
-            "DOID:3310",
-            "HP:0000964",
-            "NCIT:C3001",
-            "UMLS:C0013595",
-            "MESH:D004485",
-            "MEDDRA:10014200",
-            "MEDDRA:10014206",
-            "MEDDRA:10012454",
-            "ICD10:L20",
-            "MEDDRA:10014184",
-            "OMIM.PS:603165",
-            "MEDDRA:10014209",
-            "PSY:15950",
-            "MONDO:0004980",
-            "OMIM:PS603165"
-          ],
-          "id": "MONDO:0004980",
-          "category": "biolink:Disease",
-          "all_names": [
-            "atopic dermatitis",
-            "atopic eczema",
-            "eczema",
-            "Eczema"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/atopic_dermatitis",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313237,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
-              "name": "atopic eczema",
-              "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SYMP:0000289",
-                "EFO:0000274",
-                "DOID:3310",
-                "HP:0000964",
-                "NCIT:C3001",
-                "UMLS:C0013595",
-                "MESH:D004485",
-                "MEDDRA:10014200",
-                "MEDDRA:10014206",
-                "MEDDRA:10012454",
-                "ICD10:L20",
-                "MEDDRA:10014184",
-                "OMIM.PS:603165",
-                "MEDDRA:10014209",
-                "PSY:15950",
-                "MONDO:0004980",
-                "OMIM:PS603165"
-              ],
-              "id": "MONDO:0004980",
-              "category": "biolink:Disease",
-              "all_names": [
-                "atopic dermatitis",
-                "atopic eczema",
-                "eczema",
-                "Eczema"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/atopic_dermatitis",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10000196,
-            "start": 569,
-            "end": 313237,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12775314': {'publication date': '2003 Jun', 'sentence': 'These data show clobetasone butyrate 0.05% is more effective than 1.0% hydrocortisone in the treatment of eczema and more effective than flurandrenolone 0.0125% (p=0.01%) and a potent topical steroid hydrocortisone butyrate (p<0.05), in the treatment of psoriasis.', 'subject score': 827, 'object score': 1000}, 'PMID:13676318': {'publication date': '1959 Aug', 'sentence': 'Aureomycin, chloramphenicol and hydrocortisone in ointments and pastes as a treatment for eczema.', 'subject score': 1000, 'object score': 1000}, 'PMID:29244413': {'publication date': '1965 Jan-Feb', 'sentence': 'The Management of Pyodermas and Eczematous Dermatoses with Varied Combinations of Neomycin, Bacitracin, Sulphacetamide and Hydrocortisone in an Ointment Base.', 'subject score': 1000, 'object score': 853}, 'PMID:6244198': {'publication date': '1980', 'sentence': 'Study of the effects of hydrocortisone and hydrocortisone 17-butyrate ointments on plasma ACTH levels and Synacthen responses in children with eczema.', 'subject score': 1000, 'object score': 1000}, 'PMID:82309': {'publication date': '1978 Nov 01', 'sentence': 'Administering sexual hormons the physician takes advantage of the sebosuppressive effect of female sexual hormons as he does of the antiallergic activity of the hormon cortisol (and related compounds) in the treatment of eczemas.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0013595---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10221382",
-              "object": "MONDO:0004980",
-              "publications": [
-                "PMID:12775314",
-                "PMID:13676318",
-                "PMID:29244413",
-                "PMID:6244198",
-                "PMID:82309"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:26657985': {'publication date': '2015 Dec', 'sentence': 'The incidence of psychological symptoms as somatization, obsessive-compulsive symptoms, depression, anxiety, phobia, and nonspecific symptoms is statistically increased in pregnant women with elevated morning cortisol, but in women with elevated afternoon cortisol also occurring aggressiveness and paranoia.', 'subject score': 851, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 526488,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0003699",
-          "name": "phobic disorder",
-          "description": "Disorders characterized by persistent, unrealistic, intense fear of an object, activity, or situation.; An anxiety disorder characterized by an intense, irrational fear of an object, activity, or situation. The individual seeks to avoid the object, activity, or situation. In adults, the individual recognizes that the fear is excessive or unreasonable.; Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid. The individual recognizes the fear as excessive or unreasonable.; A phobia is a type of anxiety disorder. It is a strong, irrational fear of something that poses little or no real danger. There are many specific phobias. Acrophobia is a fear of heights. Agoraphobia is a fear of public places, and claustrophobia is a fear of closed-in places. If you become anxious and extremely self-conscious in everyday social situations, you could have a social phobia. Other common phobias involve tunnels, highway driving, water, flying, animals and blood.  People with phobias try to avoid what they are afraid of. If they cannot, they may experience: Panic and fear Rapid heartbeat Shortness of breath Trembling A strong desire to get away  Phobias usually start in children or teens, and continue into adulthood. The causes of specific phobias are not known, but they sometimes run in families.  Treatment helps most people with phobias. Options include medicines, therapy or both. NIH: National Institute of Mental Health; UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "NCIT:C35420",
-            "SNOMEDCT:386808001",
-            "NBO:0000246",
-            "ICD9:300.2",
-            "MONDO:0003699",
-            "ICD10:F40",
-            "MEDDRA:10034919",
-            "MESH:D010698",
-            "UMLS:C0349231",
-            "MEDDRA:10034922",
-            "SNOMEDCT:386810004",
-            "ICD9:300.20",
-            "MEDDRA:10034912",
-            "MEDDRA:10034917",
-            "EFO:1001908",
-            "DOID:591",
-            "MEDDRA:10034915"
-          ],
-          "id": "MONDO:0003699",
-          "category": "biolink:Disease",
-          "all_names": [
-            "phobic disorder",
-            "Phobia",
-            "phobia",
-            "Phobic anxiety disorder",
-            "Phobic Disorders",
-            "Phobia, unspecified",
-            "Phobic disorders"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/anxiety_disorde"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526488,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0003699",
-              "name": "phobic disorder",
-              "description": "Disorders characterized by persistent, unrealistic, intense fear of an object, activity, or situation.; An anxiety disorder characterized by an intense, irrational fear of an object, activity, or situation. The individual seeks to avoid the object, activity, or situation. In adults, the individual recognizes that the fear is excessive or unreasonable.; Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid. The individual recognizes the fear as excessive or unreasonable.; A phobia is a type of anxiety disorder. It is a strong, irrational fear of something that poses little or no real danger. There are many specific phobias. Acrophobia is a fear of heights. Agoraphobia is a fear of public places, and claustrophobia is a fear of closed-in places. If you become anxious and extremely self-conscious in everyday social situations, you could have a social phobia. Other common phobias involve tunnels, highway driving, water, flying, animals and blood.  People with phobias try to avoid what they are afraid of. If they cannot, they may experience: Panic and fear Rapid heartbeat Shortness of breath Trembling A strong desire to get away  Phobias usually start in children or teens, and continue into adulthood. The causes of specific phobias are not known, but they sometimes run in families.  Treatment helps most people with phobias. Options include medicines, therapy or both. NIH: National Institute of Mental Health; UMLS Semantic Type: STY:T048; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "NCIT:C35420",
-                "SNOMEDCT:386808001",
-                "NBO:0000246",
-                "ICD9:300.2",
-                "MONDO:0003699",
-                "ICD10:F40",
-                "MEDDRA:10034919",
-                "MESH:D010698",
-                "UMLS:C0349231",
-                "MEDDRA:10034922",
-                "SNOMEDCT:386810004",
-                "ICD9:300.20",
-                "MEDDRA:10034912",
-                "MEDDRA:10034917",
-                "EFO:1001908",
-                "DOID:591",
-                "MEDDRA:10034915"
-              ],
-              "id": "MONDO:0003699",
-              "category": "biolink:Disease",
-              "all_names": [
-                "phobic disorder",
-                "Phobia",
-                "phobia",
-                "Phobic anxiety disorder",
-                "Phobic Disorders",
-                "Phobia, unspecified",
-                "Phobic disorders"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/anxiety_disorde"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18335343,
-            "start": 569,
-            "end": 526488,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26657985': {'publication date': '2015 Dec', 'sentence': 'The incidence of psychological symptoms as somatization, obsessive-compulsive symptoms, depression, anxiety, phobia, and nonspecific symptoms is statistically increased in pregnant women with elevated morning cortisol, but in women with elevated afternoon cortisol also occurring aggressiveness and paranoia.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0349231---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "18705900",
-              "object": "MONDO:0003699",
-              "publications": [
-                "PMID:26657985"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:32754522': {'publication date': '2020 May', 'sentence': 'Aims and Objective: To evaluate the efficacy of injection placentrex and injection hydrocortisone in oral submucous fibrosis patients in increasing mouth opening, burning sensation, and improve the mucosal lining.', 'subject score': 888, 'object score': 916}}",
-    "p2": {
-      "start": {
-        "identity": 521389,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018166",
-          "name": "oral submucous fibrosis",
-          "description": "Oral submucous fibrosis (OSMF) is a chronic, progressive disease that alters the fibroelasticity of the oral submucosa, prevalent in India and Southeast Asia but rare elsewhere, and characterized by burning and pain in the oral cavity, loss of gustatory sensation, the presence of blanched fibrous bands and stiffening of the oral mucosa and oro-pharynx (leading to trismus and a progressive reduction in mouth opening) and an increased risk of developing oral squamous cell cancer (3-19%). It is usually associated with the chewing of the areca nut (an ingredient in betel quid) but the exact etiology is unknown and there is currently no effective treatment.",
-          "equivalent_curies": [
-            "MONDO:0018166",
-            "ICD10:K13.5",
-            "UMLS:C0029171",
-            "UMLS:C0029172",
-            "MESH:D009914",
-            "MEDDRA:10031023",
-            "EFO:1001818",
-            "MEDDRA:10031025",
-            "MEDDRA:10056775",
-            "ICD9:528.8",
-            "SNOMEDCT:32883009",
-            "NCIT:C34866",
-            "DOID:5773",
-            "ORPHANET:357154"
-          ],
-          "id": "MONDO:0018166",
-          "category": "biolink:Disease",
-          "all_names": [
-            "oral submucous fibrosis",
-            "Oral Submucous Fibrosis",
-            "Oral submucosal fibrosis, including of tongue",
-            "Oral submucous fibrosis",
-            "Oral Cavity Submucous Fibrosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/oral_submucous_fibrosis",
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6627879/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 521389,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018166",
-              "name": "oral submucous fibrosis",
-              "description": "Oral submucous fibrosis (OSMF) is a chronic, progressive disease that alters the fibroelasticity of the oral submucosa, prevalent in India and Southeast Asia but rare elsewhere, and characterized by burning and pain in the oral cavity, loss of gustatory sensation, the presence of blanched fibrous bands and stiffening of the oral mucosa and oro-pharynx (leading to trismus and a progressive reduction in mouth opening) and an increased risk of developing oral squamous cell cancer (3-19%). It is usually associated with the chewing of the areca nut (an ingredient in betel quid) but the exact etiology is unknown and there is currently no effective treatment.",
-              "equivalent_curies": [
-                "MONDO:0018166",
-                "ICD10:K13.5",
-                "UMLS:C0029171",
-                "UMLS:C0029172",
-                "MESH:D009914",
-                "MEDDRA:10031023",
-                "EFO:1001818",
-                "MEDDRA:10031025",
-                "MEDDRA:10056775",
-                "ICD9:528.8",
-                "SNOMEDCT:32883009",
-                "NCIT:C34866",
-                "DOID:5773",
-                "ORPHANET:357154"
-              ],
-              "id": "MONDO:0018166",
-              "category": "biolink:Disease",
-              "all_names": [
-                "oral submucous fibrosis",
-                "Oral Submucous Fibrosis",
-                "Oral submucosal fibrosis, including of tongue",
-                "Oral submucous fibrosis",
-                "Oral Cavity Submucous Fibrosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/oral_submucous_fibrosis",
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6627879/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21922849,
-            "start": 569,
-            "end": 521389,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32754522': {'publication date': '2020 May', 'sentence': 'Aims and Objective: To evaluate the efficacy of injection placentrex and injection hydrocortisone in oral submucous fibrosis patients in increasing mouth opening, burning sensation, and improve the mucosal lining.', 'subject score': 888, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0029172---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "22345112",
-              "object": "MONDO:0018166",
-              "publications": [
-                "PMID:32754522"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:20851499': {'publication date': '2011 Apr', 'sentence': 'ME-609 (Xerese, Xerclear) is a combination of 5% acyclovir and 1% hydrocortisone developed for the topical treatment of HSL.', 'subject score': 861, 'object score': 923}, 'PMID:21954513': {'publication date': '2011 Sep', 'sentence': 'A cream containing 5% aciclovir and 1% hydrocortisone has been authorised in France for symptomatic treatment of herpes labialis in adults and adolescents 12 years of age and older.', 'subject score': 861, 'object score': 1000}, 'PMID:28971780': {'publication date': '2017', 'sentence': 'Topical antiviral agents such as 5% acyclovir cream/ointment (Zovirax) +/- hydrocortisone (Xerese), 1% penciclovir (Denavir) cream, and 50 mg Buccal Adhesive Tablet (ABT-50 mg) can also be used for episodic treatment of herpes labialis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 547959,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043653",
-          "name": "herpes labialis",
-          "description": "Herpes simplex, caused by type 1 virus, primarily spread by oral secretions and usually occurring as a concomitant of fever. It may also develop in the absence of fever or prior illness. It commonly involves the facial region, especially the lips and the nares. (Dorland, 27th ed.); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10019942",
-            "MEDDRA:10049352",
-            "MEDDRA:10049362",
-            "UMLS:C0019345",
-            "MEDDRA:10082141",
-            "MEDDRA:10009865",
-            "SNOMEDCT:1475003",
-            "MEDDRA:10009864",
-            "MEDDRA:10016564",
-            "EFO:1001347",
-            "MEDDRA:10019946",
-            "NCIT:C34695",
-            "MESH:D006560",
-            "MONDO:0043653"
-          ],
-          "id": "MONDO:0043653",
-          "category": "biolink:Disease",
-          "all_names": [
-            "herpes labialis",
-            "Cold Sore",
-            "Herpes Labialis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 547959,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043653",
-              "name": "herpes labialis",
-              "description": "Herpes simplex, caused by type 1 virus, primarily spread by oral secretions and usually occurring as a concomitant of fever. It may also develop in the absence of fever or prior illness. It commonly involves the facial region, especially the lips and the nares. (Dorland, 27th ed.); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10019942",
-                "MEDDRA:10049352",
-                "MEDDRA:10049362",
-                "UMLS:C0019345",
-                "MEDDRA:10082141",
-                "MEDDRA:10009865",
-                "SNOMEDCT:1475003",
-                "MEDDRA:10009864",
-                "MEDDRA:10016564",
-                "EFO:1001347",
-                "MEDDRA:10019946",
-                "NCIT:C34695",
-                "MESH:D006560",
-                "MONDO:0043653"
-              ],
-              "id": "MONDO:0043653",
-              "category": "biolink:Disease",
-              "all_names": [
-                "herpes labialis",
-                "Cold Sore",
-                "Herpes Labialis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14894857,
-            "start": 569,
-            "end": 547959,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20851499': {'publication date': '2011 Apr', 'sentence': 'ME-609 (Xerese, Xerclear) is a combination of 5% acyclovir and 1% hydrocortisone developed for the topical treatment of HSL.', 'subject score': 861, 'object score': 923}, 'PMID:21954513': {'publication date': '2011 Sep', 'sentence': 'A cream containing 5% aciclovir and 1% hydrocortisone has been authorised in France for symptomatic treatment of herpes labialis in adults and adolescents 12 years of age and older.', 'subject score': 861, 'object score': 1000}, 'PMID:28971780': {'publication date': '2017', 'sentence': 'Topical antiviral agents such as 5% acyclovir cream/ointment (Zovirax) +/- hydrocortisone (Xerese), 1% penciclovir (Denavir) cream, and 50 mg Buccal Adhesive Tablet (ABT-50 mg) can also be used for episodic treatment of herpes labialis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0019345---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "15213238",
-              "object": "MONDO:0043653",
-              "publications": [
-                "PMID:20851499",
-                "PMID:21954513",
-                "PMID:28971780"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:11094926': {'publication date': '2000 Feb', 'sentence': 'OBJECTIVE: To compare cortisol levels, diurnal cycles of cortisol, and reactivity of cortisol to psychological stress in fibromyalgia (FM) and rheumatoid arthritis (RA) patients in their natural environment, and to examine the effect on results of accounting for differences among the groups in psychological stress and other lifestyle and psychosocial variables.', 'subject score': 1000, 'object score': 1000}, 'PMID:16884460': {'publication date': '2006 Aug', 'sentence': 'Counterbalance between leptin and cortisol may be associated with fibromyalgia.', 'subject score': 1000, 'object score': 1000}, 'PMID:17188125': {'publication date': '2007 Jan', 'sentence': 'OBJECTIVE: Fibromyalgia syndrome (FMS) has been associated with decreased cortisol secretion.', 'subject score': 851, 'object score': 1000}, 'PMID:19120140': {'publication date': '2008 Dec', 'sentence': 'A lack of cortisol, potentially due to an adrenocortical deficit is postulated in FMS.', 'subject score': 1000, 'object score': 1000}, 'PMID:19457504': {'publication date': '2009 Jul 18', 'sentence': 'RESULTS: Urinary cortisol in FM was 65.0 microg/l (median), which was significantly lower than that of the healthy group (80.0 microg/l), p<0.001.', 'subject score': 888, 'object score': 1000}, 'PMID:20467005': {'publication date': '2010 Jun', 'sentence': 'Fibromyalgia and osteoarthritis groups showed similar secretory patterns, and maltreatment was associated with elevated cortisol in both.', 'subject score': 888, 'object score': 1000}, 'PMID:21887116': {'publication date': '2011', 'sentence': 'To date, published studies have not investigated the effects of yoga on cortisol in FM.', 'subject score': 1000, 'object score': 1000}, 'PMID:24478898': {'publication date': '2014 Jan', 'sentence': 'Evaluation of salivary cortisol and anxiety levels in myofascial pain dysfunction syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:2607509': {'publication date': '1989 Nov', 'sentence': 'These data suggest alteration in the pituitary hypothalamic axis with respect to cortisol secretion in fibromyalgia syndrome, perhaps as a consequence of chronic pain.', 'subject score': 888, 'object score': 1000}, 'PMID:34437747': {'publication date': '2021 Aug 26', 'sentence': 'CONCLUSIONS: This study indicates elevated salivary cortisol in FM and those at high risk, and identifies anxiety, depression and sleep problems as potential contributing factors.', 'subject score': 851, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 547810,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005546",
-          "name": "fibromyalgia",
-          "description": "A common nonarticular rheumatic condition that is characterized by muscle pain, tenderness, and stiffness.; A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.; Inflammation and fibrous degeneration of a muscle.; A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10016631",
-            "MEDDRA:10048439",
-            "MEDDRA:10028363",
-            "PSY:19685",
-            "SNOMEDCT:56557000",
-            "SNOMEDCT:726531007",
-            "NCIT:C50566",
-            "ORPHANET:41842",
-            "SNOMEDCT:203082005",
-            "MEDDRA:10063041",
-            "MONDO:0005546",
-            "SNOMEDCT:203102006",
-            "MEDDRA:10016663",
-            "DOID:631",
-            "EFO:0005687",
-            "MESH:D005356",
-            "ICD10:M79.7",
-            "NCIT:C87497",
-            "MEDDRA:10079197",
-            "UMLS:C0016053"
-          ],
-          "id": "MONDO:0005546",
-          "category": "biolink:Disease",
-          "all_names": [
-            "fibromyalgia",
-            "Fibromyalgia",
-            "Fibromyositis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:33024295",
-            "https://www.ncbi.nlm.nih.gov/labs/pmc/articles/pmc7660651/",
-            "PMID:30486733",
-            "PMID:32120395"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 547810,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005546",
-              "name": "fibromyalgia",
-              "description": "A common nonarticular rheumatic condition that is characterized by muscle pain, tenderness, and stiffness.; A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.; Inflammation and fibrous degeneration of a muscle.; A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10016631",
-                "MEDDRA:10048439",
-                "MEDDRA:10028363",
-                "PSY:19685",
-                "SNOMEDCT:56557000",
-                "SNOMEDCT:726531007",
-                "NCIT:C50566",
-                "ORPHANET:41842",
-                "SNOMEDCT:203082005",
-                "MEDDRA:10063041",
-                "MONDO:0005546",
-                "SNOMEDCT:203102006",
-                "MEDDRA:10016663",
-                "DOID:631",
-                "EFO:0005687",
-                "MESH:D005356",
-                "ICD10:M79.7",
-                "NCIT:C87497",
-                "MEDDRA:10079197",
-                "UMLS:C0016053"
-              ],
-              "id": "MONDO:0005546",
-              "category": "biolink:Disease",
-              "all_names": [
-                "fibromyalgia",
-                "Fibromyalgia",
-                "Fibromyositis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:33024295",
-                "https://www.ncbi.nlm.nih.gov/labs/pmc/articles/pmc7660651/",
-                "PMID:30486733",
-                "PMID:32120395"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8388036,
-            "start": 569,
-            "end": 547810,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11094926': {'publication date': '2000 Feb', 'sentence': 'OBJECTIVE: To compare cortisol levels, diurnal cycles of cortisol, and reactivity of cortisol to psychological stress in fibromyalgia (FM) and rheumatoid arthritis (RA) patients in their natural environment, and to examine the effect on results of accounting for differences among the groups in psychological stress and other lifestyle and psychosocial variables.', 'subject score': 1000, 'object score': 1000}, 'PMID:16884460': {'publication date': '2006 Aug', 'sentence': 'Counterbalance between leptin and cortisol may be associated with fibromyalgia.', 'subject score': 1000, 'object score': 1000}, 'PMID:17188125': {'publication date': '2007 Jan', 'sentence': 'OBJECTIVE: Fibromyalgia syndrome (FMS) has been associated with decreased cortisol secretion.', 'subject score': 851, 'object score': 1000}, 'PMID:19120140': {'publication date': '2008 Dec', 'sentence': 'A lack of cortisol, potentially due to an adrenocortical deficit is postulated in FMS.', 'subject score': 1000, 'object score': 1000}, 'PMID:19457504': {'publication date': '2009 Jul 18', 'sentence': 'RESULTS: Urinary cortisol in FM was 65.0 microg/l (median), which was significantly lower than that of the healthy group (80.0 microg/l), p<0.001.', 'subject score': 888, 'object score': 1000}, 'PMID:20467005': {'publication date': '2010 Jun', 'sentence': 'Fibromyalgia and osteoarthritis groups showed similar secretory patterns, and maltreatment was associated with elevated cortisol in both.', 'subject score': 888, 'object score': 1000}, 'PMID:21887116': {'publication date': '2011', 'sentence': 'To date, published studies have not investigated the effects of yoga on cortisol in FM.', 'subject score': 1000, 'object score': 1000}, 'PMID:24478898': {'publication date': '2014 Jan', 'sentence': 'Evaluation of salivary cortisol and anxiety levels in myofascial pain dysfunction syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:2607509': {'publication date': '1989 Nov', 'sentence': 'These data suggest alteration in the pituitary hypothalamic axis with respect to cortisol secretion in fibromyalgia syndrome, perhaps as a consequence of chronic pain.', 'subject score': 888, 'object score': 1000}, 'PMID:34437747': {'publication date': '2021 Aug 26', 'sentence': 'CONCLUSIONS: This study indicates elevated salivary cortisol in FM and those at high risk, and identifies anxiety, depression and sleep problems as potential contributing factors.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0016053---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8570630",
-              "object": "MONDO:0005546",
-              "publications": [
-                "PMID:11094926",
-                "PMID:16884460",
-                "PMID:17188125",
-                "PMID:19120140",
-                "PMID:19457504",
-                "PMID:20467005",
-                "PMID:21887116",
-                "PMID:24478898",
-                "PMID:2607509",
-                "PMID:34437747"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:36831148': {'publication date': '2023 Feb 18', 'sentence': 'In this perspective paper, we focus on the neuro-endocrine interactions that occur between progesterone, allopregnanolone, and cortisol during pregnancy, and propose that they align with our previously proposed model of FM pathogenesis based on GABAergic \"weakening\" in a thalamocortical neural loop system.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 547810,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005546",
-          "name": "fibromyalgia",
-          "description": "A common nonarticular rheumatic condition that is characterized by muscle pain, tenderness, and stiffness.; A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.; Inflammation and fibrous degeneration of a muscle.; A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10016631",
-            "MEDDRA:10048439",
-            "MEDDRA:10028363",
-            "PSY:19685",
-            "SNOMEDCT:56557000",
-            "SNOMEDCT:726531007",
-            "NCIT:C50566",
-            "ORPHANET:41842",
-            "SNOMEDCT:203082005",
-            "MEDDRA:10063041",
-            "MONDO:0005546",
-            "SNOMEDCT:203102006",
-            "MEDDRA:10016663",
-            "DOID:631",
-            "EFO:0005687",
-            "MESH:D005356",
-            "ICD10:M79.7",
-            "NCIT:C87497",
-            "MEDDRA:10079197",
-            "UMLS:C0016053"
-          ],
-          "id": "MONDO:0005546",
-          "category": "biolink:Disease",
-          "all_names": [
-            "fibromyalgia",
-            "Fibromyalgia",
-            "Fibromyositis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:33024295",
-            "https://www.ncbi.nlm.nih.gov/labs/pmc/articles/pmc7660651/",
-            "PMID:30486733",
-            "PMID:32120395"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 547810,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005546",
-              "name": "fibromyalgia",
-              "description": "A common nonarticular rheumatic condition that is characterized by muscle pain, tenderness, and stiffness.; A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.; Inflammation and fibrous degeneration of a muscle.; A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10016631",
-                "MEDDRA:10048439",
-                "MEDDRA:10028363",
-                "PSY:19685",
-                "SNOMEDCT:56557000",
-                "SNOMEDCT:726531007",
-                "NCIT:C50566",
-                "ORPHANET:41842",
-                "SNOMEDCT:203082005",
-                "MEDDRA:10063041",
-                "MONDO:0005546",
-                "SNOMEDCT:203102006",
-                "MEDDRA:10016663",
-                "DOID:631",
-                "EFO:0005687",
-                "MESH:D005356",
-                "ICD10:M79.7",
-                "NCIT:C87497",
-                "MEDDRA:10079197",
-                "UMLS:C0016053"
-              ],
-              "id": "MONDO:0005546",
-              "category": "biolink:Disease",
-              "all_names": [
-                "fibromyalgia",
-                "Fibromyalgia",
-                "Fibromyositis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:33024295",
-                "https://www.ncbi.nlm.nih.gov/labs/pmc/articles/pmc7660651/",
-                "PMID:30486733",
-                "PMID:32120395"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24934283,
-            "start": 569,
-            "end": 547810,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:36831148': {'publication date': '2023 Feb 18', 'sentence': 'In this perspective paper, we focus on the neuro-endocrine interactions that occur between progesterone, allopregnanolone, and cortisol during pregnancy, and propose that they align with our previously proposed model of FM pathogenesis based on GABAergic \"weakening\" in a thalamocortical neural loop system.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0016053---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "25383174",
-              "object": "MONDO:0005546",
-              "publications": [
-                "PMID:36831148"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:29389485': {'publication date': '2018 Feb', 'sentence': 'They answered the Fibromyalgia Impact Questionnaire (FIQ), Perceived Stress Questionnaire (PSQ) and McGill Pain Questionnaire (MPQ-Br), and collected saliva to evaluate CC before and after the end of each month.', 'subject score': 694, 'object score': 851}, 'PMID:36728497': {'publication date': '2023 Jan 05', 'sentence': 'No main effect of FMS was found on altered levels of blood cortisol, ACTH, CRH, and epinephrine.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 547810,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005546",
-          "name": "fibromyalgia",
-          "description": "A common nonarticular rheumatic condition that is characterized by muscle pain, tenderness, and stiffness.; A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.; Inflammation and fibrous degeneration of a muscle.; A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10016631",
-            "MEDDRA:10048439",
-            "MEDDRA:10028363",
-            "PSY:19685",
-            "SNOMEDCT:56557000",
-            "SNOMEDCT:726531007",
-            "NCIT:C50566",
-            "ORPHANET:41842",
-            "SNOMEDCT:203082005",
-            "MEDDRA:10063041",
-            "MONDO:0005546",
-            "SNOMEDCT:203102006",
-            "MEDDRA:10016663",
-            "DOID:631",
-            "EFO:0005687",
-            "MESH:D005356",
-            "ICD10:M79.7",
-            "NCIT:C87497",
-            "MEDDRA:10079197",
-            "UMLS:C0016053"
-          ],
-          "id": "MONDO:0005546",
-          "category": "biolink:Disease",
-          "all_names": [
-            "fibromyalgia",
-            "Fibromyalgia",
-            "Fibromyositis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:33024295",
-            "https://www.ncbi.nlm.nih.gov/labs/pmc/articles/pmc7660651/",
-            "PMID:30486733",
-            "PMID:32120395"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 547810,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005546",
-              "name": "fibromyalgia",
-              "description": "A common nonarticular rheumatic condition that is characterized by muscle pain, tenderness, and stiffness.; A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.; Inflammation and fibrous degeneration of a muscle.; A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10016631",
-                "MEDDRA:10048439",
-                "MEDDRA:10028363",
-                "PSY:19685",
-                "SNOMEDCT:56557000",
-                "SNOMEDCT:726531007",
-                "NCIT:C50566",
-                "ORPHANET:41842",
-                "SNOMEDCT:203082005",
-                "MEDDRA:10063041",
-                "MONDO:0005546",
-                "SNOMEDCT:203102006",
-                "MEDDRA:10016663",
-                "DOID:631",
-                "EFO:0005687",
-                "MESH:D005356",
-                "ICD10:M79.7",
-                "NCIT:C87497",
-                "MEDDRA:10079197",
-                "UMLS:C0016053"
-              ],
-              "id": "MONDO:0005546",
-              "category": "biolink:Disease",
-              "all_names": [
-                "fibromyalgia",
-                "Fibromyalgia",
-                "Fibromyositis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:33024295",
-                "https://www.ncbi.nlm.nih.gov/labs/pmc/articles/pmc7660651/",
-                "PMID:30486733",
-                "PMID:32120395"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19745219,
-            "start": 569,
-            "end": 547810,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29389485': {'publication date': '2018 Feb', 'sentence': 'They answered the Fibromyalgia Impact Questionnaire (FIQ), Perceived Stress Questionnaire (PSQ) and McGill Pain Questionnaire (MPQ-Br), and collected saliva to evaluate CC before and after the end of each month.', 'subject score': 694, 'object score': 851}, 'PMID:36728497': {'publication date': '2023 Jan 05', 'sentence': 'No main effect of FMS was found on altered levels of blood cortisol, ACTH, CRH, and epinephrine.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0016053---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "20137862",
-              "object": "MONDO:0005546",
-              "publications": [
-                "PMID:29389485",
-                "PMID:36728497"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10335725': {'publication date': '1999 May', 'sentence': 'Graded ACTH infusion revealed similar increases in cortisol in women with fibromyalgia and healthy controls.', 'subject score': 1000, 'object score': 1000}, 'PMID:11094926': {'publication date': '2000 Feb', 'sentence': 'A naturalistic evaluation of cortisol secretion in persons with fibromyalgia and rheumatoid arthritis.', 'subject score': 888, 'object score': 1000}, 'PMID:15142269': {'publication date': '2004', 'sentence': 'We investigated abnormalities of the hypothalamic-pituitary-gonadal axis and cortisol concentrations in women with fibromyalgia and chronic fatigue syndrome (CFS) who were in the follicular phase of their menstrual cycle, and whether their scores for depressive symptoms were related to levels of these hormones.', 'subject score': 888, 'object score': 1000}, 'PMID:15157948': {'publication date': '2004 Jul', 'sentence': 'Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:15479904': {'publication date': '2004 Nov', 'sentence': 'CONCLUSION: Despite low cortisol concentrations in young women with FM, there is no abnormality in HPG axis hormones.', 'subject score': 851, 'object score': 1000}, 'PMID:19102778': {'publication date': '2008 Dec 22', 'sentence': 'Our aim was to demonstrate that urinary cortisol was lower in patients with FM than in healthy subjects.', 'subject score': 888, 'object score': 1000}, 'PMID:21682138': {'publication date': '2011 Apr', 'sentence': 'Moreover, there are reports of deficiency of serotonin, melatonin, cortisol and cytokines in FMS patients, which are fully regulated by circadian rhythm.', 'subject score': 1000, 'object score': 901}, 'PMID:22000300': {'publication date': '2012 May', 'sentence': 'PPT measurement did induce three times higher cortisol and four times higher IL-6 levels in FMS patients, but no change in their ACTH levels.', 'subject score': 816, 'object score': 901}, 'PMID:24426206': {'publication date': '2013 Apr', 'sentence': 'It could be concluded that there is an abnormality in circadian secretion of cortisol in female FMS patients.', 'subject score': 1000, 'object score': 861}, 'PMID:30209437': {'publication date': '2018 Sep 11', 'sentence': 'This study aims to evaluate the probable relationship between intestinal dysbiosis and altered secretion of hormones and vitamins such as cortisol, serotonin, Vitamin D and thyroid hormones in a patient with fibromyalgia.', 'subject score': 1000, 'object score': 1000}, 'PMID:30785911': {'publication date': '2019', 'sentence': 'The objective of this study was to verify the effects of aerobic exercise associated with tryptophan (TRP) supplementation on hyperalgesia, as well as on cortisol, IL-6 and TNF concentrations in female rats with experimental fibromyalgia (FM).', 'subject score': 1000, 'object score': 888}, 'PMID:32149617': {'publication date': '2020 Mar 05', 'sentence': 'RESULTS: Our results show that the clearance rate of cortisol is lower in FMS patients as compared to their matched healthy individuals based on a simplified cortisol secretion model.', 'subject score': 1000, 'object score': 901}, 'PMID:5245506': {'publication date': '1967 Jan', 'sentence': '[The use of hydrocortisone in the treatment of tendovaginitis and fibromyositis].', 'subject score': 1000, 'object score': 1000}, 'PMID:7980669': {'publication date': '1994 Nov', 'sentence': 'OBJECTIVE: To examine basal and stimulated hypothalamic-pituitary-adrenal (HPA) axis and related hormone levels, including adrenocorticotropin (ACTH), cortisol, arginine vasopressin (AVP), and neuropeptide Y (NPY), in patients with fibromyalgia (FM).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 547810,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005546",
-          "name": "fibromyalgia",
-          "description": "A common nonarticular rheumatic condition that is characterized by muscle pain, tenderness, and stiffness.; A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.; Inflammation and fibrous degeneration of a muscle.; A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10016631",
-            "MEDDRA:10048439",
-            "MEDDRA:10028363",
-            "PSY:19685",
-            "SNOMEDCT:56557000",
-            "SNOMEDCT:726531007",
-            "NCIT:C50566",
-            "ORPHANET:41842",
-            "SNOMEDCT:203082005",
-            "MEDDRA:10063041",
-            "MONDO:0005546",
-            "SNOMEDCT:203102006",
-            "MEDDRA:10016663",
-            "DOID:631",
-            "EFO:0005687",
-            "MESH:D005356",
-            "ICD10:M79.7",
-            "NCIT:C87497",
-            "MEDDRA:10079197",
-            "UMLS:C0016053"
-          ],
-          "id": "MONDO:0005546",
-          "category": "biolink:Disease",
-          "all_names": [
-            "fibromyalgia",
-            "Fibromyalgia",
-            "Fibromyositis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:33024295",
-            "https://www.ncbi.nlm.nih.gov/labs/pmc/articles/pmc7660651/",
-            "PMID:30486733",
-            "PMID:32120395"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 547810,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005546",
-              "name": "fibromyalgia",
-              "description": "A common nonarticular rheumatic condition that is characterized by muscle pain, tenderness, and stiffness.; A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.; Inflammation and fibrous degeneration of a muscle.; A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10016631",
-                "MEDDRA:10048439",
-                "MEDDRA:10028363",
-                "PSY:19685",
-                "SNOMEDCT:56557000",
-                "SNOMEDCT:726531007",
-                "NCIT:C50566",
-                "ORPHANET:41842",
-                "SNOMEDCT:203082005",
-                "MEDDRA:10063041",
-                "MONDO:0005546",
-                "SNOMEDCT:203102006",
-                "MEDDRA:10016663",
-                "DOID:631",
-                "EFO:0005687",
-                "MESH:D005356",
-                "ICD10:M79.7",
-                "NCIT:C87497",
-                "MEDDRA:10079197",
-                "UMLS:C0016053"
-              ],
-              "id": "MONDO:0005546",
-              "category": "biolink:Disease",
-              "all_names": [
-                "fibromyalgia",
-                "Fibromyalgia",
-                "Fibromyositis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:33024295",
-                "https://www.ncbi.nlm.nih.gov/labs/pmc/articles/pmc7660651/",
-                "PMID:30486733",
-                "PMID:32120395"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7253757,
-            "start": 569,
-            "end": 547810,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10335725': {'publication date': '1999 May', 'sentence': 'Graded ACTH infusion revealed similar increases in cortisol in women with fibromyalgia and healthy controls.', 'subject score': 1000, 'object score': 1000}, 'PMID:11094926': {'publication date': '2000 Feb', 'sentence': 'A naturalistic evaluation of cortisol secretion in persons with fibromyalgia and rheumatoid arthritis.', 'subject score': 888, 'object score': 1000}, 'PMID:15142269': {'publication date': '2004', 'sentence': 'We investigated abnormalities of the hypothalamic-pituitary-gonadal axis and cortisol concentrations in women with fibromyalgia and chronic fatigue syndrome (CFS) who were in the follicular phase of their menstrual cycle, and whether their scores for depressive symptoms were related to levels of these hormones.', 'subject score': 888, 'object score': 1000}, 'PMID:15157948': {'publication date': '2004 Jul', 'sentence': 'Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:15479904': {'publication date': '2004 Nov', 'sentence': 'CONCLUSION: Despite low cortisol concentrations in young women with FM, there is no abnormality in HPG axis hormones.', 'subject score': 851, 'object score': 1000}, 'PMID:19102778': {'publication date': '2008 Dec 22', 'sentence': 'Our aim was to demonstrate that urinary cortisol was lower in patients with FM than in healthy subjects.', 'subject score': 888, 'object score': 1000}, 'PMID:21682138': {'publication date': '2011 Apr', 'sentence': 'Moreover, there are reports of deficiency of serotonin, melatonin, cortisol and cytokines in FMS patients, which are fully regulated by circadian rhythm.', 'subject score': 1000, 'object score': 901}, 'PMID:22000300': {'publication date': '2012 May', 'sentence': 'PPT measurement did induce three times higher cortisol and four times higher IL-6 levels in FMS patients, but no change in their ACTH levels.', 'subject score': 816, 'object score': 901}, 'PMID:24426206': {'publication date': '2013 Apr', 'sentence': 'It could be concluded that there is an abnormality in circadian secretion of cortisol in female FMS patients.', 'subject score': 1000, 'object score': 861}, 'PMID:30209437': {'publication date': '2018 Sep 11', 'sentence': 'This study aims to evaluate the probable relationship between intestinal dysbiosis and altered secretion of hormones and vitamins such as cortisol, serotonin, Vitamin D and thyroid hormones in a patient with fibromyalgia.', 'subject score': 1000, 'object score': 1000}, 'PMID:30785911': {'publication date': '2019', 'sentence': 'The objective of this study was to verify the effects of aerobic exercise associated with tryptophan (TRP) supplementation on hyperalgesia, as well as on cortisol, IL-6 and TNF concentrations in female rats with experimental fibromyalgia (FM).', 'subject score': 1000, 'object score': 888}, 'PMID:32149617': {'publication date': '2020 Mar 05', 'sentence': 'RESULTS: Our results show that the clearance rate of cortisol is lower in FMS patients as compared to their matched healthy individuals based on a simplified cortisol secretion model.', 'subject score': 1000, 'object score': 901}, 'PMID:5245506': {'publication date': '1967 Jan', 'sentence': '[The use of hydrocortisone in the treatment of tendovaginitis and fibromyositis].', 'subject score': 1000, 'object score': 1000}, 'PMID:7980669': {'publication date': '1994 Nov', 'sentence': 'OBJECTIVE: To examine basal and stimulated hypothalamic-pituitary-adrenal (HPA) axis and related hormone levels, including adrenocorticotropin (ACTH), cortisol, arginine vasopressin (AVP), and neuropeptide Y (NPY), in patients with fibromyalgia (FM).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0016053---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7402054",
-              "object": "MONDO:0005546",
-              "publications": [
-                "PMID:10335725",
-                "PMID:11094926",
-                "PMID:15142269",
-                "PMID:15157948",
-                "PMID:15479904",
-                "PMID:19102778",
-                "PMID:21682138",
-                "PMID:22000300",
-                "PMID:24426206",
-                "PMID:30209437",
-                "PMID:30785911",
-                "PMID:32149617",
-                "PMID:5245506",
-                "PMID:7980669"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:11955464': {'publication date': '2002 Apr 15', 'sentence': 'The effect on cortisol supports the above conclusion and is consistent with HPA axis perturbation in opioid dependence as reported in other studies and extends these observations to stable methadone-maintained patients.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 303504,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005530",
-          "name": "opiate dependence",
-          "description": "Disorders related to or resulting from abuse or misuse of OPIOIDS.; Addiction to opioids. [ORCID:0000-0002-4095-8489, PMID:27508068]; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "MESH:D009293",
-            "MEDDRA:10030896",
-            "MEDDRA:10030892",
-            "SNOMEDCT:75544000",
-            "ICD9:304.00",
-            "UMLS:C0027412",
-            "HP:0033515",
-            "MONDO:0005530",
-            "MEDDRA:10012346",
-            "ICD10:F11.2",
-            "DOID:2559",
-            "UMLS:C0524662"
-          ],
-          "id": "MONDO:0005530",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Opioid type dependence, unspecified",
-            "Opiate Addiction",
-            "opiate dependence",
-            "Opioid addiction",
-            "Opioid-Related Disorders"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/opiate_dependency",
-            "https://orcid.org/0000-0002-4095-8489",
-            "PMID:27508068"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 303504,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005530",
-              "name": "opiate dependence",
-              "description": "Disorders related to or resulting from abuse or misuse of OPIOIDS.; Addiction to opioids. [ORCID:0000-0002-4095-8489, PMID:27508068]; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "MESH:D009293",
-                "MEDDRA:10030896",
-                "MEDDRA:10030892",
-                "SNOMEDCT:75544000",
-                "ICD9:304.00",
-                "UMLS:C0027412",
-                "HP:0033515",
-                "MONDO:0005530",
-                "MEDDRA:10012346",
-                "ICD10:F11.2",
-                "DOID:2559",
-                "UMLS:C0524662"
-              ],
-              "id": "MONDO:0005530",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Opioid type dependence, unspecified",
-                "Opiate Addiction",
-                "opiate dependence",
-                "Opioid addiction",
-                "Opioid-Related Disorders"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/opiate_dependency",
-                "https://orcid.org/0000-0002-4095-8489",
-                "PMID:27508068"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9288120,
-            "start": 569,
-            "end": 303504,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11955464': {'publication date': '2002 Apr 15', 'sentence': 'The effect on cortisol supports the above conclusion and is consistent with HPA axis perturbation in opioid dependence as reported in other studies and extends these observations to stable methadone-maintained patients.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0524662---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9492934",
-              "object": "MONDO:0005530",
-              "publications": [
-                "PMID:11955464"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:36564159': {'publication date': '2022 Dec 23', 'sentence': 'The present study reported a case of hydrocortisone-induced blood pressure reduction in a patient with anterior pituitary hypofunction due to allergic reaction.', 'subject score': 875, 'object score': 875}}",
-    "p2": {
-      "start": {
-        "identity": 319508,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005468",
-          "name": "hypotensive disorder",
-          "description": "Blood pressure that is abnormally low.; Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.; Low Blood Pressure, vascular hypotension. [HPO:probinson]; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "MEDDRA:10036638",
-            "PDQ:CDR0000041785",
-            "MEDDRA:10021099",
-            "MEDDRA:10024896",
-            "MEDDRA:10024895",
-            "MEDDRA:10003146",
-            "MEDDRA:10024982",
-            "MEDDRA:10021106",
-            "EFO:0005251",
-            "SYMP:0000059",
-            "SNOMEDCT:45007003",
-            "NCIT:C3128",
-            "MEDDRA:10016174",
-            "PSY:24060",
-            "MEDDRA:10005744",
-            "MEDDRA:10066331",
-            "HP:0002615",
-            "ICD9:458",
-            "MEDDRA:10005753",
-            "MEDDRA:10005734",
-            "MEDDRA:10021097",
-            "MEDDRA:10013645",
-            "MEDDRA:10013644",
-            "MEDDRA:10006065",
-            "MONDO:0005468",
-            "MEDDRA:10003169",
-            "MEDDRA:10005743",
-            "MEDDRA:10006064",
-            "UMLS:C0020649",
-            "MESH:D007022"
-          ],
-          "id": "MONDO:0005468",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hypotensive disorder",
-            "hypotension",
-            "Hypotension"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:DiseaseOrPhenotypicFeature",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://github.com/monarch-initiative/mondo/issues/1030"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319508,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005468",
-              "name": "hypotensive disorder",
-              "description": "Blood pressure that is abnormally low.; Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.; Low Blood Pressure, vascular hypotension. [HPO:probinson]; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "MEDDRA:10036638",
-                "PDQ:CDR0000041785",
-                "MEDDRA:10021099",
-                "MEDDRA:10024896",
-                "MEDDRA:10024895",
-                "MEDDRA:10003146",
-                "MEDDRA:10024982",
-                "MEDDRA:10021106",
-                "EFO:0005251",
-                "SYMP:0000059",
-                "SNOMEDCT:45007003",
-                "NCIT:C3128",
-                "MEDDRA:10016174",
-                "PSY:24060",
-                "MEDDRA:10005744",
-                "MEDDRA:10066331",
-                "HP:0002615",
-                "ICD9:458",
-                "MEDDRA:10005753",
-                "MEDDRA:10005734",
-                "MEDDRA:10021097",
-                "MEDDRA:10013645",
-                "MEDDRA:10013644",
-                "MEDDRA:10006065",
-                "MONDO:0005468",
-                "MEDDRA:10003169",
-                "MEDDRA:10005743",
-                "MEDDRA:10006064",
-                "UMLS:C0020649",
-                "MESH:D007022"
-              ],
-              "id": "MONDO:0005468",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hypotensive disorder",
-                "hypotension",
-                "Hypotension"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:DiseaseOrPhenotypicFeature",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://github.com/monarch-initiative/mondo/issues/1030"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24758053,
-            "start": 569,
-            "end": 319508,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:36564159': {'publication date': '2022 Dec 23', 'sentence': 'The present study reported a case of hydrocortisone-induced blood pressure reduction in a patient with anterior pituitary hypofunction due to allergic reaction.', 'subject score': 875, 'object score': 875}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0020649---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "25205462",
-              "object": "MONDO:0005468",
-              "publications": [
-                "PMID:36564159"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:19691511': {'publication date': '2009 Jun', 'sentence': 'NEW OR UNIQUE INFORMATION PROVIDED: This case is the first published report of hydrocortisone-responsive hypotension and transient CIRCI associated with naturally occurring septic shock in a dog.', 'subject score': 851, 'object score': 851}, 'PMID:22721515': {'publication date': '2012 May', 'sentence': 'Starting during normothermic cardiopulmonary bypass (CPB), hypotension occurred, refractory to phenylephrine, noradrenaline, terlipressin, hydrocortisone and dexchlorpheniramine.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319508,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005468",
-          "name": "hypotensive disorder",
-          "description": "Blood pressure that is abnormally low.; Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.; Low Blood Pressure, vascular hypotension. [HPO:probinson]; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "MEDDRA:10036638",
-            "PDQ:CDR0000041785",
-            "MEDDRA:10021099",
-            "MEDDRA:10024896",
-            "MEDDRA:10024895",
-            "MEDDRA:10003146",
-            "MEDDRA:10024982",
-            "MEDDRA:10021106",
-            "EFO:0005251",
-            "SYMP:0000059",
-            "SNOMEDCT:45007003",
-            "NCIT:C3128",
-            "MEDDRA:10016174",
-            "PSY:24060",
-            "MEDDRA:10005744",
-            "MEDDRA:10066331",
-            "HP:0002615",
-            "ICD9:458",
-            "MEDDRA:10005753",
-            "MEDDRA:10005734",
-            "MEDDRA:10021097",
-            "MEDDRA:10013645",
-            "MEDDRA:10013644",
-            "MEDDRA:10006065",
-            "MONDO:0005468",
-            "MEDDRA:10003169",
-            "MEDDRA:10005743",
-            "MEDDRA:10006064",
-            "UMLS:C0020649",
-            "MESH:D007022"
-          ],
-          "id": "MONDO:0005468",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hypotensive disorder",
-            "hypotension",
-            "Hypotension"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:DiseaseOrPhenotypicFeature",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://github.com/monarch-initiative/mondo/issues/1030"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319508,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005468",
-              "name": "hypotensive disorder",
-              "description": "Blood pressure that is abnormally low.; Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.; Low Blood Pressure, vascular hypotension. [HPO:probinson]; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "MEDDRA:10036638",
-                "PDQ:CDR0000041785",
-                "MEDDRA:10021099",
-                "MEDDRA:10024896",
-                "MEDDRA:10024895",
-                "MEDDRA:10003146",
-                "MEDDRA:10024982",
-                "MEDDRA:10021106",
-                "EFO:0005251",
-                "SYMP:0000059",
-                "SNOMEDCT:45007003",
-                "NCIT:C3128",
-                "MEDDRA:10016174",
-                "PSY:24060",
-                "MEDDRA:10005744",
-                "MEDDRA:10066331",
-                "HP:0002615",
-                "ICD9:458",
-                "MEDDRA:10005753",
-                "MEDDRA:10005734",
-                "MEDDRA:10021097",
-                "MEDDRA:10013645",
-                "MEDDRA:10013644",
-                "MEDDRA:10006065",
-                "MONDO:0005468",
-                "MEDDRA:10003169",
-                "MEDDRA:10005743",
-                "MEDDRA:10006064",
-                "UMLS:C0020649",
-                "MESH:D007022"
-              ],
-              "id": "MONDO:0005468",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hypotensive disorder",
-                "hypotension",
-                "Hypotension"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:DiseaseOrPhenotypicFeature",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://github.com/monarch-initiative/mondo/issues/1030"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14230402,
-            "start": 569,
-            "end": 319508,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19691511': {'publication date': '2009 Jun', 'sentence': 'NEW OR UNIQUE INFORMATION PROVIDED: This case is the first published report of hydrocortisone-responsive hypotension and transient CIRCI associated with naturally occurring septic shock in a dog.', 'subject score': 851, 'object score': 851}, 'PMID:22721515': {'publication date': '2012 May', 'sentence': 'Starting during normothermic cardiopulmonary bypass (CPB), hypotension occurred, refractory to phenylephrine, noradrenaline, terlipressin, hydrocortisone and dexchlorpheniramine.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0020649---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14533429",
-              "object": "MONDO:0005468",
-              "publications": [
-                "PMID:19691511",
-                "PMID:22721515"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:17568152': {'publication date': '2007', 'sentence': 'Hypotension after recruitment was reduced by HC (0 vs. 30%).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319508,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005468",
-          "name": "hypotensive disorder",
-          "description": "Blood pressure that is abnormally low.; Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.; Low Blood Pressure, vascular hypotension. [HPO:probinson]; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "MEDDRA:10036638",
-            "PDQ:CDR0000041785",
-            "MEDDRA:10021099",
-            "MEDDRA:10024896",
-            "MEDDRA:10024895",
-            "MEDDRA:10003146",
-            "MEDDRA:10024982",
-            "MEDDRA:10021106",
-            "EFO:0005251",
-            "SYMP:0000059",
-            "SNOMEDCT:45007003",
-            "NCIT:C3128",
-            "MEDDRA:10016174",
-            "PSY:24060",
-            "MEDDRA:10005744",
-            "MEDDRA:10066331",
-            "HP:0002615",
-            "ICD9:458",
-            "MEDDRA:10005753",
-            "MEDDRA:10005734",
-            "MEDDRA:10021097",
-            "MEDDRA:10013645",
-            "MEDDRA:10013644",
-            "MEDDRA:10006065",
-            "MONDO:0005468",
-            "MEDDRA:10003169",
-            "MEDDRA:10005743",
-            "MEDDRA:10006064",
-            "UMLS:C0020649",
-            "MESH:D007022"
-          ],
-          "id": "MONDO:0005468",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hypotensive disorder",
-            "hypotension",
-            "Hypotension"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:DiseaseOrPhenotypicFeature",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://github.com/monarch-initiative/mondo/issues/1030"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319508,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005468",
-              "name": "hypotensive disorder",
-              "description": "Blood pressure that is abnormally low.; Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.; Low Blood Pressure, vascular hypotension. [HPO:probinson]; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "MEDDRA:10036638",
-                "PDQ:CDR0000041785",
-                "MEDDRA:10021099",
-                "MEDDRA:10024896",
-                "MEDDRA:10024895",
-                "MEDDRA:10003146",
-                "MEDDRA:10024982",
-                "MEDDRA:10021106",
-                "EFO:0005251",
-                "SYMP:0000059",
-                "SNOMEDCT:45007003",
-                "NCIT:C3128",
-                "MEDDRA:10016174",
-                "PSY:24060",
-                "MEDDRA:10005744",
-                "MEDDRA:10066331",
-                "HP:0002615",
-                "ICD9:458",
-                "MEDDRA:10005753",
-                "MEDDRA:10005734",
-                "MEDDRA:10021097",
-                "MEDDRA:10013645",
-                "MEDDRA:10013644",
-                "MEDDRA:10006065",
-                "MONDO:0005468",
-                "MEDDRA:10003169",
-                "MEDDRA:10005743",
-                "MEDDRA:10006064",
-                "UMLS:C0020649",
-                "MESH:D007022"
-              ],
-              "id": "MONDO:0005468",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hypotensive disorder",
-                "hypotension",
-                "Hypotension"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:DiseaseOrPhenotypicFeature",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://github.com/monarch-initiative/mondo/issues/1030"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12902220,
-            "start": 569,
-            "end": 319508,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17568152': {'publication date': '2007', 'sentence': 'Hypotension after recruitment was reduced by HC (0 vs. 30%).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:inhibits---biolink:causes---activity---None---UMLS:C0020649---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13180935",
-              "object": "MONDO:0005468",
-              "publications": [
-                "PMID:17568152"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11919326': {'publication date': '2002 Apr', 'sentence': 'After 24-h age, a subgroup (n = 8) received up to four doses (0.5-1.0 mg/kg each) of hydrocortisone for refractory hypotension.', 'subject score': 1000, 'object score': 888}, 'PMID:15162902': {'publication date': '2004 May', 'sentence': 'Initial symptoms of oral angioedema and laryngopharyngeal constriction progressed to dyspnea, tachypnea, hypotension, and tachycardia, all of which quickly resolved after immediate treatment with hydrocortisone, diphenhydramine, and epinephrine.', 'subject score': 1000, 'object score': 1000}, 'PMID:15329742': {'publication date': '2005 Feb', 'sentence': 'We conducted a randomized-controlled trial to determine the potential role on adrenal insufficiency in early neonatal hypotension and to determine the effectiveness of prophylactic HC in reducing treatment of hypotension in ELBW infants.', 'subject score': 888, 'object score': 1000}, 'PMID:16452355': {'publication date': '2006 Feb', 'sentence': 'CONCLUSIONS: A stress dose of hydrocortisone was effective in treating refractory hypotension in VLBW infants.', 'subject score': 1000, 'object score': 851}, 'PMID:16510650': {'publication date': '2006 Mar', 'sentence': 'CONCLUSIONS: The common early use of hydrocortisone for hypotension and the high morbidity and mortality in children receiving such treatment has not been recognized previously and prospective trials evaluating the short- and long-term risk/benefit of such treatment are urgently required.', 'subject score': 1000, 'object score': 1000}, 'PMID:16572567': {'publication date': '2006', 'sentence': \"During 2 infectious episodes, this patient's dosage of hydrocortisone had to be doubled to control symptomatic hypotension, lethargy, diffuse weakness, and anorexia.\", 'subject score': 1000, 'object score': 888}, 'PMID:17319465': {'publication date': '2006', 'sentence': 'Replacement doses of hydrocortisone and vasopressin may reduce mortality and improve hypotension, respectively, in a subgroup of patients with catecholamine-refractory septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:1811442': {'publication date': '1991 Dec', 'sentence': 'Frusemide for raised central venous pressure and pulmonary oedema, crystalloid infusion for reduced central venous pressure, and hydrocortisone and dopamine for hypotension were used as standard therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:18337742': {'publication date': '2008 Jun', 'sentence': 'OBJECTIVE: The purpose of this observation was to evaluate the safety and efficacy of hydrocortisone (HC) for the treatment of refractory hypotension in term and preterm infants.', 'subject score': 1000, 'object score': 888}, 'PMID:19160190': {'publication date': '2009 Jan 21', 'sentence': 'Most studies evaluated the use of dexamethasone but we also included studies that assessed hydrocortisone, even if it was used to manage hypotension.', 'subject score': 888, 'object score': 1000}, 'PMID:19693023': {'publication date': '2010 Jun', 'sentence': 'OBJECTIVE: To examine the efficacy of hydrocortisone for treatment of hypotension and reduction of vasopressor requirements in preterm infants.', 'subject score': 1000, 'object score': 1000}, 'PMID:20091516': {'publication date': '2010 Jan 20', 'sentence': 'Most studies evaluated the use of dexamethasone but we also included studies that assessed hydrocortisone, even if it was used to manage hypotension.', 'subject score': 888, 'object score': 1000}, 'PMID:21292456': {'publication date': '2011 Mar', 'sentence': 'The incidence of hypotension (61% vs 33%; P<0.05), patent ductus arteriosus (50% vs 17%; P<0.05), dopamine treatment (39% vs 16%; P<0.05), and hydrocortisone treatment (25% vs 6%; p<0.05) was higher in the HTOP group.', 'subject score': 888, 'object score': 1000}, 'PMID:21429058': {'publication date': '2011 Dec', 'sentence': 'Twelve infants (10%) were treated with HC for refractory hypotension (HC group).', 'subject score': 1000, 'object score': 888}, 'PMID:2154137': {'publication date': '1990 Jan', 'sentence': 'In contrast, the large vasopressin response to severe hypotension in the control experiments (from 3.1 +/- 0.3 to 270 +/- 113 pg/ml) was significantly attenuated by cortisol infusion in a dose-dependent manner.', 'subject score': 888, 'object score': 888}, 'PMID:22012173': {'publication date': '2012 Feb', 'sentence': 'Hydrocortisone for refractory hypotension of very low birth weight infant with patent ductus arteriosus: a case report.', 'subject score': 1000, 'object score': 888}, 'PMID:22341536': {'publication date': '2012 Mar', 'sentence': 'Hydrocortisone therapy is increasingly used to treat hypotension in critically ill newborns; however, the outcomes of this therapy must be evaluated in randomized trials.', 'subject score': 888, 'object score': 1000}, 'PMID:23904065': {'publication date': '2014 Aug', 'sentence': 'In this pilot study the authors demonstrate the feasibility, effectiveness and safety of the combined early treatment with hydrocortisone and dopamine for refractory hypotension in preterm newborns.', 'subject score': 1000, 'object score': 888}, 'PMID:24139558': {'publication date': '2014 Jun', 'sentence': 'There are a small number of reports on the use of hydrocortisone (HC) for the treatment of refractory hypotension in infants.', 'subject score': 1000, 'object score': 888}, 'PMID:24190402': {'publication date': '2014 Sep', 'sentence': \"Adding hydrocortisone as 1st line of inotropic treatment for hypotension in very low birth weight infants: authors' reply.\", 'subject score': 872, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319508,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005468",
-          "name": "hypotensive disorder",
-          "description": "Blood pressure that is abnormally low.; Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.; Low Blood Pressure, vascular hypotension. [HPO:probinson]; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "MEDDRA:10036638",
-            "PDQ:CDR0000041785",
-            "MEDDRA:10021099",
-            "MEDDRA:10024896",
-            "MEDDRA:10024895",
-            "MEDDRA:10003146",
-            "MEDDRA:10024982",
-            "MEDDRA:10021106",
-            "EFO:0005251",
-            "SYMP:0000059",
-            "SNOMEDCT:45007003",
-            "NCIT:C3128",
-            "MEDDRA:10016174",
-            "PSY:24060",
-            "MEDDRA:10005744",
-            "MEDDRA:10066331",
-            "HP:0002615",
-            "ICD9:458",
-            "MEDDRA:10005753",
-            "MEDDRA:10005734",
-            "MEDDRA:10021097",
-            "MEDDRA:10013645",
-            "MEDDRA:10013644",
-            "MEDDRA:10006065",
-            "MONDO:0005468",
-            "MEDDRA:10003169",
-            "MEDDRA:10005743",
-            "MEDDRA:10006064",
-            "UMLS:C0020649",
-            "MESH:D007022"
-          ],
-          "id": "MONDO:0005468",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hypotensive disorder",
-            "hypotension",
-            "Hypotension"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:DiseaseOrPhenotypicFeature",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://github.com/monarch-initiative/mondo/issues/1030"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319508,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005468",
-              "name": "hypotensive disorder",
-              "description": "Blood pressure that is abnormally low.; Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.; Low Blood Pressure, vascular hypotension. [HPO:probinson]; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "MEDDRA:10036638",
-                "PDQ:CDR0000041785",
-                "MEDDRA:10021099",
-                "MEDDRA:10024896",
-                "MEDDRA:10024895",
-                "MEDDRA:10003146",
-                "MEDDRA:10024982",
-                "MEDDRA:10021106",
-                "EFO:0005251",
-                "SYMP:0000059",
-                "SNOMEDCT:45007003",
-                "NCIT:C3128",
-                "MEDDRA:10016174",
-                "PSY:24060",
-                "MEDDRA:10005744",
-                "MEDDRA:10066331",
-                "HP:0002615",
-                "ICD9:458",
-                "MEDDRA:10005753",
-                "MEDDRA:10005734",
-                "MEDDRA:10021097",
-                "MEDDRA:10013645",
-                "MEDDRA:10013644",
-                "MEDDRA:10006065",
-                "MONDO:0005468",
-                "MEDDRA:10003169",
-                "MEDDRA:10005743",
-                "MEDDRA:10006064",
-                "UMLS:C0020649",
-                "MESH:D007022"
-              ],
-              "id": "MONDO:0005468",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hypotensive disorder",
-                "hypotension",
-                "Hypotension"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:DiseaseOrPhenotypicFeature",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://github.com/monarch-initiative/mondo/issues/1030"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9256009,
-            "start": 569,
-            "end": 319508,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:11919326': {'publication date': '2002 Apr', 'sentence': 'After 24-h age, a subgroup (n = 8) received up to four doses (0.5-1.0 mg/kg each) of hydrocortisone for refractory hypotension.', 'subject score': 1000, 'object score': 888}, 'PMID:15162902': {'publication date': '2004 May', 'sentence': 'Initial symptoms of oral angioedema and laryngopharyngeal constriction progressed to dyspnea, tachypnea, hypotension, and tachycardia, all of which quickly resolved after immediate treatment with hydrocortisone, diphenhydramine, and epinephrine.', 'subject score': 1000, 'object score': 1000}, 'PMID:15329742': {'publication date': '2005 Feb', 'sentence': 'We conducted a randomized-controlled trial to determine the potential role on adrenal insufficiency in early neonatal hypotension and to determine the effectiveness of prophylactic HC in reducing treatment of hypotension in ELBW infants.', 'subject score': 888, 'object score': 1000}, 'PMID:16452355': {'publication date': '2006 Feb', 'sentence': 'CONCLUSIONS: A stress dose of hydrocortisone was effective in treating refractory hypotension in VLBW infants.', 'subject score': 1000, 'object score': 851}, 'PMID:16510650': {'publication date': '2006 Mar', 'sentence': 'CONCLUSIONS: The common early use of hydrocortisone for hypotension and the high morbidity and mortality in children receiving such treatment has not been recognized previously and prospective trials evaluating the short- and long-term risk/benefit of such treatment are urgently required.', 'subject score': 1000, 'object score': 1000}, 'PMID:16572567': {'publication date': '2006', 'sentence': \"During 2 infectious episodes, this patient's dosage of hydrocortisone had to be doubled to control symptomatic hypotension, lethargy, diffuse weakness, and anorexia.\", 'subject score': 1000, 'object score': 888}, 'PMID:17319465': {'publication date': '2006', 'sentence': 'Replacement doses of hydrocortisone and vasopressin may reduce mortality and improve hypotension, respectively, in a subgroup of patients with catecholamine-refractory septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:1811442': {'publication date': '1991 Dec', 'sentence': 'Frusemide for raised central venous pressure and pulmonary oedema, crystalloid infusion for reduced central venous pressure, and hydrocortisone and dopamine for hypotension were used as standard therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:18337742': {'publication date': '2008 Jun', 'sentence': 'OBJECTIVE: The purpose of this observation was to evaluate the safety and efficacy of hydrocortisone (HC) for the treatment of refractory hypotension in term and preterm infants.', 'subject score': 1000, 'object score': 888}, 'PMID:19160190': {'publication date': '2009 Jan 21', 'sentence': 'Most studies evaluated the use of dexamethasone but we also included studies that assessed hydrocortisone, even if it was used to manage hypotension.', 'subject score': 888, 'object score': 1000}, 'PMID:19693023': {'publication date': '2010 Jun', 'sentence': 'OBJECTIVE: To examine the efficacy of hydrocortisone for treatment of hypotension and reduction of vasopressor requirements in preterm infants.', 'subject score': 1000, 'object score': 1000}, 'PMID:20091516': {'publication date': '2010 Jan 20', 'sentence': 'Most studies evaluated the use of dexamethasone but we also included studies that assessed hydrocortisone, even if it was used to manage hypotension.', 'subject score': 888, 'object score': 1000}, 'PMID:21292456': {'publication date': '2011 Mar', 'sentence': 'The incidence of hypotension (61% vs 33%; P<0.05), patent ductus arteriosus (50% vs 17%; P<0.05), dopamine treatment (39% vs 16%; P<0.05), and hydrocortisone treatment (25% vs 6%; p<0.05) was higher in the HTOP group.', 'subject score': 888, 'object score': 1000}, 'PMID:21429058': {'publication date': '2011 Dec', 'sentence': 'Twelve infants (10%) were treated with HC for refractory hypotension (HC group).', 'subject score': 1000, 'object score': 888}, 'PMID:2154137': {'publication date': '1990 Jan', 'sentence': 'In contrast, the large vasopressin response to severe hypotension in the control experiments (from 3.1 +/- 0.3 to 270 +/- 113 pg/ml) was significantly attenuated by cortisol infusion in a dose-dependent manner.', 'subject score': 888, 'object score': 888}, 'PMID:22012173': {'publication date': '2012 Feb', 'sentence': 'Hydrocortisone for refractory hypotension of very low birth weight infant with patent ductus arteriosus: a case report.', 'subject score': 1000, 'object score': 888}, 'PMID:22341536': {'publication date': '2012 Mar', 'sentence': 'Hydrocortisone therapy is increasingly used to treat hypotension in critically ill newborns; however, the outcomes of this therapy must be evaluated in randomized trials.', 'subject score': 888, 'object score': 1000}, 'PMID:23904065': {'publication date': '2014 Aug', 'sentence': 'In this pilot study the authors demonstrate the feasibility, effectiveness and safety of the combined early treatment with hydrocortisone and dopamine for refractory hypotension in preterm newborns.', 'subject score': 1000, 'object score': 888}, 'PMID:24139558': {'publication date': '2014 Jun', 'sentence': 'There are a small number of reports on the use of hydrocortisone (HC) for the treatment of refractory hypotension in infants.', 'subject score': 1000, 'object score': 888}, 'PMID:24190402': {'publication date': '2014 Sep', 'sentence': \"Adding hydrocortisone as 1st line of inotropic treatment for hypotension in very low birth weight infants: authors' reply.\", 'subject score': 872, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0020649---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9459897",
-              "object": "MONDO:0005468",
-              "publications": [
-                "PMID:11919326",
-                "PMID:15162902",
-                "PMID:15329742",
-                "PMID:16452355",
-                "PMID:16510650",
-                "PMID:16572567",
-                "PMID:17319465",
-                "PMID:1811442",
-                "PMID:18337742",
-                "PMID:19160190",
-                "PMID:19693023",
-                "PMID:20091516",
-                "PMID:21292456",
-                "PMID:21429058",
-                "PMID:2154137",
-                "PMID:22012173",
-                "PMID:22341536",
-                "PMID:23904065",
-                "PMID:24139558",
-                "PMID:24190402"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:16757401': {'publication date': '2006 Apr-Jun', 'sentence': 'At multiple regression analyses, HOMA-IR on admission in the IR group significantly correlated with thyroid-stimulating hormone, glucagon, and cortisol.', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 314596,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-          "name": "Insulin resistance",
-          "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "NCIT:C113101",
-            "UMLS:C0021655",
-            "MEDDRA:10022489",
-            "SNOMEDCT:48606007",
-            "MESH:D007333",
-            "EFO:0002614",
-            "HP:0000855",
-            "SNOMEDCT:763325000"
-          ],
-          "id": "HP:0000855",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Insulin resistance",
-            "insulin resistance",
-            "Insulin Resistance"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314596,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-              "name": "Insulin resistance",
-              "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "NCIT:C113101",
-                "UMLS:C0021655",
-                "MEDDRA:10022489",
-                "SNOMEDCT:48606007",
-                "MESH:D007333",
-                "EFO:0002614",
-                "HP:0000855",
-                "SNOMEDCT:763325000"
-              ],
-              "id": "HP:0000855",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Insulin resistance",
-                "insulin resistance",
-                "Insulin Resistance"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12266984,
-            "start": 314596,
-            "end": 569,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16757401': {'publication date': '2006 Apr-Jun', 'sentence': 'At multiple regression analyses, HOMA-IR on admission in the IR group significantly correlated with thyroid-stimulating hormone, glucagon, and cortisol.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0021655---SEMMEDDB:associated_with---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "HP:0000855",
-              "id": "12533519",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:16757401"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:10692082': {'publication date': '2000 Feb', 'sentence': \"OBJECTIVES: Recent data suggest that higher plasma cortisol may be associated with hypertension and insulin resistance in otherwise healthy men, as it is in Cushing's syndrome.\", 'subject score': 840, 'object score': 1000}, 'PMID:11916927': {'publication date': '2002 Apr', 'sentence': 'In common with the GR, 11beta-HSD1 expression in myoblasts incubated with physiological concentrations of cortisol in vitro was positively associated with levels of insulin resistance (r(2) = 0.68, P < 0.001), BMI (r(2) = 0.63, P < 0.005), and blood pressure (r(2) = 0.27, P < 0.05).', 'subject score': 1000, 'object score': 1000}, 'PMID:14557475': {'publication date': '2003 Oct', 'sentence': 'Higher excretion of 5beta-reduced cortisol metabolites was independently associated with insulin resistance and hypertriglyceridemia.', 'subject score': 775, 'object score': 1000}, 'PMID:15026790': {'publication date': '2004 Mar 22', 'sentence': 'Therefore, it would appear that low leptin concentrations, increased fat oxidation and insulin resistance are associated with increased concentrations of cortisol and interleukin-6 in weight-losing patients with pancreatic cancer.', 'subject score': 1000, 'object score': 1000}, 'PMID:15142652': {'publication date': '2004', 'sentence': 'Prolonged exposure to high levels of cortisol is associated with insulin resistance, as exemplified by the metabolic syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:15256820': {'publication date': '2004', 'sentence': 'These facts point to an association between cortisol and insulin resistance in obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:16009799': {'publication date': '2005 Jul 19', 'sentence': 'CONCLUSIONS: This is the first population-based prospective study that has found a specific association between cortisol:testosterone ratio and incident ischemic heart disease, apparently mediated through the insulin resistance syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:19050176': {'publication date': '2009 Feb', 'sentence': 'Controversy exists as to whether endogenous cortisol production is associated with visceral obesity and insulin resistance in humans.', 'subject score': 851, 'object score': 1000}, 'PMID:19342030': {'publication date': '2010 Mar 01', 'sentence': 'CONCLUSION(S): Obesity and insulin resistance are associated with lower morning cortisol and DHEAS but increased cortisol and DHEA responses after glucose ingestion.', 'subject score': 851, 'object score': 1000}, 'PMID:20354921': {'publication date': '2010 Apr', 'sentence': 'However, the aetiological role of CBG and cortisol in insulin resistance is uncertain, although in males, cortisol and CBG could be subtly related to the degree of insulin resistance.', 'subject score': 1000, 'object score': 1000}, 'PMID:21475800': {'publication date': '2009', 'sentence': 'Though vasopressin responders with subclinical CS had lower autonomous cortisol secretion, they had a high prevalence of hypertension, in which insulin resistance was closely correlated with cortisol response to vasopressin.', 'subject score': 815, 'object score': 1000}, 'PMID:22283617': {'publication date': '2012 Apr', 'sentence': 'Higher levels of cortisol correlated with increased insulin resistance after the jump.', 'subject score': 1000, 'object score': 901}, 'PMID:23577182': {'publication date': '2013', 'sentence': \"10% of the elderly population has an 'adrenal incidentaloma', up to 20% of these show low-grade autonomous cortisol secretion and 60% of patients with autonomous cortisol secretion have insulin resistance.\", 'subject score': 828, 'object score': 1000}, 'PMID:24926956': {'publication date': '2014 Sep', 'sentence': 'CONTEXT: Adult-onset GH deficiency (GHD) increases visceral adiposity and the activity of the enzyme 11beta-hydroxysteroid dehydrogenase, which converts cortisone (E) to cortisol (F), both linked to insulin resistance and increased cardiovascular risk.', 'subject score': 1000, 'object score': 1000}, 'PMID:2647890': {'publication date': '1989 Mar', 'sentence': 'These results demonstrate that timed daily injections of cortisol and prolactin in specific temporal relationships can produce marked reductions in obesity, hyperinsulinaemia and insulin resistance in the Syrian hamster that persist long after the termination of treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:26934392': {'publication date': '2016 05', 'sentence': 'DESIGN: Follicular fluid and granulosa cells were collected from non-PCOS and PCOS patients with and without IR to measure cortisol concentration and the amounts of 11beta-HSD1 and -2, which were then correlated with IR status.', 'subject score': 694, 'object score': 901}, 'PMID:29223281': {'publication date': '2017 10', 'sentence': \"Higher nocturnal cortisol exposure is observed in patients with Cushing's syndrome and adrenal incidentalomas with autonomous cortisol secretion and is associated with insulin resistance, and increased cardiovascular risk and mortality.\", 'subject score': 828, 'object score': 1000}, 'PMID:29618067': {'publication date': '2018 Jul 01', 'sentence': 'Objective: To investigate whether the abundance of 11?-hydroxysteroid dehydrogenases (11?-HSDs) 1 and 2 and cortisol as well as the insulin signaling pathway are altered in PCOS endometrium and to clarify the relationship between endometrial IR and local cortisol.', 'subject score': 888, 'object score': 901}, 'PMID:31176299': {'publication date': '2019 Jun 01', 'sentence': 'CONCLUSION: In the CoLaus study of healthy adults, basal salivary cortisol was not associated with incident IR or T2DM.', 'subject score': 851, 'object score': 901}, 'PMID:31664610': {'publication date': '2019 Oct 29', 'sentence': 'The inhibition of 11beta-HSD1 has been shown to attenuate the development of type 2 diabetes mellitus, insulin resistance, metabolic syndrome and other diseases mediated by excessive cortisol production.', 'subject score': 851, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 314596,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-          "name": "Insulin resistance",
-          "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "NCIT:C113101",
-            "UMLS:C0021655",
-            "MEDDRA:10022489",
-            "SNOMEDCT:48606007",
-            "MESH:D007333",
-            "EFO:0002614",
-            "HP:0000855",
-            "SNOMEDCT:763325000"
-          ],
-          "id": "HP:0000855",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Insulin resistance",
-            "insulin resistance",
-            "Insulin Resistance"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314596,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-              "name": "Insulin resistance",
-              "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "NCIT:C113101",
-                "UMLS:C0021655",
-                "MEDDRA:10022489",
-                "SNOMEDCT:48606007",
-                "MESH:D007333",
-                "EFO:0002614",
-                "HP:0000855",
-                "SNOMEDCT:763325000"
-              ],
-              "id": "HP:0000855",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Insulin resistance",
-                "insulin resistance",
-                "Insulin Resistance"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7849951,
-            "start": 569,
-            "end": 314596,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10692082': {'publication date': '2000 Feb', 'sentence': \"OBJECTIVES: Recent data suggest that higher plasma cortisol may be associated with hypertension and insulin resistance in otherwise healthy men, as it is in Cushing's syndrome.\", 'subject score': 840, 'object score': 1000}, 'PMID:11916927': {'publication date': '2002 Apr', 'sentence': 'In common with the GR, 11beta-HSD1 expression in myoblasts incubated with physiological concentrations of cortisol in vitro was positively associated with levels of insulin resistance (r(2) = 0.68, P < 0.001), BMI (r(2) = 0.63, P < 0.005), and blood pressure (r(2) = 0.27, P < 0.05).', 'subject score': 1000, 'object score': 1000}, 'PMID:14557475': {'publication date': '2003 Oct', 'sentence': 'Higher excretion of 5beta-reduced cortisol metabolites was independently associated with insulin resistance and hypertriglyceridemia.', 'subject score': 775, 'object score': 1000}, 'PMID:15026790': {'publication date': '2004 Mar 22', 'sentence': 'Therefore, it would appear that low leptin concentrations, increased fat oxidation and insulin resistance are associated with increased concentrations of cortisol and interleukin-6 in weight-losing patients with pancreatic cancer.', 'subject score': 1000, 'object score': 1000}, 'PMID:15142652': {'publication date': '2004', 'sentence': 'Prolonged exposure to high levels of cortisol is associated with insulin resistance, as exemplified by the metabolic syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:15256820': {'publication date': '2004', 'sentence': 'These facts point to an association between cortisol and insulin resistance in obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:16009799': {'publication date': '2005 Jul 19', 'sentence': 'CONCLUSIONS: This is the first population-based prospective study that has found a specific association between cortisol:testosterone ratio and incident ischemic heart disease, apparently mediated through the insulin resistance syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:19050176': {'publication date': '2009 Feb', 'sentence': 'Controversy exists as to whether endogenous cortisol production is associated with visceral obesity and insulin resistance in humans.', 'subject score': 851, 'object score': 1000}, 'PMID:19342030': {'publication date': '2010 Mar 01', 'sentence': 'CONCLUSION(S): Obesity and insulin resistance are associated with lower morning cortisol and DHEAS but increased cortisol and DHEA responses after glucose ingestion.', 'subject score': 851, 'object score': 1000}, 'PMID:20354921': {'publication date': '2010 Apr', 'sentence': 'However, the aetiological role of CBG and cortisol in insulin resistance is uncertain, although in males, cortisol and CBG could be subtly related to the degree of insulin resistance.', 'subject score': 1000, 'object score': 1000}, 'PMID:21475800': {'publication date': '2009', 'sentence': 'Though vasopressin responders with subclinical CS had lower autonomous cortisol secretion, they had a high prevalence of hypertension, in which insulin resistance was closely correlated with cortisol response to vasopressin.', 'subject score': 815, 'object score': 1000}, 'PMID:22283617': {'publication date': '2012 Apr', 'sentence': 'Higher levels of cortisol correlated with increased insulin resistance after the jump.', 'subject score': 1000, 'object score': 901}, 'PMID:23577182': {'publication date': '2013', 'sentence': \"10% of the elderly population has an 'adrenal incidentaloma', up to 20% of these show low-grade autonomous cortisol secretion and 60% of patients with autonomous cortisol secretion have insulin resistance.\", 'subject score': 828, 'object score': 1000}, 'PMID:24926956': {'publication date': '2014 Sep', 'sentence': 'CONTEXT: Adult-onset GH deficiency (GHD) increases visceral adiposity and the activity of the enzyme 11beta-hydroxysteroid dehydrogenase, which converts cortisone (E) to cortisol (F), both linked to insulin resistance and increased cardiovascular risk.', 'subject score': 1000, 'object score': 1000}, 'PMID:2647890': {'publication date': '1989 Mar', 'sentence': 'These results demonstrate that timed daily injections of cortisol and prolactin in specific temporal relationships can produce marked reductions in obesity, hyperinsulinaemia and insulin resistance in the Syrian hamster that persist long after the termination of treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:26934392': {'publication date': '2016 05', 'sentence': 'DESIGN: Follicular fluid and granulosa cells were collected from non-PCOS and PCOS patients with and without IR to measure cortisol concentration and the amounts of 11beta-HSD1 and -2, which were then correlated with IR status.', 'subject score': 694, 'object score': 901}, 'PMID:29223281': {'publication date': '2017 10', 'sentence': \"Higher nocturnal cortisol exposure is observed in patients with Cushing's syndrome and adrenal incidentalomas with autonomous cortisol secretion and is associated with insulin resistance, and increased cardiovascular risk and mortality.\", 'subject score': 828, 'object score': 1000}, 'PMID:29618067': {'publication date': '2018 Jul 01', 'sentence': 'Objective: To investigate whether the abundance of 11?-hydroxysteroid dehydrogenases (11?-HSDs) 1 and 2 and cortisol as well as the insulin signaling pathway are altered in PCOS endometrium and to clarify the relationship between endometrial IR and local cortisol.', 'subject score': 888, 'object score': 901}, 'PMID:31176299': {'publication date': '2019 Jun 01', 'sentence': 'CONCLUSION: In the CoLaus study of healthy adults, basal salivary cortisol was not associated with incident IR or T2DM.', 'subject score': 851, 'object score': 901}, 'PMID:31664610': {'publication date': '2019 Oct 29', 'sentence': 'The inhibition of 11beta-HSD1 has been shown to attenuate the development of type 2 diabetes mellitus, insulin resistance, metabolic syndrome and other diseases mediated by excessive cortisol production.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0021655---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8017438",
-              "object": "HP:0000855",
-              "publications": [
-                "PMID:10692082",
-                "PMID:11916927",
-                "PMID:14557475",
-                "PMID:15026790",
-                "PMID:15142652",
-                "PMID:15256820",
-                "PMID:16009799",
-                "PMID:19050176",
-                "PMID:19342030",
-                "PMID:20354921",
-                "PMID:21475800",
-                "PMID:22283617",
-                "PMID:23577182",
-                "PMID:24926956",
-                "PMID:2647890",
-                "PMID:26934392",
-                "PMID:29223281",
-                "PMID:29618067",
-                "PMID:31176299",
-                "PMID:31664610"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:10634968': {'publication date': '1999', 'sentence': 'Cortisol counteracts the insulin activation of glycogen synthase in muscle, the insulin inhibition of hepatic glucose production and the insulin inhibition of lipolysis in adipose tissue, leading to the well-established systemic insulin resistance caused by excess cortisol.', 'subject score': 853, 'object score': 840}, 'PMID:12397528': {'publication date': '2002 Oct', 'sentence': 'Evidence is presented, that by the action of 11 beta-hydroxysteroid dehydrogenase 1 (11 beta HSD1) higher intracellular cortisol concentration may be created that may be relevant to induce insulin resistance and metabolic disturbances.', 'subject score': 597, 'object score': 1000}, 'PMID:15823722': {'publication date': '2005', 'sentence': 'Chromium picolinate may favorably influence the vascular risk associated with smoking by combating cortisol-induced insulin resistance.', 'subject score': 798, 'object score': 798}, 'PMID:1605044': {'publication date': '1992 Apr', 'sentence': 'These results suggest that the insulin resistance caused by cortisol is elicited in a stepwise manner, starting with an inhibition in the glycogen synthesis system in insulin-sensitive muscles, later including all muscles as well as 2-deoxyglucose uptake.', 'subject score': 1000, 'object score': 1000}, 'PMID:16772320': {'publication date': '2006 Nov', 'sentence': 'Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:16893715': {'publication date': '2006 Aug 15', 'sentence': 'Although initial studies in transgenic mice and humans are encouraging, more data are required to conclusively prove the hypothesis that the adipose-tissue-specific overexpression of HSD1 and the resultant increase in tissue-specific cortisol concentrations result in human obesity, insulin resistance, high blood pressure, and metabolic syndrome.', 'subject score': 750, 'object score': 1000}, 'PMID:1773700': {'publication date': '1991 Dec', 'sentence': 'Cortisol and testosterone have \"permissive\" effect on adipose lipolysis and therefore amplify lipolytic stimulation; FFA, cortisol, and testosterone thus have powerful combined effects, resulting in insulin resistance and increased hepatic gluconeogenesis.', 'subject score': 1000, 'object score': 1000}, 'PMID:18789704': {'publication date': '2008 Oct 01', 'sentence': 'Excess 11beta-HSD1 or cortisol leads to insulin resistance and metabolic syndrome in animal models and in humans.', 'subject score': 1000, 'object score': 1000}, 'PMID:19131173': {'publication date': '2009 Jun', 'sentence': 'In conclusion olanzapine OST and ODT equally elevated the prolactin concentration and significantly shifted its acrophase, thus dissociating PRL and cortisol, while both formulations induced similar insulin resistance as evidenced by the elevated HOMA-IR.', 'subject score': 1000, 'object score': 865}, 'PMID:21510838': {'publication date': '2011', 'sentence': 'Excess cortisol or 11beta-HSD1 leads to insulin resistance and metabolic syndrome.', 'subject score': 853, 'object score': 1000}, 'PMID:23389468': {'publication date': '2014 Apr', 'sentence': 'Excess cortisol and GH induce insulin resistance, a central feature of type 2 diabetes (T2D).', 'subject score': 853, 'object score': 1000}, 'PMID:23426618': {'publication date': '2013 Apr', 'sentence': 'RESULTS: Hydrocortisone induced systemic insulin resistance but failed to cause sc adipose tissue insulin resistance as measured by suppression of adipose tissue lipolysis and enhanced insulin-stimulated pyruvate generation.', 'subject score': 1000, 'object score': 901}, 'PMID:23577182': {'publication date': '2013', 'sentence': 'Cortisol excess is known to cause insulin resistance, an independent cardiovascular risk marker, however in patients with adrenal incidentalomas it is unknown whether their insulin resistance is secondary to the excess cortisol and therefore potentially reversible.', 'subject score': 853, 'object score': 1000}, 'PMID:24967820': {'publication date': '2014', 'sentence': 'In contrast, both groups of mice lacking functional incretin receptors displayed substantially impaired islet adaptations to insulin resistance induced by hydrocortisone, including marked curtailment of expansion of islet area, beta cell mass and islet number.', 'subject score': 1000, 'object score': 1000}, 'PMID:27465830': {'publication date': '2016 11 15', 'sentence': 'In contrast, hydrocortisone-induced insulin resistance increased islet number (p < 0.01) and beta-cell mass (p < 0.001).', 'subject score': 861, 'object score': 861}, 'PMID:29225114': {'publication date': '2018 May - Jun', 'sentence': 'Furthermore, fructose in the brain, either from fructose uptake via the blood brain barrier or endogenous formation from glucose via the polyol pathway stimulates an increased release of cortisol causing hepatic gluconeogenesis leading to overall insulin resistance and further body fattening.', 'subject score': 1000, 'object score': 901}, 'PMID:32133575': {'publication date': '2020 Mar 04', 'sentence': \"Prolonged excess cortisol leads to visceral adiposity, insulin resistance, hyperglycemia, memory dysfunction, cognitive impairment, and more severe Alzheimer's disease phenotypes.\", 'subject score': 851, 'object score': 1000}, 'PMID:33419065': {'publication date': '2021 Jan 06', 'sentence': 'During sleep at night, the gradual development of insulin resistance, due to growth hormone and cortisol surges, ensures that blood glucose levels will be maintained within normal levels by: (a) switching from glucose to NEFA oxidation in muscle; (b) modulating glucose production from the liver/kidneys.', 'subject score': 694, 'object score': 1000}, 'PMID:3517554': {'publication date': '1986 May', 'sentence': \"The data demonstrate that acute elevation of plasma cortisol to levels near those observed in severe stress results in insulin resistance of peripheral and hepatic glucose metabolism but in unimpaired insulin effects on plasma FFA and branched chain amino acids, suggesting that cortisol's lipolytic and proteolytic effects are antagonized by elevated plasma insulin levels.\", 'subject score': 888, 'object score': 1000}, 'PMID:6348064': {'publication date': '1983 Sep', 'sentence': 'These results, particularly the marked decrease in MGD, a typical feature of postreceptor defects, indicate that cortisol-induced insulin resistance in man is due to an impairment of peripheral insulin action located beyond the hormone-receptor binding step.', 'subject score': 861, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 314596,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-          "name": "Insulin resistance",
-          "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "NCIT:C113101",
-            "UMLS:C0021655",
-            "MEDDRA:10022489",
-            "SNOMEDCT:48606007",
-            "MESH:D007333",
-            "EFO:0002614",
-            "HP:0000855",
-            "SNOMEDCT:763325000"
-          ],
-          "id": "HP:0000855",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Insulin resistance",
-            "insulin resistance",
-            "Insulin Resistance"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314596,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-              "name": "Insulin resistance",
-              "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "NCIT:C113101",
-                "UMLS:C0021655",
-                "MEDDRA:10022489",
-                "SNOMEDCT:48606007",
-                "MESH:D007333",
-                "EFO:0002614",
-                "HP:0000855",
-                "SNOMEDCT:763325000"
-              ],
-              "id": "HP:0000855",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Insulin resistance",
-                "insulin resistance",
-                "Insulin Resistance"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7764698,
-            "start": 569,
-            "end": 314596,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10634968': {'publication date': '1999', 'sentence': 'Cortisol counteracts the insulin activation of glycogen synthase in muscle, the insulin inhibition of hepatic glucose production and the insulin inhibition of lipolysis in adipose tissue, leading to the well-established systemic insulin resistance caused by excess cortisol.', 'subject score': 853, 'object score': 840}, 'PMID:12397528': {'publication date': '2002 Oct', 'sentence': 'Evidence is presented, that by the action of 11 beta-hydroxysteroid dehydrogenase 1 (11 beta HSD1) higher intracellular cortisol concentration may be created that may be relevant to induce insulin resistance and metabolic disturbances.', 'subject score': 597, 'object score': 1000}, 'PMID:15823722': {'publication date': '2005', 'sentence': 'Chromium picolinate may favorably influence the vascular risk associated with smoking by combating cortisol-induced insulin resistance.', 'subject score': 798, 'object score': 798}, 'PMID:1605044': {'publication date': '1992 Apr', 'sentence': 'These results suggest that the insulin resistance caused by cortisol is elicited in a stepwise manner, starting with an inhibition in the glycogen synthesis system in insulin-sensitive muscles, later including all muscles as well as 2-deoxyglucose uptake.', 'subject score': 1000, 'object score': 1000}, 'PMID:16772320': {'publication date': '2006 Nov', 'sentence': 'Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:16893715': {'publication date': '2006 Aug 15', 'sentence': 'Although initial studies in transgenic mice and humans are encouraging, more data are required to conclusively prove the hypothesis that the adipose-tissue-specific overexpression of HSD1 and the resultant increase in tissue-specific cortisol concentrations result in human obesity, insulin resistance, high blood pressure, and metabolic syndrome.', 'subject score': 750, 'object score': 1000}, 'PMID:1773700': {'publication date': '1991 Dec', 'sentence': 'Cortisol and testosterone have \"permissive\" effect on adipose lipolysis and therefore amplify lipolytic stimulation; FFA, cortisol, and testosterone thus have powerful combined effects, resulting in insulin resistance and increased hepatic gluconeogenesis.', 'subject score': 1000, 'object score': 1000}, 'PMID:18789704': {'publication date': '2008 Oct 01', 'sentence': 'Excess 11beta-HSD1 or cortisol leads to insulin resistance and metabolic syndrome in animal models and in humans.', 'subject score': 1000, 'object score': 1000}, 'PMID:19131173': {'publication date': '2009 Jun', 'sentence': 'In conclusion olanzapine OST and ODT equally elevated the prolactin concentration and significantly shifted its acrophase, thus dissociating PRL and cortisol, while both formulations induced similar insulin resistance as evidenced by the elevated HOMA-IR.', 'subject score': 1000, 'object score': 865}, 'PMID:21510838': {'publication date': '2011', 'sentence': 'Excess cortisol or 11beta-HSD1 leads to insulin resistance and metabolic syndrome.', 'subject score': 853, 'object score': 1000}, 'PMID:23389468': {'publication date': '2014 Apr', 'sentence': 'Excess cortisol and GH induce insulin resistance, a central feature of type 2 diabetes (T2D).', 'subject score': 853, 'object score': 1000}, 'PMID:23426618': {'publication date': '2013 Apr', 'sentence': 'RESULTS: Hydrocortisone induced systemic insulin resistance but failed to cause sc adipose tissue insulin resistance as measured by suppression of adipose tissue lipolysis and enhanced insulin-stimulated pyruvate generation.', 'subject score': 1000, 'object score': 901}, 'PMID:23577182': {'publication date': '2013', 'sentence': 'Cortisol excess is known to cause insulin resistance, an independent cardiovascular risk marker, however in patients with adrenal incidentalomas it is unknown whether their insulin resistance is secondary to the excess cortisol and therefore potentially reversible.', 'subject score': 853, 'object score': 1000}, 'PMID:24967820': {'publication date': '2014', 'sentence': 'In contrast, both groups of mice lacking functional incretin receptors displayed substantially impaired islet adaptations to insulin resistance induced by hydrocortisone, including marked curtailment of expansion of islet area, beta cell mass and islet number.', 'subject score': 1000, 'object score': 1000}, 'PMID:27465830': {'publication date': '2016 11 15', 'sentence': 'In contrast, hydrocortisone-induced insulin resistance increased islet number (p < 0.01) and beta-cell mass (p < 0.001).', 'subject score': 861, 'object score': 861}, 'PMID:29225114': {'publication date': '2018 May - Jun', 'sentence': 'Furthermore, fructose in the brain, either from fructose uptake via the blood brain barrier or endogenous formation from glucose via the polyol pathway stimulates an increased release of cortisol causing hepatic gluconeogenesis leading to overall insulin resistance and further body fattening.', 'subject score': 1000, 'object score': 901}, 'PMID:32133575': {'publication date': '2020 Mar 04', 'sentence': \"Prolonged excess cortisol leads to visceral adiposity, insulin resistance, hyperglycemia, memory dysfunction, cognitive impairment, and more severe Alzheimer's disease phenotypes.\", 'subject score': 851, 'object score': 1000}, 'PMID:33419065': {'publication date': '2021 Jan 06', 'sentence': 'During sleep at night, the gradual development of insulin resistance, due to growth hormone and cortisol surges, ensures that blood glucose levels will be maintained within normal levels by: (a) switching from glucose to NEFA oxidation in muscle; (b) modulating glucose production from the liver/kidneys.', 'subject score': 694, 'object score': 1000}, 'PMID:3517554': {'publication date': '1986 May', 'sentence': \"The data demonstrate that acute elevation of plasma cortisol to levels near those observed in severe stress results in insulin resistance of peripheral and hepatic glucose metabolism but in unimpaired insulin effects on plasma FFA and branched chain amino acids, suggesting that cortisol's lipolytic and proteolytic effects are antagonized by elevated plasma insulin levels.\", 'subject score': 888, 'object score': 1000}, 'PMID:6348064': {'publication date': '1983 Sep', 'sentence': 'These results, particularly the marked decrease in MGD, a typical feature of postreceptor defects, indicate that cortisol-induced insulin resistance in man is due to an impairment of peripheral insulin action located beyond the hormone-receptor binding step.', 'subject score': 861, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0021655---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7929803",
-              "object": "HP:0000855",
-              "publications": [
-                "PMID:10634968",
-                "PMID:12397528",
-                "PMID:15823722",
-                "PMID:1605044",
-                "PMID:16772320",
-                "PMID:16893715",
-                "PMID:1773700",
-                "PMID:18789704",
-                "PMID:19131173",
-                "PMID:21510838",
-                "PMID:23389468",
-                "PMID:23426618",
-                "PMID:23577182",
-                "PMID:24967820",
-                "PMID:27465830",
-                "PMID:29225114",
-                "PMID:32133575",
-                "PMID:33419065",
-                "PMID:3517554",
-                "PMID:6348064"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:2043222': {'publication date': '1991', 'sentence': 'Adrenaline induces the early posthypoglycaemic insulin resistance, whereas cortisol and growth hormone are important for the insulin resistance that is observed later following hypoglycaemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:32670417': {'publication date': '2020', 'sentence': 'In the subjects exposed to frequent/chronic psychological stressors, cortisol and oxidative stress marker affected IR incidence, being statistically attenuated, though, following adjustment for metabolic syndrome, or its components.', 'subject score': 1000, 'object score': 901}, 'PMID:8708543': {'publication date': '1996 May', 'sentence': 'The results of this study in elderly subjects suggest that in women cortisol may be implicated in the age-associated insulin resistance.', 'subject score': 888, 'object score': 824}}",
-    "p2": {
-      "start": {
-        "identity": 314596,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-          "name": "Insulin resistance",
-          "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "NCIT:C113101",
-            "UMLS:C0021655",
-            "MEDDRA:10022489",
-            "SNOMEDCT:48606007",
-            "MESH:D007333",
-            "EFO:0002614",
-            "HP:0000855",
-            "SNOMEDCT:763325000"
-          ],
-          "id": "HP:0000855",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Insulin resistance",
-            "insulin resistance",
-            "Insulin Resistance"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314596,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-              "name": "Insulin resistance",
-              "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "NCIT:C113101",
-                "UMLS:C0021655",
-                "MEDDRA:10022489",
-                "SNOMEDCT:48606007",
-                "MESH:D007333",
-                "EFO:0002614",
-                "HP:0000855",
-                "SNOMEDCT:763325000"
-              ],
-              "id": "HP:0000855",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Insulin resistance",
-                "insulin resistance",
-                "Insulin Resistance"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14654843,
-            "start": 569,
-            "end": 314596,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2043222': {'publication date': '1991', 'sentence': 'Adrenaline induces the early posthypoglycaemic insulin resistance, whereas cortisol and growth hormone are important for the insulin resistance that is observed later following hypoglycaemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:32670417': {'publication date': '2020', 'sentence': 'In the subjects exposed to frequent/chronic psychological stressors, cortisol and oxidative stress marker affected IR incidence, being statistically attenuated, though, following adjustment for metabolic syndrome, or its components.', 'subject score': 1000, 'object score': 901}, 'PMID:8708543': {'publication date': '1996 May', 'sentence': 'The results of this study in elderly subjects suggest that in women cortisol may be implicated in the age-associated insulin resistance.', 'subject score': 888, 'object score': 824}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0021655---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14970164",
-              "object": "HP:0000855",
-              "publications": [
-                "PMID:2043222",
-                "PMID:32670417",
-                "PMID:8708543"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:10664531': {'publication date': '2000 Feb', 'sentence': 'ii) Reduction of cortisone to cortisol in the liver may increase insulin resistance in type 2 diabetes mellitus, and inhibition of the enzyme may lead to a decrease in gluconeogenesis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15257241': {'publication date': '2004 Jun 05', 'sentence': 'INTRA-CELL CORTISOL: Attention is also focused on the potential implication of cortisol in the genesis of metabolic syndrome, because cortisol is a potent antagonist of the effect of insulin and its presence in excess enhances visceral obesity and insulin resistance.', 'subject score': 1000, 'object score': 1000}, 'PMID:21249616': {'publication date': '2011 Apr', 'sentence': 'In obesity, adipose tissue 11betaHSD1 is upregulated, leading to the generation of higher tissue levels of cortisol, which may increase insulin resistance.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 314596,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-          "name": "Insulin resistance",
-          "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "NCIT:C113101",
-            "UMLS:C0021655",
-            "MEDDRA:10022489",
-            "SNOMEDCT:48606007",
-            "MESH:D007333",
-            "EFO:0002614",
-            "HP:0000855",
-            "SNOMEDCT:763325000"
-          ],
-          "id": "HP:0000855",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Insulin resistance",
-            "insulin resistance",
-            "Insulin Resistance"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314596,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-              "name": "Insulin resistance",
-              "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "NCIT:C113101",
-                "UMLS:C0021655",
-                "MEDDRA:10022489",
-                "SNOMEDCT:48606007",
-                "MESH:D007333",
-                "EFO:0002614",
-                "HP:0000855",
-                "SNOMEDCT:763325000"
-              ],
-              "id": "HP:0000855",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Insulin resistance",
-                "insulin resistance",
-                "Insulin Resistance"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7807812,
-            "start": 569,
-            "end": 314596,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10664531': {'publication date': '2000 Feb', 'sentence': 'ii) Reduction of cortisone to cortisol in the liver may increase insulin resistance in type 2 diabetes mellitus, and inhibition of the enzyme may lead to a decrease in gluconeogenesis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15257241': {'publication date': '2004 Jun 05', 'sentence': 'INTRA-CELL CORTISOL: Attention is also focused on the potential implication of cortisol in the genesis of metabolic syndrome, because cortisol is a potent antagonist of the effect of insulin and its presence in excess enhances visceral obesity and insulin resistance.', 'subject score': 1000, 'object score': 1000}, 'PMID:21249616': {'publication date': '2011 Apr', 'sentence': 'In obesity, adipose tissue 11betaHSD1 is upregulated, leading to the generation of higher tissue levels of cortisol, which may increase insulin resistance.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0021655---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7974249",
-              "object": "HP:0000855",
-              "publications": [
-                "PMID:10664531",
-                "PMID:15257241",
-                "PMID:21249616"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:18402944': {'publication date': '2009 Mar', 'sentence': 'OBJECTIVE: To investigate possible effects of insulin-sensitizing treatment on cortisol metabolism in insulin-resistant patients with polycystic ovary syndrome (PCOS).', 'subject score': 888, 'object score': 877}, 'PMID:34043794': {'publication date': '2021 May 27', 'sentence': 'Clamping cortisol and testosterone alleviated the development of overall insulin resistance (p=0.046) and hyperinsulinemia (p=0.014) by 50%.', 'subject score': 888, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 314596,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-          "name": "Insulin resistance",
-          "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "NCIT:C113101",
-            "UMLS:C0021655",
-            "MEDDRA:10022489",
-            "SNOMEDCT:48606007",
-            "MESH:D007333",
-            "EFO:0002614",
-            "HP:0000855",
-            "SNOMEDCT:763325000"
-          ],
-          "id": "HP:0000855",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Insulin resistance",
-            "insulin resistance",
-            "Insulin Resistance"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314596,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-              "name": "Insulin resistance",
-              "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "NCIT:C113101",
-                "UMLS:C0021655",
-                "MEDDRA:10022489",
-                "SNOMEDCT:48606007",
-                "MESH:D007333",
-                "EFO:0002614",
-                "HP:0000855",
-                "SNOMEDCT:763325000"
-              ],
-              "id": "HP:0000855",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Insulin resistance",
-                "insulin resistance",
-                "Insulin Resistance"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13403715,
-            "start": 569,
-            "end": 314596,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18402944': {'publication date': '2009 Mar', 'sentence': 'OBJECTIVE: To investigate possible effects of insulin-sensitizing treatment on cortisol metabolism in insulin-resistant patients with polycystic ovary syndrome (PCOS).', 'subject score': 888, 'object score': 877}, 'PMID:34043794': {'publication date': '2021 May 27', 'sentence': 'Clamping cortisol and testosterone alleviated the development of overall insulin resistance (p=0.046) and hyperinsulinemia (p=0.014) by 50%.', 'subject score': 888, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0021655---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13691671",
-              "object": "HP:0000855",
-              "publications": [
-                "PMID:18402944",
-                "PMID:34043794"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:produces",
-    "r2.publications_info": "{'PMID:19050176': {'publication date': '2009 Feb', 'sentence': 'Enhanced cortisol production rates, free cortisol, and 11beta-HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss.', 'subject score': 1000, 'object score': 764}, 'PMID:3328721': {'publication date': '1987 Nov', 'sentence': 'This prolonged insulin resistance is largely related to release of growth hormone and cortisol.', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 314596,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-          "name": "Insulin resistance",
-          "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "NCIT:C113101",
-            "UMLS:C0021655",
-            "MEDDRA:10022489",
-            "SNOMEDCT:48606007",
-            "MESH:D007333",
-            "EFO:0002614",
-            "HP:0000855",
-            "SNOMEDCT:763325000"
-          ],
-          "id": "HP:0000855",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Insulin resistance",
-            "insulin resistance",
-            "Insulin Resistance"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314596,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-              "name": "Insulin resistance",
-              "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "NCIT:C113101",
-                "UMLS:C0021655",
-                "MEDDRA:10022489",
-                "SNOMEDCT:48606007",
-                "MESH:D007333",
-                "EFO:0002614",
-                "HP:0000855",
-                "SNOMEDCT:763325000"
-              ],
-              "id": "HP:0000855",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Insulin resistance",
-                "insulin resistance",
-                "Insulin Resistance"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13806069,
-            "start": 314596,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19050176': {'publication date': '2009 Feb', 'sentence': 'Enhanced cortisol production rates, free cortisol, and 11beta-HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss.', 'subject score': 1000, 'object score': 764}, 'PMID:3328721': {'publication date': '1987 Nov', 'sentence': 'This prolonged insulin resistance is largely related to release of growth hormone and cortisol.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0021655---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "HP:0000855",
-              "id": "14100936",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:19050176",
-                "PMID:3328721"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:16334949': {'publication date': '2005 Nov', 'sentence': 'Assuming a single dose of hydrocortisone improves sensitivity of peripheral tissues to insulin, it may be an interesting candidate for use in reducing insulin resistance in peripheral tissues of horses with several disease states.', 'subject score': 1000, 'object score': 884}}",
-    "p2": {
-      "start": {
-        "identity": 314596,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-          "name": "Insulin resistance",
-          "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "NCIT:C113101",
-            "UMLS:C0021655",
-            "MEDDRA:10022489",
-            "SNOMEDCT:48606007",
-            "MESH:D007333",
-            "EFO:0002614",
-            "HP:0000855",
-            "SNOMEDCT:763325000"
-          ],
-          "id": "HP:0000855",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Insulin resistance",
-            "insulin resistance",
-            "Insulin Resistance"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314596,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-              "name": "Insulin resistance",
-              "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "NCIT:C113101",
-                "UMLS:C0021655",
-                "MEDDRA:10022489",
-                "SNOMEDCT:48606007",
-                "MESH:D007333",
-                "EFO:0002614",
-                "HP:0000855",
-                "SNOMEDCT:763325000"
-              ],
-              "id": "HP:0000855",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Insulin resistance",
-                "insulin resistance",
-                "Insulin Resistance"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11927457,
-            "start": 569,
-            "end": 314596,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16334949': {'publication date': '2005 Nov', 'sentence': 'Assuming a single dose of hydrocortisone improves sensitivity of peripheral tissues to insulin, it may be an interesting candidate for use in reducing insulin resistance in peripheral tissues of horses with several disease states.', 'subject score': 1000, 'object score': 884}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0021655---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "12187318",
-              "object": "HP:0000855",
-              "publications": [
-                "PMID:16334949"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:10682389': {'publication date': '2000 Jan', 'sentence': 'In conclusion, the data presented here suggest that cortisol can contribute to insulin resistance in ponies with hyperlipoproteinaemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:15607573': {'publication date': '2005', 'sentence': 'Since cortisol promotes development of visceral obesity, and has a direct negative impact on insulin function throughout the body, even a modest sustained up-regulation of cortisol production may have the potential to increase risk for insulin resistance syndrome and type 2 diabetes.', 'subject score': 888, 'object score': 1000}, 'PMID:17295610': {'publication date': '2007 Jul', 'sentence': 'We hypothesize that cortisol is associated with impaired microvascular function and that this contributes to cortisol-associated high blood pressure and insulin resistance.', 'subject score': 1000, 'object score': 1000}, 'PMID:19087258': {'publication date': '2008', 'sentence': 'Model assessment identified cortisol as the best predictor of insulin resistance, followed by IL6, leptin and adiponectin.', 'subject score': 1000, 'object score': 1000}, 'PMID:23926399': {'publication date': '2011 Oct', 'sentence': 'In type 1 diabetes, GH, glucagon and cortisol hypersecretion may contribute to insulin resistance, but the mechanism remains unclear.', 'subject score': 694, 'object score': 1000}, 'PMID:25658017': {'publication date': '2015 Apr', 'sentence': 'Elevated cortisol and metanephrine levels may contribute to insulin resistance by increasing lipolysis and NEFA levels.', 'subject score': 888, 'object score': 1000}, 'PMID:26830350': {'publication date': '2016 Jul 05', 'sentence': 'After adjusting for potential confounders, cortisol was an independent positive predictor for HOMA-IR (P < 0.05).', 'subject score': 1000, 'object score': 742}, 'PMID:26934392': {'publication date': '2016 05', 'sentence': 'The consequent excessive cortisol might contribute to IR of the granulosa cells in PCOS patients by attenuating Akt phosphorylation via induction of phosphatase and tensin homolog deleted on chromosome 10 expression, which might be further exacerbated by the induction of 11beta-HSD1.', 'subject score': 790, 'object score': 1000}, 'PMID:31176299': {'publication date': '2019 Jun 01', 'sentence': 'We aimed to evaluate if basal salivary cortisol may predict occurrence of new insulin resistance (IR) or T2DM.', 'subject score': 851, 'object score': 901}, 'PMID:31902257': {'publication date': '2020 Jan 06', 'sentence': 'The upregulation of 11beta-HSD1 in ovarian granulosa cells by cortisol and interleukin-1beta in polycystic ovary syndrome.Our previous study have demonstrated the elevated cortisol concentration in the follicular fluid (FF) contributed to the insulin resistance of the granulosa cells (GCs) in PCOS, but the complicated cortisol generation mechanisms are still unknown.', 'subject score': 851, 'object score': 1000}, 'PMID:8394500': {'publication date': '1993 May', 'sentence': 'There is a diminished uptake of glucose by the tissues, a condition also found in parturient paresis of dairy cows when elevated hydrocortisone promotes insulin resistance and hyperglycaemia.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 314596,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-          "name": "Insulin resistance",
-          "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "NCIT:C113101",
-            "UMLS:C0021655",
-            "MEDDRA:10022489",
-            "SNOMEDCT:48606007",
-            "MESH:D007333",
-            "EFO:0002614",
-            "HP:0000855",
-            "SNOMEDCT:763325000"
-          ],
-          "id": "HP:0000855",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Insulin resistance",
-            "insulin resistance",
-            "Insulin Resistance"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314596,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000855",
-              "name": "Insulin resistance",
-              "description": "Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels. [HPO:probinson]; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; Increased resistance towards insulin, that is, diminished effectiveness of insulin in reducing blood glucose levels.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "NCIT:C113101",
-                "UMLS:C0021655",
-                "MEDDRA:10022489",
-                "SNOMEDCT:48606007",
-                "MESH:D007333",
-                "EFO:0002614",
-                "HP:0000855",
-                "SNOMEDCT:763325000"
-              ],
-              "id": "HP:0000855",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Insulin resistance",
-                "insulin resistance",
-                "Insulin Resistance"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7834978,
-            "start": 569,
-            "end": 314596,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10682389': {'publication date': '2000 Jan', 'sentence': 'In conclusion, the data presented here suggest that cortisol can contribute to insulin resistance in ponies with hyperlipoproteinaemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:15607573': {'publication date': '2005', 'sentence': 'Since cortisol promotes development of visceral obesity, and has a direct negative impact on insulin function throughout the body, even a modest sustained up-regulation of cortisol production may have the potential to increase risk for insulin resistance syndrome and type 2 diabetes.', 'subject score': 888, 'object score': 1000}, 'PMID:17295610': {'publication date': '2007 Jul', 'sentence': 'We hypothesize that cortisol is associated with impaired microvascular function and that this contributes to cortisol-associated high blood pressure and insulin resistance.', 'subject score': 1000, 'object score': 1000}, 'PMID:19087258': {'publication date': '2008', 'sentence': 'Model assessment identified cortisol as the best predictor of insulin resistance, followed by IL6, leptin and adiponectin.', 'subject score': 1000, 'object score': 1000}, 'PMID:23926399': {'publication date': '2011 Oct', 'sentence': 'In type 1 diabetes, GH, glucagon and cortisol hypersecretion may contribute to insulin resistance, but the mechanism remains unclear.', 'subject score': 694, 'object score': 1000}, 'PMID:25658017': {'publication date': '2015 Apr', 'sentence': 'Elevated cortisol and metanephrine levels may contribute to insulin resistance by increasing lipolysis and NEFA levels.', 'subject score': 888, 'object score': 1000}, 'PMID:26830350': {'publication date': '2016 Jul 05', 'sentence': 'After adjusting for potential confounders, cortisol was an independent positive predictor for HOMA-IR (P < 0.05).', 'subject score': 1000, 'object score': 742}, 'PMID:26934392': {'publication date': '2016 05', 'sentence': 'The consequent excessive cortisol might contribute to IR of the granulosa cells in PCOS patients by attenuating Akt phosphorylation via induction of phosphatase and tensin homolog deleted on chromosome 10 expression, which might be further exacerbated by the induction of 11beta-HSD1.', 'subject score': 790, 'object score': 1000}, 'PMID:31176299': {'publication date': '2019 Jun 01', 'sentence': 'We aimed to evaluate if basal salivary cortisol may predict occurrence of new insulin resistance (IR) or T2DM.', 'subject score': 851, 'object score': 901}, 'PMID:31902257': {'publication date': '2020 Jan 06', 'sentence': 'The upregulation of 11beta-HSD1 in ovarian granulosa cells by cortisol and interleukin-1beta in polycystic ovary syndrome.Our previous study have demonstrated the elevated cortisol concentration in the follicular fluid (FF) contributed to the insulin resistance of the granulosa cells (GCs) in PCOS, but the complicated cortisol generation mechanisms are still unknown.', 'subject score': 851, 'object score': 1000}, 'PMID:8394500': {'publication date': '1993 May', 'sentence': 'There is a diminished uptake of glucose by the tissues, a condition also found in parturient paresis of dairy cows when elevated hydrocortisone promotes insulin resistance and hyperglycaemia.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:predisposes---None---None---None---UMLS:C0021655---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8002300",
-              "object": "HP:0000855",
-              "publications": [
-                "PMID:10682389",
-                "PMID:15607573",
-                "PMID:17295610",
-                "PMID:19087258",
-                "PMID:23926399",
-                "PMID:25658017",
-                "PMID:26830350",
-                "PMID:26934392",
-                "PMID:31176299",
-                "PMID:31902257",
-                "PMID:8394500"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:8522825': {'publication date': '1995 Jul', 'sentence': 'Cortisol deficiency is common in late stage HIV disease, but symptoms of fatigue and postural hypotension, as well as biochemical findings, are poor predictors of cortisol deficiency.', 'subject score': 888, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 517695,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005109",
-          "name": "HIV infectious disease",
-          "description": "A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.",
-          "equivalent_curies": [
-            "UMLS:C0019693",
-            "ICD9:042-042.99",
-            "SNOMEDCT:86406008",
-            "NCIT:C3108",
-            "MEDDRA:10020161",
-            "PDQ:CDR0000585059",
-            "MEDDRA:10020443",
-            "MEDDRA:10020160",
-            "MONDO:0005109",
-            "EFO:0000764",
-            "MEDDRA:10020172",
-            "MESH:D015658",
-            "DOID:526"
-          ],
-          "id": "MONDO:0005109",
-          "category": "biolink:Disease",
-          "all_names": [
-            "human immunodeficiency virus infectious disease",
-            "HIV infection",
-            "HIV infectious disease",
-            "HIV Infection",
-            "Human immunodeficiency virus [hiv] infection",
-            "HIV Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/hiv",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000602.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517695,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005109",
-              "name": "HIV infectious disease",
-              "description": "A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.",
-              "equivalent_curies": [
-                "UMLS:C0019693",
-                "ICD9:042-042.99",
-                "SNOMEDCT:86406008",
-                "NCIT:C3108",
-                "MEDDRA:10020161",
-                "PDQ:CDR0000585059",
-                "MEDDRA:10020443",
-                "MEDDRA:10020160",
-                "MONDO:0005109",
-                "EFO:0000764",
-                "MEDDRA:10020172",
-                "MESH:D015658",
-                "DOID:526"
-              ],
-              "id": "MONDO:0005109",
-              "category": "biolink:Disease",
-              "all_names": [
-                "human immunodeficiency virus infectious disease",
-                "HIV infection",
-                "HIV infectious disease",
-                "HIV Infection",
-                "Human immunodeficiency virus [hiv] infection",
-                "HIV Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/hiv",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000602.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26552751,
-            "start": 569,
-            "end": 517695,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8522825': {'publication date': '1995 Jul', 'sentence': 'Cortisol deficiency is common in late stage HIV disease, but symptoms of fatigue and postural hypotension, as well as biochemical findings, are poor predictors of cortisol deficiency.', 'subject score': 888, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0019693---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "27027571",
-              "object": "MONDO:0005109",
-              "publications": [
-                "PMID:8522825"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:12627047': {'publication date': '2003 Jan', 'sentence': 'The effects of stressful life events, coping, and cortisol on HIV infection.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 517695,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005109",
-          "name": "HIV infectious disease",
-          "description": "A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.",
-          "equivalent_curies": [
-            "UMLS:C0019693",
-            "ICD9:042-042.99",
-            "SNOMEDCT:86406008",
-            "NCIT:C3108",
-            "MEDDRA:10020161",
-            "PDQ:CDR0000585059",
-            "MEDDRA:10020443",
-            "MEDDRA:10020160",
-            "MONDO:0005109",
-            "EFO:0000764",
-            "MEDDRA:10020172",
-            "MESH:D015658",
-            "DOID:526"
-          ],
-          "id": "MONDO:0005109",
-          "category": "biolink:Disease",
-          "all_names": [
-            "human immunodeficiency virus infectious disease",
-            "HIV infection",
-            "HIV infectious disease",
-            "HIV Infection",
-            "Human immunodeficiency virus [hiv] infection",
-            "HIV Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/hiv",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000602.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517695,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005109",
-              "name": "HIV infectious disease",
-              "description": "A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.",
-              "equivalent_curies": [
-                "UMLS:C0019693",
-                "ICD9:042-042.99",
-                "SNOMEDCT:86406008",
-                "NCIT:C3108",
-                "MEDDRA:10020161",
-                "PDQ:CDR0000585059",
-                "MEDDRA:10020443",
-                "MEDDRA:10020160",
-                "MONDO:0005109",
-                "EFO:0000764",
-                "MEDDRA:10020172",
-                "MESH:D015658",
-                "DOID:526"
-              ],
-              "id": "MONDO:0005109",
-              "category": "biolink:Disease",
-              "all_names": [
-                "human immunodeficiency virus infectious disease",
-                "HIV infection",
-                "HIV infectious disease",
-                "HIV Infection",
-                "Human immunodeficiency virus [hiv] infection",
-                "HIV Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/hiv",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000602.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9851332,
-            "start": 569,
-            "end": 517695,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12627047': {'publication date': '2003 Jan', 'sentence': 'The effects of stressful life events, coping, and cortisol on HIV infection.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0019693---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10074536",
-              "object": "MONDO:0005109",
-              "publications": [
-                "PMID:12627047"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:18778540': {'publication date': '2008', 'sentence': 'Except in one patient with HIV infection, all the signs and symptoms improved after antituberculous and hydrocortisone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:7620208': {'publication date': '1995 Mar', 'sentence': 'The synergistic inhibitory effect of cortisol- and HIV-derived soluble products in patients with HIV infections are consistent with a model that proposes that stress and circulating HIV-1-derived products may be involved in the progression of HIV infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:8543334': {'publication date': '1995 Aug', 'sentence': 'The selective inhibitory effects of cortisol and ACTH in patients with HIV infections are consistent with a model which proposes that stress related neurohormones and/or neuropeptides may be involved in the progression of HIV infections.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 517695,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005109",
-          "name": "HIV infectious disease",
-          "description": "A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.",
-          "equivalent_curies": [
-            "UMLS:C0019693",
-            "ICD9:042-042.99",
-            "SNOMEDCT:86406008",
-            "NCIT:C3108",
-            "MEDDRA:10020161",
-            "PDQ:CDR0000585059",
-            "MEDDRA:10020443",
-            "MEDDRA:10020160",
-            "MONDO:0005109",
-            "EFO:0000764",
-            "MEDDRA:10020172",
-            "MESH:D015658",
-            "DOID:526"
-          ],
-          "id": "MONDO:0005109",
-          "category": "biolink:Disease",
-          "all_names": [
-            "human immunodeficiency virus infectious disease",
-            "HIV infection",
-            "HIV infectious disease",
-            "HIV Infection",
-            "Human immunodeficiency virus [hiv] infection",
-            "HIV Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/hiv",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000602.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517695,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005109",
-              "name": "HIV infectious disease",
-              "description": "A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.",
-              "equivalent_curies": [
-                "UMLS:C0019693",
-                "ICD9:042-042.99",
-                "SNOMEDCT:86406008",
-                "NCIT:C3108",
-                "MEDDRA:10020161",
-                "PDQ:CDR0000585059",
-                "MEDDRA:10020443",
-                "MEDDRA:10020160",
-                "MONDO:0005109",
-                "EFO:0000764",
-                "MEDDRA:10020172",
-                "MESH:D015658",
-                "DOID:526"
-              ],
-              "id": "MONDO:0005109",
-              "category": "biolink:Disease",
-              "all_names": [
-                "human immunodeficiency virus infectious disease",
-                "HIV infection",
-                "HIV infectious disease",
-                "HIV Infection",
-                "Human immunodeficiency virus [hiv] infection",
-                "HIV Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/hiv",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000602.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13658519,
-            "start": 569,
-            "end": 517695,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18778540': {'publication date': '2008', 'sentence': 'Except in one patient with HIV infection, all the signs and symptoms improved after antituberculous and hydrocortisone treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:7620208': {'publication date': '1995 Mar', 'sentence': 'The synergistic inhibitory effect of cortisol- and HIV-derived soluble products in patients with HIV infections are consistent with a model that proposes that stress and circulating HIV-1-derived products may be involved in the progression of HIV infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:8543334': {'publication date': '1995 Aug', 'sentence': 'The selective inhibitory effects of cortisol and ACTH in patients with HIV infections are consistent with a model which proposes that stress related neurohormones and/or neuropeptides may be involved in the progression of HIV infections.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0019693---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13951019",
-              "object": "MONDO:0005109",
-              "publications": [
-                "PMID:18778540",
-                "PMID:7620208",
-                "PMID:8543334"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:produces",
-    "r2.publications_info": "{'PMID:9264144': {'publication date': '1997', 'sentence': 'It was suggested that the progressive shift from type 1 to type 2 cytokine production characteristic of HIV infection could be at least partially provoked by the increase in the production of cortisol and the reduction of DHEA.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 517695,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005109",
-          "name": "HIV infectious disease",
-          "description": "A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.",
-          "equivalent_curies": [
-            "UMLS:C0019693",
-            "ICD9:042-042.99",
-            "SNOMEDCT:86406008",
-            "NCIT:C3108",
-            "MEDDRA:10020161",
-            "PDQ:CDR0000585059",
-            "MEDDRA:10020443",
-            "MEDDRA:10020160",
-            "MONDO:0005109",
-            "EFO:0000764",
-            "MEDDRA:10020172",
-            "MESH:D015658",
-            "DOID:526"
-          ],
-          "id": "MONDO:0005109",
-          "category": "biolink:Disease",
-          "all_names": [
-            "human immunodeficiency virus infectious disease",
-            "HIV infection",
-            "HIV infectious disease",
-            "HIV Infection",
-            "Human immunodeficiency virus [hiv] infection",
-            "HIV Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/hiv",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000602.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517695,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005109",
-              "name": "HIV infectious disease",
-              "description": "A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.",
-              "equivalent_curies": [
-                "UMLS:C0019693",
-                "ICD9:042-042.99",
-                "SNOMEDCT:86406008",
-                "NCIT:C3108",
-                "MEDDRA:10020161",
-                "PDQ:CDR0000585059",
-                "MEDDRA:10020443",
-                "MEDDRA:10020160",
-                "MONDO:0005109",
-                "EFO:0000764",
-                "MEDDRA:10020172",
-                "MESH:D015658",
-                "DOID:526"
-              ],
-              "id": "MONDO:0005109",
-              "category": "biolink:Disease",
-              "all_names": [
-                "human immunodeficiency virus infectious disease",
-                "HIV infection",
-                "HIV infectious disease",
-                "HIV Infection",
-                "Human immunodeficiency virus [hiv] infection",
-                "HIV Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/hiv",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000602.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26954921,
-            "start": 517695,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:9264144': {'publication date': '1997', 'sentence': 'It was suggested that the progressive shift from type 1 to type 2 cytokine production characteristic of HIV infection could be at least partially provoked by the increase in the production of cortisol and the reduction of DHEA.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0019693---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0005109",
-              "id": "27426083",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:9264144"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12832253': {'publication date': '2003 Jul', 'sentence': 'METHOD: Adrenocorticotropic hormone (ACTH), cortisol, and interleukin-6 (IL-6) plasma concentrations were measured in 14 patients with malignant melanoma at regular intervals during the first 12 weeks of IFN-alpha therapy, both immediately before and 1, 2, and 3 hours after IFN-alpha administration.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318348,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005105",
-          "name": "melanoma",
-          "description": "A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.; A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445); The presence of a melanoma, a malignant cancer originating from pigment producing melanocytes. Melanoma can originate from the skin or the pigmented layers of the eye (the uvea). [HPO:probinson]; Melanoma is the most serious type of skin cancer. Often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. Most melanomas have a black or black-blue area. Melanoma may also appear as a new mole. It may be black, abnormal, or \"ugly looking.\" Thinking of \"ABCDE\" can help you remember what to watch for:   Asymmetry - the shape of one half does not match the other  Border - the edges are ragged, blurred or irregular  Color - the color is uneven and may include shades of black, brown and tan  Diameter - there is a change in size, usually an increase Evolving - the mole has changed over the past few weeks or months  Surgery is the first treatment of all stages of melanoma. Other treatments include chemotherapy and radiation, biologic, and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "UMLS:C0025202",
-            "EFO:0000756",
-            "PDQ:CDR0000038833",
-            "NCIT:C3224",
-            "SNOMEDCT:372244006",
-            "MEDDRA:10053571",
-            "HP:0002861",
-            "MEDDRA:10025650",
-            "UMLS:CN971653",
-            "MONDO:0005105",
-            "MESH:D008545",
-            "ORPHANET:411533",
-            "MEDDRA:10027150",
-            "SNOMEDCT:1162635006",
-            "KEGG.DISEASE:05218",
-            "DOID:1909"
-          ],
-          "id": "MONDO:0005105",
-          "category": "biolink:Disease",
-          "all_names": [
-            "melanoma",
-            "Melanoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/melanoma",
-            "PMID:22123420",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318348,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005105",
-              "name": "melanoma",
-              "description": "A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.; A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445); The presence of a melanoma, a malignant cancer originating from pigment producing melanocytes. Melanoma can originate from the skin or the pigmented layers of the eye (the uvea). [HPO:probinson]; Melanoma is the most serious type of skin cancer. Often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. Most melanomas have a black or black-blue area. Melanoma may also appear as a new mole. It may be black, abnormal, or \"ugly looking.\" Thinking of \"ABCDE\" can help you remember what to watch for:   Asymmetry - the shape of one half does not match the other  Border - the edges are ragged, blurred or irregular  Color - the color is uneven and may include shades of black, brown and tan  Diameter - there is a change in size, usually an increase Evolving - the mole has changed over the past few weeks or months  Surgery is the first treatment of all stages of melanoma. Other treatments include chemotherapy and radiation, biologic, and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "UMLS:C0025202",
-                "EFO:0000756",
-                "PDQ:CDR0000038833",
-                "NCIT:C3224",
-                "SNOMEDCT:372244006",
-                "MEDDRA:10053571",
-                "HP:0002861",
-                "MEDDRA:10025650",
-                "UMLS:CN971653",
-                "MONDO:0005105",
-                "MESH:D008545",
-                "ORPHANET:411533",
-                "MEDDRA:10027150",
-                "SNOMEDCT:1162635006",
-                "KEGG.DISEASE:05218",
-                "DOID:1909"
-              ],
-              "id": "MONDO:0005105",
-              "category": "biolink:Disease",
-              "all_names": [
-                "melanoma",
-                "Melanoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/melanoma",
-                "PMID:22123420",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10057979,
-            "start": 569,
-            "end": 318348,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12832253': {'publication date': '2003 Jul', 'sentence': 'METHOD: Adrenocorticotropic hormone (ACTH), cortisol, and interleukin-6 (IL-6) plasma concentrations were measured in 14 patients with malignant melanoma at regular intervals during the first 12 weeks of IFN-alpha therapy, both immediately before and 1, 2, and 3 hours after IFN-alpha administration.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0025202---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10280121",
-              "object": "MONDO:0005105",
-              "publications": [
-                "PMID:12832253"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:6376378': {'publication date': '1984 Jun 15', 'sentence': 'Growth of ovarian, lung, breast, and kidney carcinomas was increased by 136%, 126%, 78% and 69%, respectively, whereas melanomas, sarcomas, and colon tumors were inhibited by hydrocortisone.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318348,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005105",
-          "name": "melanoma",
-          "description": "A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.; A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445); The presence of a melanoma, a malignant cancer originating from pigment producing melanocytes. Melanoma can originate from the skin or the pigmented layers of the eye (the uvea). [HPO:probinson]; Melanoma is the most serious type of skin cancer. Often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. Most melanomas have a black or black-blue area. Melanoma may also appear as a new mole. It may be black, abnormal, or \"ugly looking.\" Thinking of \"ABCDE\" can help you remember what to watch for:   Asymmetry - the shape of one half does not match the other  Border - the edges are ragged, blurred or irregular  Color - the color is uneven and may include shades of black, brown and tan  Diameter - there is a change in size, usually an increase Evolving - the mole has changed over the past few weeks or months  Surgery is the first treatment of all stages of melanoma. Other treatments include chemotherapy and radiation, biologic, and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "UMLS:C0025202",
-            "EFO:0000756",
-            "PDQ:CDR0000038833",
-            "NCIT:C3224",
-            "SNOMEDCT:372244006",
-            "MEDDRA:10053571",
-            "HP:0002861",
-            "MEDDRA:10025650",
-            "UMLS:CN971653",
-            "MONDO:0005105",
-            "MESH:D008545",
-            "ORPHANET:411533",
-            "MEDDRA:10027150",
-            "SNOMEDCT:1162635006",
-            "KEGG.DISEASE:05218",
-            "DOID:1909"
-          ],
-          "id": "MONDO:0005105",
-          "category": "biolink:Disease",
-          "all_names": [
-            "melanoma",
-            "Melanoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/melanoma",
-            "PMID:22123420",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318348,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005105",
-              "name": "melanoma",
-              "description": "A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.; A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445); The presence of a melanoma, a malignant cancer originating from pigment producing melanocytes. Melanoma can originate from the skin or the pigmented layers of the eye (the uvea). [HPO:probinson]; Melanoma is the most serious type of skin cancer. Often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. Most melanomas have a black or black-blue area. Melanoma may also appear as a new mole. It may be black, abnormal, or \"ugly looking.\" Thinking of \"ABCDE\" can help you remember what to watch for:   Asymmetry - the shape of one half does not match the other  Border - the edges are ragged, blurred or irregular  Color - the color is uneven and may include shades of black, brown and tan  Diameter - there is a change in size, usually an increase Evolving - the mole has changed over the past few weeks or months  Surgery is the first treatment of all stages of melanoma. Other treatments include chemotherapy and radiation, biologic, and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "UMLS:C0025202",
-                "EFO:0000756",
-                "PDQ:CDR0000038833",
-                "NCIT:C3224",
-                "SNOMEDCT:372244006",
-                "MEDDRA:10053571",
-                "HP:0002861",
-                "MEDDRA:10025650",
-                "UMLS:CN971653",
-                "MONDO:0005105",
-                "MESH:D008545",
-                "ORPHANET:411533",
-                "MEDDRA:10027150",
-                "SNOMEDCT:1162635006",
-                "KEGG.DISEASE:05218",
-                "DOID:1909"
-              ],
-              "id": "MONDO:0005105",
-              "category": "biolink:Disease",
-              "all_names": [
-                "melanoma",
-                "Melanoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/melanoma",
-                "PMID:22123420",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25671416,
-            "start": 569,
-            "end": 318348,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:6376378': {'publication date': '1984 Jun 15', 'sentence': 'Growth of ovarian, lung, breast, and kidney carcinomas was increased by 136%, 126%, 78% and 69%, respectively, whereas melanomas, sarcomas, and colon tumors were inhibited by hydrocortisone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:disrupts---None---None---None---UMLS:C0025202---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "26128287",
-              "object": "MONDO:0005105",
-              "publications": [
-                "PMID:6376378"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:13249258': {'publication date': '1955 May 27', 'sentence': 'The use of hydrocortisone in ulcerative colitis:  preliminary observations.', 'subject score': 1000, 'object score': 1000}, 'PMID:13518363': {'publication date': '1958 Mar', 'sentence': 'Absorption of cortisol from the colon in ulcerative colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:6307809': {'publication date': '1983 Sep', 'sentence': 'ACTH vs. hydrocortisone in ulcerative colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7199714': {'publication date': '1981 Sep 28', 'sentence': '[Diurnal rhythm of plasma cortisol in ulcerative colitis].', 'subject score': 888, 'object score': 1000}, 'PMID:9741018': {'publication date': '1998 Aug', 'sentence': \"The effectiveness of intravenous corticotrophin versus hydrocortisone in ulcerative colitis has been determined including whether previous steroid therapy influenced the better response to one rather than the other, but no such studies have ever been done in Crohn's disease.\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10258383,
-            "start": 569,
-            "end": 322104,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13249258': {'publication date': '1955 May 27', 'sentence': 'The use of hydrocortisone in ulcerative colitis:  preliminary observations.', 'subject score': 1000, 'object score': 1000}, 'PMID:13518363': {'publication date': '1958 Mar', 'sentence': 'Absorption of cortisol from the colon in ulcerative colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:6307809': {'publication date': '1983 Sep', 'sentence': 'ACTH vs. hydrocortisone in ulcerative colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7199714': {'publication date': '1981 Sep 28', 'sentence': '[Diurnal rhythm of plasma cortisol in ulcerative colitis].', 'subject score': 888, 'object score': 1000}, 'PMID:9741018': {'publication date': '1998 Aug', 'sentence': \"The effectiveness of intravenous corticotrophin versus hydrocortisone in ulcerative colitis has been determined including whether previous steroid therapy influenced the better response to one rather than the other, but no such studies have ever been done in Crohn's disease.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10484611",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:13249258",
-                "PMID:13518363",
-                "PMID:6307809",
-                "PMID:7199714",
-                "PMID:9741018"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:13374319': {'publication date': '1956 Dec 01', 'sentence': 'Treatment of ulcerative colitis with local hydrocortisone.', 'subject score': 888, 'object score': 1000}, 'PMID:13402775': {'publication date': '1957 Feb', 'sentence': 'The use of ACTH, cortisone, hydrocortisone and related compounds in the management of ulcerative colitis; experience in 180 patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:13474175': {'publication date': '1957 Sep', 'sentence': 'The longterm treatment of ulcerative colitis with hydrocortisone, prednisone and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:13567689': {'publication date': '1958 Jun', 'sentence': 'Treatment of ulcerative colitis with local hydrocortisone.', 'subject score': 888, 'object score': 1000}, 'PMID:13669781': {'publication date': '1959 Aug', 'sentence': 'Rectal cortisol in the therapy of ulcerative colitis.', 'subject score': 888, 'object score': 1000}, 'PMID:13689058': {'publication date': '1960 Nov', 'sentence': '[Local application of hydrocortisone in the treatment of ulcerative colitis].', 'subject score': 1000, 'object score': 1000}, 'PMID:13713786': {'publication date': '1961 Jun', 'sentence': 'Rectal hydrocortisone for ulcerative colitis refractory to oral corticosteroids.', 'subject score': 888, 'object score': 1000}, 'PMID:13963047': {'publication date': '1962 Oct 26', 'sentence': '[Ulcerative colitis and proctosigmoiditis treated locally with hydrocortisone].', 'subject score': 1000, 'object score': 1000}, 'PMID:15507500': {'publication date': '2004 Dec', 'sentence': 'CASE SUMMARY: A 28-year-old man previously diagnosed with ulcerative colitis was admitted to the internal medicine department due to exacerbation of the condition and treated with intravenous hydrocortisone, followed by treatment with intravenous cyclosporine.', 'subject score': 888, 'object score': 1000}, 'PMID:1790809': {'publication date': '1991', 'sentence': \"Patients with nonspecific ulcerative colitis and Crohn's disease were treated with drug therapy (prednisolone, sulphasalazine, metronidazole per os and hydrocortisone per rectum) and subjected to 12 sessions of HBO.\", 'subject score': 901, 'object score': 901}, 'PMID:18442203': {'publication date': '2008 Apr 28', 'sentence': 'RESULTS: Fifteen patients were included, 7 with UC unresponsive or intolerant to i.v. hydrocortisone, and 8 with active disease despite oral steroids (all but one with therapeutic dosage and duration of immunomodulation).', 'subject score': 827, 'object score': 1000}, 'PMID:19005257': {'publication date': '2008', 'sentence': 'METHODS: 10 severe ulcerative colitis patients refractory to intravenous hydrocortisone administered for at least 7 days and candidate for colectomy were selected to receive a single infusion of infliximab (5 mg/kg).', 'subject score': 888, 'object score': 798}, 'PMID:3031150': {'publication date': '1987 Feb', 'sentence': 'We looked for factors predicting the therapeutic outcome in 66 patients with severe ulcerative colitis treated with intravenous hydrocortisone or corticotropin (ACTH) for 10 days.', 'subject score': 888, 'object score': 901}, 'PMID:6305758': {'publication date': '1983 Aug', 'sentence': 'Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7733079': {'publication date': '1995 May', 'sentence': 'Low Pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative colitis: a randomized, double-blind study.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10291551,
-            "start": 569,
-            "end": 322104,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13374319': {'publication date': '1956 Dec 01', 'sentence': 'Treatment of ulcerative colitis with local hydrocortisone.', 'subject score': 888, 'object score': 1000}, 'PMID:13402775': {'publication date': '1957 Feb', 'sentence': 'The use of ACTH, cortisone, hydrocortisone and related compounds in the management of ulcerative colitis; experience in 180 patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:13474175': {'publication date': '1957 Sep', 'sentence': 'The longterm treatment of ulcerative colitis with hydrocortisone, prednisone and prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:13567689': {'publication date': '1958 Jun', 'sentence': 'Treatment of ulcerative colitis with local hydrocortisone.', 'subject score': 888, 'object score': 1000}, 'PMID:13669781': {'publication date': '1959 Aug', 'sentence': 'Rectal cortisol in the therapy of ulcerative colitis.', 'subject score': 888, 'object score': 1000}, 'PMID:13689058': {'publication date': '1960 Nov', 'sentence': '[Local application of hydrocortisone in the treatment of ulcerative colitis].', 'subject score': 1000, 'object score': 1000}, 'PMID:13713786': {'publication date': '1961 Jun', 'sentence': 'Rectal hydrocortisone for ulcerative colitis refractory to oral corticosteroids.', 'subject score': 888, 'object score': 1000}, 'PMID:13963047': {'publication date': '1962 Oct 26', 'sentence': '[Ulcerative colitis and proctosigmoiditis treated locally with hydrocortisone].', 'subject score': 1000, 'object score': 1000}, 'PMID:15507500': {'publication date': '2004 Dec', 'sentence': 'CASE SUMMARY: A 28-year-old man previously diagnosed with ulcerative colitis was admitted to the internal medicine department due to exacerbation of the condition and treated with intravenous hydrocortisone, followed by treatment with intravenous cyclosporine.', 'subject score': 888, 'object score': 1000}, 'PMID:1790809': {'publication date': '1991', 'sentence': \"Patients with nonspecific ulcerative colitis and Crohn's disease were treated with drug therapy (prednisolone, sulphasalazine, metronidazole per os and hydrocortisone per rectum) and subjected to 12 sessions of HBO.\", 'subject score': 901, 'object score': 901}, 'PMID:18442203': {'publication date': '2008 Apr 28', 'sentence': 'RESULTS: Fifteen patients were included, 7 with UC unresponsive or intolerant to i.v. hydrocortisone, and 8 with active disease despite oral steroids (all but one with therapeutic dosage and duration of immunomodulation).', 'subject score': 827, 'object score': 1000}, 'PMID:19005257': {'publication date': '2008', 'sentence': 'METHODS: 10 severe ulcerative colitis patients refractory to intravenous hydrocortisone administered for at least 7 days and candidate for colectomy were selected to receive a single infusion of infliximab (5 mg/kg).', 'subject score': 888, 'object score': 798}, 'PMID:3031150': {'publication date': '1987 Feb', 'sentence': 'We looked for factors predicting the therapeutic outcome in 66 patients with severe ulcerative colitis treated with intravenous hydrocortisone or corticotropin (ACTH) for 10 days.', 'subject score': 888, 'object score': 901}, 'PMID:6305758': {'publication date': '1983 Aug', 'sentence': 'Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7733079': {'publication date': '1995 May', 'sentence': 'Low Pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative colitis: a randomized, double-blind study.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10518308",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:13374319",
-                "PMID:13402775",
-                "PMID:13474175",
-                "PMID:13567689",
-                "PMID:13669781",
-                "PMID:13689058",
-                "PMID:13713786",
-                "PMID:13963047",
-                "PMID:15507500",
-                "PMID:1790809",
-                "PMID:18442203",
-                "PMID:19005257",
-                "PMID:3031150",
-                "PMID:6305758",
-                "PMID:7733079"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:15457124': {'publication date': '2004 Oct', 'sentence': 'A prospective study was performed to investigate the combination of the aromatase inhibitor aminoglutethimide and hydrocortisone in androgen-independent prostate cancer with changes in prostate-specific antigen (PSA) level as main determinant for response.', 'subject score': 1000, 'object score': 861}, 'PMID:19887483': {'publication date': '2009 Nov 15', 'sentence': 'Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.', 'subject score': 1000, 'object score': 840}, 'PMID:28692205': {'publication date': '2018 Jan', 'sentence': 'OBJECTIVE: To investigate the effect of chronic stress as measured in cortisol concentrations upon the association between psychological resilience (PR) and depression in prostate cancer (PCa) patients.', 'subject score': 888, 'object score': 1000}, 'PMID:7666079': {'publication date': '1995 Sep', 'sentence': 'Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 319116,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008315",
-          "name": "prostate cancer",
-          "description": "A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.; Tumors or cancer of the PROSTATE.; A cancer of the prostate. [HPO:probinson]; What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it:  Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to:  Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer.    What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include:  Problems urinating (peeing), such as:  A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen   Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm)  But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you:  Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer  What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include:  A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate.  If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options:  Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation:  Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer.   Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer.  Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include:  Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0008315",
-            "ICD10:C61",
-            "MEDDRA:10026389",
-            "MEDDRA:10007113",
-            "DOID:10283",
-            "MEDDRA:10036908",
-            "UMLS:C0376358",
-            "SNOMEDCT:399068003",
-            "ICD9:185",
-            "PDQ:CDR0000038782",
-            "MEDDRA:10036910",
-            "MEDDRA:10036946",
-            "KEGG.DISEASE:05215",
-            "NCIT:C7378",
-            "MESH:D011471",
-            "HP:0012125",
-            "MEDDRA:10060862"
-          ],
-          "id": "MONDO:0008315",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Malignant Prostate Neoplasm",
-            "prostate cancer",
-            "Prostate cancer",
-            "Prostatic Neoplasms",
-            "Malignant neoplasm of prostate"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=445079",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319116,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008315",
-              "name": "prostate cancer",
-              "description": "A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.; Tumors or cancer of the PROSTATE.; A cancer of the prostate. [HPO:probinson]; What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it:  Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to:  Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer.    What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include:  Problems urinating (peeing), such as:  A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen   Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm)  But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you:  Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer  What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include:  A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate.  If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options:  Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation:  Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer.   Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer.  Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include:  Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0008315",
-                "ICD10:C61",
-                "MEDDRA:10026389",
-                "MEDDRA:10007113",
-                "DOID:10283",
-                "MEDDRA:10036908",
-                "UMLS:C0376358",
-                "SNOMEDCT:399068003",
-                "ICD9:185",
-                "PDQ:CDR0000038782",
-                "MEDDRA:10036910",
-                "MEDDRA:10036946",
-                "KEGG.DISEASE:05215",
-                "NCIT:C7378",
-                "MESH:D011471",
-                "HP:0012125",
-                "MEDDRA:10060862"
-              ],
-              "id": "MONDO:0008315",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Malignant Prostate Neoplasm",
-                "prostate cancer",
-                "Prostate cancer",
-                "Prostatic Neoplasms",
-                "Malignant neoplasm of prostate"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=445079",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11198021,
-            "start": 569,
-            "end": 319116,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15457124': {'publication date': '2004 Oct', 'sentence': 'A prospective study was performed to investigate the combination of the aromatase inhibitor aminoglutethimide and hydrocortisone in androgen-independent prostate cancer with changes in prostate-specific antigen (PSA) level as main determinant for response.', 'subject score': 1000, 'object score': 861}, 'PMID:19887483': {'publication date': '2009 Nov 15', 'sentence': 'Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.', 'subject score': 1000, 'object score': 840}, 'PMID:28692205': {'publication date': '2018 Jan', 'sentence': 'OBJECTIVE: To investigate the effect of chronic stress as measured in cortisol concentrations upon the association between psychological resilience (PR) and depression in prostate cancer (PCa) patients.', 'subject score': 888, 'object score': 1000}, 'PMID:7666079': {'publication date': '1995 Sep', 'sentence': 'Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0376358---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "11442939",
-              "object": "MONDO:0008315",
-              "publications": [
-                "PMID:15457124",
-                "PMID:19887483",
-                "PMID:28692205",
-                "PMID:7666079"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12131305': {'publication date': '2002 Aug', 'sentence': 'Therefore, a prospective phase II study was conducted to assess the efficacy and safety of a regimen of low dose (200 mg.) oral ketoconazole 3 times daily with replacement doses of hydrocortisone in men with androgen independent prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:1384013': {'publication date': '1992', 'sentence': 'Natural killer (NK) cell activity was studied together with tumor marker serotests (PSA, PAP) and blood testosterone, estradiol, cortisol, and prolactin concentrations in treated prostate cancer patients.', 'subject score': 1000, 'object score': 850}, 'PMID:14598689': {'publication date': '2003 Sep', 'sentence': 'We measured serum concentrations of testosterone (T), 4-androstene-3, 17-dione (A-dione), dehydroepiandrosterone (DHEA), LH, follicle-stimulating hormone (FSH), adrenocorticotropic hormone (ACTH) and cortisol before and after 3-12 months of the first hormonal treatment in 17 prostatic cancer patients who had received ORX (8 cases) or LHRH (9 cases).', 'subject score': 1000, 'object score': 824}, 'PMID:15879788': {'publication date': '2005 Jun', 'sentence': 'Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.', 'subject score': 1000, 'object score': 861}, 'PMID:20029646': {'publication date': '2009', 'sentence': 'A 59-year-old man treated with warfarin for aortic valve replacement was prescribed high-dose ketoconazole and hydrocortisone for the treatment of prostate cancer.', 'subject score': 1000, 'object score': 1000}, 'PMID:2161578': {'publication date': '1990', 'sentence': \"Basal serum levels and ACTH-induced increments ('delta-values') of dehydroepiandrosterone (DHA) and its sulfate (DHAS), 4-androstene-3,17-dione (A-4), 17 alpha-hydroxyprogesterone (17-OHP), cortisol and testosterone and serum albumin levels were studied in patients with prostatic cancer before treatment and after orchidectomy or during estrogen treatment (intramuscular polyestradiol phosphate during the first 3 months, followed by another 3 months with additional oral ethinyl estradiol).\", 'subject score': 1000, 'object score': 1000}, 'PMID:2734983': {'publication date': '1989', 'sentence': 'Serum levels of testosterone (T), 17 alpha-hydroxyprogesterone (17OHP), 4-androstene-3,17-dione (A-4), dehydroepiandrosterone (DHA), dehydroepiandrosterone sulfate (DHAS) and cortisol were measured before and after 6 months of treatment in prostatic cancer patients treated by orchidectomy (ORX) or with oral + parenteral estrogens (OE), single parenteral estrogens (PE; 160 or 320 mg polyestradiol phosphate i.m. every fourth week), estramustine phosphate (ECYT) or LHRH agonist without (LHRH) or with (LHRH-F) flutamide.', 'subject score': 1000, 'object score': 901}, 'PMID:2752257': {'publication date': '1989 Jun', 'sentence': 'The effect of further adrenal androgen blockade with aminoglutethimide (AG) plus low dose hydrocortisone (HC) was studied in 119 patients with clinical stage D2 prostate cancer who previously progressed after standard hormone therapy and were under progression while receiving the combination therapy with Flutamide and castration.', 'subject score': 901, 'object score': 857}, 'PMID:2958420': {'publication date': '1987 Aug', 'sentence': 'Peripheral serum levels of dehydroepiandrosterone (DHA) and its sulphate (DHAS), 4-androstene-3, 17-dione (A-4), 17 alpha-hydroxyprogesterone (17-OHP), cortisol and albumin were measured in patients with prostatic cancer before treatment and after orchidectomy or during combined oral and intramuscular oestrogen treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:29696999': {'publication date': '2018 Apr 01', 'sentence': 'Sexual well-being and diurnal cortisol after prostate cancer treatment.', 'subject score': 888, 'object score': 901}, 'PMID:7545218': {'publication date': '1995 Sep', 'sentence': 'Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:7666079': {'publication date': '1995 Sep', 'sentence': 'PURPOSE: The combination of suramin and hydrocortisone has shown clinical benefit in patients with androgen-independent prostate cancer.', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 319116,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008315",
-          "name": "prostate cancer",
-          "description": "A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.; Tumors or cancer of the PROSTATE.; A cancer of the prostate. [HPO:probinson]; What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it:  Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to:  Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer.    What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include:  Problems urinating (peeing), such as:  A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen   Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm)  But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you:  Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer  What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include:  A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate.  If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options:  Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation:  Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer.   Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer.  Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include:  Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0008315",
-            "ICD10:C61",
-            "MEDDRA:10026389",
-            "MEDDRA:10007113",
-            "DOID:10283",
-            "MEDDRA:10036908",
-            "UMLS:C0376358",
-            "SNOMEDCT:399068003",
-            "ICD9:185",
-            "PDQ:CDR0000038782",
-            "MEDDRA:10036910",
-            "MEDDRA:10036946",
-            "KEGG.DISEASE:05215",
-            "NCIT:C7378",
-            "MESH:D011471",
-            "HP:0012125",
-            "MEDDRA:10060862"
-          ],
-          "id": "MONDO:0008315",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Malignant Prostate Neoplasm",
-            "prostate cancer",
-            "Prostate cancer",
-            "Prostatic Neoplasms",
-            "Malignant neoplasm of prostate"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=445079",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319116,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008315",
-              "name": "prostate cancer",
-              "description": "A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.; Tumors or cancer of the PROSTATE.; A cancer of the prostate. [HPO:probinson]; What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it:  Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to:  Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer.    What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include:  Problems urinating (peeing), such as:  A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen   Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm)  But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you:  Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer  What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include:  A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate.  If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options:  Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation:  Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer.   Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer.  Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include:  Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0008315",
-                "ICD10:C61",
-                "MEDDRA:10026389",
-                "MEDDRA:10007113",
-                "DOID:10283",
-                "MEDDRA:10036908",
-                "UMLS:C0376358",
-                "SNOMEDCT:399068003",
-                "ICD9:185",
-                "PDQ:CDR0000038782",
-                "MEDDRA:10036910",
-                "MEDDRA:10036946",
-                "KEGG.DISEASE:05215",
-                "NCIT:C7378",
-                "MESH:D011471",
-                "HP:0012125",
-                "MEDDRA:10060862"
-              ],
-              "id": "MONDO:0008315",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Malignant Prostate Neoplasm",
-                "prostate cancer",
-                "Prostate cancer",
-                "Prostatic Neoplasms",
-                "Malignant neoplasm of prostate"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=445079",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9456491,
-            "start": 569,
-            "end": 319116,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12131305': {'publication date': '2002 Aug', 'sentence': 'Therefore, a prospective phase II study was conducted to assess the efficacy and safety of a regimen of low dose (200 mg.) oral ketoconazole 3 times daily with replacement doses of hydrocortisone in men with androgen independent prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:1384013': {'publication date': '1992', 'sentence': 'Natural killer (NK) cell activity was studied together with tumor marker serotests (PSA, PAP) and blood testosterone, estradiol, cortisol, and prolactin concentrations in treated prostate cancer patients.', 'subject score': 1000, 'object score': 850}, 'PMID:14598689': {'publication date': '2003 Sep', 'sentence': 'We measured serum concentrations of testosterone (T), 4-androstene-3, 17-dione (A-dione), dehydroepiandrosterone (DHEA), LH, follicle-stimulating hormone (FSH), adrenocorticotropic hormone (ACTH) and cortisol before and after 3-12 months of the first hormonal treatment in 17 prostatic cancer patients who had received ORX (8 cases) or LHRH (9 cases).', 'subject score': 1000, 'object score': 824}, 'PMID:15879788': {'publication date': '2005 Jun', 'sentence': 'Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.', 'subject score': 1000, 'object score': 861}, 'PMID:20029646': {'publication date': '2009', 'sentence': 'A 59-year-old man treated with warfarin for aortic valve replacement was prescribed high-dose ketoconazole and hydrocortisone for the treatment of prostate cancer.', 'subject score': 1000, 'object score': 1000}, 'PMID:2161578': {'publication date': '1990', 'sentence': \"Basal serum levels and ACTH-induced increments ('delta-values') of dehydroepiandrosterone (DHA) and its sulfate (DHAS), 4-androstene-3,17-dione (A-4), 17 alpha-hydroxyprogesterone (17-OHP), cortisol and testosterone and serum albumin levels were studied in patients with prostatic cancer before treatment and after orchidectomy or during estrogen treatment (intramuscular polyestradiol phosphate during the first 3 months, followed by another 3 months with additional oral ethinyl estradiol).\", 'subject score': 1000, 'object score': 1000}, 'PMID:2734983': {'publication date': '1989', 'sentence': 'Serum levels of testosterone (T), 17 alpha-hydroxyprogesterone (17OHP), 4-androstene-3,17-dione (A-4), dehydroepiandrosterone (DHA), dehydroepiandrosterone sulfate (DHAS) and cortisol were measured before and after 6 months of treatment in prostatic cancer patients treated by orchidectomy (ORX) or with oral + parenteral estrogens (OE), single parenteral estrogens (PE; 160 or 320 mg polyestradiol phosphate i.m. every fourth week), estramustine phosphate (ECYT) or LHRH agonist without (LHRH) or with (LHRH-F) flutamide.', 'subject score': 1000, 'object score': 901}, 'PMID:2752257': {'publication date': '1989 Jun', 'sentence': 'The effect of further adrenal androgen blockade with aminoglutethimide (AG) plus low dose hydrocortisone (HC) was studied in 119 patients with clinical stage D2 prostate cancer who previously progressed after standard hormone therapy and were under progression while receiving the combination therapy with Flutamide and castration.', 'subject score': 901, 'object score': 857}, 'PMID:2958420': {'publication date': '1987 Aug', 'sentence': 'Peripheral serum levels of dehydroepiandrosterone (DHA) and its sulphate (DHAS), 4-androstene-3, 17-dione (A-4), 17 alpha-hydroxyprogesterone (17-OHP), cortisol and albumin were measured in patients with prostatic cancer before treatment and after orchidectomy or during combined oral and intramuscular oestrogen treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:29696999': {'publication date': '2018 Apr 01', 'sentence': 'Sexual well-being and diurnal cortisol after prostate cancer treatment.', 'subject score': 888, 'object score': 901}, 'PMID:7545218': {'publication date': '1995 Sep', 'sentence': 'Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.', 'subject score': 1000, 'object score': 861}, 'PMID:7666079': {'publication date': '1995 Sep', 'sentence': 'PURPOSE: The combination of suramin and hydrocortisone has shown clinical benefit in patients with androgen-independent prostate cancer.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0376358---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9665107",
-              "object": "MONDO:0008315",
-              "publications": [
-                "PMID:12131305",
-                "PMID:1384013",
-                "PMID:14598689",
-                "PMID:15879788",
-                "PMID:20029646",
-                "PMID:2161578",
-                "PMID:2734983",
-                "PMID:2752257",
-                "PMID:2958420",
-                "PMID:29696999",
-                "PMID:7545218",
-                "PMID:7666079"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:produces",
-    "r2.publications_info": "{'PMID:10906738': {'publication date': '2000 Aug 01', 'sentence': 'CONCLUSIONS: Patients with newly diagnosed, untreated PC yielded significantly higher cortisol and lower estradiol serum concentrations than controls.', 'subject score': 901, 'object score': 773}}",
-    "p2": {
-      "start": {
-        "identity": 319116,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008315",
-          "name": "prostate cancer",
-          "description": "A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.; Tumors or cancer of the PROSTATE.; A cancer of the prostate. [HPO:probinson]; What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it:  Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to:  Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer.    What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include:  Problems urinating (peeing), such as:  A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen   Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm)  But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you:  Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer  What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include:  A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate.  If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options:  Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation:  Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer.   Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer.  Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include:  Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0008315",
-            "ICD10:C61",
-            "MEDDRA:10026389",
-            "MEDDRA:10007113",
-            "DOID:10283",
-            "MEDDRA:10036908",
-            "UMLS:C0376358",
-            "SNOMEDCT:399068003",
-            "ICD9:185",
-            "PDQ:CDR0000038782",
-            "MEDDRA:10036910",
-            "MEDDRA:10036946",
-            "KEGG.DISEASE:05215",
-            "NCIT:C7378",
-            "MESH:D011471",
-            "HP:0012125",
-            "MEDDRA:10060862"
-          ],
-          "id": "MONDO:0008315",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Malignant Prostate Neoplasm",
-            "prostate cancer",
-            "Prostate cancer",
-            "Prostatic Neoplasms",
-            "Malignant neoplasm of prostate"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=445079",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319116,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008315",
-              "name": "prostate cancer",
-              "description": "A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.; Tumors or cancer of the PROSTATE.; A cancer of the prostate. [HPO:probinson]; What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it:  Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to:  Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer.    What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include:  Problems urinating (peeing), such as:  A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen   Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm)  But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you:  Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer  What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include:  A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate.  If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options:  Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation:  Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer.   Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer.  Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include:  Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0008315",
-                "ICD10:C61",
-                "MEDDRA:10026389",
-                "MEDDRA:10007113",
-                "DOID:10283",
-                "MEDDRA:10036908",
-                "UMLS:C0376358",
-                "SNOMEDCT:399068003",
-                "ICD9:185",
-                "PDQ:CDR0000038782",
-                "MEDDRA:10036910",
-                "MEDDRA:10036946",
-                "KEGG.DISEASE:05215",
-                "NCIT:C7378",
-                "MESH:D011471",
-                "HP:0012125",
-                "MEDDRA:10060862"
-              ],
-              "id": "MONDO:0008315",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Malignant Prostate Neoplasm",
-                "prostate cancer",
-                "Prostate cancer",
-                "Prostatic Neoplasms",
-                "Malignant neoplasm of prostate"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=445079",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8153060,
-            "start": 319116,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10906738': {'publication date': '2000 Aug 01', 'sentence': 'CONCLUSIONS: Patients with newly diagnosed, untreated PC yielded significantly higher cortisol and lower estradiol serum concentrations than controls.', 'subject score': 901, 'object score': 773}}",
-              "kg2_ids": [
-                "UMLS:C0376358---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0008315",
-              "id": "8328567",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:10906738"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:13924001': {'publication date': '1962 May-Jun', 'sentence': '[The adrenal cortex and hydrocortisone metabolism in experimental myocardial infarct].', 'subject score': 888, 'object score': 901}, 'PMID:14033341': {'publication date': '1963 Mar', 'sentence': 'Plasma cortisol in myocardial infarction.', 'subject score': 888, 'object score': 1000}, 'PMID:14187467': {'publication date': '1964 Oct 10', 'sentence': 'HYDROCORTISONE IN SEVERE MYOCARDIAL INFARCTION.', 'subject score': 1000, 'object score': 901}, 'PMID:14255194': {'publication date': '1964 Jul-Aug', 'sentence': '[THERAPEUTIC USE OF HYDROCORTISONE AND THE FUNCTIONAL STATE OF THE ADRENAL CORTEX IN MYOCARDIAL INFARCT, COMPLICATED BY COLLAPSE].', 'subject score': 1000, 'object score': 1000}, 'PMID:30691725': {'publication date': '2019 Apr', 'sentence': 'Stress hyperglycemia: A prospective study examining the relationship between glucose, cortisol and diabetes in myocardial infarction.', 'subject score': 1000, 'object score': 1000}, 'PMID:369021': {'publication date': '1978', 'sentence': '[Changes in the level and metabolism of a number of hormones (insulin, somatotropin, thyrotropin, thyroid hormones, ACTH and cortisol) in myocardial infarct in vitro and in vivo according to the radioisotope dilution tests].', 'subject score': 1000, 'object score': 1000}, 'PMID:6670263': {'publication date': '1983 Oct 15', 'sentence': '[Use of large doses of hydrocortisone in the treatment of shock in myocardial infarct].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317845,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005068",
-          "name": "myocardial infarction",
-          "description": "Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin. [HPO:probinson]; Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021758",
-            "EFO:0000612",
-            "MEDDRA:10019250",
-            "MEDDRA:10028595",
-            "MONDO:0005068",
-            "SNOMEDCT:22298006",
-            "HP:0001658",
-            "NCIT:C27996",
-            "MEDDRA:10003723",
-            "ICD10:I21",
-            "MEDDRA:10003724",
-            "MESH:D009203",
-            "DOID:5844",
-            "UMLS:C0027051",
-            "MEDDRA:10028596"
-          ],
-          "id": "MONDO:0005068",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myocardial Infarction",
-            "Myocardial infarction",
-            "myocardial infarction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0001-5208-3432",
-            "PMID:17951287",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://en.wikipedia.org/wiki/myocardial_infarction"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317845,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005068",
-              "name": "myocardial infarction",
-              "description": "Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin. [HPO:probinson]; Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021758",
-                "EFO:0000612",
-                "MEDDRA:10019250",
-                "MEDDRA:10028595",
-                "MONDO:0005068",
-                "SNOMEDCT:22298006",
-                "HP:0001658",
-                "NCIT:C27996",
-                "MEDDRA:10003723",
-                "ICD10:I21",
-                "MEDDRA:10003724",
-                "MESH:D009203",
-                "DOID:5844",
-                "UMLS:C0027051",
-                "MEDDRA:10028596"
-              ],
-              "id": "MONDO:0005068",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myocardial Infarction",
-                "Myocardial infarction",
-                "myocardial infarction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0001-5208-3432",
-                "PMID:17951287",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://en.wikipedia.org/wiki/myocardial_infarction"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10416618,
-            "start": 569,
-            "end": 317845,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13924001': {'publication date': '1962 May-Jun', 'sentence': '[The adrenal cortex and hydrocortisone metabolism in experimental myocardial infarct].', 'subject score': 888, 'object score': 901}, 'PMID:14033341': {'publication date': '1963 Mar', 'sentence': 'Plasma cortisol in myocardial infarction.', 'subject score': 888, 'object score': 1000}, 'PMID:14187467': {'publication date': '1964 Oct 10', 'sentence': 'HYDROCORTISONE IN SEVERE MYOCARDIAL INFARCTION.', 'subject score': 1000, 'object score': 901}, 'PMID:14255194': {'publication date': '1964 Jul-Aug', 'sentence': '[THERAPEUTIC USE OF HYDROCORTISONE AND THE FUNCTIONAL STATE OF THE ADRENAL CORTEX IN MYOCARDIAL INFARCT, COMPLICATED BY COLLAPSE].', 'subject score': 1000, 'object score': 1000}, 'PMID:30691725': {'publication date': '2019 Apr', 'sentence': 'Stress hyperglycemia: A prospective study examining the relationship between glucose, cortisol and diabetes in myocardial infarction.', 'subject score': 1000, 'object score': 1000}, 'PMID:369021': {'publication date': '1978', 'sentence': '[Changes in the level and metabolism of a number of hormones (insulin, somatotropin, thyrotropin, thyroid hormones, ACTH and cortisol) in myocardial infarct in vitro and in vivo according to the radioisotope dilution tests].', 'subject score': 1000, 'object score': 1000}, 'PMID:6670263': {'publication date': '1983 Oct 15', 'sentence': '[Use of large doses of hydrocortisone in the treatment of shock in myocardial infarct].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0027051---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10649902",
-              "object": "MONDO:0005068",
-              "publications": [
-                "PMID:13924001",
-                "PMID:14033341",
-                "PMID:14187467",
-                "PMID:14255194",
-                "PMID:30691725",
-                "PMID:369021",
-                "PMID:6670263"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:8145427': {'publication date': '1993', 'sentence': 'In acute MI, there were elevated plasma levels of cortisol depending on the MI severity with a small repeated peak of its increase on day 14 and its subsequent decrease, except deaths.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 317845,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005068",
-          "name": "myocardial infarction",
-          "description": "Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin. [HPO:probinson]; Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021758",
-            "EFO:0000612",
-            "MEDDRA:10019250",
-            "MEDDRA:10028595",
-            "MONDO:0005068",
-            "SNOMEDCT:22298006",
-            "HP:0001658",
-            "NCIT:C27996",
-            "MEDDRA:10003723",
-            "ICD10:I21",
-            "MEDDRA:10003724",
-            "MESH:D009203",
-            "DOID:5844",
-            "UMLS:C0027051",
-            "MEDDRA:10028596"
-          ],
-          "id": "MONDO:0005068",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myocardial Infarction",
-            "Myocardial infarction",
-            "myocardial infarction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0001-5208-3432",
-            "PMID:17951287",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://en.wikipedia.org/wiki/myocardial_infarction"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317845,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005068",
-              "name": "myocardial infarction",
-              "description": "Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin. [HPO:probinson]; Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021758",
-                "EFO:0000612",
-                "MEDDRA:10019250",
-                "MEDDRA:10028595",
-                "MONDO:0005068",
-                "SNOMEDCT:22298006",
-                "HP:0001658",
-                "NCIT:C27996",
-                "MEDDRA:10003723",
-                "ICD10:I21",
-                "MEDDRA:10003724",
-                "MESH:D009203",
-                "DOID:5844",
-                "UMLS:C0027051",
-                "MEDDRA:10028596"
-              ],
-              "id": "MONDO:0005068",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myocardial Infarction",
-                "Myocardial infarction",
-                "myocardial infarction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0001-5208-3432",
-                "PMID:17951287",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://en.wikipedia.org/wiki/myocardial_infarction"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26363920,
-            "start": 569,
-            "end": 317845,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8145427': {'publication date': '1993', 'sentence': 'In acute MI, there were elevated plasma levels of cortisol depending on the MI severity with a small repeated peak of its increase on day 14 and its subsequent decrease, except deaths.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0027051---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "26840479",
-              "object": "MONDO:0005068",
-              "publications": [
-                "PMID:8145427"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1717735': {'publication date': '1991 Jun', 'sentence': 'The paper yields the results of the study into the elimination of exogenous cortisol from the blood bed in 26 patients with myocardial infarction.', 'subject score': 888, 'object score': 1000}, 'PMID:21537104': {'publication date': '2011', 'sentence': 'The outcomes under study include morning saliva cortisol, treatment for hypertension, self-reported hypertension, and myocardial infarction.', 'subject score': 851, 'object score': 1000}, 'PMID:24656116': {'publication date': '2014 Jun', 'sentence': 'CONCLUSIONS: A high baseline plasma TC was associated with a trend toward increased mortality in patients with cardiogenic shock post-AMI.', 'subject score': 822, 'object score': 864}, 'PMID:4459728': {'publication date': '1974 Dec', 'sentence': '[Clinical considerations on the use of hydrocortisone in the treatment of myocardial infarct].', 'subject score': 1000, 'object score': 1000}, 'PMID:5096585': {'publication date': '1971', 'sentence': '[Free and transcortin-bound hydrocortisone in patients with myocardial infarct complicated by cardiogenic shock].', 'subject score': 802, 'object score': 1000}, 'PMID:5504121': {'publication date': '1970 Oct', 'sentence': '[Urinary levels of hydrocortisone, cortisone and their metabolites in patients with myocardial infarct in the acute period of the disease].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317845,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005068",
-          "name": "myocardial infarction",
-          "description": "Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin. [HPO:probinson]; Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021758",
-            "EFO:0000612",
-            "MEDDRA:10019250",
-            "MEDDRA:10028595",
-            "MONDO:0005068",
-            "SNOMEDCT:22298006",
-            "HP:0001658",
-            "NCIT:C27996",
-            "MEDDRA:10003723",
-            "ICD10:I21",
-            "MEDDRA:10003724",
-            "MESH:D009203",
-            "DOID:5844",
-            "UMLS:C0027051",
-            "MEDDRA:10028596"
-          ],
-          "id": "MONDO:0005068",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myocardial Infarction",
-            "Myocardial infarction",
-            "myocardial infarction"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0001-5208-3432",
-            "PMID:17951287",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://en.wikipedia.org/wiki/myocardial_infarction"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317845,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005068",
-              "name": "myocardial infarction",
-              "description": "Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin. [HPO:probinson]; Necrosis of the myocardium caused by an obstruction of the blood supply to the heart and often associated with chest pain, shortness of breath, palpitations, and anxiety as well as characteristic EKG findings and elevation of serum markers including creatine kinase-MB fraction and troponin.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021758",
-                "EFO:0000612",
-                "MEDDRA:10019250",
-                "MEDDRA:10028595",
-                "MONDO:0005068",
-                "SNOMEDCT:22298006",
-                "HP:0001658",
-                "NCIT:C27996",
-                "MEDDRA:10003723",
-                "ICD10:I21",
-                "MEDDRA:10003724",
-                "MESH:D009203",
-                "DOID:5844",
-                "UMLS:C0027051",
-                "MEDDRA:10028596"
-              ],
-              "id": "MONDO:0005068",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myocardial Infarction",
-                "Myocardial infarction",
-                "myocardial infarction"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0001-5208-3432",
-                "PMID:17951287",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://en.wikipedia.org/wiki/myocardial_infarction"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12608498,
-            "start": 569,
-            "end": 317845,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1717735': {'publication date': '1991 Jun', 'sentence': 'The paper yields the results of the study into the elimination of exogenous cortisol from the blood bed in 26 patients with myocardial infarction.', 'subject score': 888, 'object score': 1000}, 'PMID:21537104': {'publication date': '2011', 'sentence': 'The outcomes under study include morning saliva cortisol, treatment for hypertension, self-reported hypertension, and myocardial infarction.', 'subject score': 851, 'object score': 1000}, 'PMID:24656116': {'publication date': '2014 Jun', 'sentence': 'CONCLUSIONS: A high baseline plasma TC was associated with a trend toward increased mortality in patients with cardiogenic shock post-AMI.', 'subject score': 822, 'object score': 864}, 'PMID:4459728': {'publication date': '1974 Dec', 'sentence': '[Clinical considerations on the use of hydrocortisone in the treatment of myocardial infarct].', 'subject score': 1000, 'object score': 1000}, 'PMID:5096585': {'publication date': '1971', 'sentence': '[Free and transcortin-bound hydrocortisone in patients with myocardial infarct complicated by cardiogenic shock].', 'subject score': 802, 'object score': 1000}, 'PMID:5504121': {'publication date': '1970 Oct', 'sentence': '[Urinary levels of hydrocortisone, cortisone and their metabolites in patients with myocardial infarct in the acute period of the disease].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0027051---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "12881395",
-              "object": "MONDO:0005068",
-              "publications": [
-                "PMID:1717735",
-                "PMID:21537104",
-                "PMID:24656116",
-                "PMID:4459728",
-                "PMID:5096585",
-                "PMID:5504121"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:4358928': {'publication date': '1973 Dec 19', 'sentence': 'Independence of theta and TL surface antigens and killing by thymidine, cortisol, phytohemagglutinin, and cyclic AMP in a murine lymphoma.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 319679,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-          "name": "lymphoma",
-          "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:115244002",
-            "DOID:0060058",
-            "MONDO:0005062",
-            "SNOMEDCT:118600007",
-            "HP:0002665",
-            "NCIT:C7065",
-            "EFO:0000574",
-            "ORPHANET:223735",
-            "MESH:D008223",
-            "SNOMEDCT:188676008",
-            "PDQ:CDR0000041429",
-            "MEDDRA:10025316",
-            "UMLS:C0024299",
-            "NCIT:C3208",
-            "MEDDRA:10025632",
-            "MEDDRA:10025310",
-            "MEDDRA:10025633",
-            "SNOMEDCT:1163043007",
-            "ICD10:C85.9",
-            "UMLS:C1536843",
-            "UMLS:C0334621",
-            "MEDDRA:10025315"
-          ],
-          "id": "MONDO:0005062",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphocytic Neoplasm",
-            "Lymphoma",
-            "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-            "lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/lymphoma",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319679,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-              "name": "lymphoma",
-              "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:115244002",
-                "DOID:0060058",
-                "MONDO:0005062",
-                "SNOMEDCT:118600007",
-                "HP:0002665",
-                "NCIT:C7065",
-                "EFO:0000574",
-                "ORPHANET:223735",
-                "MESH:D008223",
-                "SNOMEDCT:188676008",
-                "PDQ:CDR0000041429",
-                "MEDDRA:10025316",
-                "UMLS:C0024299",
-                "NCIT:C3208",
-                "MEDDRA:10025632",
-                "MEDDRA:10025310",
-                "MEDDRA:10025633",
-                "SNOMEDCT:1163043007",
-                "ICD10:C85.9",
-                "UMLS:C1536843",
-                "UMLS:C0334621",
-                "MEDDRA:10025315"
-              ],
-              "id": "MONDO:0005062",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphocytic Neoplasm",
-                "Lymphoma",
-                "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-                "lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/lymphoma",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25344361,
-            "start": 569,
-            "end": 319679,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:4358928': {'publication date': '1973 Dec 19', 'sentence': 'Independence of theta and TL surface antigens and killing by thymidine, cortisol, phytohemagglutinin, and cyclic AMP in a murine lymphoma.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0024299---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "25797574",
-              "object": "MONDO:0005062",
-              "publications": [
-                "PMID:4358928"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:26271105': {'publication date': '2016 Oct', 'sentence': 'INTRODUCTION: Intrathecal administration of methotrexate, cytarabine, and hydrocortisone is commonly used to treat and prevent central nervous system involvement in leukemias and lymphomas.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319679,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-          "name": "lymphoma",
-          "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:115244002",
-            "DOID:0060058",
-            "MONDO:0005062",
-            "SNOMEDCT:118600007",
-            "HP:0002665",
-            "NCIT:C7065",
-            "EFO:0000574",
-            "ORPHANET:223735",
-            "MESH:D008223",
-            "SNOMEDCT:188676008",
-            "PDQ:CDR0000041429",
-            "MEDDRA:10025316",
-            "UMLS:C0024299",
-            "NCIT:C3208",
-            "MEDDRA:10025632",
-            "MEDDRA:10025310",
-            "MEDDRA:10025633",
-            "SNOMEDCT:1163043007",
-            "ICD10:C85.9",
-            "UMLS:C1536843",
-            "UMLS:C0334621",
-            "MEDDRA:10025315"
-          ],
-          "id": "MONDO:0005062",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphocytic Neoplasm",
-            "Lymphoma",
-            "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-            "lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/lymphoma",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319679,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-              "name": "lymphoma",
-              "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:115244002",
-                "DOID:0060058",
-                "MONDO:0005062",
-                "SNOMEDCT:118600007",
-                "HP:0002665",
-                "NCIT:C7065",
-                "EFO:0000574",
-                "ORPHANET:223735",
-                "MESH:D008223",
-                "SNOMEDCT:188676008",
-                "PDQ:CDR0000041429",
-                "MEDDRA:10025316",
-                "UMLS:C0024299",
-                "NCIT:C3208",
-                "MEDDRA:10025632",
-                "MEDDRA:10025310",
-                "MEDDRA:10025633",
-                "SNOMEDCT:1163043007",
-                "ICD10:C85.9",
-                "UMLS:C1536843",
-                "UMLS:C0334621",
-                "MEDDRA:10025315"
-              ],
-              "id": "MONDO:0005062",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphocytic Neoplasm",
-                "Lymphoma",
-                "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-                "lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/lymphoma",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18127861,
-            "start": 569,
-            "end": 319679,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26271105': {'publication date': '2016 Oct', 'sentence': 'INTRODUCTION: Intrathecal administration of methotrexate, cytarabine, and hydrocortisone is commonly used to treat and prevent central nervous system involvement in leukemias and lymphomas.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0024299---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "18495054",
-              "object": "MONDO:0005062",
-              "publications": [
-                "PMID:26271105"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:3167775': {'publication date': '1988 Oct 15', 'sentence': 'The serum cortisol concentration in the LYMPH patients was 285 +/- 74 nmol/l.', 'subject score': 901, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 319679,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-          "name": "lymphoma",
-          "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:115244002",
-            "DOID:0060058",
-            "MONDO:0005062",
-            "SNOMEDCT:118600007",
-            "HP:0002665",
-            "NCIT:C7065",
-            "EFO:0000574",
-            "ORPHANET:223735",
-            "MESH:D008223",
-            "SNOMEDCT:188676008",
-            "PDQ:CDR0000041429",
-            "MEDDRA:10025316",
-            "UMLS:C0024299",
-            "NCIT:C3208",
-            "MEDDRA:10025632",
-            "MEDDRA:10025310",
-            "MEDDRA:10025633",
-            "SNOMEDCT:1163043007",
-            "ICD10:C85.9",
-            "UMLS:C1536843",
-            "UMLS:C0334621",
-            "MEDDRA:10025315"
-          ],
-          "id": "MONDO:0005062",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphocytic Neoplasm",
-            "Lymphoma",
-            "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-            "lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/lymphoma",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319679,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-              "name": "lymphoma",
-              "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:115244002",
-                "DOID:0060058",
-                "MONDO:0005062",
-                "SNOMEDCT:118600007",
-                "HP:0002665",
-                "NCIT:C7065",
-                "EFO:0000574",
-                "ORPHANET:223735",
-                "MESH:D008223",
-                "SNOMEDCT:188676008",
-                "PDQ:CDR0000041429",
-                "MEDDRA:10025316",
-                "UMLS:C0024299",
-                "NCIT:C3208",
-                "MEDDRA:10025632",
-                "MEDDRA:10025310",
-                "MEDDRA:10025633",
-                "SNOMEDCT:1163043007",
-                "ICD10:C85.9",
-                "UMLS:C1536843",
-                "UMLS:C0334621",
-                "MEDDRA:10025315"
-              ],
-              "id": "MONDO:0005062",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphocytic Neoplasm",
-                "Lymphoma",
-                "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-                "lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/lymphoma",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20956434,
-            "start": 569,
-            "end": 319679,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3167775': {'publication date': '1988 Oct 15', 'sentence': 'The serum cortisol concentration in the LYMPH patients was 285 +/- 74 nmol/l.', 'subject score': 901, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0024299---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "21368080",
-              "object": "MONDO:0005062",
-              "publications": [
-                "PMID:3167775"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:26271105': {'publication date': '2016 Oct', 'sentence': 'INTRODUCTION: Intrathecal administration of methotrexate, cytarabine, and hydrocortisone is commonly used to treat and prevent central nervous system involvement in leukemias and lymphomas.', 'subject score': 1000, 'object score': 1000}, 'PMID:3736113': {'publication date': '1986', 'sentence': 'The investigations included also mice submitted to non-leukemogenic irradiation (1 X 1.5 and 1 X 4.5 Gy) and mice submitted to an additional treatment with hydrocortisone, which delays leukemia development after methylnitrosourea.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 315770,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005059",
-          "name": "leukemia",
-          "description": "A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3161\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3161\" NCI Thesaurus); A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.; A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006); A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding  When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets  The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time.  The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age  What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding.  Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes  Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10045991",
-            "MEDDRA:10024329",
-            "ICD9:208",
-            "ICD10:C95.90",
-            "MEDDRA:10060430",
-            "MEDDRA:10024314",
-            "MEDDRA:10024323",
-            "MEDDRA:10024351",
-            "HP:0001909",
-            "SNOMEDCT:87163000",
-            "SNOMEDCT:1162768007",
-            "MEDDRA:10045992",
-            "MEDDRA:10060500",
-            "NCIT:C3161",
-            "EFO:0000565",
-            "MEDDRA:10045994",
-            "SNOMEDCT:93143009",
-            "MEDDRA:10024288",
-            "MEDDRA:10024352",
-            "MEDDRA:10024312",
-            "DOID:1240",
-            "UMLS:C0023418",
-            "PDQ:CDR0000041186",
-            "MESH:D007938",
-            "MONDO:0005059",
-            "MEDDRA:10024324"
-          ],
-          "id": "MONDO:0005059",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia of unspecified cell type",
-            "Leukemia",
-            "leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/leukemia",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=45343",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315770,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005059",
-              "name": "leukemia",
-              "description": "A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3161\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3161\" NCI Thesaurus); A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.; A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006); A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding  When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets  The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time.  The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age  What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding.  Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes  Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10045991",
-                "MEDDRA:10024329",
-                "ICD9:208",
-                "ICD10:C95.90",
-                "MEDDRA:10060430",
-                "MEDDRA:10024314",
-                "MEDDRA:10024323",
-                "MEDDRA:10024351",
-                "HP:0001909",
-                "SNOMEDCT:87163000",
-                "SNOMEDCT:1162768007",
-                "MEDDRA:10045992",
-                "MEDDRA:10060500",
-                "NCIT:C3161",
-                "EFO:0000565",
-                "MEDDRA:10045994",
-                "SNOMEDCT:93143009",
-                "MEDDRA:10024288",
-                "MEDDRA:10024352",
-                "MEDDRA:10024312",
-                "DOID:1240",
-                "UMLS:C0023418",
-                "PDQ:CDR0000041186",
-                "MESH:D007938",
-                "MONDO:0005059",
-                "MEDDRA:10024324"
-              ],
-              "id": "MONDO:0005059",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia of unspecified cell type",
-                "Leukemia",
-                "leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/leukemia",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=45343",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18127860,
-            "start": 569,
-            "end": 315770,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26271105': {'publication date': '2016 Oct', 'sentence': 'INTRODUCTION: Intrathecal administration of methotrexate, cytarabine, and hydrocortisone is commonly used to treat and prevent central nervous system involvement in leukemias and lymphomas.', 'subject score': 1000, 'object score': 1000}, 'PMID:3736113': {'publication date': '1986', 'sentence': 'The investigations included also mice submitted to non-leukemogenic irradiation (1 X 1.5 and 1 X 4.5 Gy) and mice submitted to an additional treatment with hydrocortisone, which delays leukemia development after methylnitrosourea.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0023418---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "18495053",
-              "object": "MONDO:0005059",
-              "publications": [
-                "PMID:26271105",
-                "PMID:3736113"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:34579671': {'publication date': '2021 Sep 27', 'sentence': 'Study protocol: DexaDays-2, hydrocortisone for treatment of dexamethasone-induced neurobehavioral side effects in pediatric leukemia patients: a double-blind placebo controlled randomized intervention study with cross-over design.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 315770,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005059",
-          "name": "leukemia",
-          "description": "A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3161\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3161\" NCI Thesaurus); A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.; A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006); A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding  When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets  The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time.  The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age  What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding.  Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes  Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10045991",
-            "MEDDRA:10024329",
-            "ICD9:208",
-            "ICD10:C95.90",
-            "MEDDRA:10060430",
-            "MEDDRA:10024314",
-            "MEDDRA:10024323",
-            "MEDDRA:10024351",
-            "HP:0001909",
-            "SNOMEDCT:87163000",
-            "SNOMEDCT:1162768007",
-            "MEDDRA:10045992",
-            "MEDDRA:10060500",
-            "NCIT:C3161",
-            "EFO:0000565",
-            "MEDDRA:10045994",
-            "SNOMEDCT:93143009",
-            "MEDDRA:10024288",
-            "MEDDRA:10024352",
-            "MEDDRA:10024312",
-            "DOID:1240",
-            "UMLS:C0023418",
-            "PDQ:CDR0000041186",
-            "MESH:D007938",
-            "MONDO:0005059",
-            "MEDDRA:10024324"
-          ],
-          "id": "MONDO:0005059",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia of unspecified cell type",
-            "Leukemia",
-            "leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/leukemia",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=45343",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315770,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005059",
-              "name": "leukemia",
-              "description": "A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3161\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3161\" NCI Thesaurus); A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.; A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006); A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding  When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets  The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time.  The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age  What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding.  Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes  Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10045991",
-                "MEDDRA:10024329",
-                "ICD9:208",
-                "ICD10:C95.90",
-                "MEDDRA:10060430",
-                "MEDDRA:10024314",
-                "MEDDRA:10024323",
-                "MEDDRA:10024351",
-                "HP:0001909",
-                "SNOMEDCT:87163000",
-                "SNOMEDCT:1162768007",
-                "MEDDRA:10045992",
-                "MEDDRA:10060500",
-                "NCIT:C3161",
-                "EFO:0000565",
-                "MEDDRA:10045994",
-                "SNOMEDCT:93143009",
-                "MEDDRA:10024288",
-                "MEDDRA:10024352",
-                "MEDDRA:10024312",
-                "DOID:1240",
-                "UMLS:C0023418",
-                "PDQ:CDR0000041186",
-                "MESH:D007938",
-                "MONDO:0005059",
-                "MEDDRA:10024324"
-              ],
-              "id": "MONDO:0005059",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia of unspecified cell type",
-                "Leukemia",
-                "leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/leukemia",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=45343",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23333501,
-            "start": 569,
-            "end": 315770,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34579671': {'publication date': '2021 Sep 27', 'sentence': 'Study protocol: DexaDays-2, hydrocortisone for treatment of dexamethasone-induced neurobehavioral side effects in pediatric leukemia patients: a double-blind placebo controlled randomized intervention study with cross-over design.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0023418---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "23769275",
-              "object": "MONDO:0005059",
-              "publications": [
-                "PMID:34579671"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:7355482': {'publication date': '1980 Feb', 'sentence': 'Amplication by hydrocortisone of the induction of cytotoxic response in vitro to syngeneic murine leukemias.', 'subject score': 1000, 'object score': 790}}",
-    "p2": {
-      "start": {
-        "identity": 315770,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005059",
-          "name": "leukemia",
-          "description": "A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3161\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3161\" NCI Thesaurus); A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.; A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006); A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding  When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets  The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time.  The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age  What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding.  Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes  Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10045991",
-            "MEDDRA:10024329",
-            "ICD9:208",
-            "ICD10:C95.90",
-            "MEDDRA:10060430",
-            "MEDDRA:10024314",
-            "MEDDRA:10024323",
-            "MEDDRA:10024351",
-            "HP:0001909",
-            "SNOMEDCT:87163000",
-            "SNOMEDCT:1162768007",
-            "MEDDRA:10045992",
-            "MEDDRA:10060500",
-            "NCIT:C3161",
-            "EFO:0000565",
-            "MEDDRA:10045994",
-            "SNOMEDCT:93143009",
-            "MEDDRA:10024288",
-            "MEDDRA:10024352",
-            "MEDDRA:10024312",
-            "DOID:1240",
-            "UMLS:C0023418",
-            "PDQ:CDR0000041186",
-            "MESH:D007938",
-            "MONDO:0005059",
-            "MEDDRA:10024324"
-          ],
-          "id": "MONDO:0005059",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia of unspecified cell type",
-            "Leukemia",
-            "leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/leukemia",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=45343",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315770,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005059",
-              "name": "leukemia",
-              "description": "A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3161\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3161\" NCI Thesaurus); A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.; A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006); A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding  When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets  The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time.  The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age  What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding.  Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes  Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10045991",
-                "MEDDRA:10024329",
-                "ICD9:208",
-                "ICD10:C95.90",
-                "MEDDRA:10060430",
-                "MEDDRA:10024314",
-                "MEDDRA:10024323",
-                "MEDDRA:10024351",
-                "HP:0001909",
-                "SNOMEDCT:87163000",
-                "SNOMEDCT:1162768007",
-                "MEDDRA:10045992",
-                "MEDDRA:10060500",
-                "NCIT:C3161",
-                "EFO:0000565",
-                "MEDDRA:10045994",
-                "SNOMEDCT:93143009",
-                "MEDDRA:10024288",
-                "MEDDRA:10024352",
-                "MEDDRA:10024312",
-                "DOID:1240",
-                "UMLS:C0023418",
-                "PDQ:CDR0000041186",
-                "MESH:D007938",
-                "MONDO:0005059",
-                "MEDDRA:10024324"
-              ],
-              "id": "MONDO:0005059",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia of unspecified cell type",
-                "Leukemia",
-                "leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/leukemia",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=45343",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25968747,
-            "start": 569,
-            "end": 315770,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7355482': {'publication date': '1980 Feb', 'sentence': 'Amplication by hydrocortisone of the induction of cytotoxic response in vitro to syngeneic murine leukemias.', 'subject score': 1000, 'object score': 790}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:disrupts---None---None---None---UMLS:C0023418---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "26428860",
-              "object": "MONDO:0005059",
-              "publications": [
-                "PMID:7355482"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:1860896': {'publication date': '1991 Jul', 'sentence': 'Hydrocortisone in culture protects the blast cells in acute myeloblastic leukemia from the lethal effects of cytosine arabinoside.', 'subject score': 1000, 'object score': 1000}, 'PMID:3878438': {'publication date': '1985', 'sentence': 'Response to hydrocortisone of blast progenitors in acute myeloblastic leukemia: an aspect of lineage infidelity.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321063,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018874",
-          "name": "acute myeloid leukemia",
-          "description": "A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification). (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3171\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3171\" NCI Thesaurus); Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.; A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).; Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.; A form of leukemia characterized by overproduction of an early myeloid cell. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:91861009",
-            "ICD9:205.0",
-            "MEDDRA:10024346",
-            "MEDDRA:10000801",
-            "MEDDRA:10060354",
-            "KEGG.DISEASE:05221",
-            "EFO:0000222",
-            "PDQ:CDR0000043424",
-            "MEDDRA:10000886",
-            "HP:0004808",
-            "MEDDRA:10060394",
-            "MESH:D015470",
-            "MEDDRA:10051003",
-            "MONDO:0100173",
-            "MEDDRA:10000878",
-            "MEDDRA:10060553",
-            "MEDDRA:10024291",
-            "SNOMEDCT:1162928000",
-            "MEDDRA:10054296",
-            "ORPHANET:519",
-            "MEDDRA:10000880",
-            "UMLS:C3275959",
-            "MEDDRA:10028552",
-            "MONDO:0018874",
-            "OMIM:601626",
-            "MEDDRA:10000884",
-            "DOID:9119",
-            "MEDDRA:10029549",
-            "MEDDRA:10029551",
-            "UMLS:C0023467",
-            "NCIT:C3171",
-            "MEDDRA:10060557",
-            "MEDDRA:10028557"
-          ],
-          "id": "MONDO:0018874",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia, acute myeloid related phenotypic feature",
-            "Leukemia, Myelocytic, Acute",
-            "Acute myeloid leukemia",
-            "acute myeloid leukemia",
-            "leukemia, acute myeloid, susceptibility to",
-            "Leukemia, acute myeloid, susceptibility to",
-            "Acute Myeloid Leukemia",
-            "Leukemia, Myeloid, Acute",
-            "Myeloid leukemia, acute"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=44363",
-            "http://cancergenome.nih.gov/cancersselected/acutemyeloidleukemia",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.cancer.org/cancer/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.htm",
-            "http://en.wikipedia.org/wiki/acute_myeloid_leukemia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321063,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018874",
-              "name": "acute myeloid leukemia",
-              "description": "A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification). (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3171\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3171\" NCI Thesaurus); Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.; A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).; Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.; A form of leukemia characterized by overproduction of an early myeloid cell. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:91861009",
-                "ICD9:205.0",
-                "MEDDRA:10024346",
-                "MEDDRA:10000801",
-                "MEDDRA:10060354",
-                "KEGG.DISEASE:05221",
-                "EFO:0000222",
-                "PDQ:CDR0000043424",
-                "MEDDRA:10000886",
-                "HP:0004808",
-                "MEDDRA:10060394",
-                "MESH:D015470",
-                "MEDDRA:10051003",
-                "MONDO:0100173",
-                "MEDDRA:10000878",
-                "MEDDRA:10060553",
-                "MEDDRA:10024291",
-                "SNOMEDCT:1162928000",
-                "MEDDRA:10054296",
-                "ORPHANET:519",
-                "MEDDRA:10000880",
-                "UMLS:C3275959",
-                "MEDDRA:10028552",
-                "MONDO:0018874",
-                "OMIM:601626",
-                "MEDDRA:10000884",
-                "DOID:9119",
-                "MEDDRA:10029549",
-                "MEDDRA:10029551",
-                "UMLS:C0023467",
-                "NCIT:C3171",
-                "MEDDRA:10060557",
-                "MEDDRA:10028557"
-              ],
-              "id": "MONDO:0018874",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia, acute myeloid related phenotypic feature",
-                "Leukemia, Myelocytic, Acute",
-                "Acute myeloid leukemia",
-                "acute myeloid leukemia",
-                "leukemia, acute myeloid, susceptibility to",
-                "Leukemia, acute myeloid, susceptibility to",
-                "Acute Myeloid Leukemia",
-                "Leukemia, Myeloid, Acute",
-                "Myeloid leukemia, acute"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=44363",
-                "http://cancergenome.nih.gov/cancersselected/acutemyeloidleukemia",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.cancer.org/cancer/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.htm",
-                "http://en.wikipedia.org/wiki/acute_myeloid_leukemia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13553984,
-            "start": 569,
-            "end": 321063,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1860896': {'publication date': '1991 Jul', 'sentence': 'Hydrocortisone in culture protects the blast cells in acute myeloblastic leukemia from the lethal effects of cytosine arabinoside.', 'subject score': 1000, 'object score': 1000}, 'PMID:3878438': {'publication date': '1985', 'sentence': 'Response to hydrocortisone of blast progenitors in acute myeloblastic leukemia: an aspect of lineage infidelity.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0023467---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13844584",
-              "object": "MONDO:0018874",
-              "publications": [
-                "PMID:1860896",
-                "PMID:3878438"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:13234340': {'publication date': '1955 Jan 29', 'sentence': 'Hydrocortisone in treatment of allergic conjunctivitis, allergic rhinitis, and bronchial asthma.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 325169,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005642",
-          "name": "atopic conjunctivitis",
-          "description": "A chronic conjunctivitis that is an inflammation of the conjunctiva involing red, itchy, and watery eyes a resulting from an exposure to an allergen or an irritant.",
-          "equivalent_curies": [
-            "MONDO:0005642",
-            "UMLS:C0009766",
-            "MEDDRA:10010744",
-            "EFO:0007141",
-            "MEDDRA:10080573",
-            "SNOMEDCT:231854006",
-            "NCIT:C34506",
-            "MEDDRA:10001709",
-            "MESH:D003233",
-            "HP:0007879",
-            "DOID:11204",
-            "SNOMEDCT:473460002"
-          ],
-          "id": "MONDO:0005642",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Allergic conjunctivitis",
-            "Allergic Conjunctivitis",
-            "Conjunctivitis, Allergic",
-            "allergic conjunctivitis",
-            "atopic conjunctivitis",
-            "Atopic Conjunctivitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/allergic_conjunctivitis",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 325169,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005642",
-              "name": "atopic conjunctivitis",
-              "description": "A chronic conjunctivitis that is an inflammation of the conjunctiva involing red, itchy, and watery eyes a resulting from an exposure to an allergen or an irritant.",
-              "equivalent_curies": [
-                "MONDO:0005642",
-                "UMLS:C0009766",
-                "MEDDRA:10010744",
-                "EFO:0007141",
-                "MEDDRA:10080573",
-                "SNOMEDCT:231854006",
-                "NCIT:C34506",
-                "MEDDRA:10001709",
-                "MESH:D003233",
-                "HP:0007879",
-                "DOID:11204",
-                "SNOMEDCT:473460002"
-              ],
-              "id": "MONDO:0005642",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Allergic conjunctivitis",
-                "Allergic Conjunctivitis",
-                "Conjunctivitis, Allergic",
-                "allergic conjunctivitis",
-                "atopic conjunctivitis",
-                "Atopic Conjunctivitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/allergic_conjunctivitis",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10254325,
-            "start": 569,
-            "end": 325169,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13234340': {'publication date': '1955 Jan 29', 'sentence': 'Hydrocortisone in treatment of allergic conjunctivitis, allergic rhinitis, and bronchial asthma.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0009766---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10480635",
-              "object": "MONDO:0005642",
-              "publications": [
-                "PMID:13234340"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:15557131': {'publication date': '2005 Feb 01', 'sentence': 'We hypothesize that hydrocortisone infusion in severe community-acquired pneumonia attenuates systemic inflammation and leads to earlier resolution of pneumonia and a reduction in sepsis-related complications.', 'subject score': 888, 'object score': 833}, 'PMID:17698896': {'publication date': '2007 Sep', 'sentence': 'Finally, a pilot study has found that hydrocortisone lowers morbidity and mortality in SCAP.', 'subject score': 1000, 'object score': 833}, 'PMID:17702966': {'publication date': '2007 Nov 01', 'sentence': 'OBJECTIVES: To investigate the predictive value of TC and FC in community-acquired pneumonia (CAP).', 'subject score': 888, 'object score': 851}, 'PMID:18753464': {'publication date': '2008 Nov', 'sentence': 'However, the predictive value of total cortisol and of the presence of critical illness-related corticosteroid insufficiency (CIRCI) in severe community-acquired pneumonia (CAP) remains to be thoroughly evaluated.', 'subject score': 888, 'object score': 833}, 'PMID:20236471': {'publication date': '2010', 'sentence': 'Elevated levels of pro-adrenomedullin, copeptin (which is produced in equimolar amounts to vasopressin), natriuretic peptides and cortisol are significantly related to mortality in community-acquired pneumonia, as are other prohormones such as pro-atrial natriuretic peptide, coagulation markers, and other combinations of inflammatory cytokine profiles.', 'subject score': 1000, 'object score': 851}, 'PMID:20723107': {'publication date': '2010 Jun', 'sentence': 'Continuous hydrocortisone infusion in severe pediatric community-acquired pneumonia (CAP).', 'subject score': 901, 'object score': 822}, 'PMID:22402329': {'publication date': '2012 Jun', 'sentence': 'Delta-cortisol could be another meaningful biomarker in CAP.', 'subject score': 861, 'object score': 851}, 'PMID:23018905': {'publication date': '2013 Apr', 'sentence': 'New cardiovascular or stress-related biomarkers like copeptin, midregional proadrenomedullin and cortisol have been repeatedly linked with outcome and disease course in CAP and improved clinical scoring in observational studies.', 'subject score': 1000, 'object score': 851}, 'PMID:24910975': {'publication date': '2014', 'sentence': 'CONCLUSION: Cortisol, DHEAS and their ratios correlate with CAP severity, and cortisol and DHEA predict mortality.', 'subject score': 1000, 'object score': 833}, 'PMID:30485501': {'publication date': '2018 Nov 28', 'sentence': 'CONCLUSIONS: Neither baseline nor stimulated cortisol after low-dose cosyntropin testing at a dose of 1 ug predicted glucocorticoid responsiveness in mild to moderate CAP.', 'subject score': 861, 'object score': 851}, 'PMID:35881034': {'publication date': '2022 Aug 01', 'sentence': 'CONCLUSION: Hydrocortisone, ascorbic acid, and thiamine therapy has minimal benefits in pneumonia.', 'subject score': 1000, 'object score': 1000}, 'PMID:8339624': {'publication date': '1993 Aug', 'sentence': 'Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia.', 'subject score': 1000, 'object score': 833}}",
-    "p2": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11283939,
-            "start": 569,
-            "end": 321523,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15557131': {'publication date': '2005 Feb 01', 'sentence': 'We hypothesize that hydrocortisone infusion in severe community-acquired pneumonia attenuates systemic inflammation and leads to earlier resolution of pneumonia and a reduction in sepsis-related complications.', 'subject score': 888, 'object score': 833}, 'PMID:17698896': {'publication date': '2007 Sep', 'sentence': 'Finally, a pilot study has found that hydrocortisone lowers morbidity and mortality in SCAP.', 'subject score': 1000, 'object score': 833}, 'PMID:17702966': {'publication date': '2007 Nov 01', 'sentence': 'OBJECTIVES: To investigate the predictive value of TC and FC in community-acquired pneumonia (CAP).', 'subject score': 888, 'object score': 851}, 'PMID:18753464': {'publication date': '2008 Nov', 'sentence': 'However, the predictive value of total cortisol and of the presence of critical illness-related corticosteroid insufficiency (CIRCI) in severe community-acquired pneumonia (CAP) remains to be thoroughly evaluated.', 'subject score': 888, 'object score': 833}, 'PMID:20236471': {'publication date': '2010', 'sentence': 'Elevated levels of pro-adrenomedullin, copeptin (which is produced in equimolar amounts to vasopressin), natriuretic peptides and cortisol are significantly related to mortality in community-acquired pneumonia, as are other prohormones such as pro-atrial natriuretic peptide, coagulation markers, and other combinations of inflammatory cytokine profiles.', 'subject score': 1000, 'object score': 851}, 'PMID:20723107': {'publication date': '2010 Jun', 'sentence': 'Continuous hydrocortisone infusion in severe pediatric community-acquired pneumonia (CAP).', 'subject score': 901, 'object score': 822}, 'PMID:22402329': {'publication date': '2012 Jun', 'sentence': 'Delta-cortisol could be another meaningful biomarker in CAP.', 'subject score': 861, 'object score': 851}, 'PMID:23018905': {'publication date': '2013 Apr', 'sentence': 'New cardiovascular or stress-related biomarkers like copeptin, midregional proadrenomedullin and cortisol have been repeatedly linked with outcome and disease course in CAP and improved clinical scoring in observational studies.', 'subject score': 1000, 'object score': 851}, 'PMID:24910975': {'publication date': '2014', 'sentence': 'CONCLUSION: Cortisol, DHEAS and their ratios correlate with CAP severity, and cortisol and DHEA predict mortality.', 'subject score': 1000, 'object score': 833}, 'PMID:30485501': {'publication date': '2018 Nov 28', 'sentence': 'CONCLUSIONS: Neither baseline nor stimulated cortisol after low-dose cosyntropin testing at a dose of 1 ug predicted glucocorticoid responsiveness in mild to moderate CAP.', 'subject score': 861, 'object score': 851}, 'PMID:35881034': {'publication date': '2022 Aug 01', 'sentence': 'CONCLUSION: Hydrocortisone, ascorbic acid, and thiamine therapy has minimal benefits in pneumonia.', 'subject score': 1000, 'object score': 1000}, 'PMID:8339624': {'publication date': '1993 Aug', 'sentence': 'Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia.', 'subject score': 1000, 'object score': 833}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "11530989",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:15557131",
-                "PMID:17698896",
-                "PMID:17702966",
-                "PMID:18753464",
-                "PMID:20236471",
-                "PMID:20723107",
-                "PMID:22402329",
-                "PMID:23018905",
-                "PMID:24910975",
-                "PMID:30485501",
-                "PMID:35881034",
-                "PMID:8339624"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:28335807': {'publication date': '2017 03 24', 'sentence': 'BACKGROUND: The hypothalamic-pituitary-adrenal stress axis plays a crucial role in community-acquired pneumonia (CAP), with high cortisol being associated with disease severity and corticosteroid treatment resulting in earlier time to recovery.', 'subject score': 888, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19171098,
-            "start": 569,
-            "end": 321523,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28335807': {'publication date': '2017 03 24', 'sentence': 'BACKGROUND: The hypothalamic-pituitary-adrenal stress axis plays a crucial role in community-acquired pneumonia (CAP), with high cortisol being associated with disease severity and corticosteroid treatment resulting in earlier time to recovery.', 'subject score': 888, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "19555227",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:28335807"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12524982': {'publication date': '2002', 'sentence': 'The use of extracorporeal immunopharmacotherapy with diucifon in 53 patients and the retrosternal injection of isoniazid in combination with hydrocortisone in 43 patients have shown their efficiencies in the treatment of patients with caseous pneumonia.', 'subject score': 1000, 'object score': 861}, 'PMID:15557131': {'publication date': '2005 Feb 01', 'sentence': 'Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study.', 'subject score': 888, 'object score': 833}, 'PMID:15719662': {'publication date': '2004', 'sentence': 'The use of extracorporeal immune pharmacotherapy with diucifon in 53 patients and the retrosternal administration of isoniazid with hydrocortisone in 43 patients showed the efficiency of these methods in the treatment of patients with caseous pneumonia.', 'subject score': 1000, 'object score': 861}, 'PMID:16148196': {'publication date': '2005 Sep 15', 'sentence': 'Hydrocortisone infusion for severe community-acquired pneumonia: the role of relative adrenal insufficiency.', 'subject score': 888, 'object score': 833}, 'PMID:30029205': {'publication date': '2018 Oct', 'sentence': 'PURPOSE: To evaluate the efficacy of combined vitamin C, hydrocortisone, and thiamine in patients with severe pneumonia.', 'subject score': 1000, 'object score': 888}, 'PMID:32513653': {'publication date': '2020 Jun 08', 'sentence': 'As per BSG guidance, intravenous hydrocortisone was considered appropriate as initial management; only in patients with COVID-19 pneumonia was its use deemed uncertain.', 'subject score': 888, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9756082,
-            "start": 569,
-            "end": 321523,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12524982': {'publication date': '2002', 'sentence': 'The use of extracorporeal immunopharmacotherapy with diucifon in 53 patients and the retrosternal injection of isoniazid in combination with hydrocortisone in 43 patients have shown their efficiencies in the treatment of patients with caseous pneumonia.', 'subject score': 1000, 'object score': 861}, 'PMID:15557131': {'publication date': '2005 Feb 01', 'sentence': 'Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study.', 'subject score': 888, 'object score': 833}, 'PMID:15719662': {'publication date': '2004', 'sentence': 'The use of extracorporeal immune pharmacotherapy with diucifon in 53 patients and the retrosternal administration of isoniazid with hydrocortisone in 43 patients showed the efficiency of these methods in the treatment of patients with caseous pneumonia.', 'subject score': 1000, 'object score': 861}, 'PMID:16148196': {'publication date': '2005 Sep 15', 'sentence': 'Hydrocortisone infusion for severe community-acquired pneumonia: the role of relative adrenal insufficiency.', 'subject score': 888, 'object score': 833}, 'PMID:30029205': {'publication date': '2018 Oct', 'sentence': 'PURPOSE: To evaluate the efficacy of combined vitamin C, hydrocortisone, and thiamine in patients with severe pneumonia.', 'subject score': 1000, 'object score': 888}, 'PMID:32513653': {'publication date': '2020 Jun 08', 'sentence': 'As per BSG guidance, intravenous hydrocortisone was considered appropriate as initial management; only in patients with COVID-19 pneumonia was its use deemed uncertain.', 'subject score': 888, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9971730",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:12524982",
-                "PMID:15557131",
-                "PMID:15719662",
-                "PMID:16148196",
-                "PMID:30029205",
-                "PMID:32513653"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:produces",
-    "r2.publications_info": "{'PMID:15780497': {'publication date': '2005', 'sentence': 'The reduction in local cortisol production which diminishes the endogenous anti-inflammatory effects, also allows for the progression of both vascular and pulmonary inflammation.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11479184,
-            "start": 321523,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:15780497': {'publication date': '2005', 'sentence': 'The reduction in local cortisol production which diminishes the endogenous anti-inflammatory effects, also allows for the progression of both vascular and pulmonary inflammation.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0032285---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0005249",
-              "id": "11730055",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:15780497"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:31043325': {'publication date': '2019 06', 'sentence': 'Insufficient cortisol limits the ability of the sick newborn to handle stress and inhibit pulmonary inflammation.', 'subject score': 888, 'object score': 1000}, 'PMID:413820': {'publication date': '1977 Dec', 'sentence': 'Only hydrocortisone and prednisolone suppressed LPS pneumonia.', 'subject score': 861, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20614302,
-            "start": 569,
-            "end": 321523,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31043325': {'publication date': '2019 06', 'sentence': 'Insufficient cortisol limits the ability of the sick newborn to handle stress and inhibit pulmonary inflammation.', 'subject score': 888, 'object score': 1000}, 'PMID:413820': {'publication date': '1977 Dec', 'sentence': 'Only hydrocortisone and prednisolone suppressed LPS pneumonia.', 'subject score': 861, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:disrupts---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "21020907",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:31043325",
-                "PMID:413820"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:21427372': {'publication date': '2011 Mar 23', 'sentence': 'CONCLUSION: In intubated trauma patients, the use of an intravenous stress-dose of hydrocortisone, compared with placebo, resulted in a decreased risk of hospital-acquired pneumonia.', 'subject score': 1000, 'object score': 901}, 'PMID:25066331': {'publication date': '2014 Sep', 'sentence': 'Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trial.', 'subject score': 1000, 'object score': 901}, 'PMID:25289930': {'publication date': '2014 Dec', 'sentence': 'Hydrocortisone reduces the rate of pneumonia in patients with trauma.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15220892,
-            "start": 569,
-            "end": 321523,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21427372': {'publication date': '2011 Mar 23', 'sentence': 'CONCLUSION: In intubated trauma patients, the use of an intravenous stress-dose of hydrocortisone, compared with placebo, resulted in a decreased risk of hospital-acquired pneumonia.', 'subject score': 1000, 'object score': 901}, 'PMID:25066331': {'publication date': '2014 Sep', 'sentence': 'Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trial.', 'subject score': 1000, 'object score': 901}, 'PMID:25289930': {'publication date': '2014 Dec', 'sentence': 'Hydrocortisone reduces the rate of pneumonia in patients with trauma.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "15540854",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:21427372",
-                "PMID:25066331",
-                "PMID:25289930"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:10654949': {'publication date': '2000 Feb', 'sentence': 'OBJECTIVE: To investigate the relationship of cortisol concentrations during the first week of life to patent ductus arteriosus (PDA), markers of lung inflammation, and respiratory outcome in very low birth weight infants.', 'subject score': 888, 'object score': 1000}, 'PMID:22501026': {'publication date': '2012 Apr 13', 'sentence': 'In subgroup analyses, cortisol independently predicted critical pneumonia when compared to procalcitonin, the CURB65 score and minor criteria for severe pneumonia according to the 2007 ATS/IDSA-guideline.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7794478,
-            "start": 569,
-            "end": 321523,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10654949': {'publication date': '2000 Feb', 'sentence': 'OBJECTIVE: To investigate the relationship of cortisol concentrations during the first week of life to patent ductus arteriosus (PDA), markers of lung inflammation, and respiratory outcome in very low birth weight infants.', 'subject score': 888, 'object score': 1000}, 'PMID:22501026': {'publication date': '2012 Apr 13', 'sentence': 'In subgroup analyses, cortisol independently predicted critical pneumonia when compared to procalcitonin, the CURB65 score and minor criteria for severe pneumonia according to the 2007 ATS/IDSA-guideline.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:predisposes---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7960726",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:10654949",
-                "PMID:22501026"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:10084590': {'publication date': '1999 Mar', 'sentence': 'Cortisol metabolism in human obesity: impaired cortisone-->cortisol conversion in subjects with central adiposity.', 'subject score': 888, 'object score': 888}, 'PMID:10678256': {'publication date': '2000 Jan', 'sentence': 'RESEARCH METHODS AND PROCEDURES: Body composition (DXA), visceral obesity (computed tomography), leptin, cortisol, insulin, and sex hormone-binding globulin (SHBG) concentrations were measured in 54 obese (body mass index [BMI] = 32.0+/-4.5 kg/m2; mean +/- SD), women (60+/-6 years) before and after a 6-month hypocaloric diet (250 to 350 kcal/day deficit).', 'subject score': 1000, 'object score': 861}, 'PMID:10692082': {'publication date': '2000 Feb', 'sentence': 'RESULTS: Plasma cortisol was lower in relatively obese subjects: in men, this was observed only in the 2 h sample (r = -0.23, P = 0.02) and in women only in the fasting sample (r = -0.26, P < 0.01).', 'subject score': 888, 'object score': 773}, 'PMID:10997615': {'publication date': '2000 Jun', 'sentence': 'Indeed, obesity, mostly visceral type, is associated with an increased cortisol clearance and 11-beta hydroxysteroid dehydrogenase activity in the omental fat.', 'subject score': 851, 'object score': 1000}, 'PMID:11050809': {'publication date': '2000', 'sentence': 'In DM (47/48) total urinary cortisol (UF) levels were similar to those found in Ob and N.', 'subject score': 851, 'object score': 1000}, 'PMID:11054598': {'publication date': '2000 Oct', 'sentence': 'Cortisol in obesity is a much-studied problem.', 'subject score': 1000, 'object score': 1000}, 'PMID:11095438': {'publication date': '2000 Nov', 'sentence': 'Anxiety and depression may be associated with oversecretion of cortisol and could represent a confounding factor in the evaluation of the HPA axis in different obesity phenotypes.', 'subject score': 1000, 'object score': 828}, 'PMID:11238541': {'publication date': '2001 Mar', 'sentence': 'This study addressed whether the same tissue-specific disruption of cortisol metabolism occurs in human obesity.', 'subject score': 888, 'object score': 888}, 'PMID:11316764': {'publication date': '2001 May', 'sentence': 'This autocrine and/or paracrine regulation is tissue specific and explains recent clinical data and animal studies evaluating cortisol metabolism in obesity.', 'subject score': 888, 'object score': 1000}, 'PMID:115194': {'publication date': '1979 Aug', 'sentence': \"Results before fasting: T4, T3, TBG, cortisol, CBG, alpha 2-haptoglobin and complement C'3 of the obese patients were elevated when compared with healthy normal weight controls, whereas rT3, T4/TBG ratio, T3/TBG ratio, TSH, coritsol/cbg ratio, growth hormone, prolactin, parathyrin and transferrin of the obese group were normal.\", 'subject score': 1000, 'object score': 888}, 'PMID:11527096': {'publication date': '2001 Jun', 'sentence': 'Most intriguingly, the changes in 11beta-HSD1 are tissue-specific, and generation of cortisol from inactive cortisone appears to be increased in adipose tissue in obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:12055988': {'publication date': '2002 Mar', 'sentence': \"The increase in cortisol secretion in obesity needs to be distinguished from Cushing's syndrome, the decrease in thyroid hormone levels in anorexia nervosa needs to be distinguished from secondary hypothyroidism, and the increase in cortisol secretion observed in anorexia nervosa requires a differential diagnosis with primary depressive disorder.\", 'subject score': 888, 'object score': 1000}, 'PMID:12105278': {'publication date': '2002 Jul', 'sentence': 'OBJECTIVE: There is considerable evidence that cortisol secretion is associated with obesity.', 'subject score': 888, 'object score': 1000}, 'PMID:12161549': {'publication date': '2002 Aug', 'sentence': 'Because hypothalamic lesions may explain daytime sleepiness in craniopharyngioma patients, salivary melatonin and cortisol concentrations were examined in obese and nonobese craniopharyngioma patients (n = 79), patients with hypothalamic pilocytic astrocytoma (n = 19), and control subjects (n = 30).', 'subject score': 888, 'object score': 1000}, 'PMID:1231837': {'publication date': '1975 Nov 15', 'sentence': '[Biorhythm of plasma cortisol in obesity].', 'subject score': 888, 'object score': 1000}, 'PMID:12788882': {'publication date': '2003 Jun', 'sentence': 'Our data support the hypothesis that increased regeneration of cortisol in adipose tissue influences metabolic sequelae of human obesity.', 'subject score': 1000, 'object score': 888}, 'PMID:1298871': {'publication date': '1992 Jul-Sep', 'sentence': '[Effect of 5-hydroxytryptophan on the secretion of PRL, GH, TSH and cortisol in obesity].', 'subject score': 1000, 'object score': 1000}, 'PMID:1319389': {'publication date': '1992 Jan', 'sentence': 'Effects of naloxone on adrenocorticotrophin (ACTH) and cortisol in obese subjects.', 'subject score': 1000, 'object score': 872}, 'PMID:14216471': {'publication date': '1964 Sep', 'sentence': 'CORTISOL METABOLISM IN OBESITY.', 'subject score': 888, 'object score': 1000}, 'PMID:14474905': {'publication date': '1962 Jun', 'sentence': 'Cortisol production rates in obesity.', 'subject score': 840, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318216,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318216,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7042224,
-            "start": 569,
-            "end": 318216,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10084590': {'publication date': '1999 Mar', 'sentence': 'Cortisol metabolism in human obesity: impaired cortisone-->cortisol conversion in subjects with central adiposity.', 'subject score': 888, 'object score': 888}, 'PMID:10678256': {'publication date': '2000 Jan', 'sentence': 'RESEARCH METHODS AND PROCEDURES: Body composition (DXA), visceral obesity (computed tomography), leptin, cortisol, insulin, and sex hormone-binding globulin (SHBG) concentrations were measured in 54 obese (body mass index [BMI] = 32.0+/-4.5 kg/m2; mean +/- SD), women (60+/-6 years) before and after a 6-month hypocaloric diet (250 to 350 kcal/day deficit).', 'subject score': 1000, 'object score': 861}, 'PMID:10692082': {'publication date': '2000 Feb', 'sentence': 'RESULTS: Plasma cortisol was lower in relatively obese subjects: in men, this was observed only in the 2 h sample (r = -0.23, P = 0.02) and in women only in the fasting sample (r = -0.26, P < 0.01).', 'subject score': 888, 'object score': 773}, 'PMID:10997615': {'publication date': '2000 Jun', 'sentence': 'Indeed, obesity, mostly visceral type, is associated with an increased cortisol clearance and 11-beta hydroxysteroid dehydrogenase activity in the omental fat.', 'subject score': 851, 'object score': 1000}, 'PMID:11050809': {'publication date': '2000', 'sentence': 'In DM (47/48) total urinary cortisol (UF) levels were similar to those found in Ob and N.', 'subject score': 851, 'object score': 1000}, 'PMID:11054598': {'publication date': '2000 Oct', 'sentence': 'Cortisol in obesity is a much-studied problem.', 'subject score': 1000, 'object score': 1000}, 'PMID:11095438': {'publication date': '2000 Nov', 'sentence': 'Anxiety and depression may be associated with oversecretion of cortisol and could represent a confounding factor in the evaluation of the HPA axis in different obesity phenotypes.', 'subject score': 1000, 'object score': 828}, 'PMID:11238541': {'publication date': '2001 Mar', 'sentence': 'This study addressed whether the same tissue-specific disruption of cortisol metabolism occurs in human obesity.', 'subject score': 888, 'object score': 888}, 'PMID:11316764': {'publication date': '2001 May', 'sentence': 'This autocrine and/or paracrine regulation is tissue specific and explains recent clinical data and animal studies evaluating cortisol metabolism in obesity.', 'subject score': 888, 'object score': 1000}, 'PMID:115194': {'publication date': '1979 Aug', 'sentence': \"Results before fasting: T4, T3, TBG, cortisol, CBG, alpha 2-haptoglobin and complement C'3 of the obese patients were elevated when compared with healthy normal weight controls, whereas rT3, T4/TBG ratio, T3/TBG ratio, TSH, coritsol/cbg ratio, growth hormone, prolactin, parathyrin and transferrin of the obese group were normal.\", 'subject score': 1000, 'object score': 888}, 'PMID:11527096': {'publication date': '2001 Jun', 'sentence': 'Most intriguingly, the changes in 11beta-HSD1 are tissue-specific, and generation of cortisol from inactive cortisone appears to be increased in adipose tissue in obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:12055988': {'publication date': '2002 Mar', 'sentence': \"The increase in cortisol secretion in obesity needs to be distinguished from Cushing's syndrome, the decrease in thyroid hormone levels in anorexia nervosa needs to be distinguished from secondary hypothyroidism, and the increase in cortisol secretion observed in anorexia nervosa requires a differential diagnosis with primary depressive disorder.\", 'subject score': 888, 'object score': 1000}, 'PMID:12105278': {'publication date': '2002 Jul', 'sentence': 'OBJECTIVE: There is considerable evidence that cortisol secretion is associated with obesity.', 'subject score': 888, 'object score': 1000}, 'PMID:12161549': {'publication date': '2002 Aug', 'sentence': 'Because hypothalamic lesions may explain daytime sleepiness in craniopharyngioma patients, salivary melatonin and cortisol concentrations were examined in obese and nonobese craniopharyngioma patients (n = 79), patients with hypothalamic pilocytic astrocytoma (n = 19), and control subjects (n = 30).', 'subject score': 888, 'object score': 1000}, 'PMID:1231837': {'publication date': '1975 Nov 15', 'sentence': '[Biorhythm of plasma cortisol in obesity].', 'subject score': 888, 'object score': 1000}, 'PMID:12788882': {'publication date': '2003 Jun', 'sentence': 'Our data support the hypothesis that increased regeneration of cortisol in adipose tissue influences metabolic sequelae of human obesity.', 'subject score': 1000, 'object score': 888}, 'PMID:1298871': {'publication date': '1992 Jul-Sep', 'sentence': '[Effect of 5-hydroxytryptophan on the secretion of PRL, GH, TSH and cortisol in obesity].', 'subject score': 1000, 'object score': 1000}, 'PMID:1319389': {'publication date': '1992 Jan', 'sentence': 'Effects of naloxone on adrenocorticotrophin (ACTH) and cortisol in obese subjects.', 'subject score': 1000, 'object score': 872}, 'PMID:14216471': {'publication date': '1964 Sep', 'sentence': 'CORTISOL METABOLISM IN OBESITY.', 'subject score': 888, 'object score': 1000}, 'PMID:14474905': {'publication date': '1962 Jun', 'sentence': 'Cortisol production rates in obesity.', 'subject score': 840, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0028754---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7182905",
-              "object": "MONDO:0011122",
-              "publications": [
-                "PMID:10084590",
-                "PMID:10678256",
-                "PMID:10692082",
-                "PMID:10997615",
-                "PMID:11050809",
-                "PMID:11054598",
-                "PMID:11095438",
-                "PMID:11238541",
-                "PMID:11316764",
-                "PMID:115194",
-                "PMID:11527096",
-                "PMID:12055988",
-                "PMID:12105278",
-                "PMID:12161549",
-                "PMID:1231837",
-                "PMID:12788882",
-                "PMID:1298871",
-                "PMID:1319389",
-                "PMID:14216471",
-                "PMID:14474905"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:16893715': {'publication date': '2006 Aug 15', 'sentence': 'Although initial studies in transgenic mice and humans are encouraging, more data are required to conclusively prove the hypothesis that the adipose-tissue-specific overexpression of HSD1 and the resultant increase in tissue-specific cortisol concentrations result in human obesity, insulin resistance, high blood pressure, and metabolic syndrome.', 'subject score': 750, 'object score': 888}, 'PMID:17558491': {'publication date': '2007 Oct', 'sentence': 'CONTEXT: Changes in cortisol metabolism due to altered activity of the enzyme 11beta-hydroxysteroid dehydrogenase (11beta-HSD) have been implicated in the pathogenesis of hypertension, obesity and the metabolic syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:22146091': {'publication date': '2012 May', 'sentence': 'Moreover, chronic alterations in cortisol secretion in children may affect the timing of puberty, final stature, and body composition, as well as cause early-onset obesity, metabolic syndrome, and type 2 diabetes mellitus.', 'subject score': 888, 'object score': 851}, 'PMID:23505190': {'publication date': '2013 Jan', 'sentence': 'OBJECTIVE: Circulating cortisol and psychosocial stress may contribute to the pathogenesis of obesity and metabolic syndrome (MS).', 'subject score': 1000, 'object score': 1000}, 'PMID:24384019': {'publication date': '2014 Jan', 'sentence': 'CONTEXT: Pathologically increased cortisol exposure induces obesity, but it is not known whether relatively high cortisol within the physiological range is related to childhood obesity.', 'subject score': 583, 'object score': 1000}, 'PMID:28567298': {'publication date': '2017', 'sentence': 'He was initially misdiagnosed as having an adrenal insufficiency and developed cushingoid features and obesity secondary to hydrocortisone treatment and excessive sugar intake.', 'subject score': 888, 'object score': 1000}, 'PMID:36446324': {'publication date': '2022', 'sentence': 'Proponents of the \"Energy Storage\" hypothesis point to data implicating monogenetic disorders, the ventromedial hypothalamus, insulin, cortisol, and the adipocyte itself in the pathogenesis of obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:7550541': {'publication date': '1995 May', 'sentence': 'Cortisol in the presence of relatively high insulin concentrations can promote the deposition of energy and lead to obesity.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318216,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318216,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12377074,
-            "start": 569,
-            "end": 318216,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16893715': {'publication date': '2006 Aug 15', 'sentence': 'Although initial studies in transgenic mice and humans are encouraging, more data are required to conclusively prove the hypothesis that the adipose-tissue-specific overexpression of HSD1 and the resultant increase in tissue-specific cortisol concentrations result in human obesity, insulin resistance, high blood pressure, and metabolic syndrome.', 'subject score': 750, 'object score': 888}, 'PMID:17558491': {'publication date': '2007 Oct', 'sentence': 'CONTEXT: Changes in cortisol metabolism due to altered activity of the enzyme 11beta-hydroxysteroid dehydrogenase (11beta-HSD) have been implicated in the pathogenesis of hypertension, obesity and the metabolic syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:22146091': {'publication date': '2012 May', 'sentence': 'Moreover, chronic alterations in cortisol secretion in children may affect the timing of puberty, final stature, and body composition, as well as cause early-onset obesity, metabolic syndrome, and type 2 diabetes mellitus.', 'subject score': 888, 'object score': 851}, 'PMID:23505190': {'publication date': '2013 Jan', 'sentence': 'OBJECTIVE: Circulating cortisol and psychosocial stress may contribute to the pathogenesis of obesity and metabolic syndrome (MS).', 'subject score': 1000, 'object score': 1000}, 'PMID:24384019': {'publication date': '2014 Jan', 'sentence': 'CONTEXT: Pathologically increased cortisol exposure induces obesity, but it is not known whether relatively high cortisol within the physiological range is related to childhood obesity.', 'subject score': 583, 'object score': 1000}, 'PMID:28567298': {'publication date': '2017', 'sentence': 'He was initially misdiagnosed as having an adrenal insufficiency and developed cushingoid features and obesity secondary to hydrocortisone treatment and excessive sugar intake.', 'subject score': 888, 'object score': 1000}, 'PMID:36446324': {'publication date': '2022', 'sentence': 'Proponents of the \"Energy Storage\" hypothesis point to data implicating monogenetic disorders, the ventromedial hypothalamus, insulin, cortisol, and the adipocyte itself in the pathogenesis of obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:7550541': {'publication date': '1995 May', 'sentence': 'Cortisol in the presence of relatively high insulin concentrations can promote the deposition of energy and lead to obesity.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0028754---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "12645476",
-              "object": "MONDO:0011122",
-              "publications": [
-                "PMID:16893715",
-                "PMID:17558491",
-                "PMID:22146091",
-                "PMID:23505190",
-                "PMID:24384019",
-                "PMID:28567298",
-                "PMID:36446324",
-                "PMID:7550541"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:15257241': {'publication date': '2004 Jun 05', 'sentence': 'INTRA-CELL CORTISOL: Attention is also focused on the potential implication of cortisol in the genesis of metabolic syndrome, because cortisol is a potent antagonist of the effect of insulin and its presence in excess enhances visceral obesity and insulin resistance.', 'subject score': 1000, 'object score': 888}, 'PMID:20109546': {'publication date': '2010 Aug', 'sentence': 'Cortisol secretion and glucocorticoid excretion rates are regularly increased in obesity and associate with indices of body size and visceral adiposity.', 'subject score': 888, 'object score': 1000}, 'PMID:28771488': {'publication date': '2017', 'sentence': 'Plasma cortisol concentrations were increased (P<0.05) in MO vs.', 'subject score': 890, 'object score': 888}, 'PMID:9039335': {'publication date': '1996 Dec', 'sentence': 'CONCLUSION: Our results suggest that DHEA may vary independently of circulating cortisol, and that the cortisol response to food is enhanced in obese subjects, particularly in those with central obesity.', 'subject score': 888, 'object score': 872}}",
-    "p2": {
-      "start": {
-        "identity": 318216,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318216,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11061930,
-            "start": 569,
-            "end": 318216,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15257241': {'publication date': '2004 Jun 05', 'sentence': 'INTRA-CELL CORTISOL: Attention is also focused on the potential implication of cortisol in the genesis of metabolic syndrome, because cortisol is a potent antagonist of the effect of insulin and its presence in excess enhances visceral obesity and insulin resistance.', 'subject score': 1000, 'object score': 888}, 'PMID:20109546': {'publication date': '2010 Aug', 'sentence': 'Cortisol secretion and glucocorticoid excretion rates are regularly increased in obesity and associate with indices of body size and visceral adiposity.', 'subject score': 888, 'object score': 1000}, 'PMID:28771488': {'publication date': '2017', 'sentence': 'Plasma cortisol concentrations were increased (P<0.05) in MO vs.', 'subject score': 890, 'object score': 888}, 'PMID:9039335': {'publication date': '1996 Dec', 'sentence': 'CONCLUSION: Our results suggest that DHEA may vary independently of circulating cortisol, and that the cortisol response to food is enhanced in obese subjects, particularly in those with central obesity.', 'subject score': 888, 'object score': 872}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0028754---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "11304252",
-              "object": "MONDO:0011122",
-              "publications": [
-                "PMID:15257241",
-                "PMID:20109546",
-                "PMID:28771488",
-                "PMID:9039335"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:10692082': {'publication date': '2000 Feb', 'sentence': 'However, after adjusting for the effect of obesity by multiple regression, higher plasma cortisol was independently associated with higher diastolic blood pressure in men (r = 0.21, P = 0.04) but not in women, and higher fasting serum triglyceride levels in women (r = 0.28, P < 0. 001) but not in men.', 'subject score': 840, 'object score': 1000}, 'PMID:11238541': {'publication date': '2001 Mar', 'sentence': 'However, changes in 11beta-HSD1 are tissue-specific: strikingly enhanced reactivation of cortisone to cortisol in subcutaneous adipose tissue may exacerbate obesity; and it may be beneficial to inhibit this enzyme in adipose tissue in obese patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:1158040': {'publication date': '1975 Aug', 'sentence': 'Effect of physical exercise on secretion of growth hormone, glucagon, and cortisol in obese and diabetic children.', 'subject score': 1000, 'object score': 1000}, 'PMID:12055988': {'publication date': '2002 Mar', 'sentence': 'The effects of obesity and starvation on thyroid hormone, GH, and cortisol secretion are summarized in Table 1.', 'subject score': 888, 'object score': 1000}, 'PMID:15356083': {'publication date': '2004 Sep', 'sentence': 'These data suggest that salivary cortisol and lipolytic responses are not necessarily linked, but are altered in obesity.', 'subject score': 888, 'object score': 1000}, 'PMID:1666898': {'publication date': '1991 Dec', 'sentence': 'The effects of glucose ingestion and fasting on plasma immunoreactive beta-endorphin, adrenocorticotropic hormone and cortisol in obese subjects.', 'subject score': 1000, 'object score': 872}, 'PMID:16958791': {'publication date': '2006 Oct', 'sentence': 'In the present study, we investigated the effect of naturally acquired obesity on cortisol, insulin-like growth factor (IGF)-1 and prolactin secretion in dogs.', 'subject score': 1000, 'object score': 790}, 'PMID:24983396': {'publication date': '2014 Aug', 'sentence': 'PURPOSE OF REVIEW: To review recent progress in the field of cortisol exposure and sensitivity, and its implications for research concerning obesity and related metabolic disturbances.', 'subject score': 694, 'object score': 802}, 'PMID:25618798': {'publication date': '2015 Apr', 'sentence': 'The effect of body temperature, melatonin and cortisol on obesity in women: A biochemical evaluation?', 'subject score': 1000, 'object score': 1000}, 'PMID:2847928': {'publication date': '1988', 'sentence': 'Effect of clonidine on beta-endorphin, ACTH and cortisol secretion in essential hypertension and obesity.', 'subject score': 888, 'object score': 1000}, 'PMID:29262485': {'publication date': '2017 Dec 06', 'sentence': 'Conclusion: Hair cortisol had a significant relation with overweight and obesity in 6-9 years old childhood especially among girls.', 'subject score': 888, 'object score': 1000}, 'PMID:30118922': {'publication date': '2018 Dec', 'sentence': 'Perceived weight discrimination significantly mediated associations between obesity and hair cortisol (beta = 0.021, SE = 0.007, 95% CI 0.007-0.036) and BMI and hair cortisol (beta = 0.001, SE = 0.0004, 95% CI 0.0004-0.002), accounting for 19% of the total effect of obesity and 23% of the total effect of BMI on hair cortisol.', 'subject score': 888, 'object score': 1000}, 'PMID:3155995': {'publication date': '1985 Feb 15', 'sentence': '[The effect of physical activity in obese subjects on the levels of cortisol, glucagon and beta-endorphins in the blood].', 'subject score': 1000, 'object score': 872}, 'PMID:31863690': {'publication date': '2019 Dec 01', 'sentence': 'Cortisol and IGF-I SDS were divided in quartiles and then crossed to explore the reciprocal influence of high/high, low/low, and high/low levels of each one on the metabolic alterations of obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:32546861': {'publication date': '2020 Jun 16', 'sentence': 'Amygdala networks, cumulative cortisol, and weight loss in adolescents with excess weight.OBJECTIVE: The amygdala is importantly involved in stress and obesity, but its role on weight change and diet-related stress remains unexplored among adolescents with excess weight.', 'subject score': 888, 'object score': 1000}, 'PMID:36714602': {'publication date': '2022', 'sentence': 'Conclusions: Although women with obesity reported higher perceived stress, they had lower urinary cortisol than women with normal BMI, and gestation-related increases in cortisol were similar across weight groups and unrelated to perceived stress, suggesting that physiological factors that drive increases in cortisol as pregnancy may outweigh effects of stress and adiposity.', 'subject score': 1000, 'object score': 1000}, 'PMID:679499': {'publication date': '1978 Jul', 'sentence': 'The circadian rhythm of cortisol was not altered in obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:9589697': {'publication date': '1998 May', 'sentence': 'These observations suggest that cortisol clearance is altered in obesity, and this may account for activation of the hypothalamic-pituitary-adrenal axis.', 'subject score': 888, 'object score': 1000}, 'PMID:9760012': {'publication date': '1998 Sep', 'sentence': 'Effect of fat distribution on the pharmacokinetics of cortisol in obesity.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318216,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318216,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7849953,
-            "start": 569,
-            "end": 318216,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10692082': {'publication date': '2000 Feb', 'sentence': 'However, after adjusting for the effect of obesity by multiple regression, higher plasma cortisol was independently associated with higher diastolic blood pressure in men (r = 0.21, P = 0.04) but not in women, and higher fasting serum triglyceride levels in women (r = 0.28, P < 0. 001) but not in men.', 'subject score': 840, 'object score': 1000}, 'PMID:11238541': {'publication date': '2001 Mar', 'sentence': 'However, changes in 11beta-HSD1 are tissue-specific: strikingly enhanced reactivation of cortisone to cortisol in subcutaneous adipose tissue may exacerbate obesity; and it may be beneficial to inhibit this enzyme in adipose tissue in obese patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:1158040': {'publication date': '1975 Aug', 'sentence': 'Effect of physical exercise on secretion of growth hormone, glucagon, and cortisol in obese and diabetic children.', 'subject score': 1000, 'object score': 1000}, 'PMID:12055988': {'publication date': '2002 Mar', 'sentence': 'The effects of obesity and starvation on thyroid hormone, GH, and cortisol secretion are summarized in Table 1.', 'subject score': 888, 'object score': 1000}, 'PMID:15356083': {'publication date': '2004 Sep', 'sentence': 'These data suggest that salivary cortisol and lipolytic responses are not necessarily linked, but are altered in obesity.', 'subject score': 888, 'object score': 1000}, 'PMID:1666898': {'publication date': '1991 Dec', 'sentence': 'The effects of glucose ingestion and fasting on plasma immunoreactive beta-endorphin, adrenocorticotropic hormone and cortisol in obese subjects.', 'subject score': 1000, 'object score': 872}, 'PMID:16958791': {'publication date': '2006 Oct', 'sentence': 'In the present study, we investigated the effect of naturally acquired obesity on cortisol, insulin-like growth factor (IGF)-1 and prolactin secretion in dogs.', 'subject score': 1000, 'object score': 790}, 'PMID:24983396': {'publication date': '2014 Aug', 'sentence': 'PURPOSE OF REVIEW: To review recent progress in the field of cortisol exposure and sensitivity, and its implications for research concerning obesity and related metabolic disturbances.', 'subject score': 694, 'object score': 802}, 'PMID:25618798': {'publication date': '2015 Apr', 'sentence': 'The effect of body temperature, melatonin and cortisol on obesity in women: A biochemical evaluation?', 'subject score': 1000, 'object score': 1000}, 'PMID:2847928': {'publication date': '1988', 'sentence': 'Effect of clonidine on beta-endorphin, ACTH and cortisol secretion in essential hypertension and obesity.', 'subject score': 888, 'object score': 1000}, 'PMID:29262485': {'publication date': '2017 Dec 06', 'sentence': 'Conclusion: Hair cortisol had a significant relation with overweight and obesity in 6-9 years old childhood especially among girls.', 'subject score': 888, 'object score': 1000}, 'PMID:30118922': {'publication date': '2018 Dec', 'sentence': 'Perceived weight discrimination significantly mediated associations between obesity and hair cortisol (beta = 0.021, SE = 0.007, 95% CI 0.007-0.036) and BMI and hair cortisol (beta = 0.001, SE = 0.0004, 95% CI 0.0004-0.002), accounting for 19% of the total effect of obesity and 23% of the total effect of BMI on hair cortisol.', 'subject score': 888, 'object score': 1000}, 'PMID:3155995': {'publication date': '1985 Feb 15', 'sentence': '[The effect of physical activity in obese subjects on the levels of cortisol, glucagon and beta-endorphins in the blood].', 'subject score': 1000, 'object score': 872}, 'PMID:31863690': {'publication date': '2019 Dec 01', 'sentence': 'Cortisol and IGF-I SDS were divided in quartiles and then crossed to explore the reciprocal influence of high/high, low/low, and high/low levels of each one on the metabolic alterations of obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:32546861': {'publication date': '2020 Jun 16', 'sentence': 'Amygdala networks, cumulative cortisol, and weight loss in adolescents with excess weight.OBJECTIVE: The amygdala is importantly involved in stress and obesity, but its role on weight change and diet-related stress remains unexplored among adolescents with excess weight.', 'subject score': 888, 'object score': 1000}, 'PMID:36714602': {'publication date': '2022', 'sentence': 'Conclusions: Although women with obesity reported higher perceived stress, they had lower urinary cortisol than women with normal BMI, and gestation-related increases in cortisol were similar across weight groups and unrelated to perceived stress, suggesting that physiological factors that drive increases in cortisol as pregnancy may outweigh effects of stress and adiposity.', 'subject score': 1000, 'object score': 1000}, 'PMID:679499': {'publication date': '1978 Jul', 'sentence': 'The circadian rhythm of cortisol was not altered in obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:9589697': {'publication date': '1998 May', 'sentence': 'These observations suggest that cortisol clearance is altered in obesity, and this may account for activation of the hypothalamic-pituitary-adrenal axis.', 'subject score': 888, 'object score': 1000}, 'PMID:9760012': {'publication date': '1998 Sep', 'sentence': 'Effect of fat distribution on the pharmacokinetics of cortisol in obesity.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0028754---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8017440",
-              "object": "MONDO:0011122",
-              "publications": [
-                "PMID:10692082",
-                "PMID:11238541",
-                "PMID:1158040",
-                "PMID:12055988",
-                "PMID:15356083",
-                "PMID:1666898",
-                "PMID:16958791",
-                "PMID:24983396",
-                "PMID:25618798",
-                "PMID:2847928",
-                "PMID:29262485",
-                "PMID:30118922",
-                "PMID:3155995",
-                "PMID:31863690",
-                "PMID:32546861",
-                "PMID:36714602",
-                "PMID:679499",
-                "PMID:9589697",
-                "PMID:9760012"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10968480': {'publication date': '2000 Jul-Aug', 'sentence': 'We studied the interactions of leptin, insulin and cortisol in obese children and adolescents at different stages of maturation.', 'subject score': 1000, 'object score': 888}, 'PMID:10997634': {'publication date': '2000 Jun', 'sentence': 'Increased response of cortisol and ACTH to corticotrophin releasing hormone in centrally obese men, but not in post-menopausal women.', 'subject score': 1000, 'object score': 790}, 'PMID:11428718': {'publication date': '2001 Feb-May', 'sentence': 'The results presented are consistent with a lower overall cortisol secretion in the morbid obese women, which also show a narrower margin of variation in cortisol secretion than non-obese controls.', 'subject score': 888, 'object score': 773}, 'PMID:11454512': {'publication date': '2001 Aug', 'sentence': 'OBJECTIVE: To compare salivary, plasma and urinary free cortisol (UFC) measurements in patients with anorexia nervosa, in whom an overdrive of the hypothalamic-pituitary-adrenal (HPA) axis is well established but information on salivary cortisol is lacking, in viscerally obese patients in whom subtle abnormalities of cortisol secretion and metabolism are postulated, and in normal-weight healthy women.', 'subject score': 888, 'object score': 790}, 'PMID:11889189': {'publication date': '2002 Mar', 'sentence': \"As exemplified in patients with Cushing's syndrome, glucocorticoids play an important role in regulating adipose tissue distribution and function, but circulating cortisol concentrations are normal in most patients with obesity.\", 'subject score': 851, 'object score': 1000}, 'PMID:12107245': {'publication date': '2002 Jul', 'sentence': 'Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity.', 'subject score': 851, 'object score': 888}, 'PMID:12530648': {'publication date': '2002 Nov', 'sentence': 'In humans, glucocorticoids are important regulators of adipose tissue distribution and function but circulating cortisol concentrations are normal in most patients with obesity.', 'subject score': 851, 'object score': 1000}, 'PMID:12688161': {'publication date': '2002', 'sentence': 'Fasting plasma levels of both cortisol and sex hormone binding globulin (SHBG) in obese women were significantly inversely related to anthropometric characteristics of body fat distribution.', 'subject score': 1000, 'object score': 888}, 'PMID:14711067': {'publication date': '2003 Dec', 'sentence': 'Cortisol, ACTH, and urine free cortisol levels are usually normal; however, a hyperresponsiveness of the HPA axis with increased cortisol and ACTH response to stimulatory tests is observed in centrally obese individuals.', 'subject score': 888, 'object score': 790}, 'PMID:14763916': {'publication date': '2004 Feb', 'sentence': 'We suggest that activation of cortisol secretion is not an irreversible intrinsic abnormality in obese patients, and speculate that dietary content has an important influence on the neuroendocrine response to weight loss.', 'subject score': 888, 'object score': 888}, 'PMID:15256820': {'publication date': '2004', 'sentence': 'CONCLUSIONS: Cortisol was moderately increased in insulin-resistant, obese children and related to insulin resistance.', 'subject score': 1000, 'object score': 843}, 'PMID:15481772': {'publication date': '1997 Aug', 'sentence': 'MEASUREMENTS: Evaluation of TGF-beta1, insulin, prolactin, sex-hormone binding globulin, androstenedione, free triiodothyronine, free tetraiodothyronine, thyroid-stimulating hormone, dehydroepiandrosterone-sulfate, testosterone, insulin-like growth factor 1, cortisol and adrenocorticotropic hormone plasma concentrations in obese women.', 'subject score': 1000, 'object score': 888}, 'PMID:15481773': {'publication date': '1997 Aug', 'sentence': 'Incremental areas of ACTH and cortisol were significantly higher in women with visceral obesity than in those with subcutaneous obesity and controls.', 'subject score': 1000, 'object score': 888}, 'PMID:15537170': {'publication date': '2004', 'sentence': 'The aim of this study was to investigate the response of cortisol, insulin and lipid parameters [serum Lipoprotein Lipase activity, choleseryl-ester transfer protein, triglycerides, total Cholesterol, High Density Lipoprotein, Free Fatty Acids] during the perioperative period in obese patients undergoing laparoscopic cholecystectomy.', 'subject score': 1000, 'object score': 888}, 'PMID:15985478': {'publication date': '2005 Sep', 'sentence': 'Inhibition of cortisol biosynthesis decreases circulating leptin levels in obese humans.', 'subject score': 840, 'object score': 888}, 'PMID:16332937': {'publication date': '2006 Feb', 'sentence': 'Lower excess postexercise oxygen consumption and altered growth hormone and cortisol responses to exercise in obese men.', 'subject score': 888, 'object score': 888}, 'PMID:163455': {'publication date': '1975 Jan 24', 'sentence': 'Changes in plasma cortisol during the tolbutamide test were evaluated in normal subjects and in obese patients with a normal (D = 60,1 plus or minus 8,3) or reduced (D = 23,2 plus or minus 9,5) blood sugar decrease coefficient.', 'subject score': 888, 'object score': 888}, 'PMID:16353581': {'publication date': '1994 Jul', 'sentence': 'There was no difference in baseline values of prolactin (PRL), corticotropin (ACTH) and cortisol in non-obese controls, obese before and obese after weight loss.', 'subject score': 1000, 'object score': 773}, 'PMID:16772320': {'publication date': '2006 Nov', 'sentence': 'The increase of PAI-1 between time(180) and time(240) after HC was higher in obese women (+25%) than in controls (+12%) (P < 0.05), whereas no differential effect between groups was observed for free fatty acids or adiponectin.', 'subject score': 1000, 'object score': 888}, 'PMID:17505053': {'publication date': '2007 Aug', 'sentence': 'We compared the circadian profiles of cortisol in obese men with [obSAS+; apnea-hypopnea index (AHI) >or= 20/h] and without SAS (obSAS-; AHI <or= 5/h).', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 318216,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318216,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8234463,
-            "start": 569,
-            "end": 318216,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10968480': {'publication date': '2000 Jul-Aug', 'sentence': 'We studied the interactions of leptin, insulin and cortisol in obese children and adolescents at different stages of maturation.', 'subject score': 1000, 'object score': 888}, 'PMID:10997634': {'publication date': '2000 Jun', 'sentence': 'Increased response of cortisol and ACTH to corticotrophin releasing hormone in centrally obese men, but not in post-menopausal women.', 'subject score': 1000, 'object score': 790}, 'PMID:11428718': {'publication date': '2001 Feb-May', 'sentence': 'The results presented are consistent with a lower overall cortisol secretion in the morbid obese women, which also show a narrower margin of variation in cortisol secretion than non-obese controls.', 'subject score': 888, 'object score': 773}, 'PMID:11454512': {'publication date': '2001 Aug', 'sentence': 'OBJECTIVE: To compare salivary, plasma and urinary free cortisol (UFC) measurements in patients with anorexia nervosa, in whom an overdrive of the hypothalamic-pituitary-adrenal (HPA) axis is well established but information on salivary cortisol is lacking, in viscerally obese patients in whom subtle abnormalities of cortisol secretion and metabolism are postulated, and in normal-weight healthy women.', 'subject score': 888, 'object score': 790}, 'PMID:11889189': {'publication date': '2002 Mar', 'sentence': \"As exemplified in patients with Cushing's syndrome, glucocorticoids play an important role in regulating adipose tissue distribution and function, but circulating cortisol concentrations are normal in most patients with obesity.\", 'subject score': 851, 'object score': 1000}, 'PMID:12107245': {'publication date': '2002 Jul', 'sentence': 'Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity.', 'subject score': 851, 'object score': 888}, 'PMID:12530648': {'publication date': '2002 Nov', 'sentence': 'In humans, glucocorticoids are important regulators of adipose tissue distribution and function but circulating cortisol concentrations are normal in most patients with obesity.', 'subject score': 851, 'object score': 1000}, 'PMID:12688161': {'publication date': '2002', 'sentence': 'Fasting plasma levels of both cortisol and sex hormone binding globulin (SHBG) in obese women were significantly inversely related to anthropometric characteristics of body fat distribution.', 'subject score': 1000, 'object score': 888}, 'PMID:14711067': {'publication date': '2003 Dec', 'sentence': 'Cortisol, ACTH, and urine free cortisol levels are usually normal; however, a hyperresponsiveness of the HPA axis with increased cortisol and ACTH response to stimulatory tests is observed in centrally obese individuals.', 'subject score': 888, 'object score': 790}, 'PMID:14763916': {'publication date': '2004 Feb', 'sentence': 'We suggest that activation of cortisol secretion is not an irreversible intrinsic abnormality in obese patients, and speculate that dietary content has an important influence on the neuroendocrine response to weight loss.', 'subject score': 888, 'object score': 888}, 'PMID:15256820': {'publication date': '2004', 'sentence': 'CONCLUSIONS: Cortisol was moderately increased in insulin-resistant, obese children and related to insulin resistance.', 'subject score': 1000, 'object score': 843}, 'PMID:15481772': {'publication date': '1997 Aug', 'sentence': 'MEASUREMENTS: Evaluation of TGF-beta1, insulin, prolactin, sex-hormone binding globulin, androstenedione, free triiodothyronine, free tetraiodothyronine, thyroid-stimulating hormone, dehydroepiandrosterone-sulfate, testosterone, insulin-like growth factor 1, cortisol and adrenocorticotropic hormone plasma concentrations in obese women.', 'subject score': 1000, 'object score': 888}, 'PMID:15481773': {'publication date': '1997 Aug', 'sentence': 'Incremental areas of ACTH and cortisol were significantly higher in women with visceral obesity than in those with subcutaneous obesity and controls.', 'subject score': 1000, 'object score': 888}, 'PMID:15537170': {'publication date': '2004', 'sentence': 'The aim of this study was to investigate the response of cortisol, insulin and lipid parameters [serum Lipoprotein Lipase activity, choleseryl-ester transfer protein, triglycerides, total Cholesterol, High Density Lipoprotein, Free Fatty Acids] during the perioperative period in obese patients undergoing laparoscopic cholecystectomy.', 'subject score': 1000, 'object score': 888}, 'PMID:15985478': {'publication date': '2005 Sep', 'sentence': 'Inhibition of cortisol biosynthesis decreases circulating leptin levels in obese humans.', 'subject score': 840, 'object score': 888}, 'PMID:16332937': {'publication date': '2006 Feb', 'sentence': 'Lower excess postexercise oxygen consumption and altered growth hormone and cortisol responses to exercise in obese men.', 'subject score': 888, 'object score': 888}, 'PMID:163455': {'publication date': '1975 Jan 24', 'sentence': 'Changes in plasma cortisol during the tolbutamide test were evaluated in normal subjects and in obese patients with a normal (D = 60,1 plus or minus 8,3) or reduced (D = 23,2 plus or minus 9,5) blood sugar decrease coefficient.', 'subject score': 888, 'object score': 888}, 'PMID:16353581': {'publication date': '1994 Jul', 'sentence': 'There was no difference in baseline values of prolactin (PRL), corticotropin (ACTH) and cortisol in non-obese controls, obese before and obese after weight loss.', 'subject score': 1000, 'object score': 773}, 'PMID:16772320': {'publication date': '2006 Nov', 'sentence': 'The increase of PAI-1 between time(180) and time(240) after HC was higher in obese women (+25%) than in controls (+12%) (P < 0.05), whereas no differential effect between groups was observed for free fatty acids or adiponectin.', 'subject score': 1000, 'object score': 888}, 'PMID:17505053': {'publication date': '2007 Aug', 'sentence': 'We compared the circadian profiles of cortisol in obese men with [obSAS+; apnea-hypopnea index (AHI) >or= 20/h] and without SAS (obSAS-; AHI <or= 5/h).', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0028754---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8412499",
-              "object": "MONDO:0011122",
-              "publications": [
-                "PMID:10968480",
-                "PMID:10997634",
-                "PMID:11428718",
-                "PMID:11454512",
-                "PMID:11889189",
-                "PMID:12107245",
-                "PMID:12530648",
-                "PMID:12688161",
-                "PMID:14711067",
-                "PMID:14763916",
-                "PMID:15256820",
-                "PMID:15481772",
-                "PMID:15481773",
-                "PMID:15537170",
-                "PMID:15985478",
-                "PMID:16332937",
-                "PMID:163455",
-                "PMID:16353581",
-                "PMID:16772320",
-                "PMID:17505053"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:produces",
-    "r2.publications_info": "{'PMID:18676028': {'publication date': '2008 Sep 15', 'sentence': 'Obesity is also related to dysregulation of cortisol production by the pre-receptor enzyme, 11beta-hydroxysteroid dehydrogenase, and we speculate that this may have a role in the pathogenesis of obesity and raised ICP seen in IIH.', 'subject score': 1000, 'object score': 888}, 'PMID:22934546': {'publication date': '2012 Nov', 'sentence': 'Further studies indicate the inverse relationship between type 1 diabetes and type 2 diabetes/obesity is due to cortisol production.', 'subject score': 916, 'object score': 888}, 'PMID:23455734': {'publication date': '2013', 'sentence': 'OBJECTIVES: Visceral obesity may be due to the dysregulation of cortisol production or metabolism that lead to metabolic disease.', 'subject score': 888, 'object score': 888}, 'PMID:2682149': {'publication date': '1989 Oct', 'sentence': 'In humans, studies have reported that some obese subjects hypersecrete cortisol and have an increase in the cortisol production rate.', 'subject score': 872, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 318216,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318216,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13589642,
-            "start": 318216,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:18676028': {'publication date': '2008 Sep 15', 'sentence': 'Obesity is also related to dysregulation of cortisol production by the pre-receptor enzyme, 11beta-hydroxysteroid dehydrogenase, and we speculate that this may have a role in the pathogenesis of obesity and raised ICP seen in IIH.', 'subject score': 1000, 'object score': 888}, 'PMID:22934546': {'publication date': '2012 Nov', 'sentence': 'Further studies indicate the inverse relationship between type 1 diabetes and type 2 diabetes/obesity is due to cortisol production.', 'subject score': 916, 'object score': 888}, 'PMID:23455734': {'publication date': '2013', 'sentence': 'OBJECTIVES: Visceral obesity may be due to the dysregulation of cortisol production or metabolism that lead to metabolic disease.', 'subject score': 888, 'object score': 888}, 'PMID:2682149': {'publication date': '1989 Oct', 'sentence': 'In humans, studies have reported that some obese subjects hypersecrete cortisol and have an increase in the cortisol production rate.', 'subject score': 872, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0028754---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0011122",
-              "id": "13891079",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:18676028",
-                "PMID:22934546",
-                "PMID:23455734",
-                "PMID:2682149"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:21964795': {'publication date': '2012 Mar', 'sentence': 'BACKGROUND: Hepatic 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) activity, which converts cortisone (inactive) to cortisol, is downregulated in obesity.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318216,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318216,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15569401,
-            "start": 569,
-            "end": 318216,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21964795': {'publication date': '2012 Mar', 'sentence': 'BACKGROUND: Hepatic 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) activity, which converts cortisone (inactive) to cortisol, is downregulated in obesity.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:disrupts---None---None---None---UMLS:C0028754---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "15895489",
-              "object": "MONDO:0011122",
-              "publications": [
-                "PMID:21964795"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:27891832': {'publication date': '2016 Dec', 'sentence': 'Further, because infant formula contains only trace amounts of glucocorticoids, these findings suggest that cortisol in milk is a novel biological pathway through which breastfeeding may protect against later obesity.', 'subject score': 1000, 'object score': 872}, 'PMID:2844443': {'publication date': '1988 Jan', 'sentence': 'The peak ACTH response to CRF was less in the obese but this was not significant (obese ACTH +/- SEM, 31 +/- 4 ng/l, controls 39 +/- 4 ng/l) whereas the peak cortisol was significantly reduced in the obese (obese cortisol, 456 +/- 21 nmol/l, controls 638 +/- 50 nmol/l).', 'subject score': 861, 'object score': 1000}, 'PMID:873764': {'publication date': '1977 May', 'sentence': 'The responses of cortisol and GH were reduced in the obese subjects as compared with the normal-weight subjects.', 'subject score': 1000, 'object score': 872}}",
-    "p2": {
-      "start": {
-        "identity": 318216,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318216,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18961170,
-            "start": 569,
-            "end": 318216,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27891832': {'publication date': '2016 Dec', 'sentence': 'Further, because infant formula contains only trace amounts of glucocorticoids, these findings suggest that cortisol in milk is a novel biological pathway through which breastfeeding may protect against later obesity.', 'subject score': 1000, 'object score': 872}, 'PMID:2844443': {'publication date': '1988 Jan', 'sentence': 'The peak ACTH response to CRF was less in the obese but this was not significant (obese ACTH +/- SEM, 31 +/- 4 ng/l, controls 39 +/- 4 ng/l) whereas the peak cortisol was significantly reduced in the obese (obese cortisol, 456 +/- 21 nmol/l, controls 638 +/- 50 nmol/l).', 'subject score': 861, 'object score': 1000}, 'PMID:873764': {'publication date': '1977 May', 'sentence': 'The responses of cortisol and GH were reduced in the obese subjects as compared with the normal-weight subjects.', 'subject score': 1000, 'object score': 872}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0028754---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "19342068",
-              "object": "MONDO:0011122",
-              "publications": [
-                "PMID:27891832",
-                "PMID:2844443",
-                "PMID:873764"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:exacerbates",
-    "r2.publications_info": "{'PMID:10762282': {'publication date': '2000 Apr', 'sentence': 'In view of the stimulatory effects of insulin and cortisol on adipogenesis, long-term stimulation of 11betaHSD reductase activity by insulin could aggravate visceral obesity.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 318216,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318216,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7952217,
-            "start": 569,
-            "end": 318216,
-            "type": "biolink:exacerbates",
-            "properties": {
-              "predicate": "biolink:exacerbates",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10762282': {'publication date': '2000 Apr', 'sentence': 'In view of the stimulatory effects of insulin and cortisol on adipogenesis, long-term stimulation of 11betaHSD reductase activity by insulin could aggravate visceral obesity.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:complicates---None---None---None---UMLS:C0028754---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8122784",
-              "object": "MONDO:0011122",
-              "publications": [
-                "PMID:10762282"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:1338326': {'publication date': '1992 Dec', 'sentence': 'The synergism between insulin and cortisol in stimulating energy deposition, associated with a decreased effect of corticotropin-releasing factor in stimulating energy expenditure, is likely to contribute to the development of obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:15607573': {'publication date': '2005', 'sentence': 'Since cortisol promotes development of visceral obesity, and has a direct negative impact on insulin function throughout the body, even a modest sustained up-regulation of cortisol production may have the potential to increase risk for insulin resistance syndrome and type 2 diabetes.', 'subject score': 1000, 'object score': 888}, 'PMID:23512832': {'publication date': '2013 Dec', 'sentence': 'OBJECTIVES: Increased intra-adipose cortisol is thought to promote obesity, but few human studies have investigated intra-adipose glucocorticoid hormones and none have demonstrated prospective changes with fat loss.', 'subject score': 775, 'object score': 1000}, 'PMID:28229550': {'publication date': '2017 03', 'sentence': 'OBJECTIVE: Chronic cortisol exposure is hypothesized to contribute to obesity.', 'subject score': 623, 'object score': 1000}, 'PMID:30849107': {'publication date': '2019', 'sentence': 'Association between hair cortisol concentration and dietary intake among normal weight preschool children predisposed to overweight and obesity.', 'subject score': 623, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318216,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318216,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10293634,
-            "start": 569,
-            "end": 318216,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1338326': {'publication date': '1992 Dec', 'sentence': 'The synergism between insulin and cortisol in stimulating energy deposition, associated with a decreased effect of corticotropin-releasing factor in stimulating energy expenditure, is likely to contribute to the development of obesity.', 'subject score': 1000, 'object score': 1000}, 'PMID:15607573': {'publication date': '2005', 'sentence': 'Since cortisol promotes development of visceral obesity, and has a direct negative impact on insulin function throughout the body, even a modest sustained up-regulation of cortisol production may have the potential to increase risk for insulin resistance syndrome and type 2 diabetes.', 'subject score': 1000, 'object score': 888}, 'PMID:23512832': {'publication date': '2013 Dec', 'sentence': 'OBJECTIVES: Increased intra-adipose cortisol is thought to promote obesity, but few human studies have investigated intra-adipose glucocorticoid hormones and none have demonstrated prospective changes with fat loss.', 'subject score': 775, 'object score': 1000}, 'PMID:28229550': {'publication date': '2017 03', 'sentence': 'OBJECTIVE: Chronic cortisol exposure is hypothesized to contribute to obesity.', 'subject score': 623, 'object score': 1000}, 'PMID:30849107': {'publication date': '2019', 'sentence': 'Association between hair cortisol concentration and dietary intake among normal weight preschool children predisposed to overweight and obesity.', 'subject score': 623, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:predisposes---None---None---None---UMLS:C0028754---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10520517",
-              "object": "MONDO:0011122",
-              "publications": [
-                "PMID:1338326",
-                "PMID:15607573",
-                "PMID:23512832",
-                "PMID:28229550",
-                "PMID:30849107"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:19015613': {'publication date': '2008', 'sentence': 'Here, we report a case of fatal ATLS complicating intrathecal injections of methotrexate, cytarabine and hydrocortisone for acute lymphoblastic leukemia which relapsed with meningeal involvement after allogeneic stem cell transplantation.', 'subject score': 1000, 'object score': 1000}, 'PMID:27161966': {'publication date': '2016 07 01', 'sentence': 'CONCLUSION: Our results suggest that adding a physiologic dose of hydrocortisone to dexamethasone treatment can reduce the occurrence of serious neuropsychological adverse effects and sleep-related difficulties in pediatric patients with ALL.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 323831,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-          "name": "acute lymphoblastic leukemia",
-          "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "HP:0006721",
-            "MONDO:0004967",
-            "MEDDRA:10000848",
-            "MEDDRA:10000849",
-            "MEDDRA:10025305",
-            "ORPHANET:513",
-            "MEDDRA:10025301",
-            "ICD10:C91.00",
-            "UMLS:C0023453",
-            "DOID:9952",
-            "MEDDRA:10000844",
-            "MEDDRA:10000846",
-            "MEDDRA:10000845",
-            "MEDDRA:10024338",
-            "ICD10:C91",
-            "MESH:D054198",
-            "UMLS:C1961102",
-            "MEDDRA:10060555",
-            "NCIT:C3167",
-            "PDQ:CDR0000043423",
-            "MEDDRA:10024290",
-            "MEDDRA:10000842",
-            "NCIT:C27281",
-            "ICD9:204",
-            "DOID:1037",
-            "MEDDRA:10000843",
-            "EFO:0000220",
-            "SNOMEDCT:128822004",
-            "ICD9:204.0",
-            "UMLS:C0023449",
-            "MEDDRA:10060390",
-            "SNOMEDCT:91857003"
-          ],
-          "id": "MONDO:0004967",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute lymphoblastic leukemia",
-            "lymphoid leukemia",
-            "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-            "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-            "L2 Acute Lymphoblastic Leukemia",
-            "acute lymphocytic leukemia",
-            "Lymphoid leukemia, acute",
-            "acute lymphoblastic leukemia",
-            "Acute lymphocytic leukemia",
-            "Acute Lymphoblastic Leukemia",
-            "Lymphoid leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=46332",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=616067",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323831,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-              "name": "acute lymphoblastic leukemia",
-              "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "HP:0006721",
-                "MONDO:0004967",
-                "MEDDRA:10000848",
-                "MEDDRA:10000849",
-                "MEDDRA:10025305",
-                "ORPHANET:513",
-                "MEDDRA:10025301",
-                "ICD10:C91.00",
-                "UMLS:C0023453",
-                "DOID:9952",
-                "MEDDRA:10000844",
-                "MEDDRA:10000846",
-                "MEDDRA:10000845",
-                "MEDDRA:10024338",
-                "ICD10:C91",
-                "MESH:D054198",
-                "UMLS:C1961102",
-                "MEDDRA:10060555",
-                "NCIT:C3167",
-                "PDQ:CDR0000043423",
-                "MEDDRA:10024290",
-                "MEDDRA:10000842",
-                "NCIT:C27281",
-                "ICD9:204",
-                "DOID:1037",
-                "MEDDRA:10000843",
-                "EFO:0000220",
-                "SNOMEDCT:128822004",
-                "ICD9:204.0",
-                "UMLS:C0023449",
-                "MEDDRA:10060390",
-                "SNOMEDCT:91857003"
-              ],
-              "id": "MONDO:0004967",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute lymphoblastic leukemia",
-                "lymphoid leukemia",
-                "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-                "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-                "L2 Acute Lymphoblastic Leukemia",
-                "acute lymphocytic leukemia",
-                "Lymphoid leukemia, acute",
-                "acute lymphoblastic leukemia",
-                "Acute lymphocytic leukemia",
-                "Acute Lymphoblastic Leukemia",
-                "Lymphoid leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=46332",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=616067",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13781035,
-            "start": 569,
-            "end": 323831,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19015613': {'publication date': '2008', 'sentence': 'Here, we report a case of fatal ATLS complicating intrathecal injections of methotrexate, cytarabine and hydrocortisone for acute lymphoblastic leukemia which relapsed with meningeal involvement after allogeneic stem cell transplantation.', 'subject score': 1000, 'object score': 1000}, 'PMID:27161966': {'publication date': '2016 07 01', 'sentence': 'CONCLUSION: Our results suggest that adding a physiologic dose of hydrocortisone to dexamethasone treatment can reduce the occurrence of serious neuropsychological adverse effects and sleep-related difficulties in pediatric patients with ALL.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0023449---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14075841",
-              "object": "MONDO:0004967",
-              "publications": [
-                "PMID:19015613",
-                "PMID:27161966"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:1945747': {'publication date': '1991 Jul', 'sentence': 'It is concluded that bile acids are potent endogenous inhibitors of 11 beta-HSD and, therefore, could participate in abnormalities of cortisol metabolism observed in liver cirrhosis and extrahepatic biliary obstruction and, possibly, after ingestion of bile acids.', 'subject score': 888, 'object score': 1000}, 'PMID:4480665': {'publication date': '1974 Dec', 'sentence': 'Cortisol metabolism in liver cirrhosis.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 307894,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005155",
-          "name": "cirrhosis of liver",
-          "description": "A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.; Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.; A chronic disorder of the liver in which liver tissue becomes scarred and is partially replaced by regenerative nodules and fibrotic tissue resulting in loss of liver function. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10024667",
-            "ICD10:K74.60",
-            "NCIT:C2951",
-            "MESH:D008103",
-            "HP:0001394",
-            "MEDDRA:10019642",
-            "MONDO:0005155",
-            "EFO:0001422",
-            "UMLS:C0023890",
-            "MEDDRA:10009211",
-            "MEDDRA:10009213",
-            "MEDDRA:10019641",
-            "SNOMEDCT:19943007",
-            "DOID:5082"
-          ],
-          "id": "MONDO:0005155",
-          "category": "biolink:Disease",
-          "all_names": [
-            "liver cirrhosis",
-            "Cirrhosis",
-            "cirrhosis of liver",
-            "Liver Cirrhosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 307894,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005155",
-              "name": "cirrhosis of liver",
-              "description": "A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.; Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.; A chronic disorder of the liver in which liver tissue becomes scarred and is partially replaced by regenerative nodules and fibrotic tissue resulting in loss of liver function. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10024667",
-                "ICD10:K74.60",
-                "NCIT:C2951",
-                "MESH:D008103",
-                "HP:0001394",
-                "MEDDRA:10019642",
-                "MONDO:0005155",
-                "EFO:0001422",
-                "UMLS:C0023890",
-                "MEDDRA:10009211",
-                "MEDDRA:10009213",
-                "MEDDRA:10019641",
-                "SNOMEDCT:19943007",
-                "DOID:5082"
-              ],
-              "id": "MONDO:0005155",
-              "category": "biolink:Disease",
-              "all_names": [
-                "liver cirrhosis",
-                "Cirrhosis",
-                "cirrhosis of liver",
-                "Liver Cirrhosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14087042,
-            "start": 569,
-            "end": 307894,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1945747': {'publication date': '1991 Jul', 'sentence': 'It is concluded that bile acids are potent endogenous inhibitors of 11 beta-HSD and, therefore, could participate in abnormalities of cortisol metabolism observed in liver cirrhosis and extrahepatic biliary obstruction and, possibly, after ingestion of bile acids.', 'subject score': 888, 'object score': 1000}, 'PMID:4480665': {'publication date': '1974 Dec', 'sentence': 'Cortisol metabolism in liver cirrhosis.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0023890---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14387016",
-              "object": "MONDO:0005155",
-              "publications": [
-                "PMID:1945747",
-                "PMID:4480665"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:19690646': {'publication date': '2007 Feb 07', 'sentence': 'The urinary ratio of 6 beta-hydroxycortisol/cortisol (6 beta-OHC/C) as a biomarker of CYP3A4 metabolizing activity has been studied in Egyptian patients with chronic liver cirrhosis associated with previous hepatic Schistosomiasis infection to determine any possible alteration in enzyme activity.', 'subject score': 916, 'object score': 901}, 'PMID:35449323': {'publication date': '2022 Apr 22', 'sentence': 'Urinary free cortisol constitutes an index of adrenal cortisol production; however, it has never been used in assessing adrenal function in patients with liver cirrhosis.', 'subject score': 790, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 307894,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005155",
-          "name": "cirrhosis of liver",
-          "description": "A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.; Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.; A chronic disorder of the liver in which liver tissue becomes scarred and is partially replaced by regenerative nodules and fibrotic tissue resulting in loss of liver function. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10024667",
-            "ICD10:K74.60",
-            "NCIT:C2951",
-            "MESH:D008103",
-            "HP:0001394",
-            "MEDDRA:10019642",
-            "MONDO:0005155",
-            "EFO:0001422",
-            "UMLS:C0023890",
-            "MEDDRA:10009211",
-            "MEDDRA:10009213",
-            "MEDDRA:10019641",
-            "SNOMEDCT:19943007",
-            "DOID:5082"
-          ],
-          "id": "MONDO:0005155",
-          "category": "biolink:Disease",
-          "all_names": [
-            "liver cirrhosis",
-            "Cirrhosis",
-            "cirrhosis of liver",
-            "Liver Cirrhosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 307894,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005155",
-              "name": "cirrhosis of liver",
-              "description": "A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.; Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.; A chronic disorder of the liver in which liver tissue becomes scarred and is partially replaced by regenerative nodules and fibrotic tissue resulting in loss of liver function. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10024667",
-                "ICD10:K74.60",
-                "NCIT:C2951",
-                "MESH:D008103",
-                "HP:0001394",
-                "MEDDRA:10019642",
-                "MONDO:0005155",
-                "EFO:0001422",
-                "UMLS:C0023890",
-                "MEDDRA:10009211",
-                "MEDDRA:10009213",
-                "MEDDRA:10019641",
-                "SNOMEDCT:19943007",
-                "DOID:5082"
-              ],
-              "id": "MONDO:0005155",
-              "category": "biolink:Disease",
-              "all_names": [
-                "liver cirrhosis",
-                "Cirrhosis",
-                "cirrhosis of liver",
-                "Liver Cirrhosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14229887,
-            "start": 569,
-            "end": 307894,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19690646': {'publication date': '2007 Feb 07', 'sentence': 'The urinary ratio of 6 beta-hydroxycortisol/cortisol (6 beta-OHC/C) as a biomarker of CYP3A4 metabolizing activity has been studied in Egyptian patients with chronic liver cirrhosis associated with previous hepatic Schistosomiasis infection to determine any possible alteration in enzyme activity.', 'subject score': 916, 'object score': 901}, 'PMID:35449323': {'publication date': '2022 Apr 22', 'sentence': 'Urinary free cortisol constitutes an index of adrenal cortisol production; however, it has never been used in assessing adrenal function in patients with liver cirrhosis.', 'subject score': 790, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0023890---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14532907",
-              "object": "MONDO:0005155",
-              "publications": [
-                "PMID:19690646",
-                "PMID:35449323"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:produces",
-    "r2.publications_info": "{'PMID:35449323': {'publication date': '2022 Apr 22', 'sentence': 'CONCLUSIONS: This study suggests that 24 h urinary free cortisol could be considered as a potential index of adrenal cortisol production in patients with liver cirrhosis and it potentially detects patients with a high mortality risk.', 'subject score': 1000, 'object score': 790}}",
-    "p2": {
-      "start": {
-        "identity": 307894,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005155",
-          "name": "cirrhosis of liver",
-          "description": "A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.; Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.; A chronic disorder of the liver in which liver tissue becomes scarred and is partially replaced by regenerative nodules and fibrotic tissue resulting in loss of liver function. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10024667",
-            "ICD10:K74.60",
-            "NCIT:C2951",
-            "MESH:D008103",
-            "HP:0001394",
-            "MEDDRA:10019642",
-            "MONDO:0005155",
-            "EFO:0001422",
-            "UMLS:C0023890",
-            "MEDDRA:10009211",
-            "MEDDRA:10009213",
-            "MEDDRA:10019641",
-            "SNOMEDCT:19943007",
-            "DOID:5082"
-          ],
-          "id": "MONDO:0005155",
-          "category": "biolink:Disease",
-          "all_names": [
-            "liver cirrhosis",
-            "Cirrhosis",
-            "cirrhosis of liver",
-            "Liver Cirrhosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 307894,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005155",
-              "name": "cirrhosis of liver",
-              "description": "A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.; Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.; A chronic disorder of the liver in which liver tissue becomes scarred and is partially replaced by regenerative nodules and fibrotic tissue resulting in loss of liver function. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10024667",
-                "ICD10:K74.60",
-                "NCIT:C2951",
-                "MESH:D008103",
-                "HP:0001394",
-                "MEDDRA:10019642",
-                "MONDO:0005155",
-                "EFO:0001422",
-                "UMLS:C0023890",
-                "MEDDRA:10009211",
-                "MEDDRA:10009213",
-                "MEDDRA:10019641",
-                "SNOMEDCT:19943007",
-                "DOID:5082"
-              ],
-              "id": "MONDO:0005155",
-              "category": "biolink:Disease",
-              "all_names": [
-                "liver cirrhosis",
-                "Cirrhosis",
-                "cirrhosis of liver",
-                "Liver Cirrhosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23986403,
-            "start": 307894,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:35449323': {'publication date': '2022 Apr 22', 'sentence': 'CONCLUSIONS: This study suggests that 24 h urinary free cortisol could be considered as a potential index of adrenal cortisol production in patients with liver cirrhosis and it potentially detects patients with a high mortality risk.', 'subject score': 1000, 'object score': 790}}",
-              "kg2_ids": [
-                "UMLS:C0023890---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0005155",
-              "id": "24427531",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:35449323"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:11433135': {'publication date': '2001', 'sentence': 'OBJECTIVES: Elderly women with proximal femur fracture show abnormal persistence of increased cortisol concentrations, which could contribute to the high morbidity associated with this injury.', 'subject score': 851, 'object score': 1000}, 'PMID:20003512': {'publication date': '2009 Dec 15', 'sentence': 'Postnatal dexamethasone or cortisol, at the doses tested, did not have important effects on lung function or injury, suggesting that corticosteroids given at birth will not decrease resuscitation mediated injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:2082258': {'publication date': '1990 Nov-Dec', 'sentence': '[Sensitivity of phagocytes in the blood and bronchoalveolar tract to hydrocortisone in acute injury of the respiratory organs].', 'subject score': 1000, 'object score': 888}, 'PMID:23218665': {'publication date': '2013 Feb', 'sentence': 'The role of cortisol in chronic binge alcohol-induced cerebellar injury: Ovine model.', 'subject score': 1000, 'object score': 809}, 'PMID:27604139': {'publication date': '2016 Oct 31', 'sentence': 'Effects of hydrocortisone on activation of inflammation via interleukin-33 in ventilator-induced lung injury.', 'subject score': 1000, 'object score': 861}, 'PMID:30590339': {'publication date': '2019 04', 'sentence': 'Follow-up analyses suggested the possibility that this pattern of lower cortisol for those who engage in NSSI was present in females and males, and was more pronounced in those with repeated NSSI (but not subthreshold NSSI) and those with a history of NSSI and suicide attempts.', 'subject score': 888, 'object score': 734}, 'PMID:31388512': {'publication date': '2019', 'sentence': 'The balance of these steroids after injury appears to influence outcomes in injured humans, with high cortisol: DHEAS ratio associated with increased morbidity and mortality.', 'subject score': 888, 'object score': 1000}, 'PMID:3913164': {'publication date': '1985 Dec', 'sentence': 'This symptom is connected with high blood levels of cortisol, which are probably also involved in the injuries to connective tissue known in scurvy.', 'subject score': 1000, 'object score': 1000}, 'PMID:4570817': {'publication date': '1973 Mar 01', 'sentence': '[Complications following administration of hydrocortisone in injuries of the locomotor system].', 'subject score': 1000, 'object score': 1000}, 'PMID:5863706': {'publication date': '1965', 'sentence': '[Effect of hydrocortisone on the extinction in injuries of the shock-absorbing apparatus of the knee joint].', 'subject score': 1000, 'object score': 1000}, 'PMID:6887289': {'publication date': '1983 Aug', 'sentence': 'Similar elevations in glucose and cortisol have been found to correlate with both injury severity and survival.', 'subject score': 1000, 'object score': 888}, 'PMID:7986163': {'publication date': '1994 Dec', 'sentence': 'INTERVENTIONS: The catabolic hormones epinephrine, cortisol, and glucagon were infused simultaneously into the femoral artery of five healthy volunteers, thus acutely simulating the hormonal milieu associated with a severe injury.', 'subject score': 1000, 'object score': 888}, 'PMID:13782584': {'publication date': '1960 Dec', 'sentence': '[The metabolism of cortisol in trauma].', 'subject score': 1000, 'object score': 1000}, 'PMID:17558491': {'publication date': '2007 Oct', 'sentence': 'There were no significant correlations observed between total plasma cortisol or cortisone and sickness severity in the sepsis and trauma cohorts.', 'subject score': 851, 'object score': 872}, 'PMID:19389455': {'publication date': '2009 Aug 01', 'sentence': 'Significantly blunted plasma cortisol and ACTH responses in response to dex/CRH administration were found in the trauma exposed compared to the non-exposed women (F(1,20)=5.08, p=0.04 and F(1,20)=5.23, p=0.03 respectively).', 'subject score': 750, 'object score': 1000}, 'PMID:20419739': {'publication date': '2010 Apr', 'sentence': 'This study explores the associations between morning cortisol, trauma, and suicide attempts or ideation among young people.', 'subject score': 888, 'object score': 1000}, 'PMID:21641725': {'publication date': '2012 Jan', 'sentence': 'CONCLUSION: Childhood trauma in adults with personality disorder is associated with blunted cortisol and ACTH secretion following DEX/CRH challenge.', 'subject score': 861, 'object score': 888}, 'PMID:23726317': {'publication date': '2013 Nov 01', 'sentence': 'Association between childhood trauma and low hair cortisol in depressed patients and healthy control subjects.', 'subject score': 851, 'object score': 888}, 'PMID:23907073': {'publication date': '2014 Jan', 'sentence': 'Association of DHEA, DHEAS, and cortisol with childhood trauma exposure and post-traumatic stress disorder.', 'subject score': 1000, 'object score': 623}, 'PMID:25459889': {'publication date': '2015 Feb', 'sentence': 'RESULTS: There was no association between early childhood trauma and cortisol as measured over the 7-day period.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8785487,
-            "start": 569,
-            "end": 546804,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11433135': {'publication date': '2001', 'sentence': 'OBJECTIVES: Elderly women with proximal femur fracture show abnormal persistence of increased cortisol concentrations, which could contribute to the high morbidity associated with this injury.', 'subject score': 851, 'object score': 1000}, 'PMID:20003512': {'publication date': '2009 Dec 15', 'sentence': 'Postnatal dexamethasone or cortisol, at the doses tested, did not have important effects on lung function or injury, suggesting that corticosteroids given at birth will not decrease resuscitation mediated injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:2082258': {'publication date': '1990 Nov-Dec', 'sentence': '[Sensitivity of phagocytes in the blood and bronchoalveolar tract to hydrocortisone in acute injury of the respiratory organs].', 'subject score': 1000, 'object score': 888}, 'PMID:23218665': {'publication date': '2013 Feb', 'sentence': 'The role of cortisol in chronic binge alcohol-induced cerebellar injury: Ovine model.', 'subject score': 1000, 'object score': 809}, 'PMID:27604139': {'publication date': '2016 Oct 31', 'sentence': 'Effects of hydrocortisone on activation of inflammation via interleukin-33 in ventilator-induced lung injury.', 'subject score': 1000, 'object score': 861}, 'PMID:30590339': {'publication date': '2019 04', 'sentence': 'Follow-up analyses suggested the possibility that this pattern of lower cortisol for those who engage in NSSI was present in females and males, and was more pronounced in those with repeated NSSI (but not subthreshold NSSI) and those with a history of NSSI and suicide attempts.', 'subject score': 888, 'object score': 734}, 'PMID:31388512': {'publication date': '2019', 'sentence': 'The balance of these steroids after injury appears to influence outcomes in injured humans, with high cortisol: DHEAS ratio associated with increased morbidity and mortality.', 'subject score': 888, 'object score': 1000}, 'PMID:3913164': {'publication date': '1985 Dec', 'sentence': 'This symptom is connected with high blood levels of cortisol, which are probably also involved in the injuries to connective tissue known in scurvy.', 'subject score': 1000, 'object score': 1000}, 'PMID:4570817': {'publication date': '1973 Mar 01', 'sentence': '[Complications following administration of hydrocortisone in injuries of the locomotor system].', 'subject score': 1000, 'object score': 1000}, 'PMID:5863706': {'publication date': '1965', 'sentence': '[Effect of hydrocortisone on the extinction in injuries of the shock-absorbing apparatus of the knee joint].', 'subject score': 1000, 'object score': 1000}, 'PMID:6887289': {'publication date': '1983 Aug', 'sentence': 'Similar elevations in glucose and cortisol have been found to correlate with both injury severity and survival.', 'subject score': 1000, 'object score': 888}, 'PMID:7986163': {'publication date': '1994 Dec', 'sentence': 'INTERVENTIONS: The catabolic hormones epinephrine, cortisol, and glucagon were infused simultaneously into the femoral artery of five healthy volunteers, thus acutely simulating the hormonal milieu associated with a severe injury.', 'subject score': 1000, 'object score': 888}, 'PMID:13782584': {'publication date': '1960 Dec', 'sentence': '[The metabolism of cortisol in trauma].', 'subject score': 1000, 'object score': 1000}, 'PMID:17558491': {'publication date': '2007 Oct', 'sentence': 'There were no significant correlations observed between total plasma cortisol or cortisone and sickness severity in the sepsis and trauma cohorts.', 'subject score': 851, 'object score': 872}, 'PMID:19389455': {'publication date': '2009 Aug 01', 'sentence': 'Significantly blunted plasma cortisol and ACTH responses in response to dex/CRH administration were found in the trauma exposed compared to the non-exposed women (F(1,20)=5.08, p=0.04 and F(1,20)=5.23, p=0.03 respectively).', 'subject score': 750, 'object score': 1000}, 'PMID:20419739': {'publication date': '2010 Apr', 'sentence': 'This study explores the associations between morning cortisol, trauma, and suicide attempts or ideation among young people.', 'subject score': 888, 'object score': 1000}, 'PMID:21641725': {'publication date': '2012 Jan', 'sentence': 'CONCLUSION: Childhood trauma in adults with personality disorder is associated with blunted cortisol and ACTH secretion following DEX/CRH challenge.', 'subject score': 861, 'object score': 888}, 'PMID:23726317': {'publication date': '2013 Nov 01', 'sentence': 'Association between childhood trauma and low hair cortisol in depressed patients and healthy control subjects.', 'subject score': 851, 'object score': 888}, 'PMID:23907073': {'publication date': '2014 Jan', 'sentence': 'Association of DHEA, DHEAS, and cortisol with childhood trauma exposure and post-traumatic stress disorder.', 'subject score': 1000, 'object score': 623}, 'PMID:25459889': {'publication date': '2015 Feb', 'sentence': 'RESULTS: There was no association between early childhood trauma and cortisol as measured over the 7-day period.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C3263723---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0043251---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8977987",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:21641725",
-                "PMID:4570817",
-                "PMID:25705799",
-                "PMID:30248494",
-                "PMID:8222688",
-                "PMID:11433135",
-                "PMID:7986163",
-                "PMID:36921662",
-                "PMID:2082258",
-                "PMID:23726317",
-                "PMID:20003512",
-                "PMID:32072017",
-                "PMID:33192700",
-                "PMID:13782584",
-                "PMID:5863706",
-                "PMID:19389455",
-                "PMID:30844606",
-                "PMID:6887289",
-                "PMID:23218665",
-                "PMID:3223434"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:25821896': {'publication date': '2015 Aug', 'sentence': 'The results of our study confirm that thymol has strong ameliorative effect against hydrocortisone-induced oxidative stress injury in hepatic tissues.', 'subject score': 840, 'object score': 840}, 'PMID:30672332': {'publication date': '2019', 'sentence': 'Vitamin C Prevents Hydrocortisone-Induced Injury in HMEC-1 through Promoting Bestrophin-3 Expression.', 'subject score': 851, 'object score': 851}, 'PMID:31547969': {'publication date': '2019 11', 'sentence': 'Basic science studies suggest that high circulating levels of cortisol may directly cause organ injury.', 'subject score': 1000, 'object score': 888}, 'PMID:9151238': {'publication date': '1997 Feb', 'sentence': 'These compounds prevented injury during in vivo experiments, such as hydrocortisone-induced cataracts, endotoxin shock and CCl4-induced liver injury (isolated hepatocytes and rats).', 'subject score': 851, 'object score': 833}, 'PMID:25982069': {'publication date': '2015 Aug', 'sentence': 'This is the first report on the effects of cortisol and BDNF induced trauma in child and adolescent victims of sexual abuse.', 'subject score': 1000, 'object score': 1000}, 'PMID:3495144': {'publication date': '1987 Jun', 'sentence': 'Technetium-99m imaging of bone trauma: reduced sensitivity caused by hydrocortisone in rabbits.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17865024,
-            "start": 569,
-            "end": 546804,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25821896': {'publication date': '2015 Aug', 'sentence': 'The results of our study confirm that thymol has strong ameliorative effect against hydrocortisone-induced oxidative stress injury in hepatic tissues.', 'subject score': 840, 'object score': 840}, 'PMID:30672332': {'publication date': '2019', 'sentence': 'Vitamin C Prevents Hydrocortisone-Induced Injury in HMEC-1 through Promoting Bestrophin-3 Expression.', 'subject score': 851, 'object score': 851}, 'PMID:31547969': {'publication date': '2019 11', 'sentence': 'Basic science studies suggest that high circulating levels of cortisol may directly cause organ injury.', 'subject score': 1000, 'object score': 888}, 'PMID:9151238': {'publication date': '1997 Feb', 'sentence': 'These compounds prevented injury during in vivo experiments, such as hydrocortisone-induced cataracts, endotoxin shock and CCl4-induced liver injury (isolated hepatocytes and rats).', 'subject score': 851, 'object score': 833}, 'PMID:25982069': {'publication date': '2015 Aug', 'sentence': 'This is the first report on the effects of cortisol and BDNF induced trauma in child and adolescent victims of sexual abuse.', 'subject score': 1000, 'object score': 1000}, 'PMID:3495144': {'publication date': '1987 Jun', 'sentence': 'Technetium-99m imaging of bone trauma: reduced sensitivity caused by hydrocortisone in rabbits.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C3263723---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0043251---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "18240145",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:3495144",
-                "PMID:9151238",
-                "PMID:30672332",
-                "PMID:25821896",
-                "PMID:25982069",
-                "PMID:31547969"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:20109364': {'publication date': '2010 Feb', 'sentence': 'RESULTS: Within 24 hours following TBI, the concentrations of total cortisol, ACTH and gastrin increased proportionally to the severity of injury, especially significant in the experimental group (P less than 0.05).', 'subject score': 888, 'object score': 1000}, 'PMID:3339690': {'publication date': '1988 Jan', 'sentence': 'When the dogs were considered as one group the mean plasma cortisol concentration increased promptly 10 min after injury (p less than 0.05) and reached its peak at 1 hour and then decreased.', 'subject score': 824, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14486782,
-            "start": 569,
-            "end": 546804,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20109364': {'publication date': '2010 Feb', 'sentence': 'RESULTS: Within 24 hours following TBI, the concentrations of total cortisol, ACTH and gastrin increased proportionally to the severity of injury, especially significant in the experimental group (P less than 0.05).', 'subject score': 888, 'object score': 1000}, 'PMID:3339690': {'publication date': '1988 Jan', 'sentence': 'When the dogs were considered as one group the mean plasma cortisol concentration increased promptly 10 min after injury (p less than 0.05) and reached its peak at 1 hour and then decreased.', 'subject score': 824, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C3263723---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "14804311",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:20109364",
-                "PMID:3339690"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:13396133': {'publication date': '1957 Jan', 'sentence': 'The effect of hydrocortisone on standardized skin-surface trauma.', 'subject score': 1000, 'object score': 775}, 'PMID:2305936': {'publication date': '1990 Mar', 'sentence': 'Increased plasma levels of the catabolic hormones glucagon, epinephrine, and cortisol have been implicated in mediating various metabolic alterations in trauma and sepsis.', 'subject score': 1000, 'object score': 1000}, 'PMID:25982069': {'publication date': '2015 Aug', 'sentence': 'CONCLUSIONS: The results of the present study suggest that cortisol and BDNF could be biological molecular mediators of the effects of trauma on biological and psychological systems.', 'subject score': 1000, 'object score': 1000}, 'PMID:30197200': {'publication date': '2018 Dec', 'sentence': 'CONCLUSIONS: These findings underscore the need to consider complex interactions among maternal trauma, disrupted in utero cortisol production, and fetal sex to fully elucidate intergenerational effects of maternal lifetime trauma.', 'subject score': 775, 'object score': 802}, 'PMID:6516244': {'publication date': '1984', 'sentence': '[The effect of trauma, exogenous hydrocortisone and adrenalectomy on the histological structure of the thymus in mice].', 'subject score': 888, 'object score': 1000}, 'PMID:6887289': {'publication date': '1983 Aug', 'sentence': 'The lack of correlation of increased cortisol with injury severity suggests an interaction of multiple hormones resulting in the increase in osmolality and glucose.', 'subject score': 888, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10296638,
-            "start": 569,
-            "end": 546804,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13396133': {'publication date': '1957 Jan', 'sentence': 'The effect of hydrocortisone on standardized skin-surface trauma.', 'subject score': 1000, 'object score': 775}, 'PMID:2305936': {'publication date': '1990 Mar', 'sentence': 'Increased plasma levels of the catabolic hormones glucagon, epinephrine, and cortisol have been implicated in mediating various metabolic alterations in trauma and sepsis.', 'subject score': 1000, 'object score': 1000}, 'PMID:25982069': {'publication date': '2015 Aug', 'sentence': 'CONCLUSIONS: The results of the present study suggest that cortisol and BDNF could be biological molecular mediators of the effects of trauma on biological and psychological systems.', 'subject score': 1000, 'object score': 1000}, 'PMID:30197200': {'publication date': '2018 Dec', 'sentence': 'CONCLUSIONS: These findings underscore the need to consider complex interactions among maternal trauma, disrupted in utero cortisol production, and fetal sex to fully elucidate intergenerational effects of maternal lifetime trauma.', 'subject score': 775, 'object score': 802}, 'PMID:6516244': {'publication date': '1984', 'sentence': '[The effect of trauma, exogenous hydrocortisone and adrenalectomy on the histological structure of the thymus in mice].', 'subject score': 888, 'object score': 1000}, 'PMID:6887289': {'publication date': '1983 Aug', 'sentence': 'The lack of correlation of increased cortisol with injury severity suggests an interaction of multiple hormones resulting in the increase in osmolality and glucose.', 'subject score': 888, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0043251---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C3263723---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10523644",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:6516244",
-                "PMID:30197200",
-                "PMID:2305936",
-                "PMID:25982069",
-                "PMID:13396133",
-                "PMID:6887289"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:16055307': {'publication date': '2005 Nov 15', 'sentence': 'Diurnal cortisol in schizophrenia patients with childhood trauma.', 'subject score': 888, 'object score': 888}, 'PMID:16352953': {'publication date': '2005 Dec', 'sentence': 'OBJECTIVE: To assess the pressor response to phenylephrine infusion before and after hydrocortisone in severe trauma patients and to correlate this response with their adrenal reserve.', 'subject score': 1000, 'object score': 851}, 'PMID:17296270': {'publication date': '2007 Apr', 'sentence': 'Salivary cortisol, plasma cortisol and ACTH suppression as well as CBG levels did not differ between PTSD patients and trauma controls.', 'subject score': 888, 'object score': 872}, 'PMID:22777514': {'publication date': '2012 Oct', 'sentence': 'METHODS: This was a sub-study of the HYPOLYTE multi-centre, randomized, double-blind, placebo-controlled trial of hydrocortisone in trauma patients (NCT00563303).', 'subject score': 1000, 'object score': 888}, 'PMID:23126006': {'publication date': '2012 Sep', 'sentence': '[Effects of hydrocortisone in trauma patients].', 'subject score': 1000, 'object score': 888}, 'PMID:25808607': {'publication date': '2017 08', 'sentence': 'METHODS: Early trauma and current perceived stress were assessed in 28 treated schizophrenia cases, along with salivary cortisol, brain volumes, cognition and symptoms.', 'subject score': 888, 'object score': 888}, 'PMID:4002110': {'publication date': '1985 Jun', 'sentence': 'Plasma beta-endorphin, cortisol and total opioid-like activities were measured upon arrival at the hospital in ten patients with extensive trauma and in a state of shock and 11 patients with minor injury.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11710389,
-            "start": 569,
-            "end": 546804,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16055307': {'publication date': '2005 Nov 15', 'sentence': 'Diurnal cortisol in schizophrenia patients with childhood trauma.', 'subject score': 888, 'object score': 888}, 'PMID:16352953': {'publication date': '2005 Dec', 'sentence': 'OBJECTIVE: To assess the pressor response to phenylephrine infusion before and after hydrocortisone in severe trauma patients and to correlate this response with their adrenal reserve.', 'subject score': 1000, 'object score': 851}, 'PMID:17296270': {'publication date': '2007 Apr', 'sentence': 'Salivary cortisol, plasma cortisol and ACTH suppression as well as CBG levels did not differ between PTSD patients and trauma controls.', 'subject score': 888, 'object score': 872}, 'PMID:22777514': {'publication date': '2012 Oct', 'sentence': 'METHODS: This was a sub-study of the HYPOLYTE multi-centre, randomized, double-blind, placebo-controlled trial of hydrocortisone in trauma patients (NCT00563303).', 'subject score': 1000, 'object score': 888}, 'PMID:23126006': {'publication date': '2012 Sep', 'sentence': '[Effects of hydrocortisone in trauma patients].', 'subject score': 1000, 'object score': 888}, 'PMID:25808607': {'publication date': '2017 08', 'sentence': 'METHODS: Early trauma and current perceived stress were assessed in 28 treated schizophrenia cases, along with salivary cortisol, brain volumes, cognition and symptoms.', 'subject score': 888, 'object score': 888}, 'PMID:4002110': {'publication date': '1985 Jun', 'sentence': 'Plasma beta-endorphin, cortisol and total opioid-like activities were measured upon arrival at the hospital in ten patients with extensive trauma and in a state of shock and 11 patients with minor injury.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0043251---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "11965490",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:16055307",
-                "PMID:16352953",
-                "PMID:17296270",
-                "PMID:22777514",
-                "PMID:23126006",
-                "PMID:25808607",
-                "PMID:4002110"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:21741804': {'publication date': '2011 Nov', 'sentence': 'High-dose hydrocortisone treatment given in the first few hours after a traumatic experience was associated with significant favorable changes in the trajectory of exposure to trauma, as expressed by the reduced risk of the development of PTSD post-trauma.', 'subject score': 861, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15427277,
-            "start": 569,
-            "end": 546804,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21741804': {'publication date': '2011 Nov', 'sentence': 'High-dose hydrocortisone treatment given in the first few hours after a traumatic experience was associated with significant favorable changes in the trajectory of exposure to trauma, as expressed by the reduced risk of the development of PTSD post-trauma.', 'subject score': 861, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:disrupts---None---None---None---UMLS:C0043251---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "15750557",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:21741804"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:26756781': {'publication date': '2016 05', 'sentence': 'These findings suggest that HC may protect against hyperoxic injury in the developing pulmonary vasculature.', 'subject score': 1000, 'object score': 853}, 'PMID:4085992': {'publication date': '1985 Dec', 'sentence': 'Testosterone, estradiol, and cortisol were tested using an immersion technique to minimize trauma, and we also examined metyrapone, a blocker of cortisol biosynthesis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18386662,
-            "start": 569,
-            "end": 546804,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26756781': {'publication date': '2016 05', 'sentence': 'These findings suggest that HC may protect against hyperoxic injury in the developing pulmonary vasculature.', 'subject score': 1000, 'object score': 853}, 'PMID:4085992': {'publication date': '1985 Dec', 'sentence': 'Testosterone, estradiol, and cortisol were tested using an immersion technique to minimize trauma, and we also examined metyrapone, a blocker of cortisol biosynthesis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C3263723---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0043251---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "18758297",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:26756781",
-                "PMID:4085992"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:18431270': {'publication date': '2008 Mar', 'sentence': 'Plasma leptin and ghrelin levels in endotoxin-treated dogs were correlated with serum nitric oxide (r = .955 and r = .890; p < .001), procalcitonin (r = .825 and r = .716; p < .001), cortisol (r = .823 and r = .786; p < .001), and hepatorenal injury markers (r = .580 to .745 and r = .393 to .574; p < .05 to .01).', 'subject score': 1000, 'object score': 660}, 'PMID:21684014': {'publication date': '2011 Oct 30', 'sentence': 'To address gaps in the literature related to the contribution of childhood trauma on aggression, we evaluated salivary cortisol and heart rate changes to psychological challenge in aggressive children with various degrees of trauma.', 'subject score': 888, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 546804,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546804,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13424533,
-            "start": 569,
-            "end": 546804,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18431270': {'publication date': '2008 Mar', 'sentence': 'Plasma leptin and ghrelin levels in endotoxin-treated dogs were correlated with serum nitric oxide (r = .955 and r = .890; p < .001), procalcitonin (r = .825 and r = .716; p < .001), cortisol (r = .823 and r = .786; p < .001), and hepatorenal injury markers (r = .580 to .745 and r = .393 to .574; p < .05 to .01).', 'subject score': 1000, 'object score': 660}, 'PMID:21684014': {'publication date': '2011 Oct 30', 'sentence': 'To address gaps in the literature related to the contribution of childhood trauma on aggression, we evaluated salivary cortisol and heart rate changes to psychological challenge in aggressive children with various degrees of trauma.', 'subject score': 888, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:predisposes---None---None---None---UMLS:C3263723---SEMMEDDB:",
-                "UMLS:C0020268---SEMMEDDB:predisposes---None---None---None---UMLS:C0043251---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "13712588",
-              "object": "MONDO:0021178",
-              "publications": [
-                "PMID:18431270",
-                "PMID:21684014"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:32682157': {'publication date': '2020 Jul 06', 'sentence': 'The results presented herein imply that the three families of cyanine dyes, in particular compounds 5a-f, show high potential as selective scaffolds to treat C. albicans infections.', 'subject score': 813, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 546907,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C3714514",
-          "name": "Infection",
-          "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "UMLS:C3714514",
-            "MEDDRA:10021842",
-            "NCIT:C128320",
-            "MEDDRA:10021789",
-            "MESH:D007239"
-          ],
-          "id": "UMLS:C3714514",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infection",
-            "Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546907,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C3714514",
-              "name": "Infection",
-              "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "UMLS:C3714514",
-                "MEDDRA:10021842",
-                "NCIT:C128320",
-                "MEDDRA:10021789",
-                "MESH:D007239"
-              ],
-              "id": "UMLS:C3714514",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infection",
-                "Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21860162,
-            "start": 569,
-            "end": 546907,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32682157': {'publication date': '2020 Jul 06', 'sentence': 'The results presented herein imply that the three families of cyanine dyes, in particular compounds 5a-f, show high potential as selective scaffolds to treat C. albicans infections.', 'subject score': 813, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C3714514---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "22282269",
-              "object": "UMLS:C3714514",
-              "publications": [
-                "PMID:32682157"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:13386145': {'publication date': '1956', 'sentence': '[Use of cortisone and hydrocortisone in eye diseases].', 'subject score': 1000, 'object score': 1000}, 'PMID:14373050': {'publication date': '1955', 'sentence': 'Hydrocortisone and ACTH in eye disease.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 308745,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005328",
-          "name": "eye disorder",
-          "description": "Diseases or defects of the eye. Use VISION DISORDERS for other pathology involving visual neural pathways.; A non-neoplastic or neoplastic disorder that affects the eye. Representative examples include conjunctivitis, glaucoma, cataract, conjunctival squamous cell carcinoma, uveal melanoma, and retinoblastoma.; Diseases affecting the eye.; Any abnormality of the eye, including location, spacing, and intraocular abnormalities. [HPO:probinson]; Some eye problems are minor and don't last long. But some can lead to a permanent loss of vision. Common eye problems include: Refractive errors Cataracts - clouded lenses Optic nerve disorders, including glaucoma Retinal disorders - problems with the nerve layer at the back of the eye Macular degeneration - a disease that destroys sharp, central vision Diabetic eye problems Conjunctivitis - an infection also known as pink eye  Your best defense is to have regular checkups, because eye diseases do not always have symptoms. Early detection and treatment could prevent vision loss. See an eye care professional right away if you have a sudden change in vision, if everything looks dim, or if you see flashes of light. Other symptoms that need quick attention are pain, double vision, fluid coming from the eye, and inflammation. NIH: National Eye Institute ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0015397",
-            "NCIT:C26767",
-            "MEDDRA:10045783",
-            "MEDDRA:10013221",
-            "MEDDRA:10015919",
-            "MEDDRA:10054716",
-            "ICD9:360.29",
-            "MESH:D005128",
-            "EFO:0003966",
-            "MEDDRA:10015916",
-            "MEDDRA:10059159",
-            "UMLS:C0015393",
-            "ICD10:H44",
-            "MEDDRA:10045790",
-            "HP:0000478",
-            "SNOMEDCT:19416009",
-            "MEDDRA:10015913",
-            "MEDDRA:10030874",
-            "NCIT:C98887",
-            "MEDDRA:10010435",
-            "MEDDRA:10010462",
-            "MEDDRA:10015949",
-            "UMLS:C4316870",
-            "MEDDRA:10015904",
-            "MESH:D005124",
-            "MEDDRA:10015920",
-            "MEDDRA:10015903",
-            "MEDDRA:10015918",
-            "MONDO:0005328",
-            "SNOMEDCT:371405004",
-            "ICD9:379.90",
-            "DOID:5614",
-            "UMLS:C0154780",
-            "DOID:1242",
-            "MEDDRA:10045628",
-            "ICD10:H44.39"
-          ],
-          "id": "MONDO:0005328",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Disorder of eye, unspecified",
-            "Eye Abnormalities",
-            "Other degenerative disorders of globe",
-            "eye disease",
-            "Congenital Eye Disorder",
-            "globe disease",
-            "Disorder of eye",
-            "Abnormality of the eye",
-            "eye disorder",
-            "Eye Diseases",
-            "Eye Disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/eye_disease",
-            "https://en.wikipedia.org/wiki/globe_(human_eye)",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-5316-1399"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308745,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005328",
-              "name": "eye disorder",
-              "description": "Diseases or defects of the eye. Use VISION DISORDERS for other pathology involving visual neural pathways.; A non-neoplastic or neoplastic disorder that affects the eye. Representative examples include conjunctivitis, glaucoma, cataract, conjunctival squamous cell carcinoma, uveal melanoma, and retinoblastoma.; Diseases affecting the eye.; Any abnormality of the eye, including location, spacing, and intraocular abnormalities. [HPO:probinson]; Some eye problems are minor and don't last long. But some can lead to a permanent loss of vision. Common eye problems include: Refractive errors Cataracts - clouded lenses Optic nerve disorders, including glaucoma Retinal disorders - problems with the nerve layer at the back of the eye Macular degeneration - a disease that destroys sharp, central vision Diabetic eye problems Conjunctivitis - an infection also known as pink eye  Your best defense is to have regular checkups, because eye diseases do not always have symptoms. Early detection and treatment could prevent vision loss. See an eye care professional right away if you have a sudden change in vision, if everything looks dim, or if you see flashes of light. Other symptoms that need quick attention are pain, double vision, fluid coming from the eye, and inflammation. NIH: National Eye Institute ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0015397",
-                "NCIT:C26767",
-                "MEDDRA:10045783",
-                "MEDDRA:10013221",
-                "MEDDRA:10015919",
-                "MEDDRA:10054716",
-                "ICD9:360.29",
-                "MESH:D005128",
-                "EFO:0003966",
-                "MEDDRA:10015916",
-                "MEDDRA:10059159",
-                "UMLS:C0015393",
-                "ICD10:H44",
-                "MEDDRA:10045790",
-                "HP:0000478",
-                "SNOMEDCT:19416009",
-                "MEDDRA:10015913",
-                "MEDDRA:10030874",
-                "NCIT:C98887",
-                "MEDDRA:10010435",
-                "MEDDRA:10010462",
-                "MEDDRA:10015949",
-                "UMLS:C4316870",
-                "MEDDRA:10015904",
-                "MESH:D005124",
-                "MEDDRA:10015920",
-                "MEDDRA:10015903",
-                "MEDDRA:10015918",
-                "MONDO:0005328",
-                "SNOMEDCT:371405004",
-                "ICD9:379.90",
-                "DOID:5614",
-                "UMLS:C0154780",
-                "DOID:1242",
-                "MEDDRA:10045628",
-                "ICD10:H44.39"
-              ],
-              "id": "MONDO:0005328",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Disorder of eye, unspecified",
-                "Eye Abnormalities",
-                "Other degenerative disorders of globe",
-                "eye disease",
-                "Congenital Eye Disorder",
-                "globe disease",
-                "Disorder of eye",
-                "Abnormality of the eye",
-                "eye disorder",
-                "Eye Diseases",
-                "Eye Disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/eye_disease",
-                "https://en.wikipedia.org/wiki/globe_(human_eye)",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-5316-1399"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10294481,
-            "start": 569,
-            "end": 308745,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13386145': {'publication date': '1956', 'sentence': '[Use of cortisone and hydrocortisone in eye diseases].', 'subject score': 1000, 'object score': 1000}, 'PMID:14373050': {'publication date': '1955', 'sentence': 'Hydrocortisone and ACTH in eye disease.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0015397---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10521296",
-              "object": "MONDO:0005328",
-              "publications": [
-                "PMID:13386145",
-                "PMID:14373050"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:14933543': {'publication date': '1952 Jul', 'sentence': 'Topical compound F in the treatment of anterior segment eye disease; a preliminary report.', 'subject score': 901, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 308745,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005328",
-          "name": "eye disorder",
-          "description": "Diseases or defects of the eye. Use VISION DISORDERS for other pathology involving visual neural pathways.; A non-neoplastic or neoplastic disorder that affects the eye. Representative examples include conjunctivitis, glaucoma, cataract, conjunctival squamous cell carcinoma, uveal melanoma, and retinoblastoma.; Diseases affecting the eye.; Any abnormality of the eye, including location, spacing, and intraocular abnormalities. [HPO:probinson]; Some eye problems are minor and don't last long. But some can lead to a permanent loss of vision. Common eye problems include: Refractive errors Cataracts - clouded lenses Optic nerve disorders, including glaucoma Retinal disorders - problems with the nerve layer at the back of the eye Macular degeneration - a disease that destroys sharp, central vision Diabetic eye problems Conjunctivitis - an infection also known as pink eye  Your best defense is to have regular checkups, because eye diseases do not always have symptoms. Early detection and treatment could prevent vision loss. See an eye care professional right away if you have a sudden change in vision, if everything looks dim, or if you see flashes of light. Other symptoms that need quick attention are pain, double vision, fluid coming from the eye, and inflammation. NIH: National Eye Institute ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0015397",
-            "NCIT:C26767",
-            "MEDDRA:10045783",
-            "MEDDRA:10013221",
-            "MEDDRA:10015919",
-            "MEDDRA:10054716",
-            "ICD9:360.29",
-            "MESH:D005128",
-            "EFO:0003966",
-            "MEDDRA:10015916",
-            "MEDDRA:10059159",
-            "UMLS:C0015393",
-            "ICD10:H44",
-            "MEDDRA:10045790",
-            "HP:0000478",
-            "SNOMEDCT:19416009",
-            "MEDDRA:10015913",
-            "MEDDRA:10030874",
-            "NCIT:C98887",
-            "MEDDRA:10010435",
-            "MEDDRA:10010462",
-            "MEDDRA:10015949",
-            "UMLS:C4316870",
-            "MEDDRA:10015904",
-            "MESH:D005124",
-            "MEDDRA:10015920",
-            "MEDDRA:10015903",
-            "MEDDRA:10015918",
-            "MONDO:0005328",
-            "SNOMEDCT:371405004",
-            "ICD9:379.90",
-            "DOID:5614",
-            "UMLS:C0154780",
-            "DOID:1242",
-            "MEDDRA:10045628",
-            "ICD10:H44.39"
-          ],
-          "id": "MONDO:0005328",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Disorder of eye, unspecified",
-            "Eye Abnormalities",
-            "Other degenerative disorders of globe",
-            "eye disease",
-            "Congenital Eye Disorder",
-            "globe disease",
-            "Disorder of eye",
-            "Abnormality of the eye",
-            "eye disorder",
-            "Eye Diseases",
-            "Eye Disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/eye_disease",
-            "https://en.wikipedia.org/wiki/globe_(human_eye)",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-5316-1399"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 308745,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005328",
-              "name": "eye disorder",
-              "description": "Diseases or defects of the eye. Use VISION DISORDERS for other pathology involving visual neural pathways.; A non-neoplastic or neoplastic disorder that affects the eye. Representative examples include conjunctivitis, glaucoma, cataract, conjunctival squamous cell carcinoma, uveal melanoma, and retinoblastoma.; Diseases affecting the eye.; Any abnormality of the eye, including location, spacing, and intraocular abnormalities. [HPO:probinson]; Some eye problems are minor and don't last long. But some can lead to a permanent loss of vision. Common eye problems include: Refractive errors Cataracts - clouded lenses Optic nerve disorders, including glaucoma Retinal disorders - problems with the nerve layer at the back of the eye Macular degeneration - a disease that destroys sharp, central vision Diabetic eye problems Conjunctivitis - an infection also known as pink eye  Your best defense is to have regular checkups, because eye diseases do not always have symptoms. Early detection and treatment could prevent vision loss. See an eye care professional right away if you have a sudden change in vision, if everything looks dim, or if you see flashes of light. Other symptoms that need quick attention are pain, double vision, fluid coming from the eye, and inflammation. NIH: National Eye Institute ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0015397",
-                "NCIT:C26767",
-                "MEDDRA:10045783",
-                "MEDDRA:10013221",
-                "MEDDRA:10015919",
-                "MEDDRA:10054716",
-                "ICD9:360.29",
-                "MESH:D005128",
-                "EFO:0003966",
-                "MEDDRA:10015916",
-                "MEDDRA:10059159",
-                "UMLS:C0015393",
-                "ICD10:H44",
-                "MEDDRA:10045790",
-                "HP:0000478",
-                "SNOMEDCT:19416009",
-                "MEDDRA:10015913",
-                "MEDDRA:10030874",
-                "NCIT:C98887",
-                "MEDDRA:10010435",
-                "MEDDRA:10010462",
-                "MEDDRA:10015949",
-                "UMLS:C4316870",
-                "MEDDRA:10015904",
-                "MESH:D005124",
-                "MEDDRA:10015920",
-                "MEDDRA:10015903",
-                "MEDDRA:10015918",
-                "MONDO:0005328",
-                "SNOMEDCT:371405004",
-                "ICD9:379.90",
-                "DOID:5614",
-                "UMLS:C0154780",
-                "DOID:1242",
-                "MEDDRA:10045628",
-                "ICD10:H44.39"
-              ],
-              "id": "MONDO:0005328",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Disorder of eye, unspecified",
-                "Eye Abnormalities",
-                "Other degenerative disorders of globe",
-                "eye disease",
-                "Congenital Eye Disorder",
-                "globe disease",
-                "Disorder of eye",
-                "Abnormality of the eye",
-                "eye disorder",
-                "Eye Diseases",
-                "Eye Disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/eye_disease",
-                "https://en.wikipedia.org/wiki/globe_(human_eye)",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-5316-1399"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10793554,
-            "start": 569,
-            "end": 308745,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14933543': {'publication date': '1952 Jul', 'sentence': 'Topical compound F in the treatment of anterior segment eye disease; a preliminary report.', 'subject score': 901, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0015397---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "11029944",
-              "object": "MONDO:0005328",
-              "publications": [
-                "PMID:14933543"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:11251036': {'publication date': '2001 Feb', 'sentence': 'Hydrocortisone infusion in septic shock differentially regulated the cytokine responses.', 'subject score': 888, 'object score': 1000}, 'PMID:11271077': {'publication date': '2000 Dec', 'sentence': 'Hydrocortisone and the reduction of vasopressors in septic shock: therapy or only chart cosmetics?', 'subject score': 1000, 'object score': 1000}, 'PMID:11800521': {'publication date': '2001 Dec', 'sentence': 'Recent studies with stress doses of hydrocortisone in sepsis and septic shock have shown a marked haemodynamic improvement, but whether patients with relative adrenal dysfunction benefit most from this treatment and whether there is definitely an effect on outcome is still undecided.', 'subject score': 1000, 'object score': 1000}, 'PMID:11868733': {'publication date': '2001 Aug', 'sentence': 'More recently, work by Annane et al. using lower doses closer to those that might constitute a stress dose of hydrocortisone have shown encouraging results with a 30% decrease in mortality in septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:12614129': {'publication date': '2003', 'sentence': 'Hydrocortisone and fludrocortisone improved 28-day survival in septic shock and adrenal insufficiency.', 'subject score': 1000, 'object score': 1000}, 'PMID:16263835': {'publication date': '2006 Jan', 'sentence': 'Recently, low total cortisol increments after tetracosactrin have been associated with increased mortality and hemodynamic responsiveness to exogenous hydrocortisone in septic shock (SS), a phenomenon termed by some investigators as relative adrenal insufficiency (RAI).', 'subject score': 888, 'object score': 1000}, 'PMID:16608898': {'publication date': '2006 Jul', 'sentence': 'However, most severe disease and mortality is associated with an increased cortisol to DHEA ratio, which may represent a novel prognostic marker in septic shock.', 'subject score': 888, 'object score': 1000}, 'PMID:1669084': {'publication date': '1991', 'sentence': 'An effect of hydrocortisone and dopamine on beta-glucuronidase activity in the lung tissue in experimental septic shock was analysed.', 'subject score': 1000, 'object score': 901}, 'PMID:17021536': {'publication date': '2004 Apr', 'sentence': 'Together with new findings on low-dose hydrocortisone, this stresses the relevance of adjunctive therapy in severe sepsis and septic shock.', 'subject score': 901, 'object score': 1000}, 'PMID:17316466': {'publication date': '2007', 'sentence': \"A good example of this is the conflict between intensive insulin therapy and 'low dose' hydrocortisone in septic shock.\", 'subject score': 901, 'object score': 1000}, 'PMID:17658222': {'publication date': '2008', 'sentence': 'Mineralocorticoid effects due to cortisol inactivation overload explain the beneficial use of hydrocortisone in septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:17906853': {'publication date': '2008 Feb', 'sentence': 'Stress doses of hydrocortisone in septic shock: beneficial effects on opsonization-dependent neutrophil functions.', 'subject score': 1000, 'object score': 1000}, 'PMID:19004144': {'publication date': '2008 May-Jun', 'sentence': 'Does low dose hydrocortisone reduce mortality in septic shock?', 'subject score': 901, 'object score': 1000}, 'PMID:19057445': {'publication date': '2009 Jan', 'sentence': 'CONCLUSIONS: Our data, although, inconclusive favor the need for a study with a larger sample size to clearly define role of low-dose hydrocortisone in pediatric septic shock in developing countries, while taking in consideration effect of malnutrition, delayed presentations, and their interactions with the hypothalamic-pituitary-adrenocortical axis.', 'subject score': 901, 'object score': 901}, 'PMID:19326575': {'publication date': '2009 Apr', 'sentence': 'CONCLUSIONS: The administration of moderate doses of hydrocortisone in septic shock results in a modest but consistent improvement in capillary perfusion, independent of the response to the ACTH test.', 'subject score': 1000, 'object score': 1000}, 'PMID:19652948': {'publication date': '2009 Nov', 'sentence': 'METHODS: An a-priori sub-study of the CORTICUS multi-centre, randomised, double-blind, placebo-controlled trial of hydrocortisone in septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:21479650': {'publication date': '2011 Apr', 'sentence': 'Concomitant hydrocortisone and arginine vasopressin therapy increases arginine vasopressin plasma levels and may improve survival in septic shock.', 'subject score': 888, 'object score': 1000}, 'PMID:21993448': {'publication date': '2012 Jan', 'sentence': 'The aim of this prospective observational study was to investigate serial changes in plasma total and free cortisol and tissue cortisol activity in septic shock.', 'subject score': 790, 'object score': 1000}, 'PMID:22269144': {'publication date': '2012 Apr', 'sentence': 'The consensus statement from the international task force of the American College of Critical Care medicine recommends 100 mg of intravenous hydrocortisone for patients with adrenal insufficiency in septic shock, but in patients undergoing surgery, especially with extracorporeal circulation, the dosage may even be higher.', 'subject score': 888, 'object score': 1000}, 'PMID:22584796': {'publication date': '2012 Aug', 'sentence': 'Gluco- and mineralocorticoid biological effects of a 7-day treatment with low doses of hydrocortisone and fludrocortisone in septic shock.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 528832,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-          "name": "toxic shock syndrome",
-          "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C35498",
-            "UMLS:C0600327",
-            "UMLS:CN204669",
-            "MEDDRA:10044248",
-            "MESH:D012772",
-            "MEDDRA:10044249",
-            "SNOMEDCT:18504008",
-            "DOID:14115",
-            "MEDDRA:10042852",
-            "UMLS:C0036983",
-            "ORPHANET:36234",
-            "SNOMEDCT:76571007",
-            "MEDDRA:10040580",
-            "NCIT:C35018",
-            "MEDDRA:10040070",
-            "ICD9:040.82",
-            "ICD10:A48.3",
-            "MONDO:0001881",
-            "EFO:0006834",
-            "SYMP:0000451"
-          ],
-          "id": "MONDO:0001881",
-          "category": "biolink:Disease",
-          "all_names": [
-            "toxic shock syndrome",
-            "Septic Shock",
-            "Shock, Septic",
-            "Toxic Shock Syndrome",
-            "Bacterial toxic-shock syndrome",
-            "septic shock",
-            "Toxic shock syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 528832,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-              "name": "toxic shock syndrome",
-              "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C35498",
-                "UMLS:C0600327",
-                "UMLS:CN204669",
-                "MEDDRA:10044248",
-                "MESH:D012772",
-                "MEDDRA:10044249",
-                "SNOMEDCT:18504008",
-                "DOID:14115",
-                "MEDDRA:10042852",
-                "UMLS:C0036983",
-                "ORPHANET:36234",
-                "SNOMEDCT:76571007",
-                "MEDDRA:10040580",
-                "NCIT:C35018",
-                "MEDDRA:10040070",
-                "ICD9:040.82",
-                "ICD10:A48.3",
-                "MONDO:0001881",
-                "EFO:0006834",
-                "SYMP:0000451"
-              ],
-              "id": "MONDO:0001881",
-              "category": "biolink:Disease",
-              "all_names": [
-                "toxic shock syndrome",
-                "Septic Shock",
-                "Shock, Septic",
-                "Toxic Shock Syndrome",
-                "Bacterial toxic-shock syndrome",
-                "septic shock",
-                "Toxic shock syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8566750,
-            "start": 569,
-            "end": 528832,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11251036': {'publication date': '2001 Feb', 'sentence': 'Hydrocortisone infusion in septic shock differentially regulated the cytokine responses.', 'subject score': 888, 'object score': 1000}, 'PMID:11271077': {'publication date': '2000 Dec', 'sentence': 'Hydrocortisone and the reduction of vasopressors in septic shock: therapy or only chart cosmetics?', 'subject score': 1000, 'object score': 1000}, 'PMID:11800521': {'publication date': '2001 Dec', 'sentence': 'Recent studies with stress doses of hydrocortisone in sepsis and septic shock have shown a marked haemodynamic improvement, but whether patients with relative adrenal dysfunction benefit most from this treatment and whether there is definitely an effect on outcome is still undecided.', 'subject score': 1000, 'object score': 1000}, 'PMID:11868733': {'publication date': '2001 Aug', 'sentence': 'More recently, work by Annane et al. using lower doses closer to those that might constitute a stress dose of hydrocortisone have shown encouraging results with a 30% decrease in mortality in septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:12614129': {'publication date': '2003', 'sentence': 'Hydrocortisone and fludrocortisone improved 28-day survival in septic shock and adrenal insufficiency.', 'subject score': 1000, 'object score': 1000}, 'PMID:16263835': {'publication date': '2006 Jan', 'sentence': 'Recently, low total cortisol increments after tetracosactrin have been associated with increased mortality and hemodynamic responsiveness to exogenous hydrocortisone in septic shock (SS), a phenomenon termed by some investigators as relative adrenal insufficiency (RAI).', 'subject score': 888, 'object score': 1000}, 'PMID:16608898': {'publication date': '2006 Jul', 'sentence': 'However, most severe disease and mortality is associated with an increased cortisol to DHEA ratio, which may represent a novel prognostic marker in septic shock.', 'subject score': 888, 'object score': 1000}, 'PMID:1669084': {'publication date': '1991', 'sentence': 'An effect of hydrocortisone and dopamine on beta-glucuronidase activity in the lung tissue in experimental septic shock was analysed.', 'subject score': 1000, 'object score': 901}, 'PMID:17021536': {'publication date': '2004 Apr', 'sentence': 'Together with new findings on low-dose hydrocortisone, this stresses the relevance of adjunctive therapy in severe sepsis and septic shock.', 'subject score': 901, 'object score': 1000}, 'PMID:17316466': {'publication date': '2007', 'sentence': \"A good example of this is the conflict between intensive insulin therapy and 'low dose' hydrocortisone in septic shock.\", 'subject score': 901, 'object score': 1000}, 'PMID:17658222': {'publication date': '2008', 'sentence': 'Mineralocorticoid effects due to cortisol inactivation overload explain the beneficial use of hydrocortisone in septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:17906853': {'publication date': '2008 Feb', 'sentence': 'Stress doses of hydrocortisone in septic shock: beneficial effects on opsonization-dependent neutrophil functions.', 'subject score': 1000, 'object score': 1000}, 'PMID:19004144': {'publication date': '2008 May-Jun', 'sentence': 'Does low dose hydrocortisone reduce mortality in septic shock?', 'subject score': 901, 'object score': 1000}, 'PMID:19057445': {'publication date': '2009 Jan', 'sentence': 'CONCLUSIONS: Our data, although, inconclusive favor the need for a study with a larger sample size to clearly define role of low-dose hydrocortisone in pediatric septic shock in developing countries, while taking in consideration effect of malnutrition, delayed presentations, and their interactions with the hypothalamic-pituitary-adrenocortical axis.', 'subject score': 901, 'object score': 901}, 'PMID:19326575': {'publication date': '2009 Apr', 'sentence': 'CONCLUSIONS: The administration of moderate doses of hydrocortisone in septic shock results in a modest but consistent improvement in capillary perfusion, independent of the response to the ACTH test.', 'subject score': 1000, 'object score': 1000}, 'PMID:19652948': {'publication date': '2009 Nov', 'sentence': 'METHODS: An a-priori sub-study of the CORTICUS multi-centre, randomised, double-blind, placebo-controlled trial of hydrocortisone in septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:21479650': {'publication date': '2011 Apr', 'sentence': 'Concomitant hydrocortisone and arginine vasopressin therapy increases arginine vasopressin plasma levels and may improve survival in septic shock.', 'subject score': 888, 'object score': 1000}, 'PMID:21993448': {'publication date': '2012 Jan', 'sentence': 'The aim of this prospective observational study was to investigate serial changes in plasma total and free cortisol and tissue cortisol activity in septic shock.', 'subject score': 790, 'object score': 1000}, 'PMID:22269144': {'publication date': '2012 Apr', 'sentence': 'The consensus statement from the international task force of the American College of Critical Care medicine recommends 100 mg of intravenous hydrocortisone for patients with adrenal insufficiency in septic shock, but in patients undergoing surgery, especially with extracorporeal circulation, the dosage may even be higher.', 'subject score': 888, 'object score': 1000}, 'PMID:22584796': {'publication date': '2012 Aug', 'sentence': 'Gluco- and mineralocorticoid biological effects of a 7-day treatment with low doses of hydrocortisone and fludrocortisone in septic shock.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:associated_with---None---None---None---UMLS:C0036983---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "8763179",
-              "object": "MONDO:0001881",
-              "publications": [
-                "PMID:11251036",
-                "PMID:11271077",
-                "PMID:11800521",
-                "PMID:11868733",
-                "PMID:12614129",
-                "PMID:16263835",
-                "PMID:16608898",
-                "PMID:1669084",
-                "PMID:17021536",
-                "PMID:17316466",
-                "PMID:17658222",
-                "PMID:17906853",
-                "PMID:19004144",
-                "PMID:19057445",
-                "PMID:19326575",
-                "PMID:19652948",
-                "PMID:21479650",
-                "PMID:21993448",
-                "PMID:22269144",
-                "PMID:22584796"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:9881838': {'publication date': '1998 Jul', 'sentence': 'The suppression of the anti-inflammatory effects of cortisol as a result of states of excessive stress leads to hypercatabolic diseases such as AIDS, sepsis and toxic shock syndrome and protein calorie malnutrition (NAIDS).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 528832,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-          "name": "toxic shock syndrome",
-          "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C35498",
-            "UMLS:C0600327",
-            "UMLS:CN204669",
-            "MEDDRA:10044248",
-            "MESH:D012772",
-            "MEDDRA:10044249",
-            "SNOMEDCT:18504008",
-            "DOID:14115",
-            "MEDDRA:10042852",
-            "UMLS:C0036983",
-            "ORPHANET:36234",
-            "SNOMEDCT:76571007",
-            "MEDDRA:10040580",
-            "NCIT:C35018",
-            "MEDDRA:10040070",
-            "ICD9:040.82",
-            "ICD10:A48.3",
-            "MONDO:0001881",
-            "EFO:0006834",
-            "SYMP:0000451"
-          ],
-          "id": "MONDO:0001881",
-          "category": "biolink:Disease",
-          "all_names": [
-            "toxic shock syndrome",
-            "Septic Shock",
-            "Shock, Septic",
-            "Toxic Shock Syndrome",
-            "Bacterial toxic-shock syndrome",
-            "septic shock",
-            "Toxic shock syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 528832,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-              "name": "toxic shock syndrome",
-              "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C35498",
-                "UMLS:C0600327",
-                "UMLS:CN204669",
-                "MEDDRA:10044248",
-                "MESH:D012772",
-                "MEDDRA:10044249",
-                "SNOMEDCT:18504008",
-                "DOID:14115",
-                "MEDDRA:10042852",
-                "UMLS:C0036983",
-                "ORPHANET:36234",
-                "SNOMEDCT:76571007",
-                "MEDDRA:10040580",
-                "NCIT:C35018",
-                "MEDDRA:10040070",
-                "ICD9:040.82",
-                "ICD10:A48.3",
-                "MONDO:0001881",
-                "EFO:0006834",
-                "SYMP:0000451"
-              ],
-              "id": "MONDO:0001881",
-              "category": "biolink:Disease",
-              "all_names": [
-                "toxic shock syndrome",
-                "Septic Shock",
-                "Shock, Septic",
-                "Toxic Shock Syndrome",
-                "Bacterial toxic-shock syndrome",
-                "septic shock",
-                "Toxic shock syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 27272384,
-            "start": 569,
-            "end": 528832,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9881838': {'publication date': '1998 Jul', 'sentence': 'The suppression of the anti-inflammatory effects of cortisol as a result of states of excessive stress leads to hypercatabolic diseases such as AIDS, sepsis and toxic shock syndrome and protein calorie malnutrition (NAIDS).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:causes---None---None---None---UMLS:C0600327---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "27747116",
-              "object": "MONDO:0001881",
-              "publications": [
-                "PMID:9881838"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:25942482': {'publication date': '2015 Jul', 'sentence': 'CONCLUSIONS: Early PN did not affect plasma concentrations of ACTH and (free) cortisol, but increased the incidence of septic shock, which statistically explained why more patients on early PN received corticosteroids.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 528832,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-          "name": "toxic shock syndrome",
-          "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C35498",
-            "UMLS:C0600327",
-            "UMLS:CN204669",
-            "MEDDRA:10044248",
-            "MESH:D012772",
-            "MEDDRA:10044249",
-            "SNOMEDCT:18504008",
-            "DOID:14115",
-            "MEDDRA:10042852",
-            "UMLS:C0036983",
-            "ORPHANET:36234",
-            "SNOMEDCT:76571007",
-            "MEDDRA:10040580",
-            "NCIT:C35018",
-            "MEDDRA:10040070",
-            "ICD9:040.82",
-            "ICD10:A48.3",
-            "MONDO:0001881",
-            "EFO:0006834",
-            "SYMP:0000451"
-          ],
-          "id": "MONDO:0001881",
-          "category": "biolink:Disease",
-          "all_names": [
-            "toxic shock syndrome",
-            "Septic Shock",
-            "Shock, Septic",
-            "Toxic Shock Syndrome",
-            "Bacterial toxic-shock syndrome",
-            "septic shock",
-            "Toxic shock syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 528832,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-              "name": "toxic shock syndrome",
-              "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C35498",
-                "UMLS:C0600327",
-                "UMLS:CN204669",
-                "MEDDRA:10044248",
-                "MESH:D012772",
-                "MEDDRA:10044249",
-                "SNOMEDCT:18504008",
-                "DOID:14115",
-                "MEDDRA:10042852",
-                "UMLS:C0036983",
-                "ORPHANET:36234",
-                "SNOMEDCT:76571007",
-                "MEDDRA:10040580",
-                "NCIT:C35018",
-                "MEDDRA:10040070",
-                "ICD9:040.82",
-                "ICD10:A48.3",
-                "MONDO:0001881",
-                "EFO:0006834",
-                "SYMP:0000451"
-              ],
-              "id": "MONDO:0001881",
-              "category": "biolink:Disease",
-              "all_names": [
-                "toxic shock syndrome",
-                "Septic Shock",
-                "Shock, Septic",
-                "Toxic Shock Syndrome",
-                "Bacterial toxic-shock syndrome",
-                "septic shock",
-                "Toxic shock syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17946115,
-            "start": 569,
-            "end": 528832,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25942482': {'publication date': '2015 Jul', 'sentence': 'CONCLUSIONS: Early PN did not affect plasma concentrations of ACTH and (free) cortisol, but increased the incidence of septic shock, which statistically explained why more patients on early PN received corticosteroids.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0036983---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "18310128",
-              "object": "MONDO:0001881",
-              "publications": [
-                "PMID:25942482"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:12426230': {'publication date': '2003 Feb 15', 'sentence': 'Immunologic and hemodynamic effects of \"low-dose\" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study.', 'subject score': 901, 'object score': 1000}, 'PMID:17509634': {'publication date': '2007 Jun', 'sentence': 'Recently, it was demonstrated that hydrocortisone has immunologic effects in septic shock and therefore may affect cell adhesion molecules.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 528832,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-          "name": "toxic shock syndrome",
-          "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C35498",
-            "UMLS:C0600327",
-            "UMLS:CN204669",
-            "MEDDRA:10044248",
-            "MESH:D012772",
-            "MEDDRA:10044249",
-            "SNOMEDCT:18504008",
-            "DOID:14115",
-            "MEDDRA:10042852",
-            "UMLS:C0036983",
-            "ORPHANET:36234",
-            "SNOMEDCT:76571007",
-            "MEDDRA:10040580",
-            "NCIT:C35018",
-            "MEDDRA:10040070",
-            "ICD9:040.82",
-            "ICD10:A48.3",
-            "MONDO:0001881",
-            "EFO:0006834",
-            "SYMP:0000451"
-          ],
-          "id": "MONDO:0001881",
-          "category": "biolink:Disease",
-          "all_names": [
-            "toxic shock syndrome",
-            "Septic Shock",
-            "Shock, Septic",
-            "Toxic Shock Syndrome",
-            "Bacterial toxic-shock syndrome",
-            "septic shock",
-            "Toxic shock syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 528832,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-              "name": "toxic shock syndrome",
-              "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C35498",
-                "UMLS:C0600327",
-                "UMLS:CN204669",
-                "MEDDRA:10044248",
-                "MESH:D012772",
-                "MEDDRA:10044249",
-                "SNOMEDCT:18504008",
-                "DOID:14115",
-                "MEDDRA:10042852",
-                "UMLS:C0036983",
-                "ORPHANET:36234",
-                "SNOMEDCT:76571007",
-                "MEDDRA:10040580",
-                "NCIT:C35018",
-                "MEDDRA:10040070",
-                "ICD9:040.82",
-                "ICD10:A48.3",
-                "MONDO:0001881",
-                "EFO:0006834",
-                "SYMP:0000451"
-              ],
-              "id": "MONDO:0001881",
-              "category": "biolink:Disease",
-              "all_names": [
-                "toxic shock syndrome",
-                "Septic Shock",
-                "Shock, Septic",
-                "Toxic Shock Syndrome",
-                "Bacterial toxic-shock syndrome",
-                "septic shock",
-                "Toxic shock syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9659155,
-            "start": 569,
-            "end": 528832,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12426230': {'publication date': '2003 Feb 15', 'sentence': 'Immunologic and hemodynamic effects of \"low-dose\" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study.', 'subject score': 901, 'object score': 1000}, 'PMID:17509634': {'publication date': '2007 Jun', 'sentence': 'Recently, it was demonstrated that hydrocortisone has immunologic effects in septic shock and therefore may affect cell adhesion molecules.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:affects---None---None---None---UMLS:C0036983---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "9872405",
-              "object": "MONDO:0001881",
-              "publications": [
-                "PMID:12426230",
-                "PMID:17509634"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10678798': {'publication date': '1999 Dec', 'sentence': 'Two recent small randomized trials evaluating a 5- to 12-day course of low dose hydrocortisone in patients with septic shock have reported a significant clinical improvement and a reduction in mortality.', 'subject score': 901, 'object score': 1000}, 'PMID:11271081': {'publication date': '2000 Dec', 'sentence': 'PATIENTS: Twenty consecutive patients with septic shock and a cardiac index of 3.5 l/min or higher, started on \"low-dose\" hydrocortisone therapy (100 mg bolus, 10 mg/h for 7 days and subsequent tapering) within 72 h of the onset of shock.', 'subject score': 861, 'object score': 1000}, 'PMID:11333472': {'publication date': '2001 May', 'sentence': 'CONCLUSIONS: Plasma cortisol and ACTH levels were increased in children with sepsis and septic shock.', 'subject score': 888, 'object score': 1000}, 'PMID:11445745': {'publication date': '2001 Jul', 'sentence': 'OBJECTIVE: To gather the data to provide a rationale for using replacement therapy with hydrocortisone in septic shock patients.', 'subject score': 1000, 'object score': 901}, 'PMID:12186604': {'publication date': '2002 Aug 21', 'sentence': 'Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:12426230': {'publication date': '2003 Feb 15', 'sentence': 'Within the last few years, increasing evidence of relative adrenal insufficiency in septic shock evoked a reassessment of hydrocortisone therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:12545007': {'publication date': '2003 Jan', 'sentence': 'OBJECTIVE: To determine whether a baseline (random) cortisol concentration <25 microg/dL in patients with septic shock was a better discriminator of adrenal insufficiency than the standard (250 microg) and the low-dose (1 microg) corticotropin stimulation tests as assessed by the hemodynamic response to steroid replacement.', 'subject score': 694, 'object score': 1000}, 'PMID:12592960': {'publication date': '2003 Jan', 'sentence': 'Recently, a new concept has emerged with more promising results--low dose, long-term hydrocortisone therapy- and this approach is now being evaluated in the treatment of septic shock.', 'subject score': 861, 'object score': 1000}, 'PMID:12766716': {'publication date': '2003 Apr', 'sentence': 'There is no concordance in literature about the role of replacement therapy with hydrocortisone on survival in patients with septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:13678564': {'publication date': '2003 Oct', 'sentence': 'Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:14714106': {'publication date': '2004 Feb', 'sentence': 'PATIENTS: Septic shock patients (n=300) included in a placebo-controlled randomized double-blind study on the efficacy and safety of a 7-day treatment with 50 mg hydrocortisone every 6 h intravenously and 50 microg fludrocortisone every 24 h orally.', 'subject score': 790, 'object score': 901}, 'PMID:15179130': {'publication date': '2004 Apr', 'sentence': 'The aim of the present study was to investigate whether the plasma levels of soluble CAMs, reflecting in vivo endothelial activation, could be modulated in patients with septic shock treated by hydrocortisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:15482661': {'publication date': '2004 Sep', 'sentence': '[Effects of different doses of hydrocortisone on acute lung injury in rats with early septic shock induced by Escherichia coli].', 'subject score': 1000, 'object score': 901}, 'PMID:16276166': {'publication date': '2005 Nov', 'sentence': 'OBJECTIVES: To investigate the effect of low-dose hydrocortisone on time to shock reversal, the cytokine profile, and its relation to adrenal function in patients with early septic shock.', 'subject score': 901, 'object score': 901}, 'PMID:1669084': {'publication date': '1991', 'sentence': 'It was found, that hydrocortisone and dopamine given together increase the stability of the pulmonary lysosomes indicating a value of such management of the septic shock in man.', 'subject score': 1000, 'object score': 1000}, 'PMID:17003064': {'publication date': '2007 Feb', 'sentence': 'What is the rationale for hydrocortisone treatment in children with infection-related adrenal insufficiency and septic shock?', 'subject score': 888, 'object score': 1000}, 'PMID:17325831': {'publication date': '2007 Apr', 'sentence': 'CONCLUSIONS: Bolus injections of hydrocortisone may induce significant increases of blood glucose in patients with septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:17509634': {'publication date': '2007 Jun', 'sentence': 'CONCLUSIONS: Hydrocortisone mediates immunmodulating effects in therapy of patients suffering of septic shock without involvement of specific platelet receptors in vitro.', 'subject score': 1000, 'object score': 1000}, 'PMID:17551886': {'publication date': '2007 Jun 15', 'sentence': 'TREATMENT AND COURSE: The patient was admitted to the intensive care unit and initially treated with intravenous piperacillin/tazobactam and hydrocortisone for septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:17596656': {'publication date': '2007 Jun', 'sentence': 'Because high levels of cortisol are frequently observed in patients with septic shock, low levels of serum cortisol are considered indicative of relative adrenal insufficiency (RAI).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 528832,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-          "name": "toxic shock syndrome",
-          "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C35498",
-            "UMLS:C0600327",
-            "UMLS:CN204669",
-            "MEDDRA:10044248",
-            "MESH:D012772",
-            "MEDDRA:10044249",
-            "SNOMEDCT:18504008",
-            "DOID:14115",
-            "MEDDRA:10042852",
-            "UMLS:C0036983",
-            "ORPHANET:36234",
-            "SNOMEDCT:76571007",
-            "MEDDRA:10040580",
-            "NCIT:C35018",
-            "MEDDRA:10040070",
-            "ICD9:040.82",
-            "ICD10:A48.3",
-            "MONDO:0001881",
-            "EFO:0006834",
-            "SYMP:0000451"
-          ],
-          "id": "MONDO:0001881",
-          "category": "biolink:Disease",
-          "all_names": [
-            "toxic shock syndrome",
-            "Septic Shock",
-            "Shock, Septic",
-            "Toxic Shock Syndrome",
-            "Bacterial toxic-shock syndrome",
-            "septic shock",
-            "Toxic shock syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 528832,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-              "name": "toxic shock syndrome",
-              "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C35498",
-                "UMLS:C0600327",
-                "UMLS:CN204669",
-                "MEDDRA:10044248",
-                "MESH:D012772",
-                "MEDDRA:10044249",
-                "SNOMEDCT:18504008",
-                "DOID:14115",
-                "MEDDRA:10042852",
-                "UMLS:C0036983",
-                "ORPHANET:36234",
-                "SNOMEDCT:76571007",
-                "MEDDRA:10040580",
-                "NCIT:C35018",
-                "MEDDRA:10040070",
-                "ICD9:040.82",
-                "ICD10:A48.3",
-                "MONDO:0001881",
-                "EFO:0006834",
-                "SYMP:0000451"
-              ],
-              "id": "MONDO:0001881",
-              "category": "biolink:Disease",
-              "all_names": [
-                "toxic shock syndrome",
-                "Septic Shock",
-                "Shock, Septic",
-                "Toxic Shock Syndrome",
-                "Bacterial toxic-shock syndrome",
-                "septic shock",
-                "Toxic shock syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7829565,
-            "start": 569,
-            "end": 528832,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10678798': {'publication date': '1999 Dec', 'sentence': 'Two recent small randomized trials evaluating a 5- to 12-day course of low dose hydrocortisone in patients with septic shock have reported a significant clinical improvement and a reduction in mortality.', 'subject score': 901, 'object score': 1000}, 'PMID:11271081': {'publication date': '2000 Dec', 'sentence': 'PATIENTS: Twenty consecutive patients with septic shock and a cardiac index of 3.5 l/min or higher, started on \"low-dose\" hydrocortisone therapy (100 mg bolus, 10 mg/h for 7 days and subsequent tapering) within 72 h of the onset of shock.', 'subject score': 861, 'object score': 1000}, 'PMID:11333472': {'publication date': '2001 May', 'sentence': 'CONCLUSIONS: Plasma cortisol and ACTH levels were increased in children with sepsis and septic shock.', 'subject score': 888, 'object score': 1000}, 'PMID:11445745': {'publication date': '2001 Jul', 'sentence': 'OBJECTIVE: To gather the data to provide a rationale for using replacement therapy with hydrocortisone in septic shock patients.', 'subject score': 1000, 'object score': 901}, 'PMID:12186604': {'publication date': '2002 Aug 21', 'sentence': 'Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:12426230': {'publication date': '2003 Feb 15', 'sentence': 'Within the last few years, increasing evidence of relative adrenal insufficiency in septic shock evoked a reassessment of hydrocortisone therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:12545007': {'publication date': '2003 Jan', 'sentence': 'OBJECTIVE: To determine whether a baseline (random) cortisol concentration <25 microg/dL in patients with septic shock was a better discriminator of adrenal insufficiency than the standard (250 microg) and the low-dose (1 microg) corticotropin stimulation tests as assessed by the hemodynamic response to steroid replacement.', 'subject score': 694, 'object score': 1000}, 'PMID:12592960': {'publication date': '2003 Jan', 'sentence': 'Recently, a new concept has emerged with more promising results--low dose, long-term hydrocortisone therapy- and this approach is now being evaluated in the treatment of septic shock.', 'subject score': 861, 'object score': 1000}, 'PMID:12766716': {'publication date': '2003 Apr', 'sentence': 'There is no concordance in literature about the role of replacement therapy with hydrocortisone on survival in patients with septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:13678564': {'publication date': '2003 Oct', 'sentence': 'Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:14714106': {'publication date': '2004 Feb', 'sentence': 'PATIENTS: Septic shock patients (n=300) included in a placebo-controlled randomized double-blind study on the efficacy and safety of a 7-day treatment with 50 mg hydrocortisone every 6 h intravenously and 50 microg fludrocortisone every 24 h orally.', 'subject score': 790, 'object score': 901}, 'PMID:15179130': {'publication date': '2004 Apr', 'sentence': 'The aim of the present study was to investigate whether the plasma levels of soluble CAMs, reflecting in vivo endothelial activation, could be modulated in patients with septic shock treated by hydrocortisone.', 'subject score': 1000, 'object score': 1000}, 'PMID:15482661': {'publication date': '2004 Sep', 'sentence': '[Effects of different doses of hydrocortisone on acute lung injury in rats with early septic shock induced by Escherichia coli].', 'subject score': 1000, 'object score': 901}, 'PMID:16276166': {'publication date': '2005 Nov', 'sentence': 'OBJECTIVES: To investigate the effect of low-dose hydrocortisone on time to shock reversal, the cytokine profile, and its relation to adrenal function in patients with early septic shock.', 'subject score': 901, 'object score': 901}, 'PMID:1669084': {'publication date': '1991', 'sentence': 'It was found, that hydrocortisone and dopamine given together increase the stability of the pulmonary lysosomes indicating a value of such management of the septic shock in man.', 'subject score': 1000, 'object score': 1000}, 'PMID:17003064': {'publication date': '2007 Feb', 'sentence': 'What is the rationale for hydrocortisone treatment in children with infection-related adrenal insufficiency and septic shock?', 'subject score': 888, 'object score': 1000}, 'PMID:17325831': {'publication date': '2007 Apr', 'sentence': 'CONCLUSIONS: Bolus injections of hydrocortisone may induce significant increases of blood glucose in patients with septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:17509634': {'publication date': '2007 Jun', 'sentence': 'CONCLUSIONS: Hydrocortisone mediates immunmodulating effects in therapy of patients suffering of septic shock without involvement of specific platelet receptors in vitro.', 'subject score': 1000, 'object score': 1000}, 'PMID:17551886': {'publication date': '2007 Jun 15', 'sentence': 'TREATMENT AND COURSE: The patient was admitted to the intensive care unit and initially treated with intravenous piperacillin/tazobactam and hydrocortisone for septic shock.', 'subject score': 1000, 'object score': 1000}, 'PMID:17596656': {'publication date': '2007 Jun', 'sentence': 'Because high levels of cortisol are frequently observed in patients with septic shock, low levels of serum cortisol are considered indicative of relative adrenal insufficiency (RAI).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0036983---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "7996696",
-              "object": "MONDO:0001881",
-              "publications": [
-                "PMID:10678798",
-                "PMID:11271081",
-                "PMID:11333472",
-                "PMID:11445745",
-                "PMID:12186604",
-                "PMID:12426230",
-                "PMID:12545007",
-                "PMID:12592960",
-                "PMID:12766716",
-                "PMID:13678564",
-                "PMID:14714106",
-                "PMID:15179130",
-                "PMID:15482661",
-                "PMID:16276166",
-                "PMID:1669084",
-                "PMID:17003064",
-                "PMID:17325831",
-                "PMID:17509634",
-                "PMID:17551886",
-                "PMID:17596656"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:produces",
-    "r2.publications_info": "{'PMID:21757092': {'publication date': '2011 Jul', 'sentence': 'CIRCI is characterized by an inadequate production of cortisol in relation to an increased demand during periods of severe stress, particularly in critical illnesses such as sepsis or septic shock.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 528832,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-          "name": "toxic shock syndrome",
-          "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C35498",
-            "UMLS:C0600327",
-            "UMLS:CN204669",
-            "MEDDRA:10044248",
-            "MESH:D012772",
-            "MEDDRA:10044249",
-            "SNOMEDCT:18504008",
-            "DOID:14115",
-            "MEDDRA:10042852",
-            "UMLS:C0036983",
-            "ORPHANET:36234",
-            "SNOMEDCT:76571007",
-            "MEDDRA:10040580",
-            "NCIT:C35018",
-            "MEDDRA:10040070",
-            "ICD9:040.82",
-            "ICD10:A48.3",
-            "MONDO:0001881",
-            "EFO:0006834",
-            "SYMP:0000451"
-          ],
-          "id": "MONDO:0001881",
-          "category": "biolink:Disease",
-          "all_names": [
-            "toxic shock syndrome",
-            "Septic Shock",
-            "Shock, Septic",
-            "Toxic Shock Syndrome",
-            "Bacterial toxic-shock syndrome",
-            "septic shock",
-            "Toxic shock syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 528832,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-              "name": "toxic shock syndrome",
-              "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C35498",
-                "UMLS:C0600327",
-                "UMLS:CN204669",
-                "MEDDRA:10044248",
-                "MESH:D012772",
-                "MEDDRA:10044249",
-                "SNOMEDCT:18504008",
-                "DOID:14115",
-                "MEDDRA:10042852",
-                "UMLS:C0036983",
-                "ORPHANET:36234",
-                "SNOMEDCT:76571007",
-                "MEDDRA:10040580",
-                "NCIT:C35018",
-                "MEDDRA:10040070",
-                "ICD9:040.82",
-                "ICD10:A48.3",
-                "MONDO:0001881",
-                "EFO:0006834",
-                "SYMP:0000451"
-              ],
-              "id": "MONDO:0001881",
-              "category": "biolink:Disease",
-              "all_names": [
-                "toxic shock syndrome",
-                "Septic Shock",
-                "Shock, Septic",
-                "Toxic Shock Syndrome",
-                "Bacterial toxic-shock syndrome",
-                "septic shock",
-                "Toxic shock syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15437053,
-            "start": 528832,
-            "end": 569,
-            "type": "biolink:produces",
-            "properties": {
-              "predicate": "biolink:produces",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21757092': {'publication date': '2011 Jul', 'sentence': 'CIRCI is characterized by an inadequate production of cortisol in relation to an increased demand during periods of severe stress, particularly in critical illnesses such as sepsis or septic shock.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0036983---SEMMEDDB:produces---None---None---None---UMLS:C0020268---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0001881",
-              "id": "15760263",
-              "object": "PUBCHEM.COMPOUND:5754",
-              "publications": [
-                "PMID:21757092"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:27695824': {'publication date': '2016 Nov 01', 'sentence': 'Conclusions and Relevance: Among adults with severe sepsis not in septic shock, use of hydrocortisone compared with placebo did not reduce the risk of septic shock within 14 days.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 528832,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-          "name": "toxic shock syndrome",
-          "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C35498",
-            "UMLS:C0600327",
-            "UMLS:CN204669",
-            "MEDDRA:10044248",
-            "MESH:D012772",
-            "MEDDRA:10044249",
-            "SNOMEDCT:18504008",
-            "DOID:14115",
-            "MEDDRA:10042852",
-            "UMLS:C0036983",
-            "ORPHANET:36234",
-            "SNOMEDCT:76571007",
-            "MEDDRA:10040580",
-            "NCIT:C35018",
-            "MEDDRA:10040070",
-            "ICD9:040.82",
-            "ICD10:A48.3",
-            "MONDO:0001881",
-            "EFO:0006834",
-            "SYMP:0000451"
-          ],
-          "id": "MONDO:0001881",
-          "category": "biolink:Disease",
-          "all_names": [
-            "toxic shock syndrome",
-            "Septic Shock",
-            "Shock, Septic",
-            "Toxic Shock Syndrome",
-            "Bacterial toxic-shock syndrome",
-            "septic shock",
-            "Toxic shock syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 528832,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-              "name": "toxic shock syndrome",
-              "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C35498",
-                "UMLS:C0600327",
-                "UMLS:CN204669",
-                "MEDDRA:10044248",
-                "MESH:D012772",
-                "MEDDRA:10044249",
-                "SNOMEDCT:18504008",
-                "DOID:14115",
-                "MEDDRA:10042852",
-                "UMLS:C0036983",
-                "ORPHANET:36234",
-                "SNOMEDCT:76571007",
-                "MEDDRA:10040580",
-                "NCIT:C35018",
-                "MEDDRA:10040070",
-                "ICD9:040.82",
-                "ICD10:A48.3",
-                "MONDO:0001881",
-                "EFO:0006834",
-                "SYMP:0000451"
-              ],
-              "id": "MONDO:0001881",
-              "category": "biolink:Disease",
-              "all_names": [
-                "toxic shock syndrome",
-                "Septic Shock",
-                "Shock, Septic",
-                "Toxic Shock Syndrome",
-                "Bacterial toxic-shock syndrome",
-                "septic shock",
-                "Toxic shock syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18866296,
-            "start": 569,
-            "end": 528832,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27695824': {'publication date': '2016 Nov 01', 'sentence': 'Conclusions and Relevance: Among adults with severe sepsis not in septic shock, use of hydrocortisone compared with placebo did not reduce the risk of septic shock within 14 days.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:prevents---None---None---None---UMLS:C0036983---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "19245686",
-              "object": "MONDO:0001881",
-              "publications": [
-                "PMID:27695824"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:1678460': {'publication date': '1991 Aug 24', 'sentence': 'Contribution of cortisol deficiency to septic shock.', 'subject score': 888, 'object score': 1000}, 'PMID:20455885': {'publication date': '2010 Sep', 'sentence': 'Free cortisol, and to a lesser extent total cortisol, but not NOx concentrations, predicted septic shock.', 'subject score': 833, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 528832,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-          "name": "toxic shock syndrome",
-          "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C35498",
-            "UMLS:C0600327",
-            "UMLS:CN204669",
-            "MEDDRA:10044248",
-            "MESH:D012772",
-            "MEDDRA:10044249",
-            "SNOMEDCT:18504008",
-            "DOID:14115",
-            "MEDDRA:10042852",
-            "UMLS:C0036983",
-            "ORPHANET:36234",
-            "SNOMEDCT:76571007",
-            "MEDDRA:10040580",
-            "NCIT:C35018",
-            "MEDDRA:10040070",
-            "ICD9:040.82",
-            "ICD10:A48.3",
-            "MONDO:0001881",
-            "EFO:0006834",
-            "SYMP:0000451"
-          ],
-          "id": "MONDO:0001881",
-          "category": "biolink:Disease",
-          "all_names": [
-            "toxic shock syndrome",
-            "Septic Shock",
-            "Shock, Septic",
-            "Toxic Shock Syndrome",
-            "Bacterial toxic-shock syndrome",
-            "septic shock",
-            "Toxic shock syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 528832,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001881",
-              "name": "toxic shock syndrome",
-              "description": "A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.; Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C35498",
-                "UMLS:C0600327",
-                "UMLS:CN204669",
-                "MEDDRA:10044248",
-                "MESH:D012772",
-                "MEDDRA:10044249",
-                "SNOMEDCT:18504008",
-                "DOID:14115",
-                "MEDDRA:10042852",
-                "UMLS:C0036983",
-                "ORPHANET:36234",
-                "SNOMEDCT:76571007",
-                "MEDDRA:10040580",
-                "NCIT:C35018",
-                "MEDDRA:10040070",
-                "ICD9:040.82",
-                "ICD10:A48.3",
-                "MONDO:0001881",
-                "EFO:0006834",
-                "SYMP:0000451"
-              ],
-              "id": "MONDO:0001881",
-              "category": "biolink:Disease",
-              "all_names": [
-                "toxic shock syndrome",
-                "Septic Shock",
-                "Shock, Septic",
-                "Toxic Shock Syndrome",
-                "Bacterial toxic-shock syndrome",
-                "septic shock",
-                "Toxic shock syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/toxic_shock_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12288777,
-            "start": 569,
-            "end": 528832,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1678460': {'publication date': '1991 Aug 24', 'sentence': 'Contribution of cortisol deficiency to septic shock.', 'subject score': 888, 'object score': 1000}, 'PMID:20455885': {'publication date': '2010 Sep', 'sentence': 'Free cortisol, and to a lesser extent total cortisol, but not NOx concentrations, predicted septic shock.', 'subject score': 833, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:predisposes---None---None---None---UMLS:C0036983---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "12555774",
-              "object": "MONDO:0001881",
-              "publications": [
-                "PMID:1678460",
-                "PMID:20455885"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:13368875': {'publication date': '1956 Oct', 'sentence': 'Alopecia areata, partialis, and totalis; treatment with cortisone, hydrocortisone and their analogs, prednisone and prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 320422,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000687",
-          "name": "diffuse alopecia areata",
-          "description": "Transient, non-scarring hair loss and preservation of the hair follicle located in in well-defined patches. []; Transient, non-scarring hair loss and preservation of the hair follicle located in in well-defined patches.; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "SNOMEDCT:201138007",
-            "MESH:C531609",
-            "SNOMEDCT:68225006",
-            "DOID:0060157",
-            "UMLS:C0002171",
-            "HP:0002232",
-            "UMLS:C0406458",
-            "MEDDRA:10001761",
-            "SNOMEDCT:46586006",
-            "UMLS:C0263479",
-            "MEDDRA:10073736",
-            "MONDO:0000687",
-            "UMLS:C1862862",
-            "MESH:D000506"
-          ],
-          "id": "MONDO:0000687",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Diffuse alopecia",
-            "Alopecia Areata",
-            "diffuse alopecia areata",
-            "Patchy alopecia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/alopecia_areata"
-          ]
-        }
-      },
-      "end": {
-        "identity": 569,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Hydrocortisone",
-          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-          "equivalent_curies": [
-            "DRUGBANK:DB00741",
-            "PSY:12030",
-            "DrugCentral:1388",
-            "CHEBI:180955",
-            "ATC:S02BA01",
-            "RXNORM:5492",
-            "HMDB:HMDB0000063",
-            "NDDF:002147",
-            "KEGG.COMPOUND:C00735",
-            "ATC:A01AC03",
-            "ATC:D07AA02",
-            "KEGG.DRUG:D00088",
-            "PUBCHEM.COMPOUND:5754",
-            "ATC:H02AB09",
-            "ATC:C05AA01",
-            "UMLS:C0020268",
-            "NCIT:C2290",
-            "PSY:23640",
-            "CAS:50-23-7",
-            "PathWhiz.Compound:45",
-            "ATC:S01BA02",
-            "UNII:WI4X0X7BPJ",
-            "ATC:A07EA02",
-            "ATC:D07XA01",
-            "CHEBI:17650",
-            "GTOPDB:2868",
-            "MESH:D006854",
-            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-            "ATC:S01CB03",
-            "CHEMBL.COMPOUND:CHEMBL389621"
-          ],
-          "id": "PUBCHEM.COMPOUND:5754",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Hydrocortisone",
-            "cortisol",
-            "Hydrocortisone (JP18/USP/INN)",
-            "hydrocortisone",
-            "Cortisol",
-            "17-hydroxycorticosterone",
-            "HYDROCORTISONE",
-            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:2970549",
-            "PMID:29729985",
-            "PMID:18666772",
-            "PMID:2031862",
-            "PMID:24128814",
-            "PMID:19256501",
-            "PMID:27692996",
-            "PMID:30419492",
-            "PMID:18289853"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320422,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000687",
-              "name": "diffuse alopecia areata",
-              "description": "Transient, non-scarring hair loss and preservation of the hair follicle located in in well-defined patches. []; Transient, non-scarring hair loss and preservation of the hair follicle located in in well-defined patches.; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "SNOMEDCT:201138007",
-                "MESH:C531609",
-                "SNOMEDCT:68225006",
-                "DOID:0060157",
-                "UMLS:C0002171",
-                "HP:0002232",
-                "UMLS:C0406458",
-                "MEDDRA:10001761",
-                "SNOMEDCT:46586006",
-                "UMLS:C0263479",
-                "MEDDRA:10073736",
-                "MONDO:0000687",
-                "UMLS:C1862862",
-                "MESH:D000506"
-              ],
-              "id": "MONDO:0000687",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Diffuse alopecia",
-                "Alopecia Areata",
-                "diffuse alopecia areata",
-                "Patchy alopecia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/alopecia_areata"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10290270,
-            "start": 569,
-            "end": 320422,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13368875': {'publication date': '1956 Oct', 'sentence': 'Alopecia areata, partialis, and totalis; treatment with cortisone, hydrocortisone and their analogs, prednisone and prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0002171---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5754",
-              "id": "10516843",
-              "object": "MONDO:0000687",
-              "publications": [
-                "PMID:13368875"
-              ]
-            }
-          },
-          "end": {
-            "identity": 569,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Hydrocortisone",
-              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
-              "equivalent_curies": [
-                "DRUGBANK:DB00741",
-                "PSY:12030",
-                "DrugCentral:1388",
-                "CHEBI:180955",
-                "ATC:S02BA01",
-                "RXNORM:5492",
-                "HMDB:HMDB0000063",
-                "NDDF:002147",
-                "KEGG.COMPOUND:C00735",
-                "ATC:A01AC03",
-                "ATC:D07AA02",
-                "KEGG.DRUG:D00088",
-                "PUBCHEM.COMPOUND:5754",
-                "ATC:H02AB09",
-                "ATC:C05AA01",
-                "UMLS:C0020268",
-                "NCIT:C2290",
-                "PSY:23640",
-                "CAS:50-23-7",
-                "PathWhiz.Compound:45",
-                "ATC:S01BA02",
-                "UNII:WI4X0X7BPJ",
-                "ATC:A07EA02",
-                "ATC:D07XA01",
-                "CHEBI:17650",
-                "GTOPDB:2868",
-                "MESH:D006854",
-                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
-                "ATC:S01CB03",
-                "CHEMBL.COMPOUND:CHEMBL389621"
-              ],
-              "id": "PUBCHEM.COMPOUND:5754",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Hydrocortisone",
-                "cortisol",
-                "Hydrocortisone (JP18/USP/INN)",
-                "hydrocortisone",
-                "Cortisol",
-                "17-hydroxycorticosterone",
-                "HYDROCORTISONE",
-                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:2970549",
-                "PMID:29729985",
-                "PMID:18666772",
-                "PMID:2031862",
-                "PMID:24128814",
-                "PMID:19256501",
-                "PMID:27692996",
-                "PMID:30419492",
-                "PMID:18289853"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:16651362': {'publication date': '2006 May', 'sentence': 'Hypertrophic cardiomyopathy in preterm infants treated with methylprednisolone for bronchopulmonary dysplasia.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 722907,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-          "name": "bronchopulmonary dysplasia",
-          "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:70589",
-            "MESH:D001997",
-            "MONDO:0019091",
-            "SNOMEDCT:67569000",
-            "MEDDRA:10066204",
-            "UMLS:C0006287",
-            "NCIT:C90599",
-            "DOID:11650",
-            "MEDDRA:10006475"
-          ],
-          "id": "MONDO:0019091",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bronchopulmonary Dysplasia",
-            "obsolete_bronchopulmonary dysplasia",
-            "bronchopulmonary dysplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 722907,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-              "name": "bronchopulmonary dysplasia",
-              "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:70589",
-                "MESH:D001997",
-                "MONDO:0019091",
-                "SNOMEDCT:67569000",
-                "MEDDRA:10066204",
-                "UMLS:C0006287",
-                "NCIT:C90599",
-                "DOID:11650",
-                "MEDDRA:10006475"
-              ],
-              "id": "MONDO:0019091",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bronchopulmonary Dysplasia",
-                "obsolete_bronchopulmonary dysplasia",
-                "bronchopulmonary dysplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12185216,
-            "start": 570,
-            "end": 722907,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16651362': {'publication date': '2006 May', 'sentence': 'Hypertrophic cardiomyopathy in preterm infants treated with methylprednisolone for bronchopulmonary dysplasia.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0006287---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "12450216",
-              "object": "MONDO:0019091",
-              "publications": [
-                "PMID:16651362"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15574579': {'publication date': '2005 Jan', 'sentence': 'The hematologic evaluations and her clinical course revealed the diagnosis of TTP, so plasma exchange and methyl-prednisolone therapy were initiated.', 'subject score': 888, 'object score': 1000}, 'PMID:2120885': {'publication date': '1990', 'sentence': 'High-dose intravenous methylprednisolone for thrombotic thrombocytopenic purpura.', 'subject score': 861, 'object score': 1000}, 'PMID:23659403': {'publication date': '2013 May', 'sentence': 'Treatment of thrombotic thrombocytopenic purpura with exchange plasmapheresis and methylprednisolone was of paramount importance and the patient was discharged home on day 30 with complete recovery of haematological, neurological and renal function.', 'subject score': 1000, 'object score': 1000}, 'PMID:3394714': {'publication date': '1988 Jun', 'sentence': 'Intravenous high dose methylprednisolone for thrombotic thrombocytopenic purpura.', 'subject score': 861, 'object score': 1000}, 'PMID:34577835': {'publication date': '2021 Aug 31', 'sentence': 'A diagnosis of probable catastrophic antiphospholipid syndrome (CAPS) was established and treatment with low molecular weight heparin, intravenous methylprednisolone, plasmapheresis, and rituximab was initiated, followed by resolution of AKI, diplopia, and TMA with complete depletion of CD19+B-lymphocytes (CD19+B-Ly) after one month.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 592657,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018896",
-          "name": "thrombotic thrombocytopenic purpura",
-          "description": "An acute or subacute syndrome characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities and neurologic abnormalities such as seizures, hemiplegia, and visual disturbances. Drugs and bacteria have been implicated as etiologic factors. The introduction of plasma exchange has significantly lowered the mortality rate. If untreated, the mortality rate is high. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C78797\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C78797\" NCI Thesaurus); A coagulation disorder characterized by extensive formation of thrombi in small blood vessels throughout the body due to low levels of ADAMTS13 protein, and resulting in consumption of circulating platelets, which is characterized by thrombocytopenia, anemia, neurologic changes, and sometimes fever and renal dysfunction.; An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10037562",
-            "MONDO:0018896",
-            "UMLS:C0034155",
-            "ORPHANET:54057",
-            "ICD10:M31.19",
-            "SNOMEDCT:78129009",
-            "NCIT:C78797",
-            "MEDDRA:10073197",
-            "MESH:D011697",
-            "PDQ:CDR0000694585",
-            "MEDDRA:10043562",
-            "DOID:10772",
-            "MEDDRA:10043648",
-            "MEDDRA:10037563"
-          ],
-          "id": "MONDO:0018896",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Thrombotic Thrombocytopenic Purpura",
-            "Thrombotic thrombocytopenic purpura",
-            "thrombotic thrombocytopenic purpura",
-            "Purpura, Thrombotic Thrombocytopenic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 592657,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018896",
-              "name": "thrombotic thrombocytopenic purpura",
-              "description": "An acute or subacute syndrome characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities and neurologic abnormalities such as seizures, hemiplegia, and visual disturbances. Drugs and bacteria have been implicated as etiologic factors. The introduction of plasma exchange has significantly lowered the mortality rate. If untreated, the mortality rate is high. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C78797\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C78797\" NCI Thesaurus); A coagulation disorder characterized by extensive formation of thrombi in small blood vessels throughout the body due to low levels of ADAMTS13 protein, and resulting in consumption of circulating platelets, which is characterized by thrombocytopenia, anemia, neurologic changes, and sometimes fever and renal dysfunction.; An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10037562",
-                "MONDO:0018896",
-                "UMLS:C0034155",
-                "ORPHANET:54057",
-                "ICD10:M31.19",
-                "SNOMEDCT:78129009",
-                "NCIT:C78797",
-                "MEDDRA:10073197",
-                "MESH:D011697",
-                "PDQ:CDR0000694585",
-                "MEDDRA:10043562",
-                "DOID:10772",
-                "MEDDRA:10043648",
-                "MEDDRA:10037563"
-              ],
-              "id": "MONDO:0018896",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Thrombotic Thrombocytopenic Purpura",
-                "Thrombotic thrombocytopenic purpura",
-                "thrombotic thrombocytopenic purpura",
-                "Purpura, Thrombotic Thrombocytopenic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11299900,
-            "start": 570,
-            "end": 592657,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15574579': {'publication date': '2005 Jan', 'sentence': 'The hematologic evaluations and her clinical course revealed the diagnosis of TTP, so plasma exchange and methyl-prednisolone therapy were initiated.', 'subject score': 888, 'object score': 1000}, 'PMID:2120885': {'publication date': '1990', 'sentence': 'High-dose intravenous methylprednisolone for thrombotic thrombocytopenic purpura.', 'subject score': 861, 'object score': 1000}, 'PMID:23659403': {'publication date': '2013 May', 'sentence': 'Treatment of thrombotic thrombocytopenic purpura with exchange plasmapheresis and methylprednisolone was of paramount importance and the patient was discharged home on day 30 with complete recovery of haematological, neurological and renal function.', 'subject score': 1000, 'object score': 1000}, 'PMID:3394714': {'publication date': '1988 Jun', 'sentence': 'Intravenous high dose methylprednisolone for thrombotic thrombocytopenic purpura.', 'subject score': 861, 'object score': 1000}, 'PMID:34577835': {'publication date': '2021 Aug 31', 'sentence': 'A diagnosis of probable catastrophic antiphospholipid syndrome (CAPS) was established and treatment with low molecular weight heparin, intravenous methylprednisolone, plasmapheresis, and rituximab was initiated, followed by resolution of AKI, diplopia, and TMA with complete depletion of CD19+B-lymphocytes (CD19+B-Ly) after one month.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0034155---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "11547088",
-              "object": "MONDO:0018896",
-              "publications": [
-                "PMID:15574579",
-                "PMID:2120885",
-                "PMID:23659403",
-                "PMID:3394714",
-                "PMID:34577835"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:8701487': {'publication date': '1996 Apr-Jun', 'sentence': 'Treatment of X-linked lymphoproliferative disease (Duncan disease) with high-dose methylprednisolone and etoposide (VP-16).', 'subject score': 901, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 323610,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016537",
-          "name": "lymphoproliferative syndrome",
-          "description": "A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C9308\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C9308\" NCI Thesaurus); A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).; Disorders characterized by proliferation of lymphoid tissue, general or unspecified.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "UMLS:C0024314",
-            "OMIM:PS308240",
-            "MESH:D008232",
-            "NCIT:C9308",
-            "SNOMEDCT:84631004",
-            "PDQ:CDR0000617669",
-            "ORPHANET:238510",
-            "SNOMEDCT:277466009",
-            "MEDDRA:10025351",
-            "UMLS:CN201619",
-            "OMIM.PS:308240",
-            "MEDDRA:10061232",
-            "SNOMEDCT:414629003",
-            "HP:0005523",
-            "MONDO:0016537",
-            "DOID:0060704"
-          ],
-          "id": "MONDO:0016537",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphoproliferative disorder",
-            "obsolete_lymphoproliferative syndrome",
-            "Lymphoproliferative Disorder",
-            "lymphoproliferative disorder",
-            "Lymphoproliferative Disorders",
-            "lymphoproliferative syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:22197273",
-            "PMID:198660"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323610,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016537",
-              "name": "lymphoproliferative syndrome",
-              "description": "A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C9308\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C9308\" NCI Thesaurus); A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).; Disorders characterized by proliferation of lymphoid tissue, general or unspecified.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "UMLS:C0024314",
-                "OMIM:PS308240",
-                "MESH:D008232",
-                "NCIT:C9308",
-                "SNOMEDCT:84631004",
-                "PDQ:CDR0000617669",
-                "ORPHANET:238510",
-                "SNOMEDCT:277466009",
-                "MEDDRA:10025351",
-                "UMLS:CN201619",
-                "OMIM.PS:308240",
-                "MEDDRA:10061232",
-                "SNOMEDCT:414629003",
-                "HP:0005523",
-                "MONDO:0016537",
-                "DOID:0060704"
-              ],
-              "id": "MONDO:0016537",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphoproliferative disorder",
-                "obsolete_lymphoproliferative syndrome",
-                "Lymphoproliferative Disorder",
-                "lymphoproliferative disorder",
-                "Lymphoproliferative Disorders",
-                "lymphoproliferative syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:22197273",
-                "PMID:198660"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26659955,
-            "start": 570,
-            "end": 323610,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8701487': {'publication date': '1996 Apr-Jun', 'sentence': 'Treatment of X-linked lymphoproliferative disease (Duncan disease) with high-dose methylprednisolone and etoposide (VP-16).', 'subject score': 901, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0024314---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "27127545",
-              "object": "MONDO:0016537",
-              "publications": [
-                "PMID:8701487"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:12215328': {'publication date': '2002 Sep', 'sentence': 'Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization.', 'subject score': 1000, 'object score': 916}}",
-    "p2": {
-      "start": {
-        "identity": 709798,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011972",
-          "name": "ovarian hyperstimulation syndrome",
-          "description": "A complication of ovulation induction in infertility treatment. It is graded by the severity of symptoms which include ovary enlargement, multiple ovarian follicles; ovarian cysts; ascites; and generalized edema. The full-blown syndrome may lead to renal failure, respiratory distress, and even death. Increased capillary permeability is caused by the vasoactive substances, such as vascular endothelial growth factors, secreted by the overly-stimulated ovaries.",
-          "equivalent_curies": [
-            "OMIM:608115",
-            "MESH:D016471",
-            "ORPHANET:64739",
-            "SNOMEDCT:129635004",
-            "DOID:5425",
-            "MONDO:0011972",
-            "MEDDRA:10033266",
-            "UMLS:C0085083",
-            "UMLS:C3494162"
-          ],
-          "id": "MONDO:0011972",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Ovarian hyperstimulation syndrome related phenotypic feature",
-            "ovarian hyperstimulation syndrome",
-            "Ovarian Hyperstimulation Syndrome",
-            "Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous",
-            "obsolete_ovarian hyperstimulation syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3205536/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 709798,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011972",
-              "name": "ovarian hyperstimulation syndrome",
-              "description": "A complication of ovulation induction in infertility treatment. It is graded by the severity of symptoms which include ovary enlargement, multiple ovarian follicles; ovarian cysts; ascites; and generalized edema. The full-blown syndrome may lead to renal failure, respiratory distress, and even death. Increased capillary permeability is caused by the vasoactive substances, such as vascular endothelial growth factors, secreted by the overly-stimulated ovaries.",
-              "equivalent_curies": [
-                "OMIM:608115",
-                "MESH:D016471",
-                "ORPHANET:64739",
-                "SNOMEDCT:129635004",
-                "DOID:5425",
-                "MONDO:0011972",
-                "MEDDRA:10033266",
-                "UMLS:C0085083",
-                "UMLS:C3494162"
-              ],
-              "id": "MONDO:0011972",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Ovarian hyperstimulation syndrome related phenotypic feature",
-                "ovarian hyperstimulation syndrome",
-                "Ovarian Hyperstimulation Syndrome",
-                "Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous",
-                "obsolete_ovarian hyperstimulation syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3205536/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9534432,
-            "start": 570,
-            "end": 709798,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12215328': {'publication date': '2002 Sep', 'sentence': 'Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization.', 'subject score': 1000, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:prevents---None---None---None---UMLS:C0085083---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "9744990",
-              "object": "MONDO:0011972",
-              "publications": [
-                "PMID:12215328"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:10477400': {'publication date': '1999 Sep', 'sentence': 'The increased CSF levels of TNF-sRp55 in response to MP circumstantially suggest that this receptor could partially account for the beneficial effects of MP in acute MS.', 'subject score': 1000, 'object score': 901}, 'PMID:10933772': {'publication date': '2000 Apr', 'sentence': 'PURPOSE: To demonstrate the safety and effectiveness of intravenous methylprednisolone (IVMP) in the treatment of uveitis in association with multiple sclerosis (MS).', 'subject score': 888, 'object score': 1000}, 'PMID:14760960': {'publication date': '2004 Feb', 'sentence': 'We compared the efficacy of the combination of intravenous immunoglobulins (IVIg) and IVMP with the standard treatment of IVMP alone in promoting recovery from moderate to severe acute relapses in MS.', 'subject score': 888, 'object score': 1000}, 'PMID:15452302': {'publication date': '2004 Sep 28', 'sentence': 'The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis.', 'subject score': 888, 'object score': 1000}, 'PMID:15596745': {'publication date': '2004 Dec 14', 'sentence': 'IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS.', 'subject score': 1000, 'object score': 1000}, 'PMID:15781847': {'publication date': '2005 Mar 22', 'sentence': 'The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis.', 'subject score': 888, 'object score': 1000}, 'PMID:15794385': {'publication date': '2005 Apr', 'sentence': 'Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.', 'subject score': 1000, 'object score': 1000}, 'PMID:16719908': {'publication date': '2006 May 23', 'sentence': 'CONCLUSION: Monthly IV-MP reduces inflammatory activity and T2 lesion volume in RR-MS.', 'subject score': 851, 'object score': 901}, 'PMID:17463078': {'publication date': '2007 May', 'sentence': 'Anaphylactic reaction to methylprednisolone in multiple sclerosis: a practical approach to alternative corticosteroids.', 'subject score': 1000, 'object score': 1000}, 'PMID:18336625': {'publication date': '2008 Aug', 'sentence': 'The effects of methylprednisolone and mitoxantrone on CCL5-induced migration of lymphocytes in multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:18342057': {'publication date': '2008 Jan', 'sentence': '[Cognitive impact of mitoxantrone and methylprednisolone in multiple sclerosis: an open label study].', 'subject score': 1000, 'object score': 1000}, 'PMID:19949030': {'publication date': '2009 Dec 01', 'sentence': 'A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS.', 'subject score': 888, 'object score': 1000}, 'PMID:21831398': {'publication date': '2011 Oct 15', 'sentence': 'BACKGROUND: High-dose intravenous methylprednisolone is the most common therapeutic modality to treat acute exacerbations in multiple sclerosis (MS).', 'subject score': 861, 'object score': 1000}, 'PMID:24289841': {'publication date': '2013 Dec', 'sentence': 'These include: access to high-dose methylprednisolone in the home, ensuring appropriate supervision and support; participation in national clinical research programs coordinated from hospital centers of excellence; provision of multidisciplinary clinic services where healthcare professionals across different disciplines can attend to the patient on the same day in the same center of care; development of individual and group-based cognitive therapy programs; educational programs focusing on the management of fatigue and cognitive impairment associated with MS; and educational programs focusing on optimal use of immunomodulating agents in MS patients.', 'subject score': 901, 'object score': 1000}, 'PMID:24604685': {'publication date': '2014 Dec', 'sentence': 'Efficacy of combination therapy with erythropoietin and methylprednisolone in clinical recovery of severe relapse in multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2668784': {'publication date': '1989 Aug', 'sentence': 'A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28450891': {'publication date': '2017 Jan', 'sentence': 'CONCLUSIONS: This study provided class II evidence that ACTH produced better examiner-assessed cumulative rates of relapses per patient than IVMP in the adjunctive treatment of breakthrough disease in multiple sclerosis.', 'subject score': 888, 'object score': 1000}, 'PMID:30603546': {'publication date': '2018 Apr', 'sentence': 'Combination treatment with MP and BM-MSCs provides a novel treatment protocol for enhancing therapeutic effects in MS.', 'subject score': 1000, 'object score': 1000}, 'PMID:3063777': {'publication date': '1988 Aug', 'sentence': 'Methylprednisolone in multiple sclerosis: a comparative dose study.', 'subject score': 1000, 'object score': 1000}, 'PMID:3065667': {'publication date': '1988 May-Jun', 'sentence': '[Prospective evaluation of the effectiveness of high doses of methylprednisolone in multiple sclerosis].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 522619,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005301",
-          "name": "multiple sclerosis",
-          "description": "An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D009103",
-            "NCIT:C3243",
-            "MEDDRA:10039720",
-            "EFO:0003885",
-            "ORPHANET:802",
-            "MEDDRA:10028245",
-            "PSY:32490",
-            "ICD9:340",
-            "MONDO:0005301",
-            "MEDDRA:10028053",
-            "UMLS:C0026769",
-            "MEDDRA:10013451",
-            "SNOMEDCT:24700007",
-            "ICD10:G35",
-            "PDQ:CDR0000691761",
-            "DOID:2377"
-          ],
-          "id": "MONDO:0005301",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Multiple Sclerosis",
-            "obsolete_multiple sclerosis",
-            "Multiple sclerosis",
-            "multiple sclerosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://ghr.nlm.nih.gov/condition/multiple-sclerosis",
-            "http://en.wikipedia.org/wiki/multiple_sclerosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 522619,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005301",
-              "name": "multiple sclerosis",
-              "description": "An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D009103",
-                "NCIT:C3243",
-                "MEDDRA:10039720",
-                "EFO:0003885",
-                "ORPHANET:802",
-                "MEDDRA:10028245",
-                "PSY:32490",
-                "ICD9:340",
-                "MONDO:0005301",
-                "MEDDRA:10028053",
-                "UMLS:C0026769",
-                "MEDDRA:10013451",
-                "SNOMEDCT:24700007",
-                "ICD10:G35",
-                "PDQ:CDR0000691761",
-                "DOID:2377"
-              ],
-              "id": "MONDO:0005301",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Multiple Sclerosis",
-                "obsolete_multiple sclerosis",
-                "Multiple sclerosis",
-                "multiple sclerosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://ghr.nlm.nih.gov/condition/multiple-sclerosis",
-                "http://en.wikipedia.org/wiki/multiple_sclerosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7511443,
-            "start": 570,
-            "end": 522619,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10477400': {'publication date': '1999 Sep', 'sentence': 'The increased CSF levels of TNF-sRp55 in response to MP circumstantially suggest that this receptor could partially account for the beneficial effects of MP in acute MS.', 'subject score': 1000, 'object score': 901}, 'PMID:10933772': {'publication date': '2000 Apr', 'sentence': 'PURPOSE: To demonstrate the safety and effectiveness of intravenous methylprednisolone (IVMP) in the treatment of uveitis in association with multiple sclerosis (MS).', 'subject score': 888, 'object score': 1000}, 'PMID:14760960': {'publication date': '2004 Feb', 'sentence': 'We compared the efficacy of the combination of intravenous immunoglobulins (IVIg) and IVMP with the standard treatment of IVMP alone in promoting recovery from moderate to severe acute relapses in MS.', 'subject score': 888, 'object score': 1000}, 'PMID:15452302': {'publication date': '2004 Sep 28', 'sentence': 'The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis.', 'subject score': 888, 'object score': 1000}, 'PMID:15596745': {'publication date': '2004 Dec 14', 'sentence': 'IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS.', 'subject score': 1000, 'object score': 1000}, 'PMID:15781847': {'publication date': '2005 Mar 22', 'sentence': 'The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis.', 'subject score': 888, 'object score': 1000}, 'PMID:15794385': {'publication date': '2005 Apr', 'sentence': 'Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.', 'subject score': 1000, 'object score': 1000}, 'PMID:16719908': {'publication date': '2006 May 23', 'sentence': 'CONCLUSION: Monthly IV-MP reduces inflammatory activity and T2 lesion volume in RR-MS.', 'subject score': 851, 'object score': 901}, 'PMID:17463078': {'publication date': '2007 May', 'sentence': 'Anaphylactic reaction to methylprednisolone in multiple sclerosis: a practical approach to alternative corticosteroids.', 'subject score': 1000, 'object score': 1000}, 'PMID:18336625': {'publication date': '2008 Aug', 'sentence': 'The effects of methylprednisolone and mitoxantrone on CCL5-induced migration of lymphocytes in multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:18342057': {'publication date': '2008 Jan', 'sentence': '[Cognitive impact of mitoxantrone and methylprednisolone in multiple sclerosis: an open label study].', 'subject score': 1000, 'object score': 1000}, 'PMID:19949030': {'publication date': '2009 Dec 01', 'sentence': 'A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS.', 'subject score': 888, 'object score': 1000}, 'PMID:21831398': {'publication date': '2011 Oct 15', 'sentence': 'BACKGROUND: High-dose intravenous methylprednisolone is the most common therapeutic modality to treat acute exacerbations in multiple sclerosis (MS).', 'subject score': 861, 'object score': 1000}, 'PMID:24289841': {'publication date': '2013 Dec', 'sentence': 'These include: access to high-dose methylprednisolone in the home, ensuring appropriate supervision and support; participation in national clinical research programs coordinated from hospital centers of excellence; provision of multidisciplinary clinic services where healthcare professionals across different disciplines can attend to the patient on the same day in the same center of care; development of individual and group-based cognitive therapy programs; educational programs focusing on the management of fatigue and cognitive impairment associated with MS; and educational programs focusing on optimal use of immunomodulating agents in MS patients.', 'subject score': 901, 'object score': 1000}, 'PMID:24604685': {'publication date': '2014 Dec', 'sentence': 'Efficacy of combination therapy with erythropoietin and methylprednisolone in clinical recovery of severe relapse in multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2668784': {'publication date': '1989 Aug', 'sentence': 'A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28450891': {'publication date': '2017 Jan', 'sentence': 'CONCLUSIONS: This study provided class II evidence that ACTH produced better examiner-assessed cumulative rates of relapses per patient than IVMP in the adjunctive treatment of breakthrough disease in multiple sclerosis.', 'subject score': 888, 'object score': 1000}, 'PMID:30603546': {'publication date': '2018 Apr', 'sentence': 'Combination treatment with MP and BM-MSCs provides a novel treatment protocol for enhancing therapeutic effects in MS.', 'subject score': 1000, 'object score': 1000}, 'PMID:3063777': {'publication date': '1988 Aug', 'sentence': 'Methylprednisolone in multiple sclerosis: a comparative dose study.', 'subject score': 1000, 'object score': 1000}, 'PMID:3065667': {'publication date': '1988 May-Jun', 'sentence': '[Prospective evaluation of the effectiveness of high doses of methylprednisolone in multiple sclerosis].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0026769---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7668599",
-              "object": "MONDO:0005301",
-              "publications": [
-                "PMID:10477400",
-                "PMID:10933772",
-                "PMID:14760960",
-                "PMID:15452302",
-                "PMID:15596745",
-                "PMID:15781847",
-                "PMID:15794385",
-                "PMID:16719908",
-                "PMID:17463078",
-                "PMID:18336625",
-                "PMID:18342057",
-                "PMID:19949030",
-                "PMID:21831398",
-                "PMID:24289841",
-                "PMID:24604685",
-                "PMID:2668784",
-                "PMID:28450891",
-                "PMID:30603546",
-                "PMID:3063777",
-                "PMID:3065667"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:12113297': {'publication date': '2002 May', 'sentence': 'These results suggest that increasing the uric acid concentration may represent one of the possible mechanisms of action of methylprednisolone in multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:14607304': {'publication date': '2003 Dec 15', 'sentence': 'Immune parameters associated with early treatment effects of high-dose intravenous methylprednisolone in multiple sclerosis.', 'subject score': 861, 'object score': 1000}, 'PMID:15503100': {'publication date': '2004 Oct', 'sentence': 'Suppression of immune system genes by methylprednisolone in exacerbations of multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:16135002': {'publication date': '2005 Oct', 'sentence': 'METHODS: Nasal NO was measured in 15 patients without any history of allergy or chronic airway disorder who were treated for 3 days with a daily dose of 1000 mg methylprednisolone for an exacerbation of multiple sclerosis.', 'subject score': 790, 'object score': 1000}, 'PMID:16441245': {'publication date': '2006 Mar', 'sentence': 'Our purpose was to analyze the effect of IVMP on the expression of chemokine receptor 5 (CCR5) protein in blood in acute MS exacerbation.', 'subject score': 888, 'object score': 658}, 'PMID:16723156': {'publication date': '2006 Jul', 'sentence': 'The aim of our study was to determine whether high doses of intravenous methylprednisolone have significant impact on immune parameters during the multiple sclerosis (MS) exacerbations.', 'subject score': 888, 'object score': 734}, 'PMID:2291728': {'publication date': '1990 Dec', 'sentence': 'Methylprednisolone in multiple sclerosis exacerbation: changes in CSF parameters.', 'subject score': 1000, 'object score': 734}, 'PMID:2540005': {'publication date': '1989', 'sentence': '30 patients with acute exacerbations of multiple sclerosis were treated by ACTH, dexamethasone or methylprednisolone in a double-blind randomized study.', 'subject score': 1000, 'object score': 1000}, 'PMID:26120075': {'publication date': '2016 Feb', 'sentence': 'Because IVMP doses significantly higher than 30 mg are usually required to treat MS exacerbations, the lower cortisol-equivalent exposure of 80 U ACTH analog supports the hypothesis that efficacy of ACTH analog results from both steroid-dependent and -independent properties.', 'subject score': 851, 'object score': 734}, 'PMID:27154441': {'publication date': '2016', 'sentence': 'These observations demonstrate one of the potential mechanisms of MP action in MS, distinct from inducing cell apoptosis, and suggests the new targets for development of more effective MS treatments.', 'subject score': 694, 'object score': 1000}, 'PMID:6842212': {'publication date': '1983 Jan', 'sentence': 'High dose intravenous methyl prednisolone in acute exacerbations of multiple sclerosis.', 'subject score': 861, 'object score': 1000}, 'PMID:6967197': {'publication date': '1980 Jul', 'sentence': 'Prolonged effects of large-dose methylprednisolone infusion in multiple sclerosis.', 'subject score': 833, 'object score': 1000}, 'PMID:8060761': {'publication date': '1994 May', 'sentence': 'Although cloaked in controversy, some recent highlights include the possibility that high-dose intravenous methylprednisolone may affect the development of multiple sclerosis, the suggestion that prednisone may have little efficacy in the management of high-risk pregnancy in patients with antiphospholipid antibodies, and several observations that administration of calcium and vitamin D prevents bone loss in patients receiving steroids.', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 522619,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005301",
-          "name": "multiple sclerosis",
-          "description": "An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D009103",
-            "NCIT:C3243",
-            "MEDDRA:10039720",
-            "EFO:0003885",
-            "ORPHANET:802",
-            "MEDDRA:10028245",
-            "PSY:32490",
-            "ICD9:340",
-            "MONDO:0005301",
-            "MEDDRA:10028053",
-            "UMLS:C0026769",
-            "MEDDRA:10013451",
-            "SNOMEDCT:24700007",
-            "ICD10:G35",
-            "PDQ:CDR0000691761",
-            "DOID:2377"
-          ],
-          "id": "MONDO:0005301",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Multiple Sclerosis",
-            "obsolete_multiple sclerosis",
-            "Multiple sclerosis",
-            "multiple sclerosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://ghr.nlm.nih.gov/condition/multiple-sclerosis",
-            "http://en.wikipedia.org/wiki/multiple_sclerosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 522619,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005301",
-              "name": "multiple sclerosis",
-              "description": "An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D009103",
-                "NCIT:C3243",
-                "MEDDRA:10039720",
-                "EFO:0003885",
-                "ORPHANET:802",
-                "MEDDRA:10028245",
-                "PSY:32490",
-                "ICD9:340",
-                "MONDO:0005301",
-                "MEDDRA:10028053",
-                "UMLS:C0026769",
-                "MEDDRA:10013451",
-                "SNOMEDCT:24700007",
-                "ICD10:G35",
-                "PDQ:CDR0000691761",
-                "DOID:2377"
-              ],
-              "id": "MONDO:0005301",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Multiple Sclerosis",
-                "obsolete_multiple sclerosis",
-                "Multiple sclerosis",
-                "multiple sclerosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://ghr.nlm.nih.gov/condition/multiple-sclerosis",
-                "http://en.wikipedia.org/wiki/multiple_sclerosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9438360,
-            "start": 570,
-            "end": 522619,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12113297': {'publication date': '2002 May', 'sentence': 'These results suggest that increasing the uric acid concentration may represent one of the possible mechanisms of action of methylprednisolone in multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:14607304': {'publication date': '2003 Dec 15', 'sentence': 'Immune parameters associated with early treatment effects of high-dose intravenous methylprednisolone in multiple sclerosis.', 'subject score': 861, 'object score': 1000}, 'PMID:15503100': {'publication date': '2004 Oct', 'sentence': 'Suppression of immune system genes by methylprednisolone in exacerbations of multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:16135002': {'publication date': '2005 Oct', 'sentence': 'METHODS: Nasal NO was measured in 15 patients without any history of allergy or chronic airway disorder who were treated for 3 days with a daily dose of 1000 mg methylprednisolone for an exacerbation of multiple sclerosis.', 'subject score': 790, 'object score': 1000}, 'PMID:16441245': {'publication date': '2006 Mar', 'sentence': 'Our purpose was to analyze the effect of IVMP on the expression of chemokine receptor 5 (CCR5) protein in blood in acute MS exacerbation.', 'subject score': 888, 'object score': 658}, 'PMID:16723156': {'publication date': '2006 Jul', 'sentence': 'The aim of our study was to determine whether high doses of intravenous methylprednisolone have significant impact on immune parameters during the multiple sclerosis (MS) exacerbations.', 'subject score': 888, 'object score': 734}, 'PMID:2291728': {'publication date': '1990 Dec', 'sentence': 'Methylprednisolone in multiple sclerosis exacerbation: changes in CSF parameters.', 'subject score': 1000, 'object score': 734}, 'PMID:2540005': {'publication date': '1989', 'sentence': '30 patients with acute exacerbations of multiple sclerosis were treated by ACTH, dexamethasone or methylprednisolone in a double-blind randomized study.', 'subject score': 1000, 'object score': 1000}, 'PMID:26120075': {'publication date': '2016 Feb', 'sentence': 'Because IVMP doses significantly higher than 30 mg are usually required to treat MS exacerbations, the lower cortisol-equivalent exposure of 80 U ACTH analog supports the hypothesis that efficacy of ACTH analog results from both steroid-dependent and -independent properties.', 'subject score': 851, 'object score': 734}, 'PMID:27154441': {'publication date': '2016', 'sentence': 'These observations demonstrate one of the potential mechanisms of MP action in MS, distinct from inducing cell apoptosis, and suggests the new targets for development of more effective MS treatments.', 'subject score': 694, 'object score': 1000}, 'PMID:6842212': {'publication date': '1983 Jan', 'sentence': 'High dose intravenous methyl prednisolone in acute exacerbations of multiple sclerosis.', 'subject score': 861, 'object score': 1000}, 'PMID:6967197': {'publication date': '1980 Jul', 'sentence': 'Prolonged effects of large-dose methylprednisolone infusion in multiple sclerosis.', 'subject score': 833, 'object score': 1000}, 'PMID:8060761': {'publication date': '1994 May', 'sentence': 'Although cloaked in controversy, some recent highlights include the possibility that high-dose intravenous methylprednisolone may affect the development of multiple sclerosis, the suggestion that prednisone may have little efficacy in the management of high-risk pregnancy in patients with antiphospholipid antibodies, and several observations that administration of calcium and vitamin D prevents bone loss in patients receiving steroids.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0026769---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "9646753",
-              "object": "MONDO:0005301",
-              "publications": [
-                "PMID:12113297",
-                "PMID:14607304",
-                "PMID:15503100",
-                "PMID:16135002",
-                "PMID:16441245",
-                "PMID:16723156",
-                "PMID:2291728",
-                "PMID:2540005",
-                "PMID:26120075",
-                "PMID:27154441",
-                "PMID:6842212",
-                "PMID:6967197",
-                "PMID:8060761"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10477400': {'publication date': '1999 Sep', 'sentence': 'The same determinations were repeated on plasma and on CSF samples that were collected after the MS patients had ended a six-day treatment with high-dose methylprednisolone (MP).', 'subject score': 901, 'object score': 901}, 'PMID:10675582': {'publication date': '2000 Feb 01', 'sentence': 'The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis.', 'subject score': 851, 'object score': 1000}, 'PMID:10933772': {'publication date': '2000 Apr', 'sentence': 'High-dose IVMP has previously been shown to be effective in the treatment of inflammatory eye disease and MS.', 'subject score': 861, 'object score': 1000}, 'PMID:11034713': {'publication date': '2000', 'sentence': \"REVIEWER'S CONCLUSIONS: We found evidence favouring the corticosteroid MP for acute exacerbation in MS patients.\", 'subject score': 888, 'object score': 901}, 'PMID:11176941': {'publication date': '2001 Jan', 'sentence': 'High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes.', 'subject score': 861, 'object score': 1000}, 'PMID:11279971': {'publication date': '1999 Sep', 'sentence': 'RESULTS: Both patients had a diagnostic lumbar puncture for suspected multiple sclerosis and were treated with high-dose intravenous methylprednisolone.', 'subject score': 861, 'object score': 901}, 'PMID:11319388': {'publication date': '2001 Mar', 'sentence': 'CASE REPORT: A thirty year-old-woman presented, a few hours after intravenous administration of methylprednisolone indicated for multiple sclerosis, a maculopapulous rash predominant in the folds rapidly becoming pustulous with malaise, fever and neutrophilia.', 'subject score': 1000, 'object score': 1000}, 'PMID:11784351': {'publication date': '2001 Nov', 'sentence': 'Here, we report a serial analysis of CSF CXCL10 and CCL2 concentrations in 22 patients with attacks of MS or acute optic neuritis (ON) treated with methylprednisolone, and 26 patients treated with placebo in two randomized controlled trials.', 'subject score': 1000, 'object score': 1000}, 'PMID:11882048': {'publication date': '2002 Jan', 'sentence': 'Relapses of multiple sclerosis (MS) are treated commonly with high-dose intravenous methylprednisolone (MP) given over a period of 3-5 days.', 'subject score': 861, 'object score': 1000}, 'PMID:11886356': {'publication date': '2002 Mar', 'sentence': 'A transcranial magnetic stimulation study evaluating methylprednisolone treatment in multiple sclerosis.', 'subject score': 786, 'object score': 1000}, 'PMID:11886358': {'publication date': '2002 Mar', 'sentence': 'Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:11929083': {'publication date': '2002 Feb', 'sentence': 'We assessed 23 subjects (15 women and 8 men) suffering from multiple sclerosis and treated with methylprednisolone (1 g i.v. for 10 days) followed by oral prednisone for 9 days; patients affected by diseases involving bone or treated during the previous 6 months with drugs influencing bone metabolism were excluded.', 'subject score': 1000, 'object score': 1000}, 'PMID:11960657': {'publication date': '2002 Apr', 'sentence': 'Cerebrospinal fluid levels of nitric oxide metabolites predict response to methylprednisolone treatment in multiple sclerosis and optic neuritis.', 'subject score': 888, 'object score': 1000}, 'PMID:12020259': {'publication date': '2002 May', 'sentence': 'PATIENTS: Eight patients with MS in exacerbation were studied before and 3 and 24 hours after intravenous methylprednisolone treatment, 1 g.', 'subject score': 851, 'object score': 1000}, 'PMID:12113297': {'publication date': '2002 May', 'sentence': 'High-dose methylprednisolone therapy in multiple sclerosis increases serum uric acid levels.', 'subject score': 861, 'object score': 1000}, 'PMID:12356209': {'publication date': '2002 Oct', 'sentence': 'Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone.', 'subject score': 861, 'object score': 901}, 'PMID:1370864': {'publication date': '1992 Jan', 'sentence': 'A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone.', 'subject score': 861, 'object score': 861}, 'PMID:14568494': {'publication date': '2003 Oct', 'sentence': 'Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy.', 'subject score': 861, 'object score': 901}, 'PMID:14760960': {'publication date': '2004 Feb', 'sentence': 'BACKGROUND: Some patients with multiple sclerosis (MS) do not show a clear improvement of acute relapses after treatment with intravenous methylprednisolone (IVMP).', 'subject score': 888, 'object score': 1000}, 'PMID:15327039': {'publication date': '2004 Aug', 'sentence': 'METHODS: Retrospective open-label study of medical records from 51 patients with clinically isolated syndromes or relapsing-remitting MS treated with IVMP for an acute attack (54 attacks).', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 522619,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005301",
-          "name": "multiple sclerosis",
-          "description": "An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D009103",
-            "NCIT:C3243",
-            "MEDDRA:10039720",
-            "EFO:0003885",
-            "ORPHANET:802",
-            "MEDDRA:10028245",
-            "PSY:32490",
-            "ICD9:340",
-            "MONDO:0005301",
-            "MEDDRA:10028053",
-            "UMLS:C0026769",
-            "MEDDRA:10013451",
-            "SNOMEDCT:24700007",
-            "ICD10:G35",
-            "PDQ:CDR0000691761",
-            "DOID:2377"
-          ],
-          "id": "MONDO:0005301",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Multiple Sclerosis",
-            "obsolete_multiple sclerosis",
-            "Multiple sclerosis",
-            "multiple sclerosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://ghr.nlm.nih.gov/condition/multiple-sclerosis",
-            "http://en.wikipedia.org/wiki/multiple_sclerosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 522619,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005301",
-              "name": "multiple sclerosis",
-              "description": "An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D009103",
-                "NCIT:C3243",
-                "MEDDRA:10039720",
-                "EFO:0003885",
-                "ORPHANET:802",
-                "MEDDRA:10028245",
-                "PSY:32490",
-                "ICD9:340",
-                "MONDO:0005301",
-                "MEDDRA:10028053",
-                "UMLS:C0026769",
-                "MEDDRA:10013451",
-                "SNOMEDCT:24700007",
-                "ICD10:G35",
-                "PDQ:CDR0000691761",
-                "DOID:2377"
-              ],
-              "id": "MONDO:0005301",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Multiple Sclerosis",
-                "obsolete_multiple sclerosis",
-                "Multiple sclerosis",
-                "multiple sclerosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://ghr.nlm.nih.gov/condition/multiple-sclerosis",
-                "http://en.wikipedia.org/wiki/multiple_sclerosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7511438,
-            "start": 570,
-            "end": 522619,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10477400': {'publication date': '1999 Sep', 'sentence': 'The same determinations were repeated on plasma and on CSF samples that were collected after the MS patients had ended a six-day treatment with high-dose methylprednisolone (MP).', 'subject score': 901, 'object score': 901}, 'PMID:10675582': {'publication date': '2000 Feb 01', 'sentence': 'The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis.', 'subject score': 851, 'object score': 1000}, 'PMID:10933772': {'publication date': '2000 Apr', 'sentence': 'High-dose IVMP has previously been shown to be effective in the treatment of inflammatory eye disease and MS.', 'subject score': 861, 'object score': 1000}, 'PMID:11034713': {'publication date': '2000', 'sentence': \"REVIEWER'S CONCLUSIONS: We found evidence favouring the corticosteroid MP for acute exacerbation in MS patients.\", 'subject score': 888, 'object score': 901}, 'PMID:11176941': {'publication date': '2001 Jan', 'sentence': 'High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes.', 'subject score': 861, 'object score': 1000}, 'PMID:11279971': {'publication date': '1999 Sep', 'sentence': 'RESULTS: Both patients had a diagnostic lumbar puncture for suspected multiple sclerosis and were treated with high-dose intravenous methylprednisolone.', 'subject score': 861, 'object score': 901}, 'PMID:11319388': {'publication date': '2001 Mar', 'sentence': 'CASE REPORT: A thirty year-old-woman presented, a few hours after intravenous administration of methylprednisolone indicated for multiple sclerosis, a maculopapulous rash predominant in the folds rapidly becoming pustulous with malaise, fever and neutrophilia.', 'subject score': 1000, 'object score': 1000}, 'PMID:11784351': {'publication date': '2001 Nov', 'sentence': 'Here, we report a serial analysis of CSF CXCL10 and CCL2 concentrations in 22 patients with attacks of MS or acute optic neuritis (ON) treated with methylprednisolone, and 26 patients treated with placebo in two randomized controlled trials.', 'subject score': 1000, 'object score': 1000}, 'PMID:11882048': {'publication date': '2002 Jan', 'sentence': 'Relapses of multiple sclerosis (MS) are treated commonly with high-dose intravenous methylprednisolone (MP) given over a period of 3-5 days.', 'subject score': 861, 'object score': 1000}, 'PMID:11886356': {'publication date': '2002 Mar', 'sentence': 'A transcranial magnetic stimulation study evaluating methylprednisolone treatment in multiple sclerosis.', 'subject score': 786, 'object score': 1000}, 'PMID:11886358': {'publication date': '2002 Mar', 'sentence': 'Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:11929083': {'publication date': '2002 Feb', 'sentence': 'We assessed 23 subjects (15 women and 8 men) suffering from multiple sclerosis and treated with methylprednisolone (1 g i.v. for 10 days) followed by oral prednisone for 9 days; patients affected by diseases involving bone or treated during the previous 6 months with drugs influencing bone metabolism were excluded.', 'subject score': 1000, 'object score': 1000}, 'PMID:11960657': {'publication date': '2002 Apr', 'sentence': 'Cerebrospinal fluid levels of nitric oxide metabolites predict response to methylprednisolone treatment in multiple sclerosis and optic neuritis.', 'subject score': 888, 'object score': 1000}, 'PMID:12020259': {'publication date': '2002 May', 'sentence': 'PATIENTS: Eight patients with MS in exacerbation were studied before and 3 and 24 hours after intravenous methylprednisolone treatment, 1 g.', 'subject score': 851, 'object score': 1000}, 'PMID:12113297': {'publication date': '2002 May', 'sentence': 'High-dose methylprednisolone therapy in multiple sclerosis increases serum uric acid levels.', 'subject score': 861, 'object score': 1000}, 'PMID:12356209': {'publication date': '2002 Oct', 'sentence': 'Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone.', 'subject score': 861, 'object score': 901}, 'PMID:1370864': {'publication date': '1992 Jan', 'sentence': 'A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone.', 'subject score': 861, 'object score': 861}, 'PMID:14568494': {'publication date': '2003 Oct', 'sentence': 'Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy.', 'subject score': 861, 'object score': 901}, 'PMID:14760960': {'publication date': '2004 Feb', 'sentence': 'BACKGROUND: Some patients with multiple sclerosis (MS) do not show a clear improvement of acute relapses after treatment with intravenous methylprednisolone (IVMP).', 'subject score': 888, 'object score': 1000}, 'PMID:15327039': {'publication date': '2004 Aug', 'sentence': 'METHODS: Retrospective open-label study of medical records from 51 patients with clinically isolated syndromes or relapsing-remitting MS treated with IVMP for an acute attack (54 attacks).', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0026769---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7668594",
-              "object": "MONDO:0005301",
-              "publications": [
-                "PMID:10477400",
-                "PMID:10675582",
-                "PMID:10933772",
-                "PMID:11034713",
-                "PMID:11176941",
-                "PMID:11279971",
-                "PMID:11319388",
-                "PMID:11784351",
-                "PMID:11882048",
-                "PMID:11886356",
-                "PMID:11886358",
-                "PMID:11929083",
-                "PMID:11960657",
-                "PMID:12020259",
-                "PMID:12113297",
-                "PMID:12356209",
-                "PMID:1370864",
-                "PMID:14568494",
-                "PMID:14760960",
-                "PMID:15327039"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:20219784': {'publication date': '2010 Jun', 'sentence': 'Response of symptoms and synovitis to intra-muscular methylprednisolone in osteoarthritis of the hand: an ultrasonographic study.', 'subject score': 851, 'object score': 1000}, 'PMID:6586148': {'publication date': '1983 Dec', 'sentence': 'Plasma concentrations of methylprednisolone following intra-articular injection were measured in rheumatoid arthritis and osteoarthritis patients.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 319030,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319030,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14567812,
-            "start": 570,
-            "end": 319030,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20219784': {'publication date': '2010 Jun', 'sentence': 'Response of symptoms and synovitis to intra-muscular methylprednisolone in osteoarthritis of the hand: an ultrasonographic study.', 'subject score': 851, 'object score': 1000}, 'PMID:6586148': {'publication date': '1983 Dec', 'sentence': 'Plasma concentrations of methylprednisolone following intra-articular injection were measured in rheumatoid arthritis and osteoarthritis patients.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14876749",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:20219784",
-                "PMID:6586148"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:26150628': {'publication date': '2015 Jul 06', 'sentence': 'We report a case of a 68-year-old woman who presented with severe abdominal pain, nausea and vomiting, 3 days after the initiation of low-dose methylprednisolone for osteoarthritis.', 'subject score': 901, 'object score': 1000}, 'PMID:6586148': {'publication date': '1983 Dec', 'sentence': 'A comparison of plasma methylprednisolone concentrations following intra-articular injection in patients with rheumatoid arthritis and osteoarthritis.', 'subject score': 890, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319030,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319030,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18061671,
-            "start": 570,
-            "end": 319030,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26150628': {'publication date': '2015 Jul 06', 'sentence': 'We report a case of a 68-year-old woman who presented with severe abdominal pain, nausea and vomiting, 3 days after the initiation of low-dose methylprednisolone for osteoarthritis.', 'subject score': 901, 'object score': 1000}, 'PMID:6586148': {'publication date': '1983 Dec', 'sentence': 'A comparison of plasma methylprednisolone concentrations following intra-articular injection in patients with rheumatoid arthritis and osteoarthritis.', 'subject score': 890, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "18427985",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:26150628",
-                "PMID:6586148"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:10359882': {'publication date': '1999 Jun', 'sentence': 'Such an effect has been demonstrated between clarithromycin and methylprednisolone, two drugs that may be administered concomitantly in asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:10567626': {'publication date': '1999 Dec', 'sentence': 'In blood mononuclear cells methylprednisolone reduced LTC(4) synthesis in asthmatic subjects from 1.26 to 0.79 ng/10(6) cells (95% CI for the reduction 0.26 to 0.79, p = 0.014) and tended to reduce LTC(4) synthesis in normal subjects from 1.51 to 0.86 ng/10(6) cells (p = 0.08).', 'subject score': 861, 'object score': 872}, 'PMID:20667503': {'publication date': '2010 Oct 31', 'sentence': 'Methylprednisolone (MP) is an important corticosteroid used in the treatment (through inhalation) of lung inflammation associated with asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:31308569': {'publication date': '2019 Jul', 'sentence': 'Single Intramuscular Methylprednisolone dose in Asthma and Chronic Obstructive Pulmonary Disease Patients on Discharge.', 'subject score': 833, 'object score': 1000}, 'PMID:7385823': {'publication date': '1980 Feb', 'sentence': 'Intravenously given methylprednisolone in refractory asthma.', 'subject score': 827, 'object score': 888}, 'PMID:8430965': {'publication date': '1993 Feb', 'sentence': 'A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids.', 'subject score': 1000, 'object score': 872}}",
-    "p2": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7293560,
-            "start": 570,
-            "end": 321528,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10359882': {'publication date': '1999 Jun', 'sentence': 'Such an effect has been demonstrated between clarithromycin and methylprednisolone, two drugs that may be administered concomitantly in asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:10567626': {'publication date': '1999 Dec', 'sentence': 'In blood mononuclear cells methylprednisolone reduced LTC(4) synthesis in asthmatic subjects from 1.26 to 0.79 ng/10(6) cells (95% CI for the reduction 0.26 to 0.79, p = 0.014) and tended to reduce LTC(4) synthesis in normal subjects from 1.51 to 0.86 ng/10(6) cells (p = 0.08).', 'subject score': 861, 'object score': 872}, 'PMID:20667503': {'publication date': '2010 Oct 31', 'sentence': 'Methylprednisolone (MP) is an important corticosteroid used in the treatment (through inhalation) of lung inflammation associated with asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:31308569': {'publication date': '2019 Jul', 'sentence': 'Single Intramuscular Methylprednisolone dose in Asthma and Chronic Obstructive Pulmonary Disease Patients on Discharge.', 'subject score': 833, 'object score': 1000}, 'PMID:7385823': {'publication date': '1980 Feb', 'sentence': 'Intravenously given methylprednisolone in refractory asthma.', 'subject score': 827, 'object score': 888}, 'PMID:8430965': {'publication date': '1993 Feb', 'sentence': 'A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids.', 'subject score': 1000, 'object score': 872}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7443745",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:10359882",
-                "PMID:10567626",
-                "PMID:20667503",
-                "PMID:31308569",
-                "PMID:7385823",
-                "PMID:8430965"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:11115436': {'publication date': '2000 Dec', 'sentence': 'STUDY OBJECTIVES: To assess whether IV methylprednisolone exerts a specific early effect on dyspnea in patients with an exacerbation of asthma.', 'subject score': 888, 'object score': 1000}, 'PMID:21966609': {'publication date': '2011 Oct', 'sentence': 'Symptoms of asthma exacerbations improved with short-term treatments of systemic steroids, including methylprednisolone or deflazacort, which had been well tolerated.', 'subject score': 1000, 'object score': 694}, 'PMID:24565723': {'publication date': '2013 Nov-Dec', 'sentence': 'The use of a tapering dose of methylprednisolone for asthma exacerbations: is it adequate?', 'subject score': 1000, 'object score': 694}}",
-    "p2": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8413579,
-            "start": 570,
-            "end": 321528,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11115436': {'publication date': '2000 Dec', 'sentence': 'STUDY OBJECTIVES: To assess whether IV methylprednisolone exerts a specific early effect on dyspnea in patients with an exacerbation of asthma.', 'subject score': 888, 'object score': 1000}, 'PMID:21966609': {'publication date': '2011 Oct', 'sentence': 'Symptoms of asthma exacerbations improved with short-term treatments of systemic steroids, including methylprednisolone or deflazacort, which had been well tolerated.', 'subject score': 1000, 'object score': 694}, 'PMID:24565723': {'publication date': '2013 Nov-Dec', 'sentence': 'The use of a tapering dose of methylprednisolone for asthma exacerbations: is it adequate?', 'subject score': 1000, 'object score': 694}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8596544",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:11115436",
-                "PMID:21966609",
-                "PMID:24565723"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11249603': {'publication date': '2000 Sep', 'sentence': 'Methylprednisolone suleptanate (Promedrol) is a prodrug of methylprednisolone being developed by Pharmacia Corp (formerly Pharmacia & Upjohn) for the treatment of asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:12400872': {'publication date': '2002 Sep', 'sentence': 'In contrast, the expression of GRalpha and c-jun mRNAs did not correlate with the IC50 for prednisolone and methylprednisolone in asthma patients.', 'subject score': 1000, 'object score': 888}, 'PMID:15302718': {'publication date': '2004 Aug', 'sentence': 'OBJECTIVE: To compare the efficacy of long-acting IM methylprednisolone to tapering oral methylprednisolone in adult asthmatic patients discharged from the emergency department (ED).', 'subject score': 825, 'object score': 851}, 'PMID:22726275': {'publication date': '2012 Dec', 'sentence': 'These control patients were selected from 71 patients admitted due to pneumonia or bronchitis caused by H1N1 pdm 09, and were chosen according to age, absence of pretreatment with oseltamivir before admission, presence of a past history of asthma, use of antibiotics, and combination of inhalation of a beta2 agonist and treatment with i.v. methylprednisolone for asthma attack.', 'subject score': 827, 'object score': 1000}, 'PMID:25125034': {'publication date': '2014 Oct', 'sentence': 'Hereinafter is reported the case of a 2-year-old girl hospitalized in the pediatric intensive care unit for ASA, which was treated with high-flow oxygen therapy and intravenous methylprednisolone and salbutamol.', 'subject score': 888, 'object score': 1000}, 'PMID:3543111': {'publication date': '1986', 'sentence': 'Described is such a reaction resulting in cardiopulmonary collapse in a 66-year-old asthmatic treated with intravenous methylprednisolone.', 'subject score': 888, 'object score': 775}, 'PMID:3665340': {'publication date': '1987 Oct', 'sentence': 'Prednisolone and methylprednisolone pharmacokinetic parameters were evaluated in asthmatic children receiving concomitant anticonvulsant therapy.', 'subject score': 851, 'object score': 888}, 'PMID:36929864': {'publication date': '2023 Mar 17', 'sentence': 'Dexamethasone versus methylprednisolone for critical asthma: A single center, open-label, parallel-group clinical trial.', 'subject score': 1000, 'object score': 888}, 'PMID:3700892': {'publication date': '1986 May', 'sentence': 'Some indications for depot methylprednisolone for asthma or other severe allergic disease.', 'subject score': 861, 'object score': 1000}, 'PMID:5521178': {'publication date': '1970 Oct', 'sentence': 'Alternate day methylprednisolone therapy in asthma.', 'subject score': 852, 'object score': 1000}, 'PMID:8069995': {'publication date': '1994 Jun', 'sentence': 'Following admission, he required intensive nonventilatory management of his asthma, including intravenous salbutamol, methylprednisolone, and aminophylline, as well as use of an ipratroprium bromide inhaler and 100% oxygen by mask.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8574607,
-            "start": 570,
-            "end": 321528,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11249603': {'publication date': '2000 Sep', 'sentence': 'Methylprednisolone suleptanate (Promedrol) is a prodrug of methylprednisolone being developed by Pharmacia Corp (formerly Pharmacia & Upjohn) for the treatment of asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:12400872': {'publication date': '2002 Sep', 'sentence': 'In contrast, the expression of GRalpha and c-jun mRNAs did not correlate with the IC50 for prednisolone and methylprednisolone in asthma patients.', 'subject score': 1000, 'object score': 888}, 'PMID:15302718': {'publication date': '2004 Aug', 'sentence': 'OBJECTIVE: To compare the efficacy of long-acting IM methylprednisolone to tapering oral methylprednisolone in adult asthmatic patients discharged from the emergency department (ED).', 'subject score': 825, 'object score': 851}, 'PMID:22726275': {'publication date': '2012 Dec', 'sentence': 'These control patients were selected from 71 patients admitted due to pneumonia or bronchitis caused by H1N1 pdm 09, and were chosen according to age, absence of pretreatment with oseltamivir before admission, presence of a past history of asthma, use of antibiotics, and combination of inhalation of a beta2 agonist and treatment with i.v. methylprednisolone for asthma attack.', 'subject score': 827, 'object score': 1000}, 'PMID:25125034': {'publication date': '2014 Oct', 'sentence': 'Hereinafter is reported the case of a 2-year-old girl hospitalized in the pediatric intensive care unit for ASA, which was treated with high-flow oxygen therapy and intravenous methylprednisolone and salbutamol.', 'subject score': 888, 'object score': 1000}, 'PMID:3543111': {'publication date': '1986', 'sentence': 'Described is such a reaction resulting in cardiopulmonary collapse in a 66-year-old asthmatic treated with intravenous methylprednisolone.', 'subject score': 888, 'object score': 775}, 'PMID:3665340': {'publication date': '1987 Oct', 'sentence': 'Prednisolone and methylprednisolone pharmacokinetic parameters were evaluated in asthmatic children receiving concomitant anticonvulsant therapy.', 'subject score': 851, 'object score': 888}, 'PMID:36929864': {'publication date': '2023 Mar 17', 'sentence': 'Dexamethasone versus methylprednisolone for critical asthma: A single center, open-label, parallel-group clinical trial.', 'subject score': 1000, 'object score': 888}, 'PMID:3700892': {'publication date': '1986 May', 'sentence': 'Some indications for depot methylprednisolone for asthma or other severe allergic disease.', 'subject score': 861, 'object score': 1000}, 'PMID:5521178': {'publication date': '1970 Oct', 'sentence': 'Alternate day methylprednisolone therapy in asthma.', 'subject score': 852, 'object score': 1000}, 'PMID:8069995': {'publication date': '1994 Jun', 'sentence': 'Following admission, he required intensive nonventilatory management of his asthma, including intravenous salbutamol, methylprednisolone, and aminophylline, as well as use of an ipratroprium bromide inhaler and 100% oxygen by mask.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8761529",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:11249603",
-                "PMID:12400872",
-                "PMID:15302718",
-                "PMID:22726275",
-                "PMID:25125034",
-                "PMID:3543111",
-                "PMID:3665340",
-                "PMID:36929864",
-                "PMID:3700892",
-                "PMID:5521178",
-                "PMID:8069995"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:2042763': {'publication date': '1991 Jun', 'sentence': 'Methylprednisolone prevents propranolol-induced airway hyperreactivity in the Basenji-greyhound dog.', 'subject score': 1000, 'object score': 861}, 'PMID:3700892': {'publication date': '1986 May', 'sentence': 'We describe cases in which we have to advise depot methylprednisolone to prevent potentially fatal asthma or vasculitis, although this type of therapy is suboptimal in terms of avoiding sustained corticosteroid levels in tissue, adrenal cortical suppression, and potential side effects.', 'subject score': 861, 'object score': 790}}",
-    "p2": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14644973,
-            "start": 570,
-            "end": 321528,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2042763': {'publication date': '1991 Jun', 'sentence': 'Methylprednisolone prevents propranolol-induced airway hyperreactivity in the Basenji-greyhound dog.', 'subject score': 1000, 'object score': 861}, 'PMID:3700892': {'publication date': '1986 May', 'sentence': 'We describe cases in which we have to advise depot methylprednisolone to prevent potentially fatal asthma or vasculitis, although this type of therapy is suboptimal in terms of avoiding sustained corticosteroid levels in tissue, adrenal cortical suppression, and potential side effects.', 'subject score': 861, 'object score': 790}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:prevents---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14967074",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:2042763",
-                "PMID:3700892"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:18183612': {'publication date': '2008 May', 'sentence': 'Following treatment with etanercept, ibuprofen, methylprednisolone, and phenylbutazone for 3 weeks, MAS deteriorated and fatal cerebral edema occurred within only 24 h.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 703976,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015545",
-          "name": "macrophage activation syndrome",
-          "description": "A complication of rheumatic disease that is caused by excessive activation and uncontrolled proliferation of T lymphocytes and well-differentiated macrophages. It is characterized by fever, pancytopenia, liver insufficiency, coagulopathy and neurologic symptoms.; A serious complication of childhood systemic inflammatory disorders that is thought to be caused by excessive activation and proliferation of T-LYMPHOCYTES and MACROPHAGES. It is seen predominantly in children with systemic onset JUVENILE IDIOPATHIC ARTHRITIS.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10053867",
-            "MESH:D055501",
-            "ORPHANET:158061",
-            "MONDO:0015545",
-            "SNOMEDCT:430478003",
-            "UMLS:C1096155",
-            "NCIT:C114471",
-            "EFO:1001806"
-          ],
-          "id": "MONDO:0015545",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Macrophage Activation Syndrome",
-            "macrophage activation syndrome",
-            "Macrophage activation syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 703976,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015545",
-              "name": "macrophage activation syndrome",
-              "description": "A complication of rheumatic disease that is caused by excessive activation and uncontrolled proliferation of T lymphocytes and well-differentiated macrophages. It is characterized by fever, pancytopenia, liver insufficiency, coagulopathy and neurologic symptoms.; A serious complication of childhood systemic inflammatory disorders that is thought to be caused by excessive activation and proliferation of T-LYMPHOCYTES and MACROPHAGES. It is seen predominantly in children with systemic onset JUVENILE IDIOPATHIC ARTHRITIS.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10053867",
-                "MESH:D055501",
-                "ORPHANET:158061",
-                "MONDO:0015545",
-                "SNOMEDCT:430478003",
-                "UMLS:C1096155",
-                "NCIT:C114471",
-                "EFO:1001806"
-              ],
-              "id": "MONDO:0015545",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Macrophage Activation Syndrome",
-                "macrophage activation syndrome",
-                "Macrophage activation syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13248806,
-            "start": 570,
-            "end": 703976,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18183612': {'publication date': '2008 May', 'sentence': 'Following treatment with etanercept, ibuprofen, methylprednisolone, and phenylbutazone for 3 weeks, MAS deteriorated and fatal cerebral edema occurred within only 24 h.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C1096155---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "13533673",
-              "object": "MONDO:0015545",
-              "publications": [
-                "PMID:18183612"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:32928810': {'publication date': '2020 Sep 14', 'sentence': 'Patient underwent treatment with milrinone and methylprednisolone that showed reduction in myocardial inflammation and significantly improved myocardial contractility.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 314697,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004496",
-          "name": "myocarditis",
-          "description": "Myocarditis is a condition that is characterized by inflammation of the heart muscle (myocardium). Some affected people have no noticeable symptoms of the condition. When present, signs and symptoms may include chest pain, abnormal heartbeat, shortness of breath, fatigue, signs of infection (i.e. fever, headache, sore throat, diarrhea), and leg swelling. Myocarditis can be caused by a variety of factors including infections (viral, bacterial, parasitic, and fungal), allergic reactions to certain medications, and exposure to certain chemicals. It can also be associated with other inflammatory conditions such as lupus, Wegener's granulomatosis, giant cell arteritis and Takayasu's arteritis. Most cases occur sporadically in people with no family history of the condition. Treatment aims to address the underlying cause of the condition. Medications and rarely, a heart transplant may be needed if the heart muscle becomes weak.",
-          "equivalent_curies": [
-            "MESH:D009205",
-            "MEDDRA:10028613",
-            "HP:0012819",
-            "DOID:820",
-            "KEGG.DISEASE:05416",
-            "UMLS:C0027059",
-            "MEDDRA:10028606",
-            "ICD9:429.0",
-            "SYMP:0000095",
-            "SNOMEDCT:50920009",
-            "EFO:0009609",
-            "NCIT:C34831",
-            "MEDDRA:10028619",
-            "MONDO:0004496",
-            "ICD10:I51.4"
-          ],
-          "id": "MONDO:0004496",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myocarditis",
-            "Myocarditis, unspecified",
-            "myocarditis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/myocarditis",
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:21304213",
-            "PMID:22361396",
-            "https://rarediseases.info.nih.gov/diseases/7137/myocarditis",
-            "PMID:22185868",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314697,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004496",
-              "name": "myocarditis",
-              "description": "Myocarditis is a condition that is characterized by inflammation of the heart muscle (myocardium). Some affected people have no noticeable symptoms of the condition. When present, signs and symptoms may include chest pain, abnormal heartbeat, shortness of breath, fatigue, signs of infection (i.e. fever, headache, sore throat, diarrhea), and leg swelling. Myocarditis can be caused by a variety of factors including infections (viral, bacterial, parasitic, and fungal), allergic reactions to certain medications, and exposure to certain chemicals. It can also be associated with other inflammatory conditions such as lupus, Wegener's granulomatosis, giant cell arteritis and Takayasu's arteritis. Most cases occur sporadically in people with no family history of the condition. Treatment aims to address the underlying cause of the condition. Medications and rarely, a heart transplant may be needed if the heart muscle becomes weak.",
-              "equivalent_curies": [
-                "MESH:D009205",
-                "MEDDRA:10028613",
-                "HP:0012819",
-                "DOID:820",
-                "KEGG.DISEASE:05416",
-                "UMLS:C0027059",
-                "MEDDRA:10028606",
-                "ICD9:429.0",
-                "SYMP:0000095",
-                "SNOMEDCT:50920009",
-                "EFO:0009609",
-                "NCIT:C34831",
-                "MEDDRA:10028619",
-                "MONDO:0004496",
-                "ICD10:I51.4"
-              ],
-              "id": "MONDO:0004496",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myocarditis",
-                "Myocarditis, unspecified",
-                "myocarditis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/myocarditis",
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:21304213",
-                "PMID:22361396",
-                "https://rarediseases.info.nih.gov/diseases/7137/myocarditis",
-                "PMID:22185868",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22071898,
-            "start": 570,
-            "end": 314697,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32928810': {'publication date': '2020 Sep 14', 'sentence': 'Patient underwent treatment with milrinone and methylprednisolone that showed reduction in myocardial inflammation and significantly improved myocardial contractility.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0027059---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "22495910",
-              "object": "MONDO:0004496",
-              "publications": [
-                "PMID:32928810"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:32928810': {'publication date': '2020 Sep 14', 'sentence': 'Although, not described in the literature, we have found conjunctive use of milrinone and methylprednisolone effective in patient with SARS-CoV-2 fulminant myocarditis.', 'subject score': 1000, 'object score': 850}, 'PMID:37114131': {'publication date': '2023', 'sentence': 'COVID-19-associated myocarditis was successfully treated with methylprednisolone, intravenous immunoglobulins and Anakinra.', 'subject score': 1000, 'object score': 802}}",
-    "p2": {
-      "start": {
-        "identity": 314697,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004496",
-          "name": "myocarditis",
-          "description": "Myocarditis is a condition that is characterized by inflammation of the heart muscle (myocardium). Some affected people have no noticeable symptoms of the condition. When present, signs and symptoms may include chest pain, abnormal heartbeat, shortness of breath, fatigue, signs of infection (i.e. fever, headache, sore throat, diarrhea), and leg swelling. Myocarditis can be caused by a variety of factors including infections (viral, bacterial, parasitic, and fungal), allergic reactions to certain medications, and exposure to certain chemicals. It can also be associated with other inflammatory conditions such as lupus, Wegener's granulomatosis, giant cell arteritis and Takayasu's arteritis. Most cases occur sporadically in people with no family history of the condition. Treatment aims to address the underlying cause of the condition. Medications and rarely, a heart transplant may be needed if the heart muscle becomes weak.",
-          "equivalent_curies": [
-            "MESH:D009205",
-            "MEDDRA:10028613",
-            "HP:0012819",
-            "DOID:820",
-            "KEGG.DISEASE:05416",
-            "UMLS:C0027059",
-            "MEDDRA:10028606",
-            "ICD9:429.0",
-            "SYMP:0000095",
-            "SNOMEDCT:50920009",
-            "EFO:0009609",
-            "NCIT:C34831",
-            "MEDDRA:10028619",
-            "MONDO:0004496",
-            "ICD10:I51.4"
-          ],
-          "id": "MONDO:0004496",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myocarditis",
-            "Myocarditis, unspecified",
-            "myocarditis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/myocarditis",
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:21304213",
-            "PMID:22361396",
-            "https://rarediseases.info.nih.gov/diseases/7137/myocarditis",
-            "PMID:22185868",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314697,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004496",
-              "name": "myocarditis",
-              "description": "Myocarditis is a condition that is characterized by inflammation of the heart muscle (myocardium). Some affected people have no noticeable symptoms of the condition. When present, signs and symptoms may include chest pain, abnormal heartbeat, shortness of breath, fatigue, signs of infection (i.e. fever, headache, sore throat, diarrhea), and leg swelling. Myocarditis can be caused by a variety of factors including infections (viral, bacterial, parasitic, and fungal), allergic reactions to certain medications, and exposure to certain chemicals. It can also be associated with other inflammatory conditions such as lupus, Wegener's granulomatosis, giant cell arteritis and Takayasu's arteritis. Most cases occur sporadically in people with no family history of the condition. Treatment aims to address the underlying cause of the condition. Medications and rarely, a heart transplant may be needed if the heart muscle becomes weak.",
-              "equivalent_curies": [
-                "MESH:D009205",
-                "MEDDRA:10028613",
-                "HP:0012819",
-                "DOID:820",
-                "KEGG.DISEASE:05416",
-                "UMLS:C0027059",
-                "MEDDRA:10028606",
-                "ICD9:429.0",
-                "SYMP:0000095",
-                "SNOMEDCT:50920009",
-                "EFO:0009609",
-                "NCIT:C34831",
-                "MEDDRA:10028619",
-                "MONDO:0004496",
-                "ICD10:I51.4"
-              ],
-              "id": "MONDO:0004496",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myocarditis",
-                "Myocarditis, unspecified",
-                "myocarditis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/myocarditis",
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:21304213",
-                "PMID:22361396",
-                "https://rarediseases.info.nih.gov/diseases/7137/myocarditis",
-                "PMID:22185868",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22071900,
-            "start": 570,
-            "end": 314697,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32928810': {'publication date': '2020 Sep 14', 'sentence': 'Although, not described in the literature, we have found conjunctive use of milrinone and methylprednisolone effective in patient with SARS-CoV-2 fulminant myocarditis.', 'subject score': 1000, 'object score': 850}, 'PMID:37114131': {'publication date': '2023', 'sentence': 'COVID-19-associated myocarditis was successfully treated with methylprednisolone, intravenous immunoglobulins and Anakinra.', 'subject score': 1000, 'object score': 802}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0027059---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "22495912",
-              "object": "MONDO:0004496",
-              "publications": [
-                "PMID:32928810",
-                "PMID:37114131"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:34018132': {'publication date': '2021 May 20', 'sentence': 'Methylprednisolone Pulses in West Syndrome: A New Weapon in the Armory-Is it Needed?', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317095,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018097",
-          "name": "West syndrome",
-          "description": "A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages [HPO:jalbers, PMID:28276060]; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0011097",
-            "MONDO:0018097",
-            "MEDDRA:10021750",
-            "UMLS:C0037769",
-            "NCIT:C84788",
-            "MEDDRA:10058893",
-            "MEDDRA:10039371",
-            "SNOMEDCT:28055006",
-            "DOID:0050562",
-            "MESH:D013036",
-            "UMLS:C1527366",
-            "ORPHANET:3451"
-          ],
-          "id": "MONDO:0018097",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_West syndrome",
-            "Salaam Seizures",
-            "West Syndrome",
-            "Spasms, Infantile",
-            "West syndrome",
-            "Epileptic spasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28276060",
-            "PMID:24268986",
-            "https://rarediseases.org/rare-diseases/west-syndrome/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317095,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018097",
-              "name": "West syndrome",
-              "description": "A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages [HPO:jalbers, PMID:28276060]; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0011097",
-                "MONDO:0018097",
-                "MEDDRA:10021750",
-                "UMLS:C0037769",
-                "NCIT:C84788",
-                "MEDDRA:10058893",
-                "MEDDRA:10039371",
-                "SNOMEDCT:28055006",
-                "DOID:0050562",
-                "MESH:D013036",
-                "UMLS:C1527366",
-                "ORPHANET:3451"
-              ],
-              "id": "MONDO:0018097",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_West syndrome",
-                "Salaam Seizures",
-                "West Syndrome",
-                "Spasms, Infantile",
-                "West syndrome",
-                "Epileptic spasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28276060",
-                "PMID:24268986",
-                "https://rarediseases.org/rare-diseases/west-syndrome/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22933478,
-            "start": 570,
-            "end": 317095,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34018132': {'publication date': '2021 May 20', 'sentence': 'Methylprednisolone Pulses in West Syndrome: A New Weapon in the Armory-Is it Needed?', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0037769---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "23364897",
-              "object": "MONDO:0018097",
-              "publications": [
-                "PMID:34018132"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:20142465': {'publication date': '2010 Aug', 'sentence': 'The authors report their experience with intravenous methylprednisolone for the treatment of infantile spasms.', 'subject score': 888, 'object score': 1000}, 'PMID:33103229': {'publication date': '2020 Oct 26', 'sentence': 'Safety, Feasibility and Effectiveness of Pulse Methylprednisolone Therapy in Comparison with Intramuscular Adrenocorticotropic Hormone in Children with West Syndrome.OBJECTIVE: To assess the feasibility, effectiveness, and safety of pulse methylprednisolone in comparison with intramuscular adrenocorticotropic hormone (ACTH) therapy in children with West syndrome (WS).', 'subject score': 861, 'object score': 1000}, 'PMID:33575989': {'publication date': '2021 Feb 11', 'sentence': 'OBJECTIVE: To compare intravenous methylprednisolone (IVMP) with oral prednisolone (OP) for the treatment of West syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:35087722': {'publication date': '2021 Dec', 'sentence': 'This study has been done to evaluate the efficacy of pulse methylprednisolone as compared to ACTH in children with West syndrome.', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317095,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018097",
-          "name": "West syndrome",
-          "description": "A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages [HPO:jalbers, PMID:28276060]; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0011097",
-            "MONDO:0018097",
-            "MEDDRA:10021750",
-            "UMLS:C0037769",
-            "NCIT:C84788",
-            "MEDDRA:10058893",
-            "MEDDRA:10039371",
-            "SNOMEDCT:28055006",
-            "DOID:0050562",
-            "MESH:D013036",
-            "UMLS:C1527366",
-            "ORPHANET:3451"
-          ],
-          "id": "MONDO:0018097",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_West syndrome",
-            "Salaam Seizures",
-            "West Syndrome",
-            "Spasms, Infantile",
-            "West syndrome",
-            "Epileptic spasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28276060",
-            "PMID:24268986",
-            "https://rarediseases.org/rare-diseases/west-syndrome/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317095,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018097",
-              "name": "West syndrome",
-              "description": "A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages [HPO:jalbers, PMID:28276060]; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0011097",
-                "MONDO:0018097",
-                "MEDDRA:10021750",
-                "UMLS:C0037769",
-                "NCIT:C84788",
-                "MEDDRA:10058893",
-                "MEDDRA:10039371",
-                "SNOMEDCT:28055006",
-                "DOID:0050562",
-                "MESH:D013036",
-                "UMLS:C1527366",
-                "ORPHANET:3451"
-              ],
-              "id": "MONDO:0018097",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_West syndrome",
-                "Salaam Seizures",
-                "West Syndrome",
-                "Spasms, Infantile",
-                "West syndrome",
-                "Epileptic spasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28276060",
-                "PMID:24268986",
-                "https://rarediseases.org/rare-diseases/west-syndrome/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14517189,
-            "start": 570,
-            "end": 317095,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20142465': {'publication date': '2010 Aug', 'sentence': 'The authors report their experience with intravenous methylprednisolone for the treatment of infantile spasms.', 'subject score': 888, 'object score': 1000}, 'PMID:33103229': {'publication date': '2020 Oct 26', 'sentence': 'Safety, Feasibility and Effectiveness of Pulse Methylprednisolone Therapy in Comparison with Intramuscular Adrenocorticotropic Hormone in Children with West Syndrome.OBJECTIVE: To assess the feasibility, effectiveness, and safety of pulse methylprednisolone in comparison with intramuscular adrenocorticotropic hormone (ACTH) therapy in children with West syndrome (WS).', 'subject score': 861, 'object score': 1000}, 'PMID:33575989': {'publication date': '2021 Feb 11', 'sentence': 'OBJECTIVE: To compare intravenous methylprednisolone (IVMP) with oral prednisolone (OP) for the treatment of West syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:35087722': {'publication date': '2021 Dec', 'sentence': 'This study has been done to evaluate the efficacy of pulse methylprednisolone as compared to ACTH in children with West syndrome.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0037769---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14825096",
-              "object": "MONDO:0018097",
-              "publications": [
-                "PMID:20142465",
-                "PMID:33103229",
-                "PMID:33575989",
-                "PMID:35087722"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:29068514': {'publication date': '2018 05', 'sentence': 'High incidence of aseptic hip necrosis in Hodgkin lymphoma patients treated with escalated BEACOPP receiving methylprednisolone.', 'subject score': 733, 'object score': 901}, 'PMID:8406379': {'publication date': '1993', 'sentence': \"Retrospective analysis of 34 patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's and Hodgkin's lymphoma treated with high dose methylprednisolone showed 11 responses including two complete remissions among nine patients with CLL.\", 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318155,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004952",
-          "name": "Hodgkins lymphoma",
-          "description": "A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma has a bimodal age distribution, and involves primarily lymph nodes. Current therapy for Hodgkin lymphoma has resulted in an excellent outcome and cure for the majority of patients. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C9357\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C9357\" NCI Thesaurus); UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10020309",
-            "SNOMEDCT:1163005009",
-            "ORPHANET:98293",
-            "UMLS:C5235037",
-            "NCIT:C6914",
-            "MEDDRA:10020255",
-            "SNOMEDCT:118606001",
-            "MEDDRA:10063666",
-            "SNOMEDCT:46923007",
-            "ICD10:C81",
-            "UMLS:C0019829",
-            "ICD9:201.2",
-            "SNOMEDCT:836277009",
-            "SNOMEDCT:74189002",
-            "MEDDRA:10020206",
-            "MESH:D006689",
-            "MEDDRA:10020328",
-            "MEDDRA:10020329",
-            "HP:0012189",
-            "SNOMEDCT:118599009",
-            "NCIT:C9357",
-            "ICD9:201",
-            "NCIT:C26956",
-            "SNOMEDCT:118605002",
-            "SNOMEDCT:118602004",
-            "NCIT:C164145",
-            "PDQ:CDR0000041646",
-            "MEDDRA:10025319",
-            "MEDDRA:10020318",
-            "EFO:0000183",
-            "DOID:8567",
-            "SNOMEDCT:14537002",
-            "MONDO:0004952",
-            "SNOMEDCT:836276000",
-            "MEDDRA:10020339",
-            "SNOMEDCT:70600005"
-          ],
-          "id": "MONDO:0004952",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hodgkin Lymphoma",
-            "Hodgkin lymphoma",
-            "Hodgkin's Paragranuloma",
-            "Hodgkin's sarcoma",
-            "Hodgkin sarcoma",
-            "Hodgkin's lymphoma",
-            "Hodgkins lymphoma",
-            "Hodgkin's Granuloma",
-            "Hodgkin's Sarcoma",
-            "Hodgkin Disease",
-            "Hodgkin's disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/hodgkin%27s_lymphoma",
-            "PMID:22835602",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318155,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004952",
-              "name": "Hodgkins lymphoma",
-              "description": "A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma has a bimodal age distribution, and involves primarily lymph nodes. Current therapy for Hodgkin lymphoma has resulted in an excellent outcome and cure for the majority of patients. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C9357\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C9357\" NCI Thesaurus); UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10020309",
-                "SNOMEDCT:1163005009",
-                "ORPHANET:98293",
-                "UMLS:C5235037",
-                "NCIT:C6914",
-                "MEDDRA:10020255",
-                "SNOMEDCT:118606001",
-                "MEDDRA:10063666",
-                "SNOMEDCT:46923007",
-                "ICD10:C81",
-                "UMLS:C0019829",
-                "ICD9:201.2",
-                "SNOMEDCT:836277009",
-                "SNOMEDCT:74189002",
-                "MEDDRA:10020206",
-                "MESH:D006689",
-                "MEDDRA:10020328",
-                "MEDDRA:10020329",
-                "HP:0012189",
-                "SNOMEDCT:118599009",
-                "NCIT:C9357",
-                "ICD9:201",
-                "NCIT:C26956",
-                "SNOMEDCT:118605002",
-                "SNOMEDCT:118602004",
-                "NCIT:C164145",
-                "PDQ:CDR0000041646",
-                "MEDDRA:10025319",
-                "MEDDRA:10020318",
-                "EFO:0000183",
-                "DOID:8567",
-                "SNOMEDCT:14537002",
-                "MONDO:0004952",
-                "SNOMEDCT:836276000",
-                "MEDDRA:10020339",
-                "SNOMEDCT:70600005"
-              ],
-              "id": "MONDO:0004952",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hodgkin Lymphoma",
-                "Hodgkin lymphoma",
-                "Hodgkin's Paragranuloma",
-                "Hodgkin's sarcoma",
-                "Hodgkin sarcoma",
-                "Hodgkin's lymphoma",
-                "Hodgkins lymphoma",
-                "Hodgkin's Granuloma",
-                "Hodgkin's Sarcoma",
-                "Hodgkin Disease",
-                "Hodgkin's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/hodgkin%27s_lymphoma",
-                "PMID:22835602",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19572345,
-            "start": 570,
-            "end": 318155,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29068514': {'publication date': '2018 05', 'sentence': 'High incidence of aseptic hip necrosis in Hodgkin lymphoma patients treated with escalated BEACOPP receiving methylprednisolone.', 'subject score': 733, 'object score': 901}, 'PMID:8406379': {'publication date': '1993', 'sentence': \"Retrospective analysis of 34 patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's and Hodgkin's lymphoma treated with high dose methylprednisolone showed 11 responses including two complete remissions among nine patients with CLL.\", 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0019829---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "19962298",
-              "object": "MONDO:0004952",
-              "publications": [
-                "PMID:29068514",
-                "PMID:8406379"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10835091': {'publication date': '2000 Jun', 'sentence': 'Additional antiinflammatory therapy, such as IV methylprednisolone and IV cyclophosphamide, may be helpful in treating persistent KD.', 'subject score': 888, 'object score': 861}, 'PMID:15005973': {'publication date': '2004 Mar', 'sentence': 'Pulse methylprednisolone therapy in the treatment of immune globulin-resistant Kawasaki disease: case report and review of the literature.', 'subject score': 790, 'object score': 857}, 'PMID:17301297': {'publication date': '2007 Feb 15', 'sentence': 'METHODS: We conducted a multicenter, randomized, double-blind, placebo-controlled trial to determine whether the addition of intravenous methylprednisolone to conventional primary therapy for Kawasaki disease reduces the risk of coronary-artery abnormalities.', 'subject score': 888, 'object score': 1000}, 'PMID:17962370': {'publication date': '2008 Feb', 'sentence': 'CONCLUSIONS: The findings suggest that IVMP is an effective additional treatment for IVIG-resistant KD.', 'subject score': 888, 'object score': 857}, 'PMID:18446365': {'publication date': '2009 Feb', 'sentence': 'Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease.', 'subject score': 861, 'object score': 901}, 'PMID:20431427': {'publication date': '2010 Oct', 'sentence': 'To our knowledge, this is the first report to document the use of infliximab and methylprednisolone as first line therapy for Kawasaki disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:22222048': {'publication date': '2012 Jan 05', 'sentence': 'We describe a 16 year old girl who presented with fever, arthritis and two giant coronary artery aneurysms, initially diagnosed as atypical Kawasaki disease and treated with IVIG and methylprednisolone.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 531222,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0012727",
-          "name": "mucocutaneous lymph node syndrome",
-          "description": "A vasculitis characterized by inflammation of the arteries, particularly the coronary arteries. The vasculitis may lead to aneurysm formation and possibly, heart attacks. It affects young children who usually present with persistent high fever, redness of the mucous membranes of the mouth, redness of the palms and soles, skin rashes, lymphadenitis, and joint pain and swelling.; An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:13378",
-            "ICD9:446.1",
-            "MEDDRA:10000747",
-            "SNOMEDCT:75053002",
-            "MESH:C537014",
-            "UMLS:C0026691",
-            "UMLS:C2936917",
-            "EFO:0004246",
-            "MESH:D009080",
-            "MEDDRA:10023320",
-            "ICD10:M30.3",
-            "NCIT:C34825",
-            "MONDO:0012727",
-            "MEDDRA:10028083",
-            "OMIM:611775",
-            "ORPHANET:2331"
-          ],
-          "id": "MONDO:0012727",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infantile polyarteritis",
-            "Kawasaki disease",
-            "Kawasaki disease related phenotypic feature",
-            "Kawasaki Disease",
-            "mucocutaneous lymph node syndrome",
-            "Mucocutaneous Lymph Node Syndrome",
-            "Acute febrile mucocutaneous lymph node syndrome [MCLS]"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/kawasaki_disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 531222,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0012727",
-              "name": "mucocutaneous lymph node syndrome",
-              "description": "A vasculitis characterized by inflammation of the arteries, particularly the coronary arteries. The vasculitis may lead to aneurysm formation and possibly, heart attacks. It affects young children who usually present with persistent high fever, redness of the mucous membranes of the mouth, redness of the palms and soles, skin rashes, lymphadenitis, and joint pain and swelling.; An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:13378",
-                "ICD9:446.1",
-                "MEDDRA:10000747",
-                "SNOMEDCT:75053002",
-                "MESH:C537014",
-                "UMLS:C0026691",
-                "UMLS:C2936917",
-                "EFO:0004246",
-                "MESH:D009080",
-                "MEDDRA:10023320",
-                "ICD10:M30.3",
-                "NCIT:C34825",
-                "MONDO:0012727",
-                "MEDDRA:10028083",
-                "OMIM:611775",
-                "ORPHANET:2331"
-              ],
-              "id": "MONDO:0012727",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infantile polyarteritis",
-                "Kawasaki disease",
-                "Kawasaki disease related phenotypic feature",
-                "Kawasaki Disease",
-                "mucocutaneous lymph node syndrome",
-                "Mucocutaneous Lymph Node Syndrome",
-                "Acute febrile mucocutaneous lymph node syndrome [MCLS]"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/kawasaki_disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8053979,
-            "start": 570,
-            "end": 531222,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10835091': {'publication date': '2000 Jun', 'sentence': 'Additional antiinflammatory therapy, such as IV methylprednisolone and IV cyclophosphamide, may be helpful in treating persistent KD.', 'subject score': 888, 'object score': 861}, 'PMID:15005973': {'publication date': '2004 Mar', 'sentence': 'Pulse methylprednisolone therapy in the treatment of immune globulin-resistant Kawasaki disease: case report and review of the literature.', 'subject score': 790, 'object score': 857}, 'PMID:17301297': {'publication date': '2007 Feb 15', 'sentence': 'METHODS: We conducted a multicenter, randomized, double-blind, placebo-controlled trial to determine whether the addition of intravenous methylprednisolone to conventional primary therapy for Kawasaki disease reduces the risk of coronary-artery abnormalities.', 'subject score': 888, 'object score': 1000}, 'PMID:17962370': {'publication date': '2008 Feb', 'sentence': 'CONCLUSIONS: The findings suggest that IVMP is an effective additional treatment for IVIG-resistant KD.', 'subject score': 888, 'object score': 857}, 'PMID:18446365': {'publication date': '2009 Feb', 'sentence': 'Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease.', 'subject score': 861, 'object score': 901}, 'PMID:20431427': {'publication date': '2010 Oct', 'sentence': 'To our knowledge, this is the first report to document the use of infliximab and methylprednisolone as first line therapy for Kawasaki disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:22222048': {'publication date': '2012 Jan 05', 'sentence': 'We describe a 16 year old girl who presented with fever, arthritis and two giant coronary artery aneurysms, initially diagnosed as atypical Kawasaki disease and treated with IVIG and methylprednisolone.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0026691---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8227578",
-              "object": "MONDO:0012727",
-              "publications": [
-                "PMID:10835091",
-                "PMID:15005973",
-                "PMID:17301297",
-                "PMID:17962370",
-                "PMID:18446365",
-                "PMID:20431427",
-                "PMID:22222048"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:35242662': {'publication date': '2022 Jan', 'sentence': \"After 2 months of treatment with systemic methylprednisolone, cyclophosphamide, and prednisone, the patient's abdominal pain was relieved.\", 'subject score': 888, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 321354,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0002027",
-          "name": "Abdominal pain",
-          "description": "Painful sensation in the abdominal region.; Sensation of discomfort, distress, or agony in the abdominal region.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) and perceived to originate in the abdomen. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "SYMP:0000457",
-            "MEDDRA:10018796",
-            "MEDDRA:10046318",
-            "MEDDRA:10000059",
-            "HP:0002027",
-            "MEDDRA:10042076",
-            "MEDDRA:10042126",
-            "MEDDRA:10045148",
-            "UMLS:C0235309",
-            "MEDDRA:10004226",
-            "MEDDRA:10042101",
-            "MEDDRA:10000429",
-            "MEDDRA:10033374",
-            "MEDDRA:10033492",
-            "UMLS:C0232487",
-            "MEDDRA:10017814",
-            "MEDDRA:10017999",
-            "MEDDRA:10064906",
-            "SNOMEDCT:43364001",
-            "UMLS:C0687713",
-            "UMLS:C0221512",
-            "SNOMEDCT:271681002",
-            "MEDDRA:10042112",
-            "MEDDRA:10033402",
-            "NCIT:C78320",
-            "MEDDRA:10018000",
-            "UMLS:C0000737",
-            "MEDDRA:10042124",
-            "MEDDRA:10018241",
-            "NCIT:C78630",
-            "SYMP:0000188",
-            "SNOMEDCT:21522001",
-            "MEDDRA:10000085",
-            "NCIT:C26682",
-            "MEDDRA:10013084",
-            "SNOMEDCT:162059005",
-            "MEDDRA:10000081",
-            "ICD9:789.0",
-            "MESH:D015746"
-          ],
-          "id": "HP:0002027",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Abdominal Pain",
-            "Abdominal discomfort",
-            "Upset stomach",
-            "Stomach Pain",
-            "abdominal discomfort",
-            "Stomach ache",
-            "Abdominal pain",
-            "Gastrointestinal Pain",
-            "abdominal pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://medlineplus.gov/ency/article/003120.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321354,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002027",
-              "name": "Abdominal pain",
-              "description": "Painful sensation in the abdominal region.; Sensation of discomfort, distress, or agony in the abdominal region.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) and perceived to originate in the abdomen. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "SYMP:0000457",
-                "MEDDRA:10018796",
-                "MEDDRA:10046318",
-                "MEDDRA:10000059",
-                "HP:0002027",
-                "MEDDRA:10042076",
-                "MEDDRA:10042126",
-                "MEDDRA:10045148",
-                "UMLS:C0235309",
-                "MEDDRA:10004226",
-                "MEDDRA:10042101",
-                "MEDDRA:10000429",
-                "MEDDRA:10033374",
-                "MEDDRA:10033492",
-                "UMLS:C0232487",
-                "MEDDRA:10017814",
-                "MEDDRA:10017999",
-                "MEDDRA:10064906",
-                "SNOMEDCT:43364001",
-                "UMLS:C0687713",
-                "UMLS:C0221512",
-                "SNOMEDCT:271681002",
-                "MEDDRA:10042112",
-                "MEDDRA:10033402",
-                "NCIT:C78320",
-                "MEDDRA:10018000",
-                "UMLS:C0000737",
-                "MEDDRA:10042124",
-                "MEDDRA:10018241",
-                "NCIT:C78630",
-                "SYMP:0000188",
-                "SNOMEDCT:21522001",
-                "MEDDRA:10000085",
-                "NCIT:C26682",
-                "MEDDRA:10013084",
-                "SNOMEDCT:162059005",
-                "MEDDRA:10000081",
-                "ICD9:789.0",
-                "MESH:D015746"
-              ],
-              "id": "HP:0002027",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Abdominal Pain",
-                "Abdominal discomfort",
-                "Upset stomach",
-                "Stomach Pain",
-                "abdominal discomfort",
-                "Stomach ache",
-                "Abdominal pain",
-                "Gastrointestinal Pain",
-                "abdominal pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://medlineplus.gov/ency/article/003120.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23833296,
-            "start": 570,
-            "end": 321354,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35242662': {'publication date': '2022 Jan', 'sentence': \"After 2 months of treatment with systemic methylprednisolone, cyclophosphamide, and prednisone, the patient's abdominal pain was relieved.\", 'subject score': 888, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0000737---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "24273559",
-              "object": "HP:0002027",
-              "publications": [
-                "PMID:35242662"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:25868427': {'publication date': '2015 Nov', 'sentence': 'Treatment with a pulse of methylprednisolone reduced both abdominal pain and lesion size.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321354,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0002027",
-          "name": "Abdominal pain",
-          "description": "Painful sensation in the abdominal region.; Sensation of discomfort, distress, or agony in the abdominal region.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) and perceived to originate in the abdomen. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "SYMP:0000457",
-            "MEDDRA:10018796",
-            "MEDDRA:10046318",
-            "MEDDRA:10000059",
-            "HP:0002027",
-            "MEDDRA:10042076",
-            "MEDDRA:10042126",
-            "MEDDRA:10045148",
-            "UMLS:C0235309",
-            "MEDDRA:10004226",
-            "MEDDRA:10042101",
-            "MEDDRA:10000429",
-            "MEDDRA:10033374",
-            "MEDDRA:10033492",
-            "UMLS:C0232487",
-            "MEDDRA:10017814",
-            "MEDDRA:10017999",
-            "MEDDRA:10064906",
-            "SNOMEDCT:43364001",
-            "UMLS:C0687713",
-            "UMLS:C0221512",
-            "SNOMEDCT:271681002",
-            "MEDDRA:10042112",
-            "MEDDRA:10033402",
-            "NCIT:C78320",
-            "MEDDRA:10018000",
-            "UMLS:C0000737",
-            "MEDDRA:10042124",
-            "MEDDRA:10018241",
-            "NCIT:C78630",
-            "SYMP:0000188",
-            "SNOMEDCT:21522001",
-            "MEDDRA:10000085",
-            "NCIT:C26682",
-            "MEDDRA:10013084",
-            "SNOMEDCT:162059005",
-            "MEDDRA:10000081",
-            "ICD9:789.0",
-            "MESH:D015746"
-          ],
-          "id": "HP:0002027",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Abdominal Pain",
-            "Abdominal discomfort",
-            "Upset stomach",
-            "Stomach Pain",
-            "abdominal discomfort",
-            "Stomach ache",
-            "Abdominal pain",
-            "Gastrointestinal Pain",
-            "abdominal pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://medlineplus.gov/ency/article/003120.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321354,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002027",
-              "name": "Abdominal pain",
-              "description": "Painful sensation in the abdominal region.; Sensation of discomfort, distress, or agony in the abdominal region.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) and perceived to originate in the abdomen. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "SYMP:0000457",
-                "MEDDRA:10018796",
-                "MEDDRA:10046318",
-                "MEDDRA:10000059",
-                "HP:0002027",
-                "MEDDRA:10042076",
-                "MEDDRA:10042126",
-                "MEDDRA:10045148",
-                "UMLS:C0235309",
-                "MEDDRA:10004226",
-                "MEDDRA:10042101",
-                "MEDDRA:10000429",
-                "MEDDRA:10033374",
-                "MEDDRA:10033492",
-                "UMLS:C0232487",
-                "MEDDRA:10017814",
-                "MEDDRA:10017999",
-                "MEDDRA:10064906",
-                "SNOMEDCT:43364001",
-                "UMLS:C0687713",
-                "UMLS:C0221512",
-                "SNOMEDCT:271681002",
-                "MEDDRA:10042112",
-                "MEDDRA:10033402",
-                "NCIT:C78320",
-                "MEDDRA:10018000",
-                "UMLS:C0000737",
-                "MEDDRA:10042124",
-                "MEDDRA:10018241",
-                "NCIT:C78630",
-                "SYMP:0000188",
-                "SNOMEDCT:21522001",
-                "MEDDRA:10000085",
-                "NCIT:C26682",
-                "MEDDRA:10013084",
-                "SNOMEDCT:162059005",
-                "MEDDRA:10000081",
-                "ICD9:789.0",
-                "MESH:D015746"
-              ],
-              "id": "HP:0002027",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Abdominal Pain",
-                "Abdominal discomfort",
-                "Upset stomach",
-                "Stomach Pain",
-                "abdominal discomfort",
-                "Stomach ache",
-                "Abdominal pain",
-                "Gastrointestinal Pain",
-                "abdominal pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://medlineplus.gov/ency/article/003120.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17902875,
-            "start": 570,
-            "end": 321354,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25868427': {'publication date': '2015 Nov', 'sentence': 'Treatment with a pulse of methylprednisolone reduced both abdominal pain and lesion size.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:prevents---None---None---None---UMLS:C0000737---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "18266414",
-              "object": "HP:0002027",
-              "publications": [
-                "PMID:25868427"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:18386553': {'publication date': '2008 Jan', 'sentence': 'A 46 year old woman who presented with severe multiorgans involvement including liver brain, cardio-pulmonary failure, gastrointestinal bleeding, progressive cytopenia, DIC and hemophagocytic syndrome during the convalescent phase of Dengue type II has been successfully treated primarily with pulse methyl prednisolone and high dose intravenous immunoglobulin G.', 'subject score': 901, 'object score': 1000}, 'PMID:21411984': {'publication date': '2011', 'sentence': 'CsA (4 mg/kg/day) plus mPSL treatment dramatically improved HPS with DIC, reduced subcutaneous tumors within 2 weeks, and finally induced complete remission (CR) after 3 months.', 'subject score': 851, 'object score': 1000}, 'PMID:27998299': {'publication date': '2016 Dec 20', 'sentence': 'Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature.', 'subject score': 1000, 'object score': 901}, 'PMID:32126983': {'publication date': '2020 Mar 03', 'sentence': 'On the basis of antiinfection treatment, methylprednisolone was used to control HLH.', 'subject score': 1000, 'object score': 1000}, 'PMID:32991435': {'publication date': '2020 Sep 25', 'sentence': 'INTERVENTIONS: The patient experienced pulse therapy with methylprednisolone for hemophagocytic lymphohistiocytosis, followed by initial therapy for multiple myeloma with cyclophosphamide and dexamethasone.', 'subject score': 1000, 'object score': 1000}, 'PMID:33967148': {'publication date': '2021', 'sentence': 'The mPSL dose was again increased to 2 mg/kg for the treatment of hemophagocytic syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:35265543': {'publication date': '2022', 'sentence': 'A diagnosis of hemophagocytic lymphohistiocytosis was assumed and pulse methylprednisolone therapy initiated.', 'subject score': 790, 'object score': 1000}, 'PMID:36064566': {'publication date': '2022 Sep 05', 'sentence': 'He was diagnosed with HLH and was treated with methylprednisolone and cyclosporine.', 'subject score': 1000, 'object score': 1000}, 'PMID:9785977': {'publication date': '1998 Aug', 'sentence': 'The patient was treated with gamma-globulin and methylprednisolone for hemophagocytic syndrome, but died of respiratory insufficiency with progressive hyperbilirubinemia and trombocytopenia on the 29th hospital day, A postmortem examination showed proliferation of lymphoma cells within the small blood vessels of the brain, lungs, liver, and many other organs, but the bone marrow was not involved.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 516028,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015540",
-          "name": "hemophagocytic syndrome",
-          "description": "A classification of rare, non-neoplastic, proliferative disorders of the hematologic system. Primary or familial hemophagocytic lymphohistiocytosis (HLH) is inherited with an autosomal recessive pattern with five known subtypes differentiated by specific genetic mutations. Secondary manifestation of HLH is usually seen in hyperactivated immunologic states such as infection, autoimmune disease or malignancy. Histiocytes in the bone marrow, spleen or lymph nodes become activated to the point that phagocytosis proceeds unchecked. Clinical signs usually present within the first decade and include fever, jaundice, hepatosplenomegaly, lymphadenopathy and skin rash. Prompt initiation of treatment improves survival though prognosis remains poor even with intervention.; Proliferation of HISTIOCYTES in response to viral, bacterial, fungal, or parasitic infections.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0015540",
-            "UMLS:C0024291",
-            "NCIT:C35439",
-            "ORPHANET:158032",
-            "DOID:0050120",
-            "SNOMEDCT:234437005",
-            "UMLS:C3887558",
-            "OMIM:PS267700",
-            "NCIT:C34792",
-            "PDQ:CDR0000486910",
-            "MEDDRA:10071583",
-            "ICD10:D76.1",
-            "MEDDRA:10071580",
-            "MEDDRA:10058139",
-            "MESH:D051359",
-            "MEDDRA:10058125"
-          ],
-          "id": "MONDO:0015540",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hemophagocytic Syndrome",
-            "hemophagocytic syndrome",
-            "Hemophagocytic syndrome",
-            "Hemophagocytic Lymphohistiocytosis",
-            "hemophagocytic lymphohistiocytosis",
-            "Lymphohistiocytosis, Hemophagocytic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.scielo.br/scielo.php?script=sci_arttext&pid=s1516-31801997000500007&lng=pt&nrm=iso",
-            "http://ghr.nlm.nih.gov/condition/familial-hemophagocytic-lymphohistiocytosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 516028,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015540",
-              "name": "hemophagocytic syndrome",
-              "description": "A classification of rare, non-neoplastic, proliferative disorders of the hematologic system. Primary or familial hemophagocytic lymphohistiocytosis (HLH) is inherited with an autosomal recessive pattern with five known subtypes differentiated by specific genetic mutations. Secondary manifestation of HLH is usually seen in hyperactivated immunologic states such as infection, autoimmune disease or malignancy. Histiocytes in the bone marrow, spleen or lymph nodes become activated to the point that phagocytosis proceeds unchecked. Clinical signs usually present within the first decade and include fever, jaundice, hepatosplenomegaly, lymphadenopathy and skin rash. Prompt initiation of treatment improves survival though prognosis remains poor even with intervention.; Proliferation of HISTIOCYTES in response to viral, bacterial, fungal, or parasitic infections.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0015540",
-                "UMLS:C0024291",
-                "NCIT:C35439",
-                "ORPHANET:158032",
-                "DOID:0050120",
-                "SNOMEDCT:234437005",
-                "UMLS:C3887558",
-                "OMIM:PS267700",
-                "NCIT:C34792",
-                "PDQ:CDR0000486910",
-                "MEDDRA:10071583",
-                "ICD10:D76.1",
-                "MEDDRA:10071580",
-                "MEDDRA:10058139",
-                "MESH:D051359",
-                "MEDDRA:10058125"
-              ],
-              "id": "MONDO:0015540",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hemophagocytic Syndrome",
-                "hemophagocytic syndrome",
-                "Hemophagocytic syndrome",
-                "Hemophagocytic Lymphohistiocytosis",
-                "hemophagocytic lymphohistiocytosis",
-                "Lymphohistiocytosis, Hemophagocytic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.scielo.br/scielo.php?script=sci_arttext&pid=s1516-31801997000500007&lng=pt&nrm=iso",
-                "http://ghr.nlm.nih.gov/condition/familial-hemophagocytic-lymphohistiocytosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13391724,
-            "start": 570,
-            "end": 516028,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18386553': {'publication date': '2008 Jan', 'sentence': 'A 46 year old woman who presented with severe multiorgans involvement including liver brain, cardio-pulmonary failure, gastrointestinal bleeding, progressive cytopenia, DIC and hemophagocytic syndrome during the convalescent phase of Dengue type II has been successfully treated primarily with pulse methyl prednisolone and high dose intravenous immunoglobulin G.', 'subject score': 901, 'object score': 1000}, 'PMID:21411984': {'publication date': '2011', 'sentence': 'CsA (4 mg/kg/day) plus mPSL treatment dramatically improved HPS with DIC, reduced subcutaneous tumors within 2 weeks, and finally induced complete remission (CR) after 3 months.', 'subject score': 851, 'object score': 1000}, 'PMID:27998299': {'publication date': '2016 Dec 20', 'sentence': 'Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature.', 'subject score': 1000, 'object score': 901}, 'PMID:32126983': {'publication date': '2020 Mar 03', 'sentence': 'On the basis of antiinfection treatment, methylprednisolone was used to control HLH.', 'subject score': 1000, 'object score': 1000}, 'PMID:32991435': {'publication date': '2020 Sep 25', 'sentence': 'INTERVENTIONS: The patient experienced pulse therapy with methylprednisolone for hemophagocytic lymphohistiocytosis, followed by initial therapy for multiple myeloma with cyclophosphamide and dexamethasone.', 'subject score': 1000, 'object score': 1000}, 'PMID:33967148': {'publication date': '2021', 'sentence': 'The mPSL dose was again increased to 2 mg/kg for the treatment of hemophagocytic syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:35265543': {'publication date': '2022', 'sentence': 'A diagnosis of hemophagocytic lymphohistiocytosis was assumed and pulse methylprednisolone therapy initiated.', 'subject score': 790, 'object score': 1000}, 'PMID:36064566': {'publication date': '2022 Sep 05', 'sentence': 'He was diagnosed with HLH and was treated with methylprednisolone and cyclosporine.', 'subject score': 1000, 'object score': 1000}, 'PMID:9785977': {'publication date': '1998 Aug', 'sentence': 'The patient was treated with gamma-globulin and methylprednisolone for hemophagocytic syndrome, but died of respiratory insufficiency with progressive hyperbilirubinemia and trombocytopenia on the 29th hospital day, A postmortem examination showed proliferation of lymphoma cells within the small blood vessels of the brain, lungs, liver, and many other organs, but the bone marrow was not involved.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0024291---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "13679356",
-              "object": "MONDO:0015540",
-              "publications": [
-                "PMID:18386553",
-                "PMID:21411984",
-                "PMID:27998299",
-                "PMID:32126983",
-                "PMID:32991435",
-                "PMID:33967148",
-                "PMID:35265543",
-                "PMID:36064566",
-                "PMID:9785977"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:476617': {'publication date': '1979 Oct', 'sentence': 'The effect of methylprednisolone (MP) on the cell kinetic response to cyclophosphamide (CP) and Adriamycin (ADR) in C3H/HeJ spontaneous mammary tumors and hematopoietic tissue was investigated.', 'subject score': 1000, 'object score': 774}}",
-    "p2": {
-      "start": {
-        "identity": 315465,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021100",
-          "name": "breast neoplasm",
-          "description": "A benign or malignant neoplasm of the breast parenchyma. It can originate from the ducts, lobules or the breast adipose tissue. Breast neoplasms are much more common in females than males.; Cancer of the human MAMMARY GLAND.; A tumor (abnormal growth of tissue) of the breast. [HPO:probinson]",
-          "equivalent_curies": [
-            "UMLS:CN236627",
-            "SNOMEDCT:126926005",
-            "MEDDRA:10006285",
-            "MEDDRA:10028985",
-            "PSY:29330",
-            "MONDO:0021100",
-            "EFO:0003869",
-            "UMLS:C1458155",
-            "HP:0100013",
-            "NCIT:C2910",
-            "MESH:D001943",
-            "PSY:06940",
-            "MEDDRA:10006279"
-          ],
-          "id": "MONDO:0021100",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Breast Neoplasm",
-            "Neoplasm of the breast",
-            "Mammary Neoplasms",
-            "breast neoplasm",
-            "Breast Neoplasms"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315465,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021100",
-              "name": "breast neoplasm",
-              "description": "A benign or malignant neoplasm of the breast parenchyma. It can originate from the ducts, lobules or the breast adipose tissue. Breast neoplasms are much more common in females than males.; Cancer of the human MAMMARY GLAND.; A tumor (abnormal growth of tissue) of the breast. [HPO:probinson]",
-              "equivalent_curies": [
-                "UMLS:CN236627",
-                "SNOMEDCT:126926005",
-                "MEDDRA:10006285",
-                "MEDDRA:10028985",
-                "PSY:29330",
-                "MONDO:0021100",
-                "EFO:0003869",
-                "UMLS:C1458155",
-                "HP:0100013",
-                "NCIT:C2910",
-                "MESH:D001943",
-                "PSY:06940",
-                "MEDDRA:10006279"
-              ],
-              "id": "MONDO:0021100",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Breast Neoplasm",
-                "Neoplasm of the breast",
-                "Mammary Neoplasms",
-                "breast neoplasm",
-                "Breast Neoplasms"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25392251,
-            "start": 570,
-            "end": 315465,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:476617': {'publication date': '1979 Oct', 'sentence': 'The effect of methylprednisolone (MP) on the cell kinetic response to cyclophosphamide (CP) and Adriamycin (ADR) in C3H/HeJ spontaneous mammary tumors and hematopoietic tissue was investigated.', 'subject score': 1000, 'object score': 774}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C1458155---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "25845844",
-              "object": "MONDO:0021100",
-              "publications": [
-                "PMID:476617"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:21217889': {'publication date': '2010 Dec', 'sentence': 'Herein, we present our experience of management of such cases with a single epidural injection of local anaesthetic, tramadol and methylprednisolone, and table tilt for management of both radiculopathies.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 577557,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002959",
-          "name": "radiculopathy",
-          "description": "Disease involving a spinal nerve root (see spinal nerve roots) which may result from compression related to intervertebral disk displacement; spinal cord injuries; spinal diseases; and other conditions. Clinical manifestations include radicular pain, weakness, and sensory loss referable to structures innervated by the involved nerve root. // COMMENTS: Editor note: DO classifies under polyradiculopathy, which we invert",
-          "equivalent_curies": [
-            "MEDDRA:10052442",
-            "ICD10:M54.1",
-            "SNOMEDCT:72274001",
-            "MESH:D011843",
-            "MONDO:0002959",
-            "MEDDRA:10041587",
-            "MEDDRA:10037779",
-            "UMLS:C0700594",
-            "DOID:4306",
-            "MEDDRA:10037780",
-            "UMLS:C1527351"
-          ],
-          "id": "MONDO:0002959",
-          "category": "biolink:Disease",
-          "all_names": [
-            "radiculopathy",
-            "Nerve Root Disorder",
-            "Radiculopathy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/radiculopathy",
-            "https://www.hopkinsmedicine.org/health/conditions-and-diseases/radiculopathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 577557,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002959",
-              "name": "radiculopathy",
-              "description": "Disease involving a spinal nerve root (see spinal nerve roots) which may result from compression related to intervertebral disk displacement; spinal cord injuries; spinal diseases; and other conditions. Clinical manifestations include radicular pain, weakness, and sensory loss referable to structures innervated by the involved nerve root. // COMMENTS: Editor note: DO classifies under polyradiculopathy, which we invert",
-              "equivalent_curies": [
-                "MEDDRA:10052442",
-                "ICD10:M54.1",
-                "SNOMEDCT:72274001",
-                "MESH:D011843",
-                "MONDO:0002959",
-                "MEDDRA:10041587",
-                "MEDDRA:10037779",
-                "UMLS:C0700594",
-                "DOID:4306",
-                "MEDDRA:10037780",
-                "UMLS:C1527351"
-              ],
-              "id": "MONDO:0002959",
-              "category": "biolink:Disease",
-              "all_names": [
-                "radiculopathy",
-                "Nerve Root Disorder",
-                "Radiculopathy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/radiculopathy",
-                "https://www.hopkinsmedicine.org/health/conditions-and-diseases/radiculopathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15090097,
-            "start": 570,
-            "end": 577557,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21217889': {'publication date': '2010 Dec', 'sentence': 'Herein, we present our experience of management of such cases with a single epidural injection of local anaesthetic, tramadol and methylprednisolone, and table tilt for management of both radiculopathies.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0700594---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "15407991",
-              "object": "MONDO:0002959",
-              "publications": [
-                "PMID:21217889"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:24841498': {'publication date': '2014 Oct', 'sentence': 'Our case likely represents worsening of DON due to soft tissue swelling secondary to OR despite cover with IVMP in a patient previously responsive to IVMP alone.', 'subject score': 888, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 546730,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002135",
-          "name": "optic nerve disorder",
-          "description": "A non-neoplastic or neoplastic disorder affecting the optic nerve (second cranial nerve).; Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.; The optic nerve is a bundle of more than 1 million nerve fibers that carry visual messages. You have one connecting the back of each eye (your retina) to your brain. Damage to an optic nerve can cause vision loss. The type of vision loss and how severe it is depends on where the damage occurs. It may affect one or both eyes. There are many different types of optic nerve disorders, including:  Glaucoma is a group of diseases that are the leading cause of blindness in the United States. Glaucoma usually happens when the fluid pressure inside the eyes slowly rises and damages the optic nerve. Optic neuritis is an inflammation of the optic nerve. Causes include infections and immune-related illnesses such as multiple sclerosis. Sometimes the cause is unknown. Optic nerve atrophy is damage to the optic nerve. Causes include poor blood flow to the eye, disease, trauma, or exposure to toxic substances. Optic nerve head drusen are pockets of protein and calcium salts that build up in the optic nerve over time  Contact your health care provider if you are having vision problems. Tests for optic nerve disorders may include eye exams, ophthalmoscopy (an examination of the back of your eye), and imaging tests. Treatment depends on which disorder that you have. With some optic nerve disorders, you may get your vision back. With others, there is no treatment, or treatment may only prevent further vision loss.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10061322",
-            "MESH:D009901",
-            "SNOMEDCT:77157004",
-            "UMLS:C0029132",
-            "NCIT:C79698",
-            "MONDO:0002135",
-            "DOID:1891",
-            "MEDDRA:10030932"
-          ],
-          "id": "MONDO:0002135",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Disorder of the optic nerve",
-            "Optic Nerve Disorder",
-            "optic nerve disease",
-            "Optic Nerve Diseases",
-            "optic nerve disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nature.com/eye/journal/v18/n11/full/6701575a.htm",
-            "http://www.academy.org.uk/lectures/barnard3.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546730,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002135",
-              "name": "optic nerve disorder",
-              "description": "A non-neoplastic or neoplastic disorder affecting the optic nerve (second cranial nerve).; Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.; The optic nerve is a bundle of more than 1 million nerve fibers that carry visual messages. You have one connecting the back of each eye (your retina) to your brain. Damage to an optic nerve can cause vision loss. The type of vision loss and how severe it is depends on where the damage occurs. It may affect one or both eyes. There are many different types of optic nerve disorders, including:  Glaucoma is a group of diseases that are the leading cause of blindness in the United States. Glaucoma usually happens when the fluid pressure inside the eyes slowly rises and damages the optic nerve. Optic neuritis is an inflammation of the optic nerve. Causes include infections and immune-related illnesses such as multiple sclerosis. Sometimes the cause is unknown. Optic nerve atrophy is damage to the optic nerve. Causes include poor blood flow to the eye, disease, trauma, or exposure to toxic substances. Optic nerve head drusen are pockets of protein and calcium salts that build up in the optic nerve over time  Contact your health care provider if you are having vision problems. Tests for optic nerve disorders may include eye exams, ophthalmoscopy (an examination of the back of your eye), and imaging tests. Treatment depends on which disorder that you have. With some optic nerve disorders, you may get your vision back. With others, there is no treatment, or treatment may only prevent further vision loss.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10061322",
-                "MESH:D009901",
-                "SNOMEDCT:77157004",
-                "UMLS:C0029132",
-                "NCIT:C79698",
-                "MONDO:0002135",
-                "DOID:1891",
-                "MEDDRA:10030932"
-              ],
-              "id": "MONDO:0002135",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Disorder of the optic nerve",
-                "Optic Nerve Disorder",
-                "optic nerve disease",
-                "Optic Nerve Diseases",
-                "optic nerve disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nature.com/eye/journal/v18/n11/full/6701575a.htm",
-                "http://www.academy.org.uk/lectures/barnard3.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17294741,
-            "start": 570,
-            "end": 546730,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24841498': {'publication date': '2014 Oct', 'sentence': 'Our case likely represents worsening of DON due to soft tissue swelling secondary to OR despite cover with IVMP in a patient previously responsive to IVMP alone.', 'subject score': 888, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0029132---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "17649050",
-              "object": "MONDO:0002135",
-              "publications": [
-                "PMID:24841498"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:17452966': {'publication date': '2007 May', 'sentence': 'Dysthyroid optic neuropathy is best treated with intravenous pulsed methylprednisolone; if visual functions do not recover, urgent surgical decompression is indicated.', 'subject score': 840, 'object score': 901}, 'PMID:21663445': {'publication date': '2011 Jun', 'sentence': 'CONCLUSION: Intravenous high-dose methyl prednisolone may have benefits in the treatment of methanol optic neuropathy.', 'subject score': 861, 'object score': 901}, 'PMID:24417307': {'publication date': '2014 May', 'sentence': 'METHODS: Twenty-four DON patients (40 eyes) treated with iv-MP from 2007 to 2012 were included in the study.', 'subject score': 888, 'object score': 762}, 'PMID:24920512': {'publication date': '2014 Jun 11', 'sentence': 'Intravenous methylprednisolone was used to reverse optic neuropathy and to prevent OD visual loss.', 'subject score': 888, 'object score': 1000}, 'PMID:25705536': {'publication date': '2015', 'sentence': 'Optic neuropathy was treated with intravenous pulse methylprednisolone.', 'subject score': 802, 'object score': 1000}, 'PMID:2771352': {'publication date': '1989 Jul', 'sentence': 'Pulse methylprednisolone therapy appears to be beneficial in the initial management of severe dysthyroid optic neuropathy.', 'subject score': 790, 'object score': 824}, 'PMID:29927882': {'publication date': '2018 Jul/Aug', 'sentence': 'There has only been one controlled trial comparing high-dose intravenous methylprednisolone to bony orbital decompression for DON.', 'subject score': 861, 'object score': 901}, 'PMID:33710036': {'publication date': '2021 Mar 08', 'sentence': 'Three cases of dysthyroid optic neuropathy, refractory to methylprednisolone therapy improved after initiation of teprotumumab.', 'subject score': 888, 'object score': 901}, 'PMID:35456161': {'publication date': '2022 Apr 07', 'sentence': 'CONCLUSIONS: The results of this study suggest that additional treatment with 12 pulses of ivMP improves or stabilizes the outcome of basic therapy in patients with DON.', 'subject score': 888, 'object score': 901}, 'PMID:36690985': {'publication date': '2023 Jan 23', 'sentence': 'AIM: To study the efficacy of intravenous pulse methylprednisolone (IVMP) in treating dysthyroid optic neuropathy (DON) and to identify factors predicting poor response to the treatment.', 'subject score': 802, 'object score': 824}, 'PMID:7732488': {'publication date': '1995 Feb', 'sentence': 'When she was admitted three days later, she was diagnosed as having optic neuropathy, and immediate treatment with methylprednisolone (1 g/day for three days) followed by prednisolone (50 mg/day) resulted in complete disappearance of the above symptoms by Feb.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 546730,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002135",
-          "name": "optic nerve disorder",
-          "description": "A non-neoplastic or neoplastic disorder affecting the optic nerve (second cranial nerve).; Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.; The optic nerve is a bundle of more than 1 million nerve fibers that carry visual messages. You have one connecting the back of each eye (your retina) to your brain. Damage to an optic nerve can cause vision loss. The type of vision loss and how severe it is depends on where the damage occurs. It may affect one or both eyes. There are many different types of optic nerve disorders, including:  Glaucoma is a group of diseases that are the leading cause of blindness in the United States. Glaucoma usually happens when the fluid pressure inside the eyes slowly rises and damages the optic nerve. Optic neuritis is an inflammation of the optic nerve. Causes include infections and immune-related illnesses such as multiple sclerosis. Sometimes the cause is unknown. Optic nerve atrophy is damage to the optic nerve. Causes include poor blood flow to the eye, disease, trauma, or exposure to toxic substances. Optic nerve head drusen are pockets of protein and calcium salts that build up in the optic nerve over time  Contact your health care provider if you are having vision problems. Tests for optic nerve disorders may include eye exams, ophthalmoscopy (an examination of the back of your eye), and imaging tests. Treatment depends on which disorder that you have. With some optic nerve disorders, you may get your vision back. With others, there is no treatment, or treatment may only prevent further vision loss.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10061322",
-            "MESH:D009901",
-            "SNOMEDCT:77157004",
-            "UMLS:C0029132",
-            "NCIT:C79698",
-            "MONDO:0002135",
-            "DOID:1891",
-            "MEDDRA:10030932"
-          ],
-          "id": "MONDO:0002135",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Disorder of the optic nerve",
-            "Optic Nerve Disorder",
-            "optic nerve disease",
-            "Optic Nerve Diseases",
-            "optic nerve disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nature.com/eye/journal/v18/n11/full/6701575a.htm",
-            "http://www.academy.org.uk/lectures/barnard3.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546730,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002135",
-              "name": "optic nerve disorder",
-              "description": "A non-neoplastic or neoplastic disorder affecting the optic nerve (second cranial nerve).; Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.; The optic nerve is a bundle of more than 1 million nerve fibers that carry visual messages. You have one connecting the back of each eye (your retina) to your brain. Damage to an optic nerve can cause vision loss. The type of vision loss and how severe it is depends on where the damage occurs. It may affect one or both eyes. There are many different types of optic nerve disorders, including:  Glaucoma is a group of diseases that are the leading cause of blindness in the United States. Glaucoma usually happens when the fluid pressure inside the eyes slowly rises and damages the optic nerve. Optic neuritis is an inflammation of the optic nerve. Causes include infections and immune-related illnesses such as multiple sclerosis. Sometimes the cause is unknown. Optic nerve atrophy is damage to the optic nerve. Causes include poor blood flow to the eye, disease, trauma, or exposure to toxic substances. Optic nerve head drusen are pockets of protein and calcium salts that build up in the optic nerve over time  Contact your health care provider if you are having vision problems. Tests for optic nerve disorders may include eye exams, ophthalmoscopy (an examination of the back of your eye), and imaging tests. Treatment depends on which disorder that you have. With some optic nerve disorders, you may get your vision back. With others, there is no treatment, or treatment may only prevent further vision loss.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10061322",
-                "MESH:D009901",
-                "SNOMEDCT:77157004",
-                "UMLS:C0029132",
-                "NCIT:C79698",
-                "MONDO:0002135",
-                "DOID:1891",
-                "MEDDRA:10030932"
-              ],
-              "id": "MONDO:0002135",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Disorder of the optic nerve",
-                "Optic Nerve Disorder",
-                "optic nerve disease",
-                "Optic Nerve Diseases",
-                "optic nerve disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nature.com/eye/journal/v18/n11/full/6701575a.htm",
-                "http://www.academy.org.uk/lectures/barnard3.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12819069,
-            "start": 570,
-            "end": 546730,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17452966': {'publication date': '2007 May', 'sentence': 'Dysthyroid optic neuropathy is best treated with intravenous pulsed methylprednisolone; if visual functions do not recover, urgent surgical decompression is indicated.', 'subject score': 840, 'object score': 901}, 'PMID:21663445': {'publication date': '2011 Jun', 'sentence': 'CONCLUSION: Intravenous high-dose methyl prednisolone may have benefits in the treatment of methanol optic neuropathy.', 'subject score': 861, 'object score': 901}, 'PMID:24417307': {'publication date': '2014 May', 'sentence': 'METHODS: Twenty-four DON patients (40 eyes) treated with iv-MP from 2007 to 2012 were included in the study.', 'subject score': 888, 'object score': 762}, 'PMID:24920512': {'publication date': '2014 Jun 11', 'sentence': 'Intravenous methylprednisolone was used to reverse optic neuropathy and to prevent OD visual loss.', 'subject score': 888, 'object score': 1000}, 'PMID:25705536': {'publication date': '2015', 'sentence': 'Optic neuropathy was treated with intravenous pulse methylprednisolone.', 'subject score': 802, 'object score': 1000}, 'PMID:2771352': {'publication date': '1989 Jul', 'sentence': 'Pulse methylprednisolone therapy appears to be beneficial in the initial management of severe dysthyroid optic neuropathy.', 'subject score': 790, 'object score': 824}, 'PMID:29927882': {'publication date': '2018 Jul/Aug', 'sentence': 'There has only been one controlled trial comparing high-dose intravenous methylprednisolone to bony orbital decompression for DON.', 'subject score': 861, 'object score': 901}, 'PMID:33710036': {'publication date': '2021 Mar 08', 'sentence': 'Three cases of dysthyroid optic neuropathy, refractory to methylprednisolone therapy improved after initiation of teprotumumab.', 'subject score': 888, 'object score': 901}, 'PMID:35456161': {'publication date': '2022 Apr 07', 'sentence': 'CONCLUSIONS: The results of this study suggest that additional treatment with 12 pulses of ivMP improves or stabilizes the outcome of basic therapy in patients with DON.', 'subject score': 888, 'object score': 901}, 'PMID:36690985': {'publication date': '2023 Jan 23', 'sentence': 'AIM: To study the efficacy of intravenous pulse methylprednisolone (IVMP) in treating dysthyroid optic neuropathy (DON) and to identify factors predicting poor response to the treatment.', 'subject score': 802, 'object score': 824}, 'PMID:7732488': {'publication date': '1995 Feb', 'sentence': 'When she was admitted three days later, she was diagnosed as having optic neuropathy, and immediate treatment with methylprednisolone (1 g/day for three days) followed by prednisolone (50 mg/day) resulted in complete disappearance of the above symptoms by Feb.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0029132---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "13096165",
-              "object": "MONDO:0002135",
-              "publications": [
-                "PMID:17452966",
-                "PMID:21663445",
-                "PMID:24417307",
-                "PMID:24920512",
-                "PMID:25705536",
-                "PMID:2771352",
-                "PMID:29927882",
-                "PMID:33710036",
-                "PMID:35456161",
-                "PMID:36690985",
-                "PMID:7732488"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:33692629': {'publication date': '2021', 'sentence': 'Caspofungin, TMP-SMX, clindamycin and MP were used to treat    P. jirovecii     pneumonia (PJP).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 310888,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019121",
-          "name": "pneumocystosis",
-          "description": "Pneumonia resulting from infection with Pneumocystis jirovecii, frequently seen in the immunologically compromised, such as persons with AIDS, or steroid-treated individuals, the elderly, or premature or debilitated babies during their first three months. Patients may be only slightly febrile (or even afebrile), but are likely to be extremely weak, dyspneic, and cyanotic. This is a major cause of morbidity among patients with AIDS.; A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.; Pneumocystis carinii pneumonia is an opportunistic infection that occurs in immunosuppressed populations. [PMID:10537385]; An opportunistic disease caused by invasion of unicellular fungus Pneumocystis jirovecii. Transmission of P. jirovecii cysts takes place through the airborne route, and usually, its presence in lungs is asymptomatic. However, people with impaired immunity, especially those with CD4+ T cell count below 200/microliter, are still at risk of the development of Pneumocystis pneumonia due to P. jirovecii invasion. Symptoms induced by this disease are not specific: progressive dyspnoea, non-productive cough, low-grade fever, arterial partial pressure of oxygen below 65 mmHg, and chest radiographs demonstrating bilateral, interstitial shadowing. [PMID:26281787]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:415125002",
-            "MESH:D011020",
-            "MEDDRA:10035661",
-            "HP:0034286",
-            "SNOMEDCT:88860002",
-            "MEDDRA:10035662",
-            "ICD9:136.3",
-            "UMLS:C1535939",
-            "ORPHANET:723",
-            "MEDDRA:10051460",
-            "DOID:11339",
-            "MEDDRA:10064108",
-            "MONDO:0019121",
-            "EFO:0007448",
-            "MEDDRA:10073755",
-            "ICD10:B59",
-            "MEDDRA:10035659",
-            "NCIT:C3334"
-          ],
-          "id": "MONDO:0019121",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumocystis carinii pneumonia",
-            "Pneumocystosis",
-            "Pneumocystis Pneumonia",
-            "Pneumocystis jiroveci pneumonia",
-            "pneumocystosis",
-            "Pneumonia, Pneumocystis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=pneumocystis%20carinii%20pneumonia",
-            "PMID:10537385",
-            "https://rarediseases.info.nih.gov/diseases/4386/pneumocystosis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000671.htm",
-            "PMID:26281787"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310888,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019121",
-              "name": "pneumocystosis",
-              "description": "Pneumonia resulting from infection with Pneumocystis jirovecii, frequently seen in the immunologically compromised, such as persons with AIDS, or steroid-treated individuals, the elderly, or premature or debilitated babies during their first three months. Patients may be only slightly febrile (or even afebrile), but are likely to be extremely weak, dyspneic, and cyanotic. This is a major cause of morbidity among patients with AIDS.; A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.; Pneumocystis carinii pneumonia is an opportunistic infection that occurs in immunosuppressed populations. [PMID:10537385]; An opportunistic disease caused by invasion of unicellular fungus Pneumocystis jirovecii. Transmission of P. jirovecii cysts takes place through the airborne route, and usually, its presence in lungs is asymptomatic. However, people with impaired immunity, especially those with CD4+ T cell count below 200/microliter, are still at risk of the development of Pneumocystis pneumonia due to P. jirovecii invasion. Symptoms induced by this disease are not specific: progressive dyspnoea, non-productive cough, low-grade fever, arterial partial pressure of oxygen below 65 mmHg, and chest radiographs demonstrating bilateral, interstitial shadowing. [PMID:26281787]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:415125002",
-                "MESH:D011020",
-                "MEDDRA:10035661",
-                "HP:0034286",
-                "SNOMEDCT:88860002",
-                "MEDDRA:10035662",
-                "ICD9:136.3",
-                "UMLS:C1535939",
-                "ORPHANET:723",
-                "MEDDRA:10051460",
-                "DOID:11339",
-                "MEDDRA:10064108",
-                "MONDO:0019121",
-                "EFO:0007448",
-                "MEDDRA:10073755",
-                "ICD10:B59",
-                "MEDDRA:10035659",
-                "NCIT:C3334"
-              ],
-              "id": "MONDO:0019121",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumocystis carinii pneumonia",
-                "Pneumocystosis",
-                "Pneumocystis Pneumonia",
-                "Pneumocystis jiroveci pneumonia",
-                "pneumocystosis",
-                "Pneumonia, Pneumocystis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=pneumocystis%20carinii%20pneumonia",
-                "PMID:10537385",
-                "https://rarediseases.info.nih.gov/diseases/4386/pneumocystosis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000671.htm",
-                "PMID:26281787"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22686548,
-            "start": 570,
-            "end": 310888,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:33692629': {'publication date': '2021', 'sentence': 'Caspofungin, TMP-SMX, clindamycin and MP were used to treat    P. jirovecii     pneumonia (PJP).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C1535939---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "23116362",
-              "object": "MONDO:0019121",
-              "publications": [
-                "PMID:33692629"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10571336': {'publication date': '1999 Nov', 'sentence': 'CONCLUSIONS: The ONTT has led to a dramatic reduction in the use of oral prednisone without a preceding course of intravenous methylprednisolone in the treatment of acute optic neuritis.', 'subject score': 888, 'object score': 901}, 'PMID:11389809': {'publication date': '2001 Jul', 'sentence': 'In all cases of typical acute monosymptomatic demyelinating optic neuritis, oral prednisone alone at a dose of 1 mg/kg per day, without prior treatment with IV methylprednisolone (1 g per day for 3 days), may increase the risk for recurrent optic neuritis, and should be avoided.', 'subject score': 888, 'object score': 787}, 'PMID:11784351': {'publication date': '2001 Nov', 'sentence': 'Here, we report a serial analysis of CSF CXCL10 and CCL2 concentrations in 22 patients with attacks of MS or acute optic neuritis (ON) treated with methylprednisolone, and 26 patients treated with placebo in two randomized controlled trials.', 'subject score': 1000, 'object score': 901}, 'PMID:11960657': {'publication date': '2002 Apr', 'sentence': 'Cerebrospinal fluid levels of nitric oxide metabolites predict response to methylprednisolone treatment in multiple sclerosis and optic neuritis.', 'subject score': 888, 'object score': 1000}, 'PMID:12757063': {'publication date': '2003 Mar', 'sentence': 'OBJECTIVE: To determine clinical characteristics of patients with optic neuritis and visual outcome after intravenous methylprednisolone treatment.', 'subject score': 851, 'object score': 1000}, 'PMID:17699944': {'publication date': '2007 Sep-Oct', 'sentence': 'AIM: To compare the efficacy of intravenous methylprednisolone and intravenous dexamethasone on visual recovery and evaluate their side-effects for the treatment of optic neuritis.', 'subject score': 888, 'object score': 1000}, 'PMID:18586870': {'publication date': '2008 Nov', 'sentence': 'PURPOSE: Methylprednisolone (MP) is commonly used to treat traumatic optic neuropathy and optic neuritis, but its benefit in terms of neuronal survival remains controversial.', 'subject score': 1000, 'object score': 1000}, 'PMID:22169982': {'publication date': '2012 Jun', 'sentence': 'Eight patients with documented idiopathic unilateral optic neuritis who did not improve with methyl prednisolone followed by oral steroids as per the Optic Neuritis Treatment Trial (ONTT) were administered Mw 5 ml in 500 ml normal saline, 30 days after the last of dose of steroids had been administered.', 'subject score': 1000, 'object score': 861}, 'PMID:22888383': {'publication date': '2012', 'sentence': 'According to Optic Neuritis Treatment Trial (ONTT) the first line of treatment is intravenous methylprednisolone with faster recovery and less chance of recurrence of ON and conversion to MS.', 'subject score': 888, 'object score': 861}, 'PMID:25605544': {'publication date': '2015 May', 'sentence': 'PURPOSE: To compare the effect of adding recombinant human erythropoietin (rhEPO) to intravenous methylprednisolone for the treatment of unilateral acute optic neuritis of unknown or demyelinative origin on the logarithm of the minimum angle of resolution (logMAR), perimetric variables [mean deviation (MD) and pattern standard deviation (PSD)], and retinal nerve fiber layer (RNFL) thickness in optical coherence tomography (OCT).', 'subject score': 888, 'object score': 861}, 'PMID:27566880': {'publication date': '2016 Oct', 'sentence': 'METHODS: This retrospective descriptive monocentric study included nine patients with ON treated with orally administered methylprednisolone at 1000 mg per day for three to five days.', 'subject score': 827, 'object score': 1000}, 'PMID:30268104': {'publication date': '2018 Sep 29', 'sentence': 'METHODS: Retrospective analysis of patients treated with oral or intravenous high-dose (?500 mg per day) methylprednisolone for acute ON of unknown or demyelinating etiology.', 'subject score': 1000, 'object score': 901}, 'PMID:30487360': {'publication date': '2018 Nov 29', 'sentence': 'Although treatment with methylprednisolone therapy provided relief, 3 months later she developed optic neuritis on the other side.', 'subject score': 888, 'object score': 1000}, 'PMID:35849047': {'publication date': '2022 Jul 14', 'sentence': 'He had been hospitalized two weeks prior for optic neuritis and treated with intravenous methylprednisolone.', 'subject score': 888, 'object score': 1000}, 'PMID:35859635': {'publication date': '2022', 'sentence': 'For each recurrent episode of optic neuritis she was treated with intravenous methylprednisolone, following which visual acuity, colour vision, and visual field improved to normal.', 'subject score': 888, 'object score': 1000}, 'PMID:36977296': {'publication date': '2023 Feb 28', 'sentence': 'Early treatment with intravenous methylprednisolone may be important for achieving at least 0.3 logMAR visual recovery in Thai patients with optic neuritis.', 'subject score': 888, 'object score': 1000}, 'PMID:37094997': {'publication date': '2023 Jul', 'sentence': 'We assessed its long-term safety and efficacy as an adjunct to methylprednisolone in patients with optic neuritis and focused on conversions to multiple sclerosis (MS).', 'subject score': 1000, 'object score': 1000}, 'PMID:3940867': {'publication date': '1986', 'sentence': 'We studied 8 patients with definite multiple sclerosis (3 with acute relapse, 5 with progression), and 2 patients with acute optic neuritis, who were treated with methylprednisolone infusions, 1 g daily for 3 days.', 'subject score': 872, 'object score': 901}, 'PMID:8481565': {'publication date': '1993 Apr', 'sentence': 'Methylprednisolone may have a minor role in the treatment of very severe, acute optic neuritis but prednisone use may predispose patients to recurrent optic neuritis.', 'subject score': 1000, 'object score': 840}, 'PMID:8813496': {'publication date': '1995-1996', 'sentence': 'Forty-eight patients with acute optic neuritis were treated orally either with methylprednisolone (100 mg per day initially, dosage reduction every 3 days; n = 15) or with thiamine (100 mg per day; n = 33) in the control group, 36 of them in a double-blind procedure.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 318789,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005885",
-          "name": "optic neuritis",
-          "description": "A disorder characterized by inflammation of the optic nerve. Causes include autoimmune disorders, infections, toxins, drugs, and multiple sclerosis. It may manifest with acute loss of vision and pain.; Inflammation of the optic nerve. Commonly associated conditions include autoimmune disorders such as MULTIPLE SCLEROSIS, infections, and granulomatous diseases. Clinical features include retro-orbital pain that is aggravated by eye movement, loss of color vision, and contrast sensitivity that may progress to severe visual loss, an afferent pupillary defect (Marcus-Gunn pupil), and in some instances optic disc hyperemia and swelling. Inflammation may occur in the portion of the nerve within the globe (neuropapillitis or anterior optic neuritis) or the portion behind the globe (retrobulbar neuritis or posterior optic neuritis).; Inflammation of the optic nerve. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D009902",
-            "NCIT:C84950",
-            "DOID:1210",
-            "HP:0100653",
-            "ICD10:H46",
-            "MEDDRA:10030942",
-            "MONDO:0005885",
-            "UMLS:C0029134",
-            "EFO:0007405",
-            "MEDDRA:10030946",
-            "ICD9:377.3",
-            "MEDDRA:10029247",
-            "MEDDRA:10030944",
-            "SNOMEDCT:66760008"
-          ],
-          "id": "MONDO:0005885",
-          "category": "biolink:Disease",
-          "all_names": [
-            "optic neuritis",
-            "Optic neuritis",
-            "Optic Neuritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.mayoclinic.org/diseases-conditions/optic-neuritis/symptoms-causes/syc-20354953",
-            "https://rarediseases.info.nih.gov/diseases/7320/optic-neuritis",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318789,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005885",
-              "name": "optic neuritis",
-              "description": "A disorder characterized by inflammation of the optic nerve. Causes include autoimmune disorders, infections, toxins, drugs, and multiple sclerosis. It may manifest with acute loss of vision and pain.; Inflammation of the optic nerve. Commonly associated conditions include autoimmune disorders such as MULTIPLE SCLEROSIS, infections, and granulomatous diseases. Clinical features include retro-orbital pain that is aggravated by eye movement, loss of color vision, and contrast sensitivity that may progress to severe visual loss, an afferent pupillary defect (Marcus-Gunn pupil), and in some instances optic disc hyperemia and swelling. Inflammation may occur in the portion of the nerve within the globe (neuropapillitis or anterior optic neuritis) or the portion behind the globe (retrobulbar neuritis or posterior optic neuritis).; Inflammation of the optic nerve. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D009902",
-                "NCIT:C84950",
-                "DOID:1210",
-                "HP:0100653",
-                "ICD10:H46",
-                "MEDDRA:10030942",
-                "MONDO:0005885",
-                "UMLS:C0029134",
-                "EFO:0007405",
-                "MEDDRA:10030946",
-                "ICD9:377.3",
-                "MEDDRA:10029247",
-                "MEDDRA:10030944",
-                "SNOMEDCT:66760008"
-              ],
-              "id": "MONDO:0005885",
-              "category": "biolink:Disease",
-              "all_names": [
-                "optic neuritis",
-                "Optic neuritis",
-                "Optic Neuritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.mayoclinic.org/diseases-conditions/optic-neuritis/symptoms-causes/syc-20354953",
-                "https://rarediseases.info.nih.gov/diseases/7320/optic-neuritis",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7665184,
-            "start": 570,
-            "end": 318789,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10571336': {'publication date': '1999 Nov', 'sentence': 'CONCLUSIONS: The ONTT has led to a dramatic reduction in the use of oral prednisone without a preceding course of intravenous methylprednisolone in the treatment of acute optic neuritis.', 'subject score': 888, 'object score': 901}, 'PMID:11389809': {'publication date': '2001 Jul', 'sentence': 'In all cases of typical acute monosymptomatic demyelinating optic neuritis, oral prednisone alone at a dose of 1 mg/kg per day, without prior treatment with IV methylprednisolone (1 g per day for 3 days), may increase the risk for recurrent optic neuritis, and should be avoided.', 'subject score': 888, 'object score': 787}, 'PMID:11784351': {'publication date': '2001 Nov', 'sentence': 'Here, we report a serial analysis of CSF CXCL10 and CCL2 concentrations in 22 patients with attacks of MS or acute optic neuritis (ON) treated with methylprednisolone, and 26 patients treated with placebo in two randomized controlled trials.', 'subject score': 1000, 'object score': 901}, 'PMID:11960657': {'publication date': '2002 Apr', 'sentence': 'Cerebrospinal fluid levels of nitric oxide metabolites predict response to methylprednisolone treatment in multiple sclerosis and optic neuritis.', 'subject score': 888, 'object score': 1000}, 'PMID:12757063': {'publication date': '2003 Mar', 'sentence': 'OBJECTIVE: To determine clinical characteristics of patients with optic neuritis and visual outcome after intravenous methylprednisolone treatment.', 'subject score': 851, 'object score': 1000}, 'PMID:17699944': {'publication date': '2007 Sep-Oct', 'sentence': 'AIM: To compare the efficacy of intravenous methylprednisolone and intravenous dexamethasone on visual recovery and evaluate their side-effects for the treatment of optic neuritis.', 'subject score': 888, 'object score': 1000}, 'PMID:18586870': {'publication date': '2008 Nov', 'sentence': 'PURPOSE: Methylprednisolone (MP) is commonly used to treat traumatic optic neuropathy and optic neuritis, but its benefit in terms of neuronal survival remains controversial.', 'subject score': 1000, 'object score': 1000}, 'PMID:22169982': {'publication date': '2012 Jun', 'sentence': 'Eight patients with documented idiopathic unilateral optic neuritis who did not improve with methyl prednisolone followed by oral steroids as per the Optic Neuritis Treatment Trial (ONTT) were administered Mw 5 ml in 500 ml normal saline, 30 days after the last of dose of steroids had been administered.', 'subject score': 1000, 'object score': 861}, 'PMID:22888383': {'publication date': '2012', 'sentence': 'According to Optic Neuritis Treatment Trial (ONTT) the first line of treatment is intravenous methylprednisolone with faster recovery and less chance of recurrence of ON and conversion to MS.', 'subject score': 888, 'object score': 861}, 'PMID:25605544': {'publication date': '2015 May', 'sentence': 'PURPOSE: To compare the effect of adding recombinant human erythropoietin (rhEPO) to intravenous methylprednisolone for the treatment of unilateral acute optic neuritis of unknown or demyelinative origin on the logarithm of the minimum angle of resolution (logMAR), perimetric variables [mean deviation (MD) and pattern standard deviation (PSD)], and retinal nerve fiber layer (RNFL) thickness in optical coherence tomography (OCT).', 'subject score': 888, 'object score': 861}, 'PMID:27566880': {'publication date': '2016 Oct', 'sentence': 'METHODS: This retrospective descriptive monocentric study included nine patients with ON treated with orally administered methylprednisolone at 1000 mg per day for three to five days.', 'subject score': 827, 'object score': 1000}, 'PMID:30268104': {'publication date': '2018 Sep 29', 'sentence': 'METHODS: Retrospective analysis of patients treated with oral or intravenous high-dose (?500 mg per day) methylprednisolone for acute ON of unknown or demyelinating etiology.', 'subject score': 1000, 'object score': 901}, 'PMID:30487360': {'publication date': '2018 Nov 29', 'sentence': 'Although treatment with methylprednisolone therapy provided relief, 3 months later she developed optic neuritis on the other side.', 'subject score': 888, 'object score': 1000}, 'PMID:35849047': {'publication date': '2022 Jul 14', 'sentence': 'He had been hospitalized two weeks prior for optic neuritis and treated with intravenous methylprednisolone.', 'subject score': 888, 'object score': 1000}, 'PMID:35859635': {'publication date': '2022', 'sentence': 'For each recurrent episode of optic neuritis she was treated with intravenous methylprednisolone, following which visual acuity, colour vision, and visual field improved to normal.', 'subject score': 888, 'object score': 1000}, 'PMID:36977296': {'publication date': '2023 Feb 28', 'sentence': 'Early treatment with intravenous methylprednisolone may be important for achieving at least 0.3 logMAR visual recovery in Thai patients with optic neuritis.', 'subject score': 888, 'object score': 1000}, 'PMID:37094997': {'publication date': '2023 Jul', 'sentence': 'We assessed its long-term safety and efficacy as an adjunct to methylprednisolone in patients with optic neuritis and focused on conversions to multiple sclerosis (MS).', 'subject score': 1000, 'object score': 1000}, 'PMID:3940867': {'publication date': '1986', 'sentence': 'We studied 8 patients with definite multiple sclerosis (3 with acute relapse, 5 with progression), and 2 patients with acute optic neuritis, who were treated with methylprednisolone infusions, 1 g daily for 3 days.', 'subject score': 872, 'object score': 901}, 'PMID:8481565': {'publication date': '1993 Apr', 'sentence': 'Methylprednisolone may have a minor role in the treatment of very severe, acute optic neuritis but prednisone use may predispose patients to recurrent optic neuritis.', 'subject score': 1000, 'object score': 840}, 'PMID:8813496': {'publication date': '1995-1996', 'sentence': 'Forty-eight patients with acute optic neuritis were treated orally either with methylprednisolone (100 mg per day initially, dosage reduction every 3 days; n = 15) or with thiamine (100 mg per day; n = 33) in the control group, 36 of them in a double-blind procedure.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0029134---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7827490",
-              "object": "MONDO:0005885",
-              "publications": [
-                "PMID:10571336",
-                "PMID:11389809",
-                "PMID:11784351",
-                "PMID:11960657",
-                "PMID:12757063",
-                "PMID:17699944",
-                "PMID:18586870",
-                "PMID:22169982",
-                "PMID:22888383",
-                "PMID:25605544",
-                "PMID:27566880",
-                "PMID:30268104",
-                "PMID:30487360",
-                "PMID:35849047",
-                "PMID:35859635",
-                "PMID:36977296",
-                "PMID:37094997",
-                "PMID:3940867",
-                "PMID:8481565",
-                "PMID:8813496"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12895319': {'publication date': '2003 Jun', 'sentence': 'Twenty-nine of the 30 SARS patients were treated by methylprednisolone.', 'subject score': 1000, 'object score': 790}, 'PMID:15059370': {'publication date': '2004 Mar', 'sentence': 'CONCLUSIONS: Over-dose administration of methylprednisolone in SARS patients leads to a high frequency of diabetes.', 'subject score': 1000, 'object score': 888}, 'PMID:15214887': {'publication date': '2004 Jul', 'sentence': 'Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients.', 'subject score': 831, 'object score': 888}, 'PMID:15254615': {'publication date': '2004', 'sentence': 'High dose intravenous methylprednisolone in the treatment of severe acute respiratory syndrome.', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 523855,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005091",
-          "name": "severe acute respiratory syndrome",
-          "description": "A viral respiratory infection caused by the SARS coronavirus. It is transmitted through close person-to-person contact. It is manifested with high fever, headache, dry cough and myalgias. It may progress to pneumonia and cause death.; A viral disorder characterized by high FEVER, dry COUGH, shortness of breath (DYSPNEA) or breathing difficulties, and atypical PNEUMONIA. A virus in the genus CORONAVIRUS is the suspected agent.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10061986",
-            "UMLS:C1175175",
-            "NCIT:C85064",
-            "ICD9:079.82",
-            "ICD10:J12.81",
-            "MONDO:0005091",
-            "MEDDRA:10084784",
-            "SNOMEDCT:398447004",
-            "MESH:D045169",
-            "DOID:2945",
-            "ORPHANET:140896",
-            "EFO:0000694",
-            "MEDDRA:10061982"
-          ],
-          "id": "MONDO:0005091",
-          "category": "biolink:Disease",
-          "all_names": [
-            "SARS-associated coronavirus",
-            "Acute respiratory coronavirus infection",
-            "severe acute respiratory syndrome",
-            "Severe Acute Respiratory Syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/severe_acute_respiratory_syndrome",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=sars"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 523855,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005091",
-              "name": "severe acute respiratory syndrome",
-              "description": "A viral respiratory infection caused by the SARS coronavirus. It is transmitted through close person-to-person contact. It is manifested with high fever, headache, dry cough and myalgias. It may progress to pneumonia and cause death.; A viral disorder characterized by high FEVER, dry COUGH, shortness of breath (DYSPNEA) or breathing difficulties, and atypical PNEUMONIA. A virus in the genus CORONAVIRUS is the suspected agent.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10061986",
-                "UMLS:C1175175",
-                "NCIT:C85064",
-                "ICD9:079.82",
-                "ICD10:J12.81",
-                "MONDO:0005091",
-                "MEDDRA:10084784",
-                "SNOMEDCT:398447004",
-                "MESH:D045169",
-                "DOID:2945",
-                "ORPHANET:140896",
-                "EFO:0000694",
-                "MEDDRA:10061982"
-              ],
-              "id": "MONDO:0005091",
-              "category": "biolink:Disease",
-              "all_names": [
-                "SARS-associated coronavirus",
-                "Acute respiratory coronavirus infection",
-                "severe acute respiratory syndrome",
-                "Severe Acute Respiratory Syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/severe_acute_respiratory_syndrome",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=sars"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10117350,
-            "start": 570,
-            "end": 523855,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12895319': {'publication date': '2003 Jun', 'sentence': 'Twenty-nine of the 30 SARS patients were treated by methylprednisolone.', 'subject score': 1000, 'object score': 790}, 'PMID:15059370': {'publication date': '2004 Mar', 'sentence': 'CONCLUSIONS: Over-dose administration of methylprednisolone in SARS patients leads to a high frequency of diabetes.', 'subject score': 1000, 'object score': 888}, 'PMID:15214887': {'publication date': '2004 Jul', 'sentence': 'Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients.', 'subject score': 831, 'object score': 888}, 'PMID:15254615': {'publication date': '2004', 'sentence': 'High dose intravenous methylprednisolone in the treatment of severe acute respiratory syndrome.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C1175175---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10341065",
-              "object": "MONDO:0005091",
-              "publications": [
-                "PMID:12895319",
-                "PMID:15059370",
-                "PMID:15214887",
-                "PMID:15254615"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:27888990': {'publication date': '2016 12', 'sentence': 'CONCLUSION: Results show that inhalation of budesonide (2 mg 3 times/day) and systemic methylprednisolone (40 mg/day) had similar clinical outcome in AECOPD.', 'subject score': 888, 'object score': 833}, 'PMID:31308569': {'publication date': '2019 Jul', 'sentence': 'Single Intramuscular Methylprednisolone dose in Asthma and Chronic Obstructive Pulmonary Disease Patients on Discharge.', 'subject score': 833, 'object score': 928}}",
-    "p2": {
-      "start": {
-        "identity": 324986,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-          "name": "chronic obstructive pulmonary disease",
-          "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-          "equivalent_curies": [
-            "MESH:D029424",
-            "MEDDRA:10010952",
-            "MEDDRA:10009025",
-            "ICD10:J44.9",
-            "UMLS:C1527303",
-            "NCIT:C3199",
-            "UMLS:C0024117",
-            "MEDDRA:10064611",
-            "MEDDRA:10009026",
-            "MEDDRA:10029972",
-            "DOID:3083",
-            "MONDO:0005002",
-            "MEDDRA:10009032",
-            "MEDDRA:10070975",
-            "EFO:0000341",
-            "SNOMEDCT:13645005",
-            "MEDDRA:10009033",
-            "HP:0006510",
-            "MEDDRA:10008828"
-          ],
-          "id": "MONDO:0005002",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic Obstructive Pulmonary Disease",
-            "chronic obstructive pulmonary disease",
-            "Chronic pulmonary obstruction",
-            "Chronic Airflow Obstruction",
-            "Chronic Obstructive Airway Disease",
-            "Pulmonary Disease, Chronic Obstructive"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health-topics/copd",
-            "PMID:32800196",
-            "PMID:28513453",
-            "PMID:25943942",
-            "PMID:32745458"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 324986,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-              "name": "chronic obstructive pulmonary disease",
-              "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-              "equivalent_curies": [
-                "MESH:D029424",
-                "MEDDRA:10010952",
-                "MEDDRA:10009025",
-                "ICD10:J44.9",
-                "UMLS:C1527303",
-                "NCIT:C3199",
-                "UMLS:C0024117",
-                "MEDDRA:10064611",
-                "MEDDRA:10009026",
-                "MEDDRA:10029972",
-                "DOID:3083",
-                "MONDO:0005002",
-                "MEDDRA:10009032",
-                "MEDDRA:10070975",
-                "EFO:0000341",
-                "SNOMEDCT:13645005",
-                "MEDDRA:10009033",
-                "HP:0006510",
-                "MEDDRA:10008828"
-              ],
-              "id": "MONDO:0005002",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic Obstructive Pulmonary Disease",
-                "chronic obstructive pulmonary disease",
-                "Chronic pulmonary obstruction",
-                "Chronic Airflow Obstruction",
-                "Chronic Obstructive Airway Disease",
-                "Pulmonary Disease, Chronic Obstructive"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health-topics/copd",
-                "PMID:32800196",
-                "PMID:28513453",
-                "PMID:25943942",
-                "PMID:32745458"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18959476,
-            "start": 570,
-            "end": 324986,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27888990': {'publication date': '2016 12', 'sentence': 'CONCLUSION: Results show that inhalation of budesonide (2 mg 3 times/day) and systemic methylprednisolone (40 mg/day) had similar clinical outcome in AECOPD.', 'subject score': 888, 'object score': 833}, 'PMID:31308569': {'publication date': '2019 Jul', 'sentence': 'Single Intramuscular Methylprednisolone dose in Asthma and Chronic Obstructive Pulmonary Disease Patients on Discharge.', 'subject score': 833, 'object score': 928}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0024117---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "19340184",
-              "object": "MONDO:0005002",
-              "publications": [
-                "PMID:27888990",
-                "PMID:31308569"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:11812271': {'publication date': '2002 Feb', 'sentence': 'OBJECTIVE: Compare the therapeutic efficacy of an oral/metered-dose inhaler (oral/MDI) regimen to an intravenous/nebulizer (I.V./neb) regimen of methylprednisolone, cefuroxime, and inhaled albuterol and ipratropium bromide in patients hospitalized for exacerbations of chronic obstructive pulmonary disease (COPD).', 'subject score': 1000, 'object score': 1000}, 'PMID:12753536': {'publication date': '2003 Jun', 'sentence': 'CONCLUSIONS: An adequate and tapering dose of MP used in acute exacerbations of COPD can relieve the inflammatory reaction in airways and reduce airway spasm more promptly than DXM.', 'subject score': 1000, 'object score': 1000}, 'PMID:28286842': {'publication date': '2017', 'sentence': 'Methyl prednisolone vs Dexamethasone in Management of COPD Exacerbation; a Randomized Clinical Trial.', 'subject score': 1000, 'object score': 771}}",
-    "p2": {
-      "start": {
-        "identity": 324986,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-          "name": "chronic obstructive pulmonary disease",
-          "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-          "equivalent_curies": [
-            "MESH:D029424",
-            "MEDDRA:10010952",
-            "MEDDRA:10009025",
-            "ICD10:J44.9",
-            "UMLS:C1527303",
-            "NCIT:C3199",
-            "UMLS:C0024117",
-            "MEDDRA:10064611",
-            "MEDDRA:10009026",
-            "MEDDRA:10029972",
-            "DOID:3083",
-            "MONDO:0005002",
-            "MEDDRA:10009032",
-            "MEDDRA:10070975",
-            "EFO:0000341",
-            "SNOMEDCT:13645005",
-            "MEDDRA:10009033",
-            "HP:0006510",
-            "MEDDRA:10008828"
-          ],
-          "id": "MONDO:0005002",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic Obstructive Pulmonary Disease",
-            "chronic obstructive pulmonary disease",
-            "Chronic pulmonary obstruction",
-            "Chronic Airflow Obstruction",
-            "Chronic Obstructive Airway Disease",
-            "Pulmonary Disease, Chronic Obstructive"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health-topics/copd",
-            "PMID:32800196",
-            "PMID:28513453",
-            "PMID:25943942",
-            "PMID:32745458"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 324986,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-              "name": "chronic obstructive pulmonary disease",
-              "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-              "equivalent_curies": [
-                "MESH:D029424",
-                "MEDDRA:10010952",
-                "MEDDRA:10009025",
-                "ICD10:J44.9",
-                "UMLS:C1527303",
-                "NCIT:C3199",
-                "UMLS:C0024117",
-                "MEDDRA:10064611",
-                "MEDDRA:10009026",
-                "MEDDRA:10029972",
-                "DOID:3083",
-                "MONDO:0005002",
-                "MEDDRA:10009032",
-                "MEDDRA:10070975",
-                "EFO:0000341",
-                "SNOMEDCT:13645005",
-                "MEDDRA:10009033",
-                "HP:0006510",
-                "MEDDRA:10008828"
-              ],
-              "id": "MONDO:0005002",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic Obstructive Pulmonary Disease",
-                "chronic obstructive pulmonary disease",
-                "Chronic pulmonary obstruction",
-                "Chronic Airflow Obstruction",
-                "Chronic Obstructive Airway Disease",
-                "Pulmonary Disease, Chronic Obstructive"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health-topics/copd",
-                "PMID:32800196",
-                "PMID:28513453",
-                "PMID:25943942",
-                "PMID:32745458"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9144854,
-            "start": 570,
-            "end": 324986,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11812271': {'publication date': '2002 Feb', 'sentence': 'OBJECTIVE: Compare the therapeutic efficacy of an oral/metered-dose inhaler (oral/MDI) regimen to an intravenous/nebulizer (I.V./neb) regimen of methylprednisolone, cefuroxime, and inhaled albuterol and ipratropium bromide in patients hospitalized for exacerbations of chronic obstructive pulmonary disease (COPD).', 'subject score': 1000, 'object score': 1000}, 'PMID:12753536': {'publication date': '2003 Jun', 'sentence': 'CONCLUSIONS: An adequate and tapering dose of MP used in acute exacerbations of COPD can relieve the inflammatory reaction in airways and reduce airway spasm more promptly than DXM.', 'subject score': 1000, 'object score': 1000}, 'PMID:28286842': {'publication date': '2017', 'sentence': 'Methyl prednisolone vs Dexamethasone in Management of COPD Exacerbation; a Randomized Clinical Trial.', 'subject score': 1000, 'object score': 771}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0024117---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "9346353",
-              "object": "MONDO:0005002",
-              "publications": [
-                "PMID:11812271",
-                "PMID:12753536",
-                "PMID:28286842"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:18306904': {'publication date': '2007 Nov-Dec', 'sentence': 'In conclusion, methylprednisolone in combination with conventional medical therapy not only improved lung function values but also mean nocturnal oxyhemoglobin saturation and sleep duration in clinically stabilized COPD patients who experience nocturnal oxyhemoglobin desaturation.', 'subject score': 1000, 'object score': 775}, 'PMID:21756523': {'publication date': '2011 May', 'sentence': 'OBJECTIVE: To compare intravenous (IV) methylprednisolone (MP) followed by oral MP with IV hydrocortisone (HC) followed by oral prednisolone in patients with AECOPD.', 'subject score': 888, 'object score': 833}, 'PMID:35129068': {'publication date': '2022 Feb', 'sentence': 'We carried out this study with the aim of exploring the underlying mechanism of methylprednisolone (MP) treating the COPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:36176448': {'publication date': '2022', 'sentence': 'Objective:     To assess the cost-effectiveness of nebulized budesonide and intravenous methylprednisolone in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in a real-world setting.', 'subject score': 888, 'object score': 805}, 'PMID:36242002': {'publication date': '2022 Oct 14', 'sentence': 'After Methylprednisolone treatment of acute exacerbated COPD patients, however, the mitotic effect was further amplified, but it was followed by a deficient differentiation capacity.', 'subject score': 888, 'object score': 863}, 'PMID:7032378': {'publication date': '1982 Jan', 'sentence': 'We compared a 2-week course of 32 mg/d methylprednisolone with placebo in a double-blind crossover trial in 46 well-characterized patients with stable chronic obstructive pulmonary disease.', 'subject score': 763, 'object score': 937}}",
-    "p2": {
-      "start": {
-        "identity": 324986,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-          "name": "chronic obstructive pulmonary disease",
-          "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-          "equivalent_curies": [
-            "MESH:D029424",
-            "MEDDRA:10010952",
-            "MEDDRA:10009025",
-            "ICD10:J44.9",
-            "UMLS:C1527303",
-            "NCIT:C3199",
-            "UMLS:C0024117",
-            "MEDDRA:10064611",
-            "MEDDRA:10009026",
-            "MEDDRA:10029972",
-            "DOID:3083",
-            "MONDO:0005002",
-            "MEDDRA:10009032",
-            "MEDDRA:10070975",
-            "EFO:0000341",
-            "SNOMEDCT:13645005",
-            "MEDDRA:10009033",
-            "HP:0006510",
-            "MEDDRA:10008828"
-          ],
-          "id": "MONDO:0005002",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic Obstructive Pulmonary Disease",
-            "chronic obstructive pulmonary disease",
-            "Chronic pulmonary obstruction",
-            "Chronic Airflow Obstruction",
-            "Chronic Obstructive Airway Disease",
-            "Pulmonary Disease, Chronic Obstructive"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health-topics/copd",
-            "PMID:32800196",
-            "PMID:28513453",
-            "PMID:25943942",
-            "PMID:32745458"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 324986,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-              "name": "chronic obstructive pulmonary disease",
-              "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-              "equivalent_curies": [
-                "MESH:D029424",
-                "MEDDRA:10010952",
-                "MEDDRA:10009025",
-                "ICD10:J44.9",
-                "UMLS:C1527303",
-                "NCIT:C3199",
-                "UMLS:C0024117",
-                "MEDDRA:10064611",
-                "MEDDRA:10009026",
-                "MEDDRA:10029972",
-                "DOID:3083",
-                "MONDO:0005002",
-                "MEDDRA:10009032",
-                "MEDDRA:10070975",
-                "EFO:0000341",
-                "SNOMEDCT:13645005",
-                "MEDDRA:10009033",
-                "HP:0006510",
-                "MEDDRA:10008828"
-              ],
-              "id": "MONDO:0005002",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic Obstructive Pulmonary Disease",
-                "chronic obstructive pulmonary disease",
-                "Chronic pulmonary obstruction",
-                "Chronic Airflow Obstruction",
-                "Chronic Obstructive Airway Disease",
-                "Pulmonary Disease, Chronic Obstructive"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health-topics/copd",
-                "PMID:32800196",
-                "PMID:28513453",
-                "PMID:25943942",
-                "PMID:32745458"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13332831,
-            "start": 570,
-            "end": 324986,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18306904': {'publication date': '2007 Nov-Dec', 'sentence': 'In conclusion, methylprednisolone in combination with conventional medical therapy not only improved lung function values but also mean nocturnal oxyhemoglobin saturation and sleep duration in clinically stabilized COPD patients who experience nocturnal oxyhemoglobin desaturation.', 'subject score': 1000, 'object score': 775}, 'PMID:21756523': {'publication date': '2011 May', 'sentence': 'OBJECTIVE: To compare intravenous (IV) methylprednisolone (MP) followed by oral MP with IV hydrocortisone (HC) followed by oral prednisolone in patients with AECOPD.', 'subject score': 888, 'object score': 833}, 'PMID:35129068': {'publication date': '2022 Feb', 'sentence': 'We carried out this study with the aim of exploring the underlying mechanism of methylprednisolone (MP) treating the COPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:36176448': {'publication date': '2022', 'sentence': 'Objective:     To assess the cost-effectiveness of nebulized budesonide and intravenous methylprednisolone in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in a real-world setting.', 'subject score': 888, 'object score': 805}, 'PMID:36242002': {'publication date': '2022 Oct 14', 'sentence': 'After Methylprednisolone treatment of acute exacerbated COPD patients, however, the mitotic effect was further amplified, but it was followed by a deficient differentiation capacity.', 'subject score': 888, 'object score': 863}, 'PMID:7032378': {'publication date': '1982 Jan', 'sentence': 'We compared a 2-week course of 32 mg/d methylprednisolone with placebo in a double-blind crossover trial in 46 well-characterized patients with stable chronic obstructive pulmonary disease.', 'subject score': 763, 'object score': 937}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0024117---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "13619118",
-              "object": "MONDO:0005002",
-              "publications": [
-                "PMID:18306904",
-                "PMID:21756523",
-                "PMID:35129068",
-                "PMID:36176448",
-                "PMID:36242002",
-                "PMID:7032378"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:19139319': {'publication date': '2009 Jan 12', 'sentence': 'CONCLUSION: In this single-center trial, combined vasopressin-epinephrine and methylprednisolone during resuscitation and stress-dose hydrocortisone in postresuscitation shock improved survival in refractory in-hospital cardiac arrest.', 'subject score': 1000, 'object score': 794}}",
-    "p2": {
-      "start": {
-        "identity": 318021,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000745",
-          "name": "cardiac arrest",
-          "description": "The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.; Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.; An abrupt loss of heart function. []; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:0060319",
-            "ICD10:I46",
-            "MEDDRA:10003109",
-            "UMLS:C0018790",
-            "HP:0001695",
-            "SNOMEDCT:410429000",
-            "MEDDRA:10082515",
-            "UMLS:C0444720",
-            "SNOMEDCT:397829000",
-            "MEDDRA:10003589",
-            "NCIT:C50479",
-            "PSY:07595",
-            "MEDDRA:10019249",
-            "SNOMEDCT:261195002",
-            "MEDDRA:10003587",
-            "MEDDRA:10047284",
-            "MESH:D006323",
-            "MONDO:0000745",
-            "MEDDRA:10041914",
-            "EFO:0009492",
-            "MEDDRA:10003586",
-            "MEDDRA:10007515",
-            "ICD9:427.5",
-            "MEDDRA:10047285"
-          ],
-          "id": "MONDO:0000745",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiac Arrest",
-            "cardiac arrest",
-            "Cardiac arrest",
-            "Heart Arrest"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/cardiacarrest.htm",
-            "http://en.wikipedia.org/wiki/cardiac_arrest",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318021,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000745",
-              "name": "cardiac arrest",
-              "description": "The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.; Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.; An abrupt loss of heart function. []; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:0060319",
-                "ICD10:I46",
-                "MEDDRA:10003109",
-                "UMLS:C0018790",
-                "HP:0001695",
-                "SNOMEDCT:410429000",
-                "MEDDRA:10082515",
-                "UMLS:C0444720",
-                "SNOMEDCT:397829000",
-                "MEDDRA:10003589",
-                "NCIT:C50479",
-                "PSY:07595",
-                "MEDDRA:10019249",
-                "SNOMEDCT:261195002",
-                "MEDDRA:10003587",
-                "MEDDRA:10047284",
-                "MESH:D006323",
-                "MONDO:0000745",
-                "MEDDRA:10041914",
-                "EFO:0009492",
-                "MEDDRA:10003586",
-                "MEDDRA:10007515",
-                "ICD9:427.5",
-                "MEDDRA:10047285"
-              ],
-              "id": "MONDO:0000745",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiac Arrest",
-                "cardiac arrest",
-                "Cardiac arrest",
-                "Heart Arrest"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/cardiacarrest.htm",
-                "http://en.wikipedia.org/wiki/cardiac_arrest",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13869973,
-            "start": 570,
-            "end": 318021,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19139319': {'publication date': '2009 Jan 12', 'sentence': 'CONCLUSION: In this single-center trial, combined vasopressin-epinephrine and methylprednisolone during resuscitation and stress-dose hydrocortisone in postresuscitation shock improved survival in refractory in-hospital cardiac arrest.', 'subject score': 1000, 'object score': 794}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0018790---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14166179",
-              "object": "MONDO:0000745",
-              "publications": [
-                "PMID:19139319"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:34587236': {'publication date': '2021 Sep 29', 'sentence': 'Effect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital Cardiac Arrest: A Randomized Clinical Trial.', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 318021,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000745",
-          "name": "cardiac arrest",
-          "description": "The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.; Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.; An abrupt loss of heart function. []; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:0060319",
-            "ICD10:I46",
-            "MEDDRA:10003109",
-            "UMLS:C0018790",
-            "HP:0001695",
-            "SNOMEDCT:410429000",
-            "MEDDRA:10082515",
-            "UMLS:C0444720",
-            "SNOMEDCT:397829000",
-            "MEDDRA:10003589",
-            "NCIT:C50479",
-            "PSY:07595",
-            "MEDDRA:10019249",
-            "SNOMEDCT:261195002",
-            "MEDDRA:10003587",
-            "MEDDRA:10047284",
-            "MESH:D006323",
-            "MONDO:0000745",
-            "MEDDRA:10041914",
-            "EFO:0009492",
-            "MEDDRA:10003586",
-            "MEDDRA:10007515",
-            "ICD9:427.5",
-            "MEDDRA:10047285"
-          ],
-          "id": "MONDO:0000745",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiac Arrest",
-            "cardiac arrest",
-            "Cardiac arrest",
-            "Heart Arrest"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/cardiacarrest.htm",
-            "http://en.wikipedia.org/wiki/cardiac_arrest",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318021,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000745",
-              "name": "cardiac arrest",
-              "description": "The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.; Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.; An abrupt loss of heart function. []; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:0060319",
-                "ICD10:I46",
-                "MEDDRA:10003109",
-                "UMLS:C0018790",
-                "HP:0001695",
-                "SNOMEDCT:410429000",
-                "MEDDRA:10082515",
-                "UMLS:C0444720",
-                "SNOMEDCT:397829000",
-                "MEDDRA:10003589",
-                "NCIT:C50479",
-                "PSY:07595",
-                "MEDDRA:10019249",
-                "SNOMEDCT:261195002",
-                "MEDDRA:10003587",
-                "MEDDRA:10047284",
-                "MESH:D006323",
-                "MONDO:0000745",
-                "MEDDRA:10041914",
-                "EFO:0009492",
-                "MEDDRA:10003586",
-                "MEDDRA:10007515",
-                "ICD9:427.5",
-                "MEDDRA:10047285"
-              ],
-              "id": "MONDO:0000745",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiac Arrest",
-                "cardiac arrest",
-                "Cardiac arrest",
-                "Heart Arrest"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/cardiacarrest.htm",
-                "http://en.wikipedia.org/wiki/cardiac_arrest",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23337086,
-            "start": 570,
-            "end": 318021,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34587236': {'publication date': '2021 Sep 29', 'sentence': 'Effect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital Cardiac Arrest: A Randomized Clinical Trial.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0018790---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "23772707",
-              "object": "MONDO:0000745",
-              "publications": [
-                "PMID:34587236"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:20591548': {'publication date': '2010 Sep', 'sentence': 'In orthognathic surgery, methylprednisolone > or =85 mg administered intravenously seemed sufficient to produce a significant decrease in edema, and several trials pointed toward a neuroregeneration effect, but no statistical analysis could be performed.', 'subject score': 1000, 'object score': 1000}, 'PMID:3304412': {'publication date': '1987 Aug', 'sentence': 'The influence of methylprednisolone on post-operative swelling following oral surgery.', 'subject score': 1000, 'object score': 802}}",
-    "p2": {
-      "start": {
-        "identity": 313324,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-          "name": "Edema",
-          "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MEDDRA:10030114",
-            "MEDDRA:10014234",
-            "MEDDRA:10014210",
-            "MEDDRA:10005890",
-            "HP:0000969",
-            "SNOMEDCT:267038008",
-            "SNOMEDCT:43498006",
-            "SNOMEDCT:79654002",
-            "MESH:D004487",
-            "UMLS:C0013604",
-            "MEDDRA:10016807",
-            "EFO:0009373",
-            "SNOMEDCT:423666004",
-            "UMLS:C0268000",
-            "NCIT:C3002",
-            "MEDDRA:10030095",
-            "SNOMEDCT:20741006",
-            "SYMP:0000538"
-          ],
-          "id": "HP:0000969",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Edema",
-            "Body fluid retention",
-            "edema"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313324,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-              "name": "Edema",
-              "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MEDDRA:10030114",
-                "MEDDRA:10014234",
-                "MEDDRA:10014210",
-                "MEDDRA:10005890",
-                "HP:0000969",
-                "SNOMEDCT:267038008",
-                "SNOMEDCT:43498006",
-                "SNOMEDCT:79654002",
-                "MESH:D004487",
-                "UMLS:C0013604",
-                "MEDDRA:10016807",
-                "EFO:0009373",
-                "SNOMEDCT:423666004",
-                "UMLS:C0268000",
-                "NCIT:C3002",
-                "MEDDRA:10030095",
-                "SNOMEDCT:20741006",
-                "SYMP:0000538"
-              ],
-              "id": "HP:0000969",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Edema",
-                "Body fluid retention",
-                "edema"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14760549,
-            "start": 570,
-            "end": 313324,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20591548': {'publication date': '2010 Sep', 'sentence': 'In orthognathic surgery, methylprednisolone > or =85 mg administered intravenously seemed sufficient to produce a significant decrease in edema, and several trials pointed toward a neuroregeneration effect, but no statistical analysis could be performed.', 'subject score': 1000, 'object score': 1000}, 'PMID:3304412': {'publication date': '1987 Aug', 'sentence': 'The influence of methylprednisolone on post-operative swelling following oral surgery.', 'subject score': 1000, 'object score': 802}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0013604---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "15072844",
-              "object": "HP:0000969",
-              "publications": [
-                "PMID:20591548",
-                "PMID:3304412"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:35099248': {'publication date': '2021 Dec 31', 'sentence': 'MP was administrated in three alternative ways: intraperitoneally during the induction of cytotoxic edema or immediately after finishing cytotoxic edema induction in a dose of 100 mg/kg b.w.; into the internal carotid artery within 2 h after finishing cytotoxic edema induction in a dose of 50 mg/kg b.w.; into internal carotid artery 10 min after edema induction by BBBd in a dose of 50 mg/kg b.w.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 313324,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-          "name": "Edema",
-          "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MEDDRA:10030114",
-            "MEDDRA:10014234",
-            "MEDDRA:10014210",
-            "MEDDRA:10005890",
-            "HP:0000969",
-            "SNOMEDCT:267038008",
-            "SNOMEDCT:43498006",
-            "SNOMEDCT:79654002",
-            "MESH:D004487",
-            "UMLS:C0013604",
-            "MEDDRA:10016807",
-            "EFO:0009373",
-            "SNOMEDCT:423666004",
-            "UMLS:C0268000",
-            "NCIT:C3002",
-            "MEDDRA:10030095",
-            "SNOMEDCT:20741006",
-            "SYMP:0000538"
-          ],
-          "id": "HP:0000969",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Edema",
-            "Body fluid retention",
-            "edema"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313324,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-              "name": "Edema",
-              "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MEDDRA:10030114",
-                "MEDDRA:10014234",
-                "MEDDRA:10014210",
-                "MEDDRA:10005890",
-                "HP:0000969",
-                "SNOMEDCT:267038008",
-                "SNOMEDCT:43498006",
-                "SNOMEDCT:79654002",
-                "MESH:D004487",
-                "UMLS:C0013604",
-                "MEDDRA:10016807",
-                "EFO:0009373",
-                "SNOMEDCT:423666004",
-                "UMLS:C0268000",
-                "NCIT:C3002",
-                "MEDDRA:10030095",
-                "SNOMEDCT:20741006",
-                "SYMP:0000538"
-              ],
-              "id": "HP:0000969",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Edema",
-                "Body fluid retention",
-                "edema"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23723372,
-            "start": 570,
-            "end": 313324,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35099248': {'publication date': '2021 Dec 31', 'sentence': 'MP was administrated in three alternative ways: intraperitoneally during the induction of cytotoxic edema or immediately after finishing cytotoxic edema induction in a dose of 100 mg/kg b.w.; into the internal carotid artery within 2 h after finishing cytotoxic edema induction in a dose of 50 mg/kg b.w.; into internal carotid artery 10 min after edema induction by BBBd in a dose of 50 mg/kg b.w.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:causes---None---None---None---UMLS:C0013604---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "24161886",
-              "object": "HP:0000969",
-              "publications": [
-                "PMID:35099248"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:11549377': {'publication date': '2001 Sep 21', 'sentence': 'Similar to the CRPS clinical response to glucocorticoids, we now demonstrate that chronic hindpaw edema in the sciatic transection CRPS model is reversed by a continuous infusion of MP (3 mg/kg/day over 21 days), and this anti-edematous effect persists for at least 1 week after discontinuing MP.', 'subject score': 1000, 'object score': 790}, 'PMID:1335518': {'publication date': '1992', 'sentence': 'MP had little effect in decreasing FITC-D extravasation and cord edema when given at a lower dose (bolus of 30 mg/kg with continued infusion of 1.3 mg/kg/h for 23 h).', 'subject score': 1000, 'object score': 861}, 'PMID:24332587': {'publication date': '2014 May', 'sentence': 'Effect of the route of administration of methylprednisolone on oedema and trismus in impacted lower third molar surgery.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 313324,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-          "name": "Edema",
-          "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MEDDRA:10030114",
-            "MEDDRA:10014234",
-            "MEDDRA:10014210",
-            "MEDDRA:10005890",
-            "HP:0000969",
-            "SNOMEDCT:267038008",
-            "SNOMEDCT:43498006",
-            "SNOMEDCT:79654002",
-            "MESH:D004487",
-            "UMLS:C0013604",
-            "MEDDRA:10016807",
-            "EFO:0009373",
-            "SNOMEDCT:423666004",
-            "UMLS:C0268000",
-            "NCIT:C3002",
-            "MEDDRA:10030095",
-            "SNOMEDCT:20741006",
-            "SYMP:0000538"
-          ],
-          "id": "HP:0000969",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Edema",
-            "Body fluid retention",
-            "edema"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313324,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-              "name": "Edema",
-              "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MEDDRA:10030114",
-                "MEDDRA:10014234",
-                "MEDDRA:10014210",
-                "MEDDRA:10005890",
-                "HP:0000969",
-                "SNOMEDCT:267038008",
-                "SNOMEDCT:43498006",
-                "SNOMEDCT:79654002",
-                "MESH:D004487",
-                "UMLS:C0013604",
-                "MEDDRA:10016807",
-                "EFO:0009373",
-                "SNOMEDCT:423666004",
-                "UMLS:C0268000",
-                "NCIT:C3002",
-                "MEDDRA:10030095",
-                "SNOMEDCT:20741006",
-                "SYMP:0000538"
-              ],
-              "id": "HP:0000969",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Edema",
-                "Body fluid retention",
-                "edema"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8900685,
-            "start": 570,
-            "end": 313324,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11549377': {'publication date': '2001 Sep 21', 'sentence': 'Similar to the CRPS clinical response to glucocorticoids, we now demonstrate that chronic hindpaw edema in the sciatic transection CRPS model is reversed by a continuous infusion of MP (3 mg/kg/day over 21 days), and this anti-edematous effect persists for at least 1 week after discontinuing MP.', 'subject score': 1000, 'object score': 790}, 'PMID:1335518': {'publication date': '1992', 'sentence': 'MP had little effect in decreasing FITC-D extravasation and cord edema when given at a lower dose (bolus of 30 mg/kg with continued infusion of 1.3 mg/kg/h for 23 h).', 'subject score': 1000, 'object score': 861}, 'PMID:24332587': {'publication date': '2014 May', 'sentence': 'Effect of the route of administration of methylprednisolone on oedema and trismus in impacted lower third molar surgery.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0013604---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "9107378",
-              "object": "HP:0000969",
-              "publications": [
-                "PMID:11549377",
-                "PMID:1335518",
-                "PMID:24332587"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10494671': {'publication date': '1999 Jul', 'sentence': 'Lipid peroxidation and oedema in experimental brain injury: comparison of treatment with methylprednisolone, tirilazad mesylate and vitamin E.', 'subject score': 1000, 'object score': 1000}, 'PMID:24117451': {'publication date': '2015 Mar', 'sentence': 'PURPOSE: The purpose of this study is to report a case of atypical serpiginous choroiditis presenting with disc edema and exudative retinal detachment, treated successfully with intravenous methyl prednisolone.', 'subject score': 888, 'object score': 861}, 'PMID:2493689': {'publication date': '1989 Feb', 'sentence': 'Treatment with MP immediately after NO2 was ineffective since mortality rates, W/D ratios, and alveolar and interstitial edema were not lower in the treated animals; there was significantly more intestitial edema in the middle lobes of the latter.', 'subject score': 888, 'object score': 1000}, 'PMID:25215167': {'publication date': '2014', 'sentence': 'The medical treatment of the patient consisted of anti-edema treatment with methylprednisolone in the first 24 hours; 330 mg of methylprednisolone infused in the first hour, followed by 59 mg per hour during the next 23 hours.', 'subject score': 1000, 'object score': 790}, 'PMID:2709033': {'publication date': '1989 Jan', 'sentence': 'Since brain water content is increased in normal appearing white matter of multiple sclerosis patients, and is significantly reduced by high-dose methylprednisolone, resolution of oedema may contribute to the rapid spontaneous or corticosteroid induced symptomatic recovery that characterises the disease in its early stages.', 'subject score': 901, 'object score': 1000}, 'PMID:28572712': {'publication date': '2017', 'sentence': 'Although MP has been thought to help in the resolution of edema, there are no scientific grounds to support this assertion.', 'subject score': 1000, 'object score': 1000}, 'PMID:29513816': {'publication date': '2018 Feb', 'sentence': 'PURPOSE: To investigate the effects of aquaporin 4 (AQP4) and inward rectifier potassium channel 4.1 (Kir4.1) on medullospinal edema after treatment with methylprednisolone (MP) to suppress acute spinal cord injury (ASCI) in rats.', 'subject score': 1000, 'object score': 861}, 'PMID:30314709': {'publication date': '2018 Oct 09', 'sentence': 'Within the purview of the limitations of this review, the results showed that MP administered via any route significantly improves oedema in the early postoperative period, but has no effect on late postoperative oedema.', 'subject score': 1000, 'object score': 1000}, 'PMID:32590413': {'publication date': '2020 Jun 23', 'sentence': 'Treatment with methylprednisolone resulted in resolution of the oedema, and a marked decrease in the subsequent accumulation of microhaemorrhages.', 'subject score': 1000, 'object score': 1000}, 'PMID:7277532': {'publication date': '1981 Oct', 'sentence': 'Furthermore, rate of edema formation is attenuated by methylprednisolone pretreatment.', 'subject score': 888, 'object score': 888}, 'PMID:735666': {'publication date': '1978', 'sentence': 'The edema in the ischemic segments tended to be less marked in rats treated with methylprednisolone.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 313324,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-          "name": "Edema",
-          "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MEDDRA:10030114",
-            "MEDDRA:10014234",
-            "MEDDRA:10014210",
-            "MEDDRA:10005890",
-            "HP:0000969",
-            "SNOMEDCT:267038008",
-            "SNOMEDCT:43498006",
-            "SNOMEDCT:79654002",
-            "MESH:D004487",
-            "UMLS:C0013604",
-            "MEDDRA:10016807",
-            "EFO:0009373",
-            "SNOMEDCT:423666004",
-            "UMLS:C0268000",
-            "NCIT:C3002",
-            "MEDDRA:10030095",
-            "SNOMEDCT:20741006",
-            "SYMP:0000538"
-          ],
-          "id": "HP:0000969",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Edema",
-            "Body fluid retention",
-            "edema"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313324,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-              "name": "Edema",
-              "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MEDDRA:10030114",
-                "MEDDRA:10014234",
-                "MEDDRA:10014210",
-                "MEDDRA:10005890",
-                "HP:0000969",
-                "SNOMEDCT:267038008",
-                "SNOMEDCT:43498006",
-                "SNOMEDCT:79654002",
-                "MESH:D004487",
-                "UMLS:C0013604",
-                "MEDDRA:10016807",
-                "EFO:0009373",
-                "SNOMEDCT:423666004",
-                "UMLS:C0268000",
-                "NCIT:C3002",
-                "MEDDRA:10030095",
-                "SNOMEDCT:20741006",
-                "SYMP:0000538"
-              ],
-              "id": "HP:0000969",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Edema",
-                "Body fluid retention",
-                "edema"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7542390,
-            "start": 570,
-            "end": 313324,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10494671': {'publication date': '1999 Jul', 'sentence': 'Lipid peroxidation and oedema in experimental brain injury: comparison of treatment with methylprednisolone, tirilazad mesylate and vitamin E.', 'subject score': 1000, 'object score': 1000}, 'PMID:24117451': {'publication date': '2015 Mar', 'sentence': 'PURPOSE: The purpose of this study is to report a case of atypical serpiginous choroiditis presenting with disc edema and exudative retinal detachment, treated successfully with intravenous methyl prednisolone.', 'subject score': 888, 'object score': 861}, 'PMID:2493689': {'publication date': '1989 Feb', 'sentence': 'Treatment with MP immediately after NO2 was ineffective since mortality rates, W/D ratios, and alveolar and interstitial edema were not lower in the treated animals; there was significantly more intestitial edema in the middle lobes of the latter.', 'subject score': 888, 'object score': 1000}, 'PMID:25215167': {'publication date': '2014', 'sentence': 'The medical treatment of the patient consisted of anti-edema treatment with methylprednisolone in the first 24 hours; 330 mg of methylprednisolone infused in the first hour, followed by 59 mg per hour during the next 23 hours.', 'subject score': 1000, 'object score': 790}, 'PMID:2709033': {'publication date': '1989 Jan', 'sentence': 'Since brain water content is increased in normal appearing white matter of multiple sclerosis patients, and is significantly reduced by high-dose methylprednisolone, resolution of oedema may contribute to the rapid spontaneous or corticosteroid induced symptomatic recovery that characterises the disease in its early stages.', 'subject score': 901, 'object score': 1000}, 'PMID:28572712': {'publication date': '2017', 'sentence': 'Although MP has been thought to help in the resolution of edema, there are no scientific grounds to support this assertion.', 'subject score': 1000, 'object score': 1000}, 'PMID:29513816': {'publication date': '2018 Feb', 'sentence': 'PURPOSE: To investigate the effects of aquaporin 4 (AQP4) and inward rectifier potassium channel 4.1 (Kir4.1) on medullospinal edema after treatment with methylprednisolone (MP) to suppress acute spinal cord injury (ASCI) in rats.', 'subject score': 1000, 'object score': 861}, 'PMID:30314709': {'publication date': '2018 Oct 09', 'sentence': 'Within the purview of the limitations of this review, the results showed that MP administered via any route significantly improves oedema in the early postoperative period, but has no effect on late postoperative oedema.', 'subject score': 1000, 'object score': 1000}, 'PMID:32590413': {'publication date': '2020 Jun 23', 'sentence': 'Treatment with methylprednisolone resulted in resolution of the oedema, and a marked decrease in the subsequent accumulation of microhaemorrhages.', 'subject score': 1000, 'object score': 1000}, 'PMID:7277532': {'publication date': '1981 Oct', 'sentence': 'Furthermore, rate of edema formation is attenuated by methylprednisolone pretreatment.', 'subject score': 888, 'object score': 888}, 'PMID:735666': {'publication date': '1978', 'sentence': 'The edema in the ischemic segments tended to be less marked in rats treated with methylprednisolone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0013604---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7700869",
-              "object": "HP:0000969",
-              "publications": [
-                "PMID:10494671",
-                "PMID:24117451",
-                "PMID:2493689",
-                "PMID:25215167",
-                "PMID:2709033",
-                "PMID:28572712",
-                "PMID:29513816",
-                "PMID:30314709",
-                "PMID:32590413",
-                "PMID:7277532",
-                "PMID:735666"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:28666096': {'publication date': '2017 Nov', 'sentence': 'RESULTS: Both methylprednisolone and dexamethasone significantly reduced swelling and trismus (P < .05, Kruskal-Wallis test), whereas the methylprednisolone group had significantly less pain (P < .05, Kruskal-Wallis test) and consumed a lower amount of analgesics (P < .05, chi2 test) during the early postoperative days.', 'subject score': 1000, 'object score': 775}, 'PMID:29513816': {'publication date': '2018 Feb', 'sentence': 'CONCLUSION: Methylprednisolone inhibited medullospinal edema in rats with acute spinal cord injury, possibly by reducing the coexpression of aquaporin 4 and Kir4.1 in medullospinal tissues.', 'subject score': 1000, 'object score': 861}, 'PMID:30143486': {'publication date': '2018 Jul', 'sentence': 'MP inhibited spinal edema in rats with ASCI, which might be related to the reduced AQP4 expression in spinal tissues.', 'subject score': 1000, 'object score': 888}, 'PMID:3744476': {'publication date': '1986 Sep', 'sentence': 'In separate experiments, MP inhibited intradermal edema formation and protein exudation induced in rats by histamine, platelet activating factor, or C5a.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 313324,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-          "name": "Edema",
-          "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MEDDRA:10030114",
-            "MEDDRA:10014234",
-            "MEDDRA:10014210",
-            "MEDDRA:10005890",
-            "HP:0000969",
-            "SNOMEDCT:267038008",
-            "SNOMEDCT:43498006",
-            "SNOMEDCT:79654002",
-            "MESH:D004487",
-            "UMLS:C0013604",
-            "MEDDRA:10016807",
-            "EFO:0009373",
-            "SNOMEDCT:423666004",
-            "UMLS:C0268000",
-            "NCIT:C3002",
-            "MEDDRA:10030095",
-            "SNOMEDCT:20741006",
-            "SYMP:0000538"
-          ],
-          "id": "HP:0000969",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Edema",
-            "Body fluid retention",
-            "edema"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313324,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-              "name": "Edema",
-              "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MEDDRA:10030114",
-                "MEDDRA:10014234",
-                "MEDDRA:10014210",
-                "MEDDRA:10005890",
-                "HP:0000969",
-                "SNOMEDCT:267038008",
-                "SNOMEDCT:43498006",
-                "SNOMEDCT:79654002",
-                "MESH:D004487",
-                "UMLS:C0013604",
-                "MEDDRA:10016807",
-                "EFO:0009373",
-                "SNOMEDCT:423666004",
-                "UMLS:C0268000",
-                "NCIT:C3002",
-                "MEDDRA:10030095",
-                "SNOMEDCT:20741006",
-                "SYMP:0000538"
-              ],
-              "id": "HP:0000969",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Edema",
-                "Body fluid retention",
-                "edema"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19357722,
-            "start": 570,
-            "end": 313324,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28666096': {'publication date': '2017 Nov', 'sentence': 'RESULTS: Both methylprednisolone and dexamethasone significantly reduced swelling and trismus (P < .05, Kruskal-Wallis test), whereas the methylprednisolone group had significantly less pain (P < .05, Kruskal-Wallis test) and consumed a lower amount of analgesics (P < .05, chi2 test) during the early postoperative days.', 'subject score': 1000, 'object score': 775}, 'PMID:29513816': {'publication date': '2018 Feb', 'sentence': 'CONCLUSION: Methylprednisolone inhibited medullospinal edema in rats with acute spinal cord injury, possibly by reducing the coexpression of aquaporin 4 and Kir4.1 in medullospinal tissues.', 'subject score': 1000, 'object score': 861}, 'PMID:30143486': {'publication date': '2018 Jul', 'sentence': 'MP inhibited spinal edema in rats with ASCI, which might be related to the reduced AQP4 expression in spinal tissues.', 'subject score': 1000, 'object score': 888}, 'PMID:3744476': {'publication date': '1986 Sep', 'sentence': 'In separate experiments, MP inhibited intradermal edema formation and protein exudation induced in rats by histamine, platelet activating factor, or C5a.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:disrupts---None---None---None---UMLS:C0013604---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "19744632",
-              "object": "HP:0000969",
-              "publications": [
-                "PMID:28666096",
-                "PMID:29513816",
-                "PMID:30143486",
-                "PMID:3744476"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:10342417': {'publication date': '1999 Apr', 'sentence': 'Methylprednisolone prevents the development of autotomy and neuropathic edema in rats, but has no effect on nociceptive thresholds.', 'subject score': 1000, 'object score': 853}, 'PMID:15232723': {'publication date': '2004 Dec', 'sentence': 'Methylprednisolone (MP), by reducing edema and protecting the cell membrane against peroxidation, is the only pharmacological agent with a proven clinically beneficial effect on SCI.', 'subject score': 1000, 'object score': 872}, 'PMID:2243858': {'publication date': '1990 Dec', 'sentence': 'The efficacy of methylprednisolone in reducing flap edema.', 'subject score': 1000, 'object score': 840}, 'PMID:25933144': {'publication date': '2015 May', 'sentence': 'CONCLUSIONS: As a result of the evaluation of MP efficacy in different models of facial nerve palsy, we may say that this drug was without effect on nerve healing in paralysis due to nerve section and that it only reduced nervous edema in paralysis induced by Type 1 HSV, whereas it had positive effects on healing in the type of paralysis caused by nerve compression.', 'subject score': 694, 'object score': 888}, 'PMID:28666096': {'publication date': '2017 Nov', 'sentence': 'CONCLUSIONS: The study findings suggest that a single preoperative dose of dexamethasone versus methylprednisolone was equally effective in reducing postoperative swelling and trismus.', 'subject score': 1000, 'object score': 785}, 'PMID:28793837': {'publication date': '2017 Nov', 'sentence': 'AIMS To determine if equine fescue oedema (EFO) induced by grazing Mediterranean-type tall fescue (Lolium arundinaceum) infected with selected endophytes (Epichloe coenophiala) could be prevented by treatment with the corticosteroid, methylprednisolone, and anti-histamine, cetirizine, and to determine concentrations of lolines, specifically N-acetyl norloline (NANL), in grasses grazed by horses that did and did not develop EFO.', 'subject score': 1000, 'object score': 802}, 'PMID:3174874': {'publication date': '1988 Nov', 'sentence': 'A single perioperative dose of methylprednisolone was ineffective in decreasing edema formation and preserving tissue.', 'subject score': 1000, 'object score': 851}, 'PMID:3533126': {'publication date': '1986 Oct', 'sentence': 'On the third postoperative day methylprednisolone reduced measured swelling by 29% compared to paracetamol (P = 0.03).', 'subject score': 775, 'object score': 888}, 'PMID:3881262': {'publication date': '1985', 'sentence': 'These results indicate that methylprednisolone, at least for a short period of time, produces a definite decrease in apparent tumor size, in addition to the reduction of peritumoral edema.', 'subject score': 1000, 'object score': 861}, 'PMID:8303761': {'publication date': '1994 Feb', 'sentence': 'However, methylprednisolone treatment did not reduce hemispheric edema in animals that died early after temporary middle cerebral artery occlusion.', 'subject score': 888, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 313324,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-          "name": "Edema",
-          "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MEDDRA:10030114",
-            "MEDDRA:10014234",
-            "MEDDRA:10014210",
-            "MEDDRA:10005890",
-            "HP:0000969",
-            "SNOMEDCT:267038008",
-            "SNOMEDCT:43498006",
-            "SNOMEDCT:79654002",
-            "MESH:D004487",
-            "UMLS:C0013604",
-            "MEDDRA:10016807",
-            "EFO:0009373",
-            "SNOMEDCT:423666004",
-            "UMLS:C0268000",
-            "NCIT:C3002",
-            "MEDDRA:10030095",
-            "SNOMEDCT:20741006",
-            "SYMP:0000538"
-          ],
-          "id": "HP:0000969",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Edema",
-            "Body fluid retention",
-            "edema"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313324,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-              "name": "Edema",
-              "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MEDDRA:10030114",
-                "MEDDRA:10014234",
-                "MEDDRA:10014210",
-                "MEDDRA:10005890",
-                "HP:0000969",
-                "SNOMEDCT:267038008",
-                "SNOMEDCT:43498006",
-                "SNOMEDCT:79654002",
-                "MESH:D004487",
-                "UMLS:C0013604",
-                "MEDDRA:10016807",
-                "EFO:0009373",
-                "SNOMEDCT:423666004",
-                "UMLS:C0268000",
-                "NCIT:C3002",
-                "MEDDRA:10030095",
-                "SNOMEDCT:20741006",
-                "SYMP:0000538"
-              ],
-              "id": "HP:0000969",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Edema",
-                "Body fluid retention",
-                "edema"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7265701,
-            "start": 570,
-            "end": 313324,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10342417': {'publication date': '1999 Apr', 'sentence': 'Methylprednisolone prevents the development of autotomy and neuropathic edema in rats, but has no effect on nociceptive thresholds.', 'subject score': 1000, 'object score': 853}, 'PMID:15232723': {'publication date': '2004 Dec', 'sentence': 'Methylprednisolone (MP), by reducing edema and protecting the cell membrane against peroxidation, is the only pharmacological agent with a proven clinically beneficial effect on SCI.', 'subject score': 1000, 'object score': 872}, 'PMID:2243858': {'publication date': '1990 Dec', 'sentence': 'The efficacy of methylprednisolone in reducing flap edema.', 'subject score': 1000, 'object score': 840}, 'PMID:25933144': {'publication date': '2015 May', 'sentence': 'CONCLUSIONS: As a result of the evaluation of MP efficacy in different models of facial nerve palsy, we may say that this drug was without effect on nerve healing in paralysis due to nerve section and that it only reduced nervous edema in paralysis induced by Type 1 HSV, whereas it had positive effects on healing in the type of paralysis caused by nerve compression.', 'subject score': 694, 'object score': 888}, 'PMID:28666096': {'publication date': '2017 Nov', 'sentence': 'CONCLUSIONS: The study findings suggest that a single preoperative dose of dexamethasone versus methylprednisolone was equally effective in reducing postoperative swelling and trismus.', 'subject score': 1000, 'object score': 785}, 'PMID:28793837': {'publication date': '2017 Nov', 'sentence': 'AIMS To determine if equine fescue oedema (EFO) induced by grazing Mediterranean-type tall fescue (Lolium arundinaceum) infected with selected endophytes (Epichloe coenophiala) could be prevented by treatment with the corticosteroid, methylprednisolone, and anti-histamine, cetirizine, and to determine concentrations of lolines, specifically N-acetyl norloline (NANL), in grasses grazed by horses that did and did not develop EFO.', 'subject score': 1000, 'object score': 802}, 'PMID:3174874': {'publication date': '1988 Nov', 'sentence': 'A single perioperative dose of methylprednisolone was ineffective in decreasing edema formation and preserving tissue.', 'subject score': 1000, 'object score': 851}, 'PMID:3533126': {'publication date': '1986 Oct', 'sentence': 'On the third postoperative day methylprednisolone reduced measured swelling by 29% compared to paracetamol (P = 0.03).', 'subject score': 775, 'object score': 888}, 'PMID:3881262': {'publication date': '1985', 'sentence': 'These results indicate that methylprednisolone, at least for a short period of time, produces a definite decrease in apparent tumor size, in addition to the reduction of peritumoral edema.', 'subject score': 1000, 'object score': 861}, 'PMID:8303761': {'publication date': '1994 Feb', 'sentence': 'However, methylprednisolone treatment did not reduce hemispheric edema in animals that died early after temporary middle cerebral artery occlusion.', 'subject score': 888, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:prevents---None---None---None---UMLS:C0013604---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7414405",
-              "object": "HP:0000969",
-              "publications": [
-                "PMID:10342417",
-                "PMID:15232723",
-                "PMID:2243858",
-                "PMID:25933144",
-                "PMID:28666096",
-                "PMID:28793837",
-                "PMID:3174874",
-                "PMID:3533126",
-                "PMID:3881262",
-                "PMID:8303761"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:10644791': {'publication date': '2000 Feb', 'sentence': 'Extraocular muscle responses to high dose intravenous methylprednisolone in myasthenia gravis.', 'subject score': 861, 'object score': 1000}, 'PMID:16930359': {'publication date': '2006 Sep', 'sentence': 'The aim of this study was to evaluate the long-term adverse effect (AE) profile of azathioprine (AZA) plus methylprednisolone combined immunosuppressive treatment in myasthenia gravis (MG) in a larger patient cohort.', 'subject score': 851, 'object score': 1000}, 'PMID:4062612': {'publication date': '1985 Dec', 'sentence': 'High-dose intravenous methylprednisolone in myasthenia gravis.', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 518734,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009688",
-          "name": "myasthenia gravis",
-          "description": "A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness. It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.; A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.; Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest. Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker. Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps. Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:G70.00",
-            "ICD9:358.0",
-            "OMIM:254200",
-            "PSY:32760",
-            "MESH:D009157",
-            "MEDDRA:10028420",
-            "ICD10:G70.0",
-            "EFO:0004991",
-            "ICD9:358.00",
-            "ORPHANET:589",
-            "UMLS:C1260409",
-            "MEDDRA:10028417",
-            "DOID:437",
-            "UMLS:C0026896",
-            "SNOMEDCT:91637004",
-            "MONDO:0009688",
-            "NCIT:C60989"
-          ],
-          "id": "MONDO:0009688",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myasthenia gravis without (acute) exacerbation",
-            "myasthenia gravis without acute exacerbation",
-            "myasthenia gravis",
-            "Myasthenia Gravis",
-            "Myasthenia gravis",
-            "Myasthenia gravis related phenotypic feature"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.ninds.nih.gov/disorders/patient-caregiver-education/fact-sheets/myasthenia-gravis-fact-sheet"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 518734,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009688",
-              "name": "myasthenia gravis",
-              "description": "A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness. It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.; A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.; Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest. Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker. Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps. Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:G70.00",
-                "ICD9:358.0",
-                "OMIM:254200",
-                "PSY:32760",
-                "MESH:D009157",
-                "MEDDRA:10028420",
-                "ICD10:G70.0",
-                "EFO:0004991",
-                "ICD9:358.00",
-                "ORPHANET:589",
-                "UMLS:C1260409",
-                "MEDDRA:10028417",
-                "DOID:437",
-                "UMLS:C0026896",
-                "SNOMEDCT:91637004",
-                "MONDO:0009688",
-                "NCIT:C60989"
-              ],
-              "id": "MONDO:0009688",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myasthenia gravis without (acute) exacerbation",
-                "myasthenia gravis without acute exacerbation",
-                "myasthenia gravis",
-                "Myasthenia Gravis",
-                "Myasthenia gravis",
-                "Myasthenia gravis related phenotypic feature"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.ninds.nih.gov/disorders/patient-caregiver-education/fact-sheets/myasthenia-gravis-fact-sheet"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7779197,
-            "start": 570,
-            "end": 518734,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10644791': {'publication date': '2000 Feb', 'sentence': 'Extraocular muscle responses to high dose intravenous methylprednisolone in myasthenia gravis.', 'subject score': 861, 'object score': 1000}, 'PMID:16930359': {'publication date': '2006 Sep', 'sentence': 'The aim of this study was to evaluate the long-term adverse effect (AE) profile of azathioprine (AZA) plus methylprednisolone combined immunosuppressive treatment in myasthenia gravis (MG) in a larger patient cohort.', 'subject score': 851, 'object score': 1000}, 'PMID:4062612': {'publication date': '1985 Dec', 'sentence': 'High-dose intravenous methylprednisolone in myasthenia gravis.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0026896---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7944646",
-              "object": "MONDO:0009688",
-              "publications": [
-                "PMID:10644791",
-                "PMID:16930359",
-                "PMID:4062612"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:2319723': {'publication date': '1990 Mar', 'sentence': '[Treatment of invasive thymoma with myasthenia gravis: a case report responsive to azathioprine and methylprednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:33318935': {'publication date': '2021 Jan', 'sentence': 'Myocarditis with concomitant myasthenia gravis (MG) has a mortality rate of 50%, and a high dose of methylprednisolone (mPSL) should be administered with careful attention to MG exacerbation.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 518734,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009688",
-          "name": "myasthenia gravis",
-          "description": "A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness. It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.; A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.; Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest. Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker. Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps. Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:G70.00",
-            "ICD9:358.0",
-            "OMIM:254200",
-            "PSY:32760",
-            "MESH:D009157",
-            "MEDDRA:10028420",
-            "ICD10:G70.0",
-            "EFO:0004991",
-            "ICD9:358.00",
-            "ORPHANET:589",
-            "UMLS:C1260409",
-            "MEDDRA:10028417",
-            "DOID:437",
-            "UMLS:C0026896",
-            "SNOMEDCT:91637004",
-            "MONDO:0009688",
-            "NCIT:C60989"
-          ],
-          "id": "MONDO:0009688",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myasthenia gravis without (acute) exacerbation",
-            "myasthenia gravis without acute exacerbation",
-            "myasthenia gravis",
-            "Myasthenia Gravis",
-            "Myasthenia gravis",
-            "Myasthenia gravis related phenotypic feature"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.ninds.nih.gov/disorders/patient-caregiver-education/fact-sheets/myasthenia-gravis-fact-sheet"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 518734,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009688",
-              "name": "myasthenia gravis",
-              "description": "A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness. It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.; A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.; Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest. Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker. Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps. Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:G70.00",
-                "ICD9:358.0",
-                "OMIM:254200",
-                "PSY:32760",
-                "MESH:D009157",
-                "MEDDRA:10028420",
-                "ICD10:G70.0",
-                "EFO:0004991",
-                "ICD9:358.00",
-                "ORPHANET:589",
-                "UMLS:C1260409",
-                "MEDDRA:10028417",
-                "DOID:437",
-                "UMLS:C0026896",
-                "SNOMEDCT:91637004",
-                "MONDO:0009688",
-                "NCIT:C60989"
-              ],
-              "id": "MONDO:0009688",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myasthenia gravis without (acute) exacerbation",
-                "myasthenia gravis without acute exacerbation",
-                "myasthenia gravis",
-                "Myasthenia Gravis",
-                "Myasthenia gravis",
-                "Myasthenia gravis related phenotypic feature"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.ninds.nih.gov/disorders/patient-caregiver-education/fact-sheets/myasthenia-gravis-fact-sheet"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16296294,
-            "start": 570,
-            "end": 518734,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2319723': {'publication date': '1990 Mar', 'sentence': '[Treatment of invasive thymoma with myasthenia gravis: a case report responsive to azathioprine and methylprednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:33318935': {'publication date': '2021 Jan', 'sentence': 'Myocarditis with concomitant myasthenia gravis (MG) has a mortality rate of 50%, and a high dose of methylprednisolone (mPSL) should be administered with careful attention to MG exacerbation.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0026896---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "16634377",
-              "object": "MONDO:0009688",
-              "publications": [
-                "PMID:2319723",
-                "PMID:33318935"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11093687': {'publication date': '2000 Nov', 'sentence': 'Treatment with methylprednisolone for myasthenia gravis was associated with a marked decrease in both biochemical markers of bone formation and resorption without any changes in endogenous cAMP and serum levels of calcium, PTH, and 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3].', 'subject score': 1000, 'object score': 1000}, 'PMID:18632163': {'publication date': '2008 Sep 15', 'sentence': 'Myasthenia gravis (MG) is frequently treated by corticosteroids such as methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:23158712': {'publication date': '2012 Sep 18', 'sentence': 'CONCLUSION: (1) The combined treatment of middle-dose cyclophosphamide and methylprednisolone for MG patients in crisis is both effective and safe.', 'subject score': 1000, 'object score': 901}, 'PMID:28299711': {'publication date': '2018 Jan', 'sentence': 'Methylprednisolone and immunosuppressive therapy are highly effective in MG patients with normal thymus tissue and MG patients with thymic hyperplasia compared to MG patients with thymomas alone.', 'subject score': 1000, 'object score': 901}, 'PMID:32145521': {'publication date': '2020 Feb 19', 'sentence': 'CONCLUSION: Disease severity and thymectomy before IVMP are related to initial deterioration in MG patients.', 'subject score': 888, 'object score': 901}, 'PMID:34627357': {'publication date': '2021 Oct 10', 'sentence': 'CASE PRESENTATION: A 31-year-old Asian woman was admitted to our hospital for myasthenia gravis and treated with methylprednisolone and pyridostigmine bromide 3 months postpartum.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 518734,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009688",
-          "name": "myasthenia gravis",
-          "description": "A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness. It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.; A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.; Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest. Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker. Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps. Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:G70.00",
-            "ICD9:358.0",
-            "OMIM:254200",
-            "PSY:32760",
-            "MESH:D009157",
-            "MEDDRA:10028420",
-            "ICD10:G70.0",
-            "EFO:0004991",
-            "ICD9:358.00",
-            "ORPHANET:589",
-            "UMLS:C1260409",
-            "MEDDRA:10028417",
-            "DOID:437",
-            "UMLS:C0026896",
-            "SNOMEDCT:91637004",
-            "MONDO:0009688",
-            "NCIT:C60989"
-          ],
-          "id": "MONDO:0009688",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myasthenia gravis without (acute) exacerbation",
-            "myasthenia gravis without acute exacerbation",
-            "myasthenia gravis",
-            "Myasthenia Gravis",
-            "Myasthenia gravis",
-            "Myasthenia gravis related phenotypic feature"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.ninds.nih.gov/disorders/patient-caregiver-education/fact-sheets/myasthenia-gravis-fact-sheet"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 518734,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009688",
-              "name": "myasthenia gravis",
-              "description": "A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness. It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.; A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.; Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest. Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker. Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps. Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:G70.00",
-                "ICD9:358.0",
-                "OMIM:254200",
-                "PSY:32760",
-                "MESH:D009157",
-                "MEDDRA:10028420",
-                "ICD10:G70.0",
-                "EFO:0004991",
-                "ICD9:358.00",
-                "ORPHANET:589",
-                "UMLS:C1260409",
-                "MEDDRA:10028417",
-                "DOID:437",
-                "UMLS:C0026896",
-                "SNOMEDCT:91637004",
-                "MONDO:0009688",
-                "NCIT:C60989"
-              ],
-              "id": "MONDO:0009688",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myasthenia gravis without (acute) exacerbation",
-                "myasthenia gravis without acute exacerbation",
-                "myasthenia gravis",
-                "Myasthenia Gravis",
-                "Myasthenia gravis",
-                "Myasthenia gravis related phenotypic feature"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.ninds.nih.gov/disorders/patient-caregiver-education/fact-sheets/myasthenia-gravis-fact-sheet"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8386295,
-            "start": 570,
-            "end": 518734,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11093687': {'publication date': '2000 Nov', 'sentence': 'Treatment with methylprednisolone for myasthenia gravis was associated with a marked decrease in both biochemical markers of bone formation and resorption without any changes in endogenous cAMP and serum levels of calcium, PTH, and 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3].', 'subject score': 1000, 'object score': 1000}, 'PMID:18632163': {'publication date': '2008 Sep 15', 'sentence': 'Myasthenia gravis (MG) is frequently treated by corticosteroids such as methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:23158712': {'publication date': '2012 Sep 18', 'sentence': 'CONCLUSION: (1) The combined treatment of middle-dose cyclophosphamide and methylprednisolone for MG patients in crisis is both effective and safe.', 'subject score': 1000, 'object score': 901}, 'PMID:28299711': {'publication date': '2018 Jan', 'sentence': 'Methylprednisolone and immunosuppressive therapy are highly effective in MG patients with normal thymus tissue and MG patients with thymic hyperplasia compared to MG patients with thymomas alone.', 'subject score': 1000, 'object score': 901}, 'PMID:32145521': {'publication date': '2020 Feb 19', 'sentence': 'CONCLUSION: Disease severity and thymectomy before IVMP are related to initial deterioration in MG patients.', 'subject score': 888, 'object score': 901}, 'PMID:34627357': {'publication date': '2021 Oct 10', 'sentence': 'CASE PRESENTATION: A 31-year-old Asian woman was admitted to our hospital for myasthenia gravis and treated with methylprednisolone and pyridostigmine bromide 3 months postpartum.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0026896---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8568939",
-              "object": "MONDO:0009688",
-              "publications": [
-                "PMID:11093687",
-                "PMID:18632163",
-                "PMID:23158712",
-                "PMID:28299711",
-                "PMID:32145521",
-                "PMID:34627357"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12775535': {'publication date': '2003 Jul-Aug', 'sentence': 'The effects of HDMP should be explored in patients with other subtypes of AML who present with MT.', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 323565,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0020076",
-          "name": "myeloproliferative neoplasm",
-          "description": "A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C4345\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C4345\" NCI Thesaurus); A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008); UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "UMLS:C0027022",
-            "ICD10:D47.1",
-            "SNOMEDCT:109993000",
-            "EFO:0002428",
-            "SNOMEDCT:414794006",
-            "UMLS:C1292778",
-            "MEDDRA:10028577",
-            "MEDDRA:10013238",
-            "NCIT:C4345",
-            "HP:0005547",
-            "MONDO:0020076",
-            "MESH:D009196",
-            "ORPHANET:98274",
-            "SNOMEDCT:425333006",
-            "DOID:2226",
-            "MEDDRA:10077465",
-            "MEDDRA:10028576"
-          ],
-          "id": "MONDO:0020076",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic myeloproliferative disorder",
-            "Myeloproliferative neoplasm",
-            "Myeloproliferative Neoplasm",
-            "Myeloproliferative disorder",
-            "Myeloproliferative disease",
-            "Myeloproliferative Disorders",
-            "myeloproliferative neoplasm",
-            "chronic myeloproliferative disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/cancertopics/types/myeloproliferative",
-            "http://www.bloodjournal.org/content/114/5/937.long",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323565,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0020076",
-              "name": "myeloproliferative neoplasm",
-              "description": "A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C4345\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C4345\" NCI Thesaurus); A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008); UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "UMLS:C0027022",
-                "ICD10:D47.1",
-                "SNOMEDCT:109993000",
-                "EFO:0002428",
-                "SNOMEDCT:414794006",
-                "UMLS:C1292778",
-                "MEDDRA:10028577",
-                "MEDDRA:10013238",
-                "NCIT:C4345",
-                "HP:0005547",
-                "MONDO:0020076",
-                "MESH:D009196",
-                "ORPHANET:98274",
-                "SNOMEDCT:425333006",
-                "DOID:2226",
-                "MEDDRA:10077465",
-                "MEDDRA:10028576"
-              ],
-              "id": "MONDO:0020076",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic myeloproliferative disorder",
-                "Myeloproliferative neoplasm",
-                "Myeloproliferative Neoplasm",
-                "Myeloproliferative disorder",
-                "Myeloproliferative disease",
-                "Myeloproliferative Disorders",
-                "myeloproliferative neoplasm",
-                "chronic myeloproliferative disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/cancertopics/types/myeloproliferative",
-                "http://www.bloodjournal.org/content/114/5/937.long",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10000381,
-            "start": 570,
-            "end": 323565,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12775535': {'publication date': '2003 Jul-Aug', 'sentence': 'The effects of HDMP should be explored in patients with other subtypes of AML who present with MT.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0027022---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10221573",
-              "object": "MONDO:0020076",
-              "publications": [
-                "PMID:12775535"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:32563494': {'publication date': '2020 Aug', 'sentence': 'Neurologically, the therapeutic dosages of anticoagulants are linked to the high incidence of thrombotic complexities, while methylprednisolone is associated with myopathy.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 322010,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005336",
-          "name": "myopathy",
-          "description": "A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. [HPO:probinson]; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C101216",
-            "MEDDRA:10028641",
-            "MEDDRA:10028640",
-            "MEDDRA:10028300",
-            "MEDDRA:10028649",
-            "ICD10:G72.9",
-            "MEDDRA:10028302",
-            "MEDDRA:10028301",
-            "SNOMEDCT:129565002",
-            "ICD9:359.9",
-            "HP:0003198",
-            "EFO:0004145",
-            "DOID:423",
-            "MONDO:0005336",
-            "UMLS:C0026848",
-            "MESH:D009135",
-            "MEDDRA:10013237"
-          ],
-          "id": "MONDO:0005336",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myopathy, unspecified",
-            "Myopathy",
-            "myopathy",
-            "Muscular Diseases"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/myopathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322010,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005336",
-              "name": "myopathy",
-              "description": "A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. [HPO:probinson]; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C101216",
-                "MEDDRA:10028641",
-                "MEDDRA:10028640",
-                "MEDDRA:10028300",
-                "MEDDRA:10028649",
-                "ICD10:G72.9",
-                "MEDDRA:10028302",
-                "MEDDRA:10028301",
-                "SNOMEDCT:129565002",
-                "ICD9:359.9",
-                "HP:0003198",
-                "EFO:0004145",
-                "DOID:423",
-                "MONDO:0005336",
-                "UMLS:C0026848",
-                "MESH:D009135",
-                "MEDDRA:10013237"
-              ],
-              "id": "MONDO:0005336",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myopathy, unspecified",
-                "Myopathy",
-                "myopathy",
-                "Muscular Diseases"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/myopathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21754545,
-            "start": 570,
-            "end": 322010,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32563494': {'publication date': '2020 Aug', 'sentence': 'Neurologically, the therapeutic dosages of anticoagulants are linked to the high incidence of thrombotic complexities, while methylprednisolone is associated with myopathy.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0026848---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "22175056",
-              "object": "MONDO:0005336",
-              "publications": [
-                "PMID:32563494"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:11058428': {'publication date': '2000 Nov', 'sentence': 'To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.', 'subject score': 1000, 'object score': 851}, 'PMID:15534623': {'publication date': '2005 Apr', 'sentence': 'CONCLUSION: Our data suggest that MP in the dose recommended by the NASCIS may cause ACM.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 322010,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005336",
-          "name": "myopathy",
-          "description": "A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. [HPO:probinson]; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C101216",
-            "MEDDRA:10028641",
-            "MEDDRA:10028640",
-            "MEDDRA:10028300",
-            "MEDDRA:10028649",
-            "ICD10:G72.9",
-            "MEDDRA:10028302",
-            "MEDDRA:10028301",
-            "SNOMEDCT:129565002",
-            "ICD9:359.9",
-            "HP:0003198",
-            "EFO:0004145",
-            "DOID:423",
-            "MONDO:0005336",
-            "UMLS:C0026848",
-            "MESH:D009135",
-            "MEDDRA:10013237"
-          ],
-          "id": "MONDO:0005336",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myopathy, unspecified",
-            "Myopathy",
-            "myopathy",
-            "Muscular Diseases"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/myopathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322010,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005336",
-              "name": "myopathy",
-              "description": "A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. [HPO:probinson]; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C101216",
-                "MEDDRA:10028641",
-                "MEDDRA:10028640",
-                "MEDDRA:10028300",
-                "MEDDRA:10028649",
-                "ICD10:G72.9",
-                "MEDDRA:10028302",
-                "MEDDRA:10028301",
-                "SNOMEDCT:129565002",
-                "ICD9:359.9",
-                "HP:0003198",
-                "EFO:0004145",
-                "DOID:423",
-                "MONDO:0005336",
-                "UMLS:C0026848",
-                "MESH:D009135",
-                "MEDDRA:10013237"
-              ],
-              "id": "MONDO:0005336",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myopathy, unspecified",
-                "Myopathy",
-                "myopathy",
-                "Muscular Diseases"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/myopathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8344300,
-            "start": 570,
-            "end": 322010,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11058428': {'publication date': '2000 Nov', 'sentence': 'To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.', 'subject score': 1000, 'object score': 851}, 'PMID:15534623': {'publication date': '2005 Apr', 'sentence': 'CONCLUSION: Our data suggest that MP in the dose recommended by the NASCIS may cause ACM.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:causes---None---None---None---UMLS:C0026848---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8525599",
-              "object": "MONDO:0005336",
-              "publications": [
-                "PMID:11058428",
-                "PMID:15534623"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:36808229': {'publication date': '2023 Feb 21', 'sentence': 'PURPOSE: To report the therapeutic efficacy of intravenous methylprednisolone (IVMP) in patients with restrictive myopathy caused by thyroid eye disease (TED).', 'subject score': 888, 'object score': 853}, 'PMID:8970055': {'publication date': '1996 Dec', 'sentence': 'The calcifications turned into generalized heterotopic calcinosis with an exoskeleton-like pattern, despite successful treatment of her myopathy with methylprednisolone and immunosuppressive drugs.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 322010,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005336",
-          "name": "myopathy",
-          "description": "A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. [HPO:probinson]; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C101216",
-            "MEDDRA:10028641",
-            "MEDDRA:10028640",
-            "MEDDRA:10028300",
-            "MEDDRA:10028649",
-            "ICD10:G72.9",
-            "MEDDRA:10028302",
-            "MEDDRA:10028301",
-            "SNOMEDCT:129565002",
-            "ICD9:359.9",
-            "HP:0003198",
-            "EFO:0004145",
-            "DOID:423",
-            "MONDO:0005336",
-            "UMLS:C0026848",
-            "MESH:D009135",
-            "MEDDRA:10013237"
-          ],
-          "id": "MONDO:0005336",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myopathy, unspecified",
-            "Myopathy",
-            "myopathy",
-            "Muscular Diseases"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/myopathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322010,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005336",
-              "name": "myopathy",
-              "description": "A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. [HPO:probinson]; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C101216",
-                "MEDDRA:10028641",
-                "MEDDRA:10028640",
-                "MEDDRA:10028300",
-                "MEDDRA:10028649",
-                "ICD10:G72.9",
-                "MEDDRA:10028302",
-                "MEDDRA:10028301",
-                "SNOMEDCT:129565002",
-                "ICD9:359.9",
-                "HP:0003198",
-                "EFO:0004145",
-                "DOID:423",
-                "MONDO:0005336",
-                "UMLS:C0026848",
-                "MESH:D009135",
-                "MEDDRA:10013237"
-              ],
-              "id": "MONDO:0005336",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myopathy, unspecified",
-                "Myopathy",
-                "myopathy",
-                "Muscular Diseases"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/myopathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24917650,
-            "start": 570,
-            "end": 322010,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:36808229': {'publication date': '2023 Feb 21', 'sentence': 'PURPOSE: To report the therapeutic efficacy of intravenous methylprednisolone (IVMP) in patients with restrictive myopathy caused by thyroid eye disease (TED).', 'subject score': 888, 'object score': 853}, 'PMID:8970055': {'publication date': '1996 Dec', 'sentence': 'The calcifications turned into generalized heterotopic calcinosis with an exoskeleton-like pattern, despite successful treatment of her myopathy with methylprednisolone and immunosuppressive drugs.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0026848---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "25366540",
-              "object": "MONDO:0005336",
-              "publications": [
-                "PMID:36808229",
-                "PMID:8970055"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:30787634': {'publication date': '2019', 'sentence': 'Conclusion: Based on the current data, the efficacy and safety of local injection of triamcinolone and methylprednisolone at doses of 20 and 40 mg were associated with a significant improvement in pain, functional status, and strength.', 'subject score': 1000, 'object score': 1000}, 'PMID:32701926': {'publication date': '2020 Jul 23', 'sentence': 'RESULTS: Methylprednisolone revealed no significant differences in pain, trismus and QoL compared with placebo.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20475120,
-            "start": 570,
-            "end": 316891,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30787634': {'publication date': '2019', 'sentence': 'Conclusion: Based on the current data, the efficacy and safety of local injection of triamcinolone and methylprednisolone at doses of 20 and 40 mg were associated with a significant improvement in pain, functional status, and strength.', 'subject score': 1000, 'object score': 1000}, 'PMID:32701926': {'publication date': '2020 Jul 23', 'sentence': 'RESULTS: Methylprednisolone revealed no significant differences in pain, trismus and QoL compared with placebo.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "20879022",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:30787634",
-                "PMID:32701926"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:21983374': {'publication date': '2011 Oct', 'sentence': 'The increased interval in the administration of MP resulted in slightly greater pain and an increased prevalence of NeP.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15580751,
-            "start": 570,
-            "end": 316891,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21983374': {'publication date': '2011 Oct', 'sentence': 'The increased interval in the administration of MP resulted in slightly greater pain and an increased prevalence of NeP.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:causes---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "15906641",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:21983374"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:21983374': {'publication date': '2011 Oct', 'sentence': 'CONCLUSION: Although the delayed administration of high-dose MP did not significantly increase the severity of pain or prevalence of NeP, it should still be avoided due to the increased risk of serious side effects.', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15580752,
-            "start": 570,
-            "end": 316891,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21983374': {'publication date': '2011 Oct', 'sentence': 'CONCLUSION: Although the delayed administration of high-dose MP did not significantly increase the severity of pain or prevalence of NeP, it should still be avoided due to the increased risk of serious side effects.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "15906642",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:21983374"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:14600686': {'publication date': '2003 Nov', 'sentence': 'Comparison of the effects of 2 doses of methylprednisolone on pain, swelling, and trismus after third molar surgery.', 'subject score': 1000, 'object score': 1000}, 'PMID:17426908': {'publication date': '2007 Oct', 'sentence': 'Different pain symptoms and the effect of methylprednisolone on pain are evaluated.', 'subject score': 1000, 'object score': 1000}, 'PMID:21131371': {'publication date': '2011 Feb', 'sentence': 'Effect of high-dose preoperative methylprednisolone on pain and recovery after total knee arthroplasty: a randomized, placebo-controlled trial.', 'subject score': 861, 'object score': 1000}, 'PMID:24959459': {'publication date': '2014 Apr', 'sentence': 'Effect of intravenous methylprednisolone on pain after intertrochanteric femoral fracture surgery.', 'subject score': 888, 'object score': 1000}, 'PMID:25564196': {'publication date': '2017 Jan', 'sentence': 'The purpose of the study was to evaluate the effect of a single preoperative dose of systemic methylprednisolone on postsurgical pain after fast-track UKA.', 'subject score': 888, 'object score': 861}, 'PMID:27077747': {'publication date': '2016', 'sentence': 'Effect of Pulsed Methylprednisolone on Pain, in Patients with HTLV-1-Associated Myelopathy.', 'subject score': 872, 'object score': 1000}, 'PMID:28361779': {'publication date': '2016 01', 'sentence': 'Present study sought to determine effects of intrathecally delivered methylprednisolone on pain-like behaviour and pain-associated markers in three well established rodent pain models: (1) intraplantar carrageenan, (2) intraplantar formalin, and (3) ligation of L5/L6 spinal nerves (SNL model).', 'subject score': 773, 'object score': 1000}, 'PMID:28842370': {'publication date': '2017 Dec', 'sentence': 'The Effect of Preoperative Intra-Articular Methylprednisolone on Pain After TKA: A Randomized Double-Blinded Placebo Controlled Trial in Patients With High-Pain Knee Osteoarthritis and Sensitization.', 'subject score': 861, 'object score': 1000}, 'PMID:29200067': {'publication date': '2018 May', 'sentence': 'The estimated effect of 125 mg of methylprednisolone on pain at rest during the first 3 days after surgery was a nonsignificant increase of 0.2 (95% confidence interval, -0.5 to 0.9; P = .571) on the 11-point numerical rating scale.', 'subject score': 1000, 'object score': 1000}, 'PMID:3457335': {'publication date': '1986 Feb', 'sentence': 'The effect of methylprednisolone on pain, trismus, and swelling after removal of third molars.', 'subject score': 1000, 'object score': 1000}, 'PMID:35251416': {'publication date': '2022', 'sentence': 'Conclusions: Infiltration injection of dexamethasone and methylprednisolone had a significant effect in reducing pain after the endodontic treatment in necrotic pulp teeth, but between 6 and 12 hours, methylprednisolone had significantly more effect on pain relief than dexamethasone.', 'subject score': 1000, 'object score': 888}, 'PMID:9010948': {'publication date': '1997 Jan-Feb', 'sentence': 'Effect of local methylprednisolone on pain in a nerve injury model.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10609908,
-            "start": 570,
-            "end": 316891,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14600686': {'publication date': '2003 Nov', 'sentence': 'Comparison of the effects of 2 doses of methylprednisolone on pain, swelling, and trismus after third molar surgery.', 'subject score': 1000, 'object score': 1000}, 'PMID:17426908': {'publication date': '2007 Oct', 'sentence': 'Different pain symptoms and the effect of methylprednisolone on pain are evaluated.', 'subject score': 1000, 'object score': 1000}, 'PMID:21131371': {'publication date': '2011 Feb', 'sentence': 'Effect of high-dose preoperative methylprednisolone on pain and recovery after total knee arthroplasty: a randomized, placebo-controlled trial.', 'subject score': 861, 'object score': 1000}, 'PMID:24959459': {'publication date': '2014 Apr', 'sentence': 'Effect of intravenous methylprednisolone on pain after intertrochanteric femoral fracture surgery.', 'subject score': 888, 'object score': 1000}, 'PMID:25564196': {'publication date': '2017 Jan', 'sentence': 'The purpose of the study was to evaluate the effect of a single preoperative dose of systemic methylprednisolone on postsurgical pain after fast-track UKA.', 'subject score': 888, 'object score': 861}, 'PMID:27077747': {'publication date': '2016', 'sentence': 'Effect of Pulsed Methylprednisolone on Pain, in Patients with HTLV-1-Associated Myelopathy.', 'subject score': 872, 'object score': 1000}, 'PMID:28361779': {'publication date': '2016 01', 'sentence': 'Present study sought to determine effects of intrathecally delivered methylprednisolone on pain-like behaviour and pain-associated markers in three well established rodent pain models: (1) intraplantar carrageenan, (2) intraplantar formalin, and (3) ligation of L5/L6 spinal nerves (SNL model).', 'subject score': 773, 'object score': 1000}, 'PMID:28842370': {'publication date': '2017 Dec', 'sentence': 'The Effect of Preoperative Intra-Articular Methylprednisolone on Pain After TKA: A Randomized Double-Blinded Placebo Controlled Trial in Patients With High-Pain Knee Osteoarthritis and Sensitization.', 'subject score': 861, 'object score': 1000}, 'PMID:29200067': {'publication date': '2018 May', 'sentence': 'The estimated effect of 125 mg of methylprednisolone on pain at rest during the first 3 days after surgery was a nonsignificant increase of 0.2 (95% confidence interval, -0.5 to 0.9; P = .571) on the 11-point numerical rating scale.', 'subject score': 1000, 'object score': 1000}, 'PMID:3457335': {'publication date': '1986 Feb', 'sentence': 'The effect of methylprednisolone on pain, trismus, and swelling after removal of third molars.', 'subject score': 1000, 'object score': 1000}, 'PMID:35251416': {'publication date': '2022', 'sentence': 'Conclusions: Infiltration injection of dexamethasone and methylprednisolone had a significant effect in reducing pain after the endodontic treatment in necrotic pulp teeth, but between 6 and 12 hours, methylprednisolone had significantly more effect on pain relief than dexamethasone.', 'subject score': 1000, 'object score': 888}, 'PMID:9010948': {'publication date': '1997 Jan-Feb', 'sentence': 'Effect of local methylprednisolone on pain in a nerve injury model.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10845505",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:14600686",
-                "PMID:17426908",
-                "PMID:21131371",
-                "PMID:24959459",
-                "PMID:25564196",
-                "PMID:27077747",
-                "PMID:28361779",
-                "PMID:28842370",
-                "PMID:29200067",
-                "PMID:3457335",
-                "PMID:35251416",
-                "PMID:9010948"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10692608': {'publication date': '2000 Mar', 'sentence': 'A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm.', 'subject score': 1000, 'object score': 1000}, 'PMID:11513340': {'publication date': '2001 Aug', 'sentence': 'CONCLUSIONS: 1) In LSRPN, pain and neurological deficits improved (often dramatically) with IV MP treatment.', 'subject score': 851, 'object score': 1000}, 'PMID:11576210': {'publication date': '2001 Sep', 'sentence': 'In both cases, the pain was refractory to treatment with indomethacin, carbamazepine, and hypnotics, and only intravenous methylprednisolone with oral carbamazepine may have been partially effective in one case.', 'subject score': 790, 'object score': 1000}, 'PMID:11892709': {'publication date': '2002 Jan-Feb', 'sentence': 'CONCLUSION: These results suggest that periarticular injection of methylprednisolone may be effective in the treatment of pain in the region of the SIJ in non-spondylarthropathic patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:15778611': {'publication date': '2005 Apr', 'sentence': 'In addition, topical methylprednisolone (1 mg/mL) was necessary to control inflammation and pain.', 'subject score': 861, 'object score': 1000}, 'PMID:17178485': {'publication date': '2007 Jan', 'sentence': 'We observed only marginal difference between methylprednisolone and ketoprofen to relieve pain after this surgery.', 'subject score': 1000, 'object score': 1000}, 'PMID:2410117': {'publication date': '1985 Jul-Aug', 'sentence': 'Mean intensity of pain (visual analogue, 0-100 +/- SD) was 36.8 +/- 14 after MP treatment and 57.7 +/- 15 after placebo (P less than 0.01).', 'subject score': 888, 'object score': 1000}, 'PMID:26272452': {'publication date': '2015 Aug 14', 'sentence': 'Our data are intended to quantify the amount of ropivacaine and methylprednisolone needed by patients undergoing major abdominal surgery, to be stored in a new nanotechnology device for sustained pain treatment after surgery.', 'subject score': 1000, 'object score': 851}, 'PMID:27676662': {'publication date': '2016', 'sentence': 'OBJECTIVES: The present study aimed to evaluate the effect of adding calcitonin to local anesthetic and methylprednisolone using a modified coronoid approach in management of trigeminal neuralgia pain involving the mandibular and/or maxillary branches.', 'subject score': 1000, 'object score': 901}, 'PMID:28043311': {'publication date': '2016 Dec', 'sentence': 'OBJECTIVE: To determine the association between shoulder impingement and morphological characteristics of acromion and the role of sub-acromial injection of methylprednisolone in the short-term treatment for relieving pain and improve functional disability of these patients.', 'subject score': 1000, 'object score': 872}, 'PMID:28361779': {'publication date': '2016 01', 'sentence': 'IMPLICATIONS: Our results do not support use of intrathecal methylprednisolone in the treatment of pain.', 'subject score': 861, 'object score': 1000}, 'PMID:28652804': {'publication date': '2017', 'sentence': 'After treatment with analgesics such as gabapentin, mecobalamin, and dexamethasone/methylprednisolone for 1 week, the myodynamia had improved, but progressive pain persisted.', 'subject score': 888, 'object score': 888}, 'PMID:28803906': {'publication date': '2018 Mar', 'sentence': 'There is high evidence that HA is no different from methylprednisolone for pain at 1 month (SMD=.02; 95% CI, -.18 to .22; P=.85).', 'subject score': 1000, 'object score': 1000}, 'PMID:31083213': {'publication date': '2019 May', 'sentence': 'INTERVENTIONS: Intravenous methylprednisolone partially relieved the pain and paralysis.', 'subject score': 888, 'object score': 1000}, 'PMID:33961817': {'publication date': '2021 May 04', 'sentence': 'Low dose of methylprednisolone for pain and immune function after thoracic surgery.', 'subject score': 1000, 'object score': 1000}, 'PMID:35521428': {'publication date': '2022', 'sentence': 'Conclusion: Lidocaine in combination with methylprednisolone can significantly alleviate pain and reduce the usage of sufentanil after bilateral uterine artery embolization.', 'subject score': 1000, 'object score': 1000}, 'PMID:35742079': {'publication date': '2022 Jun 01', 'sentence': 'Efficacy of Methylprednisolone Compared to Other Drugs for Pain, Swelling, and Trismus Control after Third Molar Surgery: A Meta-Analysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:37168455': {'publication date': '2023', 'sentence': 'Efficacy of Preemptive Dexamethasone versus Methylprednisolone in the Management of Postoperative Discomfort and Pain after Mandibular Third Molar Surgery: A Systematic Review and Meta-Analysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:4479290': {'publication date': '1974 Sep-Oct', 'sentence': 'Subarachnoid methylprednisolone for relief of sciatic pain secondary to space-occupying lesion: a case report.', 'subject score': 861, 'object score': 861}, 'PMID:6288150': {'publication date': '1982', 'sentence': 'Solitary eosinophilic granulomata of bone also reportedly respond positively to direct injections fo methylprednisolone into the lesion by signs of healing and with relief of pain.', 'subject score': 851, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7851287,
-            "start": 570,
-            "end": 316891,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10692608': {'publication date': '2000 Mar', 'sentence': 'A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm.', 'subject score': 1000, 'object score': 1000}, 'PMID:11513340': {'publication date': '2001 Aug', 'sentence': 'CONCLUSIONS: 1) In LSRPN, pain and neurological deficits improved (often dramatically) with IV MP treatment.', 'subject score': 851, 'object score': 1000}, 'PMID:11576210': {'publication date': '2001 Sep', 'sentence': 'In both cases, the pain was refractory to treatment with indomethacin, carbamazepine, and hypnotics, and only intravenous methylprednisolone with oral carbamazepine may have been partially effective in one case.', 'subject score': 790, 'object score': 1000}, 'PMID:11892709': {'publication date': '2002 Jan-Feb', 'sentence': 'CONCLUSION: These results suggest that periarticular injection of methylprednisolone may be effective in the treatment of pain in the region of the SIJ in non-spondylarthropathic patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:15778611': {'publication date': '2005 Apr', 'sentence': 'In addition, topical methylprednisolone (1 mg/mL) was necessary to control inflammation and pain.', 'subject score': 861, 'object score': 1000}, 'PMID:17178485': {'publication date': '2007 Jan', 'sentence': 'We observed only marginal difference between methylprednisolone and ketoprofen to relieve pain after this surgery.', 'subject score': 1000, 'object score': 1000}, 'PMID:2410117': {'publication date': '1985 Jul-Aug', 'sentence': 'Mean intensity of pain (visual analogue, 0-100 +/- SD) was 36.8 +/- 14 after MP treatment and 57.7 +/- 15 after placebo (P less than 0.01).', 'subject score': 888, 'object score': 1000}, 'PMID:26272452': {'publication date': '2015 Aug 14', 'sentence': 'Our data are intended to quantify the amount of ropivacaine and methylprednisolone needed by patients undergoing major abdominal surgery, to be stored in a new nanotechnology device for sustained pain treatment after surgery.', 'subject score': 1000, 'object score': 851}, 'PMID:27676662': {'publication date': '2016', 'sentence': 'OBJECTIVES: The present study aimed to evaluate the effect of adding calcitonin to local anesthetic and methylprednisolone using a modified coronoid approach in management of trigeminal neuralgia pain involving the mandibular and/or maxillary branches.', 'subject score': 1000, 'object score': 901}, 'PMID:28043311': {'publication date': '2016 Dec', 'sentence': 'OBJECTIVE: To determine the association between shoulder impingement and morphological characteristics of acromion and the role of sub-acromial injection of methylprednisolone in the short-term treatment for relieving pain and improve functional disability of these patients.', 'subject score': 1000, 'object score': 872}, 'PMID:28361779': {'publication date': '2016 01', 'sentence': 'IMPLICATIONS: Our results do not support use of intrathecal methylprednisolone in the treatment of pain.', 'subject score': 861, 'object score': 1000}, 'PMID:28652804': {'publication date': '2017', 'sentence': 'After treatment with analgesics such as gabapentin, mecobalamin, and dexamethasone/methylprednisolone for 1 week, the myodynamia had improved, but progressive pain persisted.', 'subject score': 888, 'object score': 888}, 'PMID:28803906': {'publication date': '2018 Mar', 'sentence': 'There is high evidence that HA is no different from methylprednisolone for pain at 1 month (SMD=.02; 95% CI, -.18 to .22; P=.85).', 'subject score': 1000, 'object score': 1000}, 'PMID:31083213': {'publication date': '2019 May', 'sentence': 'INTERVENTIONS: Intravenous methylprednisolone partially relieved the pain and paralysis.', 'subject score': 888, 'object score': 1000}, 'PMID:33961817': {'publication date': '2021 May 04', 'sentence': 'Low dose of methylprednisolone for pain and immune function after thoracic surgery.', 'subject score': 1000, 'object score': 1000}, 'PMID:35521428': {'publication date': '2022', 'sentence': 'Conclusion: Lidocaine in combination with methylprednisolone can significantly alleviate pain and reduce the usage of sufentanil after bilateral uterine artery embolization.', 'subject score': 1000, 'object score': 1000}, 'PMID:35742079': {'publication date': '2022 Jun 01', 'sentence': 'Efficacy of Methylprednisolone Compared to Other Drugs for Pain, Swelling, and Trismus Control after Third Molar Surgery: A Meta-Analysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:37168455': {'publication date': '2023', 'sentence': 'Efficacy of Preemptive Dexamethasone versus Methylprednisolone in the Management of Postoperative Discomfort and Pain after Mandibular Third Molar Surgery: A Systematic Review and Meta-Analysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:4479290': {'publication date': '1974 Sep-Oct', 'sentence': 'Subarachnoid methylprednisolone for relief of sciatic pain secondary to space-occupying lesion: a case report.', 'subject score': 861, 'object score': 861}, 'PMID:6288150': {'publication date': '1982', 'sentence': 'Solitary eosinophilic granulomata of bone also reportedly respond positively to direct injections fo methylprednisolone into the lesion by signs of healing and with relief of pain.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8018847",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:10692608",
-                "PMID:11513340",
-                "PMID:11576210",
-                "PMID:11892709",
-                "PMID:15778611",
-                "PMID:17178485",
-                "PMID:2410117",
-                "PMID:26272452",
-                "PMID:27676662",
-                "PMID:28043311",
-                "PMID:28361779",
-                "PMID:28652804",
-                "PMID:28803906",
-                "PMID:31083213",
-                "PMID:33961817",
-                "PMID:35521428",
-                "PMID:35742079",
-                "PMID:37168455",
-                "PMID:4479290",
-                "PMID:6288150"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:15041599': {'publication date': '2004 Apr', 'sentence': 'In addition, we detected that sufentanil provided prolonged pain relief up to 24 h when compared with control, whereas when we combined sufentanil plus methylprednisolone, we found that it further reduced pain and use of analgesics when compared with sufentanil.', 'subject score': 851, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10868383,
-            "start": 570,
-            "end": 316891,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15041599': {'publication date': '2004 Apr', 'sentence': 'In addition, we detected that sufentanil provided prolonged pain relief up to 24 h when compared with control, whereas when we combined sufentanil plus methylprednisolone, we found that it further reduced pain and use of analgesics when compared with sufentanil.', 'subject score': 851, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:disrupts---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "11106658",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:15041599"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:10919304': {'publication date': '2000 Jun', 'sentence': 'Combined methylprednisolone, bupivacaine and morphine reduced pain, joint swelling, time of immobilization, duration of sick leave and return to sports after the arthroscopic procedure.', 'subject score': 888, 'object score': 1000}, 'PMID:15846603': {'publication date': '2005 Apr 18', 'sentence': 'For acute whiplash, administering intravenous methylprednisolone within eight hours reduced pain at one week, and sick leave but not pain at six months compared to placebo.', 'subject score': 888, 'object score': 1000}, 'PMID:16428536': {'publication date': '2006 Feb', 'sentence': 'Methylprednisolone reduces pain, emesis, and fatigue after breast augmentation surgery: a single-dose, randomized, parallel-group study with methylprednisolone 125 mg, parecoxib 40 mg, and placebo.', 'subject score': 1000, 'object score': 1000}, 'PMID:16652427': {'publication date': '2006 May', 'sentence': 'For acute whiplash, administering intravenous methylprednisolone within 8 hours reduced pain at one week [SMD -0.90 (95% CI -1.57 to -0.24)], and sick leave but not pain at 6 months compared to placebo.', 'subject score': 888, 'object score': 1000}, 'PMID:17636629': {'publication date': '2007 Jul 18', 'sentence': 'For acute whiplash, administering intravenous methylprednisolone within eight hours of injury reduced pain at one week (SMD -0.90, 95% CI -1.57 to -0.24), and sick leave but not pain at six months compared to placebo in one trial.', 'subject score': 888, 'object score': 1000}, 'PMID:24333776': {'publication date': '2014 Mar', 'sentence': 'Because treatment with glucocorticoids is effective in early complex regional pain syndrome, we investigated whether methylprednisolone (MP) reduces pain and sciatic nerve neuropeptide content in NEP ko and wt mice with nerve injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:24929444': {'publication date': '2015 Sep', 'sentence': 'Methylprednisolone was not shown to be effective for reducing pain.', 'subject score': 1000, 'object score': 872}, 'PMID:25564196': {'publication date': '2017 Jan', 'sentence': 'CONCLUSION: Addition of a single preoperative dose of 125 mg systemic methylprednisolone to a multimodal analgesic regime significantly reduced postsurgical pain and opioid consumption and decreased knee swelling in the first 24 h after fast-track UKA.', 'subject score': 775, 'object score': 861}, 'PMID:26501386': {'publication date': '2015 Dec', 'sentence': 'Methylprednisolone Does Not Reduce Persistent Pain after Cardiac Surgery.', 'subject score': 1000, 'object score': 888}, 'PMID:27737513': {'publication date': '2016 Oct 14', 'sentence': 'Based on a small study, BoNT/A (versus lidocaine/methylprednisolone) does not decrease phantom limb pain.', 'subject score': 888, 'object score': 901}, 'PMID:28977390': {'publication date': '2018 Jan 01', 'sentence': 'Methylprednisolone significantly decreased median pain scores on the day of surgery: at rest (numeric rating scale 1.6 vs 2.0, P = 0.019) and after mobilization to a sitting position (numeric rating scale 1.7 vs 2.5, P = 0.004) but not during arm abduction and coughing (P = 0.052 and P = 0.083, respectively).', 'subject score': 1000, 'object score': 861}, 'PMID:29200067': {'publication date': '2018 May', 'sentence': 'BACKGROUND: Methylprednisolone administered intravenously preoperatively has been shown to reduce pain, nausea, and fatigue after elective surgery.', 'subject score': 1000, 'object score': 1000}, 'PMID:29574247': {'publication date': '2018 May', 'sentence': 'Methylprednisolone showed comparable efficacy in reducing pain and improving functional recovery to HA.', 'subject score': 1000, 'object score': 872}, 'PMID:29642145': {'publication date': '2018 Apr', 'sentence': 'BACKGROUND: To evaluate the efficacy and safety of intra-articular methylprednisolone for reducing pain in patients with knee osteoarthritis.', 'subject score': 901, 'object score': 872}, 'PMID:29873217': {'publication date': '2018 May', 'sentence': 'At the same time, anesthetic warming method and changing the ratio of methylprednisolone can further reduce the incidence of vertigo and pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:30240024': {'publication date': '2018 Sep 21', 'sentence': 'CONCLUSION: Methylprednisolone provided no additional benefit for reducing pain, but caused more harm compared with saline following a single-dose IA injection in patients with TMJ arthralgia.', 'subject score': 1000, 'object score': 872}, 'PMID:30314709': {'publication date': '2018 Oct 09', 'sentence': 'Oral and intra-masseteric MP also seems to reduce pain and trismus in the early postoperative period.', 'subject score': 828, 'object score': 1000}, 'PMID:31124986': {'publication date': '2019 May', 'sentence': 'Intra-articular injection of methylprednisolone for reducing pain in knee osteoarthritis: A systematic review and meta-analysis: Retraction.', 'subject score': 1000, 'object score': 872}, 'PMID:31155459': {'publication date': '2019 Aug', 'sentence': 'CONCLUSION: Addition of methylprednisolone to periarticular infiltration cocktail for patients undergoing TKA has significant influence on reduction of pain in the early postoperative period and patients are able to regain knee flexion more quickly.', 'subject score': 1000, 'object score': 1000}, 'PMID:31589558': {'publication date': '2019 Nov', 'sentence': 'Can Photobiomodulation Therapy Be an Alternative to Methylprednisolone in Reducing Pain, Swelling, and Trismus After Removal of Impacted Third Molars?', 'subject score': 1000, 'object score': 872}}",
-    "p2": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8168569,
-            "start": 570,
-            "end": 316891,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10919304': {'publication date': '2000 Jun', 'sentence': 'Combined methylprednisolone, bupivacaine and morphine reduced pain, joint swelling, time of immobilization, duration of sick leave and return to sports after the arthroscopic procedure.', 'subject score': 888, 'object score': 1000}, 'PMID:15846603': {'publication date': '2005 Apr 18', 'sentence': 'For acute whiplash, administering intravenous methylprednisolone within eight hours reduced pain at one week, and sick leave but not pain at six months compared to placebo.', 'subject score': 888, 'object score': 1000}, 'PMID:16428536': {'publication date': '2006 Feb', 'sentence': 'Methylprednisolone reduces pain, emesis, and fatigue after breast augmentation surgery: a single-dose, randomized, parallel-group study with methylprednisolone 125 mg, parecoxib 40 mg, and placebo.', 'subject score': 1000, 'object score': 1000}, 'PMID:16652427': {'publication date': '2006 May', 'sentence': 'For acute whiplash, administering intravenous methylprednisolone within 8 hours reduced pain at one week [SMD -0.90 (95% CI -1.57 to -0.24)], and sick leave but not pain at 6 months compared to placebo.', 'subject score': 888, 'object score': 1000}, 'PMID:17636629': {'publication date': '2007 Jul 18', 'sentence': 'For acute whiplash, administering intravenous methylprednisolone within eight hours of injury reduced pain at one week (SMD -0.90, 95% CI -1.57 to -0.24), and sick leave but not pain at six months compared to placebo in one trial.', 'subject score': 888, 'object score': 1000}, 'PMID:24333776': {'publication date': '2014 Mar', 'sentence': 'Because treatment with glucocorticoids is effective in early complex regional pain syndrome, we investigated whether methylprednisolone (MP) reduces pain and sciatic nerve neuropeptide content in NEP ko and wt mice with nerve injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:24929444': {'publication date': '2015 Sep', 'sentence': 'Methylprednisolone was not shown to be effective for reducing pain.', 'subject score': 1000, 'object score': 872}, 'PMID:25564196': {'publication date': '2017 Jan', 'sentence': 'CONCLUSION: Addition of a single preoperative dose of 125 mg systemic methylprednisolone to a multimodal analgesic regime significantly reduced postsurgical pain and opioid consumption and decreased knee swelling in the first 24 h after fast-track UKA.', 'subject score': 775, 'object score': 861}, 'PMID:26501386': {'publication date': '2015 Dec', 'sentence': 'Methylprednisolone Does Not Reduce Persistent Pain after Cardiac Surgery.', 'subject score': 1000, 'object score': 888}, 'PMID:27737513': {'publication date': '2016 Oct 14', 'sentence': 'Based on a small study, BoNT/A (versus lidocaine/methylprednisolone) does not decrease phantom limb pain.', 'subject score': 888, 'object score': 901}, 'PMID:28977390': {'publication date': '2018 Jan 01', 'sentence': 'Methylprednisolone significantly decreased median pain scores on the day of surgery: at rest (numeric rating scale 1.6 vs 2.0, P = 0.019) and after mobilization to a sitting position (numeric rating scale 1.7 vs 2.5, P = 0.004) but not during arm abduction and coughing (P = 0.052 and P = 0.083, respectively).', 'subject score': 1000, 'object score': 861}, 'PMID:29200067': {'publication date': '2018 May', 'sentence': 'BACKGROUND: Methylprednisolone administered intravenously preoperatively has been shown to reduce pain, nausea, and fatigue after elective surgery.', 'subject score': 1000, 'object score': 1000}, 'PMID:29574247': {'publication date': '2018 May', 'sentence': 'Methylprednisolone showed comparable efficacy in reducing pain and improving functional recovery to HA.', 'subject score': 1000, 'object score': 872}, 'PMID:29642145': {'publication date': '2018 Apr', 'sentence': 'BACKGROUND: To evaluate the efficacy and safety of intra-articular methylprednisolone for reducing pain in patients with knee osteoarthritis.', 'subject score': 901, 'object score': 872}, 'PMID:29873217': {'publication date': '2018 May', 'sentence': 'At the same time, anesthetic warming method and changing the ratio of methylprednisolone can further reduce the incidence of vertigo and pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:30240024': {'publication date': '2018 Sep 21', 'sentence': 'CONCLUSION: Methylprednisolone provided no additional benefit for reducing pain, but caused more harm compared with saline following a single-dose IA injection in patients with TMJ arthralgia.', 'subject score': 1000, 'object score': 872}, 'PMID:30314709': {'publication date': '2018 Oct 09', 'sentence': 'Oral and intra-masseteric MP also seems to reduce pain and trismus in the early postoperative period.', 'subject score': 828, 'object score': 1000}, 'PMID:31124986': {'publication date': '2019 May', 'sentence': 'Intra-articular injection of methylprednisolone for reducing pain in knee osteoarthritis: A systematic review and meta-analysis: Retraction.', 'subject score': 1000, 'object score': 872}, 'PMID:31155459': {'publication date': '2019 Aug', 'sentence': 'CONCLUSION: Addition of methylprednisolone to periarticular infiltration cocktail for patients undergoing TKA has significant influence on reduction of pain in the early postoperative period and patients are able to regain knee flexion more quickly.', 'subject score': 1000, 'object score': 1000}, 'PMID:31589558': {'publication date': '2019 Nov', 'sentence': 'Can Photobiomodulation Therapy Be an Alternative to Methylprednisolone in Reducing Pain, Swelling, and Trismus After Removal of Impacted Third Molars?', 'subject score': 1000, 'object score': 872}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:prevents---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8345063",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:10919304",
-                "PMID:15846603",
-                "PMID:16428536",
-                "PMID:16652427",
-                "PMID:17636629",
-                "PMID:24333776",
-                "PMID:24929444",
-                "PMID:25564196",
-                "PMID:26501386",
-                "PMID:27737513",
-                "PMID:28977390",
-                "PMID:29200067",
-                "PMID:29574247",
-                "PMID:29642145",
-                "PMID:29873217",
-                "PMID:30240024",
-                "PMID:30314709",
-                "PMID:31124986",
-                "PMID:31155459",
-                "PMID:31589558"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:6895043': {'publication date': '1981 Aug', 'sentence': '1 The present study was undertaken to characterize the spectrum of arachidonic acid metabolites present in synovial effusions of patients with rheumatoid or psoriatic arthritis, and to compare changes in their concentration following a short-term treatment with 6alpha-methyl-prednisolone (6-MeP: 4-8 mg/day) or indoprofen (1.2 g/day), a nonsteroidal anti-inflammatory agent with proven synovial prostaglandin inhibitory effect.2 Measurements of prostaglandin E(2) (PGE(2)), thromboxane (TX) B(2), 6-keto-PGF(1alpha) and PGF(2alpha) were performed by radioimmunoassay techniques in synovial effusions obtained from 23 patients, and validated by thin-layer chromatographic analysis of the extracted immunoreactivity.3 PGE(2) and TXB(2) accounted for more than 60% of the total immunoreactivity in untreated patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:9694057': {'publication date': '1998', 'sentence': 'Methylprednisolone was the most prescribed corticosteroid, both in RA patients (63.2%) and in PA patients (65.9%).', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 536164,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011849",
-          "name": "psoriatic arthritis",
-          "description": "Joint inflammation associated with psoriasis.; A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people with psoriasis have psoriatic arthritis. It causes pain, stiffness, and swelling of the joints. It is often mild, but can sometimes be serious and affect many joints. The joint and skin problems don't always happen at the same time. Your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. There is no cure, but medicines can help control inflammation and pain. In rare cases, you might need surgery to repair or replace damaged joints.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10037163",
-            "EFO:0003778",
-            "UMLS:C0003872",
-            "DOID:9008",
-            "ORPHANET:40050",
-            "MEDDRA:10003377",
-            "ICD9:696.0",
-            "NCIT:C61277",
-            "MONDO:0011849",
-            "SNOMEDCT:156370009",
-            "MEDDRA:10037162",
-            "MESH:D015535",
-            "MEDDRA:10037160",
-            "ICD10:L40.5"
-          ],
-          "id": "MONDO:0011849",
-          "category": "biolink:Disease",
-          "all_names": [
-            "psoriatic arthritis",
-            "Arthritis, Psoriatic",
-            "Psoriatic arthropathy",
-            "Psoriatic Arthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/psoriatic_arthropathy",
-            "https://ghr.nlm.nih.gov/condition/psoriatic-arthritis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000413.htm",
-            "http://www.mayoclinic.com/health/psoriatic-arthritis/ds00476"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 536164,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011849",
-              "name": "psoriatic arthritis",
-              "description": "Joint inflammation associated with psoriasis.; A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people with psoriasis have psoriatic arthritis. It causes pain, stiffness, and swelling of the joints. It is often mild, but can sometimes be serious and affect many joints. The joint and skin problems don't always happen at the same time. Your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. There is no cure, but medicines can help control inflammation and pain. In rare cases, you might need surgery to repair or replace damaged joints.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10037163",
-                "EFO:0003778",
-                "UMLS:C0003872",
-                "DOID:9008",
-                "ORPHANET:40050",
-                "MEDDRA:10003377",
-                "ICD9:696.0",
-                "NCIT:C61277",
-                "MONDO:0011849",
-                "SNOMEDCT:156370009",
-                "MEDDRA:10037162",
-                "MESH:D015535",
-                "MEDDRA:10037160",
-                "ICD10:L40.5"
-              ],
-              "id": "MONDO:0011849",
-              "category": "biolink:Disease",
-              "all_names": [
-                "psoriatic arthritis",
-                "Arthritis, Psoriatic",
-                "Psoriatic arthropathy",
-                "Psoriatic Arthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/psoriatic_arthropathy",
-                "https://ghr.nlm.nih.gov/condition/psoriatic-arthritis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000413.htm",
-                "http://www.mayoclinic.com/health/psoriatic-arthritis/ds00476"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25848127,
-            "start": 570,
-            "end": 536164,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:6895043': {'publication date': '1981 Aug', 'sentence': '1 The present study was undertaken to characterize the spectrum of arachidonic acid metabolites present in synovial effusions of patients with rheumatoid or psoriatic arthritis, and to compare changes in their concentration following a short-term treatment with 6alpha-methyl-prednisolone (6-MeP: 4-8 mg/day) or indoprofen (1.2 g/day), a nonsteroidal anti-inflammatory agent with proven synovial prostaglandin inhibitory effect.2 Measurements of prostaglandin E(2) (PGE(2)), thromboxane (TX) B(2), 6-keto-PGF(1alpha) and PGF(2alpha) were performed by radioimmunoassay techniques in synovial effusions obtained from 23 patients, and validated by thin-layer chromatographic analysis of the extracted immunoreactivity.3 PGE(2) and TXB(2) accounted for more than 60% of the total immunoreactivity in untreated patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:9694057': {'publication date': '1998', 'sentence': 'Methylprednisolone was the most prescribed corticosteroid, both in RA patients (63.2%) and in PA patients (65.9%).', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0003872---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "26307075",
-              "object": "MONDO:0011849",
-              "publications": [
-                "PMID:6895043",
-                "PMID:9694057"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:1929552': {'publication date': '1991', 'sentence': 'The impaired effect on lymphocyte blastogenesis of glucocorticoids administered in vivo, in contrast to a normal in vitro reaction to dexamethasone, together with recent findings of an altered glucocorticoid receptor pharmacology in AD, points to a decreased biological in vivo efficiency of methylprednisolone in atopic dermatitis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 320151,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-          "name": "dermatitis, atopic",
-          "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MESH:C566404",
-            "MEDDRA:10012434",
-            "SNOMEDCT:24079001",
-            "MONDO:0011292",
-            "MEDDRA:10003641",
-            "MONDO:0100181",
-            "MEDDRA:10014191",
-            "OMIM:603165",
-            "HP:0001047",
-            "MEDDRA:10001711",
-            "MEDDRA:10003639",
-            "UMLS:C0011615",
-            "UMLS:C4280605",
-            "UMLS:C1864155",
-            "MEDDRA:10012438",
-            "MEDDRA:10014188",
-            "MEDDRA:10001712",
-            "MESH:D003876",
-            "SNOMEDCT:200775004"
-          ],
-          "id": "MONDO:0011292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis, Atopic, 1",
-            "dermatitis, atopic",
-            "Dermatitis, Atopic",
-            "Baby eczema",
-            "Dermatitis, atopic related phenotypic feature",
-            "Atopic dermatitis",
-            "dermatitis, atopic, 1"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:27904186",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320151,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-              "name": "dermatitis, atopic",
-              "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MESH:C566404",
-                "MEDDRA:10012434",
-                "SNOMEDCT:24079001",
-                "MONDO:0011292",
-                "MEDDRA:10003641",
-                "MONDO:0100181",
-                "MEDDRA:10014191",
-                "OMIM:603165",
-                "HP:0001047",
-                "MEDDRA:10001711",
-                "MEDDRA:10003639",
-                "UMLS:C0011615",
-                "UMLS:C4280605",
-                "UMLS:C1864155",
-                "MEDDRA:10012438",
-                "MEDDRA:10014188",
-                "MEDDRA:10001712",
-                "MESH:D003876",
-                "SNOMEDCT:200775004"
-              ],
-              "id": "MONDO:0011292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis, Atopic, 1",
-                "dermatitis, atopic",
-                "Dermatitis, Atopic",
-                "Baby eczema",
-                "Dermatitis, atopic related phenotypic feature",
-                "Atopic dermatitis",
-                "dermatitis, atopic, 1"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:27904186",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13979810,
-            "start": 570,
-            "end": 320151,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1929552': {'publication date': '1991', 'sentence': 'The impaired effect on lymphocyte blastogenesis of glucocorticoids administered in vivo, in contrast to a normal in vitro reaction to dexamethasone, together with recent findings of an altered glucocorticoid receptor pharmacology in AD, points to a decreased biological in vivo efficiency of methylprednisolone in atopic dermatitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0011615---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14278238",
-              "object": "MONDO:0011292",
-              "publications": [
-                "PMID:1929552"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12603681': {'publication date': '2003 Feb', 'sentence': 'The objective of this multicentre, parallel, blinded, randomized controlled study was to evaluate the efficacy and the safety of cyclosporine (CsA group, 117 dogs) in comparison with methylprednisolone (MP group, 59 dogs) in the treatment of atopic dermatitis for 4 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:15200072': {'publication date': '2004 May 29', 'sentence': 'Remission of the clinical signs of atopic dermatitis in dogs after cessation of treatment with cyclosporin A or methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:1678223': {'publication date': '1991', 'sentence': 'We therefore studied the serum concentrations of cortisol, prolactin and adrenocorticotropin under baseline conditions, after 1 mg dexamethasone and after a defined methylprednisolone treatment in 15 patients with atopic dermatitis, in comparison with 10 healthy controls.', 'subject score': 790, 'object score': 1000}, 'PMID:36136706': {'publication date': '2022 Sep 09', 'sentence': 'A Pilot Randomized Trial to Compare Polyuria and Polydipsia during a Short Course of Prednisolone or Methylprednisolone in Dogs with Atopic Dermatitis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 320151,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-          "name": "dermatitis, atopic",
-          "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MESH:C566404",
-            "MEDDRA:10012434",
-            "SNOMEDCT:24079001",
-            "MONDO:0011292",
-            "MEDDRA:10003641",
-            "MONDO:0100181",
-            "MEDDRA:10014191",
-            "OMIM:603165",
-            "HP:0001047",
-            "MEDDRA:10001711",
-            "MEDDRA:10003639",
-            "UMLS:C0011615",
-            "UMLS:C4280605",
-            "UMLS:C1864155",
-            "MEDDRA:10012438",
-            "MEDDRA:10014188",
-            "MEDDRA:10001712",
-            "MESH:D003876",
-            "SNOMEDCT:200775004"
-          ],
-          "id": "MONDO:0011292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis, Atopic, 1",
-            "dermatitis, atopic",
-            "Dermatitis, Atopic",
-            "Baby eczema",
-            "Dermatitis, atopic related phenotypic feature",
-            "Atopic dermatitis",
-            "dermatitis, atopic, 1"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:27904186",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320151,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-              "name": "dermatitis, atopic",
-              "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MESH:C566404",
-                "MEDDRA:10012434",
-                "SNOMEDCT:24079001",
-                "MONDO:0011292",
-                "MEDDRA:10003641",
-                "MONDO:0100181",
-                "MEDDRA:10014191",
-                "OMIM:603165",
-                "HP:0001047",
-                "MEDDRA:10001711",
-                "MEDDRA:10003639",
-                "UMLS:C0011615",
-                "UMLS:C4280605",
-                "UMLS:C1864155",
-                "MEDDRA:10012438",
-                "MEDDRA:10014188",
-                "MEDDRA:10001712",
-                "MESH:D003876",
-                "SNOMEDCT:200775004"
-              ],
-              "id": "MONDO:0011292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis, Atopic, 1",
-                "dermatitis, atopic",
-                "Dermatitis, Atopic",
-                "Baby eczema",
-                "Dermatitis, atopic related phenotypic feature",
-                "Atopic dermatitis",
-                "dermatitis, atopic, 1"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:27904186",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9820760,
-            "start": 570,
-            "end": 320151,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12603681': {'publication date': '2003 Feb', 'sentence': 'The objective of this multicentre, parallel, blinded, randomized controlled study was to evaluate the efficacy and the safety of cyclosporine (CsA group, 117 dogs) in comparison with methylprednisolone (MP group, 59 dogs) in the treatment of atopic dermatitis for 4 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:15200072': {'publication date': '2004 May 29', 'sentence': 'Remission of the clinical signs of atopic dermatitis in dogs after cessation of treatment with cyclosporin A or methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:1678223': {'publication date': '1991', 'sentence': 'We therefore studied the serum concentrations of cortisol, prolactin and adrenocorticotropin under baseline conditions, after 1 mg dexamethasone and after a defined methylprednisolone treatment in 15 patients with atopic dermatitis, in comparison with 10 healthy controls.', 'subject score': 790, 'object score': 1000}, 'PMID:36136706': {'publication date': '2022 Sep 09', 'sentence': 'A Pilot Randomized Trial to Compare Polyuria and Polydipsia during a Short Course of Prednisolone or Methylprednisolone in Dogs with Atopic Dermatitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0011615---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10049014",
-              "object": "MONDO:0011292",
-              "publications": [
-                "PMID:12603681",
-                "PMID:15200072",
-                "PMID:1678223",
-                "PMID:36136706"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:24332587': {'publication date': '2014 May', 'sentence': 'The purpose of this study was to evaluate the efficacy of supraperiosteal injection of methylprednisolone compared with an oral tablet form and intravenous (i.v.) injection in the prevention of postoperative pain and oedema associated with inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:24481505': {'publication date': '2014 Sep-Oct', 'sentence': 'After initial treatment with pulsed intravenous methylprednisolone, followed by rituximab and radiotherapy, there was a marked improvement in orbital inflammation and clinical and radiological improvement in the compressive optic neuropathy.', 'subject score': 840, 'object score': 888}, 'PMID:24692123': {'publication date': '2014 Apr 28', 'sentence': 'Glutathione PEGylated liposomal methylprednisolone (2B3-201) has been developed as treatment for neuroinflammatory conditions and was evaluated in ocular inflammation.', 'subject score': 775, 'object score': 888}, 'PMID:2472021': {'publication date': '1989 Jun 16', 'sentence': 'Methylprednisolone and uridine were both examined in this model due to their roles in inflammation and RNA synthesis, respectively.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16984564,
-            "start": 570,
-            "end": 183319,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24332587': {'publication date': '2014 May', 'sentence': 'The purpose of this study was to evaluate the efficacy of supraperiosteal injection of methylprednisolone compared with an oral tablet form and intravenous (i.v.) injection in the prevention of postoperative pain and oedema associated with inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:24481505': {'publication date': '2014 Sep-Oct', 'sentence': 'After initial treatment with pulsed intravenous methylprednisolone, followed by rituximab and radiotherapy, there was a marked improvement in orbital inflammation and clinical and radiological improvement in the compressive optic neuropathy.', 'subject score': 840, 'object score': 888}, 'PMID:24692123': {'publication date': '2014 Apr 28', 'sentence': 'Glutathione PEGylated liposomal methylprednisolone (2B3-201) has been developed as treatment for neuroinflammatory conditions and was evaluated in ocular inflammation.', 'subject score': 775, 'object score': 888}, 'PMID:2472021': {'publication date': '1989 Jun 16', 'sentence': 'Methylprednisolone and uridine were both examined in this model due to their roles in inflammation and RNA synthesis, respectively.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "17333962",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:24332587",
-                "PMID:24481505",
-                "PMID:24692123",
-                "PMID:2472021"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:26344122': {'publication date': '2015 Oct', 'sentence': \"On the other hand, daily administration of methylprednisolone and tenoxicam for 4 weeks caused increased inflammation and fibrosis and wasn't affective on protection of nerve physiomorphology.\", 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18166641,
-            "start": 570,
-            "end": 183319,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26344122': {'publication date': '2015 Oct', 'sentence': \"On the other hand, daily administration of methylprednisolone and tenoxicam for 4 weeks caused increased inflammation and fibrosis and wasn't affective on protection of nerve physiomorphology.\", 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:causes---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "18534953",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:26344122"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:35439827': {'publication date': '2022 Apr 19', 'sentence': \"Methylprednisolone increases some astrogliosis and inflammation biomarkers' levels; however, it did not affect the apoptotic biomarkers.\", 'subject score': 1000, 'object score': 623}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23979844,
-            "start": 570,
-            "end": 183319,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35439827': {'publication date': '2022 Apr 19', 'sentence': \"Methylprednisolone increases some astrogliosis and inflammation biomarkers' levels; however, it did not affect the apoptotic biomarkers.\", 'subject score': 1000, 'object score': 623}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "24420470",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:35439827"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:34158797': {'publication date': '2021', 'sentence': 'Effect of Methylprednisolone on Inflammation and Coagulation in Patients with Severe COVID-19: A Retrospective Cohort Study.', 'subject score': 1000, 'object score': 1000}, 'PMID:6346605': {'publication date': '1983 Jul', 'sentence': 'Two prophylactic immunosuppressive drugs, cyclosporine and methylprednisolone (MP), were compared for their effect on the in situ inflammatory reaction of granulation tissue formation and on wound healing.', 'subject score': 1000, 'object score': 888}, 'PMID:650062': {'publication date': '1978 Jun', 'sentence': 'The effect of methyl prednisolone on meningeal inflammation.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23039988,
-            "start": 570,
-            "end": 183319,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34158797': {'publication date': '2021', 'sentence': 'Effect of Methylprednisolone on Inflammation and Coagulation in Patients with Severe COVID-19: A Retrospective Cohort Study.', 'subject score': 1000, 'object score': 1000}, 'PMID:6346605': {'publication date': '1983 Jul', 'sentence': 'Two prophylactic immunosuppressive drugs, cyclosporine and methylprednisolone (MP), were compared for their effect on the in situ inflammatory reaction of granulation tissue formation and on wound healing.', 'subject score': 1000, 'object score': 888}, 'PMID:650062': {'publication date': '1978 Jun', 'sentence': 'The effect of methyl prednisolone on meningeal inflammation.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "23472756",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:34158797",
-                "PMID:6346605",
-                "PMID:650062"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10414517': {'publication date': '1999 Jun', 'sentence': 'Methylprednisolone treatment resulted in the greatest reduction in the inflammatory cell infiltrate but the numbers of infected neurons did not increase concomitantly.', 'subject score': 888, 'object score': 901}, 'PMID:11934518': {'publication date': '2002 Apr', 'sentence': 'Since sequential MRI studies showed prompt reduction of the cord swelling, the high-dose methylprednisolone therapy employed seemed to have been effective for improvement of inflammation.', 'subject score': 861, 'object score': 1000}, 'PMID:15778611': {'publication date': '2005 Apr', 'sentence': 'In addition, topical methylprednisolone (1 mg/mL) was necessary to control inflammation and pain.', 'subject score': 861, 'object score': 1000}, 'PMID:16419423': {'publication date': '2005', 'sentence': 'CONCLUSION: The intensity of ocular inflammation in the group receiving HBO therapy combined with anterior subtenon injection of methylprednisolone therapy was lower than in the other groups.', 'subject score': 888, 'object score': 888}, 'PMID:16878063': {'publication date': '2006 Aug 01', 'sentence': 'OBJECTIVE: To compare the efficacy of methylprednisolone (corticoid) versus diclofenac (nonsteroidal anti-inflammatory--NSAID) in the treatment of inflammation and trismus after the surgical removal of lower third molars.', 'subject score': 1000, 'object score': 1000}, 'PMID:17237695': {'publication date': '2007 Jan-Feb', 'sentence': 'Topical cyclosporine and 1% methylprednisolone eliminated the anterior segment inflammation; subsequent treatment with systemic prednisone reduced the ptosis and edema.', 'subject score': 861, 'object score': 901}, 'PMID:18554795': {'publication date': '2008 Aug 01', 'sentence': 'These findings suggest that the brain responds to OVA stimulation in a rat model of allergic asthma and that MP treatment cannot only ameliorate airway inflammation but also OVA-induced effects.', 'subject score': 888, 'object score': 861}, 'PMID:20383416': {'publication date': '2010 Apr', 'sentence': 'CONCLUSION: In the early stage of cerulein induced AP, the administration of etanercept plus MP attenuated pancreatic inflammation and significant damage in rats.', 'subject score': 851, 'object score': 888}, 'PMID:25037177': {'publication date': '2014 Sep 15', 'sentence': 'Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis.', 'subject score': 775, 'object score': 888}, 'PMID:27288919': {'publication date': '2016 Jul 15', 'sentence': 'Expression levels of TNF-alpha, IL-4, and IL-5 were also found significantly reduced after treatment with both PI extract and MP, which might have resulted in the amelioration of airway inflammation.', 'subject score': 1000, 'object score': 861}, 'PMID:27904502': {'publication date': '2016 Oct', 'sentence': 'Our results demonstrated that a combined treatment with methylprednisolone and rosiglitazone had a more pronounced effect on attenuation of inflammation and cell apoptosis, as well as increased functional recovery, compared with either single treatment alone, indicating that a combination better promoted recovery of neurological function after injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:29253747': {'publication date': '2018 02', 'sentence': 'CONCLUSION: Administration of MPN to BDDs at specified periods until kidney harvest resulted in less systemic inflammation in the BDDs and improved renal function in kidney graft recipients compared with common MPN therapy.', 'subject score': 851, 'object score': 790}, 'PMID:29879013': {'publication date': '2018 Jun', 'sentence': 'INTERVENTIONS: He was treated with gamma globulin (2 g/kg) for 1 day, mannitol and furosemide to reduce intracranial pressure, human albumin to correct hypoproteinemia, methylprednisolone to control inflammation, and both aspirin and dipyridamole for anticoagulation.', 'subject score': 1000, 'object score': 1000}, 'PMID:8032946': {'publication date': '1994 Apr 25', 'sentence': 'Methylprednisolone attenuates inflammation, increase of brain water content and intracranial pressure, but does not influence cerebral blood flow changes in experimental pneumococcal meningitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:9361341': {'publication date': '1997 Nov', 'sentence': 'Lazaroids are developed nonglucocorticoid analogues of methylprednisolone with multiple actions, including the scavenging of reactive oxygen species, the attenuation of inflammation, and the stabilization of biological membranes.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7399713,
-            "start": 570,
-            "end": 183319,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:10414517': {'publication date': '1999 Jun', 'sentence': 'Methylprednisolone treatment resulted in the greatest reduction in the inflammatory cell infiltrate but the numbers of infected neurons did not increase concomitantly.', 'subject score': 888, 'object score': 901}, 'PMID:11934518': {'publication date': '2002 Apr', 'sentence': 'Since sequential MRI studies showed prompt reduction of the cord swelling, the high-dose methylprednisolone therapy employed seemed to have been effective for improvement of inflammation.', 'subject score': 861, 'object score': 1000}, 'PMID:15778611': {'publication date': '2005 Apr', 'sentence': 'In addition, topical methylprednisolone (1 mg/mL) was necessary to control inflammation and pain.', 'subject score': 861, 'object score': 1000}, 'PMID:16419423': {'publication date': '2005', 'sentence': 'CONCLUSION: The intensity of ocular inflammation in the group receiving HBO therapy combined with anterior subtenon injection of methylprednisolone therapy was lower than in the other groups.', 'subject score': 888, 'object score': 888}, 'PMID:16878063': {'publication date': '2006 Aug 01', 'sentence': 'OBJECTIVE: To compare the efficacy of methylprednisolone (corticoid) versus diclofenac (nonsteroidal anti-inflammatory--NSAID) in the treatment of inflammation and trismus after the surgical removal of lower third molars.', 'subject score': 1000, 'object score': 1000}, 'PMID:17237695': {'publication date': '2007 Jan-Feb', 'sentence': 'Topical cyclosporine and 1% methylprednisolone eliminated the anterior segment inflammation; subsequent treatment with systemic prednisone reduced the ptosis and edema.', 'subject score': 861, 'object score': 901}, 'PMID:18554795': {'publication date': '2008 Aug 01', 'sentence': 'These findings suggest that the brain responds to OVA stimulation in a rat model of allergic asthma and that MP treatment cannot only ameliorate airway inflammation but also OVA-induced effects.', 'subject score': 888, 'object score': 861}, 'PMID:20383416': {'publication date': '2010 Apr', 'sentence': 'CONCLUSION: In the early stage of cerulein induced AP, the administration of etanercept plus MP attenuated pancreatic inflammation and significant damage in rats.', 'subject score': 851, 'object score': 888}, 'PMID:25037177': {'publication date': '2014 Sep 15', 'sentence': 'Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis.', 'subject score': 775, 'object score': 888}, 'PMID:27288919': {'publication date': '2016 Jul 15', 'sentence': 'Expression levels of TNF-alpha, IL-4, and IL-5 were also found significantly reduced after treatment with both PI extract and MP, which might have resulted in the amelioration of airway inflammation.', 'subject score': 1000, 'object score': 861}, 'PMID:27904502': {'publication date': '2016 Oct', 'sentence': 'Our results demonstrated that a combined treatment with methylprednisolone and rosiglitazone had a more pronounced effect on attenuation of inflammation and cell apoptosis, as well as increased functional recovery, compared with either single treatment alone, indicating that a combination better promoted recovery of neurological function after injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:29253747': {'publication date': '2018 02', 'sentence': 'CONCLUSION: Administration of MPN to BDDs at specified periods until kidney harvest resulted in less systemic inflammation in the BDDs and improved renal function in kidney graft recipients compared with common MPN therapy.', 'subject score': 851, 'object score': 790}, 'PMID:29879013': {'publication date': '2018 Jun', 'sentence': 'INTERVENTIONS: He was treated with gamma globulin (2 g/kg) for 1 day, mannitol and furosemide to reduce intracranial pressure, human albumin to correct hypoproteinemia, methylprednisolone to control inflammation, and both aspirin and dipyridamole for anticoagulation.', 'subject score': 1000, 'object score': 1000}, 'PMID:8032946': {'publication date': '1994 Apr 25', 'sentence': 'Methylprednisolone attenuates inflammation, increase of brain water content and intracranial pressure, but does not influence cerebral blood flow changes in experimental pneumococcal meningitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:9361341': {'publication date': '1997 Nov', 'sentence': 'Lazaroids are developed nonglucocorticoid analogues of methylprednisolone with multiple actions, including the scavenging of reactive oxygen species, the attenuation of inflammation, and the stabilization of biological membranes.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7552935",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:10414517",
-                "PMID:11934518",
-                "PMID:15778611",
-                "PMID:16419423",
-                "PMID:16878063",
-                "PMID:17237695",
-                "PMID:18554795",
-                "PMID:20383416",
-                "PMID:25037177",
-                "PMID:27288919",
-                "PMID:27904502",
-                "PMID:29253747",
-                "PMID:29879013",
-                "PMID:8032946",
-                "PMID:9361341"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:11150324': {'publication date': '2001 Jan 01', 'sentence': 'These findings demonstrate that MP may suppress post-traumatic inflammatory reaction by inhibiting both the AP-1 and NF-kappaB transcription cascades via a GR mechanism.', 'subject score': 1000, 'object score': 861}, 'PMID:17149544': {'publication date': '2007 Jun', 'sentence': 'In conclusion, results indicate that late use of MP yields adverse post-MI structure/function outcomes that correlate with suppression of inflammation and increased MMP activity.', 'subject score': 1000, 'object score': 1000}, 'PMID:23602068': {'publication date': '2013 Jun', 'sentence': 'Methylprednisolone in neonatal cardiac surgery: reduced inflammation without improved clinical outcome.', 'subject score': 1000, 'object score': 888}, 'PMID:2395047': {'publication date': '1990 Sep', 'sentence': 'This study compared two nonsteroidal anti-inflammatory drugs (NSAIDs), flurbiprofen and ibuprofen, with a prototype glucocorticoid, methylprednisolone, in two replicate placebo-controlled studies for suppression of inflammation due to the surgical removal of impacted third molars.', 'subject score': 1000, 'object score': 1000}, 'PMID:24396446': {'publication date': '2014 Feb', 'sentence': 'Prophylactic administration of methylprednisolone during the perioperative period may reduce the incidence of specific types of postoperative complications and inhibit the postoperative inflammatory reaction.', 'subject score': 1000, 'object score': 901}, 'PMID:27446512': {'publication date': '2016 Jul', 'sentence': 'CONCLUSION: Combining MP and TR is therapeutically more effective in improving functional recovery, inhibiting inflammation and glial scar formation after acute SCI.', 'subject score': 1000, 'object score': 1000}, 'PMID:27775998': {'publication date': '2017 02', 'sentence': 'The authors evaluated the effect of high-dose methylprednisolone to suppress inflammation on the incidence of delirium and postoperative quality of recovery after cardiac surgery.', 'subject score': 901, 'object score': 1000}, 'PMID:28962262': {'publication date': '2014', 'sentence': 'In conclusion, immunosuppression therapy with intravenous methylprednisolone and cyclophosphamide may counteract immune mediated inflammation after paraquat poisoning and improve survival of patients with admission eGFR < 50 ml/min/1.73 m2 and WBC count > 11,000/MUL.', 'subject score': 888, 'object score': 840}, 'PMID:29977750': {'publication date': '2018', 'sentence': 'We used mPSL to inhibit the inflammation following liposteroid administration.', 'subject score': 1000, 'object score': 1000}, 'PMID:34384886': {'publication date': '2021 Aug 09', 'sentence': 'For moderate or severe patients, the immunosuppressive agents were largely reduced or even interrupted, low-dose IVIG was adopted, and low-dose methylprednisolone (MP) was used to inhibit inflammation and rejection.', 'subject score': 901, 'object score': 1000}, 'PMID:3555968': {'publication date': '1987 Mar', 'sentence': 'Leucocyte and polymorphonuclear counts and viscosity measurement of the synovial fluid were performed before and 14 days after injection, which showed methylprednisolone to be significantly superior to bufexamac in suppressing inflammation.', 'subject score': 1000, 'object score': 872}, 'PMID:35949317': {'publication date': '2022 Sep', 'sentence': 'Collectively, the present results suggested that combination treatment of AZM and MP could inhibit    M. pneumoniae     infection-induced inflammation, cell viability loss and promoted apoptosis partly by regulating miR-499a-5p/STAT3 axis.', 'subject score': 1000, 'object score': 875}, 'PMID:6346605': {'publication date': '1983 Jul', 'sentence': 'No reduction in the number of inflammatory cells was observed in the cyclosporine-treated sponges compared with the controls, whereas MP suppressed the inflammation strongly.', 'subject score': 1000, 'object score': 861}, 'PMID:7519120': {'publication date': '1994 Aug 15', 'sentence': 'To test the possibility that inflammation is the key element in the development of these wound tumors, we used beta-methylprednisolone, an antiinflammatory drug that inhibits inflammation (including blood vessel leakage), to determine if wound tumor development could be prevented.', 'subject score': 861, 'object score': 1000}, 'PMID:8667252': {'publication date': '1996 Jun', 'sentence': 'The corticosteroid, methylprednisolone (medrol), and the nonsteroidal antiinflammatory drug, flurbiprofen (Ansaid), administered at 2 mg/kg (p.o.), suppressed the clinical signs of CIA, and caused 79 to 83% inhibition of hind paw inflammation.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8456261,
-            "start": 570,
-            "end": 183319,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11150324': {'publication date': '2001 Jan 01', 'sentence': 'These findings demonstrate that MP may suppress post-traumatic inflammatory reaction by inhibiting both the AP-1 and NF-kappaB transcription cascades via a GR mechanism.', 'subject score': 1000, 'object score': 861}, 'PMID:17149544': {'publication date': '2007 Jun', 'sentence': 'In conclusion, results indicate that late use of MP yields adverse post-MI structure/function outcomes that correlate with suppression of inflammation and increased MMP activity.', 'subject score': 1000, 'object score': 1000}, 'PMID:23602068': {'publication date': '2013 Jun', 'sentence': 'Methylprednisolone in neonatal cardiac surgery: reduced inflammation without improved clinical outcome.', 'subject score': 1000, 'object score': 888}, 'PMID:2395047': {'publication date': '1990 Sep', 'sentence': 'This study compared two nonsteroidal anti-inflammatory drugs (NSAIDs), flurbiprofen and ibuprofen, with a prototype glucocorticoid, methylprednisolone, in two replicate placebo-controlled studies for suppression of inflammation due to the surgical removal of impacted third molars.', 'subject score': 1000, 'object score': 1000}, 'PMID:24396446': {'publication date': '2014 Feb', 'sentence': 'Prophylactic administration of methylprednisolone during the perioperative period may reduce the incidence of specific types of postoperative complications and inhibit the postoperative inflammatory reaction.', 'subject score': 1000, 'object score': 901}, 'PMID:27446512': {'publication date': '2016 Jul', 'sentence': 'CONCLUSION: Combining MP and TR is therapeutically more effective in improving functional recovery, inhibiting inflammation and glial scar formation after acute SCI.', 'subject score': 1000, 'object score': 1000}, 'PMID:27775998': {'publication date': '2017 02', 'sentence': 'The authors evaluated the effect of high-dose methylprednisolone to suppress inflammation on the incidence of delirium and postoperative quality of recovery after cardiac surgery.', 'subject score': 901, 'object score': 1000}, 'PMID:28962262': {'publication date': '2014', 'sentence': 'In conclusion, immunosuppression therapy with intravenous methylprednisolone and cyclophosphamide may counteract immune mediated inflammation after paraquat poisoning and improve survival of patients with admission eGFR < 50 ml/min/1.73 m2 and WBC count > 11,000/MUL.', 'subject score': 888, 'object score': 840}, 'PMID:29977750': {'publication date': '2018', 'sentence': 'We used mPSL to inhibit the inflammation following liposteroid administration.', 'subject score': 1000, 'object score': 1000}, 'PMID:34384886': {'publication date': '2021 Aug 09', 'sentence': 'For moderate or severe patients, the immunosuppressive agents were largely reduced or even interrupted, low-dose IVIG was adopted, and low-dose methylprednisolone (MP) was used to inhibit inflammation and rejection.', 'subject score': 901, 'object score': 1000}, 'PMID:3555968': {'publication date': '1987 Mar', 'sentence': 'Leucocyte and polymorphonuclear counts and viscosity measurement of the synovial fluid were performed before and 14 days after injection, which showed methylprednisolone to be significantly superior to bufexamac in suppressing inflammation.', 'subject score': 1000, 'object score': 872}, 'PMID:35949317': {'publication date': '2022 Sep', 'sentence': 'Collectively, the present results suggested that combination treatment of AZM and MP could inhibit    M. pneumoniae     infection-induced inflammation, cell viability loss and promoted apoptosis partly by regulating miR-499a-5p/STAT3 axis.', 'subject score': 1000, 'object score': 875}, 'PMID:6346605': {'publication date': '1983 Jul', 'sentence': 'No reduction in the number of inflammatory cells was observed in the cyclosporine-treated sponges compared with the controls, whereas MP suppressed the inflammation strongly.', 'subject score': 1000, 'object score': 861}, 'PMID:7519120': {'publication date': '1994 Aug 15', 'sentence': 'To test the possibility that inflammation is the key element in the development of these wound tumors, we used beta-methylprednisolone, an antiinflammatory drug that inhibits inflammation (including blood vessel leakage), to determine if wound tumor development could be prevented.', 'subject score': 861, 'object score': 1000}, 'PMID:8667252': {'publication date': '1996 Jun', 'sentence': 'The corticosteroid, methylprednisolone (medrol), and the nonsteroidal antiinflammatory drug, flurbiprofen (Ansaid), administered at 2 mg/kg (p.o.), suppressed the clinical signs of CIA, and caused 79 to 83% inhibition of hind paw inflammation.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:disrupts---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8640603",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:11150324",
-                "PMID:17149544",
-                "PMID:23602068",
-                "PMID:2395047",
-                "PMID:24396446",
-                "PMID:27446512",
-                "PMID:27775998",
-                "PMID:28962262",
-                "PMID:29977750",
-                "PMID:34384886",
-                "PMID:3555968",
-                "PMID:35949317",
-                "PMID:6346605",
-                "PMID:7519120",
-                "PMID:8667252"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:12111861': {'publication date': '2002 May 01', 'sentence': 'Because a common therapy for acute spinal cord injury is the use of an antiinflammatory synthetic glucocorticoid (methylprednisolone), we sought to determine mechanisms contributing to inflammation shortly after acute injury.', 'subject score': 1000, 'object score': 861}, 'PMID:21983371': {'publication date': '2012 Feb', 'sentence': 'CONCLUSIONS: In early acute respiratory distress syndrome, administration of methylprednisolone was associated with improvement in important biomarkers of inflammation and coagulation and clinical outcomes.', 'subject score': 1000, 'object score': 1000}, 'PMID:23395471': {'publication date': '2013 Apr', 'sentence': 'RESULTS: At days 2 and 5, methylprednisolone treatment showed a 2.1- to 5.8-fold reduction (P < .05) in inflammation markers over PRP.', 'subject score': 888, 'object score': 791}, 'PMID:26272452': {'publication date': '2015 Aug 14', 'sentence': 'In our study, we want to investigate the effect of CWI with local anesthetic + methylprednisolone on acute and persistent pain, correlating clinical data with biomarkers of inflammation and genetic background.', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9436828,
-            "start": 570,
-            "end": 183319,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12111861': {'publication date': '2002 May 01', 'sentence': 'Because a common therapy for acute spinal cord injury is the use of an antiinflammatory synthetic glucocorticoid (methylprednisolone), we sought to determine mechanisms contributing to inflammation shortly after acute injury.', 'subject score': 1000, 'object score': 861}, 'PMID:21983371': {'publication date': '2012 Feb', 'sentence': 'CONCLUSIONS: In early acute respiratory distress syndrome, administration of methylprednisolone was associated with improvement in important biomarkers of inflammation and coagulation and clinical outcomes.', 'subject score': 1000, 'object score': 1000}, 'PMID:23395471': {'publication date': '2013 Apr', 'sentence': 'RESULTS: At days 2 and 5, methylprednisolone treatment showed a 2.1- to 5.8-fold reduction (P < .05) in inflammation markers over PRP.', 'subject score': 888, 'object score': 791}, 'PMID:26272452': {'publication date': '2015 Aug 14', 'sentence': 'In our study, we want to investigate the effect of CWI with local anesthetic + methylprednisolone on acute and persistent pain, correlating clinical data with biomarkers of inflammation and genetic background.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:predisposes---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "9645180",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:12111861",
-                "PMID:21983371",
-                "PMID:23395471",
-                "PMID:26272452"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:14496719': {'publication date': '1961', 'sentence': 'Rectal absorption of radioactive 6-alpha-methyl prednisolone in ulcerative colitis.', 'subject score': 785, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10532450,
-            "start": 570,
-            "end": 322104,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14496719': {'publication date': '1961', 'sentence': 'Rectal absorption of radioactive 6-alpha-methyl prednisolone in ulcerative colitis.', 'subject score': 785, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10763477",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:14496719"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:12603510': {'publication date': '2003 Mar', 'sentence': 'Steatohepatitis during methylprednisolone therapy for ulcerative colitis exacerbation.', 'subject score': 888, 'object score': 734}}",
-    "p2": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9831607,
-            "start": 570,
-            "end": 322104,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12603510': {'publication date': '2003 Mar', 'sentence': 'Steatohepatitis during methylprednisolone therapy for ulcerative colitis exacerbation.', 'subject score': 888, 'object score': 734}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10048898",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:12603510"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11040177': {'publication date': '2000 Oct', 'sentence': 'The current study evaluated the efficacy and safety of unfractionated heparin in the treatment of ulcerative colitis in comparison with methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:12405248': {'publication date': '2002 Sep', 'sentence': 'AIM: To evaluate the efficacy of Infliximab in the treatment of severe ulcerative colitis refractory to conventional therapy PATIENTS AND METHODS: A series of 13 patients with severe ulcerative colitis, refractory to therapy with methyl-prednisolone, 60 mg daily for seven or more days, were treated with a single intravenous infusion of Infliximab 5 mg/kg.', 'subject score': 1000, 'object score': 901}, 'PMID:15638237': {'publication date': '2004 Sep-Oct', 'sentence': 'Thirteen patients with severe UC, refractory to therapy with methyl-prednisolone, 60 mg IV daily were treated with a single intravenous infusion of Infliximab 5 mg/kg.', 'subject score': 1000, 'object score': 901}, 'PMID:16937542': {'publication date': '2006 Aug 28', 'sentence': 'Being diagnosed as having severe active left-side UC, she was successfully treated with intravenous methylprednisolone followed by prednisolone and leukocytapheresis.', 'subject score': 888, 'object score': 839}, 'PMID:18823440': {'publication date': '2008 Nov', 'sentence': 'CONCLUSION: GCAP results were superior to MP for the treatment of UC, even though no statistically significant difference was observed.', 'subject score': 1000, 'object score': 1000}, 'PMID:19399380': {'publication date': '2010 Jan', 'sentence': 'We report a 48-year-old male diagnosed with ulcerative colitis in 1995, who received long-term methylprednisolone therapy.', 'subject score': 861, 'object score': 1000}, 'PMID:2303687': {'publication date': '1990 Feb', 'sentence': 'High-dose methylprednisolone in the treatment of active ulcerative colitis.', 'subject score': 901, 'object score': 901}, 'PMID:25405041': {'publication date': '2014', 'sentence': 'After a complicated hospital course, she was eventually diagnosed with ulcerative colitis and enteropathic arthritis, treated with intravenous methylprednisolone, mesalamine, and infliximab which resulted in resolution of her symptoms.', 'subject score': 888, 'object score': 1000}, 'PMID:34720954': {'publication date': '2021', 'sentence': 'His UC was managed with methylprednisolone (60 mg IV daily), proton pump inhibitors, mesalamine, ciprofloxacin, and metronidazole.', 'subject score': 1000, 'object score': 1000}, 'PMID:35339135': {'publication date': '2022 03', 'sentence': 'Here, we report a case of mucocutaneous pyoderma gangrenosum as a preceding sign of ulcerative colitis that responded to treatment with methylprednisolone and infliximab.', 'subject score': 1000, 'object score': 1000}, 'PMID:9552221': {'publication date': '1998 Feb', 'sentence': 'To this end, we performed a randomized, 5-day study with either oral enterically coated amoxicillin-clavulanic acid (1 g + 250 mg, t.i.d.); i.v. methylprednisolone (40 mg/day) and oral placebo (t.i.d.); or both i.v. methylprednisolone and oral amoxicillin-clavulanic acid as above, in 30 patients with clinically active ulcerative colitis.', 'subject score': 827, 'object score': 824}}",
-    "p2": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8323580,
-            "start": 570,
-            "end": 322104,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11040177': {'publication date': '2000 Oct', 'sentence': 'The current study evaluated the efficacy and safety of unfractionated heparin in the treatment of ulcerative colitis in comparison with methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:12405248': {'publication date': '2002 Sep', 'sentence': 'AIM: To evaluate the efficacy of Infliximab in the treatment of severe ulcerative colitis refractory to conventional therapy PATIENTS AND METHODS: A series of 13 patients with severe ulcerative colitis, refractory to therapy with methyl-prednisolone, 60 mg daily for seven or more days, were treated with a single intravenous infusion of Infliximab 5 mg/kg.', 'subject score': 1000, 'object score': 901}, 'PMID:15638237': {'publication date': '2004 Sep-Oct', 'sentence': 'Thirteen patients with severe UC, refractory to therapy with methyl-prednisolone, 60 mg IV daily were treated with a single intravenous infusion of Infliximab 5 mg/kg.', 'subject score': 1000, 'object score': 901}, 'PMID:16937542': {'publication date': '2006 Aug 28', 'sentence': 'Being diagnosed as having severe active left-side UC, she was successfully treated with intravenous methylprednisolone followed by prednisolone and leukocytapheresis.', 'subject score': 888, 'object score': 839}, 'PMID:18823440': {'publication date': '2008 Nov', 'sentence': 'CONCLUSION: GCAP results were superior to MP for the treatment of UC, even though no statistically significant difference was observed.', 'subject score': 1000, 'object score': 1000}, 'PMID:19399380': {'publication date': '2010 Jan', 'sentence': 'We report a 48-year-old male diagnosed with ulcerative colitis in 1995, who received long-term methylprednisolone therapy.', 'subject score': 861, 'object score': 1000}, 'PMID:2303687': {'publication date': '1990 Feb', 'sentence': 'High-dose methylprednisolone in the treatment of active ulcerative colitis.', 'subject score': 901, 'object score': 901}, 'PMID:25405041': {'publication date': '2014', 'sentence': 'After a complicated hospital course, she was eventually diagnosed with ulcerative colitis and enteropathic arthritis, treated with intravenous methylprednisolone, mesalamine, and infliximab which resulted in resolution of her symptoms.', 'subject score': 888, 'object score': 1000}, 'PMID:34720954': {'publication date': '2021', 'sentence': 'His UC was managed with methylprednisolone (60 mg IV daily), proton pump inhibitors, mesalamine, ciprofloxacin, and metronidazole.', 'subject score': 1000, 'object score': 1000}, 'PMID:35339135': {'publication date': '2022 03', 'sentence': 'Here, we report a case of mucocutaneous pyoderma gangrenosum as a preceding sign of ulcerative colitis that responded to treatment with methylprednisolone and infliximab.', 'subject score': 1000, 'object score': 1000}, 'PMID:9552221': {'publication date': '1998 Feb', 'sentence': 'To this end, we performed a randomized, 5-day study with either oral enterically coated amoxicillin-clavulanic acid (1 g + 250 mg, t.i.d.); i.v. methylprednisolone (40 mg/day) and oral placebo (t.i.d.); or both i.v. methylprednisolone and oral amoxicillin-clavulanic acid as above, in 30 patients with clinically active ulcerative colitis.', 'subject score': 827, 'object score': 824}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8503951",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:11040177",
-                "PMID:12405248",
-                "PMID:15638237",
-                "PMID:16937542",
-                "PMID:18823440",
-                "PMID:19399380",
-                "PMID:2303687",
-                "PMID:25405041",
-                "PMID:34720954",
-                "PMID:35339135",
-                "PMID:9552221"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:34291223': {'publication date': '2021 Jul', 'sentence': 'Methylprednisolone and 60 Days in Hospital Survival in Coronavirus Disease 2019 Pneumonia.', 'subject score': 1000, 'object score': 916}, 'PMID:34545308': {'publication date': '2021 Oct', 'sentence': 'Dexamethasone or methylprednisolone therapy in covid-19 pneumonia: A retrospective and comparative study of 513 cases.', 'subject score': 888, 'object score': 827}, 'PMID:35361632': {'publication date': '2022 Mar 31', 'sentence': 'We evaluated the efficacy and safety of pulse intravenous methylprednisolone in addition to standard treatment in COVID-19 pneumonia.', 'subject score': 790, 'object score': 802}}",
-    "p2": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23140725,
-            "start": 570,
-            "end": 321523,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34291223': {'publication date': '2021 Jul', 'sentence': 'Methylprednisolone and 60 Days in Hospital Survival in Coronavirus Disease 2019 Pneumonia.', 'subject score': 1000, 'object score': 916}, 'PMID:34545308': {'publication date': '2021 Oct', 'sentence': 'Dexamethasone or methylprednisolone therapy in covid-19 pneumonia: A retrospective and comparative study of 513 cases.', 'subject score': 888, 'object score': 827}, 'PMID:35361632': {'publication date': '2022 Mar 31', 'sentence': 'We evaluated the efficacy and safety of pulse intravenous methylprednisolone in addition to standard treatment in COVID-19 pneumonia.', 'subject score': 790, 'object score': 802}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "23573980",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:34291223",
-                "PMID:34545308",
-                "PMID:35361632"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:24289285': {'publication date': '2013 Dec 01', 'sentence': 'Pneumocystis pneumonia induced by this dose of tacrolimus has been reported in many cases; however, we encountered a rare case of Pneumocystis pneumonia induced by low-dose tacrolimus and methylprednisolone.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16958248,
-            "start": 570,
-            "end": 321523,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24289285': {'publication date': '2013 Dec 01', 'sentence': 'Pneumocystis pneumonia induced by this dose of tacrolimus has been reported in many cases; however, we encountered a rare case of Pneumocystis pneumonia induced by low-dose tacrolimus and methylprednisolone.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:causes---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "17307095",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:24289285"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10879669': {'publication date': '2000 Jun', 'sentence': 'High-dose methylprednisolone was administered for treatment of the pneumonitis.', 'subject score': 901, 'object score': 1000}, 'PMID:11594518': {'publication date': '2001 Aug', 'sentence': 'Remission of acute myeloblastic leukemia after severe pneumonia treated with high-dose methylprednisolone.', 'subject score': 901, 'object score': 888}, 'PMID:12073575': {'publication date': '2002 May', 'sentence': 'Since human herpes virus-6 (HHV-6) was detected in BAL specimens by the polymerase chain reaction (PCR), a diagnosis of a pneumonitis-like BOOP shadow related to HHV-6 was made, and he was treated with methylprednisolone and ganciclovir (GCV).', 'subject score': 1000, 'object score': 1000}, 'PMID:16636525': {'publication date': '2006 May', 'sentence': 'This is the first report describing the treatment of pulse methylprednisolone therapy in fatal adenovirus pneumonia.', 'subject score': 790, 'object score': 851}, 'PMID:18712461': {'publication date': '2008 Oct', 'sentence': 'We report a case of severe parainfluenza (PIV) 3 pneumonia in a hematopoietic stem cell transplant recipient that was successfully treated with oral ribavirin and methylprednisolone.', 'subject score': 1000, 'object score': 888}, 'PMID:20667503': {'publication date': '2010 Oct 31', 'sentence': 'In vivo efficacy of dendrimer-methylprednisolone conjugate formulation for the treatment of lung inflammation.', 'subject score': 566, 'object score': 1000}, 'PMID:21718474': {'publication date': '2011 Jun 30', 'sentence': 'STUDY DESIGN: This is a randomized double-blind clinical trial to test the efficacy of pulse treatment with methylprednisolone in patients with leptospirotic pneumonitis, compared with a placebo.', 'subject score': 1000, 'object score': 861}, 'PMID:22251837': {'publication date': '2012 02', 'sentence': 'Administration of an antiviral agent (acyclovir), an antibacterial agent (linezolid), and a corticosteroid (methylprednisolone) successfully improved the pneumonia and ARDS.', 'subject score': 1000, 'object score': 1000}, 'PMID:24289285': {'publication date': '2013 Dec 01', 'sentence': 'CASE PRESENTATION: We herein report the case of an 82-year-old Asian Japanese female with rheumatoid arthritis and Pneumocystis pneumonia who was being treated with low-dose tacrolimus and low-dose methylprednisolone therapy.', 'subject score': 861, 'object score': 888}, 'PMID:25374741': {'publication date': '2013', 'sentence': 'Investigations revealed thrombocytopenia, CSF lymphocytosis, ANA and dsDNA positivity, hypocomplementemia, and pneumonitis following which he was treated with pulse methylprednisolone.', 'subject score': 861, 'object score': 1000}, 'PMID:28185527': {'publication date': '2017 05', 'sentence': 'For remaining 12 patients, bleomycin was discontinued and methylprednisolone given, all showed resolution of the pneumonitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:29735504': {'publication date': '2018 May 07', 'sentence': 'His clinical condition improved once he received high-dose intravenous methylprednisolone to treat pneumonitis.', 'subject score': 861, 'object score': 1000}, 'PMID:29881712': {'publication date': '2018 May-Jun', 'sentence': 'Results: The pulmonary inflammation and fibrosis were significantly decreased in groups treated with methylprednisolone and N. sativa extract compared to bleomycin group in both early and late prevention groups (p<0.001).', 'subject score': 1000, 'object score': 1000}, 'PMID:32792492': {'publication date': '2020 08 13', 'sentence': 'Thirty of 31 patients (96.77%) had stopped mPSL due to improvement of pneumonia.', 'subject score': 861, 'object score': 1000}, 'PMID:32893160': {'publication date': '2020 Aug 28', 'sentence': 'Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases.', 'subject score': 1000, 'object score': 875}, 'PMID:33072814': {'publication date': '2020 Oct', 'sentence': 'Conclusion: In patients with severe COVID-19 pneumonia, early administration of prolonged MP treatment was associated with a significantly lower hazard of death (71%) and decreased ventilator dependence.', 'subject score': 851, 'object score': 875}, 'PMID:33219551': {'publication date': '2020 Nov 20', 'sentence': 'High-Dose Methylprednisolone in Nonintubated Patients with Severe COVID-19 Pneumonia.', 'subject score': 901, 'object score': 875}, 'PMID:33451758': {'publication date': '2020 Dec 17', 'sentence': 'The second case was a 58-year-old man who fully recovered from COVID-19 pneumonia with treatment with methylprednisolone, MMF, azithromycin, favipiravir, hydroxychloroquine, and reduction in immunosuppression dosage.', 'subject score': 1000, 'object score': 916}, 'PMID:33692687': {'publication date': '2021', 'sentence': 'Conclusion:     We showed that intermediate and high doses methylprednisolone share most potential to target BD-induced lung inflammation in rats.', 'subject score': 890, 'object score': 857}, 'PMID:33778162': {'publication date': '2021', 'sentence': 'Alongside supportive care and lopinavir/ritonavir antiviral drugs, a low dosage of methylprednisolone was administered over a short period to attenuate lung inflammation.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8116926,
-            "start": 570,
-            "end": 321523,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10879669': {'publication date': '2000 Jun', 'sentence': 'High-dose methylprednisolone was administered for treatment of the pneumonitis.', 'subject score': 901, 'object score': 1000}, 'PMID:11594518': {'publication date': '2001 Aug', 'sentence': 'Remission of acute myeloblastic leukemia after severe pneumonia treated with high-dose methylprednisolone.', 'subject score': 901, 'object score': 888}, 'PMID:12073575': {'publication date': '2002 May', 'sentence': 'Since human herpes virus-6 (HHV-6) was detected in BAL specimens by the polymerase chain reaction (PCR), a diagnosis of a pneumonitis-like BOOP shadow related to HHV-6 was made, and he was treated with methylprednisolone and ganciclovir (GCV).', 'subject score': 1000, 'object score': 1000}, 'PMID:16636525': {'publication date': '2006 May', 'sentence': 'This is the first report describing the treatment of pulse methylprednisolone therapy in fatal adenovirus pneumonia.', 'subject score': 790, 'object score': 851}, 'PMID:18712461': {'publication date': '2008 Oct', 'sentence': 'We report a case of severe parainfluenza (PIV) 3 pneumonia in a hematopoietic stem cell transplant recipient that was successfully treated with oral ribavirin and methylprednisolone.', 'subject score': 1000, 'object score': 888}, 'PMID:20667503': {'publication date': '2010 Oct 31', 'sentence': 'In vivo efficacy of dendrimer-methylprednisolone conjugate formulation for the treatment of lung inflammation.', 'subject score': 566, 'object score': 1000}, 'PMID:21718474': {'publication date': '2011 Jun 30', 'sentence': 'STUDY DESIGN: This is a randomized double-blind clinical trial to test the efficacy of pulse treatment with methylprednisolone in patients with leptospirotic pneumonitis, compared with a placebo.', 'subject score': 1000, 'object score': 861}, 'PMID:22251837': {'publication date': '2012 02', 'sentence': 'Administration of an antiviral agent (acyclovir), an antibacterial agent (linezolid), and a corticosteroid (methylprednisolone) successfully improved the pneumonia and ARDS.', 'subject score': 1000, 'object score': 1000}, 'PMID:24289285': {'publication date': '2013 Dec 01', 'sentence': 'CASE PRESENTATION: We herein report the case of an 82-year-old Asian Japanese female with rheumatoid arthritis and Pneumocystis pneumonia who was being treated with low-dose tacrolimus and low-dose methylprednisolone therapy.', 'subject score': 861, 'object score': 888}, 'PMID:25374741': {'publication date': '2013', 'sentence': 'Investigations revealed thrombocytopenia, CSF lymphocytosis, ANA and dsDNA positivity, hypocomplementemia, and pneumonitis following which he was treated with pulse methylprednisolone.', 'subject score': 861, 'object score': 1000}, 'PMID:28185527': {'publication date': '2017 05', 'sentence': 'For remaining 12 patients, bleomycin was discontinued and methylprednisolone given, all showed resolution of the pneumonitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:29735504': {'publication date': '2018 May 07', 'sentence': 'His clinical condition improved once he received high-dose intravenous methylprednisolone to treat pneumonitis.', 'subject score': 861, 'object score': 1000}, 'PMID:29881712': {'publication date': '2018 May-Jun', 'sentence': 'Results: The pulmonary inflammation and fibrosis were significantly decreased in groups treated with methylprednisolone and N. sativa extract compared to bleomycin group in both early and late prevention groups (p<0.001).', 'subject score': 1000, 'object score': 1000}, 'PMID:32792492': {'publication date': '2020 08 13', 'sentence': 'Thirty of 31 patients (96.77%) had stopped mPSL due to improvement of pneumonia.', 'subject score': 861, 'object score': 1000}, 'PMID:32893160': {'publication date': '2020 Aug 28', 'sentence': 'Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases.', 'subject score': 1000, 'object score': 875}, 'PMID:33072814': {'publication date': '2020 Oct', 'sentence': 'Conclusion: In patients with severe COVID-19 pneumonia, early administration of prolonged MP treatment was associated with a significantly lower hazard of death (71%) and decreased ventilator dependence.', 'subject score': 851, 'object score': 875}, 'PMID:33219551': {'publication date': '2020 Nov 20', 'sentence': 'High-Dose Methylprednisolone in Nonintubated Patients with Severe COVID-19 Pneumonia.', 'subject score': 901, 'object score': 875}, 'PMID:33451758': {'publication date': '2020 Dec 17', 'sentence': 'The second case was a 58-year-old man who fully recovered from COVID-19 pneumonia with treatment with methylprednisolone, MMF, azithromycin, favipiravir, hydroxychloroquine, and reduction in immunosuppression dosage.', 'subject score': 1000, 'object score': 916}, 'PMID:33692687': {'publication date': '2021', 'sentence': 'Conclusion:     We showed that intermediate and high doses methylprednisolone share most potential to target BD-induced lung inflammation in rats.', 'subject score': 890, 'object score': 857}, 'PMID:33778162': {'publication date': '2021', 'sentence': 'Alongside supportive care and lopinavir/ritonavir antiviral drugs, a low dosage of methylprednisolone was administered over a short period to attenuate lung inflammation.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8291810",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:10879669",
-                "PMID:11594518",
-                "PMID:12073575",
-                "PMID:16636525",
-                "PMID:18712461",
-                "PMID:20667503",
-                "PMID:21718474",
-                "PMID:22251837",
-                "PMID:24289285",
-                "PMID:25374741",
-                "PMID:28185527",
-                "PMID:29735504",
-                "PMID:29881712",
-                "PMID:32792492",
-                "PMID:32893160",
-                "PMID:33072814",
-                "PMID:33219551",
-                "PMID:33451758",
-                "PMID:33692687",
-                "PMID:33778162"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:25600919': {'publication date': '2015 Jan', 'sentence': 'Chronically impaired renal function and the use of methylprednisolone may be the risk factors for SP.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17740933,
-            "start": 570,
-            "end": 321523,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25600919': {'publication date': '2015 Jan', 'sentence': 'Chronically impaired renal function and the use of methylprednisolone may be the risk factors for SP.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:predisposes---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "18106042",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:25600919"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:1947472': {'publication date': '1991', 'sentence': 'Long-term results of high-dose methylprednisolone in aplastic anemia.', 'subject score': 901, 'object score': 1000}, 'PMID:3573329': {'publication date': '1987 Jan', 'sentence': '[Therapeutic results of high-dose bolus methylprednisolone and prediction of response by in vitro tests in aplastic anemia].', 'subject score': 824, 'object score': 1000}, 'PMID:8984042': {'publication date': '1995 Oct', 'sentence': 'This observation is in stark contrast with previous trials on use of HDMP in SAA.', 'subject score': 901, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 315782,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
-          "name": "aplastic anemia",
-          "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What causes aplastic anemia? The causes of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0015909",
-            "MEDDRA:10002037",
-            "HP:0001915",
-            "MEDDRA:10002967",
-            "MEDDRA:10002274",
-            "MEDDRA:10002969",
-            "MESH:D000741",
-            "SNOMEDCT:306058006",
-            "PDQ:CDR0000489004",
-            "NCIT:C2870",
-            "MEDDRA:10002968",
-            "DOID:12449",
-            "MEDDRA:10002970",
-            "ICD9:284.9",
-            "SNOMEDCT:304132006",
-            "UMLS:C0002874",
-            "ICD10:D61.9",
-            "ORPHANET:182040"
-          ],
-          "id": "MONDO:0015909",
-          "category": "biolink:Disease",
-          "all_names": [
-            "aplastic anemia",
-            "Aplastic Anemia",
-            "Aplastic anemia",
-            "Aplastic anemia, unspecified",
-            "obsolete_Medullar aplasia",
-            "Anemia, Aplastic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
-            "http://en.wikipedia.org/wiki/aplastic_anemia",
-            "PMID:21239768",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315782,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
-              "name": "aplastic anemia",
-              "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What causes aplastic anemia? The causes of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0015909",
-                "MEDDRA:10002037",
-                "HP:0001915",
-                "MEDDRA:10002967",
-                "MEDDRA:10002274",
-                "MEDDRA:10002969",
-                "MESH:D000741",
-                "SNOMEDCT:306058006",
-                "PDQ:CDR0000489004",
-                "NCIT:C2870",
-                "MEDDRA:10002968",
-                "DOID:12449",
-                "MEDDRA:10002970",
-                "ICD9:284.9",
-                "SNOMEDCT:304132006",
-                "UMLS:C0002874",
-                "ICD10:D61.9",
-                "ORPHANET:182040"
-              ],
-              "id": "MONDO:0015909",
-              "category": "biolink:Disease",
-              "all_names": [
-                "aplastic anemia",
-                "Aplastic Anemia",
-                "Aplastic anemia",
-                "Aplastic anemia, unspecified",
-                "obsolete_Medullar aplasia",
-                "Anemia, Aplastic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
-                "http://en.wikipedia.org/wiki/aplastic_anemia",
-                "PMID:21239768",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14098746,
-            "start": 570,
-            "end": 315782,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1947472': {'publication date': '1991', 'sentence': 'Long-term results of high-dose methylprednisolone in aplastic anemia.', 'subject score': 901, 'object score': 1000}, 'PMID:3573329': {'publication date': '1987 Jan', 'sentence': '[Therapeutic results of high-dose bolus methylprednisolone and prediction of response by in vitro tests in aplastic anemia].', 'subject score': 824, 'object score': 1000}, 'PMID:8984042': {'publication date': '1995 Oct', 'sentence': 'This observation is in stark contrast with previous trials on use of HDMP in SAA.', 'subject score': 901, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0002874---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14399082",
-              "object": "MONDO:0015909",
-              "publications": [
-                "PMID:1947472",
-                "PMID:3573329",
-                "PMID:8984042"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10466441': {'publication date': '1999 Jul', 'sentence': 'Neutropenic infections are the major cause of morbidity and mortality in the treatment of aplastic anemia (AA) with antilymphocyte globulin (ALG), cyclosporin A (CSA), and methylprednisolone (MP).', 'subject score': 1000, 'object score': 1000}, 'PMID:12393680': {'publication date': '2003 Feb 15', 'sentence': 'Immunosuppression with antithymocyte globulin, (methyl)prednisolone, and cyclosporin A is considered the treatment of choice for the patient with aplastic anemia without a donor for standard-risk stem cell transplantation.', 'subject score': 1000, 'object score': 1000}, 'PMID:1542816': {'publication date': '1992 Mar 07', 'sentence': 'Antilymphocyte globulin and high-dose methylprednisolone improve survival in patients with aplastic anaemia without additional financial costs.', 'subject score': 901, 'object score': 1000}, 'PMID:1863830': {'publication date': '1991 Aug', 'sentence': 'We report a case of SLE related aplastic anaemia in which therapy with methylprednisolone and high dose cyclophosphamide followed by prednisolone and azathioprine resulted in complete clinical and haematological remission.', 'subject score': 1000, 'object score': 1000}, 'PMID:2012072': {'publication date': '1991 Apr', 'sentence': 'Treatment of aplastic anaemia with antilymphocyte globulin and high-dose methylprednisolone.', 'subject score': 901, 'object score': 1000}, 'PMID:2017225': {'publication date': '1991 May 09', 'sentence': 'CONCLUSIONS: Immunosuppressive treatment of aplastic anemia with antilymphocyte globulin, methylprednisolone, and cyclosporine appears to be more effective than a regimen of antilymphocyte globulin and methylprednisolone without cyclosporine and may thus represent a treatment of choice for patients who are not eligible for bone marrow transplantation.', 'subject score': 1000, 'object score': 1000}, 'PMID:22479166': {'publication date': '2011 Jul', 'sentence': 'We present an adolescent with SAA and preexisting bradycardia who underwent immunosuppression therapy with ATG, methylprednisolone, and tacrolimus and developed profound sinus bradycardia with successive doses of ATG.', 'subject score': 1000, 'object score': 901}, 'PMID:2381070': {'publication date': '1990 Apr', 'sentence': 'Here, we will discuss this case of aplastic anemia which responded to repeated bolus methylprednisolone therapy, with minimal side effects, and discuss its effectiveness.', 'subject score': 775, 'object score': 1000}, 'PMID:25184310': {'publication date': '2014 Nov', 'sentence': 'CONCLUSIONS: hATG with methylprednisolone and CSA is recommended for front-line treatment of AA, whereas rATG is reserved for salvage therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:2741916': {'publication date': '1989 Jul', 'sentence': 'A patient with aplastic anemia, who had been unresponsive to androgens, antithymocyte globulin, high-dose methylprednisolone, and cyclosporine, responded to treatment with 3-beta-etiocholanolone, nandrolone decanoate, and prednisolone acetate.', 'subject score': 901, 'object score': 1000}, 'PMID:3107306': {'publication date': '1986', 'sentence': 'We recommend combined immunosuppressive treatment with ATG and high-dose MP as a highly feasible, safe and effectful therapy for patients with transfusion-dependent SAA.', 'subject score': 901, 'object score': 798}, 'PMID:3259191': {'publication date': '1988 Apr', 'sentence': 'Methylprednisolone therapy in aplastic anaemia: correlation of in vitro tests and lymphocyte subsets with clinical response.', 'subject score': 888, 'object score': 1000}, 'PMID:3366221': {'publication date': '1988 Apr', 'sentence': 'A 22-yr-old man with aplastic anaemia was treated with high dose methylprednisolone.', 'subject score': 901, 'object score': 1000}, 'PMID:3492629': {'publication date': '1986 Nov 17', 'sentence': 'Treatment of aplastic anemia with cyclosporin A, methylprednisolone, and antithymocyte globulin.', 'subject score': 1000, 'object score': 1000}, 'PMID:3524596': {'publication date': '1986 Jun', 'sentence': 'Methylprednisolone treatment in aplastic anaemia.', 'subject score': 888, 'object score': 1000}, 'PMID:3820608': {'publication date': '1986 Oct', 'sentence': '[Significance of corticosteroid administration including bolus methylprednisolone therapy as the preconditioning of hematopoiesis in the treatment of aplastic anemia].', 'subject score': 790, 'object score': 1000}, 'PMID:6481979': {'publication date': '1984 Jun', 'sentence': '[Bolus methylprednisolone therapy for aplastic anemia: a case report].', 'subject score': 790, 'object score': 1000}, 'PMID:7053691': {'publication date': '1982 Jan', 'sentence': 'Bolous of methylprednisolone for aplastic anemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:8217834': {'publication date': '1993 Aug', 'sentence': 'Avascular necrosis of bone (AVN) occurring in patients with aplastic anaemia (AA) treated with antilymphocyte globulin (ALG) followed by high-dose methylprednisolone (HDMP) has been studied retrospectively.', 'subject score': 901, 'object score': 1000}, 'PMID:8435323': {'publication date': '1993 Jan', 'sentence': 'In conclusion, the addition of androgens to HALG and methylprednisolone as first line treatment of aplastic anaemia significantly improves the response rate at 4 months, particularly in females with low neutrophil counts, although there is no significant effect on short-term survival.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 315782,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
-          "name": "aplastic anemia",
-          "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What causes aplastic anemia? The causes of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0015909",
-            "MEDDRA:10002037",
-            "HP:0001915",
-            "MEDDRA:10002967",
-            "MEDDRA:10002274",
-            "MEDDRA:10002969",
-            "MESH:D000741",
-            "SNOMEDCT:306058006",
-            "PDQ:CDR0000489004",
-            "NCIT:C2870",
-            "MEDDRA:10002968",
-            "DOID:12449",
-            "MEDDRA:10002970",
-            "ICD9:284.9",
-            "SNOMEDCT:304132006",
-            "UMLS:C0002874",
-            "ICD10:D61.9",
-            "ORPHANET:182040"
-          ],
-          "id": "MONDO:0015909",
-          "category": "biolink:Disease",
-          "all_names": [
-            "aplastic anemia",
-            "Aplastic Anemia",
-            "Aplastic anemia",
-            "Aplastic anemia, unspecified",
-            "obsolete_Medullar aplasia",
-            "Anemia, Aplastic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
-            "http://en.wikipedia.org/wiki/aplastic_anemia",
-            "PMID:21239768",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315782,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
-              "name": "aplastic anemia",
-              "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What causes aplastic anemia? The causes of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0015909",
-                "MEDDRA:10002037",
-                "HP:0001915",
-                "MEDDRA:10002967",
-                "MEDDRA:10002274",
-                "MEDDRA:10002969",
-                "MESH:D000741",
-                "SNOMEDCT:306058006",
-                "PDQ:CDR0000489004",
-                "NCIT:C2870",
-                "MEDDRA:10002968",
-                "DOID:12449",
-                "MEDDRA:10002970",
-                "ICD9:284.9",
-                "SNOMEDCT:304132006",
-                "UMLS:C0002874",
-                "ICD10:D61.9",
-                "ORPHANET:182040"
-              ],
-              "id": "MONDO:0015909",
-              "category": "biolink:Disease",
-              "all_names": [
-                "aplastic anemia",
-                "Aplastic Anemia",
-                "Aplastic anemia",
-                "Aplastic anemia, unspecified",
-                "obsolete_Medullar aplasia",
-                "Anemia, Aplastic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
-                "http://en.wikipedia.org/wiki/aplastic_anemia",
-                "PMID:21239768",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7480314,
-            "start": 570,
-            "end": 315782,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10466441': {'publication date': '1999 Jul', 'sentence': 'Neutropenic infections are the major cause of morbidity and mortality in the treatment of aplastic anemia (AA) with antilymphocyte globulin (ALG), cyclosporin A (CSA), and methylprednisolone (MP).', 'subject score': 1000, 'object score': 1000}, 'PMID:12393680': {'publication date': '2003 Feb 15', 'sentence': 'Immunosuppression with antithymocyte globulin, (methyl)prednisolone, and cyclosporin A is considered the treatment of choice for the patient with aplastic anemia without a donor for standard-risk stem cell transplantation.', 'subject score': 1000, 'object score': 1000}, 'PMID:1542816': {'publication date': '1992 Mar 07', 'sentence': 'Antilymphocyte globulin and high-dose methylprednisolone improve survival in patients with aplastic anaemia without additional financial costs.', 'subject score': 901, 'object score': 1000}, 'PMID:1863830': {'publication date': '1991 Aug', 'sentence': 'We report a case of SLE related aplastic anaemia in which therapy with methylprednisolone and high dose cyclophosphamide followed by prednisolone and azathioprine resulted in complete clinical and haematological remission.', 'subject score': 1000, 'object score': 1000}, 'PMID:2012072': {'publication date': '1991 Apr', 'sentence': 'Treatment of aplastic anaemia with antilymphocyte globulin and high-dose methylprednisolone.', 'subject score': 901, 'object score': 1000}, 'PMID:2017225': {'publication date': '1991 May 09', 'sentence': 'CONCLUSIONS: Immunosuppressive treatment of aplastic anemia with antilymphocyte globulin, methylprednisolone, and cyclosporine appears to be more effective than a regimen of antilymphocyte globulin and methylprednisolone without cyclosporine and may thus represent a treatment of choice for patients who are not eligible for bone marrow transplantation.', 'subject score': 1000, 'object score': 1000}, 'PMID:22479166': {'publication date': '2011 Jul', 'sentence': 'We present an adolescent with SAA and preexisting bradycardia who underwent immunosuppression therapy with ATG, methylprednisolone, and tacrolimus and developed profound sinus bradycardia with successive doses of ATG.', 'subject score': 1000, 'object score': 901}, 'PMID:2381070': {'publication date': '1990 Apr', 'sentence': 'Here, we will discuss this case of aplastic anemia which responded to repeated bolus methylprednisolone therapy, with minimal side effects, and discuss its effectiveness.', 'subject score': 775, 'object score': 1000}, 'PMID:25184310': {'publication date': '2014 Nov', 'sentence': 'CONCLUSIONS: hATG with methylprednisolone and CSA is recommended for front-line treatment of AA, whereas rATG is reserved for salvage therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:2741916': {'publication date': '1989 Jul', 'sentence': 'A patient with aplastic anemia, who had been unresponsive to androgens, antithymocyte globulin, high-dose methylprednisolone, and cyclosporine, responded to treatment with 3-beta-etiocholanolone, nandrolone decanoate, and prednisolone acetate.', 'subject score': 901, 'object score': 1000}, 'PMID:3107306': {'publication date': '1986', 'sentence': 'We recommend combined immunosuppressive treatment with ATG and high-dose MP as a highly feasible, safe and effectful therapy for patients with transfusion-dependent SAA.', 'subject score': 901, 'object score': 798}, 'PMID:3259191': {'publication date': '1988 Apr', 'sentence': 'Methylprednisolone therapy in aplastic anaemia: correlation of in vitro tests and lymphocyte subsets with clinical response.', 'subject score': 888, 'object score': 1000}, 'PMID:3366221': {'publication date': '1988 Apr', 'sentence': 'A 22-yr-old man with aplastic anaemia was treated with high dose methylprednisolone.', 'subject score': 901, 'object score': 1000}, 'PMID:3492629': {'publication date': '1986 Nov 17', 'sentence': 'Treatment of aplastic anemia with cyclosporin A, methylprednisolone, and antithymocyte globulin.', 'subject score': 1000, 'object score': 1000}, 'PMID:3524596': {'publication date': '1986 Jun', 'sentence': 'Methylprednisolone treatment in aplastic anaemia.', 'subject score': 888, 'object score': 1000}, 'PMID:3820608': {'publication date': '1986 Oct', 'sentence': '[Significance of corticosteroid administration including bolus methylprednisolone therapy as the preconditioning of hematopoiesis in the treatment of aplastic anemia].', 'subject score': 790, 'object score': 1000}, 'PMID:6481979': {'publication date': '1984 Jun', 'sentence': '[Bolus methylprednisolone therapy for aplastic anemia: a case report].', 'subject score': 790, 'object score': 1000}, 'PMID:7053691': {'publication date': '1982 Jan', 'sentence': 'Bolous of methylprednisolone for aplastic anemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:8217834': {'publication date': '1993 Aug', 'sentence': 'Avascular necrosis of bone (AVN) occurring in patients with aplastic anaemia (AA) treated with antilymphocyte globulin (ALG) followed by high-dose methylprednisolone (HDMP) has been studied retrospectively.', 'subject score': 901, 'object score': 1000}, 'PMID:8435323': {'publication date': '1993 Jan', 'sentence': 'In conclusion, the addition of androgens to HALG and methylprednisolone as first line treatment of aplastic anaemia significantly improves the response rate at 4 months, particularly in females with low neutrophil counts, although there is no significant effect on short-term survival.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0002874---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7649490",
-              "object": "MONDO:0015909",
-              "publications": [
-                "PMID:10466441",
-                "PMID:12393680",
-                "PMID:1542816",
-                "PMID:1863830",
-                "PMID:2012072",
-                "PMID:2017225",
-                "PMID:22479166",
-                "PMID:2381070",
-                "PMID:25184310",
-                "PMID:2741916",
-                "PMID:3107306",
-                "PMID:3259191",
-                "PMID:3366221",
-                "PMID:3492629",
-                "PMID:3524596",
-                "PMID:3820608",
-                "PMID:6481979",
-                "PMID:7053691",
-                "PMID:8217834",
-                "PMID:8435323"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:17548927': {'publication date': '2007 Jun', 'sentence': 'We describe that high-dose methylprednisolone (20 mg/kg) can induce multifocal osteonecrosis (ON) in conjunction with thrombocytopenia, hypofibrinogenemia, and hyperlipemia.', 'subject score': 901, 'object score': 1000}, 'PMID:32727666': {'publication date': '2020 Jul 02', 'sentence': 'Oxaliplatin and Methylprednisolone-induced Thrombocytopenia and Monocytopenia, Owing to Anti-GPIIbIIIa and -CD36 Antibodies in a Patient With Colorectal Cancer.', 'subject score': 851, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 316686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002049",
-          "name": "thrombocytopenia",
-          "description": "A reduction in the number of circulating thrombocytes. [HPO:probinson]; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T034",
-          "equivalent_curies": [
-            "UMLS:C0392386",
-            "SNOMEDCT:302215000",
-            "MEDDRA:10035545",
-            "MEDDRA:10043555",
-            "PDQ:CDR0000041408",
-            "MEDDRA:10024922",
-            "ICD10:D69.6",
-            "HP:0001873",
-            "NCIT:C3408",
-            "NCIT:C162108",
-            "MEDDRA:10035528",
-            "UMLS:C5201036",
-            "MEDDRA:10043560",
-            "DOID:1588",
-            "UMLS:CN130080",
-            "SYMP:0000114",
-            "MEDDRA:10038213",
-            "MEDDRA:10043546",
-            "MESH:D013921",
-            "MEDDRA:10035529",
-            "MEDDRA:10043569",
-            "UMLS:C0040034",
-            "MEDDRA:10043554",
-            "ICD9:287.5",
-            "MONDO:0002049",
-            "SNOMEDCT:415116008"
-          ],
-          "id": "MONDO:0002049",
-          "category": "biolink:Disease",
-          "all_names": [
-            "thrombocytopenia",
-            "Thrombocytopenia, unspecified",
-            "Low Platelet Count",
-            "Thrombocytopenia",
-            "Decreased platelet count"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/thrombocytopenia",
-            "http://www.merckmanuals.com/professional/hematology_and_oncology/thrombocytopenia_and_platelet_dysfunction/overview_of_platelet_disorders.htm",
-            "http://ghr.nlm.nih.gov/glossary=thrombocytopenia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002049",
-              "name": "thrombocytopenia",
-              "description": "A reduction in the number of circulating thrombocytes. [HPO:probinson]; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T034",
-              "equivalent_curies": [
-                "UMLS:C0392386",
-                "SNOMEDCT:302215000",
-                "MEDDRA:10035545",
-                "MEDDRA:10043555",
-                "PDQ:CDR0000041408",
-                "MEDDRA:10024922",
-                "ICD10:D69.6",
-                "HP:0001873",
-                "NCIT:C3408",
-                "NCIT:C162108",
-                "MEDDRA:10035528",
-                "UMLS:C5201036",
-                "MEDDRA:10043560",
-                "DOID:1588",
-                "UMLS:CN130080",
-                "SYMP:0000114",
-                "MEDDRA:10038213",
-                "MEDDRA:10043546",
-                "MESH:D013921",
-                "MEDDRA:10035529",
-                "MEDDRA:10043569",
-                "UMLS:C0040034",
-                "MEDDRA:10043554",
-                "ICD9:287.5",
-                "MONDO:0002049",
-                "SNOMEDCT:415116008"
-              ],
-              "id": "MONDO:0002049",
-              "category": "biolink:Disease",
-              "all_names": [
-                "thrombocytopenia",
-                "Thrombocytopenia, unspecified",
-                "Low Platelet Count",
-                "Thrombocytopenia",
-                "Decreased platelet count"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/thrombocytopenia",
-                "http://www.merckmanuals.com/professional/hematology_and_oncology/thrombocytopenia_and_platelet_dysfunction/overview_of_platelet_disorders.htm",
-                "http://ghr.nlm.nih.gov/glossary=thrombocytopenia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12887856,
-            "start": 570,
-            "end": 316686,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17548927': {'publication date': '2007 Jun', 'sentence': 'We describe that high-dose methylprednisolone (20 mg/kg) can induce multifocal osteonecrosis (ON) in conjunction with thrombocytopenia, hypofibrinogenemia, and hyperlipemia.', 'subject score': 901, 'object score': 1000}, 'PMID:32727666': {'publication date': '2020 Jul 02', 'sentence': 'Oxaliplatin and Methylprednisolone-induced Thrombocytopenia and Monocytopenia, Owing to Anti-GPIIbIIIa and -CD36 Antibodies in a Patient With Colorectal Cancer.', 'subject score': 851, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:causes---None---None---None---UMLS:C0040034---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "13166073",
-              "object": "MONDO:0002049",
-              "publications": [
-                "PMID:17548927",
-                "PMID:32727666"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10734662': {'publication date': '2000 Mar', 'sentence': 'After a course of high-dose methylprednisolone therapy with a diagnosis of Evans syndrome, complete response for thrombocytopenia and partial response for anemia was achieved.', 'subject score': 861, 'object score': 1000}, 'PMID:1414159': {'publication date': '1992', 'sentence': 'Pulse therapy with methylprednisolone reversed both thrombocytopenia and myelofibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1719258': {'publication date': '1991 Sep', 'sentence': 'The pulse therapy of methylprednisolone and high dose of gamma-globulin improved lymphadenopathy, thrombocytopenia and anemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:23796671': {'publication date': '2013 Apr', 'sentence': 'Efficacy of high-dose methylprednisolone in patients with Crimean-Congo haemorrhagic fever and severe thrombocytopenia.', 'subject score': 901, 'object score': 888}, 'PMID:25518779': {'publication date': '2014 Nov', 'sentence': 'The thrombocytopenia was resistant to intravenous immunoglobulin and methylprednisolone but responded well to Rituximab.', 'subject score': 1000, 'object score': 1000}, 'PMID:28983416': {'publication date': '2017 Sep', 'sentence': 'Here we report a further case of atrial fibrillation following high-dose i.v. methylprednisolone (HDIVMP) therapy of severe thrombocytopenia in a female patient with a flare-up of systemic lupus erythematosus (SLE).', 'subject score': 774, 'object score': 888}, 'PMID:33378749': {'publication date': '2020 Dec 30', 'sentence': 'All patients with thrombocytopenia were treated by methylprednisolone with or without platelet transfusion and recovered without major organ hemorrhage.', 'subject score': 1000, 'object score': 1000}, 'PMID:6487937': {'publication date': '1984 Nov', 'sentence': 'IVMP may be an effective treatment for SLE-associated thrombocytopenia but repeated courses may result in a reduced platelet response.', 'subject score': 888, 'object score': 850}}",
-    "p2": {
-      "start": {
-        "identity": 316686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002049",
-          "name": "thrombocytopenia",
-          "description": "A reduction in the number of circulating thrombocytes. [HPO:probinson]; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T034",
-          "equivalent_curies": [
-            "UMLS:C0392386",
-            "SNOMEDCT:302215000",
-            "MEDDRA:10035545",
-            "MEDDRA:10043555",
-            "PDQ:CDR0000041408",
-            "MEDDRA:10024922",
-            "ICD10:D69.6",
-            "HP:0001873",
-            "NCIT:C3408",
-            "NCIT:C162108",
-            "MEDDRA:10035528",
-            "UMLS:C5201036",
-            "MEDDRA:10043560",
-            "DOID:1588",
-            "UMLS:CN130080",
-            "SYMP:0000114",
-            "MEDDRA:10038213",
-            "MEDDRA:10043546",
-            "MESH:D013921",
-            "MEDDRA:10035529",
-            "MEDDRA:10043569",
-            "UMLS:C0040034",
-            "MEDDRA:10043554",
-            "ICD9:287.5",
-            "MONDO:0002049",
-            "SNOMEDCT:415116008"
-          ],
-          "id": "MONDO:0002049",
-          "category": "biolink:Disease",
-          "all_names": [
-            "thrombocytopenia",
-            "Thrombocytopenia, unspecified",
-            "Low Platelet Count",
-            "Thrombocytopenia",
-            "Decreased platelet count"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/thrombocytopenia",
-            "http://www.merckmanuals.com/professional/hematology_and_oncology/thrombocytopenia_and_platelet_dysfunction/overview_of_platelet_disorders.htm",
-            "http://ghr.nlm.nih.gov/glossary=thrombocytopenia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002049",
-              "name": "thrombocytopenia",
-              "description": "A reduction in the number of circulating thrombocytes. [HPO:probinson]; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T034",
-              "equivalent_curies": [
-                "UMLS:C0392386",
-                "SNOMEDCT:302215000",
-                "MEDDRA:10035545",
-                "MEDDRA:10043555",
-                "PDQ:CDR0000041408",
-                "MEDDRA:10024922",
-                "ICD10:D69.6",
-                "HP:0001873",
-                "NCIT:C3408",
-                "NCIT:C162108",
-                "MEDDRA:10035528",
-                "UMLS:C5201036",
-                "MEDDRA:10043560",
-                "DOID:1588",
-                "UMLS:CN130080",
-                "SYMP:0000114",
-                "MEDDRA:10038213",
-                "MEDDRA:10043546",
-                "MESH:D013921",
-                "MEDDRA:10035529",
-                "MEDDRA:10043569",
-                "UMLS:C0040034",
-                "MEDDRA:10043554",
-                "ICD9:287.5",
-                "MONDO:0002049",
-                "SNOMEDCT:415116008"
-              ],
-              "id": "MONDO:0002049",
-              "category": "biolink:Disease",
-              "all_names": [
-                "thrombocytopenia",
-                "Thrombocytopenia, unspecified",
-                "Low Platelet Count",
-                "Thrombocytopenia",
-                "Decreased platelet count"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/thrombocytopenia",
-                "http://www.merckmanuals.com/professional/hematology_and_oncology/thrombocytopenia_and_platelet_dysfunction/overview_of_platelet_disorders.htm",
-                "http://ghr.nlm.nih.gov/glossary=thrombocytopenia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7912789,
-            "start": 570,
-            "end": 316686,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10734662': {'publication date': '2000 Mar', 'sentence': 'After a course of high-dose methylprednisolone therapy with a diagnosis of Evans syndrome, complete response for thrombocytopenia and partial response for anemia was achieved.', 'subject score': 861, 'object score': 1000}, 'PMID:1414159': {'publication date': '1992', 'sentence': 'Pulse therapy with methylprednisolone reversed both thrombocytopenia and myelofibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1719258': {'publication date': '1991 Sep', 'sentence': 'The pulse therapy of methylprednisolone and high dose of gamma-globulin improved lymphadenopathy, thrombocytopenia and anemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:23796671': {'publication date': '2013 Apr', 'sentence': 'Efficacy of high-dose methylprednisolone in patients with Crimean-Congo haemorrhagic fever and severe thrombocytopenia.', 'subject score': 901, 'object score': 888}, 'PMID:25518779': {'publication date': '2014 Nov', 'sentence': 'The thrombocytopenia was resistant to intravenous immunoglobulin and methylprednisolone but responded well to Rituximab.', 'subject score': 1000, 'object score': 1000}, 'PMID:28983416': {'publication date': '2017 Sep', 'sentence': 'Here we report a further case of atrial fibrillation following high-dose i.v. methylprednisolone (HDIVMP) therapy of severe thrombocytopenia in a female patient with a flare-up of systemic lupus erythematosus (SLE).', 'subject score': 774, 'object score': 888}, 'PMID:33378749': {'publication date': '2020 Dec 30', 'sentence': 'All patients with thrombocytopenia were treated by methylprednisolone with or without platelet transfusion and recovered without major organ hemorrhage.', 'subject score': 1000, 'object score': 1000}, 'PMID:6487937': {'publication date': '1984 Nov', 'sentence': 'IVMP may be an effective treatment for SLE-associated thrombocytopenia but repeated courses may result in a reduced platelet response.', 'subject score': 888, 'object score': 850}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0040034---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8083160",
-              "object": "MONDO:0002049",
-              "publications": [
-                "PMID:10734662",
-                "PMID:1414159",
-                "PMID:1719258",
-                "PMID:23796671",
-                "PMID:25518779",
-                "PMID:28983416",
-                "PMID:33378749",
-                "PMID:6487937"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:2611311': {'publication date': '1989 Nov', 'sentence': 'Methylprednisolone only inhibited granulocytopenia and thrombocytopenia when zymosan-activated serum or fibrinogen-depleted plasma were infused.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002049",
-          "name": "thrombocytopenia",
-          "description": "A reduction in the number of circulating thrombocytes. [HPO:probinson]; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T034",
-          "equivalent_curies": [
-            "UMLS:C0392386",
-            "SNOMEDCT:302215000",
-            "MEDDRA:10035545",
-            "MEDDRA:10043555",
-            "PDQ:CDR0000041408",
-            "MEDDRA:10024922",
-            "ICD10:D69.6",
-            "HP:0001873",
-            "NCIT:C3408",
-            "NCIT:C162108",
-            "MEDDRA:10035528",
-            "UMLS:C5201036",
-            "MEDDRA:10043560",
-            "DOID:1588",
-            "UMLS:CN130080",
-            "SYMP:0000114",
-            "MEDDRA:10038213",
-            "MEDDRA:10043546",
-            "MESH:D013921",
-            "MEDDRA:10035529",
-            "MEDDRA:10043569",
-            "UMLS:C0040034",
-            "MEDDRA:10043554",
-            "ICD9:287.5",
-            "MONDO:0002049",
-            "SNOMEDCT:415116008"
-          ],
-          "id": "MONDO:0002049",
-          "category": "biolink:Disease",
-          "all_names": [
-            "thrombocytopenia",
-            "Thrombocytopenia, unspecified",
-            "Low Platelet Count",
-            "Thrombocytopenia",
-            "Decreased platelet count"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/thrombocytopenia",
-            "http://www.merckmanuals.com/professional/hematology_and_oncology/thrombocytopenia_and_platelet_dysfunction/overview_of_platelet_disorders.htm",
-            "http://ghr.nlm.nih.gov/glossary=thrombocytopenia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002049",
-              "name": "thrombocytopenia",
-              "description": "A reduction in the number of circulating thrombocytes. [HPO:probinson]; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T034",
-              "equivalent_curies": [
-                "UMLS:C0392386",
-                "SNOMEDCT:302215000",
-                "MEDDRA:10035545",
-                "MEDDRA:10043555",
-                "PDQ:CDR0000041408",
-                "MEDDRA:10024922",
-                "ICD10:D69.6",
-                "HP:0001873",
-                "NCIT:C3408",
-                "NCIT:C162108",
-                "MEDDRA:10035528",
-                "UMLS:C5201036",
-                "MEDDRA:10043560",
-                "DOID:1588",
-                "UMLS:CN130080",
-                "SYMP:0000114",
-                "MEDDRA:10038213",
-                "MEDDRA:10043546",
-                "MESH:D013921",
-                "MEDDRA:10035529",
-                "MEDDRA:10043569",
-                "UMLS:C0040034",
-                "MEDDRA:10043554",
-                "ICD9:287.5",
-                "MONDO:0002049",
-                "SNOMEDCT:415116008"
-              ],
-              "id": "MONDO:0002049",
-              "category": "biolink:Disease",
-              "all_names": [
-                "thrombocytopenia",
-                "Thrombocytopenia, unspecified",
-                "Low Platelet Count",
-                "Thrombocytopenia",
-                "Decreased platelet count"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/thrombocytopenia",
-                "http://www.merckmanuals.com/professional/hematology_and_oncology/thrombocytopenia_and_platelet_dysfunction/overview_of_platelet_disorders.htm",
-                "http://ghr.nlm.nih.gov/glossary=thrombocytopenia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18041857,
-            "start": 570,
-            "end": 316686,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2611311': {'publication date': '1989 Nov', 'sentence': 'Methylprednisolone only inhibited granulocytopenia and thrombocytopenia when zymosan-activated serum or fibrinogen-depleted plasma were infused.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:disrupts---None---None---None---UMLS:C0040034---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "18407557",
-              "object": "MONDO:0002049",
-              "publications": [
-                "PMID:2611311"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:10872756': {'publication date': '2000 Jun', 'sentence': 'Despite the lucrative \"off label\" markets for methylprednisolone in SCI, no Food and Drug Association indication has been obtained.', 'subject score': 1000, 'object score': 1000}, 'PMID:10879751': {'publication date': '2000 Jul', 'sentence': 'In the strictest sense, 24-hour administration of methylprednisolone must still be considered experimental for use in clinical SCI.', 'subject score': 1000, 'object score': 916}, 'PMID:10879762': {'publication date': '2000 Jul', 'sentence': 'Comparison of the effects of melatonin and methylprednisolone in experimental spinal cord injury.', 'subject score': 1000, 'object score': 916}, 'PMID:11011817': {'publication date': '2000 Sep', 'sentence': 'Riluzole and methylprednisolone combined treatment improves functional recovery in traumatic spinal cord injury.', 'subject score': 1000, 'object score': 916}, 'PMID:15716618': {'publication date': '2005 Feb', 'sentence': 'Methylprednisolone(MP), a glucocorticoid steroid, has an anti-inflammatory action and seems to inhibit the formation of oxygen free radicals produced during lipid peroxidation in a spinal cord injury(SCI).', 'subject score': 1000, 'object score': 1000}, 'PMID:16506468': {'publication date': '2006 Jan', 'sentence': 'The authors of this study evaluated ATL-146e and methylprednisolone for their ability to preserve neuronal viability and motor function in experimental SCI.', 'subject score': 1000, 'object score': 916}, 'PMID:17031918': {'publication date': '1999 Jan 15', 'sentence': 'To date, methylprednisolone is the only effective neuroprotective agent that has been established for use in human SCI, and the only therapeutic time window established in human SCI is a maximum trauma-to-treatment time of 8 hours.', 'subject score': 1000, 'object score': 916}, 'PMID:17486444': {'publication date': '2007 Sep', 'sentence': 'The effects of hyperbaric oxygen (HBO) therapy or methylprednisolone on the oxidative status were evaluated in experimental spinal cord injury.', 'subject score': 1000, 'object score': 916}, 'PMID:1857175': {'publication date': '1991 Jul 10', 'sentence': '[Methylprednisolone improves prognosis in traumatic spinal cord injuries].', 'subject score': 1000, 'object score': 916}, 'PMID:19519725': {'publication date': '2009 Sep', 'sentence': 'Effects of dexmedetomidine or methylprednisolone on inflammatory responses in spinal cord injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:20209390': {'publication date': '2010 Jan', 'sentence': 'CONCLUSION: Methylprednisolone, NAC and methylprednisolone plus NAC treatments have potential biochemical benefits in preventing secondary injury in experimental spinal cord injury in rats.', 'subject score': 1000, 'object score': 916}, 'PMID:20831552': {'publication date': '2010 Aug', 'sentence': 'Methylprednisolone worsening neuropathic pain in non-traumatic thoracic myelopathy.', 'subject score': 1000, 'object score': 824}, 'PMID:21611834': {'publication date': '2011 Oct', 'sentence': 'Methylprednisolone, the only currently available therapy renders limited protection in SCI.', 'subject score': 1000, 'object score': 1000}, 'PMID:21994079': {'publication date': '2012 Mar', 'sentence': 'A review: the role of high dose methylprednisolone in spinal cord trauma in children.', 'subject score': 901, 'object score': 1000}, 'PMID:22158284': {'publication date': '2011 Dec', 'sentence': 'Spinal cord injuries in older children: is there a role for high-dose methylprednisolone?', 'subject score': 901, 'object score': 1000}, 'PMID:2258942': {'publication date': '1990', 'sentence': 'Methylprednisolone in spinal cord injury: the possible mechanism of action.', 'subject score': 1000, 'object score': 1000}, 'PMID:22640221': {'publication date': '2012 Jun', 'sentence': 'Stability, disposition, and penetration of catalytic antioxidants Mn-porphyrin and Mn-salen and of methylprednisolone in spinal cord injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:24871822': {'publication date': '2015 Jan', 'sentence': 'Effects of intrathecal caffeic acid phenethyl ester and methylprednisolone on oxidant/antioxidant status in traumatic spinal cord injuries.', 'subject score': 1000, 'object score': 916}, 'PMID:25047053': {'publication date': '2014 Sep', 'sentence': 'Effects of methylprednisolone and 4-chloro-3-hydroxyanthranilic acid in experimental spinal cord injury in the guinea pig appear to be mediated by different and potentially complementary mechanisms.', 'subject score': 1000, 'object score': 916}, 'PMID:25333652': {'publication date': '2015 Aug', 'sentence': 'Low dose methotrexate is more effective as compared to methylprednisolone in secondary spinal cord injury.', 'subject score': 1000, 'object score': 916}}",
-    "p2": {
-      "start": {
-        "identity": 539362,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043797",
-          "name": "spinal cord injury",
-          "description": "Traumatic damage of the spinal cord.; Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).; Your spinal cord is a bundle of nerves that runs down the middle of your back. It carries signals back and forth between your body and your brain. A spinal cord injury disrupts the signals. Spinal cord injuries usually begin with a blow that fractures (breaks) or dislocates your vertebrae, the bone disks that make up your spine. Most injuries don't cut through your spinal cord. Instead, they cause damage when pieces of vertebrae tear into cord tissue or press down on the nerve parts that carry signals. Spinal cord injuries can be complete or incomplete. With a complete spinal cord injury, the cord can't send signals below the level of the injury. As a result, you are paralyzed below the injury. With an incomplete injury, you have some movement and sensation below the injury. A spinal cord injury is a medical emergency. Immediate treatment can reduce long-term effects. Treatments may include medicines, braces or traction to stabilize the spine, and surgery. Later treatment usually includes medicines and rehabilitation therapy. Mobility aids and assistive devices may help you to get around and do some daily tasks. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "EFO:1001919",
-            "MESH:D013119",
-            "ORPHANET:90058",
-            "SNOMEDCT:90584004",
-            "MONDO:0043797",
-            "UMLS:C0037929",
-            "MEDDRA:10041552",
-            "NCIT:C50750"
-          ],
-          "id": "MONDO:0043797",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Spinal Cord Injury",
-            "spinal cord injury",
-            "Spinal Cord Injuries",
-            "Spinal cord injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 539362,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043797",
-              "name": "spinal cord injury",
-              "description": "Traumatic damage of the spinal cord.; Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).; Your spinal cord is a bundle of nerves that runs down the middle of your back. It carries signals back and forth between your body and your brain. A spinal cord injury disrupts the signals. Spinal cord injuries usually begin with a blow that fractures (breaks) or dislocates your vertebrae, the bone disks that make up your spine. Most injuries don't cut through your spinal cord. Instead, they cause damage when pieces of vertebrae tear into cord tissue or press down on the nerve parts that carry signals. Spinal cord injuries can be complete or incomplete. With a complete spinal cord injury, the cord can't send signals below the level of the injury. As a result, you are paralyzed below the injury. With an incomplete injury, you have some movement and sensation below the injury. A spinal cord injury is a medical emergency. Immediate treatment can reduce long-term effects. Treatments may include medicines, braces or traction to stabilize the spine, and surgery. Later treatment usually includes medicines and rehabilitation therapy. Mobility aids and assistive devices may help you to get around and do some daily tasks. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "EFO:1001919",
-                "MESH:D013119",
-                "ORPHANET:90058",
-                "SNOMEDCT:90584004",
-                "MONDO:0043797",
-                "UMLS:C0037929",
-                "MEDDRA:10041552",
-                "NCIT:C50750"
-              ],
-              "id": "MONDO:0043797",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Spinal Cord Injury",
-                "spinal cord injury",
-                "Spinal Cord Injuries",
-                "Spinal cord injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8107688,
-            "start": 570,
-            "end": 539362,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10872756': {'publication date': '2000 Jun', 'sentence': 'Despite the lucrative \"off label\" markets for methylprednisolone in SCI, no Food and Drug Association indication has been obtained.', 'subject score': 1000, 'object score': 1000}, 'PMID:10879751': {'publication date': '2000 Jul', 'sentence': 'In the strictest sense, 24-hour administration of methylprednisolone must still be considered experimental for use in clinical SCI.', 'subject score': 1000, 'object score': 916}, 'PMID:10879762': {'publication date': '2000 Jul', 'sentence': 'Comparison of the effects of melatonin and methylprednisolone in experimental spinal cord injury.', 'subject score': 1000, 'object score': 916}, 'PMID:11011817': {'publication date': '2000 Sep', 'sentence': 'Riluzole and methylprednisolone combined treatment improves functional recovery in traumatic spinal cord injury.', 'subject score': 1000, 'object score': 916}, 'PMID:15716618': {'publication date': '2005 Feb', 'sentence': 'Methylprednisolone(MP), a glucocorticoid steroid, has an anti-inflammatory action and seems to inhibit the formation of oxygen free radicals produced during lipid peroxidation in a spinal cord injury(SCI).', 'subject score': 1000, 'object score': 1000}, 'PMID:16506468': {'publication date': '2006 Jan', 'sentence': 'The authors of this study evaluated ATL-146e and methylprednisolone for their ability to preserve neuronal viability and motor function in experimental SCI.', 'subject score': 1000, 'object score': 916}, 'PMID:17031918': {'publication date': '1999 Jan 15', 'sentence': 'To date, methylprednisolone is the only effective neuroprotective agent that has been established for use in human SCI, and the only therapeutic time window established in human SCI is a maximum trauma-to-treatment time of 8 hours.', 'subject score': 1000, 'object score': 916}, 'PMID:17486444': {'publication date': '2007 Sep', 'sentence': 'The effects of hyperbaric oxygen (HBO) therapy or methylprednisolone on the oxidative status were evaluated in experimental spinal cord injury.', 'subject score': 1000, 'object score': 916}, 'PMID:1857175': {'publication date': '1991 Jul 10', 'sentence': '[Methylprednisolone improves prognosis in traumatic spinal cord injuries].', 'subject score': 1000, 'object score': 916}, 'PMID:19519725': {'publication date': '2009 Sep', 'sentence': 'Effects of dexmedetomidine or methylprednisolone on inflammatory responses in spinal cord injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:20209390': {'publication date': '2010 Jan', 'sentence': 'CONCLUSION: Methylprednisolone, NAC and methylprednisolone plus NAC treatments have potential biochemical benefits in preventing secondary injury in experimental spinal cord injury in rats.', 'subject score': 1000, 'object score': 916}, 'PMID:20831552': {'publication date': '2010 Aug', 'sentence': 'Methylprednisolone worsening neuropathic pain in non-traumatic thoracic myelopathy.', 'subject score': 1000, 'object score': 824}, 'PMID:21611834': {'publication date': '2011 Oct', 'sentence': 'Methylprednisolone, the only currently available therapy renders limited protection in SCI.', 'subject score': 1000, 'object score': 1000}, 'PMID:21994079': {'publication date': '2012 Mar', 'sentence': 'A review: the role of high dose methylprednisolone in spinal cord trauma in children.', 'subject score': 901, 'object score': 1000}, 'PMID:22158284': {'publication date': '2011 Dec', 'sentence': 'Spinal cord injuries in older children: is there a role for high-dose methylprednisolone?', 'subject score': 901, 'object score': 1000}, 'PMID:2258942': {'publication date': '1990', 'sentence': 'Methylprednisolone in spinal cord injury: the possible mechanism of action.', 'subject score': 1000, 'object score': 1000}, 'PMID:22640221': {'publication date': '2012 Jun', 'sentence': 'Stability, disposition, and penetration of catalytic antioxidants Mn-porphyrin and Mn-salen and of methylprednisolone in spinal cord injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:24871822': {'publication date': '2015 Jan', 'sentence': 'Effects of intrathecal caffeic acid phenethyl ester and methylprednisolone on oxidant/antioxidant status in traumatic spinal cord injuries.', 'subject score': 1000, 'object score': 916}, 'PMID:25047053': {'publication date': '2014 Sep', 'sentence': 'Effects of methylprednisolone and 4-chloro-3-hydroxyanthranilic acid in experimental spinal cord injury in the guinea pig appear to be mediated by different and potentially complementary mechanisms.', 'subject score': 1000, 'object score': 916}, 'PMID:25333652': {'publication date': '2015 Aug', 'sentence': 'Low dose methotrexate is more effective as compared to methylprednisolone in secondary spinal cord injury.', 'subject score': 1000, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0037929---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8282330",
-              "object": "MONDO:0043797",
-              "publications": [
-                "PMID:10872756",
-                "PMID:10879751",
-                "PMID:10879762",
-                "PMID:11011817",
-                "PMID:15716618",
-                "PMID:16506468",
-                "PMID:17031918",
-                "PMID:17486444",
-                "PMID:1857175",
-                "PMID:19519725",
-                "PMID:20209390",
-                "PMID:20831552",
-                "PMID:21611834",
-                "PMID:21994079",
-                "PMID:22158284",
-                "PMID:2258942",
-                "PMID:22640221",
-                "PMID:24871822",
-                "PMID:25047053",
-                "PMID:25333652"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:1588630': {'publication date': '1992 Mar', 'sentence': 'The study strongly suggests that methylprednisolone has significant beneficial effects in human spinal cord injury, that these effects occur only when the drug is given within 8 hr, and that it helps even in patients with severe spinal cord injuries.', 'subject score': 1000, 'object score': 916}, 'PMID:16018585': {'publication date': '2005 Mar', 'sentence': 'This study was aimed to investigate the possible beneficial effects of Ebselen in comparison with Methylprednisolone in experimental SCI.', 'subject score': 1000, 'object score': 916}, 'PMID:21139782': {'publication date': '2007 Oct', 'sentence': 'CONCLUSION: First aid measures of early closed reduction or realignment and immobilization of the cervical spine, breathing support and high-dose methylprednisolone were most important in the treatment for traumatic spinal cord injury.', 'subject score': 901, 'object score': 916}, 'PMID:21167389': {'publication date': '2010 Oct', 'sentence': 'BACKGROUND AND AIMS: We undertook this study to investigate the possible beneficial effects of combined hypothermia and hyperbaric oxygen (HBO) treatment in comparison with methylprednisolone in experimental spinal cord injury (SCI).', 'subject score': 1000, 'object score': 916}, 'PMID:25206681': {'publication date': '2013 Feb 15', 'sentence': 'Methylprednisolone plays an effective role in treating spinal cord injury, but the effect of methylprednisolone on Nogo-A in the injured spinal cord remains unknown.', 'subject score': 1000, 'object score': 916}, 'PMID:2907111': {'publication date': '1988 Dec', 'sentence': 'Effects of methyl prednisolone, dimethyl sulphoxide and naloxone in experimental spinal cord injuries in rats.', 'subject score': 1000, 'object score': 916}, 'PMID:31760579': {'publication date': '2019 Nov 23', 'sentence': 'OBJECTIVE: To investigate the functions and mechanisms of methylprednisolone (MP) through endothelin receptor B (EDNRB) on the cell proliferation of neural progenitor cells (NPCs) to regulate spinal cord injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:8876716': {'publication date': '1996 Oct', 'sentence': 'The effects of taxol, methylprednisolone, and 4-aminopyridine in compressive spinal cord injury: a qualitative experimental study.', 'subject score': 1000, 'object score': 923}}",
-    "p2": {
-      "start": {
-        "identity": 539362,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043797",
-          "name": "spinal cord injury",
-          "description": "Traumatic damage of the spinal cord.; Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).; Your spinal cord is a bundle of nerves that runs down the middle of your back. It carries signals back and forth between your body and your brain. A spinal cord injury disrupts the signals. Spinal cord injuries usually begin with a blow that fractures (breaks) or dislocates your vertebrae, the bone disks that make up your spine. Most injuries don't cut through your spinal cord. Instead, they cause damage when pieces of vertebrae tear into cord tissue or press down on the nerve parts that carry signals. Spinal cord injuries can be complete or incomplete. With a complete spinal cord injury, the cord can't send signals below the level of the injury. As a result, you are paralyzed below the injury. With an incomplete injury, you have some movement and sensation below the injury. A spinal cord injury is a medical emergency. Immediate treatment can reduce long-term effects. Treatments may include medicines, braces or traction to stabilize the spine, and surgery. Later treatment usually includes medicines and rehabilitation therapy. Mobility aids and assistive devices may help you to get around and do some daily tasks. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "EFO:1001919",
-            "MESH:D013119",
-            "ORPHANET:90058",
-            "SNOMEDCT:90584004",
-            "MONDO:0043797",
-            "UMLS:C0037929",
-            "MEDDRA:10041552",
-            "NCIT:C50750"
-          ],
-          "id": "MONDO:0043797",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Spinal Cord Injury",
-            "spinal cord injury",
-            "Spinal Cord Injuries",
-            "Spinal cord injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 539362,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043797",
-              "name": "spinal cord injury",
-              "description": "Traumatic damage of the spinal cord.; Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).; Your spinal cord is a bundle of nerves that runs down the middle of your back. It carries signals back and forth between your body and your brain. A spinal cord injury disrupts the signals. Spinal cord injuries usually begin with a blow that fractures (breaks) or dislocates your vertebrae, the bone disks that make up your spine. Most injuries don't cut through your spinal cord. Instead, they cause damage when pieces of vertebrae tear into cord tissue or press down on the nerve parts that carry signals. Spinal cord injuries can be complete or incomplete. With a complete spinal cord injury, the cord can't send signals below the level of the injury. As a result, you are paralyzed below the injury. With an incomplete injury, you have some movement and sensation below the injury. A spinal cord injury is a medical emergency. Immediate treatment can reduce long-term effects. Treatments may include medicines, braces or traction to stabilize the spine, and surgery. Later treatment usually includes medicines and rehabilitation therapy. Mobility aids and assistive devices may help you to get around and do some daily tasks. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "EFO:1001919",
-                "MESH:D013119",
-                "ORPHANET:90058",
-                "SNOMEDCT:90584004",
-                "MONDO:0043797",
-                "UMLS:C0037929",
-                "MEDDRA:10041552",
-                "NCIT:C50750"
-              ],
-              "id": "MONDO:0043797",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Spinal Cord Injury",
-                "spinal cord injury",
-                "Spinal Cord Injuries",
-                "Spinal cord injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11567370,
-            "start": 570,
-            "end": 539362,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1588630': {'publication date': '1992 Mar', 'sentence': 'The study strongly suggests that methylprednisolone has significant beneficial effects in human spinal cord injury, that these effects occur only when the drug is given within 8 hr, and that it helps even in patients with severe spinal cord injuries.', 'subject score': 1000, 'object score': 916}, 'PMID:16018585': {'publication date': '2005 Mar', 'sentence': 'This study was aimed to investigate the possible beneficial effects of Ebselen in comparison with Methylprednisolone in experimental SCI.', 'subject score': 1000, 'object score': 916}, 'PMID:21139782': {'publication date': '2007 Oct', 'sentence': 'CONCLUSION: First aid measures of early closed reduction or realignment and immobilization of the cervical spine, breathing support and high-dose methylprednisolone were most important in the treatment for traumatic spinal cord injury.', 'subject score': 901, 'object score': 916}, 'PMID:21167389': {'publication date': '2010 Oct', 'sentence': 'BACKGROUND AND AIMS: We undertook this study to investigate the possible beneficial effects of combined hypothermia and hyperbaric oxygen (HBO) treatment in comparison with methylprednisolone in experimental spinal cord injury (SCI).', 'subject score': 1000, 'object score': 916}, 'PMID:25206681': {'publication date': '2013 Feb 15', 'sentence': 'Methylprednisolone plays an effective role in treating spinal cord injury, but the effect of methylprednisolone on Nogo-A in the injured spinal cord remains unknown.', 'subject score': 1000, 'object score': 916}, 'PMID:2907111': {'publication date': '1988 Dec', 'sentence': 'Effects of methyl prednisolone, dimethyl sulphoxide and naloxone in experimental spinal cord injuries in rats.', 'subject score': 1000, 'object score': 916}, 'PMID:31760579': {'publication date': '2019 Nov 23', 'sentence': 'OBJECTIVE: To investigate the functions and mechanisms of methylprednisolone (MP) through endothelin receptor B (EDNRB) on the cell proliferation of neural progenitor cells (NPCs) to regulate spinal cord injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:8876716': {'publication date': '1996 Oct', 'sentence': 'The effects of taxol, methylprednisolone, and 4-aminopyridine in compressive spinal cord injury: a qualitative experimental study.', 'subject score': 1000, 'object score': 923}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0037929---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "11819955",
-              "object": "MONDO:0043797",
-              "publications": [
-                "PMID:1588630",
-                "PMID:16018585",
-                "PMID:21139782",
-                "PMID:21167389",
-                "PMID:25206681",
-                "PMID:2907111",
-                "PMID:31760579",
-                "PMID:8876716"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:10668431': {'publication date': '1999', 'sentence': 'Thus, calpeptin and methylprednisolone are found to be neuroprotective in SCI.', 'subject score': 1000, 'object score': 1000}, 'PMID:11393256': {'publication date': '2001 May', 'sentence': 'These findings suggested that MPS reduces the severity of SCI, not by inhibiting the production of TNF-alpha at the site of spinal cord trauma, but by inhibiting activated leukocyte induced lipid peroxidation of the endothelial cell membrane.', 'subject score': 1000, 'object score': 1000}, 'PMID:18980475': {'publication date': '2008', 'sentence': 'CONCLUSIONS: There are a number of treatment options, including maintenance of mean arterial blood pressure > 80 mm Hg, starting methylprednisolone treatment preoperatively, and multimodality monitoring to help prevent POSCI occurrence, minimize secondary damage, and potentially improve the clinical outcome of after a POSCI.', 'subject score': 790, 'object score': 875}, 'PMID:22436574': {'publication date': '2012 Jul', 'sentence': 'And, it is as effective as methylprednisolone in preventing secondary spinal cord injury histopathologically.', 'subject score': 1000, 'object score': 811}, 'PMID:8620925': {'publication date': '1996 Apr', 'sentence': 'Clinically, methylprednisolone (MP) has been shown to be neuroprotective if administered within 8 h after spinal cord injury.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 539362,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043797",
-          "name": "spinal cord injury",
-          "description": "Traumatic damage of the spinal cord.; Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).; Your spinal cord is a bundle of nerves that runs down the middle of your back. It carries signals back and forth between your body and your brain. A spinal cord injury disrupts the signals. Spinal cord injuries usually begin with a blow that fractures (breaks) or dislocates your vertebrae, the bone disks that make up your spine. Most injuries don't cut through your spinal cord. Instead, they cause damage when pieces of vertebrae tear into cord tissue or press down on the nerve parts that carry signals. Spinal cord injuries can be complete or incomplete. With a complete spinal cord injury, the cord can't send signals below the level of the injury. As a result, you are paralyzed below the injury. With an incomplete injury, you have some movement and sensation below the injury. A spinal cord injury is a medical emergency. Immediate treatment can reduce long-term effects. Treatments may include medicines, braces or traction to stabilize the spine, and surgery. Later treatment usually includes medicines and rehabilitation therapy. Mobility aids and assistive devices may help you to get around and do some daily tasks. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "EFO:1001919",
-            "MESH:D013119",
-            "ORPHANET:90058",
-            "SNOMEDCT:90584004",
-            "MONDO:0043797",
-            "UMLS:C0037929",
-            "MEDDRA:10041552",
-            "NCIT:C50750"
-          ],
-          "id": "MONDO:0043797",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Spinal Cord Injury",
-            "spinal cord injury",
-            "Spinal Cord Injuries",
-            "Spinal cord injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 539362,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043797",
-              "name": "spinal cord injury",
-              "description": "Traumatic damage of the spinal cord.; Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).; Your spinal cord is a bundle of nerves that runs down the middle of your back. It carries signals back and forth between your body and your brain. A spinal cord injury disrupts the signals. Spinal cord injuries usually begin with a blow that fractures (breaks) or dislocates your vertebrae, the bone disks that make up your spine. Most injuries don't cut through your spinal cord. Instead, they cause damage when pieces of vertebrae tear into cord tissue or press down on the nerve parts that carry signals. Spinal cord injuries can be complete or incomplete. With a complete spinal cord injury, the cord can't send signals below the level of the injury. As a result, you are paralyzed below the injury. With an incomplete injury, you have some movement and sensation below the injury. A spinal cord injury is a medical emergency. Immediate treatment can reduce long-term effects. Treatments may include medicines, braces or traction to stabilize the spine, and surgery. Later treatment usually includes medicines and rehabilitation therapy. Mobility aids and assistive devices may help you to get around and do some daily tasks. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "EFO:1001919",
-                "MESH:D013119",
-                "ORPHANET:90058",
-                "SNOMEDCT:90584004",
-                "MONDO:0043797",
-                "UMLS:C0037929",
-                "MEDDRA:10041552",
-                "NCIT:C50750"
-              ],
-              "id": "MONDO:0043797",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Spinal Cord Injury",
-                "spinal cord injury",
-                "Spinal Cord Injuries",
-                "Spinal cord injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7813609,
-            "start": 570,
-            "end": 539362,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10668431': {'publication date': '1999', 'sentence': 'Thus, calpeptin and methylprednisolone are found to be neuroprotective in SCI.', 'subject score': 1000, 'object score': 1000}, 'PMID:11393256': {'publication date': '2001 May', 'sentence': 'These findings suggested that MPS reduces the severity of SCI, not by inhibiting the production of TNF-alpha at the site of spinal cord trauma, but by inhibiting activated leukocyte induced lipid peroxidation of the endothelial cell membrane.', 'subject score': 1000, 'object score': 1000}, 'PMID:18980475': {'publication date': '2008', 'sentence': 'CONCLUSIONS: There are a number of treatment options, including maintenance of mean arterial blood pressure > 80 mm Hg, starting methylprednisolone treatment preoperatively, and multimodality monitoring to help prevent POSCI occurrence, minimize secondary damage, and potentially improve the clinical outcome of after a POSCI.', 'subject score': 790, 'object score': 875}, 'PMID:22436574': {'publication date': '2012 Jul', 'sentence': 'And, it is as effective as methylprednisolone in preventing secondary spinal cord injury histopathologically.', 'subject score': 1000, 'object score': 811}, 'PMID:8620925': {'publication date': '1996 Apr', 'sentence': 'Clinically, methylprednisolone (MP) has been shown to be neuroprotective if administered within 8 h after spinal cord injury.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:prevents---None---None---None---UMLS:C0037929---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7980138",
-              "object": "MONDO:0043797",
-              "publications": [
-                "PMID:10668431",
-                "PMID:11393256",
-                "PMID:18980475",
-                "PMID:22436574",
-                "PMID:8620925"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:35800843': {'publication date': '2022 May', 'sentence': 'A Prospective Study Comparing the Efficacy of Local Injection of Platelet-Rich Plasma (PRP) vs Methylprednisolone in Plantar Fasciitis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 539363,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004833",
-          "name": "plantar fasciitis",
-          "description": "Inflammation of the thick tissue on the bottom of the foot (plantar fascia) causing heel pain. The plantar fascia (also called plantar aponeurosis) are bands of fibrous tissue extending from the calcaneal tuberosity to the toes. The etiology of plantar fasciitis remains controversial but is likely to involve a biomechanical imbalance. Though often presenting along with heel spur, they do not appear to be causally related.",
-          "equivalent_curies": [
-            "MEDDRA:10066146",
-            "MEDDRA:10016239",
-            "UMLS:C0149756",
-            "DOID:9600",
-            "SNOMEDCT:202882003",
-            "MESH:D036981",
-            "EFO:1001909",
-            "MEDDRA:10035155",
-            "MONDO:0004833"
-          ],
-          "id": "MONDO:0004833",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Plantar Fasciitis",
-            "plantar fasciitis",
-            "Fasciitis, Plantar"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 539363,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004833",
-              "name": "plantar fasciitis",
-              "description": "Inflammation of the thick tissue on the bottom of the foot (plantar fascia) causing heel pain. The plantar fascia (also called plantar aponeurosis) are bands of fibrous tissue extending from the calcaneal tuberosity to the toes. The etiology of plantar fasciitis remains controversial but is likely to involve a biomechanical imbalance. Though often presenting along with heel spur, they do not appear to be causally related.",
-              "equivalent_curies": [
-                "MEDDRA:10066146",
-                "MEDDRA:10016239",
-                "UMLS:C0149756",
-                "DOID:9600",
-                "SNOMEDCT:202882003",
-                "MESH:D036981",
-                "EFO:1001909",
-                "MEDDRA:10035155",
-                "MONDO:0004833"
-              ],
-              "id": "MONDO:0004833",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Plantar Fasciitis",
-                "plantar fasciitis",
-                "Fasciitis, Plantar"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24248342,
-            "start": 570,
-            "end": 539363,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35800843': {'publication date': '2022 May', 'sentence': 'A Prospective Study Comparing the Efficacy of Local Injection of Platelet-Rich Plasma (PRP) vs Methylprednisolone in Plantar Fasciitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0149756---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "24691450",
-              "object": "MONDO:0004833",
-              "publications": [
-                "PMID:35800843"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:25885380': {'publication date': '2011 Jul-Dec', 'sentence': 'OBJECTIVES: To compare the effectiveness of oral nonsteroidal antiinflammatory drugs (NSAIDs) and locally injectable steroid (methylprednisolone) in the treatment of plantar fasciitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:30828215': {'publication date': '2019 Mar-Apr', 'sentence': 'Effectiveness of extra-corporeal shock wave therapy (ESWT) vs methylprednisolone injections in plantar fasciitis.', 'subject score': 888, 'object score': 1000}, 'PMID:31413624': {'publication date': '2019', 'sentence': 'In other words, although ozone injection showed a slower efficacy than methylprednisolone, it could be used in plantar fasciitis management as an appropriate alternative.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 539363,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004833",
-          "name": "plantar fasciitis",
-          "description": "Inflammation of the thick tissue on the bottom of the foot (plantar fascia) causing heel pain. The plantar fascia (also called plantar aponeurosis) are bands of fibrous tissue extending from the calcaneal tuberosity to the toes. The etiology of plantar fasciitis remains controversial but is likely to involve a biomechanical imbalance. Though often presenting along with heel spur, they do not appear to be causally related.",
-          "equivalent_curies": [
-            "MEDDRA:10066146",
-            "MEDDRA:10016239",
-            "UMLS:C0149756",
-            "DOID:9600",
-            "SNOMEDCT:202882003",
-            "MESH:D036981",
-            "EFO:1001909",
-            "MEDDRA:10035155",
-            "MONDO:0004833"
-          ],
-          "id": "MONDO:0004833",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Plantar Fasciitis",
-            "plantar fasciitis",
-            "Fasciitis, Plantar"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 539363,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004833",
-              "name": "plantar fasciitis",
-              "description": "Inflammation of the thick tissue on the bottom of the foot (plantar fascia) causing heel pain. The plantar fascia (also called plantar aponeurosis) are bands of fibrous tissue extending from the calcaneal tuberosity to the toes. The etiology of plantar fasciitis remains controversial but is likely to involve a biomechanical imbalance. Though often presenting along with heel spur, they do not appear to be causally related.",
-              "equivalent_curies": [
-                "MEDDRA:10066146",
-                "MEDDRA:10016239",
-                "UMLS:C0149756",
-                "DOID:9600",
-                "SNOMEDCT:202882003",
-                "MESH:D036981",
-                "EFO:1001909",
-                "MEDDRA:10035155",
-                "MONDO:0004833"
-              ],
-              "id": "MONDO:0004833",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Plantar Fasciitis",
-                "plantar fasciitis",
-                "Fasciitis, Plantar"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17912349,
-            "start": 570,
-            "end": 539363,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25885380': {'publication date': '2011 Jul-Dec', 'sentence': 'OBJECTIVES: To compare the effectiveness of oral nonsteroidal antiinflammatory drugs (NSAIDs) and locally injectable steroid (methylprednisolone) in the treatment of plantar fasciitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:30828215': {'publication date': '2019 Mar-Apr', 'sentence': 'Effectiveness of extra-corporeal shock wave therapy (ESWT) vs methylprednisolone injections in plantar fasciitis.', 'subject score': 888, 'object score': 1000}, 'PMID:31413624': {'publication date': '2019', 'sentence': 'In other words, although ozone injection showed a slower efficacy than methylprednisolone, it could be used in plantar fasciitis management as an appropriate alternative.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0149756---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "18276332",
-              "object": "MONDO:0004833",
-              "publications": [
-                "PMID:25885380",
-                "PMID:30828215",
-                "PMID:31413624"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:1456416': {'publication date': '1992 Aug', 'sentence': 'Delayed hypersensitivity to 6-methyl-prednisolone in Henoch Schoenlein syndrome.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 517020,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019167",
-          "name": "immunoglobulin a vasculitis",
-          "description": "A systemic, usually self-limited immune complex vasculitis, characterized by immunoglobulin A deposition in the small vessels and kidneys. It is manifested with small hemorrhages in the skin, gastrointestinal symptoms, arthritis, and nephropathy.; A systemic non-thrombocytopenic purpura caused by HYPERSENSITIVITY VASCULITIS and deposition of IGA-containing IMMUNE COMPLEXES within the blood vessels throughout the body, including those in the kidney (KIDNEY GLOMERULUS). Clinical symptoms include URTICARIA; ERYTHEMA; ARTHRITIS; GASTROINTESTINAL HEMORRHAGE; and renal involvement. Most cases are seen in children after acute upper respiratory infections.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10002214",
-            "ICD9:287.0",
-            "MEDDRA:10002217",
-            "MEDDRA:10037552",
-            "MONDO:0019167",
-            "MEDDRA:10037565",
-            "MEDDRA:10001735",
-            "NCIT:C34963",
-            "MEDDRA:10019616",
-            "EFO:1000965",
-            "MEDDRA:10001716",
-            "DOID:11123",
-            "MEDDRA:10019615",
-            "MEDDRA:10002215",
-            "MESH:D011695",
-            "SNOMEDCT:191306005",
-            "ORPHANET:761",
-            "MEDDRA:10037551",
-            "ICD10:D69.0",
-            "MEDDRA:10039658",
-            "MEDDRA:10019617",
-            "SNOMEDCT:86074002",
-            "UMLS:C0034152",
-            "MEDDRA:10082959"
-          ],
-          "id": "MONDO:0019167",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Immunoglobulin A vasculitis",
-            "immunoglobulin A vasculitis",
-            "Allergic purpura",
-            "Henoch-Schönlein Purpura",
-            "IgA Vasculitis",
-            "Henoch-Schoenlein purpura",
-            "Henoch-Schoenlein Purpura"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://rarediseases.info.nih.gov/diseases/8204/henoch-schonlein-purpura",
-            "https://orcid.org/0000-0001-5208-3432"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517020,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019167",
-              "name": "immunoglobulin a vasculitis",
-              "description": "A systemic, usually self-limited immune complex vasculitis, characterized by immunoglobulin A deposition in the small vessels and kidneys. It is manifested with small hemorrhages in the skin, gastrointestinal symptoms, arthritis, and nephropathy.; A systemic non-thrombocytopenic purpura caused by HYPERSENSITIVITY VASCULITIS and deposition of IGA-containing IMMUNE COMPLEXES within the blood vessels throughout the body, including those in the kidney (KIDNEY GLOMERULUS). Clinical symptoms include URTICARIA; ERYTHEMA; ARTHRITIS; GASTROINTESTINAL HEMORRHAGE; and renal involvement. Most cases are seen in children after acute upper respiratory infections.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10002214",
-                "ICD9:287.0",
-                "MEDDRA:10002217",
-                "MEDDRA:10037552",
-                "MONDO:0019167",
-                "MEDDRA:10037565",
-                "MEDDRA:10001735",
-                "NCIT:C34963",
-                "MEDDRA:10019616",
-                "EFO:1000965",
-                "MEDDRA:10001716",
-                "DOID:11123",
-                "MEDDRA:10019615",
-                "MEDDRA:10002215",
-                "MESH:D011695",
-                "SNOMEDCT:191306005",
-                "ORPHANET:761",
-                "MEDDRA:10037551",
-                "ICD10:D69.0",
-                "MEDDRA:10039658",
-                "MEDDRA:10019617",
-                "SNOMEDCT:86074002",
-                "UMLS:C0034152",
-                "MEDDRA:10082959"
-              ],
-              "id": "MONDO:0019167",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Immunoglobulin A vasculitis",
-                "immunoglobulin A vasculitis",
-                "Allergic purpura",
-                "Henoch-Schönlein Purpura",
-                "IgA Vasculitis",
-                "Henoch-Schoenlein purpura",
-                "Henoch-Schoenlein Purpura"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://rarediseases.info.nih.gov/diseases/8204/henoch-schonlein-purpura",
-                "https://orcid.org/0000-0001-5208-3432"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10580548,
-            "start": 570,
-            "end": 517020,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1456416': {'publication date': '1992 Aug', 'sentence': 'Delayed hypersensitivity to 6-methyl-prednisolone in Henoch Schoenlein syndrome.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0034152---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10812685",
-              "object": "MONDO:0019167",
-              "publications": [
-                "PMID:1456416"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12533096': {'publication date': '2003 Jan', 'sentence': 'CASE DESCRIPTION: A 33-year-old woman previously treated with methylprednisolone and cyclophosphamide for Henoch-Schonlein purpura was transferred from a referring hospital because of sore throat, fever, and chills.', 'subject score': 1000, 'object score': 1000}, 'PMID:18547440': {'publication date': '2008 Jun 12', 'sentence': 'In this patient, both the Henoch-Schonlein purpura and his neurological symptoms were successfully treated with intravenous cyclophosphamide and methylprednisolone, followed by a short course of oral cyclophosphamide and long-term oral prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:19156419': {'publication date': '2009 Oct', 'sentence': 'In this patient both Schonlein-Henoch purpura and gastrointestinal haemorrhage were successfully treated with intravenous methylprednisolone, avoiding surgical intervention.', 'subject score': 888, 'object score': 1000}, 'PMID:20033243': {'publication date': '2010 Apr', 'sentence': 'Moderate HSP patients were more likely to respond to MP therapy than HCSS therapy (P < 0.05).', 'subject score': 888, 'object score': 854}}",
-    "p2": {
-      "start": {
-        "identity": 517020,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019167",
-          "name": "immunoglobulin a vasculitis",
-          "description": "A systemic, usually self-limited immune complex vasculitis, characterized by immunoglobulin A deposition in the small vessels and kidneys. It is manifested with small hemorrhages in the skin, gastrointestinal symptoms, arthritis, and nephropathy.; A systemic non-thrombocytopenic purpura caused by HYPERSENSITIVITY VASCULITIS and deposition of IGA-containing IMMUNE COMPLEXES within the blood vessels throughout the body, including those in the kidney (KIDNEY GLOMERULUS). Clinical symptoms include URTICARIA; ERYTHEMA; ARTHRITIS; GASTROINTESTINAL HEMORRHAGE; and renal involvement. Most cases are seen in children after acute upper respiratory infections.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10002214",
-            "ICD9:287.0",
-            "MEDDRA:10002217",
-            "MEDDRA:10037552",
-            "MONDO:0019167",
-            "MEDDRA:10037565",
-            "MEDDRA:10001735",
-            "NCIT:C34963",
-            "MEDDRA:10019616",
-            "EFO:1000965",
-            "MEDDRA:10001716",
-            "DOID:11123",
-            "MEDDRA:10019615",
-            "MEDDRA:10002215",
-            "MESH:D011695",
-            "SNOMEDCT:191306005",
-            "ORPHANET:761",
-            "MEDDRA:10037551",
-            "ICD10:D69.0",
-            "MEDDRA:10039658",
-            "MEDDRA:10019617",
-            "SNOMEDCT:86074002",
-            "UMLS:C0034152",
-            "MEDDRA:10082959"
-          ],
-          "id": "MONDO:0019167",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Immunoglobulin A vasculitis",
-            "immunoglobulin A vasculitis",
-            "Allergic purpura",
-            "Henoch-Schönlein Purpura",
-            "IgA Vasculitis",
-            "Henoch-Schoenlein purpura",
-            "Henoch-Schoenlein Purpura"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://rarediseases.info.nih.gov/diseases/8204/henoch-schonlein-purpura",
-            "https://orcid.org/0000-0001-5208-3432"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517020,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019167",
-              "name": "immunoglobulin a vasculitis",
-              "description": "A systemic, usually self-limited immune complex vasculitis, characterized by immunoglobulin A deposition in the small vessels and kidneys. It is manifested with small hemorrhages in the skin, gastrointestinal symptoms, arthritis, and nephropathy.; A systemic non-thrombocytopenic purpura caused by HYPERSENSITIVITY VASCULITIS and deposition of IGA-containing IMMUNE COMPLEXES within the blood vessels throughout the body, including those in the kidney (KIDNEY GLOMERULUS). Clinical symptoms include URTICARIA; ERYTHEMA; ARTHRITIS; GASTROINTESTINAL HEMORRHAGE; and renal involvement. Most cases are seen in children after acute upper respiratory infections.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10002214",
-                "ICD9:287.0",
-                "MEDDRA:10002217",
-                "MEDDRA:10037552",
-                "MONDO:0019167",
-                "MEDDRA:10037565",
-                "MEDDRA:10001735",
-                "NCIT:C34963",
-                "MEDDRA:10019616",
-                "EFO:1000965",
-                "MEDDRA:10001716",
-                "DOID:11123",
-                "MEDDRA:10019615",
-                "MEDDRA:10002215",
-                "MESH:D011695",
-                "SNOMEDCT:191306005",
-                "ORPHANET:761",
-                "MEDDRA:10037551",
-                "ICD10:D69.0",
-                "MEDDRA:10039658",
-                "MEDDRA:10019617",
-                "SNOMEDCT:86074002",
-                "UMLS:C0034152",
-                "MEDDRA:10082959"
-              ],
-              "id": "MONDO:0019167",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Immunoglobulin A vasculitis",
-                "immunoglobulin A vasculitis",
-                "Allergic purpura",
-                "Henoch-Schönlein Purpura",
-                "IgA Vasculitis",
-                "Henoch-Schoenlein purpura",
-                "Henoch-Schoenlein Purpura"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://rarediseases.info.nih.gov/diseases/8204/henoch-schonlein-purpura",
-                "https://orcid.org/0000-0001-5208-3432"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9764318,
-            "start": 570,
-            "end": 517020,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12533096': {'publication date': '2003 Jan', 'sentence': 'CASE DESCRIPTION: A 33-year-old woman previously treated with methylprednisolone and cyclophosphamide for Henoch-Schonlein purpura was transferred from a referring hospital because of sore throat, fever, and chills.', 'subject score': 1000, 'object score': 1000}, 'PMID:18547440': {'publication date': '2008 Jun 12', 'sentence': 'In this patient, both the Henoch-Schonlein purpura and his neurological symptoms were successfully treated with intravenous cyclophosphamide and methylprednisolone, followed by a short course of oral cyclophosphamide and long-term oral prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:19156419': {'publication date': '2009 Oct', 'sentence': 'In this patient both Schonlein-Henoch purpura and gastrointestinal haemorrhage were successfully treated with intravenous methylprednisolone, avoiding surgical intervention.', 'subject score': 888, 'object score': 1000}, 'PMID:20033243': {'publication date': '2010 Apr', 'sentence': 'Moderate HSP patients were more likely to respond to MP therapy than HCSS therapy (P < 0.05).', 'subject score': 888, 'object score': 854}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0034152---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "9980473",
-              "object": "MONDO:0019167",
-              "publications": [
-                "PMID:12533096",
-                "PMID:18547440",
-                "PMID:19156419",
-                "PMID:20033243"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:16926305': {'publication date': '2006 Oct', 'sentence': 'OBJECTIVE: To report the third published case, as of April 8, 2006, of methylprednisolone-induced toxic hepatitis.', 'subject score': 861, 'object score': 861}, 'PMID:26075468': {'publication date': '2015 Jun', 'sentence': 'Methylprednisolone-induced Toxic Hepatitis After Intravenous Pulsed Therapy for Multiple Sclerosis Relapses.', 'subject score': 861, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 547845,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005359",
-          "name": "drug-induced liver injury",
-          "description": "A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10019795",
-            "UMLS:C0019193",
-            "MONDO:0005359",
-            "MESH:D056486",
-            "UMLS:C4277682",
-            "EFO:0004228",
-            "SNOMEDCT:197352008"
-          ],
-          "id": "MONDO:0005359",
-          "category": "biolink:Disease",
-          "all_names": [
-            "drug-induced liver injury",
-            "Chemical and Drug Induced Liver Injury",
-            "Hepatitis, Toxic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-8169-9049"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 547845,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005359",
-              "name": "drug-induced liver injury",
-              "description": "A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10019795",
-                "UMLS:C0019193",
-                "MONDO:0005359",
-                "MESH:D056486",
-                "UMLS:C4277682",
-                "EFO:0004228",
-                "SNOMEDCT:197352008"
-              ],
-              "id": "MONDO:0005359",
-              "category": "biolink:Disease",
-              "all_names": [
-                "drug-induced liver injury",
-                "Chemical and Drug Induced Liver Injury",
-                "Hepatitis, Toxic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-8169-9049"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12403697,
-            "start": 570,
-            "end": 547845,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16926305': {'publication date': '2006 Oct', 'sentence': 'OBJECTIVE: To report the third published case, as of April 8, 2006, of methylprednisolone-induced toxic hepatitis.', 'subject score': 861, 'object score': 861}, 'PMID:26075468': {'publication date': '2015 Jun', 'sentence': 'Methylprednisolone-induced Toxic Hepatitis After Intravenous Pulsed Therapy for Multiple Sclerosis Relapses.', 'subject score': 861, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:causes---None---None---None---UMLS:C0019193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "12672767",
-              "object": "MONDO:0005359",
-              "publications": [
-                "PMID:16926305",
-                "PMID:26075468"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:28539536': {'publication date': '2017 05', 'sentence': 'Six newly diagnosed patients with MPA were initially treated with methylprednisolone and a single dose of RTX (375 mg/m2).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 708295,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019124",
-          "name": "microscopic polyangiitis",
-          "description": "A systemic necrotizing vasculitis that typically affects the small and medium-sized muscular arteries. In some cases, however, microscopic vessels are also affected (e.g., in the kidneys), a condition that has been called microscopic polyarteritis or polyangiitis; this disorder is felt to be more closely associated with Wegener granulomatosis than to classic polyarteritis nodosa.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:1144805008",
-            "MONDO:0019124",
-            "MESH:D055953",
-            "MEDDRA:10063344",
-            "ORPHANET:727",
-            "EFO:1000784",
-            "SNOMEDCT:239928004",
-            "NCIT:C70549",
-            "UMLS:C2347126"
-          ],
-          "id": "MONDO:0019124",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Microscopic Polyangiitis",
-            "Microscopic Polyarteritis",
-            "microscopic polyangiitis",
-            "Microscopic polyangiitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 708295,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019124",
-              "name": "microscopic polyangiitis",
-              "description": "A systemic necrotizing vasculitis that typically affects the small and medium-sized muscular arteries. In some cases, however, microscopic vessels are also affected (e.g., in the kidneys), a condition that has been called microscopic polyarteritis or polyangiitis; this disorder is felt to be more closely associated with Wegener granulomatosis than to classic polyarteritis nodosa.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:1144805008",
-                "MONDO:0019124",
-                "MESH:D055953",
-                "MEDDRA:10063344",
-                "ORPHANET:727",
-                "EFO:1000784",
-                "SNOMEDCT:239928004",
-                "NCIT:C70549",
-                "UMLS:C2347126"
-              ],
-              "id": "MONDO:0019124",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Microscopic Polyangiitis",
-                "Microscopic Polyarteritis",
-                "microscopic polyangiitis",
-                "Microscopic polyangiitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19288947,
-            "start": 570,
-            "end": 708295,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28539536': {'publication date': '2017 05', 'sentence': 'Six newly diagnosed patients with MPA were initially treated with methylprednisolone and a single dose of RTX (375 mg/m2).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C2347126---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "19674675",
-              "object": "MONDO:0019124",
-              "publications": [
-                "PMID:28539536"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:12682449': {'publication date': '2003 Apr', 'sentence': \"The National Heart, Lung, and Blood Institute's ARDS Network currently is testing the use of methylprednisolone in late ARDS.\", 'subject score': 1000, 'object score': 928}, 'PMID:17426195': {'publication date': '2007 Apr', 'sentence': 'Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial.', 'subject score': 888, 'object score': 851}, 'PMID:17873211': {'publication date': '2007 Sep', 'sentence': 'Methylprednisolone infusion in early severe ARDS.', 'subject score': 888, 'object score': 851}, 'PMID:17873212': {'publication date': '2007 Sep', 'sentence': 'Methylprednisolone infusion in early severe ARDS: it is pretty, but is it art?', 'subject score': 888, 'object score': 851}, 'PMID:19838137': {'publication date': '2010 May', 'sentence': 'Steroids for early acute respiratory distress syndrome: critical appraisal of Meduri GU, Golden E, Freire AX, et al: Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial.', 'subject score': 888, 'object score': 851}, 'PMID:25634565': {'publication date': '2015 Mar', 'sentence': 'Double-blind, placebo-controlled pilot randomized trial of methylprednisolone infusion in pediatric acute respiratory distress syndrome.', 'subject score': 888, 'object score': 928}, 'PMID:34284567': {'publication date': '2021 Jul 19', 'sentence': 'We present a preliminary report on our experience using high-dose pulsed methylprednisolone in COVID-19 ARDS and three-month outcomes.', 'subject score': 1000, 'object score': 901}, 'PMID:7460641': {'publication date': '1981 Feb', 'sentence': 'We evaluated the effect of pharmacologic doses of corticosteroid (methylprednisolone and dexamethasone) on alveolo-capillary permeability in human septic ARDS by examining the change in appearance of intravenously administered iodine 131 (131I) human serum albumin (I-HSA) into broncho-alveolar secretions, before and after corticosteroid administration.', 'subject score': 1000, 'object score': 888}, 'PMID:729264': {'publication date': '1978 Jul-Aug', 'sentence': 'Methylprednisolone in posttraumatic pulmonary insufficiency.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319500,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0100130",
-          "name": "adult acute respiratory distress syndrome",
-          "description": "Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.; A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:J80",
-            "MEDDRA:10042839",
-            "UMLS:C4281993",
-            "MEDDRA:10038691",
-            "MEDDRA:10040579",
-            "DOID:11394",
-            "SNOMEDCT:196153002",
-            "ORPHANET:70578",
-            "MEDDRA:10042787",
-            "SNOMEDCT:67782005",
-            "MONDO:0100130",
-            "MEDDRA:10003083",
-            "MEDDRA:10038688",
-            "MEDDRA:10001410",
-            "HP:0002643",
-            "MEDDRA:10001407",
-            "MEDDRA:10000036",
-            "UMLS:C0852283",
-            "MEDDRA:10028973",
-            "UMLS:C0035222",
-            "MEDDRA:10001052",
-            "MEDDRA:10001409",
-            "MESH:D012128",
-            "SNOMEDCT:1179627006",
-            "UMLS:C1368020"
-          ],
-          "id": "MONDO:0100130",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adult acute respiratory distress syndrome",
-            "Neonatal respiratory distress",
-            "Respiratory Distress Syndrome, Adult",
-            "adult respiratory distress syndrome",
-            "Respiratory Distress Syndrome",
-            "Adult acute respiratory distress syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5392788/",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=adult+respiratory+distress+syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319500,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0100130",
-              "name": "adult acute respiratory distress syndrome",
-              "description": "Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.; A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:J80",
-                "MEDDRA:10042839",
-                "UMLS:C4281993",
-                "MEDDRA:10038691",
-                "MEDDRA:10040579",
-                "DOID:11394",
-                "SNOMEDCT:196153002",
-                "ORPHANET:70578",
-                "MEDDRA:10042787",
-                "SNOMEDCT:67782005",
-                "MONDO:0100130",
-                "MEDDRA:10003083",
-                "MEDDRA:10038688",
-                "MEDDRA:10001410",
-                "HP:0002643",
-                "MEDDRA:10001407",
-                "MEDDRA:10000036",
-                "UMLS:C0852283",
-                "MEDDRA:10028973",
-                "UMLS:C0035222",
-                "MEDDRA:10001052",
-                "MEDDRA:10001409",
-                "MESH:D012128",
-                "SNOMEDCT:1179627006",
-                "UMLS:C1368020"
-              ],
-              "id": "MONDO:0100130",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adult acute respiratory distress syndrome",
-                "Neonatal respiratory distress",
-                "Respiratory Distress Syndrome, Adult",
-                "adult respiratory distress syndrome",
-                "Respiratory Distress Syndrome",
-                "Adult acute respiratory distress syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5392788/",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=adult+respiratory+distress+syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9911354,
-            "start": 570,
-            "end": 319500,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12682449': {'publication date': '2003 Apr', 'sentence': \"The National Heart, Lung, and Blood Institute's ARDS Network currently is testing the use of methylprednisolone in late ARDS.\", 'subject score': 1000, 'object score': 928}, 'PMID:17426195': {'publication date': '2007 Apr', 'sentence': 'Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial.', 'subject score': 888, 'object score': 851}, 'PMID:17873211': {'publication date': '2007 Sep', 'sentence': 'Methylprednisolone infusion in early severe ARDS.', 'subject score': 888, 'object score': 851}, 'PMID:17873212': {'publication date': '2007 Sep', 'sentence': 'Methylprednisolone infusion in early severe ARDS: it is pretty, but is it art?', 'subject score': 888, 'object score': 851}, 'PMID:19838137': {'publication date': '2010 May', 'sentence': 'Steroids for early acute respiratory distress syndrome: critical appraisal of Meduri GU, Golden E, Freire AX, et al: Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial.', 'subject score': 888, 'object score': 851}, 'PMID:25634565': {'publication date': '2015 Mar', 'sentence': 'Double-blind, placebo-controlled pilot randomized trial of methylprednisolone infusion in pediatric acute respiratory distress syndrome.', 'subject score': 888, 'object score': 928}, 'PMID:34284567': {'publication date': '2021 Jul 19', 'sentence': 'We present a preliminary report on our experience using high-dose pulsed methylprednisolone in COVID-19 ARDS and three-month outcomes.', 'subject score': 1000, 'object score': 901}, 'PMID:7460641': {'publication date': '1981 Feb', 'sentence': 'We evaluated the effect of pharmacologic doses of corticosteroid (methylprednisolone and dexamethasone) on alveolo-capillary permeability in human septic ARDS by examining the change in appearance of intravenously administered iodine 131 (131I) human serum albumin (I-HSA) into broncho-alveolar secretions, before and after corticosteroid administration.', 'subject score': 1000, 'object score': 888}, 'PMID:729264': {'publication date': '1978 Jul-Aug', 'sentence': 'Methylprednisolone in posttraumatic pulmonary insufficiency.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0035222---SEMMEDDB:",
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C1368020---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10130342",
-              "object": "MONDO:0100130",
-              "publications": [
-                "PMID:7460641",
-                "PMID:19838137",
-                "PMID:17873212",
-                "PMID:17873211",
-                "PMID:729264",
-                "PMID:12682449",
-                "PMID:34284567",
-                "PMID:25634565",
-                "PMID:17426195"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:29606872': {'publication date': '2018', 'sentence': 'Methods: The potential interferences Se@SiO2 nanocomposites may have to the therapeutic effect of methylprednisolone (MPS) were evaluated by classical therapeutic effect index of acute respiratory distress syndrome (ARDS), such as wet-to-dry weight ratio, inflammatory factors IL-1beta and TNF-alpha.', 'subject score': 1000, 'object score': 1000}, 'PMID:6783692': {'publication date': '1981 Apr', 'sentence': 'Effect of methylprednisolone on experimental noncardiogenic pulmonary edema.', 'subject score': 1000, 'object score': 928}, 'PMID:9669790': {'publication date': '1998 Jul 08', 'sentence': 'Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial.', 'subject score': 851, 'object score': 937}}",
-    "p2": {
-      "start": {
-        "identity": 319500,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0100130",
-          "name": "adult acute respiratory distress syndrome",
-          "description": "Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.; A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:J80",
-            "MEDDRA:10042839",
-            "UMLS:C4281993",
-            "MEDDRA:10038691",
-            "MEDDRA:10040579",
-            "DOID:11394",
-            "SNOMEDCT:196153002",
-            "ORPHANET:70578",
-            "MEDDRA:10042787",
-            "SNOMEDCT:67782005",
-            "MONDO:0100130",
-            "MEDDRA:10003083",
-            "MEDDRA:10038688",
-            "MEDDRA:10001410",
-            "HP:0002643",
-            "MEDDRA:10001407",
-            "MEDDRA:10000036",
-            "UMLS:C0852283",
-            "MEDDRA:10028973",
-            "UMLS:C0035222",
-            "MEDDRA:10001052",
-            "MEDDRA:10001409",
-            "MESH:D012128",
-            "SNOMEDCT:1179627006",
-            "UMLS:C1368020"
-          ],
-          "id": "MONDO:0100130",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adult acute respiratory distress syndrome",
-            "Neonatal respiratory distress",
-            "Respiratory Distress Syndrome, Adult",
-            "adult respiratory distress syndrome",
-            "Respiratory Distress Syndrome",
-            "Adult acute respiratory distress syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5392788/",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=adult+respiratory+distress+syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319500,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0100130",
-              "name": "adult acute respiratory distress syndrome",
-              "description": "Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.; A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:J80",
-                "MEDDRA:10042839",
-                "UMLS:C4281993",
-                "MEDDRA:10038691",
-                "MEDDRA:10040579",
-                "DOID:11394",
-                "SNOMEDCT:196153002",
-                "ORPHANET:70578",
-                "MEDDRA:10042787",
-                "SNOMEDCT:67782005",
-                "MONDO:0100130",
-                "MEDDRA:10003083",
-                "MEDDRA:10038688",
-                "MEDDRA:10001410",
-                "HP:0002643",
-                "MEDDRA:10001407",
-                "MEDDRA:10000036",
-                "UMLS:C0852283",
-                "MEDDRA:10028973",
-                "UMLS:C0035222",
-                "MEDDRA:10001052",
-                "MEDDRA:10001409",
-                "MESH:D012128",
-                "SNOMEDCT:1179627006",
-                "UMLS:C1368020"
-              ],
-              "id": "MONDO:0100130",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adult acute respiratory distress syndrome",
-                "Neonatal respiratory distress",
-                "Respiratory Distress Syndrome, Adult",
-                "adult respiratory distress syndrome",
-                "Respiratory Distress Syndrome",
-                "Adult acute respiratory distress syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5392788/",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=adult+respiratory+distress+syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19860414,
-            "start": 570,
-            "end": 319500,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29606872': {'publication date': '2018', 'sentence': 'Methods: The potential interferences Se@SiO2 nanocomposites may have to the therapeutic effect of methylprednisolone (MPS) were evaluated by classical therapeutic effect index of acute respiratory distress syndrome (ARDS), such as wet-to-dry weight ratio, inflammatory factors IL-1beta and TNF-alpha.', 'subject score': 1000, 'object score': 1000}, 'PMID:6783692': {'publication date': '1981 Apr', 'sentence': 'Effect of methylprednisolone on experimental noncardiogenic pulmonary edema.', 'subject score': 1000, 'object score': 928}, 'PMID:9669790': {'publication date': '1998 Jul 08', 'sentence': 'Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial.', 'subject score': 851, 'object score': 937}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0035222---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "20254789",
-              "object": "MONDO:0100130",
-              "publications": [
-                "PMID:29606872",
-                "PMID:6783692",
-                "PMID:9669790"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10378576': {'publication date': '1999 Jun', 'sentence': \"Severe systemic inflammatory response syndrome with shock and ARDS resulting from Still's disease: clinical response with high-dose pulse methylprednisolone therapy.\", 'subject score': 785, 'object score': 1000}, 'PMID:10389390': {'publication date': '1999 May', 'sentence': 'Levels of evidence for the pharmacological effectiveness of prolonged methylprednisolone treatment in unresolving acute respiratory distress syndrome.', 'subject score': 851, 'object score': 937}, 'PMID:10424629': {'publication date': '1999 Jul', 'sentence': 'Levels of evidence for the pharmacologic effectiveness of prolonged methylprednisolone treatment in unresolving ARDS.', 'subject score': 851, 'object score': 861}, 'PMID:11068074': {'publication date': '2000 Jul-Aug', 'sentence': 'This review approaches also the role of leukotriene modifiers in the treatment of asthma and discusses the benefit of using methylprednisolone in patients with adult respiratory distress syndrome, among many other advances in internal medicine.', 'subject score': 1000, 'object score': 1000}, 'PMID:11304898': {'publication date': '2001 Apr', 'sentence': 'Initial clearance of MP (CLo) in ARDS patients at the start of therapy increased to a maximal value (CLmax) after approximately 7 days.', 'subject score': 1000, 'object score': 928}, 'PMID:11687457': {'publication date': '2001 Nov', 'sentence': 'Our clinical studies have shown that methylprednisolone is capable of reducing the levels of TNF-alpha, IL-1 beta, and IL-6 in ARDS patients.', 'subject score': 1000, 'object score': 928}, 'PMID:12607352': {'publication date': '2002 Dec', 'sentence': 'She was diagnosed as M. pneumoniae pneumonia with acute respiratory distress syndrome and treated with clarithromycin and methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:1263566': {'publication date': '1976 May', 'sentence': 'This study demonstrated a significant improvement in mortality rate with repeated pharmacologic doses of methylprednisolone compared to previously reported mortality rates of 60 to 90 per cent in patients with shock lung syndrome treated without repeated pharmacologic doses of steroid therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:15651276': {'publication date': '2004 Nov', 'sentence': 'He was diagnosed as having acute respiratory distress syndrome due to severe pneumonia, and was treated with pulse methylprednisolone and sivelestat sodium in combination with intravenous erythromycin and ciprofloxacin.', 'subject score': 861, 'object score': 1000}, 'PMID:16625008': {'publication date': '2006 Apr 20', 'sentence': 'CONCLUSIONS: These results do not support the routine use of methylprednisolone for persistent ARDS despite the improvement in cardiopulmonary physiology.', 'subject score': 1000, 'object score': 928}, 'PMID:16891686': {'publication date': '2006 Jul', 'sentence': 'We report successful use of methyl-prednisolone in a 21-month old child with ARDS that did not improve with conventional therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:17554986': {'publication date': '2007 May', 'sentence': '[A case of legionella pneumonia associated with acute respiratory distress syndrome (ARDS) and acute renal failure treated with methylprednisolone and sivelestat].', 'subject score': 1000, 'object score': 901}, 'PMID:18657064': {'publication date': '2008 Nov', 'sentence': 'Recently, Meduri et al. found that the early use of low-dose prolonged methylprednisolone in patients with severe ALI/ARDS significantly relieved the systemic inflammatory response and improved pulmonary and extrapulmonary organ function.', 'subject score': 1000, 'object score': 802}, 'PMID:18946661': {'publication date': '2009 Jan', 'sentence': 'PATIENTS AND PARTICIPANTS: Patients enrolled in the ARDS Network study of methylprednisolone versus placebo for persistent ARDS who survived 60 days or to hospital discharge.', 'subject score': 1000, 'object score': 888}, 'PMID:19325471': {'publication date': '2009 May', 'sentence': 'STUDY SELECTION: Randomized controlled trials (RCTs) and observational studies reported in any language that used 0.5-2.5 mg.kg.d of methylprednisolone or equivalent to treat ALI/ARDS.', 'subject score': 1000, 'object score': 818}, 'PMID:20406086': {'publication date': '2010 Apr', 'sentence': 'We recommend that prolonged methylprednisolone treatment, at an initial dose of 1 mg/kg/day in early ARDS and 2 mg/kg/day in unresolving ARDS, be delivered as an infusion to avoid glycemic variability, and that infection surveillance be strictly implemented to identify infections in the absence of fever.', 'subject score': 851, 'object score': 928}, 'PMID:22004685': {'publication date': '2012 Mar', 'sentence': 'RESULTS: Mean time from the diagnosis of the ARDS to methylprednisolone treatment was 11 +/- 2 days in the intermediate  group (10 patients) and 21 +/- 8 days in the late group (9 patients).', 'subject score': 888, 'object score': 1000}, 'PMID:2214425': {'publication date': '1990 Jun', 'sentence': 'This result was considered to some extent to be better than that of our previous experience with single administration of M-PSL for patients with septic ARDS.', 'subject score': 1000, 'object score': 928}, 'PMID:22251837': {'publication date': '2012 02', 'sentence': 'Administration of an antiviral agent (acyclovir), an antibacterial agent (linezolid), and a corticosteroid (methylprednisolone) successfully improved the pneumonia and ARDS.', 'subject score': 1000, 'object score': 1000}, 'PMID:25302516': {'publication date': '2010 Dec', 'sentence': 'Therefore, more research is required to establish the safety and efficacy of methylprednisolone in pediatric patients with acute lung injury/acute respiratory distress syndrome , as well as to determine the best parameters for monitoring steroid side effects and outcomes.', 'subject score': 1000, 'object score': 818}}",
-    "p2": {
-      "start": {
-        "identity": 319500,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0100130",
-          "name": "adult acute respiratory distress syndrome",
-          "description": "Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.; A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:J80",
-            "MEDDRA:10042839",
-            "UMLS:C4281993",
-            "MEDDRA:10038691",
-            "MEDDRA:10040579",
-            "DOID:11394",
-            "SNOMEDCT:196153002",
-            "ORPHANET:70578",
-            "MEDDRA:10042787",
-            "SNOMEDCT:67782005",
-            "MONDO:0100130",
-            "MEDDRA:10003083",
-            "MEDDRA:10038688",
-            "MEDDRA:10001410",
-            "HP:0002643",
-            "MEDDRA:10001407",
-            "MEDDRA:10000036",
-            "UMLS:C0852283",
-            "MEDDRA:10028973",
-            "UMLS:C0035222",
-            "MEDDRA:10001052",
-            "MEDDRA:10001409",
-            "MESH:D012128",
-            "SNOMEDCT:1179627006",
-            "UMLS:C1368020"
-          ],
-          "id": "MONDO:0100130",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adult acute respiratory distress syndrome",
-            "Neonatal respiratory distress",
-            "Respiratory Distress Syndrome, Adult",
-            "adult respiratory distress syndrome",
-            "Respiratory Distress Syndrome",
-            "Adult acute respiratory distress syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5392788/",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=adult+respiratory+distress+syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319500,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0100130",
-              "name": "adult acute respiratory distress syndrome",
-              "description": "Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.; A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:J80",
-                "MEDDRA:10042839",
-                "UMLS:C4281993",
-                "MEDDRA:10038691",
-                "MEDDRA:10040579",
-                "DOID:11394",
-                "SNOMEDCT:196153002",
-                "ORPHANET:70578",
-                "MEDDRA:10042787",
-                "SNOMEDCT:67782005",
-                "MONDO:0100130",
-                "MEDDRA:10003083",
-                "MEDDRA:10038688",
-                "MEDDRA:10001410",
-                "HP:0002643",
-                "MEDDRA:10001407",
-                "MEDDRA:10000036",
-                "UMLS:C0852283",
-                "MEDDRA:10028973",
-                "UMLS:C0035222",
-                "MEDDRA:10001052",
-                "MEDDRA:10001409",
-                "MESH:D012128",
-                "SNOMEDCT:1179627006",
-                "UMLS:C1368020"
-              ],
-              "id": "MONDO:0100130",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adult acute respiratory distress syndrome",
-                "Neonatal respiratory distress",
-                "Respiratory Distress Syndrome, Adult",
-                "adult respiratory distress syndrome",
-                "Respiratory Distress Syndrome",
-                "Adult acute respiratory distress syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5392788/",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=adult+respiratory+distress+syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7332287,
-            "start": 570,
-            "end": 319500,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10378576': {'publication date': '1999 Jun', 'sentence': \"Severe systemic inflammatory response syndrome with shock and ARDS resulting from Still's disease: clinical response with high-dose pulse methylprednisolone therapy.\", 'subject score': 785, 'object score': 1000}, 'PMID:10389390': {'publication date': '1999 May', 'sentence': 'Levels of evidence for the pharmacological effectiveness of prolonged methylprednisolone treatment in unresolving acute respiratory distress syndrome.', 'subject score': 851, 'object score': 937}, 'PMID:10424629': {'publication date': '1999 Jul', 'sentence': 'Levels of evidence for the pharmacologic effectiveness of prolonged methylprednisolone treatment in unresolving ARDS.', 'subject score': 851, 'object score': 861}, 'PMID:11068074': {'publication date': '2000 Jul-Aug', 'sentence': 'This review approaches also the role of leukotriene modifiers in the treatment of asthma and discusses the benefit of using methylprednisolone in patients with adult respiratory distress syndrome, among many other advances in internal medicine.', 'subject score': 1000, 'object score': 1000}, 'PMID:11304898': {'publication date': '2001 Apr', 'sentence': 'Initial clearance of MP (CLo) in ARDS patients at the start of therapy increased to a maximal value (CLmax) after approximately 7 days.', 'subject score': 1000, 'object score': 928}, 'PMID:11687457': {'publication date': '2001 Nov', 'sentence': 'Our clinical studies have shown that methylprednisolone is capable of reducing the levels of TNF-alpha, IL-1 beta, and IL-6 in ARDS patients.', 'subject score': 1000, 'object score': 928}, 'PMID:12607352': {'publication date': '2002 Dec', 'sentence': 'She was diagnosed as M. pneumoniae pneumonia with acute respiratory distress syndrome and treated with clarithromycin and methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:1263566': {'publication date': '1976 May', 'sentence': 'This study demonstrated a significant improvement in mortality rate with repeated pharmacologic doses of methylprednisolone compared to previously reported mortality rates of 60 to 90 per cent in patients with shock lung syndrome treated without repeated pharmacologic doses of steroid therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:15651276': {'publication date': '2004 Nov', 'sentence': 'He was diagnosed as having acute respiratory distress syndrome due to severe pneumonia, and was treated with pulse methylprednisolone and sivelestat sodium in combination with intravenous erythromycin and ciprofloxacin.', 'subject score': 861, 'object score': 1000}, 'PMID:16625008': {'publication date': '2006 Apr 20', 'sentence': 'CONCLUSIONS: These results do not support the routine use of methylprednisolone for persistent ARDS despite the improvement in cardiopulmonary physiology.', 'subject score': 1000, 'object score': 928}, 'PMID:16891686': {'publication date': '2006 Jul', 'sentence': 'We report successful use of methyl-prednisolone in a 21-month old child with ARDS that did not improve with conventional therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:17554986': {'publication date': '2007 May', 'sentence': '[A case of legionella pneumonia associated with acute respiratory distress syndrome (ARDS) and acute renal failure treated with methylprednisolone and sivelestat].', 'subject score': 1000, 'object score': 901}, 'PMID:18657064': {'publication date': '2008 Nov', 'sentence': 'Recently, Meduri et al. found that the early use of low-dose prolonged methylprednisolone in patients with severe ALI/ARDS significantly relieved the systemic inflammatory response and improved pulmonary and extrapulmonary organ function.', 'subject score': 1000, 'object score': 802}, 'PMID:18946661': {'publication date': '2009 Jan', 'sentence': 'PATIENTS AND PARTICIPANTS: Patients enrolled in the ARDS Network study of methylprednisolone versus placebo for persistent ARDS who survived 60 days or to hospital discharge.', 'subject score': 1000, 'object score': 888}, 'PMID:19325471': {'publication date': '2009 May', 'sentence': 'STUDY SELECTION: Randomized controlled trials (RCTs) and observational studies reported in any language that used 0.5-2.5 mg.kg.d of methylprednisolone or equivalent to treat ALI/ARDS.', 'subject score': 1000, 'object score': 818}, 'PMID:20406086': {'publication date': '2010 Apr', 'sentence': 'We recommend that prolonged methylprednisolone treatment, at an initial dose of 1 mg/kg/day in early ARDS and 2 mg/kg/day in unresolving ARDS, be delivered as an infusion to avoid glycemic variability, and that infection surveillance be strictly implemented to identify infections in the absence of fever.', 'subject score': 851, 'object score': 928}, 'PMID:22004685': {'publication date': '2012 Mar', 'sentence': 'RESULTS: Mean time from the diagnosis of the ARDS to methylprednisolone treatment was 11 +/- 2 days in the intermediate  group (10 patients) and 21 +/- 8 days in the late group (9 patients).', 'subject score': 888, 'object score': 1000}, 'PMID:2214425': {'publication date': '1990 Jun', 'sentence': 'This result was considered to some extent to be better than that of our previous experience with single administration of M-PSL for patients with septic ARDS.', 'subject score': 1000, 'object score': 928}, 'PMID:22251837': {'publication date': '2012 02', 'sentence': 'Administration of an antiviral agent (acyclovir), an antibacterial agent (linezolid), and a corticosteroid (methylprednisolone) successfully improved the pneumonia and ARDS.', 'subject score': 1000, 'object score': 1000}, 'PMID:25302516': {'publication date': '2010 Dec', 'sentence': 'Therefore, more research is required to establish the safety and efficacy of methylprednisolone in pediatric patients with acute lung injury/acute respiratory distress syndrome , as well as to determine the best parameters for monitoring steroid side effects and outcomes.', 'subject score': 1000, 'object score': 818}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0035222---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7483648",
-              "object": "MONDO:0100130",
-              "publications": [
-                "PMID:10378576",
-                "PMID:10389390",
-                "PMID:10424629",
-                "PMID:11068074",
-                "PMID:11304898",
-                "PMID:11687457",
-                "PMID:12607352",
-                "PMID:1263566",
-                "PMID:15651276",
-                "PMID:16625008",
-                "PMID:16891686",
-                "PMID:17554986",
-                "PMID:18657064",
-                "PMID:18946661",
-                "PMID:19325471",
-                "PMID:20406086",
-                "PMID:22004685",
-                "PMID:2214425",
-                "PMID:22251837",
-                "PMID:25302516"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:24565635': {'publication date': '2013 Sep-Oct', 'sentence': 'The study by Van Zele et al reports positive results for a randomized, double-blind, placebo-controlled trial that used either 20 days of doxycycline (200 mg the first day, followed by 100 mg daily) or 20 days of a tapering schedule of methyl prednisolone (32 mg on days 1-5, 16 mg on days 6-10, and 8 mg on days 11-20) for the treatment of nasal polyps.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318836,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006314",
-          "name": "nasal cavity polyp",
-          "description": "Polypoidal masses arising mainly from the mucous membranes of the nose and paranasal sinuses. They are freely movable and nontender overgrowths of the mucosa that frequently accompany allergic rhinitis. [HPO:sdoelken, PMID:18728843]; Polypoidal masses arising mainly from the mucous membranes of the nose and paranasal sinuses. They are freely movable and nontender overgrowths of the mucosa that frequently accompany allergic rhinitis. // COMMENTS: Nasal polyps (NP) are benign lesions arising from the mucosa of the nasal sinuses (commonly at the outflow tract of one or more of the sinuses) or from the mucosa of the nasal cavity. The main presenting symptom of NP is nasal obstruction which is constant but can vary depending on the site and size of the polyps. Sufferers will also frequently complain of watery rhinorrhea and postnasal drip. Anosmia or hyposmia with an ensuing alteration in taste are also characteristic symptoms of NP.; Polypoidal masses arising mainly from the mucous membranes of the nose and paranasal sinuses. They are freely movable and nontender overgrowths of the mucosa that frequently accompany allergic rhinitis. // COMMENTS: Nasal polyps (NP) are benign lesions arising from the mucosa of the nasal sinuses (commonly at the outflow tract of one or more of the sinuses) or from the mucosa of the nasal cavity. The main presenting symptom of NP is nasal obstruction which is constant but can vary depending on the site and size of the polyps. Sufferers will also frequently complain of watery rhinorrhea and postnasal drip. Anosmia or hyposmia with an ensuing alteration in taste are also characteristic symptoms of NP.; UMLS Semantic Type: STY:T190",
-          "equivalent_curies": [
-            "UMLS:C0027430",
-            "MONDO:0006314",
-            "SNOMEDCT:52756005",
-            "MEDDRA:10046043",
-            "MEDDRA:10036138",
-            "MEDDRA:10028756",
-            "NCIT:C3256",
-            "HP:0100582",
-            "MEDDRA:10028754",
-            "EFO:1000391",
-            "MEDDRA:10036128",
-            "MESH:D009298",
-            "ICD9:471",
-            "SNOMEDCT:736500007"
-          ],
-          "id": "MONDO:0006314",
-          "category": "biolink:Disease",
-          "all_names": [
-            "nasal cavity polyp",
-            "Nasal Polyps",
-            "Nasal polyposis",
-            "Nasal Cavity Polyp",
-            "Nasal polyps"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:18728843",
-            "https://orcid.org/0000-0001-5889-4463",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318836,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006314",
-              "name": "nasal cavity polyp",
-              "description": "Polypoidal masses arising mainly from the mucous membranes of the nose and paranasal sinuses. They are freely movable and nontender overgrowths of the mucosa that frequently accompany allergic rhinitis. [HPO:sdoelken, PMID:18728843]; Polypoidal masses arising mainly from the mucous membranes of the nose and paranasal sinuses. They are freely movable and nontender overgrowths of the mucosa that frequently accompany allergic rhinitis. // COMMENTS: Nasal polyps (NP) are benign lesions arising from the mucosa of the nasal sinuses (commonly at the outflow tract of one or more of the sinuses) or from the mucosa of the nasal cavity. The main presenting symptom of NP is nasal obstruction which is constant but can vary depending on the site and size of the polyps. Sufferers will also frequently complain of watery rhinorrhea and postnasal drip. Anosmia or hyposmia with an ensuing alteration in taste are also characteristic symptoms of NP.; Polypoidal masses arising mainly from the mucous membranes of the nose and paranasal sinuses. They are freely movable and nontender overgrowths of the mucosa that frequently accompany allergic rhinitis. // COMMENTS: Nasal polyps (NP) are benign lesions arising from the mucosa of the nasal sinuses (commonly at the outflow tract of one or more of the sinuses) or from the mucosa of the nasal cavity. The main presenting symptom of NP is nasal obstruction which is constant but can vary depending on the site and size of the polyps. Sufferers will also frequently complain of watery rhinorrhea and postnasal drip. Anosmia or hyposmia with an ensuing alteration in taste are also characteristic symptoms of NP.; UMLS Semantic Type: STY:T190",
-              "equivalent_curies": [
-                "UMLS:C0027430",
-                "MONDO:0006314",
-                "SNOMEDCT:52756005",
-                "MEDDRA:10046043",
-                "MEDDRA:10036138",
-                "MEDDRA:10028756",
-                "NCIT:C3256",
-                "HP:0100582",
-                "MEDDRA:10028754",
-                "EFO:1000391",
-                "MEDDRA:10036128",
-                "MESH:D009298",
-                "ICD9:471",
-                "SNOMEDCT:736500007"
-              ],
-              "id": "MONDO:0006314",
-              "category": "biolink:Disease",
-              "all_names": [
-                "nasal cavity polyp",
-                "Nasal Polyps",
-                "Nasal polyposis",
-                "Nasal Cavity Polyp",
-                "Nasal polyps"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:18728843",
-                "https://orcid.org/0000-0001-5889-4463",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17127159,
-            "start": 570,
-            "end": 318836,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24565635': {'publication date': '2013 Sep-Oct', 'sentence': 'The study by Van Zele et al reports positive results for a randomized, double-blind, placebo-controlled trial that used either 20 days of doxycycline (200 mg the first day, followed by 100 mg daily) or 20 days of a tapering schedule of methyl prednisolone (32 mg on days 1-5, 16 mg on days 6-10, and 8 mg on days 11-20) for the treatment of nasal polyps.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0027430---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "17478785",
-              "object": "MONDO:0006314",
-              "publications": [
-                "PMID:24565635"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:11710505': {'publication date': '2001 Oct', 'sentence': '(3) Preliminary results of an interim analysis from an ongoing randomized, prospective study showed that methylprednisolone (plus an antiviral agent?) may be useful for improving peripheral vestibular function in vestibular neuritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28391531': {'publication date': '2017 Jun', 'sentence': 'The aim of this study was to examine the efficacy of methylprednisolone in vestibular neuritis (VN) by objective and subjective measures.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 520717,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006008",
-          "name": "vestibular neuronitis",
-          "description": "Idiopathic inflammation of the VESTIBULAR NERVE, characterized clinically by the acute or subacute onset of VERTIGO; NAUSEA; and imbalance. The COCHLEAR NERVE is typically spared and HEARING LOSS and TINNITUS do not usually occur. Symptoms usually resolve over a period of days to weeks. (Adams et al., Principles of Neurology, 6th ed, p304)",
-          "equivalent_curies": [
-            "UMLS:C0751908",
-            "MEDDRA:10047393",
-            "MEDDRA:10085178",
-            "SNOMEDCT:186738001",
-            "ICD10:H81.2",
-            "UMLS:C0153113",
-            "MEDDRA:10014980",
-            "ICD9:386.12",
-            "EFO:0007537",
-            "DOID:12683",
-            "MESH:D020338",
-            "MONDO:0006008"
-          ],
-          "id": "MONDO:0006008",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute Peripheral Vestibulopathy",
-            "Vestibular Neuronitis",
-            "vestibular neuronitis",
-            "Vestibular neuronitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:16448876",
-            "http://en.wikipedia.org/wiki/vestibular_neuritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520717,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006008",
-              "name": "vestibular neuronitis",
-              "description": "Idiopathic inflammation of the VESTIBULAR NERVE, characterized clinically by the acute or subacute onset of VERTIGO; NAUSEA; and imbalance. The COCHLEAR NERVE is typically spared and HEARING LOSS and TINNITUS do not usually occur. Symptoms usually resolve over a period of days to weeks. (Adams et al., Principles of Neurology, 6th ed, p304)",
-              "equivalent_curies": [
-                "UMLS:C0751908",
-                "MEDDRA:10047393",
-                "MEDDRA:10085178",
-                "SNOMEDCT:186738001",
-                "ICD10:H81.2",
-                "UMLS:C0153113",
-                "MEDDRA:10014980",
-                "ICD9:386.12",
-                "EFO:0007537",
-                "DOID:12683",
-                "MESH:D020338",
-                "MONDO:0006008"
-              ],
-              "id": "MONDO:0006008",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute Peripheral Vestibulopathy",
-                "Vestibular Neuronitis",
-                "vestibular neuronitis",
-                "Vestibular neuronitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:16448876",
-                "http://en.wikipedia.org/wiki/vestibular_neuritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9030871,
-            "start": 570,
-            "end": 520717,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11710505': {'publication date': '2001 Oct', 'sentence': '(3) Preliminary results of an interim analysis from an ongoing randomized, prospective study showed that methylprednisolone (plus an antiviral agent?) may be useful for improving peripheral vestibular function in vestibular neuritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28391531': {'publication date': '2017 Jun', 'sentence': 'The aim of this study was to examine the efficacy of methylprednisolone in vestibular neuritis (VN) by objective and subjective measures.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0751908---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "9229208",
-              "object": "MONDO:0006008",
-              "publications": [
-                "PMID:11710505",
-                "PMID:28391531"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15269315': {'publication date': '2004 Jul 22', 'sentence': 'METHODS: We performed a prospective, randomized, double-blind, two-by-two factorial trial in which patients with acute vestibular neuritis were randomly assigned to treatment with placebo, methylprednisolone, valacyclovir, or methylprednisolone plus valacyclovir.', 'subject score': 1000, 'object score': 1000}, 'PMID:15527718': {'publication date': '2004 Nov', 'sentence': 'Methylprednisolone, starting at 100 mg/d and tapering to 10 mg over 3 weeks, is an effective treatment for vestibular neuritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28391531': {'publication date': '2017 Jun', 'sentence': 'In this prospective RCT, methylprednisolone had no additional benefit in patients with VN who underwent vestibular exercises and received a Ginkgo biloba.', 'subject score': 1000, 'object score': 1000}, 'PMID:31163519': {'publication date': '2019 Jun', 'sentence': '[The clinical effects of methylprednisolone combined with vestibular rehabilitation and methylprednisolone in the treatment of vestibular neuritis].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 520717,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006008",
-          "name": "vestibular neuronitis",
-          "description": "Idiopathic inflammation of the VESTIBULAR NERVE, characterized clinically by the acute or subacute onset of VERTIGO; NAUSEA; and imbalance. The COCHLEAR NERVE is typically spared and HEARING LOSS and TINNITUS do not usually occur. Symptoms usually resolve over a period of days to weeks. (Adams et al., Principles of Neurology, 6th ed, p304)",
-          "equivalent_curies": [
-            "UMLS:C0751908",
-            "MEDDRA:10047393",
-            "MEDDRA:10085178",
-            "SNOMEDCT:186738001",
-            "ICD10:H81.2",
-            "UMLS:C0153113",
-            "MEDDRA:10014980",
-            "ICD9:386.12",
-            "EFO:0007537",
-            "DOID:12683",
-            "MESH:D020338",
-            "MONDO:0006008"
-          ],
-          "id": "MONDO:0006008",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute Peripheral Vestibulopathy",
-            "Vestibular Neuronitis",
-            "vestibular neuronitis",
-            "Vestibular neuronitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:16448876",
-            "http://en.wikipedia.org/wiki/vestibular_neuritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520717,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006008",
-              "name": "vestibular neuronitis",
-              "description": "Idiopathic inflammation of the VESTIBULAR NERVE, characterized clinically by the acute or subacute onset of VERTIGO; NAUSEA; and imbalance. The COCHLEAR NERVE is typically spared and HEARING LOSS and TINNITUS do not usually occur. Symptoms usually resolve over a period of days to weeks. (Adams et al., Principles of Neurology, 6th ed, p304)",
-              "equivalent_curies": [
-                "UMLS:C0751908",
-                "MEDDRA:10047393",
-                "MEDDRA:10085178",
-                "SNOMEDCT:186738001",
-                "ICD10:H81.2",
-                "UMLS:C0153113",
-                "MEDDRA:10014980",
-                "ICD9:386.12",
-                "EFO:0007537",
-                "DOID:12683",
-                "MESH:D020338",
-                "MONDO:0006008"
-              ],
-              "id": "MONDO:0006008",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute Peripheral Vestibulopathy",
-                "Vestibular Neuronitis",
-                "vestibular neuronitis",
-                "Vestibular neuronitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:16448876",
-                "http://en.wikipedia.org/wiki/vestibular_neuritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11071286,
-            "start": 570,
-            "end": 520717,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15269315': {'publication date': '2004 Jul 22', 'sentence': 'METHODS: We performed a prospective, randomized, double-blind, two-by-two factorial trial in which patients with acute vestibular neuritis were randomly assigned to treatment with placebo, methylprednisolone, valacyclovir, or methylprednisolone plus valacyclovir.', 'subject score': 1000, 'object score': 1000}, 'PMID:15527718': {'publication date': '2004 Nov', 'sentence': 'Methylprednisolone, starting at 100 mg/d and tapering to 10 mg over 3 weeks, is an effective treatment for vestibular neuritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28391531': {'publication date': '2017 Jun', 'sentence': 'In this prospective RCT, methylprednisolone had no additional benefit in patients with VN who underwent vestibular exercises and received a Ginkgo biloba.', 'subject score': 1000, 'object score': 1000}, 'PMID:31163519': {'publication date': '2019 Jun', 'sentence': '[The clinical effects of methylprednisolone combined with vestibular rehabilitation and methylprednisolone in the treatment of vestibular neuritis].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0153113---SEMMEDDB:",
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0751908---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "11313619",
-              "object": "MONDO:0006008",
-              "publications": [
-                "PMID:15527718",
-                "PMID:31163519",
-                "PMID:15269315",
-                "PMID:28391531"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11109888': {'publication date': '2000', 'sentence': \"On these basis, we have studied the efficacity of parenteral association of 30 mg/Kg/j of Aciclovir and 1 mg/Kg/j of Methylprednisolone in the treatment of Bell's palsy with less than 12 days of evolution.\", 'subject score': 1000, 'object score': 1000}, 'PMID:12410117': {'publication date': '2002 Sep', 'sentence': \"MATERIALS AND METHODS: Between 1997 and 2000, 76 patients with Bell's palsy were treated with intravenous methylprednisolone (2 mg/kg/day) and acyclovir (5-10 mg/kg/8 hours) for 7 days.\", 'subject score': 888, 'object score': 1000}, 'PMID:25878371': {'publication date': '2015 Mar-Apr', 'sentence': \"CONCLUSION: Intravenous methylprednisolone and oral prednisolone showed equivalent benefit in patients with acute Bell's palsy.\", 'subject score': 888, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 312015,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005665",
-          "name": "Bell's palsy",
-          "description": "A syndrome characterized by the acute onset of unilateral FACIAL PARALYSIS which progresses over a 2-5 day period. Weakness of the orbicularis oculi muscle and resulting incomplete eye closure may be associated with corneal injury. Pain behind the ear often precedes the onset of paralysis. This condition may be associated with HERPESVIRUS 1, HUMAN infection of the facial nerve. (Adams et al., Principles of Neurology, 6th ed, p1376); Facial nerve palsy is a dysfunction of cranial nerve VII (the facial nerve) that results in inability to control facial muscles on the affected side with weakness of the muscles of facial expression and eye closure. This can either be present in unilateral or bilateral form. [HPO:sdoelken]; Bell's palsy is the most common cause of facial paralysis. It usually affects just one side of the face. Symptoms appear suddenly and are at their worst about 48 hours after they start. They can range from mild to severe and include: Twitching Weakness Paralysis Drooping eyelid or corner of mouth Drooling Dry eye or mouth Excessive tearing in the eye Impaired ability to taste  Scientists think that a viral infection makes the facial nerve swell or become inflamed. You are most likely to get Bell's palsy if you are pregnant, diabetic or sick with a cold or flu. Three out of four patients improve without treatment. With or without treatment, most people begin to get better within 2 weeks and recover completely within 3 to 6 months.  NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005665",
-            "MESH:D020330",
-            "UMLS:C0376175",
-            "MEDDRA:10080910",
-            "ICD10:G51.0",
-            "MEDDRA:10033559",
-            "UMLS:C1858719",
-            "SNOMEDCT:193093009",
-            "ORPHANET:2810",
-            "HP:0010628",
-            "NCIT:C26769",
-            "DOID:12506",
-            "EFO:0007167",
-            "ICD9:351.0",
-            "MEDDRA:10004223"
-          ],
-          "id": "MONDO:0005665",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bell Palsy",
-            "Bell's palsy",
-            "Facial muscle weakness of muscles innervated by CN VII",
-            "Facial palsy",
-            "Cranial Nerve VII Palsy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/bell%27s_palsy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312015,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005665",
-              "name": "Bell's palsy",
-              "description": "A syndrome characterized by the acute onset of unilateral FACIAL PARALYSIS which progresses over a 2-5 day period. Weakness of the orbicularis oculi muscle and resulting incomplete eye closure may be associated with corneal injury. Pain behind the ear often precedes the onset of paralysis. This condition may be associated with HERPESVIRUS 1, HUMAN infection of the facial nerve. (Adams et al., Principles of Neurology, 6th ed, p1376); Facial nerve palsy is a dysfunction of cranial nerve VII (the facial nerve) that results in inability to control facial muscles on the affected side with weakness of the muscles of facial expression and eye closure. This can either be present in unilateral or bilateral form. [HPO:sdoelken]; Bell's palsy is the most common cause of facial paralysis. It usually affects just one side of the face. Symptoms appear suddenly and are at their worst about 48 hours after they start. They can range from mild to severe and include: Twitching Weakness Paralysis Drooping eyelid or corner of mouth Drooling Dry eye or mouth Excessive tearing in the eye Impaired ability to taste  Scientists think that a viral infection makes the facial nerve swell or become inflamed. You are most likely to get Bell's palsy if you are pregnant, diabetic or sick with a cold or flu. Three out of four patients improve without treatment. With or without treatment, most people begin to get better within 2 weeks and recover completely within 3 to 6 months.  NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005665",
-                "MESH:D020330",
-                "UMLS:C0376175",
-                "MEDDRA:10080910",
-                "ICD10:G51.0",
-                "MEDDRA:10033559",
-                "UMLS:C1858719",
-                "SNOMEDCT:193093009",
-                "ORPHANET:2810",
-                "HP:0010628",
-                "NCIT:C26769",
-                "DOID:12506",
-                "EFO:0007167",
-                "ICD9:351.0",
-                "MEDDRA:10004223"
-              ],
-              "id": "MONDO:0005665",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bell Palsy",
-                "Bell's palsy",
-                "Facial muscle weakness of muscles innervated by CN VII",
-                "Facial palsy",
-                "Cranial Nerve VII Palsy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/bell%27s_palsy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8406394,
-            "start": 570,
-            "end": 312015,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11109888': {'publication date': '2000', 'sentence': \"On these basis, we have studied the efficacity of parenteral association of 30 mg/Kg/j of Aciclovir and 1 mg/Kg/j of Methylprednisolone in the treatment of Bell's palsy with less than 12 days of evolution.\", 'subject score': 1000, 'object score': 1000}, 'PMID:12410117': {'publication date': '2002 Sep', 'sentence': \"MATERIALS AND METHODS: Between 1997 and 2000, 76 patients with Bell's palsy were treated with intravenous methylprednisolone (2 mg/kg/day) and acyclovir (5-10 mg/kg/8 hours) for 7 days.\", 'subject score': 888, 'object score': 1000}, 'PMID:25878371': {'publication date': '2015 Mar-Apr', 'sentence': \"CONCLUSION: Intravenous methylprednisolone and oral prednisolone showed equivalent benefit in patients with acute Bell's palsy.\", 'subject score': 888, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0376175---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8588816",
-              "object": "MONDO:0005665",
-              "publications": [
-                "PMID:11109888",
-                "PMID:12410117",
-                "PMID:25878371"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:3589700': {'publication date': '1987 Jun', 'sentence': \"High-dose methylprednisolone, vincristine, MTX, and ara-C (SOMA) as initial bulk reducing therapy in non-Hodgkin's lymphoma of unfavorable histology: preliminary results of an ongoing phase II study.\", 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316905,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018908",
-          "name": "non-Hodgkin lymphoma",
-          "description": "Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3211\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3211\" NCI Thesaurus); Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.; Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.; A type of lymphoma characterized microscopically by the absence of multinucleated Reed-Sternberg cells. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "UMLS:C1622254",
-            "ORPHANET:547",
-            "MESH:D008228",
-            "UMLS:C0024305",
-            "MONDO:0018908",
-            "HP:0012539",
-            "SNOMEDCT:188675007",
-            "PDQ:CDR0000038957",
-            "NCIT:C3211",
-            "SNOMEDCT:1172592001",
-            "DOID:0060060",
-            "MEDDRA:10025311",
-            "MEDDRA:10029593",
-            "SNOMEDCT:128929007",
-            "MEDDRA:10029547",
-            "UMLS:C1622813"
-          ],
-          "id": "MONDO:0018908",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Non-Hodgkin Lymphoma",
-            "Lymphoma, Non-Hodgkin",
-            "Malignant lymphoma - small cleaved cell",
-            "non-Hodgkin lymphoma",
-            "Non-Hodgkin lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/non-hodgkin_lymphoma",
-            "http://www.cancer.gov/dictionary?cdrid=45148",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316905,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018908",
-              "name": "non-Hodgkin lymphoma",
-              "description": "Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3211\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3211\" NCI Thesaurus); Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.; Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.; A type of lymphoma characterized microscopically by the absence of multinucleated Reed-Sternberg cells. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "UMLS:C1622254",
-                "ORPHANET:547",
-                "MESH:D008228",
-                "UMLS:C0024305",
-                "MONDO:0018908",
-                "HP:0012539",
-                "SNOMEDCT:188675007",
-                "PDQ:CDR0000038957",
-                "NCIT:C3211",
-                "SNOMEDCT:1172592001",
-                "DOID:0060060",
-                "MEDDRA:10025311",
-                "MEDDRA:10029593",
-                "SNOMEDCT:128929007",
-                "MEDDRA:10029547",
-                "UMLS:C1622813"
-              ],
-              "id": "MONDO:0018908",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Non-Hodgkin Lymphoma",
-                "Lymphoma, Non-Hodgkin",
-                "Malignant lymphoma - small cleaved cell",
-                "non-Hodgkin lymphoma",
-                "Non-Hodgkin lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/non-hodgkin_lymphoma",
-                "http://www.cancer.gov/dictionary?cdrid=45148",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24315911,
-            "start": 570,
-            "end": 316905,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3589700': {'publication date': '1987 Jun', 'sentence': \"High-dose methylprednisolone, vincristine, MTX, and ara-C (SOMA) as initial bulk reducing therapy in non-Hodgkin's lymphoma of unfavorable histology: preliminary results of an ongoing phase II study.\", 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0024305---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "24759961",
-              "object": "MONDO:0018908",
-              "publications": [
-                "PMID:3589700"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:403727': {'publication date': '1977 Mar', 'sentence': \"Peptichemio, a new oncolytic drug with alkylating and antimetabolic properties was employed in combination with vincristine and 6-methylprednisolone (PVP) for the treatment of diffuse non-Hodgkin's lymphomas (NHL), stages III and IV.\", 'subject score': 1000, 'object score': 908}}",
-    "p2": {
-      "start": {
-        "identity": 316905,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018908",
-          "name": "non-Hodgkin lymphoma",
-          "description": "Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3211\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3211\" NCI Thesaurus); Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.; Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.; A type of lymphoma characterized microscopically by the absence of multinucleated Reed-Sternberg cells. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "UMLS:C1622254",
-            "ORPHANET:547",
-            "MESH:D008228",
-            "UMLS:C0024305",
-            "MONDO:0018908",
-            "HP:0012539",
-            "SNOMEDCT:188675007",
-            "PDQ:CDR0000038957",
-            "NCIT:C3211",
-            "SNOMEDCT:1172592001",
-            "DOID:0060060",
-            "MEDDRA:10025311",
-            "MEDDRA:10029593",
-            "SNOMEDCT:128929007",
-            "MEDDRA:10029547",
-            "UMLS:C1622813"
-          ],
-          "id": "MONDO:0018908",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Non-Hodgkin Lymphoma",
-            "Lymphoma, Non-Hodgkin",
-            "Malignant lymphoma - small cleaved cell",
-            "non-Hodgkin lymphoma",
-            "Non-Hodgkin lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/non-hodgkin_lymphoma",
-            "http://www.cancer.gov/dictionary?cdrid=45148",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316905,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018908",
-              "name": "non-Hodgkin lymphoma",
-              "description": "Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3211\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3211\" NCI Thesaurus); Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.; Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.; A type of lymphoma characterized microscopically by the absence of multinucleated Reed-Sternberg cells. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "UMLS:C1622254",
-                "ORPHANET:547",
-                "MESH:D008228",
-                "UMLS:C0024305",
-                "MONDO:0018908",
-                "HP:0012539",
-                "SNOMEDCT:188675007",
-                "PDQ:CDR0000038957",
-                "NCIT:C3211",
-                "SNOMEDCT:1172592001",
-                "DOID:0060060",
-                "MEDDRA:10025311",
-                "MEDDRA:10029593",
-                "SNOMEDCT:128929007",
-                "MEDDRA:10029547",
-                "UMLS:C1622813"
-              ],
-              "id": "MONDO:0018908",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Non-Hodgkin Lymphoma",
-                "Lymphoma, Non-Hodgkin",
-                "Malignant lymphoma - small cleaved cell",
-                "non-Hodgkin lymphoma",
-                "Non-Hodgkin lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/non-hodgkin_lymphoma",
-                "http://www.cancer.gov/dictionary?cdrid=45148",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25282768,
-            "start": 570,
-            "end": 316905,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:403727': {'publication date': '1977 Mar', 'sentence': \"Peptichemio, a new oncolytic drug with alkylating and antimetabolic properties was employed in combination with vincristine and 6-methylprednisolone (PVP) for the treatment of diffuse non-Hodgkin's lymphomas (NHL), stages III and IV.\", 'subject score': 1000, 'object score': 908}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0024305---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "25734987",
-              "object": "MONDO:0018908",
-              "publications": [
-                "PMID:403727"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:1356175': {'publication date': '1992 Sep 26', 'sentence': 'Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis.', 'subject score': 861, 'object score': 901}, 'PMID:16820790': {'publication date': '2006 Aug', 'sentence': 'Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis.', 'subject score': 888, 'object score': 901}, 'PMID:34530647': {'publication date': '2021 Sep 16', 'sentence': 'Absence of IVMP and receiving intravenous albumin assisted diuresis during initial hospitalization increase the risk of early readmission in new onset pediatric lupus nephritis.', 'subject score': 802, 'object score': 857}, 'PMID:36510250': {'publication date': '2022 Dec 12', 'sentence': 'Furthermore, we investigated whether HSPB5 can enhance the effects of methylprednisolone, a standard-of-care drug in LN, in an endotoxemia mouse model.', 'subject score': 1000, 'object score': 1000}, 'PMID:6623376': {'publication date': '1983', 'sentence': '[Intravenous administration of high doses (pulse therapy) of methylprednisolone in lupus nephritis].', 'subject score': 1000, 'object score': 1000}, 'PMID:67320': {'publication date': '1977 Apr 23', 'sentence': 'Intravenous methylprednisolone pulses in diffuse proliferative lupus nephritis.', 'subject score': 888, 'object score': 861}, 'PMID:67530': {'publication date': '1977 May 14', 'sentence': 'High-dose methylprednisolone pulses in active lupus nephritis.', 'subject score': 901, 'object score': 901}, 'PMID:7131454': {'publication date': '1982', 'sentence': 'Monthly pulses of methylprednisolone in SLE nephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7404327': {'publication date': '1980', 'sentence': '[Ultra-high (shock) doses of methylprednisolone in lupus nephritis].', 'subject score': 1000, 'object score': 1000}, 'PMID:7920609': {'publication date': '1994 Apr', 'sentence': 'A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis.', 'subject score': 861, 'object score': 901}, 'PMID:8052927': {'publication date': '1994 Jun', 'sentence': '[Double blind trial of pulse methylprednisolone versus conventional oral prednisolone in lupus nephritis].', 'subject score': 861, 'object score': 1000}, 'PMID:8165443': {'publication date': '1994', 'sentence': 'Long term efficacy of high-dose intravenous methylprednisolone pulses in active lupus nephritis.', 'subject score': 861, 'object score': 901}, 'PMID:8810543': {'publication date': '1996 Jun', 'sentence': 'Because glomerular sclerosing index was thought to be one of the risk factors for poor renal prognosis, the indication for pulse methylprednisolone in lupus nephritis was the patients with low glomerular sclerosing index.', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 309447,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005556",
-          "name": "lupus nephritis",
-          "description": "Glomerulonephritis in the context of systemic lupus erythematosus.; Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).; Lupus nephritis is a type of glomerulonephritis that constitutes one of the most severe organ manifestations of systemic lupus erythematosus. Lupus nephritis is subclassified in six distinct classes, that represent different manifestations and severities of renal involvement and guide the therapeutic management. [ORCID:0000-0002-2234-4248, PMID:31974366]",
-          "equivalent_curies": [
-            "MEDDRA:10025140",
-            "HP:0033726",
-            "MEDDRA:10029141",
-            "DOID:0080162",
-            "NCIT:C34789",
-            "UMLS:C0024143",
-            "MESH:D008181",
-            "MEDDRA:10029142",
-            "MONDO:0005556",
-            "SNOMEDCT:68815009",
-            "MEDDRA:10040970",
-            "EFO:0005761"
-          ],
-          "id": "MONDO:0005556",
-          "category": "biolink:Disease",
-          "all_names": [
-            "lupus nephritis",
-            "Lupus nephritis",
-            "Lupus Nephritis",
-            "Lupus Glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000481.htm",
-            "PMID:31974366",
-            "https://orcid.org/0000-0002-2234-4248",
-            "https://en.wikipedia.org/wiki/lupus_nephritis#cite_note-1"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 309447,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005556",
-              "name": "lupus nephritis",
-              "description": "Glomerulonephritis in the context of systemic lupus erythematosus.; Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).; Lupus nephritis is a type of glomerulonephritis that constitutes one of the most severe organ manifestations of systemic lupus erythematosus. Lupus nephritis is subclassified in six distinct classes, that represent different manifestations and severities of renal involvement and guide the therapeutic management. [ORCID:0000-0002-2234-4248, PMID:31974366]",
-              "equivalent_curies": [
-                "MEDDRA:10025140",
-                "HP:0033726",
-                "MEDDRA:10029141",
-                "DOID:0080162",
-                "NCIT:C34789",
-                "UMLS:C0024143",
-                "MESH:D008181",
-                "MEDDRA:10029142",
-                "MONDO:0005556",
-                "SNOMEDCT:68815009",
-                "MEDDRA:10040970",
-                "EFO:0005761"
-              ],
-              "id": "MONDO:0005556",
-              "category": "biolink:Disease",
-              "all_names": [
-                "lupus nephritis",
-                "Lupus nephritis",
-                "Lupus Nephritis",
-                "Lupus Glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000481.htm",
-                "PMID:31974366",
-                "https://orcid.org/0000-0002-2234-4248",
-                "https://en.wikipedia.org/wiki/lupus_nephritis#cite_note-1"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10331288,
-            "start": 570,
-            "end": 309447,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1356175': {'publication date': '1992 Sep 26', 'sentence': 'Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis.', 'subject score': 861, 'object score': 901}, 'PMID:16820790': {'publication date': '2006 Aug', 'sentence': 'Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis.', 'subject score': 888, 'object score': 901}, 'PMID:34530647': {'publication date': '2021 Sep 16', 'sentence': 'Absence of IVMP and receiving intravenous albumin assisted diuresis during initial hospitalization increase the risk of early readmission in new onset pediatric lupus nephritis.', 'subject score': 802, 'object score': 857}, 'PMID:36510250': {'publication date': '2022 Dec 12', 'sentence': 'Furthermore, we investigated whether HSPB5 can enhance the effects of methylprednisolone, a standard-of-care drug in LN, in an endotoxemia mouse model.', 'subject score': 1000, 'object score': 1000}, 'PMID:6623376': {'publication date': '1983', 'sentence': '[Intravenous administration of high doses (pulse therapy) of methylprednisolone in lupus nephritis].', 'subject score': 1000, 'object score': 1000}, 'PMID:67320': {'publication date': '1977 Apr 23', 'sentence': 'Intravenous methylprednisolone pulses in diffuse proliferative lupus nephritis.', 'subject score': 888, 'object score': 861}, 'PMID:67530': {'publication date': '1977 May 14', 'sentence': 'High-dose methylprednisolone pulses in active lupus nephritis.', 'subject score': 901, 'object score': 901}, 'PMID:7131454': {'publication date': '1982', 'sentence': 'Monthly pulses of methylprednisolone in SLE nephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7404327': {'publication date': '1980', 'sentence': '[Ultra-high (shock) doses of methylprednisolone in lupus nephritis].', 'subject score': 1000, 'object score': 1000}, 'PMID:7920609': {'publication date': '1994 Apr', 'sentence': 'A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis.', 'subject score': 861, 'object score': 901}, 'PMID:8052927': {'publication date': '1994 Jun', 'sentence': '[Double blind trial of pulse methylprednisolone versus conventional oral prednisolone in lupus nephritis].', 'subject score': 861, 'object score': 1000}, 'PMID:8165443': {'publication date': '1994', 'sentence': 'Long term efficacy of high-dose intravenous methylprednisolone pulses in active lupus nephritis.', 'subject score': 861, 'object score': 901}, 'PMID:8810543': {'publication date': '1996 Jun', 'sentence': 'Because glomerular sclerosing index was thought to be one of the risk factors for poor renal prognosis, the indication for pulse methylprednisolone in lupus nephritis was the patients with low glomerular sclerosing index.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0024143---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10558884",
-              "object": "MONDO:0005556",
-              "publications": [
-                "PMID:1356175",
-                "PMID:16820790",
-                "PMID:34530647",
-                "PMID:36510250",
-                "PMID:6623376",
-                "PMID:67320",
-                "PMID:67530",
-                "PMID:7131454",
-                "PMID:7404327",
-                "PMID:7920609",
-                "PMID:8052927",
-                "PMID:8165443",
-                "PMID:8810543"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:36210823': {'publication date': '2022', 'sentence': 'In this study, low-dose methylprednisolone (0.8 mg/kg/day, MP) was used to induce a steroid-resistant lupus nephritis (SR-LN) mouse model in weeks one to four, and a therapeutic steroid dosage (MP 12 mg/kg/day) or a combined PNS (PNS 100 mg/kg/day) treatment was administered from week five to eight.', 'subject score': 901, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 309447,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005556",
-          "name": "lupus nephritis",
-          "description": "Glomerulonephritis in the context of systemic lupus erythematosus.; Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).; Lupus nephritis is a type of glomerulonephritis that constitutes one of the most severe organ manifestations of systemic lupus erythematosus. Lupus nephritis is subclassified in six distinct classes, that represent different manifestations and severities of renal involvement and guide the therapeutic management. [ORCID:0000-0002-2234-4248, PMID:31974366]",
-          "equivalent_curies": [
-            "MEDDRA:10025140",
-            "HP:0033726",
-            "MEDDRA:10029141",
-            "DOID:0080162",
-            "NCIT:C34789",
-            "UMLS:C0024143",
-            "MESH:D008181",
-            "MEDDRA:10029142",
-            "MONDO:0005556",
-            "SNOMEDCT:68815009",
-            "MEDDRA:10040970",
-            "EFO:0005761"
-          ],
-          "id": "MONDO:0005556",
-          "category": "biolink:Disease",
-          "all_names": [
-            "lupus nephritis",
-            "Lupus nephritis",
-            "Lupus Nephritis",
-            "Lupus Glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000481.htm",
-            "PMID:31974366",
-            "https://orcid.org/0000-0002-2234-4248",
-            "https://en.wikipedia.org/wiki/lupus_nephritis#cite_note-1"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 309447,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005556",
-              "name": "lupus nephritis",
-              "description": "Glomerulonephritis in the context of systemic lupus erythematosus.; Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).; Lupus nephritis is a type of glomerulonephritis that constitutes one of the most severe organ manifestations of systemic lupus erythematosus. Lupus nephritis is subclassified in six distinct classes, that represent different manifestations and severities of renal involvement and guide the therapeutic management. [ORCID:0000-0002-2234-4248, PMID:31974366]",
-              "equivalent_curies": [
-                "MEDDRA:10025140",
-                "HP:0033726",
-                "MEDDRA:10029141",
-                "DOID:0080162",
-                "NCIT:C34789",
-                "UMLS:C0024143",
-                "MESH:D008181",
-                "MEDDRA:10029142",
-                "MONDO:0005556",
-                "SNOMEDCT:68815009",
-                "MEDDRA:10040970",
-                "EFO:0005761"
-              ],
-              "id": "MONDO:0005556",
-              "category": "biolink:Disease",
-              "all_names": [
-                "lupus nephritis",
-                "Lupus nephritis",
-                "Lupus Nephritis",
-                "Lupus Glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000481.htm",
-                "PMID:31974366",
-                "https://orcid.org/0000-0002-2234-4248",
-                "https://en.wikipedia.org/wiki/lupus_nephritis#cite_note-1"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24515919,
-            "start": 570,
-            "end": 309447,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:36210823': {'publication date': '2022', 'sentence': 'In this study, low-dose methylprednisolone (0.8 mg/kg/day, MP) was used to induce a steroid-resistant lupus nephritis (SR-LN) mouse model in weeks one to four, and a therapeutic steroid dosage (MP 12 mg/kg/day) or a combined PNS (PNS 100 mg/kg/day) treatment was administered from week five to eight.', 'subject score': 901, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:causes---None---None---None---UMLS:C0024143---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "24973247",
-              "object": "MONDO:0005556",
-              "publications": [
-                "PMID:36210823"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12192247': {'publication date': '2002 Sep', 'sentence': 'The last significant breakthrough in the treatment of systemic lupus erythematosus (SLE) was the use of cyclophosphamide and methylprednisolone in the treatment of lupus nephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1336441': {'publication date': '1992 Dec', 'sentence': 'These results indicate that methylprednisolone treatment can serve as an effective therapeutic approach to abnormal extracellular matrix regulation in murine lupus nephritis.', 'subject score': 888, 'object score': 901}, 'PMID:17328038': {'publication date': '2007 Mar', 'sentence': 'Histologic deterioration and more flares: the case against azathioprine plus methylprednisolone in the treatment of proliferative lupus nephritis.', 'subject score': 851, 'object score': 901}, 'PMID:17328070': {'publication date': '2007 Mar', 'sentence': 'Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.', 'subject score': 851, 'object score': 901}, 'PMID:17659757': {'publication date': '2007 Aug', 'sentence': 'Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ methylprednisolone in a randomized controlled trial.', 'subject score': 888, 'object score': 901}, 'PMID:19280226': {'publication date': '2009 Jul', 'sentence': 'Cases of active LN treated with IVCY and pulse methylprednisolone who later develop severe infection that fails to respond to antibiotics should be carefully investigated for fungal infection.', 'subject score': 861, 'object score': 901}, 'PMID:21559160': {'publication date': '2010 Jul', 'sentence': 'Treatment of LN with intravenous pulse methyl prednisolone and cyclophosphamide was effective in normalizing the CSF pressure, resulting in express and dramatic resolution of symptomatology.', 'subject score': 812, 'object score': 1000}, 'PMID:22128082': {'publication date': '2012 Jun', 'sentence': 'AZA/MP can therefore serve as an alternative in patients with proliferative LN who wish to avoid gonadal toxicity of CY.', 'subject score': 888, 'object score': 901}, 'PMID:22252192': {'publication date': '2012 Jan', 'sentence': \"Treatment of LN with intravenous pulse methylprednisolone and cyclophosphamide normalised the patient's CSF pressure and symptoms.\", 'subject score': 802, 'object score': 1000}, 'PMID:22448187': {'publication date': '2010', 'sentence': 'Pulsed methylprednisolone treatment for diffuse lupus nephritis was begun on the background of lamivudine therapy.', 'subject score': 840, 'object score': 901}, 'PMID:24987977': {'publication date': '2014 Jun', 'sentence': 'Group C (SLEDAI score, < 6) included patients with lupus nephritis, treated with methylprednisolone and cyclophosphamide, reaching complete remission.', 'subject score': 1000, 'object score': 1000}, 'PMID:2525382': {'publication date': '1989 Jun', 'sentence': 'The benefit of high-dose, pulse intravenous methylprednisolone (IVMP) for some patients with active lupus nephritis would appear paradoxical, since active nephritis is associated with profound abnormalities in Fc gamma receptor function, and several studies have demonstrated that glucocorticoids decrease monocyte Fc gamma receptor expression and phagocytic function.', 'subject score': 785, 'object score': 901}, 'PMID:26018932': {'publication date': '2016 Aug', 'sentence': 'OBJECTIVE: The efficacy of double-filtration plasmapheresis (DFPP), combined with methylprednisolone, to treat diffuse proliferative lupus nephritis (LN) was studied.', 'subject score': 1000, 'object score': 861}, 'PMID:28082046': {'publication date': '2017 03', 'sentence': 'Cyclophosphamide intravenously proved to be superior and the use of cyclophosphamide in combination with methylprednisolone remained the standard protocol for the treatment of lupus nephritis for decades.', 'subject score': 1000, 'object score': 1000}, 'PMID:34413046': {'publication date': '2021 Aug 19', 'sentence': 'He was treated with high-dose methylprednisolone and mycophenolate mofetil for lupus nephritis and with penicillin for syphilis.', 'subject score': 901, 'object score': 1000}, 'PMID:34606036': {'publication date': '2021 Oct 04', 'sentence': 'A 20-year-old lady with lupus nephritis and neuropsychiatric lupus was treated with injection methylprednisolone and cyclophosphamide.', 'subject score': 888, 'object score': 1000}, 'PMID:6971057': {'publication date': '1981 Apr', 'sentence': 'To determine guidelines for treatment with high-dose intravenous methylprednisolone in lupus nephritis, we prospectively assessed the response to pulse therapy in 34 patients.', 'subject score': 861, 'object score': 1000}, 'PMID:7045314': {'publication date': '1982 Jul', 'sentence': 'Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis.', 'subject score': 790, 'object score': 861}, 'PMID:7111671': {'publication date': '1982', 'sentence': 'Treatment of diffuse proliferative lupus nephritis by intravenous high-dose methylprednisolone.', 'subject score': 861, 'object score': 861}, 'PMID:7694336': {'publication date': '1993 Sep-Oct', 'sentence': 'These data suggest that ET and ET receptor gene transcription is upregulated in the renal tissues of NZB/W F1 mice and that the beneficial treatment of lupus nephritis with MPSL is accompanied by a reduction in the elevated concentrations of ET-1, ET receptors, TGF-beta and TNF-alpha mRNAs.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 309447,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005556",
-          "name": "lupus nephritis",
-          "description": "Glomerulonephritis in the context of systemic lupus erythematosus.; Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).; Lupus nephritis is a type of glomerulonephritis that constitutes one of the most severe organ manifestations of systemic lupus erythematosus. Lupus nephritis is subclassified in six distinct classes, that represent different manifestations and severities of renal involvement and guide the therapeutic management. [ORCID:0000-0002-2234-4248, PMID:31974366]",
-          "equivalent_curies": [
-            "MEDDRA:10025140",
-            "HP:0033726",
-            "MEDDRA:10029141",
-            "DOID:0080162",
-            "NCIT:C34789",
-            "UMLS:C0024143",
-            "MESH:D008181",
-            "MEDDRA:10029142",
-            "MONDO:0005556",
-            "SNOMEDCT:68815009",
-            "MEDDRA:10040970",
-            "EFO:0005761"
-          ],
-          "id": "MONDO:0005556",
-          "category": "biolink:Disease",
-          "all_names": [
-            "lupus nephritis",
-            "Lupus nephritis",
-            "Lupus Nephritis",
-            "Lupus Glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000481.htm",
-            "PMID:31974366",
-            "https://orcid.org/0000-0002-2234-4248",
-            "https://en.wikipedia.org/wiki/lupus_nephritis#cite_note-1"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 309447,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005556",
-              "name": "lupus nephritis",
-              "description": "Glomerulonephritis in the context of systemic lupus erythematosus.; Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).; Lupus nephritis is a type of glomerulonephritis that constitutes one of the most severe organ manifestations of systemic lupus erythematosus. Lupus nephritis is subclassified in six distinct classes, that represent different manifestations and severities of renal involvement and guide the therapeutic management. [ORCID:0000-0002-2234-4248, PMID:31974366]",
-              "equivalent_curies": [
-                "MEDDRA:10025140",
-                "HP:0033726",
-                "MEDDRA:10029141",
-                "DOID:0080162",
-                "NCIT:C34789",
-                "UMLS:C0024143",
-                "MESH:D008181",
-                "MEDDRA:10029142",
-                "MONDO:0005556",
-                "SNOMEDCT:68815009",
-                "MEDDRA:10040970",
-                "EFO:0005761"
-              ],
-              "id": "MONDO:0005556",
-              "category": "biolink:Disease",
-              "all_names": [
-                "lupus nephritis",
-                "Lupus nephritis",
-                "Lupus Nephritis",
-                "Lupus Glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000481.htm",
-                "PMID:31974366",
-                "https://orcid.org/0000-0002-2234-4248",
-                "https://en.wikipedia.org/wiki/lupus_nephritis#cite_note-1"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9510354,
-            "start": 570,
-            "end": 309447,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12192247': {'publication date': '2002 Sep', 'sentence': 'The last significant breakthrough in the treatment of systemic lupus erythematosus (SLE) was the use of cyclophosphamide and methylprednisolone in the treatment of lupus nephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1336441': {'publication date': '1992 Dec', 'sentence': 'These results indicate that methylprednisolone treatment can serve as an effective therapeutic approach to abnormal extracellular matrix regulation in murine lupus nephritis.', 'subject score': 888, 'object score': 901}, 'PMID:17328038': {'publication date': '2007 Mar', 'sentence': 'Histologic deterioration and more flares: the case against azathioprine plus methylprednisolone in the treatment of proliferative lupus nephritis.', 'subject score': 851, 'object score': 901}, 'PMID:17328070': {'publication date': '2007 Mar', 'sentence': 'Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.', 'subject score': 851, 'object score': 901}, 'PMID:17659757': {'publication date': '2007 Aug', 'sentence': 'Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ methylprednisolone in a randomized controlled trial.', 'subject score': 888, 'object score': 901}, 'PMID:19280226': {'publication date': '2009 Jul', 'sentence': 'Cases of active LN treated with IVCY and pulse methylprednisolone who later develop severe infection that fails to respond to antibiotics should be carefully investigated for fungal infection.', 'subject score': 861, 'object score': 901}, 'PMID:21559160': {'publication date': '2010 Jul', 'sentence': 'Treatment of LN with intravenous pulse methyl prednisolone and cyclophosphamide was effective in normalizing the CSF pressure, resulting in express and dramatic resolution of symptomatology.', 'subject score': 812, 'object score': 1000}, 'PMID:22128082': {'publication date': '2012 Jun', 'sentence': 'AZA/MP can therefore serve as an alternative in patients with proliferative LN who wish to avoid gonadal toxicity of CY.', 'subject score': 888, 'object score': 901}, 'PMID:22252192': {'publication date': '2012 Jan', 'sentence': \"Treatment of LN with intravenous pulse methylprednisolone and cyclophosphamide normalised the patient's CSF pressure and symptoms.\", 'subject score': 802, 'object score': 1000}, 'PMID:22448187': {'publication date': '2010', 'sentence': 'Pulsed methylprednisolone treatment for diffuse lupus nephritis was begun on the background of lamivudine therapy.', 'subject score': 840, 'object score': 901}, 'PMID:24987977': {'publication date': '2014 Jun', 'sentence': 'Group C (SLEDAI score, < 6) included patients with lupus nephritis, treated with methylprednisolone and cyclophosphamide, reaching complete remission.', 'subject score': 1000, 'object score': 1000}, 'PMID:2525382': {'publication date': '1989 Jun', 'sentence': 'The benefit of high-dose, pulse intravenous methylprednisolone (IVMP) for some patients with active lupus nephritis would appear paradoxical, since active nephritis is associated with profound abnormalities in Fc gamma receptor function, and several studies have demonstrated that glucocorticoids decrease monocyte Fc gamma receptor expression and phagocytic function.', 'subject score': 785, 'object score': 901}, 'PMID:26018932': {'publication date': '2016 Aug', 'sentence': 'OBJECTIVE: The efficacy of double-filtration plasmapheresis (DFPP), combined with methylprednisolone, to treat diffuse proliferative lupus nephritis (LN) was studied.', 'subject score': 1000, 'object score': 861}, 'PMID:28082046': {'publication date': '2017 03', 'sentence': 'Cyclophosphamide intravenously proved to be superior and the use of cyclophosphamide in combination with methylprednisolone remained the standard protocol for the treatment of lupus nephritis for decades.', 'subject score': 1000, 'object score': 1000}, 'PMID:34413046': {'publication date': '2021 Aug 19', 'sentence': 'He was treated with high-dose methylprednisolone and mycophenolate mofetil for lupus nephritis and with penicillin for syphilis.', 'subject score': 901, 'object score': 1000}, 'PMID:34606036': {'publication date': '2021 Oct 04', 'sentence': 'A 20-year-old lady with lupus nephritis and neuropsychiatric lupus was treated with injection methylprednisolone and cyclophosphamide.', 'subject score': 888, 'object score': 1000}, 'PMID:6971057': {'publication date': '1981 Apr', 'sentence': 'To determine guidelines for treatment with high-dose intravenous methylprednisolone in lupus nephritis, we prospectively assessed the response to pulse therapy in 34 patients.', 'subject score': 861, 'object score': 1000}, 'PMID:7045314': {'publication date': '1982 Jul', 'sentence': 'Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis.', 'subject score': 790, 'object score': 861}, 'PMID:7111671': {'publication date': '1982', 'sentence': 'Treatment of diffuse proliferative lupus nephritis by intravenous high-dose methylprednisolone.', 'subject score': 861, 'object score': 861}, 'PMID:7694336': {'publication date': '1993 Sep-Oct', 'sentence': 'These data suggest that ET and ET receptor gene transcription is upregulated in the renal tissues of NZB/W F1 mice and that the beneficial treatment of lupus nephritis with MPSL is accompanied by a reduction in the elevated concentrations of ET-1, ET receptors, TGF-beta and TNF-alpha mRNAs.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0024143---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "9720542",
-              "object": "MONDO:0005556",
-              "publications": [
-                "PMID:12192247",
-                "PMID:1336441",
-                "PMID:17328038",
-                "PMID:17328070",
-                "PMID:17659757",
-                "PMID:19280226",
-                "PMID:21559160",
-                "PMID:22128082",
-                "PMID:22252192",
-                "PMID:22448187",
-                "PMID:24987977",
-                "PMID:2525382",
-                "PMID:26018932",
-                "PMID:28082046",
-                "PMID:34413046",
-                "PMID:34606036",
-                "PMID:6971057",
-                "PMID:7045314",
-                "PMID:7111671",
-                "PMID:7694336"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10720922': {'publication date': '2000', 'sentence': \"We describe a 44-year-old man with Wegener's granulomatosis who was treated with cyclophosphamide and methylprednisolone and who subsequently developed bilateral CMVR.\", 'subject score': 1000, 'object score': 1000}, 'PMID:1981008': {'publication date': '1990', 'sentence': \"Methylprednisolone in the treatment of Wegener's granulomatosis, polyarteritis nodosa and Churg-Strauss angiitis.\", 'subject score': 1000, 'object score': 1000}, 'PMID:8323489': {'publication date': '1993', 'sentence': \"Pulse methylprednisolone therapy in the treatment of Wegener's granulomatosis.\", 'subject score': 790, 'object score': 1000}, 'PMID:8496879': {'publication date': '1993 Apr', 'sentence': \"High dose methylprednisolone for retroorbital Wegener's granulomatosis.\", 'subject score': 901, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 531220,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0012105",
-          "name": "granulomatosis with polyangiitis",
-          "description": "A rare, autoimmune, systemic medium and small size vasculitis. It is characterized by the formation of necrotizing granulomas in the respiratory tract, necrotizing angiitis, and glomerulonephritis.; A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10072579",
-            "DOID:12132",
-            "ICD10:M31.3",
-            "MONDO:0012105",
-            "SNOMEDCT:195353004",
-            "UMLS:C3495801",
-            "OMIM:608710",
-            "UMLS:C4050407",
-            "MEDDRA:10047889",
-            "NCIT:C3444",
-            "EFO:0005297",
-            "MESH:D014890",
-            "MEDDRA:10047888",
-            "MEDDRA:10072580",
-            "ORPHANET:900",
-            "ICD9:446.4",
-            "NCIT:C123111"
-          ],
-          "id": "MONDO:0012105",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pauci-immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-            "Granulomatosis with Polyangiitis",
-            "granulomatosis with polyangiitis",
-            "Pauci-Immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-            "Granulomatosis with polyangiitis related phenotypic feature",
-            "Granulomatosis with polyangiitis",
-            "Wegener's granulomatosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/granulomatosis_with_polyangiitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 531220,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0012105",
-              "name": "granulomatosis with polyangiitis",
-              "description": "A rare, autoimmune, systemic medium and small size vasculitis. It is characterized by the formation of necrotizing granulomas in the respiratory tract, necrotizing angiitis, and glomerulonephritis.; A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10072579",
-                "DOID:12132",
-                "ICD10:M31.3",
-                "MONDO:0012105",
-                "SNOMEDCT:195353004",
-                "UMLS:C3495801",
-                "OMIM:608710",
-                "UMLS:C4050407",
-                "MEDDRA:10047889",
-                "NCIT:C3444",
-                "EFO:0005297",
-                "MESH:D014890",
-                "MEDDRA:10047888",
-                "MEDDRA:10072580",
-                "ORPHANET:900",
-                "ICD9:446.4",
-                "NCIT:C123111"
-              ],
-              "id": "MONDO:0012105",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pauci-immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-                "Granulomatosis with Polyangiitis",
-                "granulomatosis with polyangiitis",
-                "Pauci-Immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-                "Granulomatosis with polyangiitis related phenotypic feature",
-                "Granulomatosis with polyangiitis",
-                "Wegener's granulomatosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/granulomatosis_with_polyangiitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7894161,
-            "start": 570,
-            "end": 531220,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10720922': {'publication date': '2000', 'sentence': \"We describe a 44-year-old man with Wegener's granulomatosis who was treated with cyclophosphamide and methylprednisolone and who subsequently developed bilateral CMVR.\", 'subject score': 1000, 'object score': 1000}, 'PMID:1981008': {'publication date': '1990', 'sentence': \"Methylprednisolone in the treatment of Wegener's granulomatosis, polyarteritis nodosa and Churg-Strauss angiitis.\", 'subject score': 1000, 'object score': 1000}, 'PMID:8323489': {'publication date': '1993', 'sentence': \"Pulse methylprednisolone therapy in the treatment of Wegener's granulomatosis.\", 'subject score': 790, 'object score': 1000}, 'PMID:8496879': {'publication date': '1993 Apr', 'sentence': \"High dose methylprednisolone for retroorbital Wegener's granulomatosis.\", 'subject score': 901, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C3495801---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8063034",
-              "object": "MONDO:0012105",
-              "publications": [
-                "PMID:10720922",
-                "PMID:1981008",
-                "PMID:8323489",
-                "PMID:8496879"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:29679356': {'publication date': '2018 Dec', 'sentence': 'The region was identified as a significant predictor of use of intravenous methylprednisolone in MCD and MN patients.', 'subject score': 888, 'object score': 901}, 'PMID:8544420': {'publication date': '1995 Nov', 'sentence': 'A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316993,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005376",
-          "name": "membranous glomerulonephritis",
-          "description": "A slowly progressive inflammation of the glomeruli characterized by immune complex deposits at the glomerular basement membrane, resulting in a thickened membrane, and nephrotic syndrome.; An experimental rat model of human membranous nephropathy characterized by complement activation and formation of subepithelial immune deposits in the glomerular capillary wall.; A type of glomerulonephropathy characterized by thickening of the basement membrane and deposition of immune complexes in the subepithelial space. [Eurenomics:fschaefer]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005376",
-            "HP:0012578",
-            "UMLS:C0017665",
-            "DOID:10976",
-            "MESH:D015433",
-            "SNOMEDCT:77182004",
-            "MEDDRA:10018372",
-            "MEDDRA:10027170",
-            "ICD10:N03.2",
-            "NCIT:C34645",
-            "EFO:0004254"
-          ],
-          "id": "MONDO:0005376",
-          "category": "biolink:Disease",
-          "all_names": [
-            "membranous glomerulonephritis",
-            "Glomerulonephritis, Membranous",
-            "Membranous Glomerulonephritis",
-            "Membranous nephropathy",
-            "Membranous glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316993,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005376",
-              "name": "membranous glomerulonephritis",
-              "description": "A slowly progressive inflammation of the glomeruli characterized by immune complex deposits at the glomerular basement membrane, resulting in a thickened membrane, and nephrotic syndrome.; An experimental rat model of human membranous nephropathy characterized by complement activation and formation of subepithelial immune deposits in the glomerular capillary wall.; A type of glomerulonephropathy characterized by thickening of the basement membrane and deposition of immune complexes in the subepithelial space. [Eurenomics:fschaefer]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005376",
-                "HP:0012578",
-                "UMLS:C0017665",
-                "DOID:10976",
-                "MESH:D015433",
-                "SNOMEDCT:77182004",
-                "MEDDRA:10018372",
-                "MEDDRA:10027170",
-                "ICD10:N03.2",
-                "NCIT:C34645",
-                "EFO:0004254"
-              ],
-              "id": "MONDO:0005376",
-              "category": "biolink:Disease",
-              "all_names": [
-                "membranous glomerulonephritis",
-                "Glomerulonephritis, Membranous",
-                "Membranous Glomerulonephritis",
-                "Membranous nephropathy",
-                "Membranous glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19887919,
-            "start": 570,
-            "end": 316993,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29679356': {'publication date': '2018 Dec', 'sentence': 'The region was identified as a significant predictor of use of intravenous methylprednisolone in MCD and MN patients.', 'subject score': 888, 'object score': 901}, 'PMID:8544420': {'publication date': '1995 Nov', 'sentence': 'A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0017665---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "20290784",
-              "object": "MONDO:0005376",
-              "publications": [
-                "PMID:29679356",
-                "PMID:8544420"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:19229832': {'publication date': '2009', 'sentence': 'MN was treated with methylprednisolone as first-line therapy, then she was changed to rituximab for a relapse.', 'subject score': 1000, 'object score': 1000}, 'PMID:29679356': {'publication date': '2018 Dec', 'sentence': 'CONCLUSION: Use of intravenous methylprednisolone for MCD and MN differed geographically in Japan.', 'subject score': 888, 'object score': 1000}, 'PMID:3455548': {'publication date': '1987 Nov', 'sentence': 'Fifteen consecutive patients aged 24 to 70 years, with membranous nephropathy and a progressive decline in renal function, were treated with methylprednisolone, 1 g intravenously daily for five days, followed immediately by a tapering dose of oral prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316993,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005376",
-          "name": "membranous glomerulonephritis",
-          "description": "A slowly progressive inflammation of the glomeruli characterized by immune complex deposits at the glomerular basement membrane, resulting in a thickened membrane, and nephrotic syndrome.; An experimental rat model of human membranous nephropathy characterized by complement activation and formation of subepithelial immune deposits in the glomerular capillary wall.; A type of glomerulonephropathy characterized by thickening of the basement membrane and deposition of immune complexes in the subepithelial space. [Eurenomics:fschaefer]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005376",
-            "HP:0012578",
-            "UMLS:C0017665",
-            "DOID:10976",
-            "MESH:D015433",
-            "SNOMEDCT:77182004",
-            "MEDDRA:10018372",
-            "MEDDRA:10027170",
-            "ICD10:N03.2",
-            "NCIT:C34645",
-            "EFO:0004254"
-          ],
-          "id": "MONDO:0005376",
-          "category": "biolink:Disease",
-          "all_names": [
-            "membranous glomerulonephritis",
-            "Glomerulonephritis, Membranous",
-            "Membranous Glomerulonephritis",
-            "Membranous nephropathy",
-            "Membranous glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316993,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005376",
-              "name": "membranous glomerulonephritis",
-              "description": "A slowly progressive inflammation of the glomeruli characterized by immune complex deposits at the glomerular basement membrane, resulting in a thickened membrane, and nephrotic syndrome.; An experimental rat model of human membranous nephropathy characterized by complement activation and formation of subepithelial immune deposits in the glomerular capillary wall.; A type of glomerulonephropathy characterized by thickening of the basement membrane and deposition of immune complexes in the subepithelial space. [Eurenomics:fschaefer]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005376",
-                "HP:0012578",
-                "UMLS:C0017665",
-                "DOID:10976",
-                "MESH:D015433",
-                "SNOMEDCT:77182004",
-                "MEDDRA:10018372",
-                "MEDDRA:10027170",
-                "ICD10:N03.2",
-                "NCIT:C34645",
-                "EFO:0004254"
-              ],
-              "id": "MONDO:0005376",
-              "category": "biolink:Disease",
-              "all_names": [
-                "membranous glomerulonephritis",
-                "Glomerulonephritis, Membranous",
-                "Membranous Glomerulonephritis",
-                "Membranous nephropathy",
-                "Membranous glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13935281,
-            "start": 570,
-            "end": 316993,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19229832': {'publication date': '2009', 'sentence': 'MN was treated with methylprednisolone as first-line therapy, then she was changed to rituximab for a relapse.', 'subject score': 1000, 'object score': 1000}, 'PMID:29679356': {'publication date': '2018 Dec', 'sentence': 'CONCLUSION: Use of intravenous methylprednisolone for MCD and MN differed geographically in Japan.', 'subject score': 888, 'object score': 1000}, 'PMID:3455548': {'publication date': '1987 Nov', 'sentence': 'Fifteen consecutive patients aged 24 to 70 years, with membranous nephropathy and a progressive decline in renal function, were treated with methylprednisolone, 1 g intravenously daily for five days, followed immediately by a tapering dose of oral prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0017665---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14232595",
-              "object": "MONDO:0005376",
-              "publications": [
-                "PMID:19229832",
-                "PMID:29679356",
-                "PMID:3455548"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:19473630': {'publication date': '2009 Jun', 'sentence': 'Efficacy of methylprednisolone, cyclophosphamide in pediatric IgA nephropathy assessed by renal biopsy.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 311688,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005342",
-          "name": "IgA glomerulonephritis",
-          "description": "Inflammation of a specific segment of glomeruli within the kidney.; A chronic autoimmune glomerulonephritis characterized by the deposition of immunoglobulin A in the mesangium of the glomeruli. It is manifested with hematuria and mild proteinuria.; A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.; The presence of immunoglobulin A deposits in the glomerulus. [Eurenomics:ewuehl]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C34643",
-            "OMIM.PS:161950",
-            "MEDDRA:10018369",
-            "NCIT:C35280",
-            "UMLS:C0017661",
-            "MESH:D005922",
-            "EFO:0004194",
-            "UMLS:C3161650",
-            "SNOMEDCT:68779003",
-            "HP:0000794",
-            "DOID:2986",
-            "SNOMEDCT:236407003",
-            "MEDDRA:10069341",
-            "ORPHANET:34145",
-            "UMLS:C4025827",
-            "MONDO:0005342",
-            "MEDDRA:10021263"
-          ],
-          "id": "MONDO:0005342",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Glomerulonephritis, IGA",
-            "IGA Glomerulonephritis",
-            "IGA glomerulonephritis",
-            "IgA glomerulonephritis",
-            "IgA Nephropathy",
-            "Primary immunoglobulin A nephropathy (disorder)",
-            "IgA deposition in the glomerulus",
-            "Focal Glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000466.htm",
-            "http://en.wikipedia.org/wiki/iga_nephropathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311688,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005342",
-              "name": "IgA glomerulonephritis",
-              "description": "Inflammation of a specific segment of glomeruli within the kidney.; A chronic autoimmune glomerulonephritis characterized by the deposition of immunoglobulin A in the mesangium of the glomeruli. It is manifested with hematuria and mild proteinuria.; A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.; The presence of immunoglobulin A deposits in the glomerulus. [Eurenomics:ewuehl]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C34643",
-                "OMIM.PS:161950",
-                "MEDDRA:10018369",
-                "NCIT:C35280",
-                "UMLS:C0017661",
-                "MESH:D005922",
-                "EFO:0004194",
-                "UMLS:C3161650",
-                "SNOMEDCT:68779003",
-                "HP:0000794",
-                "DOID:2986",
-                "SNOMEDCT:236407003",
-                "MEDDRA:10069341",
-                "ORPHANET:34145",
-                "UMLS:C4025827",
-                "MONDO:0005342",
-                "MEDDRA:10021263"
-              ],
-              "id": "MONDO:0005342",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Glomerulonephritis, IGA",
-                "IGA Glomerulonephritis",
-                "IGA glomerulonephritis",
-                "IgA glomerulonephritis",
-                "IgA Nephropathy",
-                "Primary immunoglobulin A nephropathy (disorder)",
-                "IgA deposition in the glomerulus",
-                "Focal Glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000466.htm",
-                "http://en.wikipedia.org/wiki/iga_nephropathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14097907,
-            "start": 570,
-            "end": 311688,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19473630': {'publication date': '2009 Jun', 'sentence': 'Efficacy of methylprednisolone, cyclophosphamide in pediatric IgA nephropathy assessed by renal biopsy.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0017661---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14398237",
-              "object": "MONDO:0005342",
-              "publications": [
-                "PMID:19473630"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:19473630': {'publication date': '2009 Jun', 'sentence': 'CONCLUSIONS: Methylprednisolone and cyclophosphamide in children with Grade IV IgA nephropathy stabilized renal function and significantly reduced hematuria, proteinuria, mesangial IgA deposition, and the renal pathological activity index.', 'subject score': 1000, 'object score': 861}, 'PMID:20193265': {'publication date': '2010 Feb 05', 'sentence': 'Combination regimen of leflunomide plus methylprednisolone in a female patient with reactive arthritis and concomitant IgA nephropathy.', 'subject score': 851, 'object score': 901}, 'PMID:31586650': {'publication date': '2019 Oct 03', 'sentence': 'He was treated with methylprednisolone and cyclosporine for IgA nephropathy, thereafter with canakinumab for TRAPS.', 'subject score': 1000, 'object score': 1000}, 'PMID:36865740': {'publication date': '2023', 'sentence': 'Objective: To assess the clinical efficacy of Huangkui capsule plus methylprednisolone for immunoglobulin A (IgA) nephropathy and its effect on renal function and serum inflammatory factors.', 'subject score': 775, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 311688,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005342",
-          "name": "IgA glomerulonephritis",
-          "description": "Inflammation of a specific segment of glomeruli within the kidney.; A chronic autoimmune glomerulonephritis characterized by the deposition of immunoglobulin A in the mesangium of the glomeruli. It is manifested with hematuria and mild proteinuria.; A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.; The presence of immunoglobulin A deposits in the glomerulus. [Eurenomics:ewuehl]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C34643",
-            "OMIM.PS:161950",
-            "MEDDRA:10018369",
-            "NCIT:C35280",
-            "UMLS:C0017661",
-            "MESH:D005922",
-            "EFO:0004194",
-            "UMLS:C3161650",
-            "SNOMEDCT:68779003",
-            "HP:0000794",
-            "DOID:2986",
-            "SNOMEDCT:236407003",
-            "MEDDRA:10069341",
-            "ORPHANET:34145",
-            "UMLS:C4025827",
-            "MONDO:0005342",
-            "MEDDRA:10021263"
-          ],
-          "id": "MONDO:0005342",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Glomerulonephritis, IGA",
-            "IGA Glomerulonephritis",
-            "IGA glomerulonephritis",
-            "IgA glomerulonephritis",
-            "IgA Nephropathy",
-            "Primary immunoglobulin A nephropathy (disorder)",
-            "IgA deposition in the glomerulus",
-            "Focal Glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000466.htm",
-            "http://en.wikipedia.org/wiki/iga_nephropathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311688,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005342",
-              "name": "IgA glomerulonephritis",
-              "description": "Inflammation of a specific segment of glomeruli within the kidney.; A chronic autoimmune glomerulonephritis characterized by the deposition of immunoglobulin A in the mesangium of the glomeruli. It is manifested with hematuria and mild proteinuria.; A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.; The presence of immunoglobulin A deposits in the glomerulus. [Eurenomics:ewuehl]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C34643",
-                "OMIM.PS:161950",
-                "MEDDRA:10018369",
-                "NCIT:C35280",
-                "UMLS:C0017661",
-                "MESH:D005922",
-                "EFO:0004194",
-                "UMLS:C3161650",
-                "SNOMEDCT:68779003",
-                "HP:0000794",
-                "DOID:2986",
-                "SNOMEDCT:236407003",
-                "MEDDRA:10069341",
-                "ORPHANET:34145",
-                "UMLS:C4025827",
-                "MONDO:0005342",
-                "MEDDRA:10021263"
-              ],
-              "id": "MONDO:0005342",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Glomerulonephritis, IGA",
-                "IGA Glomerulonephritis",
-                "IGA glomerulonephritis",
-                "IgA glomerulonephritis",
-                "IgA Nephropathy",
-                "Primary immunoglobulin A nephropathy (disorder)",
-                "IgA deposition in the glomerulus",
-                "Focal Glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000466.htm",
-                "http://en.wikipedia.org/wiki/iga_nephropathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14097908,
-            "start": 570,
-            "end": 311688,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19473630': {'publication date': '2009 Jun', 'sentence': 'CONCLUSIONS: Methylprednisolone and cyclophosphamide in children with Grade IV IgA nephropathy stabilized renal function and significantly reduced hematuria, proteinuria, mesangial IgA deposition, and the renal pathological activity index.', 'subject score': 1000, 'object score': 861}, 'PMID:20193265': {'publication date': '2010 Feb 05', 'sentence': 'Combination regimen of leflunomide plus methylprednisolone in a female patient with reactive arthritis and concomitant IgA nephropathy.', 'subject score': 851, 'object score': 901}, 'PMID:31586650': {'publication date': '2019 Oct 03', 'sentence': 'He was treated with methylprednisolone and cyclosporine for IgA nephropathy, thereafter with canakinumab for TRAPS.', 'subject score': 1000, 'object score': 1000}, 'PMID:36865740': {'publication date': '2023', 'sentence': 'Objective: To assess the clinical efficacy of Huangkui capsule plus methylprednisolone for immunoglobulin A (IgA) nephropathy and its effect on renal function and serum inflammatory factors.', 'subject score': 775, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0017661---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14398238",
-              "object": "MONDO:0005342",
-              "publications": [
-                "PMID:19473630",
-                "PMID:20193265",
-                "PMID:31586650",
-                "PMID:36865740"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:3798047': {'publication date': '1986', 'sentence': 'High-dose MP may be contraindicated in patients with known heart disease.', 'subject score': 901, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 517803,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005267",
-          "name": "heart disorder",
-          "description": "A non-neoplastic or neoplastic disorder that affects the heart and/or the pericardium. Representative examples include endocarditis, pericarditis, atrial myxoma, cardiac myeloid sarcoma, and pericardial malignant mesothelioma.; Pathological conditions involving the HEART including its structural and functional abnormalities.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10019276",
-            "MEDDRA:10013199",
-            "ICD10:I51.9",
-            "ICD9:429.9",
-            "MEDDRA:10019277",
-            "UMLS:C0018799",
-            "UMLS:CN239852",
-            "DOID:114",
-            "MESH:D006331",
-            "EFO:0003777",
-            "MONDO:0005267",
-            "MEDDRA:10061024",
-            "UMLS:CN236661",
-            "MEDDRA:10007540",
-            "NCIT:C3079",
-            "MEDDRA:10007541",
-            "SNOMEDCT:56265001"
-          ],
-          "id": "MONDO:0005267",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Heart disease, unspecified",
-            "Heart Diseases",
-            "Heart Disorder",
-            "heart disease",
-            "heart disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/heart_disease",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://github.com/monarch-initiative/mondo/issues/1189"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517803,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005267",
-              "name": "heart disorder",
-              "description": "A non-neoplastic or neoplastic disorder that affects the heart and/or the pericardium. Representative examples include endocarditis, pericarditis, atrial myxoma, cardiac myeloid sarcoma, and pericardial malignant mesothelioma.; Pathological conditions involving the HEART including its structural and functional abnormalities.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10019276",
-                "MEDDRA:10013199",
-                "ICD10:I51.9",
-                "ICD9:429.9",
-                "MEDDRA:10019277",
-                "UMLS:C0018799",
-                "UMLS:CN239852",
-                "DOID:114",
-                "MESH:D006331",
-                "EFO:0003777",
-                "MONDO:0005267",
-                "MEDDRA:10061024",
-                "UMLS:CN236661",
-                "MEDDRA:10007540",
-                "NCIT:C3079",
-                "MEDDRA:10007541",
-                "SNOMEDCT:56265001"
-              ],
-              "id": "MONDO:0005267",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Heart disease, unspecified",
-                "Heart Diseases",
-                "Heart Disorder",
-                "heart disease",
-                "heart disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/heart_disease",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://github.com/monarch-initiative/mondo/issues/1189"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25190565,
-            "start": 570,
-            "end": 517803,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3798047': {'publication date': '1986', 'sentence': 'High-dose MP may be contraindicated in patients with known heart disease.', 'subject score': 901, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0018799---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "25642231",
-              "object": "MONDO:0005267",
-              "publications": [
-                "PMID:3798047"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:11454645': {'publication date': '2001 Aug', 'sentence': 'This is the first report of cyclophosphamide and methylprednisolone leading to complete and sustained resolution of GAVE in association with systemic sclerosis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 530656,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005100",
-          "name": "systemic sclerosis",
-          "description": "A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.; A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:90291",
-            "EFO:0000717",
-            "UMLS:CN206012",
-            "MEDDRA:10036814",
-            "UMLS:C0036421",
-            "ICD10:M34.0",
-            "DOID:418",
-            "UMLS:C0700318",
-            "MEDDRA:10078638",
-            "SNOMEDCT:89155008",
-            "MONDO:0005100",
-            "ICD9:710.1",
-            "MEDDRA:10042953",
-            "PDQ:CDR0000587622",
-            "MESH:D012595",
-            "NCIT:C72070"
-          ],
-          "id": "MONDO:0005100",
-          "category": "biolink:Disease",
-          "all_names": [
-            "systemic sclerosis",
-            "Scleroderma, Systemic",
-            "Systemic sclerosis",
-            "Systemic Scleroderma",
-            "systemic scleroderma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://ghr.nlm.nih.gov/condition/systemic-scleroderma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 530656,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005100",
-              "name": "systemic sclerosis",
-              "description": "A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.; A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:90291",
-                "EFO:0000717",
-                "UMLS:CN206012",
-                "MEDDRA:10036814",
-                "UMLS:C0036421",
-                "ICD10:M34.0",
-                "DOID:418",
-                "UMLS:C0700318",
-                "MEDDRA:10078638",
-                "SNOMEDCT:89155008",
-                "MONDO:0005100",
-                "ICD9:710.1",
-                "MEDDRA:10042953",
-                "PDQ:CDR0000587622",
-                "MESH:D012595",
-                "NCIT:C72070"
-              ],
-              "id": "MONDO:0005100",
-              "category": "biolink:Disease",
-              "all_names": [
-                "systemic sclerosis",
-                "Scleroderma, Systemic",
-                "Systemic sclerosis",
-                "Systemic Scleroderma",
-                "systemic scleroderma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://ghr.nlm.nih.gov/condition/systemic-scleroderma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8809853,
-            "start": 570,
-            "end": 530656,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11454645': {'publication date': '2001 Aug', 'sentence': 'This is the first report of cyclophosphamide and methylprednisolone leading to complete and sustained resolution of GAVE in association with systemic sclerosis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0036421---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "9003326",
-              "object": "MONDO:0005100",
-              "publications": [
-                "PMID:11454645"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:30134971': {'publication date': '2018 Aug 22', 'sentence': 'METHODS/DESIGN: This study is a 12-week, randomised, double-blind, placebo-controlled trial analysing the effects of high-dose intravenous methylprednisolone in very early SSc.', 'subject score': 861, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 530656,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005100",
-          "name": "systemic sclerosis",
-          "description": "A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.; A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:90291",
-            "EFO:0000717",
-            "UMLS:CN206012",
-            "MEDDRA:10036814",
-            "UMLS:C0036421",
-            "ICD10:M34.0",
-            "DOID:418",
-            "UMLS:C0700318",
-            "MEDDRA:10078638",
-            "SNOMEDCT:89155008",
-            "MONDO:0005100",
-            "ICD9:710.1",
-            "MEDDRA:10042953",
-            "PDQ:CDR0000587622",
-            "MESH:D012595",
-            "NCIT:C72070"
-          ],
-          "id": "MONDO:0005100",
-          "category": "biolink:Disease",
-          "all_names": [
-            "systemic sclerosis",
-            "Scleroderma, Systemic",
-            "Systemic sclerosis",
-            "Systemic Scleroderma",
-            "systemic scleroderma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://ghr.nlm.nih.gov/condition/systemic-scleroderma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 530656,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005100",
-              "name": "systemic sclerosis",
-              "description": "A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.; A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:90291",
-                "EFO:0000717",
-                "UMLS:CN206012",
-                "MEDDRA:10036814",
-                "UMLS:C0036421",
-                "ICD10:M34.0",
-                "DOID:418",
-                "UMLS:C0700318",
-                "MEDDRA:10078638",
-                "SNOMEDCT:89155008",
-                "MONDO:0005100",
-                "ICD9:710.1",
-                "MEDDRA:10042953",
-                "PDQ:CDR0000587622",
-                "MESH:D012595",
-                "NCIT:C72070"
-              ],
-              "id": "MONDO:0005100",
-              "category": "biolink:Disease",
-              "all_names": [
-                "systemic sclerosis",
-                "Scleroderma, Systemic",
-                "Systemic sclerosis",
-                "Systemic Scleroderma",
-                "systemic scleroderma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://ghr.nlm.nih.gov/condition/systemic-scleroderma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20132172,
-            "start": 570,
-            "end": 530656,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30134971': {'publication date': '2018 Aug 22', 'sentence': 'METHODS/DESIGN: This study is a 12-week, randomised, double-blind, placebo-controlled trial analysing the effects of high-dose intravenous methylprednisolone in very early SSc.', 'subject score': 861, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0036421---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "20530617",
-              "object": "MONDO:0005100",
-              "publications": [
-                "PMID:30134971"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:17543155': {'publication date': '2007 Mar-Apr', 'sentence': 'CONCLUSION: The results of this pilot study suggest that the combination of MMF, IV MP and low-dose GC might achieve good clinical, functional and radiological results in patients suffering from severe early SSc.', 'subject score': 888, 'object score': 861}, 'PMID:28866045': {'publication date': '2017 11', 'sentence': 'However in SSc patients, we did not find any significant reduction in these cytokine levels after MP treatment.', 'subject score': 888, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 530656,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005100",
-          "name": "systemic sclerosis",
-          "description": "A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.; A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:90291",
-            "EFO:0000717",
-            "UMLS:CN206012",
-            "MEDDRA:10036814",
-            "UMLS:C0036421",
-            "ICD10:M34.0",
-            "DOID:418",
-            "UMLS:C0700318",
-            "MEDDRA:10078638",
-            "SNOMEDCT:89155008",
-            "MONDO:0005100",
-            "ICD9:710.1",
-            "MEDDRA:10042953",
-            "PDQ:CDR0000587622",
-            "MESH:D012595",
-            "NCIT:C72070"
-          ],
-          "id": "MONDO:0005100",
-          "category": "biolink:Disease",
-          "all_names": [
-            "systemic sclerosis",
-            "Scleroderma, Systemic",
-            "Systemic sclerosis",
-            "Systemic Scleroderma",
-            "systemic scleroderma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://ghr.nlm.nih.gov/condition/systemic-scleroderma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 530656,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005100",
-              "name": "systemic sclerosis",
-              "description": "A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.; A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:90291",
-                "EFO:0000717",
-                "UMLS:CN206012",
-                "MEDDRA:10036814",
-                "UMLS:C0036421",
-                "ICD10:M34.0",
-                "DOID:418",
-                "UMLS:C0700318",
-                "MEDDRA:10078638",
-                "SNOMEDCT:89155008",
-                "MONDO:0005100",
-                "ICD9:710.1",
-                "MEDDRA:10042953",
-                "PDQ:CDR0000587622",
-                "MESH:D012595",
-                "NCIT:C72070"
-              ],
-              "id": "MONDO:0005100",
-              "category": "biolink:Disease",
-              "all_names": [
-                "systemic sclerosis",
-                "Scleroderma, Systemic",
-                "Systemic sclerosis",
-                "Systemic Scleroderma",
-                "systemic scleroderma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://ghr.nlm.nih.gov/condition/systemic-scleroderma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12883550,
-            "start": 570,
-            "end": 530656,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17543155': {'publication date': '2007 Mar-Apr', 'sentence': 'CONCLUSION: The results of this pilot study suggest that the combination of MMF, IV MP and low-dose GC might achieve good clinical, functional and radiological results in patients suffering from severe early SSc.', 'subject score': 888, 'object score': 861}, 'PMID:28866045': {'publication date': '2017 11', 'sentence': 'However in SSc patients, we did not find any significant reduction in these cytokine levels after MP treatment.', 'subject score': 888, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0036421---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "13161419",
-              "object": "MONDO:0005100",
-              "publications": [
-                "PMID:17543155",
-                "PMID:28866045"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:10996038': {'publication date': '2000 Sep', 'sentence': 'We compared lymphocyte-suppressive potencies of prednisolone and methylprednisolone in rheumatoid arthritis (RA).', 'subject score': 1000, 'object score': 1000}, 'PMID:11035124': {'publication date': '2000 Oct', 'sentence': 'The effects of pulse methylprednisolone on matrix metalloproteinase and tissue inhibitor of metalloproteinase-1 expression in rheumatoid arthritis.', 'subject score': 861, 'object score': 1000}, 'PMID:12685246': {'publication date': '2002 Nov', 'sentence': 'The objective of the paper was compare the effects and tolerability of combined therapy of multiple intravenous infusions of anti-tumour necrosis factor-alfa (TNF-alfa) monoclonal antibody (Remicade) with methotrexate versus treatment with sodium aurothiomalate and intramuscular depot methylprednisolone in rheumatoid arthritis (RA).', 'subject score': 802, 'object score': 1000}, 'PMID:13565407': {'publication date': '1958 Jul', 'sentence': 'Effects of methylprednisolone (medrol) in rheumatoid arthritis: a preliminary study.', 'subject score': 1000, 'object score': 1000}, 'PMID:13705356': {'publication date': '1961 Aug', 'sentence': '6a-Methylprednisolone in rheumatoid arthritis.', 'subject score': 888, 'object score': 1000}, 'PMID:13786528': {'publication date': '1960 Oct 15', 'sentence': 'Effectiveness of methylprednisolone and prednisolone tertiary-butylacetate intra-articularly in rheumatoid arthritis: a comparative study.', 'subject score': 1000, 'object score': 1000}, 'PMID:14010277': {'publication date': '1962 Dec', 'sentence': '[Clinical trials with 6 alpha-fluoro-16 alpha-methylprednisolone (paramethasone) in rheumatoid arthritis].', 'subject score': 805, 'object score': 1000}, 'PMID:1455374': {'publication date': '1992', 'sentence': '[Pulse therapy with methylprednisolone and cyclophosphamide in systemic juvenile rheumatoid arthritis: the results of an open, parallel, controlled, randomized, 12-month study].', 'subject score': 1000, 'object score': 916}, 'PMID:1784882': {'publication date': '1991', 'sentence': 'Intravenous regional administration of methylprednisolone in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:18322991': {'publication date': '2008 Apr', 'sentence': 'Clinical outcome and imaging changes after intraarticular (IA) application of etanercept or methylprednisolone in rheumatoid arthritis: magnetic resonance imaging and ultrasound-Doppler show no effect of IA injections in the wrist after 4 weeks.', 'subject score': 1000, 'object score': 1000}, 'PMID:1883691': {'publication date': '1991 Jun', 'sentence': 'First, a high degree of attention has been focused on the use of high-dose intravenous methylprednisolone in rheumatoid arthritis.', 'subject score': 861, 'object score': 1000}, 'PMID:23864141': {'publication date': '2013 Nov', 'sentence': 'UNLABELLED: To compare the efficacy of the addition of clarithromycin (CM) to methotrexate (MTX) and methylprednisolone (MP) in active rheumatoid arthritis (RA).', 'subject score': 1000, 'object score': 901}, 'PMID:2411240': {'publication date': '1985 Aug', 'sentence': 'The use of high-dose pulse methylprednisolone in rheumatoid arthritis.', 'subject score': 824, 'object score': 1000}, 'PMID:2865930': {'publication date': '1985 Nov', 'sentence': 'Combination therapy with pulsed methylprednisolone in rheumatoid arthritis.', 'subject score': 872, 'object score': 1000}, 'PMID:29884751': {'publication date': '2018 Aug', 'sentence': 'The occurrence of RA was available for nine studies, assessing methylprednisolone, methotrexate, a tumour necrosis factor blocker, abatacept or rituximab.', 'subject score': 1000, 'object score': 1000}, 'PMID:3204607': {'publication date': '1988 Oct', 'sentence': 'Pulse methylprednisolone in rheumatoid arthritis.', 'subject score': 861, 'object score': 1000}, 'PMID:3288292': {'publication date': '1988 Jun', 'sentence': 'Pulsed methylprednisolone in active early rheumatoid disease: a dose-ranging study.', 'subject score': 872, 'object score': 861}, 'PMID:3361533': {'publication date': '1988 Feb', 'sentence': 'Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study.', 'subject score': 1000, 'object score': 1000}, 'PMID:3536261': {'publication date': '1986 Sep', 'sentence': 'A randomized, double-blind trial comparing a pulse of 1000 with 250 mg methylprednisolone in rheumatoid arthritis.', 'subject score': 790, 'object score': 1000}, 'PMID:3724262': {'publication date': '1986 Apr 12', 'sentence': '[Effects of methylprednisolone pulses in rheumatoid arthritis].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318890,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-          "name": "rheumatoid arthritis",
-          "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C2884",
-            "PSY:44570",
-            "EFO:0000685",
-            "ICD9:714.0",
-            "KEGG.DISEASE:05323",
-            "MONDO:0008383",
-            "UMLS:C0003873",
-            "UMLS:C1306838",
-            "UMLS:C1833448",
-            "MEDDRA:10037740",
-            "MEDDRA:10039073",
-            "OMIM:180300",
-            "MESH:D001172",
-            "MEDDRA:10003268",
-            "HP:0001370",
-            "ORPHANET:284130",
-            "SNOMEDCT:69896004",
-            "ICD10:M06.9",
-            "DOID:7148",
-            "MEDDRA:10036856",
-            "MEDDRA:10042952"
-          ],
-          "id": "MONDO:0008383",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Proliferative arthritis",
-            "Arthritis, Rheumatoid",
-            "rheumatoid arthritis",
-            "Rheumatoid arthritis",
-            "Rheumatoid Arthritis",
-            "Rheumatoid arthritis related phenotypic feature",
-            "Rheumatoid arthritis, susceptibility to"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-            "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-            "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318890,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-              "name": "rheumatoid arthritis",
-              "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C2884",
-                "PSY:44570",
-                "EFO:0000685",
-                "ICD9:714.0",
-                "KEGG.DISEASE:05323",
-                "MONDO:0008383",
-                "UMLS:C0003873",
-                "UMLS:C1306838",
-                "UMLS:C1833448",
-                "MEDDRA:10037740",
-                "MEDDRA:10039073",
-                "OMIM:180300",
-                "MESH:D001172",
-                "MEDDRA:10003268",
-                "HP:0001370",
-                "ORPHANET:284130",
-                "SNOMEDCT:69896004",
-                "ICD10:M06.9",
-                "DOID:7148",
-                "MEDDRA:10036856",
-                "MEDDRA:10042952"
-              ],
-              "id": "MONDO:0008383",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Proliferative arthritis",
-                "Arthritis, Rheumatoid",
-                "rheumatoid arthritis",
-                "Rheumatoid arthritis",
-                "Rheumatoid Arthritis",
-                "Rheumatoid arthritis related phenotypic feature",
-                "Rheumatoid arthritis, susceptibility to"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-                "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-                "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8268351,
-            "start": 570,
-            "end": 318890,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10996038': {'publication date': '2000 Sep', 'sentence': 'We compared lymphocyte-suppressive potencies of prednisolone and methylprednisolone in rheumatoid arthritis (RA).', 'subject score': 1000, 'object score': 1000}, 'PMID:11035124': {'publication date': '2000 Oct', 'sentence': 'The effects of pulse methylprednisolone on matrix metalloproteinase and tissue inhibitor of metalloproteinase-1 expression in rheumatoid arthritis.', 'subject score': 861, 'object score': 1000}, 'PMID:12685246': {'publication date': '2002 Nov', 'sentence': 'The objective of the paper was compare the effects and tolerability of combined therapy of multiple intravenous infusions of anti-tumour necrosis factor-alfa (TNF-alfa) monoclonal antibody (Remicade) with methotrexate versus treatment with sodium aurothiomalate and intramuscular depot methylprednisolone in rheumatoid arthritis (RA).', 'subject score': 802, 'object score': 1000}, 'PMID:13565407': {'publication date': '1958 Jul', 'sentence': 'Effects of methylprednisolone (medrol) in rheumatoid arthritis: a preliminary study.', 'subject score': 1000, 'object score': 1000}, 'PMID:13705356': {'publication date': '1961 Aug', 'sentence': '6a-Methylprednisolone in rheumatoid arthritis.', 'subject score': 888, 'object score': 1000}, 'PMID:13786528': {'publication date': '1960 Oct 15', 'sentence': 'Effectiveness of methylprednisolone and prednisolone tertiary-butylacetate intra-articularly in rheumatoid arthritis: a comparative study.', 'subject score': 1000, 'object score': 1000}, 'PMID:14010277': {'publication date': '1962 Dec', 'sentence': '[Clinical trials with 6 alpha-fluoro-16 alpha-methylprednisolone (paramethasone) in rheumatoid arthritis].', 'subject score': 805, 'object score': 1000}, 'PMID:1455374': {'publication date': '1992', 'sentence': '[Pulse therapy with methylprednisolone and cyclophosphamide in systemic juvenile rheumatoid arthritis: the results of an open, parallel, controlled, randomized, 12-month study].', 'subject score': 1000, 'object score': 916}, 'PMID:1784882': {'publication date': '1991', 'sentence': 'Intravenous regional administration of methylprednisolone in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:18322991': {'publication date': '2008 Apr', 'sentence': 'Clinical outcome and imaging changes after intraarticular (IA) application of etanercept or methylprednisolone in rheumatoid arthritis: magnetic resonance imaging and ultrasound-Doppler show no effect of IA injections in the wrist after 4 weeks.', 'subject score': 1000, 'object score': 1000}, 'PMID:1883691': {'publication date': '1991 Jun', 'sentence': 'First, a high degree of attention has been focused on the use of high-dose intravenous methylprednisolone in rheumatoid arthritis.', 'subject score': 861, 'object score': 1000}, 'PMID:23864141': {'publication date': '2013 Nov', 'sentence': 'UNLABELLED: To compare the efficacy of the addition of clarithromycin (CM) to methotrexate (MTX) and methylprednisolone (MP) in active rheumatoid arthritis (RA).', 'subject score': 1000, 'object score': 901}, 'PMID:2411240': {'publication date': '1985 Aug', 'sentence': 'The use of high-dose pulse methylprednisolone in rheumatoid arthritis.', 'subject score': 824, 'object score': 1000}, 'PMID:2865930': {'publication date': '1985 Nov', 'sentence': 'Combination therapy with pulsed methylprednisolone in rheumatoid arthritis.', 'subject score': 872, 'object score': 1000}, 'PMID:29884751': {'publication date': '2018 Aug', 'sentence': 'The occurrence of RA was available for nine studies, assessing methylprednisolone, methotrexate, a tumour necrosis factor blocker, abatacept or rituximab.', 'subject score': 1000, 'object score': 1000}, 'PMID:3204607': {'publication date': '1988 Oct', 'sentence': 'Pulse methylprednisolone in rheumatoid arthritis.', 'subject score': 861, 'object score': 1000}, 'PMID:3288292': {'publication date': '1988 Jun', 'sentence': 'Pulsed methylprednisolone in active early rheumatoid disease: a dose-ranging study.', 'subject score': 872, 'object score': 861}, 'PMID:3361533': {'publication date': '1988 Feb', 'sentence': 'Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study.', 'subject score': 1000, 'object score': 1000}, 'PMID:3536261': {'publication date': '1986 Sep', 'sentence': 'A randomized, double-blind trial comparing a pulse of 1000 with 250 mg methylprednisolone in rheumatoid arthritis.', 'subject score': 790, 'object score': 1000}, 'PMID:3724262': {'publication date': '1986 Apr 12', 'sentence': '[Effects of methylprednisolone pulses in rheumatoid arthritis].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0003873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8447481",
-              "object": "MONDO:0008383",
-              "publications": [
-                "PMID:10996038",
-                "PMID:11035124",
-                "PMID:12685246",
-                "PMID:13565407",
-                "PMID:13705356",
-                "PMID:13786528",
-                "PMID:14010277",
-                "PMID:1455374",
-                "PMID:1784882",
-                "PMID:18322991",
-                "PMID:1883691",
-                "PMID:23864141",
-                "PMID:2411240",
-                "PMID:2865930",
-                "PMID:29884751",
-                "PMID:3204607",
-                "PMID:3288292",
-                "PMID:3361533",
-                "PMID:3536261",
-                "PMID:3724262"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:21532737': {'publication date': '2011 Apr 12', 'sentence': 'Methylprednisolone has been used in other Th1 mediated diseases such as rheumatoid arthritis in an attempt to switch off the immune response and so we investigated the efficacy of three days of high dose (1 g) intravenous methylprednisolone at the start of prednisolone therapy in leprosy Type 1 reactions and nerve function impairment.', 'subject score': 1000, 'object score': 1000}, 'PMID:3144941': {'publication date': '1988 Nov', 'sentence': \"A trial was designed to assess the effects of intramuscular sodium aurothiomalate or intravenous cyclophosphamide, or both, in combination with intravenous 'pulse' methylprednisolone in severe intractable rheumatoid arthritis.\", 'subject score': 802, 'object score': 861}, 'PMID:3361534': {'publication date': '1988 Feb', 'sentence': 'The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis.', 'subject score': 790, 'object score': 1000}, 'PMID:3361535': {'publication date': '1988 Feb', 'sentence': 'The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis.', 'subject score': 790, 'object score': 1000}, 'PMID:3361536': {'publication date': '1988 Feb', 'sentence': 'The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis.', 'subject score': 790, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318890,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-          "name": "rheumatoid arthritis",
-          "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C2884",
-            "PSY:44570",
-            "EFO:0000685",
-            "ICD9:714.0",
-            "KEGG.DISEASE:05323",
-            "MONDO:0008383",
-            "UMLS:C0003873",
-            "UMLS:C1306838",
-            "UMLS:C1833448",
-            "MEDDRA:10037740",
-            "MEDDRA:10039073",
-            "OMIM:180300",
-            "MESH:D001172",
-            "MEDDRA:10003268",
-            "HP:0001370",
-            "ORPHANET:284130",
-            "SNOMEDCT:69896004",
-            "ICD10:M06.9",
-            "DOID:7148",
-            "MEDDRA:10036856",
-            "MEDDRA:10042952"
-          ],
-          "id": "MONDO:0008383",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Proliferative arthritis",
-            "Arthritis, Rheumatoid",
-            "rheumatoid arthritis",
-            "Rheumatoid arthritis",
-            "Rheumatoid Arthritis",
-            "Rheumatoid arthritis related phenotypic feature",
-            "Rheumatoid arthritis, susceptibility to"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-            "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-            "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318890,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-              "name": "rheumatoid arthritis",
-              "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C2884",
-                "PSY:44570",
-                "EFO:0000685",
-                "ICD9:714.0",
-                "KEGG.DISEASE:05323",
-                "MONDO:0008383",
-                "UMLS:C0003873",
-                "UMLS:C1306838",
-                "UMLS:C1833448",
-                "MEDDRA:10037740",
-                "MEDDRA:10039073",
-                "OMIM:180300",
-                "MESH:D001172",
-                "MEDDRA:10003268",
-                "HP:0001370",
-                "ORPHANET:284130",
-                "SNOMEDCT:69896004",
-                "ICD10:M06.9",
-                "DOID:7148",
-                "MEDDRA:10036856",
-                "MEDDRA:10042952"
-              ],
-              "id": "MONDO:0008383",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Proliferative arthritis",
-                "Arthritis, Rheumatoid",
-                "rheumatoid arthritis",
-                "Rheumatoid arthritis",
-                "Rheumatoid Arthritis",
-                "Rheumatoid arthritis related phenotypic feature",
-                "Rheumatoid arthritis, susceptibility to"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-                "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-                "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15289478,
-            "start": 570,
-            "end": 318890,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21532737': {'publication date': '2011 Apr 12', 'sentence': 'Methylprednisolone has been used in other Th1 mediated diseases such as rheumatoid arthritis in an attempt to switch off the immune response and so we investigated the efficacy of three days of high dose (1 g) intravenous methylprednisolone at the start of prednisolone therapy in leprosy Type 1 reactions and nerve function impairment.', 'subject score': 1000, 'object score': 1000}, 'PMID:3144941': {'publication date': '1988 Nov', 'sentence': \"A trial was designed to assess the effects of intramuscular sodium aurothiomalate or intravenous cyclophosphamide, or both, in combination with intravenous 'pulse' methylprednisolone in severe intractable rheumatoid arthritis.\", 'subject score': 802, 'object score': 861}, 'PMID:3361534': {'publication date': '1988 Feb', 'sentence': 'The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis.', 'subject score': 790, 'object score': 1000}, 'PMID:3361535': {'publication date': '1988 Feb', 'sentence': 'The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis.', 'subject score': 790, 'object score': 1000}, 'PMID:3361536': {'publication date': '1988 Feb', 'sentence': 'The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis.', 'subject score': 790, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0003873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "15610554",
-              "object": "MONDO:0008383",
-              "publications": [
-                "PMID:21532737",
-                "PMID:3144941",
-                "PMID:3361534",
-                "PMID:3361535",
-                "PMID:3361536"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10587571': {'publication date': '1999 Dec', 'sentence': 'Oral low-dose glucocorticosteroids as compared with intravenous methylprednisolone pulses in the treatment of rheumatoid arthritis.', 'subject score': 888, 'object score': 1000}, 'PMID:10925599': {'publication date': '2000 Jun', 'sentence': 'Her medical history is marked by rheumatoid arthritis treated with gold salts and methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:11085818': {'publication date': '2000 Nov', 'sentence': 'The role of intravenous methylprednisolone pulses in the management of rheumatoid arthritis.', 'subject score': 888, 'object score': 1000}, 'PMID:11109615': {'publication date': '2000', 'sentence': 'AIM: To compare clinical effectiveness and tolerance of methylprednisolone (methypred) and dexamethasone (dexaven) in patients with rheumatoid arthritis (RA), to estimate side effects and complications rate.', 'subject score': 1000, 'object score': 1000}, 'PMID:11155795': {'publication date': '2000', 'sentence': 'Dynamic thermography of the knee joints in rheumatoid arthritis (RA) in the course of the first therapy of the patient with methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:13565408': {'publication date': '1958 Jul', 'sentence': 'Use of methylprednisolone in management of rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:13635880': {'publication date': '1958 Nov 01', 'sentence': '6-Methyl prednisolone in the treatment of rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:13838090': {'publication date': '1959 Nov', 'sentence': '6-alpha-Methyl prednisolone in the treatment of rheumatoid arthritis.', 'subject score': 901, 'object score': 1000}, 'PMID:13987253': {'publication date': '1962 Oct', 'sentence': '[Methylprednisolone in rhuematic fever, rheumatoid arthritis and Still syndrome in childhood].', 'subject score': 1000, 'object score': 1000}, 'PMID:15308515': {'publication date': '2004 Sep', 'sentence': 'OBJECTIVES: To compare the short term clinical and biological effects of intravenous (i.v.) pulse methylprednisolone (MP) and infliximab (IFX) in patients with severe active rheumatoid arthritis (RA) despite methotrexate (MTX) treatment.', 'subject score': 861, 'object score': 861}, 'PMID:18990945': {'publication date': '2008', 'sentence': 'This study demonstrates that conjugation of MP to a cyclodextrin-polymer may improve its efficacy, leading to lower doses and less frequent administration for a safer and more convenient management of rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1994875': {'publication date': '1991 Jan', 'sentence': 'Pulsed methylprednisolone therapy in rheumatoid arthritis.', 'subject score': 840, 'object score': 1000}, 'PMID:2015021': {'publication date': '1991 Mar', 'sentence': 'Pulsed methylprednisolone for rheumatoid arthritis.', 'subject score': 872, 'object score': 1000}, 'PMID:2075380': {'publication date': '1990', 'sentence': 'In two patients affected by active RA treated with pulse methylprednisolone therapy (1 g/day for 3 alternate days) the values of soluble IL-2R dropped from 948 to 662 U/ml and from 660 to 518 U/ml, respectively.', 'subject score': 790, 'object score': 901}, 'PMID:2187419': {'publication date': '1990 Apr', 'sentence': 'Pulse methylprednisolone therapy in rheumatoid arthritis: unproved therapy, unjustified therapy, or effective adjunctive treatment?', 'subject score': 790, 'object score': 1000}, 'PMID:2256750': {'publication date': '1990 Nov', 'sentence': 'Fatal acute pyelonephritis following pulsed methylprednisolone for rheumatoid arthritis.', 'subject score': 872, 'object score': 1000}, 'PMID:2319516': {'publication date': '1990 Feb', 'sentence': 'This prospective, double blind study was undertaken to test the efficacy of intravenous \"minipulse\" (100 mg) methylprednisolone (MP) therapy versus standard pulse (1000 mg) MP therapy in rheumatoid arthritis (RA).', 'subject score': 888, 'object score': 1000}, 'PMID:2378175': {'publication date': '1990', 'sentence': 'Intravenous pulse methylprednisolone of 1000 mg was compared with 250 mg in patients suffering from rheumatoid arthritis.', 'subject score': 802, 'object score': 1000}, 'PMID:24053746': {'publication date': '2013 Sep', 'sentence': 'Her RA was treated with pulsed methylprednisolone followed by oral steroids and methotrexate resulting in remission of the joints disease and the nephrotic syndrome.', 'subject score': 872, 'object score': 1000}, 'PMID:2411240': {'publication date': '1985 Aug', 'sentence': 'Pulse methylprednisolone therapy has been used for the treatment of rheumatoid arthritis.', 'subject score': 790, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318890,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-          "name": "rheumatoid arthritis",
-          "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C2884",
-            "PSY:44570",
-            "EFO:0000685",
-            "ICD9:714.0",
-            "KEGG.DISEASE:05323",
-            "MONDO:0008383",
-            "UMLS:C0003873",
-            "UMLS:C1306838",
-            "UMLS:C1833448",
-            "MEDDRA:10037740",
-            "MEDDRA:10039073",
-            "OMIM:180300",
-            "MESH:D001172",
-            "MEDDRA:10003268",
-            "HP:0001370",
-            "ORPHANET:284130",
-            "SNOMEDCT:69896004",
-            "ICD10:M06.9",
-            "DOID:7148",
-            "MEDDRA:10036856",
-            "MEDDRA:10042952"
-          ],
-          "id": "MONDO:0008383",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Proliferative arthritis",
-            "Arthritis, Rheumatoid",
-            "rheumatoid arthritis",
-            "Rheumatoid arthritis",
-            "Rheumatoid Arthritis",
-            "Rheumatoid arthritis related phenotypic feature",
-            "Rheumatoid arthritis, susceptibility to"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-            "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-            "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318890,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-              "name": "rheumatoid arthritis",
-              "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C2884",
-                "PSY:44570",
-                "EFO:0000685",
-                "ICD9:714.0",
-                "KEGG.DISEASE:05323",
-                "MONDO:0008383",
-                "UMLS:C0003873",
-                "UMLS:C1306838",
-                "UMLS:C1833448",
-                "MEDDRA:10037740",
-                "MEDDRA:10039073",
-                "OMIM:180300",
-                "MESH:D001172",
-                "MEDDRA:10003268",
-                "HP:0001370",
-                "ORPHANET:284130",
-                "SNOMEDCT:69896004",
-                "ICD10:M06.9",
-                "DOID:7148",
-                "MEDDRA:10036856",
-                "MEDDRA:10042952"
-              ],
-              "id": "MONDO:0008383",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Proliferative arthritis",
-                "Arthritis, Rheumatoid",
-                "rheumatoid arthritis",
-                "Rheumatoid arthritis",
-                "Rheumatoid Arthritis",
-                "Rheumatoid arthritis related phenotypic feature",
-                "Rheumatoid arthritis, susceptibility to"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-                "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-                "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7691142,
-            "start": 570,
-            "end": 318890,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10587571': {'publication date': '1999 Dec', 'sentence': 'Oral low-dose glucocorticosteroids as compared with intravenous methylprednisolone pulses in the treatment of rheumatoid arthritis.', 'subject score': 888, 'object score': 1000}, 'PMID:10925599': {'publication date': '2000 Jun', 'sentence': 'Her medical history is marked by rheumatoid arthritis treated with gold salts and methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:11085818': {'publication date': '2000 Nov', 'sentence': 'The role of intravenous methylprednisolone pulses in the management of rheumatoid arthritis.', 'subject score': 888, 'object score': 1000}, 'PMID:11109615': {'publication date': '2000', 'sentence': 'AIM: To compare clinical effectiveness and tolerance of methylprednisolone (methypred) and dexamethasone (dexaven) in patients with rheumatoid arthritis (RA), to estimate side effects and complications rate.', 'subject score': 1000, 'object score': 1000}, 'PMID:11155795': {'publication date': '2000', 'sentence': 'Dynamic thermography of the knee joints in rheumatoid arthritis (RA) in the course of the first therapy of the patient with methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:13565408': {'publication date': '1958 Jul', 'sentence': 'Use of methylprednisolone in management of rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:13635880': {'publication date': '1958 Nov 01', 'sentence': '6-Methyl prednisolone in the treatment of rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:13838090': {'publication date': '1959 Nov', 'sentence': '6-alpha-Methyl prednisolone in the treatment of rheumatoid arthritis.', 'subject score': 901, 'object score': 1000}, 'PMID:13987253': {'publication date': '1962 Oct', 'sentence': '[Methylprednisolone in rhuematic fever, rheumatoid arthritis and Still syndrome in childhood].', 'subject score': 1000, 'object score': 1000}, 'PMID:15308515': {'publication date': '2004 Sep', 'sentence': 'OBJECTIVES: To compare the short term clinical and biological effects of intravenous (i.v.) pulse methylprednisolone (MP) and infliximab (IFX) in patients with severe active rheumatoid arthritis (RA) despite methotrexate (MTX) treatment.', 'subject score': 861, 'object score': 861}, 'PMID:18990945': {'publication date': '2008', 'sentence': 'This study demonstrates that conjugation of MP to a cyclodextrin-polymer may improve its efficacy, leading to lower doses and less frequent administration for a safer and more convenient management of rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1994875': {'publication date': '1991 Jan', 'sentence': 'Pulsed methylprednisolone therapy in rheumatoid arthritis.', 'subject score': 840, 'object score': 1000}, 'PMID:2015021': {'publication date': '1991 Mar', 'sentence': 'Pulsed methylprednisolone for rheumatoid arthritis.', 'subject score': 872, 'object score': 1000}, 'PMID:2075380': {'publication date': '1990', 'sentence': 'In two patients affected by active RA treated with pulse methylprednisolone therapy (1 g/day for 3 alternate days) the values of soluble IL-2R dropped from 948 to 662 U/ml and from 660 to 518 U/ml, respectively.', 'subject score': 790, 'object score': 901}, 'PMID:2187419': {'publication date': '1990 Apr', 'sentence': 'Pulse methylprednisolone therapy in rheumatoid arthritis: unproved therapy, unjustified therapy, or effective adjunctive treatment?', 'subject score': 790, 'object score': 1000}, 'PMID:2256750': {'publication date': '1990 Nov', 'sentence': 'Fatal acute pyelonephritis following pulsed methylprednisolone for rheumatoid arthritis.', 'subject score': 872, 'object score': 1000}, 'PMID:2319516': {'publication date': '1990 Feb', 'sentence': 'This prospective, double blind study was undertaken to test the efficacy of intravenous \"minipulse\" (100 mg) methylprednisolone (MP) therapy versus standard pulse (1000 mg) MP therapy in rheumatoid arthritis (RA).', 'subject score': 888, 'object score': 1000}, 'PMID:2378175': {'publication date': '1990', 'sentence': 'Intravenous pulse methylprednisolone of 1000 mg was compared with 250 mg in patients suffering from rheumatoid arthritis.', 'subject score': 802, 'object score': 1000}, 'PMID:24053746': {'publication date': '2013 Sep', 'sentence': 'Her RA was treated with pulsed methylprednisolone followed by oral steroids and methotrexate resulting in remission of the joints disease and the nephrotic syndrome.', 'subject score': 872, 'object score': 1000}, 'PMID:2411240': {'publication date': '1985 Aug', 'sentence': 'Pulse methylprednisolone therapy has been used for the treatment of rheumatoid arthritis.', 'subject score': 790, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0003873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7853881",
-              "object": "MONDO:0008383",
-              "publications": [
-                "PMID:10587571",
-                "PMID:10925599",
-                "PMID:11085818",
-                "PMID:11109615",
-                "PMID:11155795",
-                "PMID:13565408",
-                "PMID:13635880",
-                "PMID:13838090",
-                "PMID:13987253",
-                "PMID:15308515",
-                "PMID:18990945",
-                "PMID:1994875",
-                "PMID:2015021",
-                "PMID:2075380",
-                "PMID:2187419",
-                "PMID:2256750",
-                "PMID:2319516",
-                "PMID:2378175",
-                "PMID:24053746",
-                "PMID:2411240"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:29161466': {'publication date': '2018 Sep', 'sentence': 'From indirect comparisons, most interventions showed decreased risk of developing RA compared to placebo at 12 months, reaching statistical significance for methotrexate (OR 0.16 [95% CI 0.08, 0.33]) and intramuscular methylprednisolone (OR 0.72 [95% CI 0.53, 0.99]).', 'subject score': 888, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 318890,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-          "name": "rheumatoid arthritis",
-          "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C2884",
-            "PSY:44570",
-            "EFO:0000685",
-            "ICD9:714.0",
-            "KEGG.DISEASE:05323",
-            "MONDO:0008383",
-            "UMLS:C0003873",
-            "UMLS:C1306838",
-            "UMLS:C1833448",
-            "MEDDRA:10037740",
-            "MEDDRA:10039073",
-            "OMIM:180300",
-            "MESH:D001172",
-            "MEDDRA:10003268",
-            "HP:0001370",
-            "ORPHANET:284130",
-            "SNOMEDCT:69896004",
-            "ICD10:M06.9",
-            "DOID:7148",
-            "MEDDRA:10036856",
-            "MEDDRA:10042952"
-          ],
-          "id": "MONDO:0008383",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Proliferative arthritis",
-            "Arthritis, Rheumatoid",
-            "rheumatoid arthritis",
-            "Rheumatoid arthritis",
-            "Rheumatoid Arthritis",
-            "Rheumatoid arthritis related phenotypic feature",
-            "Rheumatoid arthritis, susceptibility to"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-            "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-            "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318890,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-              "name": "rheumatoid arthritis",
-              "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C2884",
-                "PSY:44570",
-                "EFO:0000685",
-                "ICD9:714.0",
-                "KEGG.DISEASE:05323",
-                "MONDO:0008383",
-                "UMLS:C0003873",
-                "UMLS:C1306838",
-                "UMLS:C1833448",
-                "MEDDRA:10037740",
-                "MEDDRA:10039073",
-                "OMIM:180300",
-                "MESH:D001172",
-                "MEDDRA:10003268",
-                "HP:0001370",
-                "ORPHANET:284130",
-                "SNOMEDCT:69896004",
-                "ICD10:M06.9",
-                "DOID:7148",
-                "MEDDRA:10036856",
-                "MEDDRA:10042952"
-              ],
-              "id": "MONDO:0008383",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Proliferative arthritis",
-                "Arthritis, Rheumatoid",
-                "rheumatoid arthritis",
-                "Rheumatoid arthritis",
-                "Rheumatoid Arthritis",
-                "Rheumatoid arthritis related phenotypic feature",
-                "Rheumatoid arthritis, susceptibility to"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-                "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-                "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19623312,
-            "start": 570,
-            "end": 318890,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29161466': {'publication date': '2018 Sep', 'sentence': 'From indirect comparisons, most interventions showed decreased risk of developing RA compared to placebo at 12 months, reaching statistical significance for methotrexate (OR 0.16 [95% CI 0.08, 0.33]) and intramuscular methylprednisolone (OR 0.72 [95% CI 0.53, 0.99]).', 'subject score': 888, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:prevents---None---None---None---UMLS:C0003873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "20014108",
-              "object": "MONDO:0008383",
-              "publications": [
-                "PMID:29161466"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:7438892': {'publication date': '1980', 'sentence': 'Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 315770,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005059",
-          "name": "leukemia",
-          "description": "A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3161\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3161\" NCI Thesaurus); A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.; A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006); A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding  When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets  The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time.  The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age  What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding.  Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes  Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10045991",
-            "MEDDRA:10024329",
-            "ICD9:208",
-            "ICD10:C95.90",
-            "MEDDRA:10060430",
-            "MEDDRA:10024314",
-            "MEDDRA:10024323",
-            "MEDDRA:10024351",
-            "HP:0001909",
-            "SNOMEDCT:87163000",
-            "SNOMEDCT:1162768007",
-            "MEDDRA:10045992",
-            "MEDDRA:10060500",
-            "NCIT:C3161",
-            "EFO:0000565",
-            "MEDDRA:10045994",
-            "SNOMEDCT:93143009",
-            "MEDDRA:10024288",
-            "MEDDRA:10024352",
-            "MEDDRA:10024312",
-            "DOID:1240",
-            "UMLS:C0023418",
-            "PDQ:CDR0000041186",
-            "MESH:D007938",
-            "MONDO:0005059",
-            "MEDDRA:10024324"
-          ],
-          "id": "MONDO:0005059",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia of unspecified cell type",
-            "Leukemia",
-            "leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/leukemia",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=45343",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315770,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005059",
-              "name": "leukemia",
-              "description": "A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3161\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3161\" NCI Thesaurus); A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.; A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006); A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding  When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets  The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time.  The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age  What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding.  Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes  Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10045991",
-                "MEDDRA:10024329",
-                "ICD9:208",
-                "ICD10:C95.90",
-                "MEDDRA:10060430",
-                "MEDDRA:10024314",
-                "MEDDRA:10024323",
-                "MEDDRA:10024351",
-                "HP:0001909",
-                "SNOMEDCT:87163000",
-                "SNOMEDCT:1162768007",
-                "MEDDRA:10045992",
-                "MEDDRA:10060500",
-                "NCIT:C3161",
-                "EFO:0000565",
-                "MEDDRA:10045994",
-                "SNOMEDCT:93143009",
-                "MEDDRA:10024288",
-                "MEDDRA:10024352",
-                "MEDDRA:10024312",
-                "DOID:1240",
-                "UMLS:C0023418",
-                "PDQ:CDR0000041186",
-                "MESH:D007938",
-                "MONDO:0005059",
-                "MEDDRA:10024324"
-              ],
-              "id": "MONDO:0005059",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia of unspecified cell type",
-                "Leukemia",
-                "leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/leukemia",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=45343",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25990078,
-            "start": 570,
-            "end": 315770,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7438892': {'publication date': '1980', 'sentence': 'Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0023418---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "26450412",
-              "object": "MONDO:0005059",
-              "publications": [
-                "PMID:7438892"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:3799928': {'publication date': '1986', 'sentence': 'High-dose intravenous methyl-prednisolone in chronic polymyositis/dermatomyositis.', 'subject score': 861, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 530650,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016367",
-          "name": "dermatomyositis",
-          "description": "Inflammation of the skin and muscle.; A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003882",
-            "EFO:0000398",
-            "ICD10:M33",
-            "MONDO:0016367",
-            "SNOMEDCT:396230008",
-            "NCIT:C26744",
-            "DOID:10223",
-            "MEDDRA:10012503",
-            "ORPHANET:221",
-            "UMLS:C0011633",
-            "ICD9:710.3"
-          ],
-          "id": "MONDO:0016367",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatomyositis",
-            "dermatomyositis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/dermatomyositis",
-            "http://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 530650,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016367",
-              "name": "dermatomyositis",
-              "description": "Inflammation of the skin and muscle.; A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003882",
-                "EFO:0000398",
-                "ICD10:M33",
-                "MONDO:0016367",
-                "SNOMEDCT:396230008",
-                "NCIT:C26744",
-                "DOID:10223",
-                "MEDDRA:10012503",
-                "ORPHANET:221",
-                "UMLS:C0011633",
-                "ICD9:710.3"
-              ],
-              "id": "MONDO:0016367",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatomyositis",
-                "dermatomyositis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/dermatomyositis",
-                "http://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25191404,
-            "start": 570,
-            "end": 530650,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3799928': {'publication date': '1986', 'sentence': 'High-dose intravenous methyl-prednisolone in chronic polymyositis/dermatomyositis.', 'subject score': 861, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0011633---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "25642837",
-              "object": "MONDO:0016367",
-              "publications": [
-                "PMID:3799928"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:25447651': {'publication date': '2014', 'sentence': 'A Japanese woman was treated with injectable methylprednisolone and oral prednisolone for dermatomyositis.', 'subject score': 888, 'object score': 1000}, 'PMID:26552135': {'publication date': '2015 May', 'sentence': 'A 54-year-old female with dermatomyositis treated with cyclosporine and methylprednisolone presented with multiple subcutaneous nodules on her upper and lower extremities on December 2011.', 'subject score': 1000, 'object score': 1000}, 'PMID:27312550': {'publication date': '2016 May', 'sentence': 'Do Muscle Enzyme Changes Forecast Liver Injury in Polymyositis/Dermatomyositis Patients Treated with Methylprednisolone and Methotrexate?', 'subject score': 1000, 'object score': 901}, 'PMID:27478664': {'publication date': '2016', 'sentence': 'We herein report a 40-year-old woman who developed DM in the second trimester of her pregnancy and did not respond to treatment with methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:34302454': {'publication date': '2021 Jul 24', 'sentence': 'Long-term effects of early pulse methylprednisolone and intravenous immunoglobulin in patients with dermatomyositis and polymyositis.', 'subject score': 802, 'object score': 1000}, 'PMID:8657493': {'publication date': '1995 Mar', 'sentence': '[Use of intravenous megadoses of methylprednisolone for treatment of dermatomyositis in children].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 530650,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016367",
-          "name": "dermatomyositis",
-          "description": "Inflammation of the skin and muscle.; A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003882",
-            "EFO:0000398",
-            "ICD10:M33",
-            "MONDO:0016367",
-            "SNOMEDCT:396230008",
-            "NCIT:C26744",
-            "DOID:10223",
-            "MEDDRA:10012503",
-            "ORPHANET:221",
-            "UMLS:C0011633",
-            "ICD9:710.3"
-          ],
-          "id": "MONDO:0016367",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatomyositis",
-            "dermatomyositis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/dermatomyositis",
-            "http://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 530650,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016367",
-              "name": "dermatomyositis",
-              "description": "Inflammation of the skin and muscle.; A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003882",
-                "EFO:0000398",
-                "ICD10:M33",
-                "MONDO:0016367",
-                "SNOMEDCT:396230008",
-                "NCIT:C26744",
-                "DOID:10223",
-                "MEDDRA:10012503",
-                "ORPHANET:221",
-                "UMLS:C0011633",
-                "ICD9:710.3"
-              ],
-              "id": "MONDO:0016367",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatomyositis",
-                "dermatomyositis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/dermatomyositis",
-                "http://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17648046,
-            "start": 570,
-            "end": 530650,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25447651': {'publication date': '2014', 'sentence': 'A Japanese woman was treated with injectable methylprednisolone and oral prednisolone for dermatomyositis.', 'subject score': 888, 'object score': 1000}, 'PMID:26552135': {'publication date': '2015 May', 'sentence': 'A 54-year-old female with dermatomyositis treated with cyclosporine and methylprednisolone presented with multiple subcutaneous nodules on her upper and lower extremities on December 2011.', 'subject score': 1000, 'object score': 1000}, 'PMID:27312550': {'publication date': '2016 May', 'sentence': 'Do Muscle Enzyme Changes Forecast Liver Injury in Polymyositis/Dermatomyositis Patients Treated with Methylprednisolone and Methotrexate?', 'subject score': 1000, 'object score': 901}, 'PMID:27478664': {'publication date': '2016', 'sentence': 'We herein report a 40-year-old woman who developed DM in the second trimester of her pregnancy and did not respond to treatment with methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:34302454': {'publication date': '2021 Jul 24', 'sentence': 'Long-term effects of early pulse methylprednisolone and intravenous immunoglobulin in patients with dermatomyositis and polymyositis.', 'subject score': 802, 'object score': 1000}, 'PMID:8657493': {'publication date': '1995 Mar', 'sentence': '[Use of intravenous megadoses of methylprednisolone for treatment of dermatomyositis in children].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0011633---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "18008318",
-              "object": "MONDO:0016367",
-              "publications": [
-                "PMID:25447651",
-                "PMID:26552135",
-                "PMID:27312550",
-                "PMID:27478664",
-                "PMID:34302454",
-                "PMID:8657493"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:18945747': {'publication date': '2008 Dec', 'sentence': 'This study evaluated the influence of prior exposure to rituximab on response rates and survival in patients with diffuse large B-cell lymphoma treated with rituximab plus etoposide, cytarabine, cisplatinum and methylprednisolone (R-ESHAP).', 'subject score': 1000, 'object score': 922}, 'PMID:26999778': {'publication date': '2017 Sep', 'sentence': 'A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.', 'subject score': 1000, 'object score': 922}, 'PMID:31776726': {'publication date': '2019 Nov 27', 'sentence': 'The multicentre randomised phase II LEGEND trial evaluated lenalidomide in combination with rituximab, methylprednisolone and gemcitabine (R-GEM-L) vs. standard R-GEM-P as second-line treatment of DLBCL.', 'subject score': 1000, 'object score': 922}, 'PMID:35317293': {'publication date': '2022 Mar', 'sentence': 'The aim of this paper is to present a rare case of DLBCL in an 84-years-old diabetic male patient on methylprednisolone treatment for autoimmune hemolytic anemia.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 699953,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018905",
-          "name": "diffuse large B-cell lymphoma",
-          "description": "A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.; Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "NCIT:C8851",
-            "UMLS:C0079744",
-            "MEDDRA:10012819",
-            "MEDDRA:10012818",
-            "MONDO:0018905",
-            "UMLS:C2699777",
-            "NCIT:C80280",
-            "SNOMEDCT:109969005",
-            "SNOMEDCT:1172695008",
-            "MESH:D016403",
-            "ORPHANET:544",
-            "MEDDRA:10012820",
-            "DOID:0050745",
-            "EFO:0000403"
-          ],
-          "id": "MONDO:0018905",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphoma, Large B-Cell, Diffuse",
-            "diffuse large B-cell lymphoma",
-            "Diffuse Large B-Cell Lymphoma",
-            "Diffuse large B-cell lymphoma",
-            "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28487884",
-            "http://en.wikipedia.org/wiki/diffuse_large_b-cell_lymphoma",
-            "https://ncithesaurus.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&ns=ncit&code=c148392"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 699953,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018905",
-              "name": "diffuse large B-cell lymphoma",
-              "description": "A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.; Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "NCIT:C8851",
-                "UMLS:C0079744",
-                "MEDDRA:10012819",
-                "MEDDRA:10012818",
-                "MONDO:0018905",
-                "UMLS:C2699777",
-                "NCIT:C80280",
-                "SNOMEDCT:109969005",
-                "SNOMEDCT:1172695008",
-                "MESH:D016403",
-                "ORPHANET:544",
-                "MEDDRA:10012820",
-                "DOID:0050745",
-                "EFO:0000403"
-              ],
-              "id": "MONDO:0018905",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphoma, Large B-Cell, Diffuse",
-                "diffuse large B-cell lymphoma",
-                "Diffuse Large B-Cell Lymphoma",
-                "Diffuse large B-cell lymphoma",
-                "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28487884",
-                "http://en.wikipedia.org/wiki/diffuse_large_b-cell_lymphoma",
-                "https://ncithesaurus.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&ns=ncit&code=c148392"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13733934,
-            "start": 570,
-            "end": 699953,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18945747': {'publication date': '2008 Dec', 'sentence': 'This study evaluated the influence of prior exposure to rituximab on response rates and survival in patients with diffuse large B-cell lymphoma treated with rituximab plus etoposide, cytarabine, cisplatinum and methylprednisolone (R-ESHAP).', 'subject score': 1000, 'object score': 922}, 'PMID:26999778': {'publication date': '2017 Sep', 'sentence': 'A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.', 'subject score': 1000, 'object score': 922}, 'PMID:31776726': {'publication date': '2019 Nov 27', 'sentence': 'The multicentre randomised phase II LEGEND trial evaluated lenalidomide in combination with rituximab, methylprednisolone and gemcitabine (R-GEM-L) vs. standard R-GEM-P as second-line treatment of DLBCL.', 'subject score': 1000, 'object score': 922}, 'PMID:35317293': {'publication date': '2022 Mar', 'sentence': 'The aim of this paper is to present a rare case of DLBCL in an 84-years-old diabetic male patient on methylprednisolone treatment for autoimmune hemolytic anemia.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0079744---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14027935",
-              "object": "MONDO:0018905",
-              "publications": [
-                "PMID:18945747",
-                "PMID:26999778",
-                "PMID:31776726",
-                "PMID:35317293"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:8889459': {'publication date': '1996 Sep', 'sentence': \"Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease.\", 'subject score': 1000, 'object score': 901}, 'PMID:9663720': {'publication date': '1998 May', 'sentence': \"Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease.\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 322120,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-          "name": "Crohn disease",
-          "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003424",
-            "ORPHANET:206",
-            "NCIT:C37262",
-            "MEDDRA:10038281",
-            "MEDDRA:10011405",
-            "UMLS:CN043071",
-            "SNOMEDCT:50440006",
-            "MEDDRA:10057032",
-            "HP:0100280",
-            "EFO:0000384",
-            "DOID:8778",
-            "MONDO:0005011",
-            "PDQ:CDR0000714480",
-            "UMLS:C0010346",
-            "NCIT:C2965",
-            "SNOMEDCT:7620006",
-            "ICD10:K50.1",
-            "UMLS:C0156147",
-            "MEDDRA:10011398",
-            "MEDDRA:10011401",
-            "SNOMEDCT:34000006",
-            "ICD9:555.1",
-            "MEDDRA:10013099",
-            "MEDDRA:10011402",
-            "MEDDRA:10011400"
-          ],
-          "id": "MONDO:0005011",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Granulomatous Colitis",
-            "Crohn's disease of large bowel",
-            "Regional enteritis of large intestine",
-            "Crohn Disease",
-            "Crohn disease",
-            "Crohn's disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/chron%27s_disease",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322120,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-              "name": "Crohn disease",
-              "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003424",
-                "ORPHANET:206",
-                "NCIT:C37262",
-                "MEDDRA:10038281",
-                "MEDDRA:10011405",
-                "UMLS:CN043071",
-                "SNOMEDCT:50440006",
-                "MEDDRA:10057032",
-                "HP:0100280",
-                "EFO:0000384",
-                "DOID:8778",
-                "MONDO:0005011",
-                "PDQ:CDR0000714480",
-                "UMLS:C0010346",
-                "NCIT:C2965",
-                "SNOMEDCT:7620006",
-                "ICD10:K50.1",
-                "UMLS:C0156147",
-                "MEDDRA:10011398",
-                "MEDDRA:10011401",
-                "SNOMEDCT:34000006",
-                "ICD9:555.1",
-                "MEDDRA:10013099",
-                "MEDDRA:10011402",
-                "MEDDRA:10011400"
-              ],
-              "id": "MONDO:0005011",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Granulomatous Colitis",
-                "Crohn's disease of large bowel",
-                "Regional enteritis of large intestine",
-                "Crohn Disease",
-                "Crohn disease",
-                "Crohn's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/chron%27s_disease",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26759297,
-            "start": 570,
-            "end": 322120,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8889459': {'publication date': '1996 Sep', 'sentence': \"Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease.\", 'subject score': 1000, 'object score': 901}, 'PMID:9663720': {'publication date': '1998 May', 'sentence': \"Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0010346---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "27228384",
-              "object": "MONDO:0005011",
-              "publications": [
-                "PMID:8889459",
-                "PMID:9663720"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-=======
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
->>>>>>> main
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 315771,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1385273': {'publication date': '1992 Sep', 'sentence': \"An example of acute pancreatitis developing five weeks after initial treatment with 5-aminosalicylic acid (5-ASA) and methylprednisolone for severe Crohn's disease is reported in a 37 year old female patient.\", 'subject score': 1000, 'object score': 901}, 'PMID:1679736': {'publication date': '1991 Oct', 'sentence': \"These data show that enteral nutrition is less effective than a combination of 6-methylprednisolone and sulfasalazine in treating active Crohn's disease.\", 'subject score': 1000, 'object score': 861}, 'PMID:18784429': {'publication date': '2008', 'sentence': \"High-dose methylprednisolone in a pregnant woman with Crohn's disease and adrenal suppression in her newborn.\", 'subject score': 901, 'object score': 1000}, 'PMID:2857632': {'publication date': '1985 Mar', 'sentence': \"Intestinal alpha 1-antitrypsin clearance was quantified in 17 patients with clinically active Crohn's disease before and after a six-week period of treatment with sulfasalazine and methylprednisolone.\", 'subject score': 1000, 'object score': 824}, 'PMID:30244270': {'publication date': '2018 09', 'sentence': \"The patient was treated with high doses of methylprednisolone (60 mg IV), which resulted in rapid improvement of Crohn's disease and skin lesions.\", 'subject score': 1000, 'object score': 1000}, 'PMID:30532602': {'publication date': '2018', 'sentence': \"The mother was known to have Crohn's disease, treated with methylprednisolone and adalimumab up to 3 months before delivery, and latent tuberculosis, for which she used isoniazid postnatally.\", 'subject score': 1000, 'object score': 1000}, 'PMID:3338639': {'publication date': '1988 Mar', 'sentence': \"Local depot methylprednisolone injection for painful anal Crohn's disease.\", 'subject score': 775, 'object score': 865}, 'PMID:8889459': {'publication date': '1996 Sep', 'sentence': 'The present study assessed the effectiveness and safety of oral pH-modified release budesonide (BUD) in patients with active CD in comparison with 6-methylprednisolone (MPred).', 'subject score': 1000, 'object score': 901}, 'PMID:9772043': {'publication date': '1998 Oct', 'sentence': \"METHODS: Twenty-four patients with active Crohn's disease were randomized to treatment with either budesonide or 6-methylprednisolone.\", 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 322120,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002334",
-          "name": "hematopoietic and lymphoid system neoplasm",
-          "description": "A neoplasm arising from hematopoietic cells found in the bone marrow, peripheral blood, lymph nodes and spleen (organs of the hematopoietic system). Hematopoietic cell neoplasms can also involve other anatomic sites (e.g. central nervous system, gastrointestinal tract), either by metastasis, direct tumor infiltration, or neoplastic transformation of extranodal lymphoid tissues. The commonest forms are the various types of leukemia, Hodgkin and non-Hodgkin lymphomas, and myelodysplastic syndromes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C27134\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C27134\" NCI Thesaurus); A neoplasm arising from hematopoietic cells found in the bone marrow, peripheral blood, lymph nodes and spleen (organs of the hematopoietic system). Hematopoietic cell neoplasms can also involve other anatomic sites (e.g. central nervous system, gastrointestinal tract), either by metastasis, direct tumor infiltration, or neoplastic transformation of extranodal lymphoid tissues. The commonest forms are the various types of leukemia, Hodgkin and non-Hodgkin lymphomas, myeloproliferative neoplasms, and myelodysplastic syndromes.; Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.; Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). [http://www.ncbi.nlm.nih.gov/mesh?term=Hematologic%20Neoplasms]; A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10086808",
-            "HP:0004377",
-            "NCIT:C35813",
-            "MEDDRA:10061187",
-            "UMLS:C0376544",
-            "MEDDRA:10018864",
-            "SNOMEDCT:129154003",
-            "MEDDRA:10086698",
-            "SNOMEDCT:414644002",
-            "SNOMEDCT:414388001",
-            "UMLS:C1512393",
-            "MEDDRA:10066481",
-            "MEDDRA:10061195",
-            "DOID:2531",
-            "SNOMEDCT:269475001",
-            "MONDO:0002334",
-            "MESH:D019337",
-            "UMLS:C0348393",
-            "UMLS:C0376545",
-            "MEDDRA:10066476"
-          ],
-          "id": "MONDO:0002334",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hematologic cancer",
-            "Malignant tumor of lymphoid hemopoietic and related tissue",
-            "Hematopoietic Neoplasms",
-            "Hematologic Neoplasms",
-            "Hematopoietic and Lymphoid System Neoplasm",
-            "Hematological neoplasm",
-            "hematopoietic and lymphoid system neoplasm"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-          "name": "Crohn disease",
-          "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003424",
-            "ORPHANET:206",
-            "NCIT:C37262",
-            "MEDDRA:10038281",
-            "MEDDRA:10011405",
-            "UMLS:CN043071",
-            "SNOMEDCT:50440006",
-            "MEDDRA:10057032",
-            "HP:0100280",
-            "EFO:0000384",
-            "DOID:8778",
-            "MONDO:0005011",
-            "PDQ:CDR0000714480",
-            "UMLS:C0010346",
-            "NCIT:C2965",
-            "SNOMEDCT:7620006",
-            "ICD10:K50.1",
-            "UMLS:C0156147",
-            "MEDDRA:10011398",
-            "MEDDRA:10011401",
-            "SNOMEDCT:34000006",
-            "ICD9:555.1",
-            "MEDDRA:10013099",
-            "MEDDRA:10011402",
-            "MEDDRA:10011400"
-          ],
-          "id": "MONDO:0005011",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Granulomatous Colitis",
-            "Crohn's disease of large bowel",
-            "Regional enteritis of large intestine",
-            "Crohn Disease",
-            "Crohn disease",
-            "Crohn's disease"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://www.ncbi.nlm.nih.gov/mesh?term=hematologic%20neoplasms",
-            "http://en.wikipedia.org/wiki/blood_cance",
-            "http://www.cancer.gov/dictionary/?cdrid=45708"
-=======
-            "http://en.wikipedia.org/wiki/chron%27s_disease",
-            "https://orcid.org/0009-0006-4530-3154"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 315771,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002334",
-              "name": "hematopoietic and lymphoid system neoplasm",
-              "description": "A neoplasm arising from hematopoietic cells found in the bone marrow, peripheral blood, lymph nodes and spleen (organs of the hematopoietic system). Hematopoietic cell neoplasms can also involve other anatomic sites (e.g. central nervous system, gastrointestinal tract), either by metastasis, direct tumor infiltration, or neoplastic transformation of extranodal lymphoid tissues. The commonest forms are the various types of leukemia, Hodgkin and non-Hodgkin lymphomas, and myelodysplastic syndromes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C27134\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C27134\" NCI Thesaurus); A neoplasm arising from hematopoietic cells found in the bone marrow, peripheral blood, lymph nodes and spleen (organs of the hematopoietic system). Hematopoietic cell neoplasms can also involve other anatomic sites (e.g. central nervous system, gastrointestinal tract), either by metastasis, direct tumor infiltration, or neoplastic transformation of extranodal lymphoid tissues. The commonest forms are the various types of leukemia, Hodgkin and non-Hodgkin lymphomas, myeloproliferative neoplasms, and myelodysplastic syndromes.; Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.; Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). [http://www.ncbi.nlm.nih.gov/mesh?term=Hematologic%20Neoplasms]; A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10086808",
-                "HP:0004377",
-                "NCIT:C35813",
-                "MEDDRA:10061187",
-                "UMLS:C0376544",
-                "MEDDRA:10018864",
-                "SNOMEDCT:129154003",
-                "MEDDRA:10086698",
-                "SNOMEDCT:414644002",
-                "SNOMEDCT:414388001",
-                "UMLS:C1512393",
-                "MEDDRA:10066481",
-                "MEDDRA:10061195",
-                "DOID:2531",
-                "SNOMEDCT:269475001",
-                "MONDO:0002334",
-                "MESH:D019337",
-                "UMLS:C0348393",
-                "UMLS:C0376545",
-                "MEDDRA:10066476"
-              ],
-              "id": "MONDO:0002334",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hematologic cancer",
-                "Malignant tumor of lymphoid hemopoietic and related tissue",
-                "Hematopoietic Neoplasms",
-                "Hematologic Neoplasms",
-                "Hematopoietic and Lymphoid System Neoplasm",
-                "Hematological neoplasm",
-                "hematopoietic and lymphoid system neoplasm"
-=======
-            "identity": 322120,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-              "name": "Crohn disease",
-              "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003424",
-                "ORPHANET:206",
-                "NCIT:C37262",
-                "MEDDRA:10038281",
-                "MEDDRA:10011405",
-                "UMLS:CN043071",
-                "SNOMEDCT:50440006",
-                "MEDDRA:10057032",
-                "HP:0100280",
-                "EFO:0000384",
-                "DOID:8778",
-                "MONDO:0005011",
-                "PDQ:CDR0000714480",
-                "UMLS:C0010346",
-                "NCIT:C2965",
-                "SNOMEDCT:7620006",
-                "ICD10:K50.1",
-                "UMLS:C0156147",
-                "MEDDRA:10011398",
-                "MEDDRA:10011401",
-                "SNOMEDCT:34000006",
-                "ICD9:555.1",
-                "MEDDRA:10013099",
-                "MEDDRA:10011402",
-                "MEDDRA:10011400"
-              ],
-              "id": "MONDO:0005011",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Granulomatous Colitis",
-                "Crohn's disease of large bowel",
-                "Regional enteritis of large intestine",
-                "Crohn Disease",
-                "Crohn disease",
-                "Crohn's disease"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://www.ncbi.nlm.nih.gov/mesh?term=hematologic%20neoplasms",
-                "http://en.wikipedia.org/wiki/blood_cance",
-                "http://www.cancer.gov/dictionary/?cdrid=45708"
-=======
-                "http://en.wikipedia.org/wiki/chron%27s_disease",
-                "https://orcid.org/0009-0006-4530-3154"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 26507654,
-            "start": 570,
-            "end": 315771,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8406379': {'publication date': '1993', 'sentence': 'Pharmacokinetics of high dose methylprednisolone and use in hematological malignancies.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0376545---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "26974005",
-              "object": "MONDO:0002334",
-              "publications": [
-                "PMID:8406379"
-=======
-            "identity": 10405443,
-            "start": 570,
-            "end": 322120,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1385273': {'publication date': '1992 Sep', 'sentence': \"An example of acute pancreatitis developing five weeks after initial treatment with 5-aminosalicylic acid (5-ASA) and methylprednisolone for severe Crohn's disease is reported in a 37 year old female patient.\", 'subject score': 1000, 'object score': 901}, 'PMID:1679736': {'publication date': '1991 Oct', 'sentence': \"These data show that enteral nutrition is less effective than a combination of 6-methylprednisolone and sulfasalazine in treating active Crohn's disease.\", 'subject score': 1000, 'object score': 861}, 'PMID:18784429': {'publication date': '2008', 'sentence': \"High-dose methylprednisolone in a pregnant woman with Crohn's disease and adrenal suppression in her newborn.\", 'subject score': 901, 'object score': 1000}, 'PMID:2857632': {'publication date': '1985 Mar', 'sentence': \"Intestinal alpha 1-antitrypsin clearance was quantified in 17 patients with clinically active Crohn's disease before and after a six-week period of treatment with sulfasalazine and methylprednisolone.\", 'subject score': 1000, 'object score': 824}, 'PMID:30244270': {'publication date': '2018 09', 'sentence': \"The patient was treated with high doses of methylprednisolone (60 mg IV), which resulted in rapid improvement of Crohn's disease and skin lesions.\", 'subject score': 1000, 'object score': 1000}, 'PMID:30532602': {'publication date': '2018', 'sentence': \"The mother was known to have Crohn's disease, treated with methylprednisolone and adalimumab up to 3 months before delivery, and latent tuberculosis, for which she used isoniazid postnatally.\", 'subject score': 1000, 'object score': 1000}, 'PMID:3338639': {'publication date': '1988 Mar', 'sentence': \"Local depot methylprednisolone injection for painful anal Crohn's disease.\", 'subject score': 775, 'object score': 865}, 'PMID:8889459': {'publication date': '1996 Sep', 'sentence': 'The present study assessed the effectiveness and safety of oral pH-modified release budesonide (BUD) in patients with active CD in comparison with 6-methylprednisolone (MPred).', 'subject score': 1000, 'object score': 901}, 'PMID:9772043': {'publication date': '1998 Oct', 'sentence': \"METHODS: Twenty-four patients with active Crohn's disease were randomized to treatment with either budesonide or 6-methylprednisolone.\", 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0010346---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10634179",
-              "object": "MONDO:0005011",
-              "publications": [
-                "PMID:1385273",
-                "PMID:1679736",
-                "PMID:18784429",
-                "PMID:2857632",
-                "PMID:30244270",
-                "PMID:30532602",
-                "PMID:3338639",
-                "PMID:8889459",
-                "PMID:9772043"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:25858943': {'publication date': '2015 Apr 09', 'sentence': 'Methylprednisolone was temporarily stopped while a broad work up for inflammatory and neoplastic causes was pursued.', 'subject score': 1000, 'object score': 853}}",
-    "p2": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17897128,
-            "start": 570,
-            "end": 319673,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25858943': {'publication date': '2015 Apr 09', 'sentence': 'Methylprednisolone was temporarily stopped while a broad work up for inflammatory and neoplastic causes was pursued.', 'subject score': 1000, 'object score': 853}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:causes---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "18260665",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:25858943"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:9137685': {'publication date': '1996', 'sentence': 'However, high-dose steroids like dexamethasone or methylprednisolone had proven their clearcut anti-tumoral action.', 'subject score': 1000, 'object score': 574}}",
-    "p2": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26887731,
-            "start": 570,
-            "end": 319673,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9137685': {'publication date': '1996', 'sentence': 'However, high-dose steroids like dexamethasone or methylprednisolone had proven their clearcut anti-tumoral action.', 'subject score': 1000, 'object score': 574}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "27357949",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:9137685"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1984489': {'publication date': '1991 Jan', 'sentence': 'Rats with stereotactically implanted Walker 256 tumors were treated with methylprednisolone, U-74006F, U-78517F, or vehicle (0.05 N HCl) on Days 6 through 10 following implantation.', 'subject score': 1000, 'object score': 740}, 'PMID:2089884': {'publication date': '1990', 'sentence': 'Rats with stereotactically implanted Walker 256 tumours were treated with methylprednisolone (MP), U-74006F, U-78517F, or vehicle.', 'subject score': 1000, 'object score': 740}, 'PMID:32686618': {'publication date': '2020 Jul 19', 'sentence': 'Effect of hydrocortisone versus methylprednisolone on clinical outcomes in oncology patients with septic shock.BACKGROUND: Corticosteroids are used as adjunctive treatment of critical illness-related corticosteroid insufficiency in patients with septic shock.', 'subject score': 1000, 'object score': 888}, 'PMID:476617': {'publication date': '1979 Oct', 'sentence': 'Proliferative recovery in the tumor was delayed until after cessation of MP treatments.', 'subject score': 888, 'object score': 1000}, 'PMID:9169090': {'publication date': '1997 Apr', 'sentence': 'Tumors were harvested untreated, or at 1 or 8 days after cessation of MP treatment, and the RNA was extracted.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14332209,
-            "start": 570,
-            "end": 319673,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1984489': {'publication date': '1991 Jan', 'sentence': 'Rats with stereotactically implanted Walker 256 tumors were treated with methylprednisolone, U-74006F, U-78517F, or vehicle (0.05 N HCl) on Days 6 through 10 following implantation.', 'subject score': 1000, 'object score': 740}, 'PMID:2089884': {'publication date': '1990', 'sentence': 'Rats with stereotactically implanted Walker 256 tumours were treated with methylprednisolone (MP), U-74006F, U-78517F, or vehicle.', 'subject score': 1000, 'object score': 740}, 'PMID:32686618': {'publication date': '2020 Jul 19', 'sentence': 'Effect of hydrocortisone versus methylprednisolone on clinical outcomes in oncology patients with septic shock.BACKGROUND: Corticosteroids are used as adjunctive treatment of critical illness-related corticosteroid insufficiency in patients with septic shock.', 'subject score': 1000, 'object score': 888}, 'PMID:476617': {'publication date': '1979 Oct', 'sentence': 'Proliferative recovery in the tumor was delayed until after cessation of MP treatments.', 'subject score': 888, 'object score': 1000}, 'PMID:9169090': {'publication date': '1997 Apr', 'sentence': 'Tumors were harvested untreated, or at 1 or 8 days after cessation of MP treatment, and the RNA was extracted.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14636779",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:1984489",
-                "PMID:2089884",
-                "PMID:32686618",
-                "PMID:476617",
-                "PMID:9169090"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:6817574': {'publication date': '1982', 'sentence': 'Pulse methylprednisolone therapy in angioimmunoblastic lymphadenopathy.', 'subject score': 790, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 819686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004977",
-          "name": "angioimmunoblastic T-cell lymphoma",
-          "description": "A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes. It occurs in the middle aged and elderly, with an equal incidence in males and females. The clinical course is typically aggressive. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C7528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C7528\" NCI Thesaurus); A peripheral T-cell lymphoma of mature T follicular helper (TFH) cells characterized by systemic disease and a polymorphous infiltrate involving lymph nodes, with a prominent proliferation of high endothelial venules and follicular dendritic cells. EBV-positive cells are nearly always present. It is a clinically aggressive lymphoma and seen mainly in older adults. (WHO 2017); A disorder characterized by proliferation of arborizing small vessels, prominent immunoblastic proliferations and amorphous acidophilic interstitial material. Clinical manifestations include fever, sweats, weight loss, generalized lymphadenopathy and frequently hepatosplenomegaly.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:835009",
-            "EFO:1001350",
-            "MEDDRA:10002449",
-            "SNOMEDCT:52097008",
-            "MONDO:0004977",
-            "UMLS:C0020981",
-            "MEDDRA:10002451",
-            "ORPHANET:86886",
-            "MEDDRA:10079289",
-            "MEDDRA:10079282",
-            "MEDDRA:10002450",
-            "NCIT:C7528",
-            "PDQ:CDR0000042765",
-            "DOID:0111147",
-            "EFO:0000255",
-            "ICD10:C86.5",
-            "SNOMEDCT:413537009",
-            "MEDDRA:10080248",
-            "MESH:D007119"
-          ],
-          "id": "MONDO:0004977",
-          "category": "biolink:Disease",
-          "all_names": [
-            "angioimmunoblastic T-cell lymphoma",
-            "Immunoblastic Lymphadenopathy",
-            "Angioimmunoblastic T-Cell Lymphoma",
-            "Angioimmunoblastic T-cell lymphoma",
-            "Angioimmunoblastic Lymphadenopathy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:22700722",
-            "https://rarediseases.org/rare-diseases/angioimmunoblastic-t-cell-lymphoma/",
-            "https://www.lymphoma.org/aboutlymphoma/nhl/aitl/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 819686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004977",
-              "name": "angioimmunoblastic T-cell lymphoma",
-              "description": "A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes. It occurs in the middle aged and elderly, with an equal incidence in males and females. The clinical course is typically aggressive. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C7528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C7528\" NCI Thesaurus); A peripheral T-cell lymphoma of mature T follicular helper (TFH) cells characterized by systemic disease and a polymorphous infiltrate involving lymph nodes, with a prominent proliferation of high endothelial venules and follicular dendritic cells. EBV-positive cells are nearly always present. It is a clinically aggressive lymphoma and seen mainly in older adults. (WHO 2017); A disorder characterized by proliferation of arborizing small vessels, prominent immunoblastic proliferations and amorphous acidophilic interstitial material. Clinical manifestations include fever, sweats, weight loss, generalized lymphadenopathy and frequently hepatosplenomegaly.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:835009",
-                "EFO:1001350",
-                "MEDDRA:10002449",
-                "SNOMEDCT:52097008",
-                "MONDO:0004977",
-                "UMLS:C0020981",
-                "MEDDRA:10002451",
-                "ORPHANET:86886",
-                "MEDDRA:10079289",
-                "MEDDRA:10079282",
-                "MEDDRA:10002450",
-                "NCIT:C7528",
-                "PDQ:CDR0000042765",
-                "DOID:0111147",
-                "EFO:0000255",
-                "ICD10:C86.5",
-                "SNOMEDCT:413537009",
-                "MEDDRA:10080248",
-                "MESH:D007119"
-              ],
-              "id": "MONDO:0004977",
-              "category": "biolink:Disease",
-              "all_names": [
-                "angioimmunoblastic T-cell lymphoma",
-                "Immunoblastic Lymphadenopathy",
-                "Angioimmunoblastic T-Cell Lymphoma",
-                "Angioimmunoblastic T-cell lymphoma",
-                "Angioimmunoblastic Lymphadenopathy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:22700722",
-                "https://rarediseases.org/rare-diseases/angioimmunoblastic-t-cell-lymphoma/",
-                "https://www.lymphoma.org/aboutlymphoma/nhl/aitl/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25821253,
-            "start": 570,
-            "end": 819686,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:6817574': {'publication date': '1982', 'sentence': 'Pulse methylprednisolone therapy in angioimmunoblastic lymphadenopathy.', 'subject score': 790, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0020981---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "26279366",
-              "object": "MONDO:0004977",
-              "publications": [
-                "PMID:6817574"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:16330449': {'publication date': '2005 Dec', 'sentence': 'Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.', 'subject score': 901, 'object score': 1000}, 'PMID:1734216': {'publication date': '1992', 'sentence': 'These results indicate high-dose methylprednisolone is an effective agent, particularly in the treatment of established central nervous system (CNS) disease and could contribute to early CNS directed therapy in acute lymphoblastic leukaemia.', 'subject score': 901, 'object score': 1000}, 'PMID:7532164': {'publication date': '1994', 'sentence': 'The effect of high-dose methylprednisolone combined chemotherapy on CD34-positive cells in acute lymphoblastic leukemia.', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 323831,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-          "name": "acute lymphoblastic leukemia",
-          "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "HP:0006721",
-            "MONDO:0004967",
-            "MEDDRA:10000848",
-            "MEDDRA:10000849",
-            "MEDDRA:10025305",
-            "ORPHANET:513",
-            "MEDDRA:10025301",
-            "ICD10:C91.00",
-            "UMLS:C0023453",
-            "DOID:9952",
-            "MEDDRA:10000844",
-            "MEDDRA:10000846",
-            "MEDDRA:10000845",
-            "MEDDRA:10024338",
-            "ICD10:C91",
-            "MESH:D054198",
-            "UMLS:C1961102",
-            "MEDDRA:10060555",
-            "NCIT:C3167",
-            "PDQ:CDR0000043423",
-            "MEDDRA:10024290",
-            "MEDDRA:10000842",
-            "NCIT:C27281",
-            "ICD9:204",
-            "DOID:1037",
-            "MEDDRA:10000843",
-            "EFO:0000220",
-            "SNOMEDCT:128822004",
-            "ICD9:204.0",
-            "UMLS:C0023449",
-            "MEDDRA:10060390",
-            "SNOMEDCT:91857003"
-          ],
-          "id": "MONDO:0004967",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute lymphoblastic leukemia",
-            "lymphoid leukemia",
-            "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-            "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-            "L2 Acute Lymphoblastic Leukemia",
-            "acute lymphocytic leukemia",
-            "Lymphoid leukemia, acute",
-            "acute lymphoblastic leukemia",
-            "Acute lymphocytic leukemia",
-            "Acute Lymphoblastic Leukemia",
-            "Lymphoid leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=46332",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=616067",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323831,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-              "name": "acute lymphoblastic leukemia",
-              "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "HP:0006721",
-                "MONDO:0004967",
-                "MEDDRA:10000848",
-                "MEDDRA:10000849",
-                "MEDDRA:10025305",
-                "ORPHANET:513",
-                "MEDDRA:10025301",
-                "ICD10:C91.00",
-                "UMLS:C0023453",
-                "DOID:9952",
-                "MEDDRA:10000844",
-                "MEDDRA:10000846",
-                "MEDDRA:10000845",
-                "MEDDRA:10024338",
-                "ICD10:C91",
-                "MESH:D054198",
-                "UMLS:C1961102",
-                "MEDDRA:10060555",
-                "NCIT:C3167",
-                "PDQ:CDR0000043423",
-                "MEDDRA:10024290",
-                "MEDDRA:10000842",
-                "NCIT:C27281",
-                "ICD9:204",
-                "DOID:1037",
-                "MEDDRA:10000843",
-                "EFO:0000220",
-                "SNOMEDCT:128822004",
-                "ICD9:204.0",
-                "UMLS:C0023449",
-                "MEDDRA:10060390",
-                "SNOMEDCT:91857003"
-              ],
-              "id": "MONDO:0004967",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute lymphoblastic leukemia",
-                "lymphoid leukemia",
-                "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-                "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-                "L2 Acute Lymphoblastic Leukemia",
-                "acute lymphocytic leukemia",
-                "Lymphoid leukemia, acute",
-                "acute lymphoblastic leukemia",
-                "Acute lymphocytic leukemia",
-                "Acute Lymphoblastic Leukemia",
-                "Lymphoid leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=46332",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=616067",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11913110,
-            "start": 570,
-            "end": 323831,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16330449': {'publication date': '2005 Dec', 'sentence': 'Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.', 'subject score': 901, 'object score': 1000}, 'PMID:1734216': {'publication date': '1992', 'sentence': 'These results indicate high-dose methylprednisolone is an effective agent, particularly in the treatment of established central nervous system (CNS) disease and could contribute to early CNS directed therapy in acute lymphoblastic leukaemia.', 'subject score': 901, 'object score': 1000}, 'PMID:7532164': {'publication date': '1994', 'sentence': 'The effect of high-dose methylprednisolone combined chemotherapy on CD34-positive cells in acute lymphoblastic leukemia.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0023449---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "12183687",
-              "object": "MONDO:0004967",
-              "publications": [
-                "PMID:16330449",
-                "PMID:1734216",
-                "PMID:7532164"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12688320': {'publication date': '2003 Mar', 'sentence': 'We examined the effect of high-dose methylprednisolone (HDMP) on blast reduction rate and compared it to conventional dose steroid treatment, administered during the first 7+ days of the induction remission period in patients with acute lymphoblastic leukemia (ALL).', 'subject score': 901, 'object score': 1000}, 'PMID:16258745': {'publication date': '2006 Jan', 'sentence': 'We have investigated serum endothelin-1 (ET) and nitric oxide (NO) levels before and after a short course of high dose methylprednisolone (HDMP) in children with acute lymphoblastic leukemia (ALL) as an indicator of vasoconstrictor and vasodilator properties of endothelium.', 'subject score': 901, 'object score': 1000}, 'PMID:1635379': {'publication date': '1992', 'sentence': 'High-dose methylprednisolone therapy (HDMP) induces acceleration of leukocyte recovery in acute lymphoblastic leukemia (ALL) and the differentiation of myeloblasts to mature granulocytes in acute myeloblastic leukemia (AML).', 'subject score': 861, 'object score': 1000}, 'PMID:16928654': {'publication date': '2006 Oct-Nov', 'sentence': 'Comparision of the apoptotic effects on lymphoblasts and on increase of myeloid lineage cells of a short-time, high-dose methylprednisolone and the conventional-dose prednisolone treatments in children with acute lymphoblastic leukemia.', 'subject score': 901, 'object score': 1000}, 'PMID:1863545': {'publication date': '1991', 'sentence': 'Acceleration of leukocyte recovery by administration of short-course high-dose methylprednisolone in children with acute lymphoblastic leukemia.', 'subject score': 840, 'object score': 1000}, 'PMID:9020370': {'publication date': '1997 Jan', 'sentence': 'In an attempt to improve treatment outcome high-dose methylprednisolone (HDMP, 20-30 mg/kg, once a day orally) was used instead of a conventional dose of steroid (2 mg/kg/d, in 3 divided doses) in children with acute lymphoblastic leukemia (ALL) with increased risk factors.', 'subject score': 857, 'object score': 1000}, 'PMID:9678714': {'publication date': '1998 Jun', 'sentence': 'A comparison of the effect of high-dose methylprednisolone with conventional-dose prednisolone in acute lymphoblastic leukemia patients with randomization.', 'subject score': 901, 'object score': 916}, 'PMID:9842648': {'publication date': '1998', 'sentence': 'Effect of high-dose methylprednisolone and G-CSF treatments on lymphocyte subtypes in neutropenic children with acute lymphoblastic leukemia: a pilot study.', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 323831,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-          "name": "acute lymphoblastic leukemia",
-          "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "HP:0006721",
-            "MONDO:0004967",
-            "MEDDRA:10000848",
-            "MEDDRA:10000849",
-            "MEDDRA:10025305",
-            "ORPHANET:513",
-            "MEDDRA:10025301",
-            "ICD10:C91.00",
-            "UMLS:C0023453",
-            "DOID:9952",
-            "MEDDRA:10000844",
-            "MEDDRA:10000846",
-            "MEDDRA:10000845",
-            "MEDDRA:10024338",
-            "ICD10:C91",
-            "MESH:D054198",
-            "UMLS:C1961102",
-            "MEDDRA:10060555",
-            "NCIT:C3167",
-            "PDQ:CDR0000043423",
-            "MEDDRA:10024290",
-            "MEDDRA:10000842",
-            "NCIT:C27281",
-            "ICD9:204",
-            "DOID:1037",
-            "MEDDRA:10000843",
-            "EFO:0000220",
-            "SNOMEDCT:128822004",
-            "ICD9:204.0",
-            "UMLS:C0023449",
-            "MEDDRA:10060390",
-            "SNOMEDCT:91857003"
-          ],
-          "id": "MONDO:0004967",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute lymphoblastic leukemia",
-            "lymphoid leukemia",
-            "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-            "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-            "L2 Acute Lymphoblastic Leukemia",
-            "acute lymphocytic leukemia",
-            "Lymphoid leukemia, acute",
-            "acute lymphoblastic leukemia",
-            "Acute lymphocytic leukemia",
-            "Acute Lymphoblastic Leukemia",
-            "Lymphoid leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=46332",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=616067",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323831,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-              "name": "acute lymphoblastic leukemia",
-              "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "HP:0006721",
-                "MONDO:0004967",
-                "MEDDRA:10000848",
-                "MEDDRA:10000849",
-                "MEDDRA:10025305",
-                "ORPHANET:513",
-                "MEDDRA:10025301",
-                "ICD10:C91.00",
-                "UMLS:C0023453",
-                "DOID:9952",
-                "MEDDRA:10000844",
-                "MEDDRA:10000846",
-                "MEDDRA:10000845",
-                "MEDDRA:10024338",
-                "ICD10:C91",
-                "MESH:D054198",
-                "UMLS:C1961102",
-                "MEDDRA:10060555",
-                "NCIT:C3167",
-                "PDQ:CDR0000043423",
-                "MEDDRA:10024290",
-                "MEDDRA:10000842",
-                "NCIT:C27281",
-                "ICD9:204",
-                "DOID:1037",
-                "MEDDRA:10000843",
-                "EFO:0000220",
-                "SNOMEDCT:128822004",
-                "ICD9:204.0",
-                "UMLS:C0023449",
-                "MEDDRA:10060390",
-                "SNOMEDCT:91857003"
-              ],
-              "id": "MONDO:0004967",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute lymphoblastic leukemia",
-                "lymphoid leukemia",
-                "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-                "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-                "L2 Acute Lymphoblastic Leukemia",
-                "acute lymphocytic leukemia",
-                "Lymphoid leukemia, acute",
-                "acute lymphoblastic leukemia",
-                "Acute lymphocytic leukemia",
-                "Acute Lymphoblastic Leukemia",
-                "Lymphoid leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=46332",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=616067",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9917017,
-            "start": 570,
-            "end": 323831,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12688320': {'publication date': '2003 Mar', 'sentence': 'We examined the effect of high-dose methylprednisolone (HDMP) on blast reduction rate and compared it to conventional dose steroid treatment, administered during the first 7+ days of the induction remission period in patients with acute lymphoblastic leukemia (ALL).', 'subject score': 901, 'object score': 1000}, 'PMID:16258745': {'publication date': '2006 Jan', 'sentence': 'We have investigated serum endothelin-1 (ET) and nitric oxide (NO) levels before and after a short course of high dose methylprednisolone (HDMP) in children with acute lymphoblastic leukemia (ALL) as an indicator of vasoconstrictor and vasodilator properties of endothelium.', 'subject score': 901, 'object score': 1000}, 'PMID:1635379': {'publication date': '1992', 'sentence': 'High-dose methylprednisolone therapy (HDMP) induces acceleration of leukocyte recovery in acute lymphoblastic leukemia (ALL) and the differentiation of myeloblasts to mature granulocytes in acute myeloblastic leukemia (AML).', 'subject score': 861, 'object score': 1000}, 'PMID:16928654': {'publication date': '2006 Oct-Nov', 'sentence': 'Comparision of the apoptotic effects on lymphoblasts and on increase of myeloid lineage cells of a short-time, high-dose methylprednisolone and the conventional-dose prednisolone treatments in children with acute lymphoblastic leukemia.', 'subject score': 901, 'object score': 1000}, 'PMID:1863545': {'publication date': '1991', 'sentence': 'Acceleration of leukocyte recovery by administration of short-course high-dose methylprednisolone in children with acute lymphoblastic leukemia.', 'subject score': 840, 'object score': 1000}, 'PMID:9020370': {'publication date': '1997 Jan', 'sentence': 'In an attempt to improve treatment outcome high-dose methylprednisolone (HDMP, 20-30 mg/kg, once a day orally) was used instead of a conventional dose of steroid (2 mg/kg/d, in 3 divided doses) in children with acute lymphoblastic leukemia (ALL) with increased risk factors.', 'subject score': 857, 'object score': 1000}, 'PMID:9678714': {'publication date': '1998 Jun', 'sentence': 'A comparison of the effect of high-dose methylprednisolone with conventional-dose prednisolone in acute lymphoblastic leukemia patients with randomization.', 'subject score': 901, 'object score': 916}, 'PMID:9842648': {'publication date': '1998', 'sentence': 'Effect of high-dose methylprednisolone and G-CSF treatments on lymphocyte subtypes in neutropenic children with acute lymphoblastic leukemia: a pilot study.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0023449---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10136260",
-              "object": "MONDO:0004967",
-              "publications": [
-                "PMID:12688320",
-                "PMID:16258745",
-                "PMID:1635379",
-                "PMID:16928654",
-                "PMID:1863545",
-                "PMID:9020370",
-                "PMID:9678714",
-                "PMID:9842648"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:17296587': {'publication date': '2007 Feb', 'sentence': 'Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 535028,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000430",
-          "name": "mature T-cell and NK-cell non-Hodgkin lymphoma",
-          "description": "A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10034624",
-            "MONDO:0000430",
-            "MEDDRA:10034623",
-            "UMLS:C1337073",
-            "MESH:D016411",
-            "UMLS:C1337074",
-            "NCIT:C27352",
-            "UMLS:C0079774",
-            "UMLS:C5551485",
-            "UMLS:C1337079",
-            "DOID:0050743",
-            "NCIT:C7204",
-            "UMLS:C0334655",
-            "NCIT:C3468",
-            "DOID:0050749",
-            "SNOMEDCT:109977009",
-            "ICD9:202.7",
-            "SNOMEDCT:1163404000",
-            "SNOMEDCT:109975001"
-          ],
-          "id": "MONDO:0000430",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peripheral T-Cell Lymphoma, Large Cell",
-            "T-Zone Variant Peripheral T-Cell Lymphoma",
-            "mature T-cell and NK-cell non-Hodgkin lymphoma",
-            "peripheral T-cell lymphoma",
-            "T-zone lymphoma (clinical)",
-            "Lymphoma, T-Cell, Peripheral",
-            "mature T-cell and NK-cell lymphoma",
-            "Peripheral T-Cell Lymphoma",
-            "Peripheral T-cell lymphoma",
-            "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:21919697",
-            "http://www.cancer.gov/dictionary?cdrid=393800",
-            "http://www.cancer.gov/dictionary?cdrid=44062",
-            "http://en.wikipedia.org/wiki/peripheral_t-cell_lymphoma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 535028,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000430",
-              "name": "mature T-cell and NK-cell non-Hodgkin lymphoma",
-              "description": "A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10034624",
-                "MONDO:0000430",
-                "MEDDRA:10034623",
-                "UMLS:C1337073",
-                "MESH:D016411",
-                "UMLS:C1337074",
-                "NCIT:C27352",
-                "UMLS:C0079774",
-                "UMLS:C5551485",
-                "UMLS:C1337079",
-                "DOID:0050743",
-                "NCIT:C7204",
-                "UMLS:C0334655",
-                "NCIT:C3468",
-                "DOID:0050749",
-                "SNOMEDCT:109977009",
-                "ICD9:202.7",
-                "SNOMEDCT:1163404000",
-                "SNOMEDCT:109975001"
-              ],
-              "id": "MONDO:0000430",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peripheral T-Cell Lymphoma, Large Cell",
-                "T-Zone Variant Peripheral T-Cell Lymphoma",
-                "mature T-cell and NK-cell non-Hodgkin lymphoma",
-                "peripheral T-cell lymphoma",
-                "T-zone lymphoma (clinical)",
-                "Lymphoma, T-Cell, Peripheral",
-                "mature T-cell and NK-cell lymphoma",
-                "Peripheral T-Cell Lymphoma",
-                "Peripheral T-cell lymphoma",
-                "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:21919697",
-                "http://www.cancer.gov/dictionary?cdrid=393800",
-                "http://www.cancer.gov/dictionary?cdrid=44062",
-                "http://en.wikipedia.org/wiki/peripheral_t-cell_lymphoma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12700621,
-            "start": 570,
-            "end": 535028,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17296587': {'publication date': '2007 Feb', 'sentence': 'Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0079774---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "12975348",
-              "object": "MONDO:0000430",
-              "publications": [
-                "PMID:17296587"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10354391': {'publication date': '1999 Jun', 'sentence': 'Eosinophilic fasciitis associated with autoimmune thyroid disease and myelodysplasia treated with pulsed methylprednisolone and antihistamines.', 'subject score': 872, 'object score': 1000}, 'PMID:11764102': {'publication date': '2001 Dec', 'sentence': 'Results obtained with HDMP from the previous studies and the present case suggest that high-dose methylprednisolone is a promising agent in the treatment of AIDS and it is recommended as an initial treatment especially for MDS children with hypocellular bone marrow at presentation.', 'subject score': 901, 'object score': 901}, 'PMID:17483080': {'publication date': '2007 May', 'sentence': 'Selective blast cell reduction in elderly patients with acute myeloid leukemia secondary to myelodysplastic syndrome treated with methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:8655463': {'publication date': '1995', 'sentence': 'High-dose methylprednisolone (HDMP) has been shown to induce differentiation of myeloid leukemic cells with a remarkable antileukemic effect in children with various subtypes of acute myeloblastic leukemia (AML), therefore we used HDMP in the treatment of four children with myelodysplastic syndrome (MDS).', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318345,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018881",
-          "name": "myelodysplastic syndrome",
-          "description": "A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3247\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3247\" NCI Thesaurus); A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001); Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.; Clonal hematopoietic stem cell disorders characterized by dysplasia (ineffective production) in one or more hematopoietic cell lineages, leading to anemia and cytopenia. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10028534",
-            "ORPHANET:52688",
-            "SNOMEDCT:74326002",
-            "MEDDRA:10028532",
-            "MEDDRA:10042295",
-            "SNOMEDCT:188736006",
-            "NCIT:C3176",
-            "DOID:0050908",
-            "MEDDRA:10060421",
-            "UMLS:C0033027",
-            "MEDDRA:10028536",
-            "SNOMEDCT:109995007",
-            "PDQ:CDR0000039817",
-            "MESH:D011289",
-            "HP:0002863",
-            "SNOMEDCT:128826001",
-            "OMIM:614286",
-            "EFO:0000198",
-            "MEDDRA:10028533",
-            "UMLS:C3463824",
-            "MEDDRA:10054651",
-            "UMLS:C2713368",
-            "MEDDRA:10028554",
-            "MEDDRA:10054577",
-            "MESH:D054438",
-            "SNOMEDCT:128623006",
-            "UMLS:C1851971",
-            "MESH:D009190",
-            "UMLS:C1292772",
-            "MEDDRA:10028559",
-            "MEDDRA:10036587",
-            "MEDDRA:10028548",
-            "NCIT:C3247",
-            "MEDDRA:10042292",
-            "MONDO:0018881"
-          ],
-          "id": "MONDO:0018881",
-          "category": "biolink:Disease",
-          "all_names": [
-            "myelodysplastic syndrome",
-            "Myelodysplasia",
-            "Hematopoetic Myelodysplasia",
-            "Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative",
-            "Myelodysplastic syndrome",
-            "Philadelphia-Negative Myelogenous Leukemia",
-            "Myelodysplastic Syndrome",
-            "Preleukemia",
-            "Myelodysplastic Syndromes",
-            "Hypoplastic myelodysplasia",
-            "Myelodysplastic syndrome related phenotypic feature",
-            "myelodysplastic syndromes"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/myelodysplastic_syndrome",
-            "http://www.cancer.gov/dictionary?cdrid=45266",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318345,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018881",
-              "name": "myelodysplastic syndrome",
-              "description": "A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3247\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3247\" NCI Thesaurus); A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001); Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.; Clonal hematopoietic stem cell disorders characterized by dysplasia (ineffective production) in one or more hematopoietic cell lineages, leading to anemia and cytopenia. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10028534",
-                "ORPHANET:52688",
-                "SNOMEDCT:74326002",
-                "MEDDRA:10028532",
-                "MEDDRA:10042295",
-                "SNOMEDCT:188736006",
-                "NCIT:C3176",
-                "DOID:0050908",
-                "MEDDRA:10060421",
-                "UMLS:C0033027",
-                "MEDDRA:10028536",
-                "SNOMEDCT:109995007",
-                "PDQ:CDR0000039817",
-                "MESH:D011289",
-                "HP:0002863",
-                "SNOMEDCT:128826001",
-                "OMIM:614286",
-                "EFO:0000198",
-                "MEDDRA:10028533",
-                "UMLS:C3463824",
-                "MEDDRA:10054651",
-                "UMLS:C2713368",
-                "MEDDRA:10028554",
-                "MEDDRA:10054577",
-                "MESH:D054438",
-                "SNOMEDCT:128623006",
-                "UMLS:C1851971",
-                "MESH:D009190",
-                "UMLS:C1292772",
-                "MEDDRA:10028559",
-                "MEDDRA:10036587",
-                "MEDDRA:10028548",
-                "NCIT:C3247",
-                "MEDDRA:10042292",
-                "MONDO:0018881"
-              ],
-              "id": "MONDO:0018881",
-              "category": "biolink:Disease",
-              "all_names": [
-                "myelodysplastic syndrome",
-                "Myelodysplasia",
-                "Hematopoetic Myelodysplasia",
-                "Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative",
-                "Myelodysplastic syndrome",
-                "Philadelphia-Negative Myelogenous Leukemia",
-                "Myelodysplastic Syndrome",
-                "Preleukemia",
-                "Myelodysplastic Syndromes",
-                "Hypoplastic myelodysplasia",
-                "Myelodysplastic syndrome related phenotypic feature",
-                "myelodysplastic syndromes"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/myelodysplastic_syndrome",
-                "http://www.cancer.gov/dictionary?cdrid=45266",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7283288,
-            "start": 570,
-            "end": 318345,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10354391': {'publication date': '1999 Jun', 'sentence': 'Eosinophilic fasciitis associated with autoimmune thyroid disease and myelodysplasia treated with pulsed methylprednisolone and antihistamines.', 'subject score': 872, 'object score': 1000}, 'PMID:11764102': {'publication date': '2001 Dec', 'sentence': 'Results obtained with HDMP from the previous studies and the present case suggest that high-dose methylprednisolone is a promising agent in the treatment of AIDS and it is recommended as an initial treatment especially for MDS children with hypocellular bone marrow at presentation.', 'subject score': 901, 'object score': 901}, 'PMID:17483080': {'publication date': '2007 May', 'sentence': 'Selective blast cell reduction in elderly patients with acute myeloid leukemia secondary to myelodysplastic syndrome treated with methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:8655463': {'publication date': '1995', 'sentence': 'High-dose methylprednisolone (HDMP) has been shown to induce differentiation of myeloid leukemic cells with a remarkable antileukemic effect in children with various subtypes of acute myeloblastic leukemia (AML), therefore we used HDMP in the treatment of four children with myelodysplastic syndrome (MDS).', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C3463824---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7432980",
-              "object": "MONDO:0018881",
-              "publications": [
-                "PMID:10354391",
-                "PMID:11764102",
-                "PMID:17483080",
-                "PMID:8655463"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:7543720': {'publication date': '1995', 'sentence': 'Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay.', 'subject score': 1000, 'object score': 923}, 'PMID:9222284': {'publication date': '1997 May', 'sentence': 'In vitro improvement of chlorambucil-induced cytotoxicity by deflazacort and 6-methylprednisolone in B-cell chronic lymphocytic leukaemia.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 323598,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004948",
-          "name": "B-cell chronic lymphocytic leukemia",
-          "description": "The most common type of chronic lymphoid leukemia. It comprises 90% of chronic lymphoid leukemias in the United States. Morphologically, the neoplastic cells are small, round B-lymphocytes. This type of leukemia is not considered to be curable with available therapy. (WHO, 2001); A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.; A chronic lymphocytic/lymphatic/lymphoblastic leukemia (CLL) is a neoplastic disease characterized by proliferation and accumulation (blood, marrow and lymphoid organs) of morphologically mature but immunologically dysfunctional lymphocytes. A CLL is always a B-cell lymphocytic leukemia as there are no reports of cases of T-cell lymphocytic leukemias. [HPO:curators]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10051812",
-            "MEDDRA:10003908",
-            "MEDDRA:10068919",
-            "MEDDRA:10060576",
-            "MEDDRA:10068852",
-            "OMIM:151400",
-            "MEDDRA:10003909",
-            "MEDDRA:10008956",
-            "UMLS:C0855095",
-            "ICD9:204.1",
-            "MEDDRA:10060391",
-            "MEDDRA:10008976",
-            "NCIT:C7540",
-            "MEDDRA:10008957",
-            "HP:0005550",
-            "MONDO:0004948",
-            "UMLS:C0023434",
-            "MEDDRA:10024340",
-            "MEDDRA:10025306",
-            "PDQ:CDR0000038170",
-            "MEDDRA:10009310",
-            "SNOMEDCT:302841002",
-            "MEDDRA:10008960",
-            "ORPHANET:67038",
-            "SNOMEDCT:92814006",
-            "SNOMEDCT:277473004",
-            "MEDDRA:10008958",
-            "SNOMEDCT:64575004",
-            "MEDDRA:10003910",
-            "MEDDRA:10024295",
-            "ICD10:C91.10",
-            "PDQ:CDR0000037765",
-            "MEDDRA:10025302",
-            "EFO:0000095",
-            "MEDDRA:10041138",
-            "DOID:1040",
-            "SNOMEDCT:51092000",
-            "MESH:D015451",
-            "PDQ:CDR0000039824",
-            "NCIT:C3163",
-            "MEDDRA:10008993"
-          ],
-          "id": "MONDO:0004948",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic lymphatic leukemia",
-            "Lymphoid leukemia, chronic",
-            "Small Lymphocytic Lymphoma",
-            "chronic lymphocytic leukemia",
-            "Leukemia, chronic lymphocytic related phenotypic feature",
-            "Leukemia, Lymphocytic, Chronic, B-Cell",
-            "B-cell chronic lymphocytic leukemia",
-            "small lymphocytic lymphoma",
-            "Chronic Lymphocytic Leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=346545",
-            "http://en.wikipedia.org/wiki/b-cell_chronic_lymphocytic_leukemia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323598,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004948",
-              "name": "B-cell chronic lymphocytic leukemia",
-              "description": "The most common type of chronic lymphoid leukemia. It comprises 90% of chronic lymphoid leukemias in the United States. Morphologically, the neoplastic cells are small, round B-lymphocytes. This type of leukemia is not considered to be curable with available therapy. (WHO, 2001); A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.; A chronic lymphocytic/lymphatic/lymphoblastic leukemia (CLL) is a neoplastic disease characterized by proliferation and accumulation (blood, marrow and lymphoid organs) of morphologically mature but immunologically dysfunctional lymphocytes. A CLL is always a B-cell lymphocytic leukemia as there are no reports of cases of T-cell lymphocytic leukemias. [HPO:curators]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10051812",
-                "MEDDRA:10003908",
-                "MEDDRA:10068919",
-                "MEDDRA:10060576",
-                "MEDDRA:10068852",
-                "OMIM:151400",
-                "MEDDRA:10003909",
-                "MEDDRA:10008956",
-                "UMLS:C0855095",
-                "ICD9:204.1",
-                "MEDDRA:10060391",
-                "MEDDRA:10008976",
-                "NCIT:C7540",
-                "MEDDRA:10008957",
-                "HP:0005550",
-                "MONDO:0004948",
-                "UMLS:C0023434",
-                "MEDDRA:10024340",
-                "MEDDRA:10025306",
-                "PDQ:CDR0000038170",
-                "MEDDRA:10009310",
-                "SNOMEDCT:302841002",
-                "MEDDRA:10008960",
-                "ORPHANET:67038",
-                "SNOMEDCT:92814006",
-                "SNOMEDCT:277473004",
-                "MEDDRA:10008958",
-                "SNOMEDCT:64575004",
-                "MEDDRA:10003910",
-                "MEDDRA:10024295",
-                "ICD10:C91.10",
-                "PDQ:CDR0000037765",
-                "MEDDRA:10025302",
-                "EFO:0000095",
-                "MEDDRA:10041138",
-                "DOID:1040",
-                "SNOMEDCT:51092000",
-                "MESH:D015451",
-                "PDQ:CDR0000039824",
-                "NCIT:C3163",
-                "MEDDRA:10008993"
-              ],
-              "id": "MONDO:0004948",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic lymphatic leukemia",
-                "Lymphoid leukemia, chronic",
-                "Small Lymphocytic Lymphoma",
-                "chronic lymphocytic leukemia",
-                "Leukemia, chronic lymphocytic related phenotypic feature",
-                "Leukemia, Lymphocytic, Chronic, B-Cell",
-                "B-cell chronic lymphocytic leukemia",
-                "small lymphocytic lymphoma",
-                "Chronic Lymphocytic Leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=346545",
-                "http://en.wikipedia.org/wiki/b-cell_chronic_lymphocytic_leukemia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26052718,
-            "start": 570,
-            "end": 323598,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7543720': {'publication date': '1995', 'sentence': 'Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay.', 'subject score': 1000, 'object score': 923}, 'PMID:9222284': {'publication date': '1997 May', 'sentence': 'In vitro improvement of chlorambucil-induced cytotoxicity by deflazacort and 6-methylprednisolone in B-cell chronic lymphocytic leukaemia.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0023434---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "26513818",
-              "object": "MONDO:0004948",
-              "publications": [
-                "PMID:7543720",
-                "PMID:9222284"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 526827,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005306",
-          "name": "ankylosing spondylitis",
-          "description": "A bone inflammation disease that results_in inflammation in the joints of the spine and pelvis. The disease has_symptom pain, has_symptom stiffness in the spine, has_symptom stiffness in the neck, has_symptom stiffness in the hips, has_symptom stiffness in the jaw and has_symptom stiffness in the rib cage.",
-          "equivalent_curies": [
-            "MEDDRA:10048811",
-            "SNOMEDCT:9631008",
-            "MEDDRA:10002556",
-            "ICD9:720.0",
-            "ICD10:M45",
-            "MEDDRA:10041671",
-            "MEDDRA:10054041",
-            "MEDDRA:10041672",
-            "OMIM:PS106300",
-            "MEDDRA:10058813",
-            "ORPHANET:825",
-            "MONDO:0005306",
-            "MESH:D013167",
-            "EFO:0003898",
-            "DOID:7147",
-            "MEDDRA:10039082",
-            "NCIT:C84564",
-            "UMLS:C0038020",
-            "UMLS:C0038013"
-          ],
-          "id": "MONDO:0005306",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Spondylitis, Ankylosing",
-            "ankylosing spondylitis",
-            "Ankylosing Spondylitis",
-            "Ankylosing spondylitis",
-            "Spondylosis Deformans"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/ankylosing_spondylitis",
-            "http://www.mayoclinic.com/health/ankylosing-spondylitis/ds00483",
-            "http://www.spondylitis.org/about/as.aspx",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000420.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526827,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005306",
-              "name": "ankylosing spondylitis",
-              "description": "A bone inflammation disease that results_in inflammation in the joints of the spine and pelvis. The disease has_symptom pain, has_symptom stiffness in the spine, has_symptom stiffness in the neck, has_symptom stiffness in the hips, has_symptom stiffness in the jaw and has_symptom stiffness in the rib cage.",
-              "equivalent_curies": [
-                "MEDDRA:10048811",
-                "SNOMEDCT:9631008",
-                "MEDDRA:10002556",
-                "ICD9:720.0",
-                "ICD10:M45",
-                "MEDDRA:10041671",
-                "MEDDRA:10054041",
-                "MEDDRA:10041672",
-                "OMIM:PS106300",
-                "MEDDRA:10058813",
-                "ORPHANET:825",
-                "MONDO:0005306",
-                "MESH:D013167",
-                "EFO:0003898",
-                "DOID:7147",
-                "MEDDRA:10039082",
-                "NCIT:C84564",
-                "UMLS:C0038020",
-                "UMLS:C0038013"
-              ],
-              "id": "MONDO:0005306",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Spondylitis, Ankylosing",
-                "ankylosing spondylitis",
-                "Ankylosing Spondylitis",
-                "Ankylosing spondylitis",
-                "Spondylosis Deformans"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/ankylosing_spondylitis",
-                "http://www.mayoclinic.com/health/ankylosing-spondylitis/ds00483",
-                "http://www.spondylitis.org/about/as.aspx",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000420.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25594802,
-            "start": 570,
-            "end": 526827,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:6223736': {'publication date': '1983 Jul', 'sentence': 'The effects of intravenous pulse methylprednisolone on immunological and inflammatory processes in ankylosing spondylitis.', 'subject score': 802, 'object score': 1000}, 'PMID:7839156': {'publication date': '1994 Oct', 'sentence': 'Methylprednisolone and levamisole were both efficacious in AS, but levamisole was associated with occasional severe side effects.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0038013---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "26050805",
-              "object": "MONDO:0005306",
-              "publications": [
-                "PMID:6223736",
-                "PMID:7839156"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 315465,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021100",
-          "name": "breast neoplasm",
-          "description": "A benign or malignant neoplasm of the breast parenchyma. It can originate from the ducts, lobules or the breast adipose tissue. Breast neoplasms are much more common in females than males.; Cancer of the human MAMMARY GLAND.; A tumor (abnormal growth of tissue) of the breast. [HPO:probinson]",
-          "equivalent_curies": [
-            "UMLS:CN236627",
-            "SNOMEDCT:126926005",
-            "MEDDRA:10006285",
-            "MEDDRA:10028985",
-            "PSY:29330",
-            "MONDO:0021100",
-            "EFO:0003869",
-            "UMLS:C1458155",
-            "HP:0100013",
-            "NCIT:C2910",
-            "MESH:D001943",
-            "PSY:06940",
-            "MEDDRA:10006279"
-          ],
-          "id": "MONDO:0021100",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Breast Neoplasm",
-            "Neoplasm of the breast",
-            "Mammary Neoplasms",
-            "breast neoplasm",
-            "Breast Neoplasms"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315465,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021100",
-              "name": "breast neoplasm",
-              "description": "A benign or malignant neoplasm of the breast parenchyma. It can originate from the ducts, lobules or the breast adipose tissue. Breast neoplasms are much more common in females than males.; Cancer of the human MAMMARY GLAND.; A tumor (abnormal growth of tissue) of the breast. [HPO:probinson]",
-              "equivalent_curies": [
-                "UMLS:CN236627",
-                "SNOMEDCT:126926005",
-                "MEDDRA:10006285",
-                "MEDDRA:10028985",
-                "PSY:29330",
-                "MONDO:0021100",
-                "EFO:0003869",
-                "UMLS:C1458155",
-                "HP:0100013",
-                "NCIT:C2910",
-                "MESH:D001943",
-                "PSY:06940",
-                "MEDDRA:10006279"
-              ],
-              "id": "MONDO:0021100",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Breast Neoplasm",
-                "Neoplasm of the breast",
-                "Mammary Neoplasms",
-                "breast neoplasm",
-                "Breast Neoplasms"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25392251,
-            "start": 570,
-            "end": 315465,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:476617': {'publication date': '1979 Oct', 'sentence': 'The effect of methylprednisolone (MP) on the cell kinetic response to cyclophosphamide (CP) and Adriamycin (ADR) in C3H/HeJ spontaneous mammary tumors and hematopoietic tissue was investigated.', 'subject score': 1000, 'object score': 774}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C1458155---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "25845844",
-              "object": "MONDO:0021100",
-              "publications": [
-                "PMID:476617"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 530650,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016367",
-          "name": "dermatomyositis",
-          "description": "Inflammation of the skin and muscle.; A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003882",
-            "EFO:0000398",
-            "ICD10:M33",
-            "MONDO:0016367",
-            "SNOMEDCT:396230008",
-            "NCIT:C26744",
-            "DOID:10223",
-            "MEDDRA:10012503",
-            "ORPHANET:221",
-            "UMLS:C0011633",
-            "ICD9:710.3"
-          ],
-          "id": "MONDO:0016367",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatomyositis",
-            "dermatomyositis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/dermatomyositis",
-            "http://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 530650,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016367",
-              "name": "dermatomyositis",
-              "description": "Inflammation of the skin and muscle.; A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003882",
-                "EFO:0000398",
-                "ICD10:M33",
-                "MONDO:0016367",
-                "SNOMEDCT:396230008",
-                "NCIT:C26744",
-                "DOID:10223",
-                "MEDDRA:10012503",
-                "ORPHANET:221",
-                "UMLS:C0011633",
-                "ICD9:710.3"
-              ],
-              "id": "MONDO:0016367",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatomyositis",
-                "dermatomyositis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/dermatomyositis",
-                "http://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25191404,
-            "start": 570,
-            "end": 530650,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3799928': {'publication date': '1986', 'sentence': 'High-dose intravenous methyl-prednisolone in chronic polymyositis/dermatomyositis.', 'subject score': 861, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0011633---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "25642837",
-              "object": "MONDO:0016367",
-              "publications": [
-                "PMID:3799928"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 520346,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007972",
-          "name": "Meniere disease",
-          "description": "A chronic inner ear disorder affecting balance and hearing. Symptoms may include vertigo, tinnitus, and hearing loss.; A disease of the inner ear (LABYRINTH) that is characterized by fluctuating SENSORINEURAL HEARING LOSS; TINNITUS; episodic VERTIGO; and aural fullness. It is the most common form of endolymphatic hydrops.; Meniere's disease is a disorder of the inner ear. It can cause severe dizziness, a roaring sound in your ears called tinnitus, hearing loss that comes and goes and the feeling of ear pressure or pain. It usually affects just one ear. It is a common cause of hearing loss.  Attacks of dizziness may come on suddenly or after a short period of tinnitus or muffled hearing. Some people have single attacks of dizziness once in a while. Others may have many attacks close together over several days. Some people with Meniere's disease have \"drop attacks\" during which the dizziness is so bad they lose their balance and fall. Scientists don't yet know the cause. They think that it has to do with the fluid levels or the mixing of fluids in the canals of your inner ear. Doctors diagnose it based on a physical exam and your symptoms. A hearing test can check to see how it has affected your hearing. There is no cure. Treatments include medicines to control dizziness, limiting salt in your diet, and taking water pills. A device that fits into the outer ear and delivers air pulses to the middle ear can help. Severe cases may require surgery. NIH: National Institute on Deafness and Other Communication Disorders ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10027184",
-            "MEDDRA:10042823",
-            "ICD10:H81.0",
-            "UMLS:C0025281",
-            "NCIT:C185243",
-            "MONDO:0007972",
-            "UMLS:C1527320",
-            "ICD9:386.0",
-            "EFO:0006862",
-            "MEDDRA:10027183",
-            "OMIM:156000",
-            "PSY:30640",
-            "SNOMEDCT:13445001",
-            "MEDDRA:10027185",
-            "MESH:D008575",
-            "DOID:9849",
-            "ORPHANET:45360"
-          ],
-          "id": "MONDO:0007972",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Meniere disease related phenotypic feature",
-            "Meniere's disease",
-            "Meniere Disease",
-            "Menieres Disease",
-            "Meniere disease",
-            "Vertigo, Aural"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/m%c3%a9ni%c3%a8re%27s_disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520346,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007972",
-              "name": "Meniere disease",
-              "description": "A chronic inner ear disorder affecting balance and hearing. Symptoms may include vertigo, tinnitus, and hearing loss.; A disease of the inner ear (LABYRINTH) that is characterized by fluctuating SENSORINEURAL HEARING LOSS; TINNITUS; episodic VERTIGO; and aural fullness. It is the most common form of endolymphatic hydrops.; Meniere's disease is a disorder of the inner ear. It can cause severe dizziness, a roaring sound in your ears called tinnitus, hearing loss that comes and goes and the feeling of ear pressure or pain. It usually affects just one ear. It is a common cause of hearing loss.  Attacks of dizziness may come on suddenly or after a short period of tinnitus or muffled hearing. Some people have single attacks of dizziness once in a while. Others may have many attacks close together over several days. Some people with Meniere's disease have \"drop attacks\" during which the dizziness is so bad they lose their balance and fall. Scientists don't yet know the cause. They think that it has to do with the fluid levels or the mixing of fluids in the canals of your inner ear. Doctors diagnose it based on a physical exam and your symptoms. A hearing test can check to see how it has affected your hearing. There is no cure. Treatments include medicines to control dizziness, limiting salt in your diet, and taking water pills. A device that fits into the outer ear and delivers air pulses to the middle ear can help. Severe cases may require surgery. NIH: National Institute on Deafness and Other Communication Disorders ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10027184",
-                "MEDDRA:10042823",
-                "ICD10:H81.0",
-                "UMLS:C0025281",
-                "NCIT:C185243",
-                "MONDO:0007972",
-                "UMLS:C1527320",
-                "ICD9:386.0",
-                "EFO:0006862",
-                "MEDDRA:10027183",
-                "OMIM:156000",
-                "PSY:30640",
-                "SNOMEDCT:13445001",
-                "MEDDRA:10027185",
-                "MESH:D008575",
-                "DOID:9849",
-                "ORPHANET:45360"
-              ],
-              "id": "MONDO:0007972",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Meniere disease related phenotypic feature",
-                "Meniere's disease",
-                "Meniere Disease",
-                "Menieres Disease",
-                "Meniere disease",
-                "Vertigo, Aural"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/m%c3%a9ni%c3%a8re%27s_disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24879810,
-            "start": 570,
-            "end": 520346,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:36742746': {'publication date': '2022 Dec', 'sentence': \"Comparing Intratympanic Gentamicin with Methylprednisolone in Meniere's Disease with Non-Serviceable Hearing.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0025281---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "25328503",
-              "object": "MONDO:0007972",
-              "publications": [
-                "PMID:36742746"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316905,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018908",
-          "name": "non-Hodgkin lymphoma",
-          "description": "Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3211\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3211\" NCI Thesaurus); Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.; Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.; A type of lymphoma characterized microscopically by the absence of multinucleated Reed-Sternberg cells. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "UMLS:C1622254",
-            "ORPHANET:547",
-            "MESH:D008228",
-            "UMLS:C0024305",
-            "MONDO:0018908",
-            "HP:0012539",
-            "SNOMEDCT:188675007",
-            "PDQ:CDR0000038957",
-            "NCIT:C3211",
-            "SNOMEDCT:1172592001",
-            "DOID:0060060",
-            "MEDDRA:10025311",
-            "MEDDRA:10029593",
-            "SNOMEDCT:128929007",
-            "MEDDRA:10029547",
-            "UMLS:C1622813"
-          ],
-          "id": "MONDO:0018908",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Non-Hodgkin Lymphoma",
-            "Lymphoma, Non-Hodgkin",
-            "Malignant lymphoma - small cleaved cell",
-            "non-Hodgkin lymphoma",
-            "Non-Hodgkin lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/non-hodgkin_lymphoma",
-            "http://www.cancer.gov/dictionary?cdrid=45148",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316905,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018908",
-              "name": "non-Hodgkin lymphoma",
-              "description": "Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3211\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3211\" NCI Thesaurus); Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.; Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.; A type of lymphoma characterized microscopically by the absence of multinucleated Reed-Sternberg cells. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "UMLS:C1622254",
-                "ORPHANET:547",
-                "MESH:D008228",
-                "UMLS:C0024305",
-                "MONDO:0018908",
-                "HP:0012539",
-                "SNOMEDCT:188675007",
-                "PDQ:CDR0000038957",
-                "NCIT:C3211",
-                "SNOMEDCT:1172592001",
-                "DOID:0060060",
-                "MEDDRA:10025311",
-                "MEDDRA:10029593",
-                "SNOMEDCT:128929007",
-                "MEDDRA:10029547",
-                "UMLS:C1622813"
-              ],
-              "id": "MONDO:0018908",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Non-Hodgkin Lymphoma",
-                "Lymphoma, Non-Hodgkin",
-                "Malignant lymphoma - small cleaved cell",
-                "non-Hodgkin lymphoma",
-                "Non-Hodgkin lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/non-hodgkin_lymphoma",
-                "http://www.cancer.gov/dictionary?cdrid=45148",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24315911,
-            "start": 570,
-            "end": 316905,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3589700': {'publication date': '1987 Jun', 'sentence': \"High-dose methylprednisolone, vincristine, MTX, and ara-C (SOMA) as initial bulk reducing therapy in non-Hodgkin's lymphoma of unfavorable histology: preliminary results of an ongoing phase II study.\", 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0024305---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "24759961",
-              "object": "MONDO:0018908",
-              "publications": [
-                "PMID:3589700"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 539363,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004833",
-          "name": "plantar fasciitis",
-          "description": "Inflammation of the thick tissue on the bottom of the foot (plantar fascia) causing heel pain. The plantar fascia (also called plantar aponeurosis) are bands of fibrous tissue extending from the calcaneal tuberosity to the toes. The etiology of plantar fasciitis remains controversial but is likely to involve a biomechanical imbalance. Though often presenting along with heel spur, they do not appear to be causally related.",
-          "equivalent_curies": [
-            "MEDDRA:10066146",
-            "MEDDRA:10016239",
-            "UMLS:C0149756",
-            "DOID:9600",
-            "SNOMEDCT:202882003",
-            "MESH:D036981",
-            "EFO:1001909",
-            "MEDDRA:10035155",
-            "MONDO:0004833"
-          ],
-          "id": "MONDO:0004833",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Plantar Fasciitis",
-            "plantar fasciitis",
-            "Fasciitis, Plantar"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 539363,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004833",
-              "name": "plantar fasciitis",
-              "description": "Inflammation of the thick tissue on the bottom of the foot (plantar fascia) causing heel pain. The plantar fascia (also called plantar aponeurosis) are bands of fibrous tissue extending from the calcaneal tuberosity to the toes. The etiology of plantar fasciitis remains controversial but is likely to involve a biomechanical imbalance. Though often presenting along with heel spur, they do not appear to be causally related.",
-              "equivalent_curies": [
-                "MEDDRA:10066146",
-                "MEDDRA:10016239",
-                "UMLS:C0149756",
-                "DOID:9600",
-                "SNOMEDCT:202882003",
-                "MESH:D036981",
-                "EFO:1001909",
-                "MEDDRA:10035155",
-                "MONDO:0004833"
-              ],
-              "id": "MONDO:0004833",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Plantar Fasciitis",
-                "plantar fasciitis",
-                "Fasciitis, Plantar"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24248342,
-            "start": 570,
-            "end": 539363,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35800843': {'publication date': '2022 May', 'sentence': 'A Prospective Study Comparing the Efficacy of Local Injection of Platelet-Rich Plasma (PRP) vs Methylprednisolone in Plantar Fasciitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0149756---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "24691450",
-              "object": "MONDO:0004833",
-              "publications": [
-                "PMID:35800843"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 526144,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001505",
-          "name": "alcoholic hepatitis",
-          "description": "Inflammation of the liver resulting from ingestion of alcohol.; INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.",
-          "equivalent_curies": [
-            "MONDO:0001505",
-            "MEDDRA:10000649",
-            "ICD9:571.1",
-            "SNOMEDCT:235875008",
-            "MEDDRA:10019728",
-            "MESH:D006519",
-            "NCIT:C34352",
-            "UMLS:C0019187",
-            "EFO:1001345",
-            "UMLS:C0001306",
-            "DOID:12351",
-            "NCIT:C34684",
-            "MEDDRA:10001624",
-            "SNOMEDCT:9953008"
-          ],
-          "id": "MONDO:0001505",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute alcoholic hepatitis",
-            "alcoholic hepatitis",
-            "Alcoholic Hepatitis",
-            "Acute Alcoholic Hepatitis",
-            "Acute alcoholic liver disease",
-            "Hepatitis, Alcoholic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526144,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001505",
-              "name": "alcoholic hepatitis",
-              "description": "Inflammation of the liver resulting from ingestion of alcohol.; INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.",
-              "equivalent_curies": [
-                "MONDO:0001505",
-                "MEDDRA:10000649",
-                "ICD9:571.1",
-                "SNOMEDCT:235875008",
-                "MEDDRA:10019728",
-                "MESH:D006519",
-                "NCIT:C34352",
-                "UMLS:C0019187",
-                "EFO:1001345",
-                "UMLS:C0001306",
-                "DOID:12351",
-                "NCIT:C34684",
-                "MEDDRA:10001624",
-                "SNOMEDCT:9953008"
-              ],
-              "id": "MONDO:0001505",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute alcoholic hepatitis",
-                "alcoholic hepatitis",
-                "Alcoholic Hepatitis",
-                "Acute Alcoholic Hepatitis",
-                "Acute alcoholic liver disease",
-                "Hepatitis, Alcoholic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24144289,
-            "start": 570,
-            "end": 526144,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:356593': {'publication date': '1978 Apr', 'sentence': 'A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0001306---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "24586108",
-              "object": "MONDO:0001505",
-              "publications": [
-                "PMID:356593"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 517178,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005087",
-          "name": "respiratory system disorder",
-          "description": "A non-neoplastic or neoplastic disorder that affects the respiratory system. Representative examples include pneumonia, chronic obstructive pulmonary disease, pulmonary failure, lung adenoma, lung carcinoma, and tracheal carcinoma.; Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:1579",
-            "NCIT:C26871",
-            "ICD10:J98",
-            "UMLS:C0035242",
-            "UMLS:C0035204",
-            "MEDDRA:10083321",
-            "MEDDRA:10038719",
-            "UMLS:C0029582",
-            "MONDO:0005087",
-            "MESH:D012120",
-            "MESH:D012140",
-            "MEDDRA:10038683",
-            "MEDDRA:10038684",
-            "ICD9:519",
-            "EFO:0000684",
-            "ICD9:510-519.99",
-            "MEDDRA:10045755",
-            "SNOMEDCT:50043002"
-          ],
-          "id": "MONDO:0005087",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Respiratory System Disorder",
-            "Other diseases of respiratory system",
-            "respiratory system disease",
-            "Other respiratory system diseases",
-            "Respiratory Tract Diseases",
-            "Respiration Disorders",
-            "respiratory system disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=respiratory%20system",
-            "http://en.wikipedia.org/wiki/file:respiratory_system_complete_en.svg"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517178,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005087",
-              "name": "respiratory system disorder",
-              "description": "A non-neoplastic or neoplastic disorder that affects the respiratory system. Representative examples include pneumonia, chronic obstructive pulmonary disease, pulmonary failure, lung adenoma, lung carcinoma, and tracheal carcinoma.; Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:1579",
-                "NCIT:C26871",
-                "ICD10:J98",
-                "UMLS:C0035242",
-                "UMLS:C0035204",
-                "MEDDRA:10083321",
-                "MEDDRA:10038719",
-                "UMLS:C0029582",
-                "MONDO:0005087",
-                "MESH:D012120",
-                "MESH:D012140",
-                "MEDDRA:10038683",
-                "MEDDRA:10038684",
-                "ICD9:519",
-                "EFO:0000684",
-                "ICD9:510-519.99",
-                "MEDDRA:10045755",
-                "SNOMEDCT:50043002"
-              ],
-              "id": "MONDO:0005087",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Respiratory System Disorder",
-                "Other diseases of respiratory system",
-                "respiratory system disease",
-                "Other respiratory system diseases",
-                "Respiratory Tract Diseases",
-                "Respiration Disorders",
-                "respiratory system disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=respiratory%20system",
-                "http://en.wikipedia.org/wiki/file:respiratory_system_complete_en.svg"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24117567,
-            "start": 570,
-            "end": 517178,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3562396': {'publication date': '1987 Jan', 'sentence': '[Short-term therapy with methylprednisolone in exacerbated obstructive respiratory tract diseases].', 'subject score': 1000, 'object score': 875}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0035242---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "24559507",
-              "object": "MONDO:0005087",
-              "publications": [
-                "PMID:3562396"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23140725,
-            "start": 570,
-            "end": 321523,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34291223': {'publication date': '2021 Jul', 'sentence': 'Methylprednisolone and 60 Days in Hospital Survival in Coronavirus Disease 2019 Pneumonia.', 'subject score': 1000, 'object score': 916}, 'PMID:34545308': {'publication date': '2021 Oct', 'sentence': 'Dexamethasone or methylprednisolone therapy in covid-19 pneumonia: A retrospective and comparative study of 513 cases.', 'subject score': 888, 'object score': 827}, 'PMID:35361632': {'publication date': '2022 Mar 31', 'sentence': 'We evaluated the efficacy and safety of pulse intravenous methylprednisolone in addition to standard treatment in COVID-19 pneumonia.', 'subject score': 790, 'object score': 802}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "23573980",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:34291223",
-                "PMID:34545308",
-                "PMID:35361632"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318159,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007275",
-          "name": "carpal tunnel syndrome",
-          "description": "Injury to the median nerve caused by its entrapment at the wrist as it traverses through the carpal tunnel. Clinically, constrictive median neuropathy is characterized by pain, paresthesia, and weakness in the median nerve distribution of the hand. [HPO:probinson]; Injury to the median nerve caused by its entrapment at the wrist as it traverses through the carpal tunnel. Clinically, constrictive median neuropathy is characterized by pain, paresthesia, and weakness in the median nerve distribution of the hand. // COMMENTS: Constrictive median neuropathy is the major clinical feature of carpal tunnel syndrome.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T190",
-          "equivalent_curies": [
-            "ICD10:G56.0",
-            "MEDDRA:10007697",
-            "HP:0012185",
-            "MESH:D002349",
-            "UMLS:C4023009",
-            "UMLS:C0007286",
-            "ORPHANET:50838",
-            "DOID:12169",
-            "MONDO:0007275",
-            "ICD9:354.0",
-            "OMIM.PS:115430",
-            "SNOMEDCT:57406009",
-            "EFO:0004143",
-            "NCIT:C34450"
-          ],
-          "id": "MONDO:0007275",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Carpal tunnel syndrome",
-            "Constrictive median neuropathy",
-            "Carpal Tunnel Syndrome",
-            "carpal tunnel syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000433.htm",
-            "https://orthoinfo.aaos.org/en/diseases--conditions/carpal-tunnel-syndrome/",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://en.wikipedia.org/wiki/carpal_tunnel_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318159,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007275",
-              "name": "carpal tunnel syndrome",
-              "description": "Injury to the median nerve caused by its entrapment at the wrist as it traverses through the carpal tunnel. Clinically, constrictive median neuropathy is characterized by pain, paresthesia, and weakness in the median nerve distribution of the hand. [HPO:probinson]; Injury to the median nerve caused by its entrapment at the wrist as it traverses through the carpal tunnel. Clinically, constrictive median neuropathy is characterized by pain, paresthesia, and weakness in the median nerve distribution of the hand. // COMMENTS: Constrictive median neuropathy is the major clinical feature of carpal tunnel syndrome.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T190",
-              "equivalent_curies": [
-                "ICD10:G56.0",
-                "MEDDRA:10007697",
-                "HP:0012185",
-                "MESH:D002349",
-                "UMLS:C4023009",
-                "UMLS:C0007286",
-                "ORPHANET:50838",
-                "DOID:12169",
-                "MONDO:0007275",
-                "ICD9:354.0",
-                "OMIM.PS:115430",
-                "SNOMEDCT:57406009",
-                "EFO:0004143",
-                "NCIT:C34450"
-              ],
-              "id": "MONDO:0007275",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Carpal tunnel syndrome",
-                "Constrictive median neuropathy",
-                "Carpal Tunnel Syndrome",
-                "carpal tunnel syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000433.htm",
-                "https://orthoinfo.aaos.org/en/diseases--conditions/carpal-tunnel-syndrome/",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://en.wikipedia.org/wiki/carpal_tunnel_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23081986,
-            "start": 570,
-            "end": 318159,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34213870': {'publication date': '2021 Jul', 'sentence': 'Intra-Carpal Injection of Ozone versus Methylprednisolone in Carpal Tunnel Syndrome of Systemic Sclerosis Patients: A Randomized Single-Blind Clinical Trial.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0007286---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "23514846",
-              "object": "MONDO:0007275",
-              "publications": [
-                "PMID:34213870"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317095,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018097",
-          "name": "West syndrome",
-          "description": "A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages [HPO:jalbers, PMID:28276060]; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0011097",
-            "MONDO:0018097",
-            "MEDDRA:10021750",
-            "UMLS:C0037769",
-            "NCIT:C84788",
-            "MEDDRA:10058893",
-            "MEDDRA:10039371",
-            "SNOMEDCT:28055006",
-            "DOID:0050562",
-            "MESH:D013036",
-            "UMLS:C1527366",
-            "ORPHANET:3451"
-          ],
-          "id": "MONDO:0018097",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_West syndrome",
-            "Salaam Seizures",
-            "West Syndrome",
-            "Spasms, Infantile",
-            "West syndrome",
-            "Epileptic spasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28276060",
-            "PMID:24268986",
-            "https://rarediseases.org/rare-diseases/west-syndrome/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317095,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018097",
-              "name": "West syndrome",
-              "description": "A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages [HPO:jalbers, PMID:28276060]; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0011097",
-                "MONDO:0018097",
-                "MEDDRA:10021750",
-                "UMLS:C0037769",
-                "NCIT:C84788",
-                "MEDDRA:10058893",
-                "MEDDRA:10039371",
-                "SNOMEDCT:28055006",
-                "DOID:0050562",
-                "MESH:D013036",
-                "UMLS:C1527366",
-                "ORPHANET:3451"
-              ],
-              "id": "MONDO:0018097",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_West syndrome",
-                "Salaam Seizures",
-                "West Syndrome",
-                "Spasms, Infantile",
-                "West syndrome",
-                "Epileptic spasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28276060",
-                "PMID:24268986",
-                "https://rarediseases.org/rare-diseases/west-syndrome/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22933478,
-            "start": 570,
-            "end": 317095,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34018132': {'publication date': '2021 May 20', 'sentence': 'Methylprednisolone Pulses in West Syndrome: A New Weapon in the Armory-Is it Needed?', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0037769---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "23364897",
-              "object": "MONDO:0018097",
-              "publications": [
-                "PMID:34018132"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 314697,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004496",
-          "name": "myocarditis",
-          "description": "Myocarditis is a condition that is characterized by inflammation of the heart muscle (myocardium). Some affected people have no noticeable symptoms of the condition. When present, signs and symptoms may include chest pain, abnormal heartbeat, shortness of breath, fatigue, signs of infection (i.e. fever, headache, sore throat, diarrhea), and leg swelling. Myocarditis can be caused by a variety of factors including infections (viral, bacterial, parasitic, and fungal), allergic reactions to certain medications, and exposure to certain chemicals. It can also be associated with other inflammatory conditions such as lupus, Wegener's granulomatosis, giant cell arteritis and Takayasu's arteritis. Most cases occur sporadically in people with no family history of the condition. Treatment aims to address the underlying cause of the condition. Medications and rarely, a heart transplant may be needed if the heart muscle becomes weak.",
-          "equivalent_curies": [
-            "MESH:D009205",
-            "MEDDRA:10028613",
-            "HP:0012819",
-            "DOID:820",
-            "KEGG.DISEASE:05416",
-            "UMLS:C0027059",
-            "MEDDRA:10028606",
-            "ICD9:429.0",
-            "SYMP:0000095",
-            "SNOMEDCT:50920009",
-            "EFO:0009609",
-            "NCIT:C34831",
-            "MEDDRA:10028619",
-            "MONDO:0004496",
-            "ICD10:I51.4"
-          ],
-          "id": "MONDO:0004496",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myocarditis",
-            "Myocarditis, unspecified",
-            "myocarditis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/myocarditis",
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:21304213",
-            "PMID:22361396",
-            "https://rarediseases.info.nih.gov/diseases/7137/myocarditis",
-            "PMID:22185868",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314697,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004496",
-              "name": "myocarditis",
-              "description": "Myocarditis is a condition that is characterized by inflammation of the heart muscle (myocardium). Some affected people have no noticeable symptoms of the condition. When present, signs and symptoms may include chest pain, abnormal heartbeat, shortness of breath, fatigue, signs of infection (i.e. fever, headache, sore throat, diarrhea), and leg swelling. Myocarditis can be caused by a variety of factors including infections (viral, bacterial, parasitic, and fungal), allergic reactions to certain medications, and exposure to certain chemicals. It can also be associated with other inflammatory conditions such as lupus, Wegener's granulomatosis, giant cell arteritis and Takayasu's arteritis. Most cases occur sporadically in people with no family history of the condition. Treatment aims to address the underlying cause of the condition. Medications and rarely, a heart transplant may be needed if the heart muscle becomes weak.",
-              "equivalent_curies": [
-                "MESH:D009205",
-                "MEDDRA:10028613",
-                "HP:0012819",
-                "DOID:820",
-                "KEGG.DISEASE:05416",
-                "UMLS:C0027059",
-                "MEDDRA:10028606",
-                "ICD9:429.0",
-                "SYMP:0000095",
-                "SNOMEDCT:50920009",
-                "EFO:0009609",
-                "NCIT:C34831",
-                "MEDDRA:10028619",
-                "MONDO:0004496",
-                "ICD10:I51.4"
-              ],
-              "id": "MONDO:0004496",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myocarditis",
-                "Myocarditis, unspecified",
-                "myocarditis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/myocarditis",
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:21304213",
-                "PMID:22361396",
-                "https://rarediseases.info.nih.gov/diseases/7137/myocarditis",
-                "PMID:22185868",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22071898,
-            "start": 570,
-            "end": 314697,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32928810': {'publication date': '2020 Sep 14', 'sentence': 'Patient underwent treatment with milrinone and methylprednisolone that showed reduction in myocardial inflammation and significantly improved myocardial contractility.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0027059---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "22495910",
-              "object": "MONDO:0004496",
-              "publications": [
-                "PMID:32928810"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322010,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005336",
-          "name": "myopathy",
-          "description": "A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. [HPO:probinson]; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C101216",
-            "MEDDRA:10028641",
-            "MEDDRA:10028640",
-            "MEDDRA:10028300",
-            "MEDDRA:10028649",
-            "ICD10:G72.9",
-            "MEDDRA:10028302",
-            "MEDDRA:10028301",
-            "SNOMEDCT:129565002",
-            "ICD9:359.9",
-            "HP:0003198",
-            "EFO:0004145",
-            "DOID:423",
-            "MONDO:0005336",
-            "UMLS:C0026848",
-            "MESH:D009135",
-            "MEDDRA:10013237"
-          ],
-          "id": "MONDO:0005336",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myopathy, unspecified",
-            "Myopathy",
-            "myopathy",
-            "Muscular Diseases"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/myopathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322010,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005336",
-              "name": "myopathy",
-              "description": "A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. [HPO:probinson]; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C101216",
-                "MEDDRA:10028641",
-                "MEDDRA:10028640",
-                "MEDDRA:10028300",
-                "MEDDRA:10028649",
-                "ICD10:G72.9",
-                "MEDDRA:10028302",
-                "MEDDRA:10028301",
-                "SNOMEDCT:129565002",
-                "ICD9:359.9",
-                "HP:0003198",
-                "EFO:0004145",
-                "DOID:423",
-                "MONDO:0005336",
-                "UMLS:C0026848",
-                "MESH:D009135",
-                "MEDDRA:10013237"
-              ],
-              "id": "MONDO:0005336",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myopathy, unspecified",
-                "Myopathy",
-                "myopathy",
-                "Muscular Diseases"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/myopathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21754545,
-            "start": 570,
-            "end": 322010,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32563494': {'publication date': '2020 Aug', 'sentence': 'Neurologically, the therapeutic dosages of anticoagulants are linked to the high incidence of thrombotic complexities, while methylprednisolone is associated with myopathy.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0026848---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "22175056",
-              "object": "MONDO:0005336",
-              "publications": [
-                "PMID:32563494"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20475120,
-            "start": 570,
-            "end": 316891,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30787634': {'publication date': '2019', 'sentence': 'Conclusion: Based on the current data, the efficacy and safety of local injection of triamcinolone and methylprednisolone at doses of 20 and 40 mg were associated with a significant improvement in pain, functional status, and strength.', 'subject score': 1000, 'object score': 1000}, 'PMID:32701926': {'publication date': '2020 Jul 23', 'sentence': 'RESULTS: Methylprednisolone revealed no significant differences in pain, trismus and QoL compared with placebo.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "20879022",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:30787634",
-                "PMID:32701926"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 876033,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005284",
-          "name": "chronic progressive multiple sclerosis",
-          "description": "A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)",
-          "equivalent_curies": [
-            "MEDDRA:10053395",
-            "SNOMEDCT:230373008",
-            "MONDO:0005284",
-            "MESH:D020528",
-            "EFO:0003840",
-            "SNOMEDCT:816984002",
-            "UMLS:C0393665"
-          ],
-          "id": "MONDO:0005284",
-          "category": "biolink:Disease",
-          "all_names": [
-            "chronic progressive multiple sclerosis",
-            "Multiple Sclerosis, Chronic Progressive"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 876033,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005284",
-              "name": "chronic progressive multiple sclerosis",
-              "description": "A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)",
-              "equivalent_curies": [
-                "MEDDRA:10053395",
-                "SNOMEDCT:230373008",
-                "MONDO:0005284",
-                "MESH:D020528",
-                "EFO:0003840",
-                "SNOMEDCT:816984002",
-                "UMLS:C0393665"
-              ],
-              "id": "MONDO:0005284",
-              "category": "biolink:Disease",
-              "all_names": [
-                "chronic progressive multiple sclerosis",
-                "Multiple Sclerosis, Chronic Progressive"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19946128,
-            "start": 570,
-            "end": 876033,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29775134': {'publication date': '2018 May 01', 'sentence': 'OBJECTIVE: To validate the responsiveness of cerebrospinal fluid (CSF) inflammatory biomarkers to treatment with natalizumab and methylprednisolone in progressive MS and to examine the relationship between CSF inflammatory and tissue damage biomarkers.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0393665---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "20342058",
-              "object": "MONDO:0005284",
-              "publications": [
-                "PMID:29775134"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316993,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005376",
-          "name": "membranous glomerulonephritis",
-          "description": "A slowly progressive inflammation of the glomeruli characterized by immune complex deposits at the glomerular basement membrane, resulting in a thickened membrane, and nephrotic syndrome.; An experimental rat model of human membranous nephropathy characterized by complement activation and formation of subepithelial immune deposits in the glomerular capillary wall.; A type of glomerulonephropathy characterized by thickening of the basement membrane and deposition of immune complexes in the subepithelial space. [Eurenomics:fschaefer]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005376",
-            "HP:0012578",
-            "UMLS:C0017665",
-            "DOID:10976",
-            "MESH:D015433",
-            "SNOMEDCT:77182004",
-            "MEDDRA:10018372",
-            "MEDDRA:10027170",
-            "ICD10:N03.2",
-            "NCIT:C34645",
-            "EFO:0004254"
-          ],
-          "id": "MONDO:0005376",
-          "category": "biolink:Disease",
-          "all_names": [
-            "membranous glomerulonephritis",
-            "Glomerulonephritis, Membranous",
-            "Membranous Glomerulonephritis",
-            "Membranous nephropathy",
-            "Membranous glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316993,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005376",
-              "name": "membranous glomerulonephritis",
-              "description": "A slowly progressive inflammation of the glomeruli characterized by immune complex deposits at the glomerular basement membrane, resulting in a thickened membrane, and nephrotic syndrome.; An experimental rat model of human membranous nephropathy characterized by complement activation and formation of subepithelial immune deposits in the glomerular capillary wall.; A type of glomerulonephropathy characterized by thickening of the basement membrane and deposition of immune complexes in the subepithelial space. [Eurenomics:fschaefer]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005376",
-                "HP:0012578",
-                "UMLS:C0017665",
-                "DOID:10976",
-                "MESH:D015433",
-                "SNOMEDCT:77182004",
-                "MEDDRA:10018372",
-                "MEDDRA:10027170",
-                "ICD10:N03.2",
-                "NCIT:C34645",
-                "EFO:0004254"
-              ],
-              "id": "MONDO:0005376",
-              "category": "biolink:Disease",
-              "all_names": [
-                "membranous glomerulonephritis",
-                "Glomerulonephritis, Membranous",
-                "Membranous Glomerulonephritis",
-                "Membranous nephropathy",
-                "Membranous glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19887919,
-            "start": 570,
-            "end": 316993,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29679356': {'publication date': '2018 Dec', 'sentence': 'The region was identified as a significant predictor of use of intravenous methylprednisolone in MCD and MN patients.', 'subject score': 888, 'object score': 901}, 'PMID:8544420': {'publication date': '1995 Nov', 'sentence': 'A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0017665---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "20290784",
-              "object": "MONDO:0005376",
-              "publications": [
-                "PMID:29679356",
-                "PMID:8544420"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 529953,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019100",
-          "name": "neuromyelitis optica",
-          "description": "An autoimmune inflammatory syndrome characterized by optic neuritis and myelitis. Signs and symptoms include loss of vision, weakness and paralysis of the extremities, and loss of sensation.; A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10058009",
-            "MEDDRA:10077875",
-            "NCIT:C84934",
-            "MEDDRA:10052887",
-            "SNOMEDCT:25044007",
-            "MEDDRA:10029322",
-            "MEDDRA:10041225",
-            "MESH:D009471",
-            "DOID:8869",
-            "MEDDRA:10012574",
-            "ICD9:341.0",
-            "UMLS:C0027873",
-            "UMLS:C0221059",
-            "MONDO:0019100",
-            "EFO:0004256",
-            "ICD10:G36.0",
-            "ORPHANET:71211"
-          ],
-          "id": "MONDO:0019100",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neuromyelitis Optica",
-            "Neuromyelitis optica",
-            "neuromyelitis optica"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/neuromyelitis_optica",
-            "http://rarediseases.org/rare-diseases/neuromyelitis-optica/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 529953,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019100",
-              "name": "neuromyelitis optica",
-              "description": "An autoimmune inflammatory syndrome characterized by optic neuritis and myelitis. Signs and symptoms include loss of vision, weakness and paralysis of the extremities, and loss of sensation.; A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10058009",
-                "MEDDRA:10077875",
-                "NCIT:C84934",
-                "MEDDRA:10052887",
-                "SNOMEDCT:25044007",
-                "MEDDRA:10029322",
-                "MEDDRA:10041225",
-                "MESH:D009471",
-                "DOID:8869",
-                "MEDDRA:10012574",
-                "ICD9:341.0",
-                "UMLS:C0027873",
-                "UMLS:C0221059",
-                "MONDO:0019100",
-                "EFO:0004256",
-                "ICD10:G36.0",
-                "ORPHANET:71211"
-              ],
-              "id": "MONDO:0019100",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neuromyelitis Optica",
-                "Neuromyelitis optica",
-                "neuromyelitis optica"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/neuromyelitis_optica",
-                "http://rarediseases.org/rare-diseases/neuromyelitis-optica/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19879668,
-            "start": 570,
-            "end": 529953,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29671675': {'publication date': '2018 Oct', 'sentence': 'Clinical commentary on \"Two cases of anaphylactic shock by methylprednisolone in neuromyelitis optica\".', 'subject score': 1000, 'object score': 1000}, 'PMID:29671689': {'publication date': '2018 Oct', 'sentence': 'Two cases of anaphylactic shock by methylprednisolone in neuromyelitis optica.', 'subject score': 1000, 'object score': 1000}, 'PMID:33037886': {'publication date': '2021 Dec', 'sentence': 'We performed a systematic review to evaluate whether therapeutic plasma exchange (TPE) is better than conventional intravenous methylprednisolone (IVMP) in neuromyelitis optica spectrum disorders (NMOSD) patients.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0027873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "20286711",
-              "object": "MONDO:0019100",
-              "publications": [
-                "PMID:29671675",
-                "PMID:29671689",
-                "PMID:33037886"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 324986,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-          "name": "chronic obstructive pulmonary disease",
-          "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-          "equivalent_curies": [
-            "MESH:D029424",
-            "MEDDRA:10010952",
-            "MEDDRA:10009025",
-            "ICD10:J44.9",
-            "UMLS:C1527303",
-            "NCIT:C3199",
-            "UMLS:C0024117",
-            "MEDDRA:10064611",
-            "MEDDRA:10009026",
-            "MEDDRA:10029972",
-            "DOID:3083",
-            "MONDO:0005002",
-            "MEDDRA:10009032",
-            "MEDDRA:10070975",
-            "EFO:0000341",
-            "SNOMEDCT:13645005",
-            "MEDDRA:10009033",
-            "HP:0006510",
-            "MEDDRA:10008828"
-          ],
-          "id": "MONDO:0005002",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic Obstructive Pulmonary Disease",
-            "chronic obstructive pulmonary disease",
-            "Chronic pulmonary obstruction",
-            "Chronic Airflow Obstruction",
-            "Chronic Obstructive Airway Disease",
-            "Pulmonary Disease, Chronic Obstructive"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health-topics/copd",
-            "PMID:32800196",
-            "PMID:28513453",
-            "PMID:25943942",
-            "PMID:32745458"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 324986,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-              "name": "chronic obstructive pulmonary disease",
-              "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-              "equivalent_curies": [
-                "MESH:D029424",
-                "MEDDRA:10010952",
-                "MEDDRA:10009025",
-                "ICD10:J44.9",
-                "UMLS:C1527303",
-                "NCIT:C3199",
-                "UMLS:C0024117",
-                "MEDDRA:10064611",
-                "MEDDRA:10009026",
-                "MEDDRA:10029972",
-                "DOID:3083",
-                "MONDO:0005002",
-                "MEDDRA:10009032",
-                "MEDDRA:10070975",
-                "EFO:0000341",
-                "SNOMEDCT:13645005",
-                "MEDDRA:10009033",
-                "HP:0006510",
-                "MEDDRA:10008828"
-              ],
-              "id": "MONDO:0005002",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic Obstructive Pulmonary Disease",
-                "chronic obstructive pulmonary disease",
-                "Chronic pulmonary obstruction",
-                "Chronic Airflow Obstruction",
-                "Chronic Obstructive Airway Disease",
-                "Pulmonary Disease, Chronic Obstructive"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health-topics/copd",
-                "PMID:32800196",
-                "PMID:28513453",
-                "PMID:25943942",
-                "PMID:32745458"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18959476,
-            "start": 570,
-            "end": 324986,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27888990': {'publication date': '2016 12', 'sentence': 'CONCLUSION: Results show that inhalation of budesonide (2 mg 3 times/day) and systemic methylprednisolone (40 mg/day) had similar clinical outcome in AECOPD.', 'subject score': 888, 'object score': 833}, 'PMID:31308569': {'publication date': '2019 Jul', 'sentence': 'Single Intramuscular Methylprednisolone dose in Asthma and Chronic Obstructive Pulmonary Disease Patients on Discharge.', 'subject score': 833, 'object score': 928}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0024117---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "19340184",
-              "object": "MONDO:0005002",
-              "publications": [
-                "PMID:27888990",
-                "PMID:31308569"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 520401,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0013730",
-          "name": "graft versus host disease",
-          "description": "A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.; The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PDQ:CDR0000041575",
-            "NCIT:C3063",
-            "MEDDRA:10018798",
-            "UMLS:C0018133",
-            "MESH:D006086",
-            "DOID:0081267",
-            "MONDO:0013730",
-            "MEDDRA:10018799",
-            "SNOMEDCT:234646005",
-            "ICD9:279.5",
-            "ORPHANET:39812",
-            "MEDDRA:10018651"
-          ],
-          "id": "MONDO:0013730",
-          "category": "biolink:Disease",
-          "all_names": [
-            "graft versus host disease",
-            "graft-versus-host disease",
-            "Graft-versus-host disease",
-            "Graft Versus Host Disease",
-            "Graft versus host disease",
-            "Graft-vs-Host Disease",
-            "Graft vs Host Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:31466596",
-            "https://www.ncbi.nlm.nih.gov/books/nbk538235/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520401,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0013730",
-              "name": "graft versus host disease",
-              "description": "A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.; The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PDQ:CDR0000041575",
-                "NCIT:C3063",
-                "MEDDRA:10018798",
-                "UMLS:C0018133",
-                "MESH:D006086",
-                "DOID:0081267",
-                "MONDO:0013730",
-                "MEDDRA:10018799",
-                "SNOMEDCT:234646005",
-                "ICD9:279.5",
-                "ORPHANET:39812",
-                "MEDDRA:10018651"
-              ],
-              "id": "MONDO:0013730",
-              "category": "biolink:Disease",
-              "all_names": [
-                "graft versus host disease",
-                "graft-versus-host disease",
-                "Graft-versus-host disease",
-                "Graft Versus Host Disease",
-                "Graft versus host disease",
-                "Graft-vs-Host Disease",
-                "Graft vs Host Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:31466596",
-                "https://www.ncbi.nlm.nih.gov/books/nbk538235/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18564187,
-            "start": 570,
-            "end": 520401,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27086024': {'publication date': '2016 07', 'sentence': 'A Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host Disease.', 'subject score': 1000, 'object score': 928}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0018133---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "18938435",
-              "object": "MONDO:0013730",
-              "publications": [
-                "PMID:27086024"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16984564,
-            "start": 570,
-            "end": 183319,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24332587': {'publication date': '2014 May', 'sentence': 'The purpose of this study was to evaluate the efficacy of supraperiosteal injection of methylprednisolone compared with an oral tablet form and intravenous (i.v.) injection in the prevention of postoperative pain and oedema associated with inflammation.', 'subject score': 1000, 'object score': 1000}, 'PMID:24481505': {'publication date': '2014 Sep-Oct', 'sentence': 'After initial treatment with pulsed intravenous methylprednisolone, followed by rituximab and radiotherapy, there was a marked improvement in orbital inflammation and clinical and radiological improvement in the compressive optic neuropathy.', 'subject score': 840, 'object score': 888}, 'PMID:24692123': {'publication date': '2014 Apr 28', 'sentence': 'Glutathione PEGylated liposomal methylprednisolone (2B3-201) has been developed as treatment for neuroinflammatory conditions and was evaluated in ocular inflammation.', 'subject score': 775, 'object score': 888}, 'PMID:2472021': {'publication date': '1989 Jun 16', 'sentence': 'Methylprednisolone and uridine were both examined in this model due to their roles in inflammation and RNA synthesis, respectively.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "17333962",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:24332587",
-                "PMID:24481505",
-                "PMID:24692123",
-                "PMID:2472021"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316028,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008558",
-          "name": "autoimmune thrombocytopenic purpura",
-          "description": "Acquired thrombocytopenia of unknown cause, characterized by immune-mediated destruction of normal platelets. It affects both children and adults. It manifests with petechiae, purpura, and overt bleeding. Based upon the duration of the disease, it is classified as newly diagnosed (from diagnosis until 3 months), persistent (3-12 months), and chronic (lasting for more than 12 months).; Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.; The presence of thrombocytopenia in combination with detection of antiplatelet antibodies. [DDD:wouwehand]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021245",
-            "UMLS:C0398650",
-            "ORPHANET:3002",
-            "MESH:D016553",
-            "ICD9:287.31",
-            "MEDDRA:10083843",
-            "MEDDRA:10051064",
-            "MONDO:0008558",
-            "MEDDRA:10074667",
-            "OMIM:188030",
-            "DOID:8924",
-            "MEDDRA:10021243",
-            "ICD10:D69.3",
-            "EFO:0007160",
-            "NCIT:C3446"
-          ],
-          "id": "MONDO:0008558",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Purpura, Thrombocytopenic, Idiopathic",
-            "Immune thrombocytopenic purpura",
-            "Primary Immune Thrombocytopenia",
-            "Thrombocytopenic purpura, autoimmune related phenotypic feature",
-            "autoimmune thrombocytopenic purpura"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://rarediseases.org/rare-diseases/immune-thrombocytopenia/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316028,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008558",
-              "name": "autoimmune thrombocytopenic purpura",
-              "description": "Acquired thrombocytopenia of unknown cause, characterized by immune-mediated destruction of normal platelets. It affects both children and adults. It manifests with petechiae, purpura, and overt bleeding. Based upon the duration of the disease, it is classified as newly diagnosed (from diagnosis until 3 months), persistent (3-12 months), and chronic (lasting for more than 12 months).; Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.; The presence of thrombocytopenia in combination with detection of antiplatelet antibodies. [DDD:wouwehand]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021245",
-                "UMLS:C0398650",
-                "ORPHANET:3002",
-                "MESH:D016553",
-                "ICD9:287.31",
-                "MEDDRA:10083843",
-                "MEDDRA:10051064",
-                "MONDO:0008558",
-                "MEDDRA:10074667",
-                "OMIM:188030",
-                "DOID:8924",
-                "MEDDRA:10021243",
-                "ICD10:D69.3",
-                "EFO:0007160",
-                "NCIT:C3446"
-              ],
-              "id": "MONDO:0008558",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Purpura, Thrombocytopenic, Idiopathic",
-                "Immune thrombocytopenic purpura",
-                "Primary Immune Thrombocytopenia",
-                "Thrombocytopenic purpura, autoimmune related phenotypic feature",
-                "autoimmune thrombocytopenic purpura"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://rarediseases.org/rare-diseases/immune-thrombocytopenia/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16936772,
-            "start": 570,
-            "end": 316028,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2426114': {'publication date': '1986 Apr', 'sentence': 'Gamma globulin and methylprednisolone in idiopathic thrombocytopenic purpura.', 'subject score': 1000, 'object score': 1000}, 'PMID:3132807': {'publication date': '1988', 'sentence': 'Methylprednisolone in childhood idiopathic thrombocytopenic purpura.', 'subject score': 1000, 'object score': 916}, 'PMID:3443515': {'publication date': '1987 Aug', 'sentence': 'Intravenous pulse methylprednisolone in chronic ITP.', 'subject score': 802, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0398650---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "17288506",
-              "object": "MONDO:0008558",
-              "publications": [
-                "PMID:2426114",
-                "PMID:3132807",
-                "PMID:3443515"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 526461,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001509",
-          "name": "endocrine exophthalmos",
-          "description": "An autoimmune disorder of the EYE, occurring in patients with Graves disease. Subtypes include congestive (inflammation of the orbital connective tissue), myopathic (swelling and dysfunction of the extraocular muscles), and mixed congestive-myopathic ophthalmopathy.",
-          "equivalent_curies": [
-            "DOID:0081120",
-            "SNOMEDCT:276177000",
-            "ICD9:376.2",
-            "MESH:D049970",
-            "UMLS:C0339143",
-            "MONDO:0001509",
-            "MEDDRA:10084358",
-            "UMLS:C0155264",
-            "DOID:12359",
-            "MEDDRA:10014702",
-            "MEDDRA:10057889",
-            "MEDDRA:10060742",
-            "MEDDRA:10015684",
-            "EFO:1001466"
-          ],
-          "id": "MONDO:0001509",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Graves ophthalmopathy",
-            "Endocrine exophthalmos",
-            "Thyroid associated opthalmopathies",
-            "endocrine exophthalmos",
-            "Graves Ophthalmopathy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:20181974",
-            "https://orcid.org/0000-0001-7151-1615",
-            "https://en.wikipedia.org/wiki/graves%27_ophthalmopathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526461,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001509",
-              "name": "endocrine exophthalmos",
-              "description": "An autoimmune disorder of the EYE, occurring in patients with Graves disease. Subtypes include congestive (inflammation of the orbital connective tissue), myopathic (swelling and dysfunction of the extraocular muscles), and mixed congestive-myopathic ophthalmopathy.",
-              "equivalent_curies": [
-                "DOID:0081120",
-                "SNOMEDCT:276177000",
-                "ICD9:376.2",
-                "MESH:D049970",
-                "UMLS:C0339143",
-                "MONDO:0001509",
-                "MEDDRA:10084358",
-                "UMLS:C0155264",
-                "DOID:12359",
-                "MEDDRA:10014702",
-                "MEDDRA:10057889",
-                "MEDDRA:10060742",
-                "MEDDRA:10015684",
-                "EFO:1001466"
-              ],
-              "id": "MONDO:0001509",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Graves ophthalmopathy",
-                "Endocrine exophthalmos",
-                "Thyroid associated opthalmopathies",
-                "endocrine exophthalmos",
-                "Graves Ophthalmopathy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:20181974",
-                "https://orcid.org/0000-0001-7151-1615",
-                "https://en.wikipedia.org/wiki/graves%27_ophthalmopathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15609821,
-            "start": 570,
-            "end": 526461,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22029719': {'publication date': '2012 Jan', 'sentence': \"Methylprednisolone and hepatotoxicity in Graves' ophthalmopathy.\", 'subject score': 1000, 'object score': 1000}, 'PMID:30540214': {'publication date': '2019 Oct', 'sentence': 'Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease.', 'subject score': 840, 'object score': 875}, 'PMID:37176682': {'publication date': '2023 May 01', 'sentence': 'Efficacy and Safety of 6-Weekly versus 12-Weekly Intravenous Methylprednisolone in Moderate-to-Severe Active Thyroid-Associated Ophthalmopathy.', 'subject score': 775, 'object score': 863}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0339143---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "15936572",
-              "object": "MONDO:0001509",
-              "publications": [
-                "PMID:22029719",
-                "PMID:30540214",
-                "PMID:37176682"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 313324,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-          "name": "Edema",
-          "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MEDDRA:10030114",
-            "MEDDRA:10014234",
-            "MEDDRA:10014210",
-            "MEDDRA:10005890",
-            "HP:0000969",
-            "SNOMEDCT:267038008",
-            "SNOMEDCT:43498006",
-            "SNOMEDCT:79654002",
-            "MESH:D004487",
-            "UMLS:C0013604",
-            "MEDDRA:10016807",
-            "EFO:0009373",
-            "SNOMEDCT:423666004",
-            "UMLS:C0268000",
-            "NCIT:C3002",
-            "MEDDRA:10030095",
-            "SNOMEDCT:20741006",
-            "SYMP:0000538"
-          ],
-          "id": "HP:0000969",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Edema",
-            "Body fluid retention",
-            "edema"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313324,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-              "name": "Edema",
-              "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MEDDRA:10030114",
-                "MEDDRA:10014234",
-                "MEDDRA:10014210",
-                "MEDDRA:10005890",
-                "HP:0000969",
-                "SNOMEDCT:267038008",
-                "SNOMEDCT:43498006",
-                "SNOMEDCT:79654002",
-                "MESH:D004487",
-                "UMLS:C0013604",
-                "MEDDRA:10016807",
-                "EFO:0009373",
-                "SNOMEDCT:423666004",
-                "UMLS:C0268000",
-                "NCIT:C3002",
-                "MEDDRA:10030095",
-                "SNOMEDCT:20741006",
-                "SYMP:0000538"
-              ],
-              "id": "HP:0000969",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Edema",
-                "Body fluid retention",
-                "edema"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14760549,
-            "start": 570,
-            "end": 313324,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20591548': {'publication date': '2010 Sep', 'sentence': 'In orthognathic surgery, methylprednisolone > or =85 mg administered intravenously seemed sufficient to produce a significant decrease in edema, and several trials pointed toward a neuroregeneration effect, but no statistical analysis could be performed.', 'subject score': 1000, 'object score': 1000}, 'PMID:3304412': {'publication date': '1987 Aug', 'sentence': 'The influence of methylprednisolone on post-operative swelling following oral surgery.', 'subject score': 1000, 'object score': 802}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0013604---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "15072844",
-              "object": "HP:0000969",
-              "publications": [
-                "PMID:20591548",
-                "PMID:3304412"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319030,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319030,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14567812,
-            "start": 570,
-            "end": 319030,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20219784': {'publication date': '2010 Jun', 'sentence': 'Response of symptoms and synovitis to intra-muscular methylprednisolone in osteoarthritis of the hand: an ultrasonographic study.', 'subject score': 851, 'object score': 1000}, 'PMID:6586148': {'publication date': '1983 Dec', 'sentence': 'Plasma concentrations of methylprednisolone following intra-articular injection were measured in rheumatoid arthritis and osteoarthritis patients.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14876749",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:20219784",
-                "PMID:6586148"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 315782,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
-          "name": "aplastic anemia",
-          "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What causes aplastic anemia? The causes of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0015909",
-            "MEDDRA:10002037",
-            "HP:0001915",
-            "MEDDRA:10002967",
-            "MEDDRA:10002274",
-            "MEDDRA:10002969",
-            "MESH:D000741",
-            "SNOMEDCT:306058006",
-            "PDQ:CDR0000489004",
-            "NCIT:C2870",
-            "MEDDRA:10002968",
-            "DOID:12449",
-            "MEDDRA:10002970",
-            "ICD9:284.9",
-            "SNOMEDCT:304132006",
-            "UMLS:C0002874",
-            "ICD10:D61.9",
-            "ORPHANET:182040"
-          ],
-          "id": "MONDO:0015909",
-          "category": "biolink:Disease",
-          "all_names": [
-            "aplastic anemia",
-            "Aplastic Anemia",
-            "Aplastic anemia",
-            "Aplastic anemia, unspecified",
-            "obsolete_Medullar aplasia",
-            "Anemia, Aplastic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
-            "http://en.wikipedia.org/wiki/aplastic_anemia",
-            "PMID:21239768",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315782,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
-              "name": "aplastic anemia",
-              "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What causes aplastic anemia? The causes of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0015909",
-                "MEDDRA:10002037",
-                "HP:0001915",
-                "MEDDRA:10002967",
-                "MEDDRA:10002274",
-                "MEDDRA:10002969",
-                "MESH:D000741",
-                "SNOMEDCT:306058006",
-                "PDQ:CDR0000489004",
-                "NCIT:C2870",
-                "MEDDRA:10002968",
-                "DOID:12449",
-                "MEDDRA:10002970",
-                "ICD9:284.9",
-                "SNOMEDCT:304132006",
-                "UMLS:C0002874",
-                "ICD10:D61.9",
-                "ORPHANET:182040"
-              ],
-              "id": "MONDO:0015909",
-              "category": "biolink:Disease",
-              "all_names": [
-                "aplastic anemia",
-                "Aplastic Anemia",
-                "Aplastic anemia",
-                "Aplastic anemia, unspecified",
-                "obsolete_Medullar aplasia",
-                "Anemia, Aplastic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
-                "http://en.wikipedia.org/wiki/aplastic_anemia",
-                "PMID:21239768",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14098746,
-            "start": 570,
-            "end": 315782,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1947472': {'publication date': '1991', 'sentence': 'Long-term results of high-dose methylprednisolone in aplastic anemia.', 'subject score': 901, 'object score': 1000}, 'PMID:3573329': {'publication date': '1987 Jan', 'sentence': '[Therapeutic results of high-dose bolus methylprednisolone and prediction of response by in vitro tests in aplastic anemia].', 'subject score': 824, 'object score': 1000}, 'PMID:8984042': {'publication date': '1995 Oct', 'sentence': 'This observation is in stark contrast with previous trials on use of HDMP in SAA.', 'subject score': 901, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0002874---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14399082",
-              "object": "MONDO:0015909",
-              "publications": [
-                "PMID:1947472",
-                "PMID:3573329",
-                "PMID:8984042"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 311688,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005342",
-          "name": "IgA glomerulonephritis",
-          "description": "Inflammation of a specific segment of glomeruli within the kidney.; A chronic autoimmune glomerulonephritis characterized by the deposition of immunoglobulin A in the mesangium of the glomeruli. It is manifested with hematuria and mild proteinuria.; A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.; The presence of immunoglobulin A deposits in the glomerulus. [Eurenomics:ewuehl]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C34643",
-            "OMIM.PS:161950",
-            "MEDDRA:10018369",
-            "NCIT:C35280",
-            "UMLS:C0017661",
-            "MESH:D005922",
-            "EFO:0004194",
-            "UMLS:C3161650",
-            "SNOMEDCT:68779003",
-            "HP:0000794",
-            "DOID:2986",
-            "SNOMEDCT:236407003",
-            "MEDDRA:10069341",
-            "ORPHANET:34145",
-            "UMLS:C4025827",
-            "MONDO:0005342",
-            "MEDDRA:10021263"
-          ],
-          "id": "MONDO:0005342",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Glomerulonephritis, IGA",
-            "IGA Glomerulonephritis",
-            "IGA glomerulonephritis",
-            "IgA glomerulonephritis",
-            "IgA Nephropathy",
-            "Primary immunoglobulin A nephropathy (disorder)",
-            "IgA deposition in the glomerulus",
-            "Focal Glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000466.htm",
-            "http://en.wikipedia.org/wiki/iga_nephropathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311688,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005342",
-              "name": "IgA glomerulonephritis",
-              "description": "Inflammation of a specific segment of glomeruli within the kidney.; A chronic autoimmune glomerulonephritis characterized by the deposition of immunoglobulin A in the mesangium of the glomeruli. It is manifested with hematuria and mild proteinuria.; A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.; The presence of immunoglobulin A deposits in the glomerulus. [Eurenomics:ewuehl]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C34643",
-                "OMIM.PS:161950",
-                "MEDDRA:10018369",
-                "NCIT:C35280",
-                "UMLS:C0017661",
-                "MESH:D005922",
-                "EFO:0004194",
-                "UMLS:C3161650",
-                "SNOMEDCT:68779003",
-                "HP:0000794",
-                "DOID:2986",
-                "SNOMEDCT:236407003",
-                "MEDDRA:10069341",
-                "ORPHANET:34145",
-                "UMLS:C4025827",
-                "MONDO:0005342",
-                "MEDDRA:10021263"
-              ],
-              "id": "MONDO:0005342",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Glomerulonephritis, IGA",
-                "IGA Glomerulonephritis",
-                "IGA glomerulonephritis",
-                "IgA glomerulonephritis",
-                "IgA Nephropathy",
-                "Primary immunoglobulin A nephropathy (disorder)",
-                "IgA deposition in the glomerulus",
-                "Focal Glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000466.htm",
-                "http://en.wikipedia.org/wiki/iga_nephropathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14097907,
-            "start": 570,
-            "end": 311688,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19473630': {'publication date': '2009 Jun', 'sentence': 'Efficacy of methylprednisolone, cyclophosphamide in pediatric IgA nephropathy assessed by renal biopsy.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0017661---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14398237",
-              "object": "MONDO:0005342",
-              "publications": [
-                "PMID:19473630"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320151,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-          "name": "dermatitis, atopic",
-          "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MESH:C566404",
-            "MEDDRA:10012434",
-            "SNOMEDCT:24079001",
-            "MONDO:0011292",
-            "MEDDRA:10003641",
-            "MONDO:0100181",
-            "MEDDRA:10014191",
-            "OMIM:603165",
-            "HP:0001047",
-            "MEDDRA:10001711",
-            "MEDDRA:10003639",
-            "UMLS:C0011615",
-            "UMLS:C4280605",
-            "UMLS:C1864155",
-            "MEDDRA:10012438",
-            "MEDDRA:10014188",
-            "MEDDRA:10001712",
-            "MESH:D003876",
-            "SNOMEDCT:200775004"
-          ],
-          "id": "MONDO:0011292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis, Atopic, 1",
-            "dermatitis, atopic",
-            "Dermatitis, Atopic",
-            "Baby eczema",
-            "Dermatitis, atopic related phenotypic feature",
-            "Atopic dermatitis",
-            "dermatitis, atopic, 1"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:27904186",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320151,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-              "name": "dermatitis, atopic",
-              "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MESH:C566404",
-                "MEDDRA:10012434",
-                "SNOMEDCT:24079001",
-                "MONDO:0011292",
-                "MEDDRA:10003641",
-                "MONDO:0100181",
-                "MEDDRA:10014191",
-                "OMIM:603165",
-                "HP:0001047",
-                "MEDDRA:10001711",
-                "MEDDRA:10003639",
-                "UMLS:C0011615",
-                "UMLS:C4280605",
-                "UMLS:C1864155",
-                "MEDDRA:10012438",
-                "MEDDRA:10014188",
-                "MEDDRA:10001712",
-                "MESH:D003876",
-                "SNOMEDCT:200775004"
-              ],
-              "id": "MONDO:0011292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis, Atopic, 1",
-                "dermatitis, atopic",
-                "Dermatitis, Atopic",
-                "Baby eczema",
-                "Dermatitis, atopic related phenotypic feature",
-                "Atopic dermatitis",
-                "dermatitis, atopic, 1"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:27904186",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13979810,
-            "start": 570,
-            "end": 320151,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1929552': {'publication date': '1991', 'sentence': 'The impaired effect on lymphocyte blastogenesis of glucocorticoids administered in vivo, in contrast to a normal in vitro reaction to dexamethasone, together with recent findings of an altered glucocorticoid receptor pharmacology in AD, points to a decreased biological in vivo efficiency of methylprednisolone in atopic dermatitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0011615---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14278238",
-              "object": "MONDO:0011292",
-              "publications": [
-                "PMID:1929552"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318021,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000745",
-          "name": "cardiac arrest",
-          "description": "The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.; Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.; An abrupt loss of heart function. []; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:0060319",
-            "ICD10:I46",
-            "MEDDRA:10003109",
-            "UMLS:C0018790",
-            "HP:0001695",
-            "SNOMEDCT:410429000",
-            "MEDDRA:10082515",
-            "UMLS:C0444720",
-            "SNOMEDCT:397829000",
-            "MEDDRA:10003589",
-            "NCIT:C50479",
-            "PSY:07595",
-            "MEDDRA:10019249",
-            "SNOMEDCT:261195002",
-            "MEDDRA:10003587",
-            "MEDDRA:10047284",
-            "MESH:D006323",
-            "MONDO:0000745",
-            "MEDDRA:10041914",
-            "EFO:0009492",
-            "MEDDRA:10003586",
-            "MEDDRA:10007515",
-            "ICD9:427.5",
-            "MEDDRA:10047285"
-          ],
-          "id": "MONDO:0000745",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiac Arrest",
-            "cardiac arrest",
-            "Cardiac arrest",
-            "Heart Arrest"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/cardiacarrest.htm",
-            "http://en.wikipedia.org/wiki/cardiac_arrest",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318021,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000745",
-              "name": "cardiac arrest",
-              "description": "The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.; Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.; An abrupt loss of heart function. []; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:0060319",
-                "ICD10:I46",
-                "MEDDRA:10003109",
-                "UMLS:C0018790",
-                "HP:0001695",
-                "SNOMEDCT:410429000",
-                "MEDDRA:10082515",
-                "UMLS:C0444720",
-                "SNOMEDCT:397829000",
-                "MEDDRA:10003589",
-                "NCIT:C50479",
-                "PSY:07595",
-                "MEDDRA:10019249",
-                "SNOMEDCT:261195002",
-                "MEDDRA:10003587",
-                "MEDDRA:10047284",
-                "MESH:D006323",
-                "MONDO:0000745",
-                "MEDDRA:10041914",
-                "EFO:0009492",
-                "MEDDRA:10003586",
-                "MEDDRA:10007515",
-                "ICD9:427.5",
-                "MEDDRA:10047285"
-              ],
-              "id": "MONDO:0000745",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiac Arrest",
-                "cardiac arrest",
-                "Cardiac arrest",
-                "Heart Arrest"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/cardiacarrest.htm",
-                "http://en.wikipedia.org/wiki/cardiac_arrest",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13869973,
-            "start": 570,
-            "end": 318021,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19139319': {'publication date': '2009 Jan 12', 'sentence': 'CONCLUSION: In this single-center trial, combined vasopressin-epinephrine and methylprednisolone during resuscitation and stress-dose hydrocortisone in postresuscitation shock improved survival in refractory in-hospital cardiac arrest.', 'subject score': 1000, 'object score': 794}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0018790---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14166179",
-              "object": "MONDO:0000745",
-              "publications": [
-                "PMID:19139319"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 323988,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009693",
-          "name": "plasma cell myeloma",
-          "description": "A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3242\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3242\" NCI Thesaurus); A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001); A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.; A malignant plasma cell tumor growing within soft tissue or within the skeleton. [HPO:sdoelken]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10074470",
-            "MEDDRA:10028569",
-            "MEDDRA:10028228",
-            "MEDDRA:10035226",
-            "EFO:0001378",
-            "SNOMEDCT:55921005",
-            "MEDDRA:10034613",
-            "MESH:D009101",
-            "MEDDRA:10028568",
-            "MONDO:0009693",
-            "ICD9:203.0",
-            "HP:0006775",
-            "OMIM:254500",
-            "MEDDRA:10028566",
-            "ORPHANET:29073",
-            "SNOMEDCT:109989006",
-            "DOID:9538",
-            "ICD10:C90.0",
-            "UMLS:C0026764",
-            "PDQ:CDR0000042947",
-            "NCIT:C3242",
-            "SNOMEDCT:1162576007"
-          ],
-          "id": "MONDO:0009693",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Multiple myeloma",
-            "Multiple Myeloma",
-            "plasma cell myeloma",
-            "multiple myeloma",
-            "Myeloma, multiple related phenotypic feature",
-            "Plasma Cell Myeloma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=411384",
-            "http://en.wikipedia.org/wiki/multiple_myeloma",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323988,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009693",
-              "name": "plasma cell myeloma",
-              "description": "A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3242\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3242\" NCI Thesaurus); A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001); A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.; A malignant plasma cell tumor growing within soft tissue or within the skeleton. [HPO:sdoelken]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10074470",
-                "MEDDRA:10028569",
-                "MEDDRA:10028228",
-                "MEDDRA:10035226",
-                "EFO:0001378",
-                "SNOMEDCT:55921005",
-                "MEDDRA:10034613",
-                "MESH:D009101",
-                "MEDDRA:10028568",
-                "MONDO:0009693",
-                "ICD9:203.0",
-                "HP:0006775",
-                "OMIM:254500",
-                "MEDDRA:10028566",
-                "ORPHANET:29073",
-                "SNOMEDCT:109989006",
-                "DOID:9538",
-                "ICD10:C90.0",
-                "UMLS:C0026764",
-                "PDQ:CDR0000042947",
-                "NCIT:C3242",
-                "SNOMEDCT:1162576007"
-              ],
-              "id": "MONDO:0009693",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Multiple myeloma",
-                "Multiple Myeloma",
-                "plasma cell myeloma",
-                "multiple myeloma",
-                "Myeloma, multiple related phenotypic feature",
-                "Plasma Cell Myeloma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=411384",
-                "http://en.wikipedia.org/wiki/multiple_myeloma",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12473440,
-            "start": 570,
-            "end": 323988,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17026824': {'publication date': '2006 Sep', 'sentence': 'Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma.', 'subject score': 851, 'object score': 884}, 'PMID:7540069': {'publication date': '1995 Jun 15', 'sentence': 'The percentage of apoptotic cells after incubation in medium alone (spontaneous apoptosis) or in the presence of methylprednisolone (MP) or anti-Fas monoclonal antibody (triggered apoptosis) was significantly higher in MM and mainly restricted to HLA-DR+ T cells.', 'subject score': 1000, 'object score': 1000}, 'PMID:8033303': {'publication date': '1994', 'sentence': 'Bi-weekly vincristine, epirubicin and methylprednisolone in alkylator-refractory multiple myeloma.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0026764---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "12755316",
-              "object": "MONDO:0009693",
-              "publications": [
-                "PMID:17026824",
-                "PMID:7540069",
-                "PMID:8033303"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 323831,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-          "name": "acute lymphoblastic leukemia",
-          "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "HP:0006721",
-            "MONDO:0004967",
-            "MEDDRA:10000848",
-            "MEDDRA:10000849",
-            "MEDDRA:10025305",
-            "ORPHANET:513",
-            "MEDDRA:10025301",
-            "ICD10:C91.00",
-            "UMLS:C0023453",
-            "DOID:9952",
-            "MEDDRA:10000844",
-            "MEDDRA:10000846",
-            "MEDDRA:10000845",
-            "MEDDRA:10024338",
-            "ICD10:C91",
-            "MESH:D054198",
-            "UMLS:C1961102",
-            "MEDDRA:10060555",
-            "NCIT:C3167",
-            "PDQ:CDR0000043423",
-            "MEDDRA:10024290",
-            "MEDDRA:10000842",
-            "NCIT:C27281",
-            "ICD9:204",
-            "DOID:1037",
-            "MEDDRA:10000843",
-            "EFO:0000220",
-            "SNOMEDCT:128822004",
-            "ICD9:204.0",
-            "UMLS:C0023449",
-            "MEDDRA:10060390",
-            "SNOMEDCT:91857003"
-          ],
-          "id": "MONDO:0004967",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute lymphoblastic leukemia",
-            "lymphoid leukemia",
-            "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-            "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-            "L2 Acute Lymphoblastic Leukemia",
-            "acute lymphocytic leukemia",
-            "Lymphoid leukemia, acute",
-            "acute lymphoblastic leukemia",
-            "Acute lymphocytic leukemia",
-            "Acute Lymphoblastic Leukemia",
-            "Lymphoid leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=46332",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=616067",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323831,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-              "name": "acute lymphoblastic leukemia",
-              "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "HP:0006721",
-                "MONDO:0004967",
-                "MEDDRA:10000848",
-                "MEDDRA:10000849",
-                "MEDDRA:10025305",
-                "ORPHANET:513",
-                "MEDDRA:10025301",
-                "ICD10:C91.00",
-                "UMLS:C0023453",
-                "DOID:9952",
-                "MEDDRA:10000844",
-                "MEDDRA:10000846",
-                "MEDDRA:10000845",
-                "MEDDRA:10024338",
-                "ICD10:C91",
-                "MESH:D054198",
-                "UMLS:C1961102",
-                "MEDDRA:10060555",
-                "NCIT:C3167",
-                "PDQ:CDR0000043423",
-                "MEDDRA:10024290",
-                "MEDDRA:10000842",
-                "NCIT:C27281",
-                "ICD9:204",
-                "DOID:1037",
-                "MEDDRA:10000843",
-                "EFO:0000220",
-                "SNOMEDCT:128822004",
-                "ICD9:204.0",
-                "UMLS:C0023449",
-                "MEDDRA:10060390",
-                "SNOMEDCT:91857003"
-              ],
-              "id": "MONDO:0004967",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute lymphoblastic leukemia",
-                "lymphoid leukemia",
-                "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-                "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-                "L2 Acute Lymphoblastic Leukemia",
-                "acute lymphocytic leukemia",
-                "Lymphoid leukemia, acute",
-                "acute lymphoblastic leukemia",
-                "Acute lymphocytic leukemia",
-                "Acute Lymphoblastic Leukemia",
-                "Lymphoid leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=46332",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=616067",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11913110,
-            "start": 570,
-            "end": 323831,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16330449': {'publication date': '2005 Dec', 'sentence': 'Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.', 'subject score': 901, 'object score': 1000}, 'PMID:1734216': {'publication date': '1992', 'sentence': 'These results indicate high-dose methylprednisolone is an effective agent, particularly in the treatment of established central nervous system (CNS) disease and could contribute to early CNS directed therapy in acute lymphoblastic leukaemia.', 'subject score': 901, 'object score': 1000}, 'PMID:7532164': {'publication date': '1994', 'sentence': 'The effect of high-dose methylprednisolone combined chemotherapy on CD34-positive cells in acute lymphoblastic leukemia.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0023449---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "12183687",
-              "object": "MONDO:0004967",
-              "publications": [
-                "PMID:16330449",
-                "PMID:1734216",
-                "PMID:7532164"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319015,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-          "name": "systemic lupus erythematosus",
-          "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10025133",
-            "KEGG.DISEASE:05322",
-            "MEDDRA:10042820",
-            "PDQ:CDR0000608139",
-            "MEDDRA:10040967",
-            "MEDDRA:10042800",
-            "MEDDRA:10013446",
-            "MONDO:0007915",
-            "MEDDRA:10042945",
-            "MEDDRA:10024067",
-            "ICD10:M32.9",
-            "MEDDRA:10042947",
-            "ORPHANET:536",
-            "MEDDRA:10042944",
-            "UMLS:C0024141",
-            "EFO:0002690",
-            "MESH:D008180",
-            "ICD9:710.0",
-            "DOID:9074",
-            "MEDDRA:10025139",
-            "UMLS:C1835309",
-            "MEDDRA:10024065",
-            "OMIM:152700",
-            "HP:0002725",
-            "MEDDRA:10025142",
-            "NCIT:C3201",
-            "SNOMEDCT:55464009"
-          ],
-          "id": "MONDO:0007915",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Systemic lupus erythematosus",
-            "obsolete_systemic lupus erythematosus",
-            "Systemic lupus erythematosus related phenotypic feature",
-            "Lupus Erythematosus, Systemic",
-            "Excess lmw-dna",
-            "systemic lupus erythematosus",
-            "Systemic Lupus Erythematosus"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319015,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-              "name": "systemic lupus erythematosus",
-              "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10025133",
-                "KEGG.DISEASE:05322",
-                "MEDDRA:10042820",
-                "PDQ:CDR0000608139",
-                "MEDDRA:10040967",
-                "MEDDRA:10042800",
-                "MEDDRA:10013446",
-                "MONDO:0007915",
-                "MEDDRA:10042945",
-                "MEDDRA:10024067",
-                "ICD10:M32.9",
-                "MEDDRA:10042947",
-                "ORPHANET:536",
-                "MEDDRA:10042944",
-                "UMLS:C0024141",
-                "EFO:0002690",
-                "MESH:D008180",
-                "ICD9:710.0",
-                "DOID:9074",
-                "MEDDRA:10025139",
-                "UMLS:C1835309",
-                "MEDDRA:10024065",
-                "OMIM:152700",
-                "HP:0002725",
-                "MEDDRA:10025142",
-                "NCIT:C3201",
-                "SNOMEDCT:55464009"
-              ],
-              "id": "MONDO:0007915",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Systemic lupus erythematosus",
-                "obsolete_systemic lupus erythematosus",
-                "Systemic lupus erythematosus related phenotypic feature",
-                "Lupus Erythematosus, Systemic",
-                "Excess lmw-dna",
-                "systemic lupus erythematosus",
-                "Systemic Lupus Erythematosus"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11469606,
-            "start": 570,
-            "end": 319015,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15769918': {'publication date': '2005 Apr', 'sentence': 'Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus.', 'subject score': 888, 'object score': 1000}, 'PMID:2333537': {'publication date': '1990 Feb', 'sentence': 'Methylprednisolone in systemic lupus erythematosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:26629828': {'publication date': '2015', 'sentence': 'The effects of intravenous (IV) high dose methylprednisolone (MP) on Tregs have not yet been described, especially in active SLE.', 'subject score': 861, 'object score': 916}, 'PMID:3289511': {'publication date': '1988 Jun', 'sentence': 'A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus.', 'subject score': 888, 'object score': 1000}, 'PMID:3318723': {'publication date': '1987 Oct', 'sentence': 'A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment.', 'subject score': 872, 'object score': 1000}, 'PMID:7655499': {'publication date': '1995 Jun', 'sentence': 'We conclude that intravenous pulse methylprednisolone and cyclophosphamide therapy improve the prognosis of transverse myelitis associated with SLE but that a careful follow-up is needed to avoid complications due to the illness itself or secondary to the therapy.', 'subject score': 802, 'object score': 1000}, 'PMID:8400470': {'publication date': '1993 Aug', 'sentence': 'The role of magnetic resonance imaging in the diagnosis of intramedullary spinal cord abscess, and methylprednisolone and cyclophosphamide treatment of transverse myelitis in systemic lupus erythematosus are also discussed briefly.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0024141---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "11720471",
-              "object": "MONDO:0007915",
-              "publications": [
-                "PMID:15769918",
-                "PMID:2333537",
-                "PMID:26629828",
-                "PMID:3289511",
-                "PMID:3318723",
-                "PMID:7655499",
-                "PMID:8400470"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 517020,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019167",
-          "name": "immunoglobulin a vasculitis",
-          "description": "A systemic, usually self-limited immune complex vasculitis, characterized by immunoglobulin A deposition in the small vessels and kidneys. It is manifested with small hemorrhages in the skin, gastrointestinal symptoms, arthritis, and nephropathy.; A systemic non-thrombocytopenic purpura caused by HYPERSENSITIVITY VASCULITIS and deposition of IGA-containing IMMUNE COMPLEXES within the blood vessels throughout the body, including those in the kidney (KIDNEY GLOMERULUS). Clinical symptoms include URTICARIA; ERYTHEMA; ARTHRITIS; GASTROINTESTINAL HEMORRHAGE; and renal involvement. Most cases are seen in children after acute upper respiratory infections.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10002214",
-            "ICD9:287.0",
-            "MEDDRA:10002217",
-            "MEDDRA:10037552",
-            "MONDO:0019167",
-            "MEDDRA:10037565",
-            "MEDDRA:10001735",
-            "NCIT:C34963",
-            "MEDDRA:10019616",
-            "EFO:1000965",
-            "MEDDRA:10001716",
-            "DOID:11123",
-            "MEDDRA:10019615",
-            "MEDDRA:10002215",
-            "MESH:D011695",
-            "SNOMEDCT:191306005",
-            "ORPHANET:761",
-            "MEDDRA:10037551",
-            "ICD10:D69.0",
-            "MEDDRA:10039658",
-            "MEDDRA:10019617",
-            "SNOMEDCT:86074002",
-            "UMLS:C0034152",
-            "MEDDRA:10082959"
-          ],
-          "id": "MONDO:0019167",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Immunoglobulin A vasculitis",
-            "immunoglobulin A vasculitis",
-            "Allergic purpura",
-            "Henoch-Schönlein Purpura",
-            "IgA Vasculitis",
-            "Henoch-Schoenlein purpura",
-            "Henoch-Schoenlein Purpura"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://rarediseases.info.nih.gov/diseases/8204/henoch-schonlein-purpura",
-            "https://orcid.org/0000-0001-5208-3432"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517020,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019167",
-              "name": "immunoglobulin a vasculitis",
-              "description": "A systemic, usually self-limited immune complex vasculitis, characterized by immunoglobulin A deposition in the small vessels and kidneys. It is manifested with small hemorrhages in the skin, gastrointestinal symptoms, arthritis, and nephropathy.; A systemic non-thrombocytopenic purpura caused by HYPERSENSITIVITY VASCULITIS and deposition of IGA-containing IMMUNE COMPLEXES within the blood vessels throughout the body, including those in the kidney (KIDNEY GLOMERULUS). Clinical symptoms include URTICARIA; ERYTHEMA; ARTHRITIS; GASTROINTESTINAL HEMORRHAGE; and renal involvement. Most cases are seen in children after acute upper respiratory infections.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10002214",
-                "ICD9:287.0",
-                "MEDDRA:10002217",
-                "MEDDRA:10037552",
-                "MONDO:0019167",
-                "MEDDRA:10037565",
-                "MEDDRA:10001735",
-                "NCIT:C34963",
-                "MEDDRA:10019616",
-                "EFO:1000965",
-                "MEDDRA:10001716",
-                "DOID:11123",
-                "MEDDRA:10019615",
-                "MEDDRA:10002215",
-                "MESH:D011695",
-                "SNOMEDCT:191306005",
-                "ORPHANET:761",
-                "MEDDRA:10037551",
-                "ICD10:D69.0",
-                "MEDDRA:10039658",
-                "MEDDRA:10019617",
-                "SNOMEDCT:86074002",
-                "UMLS:C0034152",
-                "MEDDRA:10082959"
-              ],
-              "id": "MONDO:0019167",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Immunoglobulin A vasculitis",
-                "immunoglobulin A vasculitis",
-                "Allergic purpura",
-                "Henoch-Schönlein Purpura",
-                "IgA Vasculitis",
-                "Henoch-Schoenlein purpura",
-                "Henoch-Schoenlein Purpura"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://rarediseases.info.nih.gov/diseases/8204/henoch-schonlein-purpura",
-                "https://orcid.org/0000-0001-5208-3432"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10580548,
-            "start": 570,
-            "end": 517020,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1456416': {'publication date': '1992 Aug', 'sentence': 'Delayed hypersensitivity to 6-methyl-prednisolone in Henoch Schoenlein syndrome.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0034152---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10812685",
-              "object": "MONDO:0019167",
-              "publications": [
-                "PMID:1456416"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10532450,
-            "start": 570,
-            "end": 322104,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14496719': {'publication date': '1961', 'sentence': 'Rectal absorption of radioactive 6-alpha-methyl prednisolone in ulcerative colitis.', 'subject score': 785, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10763477",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:14496719"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 309447,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005556",
-          "name": "lupus nephritis",
-          "description": "Glomerulonephritis in the context of systemic lupus erythematosus.; Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).; Lupus nephritis is a type of glomerulonephritis that constitutes one of the most severe organ manifestations of systemic lupus erythematosus. Lupus nephritis is subclassified in six distinct classes, that represent different manifestations and severities of renal involvement and guide the therapeutic management. [ORCID:0000-0002-2234-4248, PMID:31974366]",
-          "equivalent_curies": [
-            "MEDDRA:10025140",
-            "HP:0033726",
-            "MEDDRA:10029141",
-            "DOID:0080162",
-            "NCIT:C34789",
-            "UMLS:C0024143",
-            "MESH:D008181",
-            "MEDDRA:10029142",
-            "MONDO:0005556",
-            "SNOMEDCT:68815009",
-            "MEDDRA:10040970",
-            "EFO:0005761"
-          ],
-          "id": "MONDO:0005556",
-          "category": "biolink:Disease",
-          "all_names": [
-            "lupus nephritis",
-            "Lupus nephritis",
-            "Lupus Nephritis",
-            "Lupus Glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000481.htm",
-            "PMID:31974366",
-            "https://orcid.org/0000-0002-2234-4248",
-            "https://en.wikipedia.org/wiki/lupus_nephritis#cite_note-1"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 309447,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005556",
-              "name": "lupus nephritis",
-              "description": "Glomerulonephritis in the context of systemic lupus erythematosus.; Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).; Lupus nephritis is a type of glomerulonephritis that constitutes one of the most severe organ manifestations of systemic lupus erythematosus. Lupus nephritis is subclassified in six distinct classes, that represent different manifestations and severities of renal involvement and guide the therapeutic management. [ORCID:0000-0002-2234-4248, PMID:31974366]",
-              "equivalent_curies": [
-                "MEDDRA:10025140",
-                "HP:0033726",
-                "MEDDRA:10029141",
-                "DOID:0080162",
-                "NCIT:C34789",
-                "UMLS:C0024143",
-                "MESH:D008181",
-                "MEDDRA:10029142",
-                "MONDO:0005556",
-                "SNOMEDCT:68815009",
-                "MEDDRA:10040970",
-                "EFO:0005761"
-              ],
-              "id": "MONDO:0005556",
-              "category": "biolink:Disease",
-              "all_names": [
-                "lupus nephritis",
-                "Lupus nephritis",
-                "Lupus Nephritis",
-                "Lupus Glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000481.htm",
-                "PMID:31974366",
-                "https://orcid.org/0000-0002-2234-4248",
-                "https://en.wikipedia.org/wiki/lupus_nephritis#cite_note-1"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10331288,
-            "start": 570,
-            "end": 309447,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1356175': {'publication date': '1992 Sep 26', 'sentence': 'Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis.', 'subject score': 861, 'object score': 901}, 'PMID:16820790': {'publication date': '2006 Aug', 'sentence': 'Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis.', 'subject score': 888, 'object score': 901}, 'PMID:34530647': {'publication date': '2021 Sep 16', 'sentence': 'Absence of IVMP and receiving intravenous albumin assisted diuresis during initial hospitalization increase the risk of early readmission in new onset pediatric lupus nephritis.', 'subject score': 802, 'object score': 857}, 'PMID:36510250': {'publication date': '2022 Dec 12', 'sentence': 'Furthermore, we investigated whether HSPB5 can enhance the effects of methylprednisolone, a standard-of-care drug in LN, in an endotoxemia mouse model.', 'subject score': 1000, 'object score': 1000}, 'PMID:6623376': {'publication date': '1983', 'sentence': '[Intravenous administration of high doses (pulse therapy) of methylprednisolone in lupus nephritis].', 'subject score': 1000, 'object score': 1000}, 'PMID:67320': {'publication date': '1977 Apr 23', 'sentence': 'Intravenous methylprednisolone pulses in diffuse proliferative lupus nephritis.', 'subject score': 888, 'object score': 861}, 'PMID:67530': {'publication date': '1977 May 14', 'sentence': 'High-dose methylprednisolone pulses in active lupus nephritis.', 'subject score': 901, 'object score': 901}, 'PMID:7131454': {'publication date': '1982', 'sentence': 'Monthly pulses of methylprednisolone in SLE nephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7404327': {'publication date': '1980', 'sentence': '[Ultra-high (shock) doses of methylprednisolone in lupus nephritis].', 'subject score': 1000, 'object score': 1000}, 'PMID:7920609': {'publication date': '1994 Apr', 'sentence': 'A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis.', 'subject score': 861, 'object score': 901}, 'PMID:8052927': {'publication date': '1994 Jun', 'sentence': '[Double blind trial of pulse methylprednisolone versus conventional oral prednisolone in lupus nephritis].', 'subject score': 861, 'object score': 1000}, 'PMID:8165443': {'publication date': '1994', 'sentence': 'Long term efficacy of high-dose intravenous methylprednisolone pulses in active lupus nephritis.', 'subject score': 861, 'object score': 901}, 'PMID:8810543': {'publication date': '1996 Jun', 'sentence': 'Because glomerular sclerosing index was thought to be one of the risk factors for poor renal prognosis, the indication for pulse methylprednisolone in lupus nephritis was the patients with low glomerular sclerosing index.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0024143---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10558884",
-              "object": "MONDO:0005556",
-              "publications": [
-                "PMID:1356175",
-                "PMID:16820790",
-                "PMID:34530647",
-                "PMID:36510250",
-                "PMID:6623376",
-                "PMID:67320",
-                "PMID:67530",
-                "PMID:7131454",
-                "PMID:7404327",
-                "PMID:7920609",
-                "PMID:8052927",
-                "PMID:8165443",
-                "PMID:8810543"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319500,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0100130",
-          "name": "adult acute respiratory distress syndrome",
-          "description": "Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.; A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:J80",
-            "MEDDRA:10042839",
-            "UMLS:C4281993",
-            "MEDDRA:10038691",
-            "MEDDRA:10040579",
-            "DOID:11394",
-            "SNOMEDCT:196153002",
-            "ORPHANET:70578",
-            "MEDDRA:10042787",
-            "SNOMEDCT:67782005",
-            "MONDO:0100130",
-            "MEDDRA:10003083",
-            "MEDDRA:10038688",
-            "MEDDRA:10001410",
-            "HP:0002643",
-            "MEDDRA:10001407",
-            "MEDDRA:10000036",
-            "UMLS:C0852283",
-            "MEDDRA:10028973",
-            "UMLS:C0035222",
-            "MEDDRA:10001052",
-            "MEDDRA:10001409",
-            "MESH:D012128",
-            "SNOMEDCT:1179627006",
-            "UMLS:C1368020"
-          ],
-          "id": "MONDO:0100130",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adult acute respiratory distress syndrome",
-            "Neonatal respiratory distress",
-            "Respiratory Distress Syndrome, Adult",
-            "adult respiratory distress syndrome",
-            "Respiratory Distress Syndrome",
-            "Adult acute respiratory distress syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5392788/",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=adult+respiratory+distress+syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319500,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0100130",
-              "name": "adult acute respiratory distress syndrome",
-              "description": "Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.; A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:J80",
-                "MEDDRA:10042839",
-                "UMLS:C4281993",
-                "MEDDRA:10038691",
-                "MEDDRA:10040579",
-                "DOID:11394",
-                "SNOMEDCT:196153002",
-                "ORPHANET:70578",
-                "MEDDRA:10042787",
-                "SNOMEDCT:67782005",
-                "MONDO:0100130",
-                "MEDDRA:10003083",
-                "MEDDRA:10038688",
-                "MEDDRA:10001410",
-                "HP:0002643",
-                "MEDDRA:10001407",
-                "MEDDRA:10000036",
-                "UMLS:C0852283",
-                "MEDDRA:10028973",
-                "UMLS:C0035222",
-                "MEDDRA:10001052",
-                "MEDDRA:10001409",
-                "MESH:D012128",
-                "SNOMEDCT:1179627006",
-                "UMLS:C1368020"
-              ],
-              "id": "MONDO:0100130",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adult acute respiratory distress syndrome",
-                "Neonatal respiratory distress",
-                "Respiratory Distress Syndrome, Adult",
-                "adult respiratory distress syndrome",
-                "Respiratory Distress Syndrome",
-                "Adult acute respiratory distress syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5392788/",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=adult+respiratory+distress+syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9911354,
-            "start": 570,
-            "end": 319500,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12682449': {'publication date': '2003 Apr', 'sentence': \"The National Heart, Lung, and Blood Institute's ARDS Network currently is testing the use of methylprednisolone in late ARDS.\", 'subject score': 1000, 'object score': 928}, 'PMID:17426195': {'publication date': '2007 Apr', 'sentence': 'Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial.', 'subject score': 888, 'object score': 851}, 'PMID:17873211': {'publication date': '2007 Sep', 'sentence': 'Methylprednisolone infusion in early severe ARDS.', 'subject score': 888, 'object score': 851}, 'PMID:17873212': {'publication date': '2007 Sep', 'sentence': 'Methylprednisolone infusion in early severe ARDS: it is pretty, but is it art?', 'subject score': 888, 'object score': 851}, 'PMID:19838137': {'publication date': '2010 May', 'sentence': 'Steroids for early acute respiratory distress syndrome: critical appraisal of Meduri GU, Golden E, Freire AX, et al: Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial.', 'subject score': 888, 'object score': 851}, 'PMID:25634565': {'publication date': '2015 Mar', 'sentence': 'Double-blind, placebo-controlled pilot randomized trial of methylprednisolone infusion in pediatric acute respiratory distress syndrome.', 'subject score': 888, 'object score': 928}, 'PMID:34284567': {'publication date': '2021 Jul 19', 'sentence': 'We present a preliminary report on our experience using high-dose pulsed methylprednisolone in COVID-19 ARDS and three-month outcomes.', 'subject score': 1000, 'object score': 901}, 'PMID:7460641': {'publication date': '1981 Feb', 'sentence': 'We evaluated the effect of pharmacologic doses of corticosteroid (methylprednisolone and dexamethasone) on alveolo-capillary permeability in human septic ARDS by examining the change in appearance of intravenously administered iodine 131 (131I) human serum albumin (I-HSA) into broncho-alveolar secretions, before and after corticosteroid administration.', 'subject score': 1000, 'object score': 888}, 'PMID:729264': {'publication date': '1978 Jul-Aug', 'sentence': 'Methylprednisolone in posttraumatic pulmonary insufficiency.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0035222---SEMMEDDB:",
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C1368020---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10130342",
-              "object": "MONDO:0100130",
-              "publications": [
-                "PMID:7460641",
-                "PMID:19838137",
-                "PMID:17873212",
-                "PMID:17873211",
-                "PMID:729264",
-                "PMID:12682449",
-                "PMID:34284567",
-                "PMID:25634565",
-                "PMID:17426195"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 520717,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006008",
-          "name": "vestibular neuronitis",
-          "description": "Idiopathic inflammation of the VESTIBULAR NERVE, characterized clinically by the acute or subacute onset of VERTIGO; NAUSEA; and imbalance. The COCHLEAR NERVE is typically spared and HEARING LOSS and TINNITUS do not usually occur. Symptoms usually resolve over a period of days to weeks. (Adams et al., Principles of Neurology, 6th ed, p304)",
-          "equivalent_curies": [
-            "UMLS:C0751908",
-            "MEDDRA:10047393",
-            "MEDDRA:10085178",
-            "SNOMEDCT:186738001",
-            "ICD10:H81.2",
-            "UMLS:C0153113",
-            "MEDDRA:10014980",
-            "ICD9:386.12",
-            "EFO:0007537",
-            "DOID:12683",
-            "MESH:D020338",
-            "MONDO:0006008"
-          ],
-          "id": "MONDO:0006008",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute Peripheral Vestibulopathy",
-            "Vestibular Neuronitis",
-            "vestibular neuronitis",
-            "Vestibular neuronitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:16448876",
-            "http://en.wikipedia.org/wiki/vestibular_neuritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520717,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006008",
-              "name": "vestibular neuronitis",
-              "description": "Idiopathic inflammation of the VESTIBULAR NERVE, characterized clinically by the acute or subacute onset of VERTIGO; NAUSEA; and imbalance. The COCHLEAR NERVE is typically spared and HEARING LOSS and TINNITUS do not usually occur. Symptoms usually resolve over a period of days to weeks. (Adams et al., Principles of Neurology, 6th ed, p304)",
-              "equivalent_curies": [
-                "UMLS:C0751908",
-                "MEDDRA:10047393",
-                "MEDDRA:10085178",
-                "SNOMEDCT:186738001",
-                "ICD10:H81.2",
-                "UMLS:C0153113",
-                "MEDDRA:10014980",
-                "ICD9:386.12",
-                "EFO:0007537",
-                "DOID:12683",
-                "MESH:D020338",
-                "MONDO:0006008"
-              ],
-              "id": "MONDO:0006008",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute Peripheral Vestibulopathy",
-                "Vestibular Neuronitis",
-                "vestibular neuronitis",
-                "Vestibular neuronitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:16448876",
-                "http://en.wikipedia.org/wiki/vestibular_neuritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9030871,
-            "start": 570,
-            "end": 520717,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11710505': {'publication date': '2001 Oct', 'sentence': '(3) Preliminary results of an interim analysis from an ongoing randomized, prospective study showed that methylprednisolone (plus an antiviral agent?) may be useful for improving peripheral vestibular function in vestibular neuritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28391531': {'publication date': '2017 Jun', 'sentence': 'The aim of this study was to examine the efficacy of methylprednisolone in vestibular neuritis (VN) by objective and subjective measures.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0751908---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "9229208",
-              "object": "MONDO:0006008",
-              "publications": [
-                "PMID:11710505",
-                "PMID:28391531"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 530656,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005100",
-          "name": "systemic sclerosis",
-          "description": "A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.; A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:90291",
-            "EFO:0000717",
-            "UMLS:CN206012",
-            "MEDDRA:10036814",
-            "UMLS:C0036421",
-            "ICD10:M34.0",
-            "DOID:418",
-            "UMLS:C0700318",
-            "MEDDRA:10078638",
-            "SNOMEDCT:89155008",
-            "MONDO:0005100",
-            "ICD9:710.1",
-            "MEDDRA:10042953",
-            "PDQ:CDR0000587622",
-            "MESH:D012595",
-            "NCIT:C72070"
-          ],
-          "id": "MONDO:0005100",
-          "category": "biolink:Disease",
-          "all_names": [
-            "systemic sclerosis",
-            "Scleroderma, Systemic",
-            "Systemic sclerosis",
-            "Systemic Scleroderma",
-            "systemic scleroderma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://ghr.nlm.nih.gov/condition/systemic-scleroderma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 530656,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005100",
-              "name": "systemic sclerosis",
-              "description": "A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.; A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:90291",
-                "EFO:0000717",
-                "UMLS:CN206012",
-                "MEDDRA:10036814",
-                "UMLS:C0036421",
-                "ICD10:M34.0",
-                "DOID:418",
-                "UMLS:C0700318",
-                "MEDDRA:10078638",
-                "SNOMEDCT:89155008",
-                "MONDO:0005100",
-                "ICD9:710.1",
-                "MEDDRA:10042953",
-                "PDQ:CDR0000587622",
-                "MESH:D012595",
-                "NCIT:C72070"
-              ],
-              "id": "MONDO:0005100",
-              "category": "biolink:Disease",
-              "all_names": [
-                "systemic sclerosis",
-                "Scleroderma, Systemic",
-                "Systemic sclerosis",
-                "Systemic Scleroderma",
-                "systemic scleroderma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://ghr.nlm.nih.gov/condition/systemic-scleroderma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8809853,
-            "start": 570,
-            "end": 530656,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11454645': {'publication date': '2001 Aug', 'sentence': 'This is the first report of cyclophosphamide and methylprednisolone leading to complete and sustained resolution of GAVE in association with systemic sclerosis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0036421---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "9003326",
-              "object": "MONDO:0005100",
-              "publications": [
-                "PMID:11454645"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318890,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-          "name": "rheumatoid arthritis",
-          "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C2884",
-            "PSY:44570",
-            "EFO:0000685",
-            "ICD9:714.0",
-            "KEGG.DISEASE:05323",
-            "MONDO:0008383",
-            "UMLS:C0003873",
-            "UMLS:C1306838",
-            "UMLS:C1833448",
-            "MEDDRA:10037740",
-            "MEDDRA:10039073",
-            "OMIM:180300",
-            "MESH:D001172",
-            "MEDDRA:10003268",
-            "HP:0001370",
-            "ORPHANET:284130",
-            "SNOMEDCT:69896004",
-            "ICD10:M06.9",
-            "DOID:7148",
-            "MEDDRA:10036856",
-            "MEDDRA:10042952"
-          ],
-          "id": "MONDO:0008383",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Proliferative arthritis",
-            "Arthritis, Rheumatoid",
-            "rheumatoid arthritis",
-            "Rheumatoid arthritis",
-            "Rheumatoid Arthritis",
-            "Rheumatoid arthritis related phenotypic feature",
-            "Rheumatoid arthritis, susceptibility to"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-            "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-            "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318890,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-              "name": "rheumatoid arthritis",
-              "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C2884",
-                "PSY:44570",
-                "EFO:0000685",
-                "ICD9:714.0",
-                "KEGG.DISEASE:05323",
-                "MONDO:0008383",
-                "UMLS:C0003873",
-                "UMLS:C1306838",
-                "UMLS:C1833448",
-                "MEDDRA:10037740",
-                "MEDDRA:10039073",
-                "OMIM:180300",
-                "MESH:D001172",
-                "MEDDRA:10003268",
-                "HP:0001370",
-                "ORPHANET:284130",
-                "SNOMEDCT:69896004",
-                "ICD10:M06.9",
-                "DOID:7148",
-                "MEDDRA:10036856",
-                "MEDDRA:10042952"
-              ],
-              "id": "MONDO:0008383",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Proliferative arthritis",
-                "Arthritis, Rheumatoid",
-                "rheumatoid arthritis",
-                "Rheumatoid arthritis",
-                "Rheumatoid Arthritis",
-                "Rheumatoid arthritis related phenotypic feature",
-                "Rheumatoid arthritis, susceptibility to"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-                "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-                "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8268351,
-            "start": 570,
-            "end": 318890,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10996038': {'publication date': '2000 Sep', 'sentence': 'We compared lymphocyte-suppressive potencies of prednisolone and methylprednisolone in rheumatoid arthritis (RA).', 'subject score': 1000, 'object score': 1000}, 'PMID:11035124': {'publication date': '2000 Oct', 'sentence': 'The effects of pulse methylprednisolone on matrix metalloproteinase and tissue inhibitor of metalloproteinase-1 expression in rheumatoid arthritis.', 'subject score': 861, 'object score': 1000}, 'PMID:12685246': {'publication date': '2002 Nov', 'sentence': 'The objective of the paper was compare the effects and tolerability of combined therapy of multiple intravenous infusions of anti-tumour necrosis factor-alfa (TNF-alfa) monoclonal antibody (Remicade) with methotrexate versus treatment with sodium aurothiomalate and intramuscular depot methylprednisolone in rheumatoid arthritis (RA).', 'subject score': 802, 'object score': 1000}, 'PMID:13565407': {'publication date': '1958 Jul', 'sentence': 'Effects of methylprednisolone (medrol) in rheumatoid arthritis: a preliminary study.', 'subject score': 1000, 'object score': 1000}, 'PMID:13705356': {'publication date': '1961 Aug', 'sentence': '6a-Methylprednisolone in rheumatoid arthritis.', 'subject score': 888, 'object score': 1000}, 'PMID:13786528': {'publication date': '1960 Oct 15', 'sentence': 'Effectiveness of methylprednisolone and prednisolone tertiary-butylacetate intra-articularly in rheumatoid arthritis: a comparative study.', 'subject score': 1000, 'object score': 1000}, 'PMID:14010277': {'publication date': '1962 Dec', 'sentence': '[Clinical trials with 6 alpha-fluoro-16 alpha-methylprednisolone (paramethasone) in rheumatoid arthritis].', 'subject score': 805, 'object score': 1000}, 'PMID:1455374': {'publication date': '1992', 'sentence': '[Pulse therapy with methylprednisolone and cyclophosphamide in systemic juvenile rheumatoid arthritis: the results of an open, parallel, controlled, randomized, 12-month study].', 'subject score': 1000, 'object score': 916}, 'PMID:1784882': {'publication date': '1991', 'sentence': 'Intravenous regional administration of methylprednisolone in rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:18322991': {'publication date': '2008 Apr', 'sentence': 'Clinical outcome and imaging changes after intraarticular (IA) application of etanercept or methylprednisolone in rheumatoid arthritis: magnetic resonance imaging and ultrasound-Doppler show no effect of IA injections in the wrist after 4 weeks.', 'subject score': 1000, 'object score': 1000}, 'PMID:1883691': {'publication date': '1991 Jun', 'sentence': 'First, a high degree of attention has been focused on the use of high-dose intravenous methylprednisolone in rheumatoid arthritis.', 'subject score': 861, 'object score': 1000}, 'PMID:23864141': {'publication date': '2013 Nov', 'sentence': 'UNLABELLED: To compare the efficacy of the addition of clarithromycin (CM) to methotrexate (MTX) and methylprednisolone (MP) in active rheumatoid arthritis (RA).', 'subject score': 1000, 'object score': 901}, 'PMID:2411240': {'publication date': '1985 Aug', 'sentence': 'The use of high-dose pulse methylprednisolone in rheumatoid arthritis.', 'subject score': 824, 'object score': 1000}, 'PMID:2865930': {'publication date': '1985 Nov', 'sentence': 'Combination therapy with pulsed methylprednisolone in rheumatoid arthritis.', 'subject score': 872, 'object score': 1000}, 'PMID:29884751': {'publication date': '2018 Aug', 'sentence': 'The occurrence of RA was available for nine studies, assessing methylprednisolone, methotrexate, a tumour necrosis factor blocker, abatacept or rituximab.', 'subject score': 1000, 'object score': 1000}, 'PMID:3204607': {'publication date': '1988 Oct', 'sentence': 'Pulse methylprednisolone in rheumatoid arthritis.', 'subject score': 861, 'object score': 1000}, 'PMID:3288292': {'publication date': '1988 Jun', 'sentence': 'Pulsed methylprednisolone in active early rheumatoid disease: a dose-ranging study.', 'subject score': 872, 'object score': 861}, 'PMID:3361533': {'publication date': '1988 Feb', 'sentence': 'Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study.', 'subject score': 1000, 'object score': 1000}, 'PMID:3536261': {'publication date': '1986 Sep', 'sentence': 'A randomized, double-blind trial comparing a pulse of 1000 with 250 mg methylprednisolone in rheumatoid arthritis.', 'subject score': 790, 'object score': 1000}, 'PMID:3724262': {'publication date': '1986 Apr 12', 'sentence': '[Effects of methylprednisolone pulses in rheumatoid arthritis].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0003873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8447481",
-              "object": "MONDO:0008383",
-              "publications": [
-                "PMID:10996038",
-                "PMID:11035124",
-                "PMID:12685246",
-                "PMID:13565407",
-                "PMID:13705356",
-                "PMID:13786528",
-                "PMID:14010277",
-                "PMID:1455374",
-                "PMID:1784882",
-                "PMID:18322991",
-                "PMID:1883691",
-                "PMID:23864141",
-                "PMID:2411240",
-                "PMID:2865930",
-                "PMID:29884751",
-                "PMID:3204607",
-                "PMID:3288292",
-                "PMID:3361533",
-                "PMID:3536261",
-                "PMID:3724262"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 539362,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043797",
-          "name": "spinal cord injury",
-          "description": "Traumatic damage of the spinal cord.; Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).; Your spinal cord is a bundle of nerves that runs down the middle of your back. It carries signals back and forth between your body and your brain. A spinal cord injury disrupts the signals. Spinal cord injuries usually begin with a blow that fractures (breaks) or dislocates your vertebrae, the bone disks that make up your spine. Most injuries don't cut through your spinal cord. Instead, they cause damage when pieces of vertebrae tear into cord tissue or press down on the nerve parts that carry signals. Spinal cord injuries can be complete or incomplete. With a complete spinal cord injury, the cord can't send signals below the level of the injury. As a result, you are paralyzed below the injury. With an incomplete injury, you have some movement and sensation below the injury. A spinal cord injury is a medical emergency. Immediate treatment can reduce long-term effects. Treatments may include medicines, braces or traction to stabilize the spine, and surgery. Later treatment usually includes medicines and rehabilitation therapy. Mobility aids and assistive devices may help you to get around and do some daily tasks. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "EFO:1001919",
-            "MESH:D013119",
-            "ORPHANET:90058",
-            "SNOMEDCT:90584004",
-            "MONDO:0043797",
-            "UMLS:C0037929",
-            "MEDDRA:10041552",
-            "NCIT:C50750"
-          ],
-          "id": "MONDO:0043797",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Spinal Cord Injury",
-            "spinal cord injury",
-            "Spinal Cord Injuries",
-            "Spinal cord injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 539362,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043797",
-              "name": "spinal cord injury",
-              "description": "Traumatic damage of the spinal cord.; Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).; Your spinal cord is a bundle of nerves that runs down the middle of your back. It carries signals back and forth between your body and your brain. A spinal cord injury disrupts the signals. Spinal cord injuries usually begin with a blow that fractures (breaks) or dislocates your vertebrae, the bone disks that make up your spine. Most injuries don't cut through your spinal cord. Instead, they cause damage when pieces of vertebrae tear into cord tissue or press down on the nerve parts that carry signals. Spinal cord injuries can be complete or incomplete. With a complete spinal cord injury, the cord can't send signals below the level of the injury. As a result, you are paralyzed below the injury. With an incomplete injury, you have some movement and sensation below the injury. A spinal cord injury is a medical emergency. Immediate treatment can reduce long-term effects. Treatments may include medicines, braces or traction to stabilize the spine, and surgery. Later treatment usually includes medicines and rehabilitation therapy. Mobility aids and assistive devices may help you to get around and do some daily tasks. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "EFO:1001919",
-                "MESH:D013119",
-                "ORPHANET:90058",
-                "SNOMEDCT:90584004",
-                "MONDO:0043797",
-                "UMLS:C0037929",
-                "MEDDRA:10041552",
-                "NCIT:C50750"
-              ],
-              "id": "MONDO:0043797",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Spinal Cord Injury",
-                "spinal cord injury",
-                "Spinal Cord Injuries",
-                "Spinal cord injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8107688,
-            "start": 570,
-            "end": 539362,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10872756': {'publication date': '2000 Jun', 'sentence': 'Despite the lucrative \"off label\" markets for methylprednisolone in SCI, no Food and Drug Association indication has been obtained.', 'subject score': 1000, 'object score': 1000}, 'PMID:10879751': {'publication date': '2000 Jul', 'sentence': 'In the strictest sense, 24-hour administration of methylprednisolone must still be considered experimental for use in clinical SCI.', 'subject score': 1000, 'object score': 916}, 'PMID:10879762': {'publication date': '2000 Jul', 'sentence': 'Comparison of the effects of melatonin and methylprednisolone in experimental spinal cord injury.', 'subject score': 1000, 'object score': 916}, 'PMID:11011817': {'publication date': '2000 Sep', 'sentence': 'Riluzole and methylprednisolone combined treatment improves functional recovery in traumatic spinal cord injury.', 'subject score': 1000, 'object score': 916}, 'PMID:15716618': {'publication date': '2005 Feb', 'sentence': 'Methylprednisolone(MP), a glucocorticoid steroid, has an anti-inflammatory action and seems to inhibit the formation of oxygen free radicals produced during lipid peroxidation in a spinal cord injury(SCI).', 'subject score': 1000, 'object score': 1000}, 'PMID:16506468': {'publication date': '2006 Jan', 'sentence': 'The authors of this study evaluated ATL-146e and methylprednisolone for their ability to preserve neuronal viability and motor function in experimental SCI.', 'subject score': 1000, 'object score': 916}, 'PMID:17031918': {'publication date': '1999 Jan 15', 'sentence': 'To date, methylprednisolone is the only effective neuroprotective agent that has been established for use in human SCI, and the only therapeutic time window established in human SCI is a maximum trauma-to-treatment time of 8 hours.', 'subject score': 1000, 'object score': 916}, 'PMID:17486444': {'publication date': '2007 Sep', 'sentence': 'The effects of hyperbaric oxygen (HBO) therapy or methylprednisolone on the oxidative status were evaluated in experimental spinal cord injury.', 'subject score': 1000, 'object score': 916}, 'PMID:1857175': {'publication date': '1991 Jul 10', 'sentence': '[Methylprednisolone improves prognosis in traumatic spinal cord injuries].', 'subject score': 1000, 'object score': 916}, 'PMID:19519725': {'publication date': '2009 Sep', 'sentence': 'Effects of dexmedetomidine or methylprednisolone on inflammatory responses in spinal cord injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:20209390': {'publication date': '2010 Jan', 'sentence': 'CONCLUSION: Methylprednisolone, NAC and methylprednisolone plus NAC treatments have potential biochemical benefits in preventing secondary injury in experimental spinal cord injury in rats.', 'subject score': 1000, 'object score': 916}, 'PMID:20831552': {'publication date': '2010 Aug', 'sentence': 'Methylprednisolone worsening neuropathic pain in non-traumatic thoracic myelopathy.', 'subject score': 1000, 'object score': 824}, 'PMID:21611834': {'publication date': '2011 Oct', 'sentence': 'Methylprednisolone, the only currently available therapy renders limited protection in SCI.', 'subject score': 1000, 'object score': 1000}, 'PMID:21994079': {'publication date': '2012 Mar', 'sentence': 'A review: the role of high dose methylprednisolone in spinal cord trauma in children.', 'subject score': 901, 'object score': 1000}, 'PMID:22158284': {'publication date': '2011 Dec', 'sentence': 'Spinal cord injuries in older children: is there a role for high-dose methylprednisolone?', 'subject score': 901, 'object score': 1000}, 'PMID:2258942': {'publication date': '1990', 'sentence': 'Methylprednisolone in spinal cord injury: the possible mechanism of action.', 'subject score': 1000, 'object score': 1000}, 'PMID:22640221': {'publication date': '2012 Jun', 'sentence': 'Stability, disposition, and penetration of catalytic antioxidants Mn-porphyrin and Mn-salen and of methylprednisolone in spinal cord injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:24871822': {'publication date': '2015 Jan', 'sentence': 'Effects of intrathecal caffeic acid phenethyl ester and methylprednisolone on oxidant/antioxidant status in traumatic spinal cord injuries.', 'subject score': 1000, 'object score': 916}, 'PMID:25047053': {'publication date': '2014 Sep', 'sentence': 'Effects of methylprednisolone and 4-chloro-3-hydroxyanthranilic acid in experimental spinal cord injury in the guinea pig appear to be mediated by different and potentially complementary mechanisms.', 'subject score': 1000, 'object score': 916}, 'PMID:25333652': {'publication date': '2015 Aug', 'sentence': 'Low dose methotrexate is more effective as compared to methylprednisolone in secondary spinal cord injury.', 'subject score': 1000, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0037929---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8282330",
-              "object": "MONDO:0043797",
-              "publications": [
-                "PMID:10872756",
-                "PMID:10879751",
-                "PMID:10879762",
-                "PMID:11011817",
-                "PMID:15716618",
-                "PMID:16506468",
-                "PMID:17031918",
-                "PMID:17486444",
-                "PMID:1857175",
-                "PMID:19519725",
-                "PMID:20209390",
-                "PMID:20831552",
-                "PMID:21611834",
-                "PMID:21994079",
-                "PMID:22158284",
-                "PMID:2258942",
-                "PMID:22640221",
-                "PMID:24871822",
-                "PMID:25047053",
-                "PMID:25333652"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 518734,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009688",
-          "name": "myasthenia gravis",
-          "description": "A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness. It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.; A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.; Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest. Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker. Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps. Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:G70.00",
-            "ICD9:358.0",
-            "OMIM:254200",
-            "PSY:32760",
-            "MESH:D009157",
-            "MEDDRA:10028420",
-            "ICD10:G70.0",
-            "EFO:0004991",
-            "ICD9:358.00",
-            "ORPHANET:589",
-            "UMLS:C1260409",
-            "MEDDRA:10028417",
-            "DOID:437",
-            "UMLS:C0026896",
-            "SNOMEDCT:91637004",
-            "MONDO:0009688",
-            "NCIT:C60989"
-          ],
-          "id": "MONDO:0009688",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myasthenia gravis without (acute) exacerbation",
-            "myasthenia gravis without acute exacerbation",
-            "myasthenia gravis",
-            "Myasthenia Gravis",
-            "Myasthenia gravis",
-            "Myasthenia gravis related phenotypic feature"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.ninds.nih.gov/disorders/patient-caregiver-education/fact-sheets/myasthenia-gravis-fact-sheet"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 518734,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009688",
-              "name": "myasthenia gravis",
-              "description": "A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness. It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.; A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.; Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest. Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker. Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps. Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:G70.00",
-                "ICD9:358.0",
-                "OMIM:254200",
-                "PSY:32760",
-                "MESH:D009157",
-                "MEDDRA:10028420",
-                "ICD10:G70.0",
-                "EFO:0004991",
-                "ICD9:358.00",
-                "ORPHANET:589",
-                "UMLS:C1260409",
-                "MEDDRA:10028417",
-                "DOID:437",
-                "UMLS:C0026896",
-                "SNOMEDCT:91637004",
-                "MONDO:0009688",
-                "NCIT:C60989"
-              ],
-              "id": "MONDO:0009688",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myasthenia gravis without (acute) exacerbation",
-                "myasthenia gravis without acute exacerbation",
-                "myasthenia gravis",
-                "Myasthenia Gravis",
-                "Myasthenia gravis",
-                "Myasthenia gravis related phenotypic feature"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.ninds.nih.gov/disorders/patient-caregiver-education/fact-sheets/myasthenia-gravis-fact-sheet"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7779197,
-            "start": 570,
-            "end": 518734,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10644791': {'publication date': '2000 Feb', 'sentence': 'Extraocular muscle responses to high dose intravenous methylprednisolone in myasthenia gravis.', 'subject score': 861, 'object score': 1000}, 'PMID:16930359': {'publication date': '2006 Sep', 'sentence': 'The aim of this study was to evaluate the long-term adverse effect (AE) profile of azathioprine (AZA) plus methylprednisolone combined immunosuppressive treatment in myasthenia gravis (MG) in a larger patient cohort.', 'subject score': 851, 'object score': 1000}, 'PMID:4062612': {'publication date': '1985 Dec', 'sentence': 'High-dose intravenous methylprednisolone in myasthenia gravis.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0026896---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7944646",
-              "object": "MONDO:0009688",
-              "publications": [
-                "PMID:10644791",
-                "PMID:16930359",
-                "PMID:4062612"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 522619,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005301",
-          "name": "multiple sclerosis",
-          "description": "An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D009103",
-            "NCIT:C3243",
-            "MEDDRA:10039720",
-            "EFO:0003885",
-            "ORPHANET:802",
-            "MEDDRA:10028245",
-            "PSY:32490",
-            "ICD9:340",
-            "MONDO:0005301",
-            "MEDDRA:10028053",
-            "UMLS:C0026769",
-            "MEDDRA:10013451",
-            "SNOMEDCT:24700007",
-            "ICD10:G35",
-            "PDQ:CDR0000691761",
-            "DOID:2377"
-          ],
-          "id": "MONDO:0005301",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Multiple Sclerosis",
-            "obsolete_multiple sclerosis",
-            "Multiple sclerosis",
-            "multiple sclerosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://ghr.nlm.nih.gov/condition/multiple-sclerosis",
-            "http://en.wikipedia.org/wiki/multiple_sclerosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 522619,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005301",
-              "name": "multiple sclerosis",
-              "description": "An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D009103",
-                "NCIT:C3243",
-                "MEDDRA:10039720",
-                "EFO:0003885",
-                "ORPHANET:802",
-                "MEDDRA:10028245",
-                "PSY:32490",
-                "ICD9:340",
-                "MONDO:0005301",
-                "MEDDRA:10028053",
-                "UMLS:C0026769",
-                "MEDDRA:10013451",
-                "SNOMEDCT:24700007",
-                "ICD10:G35",
-                "PDQ:CDR0000691761",
-                "DOID:2377"
-              ],
-              "id": "MONDO:0005301",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Multiple Sclerosis",
-                "obsolete_multiple sclerosis",
-                "Multiple sclerosis",
-                "multiple sclerosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://ghr.nlm.nih.gov/condition/multiple-sclerosis",
-                "http://en.wikipedia.org/wiki/multiple_sclerosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7511443,
-            "start": 570,
-            "end": 522619,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10477400': {'publication date': '1999 Sep', 'sentence': 'The increased CSF levels of TNF-sRp55 in response to MP circumstantially suggest that this receptor could partially account for the beneficial effects of MP in acute MS.', 'subject score': 1000, 'object score': 901}, 'PMID:10933772': {'publication date': '2000 Apr', 'sentence': 'PURPOSE: To demonstrate the safety and effectiveness of intravenous methylprednisolone (IVMP) in the treatment of uveitis in association with multiple sclerosis (MS).', 'subject score': 888, 'object score': 1000}, 'PMID:14760960': {'publication date': '2004 Feb', 'sentence': 'We compared the efficacy of the combination of intravenous immunoglobulins (IVIg) and IVMP with the standard treatment of IVMP alone in promoting recovery from moderate to severe acute relapses in MS.', 'subject score': 888, 'object score': 1000}, 'PMID:15452302': {'publication date': '2004 Sep 28', 'sentence': 'The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis.', 'subject score': 888, 'object score': 1000}, 'PMID:15596745': {'publication date': '2004 Dec 14', 'sentence': 'IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS.', 'subject score': 1000, 'object score': 1000}, 'PMID:15781847': {'publication date': '2005 Mar 22', 'sentence': 'The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis.', 'subject score': 888, 'object score': 1000}, 'PMID:15794385': {'publication date': '2005 Apr', 'sentence': 'Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.', 'subject score': 1000, 'object score': 1000}, 'PMID:16719908': {'publication date': '2006 May 23', 'sentence': 'CONCLUSION: Monthly IV-MP reduces inflammatory activity and T2 lesion volume in RR-MS.', 'subject score': 851, 'object score': 901}, 'PMID:17463078': {'publication date': '2007 May', 'sentence': 'Anaphylactic reaction to methylprednisolone in multiple sclerosis: a practical approach to alternative corticosteroids.', 'subject score': 1000, 'object score': 1000}, 'PMID:18336625': {'publication date': '2008 Aug', 'sentence': 'The effects of methylprednisolone and mitoxantrone on CCL5-induced migration of lymphocytes in multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:18342057': {'publication date': '2008 Jan', 'sentence': '[Cognitive impact of mitoxantrone and methylprednisolone in multiple sclerosis: an open label study].', 'subject score': 1000, 'object score': 1000}, 'PMID:19949030': {'publication date': '2009 Dec 01', 'sentence': 'A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS.', 'subject score': 888, 'object score': 1000}, 'PMID:21831398': {'publication date': '2011 Oct 15', 'sentence': 'BACKGROUND: High-dose intravenous methylprednisolone is the most common therapeutic modality to treat acute exacerbations in multiple sclerosis (MS).', 'subject score': 861, 'object score': 1000}, 'PMID:24289841': {'publication date': '2013 Dec', 'sentence': 'These include: access to high-dose methylprednisolone in the home, ensuring appropriate supervision and support; participation in national clinical research programs coordinated from hospital centers of excellence; provision of multidisciplinary clinic services where healthcare professionals across different disciplines can attend to the patient on the same day in the same center of care; development of individual and group-based cognitive therapy programs; educational programs focusing on the management of fatigue and cognitive impairment associated with MS; and educational programs focusing on optimal use of immunomodulating agents in MS patients.', 'subject score': 901, 'object score': 1000}, 'PMID:24604685': {'publication date': '2014 Dec', 'sentence': 'Efficacy of combination therapy with erythropoietin and methylprednisolone in clinical recovery of severe relapse in multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2668784': {'publication date': '1989 Aug', 'sentence': 'A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28450891': {'publication date': '2017 Jan', 'sentence': 'CONCLUSIONS: This study provided class II evidence that ACTH produced better examiner-assessed cumulative rates of relapses per patient than IVMP in the adjunctive treatment of breakthrough disease in multiple sclerosis.', 'subject score': 888, 'object score': 1000}, 'PMID:30603546': {'publication date': '2018 Apr', 'sentence': 'Combination treatment with MP and BM-MSCs provides a novel treatment protocol for enhancing therapeutic effects in MS.', 'subject score': 1000, 'object score': 1000}, 'PMID:3063777': {'publication date': '1988 Aug', 'sentence': 'Methylprednisolone in multiple sclerosis: a comparative dose study.', 'subject score': 1000, 'object score': 1000}, 'PMID:3065667': {'publication date': '1988 May-Jun', 'sentence': '[Prospective evaluation of the effectiveness of high doses of methylprednisolone in multiple sclerosis].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0026769---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7668599",
-              "object": "MONDO:0005301",
-              "publications": [
-                "PMID:10477400",
-                "PMID:10933772",
-                "PMID:14760960",
-                "PMID:15452302",
-                "PMID:15596745",
-                "PMID:15781847",
-                "PMID:15794385",
-                "PMID:16719908",
-                "PMID:17463078",
-                "PMID:18336625",
-                "PMID:18342057",
-                "PMID:19949030",
-                "PMID:21831398",
-                "PMID:24289841",
-                "PMID:24604685",
-                "PMID:2668784",
-                "PMID:28450891",
-                "PMID:30603546",
-                "PMID:3063777",
-                "PMID:3065667"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7293560,
-            "start": 570,
-            "end": 321528,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10359882': {'publication date': '1999 Jun', 'sentence': 'Such an effect has been demonstrated between clarithromycin and methylprednisolone, two drugs that may be administered concomitantly in asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:10567626': {'publication date': '1999 Dec', 'sentence': 'In blood mononuclear cells methylprednisolone reduced LTC(4) synthesis in asthmatic subjects from 1.26 to 0.79 ng/10(6) cells (95% CI for the reduction 0.26 to 0.79, p = 0.014) and tended to reduce LTC(4) synthesis in normal subjects from 1.51 to 0.86 ng/10(6) cells (p = 0.08).', 'subject score': 861, 'object score': 872}, 'PMID:20667503': {'publication date': '2010 Oct 31', 'sentence': 'Methylprednisolone (MP) is an important corticosteroid used in the treatment (through inhalation) of lung inflammation associated with asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:31308569': {'publication date': '2019 Jul', 'sentence': 'Single Intramuscular Methylprednisolone dose in Asthma and Chronic Obstructive Pulmonary Disease Patients on Discharge.', 'subject score': 833, 'object score': 1000}, 'PMID:7385823': {'publication date': '1980 Feb', 'sentence': 'Intravenously given methylprednisolone in refractory asthma.', 'subject score': 827, 'object score': 888}, 'PMID:8430965': {'publication date': '1993 Feb', 'sentence': 'A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids.', 'subject score': 1000, 'object score': 872}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7443745",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:10359882",
-                "PMID:10567626",
-                "PMID:20667503",
-                "PMID:31308569",
-                "PMID:7385823",
-                "PMID:8430965"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 309447,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005556",
-          "name": "lupus nephritis",
-          "description": "Glomerulonephritis in the context of systemic lupus erythematosus.; Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).; Lupus nephritis is a type of glomerulonephritis that constitutes one of the most severe organ manifestations of systemic lupus erythematosus. Lupus nephritis is subclassified in six distinct classes, that represent different manifestations and severities of renal involvement and guide the therapeutic management. [ORCID:0000-0002-2234-4248, PMID:31974366]",
-          "equivalent_curies": [
-            "MEDDRA:10025140",
-            "HP:0033726",
-            "MEDDRA:10029141",
-            "DOID:0080162",
-            "NCIT:C34789",
-            "UMLS:C0024143",
-            "MESH:D008181",
-            "MEDDRA:10029142",
-            "MONDO:0005556",
-            "SNOMEDCT:68815009",
-            "MEDDRA:10040970",
-            "EFO:0005761"
-          ],
-          "id": "MONDO:0005556",
-          "category": "biolink:Disease",
-          "all_names": [
-            "lupus nephritis",
-            "Lupus nephritis",
-            "Lupus Nephritis",
-            "Lupus Glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000481.htm",
-            "PMID:31974366",
-            "https://orcid.org/0000-0002-2234-4248",
-            "https://en.wikipedia.org/wiki/lupus_nephritis#cite_note-1"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 309447,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005556",
-              "name": "lupus nephritis",
-              "description": "Glomerulonephritis in the context of systemic lupus erythematosus.; Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).; Lupus nephritis is a type of glomerulonephritis that constitutes one of the most severe organ manifestations of systemic lupus erythematosus. Lupus nephritis is subclassified in six distinct classes, that represent different manifestations and severities of renal involvement and guide the therapeutic management. [ORCID:0000-0002-2234-4248, PMID:31974366]",
-              "equivalent_curies": [
-                "MEDDRA:10025140",
-                "HP:0033726",
-                "MEDDRA:10029141",
-                "DOID:0080162",
-                "NCIT:C34789",
-                "UMLS:C0024143",
-                "MESH:D008181",
-                "MEDDRA:10029142",
-                "MONDO:0005556",
-                "SNOMEDCT:68815009",
-                "MEDDRA:10040970",
-                "EFO:0005761"
-              ],
-              "id": "MONDO:0005556",
-              "category": "biolink:Disease",
-              "all_names": [
-                "lupus nephritis",
-                "Lupus nephritis",
-                "Lupus Nephritis",
-                "Lupus Glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000481.htm",
-                "PMID:31974366",
-                "https://orcid.org/0000-0002-2234-4248",
-                "https://en.wikipedia.org/wiki/lupus_nephritis#cite_note-1"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24515919,
-            "start": 570,
-            "end": 309447,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:36210823': {'publication date': '2022', 'sentence': 'In this study, low-dose methylprednisolone (0.8 mg/kg/day, MP) was used to induce a steroid-resistant lupus nephritis (SR-LN) mouse model in weeks one to four, and a therapeutic steroid dosage (MP 12 mg/kg/day) or a combined PNS (PNS 100 mg/kg/day) treatment was administered from week five to eight.', 'subject score': 901, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:causes---None---None---None---UMLS:C0024143---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "24973247",
-              "object": "MONDO:0005556",
-              "publications": [
-                "PMID:36210823"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 313324,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-          "name": "Edema",
-          "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MEDDRA:10030114",
-            "MEDDRA:10014234",
-            "MEDDRA:10014210",
-            "MEDDRA:10005890",
-            "HP:0000969",
-            "SNOMEDCT:267038008",
-            "SNOMEDCT:43498006",
-            "SNOMEDCT:79654002",
-            "MESH:D004487",
-            "UMLS:C0013604",
-            "MEDDRA:10016807",
-            "EFO:0009373",
-            "SNOMEDCT:423666004",
-            "UMLS:C0268000",
-            "NCIT:C3002",
-            "MEDDRA:10030095",
-            "SNOMEDCT:20741006",
-            "SYMP:0000538"
-          ],
-          "id": "HP:0000969",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Edema",
-            "Body fluid retention",
-            "edema"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313324,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-              "name": "Edema",
-              "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MEDDRA:10030114",
-                "MEDDRA:10014234",
-                "MEDDRA:10014210",
-                "MEDDRA:10005890",
-                "HP:0000969",
-                "SNOMEDCT:267038008",
-                "SNOMEDCT:43498006",
-                "SNOMEDCT:79654002",
-                "MESH:D004487",
-                "UMLS:C0013604",
-                "MEDDRA:10016807",
-                "EFO:0009373",
-                "SNOMEDCT:423666004",
-                "UMLS:C0268000",
-                "NCIT:C3002",
-                "MEDDRA:10030095",
-                "SNOMEDCT:20741006",
-                "SYMP:0000538"
-              ],
-              "id": "HP:0000969",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Edema",
-                "Body fluid retention",
-                "edema"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23723372,
-            "start": 570,
-            "end": 313324,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35099248': {'publication date': '2021 Dec 31', 'sentence': 'MP was administrated in three alternative ways: intraperitoneally during the induction of cytotoxic edema or immediately after finishing cytotoxic edema induction in a dose of 100 mg/kg b.w.; into the internal carotid artery within 2 h after finishing cytotoxic edema induction in a dose of 50 mg/kg b.w.; into internal carotid artery 10 min after edema induction by BBBd in a dose of 50 mg/kg b.w.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:causes---None---None---None---UMLS:C0013604---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "24161886",
-              "object": "HP:0000969",
-              "publications": [
-                "PMID:35099248"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18166641,
-            "start": 570,
-            "end": 183319,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26344122': {'publication date': '2015 Oct', 'sentence': \"On the other hand, daily administration of methylprednisolone and tenoxicam for 4 weeks caused increased inflammation and fibrosis and wasn't affective on protection of nerve physiomorphology.\", 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:causes---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "18534953",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:26344122"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17897128,
-            "start": 570,
-            "end": 319673,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25858943': {'publication date': '2015 Apr 09', 'sentence': 'Methylprednisolone was temporarily stopped while a broad work up for inflammatory and neoplastic causes was pursued.', 'subject score': 1000, 'object score': 853}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:causes---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "18260665",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:25858943"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16958248,
-            "start": 570,
-            "end": 321523,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24289285': {'publication date': '2013 Dec 01', 'sentence': 'Pneumocystis pneumonia induced by this dose of tacrolimus has been reported in many cases; however, we encountered a rare case of Pneumocystis pneumonia induced by low-dose tacrolimus and methylprednisolone.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:causes---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "17307095",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:24289285"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15580751,
-            "start": 570,
-            "end": 316891,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21983374': {'publication date': '2011 Oct', 'sentence': 'The increased interval in the administration of MP resulted in slightly greater pain and an increased prevalence of NeP.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:causes---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "15906641",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:21983374"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002049",
-          "name": "thrombocytopenia",
-          "description": "A reduction in the number of circulating thrombocytes. [HPO:probinson]; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T034",
-          "equivalent_curies": [
-            "UMLS:C0392386",
-            "SNOMEDCT:302215000",
-            "MEDDRA:10035545",
-            "MEDDRA:10043555",
-            "PDQ:CDR0000041408",
-            "MEDDRA:10024922",
-            "ICD10:D69.6",
-            "HP:0001873",
-            "NCIT:C3408",
-            "NCIT:C162108",
-            "MEDDRA:10035528",
-            "UMLS:C5201036",
-            "MEDDRA:10043560",
-            "DOID:1588",
-            "UMLS:CN130080",
-            "SYMP:0000114",
-            "MEDDRA:10038213",
-            "MEDDRA:10043546",
-            "MESH:D013921",
-            "MEDDRA:10035529",
-            "MEDDRA:10043569",
-            "UMLS:C0040034",
-            "MEDDRA:10043554",
-            "ICD9:287.5",
-            "MONDO:0002049",
-            "SNOMEDCT:415116008"
-          ],
-          "id": "MONDO:0002049",
-          "category": "biolink:Disease",
-          "all_names": [
-            "thrombocytopenia",
-            "Thrombocytopenia, unspecified",
-            "Low Platelet Count",
-            "Thrombocytopenia",
-            "Decreased platelet count"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/thrombocytopenia",
-            "http://www.merckmanuals.com/professional/hematology_and_oncology/thrombocytopenia_and_platelet_dysfunction/overview_of_platelet_disorders.htm",
-            "http://ghr.nlm.nih.gov/glossary=thrombocytopenia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002049",
-              "name": "thrombocytopenia",
-              "description": "A reduction in the number of circulating thrombocytes. [HPO:probinson]; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T034",
-              "equivalent_curies": [
-                "UMLS:C0392386",
-                "SNOMEDCT:302215000",
-                "MEDDRA:10035545",
-                "MEDDRA:10043555",
-                "PDQ:CDR0000041408",
-                "MEDDRA:10024922",
-                "ICD10:D69.6",
-                "HP:0001873",
-                "NCIT:C3408",
-                "NCIT:C162108",
-                "MEDDRA:10035528",
-                "UMLS:C5201036",
-                "MEDDRA:10043560",
-                "DOID:1588",
-                "UMLS:CN130080",
-                "SYMP:0000114",
-                "MEDDRA:10038213",
-                "MEDDRA:10043546",
-                "MESH:D013921",
-                "MEDDRA:10035529",
-                "MEDDRA:10043569",
-                "UMLS:C0040034",
-                "MEDDRA:10043554",
-                "ICD9:287.5",
-                "MONDO:0002049",
-                "SNOMEDCT:415116008"
-              ],
-              "id": "MONDO:0002049",
-              "category": "biolink:Disease",
-              "all_names": [
-                "thrombocytopenia",
-                "Thrombocytopenia, unspecified",
-                "Low Platelet Count",
-                "Thrombocytopenia",
-                "Decreased platelet count"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/thrombocytopenia",
-                "http://www.merckmanuals.com/professional/hematology_and_oncology/thrombocytopenia_and_platelet_dysfunction/overview_of_platelet_disorders.htm",
-                "http://ghr.nlm.nih.gov/glossary=thrombocytopenia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12887856,
-            "start": 570,
-            "end": 316686,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17548927': {'publication date': '2007 Jun', 'sentence': 'We describe that high-dose methylprednisolone (20 mg/kg) can induce multifocal osteonecrosis (ON) in conjunction with thrombocytopenia, hypofibrinogenemia, and hyperlipemia.', 'subject score': 901, 'object score': 1000}, 'PMID:32727666': {'publication date': '2020 Jul 02', 'sentence': 'Oxaliplatin and Methylprednisolone-induced Thrombocytopenia and Monocytopenia, Owing to Anti-GPIIbIIIa and -CD36 Antibodies in a Patient With Colorectal Cancer.', 'subject score': 851, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:causes---None---None---None---UMLS:C0040034---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "13166073",
-              "object": "MONDO:0002049",
-              "publications": [
-                "PMID:17548927",
-                "PMID:32727666"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 547845,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005359",
-          "name": "drug-induced liver injury",
-          "description": "A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10019795",
-            "UMLS:C0019193",
-            "MONDO:0005359",
-            "MESH:D056486",
-            "UMLS:C4277682",
-            "EFO:0004228",
-            "SNOMEDCT:197352008"
-          ],
-          "id": "MONDO:0005359",
-          "category": "biolink:Disease",
-          "all_names": [
-            "drug-induced liver injury",
-            "Chemical and Drug Induced Liver Injury",
-            "Hepatitis, Toxic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-8169-9049"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 547845,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005359",
-              "name": "drug-induced liver injury",
-              "description": "A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10019795",
-                "UMLS:C0019193",
-                "MONDO:0005359",
-                "MESH:D056486",
-                "UMLS:C4277682",
-                "EFO:0004228",
-                "SNOMEDCT:197352008"
-              ],
-              "id": "MONDO:0005359",
-              "category": "biolink:Disease",
-              "all_names": [
-                "drug-induced liver injury",
-                "Chemical and Drug Induced Liver Injury",
-                "Hepatitis, Toxic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-8169-9049"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12403697,
-            "start": 570,
-            "end": 547845,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16926305': {'publication date': '2006 Oct', 'sentence': 'OBJECTIVE: To report the third published case, as of April 8, 2006, of methylprednisolone-induced toxic hepatitis.', 'subject score': 861, 'object score': 861}, 'PMID:26075468': {'publication date': '2015 Jun', 'sentence': 'Methylprednisolone-induced Toxic Hepatitis After Intravenous Pulsed Therapy for Multiple Sclerosis Relapses.', 'subject score': 861, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:causes---None---None---None---UMLS:C0019193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "12672767",
-              "object": "MONDO:0005359",
-              "publications": [
-                "PMID:16926305",
-                "PMID:26075468"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322010,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005336",
-          "name": "myopathy",
-          "description": "A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. [HPO:probinson]; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C101216",
-            "MEDDRA:10028641",
-            "MEDDRA:10028640",
-            "MEDDRA:10028300",
-            "MEDDRA:10028649",
-            "ICD10:G72.9",
-            "MEDDRA:10028302",
-            "MEDDRA:10028301",
-            "SNOMEDCT:129565002",
-            "ICD9:359.9",
-            "HP:0003198",
-            "EFO:0004145",
-            "DOID:423",
-            "MONDO:0005336",
-            "UMLS:C0026848",
-            "MESH:D009135",
-            "MEDDRA:10013237"
-          ],
-          "id": "MONDO:0005336",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myopathy, unspecified",
-            "Myopathy",
-            "myopathy",
-            "Muscular Diseases"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/myopathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322010,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005336",
-              "name": "myopathy",
-              "description": "A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. [HPO:probinson]; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C101216",
-                "MEDDRA:10028641",
-                "MEDDRA:10028640",
-                "MEDDRA:10028300",
-                "MEDDRA:10028649",
-                "ICD10:G72.9",
-                "MEDDRA:10028302",
-                "MEDDRA:10028301",
-                "SNOMEDCT:129565002",
-                "ICD9:359.9",
-                "HP:0003198",
-                "EFO:0004145",
-                "DOID:423",
-                "MONDO:0005336",
-                "UMLS:C0026848",
-                "MESH:D009135",
-                "MEDDRA:10013237"
-              ],
-              "id": "MONDO:0005336",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myopathy, unspecified",
-                "Myopathy",
-                "myopathy",
-                "Muscular Diseases"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/myopathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8344300,
-            "start": 570,
-            "end": 322010,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11058428': {'publication date': '2000 Nov', 'sentence': 'To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.', 'subject score': 1000, 'object score': 851}, 'PMID:15534623': {'publication date': '2005 Apr', 'sentence': 'CONCLUSION: Our data suggest that MP in the dose recommended by the NASCIS may cause ACM.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:causes---None---None---None---UMLS:C0026848---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8525599",
-              "object": "MONDO:0005336",
-              "publications": [
-                "PMID:11058428",
-                "PMID:15534623"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26887731,
-            "start": 570,
-            "end": 319673,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9137685': {'publication date': '1996', 'sentence': 'However, high-dose steroids like dexamethasone or methylprednisolone had proven their clearcut anti-tumoral action.', 'subject score': 1000, 'object score': 574}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "27357949",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:9137685"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23979844,
-            "start": 570,
-            "end": 183319,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35439827': {'publication date': '2022 Apr 19', 'sentence': \"Methylprednisolone increases some astrogliosis and inflammation biomarkers' levels; however, it did not affect the apoptotic biomarkers.\", 'subject score': 1000, 'object score': 623}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "24420470",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:35439827"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23039988,
-            "start": 570,
-            "end": 183319,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34158797': {'publication date': '2021', 'sentence': 'Effect of Methylprednisolone on Inflammation and Coagulation in Patients with Severe COVID-19: A Retrospective Cohort Study.', 'subject score': 1000, 'object score': 1000}, 'PMID:6346605': {'publication date': '1983 Jul', 'sentence': 'Two prophylactic immunosuppressive drugs, cyclosporine and methylprednisolone (MP), were compared for their effect on the in situ inflammatory reaction of granulation tissue formation and on wound healing.', 'subject score': 1000, 'object score': 888}, 'PMID:650062': {'publication date': '1978 Jun', 'sentence': 'The effect of methyl prednisolone on meningeal inflammation.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "23472756",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:34158797",
-                "PMID:6346605",
-                "PMID:650062"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 530656,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005100",
-          "name": "systemic sclerosis",
-          "description": "A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.; A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:90291",
-            "EFO:0000717",
-            "UMLS:CN206012",
-            "MEDDRA:10036814",
-            "UMLS:C0036421",
-            "ICD10:M34.0",
-            "DOID:418",
-            "UMLS:C0700318",
-            "MEDDRA:10078638",
-            "SNOMEDCT:89155008",
-            "MONDO:0005100",
-            "ICD9:710.1",
-            "MEDDRA:10042953",
-            "PDQ:CDR0000587622",
-            "MESH:D012595",
-            "NCIT:C72070"
-          ],
-          "id": "MONDO:0005100",
-          "category": "biolink:Disease",
-          "all_names": [
-            "systemic sclerosis",
-            "Scleroderma, Systemic",
-            "Systemic sclerosis",
-            "Systemic Scleroderma",
-            "systemic scleroderma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://ghr.nlm.nih.gov/condition/systemic-scleroderma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 530656,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005100",
-              "name": "systemic sclerosis",
-              "description": "A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.; A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:90291",
-                "EFO:0000717",
-                "UMLS:CN206012",
-                "MEDDRA:10036814",
-                "UMLS:C0036421",
-                "ICD10:M34.0",
-                "DOID:418",
-                "UMLS:C0700318",
-                "MEDDRA:10078638",
-                "SNOMEDCT:89155008",
-                "MONDO:0005100",
-                "ICD9:710.1",
-                "MEDDRA:10042953",
-                "PDQ:CDR0000587622",
-                "MESH:D012595",
-                "NCIT:C72070"
-              ],
-              "id": "MONDO:0005100",
-              "category": "biolink:Disease",
-              "all_names": [
-                "systemic sclerosis",
-                "Scleroderma, Systemic",
-                "Systemic sclerosis",
-                "Systemic Scleroderma",
-                "systemic scleroderma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://ghr.nlm.nih.gov/condition/systemic-scleroderma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20132172,
-            "start": 570,
-            "end": 530656,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30134971': {'publication date': '2018 Aug 22', 'sentence': 'METHODS/DESIGN: This study is a 12-week, randomised, double-blind, placebo-controlled trial analysing the effects of high-dose intravenous methylprednisolone in very early SSc.', 'subject score': 861, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0036421---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "20530617",
-              "object": "MONDO:0005100",
-              "publications": [
-                "PMID:30134971"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319500,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0100130",
-          "name": "adult acute respiratory distress syndrome",
-          "description": "Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.; A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:J80",
-            "MEDDRA:10042839",
-            "UMLS:C4281993",
-            "MEDDRA:10038691",
-            "MEDDRA:10040579",
-            "DOID:11394",
-            "SNOMEDCT:196153002",
-            "ORPHANET:70578",
-            "MEDDRA:10042787",
-            "SNOMEDCT:67782005",
-            "MONDO:0100130",
-            "MEDDRA:10003083",
-            "MEDDRA:10038688",
-            "MEDDRA:10001410",
-            "HP:0002643",
-            "MEDDRA:10001407",
-            "MEDDRA:10000036",
-            "UMLS:C0852283",
-            "MEDDRA:10028973",
-            "UMLS:C0035222",
-            "MEDDRA:10001052",
-            "MEDDRA:10001409",
-            "MESH:D012128",
-            "SNOMEDCT:1179627006",
-            "UMLS:C1368020"
-          ],
-          "id": "MONDO:0100130",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adult acute respiratory distress syndrome",
-            "Neonatal respiratory distress",
-            "Respiratory Distress Syndrome, Adult",
-            "adult respiratory distress syndrome",
-            "Respiratory Distress Syndrome",
-            "Adult acute respiratory distress syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5392788/",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=adult+respiratory+distress+syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319500,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0100130",
-              "name": "adult acute respiratory distress syndrome",
-              "description": "Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.; A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:J80",
-                "MEDDRA:10042839",
-                "UMLS:C4281993",
-                "MEDDRA:10038691",
-                "MEDDRA:10040579",
-                "DOID:11394",
-                "SNOMEDCT:196153002",
-                "ORPHANET:70578",
-                "MEDDRA:10042787",
-                "SNOMEDCT:67782005",
-                "MONDO:0100130",
-                "MEDDRA:10003083",
-                "MEDDRA:10038688",
-                "MEDDRA:10001410",
-                "HP:0002643",
-                "MEDDRA:10001407",
-                "MEDDRA:10000036",
-                "UMLS:C0852283",
-                "MEDDRA:10028973",
-                "UMLS:C0035222",
-                "MEDDRA:10001052",
-                "MEDDRA:10001409",
-                "MESH:D012128",
-                "SNOMEDCT:1179627006",
-                "UMLS:C1368020"
-              ],
-              "id": "MONDO:0100130",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adult acute respiratory distress syndrome",
-                "Neonatal respiratory distress",
-                "Respiratory Distress Syndrome, Adult",
-                "adult respiratory distress syndrome",
-                "Respiratory Distress Syndrome",
-                "Adult acute respiratory distress syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5392788/",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=adult+respiratory+distress+syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19860414,
-            "start": 570,
-            "end": 319500,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29606872': {'publication date': '2018', 'sentence': 'Methods: The potential interferences Se@SiO2 nanocomposites may have to the therapeutic effect of methylprednisolone (MPS) were evaluated by classical therapeutic effect index of acute respiratory distress syndrome (ARDS), such as wet-to-dry weight ratio, inflammatory factors IL-1beta and TNF-alpha.', 'subject score': 1000, 'object score': 1000}, 'PMID:6783692': {'publication date': '1981 Apr', 'sentence': 'Effect of methylprednisolone on experimental noncardiogenic pulmonary edema.', 'subject score': 1000, 'object score': 928}, 'PMID:9669790': {'publication date': '1998 Jul 08', 'sentence': 'Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial.', 'subject score': 851, 'object score': 937}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0035222---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "20254789",
-              "object": "MONDO:0100130",
-              "publications": [
-                "PMID:29606872",
-                "PMID:6783692",
-                "PMID:9669790"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 546730,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002135",
-          "name": "optic nerve disorder",
-          "description": "A non-neoplastic or neoplastic disorder affecting the optic nerve (second cranial nerve).; Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.; The optic nerve is a bundle of more than 1 million nerve fibers that carry visual messages. You have one connecting the back of each eye (your retina) to your brain. Damage to an optic nerve can cause vision loss. The type of vision loss and how severe it is depends on where the damage occurs. It may affect one or both eyes. There are many different types of optic nerve disorders, including:  Glaucoma is a group of diseases that are the leading cause of blindness in the United States. Glaucoma usually happens when the fluid pressure inside the eyes slowly rises and damages the optic nerve. Optic neuritis is an inflammation of the optic nerve. Causes include infections and immune-related illnesses such as multiple sclerosis. Sometimes the cause is unknown. Optic nerve atrophy is damage to the optic nerve. Causes include poor blood flow to the eye, disease, trauma, or exposure to toxic substances. Optic nerve head drusen are pockets of protein and calcium salts that build up in the optic nerve over time  Contact your health care provider if you are having vision problems. Tests for optic nerve disorders may include eye exams, ophthalmoscopy (an examination of the back of your eye), and imaging tests. Treatment depends on which disorder that you have. With some optic nerve disorders, you may get your vision back. With others, there is no treatment, or treatment may only prevent further vision loss.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10061322",
-            "MESH:D009901",
-            "SNOMEDCT:77157004",
-            "UMLS:C0029132",
-            "NCIT:C79698",
-            "MONDO:0002135",
-            "DOID:1891",
-            "MEDDRA:10030932"
-          ],
-          "id": "MONDO:0002135",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Disorder of the optic nerve",
-            "Optic Nerve Disorder",
-            "optic nerve disease",
-            "Optic Nerve Diseases",
-            "optic nerve disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nature.com/eye/journal/v18/n11/full/6701575a.htm",
-            "http://www.academy.org.uk/lectures/barnard3.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546730,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002135",
-              "name": "optic nerve disorder",
-              "description": "A non-neoplastic or neoplastic disorder affecting the optic nerve (second cranial nerve).; Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.; The optic nerve is a bundle of more than 1 million nerve fibers that carry visual messages. You have one connecting the back of each eye (your retina) to your brain. Damage to an optic nerve can cause vision loss. The type of vision loss and how severe it is depends on where the damage occurs. It may affect one or both eyes. There are many different types of optic nerve disorders, including:  Glaucoma is a group of diseases that are the leading cause of blindness in the United States. Glaucoma usually happens when the fluid pressure inside the eyes slowly rises and damages the optic nerve. Optic neuritis is an inflammation of the optic nerve. Causes include infections and immune-related illnesses such as multiple sclerosis. Sometimes the cause is unknown. Optic nerve atrophy is damage to the optic nerve. Causes include poor blood flow to the eye, disease, trauma, or exposure to toxic substances. Optic nerve head drusen are pockets of protein and calcium salts that build up in the optic nerve over time  Contact your health care provider if you are having vision problems. Tests for optic nerve disorders may include eye exams, ophthalmoscopy (an examination of the back of your eye), and imaging tests. Treatment depends on which disorder that you have. With some optic nerve disorders, you may get your vision back. With others, there is no treatment, or treatment may only prevent further vision loss.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10061322",
-                "MESH:D009901",
-                "SNOMEDCT:77157004",
-                "UMLS:C0029132",
-                "NCIT:C79698",
-                "MONDO:0002135",
-                "DOID:1891",
-                "MEDDRA:10030932"
-              ],
-              "id": "MONDO:0002135",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Disorder of the optic nerve",
-                "Optic Nerve Disorder",
-                "optic nerve disease",
-                "Optic Nerve Diseases",
-                "optic nerve disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nature.com/eye/journal/v18/n11/full/6701575a.htm",
-                "http://www.academy.org.uk/lectures/barnard3.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17294741,
-            "start": 570,
-            "end": 546730,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24841498': {'publication date': '2014 Oct', 'sentence': 'Our case likely represents worsening of DON due to soft tissue swelling secondary to OR despite cover with IVMP in a patient previously responsive to IVMP alone.', 'subject score': 888, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0029132---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "17649050",
-              "object": "MONDO:0002135",
-              "publications": [
-                "PMID:24841498"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 518734,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009688",
-          "name": "myasthenia gravis",
-          "description": "A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness. It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.; A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.; Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest. Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker. Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps. Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:G70.00",
-            "ICD9:358.0",
-            "OMIM:254200",
-            "PSY:32760",
-            "MESH:D009157",
-            "MEDDRA:10028420",
-            "ICD10:G70.0",
-            "EFO:0004991",
-            "ICD9:358.00",
-            "ORPHANET:589",
-            "UMLS:C1260409",
-            "MEDDRA:10028417",
-            "DOID:437",
-            "UMLS:C0026896",
-            "SNOMEDCT:91637004",
-            "MONDO:0009688",
-            "NCIT:C60989"
-          ],
-          "id": "MONDO:0009688",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myasthenia gravis without (acute) exacerbation",
-            "myasthenia gravis without acute exacerbation",
-            "myasthenia gravis",
-            "Myasthenia Gravis",
-            "Myasthenia gravis",
-            "Myasthenia gravis related phenotypic feature"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.ninds.nih.gov/disorders/patient-caregiver-education/fact-sheets/myasthenia-gravis-fact-sheet"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 518734,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009688",
-              "name": "myasthenia gravis",
-              "description": "A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness. It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.; A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.; Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest. Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker. Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps. Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:G70.00",
-                "ICD9:358.0",
-                "OMIM:254200",
-                "PSY:32760",
-                "MESH:D009157",
-                "MEDDRA:10028420",
-                "ICD10:G70.0",
-                "EFO:0004991",
-                "ICD9:358.00",
-                "ORPHANET:589",
-                "UMLS:C1260409",
-                "MEDDRA:10028417",
-                "DOID:437",
-                "UMLS:C0026896",
-                "SNOMEDCT:91637004",
-                "MONDO:0009688",
-                "NCIT:C60989"
-              ],
-              "id": "MONDO:0009688",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myasthenia gravis without (acute) exacerbation",
-                "myasthenia gravis without acute exacerbation",
-                "myasthenia gravis",
-                "Myasthenia Gravis",
-                "Myasthenia gravis",
-                "Myasthenia gravis related phenotypic feature"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.ninds.nih.gov/disorders/patient-caregiver-education/fact-sheets/myasthenia-gravis-fact-sheet"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16296294,
-            "start": 570,
-            "end": 518734,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2319723': {'publication date': '1990 Mar', 'sentence': '[Treatment of invasive thymoma with myasthenia gravis: a case report responsive to azathioprine and methylprednisolone].', 'subject score': 1000, 'object score': 1000}, 'PMID:33318935': {'publication date': '2021 Jan', 'sentence': 'Myocarditis with concomitant myasthenia gravis (MG) has a mortality rate of 50%, and a high dose of methylprednisolone (mPSL) should be administered with careful attention to MG exacerbation.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0026896---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "16634377",
-              "object": "MONDO:0009688",
-              "publications": [
-                "PMID:2319723",
-                "PMID:33318935"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 529953,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019100",
-          "name": "neuromyelitis optica",
-          "description": "An autoimmune inflammatory syndrome characterized by optic neuritis and myelitis. Signs and symptoms include loss of vision, weakness and paralysis of the extremities, and loss of sensation.; A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10058009",
-            "MEDDRA:10077875",
-            "NCIT:C84934",
-            "MEDDRA:10052887",
-            "SNOMEDCT:25044007",
-            "MEDDRA:10029322",
-            "MEDDRA:10041225",
-            "MESH:D009471",
-            "DOID:8869",
-            "MEDDRA:10012574",
-            "ICD9:341.0",
-            "UMLS:C0027873",
-            "UMLS:C0221059",
-            "MONDO:0019100",
-            "EFO:0004256",
-            "ICD10:G36.0",
-            "ORPHANET:71211"
-          ],
-          "id": "MONDO:0019100",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neuromyelitis Optica",
-            "Neuromyelitis optica",
-            "neuromyelitis optica"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/neuromyelitis_optica",
-            "http://rarediseases.org/rare-diseases/neuromyelitis-optica/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 529953,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019100",
-              "name": "neuromyelitis optica",
-              "description": "An autoimmune inflammatory syndrome characterized by optic neuritis and myelitis. Signs and symptoms include loss of vision, weakness and paralysis of the extremities, and loss of sensation.; A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10058009",
-                "MEDDRA:10077875",
-                "NCIT:C84934",
-                "MEDDRA:10052887",
-                "SNOMEDCT:25044007",
-                "MEDDRA:10029322",
-                "MEDDRA:10041225",
-                "MESH:D009471",
-                "DOID:8869",
-                "MEDDRA:10012574",
-                "ICD9:341.0",
-                "UMLS:C0027873",
-                "UMLS:C0221059",
-                "MONDO:0019100",
-                "EFO:0004256",
-                "ICD10:G36.0",
-                "ORPHANET:71211"
-              ],
-              "id": "MONDO:0019100",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neuromyelitis Optica",
-                "Neuromyelitis optica",
-                "neuromyelitis optica"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/neuromyelitis_optica",
-                "http://rarediseases.org/rare-diseases/neuromyelitis-optica/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15945560,
-            "start": 570,
-            "end": 529953,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22576570': {'publication date': '2012', 'sentence': 'High-dose intravenous methylprednisolone is the first-line therapy for acute exacerbations of NMO.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0027873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "16277488",
-              "object": "MONDO:0019100",
-              "publications": [
-                "PMID:22576570"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15580752,
-            "start": 570,
-            "end": 316891,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21983374': {'publication date': '2011 Oct', 'sentence': 'CONCLUSION: Although the delayed administration of high-dose MP did not significantly increase the severity of pain or prevalence of NeP, it should still be avoided due to the increased risk of serious side effects.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "15906642",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:21983374"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318890,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-          "name": "rheumatoid arthritis",
-          "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C2884",
-            "PSY:44570",
-            "EFO:0000685",
-            "ICD9:714.0",
-            "KEGG.DISEASE:05323",
-            "MONDO:0008383",
-            "UMLS:C0003873",
-            "UMLS:C1306838",
-            "UMLS:C1833448",
-            "MEDDRA:10037740",
-            "MEDDRA:10039073",
-            "OMIM:180300",
-            "MESH:D001172",
-            "MEDDRA:10003268",
-            "HP:0001370",
-            "ORPHANET:284130",
-            "SNOMEDCT:69896004",
-            "ICD10:M06.9",
-            "DOID:7148",
-            "MEDDRA:10036856",
-            "MEDDRA:10042952"
-          ],
-          "id": "MONDO:0008383",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Proliferative arthritis",
-            "Arthritis, Rheumatoid",
-            "rheumatoid arthritis",
-            "Rheumatoid arthritis",
-            "Rheumatoid Arthritis",
-            "Rheumatoid arthritis related phenotypic feature",
-            "Rheumatoid arthritis, susceptibility to"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-            "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-            "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318890,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-              "name": "rheumatoid arthritis",
-              "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C2884",
-                "PSY:44570",
-                "EFO:0000685",
-                "ICD9:714.0",
-                "KEGG.DISEASE:05323",
-                "MONDO:0008383",
-                "UMLS:C0003873",
-                "UMLS:C1306838",
-                "UMLS:C1833448",
-                "MEDDRA:10037740",
-                "MEDDRA:10039073",
-                "OMIM:180300",
-                "MESH:D001172",
-                "MEDDRA:10003268",
-                "HP:0001370",
-                "ORPHANET:284130",
-                "SNOMEDCT:69896004",
-                "ICD10:M06.9",
-                "DOID:7148",
-                "MEDDRA:10036856",
-                "MEDDRA:10042952"
-              ],
-              "id": "MONDO:0008383",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Proliferative arthritis",
-                "Arthritis, Rheumatoid",
-                "rheumatoid arthritis",
-                "Rheumatoid arthritis",
-                "Rheumatoid Arthritis",
-                "Rheumatoid arthritis related phenotypic feature",
-                "Rheumatoid arthritis, susceptibility to"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-                "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-                "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15289478,
-            "start": 570,
-            "end": 318890,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21532737': {'publication date': '2011 Apr 12', 'sentence': 'Methylprednisolone has been used in other Th1 mediated diseases such as rheumatoid arthritis in an attempt to switch off the immune response and so we investigated the efficacy of three days of high dose (1 g) intravenous methylprednisolone at the start of prednisolone therapy in leprosy Type 1 reactions and nerve function impairment.', 'subject score': 1000, 'object score': 1000}, 'PMID:3144941': {'publication date': '1988 Nov', 'sentence': \"A trial was designed to assess the effects of intramuscular sodium aurothiomalate or intravenous cyclophosphamide, or both, in combination with intravenous 'pulse' methylprednisolone in severe intractable rheumatoid arthritis.\", 'subject score': 802, 'object score': 861}, 'PMID:3361534': {'publication date': '1988 Feb', 'sentence': 'The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis.', 'subject score': 790, 'object score': 1000}, 'PMID:3361535': {'publication date': '1988 Feb', 'sentence': 'The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis.', 'subject score': 790, 'object score': 1000}, 'PMID:3361536': {'publication date': '1988 Feb', 'sentence': 'The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis.', 'subject score': 790, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0003873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "15610554",
-              "object": "MONDO:0008383",
-              "publications": [
-                "PMID:21532737",
-                "PMID:3144941",
-                "PMID:3361534",
-                "PMID:3361535",
-                "PMID:3361536"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 520401,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0013730",
-          "name": "graft versus host disease",
-          "description": "A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.; The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PDQ:CDR0000041575",
-            "NCIT:C3063",
-            "MEDDRA:10018798",
-            "UMLS:C0018133",
-            "MESH:D006086",
-            "DOID:0081267",
-            "MONDO:0013730",
-            "MEDDRA:10018799",
-            "SNOMEDCT:234646005",
-            "ICD9:279.5",
-            "ORPHANET:39812",
-            "MEDDRA:10018651"
-          ],
-          "id": "MONDO:0013730",
-          "category": "biolink:Disease",
-          "all_names": [
-            "graft versus host disease",
-            "graft-versus-host disease",
-            "Graft-versus-host disease",
-            "Graft Versus Host Disease",
-            "Graft versus host disease",
-            "Graft-vs-Host Disease",
-            "Graft vs Host Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:31466596",
-            "https://www.ncbi.nlm.nih.gov/books/nbk538235/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520401,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0013730",
-              "name": "graft versus host disease",
-              "description": "A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.; The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PDQ:CDR0000041575",
-                "NCIT:C3063",
-                "MEDDRA:10018798",
-                "UMLS:C0018133",
-                "MESH:D006086",
-                "DOID:0081267",
-                "MONDO:0013730",
-                "MEDDRA:10018799",
-                "SNOMEDCT:234646005",
-                "ICD9:279.5",
-                "ORPHANET:39812",
-                "MEDDRA:10018651"
-              ],
-              "id": "MONDO:0013730",
-              "category": "biolink:Disease",
-              "all_names": [
-                "graft versus host disease",
-                "graft-versus-host disease",
-                "Graft-versus-host disease",
-                "Graft Versus Host Disease",
-                "Graft versus host disease",
-                "Graft-vs-Host Disease",
-                "Graft vs Host Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:31466596",
-                "https://www.ncbi.nlm.nih.gov/books/nbk538235/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14872342,
-            "start": 570,
-            "end": 520401,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20809972': {'publication date': '2010 Sep 01', 'sentence': 'Myelitis in these patients was not related to graft versus host disease or immune reconstitution and was responsive to intravenous methylprednisolone and cyclophosphamide.', 'subject score': 888, 'object score': 937}, 'PMID:27465468': {'publication date': '2016 Jul 28', 'sentence': 'After 24 cobalt Gy equivalent, he developed severe cutaneous graft-versus-host disease, sharply delineated within the radiation therapy field, which was responsive to tacrolimus and methylprednisolone.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0018133---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "15186368",
-              "object": "MONDO:0013730",
-              "publications": [
-                "PMID:20809972",
-                "PMID:27465468"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319192,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-          "name": "kidney disorder",
-          "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D007674",
-            "MEDDRA:10029154",
-            "UMLS:C0022658",
-            "NCIT:C3149",
-            "MONDO:0005240",
-            "UMLS:C1408258",
-            "DOID:557",
-            "MEDDRA:10029149",
-            "HP:0000112",
-            "MEDDRA:10051051",
-            "NCIT:C34843",
-            "MEDDRA:10038428",
-            "MEDDRA:10038429",
-            "MEDDRA:10029151",
-            "MEDDRA:10051052",
-            "EFO:0003086",
-            "SNOMEDCT:90708001",
-            "MEDDRA:10013263",
-            "PSY:27347"
-          ],
-          "id": "MONDO:0005240",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Kidney damage",
-            "kidney disease",
-            "Nephropathy",
-            "Kidney Diseases",
-            "Kidney Disorder",
-            "kidney disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319192,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-              "name": "kidney disorder",
-              "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D007674",
-                "MEDDRA:10029154",
-                "UMLS:C0022658",
-                "NCIT:C3149",
-                "MONDO:0005240",
-                "UMLS:C1408258",
-                "DOID:557",
-                "MEDDRA:10029149",
-                "HP:0000112",
-                "MEDDRA:10051051",
-                "NCIT:C34843",
-                "MEDDRA:10038428",
-                "MEDDRA:10038429",
-                "MEDDRA:10029151",
-                "MEDDRA:10051052",
-                "EFO:0003086",
-                "SNOMEDCT:90708001",
-                "MEDDRA:10013263",
-                "PSY:27347"
-              ],
-              "id": "MONDO:0005240",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Kidney damage",
-                "kidney disease",
-                "Nephropathy",
-                "Kidney Diseases",
-                "Kidney Disorder",
-                "kidney disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14582089,
-            "start": 570,
-            "end": 319192,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2025290': {'publication date': '1991 Apr 30', 'sentence': 'We investigated the effects of YM264, WEB2086, methylprednisolone and ticlopidine on puromycin-induced nephropathy in the rat.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0022658---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14891106",
-              "object": "MONDO:0005240",
-              "publications": [
-                "PMID:2025290"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 539362,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043797",
-          "name": "spinal cord injury",
-          "description": "Traumatic damage of the spinal cord.; Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).; Your spinal cord is a bundle of nerves that runs down the middle of your back. It carries signals back and forth between your body and your brain. A spinal cord injury disrupts the signals. Spinal cord injuries usually begin with a blow that fractures (breaks) or dislocates your vertebrae, the bone disks that make up your spine. Most injuries don't cut through your spinal cord. Instead, they cause damage when pieces of vertebrae tear into cord tissue or press down on the nerve parts that carry signals. Spinal cord injuries can be complete or incomplete. With a complete spinal cord injury, the cord can't send signals below the level of the injury. As a result, you are paralyzed below the injury. With an incomplete injury, you have some movement and sensation below the injury. A spinal cord injury is a medical emergency. Immediate treatment can reduce long-term effects. Treatments may include medicines, braces or traction to stabilize the spine, and surgery. Later treatment usually includes medicines and rehabilitation therapy. Mobility aids and assistive devices may help you to get around and do some daily tasks. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "EFO:1001919",
-            "MESH:D013119",
-            "ORPHANET:90058",
-            "SNOMEDCT:90584004",
-            "MONDO:0043797",
-            "UMLS:C0037929",
-            "MEDDRA:10041552",
-            "NCIT:C50750"
-          ],
-          "id": "MONDO:0043797",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Spinal Cord Injury",
-            "spinal cord injury",
-            "Spinal Cord Injuries",
-            "Spinal cord injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 539362,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043797",
-              "name": "spinal cord injury",
-              "description": "Traumatic damage of the spinal cord.; Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).; Your spinal cord is a bundle of nerves that runs down the middle of your back. It carries signals back and forth between your body and your brain. A spinal cord injury disrupts the signals. Spinal cord injuries usually begin with a blow that fractures (breaks) or dislocates your vertebrae, the bone disks that make up your spine. Most injuries don't cut through your spinal cord. Instead, they cause damage when pieces of vertebrae tear into cord tissue or press down on the nerve parts that carry signals. Spinal cord injuries can be complete or incomplete. With a complete spinal cord injury, the cord can't send signals below the level of the injury. As a result, you are paralyzed below the injury. With an incomplete injury, you have some movement and sensation below the injury. A spinal cord injury is a medical emergency. Immediate treatment can reduce long-term effects. Treatments may include medicines, braces or traction to stabilize the spine, and surgery. Later treatment usually includes medicines and rehabilitation therapy. Mobility aids and assistive devices may help you to get around and do some daily tasks. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "EFO:1001919",
-                "MESH:D013119",
-                "ORPHANET:90058",
-                "SNOMEDCT:90584004",
-                "MONDO:0043797",
-                "UMLS:C0037929",
-                "MEDDRA:10041552",
-                "NCIT:C50750"
-              ],
-              "id": "MONDO:0043797",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Spinal Cord Injury",
-                "spinal cord injury",
-                "Spinal Cord Injuries",
-                "Spinal cord injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11567370,
-            "start": 570,
-            "end": 539362,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1588630': {'publication date': '1992 Mar', 'sentence': 'The study strongly suggests that methylprednisolone has significant beneficial effects in human spinal cord injury, that these effects occur only when the drug is given within 8 hr, and that it helps even in patients with severe spinal cord injuries.', 'subject score': 1000, 'object score': 916}, 'PMID:16018585': {'publication date': '2005 Mar', 'sentence': 'This study was aimed to investigate the possible beneficial effects of Ebselen in comparison with Methylprednisolone in experimental SCI.', 'subject score': 1000, 'object score': 916}, 'PMID:21139782': {'publication date': '2007 Oct', 'sentence': 'CONCLUSION: First aid measures of early closed reduction or realignment and immobilization of the cervical spine, breathing support and high-dose methylprednisolone were most important in the treatment for traumatic spinal cord injury.', 'subject score': 901, 'object score': 916}, 'PMID:21167389': {'publication date': '2010 Oct', 'sentence': 'BACKGROUND AND AIMS: We undertook this study to investigate the possible beneficial effects of combined hypothermia and hyperbaric oxygen (HBO) treatment in comparison with methylprednisolone in experimental spinal cord injury (SCI).', 'subject score': 1000, 'object score': 916}, 'PMID:25206681': {'publication date': '2013 Feb 15', 'sentence': 'Methylprednisolone plays an effective role in treating spinal cord injury, but the effect of methylprednisolone on Nogo-A in the injured spinal cord remains unknown.', 'subject score': 1000, 'object score': 916}, 'PMID:2907111': {'publication date': '1988 Dec', 'sentence': 'Effects of methyl prednisolone, dimethyl sulphoxide and naloxone in experimental spinal cord injuries in rats.', 'subject score': 1000, 'object score': 916}, 'PMID:31760579': {'publication date': '2019 Nov 23', 'sentence': 'OBJECTIVE: To investigate the functions and mechanisms of methylprednisolone (MP) through endothelin receptor B (EDNRB) on the cell proliferation of neural progenitor cells (NPCs) to regulate spinal cord injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:8876716': {'publication date': '1996 Oct', 'sentence': 'The effects of taxol, methylprednisolone, and 4-aminopyridine in compressive spinal cord injury: a qualitative experimental study.', 'subject score': 1000, 'object score': 923}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0037929---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "11819955",
-              "object": "MONDO:0043797",
-              "publications": [
-                "PMID:1588630",
-                "PMID:16018585",
-                "PMID:21139782",
-                "PMID:21167389",
-                "PMID:25206681",
-                "PMID:2907111",
-                "PMID:31760579",
-                "PMID:8876716"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10609908,
-            "start": 570,
-            "end": 316891,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14600686': {'publication date': '2003 Nov', 'sentence': 'Comparison of the effects of 2 doses of methylprednisolone on pain, swelling, and trismus after third molar surgery.', 'subject score': 1000, 'object score': 1000}, 'PMID:17426908': {'publication date': '2007 Oct', 'sentence': 'Different pain symptoms and the effect of methylprednisolone on pain are evaluated.', 'subject score': 1000, 'object score': 1000}, 'PMID:21131371': {'publication date': '2011 Feb', 'sentence': 'Effect of high-dose preoperative methylprednisolone on pain and recovery after total knee arthroplasty: a randomized, placebo-controlled trial.', 'subject score': 861, 'object score': 1000}, 'PMID:24959459': {'publication date': '2014 Apr', 'sentence': 'Effect of intravenous methylprednisolone on pain after intertrochanteric femoral fracture surgery.', 'subject score': 888, 'object score': 1000}, 'PMID:25564196': {'publication date': '2017 Jan', 'sentence': 'The purpose of the study was to evaluate the effect of a single preoperative dose of systemic methylprednisolone on postsurgical pain after fast-track UKA.', 'subject score': 888, 'object score': 861}, 'PMID:27077747': {'publication date': '2016', 'sentence': 'Effect of Pulsed Methylprednisolone on Pain, in Patients with HTLV-1-Associated Myelopathy.', 'subject score': 872, 'object score': 1000}, 'PMID:28361779': {'publication date': '2016 01', 'sentence': 'Present study sought to determine effects of intrathecally delivered methylprednisolone on pain-like behaviour and pain-associated markers in three well established rodent pain models: (1) intraplantar carrageenan, (2) intraplantar formalin, and (3) ligation of L5/L6 spinal nerves (SNL model).', 'subject score': 773, 'object score': 1000}, 'PMID:28842370': {'publication date': '2017 Dec', 'sentence': 'The Effect of Preoperative Intra-Articular Methylprednisolone on Pain After TKA: A Randomized Double-Blinded Placebo Controlled Trial in Patients With High-Pain Knee Osteoarthritis and Sensitization.', 'subject score': 861, 'object score': 1000}, 'PMID:29200067': {'publication date': '2018 May', 'sentence': 'The estimated effect of 125 mg of methylprednisolone on pain at rest during the first 3 days after surgery was a nonsignificant increase of 0.2 (95% confidence interval, -0.5 to 0.9; P = .571) on the 11-point numerical rating scale.', 'subject score': 1000, 'object score': 1000}, 'PMID:3457335': {'publication date': '1986 Feb', 'sentence': 'The effect of methylprednisolone on pain, trismus, and swelling after removal of third molars.', 'subject score': 1000, 'object score': 1000}, 'PMID:35251416': {'publication date': '2022', 'sentence': 'Conclusions: Infiltration injection of dexamethasone and methylprednisolone had a significant effect in reducing pain after the endodontic treatment in necrotic pulp teeth, but between 6 and 12 hours, methylprednisolone had significantly more effect on pain relief than dexamethasone.', 'subject score': 1000, 'object score': 888}, 'PMID:9010948': {'publication date': '1997 Jan-Feb', 'sentence': 'Effect of local methylprednisolone on pain in a nerve injury model.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10845505",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:14600686",
-                "PMID:17426908",
-                "PMID:21131371",
-                "PMID:24959459",
-                "PMID:25564196",
-                "PMID:27077747",
-                "PMID:28361779",
-                "PMID:28842370",
-                "PMID:29200067",
-                "PMID:3457335",
-                "PMID:35251416",
-                "PMID:9010948"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9831607,
-            "start": 570,
-            "end": 322104,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12603510': {'publication date': '2003 Mar', 'sentence': 'Steatohepatitis during methylprednisolone therapy for ulcerative colitis exacerbation.', 'subject score': 888, 'object score': 734}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10048898",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:12603510"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 522619,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005301",
-          "name": "multiple sclerosis",
-          "description": "An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D009103",
-            "NCIT:C3243",
-            "MEDDRA:10039720",
-            "EFO:0003885",
-            "ORPHANET:802",
-            "MEDDRA:10028245",
-            "PSY:32490",
-            "ICD9:340",
-            "MONDO:0005301",
-            "MEDDRA:10028053",
-            "UMLS:C0026769",
-            "MEDDRA:10013451",
-            "SNOMEDCT:24700007",
-            "ICD10:G35",
-            "PDQ:CDR0000691761",
-            "DOID:2377"
-          ],
-          "id": "MONDO:0005301",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Multiple Sclerosis",
-            "obsolete_multiple sclerosis",
-            "Multiple sclerosis",
-            "multiple sclerosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://ghr.nlm.nih.gov/condition/multiple-sclerosis",
-            "http://en.wikipedia.org/wiki/multiple_sclerosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 522619,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005301",
-              "name": "multiple sclerosis",
-              "description": "An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D009103",
-                "NCIT:C3243",
-                "MEDDRA:10039720",
-                "EFO:0003885",
-                "ORPHANET:802",
-                "MEDDRA:10028245",
-                "PSY:32490",
-                "ICD9:340",
-                "MONDO:0005301",
-                "MEDDRA:10028053",
-                "UMLS:C0026769",
-                "MEDDRA:10013451",
-                "SNOMEDCT:24700007",
-                "ICD10:G35",
-                "PDQ:CDR0000691761",
-                "DOID:2377"
-              ],
-              "id": "MONDO:0005301",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Multiple Sclerosis",
-                "obsolete_multiple sclerosis",
-                "Multiple sclerosis",
-                "multiple sclerosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://ghr.nlm.nih.gov/condition/multiple-sclerosis",
-                "http://en.wikipedia.org/wiki/multiple_sclerosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9438360,
-            "start": 570,
-            "end": 522619,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12113297': {'publication date': '2002 May', 'sentence': 'These results suggest that increasing the uric acid concentration may represent one of the possible mechanisms of action of methylprednisolone in multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:14607304': {'publication date': '2003 Dec 15', 'sentence': 'Immune parameters associated with early treatment effects of high-dose intravenous methylprednisolone in multiple sclerosis.', 'subject score': 861, 'object score': 1000}, 'PMID:15503100': {'publication date': '2004 Oct', 'sentence': 'Suppression of immune system genes by methylprednisolone in exacerbations of multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:16135002': {'publication date': '2005 Oct', 'sentence': 'METHODS: Nasal NO was measured in 15 patients without any history of allergy or chronic airway disorder who were treated for 3 days with a daily dose of 1000 mg methylprednisolone for an exacerbation of multiple sclerosis.', 'subject score': 790, 'object score': 1000}, 'PMID:16441245': {'publication date': '2006 Mar', 'sentence': 'Our purpose was to analyze the effect of IVMP on the expression of chemokine receptor 5 (CCR5) protein in blood in acute MS exacerbation.', 'subject score': 888, 'object score': 658}, 'PMID:16723156': {'publication date': '2006 Jul', 'sentence': 'The aim of our study was to determine whether high doses of intravenous methylprednisolone have significant impact on immune parameters during the multiple sclerosis (MS) exacerbations.', 'subject score': 888, 'object score': 734}, 'PMID:2291728': {'publication date': '1990 Dec', 'sentence': 'Methylprednisolone in multiple sclerosis exacerbation: changes in CSF parameters.', 'subject score': 1000, 'object score': 734}, 'PMID:2540005': {'publication date': '1989', 'sentence': '30 patients with acute exacerbations of multiple sclerosis were treated by ACTH, dexamethasone or methylprednisolone in a double-blind randomized study.', 'subject score': 1000, 'object score': 1000}, 'PMID:26120075': {'publication date': '2016 Feb', 'sentence': 'Because IVMP doses significantly higher than 30 mg are usually required to treat MS exacerbations, the lower cortisol-equivalent exposure of 80 U ACTH analog supports the hypothesis that efficacy of ACTH analog results from both steroid-dependent and -independent properties.', 'subject score': 851, 'object score': 734}, 'PMID:27154441': {'publication date': '2016', 'sentence': 'These observations demonstrate one of the potential mechanisms of MP action in MS, distinct from inducing cell apoptosis, and suggests the new targets for development of more effective MS treatments.', 'subject score': 694, 'object score': 1000}, 'PMID:6842212': {'publication date': '1983 Jan', 'sentence': 'High dose intravenous methyl prednisolone in acute exacerbations of multiple sclerosis.', 'subject score': 861, 'object score': 1000}, 'PMID:6967197': {'publication date': '1980 Jul', 'sentence': 'Prolonged effects of large-dose methylprednisolone infusion in multiple sclerosis.', 'subject score': 833, 'object score': 1000}, 'PMID:8060761': {'publication date': '1994 May', 'sentence': 'Although cloaked in controversy, some recent highlights include the possibility that high-dose intravenous methylprednisolone may affect the development of multiple sclerosis, the suggestion that prednisone may have little efficacy in the management of high-risk pregnancy in patients with antiphospholipid antibodies, and several observations that administration of calcium and vitamin D prevents bone loss in patients receiving steroids.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0026769---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "9646753",
-              "object": "MONDO:0005301",
-              "publications": [
-                "PMID:12113297",
-                "PMID:14607304",
-                "PMID:15503100",
-                "PMID:16135002",
-                "PMID:16441245",
-                "PMID:16723156",
-                "PMID:2291728",
-                "PMID:2540005",
-                "PMID:26120075",
-                "PMID:27154441",
-                "PMID:6842212",
-                "PMID:6967197",
-                "PMID:8060761"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 324986,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-          "name": "chronic obstructive pulmonary disease",
-          "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-          "equivalent_curies": [
-            "MESH:D029424",
-            "MEDDRA:10010952",
-            "MEDDRA:10009025",
-            "ICD10:J44.9",
-            "UMLS:C1527303",
-            "NCIT:C3199",
-            "UMLS:C0024117",
-            "MEDDRA:10064611",
-            "MEDDRA:10009026",
-            "MEDDRA:10029972",
-            "DOID:3083",
-            "MONDO:0005002",
-            "MEDDRA:10009032",
-            "MEDDRA:10070975",
-            "EFO:0000341",
-            "SNOMEDCT:13645005",
-            "MEDDRA:10009033",
-            "HP:0006510",
-            "MEDDRA:10008828"
-          ],
-          "id": "MONDO:0005002",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic Obstructive Pulmonary Disease",
-            "chronic obstructive pulmonary disease",
-            "Chronic pulmonary obstruction",
-            "Chronic Airflow Obstruction",
-            "Chronic Obstructive Airway Disease",
-            "Pulmonary Disease, Chronic Obstructive"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health-topics/copd",
-            "PMID:32800196",
-            "PMID:28513453",
-            "PMID:25943942",
-            "PMID:32745458"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 324986,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-              "name": "chronic obstructive pulmonary disease",
-              "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-              "equivalent_curies": [
-                "MESH:D029424",
-                "MEDDRA:10010952",
-                "MEDDRA:10009025",
-                "ICD10:J44.9",
-                "UMLS:C1527303",
-                "NCIT:C3199",
-                "UMLS:C0024117",
-                "MEDDRA:10064611",
-                "MEDDRA:10009026",
-                "MEDDRA:10029972",
-                "DOID:3083",
-                "MONDO:0005002",
-                "MEDDRA:10009032",
-                "MEDDRA:10070975",
-                "EFO:0000341",
-                "SNOMEDCT:13645005",
-                "MEDDRA:10009033",
-                "HP:0006510",
-                "MEDDRA:10008828"
-              ],
-              "id": "MONDO:0005002",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic Obstructive Pulmonary Disease",
-                "chronic obstructive pulmonary disease",
-                "Chronic pulmonary obstruction",
-                "Chronic Airflow Obstruction",
-                "Chronic Obstructive Airway Disease",
-                "Pulmonary Disease, Chronic Obstructive"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health-topics/copd",
-                "PMID:32800196",
-                "PMID:28513453",
-                "PMID:25943942",
-                "PMID:32745458"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9144854,
-            "start": 570,
-            "end": 324986,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11812271': {'publication date': '2002 Feb', 'sentence': 'OBJECTIVE: Compare the therapeutic efficacy of an oral/metered-dose inhaler (oral/MDI) regimen to an intravenous/nebulizer (I.V./neb) regimen of methylprednisolone, cefuroxime, and inhaled albuterol and ipratropium bromide in patients hospitalized for exacerbations of chronic obstructive pulmonary disease (COPD).', 'subject score': 1000, 'object score': 1000}, 'PMID:12753536': {'publication date': '2003 Jun', 'sentence': 'CONCLUSIONS: An adequate and tapering dose of MP used in acute exacerbations of COPD can relieve the inflammatory reaction in airways and reduce airway spasm more promptly than DXM.', 'subject score': 1000, 'object score': 1000}, 'PMID:28286842': {'publication date': '2017', 'sentence': 'Methyl prednisolone vs Dexamethasone in Management of COPD Exacerbation; a Randomized Clinical Trial.', 'subject score': 1000, 'object score': 771}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0024117---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "9346353",
-              "object": "MONDO:0005002",
-              "publications": [
-                "PMID:11812271",
-                "PMID:12753536",
-                "PMID:28286842"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 313324,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-          "name": "Edema",
-          "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MEDDRA:10030114",
-            "MEDDRA:10014234",
-            "MEDDRA:10014210",
-            "MEDDRA:10005890",
-            "HP:0000969",
-            "SNOMEDCT:267038008",
-            "SNOMEDCT:43498006",
-            "SNOMEDCT:79654002",
-            "MESH:D004487",
-            "UMLS:C0013604",
-            "MEDDRA:10016807",
-            "EFO:0009373",
-            "SNOMEDCT:423666004",
-            "UMLS:C0268000",
-            "NCIT:C3002",
-            "MEDDRA:10030095",
-            "SNOMEDCT:20741006",
-            "SYMP:0000538"
-          ],
-          "id": "HP:0000969",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Edema",
-            "Body fluid retention",
-            "edema"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313324,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-              "name": "Edema",
-              "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MEDDRA:10030114",
-                "MEDDRA:10014234",
-                "MEDDRA:10014210",
-                "MEDDRA:10005890",
-                "HP:0000969",
-                "SNOMEDCT:267038008",
-                "SNOMEDCT:43498006",
-                "SNOMEDCT:79654002",
-                "MESH:D004487",
-                "UMLS:C0013604",
-                "MEDDRA:10016807",
-                "EFO:0009373",
-                "SNOMEDCT:423666004",
-                "UMLS:C0268000",
-                "NCIT:C3002",
-                "MEDDRA:10030095",
-                "SNOMEDCT:20741006",
-                "SYMP:0000538"
-              ],
-              "id": "HP:0000969",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Edema",
-                "Body fluid retention",
-                "edema"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8900685,
-            "start": 570,
-            "end": 313324,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11549377': {'publication date': '2001 Sep 21', 'sentence': 'Similar to the CRPS clinical response to glucocorticoids, we now demonstrate that chronic hindpaw edema in the sciatic transection CRPS model is reversed by a continuous infusion of MP (3 mg/kg/day over 21 days), and this anti-edematous effect persists for at least 1 week after discontinuing MP.', 'subject score': 1000, 'object score': 790}, 'PMID:1335518': {'publication date': '1992', 'sentence': 'MP had little effect in decreasing FITC-D extravasation and cord edema when given at a lower dose (bolus of 30 mg/kg with continued infusion of 1.3 mg/kg/h for 23 h).', 'subject score': 1000, 'object score': 861}, 'PMID:24332587': {'publication date': '2014 May', 'sentence': 'Effect of the route of administration of methylprednisolone on oedema and trismus in impacted lower third molar surgery.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0013604---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "9107378",
-              "object": "HP:0000969",
-              "publications": [
-                "PMID:11549377",
-                "PMID:1335518",
-                "PMID:24332587"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8413579,
-            "start": 570,
-            "end": 321528,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11115436': {'publication date': '2000 Dec', 'sentence': 'STUDY OBJECTIVES: To assess whether IV methylprednisolone exerts a specific early effect on dyspnea in patients with an exacerbation of asthma.', 'subject score': 888, 'object score': 1000}, 'PMID:21966609': {'publication date': '2011 Oct', 'sentence': 'Symptoms of asthma exacerbations improved with short-term treatments of systemic steroids, including methylprednisolone or deflazacort, which had been well tolerated.', 'subject score': 1000, 'object score': 694}, 'PMID:24565723': {'publication date': '2013 Nov-Dec', 'sentence': 'The use of a tapering dose of methylprednisolone for asthma exacerbations: is it adequate?', 'subject score': 1000, 'object score': 694}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8596544",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:11115436",
-                "PMID:21966609",
-                "PMID:24565723"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319015,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-          "name": "systemic lupus erythematosus",
-          "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10025133",
-            "KEGG.DISEASE:05322",
-            "MEDDRA:10042820",
-            "PDQ:CDR0000608139",
-            "MEDDRA:10040967",
-            "MEDDRA:10042800",
-            "MEDDRA:10013446",
-            "MONDO:0007915",
-            "MEDDRA:10042945",
-            "MEDDRA:10024067",
-            "ICD10:M32.9",
-            "MEDDRA:10042947",
-            "ORPHANET:536",
-            "MEDDRA:10042944",
-            "UMLS:C0024141",
-            "EFO:0002690",
-            "MESH:D008180",
-            "ICD9:710.0",
-            "DOID:9074",
-            "MEDDRA:10025139",
-            "UMLS:C1835309",
-            "MEDDRA:10024065",
-            "OMIM:152700",
-            "HP:0002725",
-            "MEDDRA:10025142",
-            "NCIT:C3201",
-            "SNOMEDCT:55464009"
-          ],
-          "id": "MONDO:0007915",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Systemic lupus erythematosus",
-            "obsolete_systemic lupus erythematosus",
-            "Systemic lupus erythematosus related phenotypic feature",
-            "Lupus Erythematosus, Systemic",
-            "Excess lmw-dna",
-            "systemic lupus erythematosus",
-            "Systemic Lupus Erythematosus"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319015,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-              "name": "systemic lupus erythematosus",
-              "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10025133",
-                "KEGG.DISEASE:05322",
-                "MEDDRA:10042820",
-                "PDQ:CDR0000608139",
-                "MEDDRA:10040967",
-                "MEDDRA:10042800",
-                "MEDDRA:10013446",
-                "MONDO:0007915",
-                "MEDDRA:10042945",
-                "MEDDRA:10024067",
-                "ICD10:M32.9",
-                "MEDDRA:10042947",
-                "ORPHANET:536",
-                "MEDDRA:10042944",
-                "UMLS:C0024141",
-                "EFO:0002690",
-                "MESH:D008180",
-                "ICD9:710.0",
-                "DOID:9074",
-                "MEDDRA:10025139",
-                "UMLS:C1835309",
-                "MEDDRA:10024065",
-                "OMIM:152700",
-                "HP:0002725",
-                "MEDDRA:10025142",
-                "NCIT:C3201",
-                "SNOMEDCT:55464009"
-              ],
-              "id": "MONDO:0007915",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Systemic lupus erythematosus",
-                "obsolete_systemic lupus erythematosus",
-                "Systemic lupus erythematosus related phenotypic feature",
-                "Lupus Erythematosus, Systemic",
-                "Excess lmw-dna",
-                "systemic lupus erythematosus",
-                "Systemic Lupus Erythematosus"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8155204,
-            "start": 570,
-            "end": 319015,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10908541': {'publication date': '2000', 'sentence': \"REVIEWER'S CONCLUSIONS: Cyclophosphamide regimen treatment is a form of care in neuropsychiatric involvement in systemic lupus erythematosus with no evidence to prove better effectiveness and safety when compared with methylprednisolone.\", 'subject score': 1000, 'object score': 1000}, 'PMID:16625558': {'publication date': '2006 Apr 19', 'sentence': 'Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:23450535': {'publication date': '2013 Feb 28', 'sentence': 'Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0024141---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8330909",
-              "object": "MONDO:0007915",
-              "publications": [
-                "PMID:10908541",
-                "PMID:16625558",
-                "PMID:23450535"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 323610,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016537",
-          "name": "lymphoproliferative syndrome",
-          "description": "A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C9308\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C9308\" NCI Thesaurus); A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).; Disorders characterized by proliferation of lymphoid tissue, general or unspecified.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "UMLS:C0024314",
-            "OMIM:PS308240",
-            "MESH:D008232",
-            "NCIT:C9308",
-            "SNOMEDCT:84631004",
-            "PDQ:CDR0000617669",
-            "ORPHANET:238510",
-            "SNOMEDCT:277466009",
-            "MEDDRA:10025351",
-            "UMLS:CN201619",
-            "OMIM.PS:308240",
-            "MEDDRA:10061232",
-            "SNOMEDCT:414629003",
-            "HP:0005523",
-            "MONDO:0016537",
-            "DOID:0060704"
-          ],
-          "id": "MONDO:0016537",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphoproliferative disorder",
-            "obsolete_lymphoproliferative syndrome",
-            "Lymphoproliferative Disorder",
-            "lymphoproliferative disorder",
-            "Lymphoproliferative Disorders",
-            "lymphoproliferative syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:22197273",
-            "PMID:198660"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323610,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016537",
-              "name": "lymphoproliferative syndrome",
-              "description": "A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C9308\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C9308\" NCI Thesaurus); A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).; Disorders characterized by proliferation of lymphoid tissue, general or unspecified.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "UMLS:C0024314",
-                "OMIM:PS308240",
-                "MESH:D008232",
-                "NCIT:C9308",
-                "SNOMEDCT:84631004",
-                "PDQ:CDR0000617669",
-                "ORPHANET:238510",
-                "SNOMEDCT:277466009",
-                "MEDDRA:10025351",
-                "UMLS:CN201619",
-                "OMIM.PS:308240",
-                "MEDDRA:10061232",
-                "SNOMEDCT:414629003",
-                "HP:0005523",
-                "MONDO:0016537",
-                "DOID:0060704"
-              ],
-              "id": "MONDO:0016537",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphoproliferative disorder",
-                "obsolete_lymphoproliferative syndrome",
-                "Lymphoproliferative Disorder",
-                "lymphoproliferative disorder",
-                "Lymphoproliferative Disorders",
-                "lymphoproliferative syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:22197273",
-                "PMID:198660"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26659955,
-            "start": 570,
-            "end": 323610,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8701487': {'publication date': '1996 Apr-Jun', 'sentence': 'Treatment of X-linked lymphoproliferative disease (Duncan disease) with high-dose methylprednisolone and etoposide (VP-16).', 'subject score': 901, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0024314---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "27127545",
-              "object": "MONDO:0016537",
-              "publications": [
-                "PMID:8701487"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 315770,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005059",
-          "name": "leukemia",
-          "description": "A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3161\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3161\" NCI Thesaurus); A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.; A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006); A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding  When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets  The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time.  The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age  What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding.  Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes  Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10045991",
-            "MEDDRA:10024329",
-            "ICD9:208",
-            "ICD10:C95.90",
-            "MEDDRA:10060430",
-            "MEDDRA:10024314",
-            "MEDDRA:10024323",
-            "MEDDRA:10024351",
-            "HP:0001909",
-            "SNOMEDCT:87163000",
-            "SNOMEDCT:1162768007",
-            "MEDDRA:10045992",
-            "MEDDRA:10060500",
-            "NCIT:C3161",
-            "EFO:0000565",
-            "MEDDRA:10045994",
-            "SNOMEDCT:93143009",
-            "MEDDRA:10024288",
-            "MEDDRA:10024352",
-            "MEDDRA:10024312",
-            "DOID:1240",
-            "UMLS:C0023418",
-            "PDQ:CDR0000041186",
-            "MESH:D007938",
-            "MONDO:0005059",
-            "MEDDRA:10024324"
-          ],
-          "id": "MONDO:0005059",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia of unspecified cell type",
-            "Leukemia",
-            "leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/leukemia",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=45343",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315770,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005059",
-              "name": "leukemia",
-              "description": "A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3161\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3161\" NCI Thesaurus); A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.; A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006); A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding  When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets  The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time.  The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age  What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding.  Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes  Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10045991",
-                "MEDDRA:10024329",
-                "ICD9:208",
-                "ICD10:C95.90",
-                "MEDDRA:10060430",
-                "MEDDRA:10024314",
-                "MEDDRA:10024323",
-                "MEDDRA:10024351",
-                "HP:0001909",
-                "SNOMEDCT:87163000",
-                "SNOMEDCT:1162768007",
-                "MEDDRA:10045992",
-                "MEDDRA:10060500",
-                "NCIT:C3161",
-                "EFO:0000565",
-                "MEDDRA:10045994",
-                "SNOMEDCT:93143009",
-                "MEDDRA:10024288",
-                "MEDDRA:10024352",
-                "MEDDRA:10024312",
-                "DOID:1240",
-                "UMLS:C0023418",
-                "PDQ:CDR0000041186",
-                "MESH:D007938",
-                "MONDO:0005059",
-                "MEDDRA:10024324"
-              ],
-              "id": "MONDO:0005059",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia of unspecified cell type",
-                "Leukemia",
-                "leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/leukemia",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=45343",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25990078,
-            "start": 570,
-            "end": 315770,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7438892': {'publication date': '1980', 'sentence': 'Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0023418---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "26450412",
-              "object": "MONDO:0005059",
-              "publications": [
-                "PMID:7438892"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 526144,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001505",
-          "name": "alcoholic hepatitis",
-          "description": "Inflammation of the liver resulting from ingestion of alcohol.; INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.",
-          "equivalent_curies": [
-            "MONDO:0001505",
-            "MEDDRA:10000649",
-            "ICD9:571.1",
-            "SNOMEDCT:235875008",
-            "MEDDRA:10019728",
-            "MESH:D006519",
-            "NCIT:C34352",
-            "UMLS:C0019187",
-            "EFO:1001345",
-            "UMLS:C0001306",
-            "DOID:12351",
-            "NCIT:C34684",
-            "MEDDRA:10001624",
-            "SNOMEDCT:9953008"
-          ],
-          "id": "MONDO:0001505",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute alcoholic hepatitis",
-            "alcoholic hepatitis",
-            "Alcoholic Hepatitis",
-            "Acute Alcoholic Hepatitis",
-            "Acute alcoholic liver disease",
-            "Hepatitis, Alcoholic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526144,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001505",
-              "name": "alcoholic hepatitis",
-              "description": "Inflammation of the liver resulting from ingestion of alcohol.; INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.",
-              "equivalent_curies": [
-                "MONDO:0001505",
-                "MEDDRA:10000649",
-                "ICD9:571.1",
-                "SNOMEDCT:235875008",
-                "MEDDRA:10019728",
-                "MESH:D006519",
-                "NCIT:C34352",
-                "UMLS:C0019187",
-                "EFO:1001345",
-                "UMLS:C0001306",
-                "DOID:12351",
-                "NCIT:C34684",
-                "MEDDRA:10001624",
-                "SNOMEDCT:9953008"
-              ],
-              "id": "MONDO:0001505",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute alcoholic hepatitis",
-                "alcoholic hepatitis",
-                "Alcoholic Hepatitis",
-                "Acute Alcoholic Hepatitis",
-                "Acute alcoholic liver disease",
-                "Hepatitis, Alcoholic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25880657,
-            "start": 570,
-            "end": 526144,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7035299': {'publication date': '1982 Jan', 'sentence': 'Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis.', 'subject score': 888, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0001306---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "26339812",
-              "object": "MONDO:0001505",
-              "publications": [
-                "PMID:7035299"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 536164,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011849",
-          "name": "psoriatic arthritis",
-          "description": "Joint inflammation associated with psoriasis.; A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people with psoriasis have psoriatic arthritis. It causes pain, stiffness, and swelling of the joints. It is often mild, but can sometimes be serious and affect many joints. The joint and skin problems don't always happen at the same time. Your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. There is no cure, but medicines can help control inflammation and pain. In rare cases, you might need surgery to repair or replace damaged joints.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10037163",
-            "EFO:0003778",
-            "UMLS:C0003872",
-            "DOID:9008",
-            "ORPHANET:40050",
-            "MEDDRA:10003377",
-            "ICD9:696.0",
-            "NCIT:C61277",
-            "MONDO:0011849",
-            "SNOMEDCT:156370009",
-            "MEDDRA:10037162",
-            "MESH:D015535",
-            "MEDDRA:10037160",
-            "ICD10:L40.5"
-          ],
-          "id": "MONDO:0011849",
-          "category": "biolink:Disease",
-          "all_names": [
-            "psoriatic arthritis",
-            "Arthritis, Psoriatic",
-            "Psoriatic arthropathy",
-            "Psoriatic Arthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/psoriatic_arthropathy",
-            "https://ghr.nlm.nih.gov/condition/psoriatic-arthritis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000413.htm",
-            "http://www.mayoclinic.com/health/psoriatic-arthritis/ds00476"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 536164,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011849",
-              "name": "psoriatic arthritis",
-              "description": "Joint inflammation associated with psoriasis.; A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.; Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people with psoriasis have psoriatic arthritis. It causes pain, stiffness, and swelling of the joints. It is often mild, but can sometimes be serious and affect many joints. The joint and skin problems don't always happen at the same time. Your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. There is no cure, but medicines can help control inflammation and pain. In rare cases, you might need surgery to repair or replace damaged joints.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10037163",
-                "EFO:0003778",
-                "UMLS:C0003872",
-                "DOID:9008",
-                "ORPHANET:40050",
-                "MEDDRA:10003377",
-                "ICD9:696.0",
-                "NCIT:C61277",
-                "MONDO:0011849",
-                "SNOMEDCT:156370009",
-                "MEDDRA:10037162",
-                "MESH:D015535",
-                "MEDDRA:10037160",
-                "ICD10:L40.5"
-              ],
-              "id": "MONDO:0011849",
-              "category": "biolink:Disease",
-              "all_names": [
-                "psoriatic arthritis",
-                "Arthritis, Psoriatic",
-                "Psoriatic arthropathy",
-                "Psoriatic Arthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/psoriatic_arthropathy",
-                "https://ghr.nlm.nih.gov/condition/psoriatic-arthritis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000413.htm",
-                "http://www.mayoclinic.com/health/psoriatic-arthritis/ds00476"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25848127,
-            "start": 570,
-            "end": 536164,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:6895043': {'publication date': '1981 Aug', 'sentence': '1 The present study was undertaken to characterize the spectrum of arachidonic acid metabolites present in synovial effusions of patients with rheumatoid or psoriatic arthritis, and to compare changes in their concentration following a short-term treatment with 6alpha-methyl-prednisolone (6-MeP: 4-8 mg/day) or indoprofen (1.2 g/day), a nonsteroidal anti-inflammatory agent with proven synovial prostaglandin inhibitory effect.2 Measurements of prostaglandin E(2) (PGE(2)), thromboxane (TX) B(2), 6-keto-PGF(1alpha) and PGF(2alpha) were performed by radioimmunoassay techniques in synovial effusions obtained from 23 patients, and validated by thin-layer chromatographic analysis of the extracted immunoreactivity.3 PGE(2) and TXB(2) accounted for more than 60% of the total immunoreactivity in untreated patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:9694057': {'publication date': '1998', 'sentence': 'Methylprednisolone was the most prescribed corticosteroid, both in RA patients (63.2%) and in PA patients (65.9%).', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0003872---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "26307075",
-              "object": "MONDO:0011849",
-              "publications": [
-                "PMID:6895043",
-                "PMID:9694057"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 819686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004977",
-          "name": "angioimmunoblastic T-cell lymphoma",
-          "description": "A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes. It occurs in the middle aged and elderly, with an equal incidence in males and females. The clinical course is typically aggressive. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C7528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C7528\" NCI Thesaurus); A peripheral T-cell lymphoma of mature T follicular helper (TFH) cells characterized by systemic disease and a polymorphous infiltrate involving lymph nodes, with a prominent proliferation of high endothelial venules and follicular dendritic cells. EBV-positive cells are nearly always present. It is a clinically aggressive lymphoma and seen mainly in older adults. (WHO 2017); A disorder characterized by proliferation of arborizing small vessels, prominent immunoblastic proliferations and amorphous acidophilic interstitial material. Clinical manifestations include fever, sweats, weight loss, generalized lymphadenopathy and frequently hepatosplenomegaly.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:835009",
-            "EFO:1001350",
-            "MEDDRA:10002449",
-            "SNOMEDCT:52097008",
-            "MONDO:0004977",
-            "UMLS:C0020981",
-            "MEDDRA:10002451",
-            "ORPHANET:86886",
-            "MEDDRA:10079289",
-            "MEDDRA:10079282",
-            "MEDDRA:10002450",
-            "NCIT:C7528",
-            "PDQ:CDR0000042765",
-            "DOID:0111147",
-            "EFO:0000255",
-            "ICD10:C86.5",
-            "SNOMEDCT:413537009",
-            "MEDDRA:10080248",
-            "MESH:D007119"
-          ],
-          "id": "MONDO:0004977",
-          "category": "biolink:Disease",
-          "all_names": [
-            "angioimmunoblastic T-cell lymphoma",
-            "Immunoblastic Lymphadenopathy",
-            "Angioimmunoblastic T-Cell Lymphoma",
-            "Angioimmunoblastic T-cell lymphoma",
-            "Angioimmunoblastic Lymphadenopathy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:22700722",
-            "https://rarediseases.org/rare-diseases/angioimmunoblastic-t-cell-lymphoma/",
-            "https://www.lymphoma.org/aboutlymphoma/nhl/aitl/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 819686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004977",
-              "name": "angioimmunoblastic T-cell lymphoma",
-              "description": "A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes. It occurs in the middle aged and elderly, with an equal incidence in males and females. The clinical course is typically aggressive. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C7528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C7528\" NCI Thesaurus); A peripheral T-cell lymphoma of mature T follicular helper (TFH) cells characterized by systemic disease and a polymorphous infiltrate involving lymph nodes, with a prominent proliferation of high endothelial venules and follicular dendritic cells. EBV-positive cells are nearly always present. It is a clinically aggressive lymphoma and seen mainly in older adults. (WHO 2017); A disorder characterized by proliferation of arborizing small vessels, prominent immunoblastic proliferations and amorphous acidophilic interstitial material. Clinical manifestations include fever, sweats, weight loss, generalized lymphadenopathy and frequently hepatosplenomegaly.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:835009",
-                "EFO:1001350",
-                "MEDDRA:10002449",
-                "SNOMEDCT:52097008",
-                "MONDO:0004977",
-                "UMLS:C0020981",
-                "MEDDRA:10002451",
-                "ORPHANET:86886",
-                "MEDDRA:10079289",
-                "MEDDRA:10079282",
-                "MEDDRA:10002450",
-                "NCIT:C7528",
-                "PDQ:CDR0000042765",
-                "DOID:0111147",
-                "EFO:0000255",
-                "ICD10:C86.5",
-                "SNOMEDCT:413537009",
-                "MEDDRA:10080248",
-                "MESH:D007119"
-              ],
-              "id": "MONDO:0004977",
-              "category": "biolink:Disease",
-              "all_names": [
-                "angioimmunoblastic T-cell lymphoma",
-                "Immunoblastic Lymphadenopathy",
-                "Angioimmunoblastic T-Cell Lymphoma",
-                "Angioimmunoblastic T-cell lymphoma",
-                "Angioimmunoblastic Lymphadenopathy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:22700722",
-                "https://rarediseases.org/rare-diseases/angioimmunoblastic-t-cell-lymphoma/",
-                "https://www.lymphoma.org/aboutlymphoma/nhl/aitl/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25821253,
-            "start": 570,
-            "end": 819686,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:6817574': {'publication date': '1982', 'sentence': 'Pulse methylprednisolone therapy in angioimmunoblastic lymphadenopathy.', 'subject score': 790, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0020981---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "26279366",
-              "object": "MONDO:0004977",
-              "publications": [
-                "PMID:6817574"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 526827,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005306",
-          "name": "ankylosing spondylitis",
-          "description": "A bone inflammation disease that results_in inflammation in the joints of the spine and pelvis. The disease has_symptom pain, has_symptom stiffness in the spine, has_symptom stiffness in the neck, has_symptom stiffness in the hips, has_symptom stiffness in the jaw and has_symptom stiffness in the rib cage.",
-          "equivalent_curies": [
-            "MEDDRA:10048811",
-            "SNOMEDCT:9631008",
-            "MEDDRA:10002556",
-            "ICD9:720.0",
-            "ICD10:M45",
-            "MEDDRA:10041671",
-            "MEDDRA:10054041",
-            "MEDDRA:10041672",
-            "OMIM:PS106300",
-            "MEDDRA:10058813",
-            "ORPHANET:825",
-            "MONDO:0005306",
-            "MESH:D013167",
-            "EFO:0003898",
-            "DOID:7147",
-            "MEDDRA:10039082",
-            "NCIT:C84564",
-            "UMLS:C0038020",
-            "UMLS:C0038013"
-          ],
-          "id": "MONDO:0005306",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Spondylitis, Ankylosing",
-            "ankylosing spondylitis",
-            "Ankylosing Spondylitis",
-            "Ankylosing spondylitis",
-            "Spondylosis Deformans"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/ankylosing_spondylitis",
-            "http://www.mayoclinic.com/health/ankylosing-spondylitis/ds00483",
-            "http://www.spondylitis.org/about/as.aspx",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000420.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526827,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005306",
-              "name": "ankylosing spondylitis",
-              "description": "A bone inflammation disease that results_in inflammation in the joints of the spine and pelvis. The disease has_symptom pain, has_symptom stiffness in the spine, has_symptom stiffness in the neck, has_symptom stiffness in the hips, has_symptom stiffness in the jaw and has_symptom stiffness in the rib cage.",
-              "equivalent_curies": [
-                "MEDDRA:10048811",
-                "SNOMEDCT:9631008",
-                "MEDDRA:10002556",
-                "ICD9:720.0",
-                "ICD10:M45",
-                "MEDDRA:10041671",
-                "MEDDRA:10054041",
-                "MEDDRA:10041672",
-                "OMIM:PS106300",
-                "MEDDRA:10058813",
-                "ORPHANET:825",
-                "MONDO:0005306",
-                "MESH:D013167",
-                "EFO:0003898",
-                "DOID:7147",
-                "MEDDRA:10039082",
-                "NCIT:C84564",
-                "UMLS:C0038020",
-                "UMLS:C0038013"
-              ],
-              "id": "MONDO:0005306",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Spondylitis, Ankylosing",
-                "ankylosing spondylitis",
-                "Ankylosing Spondylitis",
-                "Ankylosing spondylitis",
-                "Spondylosis Deformans"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/ankylosing_spondylitis",
-                "http://www.mayoclinic.com/health/ankylosing-spondylitis/ds00483",
-                "http://www.spondylitis.org/about/as.aspx",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000420.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25285882,
-            "start": 570,
-            "end": 526827,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:4042697': {'publication date': '1985 Aug', 'sentence': 'Seven patients with active AS and insufficient efficacy of NSAID for three months were treated with one gram methylprednisolone daily given intravenously for three successive days.', 'subject score': 851, 'object score': 824}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0038013---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "25738014",
-              "object": "MONDO:0005306",
-              "publications": [
-                "PMID:4042697"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316905,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018908",
-          "name": "non-Hodgkin lymphoma",
-          "description": "Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3211\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3211\" NCI Thesaurus); Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.; Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.; A type of lymphoma characterized microscopically by the absence of multinucleated Reed-Sternberg cells. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "UMLS:C1622254",
-            "ORPHANET:547",
-            "MESH:D008228",
-            "UMLS:C0024305",
-            "MONDO:0018908",
-            "HP:0012539",
-            "SNOMEDCT:188675007",
-            "PDQ:CDR0000038957",
-            "NCIT:C3211",
-            "SNOMEDCT:1172592001",
-            "DOID:0060060",
-            "MEDDRA:10025311",
-            "MEDDRA:10029593",
-            "SNOMEDCT:128929007",
-            "MEDDRA:10029547",
-            "UMLS:C1622813"
-          ],
-          "id": "MONDO:0018908",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Non-Hodgkin Lymphoma",
-            "Lymphoma, Non-Hodgkin",
-            "Malignant lymphoma - small cleaved cell",
-            "non-Hodgkin lymphoma",
-            "Non-Hodgkin lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/non-hodgkin_lymphoma",
-            "http://www.cancer.gov/dictionary?cdrid=45148",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316905,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018908",
-              "name": "non-Hodgkin lymphoma",
-              "description": "Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3211\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3211\" NCI Thesaurus); Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.; Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.; A type of lymphoma characterized microscopically by the absence of multinucleated Reed-Sternberg cells. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "UMLS:C1622254",
-                "ORPHANET:547",
-                "MESH:D008228",
-                "UMLS:C0024305",
-                "MONDO:0018908",
-                "HP:0012539",
-                "SNOMEDCT:188675007",
-                "PDQ:CDR0000038957",
-                "NCIT:C3211",
-                "SNOMEDCT:1172592001",
-                "DOID:0060060",
-                "MEDDRA:10025311",
-                "MEDDRA:10029593",
-                "SNOMEDCT:128929007",
-                "MEDDRA:10029547",
-                "UMLS:C1622813"
-              ],
-              "id": "MONDO:0018908",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Non-Hodgkin Lymphoma",
-                "Lymphoma, Non-Hodgkin",
-                "Malignant lymphoma - small cleaved cell",
-                "non-Hodgkin lymphoma",
-                "Non-Hodgkin lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/non-hodgkin_lymphoma",
-                "http://www.cancer.gov/dictionary?cdrid=45148",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25282768,
-            "start": 570,
-            "end": 316905,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:403727': {'publication date': '1977 Mar', 'sentence': \"Peptichemio, a new oncolytic drug with alkylating and antimetabolic properties was employed in combination with vincristine and 6-methylprednisolone (PVP) for the treatment of diffuse non-Hodgkin's lymphomas (NHL), stages III and IV.\", 'subject score': 1000, 'object score': 908}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0024305---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "25734987",
-              "object": "MONDO:0018908",
-              "publications": [
-                "PMID:403727"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 517803,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005267",
-          "name": "heart disorder",
-          "description": "A non-neoplastic or neoplastic disorder that affects the heart and/or the pericardium. Representative examples include endocarditis, pericarditis, atrial myxoma, cardiac myeloid sarcoma, and pericardial malignant mesothelioma.; Pathological conditions involving the HEART including its structural and functional abnormalities.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10019276",
-            "MEDDRA:10013199",
-            "ICD10:I51.9",
-            "ICD9:429.9",
-            "MEDDRA:10019277",
-            "UMLS:C0018799",
-            "UMLS:CN239852",
-            "DOID:114",
-            "MESH:D006331",
-            "EFO:0003777",
-            "MONDO:0005267",
-            "MEDDRA:10061024",
-            "UMLS:CN236661",
-            "MEDDRA:10007540",
-            "NCIT:C3079",
-            "MEDDRA:10007541",
-            "SNOMEDCT:56265001"
-          ],
-          "id": "MONDO:0005267",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Heart disease, unspecified",
-            "Heart Diseases",
-            "Heart Disorder",
-            "heart disease",
-            "heart disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/heart_disease",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://github.com/monarch-initiative/mondo/issues/1189"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517803,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005267",
-              "name": "heart disorder",
-              "description": "A non-neoplastic or neoplastic disorder that affects the heart and/or the pericardium. Representative examples include endocarditis, pericarditis, atrial myxoma, cardiac myeloid sarcoma, and pericardial malignant mesothelioma.; Pathological conditions involving the HEART including its structural and functional abnormalities.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10019276",
-                "MEDDRA:10013199",
-                "ICD10:I51.9",
-                "ICD9:429.9",
-                "MEDDRA:10019277",
-                "UMLS:C0018799",
-                "UMLS:CN239852",
-                "DOID:114",
-                "MESH:D006331",
-                "EFO:0003777",
-                "MONDO:0005267",
-                "MEDDRA:10061024",
-                "UMLS:CN236661",
-                "MEDDRA:10007540",
-                "NCIT:C3079",
-                "MEDDRA:10007541",
-                "SNOMEDCT:56265001"
-              ],
-              "id": "MONDO:0005267",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Heart disease, unspecified",
-                "Heart Diseases",
-                "Heart Disorder",
-                "heart disease",
-                "heart disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/heart_disease",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://github.com/monarch-initiative/mondo/issues/1189"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25190565,
-            "start": 570,
-            "end": 517803,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3798047': {'publication date': '1986', 'sentence': 'High-dose MP may be contraindicated in patients with known heart disease.', 'subject score': 901, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0018799---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "25642231",
-              "object": "MONDO:0005267",
-              "publications": [
-                "PMID:3798047"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322010,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005336",
-          "name": "myopathy",
-          "description": "A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. [HPO:probinson]; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C101216",
-            "MEDDRA:10028641",
-            "MEDDRA:10028640",
-            "MEDDRA:10028300",
-            "MEDDRA:10028649",
-            "ICD10:G72.9",
-            "MEDDRA:10028302",
-            "MEDDRA:10028301",
-            "SNOMEDCT:129565002",
-            "ICD9:359.9",
-            "HP:0003198",
-            "EFO:0004145",
-            "DOID:423",
-            "MONDO:0005336",
-            "UMLS:C0026848",
-            "MESH:D009135",
-            "MEDDRA:10013237"
-          ],
-          "id": "MONDO:0005336",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myopathy, unspecified",
-            "Myopathy",
-            "myopathy",
-            "Muscular Diseases"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/myopathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322010,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005336",
-              "name": "myopathy",
-              "description": "A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. [HPO:probinson]; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C101216",
-                "MEDDRA:10028641",
-                "MEDDRA:10028640",
-                "MEDDRA:10028300",
-                "MEDDRA:10028649",
-                "ICD10:G72.9",
-                "MEDDRA:10028302",
-                "MEDDRA:10028301",
-                "SNOMEDCT:129565002",
-                "ICD9:359.9",
-                "HP:0003198",
-                "EFO:0004145",
-                "DOID:423",
-                "MONDO:0005336",
-                "UMLS:C0026848",
-                "MESH:D009135",
-                "MEDDRA:10013237"
-              ],
-              "id": "MONDO:0005336",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myopathy, unspecified",
-                "Myopathy",
-                "myopathy",
-                "Muscular Diseases"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/myopathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24917650,
-            "start": 570,
-            "end": 322010,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:36808229': {'publication date': '2023 Feb 21', 'sentence': 'PURPOSE: To report the therapeutic efficacy of intravenous methylprednisolone (IVMP) in patients with restrictive myopathy caused by thyroid eye disease (TED).', 'subject score': 888, 'object score': 853}, 'PMID:8970055': {'publication date': '1996 Dec', 'sentence': 'The calcifications turned into generalized heterotopic calcinosis with an exoskeleton-like pattern, despite successful treatment of her myopathy with methylprednisolone and immunosuppressive drugs.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0026848---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "25366540",
-              "object": "MONDO:0005336",
-              "publications": [
-                "PMID:36808229",
-                "PMID:8970055"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321354,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0002027",
-          "name": "Abdominal pain",
-          "description": "Painful sensation in the abdominal region.; Sensation of discomfort, distress, or agony in the abdominal region.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) and perceived to originate in the abdomen. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "SYMP:0000457",
-            "MEDDRA:10018796",
-            "MEDDRA:10046318",
-            "MEDDRA:10000059",
-            "HP:0002027",
-            "MEDDRA:10042076",
-            "MEDDRA:10042126",
-            "MEDDRA:10045148",
-            "UMLS:C0235309",
-            "MEDDRA:10004226",
-            "MEDDRA:10042101",
-            "MEDDRA:10000429",
-            "MEDDRA:10033374",
-            "MEDDRA:10033492",
-            "UMLS:C0232487",
-            "MEDDRA:10017814",
-            "MEDDRA:10017999",
-            "MEDDRA:10064906",
-            "SNOMEDCT:43364001",
-            "UMLS:C0687713",
-            "UMLS:C0221512",
-            "SNOMEDCT:271681002",
-            "MEDDRA:10042112",
-            "MEDDRA:10033402",
-            "NCIT:C78320",
-            "MEDDRA:10018000",
-            "UMLS:C0000737",
-            "MEDDRA:10042124",
-            "MEDDRA:10018241",
-            "NCIT:C78630",
-            "SYMP:0000188",
-            "SNOMEDCT:21522001",
-            "MEDDRA:10000085",
-            "NCIT:C26682",
-            "MEDDRA:10013084",
-            "SNOMEDCT:162059005",
-            "MEDDRA:10000081",
-            "ICD9:789.0",
-            "MESH:D015746"
-          ],
-          "id": "HP:0002027",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Abdominal Pain",
-            "Abdominal discomfort",
-            "Upset stomach",
-            "Stomach Pain",
-            "abdominal discomfort",
-            "Stomach ache",
-            "Abdominal pain",
-            "Gastrointestinal Pain",
-            "abdominal pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://medlineplus.gov/ency/article/003120.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321354,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002027",
-              "name": "Abdominal pain",
-              "description": "Painful sensation in the abdominal region.; Sensation of discomfort, distress, or agony in the abdominal region.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) and perceived to originate in the abdomen. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "SYMP:0000457",
-                "MEDDRA:10018796",
-                "MEDDRA:10046318",
-                "MEDDRA:10000059",
-                "HP:0002027",
-                "MEDDRA:10042076",
-                "MEDDRA:10042126",
-                "MEDDRA:10045148",
-                "UMLS:C0235309",
-                "MEDDRA:10004226",
-                "MEDDRA:10042101",
-                "MEDDRA:10000429",
-                "MEDDRA:10033374",
-                "MEDDRA:10033492",
-                "UMLS:C0232487",
-                "MEDDRA:10017814",
-                "MEDDRA:10017999",
-                "MEDDRA:10064906",
-                "SNOMEDCT:43364001",
-                "UMLS:C0687713",
-                "UMLS:C0221512",
-                "SNOMEDCT:271681002",
-                "MEDDRA:10042112",
-                "MEDDRA:10033402",
-                "NCIT:C78320",
-                "MEDDRA:10018000",
-                "UMLS:C0000737",
-                "MEDDRA:10042124",
-                "MEDDRA:10018241",
-                "NCIT:C78630",
-                "SYMP:0000188",
-                "SNOMEDCT:21522001",
-                "MEDDRA:10000085",
-                "NCIT:C26682",
-                "MEDDRA:10013084",
-                "SNOMEDCT:162059005",
-                "MEDDRA:10000081",
-                "ICD9:789.0",
-                "MESH:D015746"
-              ],
-              "id": "HP:0002027",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Abdominal Pain",
-                "Abdominal discomfort",
-                "Upset stomach",
-                "Stomach Pain",
-                "abdominal discomfort",
-                "Stomach ache",
-                "Abdominal pain",
-                "Gastrointestinal Pain",
-                "abdominal pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://medlineplus.gov/ency/article/003120.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23833296,
-            "start": 570,
-            "end": 321354,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35242662': {'publication date': '2022 Jan', 'sentence': \"After 2 months of treatment with systemic methylprednisolone, cyclophosphamide, and prednisone, the patient's abdominal pain was relieved.\", 'subject score': 888, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0000737---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "24273559",
-              "object": "HP:0002027",
-              "publications": [
-                "PMID:35242662"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318021,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000745",
-          "name": "cardiac arrest",
-          "description": "The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.; Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.; An abrupt loss of heart function. []; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:0060319",
-            "ICD10:I46",
-            "MEDDRA:10003109",
-            "UMLS:C0018790",
-            "HP:0001695",
-            "SNOMEDCT:410429000",
-            "MEDDRA:10082515",
-            "UMLS:C0444720",
-            "SNOMEDCT:397829000",
-            "MEDDRA:10003589",
-            "NCIT:C50479",
-            "PSY:07595",
-            "MEDDRA:10019249",
-            "SNOMEDCT:261195002",
-            "MEDDRA:10003587",
-            "MEDDRA:10047284",
-            "MESH:D006323",
-            "MONDO:0000745",
-            "MEDDRA:10041914",
-            "EFO:0009492",
-            "MEDDRA:10003586",
-            "MEDDRA:10007515",
-            "ICD9:427.5",
-            "MEDDRA:10047285"
-          ],
-          "id": "MONDO:0000745",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cardiac Arrest",
-            "cardiac arrest",
-            "Cardiac arrest",
-            "Heart Arrest"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/cardiacarrest.htm",
-            "http://en.wikipedia.org/wiki/cardiac_arrest",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318021,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000745",
-              "name": "cardiac arrest",
-              "description": "The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.; Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.; An abrupt loss of heart function. []; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:0060319",
-                "ICD10:I46",
-                "MEDDRA:10003109",
-                "UMLS:C0018790",
-                "HP:0001695",
-                "SNOMEDCT:410429000",
-                "MEDDRA:10082515",
-                "UMLS:C0444720",
-                "SNOMEDCT:397829000",
-                "MEDDRA:10003589",
-                "NCIT:C50479",
-                "PSY:07595",
-                "MEDDRA:10019249",
-                "SNOMEDCT:261195002",
-                "MEDDRA:10003587",
-                "MEDDRA:10047284",
-                "MESH:D006323",
-                "MONDO:0000745",
-                "MEDDRA:10041914",
-                "EFO:0009492",
-                "MEDDRA:10003586",
-                "MEDDRA:10007515",
-                "ICD9:427.5",
-                "MEDDRA:10047285"
-              ],
-              "id": "MONDO:0000745",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cardiac Arrest",
-                "cardiac arrest",
-                "Cardiac arrest",
-                "Heart Arrest"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/cardiacarrest.htm",
-                "http://en.wikipedia.org/wiki/cardiac_arrest",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23337086,
-            "start": 570,
-            "end": 318021,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34587236': {'publication date': '2021 Sep 29', 'sentence': 'Effect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital Cardiac Arrest: A Randomized Clinical Trial.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0018790---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "23772707",
-              "object": "MONDO:0000745",
-              "publications": [
-                "PMID:34587236"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 517178,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005087",
-          "name": "respiratory system disorder",
-          "description": "A non-neoplastic or neoplastic disorder that affects the respiratory system. Representative examples include pneumonia, chronic obstructive pulmonary disease, pulmonary failure, lung adenoma, lung carcinoma, and tracheal carcinoma.; Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:1579",
-            "NCIT:C26871",
-            "ICD10:J98",
-            "UMLS:C0035242",
-            "UMLS:C0035204",
-            "MEDDRA:10083321",
-            "MEDDRA:10038719",
-            "UMLS:C0029582",
-            "MONDO:0005087",
-            "MESH:D012120",
-            "MESH:D012140",
-            "MEDDRA:10038683",
-            "MEDDRA:10038684",
-            "ICD9:519",
-            "EFO:0000684",
-            "ICD9:510-519.99",
-            "MEDDRA:10045755",
-            "SNOMEDCT:50043002"
-          ],
-          "id": "MONDO:0005087",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Respiratory System Disorder",
-            "Other diseases of respiratory system",
-            "respiratory system disease",
-            "Other respiratory system diseases",
-            "Respiratory Tract Diseases",
-            "Respiration Disorders",
-            "respiratory system disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=respiratory%20system",
-            "http://en.wikipedia.org/wiki/file:respiratory_system_complete_en.svg"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517178,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005087",
-              "name": "respiratory system disorder",
-              "description": "A non-neoplastic or neoplastic disorder that affects the respiratory system. Representative examples include pneumonia, chronic obstructive pulmonary disease, pulmonary failure, lung adenoma, lung carcinoma, and tracheal carcinoma.; Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:1579",
-                "NCIT:C26871",
-                "ICD10:J98",
-                "UMLS:C0035242",
-                "UMLS:C0035204",
-                "MEDDRA:10083321",
-                "MEDDRA:10038719",
-                "UMLS:C0029582",
-                "MONDO:0005087",
-                "MESH:D012120",
-                "MESH:D012140",
-                "MEDDRA:10038683",
-                "MEDDRA:10038684",
-                "ICD9:519",
-                "EFO:0000684",
-                "ICD9:510-519.99",
-                "MEDDRA:10045755",
-                "SNOMEDCT:50043002"
-              ],
-              "id": "MONDO:0005087",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Respiratory System Disorder",
-                "Other diseases of respiratory system",
-                "respiratory system disease",
-                "Other respiratory system diseases",
-                "Respiratory Tract Diseases",
-                "Respiration Disorders",
-                "respiratory system disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=respiratory%20system",
-                "http://en.wikipedia.org/wiki/file:respiratory_system_complete_en.svg"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22778914,
-            "start": 570,
-            "end": 517178,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:33815804': {'publication date': '2021 May', 'sentence': 'Although methylprednisolone gradually improved her respiratory condition, her oxygenation and exercise tolerance had drastically deteriorated, necessitating high-flow nasal cannula oxygen therapy.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0035204---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "23209303",
-              "object": "MONDO:0005087",
-              "publications": [
-                "PMID:33815804"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 310888,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019121",
-          "name": "pneumocystosis",
-          "description": "Pneumonia resulting from infection with Pneumocystis jirovecii, frequently seen in the immunologically compromised, such as persons with AIDS, or steroid-treated individuals, the elderly, or premature or debilitated babies during their first three months. Patients may be only slightly febrile (or even afebrile), but are likely to be extremely weak, dyspneic, and cyanotic. This is a major cause of morbidity among patients with AIDS.; A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.; Pneumocystis carinii pneumonia is an opportunistic infection that occurs in immunosuppressed populations. [PMID:10537385]; An opportunistic disease caused by invasion of unicellular fungus Pneumocystis jirovecii. Transmission of P. jirovecii cysts takes place through the airborne route, and usually, its presence in lungs is asymptomatic. However, people with impaired immunity, especially those with CD4+ T cell count below 200/microliter, are still at risk of the development of Pneumocystis pneumonia due to P. jirovecii invasion. Symptoms induced by this disease are not specific: progressive dyspnoea, non-productive cough, low-grade fever, arterial partial pressure of oxygen below 65 mmHg, and chest radiographs demonstrating bilateral, interstitial shadowing. [PMID:26281787]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:415125002",
-            "MESH:D011020",
-            "MEDDRA:10035661",
-            "HP:0034286",
-            "SNOMEDCT:88860002",
-            "MEDDRA:10035662",
-            "ICD9:136.3",
-            "UMLS:C1535939",
-            "ORPHANET:723",
-            "MEDDRA:10051460",
-            "DOID:11339",
-            "MEDDRA:10064108",
-            "MONDO:0019121",
-            "EFO:0007448",
-            "MEDDRA:10073755",
-            "ICD10:B59",
-            "MEDDRA:10035659",
-            "NCIT:C3334"
-          ],
-          "id": "MONDO:0019121",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumocystis carinii pneumonia",
-            "Pneumocystosis",
-            "Pneumocystis Pneumonia",
-            "Pneumocystis jiroveci pneumonia",
-            "pneumocystosis",
-            "Pneumonia, Pneumocystis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=pneumocystis%20carinii%20pneumonia",
-            "PMID:10537385",
-            "https://rarediseases.info.nih.gov/diseases/4386/pneumocystosis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000671.htm",
-            "PMID:26281787"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310888,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019121",
-              "name": "pneumocystosis",
-              "description": "Pneumonia resulting from infection with Pneumocystis jirovecii, frequently seen in the immunologically compromised, such as persons with AIDS, or steroid-treated individuals, the elderly, or premature or debilitated babies during their first three months. Patients may be only slightly febrile (or even afebrile), but are likely to be extremely weak, dyspneic, and cyanotic. This is a major cause of morbidity among patients with AIDS.; A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.; Pneumocystis carinii pneumonia is an opportunistic infection that occurs in immunosuppressed populations. [PMID:10537385]; An opportunistic disease caused by invasion of unicellular fungus Pneumocystis jirovecii. Transmission of P. jirovecii cysts takes place through the airborne route, and usually, its presence in lungs is asymptomatic. However, people with impaired immunity, especially those with CD4+ T cell count below 200/microliter, are still at risk of the development of Pneumocystis pneumonia due to P. jirovecii invasion. Symptoms induced by this disease are not specific: progressive dyspnoea, non-productive cough, low-grade fever, arterial partial pressure of oxygen below 65 mmHg, and chest radiographs demonstrating bilateral, interstitial shadowing. [PMID:26281787]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:415125002",
-                "MESH:D011020",
-                "MEDDRA:10035661",
-                "HP:0034286",
-                "SNOMEDCT:88860002",
-                "MEDDRA:10035662",
-                "ICD9:136.3",
-                "UMLS:C1535939",
-                "ORPHANET:723",
-                "MEDDRA:10051460",
-                "DOID:11339",
-                "MEDDRA:10064108",
-                "MONDO:0019121",
-                "EFO:0007448",
-                "MEDDRA:10073755",
-                "ICD10:B59",
-                "MEDDRA:10035659",
-                "NCIT:C3334"
-              ],
-              "id": "MONDO:0019121",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumocystis carinii pneumonia",
-                "Pneumocystosis",
-                "Pneumocystis Pneumonia",
-                "Pneumocystis jiroveci pneumonia",
-                "pneumocystosis",
-                "Pneumonia, Pneumocystis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=pneumocystis%20carinii%20pneumonia",
-                "PMID:10537385",
-                "https://rarediseases.info.nih.gov/diseases/4386/pneumocystosis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000671.htm",
-                "PMID:26281787"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22686548,
-            "start": 570,
-            "end": 310888,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:33692629': {'publication date': '2021', 'sentence': 'Caspofungin, TMP-SMX, clindamycin and MP were used to treat    P. jirovecii     pneumonia (PJP).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C1535939---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "23116362",
-              "object": "MONDO:0019121",
-              "publications": [
-                "PMID:33692629"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 314697,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004496",
-          "name": "myocarditis",
-          "description": "Myocarditis is a condition that is characterized by inflammation of the heart muscle (myocardium). Some affected people have no noticeable symptoms of the condition. When present, signs and symptoms may include chest pain, abnormal heartbeat, shortness of breath, fatigue, signs of infection (i.e. fever, headache, sore throat, diarrhea), and leg swelling. Myocarditis can be caused by a variety of factors including infections (viral, bacterial, parasitic, and fungal), allergic reactions to certain medications, and exposure to certain chemicals. It can also be associated with other inflammatory conditions such as lupus, Wegener's granulomatosis, giant cell arteritis and Takayasu's arteritis. Most cases occur sporadically in people with no family history of the condition. Treatment aims to address the underlying cause of the condition. Medications and rarely, a heart transplant may be needed if the heart muscle becomes weak.",
-          "equivalent_curies": [
-            "MESH:D009205",
-            "MEDDRA:10028613",
-            "HP:0012819",
-            "DOID:820",
-            "KEGG.DISEASE:05416",
-            "UMLS:C0027059",
-            "MEDDRA:10028606",
-            "ICD9:429.0",
-            "SYMP:0000095",
-            "SNOMEDCT:50920009",
-            "EFO:0009609",
-            "NCIT:C34831",
-            "MEDDRA:10028619",
-            "MONDO:0004496",
-            "ICD10:I51.4"
-          ],
-          "id": "MONDO:0004496",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myocarditis",
-            "Myocarditis, unspecified",
-            "myocarditis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/myocarditis",
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:21304213",
-            "PMID:22361396",
-            "https://rarediseases.info.nih.gov/diseases/7137/myocarditis",
-            "PMID:22185868",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314697,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004496",
-              "name": "myocarditis",
-              "description": "Myocarditis is a condition that is characterized by inflammation of the heart muscle (myocardium). Some affected people have no noticeable symptoms of the condition. When present, signs and symptoms may include chest pain, abnormal heartbeat, shortness of breath, fatigue, signs of infection (i.e. fever, headache, sore throat, diarrhea), and leg swelling. Myocarditis can be caused by a variety of factors including infections (viral, bacterial, parasitic, and fungal), allergic reactions to certain medications, and exposure to certain chemicals. It can also be associated with other inflammatory conditions such as lupus, Wegener's granulomatosis, giant cell arteritis and Takayasu's arteritis. Most cases occur sporadically in people with no family history of the condition. Treatment aims to address the underlying cause of the condition. Medications and rarely, a heart transplant may be needed if the heart muscle becomes weak.",
-              "equivalent_curies": [
-                "MESH:D009205",
-                "MEDDRA:10028613",
-                "HP:0012819",
-                "DOID:820",
-                "KEGG.DISEASE:05416",
-                "UMLS:C0027059",
-                "MEDDRA:10028606",
-                "ICD9:429.0",
-                "SYMP:0000095",
-                "SNOMEDCT:50920009",
-                "EFO:0009609",
-                "NCIT:C34831",
-                "MEDDRA:10028619",
-                "MONDO:0004496",
-                "ICD10:I51.4"
-              ],
-              "id": "MONDO:0004496",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myocarditis",
-                "Myocarditis, unspecified",
-                "myocarditis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/myocarditis",
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:21304213",
-                "PMID:22361396",
-                "https://rarediseases.info.nih.gov/diseases/7137/myocarditis",
-                "PMID:22185868",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22071900,
-            "start": 570,
-            "end": 314697,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32928810': {'publication date': '2020 Sep 14', 'sentence': 'Although, not described in the literature, we have found conjunctive use of milrinone and methylprednisolone effective in patient with SARS-CoV-2 fulminant myocarditis.', 'subject score': 1000, 'object score': 850}, 'PMID:37114131': {'publication date': '2023', 'sentence': 'COVID-19-associated myocarditis was successfully treated with methylprednisolone, intravenous immunoglobulins and Anakinra.', 'subject score': 1000, 'object score': 802}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0027059---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "22495912",
-              "object": "MONDO:0004496",
-              "publications": [
-                "PMID:32928810",
-                "PMID:37114131"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318155,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004952",
-          "name": "Hodgkins lymphoma",
-          "description": "A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma has a bimodal age distribution, and involves primarily lymph nodes. Current therapy for Hodgkin lymphoma has resulted in an excellent outcome and cure for the majority of patients. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C9357\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C9357\" NCI Thesaurus); UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10020309",
-            "SNOMEDCT:1163005009",
-            "ORPHANET:98293",
-            "UMLS:C5235037",
-            "NCIT:C6914",
-            "MEDDRA:10020255",
-            "SNOMEDCT:118606001",
-            "MEDDRA:10063666",
-            "SNOMEDCT:46923007",
-            "ICD10:C81",
-            "UMLS:C0019829",
-            "ICD9:201.2",
-            "SNOMEDCT:836277009",
-            "SNOMEDCT:74189002",
-            "MEDDRA:10020206",
-            "MESH:D006689",
-            "MEDDRA:10020328",
-            "MEDDRA:10020329",
-            "HP:0012189",
-            "SNOMEDCT:118599009",
-            "NCIT:C9357",
-            "ICD9:201",
-            "NCIT:C26956",
-            "SNOMEDCT:118605002",
-            "SNOMEDCT:118602004",
-            "NCIT:C164145",
-            "PDQ:CDR0000041646",
-            "MEDDRA:10025319",
-            "MEDDRA:10020318",
-            "EFO:0000183",
-            "DOID:8567",
-            "SNOMEDCT:14537002",
-            "MONDO:0004952",
-            "SNOMEDCT:836276000",
-            "MEDDRA:10020339",
-            "SNOMEDCT:70600005"
-          ],
-          "id": "MONDO:0004952",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hodgkin Lymphoma",
-            "Hodgkin lymphoma",
-            "Hodgkin's Paragranuloma",
-            "Hodgkin's sarcoma",
-            "Hodgkin sarcoma",
-            "Hodgkin's lymphoma",
-            "Hodgkins lymphoma",
-            "Hodgkin's Granuloma",
-            "Hodgkin's Sarcoma",
-            "Hodgkin Disease",
-            "Hodgkin's disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/hodgkin%27s_lymphoma",
-            "PMID:22835602",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318155,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004952",
-              "name": "Hodgkins lymphoma",
-              "description": "A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma has a bimodal age distribution, and involves primarily lymph nodes. Current therapy for Hodgkin lymphoma has resulted in an excellent outcome and cure for the majority of patients. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C9357\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C9357\" NCI Thesaurus); UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10020309",
-                "SNOMEDCT:1163005009",
-                "ORPHANET:98293",
-                "UMLS:C5235037",
-                "NCIT:C6914",
-                "MEDDRA:10020255",
-                "SNOMEDCT:118606001",
-                "MEDDRA:10063666",
-                "SNOMEDCT:46923007",
-                "ICD10:C81",
-                "UMLS:C0019829",
-                "ICD9:201.2",
-                "SNOMEDCT:836277009",
-                "SNOMEDCT:74189002",
-                "MEDDRA:10020206",
-                "MESH:D006689",
-                "MEDDRA:10020328",
-                "MEDDRA:10020329",
-                "HP:0012189",
-                "SNOMEDCT:118599009",
-                "NCIT:C9357",
-                "ICD9:201",
-                "NCIT:C26956",
-                "SNOMEDCT:118605002",
-                "SNOMEDCT:118602004",
-                "NCIT:C164145",
-                "PDQ:CDR0000041646",
-                "MEDDRA:10025319",
-                "MEDDRA:10020318",
-                "EFO:0000183",
-                "DOID:8567",
-                "SNOMEDCT:14537002",
-                "MONDO:0004952",
-                "SNOMEDCT:836276000",
-                "MEDDRA:10020339",
-                "SNOMEDCT:70600005"
-              ],
-              "id": "MONDO:0004952",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hodgkin Lymphoma",
-                "Hodgkin lymphoma",
-                "Hodgkin's Paragranuloma",
-                "Hodgkin's sarcoma",
-                "Hodgkin sarcoma",
-                "Hodgkin's lymphoma",
-                "Hodgkins lymphoma",
-                "Hodgkin's Granuloma",
-                "Hodgkin's Sarcoma",
-                "Hodgkin Disease",
-                "Hodgkin's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/hodgkin%27s_lymphoma",
-                "PMID:22835602",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19572345,
-            "start": 570,
-            "end": 318155,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29068514': {'publication date': '2018 05', 'sentence': 'High incidence of aseptic hip necrosis in Hodgkin lymphoma patients treated with escalated BEACOPP receiving methylprednisolone.', 'subject score': 733, 'object score': 901}, 'PMID:8406379': {'publication date': '1993', 'sentence': \"Retrospective analysis of 34 patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's and Hodgkin's lymphoma treated with high dose methylprednisolone showed 11 responses including two complete remissions among nine patients with CLL.\", 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0019829---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "19962298",
-              "object": "MONDO:0004952",
-              "publications": [
-                "PMID:29068514",
-                "PMID:8406379"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 708295,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019124",
-          "name": "microscopic polyangiitis",
-          "description": "A systemic necrotizing vasculitis that typically affects the small and medium-sized muscular arteries. In some cases, however, microscopic vessels are also affected (e.g., in the kidneys), a condition that has been called microscopic polyarteritis or polyangiitis; this disorder is felt to be more closely associated with Wegener granulomatosis than to classic polyarteritis nodosa.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:1144805008",
-            "MONDO:0019124",
-            "MESH:D055953",
-            "MEDDRA:10063344",
-            "ORPHANET:727",
-            "EFO:1000784",
-            "SNOMEDCT:239928004",
-            "NCIT:C70549",
-            "UMLS:C2347126"
-          ],
-          "id": "MONDO:0019124",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Microscopic Polyangiitis",
-            "Microscopic Polyarteritis",
-            "microscopic polyangiitis",
-            "Microscopic polyangiitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 708295,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019124",
-              "name": "microscopic polyangiitis",
-              "description": "A systemic necrotizing vasculitis that typically affects the small and medium-sized muscular arteries. In some cases, however, microscopic vessels are also affected (e.g., in the kidneys), a condition that has been called microscopic polyarteritis or polyangiitis; this disorder is felt to be more closely associated with Wegener granulomatosis than to classic polyarteritis nodosa.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:1144805008",
-                "MONDO:0019124",
-                "MESH:D055953",
-                "MEDDRA:10063344",
-                "ORPHANET:727",
-                "EFO:1000784",
-                "SNOMEDCT:239928004",
-                "NCIT:C70549",
-                "UMLS:C2347126"
-              ],
-              "id": "MONDO:0019124",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Microscopic Polyangiitis",
-                "Microscopic Polyarteritis",
-                "microscopic polyangiitis",
-                "Microscopic polyangiitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19288947,
-            "start": 570,
-            "end": 708295,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28539536': {'publication date': '2017 05', 'sentence': 'Six newly diagnosed patients with MPA were initially treated with methylprednisolone and a single dose of RTX (375 mg/m2).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C2347126---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "19674675",
-              "object": "MONDO:0019124",
-              "publications": [
-                "PMID:28539536"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 535220,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006649",
-          "name": "anterior ischemic optic neuropathy",
-          "description": "Anterior ischemic optic neuropathy (AION) is an eye disease characterized by infarction of the optic disk leading to vision loss. It can be nonarteritic (nonarteritic anterior ischemic optic neuropathy or NAION) or arteritic, the latter being associated with giant cell arteritis (GCA; often termed temporal arteritis). Vision loss with both varieties is typically rapid (over minutes, hours, or days) and painless. Symptoms such as a general feeling of being unwell (malaise), muscle aches and pains, headaches over the temple, pain when combing hair, pain in the jaw after chewing, and tenderness over the temporal artery (one of the major arteries of the head) may be present with giant cell arteritis. At exam, visual acuity is reduced and the optic disc is swollen. In both subtypes, visual field examination is often reduced in the inferior and central visual fields. The visual loss is usually permanent, with some recovery possibly occurring within the first weeks or months. The arteritic variety is treated with corticosteroids. Treatment of the nonarteritic variety withaspirinor corticosteroids has not been helpful.",
-          "equivalent_curies": [
-            "UMLS:C0751711",
-            "EFO:1000809",
-            "SNOMEDCT:14357004",
-            "MONDO:0006649",
-            "MEDDRA:10023041",
-            "MEDDRA:10068250",
-            "MEDDRA:10030925",
-            "ICD10:H47.01",
-            "MESH:D018917",
-            "UMLS:C0155305",
-            "MEDDRA:10030924",
-            "MEDDRA:10068243",
-            "SNOMEDCT:404659001",
-            "DOID:12010",
-            "MEDDRA:10055745",
-            "ICD9:377.41"
-          ],
-          "id": "MONDO:0006649",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Optic Neuropathy, Ischemic",
-            "Anterior Ischemic Optic Neuropathy",
-            "Ischemic optic neuropathy",
-            "anterior ischemic optic neuropathy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://rarediseases.info.nih.gov/diseases/9790/anterior-ischemic-optic-neuropathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 535220,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006649",
-              "name": "anterior ischemic optic neuropathy",
-              "description": "Anterior ischemic optic neuropathy (AION) is an eye disease characterized by infarction of the optic disk leading to vision loss. It can be nonarteritic (nonarteritic anterior ischemic optic neuropathy or NAION) or arteritic, the latter being associated with giant cell arteritis (GCA; often termed temporal arteritis). Vision loss with both varieties is typically rapid (over minutes, hours, or days) and painless. Symptoms such as a general feeling of being unwell (malaise), muscle aches and pains, headaches over the temple, pain when combing hair, pain in the jaw after chewing, and tenderness over the temporal artery (one of the major arteries of the head) may be present with giant cell arteritis. At exam, visual acuity is reduced and the optic disc is swollen. In both subtypes, visual field examination is often reduced in the inferior and central visual fields. The visual loss is usually permanent, with some recovery possibly occurring within the first weeks or months. The arteritic variety is treated with corticosteroids. Treatment of the nonarteritic variety withaspirinor corticosteroids has not been helpful.",
-              "equivalent_curies": [
-                "UMLS:C0751711",
-                "EFO:1000809",
-                "SNOMEDCT:14357004",
-                "MONDO:0006649",
-                "MEDDRA:10023041",
-                "MEDDRA:10068250",
-                "MEDDRA:10030925",
-                "ICD10:H47.01",
-                "MESH:D018917",
-                "UMLS:C0155305",
-                "MEDDRA:10030924",
-                "MEDDRA:10068243",
-                "SNOMEDCT:404659001",
-                "DOID:12010",
-                "MEDDRA:10055745",
-                "ICD9:377.41"
-              ],
-              "id": "MONDO:0006649",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Optic Neuropathy, Ischemic",
-                "Anterior Ischemic Optic Neuropathy",
-                "Ischemic optic neuropathy",
-                "anterior ischemic optic neuropathy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://rarediseases.info.nih.gov/diseases/9790/anterior-ischemic-optic-neuropathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19150648,
-            "start": 570,
-            "end": 535220,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28297028': {'publication date': '2017 03 01', 'sentence': 'Early Methylprednisolone Treatment Can Stabilize the Blood-Optic Nerve Barrier in a Rat Model of Anterior Ischemic Optic Neuropathy (rAION).', 'subject score': 851, 'object score': 780}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0751711---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "19534575",
-              "object": "MONDO:0006649",
-              "publications": [
-                "PMID:28297028"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319030,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319030,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18061671,
-            "start": 570,
-            "end": 319030,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26150628': {'publication date': '2015 Jul 06', 'sentence': 'We report a case of a 68-year-old woman who presented with severe abdominal pain, nausea and vomiting, 3 days after the initiation of low-dose methylprednisolone for osteoarthritis.', 'subject score': 901, 'object score': 1000}, 'PMID:6586148': {'publication date': '1983 Dec', 'sentence': 'A comparison of plasma methylprednisolone concentrations following intra-articular injection in patients with rheumatoid arthritis and osteoarthritis.', 'subject score': 890, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "18427985",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:26150628",
-                "PMID:6586148"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 539363,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004833",
-          "name": "plantar fasciitis",
-          "description": "Inflammation of the thick tissue on the bottom of the foot (plantar fascia) causing heel pain. The plantar fascia (also called plantar aponeurosis) are bands of fibrous tissue extending from the calcaneal tuberosity to the toes. The etiology of plantar fasciitis remains controversial but is likely to involve a biomechanical imbalance. Though often presenting along with heel spur, they do not appear to be causally related.",
-          "equivalent_curies": [
-            "MEDDRA:10066146",
-            "MEDDRA:10016239",
-            "UMLS:C0149756",
-            "DOID:9600",
-            "SNOMEDCT:202882003",
-            "MESH:D036981",
-            "EFO:1001909",
-            "MEDDRA:10035155",
-            "MONDO:0004833"
-          ],
-          "id": "MONDO:0004833",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Plantar Fasciitis",
-            "plantar fasciitis",
-            "Fasciitis, Plantar"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 539363,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004833",
-              "name": "plantar fasciitis",
-              "description": "Inflammation of the thick tissue on the bottom of the foot (plantar fascia) causing heel pain. The plantar fascia (also called plantar aponeurosis) are bands of fibrous tissue extending from the calcaneal tuberosity to the toes. The etiology of plantar fasciitis remains controversial but is likely to involve a biomechanical imbalance. Though often presenting along with heel spur, they do not appear to be causally related.",
-              "equivalent_curies": [
-                "MEDDRA:10066146",
-                "MEDDRA:10016239",
-                "UMLS:C0149756",
-                "DOID:9600",
-                "SNOMEDCT:202882003",
-                "MESH:D036981",
-                "EFO:1001909",
-                "MEDDRA:10035155",
-                "MONDO:0004833"
-              ],
-              "id": "MONDO:0004833",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Plantar Fasciitis",
-                "plantar fasciitis",
-                "Fasciitis, Plantar"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17912349,
-            "start": 570,
-            "end": 539363,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25885380': {'publication date': '2011 Jul-Dec', 'sentence': 'OBJECTIVES: To compare the effectiveness of oral nonsteroidal antiinflammatory drugs (NSAIDs) and locally injectable steroid (methylprednisolone) in the treatment of plantar fasciitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:30828215': {'publication date': '2019 Mar-Apr', 'sentence': 'Effectiveness of extra-corporeal shock wave therapy (ESWT) vs methylprednisolone injections in plantar fasciitis.', 'subject score': 888, 'object score': 1000}, 'PMID:31413624': {'publication date': '2019', 'sentence': 'In other words, although ozone injection showed a slower efficacy than methylprednisolone, it could be used in plantar fasciitis management as an appropriate alternative.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0149756---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "18276332",
-              "object": "MONDO:0004833",
-              "publications": [
-                "PMID:25885380",
-                "PMID:30828215",
-                "PMID:31413624"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 530650,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016367",
-          "name": "dermatomyositis",
-          "description": "Inflammation of the skin and muscle.; A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003882",
-            "EFO:0000398",
-            "ICD10:M33",
-            "MONDO:0016367",
-            "SNOMEDCT:396230008",
-            "NCIT:C26744",
-            "DOID:10223",
-            "MEDDRA:10012503",
-            "ORPHANET:221",
-            "UMLS:C0011633",
-            "ICD9:710.3"
-          ],
-          "id": "MONDO:0016367",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatomyositis",
-            "dermatomyositis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/dermatomyositis",
-            "http://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 530650,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016367",
-              "name": "dermatomyositis",
-              "description": "Inflammation of the skin and muscle.; A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6); UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003882",
-                "EFO:0000398",
-                "ICD10:M33",
-                "MONDO:0016367",
-                "SNOMEDCT:396230008",
-                "NCIT:C26744",
-                "DOID:10223",
-                "MEDDRA:10012503",
-                "ORPHANET:221",
-                "UMLS:C0011633",
-                "ICD9:710.3"
-              ],
-              "id": "MONDO:0016367",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatomyositis",
-                "dermatomyositis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/dermatomyositis",
-                "http://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17648046,
-            "start": 570,
-            "end": 530650,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25447651': {'publication date': '2014', 'sentence': 'A Japanese woman was treated with injectable methylprednisolone and oral prednisolone for dermatomyositis.', 'subject score': 888, 'object score': 1000}, 'PMID:26552135': {'publication date': '2015 May', 'sentence': 'A 54-year-old female with dermatomyositis treated with cyclosporine and methylprednisolone presented with multiple subcutaneous nodules on her upper and lower extremities on December 2011.', 'subject score': 1000, 'object score': 1000}, 'PMID:27312550': {'publication date': '2016 May', 'sentence': 'Do Muscle Enzyme Changes Forecast Liver Injury in Polymyositis/Dermatomyositis Patients Treated with Methylprednisolone and Methotrexate?', 'subject score': 1000, 'object score': 901}, 'PMID:27478664': {'publication date': '2016', 'sentence': 'We herein report a 40-year-old woman who developed DM in the second trimester of her pregnancy and did not respond to treatment with methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:34302454': {'publication date': '2021 Jul 24', 'sentence': 'Long-term effects of early pulse methylprednisolone and intravenous immunoglobulin in patients with dermatomyositis and polymyositis.', 'subject score': 802, 'object score': 1000}, 'PMID:8657493': {'publication date': '1995 Mar', 'sentence': '[Use of intravenous megadoses of methylprednisolone for treatment of dermatomyositis in children].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0011633---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "18008318",
-              "object": "MONDO:0016367",
-              "publications": [
-                "PMID:25447651",
-                "PMID:26552135",
-                "PMID:27312550",
-                "PMID:27478664",
-                "PMID:34302454",
-                "PMID:8657493"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318836,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006314",
-          "name": "nasal cavity polyp",
-          "description": "Polypoidal masses arising mainly from the mucous membranes of the nose and paranasal sinuses. They are freely movable and nontender overgrowths of the mucosa that frequently accompany allergic rhinitis. [HPO:sdoelken, PMID:18728843]; Polypoidal masses arising mainly from the mucous membranes of the nose and paranasal sinuses. They are freely movable and nontender overgrowths of the mucosa that frequently accompany allergic rhinitis. // COMMENTS: Nasal polyps (NP) are benign lesions arising from the mucosa of the nasal sinuses (commonly at the outflow tract of one or more of the sinuses) or from the mucosa of the nasal cavity. The main presenting symptom of NP is nasal obstruction which is constant but can vary depending on the site and size of the polyps. Sufferers will also frequently complain of watery rhinorrhea and postnasal drip. Anosmia or hyposmia with an ensuing alteration in taste are also characteristic symptoms of NP.; Polypoidal masses arising mainly from the mucous membranes of the nose and paranasal sinuses. They are freely movable and nontender overgrowths of the mucosa that frequently accompany allergic rhinitis. // COMMENTS: Nasal polyps (NP) are benign lesions arising from the mucosa of the nasal sinuses (commonly at the outflow tract of one or more of the sinuses) or from the mucosa of the nasal cavity. The main presenting symptom of NP is nasal obstruction which is constant but can vary depending on the site and size of the polyps. Sufferers will also frequently complain of watery rhinorrhea and postnasal drip. Anosmia or hyposmia with an ensuing alteration in taste are also characteristic symptoms of NP.; UMLS Semantic Type: STY:T190",
-          "equivalent_curies": [
-            "UMLS:C0027430",
-            "MONDO:0006314",
-            "SNOMEDCT:52756005",
-            "MEDDRA:10046043",
-            "MEDDRA:10036138",
-            "MEDDRA:10028756",
-            "NCIT:C3256",
-            "HP:0100582",
-            "MEDDRA:10028754",
-            "EFO:1000391",
-            "MEDDRA:10036128",
-            "MESH:D009298",
-            "ICD9:471",
-            "SNOMEDCT:736500007"
-          ],
-          "id": "MONDO:0006314",
-          "category": "biolink:Disease",
-          "all_names": [
-            "nasal cavity polyp",
-            "Nasal Polyps",
-            "Nasal polyposis",
-            "Nasal Cavity Polyp",
-            "Nasal polyps"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:18728843",
-            "https://orcid.org/0000-0001-5889-4463",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318836,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006314",
-              "name": "nasal cavity polyp",
-              "description": "Polypoidal masses arising mainly from the mucous membranes of the nose and paranasal sinuses. They are freely movable and nontender overgrowths of the mucosa that frequently accompany allergic rhinitis. [HPO:sdoelken, PMID:18728843]; Polypoidal masses arising mainly from the mucous membranes of the nose and paranasal sinuses. They are freely movable and nontender overgrowths of the mucosa that frequently accompany allergic rhinitis. // COMMENTS: Nasal polyps (NP) are benign lesions arising from the mucosa of the nasal sinuses (commonly at the outflow tract of one or more of the sinuses) or from the mucosa of the nasal cavity. The main presenting symptom of NP is nasal obstruction which is constant but can vary depending on the site and size of the polyps. Sufferers will also frequently complain of watery rhinorrhea and postnasal drip. Anosmia or hyposmia with an ensuing alteration in taste are also characteristic symptoms of NP.; Polypoidal masses arising mainly from the mucous membranes of the nose and paranasal sinuses. They are freely movable and nontender overgrowths of the mucosa that frequently accompany allergic rhinitis. // COMMENTS: Nasal polyps (NP) are benign lesions arising from the mucosa of the nasal sinuses (commonly at the outflow tract of one or more of the sinuses) or from the mucosa of the nasal cavity. The main presenting symptom of NP is nasal obstruction which is constant but can vary depending on the site and size of the polyps. Sufferers will also frequently complain of watery rhinorrhea and postnasal drip. Anosmia or hyposmia with an ensuing alteration in taste are also characteristic symptoms of NP.; UMLS Semantic Type: STY:T190",
-              "equivalent_curies": [
-                "UMLS:C0027430",
-                "MONDO:0006314",
-                "SNOMEDCT:52756005",
-                "MEDDRA:10046043",
-                "MEDDRA:10036138",
-                "MEDDRA:10028756",
-                "NCIT:C3256",
-                "HP:0100582",
-                "MEDDRA:10028754",
-                "EFO:1000391",
-                "MEDDRA:10036128",
-                "MESH:D009298",
-                "ICD9:471",
-                "SNOMEDCT:736500007"
-              ],
-              "id": "MONDO:0006314",
-              "category": "biolink:Disease",
-              "all_names": [
-                "nasal cavity polyp",
-                "Nasal Polyps",
-                "Nasal polyposis",
-                "Nasal Cavity Polyp",
-                "Nasal polyps"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:18728843",
-                "https://orcid.org/0000-0001-5889-4463",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17127159,
-            "start": 570,
-            "end": 318836,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24565635': {'publication date': '2013 Sep-Oct', 'sentence': 'The study by Van Zele et al reports positive results for a randomized, double-blind, placebo-controlled trial that used either 20 days of doxycycline (200 mg the first day, followed by 100 mg daily) or 20 days of a tapering schedule of methyl prednisolone (32 mg on days 1-5, 16 mg on days 6-10, and 8 mg on days 11-20) for the treatment of nasal polyps.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0027430---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "17478785",
-              "object": "MONDO:0006314",
-              "publications": [
-                "PMID:24565635"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 577557,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002959",
-          "name": "radiculopathy",
-          "description": "Disease involving a spinal nerve root (see spinal nerve roots) which may result from compression related to intervertebral disk displacement; spinal cord injuries; spinal diseases; and other conditions. Clinical manifestations include radicular pain, weakness, and sensory loss referable to structures innervated by the involved nerve root. // COMMENTS: Editor note: DO classifies under polyradiculopathy, which we invert",
-          "equivalent_curies": [
-            "MEDDRA:10052442",
-            "ICD10:M54.1",
-            "SNOMEDCT:72274001",
-            "MESH:D011843",
-            "MONDO:0002959",
-            "MEDDRA:10041587",
-            "MEDDRA:10037779",
-            "UMLS:C0700594",
-            "DOID:4306",
-            "MEDDRA:10037780",
-            "UMLS:C1527351"
-          ],
-          "id": "MONDO:0002959",
-          "category": "biolink:Disease",
-          "all_names": [
-            "radiculopathy",
-            "Nerve Root Disorder",
-            "Radiculopathy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/radiculopathy",
-            "https://www.hopkinsmedicine.org/health/conditions-and-diseases/radiculopathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 577557,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002959",
-              "name": "radiculopathy",
-              "description": "Disease involving a spinal nerve root (see spinal nerve roots) which may result from compression related to intervertebral disk displacement; spinal cord injuries; spinal diseases; and other conditions. Clinical manifestations include radicular pain, weakness, and sensory loss referable to structures innervated by the involved nerve root. // COMMENTS: Editor note: DO classifies under polyradiculopathy, which we invert",
-              "equivalent_curies": [
-                "MEDDRA:10052442",
-                "ICD10:M54.1",
-                "SNOMEDCT:72274001",
-                "MESH:D011843",
-                "MONDO:0002959",
-                "MEDDRA:10041587",
-                "MEDDRA:10037779",
-                "UMLS:C0700594",
-                "DOID:4306",
-                "MEDDRA:10037780",
-                "UMLS:C1527351"
-              ],
-              "id": "MONDO:0002959",
-              "category": "biolink:Disease",
-              "all_names": [
-                "radiculopathy",
-                "Nerve Root Disorder",
-                "Radiculopathy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/radiculopathy",
-                "https://www.hopkinsmedicine.org/health/conditions-and-diseases/radiculopathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15090097,
-            "start": 570,
-            "end": 577557,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21217889': {'publication date': '2010 Dec', 'sentence': 'Herein, we present our experience of management of such cases with a single epidural injection of local anaesthetic, tramadol and methylprednisolone, and table tilt for management of both radiculopathies.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0700594---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "15407991",
-              "object": "MONDO:0002959",
-              "publications": [
-                "PMID:21217889"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 529953,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019100",
-          "name": "neuromyelitis optica",
-          "description": "An autoimmune inflammatory syndrome characterized by optic neuritis and myelitis. Signs and symptoms include loss of vision, weakness and paralysis of the extremities, and loss of sensation.; A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10058009",
-            "MEDDRA:10077875",
-            "NCIT:C84934",
-            "MEDDRA:10052887",
-            "SNOMEDCT:25044007",
-            "MEDDRA:10029322",
-            "MEDDRA:10041225",
-            "MESH:D009471",
-            "DOID:8869",
-            "MEDDRA:10012574",
-            "ICD9:341.0",
-            "UMLS:C0027873",
-            "UMLS:C0221059",
-            "MONDO:0019100",
-            "EFO:0004256",
-            "ICD10:G36.0",
-            "ORPHANET:71211"
-          ],
-          "id": "MONDO:0019100",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neuromyelitis Optica",
-            "Neuromyelitis optica",
-            "neuromyelitis optica"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/neuromyelitis_optica",
-            "http://rarediseases.org/rare-diseases/neuromyelitis-optica/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 529953,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019100",
-              "name": "neuromyelitis optica",
-              "description": "An autoimmune inflammatory syndrome characterized by optic neuritis and myelitis. Signs and symptoms include loss of vision, weakness and paralysis of the extremities, and loss of sensation.; A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10058009",
-                "MEDDRA:10077875",
-                "NCIT:C84934",
-                "MEDDRA:10052887",
-                "SNOMEDCT:25044007",
-                "MEDDRA:10029322",
-                "MEDDRA:10041225",
-                "MESH:D009471",
-                "DOID:8869",
-                "MEDDRA:10012574",
-                "ICD9:341.0",
-                "UMLS:C0027873",
-                "UMLS:C0221059",
-                "MONDO:0019100",
-                "EFO:0004256",
-                "ICD10:G36.0",
-                "ORPHANET:71211"
-              ],
-              "id": "MONDO:0019100",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neuromyelitis Optica",
-                "Neuromyelitis optica",
-                "neuromyelitis optica"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/neuromyelitis_optica",
-                "http://rarediseases.org/rare-diseases/neuromyelitis-optica/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14588241,
-            "start": 570,
-            "end": 529953,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20300766': {'publication date': '2010 Dec', 'sentence': 'Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica.', 'subject score': 840, 'object score': 1000}, 'PMID:30487360': {'publication date': '2018 Nov 29', 'sentence': 'She was diagnosed with NMO and treated with methylprednisolone therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:33992860': {'publication date': '2021 May 07', 'sentence': 'Sixty-one NMOSD attacks unresponsive to IVMP were included: 22 patients received rescue IA (IVMP+IA), 24 underwent rescue plasma exchange (PE) (IVMP+PE), and 21 received no further rescue therapy (IVMP alone).', 'subject score': 888, 'object score': 901}, 'PMID:35761845': {'publication date': '2022', 'sentence': 'He was diagnosed with AQP4-positive NMOSD and was treated with high-dose intravenous methylprednisolone and plasma exchange with some improvement.', 'subject score': 861, 'object score': 873}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0027873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14897628",
-              "object": "MONDO:0019100",
-              "publications": [
-                "PMID:20300766",
-                "PMID:30487360",
-                "PMID:33992860",
-                "PMID:35761845"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317095,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018097",
-          "name": "West syndrome",
-          "description": "A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages [HPO:jalbers, PMID:28276060]; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0011097",
-            "MONDO:0018097",
-            "MEDDRA:10021750",
-            "UMLS:C0037769",
-            "NCIT:C84788",
-            "MEDDRA:10058893",
-            "MEDDRA:10039371",
-            "SNOMEDCT:28055006",
-            "DOID:0050562",
-            "MESH:D013036",
-            "UMLS:C1527366",
-            "ORPHANET:3451"
-          ],
-          "id": "MONDO:0018097",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_West syndrome",
-            "Salaam Seizures",
-            "West Syndrome",
-            "Spasms, Infantile",
-            "West syndrome",
-            "Epileptic spasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28276060",
-            "PMID:24268986",
-            "https://rarediseases.org/rare-diseases/west-syndrome/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317095,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018097",
-              "name": "West syndrome",
-              "description": "A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages [HPO:jalbers, PMID:28276060]; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; A sudden flexion, extension, or mixed extension-flexion of predominantly proximal and truncal muscles that is usually more sustained than a myoclonic movement but not as sustained as a tonic seizure. Limited forms may occur: Grimacing, head nodding, or subtle eye movements. Epileptic spasms frequently occur in clusters. Infantile spasms are the best known form, but spasms can occur at all ages // COMMENTS: The maximum age of onset is between 3 and 12 months, the peak being at 6 months. However, spasms may start from birth, or appear long after the age of 12 months, including into adulthood. Infantile spasms represent a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. West Syndrome is characterized by infantile spasms, developmental regression, and hypsarrhythmia (as demonstrated by electroencephalography).; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0011097",
-                "MONDO:0018097",
-                "MEDDRA:10021750",
-                "UMLS:C0037769",
-                "NCIT:C84788",
-                "MEDDRA:10058893",
-                "MEDDRA:10039371",
-                "SNOMEDCT:28055006",
-                "DOID:0050562",
-                "MESH:D013036",
-                "UMLS:C1527366",
-                "ORPHANET:3451"
-              ],
-              "id": "MONDO:0018097",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_West syndrome",
-                "Salaam Seizures",
-                "West Syndrome",
-                "Spasms, Infantile",
-                "West syndrome",
-                "Epileptic spasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28276060",
-                "PMID:24268986",
-                "https://rarediseases.org/rare-diseases/west-syndrome/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14517189,
-            "start": 570,
-            "end": 317095,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20142465': {'publication date': '2010 Aug', 'sentence': 'The authors report their experience with intravenous methylprednisolone for the treatment of infantile spasms.', 'subject score': 888, 'object score': 1000}, 'PMID:33103229': {'publication date': '2020 Oct 26', 'sentence': 'Safety, Feasibility and Effectiveness of Pulse Methylprednisolone Therapy in Comparison with Intramuscular Adrenocorticotropic Hormone in Children with West Syndrome.OBJECTIVE: To assess the feasibility, effectiveness, and safety of pulse methylprednisolone in comparison with intramuscular adrenocorticotropic hormone (ACTH) therapy in children with West syndrome (WS).', 'subject score': 861, 'object score': 1000}, 'PMID:33575989': {'publication date': '2021 Feb 11', 'sentence': 'OBJECTIVE: To compare intravenous methylprednisolone (IVMP) with oral prednisolone (OP) for the treatment of West syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:35087722': {'publication date': '2021 Dec', 'sentence': 'This study has been done to evaluate the efficacy of pulse methylprednisolone as compared to ACTH in children with West syndrome.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0037769---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14825096",
-              "object": "MONDO:0018097",
-              "publications": [
-                "PMID:20142465",
-                "PMID:33103229",
-                "PMID:33575989",
-                "PMID:35087722"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 520346,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007972",
-          "name": "Meniere disease",
-          "description": "A chronic inner ear disorder affecting balance and hearing. Symptoms may include vertigo, tinnitus, and hearing loss.; A disease of the inner ear (LABYRINTH) that is characterized by fluctuating SENSORINEURAL HEARING LOSS; TINNITUS; episodic VERTIGO; and aural fullness. It is the most common form of endolymphatic hydrops.; Meniere's disease is a disorder of the inner ear. It can cause severe dizziness, a roaring sound in your ears called tinnitus, hearing loss that comes and goes and the feeling of ear pressure or pain. It usually affects just one ear. It is a common cause of hearing loss.  Attacks of dizziness may come on suddenly or after a short period of tinnitus or muffled hearing. Some people have single attacks of dizziness once in a while. Others may have many attacks close together over several days. Some people with Meniere's disease have \"drop attacks\" during which the dizziness is so bad they lose their balance and fall. Scientists don't yet know the cause. They think that it has to do with the fluid levels or the mixing of fluids in the canals of your inner ear. Doctors diagnose it based on a physical exam and your symptoms. A hearing test can check to see how it has affected your hearing. There is no cure. Treatments include medicines to control dizziness, limiting salt in your diet, and taking water pills. A device that fits into the outer ear and delivers air pulses to the middle ear can help. Severe cases may require surgery. NIH: National Institute on Deafness and Other Communication Disorders ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10027184",
-            "MEDDRA:10042823",
-            "ICD10:H81.0",
-            "UMLS:C0025281",
-            "NCIT:C185243",
-            "MONDO:0007972",
-            "UMLS:C1527320",
-            "ICD9:386.0",
-            "EFO:0006862",
-            "MEDDRA:10027183",
-            "OMIM:156000",
-            "PSY:30640",
-            "SNOMEDCT:13445001",
-            "MEDDRA:10027185",
-            "MESH:D008575",
-            "DOID:9849",
-            "ORPHANET:45360"
-          ],
-          "id": "MONDO:0007972",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Meniere disease related phenotypic feature",
-            "Meniere's disease",
-            "Meniere Disease",
-            "Menieres Disease",
-            "Meniere disease",
-            "Vertigo, Aural"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/m%c3%a9ni%c3%a8re%27s_disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520346,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007972",
-              "name": "Meniere disease",
-              "description": "A chronic inner ear disorder affecting balance and hearing. Symptoms may include vertigo, tinnitus, and hearing loss.; A disease of the inner ear (LABYRINTH) that is characterized by fluctuating SENSORINEURAL HEARING LOSS; TINNITUS; episodic VERTIGO; and aural fullness. It is the most common form of endolymphatic hydrops.; Meniere's disease is a disorder of the inner ear. It can cause severe dizziness, a roaring sound in your ears called tinnitus, hearing loss that comes and goes and the feeling of ear pressure or pain. It usually affects just one ear. It is a common cause of hearing loss.  Attacks of dizziness may come on suddenly or after a short period of tinnitus or muffled hearing. Some people have single attacks of dizziness once in a while. Others may have many attacks close together over several days. Some people with Meniere's disease have \"drop attacks\" during which the dizziness is so bad they lose their balance and fall. Scientists don't yet know the cause. They think that it has to do with the fluid levels or the mixing of fluids in the canals of your inner ear. Doctors diagnose it based on a physical exam and your symptoms. A hearing test can check to see how it has affected your hearing. There is no cure. Treatments include medicines to control dizziness, limiting salt in your diet, and taking water pills. A device that fits into the outer ear and delivers air pulses to the middle ear can help. Severe cases may require surgery. NIH: National Institute on Deafness and Other Communication Disorders ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10027184",
-                "MEDDRA:10042823",
-                "ICD10:H81.0",
-                "UMLS:C0025281",
-                "NCIT:C185243",
-                "MONDO:0007972",
-                "UMLS:C1527320",
-                "ICD9:386.0",
-                "EFO:0006862",
-                "MEDDRA:10027183",
-                "OMIM:156000",
-                "PSY:30640",
-                "SNOMEDCT:13445001",
-                "MEDDRA:10027185",
-                "MESH:D008575",
-                "DOID:9849",
-                "ORPHANET:45360"
-              ],
-              "id": "MONDO:0007972",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Meniere disease related phenotypic feature",
-                "Meniere's disease",
-                "Meniere Disease",
-                "Menieres Disease",
-                "Meniere disease",
-                "Vertigo, Aural"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/m%c3%a9ni%c3%a8re%27s_disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14385226,
-            "start": 570,
-            "end": 520346,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19924013': {'publication date': '2010 Jan', 'sentence': \"OBJECTIVE: To describe the long-term efficacy of transtympanic steroids (TTS) using methyl-prednisolone in the treatment of Meniere's disease (MD).\", 'subject score': 1000, 'object score': 1000}, 'PMID:23314159': {'publication date': '2013 Apr', 'sentence': \"According to these findings, administrating ITMP to control Meniere's disease seems to be less beneficial than ITG.\", 'subject score': 802, 'object score': 1000}, 'PMID:23818540': {'publication date': '2013 Jul', 'sentence': \"Comparison of intratympanic methylprednisolone and gentamicin for Meniere's disease may be misleading.\", 'subject score': 861, 'object score': 1000}, 'PMID:23818541': {'publication date': '2013 Jul', 'sentence': \"Response to: Comparison of intratympanic methylprednisolone and gentamicin for Meniere's disease may be misleading.\", 'subject score': 861, 'object score': 1000}, 'PMID:27865535': {'publication date': '2016 12 03', 'sentence': \"Intratympanic methylprednisolone versus gentamicin in patients with unilateral Meniere's disease: a randomised, double-blind, comparative effectiveness trial.\", 'subject score': 861, 'object score': 901}, 'PMID:30412169': {'publication date': '2018', 'sentence': \"[The effectiveness of the intra-tympanic administration of methylprednisolone and gentamycin for the treatment of Meniere's disease].\", 'subject score': 1000, 'object score': 1000}, 'PMID:30870364': {'publication date': '2019 Apr', 'sentence': \"Long-Term Follow-Up of Intratympanic Methylprednisolone Versus Gentamicin in Patients With Unilateral Meniere's Disease.\", 'subject score': 861, 'object score': 901}, 'PMID:36742746': {'publication date': '2022 Dec', 'sentence': \"Abstract: To compare the effectiveness of high dose fixed alternate day intratympanic gentamicin with methylprednisolone in the treatment of patients with unilateral, intractable Meniere's disease with poor hearing.\", 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0025281---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14690661",
-              "object": "MONDO:0007972",
-              "publications": [
-                "PMID:19924013",
-                "PMID:23314159",
-                "PMID:23818540",
-                "PMID:23818541",
-                "PMID:27865535",
-                "PMID:30412169",
-                "PMID:30870364",
-                "PMID:36742746"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14332209,
-            "start": 570,
-            "end": 319673,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1984489': {'publication date': '1991 Jan', 'sentence': 'Rats with stereotactically implanted Walker 256 tumors were treated with methylprednisolone, U-74006F, U-78517F, or vehicle (0.05 N HCl) on Days 6 through 10 following implantation.', 'subject score': 1000, 'object score': 740}, 'PMID:2089884': {'publication date': '1990', 'sentence': 'Rats with stereotactically implanted Walker 256 tumours were treated with methylprednisolone (MP), U-74006F, U-78517F, or vehicle.', 'subject score': 1000, 'object score': 740}, 'PMID:32686618': {'publication date': '2020 Jul 19', 'sentence': 'Effect of hydrocortisone versus methylprednisolone on clinical outcomes in oncology patients with septic shock.BACKGROUND: Corticosteroids are used as adjunctive treatment of critical illness-related corticosteroid insufficiency in patients with septic shock.', 'subject score': 1000, 'object score': 888}, 'PMID:476617': {'publication date': '1979 Oct', 'sentence': 'Proliferative recovery in the tumor was delayed until after cessation of MP treatments.', 'subject score': 888, 'object score': 1000}, 'PMID:9169090': {'publication date': '1997 Apr', 'sentence': 'Tumors were harvested untreated, or at 1 or 8 days after cessation of MP treatment, and the RNA was extracted.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14636779",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:1984489",
-                "PMID:2089884",
-                "PMID:32686618",
-                "PMID:476617",
-                "PMID:9169090"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 311688,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005342",
-          "name": "IgA glomerulonephritis",
-          "description": "Inflammation of a specific segment of glomeruli within the kidney.; A chronic autoimmune glomerulonephritis characterized by the deposition of immunoglobulin A in the mesangium of the glomeruli. It is manifested with hematuria and mild proteinuria.; A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.; The presence of immunoglobulin A deposits in the glomerulus. [Eurenomics:ewuehl]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C34643",
-            "OMIM.PS:161950",
-            "MEDDRA:10018369",
-            "NCIT:C35280",
-            "UMLS:C0017661",
-            "MESH:D005922",
-            "EFO:0004194",
-            "UMLS:C3161650",
-            "SNOMEDCT:68779003",
-            "HP:0000794",
-            "DOID:2986",
-            "SNOMEDCT:236407003",
-            "MEDDRA:10069341",
-            "ORPHANET:34145",
-            "UMLS:C4025827",
-            "MONDO:0005342",
-            "MEDDRA:10021263"
-          ],
-          "id": "MONDO:0005342",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Glomerulonephritis, IGA",
-            "IGA Glomerulonephritis",
-            "IGA glomerulonephritis",
-            "IgA glomerulonephritis",
-            "IgA Nephropathy",
-            "Primary immunoglobulin A nephropathy (disorder)",
-            "IgA deposition in the glomerulus",
-            "Focal Glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000466.htm",
-            "http://en.wikipedia.org/wiki/iga_nephropathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311688,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005342",
-              "name": "IgA glomerulonephritis",
-              "description": "Inflammation of a specific segment of glomeruli within the kidney.; A chronic autoimmune glomerulonephritis characterized by the deposition of immunoglobulin A in the mesangium of the glomeruli. It is manifested with hematuria and mild proteinuria.; A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.; The presence of immunoglobulin A deposits in the glomerulus. [Eurenomics:ewuehl]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C34643",
-                "OMIM.PS:161950",
-                "MEDDRA:10018369",
-                "NCIT:C35280",
-                "UMLS:C0017661",
-                "MESH:D005922",
-                "EFO:0004194",
-                "UMLS:C3161650",
-                "SNOMEDCT:68779003",
-                "HP:0000794",
-                "DOID:2986",
-                "SNOMEDCT:236407003",
-                "MEDDRA:10069341",
-                "ORPHANET:34145",
-                "UMLS:C4025827",
-                "MONDO:0005342",
-                "MEDDRA:10021263"
-              ],
-              "id": "MONDO:0005342",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Glomerulonephritis, IGA",
-                "IGA Glomerulonephritis",
-                "IGA glomerulonephritis",
-                "IgA glomerulonephritis",
-                "IgA Nephropathy",
-                "Primary immunoglobulin A nephropathy (disorder)",
-                "IgA deposition in the glomerulus",
-                "Focal Glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000466.htm",
-                "http://en.wikipedia.org/wiki/iga_nephropathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14097908,
-            "start": 570,
-            "end": 311688,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19473630': {'publication date': '2009 Jun', 'sentence': 'CONCLUSIONS: Methylprednisolone and cyclophosphamide in children with Grade IV IgA nephropathy stabilized renal function and significantly reduced hematuria, proteinuria, mesangial IgA deposition, and the renal pathological activity index.', 'subject score': 1000, 'object score': 861}, 'PMID:20193265': {'publication date': '2010 Feb 05', 'sentence': 'Combination regimen of leflunomide plus methylprednisolone in a female patient with reactive arthritis and concomitant IgA nephropathy.', 'subject score': 851, 'object score': 901}, 'PMID:31586650': {'publication date': '2019 Oct 03', 'sentence': 'He was treated with methylprednisolone and cyclosporine for IgA nephropathy, thereafter with canakinumab for TRAPS.', 'subject score': 1000, 'object score': 1000}, 'PMID:36865740': {'publication date': '2023', 'sentence': 'Objective: To assess the clinical efficacy of Huangkui capsule plus methylprednisolone for immunoglobulin A (IgA) nephropathy and its effect on renal function and serum inflammatory factors.', 'subject score': 775, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0017661---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14398238",
-              "object": "MONDO:0005342",
-              "publications": [
-                "PMID:19473630",
-                "PMID:20193265",
-                "PMID:31586650",
-                "PMID:36865740"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316993,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005376",
-          "name": "membranous glomerulonephritis",
-          "description": "A slowly progressive inflammation of the glomeruli characterized by immune complex deposits at the glomerular basement membrane, resulting in a thickened membrane, and nephrotic syndrome.; An experimental rat model of human membranous nephropathy characterized by complement activation and formation of subepithelial immune deposits in the glomerular capillary wall.; A type of glomerulonephropathy characterized by thickening of the basement membrane and deposition of immune complexes in the subepithelial space. [Eurenomics:fschaefer]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005376",
-            "HP:0012578",
-            "UMLS:C0017665",
-            "DOID:10976",
-            "MESH:D015433",
-            "SNOMEDCT:77182004",
-            "MEDDRA:10018372",
-            "MEDDRA:10027170",
-            "ICD10:N03.2",
-            "NCIT:C34645",
-            "EFO:0004254"
-          ],
-          "id": "MONDO:0005376",
-          "category": "biolink:Disease",
-          "all_names": [
-            "membranous glomerulonephritis",
-            "Glomerulonephritis, Membranous",
-            "Membranous Glomerulonephritis",
-            "Membranous nephropathy",
-            "Membranous glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316993,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005376",
-              "name": "membranous glomerulonephritis",
-              "description": "A slowly progressive inflammation of the glomeruli characterized by immune complex deposits at the glomerular basement membrane, resulting in a thickened membrane, and nephrotic syndrome.; An experimental rat model of human membranous nephropathy characterized by complement activation and formation of subepithelial immune deposits in the glomerular capillary wall.; A type of glomerulonephropathy characterized by thickening of the basement membrane and deposition of immune complexes in the subepithelial space. [Eurenomics:fschaefer]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005376",
-                "HP:0012578",
-                "UMLS:C0017665",
-                "DOID:10976",
-                "MESH:D015433",
-                "SNOMEDCT:77182004",
-                "MEDDRA:10018372",
-                "MEDDRA:10027170",
-                "ICD10:N03.2",
-                "NCIT:C34645",
-                "EFO:0004254"
-              ],
-              "id": "MONDO:0005376",
-              "category": "biolink:Disease",
-              "all_names": [
-                "membranous glomerulonephritis",
-                "Glomerulonephritis, Membranous",
-                "Membranous Glomerulonephritis",
-                "Membranous nephropathy",
-                "Membranous glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13935281,
-            "start": 570,
-            "end": 316993,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19229832': {'publication date': '2009', 'sentence': 'MN was treated with methylprednisolone as first-line therapy, then she was changed to rituximab for a relapse.', 'subject score': 1000, 'object score': 1000}, 'PMID:29679356': {'publication date': '2018 Dec', 'sentence': 'CONCLUSION: Use of intravenous methylprednisolone for MCD and MN differed geographically in Japan.', 'subject score': 888, 'object score': 1000}, 'PMID:3455548': {'publication date': '1987 Nov', 'sentence': 'Fifteen consecutive patients aged 24 to 70 years, with membranous nephropathy and a progressive decline in renal function, were treated with methylprednisolone, 1 g intravenously daily for five days, followed immediately by a tapering dose of oral prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0017665---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14232595",
-              "object": "MONDO:0005376",
-              "publications": [
-                "PMID:19229832",
-                "PMID:29679356",
-                "PMID:3455548"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 699953,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018905",
-          "name": "diffuse large B-cell lymphoma",
-          "description": "A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.; Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "NCIT:C8851",
-            "UMLS:C0079744",
-            "MEDDRA:10012819",
-            "MEDDRA:10012818",
-            "MONDO:0018905",
-            "UMLS:C2699777",
-            "NCIT:C80280",
-            "SNOMEDCT:109969005",
-            "SNOMEDCT:1172695008",
-            "MESH:D016403",
-            "ORPHANET:544",
-            "MEDDRA:10012820",
-            "DOID:0050745",
-            "EFO:0000403"
-          ],
-          "id": "MONDO:0018905",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphoma, Large B-Cell, Diffuse",
-            "diffuse large B-cell lymphoma",
-            "Diffuse Large B-Cell Lymphoma",
-            "Diffuse large B-cell lymphoma",
-            "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28487884",
-            "http://en.wikipedia.org/wiki/diffuse_large_b-cell_lymphoma",
-            "https://ncithesaurus.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&ns=ncit&code=c148392"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 699953,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018905",
-              "name": "diffuse large B-cell lymphoma",
-              "description": "A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.; Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "NCIT:C8851",
-                "UMLS:C0079744",
-                "MEDDRA:10012819",
-                "MEDDRA:10012818",
-                "MONDO:0018905",
-                "UMLS:C2699777",
-                "NCIT:C80280",
-                "SNOMEDCT:109969005",
-                "SNOMEDCT:1172695008",
-                "MESH:D016403",
-                "ORPHANET:544",
-                "MEDDRA:10012820",
-                "DOID:0050745",
-                "EFO:0000403"
-              ],
-              "id": "MONDO:0018905",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphoma, Large B-Cell, Diffuse",
-                "diffuse large B-cell lymphoma",
-                "Diffuse Large B-Cell Lymphoma",
-                "Diffuse large B-cell lymphoma",
-                "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28487884",
-                "http://en.wikipedia.org/wiki/diffuse_large_b-cell_lymphoma",
-                "https://ncithesaurus.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&ns=ncit&code=c148392"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13733934,
-            "start": 570,
-            "end": 699953,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18945747': {'publication date': '2008 Dec', 'sentence': 'This study evaluated the influence of prior exposure to rituximab on response rates and survival in patients with diffuse large B-cell lymphoma treated with rituximab plus etoposide, cytarabine, cisplatinum and methylprednisolone (R-ESHAP).', 'subject score': 1000, 'object score': 922}, 'PMID:26999778': {'publication date': '2017 Sep', 'sentence': 'A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.', 'subject score': 1000, 'object score': 922}, 'PMID:31776726': {'publication date': '2019 Nov 27', 'sentence': 'The multicentre randomised phase II LEGEND trial evaluated lenalidomide in combination with rituximab, methylprednisolone and gemcitabine (R-GEM-L) vs. standard R-GEM-P as second-line treatment of DLBCL.', 'subject score': 1000, 'object score': 922}, 'PMID:35317293': {'publication date': '2022 Mar', 'sentence': 'The aim of this paper is to present a rare case of DLBCL in an 84-years-old diabetic male patient on methylprednisolone treatment for autoimmune hemolytic anemia.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0079744---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14027935",
-              "object": "MONDO:0018905",
-              "publications": [
-                "PMID:18945747",
-                "PMID:26999778",
-                "PMID:31776726",
-                "PMID:35317293"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 516028,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015540",
-          "name": "hemophagocytic syndrome",
-          "description": "A classification of rare, non-neoplastic, proliferative disorders of the hematologic system. Primary or familial hemophagocytic lymphohistiocytosis (HLH) is inherited with an autosomal recessive pattern with five known subtypes differentiated by specific genetic mutations. Secondary manifestation of HLH is usually seen in hyperactivated immunologic states such as infection, autoimmune disease or malignancy. Histiocytes in the bone marrow, spleen or lymph nodes become activated to the point that phagocytosis proceeds unchecked. Clinical signs usually present within the first decade and include fever, jaundice, hepatosplenomegaly, lymphadenopathy and skin rash. Prompt initiation of treatment improves survival though prognosis remains poor even with intervention.; Proliferation of HISTIOCYTES in response to viral, bacterial, fungal, or parasitic infections.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0015540",
-            "UMLS:C0024291",
-            "NCIT:C35439",
-            "ORPHANET:158032",
-            "DOID:0050120",
-            "SNOMEDCT:234437005",
-            "UMLS:C3887558",
-            "OMIM:PS267700",
-            "NCIT:C34792",
-            "PDQ:CDR0000486910",
-            "MEDDRA:10071583",
-            "ICD10:D76.1",
-            "MEDDRA:10071580",
-            "MEDDRA:10058139",
-            "MESH:D051359",
-            "MEDDRA:10058125"
-          ],
-          "id": "MONDO:0015540",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hemophagocytic Syndrome",
-            "hemophagocytic syndrome",
-            "Hemophagocytic syndrome",
-            "Hemophagocytic Lymphohistiocytosis",
-            "hemophagocytic lymphohistiocytosis",
-            "Lymphohistiocytosis, Hemophagocytic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.scielo.br/scielo.php?script=sci_arttext&pid=s1516-31801997000500007&lng=pt&nrm=iso",
-            "http://ghr.nlm.nih.gov/condition/familial-hemophagocytic-lymphohistiocytosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 516028,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015540",
-              "name": "hemophagocytic syndrome",
-              "description": "A classification of rare, non-neoplastic, proliferative disorders of the hematologic system. Primary or familial hemophagocytic lymphohistiocytosis (HLH) is inherited with an autosomal recessive pattern with five known subtypes differentiated by specific genetic mutations. Secondary manifestation of HLH is usually seen in hyperactivated immunologic states such as infection, autoimmune disease or malignancy. Histiocytes in the bone marrow, spleen or lymph nodes become activated to the point that phagocytosis proceeds unchecked. Clinical signs usually present within the first decade and include fever, jaundice, hepatosplenomegaly, lymphadenopathy and skin rash. Prompt initiation of treatment improves survival though prognosis remains poor even with intervention.; Proliferation of HISTIOCYTES in response to viral, bacterial, fungal, or parasitic infections.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0015540",
-                "UMLS:C0024291",
-                "NCIT:C35439",
-                "ORPHANET:158032",
-                "DOID:0050120",
-                "SNOMEDCT:234437005",
-                "UMLS:C3887558",
-                "OMIM:PS267700",
-                "NCIT:C34792",
-                "PDQ:CDR0000486910",
-                "MEDDRA:10071583",
-                "ICD10:D76.1",
-                "MEDDRA:10071580",
-                "MEDDRA:10058139",
-                "MESH:D051359",
-                "MEDDRA:10058125"
-              ],
-              "id": "MONDO:0015540",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hemophagocytic Syndrome",
-                "hemophagocytic syndrome",
-                "Hemophagocytic syndrome",
-                "Hemophagocytic Lymphohistiocytosis",
-                "hemophagocytic lymphohistiocytosis",
-                "Lymphohistiocytosis, Hemophagocytic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.scielo.br/scielo.php?script=sci_arttext&pid=s1516-31801997000500007&lng=pt&nrm=iso",
-                "http://ghr.nlm.nih.gov/condition/familial-hemophagocytic-lymphohistiocytosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13391724,
-            "start": 570,
-            "end": 516028,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18386553': {'publication date': '2008 Jan', 'sentence': 'A 46 year old woman who presented with severe multiorgans involvement including liver brain, cardio-pulmonary failure, gastrointestinal bleeding, progressive cytopenia, DIC and hemophagocytic syndrome during the convalescent phase of Dengue type II has been successfully treated primarily with pulse methyl prednisolone and high dose intravenous immunoglobulin G.', 'subject score': 901, 'object score': 1000}, 'PMID:21411984': {'publication date': '2011', 'sentence': 'CsA (4 mg/kg/day) plus mPSL treatment dramatically improved HPS with DIC, reduced subcutaneous tumors within 2 weeks, and finally induced complete remission (CR) after 3 months.', 'subject score': 851, 'object score': 1000}, 'PMID:27998299': {'publication date': '2016 Dec 20', 'sentence': 'Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature.', 'subject score': 1000, 'object score': 901}, 'PMID:32126983': {'publication date': '2020 Mar 03', 'sentence': 'On the basis of antiinfection treatment, methylprednisolone was used to control HLH.', 'subject score': 1000, 'object score': 1000}, 'PMID:32991435': {'publication date': '2020 Sep 25', 'sentence': 'INTERVENTIONS: The patient experienced pulse therapy with methylprednisolone for hemophagocytic lymphohistiocytosis, followed by initial therapy for multiple myeloma with cyclophosphamide and dexamethasone.', 'subject score': 1000, 'object score': 1000}, 'PMID:33967148': {'publication date': '2021', 'sentence': 'The mPSL dose was again increased to 2 mg/kg for the treatment of hemophagocytic syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:35265543': {'publication date': '2022', 'sentence': 'A diagnosis of hemophagocytic lymphohistiocytosis was assumed and pulse methylprednisolone therapy initiated.', 'subject score': 790, 'object score': 1000}, 'PMID:36064566': {'publication date': '2022 Sep 05', 'sentence': 'He was diagnosed with HLH and was treated with methylprednisolone and cyclosporine.', 'subject score': 1000, 'object score': 1000}, 'PMID:9785977': {'publication date': '1998 Aug', 'sentence': 'The patient was treated with gamma-globulin and methylprednisolone for hemophagocytic syndrome, but died of respiratory insufficiency with progressive hyperbilirubinemia and trombocytopenia on the 29th hospital day, A postmortem examination showed proliferation of lymphoma cells within the small blood vessels of the brain, lungs, liver, and many other organs, but the bone marrow was not involved.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0024291---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "13679356",
-              "object": "MONDO:0015540",
-              "publications": [
-                "PMID:18386553",
-                "PMID:21411984",
-                "PMID:27998299",
-                "PMID:32126983",
-                "PMID:32991435",
-                "PMID:33967148",
-                "PMID:35265543",
-                "PMID:36064566",
-                "PMID:9785977"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 324986,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-          "name": "chronic obstructive pulmonary disease",
-          "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-          "equivalent_curies": [
-            "MESH:D029424",
-            "MEDDRA:10010952",
-            "MEDDRA:10009025",
-            "ICD10:J44.9",
-            "UMLS:C1527303",
-            "NCIT:C3199",
-            "UMLS:C0024117",
-            "MEDDRA:10064611",
-            "MEDDRA:10009026",
-            "MEDDRA:10029972",
-            "DOID:3083",
-            "MONDO:0005002",
-            "MEDDRA:10009032",
-            "MEDDRA:10070975",
-            "EFO:0000341",
-            "SNOMEDCT:13645005",
-            "MEDDRA:10009033",
-            "HP:0006510",
-            "MEDDRA:10008828"
-          ],
-          "id": "MONDO:0005002",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic Obstructive Pulmonary Disease",
-            "chronic obstructive pulmonary disease",
-            "Chronic pulmonary obstruction",
-            "Chronic Airflow Obstruction",
-            "Chronic Obstructive Airway Disease",
-            "Pulmonary Disease, Chronic Obstructive"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health-topics/copd",
-            "PMID:32800196",
-            "PMID:28513453",
-            "PMID:25943942",
-            "PMID:32745458"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 324986,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-              "name": "chronic obstructive pulmonary disease",
-              "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-              "equivalent_curies": [
-                "MESH:D029424",
-                "MEDDRA:10010952",
-                "MEDDRA:10009025",
-                "ICD10:J44.9",
-                "UMLS:C1527303",
-                "NCIT:C3199",
-                "UMLS:C0024117",
-                "MEDDRA:10064611",
-                "MEDDRA:10009026",
-                "MEDDRA:10029972",
-                "DOID:3083",
-                "MONDO:0005002",
-                "MEDDRA:10009032",
-                "MEDDRA:10070975",
-                "EFO:0000341",
-                "SNOMEDCT:13645005",
-                "MEDDRA:10009033",
-                "HP:0006510",
-                "MEDDRA:10008828"
-              ],
-              "id": "MONDO:0005002",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic Obstructive Pulmonary Disease",
-                "chronic obstructive pulmonary disease",
-                "Chronic pulmonary obstruction",
-                "Chronic Airflow Obstruction",
-                "Chronic Obstructive Airway Disease",
-                "Pulmonary Disease, Chronic Obstructive"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health-topics/copd",
-                "PMID:32800196",
-                "PMID:28513453",
-                "PMID:25943942",
-                "PMID:32745458"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13332831,
-            "start": 570,
-            "end": 324986,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18306904': {'publication date': '2007 Nov-Dec', 'sentence': 'In conclusion, methylprednisolone in combination with conventional medical therapy not only improved lung function values but also mean nocturnal oxyhemoglobin saturation and sleep duration in clinically stabilized COPD patients who experience nocturnal oxyhemoglobin desaturation.', 'subject score': 1000, 'object score': 775}, 'PMID:21756523': {'publication date': '2011 May', 'sentence': 'OBJECTIVE: To compare intravenous (IV) methylprednisolone (MP) followed by oral MP with IV hydrocortisone (HC) followed by oral prednisolone in patients with AECOPD.', 'subject score': 888, 'object score': 833}, 'PMID:35129068': {'publication date': '2022 Feb', 'sentence': 'We carried out this study with the aim of exploring the underlying mechanism of methylprednisolone (MP) treating the COPD.', 'subject score': 1000, 'object score': 1000}, 'PMID:36176448': {'publication date': '2022', 'sentence': 'Objective:     To assess the cost-effectiveness of nebulized budesonide and intravenous methylprednisolone in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in a real-world setting.', 'subject score': 888, 'object score': 805}, 'PMID:36242002': {'publication date': '2022 Oct 14', 'sentence': 'After Methylprednisolone treatment of acute exacerbated COPD patients, however, the mitotic effect was further amplified, but it was followed by a deficient differentiation capacity.', 'subject score': 888, 'object score': 863}, 'PMID:7032378': {'publication date': '1982 Jan', 'sentence': 'We compared a 2-week course of 32 mg/d methylprednisolone with placebo in a double-blind crossover trial in 46 well-characterized patients with stable chronic obstructive pulmonary disease.', 'subject score': 763, 'object score': 937}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0024117---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "13619118",
-              "object": "MONDO:0005002",
-              "publications": [
-                "PMID:18306904",
-                "PMID:21756523",
-                "PMID:35129068",
-                "PMID:36176448",
-                "PMID:36242002",
-                "PMID:7032378"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 703976,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015545",
-          "name": "macrophage activation syndrome",
-          "description": "A complication of rheumatic disease that is caused by excessive activation and uncontrolled proliferation of T lymphocytes and well-differentiated macrophages. It is characterized by fever, pancytopenia, liver insufficiency, coagulopathy and neurologic symptoms.; A serious complication of childhood systemic inflammatory disorders that is thought to be caused by excessive activation and proliferation of T-LYMPHOCYTES and MACROPHAGES. It is seen predominantly in children with systemic onset JUVENILE IDIOPATHIC ARTHRITIS.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10053867",
-            "MESH:D055501",
-            "ORPHANET:158061",
-            "MONDO:0015545",
-            "SNOMEDCT:430478003",
-            "UMLS:C1096155",
-            "NCIT:C114471",
-            "EFO:1001806"
-          ],
-          "id": "MONDO:0015545",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Macrophage Activation Syndrome",
-            "macrophage activation syndrome",
-            "Macrophage activation syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 703976,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015545",
-              "name": "macrophage activation syndrome",
-              "description": "A complication of rheumatic disease that is caused by excessive activation and uncontrolled proliferation of T lymphocytes and well-differentiated macrophages. It is characterized by fever, pancytopenia, liver insufficiency, coagulopathy and neurologic symptoms.; A serious complication of childhood systemic inflammatory disorders that is thought to be caused by excessive activation and proliferation of T-LYMPHOCYTES and MACROPHAGES. It is seen predominantly in children with systemic onset JUVENILE IDIOPATHIC ARTHRITIS.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10053867",
-                "MESH:D055501",
-                "ORPHANET:158061",
-                "MONDO:0015545",
-                "SNOMEDCT:430478003",
-                "UMLS:C1096155",
-                "NCIT:C114471",
-                "EFO:1001806"
-              ],
-              "id": "MONDO:0015545",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Macrophage Activation Syndrome",
-                "macrophage activation syndrome",
-                "Macrophage activation syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13248806,
-            "start": 570,
-            "end": 703976,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18183612': {'publication date': '2008 May', 'sentence': 'Following treatment with etanercept, ibuprofen, methylprednisolone, and phenylbutazone for 3 weeks, MAS deteriorated and fatal cerebral edema occurred within only 24 h.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C1096155---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "13533673",
-              "object": "MONDO:0015545",
-              "publications": [
-                "PMID:18183612"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 530656,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005100",
-          "name": "systemic sclerosis",
-          "description": "A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.; A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:90291",
-            "EFO:0000717",
-            "UMLS:CN206012",
-            "MEDDRA:10036814",
-            "UMLS:C0036421",
-            "ICD10:M34.0",
-            "DOID:418",
-            "UMLS:C0700318",
-            "MEDDRA:10078638",
-            "SNOMEDCT:89155008",
-            "MONDO:0005100",
-            "ICD9:710.1",
-            "MEDDRA:10042953",
-            "PDQ:CDR0000587622",
-            "MESH:D012595",
-            "NCIT:C72070"
-          ],
-          "id": "MONDO:0005100",
-          "category": "biolink:Disease",
-          "all_names": [
-            "systemic sclerosis",
-            "Scleroderma, Systemic",
-            "Systemic sclerosis",
-            "Systemic Scleroderma",
-            "systemic scleroderma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://ghr.nlm.nih.gov/condition/systemic-scleroderma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 530656,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005100",
-              "name": "systemic sclerosis",
-              "description": "A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.; A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:90291",
-                "EFO:0000717",
-                "UMLS:CN206012",
-                "MEDDRA:10036814",
-                "UMLS:C0036421",
-                "ICD10:M34.0",
-                "DOID:418",
-                "UMLS:C0700318",
-                "MEDDRA:10078638",
-                "SNOMEDCT:89155008",
-                "MONDO:0005100",
-                "ICD9:710.1",
-                "MEDDRA:10042953",
-                "PDQ:CDR0000587622",
-                "MESH:D012595",
-                "NCIT:C72070"
-              ],
-              "id": "MONDO:0005100",
-              "category": "biolink:Disease",
-              "all_names": [
-                "systemic sclerosis",
-                "Scleroderma, Systemic",
-                "Systemic sclerosis",
-                "Systemic Scleroderma",
-                "systemic scleroderma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://ghr.nlm.nih.gov/condition/systemic-scleroderma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12883550,
-            "start": 570,
-            "end": 530656,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17543155': {'publication date': '2007 Mar-Apr', 'sentence': 'CONCLUSION: The results of this pilot study suggest that the combination of MMF, IV MP and low-dose GC might achieve good clinical, functional and radiological results in patients suffering from severe early SSc.', 'subject score': 888, 'object score': 861}, 'PMID:28866045': {'publication date': '2017 11', 'sentence': 'However in SSc patients, we did not find any significant reduction in these cytokine levels after MP treatment.', 'subject score': 888, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0036421---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "13161419",
-              "object": "MONDO:0005100",
-              "publications": [
-                "PMID:17543155",
-                "PMID:28866045"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 546730,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002135",
-          "name": "optic nerve disorder",
-          "description": "A non-neoplastic or neoplastic disorder affecting the optic nerve (second cranial nerve).; Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.; The optic nerve is a bundle of more than 1 million nerve fibers that carry visual messages. You have one connecting the back of each eye (your retina) to your brain. Damage to an optic nerve can cause vision loss. The type of vision loss and how severe it is depends on where the damage occurs. It may affect one or both eyes. There are many different types of optic nerve disorders, including:  Glaucoma is a group of diseases that are the leading cause of blindness in the United States. Glaucoma usually happens when the fluid pressure inside the eyes slowly rises and damages the optic nerve. Optic neuritis is an inflammation of the optic nerve. Causes include infections and immune-related illnesses such as multiple sclerosis. Sometimes the cause is unknown. Optic nerve atrophy is damage to the optic nerve. Causes include poor blood flow to the eye, disease, trauma, or exposure to toxic substances. Optic nerve head drusen are pockets of protein and calcium salts that build up in the optic nerve over time  Contact your health care provider if you are having vision problems. Tests for optic nerve disorders may include eye exams, ophthalmoscopy (an examination of the back of your eye), and imaging tests. Treatment depends on which disorder that you have. With some optic nerve disorders, you may get your vision back. With others, there is no treatment, or treatment may only prevent further vision loss.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10061322",
-            "MESH:D009901",
-            "SNOMEDCT:77157004",
-            "UMLS:C0029132",
-            "NCIT:C79698",
-            "MONDO:0002135",
-            "DOID:1891",
-            "MEDDRA:10030932"
-          ],
-          "id": "MONDO:0002135",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Disorder of the optic nerve",
-            "Optic Nerve Disorder",
-            "optic nerve disease",
-            "Optic Nerve Diseases",
-            "optic nerve disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nature.com/eye/journal/v18/n11/full/6701575a.htm",
-            "http://www.academy.org.uk/lectures/barnard3.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546730,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002135",
-              "name": "optic nerve disorder",
-              "description": "A non-neoplastic or neoplastic disorder affecting the optic nerve (second cranial nerve).; Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.; The optic nerve is a bundle of more than 1 million nerve fibers that carry visual messages. You have one connecting the back of each eye (your retina) to your brain. Damage to an optic nerve can cause vision loss. The type of vision loss and how severe it is depends on where the damage occurs. It may affect one or both eyes. There are many different types of optic nerve disorders, including:  Glaucoma is a group of diseases that are the leading cause of blindness in the United States. Glaucoma usually happens when the fluid pressure inside the eyes slowly rises and damages the optic nerve. Optic neuritis is an inflammation of the optic nerve. Causes include infections and immune-related illnesses such as multiple sclerosis. Sometimes the cause is unknown. Optic nerve atrophy is damage to the optic nerve. Causes include poor blood flow to the eye, disease, trauma, or exposure to toxic substances. Optic nerve head drusen are pockets of protein and calcium salts that build up in the optic nerve over time  Contact your health care provider if you are having vision problems. Tests for optic nerve disorders may include eye exams, ophthalmoscopy (an examination of the back of your eye), and imaging tests. Treatment depends on which disorder that you have. With some optic nerve disorders, you may get your vision back. With others, there is no treatment, or treatment may only prevent further vision loss.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10061322",
-                "MESH:D009901",
-                "SNOMEDCT:77157004",
-                "UMLS:C0029132",
-                "NCIT:C79698",
-                "MONDO:0002135",
-                "DOID:1891",
-                "MEDDRA:10030932"
-              ],
-              "id": "MONDO:0002135",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Disorder of the optic nerve",
-                "Optic Nerve Disorder",
-                "optic nerve disease",
-                "Optic Nerve Diseases",
-                "optic nerve disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nature.com/eye/journal/v18/n11/full/6701575a.htm",
-                "http://www.academy.org.uk/lectures/barnard3.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12819069,
-            "start": 570,
-            "end": 546730,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17452966': {'publication date': '2007 May', 'sentence': 'Dysthyroid optic neuropathy is best treated with intravenous pulsed methylprednisolone; if visual functions do not recover, urgent surgical decompression is indicated.', 'subject score': 840, 'object score': 901}, 'PMID:21663445': {'publication date': '2011 Jun', 'sentence': 'CONCLUSION: Intravenous high-dose methyl prednisolone may have benefits in the treatment of methanol optic neuropathy.', 'subject score': 861, 'object score': 901}, 'PMID:24417307': {'publication date': '2014 May', 'sentence': 'METHODS: Twenty-four DON patients (40 eyes) treated with iv-MP from 2007 to 2012 were included in the study.', 'subject score': 888, 'object score': 762}, 'PMID:24920512': {'publication date': '2014 Jun 11', 'sentence': 'Intravenous methylprednisolone was used to reverse optic neuropathy and to prevent OD visual loss.', 'subject score': 888, 'object score': 1000}, 'PMID:25705536': {'publication date': '2015', 'sentence': 'Optic neuropathy was treated with intravenous pulse methylprednisolone.', 'subject score': 802, 'object score': 1000}, 'PMID:2771352': {'publication date': '1989 Jul', 'sentence': 'Pulse methylprednisolone therapy appears to be beneficial in the initial management of severe dysthyroid optic neuropathy.', 'subject score': 790, 'object score': 824}, 'PMID:29927882': {'publication date': '2018 Jul/Aug', 'sentence': 'There has only been one controlled trial comparing high-dose intravenous methylprednisolone to bony orbital decompression for DON.', 'subject score': 861, 'object score': 901}, 'PMID:33710036': {'publication date': '2021 Mar 08', 'sentence': 'Three cases of dysthyroid optic neuropathy, refractory to methylprednisolone therapy improved after initiation of teprotumumab.', 'subject score': 888, 'object score': 901}, 'PMID:35456161': {'publication date': '2022 Apr 07', 'sentence': 'CONCLUSIONS: The results of this study suggest that additional treatment with 12 pulses of ivMP improves or stabilizes the outcome of basic therapy in patients with DON.', 'subject score': 888, 'object score': 901}, 'PMID:36690985': {'publication date': '2023 Jan 23', 'sentence': 'AIM: To study the efficacy of intravenous pulse methylprednisolone (IVMP) in treating dysthyroid optic neuropathy (DON) and to identify factors predicting poor response to the treatment.', 'subject score': 802, 'object score': 824}, 'PMID:7732488': {'publication date': '1995 Feb', 'sentence': 'When she was admitted three days later, she was diagnosed as having optic neuropathy, and immediate treatment with methylprednisolone (1 g/day for three days) followed by prednisolone (50 mg/day) resulted in complete disappearance of the above symptoms by Feb.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0029132---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "13096165",
-              "object": "MONDO:0002135",
-              "publications": [
-                "PMID:17452966",
-                "PMID:21663445",
-                "PMID:24417307",
-                "PMID:24920512",
-                "PMID:25705536",
-                "PMID:2771352",
-                "PMID:29927882",
-                "PMID:33710036",
-                "PMID:35456161",
-                "PMID:36690985",
-                "PMID:7732488"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 535028,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000430",
-          "name": "mature T-cell and NK-cell non-Hodgkin lymphoma",
-          "description": "A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10034624",
-            "MONDO:0000430",
-            "MEDDRA:10034623",
-            "UMLS:C1337073",
-            "MESH:D016411",
-            "UMLS:C1337074",
-            "NCIT:C27352",
-            "UMLS:C0079774",
-            "UMLS:C5551485",
-            "UMLS:C1337079",
-            "DOID:0050743",
-            "NCIT:C7204",
-            "UMLS:C0334655",
-            "NCIT:C3468",
-            "DOID:0050749",
-            "SNOMEDCT:109977009",
-            "ICD9:202.7",
-            "SNOMEDCT:1163404000",
-            "SNOMEDCT:109975001"
-          ],
-          "id": "MONDO:0000430",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peripheral T-Cell Lymphoma, Large Cell",
-            "T-Zone Variant Peripheral T-Cell Lymphoma",
-            "mature T-cell and NK-cell non-Hodgkin lymphoma",
-            "peripheral T-cell lymphoma",
-            "T-zone lymphoma (clinical)",
-            "Lymphoma, T-Cell, Peripheral",
-            "mature T-cell and NK-cell lymphoma",
-            "Peripheral T-Cell Lymphoma",
-            "Peripheral T-cell lymphoma",
-            "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:21919697",
-            "http://www.cancer.gov/dictionary?cdrid=393800",
-            "http://www.cancer.gov/dictionary?cdrid=44062",
-            "http://en.wikipedia.org/wiki/peripheral_t-cell_lymphoma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 535028,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000430",
-              "name": "mature T-cell and NK-cell non-Hodgkin lymphoma",
-              "description": "A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10034624",
-                "MONDO:0000430",
-                "MEDDRA:10034623",
-                "UMLS:C1337073",
-                "MESH:D016411",
-                "UMLS:C1337074",
-                "NCIT:C27352",
-                "UMLS:C0079774",
-                "UMLS:C5551485",
-                "UMLS:C1337079",
-                "DOID:0050743",
-                "NCIT:C7204",
-                "UMLS:C0334655",
-                "NCIT:C3468",
-                "DOID:0050749",
-                "SNOMEDCT:109977009",
-                "ICD9:202.7",
-                "SNOMEDCT:1163404000",
-                "SNOMEDCT:109975001"
-              ],
-              "id": "MONDO:0000430",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peripheral T-Cell Lymphoma, Large Cell",
-                "T-Zone Variant Peripheral T-Cell Lymphoma",
-                "mature T-cell and NK-cell non-Hodgkin lymphoma",
-                "peripheral T-cell lymphoma",
-                "T-zone lymphoma (clinical)",
-                "Lymphoma, T-Cell, Peripheral",
-                "mature T-cell and NK-cell lymphoma",
-                "Peripheral T-Cell Lymphoma",
-                "Peripheral T-cell lymphoma",
-                "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:21919697",
-                "http://www.cancer.gov/dictionary?cdrid=393800",
-                "http://www.cancer.gov/dictionary?cdrid=44062",
-                "http://en.wikipedia.org/wiki/peripheral_t-cell_lymphoma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12700621,
-            "start": 570,
-            "end": 535028,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17296587': {'publication date': '2007 Feb', 'sentence': 'Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0079774---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "12975348",
-              "object": "MONDO:0000430",
-              "publications": [
-                "PMID:17296587"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 722907,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-          "name": "bronchopulmonary dysplasia",
-          "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ORPHANET:70589",
-            "MESH:D001997",
-            "MONDO:0019091",
-            "SNOMEDCT:67569000",
-            "MEDDRA:10066204",
-            "UMLS:C0006287",
-            "NCIT:C90599",
-            "DOID:11650",
-            "MEDDRA:10006475"
-          ],
-          "id": "MONDO:0019091",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bronchopulmonary Dysplasia",
-            "obsolete_bronchopulmonary dysplasia",
-            "bronchopulmonary dysplasia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 722907,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019091",
-              "name": "bronchopulmonary dysplasia",
-              "description": "Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.; A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ORPHANET:70589",
-                "MESH:D001997",
-                "MONDO:0019091",
-                "SNOMEDCT:67569000",
-                "MEDDRA:10066204",
-                "UMLS:C0006287",
-                "NCIT:C90599",
-                "DOID:11650",
-                "MEDDRA:10006475"
-              ],
-              "id": "MONDO:0019091",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bronchopulmonary Dysplasia",
-                "obsolete_bronchopulmonary dysplasia",
-                "bronchopulmonary dysplasia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12185216,
-            "start": 570,
-            "end": 722907,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16651362': {'publication date': '2006 May', 'sentence': 'Hypertrophic cardiomyopathy in preterm infants treated with methylprednisolone for bronchopulmonary dysplasia.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0006287---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "12450216",
-              "object": "MONDO:0019091",
-              "publications": [
-                "PMID:16651362"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 323988,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009693",
-          "name": "plasma cell myeloma",
-          "description": "A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3242\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3242\" NCI Thesaurus); A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001); A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.; A malignant plasma cell tumor growing within soft tissue or within the skeleton. [HPO:sdoelken]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10074470",
-            "MEDDRA:10028569",
-            "MEDDRA:10028228",
-            "MEDDRA:10035226",
-            "EFO:0001378",
-            "SNOMEDCT:55921005",
-            "MEDDRA:10034613",
-            "MESH:D009101",
-            "MEDDRA:10028568",
-            "MONDO:0009693",
-            "ICD9:203.0",
-            "HP:0006775",
-            "OMIM:254500",
-            "MEDDRA:10028566",
-            "ORPHANET:29073",
-            "SNOMEDCT:109989006",
-            "DOID:9538",
-            "ICD10:C90.0",
-            "UMLS:C0026764",
-            "PDQ:CDR0000042947",
-            "NCIT:C3242",
-            "SNOMEDCT:1162576007"
-          ],
-          "id": "MONDO:0009693",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Multiple myeloma",
-            "Multiple Myeloma",
-            "plasma cell myeloma",
-            "multiple myeloma",
-            "Myeloma, multiple related phenotypic feature",
-            "Plasma Cell Myeloma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=411384",
-            "http://en.wikipedia.org/wiki/multiple_myeloma",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323988,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009693",
-              "name": "plasma cell myeloma",
-              "description": "A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3242\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3242\" NCI Thesaurus); A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001); A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.; A malignant plasma cell tumor growing within soft tissue or within the skeleton. [HPO:sdoelken]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10074470",
-                "MEDDRA:10028569",
-                "MEDDRA:10028228",
-                "MEDDRA:10035226",
-                "EFO:0001378",
-                "SNOMEDCT:55921005",
-                "MEDDRA:10034613",
-                "MESH:D009101",
-                "MEDDRA:10028568",
-                "MONDO:0009693",
-                "ICD9:203.0",
-                "HP:0006775",
-                "OMIM:254500",
-                "MEDDRA:10028566",
-                "ORPHANET:29073",
-                "SNOMEDCT:109989006",
-                "DOID:9538",
-                "ICD10:C90.0",
-                "UMLS:C0026764",
-                "PDQ:CDR0000042947",
-                "NCIT:C3242",
-                "SNOMEDCT:1162576007"
-              ],
-              "id": "MONDO:0009693",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Multiple myeloma",
-                "Multiple Myeloma",
-                "plasma cell myeloma",
-                "multiple myeloma",
-                "Myeloma, multiple related phenotypic feature",
-                "Plasma Cell Myeloma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=411384",
-                "http://en.wikipedia.org/wiki/multiple_myeloma",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11640925,
-            "start": 570,
-            "end": 323988,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1597118': {'publication date': '1992 Jun 05', 'sentence': 'Multiple myeloma of Stage IIa was diagnosed and she was given cytostatic therapy with 17.5 mg melphalan and 112 mg methylprednisolone daily by mouth (for 4 days at intervals of 6 weeks).', 'subject score': 775, 'object score': 1000}, 'PMID:17026824': {'publication date': '2006 Sep', 'sentence': 'Because of the known additive effect between bortezomib and glucocorticoid, we explored weekly bortezomib/methylprednisolone in patients with relapsed multiple myeloma.', 'subject score': 851, 'object score': 884}, 'PMID:17107906': {'publication date': '2006 Nov', 'sentence': 'The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis.', 'subject score': 833, 'object score': 1000}, 'PMID:2286358': {'publication date': '1990 Nov-Dec', 'sentence': 'Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone.', 'subject score': 1000, 'object score': 901}, 'PMID:26824011': {'publication date': '2015 Dec 16', 'sentence': 'Remarkable Response to Methylprednisolone in a Multiple Myeloma Patient with Nodal Disease Refractory to High-Dose Chemotherapy.', 'subject score': 1000, 'object score': 901}, 'PMID:28155827': {'publication date': '2016 Mar 23', 'sentence': 'We report a rare case of bilateral steroid-induced osteonecrosis of the proximal femora and humeri nine months after a short course of intravenous methylprednisolone for treatment of multiple myeloma.', 'subject score': 888, 'object score': 1000}, 'PMID:3207601': {'publication date': '1988 Oct', 'sentence': 'Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients.', 'subject score': 734, 'object score': 901}, 'PMID:32991435': {'publication date': '2020 Sep 25', 'sentence': 'INTERVENTIONS: The patient experienced pulse therapy with methylprednisolone for hemophagocytic lymphohistiocytosis, followed by initial therapy for multiple myeloma with cyclophosphamide and dexamethasone.', 'subject score': 1000, 'object score': 1000}, 'PMID:8370425': {'publication date': '1993 Aug', 'sentence': 'In a randomised multicentre trial a combination of methylprednisolone, vincristine, lomustine, cyclophosphamide and melphalan (MOCCA) was compared with the same regimen omitting methylprednisolone after the first course (COLA) in previously untreated patients with multiple myeloma.', 'subject score': 825, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0026764---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "11895116",
-              "object": "MONDO:0009693",
-              "publications": [
-                "PMID:1597118",
-                "PMID:17026824",
-                "PMID:17107906",
-                "PMID:2286358",
-                "PMID:26824011",
-                "PMID:28155827",
-                "PMID:3207601",
-                "PMID:32991435",
-                "PMID:8370425"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321491,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100543",
-          "name": "Cognitive impairment",
-          "description": "Abnormal cognition with deficits in thinking, reasoning, or remembering. [HPO:sdoelken]; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "MEDDRA:10009845",
-            "UMLS:C0683322",
-            "NCIT:C116921",
-            "MEDDRA:10048599",
-            "PSY:10113",
-            "UMLS:C0338656",
-            "HP:0100543",
-            "MEDDRA:10009846",
-            "MESH:D060825",
-            "SNOMEDCT:386806002",
-            "NCIT:C46083",
-            "NCIT:C27101",
-            "PSY:10103"
-          ],
-          "id": "HP:0100543",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Impaired cognition",
-            "Cognitive Disturbance",
-            "Mental impairment",
-            "Cognitive impairment",
-            "Cognitive Impairment",
-            "Cognitive Dysfunction"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321491,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100543",
-              "name": "Cognitive impairment",
-              "description": "Abnormal cognition with deficits in thinking, reasoning, or remembering. [HPO:sdoelken]; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "MEDDRA:10009845",
-                "UMLS:C0683322",
-                "NCIT:C116921",
-                "MEDDRA:10048599",
-                "PSY:10113",
-                "UMLS:C0338656",
-                "HP:0100543",
-                "MEDDRA:10009846",
-                "MESH:D060825",
-                "SNOMEDCT:386806002",
-                "NCIT:C46083",
-                "NCIT:C27101",
-                "PSY:10103"
-              ],
-              "id": "HP:0100543",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Impaired cognition",
-                "Cognitive Disturbance",
-                "Mental impairment",
-                "Cognitive impairment",
-                "Cognitive Impairment",
-                "Cognitive Dysfunction"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11628942,
-            "start": 570,
-            "end": 321491,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:15957521': {'publication date': '2005 Jun', 'sentence': 'One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:34237754': {'publication date': '2021 Jul 08', 'sentence': 'Herein, we report a case of a patient with GFAP-A with initial symptoms of psychological and cognitive impairment, which did not respond to high-dose methylprednisolone therapy but was successfully treated with protein A immunoadsorption (PAIA) therapy.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0338656---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "11882768",
-              "object": "HP:0100543",
-              "publications": [
-                "PMID:15957521",
-                "PMID:34237754"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 592657,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018896",
-          "name": "thrombotic thrombocytopenic purpura",
-          "description": "An acute or subacute syndrome characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities and neurologic abnormalities such as seizures, hemiplegia, and visual disturbances. Drugs and bacteria have been implicated as etiologic factors. The introduction of plasma exchange has significantly lowered the mortality rate. If untreated, the mortality rate is high. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C78797\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C78797\" NCI Thesaurus); A coagulation disorder characterized by extensive formation of thrombi in small blood vessels throughout the body due to low levels of ADAMTS13 protein, and resulting in consumption of circulating platelets, which is characterized by thrombocytopenia, anemia, neurologic changes, and sometimes fever and renal dysfunction.; An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10037562",
-            "MONDO:0018896",
-            "UMLS:C0034155",
-            "ORPHANET:54057",
-            "ICD10:M31.19",
-            "SNOMEDCT:78129009",
-            "NCIT:C78797",
-            "MEDDRA:10073197",
-            "MESH:D011697",
-            "PDQ:CDR0000694585",
-            "MEDDRA:10043562",
-            "DOID:10772",
-            "MEDDRA:10043648",
-            "MEDDRA:10037563"
-          ],
-          "id": "MONDO:0018896",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Thrombotic Thrombocytopenic Purpura",
-            "Thrombotic thrombocytopenic purpura",
-            "thrombotic thrombocytopenic purpura",
-            "Purpura, Thrombotic Thrombocytopenic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 592657,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018896",
-              "name": "thrombotic thrombocytopenic purpura",
-              "description": "An acute or subacute syndrome characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities and neurologic abnormalities such as seizures, hemiplegia, and visual disturbances. Drugs and bacteria have been implicated as etiologic factors. The introduction of plasma exchange has significantly lowered the mortality rate. If untreated, the mortality rate is high. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C78797\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C78797\" NCI Thesaurus); A coagulation disorder characterized by extensive formation of thrombi in small blood vessels throughout the body due to low levels of ADAMTS13 protein, and resulting in consumption of circulating platelets, which is characterized by thrombocytopenia, anemia, neurologic changes, and sometimes fever and renal dysfunction.; An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10037562",
-                "MONDO:0018896",
-                "UMLS:C0034155",
-                "ORPHANET:54057",
-                "ICD10:M31.19",
-                "SNOMEDCT:78129009",
-                "NCIT:C78797",
-                "MEDDRA:10073197",
-                "MESH:D011697",
-                "PDQ:CDR0000694585",
-                "MEDDRA:10043562",
-                "DOID:10772",
-                "MEDDRA:10043648",
-                "MEDDRA:10037563"
-              ],
-              "id": "MONDO:0018896",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Thrombotic Thrombocytopenic Purpura",
-                "Thrombotic thrombocytopenic purpura",
-                "thrombotic thrombocytopenic purpura",
-                "Purpura, Thrombotic Thrombocytopenic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11299900,
-            "start": 570,
-            "end": 592657,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15574579': {'publication date': '2005 Jan', 'sentence': 'The hematologic evaluations and her clinical course revealed the diagnosis of TTP, so plasma exchange and methyl-prednisolone therapy were initiated.', 'subject score': 888, 'object score': 1000}, 'PMID:2120885': {'publication date': '1990', 'sentence': 'High-dose intravenous methylprednisolone for thrombotic thrombocytopenic purpura.', 'subject score': 861, 'object score': 1000}, 'PMID:23659403': {'publication date': '2013 May', 'sentence': 'Treatment of thrombotic thrombocytopenic purpura with exchange plasmapheresis and methylprednisolone was of paramount importance and the patient was discharged home on day 30 with complete recovery of haematological, neurological and renal function.', 'subject score': 1000, 'object score': 1000}, 'PMID:3394714': {'publication date': '1988 Jun', 'sentence': 'Intravenous high dose methylprednisolone for thrombotic thrombocytopenic purpura.', 'subject score': 861, 'object score': 1000}, 'PMID:34577835': {'publication date': '2021 Aug 31', 'sentence': 'A diagnosis of probable catastrophic antiphospholipid syndrome (CAPS) was established and treatment with low molecular weight heparin, intravenous methylprednisolone, plasmapheresis, and rituximab was initiated, followed by resolution of AKI, diplopia, and TMA with complete depletion of CD19+B-lymphocytes (CD19+B-Ly) after one month.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0034155---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "11547088",
-              "object": "MONDO:0018896",
-              "publications": [
-                "PMID:15574579",
-                "PMID:2120885",
-                "PMID:23659403",
-                "PMID:3394714",
-                "PMID:34577835"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 520717,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006008",
-          "name": "vestibular neuronitis",
-          "description": "Idiopathic inflammation of the VESTIBULAR NERVE, characterized clinically by the acute or subacute onset of VERTIGO; NAUSEA; and imbalance. The COCHLEAR NERVE is typically spared and HEARING LOSS and TINNITUS do not usually occur. Symptoms usually resolve over a period of days to weeks. (Adams et al., Principles of Neurology, 6th ed, p304)",
-          "equivalent_curies": [
-            "UMLS:C0751908",
-            "MEDDRA:10047393",
-            "MEDDRA:10085178",
-            "SNOMEDCT:186738001",
-            "ICD10:H81.2",
-            "UMLS:C0153113",
-            "MEDDRA:10014980",
-            "ICD9:386.12",
-            "EFO:0007537",
-            "DOID:12683",
-            "MESH:D020338",
-            "MONDO:0006008"
-          ],
-          "id": "MONDO:0006008",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute Peripheral Vestibulopathy",
-            "Vestibular Neuronitis",
-            "vestibular neuronitis",
-            "Vestibular neuronitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:16448876",
-            "http://en.wikipedia.org/wiki/vestibular_neuritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520717,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006008",
-              "name": "vestibular neuronitis",
-              "description": "Idiopathic inflammation of the VESTIBULAR NERVE, characterized clinically by the acute or subacute onset of VERTIGO; NAUSEA; and imbalance. The COCHLEAR NERVE is typically spared and HEARING LOSS and TINNITUS do not usually occur. Symptoms usually resolve over a period of days to weeks. (Adams et al., Principles of Neurology, 6th ed, p304)",
-              "equivalent_curies": [
-                "UMLS:C0751908",
-                "MEDDRA:10047393",
-                "MEDDRA:10085178",
-                "SNOMEDCT:186738001",
-                "ICD10:H81.2",
-                "UMLS:C0153113",
-                "MEDDRA:10014980",
-                "ICD9:386.12",
-                "EFO:0007537",
-                "DOID:12683",
-                "MESH:D020338",
-                "MONDO:0006008"
-              ],
-              "id": "MONDO:0006008",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute Peripheral Vestibulopathy",
-                "Vestibular Neuronitis",
-                "vestibular neuronitis",
-                "Vestibular neuronitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:16448876",
-                "http://en.wikipedia.org/wiki/vestibular_neuritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11071286,
-            "start": 570,
-            "end": 520717,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15269315': {'publication date': '2004 Jul 22', 'sentence': 'METHODS: We performed a prospective, randomized, double-blind, two-by-two factorial trial in which patients with acute vestibular neuritis were randomly assigned to treatment with placebo, methylprednisolone, valacyclovir, or methylprednisolone plus valacyclovir.', 'subject score': 1000, 'object score': 1000}, 'PMID:15527718': {'publication date': '2004 Nov', 'sentence': 'Methylprednisolone, starting at 100 mg/d and tapering to 10 mg over 3 weeks, is an effective treatment for vestibular neuritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28391531': {'publication date': '2017 Jun', 'sentence': 'In this prospective RCT, methylprednisolone had no additional benefit in patients with VN who underwent vestibular exercises and received a Ginkgo biloba.', 'subject score': 1000, 'object score': 1000}, 'PMID:31163519': {'publication date': '2019 Jun', 'sentence': '[The clinical effects of methylprednisolone combined with vestibular rehabilitation and methylprednisolone in the treatment of vestibular neuritis].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0153113---SEMMEDDB:",
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0751908---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "11313619",
-              "object": "MONDO:0006008",
-              "publications": [
-                "PMID:15527718",
-                "PMID:31163519",
-                "PMID:15269315",
-                "PMID:28391531"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:14551737': {'publication date': '2003 Dec', 'sentence': 'High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities.', 'subject score': 901, 'object score': 916}, 'PMID:18310545': {'publication date': '2008 Mar', 'sentence': 'The combination of high dose methylprednisolone and rituximab induces superior overall (93%) and complete (14%) response rates compared to high dose methylprednisolone alone (overall 43%, complete remission 0%) in heavily pre-treated chronic lymphocytic leukemia patients with advanced disease.', 'subject score': 901, 'object score': 916}, 'PMID:19693094': {'publication date': '2009 Oct', 'sentence': 'This study demonstrates that HDMP and rituximab is an effective nonmyelosuppressive treatment combination for patients with CLL that warrants consideration particularly for patients with limited myeloid reserve that might not tolerate standard treatment regimens.', 'subject score': 901, 'object score': 1000}, 'PMID:20108019': {'publication date': '2010 Apr', 'sentence': 'Ocular and cerebral aspergillosis in a non-neutropenic patient following alemtuzumab and methyl prednisolone treatment for chronic lymphocytic leukaemia.', 'subject score': 888, 'object score': 1000}, 'PMID:22162701': {'publication date': '2011', 'sentence': 'We report the case of an old man treated with methylprednisolone for chronic lymphoid leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:23062459': {'publication date': '2012 Oct', 'sentence': 'CASE REPORT: We report the case of a 77 year-old man, treated by methylprednisolone for chronic lymphoid leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:30929395': {'publication date': '2019 Mar 14', 'sentence': '[Clinical efficacy of modified rituximab combined with fresh frozen plasma and methylprednisolone in the treatment of 9 patients with chronic lymphocytic leukemia with thrombocytopenia as the main manifestation].', 'subject score': 1000, 'object score': 1000}, 'PMID:31671877': {'publication date': '2019 Oct 29', 'sentence': 'Materials and Methods: We explored the efficacy and safety of a higher Rtx dose in combination with a shorter (3-day) schedule of HDMP in relapsed elderly or unfit CLL patients.', 'subject score': 901, 'object score': 854}, 'PMID:9720724': {'publication date': '1998 Sep', 'sentence': 'Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase.', 'subject score': 1000, 'object score': 850}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 323598,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004948",
-          "name": "B-cell chronic lymphocytic leukemia",
-          "description": "The most common type of chronic lymphoid leukemia. It comprises 90% of chronic lymphoid leukemias in the United States. Morphologically, the neoplastic cells are small, round B-lymphocytes. This type of leukemia is not considered to be curable with available therapy. (WHO, 2001); A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.; A chronic lymphocytic/lymphatic/lymphoblastic leukemia (CLL) is a neoplastic disease characterized by proliferation and accumulation (blood, marrow and lymphoid organs) of morphologically mature but immunologically dysfunctional lymphocytes. A CLL is always a B-cell lymphocytic leukemia as there are no reports of cases of T-cell lymphocytic leukemias. [HPO:curators]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10051812",
-            "MEDDRA:10003908",
-            "MEDDRA:10068919",
-            "MEDDRA:10060576",
-            "MEDDRA:10068852",
-            "OMIM:151400",
-            "MEDDRA:10003909",
-            "MEDDRA:10008956",
-            "UMLS:C0855095",
-            "ICD9:204.1",
-            "MEDDRA:10060391",
-            "MEDDRA:10008976",
-            "NCIT:C7540",
-            "MEDDRA:10008957",
-            "HP:0005550",
-            "MONDO:0004948",
-            "UMLS:C0023434",
-            "MEDDRA:10024340",
-            "MEDDRA:10025306",
-            "PDQ:CDR0000038170",
-            "MEDDRA:10009310",
-            "SNOMEDCT:302841002",
-            "MEDDRA:10008960",
-            "ORPHANET:67038",
-            "SNOMEDCT:92814006",
-            "SNOMEDCT:277473004",
-            "MEDDRA:10008958",
-            "SNOMEDCT:64575004",
-            "MEDDRA:10003910",
-            "MEDDRA:10024295",
-            "ICD10:C91.10",
-            "PDQ:CDR0000037765",
-            "MEDDRA:10025302",
-            "EFO:0000095",
-            "MEDDRA:10041138",
-            "DOID:1040",
-            "SNOMEDCT:51092000",
-            "MESH:D015451",
-            "PDQ:CDR0000039824",
-            "NCIT:C3163",
-            "MEDDRA:10008993"
-          ],
-          "id": "MONDO:0004948",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic lymphatic leukemia",
-            "Lymphoid leukemia, chronic",
-            "Small Lymphocytic Lymphoma",
-            "chronic lymphocytic leukemia",
-            "Leukemia, chronic lymphocytic related phenotypic feature",
-            "Leukemia, Lymphocytic, Chronic, B-Cell",
-            "B-cell chronic lymphocytic leukemia",
-            "small lymphocytic lymphoma",
-            "Chronic Lymphocytic Leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=346545",
-            "http://en.wikipedia.org/wiki/b-cell_chronic_lymphocytic_leukemia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323598,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004948",
-              "name": "B-cell chronic lymphocytic leukemia",
-              "description": "The most common type of chronic lymphoid leukemia. It comprises 90% of chronic lymphoid leukemias in the United States. Morphologically, the neoplastic cells are small, round B-lymphocytes. This type of leukemia is not considered to be curable with available therapy. (WHO, 2001); A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.; A chronic lymphocytic/lymphatic/lymphoblastic leukemia (CLL) is a neoplastic disease characterized by proliferation and accumulation (blood, marrow and lymphoid organs) of morphologically mature but immunologically dysfunctional lymphocytes. A CLL is always a B-cell lymphocytic leukemia as there are no reports of cases of T-cell lymphocytic leukemias. [HPO:curators]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10051812",
-                "MEDDRA:10003908",
-                "MEDDRA:10068919",
-                "MEDDRA:10060576",
-                "MEDDRA:10068852",
-                "OMIM:151400",
-                "MEDDRA:10003909",
-                "MEDDRA:10008956",
-                "UMLS:C0855095",
-                "ICD9:204.1",
-                "MEDDRA:10060391",
-                "MEDDRA:10008976",
-                "NCIT:C7540",
-                "MEDDRA:10008957",
-                "HP:0005550",
-                "MONDO:0004948",
-                "UMLS:C0023434",
-                "MEDDRA:10024340",
-                "MEDDRA:10025306",
-                "PDQ:CDR0000038170",
-                "MEDDRA:10009310",
-                "SNOMEDCT:302841002",
-                "MEDDRA:10008960",
-                "ORPHANET:67038",
-                "SNOMEDCT:92814006",
-                "SNOMEDCT:277473004",
-                "MEDDRA:10008958",
-                "SNOMEDCT:64575004",
-                "MEDDRA:10003910",
-                "MEDDRA:10024295",
-                "ICD10:C91.10",
-                "PDQ:CDR0000037765",
-                "MEDDRA:10025302",
-                "EFO:0000095",
-                "MEDDRA:10041138",
-                "DOID:1040",
-                "SNOMEDCT:51092000",
-                "MESH:D015451",
-                "PDQ:CDR0000039824",
-                "NCIT:C3163",
-                "MEDDRA:10008993"
-              ],
-              "id": "MONDO:0004948",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic lymphatic leukemia",
-                "Lymphoid leukemia, chronic",
-                "Small Lymphocytic Lymphoma",
-                "chronic lymphocytic leukemia",
-                "Leukemia, chronic lymphocytic related phenotypic feature",
-                "Leukemia, Lymphocytic, Chronic, B-Cell",
-                "B-cell chronic lymphocytic leukemia",
-                "small lymphocytic lymphoma",
-                "Chronic Lymphocytic Leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=346545",
-                "http://en.wikipedia.org/wiki/b-cell_chronic_lymphocytic_leukemia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10570019,
-            "start": 570,
-            "end": 323598,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14551737': {'publication date': '2003 Dec', 'sentence': 'High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities.', 'subject score': 901, 'object score': 916}, 'PMID:18310545': {'publication date': '2008 Mar', 'sentence': 'The combination of high dose methylprednisolone and rituximab induces superior overall (93%) and complete (14%) response rates compared to high dose methylprednisolone alone (overall 43%, complete remission 0%) in heavily pre-treated chronic lymphocytic leukemia patients with advanced disease.', 'subject score': 901, 'object score': 916}, 'PMID:19693094': {'publication date': '2009 Oct', 'sentence': 'This study demonstrates that HDMP and rituximab is an effective nonmyelosuppressive treatment combination for patients with CLL that warrants consideration particularly for patients with limited myeloid reserve that might not tolerate standard treatment regimens.', 'subject score': 901, 'object score': 1000}, 'PMID:20108019': {'publication date': '2010 Apr', 'sentence': 'Ocular and cerebral aspergillosis in a non-neutropenic patient following alemtuzumab and methyl prednisolone treatment for chronic lymphocytic leukaemia.', 'subject score': 888, 'object score': 1000}, 'PMID:22162701': {'publication date': '2011', 'sentence': 'We report the case of an old man treated with methylprednisolone for chronic lymphoid leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:23062459': {'publication date': '2012 Oct', 'sentence': 'CASE REPORT: We report the case of a 77 year-old man, treated by methylprednisolone for chronic lymphoid leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:30929395': {'publication date': '2019 Mar 14', 'sentence': '[Clinical efficacy of modified rituximab combined with fresh frozen plasma and methylprednisolone in the treatment of 9 patients with chronic lymphocytic leukemia with thrombocytopenia as the main manifestation].', 'subject score': 1000, 'object score': 1000}, 'PMID:31671877': {'publication date': '2019 Oct 29', 'sentence': 'Materials and Methods: We explored the efficacy and safety of a higher Rtx dose in combination with a shorter (3-day) schedule of HDMP in relapsed elderly or unfit CLL patients.', 'subject score': 901, 'object score': 854}, 'PMID:9720724': {'publication date': '1998 Sep', 'sentence': 'Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase.', 'subject score': 1000, 'object score': 850}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0023434---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10801960",
-              "object": "MONDO:0004948",
-              "publications": [
-                "PMID:14551737",
-                "PMID:18310545",
-                "PMID:19693094",
-                "PMID:20108019",
-                "PMID:22162701",
-                "PMID:23062459",
-                "PMID:30929395",
-                "PMID:31671877",
-                "PMID:9720724"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 322120,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:28297028': {'publication date': '2017 03 01', 'sentence': 'Early Methylprednisolone Treatment Can Stabilize the Blood-Optic Nerve Barrier in a Rat Model of Anterior Ischemic Optic Neuropathy (rAION).', 'subject score': 851, 'object score': 780}}",
-    "p2": {
-      "start": {
-        "identity": 535220,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-          "name": "Crohn disease",
-          "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003424",
-            "ORPHANET:206",
-            "NCIT:C37262",
-            "MEDDRA:10038281",
-            "MEDDRA:10011405",
-            "UMLS:CN043071",
-            "SNOMEDCT:50440006",
-            "MEDDRA:10057032",
-            "HP:0100280",
-            "EFO:0000384",
-            "DOID:8778",
-            "MONDO:0005011",
-            "PDQ:CDR0000714480",
-            "UMLS:C0010346",
-            "NCIT:C2965",
-            "SNOMEDCT:7620006",
-            "ICD10:K50.1",
-            "UMLS:C0156147",
-            "MEDDRA:10011398",
-            "MEDDRA:10011401",
-            "SNOMEDCT:34000006",
-            "ICD9:555.1",
-            "MEDDRA:10013099",
-            "MEDDRA:10011402",
-            "MEDDRA:10011400"
-          ],
-          "id": "MONDO:0005011",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Granulomatous Colitis",
-            "Crohn's disease of large bowel",
-            "Regional enteritis of large intestine",
-            "Crohn Disease",
-            "Crohn disease",
-            "Crohn's disease"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006649",
-          "name": "anterior ischemic optic neuropathy",
-          "description": "Anterior ischemic optic neuropathy (AION) is an eye disease characterized by infarction of the optic disk leading to vision loss. It can be nonarteritic (nonarteritic anterior ischemic optic neuropathy or NAION) or arteritic, the latter being associated with giant cell arteritis (GCA; often termed temporal arteritis). Vision loss with both varieties is typically rapid (over minutes, hours, or days) and painless. Symptoms such as a general feeling of being unwell (malaise), muscle aches and pains, headaches over the temple, pain when combing hair, pain in the jaw after chewing, and tenderness over the temporal artery (one of the major arteries of the head) may be present with giant cell arteritis. At exam, visual acuity is reduced and the optic disc is swollen. In both subtypes, visual field examination is often reduced in the inferior and central visual fields. The visual loss is usually permanent, with some recovery possibly occurring within the first weeks or months. The arteritic variety is treated with corticosteroids. Treatment of the nonarteritic variety withaspirinor corticosteroids has not been helpful.",
-          "equivalent_curies": [
-            "UMLS:C0751711",
-            "EFO:1000809",
-            "SNOMEDCT:14357004",
-            "MONDO:0006649",
-            "MEDDRA:10023041",
-            "MEDDRA:10068250",
-            "MEDDRA:10030925",
-            "ICD10:H47.01",
-            "MESH:D018917",
-            "UMLS:C0155305",
-            "MEDDRA:10030924",
-            "MEDDRA:10068243",
-            "SNOMEDCT:404659001",
-            "DOID:12010",
-            "MEDDRA:10055745",
-            "ICD9:377.41"
-          ],
-          "id": "MONDO:0006649",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Optic Neuropathy, Ischemic",
-            "Anterior Ischemic Optic Neuropathy",
-            "Ischemic optic neuropathy",
-            "anterior ischemic optic neuropathy"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://en.wikipedia.org/wiki/chron%27s_disease",
-=======
-            "https://rarediseases.info.nih.gov/diseases/9790/anterior-ischemic-optic-neuropathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 535220,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006649",
-              "name": "anterior ischemic optic neuropathy",
-              "description": "Anterior ischemic optic neuropathy (AION) is an eye disease characterized by infarction of the optic disk leading to vision loss. It can be nonarteritic (nonarteritic anterior ischemic optic neuropathy or NAION) or arteritic, the latter being associated with giant cell arteritis (GCA; often termed temporal arteritis). Vision loss with both varieties is typically rapid (over minutes, hours, or days) and painless. Symptoms such as a general feeling of being unwell (malaise), muscle aches and pains, headaches over the temple, pain when combing hair, pain in the jaw after chewing, and tenderness over the temporal artery (one of the major arteries of the head) may be present with giant cell arteritis. At exam, visual acuity is reduced and the optic disc is swollen. In both subtypes, visual field examination is often reduced in the inferior and central visual fields. The visual loss is usually permanent, with some recovery possibly occurring within the first weeks or months. The arteritic variety is treated with corticosteroids. Treatment of the nonarteritic variety withaspirinor corticosteroids has not been helpful.",
-              "equivalent_curies": [
-                "UMLS:C0751711",
-                "EFO:1000809",
-                "SNOMEDCT:14357004",
-                "MONDO:0006649",
-                "MEDDRA:10023041",
-                "MEDDRA:10068250",
-                "MEDDRA:10030925",
-                "ICD10:H47.01",
-                "MESH:D018917",
-                "UMLS:C0155305",
-                "MEDDRA:10030924",
-                "MEDDRA:10068243",
-                "SNOMEDCT:404659001",
-                "DOID:12010",
-                "MEDDRA:10055745",
-                "ICD9:377.41"
-              ],
-              "id": "MONDO:0006649",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Optic Neuropathy, Ischemic",
-                "Anterior Ischemic Optic Neuropathy",
-                "Ischemic optic neuropathy",
-                "anterior ischemic optic neuropathy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://rarediseases.info.nih.gov/diseases/9790/anterior-ischemic-optic-neuropathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19150648,
-            "start": 570,
-            "end": 535220,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28297028': {'publication date': '2017 03 01', 'sentence': 'Early Methylprednisolone Treatment Can Stabilize the Blood-Optic Nerve Barrier in a Rat Model of Anterior Ischemic Optic Neuropathy (rAION).', 'subject score': 851, 'object score': 780}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0751711---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "19534575",
-              "object": "MONDO:0006649",
-              "publications": [
-                "PMID:28297028"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:34213870': {'publication date': '2021 Jul', 'sentence': 'Intra-Carpal Injection of Ozone versus Methylprednisolone in Carpal Tunnel Syndrome of Systemic Sclerosis Patients: A Randomized Single-Blind Clinical Trial.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318159,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007275",
-          "name": "carpal tunnel syndrome",
-          "description": "Injury to the median nerve caused by its entrapment at the wrist as it traverses through the carpal tunnel. Clinically, constrictive median neuropathy is characterized by pain, paresthesia, and weakness in the median nerve distribution of the hand. [HPO:probinson]; Injury to the median nerve caused by its entrapment at the wrist as it traverses through the carpal tunnel. Clinically, constrictive median neuropathy is characterized by pain, paresthesia, and weakness in the median nerve distribution of the hand. // COMMENTS: Constrictive median neuropathy is the major clinical feature of carpal tunnel syndrome.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T190",
-          "equivalent_curies": [
-            "ICD10:G56.0",
-            "MEDDRA:10007697",
-            "HP:0012185",
-            "MESH:D002349",
-            "UMLS:C4023009",
-            "UMLS:C0007286",
-            "ORPHANET:50838",
-            "DOID:12169",
-            "MONDO:0007275",
-            "ICD9:354.0",
-            "OMIM.PS:115430",
-            "SNOMEDCT:57406009",
-            "EFO:0004143",
-            "NCIT:C34450"
-          ],
-          "id": "MONDO:0007275",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Carpal tunnel syndrome",
-            "Constrictive median neuropathy",
-            "Carpal Tunnel Syndrome",
-            "carpal tunnel syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000433.htm",
-            "https://orthoinfo.aaos.org/en/diseases--conditions/carpal-tunnel-syndrome/",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://en.wikipedia.org/wiki/carpal_tunnel_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318159,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007275",
-              "name": "carpal tunnel syndrome",
-              "description": "Injury to the median nerve caused by its entrapment at the wrist as it traverses through the carpal tunnel. Clinically, constrictive median neuropathy is characterized by pain, paresthesia, and weakness in the median nerve distribution of the hand. [HPO:probinson]; Injury to the median nerve caused by its entrapment at the wrist as it traverses through the carpal tunnel. Clinically, constrictive median neuropathy is characterized by pain, paresthesia, and weakness in the median nerve distribution of the hand. // COMMENTS: Constrictive median neuropathy is the major clinical feature of carpal tunnel syndrome.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T190",
-              "equivalent_curies": [
-                "ICD10:G56.0",
-                "MEDDRA:10007697",
-                "HP:0012185",
-                "MESH:D002349",
-                "UMLS:C4023009",
-                "UMLS:C0007286",
-                "ORPHANET:50838",
-                "DOID:12169",
-                "MONDO:0007275",
-                "ICD9:354.0",
-                "OMIM.PS:115430",
-                "SNOMEDCT:57406009",
-                "EFO:0004143",
-                "NCIT:C34450"
-              ],
-              "id": "MONDO:0007275",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Carpal tunnel syndrome",
-                "Constrictive median neuropathy",
-                "Carpal Tunnel Syndrome",
-                "carpal tunnel syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000433.htm",
-                "https://orthoinfo.aaos.org/en/diseases--conditions/carpal-tunnel-syndrome/",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://en.wikipedia.org/wiki/carpal_tunnel_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23081986,
-            "start": 570,
-            "end": 318159,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34213870': {'publication date': '2021 Jul', 'sentence': 'Intra-Carpal Injection of Ozone versus Methylprednisolone in Carpal Tunnel Syndrome of Systemic Sclerosis Patients: A Randomized Single-Blind Clinical Trial.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0007286---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "23514846",
-              "object": "MONDO:0007275",
-              "publications": [
-                "PMID:34213870"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10744412': {'publication date': '2000 Mar 04', 'sentence': 'Injection with methylprednisolone for carpal tunnel syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:10744413': {'publication date': '2000 Mar 04', 'sentence': 'Injection with methylprednisolone for carpal tunnel syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:11402116': {'publication date': '2001 Jun 12', 'sentence': 'The authors compared the effectiveness of low-dose, short-term oral prednisolone vs local methylprednisolone injection in a prospective, double-blinded, parallel treatment study of carpal tunnel syndrome (CTS).', 'subject score': 851, 'object score': 1000}, 'PMID:24026316': {'publication date': '2013 Sep 03', 'sentence': 'CONCLUSION: Methylprednisolone injections for CTS have significant benefits in relieving symptoms at 10 weeks and reducing the rate of surgery 1 year after treatment, but 3 out of 4 patients had surgery within 1 year.', 'subject score': 888, 'object score': 1000}, 'PMID:24343399': {'publication date': '2013 Dec 17', 'sentence': 'Methylprednisolone injections for the carpal tunnel syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:24490275': {'publication date': '2013 Dec 17', 'sentence': 'Methylprednisolone injections for the carpal tunnel syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:24490276': {'publication date': '2013 Dec 17', 'sentence': 'Methylprednisolone injections for the carpal tunnel syndrome.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318159,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007275",
-          "name": "carpal tunnel syndrome",
-          "description": "Injury to the median nerve caused by its entrapment at the wrist as it traverses through the carpal tunnel. Clinically, constrictive median neuropathy is characterized by pain, paresthesia, and weakness in the median nerve distribution of the hand. [HPO:probinson]; Injury to the median nerve caused by its entrapment at the wrist as it traverses through the carpal tunnel. Clinically, constrictive median neuropathy is characterized by pain, paresthesia, and weakness in the median nerve distribution of the hand. // COMMENTS: Constrictive median neuropathy is the major clinical feature of carpal tunnel syndrome.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T190",
-          "equivalent_curies": [
-            "ICD10:G56.0",
-            "MEDDRA:10007697",
-            "HP:0012185",
-            "MESH:D002349",
-            "UMLS:C4023009",
-            "UMLS:C0007286",
-            "ORPHANET:50838",
-            "DOID:12169",
-            "MONDO:0007275",
-            "ICD9:354.0",
-            "OMIM.PS:115430",
-            "SNOMEDCT:57406009",
-            "EFO:0004143",
-            "NCIT:C34450"
-          ],
-          "id": "MONDO:0007275",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Carpal tunnel syndrome",
-            "Constrictive median neuropathy",
-            "Carpal Tunnel Syndrome",
-            "carpal tunnel syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000433.htm",
-            "https://orthoinfo.aaos.org/en/diseases--conditions/carpal-tunnel-syndrome/",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://en.wikipedia.org/wiki/carpal_tunnel_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318159,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007275",
-              "name": "carpal tunnel syndrome",
-              "description": "Injury to the median nerve caused by its entrapment at the wrist as it traverses through the carpal tunnel. Clinically, constrictive median neuropathy is characterized by pain, paresthesia, and weakness in the median nerve distribution of the hand. [HPO:probinson]; Injury to the median nerve caused by its entrapment at the wrist as it traverses through the carpal tunnel. Clinically, constrictive median neuropathy is characterized by pain, paresthesia, and weakness in the median nerve distribution of the hand. // COMMENTS: Constrictive median neuropathy is the major clinical feature of carpal tunnel syndrome.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T190",
-              "equivalent_curies": [
-                "ICD10:G56.0",
-                "MEDDRA:10007697",
-                "HP:0012185",
-                "MESH:D002349",
-                "UMLS:C4023009",
-                "UMLS:C0007286",
-                "ORPHANET:50838",
-                "DOID:12169",
-                "MONDO:0007275",
-                "ICD9:354.0",
-                "OMIM.PS:115430",
-                "SNOMEDCT:57406009",
-                "EFO:0004143",
-                "NCIT:C34450"
-              ],
-              "id": "MONDO:0007275",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Carpal tunnel syndrome",
-                "Constrictive median neuropathy",
-                "Carpal Tunnel Syndrome",
-                "carpal tunnel syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000433.htm",
-                "https://orthoinfo.aaos.org/en/diseases--conditions/carpal-tunnel-syndrome/",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://en.wikipedia.org/wiki/carpal_tunnel_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7925977,
-            "start": 570,
-            "end": 318159,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10744412': {'publication date': '2000 Mar 04', 'sentence': 'Injection with methylprednisolone for carpal tunnel syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:10744413': {'publication date': '2000 Mar 04', 'sentence': 'Injection with methylprednisolone for carpal tunnel syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:11402116': {'publication date': '2001 Jun 12', 'sentence': 'The authors compared the effectiveness of low-dose, short-term oral prednisolone vs local methylprednisolone injection in a prospective, double-blinded, parallel treatment study of carpal tunnel syndrome (CTS).', 'subject score': 851, 'object score': 1000}, 'PMID:24026316': {'publication date': '2013 Sep 03', 'sentence': 'CONCLUSION: Methylprednisolone injections for CTS have significant benefits in relieving symptoms at 10 weeks and reducing the rate of surgery 1 year after treatment, but 3 out of 4 patients had surgery within 1 year.', 'subject score': 888, 'object score': 1000}, 'PMID:24343399': {'publication date': '2013 Dec 17', 'sentence': 'Methylprednisolone injections for the carpal tunnel syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:24490275': {'publication date': '2013 Dec 17', 'sentence': 'Methylprednisolone injections for the carpal tunnel syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:24490276': {'publication date': '2013 Dec 17', 'sentence': 'Methylprednisolone injections for the carpal tunnel syndrome.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0007286---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8095661",
-              "object": "MONDO:0007275",
-              "publications": [
-                "PMID:10744412",
-                "PMID:10744413",
-                "PMID:11402116",
-                "PMID:24026316",
-                "PMID:24343399",
-                "PMID:24490275",
-                "PMID:24490276"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:3562396': {'publication date': '1987 Jan', 'sentence': '[Short-term therapy with methylprednisolone in exacerbated obstructive respiratory tract diseases].', 'subject score': 1000, 'object score': 875}}",
-    "p2": {
-      "start": {
-        "identity": 517178,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005087",
-          "name": "respiratory system disorder",
-          "description": "A non-neoplastic or neoplastic disorder that affects the respiratory system. Representative examples include pneumonia, chronic obstructive pulmonary disease, pulmonary failure, lung adenoma, lung carcinoma, and tracheal carcinoma.; Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:1579",
-            "NCIT:C26871",
-            "ICD10:J98",
-            "UMLS:C0035242",
-            "UMLS:C0035204",
-            "MEDDRA:10083321",
-            "MEDDRA:10038719",
-            "UMLS:C0029582",
-            "MONDO:0005087",
-            "MESH:D012120",
-            "MESH:D012140",
-            "MEDDRA:10038683",
-            "MEDDRA:10038684",
-            "ICD9:519",
-            "EFO:0000684",
-            "ICD9:510-519.99",
-            "MEDDRA:10045755",
-            "SNOMEDCT:50043002"
-          ],
-          "id": "MONDO:0005087",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Respiratory System Disorder",
-            "Other diseases of respiratory system",
-            "respiratory system disease",
-            "Other respiratory system diseases",
-            "Respiratory Tract Diseases",
-            "Respiration Disorders",
-            "respiratory system disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=respiratory%20system",
-            "http://en.wikipedia.org/wiki/file:respiratory_system_complete_en.svg"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517178,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005087",
-              "name": "respiratory system disorder",
-              "description": "A non-neoplastic or neoplastic disorder that affects the respiratory system. Representative examples include pneumonia, chronic obstructive pulmonary disease, pulmonary failure, lung adenoma, lung carcinoma, and tracheal carcinoma.; Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:1579",
-                "NCIT:C26871",
-                "ICD10:J98",
-                "UMLS:C0035242",
-                "UMLS:C0035204",
-                "MEDDRA:10083321",
-                "MEDDRA:10038719",
-                "UMLS:C0029582",
-                "MONDO:0005087",
-                "MESH:D012120",
-                "MESH:D012140",
-                "MEDDRA:10038683",
-                "MEDDRA:10038684",
-                "ICD9:519",
-                "EFO:0000684",
-                "ICD9:510-519.99",
-                "MEDDRA:10045755",
-                "SNOMEDCT:50043002"
-              ],
-              "id": "MONDO:0005087",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Respiratory System Disorder",
-                "Other diseases of respiratory system",
-                "respiratory system disease",
-                "Other respiratory system diseases",
-                "Respiratory Tract Diseases",
-                "Respiration Disorders",
-                "respiratory system disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=respiratory%20system",
-                "http://en.wikipedia.org/wiki/file:respiratory_system_complete_en.svg"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24117567,
-            "start": 570,
-            "end": 517178,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3562396': {'publication date': '1987 Jan', 'sentence': '[Short-term therapy with methylprednisolone in exacerbated obstructive respiratory tract diseases].', 'subject score': 1000, 'object score': 875}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0035242---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "24559507",
-              "object": "MONDO:0005087",
-              "publications": [
-                "PMID:3562396"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:33815804': {'publication date': '2021 May', 'sentence': 'Although methylprednisolone gradually improved her respiratory condition, her oxygenation and exercise tolerance had drastically deteriorated, necessitating high-flow nasal cannula oxygen therapy.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 517178,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005087",
-          "name": "respiratory system disorder",
-          "description": "A non-neoplastic or neoplastic disorder that affects the respiratory system. Representative examples include pneumonia, chronic obstructive pulmonary disease, pulmonary failure, lung adenoma, lung carcinoma, and tracheal carcinoma.; Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:1579",
-            "NCIT:C26871",
-            "ICD10:J98",
-            "UMLS:C0035242",
-            "UMLS:C0035204",
-            "MEDDRA:10083321",
-            "MEDDRA:10038719",
-            "UMLS:C0029582",
-            "MONDO:0005087",
-            "MESH:D012120",
-            "MESH:D012140",
-            "MEDDRA:10038683",
-            "MEDDRA:10038684",
-            "ICD9:519",
-            "EFO:0000684",
-            "ICD9:510-519.99",
-            "MEDDRA:10045755",
-            "SNOMEDCT:50043002"
-          ],
-          "id": "MONDO:0005087",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Respiratory System Disorder",
-            "Other diseases of respiratory system",
-            "respiratory system disease",
-            "Other respiratory system diseases",
-            "Respiratory Tract Diseases",
-            "Respiration Disorders",
-            "respiratory system disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=respiratory%20system",
-            "http://en.wikipedia.org/wiki/file:respiratory_system_complete_en.svg"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517178,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005087",
-              "name": "respiratory system disorder",
-              "description": "A non-neoplastic or neoplastic disorder that affects the respiratory system. Representative examples include pneumonia, chronic obstructive pulmonary disease, pulmonary failure, lung adenoma, lung carcinoma, and tracheal carcinoma.; Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:1579",
-                "NCIT:C26871",
-                "ICD10:J98",
-                "UMLS:C0035242",
-                "UMLS:C0035204",
-                "MEDDRA:10083321",
-                "MEDDRA:10038719",
-                "UMLS:C0029582",
-                "MONDO:0005087",
-                "MESH:D012120",
-                "MESH:D012140",
-                "MEDDRA:10038683",
-                "MEDDRA:10038684",
-                "ICD9:519",
-                "EFO:0000684",
-                "ICD9:510-519.99",
-                "MEDDRA:10045755",
-                "SNOMEDCT:50043002"
-              ],
-              "id": "MONDO:0005087",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Respiratory System Disorder",
-                "Other diseases of respiratory system",
-                "respiratory system disease",
-                "Other respiratory system diseases",
-                "Respiratory Tract Diseases",
-                "Respiration Disorders",
-                "respiratory system disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=respiratory%20system",
-                "http://en.wikipedia.org/wiki/file:respiratory_system_complete_en.svg"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22778914,
-            "start": 570,
-            "end": 517178,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:33815804': {'publication date': '2021 May', 'sentence': 'Although methylprednisolone gradually improved her respiratory condition, her oxygenation and exercise tolerance had drastically deteriorated, necessitating high-flow nasal cannula oxygen therapy.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0035204---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "23209303",
-              "object": "MONDO:0005087",
-              "publications": [
-                "PMID:33815804"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:17026824': {'publication date': '2006 Sep', 'sentence': 'Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma.', 'subject score': 851, 'object score': 884}, 'PMID:7540069': {'publication date': '1995 Jun 15', 'sentence': 'The percentage of apoptotic cells after incubation in medium alone (spontaneous apoptosis) or in the presence of methylprednisolone (MP) or anti-Fas monoclonal antibody (triggered apoptosis) was significantly higher in MM and mainly restricted to HLA-DR+ T cells.', 'subject score': 1000, 'object score': 1000}, 'PMID:8033303': {'publication date': '1994', 'sentence': 'Bi-weekly vincristine, epirubicin and methylprednisolone in alkylator-refractory multiple myeloma.', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 323988,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009693",
-          "name": "plasma cell myeloma",
-          "description": "A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3242\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3242\" NCI Thesaurus); A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001); A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.; A malignant plasma cell tumor growing within soft tissue or within the skeleton. [HPO:sdoelken]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10074470",
-            "MEDDRA:10028569",
-            "MEDDRA:10028228",
-            "MEDDRA:10035226",
-            "EFO:0001378",
-            "SNOMEDCT:55921005",
-            "MEDDRA:10034613",
-            "MESH:D009101",
-            "MEDDRA:10028568",
-            "MONDO:0009693",
-            "ICD9:203.0",
-            "HP:0006775",
-            "OMIM:254500",
-            "MEDDRA:10028566",
-            "ORPHANET:29073",
-            "SNOMEDCT:109989006",
-            "DOID:9538",
-            "ICD10:C90.0",
-            "UMLS:C0026764",
-            "PDQ:CDR0000042947",
-            "NCIT:C3242",
-            "SNOMEDCT:1162576007"
-          ],
-          "id": "MONDO:0009693",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Multiple myeloma",
-            "Multiple Myeloma",
-            "plasma cell myeloma",
-            "multiple myeloma",
-            "Myeloma, multiple related phenotypic feature",
-            "Plasma Cell Myeloma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=411384",
-            "http://en.wikipedia.org/wiki/multiple_myeloma",
->>>>>>> main
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 322120,
-=======
-            "identity": 323988,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-              "name": "Crohn disease",
-              "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003424",
-                "ORPHANET:206",
-                "NCIT:C37262",
-                "MEDDRA:10038281",
-                "MEDDRA:10011405",
-                "UMLS:CN043071",
-                "SNOMEDCT:50440006",
-                "MEDDRA:10057032",
-                "HP:0100280",
-                "EFO:0000384",
-                "DOID:8778",
-                "MONDO:0005011",
-                "PDQ:CDR0000714480",
-                "UMLS:C0010346",
-                "NCIT:C2965",
-                "SNOMEDCT:7620006",
-                "ICD10:K50.1",
-                "UMLS:C0156147",
-                "MEDDRA:10011398",
-                "MEDDRA:10011401",
-                "SNOMEDCT:34000006",
-                "ICD9:555.1",
-                "MEDDRA:10013099",
-                "MEDDRA:10011402",
-                "MEDDRA:10011400"
-              ],
-              "id": "MONDO:0005011",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Granulomatous Colitis",
-                "Crohn's disease of large bowel",
-                "Regional enteritis of large intestine",
-                "Crohn Disease",
-                "Crohn disease",
-                "Crohn's disease"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009693",
-              "name": "plasma cell myeloma",
-              "description": "A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3242\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3242\" NCI Thesaurus); A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001); A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.; A malignant plasma cell tumor growing within soft tissue or within the skeleton. [HPO:sdoelken]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10074470",
-                "MEDDRA:10028569",
-                "MEDDRA:10028228",
-                "MEDDRA:10035226",
-                "EFO:0001378",
-                "SNOMEDCT:55921005",
-                "MEDDRA:10034613",
-                "MESH:D009101",
-                "MEDDRA:10028568",
-                "MONDO:0009693",
-                "ICD9:203.0",
-                "HP:0006775",
-                "OMIM:254500",
-                "MEDDRA:10028566",
-                "ORPHANET:29073",
-                "SNOMEDCT:109989006",
-                "DOID:9538",
-                "ICD10:C90.0",
-                "UMLS:C0026764",
-                "PDQ:CDR0000042947",
-                "NCIT:C3242",
-                "SNOMEDCT:1162576007"
-              ],
-              "id": "MONDO:0009693",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Multiple myeloma",
-                "Multiple Myeloma",
-                "plasma cell myeloma",
-                "multiple myeloma",
-                "Myeloma, multiple related phenotypic feature",
-                "Plasma Cell Myeloma"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://en.wikipedia.org/wiki/chron%27s_disease",
-=======
-                "http://www.cancer.gov/dictionary?cdrid=411384",
-                "http://en.wikipedia.org/wiki/multiple_myeloma",
->>>>>>> main
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 10405443,
-            "start": 570,
-            "end": 322120,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1385273': {'publication date': '1992 Sep', 'sentence': \"An example of acute pancreatitis developing five weeks after initial treatment with 5-aminosalicylic acid (5-ASA) and methylprednisolone for severe Crohn's disease is reported in a 37 year old female patient.\", 'subject score': 1000, 'object score': 901}, 'PMID:1679736': {'publication date': '1991 Oct', 'sentence': \"These data show that enteral nutrition is less effective than a combination of 6-methylprednisolone and sulfasalazine in treating active Crohn's disease.\", 'subject score': 1000, 'object score': 861}, 'PMID:18784429': {'publication date': '2008', 'sentence': \"High-dose methylprednisolone in a pregnant woman with Crohn's disease and adrenal suppression in her newborn.\", 'subject score': 901, 'object score': 1000}, 'PMID:2857632': {'publication date': '1985 Mar', 'sentence': \"Intestinal alpha 1-antitrypsin clearance was quantified in 17 patients with clinically active Crohn's disease before and after a six-week period of treatment with sulfasalazine and methylprednisolone.\", 'subject score': 1000, 'object score': 824}, 'PMID:30244270': {'publication date': '2018 09', 'sentence': \"The patient was treated with high doses of methylprednisolone (60 mg IV), which resulted in rapid improvement of Crohn's disease and skin lesions.\", 'subject score': 1000, 'object score': 1000}, 'PMID:30532602': {'publication date': '2018', 'sentence': \"The mother was known to have Crohn's disease, treated with methylprednisolone and adalimumab up to 3 months before delivery, and latent tuberculosis, for which she used isoniazid postnatally.\", 'subject score': 1000, 'object score': 1000}, 'PMID:3338639': {'publication date': '1988 Mar', 'sentence': \"Local depot methylprednisolone injection for painful anal Crohn's disease.\", 'subject score': 775, 'object score': 865}, 'PMID:8889459': {'publication date': '1996 Sep', 'sentence': 'The present study assessed the effectiveness and safety of oral pH-modified release budesonide (BUD) in patients with active CD in comparison with 6-methylprednisolone (MPred).', 'subject score': 1000, 'object score': 901}, 'PMID:9772043': {'publication date': '1998 Oct', 'sentence': \"METHODS: Twenty-four patients with active Crohn's disease were randomized to treatment with either budesonide or 6-methylprednisolone.\", 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0010346---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10634179",
-              "object": "MONDO:0005011",
-              "publications": [
-                "PMID:1385273",
-                "PMID:1679736",
-                "PMID:18784429",
-                "PMID:2857632",
-                "PMID:30244270",
-                "PMID:30532602",
-                "PMID:3338639",
-                "PMID:8889459",
-                "PMID:9772043"
-=======
-            "identity": 12473440,
-            "start": 570,
-            "end": 323988,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17026824': {'publication date': '2006 Sep', 'sentence': 'Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma.', 'subject score': 851, 'object score': 884}, 'PMID:7540069': {'publication date': '1995 Jun 15', 'sentence': 'The percentage of apoptotic cells after incubation in medium alone (spontaneous apoptosis) or in the presence of methylprednisolone (MP) or anti-Fas monoclonal antibody (triggered apoptosis) was significantly higher in MM and mainly restricted to HLA-DR+ T cells.', 'subject score': 1000, 'object score': 1000}, 'PMID:8033303': {'publication date': '1994', 'sentence': 'Bi-weekly vincristine, epirubicin and methylprednisolone in alkylator-refractory multiple myeloma.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0026764---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "12755316",
-              "object": "MONDO:0009693",
-              "publications": [
-                "PMID:17026824",
-                "PMID:7540069",
-                "PMID:8033303"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 523855,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1597118': {'publication date': '1992 Jun 05', 'sentence': 'Multiple myeloma of Stage IIa was diagnosed and she was given cytostatic therapy with 17.5 mg melphalan and 112 mg methylprednisolone daily by mouth (for 4 days at intervals of 6 weeks).', 'subject score': 775, 'object score': 1000}, 'PMID:17026824': {'publication date': '2006 Sep', 'sentence': 'Because of the known additive effect between bortezomib and glucocorticoid, we explored weekly bortezomib/methylprednisolone in patients with relapsed multiple myeloma.', 'subject score': 851, 'object score': 884}, 'PMID:17107906': {'publication date': '2006 Nov', 'sentence': 'The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis.', 'subject score': 833, 'object score': 1000}, 'PMID:2286358': {'publication date': '1990 Nov-Dec', 'sentence': 'Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone.', 'subject score': 1000, 'object score': 901}, 'PMID:26824011': {'publication date': '2015 Dec 16', 'sentence': 'Remarkable Response to Methylprednisolone in a Multiple Myeloma Patient with Nodal Disease Refractory to High-Dose Chemotherapy.', 'subject score': 1000, 'object score': 901}, 'PMID:28155827': {'publication date': '2016 Mar 23', 'sentence': 'We report a rare case of bilateral steroid-induced osteonecrosis of the proximal femora and humeri nine months after a short course of intravenous methylprednisolone for treatment of multiple myeloma.', 'subject score': 888, 'object score': 1000}, 'PMID:3207601': {'publication date': '1988 Oct', 'sentence': 'Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients.', 'subject score': 734, 'object score': 901}, 'PMID:32991435': {'publication date': '2020 Sep 25', 'sentence': 'INTERVENTIONS: The patient experienced pulse therapy with methylprednisolone for hemophagocytic lymphohistiocytosis, followed by initial therapy for multiple myeloma with cyclophosphamide and dexamethasone.', 'subject score': 1000, 'object score': 1000}, 'PMID:8370425': {'publication date': '1993 Aug', 'sentence': 'In a randomised multicentre trial a combination of methylprednisolone, vincristine, lomustine, cyclophosphamide and melphalan (MOCCA) was compared with the same regimen omitting methylprednisolone after the first course (COLA) in previously untreated patients with multiple myeloma.', 'subject score': 825, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 323988,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005091",
-          "name": "severe acute respiratory syndrome",
-          "description": "A viral respiratory infection caused by the SARS coronavirus. It is transmitted through close person-to-person contact. It is manifested with high fever, headache, dry cough and myalgias. It may progress to pneumonia and cause death.; A viral disorder characterized by high FEVER, dry COUGH, shortness of breath (DYSPNEA) or breathing difficulties, and atypical PNEUMONIA. A virus in the genus CORONAVIRUS is the suspected agent.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10061986",
-            "UMLS:C1175175",
-            "NCIT:C85064",
-            "ICD9:079.82",
-            "ICD10:J12.81",
-            "MONDO:0005091",
-            "MEDDRA:10084784",
-            "SNOMEDCT:398447004",
-            "MESH:D045169",
-            "DOID:2945",
-            "ORPHANET:140896",
-            "EFO:0000694",
-            "MEDDRA:10061982"
-          ],
-          "id": "MONDO:0005091",
-          "category": "biolink:Disease",
-          "all_names": [
-            "SARS-associated coronavirus",
-            "Acute respiratory coronavirus infection",
-            "severe acute respiratory syndrome",
-            "Severe Acute Respiratory Syndrome"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009693",
-          "name": "plasma cell myeloma",
-          "description": "A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3242\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3242\" NCI Thesaurus); A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001); A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.; A malignant plasma cell tumor growing within soft tissue or within the skeleton. [HPO:sdoelken]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10074470",
-            "MEDDRA:10028569",
-            "MEDDRA:10028228",
-            "MEDDRA:10035226",
-            "EFO:0001378",
-            "SNOMEDCT:55921005",
-            "MEDDRA:10034613",
-            "MESH:D009101",
-            "MEDDRA:10028568",
-            "MONDO:0009693",
-            "ICD9:203.0",
-            "HP:0006775",
-            "OMIM:254500",
-            "MEDDRA:10028566",
-            "ORPHANET:29073",
-            "SNOMEDCT:109989006",
-            "DOID:9538",
-            "ICD10:C90.0",
-            "UMLS:C0026764",
-            "PDQ:CDR0000042947",
-            "NCIT:C3242",
-            "SNOMEDCT:1162576007"
-          ],
-          "id": "MONDO:0009693",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Multiple myeloma",
-            "Multiple Myeloma",
-            "plasma cell myeloma",
-            "multiple myeloma",
-            "Myeloma, multiple related phenotypic feature",
-            "Plasma Cell Myeloma"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://en.wikipedia.org/wiki/severe_acute_respiratory_syndrome",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=sars"
-=======
-            "http://www.cancer.gov/dictionary?cdrid=411384",
-            "http://en.wikipedia.org/wiki/multiple_myeloma",
-            "https://orcid.org/0009-0006-4530-3154"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 523855,
-=======
-            "identity": 323988,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005091",
-              "name": "severe acute respiratory syndrome",
-              "description": "A viral respiratory infection caused by the SARS coronavirus. It is transmitted through close person-to-person contact. It is manifested with high fever, headache, dry cough and myalgias. It may progress to pneumonia and cause death.; A viral disorder characterized by high FEVER, dry COUGH, shortness of breath (DYSPNEA) or breathing difficulties, and atypical PNEUMONIA. A virus in the genus CORONAVIRUS is the suspected agent.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10061986",
-                "UMLS:C1175175",
-                "NCIT:C85064",
-                "ICD9:079.82",
-                "ICD10:J12.81",
-                "MONDO:0005091",
-                "MEDDRA:10084784",
-                "SNOMEDCT:398447004",
-                "MESH:D045169",
-                "DOID:2945",
-                "ORPHANET:140896",
-                "EFO:0000694",
-                "MEDDRA:10061982"
-              ],
-              "id": "MONDO:0005091",
-              "category": "biolink:Disease",
-              "all_names": [
-                "SARS-associated coronavirus",
-                "Acute respiratory coronavirus infection",
-                "severe acute respiratory syndrome",
-                "Severe Acute Respiratory Syndrome"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009693",
-              "name": "plasma cell myeloma",
-              "description": "A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3242\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3242\" NCI Thesaurus); A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001); A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.; A malignant plasma cell tumor growing within soft tissue or within the skeleton. [HPO:sdoelken]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10074470",
-                "MEDDRA:10028569",
-                "MEDDRA:10028228",
-                "MEDDRA:10035226",
-                "EFO:0001378",
-                "SNOMEDCT:55921005",
-                "MEDDRA:10034613",
-                "MESH:D009101",
-                "MEDDRA:10028568",
-                "MONDO:0009693",
-                "ICD9:203.0",
-                "HP:0006775",
-                "OMIM:254500",
-                "MEDDRA:10028566",
-                "ORPHANET:29073",
-                "SNOMEDCT:109989006",
-                "DOID:9538",
-                "ICD10:C90.0",
-                "UMLS:C0026764",
-                "PDQ:CDR0000042947",
-                "NCIT:C3242",
-                "SNOMEDCT:1162576007"
-              ],
-              "id": "MONDO:0009693",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Multiple myeloma",
-                "Multiple Myeloma",
-                "plasma cell myeloma",
-                "multiple myeloma",
-                "Myeloma, multiple related phenotypic feature",
-                "Plasma Cell Myeloma"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://en.wikipedia.org/wiki/severe_acute_respiratory_syndrome",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=sars"
-=======
-                "http://www.cancer.gov/dictionary?cdrid=411384",
-                "http://en.wikipedia.org/wiki/multiple_myeloma",
-                "https://orcid.org/0009-0006-4530-3154"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 10117350,
-            "start": 570,
-            "end": 523855,
-=======
-            "identity": 11640925,
-            "start": 570,
-            "end": 323988,
->>>>>>> main
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-<<<<<<< HEAD
-              "publications_info": "{'PMID:12895319': {'publication date': '2003 Jun', 'sentence': 'Twenty-nine of the 30 SARS patients were treated by methylprednisolone.', 'subject score': 1000, 'object score': 790}, 'PMID:15059370': {'publication date': '2004 Mar', 'sentence': 'CONCLUSIONS: Over-dose administration of methylprednisolone in SARS patients leads to a high frequency of diabetes.', 'subject score': 1000, 'object score': 888}, 'PMID:15214887': {'publication date': '2004 Jul', 'sentence': 'Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients.', 'subject score': 831, 'object score': 888}, 'PMID:15254615': {'publication date': '2004', 'sentence': 'High dose intravenous methylprednisolone in the treatment of severe acute respiratory syndrome.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C1175175---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10341065",
-              "object": "MONDO:0005091",
-              "publications": [
-                "PMID:12895319",
-                "PMID:15059370",
-                "PMID:15214887",
-                "PMID:15254615"
-=======
-              "publications_info": "{'PMID:1597118': {'publication date': '1992 Jun 05', 'sentence': 'Multiple myeloma of Stage IIa was diagnosed and she was given cytostatic therapy with 17.5 mg melphalan and 112 mg methylprednisolone daily by mouth (for 4 days at intervals of 6 weeks).', 'subject score': 775, 'object score': 1000}, 'PMID:17026824': {'publication date': '2006 Sep', 'sentence': 'Because of the known additive effect between bortezomib and glucocorticoid, we explored weekly bortezomib/methylprednisolone in patients with relapsed multiple myeloma.', 'subject score': 851, 'object score': 884}, 'PMID:17107906': {'publication date': '2006 Nov', 'sentence': 'The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis.', 'subject score': 833, 'object score': 1000}, 'PMID:2286358': {'publication date': '1990 Nov-Dec', 'sentence': 'Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone.', 'subject score': 1000, 'object score': 901}, 'PMID:26824011': {'publication date': '2015 Dec 16', 'sentence': 'Remarkable Response to Methylprednisolone in a Multiple Myeloma Patient with Nodal Disease Refractory to High-Dose Chemotherapy.', 'subject score': 1000, 'object score': 901}, 'PMID:28155827': {'publication date': '2016 Mar 23', 'sentence': 'We report a rare case of bilateral steroid-induced osteonecrosis of the proximal femora and humeri nine months after a short course of intravenous methylprednisolone for treatment of multiple myeloma.', 'subject score': 888, 'object score': 1000}, 'PMID:3207601': {'publication date': '1988 Oct', 'sentence': 'Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients.', 'subject score': 734, 'object score': 901}, 'PMID:32991435': {'publication date': '2020 Sep 25', 'sentence': 'INTERVENTIONS: The patient experienced pulse therapy with methylprednisolone for hemophagocytic lymphohistiocytosis, followed by initial therapy for multiple myeloma with cyclophosphamide and dexamethasone.', 'subject score': 1000, 'object score': 1000}, 'PMID:8370425': {'publication date': '1993 Aug', 'sentence': 'In a randomised multicentre trial a combination of methylprednisolone, vincristine, lomustine, cyclophosphamide and melphalan (MOCCA) was compared with the same regimen omitting methylprednisolone after the first course (COLA) in previously untreated patients with multiple myeloma.', 'subject score': 825, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0026764---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "11895116",
-              "object": "MONDO:0009693",
-              "publications": [
-                "PMID:1597118",
-                "PMID:17026824",
-                "PMID:17107906",
-                "PMID:2286358",
-                "PMID:26824011",
-                "PMID:28155827",
-                "PMID:3207601",
-                "PMID:32991435",
-                "PMID:8370425"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 520401,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:2426114': {'publication date': '1986 Apr', 'sentence': 'Gamma globulin and methylprednisolone in idiopathic thrombocytopenic purpura.', 'subject score': 1000, 'object score': 1000}, 'PMID:3132807': {'publication date': '1988', 'sentence': 'Methylprednisolone in childhood idiopathic thrombocytopenic purpura.', 'subject score': 1000, 'object score': 916}, 'PMID:3443515': {'publication date': '1987 Aug', 'sentence': 'Intravenous pulse methylprednisolone in chronic ITP.', 'subject score': 802, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 316028,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0013730",
-          "name": "graft versus host disease",
-          "description": "A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.; The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PDQ:CDR0000041575",
-            "NCIT:C3063",
-            "MEDDRA:10018798",
-            "UMLS:C0018133",
-            "MESH:D006086",
-            "DOID:0081267",
-            "MONDO:0013730",
-            "MEDDRA:10018799",
-            "SNOMEDCT:234646005",
-            "ICD9:279.5",
-            "ORPHANET:39812",
-            "MEDDRA:10018651"
-          ],
-          "id": "MONDO:0013730",
-          "category": "biolink:Disease",
-          "all_names": [
-            "graft versus host disease",
-            "graft-versus-host disease",
-            "Graft-versus-host disease",
-            "Graft Versus Host Disease",
-            "Graft versus host disease",
-            "Graft-vs-Host Disease",
-            "Graft vs Host Disease"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008558",
-          "name": "autoimmune thrombocytopenic purpura",
-          "description": "Acquired thrombocytopenia of unknown cause, characterized by immune-mediated destruction of normal platelets. It affects both children and adults. It manifests with petechiae, purpura, and overt bleeding. Based upon the duration of the disease, it is classified as newly diagnosed (from diagnosis until 3 months), persistent (3-12 months), and chronic (lasting for more than 12 months).; Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.; The presence of thrombocytopenia in combination with detection of antiplatelet antibodies. [DDD:wouwehand]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021245",
-            "UMLS:C0398650",
-            "ORPHANET:3002",
-            "MESH:D016553",
-            "ICD9:287.31",
-            "MEDDRA:10083843",
-            "MEDDRA:10051064",
-            "MONDO:0008558",
-            "MEDDRA:10074667",
-            "OMIM:188030",
-            "DOID:8924",
-            "MEDDRA:10021243",
-            "ICD10:D69.3",
-            "EFO:0007160",
-            "NCIT:C3446"
-          ],
-          "id": "MONDO:0008558",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Purpura, Thrombocytopenic, Idiopathic",
-            "Immune thrombocytopenic purpura",
-            "Primary Immune Thrombocytopenia",
-            "Thrombocytopenic purpura, autoimmune related phenotypic feature",
-            "autoimmune thrombocytopenic purpura"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "PMID:31466596",
-            "https://www.ncbi.nlm.nih.gov/books/nbk538235/"
-=======
-            "https://rarediseases.org/rare-diseases/immune-thrombocytopenia/"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 520401,
-=======
-            "identity": 316028,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0013730",
-              "name": "graft versus host disease",
-              "description": "A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.; The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PDQ:CDR0000041575",
-                "NCIT:C3063",
-                "MEDDRA:10018798",
-                "UMLS:C0018133",
-                "MESH:D006086",
-                "DOID:0081267",
-                "MONDO:0013730",
-                "MEDDRA:10018799",
-                "SNOMEDCT:234646005",
-                "ICD9:279.5",
-                "ORPHANET:39812",
-                "MEDDRA:10018651"
-              ],
-              "id": "MONDO:0013730",
-              "category": "biolink:Disease",
-              "all_names": [
-                "graft versus host disease",
-                "graft-versus-host disease",
-                "Graft-versus-host disease",
-                "Graft Versus Host Disease",
-                "Graft versus host disease",
-                "Graft-vs-Host Disease",
-                "Graft vs Host Disease"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008558",
-              "name": "autoimmune thrombocytopenic purpura",
-              "description": "Acquired thrombocytopenia of unknown cause, characterized by immune-mediated destruction of normal platelets. It affects both children and adults. It manifests with petechiae, purpura, and overt bleeding. Based upon the duration of the disease, it is classified as newly diagnosed (from diagnosis until 3 months), persistent (3-12 months), and chronic (lasting for more than 12 months).; Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.; The presence of thrombocytopenia in combination with detection of antiplatelet antibodies. [DDD:wouwehand]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021245",
-                "UMLS:C0398650",
-                "ORPHANET:3002",
-                "MESH:D016553",
-                "ICD9:287.31",
-                "MEDDRA:10083843",
-                "MEDDRA:10051064",
-                "MONDO:0008558",
-                "MEDDRA:10074667",
-                "OMIM:188030",
-                "DOID:8924",
-                "MEDDRA:10021243",
-                "ICD10:D69.3",
-                "EFO:0007160",
-                "NCIT:C3446"
-              ],
-              "id": "MONDO:0008558",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Purpura, Thrombocytopenic, Idiopathic",
-                "Immune thrombocytopenic purpura",
-                "Primary Immune Thrombocytopenia",
-                "Thrombocytopenic purpura, autoimmune related phenotypic feature",
-                "autoimmune thrombocytopenic purpura"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "PMID:31466596",
-                "https://www.ncbi.nlm.nih.gov/books/nbk538235/"
-=======
-                "https://rarediseases.org/rare-diseases/immune-thrombocytopenia/"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 10066860,
-            "start": 570,
-            "end": 520401,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12841815': {'publication date': '2003 Jul-Aug', 'sentence': 'CASE SUMMARY: A 2-year-old white boy with a history of relapsed acute lymphoblastic leukemia underwent a bone marrow transplant and developed graft-versus-host disease, which was treated with methylprednisolone.', 'subject score': 1000, 'object score': 937}, 'PMID:16924649': {'publication date': '2006 Dec', 'sentence': 'Infusion of methyl-prednisolone into superior and inferior mesenteric arteries produced dramatic improvement of diarrhea, with complete resolution of gastrointestinal graft-versus-host disease.', 'subject score': 1000, 'object score': 928}, 'PMID:2000873': {'publication date': '1991 Jan', 'sentence': 'Prednisone, methylprednisolone, methotrexate, antithymocyte globulin, and cyclosporine have been used in an effort to prevent or treat GVHD.', 'subject score': 1000, 'object score': 1000}, 'PMID:25053422': {'publication date': '2014 Dec', 'sentence': 'Intra-arterial methylprednisolone for severe steroid refractory gastrointestinal graft-versus-host disease.', 'subject score': 851, 'object score': 847}, 'PMID:26251153': {'publication date': '2015 Jul', 'sentence': 'In conclusion, hypofibrinogenemia commonly occurs in patients treated with steroids, especially those administered 2 mg/kg/day methylprednisolone for the treatment of GVHD.', 'subject score': 734, 'object score': 1000}, 'PMID:27381604': {'publication date': '2016 Jul-Aug', 'sentence': 'RESULTS: GvHD developed at day +52 and was treated with methylprednisolone, cyclosporine A, antibiotics, antiviral medication and analgesics.', 'subject score': 1000, 'object score': 1000}, 'PMID:32578242': {'publication date': '2020 Jun 23', 'sentence': 'A woman in her 60s who had received bone marrow transplantation for mycosis fungoides 2 months earlier received 30 mg methylprednisolone for graft-versus-host disease (GVHD).', 'subject score': 851, 'object score': 1000}, 'PMID:7226719': {'publication date': '1981', 'sentence': 'High dose methyl prednisolone (HDMP) was used to treat 25 episodes of graft versus host disease (GVHD) in 13 patients after bone marrow transplantation for aplastic anaemia or acute leukemia.', 'subject score': 901, 'object score': 1000}, 'PMID:7919241': {'publication date': '1994 Jul', 'sentence': 'Hyperacute GVHD developed in these patients within 7 days after bone marrow transplantation (BMT) and was rapidly aggravated inspite of cyclosporin A (CyA) and short-term methotrexate (MTX) prophylaxis and treatment with bolus methylprednisolone (mPSL).', 'subject score': 861, 'object score': 937}, 'PMID:8049448': {'publication date': '1994 Aug 15', 'sentence': 'In addition, 73 of the 147 patients were randomized to receive methylprednisolone during the first 35 days after transplant to improve GVHD prevention, whereas 74 patients were randomized not to receive methylprednisolone.', 'subject score': 1000, 'object score': 928}, 'PMID:8516797': {'publication date': '1993 Jun', 'sentence': 'Although the child developed complications including exfoliative dermatitis, delayed bone marrow regeneration, renal failure requiring dialysis, and respiratory failure requiring assisted respiration, she recovered from the episode of TA-GVHD after treatment with high-dose methylprednisolone and antithymocyte globulin.', 'subject score': 901, 'object score': 901}, 'PMID:8852031': {'publication date': '1996 Feb', 'sentence': 'Although the GVHD was successfully treated with methylprednisolone, peripheral blood neutrophils that had begun to increase disappeared in association with improvement of the GVHD and graft rejection was eventually diagnosed.', 'subject score': 1000, 'object score': 1000}, 'PMID:9384485': {'publication date': '1997 Nov', 'sentence': 'She developed graft-versus-host disease on day +15 post-transplant, for which she was treated with cyclosporin A and methyl prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0018133---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10289517",
-              "object": "MONDO:0013730",
-              "publications": [
-                "PMID:12841815",
-                "PMID:16924649",
-                "PMID:2000873",
-                "PMID:25053422",
-                "PMID:26251153",
-                "PMID:27381604",
-                "PMID:32578242",
-                "PMID:7226719",
-                "PMID:7919241",
-                "PMID:8049448",
-                "PMID:8516797",
-                "PMID:8852031",
-                "PMID:9384485"
-=======
-            "identity": 16936772,
-            "start": 570,
-            "end": 316028,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2426114': {'publication date': '1986 Apr', 'sentence': 'Gamma globulin and methylprednisolone in idiopathic thrombocytopenic purpura.', 'subject score': 1000, 'object score': 1000}, 'PMID:3132807': {'publication date': '1988', 'sentence': 'Methylprednisolone in childhood idiopathic thrombocytopenic purpura.', 'subject score': 1000, 'object score': 916}, 'PMID:3443515': {'publication date': '1987 Aug', 'sentence': 'Intravenous pulse methylprednisolone in chronic ITP.', 'subject score': 802, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0398650---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "17288506",
-              "object": "MONDO:0008558",
-              "publications": [
-                "PMID:2426114",
-                "PMID:3132807",
-                "PMID:3443515"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 323565,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10560547': {'publication date': '1999 Oct 09', 'sentence': 'CONCLUSION: A short intravenous course of high-dose methylprednisolone is effective as initial treatment of adults with ITP.', 'subject score': 901, 'object score': 1000}, 'PMID:10759004': {'publication date': '2000 Mar', 'sentence': 'Twelve patients with acute ITP were treated with high-dose methyl prednisolone and five patients were treated with intravenous immunoglobulin.', 'subject score': 901, 'object score': 916}, 'PMID:10761200': {'publication date': '2000 Mar', 'sentence': 'Treatment of childhood acute immune thrombocytopenic purpura with high-dose methylprednisolone, intravenous immunoglobulin, or the combination of both.', 'subject score': 901, 'object score': 875}, 'PMID:11809183': {'publication date': '2002 Jan 05', 'sentence': 'INTERPRETATION: Intravenous immunoglobulin and oral prednisone seems to be more effective than high-dose methylprednisolone and oral prednisone in adults with severe AITP, although the latter treatment is effective and well tolerated.', 'subject score': 901, 'object score': 916}, 'PMID:12051587': {'publication date': '2002 Jun', 'sentence': 'Clinical course of children with immune thrombocytopenic purpura treated with intravenous immunoglobulin G or megadose methylprednisolone or observed without therapy.', 'subject score': 861, 'object score': 1000}, 'PMID:12521514': {'publication date': '2002 May', 'sentence': 'Idiopathic thrombocytopenic purpura treated with pulsed high dose methylprednisolone followed by platelet transfusion.', 'subject score': 850, 'object score': 1000}, 'PMID:12621242': {'publication date': '2003 Mar', 'sentence': 'PURPOSE: To investigate combined immunosuppressive therapy with vincristine, methylprednisolone, and prolonged cyclosporine in adolescents with refractory idiopathic thrombocytopenic purpura (ITP).', 'subject score': 1000, 'object score': 916}, 'PMID:15357656': {'publication date': '2004 Sep', 'sentence': 'At week 28 of treatment with interferon (alfacon-1), undetectable HCV RNA and transaminase levels within normal limits, the patient presented with immune thrombocytopenic purpura, which was successfully treated with immunoglobulin and methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:16244777': {'publication date': '2005 Oct', 'sentence': 'In this study, coagulation parameters were investigated that might have a role in hemostatic compensation in childhood acute ITP before and after high-dose methylprednisolone (HDMP) treatment.', 'subject score': 861, 'object score': 851}, 'PMID:1712884': {'publication date': '1991 Jul 20', 'sentence': 'Megadose methylprednisolone or IVIG for idiopathic thrombocytopenic purpura.', 'subject score': 861, 'object score': 1000}, 'PMID:1817495': {'publication date': '1991', 'sentence': 'Intravenous immunoglobulin or megadose methylprednisolone for the treatment of idiopathic thrombocytopenic purpura.', 'subject score': 861, 'object score': 1000}, 'PMID:20404751': {'publication date': '2010 May', 'sentence': 'Patients with acute ITP were studied, before and after, methylprednisolone treatment.', 'subject score': 888, 'object score': 916}, 'PMID:22956408': {'publication date': '2013 Feb', 'sentence': 'In the treatment of ITP in childhood, one 50 MUg/kg dose of anti-D Ig has similar effects to IVIG and methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:2414107': {'publication date': '1985 Sep', 'sentence': 'High doses of gamma globulin and methylprednisolone therapy for idiopathic thrombocytopenic purpura in children.', 'subject score': 888, 'object score': 1000}, 'PMID:27265010': {'publication date': '2005 Dec 05', 'sentence': 'The study consisted of 21 children (aged between 1.5-14 years) with ITP treated with HDMP for 7 days.', 'subject score': 901, 'object score': 1000}, 'PMID:2910369': {'publication date': '1989 Jan', 'sentence': 'High-dose intravenous methylprednisolone for immune thrombocytopenic purpura.', 'subject score': 861, 'object score': 1000}, 'PMID:3195522': {'publication date': '1988 Dec', 'sentence': 'High-dose intravenous methylprednisolone for childhood idiopathic thrombocytopenic purpura.', 'subject score': 861, 'object score': 916}, 'PMID:32418984': {'publication date': '2020 May 18', 'sentence': 'CASE REPORT We present the case of a 53-year-old woman who developed diabetic ketoacidosis after administration of methylprednisolone during treatment of immune thrombocytopenic purpura.', 'subject score': 1000, 'object score': 1000}, 'PMID:3626155': {'publication date': '1987 May', 'sentence': 'Eleven patients with adult idiopathic thrombocytopenic purpura (ITP) were treated with bolus methylprednisolone at doses of 1 g/day for 3 days.', 'subject score': 861, 'object score': 916}, 'PMID:3679481': {'publication date': '1987 Apr', 'sentence': 'Chronic ITP treated with intravenous pulse methylprednisolone.', 'subject score': 802, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 316028,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0020076",
-          "name": "myeloproliferative neoplasm",
-          "description": "A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C4345\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C4345\" NCI Thesaurus); A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008); UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "UMLS:C0027022",
-            "ICD10:D47.1",
-            "SNOMEDCT:109993000",
-            "EFO:0002428",
-            "SNOMEDCT:414794006",
-            "UMLS:C1292778",
-            "MEDDRA:10028577",
-            "MEDDRA:10013238",
-            "NCIT:C4345",
-            "HP:0005547",
-            "MONDO:0020076",
-            "MESH:D009196",
-            "ORPHANET:98274",
-            "SNOMEDCT:425333006",
-            "DOID:2226",
-            "MEDDRA:10077465",
-            "MEDDRA:10028576"
-          ],
-          "id": "MONDO:0020076",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic myeloproliferative disorder",
-            "Myeloproliferative neoplasm",
-            "Myeloproliferative Neoplasm",
-            "Myeloproliferative disorder",
-            "Myeloproliferative disease",
-            "Myeloproliferative Disorders",
-            "myeloproliferative neoplasm",
-            "chronic myeloproliferative disorder"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008558",
-          "name": "autoimmune thrombocytopenic purpura",
-          "description": "Acquired thrombocytopenia of unknown cause, characterized by immune-mediated destruction of normal platelets. It affects both children and adults. It manifests with petechiae, purpura, and overt bleeding. Based upon the duration of the disease, it is classified as newly diagnosed (from diagnosis until 3 months), persistent (3-12 months), and chronic (lasting for more than 12 months).; Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.; The presence of thrombocytopenia in combination with detection of antiplatelet antibodies. [DDD:wouwehand]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021245",
-            "UMLS:C0398650",
-            "ORPHANET:3002",
-            "MESH:D016553",
-            "ICD9:287.31",
-            "MEDDRA:10083843",
-            "MEDDRA:10051064",
-            "MONDO:0008558",
-            "MEDDRA:10074667",
-            "OMIM:188030",
-            "DOID:8924",
-            "MEDDRA:10021243",
-            "ICD10:D69.3",
-            "EFO:0007160",
-            "NCIT:C3446"
-          ],
-          "id": "MONDO:0008558",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Purpura, Thrombocytopenic, Idiopathic",
-            "Immune thrombocytopenic purpura",
-            "Primary Immune Thrombocytopenia",
-            "Thrombocytopenic purpura, autoimmune related phenotypic feature",
-            "autoimmune thrombocytopenic purpura"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://www.cancer.gov/cancertopics/types/myeloproliferative",
-            "http://www.bloodjournal.org/content/114/5/937.long",
-            "https://orcid.org/0000-0002-0736-9199"
-=======
-            "https://rarediseases.org/rare-diseases/immune-thrombocytopenia/"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 323565,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0020076",
-              "name": "myeloproliferative neoplasm",
-              "description": "A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C4345\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C4345\" NCI Thesaurus); A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008); UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "UMLS:C0027022",
-                "ICD10:D47.1",
-                "SNOMEDCT:109993000",
-                "EFO:0002428",
-                "SNOMEDCT:414794006",
-                "UMLS:C1292778",
-                "MEDDRA:10028577",
-                "MEDDRA:10013238",
-                "NCIT:C4345",
-                "HP:0005547",
-                "MONDO:0020076",
-                "MESH:D009196",
-                "ORPHANET:98274",
-                "SNOMEDCT:425333006",
-                "DOID:2226",
-                "MEDDRA:10077465",
-                "MEDDRA:10028576"
-              ],
-              "id": "MONDO:0020076",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic myeloproliferative disorder",
-                "Myeloproliferative neoplasm",
-                "Myeloproliferative Neoplasm",
-                "Myeloproliferative disorder",
-                "Myeloproliferative disease",
-                "Myeloproliferative Disorders",
-                "myeloproliferative neoplasm",
-                "chronic myeloproliferative disorder"
-=======
-            "identity": 316028,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008558",
-              "name": "autoimmune thrombocytopenic purpura",
-              "description": "Acquired thrombocytopenia of unknown cause, characterized by immune-mediated destruction of normal platelets. It affects both children and adults. It manifests with petechiae, purpura, and overt bleeding. Based upon the duration of the disease, it is classified as newly diagnosed (from diagnosis until 3 months), persistent (3-12 months), and chronic (lasting for more than 12 months).; Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.; The presence of thrombocytopenia in combination with detection of antiplatelet antibodies. [DDD:wouwehand]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021245",
-                "UMLS:C0398650",
-                "ORPHANET:3002",
-                "MESH:D016553",
-                "ICD9:287.31",
-                "MEDDRA:10083843",
-                "MEDDRA:10051064",
-                "MONDO:0008558",
-                "MEDDRA:10074667",
-                "OMIM:188030",
-                "DOID:8924",
-                "MEDDRA:10021243",
-                "ICD10:D69.3",
-                "EFO:0007160",
-                "NCIT:C3446"
-              ],
-              "id": "MONDO:0008558",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Purpura, Thrombocytopenic, Idiopathic",
-                "Immune thrombocytopenic purpura",
-                "Primary Immune Thrombocytopenia",
-                "Thrombocytopenic purpura, autoimmune related phenotypic feature",
-                "autoimmune thrombocytopenic purpura"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://www.cancer.gov/cancertopics/types/myeloproliferative",
-                "http://www.bloodjournal.org/content/114/5/937.long",
-                "https://orcid.org/0000-0002-0736-9199"
-=======
-                "https://rarediseases.org/rare-diseases/immune-thrombocytopenia/"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 10000381,
-            "start": 570,
-            "end": 323565,
-=======
-            "identity": 7647812,
-            "start": 570,
-            "end": 316028,
->>>>>>> main
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-<<<<<<< HEAD
-              "publications_info": "{'PMID:12775535': {'publication date': '2003 Jul-Aug', 'sentence': 'The effects of HDMP should be explored in patients with other subtypes of AML who present with MT.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0027022---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10221573",
-              "object": "MONDO:0020076",
-              "publications": [
-                "PMID:12775535"
-=======
-              "publications_info": "{'PMID:10560547': {'publication date': '1999 Oct 09', 'sentence': 'CONCLUSION: A short intravenous course of high-dose methylprednisolone is effective as initial treatment of adults with ITP.', 'subject score': 901, 'object score': 1000}, 'PMID:10759004': {'publication date': '2000 Mar', 'sentence': 'Twelve patients with acute ITP were treated with high-dose methyl prednisolone and five patients were treated with intravenous immunoglobulin.', 'subject score': 901, 'object score': 916}, 'PMID:10761200': {'publication date': '2000 Mar', 'sentence': 'Treatment of childhood acute immune thrombocytopenic purpura with high-dose methylprednisolone, intravenous immunoglobulin, or the combination of both.', 'subject score': 901, 'object score': 875}, 'PMID:11809183': {'publication date': '2002 Jan 05', 'sentence': 'INTERPRETATION: Intravenous immunoglobulin and oral prednisone seems to be more effective than high-dose methylprednisolone and oral prednisone in adults with severe AITP, although the latter treatment is effective and well tolerated.', 'subject score': 901, 'object score': 916}, 'PMID:12051587': {'publication date': '2002 Jun', 'sentence': 'Clinical course of children with immune thrombocytopenic purpura treated with intravenous immunoglobulin G or megadose methylprednisolone or observed without therapy.', 'subject score': 861, 'object score': 1000}, 'PMID:12521514': {'publication date': '2002 May', 'sentence': 'Idiopathic thrombocytopenic purpura treated with pulsed high dose methylprednisolone followed by platelet transfusion.', 'subject score': 850, 'object score': 1000}, 'PMID:12621242': {'publication date': '2003 Mar', 'sentence': 'PURPOSE: To investigate combined immunosuppressive therapy with vincristine, methylprednisolone, and prolonged cyclosporine in adolescents with refractory idiopathic thrombocytopenic purpura (ITP).', 'subject score': 1000, 'object score': 916}, 'PMID:15357656': {'publication date': '2004 Sep', 'sentence': 'At week 28 of treatment with interferon (alfacon-1), undetectable HCV RNA and transaminase levels within normal limits, the patient presented with immune thrombocytopenic purpura, which was successfully treated with immunoglobulin and methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:16244777': {'publication date': '2005 Oct', 'sentence': 'In this study, coagulation parameters were investigated that might have a role in hemostatic compensation in childhood acute ITP before and after high-dose methylprednisolone (HDMP) treatment.', 'subject score': 861, 'object score': 851}, 'PMID:1712884': {'publication date': '1991 Jul 20', 'sentence': 'Megadose methylprednisolone or IVIG for idiopathic thrombocytopenic purpura.', 'subject score': 861, 'object score': 1000}, 'PMID:1817495': {'publication date': '1991', 'sentence': 'Intravenous immunoglobulin or megadose methylprednisolone for the treatment of idiopathic thrombocytopenic purpura.', 'subject score': 861, 'object score': 1000}, 'PMID:20404751': {'publication date': '2010 May', 'sentence': 'Patients with acute ITP were studied, before and after, methylprednisolone treatment.', 'subject score': 888, 'object score': 916}, 'PMID:22956408': {'publication date': '2013 Feb', 'sentence': 'In the treatment of ITP in childhood, one 50 MUg/kg dose of anti-D Ig has similar effects to IVIG and methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:2414107': {'publication date': '1985 Sep', 'sentence': 'High doses of gamma globulin and methylprednisolone therapy for idiopathic thrombocytopenic purpura in children.', 'subject score': 888, 'object score': 1000}, 'PMID:27265010': {'publication date': '2005 Dec 05', 'sentence': 'The study consisted of 21 children (aged between 1.5-14 years) with ITP treated with HDMP for 7 days.', 'subject score': 901, 'object score': 1000}, 'PMID:2910369': {'publication date': '1989 Jan', 'sentence': 'High-dose intravenous methylprednisolone for immune thrombocytopenic purpura.', 'subject score': 861, 'object score': 1000}, 'PMID:3195522': {'publication date': '1988 Dec', 'sentence': 'High-dose intravenous methylprednisolone for childhood idiopathic thrombocytopenic purpura.', 'subject score': 861, 'object score': 916}, 'PMID:32418984': {'publication date': '2020 May 18', 'sentence': 'CASE REPORT We present the case of a 53-year-old woman who developed diabetic ketoacidosis after administration of methylprednisolone during treatment of immune thrombocytopenic purpura.', 'subject score': 1000, 'object score': 1000}, 'PMID:3626155': {'publication date': '1987 May', 'sentence': 'Eleven patients with adult idiopathic thrombocytopenic purpura (ITP) were treated with bolus methylprednisolone at doses of 1 g/day for 3 days.', 'subject score': 861, 'object score': 916}, 'PMID:3679481': {'publication date': '1987 Apr', 'sentence': 'Chronic ITP treated with intravenous pulse methylprednisolone.', 'subject score': 802, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0398650---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7808987",
-              "object": "MONDO:0008558",
-              "publications": [
-                "PMID:10560547",
-                "PMID:10759004",
-                "PMID:10761200",
-                "PMID:11809183",
-                "PMID:12051587",
-                "PMID:12521514",
-                "PMID:12621242",
-                "PMID:15357656",
-                "PMID:16244777",
-                "PMID:1712884",
-                "PMID:1817495",
-                "PMID:20404751",
-                "PMID:22956408",
-                "PMID:2414107",
-                "PMID:27265010",
-                "PMID:2910369",
-                "PMID:3195522",
-                "PMID:32418984",
-                "PMID:3626155",
-                "PMID:3679481"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 323831,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:29671675': {'publication date': '2018 Oct', 'sentence': 'Clinical commentary on \"Two cases of anaphylactic shock by methylprednisolone in neuromyelitis optica\".', 'subject score': 1000, 'object score': 1000}, 'PMID:29671689': {'publication date': '2018 Oct', 'sentence': 'Two cases of anaphylactic shock by methylprednisolone in neuromyelitis optica.', 'subject score': 1000, 'object score': 1000}, 'PMID:33037886': {'publication date': '2021 Dec', 'sentence': 'We performed a systematic review to evaluate whether therapeutic plasma exchange (TPE) is better than conventional intravenous methylprednisolone (IVMP) in neuromyelitis optica spectrum disorders (NMOSD) patients.', 'subject score': 851, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 529953,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-          "name": "acute lymphoblastic leukemia",
-          "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "HP:0006721",
-            "MONDO:0004967",
-            "MEDDRA:10000848",
-            "MEDDRA:10000849",
-            "MEDDRA:10025305",
-            "ORPHANET:513",
-            "MEDDRA:10025301",
-            "ICD10:C91.00",
-            "UMLS:C0023453",
-            "DOID:9952",
-            "MEDDRA:10000844",
-            "MEDDRA:10000846",
-            "MEDDRA:10000845",
-            "MEDDRA:10024338",
-            "ICD10:C91",
-            "MESH:D054198",
-            "UMLS:C1961102",
-            "MEDDRA:10060555",
-            "NCIT:C3167",
-            "PDQ:CDR0000043423",
-            "MEDDRA:10024290",
-            "MEDDRA:10000842",
-            "NCIT:C27281",
-            "ICD9:204",
-            "DOID:1037",
-            "MEDDRA:10000843",
-            "EFO:0000220",
-            "SNOMEDCT:128822004",
-            "ICD9:204.0",
-            "UMLS:C0023449",
-            "MEDDRA:10060390",
-            "SNOMEDCT:91857003"
-          ],
-          "id": "MONDO:0004967",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute lymphoblastic leukemia",
-            "lymphoid leukemia",
-            "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-            "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-            "L2 Acute Lymphoblastic Leukemia",
-            "acute lymphocytic leukemia",
-            "Lymphoid leukemia, acute",
-            "acute lymphoblastic leukemia",
-            "Acute lymphocytic leukemia",
-            "Acute Lymphoblastic Leukemia",
-            "Lymphoid leukemia"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019100",
-          "name": "neuromyelitis optica",
-          "description": "An autoimmune inflammatory syndrome characterized by optic neuritis and myelitis. Signs and symptoms include loss of vision, weakness and paralysis of the extremities, and loss of sensation.; A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10058009",
-            "MEDDRA:10077875",
-            "NCIT:C84934",
-            "MEDDRA:10052887",
-            "SNOMEDCT:25044007",
-            "MEDDRA:10029322",
-            "MEDDRA:10041225",
-            "MESH:D009471",
-            "DOID:8869",
-            "MEDDRA:10012574",
-            "ICD9:341.0",
-            "UMLS:C0027873",
-            "UMLS:C0221059",
-            "MONDO:0019100",
-            "EFO:0004256",
-            "ICD10:G36.0",
-            "ORPHANET:71211"
-          ],
-          "id": "MONDO:0019100",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neuromyelitis Optica",
-            "Neuromyelitis optica",
-            "neuromyelitis optica"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://www.cancer.gov/dictionary?cdrid=46332",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=616067",
-=======
-            "http://en.wikipedia.org/wiki/neuromyelitis_optica",
-            "http://rarediseases.org/rare-diseases/neuromyelitis-optica/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 529953,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019100",
-              "name": "neuromyelitis optica",
-              "description": "An autoimmune inflammatory syndrome characterized by optic neuritis and myelitis. Signs and symptoms include loss of vision, weakness and paralysis of the extremities, and loss of sensation.; A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10058009",
-                "MEDDRA:10077875",
-                "NCIT:C84934",
-                "MEDDRA:10052887",
-                "SNOMEDCT:25044007",
-                "MEDDRA:10029322",
-                "MEDDRA:10041225",
-                "MESH:D009471",
-                "DOID:8869",
-                "MEDDRA:10012574",
-                "ICD9:341.0",
-                "UMLS:C0027873",
-                "UMLS:C0221059",
-                "MONDO:0019100",
-                "EFO:0004256",
-                "ICD10:G36.0",
-                "ORPHANET:71211"
-              ],
-              "id": "MONDO:0019100",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neuromyelitis Optica",
-                "Neuromyelitis optica",
-                "neuromyelitis optica"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/neuromyelitis_optica",
-                "http://rarediseases.org/rare-diseases/neuromyelitis-optica/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19879668,
-            "start": 570,
-            "end": 529953,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29671675': {'publication date': '2018 Oct', 'sentence': 'Clinical commentary on \"Two cases of anaphylactic shock by methylprednisolone in neuromyelitis optica\".', 'subject score': 1000, 'object score': 1000}, 'PMID:29671689': {'publication date': '2018 Oct', 'sentence': 'Two cases of anaphylactic shock by methylprednisolone in neuromyelitis optica.', 'subject score': 1000, 'object score': 1000}, 'PMID:33037886': {'publication date': '2021 Dec', 'sentence': 'We performed a systematic review to evaluate whether therapeutic plasma exchange (TPE) is better than conventional intravenous methylprednisolone (IVMP) in neuromyelitis optica spectrum disorders (NMOSD) patients.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0027873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "20286711",
-              "object": "MONDO:0019100",
-              "publications": [
-                "PMID:29671675",
-                "PMID:29671689",
-                "PMID:33037886"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:22576570': {'publication date': '2012', 'sentence': 'High-dose intravenous methylprednisolone is the first-line therapy for acute exacerbations of NMO.', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 529953,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019100",
-          "name": "neuromyelitis optica",
-          "description": "An autoimmune inflammatory syndrome characterized by optic neuritis and myelitis. Signs and symptoms include loss of vision, weakness and paralysis of the extremities, and loss of sensation.; A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10058009",
-            "MEDDRA:10077875",
-            "NCIT:C84934",
-            "MEDDRA:10052887",
-            "SNOMEDCT:25044007",
-            "MEDDRA:10029322",
-            "MEDDRA:10041225",
-            "MESH:D009471",
-            "DOID:8869",
-            "MEDDRA:10012574",
-            "ICD9:341.0",
-            "UMLS:C0027873",
-            "UMLS:C0221059",
-            "MONDO:0019100",
-            "EFO:0004256",
-            "ICD10:G36.0",
-            "ORPHANET:71211"
-          ],
-          "id": "MONDO:0019100",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neuromyelitis Optica",
-            "Neuromyelitis optica",
-            "neuromyelitis optica"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/neuromyelitis_optica",
-            "http://rarediseases.org/rare-diseases/neuromyelitis-optica/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 529953,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019100",
-              "name": "neuromyelitis optica",
-              "description": "An autoimmune inflammatory syndrome characterized by optic neuritis and myelitis. Signs and symptoms include loss of vision, weakness and paralysis of the extremities, and loss of sensation.; A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10058009",
-                "MEDDRA:10077875",
-                "NCIT:C84934",
-                "MEDDRA:10052887",
-                "SNOMEDCT:25044007",
-                "MEDDRA:10029322",
-                "MEDDRA:10041225",
-                "MESH:D009471",
-                "DOID:8869",
-                "MEDDRA:10012574",
-                "ICD9:341.0",
-                "UMLS:C0027873",
-                "UMLS:C0221059",
-                "MONDO:0019100",
-                "EFO:0004256",
-                "ICD10:G36.0",
-                "ORPHANET:71211"
-              ],
-              "id": "MONDO:0019100",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neuromyelitis Optica",
-                "Neuromyelitis optica",
-                "neuromyelitis optica"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/neuromyelitis_optica",
-                "http://rarediseases.org/rare-diseases/neuromyelitis-optica/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15945560,
-            "start": 570,
-            "end": 529953,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22576570': {'publication date': '2012', 'sentence': 'High-dose intravenous methylprednisolone is the first-line therapy for acute exacerbations of NMO.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0027873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "16277488",
-              "object": "MONDO:0019100",
-              "publications": [
-                "PMID:22576570"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:20300766': {'publication date': '2010 Dec', 'sentence': 'Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica.', 'subject score': 840, 'object score': 1000}, 'PMID:30487360': {'publication date': '2018 Nov 29', 'sentence': 'She was diagnosed with NMO and treated with methylprednisolone therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:33992860': {'publication date': '2021 May 07', 'sentence': 'Sixty-one NMOSD attacks unresponsive to IVMP were included: 22 patients received rescue IA (IVMP+IA), 24 underwent rescue plasma exchange (PE) (IVMP+PE), and 21 received no further rescue therapy (IVMP alone).', 'subject score': 888, 'object score': 901}, 'PMID:35761845': {'publication date': '2022', 'sentence': 'He was diagnosed with AQP4-positive NMOSD and was treated with high-dose intravenous methylprednisolone and plasma exchange with some improvement.', 'subject score': 861, 'object score': 873}}",
-    "p2": {
-      "start": {
-        "identity": 529953,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019100",
-          "name": "neuromyelitis optica",
-          "description": "An autoimmune inflammatory syndrome characterized by optic neuritis and myelitis. Signs and symptoms include loss of vision, weakness and paralysis of the extremities, and loss of sensation.; A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10058009",
-            "MEDDRA:10077875",
-            "NCIT:C84934",
-            "MEDDRA:10052887",
-            "SNOMEDCT:25044007",
-            "MEDDRA:10029322",
-            "MEDDRA:10041225",
-            "MESH:D009471",
-            "DOID:8869",
-            "MEDDRA:10012574",
-            "ICD9:341.0",
-            "UMLS:C0027873",
-            "UMLS:C0221059",
-            "MONDO:0019100",
-            "EFO:0004256",
-            "ICD10:G36.0",
-            "ORPHANET:71211"
-          ],
-          "id": "MONDO:0019100",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neuromyelitis Optica",
-            "Neuromyelitis optica",
-            "neuromyelitis optica"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/neuromyelitis_optica",
-            "http://rarediseases.org/rare-diseases/neuromyelitis-optica/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 529953,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019100",
-              "name": "neuromyelitis optica",
-              "description": "An autoimmune inflammatory syndrome characterized by optic neuritis and myelitis. Signs and symptoms include loss of vision, weakness and paralysis of the extremities, and loss of sensation.; A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10058009",
-                "MEDDRA:10077875",
-                "NCIT:C84934",
-                "MEDDRA:10052887",
-                "SNOMEDCT:25044007",
-                "MEDDRA:10029322",
-                "MEDDRA:10041225",
-                "MESH:D009471",
-                "DOID:8869",
-                "MEDDRA:10012574",
-                "ICD9:341.0",
-                "UMLS:C0027873",
-                "UMLS:C0221059",
-                "MONDO:0019100",
-                "EFO:0004256",
-                "ICD10:G36.0",
-                "ORPHANET:71211"
-              ],
-              "id": "MONDO:0019100",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neuromyelitis Optica",
-                "Neuromyelitis optica",
-                "neuromyelitis optica"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/neuromyelitis_optica",
-                "http://rarediseases.org/rare-diseases/neuromyelitis-optica/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14588241,
-            "start": 570,
-            "end": 529953,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20300766': {'publication date': '2010 Dec', 'sentence': 'Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica.', 'subject score': 840, 'object score': 1000}, 'PMID:30487360': {'publication date': '2018 Nov 29', 'sentence': 'She was diagnosed with NMO and treated with methylprednisolone therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:33992860': {'publication date': '2021 May 07', 'sentence': 'Sixty-one NMOSD attacks unresponsive to IVMP were included: 22 patients received rescue IA (IVMP+IA), 24 underwent rescue plasma exchange (PE) (IVMP+PE), and 21 received no further rescue therapy (IVMP alone).', 'subject score': 888, 'object score': 901}, 'PMID:35761845': {'publication date': '2022', 'sentence': 'He was diagnosed with AQP4-positive NMOSD and was treated with high-dose intravenous methylprednisolone and plasma exchange with some improvement.', 'subject score': 861, 'object score': 873}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0027873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14897628",
-              "object": "MONDO:0019100",
-              "publications": [
-                "PMID:20300766",
-                "PMID:30487360",
-                "PMID:33992860",
-                "PMID:35761845"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:2025290': {'publication date': '1991 Apr 30', 'sentence': 'We investigated the effects of YM264, WEB2086, methylprednisolone and ticlopidine on puromycin-induced nephropathy in the rat.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 319192,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-          "name": "kidney disorder",
-          "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D007674",
-            "MEDDRA:10029154",
-            "UMLS:C0022658",
-            "NCIT:C3149",
-            "MONDO:0005240",
-            "UMLS:C1408258",
-            "DOID:557",
-            "MEDDRA:10029149",
-            "HP:0000112",
-            "MEDDRA:10051051",
-            "NCIT:C34843",
-            "MEDDRA:10038428",
-            "MEDDRA:10038429",
-            "MEDDRA:10029151",
-            "MEDDRA:10051052",
-            "EFO:0003086",
-            "SNOMEDCT:90708001",
-            "MEDDRA:10013263",
-            "PSY:27347"
-          ],
-          "id": "MONDO:0005240",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Kidney damage",
-            "kidney disease",
-            "Nephropathy",
-            "Kidney Diseases",
-            "Kidney Disorder",
-            "kidney disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-            "https://orcid.org/0000-0002-6601-2165",
->>>>>>> main
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 323831,
-=======
-            "identity": 319192,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-              "name": "acute lymphoblastic leukemia",
-              "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "HP:0006721",
-                "MONDO:0004967",
-                "MEDDRA:10000848",
-                "MEDDRA:10000849",
-                "MEDDRA:10025305",
-                "ORPHANET:513",
-                "MEDDRA:10025301",
-                "ICD10:C91.00",
-                "UMLS:C0023453",
-                "DOID:9952",
-                "MEDDRA:10000844",
-                "MEDDRA:10000846",
-                "MEDDRA:10000845",
-                "MEDDRA:10024338",
-                "ICD10:C91",
-                "MESH:D054198",
-                "UMLS:C1961102",
-                "MEDDRA:10060555",
-                "NCIT:C3167",
-                "PDQ:CDR0000043423",
-                "MEDDRA:10024290",
-                "MEDDRA:10000842",
-                "NCIT:C27281",
-                "ICD9:204",
-                "DOID:1037",
-                "MEDDRA:10000843",
-                "EFO:0000220",
-                "SNOMEDCT:128822004",
-                "ICD9:204.0",
-                "UMLS:C0023449",
-                "MEDDRA:10060390",
-                "SNOMEDCT:91857003"
-              ],
-              "id": "MONDO:0004967",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute lymphoblastic leukemia",
-                "lymphoid leukemia",
-                "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-                "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-                "L2 Acute Lymphoblastic Leukemia",
-                "acute lymphocytic leukemia",
-                "Lymphoid leukemia, acute",
-                "acute lymphoblastic leukemia",
-                "Acute lymphocytic leukemia",
-                "Acute Lymphoblastic Leukemia",
-                "Lymphoid leukemia"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-              "name": "kidney disorder",
-              "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D007674",
-                "MEDDRA:10029154",
-                "UMLS:C0022658",
-                "NCIT:C3149",
-                "MONDO:0005240",
-                "UMLS:C1408258",
-                "DOID:557",
-                "MEDDRA:10029149",
-                "HP:0000112",
-                "MEDDRA:10051051",
-                "NCIT:C34843",
-                "MEDDRA:10038428",
-                "MEDDRA:10038429",
-                "MEDDRA:10029151",
-                "MEDDRA:10051052",
-                "EFO:0003086",
-                "SNOMEDCT:90708001",
-                "MEDDRA:10013263",
-                "PSY:27347"
-              ],
-              "id": "MONDO:0005240",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Kidney damage",
-                "kidney disease",
-                "Nephropathy",
-                "Kidney Diseases",
-                "Kidney Disorder",
-                "kidney disorder"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://www.cancer.gov/dictionary?cdrid=46332",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=616067",
-=======
-                "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-                "https://orcid.org/0000-0002-6601-2165",
->>>>>>> main
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 9917017,
-            "start": 570,
-            "end": 323831,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12688320': {'publication date': '2003 Mar', 'sentence': 'We examined the effect of high-dose methylprednisolone (HDMP) on blast reduction rate and compared it to conventional dose steroid treatment, administered during the first 7+ days of the induction remission period in patients with acute lymphoblastic leukemia (ALL).', 'subject score': 901, 'object score': 1000}, 'PMID:16258745': {'publication date': '2006 Jan', 'sentence': 'We have investigated serum endothelin-1 (ET) and nitric oxide (NO) levels before and after a short course of high dose methylprednisolone (HDMP) in children with acute lymphoblastic leukemia (ALL) as an indicator of vasoconstrictor and vasodilator properties of endothelium.', 'subject score': 901, 'object score': 1000}, 'PMID:1635379': {'publication date': '1992', 'sentence': 'High-dose methylprednisolone therapy (HDMP) induces acceleration of leukocyte recovery in acute lymphoblastic leukemia (ALL) and the differentiation of myeloblasts to mature granulocytes in acute myeloblastic leukemia (AML).', 'subject score': 861, 'object score': 1000}, 'PMID:16928654': {'publication date': '2006 Oct-Nov', 'sentence': 'Comparision of the apoptotic effects on lymphoblasts and on increase of myeloid lineage cells of a short-time, high-dose methylprednisolone and the conventional-dose prednisolone treatments in children with acute lymphoblastic leukemia.', 'subject score': 901, 'object score': 1000}, 'PMID:1863545': {'publication date': '1991', 'sentence': 'Acceleration of leukocyte recovery by administration of short-course high-dose methylprednisolone in children with acute lymphoblastic leukemia.', 'subject score': 840, 'object score': 1000}, 'PMID:9020370': {'publication date': '1997 Jan', 'sentence': 'In an attempt to improve treatment outcome high-dose methylprednisolone (HDMP, 20-30 mg/kg, once a day orally) was used instead of a conventional dose of steroid (2 mg/kg/d, in 3 divided doses) in children with acute lymphoblastic leukemia (ALL) with increased risk factors.', 'subject score': 857, 'object score': 1000}, 'PMID:9678714': {'publication date': '1998 Jun', 'sentence': 'A comparison of the effect of high-dose methylprednisolone with conventional-dose prednisolone in acute lymphoblastic leukemia patients with randomization.', 'subject score': 901, 'object score': 916}, 'PMID:9842648': {'publication date': '1998', 'sentence': 'Effect of high-dose methylprednisolone and G-CSF treatments on lymphocyte subtypes in neutropenic children with acute lymphoblastic leukemia: a pilot study.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0023449---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10136260",
-              "object": "MONDO:0004967",
-              "publications": [
-                "PMID:12688320",
-                "PMID:16258745",
-                "PMID:1635379",
-                "PMID:16928654",
-                "PMID:1863545",
-                "PMID:9020370",
-                "PMID:9678714",
-                "PMID:9842648"
-=======
-            "identity": 14582089,
-            "start": 570,
-            "end": 319192,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2025290': {'publication date': '1991 Apr 30', 'sentence': 'We investigated the effects of YM264, WEB2086, methylprednisolone and ticlopidine on puromycin-induced nephropathy in the rat.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0022658---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14891106",
-              "object": "MONDO:0005240",
-              "publications": [
-                "PMID:2025290"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 320151,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-          "name": "dermatitis, atopic",
-          "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MESH:C566404",
-            "MEDDRA:10012434",
-            "SNOMEDCT:24079001",
-            "MONDO:0011292",
-            "MEDDRA:10003641",
-            "MONDO:0100181",
-            "MEDDRA:10014191",
-            "OMIM:603165",
-            "HP:0001047",
-            "MEDDRA:10001711",
-            "MEDDRA:10003639",
-            "UMLS:C0011615",
-            "UMLS:C4280605",
-            "UMLS:C1864155",
-            "MEDDRA:10012438",
-            "MEDDRA:10014188",
-            "MEDDRA:10001712",
-            "MESH:D003876",
-            "SNOMEDCT:200775004"
-          ],
-          "id": "MONDO:0011292",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Dermatitis, Atopic, 1",
-            "dermatitis, atopic",
-            "Dermatitis, Atopic",
-            "Baby eczema",
-            "Dermatitis, atopic related phenotypic feature",
-            "Atopic dermatitis",
-            "dermatitis, atopic, 1"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:27904186",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320151,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011292",
-              "name": "dermatitis, atopic",
-              "description": "Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. [HPO:probinson, PMID:27904186]; Atopic dermatitis (AD) or atopic eczema is an itchy, inflammatory skin condition with a predilection for the skin flexures. It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage. // COMMENTS: In infants, atopic dermatitis is known as infantile eczema.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MESH:C566404",
-                "MEDDRA:10012434",
-                "SNOMEDCT:24079001",
-                "MONDO:0011292",
-                "MEDDRA:10003641",
-                "MONDO:0100181",
-                "MEDDRA:10014191",
-                "OMIM:603165",
-                "HP:0001047",
-                "MEDDRA:10001711",
-                "MEDDRA:10003639",
-                "UMLS:C0011615",
-                "UMLS:C4280605",
-                "UMLS:C1864155",
-                "MEDDRA:10012438",
-                "MEDDRA:10014188",
-                "MEDDRA:10001712",
-                "MESH:D003876",
-                "SNOMEDCT:200775004"
-              ],
-              "id": "MONDO:0011292",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Dermatitis, Atopic, 1",
-                "dermatitis, atopic",
-                "Dermatitis, Atopic",
-                "Baby eczema",
-                "Dermatitis, atopic related phenotypic feature",
-                "Atopic dermatitis",
-                "dermatitis, atopic, 1"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:27904186",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9820760,
-            "start": 570,
-            "end": 320151,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12603681': {'publication date': '2003 Feb', 'sentence': 'The objective of this multicentre, parallel, blinded, randomized controlled study was to evaluate the efficacy and the safety of cyclosporine (CsA group, 117 dogs) in comparison with methylprednisolone (MP group, 59 dogs) in the treatment of atopic dermatitis for 4 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:15200072': {'publication date': '2004 May 29', 'sentence': 'Remission of the clinical signs of atopic dermatitis in dogs after cessation of treatment with cyclosporin A or methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:1678223': {'publication date': '1991', 'sentence': 'We therefore studied the serum concentrations of cortisol, prolactin and adrenocorticotropin under baseline conditions, after 1 mg dexamethasone and after a defined methylprednisolone treatment in 15 patients with atopic dermatitis, in comparison with 10 healthy controls.', 'subject score': 790, 'object score': 1000}, 'PMID:36136706': {'publication date': '2022 Sep 09', 'sentence': 'A Pilot Randomized Trial to Compare Polyuria and Polydipsia during a Short Course of Prednisolone or Methylprednisolone in Dogs with Atopic Dermatitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0011615---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10049014",
-              "object": "MONDO:0011292",
-              "publications": [
-                "PMID:12603681",
-                "PMID:15200072",
-                "PMID:1678223",
-                "PMID:36136706"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 517020,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019167",
-          "name": "immunoglobulin a vasculitis",
-          "description": "A systemic, usually self-limited immune complex vasculitis, characterized by immunoglobulin A deposition in the small vessels and kidneys. It is manifested with small hemorrhages in the skin, gastrointestinal symptoms, arthritis, and nephropathy.; A systemic non-thrombocytopenic purpura caused by HYPERSENSITIVITY VASCULITIS and deposition of IGA-containing IMMUNE COMPLEXES within the blood vessels throughout the body, including those in the kidney (KIDNEY GLOMERULUS). Clinical symptoms include URTICARIA; ERYTHEMA; ARTHRITIS; GASTROINTESTINAL HEMORRHAGE; and renal involvement. Most cases are seen in children after acute upper respiratory infections.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10002214",
-            "ICD9:287.0",
-            "MEDDRA:10002217",
-            "MEDDRA:10037552",
-            "MONDO:0019167",
-            "MEDDRA:10037565",
-            "MEDDRA:10001735",
-            "NCIT:C34963",
-            "MEDDRA:10019616",
-            "EFO:1000965",
-            "MEDDRA:10001716",
-            "DOID:11123",
-            "MEDDRA:10019615",
-            "MEDDRA:10002215",
-            "MESH:D011695",
-            "SNOMEDCT:191306005",
-            "ORPHANET:761",
-            "MEDDRA:10037551",
-            "ICD10:D69.0",
-            "MEDDRA:10039658",
-            "MEDDRA:10019617",
-            "SNOMEDCT:86074002",
-            "UMLS:C0034152",
-            "MEDDRA:10082959"
-          ],
-          "id": "MONDO:0019167",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Immunoglobulin A vasculitis",
-            "immunoglobulin A vasculitis",
-            "Allergic purpura",
-            "Henoch-Schönlein Purpura",
-            "IgA Vasculitis",
-            "Henoch-Schoenlein purpura",
-            "Henoch-Schoenlein Purpura"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://rarediseases.info.nih.gov/diseases/8204/henoch-schonlein-purpura",
-            "https://orcid.org/0000-0001-5208-3432"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517020,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019167",
-              "name": "immunoglobulin a vasculitis",
-              "description": "A systemic, usually self-limited immune complex vasculitis, characterized by immunoglobulin A deposition in the small vessels and kidneys. It is manifested with small hemorrhages in the skin, gastrointestinal symptoms, arthritis, and nephropathy.; A systemic non-thrombocytopenic purpura caused by HYPERSENSITIVITY VASCULITIS and deposition of IGA-containing IMMUNE COMPLEXES within the blood vessels throughout the body, including those in the kidney (KIDNEY GLOMERULUS). Clinical symptoms include URTICARIA; ERYTHEMA; ARTHRITIS; GASTROINTESTINAL HEMORRHAGE; and renal involvement. Most cases are seen in children after acute upper respiratory infections.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10002214",
-                "ICD9:287.0",
-                "MEDDRA:10002217",
-                "MEDDRA:10037552",
-                "MONDO:0019167",
-                "MEDDRA:10037565",
-                "MEDDRA:10001735",
-                "NCIT:C34963",
-                "MEDDRA:10019616",
-                "EFO:1000965",
-                "MEDDRA:10001716",
-                "DOID:11123",
-                "MEDDRA:10019615",
-                "MEDDRA:10002215",
-                "MESH:D011695",
-                "SNOMEDCT:191306005",
-                "ORPHANET:761",
-                "MEDDRA:10037551",
-                "ICD10:D69.0",
-                "MEDDRA:10039658",
-                "MEDDRA:10019617",
-                "SNOMEDCT:86074002",
-                "UMLS:C0034152",
-                "MEDDRA:10082959"
-              ],
-              "id": "MONDO:0019167",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Immunoglobulin A vasculitis",
-                "immunoglobulin A vasculitis",
-                "Allergic purpura",
-                "Henoch-Schönlein Purpura",
-                "IgA Vasculitis",
-                "Henoch-Schoenlein purpura",
-                "Henoch-Schoenlein Purpura"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://rarediseases.info.nih.gov/diseases/8204/henoch-schonlein-purpura",
-                "https://orcid.org/0000-0001-5208-3432"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9764318,
-            "start": 570,
-            "end": 517020,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12533096': {'publication date': '2003 Jan', 'sentence': 'CASE DESCRIPTION: A 33-year-old woman previously treated with methylprednisolone and cyclophosphamide for Henoch-Schonlein purpura was transferred from a referring hospital because of sore throat, fever, and chills.', 'subject score': 1000, 'object score': 1000}, 'PMID:18547440': {'publication date': '2008 Jun 12', 'sentence': 'In this patient, both the Henoch-Schonlein purpura and his neurological symptoms were successfully treated with intravenous cyclophosphamide and methylprednisolone, followed by a short course of oral cyclophosphamide and long-term oral prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:19156419': {'publication date': '2009 Oct', 'sentence': 'In this patient both Schonlein-Henoch purpura and gastrointestinal haemorrhage were successfully treated with intravenous methylprednisolone, avoiding surgical intervention.', 'subject score': 888, 'object score': 1000}, 'PMID:20033243': {'publication date': '2010 Apr', 'sentence': 'Moderate HSP patients were more likely to respond to MP therapy than HCSS therapy (P < 0.05).', 'subject score': 888, 'object score': 854}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0034152---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "9980473",
-              "object": "MONDO:0019167",
-              "publications": [
-                "PMID:12533096",
-                "PMID:18547440",
-                "PMID:19156419",
-                "PMID:20033243"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 309447,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005556",
-          "name": "lupus nephritis",
-          "description": "Glomerulonephritis in the context of systemic lupus erythematosus.; Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).; Lupus nephritis is a type of glomerulonephritis that constitutes one of the most severe organ manifestations of systemic lupus erythematosus. Lupus nephritis is subclassified in six distinct classes, that represent different manifestations and severities of renal involvement and guide the therapeutic management. [ORCID:0000-0002-2234-4248, PMID:31974366]",
-          "equivalent_curies": [
-            "MEDDRA:10025140",
-            "HP:0033726",
-            "MEDDRA:10029141",
-            "DOID:0080162",
-            "NCIT:C34789",
-            "UMLS:C0024143",
-            "MESH:D008181",
-            "MEDDRA:10029142",
-            "MONDO:0005556",
-            "SNOMEDCT:68815009",
-            "MEDDRA:10040970",
-            "EFO:0005761"
-          ],
-          "id": "MONDO:0005556",
-          "category": "biolink:Disease",
-          "all_names": [
-            "lupus nephritis",
-            "Lupus nephritis",
-            "Lupus Nephritis",
-            "Lupus Glomerulonephritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000481.htm",
-            "PMID:31974366",
-            "https://orcid.org/0000-0002-2234-4248",
-            "https://en.wikipedia.org/wiki/lupus_nephritis#cite_note-1"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 309447,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005556",
-              "name": "lupus nephritis",
-              "description": "Glomerulonephritis in the context of systemic lupus erythematosus.; Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).; Lupus nephritis is a type of glomerulonephritis that constitutes one of the most severe organ manifestations of systemic lupus erythematosus. Lupus nephritis is subclassified in six distinct classes, that represent different manifestations and severities of renal involvement and guide the therapeutic management. [ORCID:0000-0002-2234-4248, PMID:31974366]",
-              "equivalent_curies": [
-                "MEDDRA:10025140",
-                "HP:0033726",
-                "MEDDRA:10029141",
-                "DOID:0080162",
-                "NCIT:C34789",
-                "UMLS:C0024143",
-                "MESH:D008181",
-                "MEDDRA:10029142",
-                "MONDO:0005556",
-                "SNOMEDCT:68815009",
-                "MEDDRA:10040970",
-                "EFO:0005761"
-              ],
-              "id": "MONDO:0005556",
-              "category": "biolink:Disease",
-              "all_names": [
-                "lupus nephritis",
-                "Lupus nephritis",
-                "Lupus Nephritis",
-                "Lupus Glomerulonephritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000481.htm",
-                "PMID:31974366",
-                "https://orcid.org/0000-0002-2234-4248",
-                "https://en.wikipedia.org/wiki/lupus_nephritis#cite_note-1"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9510354,
-            "start": 570,
-            "end": 309447,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12192247': {'publication date': '2002 Sep', 'sentence': 'The last significant breakthrough in the treatment of systemic lupus erythematosus (SLE) was the use of cyclophosphamide and methylprednisolone in the treatment of lupus nephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1336441': {'publication date': '1992 Dec', 'sentence': 'These results indicate that methylprednisolone treatment can serve as an effective therapeutic approach to abnormal extracellular matrix regulation in murine lupus nephritis.', 'subject score': 888, 'object score': 901}, 'PMID:17328038': {'publication date': '2007 Mar', 'sentence': 'Histologic deterioration and more flares: the case against azathioprine plus methylprednisolone in the treatment of proliferative lupus nephritis.', 'subject score': 851, 'object score': 901}, 'PMID:17328070': {'publication date': '2007 Mar', 'sentence': 'Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.', 'subject score': 851, 'object score': 901}, 'PMID:17659757': {'publication date': '2007 Aug', 'sentence': 'Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ methylprednisolone in a randomized controlled trial.', 'subject score': 888, 'object score': 901}, 'PMID:19280226': {'publication date': '2009 Jul', 'sentence': 'Cases of active LN treated with IVCY and pulse methylprednisolone who later develop severe infection that fails to respond to antibiotics should be carefully investigated for fungal infection.', 'subject score': 861, 'object score': 901}, 'PMID:21559160': {'publication date': '2010 Jul', 'sentence': 'Treatment of LN with intravenous pulse methyl prednisolone and cyclophosphamide was effective in normalizing the CSF pressure, resulting in express and dramatic resolution of symptomatology.', 'subject score': 812, 'object score': 1000}, 'PMID:22128082': {'publication date': '2012 Jun', 'sentence': 'AZA/MP can therefore serve as an alternative in patients with proliferative LN who wish to avoid gonadal toxicity of CY.', 'subject score': 888, 'object score': 901}, 'PMID:22252192': {'publication date': '2012 Jan', 'sentence': \"Treatment of LN with intravenous pulse methylprednisolone and cyclophosphamide normalised the patient's CSF pressure and symptoms.\", 'subject score': 802, 'object score': 1000}, 'PMID:22448187': {'publication date': '2010', 'sentence': 'Pulsed methylprednisolone treatment for diffuse lupus nephritis was begun on the background of lamivudine therapy.', 'subject score': 840, 'object score': 901}, 'PMID:24987977': {'publication date': '2014 Jun', 'sentence': 'Group C (SLEDAI score, < 6) included patients with lupus nephritis, treated with methylprednisolone and cyclophosphamide, reaching complete remission.', 'subject score': 1000, 'object score': 1000}, 'PMID:2525382': {'publication date': '1989 Jun', 'sentence': 'The benefit of high-dose, pulse intravenous methylprednisolone (IVMP) for some patients with active lupus nephritis would appear paradoxical, since active nephritis is associated with profound abnormalities in Fc gamma receptor function, and several studies have demonstrated that glucocorticoids decrease monocyte Fc gamma receptor expression and phagocytic function.', 'subject score': 785, 'object score': 901}, 'PMID:26018932': {'publication date': '2016 Aug', 'sentence': 'OBJECTIVE: The efficacy of double-filtration plasmapheresis (DFPP), combined with methylprednisolone, to treat diffuse proliferative lupus nephritis (LN) was studied.', 'subject score': 1000, 'object score': 861}, 'PMID:28082046': {'publication date': '2017 03', 'sentence': 'Cyclophosphamide intravenously proved to be superior and the use of cyclophosphamide in combination with methylprednisolone remained the standard protocol for the treatment of lupus nephritis for decades.', 'subject score': 1000, 'object score': 1000}, 'PMID:34413046': {'publication date': '2021 Aug 19', 'sentence': 'He was treated with high-dose methylprednisolone and mycophenolate mofetil for lupus nephritis and with penicillin for syphilis.', 'subject score': 901, 'object score': 1000}, 'PMID:34606036': {'publication date': '2021 Oct 04', 'sentence': 'A 20-year-old lady with lupus nephritis and neuropsychiatric lupus was treated with injection methylprednisolone and cyclophosphamide.', 'subject score': 888, 'object score': 1000}, 'PMID:6971057': {'publication date': '1981 Apr', 'sentence': 'To determine guidelines for treatment with high-dose intravenous methylprednisolone in lupus nephritis, we prospectively assessed the response to pulse therapy in 34 patients.', 'subject score': 861, 'object score': 1000}, 'PMID:7045314': {'publication date': '1982 Jul', 'sentence': 'Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis.', 'subject score': 790, 'object score': 861}, 'PMID:7111671': {'publication date': '1982', 'sentence': 'Treatment of diffuse proliferative lupus nephritis by intravenous high-dose methylprednisolone.', 'subject score': 861, 'object score': 861}, 'PMID:7694336': {'publication date': '1993 Sep-Oct', 'sentence': 'These data suggest that ET and ET receptor gene transcription is upregulated in the renal tissues of NZB/W F1 mice and that the beneficial treatment of lupus nephritis with MPSL is accompanied by a reduction in the elevated concentrations of ET-1, ET receptors, TGF-beta and TNF-alpha mRNAs.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0024143---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "9720542",
-              "object": "MONDO:0005556",
-              "publications": [
-                "PMID:12192247",
-                "PMID:1336441",
-                "PMID:17328038",
-                "PMID:17328070",
-                "PMID:17659757",
-                "PMID:19280226",
-                "PMID:21559160",
-                "PMID:22128082",
-                "PMID:22252192",
-                "PMID:22448187",
-                "PMID:24987977",
-                "PMID:2525382",
-                "PMID:26018932",
-                "PMID:28082046",
-                "PMID:34413046",
-                "PMID:34606036",
-                "PMID:6971057",
-                "PMID:7045314",
-                "PMID:7111671",
-                "PMID:7694336"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321528,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8574607,
-            "start": 570,
-            "end": 321528,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11249603': {'publication date': '2000 Sep', 'sentence': 'Methylprednisolone suleptanate (Promedrol) is a prodrug of methylprednisolone being developed by Pharmacia Corp (formerly Pharmacia & Upjohn) for the treatment of asthma.', 'subject score': 1000, 'object score': 1000}, 'PMID:12400872': {'publication date': '2002 Sep', 'sentence': 'In contrast, the expression of GRalpha and c-jun mRNAs did not correlate with the IC50 for prednisolone and methylprednisolone in asthma patients.', 'subject score': 1000, 'object score': 888}, 'PMID:15302718': {'publication date': '2004 Aug', 'sentence': 'OBJECTIVE: To compare the efficacy of long-acting IM methylprednisolone to tapering oral methylprednisolone in adult asthmatic patients discharged from the emergency department (ED).', 'subject score': 825, 'object score': 851}, 'PMID:22726275': {'publication date': '2012 Dec', 'sentence': 'These control patients were selected from 71 patients admitted due to pneumonia or bronchitis caused by H1N1 pdm 09, and were chosen according to age, absence of pretreatment with oseltamivir before admission, presence of a past history of asthma, use of antibiotics, and combination of inhalation of a beta2 agonist and treatment with i.v. methylprednisolone for asthma attack.', 'subject score': 827, 'object score': 1000}, 'PMID:25125034': {'publication date': '2014 Oct', 'sentence': 'Hereinafter is reported the case of a 2-year-old girl hospitalized in the pediatric intensive care unit for ASA, which was treated with high-flow oxygen therapy and intravenous methylprednisolone and salbutamol.', 'subject score': 888, 'object score': 1000}, 'PMID:3543111': {'publication date': '1986', 'sentence': 'Described is such a reaction resulting in cardiopulmonary collapse in a 66-year-old asthmatic treated with intravenous methylprednisolone.', 'subject score': 888, 'object score': 775}, 'PMID:3665340': {'publication date': '1987 Oct', 'sentence': 'Prednisolone and methylprednisolone pharmacokinetic parameters were evaluated in asthmatic children receiving concomitant anticonvulsant therapy.', 'subject score': 851, 'object score': 888}, 'PMID:36929864': {'publication date': '2023 Mar 17', 'sentence': 'Dexamethasone versus methylprednisolone for critical asthma: A single center, open-label, parallel-group clinical trial.', 'subject score': 1000, 'object score': 888}, 'PMID:3700892': {'publication date': '1986 May', 'sentence': 'Some indications for depot methylprednisolone for asthma or other severe allergic disease.', 'subject score': 861, 'object score': 1000}, 'PMID:5521178': {'publication date': '1970 Oct', 'sentence': 'Alternate day methylprednisolone therapy in asthma.', 'subject score': 852, 'object score': 1000}, 'PMID:8069995': {'publication date': '1994 Jun', 'sentence': 'Following admission, he required intensive nonventilatory management of his asthma, including intravenous salbutamol, methylprednisolone, and aminophylline, as well as use of an ipratroprium bromide inhaler and 100% oxygen by mask.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8761529",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:11249603",
-                "PMID:12400872",
-                "PMID:15302718",
-                "PMID:22726275",
-                "PMID:25125034",
-                "PMID:3543111",
-                "PMID:3665340",
-                "PMID:36929864",
-                "PMID:3700892",
-                "PMID:5521178",
-                "PMID:8069995"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 312015,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005665",
-          "name": "Bell's palsy",
-          "description": "A syndrome characterized by the acute onset of unilateral FACIAL PARALYSIS which progresses over a 2-5 day period. Weakness of the orbicularis oculi muscle and resulting incomplete eye closure may be associated with corneal injury. Pain behind the ear often precedes the onset of paralysis. This condition may be associated with HERPESVIRUS 1, HUMAN infection of the facial nerve. (Adams et al., Principles of Neurology, 6th ed, p1376); Facial nerve palsy is a dysfunction of cranial nerve VII (the facial nerve) that results in inability to control facial muscles on the affected side with weakness of the muscles of facial expression and eye closure. This can either be present in unilateral or bilateral form. [HPO:sdoelken]; Bell's palsy is the most common cause of facial paralysis. It usually affects just one side of the face. Symptoms appear suddenly and are at their worst about 48 hours after they start. They can range from mild to severe and include: Twitching Weakness Paralysis Drooping eyelid or corner of mouth Drooling Dry eye or mouth Excessive tearing in the eye Impaired ability to taste  Scientists think that a viral infection makes the facial nerve swell or become inflamed. You are most likely to get Bell's palsy if you are pregnant, diabetic or sick with a cold or flu. Three out of four patients improve without treatment. With or without treatment, most people begin to get better within 2 weeks and recover completely within 3 to 6 months.  NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005665",
-            "MESH:D020330",
-            "UMLS:C0376175",
-            "MEDDRA:10080910",
-            "ICD10:G51.0",
-            "MEDDRA:10033559",
-            "UMLS:C1858719",
-            "SNOMEDCT:193093009",
-            "ORPHANET:2810",
-            "HP:0010628",
-            "NCIT:C26769",
-            "DOID:12506",
-            "EFO:0007167",
-            "ICD9:351.0",
-            "MEDDRA:10004223"
-          ],
-          "id": "MONDO:0005665",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bell Palsy",
-            "Bell's palsy",
-            "Facial muscle weakness of muscles innervated by CN VII",
-            "Facial palsy",
-            "Cranial Nerve VII Palsy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/bell%27s_palsy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 312015,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005665",
-              "name": "Bell's palsy",
-              "description": "A syndrome characterized by the acute onset of unilateral FACIAL PARALYSIS which progresses over a 2-5 day period. Weakness of the orbicularis oculi muscle and resulting incomplete eye closure may be associated with corneal injury. Pain behind the ear often precedes the onset of paralysis. This condition may be associated with HERPESVIRUS 1, HUMAN infection of the facial nerve. (Adams et al., Principles of Neurology, 6th ed, p1376); Facial nerve palsy is a dysfunction of cranial nerve VII (the facial nerve) that results in inability to control facial muscles on the affected side with weakness of the muscles of facial expression and eye closure. This can either be present in unilateral or bilateral form. [HPO:sdoelken]; Bell's palsy is the most common cause of facial paralysis. It usually affects just one side of the face. Symptoms appear suddenly and are at their worst about 48 hours after they start. They can range from mild to severe and include: Twitching Weakness Paralysis Drooping eyelid or corner of mouth Drooling Dry eye or mouth Excessive tearing in the eye Impaired ability to taste  Scientists think that a viral infection makes the facial nerve swell or become inflamed. You are most likely to get Bell's palsy if you are pregnant, diabetic or sick with a cold or flu. Three out of four patients improve without treatment. With or without treatment, most people begin to get better within 2 weeks and recover completely within 3 to 6 months.  NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005665",
-                "MESH:D020330",
-                "UMLS:C0376175",
-                "MEDDRA:10080910",
-                "ICD10:G51.0",
-                "MEDDRA:10033559",
-                "UMLS:C1858719",
-                "SNOMEDCT:193093009",
-                "ORPHANET:2810",
-                "HP:0010628",
-                "NCIT:C26769",
-                "DOID:12506",
-                "EFO:0007167",
-                "ICD9:351.0",
-                "MEDDRA:10004223"
-              ],
-              "id": "MONDO:0005665",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bell Palsy",
-                "Bell's palsy",
-                "Facial muscle weakness of muscles innervated by CN VII",
-                "Facial palsy",
-                "Cranial Nerve VII Palsy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/bell%27s_palsy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8406394,
-            "start": 570,
-            "end": 312015,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11109888': {'publication date': '2000', 'sentence': \"On these basis, we have studied the efficacity of parenteral association of 30 mg/Kg/j of Aciclovir and 1 mg/Kg/j of Methylprednisolone in the treatment of Bell's palsy with less than 12 days of evolution.\", 'subject score': 1000, 'object score': 1000}, 'PMID:12410117': {'publication date': '2002 Sep', 'sentence': \"MATERIALS AND METHODS: Between 1997 and 2000, 76 patients with Bell's palsy were treated with intravenous methylprednisolone (2 mg/kg/day) and acyclovir (5-10 mg/kg/8 hours) for 7 days.\", 'subject score': 888, 'object score': 1000}, 'PMID:25878371': {'publication date': '2015 Mar-Apr', 'sentence': \"CONCLUSION: Intravenous methylprednisolone and oral prednisolone showed equivalent benefit in patients with acute Bell's palsy.\", 'subject score': 888, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0376175---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8588816",
-              "object": "MONDO:0005665",
-              "publications": [
-                "PMID:11109888",
-                "PMID:12410117",
-                "PMID:25878371"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 518734,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009688",
-          "name": "myasthenia gravis",
-          "description": "A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness. It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.; A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.; Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest. Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker. Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps. Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:G70.00",
-            "ICD9:358.0",
-            "OMIM:254200",
-            "PSY:32760",
-            "MESH:D009157",
-            "MEDDRA:10028420",
-            "ICD10:G70.0",
-            "EFO:0004991",
-            "ICD9:358.00",
-            "ORPHANET:589",
-            "UMLS:C1260409",
-            "MEDDRA:10028417",
-            "DOID:437",
-            "UMLS:C0026896",
-            "SNOMEDCT:91637004",
-            "MONDO:0009688",
-            "NCIT:C60989"
-          ],
-          "id": "MONDO:0009688",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Myasthenia gravis without (acute) exacerbation",
-            "myasthenia gravis without acute exacerbation",
-            "myasthenia gravis",
-            "Myasthenia Gravis",
-            "Myasthenia gravis",
-            "Myasthenia gravis related phenotypic feature"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.ninds.nih.gov/disorders/patient-caregiver-education/fact-sheets/myasthenia-gravis-fact-sheet"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 518734,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009688",
-              "name": "myasthenia gravis",
-              "description": "A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness. It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.; A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.; Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest. Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker. Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps. Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:G70.00",
-                "ICD9:358.0",
-                "OMIM:254200",
-                "PSY:32760",
-                "MESH:D009157",
-                "MEDDRA:10028420",
-                "ICD10:G70.0",
-                "EFO:0004991",
-                "ICD9:358.00",
-                "ORPHANET:589",
-                "UMLS:C1260409",
-                "MEDDRA:10028417",
-                "DOID:437",
-                "UMLS:C0026896",
-                "SNOMEDCT:91637004",
-                "MONDO:0009688",
-                "NCIT:C60989"
-              ],
-              "id": "MONDO:0009688",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Myasthenia gravis without (acute) exacerbation",
-                "myasthenia gravis without acute exacerbation",
-                "myasthenia gravis",
-                "Myasthenia Gravis",
-                "Myasthenia gravis",
-                "Myasthenia gravis related phenotypic feature"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.ninds.nih.gov/disorders/patient-caregiver-education/fact-sheets/myasthenia-gravis-fact-sheet"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8386295,
-            "start": 570,
-            "end": 518734,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11093687': {'publication date': '2000 Nov', 'sentence': 'Treatment with methylprednisolone for myasthenia gravis was associated with a marked decrease in both biochemical markers of bone formation and resorption without any changes in endogenous cAMP and serum levels of calcium, PTH, and 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3].', 'subject score': 1000, 'object score': 1000}, 'PMID:18632163': {'publication date': '2008 Sep 15', 'sentence': 'Myasthenia gravis (MG) is frequently treated by corticosteroids such as methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:23158712': {'publication date': '2012 Sep 18', 'sentence': 'CONCLUSION: (1) The combined treatment of middle-dose cyclophosphamide and methylprednisolone for MG patients in crisis is both effective and safe.', 'subject score': 1000, 'object score': 901}, 'PMID:28299711': {'publication date': '2018 Jan', 'sentence': 'Methylprednisolone and immunosuppressive therapy are highly effective in MG patients with normal thymus tissue and MG patients with thymic hyperplasia compared to MG patients with thymomas alone.', 'subject score': 1000, 'object score': 901}, 'PMID:32145521': {'publication date': '2020 Feb 19', 'sentence': 'CONCLUSION: Disease severity and thymectomy before IVMP are related to initial deterioration in MG patients.', 'subject score': 888, 'object score': 901}, 'PMID:34627357': {'publication date': '2021 Oct 10', 'sentence': 'CASE PRESENTATION: A 31-year-old Asian woman was admitted to our hospital for myasthenia gravis and treated with methylprednisolone and pyridostigmine bromide 3 months postpartum.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0026896---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8568939",
-              "object": "MONDO:0009688",
-              "publications": [
-                "PMID:11093687",
-                "PMID:18632163",
-                "PMID:23158712",
-                "PMID:28299711",
-                "PMID:32145521",
-                "PMID:34627357"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 526461,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001509",
-          "name": "endocrine exophthalmos",
-          "description": "An autoimmune disorder of the EYE, occurring in patients with Graves disease. Subtypes include congestive (inflammation of the orbital connective tissue), myopathic (swelling and dysfunction of the extraocular muscles), and mixed congestive-myopathic ophthalmopathy.",
-          "equivalent_curies": [
-            "DOID:0081120",
-            "SNOMEDCT:276177000",
-            "ICD9:376.2",
-            "MESH:D049970",
-            "UMLS:C0339143",
-            "MONDO:0001509",
-            "MEDDRA:10084358",
-            "UMLS:C0155264",
-            "DOID:12359",
-            "MEDDRA:10014702",
-            "MEDDRA:10057889",
-            "MEDDRA:10060742",
-            "MEDDRA:10015684",
-            "EFO:1001466"
-          ],
-          "id": "MONDO:0001509",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Graves ophthalmopathy",
-            "Endocrine exophthalmos",
-            "Thyroid associated opthalmopathies",
-            "endocrine exophthalmos",
-            "Graves Ophthalmopathy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:20181974",
-            "https://orcid.org/0000-0001-7151-1615",
-            "https://en.wikipedia.org/wiki/graves%27_ophthalmopathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526461,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001509",
-              "name": "endocrine exophthalmos",
-              "description": "An autoimmune disorder of the EYE, occurring in patients with Graves disease. Subtypes include congestive (inflammation of the orbital connective tissue), myopathic (swelling and dysfunction of the extraocular muscles), and mixed congestive-myopathic ophthalmopathy.",
-              "equivalent_curies": [
-                "DOID:0081120",
-                "SNOMEDCT:276177000",
-                "ICD9:376.2",
-                "MESH:D049970",
-                "UMLS:C0339143",
-                "MONDO:0001509",
-                "MEDDRA:10084358",
-                "UMLS:C0155264",
-                "DOID:12359",
-                "MEDDRA:10014702",
-                "MEDDRA:10057889",
-                "MEDDRA:10060742",
-                "MEDDRA:10015684",
-                "EFO:1001466"
-              ],
-              "id": "MONDO:0001509",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Graves ophthalmopathy",
-                "Endocrine exophthalmos",
-                "Thyroid associated opthalmopathies",
-                "endocrine exophthalmos",
-                "Graves Ophthalmopathy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:20181974",
-                "https://orcid.org/0000-0001-7151-1615",
-                "https://en.wikipedia.org/wiki/graves%27_ophthalmopathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8380125,
-            "start": 570,
-            "end": 526461,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11089418': {'publication date': '2000 May-Jun', 'sentence': \"PATIENTS AND METHODS: Fourteen euthyroid patients with severe Graves' ophthalmopathy were treated with high-dose intravenous methylprednisolone during 6 months and followed-up for 24-48 months by clinical and ophthalmological assessment.\", 'subject score': 861, 'object score': 901}, 'PMID:1345455': {'publication date': '1992', 'sentence': \"Combined cyclosporin-A and methylprednisolone treatment of Graves' ophthalmopathy.\", 'subject score': 888, 'object score': 1000}, 'PMID:15510744': {'publication date': '2002 Sep', 'sentence': \"METHODS: Using enzyme linked immunosorbent assay (ELISA) systems, we measured serum concentrations of IL-1alpha, IL-1beta and sIL-1ra in 18 normal controls, 20 active GO, 20 inactive GO, 18 Graves' disease(GD) on patients without ophthalmopathy and 10 active GO patients after high-dose IV methylprednisolone therapy.\", 'subject score': 840, 'object score': 798}, 'PMID:1582520': {'publication date': '1992 Mar 20', 'sentence': \"Fifteen patients with Graves' ophthalmopathy (GO) were treated with intravenous methylprednisolone (steroid pulse therapy, 1g daily for 3 days a week, 2-4 times) and followed up by ophthalmological assessment and magnetic resonance imaging (MRI).\", 'subject score': 888, 'object score': 1000}, 'PMID:15936323': {'publication date': '2005 Jun', 'sentence': \"Early effects of methylprednisolone infusion on serum cystatin C in patients with severe Graves' ophthalmopathy.\", 'subject score': 888, 'object score': 901}, 'PMID:16117697': {'publication date': '2005 Aug', 'sentence': 'CONCLUSIONS: High-dose, pulsed intravenous MP is an effective medical treatment for severe TAO.', 'subject score': 888, 'object score': 908}, 'PMID:16791713': {'publication date': '2006 Apr', 'sentence': \"Acute myocardial infarction during high-dose methylprednisolone therapy for Graves' ophthalmopathy.\", 'subject score': 861, 'object score': 1000}, 'PMID:17465867': {'publication date': '2007 Apr', 'sentence': 'CONCLUSION: IVMP in GO patients causes dose-dependent liver damage by a direct toxic effect of glucocorticoids on hepatocytes.', 'subject score': 851, 'object score': 901}, 'PMID:1920963': {'publication date': '1991 May-Jun', 'sentence': 'We report a case of minimal thyroid ophthalmopathy treated with intravenous methylprednisolone, in which precise identification of the involved muscle was possible with the use of surface coil magnetic resonance (MR) imaging.', 'subject score': 888, 'object score': 901}, 'PMID:19627724': {'publication date': '2009 Mar', 'sentence': 'CONCLUSIONS: The treatment of GO with MTPiv is safe and effective, with a lower recurrence rate when using dosing regimen A.', 'subject score': 1000, 'object score': 1000}, 'PMID:22811284': {'publication date': '2012', 'sentence': 'PATIENTS AND RESEARCH DESIGN: Nine patients with severe and active GO were treated with high-dose methylprednisolone (1 g day(-1) three times within 1 week, then 0.5 g day(-1) seven times for 2 weeks) combined with plasma filtration (twice a week in weeks 1, 2, 4, 7, and 10).', 'subject score': 901, 'object score': 901}, 'PMID:24251142': {'publication date': '2013 Oct', 'sentence': \"Pulse dexamethasone therapy versus pulse methylprednisolone therapy for treatment of Graves's ophthalmopathy.\", 'subject score': 790, 'object score': 1000}, 'PMID:27853049': {'publication date': '2017 Feb 27', 'sentence': \"The intravenous methylprednisolone (iv MP) strategy for Graves' ophthalmopathy (GO) and evaluation of its activity against the disease warrants further exploration.\", 'subject score': 851, 'object score': 1000}, 'PMID:2906260': {'publication date': '1988 Dec 17', 'sentence': \"Eleven euthyroid patients with severe Graves' eye disease were treated with intravenous methylprednisolone and followed up for six months or more by ophthalmological assessment, orbital computed tomography (CT), photographs, and antibody measurements.\", 'subject score': 888, 'object score': 916}, 'PMID:30103255': {'publication date': '2018 Dec', 'sentence': 'CONCLUSION: This study suggests that the initiation of an SSA, using methotrexate as first-line, with limited adjuvant IVMP is an effective and safe treatment for moderate-to-severely active TED, resulting in a significant reduction in both disease activity and total steroid load.', 'subject score': 833, 'object score': 789}, 'PMID:30540214': {'publication date': '2019 Oct', 'sentence': 'Conclusion: With adequate screening and follow-up, six repeated cycles of high dose pulsed IVMP is an effective treatment for TED and can significantly reduce the morbidity associated with this debilitating condition.', 'subject score': 888, 'object score': 1000}, 'PMID:30624412': {'publication date': '2019', 'sentence': 'PURPOSE: To compare the efficacy and safety of adjunctive oral methotrexate with intravenous pulsed methylprednisolone against methylprednisolone alone in the treatment of severe thyroid eye disease.', 'subject score': 1000, 'object score': 916}, 'PMID:31890036': {'publication date': '2019', 'sentence': 'We also present recommendations and precautions which should be taken prior to initiation of intravenous pulses of methylprednisolone treatment for GO.', 'subject score': 888, 'object score': 1000}, 'PMID:32537950': {'publication date': '2020 Jun 15', 'sentence': 'We included 54 active moderate-to-severe GO patients treated with 4.5 g intravenous MPD over 12 weeks between November 2011 and November 2018.', 'subject score': 840, 'object score': 833}, 'PMID:32595602': {'publication date': '2020', 'sentence': \"Objective:     To evaluate the recurrence rate in Graves' patients who, in addition to standard ATD, were treated or not treated with parenteral methylprednisolone (MPDS) for GO.\", 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0339143---SEMMEDDB:",
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0155264---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8562694",
-              "object": "MONDO:0001509",
-              "publications": [
-                "PMID:2906260",
-                "PMID:36811756",
-                "PMID:31890036",
-                "PMID:30624412",
-                "PMID:35831587",
-                "PMID:27853049",
-                "PMID:1582520",
-                "PMID:16791713",
-                "PMID:33439464",
-                "PMID:33539318",
-                "PMID:17465867",
-                "PMID:1345455",
-                "PMID:35175298",
-                "PMID:16117697",
-                "PMID:24251142",
-                "PMID:30540214",
-                "PMID:19627724",
-                "PMID:32537950",
-                "PMID:30103255",
-                "PMID:20393724"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8323580,
-            "start": 570,
-            "end": 322104,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11040177': {'publication date': '2000 Oct', 'sentence': 'The current study evaluated the efficacy and safety of unfractionated heparin in the treatment of ulcerative colitis in comparison with methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:12405248': {'publication date': '2002 Sep', 'sentence': 'AIM: To evaluate the efficacy of Infliximab in the treatment of severe ulcerative colitis refractory to conventional therapy PATIENTS AND METHODS: A series of 13 patients with severe ulcerative colitis, refractory to therapy with methyl-prednisolone, 60 mg daily for seven or more days, were treated with a single intravenous infusion of Infliximab 5 mg/kg.', 'subject score': 1000, 'object score': 901}, 'PMID:15638237': {'publication date': '2004 Sep-Oct', 'sentence': 'Thirteen patients with severe UC, refractory to therapy with methyl-prednisolone, 60 mg IV daily were treated with a single intravenous infusion of Infliximab 5 mg/kg.', 'subject score': 1000, 'object score': 901}, 'PMID:16937542': {'publication date': '2006 Aug 28', 'sentence': 'Being diagnosed as having severe active left-side UC, she was successfully treated with intravenous methylprednisolone followed by prednisolone and leukocytapheresis.', 'subject score': 888, 'object score': 839}, 'PMID:18823440': {'publication date': '2008 Nov', 'sentence': 'CONCLUSION: GCAP results were superior to MP for the treatment of UC, even though no statistically significant difference was observed.', 'subject score': 1000, 'object score': 1000}, 'PMID:19399380': {'publication date': '2010 Jan', 'sentence': 'We report a 48-year-old male diagnosed with ulcerative colitis in 1995, who received long-term methylprednisolone therapy.', 'subject score': 861, 'object score': 1000}, 'PMID:2303687': {'publication date': '1990 Feb', 'sentence': 'High-dose methylprednisolone in the treatment of active ulcerative colitis.', 'subject score': 901, 'object score': 901}, 'PMID:25405041': {'publication date': '2014', 'sentence': 'After a complicated hospital course, she was eventually diagnosed with ulcerative colitis and enteropathic arthritis, treated with intravenous methylprednisolone, mesalamine, and infliximab which resulted in resolution of her symptoms.', 'subject score': 888, 'object score': 1000}, 'PMID:34720954': {'publication date': '2021', 'sentence': 'His UC was managed with methylprednisolone (60 mg IV daily), proton pump inhibitors, mesalamine, ciprofloxacin, and metronidazole.', 'subject score': 1000, 'object score': 1000}, 'PMID:35339135': {'publication date': '2022 03', 'sentence': 'Here, we report a case of mucocutaneous pyoderma gangrenosum as a preceding sign of ulcerative colitis that responded to treatment with methylprednisolone and infliximab.', 'subject score': 1000, 'object score': 1000}, 'PMID:9552221': {'publication date': '1998 Feb', 'sentence': 'To this end, we performed a randomized, 5-day study with either oral enterically coated amoxicillin-clavulanic acid (1 g + 250 mg, t.i.d.); i.v. methylprednisolone (40 mg/day) and oral placebo (t.i.d.); or both i.v. methylprednisolone and oral amoxicillin-clavulanic acid as above, in 30 patients with clinically active ulcerative colitis.', 'subject score': 827, 'object score': 824}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8503951",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:11040177",
-                "PMID:12405248",
-                "PMID:15638237",
-                "PMID:16937542",
-                "PMID:18823440",
-                "PMID:19399380",
-                "PMID:2303687",
-                "PMID:25405041",
-                "PMID:34720954",
-                "PMID:35339135",
-                "PMID:9552221"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11008357': {'publication date': '2000 May', 'sentence': 'Post partum acute renal failure and type IV lupus nephropathy were treated with hemodialysis, methylprednisolone, cyclophosphamide and prednisone.', 'subject score': 1000, 'object score': 824}, 'PMID:11322372': {'publication date': '2001 Mar', 'sentence': 'Although much of the interest in pulse methylprednisolone therapy (PMT) has centered around its use in children with focal segmental glomerulosclerosis, PMT has also been shown to be effective in the treatment of other proteinuric renal diseases.', 'subject score': 790, 'object score': 877}, 'PMID:11533799': {'publication date': '2000 Mar', 'sentence': 'All the patients received steroids, 95% (73) in the form of prednisolone and 5% in the form of methylprednisolone; cytotoxics either cyclophosphamide or azathioprine mainly for renal disease were prescribed to 25 patients, Complications were hypertension (18 patients), renal failure (7 patients), cerebral vascular disease (3 patients).', 'subject score': 1000, 'object score': 1000}, 'PMID:1680256': {'publication date': '1991 Jun', 'sentence': 'Marked improvement, incl. improvement of the nephropathy, was recorded after pulsed treatment with methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:18408582': {'publication date': '2008 Apr 15', 'sentence': 'Management of BKN involved reducing immunosuppression; cidofovir was used in two patients and methylprednisolone in five for acute rejection.', 'subject score': 1000, 'object score': 861}, 'PMID:21902765': {'publication date': '2011 Dec', 'sentence': 'As to the treatment of IgAN and HSPN, we evaluated the efficacy of multidrug combination therapy (prednisolone, warfarin, and dipyridamole, including mizoribine) for diffuse IgAN and the efficacy of methylprednisolone and urokinase pulse therapy plus immunosuppressive drugs for severe HSPN in children.', 'subject score': 1000, 'object score': 901}, 'PMID:2332864': {'publication date': '1990 Mar', 'sentence': \"Intravenous pulse methylprednisolone for the treatment of a child with Sjogren's nephropathy.\", 'subject score': 802, 'object score': 861}, 'PMID:27234773': {'publication date': '2016 Apr', 'sentence': 'OBJECTIVE: We report the clinical course and pathologic findings of a kidney transplant donor who was diagnosed with immunoglobulin A (IgA) nephropathy by means of preimplantation biopsy and was later treated with methylprednisolone and tonsillectomy.', 'subject score': 1000, 'object score': 901}, 'PMID:32168938': {'publication date': '2020 Mar 11', 'sentence': 'Methylprednisolone (MP) is often used in the treatment of various kidney diseases, but overcoming the systemic side effects caused by its nonspecific distribution in the body is a challenge.', 'subject score': 1000, 'object score': 901}, 'PMID:33243202': {'publication date': '2020 Nov 26', 'sentence': 'RESULTS: It was found that all 7 patients had been receiving methylprednisolone for renal disease at a median dose of 20 mg per day and a median duration of 4 months before developing nocardiosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:35845574': {'publication date': '2022', 'sentence': 'Conclusion: The clinical efficacy of Huangkui capsule plus methylprednisolone in the treatment of patients with nephropathy is remarkable.', 'subject score': 775, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319192,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-          "name": "kidney disorder",
-          "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D007674",
-            "MEDDRA:10029154",
-            "UMLS:C0022658",
-            "NCIT:C3149",
-            "MONDO:0005240",
-            "UMLS:C1408258",
-            "DOID:557",
-            "MEDDRA:10029149",
-            "HP:0000112",
-            "MEDDRA:10051051",
-            "NCIT:C34843",
-            "MEDDRA:10038428",
-            "MEDDRA:10038429",
-            "MEDDRA:10029151",
-            "MEDDRA:10051052",
-            "EFO:0003086",
-            "SNOMEDCT:90708001",
-            "MEDDRA:10013263",
-            "PSY:27347"
-          ],
-          "id": "MONDO:0005240",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Kidney damage",
-            "kidney disease",
-            "Nephropathy",
-            "Kidney Diseases",
-            "Kidney Disorder",
-            "kidney disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319192,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005240",
-              "name": "kidney disorder",
-              "description": "A term referring to any disease affecting the kidneys.; A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).; Pathological processes of the KIDNEY or its component tissues.; A nonspecific term referring to disease or damage of the kidneys. [HPO:curators]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D007674",
-                "MEDDRA:10029154",
-                "UMLS:C0022658",
-                "NCIT:C3149",
-                "MONDO:0005240",
-                "UMLS:C1408258",
-                "DOID:557",
-                "MEDDRA:10029149",
-                "HP:0000112",
-                "MEDDRA:10051051",
-                "NCIT:C34843",
-                "MEDDRA:10038428",
-                "MEDDRA:10038429",
-                "MEDDRA:10029151",
-                "MEDDRA:10051052",
-                "EFO:0003086",
-                "SNOMEDCT:90708001",
-                "MEDDRA:10013263",
-                "PSY:27347"
-              ],
-              "id": "MONDO:0005240",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Kidney damage",
-                "kidney disease",
-                "Nephropathy",
-                "Kidney Diseases",
-                "Kidney Disorder",
-                "kidney disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/kidneydiseases.htm",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8285148,
-            "start": 570,
-            "end": 319192,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11008357': {'publication date': '2000 May', 'sentence': 'Post partum acute renal failure and type IV lupus nephropathy were treated with hemodialysis, methylprednisolone, cyclophosphamide and prednisone.', 'subject score': 1000, 'object score': 824}, 'PMID:11322372': {'publication date': '2001 Mar', 'sentence': 'Although much of the interest in pulse methylprednisolone therapy (PMT) has centered around its use in children with focal segmental glomerulosclerosis, PMT has also been shown to be effective in the treatment of other proteinuric renal diseases.', 'subject score': 790, 'object score': 877}, 'PMID:11533799': {'publication date': '2000 Mar', 'sentence': 'All the patients received steroids, 95% (73) in the form of prednisolone and 5% in the form of methylprednisolone; cytotoxics either cyclophosphamide or azathioprine mainly for renal disease were prescribed to 25 patients, Complications were hypertension (18 patients), renal failure (7 patients), cerebral vascular disease (3 patients).', 'subject score': 1000, 'object score': 1000}, 'PMID:1680256': {'publication date': '1991 Jun', 'sentence': 'Marked improvement, incl. improvement of the nephropathy, was recorded after pulsed treatment with methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:18408582': {'publication date': '2008 Apr 15', 'sentence': 'Management of BKN involved reducing immunosuppression; cidofovir was used in two patients and methylprednisolone in five for acute rejection.', 'subject score': 1000, 'object score': 861}, 'PMID:21902765': {'publication date': '2011 Dec', 'sentence': 'As to the treatment of IgAN and HSPN, we evaluated the efficacy of multidrug combination therapy (prednisolone, warfarin, and dipyridamole, including mizoribine) for diffuse IgAN and the efficacy of methylprednisolone and urokinase pulse therapy plus immunosuppressive drugs for severe HSPN in children.', 'subject score': 1000, 'object score': 901}, 'PMID:2332864': {'publication date': '1990 Mar', 'sentence': \"Intravenous pulse methylprednisolone for the treatment of a child with Sjogren's nephropathy.\", 'subject score': 802, 'object score': 861}, 'PMID:27234773': {'publication date': '2016 Apr', 'sentence': 'OBJECTIVE: We report the clinical course and pathologic findings of a kidney transplant donor who was diagnosed with immunoglobulin A (IgA) nephropathy by means of preimplantation biopsy and was later treated with methylprednisolone and tonsillectomy.', 'subject score': 1000, 'object score': 901}, 'PMID:32168938': {'publication date': '2020 Mar 11', 'sentence': 'Methylprednisolone (MP) is often used in the treatment of various kidney diseases, but overcoming the systemic side effects caused by its nonspecific distribution in the body is a challenge.', 'subject score': 1000, 'object score': 901}, 'PMID:33243202': {'publication date': '2020 Nov 26', 'sentence': 'RESULTS: It was found that all 7 patients had been receiving methylprednisolone for renal disease at a median dose of 20 mg per day and a median duration of 4 months before developing nocardiosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:35845574': {'publication date': '2022', 'sentence': 'Conclusion: The clinical efficacy of Huangkui capsule plus methylprednisolone in the treatment of patients with nephropathy is remarkable.', 'subject score': 775, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0022658---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8464737",
-              "object": "MONDO:0005240",
-              "publications": [
-                "PMID:11008357",
-                "PMID:11322372",
-                "PMID:11533799",
-                "PMID:1680256",
-                "PMID:18408582",
-                "PMID:21902765",
-                "PMID:2332864",
-                "PMID:27234773",
-                "PMID:32168938",
-                "PMID:33243202",
-                "PMID:35845574"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:8406379': {'publication date': '1993', 'sentence': 'Pharmacokinetics of high dose methylprednisolone and use in hematological malignancies.', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 315771,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002334",
-          "name": "hematopoietic and lymphoid system neoplasm",
-          "description": "A neoplasm arising from hematopoietic cells found in the bone marrow, peripheral blood, lymph nodes and spleen (organs of the hematopoietic system). Hematopoietic cell neoplasms can also involve other anatomic sites (e.g. central nervous system, gastrointestinal tract), either by metastasis, direct tumor infiltration, or neoplastic transformation of extranodal lymphoid tissues. The commonest forms are the various types of leukemia, Hodgkin and non-Hodgkin lymphomas, and myelodysplastic syndromes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C27134\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C27134\" NCI Thesaurus); A neoplasm arising from hematopoietic cells found in the bone marrow, peripheral blood, lymph nodes and spleen (organs of the hematopoietic system). Hematopoietic cell neoplasms can also involve other anatomic sites (e.g. central nervous system, gastrointestinal tract), either by metastasis, direct tumor infiltration, or neoplastic transformation of extranodal lymphoid tissues. The commonest forms are the various types of leukemia, Hodgkin and non-Hodgkin lymphomas, myeloproliferative neoplasms, and myelodysplastic syndromes.; Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.; Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). [http://www.ncbi.nlm.nih.gov/mesh?term=Hematologic%20Neoplasms]; A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10086808",
-            "HP:0004377",
-            "NCIT:C35813",
-            "MEDDRA:10061187",
-            "UMLS:C0376544",
-            "MEDDRA:10018864",
-            "SNOMEDCT:129154003",
-            "MEDDRA:10086698",
-            "SNOMEDCT:414644002",
-            "SNOMEDCT:414388001",
-            "UMLS:C1512393",
-            "MEDDRA:10066481",
-            "MEDDRA:10061195",
-            "DOID:2531",
-            "SNOMEDCT:269475001",
-            "MONDO:0002334",
-            "MESH:D019337",
-            "UMLS:C0348393",
-            "UMLS:C0376545",
-            "MEDDRA:10066476"
-          ],
-          "id": "MONDO:0002334",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hematologic cancer",
-            "Malignant tumor of lymphoid hemopoietic and related tissue",
-            "Hematopoietic Neoplasms",
-            "Hematologic Neoplasms",
-            "Hematopoietic and Lymphoid System Neoplasm",
-            "Hematological neoplasm",
-            "hematopoietic and lymphoid system neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.ncbi.nlm.nih.gov/mesh?term=hematologic%20neoplasms",
-            "http://en.wikipedia.org/wiki/blood_cance",
-            "http://www.cancer.gov/dictionary/?cdrid=45708"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315771,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002334",
-              "name": "hematopoietic and lymphoid system neoplasm",
-              "description": "A neoplasm arising from hematopoietic cells found in the bone marrow, peripheral blood, lymph nodes and spleen (organs of the hematopoietic system). Hematopoietic cell neoplasms can also involve other anatomic sites (e.g. central nervous system, gastrointestinal tract), either by metastasis, direct tumor infiltration, or neoplastic transformation of extranodal lymphoid tissues. The commonest forms are the various types of leukemia, Hodgkin and non-Hodgkin lymphomas, and myelodysplastic syndromes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C27134\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C27134\" NCI Thesaurus); A neoplasm arising from hematopoietic cells found in the bone marrow, peripheral blood, lymph nodes and spleen (organs of the hematopoietic system). Hematopoietic cell neoplasms can also involve other anatomic sites (e.g. central nervous system, gastrointestinal tract), either by metastasis, direct tumor infiltration, or neoplastic transformation of extranodal lymphoid tissues. The commonest forms are the various types of leukemia, Hodgkin and non-Hodgkin lymphomas, myeloproliferative neoplasms, and myelodysplastic syndromes.; Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.; Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). [http://www.ncbi.nlm.nih.gov/mesh?term=Hematologic%20Neoplasms]; A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10086808",
-                "HP:0004377",
-                "NCIT:C35813",
-                "MEDDRA:10061187",
-                "UMLS:C0376544",
-                "MEDDRA:10018864",
-                "SNOMEDCT:129154003",
-                "MEDDRA:10086698",
-                "SNOMEDCT:414644002",
-                "SNOMEDCT:414388001",
-                "UMLS:C1512393",
-                "MEDDRA:10066481",
-                "MEDDRA:10061195",
-                "DOID:2531",
-                "SNOMEDCT:269475001",
-                "MONDO:0002334",
-                "MESH:D019337",
-                "UMLS:C0348393",
-                "UMLS:C0376545",
-                "MEDDRA:10066476"
-              ],
-              "id": "MONDO:0002334",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hematologic cancer",
-                "Malignant tumor of lymphoid hemopoietic and related tissue",
-                "Hematopoietic Neoplasms",
-                "Hematologic Neoplasms",
-                "Hematopoietic and Lymphoid System Neoplasm",
-                "Hematological neoplasm",
-                "hematopoietic and lymphoid system neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.ncbi.nlm.nih.gov/mesh?term=hematologic%20neoplasms",
-                "http://en.wikipedia.org/wiki/blood_cance",
-                "http://www.cancer.gov/dictionary/?cdrid=45708"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26507654,
-            "start": 570,
-            "end": 315771,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8406379': {'publication date': '1993', 'sentence': 'Pharmacokinetics of high dose methylprednisolone and use in hematological malignancies.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0376545---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "26974005",
-              "object": "MONDO:0002334",
-              "publications": [
-                "PMID:8406379"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:22029719': {'publication date': '2012 Jan', 'sentence': \"Methylprednisolone and hepatotoxicity in Graves' ophthalmopathy.\", 'subject score': 1000, 'object score': 1000}, 'PMID:30540214': {'publication date': '2019 Oct', 'sentence': 'Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease.', 'subject score': 840, 'object score': 875}, 'PMID:37176682': {'publication date': '2023 May 01', 'sentence': 'Efficacy and Safety of 6-Weekly versus 12-Weekly Intravenous Methylprednisolone in Moderate-to-Severe Active Thyroid-Associated Ophthalmopathy.', 'subject score': 775, 'object score': 863}}",
-    "p2": {
-      "start": {
-        "identity": 526461,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001509",
-          "name": "endocrine exophthalmos",
-          "description": "An autoimmune disorder of the EYE, occurring in patients with Graves disease. Subtypes include congestive (inflammation of the orbital connective tissue), myopathic (swelling and dysfunction of the extraocular muscles), and mixed congestive-myopathic ophthalmopathy.",
-          "equivalent_curies": [
-            "DOID:0081120",
-            "SNOMEDCT:276177000",
-            "ICD9:376.2",
-            "MESH:D049970",
-            "UMLS:C0339143",
-            "MONDO:0001509",
-            "MEDDRA:10084358",
-            "UMLS:C0155264",
-            "DOID:12359",
-            "MEDDRA:10014702",
-            "MEDDRA:10057889",
-            "MEDDRA:10060742",
-            "MEDDRA:10015684",
-            "EFO:1001466"
-          ],
-          "id": "MONDO:0001509",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Graves ophthalmopathy",
-            "Endocrine exophthalmos",
-            "Thyroid associated opthalmopathies",
-            "endocrine exophthalmos",
-            "Graves Ophthalmopathy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:20181974",
-            "https://orcid.org/0000-0001-7151-1615",
-            "https://en.wikipedia.org/wiki/graves%27_ophthalmopathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526461,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001509",
-              "name": "endocrine exophthalmos",
-              "description": "An autoimmune disorder of the EYE, occurring in patients with Graves disease. Subtypes include congestive (inflammation of the orbital connective tissue), myopathic (swelling and dysfunction of the extraocular muscles), and mixed congestive-myopathic ophthalmopathy.",
-              "equivalent_curies": [
-                "DOID:0081120",
-                "SNOMEDCT:276177000",
-                "ICD9:376.2",
-                "MESH:D049970",
-                "UMLS:C0339143",
-                "MONDO:0001509",
-                "MEDDRA:10084358",
-                "UMLS:C0155264",
-                "DOID:12359",
-                "MEDDRA:10014702",
-                "MEDDRA:10057889",
-                "MEDDRA:10060742",
-                "MEDDRA:10015684",
-                "EFO:1001466"
-              ],
-              "id": "MONDO:0001509",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Graves ophthalmopathy",
-                "Endocrine exophthalmos",
-                "Thyroid associated opthalmopathies",
-                "endocrine exophthalmos",
-                "Graves Ophthalmopathy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:20181974",
-                "https://orcid.org/0000-0001-7151-1615",
-                "https://en.wikipedia.org/wiki/graves%27_ophthalmopathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15609821,
-            "start": 570,
-            "end": 526461,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22029719': {'publication date': '2012 Jan', 'sentence': \"Methylprednisolone and hepatotoxicity in Graves' ophthalmopathy.\", 'subject score': 1000, 'object score': 1000}, 'PMID:30540214': {'publication date': '2019 Oct', 'sentence': 'Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease.', 'subject score': 840, 'object score': 875}, 'PMID:37176682': {'publication date': '2023 May 01', 'sentence': 'Efficacy and Safety of 6-Weekly versus 12-Weekly Intravenous Methylprednisolone in Moderate-to-Severe Active Thyroid-Associated Ophthalmopathy.', 'subject score': 775, 'object score': 863}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0339143---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "15936572",
-              "object": "MONDO:0001509",
-              "publications": [
-                "PMID:22029719",
-                "PMID:30540214",
-                "PMID:37176682"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11089418': {'publication date': '2000 May-Jun', 'sentence': \"PATIENTS AND METHODS: Fourteen euthyroid patients with severe Graves' ophthalmopathy were treated with high-dose intravenous methylprednisolone during 6 months and followed-up for 24-48 months by clinical and ophthalmological assessment.\", 'subject score': 861, 'object score': 901}, 'PMID:1345455': {'publication date': '1992', 'sentence': \"Combined cyclosporin-A and methylprednisolone treatment of Graves' ophthalmopathy.\", 'subject score': 888, 'object score': 1000}, 'PMID:15510744': {'publication date': '2002 Sep', 'sentence': \"METHODS: Using enzyme linked immunosorbent assay (ELISA) systems, we measured serum concentrations of IL-1alpha, IL-1beta and sIL-1ra in 18 normal controls, 20 active GO, 20 inactive GO, 18 Graves' disease(GD) on patients without ophthalmopathy and 10 active GO patients after high-dose IV methylprednisolone therapy.\", 'subject score': 840, 'object score': 798}, 'PMID:1582520': {'publication date': '1992 Mar 20', 'sentence': \"Fifteen patients with Graves' ophthalmopathy (GO) were treated with intravenous methylprednisolone (steroid pulse therapy, 1g daily for 3 days a week, 2-4 times) and followed up by ophthalmological assessment and magnetic resonance imaging (MRI).\", 'subject score': 888, 'object score': 1000}, 'PMID:15936323': {'publication date': '2005 Jun', 'sentence': \"Early effects of methylprednisolone infusion on serum cystatin C in patients with severe Graves' ophthalmopathy.\", 'subject score': 888, 'object score': 901}, 'PMID:16117697': {'publication date': '2005 Aug', 'sentence': 'CONCLUSIONS: High-dose, pulsed intravenous MP is an effective medical treatment for severe TAO.', 'subject score': 888, 'object score': 908}, 'PMID:16791713': {'publication date': '2006 Apr', 'sentence': \"Acute myocardial infarction during high-dose methylprednisolone therapy for Graves' ophthalmopathy.\", 'subject score': 861, 'object score': 1000}, 'PMID:17465867': {'publication date': '2007 Apr', 'sentence': 'CONCLUSION: IVMP in GO patients causes dose-dependent liver damage by a direct toxic effect of glucocorticoids on hepatocytes.', 'subject score': 851, 'object score': 901}, 'PMID:1920963': {'publication date': '1991 May-Jun', 'sentence': 'We report a case of minimal thyroid ophthalmopathy treated with intravenous methylprednisolone, in which precise identification of the involved muscle was possible with the use of surface coil magnetic resonance (MR) imaging.', 'subject score': 888, 'object score': 901}, 'PMID:19627724': {'publication date': '2009 Mar', 'sentence': 'CONCLUSIONS: The treatment of GO with MTPiv is safe and effective, with a lower recurrence rate when using dosing regimen A.', 'subject score': 1000, 'object score': 1000}, 'PMID:22811284': {'publication date': '2012', 'sentence': 'PATIENTS AND RESEARCH DESIGN: Nine patients with severe and active GO were treated with high-dose methylprednisolone (1 g day(-1) three times within 1 week, then 0.5 g day(-1) seven times for 2 weeks) combined with plasma filtration (twice a week in weeks 1, 2, 4, 7, and 10).', 'subject score': 901, 'object score': 901}, 'PMID:24251142': {'publication date': '2013 Oct', 'sentence': \"Pulse dexamethasone therapy versus pulse methylprednisolone therapy for treatment of Graves's ophthalmopathy.\", 'subject score': 790, 'object score': 1000}, 'PMID:27853049': {'publication date': '2017 Feb 27', 'sentence': \"The intravenous methylprednisolone (iv MP) strategy for Graves' ophthalmopathy (GO) and evaluation of its activity against the disease warrants further exploration.\", 'subject score': 851, 'object score': 1000}, 'PMID:2906260': {'publication date': '1988 Dec 17', 'sentence': \"Eleven euthyroid patients with severe Graves' eye disease were treated with intravenous methylprednisolone and followed up for six months or more by ophthalmological assessment, orbital computed tomography (CT), photographs, and antibody measurements.\", 'subject score': 888, 'object score': 916}, 'PMID:30103255': {'publication date': '2018 Dec', 'sentence': 'CONCLUSION: This study suggests that the initiation of an SSA, using methotrexate as first-line, with limited adjuvant IVMP is an effective and safe treatment for moderate-to-severely active TED, resulting in a significant reduction in both disease activity and total steroid load.', 'subject score': 833, 'object score': 789}, 'PMID:30540214': {'publication date': '2019 Oct', 'sentence': 'Conclusion: With adequate screening and follow-up, six repeated cycles of high dose pulsed IVMP is an effective treatment for TED and can significantly reduce the morbidity associated with this debilitating condition.', 'subject score': 888, 'object score': 1000}, 'PMID:30624412': {'publication date': '2019', 'sentence': 'PURPOSE: To compare the efficacy and safety of adjunctive oral methotrexate with intravenous pulsed methylprednisolone against methylprednisolone alone in the treatment of severe thyroid eye disease.', 'subject score': 1000, 'object score': 916}, 'PMID:31890036': {'publication date': '2019', 'sentence': 'We also present recommendations and precautions which should be taken prior to initiation of intravenous pulses of methylprednisolone treatment for GO.', 'subject score': 888, 'object score': 1000}, 'PMID:32537950': {'publication date': '2020 Jun 15', 'sentence': 'We included 54 active moderate-to-severe GO patients treated with 4.5 g intravenous MPD over 12 weeks between November 2011 and November 2018.', 'subject score': 840, 'object score': 833}, 'PMID:32595602': {'publication date': '2020', 'sentence': \"Objective:     To evaluate the recurrence rate in Graves' patients who, in addition to standard ATD, were treated or not treated with parenteral methylprednisolone (MPDS) for GO.\", 'subject score': 861, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 526461,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001509",
-          "name": "endocrine exophthalmos",
-          "description": "An autoimmune disorder of the EYE, occurring in patients with Graves disease. Subtypes include congestive (inflammation of the orbital connective tissue), myopathic (swelling and dysfunction of the extraocular muscles), and mixed congestive-myopathic ophthalmopathy.",
-          "equivalent_curies": [
-            "DOID:0081120",
-            "SNOMEDCT:276177000",
-            "ICD9:376.2",
-            "MESH:D049970",
-            "UMLS:C0339143",
-            "MONDO:0001509",
-            "MEDDRA:10084358",
-            "UMLS:C0155264",
-            "DOID:12359",
-            "MEDDRA:10014702",
-            "MEDDRA:10057889",
-            "MEDDRA:10060742",
-            "MEDDRA:10015684",
-            "EFO:1001466"
-          ],
-          "id": "MONDO:0001509",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Graves ophthalmopathy",
-            "Endocrine exophthalmos",
-            "Thyroid associated opthalmopathies",
-            "endocrine exophthalmos",
-            "Graves Ophthalmopathy"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:20181974",
-            "https://orcid.org/0000-0001-7151-1615",
-            "https://en.wikipedia.org/wiki/graves%27_ophthalmopathy"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526461,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001509",
-              "name": "endocrine exophthalmos",
-              "description": "An autoimmune disorder of the EYE, occurring in patients with Graves disease. Subtypes include congestive (inflammation of the orbital connective tissue), myopathic (swelling and dysfunction of the extraocular muscles), and mixed congestive-myopathic ophthalmopathy.",
-              "equivalent_curies": [
-                "DOID:0081120",
-                "SNOMEDCT:276177000",
-                "ICD9:376.2",
-                "MESH:D049970",
-                "UMLS:C0339143",
-                "MONDO:0001509",
-                "MEDDRA:10084358",
-                "UMLS:C0155264",
-                "DOID:12359",
-                "MEDDRA:10014702",
-                "MEDDRA:10057889",
-                "MEDDRA:10060742",
-                "MEDDRA:10015684",
-                "EFO:1001466"
-              ],
-              "id": "MONDO:0001509",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Graves ophthalmopathy",
-                "Endocrine exophthalmos",
-                "Thyroid associated opthalmopathies",
-                "endocrine exophthalmos",
-                "Graves Ophthalmopathy"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:20181974",
-                "https://orcid.org/0000-0001-7151-1615",
-                "https://en.wikipedia.org/wiki/graves%27_ophthalmopathy"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8380125,
-            "start": 570,
-            "end": 526461,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11089418': {'publication date': '2000 May-Jun', 'sentence': \"PATIENTS AND METHODS: Fourteen euthyroid patients with severe Graves' ophthalmopathy were treated with high-dose intravenous methylprednisolone during 6 months and followed-up for 24-48 months by clinical and ophthalmological assessment.\", 'subject score': 861, 'object score': 901}, 'PMID:1345455': {'publication date': '1992', 'sentence': \"Combined cyclosporin-A and methylprednisolone treatment of Graves' ophthalmopathy.\", 'subject score': 888, 'object score': 1000}, 'PMID:15510744': {'publication date': '2002 Sep', 'sentence': \"METHODS: Using enzyme linked immunosorbent assay (ELISA) systems, we measured serum concentrations of IL-1alpha, IL-1beta and sIL-1ra in 18 normal controls, 20 active GO, 20 inactive GO, 18 Graves' disease(GD) on patients without ophthalmopathy and 10 active GO patients after high-dose IV methylprednisolone therapy.\", 'subject score': 840, 'object score': 798}, 'PMID:1582520': {'publication date': '1992 Mar 20', 'sentence': \"Fifteen patients with Graves' ophthalmopathy (GO) were treated with intravenous methylprednisolone (steroid pulse therapy, 1g daily for 3 days a week, 2-4 times) and followed up by ophthalmological assessment and magnetic resonance imaging (MRI).\", 'subject score': 888, 'object score': 1000}, 'PMID:15936323': {'publication date': '2005 Jun', 'sentence': \"Early effects of methylprednisolone infusion on serum cystatin C in patients with severe Graves' ophthalmopathy.\", 'subject score': 888, 'object score': 901}, 'PMID:16117697': {'publication date': '2005 Aug', 'sentence': 'CONCLUSIONS: High-dose, pulsed intravenous MP is an effective medical treatment for severe TAO.', 'subject score': 888, 'object score': 908}, 'PMID:16791713': {'publication date': '2006 Apr', 'sentence': \"Acute myocardial infarction during high-dose methylprednisolone therapy for Graves' ophthalmopathy.\", 'subject score': 861, 'object score': 1000}, 'PMID:17465867': {'publication date': '2007 Apr', 'sentence': 'CONCLUSION: IVMP in GO patients causes dose-dependent liver damage by a direct toxic effect of glucocorticoids on hepatocytes.', 'subject score': 851, 'object score': 901}, 'PMID:1920963': {'publication date': '1991 May-Jun', 'sentence': 'We report a case of minimal thyroid ophthalmopathy treated with intravenous methylprednisolone, in which precise identification of the involved muscle was possible with the use of surface coil magnetic resonance (MR) imaging.', 'subject score': 888, 'object score': 901}, 'PMID:19627724': {'publication date': '2009 Mar', 'sentence': 'CONCLUSIONS: The treatment of GO with MTPiv is safe and effective, with a lower recurrence rate when using dosing regimen A.', 'subject score': 1000, 'object score': 1000}, 'PMID:22811284': {'publication date': '2012', 'sentence': 'PATIENTS AND RESEARCH DESIGN: Nine patients with severe and active GO were treated with high-dose methylprednisolone (1 g day(-1) three times within 1 week, then 0.5 g day(-1) seven times for 2 weeks) combined with plasma filtration (twice a week in weeks 1, 2, 4, 7, and 10).', 'subject score': 901, 'object score': 901}, 'PMID:24251142': {'publication date': '2013 Oct', 'sentence': \"Pulse dexamethasone therapy versus pulse methylprednisolone therapy for treatment of Graves's ophthalmopathy.\", 'subject score': 790, 'object score': 1000}, 'PMID:27853049': {'publication date': '2017 Feb 27', 'sentence': \"The intravenous methylprednisolone (iv MP) strategy for Graves' ophthalmopathy (GO) and evaluation of its activity against the disease warrants further exploration.\", 'subject score': 851, 'object score': 1000}, 'PMID:2906260': {'publication date': '1988 Dec 17', 'sentence': \"Eleven euthyroid patients with severe Graves' eye disease were treated with intravenous methylprednisolone and followed up for six months or more by ophthalmological assessment, orbital computed tomography (CT), photographs, and antibody measurements.\", 'subject score': 888, 'object score': 916}, 'PMID:30103255': {'publication date': '2018 Dec', 'sentence': 'CONCLUSION: This study suggests that the initiation of an SSA, using methotrexate as first-line, with limited adjuvant IVMP is an effective and safe treatment for moderate-to-severely active TED, resulting in a significant reduction in both disease activity and total steroid load.', 'subject score': 833, 'object score': 789}, 'PMID:30540214': {'publication date': '2019 Oct', 'sentence': 'Conclusion: With adequate screening and follow-up, six repeated cycles of high dose pulsed IVMP is an effective treatment for TED and can significantly reduce the morbidity associated with this debilitating condition.', 'subject score': 888, 'object score': 1000}, 'PMID:30624412': {'publication date': '2019', 'sentence': 'PURPOSE: To compare the efficacy and safety of adjunctive oral methotrexate with intravenous pulsed methylprednisolone against methylprednisolone alone in the treatment of severe thyroid eye disease.', 'subject score': 1000, 'object score': 916}, 'PMID:31890036': {'publication date': '2019', 'sentence': 'We also present recommendations and precautions which should be taken prior to initiation of intravenous pulses of methylprednisolone treatment for GO.', 'subject score': 888, 'object score': 1000}, 'PMID:32537950': {'publication date': '2020 Jun 15', 'sentence': 'We included 54 active moderate-to-severe GO patients treated with 4.5 g intravenous MPD over 12 weeks between November 2011 and November 2018.', 'subject score': 840, 'object score': 833}, 'PMID:32595602': {'publication date': '2020', 'sentence': \"Objective:     To evaluate the recurrence rate in Graves' patients who, in addition to standard ATD, were treated or not treated with parenteral methylprednisolone (MPDS) for GO.\", 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0339143---SEMMEDDB:",
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0155264---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8562694",
-              "object": "MONDO:0001509",
-              "publications": [
-                "PMID:2906260",
-                "PMID:36811756",
-                "PMID:31890036",
-                "PMID:30624412",
-                "PMID:35831587",
-                "PMID:27853049",
-                "PMID:1582520",
-                "PMID:16791713",
-                "PMID:33439464",
-                "PMID:33539318",
-                "PMID:17465867",
-                "PMID:1345455",
-                "PMID:35175298",
-                "PMID:16117697",
-                "PMID:24251142",
-                "PMID:30540214",
-                "PMID:19627724",
-                "PMID:32537950",
-                "PMID:30103255",
-                "PMID:20393724"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:356593': {'publication date': '1978 Apr', 'sentence': 'A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 526144,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001505",
-          "name": "alcoholic hepatitis",
-          "description": "Inflammation of the liver resulting from ingestion of alcohol.; INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.",
-          "equivalent_curies": [
-            "MONDO:0001505",
-            "MEDDRA:10000649",
-            "ICD9:571.1",
-            "SNOMEDCT:235875008",
-            "MEDDRA:10019728",
-            "MESH:D006519",
-            "NCIT:C34352",
-            "UMLS:C0019187",
-            "EFO:1001345",
-            "UMLS:C0001306",
-            "DOID:12351",
-            "NCIT:C34684",
-            "MEDDRA:10001624",
-            "SNOMEDCT:9953008"
-          ],
-          "id": "MONDO:0001505",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute alcoholic hepatitis",
-            "alcoholic hepatitis",
-            "Alcoholic Hepatitis",
-            "Acute Alcoholic Hepatitis",
-            "Acute alcoholic liver disease",
-            "Hepatitis, Alcoholic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526144,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001505",
-              "name": "alcoholic hepatitis",
-              "description": "Inflammation of the liver resulting from ingestion of alcohol.; INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.",
-              "equivalent_curies": [
-                "MONDO:0001505",
-                "MEDDRA:10000649",
-                "ICD9:571.1",
-                "SNOMEDCT:235875008",
-                "MEDDRA:10019728",
-                "MESH:D006519",
-                "NCIT:C34352",
-                "UMLS:C0019187",
-                "EFO:1001345",
-                "UMLS:C0001306",
-                "DOID:12351",
-                "NCIT:C34684",
-                "MEDDRA:10001624",
-                "SNOMEDCT:9953008"
-              ],
-              "id": "MONDO:0001505",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute alcoholic hepatitis",
-                "alcoholic hepatitis",
-                "Alcoholic Hepatitis",
-                "Acute Alcoholic Hepatitis",
-                "Acute alcoholic liver disease",
-                "Hepatitis, Alcoholic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24144289,
-            "start": 570,
-            "end": 526144,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:356593': {'publication date': '1978 Apr', 'sentence': 'A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0001306---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "24586108",
-              "object": "MONDO:0001505",
-              "publications": [
-                "PMID:356593"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:7035299': {'publication date': '1982 Jan', 'sentence': 'Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis.', 'subject score': 888, 'object score': 916}}",
-    "p2": {
-      "start": {
-        "identity": 526144,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001505",
-          "name": "alcoholic hepatitis",
-          "description": "Inflammation of the liver resulting from ingestion of alcohol.; INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.",
-          "equivalent_curies": [
-            "MONDO:0001505",
-            "MEDDRA:10000649",
-            "ICD9:571.1",
-            "SNOMEDCT:235875008",
-            "MEDDRA:10019728",
-            "MESH:D006519",
-            "NCIT:C34352",
-            "UMLS:C0019187",
-            "EFO:1001345",
-            "UMLS:C0001306",
-            "DOID:12351",
-            "NCIT:C34684",
-            "MEDDRA:10001624",
-            "SNOMEDCT:9953008"
-          ],
-          "id": "MONDO:0001505",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute alcoholic hepatitis",
-            "alcoholic hepatitis",
-            "Alcoholic Hepatitis",
-            "Acute Alcoholic Hepatitis",
-            "Acute alcoholic liver disease",
-            "Hepatitis, Alcoholic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 526144,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001505",
-              "name": "alcoholic hepatitis",
-              "description": "Inflammation of the liver resulting from ingestion of alcohol.; INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.",
-              "equivalent_curies": [
-                "MONDO:0001505",
-                "MEDDRA:10000649",
-                "ICD9:571.1",
-                "SNOMEDCT:235875008",
-                "MEDDRA:10019728",
-                "MESH:D006519",
-                "NCIT:C34352",
-                "UMLS:C0019187",
-                "EFO:1001345",
-                "UMLS:C0001306",
-                "DOID:12351",
-                "NCIT:C34684",
-                "MEDDRA:10001624",
-                "SNOMEDCT:9953008"
-              ],
-              "id": "MONDO:0001505",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute alcoholic hepatitis",
-                "alcoholic hepatitis",
-                "Alcoholic Hepatitis",
-                "Acute Alcoholic Hepatitis",
-                "Acute alcoholic liver disease",
-                "Hepatitis, Alcoholic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25880657,
-            "start": 570,
-            "end": 526144,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7035299': {'publication date': '1982 Jan', 'sentence': 'Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis.', 'subject score': 888, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0001306---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "26339812",
-              "object": "MONDO:0001505",
-              "publications": [
-                "PMID:7035299"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10979493': {'publication date': '2000', 'sentence': 'To resolve the controversy over whether corticosteroids promote or inhibit the resolution of sinusitis, we present a prospective study of 80 rabbits with surgically introduced pseudomonal sinusitis that were then treated in one of four arms: control, ceftazidime, methylprednisolone, and ceftazidime with methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:30969044': {'publication date': '2019 Apr 09', 'sentence': 'The diagnosis was changed to GPA and he started treatment with methylprednisolone, rituximab and cyclophosphamide with good response on vision, sinusitis and ulcerations.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 318463,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005961",
-          "name": "sinusitis",
-          "description": "A paranasal sinus disease involving inflammation of the paranasal sinuses resulting from bacterial, fungal, viral infection, allergic or autoimmune issues. Symptoms can include fever, weakness, fatigue, cough and congestion. There may also be mucus drainage in the back of the throat, called postnasal drip.",
-          "equivalent_curies": [
-            "MEDDRA:10040753",
-            "ICD9:461",
-            "MEDDRA:10040745",
-            "MEDDRA:10040756",
-            "MESH:D012852",
-            "ICD10:J01",
-            "MONDO:0005961",
-            "SNOMEDCT:36971009",
-            "NCIT:C35024",
-            "EFO:0007486",
-            "SYMP:0000134",
-            "DOID:0050127",
-            "HP:0000246",
-            "MEDDRA:10078707",
-            "UMLS:C0037199"
-          ],
-          "id": "MONDO:0005961",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute sinusitis",
-            "Sinusitis",
-            "sinusitis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5889-4463",
-            "http://en.wikipedia.org/wiki/sinusitis",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c35024&ns=nci_thesaurus&key=1218436475&b=1&n=n"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318463,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005961",
-              "name": "sinusitis",
-              "description": "A paranasal sinus disease involving inflammation of the paranasal sinuses resulting from bacterial, fungal, viral infection, allergic or autoimmune issues. Symptoms can include fever, weakness, fatigue, cough and congestion. There may also be mucus drainage in the back of the throat, called postnasal drip.",
-              "equivalent_curies": [
-                "MEDDRA:10040753",
-                "ICD9:461",
-                "MEDDRA:10040745",
-                "MEDDRA:10040756",
-                "MESH:D012852",
-                "ICD10:J01",
-                "MONDO:0005961",
-                "SNOMEDCT:36971009",
-                "NCIT:C35024",
-                "EFO:0007486",
-                "SYMP:0000134",
-                "DOID:0050127",
-                "HP:0000246",
-                "MEDDRA:10078707",
-                "UMLS:C0037199"
-              ],
-              "id": "MONDO:0005961",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute sinusitis",
-                "Sinusitis",
-                "sinusitis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5889-4463",
-                "http://en.wikipedia.org/wiki/sinusitis",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c35024&ns=nci_thesaurus&key=1218436475&b=1&n=n"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8236236,
-            "start": 570,
-            "end": 318463,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10979493': {'publication date': '2000', 'sentence': 'To resolve the controversy over whether corticosteroids promote or inhibit the resolution of sinusitis, we present a prospective study of 80 rabbits with surgically introduced pseudomonal sinusitis that were then treated in one of four arms: control, ceftazidime, methylprednisolone, and ceftazidime with methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:30969044': {'publication date': '2019 Apr 09', 'sentence': 'The diagnosis was changed to GPA and he started treatment with methylprednisolone, rituximab and cyclophosphamide with good response on vision, sinusitis and ulcerations.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0037199---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8427466",
-              "object": "MONDO:0005961",
-              "publications": [
-                "PMID:10979493",
-                "PMID:30969044"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:15769918': {'publication date': '2005 Apr', 'sentence': 'Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus.', 'subject score': 888, 'object score': 1000}, 'PMID:2333537': {'publication date': '1990 Feb', 'sentence': 'Methylprednisolone in systemic lupus erythematosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:26629828': {'publication date': '2015', 'sentence': 'The effects of intravenous (IV) high dose methylprednisolone (MP) on Tregs have not yet been described, especially in active SLE.', 'subject score': 861, 'object score': 916}, 'PMID:3289511': {'publication date': '1988 Jun', 'sentence': 'A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus.', 'subject score': 888, 'object score': 1000}, 'PMID:3318723': {'publication date': '1987 Oct', 'sentence': 'A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment.', 'subject score': 872, 'object score': 1000}, 'PMID:7655499': {'publication date': '1995 Jun', 'sentence': 'We conclude that intravenous pulse methylprednisolone and cyclophosphamide therapy improve the prognosis of transverse myelitis associated with SLE but that a careful follow-up is needed to avoid complications due to the illness itself or secondary to the therapy.', 'subject score': 802, 'object score': 1000}, 'PMID:8400470': {'publication date': '1993 Aug', 'sentence': 'The role of magnetic resonance imaging in the diagnosis of intramedullary spinal cord abscess, and methylprednisolone and cyclophosphamide treatment of transverse myelitis in systemic lupus erythematosus are also discussed briefly.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319015,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-          "name": "systemic lupus erythematosus",
-          "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10025133",
-            "KEGG.DISEASE:05322",
-            "MEDDRA:10042820",
-            "PDQ:CDR0000608139",
-            "MEDDRA:10040967",
-            "MEDDRA:10042800",
-            "MEDDRA:10013446",
-            "MONDO:0007915",
-            "MEDDRA:10042945",
-            "MEDDRA:10024067",
-            "ICD10:M32.9",
-            "MEDDRA:10042947",
-            "ORPHANET:536",
-            "MEDDRA:10042944",
-            "UMLS:C0024141",
-            "EFO:0002690",
-            "MESH:D008180",
-            "ICD9:710.0",
-            "DOID:9074",
-            "MEDDRA:10025139",
-            "UMLS:C1835309",
-            "MEDDRA:10024065",
-            "OMIM:152700",
-            "HP:0002725",
-            "MEDDRA:10025142",
-            "NCIT:C3201",
-            "SNOMEDCT:55464009"
-          ],
-          "id": "MONDO:0007915",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Systemic lupus erythematosus",
-            "obsolete_systemic lupus erythematosus",
-            "Systemic lupus erythematosus related phenotypic feature",
-            "Lupus Erythematosus, Systemic",
-            "Excess lmw-dna",
-            "systemic lupus erythematosus",
-            "Systemic Lupus Erythematosus"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319015,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-              "name": "systemic lupus erythematosus",
-              "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10025133",
-                "KEGG.DISEASE:05322",
-                "MEDDRA:10042820",
-                "PDQ:CDR0000608139",
-                "MEDDRA:10040967",
-                "MEDDRA:10042800",
-                "MEDDRA:10013446",
-                "MONDO:0007915",
-                "MEDDRA:10042945",
-                "MEDDRA:10024067",
-                "ICD10:M32.9",
-                "MEDDRA:10042947",
-                "ORPHANET:536",
-                "MEDDRA:10042944",
-                "UMLS:C0024141",
-                "EFO:0002690",
-                "MESH:D008180",
-                "ICD9:710.0",
-                "DOID:9074",
-                "MEDDRA:10025139",
-                "UMLS:C1835309",
-                "MEDDRA:10024065",
-                "OMIM:152700",
-                "HP:0002725",
-                "MEDDRA:10025142",
-                "NCIT:C3201",
-                "SNOMEDCT:55464009"
-              ],
-              "id": "MONDO:0007915",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Systemic lupus erythematosus",
-                "obsolete_systemic lupus erythematosus",
-                "Systemic lupus erythematosus related phenotypic feature",
-                "Lupus Erythematosus, Systemic",
-                "Excess lmw-dna",
-                "systemic lupus erythematosus",
-                "Systemic Lupus Erythematosus"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11469606,
-            "start": 570,
-            "end": 319015,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15769918': {'publication date': '2005 Apr', 'sentence': 'Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus.', 'subject score': 888, 'object score': 1000}, 'PMID:2333537': {'publication date': '1990 Feb', 'sentence': 'Methylprednisolone in systemic lupus erythematosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:26629828': {'publication date': '2015', 'sentence': 'The effects of intravenous (IV) high dose methylprednisolone (MP) on Tregs have not yet been described, especially in active SLE.', 'subject score': 861, 'object score': 916}, 'PMID:3289511': {'publication date': '1988 Jun', 'sentence': 'A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus.', 'subject score': 888, 'object score': 1000}, 'PMID:3318723': {'publication date': '1987 Oct', 'sentence': 'A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment.', 'subject score': 872, 'object score': 1000}, 'PMID:7655499': {'publication date': '1995 Jun', 'sentence': 'We conclude that intravenous pulse methylprednisolone and cyclophosphamide therapy improve the prognosis of transverse myelitis associated with SLE but that a careful follow-up is needed to avoid complications due to the illness itself or secondary to the therapy.', 'subject score': 802, 'object score': 1000}, 'PMID:8400470': {'publication date': '1993 Aug', 'sentence': 'The role of magnetic resonance imaging in the diagnosis of intramedullary spinal cord abscess, and methylprednisolone and cyclophosphamide treatment of transverse myelitis in systemic lupus erythematosus are also discussed briefly.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0024141---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "11720471",
-              "object": "MONDO:0007915",
-              "publications": [
-                "PMID:15769918",
-                "PMID:2333537",
-                "PMID:26629828",
-                "PMID:3289511",
-                "PMID:3318723",
-                "PMID:7655499",
-                "PMID:8400470"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:10908541': {'publication date': '2000', 'sentence': \"REVIEWER'S CONCLUSIONS: Cyclophosphamide regimen treatment is a form of care in neuropsychiatric involvement in systemic lupus erythematosus with no evidence to prove better effectiveness and safety when compared with methylprednisolone.\", 'subject score': 1000, 'object score': 1000}, 'PMID:16625558': {'publication date': '2006 Apr 19', 'sentence': 'Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:23450535': {'publication date': '2013 Feb 28', 'sentence': 'Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319015,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-          "name": "systemic lupus erythematosus",
-          "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10025133",
-            "KEGG.DISEASE:05322",
-            "MEDDRA:10042820",
-            "PDQ:CDR0000608139",
-            "MEDDRA:10040967",
-            "MEDDRA:10042800",
-            "MEDDRA:10013446",
-            "MONDO:0007915",
-            "MEDDRA:10042945",
-            "MEDDRA:10024067",
-            "ICD10:M32.9",
-            "MEDDRA:10042947",
-            "ORPHANET:536",
-            "MEDDRA:10042944",
-            "UMLS:C0024141",
-            "EFO:0002690",
-            "MESH:D008180",
-            "ICD9:710.0",
-            "DOID:9074",
-            "MEDDRA:10025139",
-            "UMLS:C1835309",
-            "MEDDRA:10024065",
-            "OMIM:152700",
-            "HP:0002725",
-            "MEDDRA:10025142",
-            "NCIT:C3201",
-            "SNOMEDCT:55464009"
-          ],
-          "id": "MONDO:0007915",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Systemic lupus erythematosus",
-            "obsolete_systemic lupus erythematosus",
-            "Systemic lupus erythematosus related phenotypic feature",
-            "Lupus Erythematosus, Systemic",
-            "Excess lmw-dna",
-            "systemic lupus erythematosus",
-            "Systemic Lupus Erythematosus"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319015,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-              "name": "systemic lupus erythematosus",
-              "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10025133",
-                "KEGG.DISEASE:05322",
-                "MEDDRA:10042820",
-                "PDQ:CDR0000608139",
-                "MEDDRA:10040967",
-                "MEDDRA:10042800",
-                "MEDDRA:10013446",
-                "MONDO:0007915",
-                "MEDDRA:10042945",
-                "MEDDRA:10024067",
-                "ICD10:M32.9",
-                "MEDDRA:10042947",
-                "ORPHANET:536",
-                "MEDDRA:10042944",
-                "UMLS:C0024141",
-                "EFO:0002690",
-                "MESH:D008180",
-                "ICD9:710.0",
-                "DOID:9074",
-                "MEDDRA:10025139",
-                "UMLS:C1835309",
-                "MEDDRA:10024065",
-                "OMIM:152700",
-                "HP:0002725",
-                "MEDDRA:10025142",
-                "NCIT:C3201",
-                "SNOMEDCT:55464009"
-              ],
-              "id": "MONDO:0007915",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Systemic lupus erythematosus",
-                "obsolete_systemic lupus erythematosus",
-                "Systemic lupus erythematosus related phenotypic feature",
-                "Lupus Erythematosus, Systemic",
-                "Excess lmw-dna",
-                "systemic lupus erythematosus",
-                "Systemic Lupus Erythematosus"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8155204,
-            "start": 570,
-            "end": 319015,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10908541': {'publication date': '2000', 'sentence': \"REVIEWER'S CONCLUSIONS: Cyclophosphamide regimen treatment is a form of care in neuropsychiatric involvement in systemic lupus erythematosus with no evidence to prove better effectiveness and safety when compared with methylprednisolone.\", 'subject score': 1000, 'object score': 1000}, 'PMID:16625558': {'publication date': '2006 Apr 19', 'sentence': 'Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:23450535': {'publication date': '2013 Feb 28', 'sentence': 'Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0024141---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8330909",
-              "object": "MONDO:0007915",
-              "publications": [
-                "PMID:10908541",
-                "PMID:16625558",
-                "PMID:23450535"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10908541': {'publication date': '2000', 'sentence': 'MAIN RESULTS: We found no randomised controlled trials comparing cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in the systemic lupus erythematosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:12192247': {'publication date': '2002 Sep', 'sentence': 'The last significant breakthrough in the treatment of systemic lupus erythematosus (SLE) was the use of cyclophosphamide and methylprednisolone in the treatment of lupus nephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:12833245': {'publication date': '2003 Jun', 'sentence': 'AIM: To review the mechanisms of action and evidence for clinical use of IV MEP in the treatment of SLE.', 'subject score': 888, 'object score': 1000}, 'PMID:12945723': {'publication date': '2003', 'sentence': 'We describe an SLE patient with IT refractory to high-dose corticosteroids, pulse methylprednisolone and intravenous immunoglobulin therapy, whose platelet counts normalized during therapy with mycophenolate mofetil (MMF).', 'subject score': 861, 'object score': 916}, 'PMID:13664558': {'publication date': '1959 Jul 25', 'sentence': 'Methylprednisolone (medrol) in the treatment of systemic lupus erythematosus; analysis of results in forty cases.', 'subject score': 1000, 'object score': 1000}, 'PMID:14748998': {'publication date': '2003 Jun', 'sentence': 'OBJECTIVE: To study the effect of methylprednisolone (MP) and cyclophosphamide (CPA) intermittent intravenous pulse therapy and the clinical prognosis in children with severe juvenile onset systemic lupus erythematosus (JOSLE).', 'subject score': 1000, 'object score': 851}, 'PMID:1509720': {'publication date': '1992 May', 'sentence': 'The activity of systemic lupus erythematosus was controlled by pulsed treatment with methyl prednisolone followed by long-term oral glucocorticoid and immunosuppressive therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:15610913': {'publication date': '2004 Sep-Oct', 'sentence': 'BACKGROUND: The aim of the study is to analyze retrospectively the effect of low-dose methylprednisolone (MP) and cyclophosphamide (CYC) pulse therapy on anticardiolipin antibodies (aCL) serum levels in patients with systemic lupus erythematosus (SLE).', 'subject score': 901, 'object score': 1000}, 'PMID:16625558': {'publication date': '2006 Apr 19', 'sentence': 'MAIN RESULTS: We found one randomised controlled trial of 32 patients comparing cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in the systemic lupus erythematosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:16862047': {'publication date': '2006 Jul', 'sentence': 'NP damage is prevalent in Chinese patients with SLE and is independently associated with more active disease at diagnosis, antiphospholipid antibodies and the use of pulse methylprednisolone therapy.', 'subject score': 790, 'object score': 1000}, 'PMID:17664228': {'publication date': '2007', 'sentence': 'High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus.', 'subject score': 861, 'object score': 916}, 'PMID:17917096': {'publication date': '2007', 'sentence': 'The SLE was treated successfully with methylprednisolone and chloroquine, and low dose maintenance steroid was continued with bisphosphonate protection until December 1994 when she suffered multiple vertebral fractures.', 'subject score': 1000, 'object score': 1000}, 'PMID:20054604': {'publication date': '2010 Jun', 'sentence': 'The activity of systemic lupus erythematosus was controlled by pulsed treatment with methyl prednisolone followed by long-term oral glucocorticoid and immunosuppressive therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:2084249': {'publication date': '1990 Dec', 'sentence': 'We describe 2 patients with systemic lupus erythematosus (SLE) who developed an acute psychosis and a cerebrovascular accident after pulse methylprednisolone therapy.', 'subject score': 790, 'object score': 1000}, 'PMID:21558137': {'publication date': '2011 May', 'sentence': 'Clinical, laboratory test, SLEDAI-2K, predictors of mortality (APACHE II) and different treatments including cyclophosphamide, methylprednisolone and rituximab were evaluated in SLE patients who were diagnosed with DAH, to determine potential association with mortality.', 'subject score': 1000, 'object score': 916}, 'PMID:22448187': {'publication date': '2010', 'sentence': 'A 35-year-old Caucasian woman with proven systemic lupus erythematosus (SLE) had been effectively managed with hydroxychloroquine and methylprednisolone for many years.', 'subject score': 1000, 'object score': 923}, 'PMID:22884160': {'publication date': '2012 Jun', 'sentence': 'A 16-year-old female patient with systemic lupus erythematosus (SLE) presented with abdominal pain and oliguria, after one month of hospital treatment with methylprednisolone and cyclophosphamide.', 'subject score': 1000, 'object score': 1000}, 'PMID:23450535': {'publication date': '2013 Feb 28', 'sentence': 'SELECTION CRITERIA: We included all randomised controlled trials that compared cyclophosphamide to methylprednisolone in patients with SLE of any age and gender and presenting with any kind of neuropsychiatric manifestations.', 'subject score': 1000, 'object score': 1000}, 'PMID:24635166': {'publication date': '2014 Jul', 'sentence': 'The frequencies of peripheral blood T helper type 22 (Th22), IL-22(+) Th17, IL-22(+) Th1 and Th17 cells and the concentrations of serum IL-22, IL-17 and interferon (IFN)-gamma in SLE patients receiving 4 weeks of treatment with cyclophosphamide (CYC), methylprednisolone and hydroxychloroquine (HCQ) were characterized by flow cytometry analysis and enzyme-linked immunosorbent assay (ELISA).', 'subject score': 1000, 'object score': 916}, 'PMID:25054737': {'publication date': '2014 Aug', 'sentence': 'The percentages of CD4EBI3 T cells and serum IL-35 levels in 10 untreated patients with active SLE were increased at days l, 3, and 7 after the treatment with methylprednisolone (0.8 mg.kg.d) compared with the percentages before the treatment.', 'subject score': 1000, 'object score': 916}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319015,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-          "name": "systemic lupus erythematosus",
-          "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10025133",
-            "KEGG.DISEASE:05322",
-            "MEDDRA:10042820",
-            "PDQ:CDR0000608139",
-            "MEDDRA:10040967",
-            "MEDDRA:10042800",
-            "MEDDRA:10013446",
-            "MONDO:0007915",
-            "MEDDRA:10042945",
-            "MEDDRA:10024067",
-            "ICD10:M32.9",
-            "MEDDRA:10042947",
-            "ORPHANET:536",
-            "MEDDRA:10042944",
-            "UMLS:C0024141",
-            "EFO:0002690",
-            "MESH:D008180",
-            "ICD9:710.0",
-            "DOID:9074",
-            "MEDDRA:10025139",
-            "UMLS:C1835309",
-            "MEDDRA:10024065",
-            "OMIM:152700",
-            "HP:0002725",
-            "MEDDRA:10025142",
-            "NCIT:C3201",
-            "SNOMEDCT:55464009"
-          ],
-          "id": "MONDO:0007915",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Systemic lupus erythematosus",
-            "obsolete_systemic lupus erythematosus",
-            "Systemic lupus erythematosus related phenotypic feature",
-            "Lupus Erythematosus, Systemic",
-            "Excess lmw-dna",
-            "systemic lupus erythematosus",
-            "Systemic Lupus Erythematosus"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319015,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
-              "name": "systemic lupus erythematosus",
-              "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10025133",
-                "KEGG.DISEASE:05322",
-                "MEDDRA:10042820",
-                "PDQ:CDR0000608139",
-                "MEDDRA:10040967",
-                "MEDDRA:10042800",
-                "MEDDRA:10013446",
-                "MONDO:0007915",
-                "MEDDRA:10042945",
-                "MEDDRA:10024067",
-                "ICD10:M32.9",
-                "MEDDRA:10042947",
-                "ORPHANET:536",
-                "MEDDRA:10042944",
-                "UMLS:C0024141",
-                "EFO:0002690",
-                "MESH:D008180",
-                "ICD9:710.0",
-                "DOID:9074",
-                "MEDDRA:10025139",
-                "UMLS:C1835309",
-                "MEDDRA:10024065",
-                "OMIM:152700",
-                "HP:0002725",
-                "MEDDRA:10025142",
-                "NCIT:C3201",
-                "SNOMEDCT:55464009"
-              ],
-              "id": "MONDO:0007915",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Systemic lupus erythematosus",
-                "obsolete_systemic lupus erythematosus",
-                "Systemic lupus erythematosus related phenotypic feature",
-                "Lupus Erythematosus, Systemic",
-                "Excess lmw-dna",
-                "systemic lupus erythematosus",
-                "Systemic Lupus Erythematosus"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8147998,
-            "start": 570,
-            "end": 319015,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10908541': {'publication date': '2000', 'sentence': 'MAIN RESULTS: We found no randomised controlled trials comparing cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in the systemic lupus erythematosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:12192247': {'publication date': '2002 Sep', 'sentence': 'The last significant breakthrough in the treatment of systemic lupus erythematosus (SLE) was the use of cyclophosphamide and methylprednisolone in the treatment of lupus nephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:12833245': {'publication date': '2003 Jun', 'sentence': 'AIM: To review the mechanisms of action and evidence for clinical use of IV MEP in the treatment of SLE.', 'subject score': 888, 'object score': 1000}, 'PMID:12945723': {'publication date': '2003', 'sentence': 'We describe an SLE patient with IT refractory to high-dose corticosteroids, pulse methylprednisolone and intravenous immunoglobulin therapy, whose platelet counts normalized during therapy with mycophenolate mofetil (MMF).', 'subject score': 861, 'object score': 916}, 'PMID:13664558': {'publication date': '1959 Jul 25', 'sentence': 'Methylprednisolone (medrol) in the treatment of systemic lupus erythematosus; analysis of results in forty cases.', 'subject score': 1000, 'object score': 1000}, 'PMID:14748998': {'publication date': '2003 Jun', 'sentence': 'OBJECTIVE: To study the effect of methylprednisolone (MP) and cyclophosphamide (CPA) intermittent intravenous pulse therapy and the clinical prognosis in children with severe juvenile onset systemic lupus erythematosus (JOSLE).', 'subject score': 1000, 'object score': 851}, 'PMID:1509720': {'publication date': '1992 May', 'sentence': 'The activity of systemic lupus erythematosus was controlled by pulsed treatment with methyl prednisolone followed by long-term oral glucocorticoid and immunosuppressive therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:15610913': {'publication date': '2004 Sep-Oct', 'sentence': 'BACKGROUND: The aim of the study is to analyze retrospectively the effect of low-dose methylprednisolone (MP) and cyclophosphamide (CYC) pulse therapy on anticardiolipin antibodies (aCL) serum levels in patients with systemic lupus erythematosus (SLE).', 'subject score': 901, 'object score': 1000}, 'PMID:16625558': {'publication date': '2006 Apr 19', 'sentence': 'MAIN RESULTS: We found one randomised controlled trial of 32 patients comparing cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in the systemic lupus erythematosus.', 'subject score': 1000, 'object score': 1000}, 'PMID:16862047': {'publication date': '2006 Jul', 'sentence': 'NP damage is prevalent in Chinese patients with SLE and is independently associated with more active disease at diagnosis, antiphospholipid antibodies and the use of pulse methylprednisolone therapy.', 'subject score': 790, 'object score': 1000}, 'PMID:17664228': {'publication date': '2007', 'sentence': 'High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus.', 'subject score': 861, 'object score': 916}, 'PMID:17917096': {'publication date': '2007', 'sentence': 'The SLE was treated successfully with methylprednisolone and chloroquine, and low dose maintenance steroid was continued with bisphosphonate protection until December 1994 when she suffered multiple vertebral fractures.', 'subject score': 1000, 'object score': 1000}, 'PMID:20054604': {'publication date': '2010 Jun', 'sentence': 'The activity of systemic lupus erythematosus was controlled by pulsed treatment with methyl prednisolone followed by long-term oral glucocorticoid and immunosuppressive therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:2084249': {'publication date': '1990 Dec', 'sentence': 'We describe 2 patients with systemic lupus erythematosus (SLE) who developed an acute psychosis and a cerebrovascular accident after pulse methylprednisolone therapy.', 'subject score': 790, 'object score': 1000}, 'PMID:21558137': {'publication date': '2011 May', 'sentence': 'Clinical, laboratory test, SLEDAI-2K, predictors of mortality (APACHE II) and different treatments including cyclophosphamide, methylprednisolone and rituximab were evaluated in SLE patients who were diagnosed with DAH, to determine potential association with mortality.', 'subject score': 1000, 'object score': 916}, 'PMID:22448187': {'publication date': '2010', 'sentence': 'A 35-year-old Caucasian woman with proven systemic lupus erythematosus (SLE) had been effectively managed with hydroxychloroquine and methylprednisolone for many years.', 'subject score': 1000, 'object score': 923}, 'PMID:22884160': {'publication date': '2012 Jun', 'sentence': 'A 16-year-old female patient with systemic lupus erythematosus (SLE) presented with abdominal pain and oliguria, after one month of hospital treatment with methylprednisolone and cyclophosphamide.', 'subject score': 1000, 'object score': 1000}, 'PMID:23450535': {'publication date': '2013 Feb 28', 'sentence': 'SELECTION CRITERIA: We included all randomised controlled trials that compared cyclophosphamide to methylprednisolone in patients with SLE of any age and gender and presenting with any kind of neuropsychiatric manifestations.', 'subject score': 1000, 'object score': 1000}, 'PMID:24635166': {'publication date': '2014 Jul', 'sentence': 'The frequencies of peripheral blood T helper type 22 (Th22), IL-22(+) Th17, IL-22(+) Th1 and Th17 cells and the concentrations of serum IL-22, IL-17 and interferon (IFN)-gamma in SLE patients receiving 4 weeks of treatment with cyclophosphamide (CYC), methylprednisolone and hydroxychloroquine (HCQ) were characterized by flow cytometry analysis and enzyme-linked immunosorbent assay (ELISA).', 'subject score': 1000, 'object score': 916}, 'PMID:25054737': {'publication date': '2014 Aug', 'sentence': 'The percentages of CD4EBI3 T cells and serum IL-35 levels in 10 untreated patients with active SLE were increased at days l, 3, and 7 after the treatment with methylprednisolone (0.8 mg.kg.d) compared with the percentages before the treatment.', 'subject score': 1000, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0024141---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8330903",
-              "object": "MONDO:0007915",
-              "publications": [
-                "PMID:10908541",
-                "PMID:12192247",
-                "PMID:12833245",
-                "PMID:12945723",
-                "PMID:13664558",
-                "PMID:14748998",
-                "PMID:1509720",
-                "PMID:15610913",
-                "PMID:16625558",
-                "PMID:16862047",
-                "PMID:17664228",
-                "PMID:17917096",
-                "PMID:20054604",
-                "PMID:2084249",
-                "PMID:21558137",
-                "PMID:22448187",
-                "PMID:22884160",
-                "PMID:23450535",
-                "PMID:24635166",
-                "PMID:25054737"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 321523,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15957521': {'publication date': '2005 Jun', 'sentence': 'One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:34237754': {'publication date': '2021 Jul 08', 'sentence': 'Herein, we report a case of a patient with GFAP-A with initial symptoms of psychological and cognitive impairment, which did not respond to high-dose methylprednisolone therapy but was successfully treated with protein A immunoadsorption (PAIA) therapy.', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321491,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8116926,
-            "start": 570,
-            "end": 321523,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10879669': {'publication date': '2000 Jun', 'sentence': 'High-dose methylprednisolone was administered for treatment of the pneumonitis.', 'subject score': 901, 'object score': 1000}, 'PMID:11594518': {'publication date': '2001 Aug', 'sentence': 'Remission of acute myeloblastic leukemia after severe pneumonia treated with high-dose methylprednisolone.', 'subject score': 901, 'object score': 888}, 'PMID:12073575': {'publication date': '2002 May', 'sentence': 'Since human herpes virus-6 (HHV-6) was detected in BAL specimens by the polymerase chain reaction (PCR), a diagnosis of a pneumonitis-like BOOP shadow related to HHV-6 was made, and he was treated with methylprednisolone and ganciclovir (GCV).', 'subject score': 1000, 'object score': 1000}, 'PMID:16636525': {'publication date': '2006 May', 'sentence': 'This is the first report describing the treatment of pulse methylprednisolone therapy in fatal adenovirus pneumonia.', 'subject score': 790, 'object score': 851}, 'PMID:18712461': {'publication date': '2008 Oct', 'sentence': 'We report a case of severe parainfluenza (PIV) 3 pneumonia in a hematopoietic stem cell transplant recipient that was successfully treated with oral ribavirin and methylprednisolone.', 'subject score': 1000, 'object score': 888}, 'PMID:20667503': {'publication date': '2010 Oct 31', 'sentence': 'In vivo efficacy of dendrimer-methylprednisolone conjugate formulation for the treatment of lung inflammation.', 'subject score': 566, 'object score': 1000}, 'PMID:21718474': {'publication date': '2011 Jun 30', 'sentence': 'STUDY DESIGN: This is a randomized double-blind clinical trial to test the efficacy of pulse treatment with methylprednisolone in patients with leptospirotic pneumonitis, compared with a placebo.', 'subject score': 1000, 'object score': 861}, 'PMID:22251837': {'publication date': '2012 02', 'sentence': 'Administration of an antiviral agent (acyclovir), an antibacterial agent (linezolid), and a corticosteroid (methylprednisolone) successfully improved the pneumonia and ARDS.', 'subject score': 1000, 'object score': 1000}, 'PMID:24289285': {'publication date': '2013 Dec 01', 'sentence': 'CASE PRESENTATION: We herein report the case of an 82-year-old Asian Japanese female with rheumatoid arthritis and Pneumocystis pneumonia who was being treated with low-dose tacrolimus and low-dose methylprednisolone therapy.', 'subject score': 861, 'object score': 888}, 'PMID:25374741': {'publication date': '2013', 'sentence': 'Investigations revealed thrombocytopenia, CSF lymphocytosis, ANA and dsDNA positivity, hypocomplementemia, and pneumonitis following which he was treated with pulse methylprednisolone.', 'subject score': 861, 'object score': 1000}, 'PMID:28185527': {'publication date': '2017 05', 'sentence': 'For remaining 12 patients, bleomycin was discontinued and methylprednisolone given, all showed resolution of the pneumonitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:29735504': {'publication date': '2018 May 07', 'sentence': 'His clinical condition improved once he received high-dose intravenous methylprednisolone to treat pneumonitis.', 'subject score': 861, 'object score': 1000}, 'PMID:29881712': {'publication date': '2018 May-Jun', 'sentence': 'Results: The pulmonary inflammation and fibrosis were significantly decreased in groups treated with methylprednisolone and N. sativa extract compared to bleomycin group in both early and late prevention groups (p<0.001).', 'subject score': 1000, 'object score': 1000}, 'PMID:32792492': {'publication date': '2020 08 13', 'sentence': 'Thirty of 31 patients (96.77%) had stopped mPSL due to improvement of pneumonia.', 'subject score': 861, 'object score': 1000}, 'PMID:32893160': {'publication date': '2020 Aug 28', 'sentence': 'Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases.', 'subject score': 1000, 'object score': 875}, 'PMID:33072814': {'publication date': '2020 Oct', 'sentence': 'Conclusion: In patients with severe COVID-19 pneumonia, early administration of prolonged MP treatment was associated with a significantly lower hazard of death (71%) and decreased ventilator dependence.', 'subject score': 851, 'object score': 875}, 'PMID:33219551': {'publication date': '2020 Nov 20', 'sentence': 'High-Dose Methylprednisolone in Nonintubated Patients with Severe COVID-19 Pneumonia.', 'subject score': 901, 'object score': 875}, 'PMID:33451758': {'publication date': '2020 Dec 17', 'sentence': 'The second case was a 58-year-old man who fully recovered from COVID-19 pneumonia with treatment with methylprednisolone, MMF, azithromycin, favipiravir, hydroxychloroquine, and reduction in immunosuppression dosage.', 'subject score': 1000, 'object score': 916}, 'PMID:33692687': {'publication date': '2021', 'sentence': 'Conclusion:     We showed that intermediate and high doses methylprednisolone share most potential to target BD-induced lung inflammation in rats.', 'subject score': 890, 'object score': 857}, 'PMID:33778162': {'publication date': '2021', 'sentence': 'Alongside supportive care and lopinavir/ritonavir antiviral drugs, a low dosage of methylprednisolone was administered over a short period to attenuate lung inflammation.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8291810",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:10879669",
-                "PMID:11594518",
-                "PMID:12073575",
-                "PMID:16636525",
-                "PMID:18712461",
-                "PMID:20667503",
-                "PMID:21718474",
-                "PMID:22251837",
-                "PMID:24289285",
-                "PMID:25374741",
-                "PMID:28185527",
-                "PMID:29735504",
-                "PMID:29881712",
-                "PMID:32792492",
-                "PMID:32893160",
-                "PMID:33072814",
-                "PMID:33219551",
-                "PMID:33451758",
-                "PMID:33692687",
-                "PMID:33778162"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 531222,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0012727",
-          "name": "mucocutaneous lymph node syndrome",
-          "description": "A vasculitis characterized by inflammation of the arteries, particularly the coronary arteries. The vasculitis may lead to aneurysm formation and possibly, heart attacks. It affects young children who usually present with persistent high fever, redness of the mucous membranes of the mouth, redness of the palms and soles, skin rashes, lymphadenitis, and joint pain and swelling.; An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:13378",
-            "ICD9:446.1",
-            "MEDDRA:10000747",
-            "SNOMEDCT:75053002",
-            "MESH:C537014",
-            "UMLS:C0026691",
-            "UMLS:C2936917",
-            "EFO:0004246",
-            "MESH:D009080",
-            "MEDDRA:10023320",
-            "ICD10:M30.3",
-            "NCIT:C34825",
-            "MONDO:0012727",
-            "MEDDRA:10028083",
-            "OMIM:611775",
-            "ORPHANET:2331"
-          ],
-          "id": "MONDO:0012727",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infantile polyarteritis",
-            "Kawasaki disease",
-            "Kawasaki disease related phenotypic feature",
-            "Kawasaki Disease",
-            "mucocutaneous lymph node syndrome",
-            "Mucocutaneous Lymph Node Syndrome",
-            "Acute febrile mucocutaneous lymph node syndrome [MCLS]"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/kawasaki_disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 531222,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0012727",
-              "name": "mucocutaneous lymph node syndrome",
-              "description": "A vasculitis characterized by inflammation of the arteries, particularly the coronary arteries. The vasculitis may lead to aneurysm formation and possibly, heart attacks. It affects young children who usually present with persistent high fever, redness of the mucous membranes of the mouth, redness of the palms and soles, skin rashes, lymphadenitis, and joint pain and swelling.; An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:13378",
-                "ICD9:446.1",
-                "MEDDRA:10000747",
-                "SNOMEDCT:75053002",
-                "MESH:C537014",
-                "UMLS:C0026691",
-                "UMLS:C2936917",
-                "EFO:0004246",
-                "MESH:D009080",
-                "MEDDRA:10023320",
-                "ICD10:M30.3",
-                "NCIT:C34825",
-                "MONDO:0012727",
-                "MEDDRA:10028083",
-                "OMIM:611775",
-                "ORPHANET:2331"
-              ],
-              "id": "MONDO:0012727",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infantile polyarteritis",
-                "Kawasaki disease",
-                "Kawasaki disease related phenotypic feature",
-                "Kawasaki Disease",
-                "mucocutaneous lymph node syndrome",
-                "Mucocutaneous Lymph Node Syndrome",
-                "Acute febrile mucocutaneous lymph node syndrome [MCLS]"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/kawasaki_disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8053979,
-            "start": 570,
-            "end": 531222,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10835091': {'publication date': '2000 Jun', 'sentence': 'Additional antiinflammatory therapy, such as IV methylprednisolone and IV cyclophosphamide, may be helpful in treating persistent KD.', 'subject score': 888, 'object score': 861}, 'PMID:15005973': {'publication date': '2004 Mar', 'sentence': 'Pulse methylprednisolone therapy in the treatment of immune globulin-resistant Kawasaki disease: case report and review of the literature.', 'subject score': 790, 'object score': 857}, 'PMID:17301297': {'publication date': '2007 Feb 15', 'sentence': 'METHODS: We conducted a multicenter, randomized, double-blind, placebo-controlled trial to determine whether the addition of intravenous methylprednisolone to conventional primary therapy for Kawasaki disease reduces the risk of coronary-artery abnormalities.', 'subject score': 888, 'object score': 1000}, 'PMID:17962370': {'publication date': '2008 Feb', 'sentence': 'CONCLUSIONS: The findings suggest that IVMP is an effective additional treatment for IVIG-resistant KD.', 'subject score': 888, 'object score': 857}, 'PMID:18446365': {'publication date': '2009 Feb', 'sentence': 'Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease.', 'subject score': 861, 'object score': 901}, 'PMID:20431427': {'publication date': '2010 Oct', 'sentence': 'To our knowledge, this is the first report to document the use of infliximab and methylprednisolone as first line therapy for Kawasaki disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:22222048': {'publication date': '2012 Jan 05', 'sentence': 'We describe a 16 year old girl who presented with fever, arthritis and two giant coronary artery aneurysms, initially diagnosed as atypical Kawasaki disease and treated with IVIG and methylprednisolone.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0026691---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8227578",
-              "object": "MONDO:0012727",
-              "publications": [
-                "PMID:10835091",
-                "PMID:15005973",
-                "PMID:17301297",
-                "PMID:17962370",
-                "PMID:18446365",
-                "PMID:20431427",
-                "PMID:22222048"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318159,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007275",
-          "name": "carpal tunnel syndrome",
-          "description": "Injury to the median nerve caused by its entrapment at the wrist as it traverses through the carpal tunnel. Clinically, constrictive median neuropathy is characterized by pain, paresthesia, and weakness in the median nerve distribution of the hand. [HPO:probinson]; Injury to the median nerve caused by its entrapment at the wrist as it traverses through the carpal tunnel. Clinically, constrictive median neuropathy is characterized by pain, paresthesia, and weakness in the median nerve distribution of the hand. // COMMENTS: Constrictive median neuropathy is the major clinical feature of carpal tunnel syndrome.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T190",
-          "equivalent_curies": [
-            "ICD10:G56.0",
-            "MEDDRA:10007697",
-            "HP:0012185",
-            "MESH:D002349",
-            "UMLS:C4023009",
-            "UMLS:C0007286",
-            "ORPHANET:50838",
-            "DOID:12169",
-            "MONDO:0007275",
-            "ICD9:354.0",
-            "OMIM.PS:115430",
-            "SNOMEDCT:57406009",
-            "EFO:0004143",
-            "NCIT:C34450"
-          ],
-          "id": "MONDO:0007275",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Carpal tunnel syndrome",
-            "Constrictive median neuropathy",
-            "Carpal Tunnel Syndrome",
-            "carpal tunnel syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://medlineplus.gov/ency/article/000433.htm",
-            "https://orthoinfo.aaos.org/en/diseases--conditions/carpal-tunnel-syndrome/",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://en.wikipedia.org/wiki/carpal_tunnel_syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318159,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007275",
-              "name": "carpal tunnel syndrome",
-              "description": "Injury to the median nerve caused by its entrapment at the wrist as it traverses through the carpal tunnel. Clinically, constrictive median neuropathy is characterized by pain, paresthesia, and weakness in the median nerve distribution of the hand. [HPO:probinson]; Injury to the median nerve caused by its entrapment at the wrist as it traverses through the carpal tunnel. Clinically, constrictive median neuropathy is characterized by pain, paresthesia, and weakness in the median nerve distribution of the hand. // COMMENTS: Constrictive median neuropathy is the major clinical feature of carpal tunnel syndrome.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T190",
-              "equivalent_curies": [
-                "ICD10:G56.0",
-                "MEDDRA:10007697",
-                "HP:0012185",
-                "MESH:D002349",
-                "UMLS:C4023009",
-                "UMLS:C0007286",
-                "ORPHANET:50838",
-                "DOID:12169",
-                "MONDO:0007275",
-                "ICD9:354.0",
-                "OMIM.PS:115430",
-                "SNOMEDCT:57406009",
-                "EFO:0004143",
-                "NCIT:C34450"
-              ],
-              "id": "MONDO:0007275",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Carpal tunnel syndrome",
-                "Constrictive median neuropathy",
-                "Carpal Tunnel Syndrome",
-                "carpal tunnel syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://medlineplus.gov/ency/article/000433.htm",
-                "https://orthoinfo.aaos.org/en/diseases--conditions/carpal-tunnel-syndrome/",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://en.wikipedia.org/wiki/carpal_tunnel_syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7925977,
-            "start": 570,
-            "end": 318159,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10744412': {'publication date': '2000 Mar 04', 'sentence': 'Injection with methylprednisolone for carpal tunnel syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:10744413': {'publication date': '2000 Mar 04', 'sentence': 'Injection with methylprednisolone for carpal tunnel syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:11402116': {'publication date': '2001 Jun 12', 'sentence': 'The authors compared the effectiveness of low-dose, short-term oral prednisolone vs local methylprednisolone injection in a prospective, double-blinded, parallel treatment study of carpal tunnel syndrome (CTS).', 'subject score': 851, 'object score': 1000}, 'PMID:24026316': {'publication date': '2013 Sep 03', 'sentence': 'CONCLUSION: Methylprednisolone injections for CTS have significant benefits in relieving symptoms at 10 weeks and reducing the rate of surgery 1 year after treatment, but 3 out of 4 patients had surgery within 1 year.', 'subject score': 888, 'object score': 1000}, 'PMID:24343399': {'publication date': '2013 Dec 17', 'sentence': 'Methylprednisolone injections for the carpal tunnel syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:24490275': {'publication date': '2013 Dec 17', 'sentence': 'Methylprednisolone injections for the carpal tunnel syndrome.', 'subject score': 888, 'object score': 1000}, 'PMID:24490276': {'publication date': '2013 Dec 17', 'sentence': 'Methylprednisolone injections for the carpal tunnel syndrome.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0007286---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8095661",
-              "object": "MONDO:0007275",
-              "publications": [
-                "PMID:10744412",
-                "PMID:10744413",
-                "PMID:11402116",
-                "PMID:24026316",
-                "PMID:24343399",
-                "PMID:24490275",
-                "PMID:24490276"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002049",
-          "name": "thrombocytopenia",
-          "description": "A reduction in the number of circulating thrombocytes. [HPO:probinson]; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T034",
-          "equivalent_curies": [
-            "UMLS:C0392386",
-            "SNOMEDCT:302215000",
-            "MEDDRA:10035545",
-            "MEDDRA:10043555",
-            "PDQ:CDR0000041408",
-            "MEDDRA:10024922",
-            "ICD10:D69.6",
-            "HP:0001873",
-            "NCIT:C3408",
-            "NCIT:C162108",
-            "MEDDRA:10035528",
-            "UMLS:C5201036",
-            "MEDDRA:10043560",
-            "DOID:1588",
-            "UMLS:CN130080",
-            "SYMP:0000114",
-            "MEDDRA:10038213",
-            "MEDDRA:10043546",
-            "MESH:D013921",
-            "MEDDRA:10035529",
-            "MEDDRA:10043569",
-            "UMLS:C0040034",
-            "MEDDRA:10043554",
-            "ICD9:287.5",
-            "MONDO:0002049",
-            "SNOMEDCT:415116008"
-          ],
-          "id": "MONDO:0002049",
-          "category": "biolink:Disease",
-          "all_names": [
-            "thrombocytopenia",
-            "Thrombocytopenia, unspecified",
-            "Low Platelet Count",
-            "Thrombocytopenia",
-            "Decreased platelet count"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/thrombocytopenia",
-            "http://www.merckmanuals.com/professional/hematology_and_oncology/thrombocytopenia_and_platelet_dysfunction/overview_of_platelet_disorders.htm",
-            "http://ghr.nlm.nih.gov/glossary=thrombocytopenia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002049",
-              "name": "thrombocytopenia",
-              "description": "A reduction in the number of circulating thrombocytes. [HPO:probinson]; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T034",
-              "equivalent_curies": [
-                "UMLS:C0392386",
-                "SNOMEDCT:302215000",
-                "MEDDRA:10035545",
-                "MEDDRA:10043555",
-                "PDQ:CDR0000041408",
-                "MEDDRA:10024922",
-                "ICD10:D69.6",
-                "HP:0001873",
-                "NCIT:C3408",
-                "NCIT:C162108",
-                "MEDDRA:10035528",
-                "UMLS:C5201036",
-                "MEDDRA:10043560",
-                "DOID:1588",
-                "UMLS:CN130080",
-                "SYMP:0000114",
-                "MEDDRA:10038213",
-                "MEDDRA:10043546",
-                "MESH:D013921",
-                "MEDDRA:10035529",
-                "MEDDRA:10043569",
-                "UMLS:C0040034",
-                "MEDDRA:10043554",
-                "ICD9:287.5",
-                "MONDO:0002049",
-                "SNOMEDCT:415116008"
-              ],
-              "id": "MONDO:0002049",
-              "category": "biolink:Disease",
-              "all_names": [
-                "thrombocytopenia",
-                "Thrombocytopenia, unspecified",
-                "Low Platelet Count",
-                "Thrombocytopenia",
-                "Decreased platelet count"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/thrombocytopenia",
-                "http://www.merckmanuals.com/professional/hematology_and_oncology/thrombocytopenia_and_platelet_dysfunction/overview_of_platelet_disorders.htm",
-                "http://ghr.nlm.nih.gov/glossary=thrombocytopenia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7912789,
-            "start": 570,
-            "end": 316686,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10734662': {'publication date': '2000 Mar', 'sentence': 'After a course of high-dose methylprednisolone therapy with a diagnosis of Evans syndrome, complete response for thrombocytopenia and partial response for anemia was achieved.', 'subject score': 861, 'object score': 1000}, 'PMID:1414159': {'publication date': '1992', 'sentence': 'Pulse therapy with methylprednisolone reversed both thrombocytopenia and myelofibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1719258': {'publication date': '1991 Sep', 'sentence': 'The pulse therapy of methylprednisolone and high dose of gamma-globulin improved lymphadenopathy, thrombocytopenia and anemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:23796671': {'publication date': '2013 Apr', 'sentence': 'Efficacy of high-dose methylprednisolone in patients with Crimean-Congo haemorrhagic fever and severe thrombocytopenia.', 'subject score': 901, 'object score': 888}, 'PMID:25518779': {'publication date': '2014 Nov', 'sentence': 'The thrombocytopenia was resistant to intravenous immunoglobulin and methylprednisolone but responded well to Rituximab.', 'subject score': 1000, 'object score': 1000}, 'PMID:28983416': {'publication date': '2017 Sep', 'sentence': 'Here we report a further case of atrial fibrillation following high-dose i.v. methylprednisolone (HDIVMP) therapy of severe thrombocytopenia in a female patient with a flare-up of systemic lupus erythematosus (SLE).', 'subject score': 774, 'object score': 888}, 'PMID:33378749': {'publication date': '2020 Dec 30', 'sentence': 'All patients with thrombocytopenia were treated by methylprednisolone with or without platelet transfusion and recovered without major organ hemorrhage.', 'subject score': 1000, 'object score': 1000}, 'PMID:6487937': {'publication date': '1984 Nov', 'sentence': 'IVMP may be an effective treatment for SLE-associated thrombocytopenia but repeated courses may result in a reduced platelet response.', 'subject score': 888, 'object score': 850}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0040034---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8083160",
-              "object": "MONDO:0002049",
-              "publications": [
-                "PMID:10734662",
-                "PMID:1414159",
-                "PMID:1719258",
-                "PMID:23796671",
-                "PMID:25518779",
-                "PMID:28983416",
-                "PMID:33378749",
-                "PMID:6487937"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 531220,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0012105",
-          "name": "granulomatosis with polyangiitis",
-          "description": "A rare, autoimmune, systemic medium and small size vasculitis. It is characterized by the formation of necrotizing granulomas in the respiratory tract, necrotizing angiitis, and glomerulonephritis.; A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10072579",
-            "DOID:12132",
-            "ICD10:M31.3",
-            "MONDO:0012105",
-            "SNOMEDCT:195353004",
-            "UMLS:C3495801",
-            "OMIM:608710",
-            "UMLS:C4050407",
-            "MEDDRA:10047889",
-            "NCIT:C3444",
-            "EFO:0005297",
-            "MESH:D014890",
-            "MEDDRA:10047888",
-            "MEDDRA:10072580",
-            "ORPHANET:900",
-            "ICD9:446.4",
-            "NCIT:C123111"
-          ],
-          "id": "MONDO:0012105",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pauci-immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-            "Granulomatosis with Polyangiitis",
-            "granulomatosis with polyangiitis",
-            "Pauci-Immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-            "Granulomatosis with polyangiitis related phenotypic feature",
-            "Granulomatosis with polyangiitis",
-            "Wegener's granulomatosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/granulomatosis_with_polyangiitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 531220,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0012105",
-              "name": "granulomatosis with polyangiitis",
-              "description": "A rare, autoimmune, systemic medium and small size vasculitis. It is characterized by the formation of necrotizing granulomas in the respiratory tract, necrotizing angiitis, and glomerulonephritis.; A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10072579",
-                "DOID:12132",
-                "ICD10:M31.3",
-                "MONDO:0012105",
-                "SNOMEDCT:195353004",
-                "UMLS:C3495801",
-                "OMIM:608710",
-                "UMLS:C4050407",
-                "MEDDRA:10047889",
-                "NCIT:C3444",
-                "EFO:0005297",
-                "MESH:D014890",
-                "MEDDRA:10047888",
-                "MEDDRA:10072580",
-                "ORPHANET:900",
-                "ICD9:446.4",
-                "NCIT:C123111"
-              ],
-              "id": "MONDO:0012105",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pauci-immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-                "Granulomatosis with Polyangiitis",
-                "granulomatosis with polyangiitis",
-                "Pauci-Immune Glomerulonephritis associated with Granulomatosis with Polyangiitis",
-                "Granulomatosis with polyangiitis related phenotypic feature",
-                "Granulomatosis with polyangiitis",
-                "Wegener's granulomatosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/granulomatosis_with_polyangiitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7894161,
-            "start": 570,
-            "end": 531220,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10720922': {'publication date': '2000', 'sentence': \"We describe a 44-year-old man with Wegener's granulomatosis who was treated with cyclophosphamide and methylprednisolone and who subsequently developed bilateral CMVR.\", 'subject score': 1000, 'object score': 1000}, 'PMID:1981008': {'publication date': '1990', 'sentence': \"Methylprednisolone in the treatment of Wegener's granulomatosis, polyarteritis nodosa and Churg-Strauss angiitis.\", 'subject score': 1000, 'object score': 1000}, 'PMID:8323489': {'publication date': '1993', 'sentence': \"Pulse methylprednisolone therapy in the treatment of Wegener's granulomatosis.\", 'subject score': 790, 'object score': 1000}, 'PMID:8496879': {'publication date': '1993 Apr', 'sentence': \"High dose methylprednisolone for retroorbital Wegener's granulomatosis.\", 'subject score': 901, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C3495801---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8063034",
-              "object": "MONDO:0012105",
-              "publications": [
-                "PMID:10720922",
-                "PMID:1981008",
-                "PMID:8323489",
-                "PMID:8496879"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7851287,
-            "start": 570,
-            "end": 316891,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10692608': {'publication date': '2000 Mar', 'sentence': 'A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm.', 'subject score': 1000, 'object score': 1000}, 'PMID:11513340': {'publication date': '2001 Aug', 'sentence': 'CONCLUSIONS: 1) In LSRPN, pain and neurological deficits improved (often dramatically) with IV MP treatment.', 'subject score': 851, 'object score': 1000}, 'PMID:11576210': {'publication date': '2001 Sep', 'sentence': 'In both cases, the pain was refractory to treatment with indomethacin, carbamazepine, and hypnotics, and only intravenous methylprednisolone with oral carbamazepine may have been partially effective in one case.', 'subject score': 790, 'object score': 1000}, 'PMID:11892709': {'publication date': '2002 Jan-Feb', 'sentence': 'CONCLUSION: These results suggest that periarticular injection of methylprednisolone may be effective in the treatment of pain in the region of the SIJ in non-spondylarthropathic patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:15778611': {'publication date': '2005 Apr', 'sentence': 'In addition, topical methylprednisolone (1 mg/mL) was necessary to control inflammation and pain.', 'subject score': 861, 'object score': 1000}, 'PMID:17178485': {'publication date': '2007 Jan', 'sentence': 'We observed only marginal difference between methylprednisolone and ketoprofen to relieve pain after this surgery.', 'subject score': 1000, 'object score': 1000}, 'PMID:2410117': {'publication date': '1985 Jul-Aug', 'sentence': 'Mean intensity of pain (visual analogue, 0-100 +/- SD) was 36.8 +/- 14 after MP treatment and 57.7 +/- 15 after placebo (P less than 0.01).', 'subject score': 888, 'object score': 1000}, 'PMID:26272452': {'publication date': '2015 Aug 14', 'sentence': 'Our data are intended to quantify the amount of ropivacaine and methylprednisolone needed by patients undergoing major abdominal surgery, to be stored in a new nanotechnology device for sustained pain treatment after surgery.', 'subject score': 1000, 'object score': 851}, 'PMID:27676662': {'publication date': '2016', 'sentence': 'OBJECTIVES: The present study aimed to evaluate the effect of adding calcitonin to local anesthetic and methylprednisolone using a modified coronoid approach in management of trigeminal neuralgia pain involving the mandibular and/or maxillary branches.', 'subject score': 1000, 'object score': 901}, 'PMID:28043311': {'publication date': '2016 Dec', 'sentence': 'OBJECTIVE: To determine the association between shoulder impingement and morphological characteristics of acromion and the role of sub-acromial injection of methylprednisolone in the short-term treatment for relieving pain and improve functional disability of these patients.', 'subject score': 1000, 'object score': 872}, 'PMID:28361779': {'publication date': '2016 01', 'sentence': 'IMPLICATIONS: Our results do not support use of intrathecal methylprednisolone in the treatment of pain.', 'subject score': 861, 'object score': 1000}, 'PMID:28652804': {'publication date': '2017', 'sentence': 'After treatment with analgesics such as gabapentin, mecobalamin, and dexamethasone/methylprednisolone for 1 week, the myodynamia had improved, but progressive pain persisted.', 'subject score': 888, 'object score': 888}, 'PMID:28803906': {'publication date': '2018 Mar', 'sentence': 'There is high evidence that HA is no different from methylprednisolone for pain at 1 month (SMD=.02; 95% CI, -.18 to .22; P=.85).', 'subject score': 1000, 'object score': 1000}, 'PMID:31083213': {'publication date': '2019 May', 'sentence': 'INTERVENTIONS: Intravenous methylprednisolone partially relieved the pain and paralysis.', 'subject score': 888, 'object score': 1000}, 'PMID:33961817': {'publication date': '2021 May 04', 'sentence': 'Low dose of methylprednisolone for pain and immune function after thoracic surgery.', 'subject score': 1000, 'object score': 1000}, 'PMID:35521428': {'publication date': '2022', 'sentence': 'Conclusion: Lidocaine in combination with methylprednisolone can significantly alleviate pain and reduce the usage of sufentanil after bilateral uterine artery embolization.', 'subject score': 1000, 'object score': 1000}, 'PMID:35742079': {'publication date': '2022 Jun 01', 'sentence': 'Efficacy of Methylprednisolone Compared to Other Drugs for Pain, Swelling, and Trismus Control after Third Molar Surgery: A Meta-Analysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:37168455': {'publication date': '2023', 'sentence': 'Efficacy of Preemptive Dexamethasone versus Methylprednisolone in the Management of Postoperative Discomfort and Pain after Mandibular Third Molar Surgery: A Systematic Review and Meta-Analysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:4479290': {'publication date': '1974 Sep-Oct', 'sentence': 'Subarachnoid methylprednisolone for relief of sciatic pain secondary to space-occupying lesion: a case report.', 'subject score': 861, 'object score': 861}, 'PMID:6288150': {'publication date': '1982', 'sentence': 'Solitary eosinophilic granulomata of bone also reportedly respond positively to direct injections fo methylprednisolone into the lesion by signs of healing and with relief of pain.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8018847",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:10692608",
-                "PMID:11513340",
-                "PMID:11576210",
-                "PMID:11892709",
-                "PMID:15778611",
-                "PMID:17178485",
-                "PMID:2410117",
-                "PMID:26272452",
-                "PMID:27676662",
-                "PMID:28043311",
-                "PMID:28361779",
-                "PMID:28652804",
-                "PMID:28803906",
-                "PMID:31083213",
-                "PMID:33961817",
-                "PMID:35521428",
-                "PMID:35742079",
-                "PMID:37168455",
-                "PMID:4479290",
-                "PMID:6288150"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 876033,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005284",
-          "name": "chronic progressive multiple sclerosis",
-          "description": "A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)",
-          "equivalent_curies": [
-            "MEDDRA:10053395",
-            "SNOMEDCT:230373008",
-            "MONDO:0005284",
-            "MESH:D020528",
-            "EFO:0003840",
-            "SNOMEDCT:816984002",
-            "UMLS:C0393665"
-          ],
-          "id": "MONDO:0005284",
-          "category": "biolink:Disease",
-          "all_names": [
-            "chronic progressive multiple sclerosis",
-            "Multiple Sclerosis, Chronic Progressive"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 876033,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005284",
-              "name": "chronic progressive multiple sclerosis",
-              "description": "A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)",
-              "equivalent_curies": [
-                "MEDDRA:10053395",
-                "SNOMEDCT:230373008",
-                "MONDO:0005284",
-                "MESH:D020528",
-                "EFO:0003840",
-                "SNOMEDCT:816984002",
-                "UMLS:C0393665"
-              ],
-              "id": "MONDO:0005284",
-              "category": "biolink:Disease",
-              "all_names": [
-                "chronic progressive multiple sclerosis",
-                "Multiple Sclerosis, Chronic Progressive"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7740766,
-            "start": 570,
-            "end": 876033,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10618696': {'publication date': '1999 Dec', 'sentence': 'OBJECTIVE: To determine if there are variables linked to responsiveness to pulse cyclophosphamide/methylprednisolone therapy in progressive Multiple Sclerosis (MS).', 'subject score': 775, 'object score': 1000}, 'PMID:8456594': {'publication date': '1993 Feb', 'sentence': 'High-dose methylprednisolone infusions in relapsing and in chronic progressive multiple sclerosis patients.', 'subject score': 850, 'object score': 928}, 'PMID:9683547': {'publication date': '1998 Jul', 'sentence': 'We have previously reported increased anti-CD3-induced IL-4 secretion by T cells in progressive MS patients treated with cyclophosphamide plus methylprednisolone (CY/MP) which was associated with eosinophilia.', 'subject score': 851, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0393665---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7905007",
-              "object": "MONDO:0005284",
-              "publications": [
-                "PMID:10618696",
-                "PMID:8456594",
-                "PMID:9683547"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318890,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-          "name": "rheumatoid arthritis",
-          "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C2884",
-            "PSY:44570",
-            "EFO:0000685",
-            "ICD9:714.0",
-            "KEGG.DISEASE:05323",
-            "MONDO:0008383",
-            "UMLS:C0003873",
-            "UMLS:C1306838",
-            "UMLS:C1833448",
-            "MEDDRA:10037740",
-            "MEDDRA:10039073",
-            "OMIM:180300",
-            "MESH:D001172",
-            "MEDDRA:10003268",
-            "HP:0001370",
-            "ORPHANET:284130",
-            "SNOMEDCT:69896004",
-            "ICD10:M06.9",
-            "DOID:7148",
-            "MEDDRA:10036856",
-            "MEDDRA:10042952"
-          ],
-          "id": "MONDO:0008383",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Proliferative arthritis",
-            "Arthritis, Rheumatoid",
-            "rheumatoid arthritis",
-            "Rheumatoid arthritis",
-            "Rheumatoid Arthritis",
-            "Rheumatoid arthritis related phenotypic feature",
-            "Rheumatoid arthritis, susceptibility to"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-            "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-            "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318890,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-              "name": "rheumatoid arthritis",
-              "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C2884",
-                "PSY:44570",
-                "EFO:0000685",
-                "ICD9:714.0",
-                "KEGG.DISEASE:05323",
-                "MONDO:0008383",
-                "UMLS:C0003873",
-                "UMLS:C1306838",
-                "UMLS:C1833448",
-                "MEDDRA:10037740",
-                "MEDDRA:10039073",
-                "OMIM:180300",
-                "MESH:D001172",
-                "MEDDRA:10003268",
-                "HP:0001370",
-                "ORPHANET:284130",
-                "SNOMEDCT:69896004",
-                "ICD10:M06.9",
-                "DOID:7148",
-                "MEDDRA:10036856",
-                "MEDDRA:10042952"
-              ],
-              "id": "MONDO:0008383",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Proliferative arthritis",
-                "Arthritis, Rheumatoid",
-                "rheumatoid arthritis",
-                "Rheumatoid arthritis",
-                "Rheumatoid Arthritis",
-                "Rheumatoid arthritis related phenotypic feature",
-                "Rheumatoid arthritis, susceptibility to"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-                "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-                "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7691142,
-            "start": 570,
-            "end": 318890,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10587571': {'publication date': '1999 Dec', 'sentence': 'Oral low-dose glucocorticosteroids as compared with intravenous methylprednisolone pulses in the treatment of rheumatoid arthritis.', 'subject score': 888, 'object score': 1000}, 'PMID:10925599': {'publication date': '2000 Jun', 'sentence': 'Her medical history is marked by rheumatoid arthritis treated with gold salts and methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:11085818': {'publication date': '2000 Nov', 'sentence': 'The role of intravenous methylprednisolone pulses in the management of rheumatoid arthritis.', 'subject score': 888, 'object score': 1000}, 'PMID:11109615': {'publication date': '2000', 'sentence': 'AIM: To compare clinical effectiveness and tolerance of methylprednisolone (methypred) and dexamethasone (dexaven) in patients with rheumatoid arthritis (RA), to estimate side effects and complications rate.', 'subject score': 1000, 'object score': 1000}, 'PMID:11155795': {'publication date': '2000', 'sentence': 'Dynamic thermography of the knee joints in rheumatoid arthritis (RA) in the course of the first therapy of the patient with methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:13565408': {'publication date': '1958 Jul', 'sentence': 'Use of methylprednisolone in management of rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:13635880': {'publication date': '1958 Nov 01', 'sentence': '6-Methyl prednisolone in the treatment of rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:13838090': {'publication date': '1959 Nov', 'sentence': '6-alpha-Methyl prednisolone in the treatment of rheumatoid arthritis.', 'subject score': 901, 'object score': 1000}, 'PMID:13987253': {'publication date': '1962 Oct', 'sentence': '[Methylprednisolone in rhuematic fever, rheumatoid arthritis and Still syndrome in childhood].', 'subject score': 1000, 'object score': 1000}, 'PMID:15308515': {'publication date': '2004 Sep', 'sentence': 'OBJECTIVES: To compare the short term clinical and biological effects of intravenous (i.v.) pulse methylprednisolone (MP) and infliximab (IFX) in patients with severe active rheumatoid arthritis (RA) despite methotrexate (MTX) treatment.', 'subject score': 861, 'object score': 861}, 'PMID:18990945': {'publication date': '2008', 'sentence': 'This study demonstrates that conjugation of MP to a cyclodextrin-polymer may improve its efficacy, leading to lower doses and less frequent administration for a safer and more convenient management of rheumatoid arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1994875': {'publication date': '1991 Jan', 'sentence': 'Pulsed methylprednisolone therapy in rheumatoid arthritis.', 'subject score': 840, 'object score': 1000}, 'PMID:2015021': {'publication date': '1991 Mar', 'sentence': 'Pulsed methylprednisolone for rheumatoid arthritis.', 'subject score': 872, 'object score': 1000}, 'PMID:2075380': {'publication date': '1990', 'sentence': 'In two patients affected by active RA treated with pulse methylprednisolone therapy (1 g/day for 3 alternate days) the values of soluble IL-2R dropped from 948 to 662 U/ml and from 660 to 518 U/ml, respectively.', 'subject score': 790, 'object score': 901}, 'PMID:2187419': {'publication date': '1990 Apr', 'sentence': 'Pulse methylprednisolone therapy in rheumatoid arthritis: unproved therapy, unjustified therapy, or effective adjunctive treatment?', 'subject score': 790, 'object score': 1000}, 'PMID:2256750': {'publication date': '1990 Nov', 'sentence': 'Fatal acute pyelonephritis following pulsed methylprednisolone for rheumatoid arthritis.', 'subject score': 872, 'object score': 1000}, 'PMID:2319516': {'publication date': '1990 Feb', 'sentence': 'This prospective, double blind study was undertaken to test the efficacy of intravenous \"minipulse\" (100 mg) methylprednisolone (MP) therapy versus standard pulse (1000 mg) MP therapy in rheumatoid arthritis (RA).', 'subject score': 888, 'object score': 1000}, 'PMID:2378175': {'publication date': '1990', 'sentence': 'Intravenous pulse methylprednisolone of 1000 mg was compared with 250 mg in patients suffering from rheumatoid arthritis.', 'subject score': 802, 'object score': 1000}, 'PMID:24053746': {'publication date': '2013 Sep', 'sentence': 'Her RA was treated with pulsed methylprednisolone followed by oral steroids and methotrexate resulting in remission of the joints disease and the nephrotic syndrome.', 'subject score': 872, 'object score': 1000}, 'PMID:2411240': {'publication date': '1985 Aug', 'sentence': 'Pulse methylprednisolone therapy has been used for the treatment of rheumatoid arthritis.', 'subject score': 790, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0003873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7853881",
-              "object": "MONDO:0008383",
-              "publications": [
-                "PMID:10587571",
-                "PMID:10925599",
-                "PMID:11085818",
-                "PMID:11109615",
-                "PMID:11155795",
-                "PMID:13565408",
-                "PMID:13635880",
-                "PMID:13838090",
-                "PMID:13987253",
-                "PMID:15308515",
-                "PMID:18990945",
-                "PMID:1994875",
-                "PMID:2015021",
-                "PMID:2075380",
-                "PMID:2187419",
-                "PMID:2256750",
-                "PMID:2319516",
-                "PMID:2378175",
-                "PMID:24053746",
-                "PMID:2411240"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318789,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005885",
-          "name": "optic neuritis",
-          "description": "A disorder characterized by inflammation of the optic nerve. Causes include autoimmune disorders, infections, toxins, drugs, and multiple sclerosis. It may manifest with acute loss of vision and pain.; Inflammation of the optic nerve. Commonly associated conditions include autoimmune disorders such as MULTIPLE SCLEROSIS, infections, and granulomatous diseases. Clinical features include retro-orbital pain that is aggravated by eye movement, loss of color vision, and contrast sensitivity that may progress to severe visual loss, an afferent pupillary defect (Marcus-Gunn pupil), and in some instances optic disc hyperemia and swelling. Inflammation may occur in the portion of the nerve within the globe (neuropapillitis or anterior optic neuritis) or the portion behind the globe (retrobulbar neuritis or posterior optic neuritis).; Inflammation of the optic nerve. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D009902",
-            "NCIT:C84950",
-            "DOID:1210",
-            "HP:0100653",
-            "ICD10:H46",
-            "MEDDRA:10030942",
-            "MONDO:0005885",
-            "UMLS:C0029134",
-            "EFO:0007405",
-            "MEDDRA:10030946",
-            "ICD9:377.3",
-            "MEDDRA:10029247",
-            "MEDDRA:10030944",
-            "SNOMEDCT:66760008"
-          ],
-          "id": "MONDO:0005885",
-          "category": "biolink:Disease",
-          "all_names": [
-            "optic neuritis",
-            "Optic neuritis",
-            "Optic Neuritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.mayoclinic.org/diseases-conditions/optic-neuritis/symptoms-causes/syc-20354953",
-            "https://rarediseases.info.nih.gov/diseases/7320/optic-neuritis",
-=======
-          "iri": "http://purl.obolibrary.org/obo/HP_0100543",
-          "name": "Cognitive impairment",
-          "description": "Abnormal cognition with deficits in thinking, reasoning, or remembering. [HPO:sdoelken]; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "MEDDRA:10009845",
-            "UMLS:C0683322",
-            "NCIT:C116921",
-            "MEDDRA:10048599",
-            "PSY:10113",
-            "UMLS:C0338656",
-            "HP:0100543",
-            "MEDDRA:10009846",
-            "MESH:D060825",
-            "SNOMEDCT:386806002",
-            "NCIT:C46083",
-            "NCIT:C27101",
-            "PSY:10103"
-          ],
-          "id": "HP:0100543",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Impaired cognition",
-            "Cognitive Disturbance",
-            "Mental impairment",
-            "Cognitive impairment",
-            "Cognitive Impairment",
-            "Cognitive Dysfunction"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
->>>>>>> main
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 318789,
-=======
-            "identity": 321491,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005885",
-              "name": "optic neuritis",
-              "description": "A disorder characterized by inflammation of the optic nerve. Causes include autoimmune disorders, infections, toxins, drugs, and multiple sclerosis. It may manifest with acute loss of vision and pain.; Inflammation of the optic nerve. Commonly associated conditions include autoimmune disorders such as MULTIPLE SCLEROSIS, infections, and granulomatous diseases. Clinical features include retro-orbital pain that is aggravated by eye movement, loss of color vision, and contrast sensitivity that may progress to severe visual loss, an afferent pupillary defect (Marcus-Gunn pupil), and in some instances optic disc hyperemia and swelling. Inflammation may occur in the portion of the nerve within the globe (neuropapillitis or anterior optic neuritis) or the portion behind the globe (retrobulbar neuritis or posterior optic neuritis).; Inflammation of the optic nerve. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D009902",
-                "NCIT:C84950",
-                "DOID:1210",
-                "HP:0100653",
-                "ICD10:H46",
-                "MEDDRA:10030942",
-                "MONDO:0005885",
-                "UMLS:C0029134",
-                "EFO:0007405",
-                "MEDDRA:10030946",
-                "ICD9:377.3",
-                "MEDDRA:10029247",
-                "MEDDRA:10030944",
-                "SNOMEDCT:66760008"
-              ],
-              "id": "MONDO:0005885",
-              "category": "biolink:Disease",
-              "all_names": [
-                "optic neuritis",
-                "Optic neuritis",
-                "Optic Neuritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.mayoclinic.org/diseases-conditions/optic-neuritis/symptoms-causes/syc-20354953",
-                "https://rarediseases.info.nih.gov/diseases/7320/optic-neuritis",
-=======
-              "iri": "http://purl.obolibrary.org/obo/HP_0100543",
-              "name": "Cognitive impairment",
-              "description": "Abnormal cognition with deficits in thinking, reasoning, or remembering. [HPO:sdoelken]; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "MEDDRA:10009845",
-                "UMLS:C0683322",
-                "NCIT:C116921",
-                "MEDDRA:10048599",
-                "PSY:10113",
-                "UMLS:C0338656",
-                "HP:0100543",
-                "MEDDRA:10009846",
-                "MESH:D060825",
-                "SNOMEDCT:386806002",
-                "NCIT:C46083",
-                "NCIT:C27101",
-                "PSY:10103"
-              ],
-              "id": "HP:0100543",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Impaired cognition",
-                "Cognitive Disturbance",
-                "Mental impairment",
-                "Cognitive impairment",
-                "Cognitive Impairment",
-                "Cognitive Dysfunction"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
->>>>>>> main
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 7665184,
-            "start": 570,
-            "end": 318789,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10571336': {'publication date': '1999 Nov', 'sentence': 'CONCLUSIONS: The ONTT has led to a dramatic reduction in the use of oral prednisone without a preceding course of intravenous methylprednisolone in the treatment of acute optic neuritis.', 'subject score': 888, 'object score': 901}, 'PMID:11389809': {'publication date': '2001 Jul', 'sentence': 'In all cases of typical acute monosymptomatic demyelinating optic neuritis, oral prednisone alone at a dose of 1 mg/kg per day, without prior treatment with IV methylprednisolone (1 g per day for 3 days), may increase the risk for recurrent optic neuritis, and should be avoided.', 'subject score': 888, 'object score': 787}, 'PMID:11784351': {'publication date': '2001 Nov', 'sentence': 'Here, we report a serial analysis of CSF CXCL10 and CCL2 concentrations in 22 patients with attacks of MS or acute optic neuritis (ON) treated with methylprednisolone, and 26 patients treated with placebo in two randomized controlled trials.', 'subject score': 1000, 'object score': 901}, 'PMID:11960657': {'publication date': '2002 Apr', 'sentence': 'Cerebrospinal fluid levels of nitric oxide metabolites predict response to methylprednisolone treatment in multiple sclerosis and optic neuritis.', 'subject score': 888, 'object score': 1000}, 'PMID:12757063': {'publication date': '2003 Mar', 'sentence': 'OBJECTIVE: To determine clinical characteristics of patients with optic neuritis and visual outcome after intravenous methylprednisolone treatment.', 'subject score': 851, 'object score': 1000}, 'PMID:17699944': {'publication date': '2007 Sep-Oct', 'sentence': 'AIM: To compare the efficacy of intravenous methylprednisolone and intravenous dexamethasone on visual recovery and evaluate their side-effects for the treatment of optic neuritis.', 'subject score': 888, 'object score': 1000}, 'PMID:18586870': {'publication date': '2008 Nov', 'sentence': 'PURPOSE: Methylprednisolone (MP) is commonly used to treat traumatic optic neuropathy and optic neuritis, but its benefit in terms of neuronal survival remains controversial.', 'subject score': 1000, 'object score': 1000}, 'PMID:22169982': {'publication date': '2012 Jun', 'sentence': 'Eight patients with documented idiopathic unilateral optic neuritis who did not improve with methyl prednisolone followed by oral steroids as per the Optic Neuritis Treatment Trial (ONTT) were administered Mw 5 ml in 500 ml normal saline, 30 days after the last of dose of steroids had been administered.', 'subject score': 1000, 'object score': 861}, 'PMID:22888383': {'publication date': '2012', 'sentence': 'According to Optic Neuritis Treatment Trial (ONTT) the first line of treatment is intravenous methylprednisolone with faster recovery and less chance of recurrence of ON and conversion to MS.', 'subject score': 888, 'object score': 861}, 'PMID:25605544': {'publication date': '2015 May', 'sentence': 'PURPOSE: To compare the effect of adding recombinant human erythropoietin (rhEPO) to intravenous methylprednisolone for the treatment of unilateral acute optic neuritis of unknown or demyelinative origin on the logarithm of the minimum angle of resolution (logMAR), perimetric variables [mean deviation (MD) and pattern standard deviation (PSD)], and retinal nerve fiber layer (RNFL) thickness in optical coherence tomography (OCT).', 'subject score': 888, 'object score': 861}, 'PMID:27566880': {'publication date': '2016 Oct', 'sentence': 'METHODS: This retrospective descriptive monocentric study included nine patients with ON treated with orally administered methylprednisolone at 1000 mg per day for three to five days.', 'subject score': 827, 'object score': 1000}, 'PMID:30268104': {'publication date': '2018 Sep 29', 'sentence': 'METHODS: Retrospective analysis of patients treated with oral or intravenous high-dose (?500 mg per day) methylprednisolone for acute ON of unknown or demyelinating etiology.', 'subject score': 1000, 'object score': 901}, 'PMID:30487360': {'publication date': '2018 Nov 29', 'sentence': 'Although treatment with methylprednisolone therapy provided relief, 3 months later she developed optic neuritis on the other side.', 'subject score': 888, 'object score': 1000}, 'PMID:35849047': {'publication date': '2022 Jul 14', 'sentence': 'He had been hospitalized two weeks prior for optic neuritis and treated with intravenous methylprednisolone.', 'subject score': 888, 'object score': 1000}, 'PMID:35859635': {'publication date': '2022', 'sentence': 'For each recurrent episode of optic neuritis she was treated with intravenous methylprednisolone, following which visual acuity, colour vision, and visual field improved to normal.', 'subject score': 888, 'object score': 1000}, 'PMID:36977296': {'publication date': '2023 Feb 28', 'sentence': 'Early treatment with intravenous methylprednisolone may be important for achieving at least 0.3 logMAR visual recovery in Thai patients with optic neuritis.', 'subject score': 888, 'object score': 1000}, 'PMID:37094997': {'publication date': '2023 Jul', 'sentence': 'We assessed its long-term safety and efficacy as an adjunct to methylprednisolone in patients with optic neuritis and focused on conversions to multiple sclerosis (MS).', 'subject score': 1000, 'object score': 1000}, 'PMID:3940867': {'publication date': '1986', 'sentence': 'We studied 8 patients with definite multiple sclerosis (3 with acute relapse, 5 with progression), and 2 patients with acute optic neuritis, who were treated with methylprednisolone infusions, 1 g daily for 3 days.', 'subject score': 872, 'object score': 901}, 'PMID:8481565': {'publication date': '1993 Apr', 'sentence': 'Methylprednisolone may have a minor role in the treatment of very severe, acute optic neuritis but prednisone use may predispose patients to recurrent optic neuritis.', 'subject score': 1000, 'object score': 840}, 'PMID:8813496': {'publication date': '1995-1996', 'sentence': 'Forty-eight patients with acute optic neuritis were treated orally either with methylprednisolone (100 mg per day initially, dosage reduction every 3 days; n = 15) or with thiamine (100 mg per day; n = 33) in the control group, 36 of them in a double-blind procedure.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0029134---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7827490",
-              "object": "MONDO:0005885",
-              "publications": [
-                "PMID:10571336",
-                "PMID:11389809",
-                "PMID:11784351",
-                "PMID:11960657",
-                "PMID:12757063",
-                "PMID:17699944",
-                "PMID:18586870",
-                "PMID:22169982",
-                "PMID:22888383",
-                "PMID:25605544",
-                "PMID:27566880",
-                "PMID:30268104",
-                "PMID:30487360",
-                "PMID:35849047",
-                "PMID:35859635",
-                "PMID:36977296",
-                "PMID:37094997",
-                "PMID:3940867",
-                "PMID:8481565",
-                "PMID:8813496"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316028,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008558",
-          "name": "autoimmune thrombocytopenic purpura",
-          "description": "Acquired thrombocytopenia of unknown cause, characterized by immune-mediated destruction of normal platelets. It affects both children and adults. It manifests with petechiae, purpura, and overt bleeding. Based upon the duration of the disease, it is classified as newly diagnosed (from diagnosis until 3 months), persistent (3-12 months), and chronic (lasting for more than 12 months).; Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.; The presence of thrombocytopenia in combination with detection of antiplatelet antibodies. [DDD:wouwehand]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021245",
-            "UMLS:C0398650",
-            "ORPHANET:3002",
-            "MESH:D016553",
-            "ICD9:287.31",
-            "MEDDRA:10083843",
-            "MEDDRA:10051064",
-            "MONDO:0008558",
-            "MEDDRA:10074667",
-            "OMIM:188030",
-            "DOID:8924",
-            "MEDDRA:10021243",
-            "ICD10:D69.3",
-            "EFO:0007160",
-            "NCIT:C3446"
-          ],
-          "id": "MONDO:0008558",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Purpura, Thrombocytopenic, Idiopathic",
-            "Immune thrombocytopenic purpura",
-            "Primary Immune Thrombocytopenia",
-            "Thrombocytopenic purpura, autoimmune related phenotypic feature",
-            "autoimmune thrombocytopenic purpura"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://rarediseases.org/rare-diseases/immune-thrombocytopenia/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316028,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008558",
-              "name": "autoimmune thrombocytopenic purpura",
-              "description": "Acquired thrombocytopenia of unknown cause, characterized by immune-mediated destruction of normal platelets. It affects both children and adults. It manifests with petechiae, purpura, and overt bleeding. Based upon the duration of the disease, it is classified as newly diagnosed (from diagnosis until 3 months), persistent (3-12 months), and chronic (lasting for more than 12 months).; Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.; The presence of thrombocytopenia in combination with detection of antiplatelet antibodies. [DDD:wouwehand]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021245",
-                "UMLS:C0398650",
-                "ORPHANET:3002",
-                "MESH:D016553",
-                "ICD9:287.31",
-                "MEDDRA:10083843",
-                "MEDDRA:10051064",
-                "MONDO:0008558",
-                "MEDDRA:10074667",
-                "OMIM:188030",
-                "DOID:8924",
-                "MEDDRA:10021243",
-                "ICD10:D69.3",
-                "EFO:0007160",
-                "NCIT:C3446"
-              ],
-              "id": "MONDO:0008558",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Purpura, Thrombocytopenic, Idiopathic",
-                "Immune thrombocytopenic purpura",
-                "Primary Immune Thrombocytopenia",
-                "Thrombocytopenic purpura, autoimmune related phenotypic feature",
-                "autoimmune thrombocytopenic purpura"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://rarediseases.org/rare-diseases/immune-thrombocytopenia/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7647812,
-            "start": 570,
-            "end": 316028,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10560547': {'publication date': '1999 Oct 09', 'sentence': 'CONCLUSION: A short intravenous course of high-dose methylprednisolone is effective as initial treatment of adults with ITP.', 'subject score': 901, 'object score': 1000}, 'PMID:10759004': {'publication date': '2000 Mar', 'sentence': 'Twelve patients with acute ITP were treated with high-dose methyl prednisolone and five patients were treated with intravenous immunoglobulin.', 'subject score': 901, 'object score': 916}, 'PMID:10761200': {'publication date': '2000 Mar', 'sentence': 'Treatment of childhood acute immune thrombocytopenic purpura with high-dose methylprednisolone, intravenous immunoglobulin, or the combination of both.', 'subject score': 901, 'object score': 875}, 'PMID:11809183': {'publication date': '2002 Jan 05', 'sentence': 'INTERPRETATION: Intravenous immunoglobulin and oral prednisone seems to be more effective than high-dose methylprednisolone and oral prednisone in adults with severe AITP, although the latter treatment is effective and well tolerated.', 'subject score': 901, 'object score': 916}, 'PMID:12051587': {'publication date': '2002 Jun', 'sentence': 'Clinical course of children with immune thrombocytopenic purpura treated with intravenous immunoglobulin G or megadose methylprednisolone or observed without therapy.', 'subject score': 861, 'object score': 1000}, 'PMID:12521514': {'publication date': '2002 May', 'sentence': 'Idiopathic thrombocytopenic purpura treated with pulsed high dose methylprednisolone followed by platelet transfusion.', 'subject score': 850, 'object score': 1000}, 'PMID:12621242': {'publication date': '2003 Mar', 'sentence': 'PURPOSE: To investigate combined immunosuppressive therapy with vincristine, methylprednisolone, and prolonged cyclosporine in adolescents with refractory idiopathic thrombocytopenic purpura (ITP).', 'subject score': 1000, 'object score': 916}, 'PMID:15357656': {'publication date': '2004 Sep', 'sentence': 'At week 28 of treatment with interferon (alfacon-1), undetectable HCV RNA and transaminase levels within normal limits, the patient presented with immune thrombocytopenic purpura, which was successfully treated with immunoglobulin and methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:16244777': {'publication date': '2005 Oct', 'sentence': 'In this study, coagulation parameters were investigated that might have a role in hemostatic compensation in childhood acute ITP before and after high-dose methylprednisolone (HDMP) treatment.', 'subject score': 861, 'object score': 851}, 'PMID:1712884': {'publication date': '1991 Jul 20', 'sentence': 'Megadose methylprednisolone or IVIG for idiopathic thrombocytopenic purpura.', 'subject score': 861, 'object score': 1000}, 'PMID:1817495': {'publication date': '1991', 'sentence': 'Intravenous immunoglobulin or megadose methylprednisolone for the treatment of idiopathic thrombocytopenic purpura.', 'subject score': 861, 'object score': 1000}, 'PMID:20404751': {'publication date': '2010 May', 'sentence': 'Patients with acute ITP were studied, before and after, methylprednisolone treatment.', 'subject score': 888, 'object score': 916}, 'PMID:22956408': {'publication date': '2013 Feb', 'sentence': 'In the treatment of ITP in childhood, one 50 MUg/kg dose of anti-D Ig has similar effects to IVIG and methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:2414107': {'publication date': '1985 Sep', 'sentence': 'High doses of gamma globulin and methylprednisolone therapy for idiopathic thrombocytopenic purpura in children.', 'subject score': 888, 'object score': 1000}, 'PMID:27265010': {'publication date': '2005 Dec 05', 'sentence': 'The study consisted of 21 children (aged between 1.5-14 years) with ITP treated with HDMP for 7 days.', 'subject score': 901, 'object score': 1000}, 'PMID:2910369': {'publication date': '1989 Jan', 'sentence': 'High-dose intravenous methylprednisolone for immune thrombocytopenic purpura.', 'subject score': 861, 'object score': 1000}, 'PMID:3195522': {'publication date': '1988 Dec', 'sentence': 'High-dose intravenous methylprednisolone for childhood idiopathic thrombocytopenic purpura.', 'subject score': 861, 'object score': 916}, 'PMID:32418984': {'publication date': '2020 May 18', 'sentence': 'CASE REPORT We present the case of a 53-year-old woman who developed diabetic ketoacidosis after administration of methylprednisolone during treatment of immune thrombocytopenic purpura.', 'subject score': 1000, 'object score': 1000}, 'PMID:3626155': {'publication date': '1987 May', 'sentence': 'Eleven patients with adult idiopathic thrombocytopenic purpura (ITP) were treated with bolus methylprednisolone at doses of 1 g/day for 3 days.', 'subject score': 861, 'object score': 916}, 'PMID:3679481': {'publication date': '1987 Apr', 'sentence': 'Chronic ITP treated with intravenous pulse methylprednisolone.', 'subject score': 802, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0398650---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7808987",
-              "object": "MONDO:0008558",
-              "publications": [
-                "PMID:10560547",
-                "PMID:10759004",
-                "PMID:10761200",
-                "PMID:11809183",
-                "PMID:12051587",
-                "PMID:12521514",
-                "PMID:12621242",
-                "PMID:15357656",
-                "PMID:16244777",
-                "PMID:1712884",
-                "PMID:1817495",
-                "PMID:20404751",
-                "PMID:22956408",
-                "PMID:2414107",
-                "PMID:27265010",
-                "PMID:2910369",
-                "PMID:3195522",
-                "PMID:32418984",
-                "PMID:3626155",
-                "PMID:3679481"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 313324,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-          "name": "Edema",
-          "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MEDDRA:10030114",
-            "MEDDRA:10014234",
-            "MEDDRA:10014210",
-            "MEDDRA:10005890",
-            "HP:0000969",
-            "SNOMEDCT:267038008",
-            "SNOMEDCT:43498006",
-            "SNOMEDCT:79654002",
-            "MESH:D004487",
-            "UMLS:C0013604",
-            "MEDDRA:10016807",
-            "EFO:0009373",
-            "SNOMEDCT:423666004",
-            "UMLS:C0268000",
-            "NCIT:C3002",
-            "MEDDRA:10030095",
-            "SNOMEDCT:20741006",
-            "SYMP:0000538"
-          ],
-          "id": "HP:0000969",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Edema",
-            "Body fluid retention",
-            "edema"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313324,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-              "name": "Edema",
-              "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MEDDRA:10030114",
-                "MEDDRA:10014234",
-                "MEDDRA:10014210",
-                "MEDDRA:10005890",
-                "HP:0000969",
-                "SNOMEDCT:267038008",
-                "SNOMEDCT:43498006",
-                "SNOMEDCT:79654002",
-                "MESH:D004487",
-                "UMLS:C0013604",
-                "MEDDRA:10016807",
-                "EFO:0009373",
-                "SNOMEDCT:423666004",
-                "UMLS:C0268000",
-                "NCIT:C3002",
-                "MEDDRA:10030095",
-                "SNOMEDCT:20741006",
-                "SYMP:0000538"
-              ],
-              "id": "HP:0000969",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Edema",
-                "Body fluid retention",
-                "edema"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7542390,
-            "start": 570,
-            "end": 313324,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10494671': {'publication date': '1999 Jul', 'sentence': 'Lipid peroxidation and oedema in experimental brain injury: comparison of treatment with methylprednisolone, tirilazad mesylate and vitamin E.', 'subject score': 1000, 'object score': 1000}, 'PMID:24117451': {'publication date': '2015 Mar', 'sentence': 'PURPOSE: The purpose of this study is to report a case of atypical serpiginous choroiditis presenting with disc edema and exudative retinal detachment, treated successfully with intravenous methyl prednisolone.', 'subject score': 888, 'object score': 861}, 'PMID:2493689': {'publication date': '1989 Feb', 'sentence': 'Treatment with MP immediately after NO2 was ineffective since mortality rates, W/D ratios, and alveolar and interstitial edema were not lower in the treated animals; there was significantly more intestitial edema in the middle lobes of the latter.', 'subject score': 888, 'object score': 1000}, 'PMID:25215167': {'publication date': '2014', 'sentence': 'The medical treatment of the patient consisted of anti-edema treatment with methylprednisolone in the first 24 hours; 330 mg of methylprednisolone infused in the first hour, followed by 59 mg per hour during the next 23 hours.', 'subject score': 1000, 'object score': 790}, 'PMID:2709033': {'publication date': '1989 Jan', 'sentence': 'Since brain water content is increased in normal appearing white matter of multiple sclerosis patients, and is significantly reduced by high-dose methylprednisolone, resolution of oedema may contribute to the rapid spontaneous or corticosteroid induced symptomatic recovery that characterises the disease in its early stages.', 'subject score': 901, 'object score': 1000}, 'PMID:28572712': {'publication date': '2017', 'sentence': 'Although MP has been thought to help in the resolution of edema, there are no scientific grounds to support this assertion.', 'subject score': 1000, 'object score': 1000}, 'PMID:29513816': {'publication date': '2018 Feb', 'sentence': 'PURPOSE: To investigate the effects of aquaporin 4 (AQP4) and inward rectifier potassium channel 4.1 (Kir4.1) on medullospinal edema after treatment with methylprednisolone (MP) to suppress acute spinal cord injury (ASCI) in rats.', 'subject score': 1000, 'object score': 861}, 'PMID:30314709': {'publication date': '2018 Oct 09', 'sentence': 'Within the purview of the limitations of this review, the results showed that MP administered via any route significantly improves oedema in the early postoperative period, but has no effect on late postoperative oedema.', 'subject score': 1000, 'object score': 1000}, 'PMID:32590413': {'publication date': '2020 Jun 23', 'sentence': 'Treatment with methylprednisolone resulted in resolution of the oedema, and a marked decrease in the subsequent accumulation of microhaemorrhages.', 'subject score': 1000, 'object score': 1000}, 'PMID:7277532': {'publication date': '1981 Oct', 'sentence': 'Furthermore, rate of edema formation is attenuated by methylprednisolone pretreatment.', 'subject score': 888, 'object score': 888}, 'PMID:735666': {'publication date': '1978', 'sentence': 'The edema in the ischemic segments tended to be less marked in rats treated with methylprednisolone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0013604---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7700869",
-              "object": "HP:0000969",
-              "publications": [
-                "PMID:10494671",
-                "PMID:24117451",
-                "PMID:2493689",
-                "PMID:25215167",
-                "PMID:2709033",
-                "PMID:28572712",
-                "PMID:29513816",
-                "PMID:30314709",
-                "PMID:32590413",
-                "PMID:7277532",
-                "PMID:735666"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 522619,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005301",
-          "name": "multiple sclerosis",
-          "description": "An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D009103",
-            "NCIT:C3243",
-            "MEDDRA:10039720",
-            "EFO:0003885",
-            "ORPHANET:802",
-            "MEDDRA:10028245",
-            "PSY:32490",
-            "ICD9:340",
-            "MONDO:0005301",
-            "MEDDRA:10028053",
-            "UMLS:C0026769",
-            "MEDDRA:10013451",
-            "SNOMEDCT:24700007",
-            "ICD10:G35",
-            "PDQ:CDR0000691761",
-            "DOID:2377"
-          ],
-          "id": "MONDO:0005301",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Multiple Sclerosis",
-            "obsolete_multiple sclerosis",
-            "Multiple sclerosis",
-            "multiple sclerosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://ghr.nlm.nih.gov/condition/multiple-sclerosis",
-            "http://en.wikipedia.org/wiki/multiple_sclerosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 522619,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005301",
-              "name": "multiple sclerosis",
-              "description": "An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D009103",
-                "NCIT:C3243",
-                "MEDDRA:10039720",
-                "EFO:0003885",
-                "ORPHANET:802",
-                "MEDDRA:10028245",
-                "PSY:32490",
-                "ICD9:340",
-                "MONDO:0005301",
-                "MEDDRA:10028053",
-                "UMLS:C0026769",
-                "MEDDRA:10013451",
-                "SNOMEDCT:24700007",
-                "ICD10:G35",
-                "PDQ:CDR0000691761",
-                "DOID:2377"
-              ],
-              "id": "MONDO:0005301",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Multiple Sclerosis",
-                "obsolete_multiple sclerosis",
-                "Multiple sclerosis",
-                "multiple sclerosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://ghr.nlm.nih.gov/condition/multiple-sclerosis",
-                "http://en.wikipedia.org/wiki/multiple_sclerosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7511438,
-            "start": 570,
-            "end": 522619,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10477400': {'publication date': '1999 Sep', 'sentence': 'The same determinations were repeated on plasma and on CSF samples that were collected after the MS patients had ended a six-day treatment with high-dose methylprednisolone (MP).', 'subject score': 901, 'object score': 901}, 'PMID:10675582': {'publication date': '2000 Feb 01', 'sentence': 'The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis.', 'subject score': 851, 'object score': 1000}, 'PMID:10933772': {'publication date': '2000 Apr', 'sentence': 'High-dose IVMP has previously been shown to be effective in the treatment of inflammatory eye disease and MS.', 'subject score': 861, 'object score': 1000}, 'PMID:11034713': {'publication date': '2000', 'sentence': \"REVIEWER'S CONCLUSIONS: We found evidence favouring the corticosteroid MP for acute exacerbation in MS patients.\", 'subject score': 888, 'object score': 901}, 'PMID:11176941': {'publication date': '2001 Jan', 'sentence': 'High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes.', 'subject score': 861, 'object score': 1000}, 'PMID:11279971': {'publication date': '1999 Sep', 'sentence': 'RESULTS: Both patients had a diagnostic lumbar puncture for suspected multiple sclerosis and were treated with high-dose intravenous methylprednisolone.', 'subject score': 861, 'object score': 901}, 'PMID:11319388': {'publication date': '2001 Mar', 'sentence': 'CASE REPORT: A thirty year-old-woman presented, a few hours after intravenous administration of methylprednisolone indicated for multiple sclerosis, a maculopapulous rash predominant in the folds rapidly becoming pustulous with malaise, fever and neutrophilia.', 'subject score': 1000, 'object score': 1000}, 'PMID:11784351': {'publication date': '2001 Nov', 'sentence': 'Here, we report a serial analysis of CSF CXCL10 and CCL2 concentrations in 22 patients with attacks of MS or acute optic neuritis (ON) treated with methylprednisolone, and 26 patients treated with placebo in two randomized controlled trials.', 'subject score': 1000, 'object score': 1000}, 'PMID:11882048': {'publication date': '2002 Jan', 'sentence': 'Relapses of multiple sclerosis (MS) are treated commonly with high-dose intravenous methylprednisolone (MP) given over a period of 3-5 days.', 'subject score': 861, 'object score': 1000}, 'PMID:11886356': {'publication date': '2002 Mar', 'sentence': 'A transcranial magnetic stimulation study evaluating methylprednisolone treatment in multiple sclerosis.', 'subject score': 786, 'object score': 1000}, 'PMID:11886358': {'publication date': '2002 Mar', 'sentence': 'Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:11929083': {'publication date': '2002 Feb', 'sentence': 'We assessed 23 subjects (15 women and 8 men) suffering from multiple sclerosis and treated with methylprednisolone (1 g i.v. for 10 days) followed by oral prednisone for 9 days; patients affected by diseases involving bone or treated during the previous 6 months with drugs influencing bone metabolism were excluded.', 'subject score': 1000, 'object score': 1000}, 'PMID:11960657': {'publication date': '2002 Apr', 'sentence': 'Cerebrospinal fluid levels of nitric oxide metabolites predict response to methylprednisolone treatment in multiple sclerosis and optic neuritis.', 'subject score': 888, 'object score': 1000}, 'PMID:12020259': {'publication date': '2002 May', 'sentence': 'PATIENTS: Eight patients with MS in exacerbation were studied before and 3 and 24 hours after intravenous methylprednisolone treatment, 1 g.', 'subject score': 851, 'object score': 1000}, 'PMID:12113297': {'publication date': '2002 May', 'sentence': 'High-dose methylprednisolone therapy in multiple sclerosis increases serum uric acid levels.', 'subject score': 861, 'object score': 1000}, 'PMID:12356209': {'publication date': '2002 Oct', 'sentence': 'Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone.', 'subject score': 861, 'object score': 901}, 'PMID:1370864': {'publication date': '1992 Jan', 'sentence': 'A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone.', 'subject score': 861, 'object score': 861}, 'PMID:14568494': {'publication date': '2003 Oct', 'sentence': 'Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy.', 'subject score': 861, 'object score': 901}, 'PMID:14760960': {'publication date': '2004 Feb', 'sentence': 'BACKGROUND: Some patients with multiple sclerosis (MS) do not show a clear improvement of acute relapses after treatment with intravenous methylprednisolone (IVMP).', 'subject score': 888, 'object score': 1000}, 'PMID:15327039': {'publication date': '2004 Aug', 'sentence': 'METHODS: Retrospective open-label study of medical records from 51 patients with clinically isolated syndromes or relapsing-remitting MS treated with IVMP for an acute attack (54 attacks).', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0026769---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7668594",
-              "object": "MONDO:0005301",
-              "publications": [
-                "PMID:10477400",
-                "PMID:10675582",
-                "PMID:10933772",
-                "PMID:11034713",
-                "PMID:11176941",
-                "PMID:11279971",
-                "PMID:11319388",
-                "PMID:11784351",
-                "PMID:11882048",
-                "PMID:11886356",
-                "PMID:11886358",
-                "PMID:11929083",
-                "PMID:11960657",
-                "PMID:12020259",
-                "PMID:12113297",
-                "PMID:12356209",
-                "PMID:1370864",
-                "PMID:14568494",
-                "PMID:14760960",
-                "PMID:15327039"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 315782,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
-          "name": "aplastic anemia",
-          "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What causes aplastic anemia? The causes of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0015909",
-            "MEDDRA:10002037",
-            "HP:0001915",
-            "MEDDRA:10002967",
-            "MEDDRA:10002274",
-            "MEDDRA:10002969",
-            "MESH:D000741",
-            "SNOMEDCT:306058006",
-            "PDQ:CDR0000489004",
-            "NCIT:C2870",
-            "MEDDRA:10002968",
-            "DOID:12449",
-            "MEDDRA:10002970",
-            "ICD9:284.9",
-            "SNOMEDCT:304132006",
-            "UMLS:C0002874",
-            "ICD10:D61.9",
-            "ORPHANET:182040"
-          ],
-          "id": "MONDO:0015909",
-          "category": "biolink:Disease",
-          "all_names": [
-            "aplastic anemia",
-            "Aplastic Anemia",
-            "Aplastic anemia",
-            "Aplastic anemia, unspecified",
-            "obsolete_Medullar aplasia",
-            "Anemia, Aplastic"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
-            "http://en.wikipedia.org/wiki/aplastic_anemia",
-            "PMID:21239768",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315782,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
-              "name": "aplastic anemia",
-              "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What causes aplastic anemia? The causes of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0015909",
-                "MEDDRA:10002037",
-                "HP:0001915",
-                "MEDDRA:10002967",
-                "MEDDRA:10002274",
-                "MEDDRA:10002969",
-                "MESH:D000741",
-                "SNOMEDCT:306058006",
-                "PDQ:CDR0000489004",
-                "NCIT:C2870",
-                "MEDDRA:10002968",
-                "DOID:12449",
-                "MEDDRA:10002970",
-                "ICD9:284.9",
-                "SNOMEDCT:304132006",
-                "UMLS:C0002874",
-                "ICD10:D61.9",
-                "ORPHANET:182040"
-              ],
-              "id": "MONDO:0015909",
-              "category": "biolink:Disease",
-              "all_names": [
-                "aplastic anemia",
-                "Aplastic Anemia",
-                "Aplastic anemia",
-                "Aplastic anemia, unspecified",
-                "obsolete_Medullar aplasia",
-                "Anemia, Aplastic"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
-                "http://en.wikipedia.org/wiki/aplastic_anemia",
-                "PMID:21239768",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7480314,
-            "start": 570,
-            "end": 315782,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10466441': {'publication date': '1999 Jul', 'sentence': 'Neutropenic infections are the major cause of morbidity and mortality in the treatment of aplastic anemia (AA) with antilymphocyte globulin (ALG), cyclosporin A (CSA), and methylprednisolone (MP).', 'subject score': 1000, 'object score': 1000}, 'PMID:12393680': {'publication date': '2003 Feb 15', 'sentence': 'Immunosuppression with antithymocyte globulin, (methyl)prednisolone, and cyclosporin A is considered the treatment of choice for the patient with aplastic anemia without a donor for standard-risk stem cell transplantation.', 'subject score': 1000, 'object score': 1000}, 'PMID:1542816': {'publication date': '1992 Mar 07', 'sentence': 'Antilymphocyte globulin and high-dose methylprednisolone improve survival in patients with aplastic anaemia without additional financial costs.', 'subject score': 901, 'object score': 1000}, 'PMID:1863830': {'publication date': '1991 Aug', 'sentence': 'We report a case of SLE related aplastic anaemia in which therapy with methylprednisolone and high dose cyclophosphamide followed by prednisolone and azathioprine resulted in complete clinical and haematological remission.', 'subject score': 1000, 'object score': 1000}, 'PMID:2012072': {'publication date': '1991 Apr', 'sentence': 'Treatment of aplastic anaemia with antilymphocyte globulin and high-dose methylprednisolone.', 'subject score': 901, 'object score': 1000}, 'PMID:2017225': {'publication date': '1991 May 09', 'sentence': 'CONCLUSIONS: Immunosuppressive treatment of aplastic anemia with antilymphocyte globulin, methylprednisolone, and cyclosporine appears to be more effective than a regimen of antilymphocyte globulin and methylprednisolone without cyclosporine and may thus represent a treatment of choice for patients who are not eligible for bone marrow transplantation.', 'subject score': 1000, 'object score': 1000}, 'PMID:22479166': {'publication date': '2011 Jul', 'sentence': 'We present an adolescent with SAA and preexisting bradycardia who underwent immunosuppression therapy with ATG, methylprednisolone, and tacrolimus and developed profound sinus bradycardia with successive doses of ATG.', 'subject score': 1000, 'object score': 901}, 'PMID:2381070': {'publication date': '1990 Apr', 'sentence': 'Here, we will discuss this case of aplastic anemia which responded to repeated bolus methylprednisolone therapy, with minimal side effects, and discuss its effectiveness.', 'subject score': 775, 'object score': 1000}, 'PMID:25184310': {'publication date': '2014 Nov', 'sentence': 'CONCLUSIONS: hATG with methylprednisolone and CSA is recommended for front-line treatment of AA, whereas rATG is reserved for salvage therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:2741916': {'publication date': '1989 Jul', 'sentence': 'A patient with aplastic anemia, who had been unresponsive to androgens, antithymocyte globulin, high-dose methylprednisolone, and cyclosporine, responded to treatment with 3-beta-etiocholanolone, nandrolone decanoate, and prednisolone acetate.', 'subject score': 901, 'object score': 1000}, 'PMID:3107306': {'publication date': '1986', 'sentence': 'We recommend combined immunosuppressive treatment with ATG and high-dose MP as a highly feasible, safe and effectful therapy for patients with transfusion-dependent SAA.', 'subject score': 901, 'object score': 798}, 'PMID:3259191': {'publication date': '1988 Apr', 'sentence': 'Methylprednisolone therapy in aplastic anaemia: correlation of in vitro tests and lymphocyte subsets with clinical response.', 'subject score': 888, 'object score': 1000}, 'PMID:3366221': {'publication date': '1988 Apr', 'sentence': 'A 22-yr-old man with aplastic anaemia was treated with high dose methylprednisolone.', 'subject score': 901, 'object score': 1000}, 'PMID:3492629': {'publication date': '1986 Nov 17', 'sentence': 'Treatment of aplastic anemia with cyclosporin A, methylprednisolone, and antithymocyte globulin.', 'subject score': 1000, 'object score': 1000}, 'PMID:3524596': {'publication date': '1986 Jun', 'sentence': 'Methylprednisolone treatment in aplastic anaemia.', 'subject score': 888, 'object score': 1000}, 'PMID:3820608': {'publication date': '1986 Oct', 'sentence': '[Significance of corticosteroid administration including bolus methylprednisolone therapy as the preconditioning of hematopoiesis in the treatment of aplastic anemia].', 'subject score': 790, 'object score': 1000}, 'PMID:6481979': {'publication date': '1984 Jun', 'sentence': '[Bolus methylprednisolone therapy for aplastic anemia: a case report].', 'subject score': 790, 'object score': 1000}, 'PMID:7053691': {'publication date': '1982 Jan', 'sentence': 'Bolous of methylprednisolone for aplastic anemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:8217834': {'publication date': '1993 Aug', 'sentence': 'Avascular necrosis of bone (AVN) occurring in patients with aplastic anaemia (AA) treated with antilymphocyte globulin (ALG) followed by high-dose methylprednisolone (HDMP) has been studied retrospectively.', 'subject score': 901, 'object score': 1000}, 'PMID:8435323': {'publication date': '1993 Jan', 'sentence': 'In conclusion, the addition of androgens to HALG and methylprednisolone as first line treatment of aplastic anaemia significantly improves the response rate at 4 months, particularly in females with low neutrophil counts, although there is no significant effect on short-term survival.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0002874---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7649490",
-              "object": "MONDO:0015909",
-              "publications": [
-                "PMID:10466441",
-                "PMID:12393680",
-                "PMID:1542816",
-                "PMID:1863830",
-                "PMID:2012072",
-                "PMID:2017225",
-                "PMID:22479166",
-                "PMID:2381070",
-                "PMID:25184310",
-                "PMID:2741916",
-                "PMID:3107306",
-                "PMID:3259191",
-                "PMID:3366221",
-                "PMID:3492629",
-                "PMID:3524596",
-                "PMID:3820608",
-                "PMID:6481979",
-                "PMID:7053691",
-                "PMID:8217834",
-                "PMID:8435323"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7399713,
-            "start": 570,
-            "end": 183319,
-=======
-            "identity": 11628942,
-            "start": 570,
-            "end": 321491,
->>>>>>> main
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-<<<<<<< HEAD
-              "publications_info": "{'PMID:10414517': {'publication date': '1999 Jun', 'sentence': 'Methylprednisolone treatment resulted in the greatest reduction in the inflammatory cell infiltrate but the numbers of infected neurons did not increase concomitantly.', 'subject score': 888, 'object score': 901}, 'PMID:11934518': {'publication date': '2002 Apr', 'sentence': 'Since sequential MRI studies showed prompt reduction of the cord swelling, the high-dose methylprednisolone therapy employed seemed to have been effective for improvement of inflammation.', 'subject score': 861, 'object score': 1000}, 'PMID:15778611': {'publication date': '2005 Apr', 'sentence': 'In addition, topical methylprednisolone (1 mg/mL) was necessary to control inflammation and pain.', 'subject score': 861, 'object score': 1000}, 'PMID:16419423': {'publication date': '2005', 'sentence': 'CONCLUSION: The intensity of ocular inflammation in the group receiving HBO therapy combined with anterior subtenon injection of methylprednisolone therapy was lower than in the other groups.', 'subject score': 888, 'object score': 888}, 'PMID:16878063': {'publication date': '2006 Aug 01', 'sentence': 'OBJECTIVE: To compare the efficacy of methylprednisolone (corticoid) versus diclofenac (nonsteroidal anti-inflammatory--NSAID) in the treatment of inflammation and trismus after the surgical removal of lower third molars.', 'subject score': 1000, 'object score': 1000}, 'PMID:17237695': {'publication date': '2007 Jan-Feb', 'sentence': 'Topical cyclosporine and 1% methylprednisolone eliminated the anterior segment inflammation; subsequent treatment with systemic prednisone reduced the ptosis and edema.', 'subject score': 861, 'object score': 901}, 'PMID:18554795': {'publication date': '2008 Aug 01', 'sentence': 'These findings suggest that the brain responds to OVA stimulation in a rat model of allergic asthma and that MP treatment cannot only ameliorate airway inflammation but also OVA-induced effects.', 'subject score': 888, 'object score': 861}, 'PMID:20383416': {'publication date': '2010 Apr', 'sentence': 'CONCLUSION: In the early stage of cerulein induced AP, the administration of etanercept plus MP attenuated pancreatic inflammation and significant damage in rats.', 'subject score': 851, 'object score': 888}, 'PMID:25037177': {'publication date': '2014 Sep 15', 'sentence': 'Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis.', 'subject score': 775, 'object score': 888}, 'PMID:27288919': {'publication date': '2016 Jul 15', 'sentence': 'Expression levels of TNF-alpha, IL-4, and IL-5 were also found significantly reduced after treatment with both PI extract and MP, which might have resulted in the amelioration of airway inflammation.', 'subject score': 1000, 'object score': 861}, 'PMID:27904502': {'publication date': '2016 Oct', 'sentence': 'Our results demonstrated that a combined treatment with methylprednisolone and rosiglitazone had a more pronounced effect on attenuation of inflammation and cell apoptosis, as well as increased functional recovery, compared with either single treatment alone, indicating that a combination better promoted recovery of neurological function after injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:29253747': {'publication date': '2018 02', 'sentence': 'CONCLUSION: Administration of MPN to BDDs at specified periods until kidney harvest resulted in less systemic inflammation in the BDDs and improved renal function in kidney graft recipients compared with common MPN therapy.', 'subject score': 851, 'object score': 790}, 'PMID:29879013': {'publication date': '2018 Jun', 'sentence': 'INTERVENTIONS: He was treated with gamma globulin (2 g/kg) for 1 day, mannitol and furosemide to reduce intracranial pressure, human albumin to correct hypoproteinemia, methylprednisolone to control inflammation, and both aspirin and dipyridamole for anticoagulation.', 'subject score': 1000, 'object score': 1000}, 'PMID:8032946': {'publication date': '1994 Apr 25', 'sentence': 'Methylprednisolone attenuates inflammation, increase of brain water content and intracranial pressure, but does not influence cerebral blood flow changes in experimental pneumococcal meningitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:9361341': {'publication date': '1997 Nov', 'sentence': 'Lazaroids are developed nonglucocorticoid analogues of methylprednisolone with multiple actions, including the scavenging of reactive oxygen species, the attenuation of inflammation, and the stabilization of biological membranes.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7552935",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:10414517",
-                "PMID:11934518",
-                "PMID:15778611",
-                "PMID:16419423",
-                "PMID:16878063",
-                "PMID:17237695",
-                "PMID:18554795",
-                "PMID:20383416",
-                "PMID:25037177",
-                "PMID:27288919",
-                "PMID:27904502",
-                "PMID:29253747",
-                "PMID:29879013",
-                "PMID:8032946",
-                "PMID:9361341"
-=======
-              "publications_info": "{'PMID:15957521': {'publication date': '2005 Jun', 'sentence': 'One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:34237754': {'publication date': '2021 Jul 08', 'sentence': 'Herein, we report a case of a patient with GFAP-A with initial symptoms of psychological and cognitive impairment, which did not respond to high-dose methylprednisolone therapy but was successfully treated with protein A immunoadsorption (PAIA) therapy.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0338656---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "11882768",
-              "object": "HP:0100543",
-              "publications": [
-                "PMID:15957521",
-                "PMID:34237754"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 319500,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0100130",
-          "name": "adult acute respiratory distress syndrome",
-          "description": "Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.; A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:J80",
-            "MEDDRA:10042839",
-            "UMLS:C4281993",
-            "MEDDRA:10038691",
-            "MEDDRA:10040579",
-            "DOID:11394",
-            "SNOMEDCT:196153002",
-            "ORPHANET:70578",
-            "MEDDRA:10042787",
-            "SNOMEDCT:67782005",
-            "MONDO:0100130",
-            "MEDDRA:10003083",
-            "MEDDRA:10038688",
-            "MEDDRA:10001410",
-            "HP:0002643",
-            "MEDDRA:10001407",
-            "MEDDRA:10000036",
-            "UMLS:C0852283",
-            "MEDDRA:10028973",
-            "UMLS:C0035222",
-            "MEDDRA:10001052",
-            "MEDDRA:10001409",
-            "MESH:D012128",
-            "SNOMEDCT:1179627006",
-            "UMLS:C1368020"
-          ],
-          "id": "MONDO:0100130",
-          "category": "biolink:Disease",
-          "all_names": [
-            "adult acute respiratory distress syndrome",
-            "Neonatal respiratory distress",
-            "Respiratory Distress Syndrome, Adult",
-            "adult respiratory distress syndrome",
-            "Respiratory Distress Syndrome",
-            "Adult acute respiratory distress syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5392788/",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=adult+respiratory+distress+syndrome"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319500,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0100130",
-              "name": "adult acute respiratory distress syndrome",
-              "description": "Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.; A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:J80",
-                "MEDDRA:10042839",
-                "UMLS:C4281993",
-                "MEDDRA:10038691",
-                "MEDDRA:10040579",
-                "DOID:11394",
-                "SNOMEDCT:196153002",
-                "ORPHANET:70578",
-                "MEDDRA:10042787",
-                "SNOMEDCT:67782005",
-                "MONDO:0100130",
-                "MEDDRA:10003083",
-                "MEDDRA:10038688",
-                "MEDDRA:10001410",
-                "HP:0002643",
-                "MEDDRA:10001407",
-                "MEDDRA:10000036",
-                "UMLS:C0852283",
-                "MEDDRA:10028973",
-                "UMLS:C0035222",
-                "MEDDRA:10001052",
-                "MEDDRA:10001409",
-                "MESH:D012128",
-                "SNOMEDCT:1179627006",
-                "UMLS:C1368020"
-              ],
-              "id": "MONDO:0100130",
-              "category": "biolink:Disease",
-              "all_names": [
-                "adult acute respiratory distress syndrome",
-                "Neonatal respiratory distress",
-                "Respiratory Distress Syndrome, Adult",
-                "adult respiratory distress syndrome",
-                "Respiratory Distress Syndrome",
-                "Adult acute respiratory distress syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5392788/",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=adult+respiratory+distress+syndrome"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7332287,
-            "start": 570,
-            "end": 319500,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10378576': {'publication date': '1999 Jun', 'sentence': \"Severe systemic inflammatory response syndrome with shock and ARDS resulting from Still's disease: clinical response with high-dose pulse methylprednisolone therapy.\", 'subject score': 785, 'object score': 1000}, 'PMID:10389390': {'publication date': '1999 May', 'sentence': 'Levels of evidence for the pharmacological effectiveness of prolonged methylprednisolone treatment in unresolving acute respiratory distress syndrome.', 'subject score': 851, 'object score': 937}, 'PMID:10424629': {'publication date': '1999 Jul', 'sentence': 'Levels of evidence for the pharmacologic effectiveness of prolonged methylprednisolone treatment in unresolving ARDS.', 'subject score': 851, 'object score': 861}, 'PMID:11068074': {'publication date': '2000 Jul-Aug', 'sentence': 'This review approaches also the role of leukotriene modifiers in the treatment of asthma and discusses the benefit of using methylprednisolone in patients with adult respiratory distress syndrome, among many other advances in internal medicine.', 'subject score': 1000, 'object score': 1000}, 'PMID:11304898': {'publication date': '2001 Apr', 'sentence': 'Initial clearance of MP (CLo) in ARDS patients at the start of therapy increased to a maximal value (CLmax) after approximately 7 days.', 'subject score': 1000, 'object score': 928}, 'PMID:11687457': {'publication date': '2001 Nov', 'sentence': 'Our clinical studies have shown that methylprednisolone is capable of reducing the levels of TNF-alpha, IL-1 beta, and IL-6 in ARDS patients.', 'subject score': 1000, 'object score': 928}, 'PMID:12607352': {'publication date': '2002 Dec', 'sentence': 'She was diagnosed as M. pneumoniae pneumonia with acute respiratory distress syndrome and treated with clarithromycin and methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:1263566': {'publication date': '1976 May', 'sentence': 'This study demonstrated a significant improvement in mortality rate with repeated pharmacologic doses of methylprednisolone compared to previously reported mortality rates of 60 to 90 per cent in patients with shock lung syndrome treated without repeated pharmacologic doses of steroid therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:15651276': {'publication date': '2004 Nov', 'sentence': 'He was diagnosed as having acute respiratory distress syndrome due to severe pneumonia, and was treated with pulse methylprednisolone and sivelestat sodium in combination with intravenous erythromycin and ciprofloxacin.', 'subject score': 861, 'object score': 1000}, 'PMID:16625008': {'publication date': '2006 Apr 20', 'sentence': 'CONCLUSIONS: These results do not support the routine use of methylprednisolone for persistent ARDS despite the improvement in cardiopulmonary physiology.', 'subject score': 1000, 'object score': 928}, 'PMID:16891686': {'publication date': '2006 Jul', 'sentence': 'We report successful use of methyl-prednisolone in a 21-month old child with ARDS that did not improve with conventional therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:17554986': {'publication date': '2007 May', 'sentence': '[A case of legionella pneumonia associated with acute respiratory distress syndrome (ARDS) and acute renal failure treated with methylprednisolone and sivelestat].', 'subject score': 1000, 'object score': 901}, 'PMID:18657064': {'publication date': '2008 Nov', 'sentence': 'Recently, Meduri et al. found that the early use of low-dose prolonged methylprednisolone in patients with severe ALI/ARDS significantly relieved the systemic inflammatory response and improved pulmonary and extrapulmonary organ function.', 'subject score': 1000, 'object score': 802}, 'PMID:18946661': {'publication date': '2009 Jan', 'sentence': 'PATIENTS AND PARTICIPANTS: Patients enrolled in the ARDS Network study of methylprednisolone versus placebo for persistent ARDS who survived 60 days or to hospital discharge.', 'subject score': 1000, 'object score': 888}, 'PMID:19325471': {'publication date': '2009 May', 'sentence': 'STUDY SELECTION: Randomized controlled trials (RCTs) and observational studies reported in any language that used 0.5-2.5 mg.kg.d of methylprednisolone or equivalent to treat ALI/ARDS.', 'subject score': 1000, 'object score': 818}, 'PMID:20406086': {'publication date': '2010 Apr', 'sentence': 'We recommend that prolonged methylprednisolone treatment, at an initial dose of 1 mg/kg/day in early ARDS and 2 mg/kg/day in unresolving ARDS, be delivered as an infusion to avoid glycemic variability, and that infection surveillance be strictly implemented to identify infections in the absence of fever.', 'subject score': 851, 'object score': 928}, 'PMID:22004685': {'publication date': '2012 Mar', 'sentence': 'RESULTS: Mean time from the diagnosis of the ARDS to methylprednisolone treatment was 11 +/- 2 days in the intermediate  group (10 patients) and 21 +/- 8 days in the late group (9 patients).', 'subject score': 888, 'object score': 1000}, 'PMID:2214425': {'publication date': '1990 Jun', 'sentence': 'This result was considered to some extent to be better than that of our previous experience with single administration of M-PSL for patients with septic ARDS.', 'subject score': 1000, 'object score': 928}, 'PMID:22251837': {'publication date': '2012 02', 'sentence': 'Administration of an antiviral agent (acyclovir), an antibacterial agent (linezolid), and a corticosteroid (methylprednisolone) successfully improved the pneumonia and ARDS.', 'subject score': 1000, 'object score': 1000}, 'PMID:25302516': {'publication date': '2010 Dec', 'sentence': 'Therefore, more research is required to establish the safety and efficacy of methylprednisolone in pediatric patients with acute lung injury/acute respiratory distress syndrome , as well as to determine the best parameters for monitoring steroid side effects and outcomes.', 'subject score': 1000, 'object score': 818}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0035222---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7483648",
-              "object": "MONDO:0100130",
-              "publications": [
-                "PMID:10378576",
-                "PMID:10389390",
-                "PMID:10424629",
-                "PMID:11068074",
-                "PMID:11304898",
-                "PMID:11687457",
-                "PMID:12607352",
-                "PMID:1263566",
-                "PMID:15651276",
-                "PMID:16625008",
-                "PMID:16891686",
-                "PMID:17554986",
-                "PMID:18657064",
-                "PMID:18946661",
-                "PMID:19325471",
-                "PMID:20406086",
-                "PMID:22004685",
-                "PMID:2214425",
-                "PMID:22251837",
-                "PMID:25302516"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318345,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018881",
-          "name": "myelodysplastic syndrome",
-          "description": "A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3247\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3247\" NCI Thesaurus); A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001); Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.; Clonal hematopoietic stem cell disorders characterized by dysplasia (ineffective production) in one or more hematopoietic cell lineages, leading to anemia and cytopenia. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10028534",
-            "ORPHANET:52688",
-            "SNOMEDCT:74326002",
-            "MEDDRA:10028532",
-            "MEDDRA:10042295",
-            "SNOMEDCT:188736006",
-            "NCIT:C3176",
-            "DOID:0050908",
-            "MEDDRA:10060421",
-            "UMLS:C0033027",
-            "MEDDRA:10028536",
-            "SNOMEDCT:109995007",
-            "PDQ:CDR0000039817",
-            "MESH:D011289",
-            "HP:0002863",
-            "SNOMEDCT:128826001",
-            "OMIM:614286",
-            "EFO:0000198",
-            "MEDDRA:10028533",
-            "UMLS:C3463824",
-            "MEDDRA:10054651",
-            "UMLS:C2713368",
-            "MEDDRA:10028554",
-            "MEDDRA:10054577",
-            "MESH:D054438",
-            "SNOMEDCT:128623006",
-            "UMLS:C1851971",
-            "MESH:D009190",
-            "UMLS:C1292772",
-            "MEDDRA:10028559",
-            "MEDDRA:10036587",
-            "MEDDRA:10028548",
-            "NCIT:C3247",
-            "MEDDRA:10042292",
-            "MONDO:0018881"
-          ],
-          "id": "MONDO:0018881",
-          "category": "biolink:Disease",
-          "all_names": [
-            "myelodysplastic syndrome",
-            "Myelodysplasia",
-            "Hematopoetic Myelodysplasia",
-            "Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative",
-            "Myelodysplastic syndrome",
-            "Philadelphia-Negative Myelogenous Leukemia",
-            "Myelodysplastic Syndrome",
-            "Preleukemia",
-            "Myelodysplastic Syndromes",
-            "Hypoplastic myelodysplasia",
-            "Myelodysplastic syndrome related phenotypic feature",
-            "myelodysplastic syndromes"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/myelodysplastic_syndrome",
-            "http://www.cancer.gov/dictionary?cdrid=45266",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318345,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018881",
-              "name": "myelodysplastic syndrome",
-              "description": "A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3247\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3247\" NCI Thesaurus); A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001); Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.; Clonal hematopoietic stem cell disorders characterized by dysplasia (ineffective production) in one or more hematopoietic cell lineages, leading to anemia and cytopenia. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10028534",
-                "ORPHANET:52688",
-                "SNOMEDCT:74326002",
-                "MEDDRA:10028532",
-                "MEDDRA:10042295",
-                "SNOMEDCT:188736006",
-                "NCIT:C3176",
-                "DOID:0050908",
-                "MEDDRA:10060421",
-                "UMLS:C0033027",
-                "MEDDRA:10028536",
-                "SNOMEDCT:109995007",
-                "PDQ:CDR0000039817",
-                "MESH:D011289",
-                "HP:0002863",
-                "SNOMEDCT:128826001",
-                "OMIM:614286",
-                "EFO:0000198",
-                "MEDDRA:10028533",
-                "UMLS:C3463824",
-                "MEDDRA:10054651",
-                "UMLS:C2713368",
-                "MEDDRA:10028554",
-                "MEDDRA:10054577",
-                "MESH:D054438",
-                "SNOMEDCT:128623006",
-                "UMLS:C1851971",
-                "MESH:D009190",
-                "UMLS:C1292772",
-                "MEDDRA:10028559",
-                "MEDDRA:10036587",
-                "MEDDRA:10028548",
-                "NCIT:C3247",
-                "MEDDRA:10042292",
-                "MONDO:0018881"
-              ],
-              "id": "MONDO:0018881",
-              "category": "biolink:Disease",
-              "all_names": [
-                "myelodysplastic syndrome",
-                "Myelodysplasia",
-                "Hematopoetic Myelodysplasia",
-                "Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative",
-                "Myelodysplastic syndrome",
-                "Philadelphia-Negative Myelogenous Leukemia",
-                "Myelodysplastic Syndrome",
-                "Preleukemia",
-                "Myelodysplastic Syndromes",
-                "Hypoplastic myelodysplasia",
-                "Myelodysplastic syndrome related phenotypic feature",
-                "myelodysplastic syndromes"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/myelodysplastic_syndrome",
-                "http://www.cancer.gov/dictionary?cdrid=45266",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7283288,
-            "start": 570,
-            "end": 318345,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10354391': {'publication date': '1999 Jun', 'sentence': 'Eosinophilic fasciitis associated with autoimmune thyroid disease and myelodysplasia treated with pulsed methylprednisolone and antihistamines.', 'subject score': 872, 'object score': 1000}, 'PMID:11764102': {'publication date': '2001 Dec', 'sentence': 'Results obtained with HDMP from the previous studies and the present case suggest that high-dose methylprednisolone is a promising agent in the treatment of AIDS and it is recommended as an initial treatment especially for MDS children with hypocellular bone marrow at presentation.', 'subject score': 901, 'object score': 901}, 'PMID:17483080': {'publication date': '2007 May', 'sentence': 'Selective blast cell reduction in elderly patients with acute myeloid leukemia secondary to myelodysplastic syndrome treated with methylprednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:8655463': {'publication date': '1995', 'sentence': 'High-dose methylprednisolone (HDMP) has been shown to induce differentiation of myeloid leukemic cells with a remarkable antileukemic effect in children with various subtypes of acute myeloblastic leukemia (AML), therefore we used HDMP in the treatment of four children with myelodysplastic syndrome (MDS).', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C3463824---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7432980",
-              "object": "MONDO:0018881",
-              "publications": [
-                "PMID:10354391",
-                "PMID:11764102",
-                "PMID:17483080",
-                "PMID:8655463"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 313324,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-          "name": "Edema",
-          "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MEDDRA:10030114",
-            "MEDDRA:10014234",
-            "MEDDRA:10014210",
-            "MEDDRA:10005890",
-            "HP:0000969",
-            "SNOMEDCT:267038008",
-            "SNOMEDCT:43498006",
-            "SNOMEDCT:79654002",
-            "MESH:D004487",
-            "UMLS:C0013604",
-            "MEDDRA:10016807",
-            "EFO:0009373",
-            "SNOMEDCT:423666004",
-            "UMLS:C0268000",
-            "NCIT:C3002",
-            "MEDDRA:10030095",
-            "SNOMEDCT:20741006",
-            "SYMP:0000538"
-          ],
-          "id": "HP:0000969",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Edema",
-            "Body fluid retention",
-            "edema"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313324,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-              "name": "Edema",
-              "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MEDDRA:10030114",
-                "MEDDRA:10014234",
-                "MEDDRA:10014210",
-                "MEDDRA:10005890",
-                "HP:0000969",
-                "SNOMEDCT:267038008",
-                "SNOMEDCT:43498006",
-                "SNOMEDCT:79654002",
-                "MESH:D004487",
-                "UMLS:C0013604",
-                "MEDDRA:10016807",
-                "EFO:0009373",
-                "SNOMEDCT:423666004",
-                "UMLS:C0268000",
-                "NCIT:C3002",
-                "MEDDRA:10030095",
-                "SNOMEDCT:20741006",
-                "SYMP:0000538"
-              ],
-              "id": "HP:0000969",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Edema",
-                "Body fluid retention",
-                "edema"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19357722,
-            "start": 570,
-            "end": 313324,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28666096': {'publication date': '2017 Nov', 'sentence': 'RESULTS: Both methylprednisolone and dexamethasone significantly reduced swelling and trismus (P < .05, Kruskal-Wallis test), whereas the methylprednisolone group had significantly less pain (P < .05, Kruskal-Wallis test) and consumed a lower amount of analgesics (P < .05, chi2 test) during the early postoperative days.', 'subject score': 1000, 'object score': 775}, 'PMID:29513816': {'publication date': '2018 Feb', 'sentence': 'CONCLUSION: Methylprednisolone inhibited medullospinal edema in rats with acute spinal cord injury, possibly by reducing the coexpression of aquaporin 4 and Kir4.1 in medullospinal tissues.', 'subject score': 1000, 'object score': 861}, 'PMID:30143486': {'publication date': '2018 Jul', 'sentence': 'MP inhibited spinal edema in rats with ASCI, which might be related to the reduced AQP4 expression in spinal tissues.', 'subject score': 1000, 'object score': 888}, 'PMID:3744476': {'publication date': '1986 Sep', 'sentence': 'In separate experiments, MP inhibited intradermal edema formation and protein exudation induced in rats by histamine, platelet activating factor, or C5a.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:disrupts---None---None---None---UMLS:C0013604---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "19744632",
-              "object": "HP:0000969",
-              "publications": [
-                "PMID:28666096",
-                "PMID:29513816",
-                "PMID:30143486",
-                "PMID:3744476"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316686,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002049",
-          "name": "thrombocytopenia",
-          "description": "A reduction in the number of circulating thrombocytes. [HPO:probinson]; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T034",
-          "equivalent_curies": [
-            "UMLS:C0392386",
-            "SNOMEDCT:302215000",
-            "MEDDRA:10035545",
-            "MEDDRA:10043555",
-            "PDQ:CDR0000041408",
-            "MEDDRA:10024922",
-            "ICD10:D69.6",
-            "HP:0001873",
-            "NCIT:C3408",
-            "NCIT:C162108",
-            "MEDDRA:10035528",
-            "UMLS:C5201036",
-            "MEDDRA:10043560",
-            "DOID:1588",
-            "UMLS:CN130080",
-            "SYMP:0000114",
-            "MEDDRA:10038213",
-            "MEDDRA:10043546",
-            "MESH:D013921",
-            "MEDDRA:10035529",
-            "MEDDRA:10043569",
-            "UMLS:C0040034",
-            "MEDDRA:10043554",
-            "ICD9:287.5",
-            "MONDO:0002049",
-            "SNOMEDCT:415116008"
-          ],
-          "id": "MONDO:0002049",
-          "category": "biolink:Disease",
-          "all_names": [
-            "thrombocytopenia",
-            "Thrombocytopenia, unspecified",
-            "Low Platelet Count",
-            "Thrombocytopenia",
-            "Decreased platelet count"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/thrombocytopenia",
-            "http://www.merckmanuals.com/professional/hematology_and_oncology/thrombocytopenia_and_platelet_dysfunction/overview_of_platelet_disorders.htm",
-            "http://ghr.nlm.nih.gov/glossary=thrombocytopenia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316686,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002049",
-              "name": "thrombocytopenia",
-              "description": "A reduction in the number of circulating thrombocytes. [HPO:probinson]; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major causes; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T034",
-              "equivalent_curies": [
-                "UMLS:C0392386",
-                "SNOMEDCT:302215000",
-                "MEDDRA:10035545",
-                "MEDDRA:10043555",
-                "PDQ:CDR0000041408",
-                "MEDDRA:10024922",
-                "ICD10:D69.6",
-                "HP:0001873",
-                "NCIT:C3408",
-                "NCIT:C162108",
-                "MEDDRA:10035528",
-                "UMLS:C5201036",
-                "MEDDRA:10043560",
-                "DOID:1588",
-                "UMLS:CN130080",
-                "SYMP:0000114",
-                "MEDDRA:10038213",
-                "MEDDRA:10043546",
-                "MESH:D013921",
-                "MEDDRA:10035529",
-                "MEDDRA:10043569",
-                "UMLS:C0040034",
-                "MEDDRA:10043554",
-                "ICD9:287.5",
-                "MONDO:0002049",
-                "SNOMEDCT:415116008"
-              ],
-              "id": "MONDO:0002049",
-              "category": "biolink:Disease",
-              "all_names": [
-                "thrombocytopenia",
-                "Thrombocytopenia, unspecified",
-                "Low Platelet Count",
-                "Thrombocytopenia",
-                "Decreased platelet count"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/thrombocytopenia",
-                "http://www.merckmanuals.com/professional/hematology_and_oncology/thrombocytopenia_and_platelet_dysfunction/overview_of_platelet_disorders.htm",
-                "http://ghr.nlm.nih.gov/glossary=thrombocytopenia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18041857,
-            "start": 570,
-            "end": 316686,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2611311': {'publication date': '1989 Nov', 'sentence': 'Methylprednisolone only inhibited granulocytopenia and thrombocytopenia when zymosan-activated serum or fibrinogen-depleted plasma were infused.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:disrupts---None---None---None---UMLS:C0040034---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "18407557",
-              "object": "MONDO:0002049",
-              "publications": [
-                "PMID:2611311"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10868383,
-            "start": 570,
-            "end": 316891,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15041599': {'publication date': '2004 Apr', 'sentence': 'In addition, we detected that sufentanil provided prolonged pain relief up to 24 h when compared with control, whereas when we combined sufentanil plus methylprednisolone, we found that it further reduced pain and use of analgesics when compared with sufentanil.', 'subject score': 851, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:disrupts---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "11106658",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:15041599"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8456261,
-            "start": 570,
-            "end": 183319,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11150324': {'publication date': '2001 Jan 01', 'sentence': 'These findings demonstrate that MP may suppress post-traumatic inflammatory reaction by inhibiting both the AP-1 and NF-kappaB transcription cascades via a GR mechanism.', 'subject score': 1000, 'object score': 861}, 'PMID:17149544': {'publication date': '2007 Jun', 'sentence': 'In conclusion, results indicate that late use of MP yields adverse post-MI structure/function outcomes that correlate with suppression of inflammation and increased MMP activity.', 'subject score': 1000, 'object score': 1000}, 'PMID:23602068': {'publication date': '2013 Jun', 'sentence': 'Methylprednisolone in neonatal cardiac surgery: reduced inflammation without improved clinical outcome.', 'subject score': 1000, 'object score': 888}, 'PMID:2395047': {'publication date': '1990 Sep', 'sentence': 'This study compared two nonsteroidal anti-inflammatory drugs (NSAIDs), flurbiprofen and ibuprofen, with a prototype glucocorticoid, methylprednisolone, in two replicate placebo-controlled studies for suppression of inflammation due to the surgical removal of impacted third molars.', 'subject score': 1000, 'object score': 1000}, 'PMID:24396446': {'publication date': '2014 Feb', 'sentence': 'Prophylactic administration of methylprednisolone during the perioperative period may reduce the incidence of specific types of postoperative complications and inhibit the postoperative inflammatory reaction.', 'subject score': 1000, 'object score': 901}, 'PMID:27446512': {'publication date': '2016 Jul', 'sentence': 'CONCLUSION: Combining MP and TR is therapeutically more effective in improving functional recovery, inhibiting inflammation and glial scar formation after acute SCI.', 'subject score': 1000, 'object score': 1000}, 'PMID:27775998': {'publication date': '2017 02', 'sentence': 'The authors evaluated the effect of high-dose methylprednisolone to suppress inflammation on the incidence of delirium and postoperative quality of recovery after cardiac surgery.', 'subject score': 901, 'object score': 1000}, 'PMID:28962262': {'publication date': '2014', 'sentence': 'In conclusion, immunosuppression therapy with intravenous methylprednisolone and cyclophosphamide may counteract immune mediated inflammation after paraquat poisoning and improve survival of patients with admission eGFR < 50 ml/min/1.73 m2 and WBC count > 11,000/MUL.', 'subject score': 888, 'object score': 840}, 'PMID:29977750': {'publication date': '2018', 'sentence': 'We used mPSL to inhibit the inflammation following liposteroid administration.', 'subject score': 1000, 'object score': 1000}, 'PMID:34384886': {'publication date': '2021 Aug 09', 'sentence': 'For moderate or severe patients, the immunosuppressive agents were largely reduced or even interrupted, low-dose IVIG was adopted, and low-dose methylprednisolone (MP) was used to inhibit inflammation and rejection.', 'subject score': 901, 'object score': 1000}, 'PMID:3555968': {'publication date': '1987 Mar', 'sentence': 'Leucocyte and polymorphonuclear counts and viscosity measurement of the synovial fluid were performed before and 14 days after injection, which showed methylprednisolone to be significantly superior to bufexamac in suppressing inflammation.', 'subject score': 1000, 'object score': 872}, 'PMID:35949317': {'publication date': '2022 Sep', 'sentence': 'Collectively, the present results suggested that combination treatment of AZM and MP could inhibit    M. pneumoniae     infection-induced inflammation, cell viability loss and promoted apoptosis partly by regulating miR-499a-5p/STAT3 axis.', 'subject score': 1000, 'object score': 875}, 'PMID:6346605': {'publication date': '1983 Jul', 'sentence': 'No reduction in the number of inflammatory cells was observed in the cyclosporine-treated sponges compared with the controls, whereas MP suppressed the inflammation strongly.', 'subject score': 1000, 'object score': 861}, 'PMID:7519120': {'publication date': '1994 Aug 15', 'sentence': 'To test the possibility that inflammation is the key element in the development of these wound tumors, we used beta-methylprednisolone, an antiinflammatory drug that inhibits inflammation (including blood vessel leakage), to determine if wound tumor development could be prevented.', 'subject score': 861, 'object score': 1000}, 'PMID:8667252': {'publication date': '1996 Jun', 'sentence': 'The corticosteroid, methylprednisolone (medrol), and the nonsteroidal antiinflammatory drug, flurbiprofen (Ansaid), administered at 2 mg/kg (p.o.), suppressed the clinical signs of CIA, and caused 79 to 83% inhibition of hind paw inflammation.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:disrupts---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8640603",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:11150324",
-                "PMID:17149544",
-                "PMID:23602068",
-                "PMID:2395047",
-                "PMID:24396446",
-                "PMID:27446512",
-                "PMID:27775998",
-                "PMID:28962262",
-                "PMID:29977750",
-                "PMID:34384886",
-                "PMID:3555968",
-                "PMID:35949317",
-                "PMID:6346605",
-                "PMID:7519120",
-                "PMID:8667252"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:34803868': {'publication date': '2021', 'sentence': 'This study assessed the effectiveness of a ganciclovir, methylprednisolone, and immunoglobulin combination (TAGMIC) therapy in decreasing cognitive impairment and mortality among patients with Japanese encephalitis.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 321491,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100543",
-          "name": "Cognitive impairment",
-          "description": "Abnormal cognition with deficits in thinking, reasoning, or remembering. [HPO:sdoelken]; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; UMLS Semantic Type: STY:T048",
-          "equivalent_curies": [
-            "MEDDRA:10009845",
-            "UMLS:C0683322",
-            "NCIT:C116921",
-            "MEDDRA:10048599",
-            "PSY:10113",
-            "UMLS:C0338656",
-            "HP:0100543",
-            "MEDDRA:10009846",
-            "MESH:D060825",
-            "SNOMEDCT:386806002",
-            "NCIT:C46083",
-            "NCIT:C27101",
-            "PSY:10103"
-          ],
-          "id": "HP:0100543",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Impaired cognition",
-            "Cognitive Disturbance",
-            "Mental impairment",
-            "Cognitive impairment",
-            "Cognitive Impairment",
-            "Cognitive Dysfunction"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321491,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100543",
-              "name": "Cognitive impairment",
-              "description": "Abnormal cognition with deficits in thinking, reasoning, or remembering. [HPO:sdoelken]; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; Abnormal cognition with deficits in thinking, reasoning, or remembering. // COMMENTS: An individual with cognitive impairment may have trouble remembering, learning new things, concentrating, or making decisions.; UMLS Semantic Type: STY:T048",
-              "equivalent_curies": [
-                "MEDDRA:10009845",
-                "UMLS:C0683322",
-                "NCIT:C116921",
-                "MEDDRA:10048599",
-                "PSY:10113",
-                "UMLS:C0338656",
-                "HP:0100543",
-                "MEDDRA:10009846",
-                "MESH:D060825",
-                "SNOMEDCT:386806002",
-                "NCIT:C46083",
-                "NCIT:C27101",
-                "PSY:10103"
-              ],
-              "id": "HP:0100543",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Impaired cognition",
-                "Cognitive Disturbance",
-                "Mental impairment",
-                "Cognitive impairment",
-                "Cognitive Impairment",
-                "Cognitive Dysfunction"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23492029,
-            "start": 570,
-            "end": 321491,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34803868': {'publication date': '2021', 'sentence': 'This study assessed the effectiveness of a ganciclovir, methylprednisolone, and immunoglobulin combination (TAGMIC) therapy in decreasing cognitive impairment and mortality among patients with Japanese encephalitis.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:prevents---None---None---None---UMLS:C0338656---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "23934495",
-              "object": "HP:0100543",
-              "publications": [
-                "PMID:34803868"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 318890,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:29775134': {'publication date': '2018 May 01', 'sentence': 'OBJECTIVE: To validate the responsiveness of cerebrospinal fluid (CSF) inflammatory biomarkers to treatment with natalizumab and methylprednisolone in progressive MS and to examine the relationship between CSF inflammatory and tissue damage biomarkers.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 876033,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-          "name": "rheumatoid arthritis",
-          "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C2884",
-            "PSY:44570",
-            "EFO:0000685",
-            "ICD9:714.0",
-            "KEGG.DISEASE:05323",
-            "MONDO:0008383",
-            "UMLS:C0003873",
-            "UMLS:C1306838",
-            "UMLS:C1833448",
-            "MEDDRA:10037740",
-            "MEDDRA:10039073",
-            "OMIM:180300",
-            "MESH:D001172",
-            "MEDDRA:10003268",
-            "HP:0001370",
-            "ORPHANET:284130",
-            "SNOMEDCT:69896004",
-            "ICD10:M06.9",
-            "DOID:7148",
-            "MEDDRA:10036856",
-            "MEDDRA:10042952"
-          ],
-          "id": "MONDO:0008383",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Proliferative arthritis",
-            "Arthritis, Rheumatoid",
-            "rheumatoid arthritis",
-            "Rheumatoid arthritis",
-            "Rheumatoid Arthritis",
-            "Rheumatoid arthritis related phenotypic feature",
-            "Rheumatoid arthritis, susceptibility to"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005284",
-          "name": "chronic progressive multiple sclerosis",
-          "description": "A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)",
-          "equivalent_curies": [
-            "MEDDRA:10053395",
-            "SNOMEDCT:230373008",
-            "MONDO:0005284",
-            "MESH:D020528",
-            "EFO:0003840",
-            "SNOMEDCT:816984002",
-            "UMLS:C0393665"
-          ],
-          "id": "MONDO:0005284",
-          "category": "biolink:Disease",
-          "all_names": [
-            "chronic progressive multiple sclerosis",
-            "Multiple Sclerosis, Chronic Progressive"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 876033,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005284",
-              "name": "chronic progressive multiple sclerosis",
-              "description": "A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)",
-              "equivalent_curies": [
-                "MEDDRA:10053395",
-                "SNOMEDCT:230373008",
-                "MONDO:0005284",
-                "MESH:D020528",
-                "EFO:0003840",
-                "SNOMEDCT:816984002",
-                "UMLS:C0393665"
-              ],
-              "id": "MONDO:0005284",
-              "category": "biolink:Disease",
-              "all_names": [
-                "chronic progressive multiple sclerosis",
-                "Multiple Sclerosis, Chronic Progressive"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19946128,
-            "start": 570,
-            "end": 876033,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29775134': {'publication date': '2018 May 01', 'sentence': 'OBJECTIVE: To validate the responsiveness of cerebrospinal fluid (CSF) inflammatory biomarkers to treatment with natalizumab and methylprednisolone in progressive MS and to examine the relationship between CSF inflammatory and tissue damage biomarkers.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0393665---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "20342058",
-              "object": "MONDO:0005284",
-              "publications": [
-                "PMID:29775134"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10618696': {'publication date': '1999 Dec', 'sentence': 'OBJECTIVE: To determine if there are variables linked to responsiveness to pulse cyclophosphamide/methylprednisolone therapy in progressive Multiple Sclerosis (MS).', 'subject score': 775, 'object score': 1000}, 'PMID:8456594': {'publication date': '1993 Feb', 'sentence': 'High-dose methylprednisolone infusions in relapsing and in chronic progressive multiple sclerosis patients.', 'subject score': 850, 'object score': 928}, 'PMID:9683547': {'publication date': '1998 Jul', 'sentence': 'We have previously reported increased anti-CD3-induced IL-4 secretion by T cells in progressive MS patients treated with cyclophosphamide plus methylprednisolone (CY/MP) which was associated with eosinophilia.', 'subject score': 851, 'object score': 916}}",
-    "p2": {
-      "start": {
-        "identity": 876033,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005284",
-          "name": "chronic progressive multiple sclerosis",
-          "description": "A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)",
-          "equivalent_curies": [
-            "MEDDRA:10053395",
-            "SNOMEDCT:230373008",
-            "MONDO:0005284",
-            "MESH:D020528",
-            "EFO:0003840",
-            "SNOMEDCT:816984002",
-            "UMLS:C0393665"
-          ],
-          "id": "MONDO:0005284",
-          "category": "biolink:Disease",
-          "all_names": [
-            "chronic progressive multiple sclerosis",
-            "Multiple Sclerosis, Chronic Progressive"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 876033,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005284",
-              "name": "chronic progressive multiple sclerosis",
-              "description": "A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)",
-              "equivalent_curies": [
-                "MEDDRA:10053395",
-                "SNOMEDCT:230373008",
-                "MONDO:0005284",
-                "MESH:D020528",
-                "EFO:0003840",
-                "SNOMEDCT:816984002",
-                "UMLS:C0393665"
-              ],
-              "id": "MONDO:0005284",
-              "category": "biolink:Disease",
-              "all_names": [
-                "chronic progressive multiple sclerosis",
-                "Multiple Sclerosis, Chronic Progressive"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7740766,
-            "start": 570,
-            "end": 876033,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10618696': {'publication date': '1999 Dec', 'sentence': 'OBJECTIVE: To determine if there are variables linked to responsiveness to pulse cyclophosphamide/methylprednisolone therapy in progressive Multiple Sclerosis (MS).', 'subject score': 775, 'object score': 1000}, 'PMID:8456594': {'publication date': '1993 Feb', 'sentence': 'High-dose methylprednisolone infusions in relapsing and in chronic progressive multiple sclerosis patients.', 'subject score': 850, 'object score': 928}, 'PMID:9683547': {'publication date': '1998 Jul', 'sentence': 'We have previously reported increased anti-CD3-induced IL-4 secretion by T cells in progressive MS patients treated with cyclophosphamide plus methylprednisolone (CY/MP) which was associated with eosinophilia.', 'subject score': 851, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0393665---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7905007",
-              "object": "MONDO:0005284",
-              "publications": [
-                "PMID:10618696",
-                "PMID:8456594",
-                "PMID:9683547"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:6223736': {'publication date': '1983 Jul', 'sentence': 'The effects of intravenous pulse methylprednisolone on immunological and inflammatory processes in ankylosing spondylitis.', 'subject score': 802, 'object score': 1000}, 'PMID:7839156': {'publication date': '1994 Oct', 'sentence': 'Methylprednisolone and levamisole were both efficacious in AS, but levamisole was associated with occasional severe side effects.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 526827,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005306",
-          "name": "ankylosing spondylitis",
-          "description": "A bone inflammation disease that results_in inflammation in the joints of the spine and pelvis. The disease has_symptom pain, has_symptom stiffness in the spine, has_symptom stiffness in the neck, has_symptom stiffness in the hips, has_symptom stiffness in the jaw and has_symptom stiffness in the rib cage.",
-          "equivalent_curies": [
-            "MEDDRA:10048811",
-            "SNOMEDCT:9631008",
-            "MEDDRA:10002556",
-            "ICD9:720.0",
-            "ICD10:M45",
-            "MEDDRA:10041671",
-            "MEDDRA:10054041",
-            "MEDDRA:10041672",
-            "OMIM:PS106300",
-            "MEDDRA:10058813",
-            "ORPHANET:825",
-            "MONDO:0005306",
-            "MESH:D013167",
-            "EFO:0003898",
-            "DOID:7147",
-            "MEDDRA:10039082",
-            "NCIT:C84564",
-            "UMLS:C0038020",
-            "UMLS:C0038013"
-          ],
-          "id": "MONDO:0005306",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Spondylitis, Ankylosing",
-            "ankylosing spondylitis",
-            "Ankylosing Spondylitis",
-            "Ankylosing spondylitis",
-            "Spondylosis Deformans"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-            "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-            "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-=======
-            "http://en.wikipedia.org/wiki/ankylosing_spondylitis",
-            "http://www.mayoclinic.com/health/ankylosing-spondylitis/ds00483",
-            "http://www.spondylitis.org/about/as.aspx",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000420.htm"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 318890,
-=======
-            "identity": 526827,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0008383",
-              "name": "rheumatoid arthritis",
-              "description": "A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.; A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.; Inflammatory changes in the synovial membranes and articular structures with widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, as well as atrophy and rarefaction of bony structures. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C2884",
-                "PSY:44570",
-                "EFO:0000685",
-                "ICD9:714.0",
-                "KEGG.DISEASE:05323",
-                "MONDO:0008383",
-                "UMLS:C0003873",
-                "UMLS:C1306838",
-                "UMLS:C1833448",
-                "MEDDRA:10037740",
-                "MEDDRA:10039073",
-                "OMIM:180300",
-                "MESH:D001172",
-                "MEDDRA:10003268",
-                "HP:0001370",
-                "ORPHANET:284130",
-                "SNOMEDCT:69896004",
-                "ICD10:M06.9",
-                "DOID:7148",
-                "MEDDRA:10036856",
-                "MEDDRA:10042952"
-              ],
-              "id": "MONDO:0008383",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Proliferative arthritis",
-                "Arthritis, Rheumatoid",
-                "rheumatoid arthritis",
-                "Rheumatoid arthritis",
-                "Rheumatoid Arthritis",
-                "Rheumatoid arthritis related phenotypic feature",
-                "Rheumatoid arthritis, susceptibility to"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005306",
-              "name": "ankylosing spondylitis",
-              "description": "A bone inflammation disease that results_in inflammation in the joints of the spine and pelvis. The disease has_symptom pain, has_symptom stiffness in the spine, has_symptom stiffness in the neck, has_symptom stiffness in the hips, has_symptom stiffness in the jaw and has_symptom stiffness in the rib cage.",
-              "equivalent_curies": [
-                "MEDDRA:10048811",
-                "SNOMEDCT:9631008",
-                "MEDDRA:10002556",
-                "ICD9:720.0",
-                "ICD10:M45",
-                "MEDDRA:10041671",
-                "MEDDRA:10054041",
-                "MEDDRA:10041672",
-                "OMIM:PS106300",
-                "MEDDRA:10058813",
-                "ORPHANET:825",
-                "MONDO:0005306",
-                "MESH:D013167",
-                "EFO:0003898",
-                "DOID:7147",
-                "MEDDRA:10039082",
-                "NCIT:C84564",
-                "UMLS:C0038020",
-                "UMLS:C0038013"
-              ],
-              "id": "MONDO:0005306",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Spondylitis, Ankylosing",
-                "ankylosing spondylitis",
-                "Ankylosing Spondylitis",
-                "Ankylosing spondylitis",
-                "Spondylosis Deformans"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rheumatoid%20arthritis",
-                "http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388",
-                "http://en.wikipedia.org/wiki/rheumatoid_arthritis"
-=======
-                "http://en.wikipedia.org/wiki/ankylosing_spondylitis",
-                "http://www.mayoclinic.com/health/ankylosing-spondylitis/ds00483",
-                "http://www.spondylitis.org/about/as.aspx",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000420.htm"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 19623312,
-            "start": 570,
-            "end": 318890,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29161466': {'publication date': '2018 Sep', 'sentence': 'From indirect comparisons, most interventions showed decreased risk of developing RA compared to placebo at 12 months, reaching statistical significance for methotrexate (OR 0.16 [95% CI 0.08, 0.33]) and intramuscular methylprednisolone (OR 0.72 [95% CI 0.53, 0.99]).', 'subject score': 888, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:prevents---None---None---None---UMLS:C0003873---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "20014108",
-              "object": "MONDO:0008383",
-              "publications": [
-                "PMID:29161466"
-=======
-            "identity": 25594802,
-            "start": 570,
-            "end": 526827,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:6223736': {'publication date': '1983 Jul', 'sentence': 'The effects of intravenous pulse methylprednisolone on immunological and inflammatory processes in ankylosing spondylitis.', 'subject score': 802, 'object score': 1000}, 'PMID:7839156': {'publication date': '1994 Oct', 'sentence': 'Methylprednisolone and levamisole were both efficacious in AS, but levamisole was associated with occasional severe side effects.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0038013---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "26050805",
-              "object": "MONDO:0005306",
-              "publications": [
-                "PMID:6223736",
-                "PMID:7839156"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 321354,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:4042697': {'publication date': '1985 Aug', 'sentence': 'Seven patients with active AS and insufficient efficacy of NSAID for three months were treated with one gram methylprednisolone daily given intravenously for three successive days.', 'subject score': 851, 'object score': 824}}",
-    "p2": {
-      "start": {
-        "identity": 526827,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/HP_0002027",
-          "name": "Abdominal pain",
-          "description": "Painful sensation in the abdominal region.; Sensation of discomfort, distress, or agony in the abdominal region.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) and perceived to originate in the abdomen. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "SYMP:0000457",
-            "MEDDRA:10018796",
-            "MEDDRA:10046318",
-            "MEDDRA:10000059",
-            "HP:0002027",
-            "MEDDRA:10042076",
-            "MEDDRA:10042126",
-            "MEDDRA:10045148",
-            "UMLS:C0235309",
-            "MEDDRA:10004226",
-            "MEDDRA:10042101",
-            "MEDDRA:10000429",
-            "MEDDRA:10033374",
-            "MEDDRA:10033492",
-            "UMLS:C0232487",
-            "MEDDRA:10017814",
-            "MEDDRA:10017999",
-            "MEDDRA:10064906",
-            "SNOMEDCT:43364001",
-            "UMLS:C0687713",
-            "UMLS:C0221512",
-            "SNOMEDCT:271681002",
-            "MEDDRA:10042112",
-            "MEDDRA:10033402",
-            "NCIT:C78320",
-            "MEDDRA:10018000",
-            "UMLS:C0000737",
-            "MEDDRA:10042124",
-            "MEDDRA:10018241",
-            "NCIT:C78630",
-            "SYMP:0000188",
-            "SNOMEDCT:21522001",
-            "MEDDRA:10000085",
-            "NCIT:C26682",
-            "MEDDRA:10013084",
-            "SNOMEDCT:162059005",
-            "MEDDRA:10000081",
-            "ICD9:789.0",
-            "MESH:D015746"
-          ],
-          "id": "HP:0002027",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Abdominal Pain",
-            "Abdominal discomfort",
-            "Upset stomach",
-            "Stomach Pain",
-            "abdominal discomfort",
-            "Stomach ache",
-            "Abdominal pain",
-            "Gastrointestinal Pain",
-            "abdominal pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://medlineplus.gov/ency/article/003120.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321354,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002027",
-              "name": "Abdominal pain",
-              "description": "Painful sensation in the abdominal region.; Sensation of discomfort, distress, or agony in the abdominal region.; An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) and perceived to originate in the abdomen. [HPO:probinson]; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "SYMP:0000457",
-                "MEDDRA:10018796",
-                "MEDDRA:10046318",
-                "MEDDRA:10000059",
-                "HP:0002027",
-                "MEDDRA:10042076",
-                "MEDDRA:10042126",
-                "MEDDRA:10045148",
-                "UMLS:C0235309",
-                "MEDDRA:10004226",
-                "MEDDRA:10042101",
-                "MEDDRA:10000429",
-                "MEDDRA:10033374",
-                "MEDDRA:10033492",
-                "UMLS:C0232487",
-                "MEDDRA:10017814",
-                "MEDDRA:10017999",
-                "MEDDRA:10064906",
-                "SNOMEDCT:43364001",
-                "UMLS:C0687713",
-                "UMLS:C0221512",
-                "SNOMEDCT:271681002",
-                "MEDDRA:10042112",
-                "MEDDRA:10033402",
-                "NCIT:C78320",
-                "MEDDRA:10018000",
-                "UMLS:C0000737",
-                "MEDDRA:10042124",
-                "MEDDRA:10018241",
-                "NCIT:C78630",
-                "SYMP:0000188",
-                "SNOMEDCT:21522001",
-                "MEDDRA:10000085",
-                "NCIT:C26682",
-                "MEDDRA:10013084",
-                "SNOMEDCT:162059005",
-                "MEDDRA:10000081",
-                "ICD9:789.0",
-                "MESH:D015746"
-              ],
-              "id": "HP:0002027",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Abdominal Pain",
-                "Abdominal discomfort",
-                "Upset stomach",
-                "Stomach Pain",
-                "abdominal discomfort",
-                "Stomach ache",
-                "Abdominal pain",
-                "Gastrointestinal Pain",
-                "abdominal pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://medlineplus.gov/ency/article/003120.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17902875,
-            "start": 570,
-            "end": 321354,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25868427': {'publication date': '2015 Nov', 'sentence': 'Treatment with a pulse of methylprednisolone reduced both abdominal pain and lesion size.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:prevents---None---None---None---UMLS:C0000737---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "18266414",
-              "object": "HP:0002027",
-              "publications": [
-                "PMID:25868427"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321528,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005306",
-          "name": "ankylosing spondylitis",
-          "description": "A bone inflammation disease that results_in inflammation in the joints of the spine and pelvis. The disease has_symptom pain, has_symptom stiffness in the spine, has_symptom stiffness in the neck, has_symptom stiffness in the hips, has_symptom stiffness in the jaw and has_symptom stiffness in the rib cage.",
-          "equivalent_curies": [
-            "MEDDRA:10048811",
-            "SNOMEDCT:9631008",
-            "MEDDRA:10002556",
-            "ICD9:720.0",
-            "ICD10:M45",
-            "MEDDRA:10041671",
-            "MEDDRA:10054041",
-            "MEDDRA:10041672",
-            "OMIM:PS106300",
-            "MEDDRA:10058813",
-            "ORPHANET:825",
-            "MONDO:0005306",
-            "MESH:D013167",
-            "EFO:0003898",
-            "DOID:7147",
-            "MEDDRA:10039082",
-            "NCIT:C84564",
-            "UMLS:C0038020",
-            "UMLS:C0038013"
-          ],
-          "id": "MONDO:0005306",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Spondylitis, Ankylosing",
-            "ankylosing spondylitis",
-            "Ankylosing Spondylitis",
-            "Ankylosing spondylitis",
-            "Spondylosis Deformans"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-            "https://orcid.org/0000-0002-0736-9199"
-=======
-            "http://en.wikipedia.org/wiki/ankylosing_spondylitis",
-            "http://www.mayoclinic.com/health/ankylosing-spondylitis/ds00483",
-            "http://www.spondylitis.org/about/as.aspx",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000420.htm"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 321528,
-=======
-            "identity": 526827,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005306",
-              "name": "ankylosing spondylitis",
-              "description": "A bone inflammation disease that results_in inflammation in the joints of the spine and pelvis. The disease has_symptom pain, has_symptom stiffness in the spine, has_symptom stiffness in the neck, has_symptom stiffness in the hips, has_symptom stiffness in the jaw and has_symptom stiffness in the rib cage.",
-              "equivalent_curies": [
-                "MEDDRA:10048811",
-                "SNOMEDCT:9631008",
-                "MEDDRA:10002556",
-                "ICD9:720.0",
-                "ICD10:M45",
-                "MEDDRA:10041671",
-                "MEDDRA:10054041",
-                "MEDDRA:10041672",
-                "OMIM:PS106300",
-                "MEDDRA:10058813",
-                "ORPHANET:825",
-                "MONDO:0005306",
-                "MESH:D013167",
-                "EFO:0003898",
-                "DOID:7147",
-                "MEDDRA:10039082",
-                "NCIT:C84564",
-                "UMLS:C0038020",
-                "UMLS:C0038013"
-              ],
-              "id": "MONDO:0005306",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Spondylitis, Ankylosing",
-                "ankylosing spondylitis",
-                "Ankylosing Spondylitis",
-                "Ankylosing spondylitis",
-                "Spondylosis Deformans"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
-                "https://orcid.org/0000-0002-0736-9199"
-=======
-                "http://en.wikipedia.org/wiki/ankylosing_spondylitis",
-                "http://www.mayoclinic.com/health/ankylosing-spondylitis/ds00483",
-                "http://www.spondylitis.org/about/as.aspx",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000420.htm"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 14644973,
-            "start": 570,
-            "end": 321528,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2042763': {'publication date': '1991 Jun', 'sentence': 'Methylprednisolone prevents propranolol-induced airway hyperreactivity in the Basenji-greyhound dog.', 'subject score': 1000, 'object score': 861}, 'PMID:3700892': {'publication date': '1986 May', 'sentence': 'We describe cases in which we have to advise depot methylprednisolone to prevent potentially fatal asthma or vasculitis, although this type of therapy is suboptimal in terms of avoiding sustained corticosteroid levels in tissue, adrenal cortical suppression, and potential side effects.', 'subject score': 861, 'object score': 790}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:prevents---None---None---None---UMLS:C0004096---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14967074",
-              "object": "MONDO:0004979",
-              "publications": [
-                "PMID:2042763",
-                "PMID:3700892"
-=======
-            "identity": 25285882,
-            "start": 570,
-            "end": 526827,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:4042697': {'publication date': '1985 Aug', 'sentence': 'Seven patients with active AS and insufficient efficacy of NSAID for three months were treated with one gram methylprednisolone daily given intravenously for three successive days.', 'subject score': 851, 'object score': 824}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0038013---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "25738014",
-              "object": "MONDO:0005306",
-              "publications": [
-                "PMID:4042697"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 709798,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:27086024': {'publication date': '2016 07', 'sentence': 'A Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host Disease.', 'subject score': 1000, 'object score': 928}}",
-    "p2": {
-      "start": {
-        "identity": 520401,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011972",
-          "name": "ovarian hyperstimulation syndrome",
-          "description": "A complication of ovulation induction in infertility treatment. It is graded by the severity of symptoms which include ovary enlargement, multiple ovarian follicles; ovarian cysts; ascites; and generalized edema. The full-blown syndrome may lead to renal failure, respiratory distress, and even death. Increased capillary permeability is caused by the vasoactive substances, such as vascular endothelial growth factors, secreted by the overly-stimulated ovaries.",
-          "equivalent_curies": [
-            "OMIM:608115",
-            "MESH:D016471",
-            "ORPHANET:64739",
-            "SNOMEDCT:129635004",
-            "DOID:5425",
-            "MONDO:0011972",
-            "MEDDRA:10033266",
-            "UMLS:C0085083",
-            "UMLS:C3494162"
-          ],
-          "id": "MONDO:0011972",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Ovarian hyperstimulation syndrome related phenotypic feature",
-            "ovarian hyperstimulation syndrome",
-            "Ovarian Hyperstimulation Syndrome",
-            "Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous",
-            "obsolete_ovarian hyperstimulation syndrome"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0013730",
-          "name": "graft versus host disease",
-          "description": "A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.; The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PDQ:CDR0000041575",
-            "NCIT:C3063",
-            "MEDDRA:10018798",
-            "UMLS:C0018133",
-            "MESH:D006086",
-            "DOID:0081267",
-            "MONDO:0013730",
-            "MEDDRA:10018799",
-            "SNOMEDCT:234646005",
-            "ICD9:279.5",
-            "ORPHANET:39812",
-            "MEDDRA:10018651"
-          ],
-          "id": "MONDO:0013730",
-          "category": "biolink:Disease",
-          "all_names": [
-            "graft versus host disease",
-            "graft-versus-host disease",
-            "Graft-versus-host disease",
-            "Graft Versus Host Disease",
-            "Graft versus host disease",
-            "Graft-vs-Host Disease",
-            "Graft vs Host Disease"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3205536/"
-=======
-            "PMID:31466596",
-            "https://www.ncbi.nlm.nih.gov/books/nbk538235/"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 709798,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011972",
-              "name": "ovarian hyperstimulation syndrome",
-              "description": "A complication of ovulation induction in infertility treatment. It is graded by the severity of symptoms which include ovary enlargement, multiple ovarian follicles; ovarian cysts; ascites; and generalized edema. The full-blown syndrome may lead to renal failure, respiratory distress, and even death. Increased capillary permeability is caused by the vasoactive substances, such as vascular endothelial growth factors, secreted by the overly-stimulated ovaries.",
-              "equivalent_curies": [
-                "OMIM:608115",
-                "MESH:D016471",
-                "ORPHANET:64739",
-                "SNOMEDCT:129635004",
-                "DOID:5425",
-                "MONDO:0011972",
-                "MEDDRA:10033266",
-                "UMLS:C0085083",
-                "UMLS:C3494162"
-              ],
-              "id": "MONDO:0011972",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Ovarian hyperstimulation syndrome related phenotypic feature",
-                "ovarian hyperstimulation syndrome",
-                "Ovarian Hyperstimulation Syndrome",
-                "Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous",
-                "obsolete_ovarian hyperstimulation syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3205536/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9534432,
-            "start": 570,
-            "end": 709798,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12215328': {'publication date': '2002 Sep', 'sentence': 'Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization.', 'subject score': 1000, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:prevents---None---None---None---UMLS:C0085083---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "9744990",
-              "object": "MONDO:0011972",
-              "publications": [
-                "PMID:12215328"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-=======
-            "identity": 520401,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0013730",
-              "name": "graft versus host disease",
-              "description": "A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.; The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PDQ:CDR0000041575",
-                "NCIT:C3063",
-                "MEDDRA:10018798",
-                "UMLS:C0018133",
-                "MESH:D006086",
-                "DOID:0081267",
-                "MONDO:0013730",
-                "MEDDRA:10018799",
-                "SNOMEDCT:234646005",
-                "ICD9:279.5",
-                "ORPHANET:39812",
-                "MEDDRA:10018651"
-              ],
-              "id": "MONDO:0013730",
-              "category": "biolink:Disease",
-              "all_names": [
-                "graft versus host disease",
-                "graft-versus-host disease",
-                "Graft-versus-host disease",
-                "Graft Versus Host Disease",
-                "Graft versus host disease",
-                "Graft-vs-Host Disease",
-                "Graft vs Host Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:31466596",
-                "https://www.ncbi.nlm.nih.gov/books/nbk538235/"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 8168569,
-            "start": 570,
-            "end": 316891,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10919304': {'publication date': '2000 Jun', 'sentence': 'Combined methylprednisolone, bupivacaine and morphine reduced pain, joint swelling, time of immobilization, duration of sick leave and return to sports after the arthroscopic procedure.', 'subject score': 888, 'object score': 1000}, 'PMID:15846603': {'publication date': '2005 Apr 18', 'sentence': 'For acute whiplash, administering intravenous methylprednisolone within eight hours reduced pain at one week, and sick leave but not pain at six months compared to placebo.', 'subject score': 888, 'object score': 1000}, 'PMID:16428536': {'publication date': '2006 Feb', 'sentence': 'Methylprednisolone reduces pain, emesis, and fatigue after breast augmentation surgery: a single-dose, randomized, parallel-group study with methylprednisolone 125 mg, parecoxib 40 mg, and placebo.', 'subject score': 1000, 'object score': 1000}, 'PMID:16652427': {'publication date': '2006 May', 'sentence': 'For acute whiplash, administering intravenous methylprednisolone within 8 hours reduced pain at one week [SMD -0.90 (95% CI -1.57 to -0.24)], and sick leave but not pain at 6 months compared to placebo.', 'subject score': 888, 'object score': 1000}, 'PMID:17636629': {'publication date': '2007 Jul 18', 'sentence': 'For acute whiplash, administering intravenous methylprednisolone within eight hours of injury reduced pain at one week (SMD -0.90, 95% CI -1.57 to -0.24), and sick leave but not pain at six months compared to placebo in one trial.', 'subject score': 888, 'object score': 1000}, 'PMID:24333776': {'publication date': '2014 Mar', 'sentence': 'Because treatment with glucocorticoids is effective in early complex regional pain syndrome, we investigated whether methylprednisolone (MP) reduces pain and sciatic nerve neuropeptide content in NEP ko and wt mice with nerve injury.', 'subject score': 1000, 'object score': 1000}, 'PMID:24929444': {'publication date': '2015 Sep', 'sentence': 'Methylprednisolone was not shown to be effective for reducing pain.', 'subject score': 1000, 'object score': 872}, 'PMID:25564196': {'publication date': '2017 Jan', 'sentence': 'CONCLUSION: Addition of a single preoperative dose of 125 mg systemic methylprednisolone to a multimodal analgesic regime significantly reduced postsurgical pain and opioid consumption and decreased knee swelling in the first 24 h after fast-track UKA.', 'subject score': 775, 'object score': 861}, 'PMID:26501386': {'publication date': '2015 Dec', 'sentence': 'Methylprednisolone Does Not Reduce Persistent Pain after Cardiac Surgery.', 'subject score': 1000, 'object score': 888}, 'PMID:27737513': {'publication date': '2016 Oct 14', 'sentence': 'Based on a small study, BoNT/A (versus lidocaine/methylprednisolone) does not decrease phantom limb pain.', 'subject score': 888, 'object score': 901}, 'PMID:28977390': {'publication date': '2018 Jan 01', 'sentence': 'Methylprednisolone significantly decreased median pain scores on the day of surgery: at rest (numeric rating scale 1.6 vs 2.0, P = 0.019) and after mobilization to a sitting position (numeric rating scale 1.7 vs 2.5, P = 0.004) but not during arm abduction and coughing (P = 0.052 and P = 0.083, respectively).', 'subject score': 1000, 'object score': 861}, 'PMID:29200067': {'publication date': '2018 May', 'sentence': 'BACKGROUND: Methylprednisolone administered intravenously preoperatively has been shown to reduce pain, nausea, and fatigue after elective surgery.', 'subject score': 1000, 'object score': 1000}, 'PMID:29574247': {'publication date': '2018 May', 'sentence': 'Methylprednisolone showed comparable efficacy in reducing pain and improving functional recovery to HA.', 'subject score': 1000, 'object score': 872}, 'PMID:29642145': {'publication date': '2018 Apr', 'sentence': 'BACKGROUND: To evaluate the efficacy and safety of intra-articular methylprednisolone for reducing pain in patients with knee osteoarthritis.', 'subject score': 901, 'object score': 872}, 'PMID:29873217': {'publication date': '2018 May', 'sentence': 'At the same time, anesthetic warming method and changing the ratio of methylprednisolone can further reduce the incidence of vertigo and pain.', 'subject score': 1000, 'object score': 1000}, 'PMID:30240024': {'publication date': '2018 Sep 21', 'sentence': 'CONCLUSION: Methylprednisolone provided no additional benefit for reducing pain, but caused more harm compared with saline following a single-dose IA injection in patients with TMJ arthralgia.', 'subject score': 1000, 'object score': 872}, 'PMID:30314709': {'publication date': '2018 Oct 09', 'sentence': 'Oral and intra-masseteric MP also seems to reduce pain and trismus in the early postoperative period.', 'subject score': 828, 'object score': 1000}, 'PMID:31124986': {'publication date': '2019 May', 'sentence': 'Intra-articular injection of methylprednisolone for reducing pain in knee osteoarthritis: A systematic review and meta-analysis: Retraction.', 'subject score': 1000, 'object score': 872}, 'PMID:31155459': {'publication date': '2019 Aug', 'sentence': 'CONCLUSION: Addition of methylprednisolone to periarticular infiltration cocktail for patients undergoing TKA has significant influence on reduction of pain in the early postoperative period and patients are able to regain knee flexion more quickly.', 'subject score': 1000, 'object score': 1000}, 'PMID:31589558': {'publication date': '2019 Nov', 'sentence': 'Can Photobiomodulation Therapy Be an Alternative to Methylprednisolone in Reducing Pain, Swelling, and Trismus After Removal of Impacted Third Molars?', 'subject score': 1000, 'object score': 872}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:prevents---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8345063",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:10919304",
-                "PMID:15846603",
-                "PMID:16428536",
-                "PMID:16652427",
-                "PMID:17636629",
-                "PMID:24333776",
-                "PMID:24929444",
-                "PMID:25564196",
-                "PMID:26501386",
-                "PMID:27737513",
-                "PMID:28977390",
-                "PMID:29200067",
-                "PMID:29574247",
-                "PMID:29642145",
-                "PMID:29873217",
-                "PMID:30240024",
-                "PMID:30314709",
-                "PMID:31124986",
-                "PMID:31155459",
-                "PMID:31589558"
-=======
-            "identity": 18564187,
-            "start": 570,
-            "end": 520401,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27086024': {'publication date': '2016 07', 'sentence': 'A Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host Disease.', 'subject score': 1000, 'object score': 928}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0018133---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "18938435",
-              "object": "MONDO:0013730",
-              "publications": [
-                "PMID:27086024"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:20809972': {'publication date': '2010 Sep 01', 'sentence': 'Myelitis in these patients was not related to graft versus host disease or immune reconstitution and was responsive to intravenous methylprednisolone and cyclophosphamide.', 'subject score': 888, 'object score': 937}, 'PMID:27465468': {'publication date': '2016 Jul 28', 'sentence': 'After 24 cobalt Gy equivalent, he developed severe cutaneous graft-versus-host disease, sharply delineated within the radiation therapy field, which was responsive to tacrolimus and methylprednisolone.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 520401,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0013730",
-          "name": "graft versus host disease",
-          "description": "A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.; The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PDQ:CDR0000041575",
-            "NCIT:C3063",
-            "MEDDRA:10018798",
-            "UMLS:C0018133",
-            "MESH:D006086",
-            "DOID:0081267",
-            "MONDO:0013730",
-            "MEDDRA:10018799",
-            "SNOMEDCT:234646005",
-            "ICD9:279.5",
-            "ORPHANET:39812",
-            "MEDDRA:10018651"
-          ],
-          "id": "MONDO:0013730",
-          "category": "biolink:Disease",
-          "all_names": [
-            "graft versus host disease",
-            "graft-versus-host disease",
-            "Graft-versus-host disease",
-            "Graft Versus Host Disease",
-            "Graft versus host disease",
-            "Graft-vs-Host Disease",
-            "Graft vs Host Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:31466596",
-            "https://www.ncbi.nlm.nih.gov/books/nbk538235/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520401,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0013730",
-              "name": "graft versus host disease",
-              "description": "A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.; The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PDQ:CDR0000041575",
-                "NCIT:C3063",
-                "MEDDRA:10018798",
-                "UMLS:C0018133",
-                "MESH:D006086",
-                "DOID:0081267",
-                "MONDO:0013730",
-                "MEDDRA:10018799",
-                "SNOMEDCT:234646005",
-                "ICD9:279.5",
-                "ORPHANET:39812",
-                "MEDDRA:10018651"
-              ],
-              "id": "MONDO:0013730",
-              "category": "biolink:Disease",
-              "all_names": [
-                "graft versus host disease",
-                "graft-versus-host disease",
-                "Graft-versus-host disease",
-                "Graft Versus Host Disease",
-                "Graft versus host disease",
-                "Graft-vs-Host Disease",
-                "Graft vs Host Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:31466596",
-                "https://www.ncbi.nlm.nih.gov/books/nbk538235/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14872342,
-            "start": 570,
-            "end": 520401,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20809972': {'publication date': '2010 Sep 01', 'sentence': 'Myelitis in these patients was not related to graft versus host disease or immune reconstitution and was responsive to intravenous methylprednisolone and cyclophosphamide.', 'subject score': 888, 'object score': 937}, 'PMID:27465468': {'publication date': '2016 Jul 28', 'sentence': 'After 24 cobalt Gy equivalent, he developed severe cutaneous graft-versus-host disease, sharply delineated within the radiation therapy field, which was responsive to tacrolimus and methylprednisolone.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:affects---None---None---None---UMLS:C0018133---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "15186368",
-              "object": "MONDO:0013730",
-              "publications": [
-                "PMID:20809972",
-                "PMID:27465468"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12841815': {'publication date': '2003 Jul-Aug', 'sentence': 'CASE SUMMARY: A 2-year-old white boy with a history of relapsed acute lymphoblastic leukemia underwent a bone marrow transplant and developed graft-versus-host disease, which was treated with methylprednisolone.', 'subject score': 1000, 'object score': 937}, 'PMID:16924649': {'publication date': '2006 Dec', 'sentence': 'Infusion of methyl-prednisolone into superior and inferior mesenteric arteries produced dramatic improvement of diarrhea, with complete resolution of gastrointestinal graft-versus-host disease.', 'subject score': 1000, 'object score': 928}, 'PMID:2000873': {'publication date': '1991 Jan', 'sentence': 'Prednisone, methylprednisolone, methotrexate, antithymocyte globulin, and cyclosporine have been used in an effort to prevent or treat GVHD.', 'subject score': 1000, 'object score': 1000}, 'PMID:25053422': {'publication date': '2014 Dec', 'sentence': 'Intra-arterial methylprednisolone for severe steroid refractory gastrointestinal graft-versus-host disease.', 'subject score': 851, 'object score': 847}, 'PMID:26251153': {'publication date': '2015 Jul', 'sentence': 'In conclusion, hypofibrinogenemia commonly occurs in patients treated with steroids, especially those administered 2 mg/kg/day methylprednisolone for the treatment of GVHD.', 'subject score': 734, 'object score': 1000}, 'PMID:27381604': {'publication date': '2016 Jul-Aug', 'sentence': 'RESULTS: GvHD developed at day +52 and was treated with methylprednisolone, cyclosporine A, antibiotics, antiviral medication and analgesics.', 'subject score': 1000, 'object score': 1000}, 'PMID:32578242': {'publication date': '2020 Jun 23', 'sentence': 'A woman in her 60s who had received bone marrow transplantation for mycosis fungoides 2 months earlier received 30 mg methylprednisolone for graft-versus-host disease (GVHD).', 'subject score': 851, 'object score': 1000}, 'PMID:7226719': {'publication date': '1981', 'sentence': 'High dose methyl prednisolone (HDMP) was used to treat 25 episodes of graft versus host disease (GVHD) in 13 patients after bone marrow transplantation for aplastic anaemia or acute leukemia.', 'subject score': 901, 'object score': 1000}, 'PMID:7919241': {'publication date': '1994 Jul', 'sentence': 'Hyperacute GVHD developed in these patients within 7 days after bone marrow transplantation (BMT) and was rapidly aggravated inspite of cyclosporin A (CyA) and short-term methotrexate (MTX) prophylaxis and treatment with bolus methylprednisolone (mPSL).', 'subject score': 861, 'object score': 937}, 'PMID:8049448': {'publication date': '1994 Aug 15', 'sentence': 'In addition, 73 of the 147 patients were randomized to receive methylprednisolone during the first 35 days after transplant to improve GVHD prevention, whereas 74 patients were randomized not to receive methylprednisolone.', 'subject score': 1000, 'object score': 928}, 'PMID:8516797': {'publication date': '1993 Jun', 'sentence': 'Although the child developed complications including exfoliative dermatitis, delayed bone marrow regeneration, renal failure requiring dialysis, and respiratory failure requiring assisted respiration, she recovered from the episode of TA-GVHD after treatment with high-dose methylprednisolone and antithymocyte globulin.', 'subject score': 901, 'object score': 901}, 'PMID:8852031': {'publication date': '1996 Feb', 'sentence': 'Although the GVHD was successfully treated with methylprednisolone, peripheral blood neutrophils that had begun to increase disappeared in association with improvement of the GVHD and graft rejection was eventually diagnosed.', 'subject score': 1000, 'object score': 1000}, 'PMID:9384485': {'publication date': '1997 Nov', 'sentence': 'She developed graft-versus-host disease on day +15 post-transplant, for which she was treated with cyclosporin A and methyl prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 520401,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0013730",
-          "name": "graft versus host disease",
-          "description": "A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.; The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PDQ:CDR0000041575",
-            "NCIT:C3063",
-            "MEDDRA:10018798",
-            "UMLS:C0018133",
-            "MESH:D006086",
-            "DOID:0081267",
-            "MONDO:0013730",
-            "MEDDRA:10018799",
-            "SNOMEDCT:234646005",
-            "ICD9:279.5",
-            "ORPHANET:39812",
-            "MEDDRA:10018651"
-          ],
-          "id": "MONDO:0013730",
-          "category": "biolink:Disease",
-          "all_names": [
-            "graft versus host disease",
-            "graft-versus-host disease",
-            "Graft-versus-host disease",
-            "Graft Versus Host Disease",
-            "Graft versus host disease",
-            "Graft-vs-Host Disease",
-            "Graft vs Host Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:31466596",
-            "https://www.ncbi.nlm.nih.gov/books/nbk538235/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520401,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0013730",
-              "name": "graft versus host disease",
-              "description": "A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.; The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PDQ:CDR0000041575",
-                "NCIT:C3063",
-                "MEDDRA:10018798",
-                "UMLS:C0018133",
-                "MESH:D006086",
-                "DOID:0081267",
-                "MONDO:0013730",
-                "MEDDRA:10018799",
-                "SNOMEDCT:234646005",
-                "ICD9:279.5",
-                "ORPHANET:39812",
-                "MEDDRA:10018651"
-              ],
-              "id": "MONDO:0013730",
-              "category": "biolink:Disease",
-              "all_names": [
-                "graft versus host disease",
-                "graft-versus-host disease",
-                "Graft-versus-host disease",
-                "Graft Versus Host Disease",
-                "Graft versus host disease",
-                "Graft-vs-Host Disease",
-                "Graft vs Host Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:31466596",
-                "https://www.ncbi.nlm.nih.gov/books/nbk538235/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10066860,
-            "start": 570,
-            "end": 520401,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12841815': {'publication date': '2003 Jul-Aug', 'sentence': 'CASE SUMMARY: A 2-year-old white boy with a history of relapsed acute lymphoblastic leukemia underwent a bone marrow transplant and developed graft-versus-host disease, which was treated with methylprednisolone.', 'subject score': 1000, 'object score': 937}, 'PMID:16924649': {'publication date': '2006 Dec', 'sentence': 'Infusion of methyl-prednisolone into superior and inferior mesenteric arteries produced dramatic improvement of diarrhea, with complete resolution of gastrointestinal graft-versus-host disease.', 'subject score': 1000, 'object score': 928}, 'PMID:2000873': {'publication date': '1991 Jan', 'sentence': 'Prednisone, methylprednisolone, methotrexate, antithymocyte globulin, and cyclosporine have been used in an effort to prevent or treat GVHD.', 'subject score': 1000, 'object score': 1000}, 'PMID:25053422': {'publication date': '2014 Dec', 'sentence': 'Intra-arterial methylprednisolone for severe steroid refractory gastrointestinal graft-versus-host disease.', 'subject score': 851, 'object score': 847}, 'PMID:26251153': {'publication date': '2015 Jul', 'sentence': 'In conclusion, hypofibrinogenemia commonly occurs in patients treated with steroids, especially those administered 2 mg/kg/day methylprednisolone for the treatment of GVHD.', 'subject score': 734, 'object score': 1000}, 'PMID:27381604': {'publication date': '2016 Jul-Aug', 'sentence': 'RESULTS: GvHD developed at day +52 and was treated with methylprednisolone, cyclosporine A, antibiotics, antiviral medication and analgesics.', 'subject score': 1000, 'object score': 1000}, 'PMID:32578242': {'publication date': '2020 Jun 23', 'sentence': 'A woman in her 60s who had received bone marrow transplantation for mycosis fungoides 2 months earlier received 30 mg methylprednisolone for graft-versus-host disease (GVHD).', 'subject score': 851, 'object score': 1000}, 'PMID:7226719': {'publication date': '1981', 'sentence': 'High dose methyl prednisolone (HDMP) was used to treat 25 episodes of graft versus host disease (GVHD) in 13 patients after bone marrow transplantation for aplastic anaemia or acute leukemia.', 'subject score': 901, 'object score': 1000}, 'PMID:7919241': {'publication date': '1994 Jul', 'sentence': 'Hyperacute GVHD developed in these patients within 7 days after bone marrow transplantation (BMT) and was rapidly aggravated inspite of cyclosporin A (CyA) and short-term methotrexate (MTX) prophylaxis and treatment with bolus methylprednisolone (mPSL).', 'subject score': 861, 'object score': 937}, 'PMID:8049448': {'publication date': '1994 Aug 15', 'sentence': 'In addition, 73 of the 147 patients were randomized to receive methylprednisolone during the first 35 days after transplant to improve GVHD prevention, whereas 74 patients were randomized not to receive methylprednisolone.', 'subject score': 1000, 'object score': 928}, 'PMID:8516797': {'publication date': '1993 Jun', 'sentence': 'Although the child developed complications including exfoliative dermatitis, delayed bone marrow regeneration, renal failure requiring dialysis, and respiratory failure requiring assisted respiration, she recovered from the episode of TA-GVHD after treatment with high-dose methylprednisolone and antithymocyte globulin.', 'subject score': 901, 'object score': 901}, 'PMID:8852031': {'publication date': '1996 Feb', 'sentence': 'Although the GVHD was successfully treated with methylprednisolone, peripheral blood neutrophils that had begun to increase disappeared in association with improvement of the GVHD and graft rejection was eventually diagnosed.', 'subject score': 1000, 'object score': 1000}, 'PMID:9384485': {'publication date': '1997 Nov', 'sentence': 'She developed graft-versus-host disease on day +15 post-transplant, for which she was treated with cyclosporin A and methyl prednisolone.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0018133---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "10289517",
-              "object": "MONDO:0013730",
-              "publications": [
-                "PMID:12841815",
-                "PMID:16924649",
-                "PMID:2000873",
-                "PMID:25053422",
-                "PMID:26251153",
-                "PMID:27381604",
-                "PMID:32578242",
-                "PMID:7226719",
-                "PMID:7919241",
-                "PMID:8049448",
-                "PMID:8516797",
-                "PMID:8852031",
-                "PMID:9384485"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:10879106': {'publication date': '2000 May', 'sentence': 'Forty-eight patients who underwent bone marrow transplantation (BMT) from serologically HLA-matched unrelated donors received tacrolimus (FK506) alone or with methotrexate (MTX) and/or methylprednisolone (mPSL) to prevent graft-versus-host disease (GVHD).', 'subject score': 1000, 'object score': 1000}, 'PMID:11213682': {'publication date': '2000 Sep-Oct', 'sentence': 'Graft versus host disease (GVHD) was prevented with Methotrexate (MTX), Methylprednisolone (MPDN) and Cyclosporin A (CsA).', 'subject score': 1000, 'object score': 1000}, 'PMID:1398275': {'publication date': '1992', 'sentence': 'Functional depletion of T cells by vincristine and methylprednisolone as an in vitro model for the prevention of graft versus host disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:29621063': {'publication date': '2018 Aug', 'sentence': 'Cyclosporine or tacrolimus, methotrexate, mycophenolate mofetil, and methylprednisolone were administered to prevent graft-versus-host disease (GVHD).', 'subject score': 1000, 'object score': 1000}, 'PMID:7951097': {'publication date': '1994 Jul', 'sentence': 'Cyclosporine (CYA) and methylprednisolone were given to prevent GVHD.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 520401,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0013730",
-          "name": "graft versus host disease",
-          "description": "A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.; The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PDQ:CDR0000041575",
-            "NCIT:C3063",
-            "MEDDRA:10018798",
-            "UMLS:C0018133",
-            "MESH:D006086",
-            "DOID:0081267",
-            "MONDO:0013730",
-            "MEDDRA:10018799",
-            "SNOMEDCT:234646005",
-            "ICD9:279.5",
-            "ORPHANET:39812",
-            "MEDDRA:10018651"
-          ],
-          "id": "MONDO:0013730",
-          "category": "biolink:Disease",
-          "all_names": [
-            "graft versus host disease",
-            "graft-versus-host disease",
-            "Graft-versus-host disease",
-            "Graft Versus Host Disease",
-            "Graft versus host disease",
-            "Graft-vs-Host Disease",
-            "Graft vs Host Disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:31466596",
-            "https://www.ncbi.nlm.nih.gov/books/nbk538235/"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520401,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0013730",
-              "name": "graft versus host disease",
-              "description": "A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.; The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PDQ:CDR0000041575",
-                "NCIT:C3063",
-                "MEDDRA:10018798",
-                "UMLS:C0018133",
-                "MESH:D006086",
-                "DOID:0081267",
-                "MONDO:0013730",
-                "MEDDRA:10018799",
-                "SNOMEDCT:234646005",
-                "ICD9:279.5",
-                "ORPHANET:39812",
-                "MEDDRA:10018651"
-              ],
-              "id": "MONDO:0013730",
-              "category": "biolink:Disease",
-              "all_names": [
-                "graft versus host disease",
-                "graft-versus-host disease",
-                "Graft-versus-host disease",
-                "Graft Versus Host Disease",
-                "Graft versus host disease",
-                "Graft-vs-Host Disease",
-                "Graft vs Host Disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:31466596",
-                "https://www.ncbi.nlm.nih.gov/books/nbk538235/"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8116406,
-            "start": 570,
-            "end": 520401,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10879106': {'publication date': '2000 May', 'sentence': 'Forty-eight patients who underwent bone marrow transplantation (BMT) from serologically HLA-matched unrelated donors received tacrolimus (FK506) alone or with methotrexate (MTX) and/or methylprednisolone (mPSL) to prevent graft-versus-host disease (GVHD).', 'subject score': 1000, 'object score': 1000}, 'PMID:11213682': {'publication date': '2000 Sep-Oct', 'sentence': 'Graft versus host disease (GVHD) was prevented with Methotrexate (MTX), Methylprednisolone (MPDN) and Cyclosporin A (CsA).', 'subject score': 1000, 'object score': 1000}, 'PMID:1398275': {'publication date': '1992', 'sentence': 'Functional depletion of T cells by vincristine and methylprednisolone as an in vitro model for the prevention of graft versus host disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:29621063': {'publication date': '2018 Aug', 'sentence': 'Cyclosporine or tacrolimus, methotrexate, mycophenolate mofetil, and methylprednisolone were administered to prevent graft-versus-host disease (GVHD).', 'subject score': 1000, 'object score': 1000}, 'PMID:7951097': {'publication date': '1994 Jul', 'sentence': 'Cyclosporine (CYA) and methylprednisolone were given to prevent GVHD.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:prevents---None---None---None---UMLS:C0018133---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "8291272",
-              "object": "MONDO:0013730",
-              "publications": [
-                "PMID:10879106",
-                "PMID:11213682",
-                "PMID:1398275",
-                "PMID:29621063",
-                "PMID:7951097"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 539362,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:36742746': {'publication date': '2022 Dec', 'sentence': \"Comparing Intratympanic Gentamicin with Methylprednisolone in Meniere's Disease with Non-Serviceable Hearing.\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 520346,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043797",
-          "name": "spinal cord injury",
-          "description": "Traumatic damage of the spinal cord.; Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).; Your spinal cord is a bundle of nerves that runs down the middle of your back. It carries signals back and forth between your body and your brain. A spinal cord injury disrupts the signals. Spinal cord injuries usually begin with a blow that fractures (breaks) or dislocates your vertebrae, the bone disks that make up your spine. Most injuries don't cut through your spinal cord. Instead, they cause damage when pieces of vertebrae tear into cord tissue or press down on the nerve parts that carry signals. Spinal cord injuries can be complete or incomplete. With a complete spinal cord injury, the cord can't send signals below the level of the injury. As a result, you are paralyzed below the injury. With an incomplete injury, you have some movement and sensation below the injury. A spinal cord injury is a medical emergency. Immediate treatment can reduce long-term effects. Treatments may include medicines, braces or traction to stabilize the spine, and surgery. Later treatment usually includes medicines and rehabilitation therapy. Mobility aids and assistive devices may help you to get around and do some daily tasks. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "EFO:1001919",
-            "MESH:D013119",
-            "ORPHANET:90058",
-            "SNOMEDCT:90584004",
-            "MONDO:0043797",
-            "UMLS:C0037929",
-            "MEDDRA:10041552",
-            "NCIT:C50750"
-          ],
-          "id": "MONDO:0043797",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Spinal Cord Injury",
-            "spinal cord injury",
-            "Spinal Cord Injuries",
-            "Spinal cord injury"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007972",
-          "name": "Meniere disease",
-          "description": "A chronic inner ear disorder affecting balance and hearing. Symptoms may include vertigo, tinnitus, and hearing loss.; A disease of the inner ear (LABYRINTH) that is characterized by fluctuating SENSORINEURAL HEARING LOSS; TINNITUS; episodic VERTIGO; and aural fullness. It is the most common form of endolymphatic hydrops.; Meniere's disease is a disorder of the inner ear. It can cause severe dizziness, a roaring sound in your ears called tinnitus, hearing loss that comes and goes and the feeling of ear pressure or pain. It usually affects just one ear. It is a common cause of hearing loss.  Attacks of dizziness may come on suddenly or after a short period of tinnitus or muffled hearing. Some people have single attacks of dizziness once in a while. Others may have many attacks close together over several days. Some people with Meniere's disease have \"drop attacks\" during which the dizziness is so bad they lose their balance and fall. Scientists don't yet know the cause. They think that it has to do with the fluid levels or the mixing of fluids in the canals of your inner ear. Doctors diagnose it based on a physical exam and your symptoms. A hearing test can check to see how it has affected your hearing. There is no cure. Treatments include medicines to control dizziness, limiting salt in your diet, and taking water pills. A device that fits into the outer ear and delivers air pulses to the middle ear can help. Severe cases may require surgery. NIH: National Institute on Deafness and Other Communication Disorders ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10027184",
-            "MEDDRA:10042823",
-            "ICD10:H81.0",
-            "UMLS:C0025281",
-            "NCIT:C185243",
-            "MONDO:0007972",
-            "UMLS:C1527320",
-            "ICD9:386.0",
-            "EFO:0006862",
-            "MEDDRA:10027183",
-            "OMIM:156000",
-            "PSY:30640",
-            "SNOMEDCT:13445001",
-            "MEDDRA:10027185",
-            "MESH:D008575",
-            "DOID:9849",
-            "ORPHANET:45360"
-          ],
-          "id": "MONDO:0007972",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Meniere disease related phenotypic feature",
-            "Meniere's disease",
-            "Meniere Disease",
-            "Menieres Disease",
-            "Meniere disease",
-            "Vertigo, Aural"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/m%c3%a9ni%c3%a8re%27s_disease"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 539362,
-=======
-            "identity": 520346,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043797",
-              "name": "spinal cord injury",
-              "description": "Traumatic damage of the spinal cord.; Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).; Your spinal cord is a bundle of nerves that runs down the middle of your back. It carries signals back and forth between your body and your brain. A spinal cord injury disrupts the signals. Spinal cord injuries usually begin with a blow that fractures (breaks) or dislocates your vertebrae, the bone disks that make up your spine. Most injuries don't cut through your spinal cord. Instead, they cause damage when pieces of vertebrae tear into cord tissue or press down on the nerve parts that carry signals. Spinal cord injuries can be complete or incomplete. With a complete spinal cord injury, the cord can't send signals below the level of the injury. As a result, you are paralyzed below the injury. With an incomplete injury, you have some movement and sensation below the injury. A spinal cord injury is a medical emergency. Immediate treatment can reduce long-term effects. Treatments may include medicines, braces or traction to stabilize the spine, and surgery. Later treatment usually includes medicines and rehabilitation therapy. Mobility aids and assistive devices may help you to get around and do some daily tasks. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "EFO:1001919",
-                "MESH:D013119",
-                "ORPHANET:90058",
-                "SNOMEDCT:90584004",
-                "MONDO:0043797",
-                "UMLS:C0037929",
-                "MEDDRA:10041552",
-                "NCIT:C50750"
-              ],
-              "id": "MONDO:0043797",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Spinal Cord Injury",
-                "spinal cord injury",
-                "Spinal Cord Injuries",
-                "Spinal cord injury"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7813609,
-            "start": 570,
-            "end": 539362,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10668431': {'publication date': '1999', 'sentence': 'Thus, calpeptin and methylprednisolone are found to be neuroprotective in SCI.', 'subject score': 1000, 'object score': 1000}, 'PMID:11393256': {'publication date': '2001 May', 'sentence': 'These findings suggested that MPS reduces the severity of SCI, not by inhibiting the production of TNF-alpha at the site of spinal cord trauma, but by inhibiting activated leukocyte induced lipid peroxidation of the endothelial cell membrane.', 'subject score': 1000, 'object score': 1000}, 'PMID:18980475': {'publication date': '2008', 'sentence': 'CONCLUSIONS: There are a number of treatment options, including maintenance of mean arterial blood pressure > 80 mm Hg, starting methylprednisolone treatment preoperatively, and multimodality monitoring to help prevent POSCI occurrence, minimize secondary damage, and potentially improve the clinical outcome of after a POSCI.', 'subject score': 790, 'object score': 875}, 'PMID:22436574': {'publication date': '2012 Jul', 'sentence': 'And, it is as effective as methylprednisolone in preventing secondary spinal cord injury histopathologically.', 'subject score': 1000, 'object score': 811}, 'PMID:8620925': {'publication date': '1996 Apr', 'sentence': 'Clinically, methylprednisolone (MP) has been shown to be neuroprotective if administered within 8 h after spinal cord injury.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:prevents---None---None---None---UMLS:C0037929---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7980138",
-              "object": "MONDO:0043797",
-              "publications": [
-                "PMID:10668431",
-                "PMID:11393256",
-                "PMID:18980475",
-                "PMID:22436574",
-                "PMID:8620925"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 313324,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-          "name": "Edema",
-          "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MEDDRA:10030114",
-            "MEDDRA:10014234",
-            "MEDDRA:10014210",
-            "MEDDRA:10005890",
-            "HP:0000969",
-            "SNOMEDCT:267038008",
-            "SNOMEDCT:43498006",
-            "SNOMEDCT:79654002",
-            "MESH:D004487",
-            "UMLS:C0013604",
-            "MEDDRA:10016807",
-            "EFO:0009373",
-            "SNOMEDCT:423666004",
-            "UMLS:C0268000",
-            "NCIT:C3002",
-            "MEDDRA:10030095",
-            "SNOMEDCT:20741006",
-            "SYMP:0000538"
-          ],
-          "id": "HP:0000969",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Edema",
-            "Body fluid retention",
-            "edema"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 313324,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0000969",
-              "name": "Edema",
-              "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MEDDRA:10030114",
-                "MEDDRA:10014234",
-                "MEDDRA:10014210",
-                "MEDDRA:10005890",
-                "HP:0000969",
-                "SNOMEDCT:267038008",
-                "SNOMEDCT:43498006",
-                "SNOMEDCT:79654002",
-                "MESH:D004487",
-                "UMLS:C0013604",
-                "MEDDRA:10016807",
-                "EFO:0009373",
-                "SNOMEDCT:423666004",
-                "UMLS:C0268000",
-                "NCIT:C3002",
-                "MEDDRA:10030095",
-                "SNOMEDCT:20741006",
-                "SYMP:0000538"
-              ],
-              "id": "HP:0000969",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Edema",
-                "Body fluid retention",
-                "edema"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7265701,
-            "start": 570,
-            "end": 313324,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10342417': {'publication date': '1999 Apr', 'sentence': 'Methylprednisolone prevents the development of autotomy and neuropathic edema in rats, but has no effect on nociceptive thresholds.', 'subject score': 1000, 'object score': 853}, 'PMID:15232723': {'publication date': '2004 Dec', 'sentence': 'Methylprednisolone (MP), by reducing edema and protecting the cell membrane against peroxidation, is the only pharmacological agent with a proven clinically beneficial effect on SCI.', 'subject score': 1000, 'object score': 872}, 'PMID:2243858': {'publication date': '1990 Dec', 'sentence': 'The efficacy of methylprednisolone in reducing flap edema.', 'subject score': 1000, 'object score': 840}, 'PMID:25933144': {'publication date': '2015 May', 'sentence': 'CONCLUSIONS: As a result of the evaluation of MP efficacy in different models of facial nerve palsy, we may say that this drug was without effect on nerve healing in paralysis due to nerve section and that it only reduced nervous edema in paralysis induced by Type 1 HSV, whereas it had positive effects on healing in the type of paralysis caused by nerve compression.', 'subject score': 694, 'object score': 888}, 'PMID:28666096': {'publication date': '2017 Nov', 'sentence': 'CONCLUSIONS: The study findings suggest that a single preoperative dose of dexamethasone versus methylprednisolone was equally effective in reducing postoperative swelling and trismus.', 'subject score': 1000, 'object score': 785}, 'PMID:28793837': {'publication date': '2017 Nov', 'sentence': 'AIMS To determine if equine fescue oedema (EFO) induced by grazing Mediterranean-type tall fescue (Lolium arundinaceum) infected with selected endophytes (Epichloe coenophiala) could be prevented by treatment with the corticosteroid, methylprednisolone, and anti-histamine, cetirizine, and to determine concentrations of lolines, specifically N-acetyl norloline (NANL), in grasses grazed by horses that did and did not develop EFO.', 'subject score': 1000, 'object score': 802}, 'PMID:3174874': {'publication date': '1988 Nov', 'sentence': 'A single perioperative dose of methylprednisolone was ineffective in decreasing edema formation and preserving tissue.', 'subject score': 1000, 'object score': 851}, 'PMID:3533126': {'publication date': '1986 Oct', 'sentence': 'On the third postoperative day methylprednisolone reduced measured swelling by 29% compared to paracetamol (P = 0.03).', 'subject score': 775, 'object score': 888}, 'PMID:3881262': {'publication date': '1985', 'sentence': 'These results indicate that methylprednisolone, at least for a short period of time, produces a definite decrease in apparent tumor size, in addition to the reduction of peritumoral edema.', 'subject score': 1000, 'object score': 861}, 'PMID:8303761': {'publication date': '1994 Feb', 'sentence': 'However, methylprednisolone treatment did not reduce hemispheric edema in animals that died early after temporary middle cerebral artery occlusion.', 'subject score': 888, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:prevents---None---None---None---UMLS:C0013604---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "7414405",
-              "object": "HP:0000969",
-              "publications": [
-                "PMID:10342417",
-                "PMID:15232723",
-                "PMID:2243858",
-                "PMID:25933144",
-                "PMID:28666096",
-                "PMID:28793837",
-                "PMID:3174874",
-                "PMID:3533126",
-                "PMID:3881262",
-                "PMID:8303761"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007972",
-              "name": "Meniere disease",
-              "description": "A chronic inner ear disorder affecting balance and hearing. Symptoms may include vertigo, tinnitus, and hearing loss.; A disease of the inner ear (LABYRINTH) that is characterized by fluctuating SENSORINEURAL HEARING LOSS; TINNITUS; episodic VERTIGO; and aural fullness. It is the most common form of endolymphatic hydrops.; Meniere's disease is a disorder of the inner ear. It can cause severe dizziness, a roaring sound in your ears called tinnitus, hearing loss that comes and goes and the feeling of ear pressure or pain. It usually affects just one ear. It is a common cause of hearing loss.  Attacks of dizziness may come on suddenly or after a short period of tinnitus or muffled hearing. Some people have single attacks of dizziness once in a while. Others may have many attacks close together over several days. Some people with Meniere's disease have \"drop attacks\" during which the dizziness is so bad they lose their balance and fall. Scientists don't yet know the cause. They think that it has to do with the fluid levels or the mixing of fluids in the canals of your inner ear. Doctors diagnose it based on a physical exam and your symptoms. A hearing test can check to see how it has affected your hearing. There is no cure. Treatments include medicines to control dizziness, limiting salt in your diet, and taking water pills. A device that fits into the outer ear and delivers air pulses to the middle ear can help. Severe cases may require surgery. NIH: National Institute on Deafness and Other Communication Disorders ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10027184",
-                "MEDDRA:10042823",
-                "ICD10:H81.0",
-                "UMLS:C0025281",
-                "NCIT:C185243",
-                "MONDO:0007972",
-                "UMLS:C1527320",
-                "ICD9:386.0",
-                "EFO:0006862",
-                "MEDDRA:10027183",
-                "OMIM:156000",
-                "PSY:30640",
-                "SNOMEDCT:13445001",
-                "MEDDRA:10027185",
-                "MESH:D008575",
-                "DOID:9849",
-                "ORPHANET:45360"
-              ],
-              "id": "MONDO:0007972",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Meniere disease related phenotypic feature",
-                "Meniere's disease",
-                "Meniere Disease",
-                "Menieres Disease",
-                "Meniere disease",
-                "Vertigo, Aural"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-=======
-                "http://en.wikipedia.org/wiki/m%c3%a9ni%c3%a8re%27s_disease"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 17740933,
-            "start": 570,
-            "end": 321523,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25600919': {'publication date': '2015 Jan', 'sentence': 'Chronically impaired renal function and the use of methylprednisolone may be the risk factors for SP.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:predisposes---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "18106042",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:25600919"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9436828,
-            "start": 570,
-            "end": 183319,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12111861': {'publication date': '2002 May 01', 'sentence': 'Because a common therapy for acute spinal cord injury is the use of an antiinflammatory synthetic glucocorticoid (methylprednisolone), we sought to determine mechanisms contributing to inflammation shortly after acute injury.', 'subject score': 1000, 'object score': 861}, 'PMID:21983371': {'publication date': '2012 Feb', 'sentence': 'CONCLUSIONS: In early acute respiratory distress syndrome, administration of methylprednisolone was associated with improvement in important biomarkers of inflammation and coagulation and clinical outcomes.', 'subject score': 1000, 'object score': 1000}, 'PMID:23395471': {'publication date': '2013 Apr', 'sentence': 'RESULTS: At days 2 and 5, methylprednisolone treatment showed a 2.1- to 5.8-fold reduction (P < .05) in inflammation markers over PRP.', 'subject score': 888, 'object score': 791}, 'PMID:26272452': {'publication date': '2015 Aug 14', 'sentence': 'In our study, we want to investigate the effect of CWI with local anesthetic + methylprednisolone on acute and persistent pain, correlating clinical data with biomarkers of inflammation and genetic background.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:predisposes---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "9645180",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:12111861",
-                "PMID:21983371",
-                "PMID:23395471",
-                "PMID:26272452"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 576,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefotaxime",
-          "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C06885",
-            "DRUGBANK:DB00493",
-            "UNII:N2GI8B1GK7",
-            "NCIT:C354",
-            "DrugCentral:546",
-            "UMLS:C0007554",
-            "ATC:J01DD01",
-            "GTOPDB:10893",
-            "MESH:D002439",
-            "PUBCHEM.COMPOUND:5742673",
-            "HMDB:HMDB0014636",
-            "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-            "CHEBI:204928",
-            "PDQ:CDR0000039177",
-            "RXNORM:2186",
-            "CAS:60846-21-1",
-            "KEGG.DRUG:D07647",
-            "NDDF:004845",
-            "CHEMBL.COMPOUND:CHEMBL1730"
-          ],
-          "id": "PUBCHEM.COMPOUND:5742673",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Cefotaxime (INN)",
-            "cefotaxime",
-            "cefotaxime sodium salt",
-            "CEFOTAXIME",
-            "Cefotaxime"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20643901",
-            "PMID:19858254",
-            "PMID:17938180",
-            "PMID:17846134",
-            "PMID:17074790",
-            "PMID:17438056",
-            "PMID:19581459",
-            "PMID:22494615",
-            "PMID:1847430",
-            "PMID:18180346"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12631501,
-            "start": 576,
-            "end": 320039,
-=======
-            "identity": 24879810,
-            "start": 570,
-            "end": 520346,
->>>>>>> main
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-<<<<<<< HEAD
-              "publications_info": "{'PMID:1720432': {'publication date': '1991 Sep', 'sentence': 'Combined treatments of rG-CSF with cefotaxime, cefazolin, fosfomycin, gentamicin or amphotericin B were evaluated in systemic infections with Pseudomonas aeruginosa, Escherichia coli, Serratia marcescens, Staphylococcus aureus and Candida albicans in leucopenic mice induced by pretreatment with cyclophosphamide.', 'subject score': 1000, 'object score': 983}}",
-              "kg2_ids": [
-                "UMLS:C0007554---SEMMEDDB:associated_with---None---None---None---UMLS:C0243026---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5742673",
-              "id": "12905337",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:1720432"
-=======
-              "publications_info": "{'PMID:36742746': {'publication date': '2022 Dec', 'sentence': \"Comparing Intratympanic Gentamicin with Methylprednisolone in Meniere's Disease with Non-Serviceable Hearing.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:associated_with---None---None---None---UMLS:C0025281---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "25328503",
-              "object": "MONDO:0007972",
-              "publications": [
-                "PMID:36742746"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-<<<<<<< HEAD
-            "identity": 576,
-            "labels": [
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-            ],
-            "properties": {
-              "name": "Cefotaxime",
-              "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C06885",
-                "DRUGBANK:DB00493",
-                "UNII:N2GI8B1GK7",
-                "NCIT:C354",
-                "DrugCentral:546",
-                "UMLS:C0007554",
-                "ATC:J01DD01",
-                "GTOPDB:10893",
-                "MESH:D002439",
-                "PUBCHEM.COMPOUND:5742673",
-                "HMDB:HMDB0014636",
-                "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-                "CHEBI:204928",
-                "PDQ:CDR0000039177",
-                "RXNORM:2186",
-                "CAS:60846-21-1",
-                "KEGG.DRUG:D07647",
-                "NDDF:004845",
-                "CHEMBL.COMPOUND:CHEMBL1730"
-              ],
-              "id": "PUBCHEM.COMPOUND:5742673",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Cefotaxime (INN)",
-                "cefotaxime",
-                "cefotaxime sodium salt",
-                "CEFOTAXIME",
-                "Cefotaxime"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20643901",
-                "PMID:19858254",
-                "PMID:17938180",
-                "PMID:17846134",
-                "PMID:17074790",
-                "PMID:17438056",
-                "PMID:19581459",
-                "PMID:22494615",
-                "PMID:1847430",
-                "PMID:18180346"
-=======
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
->>>>>>> main
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:19924013': {'publication date': '2010 Jan', 'sentence': \"OBJECTIVE: To describe the long-term efficacy of transtympanic steroids (TTS) using methyl-prednisolone in the treatment of Meniere's disease (MD).\", 'subject score': 1000, 'object score': 1000}, 'PMID:23314159': {'publication date': '2013 Apr', 'sentence': \"According to these findings, administrating ITMP to control Meniere's disease seems to be less beneficial than ITG.\", 'subject score': 802, 'object score': 1000}, 'PMID:23818540': {'publication date': '2013 Jul', 'sentence': \"Comparison of intratympanic methylprednisolone and gentamicin for Meniere's disease may be misleading.\", 'subject score': 861, 'object score': 1000}, 'PMID:23818541': {'publication date': '2013 Jul', 'sentence': \"Response to: Comparison of intratympanic methylprednisolone and gentamicin for Meniere's disease may be misleading.\", 'subject score': 861, 'object score': 1000}, 'PMID:27865535': {'publication date': '2016 12 03', 'sentence': \"Intratympanic methylprednisolone versus gentamicin in patients with unilateral Meniere's disease: a randomised, double-blind, comparative effectiveness trial.\", 'subject score': 861, 'object score': 901}, 'PMID:30412169': {'publication date': '2018', 'sentence': \"[The effectiveness of the intra-tympanic administration of methylprednisolone and gentamycin for the treatment of Meniere's disease].\", 'subject score': 1000, 'object score': 1000}, 'PMID:30870364': {'publication date': '2019 Apr', 'sentence': \"Long-Term Follow-Up of Intratympanic Methylprednisolone Versus Gentamicin in Patients With Unilateral Meniere's Disease.\", 'subject score': 861, 'object score': 901}, 'PMID:36742746': {'publication date': '2022 Dec', 'sentence': \"Abstract: To compare the effectiveness of high dose fixed alternate day intratympanic gentamicin with methylprednisolone in the treatment of patients with unilateral, intractable Meniere's disease with poor hearing.\", 'subject score': 1000, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 520346,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007972",
-          "name": "Meniere disease",
-          "description": "A chronic inner ear disorder affecting balance and hearing. Symptoms may include vertigo, tinnitus, and hearing loss.; A disease of the inner ear (LABYRINTH) that is characterized by fluctuating SENSORINEURAL HEARING LOSS; TINNITUS; episodic VERTIGO; and aural fullness. It is the most common form of endolymphatic hydrops.; Meniere's disease is a disorder of the inner ear. It can cause severe dizziness, a roaring sound in your ears called tinnitus, hearing loss that comes and goes and the feeling of ear pressure or pain. It usually affects just one ear. It is a common cause of hearing loss.  Attacks of dizziness may come on suddenly or after a short period of tinnitus or muffled hearing. Some people have single attacks of dizziness once in a while. Others may have many attacks close together over several days. Some people with Meniere's disease have \"drop attacks\" during which the dizziness is so bad they lose their balance and fall. Scientists don't yet know the cause. They think that it has to do with the fluid levels or the mixing of fluids in the canals of your inner ear. Doctors diagnose it based on a physical exam and your symptoms. A hearing test can check to see how it has affected your hearing. There is no cure. Treatments include medicines to control dizziness, limiting salt in your diet, and taking water pills. A device that fits into the outer ear and delivers air pulses to the middle ear can help. Severe cases may require surgery. NIH: National Institute on Deafness and Other Communication Disorders ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10027184",
-            "MEDDRA:10042823",
-            "ICD10:H81.0",
-            "UMLS:C0025281",
-            "NCIT:C185243",
-            "MONDO:0007972",
-            "UMLS:C1527320",
-            "ICD9:386.0",
-            "EFO:0006862",
-            "MEDDRA:10027183",
-            "OMIM:156000",
-            "PSY:30640",
-            "SNOMEDCT:13445001",
-            "MEDDRA:10027185",
-            "MESH:D008575",
-            "DOID:9849",
-            "ORPHANET:45360"
-          ],
-          "id": "MONDO:0007972",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Meniere disease related phenotypic feature",
-            "Meniere's disease",
-            "Meniere Disease",
-            "Menieres Disease",
-            "Meniere disease",
-            "Vertigo, Aural"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/m%c3%a9ni%c3%a8re%27s_disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 570,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Methylprednisolone",
-          "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-          "equivalent_curies": [
-            "ATC:H02AB04",
-            "RXNORM:6902",
-            "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-            "CAS:83-43-2",
-            "GTOPDB:7088",
-            "UMLS:C0025815",
-            "KEGG.DRUG:D00407",
-            "PUBCHEM.COMPOUND:6741",
-            "DRUGBANK:DB00959",
-            "UNII:X4W7ZR7023",
-            "MESH:D008775",
-            "HMDB:HMDB0015094",
-            "ATC:D07AA01",
-            "CHEMBL.COMPOUND:CHEMBL650",
-            "CHEBI:6888",
-            "NCIT:C647",
-            "DrugCentral:1768",
-            "ATC:D10AA02"
-          ],
-          "id": "PUBCHEM.COMPOUND:6741",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "medralone",
-            "METHYLPREDNISOLONE",
-            "Methylprednisolone",
-            "methylprednisolone",
-            "6alpha-methylprednisolone",
-            "Methylprednisolone (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:11413487",
-            "PMID:20022146",
-            "PMID:20014752",
-            "PMID:15646539",
-            "PMID:23571415",
-            "PMID:16042225",
-            "PMID:14294877",
-            "PMID:18177009",
-            "PMID:3783574",
-            "PMID:16902246"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520346,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007972",
-              "name": "Meniere disease",
-              "description": "A chronic inner ear disorder affecting balance and hearing. Symptoms may include vertigo, tinnitus, and hearing loss.; A disease of the inner ear (LABYRINTH) that is characterized by fluctuating SENSORINEURAL HEARING LOSS; TINNITUS; episodic VERTIGO; and aural fullness. It is the most common form of endolymphatic hydrops.; Meniere's disease is a disorder of the inner ear. It can cause severe dizziness, a roaring sound in your ears called tinnitus, hearing loss that comes and goes and the feeling of ear pressure or pain. It usually affects just one ear. It is a common cause of hearing loss.  Attacks of dizziness may come on suddenly or after a short period of tinnitus or muffled hearing. Some people have single attacks of dizziness once in a while. Others may have many attacks close together over several days. Some people with Meniere's disease have \"drop attacks\" during which the dizziness is so bad they lose their balance and fall. Scientists don't yet know the cause. They think that it has to do with the fluid levels or the mixing of fluids in the canals of your inner ear. Doctors diagnose it based on a physical exam and your symptoms. A hearing test can check to see how it has affected your hearing. There is no cure. Treatments include medicines to control dizziness, limiting salt in your diet, and taking water pills. A device that fits into the outer ear and delivers air pulses to the middle ear can help. Severe cases may require surgery. NIH: National Institute on Deafness and Other Communication Disorders ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10027184",
-                "MEDDRA:10042823",
-                "ICD10:H81.0",
-                "UMLS:C0025281",
-                "NCIT:C185243",
-                "MONDO:0007972",
-                "UMLS:C1527320",
-                "ICD9:386.0",
-                "EFO:0006862",
-                "MEDDRA:10027183",
-                "OMIM:156000",
-                "PSY:30640",
-                "SNOMEDCT:13445001",
-                "MEDDRA:10027185",
-                "MESH:D008575",
-                "DOID:9849",
-                "ORPHANET:45360"
-              ],
-              "id": "MONDO:0007972",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Meniere disease related phenotypic feature",
-                "Meniere's disease",
-                "Meniere Disease",
-                "Menieres Disease",
-                "Meniere disease",
-                "Vertigo, Aural"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/m%c3%a9ni%c3%a8re%27s_disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14385226,
-            "start": 570,
-            "end": 520346,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19924013': {'publication date': '2010 Jan', 'sentence': \"OBJECTIVE: To describe the long-term efficacy of transtympanic steroids (TTS) using methyl-prednisolone in the treatment of Meniere's disease (MD).\", 'subject score': 1000, 'object score': 1000}, 'PMID:23314159': {'publication date': '2013 Apr', 'sentence': \"According to these findings, administrating ITMP to control Meniere's disease seems to be less beneficial than ITG.\", 'subject score': 802, 'object score': 1000}, 'PMID:23818540': {'publication date': '2013 Jul', 'sentence': \"Comparison of intratympanic methylprednisolone and gentamicin for Meniere's disease may be misleading.\", 'subject score': 861, 'object score': 1000}, 'PMID:23818541': {'publication date': '2013 Jul', 'sentence': \"Response to: Comparison of intratympanic methylprednisolone and gentamicin for Meniere's disease may be misleading.\", 'subject score': 861, 'object score': 1000}, 'PMID:27865535': {'publication date': '2016 12 03', 'sentence': \"Intratympanic methylprednisolone versus gentamicin in patients with unilateral Meniere's disease: a randomised, double-blind, comparative effectiveness trial.\", 'subject score': 861, 'object score': 901}, 'PMID:30412169': {'publication date': '2018', 'sentence': \"[The effectiveness of the intra-tympanic administration of methylprednisolone and gentamycin for the treatment of Meniere's disease].\", 'subject score': 1000, 'object score': 1000}, 'PMID:30870364': {'publication date': '2019 Apr', 'sentence': \"Long-Term Follow-Up of Intratympanic Methylprednisolone Versus Gentamicin in Patients With Unilateral Meniere's Disease.\", 'subject score': 861, 'object score': 901}, 'PMID:36742746': {'publication date': '2022 Dec', 'sentence': \"Abstract: To compare the effectiveness of high dose fixed alternate day intratympanic gentamicin with methylprednisolone in the treatment of patients with unilateral, intractable Meniere's disease with poor hearing.\", 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0025815---SEMMEDDB:treats---None---None---None---UMLS:C0025281---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:6741",
-              "id": "14690661",
-              "object": "MONDO:0007972",
-              "publications": [
-                "PMID:19924013",
-                "PMID:23314159",
-                "PMID:23818540",
-                "PMID:23818541",
-                "PMID:27865535",
-                "PMID:30412169",
-                "PMID:30870364",
-                "PMID:36742746"
-              ]
-            }
-          },
-          "end": {
-            "identity": 570,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Methylprednisolone",
-              "description": "Methylprednisolone is only found in individuals that have used or taken this drug. It is a prednisolone derivative with similar anti-inflammatory action. [PubChem]Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.",
-              "equivalent_curies": [
-                "ATC:H02AB04",
-                "RXNORM:6902",
-                "INCHIKEY:VHRSUDSXCMQTMA-PJHHCJLFSA-N",
-                "CAS:83-43-2",
-                "GTOPDB:7088",
-                "UMLS:C0025815",
-                "KEGG.DRUG:D00407",
-                "PUBCHEM.COMPOUND:6741",
-                "DRUGBANK:DB00959",
-                "UNII:X4W7ZR7023",
-                "MESH:D008775",
-                "HMDB:HMDB0015094",
-                "ATC:D07AA01",
-                "CHEMBL.COMPOUND:CHEMBL650",
-                "CHEBI:6888",
-                "NCIT:C647",
-                "DrugCentral:1768",
-                "ATC:D10AA02"
-              ],
-              "id": "PUBCHEM.COMPOUND:6741",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "medralone",
-                "METHYLPREDNISOLONE",
-                "Methylprednisolone",
-                "methylprednisolone",
-                "6alpha-methylprednisolone",
-                "Methylprednisolone (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:11413487",
-                "PMID:20022146",
-                "PMID:20014752",
-                "PMID:15646539",
-                "PMID:23571415",
-                "PMID:16042225",
-                "PMID:14294877",
-                "PMID:18177009",
-                "PMID:3783574",
-                "PMID:16902246"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:35515906': {'publication date': '2019 Feb 11', 'sentence': 'One such marker, CTX-M-15, expressed by Enterobacteriaceae produces beta-lactamases, which hydrolyze the cephalosporin group of antibiotics, such as cefotaxime, used in the treatment of both Gram-positive and negative bacterial infections.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 538307,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-          ]
-        }
-      },
-      "end": {
-        "identity": 576,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefotaxime",
-          "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C06885",
-            "DRUGBANK:DB00493",
-            "UNII:N2GI8B1GK7",
-            "NCIT:C354",
-            "DrugCentral:546",
-            "UMLS:C0007554",
-            "ATC:J01DD01",
-            "GTOPDB:10893",
-            "MESH:D002439",
-            "PUBCHEM.COMPOUND:5742673",
-            "HMDB:HMDB0014636",
-            "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-            "CHEBI:204928",
-            "PDQ:CDR0000039177",
-            "RXNORM:2186",
-            "CAS:60846-21-1",
-            "KEGG.DRUG:D07647",
-            "NDDF:004845",
-            "CHEMBL.COMPOUND:CHEMBL1730"
-          ],
-          "id": "PUBCHEM.COMPOUND:5742673",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Cefotaxime (INN)",
-            "cefotaxime",
-            "cefotaxime sodium salt",
-            "CEFOTAXIME",
-            "Cefotaxime"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20643901",
-            "PMID:19858254",
-            "PMID:17938180",
-            "PMID:17846134",
-            "PMID:17074790",
-            "PMID:17438056",
-            "PMID:19581459",
-            "PMID:22494615",
-            "PMID:1847430",
-            "PMID:18180346"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538307,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24033882,
-            "start": 576,
-            "end": 538307,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35515906': {'publication date': '2019 Feb 11', 'sentence': 'One such marker, CTX-M-15, expressed by Enterobacteriaceae produces beta-lactamases, which hydrolyze the cephalosporin group of antibiotics, such as cefotaxime, used in the treatment of both Gram-positive and negative bacterial infections.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0007554---SEMMEDDB:affects---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5742673",
-              "id": "24475300",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:35515906"
-              ]
-            }
-          },
-          "end": {
-            "identity": 576,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefotaxime",
-              "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C06885",
-                "DRUGBANK:DB00493",
-                "UNII:N2GI8B1GK7",
-                "NCIT:C354",
-                "DrugCentral:546",
-                "UMLS:C0007554",
-                "ATC:J01DD01",
-                "GTOPDB:10893",
-                "MESH:D002439",
-                "PUBCHEM.COMPOUND:5742673",
-                "HMDB:HMDB0014636",
-                "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-                "CHEBI:204928",
-                "PDQ:CDR0000039177",
-                "RXNORM:2186",
-                "CAS:60846-21-1",
-                "KEGG.DRUG:D07647",
-                "NDDF:004845",
-                "CHEMBL.COMPOUND:CHEMBL1730"
-              ],
-              "id": "PUBCHEM.COMPOUND:5742673",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Cefotaxime (INN)",
-                "cefotaxime",
-                "cefotaxime sodium salt",
-                "CEFOTAXIME",
-                "Cefotaxime"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20643901",
-                "PMID:19858254",
-                "PMID:17938180",
-                "PMID:17846134",
-                "PMID:17074790",
-                "PMID:17438056",
-                "PMID:19581459",
-                "PMID:22494615",
-                "PMID:1847430",
-                "PMID:18180346"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10782908': {'publication date': '2000 Apr', 'sentence': 'These results suggest that amoxicillin-clavulanic acid is an effective alternative to cefotaxime for the empirical treatment of bacterial infections in cirrhosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1571464': {'publication date': '1992 Jan', 'sentence': 'Cefotaxime has been used to treat serious bacterial infections in children since 1982.', 'subject score': 1000, 'object score': 901}, 'PMID:18611720': {'publication date': '1996 Apr', 'sentence': 'The combination of the beta-lactamase inhibitor sulbactam and a ureidopenicillin or cefotaxime was highly effiacious in patients with severe bacterial infections investigated in this study.', 'subject score': 1000, 'object score': 901}, 'PMID:1943983': {'publication date': '1991 Sep 15', 'sentence': 'An open multicenter study on inpatients of 12 german hospitals was performed to investigate efficacy and safety of sulbactam in combination with mezlocillin, piperacillin or cefotaxim in severe bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:2668427': {'publication date': '1989 Sep', 'sentence': 'Once-daily therapy with ceftriaxone compared with daily multiple-dose therapy with cefotaxime for serious bacterial infections: a randomized, double-blind study.', 'subject score': 1000, 'object score': 901}, 'PMID:2668428': {'publication date': '1989 Sep', 'sentence': 'Ceftriaxone was compared with cefotaxime for the treatment of serious bacterial infections in a prospective, randomized, double-blind clinical trial.', 'subject score': 1000, 'object score': 901}, 'PMID:3901208': {'publication date': '1985', 'sentence': 'Comparative clinical evaluation of imipenem/cilastatin vs. cefotaxime in treatment of severe bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:4083974': {'publication date': '1985 Aug-Sep', 'sentence': 'The serum kinetics of intravenous cefotaxime was studied in 13 neonates and 5 infants presenting with bacterial infections in order to establish the dosage and route of administration.', 'subject score': 888, 'object score': 1000}, 'PMID:6089633': {'publication date': '1984 Oct', 'sentence': 'We conclude that cefotaxime may be more effective and less toxic than nafcillin plus tobramycin for patients with serious bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:6250982': {'publication date': '1980', 'sentence': 'The cefotaxime concentrations found in serum and tissue lead us to expect successful therapy when cefotaxime is used to treat bacterial infections with sensitive pathogens in the urogenital tract.', 'subject score': 1000, 'object score': 1000}, 'PMID:6259603': {'publication date': '1981 Feb 26', 'sentence': 'Seventeen septicaemia, 18 urinary tract infections, 13 acute bacterial pulmonary infections and 7 infections at various other site were treated with cefotaxime, and, in 48 cases, with cefotaxime alone.', 'subject score': 1000, 'object score': 798}, 'PMID:6259612': {'publication date': '1981 Feb 26', 'sentence': 'Cefotaxime at a daily dose of 2 g intramuscularly for 12 days, showed very good efficacy in the treatment of various bacterial infections of the lower respiratory tract.', 'subject score': 1000, 'object score': 901}, 'PMID:6285810': {'publication date': '1982 Mar', 'sentence': 'Cefotaxime therapy of serious bacterial infection in adults.', 'subject score': 888, 'object score': 901}, 'PMID:6294794': {'publication date': '1982', 'sentence': 'Clinical trials of cefotaxime for the treatment of bacterial infections of the lower respiratory tract.', 'subject score': 1000, 'object score': 1000}, 'PMID:6321080': {'publication date': '1984 Apr', 'sentence': 'Evaluation of cefotaxime in bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:7587054': {'publication date': '1995 May-Jun', 'sentence': 'Therapeutic options for cefotaxime in the management of bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:8731830': {'publication date': '1995 Oct', 'sentence': '[A randomized controlled clinical trial of sulperazone as compared with cefotaxime in the treatment of bacterial infections].', 'subject score': 1000, 'object score': 1000}, 'PMID:9114206': {'publication date': '1997 Mar', 'sentence': 'We conducted a randomized, open-label, controlled, multicenter study to compare sulbactam/cefoperazone with cefotaxime in terms of efficacy and safety for the treatment of hospitalized patients with moderate-to-severe bacterial infections.', 'subject score': 1000, 'object score': 893}}",
-    "p2": {
-      "start": {
-        "identity": 538307,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-          ]
-        }
-      },
-      "end": {
-        "identity": 576,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefotaxime",
-          "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C06885",
-            "DRUGBANK:DB00493",
-            "UNII:N2GI8B1GK7",
-            "NCIT:C354",
-            "DrugCentral:546",
-            "UMLS:C0007554",
-            "ATC:J01DD01",
-            "GTOPDB:10893",
-            "MESH:D002439",
-            "PUBCHEM.COMPOUND:5742673",
-            "HMDB:HMDB0014636",
-            "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-            "CHEBI:204928",
-            "PDQ:CDR0000039177",
-            "RXNORM:2186",
-            "CAS:60846-21-1",
-            "KEGG.DRUG:D07647",
-            "NDDF:004845",
-            "CHEMBL.COMPOUND:CHEMBL1730"
-          ],
-          "id": "PUBCHEM.COMPOUND:5742673",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Cefotaxime (INN)",
-            "cefotaxime",
-            "cefotaxime sodium salt",
-            "CEFOTAXIME",
-            "Cefotaxime"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20643901",
-            "PMID:19858254",
-            "PMID:17938180",
-            "PMID:17846134",
-            "PMID:17074790",
-            "PMID:17438056",
-            "PMID:19581459",
-            "PMID:22494615",
-            "PMID:1847430",
-            "PMID:18180346"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538307,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7982149,
-            "start": 576,
-            "end": 538307,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10782908': {'publication date': '2000 Apr', 'sentence': 'These results suggest that amoxicillin-clavulanic acid is an effective alternative to cefotaxime for the empirical treatment of bacterial infections in cirrhosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1571464': {'publication date': '1992 Jan', 'sentence': 'Cefotaxime has been used to treat serious bacterial infections in children since 1982.', 'subject score': 1000, 'object score': 901}, 'PMID:18611720': {'publication date': '1996 Apr', 'sentence': 'The combination of the beta-lactamase inhibitor sulbactam and a ureidopenicillin or cefotaxime was highly effiacious in patients with severe bacterial infections investigated in this study.', 'subject score': 1000, 'object score': 901}, 'PMID:1943983': {'publication date': '1991 Sep 15', 'sentence': 'An open multicenter study on inpatients of 12 german hospitals was performed to investigate efficacy and safety of sulbactam in combination with mezlocillin, piperacillin or cefotaxim in severe bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:2668427': {'publication date': '1989 Sep', 'sentence': 'Once-daily therapy with ceftriaxone compared with daily multiple-dose therapy with cefotaxime for serious bacterial infections: a randomized, double-blind study.', 'subject score': 1000, 'object score': 901}, 'PMID:2668428': {'publication date': '1989 Sep', 'sentence': 'Ceftriaxone was compared with cefotaxime for the treatment of serious bacterial infections in a prospective, randomized, double-blind clinical trial.', 'subject score': 1000, 'object score': 901}, 'PMID:3901208': {'publication date': '1985', 'sentence': 'Comparative clinical evaluation of imipenem/cilastatin vs. cefotaxime in treatment of severe bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:4083974': {'publication date': '1985 Aug-Sep', 'sentence': 'The serum kinetics of intravenous cefotaxime was studied in 13 neonates and 5 infants presenting with bacterial infections in order to establish the dosage and route of administration.', 'subject score': 888, 'object score': 1000}, 'PMID:6089633': {'publication date': '1984 Oct', 'sentence': 'We conclude that cefotaxime may be more effective and less toxic than nafcillin plus tobramycin for patients with serious bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:6250982': {'publication date': '1980', 'sentence': 'The cefotaxime concentrations found in serum and tissue lead us to expect successful therapy when cefotaxime is used to treat bacterial infections with sensitive pathogens in the urogenital tract.', 'subject score': 1000, 'object score': 1000}, 'PMID:6259603': {'publication date': '1981 Feb 26', 'sentence': 'Seventeen septicaemia, 18 urinary tract infections, 13 acute bacterial pulmonary infections and 7 infections at various other site were treated with cefotaxime, and, in 48 cases, with cefotaxime alone.', 'subject score': 1000, 'object score': 798}, 'PMID:6259612': {'publication date': '1981 Feb 26', 'sentence': 'Cefotaxime at a daily dose of 2 g intramuscularly for 12 days, showed very good efficacy in the treatment of various bacterial infections of the lower respiratory tract.', 'subject score': 1000, 'object score': 901}, 'PMID:6285810': {'publication date': '1982 Mar', 'sentence': 'Cefotaxime therapy of serious bacterial infection in adults.', 'subject score': 888, 'object score': 901}, 'PMID:6294794': {'publication date': '1982', 'sentence': 'Clinical trials of cefotaxime for the treatment of bacterial infections of the lower respiratory tract.', 'subject score': 1000, 'object score': 1000}, 'PMID:6321080': {'publication date': '1984 Apr', 'sentence': 'Evaluation of cefotaxime in bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:7587054': {'publication date': '1995 May-Jun', 'sentence': 'Therapeutic options for cefotaxime in the management of bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:8731830': {'publication date': '1995 Oct', 'sentence': '[A randomized controlled clinical trial of sulperazone as compared with cefotaxime in the treatment of bacterial infections].', 'subject score': 1000, 'object score': 1000}, 'PMID:9114206': {'publication date': '1997 Mar', 'sentence': 'We conducted a randomized, open-label, controlled, multicenter study to compare sulbactam/cefoperazone with cefotaxime in terms of efficacy and safety for the treatment of hospitalized patients with moderate-to-severe bacterial infections.', 'subject score': 1000, 'object score': 893}}",
-              "kg2_ids": [
-                "UMLS:C0007554---SEMMEDDB:treats---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5742673",
-              "id": "8153267",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:10782908",
-                "PMID:1571464",
-                "PMID:18611720",
-                "PMID:1943983",
-                "PMID:2668427",
-                "PMID:2668428",
-                "PMID:3901208",
-                "PMID:4083974",
-                "PMID:6089633",
-                "PMID:6250982",
-                "PMID:6259603",
-                "PMID:6259612",
-                "PMID:6285810",
-                "PMID:6294794",
-                "PMID:6321080",
-                "PMID:7587054",
-                "PMID:8731830",
-                "PMID:9114206"
-              ]
-            }
-          },
-          "end": {
-            "identity": 576,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefotaxime",
-              "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C06885",
-                "DRUGBANK:DB00493",
-                "UNII:N2GI8B1GK7",
-                "NCIT:C354",
-                "DrugCentral:546",
-                "UMLS:C0007554",
-                "ATC:J01DD01",
-                "GTOPDB:10893",
-                "MESH:D002439",
-                "PUBCHEM.COMPOUND:5742673",
-                "HMDB:HMDB0014636",
-                "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-                "CHEBI:204928",
-                "PDQ:CDR0000039177",
-                "RXNORM:2186",
-                "CAS:60846-21-1",
-                "KEGG.DRUG:D07647",
-                "NDDF:004845",
-                "CHEMBL.COMPOUND:CHEMBL1730"
-              ],
-              "id": "PUBCHEM.COMPOUND:5742673",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Cefotaxime (INN)",
-                "cefotaxime",
-                "cefotaxime sodium salt",
-                "CEFOTAXIME",
-                "Cefotaxime"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20643901",
-                "PMID:19858254",
-                "PMID:17938180",
-                "PMID:17846134",
-                "PMID:17074790",
-                "PMID:17438056",
-                "PMID:19581459",
-                "PMID:22494615",
-                "PMID:1847430",
-                "PMID:18180346"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:2659565': {'publication date': '1989 Mar', 'sentence': 'The protective effect of cefotaxime, aztreonam and gentamicin in peritonitis induced by E. coli alone or combined with B. fragilis was evaluated by analysing mortality at 24 and 48 h after bacterial inoculation and treating the animals with two doses of each antibiotic.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319329,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004522",
-          "name": "peritonitis",
-          "description": "Inflammation of the peritoneum due to infection by bacteria or fungi. Causes include liver disease, perforation of the gastrointestinal tract or biliary tract, and peritoneal dialysis. Patients usually present with abdominal pain and tenderness, fever, chills, and nausea and vomiting. It is an emergency medical condition that requires prompt medical attention and treatment.; INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.; Inflammation of the peritoneum. [HPO:probinson]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "UMLS:C0029823",
-            "MESH:D010538",
-            "MEDDRA:10034685",
-            "MEDDRA:10085062",
-            "SYMP:0000102",
-            "EFO:0008588",
-            "DOID:8283",
-            "HP:0002586",
-            "ICD9:567.8",
-            "MEDDRA:10046096",
-            "UMLS:C0267770",
-            "SNOMEDCT:86422009",
-            "MONDO:0004522",
-            "MEDDRA:10034674",
-            "ICD9:567.89",
-            "UMLS:C0031154",
-            "SNOMEDCT:48661000",
-            "NCIT:C26849"
-          ],
-          "id": "MONDO:0004522",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peritonitis",
-            "Other specified peritonitis",
-            "peritonitis",
-            "Retractile Mesenteritis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.merck.com/mmpe/sec02/ch011/ch011b.html#sec02-ch011-ch011b-402",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=peritonitis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/001335.htm",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 576,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefotaxime",
-          "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C06885",
-            "DRUGBANK:DB00493",
-            "UNII:N2GI8B1GK7",
-            "NCIT:C354",
-            "DrugCentral:546",
-            "UMLS:C0007554",
-            "ATC:J01DD01",
-            "GTOPDB:10893",
-            "MESH:D002439",
-            "PUBCHEM.COMPOUND:5742673",
-            "HMDB:HMDB0014636",
-            "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-            "CHEBI:204928",
-            "PDQ:CDR0000039177",
-            "RXNORM:2186",
-            "CAS:60846-21-1",
-            "KEGG.DRUG:D07647",
-            "NDDF:004845",
-            "CHEMBL.COMPOUND:CHEMBL1730"
-          ],
-          "id": "PUBCHEM.COMPOUND:5742673",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Cefotaxime (INN)",
-            "cefotaxime",
-            "cefotaxime sodium salt",
-            "CEFOTAXIME",
-            "Cefotaxime"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20643901",
-            "PMID:19858254",
-            "PMID:17938180",
-            "PMID:17846134",
-            "PMID:17074790",
-            "PMID:17438056",
-            "PMID:19581459",
-            "PMID:22494615",
-            "PMID:1847430",
-            "PMID:18180346"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319329,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004522",
-              "name": "peritonitis",
-              "description": "Inflammation of the peritoneum due to infection by bacteria or fungi. Causes include liver disease, perforation of the gastrointestinal tract or biliary tract, and peritoneal dialysis. Patients usually present with abdominal pain and tenderness, fever, chills, and nausea and vomiting. It is an emergency medical condition that requires prompt medical attention and treatment.; INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.; Inflammation of the peritoneum. [HPO:probinson]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "UMLS:C0029823",
-                "MESH:D010538",
-                "MEDDRA:10034685",
-                "MEDDRA:10085062",
-                "SYMP:0000102",
-                "EFO:0008588",
-                "DOID:8283",
-                "HP:0002586",
-                "ICD9:567.8",
-                "MEDDRA:10046096",
-                "UMLS:C0267770",
-                "SNOMEDCT:86422009",
-                "MONDO:0004522",
-                "MEDDRA:10034674",
-                "ICD9:567.89",
-                "UMLS:C0031154",
-                "SNOMEDCT:48661000",
-                "NCIT:C26849"
-              ],
-              "id": "MONDO:0004522",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peritonitis",
-                "Other specified peritonitis",
-                "peritonitis",
-                "Retractile Mesenteritis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.merck.com/mmpe/sec02/ch011/ch011b.html#sec02-ch011-ch011b-402",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=peritonitis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/001335.htm",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18302169,
-            "start": 576,
-            "end": 319329,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2659565': {'publication date': '1989 Mar', 'sentence': 'The protective effect of cefotaxime, aztreonam and gentamicin in peritonitis induced by E. coli alone or combined with B. fragilis was evaluated by analysing mortality at 24 and 48 h after bacterial inoculation and treating the animals with two doses of each antibiotic.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0007554---SEMMEDDB:affects---None---None---None---UMLS:C0031154---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5742673",
-              "id": "18672205",
-              "object": "MONDO:0004522",
-              "publications": [
-                "PMID:2659565"
-              ]
-            }
-          },
-          "end": {
-            "identity": 576,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefotaxime",
-              "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C06885",
-                "DRUGBANK:DB00493",
-                "UNII:N2GI8B1GK7",
-                "NCIT:C354",
-                "DrugCentral:546",
-                "UMLS:C0007554",
-                "ATC:J01DD01",
-                "GTOPDB:10893",
-                "MESH:D002439",
-                "PUBCHEM.COMPOUND:5742673",
-                "HMDB:HMDB0014636",
-                "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-                "CHEBI:204928",
-                "PDQ:CDR0000039177",
-                "RXNORM:2186",
-                "CAS:60846-21-1",
-                "KEGG.DRUG:D07647",
-                "NDDF:004845",
-                "CHEMBL.COMPOUND:CHEMBL1730"
-              ],
-              "id": "PUBCHEM.COMPOUND:5742673",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Cefotaxime (INN)",
-                "cefotaxime",
-                "cefotaxime sodium salt",
-                "CEFOTAXIME",
-                "Cefotaxime"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20643901",
-                "PMID:19858254",
-                "PMID:17938180",
-                "PMID:17846134",
-                "PMID:17074790",
-                "PMID:17438056",
-                "PMID:19581459",
-                "PMID:22494615",
-                "PMID:1847430",
-                "PMID:18180346"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:2066075': {'publication date': '1991 Jul', 'sentence': 'Aztreonam and cefotaxime were compared in 44 cirrhotic patients who had 52 episodes of gram-negative spontaneous peritonitis.', 'subject score': 1000, 'object score': 833}, 'PMID:26484045': {'publication date': '2015 Sep', 'sentence': 'Although R. mucilaginosa is generally susceptible to penicillin, ampicillin, cefotaxime, imipenem, rifampicin, and glycopeptides, there are no guidelines for the treatment of PD-associated peritonitis.', 'subject score': 1000, 'object score': 824}, 'PMID:2660995': {'publication date': '1989 Mar-Apr', 'sentence': 'It has been effective as monotherapy in the treatment of peritonitis, gynecologic infections, chronic bronchitis, and infections in patients with leukemia and granulocytopenia, as has cefotaxime when in combination with an aminoglycoside.', 'subject score': 1000, 'object score': 1000}, 'PMID:3312030': {'publication date': '1987', 'sentence': 'In a randomized controlled, clinical study the efficacy of ceftazidime at a dosage of 2 g b. i. d. was compared to that of cefotaxime at a dosage of 2 g t. i. d. or more in the treatment of pneumonia or peritonitis in intensive care patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:4000338': {'publication date': '1985', 'sentence': 'However, the mean dialysate effluent concentration of cefotaxime was increased following the resolution of the peritonitis, 165 +/- 22.7 mg per cycle on day 10 or 12 compared with 50.4 +/- 7.3 mg per cycle on day 1, suggesting enhanced peritoneal cefotaxime absorption during acute peritonitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:6094442': {'publication date': '1984 Sep', 'sentence': 'The combination of cefotaxime and metronidazole has been suggested for the treatment of peritonitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:6293712': {'publication date': '1982', 'sentence': 'Clinical evaluation of cefotaxime versus gentamicin plus clindamycin in the treatment of polymicrobial peritonitis.', 'subject score': 1000, 'object score': 861}, 'PMID:6294796': {'publication date': '1982', 'sentence': 'Clinical comparison of cefotaxime with gentamicin plus clindamycin in the treatment of peritonitis and other soft-tissue infections.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319329,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004522",
-          "name": "peritonitis",
-          "description": "Inflammation of the peritoneum due to infection by bacteria or fungi. Causes include liver disease, perforation of the gastrointestinal tract or biliary tract, and peritoneal dialysis. Patients usually present with abdominal pain and tenderness, fever, chills, and nausea and vomiting. It is an emergency medical condition that requires prompt medical attention and treatment.; INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.; Inflammation of the peritoneum. [HPO:probinson]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "UMLS:C0029823",
-            "MESH:D010538",
-            "MEDDRA:10034685",
-            "MEDDRA:10085062",
-            "SYMP:0000102",
-            "EFO:0008588",
-            "DOID:8283",
-            "HP:0002586",
-            "ICD9:567.8",
-            "MEDDRA:10046096",
-            "UMLS:C0267770",
-            "SNOMEDCT:86422009",
-            "MONDO:0004522",
-            "MEDDRA:10034674",
-            "ICD9:567.89",
-            "UMLS:C0031154",
-            "SNOMEDCT:48661000",
-            "NCIT:C26849"
-          ],
-          "id": "MONDO:0004522",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peritonitis",
-            "Other specified peritonitis",
-            "peritonitis",
-            "Retractile Mesenteritis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.merck.com/mmpe/sec02/ch011/ch011b.html#sec02-ch011-ch011b-402",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=peritonitis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/001335.htm",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 576,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefotaxime",
-          "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C06885",
-            "DRUGBANK:DB00493",
-            "UNII:N2GI8B1GK7",
-            "NCIT:C354",
-            "DrugCentral:546",
-            "UMLS:C0007554",
-            "ATC:J01DD01",
-            "GTOPDB:10893",
-            "MESH:D002439",
-            "PUBCHEM.COMPOUND:5742673",
-            "HMDB:HMDB0014636",
-            "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-            "CHEBI:204928",
-            "PDQ:CDR0000039177",
-            "RXNORM:2186",
-            "CAS:60846-21-1",
-            "KEGG.DRUG:D07647",
-            "NDDF:004845",
-            "CHEMBL.COMPOUND:CHEMBL1730"
-          ],
-          "id": "PUBCHEM.COMPOUND:5742673",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Cefotaxime (INN)",
-            "cefotaxime",
-            "cefotaxime sodium salt",
-            "CEFOTAXIME",
-            "Cefotaxime"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20643901",
-            "PMID:19858254",
-            "PMID:17938180",
-            "PMID:17846134",
-            "PMID:17074790",
-            "PMID:17438056",
-            "PMID:19581459",
-            "PMID:22494615",
-            "PMID:1847430",
-            "PMID:18180346"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319329,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004522",
-              "name": "peritonitis",
-              "description": "Inflammation of the peritoneum due to infection by bacteria or fungi. Causes include liver disease, perforation of the gastrointestinal tract or biliary tract, and peritoneal dialysis. Patients usually present with abdominal pain and tenderness, fever, chills, and nausea and vomiting. It is an emergency medical condition that requires prompt medical attention and treatment.; INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.; Inflammation of the peritoneum. [HPO:probinson]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "UMLS:C0029823",
-                "MESH:D010538",
-                "MEDDRA:10034685",
-                "MEDDRA:10085062",
-                "SYMP:0000102",
-                "EFO:0008588",
-                "DOID:8283",
-                "HP:0002586",
-                "ICD9:567.8",
-                "MEDDRA:10046096",
-                "UMLS:C0267770",
-                "SNOMEDCT:86422009",
-                "MONDO:0004522",
-                "MEDDRA:10034674",
-                "ICD9:567.89",
-                "UMLS:C0031154",
-                "SNOMEDCT:48661000",
-                "NCIT:C26849"
-              ],
-              "id": "MONDO:0004522",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peritonitis",
-                "Other specified peritonitis",
-                "peritonitis",
-                "Retractile Mesenteritis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.merck.com/mmpe/sec02/ch011/ch011b.html#sec02-ch011-ch011b-402",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=peritonitis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/001335.htm",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14806121,
-            "start": 576,
-            "end": 319329,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2066075': {'publication date': '1991 Jul', 'sentence': 'Aztreonam and cefotaxime were compared in 44 cirrhotic patients who had 52 episodes of gram-negative spontaneous peritonitis.', 'subject score': 1000, 'object score': 833}, 'PMID:26484045': {'publication date': '2015 Sep', 'sentence': 'Although R. mucilaginosa is generally susceptible to penicillin, ampicillin, cefotaxime, imipenem, rifampicin, and glycopeptides, there are no guidelines for the treatment of PD-associated peritonitis.', 'subject score': 1000, 'object score': 824}, 'PMID:2660995': {'publication date': '1989 Mar-Apr', 'sentence': 'It has been effective as monotherapy in the treatment of peritonitis, gynecologic infections, chronic bronchitis, and infections in patients with leukemia and granulocytopenia, as has cefotaxime when in combination with an aminoglycoside.', 'subject score': 1000, 'object score': 1000}, 'PMID:3312030': {'publication date': '1987', 'sentence': 'In a randomized controlled, clinical study the efficacy of ceftazidime at a dosage of 2 g b. i. d. was compared to that of cefotaxime at a dosage of 2 g t. i. d. or more in the treatment of pneumonia or peritonitis in intensive care patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:4000338': {'publication date': '1985', 'sentence': 'However, the mean dialysate effluent concentration of cefotaxime was increased following the resolution of the peritonitis, 165 +/- 22.7 mg per cycle on day 10 or 12 compared with 50.4 +/- 7.3 mg per cycle on day 1, suggesting enhanced peritoneal cefotaxime absorption during acute peritonitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:6094442': {'publication date': '1984 Sep', 'sentence': 'The combination of cefotaxime and metronidazole has been suggested for the treatment of peritonitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:6293712': {'publication date': '1982', 'sentence': 'Clinical evaluation of cefotaxime versus gentamicin plus clindamycin in the treatment of polymicrobial peritonitis.', 'subject score': 1000, 'object score': 861}, 'PMID:6294796': {'publication date': '1982', 'sentence': 'Clinical comparison of cefotaxime with gentamicin plus clindamycin in the treatment of peritonitis and other soft-tissue infections.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0007554---SEMMEDDB:treats---None---None---None---UMLS:C0031154---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5742673",
-              "id": "15119078",
-              "object": "MONDO:0004522",
-              "publications": [
-                "PMID:2066075",
-                "PMID:26484045",
-                "PMID:2660995",
-                "PMID:3312030",
-                "PMID:4000338",
-                "PMID:6094442",
-                "PMID:6293712",
-                "PMID:6294796"
-              ]
-            }
-          },
-          "end": {
-            "identity": 576,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefotaxime",
-              "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C06885",
-                "DRUGBANK:DB00493",
-                "UNII:N2GI8B1GK7",
-                "NCIT:C354",
-                "DrugCentral:546",
-                "UMLS:C0007554",
-                "ATC:J01DD01",
-                "GTOPDB:10893",
-                "MESH:D002439",
-                "PUBCHEM.COMPOUND:5742673",
-                "HMDB:HMDB0014636",
-                "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-                "CHEBI:204928",
-                "PDQ:CDR0000039177",
-                "RXNORM:2186",
-                "CAS:60846-21-1",
-                "KEGG.DRUG:D07647",
-                "NDDF:004845",
-                "CHEMBL.COMPOUND:CHEMBL1730"
-              ],
-              "id": "PUBCHEM.COMPOUND:5742673",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Cefotaxime (INN)",
-                "cefotaxime",
-                "cefotaxime sodium salt",
-                "CEFOTAXIME",
-                "Cefotaxime"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20643901",
-                "PMID:19858254",
-                "PMID:17938180",
-                "PMID:17846134",
-                "PMID:17074790",
-                "PMID:17438056",
-                "PMID:19581459",
-                "PMID:22494615",
-                "PMID:1847430",
-                "PMID:18180346"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:1720432': {'publication date': '1991 Sep', 'sentence': 'Combined treatments of rG-CSF with cefotaxime, cefazolin, fosfomycin, gentamicin or amphotericin B were evaluated in systemic infections with Pseudomonas aeruginosa, Escherichia coli, Serratia marcescens, Staphylococcus aureus and Candida albicans in leucopenic mice induced by pretreatment with cyclophosphamide.', 'subject score': 1000, 'object score': 983}}",
-    "p2": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 576,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefotaxime",
-          "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C06885",
-            "DRUGBANK:DB00493",
-            "UNII:N2GI8B1GK7",
-            "NCIT:C354",
-            "DrugCentral:546",
-            "UMLS:C0007554",
-            "ATC:J01DD01",
-            "GTOPDB:10893",
-            "MESH:D002439",
-            "PUBCHEM.COMPOUND:5742673",
-            "HMDB:HMDB0014636",
-            "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-            "CHEBI:204928",
-            "PDQ:CDR0000039177",
-            "RXNORM:2186",
-            "CAS:60846-21-1",
-            "KEGG.DRUG:D07647",
-            "NDDF:004845",
-            "CHEMBL.COMPOUND:CHEMBL1730"
-          ],
-          "id": "PUBCHEM.COMPOUND:5742673",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Cefotaxime (INN)",
-            "cefotaxime",
-            "cefotaxime sodium salt",
-            "CEFOTAXIME",
-            "Cefotaxime"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20643901",
-            "PMID:19858254",
-            "PMID:17938180",
-            "PMID:17846134",
-            "PMID:17074790",
-            "PMID:17438056",
-            "PMID:19581459",
-            "PMID:22494615",
-            "PMID:1847430",
-            "PMID:18180346"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12631501,
-            "start": 576,
-            "end": 320039,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1720432': {'publication date': '1991 Sep', 'sentence': 'Combined treatments of rG-CSF with cefotaxime, cefazolin, fosfomycin, gentamicin or amphotericin B were evaluated in systemic infections with Pseudomonas aeruginosa, Escherichia coli, Serratia marcescens, Staphylococcus aureus and Candida albicans in leucopenic mice induced by pretreatment with cyclophosphamide.', 'subject score': 1000, 'object score': 983}}",
-              "kg2_ids": [
-                "UMLS:C0007554---SEMMEDDB:associated_with---None---None---None---UMLS:C0243026---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5742673",
-              "id": "12905337",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:1720432"
-              ]
-            }
-          },
-          "end": {
-            "identity": 576,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefotaxime",
-              "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C06885",
-                "DRUGBANK:DB00493",
-                "UNII:N2GI8B1GK7",
-                "NCIT:C354",
-                "DrugCentral:546",
-                "UMLS:C0007554",
-                "ATC:J01DD01",
-                "GTOPDB:10893",
-                "MESH:D002439",
-                "PUBCHEM.COMPOUND:5742673",
-                "HMDB:HMDB0014636",
-                "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-                "CHEBI:204928",
-                "PDQ:CDR0000039177",
-                "RXNORM:2186",
-                "CAS:60846-21-1",
-                "KEGG.DRUG:D07647",
-                "NDDF:004845",
-                "CHEMBL.COMPOUND:CHEMBL1730"
-              ],
-              "id": "PUBCHEM.COMPOUND:5742673",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Cefotaxime (INN)",
-                "cefotaxime",
-                "cefotaxime sodium salt",
-                "CEFOTAXIME",
-                "Cefotaxime"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20643901",
-                "PMID:19858254",
-                "PMID:17938180",
-                "PMID:17846134",
-                "PMID:17074790",
-                "PMID:17438056",
-                "PMID:19581459",
-                "PMID:22494615",
-                "PMID:1847430",
-                "PMID:18180346"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:34787905': {'publication date': '2021 Nov 17', 'sentence': 'CONS, Staphylococcus aureus, Enterococci, Escherichia coli, Klebsiella and Enterobacter represented 91.9% of LOS episodes and were susceptible to vancomycin and cefotaxime (96.1%), vancomycin and gentamicin (97.0%) and cloxacillin and gentamicin (38.1%).', 'subject score': 1000, 'object score': 861}, 'PMID:3900946': {'publication date': '1985 Sep-Oct', 'sentence': 'Seven neonates were treated with cefotaxime during eight episodes of Gram-negative bacillary meningitis and sepsis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 576,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefotaxime",
-          "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C06885",
-            "DRUGBANK:DB00493",
-            "UNII:N2GI8B1GK7",
-            "NCIT:C354",
-            "DrugCentral:546",
-            "UMLS:C0007554",
-            "ATC:J01DD01",
-            "GTOPDB:10893",
-            "MESH:D002439",
-            "PUBCHEM.COMPOUND:5742673",
-            "HMDB:HMDB0014636",
-            "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-            "CHEBI:204928",
-            "PDQ:CDR0000039177",
-            "RXNORM:2186",
-            "CAS:60846-21-1",
-            "KEGG.DRUG:D07647",
-            "NDDF:004845",
-            "CHEMBL.COMPOUND:CHEMBL1730"
-          ],
-          "id": "PUBCHEM.COMPOUND:5742673",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Cefotaxime (INN)",
-            "cefotaxime",
-            "cefotaxime sodium salt",
-            "CEFOTAXIME",
-            "Cefotaxime"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20643901",
-            "PMID:19858254",
-            "PMID:17938180",
-            "PMID:17846134",
-            "PMID:17074790",
-            "PMID:17438056",
-            "PMID:19581459",
-            "PMID:22494615",
-            "PMID:1847430",
-            "PMID:18180346"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23485379,
-            "start": 576,
-            "end": 320039,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34787905': {'publication date': '2021 Nov 17', 'sentence': 'CONS, Staphylococcus aureus, Enterococci, Escherichia coli, Klebsiella and Enterobacter represented 91.9% of LOS episodes and were susceptible to vancomycin and cefotaxime (96.1%), vancomycin and gentamicin (97.0%) and cloxacillin and gentamicin (38.1%).', 'subject score': 1000, 'object score': 861}, 'PMID:3900946': {'publication date': '1985 Sep-Oct', 'sentence': 'Seven neonates were treated with cefotaxime during eight episodes of Gram-negative bacillary meningitis and sepsis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0007554---SEMMEDDB:affects---None---None---None---UMLS:C0036690---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5742673",
-              "id": "23922029",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:34787905",
-                "PMID:3900946"
-              ]
-            }
-          },
-          "end": {
-            "identity": 576,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefotaxime",
-              "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C06885",
-                "DRUGBANK:DB00493",
-                "UNII:N2GI8B1GK7",
-                "NCIT:C354",
-                "DrugCentral:546",
-                "UMLS:C0007554",
-                "ATC:J01DD01",
-                "GTOPDB:10893",
-                "MESH:D002439",
-                "PUBCHEM.COMPOUND:5742673",
-                "HMDB:HMDB0014636",
-                "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-                "CHEBI:204928",
-                "PDQ:CDR0000039177",
-                "RXNORM:2186",
-                "CAS:60846-21-1",
-                "KEGG.DRUG:D07647",
-                "NDDF:004845",
-                "CHEMBL.COMPOUND:CHEMBL1730"
-              ],
-              "id": "PUBCHEM.COMPOUND:5742673",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Cefotaxime (INN)",
-                "cefotaxime",
-                "cefotaxime sodium salt",
-                "CEFOTAXIME",
-                "Cefotaxime"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20643901",
-                "PMID:19858254",
-                "PMID:17938180",
-                "PMID:17846134",
-                "PMID:17074790",
-                "PMID:17438056",
-                "PMID:19581459",
-                "PMID:22494615",
-                "PMID:1847430",
-                "PMID:18180346"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 319329,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15119790': {'publication date': '2004', 'sentence': \"Due to the apparent volumes of distribution obtained (ranging from 0.48 to 0.51 L/kg), considering the overall clinical efficacy obtained (90% for the 10 mg/kg dose and 75% for the 20 mg/kg dose), and due to the rapid improvement observed after a few doses of the drug (1.8 to 2.5 doses to 'clinical improvement'), it is safe to postulate such doses of cefotaxime as excellent choices for the treatment of septicaemia in dogs.\", 'subject score': 1000, 'object score': 1000}, 'PMID:16567997': {'publication date': '2006 Apr', 'sentence': 'A preterm infant with early onset Morganella morganii sepsis was treated with cefotaxime and gentamicin after confirmation of antimicrobial susceptibility.', 'subject score': 1000, 'object score': 840}, 'PMID:18072100': {'publication date': '2005 Dec', 'sentence': 'She was admitted to the PICU and was started on ampicillin and cefotaxime for R/O sepsis.', 'subject score': 1000, 'object score': 790}, 'PMID:1889866': {'publication date': '1991', 'sentence': 'Early recognition of neonatal sepsis by a good blood culture technique and beginning of treatment on first suspicion of sepsis with cefotaxime and piperacillin can improve the results especially in intensive care patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:22514473': {'publication date': '1997 Jan', 'sentence': 'INTERVENTION: Comparison of cefepime, ceftazidime, ceftriaxone, cefotaxime and ciprofloxacin in the treatment of lower respiratory tract infections, urinary tract infections, skin/soft tissue infections, septicemia and febrile neutropenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:24978586': {'publication date': '2014', 'sentence': 'These data suggest that the combination of ciprofloxacin and cefotaxime is an effective option for the treatment of V. vulnificus sepsis in humans.', 'subject score': 1000, 'object score': 827}, 'PMID:2612239': {'publication date': '1989', 'sentence': 'Ceftriaxone versus cefotaxime in the treatment of septicemia in adults.', 'subject score': 1000, 'object score': 1000}, 'PMID:27232293': {'publication date': '2016', 'sentence': 'A sepsis of unknown origin was suspected, and intravenous treatment with gentamicin and cefotaxime was initiated.', 'subject score': 1000, 'object score': 1000}, 'PMID:30968258': {'publication date': '2019 Jul', 'sentence': 'However, as target attainment of cefotaxime in severely ill pediatric sepsis patients may differ from adults due to age-related variation in pharmacokinetics, we aimed to assess target attainment of cefotaxime in this pilot study using meningococcal septic shock patients as a model for severe sepsis.', 'subject score': 1000, 'object score': 822}, 'PMID:3302868': {'publication date': '1987 May', 'sentence': 'In a prospective, randomized study we compared cefotaxime (C) with tobramycin plus cefazolin (C + T) in the treatment of Enterobacterial septicemia.', 'subject score': 1000, 'object score': 853}, 'PMID:3334576': {'publication date': '1987 Jun', 'sentence': 'Cefotaxime (C) vs cefotaxime + amikacin (C + A) in the treatment of septicemia due to enterobacteria: a multicenter study.', 'subject score': 1000, 'object score': 1000}, 'PMID:33424507': {'publication date': '2021', 'sentence': 'Occurrence of Hyperbilirubinemia in Neonates Given a Short-term Course of Ceftriaxone versus Cefotaxime for Sepsis.', 'subject score': 1000, 'object score': 1000}, 'PMID:34787905': {'publication date': '2021 Nov 17', 'sentence': 'Combining vancomycin and gentamicin may be a safer alternative to cefotaxime for LOS, as this reduces exposure to broad-spectrum antibiotics.', 'subject score': 1000, 'object score': 901}, 'PMID:3616496': {'publication date': '1987', 'sentence': '93 patients were enrolled into a prospective randomised study to determine the efficacy and safety of netilmicin, cefotaxime or their combination in the treatment of sepsis caused by susceptible strains of Enterobacteriaceae or staphylococci.', 'subject score': 1000, 'object score': 1000}, 'PMID:3803377': {'publication date': '1986 Dec', 'sentence': 'Within twenty-four hours irreversible fulminant sepsis developed although he was treated with cefotaxime, tobramycin and erythromycin.', 'subject score': 1000, 'object score': 737}, 'PMID:3815462': {'publication date': '1986', 'sentence': 'Monotherapy with cefotaxime in septicemic patients with hematological malignancies appears to be a valuable alternative to other antibiotic regimens.', 'subject score': 1000, 'object score': 853}, 'PMID:4055053': {'publication date': '1985', 'sentence': 'Staphylococcus aureus septicaemia treated with cefotaxime.', 'subject score': 1000, 'object score': 901}, 'PMID:6096793': {'publication date': '1984 Dec', 'sentence': 'Twenty-seven septicemia, 2 urinary tract infections and 2 meningitis were treated with Cefotaxime.', 'subject score': 1000, 'object score': 790}, 'PMID:6252168': {'publication date': '1980 Sep', 'sentence': 'Cefotaxime in the treatment of septicaemia and endocarditis.', 'subject score': 1000, 'object score': 1000}, 'PMID:6252171': {'publication date': '1980 Sep', 'sentence': 'Cefotaxime in septicaemia including typhoid fever.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 320039,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004522",
-          "name": "peritonitis",
-          "description": "Inflammation of the peritoneum due to infection by bacteria or fungi. Causes include liver disease, perforation of the gastrointestinal tract or biliary tract, and peritoneal dialysis. Patients usually present with abdominal pain and tenderness, fever, chills, and nausea and vomiting. It is an emergency medical condition that requires prompt medical attention and treatment.; INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.; Inflammation of the peritoneum. [HPO:probinson]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "UMLS:C0029823",
-            "MESH:D010538",
-            "MEDDRA:10034685",
-            "MEDDRA:10085062",
-            "SYMP:0000102",
-            "EFO:0008588",
-            "DOID:8283",
-            "HP:0002586",
-            "ICD9:567.8",
-            "MEDDRA:10046096",
-            "UMLS:C0267770",
-            "SNOMEDCT:86422009",
-            "MONDO:0004522",
-            "MEDDRA:10034674",
-            "ICD9:567.89",
-            "UMLS:C0031154",
-            "SNOMEDCT:48661000",
-            "NCIT:C26849"
-          ],
-          "id": "MONDO:0004522",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peritonitis",
-            "Other specified peritonitis",
-            "peritonitis",
-            "Retractile Mesenteritis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.merck.com/mmpe/sec02/ch011/ch011b.html#sec02-ch011-ch011b-402",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=peritonitis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/001335.htm",
-            "https://orcid.org/0000-0002-0736-9199"
-=======
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 576,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefotaxime",
-          "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C06885",
-            "DRUGBANK:DB00493",
-            "UNII:N2GI8B1GK7",
-            "NCIT:C354",
-            "DrugCentral:546",
-            "UMLS:C0007554",
-            "ATC:J01DD01",
-            "GTOPDB:10893",
-            "MESH:D002439",
-            "PUBCHEM.COMPOUND:5742673",
-            "HMDB:HMDB0014636",
-            "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-            "CHEBI:204928",
-            "PDQ:CDR0000039177",
-            "RXNORM:2186",
-            "CAS:60846-21-1",
-            "KEGG.DRUG:D07647",
-            "NDDF:004845",
-            "CHEMBL.COMPOUND:CHEMBL1730"
-          ],
-          "id": "PUBCHEM.COMPOUND:5742673",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Cefotaxime (INN)",
-            "cefotaxime",
-            "cefotaxime sodium salt",
-            "CEFOTAXIME",
-            "Cefotaxime"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20643901",
-            "PMID:19858254",
-            "PMID:17938180",
-            "PMID:17846134",
-            "PMID:17074790",
-            "PMID:17438056",
-            "PMID:19581459",
-            "PMID:22494615",
-            "PMID:1847430",
-            "PMID:18180346"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 319329,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004522",
-              "name": "peritonitis",
-              "description": "Inflammation of the peritoneum due to infection by bacteria or fungi. Causes include liver disease, perforation of the gastrointestinal tract or biliary tract, and peritoneal dialysis. Patients usually present with abdominal pain and tenderness, fever, chills, and nausea and vomiting. It is an emergency medical condition that requires prompt medical attention and treatment.; INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.; Inflammation of the peritoneum. [HPO:probinson]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "UMLS:C0029823",
-                "MESH:D010538",
-                "MEDDRA:10034685",
-                "MEDDRA:10085062",
-                "SYMP:0000102",
-                "EFO:0008588",
-                "DOID:8283",
-                "HP:0002586",
-                "ICD9:567.8",
-                "MEDDRA:10046096",
-                "UMLS:C0267770",
-                "SNOMEDCT:86422009",
-                "MONDO:0004522",
-                "MEDDRA:10034674",
-                "ICD9:567.89",
-                "UMLS:C0031154",
-                "SNOMEDCT:48661000",
-                "NCIT:C26849"
-              ],
-              "id": "MONDO:0004522",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peritonitis",
-                "Other specified peritonitis",
-                "peritonitis",
-                "Retractile Mesenteritis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.merck.com/mmpe/sec02/ch011/ch011b.html#sec02-ch011-ch011b-402",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=peritonitis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/001335.htm",
-                "https://orcid.org/0000-0002-0736-9199"
-=======
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 18302169,
-            "start": 576,
-            "end": 319329,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2659565': {'publication date': '1989 Mar', 'sentence': 'The protective effect of cefotaxime, aztreonam and gentamicin in peritonitis induced by E. coli alone or combined with B. fragilis was evaluated by analysing mortality at 24 and 48 h after bacterial inoculation and treating the animals with two doses of each antibiotic.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0007554---SEMMEDDB:affects---None---None---None---UMLS:C0031154---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5742673",
-              "id": "18672205",
-              "object": "MONDO:0004522",
-              "publications": [
-                "PMID:2659565"
-=======
-            "identity": 10936544,
-            "start": 576,
-            "end": 320039,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15119790': {'publication date': '2004', 'sentence': \"Due to the apparent volumes of distribution obtained (ranging from 0.48 to 0.51 L/kg), considering the overall clinical efficacy obtained (90% for the 10 mg/kg dose and 75% for the 20 mg/kg dose), and due to the rapid improvement observed after a few doses of the drug (1.8 to 2.5 doses to 'clinical improvement'), it is safe to postulate such doses of cefotaxime as excellent choices for the treatment of septicaemia in dogs.\", 'subject score': 1000, 'object score': 1000}, 'PMID:16567997': {'publication date': '2006 Apr', 'sentence': 'A preterm infant with early onset Morganella morganii sepsis was treated with cefotaxime and gentamicin after confirmation of antimicrobial susceptibility.', 'subject score': 1000, 'object score': 840}, 'PMID:18072100': {'publication date': '2005 Dec', 'sentence': 'She was admitted to the PICU and was started on ampicillin and cefotaxime for R/O sepsis.', 'subject score': 1000, 'object score': 790}, 'PMID:1889866': {'publication date': '1991', 'sentence': 'Early recognition of neonatal sepsis by a good blood culture technique and beginning of treatment on first suspicion of sepsis with cefotaxime and piperacillin can improve the results especially in intensive care patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:22514473': {'publication date': '1997 Jan', 'sentence': 'INTERVENTION: Comparison of cefepime, ceftazidime, ceftriaxone, cefotaxime and ciprofloxacin in the treatment of lower respiratory tract infections, urinary tract infections, skin/soft tissue infections, septicemia and febrile neutropenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:24978586': {'publication date': '2014', 'sentence': 'These data suggest that the combination of ciprofloxacin and cefotaxime is an effective option for the treatment of V. vulnificus sepsis in humans.', 'subject score': 1000, 'object score': 827}, 'PMID:2612239': {'publication date': '1989', 'sentence': 'Ceftriaxone versus cefotaxime in the treatment of septicemia in adults.', 'subject score': 1000, 'object score': 1000}, 'PMID:27232293': {'publication date': '2016', 'sentence': 'A sepsis of unknown origin was suspected, and intravenous treatment with gentamicin and cefotaxime was initiated.', 'subject score': 1000, 'object score': 1000}, 'PMID:30968258': {'publication date': '2019 Jul', 'sentence': 'However, as target attainment of cefotaxime in severely ill pediatric sepsis patients may differ from adults due to age-related variation in pharmacokinetics, we aimed to assess target attainment of cefotaxime in this pilot study using meningococcal septic shock patients as a model for severe sepsis.', 'subject score': 1000, 'object score': 822}, 'PMID:3302868': {'publication date': '1987 May', 'sentence': 'In a prospective, randomized study we compared cefotaxime (C) with tobramycin plus cefazolin (C + T) in the treatment of Enterobacterial septicemia.', 'subject score': 1000, 'object score': 853}, 'PMID:3334576': {'publication date': '1987 Jun', 'sentence': 'Cefotaxime (C) vs cefotaxime + amikacin (C + A) in the treatment of septicemia due to enterobacteria: a multicenter study.', 'subject score': 1000, 'object score': 1000}, 'PMID:33424507': {'publication date': '2021', 'sentence': 'Occurrence of Hyperbilirubinemia in Neonates Given a Short-term Course of Ceftriaxone versus Cefotaxime for Sepsis.', 'subject score': 1000, 'object score': 1000}, 'PMID:34787905': {'publication date': '2021 Nov 17', 'sentence': 'Combining vancomycin and gentamicin may be a safer alternative to cefotaxime for LOS, as this reduces exposure to broad-spectrum antibiotics.', 'subject score': 1000, 'object score': 901}, 'PMID:3616496': {'publication date': '1987', 'sentence': '93 patients were enrolled into a prospective randomised study to determine the efficacy and safety of netilmicin, cefotaxime or their combination in the treatment of sepsis caused by susceptible strains of Enterobacteriaceae or staphylococci.', 'subject score': 1000, 'object score': 1000}, 'PMID:3803377': {'publication date': '1986 Dec', 'sentence': 'Within twenty-four hours irreversible fulminant sepsis developed although he was treated with cefotaxime, tobramycin and erythromycin.', 'subject score': 1000, 'object score': 737}, 'PMID:3815462': {'publication date': '1986', 'sentence': 'Monotherapy with cefotaxime in septicemic patients with hematological malignancies appears to be a valuable alternative to other antibiotic regimens.', 'subject score': 1000, 'object score': 853}, 'PMID:4055053': {'publication date': '1985', 'sentence': 'Staphylococcus aureus septicaemia treated with cefotaxime.', 'subject score': 1000, 'object score': 901}, 'PMID:6096793': {'publication date': '1984 Dec', 'sentence': 'Twenty-seven septicemia, 2 urinary tract infections and 2 meningitis were treated with Cefotaxime.', 'subject score': 1000, 'object score': 790}, 'PMID:6252168': {'publication date': '1980 Sep', 'sentence': 'Cefotaxime in the treatment of septicaemia and endocarditis.', 'subject score': 1000, 'object score': 1000}, 'PMID:6252171': {'publication date': '1980 Sep', 'sentence': 'Cefotaxime in septicaemia including typhoid fever.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0007554---SEMMEDDB:treats---None---None---None---UMLS:C0036690---SEMMEDDB:",
-                "UMLS:C0007554---SEMMEDDB:treats---None---None---None---UMLS:C0243026---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5742673",
-              "id": "11176033",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:3334576",
-                "PMID:2228845",
-                "PMID:16567997",
-                "PMID:6293715",
-                "PMID:34787905",
-                "PMID:3803377",
-                "PMID:3302868",
-                "PMID:2107064",
-                "PMID:33424507",
-                "PMID:6096793",
-                "PMID:27232293",
-                "PMID:6259603",
-                "PMID:6259601",
-                "PMID:3815462",
-                "PMID:3616496",
-                "PMID:1889866",
-                "PMID:6259602",
-                "PMID:9364293",
-                "PMID:6252168",
-                "PMID:15119790"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 576,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefotaxime",
-              "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C06885",
-                "DRUGBANK:DB00493",
-                "UNII:N2GI8B1GK7",
-                "NCIT:C354",
-                "DrugCentral:546",
-                "UMLS:C0007554",
-                "ATC:J01DD01",
-                "GTOPDB:10893",
-                "MESH:D002439",
-                "PUBCHEM.COMPOUND:5742673",
-                "HMDB:HMDB0014636",
-                "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-                "CHEBI:204928",
-                "PDQ:CDR0000039177",
-                "RXNORM:2186",
-                "CAS:60846-21-1",
-                "KEGG.DRUG:D07647",
-                "NDDF:004845",
-                "CHEMBL.COMPOUND:CHEMBL1730"
-              ],
-              "id": "PUBCHEM.COMPOUND:5742673",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Cefotaxime (INN)",
-                "cefotaxime",
-                "cefotaxime sodium salt",
-                "CEFOTAXIME",
-                "Cefotaxime"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20643901",
-                "PMID:19858254",
-                "PMID:17938180",
-                "PMID:17846134",
-                "PMID:17074790",
-                "PMID:17438056",
-                "PMID:19581459",
-                "PMID:22494615",
-                "PMID:1847430",
-                "PMID:18180346"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:2190011': {'publication date': '1990 Jan', 'sentence': 'HR 810 had more potent protective effect than ceftazidime (CAZ), cefoperazone (CPZ), and cefotaxime (CTX) on systemic infections induced by Escherichia coli Ec-31, Staphylococcus aureus SMITH, and Serratia marcescens Sm-6 in mice.', 'subject score': 1000, 'object score': 983}, 'PMID:3892854': {'publication date': '1985 Jul', 'sentence': 'Thus, a two-dose perioperative prophylactic regimen of piperacillin was as safe and as effective as a two-dose regimen of cefotaxime in preventing postoperative urinary tract infections or sepsis in these patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:7988813': {'publication date': '1994 Sep-Oct', 'sentence': 'The present results indicate that prophylactic administration of an antibiotic such as cefotaxime can reduce the incidence of bacteremia and sepsis in patients who undergo therapeutic or complicated diagnostic ERCP.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 576,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefotaxime",
-          "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C06885",
-            "DRUGBANK:DB00493",
-            "UNII:N2GI8B1GK7",
-            "NCIT:C354",
-            "DrugCentral:546",
-            "UMLS:C0007554",
-            "ATC:J01DD01",
-            "GTOPDB:10893",
-            "MESH:D002439",
-            "PUBCHEM.COMPOUND:5742673",
-            "HMDB:HMDB0014636",
-            "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-            "CHEBI:204928",
-            "PDQ:CDR0000039177",
-            "RXNORM:2186",
-            "CAS:60846-21-1",
-            "KEGG.DRUG:D07647",
-            "NDDF:004845",
-            "CHEMBL.COMPOUND:CHEMBL1730"
-          ],
-          "id": "PUBCHEM.COMPOUND:5742673",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Cefotaxime (INN)",
-            "cefotaxime",
-            "cefotaxime sodium salt",
-            "CEFOTAXIME",
-            "Cefotaxime"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20643901",
-            "PMID:19858254",
-            "PMID:17938180",
-            "PMID:17846134",
-            "PMID:17074790",
-            "PMID:17438056",
-            "PMID:19581459",
-            "PMID:22494615",
-            "PMID:1847430",
-            "PMID:18180346"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15528293,
-            "start": 576,
-            "end": 320039,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2190011': {'publication date': '1990 Jan', 'sentence': 'HR 810 had more potent protective effect than ceftazidime (CAZ), cefoperazone (CPZ), and cefotaxime (CTX) on systemic infections induced by Escherichia coli Ec-31, Staphylococcus aureus SMITH, and Serratia marcescens Sm-6 in mice.', 'subject score': 1000, 'object score': 983}, 'PMID:3892854': {'publication date': '1985 Jul', 'sentence': 'Thus, a two-dose perioperative prophylactic regimen of piperacillin was as safe and as effective as a two-dose regimen of cefotaxime in preventing postoperative urinary tract infections or sepsis in these patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:7988813': {'publication date': '1994 Sep-Oct', 'sentence': 'The present results indicate that prophylactic administration of an antibiotic such as cefotaxime can reduce the incidence of bacteremia and sepsis in patients who undergo therapeutic or complicated diagnostic ERCP.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0007554---SEMMEDDB:prevents---None---None---None---UMLS:C0243026---SEMMEDDB:",
-                "UMLS:C0007554---SEMMEDDB:prevents---None---None---None---UMLS:C0036690---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5742673",
-              "id": "15853591",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:7988813",
-                "PMID:3892854",
-                "PMID:2190011"
-              ]
-            }
-          },
-          "end": {
-            "identity": 576,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefotaxime",
-              "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C06885",
-                "DRUGBANK:DB00493",
-                "UNII:N2GI8B1GK7",
-                "NCIT:C354",
-                "DrugCentral:546",
-                "UMLS:C0007554",
-                "ATC:J01DD01",
-                "GTOPDB:10893",
-                "MESH:D002439",
-                "PUBCHEM.COMPOUND:5742673",
-                "HMDB:HMDB0014636",
-                "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-                "CHEBI:204928",
-                "PDQ:CDR0000039177",
-                "RXNORM:2186",
-                "CAS:60846-21-1",
-                "KEGG.DRUG:D07647",
-                "NDDF:004845",
-                "CHEMBL.COMPOUND:CHEMBL1730"
-              ],
-              "id": "PUBCHEM.COMPOUND:5742673",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Cefotaxime (INN)",
-                "cefotaxime",
-                "cefotaxime sodium salt",
-                "CEFOTAXIME",
-                "Cefotaxime"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20643901",
-                "PMID:19858254",
-                "PMID:17938180",
-                "PMID:17846134",
-                "PMID:17074790",
-                "PMID:17438056",
-                "PMID:19581459",
-                "PMID:22494615",
-                "PMID:1847430",
-                "PMID:18180346"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:2228844': {'publication date': '1990 Sep', 'sentence': 'Cefotaxime in the treatment of chronic osteomyelitis caused by gram-negative bacilli.', 'subject score': 1000, 'object score': 888}, 'PMID:3859212': {'publication date': '1985 Jun 07', 'sentence': 'Experience with imipenem/cilastatin and that reported for cefotaxime, ceftazidime, and ceftizoxime in the treatment of biopsy-proved osteomyelitis was compared, using data from published reports from five centers.', 'subject score': 1000, 'object score': 802}, 'PMID:4055056': {'publication date': '1985', 'sentence': 'It is concluded that cefotaxime is a useful and safe antibiotic for the treatment of osteomyelitis and septic arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:6293713': {'publication date': '1982', 'sentence': 'Cefotaxime treatment in patients with osteomyelitis and septic arthritis: a multicenter study.', 'subject score': 888, 'object score': 1000}, 'PMID:6294801': {'publication date': '1982 Sep-Oct', 'sentence': 'It is concluded that cefotaxime is a useful and safe antibiotic for the treatment of osteomyelitis and septic arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:8059796': {'publication date': '1994 Aug 15', 'sentence': 'The purpose of this study was to determine the efficacy, safety, and cost effectiveness of a third-generation cephalosporin, cefotaxime, administered via an ambulatory delivery system (ADS) in the treatment of bone and joint infections (BJI).', 'subject score': 1000, 'object score': 779}, 'PMID:8461630': {'publication date': '1993 Feb', 'sentence': 'We report the successful desensitization to cefotaxime in a patient with severe lumbar osteomyelitis of unknown bacteriology and hypersensitivity to the drug.', 'subject score': 1000, 'object score': 802}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319037,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005246",
-          "name": "osteomyelitis",
-          "description": "An acute or chronic infectious process affecting the bones.; Osteomyelitis is an inflammatory process accompanied by bone destruction and caused by an infecting microorganism. [HPO:probinson, PMID:15276398]; Like other parts of the body, bones can get infected. The infections are usually bacterial, but can also be fungal. They may spread to the bone from nearby skin or muscles, or from another part of the body through the bloodstream. People who are at risk for bone infections include those with diabetes, poor circulation, or recent injury to the bone. You may also be at risk if you are having hemodialysis.  Symptoms of bone infections include: Pain in the infected area Chills and fever Swelling, warmth, and redness  A blood test or imaging test such as an x-ray can tell if you have a bone infection. Treatment includes antibiotics and often surgery.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0008707",
-            "MEDDRA:10045927",
-            "MEDDRA:10031257",
-            "MEDDRA:10046086",
-            "SNOMEDCT:111253001",
-            "SNOMEDCT:40970001",
-            "UMLS:C2242472",
-            "MEDDRA:10031252",
-            "MEDDRA:10009091",
-            "HP:0002754",
-            "DOID:1019",
-            "UMLS:C0029443",
-            "NCIT:C26839",
-            "MESH:D010019",
-            "EFO:0003102",
-            "MEDDRA:10031259",
-            "MONDO:0005246",
-            "MEDDRA:10005977",
-            "MEDDRA:10031256",
-            "SNOMEDCT:60168000",
-            "MEDDRA:10061017",
-            "MEDDRA:10045936",
-            "MEDDRA:10009081",
-            "NCIT:C27577",
-            "ICD9:730.1",
-            "MEDDRA:10046076"
-          ],
-          "id": "MONDO:0005246",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteomyelitis",
-            "Chronic osteomyelitis",
-            "osteomyelitis",
-            "Bone Infection",
-            "Infection of bone"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://my.clevelandclinic.org/disorders/osteomyelitis/hic_osteomyelitis.aspx",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://en.wikipedia.org/wiki/osteomyelitis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000437.htm",
-            "http://www.mayoclinic.com/health/osteomyelitis/ds00759",
-            "PMID:15276398",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 576,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefotaxime",
-          "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C06885",
-            "DRUGBANK:DB00493",
-            "UNII:N2GI8B1GK7",
-            "NCIT:C354",
-            "DrugCentral:546",
-            "UMLS:C0007554",
-            "ATC:J01DD01",
-            "GTOPDB:10893",
-            "MESH:D002439",
-            "PUBCHEM.COMPOUND:5742673",
-            "HMDB:HMDB0014636",
-            "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-            "CHEBI:204928",
-            "PDQ:CDR0000039177",
-            "RXNORM:2186",
-            "CAS:60846-21-1",
-            "KEGG.DRUG:D07647",
-            "NDDF:004845",
-            "CHEMBL.COMPOUND:CHEMBL1730"
-          ],
-          "id": "PUBCHEM.COMPOUND:5742673",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Cefotaxime (INN)",
-            "cefotaxime",
-            "cefotaxime sodium salt",
-            "CEFOTAXIME",
-            "Cefotaxime"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20643901",
-            "PMID:19858254",
-            "PMID:17938180",
-            "PMID:17846134",
-            "PMID:17074790",
-            "PMID:17438056",
-            "PMID:19581459",
-            "PMID:22494615",
-            "PMID:1847430",
-            "PMID:18180346"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319037,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005246",
-              "name": "osteomyelitis",
-              "description": "An acute or chronic infectious process affecting the bones.; Osteomyelitis is an inflammatory process accompanied by bone destruction and caused by an infecting microorganism. [HPO:probinson, PMID:15276398]; Like other parts of the body, bones can get infected. The infections are usually bacterial, but can also be fungal. They may spread to the bone from nearby skin or muscles, or from another part of the body through the bloodstream. People who are at risk for bone infections include those with diabetes, poor circulation, or recent injury to the bone. You may also be at risk if you are having hemodialysis.  Symptoms of bone infections include: Pain in the infected area Chills and fever Swelling, warmth, and redness  A blood test or imaging test such as an x-ray can tell if you have a bone infection. Treatment includes antibiotics and often surgery.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0008707",
-                "MEDDRA:10045927",
-                "MEDDRA:10031257",
-                "MEDDRA:10046086",
-                "SNOMEDCT:111253001",
-                "SNOMEDCT:40970001",
-                "UMLS:C2242472",
-                "MEDDRA:10031252",
-                "MEDDRA:10009091",
-                "HP:0002754",
-                "DOID:1019",
-                "UMLS:C0029443",
-                "NCIT:C26839",
-                "MESH:D010019",
-                "EFO:0003102",
-                "MEDDRA:10031259",
-                "MONDO:0005246",
-                "MEDDRA:10005977",
-                "MEDDRA:10031256",
-                "SNOMEDCT:60168000",
-                "MEDDRA:10061017",
-                "MEDDRA:10045936",
-                "MEDDRA:10009081",
-                "NCIT:C27577",
-                "ICD9:730.1",
-                "MEDDRA:10046076"
-              ],
-              "id": "MONDO:0005246",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteomyelitis",
-                "Chronic osteomyelitis",
-                "osteomyelitis",
-                "Bone Infection",
-                "Infection of bone"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://my.clevelandclinic.org/disorders/osteomyelitis/hic_osteomyelitis.aspx",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://en.wikipedia.org/wiki/osteomyelitis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000437.htm",
-                "http://www.mayoclinic.com/health/osteomyelitis/ds00759",
-                "PMID:15276398",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15768303,
-            "start": 576,
-            "end": 319037,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2228844': {'publication date': '1990 Sep', 'sentence': 'Cefotaxime in the treatment of chronic osteomyelitis caused by gram-negative bacilli.', 'subject score': 1000, 'object score': 888}, 'PMID:3859212': {'publication date': '1985 Jun 07', 'sentence': 'Experience with imipenem/cilastatin and that reported for cefotaxime, ceftazidime, and ceftizoxime in the treatment of biopsy-proved osteomyelitis was compared, using data from published reports from five centers.', 'subject score': 1000, 'object score': 802}, 'PMID:4055056': {'publication date': '1985', 'sentence': 'It is concluded that cefotaxime is a useful and safe antibiotic for the treatment of osteomyelitis and septic arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:6293713': {'publication date': '1982', 'sentence': 'Cefotaxime treatment in patients with osteomyelitis and septic arthritis: a multicenter study.', 'subject score': 888, 'object score': 1000}, 'PMID:6294801': {'publication date': '1982 Sep-Oct', 'sentence': 'It is concluded that cefotaxime is a useful and safe antibiotic for the treatment of osteomyelitis and septic arthritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:8059796': {'publication date': '1994 Aug 15', 'sentence': 'The purpose of this study was to determine the efficacy, safety, and cost effectiveness of a third-generation cephalosporin, cefotaxime, administered via an ambulatory delivery system (ADS) in the treatment of bone and joint infections (BJI).', 'subject score': 1000, 'object score': 779}, 'PMID:8461630': {'publication date': '1993 Feb', 'sentence': 'We report the successful desensitization to cefotaxime in a patient with severe lumbar osteomyelitis of unknown bacteriology and hypersensitivity to the drug.', 'subject score': 1000, 'object score': 802}}",
-              "kg2_ids": [
-                "UMLS:C0007554---SEMMEDDB:treats---None---None---None---UMLS:C0029443---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5742673",
-              "id": "16097513",
-              "object": "MONDO:0005246",
-              "publications": [
-                "PMID:2228844",
-                "PMID:3859212",
-                "PMID:4055056",
-                "PMID:6293713",
-                "PMID:6294801",
-                "PMID:8059796",
-                "PMID:8461630"
-              ]
-            }
-          },
-          "end": {
-            "identity": 576,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefotaxime",
-              "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C06885",
-                "DRUGBANK:DB00493",
-                "UNII:N2GI8B1GK7",
-                "NCIT:C354",
-                "DrugCentral:546",
-                "UMLS:C0007554",
-                "ATC:J01DD01",
-                "GTOPDB:10893",
-                "MESH:D002439",
-                "PUBCHEM.COMPOUND:5742673",
-                "HMDB:HMDB0014636",
-                "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-                "CHEBI:204928",
-                "PDQ:CDR0000039177",
-                "RXNORM:2186",
-                "CAS:60846-21-1",
-                "KEGG.DRUG:D07647",
-                "NDDF:004845",
-                "CHEMBL.COMPOUND:CHEMBL1730"
-              ],
-              "id": "PUBCHEM.COMPOUND:5742673",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Cefotaxime (INN)",
-                "cefotaxime",
-                "cefotaxime sodium salt",
-                "CEFOTAXIME",
-                "Cefotaxime"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20643901",
-                "PMID:19858254",
-                "PMID:17938180",
-                "PMID:17846134",
-                "PMID:17074790",
-                "PMID:17438056",
-                "PMID:19581459",
-                "PMID:22494615",
-                "PMID:1847430",
-                "PMID:18180346"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 319329,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004522",
-          "name": "peritonitis",
-          "description": "Inflammation of the peritoneum due to infection by bacteria or fungi. Causes include liver disease, perforation of the gastrointestinal tract or biliary tract, and peritoneal dialysis. Patients usually present with abdominal pain and tenderness, fever, chills, and nausea and vomiting. It is an emergency medical condition that requires prompt medical attention and treatment.; INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.; Inflammation of the peritoneum. [HPO:probinson]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "UMLS:C0029823",
-            "MESH:D010538",
-            "MEDDRA:10034685",
-            "MEDDRA:10085062",
-            "SYMP:0000102",
-            "EFO:0008588",
-            "DOID:8283",
-            "HP:0002586",
-            "ICD9:567.8",
-            "MEDDRA:10046096",
-            "UMLS:C0267770",
-            "SNOMEDCT:86422009",
-            "MONDO:0004522",
-            "MEDDRA:10034674",
-            "ICD9:567.89",
-            "UMLS:C0031154",
-            "SNOMEDCT:48661000",
-            "NCIT:C26849"
-          ],
-          "id": "MONDO:0004522",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peritonitis",
-            "Other specified peritonitis",
-            "peritonitis",
-            "Retractile Mesenteritis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.merck.com/mmpe/sec02/ch011/ch011b.html#sec02-ch011-ch011b-402",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=peritonitis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/001335.htm",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 576,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefotaxime",
-          "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C06885",
-            "DRUGBANK:DB00493",
-            "UNII:N2GI8B1GK7",
-            "NCIT:C354",
-            "DrugCentral:546",
-            "UMLS:C0007554",
-            "ATC:J01DD01",
-            "GTOPDB:10893",
-            "MESH:D002439",
-            "PUBCHEM.COMPOUND:5742673",
-            "HMDB:HMDB0014636",
-            "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-            "CHEBI:204928",
-            "PDQ:CDR0000039177",
-            "RXNORM:2186",
-            "CAS:60846-21-1",
-            "KEGG.DRUG:D07647",
-            "NDDF:004845",
-            "CHEMBL.COMPOUND:CHEMBL1730"
-          ],
-          "id": "PUBCHEM.COMPOUND:5742673",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Cefotaxime (INN)",
-            "cefotaxime",
-            "cefotaxime sodium salt",
-            "CEFOTAXIME",
-            "Cefotaxime"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20643901",
-            "PMID:19858254",
-            "PMID:17938180",
-            "PMID:17846134",
-            "PMID:17074790",
-            "PMID:17438056",
-            "PMID:19581459",
-            "PMID:22494615",
-            "PMID:1847430",
-            "PMID:18180346"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319329,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004522",
-              "name": "peritonitis",
-              "description": "Inflammation of the peritoneum due to infection by bacteria or fungi. Causes include liver disease, perforation of the gastrointestinal tract or biliary tract, and peritoneal dialysis. Patients usually present with abdominal pain and tenderness, fever, chills, and nausea and vomiting. It is an emergency medical condition that requires prompt medical attention and treatment.; INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.; Inflammation of the peritoneum. [HPO:probinson]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "UMLS:C0029823",
-                "MESH:D010538",
-                "MEDDRA:10034685",
-                "MEDDRA:10085062",
-                "SYMP:0000102",
-                "EFO:0008588",
-                "DOID:8283",
-                "HP:0002586",
-                "ICD9:567.8",
-                "MEDDRA:10046096",
-                "UMLS:C0267770",
-                "SNOMEDCT:86422009",
-                "MONDO:0004522",
-                "MEDDRA:10034674",
-                "ICD9:567.89",
-                "UMLS:C0031154",
-                "SNOMEDCT:48661000",
-                "NCIT:C26849"
-              ],
-              "id": "MONDO:0004522",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peritonitis",
-                "Other specified peritonitis",
-                "peritonitis",
-                "Retractile Mesenteritis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.merck.com/mmpe/sec02/ch011/ch011b.html#sec02-ch011-ch011b-402",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=peritonitis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/001335.htm",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14806121,
-            "start": 576,
-            "end": 319329,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2066075': {'publication date': '1991 Jul', 'sentence': 'Aztreonam and cefotaxime were compared in 44 cirrhotic patients who had 52 episodes of gram-negative spontaneous peritonitis.', 'subject score': 1000, 'object score': 833}, 'PMID:26484045': {'publication date': '2015 Sep', 'sentence': 'Although R. mucilaginosa is generally susceptible to penicillin, ampicillin, cefotaxime, imipenem, rifampicin, and glycopeptides, there are no guidelines for the treatment of PD-associated peritonitis.', 'subject score': 1000, 'object score': 824}, 'PMID:2660995': {'publication date': '1989 Mar-Apr', 'sentence': 'It has been effective as monotherapy in the treatment of peritonitis, gynecologic infections, chronic bronchitis, and infections in patients with leukemia and granulocytopenia, as has cefotaxime when in combination with an aminoglycoside.', 'subject score': 1000, 'object score': 1000}, 'PMID:3312030': {'publication date': '1987', 'sentence': 'In a randomized controlled, clinical study the efficacy of ceftazidime at a dosage of 2 g b. i. d. was compared to that of cefotaxime at a dosage of 2 g t. i. d. or more in the treatment of pneumonia or peritonitis in intensive care patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:4000338': {'publication date': '1985', 'sentence': 'However, the mean dialysate effluent concentration of cefotaxime was increased following the resolution of the peritonitis, 165 +/- 22.7 mg per cycle on day 10 or 12 compared with 50.4 +/- 7.3 mg per cycle on day 1, suggesting enhanced peritoneal cefotaxime absorption during acute peritonitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:6094442': {'publication date': '1984 Sep', 'sentence': 'The combination of cefotaxime and metronidazole has been suggested for the treatment of peritonitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:6293712': {'publication date': '1982', 'sentence': 'Clinical evaluation of cefotaxime versus gentamicin plus clindamycin in the treatment of polymicrobial peritonitis.', 'subject score': 1000, 'object score': 861}, 'PMID:6294796': {'publication date': '1982', 'sentence': 'Clinical comparison of cefotaxime with gentamicin plus clindamycin in the treatment of peritonitis and other soft-tissue infections.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0007554---SEMMEDDB:treats---None---None---None---UMLS:C0031154---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5742673",
-              "id": "15119078",
-              "object": "MONDO:0004522",
-              "publications": [
-                "PMID:2066075",
-                "PMID:26484045",
-                "PMID:2660995",
-                "PMID:3312030",
-                "PMID:4000338",
-                "PMID:6094442",
-                "PMID:6293712",
-                "PMID:6294796"
-              ]
-            }
-          },
-          "end": {
-            "identity": 576,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefotaxime",
-              "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C06885",
-                "DRUGBANK:DB00493",
-                "UNII:N2GI8B1GK7",
-                "NCIT:C354",
-                "DrugCentral:546",
-                "UMLS:C0007554",
-                "ATC:J01DD01",
-                "GTOPDB:10893",
-                "MESH:D002439",
-                "PUBCHEM.COMPOUND:5742673",
-                "HMDB:HMDB0014636",
-                "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-                "CHEBI:204928",
-                "PDQ:CDR0000039177",
-                "RXNORM:2186",
-                "CAS:60846-21-1",
-                "KEGG.DRUG:D07647",
-                "NDDF:004845",
-                "CHEMBL.COMPOUND:CHEMBL1730"
-              ],
-              "id": "PUBCHEM.COMPOUND:5742673",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Cefotaxime (INN)",
-                "cefotaxime",
-                "cefotaxime sodium salt",
-                "CEFOTAXIME",
-                "Cefotaxime"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20643901",
-                "PMID:19858254",
-                "PMID:17938180",
-                "PMID:17846134",
-                "PMID:17074790",
-                "PMID:17438056",
-                "PMID:19581459",
-                "PMID:22494615",
-                "PMID:1847430",
-                "PMID:18180346"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 576,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefotaxime",
-          "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C06885",
-            "DRUGBANK:DB00493",
-            "UNII:N2GI8B1GK7",
-            "NCIT:C354",
-            "DrugCentral:546",
-            "UMLS:C0007554",
-            "ATC:J01DD01",
-            "GTOPDB:10893",
-            "MESH:D002439",
-            "PUBCHEM.COMPOUND:5742673",
-            "HMDB:HMDB0014636",
-            "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-            "CHEBI:204928",
-            "PDQ:CDR0000039177",
-            "RXNORM:2186",
-            "CAS:60846-21-1",
-            "KEGG.DRUG:D07647",
-            "NDDF:004845",
-            "CHEMBL.COMPOUND:CHEMBL1730"
-          ],
-          "id": "PUBCHEM.COMPOUND:5742673",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Cefotaxime (INN)",
-            "cefotaxime",
-            "cefotaxime sodium salt",
-            "CEFOTAXIME",
-            "Cefotaxime"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20643901",
-            "PMID:19858254",
-            "PMID:17938180",
-            "PMID:17846134",
-            "PMID:17074790",
-            "PMID:17438056",
-            "PMID:19581459",
-            "PMID:22494615",
-            "PMID:1847430",
-            "PMID:18180346"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10936544,
-            "start": 576,
-            "end": 320039,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15119790': {'publication date': '2004', 'sentence': \"Due to the apparent volumes of distribution obtained (ranging from 0.48 to 0.51 L/kg), considering the overall clinical efficacy obtained (90% for the 10 mg/kg dose and 75% for the 20 mg/kg dose), and due to the rapid improvement observed after a few doses of the drug (1.8 to 2.5 doses to 'clinical improvement'), it is safe to postulate such doses of cefotaxime as excellent choices for the treatment of septicaemia in dogs.\", 'subject score': 1000, 'object score': 1000}, 'PMID:16567997': {'publication date': '2006 Apr', 'sentence': 'A preterm infant with early onset Morganella morganii sepsis was treated with cefotaxime and gentamicin after confirmation of antimicrobial susceptibility.', 'subject score': 1000, 'object score': 840}, 'PMID:18072100': {'publication date': '2005 Dec', 'sentence': 'She was admitted to the PICU and was started on ampicillin and cefotaxime for R/O sepsis.', 'subject score': 1000, 'object score': 790}, 'PMID:1889866': {'publication date': '1991', 'sentence': 'Early recognition of neonatal sepsis by a good blood culture technique and beginning of treatment on first suspicion of sepsis with cefotaxime and piperacillin can improve the results especially in intensive care patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:22514473': {'publication date': '1997 Jan', 'sentence': 'INTERVENTION: Comparison of cefepime, ceftazidime, ceftriaxone, cefotaxime and ciprofloxacin in the treatment of lower respiratory tract infections, urinary tract infections, skin/soft tissue infections, septicemia and febrile neutropenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:24978586': {'publication date': '2014', 'sentence': 'These data suggest that the combination of ciprofloxacin and cefotaxime is an effective option for the treatment of V. vulnificus sepsis in humans.', 'subject score': 1000, 'object score': 827}, 'PMID:2612239': {'publication date': '1989', 'sentence': 'Ceftriaxone versus cefotaxime in the treatment of septicemia in adults.', 'subject score': 1000, 'object score': 1000}, 'PMID:27232293': {'publication date': '2016', 'sentence': 'A sepsis of unknown origin was suspected, and intravenous treatment with gentamicin and cefotaxime was initiated.', 'subject score': 1000, 'object score': 1000}, 'PMID:30968258': {'publication date': '2019 Jul', 'sentence': 'However, as target attainment of cefotaxime in severely ill pediatric sepsis patients may differ from adults due to age-related variation in pharmacokinetics, we aimed to assess target attainment of cefotaxime in this pilot study using meningococcal septic shock patients as a model for severe sepsis.', 'subject score': 1000, 'object score': 822}, 'PMID:3302868': {'publication date': '1987 May', 'sentence': 'In a prospective, randomized study we compared cefotaxime (C) with tobramycin plus cefazolin (C + T) in the treatment of Enterobacterial septicemia.', 'subject score': 1000, 'object score': 853}, 'PMID:3334576': {'publication date': '1987 Jun', 'sentence': 'Cefotaxime (C) vs cefotaxime + amikacin (C + A) in the treatment of septicemia due to enterobacteria: a multicenter study.', 'subject score': 1000, 'object score': 1000}, 'PMID:33424507': {'publication date': '2021', 'sentence': 'Occurrence of Hyperbilirubinemia in Neonates Given a Short-term Course of Ceftriaxone versus Cefotaxime for Sepsis.', 'subject score': 1000, 'object score': 1000}, 'PMID:34787905': {'publication date': '2021 Nov 17', 'sentence': 'Combining vancomycin and gentamicin may be a safer alternative to cefotaxime for LOS, as this reduces exposure to broad-spectrum antibiotics.', 'subject score': 1000, 'object score': 901}, 'PMID:3616496': {'publication date': '1987', 'sentence': '93 patients were enrolled into a prospective randomised study to determine the efficacy and safety of netilmicin, cefotaxime or their combination in the treatment of sepsis caused by susceptible strains of Enterobacteriaceae or staphylococci.', 'subject score': 1000, 'object score': 1000}, 'PMID:3803377': {'publication date': '1986 Dec', 'sentence': 'Within twenty-four hours irreversible fulminant sepsis developed although he was treated with cefotaxime, tobramycin and erythromycin.', 'subject score': 1000, 'object score': 737}, 'PMID:3815462': {'publication date': '1986', 'sentence': 'Monotherapy with cefotaxime in septicemic patients with hematological malignancies appears to be a valuable alternative to other antibiotic regimens.', 'subject score': 1000, 'object score': 853}, 'PMID:4055053': {'publication date': '1985', 'sentence': 'Staphylococcus aureus septicaemia treated with cefotaxime.', 'subject score': 1000, 'object score': 901}, 'PMID:6096793': {'publication date': '1984 Dec', 'sentence': 'Twenty-seven septicemia, 2 urinary tract infections and 2 meningitis were treated with Cefotaxime.', 'subject score': 1000, 'object score': 790}, 'PMID:6252168': {'publication date': '1980 Sep', 'sentence': 'Cefotaxime in the treatment of septicaemia and endocarditis.', 'subject score': 1000, 'object score': 1000}, 'PMID:6252171': {'publication date': '1980 Sep', 'sentence': 'Cefotaxime in septicaemia including typhoid fever.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0007554---SEMMEDDB:treats---None---None---None---UMLS:C0036690---SEMMEDDB:",
-                "UMLS:C0007554---SEMMEDDB:treats---None---None---None---UMLS:C0243026---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5742673",
-              "id": "11176033",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:3334576",
-                "PMID:2228845",
-                "PMID:16567997",
-                "PMID:6293715",
-                "PMID:34787905",
-                "PMID:3803377",
-                "PMID:3302868",
-                "PMID:2107064",
-                "PMID:33424507",
-                "PMID:6096793",
-                "PMID:27232293",
-                "PMID:6259603",
-                "PMID:6259601",
-                "PMID:3815462",
-                "PMID:3616496",
-                "PMID:1889866",
-                "PMID:6259602",
-                "PMID:9364293",
-                "PMID:6252168",
-                "PMID:15119790"
-              ]
-            }
-          },
-          "end": {
-            "identity": 576,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefotaxime",
-              "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C06885",
-                "DRUGBANK:DB00493",
-                "UNII:N2GI8B1GK7",
-                "NCIT:C354",
-                "DrugCentral:546",
-                "UMLS:C0007554",
-                "ATC:J01DD01",
-                "GTOPDB:10893",
-                "MESH:D002439",
-                "PUBCHEM.COMPOUND:5742673",
-                "HMDB:HMDB0014636",
-                "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-                "CHEBI:204928",
-                "PDQ:CDR0000039177",
-                "RXNORM:2186",
-                "CAS:60846-21-1",
-                "KEGG.DRUG:D07647",
-                "NDDF:004845",
-                "CHEMBL.COMPOUND:CHEMBL1730"
-              ],
-              "id": "PUBCHEM.COMPOUND:5742673",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Cefotaxime (INN)",
-                "cefotaxime",
-                "cefotaxime sodium salt",
-                "CEFOTAXIME",
-                "Cefotaxime"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20643901",
-                "PMID:19858254",
-                "PMID:17938180",
-                "PMID:17846134",
-                "PMID:17074790",
-                "PMID:17438056",
-                "PMID:19581459",
-                "PMID:22494615",
-                "PMID:1847430",
-                "PMID:18180346"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:2737215': {'publication date': '1989', 'sentence': '1,480 patients, undergoing elective orthopedic and traumatic surgery, received intragluteal injections of ceftriaxone (Rocephin) to prevent bacterial infections.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 538307,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-          ]
-        }
-      },
-      "end": {
-<<<<<<< HEAD
-        "identity": 576,
-=======
-        "identity": 578,
->>>>>>> main
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "name": "Cefotaxime",
-          "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C06885",
-            "DRUGBANK:DB00493",
-            "UNII:N2GI8B1GK7",
-            "NCIT:C354",
-            "DrugCentral:546",
-            "UMLS:C0007554",
-            "ATC:J01DD01",
-            "GTOPDB:10893",
-            "MESH:D002439",
-            "PUBCHEM.COMPOUND:5742673",
-            "HMDB:HMDB0014636",
-            "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-            "CHEBI:204928",
-            "PDQ:CDR0000039177",
-            "RXNORM:2186",
-            "CAS:60846-21-1",
-            "KEGG.DRUG:D07647",
-            "NDDF:004845",
-            "CHEMBL.COMPOUND:CHEMBL1730"
-          ],
-          "id": "PUBCHEM.COMPOUND:5742673",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Cefotaxime (INN)",
-            "cefotaxime",
-            "cefotaxime sodium salt",
-            "CEFOTAXIME",
-            "Cefotaxime"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20643901",
-            "PMID:19858254",
-            "PMID:17938180",
-            "PMID:17846134",
-            "PMID:17074790",
-            "PMID:17438056",
-            "PMID:19581459",
-            "PMID:22494615",
-            "PMID:1847430",
-            "PMID:18180346"
-=======
-          "name": "Ceftriaxone",
-          "description": "The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C817\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C817\" NCI Thesaurus); The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).; A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.",
-          "equivalent_curies": [
-            "CHEBI:29007",
-            "INCHIKEY:VAAUVRVFOQPIGI-SPQHTLEESA-N",
-            "PUBCHEM.COMPOUND:5479530",
-            "NDDF:004849",
-            "UMLS:C0035750",
-            "GTOPDB:5326",
-            "CHEMBL.COMPOUND:CHEMBL161",
-            "KEGG.COMPOUND:C06683",
-            "ATC:J01DD04",
-            "NCIT:C62020",
-            "HMDB:HMDB0015343",
-            "DRUGBANK:DB01212",
-            "KEGG.DRUG:D07659",
-            "RXNORM:2193",
-            "DrugCentral:564",
-            "UNII:75J73V1629",
-            "MESH:D002443"
-          ],
-          "id": "PUBCHEM.COMPOUND:5479530",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Rocephin",
-            "ceftriaxone",
-            "Ceftriaxone",
-            "ceftriaxone sodium",
-            "Ceftriaxone (INN)",
-            "CEFTRIAXONE"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20022146",
-            "PMID:18426899",
-            "PMID:20368407",
-            "PMID:17846134",
-            "PMID:17438056",
-            "PMID:22951041",
-            "PMID:21098249",
-            "PMID:18285482",
-            "PMID:27469981",
-            "PMID:19995919"
->>>>>>> main
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538307,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 7982149,
-            "start": 576,
-            "end": 538307,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10782908': {'publication date': '2000 Apr', 'sentence': 'These results suggest that amoxicillin-clavulanic acid is an effective alternative to cefotaxime for the empirical treatment of bacterial infections in cirrhosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1571464': {'publication date': '1992 Jan', 'sentence': 'Cefotaxime has been used to treat serious bacterial infections in children since 1982.', 'subject score': 1000, 'object score': 901}, 'PMID:18611720': {'publication date': '1996 Apr', 'sentence': 'The combination of the beta-lactamase inhibitor sulbactam and a ureidopenicillin or cefotaxime was highly effiacious in patients with severe bacterial infections investigated in this study.', 'subject score': 1000, 'object score': 901}, 'PMID:1943983': {'publication date': '1991 Sep 15', 'sentence': 'An open multicenter study on inpatients of 12 german hospitals was performed to investigate efficacy and safety of sulbactam in combination with mezlocillin, piperacillin or cefotaxim in severe bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:2668427': {'publication date': '1989 Sep', 'sentence': 'Once-daily therapy with ceftriaxone compared with daily multiple-dose therapy with cefotaxime for serious bacterial infections: a randomized, double-blind study.', 'subject score': 1000, 'object score': 901}, 'PMID:2668428': {'publication date': '1989 Sep', 'sentence': 'Ceftriaxone was compared with cefotaxime for the treatment of serious bacterial infections in a prospective, randomized, double-blind clinical trial.', 'subject score': 1000, 'object score': 901}, 'PMID:3901208': {'publication date': '1985', 'sentence': 'Comparative clinical evaluation of imipenem/cilastatin vs. cefotaxime in treatment of severe bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:4083974': {'publication date': '1985 Aug-Sep', 'sentence': 'The serum kinetics of intravenous cefotaxime was studied in 13 neonates and 5 infants presenting with bacterial infections in order to establish the dosage and route of administration.', 'subject score': 888, 'object score': 1000}, 'PMID:6089633': {'publication date': '1984 Oct', 'sentence': 'We conclude that cefotaxime may be more effective and less toxic than nafcillin plus tobramycin for patients with serious bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:6250982': {'publication date': '1980', 'sentence': 'The cefotaxime concentrations found in serum and tissue lead us to expect successful therapy when cefotaxime is used to treat bacterial infections with sensitive pathogens in the urogenital tract.', 'subject score': 1000, 'object score': 1000}, 'PMID:6259603': {'publication date': '1981 Feb 26', 'sentence': 'Seventeen septicaemia, 18 urinary tract infections, 13 acute bacterial pulmonary infections and 7 infections at various other site were treated with cefotaxime, and, in 48 cases, with cefotaxime alone.', 'subject score': 1000, 'object score': 798}, 'PMID:6259612': {'publication date': '1981 Feb 26', 'sentence': 'Cefotaxime at a daily dose of 2 g intramuscularly for 12 days, showed very good efficacy in the treatment of various bacterial infections of the lower respiratory tract.', 'subject score': 1000, 'object score': 901}, 'PMID:6285810': {'publication date': '1982 Mar', 'sentence': 'Cefotaxime therapy of serious bacterial infection in adults.', 'subject score': 888, 'object score': 901}, 'PMID:6294794': {'publication date': '1982', 'sentence': 'Clinical trials of cefotaxime for the treatment of bacterial infections of the lower respiratory tract.', 'subject score': 1000, 'object score': 1000}, 'PMID:6321080': {'publication date': '1984 Apr', 'sentence': 'Evaluation of cefotaxime in bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:7587054': {'publication date': '1995 May-Jun', 'sentence': 'Therapeutic options for cefotaxime in the management of bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:8731830': {'publication date': '1995 Oct', 'sentence': '[A randomized controlled clinical trial of sulperazone as compared with cefotaxime in the treatment of bacterial infections].', 'subject score': 1000, 'object score': 1000}, 'PMID:9114206': {'publication date': '1997 Mar', 'sentence': 'We conducted a randomized, open-label, controlled, multicenter study to compare sulbactam/cefoperazone with cefotaxime in terms of efficacy and safety for the treatment of hospitalized patients with moderate-to-severe bacterial infections.', 'subject score': 1000, 'object score': 893}}",
-              "kg2_ids": [
-                "UMLS:C0007554---SEMMEDDB:treats---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5742673",
-              "id": "8153267",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:10782908",
-                "PMID:1571464",
-                "PMID:18611720",
-                "PMID:1943983",
-                "PMID:2668427",
-                "PMID:2668428",
-                "PMID:3901208",
-                "PMID:4083974",
-                "PMID:6089633",
-                "PMID:6250982",
-                "PMID:6259603",
-                "PMID:6259612",
-                "PMID:6285810",
-                "PMID:6294794",
-                "PMID:6321080",
-                "PMID:7587054",
-                "PMID:8731830",
-                "PMID:9114206"
-              ]
-            }
-          },
-          "end": {
-            "identity": 576,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Cefotaxime",
-              "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C06885",
-                "DRUGBANK:DB00493",
-                "UNII:N2GI8B1GK7",
-                "NCIT:C354",
-                "DrugCentral:546",
-                "UMLS:C0007554",
-                "ATC:J01DD01",
-                "GTOPDB:10893",
-                "MESH:D002439",
-                "PUBCHEM.COMPOUND:5742673",
-                "HMDB:HMDB0014636",
-                "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-                "CHEBI:204928",
-                "PDQ:CDR0000039177",
-                "RXNORM:2186",
-                "CAS:60846-21-1",
-                "KEGG.DRUG:D07647",
-                "NDDF:004845",
-                "CHEMBL.COMPOUND:CHEMBL1730"
-              ],
-              "id": "PUBCHEM.COMPOUND:5742673",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Cefotaxime (INN)",
-                "cefotaxime",
-                "cefotaxime sodium salt",
-                "CEFOTAXIME",
-                "Cefotaxime"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20643901",
-                "PMID:19858254",
-                "PMID:17938180",
-                "PMID:17846134",
-                "PMID:17074790",
-                "PMID:17438056",
-                "PMID:19581459",
-                "PMID:22494615",
-                "PMID:1847430",
-                "PMID:18180346"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 576,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Cefotaxime",
-          "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C06885",
-            "DRUGBANK:DB00493",
-            "UNII:N2GI8B1GK7",
-            "NCIT:C354",
-            "DrugCentral:546",
-            "UMLS:C0007554",
-            "ATC:J01DD01",
-            "GTOPDB:10893",
-            "MESH:D002439",
-            "PUBCHEM.COMPOUND:5742673",
-            "HMDB:HMDB0014636",
-            "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-            "CHEBI:204928",
-            "PDQ:CDR0000039177",
-            "RXNORM:2186",
-            "CAS:60846-21-1",
-            "KEGG.DRUG:D07647",
-            "NDDF:004845",
-            "CHEMBL.COMPOUND:CHEMBL1730"
-          ],
-          "id": "PUBCHEM.COMPOUND:5742673",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Cefotaxime (INN)",
-            "cefotaxime",
-            "cefotaxime sodium salt",
-            "CEFOTAXIME",
-            "Cefotaxime"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20643901",
-            "PMID:19858254",
-            "PMID:17938180",
-            "PMID:17846134",
-            "PMID:17074790",
-            "PMID:17438056",
-            "PMID:19581459",
-            "PMID:22494615",
-            "PMID:1847430",
-            "PMID:18180346"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15528293,
-            "start": 576,
-            "end": 320039,
-=======
-            "identity": 18700460,
-            "start": 578,
-            "end": 538307,
->>>>>>> main
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-<<<<<<< HEAD
-              "publications_info": "{'PMID:2190011': {'publication date': '1990 Jan', 'sentence': 'HR 810 had more potent protective effect than ceftazidime (CAZ), cefoperazone (CPZ), and cefotaxime (CTX) on systemic infections induced by Escherichia coli Ec-31, Staphylococcus aureus SMITH, and Serratia marcescens Sm-6 in mice.', 'subject score': 1000, 'object score': 983}, 'PMID:3892854': {'publication date': '1985 Jul', 'sentence': 'Thus, a two-dose perioperative prophylactic regimen of piperacillin was as safe and as effective as a two-dose regimen of cefotaxime in preventing postoperative urinary tract infections or sepsis in these patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:7988813': {'publication date': '1994 Sep-Oct', 'sentence': 'The present results indicate that prophylactic administration of an antibiotic such as cefotaxime can reduce the incidence of bacteremia and sepsis in patients who undergo therapeutic or complicated diagnostic ERCP.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0007554---SEMMEDDB:prevents---None---None---None---UMLS:C0243026---SEMMEDDB:",
-                "UMLS:C0007554---SEMMEDDB:prevents---None---None---None---UMLS:C0036690---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5742673",
-              "id": "15853591",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:7988813",
-                "PMID:3892854",
-                "PMID:2190011"
-=======
-              "publications_info": "{'PMID:2737215': {'publication date': '1989', 'sentence': '1,480 patients, undergoing elective orthopedic and traumatic surgery, received intragluteal injections of ceftriaxone (Rocephin) to prevent bacterial infections.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0035750---SEMMEDDB:prevents---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5479530",
-              "id": "19081412",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:2737215"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-<<<<<<< HEAD
-            "identity": 576,
-=======
-            "identity": 578,
->>>>>>> main
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "name": "Cefotaxime",
-              "description": "A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C354\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C354\" NCI Thesaurus); A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis.; Semisynthetic broad-spectrum cephalosporin.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C06885",
-                "DRUGBANK:DB00493",
-                "UNII:N2GI8B1GK7",
-                "NCIT:C354",
-                "DrugCentral:546",
-                "UMLS:C0007554",
-                "ATC:J01DD01",
-                "GTOPDB:10893",
-                "MESH:D002439",
-                "PUBCHEM.COMPOUND:5742673",
-                "HMDB:HMDB0014636",
-                "INCHIKEY:GPRBEKHLDVQUJE-QSWIMTSFSA-N",
-                "CHEBI:204928",
-                "PDQ:CDR0000039177",
-                "RXNORM:2186",
-                "CAS:60846-21-1",
-                "KEGG.DRUG:D07647",
-                "NDDF:004845",
-                "CHEMBL.COMPOUND:CHEMBL1730"
-              ],
-              "id": "PUBCHEM.COMPOUND:5742673",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Cefotaxime (INN)",
-                "cefotaxime",
-                "cefotaxime sodium salt",
-                "CEFOTAXIME",
-                "Cefotaxime"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20643901",
-                "PMID:19858254",
-                "PMID:17938180",
-                "PMID:17846134",
-                "PMID:17074790",
-                "PMID:17438056",
-                "PMID:19581459",
-                "PMID:22494615",
-                "PMID:1847430",
-                "PMID:18180346"
-=======
-              "name": "Ceftriaxone",
-              "description": "The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C817\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C817\" NCI Thesaurus); The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).; A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.",
-              "equivalent_curies": [
-                "CHEBI:29007",
-                "INCHIKEY:VAAUVRVFOQPIGI-SPQHTLEESA-N",
-                "PUBCHEM.COMPOUND:5479530",
-                "NDDF:004849",
-                "UMLS:C0035750",
-                "GTOPDB:5326",
-                "CHEMBL.COMPOUND:CHEMBL161",
-                "KEGG.COMPOUND:C06683",
-                "ATC:J01DD04",
-                "NCIT:C62020",
-                "HMDB:HMDB0015343",
-                "DRUGBANK:DB01212",
-                "KEGG.DRUG:D07659",
-                "RXNORM:2193",
-                "DrugCentral:564",
-                "UNII:75J73V1629",
-                "MESH:D002443"
-              ],
-              "id": "PUBCHEM.COMPOUND:5479530",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Rocephin",
-                "ceftriaxone",
-                "Ceftriaxone",
-                "ceftriaxone sodium",
-                "Ceftriaxone (INN)",
-                "CEFTRIAXONE"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20022146",
-                "PMID:18426899",
-                "PMID:20368407",
-                "PMID:17846134",
-                "PMID:17438056",
-                "PMID:22951041",
-                "PMID:21098249",
-                "PMID:18285482",
-                "PMID:27469981",
-                "PMID:19995919"
->>>>>>> main
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:8419791': {'publication date': '1993 Jan 22', 'sentence': 'Most children had received prolonged and repeated courses of oral antimicrobials and/or home intravenous infusion of antimicrobials; 79% had been hospitalized for treatment of suspected LD or management of treatment complications, most notably drug-induced symptoms of gallbladder disease occurring in patients receiving ceftriaxone (Rocephin), and bloodstream infections associated with intravenous catheters.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 527330,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019632",
-          "name": "Lyme disease",
-          "description": "An infectious disease caused by the spirochete Borrelia burgdorferi. Early manifestations of infection may include fever, headache, fatigue, depression, and a characteristic skin rash called erythema migrans. Left untreated, late manifestations involving the joints, heart, and nervous system can occur.; An infectious disease caused by a spirochete, BORRELIA BURGDORFERI, which is transmitted chiefly by Ixodes dammini (see IXODES) and pacificus ticks in the United States and Ixodes ricinis (see IXODES) in Europe. It is a disease with early and late cutaneous manifestations plus involvement of the nervous system, heart, eye, and joints in variable combinations. The disease was formerly known as Lyme arthritis and first discovered at Old Lyme, Connecticut.; What is Lyme disease? Lyme disease is a bacterial infection you get from the bite of an infected tick. At first, Lyme disease usually causes symptoms such as a rash, fever, headache, and fatigue. But if it is not treated early, the infection can spread to your joints, heart, and nervous system. Prompt treatment can help you recover quickly. What causes Lyme disease? Lyme disease is caused by bacteria. In the United States, this is usually a bacterium called Borrelia burgdorferi. It spreads to humans through the bite of an infected tick. The ticks that spread it are blacklegged ticks (or deer ticks). They are usually found in the: Northeast Mid-Atlantic Upper Midwest Pacific coast, especially northern California  These ticks can attach to any part your body. But they are often found in hard-to-see areas such as your groin, armpits, and scalp. Usually the tick must be attached to you for 36 to 48 hours or more to spread the bacterium to you. Who is at risk for Lyme disease? Anyone can get a tick bite. But people who spend lots of time outdoors in wooded, grassy areas are at a higher risk. This includes campers, hikers, and people who work in gardens and parks. Most tick bites happen in the summer months when ticks are most active and people spend more time outdoors. But you can get bitten in the warmer months of early fall, or even late winter if temperatures are unusually high. And if there is a mild winter, ticks may come out earlier than usual. What are the symptoms of Lyme disease? Early symptoms of Lyme disease start between 3 to 30 days after an infected tick bites you. The symptoms can include: A red rash called erythema migrans (EM). Most people with Lyme disease get this rash. It gets bigger over several days and may feel warm. It is usually not painful or itchy. As it starts to get better, parts of it may fade. Sometimes this makes the rash look like a \"bull's-eye.\" Fever Chills Headache Fatigue Muscle and joint aches Swollen lymph nodes  If the infection is not treated, it can spread to your joints, heart, and nervous system. The symptoms may include: Severe headaches and neck stiffness Additional EM rashes on other areas of your body Facial palsy, which is a weakness in your facial muscles. It can cause drooping on one or both sides of your face. Arthritis with severe joint pain and swelling, especially in your knees and other large joints Pain that comes and goes in your tendons, muscles, joints, and bones Heart palpitations, which are feelings that your heart is skipping a beat, fluttering, pounding, or beating too hard or too fast An irregular heart beat (Lyme carditis) Episodes of dizziness or shortness of breath Inflammation of the brain and spinal cord Nerve pain Shooting pains, numbness, or tingling in the hands or feet  How is Lyme disease diagnosed? To make a diagnosis, your health care provider will consider: Your symptoms How likely it is that you were exposed to infected blacklegged ticks The possibility that other illnesses may cause similar symptoms Results of any lab tests  Most Lyme disease tests check for antibodies made by the body in response to infection. These antibodies can take several weeks to develop. If you are tested right away, it may not show that you have Lyme disease, even if you have it. So you may need to have another test later. What are the treatments for Lyme disease? Lyme disease is treated with antibiotics. The earlier you are treated, the better; it gives you the best chance of fully recovering quickly. After treatment, some patients may still have pain, fatigue, or difficulty thinking that lasts more than 6 months. This is called post-treatment Lyme disease syndrome (PTLDS). Researchers don't know why some people have PTLDS. There is no proven treatment for PTLDS; long-term antibiotics have not been shown to help. However, there are ways to help with the symptoms of PTLDS. If you have been treated for Lyme disease and still feel unwell, contact your health care provider about how to manage your symptoms. Most people do get better with time. But it can take several months before you feel all better. Can Lyme disease be prevented? To prevent Lyme disease, you should lower your risk of getting a tick bite: Avoid areas where ticks live, such as grassy, brushy, or wooded areas. If you are hiking, walk in the center of the trail to avoid brush and grass. Use an insect repellent with DEET Treat your clothing and gear with a repellant containing 0.5% permethrin Wear light-colored protective clothing, so you can easily see any ticks that get on you Wear a long-sleeve shirt and long pants. Also tuck your shirt into your pants and your pant legs into your socks. Check yourself, your children, and your pets daily for ticks. Carefully remove any ticks you find. Take a shower and wash and dry your clothes at high temperatures after being outdoors  Centers for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:11729",
-            "MESH:D020852",
-            "ORPHANET:91546",
-            "MESH:D008193",
-            "SNOMEDCT:23502006",
-            "MONDO:0019632",
-            "EFO:0008510",
-            "MEDDRA:10025170",
-            "MEDDRA:10006036",
-            "ICD10:A69.2",
-            "MEDDRA:10025169",
-            "UMLS:C0752235",
-            "NCIT:C45161",
-            "SNOMEDCT:48982009",
-            "SNOMEDCT:715507005",
-            "ICD9:088.81",
-            "MEDDRA:10067559",
-            "UMLS:C0024198"
-          ],
-          "id": "MONDO:0019632",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lyme disease",
-            "Lyme Disease",
-            "Borrelia Burgdorferi Infection",
-            "Lyme Neuroborreliosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cdc.gov/lyme/transmission/index.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ceftriaxone",
-          "description": "The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C817\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C817\" NCI Thesaurus); The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).; A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.",
-          "equivalent_curies": [
-            "CHEBI:29007",
-            "INCHIKEY:VAAUVRVFOQPIGI-SPQHTLEESA-N",
-            "PUBCHEM.COMPOUND:5479530",
-            "NDDF:004849",
-            "UMLS:C0035750",
-            "GTOPDB:5326",
-            "CHEMBL.COMPOUND:CHEMBL161",
-            "KEGG.COMPOUND:C06683",
-            "ATC:J01DD04",
-            "NCIT:C62020",
-            "HMDB:HMDB0015343",
-            "DRUGBANK:DB01212",
-            "KEGG.DRUG:D07659",
-            "RXNORM:2193",
-            "DrugCentral:564",
-            "UNII:75J73V1629",
-            "MESH:D002443"
-          ],
-          "id": "PUBCHEM.COMPOUND:5479530",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Rocephin",
-            "ceftriaxone",
-            "Ceftriaxone",
-            "ceftriaxone sodium",
-            "Ceftriaxone (INN)",
-            "CEFTRIAXONE"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20022146",
-            "PMID:18426899",
-            "PMID:20368407",
-            "PMID:17846134",
-            "PMID:17438056",
-            "PMID:22951041",
-            "PMID:21098249",
-            "PMID:18285482",
-            "PMID:27469981",
-            "PMID:19995919"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 527330,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019632",
-              "name": "Lyme disease",
-              "description": "An infectious disease caused by the spirochete Borrelia burgdorferi. Early manifestations of infection may include fever, headache, fatigue, depression, and a characteristic skin rash called erythema migrans. Left untreated, late manifestations involving the joints, heart, and nervous system can occur.; An infectious disease caused by a spirochete, BORRELIA BURGDORFERI, which is transmitted chiefly by Ixodes dammini (see IXODES) and pacificus ticks in the United States and Ixodes ricinis (see IXODES) in Europe. It is a disease with early and late cutaneous manifestations plus involvement of the nervous system, heart, eye, and joints in variable combinations. The disease was formerly known as Lyme arthritis and first discovered at Old Lyme, Connecticut.; What is Lyme disease? Lyme disease is a bacterial infection you get from the bite of an infected tick. At first, Lyme disease usually causes symptoms such as a rash, fever, headache, and fatigue. But if it is not treated early, the infection can spread to your joints, heart, and nervous system. Prompt treatment can help you recover quickly. What causes Lyme disease? Lyme disease is caused by bacteria. In the United States, this is usually a bacterium called Borrelia burgdorferi. It spreads to humans through the bite of an infected tick. The ticks that spread it are blacklegged ticks (or deer ticks). They are usually found in the: Northeast Mid-Atlantic Upper Midwest Pacific coast, especially northern California  These ticks can attach to any part your body. But they are often found in hard-to-see areas such as your groin, armpits, and scalp. Usually the tick must be attached to you for 36 to 48 hours or more to spread the bacterium to you. Who is at risk for Lyme disease? Anyone can get a tick bite. But people who spend lots of time outdoors in wooded, grassy areas are at a higher risk. This includes campers, hikers, and people who work in gardens and parks. Most tick bites happen in the summer months when ticks are most active and people spend more time outdoors. But you can get bitten in the warmer months of early fall, or even late winter if temperatures are unusually high. And if there is a mild winter, ticks may come out earlier than usual. What are the symptoms of Lyme disease? Early symptoms of Lyme disease start between 3 to 30 days after an infected tick bites you. The symptoms can include: A red rash called erythema migrans (EM). Most people with Lyme disease get this rash. It gets bigger over several days and may feel warm. It is usually not painful or itchy. As it starts to get better, parts of it may fade. Sometimes this makes the rash look like a \"bull's-eye.\" Fever Chills Headache Fatigue Muscle and joint aches Swollen lymph nodes  If the infection is not treated, it can spread to your joints, heart, and nervous system. The symptoms may include: Severe headaches and neck stiffness Additional EM rashes on other areas of your body Facial palsy, which is a weakness in your facial muscles. It can cause drooping on one or both sides of your face. Arthritis with severe joint pain and swelling, especially in your knees and other large joints Pain that comes and goes in your tendons, muscles, joints, and bones Heart palpitations, which are feelings that your heart is skipping a beat, fluttering, pounding, or beating too hard or too fast An irregular heart beat (Lyme carditis) Episodes of dizziness or shortness of breath Inflammation of the brain and spinal cord Nerve pain Shooting pains, numbness, or tingling in the hands or feet  How is Lyme disease diagnosed? To make a diagnosis, your health care provider will consider: Your symptoms How likely it is that you were exposed to infected blacklegged ticks The possibility that other illnesses may cause similar symptoms Results of any lab tests  Most Lyme disease tests check for antibodies made by the body in response to infection. These antibodies can take several weeks to develop. If you are tested right away, it may not show that you have Lyme disease, even if you have it. So you may need to have another test later. What are the treatments for Lyme disease? Lyme disease is treated with antibiotics. The earlier you are treated, the better; it gives you the best chance of fully recovering quickly. After treatment, some patients may still have pain, fatigue, or difficulty thinking that lasts more than 6 months. This is called post-treatment Lyme disease syndrome (PTLDS). Researchers don't know why some people have PTLDS. There is no proven treatment for PTLDS; long-term antibiotics have not been shown to help. However, there are ways to help with the symptoms of PTLDS. If you have been treated for Lyme disease and still feel unwell, contact your health care provider about how to manage your symptoms. Most people do get better with time. But it can take several months before you feel all better. Can Lyme disease be prevented? To prevent Lyme disease, you should lower your risk of getting a tick bite: Avoid areas where ticks live, such as grassy, brushy, or wooded areas. If you are hiking, walk in the center of the trail to avoid brush and grass. Use an insect repellent with DEET Treat your clothing and gear with a repellant containing 0.5% permethrin Wear light-colored protective clothing, so you can easily see any ticks that get on you Wear a long-sleeve shirt and long pants. Also tuck your shirt into your pants and your pant legs into your socks. Check yourself, your children, and your pets daily for ticks. Carefully remove any ticks you find. Take a shower and wash and dry your clothes at high temperatures after being outdoors  Centers for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:11729",
-                "MESH:D020852",
-                "ORPHANET:91546",
-                "MESH:D008193",
-                "SNOMEDCT:23502006",
-                "MONDO:0019632",
-                "EFO:0008510",
-                "MEDDRA:10025170",
-                "MEDDRA:10006036",
-                "ICD10:A69.2",
-                "MEDDRA:10025169",
-                "UMLS:C0752235",
-                "NCIT:C45161",
-                "SNOMEDCT:48982009",
-                "SNOMEDCT:715507005",
-                "ICD9:088.81",
-                "MEDDRA:10067559",
-                "UMLS:C0024198"
-              ],
-              "id": "MONDO:0019632",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lyme disease",
-                "Lyme Disease",
-                "Borrelia Burgdorferi Infection",
-                "Lyme Neuroborreliosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cdc.gov/lyme/transmission/index.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26514317,
-            "start": 578,
-            "end": 527330,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8419791': {'publication date': '1993 Jan 22', 'sentence': 'Most children had received prolonged and repeated courses of oral antimicrobials and/or home intravenous infusion of antimicrobials; 79% had been hospitalized for treatment of suspected LD or management of treatment complications, most notably drug-induced symptoms of gallbladder disease occurring in patients receiving ceftriaxone (Rocephin), and bloodstream infections associated with intravenous catheters.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0035750---SEMMEDDB:treats---None---None---None---UMLS:C0024198---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5479530",
-              "id": "26980543",
-              "object": "MONDO:0019632",
-              "publications": [
-                "PMID:8419791"
-              ]
-            }
-          },
-          "end": {
-            "identity": 578,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-=======
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
->>>>>>> main
-            ],
-            "properties": {
-              "name": "Ceftriaxone",
-              "description": "The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C817\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C817\" NCI Thesaurus); The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).; A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.",
-              "equivalent_curies": [
-                "CHEBI:29007",
-                "INCHIKEY:VAAUVRVFOQPIGI-SPQHTLEESA-N",
-                "PUBCHEM.COMPOUND:5479530",
-                "NDDF:004849",
-                "UMLS:C0035750",
-                "GTOPDB:5326",
-                "CHEMBL.COMPOUND:CHEMBL161",
-                "KEGG.COMPOUND:C06683",
-                "ATC:J01DD04",
-                "NCIT:C62020",
-                "HMDB:HMDB0015343",
-                "DRUGBANK:DB01212",
-                "KEGG.DRUG:D07659",
-                "RXNORM:2193",
-                "DrugCentral:564",
-                "UNII:75J73V1629",
-                "MESH:D002443"
-              ],
-              "id": "PUBCHEM.COMPOUND:5479530",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Rocephin",
-                "ceftriaxone",
-                "Ceftriaxone",
-                "ceftriaxone sodium",
-                "Ceftriaxone (INN)",
-                "CEFTRIAXONE"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20022146",
-                "PMID:18426899",
-                "PMID:20368407",
-                "PMID:17846134",
-                "PMID:17438056",
-                "PMID:22951041",
-                "PMID:21098249",
-                "PMID:18285482",
-                "PMID:27469981",
-                "PMID:19995919"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:7249792': {'publication date': '1981', 'sentence': 'Clinical study of Rocephin, a 3d generation cephalosporin, in various septicaemias.', 'subject score': 1000, 'object score': 827}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ceftriaxone",
-          "description": "The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C817\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C817\" NCI Thesaurus); The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).; A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.",
-          "equivalent_curies": [
-            "CHEBI:29007",
-            "INCHIKEY:VAAUVRVFOQPIGI-SPQHTLEESA-N",
-            "PUBCHEM.COMPOUND:5479530",
-            "NDDF:004849",
-            "UMLS:C0035750",
-            "GTOPDB:5326",
-            "CHEMBL.COMPOUND:CHEMBL161",
-            "KEGG.COMPOUND:C06683",
-            "ATC:J01DD04",
-            "NCIT:C62020",
-            "HMDB:HMDB0015343",
-            "DRUGBANK:DB01212",
-            "KEGG.DRUG:D07659",
-            "RXNORM:2193",
-            "DrugCentral:564",
-            "UNII:75J73V1629",
-            "MESH:D002443"
-          ],
-          "id": "PUBCHEM.COMPOUND:5479530",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Rocephin",
-            "ceftriaxone",
-            "Ceftriaxone",
-            "ceftriaxone sodium",
-            "Ceftriaxone (INN)",
-            "CEFTRIAXONE"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20022146",
-            "PMID:18426899",
-            "PMID:20368407",
-            "PMID:17846134",
-            "PMID:17438056",
-            "PMID:22951041",
-            "PMID:21098249",
-            "PMID:18285482",
-            "PMID:27469981",
-            "PMID:19995919"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25942158,
-            "start": 578,
-            "end": 320039,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7249792': {'publication date': '1981', 'sentence': 'Clinical study of Rocephin, a 3d generation cephalosporin, in various septicaemias.', 'subject score': 1000, 'object score': 827}}",
-              "kg2_ids": [
-                "UMLS:C0035750---SEMMEDDB:treats---None---None---None---UMLS:C0036690---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5479530",
-              "id": "26401802",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:7249792"
-              ]
-            }
-          },
-          "end": {
-            "identity": 578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ceftriaxone",
-              "description": "The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C817\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C817\" NCI Thesaurus); The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).; A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.",
-              "equivalent_curies": [
-                "CHEBI:29007",
-                "INCHIKEY:VAAUVRVFOQPIGI-SPQHTLEESA-N",
-                "PUBCHEM.COMPOUND:5479530",
-                "NDDF:004849",
-                "UMLS:C0035750",
-                "GTOPDB:5326",
-                "CHEMBL.COMPOUND:CHEMBL161",
-                "KEGG.COMPOUND:C06683",
-                "ATC:J01DD04",
-                "NCIT:C62020",
-                "HMDB:HMDB0015343",
-                "DRUGBANK:DB01212",
-                "KEGG.DRUG:D07659",
-                "RXNORM:2193",
-                "DrugCentral:564",
-                "UNII:75J73V1629",
-                "MESH:D002443"
-              ],
-              "id": "PUBCHEM.COMPOUND:5479530",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Rocephin",
-                "ceftriaxone",
-                "Ceftriaxone",
-                "ceftriaxone sodium",
-                "Ceftriaxone (INN)",
-                "CEFTRIAXONE"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20022146",
-                "PMID:18426899",
-                "PMID:20368407",
-                "PMID:17846134",
-                "PMID:17438056",
-                "PMID:22951041",
-                "PMID:21098249",
-                "PMID:18285482",
-                "PMID:27469981",
-                "PMID:19995919"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:2612238': {'publication date': '1989', 'sentence': 'The objectives of this open, prospective, randomized and comparative study were to evaluate and compare the efficacy and safety of intravenous ceftriaxone (active ingredient of Rocephin) and cefotaxime in treatment of bacterial pneumoniae.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 527033,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004652",
-          "name": "bacterial pneumonia",
-          "description": "Acute infection of the lung parenchyma caused by bacteria (e.g., Streptococcus pneumoniae, Haemophilus influenzae, Chlamydia pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila). Signs and symptoms include productive cough, fever, chills, shortness of breath, and chest pain.; Inflammation of the lung parenchyma that is caused by bacterial infections.",
-          "equivalent_curies": [
-            "DOID:874",
-            "MEDDRA:10004051",
-            "SNOMEDCT:53084003",
-            "ICD9:482.9",
-            "UMLS:C0004626",
-            "MEDDRA:10035670",
-            "NCIT:C26704",
-            "MONDO:0004652",
-            "MESH:D018410",
-            "ICD10:J15.9",
-            "MEDDRA:10060946",
-            "EFO:1001272"
-          ],
-          "id": "MONDO:0004652",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia, Bacterial",
-            "Bacterial pneumonia, unspecified",
-            "bacterial pneumonia",
-            "Bacterial Pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/bacterial_pneumonia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ceftriaxone",
-          "description": "The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C817\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C817\" NCI Thesaurus); The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).; A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.",
-          "equivalent_curies": [
-            "CHEBI:29007",
-            "INCHIKEY:VAAUVRVFOQPIGI-SPQHTLEESA-N",
-            "PUBCHEM.COMPOUND:5479530",
-            "NDDF:004849",
-            "UMLS:C0035750",
-            "GTOPDB:5326",
-            "CHEMBL.COMPOUND:CHEMBL161",
-            "KEGG.COMPOUND:C06683",
-            "ATC:J01DD04",
-            "NCIT:C62020",
-            "HMDB:HMDB0015343",
-            "DRUGBANK:DB01212",
-            "KEGG.DRUG:D07659",
-            "RXNORM:2193",
-            "DrugCentral:564",
-            "UNII:75J73V1629",
-            "MESH:D002443"
-          ],
-          "id": "PUBCHEM.COMPOUND:5479530",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Rocephin",
-            "ceftriaxone",
-            "Ceftriaxone",
-            "ceftriaxone sodium",
-            "Ceftriaxone (INN)",
-            "CEFTRIAXONE"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20022146",
-            "PMID:18426899",
-            "PMID:20368407",
-            "PMID:17846134",
-            "PMID:17438056",
-            "PMID:22951041",
-            "PMID:21098249",
-            "PMID:18285482",
-            "PMID:27469981",
-            "PMID:19995919"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 527033,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004652",
-              "name": "bacterial pneumonia",
-              "description": "Acute infection of the lung parenchyma caused by bacteria (e.g., Streptococcus pneumoniae, Haemophilus influenzae, Chlamydia pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila). Signs and symptoms include productive cough, fever, chills, shortness of breath, and chest pain.; Inflammation of the lung parenchyma that is caused by bacterial infections.",
-              "equivalent_curies": [
-                "DOID:874",
-                "MEDDRA:10004051",
-                "SNOMEDCT:53084003",
-                "ICD9:482.9",
-                "UMLS:C0004626",
-                "MEDDRA:10035670",
-                "NCIT:C26704",
-                "MONDO:0004652",
-                "MESH:D018410",
-                "ICD10:J15.9",
-                "MEDDRA:10060946",
-                "EFO:1001272"
-              ],
-              "id": "MONDO:0004652",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia, Bacterial",
-                "Bacterial pneumonia, unspecified",
-                "bacterial pneumonia",
-                "Bacterial Pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/bacterial_pneumonia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18047271,
-            "start": 578,
-            "end": 527033,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2612238': {'publication date': '1989', 'sentence': 'The objectives of this open, prospective, randomized and comparative study were to evaluate and compare the efficacy and safety of intravenous ceftriaxone (active ingredient of Rocephin) and cefotaxime in treatment of bacterial pneumoniae.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0035750---SEMMEDDB:treats---None---None---None---UMLS:C0004626---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5479530",
-              "id": "18413392",
-              "object": "MONDO:0004652",
-              "publications": [
-                "PMID:2612238"
-              ]
-            }
-          },
-          "end": {
-            "identity": 578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ceftriaxone",
-              "description": "The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C817\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C817\" NCI Thesaurus); The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).; A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.",
-              "equivalent_curies": [
-                "CHEBI:29007",
-                "INCHIKEY:VAAUVRVFOQPIGI-SPQHTLEESA-N",
-                "PUBCHEM.COMPOUND:5479530",
-                "NDDF:004849",
-                "UMLS:C0035750",
-                "GTOPDB:5326",
-                "CHEMBL.COMPOUND:CHEMBL161",
-                "KEGG.COMPOUND:C06683",
-                "ATC:J01DD04",
-                "NCIT:C62020",
-                "HMDB:HMDB0015343",
-                "DRUGBANK:DB01212",
-                "KEGG.DRUG:D07659",
-                "RXNORM:2193",
-                "DrugCentral:564",
-                "UNII:75J73V1629",
-                "MESH:D002443"
-              ],
-              "id": "PUBCHEM.COMPOUND:5479530",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Rocephin",
-                "ceftriaxone",
-                "Ceftriaxone",
-                "ceftriaxone sodium",
-                "Ceftriaxone (INN)",
-                "CEFTRIAXONE"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20022146",
-                "PMID:18426899",
-                "PMID:20368407",
-                "PMID:17846134",
-                "PMID:17438056",
-                "PMID:22951041",
-                "PMID:21098249",
-                "PMID:18285482",
-                "PMID:27469981",
-                "PMID:19995919"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 538307,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-          ]
-        }
-      },
-      "end": {
-        "identity": 578,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ceftriaxone",
-          "description": "The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C817\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C817\" NCI Thesaurus); The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).; A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.",
-          "equivalent_curies": [
-            "CHEBI:29007",
-            "INCHIKEY:VAAUVRVFOQPIGI-SPQHTLEESA-N",
-            "PUBCHEM.COMPOUND:5479530",
-            "NDDF:004849",
-            "UMLS:C0035750",
-            "GTOPDB:5326",
-            "CHEMBL.COMPOUND:CHEMBL161",
-            "KEGG.COMPOUND:C06683",
-            "ATC:J01DD04",
-            "NCIT:C62020",
-            "HMDB:HMDB0015343",
-            "DRUGBANK:DB01212",
-            "KEGG.DRUG:D07659",
-            "RXNORM:2193",
-            "DrugCentral:564",
-            "UNII:75J73V1629",
-            "MESH:D002443"
-          ],
-          "id": "PUBCHEM.COMPOUND:5479530",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Rocephin",
-            "ceftriaxone",
-            "Ceftriaxone",
-            "ceftriaxone sodium",
-            "Ceftriaxone (INN)",
-            "CEFTRIAXONE"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:20022146",
-            "PMID:18426899",
-            "PMID:20368407",
-            "PMID:17846134",
-            "PMID:17438056",
-            "PMID:22951041",
-            "PMID:21098249",
-            "PMID:18285482",
-            "PMID:27469981",
-            "PMID:19995919"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538307,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18700460,
-            "start": 578,
-            "end": 538307,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2737215': {'publication date': '1989', 'sentence': '1,480 patients, undergoing elective orthopedic and traumatic surgery, received intragluteal injections of ceftriaxone (Rocephin) to prevent bacterial infections.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0035750---SEMMEDDB:prevents---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5479530",
-              "id": "19081412",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:2737215"
-              ]
-            }
-          },
-          "end": {
-            "identity": 578,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ceftriaxone",
-              "description": "The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS). Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C817\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C817\" NCI Thesaurus); The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).; A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.",
-              "equivalent_curies": [
-                "CHEBI:29007",
-                "INCHIKEY:VAAUVRVFOQPIGI-SPQHTLEESA-N",
-                "PUBCHEM.COMPOUND:5479530",
-                "NDDF:004849",
-                "UMLS:C0035750",
-                "GTOPDB:5326",
-                "CHEMBL.COMPOUND:CHEMBL161",
-                "KEGG.COMPOUND:C06683",
-                "ATC:J01DD04",
-                "NCIT:C62020",
-                "HMDB:HMDB0015343",
-                "DRUGBANK:DB01212",
-                "KEGG.DRUG:D07659",
-                "RXNORM:2193",
-                "DrugCentral:564",
-                "UNII:75J73V1629",
-                "MESH:D002443"
-              ],
-              "id": "PUBCHEM.COMPOUND:5479530",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Rocephin",
-                "ceftriaxone",
-                "Ceftriaxone",
-                "ceftriaxone sodium",
-                "Ceftriaxone (INN)",
-                "CEFTRIAXONE"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:20022146",
-                "PMID:18426899",
-                "PMID:20368407",
-                "PMID:17846134",
-                "PMID:17438056",
-                "PMID:22951041",
-                "PMID:21098249",
-                "PMID:18285482",
-                "PMID:27469981",
-                "PMID:19995919"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:4611753': {'publication date': '1974 Oct', 'sentence': 'Proceedings: A double blind trial of carbenoxolone and geranyl farnesylacetate in gastric ulcer.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319260,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001126",
-          "name": "gastric ulcer",
-          "description": "An ulcer, that is, an erosion of an area of the gastric mucous membrane. [HPO:probinson]; An ulcer, that is, an erosion of an area of the gastric mucous membrane. // COMMENTS: The presence of a mucosal erosion equal to or greater than 0.5 cm.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10045304",
-            "HP:0002592",
-            "ICD10:K25",
-            "UMLS:C0038358",
-            "MESH:D013276",
-            "ICD9:531",
-            "MEDDRA:10045336",
-            "MEDDRA:10045374",
-            "EFO:0009454",
-            "SNOMEDCT:397825006",
-            "MEDDRA:10042116",
-            "MEDDRA:10017822",
-            "MONDO:0001126",
-            "NCIT:C3388",
-            "DOID:10808"
-          ],
-          "id": "MONDO:0001126",
-          "category": "biolink:Disease",
-          "all_names": [
-            "gastric ulcer",
-            "Stomach Ulcer",
-            "Gastric Ulcer",
-            "Gastric ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 589,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Gefarnate",
-          "description": "A water insoluble terpene fatty acid used in the treatment of gastrointestinal ulcers; it facilitates the healing and function of mucosal tissue.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "MESH:D005778",
-            "DrugCentral:1281",
-            "DRUGBANK:DB12079",
-            "INCHIKEY:ZPACYDRSPFRDHO-ROBAGEODSA-N",
-            "PUBCHEM.COMPOUND:5282182",
-            "CHEBI:31646",
-            "UNII:1ISE2Y6ULA",
-            "CHEMBL.COMPOUND:CHEMBL2105085",
-            "UMLS:C0017226",
-            "CAS:51-77-4",
-            "ATC:A02BX07",
-            "KEGG.DRUG:D01529",
-            "NCIT:C73187"
-          ],
-          "id": "PUBCHEM.COMPOUND:5282182",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "gefarnyl",
-            "Gefarnate (JP18/INN)",
-            "Gefarnate",
-            "GEFARNATE",
-            "gefarnate"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:15646539"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319260,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001126",
-              "name": "gastric ulcer",
-              "description": "An ulcer, that is, an erosion of an area of the gastric mucous membrane. [HPO:probinson]; An ulcer, that is, an erosion of an area of the gastric mucous membrane. // COMMENTS: The presence of a mucosal erosion equal to or greater than 0.5 cm.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10045304",
-                "HP:0002592",
-                "ICD10:K25",
-                "UMLS:C0038358",
-                "MESH:D013276",
-                "ICD9:531",
-                "MEDDRA:10045336",
-                "MEDDRA:10045374",
-                "EFO:0009454",
-                "SNOMEDCT:397825006",
-                "MEDDRA:10042116",
-                "MEDDRA:10017822",
-                "MONDO:0001126",
-                "NCIT:C3388",
-                "DOID:10808"
-              ],
-              "id": "MONDO:0001126",
-              "category": "biolink:Disease",
-              "all_names": [
-                "gastric ulcer",
-                "Stomach Ulcer",
-                "Gastric Ulcer",
-                "Gastric ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25373834,
-            "start": 589,
-            "end": 319260,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:4611753': {'publication date': '1974 Oct', 'sentence': 'Proceedings: A double blind trial of carbenoxolone and geranyl farnesylacetate in gastric ulcer.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0017226---SEMMEDDB:associated_with---None---None---None---UMLS:C0038358---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5282182",
-              "id": "25827448",
-              "object": "MONDO:0001126",
-              "publications": [
-                "PMID:4611753"
-              ]
-            }
-          },
-          "end": {
-            "identity": 589,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-            ],
-            "properties": {
-              "name": "Gefarnate",
-              "description": "A water insoluble terpene fatty acid used in the treatment of gastrointestinal ulcers; it facilitates the healing and function of mucosal tissue.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "MESH:D005778",
-                "DrugCentral:1281",
-                "DRUGBANK:DB12079",
-                "INCHIKEY:ZPACYDRSPFRDHO-ROBAGEODSA-N",
-                "PUBCHEM.COMPOUND:5282182",
-                "CHEBI:31646",
-                "UNII:1ISE2Y6ULA",
-                "CHEMBL.COMPOUND:CHEMBL2105085",
-                "UMLS:C0017226",
-                "CAS:51-77-4",
-                "ATC:A02BX07",
-                "KEGG.DRUG:D01529",
-                "NCIT:C73187"
-              ],
-              "id": "PUBCHEM.COMPOUND:5282182",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "gefarnyl",
-                "Gefarnate (JP18/INN)",
-                "Gefarnate",
-                "GEFARNATE",
-                "gefarnate"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:15646539"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319325,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005412",
-          "name": "duodenal ulcer",
-          "description": "An erosion of the mucous membrane in a portion of the duodenum. [HPO:probinson]; An erosion of the mucous membrane in a portion of the duodenum.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10045297",
-            "SNOMEDCT:367474008",
-            "UMLS:C0010474",
-            "EFO:0004607",
-            "SNOMEDCT:39755000",
-            "MEDDRA:10013836",
-            "MESH:D004381",
-            "NCIT:C26755",
-            "DOID:1724",
-            "ICD9:532",
-            "SNOMEDCT:51868009",
-            "UMLS:C0013295",
-            "HP:0002588",
-            "MONDO:0005412",
-            "MEDDRA:10011646",
-            "ICD10:K26"
-          ],
-          "id": "MONDO:0005412",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Duodenal Ulcer",
-            "duodenal ulcer",
-            "Curling Ulcer",
-            "Duodenal ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 589,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Gefarnate",
-          "description": "A water insoluble terpene fatty acid used in the treatment of gastrointestinal ulcers; it facilitates the healing and function of mucosal tissue.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "MESH:D005778",
-            "DrugCentral:1281",
-            "DRUGBANK:DB12079",
-            "INCHIKEY:ZPACYDRSPFRDHO-ROBAGEODSA-N",
-            "PUBCHEM.COMPOUND:5282182",
-            "CHEBI:31646",
-            "UNII:1ISE2Y6ULA",
-            "CHEMBL.COMPOUND:CHEMBL2105085",
-            "UMLS:C0017226",
-            "CAS:51-77-4",
-            "ATC:A02BX07",
-            "KEGG.DRUG:D01529",
-            "NCIT:C73187"
-          ],
-          "id": "PUBCHEM.COMPOUND:5282182",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "gefarnyl",
-            "Gefarnate (JP18/INN)",
-            "Gefarnate",
-            "GEFARNATE",
-            "gefarnate"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:15646539"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319325,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005412",
-              "name": "duodenal ulcer",
-              "description": "An erosion of the mucous membrane in a portion of the duodenum. [HPO:probinson]; An erosion of the mucous membrane in a portion of the duodenum.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10045297",
-                "SNOMEDCT:367474008",
-                "UMLS:C0010474",
-                "EFO:0004607",
-                "SNOMEDCT:39755000",
-                "MEDDRA:10013836",
-                "MESH:D004381",
-                "NCIT:C26755",
-                "DOID:1724",
-                "ICD9:532",
-                "SNOMEDCT:51868009",
-                "UMLS:C0013295",
-                "HP:0002588",
-                "MONDO:0005412",
-                "MEDDRA:10011646",
-                "ICD10:K26"
-              ],
-              "id": "MONDO:0005412",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Duodenal Ulcer",
-                "duodenal ulcer",
-                "Curling Ulcer",
-                "Duodenal ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23856511,
-            "start": 589,
-            "end": 319325,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3527182': {'publication date': '1986 Jun', 'sentence': 'A controlled double-blind study was performed in 17 institutes using gefarnate as a control drug in order to investigate the therapeutic effect and safety of pirenzepine dihydrochloride (LS 519) in duodenal ulcer.', 'subject score': 1000, 'object score': 1000}, 'PMID:4580209': {'publication date': '1973 Mar', 'sentence': 'A double-blind trial of oral gefarnate in duodenal ulcer.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0017226---SEMMEDDB:associated_with---None---None---None---UMLS:C0013295---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5282182",
-              "id": "24296137",
-              "object": "MONDO:0005412",
-              "publications": [
-                "PMID:3527182",
-                "PMID:4580209"
-              ]
-            }
-          },
-          "end": {
-            "identity": 589,
-            "labels": [
-=======
->>>>>>> main
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Gefarnate",
-              "description": "A water insoluble terpene fatty acid used in the treatment of gastrointestinal ulcers; it facilitates the healing and function of mucosal tissue.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "MESH:D005778",
-                "DrugCentral:1281",
-                "DRUGBANK:DB12079",
-                "INCHIKEY:ZPACYDRSPFRDHO-ROBAGEODSA-N",
-                "PUBCHEM.COMPOUND:5282182",
-                "CHEBI:31646",
-                "UNII:1ISE2Y6ULA",
-                "CHEMBL.COMPOUND:CHEMBL2105085",
-                "UMLS:C0017226",
-                "CAS:51-77-4",
-                "ATC:A02BX07",
-                "KEGG.DRUG:D01529",
-                "NCIT:C73187"
-              ],
-              "id": "PUBCHEM.COMPOUND:5282182",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "gefarnyl",
-                "Gefarnate (JP18/INN)",
-                "Gefarnate",
-                "GEFARNATE",
-                "gefarnate"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:15646539"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:4443658': {'publication date': '1974 Oct', 'sentence': 'Clinical trial of Gefarnate in the treatment of gastric ulcer disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:790358': {'publication date': '1976 Sep', 'sentence': 'A double blind trial of gefarnate and placebo in the treatment of gastric ulcer.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319260,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001126",
-          "name": "gastric ulcer",
-          "description": "An ulcer, that is, an erosion of an area of the gastric mucous membrane. [HPO:probinson]; An ulcer, that is, an erosion of an area of the gastric mucous membrane. // COMMENTS: The presence of a mucosal erosion equal to or greater than 0.5 cm.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10045304",
-            "HP:0002592",
-            "ICD10:K25",
-            "UMLS:C0038358",
-            "MESH:D013276",
-            "ICD9:531",
-            "MEDDRA:10045336",
-            "MEDDRA:10045374",
-            "EFO:0009454",
-            "SNOMEDCT:397825006",
-            "MEDDRA:10042116",
-            "MEDDRA:10017822",
-            "MONDO:0001126",
-            "NCIT:C3388",
-            "DOID:10808"
-          ],
-          "id": "MONDO:0001126",
-          "category": "biolink:Disease",
-          "all_names": [
-            "gastric ulcer",
-            "Stomach Ulcer",
-            "Gastric Ulcer",
-            "Gastric ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 589,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Gefarnate",
-          "description": "A water insoluble terpene fatty acid used in the treatment of gastrointestinal ulcers; it facilitates the healing and function of mucosal tissue.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "MESH:D005778",
-            "DrugCentral:1281",
-            "DRUGBANK:DB12079",
-            "INCHIKEY:ZPACYDRSPFRDHO-ROBAGEODSA-N",
-            "PUBCHEM.COMPOUND:5282182",
-            "CHEBI:31646",
-            "UNII:1ISE2Y6ULA",
-            "CHEMBL.COMPOUND:CHEMBL2105085",
-            "UMLS:C0017226",
-            "CAS:51-77-4",
-            "ATC:A02BX07",
-            "KEGG.DRUG:D01529",
-            "NCIT:C73187"
-          ],
-          "id": "PUBCHEM.COMPOUND:5282182",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "gefarnyl",
-            "Gefarnate (JP18/INN)",
-            "Gefarnate",
-            "GEFARNATE",
-            "gefarnate"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:15646539"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319260,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001126",
-              "name": "gastric ulcer",
-              "description": "An ulcer, that is, an erosion of an area of the gastric mucous membrane. [HPO:probinson]; An ulcer, that is, an erosion of an area of the gastric mucous membrane. // COMMENTS: The presence of a mucosal erosion equal to or greater than 0.5 cm.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10045304",
-                "HP:0002592",
-                "ICD10:K25",
-                "UMLS:C0038358",
-                "MESH:D013276",
-                "ICD9:531",
-                "MEDDRA:10045336",
-                "MEDDRA:10045374",
-                "EFO:0009454",
-                "SNOMEDCT:397825006",
-                "MEDDRA:10042116",
-                "MEDDRA:10017822",
-                "MONDO:0001126",
-                "NCIT:C3388",
-                "DOID:10808"
-              ],
-              "id": "MONDO:0001126",
-              "category": "biolink:Disease",
-              "all_names": [
-                "gastric ulcer",
-                "Stomach Ulcer",
-                "Gastric Ulcer",
-                "Gastric ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25357051,
-            "start": 589,
-            "end": 319260,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:4443658': {'publication date': '1974 Oct', 'sentence': 'Clinical trial of Gefarnate in the treatment of gastric ulcer disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:790358': {'publication date': '1976 Sep', 'sentence': 'A double blind trial of gefarnate and placebo in the treatment of gastric ulcer.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0017226---SEMMEDDB:treats---None---None---None---UMLS:C0038358---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5282182",
-              "id": "25810060",
-              "object": "MONDO:0001126",
-              "publications": [
-                "PMID:4443658",
-                "PMID:790358"
-              ]
-            }
-          },
-          "end": {
-            "identity": 589,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Gefarnate",
-              "description": "A water insoluble terpene fatty acid used in the treatment of gastrointestinal ulcers; it facilitates the healing and function of mucosal tissue.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "MESH:D005778",
-                "DrugCentral:1281",
-                "DRUGBANK:DB12079",
-                "INCHIKEY:ZPACYDRSPFRDHO-ROBAGEODSA-N",
-                "PUBCHEM.COMPOUND:5282182",
-                "CHEBI:31646",
-                "UNII:1ISE2Y6ULA",
-                "CHEMBL.COMPOUND:CHEMBL2105085",
-                "UMLS:C0017226",
-                "CAS:51-77-4",
-                "ATC:A02BX07",
-                "KEGG.DRUG:D01529",
-                "NCIT:C73187"
-              ],
-              "id": "PUBCHEM.COMPOUND:5282182",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "gefarnyl",
-                "Gefarnate (JP18/INN)",
-                "Gefarnate",
-                "GEFARNATE",
-                "gefarnate"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:15646539"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:6116654': {'publication date': '1981 Apr', 'sentence': 'Gefarnate at 300 mg/kg (p.o.) significantly inhibited phenylbutazone-induced gastric ulcers in rats but had no effect on other ulcer models.', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 319260,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001126",
-          "name": "gastric ulcer",
-          "description": "An ulcer, that is, an erosion of an area of the gastric mucous membrane. [HPO:probinson]; An ulcer, that is, an erosion of an area of the gastric mucous membrane. // COMMENTS: The presence of a mucosal erosion equal to or greater than 0.5 cm.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10045304",
-            "HP:0002592",
-            "ICD10:K25",
-            "UMLS:C0038358",
-            "MESH:D013276",
-            "ICD9:531",
-            "MEDDRA:10045336",
-            "MEDDRA:10045374",
-            "EFO:0009454",
-            "SNOMEDCT:397825006",
-            "MEDDRA:10042116",
-            "MEDDRA:10017822",
-            "MONDO:0001126",
-            "NCIT:C3388",
-            "DOID:10808"
-          ],
-          "id": "MONDO:0001126",
-          "category": "biolink:Disease",
-          "all_names": [
-            "gastric ulcer",
-            "Stomach Ulcer",
-            "Gastric Ulcer",
-            "Gastric ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 589,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Gefarnate",
-          "description": "A water insoluble terpene fatty acid used in the treatment of gastrointestinal ulcers; it facilitates the healing and function of mucosal tissue.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "MESH:D005778",
-            "DrugCentral:1281",
-            "DRUGBANK:DB12079",
-            "INCHIKEY:ZPACYDRSPFRDHO-ROBAGEODSA-N",
-            "PUBCHEM.COMPOUND:5282182",
-            "CHEBI:31646",
-            "UNII:1ISE2Y6ULA",
-            "CHEMBL.COMPOUND:CHEMBL2105085",
-            "UMLS:C0017226",
-            "CAS:51-77-4",
-            "ATC:A02BX07",
-            "KEGG.DRUG:D01529",
-            "NCIT:C73187"
-          ],
-          "id": "PUBCHEM.COMPOUND:5282182",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "gefarnyl",
-            "Gefarnate (JP18/INN)",
-            "Gefarnate",
-            "GEFARNATE",
-            "gefarnate"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:15646539"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319260,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001126",
-              "name": "gastric ulcer",
-              "description": "An ulcer, that is, an erosion of an area of the gastric mucous membrane. [HPO:probinson]; An ulcer, that is, an erosion of an area of the gastric mucous membrane. // COMMENTS: The presence of a mucosal erosion equal to or greater than 0.5 cm.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10045304",
-                "HP:0002592",
-                "ICD10:K25",
-                "UMLS:C0038358",
-                "MESH:D013276",
-                "ICD9:531",
-                "MEDDRA:10045336",
-                "MEDDRA:10045374",
-                "EFO:0009454",
-                "SNOMEDCT:397825006",
-                "MEDDRA:10042116",
-                "MEDDRA:10017822",
-                "MONDO:0001126",
-                "NCIT:C3388",
-                "DOID:10808"
-              ],
-              "id": "MONDO:0001126",
-              "category": "biolink:Disease",
-              "all_names": [
-                "gastric ulcer",
-                "Stomach Ulcer",
-                "Gastric Ulcer",
-                "Gastric ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25538685,
-            "start": 589,
-            "end": 319260,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:6116654': {'publication date': '1981 Apr', 'sentence': 'Gefarnate at 300 mg/kg (p.o.) significantly inhibited phenylbutazone-induced gastric ulcers in rats but had no effect on other ulcer models.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0017226---SEMMEDDB:disrupts---None---None---None---UMLS:C0038358---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5282182",
-              "id": "25993651",
-              "object": "MONDO:0001126",
-              "publications": [
-                "PMID:6116654"
-              ]
-            }
-          },
-          "end": {
-            "identity": 589,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Gefarnate",
-              "description": "A water insoluble terpene fatty acid used in the treatment of gastrointestinal ulcers; it facilitates the healing and function of mucosal tissue.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "MESH:D005778",
-                "DrugCentral:1281",
-                "DRUGBANK:DB12079",
-                "INCHIKEY:ZPACYDRSPFRDHO-ROBAGEODSA-N",
-                "PUBCHEM.COMPOUND:5282182",
-                "CHEBI:31646",
-                "UNII:1ISE2Y6ULA",
-                "CHEMBL.COMPOUND:CHEMBL2105085",
-                "UMLS:C0017226",
-                "CAS:51-77-4",
-                "ATC:A02BX07",
-                "KEGG.DRUG:D01529",
-                "NCIT:C73187"
-              ],
-              "id": "PUBCHEM.COMPOUND:5282182",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "gefarnyl",
-                "Gefarnate (JP18/INN)",
-                "Gefarnate",
-                "GEFARNATE",
-                "gefarnate"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:15646539"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:3527182': {'publication date': '1986 Jun', 'sentence': 'A controlled double-blind study was performed in 17 institutes using gefarnate as a control drug in order to investigate the therapeutic effect and safety of pirenzepine dihydrochloride (LS 519) in duodenal ulcer.', 'subject score': 1000, 'object score': 1000}, 'PMID:4580209': {'publication date': '1973 Mar', 'sentence': 'A double-blind trial of oral gefarnate in duodenal ulcer.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319325,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005412",
-          "name": "duodenal ulcer",
-          "description": "An erosion of the mucous membrane in a portion of the duodenum. [HPO:probinson]; An erosion of the mucous membrane in a portion of the duodenum.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10045297",
-            "SNOMEDCT:367474008",
-            "UMLS:C0010474",
-            "EFO:0004607",
-            "SNOMEDCT:39755000",
-            "MEDDRA:10013836",
-            "MESH:D004381",
-            "NCIT:C26755",
-            "DOID:1724",
-            "ICD9:532",
-            "SNOMEDCT:51868009",
-            "UMLS:C0013295",
-            "HP:0002588",
-            "MONDO:0005412",
-            "MEDDRA:10011646",
-            "ICD10:K26"
-          ],
-          "id": "MONDO:0005412",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Duodenal Ulcer",
-            "duodenal ulcer",
-            "Curling Ulcer",
-            "Duodenal ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 589,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Gefarnate",
-          "description": "A water insoluble terpene fatty acid used in the treatment of gastrointestinal ulcers; it facilitates the healing and function of mucosal tissue.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "MESH:D005778",
-            "DrugCentral:1281",
-            "DRUGBANK:DB12079",
-            "INCHIKEY:ZPACYDRSPFRDHO-ROBAGEODSA-N",
-            "PUBCHEM.COMPOUND:5282182",
-            "CHEBI:31646",
-            "UNII:1ISE2Y6ULA",
-            "CHEMBL.COMPOUND:CHEMBL2105085",
-            "UMLS:C0017226",
-            "CAS:51-77-4",
-            "ATC:A02BX07",
-            "KEGG.DRUG:D01529",
-            "NCIT:C73187"
-          ],
-          "id": "PUBCHEM.COMPOUND:5282182",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "gefarnyl",
-            "Gefarnate (JP18/INN)",
-            "Gefarnate",
-            "GEFARNATE",
-            "gefarnate"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:15646539"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319325,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005412",
-              "name": "duodenal ulcer",
-              "description": "An erosion of the mucous membrane in a portion of the duodenum. [HPO:probinson]; An erosion of the mucous membrane in a portion of the duodenum.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10045297",
-                "SNOMEDCT:367474008",
-                "UMLS:C0010474",
-                "EFO:0004607",
-                "SNOMEDCT:39755000",
-                "MEDDRA:10013836",
-                "MESH:D004381",
-                "NCIT:C26755",
-                "DOID:1724",
-                "ICD9:532",
-                "SNOMEDCT:51868009",
-                "UMLS:C0013295",
-                "HP:0002588",
-                "MONDO:0005412",
-                "MEDDRA:10011646",
-                "ICD10:K26"
-              ],
-              "id": "MONDO:0005412",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Duodenal Ulcer",
-                "duodenal ulcer",
-                "Curling Ulcer",
-                "Duodenal ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23856511,
-            "start": 589,
-            "end": 319325,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3527182': {'publication date': '1986 Jun', 'sentence': 'A controlled double-blind study was performed in 17 institutes using gefarnate as a control drug in order to investigate the therapeutic effect and safety of pirenzepine dihydrochloride (LS 519) in duodenal ulcer.', 'subject score': 1000, 'object score': 1000}, 'PMID:4580209': {'publication date': '1973 Mar', 'sentence': 'A double-blind trial of oral gefarnate in duodenal ulcer.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0017226---SEMMEDDB:associated_with---None---None---None---UMLS:C0013295---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5282182",
-              "id": "24296137",
-              "object": "MONDO:0005412",
-              "publications": [
-                "PMID:3527182",
-                "PMID:4580209"
-              ]
-            }
-          },
-          "end": {
-            "identity": 589,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Gefarnate",
-              "description": "A water insoluble terpene fatty acid used in the treatment of gastrointestinal ulcers; it facilitates the healing and function of mucosal tissue.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "MESH:D005778",
-                "DrugCentral:1281",
-                "DRUGBANK:DB12079",
-                "INCHIKEY:ZPACYDRSPFRDHO-ROBAGEODSA-N",
-                "PUBCHEM.COMPOUND:5282182",
-                "CHEBI:31646",
-                "UNII:1ISE2Y6ULA",
-                "CHEMBL.COMPOUND:CHEMBL2105085",
-                "UMLS:C0017226",
-                "CAS:51-77-4",
-                "ATC:A02BX07",
-                "KEGG.DRUG:D01529",
-                "NCIT:C73187"
-              ],
-              "id": "PUBCHEM.COMPOUND:5282182",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "gefarnyl",
-                "Gefarnate (JP18/INN)",
-                "Gefarnate",
-                "GEFARNATE",
-                "gefarnate"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:15646539"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:4286000': {'publication date': '1966 Jan 15', 'sentence': '[Clinicobiological evolution of duodenal ulcer treated with gefarnate].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319325,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005412",
-          "name": "duodenal ulcer",
-          "description": "An erosion of the mucous membrane in a portion of the duodenum. [HPO:probinson]; An erosion of the mucous membrane in a portion of the duodenum.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10045297",
-            "SNOMEDCT:367474008",
-            "UMLS:C0010474",
-            "EFO:0004607",
-            "SNOMEDCT:39755000",
-            "MEDDRA:10013836",
-            "MESH:D004381",
-            "NCIT:C26755",
-            "DOID:1724",
-            "ICD9:532",
-            "SNOMEDCT:51868009",
-            "UMLS:C0013295",
-            "HP:0002588",
-            "MONDO:0005412",
-            "MEDDRA:10011646",
-            "ICD10:K26"
-          ],
-          "id": "MONDO:0005412",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Duodenal Ulcer",
-            "duodenal ulcer",
-            "Curling Ulcer",
-            "Duodenal ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 589,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Gefarnate",
-          "description": "A water insoluble terpene fatty acid used in the treatment of gastrointestinal ulcers; it facilitates the healing and function of mucosal tissue.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "MESH:D005778",
-            "DrugCentral:1281",
-            "DRUGBANK:DB12079",
-            "INCHIKEY:ZPACYDRSPFRDHO-ROBAGEODSA-N",
-            "PUBCHEM.COMPOUND:5282182",
-            "CHEBI:31646",
-            "UNII:1ISE2Y6ULA",
-            "CHEMBL.COMPOUND:CHEMBL2105085",
-            "UMLS:C0017226",
-            "CAS:51-77-4",
-            "ATC:A02BX07",
-            "KEGG.DRUG:D01529",
-            "NCIT:C73187"
-          ],
-          "id": "PUBCHEM.COMPOUND:5282182",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "gefarnyl",
-            "Gefarnate (JP18/INN)",
-            "Gefarnate",
-            "GEFARNATE",
-            "gefarnate"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:15646539"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319325,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005412",
-              "name": "duodenal ulcer",
-              "description": "An erosion of the mucous membrane in a portion of the duodenum. [HPO:probinson]; An erosion of the mucous membrane in a portion of the duodenum.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10045297",
-                "SNOMEDCT:367474008",
-                "UMLS:C0010474",
-                "EFO:0004607",
-                "SNOMEDCT:39755000",
-                "MEDDRA:10013836",
-                "MESH:D004381",
-                "NCIT:C26755",
-                "DOID:1724",
-                "ICD9:532",
-                "SNOMEDCT:51868009",
-                "UMLS:C0013295",
-                "HP:0002588",
-                "MONDO:0005412",
-                "MEDDRA:10011646",
-                "ICD10:K26"
-              ],
-              "id": "MONDO:0005412",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Duodenal Ulcer",
-                "duodenal ulcer",
-                "Curling Ulcer",
-                "Duodenal ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25331533,
-            "start": 589,
-            "end": 319325,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:4286000': {'publication date': '1966 Jan 15', 'sentence': '[Clinicobiological evolution of duodenal ulcer treated with gefarnate].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0017226---SEMMEDDB:treats---None---None---None---UMLS:C0013295---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5282182",
-              "id": "25784688",
-              "object": "MONDO:0005412",
-              "publications": [
-                "PMID:4286000"
-              ]
-            }
-          },
-          "end": {
-            "identity": 589,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Gefarnate",
-              "description": "A water insoluble terpene fatty acid used in the treatment of gastrointestinal ulcers; it facilitates the healing and function of mucosal tissue.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "MESH:D005778",
-                "DrugCentral:1281",
-                "DRUGBANK:DB12079",
-                "INCHIKEY:ZPACYDRSPFRDHO-ROBAGEODSA-N",
-                "PUBCHEM.COMPOUND:5282182",
-                "CHEBI:31646",
-                "UNII:1ISE2Y6ULA",
-                "CHEMBL.COMPOUND:CHEMBL2105085",
-                "UMLS:C0017226",
-                "CAS:51-77-4",
-                "ATC:A02BX07",
-                "KEGG.DRUG:D01529",
-                "NCIT:C73187"
-              ],
-              "id": "PUBCHEM.COMPOUND:5282182",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "gefarnyl",
-                "Gefarnate (JP18/INN)",
-                "Gefarnate",
-                "GEFARNATE",
-                "gefarnate"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:15646539"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:2859256': {'publication date': '1985 Feb', 'sentence': 'One hundred and thirty-nine patients with endoscopically confirmed peptic ulcers (gastric and duodenal) entered a double blind comparative evaluation of alprazolam (1.2 mg/day), gefarnate (300 mg/day) and their combination in treatment of peptic ulcer.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 316638,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-          "name": "peptic ulcer disease",
-          "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10018053",
-            "MEDDRA:10045305",
-            "MESH:D010437",
-            "MONDO:0004247",
-            "DOID:750",
-            "UMLS:C0030920",
-            "MEDDRA:10017886",
-            "MEDDRA:10045342",
-            "ICD9:533",
-            "ICD10:K27",
-            "HP:0004398",
-            "MEDDRA:10034343",
-            "MEDDRA:10034360",
-            "MEDDRA:10045328",
-            "MEDDRA:10042834",
-            "MEDDRA:10034341",
-            "MEDDRA:10034367",
-            "MEDDRA:10037287",
-            "NCIT:C3318",
-            "SNOMEDCT:13200003",
-            "MEDDRA:10034369"
-          ],
-          "id": "MONDO:0004247",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peptic ulcer, site unspecified",
-            "Peptic Ulcer",
-            "peptic ulcer disease",
-            "Peptic ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28242110",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 589,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Gefarnate",
-          "description": "A water insoluble terpene fatty acid used in the treatment of gastrointestinal ulcers; it facilitates the healing and function of mucosal tissue.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "MESH:D005778",
-            "DrugCentral:1281",
-            "DRUGBANK:DB12079",
-            "INCHIKEY:ZPACYDRSPFRDHO-ROBAGEODSA-N",
-            "PUBCHEM.COMPOUND:5282182",
-            "CHEBI:31646",
-            "UNII:1ISE2Y6ULA",
-            "CHEMBL.COMPOUND:CHEMBL2105085",
-            "UMLS:C0017226",
-            "CAS:51-77-4",
-            "ATC:A02BX07",
-            "KEGG.DRUG:D01529",
-            "NCIT:C73187"
-          ],
-          "id": "PUBCHEM.COMPOUND:5282182",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "gefarnyl",
-            "Gefarnate (JP18/INN)",
-            "Gefarnate",
-            "GEFARNATE",
-            "gefarnate"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:15646539"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316638,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-              "name": "peptic ulcer disease",
-              "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10018053",
-                "MEDDRA:10045305",
-                "MESH:D010437",
-                "MONDO:0004247",
-                "DOID:750",
-                "UMLS:C0030920",
-                "MEDDRA:10017886",
-                "MEDDRA:10045342",
-                "ICD9:533",
-                "ICD10:K27",
-                "HP:0004398",
-                "MEDDRA:10034343",
-                "MEDDRA:10034360",
-                "MEDDRA:10045328",
-                "MEDDRA:10042834",
-                "MEDDRA:10034341",
-                "MEDDRA:10034367",
-                "MEDDRA:10037287",
-                "NCIT:C3318",
-                "SNOMEDCT:13200003",
-                "MEDDRA:10034369"
-              ],
-              "id": "MONDO:0004247",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peptic ulcer, site unspecified",
-                "Peptic Ulcer",
-                "peptic ulcer disease",
-                "Peptic ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28242110",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19316302,
-            "start": 589,
-            "end": 316638,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2859256': {'publication date': '1985 Feb', 'sentence': 'One hundred and thirty-nine patients with endoscopically confirmed peptic ulcers (gastric and duodenal) entered a double blind comparative evaluation of alprazolam (1.2 mg/day), gefarnate (300 mg/day) and their combination in treatment of peptic ulcer.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0017226---SEMMEDDB:treats---None---None---None---UMLS:C0030920---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5282182",
-              "id": "19702373",
-              "object": "MONDO:0004247",
-              "publications": [
-                "PMID:2859256"
-              ]
-            }
-          },
-          "end": {
-            "identity": 589,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Gefarnate",
-              "description": "A water insoluble terpene fatty acid used in the treatment of gastrointestinal ulcers; it facilitates the healing and function of mucosal tissue.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "MESH:D005778",
-                "DrugCentral:1281",
-                "DRUGBANK:DB12079",
-                "INCHIKEY:ZPACYDRSPFRDHO-ROBAGEODSA-N",
-                "PUBCHEM.COMPOUND:5282182",
-                "CHEBI:31646",
-                "UNII:1ISE2Y6ULA",
-                "CHEMBL.COMPOUND:CHEMBL2105085",
-                "UMLS:C0017226",
-                "CAS:51-77-4",
-                "ATC:A02BX07",
-                "KEGG.DRUG:D01529",
-                "NCIT:C73187"
-              ],
-              "id": "PUBCHEM.COMPOUND:5282182",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "gefarnyl",
-                "Gefarnate (JP18/INN)",
-                "Gefarnate",
-                "GEFARNATE",
-                "gefarnate"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:15646539"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 319260,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001126",
-          "name": "gastric ulcer",
-          "description": "An ulcer, that is, an erosion of an area of the gastric mucous membrane. [HPO:probinson]; An ulcer, that is, an erosion of an area of the gastric mucous membrane. // COMMENTS: The presence of a mucosal erosion equal to or greater than 0.5 cm.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10045304",
-            "HP:0002592",
-            "ICD10:K25",
-            "UMLS:C0038358",
-            "MESH:D013276",
-            "ICD9:531",
-            "MEDDRA:10045336",
-            "MEDDRA:10045374",
-            "EFO:0009454",
-            "SNOMEDCT:397825006",
-            "MEDDRA:10042116",
-            "MEDDRA:10017822",
-            "MONDO:0001126",
-            "NCIT:C3388",
-            "DOID:10808"
-          ],
-          "id": "MONDO:0001126",
-          "category": "biolink:Disease",
-          "all_names": [
-            "gastric ulcer",
-            "Stomach Ulcer",
-            "Gastric Ulcer",
-            "Gastric ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 589,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Gefarnate",
-          "description": "A water insoluble terpene fatty acid used in the treatment of gastrointestinal ulcers; it facilitates the healing and function of mucosal tissue.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "MESH:D005778",
-            "DrugCentral:1281",
-            "DRUGBANK:DB12079",
-            "INCHIKEY:ZPACYDRSPFRDHO-ROBAGEODSA-N",
-            "PUBCHEM.COMPOUND:5282182",
-            "CHEBI:31646",
-            "UNII:1ISE2Y6ULA",
-            "CHEMBL.COMPOUND:CHEMBL2105085",
-            "UMLS:C0017226",
-            "CAS:51-77-4",
-            "ATC:A02BX07",
-            "KEGG.DRUG:D01529",
-            "NCIT:C73187"
-          ],
-          "id": "PUBCHEM.COMPOUND:5282182",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "gefarnyl",
-            "Gefarnate (JP18/INN)",
-            "Gefarnate",
-            "GEFARNATE",
-            "gefarnate"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:15646539"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319260,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001126",
-              "name": "gastric ulcer",
-              "description": "An ulcer, that is, an erosion of an area of the gastric mucous membrane. [HPO:probinson]; An ulcer, that is, an erosion of an area of the gastric mucous membrane. // COMMENTS: The presence of a mucosal erosion equal to or greater than 0.5 cm.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10045304",
-                "HP:0002592",
-                "ICD10:K25",
-                "UMLS:C0038358",
-                "MESH:D013276",
-                "ICD9:531",
-                "MEDDRA:10045336",
-                "MEDDRA:10045374",
-                "EFO:0009454",
-                "SNOMEDCT:397825006",
-                "MEDDRA:10042116",
-                "MEDDRA:10017822",
-                "MONDO:0001126",
-                "NCIT:C3388",
-                "DOID:10808"
-              ],
-              "id": "MONDO:0001126",
-              "category": "biolink:Disease",
-              "all_names": [
-                "gastric ulcer",
-                "Stomach Ulcer",
-                "Gastric Ulcer",
-                "Gastric ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25538685,
-            "start": 589,
-            "end": 319260,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:6116654': {'publication date': '1981 Apr', 'sentence': 'Gefarnate at 300 mg/kg (p.o.) significantly inhibited phenylbutazone-induced gastric ulcers in rats but had no effect on other ulcer models.', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0017226---SEMMEDDB:disrupts---None---None---None---UMLS:C0038358---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5282182",
-              "id": "25993651",
-              "object": "MONDO:0001126",
-              "publications": [
-                "PMID:6116654"
-              ]
-            }
-          },
-          "end": {
-            "identity": 589,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Gefarnate",
-              "description": "A water insoluble terpene fatty acid used in the treatment of gastrointestinal ulcers; it facilitates the healing and function of mucosal tissue.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "MESH:D005778",
-                "DrugCentral:1281",
-                "DRUGBANK:DB12079",
-                "INCHIKEY:ZPACYDRSPFRDHO-ROBAGEODSA-N",
-                "PUBCHEM.COMPOUND:5282182",
-                "CHEBI:31646",
-                "UNII:1ISE2Y6ULA",
-                "CHEMBL.COMPOUND:CHEMBL2105085",
-                "UMLS:C0017226",
-                "CAS:51-77-4",
-                "ATC:A02BX07",
-                "KEGG.DRUG:D01529",
-                "NCIT:C73187"
-              ],
-              "id": "PUBCHEM.COMPOUND:5282182",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "gefarnyl",
-                "Gefarnate (JP18/INN)",
-                "Gefarnate",
-                "GEFARNATE",
-                "gefarnate"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:15646539"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:32395975': {'publication date': '2020 May 12', 'sentence': 'CONCLUSIONS: Regadenoson may be a safe vasodilator for CTP and MR MPI in CAD patients.', 'subject score': 1000, 'object score': 916}, 'PMID:33778521': {'publication date': '2019 Oct', 'sentence': 'Conclusion: Weight-based dosing of regadenoson for stress cardiac MRI was safe and feasible in infants and young children and played an integral role in the outcome and treatment decisions for children with coronary artery disease.(c) RSNA, 2019.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 317775,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005010",
-          "name": "coronary artery disorder",
-          "description": "Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. [HPO:probinson]; Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. // COMMENTS: Coronary artery disease, also called atherosclerotic heart disease, is the result of atheromatous plaques within the coronary arteries leading to myocardial ischemia and infarction.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003324",
-            "ICD10:I25.10",
-            "MEDDRA:10008936",
-            "EFO:0001645",
-            "MEDDRA:10011081",
-            "HP:0001677",
-            "MEDDRA:10011106",
-            "PSY:11853",
-            "SNOMEDCT:53741008",
-            "SNOMEDCT:413844008",
-            "ICD9:414.0",
-            "MEDDRA:10003211",
-            "MEDDRA:10011079",
-            "ICD10:I20-I25",
-            "ICD9:410-414.99",
-            "MEDDRA:10013210",
-            "MEDDRA:10011076",
-            "UMLS:C0010068",
-            "MEDDRA:10011080",
-            "UMLS:C1956346",
-            "UMLS:C1533195",
-            "DOID:3393",
-            "NCIT:C26732",
-            "UMLS:C0010054",
-            "SNOMEDCT:413838009",
-            "MEDDRA:10011099",
-            "MEDDRA:10013098",
-            "MEDDRA:10008937",
-            "MEDDRA:10011078",
-            "MEDDRA:10011093",
-            "MEDDRA:10068617",
-            "ICD9:414.9",
-            "ICD10:I25",
-            "MEDDRA:10011087",
-            "MESH:D003327",
-            "MEDDRA:10049175",
-            "SNOMEDCT:414024009",
-            "MEDDRA:10011082",
-            "UMLS:C0264694",
-            "MONDO:0005010"
-          ],
-          "id": "MONDO:0005010",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic ischemic heart disease, unspecified",
-            "Coronary Artery Disease",
-            "Ischemic heart disease",
-            "Coronary atherosclerosis",
-            "Coronary artery atherosclerosis",
-            "Coronary Arteriosclerosis",
-            "Coronary Heart Disease",
-            "coronary artery disease",
-            "Coronary Disease",
-            "Chronic myocardial ischemia",
-            "Coronary heart disease",
-            "coronary artery disorder"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:31420554",
-            "http://en.wikipedia.org/wiki/coronary_heart_disease",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 590,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Regadenoson",
-          "description": "An adenosine derivative and selective A2A adenosine receptor agonist with coronary vasodilating activity. Upon administration, regadenoson selectively binds to and activates the A2A adenosine receptor, which induces coronary vasodilation. This leads to an increase in coronary blood flow and enhances myocardial perfusion. Compared to adenosine, regadenoson has a longer half-life and shows higher selectivity towards the A2A adenosine receptor. This agent is a very weak agonist for the A1 adenosine receptor and has negligible affinity for the A2B and A3 adenosine receptors. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C74420\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C74420\" NCI Thesaurus); An adenosine derivative and selective A2A adenosine receptor agonist with coronary vasodilating activity. Upon administration, regadenoson selectively binds to and activates the A2A adenosine receptor, which induces coronary vasodilation. This leads to an increase in coronary blood flow and enhances myocardial perfusion. Compared to adenosine, regadenoson has a longer half-life and shows higher selectivity towards the A2A adenosine receptor. This agent is a very weak agonist for the A1 adenosine receptor and has negligible affinity for the A2B and A3 adenosine receptors.",
-          "equivalent_curies": [
-            "PDQ:CDR0000761605",
-            "NCIT:C171933",
-            "PUBCHEM.COMPOUND:219024",
-            "DRUGBANK:DB06213",
-            "CAS:313348-27-5",
-            "INCHIKEY:LZPZPHGJDAGEJZ-AKAIJSEGSA-N",
-            "GTOPDB:5596",
-            "MESH:C430916",
-            "UMLS:C1698215",
-            "UNII:7AXV542LZ4",
-            "DrugCentral:2362",
-            "CHEBI:135613",
-            "CHEMBL.COMPOUND:CHEMBL317052",
-            "RXNORM:1546015",
-            "KEGG.DRUG:D05711",
-            "NCIT:C74420",
-            "NDDF:012689",
-            "ATC:C01EB21",
-            "UMLS:C3848585",
-            "RXNORM:640062"
-          ],
-          "id": "PUBCHEM.COMPOUND:219024",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "regadenoson",
-            "Regadenoson (USAN)",
-            "Regadenoson",
-            "regadenoson anhydrous",
-            "REGADENOSON",
-            "CVT-3146",
-            "Regadenoson Anhydrous"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:12270178",
-            "PMID:17679059",
-            "PMID:31255928",
-            "PMID:22104008",
-            "PMID:22130964",
-            "PMID:26948801",
-            "PMID:25780876",
-            "PMID:24164628",
-            "PMID:15341491",
-            "PMID:18477777"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317775,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005010",
-              "name": "coronary artery disorder",
-              "description": "Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. [HPO:probinson]; Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. // COMMENTS: Coronary artery disease, also called atherosclerotic heart disease, is the result of atheromatous plaques within the coronary arteries leading to myocardial ischemia and infarction.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003324",
-                "ICD10:I25.10",
-                "MEDDRA:10008936",
-                "EFO:0001645",
-                "MEDDRA:10011081",
-                "HP:0001677",
-                "MEDDRA:10011106",
-                "PSY:11853",
-                "SNOMEDCT:53741008",
-                "SNOMEDCT:413844008",
-                "ICD9:414.0",
-                "MEDDRA:10003211",
-                "MEDDRA:10011079",
-                "ICD10:I20-I25",
-                "ICD9:410-414.99",
-                "MEDDRA:10013210",
-                "MEDDRA:10011076",
-                "UMLS:C0010068",
-                "MEDDRA:10011080",
-                "UMLS:C1956346",
-                "UMLS:C1533195",
-                "DOID:3393",
-                "NCIT:C26732",
-                "UMLS:C0010054",
-                "SNOMEDCT:413838009",
-                "MEDDRA:10011099",
-                "MEDDRA:10013098",
-                "MEDDRA:10008937",
-                "MEDDRA:10011078",
-                "MEDDRA:10011093",
-                "MEDDRA:10068617",
-                "ICD9:414.9",
-                "ICD10:I25",
-                "MEDDRA:10011087",
-                "MESH:D003327",
-                "MEDDRA:10049175",
-                "SNOMEDCT:414024009",
-                "MEDDRA:10011082",
-                "UMLS:C0264694",
-                "MONDO:0005010"
-              ],
-              "id": "MONDO:0005010",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic ischemic heart disease, unspecified",
-                "Coronary Artery Disease",
-                "Ischemic heart disease",
-                "Coronary atherosclerosis",
-                "Coronary artery atherosclerosis",
-                "Coronary Arteriosclerosis",
-                "Coronary Heart Disease",
-                "coronary artery disease",
-                "Coronary Disease",
-                "Chronic myocardial ischemia",
-                "Coronary heart disease",
-                "coronary artery disorder"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:31420554",
-                "http://en.wikipedia.org/wiki/coronary_heart_disease",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21605099,
-            "start": 590,
-            "end": 317775,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32395975': {'publication date': '2020 May 12', 'sentence': 'CONCLUSIONS: Regadenoson may be a safe vasodilator for CTP and MR MPI in CAD patients.', 'subject score': 1000, 'object score': 916}, 'PMID:33778521': {'publication date': '2019 Oct', 'sentence': 'Conclusion: Weight-based dosing of regadenoson for stress cardiac MRI was safe and feasible in infants and young children and played an integral role in the outcome and treatment decisions for children with coronary artery disease.(c) RSNA, 2019.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C1698215---SEMMEDDB:treats---None---None---None---UMLS:C0010054---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:219024",
-              "id": "22023951",
-              "object": "MONDO:0005010",
-              "publications": [
-                "PMID:32395975",
-                "PMID:33778521"
-              ]
-            }
-          },
-          "end": {
-            "identity": 590,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-=======
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
->>>>>>> main
-            ],
-            "properties": {
-              "name": "Regadenoson",
-              "description": "An adenosine derivative and selective A2A adenosine receptor agonist with coronary vasodilating activity. Upon administration, regadenoson selectively binds to and activates the A2A adenosine receptor, which induces coronary vasodilation. This leads to an increase in coronary blood flow and enhances myocardial perfusion. Compared to adenosine, regadenoson has a longer half-life and shows higher selectivity towards the A2A adenosine receptor. This agent is a very weak agonist for the A1 adenosine receptor and has negligible affinity for the A2B and A3 adenosine receptors. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C74420\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C74420\" NCI Thesaurus); An adenosine derivative and selective A2A adenosine receptor agonist with coronary vasodilating activity. Upon administration, regadenoson selectively binds to and activates the A2A adenosine receptor, which induces coronary vasodilation. This leads to an increase in coronary blood flow and enhances myocardial perfusion. Compared to adenosine, regadenoson has a longer half-life and shows higher selectivity towards the A2A adenosine receptor. This agent is a very weak agonist for the A1 adenosine receptor and has negligible affinity for the A2B and A3 adenosine receptors.",
-              "equivalent_curies": [
-                "PDQ:CDR0000761605",
-                "NCIT:C171933",
-                "PUBCHEM.COMPOUND:219024",
-                "DRUGBANK:DB06213",
-                "CAS:313348-27-5",
-                "INCHIKEY:LZPZPHGJDAGEJZ-AKAIJSEGSA-N",
-                "GTOPDB:5596",
-                "MESH:C430916",
-                "UMLS:C1698215",
-                "UNII:7AXV542LZ4",
-                "DrugCentral:2362",
-                "CHEBI:135613",
-                "CHEMBL.COMPOUND:CHEMBL317052",
-                "RXNORM:1546015",
-                "KEGG.DRUG:D05711",
-                "NCIT:C74420",
-                "NDDF:012689",
-                "ATC:C01EB21",
-                "UMLS:C3848585",
-                "RXNORM:640062"
-              ],
-              "id": "PUBCHEM.COMPOUND:219024",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "regadenoson",
-                "Regadenoson (USAN)",
-                "Regadenoson",
-                "regadenoson anhydrous",
-                "REGADENOSON",
-                "CVT-3146",
-                "Regadenoson Anhydrous"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:12270178",
-                "PMID:17679059",
-                "PMID:31255928",
-                "PMID:22104008",
-                "PMID:22130964",
-                "PMID:26948801",
-                "PMID:25780876",
-                "PMID:24164628",
-                "PMID:15341491",
-                "PMID:18477777"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1771844': {'publication date': '1991 Jul', 'sentence': 'A study is presented of the clinico-hemodynamic efficacy of mildronate in 38 patients with ischemic stroke.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 318738,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0002140",
-          "name": "Ischemic stroke",
-          "description": "An acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of brain tissue.; Stroke due to BRAIN ISCHEMIA resulting in interruption or reduction of blood flow to a part of the brain. When obstruction is due to a BLOOD CLOT formed within in a cerebral blood vessel it is a thrombotic stroke. When obstruction is formed elsewhere and moved to block a cerebral blood vessel (see CEREBRAL EMBOLISM) it is referred to as embolic stroke. Wake-up stroke refers to ischemic stroke occurring during sleep while cryptogenic stroke refers to ischemic stroke of unknown origin.; Acute ischemic stroke (AIS) is defined by the sudden loss of blood flow to an area of the brain with the resulting loss of neurologic function. It is caused by thrombosis or embolism that occludes a cerebral vessel supplying a specific area of the brain. During a vessel occlusion, there is a core area where damage to the brain is irreversible and an area of penumbra where the brain has lost function owing to decreased blood flow but is not irreversibly injured. [PMID:32054610]; A stroke is a medical emergency. There are two types - ischemic and hemorrhagic. Ischemic stroke is the more common type. It is usually caused by a blood clot that blocks or plugs a blood vessel in the brain. This keeps blood from flowing to the brain. Within minutes, brain cells begin to die. Another cause is stenosis, or narrowing of the artery. This can happen because of atherosclerosis, a disease in which plaque builds up inside your arteries. Transient ischemic attacks (TIAs) occur when the blood supply to the brain is interrupted briefly. Having a TIA can mean you are at risk for having a more serious stroke. Symptoms of stroke are: Sudden numbness or weakness of the face, arm or leg (especially on one side of the body) Sudden confusion, trouble speaking or understanding speech Sudden trouble seeing in one or both eyes Sudden trouble walking, dizziness, loss of balance or coordination Sudden severe headache with no known cause  It is important to treat strokes as quickly as possible. Blood thinners may be used to stop a stroke while it is happening by quickly dissolving the blood clot. Post-stroke rehabilitation can help people overcome disabilities caused by stroke damage. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:422504002",
-            "MEDDRA:10061256",
-            "MEDDRA:10055221",
-            "HP:0002140",
-            "NCIT:C95802",
-            "UMLS:C0948008",
-            "MESH:D000083242",
-            "MEDDRA:10023027"
-          ],
-          "id": "HP:0002140",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Ischemic Stroke",
-            "Ischemic stroke"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:32054610"
-          ]
-        }
-      },
-      "end": {
-        "identity": 593,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Meldonium",
-          "description": "An ammonium betaine that is beta-alaninate in which one of the amino hydrogens is replaced by a trimethylamino group. A clinically used cardioprotective drug that is used for treatment of heart failure, myocardial infarction, arrhythmia, atherosclerosis and diabetes.",
-          "equivalent_curies": [
-            "INCHIKEY:PVBQYTCFVWZSJK-UHFFFAOYSA-N",
-            "UNII:73H7UDN6EC",
-            "DRUGBANK:DB13723",
-            "DrugCentral:3995",
-            "CHEBI:131843",
-            "PUBCHEM.COMPOUND:123868",
-            "KEGG.DRUG:D10504",
-            "NCIT:C66079",
-            "UMLS:C0047115",
-            "CHEMBL.COMPOUND:CHEMBL2104708",
-            "MESH:C050147",
-            "ATC:C01EB22"
-          ],
-          "id": "PUBCHEM.COMPOUND:123868",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Meldonium (INN)",
-            "MELDONIUM",
-            "3-(2,2,2-trimethylhydrazine)propionate",
-            "quaterin",
-            "meldonium",
-            "Meldonium"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:36385923",
-            "PMID:24571165"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318738,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0002140",
-              "name": "Ischemic stroke",
-              "description": "An acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of brain tissue.; Stroke due to BRAIN ISCHEMIA resulting in interruption or reduction of blood flow to a part of the brain. When obstruction is due to a BLOOD CLOT formed within in a cerebral blood vessel it is a thrombotic stroke. When obstruction is formed elsewhere and moved to block a cerebral blood vessel (see CEREBRAL EMBOLISM) it is referred to as embolic stroke. Wake-up stroke refers to ischemic stroke occurring during sleep while cryptogenic stroke refers to ischemic stroke of unknown origin.; Acute ischemic stroke (AIS) is defined by the sudden loss of blood flow to an area of the brain with the resulting loss of neurologic function. It is caused by thrombosis or embolism that occludes a cerebral vessel supplying a specific area of the brain. During a vessel occlusion, there is a core area where damage to the brain is irreversible and an area of penumbra where the brain has lost function owing to decreased blood flow but is not irreversibly injured. [PMID:32054610]; A stroke is a medical emergency. There are two types - ischemic and hemorrhagic. Ischemic stroke is the more common type. It is usually caused by a blood clot that blocks or plugs a blood vessel in the brain. This keeps blood from flowing to the brain. Within minutes, brain cells begin to die. Another cause is stenosis, or narrowing of the artery. This can happen because of atherosclerosis, a disease in which plaque builds up inside your arteries. Transient ischemic attacks (TIAs) occur when the blood supply to the brain is interrupted briefly. Having a TIA can mean you are at risk for having a more serious stroke. Symptoms of stroke are: Sudden numbness or weakness of the face, arm or leg (especially on one side of the body) Sudden confusion, trouble speaking or understanding speech Sudden trouble seeing in one or both eyes Sudden trouble walking, dizziness, loss of balance or coordination Sudden severe headache with no known cause  It is important to treat strokes as quickly as possible. Blood thinners may be used to stop a stroke while it is happening by quickly dissolving the blood clot. Post-stroke rehabilitation can help people overcome disabilities caused by stroke damage. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:422504002",
-                "MEDDRA:10061256",
-                "MEDDRA:10055221",
-                "HP:0002140",
-                "NCIT:C95802",
-                "UMLS:C0948008",
-                "MESH:D000083242",
-                "MEDDRA:10023027"
-              ],
-              "id": "HP:0002140",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Ischemic Stroke",
-                "Ischemic stroke"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:32054610"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13004743,
-            "start": 593,
-            "end": 318738,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1771844': {'publication date': '1991 Jul', 'sentence': 'A study is presented of the clinico-hemodynamic efficacy of mildronate in 38 patients with ischemic stroke.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0047115---SEMMEDDB:treats---None---None---None---UMLS:C0948008---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:123868",
-              "id": "13297277",
-              "object": "HP:0002140",
-              "publications": [
-                "PMID:1771844"
-              ]
-            }
-          },
-          "end": {
-            "identity": 593,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-=======
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
->>>>>>> main
-            ],
-            "properties": {
-              "name": "Meldonium",
-              "description": "An ammonium betaine that is beta-alaninate in which one of the amino hydrogens is replaced by a trimethylamino group. A clinically used cardioprotective drug that is used for treatment of heart failure, myocardial infarction, arrhythmia, atherosclerosis and diabetes.",
-              "equivalent_curies": [
-                "INCHIKEY:PVBQYTCFVWZSJK-UHFFFAOYSA-N",
-                "UNII:73H7UDN6EC",
-                "DRUGBANK:DB13723",
-                "DrugCentral:3995",
-                "CHEBI:131843",
-                "PUBCHEM.COMPOUND:123868",
-                "KEGG.DRUG:D10504",
-                "NCIT:C66079",
-                "UMLS:C0047115",
-                "CHEMBL.COMPOUND:CHEMBL2104708",
-                "MESH:C050147",
-                "ATC:C01EB22"
-              ],
-              "id": "PUBCHEM.COMPOUND:123868",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Meldonium (INN)",
-                "MELDONIUM",
-                "3-(2,2,2-trimethylhydrazine)propionate",
-                "quaterin",
-                "meldonium",
-                "Meldonium"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:36385923",
-                "PMID:24571165"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 603,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Neobiotic",
-          "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C00384",
-            "DrugCentral:4247",
-            "ATC:A07AA01",
-            "ATC:A01AB08",
-            "ATC:B05CA09",
-            "UMLS:C4718970",
-            "NCIT:C683",
-            "ATC:S02AA07",
-            "UNII:I16QD7X297",
-            "UMLS:C4718971",
-            "PUBCHEM.COMPOUND:62403",
-            "PDQ:CDR0000755934",
-            "UMLS:C0027603",
-            "KEGG.DRUG:D08260",
-            "ATC:S01AA03",
-            "UMLS:C4718972",
-            "CAS:1405-10-3",
-            "ATC:J01GB05",
-            "ATC:S03AA01",
-            "CHEMBL.COMPOUND:CHEMBL3989769",
-            "MESH:D009355",
-            "RXNORM:7299",
-            "NDDF:002775",
-            "NCIT:C166677",
-            "ATC:D06AX04",
-            "CHEMBL.COMPOUND:CHEMBL3989533",
-            "DRUGBANK:DB00994",
-            "CHEBI:7507",
-            "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-            "ATC:R02AB01",
-            "CHEMBL.COMPOUND:CHEMBL3989751"
-          ],
-          "id": "PUBCHEM.COMPOUND:62403",
-          "category": "biolink:MolecularMixture",
-          "all_names": [
-            "Vonamycin",
-            "NEOMYCIN",
-            "NEOMYCIN PALMITATE",
-            "mycerin sulfate",
-            "NEOMYCIN SULFATE",
-            "neomycin",
-            "Neomycin",
-            "Fradiomycin",
-            "Neomycin Palmitate",
-            "Kaomycine",
-            "Neomycin (INN)"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:1095304",
-            "PMID:20014752",
-            "PMID:18725450",
-            "PMID:6224608",
-            "PMID:23571415",
-            "PMID:19438282",
-            "PMID:23062825"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17402369,
-            "start": 603,
-            "end": 183319,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25028102': {'publication date': '2015 Apr', 'sentence': 'We tested streptomycin (ST) and neomycin (NEO) as analgesic agents applied in situ in rat paw inflammation caused by formalin or carrageenan administration.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0027603---SEMMEDDB:associated_with---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:62403",
-              "id": "17758516",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:25028102"
-              ]
-            }
-          },
-          "end": {
-            "identity": 603,
-            "labels": [
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-            ],
-            "properties": {
-              "name": "Neobiotic",
-              "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C00384",
-                "DrugCentral:4247",
-                "ATC:A07AA01",
-                "ATC:A01AB08",
-                "ATC:B05CA09",
-                "UMLS:C4718970",
-                "NCIT:C683",
-                "ATC:S02AA07",
-                "UNII:I16QD7X297",
-                "UMLS:C4718971",
-                "PUBCHEM.COMPOUND:62403",
-                "PDQ:CDR0000755934",
-                "UMLS:C0027603",
-                "KEGG.DRUG:D08260",
-                "ATC:S01AA03",
-                "UMLS:C4718972",
-                "CAS:1405-10-3",
-                "ATC:J01GB05",
-                "ATC:S03AA01",
-                "CHEMBL.COMPOUND:CHEMBL3989769",
-                "MESH:D009355",
-                "RXNORM:7299",
-                "NDDF:002775",
-                "NCIT:C166677",
-                "ATC:D06AX04",
-                "CHEMBL.COMPOUND:CHEMBL3989533",
-                "DRUGBANK:DB00994",
-                "CHEBI:7507",
-                "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-                "ATC:R02AB01",
-                "CHEMBL.COMPOUND:CHEMBL3989751"
-              ],
-              "id": "PUBCHEM.COMPOUND:62403",
-              "category": "biolink:MolecularMixture",
-              "all_names": [
-                "Vonamycin",
-                "NEOMYCIN",
-                "NEOMYCIN PALMITATE",
-                "mycerin sulfate",
-                "NEOMYCIN SULFATE",
-                "neomycin",
-                "Neomycin",
-                "Fradiomycin",
-                "Neomycin Palmitate",
-                "Kaomycine",
-                "Neomycin (INN)"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:1095304",
-                "PMID:20014752",
-                "PMID:18725450",
-                "PMID:6224608",
-                "PMID:23571415",
-                "PMID:19438282",
-                "PMID:23062825"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:14125719': {'publication date': '1963 Nov', 'sentence': '[ON THE ACTION OF A NEOMYCIN AND THIOPENICOL PREPARATION IN EXPERIMENTAL BURNS].', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 533531,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043519",
-          "name": "burn",
-          "description": "A traumatic injury involving interruption of tissue cohesiveness that results from exposure to caustic chemicals, extreme heat, extreme cold or excessive radiation.; Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.; A burn is damage to your body's tissues caused by heat, chemicals, electricity, sunlight, or radiation. Scalds from hot liquids and steam, building fires and flammable liquids and gases are the most common causes of burns. Another kind is an inhalation injury, caused by breathing smoke. There are three types of burns:  First-degree burns damage only the outer layer of skin  Second-degree burns damage the outer layer and the layer underneath Third-degree burns damage or destroy the deepest layer of skin and tissues underneath  Burns can cause swelling, blistering, scarring and, in serious cases, shock, and even death. They also can lead to infections because they damage your skin's protective barrier. Treatment for burns depends on the cause of the burn, how deep it is, and how much of the body it covers. Antibiotic creams can prevent or treat infections. For more serious burns, treatment may be needed to clean the wound, replace the skin, and make sure the patient has enough fluids and nutrition. NIH: National Institute of General Medical Sciences; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-          "equivalent_curies": [
-            "MEDDRA:10006799",
-            "MESH:D002056",
-            "MEDDRA:10006634",
-            "SNOMEDCT:125666000",
-            "MEDDRA:10083300",
-            "SNOMEDCT:48333001",
-            "NCIT:C34441",
-            "MEDDRA:10006764",
-            "UMLS:C0006434",
-            "MONDO:0043519"
-          ],
-          "id": "MONDO:0043519",
-          "category": "biolink:Disease",
-          "all_names": [
-            "burn",
-            "Burn injury",
-            "Burn",
-            "Burns"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 603,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Neobiotic",
-          "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C00384",
-            "DrugCentral:4247",
-            "ATC:A07AA01",
-            "ATC:A01AB08",
-            "ATC:B05CA09",
-            "UMLS:C4718970",
-            "NCIT:C683",
-            "ATC:S02AA07",
-            "UNII:I16QD7X297",
-            "UMLS:C4718971",
-            "PUBCHEM.COMPOUND:62403",
-            "PDQ:CDR0000755934",
-            "UMLS:C0027603",
-            "KEGG.DRUG:D08260",
-            "ATC:S01AA03",
-            "UMLS:C4718972",
-            "CAS:1405-10-3",
-            "ATC:J01GB05",
-            "ATC:S03AA01",
-            "CHEMBL.COMPOUND:CHEMBL3989769",
-            "MESH:D009355",
-            "RXNORM:7299",
-            "NDDF:002775",
-            "NCIT:C166677",
-            "ATC:D06AX04",
-            "CHEMBL.COMPOUND:CHEMBL3989533",
-            "DRUGBANK:DB00994",
-            "CHEBI:7507",
-            "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-            "ATC:R02AB01",
-            "CHEMBL.COMPOUND:CHEMBL3989751"
-          ],
-          "id": "PUBCHEM.COMPOUND:62403",
-          "category": "biolink:MolecularMixture",
-          "all_names": [
-            "Vonamycin",
-            "NEOMYCIN",
-            "NEOMYCIN PALMITATE",
-            "mycerin sulfate",
-            "NEOMYCIN SULFATE",
-            "neomycin",
-            "Neomycin",
-            "Fradiomycin",
-            "Neomycin Palmitate",
-            "Kaomycine",
-            "Neomycin (INN)"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:1095304",
-            "PMID:20014752",
-            "PMID:18725450",
-            "PMID:6224608",
-            "PMID:23571415",
-            "PMID:19438282",
-            "PMID:23062825"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 533531,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043519",
-              "name": "burn",
-              "description": "A traumatic injury involving interruption of tissue cohesiveness that results from exposure to caustic chemicals, extreme heat, extreme cold or excessive radiation.; Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.; A burn is damage to your body's tissues caused by heat, chemicals, electricity, sunlight, or radiation. Scalds from hot liquids and steam, building fires and flammable liquids and gases are the most common causes of burns. Another kind is an inhalation injury, caused by breathing smoke. There are three types of burns:  First-degree burns damage only the outer layer of skin  Second-degree burns damage the outer layer and the layer underneath Third-degree burns damage or destroy the deepest layer of skin and tissues underneath  Burns can cause swelling, blistering, scarring and, in serious cases, shock, and even death. They also can lead to infections because they damage your skin's protective barrier. Treatment for burns depends on the cause of the burn, how deep it is, and how much of the body it covers. Antibiotic creams can prevent or treat infections. For more serious burns, treatment may be needed to clean the wound, replace the skin, and make sure the patient has enough fluids and nutrition. NIH: National Institute of General Medical Sciences; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
-              "equivalent_curies": [
-                "MEDDRA:10006799",
-                "MESH:D002056",
-                "MEDDRA:10006634",
-                "SNOMEDCT:125666000",
-                "MEDDRA:10083300",
-                "SNOMEDCT:48333001",
-                "NCIT:C34441",
-                "MEDDRA:10006764",
-                "UMLS:C0006434",
-                "MONDO:0043519"
-              ],
-              "id": "MONDO:0043519",
-              "category": "biolink:Disease",
-              "all_names": [
-                "burn",
-                "Burn injury",
-                "Burn",
-                "Burns"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10460533,
-            "start": 603,
-            "end": 533531,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14125719': {'publication date': '1963 Nov', 'sentence': '[ON THE ACTION OF A NEOMYCIN AND THIOPENICOL PREPARATION IN EXPERIMENTAL BURNS].', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0027603---SEMMEDDB:associated_with---None---None---None---UMLS:C0006434---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:62403",
-              "id": "10690423",
-              "object": "MONDO:0043519",
-              "publications": [
-                "PMID:14125719"
-              ]
-            }
-          },
-          "end": {
-            "identity": 603,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Neobiotic",
-              "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C00384",
-                "DrugCentral:4247",
-                "ATC:A07AA01",
-                "ATC:A01AB08",
-                "ATC:B05CA09",
-                "UMLS:C4718970",
-                "NCIT:C683",
-                "ATC:S02AA07",
-                "UNII:I16QD7X297",
-                "UMLS:C4718971",
-                "PUBCHEM.COMPOUND:62403",
-                "PDQ:CDR0000755934",
-                "UMLS:C0027603",
-                "KEGG.DRUG:D08260",
-                "ATC:S01AA03",
-                "UMLS:C4718972",
-                "CAS:1405-10-3",
-                "ATC:J01GB05",
-                "ATC:S03AA01",
-                "CHEMBL.COMPOUND:CHEMBL3989769",
-                "MESH:D009355",
-                "RXNORM:7299",
-                "NDDF:002775",
-                "NCIT:C166677",
-                "ATC:D06AX04",
-                "CHEMBL.COMPOUND:CHEMBL3989533",
-                "DRUGBANK:DB00994",
-                "CHEBI:7507",
-                "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-                "ATC:R02AB01",
-                "CHEMBL.COMPOUND:CHEMBL3989751"
-              ],
-              "id": "PUBCHEM.COMPOUND:62403",
-              "category": "biolink:MolecularMixture",
-              "all_names": [
-                "Vonamycin",
-                "NEOMYCIN",
-                "NEOMYCIN PALMITATE",
-                "mycerin sulfate",
-                "NEOMYCIN SULFATE",
-                "neomycin",
-                "Neomycin",
-                "Fradiomycin",
-                "Neomycin Palmitate",
-                "Kaomycine",
-                "Neomycin (INN)"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:1095304",
-                "PMID:20014752",
-                "PMID:18725450",
-                "PMID:6224608",
-                "PMID:23571415",
-                "PMID:19438282",
-                "PMID:23062825"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:35770845': {'publication date': '2022 Jun 30', 'sentence': 'Biodegradable polyaspartamide (PASPAM) was grafted with several functional groups to implement diverse roles-octadecylamine (C     18       ) for nano-aggregate formation, dopamine (DOPA) for adhesive function, neomycin (NEO) for inhibition of bacterial infection.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 538307,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-          ]
-        }
-      },
-      "end": {
-        "identity": 603,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Neobiotic",
-          "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C00384",
-            "DrugCentral:4247",
-            "ATC:A07AA01",
-            "ATC:A01AB08",
-            "ATC:B05CA09",
-            "UMLS:C4718970",
-            "NCIT:C683",
-            "ATC:S02AA07",
-            "UNII:I16QD7X297",
-            "UMLS:C4718971",
-            "PUBCHEM.COMPOUND:62403",
-            "PDQ:CDR0000755934",
-            "UMLS:C0027603",
-            "KEGG.DRUG:D08260",
-            "ATC:S01AA03",
-            "UMLS:C4718972",
-            "CAS:1405-10-3",
-            "ATC:J01GB05",
-            "ATC:S03AA01",
-            "CHEMBL.COMPOUND:CHEMBL3989769",
-            "MESH:D009355",
-            "RXNORM:7299",
-            "NDDF:002775",
-            "NCIT:C166677",
-            "ATC:D06AX04",
-            "CHEMBL.COMPOUND:CHEMBL3989533",
-            "DRUGBANK:DB00994",
-            "CHEBI:7507",
-            "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-            "ATC:R02AB01",
-            "CHEMBL.COMPOUND:CHEMBL3989751"
-          ],
-          "id": "PUBCHEM.COMPOUND:62403",
-          "category": "biolink:MolecularMixture",
-          "all_names": [
-            "Vonamycin",
-            "NEOMYCIN",
-            "NEOMYCIN PALMITATE",
-            "mycerin sulfate",
-            "NEOMYCIN SULFATE",
-            "neomycin",
-            "Neomycin",
-            "Fradiomycin",
-            "Neomycin Palmitate",
-            "Kaomycine",
-            "Neomycin (INN)"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:1095304",
-            "PMID:20014752",
-            "PMID:18725450",
-            "PMID:6224608",
-            "PMID:23571415",
-            "PMID:19438282",
-            "PMID:23062825"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538307,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24226674,
-            "start": 603,
-            "end": 538307,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35770845': {'publication date': '2022 Jun 30', 'sentence': 'Biodegradable polyaspartamide (PASPAM) was grafted with several functional groups to implement diverse roles-octadecylamine (C     18       ) for nano-aggregate formation, dopamine (DOPA) for adhesive function, neomycin (NEO) for inhibition of bacterial infection.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0027603---SEMMEDDB:disrupts---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:62403",
-              "id": "24669492",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:35770845"
-              ]
-            }
-          },
-          "end": {
-            "identity": 603,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Neobiotic",
-              "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C00384",
-                "DrugCentral:4247",
-                "ATC:A07AA01",
-                "ATC:A01AB08",
-                "ATC:B05CA09",
-                "UMLS:C4718970",
-                "NCIT:C683",
-                "ATC:S02AA07",
-                "UNII:I16QD7X297",
-                "UMLS:C4718971",
-                "PUBCHEM.COMPOUND:62403",
-                "PDQ:CDR0000755934",
-                "UMLS:C0027603",
-                "KEGG.DRUG:D08260",
-                "ATC:S01AA03",
-                "UMLS:C4718972",
-                "CAS:1405-10-3",
-                "ATC:J01GB05",
-                "ATC:S03AA01",
-                "CHEMBL.COMPOUND:CHEMBL3989769",
-                "MESH:D009355",
-                "RXNORM:7299",
-                "NDDF:002775",
-                "NCIT:C166677",
-                "ATC:D06AX04",
-                "CHEMBL.COMPOUND:CHEMBL3989533",
-                "DRUGBANK:DB00994",
-                "CHEBI:7507",
-                "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-                "ATC:R02AB01",
-                "CHEMBL.COMPOUND:CHEMBL3989751"
-              ],
-              "id": "PUBCHEM.COMPOUND:62403",
-              "category": "biolink:MolecularMixture",
-              "all_names": [
-                "Vonamycin",
-                "NEOMYCIN",
-                "NEOMYCIN PALMITATE",
-                "mycerin sulfate",
-                "NEOMYCIN SULFATE",
-                "neomycin",
-                "Neomycin",
-                "Fradiomycin",
-                "Neomycin Palmitate",
-                "Kaomycine",
-                "Neomycin (INN)"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:1095304",
-                "PMID:20014752",
-                "PMID:18725450",
-                "PMID:6224608",
-                "PMID:23571415",
-                "PMID:19438282",
-                "PMID:23062825"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:7353442': {'publication date': '1980', 'sentence': 'Neomycin and the combination of neomycin and bacitracin in the prevention of bacterial infection in surgery of the colon and/or rectum.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 538307,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-          ]
-        }
-      },
-      "end": {
-        "identity": 603,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Neobiotic",
-          "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C00384",
-            "DrugCentral:4247",
-            "ATC:A07AA01",
-            "ATC:A01AB08",
-            "ATC:B05CA09",
-            "UMLS:C4718970",
-            "NCIT:C683",
-            "ATC:S02AA07",
-            "UNII:I16QD7X297",
-            "UMLS:C4718971",
-            "PUBCHEM.COMPOUND:62403",
-            "PDQ:CDR0000755934",
-            "UMLS:C0027603",
-            "KEGG.DRUG:D08260",
-            "ATC:S01AA03",
-            "UMLS:C4718972",
-            "CAS:1405-10-3",
-            "ATC:J01GB05",
-            "ATC:S03AA01",
-            "CHEMBL.COMPOUND:CHEMBL3989769",
-            "MESH:D009355",
-            "RXNORM:7299",
-            "NDDF:002775",
-            "NCIT:C166677",
-            "ATC:D06AX04",
-            "CHEMBL.COMPOUND:CHEMBL3989533",
-            "DRUGBANK:DB00994",
-            "CHEBI:7507",
-            "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-            "ATC:R02AB01",
-            "CHEMBL.COMPOUND:CHEMBL3989751"
-          ],
-          "id": "PUBCHEM.COMPOUND:62403",
-          "category": "biolink:MolecularMixture",
-          "all_names": [
-            "Vonamycin",
-            "NEOMYCIN",
-            "NEOMYCIN PALMITATE",
-            "mycerin sulfate",
-            "NEOMYCIN SULFATE",
-            "neomycin",
-            "Neomycin",
-            "Fradiomycin",
-            "Neomycin Palmitate",
-            "Kaomycine",
-            "Neomycin (INN)"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:1095304",
-            "PMID:20014752",
-            "PMID:18725450",
-            "PMID:6224608",
-            "PMID:23571415",
-            "PMID:19438282",
-            "PMID:23062825"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538307,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25968342,
-            "start": 603,
-            "end": 538307,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7353442': {'publication date': '1980', 'sentence': 'Neomycin and the combination of neomycin and bacitracin in the prevention of bacterial infection in surgery of the colon and/or rectum.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0027603---SEMMEDDB:prevents---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:62403",
-              "id": "26428369",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:7353442"
-              ]
-            }
-          },
-          "end": {
-            "identity": 603,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Neobiotic",
-              "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C00384",
-                "DrugCentral:4247",
-                "ATC:A07AA01",
-                "ATC:A01AB08",
-                "ATC:B05CA09",
-                "UMLS:C4718970",
-                "NCIT:C683",
-                "ATC:S02AA07",
-                "UNII:I16QD7X297",
-                "UMLS:C4718971",
-                "PUBCHEM.COMPOUND:62403",
-                "PDQ:CDR0000755934",
-                "UMLS:C0027603",
-                "KEGG.DRUG:D08260",
-                "ATC:S01AA03",
-                "UMLS:C4718972",
-                "CAS:1405-10-3",
-                "ATC:J01GB05",
-                "ATC:S03AA01",
-                "CHEMBL.COMPOUND:CHEMBL3989769",
-                "MESH:D009355",
-                "RXNORM:7299",
-                "NDDF:002775",
-                "NCIT:C166677",
-                "ATC:D06AX04",
-                "CHEMBL.COMPOUND:CHEMBL3989533",
-                "DRUGBANK:DB00994",
-                "CHEBI:7507",
-                "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-                "ATC:R02AB01",
-                "CHEMBL.COMPOUND:CHEMBL3989751"
-              ],
-              "id": "PUBCHEM.COMPOUND:62403",
-              "category": "biolink:MolecularMixture",
-              "all_names": [
-                "Vonamycin",
-                "NEOMYCIN",
-                "NEOMYCIN PALMITATE",
-                "mycerin sulfate",
-                "NEOMYCIN SULFATE",
-                "neomycin",
-                "Neomycin",
-                "Fradiomycin",
-                "Neomycin Palmitate",
-                "Kaomycine",
-                "Neomycin (INN)"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:1095304",
-                "PMID:20014752",
-                "PMID:18725450",
-                "PMID:6224608",
-                "PMID:23571415",
-                "PMID:19438282",
-                "PMID:23062825"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:3753344': {'publication date': '1986 May', 'sentence': 'Use of neomycin for treatment of Rhodococcus equi pneumonia in foals.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 603,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Neobiotic",
-          "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C00384",
-            "DrugCentral:4247",
-            "ATC:A07AA01",
-            "ATC:A01AB08",
-            "ATC:B05CA09",
-            "UMLS:C4718970",
-            "NCIT:C683",
-            "ATC:S02AA07",
-            "UNII:I16QD7X297",
-            "UMLS:C4718971",
-            "PUBCHEM.COMPOUND:62403",
-            "PDQ:CDR0000755934",
-            "UMLS:C0027603",
-            "KEGG.DRUG:D08260",
-            "ATC:S01AA03",
-            "UMLS:C4718972",
-            "CAS:1405-10-3",
-            "ATC:J01GB05",
-            "ATC:S03AA01",
-            "CHEMBL.COMPOUND:CHEMBL3989769",
-            "MESH:D009355",
-            "RXNORM:7299",
-            "NDDF:002775",
-            "NCIT:C166677",
-            "ATC:D06AX04",
-            "CHEMBL.COMPOUND:CHEMBL3989533",
-            "DRUGBANK:DB00994",
-            "CHEBI:7507",
-            "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-            "ATC:R02AB01",
-            "CHEMBL.COMPOUND:CHEMBL3989751"
-          ],
-          "id": "PUBCHEM.COMPOUND:62403",
-          "category": "biolink:MolecularMixture",
-          "all_names": [
-            "Vonamycin",
-            "NEOMYCIN",
-            "NEOMYCIN PALMITATE",
-            "mycerin sulfate",
-            "NEOMYCIN SULFATE",
-            "neomycin",
-            "Neomycin",
-            "Fradiomycin",
-            "Neomycin Palmitate",
-            "Kaomycine",
-            "Neomycin (INN)"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:1095304",
-            "PMID:20014752",
-            "PMID:18725450",
-            "PMID:6224608",
-            "PMID:23571415",
-            "PMID:19438282",
-            "PMID:23062825"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25173144,
-            "start": 603,
-            "end": 321523,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3753344': {'publication date': '1986 May', 'sentence': 'Use of neomycin for treatment of Rhodococcus equi pneumonia in foals.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0027603---SEMMEDDB:treats---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:62403",
-              "id": "25624167",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:3753344"
-              ]
-            }
-          },
-          "end": {
-            "identity": 603,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Neobiotic",
-              "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C00384",
-                "DrugCentral:4247",
-                "ATC:A07AA01",
-                "ATC:A01AB08",
-                "ATC:B05CA09",
-                "UMLS:C4718970",
-                "NCIT:C683",
-                "ATC:S02AA07",
-                "UNII:I16QD7X297",
-                "UMLS:C4718971",
-                "PUBCHEM.COMPOUND:62403",
-                "PDQ:CDR0000755934",
-                "UMLS:C0027603",
-                "KEGG.DRUG:D08260",
-                "ATC:S01AA03",
-                "UMLS:C4718972",
-                "CAS:1405-10-3",
-                "ATC:J01GB05",
-                "ATC:S03AA01",
-                "CHEMBL.COMPOUND:CHEMBL3989769",
-                "MESH:D009355",
-                "RXNORM:7299",
-                "NDDF:002775",
-                "NCIT:C166677",
-                "ATC:D06AX04",
-                "CHEMBL.COMPOUND:CHEMBL3989533",
-                "DRUGBANK:DB00994",
-                "CHEBI:7507",
-                "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-                "ATC:R02AB01",
-                "CHEMBL.COMPOUND:CHEMBL3989751"
-              ],
-              "id": "PUBCHEM.COMPOUND:62403",
-              "category": "biolink:MolecularMixture",
-              "all_names": [
-                "Vonamycin",
-                "NEOMYCIN",
-                "NEOMYCIN PALMITATE",
-                "mycerin sulfate",
-                "NEOMYCIN SULFATE",
-                "neomycin",
-                "Neomycin",
-                "Fradiomycin",
-                "Neomycin Palmitate",
-                "Kaomycine",
-                "Neomycin (INN)"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:1095304",
-                "PMID:20014752",
-                "PMID:18725450",
-                "PMID:6224608",
-                "PMID:23571415",
-                "PMID:19438282",
-                "PMID:23062825"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:14888464': {'publication date': '1952 Jan 26', 'sentence': 'Osteomyelitis of the cervical vertebras as a complication of urinary tract disease; Proteus bacteremia treated with neomycin.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 315382,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-          "name": "bacterial infectious disease with sepsis",
-          "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C102993",
-            "ICD9:995.91",
-            "MONDO:0005229",
-            "MEDDRA:10060562",
-            "MEDDRA:10003998",
-            "MEDDRA:10003997",
-            "MEDDRA:10045641",
-            "ICD9:790.7",
-            "MEDDRA:10045642",
-            "HP:0031864",
-            "SNOMEDCT:5758002",
-            "DOID:0040085",
-            "MESH:D016470",
-            "UMLS:C0004610",
-            "MEDDRA:10003999"
-          ],
-          "id": "MONDO:0005229",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacteremia",
-            "bacterial infectious disease with sepsis",
-            "bacterial sepsis",
-            "Sepsis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:20421654"
-          ]
-        }
-      },
-      "end": {
-        "identity": 603,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Neobiotic",
-          "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C00384",
-            "DrugCentral:4247",
-            "ATC:A07AA01",
-            "ATC:A01AB08",
-            "ATC:B05CA09",
-            "UMLS:C4718970",
-            "NCIT:C683",
-            "ATC:S02AA07",
-            "UNII:I16QD7X297",
-            "UMLS:C4718971",
-            "PUBCHEM.COMPOUND:62403",
-            "PDQ:CDR0000755934",
-            "UMLS:C0027603",
-            "KEGG.DRUG:D08260",
-            "ATC:S01AA03",
-            "UMLS:C4718972",
-            "CAS:1405-10-3",
-            "ATC:J01GB05",
-            "ATC:S03AA01",
-            "CHEMBL.COMPOUND:CHEMBL3989769",
-            "MESH:D009355",
-            "RXNORM:7299",
-            "NDDF:002775",
-            "NCIT:C166677",
-            "ATC:D06AX04",
-            "CHEMBL.COMPOUND:CHEMBL3989533",
-            "DRUGBANK:DB00994",
-            "CHEBI:7507",
-            "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-            "ATC:R02AB01",
-            "CHEMBL.COMPOUND:CHEMBL3989751"
-          ],
-          "id": "PUBCHEM.COMPOUND:62403",
-          "category": "biolink:MolecularMixture",
-          "all_names": [
-            "Vonamycin",
-            "NEOMYCIN",
-            "NEOMYCIN PALMITATE",
-            "mycerin sulfate",
-            "NEOMYCIN SULFATE",
-            "neomycin",
-            "Neomycin",
-            "Fradiomycin",
-            "Neomycin Palmitate",
-            "Kaomycine",
-            "Neomycin (INN)"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:1095304",
-            "PMID:20014752",
-            "PMID:18725450",
-            "PMID:6224608",
-            "PMID:23571415",
-            "PMID:19438282",
-            "PMID:23062825"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315382,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-              "name": "bacterial infectious disease with sepsis",
-              "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C102993",
-                "ICD9:995.91",
-                "MONDO:0005229",
-                "MEDDRA:10060562",
-                "MEDDRA:10003998",
-                "MEDDRA:10003997",
-                "MEDDRA:10045641",
-                "ICD9:790.7",
-                "MEDDRA:10045642",
-                "HP:0031864",
-                "SNOMEDCT:5758002",
-                "DOID:0040085",
-                "MESH:D016470",
-                "UMLS:C0004610",
-                "MEDDRA:10003999"
-              ],
-              "id": "MONDO:0005229",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacteremia",
-                "bacterial infectious disease with sepsis",
-                "bacterial sepsis",
-                "Sepsis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:20421654"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10785992,
-            "start": 603,
-            "end": 315382,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14888464': {'publication date': '1952 Jan 26', 'sentence': 'Osteomyelitis of the cervical vertebras as a complication of urinary tract disease; Proteus bacteremia treated with neomycin.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0027603---SEMMEDDB:treats---None---None---None---UMLS:C0004610---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:62403",
-              "id": "11022701",
-              "object": "MONDO:0005229",
-              "publications": [
-                "PMID:14888464"
-              ]
-            }
-          },
-          "end": {
-            "identity": 603,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Neobiotic",
-              "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C00384",
-                "DrugCentral:4247",
-                "ATC:A07AA01",
-                "ATC:A01AB08",
-                "ATC:B05CA09",
-                "UMLS:C4718970",
-                "NCIT:C683",
-                "ATC:S02AA07",
-                "UNII:I16QD7X297",
-                "UMLS:C4718971",
-                "PUBCHEM.COMPOUND:62403",
-                "PDQ:CDR0000755934",
-                "UMLS:C0027603",
-                "KEGG.DRUG:D08260",
-                "ATC:S01AA03",
-                "UMLS:C4718972",
-                "CAS:1405-10-3",
-                "ATC:J01GB05",
-                "ATC:S03AA01",
-                "CHEMBL.COMPOUND:CHEMBL3989769",
-                "MESH:D009355",
-                "RXNORM:7299",
-                "NDDF:002775",
-                "NCIT:C166677",
-                "ATC:D06AX04",
-                "CHEMBL.COMPOUND:CHEMBL3989533",
-                "DRUGBANK:DB00994",
-                "CHEBI:7507",
-                "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-                "ATC:R02AB01",
-                "CHEMBL.COMPOUND:CHEMBL3989751"
-              ],
-              "id": "PUBCHEM.COMPOUND:62403",
-              "category": "biolink:MolecularMixture",
-              "all_names": [
-                "Vonamycin",
-                "NEOMYCIN",
-                "NEOMYCIN PALMITATE",
-                "mycerin sulfate",
-                "NEOMYCIN SULFATE",
-                "neomycin",
-                "Neomycin",
-                "Fradiomycin",
-                "Neomycin Palmitate",
-                "Kaomycine",
-                "Neomycin (INN)"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:1095304",
-                "PMID:20014752",
-                "PMID:18725450",
-                "PMID:6224608",
-                "PMID:23571415",
-                "PMID:19438282",
-                "PMID:23062825"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:29624892': {'publication date': '2018 May', 'sentence': 'Therefore, we investigated the effect of long-term exposure of an antibiotic cocktail composed of Vancomycin, Neomycin, and Streptomycin, on tumor development and progression in the ApcMin/+ mouse, an established genetic model for familial adenomatous polyposis.', 'subject score': 1000, 'object score': 888}, 'PMID:8402732': {'publication date': '1993 Oct', 'sentence': 'DLN from mice bearing either unmodified tumor or tumor transduced with cDNA encoding neomycin resistance (NeoR) or IFN gamma, were used to treat recipients harboring 3-day pulmonary metastases induced by the parental, unmodified tumor.', 'subject score': 597, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 603,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Neobiotic",
-          "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C00384",
-            "DrugCentral:4247",
-            "ATC:A07AA01",
-            "ATC:A01AB08",
-            "ATC:B05CA09",
-            "UMLS:C4718970",
-            "NCIT:C683",
-            "ATC:S02AA07",
-            "UNII:I16QD7X297",
-            "UMLS:C4718971",
-            "PUBCHEM.COMPOUND:62403",
-            "PDQ:CDR0000755934",
-            "UMLS:C0027603",
-            "KEGG.DRUG:D08260",
-            "ATC:S01AA03",
-            "UMLS:C4718972",
-            "CAS:1405-10-3",
-            "ATC:J01GB05",
-            "ATC:S03AA01",
-            "CHEMBL.COMPOUND:CHEMBL3989769",
-            "MESH:D009355",
-            "RXNORM:7299",
-            "NDDF:002775",
-            "NCIT:C166677",
-            "ATC:D06AX04",
-            "CHEMBL.COMPOUND:CHEMBL3989533",
-            "DRUGBANK:DB00994",
-            "CHEBI:7507",
-            "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-            "ATC:R02AB01",
-            "CHEMBL.COMPOUND:CHEMBL3989751"
-          ],
-          "id": "PUBCHEM.COMPOUND:62403",
-          "category": "biolink:MolecularMixture",
-          "all_names": [
-            "Vonamycin",
-            "NEOMYCIN",
-            "NEOMYCIN PALMITATE",
-            "mycerin sulfate",
-            "NEOMYCIN SULFATE",
-            "neomycin",
-            "Neomycin",
-            "Fradiomycin",
-            "Neomycin Palmitate",
-            "Kaomycine",
-            "Neomycin (INN)"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:1095304",
-            "PMID:20014752",
-            "PMID:18725450",
-            "PMID:6224608",
-            "PMID:23571415",
-            "PMID:19438282",
-            "PMID:23062825"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19868767,
-            "start": 603,
-            "end": 319673,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29624892': {'publication date': '2018 May', 'sentence': 'Therefore, we investigated the effect of long-term exposure of an antibiotic cocktail composed of Vancomycin, Neomycin, and Streptomycin, on tumor development and progression in the ApcMin/+ mouse, an established genetic model for familial adenomatous polyposis.', 'subject score': 1000, 'object score': 888}, 'PMID:8402732': {'publication date': '1993 Oct', 'sentence': 'DLN from mice bearing either unmodified tumor or tumor transduced with cDNA encoding neomycin resistance (NeoR) or IFN gamma, were used to treat recipients harboring 3-day pulmonary metastases induced by the parental, unmodified tumor.', 'subject score': 597, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0027603---SEMMEDDB:affects---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:62403",
-              "id": "20263460",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:29624892",
-                "PMID:8402732"
-              ]
-            }
-          },
-          "end": {
-            "identity": 603,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Neobiotic",
-              "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C00384",
-                "DrugCentral:4247",
-                "ATC:A07AA01",
-                "ATC:A01AB08",
-                "ATC:B05CA09",
-                "UMLS:C4718970",
-                "NCIT:C683",
-                "ATC:S02AA07",
-                "UNII:I16QD7X297",
-                "UMLS:C4718971",
-                "PUBCHEM.COMPOUND:62403",
-                "PDQ:CDR0000755934",
-                "UMLS:C0027603",
-                "KEGG.DRUG:D08260",
-                "ATC:S01AA03",
-                "UMLS:C4718972",
-                "CAS:1405-10-3",
-                "ATC:J01GB05",
-                "ATC:S03AA01",
-                "CHEMBL.COMPOUND:CHEMBL3989769",
-                "MESH:D009355",
-                "RXNORM:7299",
-                "NDDF:002775",
-                "NCIT:C166677",
-                "ATC:D06AX04",
-                "CHEMBL.COMPOUND:CHEMBL3989533",
-                "DRUGBANK:DB00994",
-                "CHEBI:7507",
-                "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-                "ATC:R02AB01",
-                "CHEMBL.COMPOUND:CHEMBL3989751"
-              ],
-              "id": "PUBCHEM.COMPOUND:62403",
-              "category": "biolink:MolecularMixture",
-              "all_names": [
-                "Vonamycin",
-                "NEOMYCIN",
-                "NEOMYCIN PALMITATE",
-                "mycerin sulfate",
-                "NEOMYCIN SULFATE",
-                "neomycin",
-                "Neomycin",
-                "Fradiomycin",
-                "Neomycin Palmitate",
-                "Kaomycine",
-                "Neomycin (INN)"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:1095304",
-                "PMID:20014752",
-                "PMID:18725450",
-                "PMID:6224608",
-                "PMID:23571415",
-                "PMID:19438282",
-                "PMID:23062825"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 183319,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 603,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Neobiotic",
-          "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C00384",
-            "DrugCentral:4247",
-            "ATC:A07AA01",
-            "ATC:A01AB08",
-            "ATC:B05CA09",
-            "UMLS:C4718970",
-            "NCIT:C683",
-            "ATC:S02AA07",
-            "UNII:I16QD7X297",
-            "UMLS:C4718971",
-            "PUBCHEM.COMPOUND:62403",
-            "PDQ:CDR0000755934",
-            "UMLS:C0027603",
-            "KEGG.DRUG:D08260",
-            "ATC:S01AA03",
-            "UMLS:C4718972",
-            "CAS:1405-10-3",
-            "ATC:J01GB05",
-            "ATC:S03AA01",
-            "CHEMBL.COMPOUND:CHEMBL3989769",
-            "MESH:D009355",
-            "RXNORM:7299",
-            "NDDF:002775",
-            "NCIT:C166677",
-            "ATC:D06AX04",
-            "CHEMBL.COMPOUND:CHEMBL3989533",
-            "DRUGBANK:DB00994",
-            "CHEBI:7507",
-            "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-            "ATC:R02AB01",
-            "CHEMBL.COMPOUND:CHEMBL3989751"
-          ],
-          "id": "PUBCHEM.COMPOUND:62403",
-          "category": "biolink:MolecularMixture",
-          "all_names": [
-            "Vonamycin",
-            "NEOMYCIN",
-            "NEOMYCIN PALMITATE",
-            "mycerin sulfate",
-            "NEOMYCIN SULFATE",
-            "neomycin",
-            "Neomycin",
-            "Fradiomycin",
-            "Neomycin Palmitate",
-            "Kaomycine",
-            "Neomycin (INN)"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:1095304",
-            "PMID:20014752",
-            "PMID:18725450",
-            "PMID:6224608",
-            "PMID:23571415",
-            "PMID:19438282",
-            "PMID:23062825"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19357323,
-            "start": 603,
-            "end": 183319,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28665034': {'publication date': '2017 08', 'sentence': 'Ultrahigh doses of gentamicin and clinically relevant doses of neomycin affect inflammation and angiogenesis in in vivo and in vitro models.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0027603---SEMMEDDB:affects---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:62403",
-              "id": "19744068",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:28665034"
-              ]
-            }
-          },
-          "end": {
-            "identity": 603,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Neobiotic",
-              "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C00384",
-                "DrugCentral:4247",
-                "ATC:A07AA01",
-                "ATC:A01AB08",
-                "ATC:B05CA09",
-                "UMLS:C4718970",
-                "NCIT:C683",
-                "ATC:S02AA07",
-                "UNII:I16QD7X297",
-                "UMLS:C4718971",
-                "PUBCHEM.COMPOUND:62403",
-                "PDQ:CDR0000755934",
-                "UMLS:C0027603",
-                "KEGG.DRUG:D08260",
-                "ATC:S01AA03",
-                "UMLS:C4718972",
-                "CAS:1405-10-3",
-                "ATC:J01GB05",
-                "ATC:S03AA01",
-                "CHEMBL.COMPOUND:CHEMBL3989769",
-                "MESH:D009355",
-                "RXNORM:7299",
-                "NDDF:002775",
-                "NCIT:C166677",
-                "ATC:D06AX04",
-                "CHEMBL.COMPOUND:CHEMBL3989533",
-                "DRUGBANK:DB00994",
-                "CHEBI:7507",
-                "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-                "ATC:R02AB01",
-                "CHEMBL.COMPOUND:CHEMBL3989751"
-              ],
-              "id": "PUBCHEM.COMPOUND:62403",
-              "category": "biolink:MolecularMixture",
-              "all_names": [
-                "Vonamycin",
-                "NEOMYCIN",
-                "NEOMYCIN PALMITATE",
-                "mycerin sulfate",
-                "NEOMYCIN SULFATE",
-                "neomycin",
-                "Neomycin",
-                "Fradiomycin",
-                "Neomycin Palmitate",
-                "Kaomycine",
-                "Neomycin (INN)"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:1095304",
-                "PMID:20014752",
-                "PMID:18725450",
-                "PMID:6224608",
-                "PMID:23571415",
-                "PMID:19438282",
-                "PMID:23062825"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 603,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Neobiotic",
-          "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C00384",
-            "DrugCentral:4247",
-            "ATC:A07AA01",
-            "ATC:A01AB08",
-            "ATC:B05CA09",
-            "UMLS:C4718970",
-            "NCIT:C683",
-            "ATC:S02AA07",
-            "UNII:I16QD7X297",
-            "UMLS:C4718971",
-            "PUBCHEM.COMPOUND:62403",
-            "PDQ:CDR0000755934",
-            "UMLS:C0027603",
-            "KEGG.DRUG:D08260",
-            "ATC:S01AA03",
-            "UMLS:C4718972",
-            "CAS:1405-10-3",
-            "ATC:J01GB05",
-            "ATC:S03AA01",
-            "CHEMBL.COMPOUND:CHEMBL3989769",
-            "MESH:D009355",
-            "RXNORM:7299",
-            "NDDF:002775",
-            "NCIT:C166677",
-            "ATC:D06AX04",
-            "CHEMBL.COMPOUND:CHEMBL3989533",
-            "DRUGBANK:DB00994",
-            "CHEBI:7507",
-            "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-            "ATC:R02AB01",
-            "CHEMBL.COMPOUND:CHEMBL3989751"
-          ],
-          "id": "PUBCHEM.COMPOUND:62403",
-          "category": "biolink:MolecularMixture",
-          "all_names": [
-            "Vonamycin",
-            "NEOMYCIN",
-            "NEOMYCIN PALMITATE",
-            "mycerin sulfate",
-            "NEOMYCIN SULFATE",
-            "neomycin",
-            "Neomycin",
-            "Fradiomycin",
-            "Neomycin Palmitate",
-            "Kaomycine",
-            "Neomycin (INN)"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:1095304",
-            "PMID:20014752",
-            "PMID:18725450",
-            "PMID:6224608",
-            "PMID:23571415",
-            "PMID:19438282",
-            "PMID:23062825"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25173144,
-            "start": 603,
-            "end": 321523,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3753344': {'publication date': '1986 May', 'sentence': 'Use of neomycin for treatment of Rhodococcus equi pneumonia in foals.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0027603---SEMMEDDB:treats---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:62403",
-              "id": "25624167",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:3753344"
-              ]
-            }
-          },
-          "end": {
-            "identity": 603,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Neobiotic",
-              "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C00384",
-                "DrugCentral:4247",
-                "ATC:A07AA01",
-                "ATC:A01AB08",
-                "ATC:B05CA09",
-                "UMLS:C4718970",
-                "NCIT:C683",
-                "ATC:S02AA07",
-                "UNII:I16QD7X297",
-                "UMLS:C4718971",
-                "PUBCHEM.COMPOUND:62403",
-                "PDQ:CDR0000755934",
-                "UMLS:C0027603",
-                "KEGG.DRUG:D08260",
-                "ATC:S01AA03",
-                "UMLS:C4718972",
-                "CAS:1405-10-3",
-                "ATC:J01GB05",
-                "ATC:S03AA01",
-                "CHEMBL.COMPOUND:CHEMBL3989769",
-                "MESH:D009355",
-                "RXNORM:7299",
-                "NDDF:002775",
-                "NCIT:C166677",
-                "ATC:D06AX04",
-                "CHEMBL.COMPOUND:CHEMBL3989533",
-                "DRUGBANK:DB00994",
-                "CHEBI:7507",
-                "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-                "ATC:R02AB01",
-                "CHEMBL.COMPOUND:CHEMBL3989751"
-              ],
-              "id": "PUBCHEM.COMPOUND:62403",
-              "category": "biolink:MolecularMixture",
-              "all_names": [
-                "Vonamycin",
-                "NEOMYCIN",
-                "NEOMYCIN PALMITATE",
-                "mycerin sulfate",
-                "NEOMYCIN SULFATE",
-                "neomycin",
-                "Neomycin",
-                "Fradiomycin",
-                "Neomycin Palmitate",
-                "Kaomycine",
-                "Neomycin (INN)"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:1095304",
-                "PMID:20014752",
-                "PMID:18725450",
-                "PMID:6224608",
-                "PMID:23571415",
-                "PMID:19438282",
-                "PMID:23062825"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 315382,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-          "name": "bacterial infectious disease with sepsis",
-          "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C102993",
-            "ICD9:995.91",
-            "MONDO:0005229",
-            "MEDDRA:10060562",
-            "MEDDRA:10003998",
-            "MEDDRA:10003997",
-            "MEDDRA:10045641",
-            "ICD9:790.7",
-            "MEDDRA:10045642",
-            "HP:0031864",
-            "SNOMEDCT:5758002",
-            "DOID:0040085",
-            "MESH:D016470",
-            "UMLS:C0004610",
-            "MEDDRA:10003999"
-          ],
-          "id": "MONDO:0005229",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacteremia",
-            "bacterial infectious disease with sepsis",
-            "bacterial sepsis",
-            "Sepsis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:20421654"
-          ]
-        }
-      },
-      "end": {
-        "identity": 603,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Neobiotic",
-          "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C00384",
-            "DrugCentral:4247",
-            "ATC:A07AA01",
-            "ATC:A01AB08",
-            "ATC:B05CA09",
-            "UMLS:C4718970",
-            "NCIT:C683",
-            "ATC:S02AA07",
-            "UNII:I16QD7X297",
-            "UMLS:C4718971",
-            "PUBCHEM.COMPOUND:62403",
-            "PDQ:CDR0000755934",
-            "UMLS:C0027603",
-            "KEGG.DRUG:D08260",
-            "ATC:S01AA03",
-            "UMLS:C4718972",
-            "CAS:1405-10-3",
-            "ATC:J01GB05",
-            "ATC:S03AA01",
-            "CHEMBL.COMPOUND:CHEMBL3989769",
-            "MESH:D009355",
-            "RXNORM:7299",
-            "NDDF:002775",
-            "NCIT:C166677",
-            "ATC:D06AX04",
-            "CHEMBL.COMPOUND:CHEMBL3989533",
-            "DRUGBANK:DB00994",
-            "CHEBI:7507",
-            "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-            "ATC:R02AB01",
-            "CHEMBL.COMPOUND:CHEMBL3989751"
-          ],
-          "id": "PUBCHEM.COMPOUND:62403",
-          "category": "biolink:MolecularMixture",
-          "all_names": [
-            "Vonamycin",
-            "NEOMYCIN",
-            "NEOMYCIN PALMITATE",
-            "mycerin sulfate",
-            "NEOMYCIN SULFATE",
-            "neomycin",
-            "Neomycin",
-            "Fradiomycin",
-            "Neomycin Palmitate",
-            "Kaomycine",
-            "Neomycin (INN)"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:1095304",
-            "PMID:20014752",
-            "PMID:18725450",
-            "PMID:6224608",
-            "PMID:23571415",
-            "PMID:19438282",
-            "PMID:23062825"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315382,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-              "name": "bacterial infectious disease with sepsis",
-              "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C102993",
-                "ICD9:995.91",
-                "MONDO:0005229",
-                "MEDDRA:10060562",
-                "MEDDRA:10003998",
-                "MEDDRA:10003997",
-                "MEDDRA:10045641",
-                "ICD9:790.7",
-                "MEDDRA:10045642",
-                "HP:0031864",
-                "SNOMEDCT:5758002",
-                "DOID:0040085",
-                "MESH:D016470",
-                "UMLS:C0004610",
-                "MEDDRA:10003999"
-              ],
-              "id": "MONDO:0005229",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacteremia",
-                "bacterial infectious disease with sepsis",
-                "bacterial sepsis",
-                "Sepsis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:20421654"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10785992,
-            "start": 603,
-            "end": 315382,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14888464': {'publication date': '1952 Jan 26', 'sentence': 'Osteomyelitis of the cervical vertebras as a complication of urinary tract disease; Proteus bacteremia treated with neomycin.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0027603---SEMMEDDB:treats---None---None---None---UMLS:C0004610---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:62403",
-              "id": "11022701",
-              "object": "MONDO:0005229",
-              "publications": [
-                "PMID:14888464"
-              ]
-            }
-          },
-          "end": {
-            "identity": 603,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Neobiotic",
-              "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C00384",
-                "DrugCentral:4247",
-                "ATC:A07AA01",
-                "ATC:A01AB08",
-                "ATC:B05CA09",
-                "UMLS:C4718970",
-                "NCIT:C683",
-                "ATC:S02AA07",
-                "UNII:I16QD7X297",
-                "UMLS:C4718971",
-                "PUBCHEM.COMPOUND:62403",
-                "PDQ:CDR0000755934",
-                "UMLS:C0027603",
-                "KEGG.DRUG:D08260",
-                "ATC:S01AA03",
-                "UMLS:C4718972",
-                "CAS:1405-10-3",
-                "ATC:J01GB05",
-                "ATC:S03AA01",
-                "CHEMBL.COMPOUND:CHEMBL3989769",
-                "MESH:D009355",
-                "RXNORM:7299",
-                "NDDF:002775",
-                "NCIT:C166677",
-                "ATC:D06AX04",
-                "CHEMBL.COMPOUND:CHEMBL3989533",
-                "DRUGBANK:DB00994",
-                "CHEBI:7507",
-                "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-                "ATC:R02AB01",
-                "CHEMBL.COMPOUND:CHEMBL3989751"
-              ],
-              "id": "PUBCHEM.COMPOUND:62403",
-              "category": "biolink:MolecularMixture",
-              "all_names": [
-                "Vonamycin",
-                "NEOMYCIN",
-                "NEOMYCIN PALMITATE",
-                "mycerin sulfate",
-                "NEOMYCIN SULFATE",
-                "neomycin",
-                "Neomycin",
-                "Fradiomycin",
-                "Neomycin Palmitate",
-                "Kaomycine",
-                "Neomycin (INN)"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:1095304",
-                "PMID:20014752",
-                "PMID:18725450",
-                "PMID:6224608",
-                "PMID:23571415",
-                "PMID:19438282",
-                "PMID:23062825"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 538307,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-          ]
-        }
-      },
-      "end": {
-        "identity": 603,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Neobiotic",
-          "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C00384",
-            "DrugCentral:4247",
-            "ATC:A07AA01",
-            "ATC:A01AB08",
-            "ATC:B05CA09",
-            "UMLS:C4718970",
-            "NCIT:C683",
-            "ATC:S02AA07",
-            "UNII:I16QD7X297",
-            "UMLS:C4718971",
-            "PUBCHEM.COMPOUND:62403",
-            "PDQ:CDR0000755934",
-            "UMLS:C0027603",
-            "KEGG.DRUG:D08260",
-            "ATC:S01AA03",
-            "UMLS:C4718972",
-            "CAS:1405-10-3",
-            "ATC:J01GB05",
-            "ATC:S03AA01",
-            "CHEMBL.COMPOUND:CHEMBL3989769",
-            "MESH:D009355",
-            "RXNORM:7299",
-            "NDDF:002775",
-            "NCIT:C166677",
-            "ATC:D06AX04",
-            "CHEMBL.COMPOUND:CHEMBL3989533",
-            "DRUGBANK:DB00994",
-            "CHEBI:7507",
-            "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-            "ATC:R02AB01",
-            "CHEMBL.COMPOUND:CHEMBL3989751"
-          ],
-          "id": "PUBCHEM.COMPOUND:62403",
-          "category": "biolink:MolecularMixture",
-          "all_names": [
-            "Vonamycin",
-            "NEOMYCIN",
-            "NEOMYCIN PALMITATE",
-            "mycerin sulfate",
-            "NEOMYCIN SULFATE",
-            "neomycin",
-            "Neomycin",
-            "Fradiomycin",
-            "Neomycin Palmitate",
-            "Kaomycine",
-            "Neomycin (INN)"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:1095304",
-            "PMID:20014752",
-            "PMID:18725450",
-            "PMID:6224608",
-            "PMID:23571415",
-            "PMID:19438282",
-            "PMID:23062825"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538307,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24226674,
-            "start": 603,
-            "end": 538307,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35770845': {'publication date': '2022 Jun 30', 'sentence': 'Biodegradable polyaspartamide (PASPAM) was grafted with several functional groups to implement diverse roles-octadecylamine (C     18       ) for nano-aggregate formation, dopamine (DOPA) for adhesive function, neomycin (NEO) for inhibition of bacterial infection.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0027603---SEMMEDDB:disrupts---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:62403",
-              "id": "24669492",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:35770845"
-              ]
-            }
-          },
-          "end": {
-            "identity": 603,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Neobiotic",
-              "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C00384",
-                "DrugCentral:4247",
-                "ATC:A07AA01",
-                "ATC:A01AB08",
-                "ATC:B05CA09",
-                "UMLS:C4718970",
-                "NCIT:C683",
-                "ATC:S02AA07",
-                "UNII:I16QD7X297",
-                "UMLS:C4718971",
-                "PUBCHEM.COMPOUND:62403",
-                "PDQ:CDR0000755934",
-                "UMLS:C0027603",
-                "KEGG.DRUG:D08260",
-                "ATC:S01AA03",
-                "UMLS:C4718972",
-                "CAS:1405-10-3",
-                "ATC:J01GB05",
-                "ATC:S03AA01",
-                "CHEMBL.COMPOUND:CHEMBL3989769",
-                "MESH:D009355",
-                "RXNORM:7299",
-                "NDDF:002775",
-                "NCIT:C166677",
-                "ATC:D06AX04",
-                "CHEMBL.COMPOUND:CHEMBL3989533",
-                "DRUGBANK:DB00994",
-                "CHEBI:7507",
-                "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-                "ATC:R02AB01",
-                "CHEMBL.COMPOUND:CHEMBL3989751"
-              ],
-              "id": "PUBCHEM.COMPOUND:62403",
-              "category": "biolink:MolecularMixture",
-              "all_names": [
-                "Vonamycin",
-                "NEOMYCIN",
-                "NEOMYCIN PALMITATE",
-                "mycerin sulfate",
-                "NEOMYCIN SULFATE",
-                "neomycin",
-                "Neomycin",
-                "Fradiomycin",
-                "Neomycin Palmitate",
-                "Kaomycine",
-                "Neomycin (INN)"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:1095304",
-                "PMID:20014752",
-                "PMID:18725450",
-                "PMID:6224608",
-                "PMID:23571415",
-                "PMID:19438282",
-                "PMID:23062825"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:23986578': {'publication date': '2013 Nov', 'sentence': \"Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma tumor formation in NOD/SCID mice is inhibited by neomycin and neamine blocking angiogenin's nuclear translocation.\", 'subject score': 1000, 'object score': 835}, 'PMID:5684861': {'publication date': '1968 Oct 19', 'sentence': 'Effect of neomycin on an inhibitor of spontaneous tumors in mice.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 603,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Neobiotic",
-          "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C00384",
-            "DrugCentral:4247",
-            "ATC:A07AA01",
-            "ATC:A01AB08",
-            "ATC:B05CA09",
-            "UMLS:C4718970",
-            "NCIT:C683",
-            "ATC:S02AA07",
-            "UNII:I16QD7X297",
-            "UMLS:C4718971",
-            "PUBCHEM.COMPOUND:62403",
-            "PDQ:CDR0000755934",
-            "UMLS:C0027603",
-            "KEGG.DRUG:D08260",
-            "ATC:S01AA03",
-            "UMLS:C4718972",
-            "CAS:1405-10-3",
-            "ATC:J01GB05",
-            "ATC:S03AA01",
-            "CHEMBL.COMPOUND:CHEMBL3989769",
-            "MESH:D009355",
-            "RXNORM:7299",
-            "NDDF:002775",
-            "NCIT:C166677",
-            "ATC:D06AX04",
-            "CHEMBL.COMPOUND:CHEMBL3989533",
-            "DRUGBANK:DB00994",
-            "CHEBI:7507",
-            "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-            "ATC:R02AB01",
-            "CHEMBL.COMPOUND:CHEMBL3989751"
-          ],
-          "id": "PUBCHEM.COMPOUND:62403",
-          "category": "biolink:MolecularMixture",
-          "all_names": [
-            "Vonamycin",
-            "NEOMYCIN",
-            "NEOMYCIN PALMITATE",
-            "mycerin sulfate",
-            "NEOMYCIN SULFATE",
-            "neomycin",
-            "Neomycin",
-            "Fradiomycin",
-            "Neomycin Palmitate",
-            "Kaomycine",
-            "Neomycin (INN)"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:1095304",
-            "PMID:20014752",
-            "PMID:18725450",
-            "PMID:6224608",
-            "PMID:23571415",
-            "PMID:19438282",
-            "PMID:23062825"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16773378,
-            "start": 603,
-            "end": 319673,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23986578': {'publication date': '2013 Nov', 'sentence': \"Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma tumor formation in NOD/SCID mice is inhibited by neomycin and neamine blocking angiogenin's nuclear translocation.\", 'subject score': 1000, 'object score': 835}, 'PMID:5684861': {'publication date': '1968 Oct 19', 'sentence': 'Effect of neomycin on an inhibitor of spontaneous tumors in mice.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0027603---SEMMEDDB:disrupts---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:62403",
-              "id": "17119153",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:23986578",
-                "PMID:5684861"
-              ]
-            }
-          },
-          "end": {
-            "identity": 603,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Neobiotic",
-              "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C00384",
-                "DrugCentral:4247",
-                "ATC:A07AA01",
-                "ATC:A01AB08",
-                "ATC:B05CA09",
-                "UMLS:C4718970",
-                "NCIT:C683",
-                "ATC:S02AA07",
-                "UNII:I16QD7X297",
-                "UMLS:C4718971",
-                "PUBCHEM.COMPOUND:62403",
-                "PDQ:CDR0000755934",
-                "UMLS:C0027603",
-                "KEGG.DRUG:D08260",
-                "ATC:S01AA03",
-                "UMLS:C4718972",
-                "CAS:1405-10-3",
-                "ATC:J01GB05",
-                "ATC:S03AA01",
-                "CHEMBL.COMPOUND:CHEMBL3989769",
-                "MESH:D009355",
-                "RXNORM:7299",
-                "NDDF:002775",
-                "NCIT:C166677",
-                "ATC:D06AX04",
-                "CHEMBL.COMPOUND:CHEMBL3989533",
-                "DRUGBANK:DB00994",
-                "CHEBI:7507",
-                "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-                "ATC:R02AB01",
-                "CHEMBL.COMPOUND:CHEMBL3989751"
-              ],
-              "id": "PUBCHEM.COMPOUND:62403",
-              "category": "biolink:MolecularMixture",
-              "all_names": [
-                "Vonamycin",
-                "NEOMYCIN",
-                "NEOMYCIN PALMITATE",
-                "mycerin sulfate",
-                "NEOMYCIN SULFATE",
-                "neomycin",
-                "Neomycin",
-                "Fradiomycin",
-                "Neomycin Palmitate",
-                "Kaomycine",
-                "Neomycin (INN)"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:1095304",
-                "PMID:20014752",
-                "PMID:18725450",
-                "PMID:6224608",
-                "PMID:23571415",
-                "PMID:19438282",
-                "PMID:23062825"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 538307,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:25028102': {'publication date': '2015 Apr', 'sentence': 'We tested streptomycin (ST) and neomycin (NEO) as analgesic agents applied in situ in rat paw inflammation caused by formalin or carrageenan administration.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-=======
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 603,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Neobiotic",
-          "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C00384",
-            "DrugCentral:4247",
-            "ATC:A07AA01",
-            "ATC:A01AB08",
-            "ATC:B05CA09",
-            "UMLS:C4718970",
-            "NCIT:C683",
-            "ATC:S02AA07",
-            "UNII:I16QD7X297",
-            "UMLS:C4718971",
-            "PUBCHEM.COMPOUND:62403",
-            "PDQ:CDR0000755934",
-            "UMLS:C0027603",
-            "KEGG.DRUG:D08260",
-            "ATC:S01AA03",
-            "UMLS:C4718972",
-            "CAS:1405-10-3",
-            "ATC:J01GB05",
-            "ATC:S03AA01",
-            "CHEMBL.COMPOUND:CHEMBL3989769",
-            "MESH:D009355",
-            "RXNORM:7299",
-            "NDDF:002775",
-            "NCIT:C166677",
-            "ATC:D06AX04",
-            "CHEMBL.COMPOUND:CHEMBL3989533",
-            "DRUGBANK:DB00994",
-            "CHEBI:7507",
-            "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-            "ATC:R02AB01",
-            "CHEMBL.COMPOUND:CHEMBL3989751"
-          ],
-          "id": "PUBCHEM.COMPOUND:62403",
-          "category": "biolink:MolecularMixture",
-          "all_names": [
-            "Vonamycin",
-            "NEOMYCIN",
-            "NEOMYCIN PALMITATE",
-            "mycerin sulfate",
-            "NEOMYCIN SULFATE",
-            "neomycin",
-            "Neomycin",
-            "Fradiomycin",
-            "Neomycin Palmitate",
-            "Kaomycine",
-            "Neomycin (INN)"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:1095304",
-            "PMID:20014752",
-            "PMID:18725450",
-            "PMID:6224608",
-            "PMID:23571415",
-            "PMID:19438282",
-            "PMID:23062825"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 538307,
-=======
-            "identity": 183319,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-=======
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 25968342,
-            "start": 603,
-            "end": 538307,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7353442': {'publication date': '1980', 'sentence': 'Neomycin and the combination of neomycin and bacitracin in the prevention of bacterial infection in surgery of the colon and/or rectum.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0027603---SEMMEDDB:prevents---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:62403",
-              "id": "26428369",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:7353442"
-=======
-            "identity": 17402369,
-            "start": 603,
-            "end": 183319,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25028102': {'publication date': '2015 Apr', 'sentence': 'We tested streptomycin (ST) and neomycin (NEO) as analgesic agents applied in situ in rat paw inflammation caused by formalin or carrageenan administration.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0027603---SEMMEDDB:associated_with---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:62403",
-              "id": "17758516",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:25028102"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 603,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Neobiotic",
-              "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C00384",
-                "DrugCentral:4247",
-                "ATC:A07AA01",
-                "ATC:A01AB08",
-                "ATC:B05CA09",
-                "UMLS:C4718970",
-                "NCIT:C683",
-                "ATC:S02AA07",
-                "UNII:I16QD7X297",
-                "UMLS:C4718971",
-                "PUBCHEM.COMPOUND:62403",
-                "PDQ:CDR0000755934",
-                "UMLS:C0027603",
-                "KEGG.DRUG:D08260",
-                "ATC:S01AA03",
-                "UMLS:C4718972",
-                "CAS:1405-10-3",
-                "ATC:J01GB05",
-                "ATC:S03AA01",
-                "CHEMBL.COMPOUND:CHEMBL3989769",
-                "MESH:D009355",
-                "RXNORM:7299",
-                "NDDF:002775",
-                "NCIT:C166677",
-                "ATC:D06AX04",
-                "CHEMBL.COMPOUND:CHEMBL3989533",
-                "DRUGBANK:DB00994",
-                "CHEBI:7507",
-                "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-                "ATC:R02AB01",
-                "CHEMBL.COMPOUND:CHEMBL3989751"
-              ],
-              "id": "PUBCHEM.COMPOUND:62403",
-              "category": "biolink:MolecularMixture",
-              "all_names": [
-                "Vonamycin",
-                "NEOMYCIN",
-                "NEOMYCIN PALMITATE",
-                "mycerin sulfate",
-                "NEOMYCIN SULFATE",
-                "neomycin",
-                "Neomycin",
-                "Fradiomycin",
-                "Neomycin Palmitate",
-                "Kaomycine",
-                "Neomycin (INN)"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:1095304",
-                "PMID:20014752",
-                "PMID:18725450",
-                "PMID:6224608",
-                "PMID:23571415",
-                "PMID:19438282",
-                "PMID:23062825"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 730112,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:28665034': {'publication date': '2017 08', 'sentence': 'Ultrahigh doses of gentamicin and clinically relevant doses of neomycin affect inflammation and angiogenesis in in vivo and in vitro models.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 183319,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "https://identifiers.org/umls:C0023485",
-          "name": "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma",
-          "description": "An acute lymphoblastic leukemia that originates from pre-B lymphocytes. The pre-B lymphoblasts contain cytoplasmic immunoglobulin.; A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "NCIT:C27798",
-            "MESH:D015452",
-            "UMLS:C0023485"
-          ],
-          "id": "UMLS:C0023485",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma",
-            "Pre-B Acute Lymphoblastic Leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-=======
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "Inflammation",
-            "inflammation"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-          ]
-        }
-      },
-      "end": {
-        "identity": 603,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Neobiotic",
-          "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "KEGG.COMPOUND:C00384",
-            "DrugCentral:4247",
-            "ATC:A07AA01",
-            "ATC:A01AB08",
-            "ATC:B05CA09",
-            "UMLS:C4718970",
-            "NCIT:C683",
-            "ATC:S02AA07",
-            "UNII:I16QD7X297",
-            "UMLS:C4718971",
-            "PUBCHEM.COMPOUND:62403",
-            "PDQ:CDR0000755934",
-            "UMLS:C0027603",
-            "KEGG.DRUG:D08260",
-            "ATC:S01AA03",
-            "UMLS:C4718972",
-            "CAS:1405-10-3",
-            "ATC:J01GB05",
-            "ATC:S03AA01",
-            "CHEMBL.COMPOUND:CHEMBL3989769",
-            "MESH:D009355",
-            "RXNORM:7299",
-            "NDDF:002775",
-            "NCIT:C166677",
-            "ATC:D06AX04",
-            "CHEMBL.COMPOUND:CHEMBL3989533",
-            "DRUGBANK:DB00994",
-            "CHEBI:7507",
-            "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-            "ATC:R02AB01",
-            "CHEMBL.COMPOUND:CHEMBL3989751"
-          ],
-          "id": "PUBCHEM.COMPOUND:62403",
-          "category": "biolink:MolecularMixture",
-          "all_names": [
-            "Vonamycin",
-            "NEOMYCIN",
-            "NEOMYCIN PALMITATE",
-            "mycerin sulfate",
-            "NEOMYCIN SULFATE",
-            "neomycin",
-            "Neomycin",
-            "Fradiomycin",
-            "Neomycin Palmitate",
-            "Kaomycine",
-            "Neomycin (INN)"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:MolecularMixture",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:1095304",
-            "PMID:20014752",
-            "PMID:18725450",
-            "PMID:6224608",
-            "PMID:23571415",
-            "PMID:19438282",
-            "PMID:23062825"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 183319,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "Inflammation",
-                "inflammation"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19357323,
-            "start": 603,
-            "end": 183319,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28665034': {'publication date': '2017 08', 'sentence': 'Ultrahigh doses of gentamicin and clinically relevant doses of neomycin affect inflammation and angiogenesis in in vivo and in vitro models.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0027603---SEMMEDDB:affects---None---None---None---UMLS:C0021368---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:62403",
-              "id": "19744068",
-              "object": "NCIT:C3137",
-              "publications": [
-                "PMID:28665034"
-              ]
-            }
-          },
-          "end": {
-            "identity": 603,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Neobiotic",
-              "description": "A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C683\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C683\" NCI Thesaurus); A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.; Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "KEGG.COMPOUND:C00384",
-                "DrugCentral:4247",
-                "ATC:A07AA01",
-                "ATC:A01AB08",
-                "ATC:B05CA09",
-                "UMLS:C4718970",
-                "NCIT:C683",
-                "ATC:S02AA07",
-                "UNII:I16QD7X297",
-                "UMLS:C4718971",
-                "PUBCHEM.COMPOUND:62403",
-                "PDQ:CDR0000755934",
-                "UMLS:C0027603",
-                "KEGG.DRUG:D08260",
-                "ATC:S01AA03",
-                "UMLS:C4718972",
-                "CAS:1405-10-3",
-                "ATC:J01GB05",
-                "ATC:S03AA01",
-                "CHEMBL.COMPOUND:CHEMBL3989769",
-                "MESH:D009355",
-                "RXNORM:7299",
-                "NDDF:002775",
-                "NCIT:C166677",
-                "ATC:D06AX04",
-                "CHEMBL.COMPOUND:CHEMBL3989533",
-                "DRUGBANK:DB00994",
-                "CHEBI:7507",
-                "INCHIKEY:OIXVKQDWLFHVGR-GQTDVWSESA-N",
-                "ATC:R02AB01",
-                "CHEMBL.COMPOUND:CHEMBL3989751"
-              ],
-              "id": "PUBCHEM.COMPOUND:62403",
-              "category": "biolink:MolecularMixture",
-              "all_names": [
-                "Vonamycin",
-                "NEOMYCIN",
-                "NEOMYCIN PALMITATE",
-                "mycerin sulfate",
-                "NEOMYCIN SULFATE",
-                "neomycin",
-                "Neomycin",
-                "Fradiomycin",
-                "Neomycin Palmitate",
-                "Kaomycine",
-                "Neomycin (INN)"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:MolecularMixture",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:1095304",
-                "PMID:20014752",
-                "PMID:18725450",
-                "PMID:6224608",
-                "PMID:23571415",
-                "PMID:19438282",
-                "PMID:23062825"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:32076826': {'publication date': '2020 Feb 20', 'sentence': 'Cytokine storm was reported in four patients (19%).In conclusion, treatment with blinatumomab is effective and tolerable in adult patients with relapsed/refractory B-ALL outside of a clinical trial stetting.', 'subject score': 1000, 'object score': 900}, 'PMID:35503708': {'publication date': '2022 May 03', 'sentence': 'Consolidation with blinatumomab in patients with newly diagnosed, high-risk DLBCL who did not progress under R-chemotherapy was better tolerated than in previous studies where blinatumomab was used for treatment of patients with lymphoma.', 'subject score': 775, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319679,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-          "name": "lymphoma",
-          "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:115244002",
-            "DOID:0060058",
-            "MONDO:0005062",
-            "SNOMEDCT:118600007",
-            "HP:0002665",
-            "NCIT:C7065",
-            "EFO:0000574",
-            "ORPHANET:223735",
-            "MESH:D008223",
-            "SNOMEDCT:188676008",
-            "PDQ:CDR0000041429",
-            "MEDDRA:10025316",
-            "UMLS:C0024299",
-            "NCIT:C3208",
-            "MEDDRA:10025632",
-            "MEDDRA:10025310",
-            "MEDDRA:10025633",
-            "SNOMEDCT:1163043007",
-            "ICD10:C85.9",
-            "UMLS:C1536843",
-            "UMLS:C0334621",
-            "MEDDRA:10025315"
-          ],
-          "id": "MONDO:0005062",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphocytic Neoplasm",
-            "Lymphoma",
-            "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-            "lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/lymphoma",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 612,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BLINATUMOMAB",
-          "description": "A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62528\" NCI Thesaurus); A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "DRUGBANK:DB09052",
-            "MESH:C510808",
-            "KEGG.DRUG:D09325",
-            "CHEMBL.COMPOUND:CHEMBL1742992",
-            "UMLS:C3853839",
-            "RXNORM:1597258",
-            "DrugCentral:4915",
-            "NCIT:C62528",
-            "UNII:4FR53SIF3A",
-            "GTOPDB:7384"
-          ],
-          "id": "UNII:4FR53SIF3A",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "blinatumomab",
-            "Blinatumomab (USAN/INN)",
-            "BLINATUMOMAB",
-            "MT-103",
-            "Blinatumomab"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25524799",
-            "PMID:25359367",
-            "PMID:25883042",
-            "PMID:23812940",
-            "PMID:25524800"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 730112,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C0023485",
-              "name": "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma",
-              "description": "An acute lymphoblastic leukemia that originates from pre-B lymphocytes. The pre-B lymphoblasts contain cytoplasmic immunoglobulin.; A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "NCIT:C27798",
-                "MESH:D015452",
-                "UMLS:C0023485"
-              ],
-              "id": "UMLS:C0023485",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma",
-                "Pre-B Acute Lymphoblastic Leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-=======
-            "identity": 319679,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-              "name": "lymphoma",
-              "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:115244002",
-                "DOID:0060058",
-                "MONDO:0005062",
-                "SNOMEDCT:118600007",
-                "HP:0002665",
-                "NCIT:C7065",
-                "EFO:0000574",
-                "ORPHANET:223735",
-                "MESH:D008223",
-                "SNOMEDCT:188676008",
-                "PDQ:CDR0000041429",
-                "MEDDRA:10025316",
-                "UMLS:C0024299",
-                "NCIT:C3208",
-                "MEDDRA:10025632",
-                "MEDDRA:10025310",
-                "MEDDRA:10025633",
-                "SNOMEDCT:1163043007",
-                "ICD10:C85.9",
-                "UMLS:C1536843",
-                "UMLS:C0334621",
-                "MEDDRA:10025315"
-              ],
-              "id": "MONDO:0005062",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphocytic Neoplasm",
-                "Lymphoma",
-                "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-                "lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/lymphoma",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 25128286,
-            "start": 612,
-            "end": 730112,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:37131217': {'publication date': '2023 May 02', 'sentence': 'Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C3853839---SEMMEDDB:associated_with---None---None---None---UMLS:C0023485---SEMMEDDB:"
-              ],
-              "subject": "UNII:4FR53SIF3A",
-              "id": "25579460",
-              "object": "UMLS:C0023485",
-              "publications": [
-                "PMID:37131217"
-=======
-            "identity": 21304784,
-            "start": 612,
-            "end": 319679,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32076826': {'publication date': '2020 Feb 20', 'sentence': 'Cytokine storm was reported in four patients (19%).In conclusion, treatment with blinatumomab is effective and tolerable in adult patients with relapsed/refractory B-ALL outside of a clinical trial stetting.', 'subject score': 1000, 'object score': 900}, 'PMID:35503708': {'publication date': '2022 May 03', 'sentence': 'Consolidation with blinatumomab in patients with newly diagnosed, high-risk DLBCL who did not progress under R-chemotherapy was better tolerated than in previous studies where blinatumomab was used for treatment of patients with lymphoma.', 'subject score': 775, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C3853839---SEMMEDDB:treats---None---None---None---UMLS:C0024299---SEMMEDDB:"
-              ],
-              "subject": "UNII:4FR53SIF3A",
-              "id": "21720587",
-              "object": "MONDO:0005062",
-              "publications": [
-                "PMID:32076826",
-                "PMID:35503708"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 612,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:Gene",
-              "biolink:GeneOrGeneProduct",
-              "biolink:GeneProductMixin",
-              "biolink:GenomicEntity",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:SmallMolecule",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
->>>>>>> main
-            ],
-            "properties": {
-              "name": "BLINATUMOMAB",
-              "description": "A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62528\" NCI Thesaurus); A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "DRUGBANK:DB09052",
-                "MESH:C510808",
-                "KEGG.DRUG:D09325",
-                "CHEMBL.COMPOUND:CHEMBL1742992",
-                "UMLS:C3853839",
-                "RXNORM:1597258",
-                "DrugCentral:4915",
-                "NCIT:C62528",
-                "UNII:4FR53SIF3A",
-                "GTOPDB:7384"
-              ],
-              "id": "UNII:4FR53SIF3A",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "blinatumomab",
-                "Blinatumomab (USAN/INN)",
-                "BLINATUMOMAB",
-                "MT-103",
-                "Blinatumomab"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25524799",
-                "PMID:25359367",
-                "PMID:25883042",
-                "PMID:23812940",
-                "PMID:25524800"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:32903593': {'publication date': '2020', 'sentence': 'The impressive clinical success of the continuously intravenously infused T cell-redirecting bispecific antibody (T-bsAb) blinatumomab (anti-CD19 x anti-CD3), and of engineered T cells expressing anti-CD19 chimeric antigen receptors (CAR-T cells) in hematological malignancies, has led to renewed interest in a novel cancer immunotherapy strategy that combines features of antibody- and cell-based therapies.', 'subject score': 1000, 'object score': 1000}, 'PMID:33435716': {'publication date': '2021 Jan 13', 'sentence': 'In 2018, blinatumomab became the first and only drug approved for the treatment of persistent MRD in any hematologic malignancy.', 'subject score': 1000, 'object score': 1000}, 'PMID:34595414': {'publication date': '2019 Jun', 'sentence': 'Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 315771,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002334",
-          "name": "hematopoietic and lymphoid system neoplasm",
-          "description": "A neoplasm arising from hematopoietic cells found in the bone marrow, peripheral blood, lymph nodes and spleen (organs of the hematopoietic system). Hematopoietic cell neoplasms can also involve other anatomic sites (e.g. central nervous system, gastrointestinal tract), either by metastasis, direct tumor infiltration, or neoplastic transformation of extranodal lymphoid tissues. The commonest forms are the various types of leukemia, Hodgkin and non-Hodgkin lymphomas, and myelodysplastic syndromes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C27134\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C27134\" NCI Thesaurus); A neoplasm arising from hematopoietic cells found in the bone marrow, peripheral blood, lymph nodes and spleen (organs of the hematopoietic system). Hematopoietic cell neoplasms can also involve other anatomic sites (e.g. central nervous system, gastrointestinal tract), either by metastasis, direct tumor infiltration, or neoplastic transformation of extranodal lymphoid tissues. The commonest forms are the various types of leukemia, Hodgkin and non-Hodgkin lymphomas, myeloproliferative neoplasms, and myelodysplastic syndromes.; Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.; Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). [http://www.ncbi.nlm.nih.gov/mesh?term=Hematologic%20Neoplasms]; A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10086808",
-            "HP:0004377",
-            "NCIT:C35813",
-            "MEDDRA:10061187",
-            "UMLS:C0376544",
-            "MEDDRA:10018864",
-            "SNOMEDCT:129154003",
-            "MEDDRA:10086698",
-            "SNOMEDCT:414644002",
-            "SNOMEDCT:414388001",
-            "UMLS:C1512393",
-            "MEDDRA:10066481",
-            "MEDDRA:10061195",
-            "DOID:2531",
-            "SNOMEDCT:269475001",
-            "MONDO:0002334",
-            "MESH:D019337",
-            "UMLS:C0348393",
-            "UMLS:C0376545",
-            "MEDDRA:10066476"
-          ],
-          "id": "MONDO:0002334",
-          "category": "biolink:Disease",
-          "all_names": [
-            "hematologic cancer",
-            "Malignant tumor of lymphoid hemopoietic and related tissue",
-            "Hematopoietic Neoplasms",
-            "Hematologic Neoplasms",
-            "Hematopoietic and Lymphoid System Neoplasm",
-            "Hematological neoplasm",
-            "hematopoietic and lymphoid system neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.ncbi.nlm.nih.gov/mesh?term=hematologic%20neoplasms",
-            "http://en.wikipedia.org/wiki/blood_cance",
-            "http://www.cancer.gov/dictionary/?cdrid=45708"
-          ]
-        }
-      },
-      "end": {
-        "identity": 612,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BLINATUMOMAB",
-          "description": "A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62528\" NCI Thesaurus); A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "DRUGBANK:DB09052",
-            "MESH:C510808",
-            "KEGG.DRUG:D09325",
-            "CHEMBL.COMPOUND:CHEMBL1742992",
-            "UMLS:C3853839",
-            "RXNORM:1597258",
-            "DrugCentral:4915",
-            "NCIT:C62528",
-            "UNII:4FR53SIF3A",
-            "GTOPDB:7384"
-          ],
-          "id": "UNII:4FR53SIF3A",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "blinatumomab",
-            "Blinatumomab (USAN/INN)",
-            "BLINATUMOMAB",
-            "MT-103",
-            "Blinatumomab"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25524799",
-            "PMID:25359367",
-            "PMID:25883042",
-            "PMID:23812940",
-            "PMID:25524800"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315771,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002334",
-              "name": "hematopoietic and lymphoid system neoplasm",
-              "description": "A neoplasm arising from hematopoietic cells found in the bone marrow, peripheral blood, lymph nodes and spleen (organs of the hematopoietic system). Hematopoietic cell neoplasms can also involve other anatomic sites (e.g. central nervous system, gastrointestinal tract), either by metastasis, direct tumor infiltration, or neoplastic transformation of extranodal lymphoid tissues. The commonest forms are the various types of leukemia, Hodgkin and non-Hodgkin lymphomas, and myelodysplastic syndromes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C27134\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C27134\" NCI Thesaurus); A neoplasm arising from hematopoietic cells found in the bone marrow, peripheral blood, lymph nodes and spleen (organs of the hematopoietic system). Hematopoietic cell neoplasms can also involve other anatomic sites (e.g. central nervous system, gastrointestinal tract), either by metastasis, direct tumor infiltration, or neoplastic transformation of extranodal lymphoid tissues. The commonest forms are the various types of leukemia, Hodgkin and non-Hodgkin lymphomas, myeloproliferative neoplasms, and myelodysplastic syndromes.; Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.; Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). [http://www.ncbi.nlm.nih.gov/mesh?term=Hematologic%20Neoplasms]; A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [HPO:probinson, NCIT:C3161]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10086808",
-                "HP:0004377",
-                "NCIT:C35813",
-                "MEDDRA:10061187",
-                "UMLS:C0376544",
-                "MEDDRA:10018864",
-                "SNOMEDCT:129154003",
-                "MEDDRA:10086698",
-                "SNOMEDCT:414644002",
-                "SNOMEDCT:414388001",
-                "UMLS:C1512393",
-                "MEDDRA:10066481",
-                "MEDDRA:10061195",
-                "DOID:2531",
-                "SNOMEDCT:269475001",
-                "MONDO:0002334",
-                "MESH:D019337",
-                "UMLS:C0348393",
-                "UMLS:C0376545",
-                "MEDDRA:10066476"
-              ],
-              "id": "MONDO:0002334",
-              "category": "biolink:Disease",
-              "all_names": [
-                "hematologic cancer",
-                "Malignant tumor of lymphoid hemopoietic and related tissue",
-                "Hematopoietic Neoplasms",
-                "Hematologic Neoplasms",
-                "Hematopoietic and Lymphoid System Neoplasm",
-                "Hematological neoplasm",
-                "hematopoietic and lymphoid system neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.ncbi.nlm.nih.gov/mesh?term=hematologic%20neoplasms",
-                "http://en.wikipedia.org/wiki/blood_cance",
-                "http://www.cancer.gov/dictionary/?cdrid=45708"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22050153,
-            "start": 612,
-            "end": 315771,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32903593': {'publication date': '2020', 'sentence': 'The impressive clinical success of the continuously intravenously infused T cell-redirecting bispecific antibody (T-bsAb) blinatumomab (anti-CD19 x anti-CD3), and of engineered T cells expressing anti-CD19 chimeric antigen receptors (CAR-T cells) in hematological malignancies, has led to renewed interest in a novel cancer immunotherapy strategy that combines features of antibody- and cell-based therapies.', 'subject score': 1000, 'object score': 1000}, 'PMID:33435716': {'publication date': '2021 Jan 13', 'sentence': 'In 2018, blinatumomab became the first and only drug approved for the treatment of persistent MRD in any hematologic malignancy.', 'subject score': 1000, 'object score': 1000}, 'PMID:34595414': {'publication date': '2019 Jun', 'sentence': 'Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C3853839---SEMMEDDB:associated_with---None---None---None---UMLS:C0376545---SEMMEDDB:"
-              ],
-              "subject": "UNII:4FR53SIF3A",
-              "id": "22474123",
-              "object": "MONDO:0002334",
-              "publications": [
-                "PMID:32903593",
-                "PMID:33435716",
-                "PMID:34595414"
-              ]
-            }
-          },
-          "end": {
-            "identity": 612,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BLINATUMOMAB",
-              "description": "A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62528\" NCI Thesaurus); A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "DRUGBANK:DB09052",
-                "MESH:C510808",
-                "KEGG.DRUG:D09325",
-                "CHEMBL.COMPOUND:CHEMBL1742992",
-                "UMLS:C3853839",
-                "RXNORM:1597258",
-                "DrugCentral:4915",
-                "NCIT:C62528",
-                "UNII:4FR53SIF3A",
-                "GTOPDB:7384"
-              ],
-              "id": "UNII:4FR53SIF3A",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "blinatumomab",
-                "Blinatumomab (USAN/INN)",
-                "BLINATUMOMAB",
-                "MT-103",
-                "Blinatumomab"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25524799",
-                "PMID:25359367",
-                "PMID:25883042",
-                "PMID:23812940",
-                "PMID:25524800"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 323831,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-          "name": "acute lymphoblastic leukemia",
-          "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "HP:0006721",
-            "MONDO:0004967",
-            "MEDDRA:10000848",
-            "MEDDRA:10000849",
-            "MEDDRA:10025305",
-            "ORPHANET:513",
-            "MEDDRA:10025301",
-            "ICD10:C91.00",
-            "UMLS:C0023453",
-            "DOID:9952",
-            "MEDDRA:10000844",
-            "MEDDRA:10000846",
-            "MEDDRA:10000845",
-            "MEDDRA:10024338",
-            "ICD10:C91",
-            "MESH:D054198",
-            "UMLS:C1961102",
-            "MEDDRA:10060555",
-            "NCIT:C3167",
-            "PDQ:CDR0000043423",
-            "MEDDRA:10024290",
-            "MEDDRA:10000842",
-            "NCIT:C27281",
-            "ICD9:204",
-            "DOID:1037",
-            "MEDDRA:10000843",
-            "EFO:0000220",
-            "SNOMEDCT:128822004",
-            "ICD9:204.0",
-            "UMLS:C0023449",
-            "MEDDRA:10060390",
-            "SNOMEDCT:91857003"
-          ],
-          "id": "MONDO:0004967",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute lymphoblastic leukemia",
-            "lymphoid leukemia",
-            "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-            "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-            "L2 Acute Lymphoblastic Leukemia",
-            "acute lymphocytic leukemia",
-            "Lymphoid leukemia, acute",
-            "acute lymphoblastic leukemia",
-            "Acute lymphocytic leukemia",
-            "Acute Lymphoblastic Leukemia",
-            "Lymphoid leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=46332",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=616067",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 612,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BLINATUMOMAB",
-          "description": "A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62528\" NCI Thesaurus); A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "DRUGBANK:DB09052",
-            "MESH:C510808",
-            "KEGG.DRUG:D09325",
-            "CHEMBL.COMPOUND:CHEMBL1742992",
-            "UMLS:C3853839",
-            "RXNORM:1597258",
-            "DrugCentral:4915",
-            "NCIT:C62528",
-            "UNII:4FR53SIF3A",
-            "GTOPDB:7384"
-          ],
-          "id": "UNII:4FR53SIF3A",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "blinatumomab",
-            "Blinatumomab (USAN/INN)",
-            "BLINATUMOMAB",
-            "MT-103",
-            "Blinatumomab"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25524799",
-            "PMID:25359367",
-            "PMID:25883042",
-            "PMID:23812940",
-            "PMID:25524800"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323831,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-              "name": "acute lymphoblastic leukemia",
-              "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "HP:0006721",
-                "MONDO:0004967",
-                "MEDDRA:10000848",
-                "MEDDRA:10000849",
-                "MEDDRA:10025305",
-                "ORPHANET:513",
-                "MEDDRA:10025301",
-                "ICD10:C91.00",
-                "UMLS:C0023453",
-                "DOID:9952",
-                "MEDDRA:10000844",
-                "MEDDRA:10000846",
-                "MEDDRA:10000845",
-                "MEDDRA:10024338",
-                "ICD10:C91",
-                "MESH:D054198",
-                "UMLS:C1961102",
-                "MEDDRA:10060555",
-                "NCIT:C3167",
-                "PDQ:CDR0000043423",
-                "MEDDRA:10024290",
-                "MEDDRA:10000842",
-                "NCIT:C27281",
-                "ICD9:204",
-                "DOID:1037",
-                "MEDDRA:10000843",
-                "EFO:0000220",
-                "SNOMEDCT:128822004",
-                "ICD9:204.0",
-                "UMLS:C0023449",
-                "MEDDRA:10060390",
-                "SNOMEDCT:91857003"
-              ],
-              "id": "MONDO:0004967",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute lymphoblastic leukemia",
-                "lymphoid leukemia",
-                "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-                "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-                "L2 Acute Lymphoblastic Leukemia",
-                "acute lymphocytic leukemia",
-                "Lymphoid leukemia, acute",
-                "acute lymphoblastic leukemia",
-                "Acute lymphocytic leukemia",
-                "Acute Lymphoblastic Leukemia",
-                "Lymphoid leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=46332",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=616067",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21529377,
-            "start": 612,
-            "end": 323831,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32314348': {'publication date': '2020 Apr 21', 'sentence': 'Blinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia (ALL).', 'subject score': 1000, 'object score': 1000}, 'PMID:32445796': {'publication date': '2020 May 20', 'sentence': 'Weighing the risks of blinatumomab prior to hematopoietic stem cell transplant in acute lymphoblastic leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:33881461': {'publication date': '2021 Apr 27', 'sentence': 'Blinatumomab, a single-chain, bispecific, T-cell-engaging antibody targeting CD19, is effective in B-precursor acute lymphoblastic leukemia (BCP-ALL), even in the context of chemotherapy-related partial T-cell immunodeficiency.', 'subject score': 1000, 'object score': 937}, 'PMID:36130863': {'publication date': '2022 Aug 15', 'sentence': 'Further, the approval of blinatumomab for MRD+ B-ALL has advanced the concept of MRD response as a clinical endpoint in ALL.', 'subject score': 1000, 'object score': 1000}, 'PMID:36794446': {'publication date': '2023 Feb 16', 'sentence': 'Timing of Intrathecal Chemotherapy and Blinatumomab Impacts Neurotoxicity in Acute Lymphoblastic Leukemia.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C3853839---SEMMEDDB:associated_with---None---None---None---UMLS:C0023449---SEMMEDDB:"
-              ],
-              "subject": "UNII:4FR53SIF3A",
-              "id": "21947892",
-              "object": "MONDO:0004967",
-              "publications": [
-                "PMID:32314348",
-                "PMID:32445796",
-                "PMID:33881461",
-                "PMID:36130863",
-                "PMID:36794446"
-              ]
-            }
-          },
-          "end": {
-            "identity": 612,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BLINATUMOMAB",
-              "description": "A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62528\" NCI Thesaurus); A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "DRUGBANK:DB09052",
-                "MESH:C510808",
-                "KEGG.DRUG:D09325",
-                "CHEMBL.COMPOUND:CHEMBL1742992",
-                "UMLS:C3853839",
-                "RXNORM:1597258",
-                "DrugCentral:4915",
-                "NCIT:C62528",
-                "UNII:4FR53SIF3A",
-                "GTOPDB:7384"
-              ],
-              "id": "UNII:4FR53SIF3A",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "blinatumomab",
-                "Blinatumomab (USAN/INN)",
-                "BLINATUMOMAB",
-                "MT-103",
-                "Blinatumomab"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25524799",
-                "PMID:25359367",
-                "PMID:25883042",
-                "PMID:23812940",
-                "PMID:25524800"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:35409391': {'publication date': '2022 Apr 05', 'sentence': 'Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy.', 'subject score': 888, 'object score': 851}, 'PMID:36198556': {'publication date': '2022', 'sentence': 'After the success of blinatumomab for treating refractory B-cell leukemia, series of clinical trials using bispecific antibodies for relapsed and refractory hematological malignancies are being conducted.', 'subject score': 1000, 'object score': 875}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 323598,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004948",
-          "name": "B-cell chronic lymphocytic leukemia",
-          "description": "The most common type of chronic lymphoid leukemia. It comprises 90% of chronic lymphoid leukemias in the United States. Morphologically, the neoplastic cells are small, round B-lymphocytes. This type of leukemia is not considered to be curable with available therapy. (WHO, 2001); A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.; A chronic lymphocytic/lymphatic/lymphoblastic leukemia (CLL) is a neoplastic disease characterized by proliferation and accumulation (blood, marrow and lymphoid organs) of morphologically mature but immunologically dysfunctional lymphocytes. A CLL is always a B-cell lymphocytic leukemia as there are no reports of cases of T-cell lymphocytic leukemias. [HPO:curators]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10051812",
-            "MEDDRA:10003908",
-            "MEDDRA:10068919",
-            "MEDDRA:10060576",
-            "MEDDRA:10068852",
-            "OMIM:151400",
-            "MEDDRA:10003909",
-            "MEDDRA:10008956",
-            "UMLS:C0855095",
-            "ICD9:204.1",
-            "MEDDRA:10060391",
-            "MEDDRA:10008976",
-            "NCIT:C7540",
-            "MEDDRA:10008957",
-            "HP:0005550",
-            "MONDO:0004948",
-            "UMLS:C0023434",
-            "MEDDRA:10024340",
-            "MEDDRA:10025306",
-            "PDQ:CDR0000038170",
-            "MEDDRA:10009310",
-            "SNOMEDCT:302841002",
-            "MEDDRA:10008960",
-            "ORPHANET:67038",
-            "SNOMEDCT:92814006",
-            "SNOMEDCT:277473004",
-            "MEDDRA:10008958",
-            "SNOMEDCT:64575004",
-            "MEDDRA:10003910",
-            "MEDDRA:10024295",
-            "ICD10:C91.10",
-            "PDQ:CDR0000037765",
-            "MEDDRA:10025302",
-            "EFO:0000095",
-            "MEDDRA:10041138",
-            "DOID:1040",
-            "SNOMEDCT:51092000",
-            "MESH:D015451",
-            "PDQ:CDR0000039824",
-            "NCIT:C3163",
-            "MEDDRA:10008993"
-          ],
-          "id": "MONDO:0004948",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic lymphatic leukemia",
-            "Lymphoid leukemia, chronic",
-            "Small Lymphocytic Lymphoma",
-            "chronic lymphocytic leukemia",
-            "Leukemia, chronic lymphocytic related phenotypic feature",
-            "Leukemia, Lymphocytic, Chronic, B-Cell",
-            "B-cell chronic lymphocytic leukemia",
-            "small lymphocytic lymphoma",
-            "Chronic Lymphocytic Leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=346545",
-            "http://en.wikipedia.org/wiki/b-cell_chronic_lymphocytic_leukemia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 612,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BLINATUMOMAB",
-          "description": "A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62528\" NCI Thesaurus); A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "DRUGBANK:DB09052",
-            "MESH:C510808",
-            "KEGG.DRUG:D09325",
-            "CHEMBL.COMPOUND:CHEMBL1742992",
-            "UMLS:C3853839",
-            "RXNORM:1597258",
-            "DrugCentral:4915",
-            "NCIT:C62528",
-            "UNII:4FR53SIF3A",
-            "GTOPDB:7384"
-          ],
-          "id": "UNII:4FR53SIF3A",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "blinatumomab",
-            "Blinatumomab (USAN/INN)",
-            "BLINATUMOMAB",
-            "MT-103",
-            "Blinatumomab"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25524799",
-            "PMID:25359367",
-            "PMID:25883042",
-            "PMID:23812940",
-            "PMID:25524800"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323598,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004948",
-              "name": "B-cell chronic lymphocytic leukemia",
-              "description": "The most common type of chronic lymphoid leukemia. It comprises 90% of chronic lymphoid leukemias in the United States. Morphologically, the neoplastic cells are small, round B-lymphocytes. This type of leukemia is not considered to be curable with available therapy. (WHO, 2001); A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.; A chronic lymphocytic/lymphatic/lymphoblastic leukemia (CLL) is a neoplastic disease characterized by proliferation and accumulation (blood, marrow and lymphoid organs) of morphologically mature but immunologically dysfunctional lymphocytes. A CLL is always a B-cell lymphocytic leukemia as there are no reports of cases of T-cell lymphocytic leukemias. [HPO:curators]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10051812",
-                "MEDDRA:10003908",
-                "MEDDRA:10068919",
-                "MEDDRA:10060576",
-                "MEDDRA:10068852",
-                "OMIM:151400",
-                "MEDDRA:10003909",
-                "MEDDRA:10008956",
-                "UMLS:C0855095",
-                "ICD9:204.1",
-                "MEDDRA:10060391",
-                "MEDDRA:10008976",
-                "NCIT:C7540",
-                "MEDDRA:10008957",
-                "HP:0005550",
-                "MONDO:0004948",
-                "UMLS:C0023434",
-                "MEDDRA:10024340",
-                "MEDDRA:10025306",
-                "PDQ:CDR0000038170",
-                "MEDDRA:10009310",
-                "SNOMEDCT:302841002",
-                "MEDDRA:10008960",
-                "ORPHANET:67038",
-                "SNOMEDCT:92814006",
-                "SNOMEDCT:277473004",
-                "MEDDRA:10008958",
-                "SNOMEDCT:64575004",
-                "MEDDRA:10003910",
-                "MEDDRA:10024295",
-                "ICD10:C91.10",
-                "PDQ:CDR0000037765",
-                "MEDDRA:10025302",
-                "EFO:0000095",
-                "MEDDRA:10041138",
-                "DOID:1040",
-                "SNOMEDCT:51092000",
-                "MESH:D015451",
-                "PDQ:CDR0000039824",
-                "NCIT:C3163",
-                "MEDDRA:10008993"
-              ],
-              "id": "MONDO:0004948",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic lymphatic leukemia",
-                "Lymphoid leukemia, chronic",
-                "Small Lymphocytic Lymphoma",
-                "chronic lymphocytic leukemia",
-                "Leukemia, chronic lymphocytic related phenotypic feature",
-                "Leukemia, Lymphocytic, Chronic, B-Cell",
-                "B-cell chronic lymphocytic leukemia",
-                "small lymphocytic lymphoma",
-                "Chronic Lymphocytic Leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=346545",
-                "http://en.wikipedia.org/wiki/b-cell_chronic_lymphocytic_leukemia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23957273,
-            "start": 612,
-            "end": 323598,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35409391': {'publication date': '2022 Apr 05', 'sentence': 'Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy.', 'subject score': 888, 'object score': 851}, 'PMID:36198556': {'publication date': '2022', 'sentence': 'After the success of blinatumomab for treating refractory B-cell leukemia, series of clinical trials using bispecific antibodies for relapsed and refractory hematological malignancies are being conducted.', 'subject score': 1000, 'object score': 875}}",
-              "kg2_ids": [
-                "UMLS:C3853839---SEMMEDDB:treats---None---None---None---UMLS:C0023434---SEMMEDDB:"
-              ],
-              "subject": "UNII:4FR53SIF3A",
-              "id": "24398401",
-              "object": "MONDO:0004948",
-              "publications": [
-                "PMID:35409391",
-                "PMID:36198556"
-              ]
-            }
-          },
-          "end": {
-            "identity": 612,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BLINATUMOMAB",
-              "description": "A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62528\" NCI Thesaurus); A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "DRUGBANK:DB09052",
-                "MESH:C510808",
-                "KEGG.DRUG:D09325",
-                "CHEMBL.COMPOUND:CHEMBL1742992",
-                "UMLS:C3853839",
-                "RXNORM:1597258",
-                "DrugCentral:4915",
-                "NCIT:C62528",
-                "UNII:4FR53SIF3A",
-                "GTOPDB:7384"
-              ],
-              "id": "UNII:4FR53SIF3A",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "blinatumomab",
-                "Blinatumomab (USAN/INN)",
-                "BLINATUMOMAB",
-                "MT-103",
-                "Blinatumomab"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25524799",
-                "PMID:25359367",
-                "PMID:25883042",
-                "PMID:23812940",
-                "PMID:25524800"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 730112,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:32314348': {'publication date': '2020 Apr 21', 'sentence': 'Blinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia (ALL).', 'subject score': 1000, 'object score': 1000}, 'PMID:32445796': {'publication date': '2020 May 20', 'sentence': 'Weighing the risks of blinatumomab prior to hematopoietic stem cell transplant in acute lymphoblastic leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:33881461': {'publication date': '2021 Apr 27', 'sentence': 'Blinatumomab, a single-chain, bispecific, T-cell-engaging antibody targeting CD19, is effective in B-precursor acute lymphoblastic leukemia (BCP-ALL), even in the context of chemotherapy-related partial T-cell immunodeficiency.', 'subject score': 1000, 'object score': 937}, 'PMID:36130863': {'publication date': '2022 Aug 15', 'sentence': 'Further, the approval of blinatumomab for MRD+ B-ALL has advanced the concept of MRD response as a clinical endpoint in ALL.', 'subject score': 1000, 'object score': 1000}, 'PMID:36794446': {'publication date': '2023 Feb 16', 'sentence': 'Timing of Intrathecal Chemotherapy and Blinatumomab Impacts Neurotoxicity in Acute Lymphoblastic Leukemia.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 323831,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "https://identifiers.org/umls:C0023485",
-          "name": "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma",
-          "description": "An acute lymphoblastic leukemia that originates from pre-B lymphocytes. The pre-B lymphoblasts contain cytoplasmic immunoglobulin.; A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "NCIT:C27798",
-            "MESH:D015452",
-            "UMLS:C0023485"
-          ],
-          "id": "UMLS:C0023485",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma",
-            "Pre-B Acute Lymphoblastic Leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-          "name": "acute lymphoblastic leukemia",
-          "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "HP:0006721",
-            "MONDO:0004967",
-            "MEDDRA:10000848",
-            "MEDDRA:10000849",
-            "MEDDRA:10025305",
-            "ORPHANET:513",
-            "MEDDRA:10025301",
-            "ICD10:C91.00",
-            "UMLS:C0023453",
-            "DOID:9952",
-            "MEDDRA:10000844",
-            "MEDDRA:10000846",
-            "MEDDRA:10000845",
-            "MEDDRA:10024338",
-            "ICD10:C91",
-            "MESH:D054198",
-            "UMLS:C1961102",
-            "MEDDRA:10060555",
-            "NCIT:C3167",
-            "PDQ:CDR0000043423",
-            "MEDDRA:10024290",
-            "MEDDRA:10000842",
-            "NCIT:C27281",
-            "ICD9:204",
-            "DOID:1037",
-            "MEDDRA:10000843",
-            "EFO:0000220",
-            "SNOMEDCT:128822004",
-            "ICD9:204.0",
-            "UMLS:C0023449",
-            "MEDDRA:10060390",
-            "SNOMEDCT:91857003"
-          ],
-          "id": "MONDO:0004967",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute lymphoblastic leukemia",
-            "lymphoid leukemia",
-            "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-            "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-            "L2 Acute Lymphoblastic Leukemia",
-            "acute lymphocytic leukemia",
-            "Lymphoid leukemia, acute",
-            "acute lymphoblastic leukemia",
-            "Acute lymphocytic leukemia",
-            "Acute Lymphoblastic Leukemia",
-            "Lymphoid leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=46332",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=616067",
-            "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 612,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BLINATUMOMAB",
-          "description": "A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62528\" NCI Thesaurus); A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "DRUGBANK:DB09052",
-            "MESH:C510808",
-            "KEGG.DRUG:D09325",
-            "CHEMBL.COMPOUND:CHEMBL1742992",
-            "UMLS:C3853839",
-            "RXNORM:1597258",
-            "DrugCentral:4915",
-            "NCIT:C62528",
-            "UNII:4FR53SIF3A",
-            "GTOPDB:7384"
-          ],
-          "id": "UNII:4FR53SIF3A",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "blinatumomab",
-            "Blinatumomab (USAN/INN)",
-            "BLINATUMOMAB",
-            "MT-103",
-            "Blinatumomab"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25524799",
-            "PMID:25359367",
-            "PMID:25883042",
-            "PMID:23812940",
-            "PMID:25524800"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 730112,
-=======
-            "identity": 323831,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "https://identifiers.org/umls:C0023485",
-              "name": "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma",
-              "description": "An acute lymphoblastic leukemia that originates from pre-B lymphocytes. The pre-B lymphoblasts contain cytoplasmic immunoglobulin.; A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "NCIT:C27798",
-                "MESH:D015452",
-                "UMLS:C0023485"
-              ],
-              "id": "UMLS:C0023485",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma",
-                "Pre-B Acute Lymphoblastic Leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-              "name": "acute lymphoblastic leukemia",
-              "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "HP:0006721",
-                "MONDO:0004967",
-                "MEDDRA:10000848",
-                "MEDDRA:10000849",
-                "MEDDRA:10025305",
-                "ORPHANET:513",
-                "MEDDRA:10025301",
-                "ICD10:C91.00",
-                "UMLS:C0023453",
-                "DOID:9952",
-                "MEDDRA:10000844",
-                "MEDDRA:10000846",
-                "MEDDRA:10000845",
-                "MEDDRA:10024338",
-                "ICD10:C91",
-                "MESH:D054198",
-                "UMLS:C1961102",
-                "MEDDRA:10060555",
-                "NCIT:C3167",
-                "PDQ:CDR0000043423",
-                "MEDDRA:10024290",
-                "MEDDRA:10000842",
-                "NCIT:C27281",
-                "ICD9:204",
-                "DOID:1037",
-                "MEDDRA:10000843",
-                "EFO:0000220",
-                "SNOMEDCT:128822004",
-                "ICD9:204.0",
-                "UMLS:C0023449",
-                "MEDDRA:10060390",
-                "SNOMEDCT:91857003"
-              ],
-              "id": "MONDO:0004967",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute lymphoblastic leukemia",
-                "lymphoid leukemia",
-                "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-                "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-                "L2 Acute Lymphoblastic Leukemia",
-                "acute lymphocytic leukemia",
-                "Lymphoid leukemia, acute",
-                "acute lymphoblastic leukemia",
-                "Acute lymphocytic leukemia",
-                "Acute Lymphoblastic Leukemia",
-                "Lymphoid leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=46332",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=616067",
-                "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 22644566,
-            "start": 612,
-            "end": 730112,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:33638292': {'publication date': '2021 Feb 26', 'sentence': 'We report on the Australian experience of blinatumomab for treatment of 24 children with relapsed/refractory precursor B-cell acute lymphoblastic leukaemia (B-ALL) and high-risk genetics, resulting in a minimal residual disease (MRD) response rate of 58%, 2-year progression-free survival (PFS) of 39% and 2-year overall survival of 63%.', 'subject score': 1000, 'object score': 923}}",
-              "kg2_ids": [
-                "UMLS:C3853839---SEMMEDDB:treats---None---None---None---UMLS:C0023485---SEMMEDDB:"
-              ],
-              "subject": "UNII:4FR53SIF3A",
-              "id": "23073290",
-              "object": "UMLS:C0023485",
-              "publications": [
-                "PMID:33638292"
-=======
-            "identity": 21529377,
-            "start": 612,
-            "end": 323831,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32314348': {'publication date': '2020 Apr 21', 'sentence': 'Blinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia (ALL).', 'subject score': 1000, 'object score': 1000}, 'PMID:32445796': {'publication date': '2020 May 20', 'sentence': 'Weighing the risks of blinatumomab prior to hematopoietic stem cell transplant in acute lymphoblastic leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:33881461': {'publication date': '2021 Apr 27', 'sentence': 'Blinatumomab, a single-chain, bispecific, T-cell-engaging antibody targeting CD19, is effective in B-precursor acute lymphoblastic leukemia (BCP-ALL), even in the context of chemotherapy-related partial T-cell immunodeficiency.', 'subject score': 1000, 'object score': 937}, 'PMID:36130863': {'publication date': '2022 Aug 15', 'sentence': 'Further, the approval of blinatumomab for MRD+ B-ALL has advanced the concept of MRD response as a clinical endpoint in ALL.', 'subject score': 1000, 'object score': 1000}, 'PMID:36794446': {'publication date': '2023 Feb 16', 'sentence': 'Timing of Intrathecal Chemotherapy and Blinatumomab Impacts Neurotoxicity in Acute Lymphoblastic Leukemia.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C3853839---SEMMEDDB:associated_with---None---None---None---UMLS:C0023449---SEMMEDDB:"
-              ],
-              "subject": "UNII:4FR53SIF3A",
-              "id": "21947892",
-              "object": "MONDO:0004967",
-              "publications": [
-                "PMID:32314348",
-                "PMID:32445796",
-                "PMID:33881461",
-                "PMID:36130863",
-                "PMID:36794446"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 612,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BLINATUMOMAB",
-              "description": "A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62528\" NCI Thesaurus); A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "DRUGBANK:DB09052",
-                "MESH:C510808",
-                "KEGG.DRUG:D09325",
-                "CHEMBL.COMPOUND:CHEMBL1742992",
-                "UMLS:C3853839",
-                "RXNORM:1597258",
-                "DrugCentral:4915",
-                "NCIT:C62528",
-                "UNII:4FR53SIF3A",
-                "GTOPDB:7384"
-              ],
-              "id": "UNII:4FR53SIF3A",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "blinatumomab",
-                "Blinatumomab (USAN/INN)",
-                "BLINATUMOMAB",
-                "MT-103",
-                "Blinatumomab"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25524799",
-                "PMID:25359367",
-                "PMID:25883042",
-                "PMID:23812940",
-                "PMID:25524800"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:32297447': {'publication date': '2020 Apr', 'sentence': 'Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.On November 15, 2018, the Committee for Medicinal Products for Human Use (CHMP) recommended the extension of indication for blinatumomab to include the treatment of adults with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL).', 'subject score': 1000, 'object score': 1000}, 'PMID:32483120': {'publication date': '2020 Jun 01', 'sentence': 'Redirecting T cells to specifically kill malignant cells has been validated as an effective anti-cancer strategy in the clinic with the approval of blinatumomab for acute lymphoblastic leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:32605497': {'publication date': '2020 Jun 30', 'sentence': 'Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab.', 'subject score': 1000, 'object score': 1000}, 'PMID:32829460': {'publication date': '2020 Aug 22', 'sentence': 'Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.', 'subject score': 1000, 'object score': 916}, 'PMID:33000968': {'publication date': '2020 Oct 01', 'sentence': 'AREAS COVERED: This review discusses the main structural and functional features of blinatumomab, and its place in the treatment of ALL.', 'subject score': 1000, 'object score': 1000}, 'PMID:33041246': {'publication date': '2021 02', 'sentence': 'Clinical precedent has been previously established for the FDA-approved bispecific T cell engager, blinatumomab, for acute lymphoblastic leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:33279175': {'publication date': '2020 12', 'sentence': 'Given the recent success of blinatumomab in the treatment of acute lymphoblastic leukemia, there is growing interest in the use of bispecific antibodies as T-cell redirecting antibody for the treatment of cancer.', 'subject score': 1000, 'object score': 1000}, 'PMID:33435716': {'publication date': '2021 Jan 13', 'sentence': 'A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.', 'subject score': 1000, 'object score': 1000}, 'PMID:33489743': {'publication date': '2021 Jun', 'sentence': 'This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:33818299': {'publication date': '2021 Jan-Dec', 'sentence': 'Encouraging clinical data have been reported for T cell-based targeting agents, such as anti-CD19/CD3 bispecific T-cell engager blinatumomab and chimeric antigen receptor (CAR)-T therapies, for acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma (B-NHL).', 'subject score': 781, 'object score': 1000}, 'PMID:33941237': {'publication date': '2021 May 03', 'sentence': 'Blinatumomab, the first BiTE approved for the treatment of acute lymphocytic leukemia (ALL), is appreciated for its high efficacy and safety.', 'subject score': 1000, 'object score': 1000}, 'PMID:34161631': {'publication date': '2021 Jun 23', 'sentence': 'Fifteen (11%) patients had Ph-like ALL; 9 (60%) were treated with blinatumomab and 6 (40%) with SOC.', 'subject score': 1000, 'object score': 1000}, 'PMID:35044079': {'publication date': '2022 Jan 19', 'sentence': 'Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real-world setting: Results from the NEUF study.', 'subject score': 1000, 'object score': 1000}, 'PMID:35053619': {'publication date': '2022 Jan 17', 'sentence': 'Although our study had some limitations with regard to its retrospective design and limited patient population, it clearly showed blinatumomab as not only a feasible but also an effective therapeutic option in pretreated children with r/r BCP-ALL, with a tolerable toxicity profile, paving the way for an HSCT procedure.', 'subject score': 1000, 'object score': 861}, 'PMID:35727173': {'publication date': '2022 Jun 21', 'sentence': 'The safety of concurrent intrathecal chemotherapy during blinatumomab in adults with acute lymphoblastic leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:35935358': {'publication date': '2022', 'sentence': 'The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:36130863': {'publication date': '2022 Aug 15', 'sentence': 'Further, the approval of blinatumomab for MRD+ B-ALL has advanced the concept of MRD response as a clinical endpoint in ALL.', 'subject score': 1000, 'object score': 818}, 'PMID:36266557': {'publication date': '2022 Oct 21', 'sentence': 'Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based Payment Arrangement.', 'subject score': 1000, 'object score': 1000}, 'PMID:36279879': {'publication date': '2022 Oct 21', 'sentence': 'We aimed to establish whether the incorporation of blinatumomab into front-line therapy for acute lymphocytic leukaemia could improve outcomes.', 'subject score': 1000, 'object score': 1000}, 'PMID:37003279': {'publication date': '2023 Mar 29', 'sentence': 'In Philadelphia chromosome-positive acute lymphocytic leukaemia, chemotherapy-free regimens combining blinatumomab and a BCR-ABL1 tyrosine kinase inhibitor are changing acute lymphocytic leukaemia therapy, highlighting the potential for these novel agents to reduce-or perhaps eliminate-the need for chemotherapy in some subtypes.', 'subject score': 1000, 'object score': 916}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 323831,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-          "name": "acute lymphoblastic leukemia",
-          "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "HP:0006721",
-            "MONDO:0004967",
-            "MEDDRA:10000848",
-            "MEDDRA:10000849",
-            "MEDDRA:10025305",
-            "ORPHANET:513",
-            "MEDDRA:10025301",
-            "ICD10:C91.00",
-            "UMLS:C0023453",
-            "DOID:9952",
-            "MEDDRA:10000844",
-            "MEDDRA:10000846",
-            "MEDDRA:10000845",
-            "MEDDRA:10024338",
-            "ICD10:C91",
-            "MESH:D054198",
-            "UMLS:C1961102",
-            "MEDDRA:10060555",
-            "NCIT:C3167",
-            "PDQ:CDR0000043423",
-            "MEDDRA:10024290",
-            "MEDDRA:10000842",
-            "NCIT:C27281",
-            "ICD9:204",
-            "DOID:1037",
-            "MEDDRA:10000843",
-            "EFO:0000220",
-            "SNOMEDCT:128822004",
-            "ICD9:204.0",
-            "UMLS:C0023449",
-            "MEDDRA:10060390",
-            "SNOMEDCT:91857003"
-          ],
-          "id": "MONDO:0004967",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute lymphoblastic leukemia",
-            "lymphoid leukemia",
-            "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-            "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-            "L2 Acute Lymphoblastic Leukemia",
-            "acute lymphocytic leukemia",
-            "Lymphoid leukemia, acute",
-            "acute lymphoblastic leukemia",
-            "Acute lymphocytic leukemia",
-            "Acute Lymphoblastic Leukemia",
-            "Lymphoid leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=46332",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.cancer.gov/dictionary?cdrid=616067",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 612,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BLINATUMOMAB",
-          "description": "A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62528\" NCI Thesaurus); A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "DRUGBANK:DB09052",
-            "MESH:C510808",
-            "KEGG.DRUG:D09325",
-            "CHEMBL.COMPOUND:CHEMBL1742992",
-            "UMLS:C3853839",
-            "RXNORM:1597258",
-            "DrugCentral:4915",
-            "NCIT:C62528",
-            "UNII:4FR53SIF3A",
-            "GTOPDB:7384"
-          ],
-          "id": "UNII:4FR53SIF3A",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "blinatumomab",
-            "Blinatumomab (USAN/INN)",
-            "BLINATUMOMAB",
-            "MT-103",
-            "Blinatumomab"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25524799",
-            "PMID:25359367",
-            "PMID:25883042",
-            "PMID:23812940",
-            "PMID:25524800"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323831,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004967",
-              "name": "acute lymphoblastic leukemia",
-              "description": "Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3167\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3167\" NCI Thesaurus); Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.; A form of acute leukemia characterized by excess lympoblasts. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "HP:0006721",
-                "MONDO:0004967",
-                "MEDDRA:10000848",
-                "MEDDRA:10000849",
-                "MEDDRA:10025305",
-                "ORPHANET:513",
-                "MEDDRA:10025301",
-                "ICD10:C91.00",
-                "UMLS:C0023453",
-                "DOID:9952",
-                "MEDDRA:10000844",
-                "MEDDRA:10000846",
-                "MEDDRA:10000845",
-                "MEDDRA:10024338",
-                "ICD10:C91",
-                "MESH:D054198",
-                "UMLS:C1961102",
-                "MEDDRA:10060555",
-                "NCIT:C3167",
-                "PDQ:CDR0000043423",
-                "MEDDRA:10024290",
-                "MEDDRA:10000842",
-                "NCIT:C27281",
-                "ICD9:204",
-                "DOID:1037",
-                "MEDDRA:10000843",
-                "EFO:0000220",
-                "SNOMEDCT:128822004",
-                "ICD9:204.0",
-                "UMLS:C0023449",
-                "MEDDRA:10060390",
-                "SNOMEDCT:91857003"
-              ],
-              "id": "MONDO:0004967",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute lymphoblastic leukemia",
-                "lymphoid leukemia",
-                "Precursor Cell Lymphoblastic Leukemia Lymphoma",
-                "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
-                "L2 Acute Lymphoblastic Leukemia",
-                "acute lymphocytic leukemia",
-                "Lymphoid leukemia, acute",
-                "acute lymphoblastic leukemia",
-                "Acute lymphocytic leukemia",
-                "Acute Lymphoblastic Leukemia",
-                "Lymphoid leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=46332",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.cancer.gov/dictionary?cdrid=616067",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21514653,
-            "start": 612,
-            "end": 323831,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32297447': {'publication date': '2020 Apr', 'sentence': 'Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.On November 15, 2018, the Committee for Medicinal Products for Human Use (CHMP) recommended the extension of indication for blinatumomab to include the treatment of adults with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL).', 'subject score': 1000, 'object score': 1000}, 'PMID:32483120': {'publication date': '2020 Jun 01', 'sentence': 'Redirecting T cells to specifically kill malignant cells has been validated as an effective anti-cancer strategy in the clinic with the approval of blinatumomab for acute lymphoblastic leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:32605497': {'publication date': '2020 Jun 30', 'sentence': 'Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab.', 'subject score': 1000, 'object score': 1000}, 'PMID:32829460': {'publication date': '2020 Aug 22', 'sentence': 'Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.', 'subject score': 1000, 'object score': 916}, 'PMID:33000968': {'publication date': '2020 Oct 01', 'sentence': 'AREAS COVERED: This review discusses the main structural and functional features of blinatumomab, and its place in the treatment of ALL.', 'subject score': 1000, 'object score': 1000}, 'PMID:33041246': {'publication date': '2021 02', 'sentence': 'Clinical precedent has been previously established for the FDA-approved bispecific T cell engager, blinatumomab, for acute lymphoblastic leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:33279175': {'publication date': '2020 12', 'sentence': 'Given the recent success of blinatumomab in the treatment of acute lymphoblastic leukemia, there is growing interest in the use of bispecific antibodies as T-cell redirecting antibody for the treatment of cancer.', 'subject score': 1000, 'object score': 1000}, 'PMID:33435716': {'publication date': '2021 Jan 13', 'sentence': 'A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.', 'subject score': 1000, 'object score': 1000}, 'PMID:33489743': {'publication date': '2021 Jun', 'sentence': 'This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:33818299': {'publication date': '2021 Jan-Dec', 'sentence': 'Encouraging clinical data have been reported for T cell-based targeting agents, such as anti-CD19/CD3 bispecific T-cell engager blinatumomab and chimeric antigen receptor (CAR)-T therapies, for acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma (B-NHL).', 'subject score': 781, 'object score': 1000}, 'PMID:33941237': {'publication date': '2021 May 03', 'sentence': 'Blinatumomab, the first BiTE approved for the treatment of acute lymphocytic leukemia (ALL), is appreciated for its high efficacy and safety.', 'subject score': 1000, 'object score': 1000}, 'PMID:34161631': {'publication date': '2021 Jun 23', 'sentence': 'Fifteen (11%) patients had Ph-like ALL; 9 (60%) were treated with blinatumomab and 6 (40%) with SOC.', 'subject score': 1000, 'object score': 1000}, 'PMID:35044079': {'publication date': '2022 Jan 19', 'sentence': 'Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real-world setting: Results from the NEUF study.', 'subject score': 1000, 'object score': 1000}, 'PMID:35053619': {'publication date': '2022 Jan 17', 'sentence': 'Although our study had some limitations with regard to its retrospective design and limited patient population, it clearly showed blinatumomab as not only a feasible but also an effective therapeutic option in pretreated children with r/r BCP-ALL, with a tolerable toxicity profile, paving the way for an HSCT procedure.', 'subject score': 1000, 'object score': 861}, 'PMID:35727173': {'publication date': '2022 Jun 21', 'sentence': 'The safety of concurrent intrathecal chemotherapy during blinatumomab in adults with acute lymphoblastic leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:35935358': {'publication date': '2022', 'sentence': 'The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:36130863': {'publication date': '2022 Aug 15', 'sentence': 'Further, the approval of blinatumomab for MRD+ B-ALL has advanced the concept of MRD response as a clinical endpoint in ALL.', 'subject score': 1000, 'object score': 818}, 'PMID:36266557': {'publication date': '2022 Oct 21', 'sentence': 'Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based Payment Arrangement.', 'subject score': 1000, 'object score': 1000}, 'PMID:36279879': {'publication date': '2022 Oct 21', 'sentence': 'We aimed to establish whether the incorporation of blinatumomab into front-line therapy for acute lymphocytic leukaemia could improve outcomes.', 'subject score': 1000, 'object score': 1000}, 'PMID:37003279': {'publication date': '2023 Mar 29', 'sentence': 'In Philadelphia chromosome-positive acute lymphocytic leukaemia, chemotherapy-free regimens combining blinatumomab and a BCR-ABL1 tyrosine kinase inhibitor are changing acute lymphocytic leukaemia therapy, highlighting the potential for these novel agents to reduce-or perhaps eliminate-the need for chemotherapy in some subtypes.', 'subject score': 1000, 'object score': 916}}",
-              "kg2_ids": [
-                "UMLS:C3853839---SEMMEDDB:treats---None---None---None---UMLS:C0023449---SEMMEDDB:"
-              ],
-              "subject": "UNII:4FR53SIF3A",
-              "id": "21932754",
-              "object": "MONDO:0004967",
-              "publications": [
-                "PMID:32297447",
-                "PMID:32483120",
-                "PMID:32605497",
-                "PMID:32829460",
-                "PMID:33000968",
-                "PMID:33041246",
-                "PMID:33279175",
-                "PMID:33435716",
-                "PMID:33489743",
-                "PMID:33818299",
-                "PMID:33941237",
-                "PMID:34161631",
-                "PMID:35044079",
-                "PMID:35053619",
-                "PMID:35727173",
-                "PMID:35935358",
-                "PMID:36130863",
-                "PMID:36266557",
-                "PMID:36279879",
-                "PMID:37003279"
-              ]
-            }
-          },
-          "end": {
-            "identity": 612,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BLINATUMOMAB",
-              "description": "A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62528\" NCI Thesaurus); A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "DRUGBANK:DB09052",
-                "MESH:C510808",
-                "KEGG.DRUG:D09325",
-                "CHEMBL.COMPOUND:CHEMBL1742992",
-                "UMLS:C3853839",
-                "RXNORM:1597258",
-                "DrugCentral:4915",
-                "NCIT:C62528",
-                "UNII:4FR53SIF3A",
-                "GTOPDB:7384"
-              ],
-              "id": "UNII:4FR53SIF3A",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "blinatumomab",
-                "Blinatumomab (USAN/INN)",
-                "BLINATUMOMAB",
-                "MT-103",
-                "Blinatumomab"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25524799",
-                "PMID:25359367",
-                "PMID:25883042",
-                "PMID:23812940",
-                "PMID:25524800"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 319679,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:37131217': {'publication date': '2023 May 02', 'sentence': 'Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 730112,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-          "name": "lymphoma",
-          "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:115244002",
-            "DOID:0060058",
-            "MONDO:0005062",
-            "SNOMEDCT:118600007",
-            "HP:0002665",
-            "NCIT:C7065",
-            "EFO:0000574",
-            "ORPHANET:223735",
-            "MESH:D008223",
-            "SNOMEDCT:188676008",
-            "PDQ:CDR0000041429",
-            "MEDDRA:10025316",
-            "UMLS:C0024299",
-            "NCIT:C3208",
-            "MEDDRA:10025632",
-            "MEDDRA:10025310",
-            "MEDDRA:10025633",
-            "SNOMEDCT:1163043007",
-            "ICD10:C85.9",
-            "UMLS:C1536843",
-            "UMLS:C0334621",
-            "MEDDRA:10025315"
-          ],
-          "id": "MONDO:0005062",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphocytic Neoplasm",
-            "Lymphoma",
-            "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-            "lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/lymphoma",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-=======
-          "iri": "https://identifiers.org/umls:C0023485",
-          "name": "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma",
-          "description": "An acute lymphoblastic leukemia that originates from pre-B lymphocytes. The pre-B lymphoblasts contain cytoplasmic immunoglobulin.; A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "NCIT:C27798",
-            "MESH:D015452",
-            "UMLS:C0023485"
-          ],
-          "id": "UMLS:C0023485",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma",
-            "Pre-B Acute Lymphoblastic Leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 612,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BLINATUMOMAB",
-          "description": "A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62528\" NCI Thesaurus); A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "DRUGBANK:DB09052",
-            "MESH:C510808",
-            "KEGG.DRUG:D09325",
-            "CHEMBL.COMPOUND:CHEMBL1742992",
-            "UMLS:C3853839",
-            "RXNORM:1597258",
-            "DrugCentral:4915",
-            "NCIT:C62528",
-            "UNII:4FR53SIF3A",
-            "GTOPDB:7384"
-          ],
-          "id": "UNII:4FR53SIF3A",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "blinatumomab",
-            "Blinatumomab (USAN/INN)",
-            "BLINATUMOMAB",
-            "MT-103",
-            "Blinatumomab"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25524799",
-            "PMID:25359367",
-            "PMID:25883042",
-            "PMID:23812940",
-            "PMID:25524800"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 319679,
-=======
-            "identity": 730112,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-              "name": "lymphoma",
-              "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:115244002",
-                "DOID:0060058",
-                "MONDO:0005062",
-                "SNOMEDCT:118600007",
-                "HP:0002665",
-                "NCIT:C7065",
-                "EFO:0000574",
-                "ORPHANET:223735",
-                "MESH:D008223",
-                "SNOMEDCT:188676008",
-                "PDQ:CDR0000041429",
-                "MEDDRA:10025316",
-                "UMLS:C0024299",
-                "NCIT:C3208",
-                "MEDDRA:10025632",
-                "MEDDRA:10025310",
-                "MEDDRA:10025633",
-                "SNOMEDCT:1163043007",
-                "ICD10:C85.9",
-                "UMLS:C1536843",
-                "UMLS:C0334621",
-                "MEDDRA:10025315"
-              ],
-              "id": "MONDO:0005062",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphocytic Neoplasm",
-                "Lymphoma",
-                "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-                "lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/lymphoma",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-=======
-              "iri": "https://identifiers.org/umls:C0023485",
-              "name": "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma",
-              "description": "An acute lymphoblastic leukemia that originates from pre-B lymphocytes. The pre-B lymphoblasts contain cytoplasmic immunoglobulin.; A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "NCIT:C27798",
-                "MESH:D015452",
-                "UMLS:C0023485"
-              ],
-              "id": "UMLS:C0023485",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma",
-                "Pre-B Acute Lymphoblastic Leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 21304784,
-            "start": 612,
-            "end": 319679,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32076826': {'publication date': '2020 Feb 20', 'sentence': 'Cytokine storm was reported in four patients (19%).In conclusion, treatment with blinatumomab is effective and tolerable in adult patients with relapsed/refractory B-ALL outside of a clinical trial stetting.', 'subject score': 1000, 'object score': 900}, 'PMID:35503708': {'publication date': '2022 May 03', 'sentence': 'Consolidation with blinatumomab in patients with newly diagnosed, high-risk DLBCL who did not progress under R-chemotherapy was better tolerated than in previous studies where blinatumomab was used for treatment of patients with lymphoma.', 'subject score': 775, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C3853839---SEMMEDDB:treats---None---None---None---UMLS:C0024299---SEMMEDDB:"
-              ],
-              "subject": "UNII:4FR53SIF3A",
-              "id": "21720587",
-              "object": "MONDO:0005062",
-              "publications": [
-                "PMID:32076826",
-                "PMID:35503708"
-=======
-            "identity": 25128286,
-            "start": 612,
-            "end": 730112,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:37131217': {'publication date': '2023 May 02', 'sentence': 'Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C3853839---SEMMEDDB:associated_with---None---None---None---UMLS:C0023485---SEMMEDDB:"
-              ],
-              "subject": "UNII:4FR53SIF3A",
-              "id": "25579460",
-              "object": "UMLS:C0023485",
-              "publications": [
-                "PMID:37131217"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 612,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BLINATUMOMAB",
-              "description": "A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62528\" NCI Thesaurus); A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "DRUGBANK:DB09052",
-                "MESH:C510808",
-                "KEGG.DRUG:D09325",
-                "CHEMBL.COMPOUND:CHEMBL1742992",
-                "UMLS:C3853839",
-                "RXNORM:1597258",
-                "DrugCentral:4915",
-                "NCIT:C62528",
-                "UNII:4FR53SIF3A",
-                "GTOPDB:7384"
-              ],
-              "id": "UNII:4FR53SIF3A",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "blinatumomab",
-                "Blinatumomab (USAN/INN)",
-                "BLINATUMOMAB",
-                "MT-103",
-                "Blinatumomab"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25524799",
-                "PMID:25359367",
-                "PMID:25883042",
-                "PMID:23812940",
-                "PMID:25524800"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:33638292': {'publication date': '2021 Feb 26', 'sentence': 'We report on the Australian experience of blinatumomab for treatment of 24 children with relapsed/refractory precursor B-cell acute lymphoblastic leukaemia (B-ALL) and high-risk genetics, resulting in a minimal residual disease (MRD) response rate of 58%, 2-year progression-free survival (PFS) of 39% and 2-year overall survival of 63%.', 'subject score': 1000, 'object score': 923}}",
-    "p2": {
-      "start": {
-        "identity": 730112,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C0023485",
-          "name": "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma",
-          "description": "An acute lymphoblastic leukemia that originates from pre-B lymphocytes. The pre-B lymphoblasts contain cytoplasmic immunoglobulin.; A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "NCIT:C27798",
-            "MESH:D015452",
-            "UMLS:C0023485"
-          ],
-          "id": "UMLS:C0023485",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma",
-            "Pre-B Acute Lymphoblastic Leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 612,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BLINATUMOMAB",
-          "description": "A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62528\" NCI Thesaurus); A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "DRUGBANK:DB09052",
-            "MESH:C510808",
-            "KEGG.DRUG:D09325",
-            "CHEMBL.COMPOUND:CHEMBL1742992",
-            "UMLS:C3853839",
-            "RXNORM:1597258",
-            "DrugCentral:4915",
-            "NCIT:C62528",
-            "UNII:4FR53SIF3A",
-            "GTOPDB:7384"
-          ],
-          "id": "UNII:4FR53SIF3A",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "blinatumomab",
-            "Blinatumomab (USAN/INN)",
-            "BLINATUMOMAB",
-            "MT-103",
-            "Blinatumomab"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:25524799",
-            "PMID:25359367",
-            "PMID:25883042",
-            "PMID:23812940",
-            "PMID:25524800"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 730112,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C0023485",
-              "name": "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma",
-              "description": "An acute lymphoblastic leukemia that originates from pre-B lymphocytes. The pre-B lymphoblasts contain cytoplasmic immunoglobulin.; A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "NCIT:C27798",
-                "MESH:D015452",
-                "UMLS:C0023485"
-              ],
-              "id": "UMLS:C0023485",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma",
-                "Pre-B Acute Lymphoblastic Leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22644566,
-            "start": 612,
-            "end": 730112,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:33638292': {'publication date': '2021 Feb 26', 'sentence': 'We report on the Australian experience of blinatumomab for treatment of 24 children with relapsed/refractory precursor B-cell acute lymphoblastic leukaemia (B-ALL) and high-risk genetics, resulting in a minimal residual disease (MRD) response rate of 58%, 2-year progression-free survival (PFS) of 39% and 2-year overall survival of 63%.', 'subject score': 1000, 'object score': 923}}",
-              "kg2_ids": [
-                "UMLS:C3853839---SEMMEDDB:treats---None---None---None---UMLS:C0023485---SEMMEDDB:"
-              ],
-              "subject": "UNII:4FR53SIF3A",
-              "id": "23073290",
-              "object": "UMLS:C0023485",
-              "publications": [
-                "PMID:33638292"
-              ]
-            }
-          },
-          "end": {
-            "identity": 612,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BLINATUMOMAB",
-              "description": "A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62528\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62528\" NCI Thesaurus); A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "DRUGBANK:DB09052",
-                "MESH:C510808",
-                "KEGG.DRUG:D09325",
-                "CHEMBL.COMPOUND:CHEMBL1742992",
-                "UMLS:C3853839",
-                "RXNORM:1597258",
-                "DrugCentral:4915",
-                "NCIT:C62528",
-                "UNII:4FR53SIF3A",
-                "GTOPDB:7384"
-              ],
-              "id": "UNII:4FR53SIF3A",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "blinatumomab",
-                "Blinatumomab (USAN/INN)",
-                "BLINATUMOMAB",
-                "MT-103",
-                "Blinatumomab"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:25524799",
-                "PMID:25359367",
-                "PMID:25883042",
-                "PMID:23812940",
-                "PMID:25524800"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:physically_interacts_with",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:28364698': {'publication date': '2017 Jun', 'sentence': 'Tested substances displayed inhibitory effect towards E. coli DNA gyrase, though less than ciprofloxacin.', 'subject score': 888, 'object score': 1000}, 'PMID:3137271': {'publication date': '1988 Sep', 'sentence': 'Higher concentrations of ciprofloxacin were required to interfere with DNA synthesis in resistant isolates compared with the parent strain, a finding indicating a relative insensitivity of DNA gyrase to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:31994086': {'publication date': '2017 May', 'sentence': 'Tested substances displayed inhibitory effect towards E. coli DNA gyrase, though less than ciprofloxacin.', 'subject score': 888, 'object score': 1000}, 'PMID:32036161': {'publication date': '2020 Feb 01', 'sentence': 'Compounds 3b, 9c showed to be very potent inhibitors towards S. aureus DNA gyrase with IC     50       values (18.75 +/- 1.2 and 19.32 +/- 0.99 uM) respectively, compared with Ciprofloxacin (26.43 +/- 0.64 uM).', 'subject score': 888, 'object score': 1000}, 'PMID:32548371': {'publication date': '2020 Jun 02', 'sentence': 'Molecular modeling techniques were employed to evaluate the binding of certain N1-modified fluoroquinolones to DNA gyrase targets from both    Staphylococcus aureus     and    Klebsiella pneumoniae     species compared with ciprofloxacin and norfloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:36148773': {'publication date': '2022 Sep 15', 'sentence': 'Moreover, compounds 5b and 5g showed potent inhibitory activities against DNA gyrase (IC     50       = 1.72 and 5.72 uM) and topoisomerase IV (4.36 and 7.77 uM) compared to ciprofloxacin with IC     50       values 0.66 and 8.16 uM, respectively.', 'subject score': 1000, 'object score': 1000}, 'PMID:37179626': {'publication date': '2023 May 09', 'sentence': 'Moreover, daidzein and khellin inhibited the DNA gyrase enzyme with IC     50       values of 0.042 and 0.822 MUg/mL, respectively, compared to ciprofloxacin with an IC     50       value of 0.018 MUg/mL.', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19187853,
-            "start": 675256,
-            "end": 616,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28364698': {'publication date': '2017 Jun', 'sentence': 'Tested substances displayed inhibitory effect towards E. coli DNA gyrase, though less than ciprofloxacin.', 'subject score': 888, 'object score': 1000}, 'PMID:3137271': {'publication date': '1988 Sep', 'sentence': 'Higher concentrations of ciprofloxacin were required to interfere with DNA synthesis in resistant isolates compared with the parent strain, a finding indicating a relative insensitivity of DNA gyrase to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:31994086': {'publication date': '2017 May', 'sentence': 'Tested substances displayed inhibitory effect towards E. coli DNA gyrase, though less than ciprofloxacin.', 'subject score': 888, 'object score': 1000}, 'PMID:32036161': {'publication date': '2020 Feb 01', 'sentence': 'Compounds 3b, 9c showed to be very potent inhibitors towards S. aureus DNA gyrase with IC     50       values (18.75 +/- 1.2 and 19.32 +/- 0.99 uM) respectively, compared with Ciprofloxacin (26.43 +/- 0.64 uM).', 'subject score': 888, 'object score': 1000}, 'PMID:32548371': {'publication date': '2020 Jun 02', 'sentence': 'Molecular modeling techniques were employed to evaluate the binding of certain N1-modified fluoroquinolones to DNA gyrase targets from both    Staphylococcus aureus     and    Klebsiella pneumoniae     species compared with ciprofloxacin and norfloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:36148773': {'publication date': '2022 Sep 15', 'sentence': 'Moreover, compounds 5b and 5g showed potent inhibitory activities against DNA gyrase (IC     50       = 1.72 and 5.72 uM) and topoisomerase IV (4.36 and 7.77 uM) compared to ciprofloxacin with IC     50       values 0.66 and 8.16 uM, respectively.', 'subject score': 1000, 'object score': 1000}, 'PMID:37179626': {'publication date': '2023 May 09', 'sentence': 'Moreover, daidzein and khellin inhibited the DNA gyrase enzyme with IC     50       values of 0.042 and 0.822 MUg/mL, respectively, compared to ciprofloxacin with an IC     50       value of 0.018 MUg/mL.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0949782---SEMMEDDB:compared_with---None---None---None---UMLS:C0008809---SEMMEDDB:",
-                "UMLS:C0949782---SEMMEDDB:lower_than---None---None---None---UMLS:C0008809---SEMMEDDB:"
-              ],
-              "subject": "MESH:D027081",
-              "id": "19572117",
-              "object": "PUBCHEM.COMPOUND:2764",
-              "publications": [
-                "PMID:32036161",
-                "PMID:28364698",
-                "PMID:3137271",
-                "PMID:36148773",
-                "PMID:37179626",
-                "PMID:31994086",
-                "PMID:32548371"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:physically_interacts_with",
-    "type(r2)": "biolink:coexists_with",
-    "r2.publications_info": "{'PMID:23804759': {'publication date': '2013 Sep', 'sentence': 'We reveal here for the first time the architecture of the full-length Thermus thermophilus DNA gyrase alone and in a cleavage complex with a 155 bp DNA duplex in the presence of the antibiotic ciprofloxacin, using cryo-electron microscopy.', 'subject score': 839, 'object score': 888}, 'PMID:2826973': {'publication date': '1987 Oct', 'sentence': 'In order to detect modification of DNA-gyrase, we performed supercoiling assays in vitro in presence of norfloxacin and ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:8619577': {'publication date': '1995 Oct', 'sentence': 'Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem.', 'subject score': 901, 'object score': 694}}",
-    "p2": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16663049,
-            "start": 675256,
-            "end": 616,
-            "type": "biolink:coexists_with",
-            "properties": {
-              "predicate": "biolink:coexists_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23804759': {'publication date': '2013 Sep', 'sentence': 'We reveal here for the first time the architecture of the full-length Thermus thermophilus DNA gyrase alone and in a cleavage complex with a 155 bp DNA duplex in the presence of the antibiotic ciprofloxacin, using cryo-electron microscopy.', 'subject score': 839, 'object score': 888}, 'PMID:2826973': {'publication date': '1987 Oct', 'sentence': 'In order to detect modification of DNA-gyrase, we performed supercoiling assays in vitro in presence of norfloxacin and ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:8619577': {'publication date': '1995 Oct', 'sentence': 'Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem.', 'subject score': 901, 'object score': 694}}",
-              "kg2_ids": [
-                "UMLS:C0949782---SEMMEDDB:coexists_with---None---None---None---UMLS:C0008809---SEMMEDDB:"
-              ],
-              "subject": "MESH:D027081",
-              "id": "17007621",
-              "object": "PUBCHEM.COMPOUND:2764",
-              "publications": [
-                "PMID:23804759",
-                "PMID:2826973",
-                "PMID:8619577"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:physically_interacts_with",
-    "type(r2)": "biolink:coexists_with",
-    "r2.publications_info": "{'PMID:1656866': {'publication date': '1991 Aug', 'sentence': 'These data indicate that persistence of Pseudomonas aeruginosa to ciprofloxacin involves changes in DNA gyrase and is associated with pleiotropic changes in outer membrane proteins and lipopolysaccharide.', 'subject score': 1000, 'object score': 1000}, 'PMID:24064645': {'publication date': '2013', 'sentence': 'PURPOSE: There are increasing reports on failure of clinical response to ciprofloxacin in typhoid fever despite the strain being sensitive to drug in in-vitro using standard guidelines and showing mutations in DNA gyrase.', 'subject score': 1000, 'object score': 1000}, 'PMID:27175500': {'publication date': '2016 Apr', 'sentence': 'The aims of this study were to investigate ciprofloxacin (CIP) and levofloxacin (LEV) minimum inhibitor concentrations (MIC), clonal relationships, mutations that occur in DNA gyrase and topoisomerase IV genes and overexpression of efflux pumps in nosocomial A.baumannii isolates.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12110069,
-            "start": 616,
-            "end": 675256,
-            "type": "biolink:coexists_with",
-            "properties": {
-              "predicate": "biolink:coexists_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1656866': {'publication date': '1991 Aug', 'sentence': 'These data indicate that persistence of Pseudomonas aeruginosa to ciprofloxacin involves changes in DNA gyrase and is associated with pleiotropic changes in outer membrane proteins and lipopolysaccharide.', 'subject score': 1000, 'object score': 1000}, 'PMID:24064645': {'publication date': '2013', 'sentence': 'PURPOSE: There are increasing reports on failure of clinical response to ciprofloxacin in typhoid fever despite the strain being sensitive to drug in in-vitro using standard guidelines and showing mutations in DNA gyrase.', 'subject score': 1000, 'object score': 1000}, 'PMID:27175500': {'publication date': '2016 Apr', 'sentence': 'The aims of this study were to investigate ciprofloxacin (CIP) and levofloxacin (LEV) minimum inhibitor concentrations (MIC), clonal relationships, mutations that occur in DNA gyrase and topoisomerase IV genes and overexpression of efflux pumps in nosocomial A.baumannii isolates.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:coexists_with---None---None---None---UMLS:C0949782---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "12385742",
-              "object": "MESH:D027081",
-              "publications": [
-                "PMID:1656866",
-                "PMID:24064645",
-                "PMID:27175500"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:physically_interacts_with",
-    "type(r2)": "biolink:physically_interacts_with",
-    "r2.publications_info": "{'PMID:10824040': {'publication date': '2000 Apr', 'sentence': 'Topoisomerase IV and DNA gyrase were purified from a ciprofloxacin-sensitive Streptococcus pneumoniae strain and from two clinical isolates of S. pneumoniae with high-level resistance to ciprofloxacin by means of a gene cloning method in Escherichia coli.', 'subject score': 1000, 'object score': 1000}, 'PMID:1649573': {'publication date': '1991 May', 'sentence': 'The DNA gyrase isolated from MP051 was 24-fold less sensitive to inhibition of supercoiling by ciprofloxacin than the DNA gyrase isolated from MP050 was.', 'subject score': 1000, 'object score': 1000}, 'PMID:2158277': {'publication date': '1990 Feb', 'sentence': 'Preparations of DNA gyrase from the quinolone-resistant posttherapy isolates were 16- to 32-fold less sensitive to inhibition of supercoiling by ciprofloxacin and nalidixic acid than was gyrase from the pretherapy isolate.', 'subject score': 1000, 'object score': 1000}, 'PMID:26663076': {'publication date': '2016 Feb 12', 'sentence': 'Taken together these experiments now show unequivocally that A. thaliana encodes an organelle-targeted DNA gyrase that is the target of the quinolone drug ciprofloxacin; this has important consequences for plant physiology and the development of herbicides.', 'subject score': 852, 'object score': 790}, 'PMID:3034057': {'publication date': '1987 Apr 27', 'sentence': 'In summary, the A subunit of DNA gyrase is a target of ciprofloxacin and other quinolones.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8039359,
-            "start": 675256,
-            "end": 616,
-            "type": "biolink:physically_interacts_with",
-            "properties": {
-              "predicate": "biolink:physically_interacts_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10824040': {'publication date': '2000 Apr', 'sentence': 'Topoisomerase IV and DNA gyrase were purified from a ciprofloxacin-sensitive Streptococcus pneumoniae strain and from two clinical isolates of S. pneumoniae with high-level resistance to ciprofloxacin by means of a gene cloning method in Escherichia coli.', 'subject score': 1000, 'object score': 1000}, 'PMID:1649573': {'publication date': '1991 May', 'sentence': 'The DNA gyrase isolated from MP051 was 24-fold less sensitive to inhibition of supercoiling by ciprofloxacin than the DNA gyrase isolated from MP050 was.', 'subject score': 1000, 'object score': 1000}, 'PMID:2158277': {'publication date': '1990 Feb', 'sentence': 'Preparations of DNA gyrase from the quinolone-resistant posttherapy isolates were 16- to 32-fold less sensitive to inhibition of supercoiling by ciprofloxacin and nalidixic acid than was gyrase from the pretherapy isolate.', 'subject score': 1000, 'object score': 1000}, 'PMID:26663076': {'publication date': '2016 Feb 12', 'sentence': 'Taken together these experiments now show unequivocally that A. thaliana encodes an organelle-targeted DNA gyrase that is the target of the quinolone drug ciprofloxacin; this has important consequences for plant physiology and the development of herbicides.', 'subject score': 852, 'object score': 790}, 'PMID:3034057': {'publication date': '1987 Apr 27', 'sentence': 'In summary, the A subunit of DNA gyrase is a target of ciprofloxacin and other quinolones.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0949782---SEMMEDDB:interacts_with---None---None---None---UMLS:C0008809---SEMMEDDB:"
-              ],
-              "subject": "MESH:D027081",
-              "id": "8212496",
-              "object": "PUBCHEM.COMPOUND:2764",
-              "publications": [
-                "PMID:10824040",
-                "PMID:1649573",
-                "PMID:2158277",
-                "PMID:26663076",
-                "PMID:3034057"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:physically_interacts_with",
-    "type(r2)": "biolink:physically_interacts_with",
-    "r2.publications_info": "{'PMID:11850491': {'publication date': '2002 Feb', 'sentence': 'UNLABELLED: Ciprofloxacin, a quinolone antibiotic drug, binds to DNA topoisomerase IV and DNA gyrase of various bacteria.', 'subject score': 1000, 'object score': 1000}, 'PMID:18677735': {'publication date': '2008 Sep 01', 'sentence': 'The mode of binding of ciprofloxacin, levofloxacin, and moxifloxacin to DNA gyrase was analyzed by means of docking calculations over the surface of the QRDR of GyrA.', 'subject score': 1000, 'object score': 1000}, 'PMID:22530906': {'publication date': '2012 May', 'sentence': 'We postulate that the enhanced potency of BSFQs against Staphylococcus aureus compared to CIP and NOR could be caused by the presence of the BS moiety that resulted in enhanced binding to DNA gyrase of Sa.', 'subject score': 1000, 'object score': 1000}, 'PMID:24327941': {'publication date': '2013', 'sentence': 'In conclusion, the AcrAB efflux system is one of the principal mechanisms contribute in ciprofloxacin resistance among K. pneumoniae isolates but there are some other mechanisms interfere with ciprofloxacin resistance such as mutation in target proteins of DNA gyrase of topoisomerase IV enzymes.', 'subject score': 694, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9184562,
-            "start": 616,
-            "end": 675256,
-            "type": "biolink:physically_interacts_with",
-            "properties": {
-              "predicate": "biolink:physically_interacts_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11850491': {'publication date': '2002 Feb', 'sentence': 'UNLABELLED: Ciprofloxacin, a quinolone antibiotic drug, binds to DNA topoisomerase IV and DNA gyrase of various bacteria.', 'subject score': 1000, 'object score': 1000}, 'PMID:18677735': {'publication date': '2008 Sep 01', 'sentence': 'The mode of binding of ciprofloxacin, levofloxacin, and moxifloxacin to DNA gyrase was analyzed by means of docking calculations over the surface of the QRDR of GyrA.', 'subject score': 1000, 'object score': 1000}, 'PMID:22530906': {'publication date': '2012 May', 'sentence': 'We postulate that the enhanced potency of BSFQs against Staphylococcus aureus compared to CIP and NOR could be caused by the presence of the BS moiety that resulted in enhanced binding to DNA gyrase of Sa.', 'subject score': 1000, 'object score': 1000}, 'PMID:24327941': {'publication date': '2013', 'sentence': 'In conclusion, the AcrAB efflux system is one of the principal mechanisms contribute in ciprofloxacin resistance among K. pneumoniae isolates but there are some other mechanisms interfere with ciprofloxacin resistance such as mutation in target proteins of DNA gyrase of topoisomerase IV enzymes.', 'subject score': 694, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:interacts_with---None---None---None---UMLS:C0949782---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "9387116",
-              "object": "MESH:D027081",
-              "publications": [
-                "PMID:11850491",
-                "PMID:18677735",
-                "PMID:22530906",
-                "PMID:24327941"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:physically_interacts_with",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:26100716': {'publication date': '2015 Sep', 'sentence': 'Plasmid-encoded protein QnrB1 protects DNA gyrase from ciprofloxacin inhibition.', 'subject score': 1000, 'object score': 888}, 'PMID:27618918': {'publication date': '2016 08', 'sentence': 'Antimicrobial susceptibility pattern and sequence analysis of DNA gyrase and DNA topoisomerase IV in Salmonella enterica serovars Typhi and Paratyphi A isolates with decreased susceptibility to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:33846132': {'publication date': '2021 Apr 12', 'sentence': 'Alanine replacement of arginine at residue 293 and a small deletion of amino acids 286-289 of GyrA resulted in a decrease in the QnrB1-mediated increase in quinolone MICs and also abolished the QnrB1 protection of purified DNA gyrase from ciprofloxacin inhibition.', 'subject score': 901, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18034605,
-            "start": 675256,
-            "end": 616,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26100716': {'publication date': '2015 Sep', 'sentence': 'Plasmid-encoded protein QnrB1 protects DNA gyrase from ciprofloxacin inhibition.', 'subject score': 1000, 'object score': 888}, 'PMID:27618918': {'publication date': '2016 08', 'sentence': 'Antimicrobial susceptibility pattern and sequence analysis of DNA gyrase and DNA topoisomerase IV in Salmonella enterica serovars Typhi and Paratyphi A isolates with decreased susceptibility to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:33846132': {'publication date': '2021 Apr 12', 'sentence': 'Alanine replacement of arginine at residue 293 and a small deletion of amino acids 286-289 of GyrA resulted in a decrease in the QnrB1-mediated increase in quinolone MICs and also abolished the QnrB1 protection of purified DNA gyrase from ciprofloxacin inhibition.', 'subject score': 901, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0949782---SEMMEDDB:inhibits---biolink:causes---activity---None---UMLS:C0008809---SEMMEDDB:"
-              ],
-              "subject": "MESH:D027081",
-              "id": "18400322",
-              "object": "PUBCHEM.COMPOUND:2764",
-              "publications": [
-                "PMID:26100716",
-                "PMID:27618918",
-                "PMID:33846132"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:physically_interacts_with",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:10543732': {'publication date': '1999 Nov', 'sentence': 'The concentrations of ciprofloxacin, sparfloxacin, levofloxacin, or ofloxacin required to inhibit wild-type topoisomerase IV were 8 to 16 times lower than those required to inhibit wild-type DNA gyrase.', 'subject score': 1000, 'object score': 861}, 'PMID:23877698': {'publication date': '2013 Oct', 'sentence': 'The broad-spectrum fluoroquinolone ciprofloxacin is a bactericidal antibiotic targeting DNA topoisomerase IV and DNA gyrase encoded by the parC and gyrA genes.', 'subject score': 764, 'object score': 1000}, 'PMID:2751986': {'publication date': '1989 May 02', 'sentence': 'The fluoroquinolone ciprofloxacin, an inhibitor of eubacterial DNA gyrase, induces single- and double-stranded DNA breaks in the plasmid pGRB-1 from the halophilic archaebacterium Halobacterium GRB when the cells are treated by this drug in a magnesium-depleted medium.', 'subject score': 872, 'object score': 877}, 'PMID:27717325': {'publication date': '2016 Oct 07', 'sentence': 'RESULTS: Ciprofloxacin, an inhibitor of bacterial DNA gyrase and topoisomerase IV, was shown to inhibit growth of C. glutamicum wild type with concomitant excretion of glutamate.', 'subject score': 1000, 'object score': 901}, 'PMID:30074404': {'publication date': '2018 Nov', 'sentence': 'Ciprofloxacin, a broad-spectrum fluoroquinolone, is a bactericidal antibiotic targeting DNA gyrase and DNA topoisomerase IV encoded by the gyrA and parC genes.', 'subject score': 1000, 'object score': 825}, 'PMID:3292209': {'publication date': '1988 Apr', 'sentence': 'The primary mechanism of action of ciprofloxacin is inhibition of bacterial DNA gyrase.', 'subject score': 1000, 'object score': 901}, 'PMID:3293157': {'publication date': '1988 May-Jun', 'sentence': 'Ciprofloxacin, like other quinolones, inhibits DNA gyrase, but its bactericidal effects are not completely reversible by inhibitors of protein or RNA synthesis.', 'subject score': 1000, 'object score': 1000}, 'PMID:34541445': {'publication date': '2021 Sep', 'sentence': 'An attractive novel herbicidal target is plant DNA gyrase, which has been demonstrated to be effectively inhibited by the known antimicrobial ciprofloxacin.', 'subject score': 840, 'object score': 1000}, 'PMID:36215786': {'publication date': '2022 Oct 05', 'sentence': 'Besides, DNA gyrase inhibition assay of compounds 6d and 6e was carried out in comparison to ciprofloxacin, and interestingly, compounds 6d and 6e disclosed promising IC50 values of 0.242 and 0.177 MUM, respectively, whereas ciprofloxacin displayed an IC50 value of 0.768 MUM, assuring the proposed mechanism of action for the afforded compounds.', 'subject score': 1000, 'object score': 861}, 'PMID:36644068': {'publication date': '2022 Dec', 'sentence': 'Ciprofloxacin inhibits the bacterial DNA-gyrase enzyme resulting in the destruction of the organism.', 'subject score': 1000, 'object score': 861}, 'PMID:7503546': {'publication date': '1995 Dec 01', 'sentence': 'However, in vitro assays to show the inhibition of supercoiling activity and stimulation of cleavable complex formation demonstrated that ciprofloxacin is a potent inhibitor of mycobacterial DNA gyrase.', 'subject score': 1000, 'object score': 901}, 'PMID:8440750': {'publication date': '1993 Feb', 'sentence': 'The 4-quinolone antibiotics nalidixic acid and ciprofloxacin are potent inhibitors of the bacterial type II topoisomerase DNA gyrase.', 'subject score': 1000, 'object score': 839}}",
-    "p2": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7620631,
-            "start": 616,
-            "end": 675256,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10543732': {'publication date': '1999 Nov', 'sentence': 'The concentrations of ciprofloxacin, sparfloxacin, levofloxacin, or ofloxacin required to inhibit wild-type topoisomerase IV were 8 to 16 times lower than those required to inhibit wild-type DNA gyrase.', 'subject score': 1000, 'object score': 861}, 'PMID:23877698': {'publication date': '2013 Oct', 'sentence': 'The broad-spectrum fluoroquinolone ciprofloxacin is a bactericidal antibiotic targeting DNA topoisomerase IV and DNA gyrase encoded by the parC and gyrA genes.', 'subject score': 764, 'object score': 1000}, 'PMID:2751986': {'publication date': '1989 May 02', 'sentence': 'The fluoroquinolone ciprofloxacin, an inhibitor of eubacterial DNA gyrase, induces single- and double-stranded DNA breaks in the plasmid pGRB-1 from the halophilic archaebacterium Halobacterium GRB when the cells are treated by this drug in a magnesium-depleted medium.', 'subject score': 872, 'object score': 877}, 'PMID:27717325': {'publication date': '2016 Oct 07', 'sentence': 'RESULTS: Ciprofloxacin, an inhibitor of bacterial DNA gyrase and topoisomerase IV, was shown to inhibit growth of C. glutamicum wild type with concomitant excretion of glutamate.', 'subject score': 1000, 'object score': 901}, 'PMID:30074404': {'publication date': '2018 Nov', 'sentence': 'Ciprofloxacin, a broad-spectrum fluoroquinolone, is a bactericidal antibiotic targeting DNA gyrase and DNA topoisomerase IV encoded by the gyrA and parC genes.', 'subject score': 1000, 'object score': 825}, 'PMID:3292209': {'publication date': '1988 Apr', 'sentence': 'The primary mechanism of action of ciprofloxacin is inhibition of bacterial DNA gyrase.', 'subject score': 1000, 'object score': 901}, 'PMID:3293157': {'publication date': '1988 May-Jun', 'sentence': 'Ciprofloxacin, like other quinolones, inhibits DNA gyrase, but its bactericidal effects are not completely reversible by inhibitors of protein or RNA synthesis.', 'subject score': 1000, 'object score': 1000}, 'PMID:34541445': {'publication date': '2021 Sep', 'sentence': 'An attractive novel herbicidal target is plant DNA gyrase, which has been demonstrated to be effectively inhibited by the known antimicrobial ciprofloxacin.', 'subject score': 840, 'object score': 1000}, 'PMID:36215786': {'publication date': '2022 Oct 05', 'sentence': 'Besides, DNA gyrase inhibition assay of compounds 6d and 6e was carried out in comparison to ciprofloxacin, and interestingly, compounds 6d and 6e disclosed promising IC50 values of 0.242 and 0.177 MUM, respectively, whereas ciprofloxacin displayed an IC50 value of 0.768 MUM, assuring the proposed mechanism of action for the afforded compounds.', 'subject score': 1000, 'object score': 861}, 'PMID:36644068': {'publication date': '2022 Dec', 'sentence': 'Ciprofloxacin inhibits the bacterial DNA-gyrase enzyme resulting in the destruction of the organism.', 'subject score': 1000, 'object score': 861}, 'PMID:7503546': {'publication date': '1995 Dec 01', 'sentence': 'However, in vitro assays to show the inhibition of supercoiling activity and stimulation of cleavable complex formation demonstrated that ciprofloxacin is a potent inhibitor of mycobacterial DNA gyrase.', 'subject score': 1000, 'object score': 901}, 'PMID:8440750': {'publication date': '1993 Feb', 'sentence': 'The 4-quinolone antibiotics nalidixic acid and ciprofloxacin are potent inhibitors of the bacterial type II topoisomerase DNA gyrase.', 'subject score': 1000, 'object score': 839}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:inhibits---biolink:causes---activity---None---UMLS:C0949782---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7781719",
-              "object": "MESH:D027081",
-              "publications": [
-                "PMID:10543732",
-                "PMID:23877698",
-                "PMID:2751986",
-                "PMID:27717325",
-                "PMID:30074404",
-                "PMID:3292209",
-                "PMID:3293157",
-                "PMID:34541445",
-                "PMID:36215786",
-                "PMID:36644068",
-                "PMID:7503546",
-                "PMID:8440750"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:affects",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:28364698': {'publication date': '2017 Jun', 'sentence': 'Tested substances displayed inhibitory effect towards E. coli DNA gyrase, though less than ciprofloxacin.', 'subject score': 888, 'object score': 1000}, 'PMID:3137271': {'publication date': '1988 Sep', 'sentence': 'Higher concentrations of ciprofloxacin were required to interfere with DNA synthesis in resistant isolates compared with the parent strain, a finding indicating a relative insensitivity of DNA gyrase to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:31994086': {'publication date': '2017 May', 'sentence': 'Tested substances displayed inhibitory effect towards E. coli DNA gyrase, though less than ciprofloxacin.', 'subject score': 888, 'object score': 1000}, 'PMID:32036161': {'publication date': '2020 Feb 01', 'sentence': 'Compounds 3b, 9c showed to be very potent inhibitors towards S. aureus DNA gyrase with IC     50       values (18.75 +/- 1.2 and 19.32 +/- 0.99 uM) respectively, compared with Ciprofloxacin (26.43 +/- 0.64 uM).', 'subject score': 888, 'object score': 1000}, 'PMID:32548371': {'publication date': '2020 Jun 02', 'sentence': 'Molecular modeling techniques were employed to evaluate the binding of certain N1-modified fluoroquinolones to DNA gyrase targets from both    Staphylococcus aureus     and    Klebsiella pneumoniae     species compared with ciprofloxacin and norfloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:36148773': {'publication date': '2022 Sep 15', 'sentence': 'Moreover, compounds 5b and 5g showed potent inhibitory activities against DNA gyrase (IC     50       = 1.72 and 5.72 uM) and topoisomerase IV (4.36 and 7.77 uM) compared to ciprofloxacin with IC     50       values 0.66 and 8.16 uM, respectively.', 'subject score': 1000, 'object score': 1000}, 'PMID:37179626': {'publication date': '2023 May 09', 'sentence': 'Moreover, daidzein and khellin inhibited the DNA gyrase enzyme with IC     50       values of 0.042 and 0.822 MUg/mL, respectively, compared to ciprofloxacin with an IC     50       value of 0.018 MUg/mL.', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19187853,
-            "start": 675256,
-            "end": 616,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28364698': {'publication date': '2017 Jun', 'sentence': 'Tested substances displayed inhibitory effect towards E. coli DNA gyrase, though less than ciprofloxacin.', 'subject score': 888, 'object score': 1000}, 'PMID:3137271': {'publication date': '1988 Sep', 'sentence': 'Higher concentrations of ciprofloxacin were required to interfere with DNA synthesis in resistant isolates compared with the parent strain, a finding indicating a relative insensitivity of DNA gyrase to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:31994086': {'publication date': '2017 May', 'sentence': 'Tested substances displayed inhibitory effect towards E. coli DNA gyrase, though less than ciprofloxacin.', 'subject score': 888, 'object score': 1000}, 'PMID:32036161': {'publication date': '2020 Feb 01', 'sentence': 'Compounds 3b, 9c showed to be very potent inhibitors towards S. aureus DNA gyrase with IC     50       values (18.75 +/- 1.2 and 19.32 +/- 0.99 uM) respectively, compared with Ciprofloxacin (26.43 +/- 0.64 uM).', 'subject score': 888, 'object score': 1000}, 'PMID:32548371': {'publication date': '2020 Jun 02', 'sentence': 'Molecular modeling techniques were employed to evaluate the binding of certain N1-modified fluoroquinolones to DNA gyrase targets from both    Staphylococcus aureus     and    Klebsiella pneumoniae     species compared with ciprofloxacin and norfloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:36148773': {'publication date': '2022 Sep 15', 'sentence': 'Moreover, compounds 5b and 5g showed potent inhibitory activities against DNA gyrase (IC     50       = 1.72 and 5.72 uM) and topoisomerase IV (4.36 and 7.77 uM) compared to ciprofloxacin with IC     50       values 0.66 and 8.16 uM, respectively.', 'subject score': 1000, 'object score': 1000}, 'PMID:37179626': {'publication date': '2023 May 09', 'sentence': 'Moreover, daidzein and khellin inhibited the DNA gyrase enzyme with IC     50       values of 0.042 and 0.822 MUg/mL, respectively, compared to ciprofloxacin with an IC     50       value of 0.018 MUg/mL.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0949782---SEMMEDDB:compared_with---None---None---None---UMLS:C0008809---SEMMEDDB:",
-                "UMLS:C0949782---SEMMEDDB:lower_than---None---None---None---UMLS:C0008809---SEMMEDDB:"
-              ],
-              "subject": "MESH:D027081",
-              "id": "19572117",
-              "object": "PUBCHEM.COMPOUND:2764",
-              "publications": [
-                "PMID:32036161",
-                "PMID:28364698",
-                "PMID:3137271",
-                "PMID:36148773",
-                "PMID:37179626",
-                "PMID:31994086",
-                "PMID:32548371"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:affects",
-    "type(r2)": "biolink:coexists_with",
-    "r2.publications_info": "{'PMID:23804759': {'publication date': '2013 Sep', 'sentence': 'We reveal here for the first time the architecture of the full-length Thermus thermophilus DNA gyrase alone and in a cleavage complex with a 155 bp DNA duplex in the presence of the antibiotic ciprofloxacin, using cryo-electron microscopy.', 'subject score': 839, 'object score': 888}, 'PMID:2826973': {'publication date': '1987 Oct', 'sentence': 'In order to detect modification of DNA-gyrase, we performed supercoiling assays in vitro in presence of norfloxacin and ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:8619577': {'publication date': '1995 Oct', 'sentence': 'Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem.', 'subject score': 901, 'object score': 694}}",
-    "p2": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16663049,
-            "start": 675256,
-            "end": 616,
-            "type": "biolink:coexists_with",
-            "properties": {
-              "predicate": "biolink:coexists_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23804759': {'publication date': '2013 Sep', 'sentence': 'We reveal here for the first time the architecture of the full-length Thermus thermophilus DNA gyrase alone and in a cleavage complex with a 155 bp DNA duplex in the presence of the antibiotic ciprofloxacin, using cryo-electron microscopy.', 'subject score': 839, 'object score': 888}, 'PMID:2826973': {'publication date': '1987 Oct', 'sentence': 'In order to detect modification of DNA-gyrase, we performed supercoiling assays in vitro in presence of norfloxacin and ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:8619577': {'publication date': '1995 Oct', 'sentence': 'Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem.', 'subject score': 901, 'object score': 694}}",
-              "kg2_ids": [
-                "UMLS:C0949782---SEMMEDDB:coexists_with---None---None---None---UMLS:C0008809---SEMMEDDB:"
-              ],
-              "subject": "MESH:D027081",
-              "id": "17007621",
-              "object": "PUBCHEM.COMPOUND:2764",
-              "publications": [
-                "PMID:23804759",
-                "PMID:2826973",
-                "PMID:8619577"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:affects",
-    "type(r2)": "biolink:coexists_with",
-    "r2.publications_info": "{'PMID:1656866': {'publication date': '1991 Aug', 'sentence': 'These data indicate that persistence of Pseudomonas aeruginosa to ciprofloxacin involves changes in DNA gyrase and is associated with pleiotropic changes in outer membrane proteins and lipopolysaccharide.', 'subject score': 1000, 'object score': 1000}, 'PMID:24064645': {'publication date': '2013', 'sentence': 'PURPOSE: There are increasing reports on failure of clinical response to ciprofloxacin in typhoid fever despite the strain being sensitive to drug in in-vitro using standard guidelines and showing mutations in DNA gyrase.', 'subject score': 1000, 'object score': 1000}, 'PMID:27175500': {'publication date': '2016 Apr', 'sentence': 'The aims of this study were to investigate ciprofloxacin (CIP) and levofloxacin (LEV) minimum inhibitor concentrations (MIC), clonal relationships, mutations that occur in DNA gyrase and topoisomerase IV genes and overexpression of efflux pumps in nosocomial A.baumannii isolates.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12110069,
-            "start": 616,
-            "end": 675256,
-            "type": "biolink:coexists_with",
-            "properties": {
-              "predicate": "biolink:coexists_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1656866': {'publication date': '1991 Aug', 'sentence': 'These data indicate that persistence of Pseudomonas aeruginosa to ciprofloxacin involves changes in DNA gyrase and is associated with pleiotropic changes in outer membrane proteins and lipopolysaccharide.', 'subject score': 1000, 'object score': 1000}, 'PMID:24064645': {'publication date': '2013', 'sentence': 'PURPOSE: There are increasing reports on failure of clinical response to ciprofloxacin in typhoid fever despite the strain being sensitive to drug in in-vitro using standard guidelines and showing mutations in DNA gyrase.', 'subject score': 1000, 'object score': 1000}, 'PMID:27175500': {'publication date': '2016 Apr', 'sentence': 'The aims of this study were to investigate ciprofloxacin (CIP) and levofloxacin (LEV) minimum inhibitor concentrations (MIC), clonal relationships, mutations that occur in DNA gyrase and topoisomerase IV genes and overexpression of efflux pumps in nosocomial A.baumannii isolates.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:coexists_with---None---None---None---UMLS:C0949782---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "12385742",
-              "object": "MESH:D027081",
-              "publications": [
-                "PMID:1656866",
-                "PMID:24064645",
-                "PMID:27175500"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:affects",
-    "type(r2)": "biolink:physically_interacts_with",
-    "r2.publications_info": "{'PMID:10824040': {'publication date': '2000 Apr', 'sentence': 'Topoisomerase IV and DNA gyrase were purified from a ciprofloxacin-sensitive Streptococcus pneumoniae strain and from two clinical isolates of S. pneumoniae with high-level resistance to ciprofloxacin by means of a gene cloning method in Escherichia coli.', 'subject score': 1000, 'object score': 1000}, 'PMID:1649573': {'publication date': '1991 May', 'sentence': 'The DNA gyrase isolated from MP051 was 24-fold less sensitive to inhibition of supercoiling by ciprofloxacin than the DNA gyrase isolated from MP050 was.', 'subject score': 1000, 'object score': 1000}, 'PMID:2158277': {'publication date': '1990 Feb', 'sentence': 'Preparations of DNA gyrase from the quinolone-resistant posttherapy isolates were 16- to 32-fold less sensitive to inhibition of supercoiling by ciprofloxacin and nalidixic acid than was gyrase from the pretherapy isolate.', 'subject score': 1000, 'object score': 1000}, 'PMID:26663076': {'publication date': '2016 Feb 12', 'sentence': 'Taken together these experiments now show unequivocally that A. thaliana encodes an organelle-targeted DNA gyrase that is the target of the quinolone drug ciprofloxacin; this has important consequences for plant physiology and the development of herbicides.', 'subject score': 852, 'object score': 790}, 'PMID:3034057': {'publication date': '1987 Apr 27', 'sentence': 'In summary, the A subunit of DNA gyrase is a target of ciprofloxacin and other quinolones.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8039359,
-            "start": 675256,
-            "end": 616,
-            "type": "biolink:physically_interacts_with",
-            "properties": {
-              "predicate": "biolink:physically_interacts_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10824040': {'publication date': '2000 Apr', 'sentence': 'Topoisomerase IV and DNA gyrase were purified from a ciprofloxacin-sensitive Streptococcus pneumoniae strain and from two clinical isolates of S. pneumoniae with high-level resistance to ciprofloxacin by means of a gene cloning method in Escherichia coli.', 'subject score': 1000, 'object score': 1000}, 'PMID:1649573': {'publication date': '1991 May', 'sentence': 'The DNA gyrase isolated from MP051 was 24-fold less sensitive to inhibition of supercoiling by ciprofloxacin than the DNA gyrase isolated from MP050 was.', 'subject score': 1000, 'object score': 1000}, 'PMID:2158277': {'publication date': '1990 Feb', 'sentence': 'Preparations of DNA gyrase from the quinolone-resistant posttherapy isolates were 16- to 32-fold less sensitive to inhibition of supercoiling by ciprofloxacin and nalidixic acid than was gyrase from the pretherapy isolate.', 'subject score': 1000, 'object score': 1000}, 'PMID:26663076': {'publication date': '2016 Feb 12', 'sentence': 'Taken together these experiments now show unequivocally that A. thaliana encodes an organelle-targeted DNA gyrase that is the target of the quinolone drug ciprofloxacin; this has important consequences for plant physiology and the development of herbicides.', 'subject score': 852, 'object score': 790}, 'PMID:3034057': {'publication date': '1987 Apr 27', 'sentence': 'In summary, the A subunit of DNA gyrase is a target of ciprofloxacin and other quinolones.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0949782---SEMMEDDB:interacts_with---None---None---None---UMLS:C0008809---SEMMEDDB:"
-              ],
-              "subject": "MESH:D027081",
-              "id": "8212496",
-              "object": "PUBCHEM.COMPOUND:2764",
-              "publications": [
-                "PMID:10824040",
-                "PMID:1649573",
-                "PMID:2158277",
-                "PMID:26663076",
-                "PMID:3034057"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:affects",
-    "type(r2)": "biolink:physically_interacts_with",
-    "r2.publications_info": "{'PMID:11850491': {'publication date': '2002 Feb', 'sentence': 'UNLABELLED: Ciprofloxacin, a quinolone antibiotic drug, binds to DNA topoisomerase IV and DNA gyrase of various bacteria.', 'subject score': 1000, 'object score': 1000}, 'PMID:18677735': {'publication date': '2008 Sep 01', 'sentence': 'The mode of binding of ciprofloxacin, levofloxacin, and moxifloxacin to DNA gyrase was analyzed by means of docking calculations over the surface of the QRDR of GyrA.', 'subject score': 1000, 'object score': 1000}, 'PMID:22530906': {'publication date': '2012 May', 'sentence': 'We postulate that the enhanced potency of BSFQs against Staphylococcus aureus compared to CIP and NOR could be caused by the presence of the BS moiety that resulted in enhanced binding to DNA gyrase of Sa.', 'subject score': 1000, 'object score': 1000}, 'PMID:24327941': {'publication date': '2013', 'sentence': 'In conclusion, the AcrAB efflux system is one of the principal mechanisms contribute in ciprofloxacin resistance among K. pneumoniae isolates but there are some other mechanisms interfere with ciprofloxacin resistance such as mutation in target proteins of DNA gyrase of topoisomerase IV enzymes.', 'subject score': 694, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9184562,
-            "start": 616,
-            "end": 675256,
-            "type": "biolink:physically_interacts_with",
-            "properties": {
-              "predicate": "biolink:physically_interacts_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11850491': {'publication date': '2002 Feb', 'sentence': 'UNLABELLED: Ciprofloxacin, a quinolone antibiotic drug, binds to DNA topoisomerase IV and DNA gyrase of various bacteria.', 'subject score': 1000, 'object score': 1000}, 'PMID:18677735': {'publication date': '2008 Sep 01', 'sentence': 'The mode of binding of ciprofloxacin, levofloxacin, and moxifloxacin to DNA gyrase was analyzed by means of docking calculations over the surface of the QRDR of GyrA.', 'subject score': 1000, 'object score': 1000}, 'PMID:22530906': {'publication date': '2012 May', 'sentence': 'We postulate that the enhanced potency of BSFQs against Staphylococcus aureus compared to CIP and NOR could be caused by the presence of the BS moiety that resulted in enhanced binding to DNA gyrase of Sa.', 'subject score': 1000, 'object score': 1000}, 'PMID:24327941': {'publication date': '2013', 'sentence': 'In conclusion, the AcrAB efflux system is one of the principal mechanisms contribute in ciprofloxacin resistance among K. pneumoniae isolates but there are some other mechanisms interfere with ciprofloxacin resistance such as mutation in target proteins of DNA gyrase of topoisomerase IV enzymes.', 'subject score': 694, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:interacts_with---None---None---None---UMLS:C0949782---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "9387116",
-              "object": "MESH:D027081",
-              "publications": [
-                "PMID:11850491",
-                "PMID:18677735",
-                "PMID:22530906",
-                "PMID:24327941"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:affects",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:26100716': {'publication date': '2015 Sep', 'sentence': 'Plasmid-encoded protein QnrB1 protects DNA gyrase from ciprofloxacin inhibition.', 'subject score': 1000, 'object score': 888}, 'PMID:27618918': {'publication date': '2016 08', 'sentence': 'Antimicrobial susceptibility pattern and sequence analysis of DNA gyrase and DNA topoisomerase IV in Salmonella enterica serovars Typhi and Paratyphi A isolates with decreased susceptibility to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:33846132': {'publication date': '2021 Apr 12', 'sentence': 'Alanine replacement of arginine at residue 293 and a small deletion of amino acids 286-289 of GyrA resulted in a decrease in the QnrB1-mediated increase in quinolone MICs and also abolished the QnrB1 protection of purified DNA gyrase from ciprofloxacin inhibition.', 'subject score': 901, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18034605,
-            "start": 675256,
-            "end": 616,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26100716': {'publication date': '2015 Sep', 'sentence': 'Plasmid-encoded protein QnrB1 protects DNA gyrase from ciprofloxacin inhibition.', 'subject score': 1000, 'object score': 888}, 'PMID:27618918': {'publication date': '2016 08', 'sentence': 'Antimicrobial susceptibility pattern and sequence analysis of DNA gyrase and DNA topoisomerase IV in Salmonella enterica serovars Typhi and Paratyphi A isolates with decreased susceptibility to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:33846132': {'publication date': '2021 Apr 12', 'sentence': 'Alanine replacement of arginine at residue 293 and a small deletion of amino acids 286-289 of GyrA resulted in a decrease in the QnrB1-mediated increase in quinolone MICs and also abolished the QnrB1 protection of purified DNA gyrase from ciprofloxacin inhibition.', 'subject score': 901, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0949782---SEMMEDDB:inhibits---biolink:causes---activity---None---UMLS:C0008809---SEMMEDDB:"
-              ],
-              "subject": "MESH:D027081",
-              "id": "18400322",
-              "object": "PUBCHEM.COMPOUND:2764",
-              "publications": [
-                "PMID:26100716",
-                "PMID:27618918",
-                "PMID:33846132"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:affects",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:10543732': {'publication date': '1999 Nov', 'sentence': 'The concentrations of ciprofloxacin, sparfloxacin, levofloxacin, or ofloxacin required to inhibit wild-type topoisomerase IV were 8 to 16 times lower than those required to inhibit wild-type DNA gyrase.', 'subject score': 1000, 'object score': 861}, 'PMID:23877698': {'publication date': '2013 Oct', 'sentence': 'The broad-spectrum fluoroquinolone ciprofloxacin is a bactericidal antibiotic targeting DNA topoisomerase IV and DNA gyrase encoded by the parC and gyrA genes.', 'subject score': 764, 'object score': 1000}, 'PMID:2751986': {'publication date': '1989 May 02', 'sentence': 'The fluoroquinolone ciprofloxacin, an inhibitor of eubacterial DNA gyrase, induces single- and double-stranded DNA breaks in the plasmid pGRB-1 from the halophilic archaebacterium Halobacterium GRB when the cells are treated by this drug in a magnesium-depleted medium.', 'subject score': 872, 'object score': 877}, 'PMID:27717325': {'publication date': '2016 Oct 07', 'sentence': 'RESULTS: Ciprofloxacin, an inhibitor of bacterial DNA gyrase and topoisomerase IV, was shown to inhibit growth of C. glutamicum wild type with concomitant excretion of glutamate.', 'subject score': 1000, 'object score': 901}, 'PMID:30074404': {'publication date': '2018 Nov', 'sentence': 'Ciprofloxacin, a broad-spectrum fluoroquinolone, is a bactericidal antibiotic targeting DNA gyrase and DNA topoisomerase IV encoded by the gyrA and parC genes.', 'subject score': 1000, 'object score': 825}, 'PMID:3292209': {'publication date': '1988 Apr', 'sentence': 'The primary mechanism of action of ciprofloxacin is inhibition of bacterial DNA gyrase.', 'subject score': 1000, 'object score': 901}, 'PMID:3293157': {'publication date': '1988 May-Jun', 'sentence': 'Ciprofloxacin, like other quinolones, inhibits DNA gyrase, but its bactericidal effects are not completely reversible by inhibitors of protein or RNA synthesis.', 'subject score': 1000, 'object score': 1000}, 'PMID:34541445': {'publication date': '2021 Sep', 'sentence': 'An attractive novel herbicidal target is plant DNA gyrase, which has been demonstrated to be effectively inhibited by the known antimicrobial ciprofloxacin.', 'subject score': 840, 'object score': 1000}, 'PMID:36215786': {'publication date': '2022 Oct 05', 'sentence': 'Besides, DNA gyrase inhibition assay of compounds 6d and 6e was carried out in comparison to ciprofloxacin, and interestingly, compounds 6d and 6e disclosed promising IC50 values of 0.242 and 0.177 MUM, respectively, whereas ciprofloxacin displayed an IC50 value of 0.768 MUM, assuring the proposed mechanism of action for the afforded compounds.', 'subject score': 1000, 'object score': 861}, 'PMID:36644068': {'publication date': '2022 Dec', 'sentence': 'Ciprofloxacin inhibits the bacterial DNA-gyrase enzyme resulting in the destruction of the organism.', 'subject score': 1000, 'object score': 861}, 'PMID:7503546': {'publication date': '1995 Dec 01', 'sentence': 'However, in vitro assays to show the inhibition of supercoiling activity and stimulation of cleavable complex formation demonstrated that ciprofloxacin is a potent inhibitor of mycobacterial DNA gyrase.', 'subject score': 1000, 'object score': 901}, 'PMID:8440750': {'publication date': '1993 Feb', 'sentence': 'The 4-quinolone antibiotics nalidixic acid and ciprofloxacin are potent inhibitors of the bacterial type II topoisomerase DNA gyrase.', 'subject score': 1000, 'object score': 839}}",
-    "p2": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7620631,
-            "start": 616,
-            "end": 675256,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10543732': {'publication date': '1999 Nov', 'sentence': 'The concentrations of ciprofloxacin, sparfloxacin, levofloxacin, or ofloxacin required to inhibit wild-type topoisomerase IV were 8 to 16 times lower than those required to inhibit wild-type DNA gyrase.', 'subject score': 1000, 'object score': 861}, 'PMID:23877698': {'publication date': '2013 Oct', 'sentence': 'The broad-spectrum fluoroquinolone ciprofloxacin is a bactericidal antibiotic targeting DNA topoisomerase IV and DNA gyrase encoded by the parC and gyrA genes.', 'subject score': 764, 'object score': 1000}, 'PMID:2751986': {'publication date': '1989 May 02', 'sentence': 'The fluoroquinolone ciprofloxacin, an inhibitor of eubacterial DNA gyrase, induces single- and double-stranded DNA breaks in the plasmid pGRB-1 from the halophilic archaebacterium Halobacterium GRB when the cells are treated by this drug in a magnesium-depleted medium.', 'subject score': 872, 'object score': 877}, 'PMID:27717325': {'publication date': '2016 Oct 07', 'sentence': 'RESULTS: Ciprofloxacin, an inhibitor of bacterial DNA gyrase and topoisomerase IV, was shown to inhibit growth of C. glutamicum wild type with concomitant excretion of glutamate.', 'subject score': 1000, 'object score': 901}, 'PMID:30074404': {'publication date': '2018 Nov', 'sentence': 'Ciprofloxacin, a broad-spectrum fluoroquinolone, is a bactericidal antibiotic targeting DNA gyrase and DNA topoisomerase IV encoded by the gyrA and parC genes.', 'subject score': 1000, 'object score': 825}, 'PMID:3292209': {'publication date': '1988 Apr', 'sentence': 'The primary mechanism of action of ciprofloxacin is inhibition of bacterial DNA gyrase.', 'subject score': 1000, 'object score': 901}, 'PMID:3293157': {'publication date': '1988 May-Jun', 'sentence': 'Ciprofloxacin, like other quinolones, inhibits DNA gyrase, but its bactericidal effects are not completely reversible by inhibitors of protein or RNA synthesis.', 'subject score': 1000, 'object score': 1000}, 'PMID:34541445': {'publication date': '2021 Sep', 'sentence': 'An attractive novel herbicidal target is plant DNA gyrase, which has been demonstrated to be effectively inhibited by the known antimicrobial ciprofloxacin.', 'subject score': 840, 'object score': 1000}, 'PMID:36215786': {'publication date': '2022 Oct 05', 'sentence': 'Besides, DNA gyrase inhibition assay of compounds 6d and 6e was carried out in comparison to ciprofloxacin, and interestingly, compounds 6d and 6e disclosed promising IC50 values of 0.242 and 0.177 MUM, respectively, whereas ciprofloxacin displayed an IC50 value of 0.768 MUM, assuring the proposed mechanism of action for the afforded compounds.', 'subject score': 1000, 'object score': 861}, 'PMID:36644068': {'publication date': '2022 Dec', 'sentence': 'Ciprofloxacin inhibits the bacterial DNA-gyrase enzyme resulting in the destruction of the organism.', 'subject score': 1000, 'object score': 861}, 'PMID:7503546': {'publication date': '1995 Dec 01', 'sentence': 'However, in vitro assays to show the inhibition of supercoiling activity and stimulation of cleavable complex formation demonstrated that ciprofloxacin is a potent inhibitor of mycobacterial DNA gyrase.', 'subject score': 1000, 'object score': 901}, 'PMID:8440750': {'publication date': '1993 Feb', 'sentence': 'The 4-quinolone antibiotics nalidixic acid and ciprofloxacin are potent inhibitors of the bacterial type II topoisomerase DNA gyrase.', 'subject score': 1000, 'object score': 839}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:inhibits---biolink:causes---activity---None---UMLS:C0949782---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7781719",
-              "object": "MESH:D027081",
-              "publications": [
-                "PMID:10543732",
-                "PMID:23877698",
-                "PMID:2751986",
-                "PMID:27717325",
-                "PMID:30074404",
-                "PMID:3292209",
-                "PMID:3293157",
-                "PMID:34541445",
-                "PMID:36215786",
-                "PMID:36644068",
-                "PMID:7503546",
-                "PMID:8440750"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:8755196': {'publication date': '1996 Jun', 'sentence': 'Efficacy of ciprofloxacin and dexamethasone in experimental pseudomonas endophthalmitis.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 881097,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016047",
-          "name": "endophthalmitis",
-          "description": "An infectious process affecting the internal structures of the eye.; Infectious condition of the internal eye.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0014236",
-            "ORPHANET:199323",
-            "MONDO:0016047",
-            "SNOMEDCT:128295000",
-            "SNOMEDCT:1847009",
-            "MEDDRA:10030869",
-            "NCIT:C34586",
-            "MESH:D009877",
-            "MEDDRA:10014801",
-            "DOID:4692"
-          ],
-          "id": "MONDO:0016047",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Endophthalmitis",
-            "endophthalmitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/endophthalmitis",
-            "https://www.merckmanuals.com/home/eye-disorders/uveitis-and-related-disorders/endophthalmitis",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=endophthalmitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 881097,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016047",
-              "name": "endophthalmitis",
-              "description": "An infectious process affecting the internal structures of the eye.; Infectious condition of the internal eye.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0014236",
-                "ORPHANET:199323",
-                "MONDO:0016047",
-                "SNOMEDCT:128295000",
-                "SNOMEDCT:1847009",
-                "MEDDRA:10030869",
-                "NCIT:C34586",
-                "MESH:D009877",
-                "MEDDRA:10014801",
-                "DOID:4692"
-              ],
-              "id": "MONDO:0016047",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Endophthalmitis",
-                "endophthalmitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/endophthalmitis",
-                "https://www.merckmanuals.com/home/eye-disorders/uveitis-and-related-disorders/endophthalmitis",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=endophthalmitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26686742,
-            "start": 616,
-            "end": 881097,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8755196': {'publication date': '1996 Jun', 'sentence': 'Efficacy of ciprofloxacin and dexamethasone in experimental pseudomonas endophthalmitis.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:associated_with---None---None---None---UMLS:C0014236---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "27155094",
-              "object": "MONDO:0016047",
-              "publications": [
-                "PMID:8755196"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-=======
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
->>>>>>> main
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 322120,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15665370': {'publication date': '2005 Feb', 'sentence': 'Ciprofloxacin in endophthalmitis: an alternative to ceftazidime and amikacin!', 'subject score': 1000, 'object score': 1000}, 'PMID:22048244': {'publication date': '2012 Apr', 'sentence': 'METHODS: Retrospective review of all patients with suspected endophthalmitis after intravitreal injections treated with intravitreal antibiotics (teicoplanin and ciprofloxacin) at a referral centre between January 2003 and December 2010.', 'subject score': 1000, 'object score': 861}, 'PMID:23607574': {'publication date': '2013 Apr 22', 'sentence': 'Fluoroquinolones like ciprofloxacin may be considered as a useful alternative in vancomycin-resistant endophthalmitis.', 'subject score': 1000, 'object score': 877}, 'PMID:8115734': {'publication date': '1993', 'sentence': 'Because of the relatively short half life, intravitreal administration of ciprofloxacin for the treatment of endophthalmitis would provide only short-term therapy and would need to be supplemented by other forms of treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:8250071': {'publication date': '1993 Dec 15', 'sentence': 'Ciprofloxacin has been proposed for the systemic treatment of endophthalmitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:8755196': {'publication date': '1996 Jun', 'sentence': 'To determine injection time and effective dose of ciprofloxacin in endophthalmitis and to evaluate the effectiveness of dexamethasone.', 'subject score': 1000, 'object score': 1000}, 'PMID:8773934': {'publication date': '1996', 'sentence': 'The objective of this work was to evaluate various methods of sustained delivery to achieve therapeutic intravitreal levels of ciprofloxacin as a potential therapy for endophthalmitis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 881097,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-          "name": "Crohn disease",
-          "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003424",
-            "ORPHANET:206",
-            "NCIT:C37262",
-            "MEDDRA:10038281",
-            "MEDDRA:10011405",
-            "UMLS:CN043071",
-            "SNOMEDCT:50440006",
-            "MEDDRA:10057032",
-            "HP:0100280",
-            "EFO:0000384",
-            "DOID:8778",
-            "MONDO:0005011",
-            "PDQ:CDR0000714480",
-            "UMLS:C0010346",
-            "NCIT:C2965",
-            "SNOMEDCT:7620006",
-            "ICD10:K50.1",
-            "UMLS:C0156147",
-            "MEDDRA:10011398",
-            "MEDDRA:10011401",
-            "SNOMEDCT:34000006",
-            "ICD9:555.1",
-            "MEDDRA:10013099",
-            "MEDDRA:10011402",
-            "MEDDRA:10011400"
-          ],
-          "id": "MONDO:0005011",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Granulomatous Colitis",
-            "Crohn's disease of large bowel",
-            "Regional enteritis of large intestine",
-            "Crohn Disease",
-            "Crohn disease",
-            "Crohn's disease"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016047",
-          "name": "endophthalmitis",
-          "description": "An infectious process affecting the internal structures of the eye.; Infectious condition of the internal eye.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0014236",
-            "ORPHANET:199323",
-            "MONDO:0016047",
-            "SNOMEDCT:128295000",
-            "SNOMEDCT:1847009",
-            "MEDDRA:10030869",
-            "NCIT:C34586",
-            "MESH:D009877",
-            "MEDDRA:10014801",
-            "DOID:4692"
-          ],
-          "id": "MONDO:0016047",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Endophthalmitis",
-            "endophthalmitis"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://en.wikipedia.org/wiki/chron%27s_disease",
-            "https://orcid.org/0009-0006-4530-3154"
-=======
-            "http://en.wikipedia.org/wiki/endophthalmitis",
-            "https://www.merckmanuals.com/home/eye-disorders/uveitis-and-related-disorders/endophthalmitis",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=endophthalmitis"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 322120,
-=======
-            "identity": 881097,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-              "name": "Crohn disease",
-              "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003424",
-                "ORPHANET:206",
-                "NCIT:C37262",
-                "MEDDRA:10038281",
-                "MEDDRA:10011405",
-                "UMLS:CN043071",
-                "SNOMEDCT:50440006",
-                "MEDDRA:10057032",
-                "HP:0100280",
-                "EFO:0000384",
-                "DOID:8778",
-                "MONDO:0005011",
-                "PDQ:CDR0000714480",
-                "UMLS:C0010346",
-                "NCIT:C2965",
-                "SNOMEDCT:7620006",
-                "ICD10:K50.1",
-                "UMLS:C0156147",
-                "MEDDRA:10011398",
-                "MEDDRA:10011401",
-                "SNOMEDCT:34000006",
-                "ICD9:555.1",
-                "MEDDRA:10013099",
-                "MEDDRA:10011402",
-                "MEDDRA:10011400"
-              ],
-              "id": "MONDO:0005011",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Granulomatous Colitis",
-                "Crohn's disease of large bowel",
-                "Regional enteritis of large intestine",
-                "Crohn Disease",
-                "Crohn disease",
-                "Crohn's disease"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016047",
-              "name": "endophthalmitis",
-              "description": "An infectious process affecting the internal structures of the eye.; Infectious condition of the internal eye.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0014236",
-                "ORPHANET:199323",
-                "MONDO:0016047",
-                "SNOMEDCT:128295000",
-                "SNOMEDCT:1847009",
-                "MEDDRA:10030869",
-                "NCIT:C34586",
-                "MESH:D009877",
-                "MEDDRA:10014801",
-                "DOID:4692"
-              ],
-              "id": "MONDO:0016047",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Endophthalmitis",
-                "endophthalmitis"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://en.wikipedia.org/wiki/chron%27s_disease",
-                "https://orcid.org/0009-0006-4530-3154"
-=======
-                "http://en.wikipedia.org/wiki/endophthalmitis",
-                "https://www.merckmanuals.com/home/eye-disorders/uveitis-and-related-disorders/endophthalmitis",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=endophthalmitis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 16495220,
-            "start": 616,
-            "end": 322120,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23525574': {'publication date': '2014 Feb', 'sentence': 'CONCLUSIONS: Combination therapy of adalimumab and ciprofloxacin is more effective than adalimumab monotherapy to achieve fistula closure in CD.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:associated_with---None---None---None---UMLS:C0010346---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "16836665",
-              "object": "MONDO:0005011",
-              "publications": [
-                "PMID:23525574"
-=======
-            "identity": 11380125,
-            "start": 616,
-            "end": 881097,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15665370': {'publication date': '2005 Feb', 'sentence': 'Ciprofloxacin in endophthalmitis: an alternative to ceftazidime and amikacin!', 'subject score': 1000, 'object score': 1000}, 'PMID:22048244': {'publication date': '2012 Apr', 'sentence': 'METHODS: Retrospective review of all patients with suspected endophthalmitis after intravitreal injections treated with intravitreal antibiotics (teicoplanin and ciprofloxacin) at a referral centre between January 2003 and December 2010.', 'subject score': 1000, 'object score': 861}, 'PMID:23607574': {'publication date': '2013 Apr 22', 'sentence': 'Fluoroquinolones like ciprofloxacin may be considered as a useful alternative in vancomycin-resistant endophthalmitis.', 'subject score': 1000, 'object score': 877}, 'PMID:8115734': {'publication date': '1993', 'sentence': 'Because of the relatively short half life, intravitreal administration of ciprofloxacin for the treatment of endophthalmitis would provide only short-term therapy and would need to be supplemented by other forms of treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:8250071': {'publication date': '1993 Dec 15', 'sentence': 'Ciprofloxacin has been proposed for the systemic treatment of endophthalmitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:8755196': {'publication date': '1996 Jun', 'sentence': 'To determine injection time and effective dose of ciprofloxacin in endophthalmitis and to evaluate the effectiveness of dexamethasone.', 'subject score': 1000, 'object score': 1000}, 'PMID:8773934': {'publication date': '1996', 'sentence': 'The objective of this work was to evaluate various methods of sustained delivery to achieve therapeutic intravitreal levels of ciprofloxacin as a potential therapy for endophthalmitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0014236---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "11628762",
-              "object": "MONDO:0016047",
-              "publications": [
-                "PMID:15665370",
-                "PMID:22048244",
-                "PMID:23607574",
-                "PMID:8115734",
-                "PMID:8250071",
-                "PMID:8755196",
-                "PMID:8773934"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:1646099': {'publication date': '1991 Mar', 'sentence': 'These studies indicate that a combination of ciprofloxacin and dexamethasone has the potential for reducing the risk of PVR formation and aiding in the prevention of endophthalmitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:30595706': {'publication date': '2018', 'sentence': 'The aim of this study was to evaluate the efficacy and clinical outcome of oral ciprofloxacin versus intravenous cefazolin/gentamicin for the prevention of endophthalmitis after penetrating ocular trauma.', 'subject score': 888, 'object score': 1000}, 'PMID:8488915': {'publication date': '1993 May 15', 'sentence': 'Therefore, ciprofloxacin may have a role in the management and prevention of endophthalmitis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 881097,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016047",
-          "name": "endophthalmitis",
-          "description": "An infectious process affecting the internal structures of the eye.; Infectious condition of the internal eye.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0014236",
-            "ORPHANET:199323",
-            "MONDO:0016047",
-            "SNOMEDCT:128295000",
-            "SNOMEDCT:1847009",
-            "MEDDRA:10030869",
-            "NCIT:C34586",
-            "MESH:D009877",
-            "MEDDRA:10014801",
-            "DOID:4692"
-          ],
-          "id": "MONDO:0016047",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Endophthalmitis",
-            "endophthalmitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/endophthalmitis",
-            "https://www.merckmanuals.com/home/eye-disorders/uveitis-and-related-disorders/endophthalmitis",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=endophthalmitis"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 675256,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Gene",
-              "biolink:GeneOrGeneProduct",
-              "biolink:GeneProductMixin",
-              "biolink:GenomicEntity",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:MolecularEntity",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-=======
-            "identity": 881097,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016047",
-              "name": "endophthalmitis",
-              "description": "An infectious process affecting the internal structures of the eye.; Infectious condition of the internal eye.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0014236",
-                "ORPHANET:199323",
-                "MONDO:0016047",
-                "SNOMEDCT:128295000",
-                "SNOMEDCT:1847009",
-                "MEDDRA:10030869",
-                "NCIT:C34586",
-                "MESH:D009877",
-                "MEDDRA:10014801",
-                "DOID:4692"
-              ],
-              "id": "MONDO:0016047",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Endophthalmitis",
-                "endophthalmitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/endophthalmitis",
-                "https://www.merckmanuals.com/home/eye-disorders/uveitis-and-related-disorders/endophthalmitis",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=endophthalmitis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 19187853,
-            "start": 675256,
-            "end": 616,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28364698': {'publication date': '2017 Jun', 'sentence': 'Tested substances displayed inhibitory effect towards E. coli DNA gyrase, though less than ciprofloxacin.', 'subject score': 888, 'object score': 1000}, 'PMID:3137271': {'publication date': '1988 Sep', 'sentence': 'Higher concentrations of ciprofloxacin were required to interfere with DNA synthesis in resistant isolates compared with the parent strain, a finding indicating a relative insensitivity of DNA gyrase to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:31994086': {'publication date': '2017 May', 'sentence': 'Tested substances displayed inhibitory effect towards E. coli DNA gyrase, though less than ciprofloxacin.', 'subject score': 888, 'object score': 1000}, 'PMID:32036161': {'publication date': '2020 Feb 01', 'sentence': 'Compounds 3b, 9c showed to be very potent inhibitors towards S. aureus DNA gyrase with IC     50       values (18.75 +/- 1.2 and 19.32 +/- 0.99 uM) respectively, compared with Ciprofloxacin (26.43 +/- 0.64 uM).', 'subject score': 888, 'object score': 1000}, 'PMID:32548371': {'publication date': '2020 Jun 02', 'sentence': 'Molecular modeling techniques were employed to evaluate the binding of certain N1-modified fluoroquinolones to DNA gyrase targets from both    Staphylococcus aureus     and    Klebsiella pneumoniae     species compared with ciprofloxacin and norfloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:36148773': {'publication date': '2022 Sep 15', 'sentence': 'Moreover, compounds 5b and 5g showed potent inhibitory activities against DNA gyrase (IC     50       = 1.72 and 5.72 uM) and topoisomerase IV (4.36 and 7.77 uM) compared to ciprofloxacin with IC     50       values 0.66 and 8.16 uM, respectively.', 'subject score': 1000, 'object score': 1000}, 'PMID:37179626': {'publication date': '2023 May 09', 'sentence': 'Moreover, daidzein and khellin inhibited the DNA gyrase enzyme with IC     50       values of 0.042 and 0.822 MUg/mL, respectively, compared to ciprofloxacin with an IC     50       value of 0.018 MUg/mL.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0949782---SEMMEDDB:compared_with---None---None---None---UMLS:C0008809---SEMMEDDB:",
-                "UMLS:C0949782---SEMMEDDB:lower_than---None---None---None---UMLS:C0008809---SEMMEDDB:"
-              ],
-              "subject": "MESH:D027081",
-              "id": "19572117",
-              "object": "PUBCHEM.COMPOUND:2764",
-              "publications": [
-                "PMID:32036161",
-                "PMID:28364698",
-                "PMID:3137271",
-                "PMID:36148773",
-                "PMID:37179626",
-                "PMID:31994086",
-                "PMID:32548371"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19187853,
-            "start": 675256,
-            "end": 616,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28364698': {'publication date': '2017 Jun', 'sentence': 'Tested substances displayed inhibitory effect towards E. coli DNA gyrase, though less than ciprofloxacin.', 'subject score': 888, 'object score': 1000}, 'PMID:3137271': {'publication date': '1988 Sep', 'sentence': 'Higher concentrations of ciprofloxacin were required to interfere with DNA synthesis in resistant isolates compared with the parent strain, a finding indicating a relative insensitivity of DNA gyrase to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:31994086': {'publication date': '2017 May', 'sentence': 'Tested substances displayed inhibitory effect towards E. coli DNA gyrase, though less than ciprofloxacin.', 'subject score': 888, 'object score': 1000}, 'PMID:32036161': {'publication date': '2020 Feb 01', 'sentence': 'Compounds 3b, 9c showed to be very potent inhibitors towards S. aureus DNA gyrase with IC     50       values (18.75 +/- 1.2 and 19.32 +/- 0.99 uM) respectively, compared with Ciprofloxacin (26.43 +/- 0.64 uM).', 'subject score': 888, 'object score': 1000}, 'PMID:32548371': {'publication date': '2020 Jun 02', 'sentence': 'Molecular modeling techniques were employed to evaluate the binding of certain N1-modified fluoroquinolones to DNA gyrase targets from both    Staphylococcus aureus     and    Klebsiella pneumoniae     species compared with ciprofloxacin and norfloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:36148773': {'publication date': '2022 Sep 15', 'sentence': 'Moreover, compounds 5b and 5g showed potent inhibitory activities against DNA gyrase (IC     50       = 1.72 and 5.72 uM) and topoisomerase IV (4.36 and 7.77 uM) compared to ciprofloxacin with IC     50       values 0.66 and 8.16 uM, respectively.', 'subject score': 1000, 'object score': 1000}, 'PMID:37179626': {'publication date': '2023 May 09', 'sentence': 'Moreover, daidzein and khellin inhibited the DNA gyrase enzyme with IC     50       values of 0.042 and 0.822 MUg/mL, respectively, compared to ciprofloxacin with an IC     50       value of 0.018 MUg/mL.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0949782---SEMMEDDB:compared_with---None---None---None---UMLS:C0008809---SEMMEDDB:",
-                "UMLS:C0949782---SEMMEDDB:lower_than---None---None---None---UMLS:C0008809---SEMMEDDB:"
-              ],
-              "subject": "MESH:D027081",
-              "id": "19572117",
-              "object": "PUBCHEM.COMPOUND:2764",
-              "publications": [
-                "PMID:32036161",
-                "PMID:28364698",
-                "PMID:3137271",
-                "PMID:36148773",
-                "PMID:37179626",
-                "PMID:31994086",
-                "PMID:32548371"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12110069,
-            "start": 616,
-            "end": 675256,
-            "type": "biolink:coexists_with",
-            "properties": {
-              "predicate": "biolink:coexists_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1656866': {'publication date': '1991 Aug', 'sentence': 'These data indicate that persistence of Pseudomonas aeruginosa to ciprofloxacin involves changes in DNA gyrase and is associated with pleiotropic changes in outer membrane proteins and lipopolysaccharide.', 'subject score': 1000, 'object score': 1000}, 'PMID:24064645': {'publication date': '2013', 'sentence': 'PURPOSE: There are increasing reports on failure of clinical response to ciprofloxacin in typhoid fever despite the strain being sensitive to drug in in-vitro using standard guidelines and showing mutations in DNA gyrase.', 'subject score': 1000, 'object score': 1000}, 'PMID:27175500': {'publication date': '2016 Apr', 'sentence': 'The aims of this study were to investigate ciprofloxacin (CIP) and levofloxacin (LEV) minimum inhibitor concentrations (MIC), clonal relationships, mutations that occur in DNA gyrase and topoisomerase IV genes and overexpression of efflux pumps in nosocomial A.baumannii isolates.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:coexists_with---None---None---None---UMLS:C0949782---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "12385742",
-              "object": "MESH:D027081",
-              "publications": [
-                "PMID:1656866",
-                "PMID:24064645",
-                "PMID:27175500"
-=======
-            "identity": 12030319,
-            "start": 616,
-            "end": 881097,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1646099': {'publication date': '1991 Mar', 'sentence': 'These studies indicate that a combination of ciprofloxacin and dexamethasone has the potential for reducing the risk of PVR formation and aiding in the prevention of endophthalmitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:30595706': {'publication date': '2018', 'sentence': 'The aim of this study was to evaluate the efficacy and clinical outcome of oral ciprofloxacin versus intravenous cefazolin/gentamicin for the prevention of endophthalmitis after penetrating ocular trauma.', 'subject score': 888, 'object score': 1000}, 'PMID:8488915': {'publication date': '1993 May 15', 'sentence': 'Therefore, ciprofloxacin may have a role in the management and prevention of endophthalmitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:prevents---None---None---None---UMLS:C0014236---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "12292532",
-              "object": "MONDO:0016047",
-              "publications": [
-                "PMID:1646099",
-                "PMID:30595706",
-                "PMID:8488915"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:11414382': {'publication date': '2000 Jan', 'sentence': 'Ciprofloxacin is effective in complicated and severe lower respiratory tract infections, including those in patients with infective exacerbations of chronic bronchitis and cystic fibrosis, and pseudomonal infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:1734188': {'publication date': '1992 Jan 06', 'sentence': 'Resistance to ciprofloxacin of respiratory pathogens in patients with cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:31663261': {'publication date': '2019 Oct 30', 'sentence': 'Reclassification of CLSI criteria for ciprofloxacin and levofloxacin susceptibility against Pseudomonas aeruginosa: Implications for patients with cystic fibrosis (CF).', 'subject score': 1000, 'object score': 1000}, 'PMID:8132376': {'publication date': '1993 Nov-Dec', 'sentence': 'Up to now, data are available on more than 1,500 paediatric patients who were given ciprofloxacin, two-thirds of whom were suffering from acute infectious bronchopulmonary exacerbations of cystic fibrosis, mainly due to Pseudomonas aeruginosa.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 523273,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009061",
-          "name": "cystic fibrosis",
-          "description": "A congenital, autosomal, metabolic disorder affecting the exocrine glands. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production that causes obstruction of passageways, including pancreatic and bile ducts, intestines, and bronchi. Symptoms usually appear in childhood, and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather secondary to increased sodium and chloride concentration in sweat.; An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003550",
-            "SNOMEDCT:190905008",
-            "UMLS:C0010674",
-            "NCIT:C2975",
-            "MEDDRA:10011762",
-            "ORPHANET:586",
-            "DOID:1485",
-            "MEDDRA:10011764",
-            "ICD9:277.0",
-            "MEDDRA:10028141",
-            "PSY:12915",
-            "MONDO:0009061",
-            "OMIM:219700",
-            "ICD10:E84"
-          ],
-          "id": "MONDO:0009061",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cystic Fibrosis",
-            "cystic fibrosis",
-            "obsolete_cystic fibrosis",
-            "Cystic fibrosis related phenotypic feature",
-            "Cystic fibrosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://ghr.nlm.nih.gov/condition/cystic-fibrosis",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/cf/",
-            "http://en.wikipedia.org/wiki/cystic_fibrosis"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-=======
-            "identity": 523273,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009061",
-              "name": "cystic fibrosis",
-              "description": "A congenital, autosomal, metabolic disorder affecting the exocrine glands. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production that causes obstruction of passageways, including pancreatic and bile ducts, intestines, and bronchi. Symptoms usually appear in childhood, and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather secondary to increased sodium and chloride concentration in sweat.; An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003550",
-                "SNOMEDCT:190905008",
-                "UMLS:C0010674",
-                "NCIT:C2975",
-                "MEDDRA:10011762",
-                "ORPHANET:586",
-                "DOID:1485",
-                "MEDDRA:10011764",
-                "ICD9:277.0",
-                "MEDDRA:10028141",
-                "PSY:12915",
-                "MONDO:0009061",
-                "OMIM:219700",
-                "ICD10:E84"
-              ],
-              "id": "MONDO:0009061",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cystic Fibrosis",
-                "cystic fibrosis",
-                "obsolete_cystic fibrosis",
-                "Cystic fibrosis related phenotypic feature",
-                "Cystic fibrosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://ghr.nlm.nih.gov/condition/cystic-fibrosis",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/cf/",
-                "http://en.wikipedia.org/wiki/cystic_fibrosis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 12110069,
-            "start": 616,
-            "end": 675256,
-            "type": "biolink:coexists_with",
-            "properties": {
-              "predicate": "biolink:coexists_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1656866': {'publication date': '1991 Aug', 'sentence': 'These data indicate that persistence of Pseudomonas aeruginosa to ciprofloxacin involves changes in DNA gyrase and is associated with pleiotropic changes in outer membrane proteins and lipopolysaccharide.', 'subject score': 1000, 'object score': 1000}, 'PMID:24064645': {'publication date': '2013', 'sentence': 'PURPOSE: There are increasing reports on failure of clinical response to ciprofloxacin in typhoid fever despite the strain being sensitive to drug in in-vitro using standard guidelines and showing mutations in DNA gyrase.', 'subject score': 1000, 'object score': 1000}, 'PMID:27175500': {'publication date': '2016 Apr', 'sentence': 'The aims of this study were to investigate ciprofloxacin (CIP) and levofloxacin (LEV) minimum inhibitor concentrations (MIC), clonal relationships, mutations that occur in DNA gyrase and topoisomerase IV genes and overexpression of efflux pumps in nosocomial A.baumannii isolates.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:coexists_with---None---None---None---UMLS:C0949782---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "12385742",
-              "object": "MESH:D027081",
-              "publications": [
-                "PMID:1656866",
-                "PMID:24064645",
-                "PMID:27175500"
-=======
-            "identity": 8753727,
-            "start": 616,
-            "end": 523273,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11414382': {'publication date': '2000 Jan', 'sentence': 'Ciprofloxacin is effective in complicated and severe lower respiratory tract infections, including those in patients with infective exacerbations of chronic bronchitis and cystic fibrosis, and pseudomonal infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:1734188': {'publication date': '1992 Jan 06', 'sentence': 'Resistance to ciprofloxacin of respiratory pathogens in patients with cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:31663261': {'publication date': '2019 Oct 30', 'sentence': 'Reclassification of CLSI criteria for ciprofloxacin and levofloxacin susceptibility against Pseudomonas aeruginosa: Implications for patients with cystic fibrosis (CF).', 'subject score': 1000, 'object score': 1000}, 'PMID:8132376': {'publication date': '1993 Nov-Dec', 'sentence': 'Up to now, data are available on more than 1,500 paediatric patients who were given ciprofloxacin, two-thirds of whom were suffering from acute infectious bronchopulmonary exacerbations of cystic fibrosis, mainly due to Pseudomonas aeruginosa.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0010674---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8956825",
-              "object": "MONDO:0009061",
-              "publications": [
-                "PMID:11414382",
-                "PMID:1734188",
-                "PMID:31663261",
-                "PMID:8132376"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10553703': {'publication date': '1999', 'sentence': 'As juveniles are especially sensitive, use of these drugs in paediatrics should be restricted to carefully selected indications (such as the use of ciprofloxacin in cystic fibrosis).', 'subject score': 1000, 'object score': 1000}, 'PMID:10587421': {'publication date': '1999 Dec', 'sentence': 'We report on a case of photosensitivity induced by indoor fluorescent strip-lighting (spectral range, 295-760 nm) in a 12-year-old girl with CF treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:10851644': {'publication date': '2000', 'sentence': 'Ciprofloxacin clinical and bacteriological efficacies, as well as tolerability mainly with respect to chondrotoxicity were evaluated in the treatment of children with mucoviscidosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:11709326': {'publication date': '2001 Dec', 'sentence': 'Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:11777658': {'publication date': '2001 Dec', 'sentence': 'Isolates of MSSA showed lower levels of susceptibility to ciprofloxacin (61-77% susceptibility) in both cystic fibrosis and neutropenia patients, and particularly high levels of resistance to ceftazidime (38% susceptibility) in cystic fibrosis units.', 'subject score': 1000, 'object score': 1000}, 'PMID:11806288': {'publication date': '2001 Sep-Oct', 'sentence': 'Until recently, only compassionate use of ciprofloxacin in children with cystic fibrosis was possible despite limited pharmacokinetic data.', 'subject score': 1000, 'object score': 1000}, 'PMID:11881187': {'publication date': '2001', 'sentence': 'The results of the prospective and comparative investigation of the linear growth of children at the age of 4 to 16 years with mucoviscidosis treated with ciprofloxacin in combination with a cephalosporin or an aminoglycoside in the main group and a cephalosporin or an aminoglycoside alone in the control group are presented.', 'subject score': 1000, 'object score': 1000}, 'PMID:12052667': {'publication date': '2002 Feb 28', 'sentence': 'Chondrotoxicity of quinolones can affect the articular cartilage and the epiphyseal growth plate in immature animals; the use of these drugs in pediatrics should be restricted to carefully selected indications (such as the use of ciprofloxacin in cystic fibrosis).', 'subject score': 1000, 'object score': 1000}, 'PMID:12856383': {'publication date': '2003 Jul', 'sentence': 'With body weight included in the model (two compartments with first-order absorption), ciprofloxacin clearance was influenced by age, and the absorption rate constant was altered in CF patients.', 'subject score': 888, 'object score': 901}, 'PMID:1489195': {'publication date': '1992 Nov', 'sentence': 'Our data indicate that the pharmacokinetic properties of ciprofloxacin are altered in cystic fibrosis patients with mild symptoms of pulmonary exacerbations and that the changes most probably are due to cystic fibrosis per se or to the impact of chronic infection.', 'subject score': 1000, 'object score': 901}, 'PMID:17012372': {'publication date': '2007 Jan', 'sentence': 'Azithromycin (AZM) and ciprofloxacin (CIP) are used clinically in CF.', 'subject score': 1000, 'object score': 1000}, 'PMID:17045852': {'publication date': '2007 May', 'sentence': 'Coagulopathy in two patients with cystic fibrosis treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:18835137': {'publication date': '2009 Mar', 'sentence': 'As a consequence, only life-threatening infections for which other antimicrobials cannot be used are possible indications for quinolones in children, for example the use of ciprofloxacin in cystic fibrosis patients with a bronchopulmonary exacerbation, chronic suppurative otitis media caused by Pseudomonas sp., complicated urinary tract infections and enteritis caused by invasive multidrug-resistant pathogens (e.g. Salmonella, Shigella).', 'subject score': 1000, 'object score': 901}, 'PMID:1907546': {'publication date': '1991 Apr', 'sentence': 'Ciprofloxacin (and possibly ofloxacin) are considered useful alternatives to parenteral agents in therapy of cystic fibrosis patients older than 18 years of age with exacerbations of pulmonary infection.', 'subject score': 1000, 'object score': 901}, 'PMID:1929312': {'publication date': '1991 Jul', 'sentence': 'The effect of pancreatic enzyme supplementation on the absorption of an oral dose of 250 mg of ciprofloxacin was studied in six patients with cystic fibrosis in a crossover design.', 'subject score': 1000, 'object score': 1000}, 'PMID:19847626': {'publication date': '2010 Jan', 'sentence': 'Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:21114393': {'publication date': '2010 Dec', 'sentence': 'CONCLUSION: These results provide a pharmacologic hypothesis-that the current dosing recommendations of ciprofloxacin for cystic fibrosis children may be suboptimal-to explain the decrease in the susceptibility of P. aeruginosa to ciprofloxacin observed in children with cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:21193474': {'publication date': '2011 Mar', 'sentence': 'CONCLUSIONS: Treatment of P. aeruginosa with oral ciprofloxacin in patients with CF may concurrently reduce antibiotic susceptibility in the commensal VGS flora, where these organisms may potentially act as a reservoir of fluoroquinolone resistance gene determinants for newly acquired and antibiotic-susceptible pathogens, particularly the Streptococcus milleri group.', 'subject score': 888, 'object score': 1000}, 'PMID:21928725': {'publication date': '2011', 'sentence': 'The PK/PD index (CMAX/MIC) for ciprofloxacin in patients with cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2292542': {'publication date': '1990 Dec', 'sentence': 'Other children with cystic fibrosis were subsequently treated with ciprofloxacin, as the need arose.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 523273,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009061",
-          "name": "cystic fibrosis",
-          "description": "A congenital, autosomal, metabolic disorder affecting the exocrine glands. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production that causes obstruction of passageways, including pancreatic and bile ducts, intestines, and bronchi. Symptoms usually appear in childhood, and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather secondary to increased sodium and chloride concentration in sweat.; An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003550",
-            "SNOMEDCT:190905008",
-            "UMLS:C0010674",
-            "NCIT:C2975",
-            "MEDDRA:10011762",
-            "ORPHANET:586",
-            "DOID:1485",
-            "MEDDRA:10011764",
-            "ICD9:277.0",
-            "MEDDRA:10028141",
-            "PSY:12915",
-            "MONDO:0009061",
-            "OMIM:219700",
-            "ICD10:E84"
-          ],
-          "id": "MONDO:0009061",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cystic Fibrosis",
-            "cystic fibrosis",
-            "obsolete_cystic fibrosis",
-            "Cystic fibrosis related phenotypic feature",
-            "Cystic fibrosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://ghr.nlm.nih.gov/condition/cystic-fibrosis",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/cf/",
-            "http://en.wikipedia.org/wiki/cystic_fibrosis"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-=======
-            "identity": 523273,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009061",
-              "name": "cystic fibrosis",
-              "description": "A congenital, autosomal, metabolic disorder affecting the exocrine glands. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production that causes obstruction of passageways, including pancreatic and bile ducts, intestines, and bronchi. Symptoms usually appear in childhood, and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather secondary to increased sodium and chloride concentration in sweat.; An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003550",
-                "SNOMEDCT:190905008",
-                "UMLS:C0010674",
-                "NCIT:C2975",
-                "MEDDRA:10011762",
-                "ORPHANET:586",
-                "DOID:1485",
-                "MEDDRA:10011764",
-                "ICD9:277.0",
-                "MEDDRA:10028141",
-                "PSY:12915",
-                "MONDO:0009061",
-                "OMIM:219700",
-                "ICD10:E84"
-              ],
-              "id": "MONDO:0009061",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cystic Fibrosis",
-                "cystic fibrosis",
-                "obsolete_cystic fibrosis",
-                "Cystic fibrosis related phenotypic feature",
-                "Cystic fibrosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://ghr.nlm.nih.gov/condition/cystic-fibrosis",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/cf/",
-                "http://en.wikipedia.org/wiki/cystic_fibrosis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 16663049,
-            "start": 675256,
-            "end": 616,
-            "type": "biolink:coexists_with",
-            "properties": {
-              "predicate": "biolink:coexists_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23804759': {'publication date': '2013 Sep', 'sentence': 'We reveal here for the first time the architecture of the full-length Thermus thermophilus DNA gyrase alone and in a cleavage complex with a 155 bp DNA duplex in the presence of the antibiotic ciprofloxacin, using cryo-electron microscopy.', 'subject score': 839, 'object score': 888}, 'PMID:2826973': {'publication date': '1987 Oct', 'sentence': 'In order to detect modification of DNA-gyrase, we performed supercoiling assays in vitro in presence of norfloxacin and ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:8619577': {'publication date': '1995 Oct', 'sentence': 'Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem.', 'subject score': 901, 'object score': 694}}",
-              "kg2_ids": [
-                "UMLS:C0949782---SEMMEDDB:coexists_with---None---None---None---UMLS:C0008809---SEMMEDDB:"
-              ],
-              "subject": "MESH:D027081",
-              "id": "17007621",
-              "object": "PUBCHEM.COMPOUND:2764",
-              "publications": [
-                "PMID:23804759",
-                "PMID:2826973",
-                "PMID:8619577"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16663049,
-            "start": 675256,
-            "end": 616,
-            "type": "biolink:coexists_with",
-            "properties": {
-              "predicate": "biolink:coexists_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23804759': {'publication date': '2013 Sep', 'sentence': 'We reveal here for the first time the architecture of the full-length Thermus thermophilus DNA gyrase alone and in a cleavage complex with a 155 bp DNA duplex in the presence of the antibiotic ciprofloxacin, using cryo-electron microscopy.', 'subject score': 839, 'object score': 888}, 'PMID:2826973': {'publication date': '1987 Oct', 'sentence': 'In order to detect modification of DNA-gyrase, we performed supercoiling assays in vitro in presence of norfloxacin and ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:8619577': {'publication date': '1995 Oct', 'sentence': 'Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem.', 'subject score': 901, 'object score': 694}}",
-              "kg2_ids": [
-                "UMLS:C0949782---SEMMEDDB:coexists_with---None---None---None---UMLS:C0008809---SEMMEDDB:"
-              ],
-              "subject": "MESH:D027081",
-              "id": "17007621",
-              "object": "PUBCHEM.COMPOUND:2764",
-              "publications": [
-                "PMID:23804759",
-                "PMID:2826973",
-                "PMID:8619577"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9184562,
-            "start": 616,
-            "end": 675256,
-            "type": "biolink:physically_interacts_with",
-            "properties": {
-              "predicate": "biolink:physically_interacts_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11850491': {'publication date': '2002 Feb', 'sentence': 'UNLABELLED: Ciprofloxacin, a quinolone antibiotic drug, binds to DNA topoisomerase IV and DNA gyrase of various bacteria.', 'subject score': 1000, 'object score': 1000}, 'PMID:18677735': {'publication date': '2008 Sep 01', 'sentence': 'The mode of binding of ciprofloxacin, levofloxacin, and moxifloxacin to DNA gyrase was analyzed by means of docking calculations over the surface of the QRDR of GyrA.', 'subject score': 1000, 'object score': 1000}, 'PMID:22530906': {'publication date': '2012 May', 'sentence': 'We postulate that the enhanced potency of BSFQs against Staphylococcus aureus compared to CIP and NOR could be caused by the presence of the BS moiety that resulted in enhanced binding to DNA gyrase of Sa.', 'subject score': 1000, 'object score': 1000}, 'PMID:24327941': {'publication date': '2013', 'sentence': 'In conclusion, the AcrAB efflux system is one of the principal mechanisms contribute in ciprofloxacin resistance among K. pneumoniae isolates but there are some other mechanisms interfere with ciprofloxacin resistance such as mutation in target proteins of DNA gyrase of topoisomerase IV enzymes.', 'subject score': 694, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:interacts_with---None---None---None---UMLS:C0949782---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "9387116",
-              "object": "MESH:D027081",
-              "publications": [
-                "PMID:11850491",
-                "PMID:18677735",
-                "PMID:22530906",
-                "PMID:24327941"
-=======
-            "identity": 7637170,
-            "start": 616,
-            "end": 523273,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10553703': {'publication date': '1999', 'sentence': 'As juveniles are especially sensitive, use of these drugs in paediatrics should be restricted to carefully selected indications (such as the use of ciprofloxacin in cystic fibrosis).', 'subject score': 1000, 'object score': 1000}, 'PMID:10587421': {'publication date': '1999 Dec', 'sentence': 'We report on a case of photosensitivity induced by indoor fluorescent strip-lighting (spectral range, 295-760 nm) in a 12-year-old girl with CF treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:10851644': {'publication date': '2000', 'sentence': 'Ciprofloxacin clinical and bacteriological efficacies, as well as tolerability mainly with respect to chondrotoxicity were evaluated in the treatment of children with mucoviscidosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:11709326': {'publication date': '2001 Dec', 'sentence': 'Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:11777658': {'publication date': '2001 Dec', 'sentence': 'Isolates of MSSA showed lower levels of susceptibility to ciprofloxacin (61-77% susceptibility) in both cystic fibrosis and neutropenia patients, and particularly high levels of resistance to ceftazidime (38% susceptibility) in cystic fibrosis units.', 'subject score': 1000, 'object score': 1000}, 'PMID:11806288': {'publication date': '2001 Sep-Oct', 'sentence': 'Until recently, only compassionate use of ciprofloxacin in children with cystic fibrosis was possible despite limited pharmacokinetic data.', 'subject score': 1000, 'object score': 1000}, 'PMID:11881187': {'publication date': '2001', 'sentence': 'The results of the prospective and comparative investigation of the linear growth of children at the age of 4 to 16 years with mucoviscidosis treated with ciprofloxacin in combination with a cephalosporin or an aminoglycoside in the main group and a cephalosporin or an aminoglycoside alone in the control group are presented.', 'subject score': 1000, 'object score': 1000}, 'PMID:12052667': {'publication date': '2002 Feb 28', 'sentence': 'Chondrotoxicity of quinolones can affect the articular cartilage and the epiphyseal growth plate in immature animals; the use of these drugs in pediatrics should be restricted to carefully selected indications (such as the use of ciprofloxacin in cystic fibrosis).', 'subject score': 1000, 'object score': 1000}, 'PMID:12856383': {'publication date': '2003 Jul', 'sentence': 'With body weight included in the model (two compartments with first-order absorption), ciprofloxacin clearance was influenced by age, and the absorption rate constant was altered in CF patients.', 'subject score': 888, 'object score': 901}, 'PMID:1489195': {'publication date': '1992 Nov', 'sentence': 'Our data indicate that the pharmacokinetic properties of ciprofloxacin are altered in cystic fibrosis patients with mild symptoms of pulmonary exacerbations and that the changes most probably are due to cystic fibrosis per se or to the impact of chronic infection.', 'subject score': 1000, 'object score': 901}, 'PMID:17012372': {'publication date': '2007 Jan', 'sentence': 'Azithromycin (AZM) and ciprofloxacin (CIP) are used clinically in CF.', 'subject score': 1000, 'object score': 1000}, 'PMID:17045852': {'publication date': '2007 May', 'sentence': 'Coagulopathy in two patients with cystic fibrosis treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:18835137': {'publication date': '2009 Mar', 'sentence': 'As a consequence, only life-threatening infections for which other antimicrobials cannot be used are possible indications for quinolones in children, for example the use of ciprofloxacin in cystic fibrosis patients with a bronchopulmonary exacerbation, chronic suppurative otitis media caused by Pseudomonas sp., complicated urinary tract infections and enteritis caused by invasive multidrug-resistant pathogens (e.g. Salmonella, Shigella).', 'subject score': 1000, 'object score': 901}, 'PMID:1907546': {'publication date': '1991 Apr', 'sentence': 'Ciprofloxacin (and possibly ofloxacin) are considered useful alternatives to parenteral agents in therapy of cystic fibrosis patients older than 18 years of age with exacerbations of pulmonary infection.', 'subject score': 1000, 'object score': 901}, 'PMID:1929312': {'publication date': '1991 Jul', 'sentence': 'The effect of pancreatic enzyme supplementation on the absorption of an oral dose of 250 mg of ciprofloxacin was studied in six patients with cystic fibrosis in a crossover design.', 'subject score': 1000, 'object score': 1000}, 'PMID:19847626': {'publication date': '2010 Jan', 'sentence': 'Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:21114393': {'publication date': '2010 Dec', 'sentence': 'CONCLUSION: These results provide a pharmacologic hypothesis-that the current dosing recommendations of ciprofloxacin for cystic fibrosis children may be suboptimal-to explain the decrease in the susceptibility of P. aeruginosa to ciprofloxacin observed in children with cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:21193474': {'publication date': '2011 Mar', 'sentence': 'CONCLUSIONS: Treatment of P. aeruginosa with oral ciprofloxacin in patients with CF may concurrently reduce antibiotic susceptibility in the commensal VGS flora, where these organisms may potentially act as a reservoir of fluoroquinolone resistance gene determinants for newly acquired and antibiotic-susceptible pathogens, particularly the Streptococcus milleri group.', 'subject score': 888, 'object score': 1000}, 'PMID:21928725': {'publication date': '2011', 'sentence': 'The PK/PD index (CMAX/MIC) for ciprofloxacin in patients with cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2292542': {'publication date': '1990 Dec', 'sentence': 'Other children with cystic fibrosis were subsequently treated with ciprofloxacin, as the need arose.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0010674---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7798648",
-              "object": "MONDO:0009061",
-              "publications": [
-                "PMID:10553703",
-                "PMID:10587421",
-                "PMID:10851644",
-                "PMID:11709326",
-                "PMID:11777658",
-                "PMID:11806288",
-                "PMID:11881187",
-                "PMID:12052667",
-                "PMID:12856383",
-                "PMID:1489195",
-                "PMID:17012372",
-                "PMID:17045852",
-                "PMID:18835137",
-                "PMID:1907546",
-                "PMID:1929312",
-                "PMID:19847626",
-                "PMID:21114393",
-                "PMID:21193474",
-                "PMID:21928725",
-                "PMID:2292542"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15910371': {'publication date': '2005', 'sentence': 'CONCLUSIONS: Ofloxacin has higher corneal penetration and ability to exceed MIC90 of common ocular contaminants than ciprofloxacin, and would be a more appropriate prophylactic choice for canine cataract patients.', 'subject score': 1000, 'object score': 851}, 'PMID:2947831': {'publication date': '1986', 'sentence': \"With these cataract models we tested the gyrase inhibitor compound, Ciprofloxacin (Bayer 09867), after 6 weeks' daily peroral application (20 mg/kg body weight) for differences in cataract progression indicating a possible cocataractogenic effect of the compound.\", 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 316730,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005129",
-          "name": "cataract",
-          "description": "Partial or complete opacity of the crystalline lens of one or both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.); Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed); A cataract is an opacity or clouding that develops in the crystalline lens of the eye or in its capsule. [HPO:probinson]; A cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery. A cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are: Blurry vision Colors that seem faded Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights. Not being able to see well at night Double vision  Frequent prescription changes in your eye wear   Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. NIH: National Eye Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "OMIM.PS:116200",
-            "SNOMEDCT:247053007",
-            "ICD10:H26",
-            "MEDDRA:10007768",
-            "ICD9:366.8",
-            "MONDO:0005129",
-            "UMLS:C0029531",
-            "MEDDRA:10007739",
-            "MEDDRA:10045649",
-            "MEDDRA:10030347",
-            "UMLS:C0086543",
-            "SNOMEDCT:193570009",
-            "SNOMEDCT:128306009",
-            "DOID:83",
-            "OMIM:PS116200",
-            "MEDDRA:10007771",
-            "MEDDRA:10024208",
-            "UMLS:C1510497",
-            "MEDDRA:10024214",
-            "MEDDRA:10024215",
-            "ICD9:366",
-            "HP:0000518",
-            "NCIT:C26713",
-            "MESH:D002386",
-            "MEDDRA:10007757"
-          ],
-          "id": "MONDO:0005129",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Other cataract",
-            "Cataract",
-            "cataract",
-            "Lens Opacities"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:10414631",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0001-6908-9849",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://en.wikipedia.org/wiki/cataract",
-            "https://orcid.org/0000-0002-6601-2165"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-=======
-            "identity": 316730,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005129",
-              "name": "cataract",
-              "description": "Partial or complete opacity of the crystalline lens of one or both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.); Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed); A cataract is an opacity or clouding that develops in the crystalline lens of the eye or in its capsule. [HPO:probinson]; A cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery. A cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are: Blurry vision Colors that seem faded Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights. Not being able to see well at night Double vision  Frequent prescription changes in your eye wear   Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. NIH: National Eye Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "OMIM.PS:116200",
-                "SNOMEDCT:247053007",
-                "ICD10:H26",
-                "MEDDRA:10007768",
-                "ICD9:366.8",
-                "MONDO:0005129",
-                "UMLS:C0029531",
-                "MEDDRA:10007739",
-                "MEDDRA:10045649",
-                "MEDDRA:10030347",
-                "UMLS:C0086543",
-                "SNOMEDCT:193570009",
-                "SNOMEDCT:128306009",
-                "DOID:83",
-                "OMIM:PS116200",
-                "MEDDRA:10007771",
-                "MEDDRA:10024208",
-                "UMLS:C1510497",
-                "MEDDRA:10024214",
-                "MEDDRA:10024215",
-                "ICD9:366",
-                "HP:0000518",
-                "NCIT:C26713",
-                "MESH:D002386",
-                "MEDDRA:10007757"
-              ],
-              "id": "MONDO:0005129",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Other cataract",
-                "Cataract",
-                "cataract",
-                "Lens Opacities"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:10414631",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0001-6908-9849",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://en.wikipedia.org/wiki/cataract",
-                "https://orcid.org/0000-0002-6601-2165"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 9184562,
-            "start": 616,
-            "end": 675256,
-            "type": "biolink:physically_interacts_with",
-            "properties": {
-              "predicate": "biolink:physically_interacts_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11850491': {'publication date': '2002 Feb', 'sentence': 'UNLABELLED: Ciprofloxacin, a quinolone antibiotic drug, binds to DNA topoisomerase IV and DNA gyrase of various bacteria.', 'subject score': 1000, 'object score': 1000}, 'PMID:18677735': {'publication date': '2008 Sep 01', 'sentence': 'The mode of binding of ciprofloxacin, levofloxacin, and moxifloxacin to DNA gyrase was analyzed by means of docking calculations over the surface of the QRDR of GyrA.', 'subject score': 1000, 'object score': 1000}, 'PMID:22530906': {'publication date': '2012 May', 'sentence': 'We postulate that the enhanced potency of BSFQs against Staphylococcus aureus compared to CIP and NOR could be caused by the presence of the BS moiety that resulted in enhanced binding to DNA gyrase of Sa.', 'subject score': 1000, 'object score': 1000}, 'PMID:24327941': {'publication date': '2013', 'sentence': 'In conclusion, the AcrAB efflux system is one of the principal mechanisms contribute in ciprofloxacin resistance among K. pneumoniae isolates but there are some other mechanisms interfere with ciprofloxacin resistance such as mutation in target proteins of DNA gyrase of topoisomerase IV enzymes.', 'subject score': 694, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:interacts_with---None---None---None---UMLS:C0949782---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "9387116",
-              "object": "MESH:D027081",
-              "publications": [
-                "PMID:11850491",
-                "PMID:18677735",
-                "PMID:22530906",
-                "PMID:24327941"
-=======
-            "identity": 11587690,
-            "start": 616,
-            "end": 316730,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15910371': {'publication date': '2005', 'sentence': 'CONCLUSIONS: Ofloxacin has higher corneal penetration and ability to exceed MIC90 of common ocular contaminants than ciprofloxacin, and would be a more appropriate prophylactic choice for canine cataract patients.', 'subject score': 1000, 'object score': 851}, 'PMID:2947831': {'publication date': '1986', 'sentence': \"With these cataract models we tested the gyrase inhibitor compound, Ciprofloxacin (Bayer 09867), after 6 weeks' daily peroral application (20 mg/kg body weight) for differences in cataract progression indicating a possible cocataractogenic effect of the compound.\", 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0086543---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "11840711",
-              "object": "MONDO:0005129",
-              "publications": [
-                "PMID:15910371",
-                "PMID:2947831"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:32915525': {'publication date': '2020 Sep 11', 'sentence': 'OBJECTIVE: To evaluate the efficacy of a fixed-dose combination of two approved drugs, Ciprofloxacin and Celecoxib, as a potential therapeutic treatment for amyotrophic lateral sclerosis (ALS).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 310237,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004976",
-          "name": "amyotrophic lateral sclerosis",
-          "description": "A neurodegenerative disorder characterized by progressive degeneration of the motor neurons of the central nervous system. It results in weakness and atrophy of the muscles which leads to an inability to initiate and control voluntary movements.; A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:0111246",
-            "NCIT:C34373",
-            "MEDDRA:10002026",
-            "OMIM:PS105400",
-            "UMLS:C0002736",
-            "DOID:332",
-            "MESH:D000690",
-            "ICD9:335.20",
-            "SNOMEDCT:86044005",
-            "MEDDRA:10052889",
-            "ORPHANET:803",
-            "HP:0007354",
-            "ICD10:G12.21",
-            "EFO:0000253",
-            "KEGG.DISEASE:05014",
-            "MONDO:0004976"
-          ],
-          "id": "MONDO:0004976",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_amyotrophic lateral sclerosis",
-            "amyotrophic lateral sclerosis-parkinsonism/dementia complex 1",
-            "Amyotrophic lateral sclerosis",
-            "amyotrophic lateral sclerosis",
-            "Amyotrophic Lateral Sclerosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/detail_als.htm",
-            "PMID:5770171",
-            "PMID:16051700",
-            "http://en.wikipedia.org/wiki/amyotrophic_lateral_sclerosis"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-=======
-            "identity": 310237,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004976",
-              "name": "amyotrophic lateral sclerosis",
-              "description": "A neurodegenerative disorder characterized by progressive degeneration of the motor neurons of the central nervous system. It results in weakness and atrophy of the muscles which leads to an inability to initiate and control voluntary movements.; A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:0111246",
-                "NCIT:C34373",
-                "MEDDRA:10002026",
-                "OMIM:PS105400",
-                "UMLS:C0002736",
-                "DOID:332",
-                "MESH:D000690",
-                "ICD9:335.20",
-                "SNOMEDCT:86044005",
-                "MEDDRA:10052889",
-                "ORPHANET:803",
-                "HP:0007354",
-                "ICD10:G12.21",
-                "EFO:0000253",
-                "KEGG.DISEASE:05014",
-                "MONDO:0004976"
-              ],
-              "id": "MONDO:0004976",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_amyotrophic lateral sclerosis",
-                "amyotrophic lateral sclerosis-parkinsonism/dementia complex 1",
-                "Amyotrophic lateral sclerosis",
-                "amyotrophic lateral sclerosis",
-                "Amyotrophic Lateral Sclerosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/detail_als.htm",
-                "PMID:5770171",
-                "PMID:16051700",
-                "http://en.wikipedia.org/wiki/amyotrophic_lateral_sclerosis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 8039359,
-            "start": 675256,
-            "end": 616,
-            "type": "biolink:physically_interacts_with",
-            "properties": {
-              "predicate": "biolink:physically_interacts_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10824040': {'publication date': '2000 Apr', 'sentence': 'Topoisomerase IV and DNA gyrase were purified from a ciprofloxacin-sensitive Streptococcus pneumoniae strain and from two clinical isolates of S. pneumoniae with high-level resistance to ciprofloxacin by means of a gene cloning method in Escherichia coli.', 'subject score': 1000, 'object score': 1000}, 'PMID:1649573': {'publication date': '1991 May', 'sentence': 'The DNA gyrase isolated from MP051 was 24-fold less sensitive to inhibition of supercoiling by ciprofloxacin than the DNA gyrase isolated from MP050 was.', 'subject score': 1000, 'object score': 1000}, 'PMID:2158277': {'publication date': '1990 Feb', 'sentence': 'Preparations of DNA gyrase from the quinolone-resistant posttherapy isolates were 16- to 32-fold less sensitive to inhibition of supercoiling by ciprofloxacin and nalidixic acid than was gyrase from the pretherapy isolate.', 'subject score': 1000, 'object score': 1000}, 'PMID:26663076': {'publication date': '2016 Feb 12', 'sentence': 'Taken together these experiments now show unequivocally that A. thaliana encodes an organelle-targeted DNA gyrase that is the target of the quinolone drug ciprofloxacin; this has important consequences for plant physiology and the development of herbicides.', 'subject score': 852, 'object score': 790}, 'PMID:3034057': {'publication date': '1987 Apr 27', 'sentence': 'In summary, the A subunit of DNA gyrase is a target of ciprofloxacin and other quinolones.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0949782---SEMMEDDB:interacts_with---None---None---None---UMLS:C0008809---SEMMEDDB:"
-              ],
-              "subject": "MESH:D027081",
-              "id": "8212496",
-              "object": "PUBCHEM.COMPOUND:2764",
-              "publications": [
-                "PMID:10824040",
-                "PMID:1649573",
-                "PMID:2158277",
-                "PMID:26663076",
-                "PMID:3034057"
-=======
-            "identity": 22060077,
-            "start": 616,
-            "end": 310237,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32915525': {'publication date': '2020 Sep 11', 'sentence': 'OBJECTIVE: To evaluate the efficacy of a fixed-dose combination of two approved drugs, Ciprofloxacin and Celecoxib, as a potential therapeutic treatment for amyotrophic lateral sclerosis (ALS).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0002736---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "22484062",
-              "object": "MONDO:0004976",
-              "publications": [
-                "PMID:32915525"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1930395': {'publication date': '1991 Nov', 'sentence': 'A patient is reported who had previously maintained a stable prothrombin time on Coumadin for 5 years, and who exhibited a marked prolongation of prothrombin time when placed on ciprofloxacin for gastroenteritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:27900889': {'publication date': '2017 Apr', 'sentence': 'Campylobacter jejuni strains coresistant to tetracycline and ciprofloxacin in patients with gastroenteritis in Croatia.', 'subject score': 1000, 'object score': 1000}, 'PMID:28857901': {'publication date': '2018 May', 'sentence': 'This report includes two cases, one presenting with right lateral thumb pain and a medical history of gastroenteritis treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:8852546': {'publication date': '1996 Jan', 'sentence': 'Despite this, the empirical use of ciprofloxacin in suspected infective gastroenteritis appeared to be only partially guided by the clinical features.', 'subject score': 1000, 'object score': 827}}",
-    "p2": {
-      "start": {
-        "identity": 546728,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002269",
-          "name": "gastroenteritis",
-          "description": "An inflammatory disorder that affects the upper and lower gastrointestinal tract. Most commonly, this is attributed to viruses; however bacteria, parasites or adverse reactions can also be the culprit. Symptoms include acute diarrhea and vomiting.; INFLAMMATION of any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Causes of gastroenteritis are many including genetic, infection, HYPERSENSITIVITY, drug effects, and CANCER.;  Have you ever had the \"stomach flu?\" What you probably had was gastroenteritis - not a type of flu at all. Gastroenteritis is an inflammation of the lining of the intestines caused by a virus, bacteria, or parasites. Viral gastroenteritis is the second most common illness in the U.S. The cause is often a norovirus infection. It spreads through contaminated food or water or by contact with an infected person. The best prevention is frequent hand washing.  Symptoms of gastroenteritis include diarrhea, abdominal pain, vomiting, headache, fever, and chills. Most people recover with no treatment. The most common problem with gastroenteritis is dehydration. This happens if you do not drink enough fluids to replace what you lose through vomiting and diarrhea. Dehydration is most common in babies, young children, older adults, and people with weak immune systems.  NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D005759",
-            "SYMP:0019159",
-            "SNOMEDCT:25374005",
-            "EFO:1001463",
-            "MEDDRA:10017888",
-            "NCIT:C34632",
-            "DOID:2326",
-            "UMLS:C0017160",
-            "MONDO:0002269",
-            "MEDDRA:10017907"
-          ],
-          "id": "MONDO:0002269",
-          "category": "biolink:Disease",
-          "all_names": [
-            "gastroenteritis",
-            "Gastroenteritis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.merck.com/mmhe/sec09/ch122/ch122a.htm"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-=======
-            "identity": 546728,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002269",
-              "name": "gastroenteritis",
-              "description": "An inflammatory disorder that affects the upper and lower gastrointestinal tract. Most commonly, this is attributed to viruses; however bacteria, parasites or adverse reactions can also be the culprit. Symptoms include acute diarrhea and vomiting.; INFLAMMATION of any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Causes of gastroenteritis are many including genetic, infection, HYPERSENSITIVITY, drug effects, and CANCER.;  Have you ever had the \"stomach flu?\" What you probably had was gastroenteritis - not a type of flu at all. Gastroenteritis is an inflammation of the lining of the intestines caused by a virus, bacteria, or parasites. Viral gastroenteritis is the second most common illness in the U.S. The cause is often a norovirus infection. It spreads through contaminated food or water or by contact with an infected person. The best prevention is frequent hand washing.  Symptoms of gastroenteritis include diarrhea, abdominal pain, vomiting, headache, fever, and chills. Most people recover with no treatment. The most common problem with gastroenteritis is dehydration. This happens if you do not drink enough fluids to replace what you lose through vomiting and diarrhea. Dehydration is most common in babies, young children, older adults, and people with weak immune systems.  NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D005759",
-                "SYMP:0019159",
-                "SNOMEDCT:25374005",
-                "EFO:1001463",
-                "MEDDRA:10017888",
-                "NCIT:C34632",
-                "DOID:2326",
-                "UMLS:C0017160",
-                "MONDO:0002269",
-                "MEDDRA:10017907"
-              ],
-              "id": "MONDO:0002269",
-              "category": "biolink:Disease",
-              "all_names": [
-                "gastroenteritis",
-                "Gastroenteritis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.merck.com/mmhe/sec09/ch122/ch122a.htm"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 8039359,
-            "start": 675256,
-            "end": 616,
-            "type": "biolink:physically_interacts_with",
-            "properties": {
-              "predicate": "biolink:physically_interacts_with",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10824040': {'publication date': '2000 Apr', 'sentence': 'Topoisomerase IV and DNA gyrase were purified from a ciprofloxacin-sensitive Streptococcus pneumoniae strain and from two clinical isolates of S. pneumoniae with high-level resistance to ciprofloxacin by means of a gene cloning method in Escherichia coli.', 'subject score': 1000, 'object score': 1000}, 'PMID:1649573': {'publication date': '1991 May', 'sentence': 'The DNA gyrase isolated from MP051 was 24-fold less sensitive to inhibition of supercoiling by ciprofloxacin than the DNA gyrase isolated from MP050 was.', 'subject score': 1000, 'object score': 1000}, 'PMID:2158277': {'publication date': '1990 Feb', 'sentence': 'Preparations of DNA gyrase from the quinolone-resistant posttherapy isolates were 16- to 32-fold less sensitive to inhibition of supercoiling by ciprofloxacin and nalidixic acid than was gyrase from the pretherapy isolate.', 'subject score': 1000, 'object score': 1000}, 'PMID:26663076': {'publication date': '2016 Feb 12', 'sentence': 'Taken together these experiments now show unequivocally that A. thaliana encodes an organelle-targeted DNA gyrase that is the target of the quinolone drug ciprofloxacin; this has important consequences for plant physiology and the development of herbicides.', 'subject score': 852, 'object score': 790}, 'PMID:3034057': {'publication date': '1987 Apr 27', 'sentence': 'In summary, the A subunit of DNA gyrase is a target of ciprofloxacin and other quinolones.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0949782---SEMMEDDB:interacts_with---None---None---None---UMLS:C0008809---SEMMEDDB:"
-              ],
-              "subject": "MESH:D027081",
-              "id": "8212496",
-              "object": "PUBCHEM.COMPOUND:2764",
-              "publications": [
-                "PMID:10824040",
-                "PMID:1649573",
-                "PMID:2158277",
-                "PMID:26663076",
-                "PMID:3034057"
-=======
-            "identity": 13986552,
-            "start": 616,
-            "end": 546728,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1930395': {'publication date': '1991 Nov', 'sentence': 'A patient is reported who had previously maintained a stable prothrombin time on Coumadin for 5 years, and who exhibited a marked prolongation of prothrombin time when placed on ciprofloxacin for gastroenteritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:27900889': {'publication date': '2017 Apr', 'sentence': 'Campylobacter jejuni strains coresistant to tetracycline and ciprofloxacin in patients with gastroenteritis in Croatia.', 'subject score': 1000, 'object score': 1000}, 'PMID:28857901': {'publication date': '2018 May', 'sentence': 'This report includes two cases, one presenting with right lateral thumb pain and a medical history of gastroenteritis treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:8852546': {'publication date': '1996 Jan', 'sentence': 'Despite this, the empirical use of ciprofloxacin in suspected infective gastroenteritis appeared to be only partially guided by the clinical features.', 'subject score': 1000, 'object score': 827}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0017160---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "14284683",
-              "object": "MONDO:0002269",
-              "publications": [
-                "PMID:1930395",
-                "PMID:27900889",
-                "PMID:28857901",
-                "PMID:8852546"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10913427': {'publication date': '2000 Jul', 'sentence': 'Despite prolonged bacteremia, the response to long-term therapy with ciprofloxacin and rifampin was excellent.', 'subject score': 1000, 'object score': 888}, 'PMID:12324938': {'publication date': '2002 Oct', 'sentence': 'In one patient, bacteremia persisted after ciprofloxacin therapy and was cleared only by removal of the dialysis catheter and a 3-week course of gentamicin.', 'subject score': 888, 'object score': 1000}, 'PMID:12423618': {'publication date': '2002 Nov', 'sentence': 'Shigella flexneri bacteraemia in an immunocompetent male treated with oral ciprofloxacin.', 'subject score': 888, 'object score': 802}, 'PMID:12951354': {'publication date': '2003 Oct', 'sentence': 'CONCLUSION: Pharmacodynamic considerations including aggressive dosing with targeted peak/MICs for aminoglycosides and ciprofloxacin are strongly associated with clinical outcome and essential to the appropriate management of P. aeruginosa bacteraemia.', 'subject score': 1000, 'object score': 901}, 'PMID:1387303': {'publication date': '1992 Jul', 'sentence': 'A combination of clarithromycin, ciprofloxacin, and amikacin for the treatment of Mycobacterium avium-Mycobacterium intracellulare bacteremia was evaluated in 12 AIDS patients.', 'subject score': 1000, 'object score': 841}, 'PMID:15140397': {'publication date': '2004', 'sentence': 'A total of 80 (60.2%) patients experienced bacteremia due to strains resistant to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:1775838': {'publication date': '1991 Nov-Dec', 'sentence': 'To the best of our knowledge, this is the first documented case of symptomatic bacteremia due to C. cinaedi that was successfully treated with ciprofloxacin.', 'subject score': 1000, 'object score': 888}, 'PMID:18036218': {'publication date': '2007 Nov 23', 'sentence': 'The bacteremic episodes were successfully treated with netilmicin, doxycycline and ciprofloxacin.', 'subject score': 1000, 'object score': 853}, 'PMID:19487049': {'publication date': '2009 Nov', 'sentence': 'CONCLUSION: P aeruginosa bacteremic isolates from patients who have been exposed to ciprofloxacin during the 30 days prior to the development of bacteremia have an increased risk of being resistant to ceftazidime, imipenem, meropenem, piperacillin-tazobactam, or ciprofloxacin and to have multidrug resistance.', 'subject score': 1000, 'object score': 1000}, 'PMID:21437168': {'publication date': '2011 Mar', 'sentence': 'CONCLUSIONS: These data indicate a close association between ciprofloxacin resistance and ESBL-production in P. mirabilis bacteremia.', 'subject score': 694, 'object score': 851}, 'PMID:2210856': {'publication date': '1990 Jul-Aug', 'sentence': 'Ciprofloxacin in the treatment of nosocomial multiply resistant Acinetobacter calcoaceticus bacteremia.', 'subject score': 1000, 'object score': 767}, 'PMID:2490638': {'publication date': '1989 Jan', 'sentence': 'The results of efficacy and safety of ciprofloxacin administered by parenteral and oral route in the treatment of severe infections-particularly, osteomyelitis and bacteremia-due to gram-negative bacilli are studied in the present work.', 'subject score': 1000, 'object score': 1000}, 'PMID:2504407': {'publication date': '1989 Jul 29', 'sentence': 'OBJECTIVE: To define an outbreak of bacteraemia due to coagulase negative staphylococci highly resistant to ciprofloxacin in a leukaemia unit, investigate the source and mode of spread of the outbreak strain, and assess control measures.', 'subject score': 1000, 'object score': 1000}, 'PMID:34722367': {'publication date': '2021 Sep', 'sentence': 'We aimed to assess the clinical success following high-dose ciprofloxacin for recurrent bacteremia from biofilm-forming multidrug resistant    Klebsiella pneumoniae     in a liver transplanted patient.', 'subject score': 901, 'object score': 888}, 'PMID:8056702': {'publication date': '1994 Apr', 'sentence': 'Bacteraemia developed in six of 78 episodes (8%) treated with ciprofloxacin, in eight of 80 (10%) allocated to ofloxacin and in 12 of 77 (16%) when pefloxacin was given.', 'subject score': 1000, 'object score': 1000}, 'PMID:8192181': {'publication date': '1994 May', 'sentence': 'Streptococcus sanguis bacteremia during ciprofloxacin therapy of a diabetic foot ulcer.', 'subject score': 888, 'object score': 901}, 'PMID:8448312': {'publication date': '1993 Jan', 'sentence': 'Oral ciprofloxacin therapy for Bacillus cereus wound infection and bacteremia.', 'subject score': 851, 'object score': 1000}, 'PMID:8676931': {'publication date': '1996 Aug 08', 'sentence': 'CONCLUSIONS: In patients with AIDS and M. avium complex bacteremia, treatment with the three-drug regimen of rifabutin, ethambutol, and clarithromycin leads to resolution of the bacteremia more frequently and more rapidly than treatment with rifampin, ethambutol, clofazimine, and ciprofloxacin, and survival rates are better.', 'subject score': 1000, 'object score': 802}, 'PMID:9096194': {'publication date': '1997 Mar', 'sentence': 'Rates of resistance to ciprofloxacin and other antimicrobial agents commonly used to treat bacteraemic infections have remained relatively low in this Canadian teaching hospital over the past 16 years.', 'subject score': 1000, 'object score': 853}}",
-    "p2": {
-      "start": {
-        "identity": 315382,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-          "name": "bacterial infectious disease with sepsis",
-          "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C102993",
-            "ICD9:995.91",
-            "MONDO:0005229",
-            "MEDDRA:10060562",
-            "MEDDRA:10003998",
-            "MEDDRA:10003997",
-            "MEDDRA:10045641",
-            "ICD9:790.7",
-            "MEDDRA:10045642",
-            "HP:0031864",
-            "SNOMEDCT:5758002",
-            "DOID:0040085",
-            "MESH:D016470",
-            "UMLS:C0004610",
-            "MEDDRA:10003999"
-          ],
-          "id": "MONDO:0005229",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacteremia",
-            "bacterial infectious disease with sepsis",
-            "bacterial sepsis",
-            "Sepsis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:20421654"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315382,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-              "name": "bacterial infectious disease with sepsis",
-              "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C102993",
-                "ICD9:995.91",
-                "MONDO:0005229",
-                "MEDDRA:10060562",
-                "MEDDRA:10003998",
-                "MEDDRA:10003997",
-                "MEDDRA:10045641",
-                "ICD9:790.7",
-                "MEDDRA:10045642",
-                "HP:0031864",
-                "SNOMEDCT:5758002",
-                "DOID:0040085",
-                "MESH:D016470",
-                "UMLS:C0004610",
-                "MEDDRA:10003999"
-              ],
-              "id": "MONDO:0005229",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacteremia",
-                "bacterial infectious disease with sepsis",
-                "bacterial sepsis",
-                "Sepsis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:20421654"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8161469,
-            "start": 616,
-            "end": 315382,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10913427': {'publication date': '2000 Jul', 'sentence': 'Despite prolonged bacteremia, the response to long-term therapy with ciprofloxacin and rifampin was excellent.', 'subject score': 1000, 'object score': 888}, 'PMID:12324938': {'publication date': '2002 Oct', 'sentence': 'In one patient, bacteremia persisted after ciprofloxacin therapy and was cleared only by removal of the dialysis catheter and a 3-week course of gentamicin.', 'subject score': 888, 'object score': 1000}, 'PMID:12423618': {'publication date': '2002 Nov', 'sentence': 'Shigella flexneri bacteraemia in an immunocompetent male treated with oral ciprofloxacin.', 'subject score': 888, 'object score': 802}, 'PMID:12951354': {'publication date': '2003 Oct', 'sentence': 'CONCLUSION: Pharmacodynamic considerations including aggressive dosing with targeted peak/MICs for aminoglycosides and ciprofloxacin are strongly associated with clinical outcome and essential to the appropriate management of P. aeruginosa bacteraemia.', 'subject score': 1000, 'object score': 901}, 'PMID:1387303': {'publication date': '1992 Jul', 'sentence': 'A combination of clarithromycin, ciprofloxacin, and amikacin for the treatment of Mycobacterium avium-Mycobacterium intracellulare bacteremia was evaluated in 12 AIDS patients.', 'subject score': 1000, 'object score': 841}, 'PMID:15140397': {'publication date': '2004', 'sentence': 'A total of 80 (60.2%) patients experienced bacteremia due to strains resistant to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:1775838': {'publication date': '1991 Nov-Dec', 'sentence': 'To the best of our knowledge, this is the first documented case of symptomatic bacteremia due to C. cinaedi that was successfully treated with ciprofloxacin.', 'subject score': 1000, 'object score': 888}, 'PMID:18036218': {'publication date': '2007 Nov 23', 'sentence': 'The bacteremic episodes were successfully treated with netilmicin, doxycycline and ciprofloxacin.', 'subject score': 1000, 'object score': 853}, 'PMID:19487049': {'publication date': '2009 Nov', 'sentence': 'CONCLUSION: P aeruginosa bacteremic isolates from patients who have been exposed to ciprofloxacin during the 30 days prior to the development of bacteremia have an increased risk of being resistant to ceftazidime, imipenem, meropenem, piperacillin-tazobactam, or ciprofloxacin and to have multidrug resistance.', 'subject score': 1000, 'object score': 1000}, 'PMID:21437168': {'publication date': '2011 Mar', 'sentence': 'CONCLUSIONS: These data indicate a close association between ciprofloxacin resistance and ESBL-production in P. mirabilis bacteremia.', 'subject score': 694, 'object score': 851}, 'PMID:2210856': {'publication date': '1990 Jul-Aug', 'sentence': 'Ciprofloxacin in the treatment of nosocomial multiply resistant Acinetobacter calcoaceticus bacteremia.', 'subject score': 1000, 'object score': 767}, 'PMID:2490638': {'publication date': '1989 Jan', 'sentence': 'The results of efficacy and safety of ciprofloxacin administered by parenteral and oral route in the treatment of severe infections-particularly, osteomyelitis and bacteremia-due to gram-negative bacilli are studied in the present work.', 'subject score': 1000, 'object score': 1000}, 'PMID:2504407': {'publication date': '1989 Jul 29', 'sentence': 'OBJECTIVE: To define an outbreak of bacteraemia due to coagulase negative staphylococci highly resistant to ciprofloxacin in a leukaemia unit, investigate the source and mode of spread of the outbreak strain, and assess control measures.', 'subject score': 1000, 'object score': 1000}, 'PMID:34722367': {'publication date': '2021 Sep', 'sentence': 'We aimed to assess the clinical success following high-dose ciprofloxacin for recurrent bacteremia from biofilm-forming multidrug resistant    Klebsiella pneumoniae     in a liver transplanted patient.', 'subject score': 901, 'object score': 888}, 'PMID:8056702': {'publication date': '1994 Apr', 'sentence': 'Bacteraemia developed in six of 78 episodes (8%) treated with ciprofloxacin, in eight of 80 (10%) allocated to ofloxacin and in 12 of 77 (16%) when pefloxacin was given.', 'subject score': 1000, 'object score': 1000}, 'PMID:8192181': {'publication date': '1994 May', 'sentence': 'Streptococcus sanguis bacteremia during ciprofloxacin therapy of a diabetic foot ulcer.', 'subject score': 888, 'object score': 901}, 'PMID:8448312': {'publication date': '1993 Jan', 'sentence': 'Oral ciprofloxacin therapy for Bacillus cereus wound infection and bacteremia.', 'subject score': 851, 'object score': 1000}, 'PMID:8676931': {'publication date': '1996 Aug 08', 'sentence': 'CONCLUSIONS: In patients with AIDS and M. avium complex bacteremia, treatment with the three-drug regimen of rifabutin, ethambutol, and clarithromycin leads to resolution of the bacteremia more frequently and more rapidly than treatment with rifampin, ethambutol, clofazimine, and ciprofloxacin, and survival rates are better.', 'subject score': 1000, 'object score': 802}, 'PMID:9096194': {'publication date': '1997 Mar', 'sentence': 'Rates of resistance to ciprofloxacin and other antimicrobial agents commonly used to treat bacteraemic infections have remained relatively low in this Canadian teaching hospital over the past 16 years.', 'subject score': 1000, 'object score': 853}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0004610---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8337570",
-              "object": "MONDO:0005229",
-              "publications": [
-                "PMID:10913427",
-                "PMID:12324938",
-                "PMID:12423618",
-                "PMID:12951354",
-                "PMID:1387303",
-                "PMID:15140397",
-                "PMID:1775838",
-                "PMID:18036218",
-                "PMID:19487049",
-                "PMID:21437168",
-                "PMID:2210856",
-                "PMID:2490638",
-                "PMID:2504407",
-                "PMID:34722367",
-                "PMID:8056702",
-                "PMID:8192181",
-                "PMID:8448312",
-                "PMID:8676931",
-                "PMID:9096194"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:1287815': {'publication date': '1992', 'sentence': 'Ciprofloxacin was administered orally in order to suppress bacteremia for 36 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:18602189': {'publication date': '2008 Aug', 'sentence': 'Modification in prescribing practices for third-generation cephalosporins and ciprofloxacin is associated with a reduction in meticillin-resistant Staphylococcus aureus bacteraemia rate.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 315382,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-          "name": "bacterial infectious disease with sepsis",
-          "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C102993",
-            "ICD9:995.91",
-            "MONDO:0005229",
-            "MEDDRA:10060562",
-            "MEDDRA:10003998",
-            "MEDDRA:10003997",
-            "MEDDRA:10045641",
-            "ICD9:790.7",
-            "MEDDRA:10045642",
-            "HP:0031864",
-            "SNOMEDCT:5758002",
-            "DOID:0040085",
-            "MESH:D016470",
-            "UMLS:C0004610",
-            "MEDDRA:10003999"
-          ],
-          "id": "MONDO:0005229",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacteremia",
-            "bacterial infectious disease with sepsis",
-            "bacterial sepsis",
-            "Sepsis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:20421654"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315382,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-              "name": "bacterial infectious disease with sepsis",
-              "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C102993",
-                "ICD9:995.91",
-                "MONDO:0005229",
-                "MEDDRA:10060562",
-                "MEDDRA:10003998",
-                "MEDDRA:10003997",
-                "MEDDRA:10045641",
-                "ICD9:790.7",
-                "MEDDRA:10045642",
-                "HP:0031864",
-                "SNOMEDCT:5758002",
-                "DOID:0040085",
-                "MESH:D016470",
-                "UMLS:C0004610",
-                "MEDDRA:10003999"
-              ],
-              "id": "MONDO:0005229",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacteremia",
-                "bacterial infectious disease with sepsis",
-                "bacterial sepsis",
-                "Sepsis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:20421654"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10100567,
-            "start": 616,
-            "end": 315382,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1287815': {'publication date': '1992', 'sentence': 'Ciprofloxacin was administered orally in order to suppress bacteremia for 36 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:18602189': {'publication date': '2008 Aug', 'sentence': 'Modification in prescribing practices for third-generation cephalosporins and ciprofloxacin is associated with a reduction in meticillin-resistant Staphylococcus aureus bacteraemia rate.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:disrupts---None---None---None---UMLS:C0004610---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "10323767",
-              "object": "MONDO:0005229",
-              "publications": [
-                "PMID:1287815",
-                "PMID:18602189"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:1450256': {'publication date': '1992 Aug-Sep', 'sentence': 'To the contrary, ciprofloxacin, even at low doses, eliminated the microorganisms early and demonstrated high efficacy in the prevention of bacteremia in the animals when these results were compared with those of the untreated group.', 'subject score': 1000, 'object score': 1000}, 'PMID:2767765': {'publication date': '1989', 'sentence': 'In the present study 45 consecutive patients undergoing intensive cytotoxic treatment received a short course of roxithromycin (10 days) in addition to ciprofloxacin for prevention of bacteremias caused by alpha-hemolytic streptococci.', 'subject score': 1000, 'object score': 1000}, 'PMID:7961196': {'publication date': '1994 Jul', 'sentence': 'Prevention of bacteraemia by systemic ciprofloxacin treatment in rat cytomegalovirus-infected immunocompromised rats.', 'subject score': 851, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 315382,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-          "name": "bacterial infectious disease with sepsis",
-          "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C102993",
-            "ICD9:995.91",
-            "MONDO:0005229",
-            "MEDDRA:10060562",
-            "MEDDRA:10003998",
-            "MEDDRA:10003997",
-            "MEDDRA:10045641",
-            "ICD9:790.7",
-            "MEDDRA:10045642",
-            "HP:0031864",
-            "SNOMEDCT:5758002",
-            "DOID:0040085",
-            "MESH:D016470",
-            "UMLS:C0004610",
-            "MEDDRA:10003999"
-          ],
-          "id": "MONDO:0005229",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacteremia",
-            "bacterial infectious disease with sepsis",
-            "bacterial sepsis",
-            "Sepsis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:20421654"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315382,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-              "name": "bacterial infectious disease with sepsis",
-              "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C102993",
-                "ICD9:995.91",
-                "MONDO:0005229",
-                "MEDDRA:10060562",
-                "MEDDRA:10003998",
-                "MEDDRA:10003997",
-                "MEDDRA:10045641",
-                "ICD9:790.7",
-                "MEDDRA:10045642",
-                "HP:0031864",
-                "SNOMEDCT:5758002",
-                "DOID:0040085",
-                "MESH:D016470",
-                "UMLS:C0004610",
-                "MEDDRA:10003999"
-              ],
-              "id": "MONDO:0005229",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacteremia",
-                "bacterial infectious disease with sepsis",
-                "bacterial sepsis",
-                "Sepsis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:20421654"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10536866,
-            "start": 616,
-            "end": 315382,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1450256': {'publication date': '1992 Aug-Sep', 'sentence': 'To the contrary, ciprofloxacin, even at low doses, eliminated the microorganisms early and demonstrated high efficacy in the prevention of bacteremia in the animals when these results were compared with those of the untreated group.', 'subject score': 1000, 'object score': 1000}, 'PMID:2767765': {'publication date': '1989', 'sentence': 'In the present study 45 consecutive patients undergoing intensive cytotoxic treatment received a short course of roxithromycin (10 days) in addition to ciprofloxacin for prevention of bacteremias caused by alpha-hemolytic streptococci.', 'subject score': 1000, 'object score': 1000}, 'PMID:7961196': {'publication date': '1994 Jul', 'sentence': 'Prevention of bacteraemia by systemic ciprofloxacin treatment in rat cytomegalovirus-infected immunocompromised rats.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:prevents---None---None---None---UMLS:C0004610---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "10767980",
-              "object": "MONDO:0005229",
-              "publications": [
-                "PMID:1450256",
-                "PMID:2767765",
-                "PMID:7961196"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:21298846': {'publication date': '2009 Aug', 'sentence': 'CONCLUSION: The present study shows a significant correlation between ciprofloxacin resistance and fluoroquinolone use, and indicates that prior fluoroquinolone use seems to be the most important risk factor for ciprofloxacin-resistant E. coli bacteremia.', 'subject score': 694, 'object score': 758}, 'PMID:7726525': {'publication date': '1995 Feb', 'sentence': 'In conclusion, our study shows a significant correlation between ciprofloxacin resistance and fluoroquinolone use and indicates that prior fluoroquinolone use seems to be the most important risk factor for CIPRO-R E. coli bacteremia.', 'subject score': 694, 'object score': 758}, 'PMID:9402356': {'publication date': '1997 Nov', 'sentence': 'Both C. difficile infection and antimicrobial (vancomycin and ciprofloxacin) use during VRE colonization were significant risk factors for VRE bacteremia in univariate analysis.', 'subject score': 1000, 'object score': 908}}",
-    "p2": {
-      "start": {
-        "identity": 315382,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-          "name": "bacterial infectious disease with sepsis",
-          "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C102993",
-            "ICD9:995.91",
-            "MONDO:0005229",
-            "MEDDRA:10060562",
-            "MEDDRA:10003998",
-            "MEDDRA:10003997",
-            "MEDDRA:10045641",
-            "ICD9:790.7",
-            "MEDDRA:10045642",
-            "HP:0031864",
-            "SNOMEDCT:5758002",
-            "DOID:0040085",
-            "MESH:D016470",
-            "UMLS:C0004610",
-            "MEDDRA:10003999"
-          ],
-          "id": "MONDO:0005229",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacteremia",
-            "bacterial infectious disease with sepsis",
-            "bacterial sepsis",
-            "Sepsis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:20421654"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315382,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-              "name": "bacterial infectious disease with sepsis",
-              "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C102993",
-                "ICD9:995.91",
-                "MONDO:0005229",
-                "MEDDRA:10060562",
-                "MEDDRA:10003998",
-                "MEDDRA:10003997",
-                "MEDDRA:10045641",
-                "ICD9:790.7",
-                "MEDDRA:10045642",
-                "HP:0031864",
-                "SNOMEDCT:5758002",
-                "DOID:0040085",
-                "MESH:D016470",
-                "UMLS:C0004610",
-                "MEDDRA:10003999"
-              ],
-              "id": "MONDO:0005229",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacteremia",
-                "bacterial infectious disease with sepsis",
-                "bacterial sepsis",
-                "Sepsis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:20421654"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15141440,
-            "start": 616,
-            "end": 315382,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21298846': {'publication date': '2009 Aug', 'sentence': 'CONCLUSION: The present study shows a significant correlation between ciprofloxacin resistance and fluoroquinolone use, and indicates that prior fluoroquinolone use seems to be the most important risk factor for ciprofloxacin-resistant E. coli bacteremia.', 'subject score': 694, 'object score': 758}, 'PMID:7726525': {'publication date': '1995 Feb', 'sentence': 'In conclusion, our study shows a significant correlation between ciprofloxacin resistance and fluoroquinolone use and indicates that prior fluoroquinolone use seems to be the most important risk factor for CIPRO-R E. coli bacteremia.', 'subject score': 694, 'object score': 758}, 'PMID:9402356': {'publication date': '1997 Nov', 'sentence': 'Both C. difficile infection and antimicrobial (vancomycin and ciprofloxacin) use during VRE colonization were significant risk factors for VRE bacteremia in univariate analysis.', 'subject score': 1000, 'object score': 908}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:predisposes---None---None---None---UMLS:C0004610---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "15459841",
-              "object": "MONDO:0005229",
-              "publications": [
-                "PMID:21298846",
-                "PMID:7726525",
-                "PMID:9402356"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:19473592': {'publication date': '2009 May', 'sentence': 'CASE SUMMARY: A 24-year-old woman was admitted to the hospital because of convulsions, severe myopathy, and acute renal failure after taking ciprofloxacin for sinusitis, and urinary tract infections.', 'subject score': 861, 'object score': 1000}, 'PMID:19925632': {'publication date': '2010 Aug', 'sentence': 'A 30-year-old woman received cefotaxime, fosfomycin and ciprofloxacin for sinusitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:21686850': {'publication date': '2009', 'sentence': 'A 30-year-old woman received cefotaxime, fosfomycin and ciprofloxacin for sinusitis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318463,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005961",
-          "name": "sinusitis",
-          "description": "A paranasal sinus disease involving inflammation of the paranasal sinuses resulting from bacterial, fungal, viral infection, allergic or autoimmune issues. Symptoms can include fever, weakness, fatigue, cough and congestion. There may also be mucus drainage in the back of the throat, called postnasal drip.",
-          "equivalent_curies": [
-            "MEDDRA:10040753",
-            "ICD9:461",
-            "MEDDRA:10040745",
-            "MEDDRA:10040756",
-            "MESH:D012852",
-            "ICD10:J01",
-            "MONDO:0005961",
-            "SNOMEDCT:36971009",
-            "NCIT:C35024",
-            "EFO:0007486",
-            "SYMP:0000134",
-            "DOID:0050127",
-            "HP:0000246",
-            "MEDDRA:10078707",
-            "UMLS:C0037199"
-          ],
-          "id": "MONDO:0005961",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute sinusitis",
-            "Sinusitis",
-            "sinusitis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5889-4463",
-            "http://en.wikipedia.org/wiki/sinusitis",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c35024&ns=nci_thesaurus&key=1218436475&b=1&n=n"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318463,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005961",
-              "name": "sinusitis",
-              "description": "A paranasal sinus disease involving inflammation of the paranasal sinuses resulting from bacterial, fungal, viral infection, allergic or autoimmune issues. Symptoms can include fever, weakness, fatigue, cough and congestion. There may also be mucus drainage in the back of the throat, called postnasal drip.",
-              "equivalent_curies": [
-                "MEDDRA:10040753",
-                "ICD9:461",
-                "MEDDRA:10040745",
-                "MEDDRA:10040756",
-                "MESH:D012852",
-                "ICD10:J01",
-                "MONDO:0005961",
-                "SNOMEDCT:36971009",
-                "NCIT:C35024",
-                "EFO:0007486",
-                "SYMP:0000134",
-                "DOID:0050127",
-                "HP:0000246",
-                "MEDDRA:10078707",
-                "UMLS:C0037199"
-              ],
-              "id": "MONDO:0005961",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute sinusitis",
-                "Sinusitis",
-                "sinusitis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5889-4463",
-                "http://en.wikipedia.org/wiki/sinusitis",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c35024&ns=nci_thesaurus&key=1218436475&b=1&n=n"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14097870,
-            "start": 616,
-            "end": 318463,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19473592': {'publication date': '2009 May', 'sentence': 'CASE SUMMARY: A 24-year-old woman was admitted to the hospital because of convulsions, severe myopathy, and acute renal failure after taking ciprofloxacin for sinusitis, and urinary tract infections.', 'subject score': 861, 'object score': 1000}, 'PMID:19925632': {'publication date': '2010 Aug', 'sentence': 'A 30-year-old woman received cefotaxime, fosfomycin and ciprofloxacin for sinusitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:21686850': {'publication date': '2009', 'sentence': 'A 30-year-old woman received cefotaxime, fosfomycin and ciprofloxacin for sinusitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0037199---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "14398199",
-              "object": "MONDO:0005961",
-              "publications": [
-                "PMID:19473592",
-                "PMID:19925632",
-                "PMID:21686850"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:1545485': {'publication date': '1992 Jan', 'sentence': 'A study was conducted to investigate the effects of ciprofloxacin in typhoid fever and to compare its efficacy with chloramphenicol.', 'subject score': 1000, 'object score': 1000}, 'PMID:15494840': {'publication date': '2004 Oct', 'sentence': 'Typhoid fever due to multiresistant Salmonella enterica serovar typhi having reduced susceptibility to ciprofloxacin and nalidixic acid resistance.', 'subject score': 1000, 'object score': 1000}, 'PMID:23817934': {'publication date': '2013 Jun', 'sentence': 'Salmonella paratyphi A was the commonest cause of enteric fever in adults with 92% resistance to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 520880,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005619",
-          "name": "typhoid fever",
-          "description": "A bacterial infectious disorder contracted by consumption of food or drink contaminated with Salmonella typhi. This disorder is common in developing countries and can be treated with antibiotics.; An acute systemic febrile infection caused by SALMONELLA TYPHI, a serotype of SALMONELLA ENTERICA.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:13258",
-            "SNOMEDCT:4834000",
-            "MESH:D014435",
-            "MONDO:0005619",
-            "MEDDRA:10045272",
-            "MEDDRA:10045275",
-            "ICD9:002.0",
-            "ICD10:A01.0",
-            "UMLS:C0041466",
-            "MEDDRA:10014862",
-            "MEDDRA:10039446",
-            "NCIT:C35089",
-            "EFO:0006789",
-            "ORPHANET:99745"
-          ],
-          "id": "MONDO:0005619",
-          "category": "biolink:Disease",
-          "all_names": [
-            "typhoid fever",
-            "Typhoid",
-            "Typhoid Fever",
-            "Typhoid fever"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.merriam-webster.com/medlineplus/typhoid%20feve"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520880,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005619",
-              "name": "typhoid fever",
-              "description": "A bacterial infectious disorder contracted by consumption of food or drink contaminated with Salmonella typhi. This disorder is common in developing countries and can be treated with antibiotics.; An acute systemic febrile infection caused by SALMONELLA TYPHI, a serotype of SALMONELLA ENTERICA.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:13258",
-                "SNOMEDCT:4834000",
-                "MESH:D014435",
-                "MONDO:0005619",
-                "MEDDRA:10045272",
-                "MEDDRA:10045275",
-                "ICD9:002.0",
-                "ICD10:A01.0",
-                "UMLS:C0041466",
-                "MEDDRA:10014862",
-                "MEDDRA:10039446",
-                "NCIT:C35089",
-                "EFO:0006789",
-                "ORPHANET:99745"
-              ],
-              "id": "MONDO:0005619",
-              "category": "biolink:Disease",
-              "all_names": [
-                "typhoid fever",
-                "Typhoid",
-                "Typhoid Fever",
-                "Typhoid fever"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.merriam-webster.com/medlineplus/typhoid%20feve"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11191830,
-            "start": 616,
-            "end": 520880,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1545485': {'publication date': '1992 Jan', 'sentence': 'A study was conducted to investigate the effects of ciprofloxacin in typhoid fever and to compare its efficacy with chloramphenicol.', 'subject score': 1000, 'object score': 1000}, 'PMID:15494840': {'publication date': '2004 Oct', 'sentence': 'Typhoid fever due to multiresistant Salmonella enterica serovar typhi having reduced susceptibility to ciprofloxacin and nalidixic acid resistance.', 'subject score': 1000, 'object score': 1000}, 'PMID:23817934': {'publication date': '2013 Jun', 'sentence': 'Salmonella paratyphi A was the commonest cause of enteric fever in adults with 92% resistance to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0041466---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "11440816",
-              "object": "MONDO:0005619",
-              "publications": [
-                "PMID:1545485",
-                "PMID:15494840",
-                "PMID:23817934"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10348767': {'publication date': '1999 Jun', 'sentence': 'To compare clinical and bacteriological efficacies of azithromycin and ciprofloxacin for typhoid fever, 123 adults with fever and signs of uncomplicated typhoid fever were entered into a randomized trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:10408519': {'publication date': '1999 Jul 10', 'sentence': 'Ciprofloxacin in typhoid fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:10807074': {'publication date': '2000 May', 'sentence': 'We believe that patients with a presumptive diagnosis of typhoid fever should be treated with ciprofloxacin and dexamethasone, even before the results of blood cultures are available.', 'subject score': 1000, 'object score': 1000}, 'PMID:11219168': {'publication date': '2000 Dec', 'sentence': 'We conclude that ciprofloxacin is commonly used in typhoid fever and has no adverse effects on growth or joint symptomology.', 'subject score': 1000, 'object score': 1000}, 'PMID:11810512': {'publication date': '1999 Sep', 'sentence': 'Antibacterial activity of cefixime was comparable to ceftriaxone, ofloxacin, and ciprofloxacin, which are often used for the treatment of typhoid fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:11816954': {'publication date': '2001 Jun', 'sentence': 'METHODS: A total of 140 children, aged 3-10 yr, clinically diagnosed as having typhoid fever, without any clinical response after 12-14 days of ciprofloxacin therapy were screened for S. typhi by blood culture.', 'subject score': 888, 'object score': 1000}, 'PMID:12138663': {'publication date': '2002 Feb', 'sentence': 'Misuse and overuse of ciprofloxacin for the treatment of typhoid fever influenced the development of ciprofloxacin resistant strains of S. enterica serotype Typhi in and around Kolkata.', 'subject score': 1000, 'object score': 1000}, 'PMID:12138664': {'publication date': '2002 Feb', 'sentence': 'The antimicrobial susceptibility tests for S. typhi performed by the disc diffusion method using NCCLS breakpoints fail to detect the increasing MIC of ciprofloxacin, leading to the inappropriate treatment of enteric fever with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:1307372': {'publication date': '1992 Oct', 'sentence': 'Typhoid fever, not responding to ciprofloxacin therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:1440832': {'publication date': '1992', 'sentence': 'This study assessed the performance of short-course ciprofloxacin for the treatment of 34 adult patients with culture-positive typhoid fever.', 'subject score': 851, 'object score': 861}, 'PMID:14511204': {'publication date': '2003 Sep-Oct', 'sentence': 'Short-course ciprofloxacin treatment for enteric fever: caveat emptor!', 'subject score': 833, 'object score': 1000}, 'PMID:1452543': {'publication date': '1992 Apr', 'sentence': 'Chloramphenicol vs ciprofloxacin in enteric fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:1474262': {'publication date': '1992 Nov', 'sentence': 'A short-course regime of ciprofloxacin for the treatment of enteric fever, is therefore, highly promising.', 'subject score': 1000, 'object score': 1000}, 'PMID:1493986': {'publication date': '1992 Nov', 'sentence': 'We conclude that 500 mg of ciprofloxacin taken orally twice daily is adequate treatment for typhoid fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:15211083': {'publication date': '2004 Jun', 'sentence': 'Ceftriaxone and ciprofloxacin remain favorable choices for treatment of patients with enteric fever in this region.', 'subject score': 1000, 'object score': 1000}, 'PMID:15380025': {'publication date': '2004 Sep 20', 'sentence': 'Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series.', 'subject score': 1000, 'object score': 1000}, 'PMID:1634483': {'publication date': '1992 Mar', 'sentence': 'We used this technique to compare the cost-effectiveness of chloramphenicol and ciprofloxacin in the treatment of enteric fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:1682560': {'publication date': '1991 Nov 02', 'sentence': 'Ciprofloxacin for typhoid fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:1684010': {'publication date': '1991', 'sentence': 'Ciprofloxacin for typhoid fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:17164172': {'publication date': '2006 Dec', 'sentence': 'Quinolone derivatives (namely, Ciprofloxacin, Norfloxacin and Chloramphenicol) can be suggested as drugs of choice for treatment of enteric fever caused by SPTA.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 520880,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005619",
-          "name": "typhoid fever",
-          "description": "A bacterial infectious disorder contracted by consumption of food or drink contaminated with Salmonella typhi. This disorder is common in developing countries and can be treated with antibiotics.; An acute systemic febrile infection caused by SALMONELLA TYPHI, a serotype of SALMONELLA ENTERICA.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:13258",
-            "SNOMEDCT:4834000",
-            "MESH:D014435",
-            "MONDO:0005619",
-            "MEDDRA:10045272",
-            "MEDDRA:10045275",
-            "ICD9:002.0",
-            "ICD10:A01.0",
-            "UMLS:C0041466",
-            "MEDDRA:10014862",
-            "MEDDRA:10039446",
-            "NCIT:C35089",
-            "EFO:0006789",
-            "ORPHANET:99745"
-          ],
-          "id": "MONDO:0005619",
-          "category": "biolink:Disease",
-          "all_names": [
-            "typhoid fever",
-            "Typhoid",
-            "Typhoid Fever",
-            "Typhoid fever"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.merriam-webster.com/medlineplus/typhoid%20feve"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520880,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005619",
-              "name": "typhoid fever",
-              "description": "A bacterial infectious disorder contracted by consumption of food or drink contaminated with Salmonella typhi. This disorder is common in developing countries and can be treated with antibiotics.; An acute systemic febrile infection caused by SALMONELLA TYPHI, a serotype of SALMONELLA ENTERICA.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:13258",
-                "SNOMEDCT:4834000",
-                "MESH:D014435",
-                "MONDO:0005619",
-                "MEDDRA:10045272",
-                "MEDDRA:10045275",
-                "ICD9:002.0",
-                "ICD10:A01.0",
-                "UMLS:C0041466",
-                "MEDDRA:10014862",
-                "MEDDRA:10039446",
-                "NCIT:C35089",
-                "EFO:0006789",
-                "ORPHANET:99745"
-              ],
-              "id": "MONDO:0005619",
-              "category": "biolink:Disease",
-              "all_names": [
-                "typhoid fever",
-                "Typhoid",
-                "Typhoid Fever",
-                "Typhoid fever"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.merriam-webster.com/medlineplus/typhoid%20feve"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7274250,
-            "start": 616,
-            "end": 520880,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10348767': {'publication date': '1999 Jun', 'sentence': 'To compare clinical and bacteriological efficacies of azithromycin and ciprofloxacin for typhoid fever, 123 adults with fever and signs of uncomplicated typhoid fever were entered into a randomized trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:10408519': {'publication date': '1999 Jul 10', 'sentence': 'Ciprofloxacin in typhoid fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:10807074': {'publication date': '2000 May', 'sentence': 'We believe that patients with a presumptive diagnosis of typhoid fever should be treated with ciprofloxacin and dexamethasone, even before the results of blood cultures are available.', 'subject score': 1000, 'object score': 1000}, 'PMID:11219168': {'publication date': '2000 Dec', 'sentence': 'We conclude that ciprofloxacin is commonly used in typhoid fever and has no adverse effects on growth or joint symptomology.', 'subject score': 1000, 'object score': 1000}, 'PMID:11810512': {'publication date': '1999 Sep', 'sentence': 'Antibacterial activity of cefixime was comparable to ceftriaxone, ofloxacin, and ciprofloxacin, which are often used for the treatment of typhoid fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:11816954': {'publication date': '2001 Jun', 'sentence': 'METHODS: A total of 140 children, aged 3-10 yr, clinically diagnosed as having typhoid fever, without any clinical response after 12-14 days of ciprofloxacin therapy were screened for S. typhi by blood culture.', 'subject score': 888, 'object score': 1000}, 'PMID:12138663': {'publication date': '2002 Feb', 'sentence': 'Misuse and overuse of ciprofloxacin for the treatment of typhoid fever influenced the development of ciprofloxacin resistant strains of S. enterica serotype Typhi in and around Kolkata.', 'subject score': 1000, 'object score': 1000}, 'PMID:12138664': {'publication date': '2002 Feb', 'sentence': 'The antimicrobial susceptibility tests for S. typhi performed by the disc diffusion method using NCCLS breakpoints fail to detect the increasing MIC of ciprofloxacin, leading to the inappropriate treatment of enteric fever with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:1307372': {'publication date': '1992 Oct', 'sentence': 'Typhoid fever, not responding to ciprofloxacin therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:1440832': {'publication date': '1992', 'sentence': 'This study assessed the performance of short-course ciprofloxacin for the treatment of 34 adult patients with culture-positive typhoid fever.', 'subject score': 851, 'object score': 861}, 'PMID:14511204': {'publication date': '2003 Sep-Oct', 'sentence': 'Short-course ciprofloxacin treatment for enteric fever: caveat emptor!', 'subject score': 833, 'object score': 1000}, 'PMID:1452543': {'publication date': '1992 Apr', 'sentence': 'Chloramphenicol vs ciprofloxacin in enteric fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:1474262': {'publication date': '1992 Nov', 'sentence': 'A short-course regime of ciprofloxacin for the treatment of enteric fever, is therefore, highly promising.', 'subject score': 1000, 'object score': 1000}, 'PMID:1493986': {'publication date': '1992 Nov', 'sentence': 'We conclude that 500 mg of ciprofloxacin taken orally twice daily is adequate treatment for typhoid fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:15211083': {'publication date': '2004 Jun', 'sentence': 'Ceftriaxone and ciprofloxacin remain favorable choices for treatment of patients with enteric fever in this region.', 'subject score': 1000, 'object score': 1000}, 'PMID:15380025': {'publication date': '2004 Sep 20', 'sentence': 'Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series.', 'subject score': 1000, 'object score': 1000}, 'PMID:1634483': {'publication date': '1992 Mar', 'sentence': 'We used this technique to compare the cost-effectiveness of chloramphenicol and ciprofloxacin in the treatment of enteric fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:1682560': {'publication date': '1991 Nov 02', 'sentence': 'Ciprofloxacin for typhoid fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:1684010': {'publication date': '1991', 'sentence': 'Ciprofloxacin for typhoid fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:17164172': {'publication date': '2006 Dec', 'sentence': 'Quinolone derivatives (namely, Ciprofloxacin, Norfloxacin and Chloramphenicol) can be suggested as drugs of choice for treatment of enteric fever caused by SPTA.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0041466---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7423320",
-              "object": "MONDO:0005619",
-              "publications": [
-                "PMID:10348767",
-                "PMID:10408519",
-                "PMID:10807074",
-                "PMID:11219168",
-                "PMID:11810512",
-                "PMID:11816954",
-                "PMID:12138663",
-                "PMID:12138664",
-                "PMID:1307372",
-                "PMID:1440832",
-                "PMID:14511204",
-                "PMID:1452543",
-                "PMID:1474262",
-                "PMID:1493986",
-                "PMID:15211083",
-                "PMID:15380025",
-                "PMID:1634483",
-                "PMID:1682560",
-                "PMID:1684010",
-                "PMID:17164172"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:10606835': {'publication date': '2000 Jan', 'sentence': 'AIMS: To examine the pharmacokinetics of ciprofloxacin and fleroxacin in plasma and sputum of patients with an acute exacerbation of chronic bronchitis or bronchiectasis following the first dose and again during the third day of treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:11414382': {'publication date': '2000 Jan', 'sentence': 'Ciprofloxacin is effective in complicated and severe lower respiratory tract infections, including those in patients with infective exacerbations of chronic bronchitis and cystic fibrosis, and pseudomonal infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:12168746': {'publication date': '2002 Jul', 'sentence': 'Double mutants in the parC and gyrA genes lead to fluoroquinolone resistance that has been found to cause bacteriological failure of the fluoroquinolones, particularly levofloxacin and ciprofloxacin, in the management of pneumonia and exacerbations of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:12445016': {'publication date': '2002 Nov', 'sentence': 'This study compared the in vitro activity of ertapenem, ceftriaxone, cefepime, ciprofloxacin and amoxicillin-clavulanate against 381 aerobic and facultative bacterial pathogens isolated from 320 patients with acute bacterial exacerbation of chronic bronchitis or community-acquired pneumonia.', 'subject score': 1000, 'object score': 1000}, 'PMID:1362752': {'publication date': '1992 Nov', 'sentence': 'Comparative clinical and microbiological study of amoxycillin-clavulanic acid and ciprofloxacin in acute purulent exacerbations of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1754733': {'publication date': '1991 Sep', 'sentence': 'Several studies have shown ciprofloxacin to be effective in the treatment of acute exacerbations of chronic bronchitis, some community-acquired and nosocomial pneumonia, and acute exacerbations of bronchopulmonary infections in cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2691479': {'publication date': '1989 Nov', 'sentence': 'This investigation compared the efficacy of oral formulations of amoxycillin/clavulanate and ciprofloxacin in acute exacerbations of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3490468': {'publication date': '1986 Sep', 'sentence': 'Ciprofloxacin in acute exacerbations of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3960693': {'publication date': '1986 Feb 21', 'sentence': 'Results are presented from 186 hospitalized patients treated for acute purulent exacerbations of chronic bronchitis with orally administered ciprofloxacin (80 patients), enoxacin (26 patients), ofloxacin (30 patients) or pefloxacin (50 patients).', 'subject score': 827, 'object score': 1000}, 'PMID:7666121': {'publication date': '1995 Apr', 'sentence': 'To determine the efficacy in vivo of pefloxacin and ciprofloxacin in the treatment of acute infectious bronchopneumopathies, 90 patients, suffering from acute exacerbation of chronic bronchitis and with no known allergies to quinolones, were admitted to the study.', 'subject score': 1000, 'object score': 1000}, 'PMID:8596127': {'publication date': '1995 Oct', 'sentence': 'Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:9385486': {'publication date': '1997 Sep-Oct', 'sentence': 'Efficacy of ciprofloxacin and clarithromycin in acute bacterial exacerbations of complicated chronic bronchitis: interim analysis.', 'subject score': 1000, 'object score': 901}, 'PMID:9440580': {'publication date': '1998 Jan', 'sentence': 'A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.', 'subject score': 1000, 'object score': 1000}, 'PMID:9449270': {'publication date': '1998 Jan', 'sentence': 'A randomized, prospective, double-blind, double-dummy, multicenter study investigated the efficacy and safety of 10 days of oral therapy with grepafloxacin at 400 mg once daily, grepafloxacin at 600 mg once daily, or ciprofloxacin at 500 mg twice daily in 624 patients with acute bacterial exacerbations of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:9798024': {'publication date': '1998 Oct', 'sentence': 'In a prospective, multicenter, double-blind study, the interval to clinical relapse in patients with acute bacterial exacerbations of chronic bronchitis from whom a pretherapy pathogen was isolated was compared following treatment with ciprofloxacin or cefuroxime axetil.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321736,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005607",
-          "name": "chronic bronchitis",
-          "description": "A type of chronic obstructive pulmonary disease characterized by chronic inflammation in the bronchial tree that results in edema, mucus production, obstruction, and reduced airflow to and from the lung alveoli. The most common cause is tobacco smoking. Signs and symptoms include coughing with excessive mucus production, and shortness of breath.; A subcategory of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. The disease is characterized by hypersecretion of mucus accompanied by a chronic (more than 3 months in 2 consecutive years) productive cough. Infectious agents are a major cause of chronic bronchitis.; Chronic inflammation of the bronchi. [HPO:probinson]; What is chronic bronchitis? Chronic bronchitis is a type of COPD (chronic obstructive pulmonary disease). COPD is a group of lung diseases that make it hard to breathe and get worse over time. The other main type of COPD is emphysema. Most people with COPD have both emphysema and chronic bronchitis, but how severe each type is can be different from person to person. Chronic bronchitis is inflammation (swelling) and irritation of the bronchial tubes. These tubes are the airways that carry air to and from the air sacs in your lungs. The irritation of the tubes causes mucus to build up. This mucus and the swelling of the tubes make it harder for your lungs to move oxygen in and carbon dioxide out of your body. What causes chronic bronchitis? The cause of chronic bronchitis is usually long-term exposure to irritants that damage your lungs and airways. In the United States, cigarette smoke is the main cause. Pipe, cigar, and other types of tobacco smoke can also cause chronic bronchitis, especially if you inhale them. Exposure to other inhaled irritants can contribute to chronic bronchitis. These include secondhand smoke, air pollution, and chemical fumes or dusts from the environment or workplace. Rarely, a genetic condition called alpha-1 antitrypsin deficiency can play a role in causing chronic bronchitis. Who is at risk for chronic bronchitis? The risk factors for chronic bronchitis include: Smoking. This the main risk factor. Up to 75% of people who have chronic bronchitis smoke or used to smoke. Long-term exposure to other lung irritants, such as secondhand smoke, air pollution, and chemical fumes and dusts from the environment or workplace. Age. Most people who have chronic bronchitis are at least 40 years old when their symptoms begin. Genetics. This includes alpha-1 antitrypsin deficiency, which is a genetic condition. Also, smokers who get chronic bronchitis are more likely to get it if they have a family history of COPD.  What are the symptoms of chronic bronchitis? At first, you may have no symptoms or only mild symptoms. As the disease gets worse, your symptoms usually become more severe. They can include: Frequent coughing or a cough that produces a lot mucus Wheezing A whistling or squeaky sound when you breathe Shortness of breath, especially with physical activity Tightness in your chest  Some people with chronic bronchitis get frequent respiratory infections such as colds and the flu. In severe cases, chronic bronchitis can cause weight loss, weakness in your lower muscles, and swelling in your ankles, feet, or legs. How is chronic bronchitis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A family history Various tests, such as lung function tests, a chest x-ray or CT scan, and blood tests  What are the treatments for chronic bronchitis? There is no cure for chronic bronchitis. However, treatments can help with symptoms, slow the progress of the disease, and improve your ability to stay active. There are also treatments to prevent or treat complications of the disease. Treatments include: Lifestyle changes, such as  Quitting smoking if you are a smoker. This is the most important step you can take to treat chronic bronchitis. Avoiding secondhand smoke and places where you might breathe in other lung irritants Ask your health care provider for an eating plan that will meet your nutritional needs. Also ask about how much physical activity you can do. Physical activity can strengthen the muscles that help you breathe and improve your overall wellness.   Medicines, such as  Bronchodilators, which relax the muscles around your airways. This helps open your airways and makes breathing easier. Most bronchodilators are taken through an inhaler. In more severe cases, the inhaler may also contain steroids to reduce inflammation. Vaccines for the flu and pneumococcal pneumonia, since people with chronic bronchitis are at higher risk for serious problems from these diseases. Antibiotics if you get a bacterial or viral lung infection   Oxygen therapy, if you have severe chronic bronchitis and low levels of oxygen in your blood. Oxygen therapy can help you breathe better. You may need extra oxygen all the time or only at certain times. Pulmonary rehabilitation, which is a program that helps improve the well-being of people who have chronic breathing problems. It may include  An exercise program Disease management training Nutritional counseling Psychological counseling  A lung transplant, as a last resort for people who have severe symptoms that have not gotten better with medicines  If you have chronic bronchitis, it's important to know when and where to get help for your symptoms. You should get emergency care if you have severe symptoms, such as trouble catching your breath or talking. Call your health care provider if your symptoms are getting worse or if you have signs of an infection, such as a fever. Can chronic bronchitis be prevented? Since smoking causes most cases of chronic bronchitis, the best way to prevent it is to not smoke. It's also important to try to avoid lung irritants such as secondhand smoke, air pollution, chemical fumes, and dusts.  NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10008843",
-            "MEDDRA:10008841",
-            "NCIT:C26722",
-            "MEDDRA:10006458",
-            "MESH:D029481",
-            "MONDO:0005607",
-            "MEDDRA:10045659",
-            "EFO:0006505",
-            "UMLS:C0008677",
-            "MEDDRA:10006459",
-            "HP:0004469",
-            "SNOMEDCT:63480004"
-          ],
-          "id": "MONDO:0005607",
-          "category": "biolink:Disease",
-          "all_names": [
-            "chronic bronchitis",
-            "Bronchitis, Chronic",
-            "Chronic bronchitis",
-            "Chronic Bronchitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321736,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005607",
-              "name": "chronic bronchitis",
-              "description": "A type of chronic obstructive pulmonary disease characterized by chronic inflammation in the bronchial tree that results in edema, mucus production, obstruction, and reduced airflow to and from the lung alveoli. The most common cause is tobacco smoking. Signs and symptoms include coughing with excessive mucus production, and shortness of breath.; A subcategory of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. The disease is characterized by hypersecretion of mucus accompanied by a chronic (more than 3 months in 2 consecutive years) productive cough. Infectious agents are a major cause of chronic bronchitis.; Chronic inflammation of the bronchi. [HPO:probinson]; What is chronic bronchitis? Chronic bronchitis is a type of COPD (chronic obstructive pulmonary disease). COPD is a group of lung diseases that make it hard to breathe and get worse over time. The other main type of COPD is emphysema. Most people with COPD have both emphysema and chronic bronchitis, but how severe each type is can be different from person to person. Chronic bronchitis is inflammation (swelling) and irritation of the bronchial tubes. These tubes are the airways that carry air to and from the air sacs in your lungs. The irritation of the tubes causes mucus to build up. This mucus and the swelling of the tubes make it harder for your lungs to move oxygen in and carbon dioxide out of your body. What causes chronic bronchitis? The cause of chronic bronchitis is usually long-term exposure to irritants that damage your lungs and airways. In the United States, cigarette smoke is the main cause. Pipe, cigar, and other types of tobacco smoke can also cause chronic bronchitis, especially if you inhale them. Exposure to other inhaled irritants can contribute to chronic bronchitis. These include secondhand smoke, air pollution, and chemical fumes or dusts from the environment or workplace. Rarely, a genetic condition called alpha-1 antitrypsin deficiency can play a role in causing chronic bronchitis. Who is at risk for chronic bronchitis? The risk factors for chronic bronchitis include: Smoking. This the main risk factor. Up to 75% of people who have chronic bronchitis smoke or used to smoke. Long-term exposure to other lung irritants, such as secondhand smoke, air pollution, and chemical fumes and dusts from the environment or workplace. Age. Most people who have chronic bronchitis are at least 40 years old when their symptoms begin. Genetics. This includes alpha-1 antitrypsin deficiency, which is a genetic condition. Also, smokers who get chronic bronchitis are more likely to get it if they have a family history of COPD.  What are the symptoms of chronic bronchitis? At first, you may have no symptoms or only mild symptoms. As the disease gets worse, your symptoms usually become more severe. They can include: Frequent coughing or a cough that produces a lot mucus Wheezing A whistling or squeaky sound when you breathe Shortness of breath, especially with physical activity Tightness in your chest  Some people with chronic bronchitis get frequent respiratory infections such as colds and the flu. In severe cases, chronic bronchitis can cause weight loss, weakness in your lower muscles, and swelling in your ankles, feet, or legs. How is chronic bronchitis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A family history Various tests, such as lung function tests, a chest x-ray or CT scan, and blood tests  What are the treatments for chronic bronchitis? There is no cure for chronic bronchitis. However, treatments can help with symptoms, slow the progress of the disease, and improve your ability to stay active. There are also treatments to prevent or treat complications of the disease. Treatments include: Lifestyle changes, such as  Quitting smoking if you are a smoker. This is the most important step you can take to treat chronic bronchitis. Avoiding secondhand smoke and places where you might breathe in other lung irritants Ask your health care provider for an eating plan that will meet your nutritional needs. Also ask about how much physical activity you can do. Physical activity can strengthen the muscles that help you breathe and improve your overall wellness.   Medicines, such as  Bronchodilators, which relax the muscles around your airways. This helps open your airways and makes breathing easier. Most bronchodilators are taken through an inhaler. In more severe cases, the inhaler may also contain steroids to reduce inflammation. Vaccines for the flu and pneumococcal pneumonia, since people with chronic bronchitis are at higher risk for serious problems from these diseases. Antibiotics if you get a bacterial or viral lung infection   Oxygen therapy, if you have severe chronic bronchitis and low levels of oxygen in your blood. Oxygen therapy can help you breathe better. You may need extra oxygen all the time or only at certain times. Pulmonary rehabilitation, which is a program that helps improve the well-being of people who have chronic breathing problems. It may include  An exercise program Disease management training Nutritional counseling Psychological counseling  A lung transplant, as a last resort for people who have severe symptoms that have not gotten better with medicines  If you have chronic bronchitis, it's important to know when and where to get help for your symptoms. You should get emergency care if you have severe symptoms, such as trouble catching your breath or talking. Call your health care provider if your symptoms are getting worse or if you have signs of an infection, such as a fever. Can chronic bronchitis be prevented? Since smoking causes most cases of chronic bronchitis, the best way to prevent it is to not smoke. It's also important to try to avoid lung irritants such as secondhand smoke, air pollution, chemical fumes, and dusts.  NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10008843",
-                "MEDDRA:10008841",
-                "NCIT:C26722",
-                "MEDDRA:10006458",
-                "MESH:D029481",
-                "MONDO:0005607",
-                "MEDDRA:10045659",
-                "EFO:0006505",
-                "UMLS:C0008677",
-                "MEDDRA:10006459",
-                "HP:0004469",
-                "SNOMEDCT:63480004"
-              ],
-              "id": "MONDO:0005607",
-              "category": "biolink:Disease",
-              "all_names": [
-                "chronic bronchitis",
-                "Bronchitis, Chronic",
-                "Chronic bronchitis",
-                "Chronic Bronchitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7711377,
-            "start": 616,
-            "end": 321736,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10606835': {'publication date': '2000 Jan', 'sentence': 'AIMS: To examine the pharmacokinetics of ciprofloxacin and fleroxacin in plasma and sputum of patients with an acute exacerbation of chronic bronchitis or bronchiectasis following the first dose and again during the third day of treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:11414382': {'publication date': '2000 Jan', 'sentence': 'Ciprofloxacin is effective in complicated and severe lower respiratory tract infections, including those in patients with infective exacerbations of chronic bronchitis and cystic fibrosis, and pseudomonal infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:12168746': {'publication date': '2002 Jul', 'sentence': 'Double mutants in the parC and gyrA genes lead to fluoroquinolone resistance that has been found to cause bacteriological failure of the fluoroquinolones, particularly levofloxacin and ciprofloxacin, in the management of pneumonia and exacerbations of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:12445016': {'publication date': '2002 Nov', 'sentence': 'This study compared the in vitro activity of ertapenem, ceftriaxone, cefepime, ciprofloxacin and amoxicillin-clavulanate against 381 aerobic and facultative bacterial pathogens isolated from 320 patients with acute bacterial exacerbation of chronic bronchitis or community-acquired pneumonia.', 'subject score': 1000, 'object score': 1000}, 'PMID:1362752': {'publication date': '1992 Nov', 'sentence': 'Comparative clinical and microbiological study of amoxycillin-clavulanic acid and ciprofloxacin in acute purulent exacerbations of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1754733': {'publication date': '1991 Sep', 'sentence': 'Several studies have shown ciprofloxacin to be effective in the treatment of acute exacerbations of chronic bronchitis, some community-acquired and nosocomial pneumonia, and acute exacerbations of bronchopulmonary infections in cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2691479': {'publication date': '1989 Nov', 'sentence': 'This investigation compared the efficacy of oral formulations of amoxycillin/clavulanate and ciprofloxacin in acute exacerbations of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3490468': {'publication date': '1986 Sep', 'sentence': 'Ciprofloxacin in acute exacerbations of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3960693': {'publication date': '1986 Feb 21', 'sentence': 'Results are presented from 186 hospitalized patients treated for acute purulent exacerbations of chronic bronchitis with orally administered ciprofloxacin (80 patients), enoxacin (26 patients), ofloxacin (30 patients) or pefloxacin (50 patients).', 'subject score': 827, 'object score': 1000}, 'PMID:7666121': {'publication date': '1995 Apr', 'sentence': 'To determine the efficacy in vivo of pefloxacin and ciprofloxacin in the treatment of acute infectious bronchopneumopathies, 90 patients, suffering from acute exacerbation of chronic bronchitis and with no known allergies to quinolones, were admitted to the study.', 'subject score': 1000, 'object score': 1000}, 'PMID:8596127': {'publication date': '1995 Oct', 'sentence': 'Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:9385486': {'publication date': '1997 Sep-Oct', 'sentence': 'Efficacy of ciprofloxacin and clarithromycin in acute bacterial exacerbations of complicated chronic bronchitis: interim analysis.', 'subject score': 1000, 'object score': 901}, 'PMID:9440580': {'publication date': '1998 Jan', 'sentence': 'A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.', 'subject score': 1000, 'object score': 1000}, 'PMID:9449270': {'publication date': '1998 Jan', 'sentence': 'A randomized, prospective, double-blind, double-dummy, multicenter study investigated the efficacy and safety of 10 days of oral therapy with grepafloxacin at 400 mg once daily, grepafloxacin at 600 mg once daily, or ciprofloxacin at 500 mg twice daily in 624 patients with acute bacterial exacerbations of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:9798024': {'publication date': '1998 Oct', 'sentence': 'In a prospective, multicenter, double-blind study, the interval to clinical relapse in patients with acute bacterial exacerbations of chronic bronchitis from whom a pretherapy pathogen was isolated was compared following treatment with ciprofloxacin or cefuroxime axetil.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0008677---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7886701",
-              "object": "MONDO:0005607",
-              "publications": [
-                "PMID:10606835",
-                "PMID:11414382",
-                "PMID:12168746",
-                "PMID:12445016",
-                "PMID:1362752",
-                "PMID:1754733",
-                "PMID:2691479",
-                "PMID:3490468",
-                "PMID:3960693",
-                "PMID:7666121",
-                "PMID:8596127",
-                "PMID:9385486",
-                "PMID:9440580",
-                "PMID:9449270",
-                "PMID:9798024"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:3490468': {'publication date': '1986 Sep', 'sentence': 'Thirty four patients with acute purulent exacerbations of chronic bronchitis were treated with 500 mg ciprofloxacin twice daily, orally, for ten days.', 'subject score': 798, 'object score': 1000}, 'PMID:3501857': {'publication date': '1987 Dec 11', 'sentence': 'Thirty four patients with acute purulent exacerbations of chronic bronchitis were treated with 500 mg ciprofloxacin twice daily, orally, for ten days.', 'subject score': 798, 'object score': 1000}, 'PMID:9440580': {'publication date': '1998 Jan', 'sentence': 'In patients suffering from an AECB with a history of moderate to severe chronic bronchitis and at least four AECBs in the previous year, ciprofloxacin treatment offered substantial clinical and economic benefits.', 'subject score': 888, 'object score': 901}, 'PMID:9767959': {'publication date': '1998 Mar 28', 'sentence': '[The role of ciprofloxacin in the treatment of chronic bronchitis].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321736,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005607",
-          "name": "chronic bronchitis",
-          "description": "A type of chronic obstructive pulmonary disease characterized by chronic inflammation in the bronchial tree that results in edema, mucus production, obstruction, and reduced airflow to and from the lung alveoli. The most common cause is tobacco smoking. Signs and symptoms include coughing with excessive mucus production, and shortness of breath.; A subcategory of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. The disease is characterized by hypersecretion of mucus accompanied by a chronic (more than 3 months in 2 consecutive years) productive cough. Infectious agents are a major cause of chronic bronchitis.; Chronic inflammation of the bronchi. [HPO:probinson]; What is chronic bronchitis? Chronic bronchitis is a type of COPD (chronic obstructive pulmonary disease). COPD is a group of lung diseases that make it hard to breathe and get worse over time. The other main type of COPD is emphysema. Most people with COPD have both emphysema and chronic bronchitis, but how severe each type is can be different from person to person. Chronic bronchitis is inflammation (swelling) and irritation of the bronchial tubes. These tubes are the airways that carry air to and from the air sacs in your lungs. The irritation of the tubes causes mucus to build up. This mucus and the swelling of the tubes make it harder for your lungs to move oxygen in and carbon dioxide out of your body. What causes chronic bronchitis? The cause of chronic bronchitis is usually long-term exposure to irritants that damage your lungs and airways. In the United States, cigarette smoke is the main cause. Pipe, cigar, and other types of tobacco smoke can also cause chronic bronchitis, especially if you inhale them. Exposure to other inhaled irritants can contribute to chronic bronchitis. These include secondhand smoke, air pollution, and chemical fumes or dusts from the environment or workplace. Rarely, a genetic condition called alpha-1 antitrypsin deficiency can play a role in causing chronic bronchitis. Who is at risk for chronic bronchitis? The risk factors for chronic bronchitis include: Smoking. This the main risk factor. Up to 75% of people who have chronic bronchitis smoke or used to smoke. Long-term exposure to other lung irritants, such as secondhand smoke, air pollution, and chemical fumes and dusts from the environment or workplace. Age. Most people who have chronic bronchitis are at least 40 years old when their symptoms begin. Genetics. This includes alpha-1 antitrypsin deficiency, which is a genetic condition. Also, smokers who get chronic bronchitis are more likely to get it if they have a family history of COPD.  What are the symptoms of chronic bronchitis? At first, you may have no symptoms or only mild symptoms. As the disease gets worse, your symptoms usually become more severe. They can include: Frequent coughing or a cough that produces a lot mucus Wheezing A whistling or squeaky sound when you breathe Shortness of breath, especially with physical activity Tightness in your chest  Some people with chronic bronchitis get frequent respiratory infections such as colds and the flu. In severe cases, chronic bronchitis can cause weight loss, weakness in your lower muscles, and swelling in your ankles, feet, or legs. How is chronic bronchitis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A family history Various tests, such as lung function tests, a chest x-ray or CT scan, and blood tests  What are the treatments for chronic bronchitis? There is no cure for chronic bronchitis. However, treatments can help with symptoms, slow the progress of the disease, and improve your ability to stay active. There are also treatments to prevent or treat complications of the disease. Treatments include: Lifestyle changes, such as  Quitting smoking if you are a smoker. This is the most important step you can take to treat chronic bronchitis. Avoiding secondhand smoke and places where you might breathe in other lung irritants Ask your health care provider for an eating plan that will meet your nutritional needs. Also ask about how much physical activity you can do. Physical activity can strengthen the muscles that help you breathe and improve your overall wellness.   Medicines, such as  Bronchodilators, which relax the muscles around your airways. This helps open your airways and makes breathing easier. Most bronchodilators are taken through an inhaler. In more severe cases, the inhaler may also contain steroids to reduce inflammation. Vaccines for the flu and pneumococcal pneumonia, since people with chronic bronchitis are at higher risk for serious problems from these diseases. Antibiotics if you get a bacterial or viral lung infection   Oxygen therapy, if you have severe chronic bronchitis and low levels of oxygen in your blood. Oxygen therapy can help you breathe better. You may need extra oxygen all the time or only at certain times. Pulmonary rehabilitation, which is a program that helps improve the well-being of people who have chronic breathing problems. It may include  An exercise program Disease management training Nutritional counseling Psychological counseling  A lung transplant, as a last resort for people who have severe symptoms that have not gotten better with medicines  If you have chronic bronchitis, it's important to know when and where to get help for your symptoms. You should get emergency care if you have severe symptoms, such as trouble catching your breath or talking. Call your health care provider if your symptoms are getting worse or if you have signs of an infection, such as a fever. Can chronic bronchitis be prevented? Since smoking causes most cases of chronic bronchitis, the best way to prevent it is to not smoke. It's also important to try to avoid lung irritants such as secondhand smoke, air pollution, chemical fumes, and dusts.  NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10008843",
-            "MEDDRA:10008841",
-            "NCIT:C26722",
-            "MEDDRA:10006458",
-            "MESH:D029481",
-            "MONDO:0005607",
-            "MEDDRA:10045659",
-            "EFO:0006505",
-            "UMLS:C0008677",
-            "MEDDRA:10006459",
-            "HP:0004469",
-            "SNOMEDCT:63480004"
-          ],
-          "id": "MONDO:0005607",
-          "category": "biolink:Disease",
-          "all_names": [
-            "chronic bronchitis",
-            "Bronchitis, Chronic",
-            "Chronic bronchitis",
-            "Chronic Bronchitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321736,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005607",
-              "name": "chronic bronchitis",
-              "description": "A type of chronic obstructive pulmonary disease characterized by chronic inflammation in the bronchial tree that results in edema, mucus production, obstruction, and reduced airflow to and from the lung alveoli. The most common cause is tobacco smoking. Signs and symptoms include coughing with excessive mucus production, and shortness of breath.; A subcategory of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. The disease is characterized by hypersecretion of mucus accompanied by a chronic (more than 3 months in 2 consecutive years) productive cough. Infectious agents are a major cause of chronic bronchitis.; Chronic inflammation of the bronchi. [HPO:probinson]; What is chronic bronchitis? Chronic bronchitis is a type of COPD (chronic obstructive pulmonary disease). COPD is a group of lung diseases that make it hard to breathe and get worse over time. The other main type of COPD is emphysema. Most people with COPD have both emphysema and chronic bronchitis, but how severe each type is can be different from person to person. Chronic bronchitis is inflammation (swelling) and irritation of the bronchial tubes. These tubes are the airways that carry air to and from the air sacs in your lungs. The irritation of the tubes causes mucus to build up. This mucus and the swelling of the tubes make it harder for your lungs to move oxygen in and carbon dioxide out of your body. What causes chronic bronchitis? The cause of chronic bronchitis is usually long-term exposure to irritants that damage your lungs and airways. In the United States, cigarette smoke is the main cause. Pipe, cigar, and other types of tobacco smoke can also cause chronic bronchitis, especially if you inhale them. Exposure to other inhaled irritants can contribute to chronic bronchitis. These include secondhand smoke, air pollution, and chemical fumes or dusts from the environment or workplace. Rarely, a genetic condition called alpha-1 antitrypsin deficiency can play a role in causing chronic bronchitis. Who is at risk for chronic bronchitis? The risk factors for chronic bronchitis include: Smoking. This the main risk factor. Up to 75% of people who have chronic bronchitis smoke or used to smoke. Long-term exposure to other lung irritants, such as secondhand smoke, air pollution, and chemical fumes and dusts from the environment or workplace. Age. Most people who have chronic bronchitis are at least 40 years old when their symptoms begin. Genetics. This includes alpha-1 antitrypsin deficiency, which is a genetic condition. Also, smokers who get chronic bronchitis are more likely to get it if they have a family history of COPD.  What are the symptoms of chronic bronchitis? At first, you may have no symptoms or only mild symptoms. As the disease gets worse, your symptoms usually become more severe. They can include: Frequent coughing or a cough that produces a lot mucus Wheezing A whistling or squeaky sound when you breathe Shortness of breath, especially with physical activity Tightness in your chest  Some people with chronic bronchitis get frequent respiratory infections such as colds and the flu. In severe cases, chronic bronchitis can cause weight loss, weakness in your lower muscles, and swelling in your ankles, feet, or legs. How is chronic bronchitis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A family history Various tests, such as lung function tests, a chest x-ray or CT scan, and blood tests  What are the treatments for chronic bronchitis? There is no cure for chronic bronchitis. However, treatments can help with symptoms, slow the progress of the disease, and improve your ability to stay active. There are also treatments to prevent or treat complications of the disease. Treatments include: Lifestyle changes, such as  Quitting smoking if you are a smoker. This is the most important step you can take to treat chronic bronchitis. Avoiding secondhand smoke and places where you might breathe in other lung irritants Ask your health care provider for an eating plan that will meet your nutritional needs. Also ask about how much physical activity you can do. Physical activity can strengthen the muscles that help you breathe and improve your overall wellness.   Medicines, such as  Bronchodilators, which relax the muscles around your airways. This helps open your airways and makes breathing easier. Most bronchodilators are taken through an inhaler. In more severe cases, the inhaler may also contain steroids to reduce inflammation. Vaccines for the flu and pneumococcal pneumonia, since people with chronic bronchitis are at higher risk for serious problems from these diseases. Antibiotics if you get a bacterial or viral lung infection   Oxygen therapy, if you have severe chronic bronchitis and low levels of oxygen in your blood. Oxygen therapy can help you breathe better. You may need extra oxygen all the time or only at certain times. Pulmonary rehabilitation, which is a program that helps improve the well-being of people who have chronic breathing problems. It may include  An exercise program Disease management training Nutritional counseling Psychological counseling  A lung transplant, as a last resort for people who have severe symptoms that have not gotten better with medicines  If you have chronic bronchitis, it's important to know when and where to get help for your symptoms. You should get emergency care if you have severe symptoms, such as trouble catching your breath or talking. Call your health care provider if your symptoms are getting worse or if you have signs of an infection, such as a fever. Can chronic bronchitis be prevented? Since smoking causes most cases of chronic bronchitis, the best way to prevent it is to not smoke. It's also important to try to avoid lung irritants such as secondhand smoke, air pollution, chemical fumes, and dusts.  NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10008843",
-                "MEDDRA:10008841",
-                "NCIT:C26722",
-                "MEDDRA:10006458",
-                "MESH:D029481",
-                "MONDO:0005607",
-                "MEDDRA:10045659",
-                "EFO:0006505",
-                "UMLS:C0008677",
-                "MEDDRA:10006459",
-                "HP:0004469",
-                "SNOMEDCT:63480004"
-              ],
-              "id": "MONDO:0005607",
-              "category": "biolink:Disease",
-              "all_names": [
-                "chronic bronchitis",
-                "Bronchitis, Chronic",
-                "Chronic bronchitis",
-                "Chronic Bronchitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23563350,
-            "start": 616,
-            "end": 321736,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3490468': {'publication date': '1986 Sep', 'sentence': 'Thirty four patients with acute purulent exacerbations of chronic bronchitis were treated with 500 mg ciprofloxacin twice daily, orally, for ten days.', 'subject score': 798, 'object score': 1000}, 'PMID:3501857': {'publication date': '1987 Dec 11', 'sentence': 'Thirty four patients with acute purulent exacerbations of chronic bronchitis were treated with 500 mg ciprofloxacin twice daily, orally, for ten days.', 'subject score': 798, 'object score': 1000}, 'PMID:9440580': {'publication date': '1998 Jan', 'sentence': 'In patients suffering from an AECB with a history of moderate to severe chronic bronchitis and at least four AECBs in the previous year, ciprofloxacin treatment offered substantial clinical and economic benefits.', 'subject score': 888, 'object score': 901}, 'PMID:9767959': {'publication date': '1998 Mar 28', 'sentence': '[The role of ciprofloxacin in the treatment of chronic bronchitis].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0008677---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "24010235",
-              "object": "MONDO:0005607",
-              "publications": [
-                "PMID:3490468",
-                "PMID:3501857",
-                "PMID:9440580",
-                "PMID:9767959"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:11247712': {'publication date': '2001 Mar 15', 'sentence': 'These findings suggest that in vitro resistance to ciprofloxacin is predictive of clinical treatment failure in patients with gonorrhea.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 506516,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004277",
-          "name": "gonorrhea",
-          "description": "An infection that is caused by Gonococcus.; A common sexually transmitted bacterial infection caused by Neisseria gonorrhoeae. It is transmitted through vaginal, oral, or anal intercourse. Infected individuals may be asymptomatic. Symptoms in males include burning sensation during urination, discharge from the penis, and painful swelling of the testes. Symptoms in females include painful urination, vaginal discharge, and vaginal bleeding between periods. If untreated, the infection may lead to pelvic inflammatory disease.; Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, NEISSERIA GONORRHOEAE, was isolated by Neisser in 1879.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:21330",
-            "UMLS:C0018081",
-            "MEDDRA:10018612",
-            "ORPHANET:100642",
-            "MEDDRA:10018615",
-            "NCIT:C92950",
-            "MESH:D006069",
-            "DOID:7551",
-            "NCIT:C35730",
-            "ICD10:A54",
-            "SNOMEDCT:15628003",
-            "MEDDRA:10081185",
-            "MEDDRA:10051970",
-            "ICD9:098",
-            "MEDDRA:10018604",
-            "MONDO:0004277"
-          ],
-          "id": "MONDO:0004277",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Gonococcal Infection",
-            "gonorrhea",
-            "Gonorrhea",
-            "Gonococcal infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cdc.gov/std/gonorrhea/stdfact-gonorrhea.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 506516,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004277",
-              "name": "gonorrhea",
-              "description": "An infection that is caused by Gonococcus.; A common sexually transmitted bacterial infection caused by Neisseria gonorrhoeae. It is transmitted through vaginal, oral, or anal intercourse. Infected individuals may be asymptomatic. Symptoms in males include burning sensation during urination, discharge from the penis, and painful swelling of the testes. Symptoms in females include painful urination, vaginal discharge, and vaginal bleeding between periods. If untreated, the infection may lead to pelvic inflammatory disease.; Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, NEISSERIA GONORRHOEAE, was isolated by Neisser in 1879.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:21330",
-                "UMLS:C0018081",
-                "MEDDRA:10018612",
-                "ORPHANET:100642",
-                "MEDDRA:10018615",
-                "NCIT:C92950",
-                "MESH:D006069",
-                "DOID:7551",
-                "NCIT:C35730",
-                "ICD10:A54",
-                "SNOMEDCT:15628003",
-                "MEDDRA:10081185",
-                "MEDDRA:10051970",
-                "ICD9:098",
-                "MEDDRA:10018604",
-                "MONDO:0004277"
-              ],
-              "id": "MONDO:0004277",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Gonococcal Infection",
-                "gonorrhea",
-                "Gonorrhea",
-                "Gonococcal infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cdc.gov/std/gonorrhea/stdfact-gonorrhea.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8571915,
-            "start": 616,
-            "end": 506516,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11247712': {'publication date': '2001 Mar 15', 'sentence': 'These findings suggest that in vitro resistance to ciprofloxacin is predictive of clinical treatment failure in patients with gonorrhea.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:predisposes---None---None---None---UMLS:C0018081---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8758764",
-              "object": "MONDO:0004277",
-              "publications": [
-                "PMID:11247712"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12567312': {'publication date': '2003 Feb 15', 'sentence': 'There are no previous reports of plague being successfully treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:21628541': {'publication date': '2011 Aug', 'sentence': 'During the initial stage of plague, intracellular Y. pestis may be less susceptible to antibiotic killing by particular antibiotics recommended for treatment of plague, such as gentamicin or doxycycline, whereas others, such as streptomycin and ciprofloxacin, may have similar efficacies against extracellular or intracellular Y. pestis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28125398': {'publication date': '2017 03', 'sentence': 'We report 5 cases of culture-confirmed human plague treated successfully with oral ciprofloxacin, including 1 case of pneumonic plague.', 'subject score': 888, 'object score': 833}, 'PMID:7847999': {'publication date': '1994 Jun', 'sentence': 'It was shown that unlike nalidixic acid the 3rd generation quinolones i.e. the nitrogen-containing quinolones (LIB-71 and LIB-80) and the fluorine-containing quinolones (pefloxacin and ciprofloxacin) were highly efficient in the prophylaxis and treatment of experimental plague in albino mice infected via the plague microbe inhalation.', 'subject score': 1000, 'object score': 888}, 'PMID:8060184': {'publication date': '1993 Jan', 'sentence': '[Effectiveness of the new quinolones, ciprofloxacin and pefloxacin in experimental plague].', 'subject score': 1000, 'object score': 888}, 'PMID:8722542': {'publication date': '1996 Apr', 'sentence': 'Ciprofloxacin may therefore be a useful antibiotic to consider for the treatment of plague.', 'subject score': 1000, 'object score': 1000}, 'PMID:9221699': {'publication date': '1997', 'sentence': 'Fluoroquinolones (ciprofloxacin and pefloxacin) and 3rd generation cephalosporins (cefoperazone, cefotaxime, ceftazidime and ceftriaxone) were comparatively studied in the prevention and treatment of experimental plague in albino mice caused by F1+ and F1- strains of the plague microbe.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 517617,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019095",
-          "name": "plague",
-          "description": "A Gram-negative bacterial infection caused by Yersinia pestis. It is usually transmitted to humans from bites of infected rodent fleas. It is manifested as a bubonic, septicemic, or pneumonic plague. In bubonic plague, the lymph nodes adjacent to the site of the skin bite are infected and enlarged. In septicemic plague, the infection spreads directly through the bloodstream. In pneumonic plague, the infection spreads to the lungs either following bubonic plague, or by inhalation of infective droplets. If untreated, it may lead to death.; An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.; Plague is an infection caused by the bacterium Yersinia pestis. The bacteria are found mainly in rats and in the fleas that feed on them. People and other animals can get plague from rat or flea bites. In the past, plague destroyed entire civilizations. Today plague is uncommon, due to better living conditions and antibiotics. There are three forms of plague:  Bubonic plague causes the tonsils, adenoids, spleen, and thymus to become inflamed. Symptoms include fever, aches, chills, and tender lymph glands. In septicemic plague, bacteria multiply in the blood. It causes fever, chills, shock, and bleeding under the skin or other organs. Pneumonic plague is the most serious form. Bacteria enter the lungs and cause pneumonia. People with the infection can spread this form to others. This type could be a bioterror agent.  Lab tests can diagnose plague. Treatment is a strong antibiotic. There is no vaccine.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10046098",
-            "ICD10:A20",
-            "MEDDRA:10048250",
-            "SNOMEDCT:58750007",
-            "UMLS:C0032064",
-            "ICD9:020",
-            "NCIT:C85015",
-            "DOID:3482",
-            "ORPHANET:707",
-            "MONDO:0019095",
-            "MEDDRA:10035148",
-            "MEDDRA:10035149",
-            "MESH:D010930"
-          ],
-          "id": "MONDO:0019095",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Plague",
-            "plague"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:29628173"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517617,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019095",
-              "name": "plague",
-              "description": "A Gram-negative bacterial infection caused by Yersinia pestis. It is usually transmitted to humans from bites of infected rodent fleas. It is manifested as a bubonic, septicemic, or pneumonic plague. In bubonic plague, the lymph nodes adjacent to the site of the skin bite are infected and enlarged. In septicemic plague, the infection spreads directly through the bloodstream. In pneumonic plague, the infection spreads to the lungs either following bubonic plague, or by inhalation of infective droplets. If untreated, it may lead to death.; An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.; Plague is an infection caused by the bacterium Yersinia pestis. The bacteria are found mainly in rats and in the fleas that feed on them. People and other animals can get plague from rat or flea bites. In the past, plague destroyed entire civilizations. Today plague is uncommon, due to better living conditions and antibiotics. There are three forms of plague:  Bubonic plague causes the tonsils, adenoids, spleen, and thymus to become inflamed. Symptoms include fever, aches, chills, and tender lymph glands. In septicemic plague, bacteria multiply in the blood. It causes fever, chills, shock, and bleeding under the skin or other organs. Pneumonic plague is the most serious form. Bacteria enter the lungs and cause pneumonia. People with the infection can spread this form to others. This type could be a bioterror agent.  Lab tests can diagnose plague. Treatment is a strong antibiotic. There is no vaccine.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10046098",
-                "ICD10:A20",
-                "MEDDRA:10048250",
-                "SNOMEDCT:58750007",
-                "UMLS:C0032064",
-                "ICD9:020",
-                "NCIT:C85015",
-                "DOID:3482",
-                "ORPHANET:707",
-                "MONDO:0019095",
-                "MEDDRA:10035148",
-                "MEDDRA:10035149",
-                "MESH:D010930"
-              ],
-              "id": "MONDO:0019095",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Plague",
-                "plague"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:29628173"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9796811,
-            "start": 616,
-            "end": 517617,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12567312': {'publication date': '2003 Feb 15', 'sentence': 'There are no previous reports of plague being successfully treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:21628541': {'publication date': '2011 Aug', 'sentence': 'During the initial stage of plague, intracellular Y. pestis may be less susceptible to antibiotic killing by particular antibiotics recommended for treatment of plague, such as gentamicin or doxycycline, whereas others, such as streptomycin and ciprofloxacin, may have similar efficacies against extracellular or intracellular Y. pestis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28125398': {'publication date': '2017 03', 'sentence': 'We report 5 cases of culture-confirmed human plague treated successfully with oral ciprofloxacin, including 1 case of pneumonic plague.', 'subject score': 888, 'object score': 833}, 'PMID:7847999': {'publication date': '1994 Jun', 'sentence': 'It was shown that unlike nalidixic acid the 3rd generation quinolones i.e. the nitrogen-containing quinolones (LIB-71 and LIB-80) and the fluorine-containing quinolones (pefloxacin and ciprofloxacin) were highly efficient in the prophylaxis and treatment of experimental plague in albino mice infected via the plague microbe inhalation.', 'subject score': 1000, 'object score': 888}, 'PMID:8060184': {'publication date': '1993 Jan', 'sentence': '[Effectiveness of the new quinolones, ciprofloxacin and pefloxacin in experimental plague].', 'subject score': 1000, 'object score': 888}, 'PMID:8722542': {'publication date': '1996 Apr', 'sentence': 'Ciprofloxacin may therefore be a useful antibiotic to consider for the treatment of plague.', 'subject score': 1000, 'object score': 1000}, 'PMID:9221699': {'publication date': '1997', 'sentence': 'Fluoroquinolones (ciprofloxacin and pefloxacin) and 3rd generation cephalosporins (cefoperazone, cefotaxime, ceftazidime and ceftriaxone) were comparatively studied in the prevention and treatment of experimental plague in albino mice caused by F1+ and F1- strains of the plague microbe.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0032064---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "10013051",
-              "object": "MONDO:0019095",
-              "publications": [
-                "PMID:12567312",
-                "PMID:21628541",
-                "PMID:28125398",
-                "PMID:7847999",
-                "PMID:8060184",
-                "PMID:8722542",
-                "PMID:9221699"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:19188359': {'publication date': '2009 Apr', 'sentence': 'Although there were major differences in pathogenesis, the recombinant F1 and V antigen vaccine and ciprofloxacin protected against plague infections caused by small- and large-particle aerosols.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 517617,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019095",
-          "name": "plague",
-          "description": "A Gram-negative bacterial infection caused by Yersinia pestis. It is usually transmitted to humans from bites of infected rodent fleas. It is manifested as a bubonic, septicemic, or pneumonic plague. In bubonic plague, the lymph nodes adjacent to the site of the skin bite are infected and enlarged. In septicemic plague, the infection spreads directly through the bloodstream. In pneumonic plague, the infection spreads to the lungs either following bubonic plague, or by inhalation of infective droplets. If untreated, it may lead to death.; An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.; Plague is an infection caused by the bacterium Yersinia pestis. The bacteria are found mainly in rats and in the fleas that feed on them. People and other animals can get plague from rat or flea bites. In the past, plague destroyed entire civilizations. Today plague is uncommon, due to better living conditions and antibiotics. There are three forms of plague:  Bubonic plague causes the tonsils, adenoids, spleen, and thymus to become inflamed. Symptoms include fever, aches, chills, and tender lymph glands. In septicemic plague, bacteria multiply in the blood. It causes fever, chills, shock, and bleeding under the skin or other organs. Pneumonic plague is the most serious form. Bacteria enter the lungs and cause pneumonia. People with the infection can spread this form to others. This type could be a bioterror agent.  Lab tests can diagnose plague. Treatment is a strong antibiotic. There is no vaccine.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10046098",
-            "ICD10:A20",
-            "MEDDRA:10048250",
-            "SNOMEDCT:58750007",
-            "UMLS:C0032064",
-            "ICD9:020",
-            "NCIT:C85015",
-            "DOID:3482",
-            "ORPHANET:707",
-            "MONDO:0019095",
-            "MEDDRA:10035148",
-            "MEDDRA:10035149",
-            "MESH:D010930"
-          ],
-          "id": "MONDO:0019095",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Plague",
-            "plague"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:29628173"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517617,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019095",
-              "name": "plague",
-              "description": "A Gram-negative bacterial infection caused by Yersinia pestis. It is usually transmitted to humans from bites of infected rodent fleas. It is manifested as a bubonic, septicemic, or pneumonic plague. In bubonic plague, the lymph nodes adjacent to the site of the skin bite are infected and enlarged. In septicemic plague, the infection spreads directly through the bloodstream. In pneumonic plague, the infection spreads to the lungs either following bubonic plague, or by inhalation of infective droplets. If untreated, it may lead to death.; An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.; Plague is an infection caused by the bacterium Yersinia pestis. The bacteria are found mainly in rats and in the fleas that feed on them. People and other animals can get plague from rat or flea bites. In the past, plague destroyed entire civilizations. Today plague is uncommon, due to better living conditions and antibiotics. There are three forms of plague:  Bubonic plague causes the tonsils, adenoids, spleen, and thymus to become inflamed. Symptoms include fever, aches, chills, and tender lymph glands. In septicemic plague, bacteria multiply in the blood. It causes fever, chills, shock, and bleeding under the skin or other organs. Pneumonic plague is the most serious form. Bacteria enter the lungs and cause pneumonia. People with the infection can spread this form to others. This type could be a bioterror agent.  Lab tests can diagnose plague. Treatment is a strong antibiotic. There is no vaccine.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10046098",
-                "ICD10:A20",
-                "MEDDRA:10048250",
-                "SNOMEDCT:58750007",
-                "UMLS:C0032064",
-                "ICD9:020",
-                "NCIT:C85015",
-                "DOID:3482",
-                "ORPHANET:707",
-                "MONDO:0019095",
-                "MEDDRA:10035148",
-                "MEDDRA:10035149",
-                "MESH:D010930"
-              ],
-              "id": "MONDO:0019095",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Plague",
-                "plague"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:29628173"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13905392,
-            "start": 616,
-            "end": 517617,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19188359': {'publication date': '2009 Apr', 'sentence': 'Although there were major differences in pathogenesis, the recombinant F1 and V antigen vaccine and ciprofloxacin protected against plague infections caused by small- and large-particle aerosols.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:prevents---None---None---None---UMLS:C0032064---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "14202377",
-              "object": "MONDO:0019095",
-              "publications": [
-                "PMID:19188359"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:24044110': {'publication date': '2013 Aug', 'sentence': 'After the induction of prostatitis, the rats were randomly divided into one of four treatment groups: control (n=8), ciprofloxacin (n=8), WSY-1075 (100 mg/kg) (n=8), and WSY-1075 (400 mg/kg) (n=8).', 'subject score': 1000, 'object score': 1000}, 'PMID:28053947': {'publication date': '2016 Dec', 'sentence': 'After the induction of prostatitis, the rats were randomly divided into one of 4 treatment groups: control (n=8), ciprofloxacin (n=8), WSY-1075 (400 mg/kg) (n=8), and WSY-1075 (400 mg/kg)+ciprofloxacin (n=8).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319601,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005280",
-          "name": "prostatitis",
-          "description": "An infectious or non-infectious inflammatory process affecting the prostate gland.; Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.; The presence of inflammation of the prostate. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10036978",
-            "MONDO:0005280",
-            "EFO:0003830",
-            "HP:0000024",
-            "NCIT:C26866",
-            "SNOMEDCT:9713002",
-            "DOID:14654",
-            "MEDDRA:10036982",
-            "ICD10:N41.9",
-            "MESH:D011472",
-            "ICD9:601.9",
-            "UMLS:C0033581"
-          ],
-          "id": "MONDO:0005280",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Prostatitis",
-            "Prostatitis, unspecified",
-            "prostatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319601,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005280",
-              "name": "prostatitis",
-              "description": "An infectious or non-infectious inflammatory process affecting the prostate gland.; Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.; The presence of inflammation of the prostate. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10036978",
-                "MONDO:0005280",
-                "EFO:0003830",
-                "HP:0000024",
-                "NCIT:C26866",
-                "SNOMEDCT:9713002",
-                "DOID:14654",
-                "MEDDRA:10036982",
-                "ICD10:N41.9",
-                "MESH:D011472",
-                "ICD9:601.9",
-                "UMLS:C0033581"
-              ],
-              "id": "MONDO:0005280",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Prostatitis",
-                "Prostatitis, unspecified",
-                "prostatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16808136,
-            "start": 616,
-            "end": 319601,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24044110': {'publication date': '2013 Aug', 'sentence': 'After the induction of prostatitis, the rats were randomly divided into one of four treatment groups: control (n=8), ciprofloxacin (n=8), WSY-1075 (100 mg/kg) (n=8), and WSY-1075 (400 mg/kg) (n=8).', 'subject score': 1000, 'object score': 1000}, 'PMID:28053947': {'publication date': '2016 Dec', 'sentence': 'After the induction of prostatitis, the rats were randomly divided into one of 4 treatment groups: control (n=8), ciprofloxacin (n=8), WSY-1075 (400 mg/kg) (n=8), and WSY-1075 (400 mg/kg)+ciprofloxacin (n=8).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:causes---None---None---None---UMLS:C0033581---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "17154464",
-              "object": "MONDO:0005280",
-              "publications": [
-                "PMID:24044110",
-                "PMID:28053947"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11751767': {'publication date': '2002 Jan', 'sentence': 'The emergence and evolution of quinolone-resistant Escherichia coli in faeces of patients with prostatitis treated with high-dose oral ciprofloxacin for 1 month were studied.', 'subject score': 861, 'object score': 1000}, 'PMID:21353135': {'publication date': '2011', 'sentence': 'In this case report, we describe a man who developed recurrent depression and suicidal ideation with a serious plan to commit suicide as definite adverse effect of ciprofloxacin, which had been prescribed for recurrent prostatitis.', 'subject score': 1000, 'object score': 888}, 'PMID:24034802': {'publication date': '2013 Sep', 'sentence': 'The overall susceptibility of E. coli to antibiotics recommended in the empiric treatment of pyelonephritis and prostatitis was preserved: ciprofloxacin (95.8%), cefotaxime (98%), gentamicin (99.4%).', 'subject score': 1000, 'object score': 1000}, 'PMID:27054125': {'publication date': '2016', 'sentence': 'CONCLUSION: These results suggested that ginseng might be an effective adjunct in CIPX treatment of prostatitis.', 'subject score': 888, 'object score': 1000}, 'PMID:3325933': {'publication date': '1987 Dec 11', 'sentence': 'Ciprofloxacin may be a useful alternative drug in the treatment of prostatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3555048': {'publication date': '1987 Apr 27', 'sentence': 'Ciprofloxacin therapy of E. coli prostatitis was a complete success in five of 12 patients, a probable success in two, and in one patient the outcome cannot be judged.', 'subject score': 888, 'object score': 901}, 'PMID:8074560': {'publication date': '1993', 'sentence': '[Use of ciprofloxacin in urinary tract infections and prostatitis].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319601,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005280",
-          "name": "prostatitis",
-          "description": "An infectious or non-infectious inflammatory process affecting the prostate gland.; Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.; The presence of inflammation of the prostate. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10036978",
-            "MONDO:0005280",
-            "EFO:0003830",
-            "HP:0000024",
-            "NCIT:C26866",
-            "SNOMEDCT:9713002",
-            "DOID:14654",
-            "MEDDRA:10036982",
-            "ICD10:N41.9",
-            "MESH:D011472",
-            "ICD9:601.9",
-            "UMLS:C0033581"
-          ],
-          "id": "MONDO:0005280",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Prostatitis",
-            "Prostatitis, unspecified",
-            "prostatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319601,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005280",
-              "name": "prostatitis",
-              "description": "An infectious or non-infectious inflammatory process affecting the prostate gland.; Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.; The presence of inflammation of the prostate. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10036978",
-                "MONDO:0005280",
-                "EFO:0003830",
-                "HP:0000024",
-                "NCIT:C26866",
-                "SNOMEDCT:9713002",
-                "DOID:14654",
-                "MEDDRA:10036982",
-                "ICD10:N41.9",
-                "MESH:D011472",
-                "ICD9:601.9",
-                "UMLS:C0033581"
-              ],
-              "id": "MONDO:0005280",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Prostatitis",
-                "Prostatitis, unspecified",
-                "prostatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9079085,
-            "start": 616,
-            "end": 319601,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11751767': {'publication date': '2002 Jan', 'sentence': 'The emergence and evolution of quinolone-resistant Escherichia coli in faeces of patients with prostatitis treated with high-dose oral ciprofloxacin for 1 month were studied.', 'subject score': 861, 'object score': 1000}, 'PMID:21353135': {'publication date': '2011', 'sentence': 'In this case report, we describe a man who developed recurrent depression and suicidal ideation with a serious plan to commit suicide as definite adverse effect of ciprofloxacin, which had been prescribed for recurrent prostatitis.', 'subject score': 1000, 'object score': 888}, 'PMID:24034802': {'publication date': '2013 Sep', 'sentence': 'The overall susceptibility of E. coli to antibiotics recommended in the empiric treatment of pyelonephritis and prostatitis was preserved: ciprofloxacin (95.8%), cefotaxime (98%), gentamicin (99.4%).', 'subject score': 1000, 'object score': 1000}, 'PMID:27054125': {'publication date': '2016', 'sentence': 'CONCLUSION: These results suggested that ginseng might be an effective adjunct in CIPX treatment of prostatitis.', 'subject score': 888, 'object score': 1000}, 'PMID:3325933': {'publication date': '1987 Dec 11', 'sentence': 'Ciprofloxacin may be a useful alternative drug in the treatment of prostatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3555048': {'publication date': '1987 Apr 27', 'sentence': 'Ciprofloxacin therapy of E. coli prostatitis was a complete success in five of 12 patients, a probable success in two, and in one patient the outcome cannot be judged.', 'subject score': 888, 'object score': 901}, 'PMID:8074560': {'publication date': '1993', 'sentence': '[Use of ciprofloxacin in urinary tract infections and prostatitis].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0033581---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "9281470",
-              "object": "MONDO:0005280",
-              "publications": [
-                "PMID:11751767",
-                "PMID:21353135",
-                "PMID:24034802",
-                "PMID:27054125",
-                "PMID:3325933",
-                "PMID:3555048",
-                "PMID:8074560"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:3814223': {'publication date': '1986 Nov', 'sentence': 'Distribution of [14C]-ciprofloxacin in experimentally induced intramuscular abscesses of rats.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 317816,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005227",
-          "name": "abscess",
-          "description": "An inflammatory process characterized by the accumulation of pus within a newly formed tissue cavity which is the result of a bacterial, fungal, or parasitic infection or the presence of a foreign body.; Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.; An abscess is a pocket of pus. You can get an abscess almost anywhere in your body. When an area of your body becomes infected, your body's immune system tries to fight the infection. White blood cells go to the infected area, collect within the damaged tissue, and cause inflammation. During this process, pus forms. Pus is a mixture of living and dead white blood cells, germs, and dead tissue.  Bacteria, viruses, parasites and swallowed objects can all lead to abscesses. Skin abscesses are easy to detect. They are red, raised and painful. Abscesses inside your body may not be obvious and can damage organs, including the brain, lungs and others. Treatments include drainage and antibiotics. ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0025615",
-            "SNOMEDCT:128477000",
-            "SNOMEDCT:44132006",
-            "UMLS:C0000833",
-            "MONDO:0005227",
-            "MESH:D000038",
-            "NCIT:C26686",
-            "MEDDRA:10000287",
-            "MEDDRA:10000269",
-            "SYMP:0000672",
-            "EFO:0003030"
-          ],
-          "id": "MONDO:0005227",
-          "category": "biolink:Disease",
-          "all_names": [
-            "abscess",
-            "Abscess"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317816,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005227",
-              "name": "abscess",
-              "description": "An inflammatory process characterized by the accumulation of pus within a newly formed tissue cavity which is the result of a bacterial, fungal, or parasitic infection or the presence of a foreign body.; Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.; An abscess is a pocket of pus. You can get an abscess almost anywhere in your body. When an area of your body becomes infected, your body's immune system tries to fight the infection. White blood cells go to the infected area, collect within the damaged tissue, and cause inflammation. During this process, pus forms. Pus is a mixture of living and dead white blood cells, germs, and dead tissue.  Bacteria, viruses, parasites and swallowed objects can all lead to abscesses. Skin abscesses are easy to detect. They are red, raised and painful. Abscesses inside your body may not be obvious and can damage organs, including the brain, lungs and others. Treatments include drainage and antibiotics. ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0025615",
-                "SNOMEDCT:128477000",
-                "SNOMEDCT:44132006",
-                "UMLS:C0000833",
-                "MONDO:0005227",
-                "MESH:D000038",
-                "NCIT:C26686",
-                "MEDDRA:10000287",
-                "MEDDRA:10000269",
-                "SYMP:0000672",
-                "EFO:0003030"
-              ],
-              "id": "MONDO:0005227",
-              "category": "biolink:Disease",
-              "all_names": [
-                "abscess",
-                "Abscess"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 25197006,
-            "start": 616,
-            "end": 317816,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3814223': {'publication date': '1986 Nov', 'sentence': 'Distribution of [14C]-ciprofloxacin in experimentally induced intramuscular abscesses of rats.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:causes---None---None---None---UMLS:C0000833---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "25648466",
-              "object": "MONDO:0005227",
-              "publications": [
-                "PMID:3814223"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:14988789': {'publication date': '2004 Feb', 'sentence': 'The patient was asymptomatic for a month, but the abscess reactivated and was treated with Vancomycin and Ciprofloxacin administered intravenously.', 'subject score': 1000, 'object score': 1000}, 'PMID:18194131': {'publication date': '2007 Dec', 'sentence': 'Treatment with intravenous meropenem (3 g/day for 3 weeks) and oral ciprofloxacin was begun, which resulted in the complete resolution of the intrarenal abscesses.', 'subject score': 888, 'object score': 861}, 'PMID:23182142': {'publication date': '2012 Oct', 'sentence': 'We report a case of recurrent, multifocal Salmonella enterica serotype Paratyphi A breast abscesses, resistant to ciprofloxacin, which relapsed despite surgery, aspiration and multiple courses of antibiotics, including co-trimoxazole and azithromycin.', 'subject score': 1000, 'object score': 888}, 'PMID:23283615': {'publication date': '2013 Jan 02', 'sentence': 'Her medical history included paroxysmal atrial fibrillation and a sigmoid diverticular abscess treated with ciprofloxacin and metronidazole.', 'subject score': 1000, 'object score': 754}, 'PMID:24296421': {'publication date': '2014 Sep', 'sentence': 'CONCLUSIONS: When gram-negative aerobes were isolated from abscesses in CD patients, more than two thirds were resistant to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:2589367': {'publication date': '1989 Nov 30', 'sentence': 'Ciprofloxacin alone or regimens combining ciprofloxacin with rifampin or rifampin plus imipenem reduced the number of E. coli in polymicrobic subcutaneous abscesses but had little effect on P. aeruginosa in polymicrobic abscesses.', 'subject score': 1000, 'object score': 861}, 'PMID:3322752': {'publication date': '1987', 'sentence': 'However, ciprofloxacin at levels of 20, 10, 5, and 1 mg/kg reduced significantly the number of E. coli cells in the abscess.', 'subject score': 1000, 'object score': 1000}, 'PMID:3814223': {'publication date': '1986 Nov', 'sentence': 'Five min after administration of ciprofloxacin, the radioactivity was found to be differentially distributed among all organs and tissues, but no radioactivity was detectable in the abscess.', 'subject score': 1000, 'object score': 1000}, 'PMID:8517727': {'publication date': '1993 May', 'sentence': 'The abscesses were caused by two Bacteroides fragilis isolates, one of which was susceptible and one of which was resistant to ofloxacin, ciprofloxacin, and lomefloxacin, alone or in combination with Escherichia coli.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317816,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005227",
-          "name": "abscess",
-          "description": "An inflammatory process characterized by the accumulation of pus within a newly formed tissue cavity which is the result of a bacterial, fungal, or parasitic infection or the presence of a foreign body.; Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.; An abscess is a pocket of pus. You can get an abscess almost anywhere in your body. When an area of your body becomes infected, your body's immune system tries to fight the infection. White blood cells go to the infected area, collect within the damaged tissue, and cause inflammation. During this process, pus forms. Pus is a mixture of living and dead white blood cells, germs, and dead tissue.  Bacteria, viruses, parasites and swallowed objects can all lead to abscesses. Skin abscesses are easy to detect. They are red, raised and painful. Abscesses inside your body may not be obvious and can damage organs, including the brain, lungs and others. Treatments include drainage and antibiotics. ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0025615",
-            "SNOMEDCT:128477000",
-            "SNOMEDCT:44132006",
-            "UMLS:C0000833",
-            "MONDO:0005227",
-            "MESH:D000038",
-            "NCIT:C26686",
-            "MEDDRA:10000287",
-            "MEDDRA:10000269",
-            "SYMP:0000672",
-            "EFO:0003030"
-          ],
-          "id": "MONDO:0005227",
-          "category": "biolink:Disease",
-          "all_names": [
-            "abscess",
-            "Abscess"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317816,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005227",
-              "name": "abscess",
-              "description": "An inflammatory process characterized by the accumulation of pus within a newly formed tissue cavity which is the result of a bacterial, fungal, or parasitic infection or the presence of a foreign body.; Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.; An abscess is a pocket of pus. You can get an abscess almost anywhere in your body. When an area of your body becomes infected, your body's immune system tries to fight the infection. White blood cells go to the infected area, collect within the damaged tissue, and cause inflammation. During this process, pus forms. Pus is a mixture of living and dead white blood cells, germs, and dead tissue.  Bacteria, viruses, parasites and swallowed objects can all lead to abscesses. Skin abscesses are easy to detect. They are red, raised and painful. Abscesses inside your body may not be obvious and can damage organs, including the brain, lungs and others. Treatments include drainage and antibiotics. ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0025615",
-                "SNOMEDCT:128477000",
-                "SNOMEDCT:44132006",
-                "UMLS:C0000833",
-                "MONDO:0005227",
-                "MESH:D000038",
-                "NCIT:C26686",
-                "MEDDRA:10000287",
-                "MEDDRA:10000269",
-                "SYMP:0000672",
-                "EFO:0003030"
-              ],
-              "id": "MONDO:0005227",
-              "category": "biolink:Disease",
-              "all_names": [
-                "abscess",
-                "Abscess"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10822361,
-            "start": 616,
-            "end": 317816,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14988789': {'publication date': '2004 Feb', 'sentence': 'The patient was asymptomatic for a month, but the abscess reactivated and was treated with Vancomycin and Ciprofloxacin administered intravenously.', 'subject score': 1000, 'object score': 1000}, 'PMID:18194131': {'publication date': '2007 Dec', 'sentence': 'Treatment with intravenous meropenem (3 g/day for 3 weeks) and oral ciprofloxacin was begun, which resulted in the complete resolution of the intrarenal abscesses.', 'subject score': 888, 'object score': 861}, 'PMID:23182142': {'publication date': '2012 Oct', 'sentence': 'We report a case of recurrent, multifocal Salmonella enterica serotype Paratyphi A breast abscesses, resistant to ciprofloxacin, which relapsed despite surgery, aspiration and multiple courses of antibiotics, including co-trimoxazole and azithromycin.', 'subject score': 1000, 'object score': 888}, 'PMID:23283615': {'publication date': '2013 Jan 02', 'sentence': 'Her medical history included paroxysmal atrial fibrillation and a sigmoid diverticular abscess treated with ciprofloxacin and metronidazole.', 'subject score': 1000, 'object score': 754}, 'PMID:24296421': {'publication date': '2014 Sep', 'sentence': 'CONCLUSIONS: When gram-negative aerobes were isolated from abscesses in CD patients, more than two thirds were resistant to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:2589367': {'publication date': '1989 Nov 30', 'sentence': 'Ciprofloxacin alone or regimens combining ciprofloxacin with rifampin or rifampin plus imipenem reduced the number of E. coli in polymicrobic subcutaneous abscesses but had little effect on P. aeruginosa in polymicrobic abscesses.', 'subject score': 1000, 'object score': 861}, 'PMID:3322752': {'publication date': '1987', 'sentence': 'However, ciprofloxacin at levels of 20, 10, 5, and 1 mg/kg reduced significantly the number of E. coli cells in the abscess.', 'subject score': 1000, 'object score': 1000}, 'PMID:3814223': {'publication date': '1986 Nov', 'sentence': 'Five min after administration of ciprofloxacin, the radioactivity was found to be differentially distributed among all organs and tissues, but no radioactivity was detectable in the abscess.', 'subject score': 1000, 'object score': 1000}, 'PMID:8517727': {'publication date': '1993 May', 'sentence': 'The abscesses were caused by two Bacteroides fragilis isolates, one of which was susceptible and one of which was resistant to ofloxacin, ciprofloxacin, and lomefloxacin, alone or in combination with Escherichia coli.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0000833---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "11059709",
-              "object": "MONDO:0005227",
-              "publications": [
-                "PMID:14988789",
-                "PMID:18194131",
-                "PMID:23182142",
-                "PMID:23283615",
-                "PMID:24296421",
-                "PMID:2589367",
-                "PMID:3322752",
-                "PMID:3814223",
-                "PMID:8517727"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:19104815': {'publication date': '2009 Aug', 'sentence': 'Doxorubicin and docetaxel, two standard antineoplastic agents in hormone-refractory prostate cancer (HRPC) therapy and ciprofloxacin were evaluated singly and in several simultaneous and sequential drug combination schemes, against PC-3 and LNCaP cell lines.', 'subject score': 1000, 'object score': 928}}",
-    "p2": {
-      "start": {
-        "identity": 610975,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/DOID_0080909",
-          "name": "castration-resistant prostate carcinoma",
-          "description": "A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.",
-          "equivalent_curies": [
-            "MESH:D064129",
-            "MONDO:0850353",
-            "DOID:0080909",
-            "MEDDRA:10076506",
-            "SNOMEDCT:427492003",
-            "UMLS:C3658267",
-            "MEDDRA:10062904",
-            "NCIT:C130234",
-            "UMLS:C1328504"
-          ],
-          "id": "DOID:0080909",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Prostatic Neoplasms, Castration-Resistant",
-            "castration-resistant prostate carcinoma",
-            "Castration-Resistant Prostate Carcinoma",
-            "Hormone refractory prostate cancer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:30324351"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 610975,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/DOID_0080909",
-              "name": "castration-resistant prostate carcinoma",
-              "description": "A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.",
-              "equivalent_curies": [
-                "MESH:D064129",
-                "MONDO:0850353",
-                "DOID:0080909",
-                "MEDDRA:10076506",
-                "SNOMEDCT:427492003",
-                "UMLS:C3658267",
-                "MEDDRA:10062904",
-                "NCIT:C130234",
-                "UMLS:C1328504"
-              ],
-              "id": "DOID:0080909",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Prostatic Neoplasms, Castration-Resistant",
-                "castration-resistant prostate carcinoma",
-                "Castration-Resistant Prostate Carcinoma",
-                "Hormone refractory prostate cancer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:30324351"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13845247,
-            "start": 616,
-            "end": 610975,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19104815': {'publication date': '2009 Aug', 'sentence': 'Doxorubicin and docetaxel, two standard antineoplastic agents in hormone-refractory prostate cancer (HRPC) therapy and ciprofloxacin were evaluated singly and in several simultaneous and sequential drug combination schemes, against PC-3 and LNCaP cell lines.', 'subject score': 1000, 'object score': 928}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C1328504---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "14141218",
-              "object": "DOID:0080909",
-              "publications": [
-                "PMID:19104815"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:1943299': {'publication date': '1991 Sep 07', 'sentence': '[Neutropenia caused by ciprofloxacin and Escherichia coli bacteremia. Bone marrow examination].', 'subject score': 1000, 'object score': 1000}, 'PMID:2041408': {'publication date': '1991 Mar 02', 'sentence': '[Ciprofloxacin-induced neutropenia: an infrequent adverse effect].', 'subject score': 851, 'object score': 851}, 'PMID:8342553': {'publication date': '1993 Jun', 'sentence': 'Ciprofloxacin-induced neutropenia and erythema multiforme.', 'subject score': 851, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 516221,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001475",
-          "name": "neutropenia",
-          "description": "A decrease in the number of NEUTROPHILS found in the blood.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029355",
-            "MEDDRA:10029354",
-            "SNOMEDCT:303011007",
-            "MONDO:0001475",
-            "DOID:1227",
-            "MESH:D009503",
-            "UMLS:C0027947",
-            "PDQ:CDR0000041387",
-            "ICD9:288.0"
-          ],
-          "id": "MONDO:0001475",
-          "category": "biolink:Disease",
-          "all_names": [
-            "neutropenia",
-            "Neutropenia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 516221,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001475",
-              "name": "neutropenia",
-              "description": "A decrease in the number of NEUTROPHILS found in the blood.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029355",
-                "MEDDRA:10029354",
-                "SNOMEDCT:303011007",
-                "MONDO:0001475",
-                "DOID:1227",
-                "MESH:D009503",
-                "UMLS:C0027947",
-                "PDQ:CDR0000041387",
-                "ICD9:288.0"
-              ],
-              "id": "MONDO:0001475",
-              "category": "biolink:Disease",
-              "all_names": [
-                "neutropenia",
-                "Neutropenia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14069823,
-            "start": 616,
-            "end": 516221,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1943299': {'publication date': '1991 Sep 07', 'sentence': '[Neutropenia caused by ciprofloxacin and Escherichia coli bacteremia. Bone marrow examination].', 'subject score': 1000, 'object score': 1000}, 'PMID:2041408': {'publication date': '1991 Mar 02', 'sentence': '[Ciprofloxacin-induced neutropenia: an infrequent adverse effect].', 'subject score': 851, 'object score': 851}, 'PMID:8342553': {'publication date': '1993 Jun', 'sentence': 'Ciprofloxacin-induced neutropenia and erythema multiforme.', 'subject score': 851, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:causes---None---None---None---UMLS:C0027947---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "14369807",
-              "object": "MONDO:0001475",
-              "publications": [
-                "PMID:1943299",
-                "PMID:2041408",
-                "PMID:8342553"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10811678': {'publication date': '2000 May', 'sentence': 'The proportion of patients who developed neutropenia and fever was 87% in the group treated with ciprofloxacin and 78% in the group treated with ciprofloxacin and rifampin (P =.25).', 'subject score': 1000, 'object score': 1000}, 'PMID:11777658': {'publication date': '2001 Dec', 'sentence': 'Isolates of MSSA showed lower levels of susceptibility to ciprofloxacin (61-77% susceptibility) in both cystic fibrosis and neutropenia patients, and particularly high levels of resistance to ceftazidime (38% susceptibility) in cystic fibrosis units.', 'subject score': 1000, 'object score': 888}, 'PMID:14688588': {'publication date': '2003 Dec', 'sentence': 'Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:1473367': {'publication date': '1992', 'sentence': '58 granulocytopenic patients with confirmed bronchopneumonia were divided retrospectively into two groups for this pilot study: group 1 included neutropenic patients with venous catheters who were treated with ciprofloxacin (CIP; 200-300 mg, i.v. b.i.d.)', 'subject score': 1000, 'object score': 767}, 'PMID:15796186': {'publication date': '2005', 'sentence': 'Our objective was to evaluate the in vivo activity of trovafloxacin and ciprofloxacin against murine leukemic cells in neutropenic mice with lung infection due to Klebsiella pneumoniae.', 'subject score': 1000, 'object score': 853}, 'PMID:16966275': {'publication date': '2006 Aug', 'sentence': 'The present study was designed to evaluate the benefit of intravenous ciprofloxacin for neutropenic patients with fever who were refractory to initial therapy given for the first 3 days.', 'subject score': 888, 'object score': 853}, 'PMID:1912558': {'publication date': '1991 Oct 01', 'sentence': 'These studies indicate that ciprofloxacin may have an immune-enhancing effect on the hematopoietic system in neutropenic mice.', 'subject score': 1000, 'object score': 853}, 'PMID:2292537': {'publication date': '1990 Dec', 'sentence': 'One infection-related death occurred 30 h after starting ciprofloxacin, and a further three patients died before the resolution of neutropenia.', 'subject score': 872, 'object score': 1000}, 'PMID:2292538': {'publication date': '1990 Dec', 'sentence': 'Prevention of infection by ciprofloxacin in neutropenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:2599653': {'publication date': '1989', 'sentence': 'The in vivo activity of ciprofloxacin against Pseudomonas aeruginosa was studied in a septicemia model in neutropenic mice and compared to that of other antibiotics with established activity against P. aeruginosa.', 'subject score': 1000, 'object score': 853}, 'PMID:2653217': {'publication date': '1989 Jan', 'sentence': 'To assess the efficacy of ciprofloxacin in neutropenic patients, we conducted a randomized prospective trial comparing the combination of ciprofloxacin and netilmicin against piperacillin plus netilmicin as an empiric treatment of fever in cancer patients with neutropenia.', 'subject score': 1000, 'object score': 853}, 'PMID:27771837': {'publication date': '2017 Feb', 'sentence': 'Bacteremia during neutropenic episodes in children undergoing hematopoietic stem cell transplantation with ciprofloxacin and penicillin prophylaxis.', 'subject score': 1000, 'object score': 853}, 'PMID:8133717': {'publication date': '1994 Jan 29', 'sentence': '[Prophylaxis with ciprofloxacin in postchemotherapy neutropenia in acute myeloid leukemia].', 'subject score': 1000, 'object score': 901}, 'PMID:8418159': {'publication date': '1993 Jan', 'sentence': 'Efficacy of anti-endotoxin monoclonal antibody E5 alone or in combination with ciprofloxacin in neutropenic rats with Pseudomonas sepsis.', 'subject score': 1000, 'object score': 853}}",
-    "p2": {
-      "start": {
-        "identity": 516221,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001475",
-          "name": "neutropenia",
-          "description": "A decrease in the number of NEUTROPHILS found in the blood.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029355",
-            "MEDDRA:10029354",
-            "SNOMEDCT:303011007",
-            "MONDO:0001475",
-            "DOID:1227",
-            "MESH:D009503",
-            "UMLS:C0027947",
-            "PDQ:CDR0000041387",
-            "ICD9:288.0"
-          ],
-          "id": "MONDO:0001475",
-          "category": "biolink:Disease",
-          "all_names": [
-            "neutropenia",
-            "Neutropenia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 516221,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001475",
-              "name": "neutropenia",
-              "description": "A decrease in the number of NEUTROPHILS found in the blood.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029355",
-                "MEDDRA:10029354",
-                "SNOMEDCT:303011007",
-                "MONDO:0001475",
-                "DOID:1227",
-                "MESH:D009503",
-                "UMLS:C0027947",
-                "PDQ:CDR0000041387",
-                "ICD9:288.0"
-              ],
-              "id": "MONDO:0001475",
-              "category": "biolink:Disease",
-              "all_names": [
-                "neutropenia",
-                "Neutropenia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8022474,
-            "start": 616,
-            "end": 516221,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10811678': {'publication date': '2000 May', 'sentence': 'The proportion of patients who developed neutropenia and fever was 87% in the group treated with ciprofloxacin and 78% in the group treated with ciprofloxacin and rifampin (P =.25).', 'subject score': 1000, 'object score': 1000}, 'PMID:11777658': {'publication date': '2001 Dec', 'sentence': 'Isolates of MSSA showed lower levels of susceptibility to ciprofloxacin (61-77% susceptibility) in both cystic fibrosis and neutropenia patients, and particularly high levels of resistance to ceftazidime (38% susceptibility) in cystic fibrosis units.', 'subject score': 1000, 'object score': 888}, 'PMID:14688588': {'publication date': '2003 Dec', 'sentence': 'Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:1473367': {'publication date': '1992', 'sentence': '58 granulocytopenic patients with confirmed bronchopneumonia were divided retrospectively into two groups for this pilot study: group 1 included neutropenic patients with venous catheters who were treated with ciprofloxacin (CIP; 200-300 mg, i.v. b.i.d.)', 'subject score': 1000, 'object score': 767}, 'PMID:15796186': {'publication date': '2005', 'sentence': 'Our objective was to evaluate the in vivo activity of trovafloxacin and ciprofloxacin against murine leukemic cells in neutropenic mice with lung infection due to Klebsiella pneumoniae.', 'subject score': 1000, 'object score': 853}, 'PMID:16966275': {'publication date': '2006 Aug', 'sentence': 'The present study was designed to evaluate the benefit of intravenous ciprofloxacin for neutropenic patients with fever who were refractory to initial therapy given for the first 3 days.', 'subject score': 888, 'object score': 853}, 'PMID:1912558': {'publication date': '1991 Oct 01', 'sentence': 'These studies indicate that ciprofloxacin may have an immune-enhancing effect on the hematopoietic system in neutropenic mice.', 'subject score': 1000, 'object score': 853}, 'PMID:2292537': {'publication date': '1990 Dec', 'sentence': 'One infection-related death occurred 30 h after starting ciprofloxacin, and a further three patients died before the resolution of neutropenia.', 'subject score': 872, 'object score': 1000}, 'PMID:2292538': {'publication date': '1990 Dec', 'sentence': 'Prevention of infection by ciprofloxacin in neutropenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:2599653': {'publication date': '1989', 'sentence': 'The in vivo activity of ciprofloxacin against Pseudomonas aeruginosa was studied in a septicemia model in neutropenic mice and compared to that of other antibiotics with established activity against P. aeruginosa.', 'subject score': 1000, 'object score': 853}, 'PMID:2653217': {'publication date': '1989 Jan', 'sentence': 'To assess the efficacy of ciprofloxacin in neutropenic patients, we conducted a randomized prospective trial comparing the combination of ciprofloxacin and netilmicin against piperacillin plus netilmicin as an empiric treatment of fever in cancer patients with neutropenia.', 'subject score': 1000, 'object score': 853}, 'PMID:27771837': {'publication date': '2017 Feb', 'sentence': 'Bacteremia during neutropenic episodes in children undergoing hematopoietic stem cell transplantation with ciprofloxacin and penicillin prophylaxis.', 'subject score': 1000, 'object score': 853}, 'PMID:8133717': {'publication date': '1994 Jan 29', 'sentence': '[Prophylaxis with ciprofloxacin in postchemotherapy neutropenia in acute myeloid leukemia].', 'subject score': 1000, 'object score': 901}, 'PMID:8418159': {'publication date': '1993 Jan', 'sentence': 'Efficacy of anti-endotoxin monoclonal antibody E5 alone or in combination with ciprofloxacin in neutropenic rats with Pseudomonas sepsis.', 'subject score': 1000, 'object score': 853}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0027947---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8194797",
-              "object": "MONDO:0001475",
-              "publications": [
-                "PMID:10811678",
-                "PMID:11777658",
-                "PMID:14688588",
-                "PMID:1473367",
-                "PMID:15796186",
-                "PMID:16966275",
-                "PMID:1912558",
-                "PMID:2292537",
-                "PMID:2292538",
-                "PMID:2599653",
-                "PMID:2653217",
-                "PMID:27771837",
-                "PMID:8133717",
-                "PMID:8418159"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11967606': {'publication date': '2002 Apr', 'sentence': 'Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough?', 'subject score': 623, 'object score': 888}, 'PMID:15623906': {'publication date': '2004 Dec', 'sentence': 'We conducted a case matched control study to observe the adverse effects of ciprofloxacin used in neonatal septicemia We enrolled 30 neonates with multidrug-resistant septicemia who were treated with intravenous ciprofloxacin for 14 days.', 'subject score': 888, 'object score': 877}, 'PMID:15776347': {'publication date': '2005 Mar 24', 'sentence': 'TREATMENT AND COURSE: Treatment of sepsis with antibiotics (ciprofloxacin, penicillin G, ceftriaxon and erythromycin in standard dosages), activated protein-C, hydrocortisone and GMA-embedded immunoglobulin led to complete cure and restoration of normal autonomic function.', 'subject score': 1000, 'object score': 1000}, 'PMID:15955670': {'publication date': '2005 Jul', 'sentence': 'Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis.', 'subject score': 888, 'object score': 901}, 'PMID:22514473': {'publication date': '1997 Jan', 'sentence': 'INTERVENTION: Comparison of cefepime, ceftazidime, ceftriaxone, cefotaxime and ciprofloxacin in the treatment of lower respiratory tract infections, urinary tract infections, skin/soft tissue infections, septicemia and febrile neutropenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:23052414': {'publication date': '2013 Apr', 'sentence': 'PURPOSE: To describe the use of ciprofloxacin and fluconazole for the treatment of sepsis in European neonatal intensive care units (NICUs) in order to better orient research aimed at acquiring essential knowledge in this critical area.', 'subject score': 1000, 'object score': 1000}, 'PMID:24978586': {'publication date': '2014', 'sentence': 'These data suggest that the combination of ciprofloxacin and cefotaxime is an effective option for the treatment of V. vulnificus sepsis in humans.', 'subject score': 1000, 'object score': 827}, 'PMID:2589376': {'publication date': '1989 Nov 30', 'sentence': 'Although ciprofloxacin was generally well tolerated with minimal side effects and adverse reactions and was efficacious in the treatment of serious septicemic infections caused by gram-negative aerobic bacilli, the development of a resistant K. pneumoniae and the recovery of a resistant P. aeruginosa during therapy in two cases are of concern and deserve further investigation.', 'subject score': 1000, 'object score': 828}, 'PMID:2620671': {'publication date': '1989 Dec', 'sentence': 'Serum levels of ciprofloxacin after single oral doses in patients with septicemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:28971862': {'publication date': '2017 12', 'sentence': 'Efficacy of Ceftriaxone, Cefepime, Doxycycline, Ciprofloxacin, and Combination Therapy for Vibrio vulnificus Foodborne Septicemia.', 'subject score': 1000, 'object score': 824}, 'PMID:2934363': {'publication date': '1985 Nov', 'sentence': 'Multiply resistant Salmonella typhimurium septicaemia in an immunocompromised patient successfully treated with ciprofloxacin.', 'subject score': 1000, 'object score': 798}, 'PMID:3112380': {'publication date': '1987 May', 'sentence': 'Two neutropenic patients with multiple resistant Pseudomonas aeruginosa septicaemia treated with ciprofloxacin.', 'subject score': 1000, 'object score': 840}, 'PMID:31188821': {'publication date': '2019 06', 'sentence': 'Outcomes of Third-Generation Cephalosporin Plus Ciprofloxacin or Doxycycline Therapy in Patients with Vibrio vulnificus Septicemia: A Propensity Score-Matched Analysis.', 'subject score': 875, 'object score': 901}, 'PMID:3325928': {'publication date': '1987 Dec 11', 'sentence': 'Influence of dose frequency on the therapeutic efficacies of ciprofloxacin and ceftazidime in experimental Klebsiella pneumoniae pneumonia and septicemia in relation to their bactericidal activities in vitro.', 'subject score': 1000, 'object score': 1000}, 'PMID:3631942': {'publication date': '1987 Aug', 'sentence': 'However, caution is suggested when this dose of ciprofloxacin is used in situations in which septicemia is caused by P. aeruginosa or S. aureus and originates outside the urinary tract.', 'subject score': 1000, 'object score': 1000}, 'PMID:8089053': {'publication date': '1994 May', 'sentence': 'Serum ciprofloxacin concentrations in patients with severe sepsis being treated with ciprofloxacin 200 mg i.v. bd irrespective of renal function.', 'subject score': 890, 'object score': 888}, 'PMID:9249215': {'publication date': '1997 Jul', 'sentence': 'Dosage reduction of ciprofloxacin in patients with severe sepsis and impaired renal function is not required unless they have co-existent intra-abdominal disease.', 'subject score': 1000, 'object score': 888}, 'PMID:9364293': {'publication date': '1997 Sep-Oct', 'sentence': \"Ciprofloxacin appears to provide a therapeutic option as a ?life-saving' therapy for newborns with sepsis produced by multiply resistant organisms.\", 'subject score': 1000, 'object score': 1000}, 'PMID:9736541': {'publication date': '1998 Sep', 'sentence': 'Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis.', 'subject score': 861, 'object score': 888}, 'PMID:9809826': {'publication date': '1998 Oct', 'sentence': 'Ciprofloxacin has been used to treat neonatal pneumonia, meningitis and septicaemia and was effective in all cases.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9299503,
-            "start": 616,
-            "end": 320039,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11967606': {'publication date': '2002 Apr', 'sentence': 'Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough?', 'subject score': 623, 'object score': 888}, 'PMID:15623906': {'publication date': '2004 Dec', 'sentence': 'We conducted a case matched control study to observe the adverse effects of ciprofloxacin used in neonatal septicemia We enrolled 30 neonates with multidrug-resistant septicemia who were treated with intravenous ciprofloxacin for 14 days.', 'subject score': 888, 'object score': 877}, 'PMID:15776347': {'publication date': '2005 Mar 24', 'sentence': 'TREATMENT AND COURSE: Treatment of sepsis with antibiotics (ciprofloxacin, penicillin G, ceftriaxon and erythromycin in standard dosages), activated protein-C, hydrocortisone and GMA-embedded immunoglobulin led to complete cure and restoration of normal autonomic function.', 'subject score': 1000, 'object score': 1000}, 'PMID:15955670': {'publication date': '2005 Jul', 'sentence': 'Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis.', 'subject score': 888, 'object score': 901}, 'PMID:22514473': {'publication date': '1997 Jan', 'sentence': 'INTERVENTION: Comparison of cefepime, ceftazidime, ceftriaxone, cefotaxime and ciprofloxacin in the treatment of lower respiratory tract infections, urinary tract infections, skin/soft tissue infections, septicemia and febrile neutropenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:23052414': {'publication date': '2013 Apr', 'sentence': 'PURPOSE: To describe the use of ciprofloxacin and fluconazole for the treatment of sepsis in European neonatal intensive care units (NICUs) in order to better orient research aimed at acquiring essential knowledge in this critical area.', 'subject score': 1000, 'object score': 1000}, 'PMID:24978586': {'publication date': '2014', 'sentence': 'These data suggest that the combination of ciprofloxacin and cefotaxime is an effective option for the treatment of V. vulnificus sepsis in humans.', 'subject score': 1000, 'object score': 827}, 'PMID:2589376': {'publication date': '1989 Nov 30', 'sentence': 'Although ciprofloxacin was generally well tolerated with minimal side effects and adverse reactions and was efficacious in the treatment of serious septicemic infections caused by gram-negative aerobic bacilli, the development of a resistant K. pneumoniae and the recovery of a resistant P. aeruginosa during therapy in two cases are of concern and deserve further investigation.', 'subject score': 1000, 'object score': 828}, 'PMID:2620671': {'publication date': '1989 Dec', 'sentence': 'Serum levels of ciprofloxacin after single oral doses in patients with septicemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:28971862': {'publication date': '2017 12', 'sentence': 'Efficacy of Ceftriaxone, Cefepime, Doxycycline, Ciprofloxacin, and Combination Therapy for Vibrio vulnificus Foodborne Septicemia.', 'subject score': 1000, 'object score': 824}, 'PMID:2934363': {'publication date': '1985 Nov', 'sentence': 'Multiply resistant Salmonella typhimurium septicaemia in an immunocompromised patient successfully treated with ciprofloxacin.', 'subject score': 1000, 'object score': 798}, 'PMID:3112380': {'publication date': '1987 May', 'sentence': 'Two neutropenic patients with multiple resistant Pseudomonas aeruginosa septicaemia treated with ciprofloxacin.', 'subject score': 1000, 'object score': 840}, 'PMID:31188821': {'publication date': '2019 06', 'sentence': 'Outcomes of Third-Generation Cephalosporin Plus Ciprofloxacin or Doxycycline Therapy in Patients with Vibrio vulnificus Septicemia: A Propensity Score-Matched Analysis.', 'subject score': 875, 'object score': 901}, 'PMID:3325928': {'publication date': '1987 Dec 11', 'sentence': 'Influence of dose frequency on the therapeutic efficacies of ciprofloxacin and ceftazidime in experimental Klebsiella pneumoniae pneumonia and septicemia in relation to their bactericidal activities in vitro.', 'subject score': 1000, 'object score': 1000}, 'PMID:3631942': {'publication date': '1987 Aug', 'sentence': 'However, caution is suggested when this dose of ciprofloxacin is used in situations in which septicemia is caused by P. aeruginosa or S. aureus and originates outside the urinary tract.', 'subject score': 1000, 'object score': 1000}, 'PMID:8089053': {'publication date': '1994 May', 'sentence': 'Serum ciprofloxacin concentrations in patients with severe sepsis being treated with ciprofloxacin 200 mg i.v. bd irrespective of renal function.', 'subject score': 890, 'object score': 888}, 'PMID:9249215': {'publication date': '1997 Jul', 'sentence': 'Dosage reduction of ciprofloxacin in patients with severe sepsis and impaired renal function is not required unless they have co-existent intra-abdominal disease.', 'subject score': 1000, 'object score': 888}, 'PMID:9364293': {'publication date': '1997 Sep-Oct', 'sentence': \"Ciprofloxacin appears to provide a therapeutic option as a ?life-saving' therapy for newborns with sepsis produced by multiply resistant organisms.\", 'subject score': 1000, 'object score': 1000}, 'PMID:9736541': {'publication date': '1998 Sep', 'sentence': 'Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis.', 'subject score': 861, 'object score': 888}, 'PMID:9809826': {'publication date': '1998 Oct', 'sentence': 'Ciprofloxacin has been used to treat neonatal pneumonia, meningitis and septicaemia and was effective in all cases.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0036690---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "9504629",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:11967606",
-                "PMID:15623906",
-                "PMID:15776347",
-                "PMID:15955670",
-                "PMID:22514473",
-                "PMID:23052414",
-                "PMID:24978586",
-                "PMID:2589376",
-                "PMID:2620671",
-                "PMID:28971862",
-                "PMID:2934363",
-                "PMID:3112380",
-                "PMID:31188821",
-                "PMID:3325928",
-                "PMID:3631942",
-                "PMID:8089053",
-                "PMID:9249215",
-                "PMID:9364293",
-                "PMID:9736541",
-                "PMID:9809826"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:21266559': {'publication date': '2011 Feb', 'sentence': 'CONCLUSIONS: The 24-hour clear-fluid diet and the use of disposable enemas combined with a regimen of ciprofloxacin decreased the rate of postbiopsy sepsis in patients who underwent transrectal ultrasound-guided prostate biopsy, but the results were not significantly different.', 'subject score': 1000, 'object score': 861}, 'PMID:23009873': {'publication date': '2013 Mar', 'sentence': 'Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate.', 'subject score': 888, 'object score': 1000}, 'PMID:23623974': {'publication date': '2013 Oct', 'sentence': 'Re: Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate: E.', 'subject score': 888, 'object score': 1000}, 'PMID:23623975': {'publication date': '2013 Apr 24', 'sentence': 'Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicaemia after transrectal ultrasound guided biopsy of the prostate.', 'subject score': 888, 'object score': 1000}, 'PMID:27075767': {'publication date': '2016 Jun', 'sentence': 'UNLABELLED: We hypothesized that combined treatment with autologous adipose-derived mesenchymal stem cell (ADMSC) and ciprofloxacin is superior to ciprofloxacin only in reducing sepsis-induced urogenital organ damage and mortality in rat sepsis syndrome (SS) caused by intrapelvic injection of cecal bacteria (1.0 * 10(4) cells per milliliter; total, 5.0 ml).', 'subject score': 1000, 'object score': 614}, 'PMID:30553114': {'publication date': '2019 Jun', 'sentence': 'FMT was therefore not an effective alternative to ciprofloxacin for preventing post-TRUSPB urinary sepsis.', 'subject score': 1000, 'object score': 749}, 'PMID:8851383': {'publication date': '1996 Feb', 'sentence': 'Oral administration of CPFX was more effective than PL-B plus KM in preventing P. aeruginosa sepsis.', 'subject score': 1000, 'object score': 852}}",
-    "p2": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15116639,
-            "start": 616,
-            "end": 320039,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21266559': {'publication date': '2011 Feb', 'sentence': 'CONCLUSIONS: The 24-hour clear-fluid diet and the use of disposable enemas combined with a regimen of ciprofloxacin decreased the rate of postbiopsy sepsis in patients who underwent transrectal ultrasound-guided prostate biopsy, but the results were not significantly different.', 'subject score': 1000, 'object score': 861}, 'PMID:23009873': {'publication date': '2013 Mar', 'sentence': 'Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate.', 'subject score': 888, 'object score': 1000}, 'PMID:23623974': {'publication date': '2013 Oct', 'sentence': 'Re: Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate: E.', 'subject score': 888, 'object score': 1000}, 'PMID:23623975': {'publication date': '2013 Apr 24', 'sentence': 'Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicaemia after transrectal ultrasound guided biopsy of the prostate.', 'subject score': 888, 'object score': 1000}, 'PMID:27075767': {'publication date': '2016 Jun', 'sentence': 'UNLABELLED: We hypothesized that combined treatment with autologous adipose-derived mesenchymal stem cell (ADMSC) and ciprofloxacin is superior to ciprofloxacin only in reducing sepsis-induced urogenital organ damage and mortality in rat sepsis syndrome (SS) caused by intrapelvic injection of cecal bacteria (1.0 * 10(4) cells per milliliter; total, 5.0 ml).', 'subject score': 1000, 'object score': 614}, 'PMID:30553114': {'publication date': '2019 Jun', 'sentence': 'FMT was therefore not an effective alternative to ciprofloxacin for preventing post-TRUSPB urinary sepsis.', 'subject score': 1000, 'object score': 749}, 'PMID:8851383': {'publication date': '1996 Feb', 'sentence': 'Oral administration of CPFX was more effective than PL-B plus KM in preventing P. aeruginosa sepsis.', 'subject score': 1000, 'object score': 852}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:prevents---None---None---None---UMLS:C0036690---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "15438014",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:21266559",
-                "PMID:23009873",
-                "PMID:23623974",
-                "PMID:23623975",
-                "PMID:27075767",
-                "PMID:30553114",
-                "PMID:8851383"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:19351314': {'publication date': '2009 Apr 06', 'sentence': 'Chromobacterium violaceum endocarditis and hepatic abscesses treated successfully with meropenem and ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:19807647': {'publication date': '2009 Oct 05', 'sentence': 'Chromobacterium violaceum endocarditis and hepatic abscesses treated successfully with meropenem and ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:29055688': {'publication date': '2017 12', 'sentence': 'Ciprofloxacin treatment for cryptogenic Klebsiella pneumoniae liver abscesses.', 'subject score': 888, 'object score': 857}}",
-    "p2": {
-      "start": {
-        "identity": 321423,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0700051",
-          "name": "liver abscess (disease)",
-          "description": "A bacterial, parasitic, or fungal abscess that develops in the liver. It is usually the result of an abdominal infection, trauma, or surgery in the right upper quadrant. Signs and symptoms include abdominal pain, nausea, vomiting, and fever.; Solitary or multiple collections of PUS within the liver as a result of infection by bacteria, protozoa, or other agents.; The presence of an abscess of the liver. [HPO:probinson]",
-          "equivalent_curies": [
-            "UMLS:C0023885",
-            "MESH:D008100",
-            "MONDO:0700051",
-            "SNOMEDCT:27916005",
-            "NCIT:C99089",
-            "MEDDRA:10024652",
-            "MEDDRA:10000300",
-            "HP:0100523"
-          ],
-          "id": "MONDO:0700051",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Liver Abscess",
-            "liver abscess (disease)",
-            "Liver abscess"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-2658-1136",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-2825-0621"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321423,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0700051",
-              "name": "liver abscess (disease)",
-              "description": "A bacterial, parasitic, or fungal abscess that develops in the liver. It is usually the result of an abdominal infection, trauma, or surgery in the right upper quadrant. Signs and symptoms include abdominal pain, nausea, vomiting, and fever.; Solitary or multiple collections of PUS within the liver as a result of infection by bacteria, protozoa, or other agents.; The presence of an abscess of the liver. [HPO:probinson]",
-              "equivalent_curies": [
-                "UMLS:C0023885",
-                "MESH:D008100",
-                "MONDO:0700051",
-                "SNOMEDCT:27916005",
-                "NCIT:C99089",
-                "MEDDRA:10024652",
-                "MEDDRA:10000300",
-                "HP:0100523"
-              ],
-              "id": "MONDO:0700051",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Liver Abscess",
-                "liver abscess (disease)",
-                "Liver abscess"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-2658-1136",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-2825-0621"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14013356,
-            "start": 616,
-            "end": 321423,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19351314': {'publication date': '2009 Apr 06', 'sentence': 'Chromobacterium violaceum endocarditis and hepatic abscesses treated successfully with meropenem and ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:19807647': {'publication date': '2009 Oct 05', 'sentence': 'Chromobacterium violaceum endocarditis and hepatic abscesses treated successfully with meropenem and ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:29055688': {'publication date': '2017 12', 'sentence': 'Ciprofloxacin treatment for cryptogenic Klebsiella pneumoniae liver abscesses.', 'subject score': 888, 'object score': 857}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0023885---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "14311974",
-              "object": "MONDO:0700051",
-              "publications": [
-                "PMID:19351314",
-                "PMID:19807647",
-                "PMID:29055688"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:23080291': {'publication date': '2013 Mar', 'sentence': 'Ciprofloxacin significantly reduced the occurrence of febrile episodes in patients with acute lymphoblastic leukemia in the induction phase of chemotherapy, but not in patients with lymphoma or in the consolidation phase of chemotherapy.', 'subject score': 1000, 'object score': 888}, 'PMID:8164024': {'publication date': '1994 May', 'sentence': 'RESULTS: In patients treated with bone marrow and PBPCs, the incidence of fever during neutropenia was reduced by ciprofloxacin and rifampin from 98% to 57%.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 212250,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-          "name": "Fever",
-          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10037660",
-            "MEDDRA:10020083",
-            "MEDDRA:10005911",
-            "UMLS:C0015967",
-            "HP:0001945",
-            "NCIT:C3038",
-            "MEDDRA:10073718",
-            "MEDDRA:10043204",
-            "MEDDRA:10037668",
-            "PDQ:CDR0000775882",
-            "PSY:19660",
-            "SNOMEDCT:386661006",
-            "MEDDRA:10016558",
-            "MEDDRA:10037663",
-            "SNOMEDCT:50177009",
-            "SYMP:0000613",
-            "MESH:D005334"
-          ],
-          "id": "HP:0001945",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "fever",
-            "Fever"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:9759682",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 212250,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-              "name": "Fever",
-              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10037660",
-                "MEDDRA:10020083",
-                "MEDDRA:10005911",
-                "UMLS:C0015967",
-                "HP:0001945",
-                "NCIT:C3038",
-                "MEDDRA:10073718",
-                "MEDDRA:10043204",
-                "MEDDRA:10037668",
-                "PDQ:CDR0000775882",
-                "PSY:19660",
-                "SNOMEDCT:386661006",
-                "MEDDRA:10016558",
-                "MEDDRA:10037663",
-                "SNOMEDCT:50177009",
-                "SYMP:0000613",
-                "MESH:D005334"
-              ],
-              "id": "HP:0001945",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "fever",
-                "Fever"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:9759682",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16226316,
-            "start": 616,
-            "end": 212250,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23080291': {'publication date': '2013 Mar', 'sentence': 'Ciprofloxacin significantly reduced the occurrence of febrile episodes in patients with acute lymphoblastic leukemia in the induction phase of chemotherapy, but not in patients with lymphoma or in the consolidation phase of chemotherapy.', 'subject score': 1000, 'object score': 888}, 'PMID:8164024': {'publication date': '1994 May', 'sentence': 'RESULTS: In patients treated with bone marrow and PBPCs, the incidence of fever during neutropenia was reduced by ciprofloxacin and rifampin from 98% to 57%.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:inhibits---biolink:causes---activity---None---UMLS:C0015967---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "16563368",
-              "object": "HP:0001945",
-              "publications": [
-                "PMID:23080291",
-                "PMID:8164024"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:11168914': {'publication date': '2000 Dec', 'sentence': '(0.18 microg /mL) and AUC (0.99 microg .h/mL) of ciprofloxacin were significantly decreased, whereas its t1/2beta (2.75 h) and MRT (4.58 h) were prolonged in febrile than in normal goats.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 212250,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-          "name": "Fever",
-          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10037660",
-            "MEDDRA:10020083",
-            "MEDDRA:10005911",
-            "UMLS:C0015967",
-            "HP:0001945",
-            "NCIT:C3038",
-            "MEDDRA:10073718",
-            "MEDDRA:10043204",
-            "MEDDRA:10037668",
-            "PDQ:CDR0000775882",
-            "PSY:19660",
-            "SNOMEDCT:386661006",
-            "MEDDRA:10016558",
-            "MEDDRA:10037663",
-            "SNOMEDCT:50177009",
-            "SYMP:0000613",
-            "MESH:D005334"
-          ],
-          "id": "HP:0001945",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "fever",
-            "Fever"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:9759682",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 212250,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-              "name": "Fever",
-              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10037660",
-                "MEDDRA:10020083",
-                "MEDDRA:10005911",
-                "UMLS:C0015967",
-                "HP:0001945",
-                "NCIT:C3038",
-                "MEDDRA:10073718",
-                "MEDDRA:10043204",
-                "MEDDRA:10037668",
-                "PDQ:CDR0000775882",
-                "PSY:19660",
-                "SNOMEDCT:386661006",
-                "MEDDRA:10016558",
-                "MEDDRA:10037663",
-                "SNOMEDCT:50177009",
-                "SYMP:0000613",
-                "MESH:D005334"
-              ],
-              "id": "HP:0001945",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "fever",
-                "Fever"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:9759682",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8475417,
-            "start": 616,
-            "end": 212250,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11168914': {'publication date': '2000 Dec', 'sentence': '(0.18 microg /mL) and AUC (0.99 microg .h/mL) of ciprofloxacin were significantly decreased, whereas its t1/2beta (2.75 h) and MRT (4.58 h) were prolonged in febrile than in normal goats.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0015967---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8669720",
-              "object": "HP:0001945",
-              "publications": [
-                "PMID:11168914"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10738231': {'publication date': '2000 Apr 01', 'sentence': 'In the current study, the authors examined the use of ciprofloxacin as outpatient management in selected patients with fever during an episode of neutropenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:10811678': {'publication date': '2000 May', 'sentence': 'The proportion of patients who developed neutropenia and fever was 87% in the group treated with ciprofloxacin and 78% in the group treated with ciprofloxacin and rifampin (P =.25).', 'subject score': 1000, 'object score': 1000}, 'PMID:12182387': {'publication date': '2002 Jun', 'sentence': 'A 14-year-old girl was seen at a community clinic with a chief complaint of abdominal pain and fevers and was treated with oral ciprofloxacin for presumed pyelonephritis.', 'subject score': 888, 'object score': 1000}, 'PMID:1388120': {'publication date': '1992 Jun', 'sentence': 'Teicoplanin plus ciprofloxacin was compared with gentamicin plus piperacillin for the empirical treatment of fever in 80 neutropenic patients.', 'subject score': 851, 'object score': 1000}, 'PMID:1399929': {'publication date': '1992 Aug', 'sentence': 'A prospective, randomized trial comparing monotherapy with high-dose ciprofloxacin versus a standard combination regimen of azlocillin and netilmicin in the empirical treatment of febrile episodes in neutropenic patients was performed.', 'subject score': 901, 'object score': 888}, 'PMID:1411313': {'publication date': '1992', 'sentence': 'Thus, this pilot study indicates that piperacillin and ciprofloxacin may be a safe and effective combination for the treatment of febrile episodes in severely neutropenic leukemia patients, which merits further investigation in randomized trials.', 'subject score': 1000, 'object score': 888}, 'PMID:14688588': {'publication date': '2003 Dec', 'sentence': 'Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:15380025': {'publication date': '2004 Sep 20', 'sentence': 'Two continued on oral or IV ciprofloxacin alone but had prolonged fevers of 9-10 days duration, one was switched to IV beta-lactam therapy after remaining febrile for 3 days on oral/IV ciprofloxacin and one was treated successfully with oral ciprofloxacin.', 'subject score': 888, 'object score': 1000}, 'PMID:16966275': {'publication date': '2006 Aug', 'sentence': 'The present study was designed to evaluate the benefit of intravenous ciprofloxacin for neutropenic patients with fever who were refractory to initial therapy given for the first 3 days.', 'subject score': 888, 'object score': 1000}, 'PMID:18611695': {'publication date': '1995 Dec', 'sentence': 'Absorption of ciprofloxacin in febrile and afebrile patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:2108911': {'publication date': '1990', 'sentence': 'In a randomized study comparing cotrimoxazole plus colistin with ciprofloxacin, each in combination with nonabsorbable antimycotics, the incidence of major infections in terms of septicemias and pneumonias as well as of minor infections and episodes of unexplained fever (FUO) was higher in patients treated with ciprofloxacin.', 'subject score': 1000, 'object score': 861}, 'PMID:2149044': {'publication date': '1990 Dec', 'sentence': 'We compared the combination of teicoplanin plus ciprofloxacin with gentamicin plus piperacillin for the empirical treatment of fever in 80 neutropenic patients.', 'subject score': 851, 'object score': 1000}, 'PMID:2180889': {'publication date': '1990 Jan', 'sentence': 'We examined the efficacy of ciprofloxacin as an empirical treatment for fever in 97 neutropenic patients in a randomized study of ciprofloxacin and benzylpenicillin versus netilmicin and piperacillin.', 'subject score': 1000, 'object score': 1000}, 'PMID:2292537': {'publication date': '1990 Dec', 'sentence': 'We conclude that high-dose intravenous ciprofloxacin may be safely employed as monotherapy in the empirical treatment of febrile episodes in neutropenic patients.', 'subject score': 861, 'object score': 888}, 'PMID:25193180': {'publication date': '2014 Oct 15', 'sentence': 'After 24h, the dog was found to have a high fever (39.5  degrees C) and was treated empirically with doxycycline/ciprofloxacin.', 'subject score': 888, 'object score': 888}, 'PMID:2653217': {'publication date': '1989 Jan', 'sentence': 'To assess the efficacy of ciprofloxacin in neutropenic patients, we conducted a randomized prospective trial comparing the combination of ciprofloxacin and netilmicin against piperacillin plus netilmicin as an empiric treatment of fever in cancer patients with neutropenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:2941290': {'publication date': '1986 Apr', 'sentence': 'The duration of fever in patients treated with ciprofloxacin was 1.5 days versus 2.3 days in the placebo group; the difference was not statistically significant.', 'subject score': 1000, 'object score': 1000}, 'PMID:32380974': {'publication date': '2020 May 07', 'sentence': 'The initial antibiotic therapy with ceftriaxone/doxycycline was switched to ciprofloxacin, resulting in the resolution of fever and symptoms.', 'subject score': 1000, 'object score': 1000}, 'PMID:32435805': {'publication date': '2020 May 21', 'sentence': 'RESULTS: Challenged animals all developed fever within 78 hours and were treated with ciprofloxacin (n = 27) or levofloxacin (n = 29) at various predetermined time points postfever.', 'subject score': 1000, 'object score': 861}, 'PMID:3468101': {'publication date': '1986 Nov', 'sentence': 'Twenty-four episodes of fever in neutropenic patients with haematological malignancy were treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 212250,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-          "name": "Fever",
-          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10037660",
-            "MEDDRA:10020083",
-            "MEDDRA:10005911",
-            "UMLS:C0015967",
-            "HP:0001945",
-            "NCIT:C3038",
-            "MEDDRA:10073718",
-            "MEDDRA:10043204",
-            "MEDDRA:10037668",
-            "PDQ:CDR0000775882",
-            "PSY:19660",
-            "SNOMEDCT:386661006",
-            "MEDDRA:10016558",
-            "MEDDRA:10037663",
-            "SNOMEDCT:50177009",
-            "SYMP:0000613",
-            "MESH:D005334"
-          ],
-          "id": "HP:0001945",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "fever",
-            "Fever"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:9759682",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 212250,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-              "name": "Fever",
-              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10037660",
-                "MEDDRA:10020083",
-                "MEDDRA:10005911",
-                "UMLS:C0015967",
-                "HP:0001945",
-                "NCIT:C3038",
-                "MEDDRA:10073718",
-                "MEDDRA:10043204",
-                "MEDDRA:10037668",
-                "PDQ:CDR0000775882",
-                "PSY:19660",
-                "SNOMEDCT:386661006",
-                "MEDDRA:10016558",
-                "MEDDRA:10037663",
-                "SNOMEDCT:50177009",
-                "SYMP:0000613",
-                "MESH:D005334"
-              ],
-              "id": "HP:0001945",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "fever",
-                "Fever"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:9759682",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7918463,
-            "start": 616,
-            "end": 212250,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:10738231': {'publication date': '2000 Apr 01', 'sentence': 'In the current study, the authors examined the use of ciprofloxacin as outpatient management in selected patients with fever during an episode of neutropenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:10811678': {'publication date': '2000 May', 'sentence': 'The proportion of patients who developed neutropenia and fever was 87% in the group treated with ciprofloxacin and 78% in the group treated with ciprofloxacin and rifampin (P =.25).', 'subject score': 1000, 'object score': 1000}, 'PMID:12182387': {'publication date': '2002 Jun', 'sentence': 'A 14-year-old girl was seen at a community clinic with a chief complaint of abdominal pain and fevers and was treated with oral ciprofloxacin for presumed pyelonephritis.', 'subject score': 888, 'object score': 1000}, 'PMID:1388120': {'publication date': '1992 Jun', 'sentence': 'Teicoplanin plus ciprofloxacin was compared with gentamicin plus piperacillin for the empirical treatment of fever in 80 neutropenic patients.', 'subject score': 851, 'object score': 1000}, 'PMID:1399929': {'publication date': '1992 Aug', 'sentence': 'A prospective, randomized trial comparing monotherapy with high-dose ciprofloxacin versus a standard combination regimen of azlocillin and netilmicin in the empirical treatment of febrile episodes in neutropenic patients was performed.', 'subject score': 901, 'object score': 888}, 'PMID:1411313': {'publication date': '1992', 'sentence': 'Thus, this pilot study indicates that piperacillin and ciprofloxacin may be a safe and effective combination for the treatment of febrile episodes in severely neutropenic leukemia patients, which merits further investigation in randomized trials.', 'subject score': 1000, 'object score': 888}, 'PMID:14688588': {'publication date': '2003 Dec', 'sentence': 'Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:15380025': {'publication date': '2004 Sep 20', 'sentence': 'Two continued on oral or IV ciprofloxacin alone but had prolonged fevers of 9-10 days duration, one was switched to IV beta-lactam therapy after remaining febrile for 3 days on oral/IV ciprofloxacin and one was treated successfully with oral ciprofloxacin.', 'subject score': 888, 'object score': 1000}, 'PMID:16966275': {'publication date': '2006 Aug', 'sentence': 'The present study was designed to evaluate the benefit of intravenous ciprofloxacin for neutropenic patients with fever who were refractory to initial therapy given for the first 3 days.', 'subject score': 888, 'object score': 1000}, 'PMID:18611695': {'publication date': '1995 Dec', 'sentence': 'Absorption of ciprofloxacin in febrile and afebrile patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:2108911': {'publication date': '1990', 'sentence': 'In a randomized study comparing cotrimoxazole plus colistin with ciprofloxacin, each in combination with nonabsorbable antimycotics, the incidence of major infections in terms of septicemias and pneumonias as well as of minor infections and episodes of unexplained fever (FUO) was higher in patients treated with ciprofloxacin.', 'subject score': 1000, 'object score': 861}, 'PMID:2149044': {'publication date': '1990 Dec', 'sentence': 'We compared the combination of teicoplanin plus ciprofloxacin with gentamicin plus piperacillin for the empirical treatment of fever in 80 neutropenic patients.', 'subject score': 851, 'object score': 1000}, 'PMID:2180889': {'publication date': '1990 Jan', 'sentence': 'We examined the efficacy of ciprofloxacin as an empirical treatment for fever in 97 neutropenic patients in a randomized study of ciprofloxacin and benzylpenicillin versus netilmicin and piperacillin.', 'subject score': 1000, 'object score': 1000}, 'PMID:2292537': {'publication date': '1990 Dec', 'sentence': 'We conclude that high-dose intravenous ciprofloxacin may be safely employed as monotherapy in the empirical treatment of febrile episodes in neutropenic patients.', 'subject score': 861, 'object score': 888}, 'PMID:25193180': {'publication date': '2014 Oct 15', 'sentence': 'After 24h, the dog was found to have a high fever (39.5  degrees C) and was treated empirically with doxycycline/ciprofloxacin.', 'subject score': 888, 'object score': 888}, 'PMID:2653217': {'publication date': '1989 Jan', 'sentence': 'To assess the efficacy of ciprofloxacin in neutropenic patients, we conducted a randomized prospective trial comparing the combination of ciprofloxacin and netilmicin against piperacillin plus netilmicin as an empiric treatment of fever in cancer patients with neutropenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:2941290': {'publication date': '1986 Apr', 'sentence': 'The duration of fever in patients treated with ciprofloxacin was 1.5 days versus 2.3 days in the placebo group; the difference was not statistically significant.', 'subject score': 1000, 'object score': 1000}, 'PMID:32380974': {'publication date': '2020 May 07', 'sentence': 'The initial antibiotic therapy with ceftriaxone/doxycycline was switched to ciprofloxacin, resulting in the resolution of fever and symptoms.', 'subject score': 1000, 'object score': 1000}, 'PMID:32435805': {'publication date': '2020 May 21', 'sentence': 'RESULTS: Challenged animals all developed fever within 78 hours and were treated with ciprofloxacin (n = 27) or levofloxacin (n = 29) at various predetermined time points postfever.', 'subject score': 1000, 'object score': 861}, 'PMID:3468101': {'publication date': '1986 Nov', 'sentence': 'Twenty-four episodes of fever in neutropenic patients with haematological malignancy were treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0015967---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8088120",
-              "object": "HP:0001945",
-              "publications": [
-                "PMID:10738231",
-                "PMID:10811678",
-                "PMID:12182387",
-                "PMID:1388120",
-                "PMID:1399929",
-                "PMID:1411313",
-                "PMID:14688588",
-                "PMID:15380025",
-                "PMID:16966275",
-                "PMID:18611695",
-                "PMID:2108911",
-                "PMID:2149044",
-                "PMID:2180889",
-                "PMID:2292537",
-                "PMID:25193180",
-                "PMID:2653217",
-                "PMID:2941290",
-                "PMID:32380974",
-                "PMID:32435805",
-                "PMID:3468101"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:8427721': {'publication date': '1993', 'sentence': 'In a prospective, randomised multicentre study performed by the GIMEMA infection program, ciprofloxacin was demonstrated to be more effective than norfloxacin for the reduction of febrile episodes, use of systemic antibiotics, and Gram-negative infections in neutropenic patients with haematological malignancies.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 212250,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-          "name": "Fever",
-          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10037660",
-            "MEDDRA:10020083",
-            "MEDDRA:10005911",
-            "UMLS:C0015967",
-            "HP:0001945",
-            "NCIT:C3038",
-            "MEDDRA:10073718",
-            "MEDDRA:10043204",
-            "MEDDRA:10037668",
-            "PDQ:CDR0000775882",
-            "PSY:19660",
-            "SNOMEDCT:386661006",
-            "MEDDRA:10016558",
-            "MEDDRA:10037663",
-            "SNOMEDCT:50177009",
-            "SYMP:0000613",
-            "MESH:D005334"
-          ],
-          "id": "HP:0001945",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "fever",
-            "Fever"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:9759682",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 212250,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-              "name": "Fever",
-              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10037660",
-                "MEDDRA:10020083",
-                "MEDDRA:10005911",
-                "UMLS:C0015967",
-                "HP:0001945",
-                "NCIT:C3038",
-                "MEDDRA:10073718",
-                "MEDDRA:10043204",
-                "MEDDRA:10037668",
-                "PDQ:CDR0000775882",
-                "PSY:19660",
-                "SNOMEDCT:386661006",
-                "MEDDRA:10016558",
-                "MEDDRA:10037663",
-                "SNOMEDCT:50177009",
-                "SYMP:0000613",
-                "MESH:D005334"
-              ],
-              "id": "HP:0001945",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "fever",
-                "Fever"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:9759682",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26518210,
-            "start": 616,
-            "end": 212250,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:8427721': {'publication date': '1993', 'sentence': 'In a prospective, randomised multicentre study performed by the GIMEMA infection program, ciprofloxacin was demonstrated to be more effective than norfloxacin for the reduction of febrile episodes, use of systemic antibiotics, and Gram-negative infections in neutropenic patients with haematological malignancies.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:disrupts---None---None---None---UMLS:C0015967---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "26984478",
-              "object": "HP:0001945",
-              "publications": [
-                "PMID:8427721"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:15216950': {'publication date': '2004 Apr', 'sentence': 'The authors studied the bactericidal action and therapeutic effectiveness of ciprofloxacin in treating external ocular infections (bacterial conjunctivitis and bacterial blepharoconjunctivitis).', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 546977,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043885",
-          "name": "eye infectious disorder",
-          "description": "An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.; Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.; Your eyes can get infections from bacteria, fungi, or viruses. Eye infections can occur in different parts of the eye and can affect just one eye or both. Two common eye infections are:  Conjunctivitis - also known as pink eye. Conjunctivitis is often due to an infection. Children frequently get it, and it is very contagious.  Stye - a bump on the eyelid that happens when bacteria from your skin get into the hair follicle of an eyelash.  Symptoms of eye infections may include redness, itching, swelling, discharge, pain, or problems with vision. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or antibiotics.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10015929",
-            "UMLS:C0015403",
-            "MESH:D015817",
-            "MEDDRA:10015936",
-            "MONDO:0043885",
-            "SNOMEDCT:128351009",
-            "NCIT:C45372",
-            "EFO:1001888"
-          ],
-          "id": "MONDO:0043885",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Eye Infection",
-            "eye infectious disorder",
-            "eye infection",
-            "Eye Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546977,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043885",
-              "name": "eye infectious disorder",
-              "description": "An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.; Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.; Your eyes can get infections from bacteria, fungi, or viruses. Eye infections can occur in different parts of the eye and can affect just one eye or both. Two common eye infections are:  Conjunctivitis - also known as pink eye. Conjunctivitis is often due to an infection. Children frequently get it, and it is very contagious.  Stye - a bump on the eyelid that happens when bacteria from your skin get into the hair follicle of an eyelash.  Symptoms of eye infections may include redness, itching, swelling, discharge, pain, or problems with vision. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or antibiotics.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10015929",
-                "UMLS:C0015403",
-                "MESH:D015817",
-                "MEDDRA:10015936",
-                "MONDO:0043885",
-                "SNOMEDCT:128351009",
-                "NCIT:C45372",
-                "EFO:1001888"
-              ],
-              "id": "MONDO:0043885",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Eye Infection",
-                "eye infectious disorder",
-                "eye infection",
-                "Eye Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11025632,
-            "start": 616,
-            "end": 546977,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15216950': {'publication date': '2004 Apr', 'sentence': 'The authors studied the bactericidal action and therapeutic effectiveness of ciprofloxacin in treating external ocular infections (bacterial conjunctivitis and bacterial blepharoconjunctivitis).', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0015403---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "11267024",
-              "object": "MONDO:0043885",
-              "publications": [
-                "PMID:15216950"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15257070': {'publication date': '2004 Aug', 'sentence': 'This PK-MB model may be very useful in optimizing treatments of various eye infections with ciprofloxacin.', 'subject score': 1000, 'object score': 901}, 'PMID:1928270': {'publication date': '1991 Oct', 'sentence': 'The growing body of experimental data supports the effectiveness of ciprofloxacin in the treatment of experimental keratitis and suggest that it be evaluated further in ocular infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:1928271': {'publication date': '1991 Oct', 'sentence': 'Topically applied ciprofloxacin eradicated or reduced all isolated bacterial species, attesting to its broad antibacterial spectrum and its potential usefulness in treating external ocular infections.', 'subject score': 827, 'object score': 861}, 'PMID:26482534': {'publication date': '2016', 'sentence': 'Ciprofloxacin is a drug active against a broad spectrum of aerobic Gram-positive and Gram-negative bacteria, for the therapy of ocular infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:26863046': {'publication date': '2017 Mar', 'sentence': 'OBJECTIVES: Ciprofloxacin (Cipro) is an antibiotic, widely used in form of ophthalmic drops (0.3%) for the treatment of eye infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:28634139': {'publication date': '2017 Aug 30', 'sentence': 'Ciprofloxacin (CIP) is an antibacterial agent prescribed for the treatment of ocular infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:3477893': {'publication date': '1986', 'sentence': 'Ciprofloxacin is a potentially useful antibiotic in eye infection.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 546977,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043885",
-          "name": "eye infectious disorder",
-          "description": "An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.; Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.; Your eyes can get infections from bacteria, fungi, or viruses. Eye infections can occur in different parts of the eye and can affect just one eye or both. Two common eye infections are:  Conjunctivitis - also known as pink eye. Conjunctivitis is often due to an infection. Children frequently get it, and it is very contagious.  Stye - a bump on the eyelid that happens when bacteria from your skin get into the hair follicle of an eyelash.  Symptoms of eye infections may include redness, itching, swelling, discharge, pain, or problems with vision. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or antibiotics.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10015929",
-            "UMLS:C0015403",
-            "MESH:D015817",
-            "MEDDRA:10015936",
-            "MONDO:0043885",
-            "SNOMEDCT:128351009",
-            "NCIT:C45372",
-            "EFO:1001888"
-          ],
-          "id": "MONDO:0043885",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Eye Infection",
-            "eye infectious disorder",
-            "eye infection",
-            "Eye Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546977,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043885",
-              "name": "eye infectious disorder",
-              "description": "An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.; Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.; Your eyes can get infections from bacteria, fungi, or viruses. Eye infections can occur in different parts of the eye and can affect just one eye or both. Two common eye infections are:  Conjunctivitis - also known as pink eye. Conjunctivitis is often due to an infection. Children frequently get it, and it is very contagious.  Stye - a bump on the eyelid that happens when bacteria from your skin get into the hair follicle of an eyelash.  Symptoms of eye infections may include redness, itching, swelling, discharge, pain, or problems with vision. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or antibiotics.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10015929",
-                "UMLS:C0015403",
-                "MESH:D015817",
-                "MEDDRA:10015936",
-                "MONDO:0043885",
-                "SNOMEDCT:128351009",
-                "NCIT:C45372",
-                "EFO:1001888"
-              ],
-              "id": "MONDO:0043885",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Eye Infection",
-                "eye infectious disorder",
-                "eye infection",
-                "Eye Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11061765,
-            "start": 616,
-            "end": 546977,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15257070': {'publication date': '2004 Aug', 'sentence': 'This PK-MB model may be very useful in optimizing treatments of various eye infections with ciprofloxacin.', 'subject score': 1000, 'object score': 901}, 'PMID:1928270': {'publication date': '1991 Oct', 'sentence': 'The growing body of experimental data supports the effectiveness of ciprofloxacin in the treatment of experimental keratitis and suggest that it be evaluated further in ocular infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:1928271': {'publication date': '1991 Oct', 'sentence': 'Topically applied ciprofloxacin eradicated or reduced all isolated bacterial species, attesting to its broad antibacterial spectrum and its potential usefulness in treating external ocular infections.', 'subject score': 827, 'object score': 861}, 'PMID:26482534': {'publication date': '2016', 'sentence': 'Ciprofloxacin is a drug active against a broad spectrum of aerobic Gram-positive and Gram-negative bacteria, for the therapy of ocular infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:26863046': {'publication date': '2017 Mar', 'sentence': 'OBJECTIVES: Ciprofloxacin (Cipro) is an antibiotic, widely used in form of ophthalmic drops (0.3%) for the treatment of eye infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:28634139': {'publication date': '2017 Aug 30', 'sentence': 'Ciprofloxacin (CIP) is an antibacterial agent prescribed for the treatment of ocular infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:3477893': {'publication date': '1986', 'sentence': 'Ciprofloxacin is a potentially useful antibiotic in eye infection.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0015403---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "11304087",
-              "object": "MONDO:0043885",
-              "publications": [
-                "PMID:15257070",
-                "PMID:1928270",
-                "PMID:1928271",
-                "PMID:26482534",
-                "PMID:26863046",
-                "PMID:28634139",
-                "PMID:3477893"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10923561': {'publication date': '2000 Jun', 'sentence': 'Is a 7-day course of ciprofloxacin effective in the treatment of uncomplicated pyelonephritis in women?', 'subject score': 1000, 'object score': 888}, 'PMID:11911553': {'publication date': '2002 Feb', 'sentence': 'OBJECTIVE: This study compared the clinical and bacteriologic efficacy and tolerability of gatifloxacin versus ciprofloxacin in adult patients with complicated UTIs or pyelonephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:12182387': {'publication date': '2002 Jun', 'sentence': 'A 14-year-old girl was seen at a community clinic with a chief complaint of abdominal pain and fevers and was treated with oral ciprofloxacin for presumed pyelonephritis.', 'subject score': 888, 'object score': 861}, 'PMID:14715044': {'publication date': '2004', 'sentence': 'Ciprofloxacin extended release: in the treatment of urinary tract infections and uncomplicated pyelonephritis.', 'subject score': 1000, 'object score': 888}, 'PMID:21410941': {'publication date': '2011 Mar 16', 'sentence': 'CASE PRESENTATION: A 22-year-old African American woman presented with a headache of two weeks duration, visual blurring and horizontal diplopia after starting ciprofloxacin for pyelonephritis.', 'subject score': 872, 'object score': 1000}, 'PMID:2181632': {'publication date': '1990', 'sentence': 'Treatment of experimental Escherichia coli pyelonephritis in rat by ciprofloxacin in comparison with tobramycin.', 'subject score': 1000, 'object score': 861}, 'PMID:22967697': {'publication date': '2012 Sep', 'sentence': 'In uncomplicated pyelonephritis, 19.5% of isolates were resistant to ciprofloxacin and 36.8% to TMP-SMX.', 'subject score': 1000, 'object score': 888}, 'PMID:23367704': {'publication date': '2013 Jan 09', 'sentence': 'The duration of treatment for uncomplicated pyelonephritis can be safely shortened to 7 days when using ciprofloxacin.', 'subject score': 1000, 'object score': 888}, 'PMID:23912522': {'publication date': '2012 Aug', 'sentence': 'CONCLUSIONS: Nitrofurantoin may be the best therapeutic option in first-line management of lower urinary tract infection and ciprofloxacin for pyelonephritis due to its effectiveness and low resistance as seen in primary healthcare practice in Pereira.', 'subject score': 1000, 'object score': 1000}, 'PMID:24034802': {'publication date': '2013 Sep', 'sentence': 'The overall susceptibility of E. coli to antibiotics recommended in the empiric treatment of pyelonephritis and prostatitis was preserved: ciprofloxacin (95.8%), cefotaxime (98%), gentamicin (99.4%).', 'subject score': 1000, 'object score': 1000}, 'PMID:25339200': {'publication date': '2015 Mar', 'sentence': 'Ciprofloxacin and cotrimoxazole are recommended to treat uncomplicated pyelonephritis and uncomplicated cystitis, respectively, provided that local resistance rates of uropathogens do not exceed specified thresholds (10 and 20 %, respectively).', 'subject score': 1000, 'object score': 888}, 'PMID:28216442': {'publication date': '2017 07', 'sentence': 'CONCLUSIONS: Our findings suggest that 7 days of TMP-SMX therapy may result in similar clinical outcomes compared with 7 days of ciprofloxacin for the treatment of pyelonephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:29253561': {'publication date': '2018 Apr', 'sentence': 'Pivmecillinam achieved success in patients with A. urinae cystitis and ciprofloxacin in patients with pyelonephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:29271346': {'publication date': '2017 12 15', 'sentence': 'Uncomplicated pyelonephritis with a mild to moderate clinical course ought to be treated with oral cefpodoxime, ceftibuten, ciprofloxacin, or levofloxacin.', 'subject score': 1000, 'object score': 888}, 'PMID:2943665': {'publication date': '1986 Jul', 'sentence': '[Ciprofloxacin and cefotaxim: pharmacokinetic and therapeutic effectiveness in E. coli pyelonephritis in rats].', 'subject score': 1000, 'object score': 901}, 'PMID:29539622': {'publication date': '2018', 'sentence': 'Mild to moderate uncomplicated pyelonephritis should be treated with oral cefpodoxime, ceftibuten, ciprofloxacin, or levofloxacin.', 'subject score': 1000, 'object score': 875}, 'PMID:31023585': {'publication date': '2019 Apr 09', 'sentence': 'Antibiotic selection and isolate susceptibility profile in patients who failed ciprofloxacin or TMP-SMX for pyelonephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:32442937': {'publication date': '2020', 'sentence': 'In women, cystitis can be treated with nitrofurantoin, cephalexin or fosfomycin, while trimethoprim-sulfamethoxazole and fluoroquinolones are not recommended; pyelonephritis can be treated with ciprofloxacin, cefixime or cephalexin in ambulatory women or ceftriaxone, cefazolin or amikacin in those who are hospitalized.', 'subject score': 1000, 'object score': 1000}, 'PMID:3325927': {'publication date': '1987 Dec 11', 'sentence': 'In the treatment of the pyelonephritis, ciprofloxacin was clearly superior to the other agents, both with respect to the percentage of sterile kidneys after treatment as with respect to the mean numbers of bacteria per kidney.', 'subject score': 1000, 'object score': 1000}, 'PMID:34167484': {'publication date': '2021 Jun 24', 'sentence': 'Treatment of pyelonephritis was characterized by more use of broader-spectrum antibiotics, use of both sulfamethoxazole-trimethoprim and ciprofloxacin increased during the study period.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317996,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006939",
-          "name": "pyelonephritis",
-          "description": "An inflammatory process affecting the kidney. The cause is most often bacterial, but may also be fungal in nature. Signs and symptoms may include fever, chills, flank pain, painful and frequent urination, cloudy or bloody urine, and confusion.; Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA.; An inflammation of the kidney involving the parenchyma of kidney, the renal pelvis and the kidney calices. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:45816000",
-            "ICD9:590.80",
-            "MEDDRA:10037604",
-            "NCIT:C34965",
-            "MONDO:0006939",
-            "MEDDRA:10037606",
-            "ICD10:N16",
-            "HP:0012330",
-            "DOID:11400",
-            "EFO:1001141",
-            "UMLS:C0034186",
-            "MESH:D011704",
-            "MEDDRA:10037596"
-          ],
-          "id": "MONDO:0006939",
-          "category": "biolink:Disease",
-          "all_names": [
-            "pyelonephritis",
-            "Pyelonephritis",
-            "Pyelonephritis, unspecified"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317996,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006939",
-              "name": "pyelonephritis",
-              "description": "An inflammatory process affecting the kidney. The cause is most often bacterial, but may also be fungal in nature. Signs and symptoms may include fever, chills, flank pain, painful and frequent urination, cloudy or bloody urine, and confusion.; Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA.; An inflammation of the kidney involving the parenchyma of kidney, the renal pelvis and the kidney calices. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:45816000",
-                "ICD9:590.80",
-                "MEDDRA:10037604",
-                "NCIT:C34965",
-                "MONDO:0006939",
-                "MEDDRA:10037606",
-                "ICD10:N16",
-                "HP:0012330",
-                "DOID:11400",
-                "EFO:1001141",
-                "UMLS:C0034186",
-                "MESH:D011704",
-                "MEDDRA:10037596"
-              ],
-              "id": "MONDO:0006939",
-              "category": "biolink:Disease",
-              "all_names": [
-                "pyelonephritis",
-                "Pyelonephritis",
-                "Pyelonephritis, unspecified"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8173809,
-            "start": 616,
-            "end": 317996,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10923561': {'publication date': '2000 Jun', 'sentence': 'Is a 7-day course of ciprofloxacin effective in the treatment of uncomplicated pyelonephritis in women?', 'subject score': 1000, 'object score': 888}, 'PMID:11911553': {'publication date': '2002 Feb', 'sentence': 'OBJECTIVE: This study compared the clinical and bacteriologic efficacy and tolerability of gatifloxacin versus ciprofloxacin in adult patients with complicated UTIs or pyelonephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:12182387': {'publication date': '2002 Jun', 'sentence': 'A 14-year-old girl was seen at a community clinic with a chief complaint of abdominal pain and fevers and was treated with oral ciprofloxacin for presumed pyelonephritis.', 'subject score': 888, 'object score': 861}, 'PMID:14715044': {'publication date': '2004', 'sentence': 'Ciprofloxacin extended release: in the treatment of urinary tract infections and uncomplicated pyelonephritis.', 'subject score': 1000, 'object score': 888}, 'PMID:21410941': {'publication date': '2011 Mar 16', 'sentence': 'CASE PRESENTATION: A 22-year-old African American woman presented with a headache of two weeks duration, visual blurring and horizontal diplopia after starting ciprofloxacin for pyelonephritis.', 'subject score': 872, 'object score': 1000}, 'PMID:2181632': {'publication date': '1990', 'sentence': 'Treatment of experimental Escherichia coli pyelonephritis in rat by ciprofloxacin in comparison with tobramycin.', 'subject score': 1000, 'object score': 861}, 'PMID:22967697': {'publication date': '2012 Sep', 'sentence': 'In uncomplicated pyelonephritis, 19.5% of isolates were resistant to ciprofloxacin and 36.8% to TMP-SMX.', 'subject score': 1000, 'object score': 888}, 'PMID:23367704': {'publication date': '2013 Jan 09', 'sentence': 'The duration of treatment for uncomplicated pyelonephritis can be safely shortened to 7 days when using ciprofloxacin.', 'subject score': 1000, 'object score': 888}, 'PMID:23912522': {'publication date': '2012 Aug', 'sentence': 'CONCLUSIONS: Nitrofurantoin may be the best therapeutic option in first-line management of lower urinary tract infection and ciprofloxacin for pyelonephritis due to its effectiveness and low resistance as seen in primary healthcare practice in Pereira.', 'subject score': 1000, 'object score': 1000}, 'PMID:24034802': {'publication date': '2013 Sep', 'sentence': 'The overall susceptibility of E. coli to antibiotics recommended in the empiric treatment of pyelonephritis and prostatitis was preserved: ciprofloxacin (95.8%), cefotaxime (98%), gentamicin (99.4%).', 'subject score': 1000, 'object score': 1000}, 'PMID:25339200': {'publication date': '2015 Mar', 'sentence': 'Ciprofloxacin and cotrimoxazole are recommended to treat uncomplicated pyelonephritis and uncomplicated cystitis, respectively, provided that local resistance rates of uropathogens do not exceed specified thresholds (10 and 20 %, respectively).', 'subject score': 1000, 'object score': 888}, 'PMID:28216442': {'publication date': '2017 07', 'sentence': 'CONCLUSIONS: Our findings suggest that 7 days of TMP-SMX therapy may result in similar clinical outcomes compared with 7 days of ciprofloxacin for the treatment of pyelonephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:29253561': {'publication date': '2018 Apr', 'sentence': 'Pivmecillinam achieved success in patients with A. urinae cystitis and ciprofloxacin in patients with pyelonephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:29271346': {'publication date': '2017 12 15', 'sentence': 'Uncomplicated pyelonephritis with a mild to moderate clinical course ought to be treated with oral cefpodoxime, ceftibuten, ciprofloxacin, or levofloxacin.', 'subject score': 1000, 'object score': 888}, 'PMID:2943665': {'publication date': '1986 Jul', 'sentence': '[Ciprofloxacin and cefotaxim: pharmacokinetic and therapeutic effectiveness in E. coli pyelonephritis in rats].', 'subject score': 1000, 'object score': 901}, 'PMID:29539622': {'publication date': '2018', 'sentence': 'Mild to moderate uncomplicated pyelonephritis should be treated with oral cefpodoxime, ceftibuten, ciprofloxacin, or levofloxacin.', 'subject score': 1000, 'object score': 875}, 'PMID:31023585': {'publication date': '2019 Apr 09', 'sentence': 'Antibiotic selection and isolate susceptibility profile in patients who failed ciprofloxacin or TMP-SMX for pyelonephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:32442937': {'publication date': '2020', 'sentence': 'In women, cystitis can be treated with nitrofurantoin, cephalexin or fosfomycin, while trimethoprim-sulfamethoxazole and fluoroquinolones are not recommended; pyelonephritis can be treated with ciprofloxacin, cefixime or cephalexin in ambulatory women or ceftriaxone, cefazolin or amikacin in those who are hospitalized.', 'subject score': 1000, 'object score': 1000}, 'PMID:3325927': {'publication date': '1987 Dec 11', 'sentence': 'In the treatment of the pyelonephritis, ciprofloxacin was clearly superior to the other agents, both with respect to the percentage of sterile kidneys after treatment as with respect to the mean numbers of bacteria per kidney.', 'subject score': 1000, 'object score': 1000}, 'PMID:34167484': {'publication date': '2021 Jun 24', 'sentence': 'Treatment of pyelonephritis was characterized by more use of broader-spectrum antibiotics, use of both sulfamethoxazole-trimethoprim and ciprofloxacin increased during the study period.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0034186---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8350437",
-              "object": "MONDO:0006939",
-              "publications": [
-                "PMID:10923561",
-                "PMID:11911553",
-                "PMID:12182387",
-                "PMID:14715044",
-                "PMID:21410941",
-                "PMID:2181632",
-                "PMID:22967697",
-                "PMID:23367704",
-                "PMID:23912522",
-                "PMID:24034802",
-                "PMID:25339200",
-                "PMID:28216442",
-                "PMID:29253561",
-                "PMID:29271346",
-                "PMID:2943665",
-                "PMID:29539622",
-                "PMID:31023585",
-                "PMID:32442937",
-                "PMID:3325927",
-                "PMID:34167484"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:8913458': {'publication date': '1996 Nov', 'sentence': 'In the present murine model of pyelonephritis, levofloxacin was superior to ciprofloxacin in preventing pyelonephritis and eradicating S. aureus.', 'subject score': 1000, 'object score': 872}}",
-    "p2": {
-      "start": {
-        "identity": 317996,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006939",
-          "name": "pyelonephritis",
-          "description": "An inflammatory process affecting the kidney. The cause is most often bacterial, but may also be fungal in nature. Signs and symptoms may include fever, chills, flank pain, painful and frequent urination, cloudy or bloody urine, and confusion.; Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA.; An inflammation of the kidney involving the parenchyma of kidney, the renal pelvis and the kidney calices. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:45816000",
-            "ICD9:590.80",
-            "MEDDRA:10037604",
-            "NCIT:C34965",
-            "MONDO:0006939",
-            "MEDDRA:10037606",
-            "ICD10:N16",
-            "HP:0012330",
-            "DOID:11400",
-            "EFO:1001141",
-            "UMLS:C0034186",
-            "MESH:D011704",
-            "MEDDRA:10037596"
-          ],
-          "id": "MONDO:0006939",
-          "category": "biolink:Disease",
-          "all_names": [
-            "pyelonephritis",
-            "Pyelonephritis",
-            "Pyelonephritis, unspecified"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317996,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006939",
-              "name": "pyelonephritis",
-              "description": "An inflammatory process affecting the kidney. The cause is most often bacterial, but may also be fungal in nature. Signs and symptoms may include fever, chills, flank pain, painful and frequent urination, cloudy or bloody urine, and confusion.; Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA.; An inflammation of the kidney involving the parenchyma of kidney, the renal pelvis and the kidney calices. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:45816000",
-                "ICD9:590.80",
-                "MEDDRA:10037604",
-                "NCIT:C34965",
-                "MONDO:0006939",
-                "MEDDRA:10037606",
-                "ICD10:N16",
-                "HP:0012330",
-                "DOID:11400",
-                "EFO:1001141",
-                "UMLS:C0034186",
-                "MESH:D011704",
-                "MEDDRA:10037596"
-              ],
-              "id": "MONDO:0006939",
-              "category": "biolink:Disease",
-              "all_names": [
-                "pyelonephritis",
-                "Pyelonephritis",
-                "Pyelonephritis, unspecified"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26773748,
-            "start": 616,
-            "end": 317996,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8913458': {'publication date': '1996 Nov', 'sentence': 'In the present murine model of pyelonephritis, levofloxacin was superior to ciprofloxacin in preventing pyelonephritis and eradicating S. aureus.', 'subject score': 1000, 'object score': 872}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:prevents---None---None---None---UMLS:C0034186---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "27242944",
-              "object": "MONDO:0006939",
-              "publications": [
-                "PMID:8913458"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:1403066': {'publication date': '1992 Feb', 'sentence': 'The achieved concentrations are above the minimum inhibitory concentrations (MICs) of ciprofloxacin for most gram-negative bacteria commonly involved in intra-abdominal infections.', 'subject score': 1000, 'object score': 983}, 'PMID:9609412': {'publication date': '1998 Apr', 'sentence': 'Bioavailability of ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections.', 'subject score': 1000, 'object score': 845}}",
-    "p2": {
-      "start": {
-        "identity": 853607,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C1112209",
-          "name": "Abdominal Infection",
-          "description": "Infection in the abdominal cavity resulting from injury, acute intestinal inflammation (e.g., acute appendicitis), intestinal perforation, or complication of abdominal surgery.; Infection within the PERITONEAL CAVITY. A frequent cause is an ANASTOMOTIC LEAK following surgery.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D059413",
-            "UMLS:C1112209",
-            "MEDDRA:10056570",
-            "SNOMEDCT:128070006",
-            "NCIT:C35669",
-            "MEDDRA:10056519"
-          ],
-          "id": "UMLS:C1112209",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Abdominal Infection",
-            "Intraabdominal Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 853607,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C1112209",
-              "name": "Abdominal Infection",
-              "description": "Infection in the abdominal cavity resulting from injury, acute intestinal inflammation (e.g., acute appendicitis), intestinal perforation, or complication of abdominal surgery.; Infection within the PERITONEAL CAVITY. A frequent cause is an ANASTOMOTIC LEAK following surgery.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D059413",
-                "UMLS:C1112209",
-                "MEDDRA:10056570",
-                "SNOMEDCT:128070006",
-                "NCIT:C35669",
-                "MEDDRA:10056519"
-              ],
-              "id": "UMLS:C1112209",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Abdominal Infection",
-                "Intraabdominal Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10442619,
-            "start": 616,
-            "end": 853607,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1403066': {'publication date': '1992 Feb', 'sentence': 'The achieved concentrations are above the minimum inhibitory concentrations (MICs) of ciprofloxacin for most gram-negative bacteria commonly involved in intra-abdominal infections.', 'subject score': 1000, 'object score': 983}, 'PMID:9609412': {'publication date': '1998 Apr', 'sentence': 'Bioavailability of ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections.', 'subject score': 1000, 'object score': 845}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C1112209---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "10672042",
-              "object": "UMLS:C1112209",
-              "publications": [
-                "PMID:1403066",
-                "PMID:9609412"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11414382': {'publication date': '2000 Jan', 'sentence': 'Ciprofloxacin is effective in the treatment of serious, non-self-limiting intra-abdominal infections, peritonitis in CAPD, pelvic inflammatory disease, endometritis and gall-bladder infections.', 'subject score': 1000, 'object score': 786}, 'PMID:15598473': {'publication date': '2004 Oct', 'sentence': 'METHODS: We review 2 prospective, comparative clinical trials conducted between 1992 and 2002 that evaluated the efficacy and safety of IV ciprofloxacin in patients with intra-abdominal infections.', 'subject score': 888, 'object score': 983}, 'PMID:33667704': {'publication date': '2021 Mar 02', 'sentence': 'Susceptibility to broad-spectrum antibiotics (metronidazole, meropenem, ciprofloxacin, clindamycin and tetracycline) most commonly used for the treatment of intra-abdominal infections (IAIs) was determined.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 853607,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C1112209",
-          "name": "Abdominal Infection",
-          "description": "Infection in the abdominal cavity resulting from injury, acute intestinal inflammation (e.g., acute appendicitis), intestinal perforation, or complication of abdominal surgery.; Infection within the PERITONEAL CAVITY. A frequent cause is an ANASTOMOTIC LEAK following surgery.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D059413",
-            "UMLS:C1112209",
-            "MEDDRA:10056570",
-            "SNOMEDCT:128070006",
-            "NCIT:C35669",
-            "MEDDRA:10056519"
-          ],
-          "id": "UMLS:C1112209",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Abdominal Infection",
-            "Intraabdominal Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 853607,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C1112209",
-              "name": "Abdominal Infection",
-              "description": "Infection in the abdominal cavity resulting from injury, acute intestinal inflammation (e.g., acute appendicitis), intestinal perforation, or complication of abdominal surgery.; Infection within the PERITONEAL CAVITY. A frequent cause is an ANASTOMOTIC LEAK following surgery.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D059413",
-                "UMLS:C1112209",
-                "MEDDRA:10056570",
-                "SNOMEDCT:128070006",
-                "NCIT:C35669",
-                "MEDDRA:10056519"
-              ],
-              "id": "UMLS:C1112209",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Abdominal Infection",
-                "Intraabdominal Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8753729,
-            "start": 616,
-            "end": 853607,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11414382': {'publication date': '2000 Jan', 'sentence': 'Ciprofloxacin is effective in the treatment of serious, non-self-limiting intra-abdominal infections, peritonitis in CAPD, pelvic inflammatory disease, endometritis and gall-bladder infections.', 'subject score': 1000, 'object score': 786}, 'PMID:15598473': {'publication date': '2004 Oct', 'sentence': 'METHODS: We review 2 prospective, comparative clinical trials conducted between 1992 and 2002 that evaluated the efficacy and safety of IV ciprofloxacin in patients with intra-abdominal infections.', 'subject score': 888, 'object score': 983}, 'PMID:33667704': {'publication date': '2021 Mar 02', 'sentence': 'Susceptibility to broad-spectrum antibiotics (metronidazole, meropenem, ciprofloxacin, clindamycin and tetracycline) most commonly used for the treatment of intra-abdominal infections (IAIs) was determined.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C1112209---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8956827",
-              "object": "UMLS:C1112209",
-              "publications": [
-                "PMID:11414382",
-                "PMID:15598473",
-                "PMID:33667704"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12019482': {'publication date': '2002', 'sentence': 'The objective of this study was to evaluate and compare the efficacy of topical otic powder, tobramycin drops and ciprofloxacin drops in patients suffering from AEO.', 'subject score': 1000, 'object score': 901}, 'PMID:15529649': {'publication date': '2004 Sep', 'sentence': 'On the basis of our findings, we conclude that the glycerin formulation of ototopical 0.3% ciprofloxacin appears to be at least as effective as the aqueous form in the treatment of acute external otitis--and in the case of otorrhea, more so.', 'subject score': 812, 'object score': 901}, 'PMID:1554468': {'publication date': '1992 Apr', 'sentence': 'Recent studies have shown oral ciprofloxacin to be effective in the treatment of chronic serous otitis media and malignant external otitis.', 'subject score': 888, 'object score': 901}, 'PMID:18314283': {'publication date': '2008 Dec', 'sentence': 'CONCLUSION: Polymixin B, gentamicin or ciprofloxacin topical preparations should be used as first line treatment of otitis externa.', 'subject score': 896, 'object score': 1000}, 'PMID:22810173': {'publication date': '2012 Dec', 'sentence': 'We suggest 3 weeks of initial combination therapy (ceftazidime + ciprofloxacin, high doses) followed by 3 weeks single therapy with ciprofloxacin in susceptible P. aeruginosa NEO.', 'subject score': 1000, 'object score': 839}, 'PMID:2313132': {'publication date': '1990 Mar', 'sentence': 'Twenty-three consecutive patients with malignant external otitis (MEO) were treated with oral ciprofloxacin, 1.5-2.25 g/day for 6 weeks.', 'subject score': 888, 'object score': 901}, 'PMID:23274083': {'publication date': '2014 Jun', 'sentence': 'Investigation of the effectiveness of Syzygium aromaticum, Lavandula angustifolia and Geranium robertianum essential oils in the treatment of acute external otitis: a comparative trial with ciprofloxacin.', 'subject score': 1000, 'object score': 901}, 'PMID:2589357': {'publication date': '1989 Nov 30', 'sentence': 'Ciprofloxacin treatment of malignant external otitis.', 'subject score': 888, 'object score': 901}, 'PMID:29018494': {'publication date': '2017 Oct', 'sentence': 'Objective  The objective of this study is to evaluate the clinical and microbiological efficacy and safety profile with oral ciprofloxacin in the external bacterial otitis (EBO) management.', 'subject score': 888, 'object score': 861}, 'PMID:3177762': {'publication date': '1988 May-Jun', 'sentence': 'This report is the first of which we are aware to document the use of Ciprofloxacin in the treatment of MEO.', 'subject score': 1000, 'object score': 901}, 'PMID:3411213': {'publication date': '1988 Jul', 'sentence': 'The authors report a case of necrotizing external otitis which was successfully treated with ciprofloxacin.', 'subject score': 1000, 'object score': 901}, 'PMID:7805430': {'publication date': '1994', 'sentence': 'Ciprofloxacin thus seems to be a particularly useful antibiotic for the treatment of malignant external otitis, both because of its clinical and bacteriological efficacy and because it is well tolerated.', 'subject score': 1000, 'object score': 901}, 'PMID:8186542': {'publication date': '1994 Feb', 'sentence': 'Initial trials have also indicated therapeutic efficacy of oral ciprofloxacin in malignant external otitis and bacterial prostatitis.', 'subject score': 888, 'object score': 901}, 'PMID:8924287': {'publication date': '1996', 'sentence': '[Prospective double-blind randomized study of the efficacy and tolerance of topical ciprofloxacin vs topical gentamicin in the treatment of simple chronic otitis media and diffuse external otitis].', 'subject score': 861, 'object score': 901}, 'PMID:9484874': {'publication date': '1997 Dec', 'sentence': 'Ciprofloxacin is the drug of choice for malignant external otitis, a disease caused by Pseudomonas aeruginosa, and it has also been used successfully for the treatment of chronic otitis media where P. aeruginosa, S. aureus and Proteus mirabilis are main pathogens.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 314857,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004795",
-          "name": "otitis externa",
-          "description": "Inflammation of the anatomical structures of the outer ear and ear canal, which is most often caused by an infectious process. Symptoms include erythema, edema, and pain.; Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.; Inflammation or infection of the external auditory canal (EAC), the auricle, or both. [http://search.medscape.com/search/?q=otitis%20externa, ORCID:0000-0001-5208-3432]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021919",
-            "NCIT:C79601",
-            "MESH:D010032",
-            "SNOMEDCT:3135009",
-            "MEDDRA:10052558",
-            "NCIT:C3299",
-            "MEDDRA:10021920",
-            "UMLS:C0029878",
-            "UMLS:C0021355",
-            "MEDDRA:10065837",
-            "HP:0410017",
-            "MEDDRA:10033072",
-            "MEDDRA:10082612",
-            "EFO:0009560",
-            "DOID:9463",
-            "ICD9:380.1",
-            "SNOMEDCT:86981007",
-            "MONDO:0004795"
-          ],
-          "id": "MONDO:0004795",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infective otitis externa",
-            "Otitis Externa",
-            "Otitis externa",
-            "otitis externa",
-            "Infectious Otitis Externa"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/otitis_externa",
-            "http://search.medscape.com/search/?q=otitis%20externa",
-            "https://orcid.org/0000-0001-5208-3432"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314857,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004795",
-              "name": "otitis externa",
-              "description": "Inflammation of the anatomical structures of the outer ear and ear canal, which is most often caused by an infectious process. Symptoms include erythema, edema, and pain.; Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.; Inflammation or infection of the external auditory canal (EAC), the auricle, or both. [http://search.medscape.com/search/?q=otitis%20externa, ORCID:0000-0001-5208-3432]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021919",
-                "NCIT:C79601",
-                "MESH:D010032",
-                "SNOMEDCT:3135009",
-                "MEDDRA:10052558",
-                "NCIT:C3299",
-                "MEDDRA:10021920",
-                "UMLS:C0029878",
-                "UMLS:C0021355",
-                "MEDDRA:10065837",
-                "HP:0410017",
-                "MEDDRA:10033072",
-                "MEDDRA:10082612",
-                "EFO:0009560",
-                "DOID:9463",
-                "ICD9:380.1",
-                "SNOMEDCT:86981007",
-                "MONDO:0004795"
-              ],
-              "id": "MONDO:0004795",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infective otitis externa",
-                "Otitis Externa",
-                "Otitis externa",
-                "otitis externa",
-                "Infectious Otitis Externa"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/otitis_externa",
-                "http://search.medscape.com/search/?q=otitis%20externa",
-                "https://orcid.org/0000-0001-5208-3432"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9345912,
-            "start": 616,
-            "end": 314857,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12019482': {'publication date': '2002', 'sentence': 'The objective of this study was to evaluate and compare the efficacy of topical otic powder, tobramycin drops and ciprofloxacin drops in patients suffering from AEO.', 'subject score': 1000, 'object score': 901}, 'PMID:15529649': {'publication date': '2004 Sep', 'sentence': 'On the basis of our findings, we conclude that the glycerin formulation of ototopical 0.3% ciprofloxacin appears to be at least as effective as the aqueous form in the treatment of acute external otitis--and in the case of otorrhea, more so.', 'subject score': 812, 'object score': 901}, 'PMID:1554468': {'publication date': '1992 Apr', 'sentence': 'Recent studies have shown oral ciprofloxacin to be effective in the treatment of chronic serous otitis media and malignant external otitis.', 'subject score': 888, 'object score': 901}, 'PMID:18314283': {'publication date': '2008 Dec', 'sentence': 'CONCLUSION: Polymixin B, gentamicin or ciprofloxacin topical preparations should be used as first line treatment of otitis externa.', 'subject score': 896, 'object score': 1000}, 'PMID:22810173': {'publication date': '2012 Dec', 'sentence': 'We suggest 3 weeks of initial combination therapy (ceftazidime + ciprofloxacin, high doses) followed by 3 weeks single therapy with ciprofloxacin in susceptible P. aeruginosa NEO.', 'subject score': 1000, 'object score': 839}, 'PMID:2313132': {'publication date': '1990 Mar', 'sentence': 'Twenty-three consecutive patients with malignant external otitis (MEO) were treated with oral ciprofloxacin, 1.5-2.25 g/day for 6 weeks.', 'subject score': 888, 'object score': 901}, 'PMID:23274083': {'publication date': '2014 Jun', 'sentence': 'Investigation of the effectiveness of Syzygium aromaticum, Lavandula angustifolia and Geranium robertianum essential oils in the treatment of acute external otitis: a comparative trial with ciprofloxacin.', 'subject score': 1000, 'object score': 901}, 'PMID:2589357': {'publication date': '1989 Nov 30', 'sentence': 'Ciprofloxacin treatment of malignant external otitis.', 'subject score': 888, 'object score': 901}, 'PMID:29018494': {'publication date': '2017 Oct', 'sentence': 'Objective  The objective of this study is to evaluate the clinical and microbiological efficacy and safety profile with oral ciprofloxacin in the external bacterial otitis (EBO) management.', 'subject score': 888, 'object score': 861}, 'PMID:3177762': {'publication date': '1988 May-Jun', 'sentence': 'This report is the first of which we are aware to document the use of Ciprofloxacin in the treatment of MEO.', 'subject score': 1000, 'object score': 901}, 'PMID:3411213': {'publication date': '1988 Jul', 'sentence': 'The authors report a case of necrotizing external otitis which was successfully treated with ciprofloxacin.', 'subject score': 1000, 'object score': 901}, 'PMID:7805430': {'publication date': '1994', 'sentence': 'Ciprofloxacin thus seems to be a particularly useful antibiotic for the treatment of malignant external otitis, both because of its clinical and bacteriological efficacy and because it is well tolerated.', 'subject score': 1000, 'object score': 901}, 'PMID:8186542': {'publication date': '1994 Feb', 'sentence': 'Initial trials have also indicated therapeutic efficacy of oral ciprofloxacin in malignant external otitis and bacterial prostatitis.', 'subject score': 888, 'object score': 901}, 'PMID:8924287': {'publication date': '1996', 'sentence': '[Prospective double-blind randomized study of the efficacy and tolerance of topical ciprofloxacin vs topical gentamicin in the treatment of simple chronic otitis media and diffuse external otitis].', 'subject score': 861, 'object score': 901}, 'PMID:9484874': {'publication date': '1997 Dec', 'sentence': 'Ciprofloxacin is the drug of choice for malignant external otitis, a disease caused by Pseudomonas aeruginosa, and it has also been used successfully for the treatment of chronic otitis media where P. aeruginosa, S. aureus and Proteus mirabilis are main pathogens.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0029878---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "9552171",
-              "object": "MONDO:0004795",
-              "publications": [
-                "PMID:12019482",
-                "PMID:15529649",
-                "PMID:1554468",
-                "PMID:18314283",
-                "PMID:22810173",
-                "PMID:2313132",
-                "PMID:23274083",
-                "PMID:2589357",
-                "PMID:29018494",
-                "PMID:3177762",
-                "PMID:3411213",
-                "PMID:7805430",
-                "PMID:8186542",
-                "PMID:8924287",
-                "PMID:9484874"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:3583969': {'publication date': '1987 Apr', 'sentence': 'The mean peak dialysate level (2.17 +/- 1.63 mg/l) exceeded the MIC of ciprofloxacin for 32 of 34 bacterial strains responsible for peritonitis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319329,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004522",
-          "name": "peritonitis",
-          "description": "Inflammation of the peritoneum due to infection by bacteria or fungi. Causes include liver disease, perforation of the gastrointestinal tract or biliary tract, and peritoneal dialysis. Patients usually present with abdominal pain and tenderness, fever, chills, and nausea and vomiting. It is an emergency medical condition that requires prompt medical attention and treatment.; INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.; Inflammation of the peritoneum. [HPO:probinson]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "UMLS:C0029823",
-            "MESH:D010538",
-            "MEDDRA:10034685",
-            "MEDDRA:10085062",
-            "SYMP:0000102",
-            "EFO:0008588",
-            "DOID:8283",
-            "HP:0002586",
-            "ICD9:567.8",
-            "MEDDRA:10046096",
-            "UMLS:C0267770",
-            "SNOMEDCT:86422009",
-            "MONDO:0004522",
-            "MEDDRA:10034674",
-            "ICD9:567.89",
-            "UMLS:C0031154",
-            "SNOMEDCT:48661000",
-            "NCIT:C26849"
-          ],
-          "id": "MONDO:0004522",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peritonitis",
-            "Other specified peritonitis",
-            "peritonitis",
-            "Retractile Mesenteritis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.merck.com/mmpe/sec02/ch011/ch011b.html#sec02-ch011-ch011b-402",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=peritonitis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/001335.htm",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319329,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004522",
-              "name": "peritonitis",
-              "description": "Inflammation of the peritoneum due to infection by bacteria or fungi. Causes include liver disease, perforation of the gastrointestinal tract or biliary tract, and peritoneal dialysis. Patients usually present with abdominal pain and tenderness, fever, chills, and nausea and vomiting. It is an emergency medical condition that requires prompt medical attention and treatment.; INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.; Inflammation of the peritoneum. [HPO:probinson]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "UMLS:C0029823",
-                "MESH:D010538",
-                "MEDDRA:10034685",
-                "MEDDRA:10085062",
-                "SYMP:0000102",
-                "EFO:0008588",
-                "DOID:8283",
-                "HP:0002586",
-                "ICD9:567.8",
-                "MEDDRA:10046096",
-                "UMLS:C0267770",
-                "SNOMEDCT:86422009",
-                "MONDO:0004522",
-                "MEDDRA:10034674",
-                "ICD9:567.89",
-                "UMLS:C0031154",
-                "SNOMEDCT:48661000",
-                "NCIT:C26849"
-              ],
-              "id": "MONDO:0004522",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peritonitis",
-                "Other specified peritonitis",
-                "peritonitis",
-                "Retractile Mesenteritis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.merck.com/mmpe/sec02/ch011/ch011b.html#sec02-ch011-ch011b-402",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=peritonitis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/001335.htm",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24272852,
-            "start": 616,
-            "end": 319329,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3583969': {'publication date': '1987 Apr', 'sentence': 'The mean peak dialysate level (2.17 +/- 1.63 mg/l) exceeded the MIC of ciprofloxacin for 32 of 34 bacterial strains responsible for peritonitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:causes---None---None---None---UMLS:C0031154---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "24716241",
-              "object": "MONDO:0004522",
-              "publications": [
-                "PMID:3583969"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 319601,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10809245': {'publication date': '2000', 'sentence': 'Peritonitis due to S. aureus ESI was significantly less frequent among patients treated with ciprofloxacin (1 vs 9 cases, p = 0.001).', 'subject score': 1000, 'object score': 1000}, 'PMID:11330568': {'publication date': '2001 Mar-Apr', 'sentence': 'Oral ciprofloxacin is ineffective in culture-negative peritonitis.', 'subject score': 888, 'object score': 901}, 'PMID:1304132': {'publication date': '1992 Dec', 'sentence': 'Forty two patients with general peritonitis were treated with ciprofloxacin and combinations of various antimicrobial drugs.', 'subject score': 1000, 'object score': 888}, 'PMID:15490984': {'publication date': '2004', 'sentence': 'OBJECTIVES: (1) To determine the pharmacokinetics of oral ciprofloxacin in CCPD patients, (2) to compare serum and dialysate ciprofloxacin concentrations with minimum inhibitory concentrations (MIC) of the gram-negative bacteria associated with peritonitis, and (3) to establish oral ciprofloxacin dosing guidelines for the empirical treatment of peritonitis in patients receiving CCPD.', 'subject score': 851, 'object score': 1000}, 'PMID:1769932': {'publication date': '1991 Jul', 'sentence': 'Low dose intraperitoneal ciprofloxacin for the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD).', 'subject score': 861, 'object score': 1000}, 'PMID:17984438': {'publication date': '2007 Nov-Dec', 'sentence': 'Ciprofloxacin for peritonitis due to gram-negative rods?', 'subject score': 1000, 'object score': 1000}, 'PMID:1912018': {'publication date': '1991', 'sentence': 'Ciprofloxacin in the treatment of gram-positive bacterial peritonitis in patients undergoing CAPD.', 'subject score': 1000, 'object score': 892}, 'PMID:19458304': {'publication date': '2009', 'sentence': 'AIM: To analyze the results of a protocol of treatment of PD-related peritonitis with ciprofloxacin, maintained over two decades.', 'subject score': 1000, 'object score': 861}, 'PMID:1982789': {'publication date': '1990', 'sentence': 'We conclude that ciprofloxacin may be useful for the treatment of CAPD peritonitis.', 'subject score': 1000, 'object score': 888}, 'PMID:2197264': {'publication date': '1990 May', 'sentence': 'Ciprofloxacin was evaluated as single-agent therapy for the empirical treatment of patients presenting with CAPD peritonitis in an open, uncontrolled trial.', 'subject score': 1000, 'object score': 928}, 'PMID:2209631': {'publication date': '1990 Aug', 'sentence': 'Pseudomonas paucimobilis peritonitis in a patient on CAPD successfully treated with ciprofloxacin and netilmicin.', 'subject score': 1000, 'object score': 901}, 'PMID:2211442': {'publication date': '1990 Jul', 'sentence': 'Short course ciprofloxacin therapy for CAPD peritonitis.', 'subject score': 833, 'object score': 888}, 'PMID:2292546': {'publication date': '1990 Dec', 'sentence': 'The advantages of oral drug administration indicate that oral ciprofloxacin is the preferred first-line treatment of CAPD-associated peritonitis.', 'subject score': 888, 'object score': 802}, 'PMID:2292547': {'publication date': '1990 Dec', 'sentence': 'Fifty-one patients were included in a prospective, randomized comparison of oral ciprofloxacin and intraperitoneal vancomycin/gentamicin in the treatment of CAPD peritonitis.', 'subject score': 888, 'object score': 888}, 'PMID:2292548': {'publication date': '1990 Dec', 'sentence': 'A comparison between intraperitoneal ciprofloxacin and intraperitoneal vancomycin and gentamicin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD).', 'subject score': 888, 'object score': 1000}, 'PMID:2338420': {'publication date': '1990 Mar', 'sentence': 'Overall a single course of oral ciprofloxacin was 76% successful as a first-line treatment for CAPD-associated peritonitis, caused by a wide range of organisms.', 'subject score': 888, 'object score': 802}, 'PMID:2510089': {'publication date': '1989', 'sentence': 'Treatment of CAPD peritonitis with oral ciprofloxacin.', 'subject score': 888, 'object score': 888}, 'PMID:2613610': {'publication date': '1989 Oct', 'sentence': 'Intraperitoneal treatment of CAPD peritonitis with ciprofloxacin.', 'subject score': 1000, 'object score': 888}, 'PMID:28360373': {'publication date': '2017 Mar-Apr', 'sentence': 'We herein report a case of peritonitis due to M. morganii resistant to third-generation cephalosporins, which was treated successfully with intraperitoneal (IP) tobramycin followed by oral ciprofloxacin.', 'subject score': 888, 'object score': 1000}, 'PMID:29437143': {'publication date': '2018 Jul-Aug', 'sentence': 'Treatment of Acinetobacter peritonitis with gentamicin, ciprofloxacin, or ceftazidime achieved comparable outcomes.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 319329,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005280",
-          "name": "prostatitis",
-          "description": "An infectious or non-infectious inflammatory process affecting the prostate gland.; Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.; The presence of inflammation of the prostate. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10036978",
-            "MONDO:0005280",
-            "EFO:0003830",
-            "HP:0000024",
-            "NCIT:C26866",
-            "SNOMEDCT:9713002",
-            "DOID:14654",
-            "MEDDRA:10036982",
-            "ICD10:N41.9",
-            "MESH:D011472",
-            "ICD9:601.9",
-            "UMLS:C0033581"
-          ],
-          "id": "MONDO:0005280",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Prostatitis",
-            "Prostatitis, unspecified",
-            "prostatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0001-5208-3432",
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004522",
-          "name": "peritonitis",
-          "description": "Inflammation of the peritoneum due to infection by bacteria or fungi. Causes include liver disease, perforation of the gastrointestinal tract or biliary tract, and peritoneal dialysis. Patients usually present with abdominal pain and tenderness, fever, chills, and nausea and vomiting. It is an emergency medical condition that requires prompt medical attention and treatment.; INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.; Inflammation of the peritoneum. [HPO:probinson]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "UMLS:C0029823",
-            "MESH:D010538",
-            "MEDDRA:10034685",
-            "MEDDRA:10085062",
-            "SYMP:0000102",
-            "EFO:0008588",
-            "DOID:8283",
-            "HP:0002586",
-            "ICD9:567.8",
-            "MEDDRA:10046096",
-            "UMLS:C0267770",
-            "SNOMEDCT:86422009",
-            "MONDO:0004522",
-            "MEDDRA:10034674",
-            "ICD9:567.89",
-            "UMLS:C0031154",
-            "SNOMEDCT:48661000",
-            "NCIT:C26849"
-          ],
-          "id": "MONDO:0004522",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peritonitis",
-            "Other specified peritonitis",
-            "peritonitis",
-            "Retractile Mesenteritis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.merck.com/mmpe/sec02/ch011/ch011b.html#sec02-ch011-ch011b-402",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=peritonitis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/001335.htm",
->>>>>>> main
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 319601,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005280",
-              "name": "prostatitis",
-              "description": "An infectious or non-infectious inflammatory process affecting the prostate gland.; Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.; The presence of inflammation of the prostate. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10036978",
-                "MONDO:0005280",
-                "EFO:0003830",
-                "HP:0000024",
-                "NCIT:C26866",
-                "SNOMEDCT:9713002",
-                "DOID:14654",
-                "MEDDRA:10036982",
-                "ICD10:N41.9",
-                "MESH:D011472",
-                "ICD9:601.9",
-                "UMLS:C0033581"
-              ],
-              "id": "MONDO:0005280",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Prostatitis",
-                "Prostatitis, unspecified",
-                "prostatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0001-5208-3432",
-=======
-            "identity": 319329,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004522",
-              "name": "peritonitis",
-              "description": "Inflammation of the peritoneum due to infection by bacteria or fungi. Causes include liver disease, perforation of the gastrointestinal tract or biliary tract, and peritoneal dialysis. Patients usually present with abdominal pain and tenderness, fever, chills, and nausea and vomiting. It is an emergency medical condition that requires prompt medical attention and treatment.; INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.; Inflammation of the peritoneum. [HPO:probinson]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "UMLS:C0029823",
-                "MESH:D010538",
-                "MEDDRA:10034685",
-                "MEDDRA:10085062",
-                "SYMP:0000102",
-                "EFO:0008588",
-                "DOID:8283",
-                "HP:0002586",
-                "ICD9:567.8",
-                "MEDDRA:10046096",
-                "UMLS:C0267770",
-                "SNOMEDCT:86422009",
-                "MONDO:0004522",
-                "MEDDRA:10034674",
-                "ICD9:567.89",
-                "UMLS:C0031154",
-                "SNOMEDCT:48661000",
-                "NCIT:C26849"
-              ],
-              "id": "MONDO:0004522",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peritonitis",
-                "Other specified peritonitis",
-                "peritonitis",
-                "Retractile Mesenteritis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.merck.com/mmpe/sec02/ch011/ch011b.html#sec02-ch011-ch011b-402",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=peritonitis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/001335.htm",
->>>>>>> main
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 16808136,
-            "start": 616,
-            "end": 319601,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:24044110': {'publication date': '2013 Aug', 'sentence': 'After the induction of prostatitis, the rats were randomly divided into one of four treatment groups: control (n=8), ciprofloxacin (n=8), WSY-1075 (100 mg/kg) (n=8), and WSY-1075 (400 mg/kg) (n=8).', 'subject score': 1000, 'object score': 1000}, 'PMID:28053947': {'publication date': '2016 Dec', 'sentence': 'After the induction of prostatitis, the rats were randomly divided into one of 4 treatment groups: control (n=8), ciprofloxacin (n=8), WSY-1075 (400 mg/kg) (n=8), and WSY-1075 (400 mg/kg)+ciprofloxacin (n=8).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:causes---None---None---None---UMLS:C0033581---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "17154464",
-              "object": "MONDO:0005280",
-              "publications": [
-                "PMID:24044110",
-                "PMID:28053947"
-=======
-            "identity": 8018541,
-            "start": 616,
-            "end": 319329,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10809245': {'publication date': '2000', 'sentence': 'Peritonitis due to S. aureus ESI was significantly less frequent among patients treated with ciprofloxacin (1 vs 9 cases, p = 0.001).', 'subject score': 1000, 'object score': 1000}, 'PMID:11330568': {'publication date': '2001 Mar-Apr', 'sentence': 'Oral ciprofloxacin is ineffective in culture-negative peritonitis.', 'subject score': 888, 'object score': 901}, 'PMID:1304132': {'publication date': '1992 Dec', 'sentence': 'Forty two patients with general peritonitis were treated with ciprofloxacin and combinations of various antimicrobial drugs.', 'subject score': 1000, 'object score': 888}, 'PMID:15490984': {'publication date': '2004', 'sentence': 'OBJECTIVES: (1) To determine the pharmacokinetics of oral ciprofloxacin in CCPD patients, (2) to compare serum and dialysate ciprofloxacin concentrations with minimum inhibitory concentrations (MIC) of the gram-negative bacteria associated with peritonitis, and (3) to establish oral ciprofloxacin dosing guidelines for the empirical treatment of peritonitis in patients receiving CCPD.', 'subject score': 851, 'object score': 1000}, 'PMID:1769932': {'publication date': '1991 Jul', 'sentence': 'Low dose intraperitoneal ciprofloxacin for the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD).', 'subject score': 861, 'object score': 1000}, 'PMID:17984438': {'publication date': '2007 Nov-Dec', 'sentence': 'Ciprofloxacin for peritonitis due to gram-negative rods?', 'subject score': 1000, 'object score': 1000}, 'PMID:1912018': {'publication date': '1991', 'sentence': 'Ciprofloxacin in the treatment of gram-positive bacterial peritonitis in patients undergoing CAPD.', 'subject score': 1000, 'object score': 892}, 'PMID:19458304': {'publication date': '2009', 'sentence': 'AIM: To analyze the results of a protocol of treatment of PD-related peritonitis with ciprofloxacin, maintained over two decades.', 'subject score': 1000, 'object score': 861}, 'PMID:1982789': {'publication date': '1990', 'sentence': 'We conclude that ciprofloxacin may be useful for the treatment of CAPD peritonitis.', 'subject score': 1000, 'object score': 888}, 'PMID:2197264': {'publication date': '1990 May', 'sentence': 'Ciprofloxacin was evaluated as single-agent therapy for the empirical treatment of patients presenting with CAPD peritonitis in an open, uncontrolled trial.', 'subject score': 1000, 'object score': 928}, 'PMID:2209631': {'publication date': '1990 Aug', 'sentence': 'Pseudomonas paucimobilis peritonitis in a patient on CAPD successfully treated with ciprofloxacin and netilmicin.', 'subject score': 1000, 'object score': 901}, 'PMID:2211442': {'publication date': '1990 Jul', 'sentence': 'Short course ciprofloxacin therapy for CAPD peritonitis.', 'subject score': 833, 'object score': 888}, 'PMID:2292546': {'publication date': '1990 Dec', 'sentence': 'The advantages of oral drug administration indicate that oral ciprofloxacin is the preferred first-line treatment of CAPD-associated peritonitis.', 'subject score': 888, 'object score': 802}, 'PMID:2292547': {'publication date': '1990 Dec', 'sentence': 'Fifty-one patients were included in a prospective, randomized comparison of oral ciprofloxacin and intraperitoneal vancomycin/gentamicin in the treatment of CAPD peritonitis.', 'subject score': 888, 'object score': 888}, 'PMID:2292548': {'publication date': '1990 Dec', 'sentence': 'A comparison between intraperitoneal ciprofloxacin and intraperitoneal vancomycin and gentamicin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD).', 'subject score': 888, 'object score': 1000}, 'PMID:2338420': {'publication date': '1990 Mar', 'sentence': 'Overall a single course of oral ciprofloxacin was 76% successful as a first-line treatment for CAPD-associated peritonitis, caused by a wide range of organisms.', 'subject score': 888, 'object score': 802}, 'PMID:2510089': {'publication date': '1989', 'sentence': 'Treatment of CAPD peritonitis with oral ciprofloxacin.', 'subject score': 888, 'object score': 888}, 'PMID:2613610': {'publication date': '1989 Oct', 'sentence': 'Intraperitoneal treatment of CAPD peritonitis with ciprofloxacin.', 'subject score': 1000, 'object score': 888}, 'PMID:28360373': {'publication date': '2017 Mar-Apr', 'sentence': 'We herein report a case of peritonitis due to M. morganii resistant to third-generation cephalosporins, which was treated successfully with intraperitoneal (IP) tobramycin followed by oral ciprofloxacin.', 'subject score': 888, 'object score': 1000}, 'PMID:29437143': {'publication date': '2018 Jul-Aug', 'sentence': 'Treatment of Acinetobacter peritonitis with gentamicin, ciprofloxacin, or ceftazidime achieved comparable outcomes.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0031154---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8190776",
-              "object": "MONDO:0004522",
-              "publications": [
-                "PMID:10809245",
-                "PMID:11330568",
-                "PMID:1304132",
-                "PMID:15490984",
-                "PMID:1769932",
-                "PMID:17984438",
-                "PMID:1912018",
-                "PMID:19458304",
-                "PMID:1982789",
-                "PMID:2197264",
-                "PMID:2209631",
-                "PMID:2211442",
-                "PMID:2292546",
-                "PMID:2292547",
-                "PMID:2292548",
-                "PMID:2338420",
-                "PMID:2510089",
-                "PMID:2613610",
-                "PMID:28360373",
-                "PMID:29437143"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 516221,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12641485': {'publication date': '2003', 'sentence': 'Fluoroquinolones such as ciprofloxacin, levofloxacin, moxifloxacin and gatifloxacin are widely used for the treatment of bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:12869605': {'publication date': '2003', 'sentence': \"The authors present three cases of Achilles tendinopathy in which the patients' symptoms were preceded by treatment for unrelated bacterial infections with ciprofloxacin.\", 'subject score': 1000, 'object score': 901}, 'PMID:1290976': {'publication date': '1992', 'sentence': '[Effect of TFX (Polfa) on the course of experimental bacterial infections in mice treated with ciprofloxacin, amikacin and cefoperazone].', 'subject score': 1000, 'object score': 901}, 'PMID:1440806': {'publication date': '1992', 'sentence': 'It is concluded that, if ciprofloxacin is to be used for treatment of malaria, a higher dose than that normally used for bacterial infections is necessary.', 'subject score': 1000, 'object score': 1000}, 'PMID:16167706': {'publication date': '2005 Jul', 'sentence': 'In the absence of culture and sensitivity information, ciprofloxacin should be considered among the first line options in the empirical treatment of severe bacterial infections among these children.', 'subject score': 1000, 'object score': 901}, 'PMID:1664832': {'publication date': '1991 Dec', 'sentence': 'The preliminary results from this study suggest that once daily temafloxacin gives high rates of clinical and bacteriological success, similar to twice daily ciprofloxacin, in the management of bacterial infections in the lower respiratory tract.', 'subject score': 776, 'object score': 1000}, 'PMID:18228018': {'publication date': '2008 Jun', 'sentence': 'PURPOSE: The uptake of (99m)Tc-UBI (29-41) was evaluated at sites of bacterial infections in rabbits before and after treatment with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:18972877': {'publication date': '2008', 'sentence': 'In this study, 3-alkyl and 3-aryl esters of hexahydroquinoline derivatives were screened for their ability to decrease bacterial resistance to ciprofloxacin (CAS 85721-33-1), which is extensively used to treat bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:19301941': {'publication date': '2009', 'sentence': 'BACKGROUND AND OBJECTIVE: Ciprofloxacin is a broad-spectrum, synthetic antibacterial used for the treatment of various bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:20100564': {'publication date': '2010 Jun', 'sentence': 'The fluorinated quinolone, ciprofloxacin, is an antibiotic effective for treating bacterial infections by inhibiting the enzyme activity of the DNA type II topoisomerases DNA gyrase and topoisomerase IV.', 'subject score': 1000, 'object score': 901}, 'PMID:20334059': {'publication date': '2009 Sep', 'sentence': 'Ciprofloxacin is a bactericidal drug which is being used widely throughout the world for the treatment of various bacterial infection.', 'subject score': 1000, 'object score': 901}, 'PMID:21570813': {'publication date': '2011 Jul', 'sentence': 'The antibiotic ciprofloxacin is used to treat EAEC infections, but a full understanding of the antimicrobial effects of ciprofloxacin is needed for more efficient treatment of bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:24153144': {'publication date': '2013 Sep', 'sentence': 'The patient presented with psoriatic plaque ulcerations uniquely limited to the active border as well as acute oral ulcerations and severe gastrointestinal upset after undergoing a course of ciprofloxacin for treatment of a bacterial infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:2490636': {'publication date': '1989 Jan', 'sentence': 'Twenty one adult patients, both males and females, with 32 bacterial infections of several localizations and moderate to severe prognosis were treated with ciprofloxacin (200 mg every 12 hours), initially intravenously and then with 500 mg every 12 hours orally during 25 +/- 11 days.', 'subject score': 1000, 'object score': 901}, 'PMID:2490638': {'publication date': '1989 Jan', 'sentence': '[Evaluation of ciprofloxacin for the treatment of severe bacterial infections].', 'subject score': 1000, 'object score': 901}, 'PMID:25526004': {'publication date': '2014 Oct 15', 'sentence': 'The patient was treated with oral ivermectin and permethrin cream, as well as ciprofloxacin for the bacterial infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:2589369': {'publication date': '1989 Nov 30', 'sentence': 'Clinical study of intravenous and oral ciprofloxacin in complicated bacterial infections.', 'subject score': 888, 'object score': 901}, 'PMID:26140184': {'publication date': '2015 Apr-Jun', 'sentence': 'CONCLUSION: Niosomal CPFX appears to be a promising approach in the management of bacterial infections, especially ophthalmic ones, and should be further evaluated by in vivo experiments.', 'subject score': 861, 'object score': 1000}, 'PMID:2618005': {'publication date': '1989', 'sentence': '[Ciprofloxacin in bacterial infections].', 'subject score': 1000, 'object score': 1000}, 'PMID:26763627': {'publication date': '2015', 'sentence': 'BACKGROUND: Ciprofloxacin is one of the main drugs to treat bacterial infections.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 538307,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001475",
-          "name": "neutropenia",
-          "description": "A decrease in the number of NEUTROPHILS found in the blood.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029355",
-            "MEDDRA:10029354",
-            "SNOMEDCT:303011007",
-            "MONDO:0001475",
-            "DOID:1227",
-            "MESH:D009503",
-            "UMLS:C0027947",
-            "PDQ:CDR0000041387",
-            "ICD9:288.0"
-          ],
-          "id": "MONDO:0001475",
-          "category": "biolink:Disease",
-          "all_names": [
-            "neutropenia",
-            "Neutropenia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 516221,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001475",
-              "name": "neutropenia",
-              "description": "A decrease in the number of NEUTROPHILS found in the blood.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029355",
-                "MEDDRA:10029354",
-                "SNOMEDCT:303011007",
-                "MONDO:0001475",
-                "DOID:1227",
-                "MESH:D009503",
-                "UMLS:C0027947",
-                "PDQ:CDR0000041387",
-                "ICD9:288.0"
-              ],
-              "id": "MONDO:0001475",
-              "category": "biolink:Disease",
-              "all_names": [
-                "neutropenia",
-                "Neutropenia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-=======
-            "identity": 538307,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 14069823,
-            "start": 616,
-            "end": 516221,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1943299': {'publication date': '1991 Sep 07', 'sentence': '[Neutropenia caused by ciprofloxacin and Escherichia coli bacteremia. Bone marrow examination].', 'subject score': 1000, 'object score': 1000}, 'PMID:2041408': {'publication date': '1991 Mar 02', 'sentence': '[Ciprofloxacin-induced neutropenia: an infrequent adverse effect].', 'subject score': 851, 'object score': 851}, 'PMID:8342553': {'publication date': '1993 Jun', 'sentence': 'Ciprofloxacin-induced neutropenia and erythema multiforme.', 'subject score': 851, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:causes---None---None---None---UMLS:C0027947---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "14369807",
-              "object": "MONDO:0001475",
-              "publications": [
-                "PMID:1943299",
-                "PMID:2041408",
-                "PMID:8342553"
-=======
-            "identity": 9869789,
-            "start": 616,
-            "end": 538307,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12641485': {'publication date': '2003', 'sentence': 'Fluoroquinolones such as ciprofloxacin, levofloxacin, moxifloxacin and gatifloxacin are widely used for the treatment of bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:12869605': {'publication date': '2003', 'sentence': \"The authors present three cases of Achilles tendinopathy in which the patients' symptoms were preceded by treatment for unrelated bacterial infections with ciprofloxacin.\", 'subject score': 1000, 'object score': 901}, 'PMID:1290976': {'publication date': '1992', 'sentence': '[Effect of TFX (Polfa) on the course of experimental bacterial infections in mice treated with ciprofloxacin, amikacin and cefoperazone].', 'subject score': 1000, 'object score': 901}, 'PMID:1440806': {'publication date': '1992', 'sentence': 'It is concluded that, if ciprofloxacin is to be used for treatment of malaria, a higher dose than that normally used for bacterial infections is necessary.', 'subject score': 1000, 'object score': 1000}, 'PMID:16167706': {'publication date': '2005 Jul', 'sentence': 'In the absence of culture and sensitivity information, ciprofloxacin should be considered among the first line options in the empirical treatment of severe bacterial infections among these children.', 'subject score': 1000, 'object score': 901}, 'PMID:1664832': {'publication date': '1991 Dec', 'sentence': 'The preliminary results from this study suggest that once daily temafloxacin gives high rates of clinical and bacteriological success, similar to twice daily ciprofloxacin, in the management of bacterial infections in the lower respiratory tract.', 'subject score': 776, 'object score': 1000}, 'PMID:18228018': {'publication date': '2008 Jun', 'sentence': 'PURPOSE: The uptake of (99m)Tc-UBI (29-41) was evaluated at sites of bacterial infections in rabbits before and after treatment with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:18972877': {'publication date': '2008', 'sentence': 'In this study, 3-alkyl and 3-aryl esters of hexahydroquinoline derivatives were screened for their ability to decrease bacterial resistance to ciprofloxacin (CAS 85721-33-1), which is extensively used to treat bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:19301941': {'publication date': '2009', 'sentence': 'BACKGROUND AND OBJECTIVE: Ciprofloxacin is a broad-spectrum, synthetic antibacterial used for the treatment of various bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:20100564': {'publication date': '2010 Jun', 'sentence': 'The fluorinated quinolone, ciprofloxacin, is an antibiotic effective for treating bacterial infections by inhibiting the enzyme activity of the DNA type II topoisomerases DNA gyrase and topoisomerase IV.', 'subject score': 1000, 'object score': 901}, 'PMID:20334059': {'publication date': '2009 Sep', 'sentence': 'Ciprofloxacin is a bactericidal drug which is being used widely throughout the world for the treatment of various bacterial infection.', 'subject score': 1000, 'object score': 901}, 'PMID:21570813': {'publication date': '2011 Jul', 'sentence': 'The antibiotic ciprofloxacin is used to treat EAEC infections, but a full understanding of the antimicrobial effects of ciprofloxacin is needed for more efficient treatment of bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:24153144': {'publication date': '2013 Sep', 'sentence': 'The patient presented with psoriatic plaque ulcerations uniquely limited to the active border as well as acute oral ulcerations and severe gastrointestinal upset after undergoing a course of ciprofloxacin for treatment of a bacterial infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:2490636': {'publication date': '1989 Jan', 'sentence': 'Twenty one adult patients, both males and females, with 32 bacterial infections of several localizations and moderate to severe prognosis were treated with ciprofloxacin (200 mg every 12 hours), initially intravenously and then with 500 mg every 12 hours orally during 25 +/- 11 days.', 'subject score': 1000, 'object score': 901}, 'PMID:2490638': {'publication date': '1989 Jan', 'sentence': '[Evaluation of ciprofloxacin for the treatment of severe bacterial infections].', 'subject score': 1000, 'object score': 901}, 'PMID:25526004': {'publication date': '2014 Oct 15', 'sentence': 'The patient was treated with oral ivermectin and permethrin cream, as well as ciprofloxacin for the bacterial infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:2589369': {'publication date': '1989 Nov 30', 'sentence': 'Clinical study of intravenous and oral ciprofloxacin in complicated bacterial infections.', 'subject score': 888, 'object score': 901}, 'PMID:26140184': {'publication date': '2015 Apr-Jun', 'sentence': 'CONCLUSION: Niosomal CPFX appears to be a promising approach in the management of bacterial infections, especially ophthalmic ones, and should be further evaluated by in vivo experiments.', 'subject score': 861, 'object score': 1000}, 'PMID:2618005': {'publication date': '1989', 'sentence': '[Ciprofloxacin in bacterial infections].', 'subject score': 1000, 'object score': 1000}, 'PMID:26763627': {'publication date': '2015', 'sentence': 'BACKGROUND: Ciprofloxacin is one of the main drugs to treat bacterial infections.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "10087799",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:12641485",
-                "PMID:12869605",
-                "PMID:1290976",
-                "PMID:1440806",
-                "PMID:16167706",
-                "PMID:1664832",
-                "PMID:18228018",
-                "PMID:18972877",
-                "PMID:19301941",
-                "PMID:20100564",
-                "PMID:20334059",
-                "PMID:21570813",
-                "PMID:24153144",
-                "PMID:2490636",
-                "PMID:2490638",
-                "PMID:25526004",
-                "PMID:2589369",
-                "PMID:26140184",
-                "PMID:2618005",
-                "PMID:26763627"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:12499786': {'publication date': '2002 Sep', 'sentence': '[Prospective randomized trial of intravenous ciprofloxacin for prevention of bacterial infection in cirrhotic patients with esophageal variceal bleeding].', 'subject score': 888, 'object score': 1000}, 'PMID:2006519': {'publication date': '1991 Mar', 'sentence': 'Ciprofloxacin appears to be effective for preventing bacterial infections in neutropenic patients.', 'subject score': 1000, 'object score': 884}, 'PMID:2048868': {'publication date': '1991 Jul 01', 'sentence': 'OBJECTIVE: To compare the efficacy of norfloxacin and ciprofloxacin in preventing bacterial infection in neutropenic patients.', 'subject score': 1000, 'object score': 884}, 'PMID:2963998': {'publication date': '1987 Dec 11', 'sentence': 'Prolonged administration of ciprofloxacin turned out to be safe and effective in preventing serious aerobic bacterial infections during the first three months after BMT.', 'subject score': 1000, 'object score': 831}, 'PMID:30429884': {'publication date': '2018', 'sentence': 'The results support that Cipro successfully reduced bacterial infection and thus encouraged faster wound closure.', 'subject score': 1000, 'object score': 1000}, 'PMID:7751732': {'publication date': '1995 Jan', 'sentence': 'These results suggest that combination with ST and CPFX is more efficacious than ST alone for the prevention of bacterial infections in granulocytopenic patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:7799026': {'publication date': '1995 Jan', 'sentence': 'CONCLUSION: CIP and TMS were equally safe and effective in the prevention of bacterial infections in BMT patients when the overall infection rate was used as the principal end point.', 'subject score': 1000, 'object score': 1000}, 'PMID:8166152': {'publication date': '1994 Apr', 'sentence': 'PURPOSE: To study whether oral ciprofloxacin would be as effective in preventing bacterial infections in severely myelosuppressed patients as selective antibiotic modulation of the gut flora with neomycin/polymyxin B sulfate/nalidixic acid (NPN).', 'subject score': 888, 'object score': 884}}",
-    "p2": {
-      "start": {
-        "identity": 538307,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538307,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9732045,
-            "start": 616,
-            "end": 538307,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12499786': {'publication date': '2002 Sep', 'sentence': '[Prospective randomized trial of intravenous ciprofloxacin for prevention of bacterial infection in cirrhotic patients with esophageal variceal bleeding].', 'subject score': 888, 'object score': 1000}, 'PMID:2006519': {'publication date': '1991 Mar', 'sentence': 'Ciprofloxacin appears to be effective for preventing bacterial infections in neutropenic patients.', 'subject score': 1000, 'object score': 884}, 'PMID:2048868': {'publication date': '1991 Jul 01', 'sentence': 'OBJECTIVE: To compare the efficacy of norfloxacin and ciprofloxacin in preventing bacterial infection in neutropenic patients.', 'subject score': 1000, 'object score': 884}, 'PMID:2963998': {'publication date': '1987 Dec 11', 'sentence': 'Prolonged administration of ciprofloxacin turned out to be safe and effective in preventing serious aerobic bacterial infections during the first three months after BMT.', 'subject score': 1000, 'object score': 831}, 'PMID:30429884': {'publication date': '2018', 'sentence': 'The results support that Cipro successfully reduced bacterial infection and thus encouraged faster wound closure.', 'subject score': 1000, 'object score': 1000}, 'PMID:7751732': {'publication date': '1995 Jan', 'sentence': 'These results suggest that combination with ST and CPFX is more efficacious than ST alone for the prevention of bacterial infections in granulocytopenic patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:7799026': {'publication date': '1995 Jan', 'sentence': 'CONCLUSION: CIP and TMS were equally safe and effective in the prevention of bacterial infections in BMT patients when the overall infection rate was used as the principal end point.', 'subject score': 1000, 'object score': 1000}, 'PMID:8166152': {'publication date': '1994 Apr', 'sentence': 'PURPOSE: To study whether oral ciprofloxacin would be as effective in preventing bacterial infections in severely myelosuppressed patients as selective antibiotic modulation of the gut flora with neomycin/polymyxin B sulfate/nalidixic acid (NPN).', 'subject score': 888, 'object score': 884}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:prevents---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "9947057",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:12499786",
-                "PMID:2006519",
-                "PMID:2048868",
-                "PMID:2963998",
-                "PMID:30429884",
-                "PMID:7751732",
-                "PMID:7799026",
-                "PMID:8166152"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15728165': {'publication date': '2005 Feb 23', 'sentence': 'Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial.', 'subject score': 1000, 'object score': 888}, 'PMID:15972473': {'publication date': '2005 Jul', 'sentence': 'Treatment of infected mice for 4 days with ciprofloxacin at 30 mg/kg of body weight twice a day cured cystitis and renal infection in noncatheterized mice.', 'subject score': 1000, 'object score': 1000}, 'PMID:1839760': {'publication date': '1991 Dec', 'sentence': 'Treatment of encrusted cystitis caused by Corynebacterium group D2 with norfloxacin, ciprofloxacin, and teicoplanin in an experimental model in rats.', 'subject score': 1000, 'object score': 861}, 'PMID:22967697': {'publication date': '2012 Sep', 'sentence': 'In uncomplicated cystitis, 9.5% of all isolates were resistant to ciprofloxacin and 24.0% to trimethoprim-sulfamethoxazole (TMP-SMX).', 'subject score': 1000, 'object score': 888}, 'PMID:25339200': {'publication date': '2015 Mar', 'sentence': 'Ciprofloxacin and cotrimoxazole are recommended to treat uncomplicated pyelonephritis and uncomplicated cystitis, respectively, provided that local resistance rates of uropathogens do not exceed specified thresholds (10 and 20 %, respectively).', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 321542,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006032",
-          "name": "cystitis",
-          "description": "Inflammation of the urinary bladder.; Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.; Inflammation of the urinary bladder. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10011781",
-            "UMLS:C0010692",
-            "EFO:1000025",
-            "MEDDRA:10011754",
-            "SNOMEDCT:38822007",
-            "MESH:D003556",
-            "DOID:1679",
-            "HP:0100577",
-            "MEDDRA:10011798",
-            "ICD9:595",
-            "NCIT:C26738",
-            "MEDDRA:10011802",
-            "ICD10:N30",
-            "MONDO:0006032",
-            "MEDDRA:10063059"
-          ],
-          "id": "MONDO:0006032",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cystitis",
-            "cystitis",
-            "Urinary bladder inflammation"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.mayoclinic.org/diseases-conditions/cystitis/symptoms-causes/syc-20371306",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321542,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006032",
-              "name": "cystitis",
-              "description": "Inflammation of the urinary bladder.; Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.; Inflammation of the urinary bladder. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10011781",
-                "UMLS:C0010692",
-                "EFO:1000025",
-                "MEDDRA:10011754",
-                "SNOMEDCT:38822007",
-                "MESH:D003556",
-                "DOID:1679",
-                "HP:0100577",
-                "MEDDRA:10011798",
-                "ICD9:595",
-                "NCIT:C26738",
-                "MEDDRA:10011802",
-                "ICD10:N30",
-                "MONDO:0006032",
-                "MEDDRA:10063059"
-              ],
-              "id": "MONDO:0006032",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cystitis",
-                "cystitis",
-                "Urinary bladder inflammation"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.mayoclinic.org/diseases-conditions/cystitis/symptoms-causes/syc-20371306",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11434740,
-            "start": 616,
-            "end": 321542,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15728165': {'publication date': '2005 Feb 23', 'sentence': 'Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial.', 'subject score': 1000, 'object score': 888}, 'PMID:15972473': {'publication date': '2005 Jul', 'sentence': 'Treatment of infected mice for 4 days with ciprofloxacin at 30 mg/kg of body weight twice a day cured cystitis and renal infection in noncatheterized mice.', 'subject score': 1000, 'object score': 1000}, 'PMID:1839760': {'publication date': '1991 Dec', 'sentence': 'Treatment of encrusted cystitis caused by Corynebacterium group D2 with norfloxacin, ciprofloxacin, and teicoplanin in an experimental model in rats.', 'subject score': 1000, 'object score': 861}, 'PMID:22967697': {'publication date': '2012 Sep', 'sentence': 'In uncomplicated cystitis, 9.5% of all isolates were resistant to ciprofloxacin and 24.0% to trimethoprim-sulfamethoxazole (TMP-SMX).', 'subject score': 1000, 'object score': 888}, 'PMID:25339200': {'publication date': '2015 Mar', 'sentence': 'Ciprofloxacin and cotrimoxazole are recommended to treat uncomplicated pyelonephritis and uncomplicated cystitis, respectively, provided that local resistance rates of uropathogens do not exceed specified thresholds (10 and 20 %, respectively).', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0010692---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "11684450",
-              "object": "MONDO:0006032",
-              "publications": [
-                "PMID:15728165",
-                "PMID:15972473",
-                "PMID:1839760",
-                "PMID:22967697",
-                "PMID:25339200"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11244532': {'publication date': '2001 Mar', 'sentence': 'We report on a young patient with nasal rhinoscleroma who achieved resolution after treatment with oral ciprofloxacin.', 'subject score': 888, 'object score': 888}, 'PMID:33650263': {'publication date': '2021 Mar 02', 'sentence': 'In a series of 23 patients, Topical ciprofloxacin was investigated as a novel option for treatment of rhinoscleroma and was found to be effective in treating the disease in all patients after 12-24 weeks.', 'subject score': 861, 'object score': 1000}, 'PMID:7630299': {'publication date': '1995 Aug', 'sentence': 'Ciprofloxacin may prove to be useful in the therapy of rhinoscleroma because it is convenient for oral administration, achieves good tissue levels, is concentrated in macrophages, and is generally well tolerated as long-term therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:8100894': {'publication date': '1993 Jul 10', 'sentence': 'Ciprofloxacin for rhinoscleroma and ozena.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 533945,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005945",
-          "name": "rhinoscleroma",
-          "description": "A granulomatous disease caused by KLEBSIELLA RHINOSCLEROMATIS infection. Despite its name, this disease is not limited to the nose and NASOPHARYNX but may affect any part of the RESPIRATORY TRACT, sometimes with extension to the lip and the skin.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:72409005",
-            "MEDDRA:10063391",
-            "DOID:11336",
-            "MONDO:0005945",
-            "MESH:D012226",
-            "EFO:0007470",
-            "MEDDRA:10039102",
-            "UMLS:C0035468",
-            "ICD9:040.1"
-          ],
-          "id": "MONDO:0005945",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Rhinoscleroma",
-            "rhinoscleroma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rhinoscleroma",
-            "http://en.wikipedia.org/wiki/rhinoscleroma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 533945,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005945",
-              "name": "rhinoscleroma",
-              "description": "A granulomatous disease caused by KLEBSIELLA RHINOSCLEROMATIS infection. Despite its name, this disease is not limited to the nose and NASOPHARYNX but may affect any part of the RESPIRATORY TRACT, sometimes with extension to the lip and the skin.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:72409005",
-                "MEDDRA:10063391",
-                "DOID:11336",
-                "MONDO:0005945",
-                "MESH:D012226",
-                "EFO:0007470",
-                "MEDDRA:10039102",
-                "UMLS:C0035468",
-                "ICD9:040.1"
-              ],
-              "id": "MONDO:0005945",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Rhinoscleroma",
-                "rhinoscleroma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rhinoscleroma",
-                "http://en.wikipedia.org/wiki/rhinoscleroma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8567724,
-            "start": 616,
-            "end": 533945,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11244532': {'publication date': '2001 Mar', 'sentence': 'We report on a young patient with nasal rhinoscleroma who achieved resolution after treatment with oral ciprofloxacin.', 'subject score': 888, 'object score': 888}, 'PMID:33650263': {'publication date': '2021 Mar 02', 'sentence': 'In a series of 23 patients, Topical ciprofloxacin was investigated as a novel option for treatment of rhinoscleroma and was found to be effective in treating the disease in all patients after 12-24 weeks.', 'subject score': 861, 'object score': 1000}, 'PMID:7630299': {'publication date': '1995 Aug', 'sentence': 'Ciprofloxacin may prove to be useful in the therapy of rhinoscleroma because it is convenient for oral administration, achieves good tissue levels, is concentrated in macrophages, and is generally well tolerated as long-term therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:8100894': {'publication date': '1993 Jul 10', 'sentence': 'Ciprofloxacin for rhinoscleroma and ozena.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0035468---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8754779",
-              "object": "MONDO:0005945",
-              "publications": [
-                "PMID:11244532",
-                "PMID:33650263",
-                "PMID:7630299",
-                "PMID:8100894"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:19747660': {'publication date': '2009 Sep', 'sentence': 'Treatment with ciprofloxacin and ceftazidime improved the hearing loss significantly.', 'subject score': 1000, 'object score': 901}, 'PMID:31086542': {'publication date': '2019', 'sentence': 'Results: There was no significant difference found for hearing loss and severity among the groups treated with ciprofloxacin, co-amoxicillin and not maintained on antibiotic therapy.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 317989,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005365",
-          "name": "hearing loss disorder",
-          "description": "A decreased magnitude of the sensory perception of sound. [HPO:probinson]; A decreased magnitude of the sensory perception of sound. // COMMENTS: Hearing loss can be categorized by which part of the auditory system is damaged, as conductive hearing loss, sensorineural hearing loss, and mixed hearing loss. Another axis of classification uses the degree of hearing impairment. The degree of hearing loss is computed by using a three frequency average taken at 500 Hz, 1,000 Hz and 2,000 Hz. The average of these three frequencies is called the Pure Tone Average (PTA). 0-20 dB is considered normal, 21-40 dB mild loss, 41-60 dB moderate loss, 61-70 dB moderately severe loss,71-90 dB severe loss, and greater than 90 dB profound loss. Note that the word deafness is occasionally used to describe partial hearing loss. The World Health Organization uses the word deafness to refer to complete loss of the ability to hear, and hearing impairment to refer to any degree of reduced hearing.; A decreased magnitude of the sensory perception of sound. // COMMENTS: Hearing loss can be categorized by which part of the auditory system is damaged, as conductive hearing loss, sensorineural hearing loss, and mixed hearing loss. Another axis of classification uses the degree of hearing impairment. The degree of hearing loss is computed by using a three frequency average taken at 500 Hz, 1,000 Hz and 2,000 Hz. The average of these three frequencies is called the Pure Tone Average (PTA). 0-20 dB is considered normal, 21-40 dB mild loss, 41-60 dB moderate loss, 61-70 dB moderately severe loss,71-90 dB severe loss, and greater than 90 dB profound loss. Note that the word deafness is occasionally used to describe partial hearing loss. The World Health Organization uses the word deafness to refer to complete loss of the ability to hear, and hearing impairment to refer to any degree of reduced hearing.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "SYMP:0000019",
-            "UMLS:C0011053",
-            "NCIT:C27644",
-            "MESH:D034381",
-            "MEDDRA:10011879",
-            "MEDDRA:10029439",
-            "MEDDRA:10019245",
-            "MEDDRA:10067879",
-            "MEDDRA:10019241",
-            "SNOMEDCT:343087000",
-            "UMLS:C3887873",
-            "NCIT:C35731",
-            "MEDDRA:10045726",
-            "MEDDRA:10050564",
-            "MONDO:0005365",
-            "MEDDRA:10019246",
-            "NCIT:C27643",
-            "NCIT:C50576",
-            "MEDDRA:10011882",
-            "MEDDRA:10045900",
-            "EFO:0004238",
-            "MEDDRA:10011892",
-            "HP:0000365",
-            "MESH:D003638",
-            "MEDDRA:10050010",
-            "ICD9:389",
-            "MEDDRA:10048865",
-            "SNOMEDCT:103276001",
-            "MEDDRA:10019869",
-            "UMLS:C1384666",
-            "SNOMEDCT:15188001",
-            "UMLS:C0339789",
-            "MEDDRA:10019247",
-            "MEDDRA:10010431",
-            "UMLS:C0018772",
-            "MEDDRA:10011878",
-            "EFO:0001063",
-            "SNOMEDCT:95828007"
-          ],
-          "id": "MONDO:0005365",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Deafness",
-            "Hearing impairment",
-            "hearing impairment",
-            "Partial Hearing Loss",
-            "Hearing loss",
-            "Hearing Impairment",
-            "deafness",
-            "Hearing Loss",
-            "hearing loss",
-            "hearing loss disorder",
-            "Congenital deafness"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317989,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005365",
-              "name": "hearing loss disorder",
-              "description": "A decreased magnitude of the sensory perception of sound. [HPO:probinson]; A decreased magnitude of the sensory perception of sound. // COMMENTS: Hearing loss can be categorized by which part of the auditory system is damaged, as conductive hearing loss, sensorineural hearing loss, and mixed hearing loss. Another axis of classification uses the degree of hearing impairment. The degree of hearing loss is computed by using a three frequency average taken at 500 Hz, 1,000 Hz and 2,000 Hz. The average of these three frequencies is called the Pure Tone Average (PTA). 0-20 dB is considered normal, 21-40 dB mild loss, 41-60 dB moderate loss, 61-70 dB moderately severe loss,71-90 dB severe loss, and greater than 90 dB profound loss. Note that the word deafness is occasionally used to describe partial hearing loss. The World Health Organization uses the word deafness to refer to complete loss of the ability to hear, and hearing impairment to refer to any degree of reduced hearing.; A decreased magnitude of the sensory perception of sound. // COMMENTS: Hearing loss can be categorized by which part of the auditory system is damaged, as conductive hearing loss, sensorineural hearing loss, and mixed hearing loss. Another axis of classification uses the degree of hearing impairment. The degree of hearing loss is computed by using a three frequency average taken at 500 Hz, 1,000 Hz and 2,000 Hz. The average of these three frequencies is called the Pure Tone Average (PTA). 0-20 dB is considered normal, 21-40 dB mild loss, 41-60 dB moderate loss, 61-70 dB moderately severe loss,71-90 dB severe loss, and greater than 90 dB profound loss. Note that the word deafness is occasionally used to describe partial hearing loss. The World Health Organization uses the word deafness to refer to complete loss of the ability to hear, and hearing impairment to refer to any degree of reduced hearing.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "SYMP:0000019",
-                "UMLS:C0011053",
-                "NCIT:C27644",
-                "MESH:D034381",
-                "MEDDRA:10011879",
-                "MEDDRA:10029439",
-                "MEDDRA:10019245",
-                "MEDDRA:10067879",
-                "MEDDRA:10019241",
-                "SNOMEDCT:343087000",
-                "UMLS:C3887873",
-                "NCIT:C35731",
-                "MEDDRA:10045726",
-                "MEDDRA:10050564",
-                "MONDO:0005365",
-                "MEDDRA:10019246",
-                "NCIT:C27643",
-                "NCIT:C50576",
-                "MEDDRA:10011882",
-                "MEDDRA:10045900",
-                "EFO:0004238",
-                "MEDDRA:10011892",
-                "HP:0000365",
-                "MESH:D003638",
-                "MEDDRA:10050010",
-                "ICD9:389",
-                "MEDDRA:10048865",
-                "SNOMEDCT:103276001",
-                "MEDDRA:10019869",
-                "UMLS:C1384666",
-                "SNOMEDCT:15188001",
-                "UMLS:C0339789",
-                "MEDDRA:10019247",
-                "MEDDRA:10010431",
-                "UMLS:C0018772",
-                "MEDDRA:10011878",
-                "EFO:0001063",
-                "SNOMEDCT:95828007"
-              ],
-              "id": "MONDO:0005365",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Deafness",
-                "Hearing impairment",
-                "hearing impairment",
-                "Partial Hearing Loss",
-                "Hearing loss",
-                "Hearing Impairment",
-                "deafness",
-                "Hearing Loss",
-                "hearing loss",
-                "hearing loss disorder",
-                "Congenital deafness"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14269424,
-            "start": 616,
-            "end": 317989,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19747660': {'publication date': '2009 Sep', 'sentence': 'Treatment with ciprofloxacin and ceftazidime improved the hearing loss significantly.', 'subject score': 1000, 'object score': 901}, 'PMID:31086542': {'publication date': '2019', 'sentence': 'Results: There was no significant difference found for hearing loss and severity among the groups treated with ciprofloxacin, co-amoxicillin and not maintained on antibiotic therapy.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C1384666---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "14572951",
-              "object": "MONDO:0005365",
-              "publications": [
-                "PMID:19747660",
-                "PMID:31086542"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:18611787': {'publication date': '1997 Mar', 'sentence': 'High dose parenteral ciprofloxacin in pleuro-pulmonary disease: a comparative pharmacolinetics of 400 and 200 mg intravenous.', 'subject score': 824, 'object score': 901}, 'PMID:19661243': {'publication date': '2009 Nov 01', 'sentence': 'METHODS: Sixty-five patients (11 males, 55 females, median age 55 yr) with M. abscessus lung disease were treated with clarithromycin, ciprofloxacin, and doxycycline, together with an initial regimen of amikacin and cefoxitin for the first 4 weeks of hospitalization.', 'subject score': 1000, 'object score': 824}, 'PMID:30105497': {'publication date': '2018 Oct', 'sentence': 'Ciprofloxacin is a broad-spectrum antibiotic for treatment of pulmonary diseases such as chronic obstructive pulmonary disease and cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7884988': {'publication date': '1995 Jan', 'sentence': '[A case of Mycobacterium fortuitum pulmonary disease in a healthy young woman successfully treated with ciprofloxacin and doxycycline].', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 321402,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005275",
-          "name": "lung disorder",
-          "description": "A non-neoplastic or neoplastic disorder affecting the lung. Representative examples of non-neoplastic disorders include chronic obstructive pulmonary disease and pneumonia. Representative examples of neoplastic disorders include benign processes (e.g., respiratory papilloma) and malignant processes (e.g., lung carcinoma and metastatic cancer to the lung).; Pathological processes involving any part of the LUNG.; Any structural anomaly of the lung. [HPO:probinson]; When you breathe, your lungs take in oxygen from the air and deliver it to the bloodstream. The cells in your body need oxygen to work and grow. During a normal day, you breathe nearly 25,000 times. People with lung disease have difficulty breathing. Millions of people in the U.S. have lung disease. If all types of lung disease are lumped together, it is the number three killer in the United States. The term lung disease refers to many disorders affecting the lungs, such as asthma, COPD, infections like influenza, pneumonia and tuberculosis, lung cancer, and many other breathing problems. Some lung diseases can lead to respiratory failure. Dept. of Health and Human Services Office on Women's Health; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10013235",
-            "MEDDRA:10049490",
-            "MEDDRA:10025083",
-            "DOID:850",
-            "MEDDRA:10051054",
-            "MESH:D008171",
-            "MONDO:0005275",
-            "MEDDRA:10013259",
-            "SNOMEDCT:19829001",
-            "ICD10:J98.4",
-            "HP:0002088",
-            "MEDDRA:10025082",
-            "EFO:0003818",
-            "UMLS:C4021760",
-            "UMLS:C0024115",
-            "MEDDRA:10037373",
-            "NCIT:C3198"
-          ],
-          "id": "MONDO:0005275",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Abnormal lung morphology",
-            "lung disorder",
-            "Lung Disorder",
-            "Lung diseases",
-            "lung disease",
-            "Lung Diseases"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000066.htm",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.niehs.nih.gov/health/topics/conditions/lung-disease/index.cfm",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321402,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005275",
-              "name": "lung disorder",
-              "description": "A non-neoplastic or neoplastic disorder affecting the lung. Representative examples of non-neoplastic disorders include chronic obstructive pulmonary disease and pneumonia. Representative examples of neoplastic disorders include benign processes (e.g., respiratory papilloma) and malignant processes (e.g., lung carcinoma and metastatic cancer to the lung).; Pathological processes involving any part of the LUNG.; Any structural anomaly of the lung. [HPO:probinson]; When you breathe, your lungs take in oxygen from the air and deliver it to the bloodstream. The cells in your body need oxygen to work and grow. During a normal day, you breathe nearly 25,000 times. People with lung disease have difficulty breathing. Millions of people in the U.S. have lung disease. If all types of lung disease are lumped together, it is the number three killer in the United States. The term lung disease refers to many disorders affecting the lungs, such as asthma, COPD, infections like influenza, pneumonia and tuberculosis, lung cancer, and many other breathing problems. Some lung diseases can lead to respiratory failure. Dept. of Health and Human Services Office on Women's Health; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10013235",
-                "MEDDRA:10049490",
-                "MEDDRA:10025083",
-                "DOID:850",
-                "MEDDRA:10051054",
-                "MESH:D008171",
-                "MONDO:0005275",
-                "MEDDRA:10013259",
-                "SNOMEDCT:19829001",
-                "ICD10:J98.4",
-                "HP:0002088",
-                "MEDDRA:10025082",
-                "EFO:0003818",
-                "UMLS:C4021760",
-                "UMLS:C0024115",
-                "MEDDRA:10037373",
-                "NCIT:C3198"
-              ],
-              "id": "MONDO:0005275",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Abnormal lung morphology",
-                "lung disorder",
-                "Lung Disorder",
-                "Lung diseases",
-                "lung disease",
-                "Lung Diseases"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000066.htm",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.niehs.nih.gov/health/topics/conditions/lung-disease/index.cfm",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13555467,
-            "start": 616,
-            "end": 321402,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18611787': {'publication date': '1997 Mar', 'sentence': 'High dose parenteral ciprofloxacin in pleuro-pulmonary disease: a comparative pharmacolinetics of 400 and 200 mg intravenous.', 'subject score': 824, 'object score': 901}, 'PMID:19661243': {'publication date': '2009 Nov 01', 'sentence': 'METHODS: Sixty-five patients (11 males, 55 females, median age 55 yr) with M. abscessus lung disease were treated with clarithromycin, ciprofloxacin, and doxycycline, together with an initial regimen of amikacin and cefoxitin for the first 4 weeks of hospitalization.', 'subject score': 1000, 'object score': 824}, 'PMID:30105497': {'publication date': '2018 Oct', 'sentence': 'Ciprofloxacin is a broad-spectrum antibiotic for treatment of pulmonary diseases such as chronic obstructive pulmonary disease and cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7884988': {'publication date': '1995 Jan', 'sentence': '[A case of Mycobacterium fortuitum pulmonary disease in a healthy young woman successfully treated with ciprofloxacin and doxycycline].', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0024115---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "13846017",
-              "object": "MONDO:0005275",
-              "publications": [
-                "PMID:18611787",
-                "PMID:19661243",
-                "PMID:30105497",
-                "PMID:7884988"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:18777242': {'publication date': '2008 Oct', 'sentence': 'According to PK/PD analysis, the liposomal CPFX exhibited potent antibacterial effects against the causative organisms of pneumonia.', 'subject score': 888, 'object score': 1000}, 'PMID:28591808': {'publication date': '2017 07 06', 'sentence': 'The antibiotic susceptibility and beta-lactamase activity of K. pneumoniae strains, including antibiotic-sensitive K. pneumoniae (KPWT), ciprofloxacin-induced resistant K. pneumoniae (KPCIP) and clinically isolated K. pneumoniae strains (KPCI237, KPCI263 and KPCI272) were determined in the absence and presence of beta-lactamase inhibitors (BLI 489, sulbactam, clavulanate and tazobactam).', 'subject score': 822, 'object score': 822}, 'PMID:30263717': {'publication date': '2017', 'sentence': 'Typhimurium (CA-ST), wild-type Klebsiella pneumoniae (WT-KP), ciprofloxacin-induced K. pneumoniae (CI-KP), and clinically-acquired antibiotic-resistant K. pneumoniae (CA-KP).', 'subject score': 833, 'object score': 833}, 'PMID:31325570': {'publication date': '2019 Oct', 'sentence': 'PBKP35-induced mutants, including bacteriophage-insensitive K. pneumoniae ATCC 23357 (BIKPWT), ciprofloxacin-induced K. pneumoniae ATCC 23357 (BIKPCIP), and clinically isolated antibiotic-resistant K. pneumoniae CCARM 10263 (BIKPCLI).', 'subject score': 769, 'object score': 769}, 'PMID:3159336': {'publication date': '1985 Apr', 'sentence': 'Activities of pefloxacin and ciprofloxacin in experimentally induced Pseudomonas pneumonia in neutropenic guinea pigs.', 'subject score': 1000, 'object score': 775}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13657825,
-            "start": 616,
-            "end": 321523,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18777242': {'publication date': '2008 Oct', 'sentence': 'According to PK/PD analysis, the liposomal CPFX exhibited potent antibacterial effects against the causative organisms of pneumonia.', 'subject score': 888, 'object score': 1000}, 'PMID:28591808': {'publication date': '2017 07 06', 'sentence': 'The antibiotic susceptibility and beta-lactamase activity of K. pneumoniae strains, including antibiotic-sensitive K. pneumoniae (KPWT), ciprofloxacin-induced resistant K. pneumoniae (KPCIP) and clinically isolated K. pneumoniae strains (KPCI237, KPCI263 and KPCI272) were determined in the absence and presence of beta-lactamase inhibitors (BLI 489, sulbactam, clavulanate and tazobactam).', 'subject score': 822, 'object score': 822}, 'PMID:30263717': {'publication date': '2017', 'sentence': 'Typhimurium (CA-ST), wild-type Klebsiella pneumoniae (WT-KP), ciprofloxacin-induced K. pneumoniae (CI-KP), and clinically-acquired antibiotic-resistant K. pneumoniae (CA-KP).', 'subject score': 833, 'object score': 833}, 'PMID:31325570': {'publication date': '2019 Oct', 'sentence': 'PBKP35-induced mutants, including bacteriophage-insensitive K. pneumoniae ATCC 23357 (BIKPWT), ciprofloxacin-induced K. pneumoniae ATCC 23357 (BIKPCIP), and clinically isolated antibiotic-resistant K. pneumoniae CCARM 10263 (BIKPCLI).', 'subject score': 769, 'object score': 769}, 'PMID:3159336': {'publication date': '1985 Apr', 'sentence': 'Activities of pefloxacin and ciprofloxacin in experimentally induced Pseudomonas pneumonia in neutropenic guinea pigs.', 'subject score': 1000, 'object score': 775}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:causes---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "13950319",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:18777242",
-                "PMID:28591808",
-                "PMID:30263717",
-                "PMID:31325570",
-                "PMID:3159336"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 539955,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:12445016': {'publication date': '2002 Nov', 'sentence': 'This study compared the in vitro activity of ertapenem, ceftriaxone, cefepime, ciprofloxacin and amoxicillin-clavulanate against 381 aerobic and facultative bacterial pathogens isolated from 320 patients with acute bacterial exacerbation of chronic bronchitis or community-acquired pneumonia.', 'subject score': 1000, 'object score': 851}, 'PMID:15318274': {'publication date': '2004 Jul', 'sentence': 'Antimicrobial resistance among these pathogens is high and E. coli and K. pneumoniae isolates with resistance to third-generation cephalosporins and ciprofloxacin are increasing.', 'subject score': 1000, 'object score': 888}, 'PMID:15729490': {'publication date': '2005 Feb', 'sentence': 'The effect of intravenous ciprofloxacin (CPFX) on hospital-acquired pneumonia was examined.', 'subject score': 888, 'object score': 901}, 'PMID:16687900': {'publication date': '2006', 'sentence': 'The resistance to carbapenems, piperacillin, gentamycin, amikacin, and ciprofloxacin was compared between ESBL-producing and non-ESBL-producing K. pneumoniae strains resistant to third-generation antibiotics.', 'subject score': 1000, 'object score': 740}, 'PMID:16801413': {'publication date': '2006 Jul', 'sentence': 'Incubation with ciprofloxacin did not alter the expression of the K. pneumoniae loci involved in resistance to APs.', 'subject score': 1000, 'object score': 623}, 'PMID:17721686': {'publication date': '2007 Aug', 'sentence': 'The data showed increased resistance rates of hospital-acquired isolates of K. pneumoniae to ceftriaxone, gentamicin, and ciprofloxacin; the data also showed that hospital-acquired, rather than outpatient isolates, were more likely to be resistant to multiple antibiotics.', 'subject score': 1000, 'object score': 888}, 'PMID:18318249': {'publication date': '2008 Feb', 'sentence': 'We studied the clinical effects of intravenous ciprofloxacin (CPFX) on community-acquired pneumonia in patients with positive Immunocard Mycoplasma test results.', 'subject score': 888, 'object score': 851}, 'PMID:19001833': {'publication date': '2008', 'sentence': 'A statistically significant positive correlation between quinolone consumption and K. pneumoniae resistance to ciprofloxacin was determined.', 'subject score': 1000, 'object score': 623}, 'PMID:19567345': {'publication date': '2009 Jun', 'sentence': 'Resistance to ciprofloxacin was higher among the ESBL-producing strains of E. coli and K. pneumoniae than the non-ESBL producers.', 'subject score': 1000, 'object score': 888}, 'PMID:19622455': {'publication date': '2009 Aug', 'sentence': 'In K. pneumoniae resistance to imipenem, ciprofloxacin and amikacin was 3.1%, 17.8% 12.4% respectively.', 'subject score': 1000, 'object score': 623}, 'PMID:20541915': {'publication date': '2010 Sep', 'sentence': 'Hypermutation in K. pneumoniae is uncommon and does not contribute to accumulation of QRDR mutations or directly to ciprofloxacin resistance.', 'subject score': 694, 'object score': 888}, 'PMID:21286930': {'publication date': '2011 Jun', 'sentence': 'Fluoroquinolone efflux activity is much more common in clinical isolates of K. pneumoniae than previously reported and it can contribute to decreased ciprofloxacin susceptibility.', 'subject score': 851, 'object score': 888}, 'PMID:21563956': {'publication date': '2011 Sep', 'sentence': 'However, 71.4% and 98.4% of qnr-negative K. pneumoniae and E. coli contained double QRDR mutations, and most presented high-level CIP resistance.', 'subject score': 559, 'object score': 775}, 'PMID:23587777': {'publication date': '2013 May', 'sentence': 'Resistance to ciprofloxacin was a component of most multidrug-resistant (MDR) phenotypes for E. coli, K. pneumoniae, E. cloacae, P. aeruginosa and S. aureus.', 'subject score': 1000, 'object score': 888}, 'PMID:27318458': {'publication date': '2016 Aug', 'sentence': 'E. coli and K. pneumoniae showed a high percentage of strains resistance to ciprofloxacin of 37% and 29%, respectively.', 'subject score': 1000, 'object score': 888}, 'PMID:27938381': {'publication date': '2016 Dec 09', 'sentence': 'Noticeable cross-resistance pattern was observed at the 1/4CIP-CIP, showing the increased resistance of K. pneumoniae to chloramphenicol, ciprofloxacin, kanamycin, levofloxacin, nalidixic acid norfloxacin, sulphamethoxazole/trimethoprim, and tetracycline.', 'subject score': 1000, 'object score': 888}, 'PMID:28435070': {'publication date': '2017 09 23', 'sentence': 'To explore the relevance of and understand the potential mechanisms behind the production of siderophores by clinical isolates of K. pneumoniae and ciprofloxacin (CIP) resistance, we divided the K. pneumoniae isolates into two groups based on bacterial siderophores production: high siderophore-yielding group (39 strains) and low siderophore-yielding group (38 strains).', 'subject score': 694, 'object score': 888}, 'PMID:28992981': {'publication date': '2018 Apr 13', 'sentence': 'CONCLUSIONS: ESBL producing E. coli and K. pneumoniae were prevalent, especially the latter, with a significant resistance to ciprofloxacin and cotrimoxazole.', 'subject score': 1000, 'object score': 888}, 'PMID:30541613': {'publication date': '2018 Dec 12', 'sentence': 'From enterobacteriaceae isolates, K. pneumonia and E. coli showed higher estimates of ciprofloxacin resistance.', 'subject score': 694, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 321523,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-          "name": "infectious disease",
-          "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005550",
-            "SNOMEDCT:189822004",
-            "PSY:10513",
-            "UMLS:C0009450",
-            "UMLS:C0001485",
-            "EFO:0005741",
-            "MEDDRA:10021881",
-            "MESH:D003141",
-            "ICD9:079.0",
-            "DOID:0050117",
-            "SNOMEDCT:40733004",
-            "SNOMEDCT:191415002",
-            "NCIT:C26726"
-          ],
-          "id": "MONDO:0005550",
-          "category": "biolink:Disease",
-          "all_names": [
-            "infectious disease",
-            "Infectious Disorder",
-            "disease by infectious agent",
-            "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-            "Communicable Diseases"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://www.merriam-webster.com/medical/communicable%20disease",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-=======
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 539955,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-              "name": "infectious disease",
-              "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005550",
-                "SNOMEDCT:189822004",
-                "PSY:10513",
-                "UMLS:C0009450",
-                "UMLS:C0001485",
-                "EFO:0005741",
-                "MEDDRA:10021881",
-                "MESH:D003141",
-                "ICD9:079.0",
-                "DOID:0050117",
-                "SNOMEDCT:40733004",
-                "SNOMEDCT:191415002",
-                "NCIT:C26726"
-              ],
-              "id": "MONDO:0005550",
-              "category": "biolink:Disease",
-              "all_names": [
-                "infectious disease",
-                "Infectious Disorder",
-                "disease by infectious agent",
-                "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-                "Communicable Diseases"
-=======
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://www.merriam-webster.com/medical/communicable%20disease",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-=======
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 9988524,
-            "start": 616,
-            "end": 539955,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12763508': {'publication date': '2003 Jun', 'sentence': 'Conversely, some broad-spectrum antibiotics, including ureidopenicillins (e.g. piperacillin-tazobactam) and ciprofloxacin, are less likely to induce C. difficile infection.', 'subject score': 1000, 'object score': 827}, 'PMID:14628617': {'publication date': '2003', 'sentence': 'RESULTS: Thirteen late surgical infections were caused by a ciprofloxacin and gentamycin-resistant P. aeruginosa.', 'subject score': 1000, 'object score': 775}, 'PMID:16220016': {'publication date': '2005 Nov-Dec', 'sentence': 'MDR S. enterica serotypes typhi and paratyphi A, with reduced susceptibility to ceftriaxone and ciprofloxacin, are among the most frequent causes of bloodstream infections in IDH, suggesting the need to monitor their susceptibility.', 'subject score': 1000, 'object score': 888}, 'PMID:21489757': {'publication date': '2011 Jun', 'sentence': 'Correlation between fluoroquinolone consumption in hospitals and ciprofloxacin resistance amongst Pseudomonas aeruginosa isolates causing healthcare-associated infections, Taiwan, 2000-2009.', 'subject score': 694, 'object score': 802}, 'PMID:2254224': {'publication date': '1990 Oct', 'sentence': 'Although the initial cases of colonization or infection with CR-MRSA can be directly related to ciprofloxacin use, many of the subsequent cases of colonization and infection were not the consequence of ciprofloxacin therapy but rather hospital transmission of existing CR-MRSA.', 'subject score': 888, 'object score': 1000}, 'PMID:2391738': {'publication date': '1990 Sep 19', 'sentence': 'We conclude that ciprofloxacin in dosages as high as 2 g daily is inadequate for treatment of chlamydial urethritis in men, often resulting in relapsing infections.', 'subject score': 1000, 'object score': 888}, 'PMID:25863835': {'publication date': '2015 Jun', 'sentence': 'We found 750-mg levofloxacin resulted in significantly fewer severe infections compared with 500-mg ciprofloxacin potentially because of its longer half-life.', 'subject score': 750, 'object score': 750}, 'PMID:30115947': {'publication date': '2018 Aug 16', 'sentence': 'To elucidate mechanisms underlying ciprofloxacin (CIP) resistance in Gram-negative pathogens causing infections to cancer patients, 169 isolates were investigated.', 'subject score': 694, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:causes---None---None---None---UMLS:C0009450---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "10209213",
-              "object": "MONDO:0005550",
-              "publications": [
-                "PMID:12763508",
-                "PMID:14628617",
-                "PMID:16220016",
-                "PMID:21489757",
-                "PMID:2254224",
-                "PMID:2391738",
-                "PMID:25863835",
-                "PMID:30115947"
-=======
-            "identity": 9677689,
-            "start": 616,
-            "end": 321523,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12445016': {'publication date': '2002 Nov', 'sentence': 'This study compared the in vitro activity of ertapenem, ceftriaxone, cefepime, ciprofloxacin and amoxicillin-clavulanate against 381 aerobic and facultative bacterial pathogens isolated from 320 patients with acute bacterial exacerbation of chronic bronchitis or community-acquired pneumonia.', 'subject score': 1000, 'object score': 851}, 'PMID:15318274': {'publication date': '2004 Jul', 'sentence': 'Antimicrobial resistance among these pathogens is high and E. coli and K. pneumoniae isolates with resistance to third-generation cephalosporins and ciprofloxacin are increasing.', 'subject score': 1000, 'object score': 888}, 'PMID:15729490': {'publication date': '2005 Feb', 'sentence': 'The effect of intravenous ciprofloxacin (CPFX) on hospital-acquired pneumonia was examined.', 'subject score': 888, 'object score': 901}, 'PMID:16687900': {'publication date': '2006', 'sentence': 'The resistance to carbapenems, piperacillin, gentamycin, amikacin, and ciprofloxacin was compared between ESBL-producing and non-ESBL-producing K. pneumoniae strains resistant to third-generation antibiotics.', 'subject score': 1000, 'object score': 740}, 'PMID:16801413': {'publication date': '2006 Jul', 'sentence': 'Incubation with ciprofloxacin did not alter the expression of the K. pneumoniae loci involved in resistance to APs.', 'subject score': 1000, 'object score': 623}, 'PMID:17721686': {'publication date': '2007 Aug', 'sentence': 'The data showed increased resistance rates of hospital-acquired isolates of K. pneumoniae to ceftriaxone, gentamicin, and ciprofloxacin; the data also showed that hospital-acquired, rather than outpatient isolates, were more likely to be resistant to multiple antibiotics.', 'subject score': 1000, 'object score': 888}, 'PMID:18318249': {'publication date': '2008 Feb', 'sentence': 'We studied the clinical effects of intravenous ciprofloxacin (CPFX) on community-acquired pneumonia in patients with positive Immunocard Mycoplasma test results.', 'subject score': 888, 'object score': 851}, 'PMID:19001833': {'publication date': '2008', 'sentence': 'A statistically significant positive correlation between quinolone consumption and K. pneumoniae resistance to ciprofloxacin was determined.', 'subject score': 1000, 'object score': 623}, 'PMID:19567345': {'publication date': '2009 Jun', 'sentence': 'Resistance to ciprofloxacin was higher among the ESBL-producing strains of E. coli and K. pneumoniae than the non-ESBL producers.', 'subject score': 1000, 'object score': 888}, 'PMID:19622455': {'publication date': '2009 Aug', 'sentence': 'In K. pneumoniae resistance to imipenem, ciprofloxacin and amikacin was 3.1%, 17.8% 12.4% respectively.', 'subject score': 1000, 'object score': 623}, 'PMID:20541915': {'publication date': '2010 Sep', 'sentence': 'Hypermutation in K. pneumoniae is uncommon and does not contribute to accumulation of QRDR mutations or directly to ciprofloxacin resistance.', 'subject score': 694, 'object score': 888}, 'PMID:21286930': {'publication date': '2011 Jun', 'sentence': 'Fluoroquinolone efflux activity is much more common in clinical isolates of K. pneumoniae than previously reported and it can contribute to decreased ciprofloxacin susceptibility.', 'subject score': 851, 'object score': 888}, 'PMID:21563956': {'publication date': '2011 Sep', 'sentence': 'However, 71.4% and 98.4% of qnr-negative K. pneumoniae and E. coli contained double QRDR mutations, and most presented high-level CIP resistance.', 'subject score': 559, 'object score': 775}, 'PMID:23587777': {'publication date': '2013 May', 'sentence': 'Resistance to ciprofloxacin was a component of most multidrug-resistant (MDR) phenotypes for E. coli, K. pneumoniae, E. cloacae, P. aeruginosa and S. aureus.', 'subject score': 1000, 'object score': 888}, 'PMID:27318458': {'publication date': '2016 Aug', 'sentence': 'E. coli and K. pneumoniae showed a high percentage of strains resistance to ciprofloxacin of 37% and 29%, respectively.', 'subject score': 1000, 'object score': 888}, 'PMID:27938381': {'publication date': '2016 Dec 09', 'sentence': 'Noticeable cross-resistance pattern was observed at the 1/4CIP-CIP, showing the increased resistance of K. pneumoniae to chloramphenicol, ciprofloxacin, kanamycin, levofloxacin, nalidixic acid norfloxacin, sulphamethoxazole/trimethoprim, and tetracycline.', 'subject score': 1000, 'object score': 888}, 'PMID:28435070': {'publication date': '2017 09 23', 'sentence': 'To explore the relevance of and understand the potential mechanisms behind the production of siderophores by clinical isolates of K. pneumoniae and ciprofloxacin (CIP) resistance, we divided the K. pneumoniae isolates into two groups based on bacterial siderophores production: high siderophore-yielding group (39 strains) and low siderophore-yielding group (38 strains).', 'subject score': 694, 'object score': 888}, 'PMID:28992981': {'publication date': '2018 Apr 13', 'sentence': 'CONCLUSIONS: ESBL producing E. coli and K. pneumoniae were prevalent, especially the latter, with a significant resistance to ciprofloxacin and cotrimoxazole.', 'subject score': 1000, 'object score': 888}, 'PMID:30541613': {'publication date': '2018 Dec 12', 'sentence': 'From enterobacteriaceae isolates, K. pneumonia and E. coli showed higher estimates of ciprofloxacin resistance.', 'subject score': 694, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "9891814",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:12445016",
-                "PMID:15318274",
-                "PMID:15729490",
-                "PMID:16687900",
-                "PMID:16801413",
-                "PMID:17721686",
-                "PMID:18318249",
-                "PMID:19001833",
-                "PMID:19567345",
-                "PMID:19622455",
-                "PMID:20541915",
-                "PMID:21286930",
-                "PMID:21563956",
-                "PMID:23587777",
-                "PMID:27318458",
-                "PMID:27938381",
-                "PMID:28435070",
-                "PMID:28992981",
-                "PMID:30541613"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10225583': {'publication date': '1999 Mar', 'sentence': 'Initial treatment of severe pneumonia with ciprofloxacin resulted in significantly less subsequent gram-negative infection and was associated with substantially lower curative costs.', 'subject score': 1000, 'object score': 888}, 'PMID:10685245': {'publication date': '1999 Jun', 'sentence': 'The infant developed sepsis and meningitis resulting from multidrug-resistant K. pneumoniae, which was treated with ciprofloxacin and gentamicin.', 'subject score': 1000, 'object score': 843}, 'PMID:10722430': {'publication date': '2000 Mar', 'sentence': 'Multivariate analysis revealed that risk factors for ciprofloxacin resistance in K. pneumoniae included prior receipt of a quinolone (P=.0065) and an ESBL-producing strain (P=.012).', 'subject score': 694, 'object score': 888}, 'PMID:11418511': {'publication date': '2001 Jul', 'sentence': 'K. pneumoniae strains resistant to ciprofloxacin were also resistant to levofloxacin.', 'subject score': 1000, 'object score': 888}, 'PMID:11709326': {'publication date': '2001 Dec', 'sentence': 'Pharmacodynamic data on ciprofloxacin indicate that a target area under the concentration-time curve from 0 to 24 h (AUC(0-24))/MIC ratio of >or=125 is necessary to achieve optimal bactericidal activity for the treatment of gram-negative pneumonia.', 'subject score': 1000, 'object score': 851}, 'PMID:11735679': {'publication date': '2001', 'sentence': 'Piperacillin/tazobactam was dominant (greater efficacy and lower costs) versus imipenem/cilastatin in intra-abdominal infections and ceftriaxone, ciprofloxacin or meropenem in pneumonia.', 'subject score': 1000, 'object score': 1000}, 'PMID:12168746': {'publication date': '2002 Jul', 'sentence': 'Double mutants in the parC and gyrA genes lead to fluoroquinolone resistance that has been found to cause bacteriological failure of the fluoroquinolones, particularly levofloxacin and ciprofloxacin, in the management of pneumonia and exacerbations of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:12375221': {'publication date': '2002 Oct', 'sentence': 'CONCLUSIONS: Due to the high success rate, even in cases with failed antimicrobial pretreatment, and the favourable risk-benefit ratio of high-dose ciprofloxacin, ciprofloxacin appears to be an attractive choice in the empiric treatment of hospital-acquired pneumonia.', 'subject score': 1000, 'object score': 901}, 'PMID:14567253': {'publication date': '2003 Aug', 'sentence': '49 cases of community-acquired pneumonia were treated by intravenous ciprofloxacin.', 'subject score': 888, 'object score': 851}, 'PMID:15318274': {'publication date': '2004 Jul', 'sentence': 'Overall, 33% of E. coli and 13% of K. pneumoniae were resistant to ciprofloxacin.', 'subject score': 1000, 'object score': 888}, 'PMID:15320954': {'publication date': '2004 Aug 22', 'sentence': 'K. pneumoniae isolates of the extended-spectrum beta-lactamase phenotype were more resistant to imipenem, ciprofloxacin, and tetracycline in our study than they are in other regions of the world.', 'subject score': 1000, 'object score': 888}, 'PMID:15729490': {'publication date': '2005 Feb', 'sentence': 'Based on the above data, intravenous CPFX may be the drug which should be recommended as the first choice for hospital-acquired pneumonia.', 'subject score': 888, 'object score': 901}, 'PMID:16312637': {'publication date': '1989 Jul', 'sentence': 'Efficacy and safety in the oral treatment of purulent chest disease and pneumonia with cefixime, ofloxacin, and ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:17122017': {'publication date': '2007 Feb', 'sentence': 'The MICs of azithromycin, doxycycline, ciprofloxacin, and enrofloxacin for 10 C. pneumoniae isolates from these bandicoots ranged from 0.015 to 1 microg/ml, 0.25 to 1 microg/ml, 0.25 to 2 microg/ml, and 0.25 to 0.5 microg/ml, respectively.', 'subject score': 1000, 'object score': 827}, 'PMID:17373114': {'publication date': '2007', 'sentence': 'Recommended treatment of Rhodococcus equi pneumonia includes particularly vancomycin, amikacin, rifampicin, imipenem, ciprofloxacin and erythromycin.', 'subject score': 1000, 'object score': 901}, 'PMID:18159305': {'publication date': '2000 Nov', 'sentence': 'A knowledge assessment showed satisfactory knowledge except in two areas - an overestimation of the prevalence of penicillin-resistant Streptococcus pneumoniae in Nova Scotia and the view that ciprofloxacin was an effective antibiotic for the treatment of CAP (42% of physicians).', 'subject score': 1000, 'object score': 851}, 'PMID:18558942': {'publication date': '2008 Jul', 'sentence': 'Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.', 'subject score': 1000, 'object score': 888}, 'PMID:18777242': {'publication date': '2008 Oct', 'sentence': 'This study indicates that pulmonary administration of CPFX could be an effective technique for the treatment of pneumonia.', 'subject score': 1000, 'object score': 1000}, 'PMID:1923916': {'publication date': '1991', 'sentence': 'When he began taking ciprofloxacin for pneumonia, he had renal and cardiac failure.', 'subject score': 861, 'object score': 1000}, 'PMID:1999086': {'publication date': '1991 Jan', 'sentence': 'Of the 17 pneumonia patients who completed ciprofloxacin treatment, 15 (88%) had resolution of signs and symptoms or improvement.', 'subject score': 888, 'object score': 790}}",
-    "p2": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7191244,
-            "start": 616,
-            "end": 321523,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10225583': {'publication date': '1999 Mar', 'sentence': 'Initial treatment of severe pneumonia with ciprofloxacin resulted in significantly less subsequent gram-negative infection and was associated with substantially lower curative costs.', 'subject score': 1000, 'object score': 888}, 'PMID:10685245': {'publication date': '1999 Jun', 'sentence': 'The infant developed sepsis and meningitis resulting from multidrug-resistant K. pneumoniae, which was treated with ciprofloxacin and gentamicin.', 'subject score': 1000, 'object score': 843}, 'PMID:10722430': {'publication date': '2000 Mar', 'sentence': 'Multivariate analysis revealed that risk factors for ciprofloxacin resistance in K. pneumoniae included prior receipt of a quinolone (P=.0065) and an ESBL-producing strain (P=.012).', 'subject score': 694, 'object score': 888}, 'PMID:11418511': {'publication date': '2001 Jul', 'sentence': 'K. pneumoniae strains resistant to ciprofloxacin were also resistant to levofloxacin.', 'subject score': 1000, 'object score': 888}, 'PMID:11709326': {'publication date': '2001 Dec', 'sentence': 'Pharmacodynamic data on ciprofloxacin indicate that a target area under the concentration-time curve from 0 to 24 h (AUC(0-24))/MIC ratio of >or=125 is necessary to achieve optimal bactericidal activity for the treatment of gram-negative pneumonia.', 'subject score': 1000, 'object score': 851}, 'PMID:11735679': {'publication date': '2001', 'sentence': 'Piperacillin/tazobactam was dominant (greater efficacy and lower costs) versus imipenem/cilastatin in intra-abdominal infections and ceftriaxone, ciprofloxacin or meropenem in pneumonia.', 'subject score': 1000, 'object score': 1000}, 'PMID:12168746': {'publication date': '2002 Jul', 'sentence': 'Double mutants in the parC and gyrA genes lead to fluoroquinolone resistance that has been found to cause bacteriological failure of the fluoroquinolones, particularly levofloxacin and ciprofloxacin, in the management of pneumonia and exacerbations of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:12375221': {'publication date': '2002 Oct', 'sentence': 'CONCLUSIONS: Due to the high success rate, even in cases with failed antimicrobial pretreatment, and the favourable risk-benefit ratio of high-dose ciprofloxacin, ciprofloxacin appears to be an attractive choice in the empiric treatment of hospital-acquired pneumonia.', 'subject score': 1000, 'object score': 901}, 'PMID:14567253': {'publication date': '2003 Aug', 'sentence': '49 cases of community-acquired pneumonia were treated by intravenous ciprofloxacin.', 'subject score': 888, 'object score': 851}, 'PMID:15318274': {'publication date': '2004 Jul', 'sentence': 'Overall, 33% of E. coli and 13% of K. pneumoniae were resistant to ciprofloxacin.', 'subject score': 1000, 'object score': 888}, 'PMID:15320954': {'publication date': '2004 Aug 22', 'sentence': 'K. pneumoniae isolates of the extended-spectrum beta-lactamase phenotype were more resistant to imipenem, ciprofloxacin, and tetracycline in our study than they are in other regions of the world.', 'subject score': 1000, 'object score': 888}, 'PMID:15729490': {'publication date': '2005 Feb', 'sentence': 'Based on the above data, intravenous CPFX may be the drug which should be recommended as the first choice for hospital-acquired pneumonia.', 'subject score': 888, 'object score': 901}, 'PMID:16312637': {'publication date': '1989 Jul', 'sentence': 'Efficacy and safety in the oral treatment of purulent chest disease and pneumonia with cefixime, ofloxacin, and ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:17122017': {'publication date': '2007 Feb', 'sentence': 'The MICs of azithromycin, doxycycline, ciprofloxacin, and enrofloxacin for 10 C. pneumoniae isolates from these bandicoots ranged from 0.015 to 1 microg/ml, 0.25 to 1 microg/ml, 0.25 to 2 microg/ml, and 0.25 to 0.5 microg/ml, respectively.', 'subject score': 1000, 'object score': 827}, 'PMID:17373114': {'publication date': '2007', 'sentence': 'Recommended treatment of Rhodococcus equi pneumonia includes particularly vancomycin, amikacin, rifampicin, imipenem, ciprofloxacin and erythromycin.', 'subject score': 1000, 'object score': 901}, 'PMID:18159305': {'publication date': '2000 Nov', 'sentence': 'A knowledge assessment showed satisfactory knowledge except in two areas - an overestimation of the prevalence of penicillin-resistant Streptococcus pneumoniae in Nova Scotia and the view that ciprofloxacin was an effective antibiotic for the treatment of CAP (42% of physicians).', 'subject score': 1000, 'object score': 851}, 'PMID:18558942': {'publication date': '2008 Jul', 'sentence': 'Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.', 'subject score': 1000, 'object score': 888}, 'PMID:18777242': {'publication date': '2008 Oct', 'sentence': 'This study indicates that pulmonary administration of CPFX could be an effective technique for the treatment of pneumonia.', 'subject score': 1000, 'object score': 1000}, 'PMID:1923916': {'publication date': '1991', 'sentence': 'When he began taking ciprofloxacin for pneumonia, he had renal and cardiac failure.', 'subject score': 861, 'object score': 1000}, 'PMID:1999086': {'publication date': '1991 Jan', 'sentence': 'Of the 17 pneumonia patients who completed ciprofloxacin treatment, 15 (88%) had resolution of signs and symptoms or improvement.', 'subject score': 888, 'object score': 790}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7337248",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:10225583",
-                "PMID:10685245",
-                "PMID:10722430",
-                "PMID:11418511",
-                "PMID:11709326",
-                "PMID:11735679",
-                "PMID:12168746",
-                "PMID:12375221",
-                "PMID:14567253",
-                "PMID:15318274",
-                "PMID:15320954",
-                "PMID:15729490",
-                "PMID:16312637",
-                "PMID:17122017",
-                "PMID:17373114",
-                "PMID:18159305",
-                "PMID:18558942",
-                "PMID:18777242",
-                "PMID:1923916",
-                "PMID:1999086"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:7486906': {'publication date': '1995 Aug', 'sentence': 'At physiologically relevant concentrations of piperacillin and ciprofloxacin, ciprofloxacin had the highest rates of killing against K. pneumoniae.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26006990,
-            "start": 616,
-            "end": 321523,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7486906': {'publication date': '1995 Aug', 'sentence': 'At physiologically relevant concentrations of piperacillin and ciprofloxacin, ciprofloxacin had the highest rates of killing against K. pneumoniae.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:disrupts---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "26466958",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:7486906"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:10933643': {'publication date': '2000 Aug', 'sentence': 'The susceptibility to ciprofloxacin decreased successively with decreasing susceptibility to cefuroxime for K. pneumoniae.', 'subject score': 1000, 'object score': 888}, 'PMID:1343609': {'publication date': '1992 Aug 11', 'sentence': 'Following completion of the study, monthly aerosolized pentamidine administered in conjunction with ciprofloxacin has provided complete protection against urinary tract infection and pneumocystis pneumonia in 30 transplant recipients unable to tolerate trimethoprim-sulfamethoxazole therapy.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8184815,
-            "start": 616,
-            "end": 321523,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10933643': {'publication date': '2000 Aug', 'sentence': 'The susceptibility to ciprofloxacin decreased successively with decreasing susceptibility to cefuroxime for K. pneumoniae.', 'subject score': 1000, 'object score': 888}, 'PMID:1343609': {'publication date': '1992 Aug 11', 'sentence': 'Following completion of the study, monthly aerosolized pentamidine administered in conjunction with ciprofloxacin has provided complete protection against urinary tract infection and pneumocystis pneumonia in 30 transplant recipients unable to tolerate trimethoprim-sulfamethoxazole therapy.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:prevents---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8364719",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:10933643",
-                "PMID:1343609"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:10049299': {'publication date': '1999 Mar', 'sentence': 'A biodegradable polymer of DL-dilactide that facilitates release of ciprofloxacin or pefloxacin at levels exceeding MICs for the causative microorganisms of chronic osteomyelitis is described.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319037,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005246",
-          "name": "osteomyelitis",
-          "description": "An acute or chronic infectious process affecting the bones.; Osteomyelitis is an inflammatory process accompanied by bone destruction and caused by an infecting microorganism. [HPO:probinson, PMID:15276398]; Like other parts of the body, bones can get infected. The infections are usually bacterial, but can also be fungal. They may spread to the bone from nearby skin or muscles, or from another part of the body through the bloodstream. People who are at risk for bone infections include those with diabetes, poor circulation, or recent injury to the bone. You may also be at risk if you are having hemodialysis.  Symptoms of bone infections include: Pain in the infected area Chills and fever Swelling, warmth, and redness  A blood test or imaging test such as an x-ray can tell if you have a bone infection. Treatment includes antibiotics and often surgery.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0008707",
-            "MEDDRA:10045927",
-            "MEDDRA:10031257",
-            "MEDDRA:10046086",
-            "SNOMEDCT:111253001",
-            "SNOMEDCT:40970001",
-            "UMLS:C2242472",
-            "MEDDRA:10031252",
-            "MEDDRA:10009091",
-            "HP:0002754",
-            "DOID:1019",
-            "UMLS:C0029443",
-            "NCIT:C26839",
-            "MESH:D010019",
-            "EFO:0003102",
-            "MEDDRA:10031259",
-            "MONDO:0005246",
-            "MEDDRA:10005977",
-            "MEDDRA:10031256",
-            "SNOMEDCT:60168000",
-            "MEDDRA:10061017",
-            "MEDDRA:10045936",
-            "MEDDRA:10009081",
-            "NCIT:C27577",
-            "ICD9:730.1",
-            "MEDDRA:10046076"
-          ],
-          "id": "MONDO:0005246",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteomyelitis",
-            "Chronic osteomyelitis",
-            "osteomyelitis",
-            "Bone Infection",
-            "Infection of bone"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://my.clevelandclinic.org/disorders/osteomyelitis/hic_osteomyelitis.aspx",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://en.wikipedia.org/wiki/osteomyelitis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000437.htm",
-            "http://www.mayoclinic.com/health/osteomyelitis/ds00759",
-            "PMID:15276398",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319037,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005246",
-              "name": "osteomyelitis",
-              "description": "An acute or chronic infectious process affecting the bones.; Osteomyelitis is an inflammatory process accompanied by bone destruction and caused by an infecting microorganism. [HPO:probinson, PMID:15276398]; Like other parts of the body, bones can get infected. The infections are usually bacterial, but can also be fungal. They may spread to the bone from nearby skin or muscles, or from another part of the body through the bloodstream. People who are at risk for bone infections include those with diabetes, poor circulation, or recent injury to the bone. You may also be at risk if you are having hemodialysis.  Symptoms of bone infections include: Pain in the infected area Chills and fever Swelling, warmth, and redness  A blood test or imaging test such as an x-ray can tell if you have a bone infection. Treatment includes antibiotics and often surgery.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0008707",
-                "MEDDRA:10045927",
-                "MEDDRA:10031257",
-                "MEDDRA:10046086",
-                "SNOMEDCT:111253001",
-                "SNOMEDCT:40970001",
-                "UMLS:C2242472",
-                "MEDDRA:10031252",
-                "MEDDRA:10009091",
-                "HP:0002754",
-                "DOID:1019",
-                "UMLS:C0029443",
-                "NCIT:C26839",
-                "MESH:D010019",
-                "EFO:0003102",
-                "MEDDRA:10031259",
-                "MONDO:0005246",
-                "MEDDRA:10005977",
-                "MEDDRA:10031256",
-                "SNOMEDCT:60168000",
-                "MEDDRA:10061017",
-                "MEDDRA:10045936",
-                "MEDDRA:10009081",
-                "NCIT:C27577",
-                "ICD9:730.1",
-                "MEDDRA:10046076"
-              ],
-              "id": "MONDO:0005246",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteomyelitis",
-                "Chronic osteomyelitis",
-                "osteomyelitis",
-                "Bone Infection",
-                "Infection of bone"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://my.clevelandclinic.org/disorders/osteomyelitis/hic_osteomyelitis.aspx",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://en.wikipedia.org/wiki/osteomyelitis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000437.htm",
-                "http://www.mayoclinic.com/health/osteomyelitis/ds00759",
-                "PMID:15276398",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 6976537,
-            "start": 616,
-            "end": 319037,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10049299': {'publication date': '1999 Mar', 'sentence': 'A biodegradable polymer of DL-dilactide that facilitates release of ciprofloxacin or pefloxacin at levels exceeding MICs for the causative microorganisms of chronic osteomyelitis is described.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:causes---None---None---None---UMLS:C0029443---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7113733",
-              "object": "MONDO:0005246",
-              "publications": [
-                "PMID:10049299"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 539955,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-          "name": "infectious disease",
-          "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005550",
-            "SNOMEDCT:189822004",
-            "PSY:10513",
-            "UMLS:C0009450",
-            "UMLS:C0001485",
-            "EFO:0005741",
-            "MEDDRA:10021881",
-            "MESH:D003141",
-            "ICD9:079.0",
-            "DOID:0050117",
-            "SNOMEDCT:40733004",
-            "SNOMEDCT:191415002",
-            "NCIT:C26726"
-          ],
-          "id": "MONDO:0005550",
-          "category": "biolink:Disease",
-          "all_names": [
-            "infectious disease",
-            "Infectious Disorder",
-            "disease by infectious agent",
-            "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-            "Communicable Diseases"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.merriam-webster.com/medical/communicable%20disease",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 539955,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-              "name": "infectious disease",
-              "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005550",
-                "SNOMEDCT:189822004",
-                "PSY:10513",
-                "UMLS:C0009450",
-                "UMLS:C0001485",
-                "EFO:0005741",
-                "MEDDRA:10021881",
-                "MESH:D003141",
-                "ICD9:079.0",
-                "DOID:0050117",
-                "SNOMEDCT:40733004",
-                "SNOMEDCT:191415002",
-                "NCIT:C26726"
-              ],
-              "id": "MONDO:0005550",
-              "category": "biolink:Disease",
-              "all_names": [
-                "infectious disease",
-                "Infectious Disorder",
-                "disease by infectious agent",
-                "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-                "Communicable Diseases"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.merriam-webster.com/medical/communicable%20disease",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21577798,
-            "start": 616,
-            "end": 539955,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32366243': {'publication date': '2020 May 04', 'sentence': 'Novel enterocin E20c purified from Enterococcus hirae 20c synergised with ss-lactams and ciprofloxacin against Salmonella enterica.BACKGROUND: An increasing rate of antibiotic resistance among Gram-negative bacterial pathogens has created an urgent need to discover novel therapeutic agents to combat infectious diseases.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0009450---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "21996198",
-              "object": "MONDO:0005550",
-              "publications": [
-                "PMID:32366243"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 212250,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-          "name": "Fever",
-          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10037660",
-            "MEDDRA:10020083",
-            "MEDDRA:10005911",
-            "UMLS:C0015967",
-            "HP:0001945",
-            "NCIT:C3038",
-            "MEDDRA:10073718",
-            "MEDDRA:10043204",
-            "MEDDRA:10037668",
-            "PDQ:CDR0000775882",
-            "PSY:19660",
-            "SNOMEDCT:386661006",
-            "MEDDRA:10016558",
-            "MEDDRA:10037663",
-            "SNOMEDCT:50177009",
-            "SYMP:0000613",
-            "MESH:D005334"
-          ],
-          "id": "HP:0001945",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "fever",
-            "Fever"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:9759682",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 212250,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-              "name": "Fever",
-              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10037660",
-                "MEDDRA:10020083",
-                "MEDDRA:10005911",
-                "UMLS:C0015967",
-                "HP:0001945",
-                "NCIT:C3038",
-                "MEDDRA:10073718",
-                "MEDDRA:10043204",
-                "MEDDRA:10037668",
-                "PDQ:CDR0000775882",
-                "PSY:19660",
-                "SNOMEDCT:386661006",
-                "MEDDRA:10016558",
-                "MEDDRA:10037663",
-                "SNOMEDCT:50177009",
-                "SYMP:0000613",
-                "MESH:D005334"
-              ],
-              "id": "HP:0001945",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "fever",
-                "Fever"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:9759682",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16226316,
-            "start": 616,
-            "end": 212250,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23080291': {'publication date': '2013 Mar', 'sentence': 'Ciprofloxacin significantly reduced the occurrence of febrile episodes in patients with acute lymphoblastic leukemia in the induction phase of chemotherapy, but not in patients with lymphoma or in the consolidation phase of chemotherapy.', 'subject score': 1000, 'object score': 888}, 'PMID:8164024': {'publication date': '1994 May', 'sentence': 'RESULTS: In patients treated with bone marrow and PBPCs, the incidence of fever during neutropenia was reduced by ciprofloxacin and rifampin from 98% to 57%.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:inhibits---biolink:causes---activity---None---UMLS:C0015967---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "16563368",
-              "object": "HP:0001945",
-              "publications": [
-                "PMID:23080291",
-                "PMID:8164024"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:2233400': {'publication date': '1990', 'sentence': 'Effect of ciprofloxacin on experimental osteomyelitis in the rabbit tibia, induced with a mixed infection of Staphylococcus epidermidis and Bacteroides thetaiotaomicron.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319037,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005246",
-          "name": "osteomyelitis",
-          "description": "An acute or chronic infectious process affecting the bones.; Osteomyelitis is an inflammatory process accompanied by bone destruction and caused by an infecting microorganism. [HPO:probinson, PMID:15276398]; Like other parts of the body, bones can get infected. The infections are usually bacterial, but can also be fungal. They may spread to the bone from nearby skin or muscles, or from another part of the body through the bloodstream. People who are at risk for bone infections include those with diabetes, poor circulation, or recent injury to the bone. You may also be at risk if you are having hemodialysis.  Symptoms of bone infections include: Pain in the infected area Chills and fever Swelling, warmth, and redness  A blood test or imaging test such as an x-ray can tell if you have a bone infection. Treatment includes antibiotics and often surgery.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0008707",
-            "MEDDRA:10045927",
-            "MEDDRA:10031257",
-            "MEDDRA:10046086",
-            "SNOMEDCT:111253001",
-            "SNOMEDCT:40970001",
-            "UMLS:C2242472",
-            "MEDDRA:10031252",
-            "MEDDRA:10009091",
-            "HP:0002754",
-            "DOID:1019",
-            "UMLS:C0029443",
-            "NCIT:C26839",
-            "MESH:D010019",
-            "EFO:0003102",
-            "MEDDRA:10031259",
-            "MONDO:0005246",
-            "MEDDRA:10005977",
-            "MEDDRA:10031256",
-            "SNOMEDCT:60168000",
-            "MEDDRA:10061017",
-            "MEDDRA:10045936",
-            "MEDDRA:10009081",
-            "NCIT:C27577",
-            "ICD9:730.1",
-            "MEDDRA:10046076"
-          ],
-          "id": "MONDO:0005246",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteomyelitis",
-            "Chronic osteomyelitis",
-            "osteomyelitis",
-            "Bone Infection",
-            "Infection of bone"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://my.clevelandclinic.org/disorders/osteomyelitis/hic_osteomyelitis.aspx",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://en.wikipedia.org/wiki/osteomyelitis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000437.htm",
-            "http://www.mayoclinic.com/health/osteomyelitis/ds00759",
-            "PMID:15276398",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319037,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005246",
-              "name": "osteomyelitis",
-              "description": "An acute or chronic infectious process affecting the bones.; Osteomyelitis is an inflammatory process accompanied by bone destruction and caused by an infecting microorganism. [HPO:probinson, PMID:15276398]; Like other parts of the body, bones can get infected. The infections are usually bacterial, but can also be fungal. They may spread to the bone from nearby skin or muscles, or from another part of the body through the bloodstream. People who are at risk for bone infections include those with diabetes, poor circulation, or recent injury to the bone. You may also be at risk if you are having hemodialysis.  Symptoms of bone infections include: Pain in the infected area Chills and fever Swelling, warmth, and redness  A blood test or imaging test such as an x-ray can tell if you have a bone infection. Treatment includes antibiotics and often surgery.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0008707",
-                "MEDDRA:10045927",
-                "MEDDRA:10031257",
-                "MEDDRA:10046086",
-                "SNOMEDCT:111253001",
-                "SNOMEDCT:40970001",
-                "UMLS:C2242472",
-                "MEDDRA:10031252",
-                "MEDDRA:10009091",
-                "HP:0002754",
-                "DOID:1019",
-                "UMLS:C0029443",
-                "NCIT:C26839",
-                "MESH:D010019",
-                "EFO:0003102",
-                "MEDDRA:10031259",
-                "MONDO:0005246",
-                "MEDDRA:10005977",
-                "MEDDRA:10031256",
-                "SNOMEDCT:60168000",
-                "MEDDRA:10061017",
-                "MEDDRA:10045936",
-                "MEDDRA:10009081",
-                "NCIT:C27577",
-                "ICD9:730.1",
-                "MEDDRA:10046076"
-              ],
-              "id": "MONDO:0005246",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteomyelitis",
-                "Chronic osteomyelitis",
-                "osteomyelitis",
-                "Bone Infection",
-                "Infection of bone"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://my.clevelandclinic.org/disorders/osteomyelitis/hic_osteomyelitis.aspx",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://en.wikipedia.org/wiki/osteomyelitis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000437.htm",
-                "http://www.mayoclinic.com/health/osteomyelitis/ds00759",
-                "PMID:15276398",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15796048,
-            "start": 616,
-            "end": 319037,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2233400': {'publication date': '1990', 'sentence': 'Effect of ciprofloxacin on experimental osteomyelitis in the rabbit tibia, induced with a mixed infection of Staphylococcus epidermidis and Bacteroides thetaiotaomicron.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0029443---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "16125923",
-              "object": "MONDO:0005246",
-              "publications": [
-                "PMID:2233400"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 322120,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10602739': {'publication date': '2000 Jan', 'sentence': 'The efficacy and safety of three oral fluoroquinolones (lomefloxacin, levofloxacin, and ciprofloxacin) for the treatment of chronic osteomyelitis were analyzed.', 'subject score': 1000, 'object score': 888}, 'PMID:15365265': {'publication date': '2004 Sep-Oct', 'sentence': 'Oral antibiotic treatment with amoxicillin-clavulanic acid was continued for 10 more days, followed by 25 days of ciprofloxacin for the osteomyelitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15793132': {'publication date': '2005 Apr', 'sentence': 'Efficacy of ciprofloxacin-releasing bioabsorbable osteoconductive bone defect filler for treatment of experimental osteomyelitis due to Staphylococcus aureus.', 'subject score': 1000, 'object score': 888}, 'PMID:15996581': {'publication date': '2005 Aug', 'sentence': 'A ciprofloxacin implant formulation composed of 12% hydroxyapatite, 36% tricalcium phosphate, 12% poly(DL-lactide) (PLA) and 40% ciprofloxacin was characterized in vivo for use in treatment of multibacterial bone infection.', 'subject score': 888, 'object score': 901}, 'PMID:17696153': {'publication date': '2008 Apr', 'sentence': 'Efficacy of ciprofloxacin implants in treating experimental osteomyelitis.', 'subject score': 1000, 'object score': 851}, 'PMID:18411320': {'publication date': '2008 Jul', 'sentence': 'Local treatment of experimental Pseudomonas aeruginosa osteomyelitis with a biodegradable dilactide polymer releasing ciprofloxacin.', 'subject score': 833, 'object score': 861}, 'PMID:18439310': {'publication date': '2008 Apr 27', 'sentence': 'Successful treatment of Mycobacterium ulcerans osteomyelitis with minor surgical debridement and prolonged rifampicin and ciprofloxacin therapy: a case report.', 'subject score': 888, 'object score': 901}, 'PMID:20409330': {'publication date': '2010 Apr 21', 'sentence': 'We report the case of a patient who received prolonged treatment with high-dose ciprofloxacin for extensive pelvic osteomyelitis.', 'subject score': 901, 'object score': 851}, 'PMID:2182039': {'publication date': '1990 Mar', 'sentence': 'We have not been presenting ciprofloxacin as a panacea, but as an effective alternative, with clear indications that can decreases the cost of the treatment of osteomyelitis associated with PVI.', 'subject score': 1000, 'object score': 1000}, 'PMID:2183710': {'publication date': '1990 Jan', 'sentence': 'We undertook a prospective, randomized comparison of oral ciprofloxacin with standard parenteral therapies for the treatment of biopsy-proven osteomyelitis caused by susceptible organisms.', 'subject score': 888, 'object score': 802}, 'PMID:2196154': {'publication date': '1990 Mar-Apr', 'sentence': 'Ciprofloxacin in the treatment of Staphylococcus aureus osteomyelitis.', 'subject score': 1000, 'object score': 901}, 'PMID:2295657': {'publication date': '1990 Jan', 'sentence': 'A group of fourteen patients who had chronic osteomyelitis and were treated with oral ciprofloxacin was compared with a group of twelve patients of similar age who had chronic osteomyelitis and received standard parenteral antibiotic therapy consisting of nafcillin, clindamycin, and gentamicin, singly or in combination.', 'subject score': 888, 'object score': 888}, 'PMID:2300517': {'publication date': '1990 Jan', 'sentence': 'Eighteen patients with osteomyelitis were treated with ciprofloxacin, 750 mg orally twice daily.', 'subject score': 1000, 'object score': 1000}, 'PMID:23507926': {'publication date': '2013', 'sentence': 'An in vitro study of composites of poly(L-lactide-co-epsilon-caprolactone), beta-tricalcium phosphate and ciprofloxacin intended for local treatment of osteomyelitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2360823': {'publication date': '1990 May', 'sentence': 'Twenty-two adult patients with osteomyelitis due to Pseudomonas aeruginosa were enrolled in an open, prospective cooperative study to determine the efficacy of oral ciprofloxacin therapy in a dosage of 750 mg twice a day.', 'subject score': 851, 'object score': 1000}, 'PMID:2490638': {'publication date': '1989 Jan', 'sentence': 'The results of efficacy and safety of ciprofloxacin administered by parenteral and oral route in the treatment of severe infections-particularly, osteomyelitis and bacteremia-due to gram-negative bacilli are studied in the present work.', 'subject score': 1000, 'object score': 1000}, 'PMID:2505355': {'publication date': '1989 Jul-Aug', 'sentence': 'The neutropenic mouse model of infection has demonstrated the synergistic effect of ciprofloxacin plus antipseudomonal penicillins; the combination of ciprofloxacin and rifampin has been superior to single agents in experimental Staphylococcus aureus osteomyelitis.', 'subject score': 1000, 'object score': 861}, 'PMID:25364693': {'publication date': '2014 Oct', 'sentence': 'However, despite its insolubility, microscopic observation, differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and X-ray diffraction showed that the developed gel was in the cubic liquid crystalline structure and have maintained their ability to progressively release ciprofloxacin. ciprofloxacin-monoolein-water (5:80:15% w/w), which released in vitro approximately 85% of ciprofloxacin after 16 days could possibly be considered as an alternative to a gentamicin-monoolein-water gel for the treatment of chronic osteomyelitis.', 'subject score': 1000, 'object score': 888}, 'PMID:25429485': {'publication date': '2014 Aug', 'sentence': 'During two weeks of peri-operative and postoperative period, chronic osteomyelitis was treated by intravenous ciprofloxacin and gentamycin, and after that by a combination of rifampicin and trimethoprim-sulfamethoxazole orally, for six months.', 'subject score': 888, 'object score': 888}, 'PMID:2661635': {'publication date': '1989 Mar-Apr', 'sentence': 'The authors also provide a detailed discussion of the efficacy of ciprofloxacin for osteomyelitis in animal studies and human trials.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319037,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-          "name": "Crohn disease",
-          "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003424",
-            "ORPHANET:206",
-            "NCIT:C37262",
-            "MEDDRA:10038281",
-            "MEDDRA:10011405",
-            "UMLS:CN043071",
-            "SNOMEDCT:50440006",
-            "MEDDRA:10057032",
-            "HP:0100280",
-            "EFO:0000384",
-            "DOID:8778",
-            "MONDO:0005011",
-            "PDQ:CDR0000714480",
-            "UMLS:C0010346",
-            "NCIT:C2965",
-            "SNOMEDCT:7620006",
-            "ICD10:K50.1",
-            "UMLS:C0156147",
-            "MEDDRA:10011398",
-            "MEDDRA:10011401",
-            "SNOMEDCT:34000006",
-            "ICD9:555.1",
-            "MEDDRA:10013099",
-            "MEDDRA:10011402",
-            "MEDDRA:10011400"
-          ],
-          "id": "MONDO:0005011",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Granulomatous Colitis",
-            "Crohn's disease of large bowel",
-            "Regional enteritis of large intestine",
-            "Crohn Disease",
-            "Crohn disease",
-            "Crohn's disease"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005246",
-          "name": "osteomyelitis",
-          "description": "An acute or chronic infectious process affecting the bones.; Osteomyelitis is an inflammatory process accompanied by bone destruction and caused by an infecting microorganism. [HPO:probinson, PMID:15276398]; Like other parts of the body, bones can get infected. The infections are usually bacterial, but can also be fungal. They may spread to the bone from nearby skin or muscles, or from another part of the body through the bloodstream. People who are at risk for bone infections include those with diabetes, poor circulation, or recent injury to the bone. You may also be at risk if you are having hemodialysis.  Symptoms of bone infections include: Pain in the infected area Chills and fever Swelling, warmth, and redness  A blood test or imaging test such as an x-ray can tell if you have a bone infection. Treatment includes antibiotics and often surgery.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0008707",
-            "MEDDRA:10045927",
-            "MEDDRA:10031257",
-            "MEDDRA:10046086",
-            "SNOMEDCT:111253001",
-            "SNOMEDCT:40970001",
-            "UMLS:C2242472",
-            "MEDDRA:10031252",
-            "MEDDRA:10009091",
-            "HP:0002754",
-            "DOID:1019",
-            "UMLS:C0029443",
-            "NCIT:C26839",
-            "MESH:D010019",
-            "EFO:0003102",
-            "MEDDRA:10031259",
-            "MONDO:0005246",
-            "MEDDRA:10005977",
-            "MEDDRA:10031256",
-            "SNOMEDCT:60168000",
-            "MEDDRA:10061017",
-            "MEDDRA:10045936",
-            "MEDDRA:10009081",
-            "NCIT:C27577",
-            "ICD9:730.1",
-            "MEDDRA:10046076"
-          ],
-          "id": "MONDO:0005246",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteomyelitis",
-            "Chronic osteomyelitis",
-            "osteomyelitis",
-            "Bone Infection",
-            "Infection of bone"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://en.wikipedia.org/wiki/chron%27s_disease",
-            "https://orcid.org/0009-0006-4530-3154"
-=======
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://my.clevelandclinic.org/disorders/osteomyelitis/hic_osteomyelitis.aspx",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://en.wikipedia.org/wiki/osteomyelitis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000437.htm",
-            "http://www.mayoclinic.com/health/osteomyelitis/ds00759",
-            "PMID:15276398",
-            "https://orcid.org/0000-0002-6601-2165"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 322120,
-=======
-            "identity": 319037,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-              "name": "Crohn disease",
-              "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003424",
-                "ORPHANET:206",
-                "NCIT:C37262",
-                "MEDDRA:10038281",
-                "MEDDRA:10011405",
-                "UMLS:CN043071",
-                "SNOMEDCT:50440006",
-                "MEDDRA:10057032",
-                "HP:0100280",
-                "EFO:0000384",
-                "DOID:8778",
-                "MONDO:0005011",
-                "PDQ:CDR0000714480",
-                "UMLS:C0010346",
-                "NCIT:C2965",
-                "SNOMEDCT:7620006",
-                "ICD10:K50.1",
-                "UMLS:C0156147",
-                "MEDDRA:10011398",
-                "MEDDRA:10011401",
-                "SNOMEDCT:34000006",
-                "ICD9:555.1",
-                "MEDDRA:10013099",
-                "MEDDRA:10011402",
-                "MEDDRA:10011400"
-              ],
-              "id": "MONDO:0005011",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Granulomatous Colitis",
-                "Crohn's disease of large bowel",
-                "Regional enteritis of large intestine",
-                "Crohn Disease",
-                "Crohn disease",
-                "Crohn's disease"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005246",
-              "name": "osteomyelitis",
-              "description": "An acute or chronic infectious process affecting the bones.; Osteomyelitis is an inflammatory process accompanied by bone destruction and caused by an infecting microorganism. [HPO:probinson, PMID:15276398]; Like other parts of the body, bones can get infected. The infections are usually bacterial, but can also be fungal. They may spread to the bone from nearby skin or muscles, or from another part of the body through the bloodstream. People who are at risk for bone infections include those with diabetes, poor circulation, or recent injury to the bone. You may also be at risk if you are having hemodialysis.  Symptoms of bone infections include: Pain in the infected area Chills and fever Swelling, warmth, and redness  A blood test or imaging test such as an x-ray can tell if you have a bone infection. Treatment includes antibiotics and often surgery.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0008707",
-                "MEDDRA:10045927",
-                "MEDDRA:10031257",
-                "MEDDRA:10046086",
-                "SNOMEDCT:111253001",
-                "SNOMEDCT:40970001",
-                "UMLS:C2242472",
-                "MEDDRA:10031252",
-                "MEDDRA:10009091",
-                "HP:0002754",
-                "DOID:1019",
-                "UMLS:C0029443",
-                "NCIT:C26839",
-                "MESH:D010019",
-                "EFO:0003102",
-                "MEDDRA:10031259",
-                "MONDO:0005246",
-                "MEDDRA:10005977",
-                "MEDDRA:10031256",
-                "SNOMEDCT:60168000",
-                "MEDDRA:10061017",
-                "MEDDRA:10045936",
-                "MEDDRA:10009081",
-                "NCIT:C27577",
-                "ICD9:730.1",
-                "MEDDRA:10046076"
-              ],
-              "id": "MONDO:0005246",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteomyelitis",
-                "Chronic osteomyelitis",
-                "osteomyelitis",
-                "Bone Infection",
-                "Infection of bone"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://en.wikipedia.org/wiki/chron%27s_disease",
-                "https://orcid.org/0009-0006-4530-3154"
-=======
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://my.clevelandclinic.org/disorders/osteomyelitis/hic_osteomyelitis.aspx",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://en.wikipedia.org/wiki/osteomyelitis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000437.htm",
-                "http://www.mayoclinic.com/health/osteomyelitis/ds00759",
-                "PMID:15276398",
-                "https://orcid.org/0000-0002-6601-2165"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 12668690,
-            "start": 616,
-            "end": 322120,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17253612': {'publication date': '2007 May', 'sentence': \"BACKGROUND: Crohn's exacerbation and pouchitis are commonly treated with ciprofloxacin and metronidazole.\", 'subject score': 1000, 'object score': 694}, 'PMID:29722812': {'publication date': '2018 Jul 12', 'sentence': 'Evidence also points to a likely modest role of various antibiotic classes in mild to moderate luminal CD, including ciprofloxacin, metronidazole, azithromycin, and rifaximin.', 'subject score': 1000, 'object score': 822}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0010346---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "12942741",
-              "object": "MONDO:0005011",
-              "publications": [
-                "PMID:17253612",
-                "PMID:29722812"
-=======
-            "identity": 7716640,
-            "start": 616,
-            "end": 319037,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10602739': {'publication date': '2000 Jan', 'sentence': 'The efficacy and safety of three oral fluoroquinolones (lomefloxacin, levofloxacin, and ciprofloxacin) for the treatment of chronic osteomyelitis were analyzed.', 'subject score': 1000, 'object score': 888}, 'PMID:15365265': {'publication date': '2004 Sep-Oct', 'sentence': 'Oral antibiotic treatment with amoxicillin-clavulanic acid was continued for 10 more days, followed by 25 days of ciprofloxacin for the osteomyelitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15793132': {'publication date': '2005 Apr', 'sentence': 'Efficacy of ciprofloxacin-releasing bioabsorbable osteoconductive bone defect filler for treatment of experimental osteomyelitis due to Staphylococcus aureus.', 'subject score': 1000, 'object score': 888}, 'PMID:15996581': {'publication date': '2005 Aug', 'sentence': 'A ciprofloxacin implant formulation composed of 12% hydroxyapatite, 36% tricalcium phosphate, 12% poly(DL-lactide) (PLA) and 40% ciprofloxacin was characterized in vivo for use in treatment of multibacterial bone infection.', 'subject score': 888, 'object score': 901}, 'PMID:17696153': {'publication date': '2008 Apr', 'sentence': 'Efficacy of ciprofloxacin implants in treating experimental osteomyelitis.', 'subject score': 1000, 'object score': 851}, 'PMID:18411320': {'publication date': '2008 Jul', 'sentence': 'Local treatment of experimental Pseudomonas aeruginosa osteomyelitis with a biodegradable dilactide polymer releasing ciprofloxacin.', 'subject score': 833, 'object score': 861}, 'PMID:18439310': {'publication date': '2008 Apr 27', 'sentence': 'Successful treatment of Mycobacterium ulcerans osteomyelitis with minor surgical debridement and prolonged rifampicin and ciprofloxacin therapy: a case report.', 'subject score': 888, 'object score': 901}, 'PMID:20409330': {'publication date': '2010 Apr 21', 'sentence': 'We report the case of a patient who received prolonged treatment with high-dose ciprofloxacin for extensive pelvic osteomyelitis.', 'subject score': 901, 'object score': 851}, 'PMID:2182039': {'publication date': '1990 Mar', 'sentence': 'We have not been presenting ciprofloxacin as a panacea, but as an effective alternative, with clear indications that can decreases the cost of the treatment of osteomyelitis associated with PVI.', 'subject score': 1000, 'object score': 1000}, 'PMID:2183710': {'publication date': '1990 Jan', 'sentence': 'We undertook a prospective, randomized comparison of oral ciprofloxacin with standard parenteral therapies for the treatment of biopsy-proven osteomyelitis caused by susceptible organisms.', 'subject score': 888, 'object score': 802}, 'PMID:2196154': {'publication date': '1990 Mar-Apr', 'sentence': 'Ciprofloxacin in the treatment of Staphylococcus aureus osteomyelitis.', 'subject score': 1000, 'object score': 901}, 'PMID:2295657': {'publication date': '1990 Jan', 'sentence': 'A group of fourteen patients who had chronic osteomyelitis and were treated with oral ciprofloxacin was compared with a group of twelve patients of similar age who had chronic osteomyelitis and received standard parenteral antibiotic therapy consisting of nafcillin, clindamycin, and gentamicin, singly or in combination.', 'subject score': 888, 'object score': 888}, 'PMID:2300517': {'publication date': '1990 Jan', 'sentence': 'Eighteen patients with osteomyelitis were treated with ciprofloxacin, 750 mg orally twice daily.', 'subject score': 1000, 'object score': 1000}, 'PMID:23507926': {'publication date': '2013', 'sentence': 'An in vitro study of composites of poly(L-lactide-co-epsilon-caprolactone), beta-tricalcium phosphate and ciprofloxacin intended for local treatment of osteomyelitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2360823': {'publication date': '1990 May', 'sentence': 'Twenty-two adult patients with osteomyelitis due to Pseudomonas aeruginosa were enrolled in an open, prospective cooperative study to determine the efficacy of oral ciprofloxacin therapy in a dosage of 750 mg twice a day.', 'subject score': 851, 'object score': 1000}, 'PMID:2490638': {'publication date': '1989 Jan', 'sentence': 'The results of efficacy and safety of ciprofloxacin administered by parenteral and oral route in the treatment of severe infections-particularly, osteomyelitis and bacteremia-due to gram-negative bacilli are studied in the present work.', 'subject score': 1000, 'object score': 1000}, 'PMID:2505355': {'publication date': '1989 Jul-Aug', 'sentence': 'The neutropenic mouse model of infection has demonstrated the synergistic effect of ciprofloxacin plus antipseudomonal penicillins; the combination of ciprofloxacin and rifampin has been superior to single agents in experimental Staphylococcus aureus osteomyelitis.', 'subject score': 1000, 'object score': 861}, 'PMID:25364693': {'publication date': '2014 Oct', 'sentence': 'However, despite its insolubility, microscopic observation, differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and X-ray diffraction showed that the developed gel was in the cubic liquid crystalline structure and have maintained their ability to progressively release ciprofloxacin. ciprofloxacin-monoolein-water (5:80:15% w/w), which released in vitro approximately 85% of ciprofloxacin after 16 days could possibly be considered as an alternative to a gentamicin-monoolein-water gel for the treatment of chronic osteomyelitis.', 'subject score': 1000, 'object score': 888}, 'PMID:25429485': {'publication date': '2014 Aug', 'sentence': 'During two weeks of peri-operative and postoperative period, chronic osteomyelitis was treated by intravenous ciprofloxacin and gentamycin, and after that by a combination of rifampicin and trimethoprim-sulfamethoxazole orally, for six months.', 'subject score': 888, 'object score': 888}, 'PMID:2661635': {'publication date': '1989 Mar-Apr', 'sentence': 'The authors also provide a detailed discussion of the efficacy of ciprofloxacin for osteomyelitis in animal studies and human trials.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0029443---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7880629",
-              "object": "MONDO:0005246",
-              "publications": [
-                "PMID:10602739",
-                "PMID:15365265",
-                "PMID:15793132",
-                "PMID:15996581",
-                "PMID:17696153",
-                "PMID:18411320",
-                "PMID:18439310",
-                "PMID:20409330",
-                "PMID:2182039",
-                "PMID:2183710",
-                "PMID:2196154",
-                "PMID:2295657",
-                "PMID:2300517",
-                "PMID:23507926",
-                "PMID:2360823",
-                "PMID:2490638",
-                "PMID:2505355",
-                "PMID:25364693",
-                "PMID:25429485",
-                "PMID:2661635"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 520880,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005619",
-          "name": "typhoid fever",
-          "description": "A bacterial infectious disorder contracted by consumption of food or drink contaminated with Salmonella typhi. This disorder is common in developing countries and can be treated with antibiotics.; An acute systemic febrile infection caused by SALMONELLA TYPHI, a serotype of SALMONELLA ENTERICA.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:13258",
-            "SNOMEDCT:4834000",
-            "MESH:D014435",
-            "MONDO:0005619",
-            "MEDDRA:10045272",
-            "MEDDRA:10045275",
-            "ICD9:002.0",
-            "ICD10:A01.0",
-            "UMLS:C0041466",
-            "MEDDRA:10014862",
-            "MEDDRA:10039446",
-            "NCIT:C35089",
-            "EFO:0006789",
-            "ORPHANET:99745"
-          ],
-          "id": "MONDO:0005619",
-          "category": "biolink:Disease",
-          "all_names": [
-            "typhoid fever",
-            "Typhoid",
-            "Typhoid Fever",
-            "Typhoid fever"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.merriam-webster.com/medlineplus/typhoid%20feve"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520880,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005619",
-              "name": "typhoid fever",
-              "description": "A bacterial infectious disorder contracted by consumption of food or drink contaminated with Salmonella typhi. This disorder is common in developing countries and can be treated with antibiotics.; An acute systemic febrile infection caused by SALMONELLA TYPHI, a serotype of SALMONELLA ENTERICA.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:13258",
-                "SNOMEDCT:4834000",
-                "MESH:D014435",
-                "MONDO:0005619",
-                "MEDDRA:10045272",
-                "MEDDRA:10045275",
-                "ICD9:002.0",
-                "ICD10:A01.0",
-                "UMLS:C0041466",
-                "MEDDRA:10014862",
-                "MEDDRA:10039446",
-                "NCIT:C35089",
-                "EFO:0006789",
-                "ORPHANET:99745"
-              ],
-              "id": "MONDO:0005619",
-              "category": "biolink:Disease",
-              "all_names": [
-                "typhoid fever",
-                "Typhoid",
-                "Typhoid Fever",
-                "Typhoid fever"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.merriam-webster.com/medlineplus/typhoid%20feve"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11191830,
-            "start": 616,
-            "end": 520880,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1545485': {'publication date': '1992 Jan', 'sentence': 'A study was conducted to investigate the effects of ciprofloxacin in typhoid fever and to compare its efficacy with chloramphenicol.', 'subject score': 1000, 'object score': 1000}, 'PMID:15494840': {'publication date': '2004 Oct', 'sentence': 'Typhoid fever due to multiresistant Salmonella enterica serovar typhi having reduced susceptibility to ciprofloxacin and nalidixic acid resistance.', 'subject score': 1000, 'object score': 1000}, 'PMID:23817934': {'publication date': '2013 Jun', 'sentence': 'Salmonella paratyphi A was the commonest cause of enteric fever in adults with 92% resistance to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0041466---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "11440816",
-              "object": "MONDO:0005619",
-              "publications": [
-                "PMID:1545485",
-                "PMID:15494840",
-                "PMID:23817934"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 546977,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043885",
-          "name": "eye infectious disorder",
-          "description": "An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.; Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.; Your eyes can get infections from bacteria, fungi, or viruses. Eye infections can occur in different parts of the eye and can affect just one eye or both. Two common eye infections are:  Conjunctivitis - also known as pink eye. Conjunctivitis is often due to an infection. Children frequently get it, and it is very contagious.  Stye - a bump on the eyelid that happens when bacteria from your skin get into the hair follicle of an eyelash.  Symptoms of eye infections may include redness, itching, swelling, discharge, pain, or problems with vision. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or antibiotics.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10015929",
-            "UMLS:C0015403",
-            "MESH:D015817",
-            "MEDDRA:10015936",
-            "MONDO:0043885",
-            "SNOMEDCT:128351009",
-            "NCIT:C45372",
-            "EFO:1001888"
-          ],
-          "id": "MONDO:0043885",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Eye Infection",
-            "eye infectious disorder",
-            "eye infection",
-            "Eye Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546977,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043885",
-              "name": "eye infectious disorder",
-              "description": "An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.; Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.; Your eyes can get infections from bacteria, fungi, or viruses. Eye infections can occur in different parts of the eye and can affect just one eye or both. Two common eye infections are:  Conjunctivitis - also known as pink eye. Conjunctivitis is often due to an infection. Children frequently get it, and it is very contagious.  Stye - a bump on the eyelid that happens when bacteria from your skin get into the hair follicle of an eyelash.  Symptoms of eye infections may include redness, itching, swelling, discharge, pain, or problems with vision. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or antibiotics.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10015929",
-                "UMLS:C0015403",
-                "MESH:D015817",
-                "MEDDRA:10015936",
-                "MONDO:0043885",
-                "SNOMEDCT:128351009",
-                "NCIT:C45372",
-                "EFO:1001888"
-              ],
-              "id": "MONDO:0043885",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Eye Infection",
-                "eye infectious disorder",
-                "eye infection",
-                "Eye Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11025632,
-            "start": 616,
-            "end": 546977,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15216950': {'publication date': '2004 Apr', 'sentence': 'The authors studied the bactericidal action and therapeutic effectiveness of ciprofloxacin in treating external ocular infections (bacterial conjunctivitis and bacterial blepharoconjunctivitis).', 'subject score': 1000, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0015403---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "11267024",
-              "object": "MONDO:0043885",
-              "publications": [
-                "PMID:15216950"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 853607,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C1112209",
-          "name": "Abdominal Infection",
-          "description": "Infection in the abdominal cavity resulting from injury, acute intestinal inflammation (e.g., acute appendicitis), intestinal perforation, or complication of abdominal surgery.; Infection within the PERITONEAL CAVITY. A frequent cause is an ANASTOMOTIC LEAK following surgery.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D059413",
-            "UMLS:C1112209",
-            "MEDDRA:10056570",
-            "SNOMEDCT:128070006",
-            "NCIT:C35669",
-            "MEDDRA:10056519"
-          ],
-          "id": "UMLS:C1112209",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Abdominal Infection",
-            "Intraabdominal Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 853607,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C1112209",
-              "name": "Abdominal Infection",
-              "description": "Infection in the abdominal cavity resulting from injury, acute intestinal inflammation (e.g., acute appendicitis), intestinal perforation, or complication of abdominal surgery.; Infection within the PERITONEAL CAVITY. A frequent cause is an ANASTOMOTIC LEAK following surgery.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D059413",
-                "UMLS:C1112209",
-                "MEDDRA:10056570",
-                "SNOMEDCT:128070006",
-                "NCIT:C35669",
-                "MEDDRA:10056519"
-              ],
-              "id": "UMLS:C1112209",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Abdominal Infection",
-                "Intraabdominal Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10442619,
-            "start": 616,
-            "end": 853607,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1403066': {'publication date': '1992 Feb', 'sentence': 'The achieved concentrations are above the minimum inhibitory concentrations (MICs) of ciprofloxacin for most gram-negative bacteria commonly involved in intra-abdominal infections.', 'subject score': 1000, 'object score': 983}, 'PMID:9609412': {'publication date': '1998 Apr', 'sentence': 'Bioavailability of ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections.', 'subject score': 1000, 'object score': 845}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C1112209---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "10672042",
-              "object": "UMLS:C1112209",
-              "publications": [
-                "PMID:1403066",
-                "PMID:9609412"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9677689,
-            "start": 616,
-            "end": 321523,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12445016': {'publication date': '2002 Nov', 'sentence': 'This study compared the in vitro activity of ertapenem, ceftriaxone, cefepime, ciprofloxacin and amoxicillin-clavulanate against 381 aerobic and facultative bacterial pathogens isolated from 320 patients with acute bacterial exacerbation of chronic bronchitis or community-acquired pneumonia.', 'subject score': 1000, 'object score': 851}, 'PMID:15318274': {'publication date': '2004 Jul', 'sentence': 'Antimicrobial resistance among these pathogens is high and E. coli and K. pneumoniae isolates with resistance to third-generation cephalosporins and ciprofloxacin are increasing.', 'subject score': 1000, 'object score': 888}, 'PMID:15729490': {'publication date': '2005 Feb', 'sentence': 'The effect of intravenous ciprofloxacin (CPFX) on hospital-acquired pneumonia was examined.', 'subject score': 888, 'object score': 901}, 'PMID:16687900': {'publication date': '2006', 'sentence': 'The resistance to carbapenems, piperacillin, gentamycin, amikacin, and ciprofloxacin was compared between ESBL-producing and non-ESBL-producing K. pneumoniae strains resistant to third-generation antibiotics.', 'subject score': 1000, 'object score': 740}, 'PMID:16801413': {'publication date': '2006 Jul', 'sentence': 'Incubation with ciprofloxacin did not alter the expression of the K. pneumoniae loci involved in resistance to APs.', 'subject score': 1000, 'object score': 623}, 'PMID:17721686': {'publication date': '2007 Aug', 'sentence': 'The data showed increased resistance rates of hospital-acquired isolates of K. pneumoniae to ceftriaxone, gentamicin, and ciprofloxacin; the data also showed that hospital-acquired, rather than outpatient isolates, were more likely to be resistant to multiple antibiotics.', 'subject score': 1000, 'object score': 888}, 'PMID:18318249': {'publication date': '2008 Feb', 'sentence': 'We studied the clinical effects of intravenous ciprofloxacin (CPFX) on community-acquired pneumonia in patients with positive Immunocard Mycoplasma test results.', 'subject score': 888, 'object score': 851}, 'PMID:19001833': {'publication date': '2008', 'sentence': 'A statistically significant positive correlation between quinolone consumption and K. pneumoniae resistance to ciprofloxacin was determined.', 'subject score': 1000, 'object score': 623}, 'PMID:19567345': {'publication date': '2009 Jun', 'sentence': 'Resistance to ciprofloxacin was higher among the ESBL-producing strains of E. coli and K. pneumoniae than the non-ESBL producers.', 'subject score': 1000, 'object score': 888}, 'PMID:19622455': {'publication date': '2009 Aug', 'sentence': 'In K. pneumoniae resistance to imipenem, ciprofloxacin and amikacin was 3.1%, 17.8% 12.4% respectively.', 'subject score': 1000, 'object score': 623}, 'PMID:20541915': {'publication date': '2010 Sep', 'sentence': 'Hypermutation in K. pneumoniae is uncommon and does not contribute to accumulation of QRDR mutations or directly to ciprofloxacin resistance.', 'subject score': 694, 'object score': 888}, 'PMID:21286930': {'publication date': '2011 Jun', 'sentence': 'Fluoroquinolone efflux activity is much more common in clinical isolates of K. pneumoniae than previously reported and it can contribute to decreased ciprofloxacin susceptibility.', 'subject score': 851, 'object score': 888}, 'PMID:21563956': {'publication date': '2011 Sep', 'sentence': 'However, 71.4% and 98.4% of qnr-negative K. pneumoniae and E. coli contained double QRDR mutations, and most presented high-level CIP resistance.', 'subject score': 559, 'object score': 775}, 'PMID:23587777': {'publication date': '2013 May', 'sentence': 'Resistance to ciprofloxacin was a component of most multidrug-resistant (MDR) phenotypes for E. coli, K. pneumoniae, E. cloacae, P. aeruginosa and S. aureus.', 'subject score': 1000, 'object score': 888}, 'PMID:27318458': {'publication date': '2016 Aug', 'sentence': 'E. coli and K. pneumoniae showed a high percentage of strains resistance to ciprofloxacin of 37% and 29%, respectively.', 'subject score': 1000, 'object score': 888}, 'PMID:27938381': {'publication date': '2016 Dec 09', 'sentence': 'Noticeable cross-resistance pattern was observed at the 1/4CIP-CIP, showing the increased resistance of K. pneumoniae to chloramphenicol, ciprofloxacin, kanamycin, levofloxacin, nalidixic acid norfloxacin, sulphamethoxazole/trimethoprim, and tetracycline.', 'subject score': 1000, 'object score': 888}, 'PMID:28435070': {'publication date': '2017 09 23', 'sentence': 'To explore the relevance of and understand the potential mechanisms behind the production of siderophores by clinical isolates of K. pneumoniae and ciprofloxacin (CIP) resistance, we divided the K. pneumoniae isolates into two groups based on bacterial siderophores production: high siderophore-yielding group (39 strains) and low siderophore-yielding group (38 strains).', 'subject score': 694, 'object score': 888}, 'PMID:28992981': {'publication date': '2018 Apr 13', 'sentence': 'CONCLUSIONS: ESBL producing E. coli and K. pneumoniae were prevalent, especially the latter, with a significant resistance to ciprofloxacin and cotrimoxazole.', 'subject score': 1000, 'object score': 888}, 'PMID:30541613': {'publication date': '2018 Dec 12', 'sentence': 'From enterobacteriaceae isolates, K. pneumonia and E. coli showed higher estimates of ciprofloxacin resistance.', 'subject score': 694, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "9891814",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:12445016",
-                "PMID:15318274",
-                "PMID:15729490",
-                "PMID:16687900",
-                "PMID:16801413",
-                "PMID:17721686",
-                "PMID:18318249",
-                "PMID:19001833",
-                "PMID:19567345",
-                "PMID:19622455",
-                "PMID:20541915",
-                "PMID:21286930",
-                "PMID:21563956",
-                "PMID:23587777",
-                "PMID:27318458",
-                "PMID:27938381",
-                "PMID:28435070",
-                "PMID:28992981",
-                "PMID:30541613"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 539955,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-          "name": "infectious disease",
-          "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005550",
-            "SNOMEDCT:189822004",
-            "PSY:10513",
-            "UMLS:C0009450",
-            "UMLS:C0001485",
-            "EFO:0005741",
-            "MEDDRA:10021881",
-            "MESH:D003141",
-            "ICD9:079.0",
-            "DOID:0050117",
-            "SNOMEDCT:40733004",
-            "SNOMEDCT:191415002",
-            "NCIT:C26726"
-          ],
-          "id": "MONDO:0005550",
-          "category": "biolink:Disease",
-          "all_names": [
-            "infectious disease",
-            "Infectious Disorder",
-            "disease by infectious agent",
-            "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-            "Communicable Diseases"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.merriam-webster.com/medical/communicable%20disease",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 539955,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-              "name": "infectious disease",
-              "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005550",
-                "SNOMEDCT:189822004",
-                "PSY:10513",
-                "UMLS:C0009450",
-                "UMLS:C0001485",
-                "EFO:0005741",
-                "MEDDRA:10021881",
-                "MESH:D003141",
-                "ICD9:079.0",
-                "DOID:0050117",
-                "SNOMEDCT:40733004",
-                "SNOMEDCT:191415002",
-                "NCIT:C26726"
-              ],
-              "id": "MONDO:0005550",
-              "category": "biolink:Disease",
-              "all_names": [
-                "infectious disease",
-                "Infectious Disorder",
-                "disease by infectious agent",
-                "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-                "Communicable Diseases"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.merriam-webster.com/medical/communicable%20disease",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8926699,
-            "start": 616,
-            "end": 539955,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11562127': {'publication date': '2001 Sep', 'sentence': 'The effect of a 21-day treatment with cefuroxime, vancomycin, tobramycin or ciprofloxacin on infection was studied in this model 42 days after surgery.', 'subject score': 1000, 'object score': 1000}, 'PMID:12821471': {'publication date': '2003 Jul', 'sentence': 'Thus, our results suggest that ciprofloxacin is at least as effective as cefotaxime-minocycline against murine A. hydrophila infections, which warrants clinical studies to delineate its role in human infections.', 'subject score': 1000, 'object score': 888}, 'PMID:15490982': {'publication date': '2004', 'sentence': 'Oral ciprofloxacin provides satisfactory results in gram-negative infections, comparable to those obtained with intraperitoneal ceftazidime or aminoglycosides.', 'subject score': 888, 'object score': 851}, 'PMID:2100081': {'publication date': '1990 Oct', 'sentence': 'The role of ciprofloxacin in treating infections caused by multiantibiotic resistant S. typhi is also discussed.', 'subject score': 1000, 'object score': 888}, 'PMID:21098755': {'publication date': '2010 Dec', 'sentence': 'Primary prophylaxis studies found no significant difference in the incidence of infections, including SBP, with norfloxacin or ciprofloxacin treatment but significantly lower incidence of gram-negative infections.', 'subject score': 888, 'object score': 851}, 'PMID:21873378': {'publication date': '2012 Jan', 'sentence': 'The presence of co-infections was an independent risk factor for clarithromycin, metronidazole and ciprofloxacin resistance.', 'subject score': 694, 'object score': 861}, 'PMID:22845325': {'publication date': '2012', 'sentence': 'Fluoroquinolones are a widely used group of antimicrobials in both human and animal medicine, with ciprofloxacin being a critically important fluoroquinolone for serious human infections.', 'subject score': 1000, 'object score': 851}, 'PMID:22958285': {'publication date': '2012 Oct', 'sentence': 'Prostate-derived P. acnes isolates (n = 24, Umea & Orebro, Sweden, 2007-2010) and a panel of control strains (n = 25, Sweden) collected from skin and deep infections were assessed for resistance to penicillin G, piperacillin-tazobactam, imipenem, gentamicin, azithromycin, erythromycin, vancomycin, ciprofloxacin, moxifloxacin, tetracycline, tigecycline, fusidic acid, clindamycin, rifampicin, linezolid, daptomycin, trimethoprim-sulfamethoxazole, and metronidazole.', 'subject score': 1000, 'object score': 888}, 'PMID:23122884': {'publication date': '2012 Dec', 'sentence': 'Infections with Salmonella enterica serovar Typhi isolates that are multidrug resistant (MDR: resistant to chloramphenicol, ampicillin, trimethoprim-sulphamethoxazole) with intermediate ciprofloxacin susceptibility are widespread in Asia but there is little information from Cambodia.', 'subject score': 851, 'object score': 1000}, 'PMID:23253321': {'publication date': '2012 Dec', 'sentence': 'This paper presents a perspective on the potential role of inhaled ciprofloxacin in such infections.', 'subject score': 888, 'object score': 1000}, 'PMID:26989670': {'publication date': '2016 Mar 16', 'sentence': 'CONCLUSION: The most effective antibiotics against gram-negative healthcare associated infections are imipenem followed by ciprofloxacin.', 'subject score': 1000, 'object score': 766}, 'PMID:29020144': {'publication date': '2017 Oct 30', 'sentence': 'Antimicrobial susceptibility testing of isolates from 4793 domestic and 1070 travel-associated infections revealed that, comparing 2004-2009 to 2010-2012, ciprofloxacin resistance increased among domestic infections (12.8% vs 16.1%).', 'subject score': 694, 'object score': 763}, 'PMID:3158073': {'publication date': '1985 Mar 30', 'sentence': 'These infections may, therefore, be favorably affected by ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:3542948': {'publication date': '1986 Nov', 'sentence': 'The progress of infection in sensitive mice with no natural immunity was delayed by ciprofloxacin although at the dosage used the mice were not cured.', 'subject score': 1000, 'object score': 1000}, 'PMID:36422605': {'publication date': '2022 Nov 15', 'sentence': 'This study aimed to analyse genetic mutations in the genomes of 25    S. aureus     isolates from infections or non-infectious ocular conditions from the USA and Australia and their relationship to ciprofloxacin resistance.', 'subject score': 888, 'object score': 852}, 'PMID:8040107': {'publication date': '1994 Mar', 'sentence': 'As prophylaxis for the granulocytopenic patient, quinolones such as norfloxacin and ciprofloxacin have been shown to be effective in reducing the incidence of morbidity attributable to Gram-negative bacteria, but they have not significantly affected the incidence of infection caused by Gram-positive bacteria.', 'subject score': 1000, 'object score': 1000}, 'PMID:8899438': {'publication date': '1996 Oct', 'sentence': 'OBJECTIVE: To evaluate endemic colonization with Staphylococcus aureus resistant to methicillin, ciprofloxacin, or both among patients of a private skilled nursing facility, with regard to colonization rate and site, and relation to infection and prior antibiotic use.', 'subject score': 1000, 'object score': 1000}, 'PMID:9002127': {'publication date': '1997 Jan', 'sentence': 'As empirical options are diminishing daily, the role of ciprofloxacin in pediatric infections is becoming increasingly significant.', 'subject score': 1000, 'object score': 888}, 'PMID:9255893': {'publication date': '1997', 'sentence': 'Influence of low dose ciprofloxacin on microbial colonization of the digestive tract in healthy volunteers during normal and during impaired colonization resistance.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0009450---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "9122989",
-              "object": "MONDO:0005550",
-              "publications": [
-                "PMID:11562127",
-                "PMID:12821471",
-                "PMID:15490982",
-                "PMID:2100081",
-                "PMID:21098755",
-                "PMID:21873378",
-                "PMID:22845325",
-                "PMID:22958285",
-                "PMID:23122884",
-                "PMID:23253321",
-                "PMID:26989670",
-                "PMID:29020144",
-                "PMID:3158073",
-                "PMID:3542948",
-                "PMID:36422605",
-                "PMID:8040107",
-                "PMID:8899438",
-                "PMID:9002127",
-                "PMID:9255893"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:11414382': {'publication date': '2000 Jan', 'sentence': 'Ciprofloxacin is effective in complicated and severe lower respiratory tract infections, including those in patients with infective exacerbations of chronic bronchitis and cystic fibrosis, and pseudomonal infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:18317040': {'publication date': '2008 Apr', 'sentence': 'In a large, randomized clinical trial, addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas infection produced microbiologic improvement correlating with clinical outcomes but not overall improvement.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 579767,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005141",
-          "name": "Pseudomonas infection",
-          "description": "Infections with bacteria of the genus PSEUDOMONAS.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:0001076",
-            "MONDO:0005141",
-            "SNOMEDCT:63398001",
-            "UMLS:C0033817",
-            "MEDDRA:10061471",
-            "MEDDRA:10037135",
-            "MESH:D011552",
-            "MEDDRA:10037132"
-          ],
-          "id": "MONDO:0005141",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pseudomonas Infections",
-            "Pseudomonas infection"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 579767,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-=======
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
->>>>>>> main
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005141",
-              "name": "Pseudomonas infection",
-              "description": "Infections with bacteria of the genus PSEUDOMONAS.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:0001076",
-                "MONDO:0005141",
-                "SNOMEDCT:63398001",
-                "UMLS:C0033817",
-                "MEDDRA:10061471",
-                "MEDDRA:10037135",
-                "MESH:D011552",
-                "MEDDRA:10037132"
-              ],
-              "id": "MONDO:0005141",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pseudomonas Infections",
-                "Pseudomonas infection"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8753728,
-            "start": 616,
-            "end": 579767,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11414382': {'publication date': '2000 Jan', 'sentence': 'Ciprofloxacin is effective in complicated and severe lower respiratory tract infections, including those in patients with infective exacerbations of chronic bronchitis and cystic fibrosis, and pseudomonal infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:18317040': {'publication date': '2008 Apr', 'sentence': 'In a large, randomized clinical trial, addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas infection produced microbiologic improvement correlating with clinical outcomes but not overall improvement.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0033817---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8956826",
-              "object": "MONDO:0005141",
-              "publications": [
-                "PMID:11414382",
-                "PMID:18317040"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 523273,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1572222': {'publication date': '1992 Mar', 'sentence': \"We used a simple Wood's light examination and culture to establish the diagnosis of Pseudomonas toe web infection and achieved rapid resolution with oral ciprofloxacin treatment and local application of Castellani's paint.\", 'subject score': 851, 'object score': 861}, 'PMID:20836302': {'publication date': '2010 Apr 15', 'sentence': 'At present time Ciprofloxacin is relatively effective antibiotic for Pseudomonas infection.', 'subject score': 851, 'object score': 1000}, 'PMID:2114953': {'publication date': '1990 Mar-Apr', 'sentence': 'Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2292542': {'publication date': '1990 Dec', 'sentence': 'The Cystic Fibrosis Clinic at the Royal Belfast Hospital for Sick Children has treated 31 children with ciprofloxacin, for serious pseudomonas infection in cystic fibrosis, and carefully monitored the safety and acceptability of the drug.', 'subject score': 1000, 'object score': 901}, 'PMID:24489509': {'publication date': '2013', 'sentence': 'The key findings were as follows: inhaled antipseudomonal antibiotic improves lung function, and probably the safest/most effective therapy; antistaphylococcal antibiotic prophylaxis increases the risk of acquiring P. aeruginosa; azithromycin significantly improves respiratory function after 6 months of treatment; a 28-day treatment with aztreonam or tobramycin significantly improves respiratory symptoms and pulmonary function; aztreonam lysine might be superior to tobramycin inhaled solution in chronic P. aeruginosa infection; oral ciprofloxacin does not produce additional benefit in those with chronic persistent pseudomonas infection but may have a role in early or first infection.', 'subject score': 888, 'object score': 826}, 'PMID:24718510': {'publication date': '2014 Apr', 'sentence': 'Pseudomonas infections of the nail organ are treated by ciprofloxacin; other bacteria are treated according to the results of culture and sensitivity testing.', 'subject score': 1000, 'object score': 1000}, 'PMID:2508586': {'publication date': '1989 Oct', 'sentence': 'Studies using either higher dosages of ciprofloxacin or combination therapy should be conducted to determine if acquired resistance can be avoided in Pseudomonas infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:3100490': {'publication date': '1986 Nov', 'sentence': 'Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:3279487': {'publication date': '1988 Jan-Feb', 'sentence': 'Ciprofloxacin and other quinolones are also effective therapy for pseudomonal infections in neutropenic animals with pneumonia, peritonitis, osteomyelitis, and endocarditis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3279495': {'publication date': '1988', 'sentence': 'Ciprofloxacin is apparently valuable for the treatment of pseudomonas infections in patients with cystic fibrosis: clinical results seem comparable to those obtained with conventional intravenous treatments.', 'subject score': 1000, 'object score': 1000}, 'PMID:35330242': {'publication date': '2022 Feb 28', 'sentence': 'Therefore, high local CIP concentrations during treatment of    Pseudomonas-Aspergillus     co-infections may increase the fungal burden.', 'subject score': 833, 'object score': 861}, 'PMID:3680089': {'publication date': '1987 Oct', 'sentence': 'Therapeutic efficacy of cefpiramide-ciprofloxacin combination in experimental Pseudomonas infections in neutropenic mice.', 'subject score': 851, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 579767,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009061",
-          "name": "cystic fibrosis",
-          "description": "A congenital, autosomal, metabolic disorder affecting the exocrine glands. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production that causes obstruction of passageways, including pancreatic and bile ducts, intestines, and bronchi. Symptoms usually appear in childhood, and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather secondary to increased sodium and chloride concentration in sweat.; An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003550",
-            "SNOMEDCT:190905008",
-            "UMLS:C0010674",
-            "NCIT:C2975",
-            "MEDDRA:10011762",
-            "ORPHANET:586",
-            "DOID:1485",
-            "MEDDRA:10011764",
-            "ICD9:277.0",
-            "MEDDRA:10028141",
-            "PSY:12915",
-            "MONDO:0009061",
-            "OMIM:219700",
-            "ICD10:E84"
-          ],
-          "id": "MONDO:0009061",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cystic Fibrosis",
-            "cystic fibrosis",
-            "obsolete_cystic fibrosis",
-            "Cystic fibrosis related phenotypic feature",
-            "Cystic fibrosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://ghr.nlm.nih.gov/condition/cystic-fibrosis",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/cf/",
-            "http://en.wikipedia.org/wiki/cystic_fibrosis"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005141",
-          "name": "Pseudomonas infection",
-          "description": "Infections with bacteria of the genus PSEUDOMONAS.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:0001076",
-            "MONDO:0005141",
-            "SNOMEDCT:63398001",
-            "UMLS:C0033817",
-            "MEDDRA:10061471",
-            "MEDDRA:10037135",
-            "MESH:D011552",
-            "MEDDRA:10037132"
-          ],
-          "id": "MONDO:0005141",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pseudomonas Infections",
-            "Pseudomonas infection"
-          ],
-          "all_categories": [
-            "biolink:Disease"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 523273,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009061",
-              "name": "cystic fibrosis",
-              "description": "A congenital, autosomal, metabolic disorder affecting the exocrine glands. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production that causes obstruction of passageways, including pancreatic and bile ducts, intestines, and bronchi. Symptoms usually appear in childhood, and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather secondary to increased sodium and chloride concentration in sweat.; An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003550",
-                "SNOMEDCT:190905008",
-                "UMLS:C0010674",
-                "NCIT:C2975",
-                "MEDDRA:10011762",
-                "ORPHANET:586",
-                "DOID:1485",
-                "MEDDRA:10011764",
-                "ICD9:277.0",
-                "MEDDRA:10028141",
-                "PSY:12915",
-                "MONDO:0009061",
-                "OMIM:219700",
-                "ICD10:E84"
-              ],
-              "id": "MONDO:0009061",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cystic Fibrosis",
-                "cystic fibrosis",
-                "obsolete_cystic fibrosis",
-                "Cystic fibrosis related phenotypic feature",
-                "Cystic fibrosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://ghr.nlm.nih.gov/condition/cystic-fibrosis",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/cf/",
-                "http://en.wikipedia.org/wiki/cystic_fibrosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8753727,
-            "start": 616,
-            "end": 523273,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11414382': {'publication date': '2000 Jan', 'sentence': 'Ciprofloxacin is effective in complicated and severe lower respiratory tract infections, including those in patients with infective exacerbations of chronic bronchitis and cystic fibrosis, and pseudomonal infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:1734188': {'publication date': '1992 Jan 06', 'sentence': 'Resistance to ciprofloxacin of respiratory pathogens in patients with cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:31663261': {'publication date': '2019 Oct 30', 'sentence': 'Reclassification of CLSI criteria for ciprofloxacin and levofloxacin susceptibility against Pseudomonas aeruginosa: Implications for patients with cystic fibrosis (CF).', 'subject score': 1000, 'object score': 1000}, 'PMID:8132376': {'publication date': '1993 Nov-Dec', 'sentence': 'Up to now, data are available on more than 1,500 paediatric patients who were given ciprofloxacin, two-thirds of whom were suffering from acute infectious bronchopulmonary exacerbations of cystic fibrosis, mainly due to Pseudomonas aeruginosa.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0010674---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8956825",
-              "object": "MONDO:0009061",
-              "publications": [
-                "PMID:11414382",
-                "PMID:1734188",
-                "PMID:31663261",
-                "PMID:8132376"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 212250,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-          "name": "Fever",
-          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10037660",
-            "MEDDRA:10020083",
-            "MEDDRA:10005911",
-            "UMLS:C0015967",
-            "HP:0001945",
-            "NCIT:C3038",
-            "MEDDRA:10073718",
-            "MEDDRA:10043204",
-            "MEDDRA:10037668",
-            "PDQ:CDR0000775882",
-            "PSY:19660",
-            "SNOMEDCT:386661006",
-            "MEDDRA:10016558",
-            "MEDDRA:10037663",
-            "SNOMEDCT:50177009",
-            "SYMP:0000613",
-            "MESH:D005334"
-          ],
-          "id": "HP:0001945",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "fever",
-            "Fever"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:9759682",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 212250,
-=======
-            "identity": 579767,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-              "name": "Fever",
-              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10037660",
-                "MEDDRA:10020083",
-                "MEDDRA:10005911",
-                "UMLS:C0015967",
-                "HP:0001945",
-                "NCIT:C3038",
-                "MEDDRA:10073718",
-                "MEDDRA:10043204",
-                "MEDDRA:10037668",
-                "PDQ:CDR0000775882",
-                "PSY:19660",
-                "SNOMEDCT:386661006",
-                "MEDDRA:10016558",
-                "MEDDRA:10037663",
-                "SNOMEDCT:50177009",
-                "SYMP:0000613",
-                "MESH:D005334"
-              ],
-              "id": "HP:0001945",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "fever",
-                "Fever"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:9759682",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8475417,
-            "start": 616,
-            "end": 212250,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11168914': {'publication date': '2000 Dec', 'sentence': '(0.18 microg /mL) and AUC (0.99 microg .h/mL) of ciprofloxacin were significantly decreased, whereas its t1/2beta (2.75 h) and MRT (4.58 h) were prolonged in febrile than in normal goats.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0015967---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8669720",
-              "object": "HP:0001945",
-              "publications": [
-                "PMID:11168914"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318598,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004822",
-          "name": "bronchiectasis",
-          "description": "Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways. [HPO:probinson]; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:J47",
-            "ICD9:494",
-            "MESH:D001987",
-            "MEDDRA:10006445",
-            "DOID:9563",
-            "MEDDRA:10006446",
-            "OMIM.PS:211400",
-            "MONDO:0004822",
-            "OMIM:PS211400",
-            "UMLS:C0006267",
-            "NCIT:C84475",
-            "HP:0002110",
-            "SNOMEDCT:12295008"
-          ],
-          "id": "MONDO:0004822",
-          "category": "biolink:Disease",
-          "all_names": [
-            "bronchiectasis",
-            "Bronchiectasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.merck.com/mmhe/sec04/ch047/ch047a.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=bronchiectasis",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318598,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004822",
-              "name": "bronchiectasis",
-              "description": "Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways. [HPO:probinson]; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:J47",
-                "ICD9:494",
-                "MESH:D001987",
-                "MEDDRA:10006445",
-                "DOID:9563",
-                "MEDDRA:10006446",
-                "OMIM.PS:211400",
-                "MONDO:0004822",
-                "OMIM:PS211400",
-                "UMLS:C0006267",
-                "NCIT:C84475",
-                "HP:0002110",
-                "SNOMEDCT:12295008"
-              ],
-              "id": "MONDO:0004822",
-              "category": "biolink:Disease",
-              "all_names": [
-                "bronchiectasis",
-                "Bronchiectasis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.merck.com/mmhe/sec04/ch047/ch047a.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=bronchiectasis",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005141",
-              "name": "Pseudomonas infection",
-              "description": "Infections with bacteria of the genus PSEUDOMONAS.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:0001076",
-                "MONDO:0005141",
-                "SNOMEDCT:63398001",
-                "UMLS:C0033817",
-                "MEDDRA:10061471",
-                "MEDDRA:10037135",
-                "MESH:D011552",
-                "MEDDRA:10037132"
-              ],
-              "id": "MONDO:0005141",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pseudomonas Infections",
-                "Pseudomonas infection"
-              ],
-              "all_categories": [
-                "biolink:Disease"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 7711380,
-            "start": 616,
-            "end": 318598,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10606835': {'publication date': '2000 Jan', 'sentence': 'AIMS: To examine the pharmacokinetics of ciprofloxacin and fleroxacin in plasma and sputum of patients with an acute exacerbation of chronic bronchitis or bronchiectasis following the first dose and again during the third day of treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:8697891': {'publication date': '1996', 'sentence': 'The findings suggest that ciprofloxacin is an effective treatment of infective exacerbations of bronchiectasis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0006267---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7886704",
-              "object": "MONDO:0004822",
-              "publications": [
-                "PMID:10606835",
-                "PMID:8697891"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321736,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005607",
-          "name": "chronic bronchitis",
-          "description": "A type of chronic obstructive pulmonary disease characterized by chronic inflammation in the bronchial tree that results in edema, mucus production, obstruction, and reduced airflow to and from the lung alveoli. The most common cause is tobacco smoking. Signs and symptoms include coughing with excessive mucus production, and shortness of breath.; A subcategory of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. The disease is characterized by hypersecretion of mucus accompanied by a chronic (more than 3 months in 2 consecutive years) productive cough. Infectious agents are a major cause of chronic bronchitis.; Chronic inflammation of the bronchi. [HPO:probinson]; What is chronic bronchitis? Chronic bronchitis is a type of COPD (chronic obstructive pulmonary disease). COPD is a group of lung diseases that make it hard to breathe and get worse over time. The other main type of COPD is emphysema. Most people with COPD have both emphysema and chronic bronchitis, but how severe each type is can be different from person to person. Chronic bronchitis is inflammation (swelling) and irritation of the bronchial tubes. These tubes are the airways that carry air to and from the air sacs in your lungs. The irritation of the tubes causes mucus to build up. This mucus and the swelling of the tubes make it harder for your lungs to move oxygen in and carbon dioxide out of your body. What causes chronic bronchitis? The cause of chronic bronchitis is usually long-term exposure to irritants that damage your lungs and airways. In the United States, cigarette smoke is the main cause. Pipe, cigar, and other types of tobacco smoke can also cause chronic bronchitis, especially if you inhale them. Exposure to other inhaled irritants can contribute to chronic bronchitis. These include secondhand smoke, air pollution, and chemical fumes or dusts from the environment or workplace. Rarely, a genetic condition called alpha-1 antitrypsin deficiency can play a role in causing chronic bronchitis. Who is at risk for chronic bronchitis? The risk factors for chronic bronchitis include: Smoking. This the main risk factor. Up to 75% of people who have chronic bronchitis smoke or used to smoke. Long-term exposure to other lung irritants, such as secondhand smoke, air pollution, and chemical fumes and dusts from the environment or workplace. Age. Most people who have chronic bronchitis are at least 40 years old when their symptoms begin. Genetics. This includes alpha-1 antitrypsin deficiency, which is a genetic condition. Also, smokers who get chronic bronchitis are more likely to get it if they have a family history of COPD.  What are the symptoms of chronic bronchitis? At first, you may have no symptoms or only mild symptoms. As the disease gets worse, your symptoms usually become more severe. They can include: Frequent coughing or a cough that produces a lot mucus Wheezing A whistling or squeaky sound when you breathe Shortness of breath, especially with physical activity Tightness in your chest  Some people with chronic bronchitis get frequent respiratory infections such as colds and the flu. In severe cases, chronic bronchitis can cause weight loss, weakness in your lower muscles, and swelling in your ankles, feet, or legs. How is chronic bronchitis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A family history Various tests, such as lung function tests, a chest x-ray or CT scan, and blood tests  What are the treatments for chronic bronchitis? There is no cure for chronic bronchitis. However, treatments can help with symptoms, slow the progress of the disease, and improve your ability to stay active. There are also treatments to prevent or treat complications of the disease. Treatments include: Lifestyle changes, such as  Quitting smoking if you are a smoker. This is the most important step you can take to treat chronic bronchitis. Avoiding secondhand smoke and places where you might breathe in other lung irritants Ask your health care provider for an eating plan that will meet your nutritional needs. Also ask about how much physical activity you can do. Physical activity can strengthen the muscles that help you breathe and improve your overall wellness.   Medicines, such as  Bronchodilators, which relax the muscles around your airways. This helps open your airways and makes breathing easier. Most bronchodilators are taken through an inhaler. In more severe cases, the inhaler may also contain steroids to reduce inflammation. Vaccines for the flu and pneumococcal pneumonia, since people with chronic bronchitis are at higher risk for serious problems from these diseases. Antibiotics if you get a bacterial or viral lung infection   Oxygen therapy, if you have severe chronic bronchitis and low levels of oxygen in your blood. Oxygen therapy can help you breathe better. You may need extra oxygen all the time or only at certain times. Pulmonary rehabilitation, which is a program that helps improve the well-being of people who have chronic breathing problems. It may include  An exercise program Disease management training Nutritional counseling Psychological counseling  A lung transplant, as a last resort for people who have severe symptoms that have not gotten better with medicines  If you have chronic bronchitis, it's important to know when and where to get help for your symptoms. You should get emergency care if you have severe symptoms, such as trouble catching your breath or talking. Call your health care provider if your symptoms are getting worse or if you have signs of an infection, such as a fever. Can chronic bronchitis be prevented? Since smoking causes most cases of chronic bronchitis, the best way to prevent it is to not smoke. It's also important to try to avoid lung irritants such as secondhand smoke, air pollution, chemical fumes, and dusts.  NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10008843",
-            "MEDDRA:10008841",
-            "NCIT:C26722",
-            "MEDDRA:10006458",
-            "MESH:D029481",
-            "MONDO:0005607",
-            "MEDDRA:10045659",
-            "EFO:0006505",
-            "UMLS:C0008677",
-            "MEDDRA:10006459",
-            "HP:0004469",
-            "SNOMEDCT:63480004"
-          ],
-          "id": "MONDO:0005607",
-          "category": "biolink:Disease",
-          "all_names": [
-            "chronic bronchitis",
-            "Bronchitis, Chronic",
-            "Chronic bronchitis",
-            "Chronic Bronchitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321736,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005607",
-              "name": "chronic bronchitis",
-              "description": "A type of chronic obstructive pulmonary disease characterized by chronic inflammation in the bronchial tree that results in edema, mucus production, obstruction, and reduced airflow to and from the lung alveoli. The most common cause is tobacco smoking. Signs and symptoms include coughing with excessive mucus production, and shortness of breath.; A subcategory of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. The disease is characterized by hypersecretion of mucus accompanied by a chronic (more than 3 months in 2 consecutive years) productive cough. Infectious agents are a major cause of chronic bronchitis.; Chronic inflammation of the bronchi. [HPO:probinson]; What is chronic bronchitis? Chronic bronchitis is a type of COPD (chronic obstructive pulmonary disease). COPD is a group of lung diseases that make it hard to breathe and get worse over time. The other main type of COPD is emphysema. Most people with COPD have both emphysema and chronic bronchitis, but how severe each type is can be different from person to person. Chronic bronchitis is inflammation (swelling) and irritation of the bronchial tubes. These tubes are the airways that carry air to and from the air sacs in your lungs. The irritation of the tubes causes mucus to build up. This mucus and the swelling of the tubes make it harder for your lungs to move oxygen in and carbon dioxide out of your body. What causes chronic bronchitis? The cause of chronic bronchitis is usually long-term exposure to irritants that damage your lungs and airways. In the United States, cigarette smoke is the main cause. Pipe, cigar, and other types of tobacco smoke can also cause chronic bronchitis, especially if you inhale them. Exposure to other inhaled irritants can contribute to chronic bronchitis. These include secondhand smoke, air pollution, and chemical fumes or dusts from the environment or workplace. Rarely, a genetic condition called alpha-1 antitrypsin deficiency can play a role in causing chronic bronchitis. Who is at risk for chronic bronchitis? The risk factors for chronic bronchitis include: Smoking. This the main risk factor. Up to 75% of people who have chronic bronchitis smoke or used to smoke. Long-term exposure to other lung irritants, such as secondhand smoke, air pollution, and chemical fumes and dusts from the environment or workplace. Age. Most people who have chronic bronchitis are at least 40 years old when their symptoms begin. Genetics. This includes alpha-1 antitrypsin deficiency, which is a genetic condition. Also, smokers who get chronic bronchitis are more likely to get it if they have a family history of COPD.  What are the symptoms of chronic bronchitis? At first, you may have no symptoms or only mild symptoms. As the disease gets worse, your symptoms usually become more severe. They can include: Frequent coughing or a cough that produces a lot mucus Wheezing A whistling or squeaky sound when you breathe Shortness of breath, especially with physical activity Tightness in your chest  Some people with chronic bronchitis get frequent respiratory infections such as colds and the flu. In severe cases, chronic bronchitis can cause weight loss, weakness in your lower muscles, and swelling in your ankles, feet, or legs. How is chronic bronchitis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A family history Various tests, such as lung function tests, a chest x-ray or CT scan, and blood tests  What are the treatments for chronic bronchitis? There is no cure for chronic bronchitis. However, treatments can help with symptoms, slow the progress of the disease, and improve your ability to stay active. There are also treatments to prevent or treat complications of the disease. Treatments include: Lifestyle changes, such as  Quitting smoking if you are a smoker. This is the most important step you can take to treat chronic bronchitis. Avoiding secondhand smoke and places where you might breathe in other lung irritants Ask your health care provider for an eating plan that will meet your nutritional needs. Also ask about how much physical activity you can do. Physical activity can strengthen the muscles that help you breathe and improve your overall wellness.   Medicines, such as  Bronchodilators, which relax the muscles around your airways. This helps open your airways and makes breathing easier. Most bronchodilators are taken through an inhaler. In more severe cases, the inhaler may also contain steroids to reduce inflammation. Vaccines for the flu and pneumococcal pneumonia, since people with chronic bronchitis are at higher risk for serious problems from these diseases. Antibiotics if you get a bacterial or viral lung infection   Oxygen therapy, if you have severe chronic bronchitis and low levels of oxygen in your blood. Oxygen therapy can help you breathe better. You may need extra oxygen all the time or only at certain times. Pulmonary rehabilitation, which is a program that helps improve the well-being of people who have chronic breathing problems. It may include  An exercise program Disease management training Nutritional counseling Psychological counseling  A lung transplant, as a last resort for people who have severe symptoms that have not gotten better with medicines  If you have chronic bronchitis, it's important to know when and where to get help for your symptoms. You should get emergency care if you have severe symptoms, such as trouble catching your breath or talking. Call your health care provider if your symptoms are getting worse or if you have signs of an infection, such as a fever. Can chronic bronchitis be prevented? Since smoking causes most cases of chronic bronchitis, the best way to prevent it is to not smoke. It's also important to try to avoid lung irritants such as secondhand smoke, air pollution, chemical fumes, and dusts.  NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10008843",
-                "MEDDRA:10008841",
-                "NCIT:C26722",
-                "MEDDRA:10006458",
-                "MESH:D029481",
-                "MONDO:0005607",
-                "MEDDRA:10045659",
-                "EFO:0006505",
-                "UMLS:C0008677",
-                "MEDDRA:10006459",
-                "HP:0004469",
-                "SNOMEDCT:63480004"
-              ],
-              "id": "MONDO:0005607",
-              "category": "biolink:Disease",
-              "all_names": [
-                "chronic bronchitis",
-                "Bronchitis, Chronic",
-                "Chronic bronchitis",
-                "Chronic Bronchitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7711377,
-            "start": 616,
-            "end": 321736,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10606835': {'publication date': '2000 Jan', 'sentence': 'AIMS: To examine the pharmacokinetics of ciprofloxacin and fleroxacin in plasma and sputum of patients with an acute exacerbation of chronic bronchitis or bronchiectasis following the first dose and again during the third day of treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:11414382': {'publication date': '2000 Jan', 'sentence': 'Ciprofloxacin is effective in complicated and severe lower respiratory tract infections, including those in patients with infective exacerbations of chronic bronchitis and cystic fibrosis, and pseudomonal infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:12168746': {'publication date': '2002 Jul', 'sentence': 'Double mutants in the parC and gyrA genes lead to fluoroquinolone resistance that has been found to cause bacteriological failure of the fluoroquinolones, particularly levofloxacin and ciprofloxacin, in the management of pneumonia and exacerbations of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:12445016': {'publication date': '2002 Nov', 'sentence': 'This study compared the in vitro activity of ertapenem, ceftriaxone, cefepime, ciprofloxacin and amoxicillin-clavulanate against 381 aerobic and facultative bacterial pathogens isolated from 320 patients with acute bacterial exacerbation of chronic bronchitis or community-acquired pneumonia.', 'subject score': 1000, 'object score': 1000}, 'PMID:1362752': {'publication date': '1992 Nov', 'sentence': 'Comparative clinical and microbiological study of amoxycillin-clavulanic acid and ciprofloxacin in acute purulent exacerbations of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1754733': {'publication date': '1991 Sep', 'sentence': 'Several studies have shown ciprofloxacin to be effective in the treatment of acute exacerbations of chronic bronchitis, some community-acquired and nosocomial pneumonia, and acute exacerbations of bronchopulmonary infections in cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2691479': {'publication date': '1989 Nov', 'sentence': 'This investigation compared the efficacy of oral formulations of amoxycillin/clavulanate and ciprofloxacin in acute exacerbations of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3490468': {'publication date': '1986 Sep', 'sentence': 'Ciprofloxacin in acute exacerbations of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3960693': {'publication date': '1986 Feb 21', 'sentence': 'Results are presented from 186 hospitalized patients treated for acute purulent exacerbations of chronic bronchitis with orally administered ciprofloxacin (80 patients), enoxacin (26 patients), ofloxacin (30 patients) or pefloxacin (50 patients).', 'subject score': 827, 'object score': 1000}, 'PMID:7666121': {'publication date': '1995 Apr', 'sentence': 'To determine the efficacy in vivo of pefloxacin and ciprofloxacin in the treatment of acute infectious bronchopneumopathies, 90 patients, suffering from acute exacerbation of chronic bronchitis and with no known allergies to quinolones, were admitted to the study.', 'subject score': 1000, 'object score': 1000}, 'PMID:8596127': {'publication date': '1995 Oct', 'sentence': 'Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:9385486': {'publication date': '1997 Sep-Oct', 'sentence': 'Efficacy of ciprofloxacin and clarithromycin in acute bacterial exacerbations of complicated chronic bronchitis: interim analysis.', 'subject score': 1000, 'object score': 901}, 'PMID:9440580': {'publication date': '1998 Jan', 'sentence': 'A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.', 'subject score': 1000, 'object score': 1000}, 'PMID:9449270': {'publication date': '1998 Jan', 'sentence': 'A randomized, prospective, double-blind, double-dummy, multicenter study investigated the efficacy and safety of 10 days of oral therapy with grepafloxacin at 400 mg once daily, grepafloxacin at 600 mg once daily, or ciprofloxacin at 500 mg twice daily in 624 patients with acute bacterial exacerbations of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:9798024': {'publication date': '1998 Oct', 'sentence': 'In a prospective, multicenter, double-blind study, the interval to clinical relapse in patients with acute bacterial exacerbations of chronic bronchitis from whom a pretherapy pathogen was isolated was compared following treatment with ciprofloxacin or cefuroxime axetil.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0008677---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7886701",
-              "object": "MONDO:0005607",
-              "publications": [
-                "PMID:10606835",
-                "PMID:11414382",
-                "PMID:12168746",
-                "PMID:12445016",
-                "PMID:1362752",
-                "PMID:1754733",
-                "PMID:2691479",
-                "PMID:3490468",
-                "PMID:3960693",
-                "PMID:7666121",
-                "PMID:8596127",
-                "PMID:9385486",
-                "PMID:9440580",
-                "PMID:9449270",
-                "PMID:9798024"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7620631,
-            "start": 616,
-            "end": 675256,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10543732': {'publication date': '1999 Nov', 'sentence': 'The concentrations of ciprofloxacin, sparfloxacin, levofloxacin, or ofloxacin required to inhibit wild-type topoisomerase IV were 8 to 16 times lower than those required to inhibit wild-type DNA gyrase.', 'subject score': 1000, 'object score': 861}, 'PMID:23877698': {'publication date': '2013 Oct', 'sentence': 'The broad-spectrum fluoroquinolone ciprofloxacin is a bactericidal antibiotic targeting DNA topoisomerase IV and DNA gyrase encoded by the parC and gyrA genes.', 'subject score': 764, 'object score': 1000}, 'PMID:2751986': {'publication date': '1989 May 02', 'sentence': 'The fluoroquinolone ciprofloxacin, an inhibitor of eubacterial DNA gyrase, induces single- and double-stranded DNA breaks in the plasmid pGRB-1 from the halophilic archaebacterium Halobacterium GRB when the cells are treated by this drug in a magnesium-depleted medium.', 'subject score': 872, 'object score': 877}, 'PMID:27717325': {'publication date': '2016 Oct 07', 'sentence': 'RESULTS: Ciprofloxacin, an inhibitor of bacterial DNA gyrase and topoisomerase IV, was shown to inhibit growth of C. glutamicum wild type with concomitant excretion of glutamate.', 'subject score': 1000, 'object score': 901}, 'PMID:30074404': {'publication date': '2018 Nov', 'sentence': 'Ciprofloxacin, a broad-spectrum fluoroquinolone, is a bactericidal antibiotic targeting DNA gyrase and DNA topoisomerase IV encoded by the gyrA and parC genes.', 'subject score': 1000, 'object score': 825}, 'PMID:3292209': {'publication date': '1988 Apr', 'sentence': 'The primary mechanism of action of ciprofloxacin is inhibition of bacterial DNA gyrase.', 'subject score': 1000, 'object score': 901}, 'PMID:3293157': {'publication date': '1988 May-Jun', 'sentence': 'Ciprofloxacin, like other quinolones, inhibits DNA gyrase, but its bactericidal effects are not completely reversible by inhibitors of protein or RNA synthesis.', 'subject score': 1000, 'object score': 1000}, 'PMID:34541445': {'publication date': '2021 Sep', 'sentence': 'An attractive novel herbicidal target is plant DNA gyrase, which has been demonstrated to be effectively inhibited by the known antimicrobial ciprofloxacin.', 'subject score': 840, 'object score': 1000}, 'PMID:36215786': {'publication date': '2022 Oct 05', 'sentence': 'Besides, DNA gyrase inhibition assay of compounds 6d and 6e was carried out in comparison to ciprofloxacin, and interestingly, compounds 6d and 6e disclosed promising IC50 values of 0.242 and 0.177 MUM, respectively, whereas ciprofloxacin displayed an IC50 value of 0.768 MUM, assuring the proposed mechanism of action for the afforded compounds.', 'subject score': 1000, 'object score': 861}, 'PMID:36644068': {'publication date': '2022 Dec', 'sentence': 'Ciprofloxacin inhibits the bacterial DNA-gyrase enzyme resulting in the destruction of the organism.', 'subject score': 1000, 'object score': 861}, 'PMID:7503546': {'publication date': '1995 Dec 01', 'sentence': 'However, in vitro assays to show the inhibition of supercoiling activity and stimulation of cleavable complex formation demonstrated that ciprofloxacin is a potent inhibitor of mycobacterial DNA gyrase.', 'subject score': 1000, 'object score': 901}, 'PMID:8440750': {'publication date': '1993 Feb', 'sentence': 'The 4-quinolone antibiotics nalidixic acid and ciprofloxacin are potent inhibitors of the bacterial type II topoisomerase DNA gyrase.', 'subject score': 1000, 'object score': 839}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:inhibits---biolink:causes---activity---None---UMLS:C0949782---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7781719",
-              "object": "MESH:D027081",
-              "publications": [
-                "PMID:10543732",
-                "PMID:23877698",
-                "PMID:2751986",
-                "PMID:27717325",
-                "PMID:30074404",
-                "PMID:3292209",
-                "PMID:3293157",
-                "PMID:34541445",
-                "PMID:36215786",
-                "PMID:36644068",
-                "PMID:7503546",
-                "PMID:8440750"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7620631,
-            "start": 616,
-            "end": 675256,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10543732': {'publication date': '1999 Nov', 'sentence': 'The concentrations of ciprofloxacin, sparfloxacin, levofloxacin, or ofloxacin required to inhibit wild-type topoisomerase IV were 8 to 16 times lower than those required to inhibit wild-type DNA gyrase.', 'subject score': 1000, 'object score': 861}, 'PMID:23877698': {'publication date': '2013 Oct', 'sentence': 'The broad-spectrum fluoroquinolone ciprofloxacin is a bactericidal antibiotic targeting DNA topoisomerase IV and DNA gyrase encoded by the parC and gyrA genes.', 'subject score': 764, 'object score': 1000}, 'PMID:2751986': {'publication date': '1989 May 02', 'sentence': 'The fluoroquinolone ciprofloxacin, an inhibitor of eubacterial DNA gyrase, induces single- and double-stranded DNA breaks in the plasmid pGRB-1 from the halophilic archaebacterium Halobacterium GRB when the cells are treated by this drug in a magnesium-depleted medium.', 'subject score': 872, 'object score': 877}, 'PMID:27717325': {'publication date': '2016 Oct 07', 'sentence': 'RESULTS: Ciprofloxacin, an inhibitor of bacterial DNA gyrase and topoisomerase IV, was shown to inhibit growth of C. glutamicum wild type with concomitant excretion of glutamate.', 'subject score': 1000, 'object score': 901}, 'PMID:30074404': {'publication date': '2018 Nov', 'sentence': 'Ciprofloxacin, a broad-spectrum fluoroquinolone, is a bactericidal antibiotic targeting DNA gyrase and DNA topoisomerase IV encoded by the gyrA and parC genes.', 'subject score': 1000, 'object score': 825}, 'PMID:3292209': {'publication date': '1988 Apr', 'sentence': 'The primary mechanism of action of ciprofloxacin is inhibition of bacterial DNA gyrase.', 'subject score': 1000, 'object score': 901}, 'PMID:3293157': {'publication date': '1988 May-Jun', 'sentence': 'Ciprofloxacin, like other quinolones, inhibits DNA gyrase, but its bactericidal effects are not completely reversible by inhibitors of protein or RNA synthesis.', 'subject score': 1000, 'object score': 1000}, 'PMID:34541445': {'publication date': '2021 Sep', 'sentence': 'An attractive novel herbicidal target is plant DNA gyrase, which has been demonstrated to be effectively inhibited by the known antimicrobial ciprofloxacin.', 'subject score': 840, 'object score': 1000}, 'PMID:36215786': {'publication date': '2022 Oct 05', 'sentence': 'Besides, DNA gyrase inhibition assay of compounds 6d and 6e was carried out in comparison to ciprofloxacin, and interestingly, compounds 6d and 6e disclosed promising IC50 values of 0.242 and 0.177 MUM, respectively, whereas ciprofloxacin displayed an IC50 value of 0.768 MUM, assuring the proposed mechanism of action for the afforded compounds.', 'subject score': 1000, 'object score': 861}, 'PMID:36644068': {'publication date': '2022 Dec', 'sentence': 'Ciprofloxacin inhibits the bacterial DNA-gyrase enzyme resulting in the destruction of the organism.', 'subject score': 1000, 'object score': 861}, 'PMID:7503546': {'publication date': '1995 Dec 01', 'sentence': 'However, in vitro assays to show the inhibition of supercoiling activity and stimulation of cleavable complex formation demonstrated that ciprofloxacin is a potent inhibitor of mycobacterial DNA gyrase.', 'subject score': 1000, 'object score': 901}, 'PMID:8440750': {'publication date': '1993 Feb', 'sentence': 'The 4-quinolone antibiotics nalidixic acid and ciprofloxacin are potent inhibitors of the bacterial type II topoisomerase DNA gyrase.', 'subject score': 1000, 'object score': 839}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:inhibits---biolink:causes---activity---None---UMLS:C0949782---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7781719",
-              "object": "MESH:D027081",
-              "publications": [
-                "PMID:10543732",
-                "PMID:23877698",
-                "PMID:2751986",
-                "PMID:27717325",
-                "PMID:30074404",
-                "PMID:3292209",
-                "PMID:3293157",
-                "PMID:34541445",
-                "PMID:36215786",
-                "PMID:36644068",
-                "PMID:7503546",
-                "PMID:8440750"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 324986,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-          "name": "chronic obstructive pulmonary disease",
-          "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-          "equivalent_curies": [
-            "MESH:D029424",
-            "MEDDRA:10010952",
-            "MEDDRA:10009025",
-            "ICD10:J44.9",
-            "UMLS:C1527303",
-            "NCIT:C3199",
-            "UMLS:C0024117",
-            "MEDDRA:10064611",
-            "MEDDRA:10009026",
-            "MEDDRA:10029972",
-            "DOID:3083",
-            "MONDO:0005002",
-            "MEDDRA:10009032",
-            "MEDDRA:10070975",
-            "EFO:0000341",
-            "SNOMEDCT:13645005",
-            "MEDDRA:10009033",
-            "HP:0006510",
-            "MEDDRA:10008828"
-          ],
-          "id": "MONDO:0005002",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic Obstructive Pulmonary Disease",
-            "chronic obstructive pulmonary disease",
-            "Chronic pulmonary obstruction",
-            "Chronic Airflow Obstruction",
-            "Chronic Obstructive Airway Disease",
-            "Pulmonary Disease, Chronic Obstructive"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health-topics/copd",
-            "PMID:32800196",
-            "PMID:28513453",
-            "PMID:25943942",
-            "PMID:32745458"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 324986,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-              "name": "chronic obstructive pulmonary disease",
-              "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-              "equivalent_curies": [
-                "MESH:D029424",
-                "MEDDRA:10010952",
-                "MEDDRA:10009025",
-                "ICD10:J44.9",
-                "UMLS:C1527303",
-                "NCIT:C3199",
-                "UMLS:C0024117",
-                "MEDDRA:10064611",
-                "MEDDRA:10009026",
-                "MEDDRA:10029972",
-                "DOID:3083",
-                "MONDO:0005002",
-                "MEDDRA:10009032",
-                "MEDDRA:10070975",
-                "EFO:0000341",
-                "SNOMEDCT:13645005",
-                "MEDDRA:10009033",
-                "HP:0006510",
-                "MEDDRA:10008828"
-              ],
-              "id": "MONDO:0005002",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic Obstructive Pulmonary Disease",
-                "chronic obstructive pulmonary disease",
-                "Chronic pulmonary obstruction",
-                "Chronic Airflow Obstruction",
-                "Chronic Obstructive Airway Disease",
-                "Pulmonary Disease, Chronic Obstructive"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health-topics/copd",
-                "PMID:32800196",
-                "PMID:28513453",
-                "PMID:25943942",
-                "PMID:32745458"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7437751,
-            "start": 616,
-            "end": 324986,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10435684': {'publication date': '1999 Jun', 'sentence': 'Azithromycin, sultamicillin, ciprofloxacin and cefaclor monohydrate were found to be effective in treating COPD exacerbations.', 'subject score': 1000, 'object score': 709}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0024117---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7592205",
-              "object": "MONDO:0005002",
-              "publications": [
-                "PMID:10435684"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18034605,
-            "start": 675256,
-            "end": 616,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26100716': {'publication date': '2015 Sep', 'sentence': 'Plasmid-encoded protein QnrB1 protects DNA gyrase from ciprofloxacin inhibition.', 'subject score': 1000, 'object score': 888}, 'PMID:27618918': {'publication date': '2016 08', 'sentence': 'Antimicrobial susceptibility pattern and sequence analysis of DNA gyrase and DNA topoisomerase IV in Salmonella enterica serovars Typhi and Paratyphi A isolates with decreased susceptibility to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:33846132': {'publication date': '2021 Apr 12', 'sentence': 'Alanine replacement of arginine at residue 293 and a small deletion of amino acids 286-289 of GyrA resulted in a decrease in the QnrB1-mediated increase in quinolone MICs and also abolished the QnrB1 protection of purified DNA gyrase from ciprofloxacin inhibition.', 'subject score': 901, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0949782---SEMMEDDB:inhibits---biolink:causes---activity---None---UMLS:C0008809---SEMMEDDB:"
-              ],
-              "subject": "MESH:D027081",
-              "id": "18400322",
-              "object": "PUBCHEM.COMPOUND:2764",
-              "publications": [
-                "PMID:26100716",
-                "PMID:27618918",
-                "PMID:33846132"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 675256,
-        "labels": [
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "iri": "http://id.nlm.nih.gov/mesh/D027081",
-          "name": "DNA Gyrase",
-          "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-          "equivalent_curies": [
-            "CHEMBL.TARGET:CHEMBL3991502",
-            "CHEMBL.TARGET:CHEMBL2311224",
-            "CHEMBL.TARGET:CHEMBL4524002",
-            "CHEMBL.TARGET:CHEMBL2311225",
-            "CHEMBL.TARGET:CHEMBL2311244",
-            "CHEMBL.TARGET:CHEMBL3038482",
-            "CHEMBL.TARGET:CHEMBL2094139",
-            "CHEMBL.TARGET:CHEMBL3390828",
-            "MESH:D027081",
-            "CHEMBL.TARGET:CHEMBL2331040",
-            "UMLS:C0949782"
-          ],
-          "id": "MESH:D027081",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "DNA Gyrase",
-            "DNA gyrase",
-            "Bacterial DNA gyrase"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:MolecularEntity"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 675256,
-            "labels": [
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "iri": "http://id.nlm.nih.gov/mesh/D027081",
-              "name": "DNA Gyrase",
-              "description": "One of the two subunits in DNA gyrase.; UMLS Semantic Type: STY:T126; UMLS Semantic Type: STY:T116",
-              "equivalent_curies": [
-                "CHEMBL.TARGET:CHEMBL3991502",
-                "CHEMBL.TARGET:CHEMBL2311224",
-                "CHEMBL.TARGET:CHEMBL4524002",
-                "CHEMBL.TARGET:CHEMBL2311225",
-                "CHEMBL.TARGET:CHEMBL2311244",
-                "CHEMBL.TARGET:CHEMBL3038482",
-                "CHEMBL.TARGET:CHEMBL2094139",
-                "CHEMBL.TARGET:CHEMBL3390828",
-                "MESH:D027081",
-                "CHEMBL.TARGET:CHEMBL2331040",
-                "UMLS:C0949782"
-              ],
-              "id": "MESH:D027081",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "DNA Gyrase",
-                "DNA gyrase",
-                "Bacterial DNA gyrase"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:MolecularEntity"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18034605,
-            "start": 675256,
-            "end": 616,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26100716': {'publication date': '2015 Sep', 'sentence': 'Plasmid-encoded protein QnrB1 protects DNA gyrase from ciprofloxacin inhibition.', 'subject score': 1000, 'object score': 888}, 'PMID:27618918': {'publication date': '2016 08', 'sentence': 'Antimicrobial susceptibility pattern and sequence analysis of DNA gyrase and DNA topoisomerase IV in Salmonella enterica serovars Typhi and Paratyphi A isolates with decreased susceptibility to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:33846132': {'publication date': '2021 Apr 12', 'sentence': 'Alanine replacement of arginine at residue 293 and a small deletion of amino acids 286-289 of GyrA resulted in a decrease in the QnrB1-mediated increase in quinolone MICs and also abolished the QnrB1 protection of purified DNA gyrase from ciprofloxacin inhibition.', 'subject score': 901, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0949782---SEMMEDDB:inhibits---biolink:causes---activity---None---UMLS:C0008809---SEMMEDDB:"
-              ],
-              "subject": "MESH:D027081",
-              "id": "18400322",
-              "object": "PUBCHEM.COMPOUND:2764",
-              "publications": [
-                "PMID:26100716",
-                "PMID:27618918",
-                "PMID:33846132"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321736,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005607",
-          "name": "chronic bronchitis",
-          "description": "A type of chronic obstructive pulmonary disease characterized by chronic inflammation in the bronchial tree that results in edema, mucus production, obstruction, and reduced airflow to and from the lung alveoli. The most common cause is tobacco smoking. Signs and symptoms include coughing with excessive mucus production, and shortness of breath.; A subcategory of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. The disease is characterized by hypersecretion of mucus accompanied by a chronic (more than 3 months in 2 consecutive years) productive cough. Infectious agents are a major cause of chronic bronchitis.; Chronic inflammation of the bronchi. [HPO:probinson]; What is chronic bronchitis? Chronic bronchitis is a type of COPD (chronic obstructive pulmonary disease). COPD is a group of lung diseases that make it hard to breathe and get worse over time. The other main type of COPD is emphysema. Most people with COPD have both emphysema and chronic bronchitis, but how severe each type is can be different from person to person. Chronic bronchitis is inflammation (swelling) and irritation of the bronchial tubes. These tubes are the airways that carry air to and from the air sacs in your lungs. The irritation of the tubes causes mucus to build up. This mucus and the swelling of the tubes make it harder for your lungs to move oxygen in and carbon dioxide out of your body. What causes chronic bronchitis? The cause of chronic bronchitis is usually long-term exposure to irritants that damage your lungs and airways. In the United States, cigarette smoke is the main cause. Pipe, cigar, and other types of tobacco smoke can also cause chronic bronchitis, especially if you inhale them. Exposure to other inhaled irritants can contribute to chronic bronchitis. These include secondhand smoke, air pollution, and chemical fumes or dusts from the environment or workplace. Rarely, a genetic condition called alpha-1 antitrypsin deficiency can play a role in causing chronic bronchitis. Who is at risk for chronic bronchitis? The risk factors for chronic bronchitis include: Smoking. This the main risk factor. Up to 75% of people who have chronic bronchitis smoke or used to smoke. Long-term exposure to other lung irritants, such as secondhand smoke, air pollution, and chemical fumes and dusts from the environment or workplace. Age. Most people who have chronic bronchitis are at least 40 years old when their symptoms begin. Genetics. This includes alpha-1 antitrypsin deficiency, which is a genetic condition. Also, smokers who get chronic bronchitis are more likely to get it if they have a family history of COPD.  What are the symptoms of chronic bronchitis? At first, you may have no symptoms or only mild symptoms. As the disease gets worse, your symptoms usually become more severe. They can include: Frequent coughing or a cough that produces a lot mucus Wheezing A whistling or squeaky sound when you breathe Shortness of breath, especially with physical activity Tightness in your chest  Some people with chronic bronchitis get frequent respiratory infections such as colds and the flu. In severe cases, chronic bronchitis can cause weight loss, weakness in your lower muscles, and swelling in your ankles, feet, or legs. How is chronic bronchitis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A family history Various tests, such as lung function tests, a chest x-ray or CT scan, and blood tests  What are the treatments for chronic bronchitis? There is no cure for chronic bronchitis. However, treatments can help with symptoms, slow the progress of the disease, and improve your ability to stay active. There are also treatments to prevent or treat complications of the disease. Treatments include: Lifestyle changes, such as  Quitting smoking if you are a smoker. This is the most important step you can take to treat chronic bronchitis. Avoiding secondhand smoke and places where you might breathe in other lung irritants Ask your health care provider for an eating plan that will meet your nutritional needs. Also ask about how much physical activity you can do. Physical activity can strengthen the muscles that help you breathe and improve your overall wellness.   Medicines, such as  Bronchodilators, which relax the muscles around your airways. This helps open your airways and makes breathing easier. Most bronchodilators are taken through an inhaler. In more severe cases, the inhaler may also contain steroids to reduce inflammation. Vaccines for the flu and pneumococcal pneumonia, since people with chronic bronchitis are at higher risk for serious problems from these diseases. Antibiotics if you get a bacterial or viral lung infection   Oxygen therapy, if you have severe chronic bronchitis and low levels of oxygen in your blood. Oxygen therapy can help you breathe better. You may need extra oxygen all the time or only at certain times. Pulmonary rehabilitation, which is a program that helps improve the well-being of people who have chronic breathing problems. It may include  An exercise program Disease management training Nutritional counseling Psychological counseling  A lung transplant, as a last resort for people who have severe symptoms that have not gotten better with medicines  If you have chronic bronchitis, it's important to know when and where to get help for your symptoms. You should get emergency care if you have severe symptoms, such as trouble catching your breath or talking. Call your health care provider if your symptoms are getting worse or if you have signs of an infection, such as a fever. Can chronic bronchitis be prevented? Since smoking causes most cases of chronic bronchitis, the best way to prevent it is to not smoke. It's also important to try to avoid lung irritants such as secondhand smoke, air pollution, chemical fumes, and dusts.  NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10008843",
-            "MEDDRA:10008841",
-            "NCIT:C26722",
-            "MEDDRA:10006458",
-            "MESH:D029481",
-            "MONDO:0005607",
-            "MEDDRA:10045659",
-            "EFO:0006505",
-            "UMLS:C0008677",
-            "MEDDRA:10006459",
-            "HP:0004469",
-            "SNOMEDCT:63480004"
-          ],
-          "id": "MONDO:0005607",
-          "category": "biolink:Disease",
-          "all_names": [
-            "chronic bronchitis",
-            "Bronchitis, Chronic",
-            "Chronic bronchitis",
-            "Chronic Bronchitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321736,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005607",
-              "name": "chronic bronchitis",
-              "description": "A type of chronic obstructive pulmonary disease characterized by chronic inflammation in the bronchial tree that results in edema, mucus production, obstruction, and reduced airflow to and from the lung alveoli. The most common cause is tobacco smoking. Signs and symptoms include coughing with excessive mucus production, and shortness of breath.; A subcategory of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. The disease is characterized by hypersecretion of mucus accompanied by a chronic (more than 3 months in 2 consecutive years) productive cough. Infectious agents are a major cause of chronic bronchitis.; Chronic inflammation of the bronchi. [HPO:probinson]; What is chronic bronchitis? Chronic bronchitis is a type of COPD (chronic obstructive pulmonary disease). COPD is a group of lung diseases that make it hard to breathe and get worse over time. The other main type of COPD is emphysema. Most people with COPD have both emphysema and chronic bronchitis, but how severe each type is can be different from person to person. Chronic bronchitis is inflammation (swelling) and irritation of the bronchial tubes. These tubes are the airways that carry air to and from the air sacs in your lungs. The irritation of the tubes causes mucus to build up. This mucus and the swelling of the tubes make it harder for your lungs to move oxygen in and carbon dioxide out of your body. What causes chronic bronchitis? The cause of chronic bronchitis is usually long-term exposure to irritants that damage your lungs and airways. In the United States, cigarette smoke is the main cause. Pipe, cigar, and other types of tobacco smoke can also cause chronic bronchitis, especially if you inhale them. Exposure to other inhaled irritants can contribute to chronic bronchitis. These include secondhand smoke, air pollution, and chemical fumes or dusts from the environment or workplace. Rarely, a genetic condition called alpha-1 antitrypsin deficiency can play a role in causing chronic bronchitis. Who is at risk for chronic bronchitis? The risk factors for chronic bronchitis include: Smoking. This the main risk factor. Up to 75% of people who have chronic bronchitis smoke or used to smoke. Long-term exposure to other lung irritants, such as secondhand smoke, air pollution, and chemical fumes and dusts from the environment or workplace. Age. Most people who have chronic bronchitis are at least 40 years old when their symptoms begin. Genetics. This includes alpha-1 antitrypsin deficiency, which is a genetic condition. Also, smokers who get chronic bronchitis are more likely to get it if they have a family history of COPD.  What are the symptoms of chronic bronchitis? At first, you may have no symptoms or only mild symptoms. As the disease gets worse, your symptoms usually become more severe. They can include: Frequent coughing or a cough that produces a lot mucus Wheezing A whistling or squeaky sound when you breathe Shortness of breath, especially with physical activity Tightness in your chest  Some people with chronic bronchitis get frequent respiratory infections such as colds and the flu. In severe cases, chronic bronchitis can cause weight loss, weakness in your lower muscles, and swelling in your ankles, feet, or legs. How is chronic bronchitis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A family history Various tests, such as lung function tests, a chest x-ray or CT scan, and blood tests  What are the treatments for chronic bronchitis? There is no cure for chronic bronchitis. However, treatments can help with symptoms, slow the progress of the disease, and improve your ability to stay active. There are also treatments to prevent or treat complications of the disease. Treatments include: Lifestyle changes, such as  Quitting smoking if you are a smoker. This is the most important step you can take to treat chronic bronchitis. Avoiding secondhand smoke and places where you might breathe in other lung irritants Ask your health care provider for an eating plan that will meet your nutritional needs. Also ask about how much physical activity you can do. Physical activity can strengthen the muscles that help you breathe and improve your overall wellness.   Medicines, such as  Bronchodilators, which relax the muscles around your airways. This helps open your airways and makes breathing easier. Most bronchodilators are taken through an inhaler. In more severe cases, the inhaler may also contain steroids to reduce inflammation. Vaccines for the flu and pneumococcal pneumonia, since people with chronic bronchitis are at higher risk for serious problems from these diseases. Antibiotics if you get a bacterial or viral lung infection   Oxygen therapy, if you have severe chronic bronchitis and low levels of oxygen in your blood. Oxygen therapy can help you breathe better. You may need extra oxygen all the time or only at certain times. Pulmonary rehabilitation, which is a program that helps improve the well-being of people who have chronic breathing problems. It may include  An exercise program Disease management training Nutritional counseling Psychological counseling  A lung transplant, as a last resort for people who have severe symptoms that have not gotten better with medicines  If you have chronic bronchitis, it's important to know when and where to get help for your symptoms. You should get emergency care if you have severe symptoms, such as trouble catching your breath or talking. Call your health care provider if your symptoms are getting worse or if you have signs of an infection, such as a fever. Can chronic bronchitis be prevented? Since smoking causes most cases of chronic bronchitis, the best way to prevent it is to not smoke. It's also important to try to avoid lung irritants such as secondhand smoke, air pollution, chemical fumes, and dusts.  NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10008843",
-                "MEDDRA:10008841",
-                "NCIT:C26722",
-                "MEDDRA:10006458",
-                "MESH:D029481",
-                "MONDO:0005607",
-                "MEDDRA:10045659",
-                "EFO:0006505",
-                "UMLS:C0008677",
-                "MEDDRA:10006459",
-                "HP:0004469",
-                "SNOMEDCT:63480004"
-              ],
-              "id": "MONDO:0005607",
-              "category": "biolink:Disease",
-              "all_names": [
-                "chronic bronchitis",
-                "Bronchitis, Chronic",
-                "Chronic bronchitis",
-                "Chronic Bronchitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23563350,
-            "start": 616,
-            "end": 321736,
-=======
-            "identity": 11429435,
-            "start": 616,
-            "end": 579767,
->>>>>>> main
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-<<<<<<< HEAD
-              "publications_info": "{'PMID:3490468': {'publication date': '1986 Sep', 'sentence': 'Thirty four patients with acute purulent exacerbations of chronic bronchitis were treated with 500 mg ciprofloxacin twice daily, orally, for ten days.', 'subject score': 798, 'object score': 1000}, 'PMID:3501857': {'publication date': '1987 Dec 11', 'sentence': 'Thirty four patients with acute purulent exacerbations of chronic bronchitis were treated with 500 mg ciprofloxacin twice daily, orally, for ten days.', 'subject score': 798, 'object score': 1000}, 'PMID:9440580': {'publication date': '1998 Jan', 'sentence': 'In patients suffering from an AECB with a history of moderate to severe chronic bronchitis and at least four AECBs in the previous year, ciprofloxacin treatment offered substantial clinical and economic benefits.', 'subject score': 888, 'object score': 901}, 'PMID:9767959': {'publication date': '1998 Mar 28', 'sentence': '[The role of ciprofloxacin in the treatment of chronic bronchitis].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0008677---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "24010235",
-              "object": "MONDO:0005607",
-              "publications": [
-                "PMID:3490468",
-                "PMID:3501857",
-                "PMID:9440580",
-                "PMID:9767959"
-=======
-              "publications_info": "{'PMID:1572222': {'publication date': '1992 Mar', 'sentence': \"We used a simple Wood's light examination and culture to establish the diagnosis of Pseudomonas toe web infection and achieved rapid resolution with oral ciprofloxacin treatment and local application of Castellani's paint.\", 'subject score': 851, 'object score': 861}, 'PMID:20836302': {'publication date': '2010 Apr 15', 'sentence': 'At present time Ciprofloxacin is relatively effective antibiotic for Pseudomonas infection.', 'subject score': 851, 'object score': 1000}, 'PMID:2114953': {'publication date': '1990 Mar-Apr', 'sentence': 'Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2292542': {'publication date': '1990 Dec', 'sentence': 'The Cystic Fibrosis Clinic at the Royal Belfast Hospital for Sick Children has treated 31 children with ciprofloxacin, for serious pseudomonas infection in cystic fibrosis, and carefully monitored the safety and acceptability of the drug.', 'subject score': 1000, 'object score': 901}, 'PMID:24489509': {'publication date': '2013', 'sentence': 'The key findings were as follows: inhaled antipseudomonal antibiotic improves lung function, and probably the safest/most effective therapy; antistaphylococcal antibiotic prophylaxis increases the risk of acquiring P. aeruginosa; azithromycin significantly improves respiratory function after 6 months of treatment; a 28-day treatment with aztreonam or tobramycin significantly improves respiratory symptoms and pulmonary function; aztreonam lysine might be superior to tobramycin inhaled solution in chronic P. aeruginosa infection; oral ciprofloxacin does not produce additional benefit in those with chronic persistent pseudomonas infection but may have a role in early or first infection.', 'subject score': 888, 'object score': 826}, 'PMID:24718510': {'publication date': '2014 Apr', 'sentence': 'Pseudomonas infections of the nail organ are treated by ciprofloxacin; other bacteria are treated according to the results of culture and sensitivity testing.', 'subject score': 1000, 'object score': 1000}, 'PMID:2508586': {'publication date': '1989 Oct', 'sentence': 'Studies using either higher dosages of ciprofloxacin or combination therapy should be conducted to determine if acquired resistance can be avoided in Pseudomonas infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:3100490': {'publication date': '1986 Nov', 'sentence': 'Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:3279487': {'publication date': '1988 Jan-Feb', 'sentence': 'Ciprofloxacin and other quinolones are also effective therapy for pseudomonal infections in neutropenic animals with pneumonia, peritonitis, osteomyelitis, and endocarditis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3279495': {'publication date': '1988', 'sentence': 'Ciprofloxacin is apparently valuable for the treatment of pseudomonas infections in patients with cystic fibrosis: clinical results seem comparable to those obtained with conventional intravenous treatments.', 'subject score': 1000, 'object score': 1000}, 'PMID:35330242': {'publication date': '2022 Feb 28', 'sentence': 'Therefore, high local CIP concentrations during treatment of    Pseudomonas-Aspergillus     co-infections may increase the fungal burden.', 'subject score': 833, 'object score': 861}, 'PMID:3680089': {'publication date': '1987 Oct', 'sentence': 'Therapeutic efficacy of cefpiramide-ciprofloxacin combination in experimental Pseudomonas infections in neutropenic mice.', 'subject score': 851, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0033817---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "11679354",
-              "object": "MONDO:0005141",
-              "publications": [
-                "PMID:1572222",
-                "PMID:20836302",
-                "PMID:2114953",
-                "PMID:2292542",
-                "PMID:24489509",
-                "PMID:24718510",
-                "PMID:2508586",
-                "PMID:3100490",
-                "PMID:3279487",
-                "PMID:3279495",
-                "PMID:35330242",
-                "PMID:3680089"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 310237,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004976",
-          "name": "amyotrophic lateral sclerosis",
-          "description": "A neurodegenerative disorder characterized by progressive degeneration of the motor neurons of the central nervous system. It results in weakness and atrophy of the muscles which leads to an inability to initiate and control voluntary movements.; A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94); UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:0111246",
-            "NCIT:C34373",
-            "MEDDRA:10002026",
-            "OMIM:PS105400",
-            "UMLS:C0002736",
-            "DOID:332",
-            "MESH:D000690",
-            "ICD9:335.20",
-            "SNOMEDCT:86044005",
-            "MEDDRA:10052889",
-            "ORPHANET:803",
-            "HP:0007354",
-            "ICD10:G12.21",
-            "EFO:0000253",
-            "KEGG.DISEASE:05014",
-            "MONDO:0004976"
-          ],
-          "id": "MONDO:0004976",
-          "category": "biolink:Disease",
-          "all_names": [
-            "obsolete_amyotrophic lateral sclerosis",
-            "amyotrophic lateral sclerosis-parkinsonism/dementia complex 1",
-            "Amyotrophic lateral sclerosis",
-            "amyotrophic lateral sclerosis",
-            "Amyotrophic Lateral Sclerosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/detail_als.htm",
-            "PMID:5770171",
-            "PMID:16051700",
-            "http://en.wikipedia.org/wiki/amyotrophic_lateral_sclerosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 310237,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004976",
-              "name": "amyotrophic lateral sclerosis",
-              "description": "A neurodegenerative disorder characterized by progressive degeneration of the motor neurons of the central nervous system. It results in weakness and atrophy of the muscles which leads to an inability to initiate and control voluntary movements.; A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94); UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:0111246",
-                "NCIT:C34373",
-                "MEDDRA:10002026",
-                "OMIM:PS105400",
-                "UMLS:C0002736",
-                "DOID:332",
-                "MESH:D000690",
-                "ICD9:335.20",
-                "SNOMEDCT:86044005",
-                "MEDDRA:10052889",
-                "ORPHANET:803",
-                "HP:0007354",
-                "ICD10:G12.21",
-                "EFO:0000253",
-                "KEGG.DISEASE:05014",
-                "MONDO:0004976"
-              ],
-              "id": "MONDO:0004976",
-              "category": "biolink:Disease",
-              "all_names": [
-                "obsolete_amyotrophic lateral sclerosis",
-                "amyotrophic lateral sclerosis-parkinsonism/dementia complex 1",
-                "Amyotrophic lateral sclerosis",
-                "amyotrophic lateral sclerosis",
-                "Amyotrophic Lateral Sclerosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/detail_als.htm",
-                "PMID:5770171",
-                "PMID:16051700",
-                "http://en.wikipedia.org/wiki/amyotrophic_lateral_sclerosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22060077,
-            "start": 616,
-            "end": 310237,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32915525': {'publication date': '2020 Sep 11', 'sentence': 'OBJECTIVE: To evaluate the efficacy of a fixed-dose combination of two approved drugs, Ciprofloxacin and Celecoxib, as a potential therapeutic treatment for amyotrophic lateral sclerosis (ALS).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0002736---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "22484062",
-              "object": "MONDO:0004976",
-              "publications": [
-                "PMID:32915525"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 546907,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C3714514",
-          "name": "Infection",
-          "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "UMLS:C3714514",
-            "MEDDRA:10021842",
-            "NCIT:C128320",
-            "MEDDRA:10021789",
-            "MESH:D007239"
-          ],
-          "id": "UMLS:C3714514",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infection",
-            "Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546907,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C3714514",
-              "name": "Infection",
-              "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "UMLS:C3714514",
-                "MEDDRA:10021842",
-                "NCIT:C128320",
-                "MEDDRA:10021789",
-                "MESH:D007239"
-              ],
-              "id": "UMLS:C3714514",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infection",
-                "Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21074888,
-            "start": 616,
-            "end": 546907,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31867477': {'publication date': '2019 Dec 17', 'sentence': 'Noncytotoxic Pyrrolobenzodiazepine-Ciprofloxacin Conjugate with Activity against    Mycobacterium tuberculosis    .The development of new antitubercular agents for the treatment of infections caused by multidrug-resistant (MDR)    Mycobacterium tuberculosis     is an urgent priority.', 'subject score': 583, 'object score': 1000}, 'PMID:31919670': {'publication date': '2020 Jan 09', 'sentence': 'In Vitro Activity of Fosfomycin in Double and Triple Combinations with Imipenem, Ciprofloxacin and Tobramycin Against Multidrug-Resistant Escherichia coli.The rates of urinary tract infection with multidrug-resistant (MDR) Escherichia coli have dramatically increased and the treatment of these infections with single and double antibiotic combinations became limited or ineffective.', 'subject score': 1000, 'object score': 1000}, 'PMID:31973270': {'publication date': '2015 Jul', 'sentence': 'The cover picture shows an SEM image of nanostructured biosilica produced by- Thalassiosira weissflogii- diatoms covalently functionalized with the radical scavenger TEMPO (green disks) and loaded with the antibiotic Ciprofloxacin (red/white capsules), which is used to combat infections related to orthopedic implants.', 'subject score': 888, 'object score': 1000}, 'PMID:32265871': {'publication date': '2020', 'sentence': 'Ciprofloxacin is the choice treatment for infections caused by    Salmonella     Typhi, however, reduced susceptibility to ciprofloxacin has been reported for this pathogen.', 'subject score': 1000, 'object score': 1000}, 'PMID:32634369': {'publication date': '2020 Jul', 'sentence': 'Here, we develop and apply a mechanistic mathematical model to data from a study comparing the effects of ciprofloxacin and ampicillin on the within-host dynamics of    Salmonella enterica     serovar Typhimurium in murine infections.', 'subject score': 1000, 'object score': 888}, 'PMID:32664334': {'publication date': '2020 Jul 10', 'sentence': 'The involvement of tobramycin and ciprofloxacin, widely used to treat CF PA lung infections, in the abundance of VBNC cells was investigated in PA biofilms models.', 'subject score': 1000, 'object score': 864}, 'PMID:33064003': {'publication date': '2020 Nov 03', 'sentence': 'The antibiotic ciprofloxacin (CIP) is extensively employed to treat infections in animal and human medicine.', 'subject score': 888, 'object score': 1000}, 'PMID:33107284': {'publication date': '2020 Oct', 'sentence': 'The aim of this study was to investigate the effects of sub-minimal inhibitory concentrations (sub-MIC) of piperacillin/tazobactam (TZP) and ciprofloxacin (CIP) which are used for the treatment of P.aeruginosa infections on biofilm formation and to investigate the relationship between the severity of biofilm formation and Quorum Sensing (QS) genes.', 'subject score': 1000, 'object score': 901}, 'PMID:33229966': {'publication date': '2020 Nov 20', 'sentence': 'OBJECTIVES: To describe the effectiveness of ciprofloxacin to treat \"susceptible\" infections, we estimated the clinical efficacy of ciprofloxacin at various minimum inhibitory concentrations (MICs) and anatomic sites.', 'subject score': 1000, 'object score': 888}, 'PMID:33460732': {'publication date': '2021 Jan 15', 'sentence': 'AIMS: Exploration of Azithromycin as an adjunctive therapy to Ciprofloxacin for treatment of P. aeruginosa infections.', 'subject score': 1000, 'object score': 901}, 'PMID:34464919': {'publication date': '2021 Aug 06', 'sentence': 'Fluconazole (FLZ) is co-administered with either ciprofloxacin (CPR) or ofloxacin (OFX) for the treatment of certain microbial infections.', 'subject score': 888, 'object score': 851}, 'PMID:34919918': {'publication date': '2021 Dec 14', 'sentence': 'Ciprofloxacin is a pharmaceutical component used for treating various tract infections.', 'subject score': 1000, 'object score': 775}, 'PMID:35796076': {'publication date': '2022 Jul 07', 'sentence': 'Conclusion:     The combination of meropenem and ciprofloxacin seems to be a good candidate for the treatment of biofilm-associated infections; none of the concentrations obtained as a result of the synergy test were clinically significant.', 'subject score': 1000, 'object score': 802}, 'PMID:36620240': {'publication date': '2022', 'sentence': 'The rise of infections that are resistant to ciprofloxacin shows that new pharmacological synergisms and derivatives are required.', 'subject score': 1000, 'object score': 1000}, 'PMID:36986580': {'publication date': '2023 Feb 21', 'sentence': 'Drug Combination of Ciprofloxacin and Polymyxin B for the Treatment of Multidrug-Resistant    Acinetobacter baumannii     Infections: A Drug Pair Limiting the Development of Resistance.', 'subject score': 1000, 'object score': 928}, 'PMID:37166011': {'publication date': '2023 May 11', 'sentence': 'The CP1-WT peptide shows significant improvement over ciprofloxacin in terms of its in vivo therapeutic efficacy in treating established infections of S.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C3714514---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "21488232",
-              "object": "UMLS:C3714514",
-              "publications": [
-                "PMID:31867477",
-                "PMID:31919670",
-                "PMID:31973270",
-                "PMID:32265871",
-                "PMID:32634369",
-                "PMID:32664334",
-                "PMID:33064003",
-                "PMID:33107284",
-                "PMID:33229966",
-                "PMID:33460732",
-                "PMID:34464919",
-                "PMID:34919918",
-                "PMID:35796076",
-                "PMID:36620240",
-                "PMID:36986580",
-                "PMID:37166011"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:29208561': {'publication date': '2018 Jul', 'sentence': 'Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319679,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-          "name": "lymphoma",
-          "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:115244002",
-            "DOID:0060058",
-            "MONDO:0005062",
-            "SNOMEDCT:118600007",
-            "HP:0002665",
-            "NCIT:C7065",
-            "EFO:0000574",
-            "ORPHANET:223735",
-            "MESH:D008223",
-            "SNOMEDCT:188676008",
-            "PDQ:CDR0000041429",
-            "MEDDRA:10025316",
-            "UMLS:C0024299",
-            "NCIT:C3208",
-            "MEDDRA:10025632",
-            "MEDDRA:10025310",
-            "MEDDRA:10025633",
-            "SNOMEDCT:1163043007",
-            "ICD10:C85.9",
-            "UMLS:C1536843",
-            "UMLS:C0334621",
-            "MEDDRA:10025315"
-          ],
-          "id": "MONDO:0005062",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphocytic Neoplasm",
-            "Lymphoma",
-            "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-            "lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/lymphoma",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319679,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-              "name": "lymphoma",
-              "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:115244002",
-                "DOID:0060058",
-                "MONDO:0005062",
-                "SNOMEDCT:118600007",
-                "HP:0002665",
-                "NCIT:C7065",
-                "EFO:0000574",
-                "ORPHANET:223735",
-                "MESH:D008223",
-                "SNOMEDCT:188676008",
-                "PDQ:CDR0000041429",
-                "MEDDRA:10025316",
-                "UMLS:C0024299",
-                "NCIT:C3208",
-                "MEDDRA:10025632",
-                "MEDDRA:10025310",
-                "MEDDRA:10025633",
-                "SNOMEDCT:1163043007",
-                "ICD10:C85.9",
-                "UMLS:C1536843",
-                "UMLS:C0334621",
-                "MEDDRA:10025315"
-              ],
-              "id": "MONDO:0005062",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphocytic Neoplasm",
-                "Lymphoma",
-                "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-                "lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/lymphoma",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19648694,
-            "start": 616,
-            "end": 319679,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29208561': {'publication date': '2018 Jul', 'sentence': 'Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0024299---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "20040173",
-              "object": "MONDO:0005062",
-              "publications": [
-                "PMID:29208561"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:18854092': {'publication date': '2008 Oct', 'sentence': 'Results of combination therapy with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in patients with myelodysplastic syndrome and acute myeloid leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:25617073': {'publication date': '2015 May', 'sentence': 'Thus, in April 2008, we changed our antibiotic prophylaxis regimen from cotrimoxazole/colistin (COT/COL) to the fluoroquinolone ciprofloxacin (CIP) in patients with acute myeloid leukemia (AML).', 'subject score': 872, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 321063,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018874",
-          "name": "acute myeloid leukemia",
-          "description": "A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification). (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3171\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3171\" NCI Thesaurus); Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.; A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).; Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.; A form of leukemia characterized by overproduction of an early myeloid cell. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:91861009",
-            "ICD9:205.0",
-            "MEDDRA:10024346",
-            "MEDDRA:10000801",
-            "MEDDRA:10060354",
-            "KEGG.DISEASE:05221",
-            "EFO:0000222",
-            "PDQ:CDR0000043424",
-            "MEDDRA:10000886",
-            "HP:0004808",
-            "MEDDRA:10060394",
-            "MESH:D015470",
-            "MEDDRA:10051003",
-            "MONDO:0100173",
-            "MEDDRA:10000878",
-            "MEDDRA:10060553",
-            "MEDDRA:10024291",
-            "SNOMEDCT:1162928000",
-            "MEDDRA:10054296",
-            "ORPHANET:519",
-            "MEDDRA:10000880",
-            "UMLS:C3275959",
-            "MEDDRA:10028552",
-            "MONDO:0018874",
-            "OMIM:601626",
-            "MEDDRA:10000884",
-            "DOID:9119",
-            "MEDDRA:10029549",
-            "MEDDRA:10029551",
-            "UMLS:C0023467",
-            "NCIT:C3171",
-            "MEDDRA:10060557",
-            "MEDDRA:10028557"
-          ],
-          "id": "MONDO:0018874",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia, acute myeloid related phenotypic feature",
-            "Leukemia, Myelocytic, Acute",
-            "Acute myeloid leukemia",
-            "acute myeloid leukemia",
-            "leukemia, acute myeloid, susceptibility to",
-            "Leukemia, acute myeloid, susceptibility to",
-            "Acute Myeloid Leukemia",
-            "Leukemia, Myeloid, Acute",
-            "Myeloid leukemia, acute"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=44363",
-            "http://cancergenome.nih.gov/cancersselected/acutemyeloidleukemia",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.cancer.org/cancer/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.htm",
-            "http://en.wikipedia.org/wiki/acute_myeloid_leukemia"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321063,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018874",
-              "name": "acute myeloid leukemia",
-              "description": "A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification). (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3171\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3171\" NCI Thesaurus); Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.; A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).; Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.; A form of leukemia characterized by overproduction of an early myeloid cell. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:91861009",
-                "ICD9:205.0",
-                "MEDDRA:10024346",
-                "MEDDRA:10000801",
-                "MEDDRA:10060354",
-                "KEGG.DISEASE:05221",
-                "EFO:0000222",
-                "PDQ:CDR0000043424",
-                "MEDDRA:10000886",
-                "HP:0004808",
-                "MEDDRA:10060394",
-                "MESH:D015470",
-                "MEDDRA:10051003",
-                "MONDO:0100173",
-                "MEDDRA:10000878",
-                "MEDDRA:10060553",
-                "MEDDRA:10024291",
-                "SNOMEDCT:1162928000",
-                "MEDDRA:10054296",
-                "ORPHANET:519",
-                "MEDDRA:10000880",
-                "UMLS:C3275959",
-                "MEDDRA:10028552",
-                "MONDO:0018874",
-                "OMIM:601626",
-                "MEDDRA:10000884",
-                "DOID:9119",
-                "MEDDRA:10029549",
-                "MEDDRA:10029551",
-                "UMLS:C0023467",
-                "NCIT:C3171",
-                "MEDDRA:10060557",
-                "MEDDRA:10028557"
-              ],
-              "id": "MONDO:0018874",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia, acute myeloid related phenotypic feature",
-                "Leukemia, Myelocytic, Acute",
-                "Acute myeloid leukemia",
-                "acute myeloid leukemia",
-                "leukemia, acute myeloid, susceptibility to",
-                "Leukemia, acute myeloid, susceptibility to",
-                "Acute Myeloid Leukemia",
-                "Leukemia, Myeloid, Acute",
-                "Myeloid leukemia, acute"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=44363",
-                "http://cancergenome.nih.gov/cancersselected/acutemyeloidleukemia",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.cancer.org/cancer/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.htm",
-                "http://en.wikipedia.org/wiki/acute_myeloid_leukemia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13711567,
-            "start": 616,
-            "end": 321063,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18854092': {'publication date': '2008 Oct', 'sentence': 'Results of combination therapy with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in patients with myelodysplastic syndrome and acute myeloid leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:25617073': {'publication date': '2015 May', 'sentence': 'Thus, in April 2008, we changed our antibiotic prophylaxis regimen from cotrimoxazole/colistin (COT/COL) to the fluoroquinolone ciprofloxacin (CIP) in patients with acute myeloid leukemia (AML).', 'subject score': 872, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0023467---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "14005051",
-              "object": "MONDO:0018874",
-              "publications": [
-                "PMID:18854092",
-                "PMID:25617073"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:27342785': {'publication date': '2016 Sep', 'sentence': 'A case of septic arthritis caused by a Mycoplasma salivarium strain resistant towards Ciprofloxacin and Clarithromycin in a patient with chronic lymphatic leukemia.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 323598,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004948",
-          "name": "B-cell chronic lymphocytic leukemia",
-          "description": "The most common type of chronic lymphoid leukemia. It comprises 90% of chronic lymphoid leukemias in the United States. Morphologically, the neoplastic cells are small, round B-lymphocytes. This type of leukemia is not considered to be curable with available therapy. (WHO, 2001); A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.; A chronic lymphocytic/lymphatic/lymphoblastic leukemia (CLL) is a neoplastic disease characterized by proliferation and accumulation (blood, marrow and lymphoid organs) of morphologically mature but immunologically dysfunctional lymphocytes. A CLL is always a B-cell lymphocytic leukemia as there are no reports of cases of T-cell lymphocytic leukemias. [HPO:curators]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10051812",
-            "MEDDRA:10003908",
-            "MEDDRA:10068919",
-            "MEDDRA:10060576",
-            "MEDDRA:10068852",
-            "OMIM:151400",
-            "MEDDRA:10003909",
-            "MEDDRA:10008956",
-            "UMLS:C0855095",
-            "ICD9:204.1",
-            "MEDDRA:10060391",
-            "MEDDRA:10008976",
-            "NCIT:C7540",
-            "MEDDRA:10008957",
-            "HP:0005550",
-            "MONDO:0004948",
-            "UMLS:C0023434",
-            "MEDDRA:10024340",
-            "MEDDRA:10025306",
-            "PDQ:CDR0000038170",
-            "MEDDRA:10009310",
-            "SNOMEDCT:302841002",
-            "MEDDRA:10008960",
-            "ORPHANET:67038",
-            "SNOMEDCT:92814006",
-            "SNOMEDCT:277473004",
-            "MEDDRA:10008958",
-            "SNOMEDCT:64575004",
-            "MEDDRA:10003910",
-            "MEDDRA:10024295",
-            "ICD10:C91.10",
-            "PDQ:CDR0000037765",
-            "MEDDRA:10025302",
-            "EFO:0000095",
-            "MEDDRA:10041138",
-            "DOID:1040",
-            "SNOMEDCT:51092000",
-            "MESH:D015451",
-            "PDQ:CDR0000039824",
-            "NCIT:C3163",
-            "MEDDRA:10008993"
-          ],
-          "id": "MONDO:0004948",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic lymphatic leukemia",
-            "Lymphoid leukemia, chronic",
-            "Small Lymphocytic Lymphoma",
-            "chronic lymphocytic leukemia",
-            "Leukemia, chronic lymphocytic related phenotypic feature",
-            "Leukemia, Lymphocytic, Chronic, B-Cell",
-            "B-cell chronic lymphocytic leukemia",
-            "small lymphocytic lymphoma",
-            "Chronic Lymphocytic Leukemia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=346545",
-            "http://en.wikipedia.org/wiki/b-cell_chronic_lymphocytic_leukemia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 323598,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004948",
-              "name": "B-cell chronic lymphocytic leukemia",
-              "description": "The most common type of chronic lymphoid leukemia. It comprises 90% of chronic lymphoid leukemias in the United States. Morphologically, the neoplastic cells are small, round B-lymphocytes. This type of leukemia is not considered to be curable with available therapy. (WHO, 2001); A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.; A chronic lymphocytic/lymphatic/lymphoblastic leukemia (CLL) is a neoplastic disease characterized by proliferation and accumulation (blood, marrow and lymphoid organs) of morphologically mature but immunologically dysfunctional lymphocytes. A CLL is always a B-cell lymphocytic leukemia as there are no reports of cases of T-cell lymphocytic leukemias. [HPO:curators]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10051812",
-                "MEDDRA:10003908",
-                "MEDDRA:10068919",
-                "MEDDRA:10060576",
-                "MEDDRA:10068852",
-                "OMIM:151400",
-                "MEDDRA:10003909",
-                "MEDDRA:10008956",
-                "UMLS:C0855095",
-                "ICD9:204.1",
-                "MEDDRA:10060391",
-                "MEDDRA:10008976",
-                "NCIT:C7540",
-                "MEDDRA:10008957",
-                "HP:0005550",
-                "MONDO:0004948",
-                "UMLS:C0023434",
-                "MEDDRA:10024340",
-                "MEDDRA:10025306",
-                "PDQ:CDR0000038170",
-                "MEDDRA:10009310",
-                "SNOMEDCT:302841002",
-                "MEDDRA:10008960",
-                "ORPHANET:67038",
-                "SNOMEDCT:92814006",
-                "SNOMEDCT:277473004",
-                "MEDDRA:10008958",
-                "SNOMEDCT:64575004",
-                "MEDDRA:10003910",
-                "MEDDRA:10024295",
-                "ICD10:C91.10",
-                "PDQ:CDR0000037765",
-                "MEDDRA:10025302",
-                "EFO:0000095",
-                "MEDDRA:10041138",
-                "DOID:1040",
-                "SNOMEDCT:51092000",
-                "MESH:D015451",
-                "PDQ:CDR0000039824",
-                "NCIT:C3163",
-                "MEDDRA:10008993"
-              ],
-              "id": "MONDO:0004948",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic lymphatic leukemia",
-                "Lymphoid leukemia, chronic",
-                "Small Lymphocytic Lymphoma",
-                "chronic lymphocytic leukemia",
-                "Leukemia, chronic lymphocytic related phenotypic feature",
-                "Leukemia, Lymphocytic, Chronic, B-Cell",
-                "B-cell chronic lymphocytic leukemia",
-                "small lymphocytic lymphoma",
-                "Chronic Lymphocytic Leukemia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=346545",
-                "http://en.wikipedia.org/wiki/b-cell_chronic_lymphocytic_leukemia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18691354,
-            "start": 616,
-            "end": 323598,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27342785': {'publication date': '2016 Sep', 'sentence': 'A case of septic arthritis caused by a Mycoplasma salivarium strain resistant towards Ciprofloxacin and Clarithromycin in a patient with chronic lymphatic leukemia.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0023434---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "19067853",
-              "object": "MONDO:0004948",
-              "publications": [
-                "PMID:27342785"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 317989,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:12763508': {'publication date': '2003 Jun', 'sentence': 'Conversely, some broad-spectrum antibiotics, including ureidopenicillins (e.g. piperacillin-tazobactam) and ciprofloxacin, are less likely to induce C. difficile infection.', 'subject score': 1000, 'object score': 827}, 'PMID:14628617': {'publication date': '2003', 'sentence': 'RESULTS: Thirteen late surgical infections were caused by a ciprofloxacin and gentamycin-resistant P. aeruginosa.', 'subject score': 1000, 'object score': 775}, 'PMID:16220016': {'publication date': '2005 Nov-Dec', 'sentence': 'MDR S. enterica serotypes typhi and paratyphi A, with reduced susceptibility to ceftriaxone and ciprofloxacin, are among the most frequent causes of bloodstream infections in IDH, suggesting the need to monitor their susceptibility.', 'subject score': 1000, 'object score': 888}, 'PMID:21489757': {'publication date': '2011 Jun', 'sentence': 'Correlation between fluoroquinolone consumption in hospitals and ciprofloxacin resistance amongst Pseudomonas aeruginosa isolates causing healthcare-associated infections, Taiwan, 2000-2009.', 'subject score': 694, 'object score': 802}, 'PMID:2254224': {'publication date': '1990 Oct', 'sentence': 'Although the initial cases of colonization or infection with CR-MRSA can be directly related to ciprofloxacin use, many of the subsequent cases of colonization and infection were not the consequence of ciprofloxacin therapy but rather hospital transmission of existing CR-MRSA.', 'subject score': 888, 'object score': 1000}, 'PMID:2391738': {'publication date': '1990 Sep 19', 'sentence': 'We conclude that ciprofloxacin in dosages as high as 2 g daily is inadequate for treatment of chlamydial urethritis in men, often resulting in relapsing infections.', 'subject score': 1000, 'object score': 888}, 'PMID:25863835': {'publication date': '2015 Jun', 'sentence': 'We found 750-mg levofloxacin resulted in significantly fewer severe infections compared with 500-mg ciprofloxacin potentially because of its longer half-life.', 'subject score': 750, 'object score': 750}, 'PMID:30115947': {'publication date': '2018 Aug 16', 'sentence': 'To elucidate mechanisms underlying ciprofloxacin (CIP) resistance in Gram-negative pathogens causing infections to cancer patients, 169 isolates were investigated.', 'subject score': 694, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 539955,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005365",
-          "name": "hearing loss disorder",
-          "description": "A decreased magnitude of the sensory perception of sound. [HPO:probinson]; A decreased magnitude of the sensory perception of sound. // COMMENTS: Hearing loss can be categorized by which part of the auditory system is damaged, as conductive hearing loss, sensorineural hearing loss, and mixed hearing loss. Another axis of classification uses the degree of hearing impairment. The degree of hearing loss is computed by using a three frequency average taken at 500 Hz, 1,000 Hz and 2,000 Hz. The average of these three frequencies is called the Pure Tone Average (PTA). 0-20 dB is considered normal, 21-40 dB mild loss, 41-60 dB moderate loss, 61-70 dB moderately severe loss,71-90 dB severe loss, and greater than 90 dB profound loss. Note that the word deafness is occasionally used to describe partial hearing loss. The World Health Organization uses the word deafness to refer to complete loss of the ability to hear, and hearing impairment to refer to any degree of reduced hearing.; A decreased magnitude of the sensory perception of sound. // COMMENTS: Hearing loss can be categorized by which part of the auditory system is damaged, as conductive hearing loss, sensorineural hearing loss, and mixed hearing loss. Another axis of classification uses the degree of hearing impairment. The degree of hearing loss is computed by using a three frequency average taken at 500 Hz, 1,000 Hz and 2,000 Hz. The average of these three frequencies is called the Pure Tone Average (PTA). 0-20 dB is considered normal, 21-40 dB mild loss, 41-60 dB moderate loss, 61-70 dB moderately severe loss,71-90 dB severe loss, and greater than 90 dB profound loss. Note that the word deafness is occasionally used to describe partial hearing loss. The World Health Organization uses the word deafness to refer to complete loss of the ability to hear, and hearing impairment to refer to any degree of reduced hearing.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "SYMP:0000019",
-            "UMLS:C0011053",
-            "NCIT:C27644",
-            "MESH:D034381",
-            "MEDDRA:10011879",
-            "MEDDRA:10029439",
-            "MEDDRA:10019245",
-            "MEDDRA:10067879",
-            "MEDDRA:10019241",
-            "SNOMEDCT:343087000",
-            "UMLS:C3887873",
-            "NCIT:C35731",
-            "MEDDRA:10045726",
-            "MEDDRA:10050564",
-            "MONDO:0005365",
-            "MEDDRA:10019246",
-            "NCIT:C27643",
-            "NCIT:C50576",
-            "MEDDRA:10011882",
-            "MEDDRA:10045900",
-            "EFO:0004238",
-            "MEDDRA:10011892",
-            "HP:0000365",
-            "MESH:D003638",
-            "MEDDRA:10050010",
-            "ICD9:389",
-            "MEDDRA:10048865",
-            "SNOMEDCT:103276001",
-            "MEDDRA:10019869",
-            "UMLS:C1384666",
-            "SNOMEDCT:15188001",
-            "UMLS:C0339789",
-            "MEDDRA:10019247",
-            "MEDDRA:10010431",
-            "UMLS:C0018772",
-            "MEDDRA:10011878",
-            "EFO:0001063",
-            "SNOMEDCT:95828007"
-          ],
-          "id": "MONDO:0005365",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Deafness",
-            "Hearing impairment",
-            "hearing impairment",
-            "Partial Hearing Loss",
-            "Hearing loss",
-            "Hearing Impairment",
-            "deafness",
-            "Hearing Loss",
-            "hearing loss",
-            "hearing loss disorder",
-            "Congenital deafness"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-          "name": "infectious disease",
-          "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005550",
-            "SNOMEDCT:189822004",
-            "PSY:10513",
-            "UMLS:C0009450",
-            "UMLS:C0001485",
-            "EFO:0005741",
-            "MEDDRA:10021881",
-            "MESH:D003141",
-            "ICD9:079.0",
-            "DOID:0050117",
-            "SNOMEDCT:40733004",
-            "SNOMEDCT:191415002",
-            "NCIT:C26726"
-          ],
-          "id": "MONDO:0005550",
-          "category": "biolink:Disease",
-          "all_names": [
-            "infectious disease",
-            "Infectious Disorder",
-            "disease by infectious agent",
-            "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-            "Communicable Diseases"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.merriam-webster.com/medical/communicable%20disease",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 317989,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005365",
-              "name": "hearing loss disorder",
-              "description": "A decreased magnitude of the sensory perception of sound. [HPO:probinson]; A decreased magnitude of the sensory perception of sound. // COMMENTS: Hearing loss can be categorized by which part of the auditory system is damaged, as conductive hearing loss, sensorineural hearing loss, and mixed hearing loss. Another axis of classification uses the degree of hearing impairment. The degree of hearing loss is computed by using a three frequency average taken at 500 Hz, 1,000 Hz and 2,000 Hz. The average of these three frequencies is called the Pure Tone Average (PTA). 0-20 dB is considered normal, 21-40 dB mild loss, 41-60 dB moderate loss, 61-70 dB moderately severe loss,71-90 dB severe loss, and greater than 90 dB profound loss. Note that the word deafness is occasionally used to describe partial hearing loss. The World Health Organization uses the word deafness to refer to complete loss of the ability to hear, and hearing impairment to refer to any degree of reduced hearing.; A decreased magnitude of the sensory perception of sound. // COMMENTS: Hearing loss can be categorized by which part of the auditory system is damaged, as conductive hearing loss, sensorineural hearing loss, and mixed hearing loss. Another axis of classification uses the degree of hearing impairment. The degree of hearing loss is computed by using a three frequency average taken at 500 Hz, 1,000 Hz and 2,000 Hz. The average of these three frequencies is called the Pure Tone Average (PTA). 0-20 dB is considered normal, 21-40 dB mild loss, 41-60 dB moderate loss, 61-70 dB moderately severe loss,71-90 dB severe loss, and greater than 90 dB profound loss. Note that the word deafness is occasionally used to describe partial hearing loss. The World Health Organization uses the word deafness to refer to complete loss of the ability to hear, and hearing impairment to refer to any degree of reduced hearing.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "SYMP:0000019",
-                "UMLS:C0011053",
-                "NCIT:C27644",
-                "MESH:D034381",
-                "MEDDRA:10011879",
-                "MEDDRA:10029439",
-                "MEDDRA:10019245",
-                "MEDDRA:10067879",
-                "MEDDRA:10019241",
-                "SNOMEDCT:343087000",
-                "UMLS:C3887873",
-                "NCIT:C35731",
-                "MEDDRA:10045726",
-                "MEDDRA:10050564",
-                "MONDO:0005365",
-                "MEDDRA:10019246",
-                "NCIT:C27643",
-                "NCIT:C50576",
-                "MEDDRA:10011882",
-                "MEDDRA:10045900",
-                "EFO:0004238",
-                "MEDDRA:10011892",
-                "HP:0000365",
-                "MESH:D003638",
-                "MEDDRA:10050010",
-                "ICD9:389",
-                "MEDDRA:10048865",
-                "SNOMEDCT:103276001",
-                "MEDDRA:10019869",
-                "UMLS:C1384666",
-                "SNOMEDCT:15188001",
-                "UMLS:C0339789",
-                "MEDDRA:10019247",
-                "MEDDRA:10010431",
-                "UMLS:C0018772",
-                "MEDDRA:10011878",
-                "EFO:0001063",
-                "SNOMEDCT:95828007"
-              ],
-              "id": "MONDO:0005365",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Deafness",
-                "Hearing impairment",
-                "hearing impairment",
-                "Partial Hearing Loss",
-                "Hearing loss",
-                "Hearing Impairment",
-                "deafness",
-                "Hearing Loss",
-                "hearing loss",
-                "hearing loss disorder",
-                "Congenital deafness"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14269424,
-            "start": 616,
-            "end": 317989,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19747660': {'publication date': '2009 Sep', 'sentence': 'Treatment with ciprofloxacin and ceftazidime improved the hearing loss significantly.', 'subject score': 1000, 'object score': 901}, 'PMID:31086542': {'publication date': '2019', 'sentence': 'Results: There was no significant difference found for hearing loss and severity among the groups treated with ciprofloxacin, co-amoxicillin and not maintained on antibiotic therapy.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C1384666---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "14572951",
-              "object": "MONDO:0005365",
-              "publications": [
-                "PMID:19747660",
-                "PMID:31086542"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318463,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005961",
-          "name": "sinusitis",
-          "description": "A paranasal sinus disease involving inflammation of the paranasal sinuses resulting from bacterial, fungal, viral infection, allergic or autoimmune issues. Symptoms can include fever, weakness, fatigue, cough and congestion. There may also be mucus drainage in the back of the throat, called postnasal drip.",
-          "equivalent_curies": [
-            "MEDDRA:10040753",
-            "ICD9:461",
-            "MEDDRA:10040745",
-            "MEDDRA:10040756",
-            "MESH:D012852",
-            "ICD10:J01",
-            "MONDO:0005961",
-            "SNOMEDCT:36971009",
-            "NCIT:C35024",
-            "EFO:0007486",
-            "SYMP:0000134",
-            "DOID:0050127",
-            "HP:0000246",
-            "MEDDRA:10078707",
-            "UMLS:C0037199"
-          ],
-          "id": "MONDO:0005961",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acute sinusitis",
-            "Sinusitis",
-            "sinusitis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5889-4463",
-            "http://en.wikipedia.org/wiki/sinusitis",
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c35024&ns=nci_thesaurus&key=1218436475&b=1&n=n"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318463,
-=======
-            "identity": 539955,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005961",
-              "name": "sinusitis",
-              "description": "A paranasal sinus disease involving inflammation of the paranasal sinuses resulting from bacterial, fungal, viral infection, allergic or autoimmune issues. Symptoms can include fever, weakness, fatigue, cough and congestion. There may also be mucus drainage in the back of the throat, called postnasal drip.",
-              "equivalent_curies": [
-                "MEDDRA:10040753",
-                "ICD9:461",
-                "MEDDRA:10040745",
-                "MEDDRA:10040756",
-                "MESH:D012852",
-                "ICD10:J01",
-                "MONDO:0005961",
-                "SNOMEDCT:36971009",
-                "NCIT:C35024",
-                "EFO:0007486",
-                "SYMP:0000134",
-                "DOID:0050127",
-                "HP:0000246",
-                "MEDDRA:10078707",
-                "UMLS:C0037199"
-              ],
-              "id": "MONDO:0005961",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acute sinusitis",
-                "Sinusitis",
-                "sinusitis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5889-4463",
-                "http://en.wikipedia.org/wiki/sinusitis",
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c35024&ns=nci_thesaurus&key=1218436475&b=1&n=n"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 14097870,
-            "start": 616,
-            "end": 318463,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19473592': {'publication date': '2009 May', 'sentence': 'CASE SUMMARY: A 24-year-old woman was admitted to the hospital because of convulsions, severe myopathy, and acute renal failure after taking ciprofloxacin for sinusitis, and urinary tract infections.', 'subject score': 861, 'object score': 1000}, 'PMID:19925632': {'publication date': '2010 Aug', 'sentence': 'A 30-year-old woman received cefotaxime, fosfomycin and ciprofloxacin for sinusitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:21686850': {'publication date': '2009', 'sentence': 'A 30-year-old woman received cefotaxime, fosfomycin and ciprofloxacin for sinusitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0037199---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "14398199",
-              "object": "MONDO:0005961",
-              "publications": [
-                "PMID:19473592",
-                "PMID:19925632",
-                "PMID:21686850"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321423,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0700051",
-          "name": "liver abscess (disease)",
-          "description": "A bacterial, parasitic, or fungal abscess that develops in the liver. It is usually the result of an abdominal infection, trauma, or surgery in the right upper quadrant. Signs and symptoms include abdominal pain, nausea, vomiting, and fever.; Solitary or multiple collections of PUS within the liver as a result of infection by bacteria, protozoa, or other agents.; The presence of an abscess of the liver. [HPO:probinson]",
-          "equivalent_curies": [
-            "UMLS:C0023885",
-            "MESH:D008100",
-            "MONDO:0700051",
-            "SNOMEDCT:27916005",
-            "NCIT:C99089",
-            "MEDDRA:10024652",
-            "MEDDRA:10000300",
-            "HP:0100523"
-          ],
-          "id": "MONDO:0700051",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Liver Abscess",
-            "liver abscess (disease)",
-            "Liver abscess"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-2658-1136",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-2825-0621"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321423,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0700051",
-              "name": "liver abscess (disease)",
-              "description": "A bacterial, parasitic, or fungal abscess that develops in the liver. It is usually the result of an abdominal infection, trauma, or surgery in the right upper quadrant. Signs and symptoms include abdominal pain, nausea, vomiting, and fever.; Solitary or multiple collections of PUS within the liver as a result of infection by bacteria, protozoa, or other agents.; The presence of an abscess of the liver. [HPO:probinson]",
-              "equivalent_curies": [
-                "UMLS:C0023885",
-                "MESH:D008100",
-                "MONDO:0700051",
-                "SNOMEDCT:27916005",
-                "NCIT:C99089",
-                "MEDDRA:10024652",
-                "MEDDRA:10000300",
-                "HP:0100523"
-              ],
-              "id": "MONDO:0700051",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Liver Abscess",
-                "liver abscess (disease)",
-                "Liver abscess"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-              "name": "infectious disease",
-              "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005550",
-                "SNOMEDCT:189822004",
-                "PSY:10513",
-                "UMLS:C0009450",
-                "UMLS:C0001485",
-                "EFO:0005741",
-                "MEDDRA:10021881",
-                "MESH:D003141",
-                "ICD9:079.0",
-                "DOID:0050117",
-                "SNOMEDCT:40733004",
-                "SNOMEDCT:191415002",
-                "NCIT:C26726"
-              ],
-              "id": "MONDO:0005550",
-              "category": "biolink:Disease",
-              "all_names": [
-                "infectious disease",
-                "Infectious Disorder",
-                "disease by infectious agent",
-                "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-                "Communicable Diseases"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://orcid.org/0000-0002-2658-1136",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-2825-0621"
-=======
-                "https://www.merriam-webster.com/medical/communicable%20disease",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 14013356,
-            "start": 616,
-            "end": 321423,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19351314': {'publication date': '2009 Apr 06', 'sentence': 'Chromobacterium violaceum endocarditis and hepatic abscesses treated successfully with meropenem and ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:19807647': {'publication date': '2009 Oct 05', 'sentence': 'Chromobacterium violaceum endocarditis and hepatic abscesses treated successfully with meropenem and ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:29055688': {'publication date': '2017 12', 'sentence': 'Ciprofloxacin treatment for cryptogenic Klebsiella pneumoniae liver abscesses.', 'subject score': 888, 'object score': 857}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0023885---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "14311974",
-              "object": "MONDO:0700051",
-              "publications": [
-                "PMID:19351314",
-                "PMID:19807647",
-                "PMID:29055688"
-=======
-            "identity": 9988524,
-            "start": 616,
-            "end": 539955,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12763508': {'publication date': '2003 Jun', 'sentence': 'Conversely, some broad-spectrum antibiotics, including ureidopenicillins (e.g. piperacillin-tazobactam) and ciprofloxacin, are less likely to induce C. difficile infection.', 'subject score': 1000, 'object score': 827}, 'PMID:14628617': {'publication date': '2003', 'sentence': 'RESULTS: Thirteen late surgical infections were caused by a ciprofloxacin and gentamycin-resistant P. aeruginosa.', 'subject score': 1000, 'object score': 775}, 'PMID:16220016': {'publication date': '2005 Nov-Dec', 'sentence': 'MDR S. enterica serotypes typhi and paratyphi A, with reduced susceptibility to ceftriaxone and ciprofloxacin, are among the most frequent causes of bloodstream infections in IDH, suggesting the need to monitor their susceptibility.', 'subject score': 1000, 'object score': 888}, 'PMID:21489757': {'publication date': '2011 Jun', 'sentence': 'Correlation between fluoroquinolone consumption in hospitals and ciprofloxacin resistance amongst Pseudomonas aeruginosa isolates causing healthcare-associated infections, Taiwan, 2000-2009.', 'subject score': 694, 'object score': 802}, 'PMID:2254224': {'publication date': '1990 Oct', 'sentence': 'Although the initial cases of colonization or infection with CR-MRSA can be directly related to ciprofloxacin use, many of the subsequent cases of colonization and infection were not the consequence of ciprofloxacin therapy but rather hospital transmission of existing CR-MRSA.', 'subject score': 888, 'object score': 1000}, 'PMID:2391738': {'publication date': '1990 Sep 19', 'sentence': 'We conclude that ciprofloxacin in dosages as high as 2 g daily is inadequate for treatment of chlamydial urethritis in men, often resulting in relapsing infections.', 'subject score': 1000, 'object score': 888}, 'PMID:25863835': {'publication date': '2015 Jun', 'sentence': 'We found 750-mg levofloxacin resulted in significantly fewer severe infections compared with 500-mg ciprofloxacin potentially because of its longer half-life.', 'subject score': 750, 'object score': 750}, 'PMID:30115947': {'publication date': '2018 Aug 16', 'sentence': 'To elucidate mechanisms underlying ciprofloxacin (CIP) resistance in Gram-negative pathogens causing infections to cancer patients, 169 isolates were investigated.', 'subject score': 694, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:causes---None---None---None---UMLS:C0009450---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "10209213",
-              "object": "MONDO:0005550",
-              "publications": [
-                "PMID:12763508",
-                "PMID:14628617",
-                "PMID:16220016",
-                "PMID:21489757",
-                "PMID:2254224",
-                "PMID:2391738",
-                "PMID:25863835",
-                "PMID:30115947"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 546728,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:32366243': {'publication date': '2020 May 04', 'sentence': 'Novel enterocin E20c purified from Enterococcus hirae 20c synergised with ss-lactams and ciprofloxacin against Salmonella enterica.BACKGROUND: An increasing rate of antibiotic resistance among Gram-negative bacterial pathogens has created an urgent need to discover novel therapeutic agents to combat infectious diseases.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 539955,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002269",
-          "name": "gastroenteritis",
-          "description": "An inflammatory disorder that affects the upper and lower gastrointestinal tract. Most commonly, this is attributed to viruses; however bacteria, parasites or adverse reactions can also be the culprit. Symptoms include acute diarrhea and vomiting.; INFLAMMATION of any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Causes of gastroenteritis are many including genetic, infection, HYPERSENSITIVITY, drug effects, and CANCER.;  Have you ever had the \"stomach flu?\" What you probably had was gastroenteritis - not a type of flu at all. Gastroenteritis is an inflammation of the lining of the intestines caused by a virus, bacteria, or parasites. Viral gastroenteritis is the second most common illness in the U.S. The cause is often a norovirus infection. It spreads through contaminated food or water or by contact with an infected person. The best prevention is frequent hand washing.  Symptoms of gastroenteritis include diarrhea, abdominal pain, vomiting, headache, fever, and chills. Most people recover with no treatment. The most common problem with gastroenteritis is dehydration. This happens if you do not drink enough fluids to replace what you lose through vomiting and diarrhea. Dehydration is most common in babies, young children, older adults, and people with weak immune systems.  NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D005759",
-            "SYMP:0019159",
-            "SNOMEDCT:25374005",
-            "EFO:1001463",
-            "MEDDRA:10017888",
-            "NCIT:C34632",
-            "DOID:2326",
-            "UMLS:C0017160",
-            "MONDO:0002269",
-            "MEDDRA:10017907"
-          ],
-          "id": "MONDO:0002269",
-          "category": "biolink:Disease",
-          "all_names": [
-            "gastroenteritis",
-            "Gastroenteritis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.merck.com/mmhe/sec09/ch122/ch122a.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546728,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002269",
-              "name": "gastroenteritis",
-              "description": "An inflammatory disorder that affects the upper and lower gastrointestinal tract. Most commonly, this is attributed to viruses; however bacteria, parasites or adverse reactions can also be the culprit. Symptoms include acute diarrhea and vomiting.; INFLAMMATION of any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Causes of gastroenteritis are many including genetic, infection, HYPERSENSITIVITY, drug effects, and CANCER.;  Have you ever had the \"stomach flu?\" What you probably had was gastroenteritis - not a type of flu at all. Gastroenteritis is an inflammation of the lining of the intestines caused by a virus, bacteria, or parasites. Viral gastroenteritis is the second most common illness in the U.S. The cause is often a norovirus infection. It spreads through contaminated food or water or by contact with an infected person. The best prevention is frequent hand washing.  Symptoms of gastroenteritis include diarrhea, abdominal pain, vomiting, headache, fever, and chills. Most people recover with no treatment. The most common problem with gastroenteritis is dehydration. This happens if you do not drink enough fluids to replace what you lose through vomiting and diarrhea. Dehydration is most common in babies, young children, older adults, and people with weak immune systems.  NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D005759",
-                "SYMP:0019159",
-                "SNOMEDCT:25374005",
-                "EFO:1001463",
-                "MEDDRA:10017888",
-                "NCIT:C34632",
-                "DOID:2326",
-                "UMLS:C0017160",
-                "MONDO:0002269",
-                "MEDDRA:10017907"
-              ],
-              "id": "MONDO:0002269",
-              "category": "biolink:Disease",
-              "all_names": [
-                "gastroenteritis",
-                "Gastroenteritis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.merck.com/mmhe/sec09/ch122/ch122a.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13986552,
-            "start": 616,
-            "end": 546728,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1930395': {'publication date': '1991 Nov', 'sentence': 'A patient is reported who had previously maintained a stable prothrombin time on Coumadin for 5 years, and who exhibited a marked prolongation of prothrombin time when placed on ciprofloxacin for gastroenteritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:27900889': {'publication date': '2017 Apr', 'sentence': 'Campylobacter jejuni strains coresistant to tetracycline and ciprofloxacin in patients with gastroenteritis in Croatia.', 'subject score': 1000, 'object score': 1000}, 'PMID:28857901': {'publication date': '2018 May', 'sentence': 'This report includes two cases, one presenting with right lateral thumb pain and a medical history of gastroenteritis treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:8852546': {'publication date': '1996 Jan', 'sentence': 'Despite this, the empirical use of ciprofloxacin in suspected infective gastroenteritis appeared to be only partially guided by the clinical features.', 'subject score': 1000, 'object score': 827}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0017160---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "14284683",
-              "object": "MONDO:0002269",
-              "publications": [
-                "PMID:1930395",
-                "PMID:27900889",
-                "PMID:28857901",
-                "PMID:8852546"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 610975,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/DOID_0080909",
-          "name": "castration-resistant prostate carcinoma",
-          "description": "A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.",
-          "equivalent_curies": [
-            "MESH:D064129",
-            "MONDO:0850353",
-            "DOID:0080909",
-            "MEDDRA:10076506",
-            "SNOMEDCT:427492003",
-            "UMLS:C3658267",
-            "MEDDRA:10062904",
-            "NCIT:C130234",
-            "UMLS:C1328504"
-          ],
-          "id": "DOID:0080909",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Prostatic Neoplasms, Castration-Resistant",
-            "castration-resistant prostate carcinoma",
-            "Castration-Resistant Prostate Carcinoma",
-            "Hormone refractory prostate cancer"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-          "name": "infectious disease",
-          "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005550",
-            "SNOMEDCT:189822004",
-            "PSY:10513",
-            "UMLS:C0009450",
-            "UMLS:C0001485",
-            "EFO:0005741",
-            "MEDDRA:10021881",
-            "MESH:D003141",
-            "ICD9:079.0",
-            "DOID:0050117",
-            "SNOMEDCT:40733004",
-            "SNOMEDCT:191415002",
-            "NCIT:C26726"
-          ],
-          "id": "MONDO:0005550",
-          "category": "biolink:Disease",
-          "all_names": [
-            "infectious disease",
-            "Infectious Disorder",
-            "disease by infectious agent",
-            "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-            "Communicable Diseases"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "PMID:30324351"
-=======
-            "https://www.merriam-webster.com/medical/communicable%20disease",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 610975,
-=======
-            "identity": 539955,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/DOID_0080909",
-              "name": "castration-resistant prostate carcinoma",
-              "description": "A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.",
-              "equivalent_curies": [
-                "MESH:D064129",
-                "MONDO:0850353",
-                "DOID:0080909",
-                "MEDDRA:10076506",
-                "SNOMEDCT:427492003",
-                "UMLS:C3658267",
-                "MEDDRA:10062904",
-                "NCIT:C130234",
-                "UMLS:C1328504"
-              ],
-              "id": "DOID:0080909",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Prostatic Neoplasms, Castration-Resistant",
-                "castration-resistant prostate carcinoma",
-                "Castration-Resistant Prostate Carcinoma",
-                "Hormone refractory prostate cancer"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-              "name": "infectious disease",
-              "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005550",
-                "SNOMEDCT:189822004",
-                "PSY:10513",
-                "UMLS:C0009450",
-                "UMLS:C0001485",
-                "EFO:0005741",
-                "MEDDRA:10021881",
-                "MESH:D003141",
-                "ICD9:079.0",
-                "DOID:0050117",
-                "SNOMEDCT:40733004",
-                "SNOMEDCT:191415002",
-                "NCIT:C26726"
-              ],
-              "id": "MONDO:0005550",
-              "category": "biolink:Disease",
-              "all_names": [
-                "infectious disease",
-                "Infectious Disorder",
-                "disease by infectious agent",
-                "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-                "Communicable Diseases"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "PMID:30324351"
-=======
-                "https://www.merriam-webster.com/medical/communicable%20disease",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 13845247,
-            "start": 616,
-            "end": 610975,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19104815': {'publication date': '2009 Aug', 'sentence': 'Doxorubicin and docetaxel, two standard antineoplastic agents in hormone-refractory prostate cancer (HRPC) therapy and ciprofloxacin were evaluated singly and in several simultaneous and sequential drug combination schemes, against PC-3 and LNCaP cell lines.', 'subject score': 1000, 'object score': 928}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C1328504---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "14141218",
-              "object": "DOID:0080909",
-              "publications": [
-                "PMID:19104815"
-=======
-            "identity": 21577798,
-            "start": 616,
-            "end": 539955,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32366243': {'publication date': '2020 May 04', 'sentence': 'Novel enterocin E20c purified from Enterococcus hirae 20c synergised with ss-lactams and ciprofloxacin against Salmonella enterica.BACKGROUND: An increasing rate of antibiotic resistance among Gram-negative bacterial pathogens has created an urgent need to discover novel therapeutic agents to combat infectious diseases.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0009450---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "21996198",
-              "object": "MONDO:0005550",
-              "publications": [
-                "PMID:32366243"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 321063,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:11562127': {'publication date': '2001 Sep', 'sentence': 'The effect of a 21-day treatment with cefuroxime, vancomycin, tobramycin or ciprofloxacin on infection was studied in this model 42 days after surgery.', 'subject score': 1000, 'object score': 1000}, 'PMID:12821471': {'publication date': '2003 Jul', 'sentence': 'Thus, our results suggest that ciprofloxacin is at least as effective as cefotaxime-minocycline against murine A. hydrophila infections, which warrants clinical studies to delineate its role in human infections.', 'subject score': 1000, 'object score': 888}, 'PMID:15490982': {'publication date': '2004', 'sentence': 'Oral ciprofloxacin provides satisfactory results in gram-negative infections, comparable to those obtained with intraperitoneal ceftazidime or aminoglycosides.', 'subject score': 888, 'object score': 851}, 'PMID:2100081': {'publication date': '1990 Oct', 'sentence': 'The role of ciprofloxacin in treating infections caused by multiantibiotic resistant S. typhi is also discussed.', 'subject score': 1000, 'object score': 888}, 'PMID:21098755': {'publication date': '2010 Dec', 'sentence': 'Primary prophylaxis studies found no significant difference in the incidence of infections, including SBP, with norfloxacin or ciprofloxacin treatment but significantly lower incidence of gram-negative infections.', 'subject score': 888, 'object score': 851}, 'PMID:21873378': {'publication date': '2012 Jan', 'sentence': 'The presence of co-infections was an independent risk factor for clarithromycin, metronidazole and ciprofloxacin resistance.', 'subject score': 694, 'object score': 861}, 'PMID:22845325': {'publication date': '2012', 'sentence': 'Fluoroquinolones are a widely used group of antimicrobials in both human and animal medicine, with ciprofloxacin being a critically important fluoroquinolone for serious human infections.', 'subject score': 1000, 'object score': 851}, 'PMID:22958285': {'publication date': '2012 Oct', 'sentence': 'Prostate-derived P. acnes isolates (n = 24, Umea & Orebro, Sweden, 2007-2010) and a panel of control strains (n = 25, Sweden) collected from skin and deep infections were assessed for resistance to penicillin G, piperacillin-tazobactam, imipenem, gentamicin, azithromycin, erythromycin, vancomycin, ciprofloxacin, moxifloxacin, tetracycline, tigecycline, fusidic acid, clindamycin, rifampicin, linezolid, daptomycin, trimethoprim-sulfamethoxazole, and metronidazole.', 'subject score': 1000, 'object score': 888}, 'PMID:23122884': {'publication date': '2012 Dec', 'sentence': 'Infections with Salmonella enterica serovar Typhi isolates that are multidrug resistant (MDR: resistant to chloramphenicol, ampicillin, trimethoprim-sulphamethoxazole) with intermediate ciprofloxacin susceptibility are widespread in Asia but there is little information from Cambodia.', 'subject score': 851, 'object score': 1000}, 'PMID:23253321': {'publication date': '2012 Dec', 'sentence': 'This paper presents a perspective on the potential role of inhaled ciprofloxacin in such infections.', 'subject score': 888, 'object score': 1000}, 'PMID:26989670': {'publication date': '2016 Mar 16', 'sentence': 'CONCLUSION: The most effective antibiotics against gram-negative healthcare associated infections are imipenem followed by ciprofloxacin.', 'subject score': 1000, 'object score': 766}, 'PMID:29020144': {'publication date': '2017 Oct 30', 'sentence': 'Antimicrobial susceptibility testing of isolates from 4793 domestic and 1070 travel-associated infections revealed that, comparing 2004-2009 to 2010-2012, ciprofloxacin resistance increased among domestic infections (12.8% vs 16.1%).', 'subject score': 694, 'object score': 763}, 'PMID:3158073': {'publication date': '1985 Mar 30', 'sentence': 'These infections may, therefore, be favorably affected by ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:3542948': {'publication date': '1986 Nov', 'sentence': 'The progress of infection in sensitive mice with no natural immunity was delayed by ciprofloxacin although at the dosage used the mice were not cured.', 'subject score': 1000, 'object score': 1000}, 'PMID:36422605': {'publication date': '2022 Nov 15', 'sentence': 'This study aimed to analyse genetic mutations in the genomes of 25    S. aureus     isolates from infections or non-infectious ocular conditions from the USA and Australia and their relationship to ciprofloxacin resistance.', 'subject score': 888, 'object score': 852}, 'PMID:8040107': {'publication date': '1994 Mar', 'sentence': 'As prophylaxis for the granulocytopenic patient, quinolones such as norfloxacin and ciprofloxacin have been shown to be effective in reducing the incidence of morbidity attributable to Gram-negative bacteria, but they have not significantly affected the incidence of infection caused by Gram-positive bacteria.', 'subject score': 1000, 'object score': 1000}, 'PMID:8899438': {'publication date': '1996 Oct', 'sentence': 'OBJECTIVE: To evaluate endemic colonization with Staphylococcus aureus resistant to methicillin, ciprofloxacin, or both among patients of a private skilled nursing facility, with regard to colonization rate and site, and relation to infection and prior antibiotic use.', 'subject score': 1000, 'object score': 1000}, 'PMID:9002127': {'publication date': '1997 Jan', 'sentence': 'As empirical options are diminishing daily, the role of ciprofloxacin in pediatric infections is becoming increasingly significant.', 'subject score': 1000, 'object score': 888}, 'PMID:9255893': {'publication date': '1997', 'sentence': 'Influence of low dose ciprofloxacin on microbial colonization of the digestive tract in healthy volunteers during normal and during impaired colonization resistance.', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 539955,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018874",
-          "name": "acute myeloid leukemia",
-          "description": "A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification). (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3171\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3171\" NCI Thesaurus); Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.; A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).; Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.; A form of leukemia characterized by overproduction of an early myeloid cell. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:91861009",
-            "ICD9:205.0",
-            "MEDDRA:10024346",
-            "MEDDRA:10000801",
-            "MEDDRA:10060354",
-            "KEGG.DISEASE:05221",
-            "EFO:0000222",
-            "PDQ:CDR0000043424",
-            "MEDDRA:10000886",
-            "HP:0004808",
-            "MEDDRA:10060394",
-            "MESH:D015470",
-            "MEDDRA:10051003",
-            "MONDO:0100173",
-            "MEDDRA:10000878",
-            "MEDDRA:10060553",
-            "MEDDRA:10024291",
-            "SNOMEDCT:1162928000",
-            "MEDDRA:10054296",
-            "ORPHANET:519",
-            "MEDDRA:10000880",
-            "UMLS:C3275959",
-            "MEDDRA:10028552",
-            "MONDO:0018874",
-            "OMIM:601626",
-            "MEDDRA:10000884",
-            "DOID:9119",
-            "MEDDRA:10029549",
-            "MEDDRA:10029551",
-            "UMLS:C0023467",
-            "NCIT:C3171",
-            "MEDDRA:10060557",
-            "MEDDRA:10028557"
-          ],
-          "id": "MONDO:0018874",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia, acute myeloid related phenotypic feature",
-            "Leukemia, Myelocytic, Acute",
-            "Acute myeloid leukemia",
-            "acute myeloid leukemia",
-            "leukemia, acute myeloid, susceptibility to",
-            "Leukemia, acute myeloid, susceptibility to",
-            "Acute Myeloid Leukemia",
-            "Leukemia, Myeloid, Acute",
-            "Myeloid leukemia, acute"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.cancer.gov/dictionary?cdrid=44363",
-            "http://cancergenome.nih.gov/cancersselected/acutemyeloidleukemia",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.cancer.org/cancer/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.htm",
-            "http://en.wikipedia.org/wiki/acute_myeloid_leukemia"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-          "name": "infectious disease",
-          "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005550",
-            "SNOMEDCT:189822004",
-            "PSY:10513",
-            "UMLS:C0009450",
-            "UMLS:C0001485",
-            "EFO:0005741",
-            "MEDDRA:10021881",
-            "MESH:D003141",
-            "ICD9:079.0",
-            "DOID:0050117",
-            "SNOMEDCT:40733004",
-            "SNOMEDCT:191415002",
-            "NCIT:C26726"
-          ],
-          "id": "MONDO:0005550",
-          "category": "biolink:Disease",
-          "all_names": [
-            "infectious disease",
-            "Infectious Disorder",
-            "disease by infectious agent",
-            "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-            "Communicable Diseases"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.merriam-webster.com/medical/communicable%20disease",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 321063,
-=======
-            "identity": 539955,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018874",
-              "name": "acute myeloid leukemia",
-              "description": "A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification). (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3171\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3171\" NCI Thesaurus); Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.; A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).; Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.; A form of leukemia characterized by overproduction of an early myeloid cell. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:91861009",
-                "ICD9:205.0",
-                "MEDDRA:10024346",
-                "MEDDRA:10000801",
-                "MEDDRA:10060354",
-                "KEGG.DISEASE:05221",
-                "EFO:0000222",
-                "PDQ:CDR0000043424",
-                "MEDDRA:10000886",
-                "HP:0004808",
-                "MEDDRA:10060394",
-                "MESH:D015470",
-                "MEDDRA:10051003",
-                "MONDO:0100173",
-                "MEDDRA:10000878",
-                "MEDDRA:10060553",
-                "MEDDRA:10024291",
-                "SNOMEDCT:1162928000",
-                "MEDDRA:10054296",
-                "ORPHANET:519",
-                "MEDDRA:10000880",
-                "UMLS:C3275959",
-                "MEDDRA:10028552",
-                "MONDO:0018874",
-                "OMIM:601626",
-                "MEDDRA:10000884",
-                "DOID:9119",
-                "MEDDRA:10029549",
-                "MEDDRA:10029551",
-                "UMLS:C0023467",
-                "NCIT:C3171",
-                "MEDDRA:10060557",
-                "MEDDRA:10028557"
-              ],
-              "id": "MONDO:0018874",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia, acute myeloid related phenotypic feature",
-                "Leukemia, Myelocytic, Acute",
-                "Acute myeloid leukemia",
-                "acute myeloid leukemia",
-                "leukemia, acute myeloid, susceptibility to",
-                "Leukemia, acute myeloid, susceptibility to",
-                "Acute Myeloid Leukemia",
-                "Leukemia, Myeloid, Acute",
-                "Myeloid leukemia, acute"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.cancer.gov/dictionary?cdrid=44363",
-                "http://cancergenome.nih.gov/cancersselected/acutemyeloidleukemia",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.cancer.org/cancer/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.htm",
-                "http://en.wikipedia.org/wiki/acute_myeloid_leukemia"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13711567,
-            "start": 616,
-            "end": 321063,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18854092': {'publication date': '2008 Oct', 'sentence': 'Results of combination therapy with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in patients with myelodysplastic syndrome and acute myeloid leukemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:25617073': {'publication date': '2015 May', 'sentence': 'Thus, in April 2008, we changed our antibiotic prophylaxis regimen from cotrimoxazole/colistin (COT/COL) to the fluoroquinolone ciprofloxacin (CIP) in patients with acute myeloid leukemia (AML).', 'subject score': 872, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0023467---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "14005051",
-              "object": "MONDO:0018874",
-              "publications": [
-                "PMID:18854092",
-                "PMID:25617073"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321402,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005275",
-          "name": "lung disorder",
-          "description": "A non-neoplastic or neoplastic disorder affecting the lung. Representative examples of non-neoplastic disorders include chronic obstructive pulmonary disease and pneumonia. Representative examples of neoplastic disorders include benign processes (e.g., respiratory papilloma) and malignant processes (e.g., lung carcinoma and metastatic cancer to the lung).; Pathological processes involving any part of the LUNG.; Any structural anomaly of the lung. [HPO:probinson]; When you breathe, your lungs take in oxygen from the air and deliver it to the bloodstream. The cells in your body need oxygen to work and grow. During a normal day, you breathe nearly 25,000 times. People with lung disease have difficulty breathing. Millions of people in the U.S. have lung disease. If all types of lung disease are lumped together, it is the number three killer in the United States. The term lung disease refers to many disorders affecting the lungs, such as asthma, COPD, infections like influenza, pneumonia and tuberculosis, lung cancer, and many other breathing problems. Some lung diseases can lead to respiratory failure. Dept. of Health and Human Services Office on Women's Health; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10013235",
-            "MEDDRA:10049490",
-            "MEDDRA:10025083",
-            "DOID:850",
-            "MEDDRA:10051054",
-            "MESH:D008171",
-            "MONDO:0005275",
-            "MEDDRA:10013259",
-            "SNOMEDCT:19829001",
-            "ICD10:J98.4",
-            "HP:0002088",
-            "MEDDRA:10025082",
-            "EFO:0003818",
-            "UMLS:C4021760",
-            "UMLS:C0024115",
-            "MEDDRA:10037373",
-            "NCIT:C3198"
-          ],
-          "id": "MONDO:0005275",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Abnormal lung morphology",
-            "lung disorder",
-            "Lung Disorder",
-            "Lung diseases",
-            "lung disease",
-            "Lung Diseases"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000066.htm",
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://www.niehs.nih.gov/health/topics/conditions/lung-disease/index.cfm",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321402,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005275",
-              "name": "lung disorder",
-              "description": "A non-neoplastic or neoplastic disorder affecting the lung. Representative examples of non-neoplastic disorders include chronic obstructive pulmonary disease and pneumonia. Representative examples of neoplastic disorders include benign processes (e.g., respiratory papilloma) and malignant processes (e.g., lung carcinoma and metastatic cancer to the lung).; Pathological processes involving any part of the LUNG.; Any structural anomaly of the lung. [HPO:probinson]; When you breathe, your lungs take in oxygen from the air and deliver it to the bloodstream. The cells in your body need oxygen to work and grow. During a normal day, you breathe nearly 25,000 times. People with lung disease have difficulty breathing. Millions of people in the U.S. have lung disease. If all types of lung disease are lumped together, it is the number three killer in the United States. The term lung disease refers to many disorders affecting the lungs, such as asthma, COPD, infections like influenza, pneumonia and tuberculosis, lung cancer, and many other breathing problems. Some lung diseases can lead to respiratory failure. Dept. of Health and Human Services Office on Women's Health; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10013235",
-                "MEDDRA:10049490",
-                "MEDDRA:10025083",
-                "DOID:850",
-                "MEDDRA:10051054",
-                "MESH:D008171",
-                "MONDO:0005275",
-                "MEDDRA:10013259",
-                "SNOMEDCT:19829001",
-                "ICD10:J98.4",
-                "HP:0002088",
-                "MEDDRA:10025082",
-                "EFO:0003818",
-                "UMLS:C4021760",
-                "UMLS:C0024115",
-                "MEDDRA:10037373",
-                "NCIT:C3198"
-              ],
-              "id": "MONDO:0005275",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Abnormal lung morphology",
-                "lung disorder",
-                "Lung Disorder",
-                "Lung diseases",
-                "lung disease",
-                "Lung Diseases"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-              "name": "infectious disease",
-              "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005550",
-                "SNOMEDCT:189822004",
-                "PSY:10513",
-                "UMLS:C0009450",
-                "UMLS:C0001485",
-                "EFO:0005741",
-                "MEDDRA:10021881",
-                "MESH:D003141",
-                "ICD9:079.0",
-                "DOID:0050117",
-                "SNOMEDCT:40733004",
-                "SNOMEDCT:191415002",
-                "NCIT:C26726"
-              ],
-              "id": "MONDO:0005550",
-              "category": "biolink:Disease",
-              "all_names": [
-                "infectious disease",
-                "Infectious Disorder",
-                "disease by infectious agent",
-                "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-                "Communicable Diseases"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000066.htm",
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://www.niehs.nih.gov/health/topics/conditions/lung-disease/index.cfm",
-                "https://orcid.org/0000-0002-0736-9199"
-=======
-                "https://www.merriam-webster.com/medical/communicable%20disease",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 13555467,
-            "start": 616,
-            "end": 321402,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18611787': {'publication date': '1997 Mar', 'sentence': 'High dose parenteral ciprofloxacin in pleuro-pulmonary disease: a comparative pharmacolinetics of 400 and 200 mg intravenous.', 'subject score': 824, 'object score': 901}, 'PMID:19661243': {'publication date': '2009 Nov 01', 'sentence': 'METHODS: Sixty-five patients (11 males, 55 females, median age 55 yr) with M. abscessus lung disease were treated with clarithromycin, ciprofloxacin, and doxycycline, together with an initial regimen of amikacin and cefoxitin for the first 4 weeks of hospitalization.', 'subject score': 1000, 'object score': 824}, 'PMID:30105497': {'publication date': '2018 Oct', 'sentence': 'Ciprofloxacin is a broad-spectrum antibiotic for treatment of pulmonary diseases such as chronic obstructive pulmonary disease and cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7884988': {'publication date': '1995 Jan', 'sentence': '[A case of Mycobacterium fortuitum pulmonary disease in a healthy young woman successfully treated with ciprofloxacin and doxycycline].', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0024115---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "13846017",
-              "object": "MONDO:0005275",
-              "publications": [
-                "PMID:18611787",
-                "PMID:19661243",
-                "PMID:30105497",
-                "PMID:7884988"
-=======
-            "identity": 8926699,
-            "start": 616,
-            "end": 539955,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11562127': {'publication date': '2001 Sep', 'sentence': 'The effect of a 21-day treatment with cefuroxime, vancomycin, tobramycin or ciprofloxacin on infection was studied in this model 42 days after surgery.', 'subject score': 1000, 'object score': 1000}, 'PMID:12821471': {'publication date': '2003 Jul', 'sentence': 'Thus, our results suggest that ciprofloxacin is at least as effective as cefotaxime-minocycline against murine A. hydrophila infections, which warrants clinical studies to delineate its role in human infections.', 'subject score': 1000, 'object score': 888}, 'PMID:15490982': {'publication date': '2004', 'sentence': 'Oral ciprofloxacin provides satisfactory results in gram-negative infections, comparable to those obtained with intraperitoneal ceftazidime or aminoglycosides.', 'subject score': 888, 'object score': 851}, 'PMID:2100081': {'publication date': '1990 Oct', 'sentence': 'The role of ciprofloxacin in treating infections caused by multiantibiotic resistant S. typhi is also discussed.', 'subject score': 1000, 'object score': 888}, 'PMID:21098755': {'publication date': '2010 Dec', 'sentence': 'Primary prophylaxis studies found no significant difference in the incidence of infections, including SBP, with norfloxacin or ciprofloxacin treatment but significantly lower incidence of gram-negative infections.', 'subject score': 888, 'object score': 851}, 'PMID:21873378': {'publication date': '2012 Jan', 'sentence': 'The presence of co-infections was an independent risk factor for clarithromycin, metronidazole and ciprofloxacin resistance.', 'subject score': 694, 'object score': 861}, 'PMID:22845325': {'publication date': '2012', 'sentence': 'Fluoroquinolones are a widely used group of antimicrobials in both human and animal medicine, with ciprofloxacin being a critically important fluoroquinolone for serious human infections.', 'subject score': 1000, 'object score': 851}, 'PMID:22958285': {'publication date': '2012 Oct', 'sentence': 'Prostate-derived P. acnes isolates (n = 24, Umea & Orebro, Sweden, 2007-2010) and a panel of control strains (n = 25, Sweden) collected from skin and deep infections were assessed for resistance to penicillin G, piperacillin-tazobactam, imipenem, gentamicin, azithromycin, erythromycin, vancomycin, ciprofloxacin, moxifloxacin, tetracycline, tigecycline, fusidic acid, clindamycin, rifampicin, linezolid, daptomycin, trimethoprim-sulfamethoxazole, and metronidazole.', 'subject score': 1000, 'object score': 888}, 'PMID:23122884': {'publication date': '2012 Dec', 'sentence': 'Infections with Salmonella enterica serovar Typhi isolates that are multidrug resistant (MDR: resistant to chloramphenicol, ampicillin, trimethoprim-sulphamethoxazole) with intermediate ciprofloxacin susceptibility are widespread in Asia but there is little information from Cambodia.', 'subject score': 851, 'object score': 1000}, 'PMID:23253321': {'publication date': '2012 Dec', 'sentence': 'This paper presents a perspective on the potential role of inhaled ciprofloxacin in such infections.', 'subject score': 888, 'object score': 1000}, 'PMID:26989670': {'publication date': '2016 Mar 16', 'sentence': 'CONCLUSION: The most effective antibiotics against gram-negative healthcare associated infections are imipenem followed by ciprofloxacin.', 'subject score': 1000, 'object score': 766}, 'PMID:29020144': {'publication date': '2017 Oct 30', 'sentence': 'Antimicrobial susceptibility testing of isolates from 4793 domestic and 1070 travel-associated infections revealed that, comparing 2004-2009 to 2010-2012, ciprofloxacin resistance increased among domestic infections (12.8% vs 16.1%).', 'subject score': 694, 'object score': 763}, 'PMID:3158073': {'publication date': '1985 Mar 30', 'sentence': 'These infections may, therefore, be favorably affected by ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:3542948': {'publication date': '1986 Nov', 'sentence': 'The progress of infection in sensitive mice with no natural immunity was delayed by ciprofloxacin although at the dosage used the mice were not cured.', 'subject score': 1000, 'object score': 1000}, 'PMID:36422605': {'publication date': '2022 Nov 15', 'sentence': 'This study aimed to analyse genetic mutations in the genomes of 25    S. aureus     isolates from infections or non-infectious ocular conditions from the USA and Australia and their relationship to ciprofloxacin resistance.', 'subject score': 888, 'object score': 852}, 'PMID:8040107': {'publication date': '1994 Mar', 'sentence': 'As prophylaxis for the granulocytopenic patient, quinolones such as norfloxacin and ciprofloxacin have been shown to be effective in reducing the incidence of morbidity attributable to Gram-negative bacteria, but they have not significantly affected the incidence of infection caused by Gram-positive bacteria.', 'subject score': 1000, 'object score': 1000}, 'PMID:8899438': {'publication date': '1996 Oct', 'sentence': 'OBJECTIVE: To evaluate endemic colonization with Staphylococcus aureus resistant to methicillin, ciprofloxacin, or both among patients of a private skilled nursing facility, with regard to colonization rate and site, and relation to infection and prior antibiotic use.', 'subject score': 1000, 'object score': 1000}, 'PMID:9002127': {'publication date': '1997 Jan', 'sentence': 'As empirical options are diminishing daily, the role of ciprofloxacin in pediatric infections is becoming increasingly significant.', 'subject score': 1000, 'object score': 888}, 'PMID:9255893': {'publication date': '1997', 'sentence': 'Influence of low dose ciprofloxacin on microbial colonization of the digestive tract in healthy volunteers during normal and during impaired colonization resistance.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0009450---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "9122989",
-              "object": "MONDO:0005550",
-              "publications": [
-                "PMID:11562127",
-                "PMID:12821471",
-                "PMID:15490982",
-                "PMID:2100081",
-                "PMID:21098755",
-                "PMID:21873378",
-                "PMID:22845325",
-                "PMID:22958285",
-                "PMID:23122884",
-                "PMID:23253321",
-                "PMID:26989670",
-                "PMID:29020144",
-                "PMID:3158073",
-                "PMID:3542948",
-                "PMID:36422605",
-                "PMID:8040107",
-                "PMID:8899438",
-                "PMID:9002127",
-                "PMID:9255893"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 317908,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005441",
-          "name": "otitis media",
-          "description": "Inflammation of the anatomical structures of the middle ear, which is most often caused by an infectious process. Symptoms include erythema and edema of the tympanic membrane, pain, and possibly fever.; Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.; Inflammation or infection of the middle ear. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:0004992",
-            "MEDDRA:10065838",
-            "MEDDRA:10046087",
-            "MEDDRA:10056747",
-            "ICD10:H66.9",
-            "MONDO:0005441",
-            "ICD9:382.9",
-            "MESH:D010033",
-            "SNOMEDCT:65363002",
-            "DOID:10754",
-            "MEDDRA:10033084",
-            "HP:0000388",
-            "UMLS:C0029882",
-            "MEDDRA:10033078",
-            "NCIT:C34885",
-            "MEDDRA:10027585"
-          ],
-          "id": "MONDO:0005441",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Otitis media",
-            "Unspecified otitis media",
-            "Otitis Media",
-            "otitis media"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/otitis_media",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317908,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005441",
-              "name": "otitis media",
-              "description": "Inflammation of the anatomical structures of the middle ear, which is most often caused by an infectious process. Symptoms include erythema and edema of the tympanic membrane, pain, and possibly fever.; Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.; Inflammation or infection of the middle ear. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:0004992",
-                "MEDDRA:10065838",
-                "MEDDRA:10046087",
-                "MEDDRA:10056747",
-                "ICD10:H66.9",
-                "MONDO:0005441",
-                "ICD9:382.9",
-                "MESH:D010033",
-                "SNOMEDCT:65363002",
-                "DOID:10754",
-                "MEDDRA:10033084",
-                "HP:0000388",
-                "UMLS:C0029882",
-                "MEDDRA:10033078",
-                "NCIT:C34885",
-                "MEDDRA:10027585"
-              ],
-              "id": "MONDO:0005441",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Otitis media",
-                "Unspecified otitis media",
-                "Otitis Media",
-                "otitis media"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/otitis_media",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13376907,
-            "start": 616,
-            "end": 317908,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1836574': {'publication date': '1991 Oct 26', 'sentence': '[Pneumococcal meningitis during ciprofloxacin therapy for otitis media].', 'subject score': 888, 'object score': 1000}, 'PMID:24971692': {'publication date': '2014 Sep 10', 'sentence': 'Ciprofloxacin is a synthetic fluoroquinolone antibiotic that has been used for systemic treatment of otitis media in adults.', 'subject score': 1000, 'object score': 1000}, 'PMID:26609503': {'publication date': '2015', 'sentence': 'Ciprofloxacin, gentamicin, norfloxacin and erythromycin can be used to treat otitis media.', 'subject score': 1000, 'object score': 1000}, 'PMID:35734305': {'publication date': '2022', 'sentence': 'Amikacin, cefepime, ciprofloxacin, and meropenem could be valuable in the empirical management of childhood OM.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0029882---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "13663890",
-              "object": "MONDO:0005441",
-              "publications": [
-                "PMID:1836574",
-                "PMID:24971692",
-                "PMID:26609503",
-                "PMID:35734305"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316730,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005129",
-          "name": "cataract",
-          "description": "Partial or complete opacity of the crystalline lens of one or both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.); Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed); A cataract is an opacity or clouding that develops in the crystalline lens of the eye or in its capsule. [HPO:probinson]; A cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery. A cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are: Blurry vision Colors that seem faded Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights. Not being able to see well at night Double vision  Frequent prescription changes in your eye wear   Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. NIH: National Eye Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "OMIM.PS:116200",
-            "SNOMEDCT:247053007",
-            "ICD10:H26",
-            "MEDDRA:10007768",
-            "ICD9:366.8",
-            "MONDO:0005129",
-            "UMLS:C0029531",
-            "MEDDRA:10007739",
-            "MEDDRA:10045649",
-            "MEDDRA:10030347",
-            "UMLS:C0086543",
-            "SNOMEDCT:193570009",
-            "SNOMEDCT:128306009",
-            "DOID:83",
-            "OMIM:PS116200",
-            "MEDDRA:10007771",
-            "MEDDRA:10024208",
-            "UMLS:C1510497",
-            "MEDDRA:10024214",
-            "MEDDRA:10024215",
-            "ICD9:366",
-            "HP:0000518",
-            "NCIT:C26713",
-            "MESH:D002386",
-            "MEDDRA:10007757"
-          ],
-          "id": "MONDO:0005129",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Other cataract",
-            "Cataract",
-            "cataract",
-            "Lens Opacities"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:10414631",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0001-6908-9849",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://en.wikipedia.org/wiki/cataract",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316730,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005129",
-              "name": "cataract",
-              "description": "Partial or complete opacity of the crystalline lens of one or both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.); Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed); A cataract is an opacity or clouding that develops in the crystalline lens of the eye or in its capsule. [HPO:probinson]; A cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery. A cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are: Blurry vision Colors that seem faded Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights. Not being able to see well at night Double vision  Frequent prescription changes in your eye wear   Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. NIH: National Eye Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "OMIM.PS:116200",
-                "SNOMEDCT:247053007",
-                "ICD10:H26",
-                "MEDDRA:10007768",
-                "ICD9:366.8",
-                "MONDO:0005129",
-                "UMLS:C0029531",
-                "MEDDRA:10007739",
-                "MEDDRA:10045649",
-                "MEDDRA:10030347",
-                "UMLS:C0086543",
-                "SNOMEDCT:193570009",
-                "SNOMEDCT:128306009",
-                "DOID:83",
-                "OMIM:PS116200",
-                "MEDDRA:10007771",
-                "MEDDRA:10024208",
-                "UMLS:C1510497",
-                "MEDDRA:10024214",
-                "MEDDRA:10024215",
-                "ICD9:366",
-                "HP:0000518",
-                "NCIT:C26713",
-                "MESH:D002386",
-                "MEDDRA:10007757"
-              ],
-              "id": "MONDO:0005129",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Other cataract",
-                "Cataract",
-                "cataract",
-                "Lens Opacities"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:10414631",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0001-6908-9849",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://en.wikipedia.org/wiki/cataract",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11587690,
-            "start": 616,
-            "end": 316730,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15910371': {'publication date': '2005', 'sentence': 'CONCLUSIONS: Ofloxacin has higher corneal penetration and ability to exceed MIC90 of common ocular contaminants than ciprofloxacin, and would be a more appropriate prophylactic choice for canine cataract patients.', 'subject score': 1000, 'object score': 851}, 'PMID:2947831': {'publication date': '1986', 'sentence': \"With these cataract models we tested the gyrase inhibitor compound, Ciprofloxacin (Bayer 09867), after 6 weeks' daily peroral application (20 mg/kg body weight) for differences in cataract progression indicating a possible cocataractogenic effect of the compound.\", 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0086543---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "11840711",
-              "object": "MONDO:0005129",
-              "publications": [
-                "PMID:15910371",
-                "PMID:2947831"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321542,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006032",
-          "name": "cystitis",
-          "description": "Inflammation of the urinary bladder.; Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.; Inflammation of the urinary bladder. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10011781",
-            "UMLS:C0010692",
-            "EFO:1000025",
-            "MEDDRA:10011754",
-            "SNOMEDCT:38822007",
-            "MESH:D003556",
-            "DOID:1679",
-            "HP:0100577",
-            "MEDDRA:10011798",
-            "ICD9:595",
-            "NCIT:C26738",
-            "MEDDRA:10011802",
-            "ICD10:N30",
-            "MONDO:0006032",
-            "MEDDRA:10063059"
-          ],
-          "id": "MONDO:0006032",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cystitis",
-            "cystitis",
-            "Urinary bladder inflammation"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.mayoclinic.org/diseases-conditions/cystitis/symptoms-causes/syc-20371306",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321542,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006032",
-              "name": "cystitis",
-              "description": "Inflammation of the urinary bladder.; Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.; Inflammation of the urinary bladder. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10011781",
-                "UMLS:C0010692",
-                "EFO:1000025",
-                "MEDDRA:10011754",
-                "SNOMEDCT:38822007",
-                "MESH:D003556",
-                "DOID:1679",
-                "HP:0100577",
-                "MEDDRA:10011798",
-                "ICD9:595",
-                "NCIT:C26738",
-                "MEDDRA:10011802",
-                "ICD10:N30",
-                "MONDO:0006032",
-                "MEDDRA:10063059"
-              ],
-              "id": "MONDO:0006032",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cystitis",
-                "cystitis",
-                "Urinary bladder inflammation"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.mayoclinic.org/diseases-conditions/cystitis/symptoms-causes/syc-20371306",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11434740,
-            "start": 616,
-            "end": 321542,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15728165': {'publication date': '2005 Feb 23', 'sentence': 'Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial.', 'subject score': 1000, 'object score': 888}, 'PMID:15972473': {'publication date': '2005 Jul', 'sentence': 'Treatment of infected mice for 4 days with ciprofloxacin at 30 mg/kg of body weight twice a day cured cystitis and renal infection in noncatheterized mice.', 'subject score': 1000, 'object score': 1000}, 'PMID:1839760': {'publication date': '1991 Dec', 'sentence': 'Treatment of encrusted cystitis caused by Corynebacterium group D2 with norfloxacin, ciprofloxacin, and teicoplanin in an experimental model in rats.', 'subject score': 1000, 'object score': 861}, 'PMID:22967697': {'publication date': '2012 Sep', 'sentence': 'In uncomplicated cystitis, 9.5% of all isolates were resistant to ciprofloxacin and 24.0% to trimethoprim-sulfamethoxazole (TMP-SMX).', 'subject score': 1000, 'object score': 888}, 'PMID:25339200': {'publication date': '2015 Mar', 'sentence': 'Ciprofloxacin and cotrimoxazole are recommended to treat uncomplicated pyelonephritis and uncomplicated cystitis, respectively, provided that local resistance rates of uropathogens do not exceed specified thresholds (10 and 20 %, respectively).', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0010692---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "11684450",
-              "object": "MONDO:0006032",
-              "publications": [
-                "PMID:15728165",
-                "PMID:15972473",
-                "PMID:1839760",
-                "PMID:22967697",
-                "PMID:25339200"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 579767,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005141",
-          "name": "Pseudomonas infection",
-          "description": "Infections with bacteria of the genus PSEUDOMONAS.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:0001076",
-            "MONDO:0005141",
-            "SNOMEDCT:63398001",
-            "UMLS:C0033817",
-            "MEDDRA:10061471",
-            "MEDDRA:10037135",
-            "MESH:D011552",
-            "MEDDRA:10037132"
-          ],
-          "id": "MONDO:0005141",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pseudomonas Infections",
-            "Pseudomonas infection"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 579767,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005141",
-              "name": "Pseudomonas infection",
-              "description": "Infections with bacteria of the genus PSEUDOMONAS.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:0001076",
-                "MONDO:0005141",
-                "SNOMEDCT:63398001",
-                "UMLS:C0033817",
-                "MEDDRA:10061471",
-                "MEDDRA:10037135",
-                "MESH:D011552",
-                "MEDDRA:10037132"
-              ],
-              "id": "MONDO:0005141",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pseudomonas Infections",
-                "Pseudomonas infection"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11429435,
-            "start": 616,
-            "end": 579767,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1572222': {'publication date': '1992 Mar', 'sentence': \"We used a simple Wood's light examination and culture to establish the diagnosis of Pseudomonas toe web infection and achieved rapid resolution with oral ciprofloxacin treatment and local application of Castellani's paint.\", 'subject score': 851, 'object score': 861}, 'PMID:20836302': {'publication date': '2010 Apr 15', 'sentence': 'At present time Ciprofloxacin is relatively effective antibiotic for Pseudomonas infection.', 'subject score': 851, 'object score': 1000}, 'PMID:2114953': {'publication date': '1990 Mar-Apr', 'sentence': 'Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2292542': {'publication date': '1990 Dec', 'sentence': 'The Cystic Fibrosis Clinic at the Royal Belfast Hospital for Sick Children has treated 31 children with ciprofloxacin, for serious pseudomonas infection in cystic fibrosis, and carefully monitored the safety and acceptability of the drug.', 'subject score': 1000, 'object score': 901}, 'PMID:24489509': {'publication date': '2013', 'sentence': 'The key findings were as follows: inhaled antipseudomonal antibiotic improves lung function, and probably the safest/most effective therapy; antistaphylococcal antibiotic prophylaxis increases the risk of acquiring P. aeruginosa; azithromycin significantly improves respiratory function after 6 months of treatment; a 28-day treatment with aztreonam or tobramycin significantly improves respiratory symptoms and pulmonary function; aztreonam lysine might be superior to tobramycin inhaled solution in chronic P. aeruginosa infection; oral ciprofloxacin does not produce additional benefit in those with chronic persistent pseudomonas infection but may have a role in early or first infection.', 'subject score': 888, 'object score': 826}, 'PMID:24718510': {'publication date': '2014 Apr', 'sentence': 'Pseudomonas infections of the nail organ are treated by ciprofloxacin; other bacteria are treated according to the results of culture and sensitivity testing.', 'subject score': 1000, 'object score': 1000}, 'PMID:2508586': {'publication date': '1989 Oct', 'sentence': 'Studies using either higher dosages of ciprofloxacin or combination therapy should be conducted to determine if acquired resistance can be avoided in Pseudomonas infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:3100490': {'publication date': '1986 Nov', 'sentence': 'Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:3279487': {'publication date': '1988 Jan-Feb', 'sentence': 'Ciprofloxacin and other quinolones are also effective therapy for pseudomonal infections in neutropenic animals with pneumonia, peritonitis, osteomyelitis, and endocarditis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3279495': {'publication date': '1988', 'sentence': 'Ciprofloxacin is apparently valuable for the treatment of pseudomonas infections in patients with cystic fibrosis: clinical results seem comparable to those obtained with conventional intravenous treatments.', 'subject score': 1000, 'object score': 1000}, 'PMID:35330242': {'publication date': '2022 Feb 28', 'sentence': 'Therefore, high local CIP concentrations during treatment of    Pseudomonas-Aspergillus     co-infections may increase the fungal burden.', 'subject score': 833, 'object score': 861}, 'PMID:3680089': {'publication date': '1987 Oct', 'sentence': 'Therapeutic efficacy of cefpiramide-ciprofloxacin combination in experimental Pseudomonas infections in neutropenic mice.', 'subject score': 851, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0033817---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "11679354",
-              "object": "MONDO:0005141",
-              "publications": [
-                "PMID:1572222",
-                "PMID:20836302",
-                "PMID:2114953",
-                "PMID:2292542",
-                "PMID:24489509",
-                "PMID:24718510",
-                "PMID:2508586",
-                "PMID:3100490",
-                "PMID:3279487",
-                "PMID:3279495",
-                "PMID:35330242",
-                "PMID:3680089"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 881097,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016047",
-          "name": "endophthalmitis",
-          "description": "An infectious process affecting the internal structures of the eye.; Infectious condition of the internal eye.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0014236",
-            "ORPHANET:199323",
-            "MONDO:0016047",
-            "SNOMEDCT:128295000",
-            "SNOMEDCT:1847009",
-            "MEDDRA:10030869",
-            "NCIT:C34586",
-            "MESH:D009877",
-            "MEDDRA:10014801",
-            "DOID:4692"
-          ],
-          "id": "MONDO:0016047",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Endophthalmitis",
-            "endophthalmitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/endophthalmitis",
-            "https://www.merckmanuals.com/home/eye-disorders/uveitis-and-related-disorders/endophthalmitis",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=endophthalmitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 881097,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016047",
-              "name": "endophthalmitis",
-              "description": "An infectious process affecting the internal structures of the eye.; Infectious condition of the internal eye.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0014236",
-                "ORPHANET:199323",
-                "MONDO:0016047",
-                "SNOMEDCT:128295000",
-                "SNOMEDCT:1847009",
-                "MEDDRA:10030869",
-                "NCIT:C34586",
-                "MESH:D009877",
-                "MEDDRA:10014801",
-                "DOID:4692"
-              ],
-              "id": "MONDO:0016047",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Endophthalmitis",
-                "endophthalmitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/endophthalmitis",
-                "https://www.merckmanuals.com/home/eye-disorders/uveitis-and-related-disorders/endophthalmitis",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=endophthalmitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11380125,
-            "start": 616,
-            "end": 881097,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15665370': {'publication date': '2005 Feb', 'sentence': 'Ciprofloxacin in endophthalmitis: an alternative to ceftazidime and amikacin!', 'subject score': 1000, 'object score': 1000}, 'PMID:22048244': {'publication date': '2012 Apr', 'sentence': 'METHODS: Retrospective review of all patients with suspected endophthalmitis after intravitreal injections treated with intravitreal antibiotics (teicoplanin and ciprofloxacin) at a referral centre between January 2003 and December 2010.', 'subject score': 1000, 'object score': 861}, 'PMID:23607574': {'publication date': '2013 Apr 22', 'sentence': 'Fluoroquinolones like ciprofloxacin may be considered as a useful alternative in vancomycin-resistant endophthalmitis.', 'subject score': 1000, 'object score': 877}, 'PMID:8115734': {'publication date': '1993', 'sentence': 'Because of the relatively short half life, intravitreal administration of ciprofloxacin for the treatment of endophthalmitis would provide only short-term therapy and would need to be supplemented by other forms of treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:8250071': {'publication date': '1993 Dec 15', 'sentence': 'Ciprofloxacin has been proposed for the systemic treatment of endophthalmitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:8755196': {'publication date': '1996 Jun', 'sentence': 'To determine injection time and effective dose of ciprofloxacin in endophthalmitis and to evaluate the effectiveness of dexamethasone.', 'subject score': 1000, 'object score': 1000}, 'PMID:8773934': {'publication date': '1996', 'sentence': 'The objective of this work was to evaluate various methods of sustained delivery to achieve therapeutic intravitreal levels of ciprofloxacin as a potential therapy for endophthalmitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0014236---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "11628762",
-              "object": "MONDO:0016047",
-              "publications": [
-                "PMID:15665370",
-                "PMID:22048244",
-                "PMID:23607574",
-                "PMID:8115734",
-                "PMID:8250071",
-                "PMID:8755196",
-                "PMID:8773934"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 324986,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-          "name": "chronic obstructive pulmonary disease",
-          "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-          "equivalent_curies": [
-            "MESH:D029424",
-            "MEDDRA:10010952",
-            "MEDDRA:10009025",
-            "ICD10:J44.9",
-            "UMLS:C1527303",
-            "NCIT:C3199",
-            "UMLS:C0024117",
-            "MEDDRA:10064611",
-            "MEDDRA:10009026",
-            "MEDDRA:10029972",
-            "DOID:3083",
-            "MONDO:0005002",
-            "MEDDRA:10009032",
-            "MEDDRA:10070975",
-            "EFO:0000341",
-            "SNOMEDCT:13645005",
-            "MEDDRA:10009033",
-            "HP:0006510",
-            "MEDDRA:10008828"
-          ],
-          "id": "MONDO:0005002",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic Obstructive Pulmonary Disease",
-            "chronic obstructive pulmonary disease",
-            "Chronic pulmonary obstruction",
-            "Chronic Airflow Obstruction",
-            "Chronic Obstructive Airway Disease",
-            "Pulmonary Disease, Chronic Obstructive"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health-topics/copd",
-            "PMID:32800196",
-            "PMID:28513453",
-            "PMID:25943942",
-            "PMID:32745458"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 324986,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-              "name": "chronic obstructive pulmonary disease",
-              "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-              "equivalent_curies": [
-                "MESH:D029424",
-                "MEDDRA:10010952",
-                "MEDDRA:10009025",
-                "ICD10:J44.9",
-                "UMLS:C1527303",
-                "NCIT:C3199",
-                "UMLS:C0024117",
-                "MEDDRA:10064611",
-                "MEDDRA:10009026",
-                "MEDDRA:10029972",
-                "DOID:3083",
-                "MONDO:0005002",
-                "MEDDRA:10009032",
-                "MEDDRA:10070975",
-                "EFO:0000341",
-                "SNOMEDCT:13645005",
-                "MEDDRA:10009033",
-                "HP:0006510",
-                "MEDDRA:10008828"
-              ],
-              "id": "MONDO:0005002",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic Obstructive Pulmonary Disease",
-                "chronic obstructive pulmonary disease",
-                "Chronic pulmonary obstruction",
-                "Chronic Airflow Obstruction",
-                "Chronic Obstructive Airway Disease",
-                "Pulmonary Disease, Chronic Obstructive"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health-topics/copd",
-                "PMID:32800196",
-                "PMID:28513453",
-                "PMID:25943942",
-                "PMID:32745458"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11317272,
-            "start": 616,
-            "end": 324986,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15592904': {'publication date': '2005 Jan', 'sentence': 'Reported here is the case of a patient with underlying chronic obstructive pulmonary disease (COPD) in whom ciprofloxacin treatment of a lower respiratory tract infection failed subsequent to ciprofloxacin treatment of an exacerbation of COPD several weeks earlier.', 'subject score': 888, 'object score': 937}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0024117---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "11564697",
-              "object": "MONDO:0005002",
-              "publications": [
-                "PMID:15592904"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 546977,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043885",
-          "name": "eye infectious disorder",
-          "description": "An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.; Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.; Your eyes can get infections from bacteria, fungi, or viruses. Eye infections can occur in different parts of the eye and can affect just one eye or both. Two common eye infections are:  Conjunctivitis - also known as pink eye. Conjunctivitis is often due to an infection. Children frequently get it, and it is very contagious.  Stye - a bump on the eyelid that happens when bacteria from your skin get into the hair follicle of an eyelash.  Symptoms of eye infections may include redness, itching, swelling, discharge, pain, or problems with vision. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or antibiotics.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10015929",
-            "UMLS:C0015403",
-            "MESH:D015817",
-            "MEDDRA:10015936",
-            "MONDO:0043885",
-            "SNOMEDCT:128351009",
-            "NCIT:C45372",
-            "EFO:1001888"
-          ],
-          "id": "MONDO:0043885",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Eye Infection",
-            "eye infectious disorder",
-            "eye infection",
-            "Eye Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546977,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043885",
-              "name": "eye infectious disorder",
-              "description": "An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.; Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.; Your eyes can get infections from bacteria, fungi, or viruses. Eye infections can occur in different parts of the eye and can affect just one eye or both. Two common eye infections are:  Conjunctivitis - also known as pink eye. Conjunctivitis is often due to an infection. Children frequently get it, and it is very contagious.  Stye - a bump on the eyelid that happens when bacteria from your skin get into the hair follicle of an eyelash.  Symptoms of eye infections may include redness, itching, swelling, discharge, pain, or problems with vision. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or antibiotics.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10015929",
-                "UMLS:C0015403",
-                "MESH:D015817",
-                "MEDDRA:10015936",
-                "MONDO:0043885",
-                "SNOMEDCT:128351009",
-                "NCIT:C45372",
-                "EFO:1001888"
-              ],
-              "id": "MONDO:0043885",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Eye Infection",
-                "eye infectious disorder",
-                "eye infection",
-                "Eye Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11061765,
-            "start": 616,
-            "end": 546977,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15257070': {'publication date': '2004 Aug', 'sentence': 'This PK-MB model may be very useful in optimizing treatments of various eye infections with ciprofloxacin.', 'subject score': 1000, 'object score': 901}, 'PMID:1928270': {'publication date': '1991 Oct', 'sentence': 'The growing body of experimental data supports the effectiveness of ciprofloxacin in the treatment of experimental keratitis and suggest that it be evaluated further in ocular infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:1928271': {'publication date': '1991 Oct', 'sentence': 'Topically applied ciprofloxacin eradicated or reduced all isolated bacterial species, attesting to its broad antibacterial spectrum and its potential usefulness in treating external ocular infections.', 'subject score': 827, 'object score': 861}, 'PMID:26482534': {'publication date': '2016', 'sentence': 'Ciprofloxacin is a drug active against a broad spectrum of aerobic Gram-positive and Gram-negative bacteria, for the therapy of ocular infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:26863046': {'publication date': '2017 Mar', 'sentence': 'OBJECTIVES: Ciprofloxacin (Cipro) is an antibiotic, widely used in form of ophthalmic drops (0.3%) for the treatment of eye infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:28634139': {'publication date': '2017 Aug 30', 'sentence': 'Ciprofloxacin (CIP) is an antibacterial agent prescribed for the treatment of ocular infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:3477893': {'publication date': '1986', 'sentence': 'Ciprofloxacin is a potentially useful antibiotic in eye infection.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0015403---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "11304087",
-              "object": "MONDO:0043885",
-              "publications": [
-                "PMID:15257070",
-                "PMID:1928270",
-                "PMID:1928271",
-                "PMID:26482534",
-                "PMID:26863046",
-                "PMID:28634139",
-                "PMID:3477893"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317816,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005227",
-          "name": "abscess",
-          "description": "An inflammatory process characterized by the accumulation of pus within a newly formed tissue cavity which is the result of a bacterial, fungal, or parasitic infection or the presence of a foreign body.; Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.; An abscess is a pocket of pus. You can get an abscess almost anywhere in your body. When an area of your body becomes infected, your body's immune system tries to fight the infection. White blood cells go to the infected area, collect within the damaged tissue, and cause inflammation. During this process, pus forms. Pus is a mixture of living and dead white blood cells, germs, and dead tissue.  Bacteria, viruses, parasites and swallowed objects can all lead to abscesses. Skin abscesses are easy to detect. They are red, raised and painful. Abscesses inside your body may not be obvious and can damage organs, including the brain, lungs and others. Treatments include drainage and antibiotics. ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "HP:0025615",
-            "SNOMEDCT:128477000",
-            "SNOMEDCT:44132006",
-            "UMLS:C0000833",
-            "MONDO:0005227",
-            "MESH:D000038",
-            "NCIT:C26686",
-            "MEDDRA:10000287",
-            "MEDDRA:10000269",
-            "SYMP:0000672",
-            "EFO:0003030"
-          ],
-          "id": "MONDO:0005227",
-          "category": "biolink:Disease",
-          "all_names": [
-            "abscess",
-            "Abscess"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317816,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005227",
-              "name": "abscess",
-              "description": "An inflammatory process characterized by the accumulation of pus within a newly formed tissue cavity which is the result of a bacterial, fungal, or parasitic infection or the presence of a foreign body.; Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.; An abscess is a pocket of pus. You can get an abscess almost anywhere in your body. When an area of your body becomes infected, your body's immune system tries to fight the infection. White blood cells go to the infected area, collect within the damaged tissue, and cause inflammation. During this process, pus forms. Pus is a mixture of living and dead white blood cells, germs, and dead tissue.  Bacteria, viruses, parasites and swallowed objects can all lead to abscesses. Skin abscesses are easy to detect. They are red, raised and painful. Abscesses inside your body may not be obvious and can damage organs, including the brain, lungs and others. Treatments include drainage and antibiotics. ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "HP:0025615",
-                "SNOMEDCT:128477000",
-                "SNOMEDCT:44132006",
-                "UMLS:C0000833",
-                "MONDO:0005227",
-                "MESH:D000038",
-                "NCIT:C26686",
-                "MEDDRA:10000287",
-                "MEDDRA:10000269",
-                "SYMP:0000672",
-                "EFO:0003030"
-              ],
-              "id": "MONDO:0005227",
-              "category": "biolink:Disease",
-              "all_names": [
-                "abscess",
-                "Abscess"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10822361,
-            "start": 616,
-            "end": 317816,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:14988789': {'publication date': '2004 Feb', 'sentence': 'The patient was asymptomatic for a month, but the abscess reactivated and was treated with Vancomycin and Ciprofloxacin administered intravenously.', 'subject score': 1000, 'object score': 1000}, 'PMID:18194131': {'publication date': '2007 Dec', 'sentence': 'Treatment with intravenous meropenem (3 g/day for 3 weeks) and oral ciprofloxacin was begun, which resulted in the complete resolution of the intrarenal abscesses.', 'subject score': 888, 'object score': 861}, 'PMID:23182142': {'publication date': '2012 Oct', 'sentence': 'We report a case of recurrent, multifocal Salmonella enterica serotype Paratyphi A breast abscesses, resistant to ciprofloxacin, which relapsed despite surgery, aspiration and multiple courses of antibiotics, including co-trimoxazole and azithromycin.', 'subject score': 1000, 'object score': 888}, 'PMID:23283615': {'publication date': '2013 Jan 02', 'sentence': 'Her medical history included paroxysmal atrial fibrillation and a sigmoid diverticular abscess treated with ciprofloxacin and metronidazole.', 'subject score': 1000, 'object score': 754}, 'PMID:24296421': {'publication date': '2014 Sep', 'sentence': 'CONCLUSIONS: When gram-negative aerobes were isolated from abscesses in CD patients, more than two thirds were resistant to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:2589367': {'publication date': '1989 Nov 30', 'sentence': 'Ciprofloxacin alone or regimens combining ciprofloxacin with rifampin or rifampin plus imipenem reduced the number of E. coli in polymicrobic subcutaneous abscesses but had little effect on P. aeruginosa in polymicrobic abscesses.', 'subject score': 1000, 'object score': 861}, 'PMID:3322752': {'publication date': '1987', 'sentence': 'However, ciprofloxacin at levels of 20, 10, 5, and 1 mg/kg reduced significantly the number of E. coli cells in the abscess.', 'subject score': 1000, 'object score': 1000}, 'PMID:3814223': {'publication date': '1986 Nov', 'sentence': 'Five min after administration of ciprofloxacin, the radioactivity was found to be differentially distributed among all organs and tissues, but no radioactivity was detectable in the abscess.', 'subject score': 1000, 'object score': 1000}, 'PMID:8517727': {'publication date': '1993 May', 'sentence': 'The abscesses were caused by two Bacteroides fragilis isolates, one of which was susceptible and one of which was resistant to ofloxacin, ciprofloxacin, and lomefloxacin, alone or in combination with Escherichia coli.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0000833---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "11059709",
-              "object": "MONDO:0005227",
-              "publications": [
-                "PMID:14988789",
-                "PMID:18194131",
-                "PMID:23182142",
-                "PMID:23283615",
-                "PMID:24296421",
-                "PMID:2589367",
-                "PMID:3322752",
-                "PMID:3814223",
-                "PMID:8517727"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 538307,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538307,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9869789,
-            "start": 616,
-            "end": 538307,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12641485': {'publication date': '2003', 'sentence': 'Fluoroquinolones such as ciprofloxacin, levofloxacin, moxifloxacin and gatifloxacin are widely used for the treatment of bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:12869605': {'publication date': '2003', 'sentence': \"The authors present three cases of Achilles tendinopathy in which the patients' symptoms were preceded by treatment for unrelated bacterial infections with ciprofloxacin.\", 'subject score': 1000, 'object score': 901}, 'PMID:1290976': {'publication date': '1992', 'sentence': '[Effect of TFX (Polfa) on the course of experimental bacterial infections in mice treated with ciprofloxacin, amikacin and cefoperazone].', 'subject score': 1000, 'object score': 901}, 'PMID:1440806': {'publication date': '1992', 'sentence': 'It is concluded that, if ciprofloxacin is to be used for treatment of malaria, a higher dose than that normally used for bacterial infections is necessary.', 'subject score': 1000, 'object score': 1000}, 'PMID:16167706': {'publication date': '2005 Jul', 'sentence': 'In the absence of culture and sensitivity information, ciprofloxacin should be considered among the first line options in the empirical treatment of severe bacterial infections among these children.', 'subject score': 1000, 'object score': 901}, 'PMID:1664832': {'publication date': '1991 Dec', 'sentence': 'The preliminary results from this study suggest that once daily temafloxacin gives high rates of clinical and bacteriological success, similar to twice daily ciprofloxacin, in the management of bacterial infections in the lower respiratory tract.', 'subject score': 776, 'object score': 1000}, 'PMID:18228018': {'publication date': '2008 Jun', 'sentence': 'PURPOSE: The uptake of (99m)Tc-UBI (29-41) was evaluated at sites of bacterial infections in rabbits before and after treatment with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:18972877': {'publication date': '2008', 'sentence': 'In this study, 3-alkyl and 3-aryl esters of hexahydroquinoline derivatives were screened for their ability to decrease bacterial resistance to ciprofloxacin (CAS 85721-33-1), which is extensively used to treat bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:19301941': {'publication date': '2009', 'sentence': 'BACKGROUND AND OBJECTIVE: Ciprofloxacin is a broad-spectrum, synthetic antibacterial used for the treatment of various bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:20100564': {'publication date': '2010 Jun', 'sentence': 'The fluorinated quinolone, ciprofloxacin, is an antibiotic effective for treating bacterial infections by inhibiting the enzyme activity of the DNA type II topoisomerases DNA gyrase and topoisomerase IV.', 'subject score': 1000, 'object score': 901}, 'PMID:20334059': {'publication date': '2009 Sep', 'sentence': 'Ciprofloxacin is a bactericidal drug which is being used widely throughout the world for the treatment of various bacterial infection.', 'subject score': 1000, 'object score': 901}, 'PMID:21570813': {'publication date': '2011 Jul', 'sentence': 'The antibiotic ciprofloxacin is used to treat EAEC infections, but a full understanding of the antimicrobial effects of ciprofloxacin is needed for more efficient treatment of bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:24153144': {'publication date': '2013 Sep', 'sentence': 'The patient presented with psoriatic plaque ulcerations uniquely limited to the active border as well as acute oral ulcerations and severe gastrointestinal upset after undergoing a course of ciprofloxacin for treatment of a bacterial infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:2490636': {'publication date': '1989 Jan', 'sentence': 'Twenty one adult patients, both males and females, with 32 bacterial infections of several localizations and moderate to severe prognosis were treated with ciprofloxacin (200 mg every 12 hours), initially intravenously and then with 500 mg every 12 hours orally during 25 +/- 11 days.', 'subject score': 1000, 'object score': 901}, 'PMID:2490638': {'publication date': '1989 Jan', 'sentence': '[Evaluation of ciprofloxacin for the treatment of severe bacterial infections].', 'subject score': 1000, 'object score': 901}, 'PMID:25526004': {'publication date': '2014 Oct 15', 'sentence': 'The patient was treated with oral ivermectin and permethrin cream, as well as ciprofloxacin for the bacterial infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:2589369': {'publication date': '1989 Nov 30', 'sentence': 'Clinical study of intravenous and oral ciprofloxacin in complicated bacterial infections.', 'subject score': 888, 'object score': 901}, 'PMID:26140184': {'publication date': '2015 Apr-Jun', 'sentence': 'CONCLUSION: Niosomal CPFX appears to be a promising approach in the management of bacterial infections, especially ophthalmic ones, and should be further evaluated by in vivo experiments.', 'subject score': 861, 'object score': 1000}, 'PMID:2618005': {'publication date': '1989', 'sentence': '[Ciprofloxacin in bacterial infections].', 'subject score': 1000, 'object score': 1000}, 'PMID:26763627': {'publication date': '2015', 'sentence': 'BACKGROUND: Ciprofloxacin is one of the main drugs to treat bacterial infections.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "10087799",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:12641485",
-                "PMID:12869605",
-                "PMID:1290976",
-                "PMID:1440806",
-                "PMID:16167706",
-                "PMID:1664832",
-                "PMID:18228018",
-                "PMID:18972877",
-                "PMID:19301941",
-                "PMID:20100564",
-                "PMID:20334059",
-                "PMID:21570813",
-                "PMID:24153144",
-                "PMID:2490636",
-                "PMID:2490638",
-                "PMID:25526004",
-                "PMID:2589369",
-                "PMID:26140184",
-                "PMID:2618005",
-                "PMID:26763627"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 517617,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019095",
-          "name": "plague",
-          "description": "A Gram-negative bacterial infection caused by Yersinia pestis. It is usually transmitted to humans from bites of infected rodent fleas. It is manifested as a bubonic, septicemic, or pneumonic plague. In bubonic plague, the lymph nodes adjacent to the site of the skin bite are infected and enlarged. In septicemic plague, the infection spreads directly through the bloodstream. In pneumonic plague, the infection spreads to the lungs either following bubonic plague, or by inhalation of infective droplets. If untreated, it may lead to death.; An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.; Plague is an infection caused by the bacterium Yersinia pestis. The bacteria are found mainly in rats and in the fleas that feed on them. People and other animals can get plague from rat or flea bites. In the past, plague destroyed entire civilizations. Today plague is uncommon, due to better living conditions and antibiotics. There are three forms of plague:  Bubonic plague causes the tonsils, adenoids, spleen, and thymus to become inflamed. Symptoms include fever, aches, chills, and tender lymph glands. In septicemic plague, bacteria multiply in the blood. It causes fever, chills, shock, and bleeding under the skin or other organs. Pneumonic plague is the most serious form. Bacteria enter the lungs and cause pneumonia. People with the infection can spread this form to others. This type could be a bioterror agent.  Lab tests can diagnose plague. Treatment is a strong antibiotic. There is no vaccine.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10046098",
-            "ICD10:A20",
-            "MEDDRA:10048250",
-            "SNOMEDCT:58750007",
-            "UMLS:C0032064",
-            "ICD9:020",
-            "NCIT:C85015",
-            "DOID:3482",
-            "ORPHANET:707",
-            "MONDO:0019095",
-            "MEDDRA:10035148",
-            "MEDDRA:10035149",
-            "MESH:D010930"
-          ],
-          "id": "MONDO:0019095",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Plague",
-            "plague"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:29628173"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 517617,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019095",
-              "name": "plague",
-              "description": "A Gram-negative bacterial infection caused by Yersinia pestis. It is usually transmitted to humans from bites of infected rodent fleas. It is manifested as a bubonic, septicemic, or pneumonic plague. In bubonic plague, the lymph nodes adjacent to the site of the skin bite are infected and enlarged. In septicemic plague, the infection spreads directly through the bloodstream. In pneumonic plague, the infection spreads to the lungs either following bubonic plague, or by inhalation of infective droplets. If untreated, it may lead to death.; An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.; Plague is an infection caused by the bacterium Yersinia pestis. The bacteria are found mainly in rats and in the fleas that feed on them. People and other animals can get plague from rat or flea bites. In the past, plague destroyed entire civilizations. Today plague is uncommon, due to better living conditions and antibiotics. There are three forms of plague:  Bubonic plague causes the tonsils, adenoids, spleen, and thymus to become inflamed. Symptoms include fever, aches, chills, and tender lymph glands. In septicemic plague, bacteria multiply in the blood. It causes fever, chills, shock, and bleeding under the skin or other organs. Pneumonic plague is the most serious form. Bacteria enter the lungs and cause pneumonia. People with the infection can spread this form to others. This type could be a bioterror agent.  Lab tests can diagnose plague. Treatment is a strong antibiotic. There is no vaccine.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10046098",
-                "ICD10:A20",
-                "MEDDRA:10048250",
-                "SNOMEDCT:58750007",
-                "UMLS:C0032064",
-                "ICD9:020",
-                "NCIT:C85015",
-                "DOID:3482",
-                "ORPHANET:707",
-                "MONDO:0019095",
-                "MEDDRA:10035148",
-                "MEDDRA:10035149",
-                "MESH:D010930"
-              ],
-              "id": "MONDO:0019095",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Plague",
-                "plague"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:29628173"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9796811,
-            "start": 616,
-            "end": 517617,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12567312': {'publication date': '2003 Feb 15', 'sentence': 'There are no previous reports of plague being successfully treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:21628541': {'publication date': '2011 Aug', 'sentence': 'During the initial stage of plague, intracellular Y. pestis may be less susceptible to antibiotic killing by particular antibiotics recommended for treatment of plague, such as gentamicin or doxycycline, whereas others, such as streptomycin and ciprofloxacin, may have similar efficacies against extracellular or intracellular Y. pestis.', 'subject score': 1000, 'object score': 1000}, 'PMID:28125398': {'publication date': '2017 03', 'sentence': 'We report 5 cases of culture-confirmed human plague treated successfully with oral ciprofloxacin, including 1 case of pneumonic plague.', 'subject score': 888, 'object score': 833}, 'PMID:7847999': {'publication date': '1994 Jun', 'sentence': 'It was shown that unlike nalidixic acid the 3rd generation quinolones i.e. the nitrogen-containing quinolones (LIB-71 and LIB-80) and the fluorine-containing quinolones (pefloxacin and ciprofloxacin) were highly efficient in the prophylaxis and treatment of experimental plague in albino mice infected via the plague microbe inhalation.', 'subject score': 1000, 'object score': 888}, 'PMID:8060184': {'publication date': '1993 Jan', 'sentence': '[Effectiveness of the new quinolones, ciprofloxacin and pefloxacin in experimental plague].', 'subject score': 1000, 'object score': 888}, 'PMID:8722542': {'publication date': '1996 Apr', 'sentence': 'Ciprofloxacin may therefore be a useful antibiotic to consider for the treatment of plague.', 'subject score': 1000, 'object score': 1000}, 'PMID:9221699': {'publication date': '1997', 'sentence': 'Fluoroquinolones (ciprofloxacin and pefloxacin) and 3rd generation cephalosporins (cefoperazone, cefotaxime, ceftazidime and ceftriaxone) were comparatively studied in the prevention and treatment of experimental plague in albino mice caused by F1+ and F1- strains of the plague microbe.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0032064---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "10013051",
-              "object": "MONDO:0019095",
-              "publications": [
-                "PMID:12567312",
-                "PMID:21628541",
-                "PMID:28125398",
-                "PMID:7847999",
-                "PMID:8060184",
-                "PMID:8722542",
-                "PMID:9221699"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 516086,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005119",
-          "name": "anthrax infection",
-          "description": "An infection caused by Bacillus anthracis bacteria. It may affect the lungs, gastrointestinal tract, or skin. Patients with lung infection present with fever, headaches, cough, chest pain and shortness of breath. Patients with gastrointestinal infection present with nausea, vomiting and bloody diarrhea. Patients with skin infection develop blisters and ulcers.; An acute infection caused by the spore-forming bacteria BACILLUS ANTHRACIS. It commonly affects hoofed animals such as sheep and goats. Infection in humans often involves the skin (cutaneous anthrax), the lungs (inhalation anthrax), or the gastrointestinal tract. Anthrax is not contagious and can be treated with antibiotics.; Anthrax is a disease caused by Bacillus anthracis, a germ that lives in soil. Many people know about it from the 2001 bioterror attacks. In the attacks, someone purposely spread anthrax through the U.S. mail. This killed five people and made 22 sick.  Anthrax is rare. It affects animals such as cattle, sheep, and goats more often than people. People can get anthrax from contact with infected animals, wool, meat, or hides. It can cause three forms of disease in people. They are:  Cutaneous, which affects the skin. People with cuts or open sores can get it if they touch the bacteria.   Inhalation, which affects the lungs. You can get this if you breathe in spores of the bacteria.   Gastrointestinal, which affects the digestive system. You can get it by eating infected meat.  Antibiotics often cure anthrax if it is diagnosed early. But many people don't know they have anthrax until it is too late to treat. A vaccine to prevent anthrax is available for people in the military and others at high risk. ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005119",
-            "MEDDRA:10003975",
-            "SNOMEDCT:409498004",
-            "NCIT:C84565",
-            "MESH:D000881",
-            "ICD9:022",
-            "MEDDRA:10002716",
-            "MEDDRA:10002713",
-            "DOID:7427",
-            "UMLS:C0003175",
-            "ICD10:A22",
-            "EFO:0000778"
-          ],
-          "id": "MONDO:0005119",
-          "category": "biolink:Disease",
-          "all_names": [
-            "anthrax infection",
-            "Anthrax disease",
-            "Anthrax",
-            "anthrax disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/anthrax",
-            "https://www.cdc.gov/anthrax/basics/index.htm",
-            "https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/anthrax",
-            "https://medlineplus.gov/ency/article/001325.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 516086,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005119",
-              "name": "anthrax infection",
-              "description": "An infection caused by Bacillus anthracis bacteria. It may affect the lungs, gastrointestinal tract, or skin. Patients with lung infection present with fever, headaches, cough, chest pain and shortness of breath. Patients with gastrointestinal infection present with nausea, vomiting and bloody diarrhea. Patients with skin infection develop blisters and ulcers.; An acute infection caused by the spore-forming bacteria BACILLUS ANTHRACIS. It commonly affects hoofed animals such as sheep and goats. Infection in humans often involves the skin (cutaneous anthrax), the lungs (inhalation anthrax), or the gastrointestinal tract. Anthrax is not contagious and can be treated with antibiotics.; Anthrax is a disease caused by Bacillus anthracis, a germ that lives in soil. Many people know about it from the 2001 bioterror attacks. In the attacks, someone purposely spread anthrax through the U.S. mail. This killed five people and made 22 sick.  Anthrax is rare. It affects animals such as cattle, sheep, and goats more often than people. People can get anthrax from contact with infected animals, wool, meat, or hides. It can cause three forms of disease in people. They are:  Cutaneous, which affects the skin. People with cuts or open sores can get it if they touch the bacteria.   Inhalation, which affects the lungs. You can get this if you breathe in spores of the bacteria.   Gastrointestinal, which affects the digestive system. You can get it by eating infected meat.  Antibiotics often cure anthrax if it is diagnosed early. But many people don't know they have anthrax until it is too late to treat. A vaccine to prevent anthrax is available for people in the military and others at high risk. ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005119",
-                "MEDDRA:10003975",
-                "SNOMEDCT:409498004",
-                "NCIT:C84565",
-                "MESH:D000881",
-                "ICD9:022",
-                "MEDDRA:10002716",
-                "MEDDRA:10002713",
-                "DOID:7427",
-                "UMLS:C0003175",
-                "ICD10:A22",
-                "EFO:0000778"
-              ],
-              "id": "MONDO:0005119",
-              "category": "biolink:Disease",
-              "all_names": [
-                "anthrax infection",
-                "Anthrax disease",
-                "Anthrax",
-                "anthrax disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/anthrax",
-                "https://www.cdc.gov/anthrax/basics/index.htm",
-                "https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/anthrax",
-                "https://medlineplus.gov/ency/article/001325.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9786099,
-            "start": 616,
-            "end": 516086,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12556279': {'publication date': '2003 Jan', 'sentence': 'Treatment and post-exposure prophylaxis for anthrax are ciprofloxacin or doxycycline.', 'subject score': 1000, 'object score': 1000}, 'PMID:14556058': {'publication date': '2003 Oct', 'sentence': 'In our series, penicillin and ciprofloxacin were effective in treatment of anthrax.', 'subject score': 1000, 'object score': 1000}, 'PMID:15163650': {'publication date': '2004 Jul', 'sentence': 'CONCLUSIONS: Gatifloxacin appeared to be more effective than moxifloxacin or ciprofloxacin, at similar doses, for early post-exposure treatment of murine systemic anthrax.', 'subject score': 1000, 'object score': 851}, 'PMID:22064542': {'publication date': '2012 Jan', 'sentence': 'Ciprofloxacin is a gold standard for the treatment of anthrax.', 'subject score': 1000, 'object score': 1000}, 'PMID:25174439': {'publication date': '2014', 'sentence': 'Broad-range antibiotics like amoxicillin, ciprofloxacin, clindamycin, streptomycin, and penicillin G are recommended for the treatment of human anthrax infections, but the threat of antibiotic resistant strains always remains.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0003175---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "10002223",
-              "object": "MONDO:0005119",
-              "publications": [
-                "PMID:12556279",
-                "PMID:14556058",
-                "PMID:15163650",
-                "PMID:22064542",
-                "PMID:25174439"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318598,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004822",
-          "name": "bronchiectasis",
-          "description": "Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways. [HPO:probinson]; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:J47",
-            "ICD9:494",
-            "MESH:D001987",
-            "MEDDRA:10006445",
-            "DOID:9563",
-            "MEDDRA:10006446",
-            "OMIM.PS:211400",
-            "MONDO:0004822",
-            "OMIM:PS211400",
-            "UMLS:C0006267",
-            "NCIT:C84475",
-            "HP:0002110",
-            "SNOMEDCT:12295008"
-          ],
-          "id": "MONDO:0004822",
-          "category": "biolink:Disease",
-          "all_names": [
-            "bronchiectasis",
-            "Bronchiectasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.merck.com/mmhe/sec04/ch047/ch047a.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=bronchiectasis",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318598,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004822",
-              "name": "bronchiectasis",
-              "description": "Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways. [HPO:probinson]; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:J47",
-                "ICD9:494",
-                "MESH:D001987",
-                "MEDDRA:10006445",
-                "DOID:9563",
-                "MEDDRA:10006446",
-                "OMIM.PS:211400",
-                "MONDO:0004822",
-                "OMIM:PS211400",
-                "UMLS:C0006267",
-                "NCIT:C84475",
-                "HP:0002110",
-                "SNOMEDCT:12295008"
-              ],
-              "id": "MONDO:0004822",
-              "category": "biolink:Disease",
-              "all_names": [
-                "bronchiectasis",
-                "Bronchiectasis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.merck.com/mmhe/sec04/ch047/ch047a.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=bronchiectasis",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9494685,
-            "start": 616,
-            "end": 318598,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12174240': {'publication date': '2002 Jul', 'sentence': 'He had severe airway obstruction and focal bronchiectasis, and responded to treatment with ciprofloxacin and clarithromycin.', 'subject score': 1000, 'object score': 888}, 'PMID:12654682': {'publication date': '2003 Apr', 'sentence': 'Five Spain(9V-3) Streptococcus pneumoniae strains were isolated from a patient with bronchiectasis who had received long-term ciprofloxacin therapy.', 'subject score': 840, 'object score': 1000}, 'PMID:23681906': {'publication date': '2013 Sep', 'sentence': 'Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.', 'subject score': 775, 'object score': 824}, 'PMID:23690368': {'publication date': '2013 Oct', 'sentence': 'Lastly, the anticipated role of inhaled ciprofloxacin in the management of NCFBE is discussed, including future considerations and potential limitations of therapy.', 'subject score': 888, 'object score': 824}, 'PMID:28778139': {'publication date': '2017 Sep', 'sentence': 'Inhaled or nebulised ciprofloxacin for the maintenance treatment of bronchiectasis.', 'subject score': 861, 'object score': 1000}, 'PMID:29077527': {'publication date': '2018 Jun', 'sentence': 'Recently, several investigators conducted phase 3 randomized controlled trials with inhaled aztreonam and ciprofloxacin in patients with NCFBE.', 'subject score': 1000, 'object score': 824}, 'PMID:30568427': {'publication date': '2018', 'sentence': 'Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis.', 'subject score': 888, 'object score': 824}, 'PMID:30658914': {'publication date': '2019 Mar', 'sentence': 'Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.', 'subject score': 851, 'object score': 824}, 'PMID:30673901': {'publication date': '2019 Jan 23', 'sentence': 'The presented results indicated the novel inhalable silk-based DPI microparticles of CIP could provide a promising strategy for the treatment of NCFB.', 'subject score': 1000, 'object score': 824}, 'PMID:31035017': {'publication date': '2019 Dec', 'sentence': 'Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection.', 'subject score': 851, 'object score': 824}, 'PMID:33469994': {'publication date': '2021 Jan 19', 'sentence': 'We conducted the present meta-analysis to comprehensively evaluate the feasibility of inhalation of ciprofloxacin in NCFB.', 'subject score': 1000, 'object score': 824}, 'PMID:33814907': {'publication date': '2021', 'sentence': 'Conclusion: Novel inhalable CIP NCMP powders are a potential new approach to improved target ability and delivery of CIP for NCFB treatment.', 'subject score': 1000, 'object score': 775}, 'PMID:7961201': {'publication date': '1994 Jul', 'sentence': 'The efficacy and safety of long-term ciprofloxacin therapy in the management of severe bronchiectasis were retrospectively assessed in patients who had taken oral ciprofloxacin continuously for at least 90 days.', 'subject score': 790, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0006267---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "9704134",
-              "object": "MONDO:0004822",
-              "publications": [
-                "PMID:12174240",
-                "PMID:12654682",
-                "PMID:23681906",
-                "PMID:23690368",
-                "PMID:28778139",
-                "PMID:29077527",
-                "PMID:30568427",
-                "PMID:30658914",
-                "PMID:30673901",
-                "PMID:31035017",
-                "PMID:33469994",
-                "PMID:33814907",
-                "PMID:7961201"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 314857,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004795",
-          "name": "otitis externa",
-          "description": "Inflammation of the anatomical structures of the outer ear and ear canal, which is most often caused by an infectious process. Symptoms include erythema, edema, and pain.; Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.; Inflammation or infection of the external auditory canal (EAC), the auricle, or both. [http://search.medscape.com/search/?q=otitis%20externa, ORCID:0000-0001-5208-3432]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021919",
-            "NCIT:C79601",
-            "MESH:D010032",
-            "SNOMEDCT:3135009",
-            "MEDDRA:10052558",
-            "NCIT:C3299",
-            "MEDDRA:10021920",
-            "UMLS:C0029878",
-            "UMLS:C0021355",
-            "MEDDRA:10065837",
-            "HP:0410017",
-            "MEDDRA:10033072",
-            "MEDDRA:10082612",
-            "EFO:0009560",
-            "DOID:9463",
-            "ICD9:380.1",
-            "SNOMEDCT:86981007",
-            "MONDO:0004795"
-          ],
-          "id": "MONDO:0004795",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infective otitis externa",
-            "Otitis Externa",
-            "Otitis externa",
-            "otitis externa",
-            "Infectious Otitis Externa"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/otitis_externa",
-            "http://search.medscape.com/search/?q=otitis%20externa",
-            "https://orcid.org/0000-0001-5208-3432"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 314857,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004795",
-              "name": "otitis externa",
-              "description": "Inflammation of the anatomical structures of the outer ear and ear canal, which is most often caused by an infectious process. Symptoms include erythema, edema, and pain.; Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.; Inflammation or infection of the external auditory canal (EAC), the auricle, or both. [http://search.medscape.com/search/?q=otitis%20externa, ORCID:0000-0001-5208-3432]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021919",
-                "NCIT:C79601",
-                "MESH:D010032",
-                "SNOMEDCT:3135009",
-                "MEDDRA:10052558",
-                "NCIT:C3299",
-                "MEDDRA:10021920",
-                "UMLS:C0029878",
-                "UMLS:C0021355",
-                "MEDDRA:10065837",
-                "HP:0410017",
-                "MEDDRA:10033072",
-                "MEDDRA:10082612",
-                "EFO:0009560",
-                "DOID:9463",
-                "ICD9:380.1",
-                "SNOMEDCT:86981007",
-                "MONDO:0004795"
-              ],
-              "id": "MONDO:0004795",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infective otitis externa",
-                "Otitis Externa",
-                "Otitis externa",
-                "otitis externa",
-                "Infectious Otitis Externa"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/otitis_externa",
-                "http://search.medscape.com/search/?q=otitis%20externa",
-                "https://orcid.org/0000-0001-5208-3432"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9345912,
-            "start": 616,
-            "end": 314857,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12019482': {'publication date': '2002', 'sentence': 'The objective of this study was to evaluate and compare the efficacy of topical otic powder, tobramycin drops and ciprofloxacin drops in patients suffering from AEO.', 'subject score': 1000, 'object score': 901}, 'PMID:15529649': {'publication date': '2004 Sep', 'sentence': 'On the basis of our findings, we conclude that the glycerin formulation of ototopical 0.3% ciprofloxacin appears to be at least as effective as the aqueous form in the treatment of acute external otitis--and in the case of otorrhea, more so.', 'subject score': 812, 'object score': 901}, 'PMID:1554468': {'publication date': '1992 Apr', 'sentence': 'Recent studies have shown oral ciprofloxacin to be effective in the treatment of chronic serous otitis media and malignant external otitis.', 'subject score': 888, 'object score': 901}, 'PMID:18314283': {'publication date': '2008 Dec', 'sentence': 'CONCLUSION: Polymixin B, gentamicin or ciprofloxacin topical preparations should be used as first line treatment of otitis externa.', 'subject score': 896, 'object score': 1000}, 'PMID:22810173': {'publication date': '2012 Dec', 'sentence': 'We suggest 3 weeks of initial combination therapy (ceftazidime + ciprofloxacin, high doses) followed by 3 weeks single therapy with ciprofloxacin in susceptible P. aeruginosa NEO.', 'subject score': 1000, 'object score': 839}, 'PMID:2313132': {'publication date': '1990 Mar', 'sentence': 'Twenty-three consecutive patients with malignant external otitis (MEO) were treated with oral ciprofloxacin, 1.5-2.25 g/day for 6 weeks.', 'subject score': 888, 'object score': 901}, 'PMID:23274083': {'publication date': '2014 Jun', 'sentence': 'Investigation of the effectiveness of Syzygium aromaticum, Lavandula angustifolia and Geranium robertianum essential oils in the treatment of acute external otitis: a comparative trial with ciprofloxacin.', 'subject score': 1000, 'object score': 901}, 'PMID:2589357': {'publication date': '1989 Nov 30', 'sentence': 'Ciprofloxacin treatment of malignant external otitis.', 'subject score': 888, 'object score': 901}, 'PMID:29018494': {'publication date': '2017 Oct', 'sentence': 'Objective  The objective of this study is to evaluate the clinical and microbiological efficacy and safety profile with oral ciprofloxacin in the external bacterial otitis (EBO) management.', 'subject score': 888, 'object score': 861}, 'PMID:3177762': {'publication date': '1988 May-Jun', 'sentence': 'This report is the first of which we are aware to document the use of Ciprofloxacin in the treatment of MEO.', 'subject score': 1000, 'object score': 901}, 'PMID:3411213': {'publication date': '1988 Jul', 'sentence': 'The authors report a case of necrotizing external otitis which was successfully treated with ciprofloxacin.', 'subject score': 1000, 'object score': 901}, 'PMID:7805430': {'publication date': '1994', 'sentence': 'Ciprofloxacin thus seems to be a particularly useful antibiotic for the treatment of malignant external otitis, both because of its clinical and bacteriological efficacy and because it is well tolerated.', 'subject score': 1000, 'object score': 901}, 'PMID:8186542': {'publication date': '1994 Feb', 'sentence': 'Initial trials have also indicated therapeutic efficacy of oral ciprofloxacin in malignant external otitis and bacterial prostatitis.', 'subject score': 888, 'object score': 901}, 'PMID:8924287': {'publication date': '1996', 'sentence': '[Prospective double-blind randomized study of the efficacy and tolerance of topical ciprofloxacin vs topical gentamicin in the treatment of simple chronic otitis media and diffuse external otitis].', 'subject score': 861, 'object score': 901}, 'PMID:9484874': {'publication date': '1997 Dec', 'sentence': 'Ciprofloxacin is the drug of choice for malignant external otitis, a disease caused by Pseudomonas aeruginosa, and it has also been used successfully for the treatment of chronic otitis media where P. aeruginosa, S. aureus and Proteus mirabilis are main pathogens.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0029878---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "9552171",
-              "object": "MONDO:0004795",
-              "publications": [
-                "PMID:12019482",
-                "PMID:15529649",
-                "PMID:1554468",
-                "PMID:18314283",
-                "PMID:22810173",
-                "PMID:2313132",
-                "PMID:23274083",
-                "PMID:2589357",
-                "PMID:29018494",
-                "PMID:3177762",
-                "PMID:3411213",
-                "PMID:7805430",
-                "PMID:8186542",
-                "PMID:8924287",
-                "PMID:9484874"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320039,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9299503,
-            "start": 616,
-            "end": 320039,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11967606': {'publication date': '2002 Apr', 'sentence': 'Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough?', 'subject score': 623, 'object score': 888}, 'PMID:15623906': {'publication date': '2004 Dec', 'sentence': 'We conducted a case matched control study to observe the adverse effects of ciprofloxacin used in neonatal septicemia We enrolled 30 neonates with multidrug-resistant septicemia who were treated with intravenous ciprofloxacin for 14 days.', 'subject score': 888, 'object score': 877}, 'PMID:15776347': {'publication date': '2005 Mar 24', 'sentence': 'TREATMENT AND COURSE: Treatment of sepsis with antibiotics (ciprofloxacin, penicillin G, ceftriaxon and erythromycin in standard dosages), activated protein-C, hydrocortisone and GMA-embedded immunoglobulin led to complete cure and restoration of normal autonomic function.', 'subject score': 1000, 'object score': 1000}, 'PMID:15955670': {'publication date': '2005 Jul', 'sentence': 'Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis.', 'subject score': 888, 'object score': 901}, 'PMID:22514473': {'publication date': '1997 Jan', 'sentence': 'INTERVENTION: Comparison of cefepime, ceftazidime, ceftriaxone, cefotaxime and ciprofloxacin in the treatment of lower respiratory tract infections, urinary tract infections, skin/soft tissue infections, septicemia and febrile neutropenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:23052414': {'publication date': '2013 Apr', 'sentence': 'PURPOSE: To describe the use of ciprofloxacin and fluconazole for the treatment of sepsis in European neonatal intensive care units (NICUs) in order to better orient research aimed at acquiring essential knowledge in this critical area.', 'subject score': 1000, 'object score': 1000}, 'PMID:24978586': {'publication date': '2014', 'sentence': 'These data suggest that the combination of ciprofloxacin and cefotaxime is an effective option for the treatment of V. vulnificus sepsis in humans.', 'subject score': 1000, 'object score': 827}, 'PMID:2589376': {'publication date': '1989 Nov 30', 'sentence': 'Although ciprofloxacin was generally well tolerated with minimal side effects and adverse reactions and was efficacious in the treatment of serious septicemic infections caused by gram-negative aerobic bacilli, the development of a resistant K. pneumoniae and the recovery of a resistant P. aeruginosa during therapy in two cases are of concern and deserve further investigation.', 'subject score': 1000, 'object score': 828}, 'PMID:2620671': {'publication date': '1989 Dec', 'sentence': 'Serum levels of ciprofloxacin after single oral doses in patients with septicemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:28971862': {'publication date': '2017 12', 'sentence': 'Efficacy of Ceftriaxone, Cefepime, Doxycycline, Ciprofloxacin, and Combination Therapy for Vibrio vulnificus Foodborne Septicemia.', 'subject score': 1000, 'object score': 824}, 'PMID:2934363': {'publication date': '1985 Nov', 'sentence': 'Multiply resistant Salmonella typhimurium septicaemia in an immunocompromised patient successfully treated with ciprofloxacin.', 'subject score': 1000, 'object score': 798}, 'PMID:3112380': {'publication date': '1987 May', 'sentence': 'Two neutropenic patients with multiple resistant Pseudomonas aeruginosa septicaemia treated with ciprofloxacin.', 'subject score': 1000, 'object score': 840}, 'PMID:31188821': {'publication date': '2019 06', 'sentence': 'Outcomes of Third-Generation Cephalosporin Plus Ciprofloxacin or Doxycycline Therapy in Patients with Vibrio vulnificus Septicemia: A Propensity Score-Matched Analysis.', 'subject score': 875, 'object score': 901}, 'PMID:3325928': {'publication date': '1987 Dec 11', 'sentence': 'Influence of dose frequency on the therapeutic efficacies of ciprofloxacin and ceftazidime in experimental Klebsiella pneumoniae pneumonia and septicemia in relation to their bactericidal activities in vitro.', 'subject score': 1000, 'object score': 1000}, 'PMID:3631942': {'publication date': '1987 Aug', 'sentence': 'However, caution is suggested when this dose of ciprofloxacin is used in situations in which septicemia is caused by P. aeruginosa or S. aureus and originates outside the urinary tract.', 'subject score': 1000, 'object score': 1000}, 'PMID:8089053': {'publication date': '1994 May', 'sentence': 'Serum ciprofloxacin concentrations in patients with severe sepsis being treated with ciprofloxacin 200 mg i.v. bd irrespective of renal function.', 'subject score': 890, 'object score': 888}, 'PMID:9249215': {'publication date': '1997 Jul', 'sentence': 'Dosage reduction of ciprofloxacin in patients with severe sepsis and impaired renal function is not required unless they have co-existent intra-abdominal disease.', 'subject score': 1000, 'object score': 888}, 'PMID:9364293': {'publication date': '1997 Sep-Oct', 'sentence': \"Ciprofloxacin appears to provide a therapeutic option as a ?life-saving' therapy for newborns with sepsis produced by multiply resistant organisms.\", 'subject score': 1000, 'object score': 1000}, 'PMID:9736541': {'publication date': '1998 Sep', 'sentence': 'Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis.', 'subject score': 861, 'object score': 888}, 'PMID:9809826': {'publication date': '1998 Oct', 'sentence': 'Ciprofloxacin has been used to treat neonatal pneumonia, meningitis and septicaemia and was effective in all cases.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0036690---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "9504629",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:11967606",
-                "PMID:15623906",
-                "PMID:15776347",
-                "PMID:15955670",
-                "PMID:22514473",
-                "PMID:23052414",
-                "PMID:24978586",
-                "PMID:2589376",
-                "PMID:2620671",
-                "PMID:28971862",
-                "PMID:2934363",
-                "PMID:3112380",
-                "PMID:31188821",
-                "PMID:3325928",
-                "PMID:3631942",
-                "PMID:8089053",
-                "PMID:9249215",
-                "PMID:9364293",
-                "PMID:9736541",
-                "PMID:9809826"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319601,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005280",
-          "name": "prostatitis",
-          "description": "An infectious or non-infectious inflammatory process affecting the prostate gland.; Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.; The presence of inflammation of the prostate. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10036978",
-            "MONDO:0005280",
-            "EFO:0003830",
-            "HP:0000024",
-            "NCIT:C26866",
-            "SNOMEDCT:9713002",
-            "DOID:14654",
-            "MEDDRA:10036982",
-            "ICD10:N41.9",
-            "MESH:D011472",
-            "ICD9:601.9",
-            "UMLS:C0033581"
-          ],
-          "id": "MONDO:0005280",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Prostatitis",
-            "Prostatitis, unspecified",
-            "prostatitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319601,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005280",
-              "name": "prostatitis",
-              "description": "An infectious or non-infectious inflammatory process affecting the prostate gland.; Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.; The presence of inflammation of the prostate. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10036978",
-                "MONDO:0005280",
-                "EFO:0003830",
-                "HP:0000024",
-                "NCIT:C26866",
-                "SNOMEDCT:9713002",
-                "DOID:14654",
-                "MEDDRA:10036982",
-                "ICD10:N41.9",
-                "MESH:D011472",
-                "ICD9:601.9",
-                "UMLS:C0033581"
-              ],
-              "id": "MONDO:0005280",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Prostatitis",
-                "Prostatitis, unspecified",
-                "prostatitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9079085,
-            "start": 616,
-            "end": 319601,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11751767': {'publication date': '2002 Jan', 'sentence': 'The emergence and evolution of quinolone-resistant Escherichia coli in faeces of patients with prostatitis treated with high-dose oral ciprofloxacin for 1 month were studied.', 'subject score': 861, 'object score': 1000}, 'PMID:21353135': {'publication date': '2011', 'sentence': 'In this case report, we describe a man who developed recurrent depression and suicidal ideation with a serious plan to commit suicide as definite adverse effect of ciprofloxacin, which had been prescribed for recurrent prostatitis.', 'subject score': 1000, 'object score': 888}, 'PMID:24034802': {'publication date': '2013 Sep', 'sentence': 'The overall susceptibility of E. coli to antibiotics recommended in the empiric treatment of pyelonephritis and prostatitis was preserved: ciprofloxacin (95.8%), cefotaxime (98%), gentamicin (99.4%).', 'subject score': 1000, 'object score': 1000}, 'PMID:27054125': {'publication date': '2016', 'sentence': 'CONCLUSION: These results suggested that ginseng might be an effective adjunct in CIPX treatment of prostatitis.', 'subject score': 888, 'object score': 1000}, 'PMID:3325933': {'publication date': '1987 Dec 11', 'sentence': 'Ciprofloxacin may be a useful alternative drug in the treatment of prostatitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3555048': {'publication date': '1987 Apr 27', 'sentence': 'Ciprofloxacin therapy of E. coli prostatitis was a complete success in five of 12 patients, a probable success in two, and in one patient the outcome cannot be judged.', 'subject score': 888, 'object score': 901}, 'PMID:8074560': {'publication date': '1993', 'sentence': '[Use of ciprofloxacin in urinary tract infections and prostatitis].', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0033581---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "9281470",
-              "object": "MONDO:0005280",
-              "publications": [
-                "PMID:11751767",
-                "PMID:21353135",
-                "PMID:24034802",
-                "PMID:27054125",
-                "PMID:3325933",
-                "PMID:3555048",
-                "PMID:8074560"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 853607,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C1112209",
-          "name": "Abdominal Infection",
-          "description": "Infection in the abdominal cavity resulting from injury, acute intestinal inflammation (e.g., acute appendicitis), intestinal perforation, or complication of abdominal surgery.; Infection within the PERITONEAL CAVITY. A frequent cause is an ANASTOMOTIC LEAK following surgery.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D059413",
-            "UMLS:C1112209",
-            "MEDDRA:10056570",
-            "SNOMEDCT:128070006",
-            "NCIT:C35669",
-            "MEDDRA:10056519"
-          ],
-          "id": "UMLS:C1112209",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Abdominal Infection",
-            "Intraabdominal Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 853607,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C1112209",
-              "name": "Abdominal Infection",
-              "description": "Infection in the abdominal cavity resulting from injury, acute intestinal inflammation (e.g., acute appendicitis), intestinal perforation, or complication of abdominal surgery.; Infection within the PERITONEAL CAVITY. A frequent cause is an ANASTOMOTIC LEAK following surgery.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D059413",
-                "UMLS:C1112209",
-                "MEDDRA:10056570",
-                "SNOMEDCT:128070006",
-                "NCIT:C35669",
-                "MEDDRA:10056519"
-              ],
-              "id": "UMLS:C1112209",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Abdominal Infection",
-                "Intraabdominal Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8753729,
-            "start": 616,
-            "end": 853607,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11414382': {'publication date': '2000 Jan', 'sentence': 'Ciprofloxacin is effective in the treatment of serious, non-self-limiting intra-abdominal infections, peritonitis in CAPD, pelvic inflammatory disease, endometritis and gall-bladder infections.', 'subject score': 1000, 'object score': 786}, 'PMID:15598473': {'publication date': '2004 Oct', 'sentence': 'METHODS: We review 2 prospective, comparative clinical trials conducted between 1992 and 2002 that evaluated the efficacy and safety of IV ciprofloxacin in patients with intra-abdominal infections.', 'subject score': 888, 'object score': 983}, 'PMID:33667704': {'publication date': '2021 Mar 02', 'sentence': 'Susceptibility to broad-spectrum antibiotics (metronidazole, meropenem, ciprofloxacin, clindamycin and tetracycline) most commonly used for the treatment of intra-abdominal infections (IAIs) was determined.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C1112209---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8956827",
-              "object": "UMLS:C1112209",
-              "publications": [
-                "PMID:11414382",
-                "PMID:15598473",
-                "PMID:33667704"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 533945,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005945",
-          "name": "rhinoscleroma",
-          "description": "A granulomatous disease caused by KLEBSIELLA RHINOSCLEROMATIS infection. Despite its name, this disease is not limited to the nose and NASOPHARYNX but may affect any part of the RESPIRATORY TRACT, sometimes with extension to the lip and the skin.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:72409005",
-            "MEDDRA:10063391",
-            "DOID:11336",
-            "MONDO:0005945",
-            "MESH:D012226",
-            "EFO:0007470",
-            "MEDDRA:10039102",
-            "UMLS:C0035468",
-            "ICD9:040.1"
-          ],
-          "id": "MONDO:0005945",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Rhinoscleroma",
-            "rhinoscleroma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rhinoscleroma",
-            "http://en.wikipedia.org/wiki/rhinoscleroma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 533945,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005945",
-              "name": "rhinoscleroma",
-              "description": "A granulomatous disease caused by KLEBSIELLA RHINOSCLEROMATIS infection. Despite its name, this disease is not limited to the nose and NASOPHARYNX but may affect any part of the RESPIRATORY TRACT, sometimes with extension to the lip and the skin.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:72409005",
-                "MEDDRA:10063391",
-                "DOID:11336",
-                "MONDO:0005945",
-                "MESH:D012226",
-                "EFO:0007470",
-                "MEDDRA:10039102",
-                "UMLS:C0035468",
-                "ICD9:040.1"
-              ],
-              "id": "MONDO:0005945",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Rhinoscleroma",
-                "rhinoscleroma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=rhinoscleroma",
-                "http://en.wikipedia.org/wiki/rhinoscleroma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8567724,
-            "start": 616,
-            "end": 533945,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11244532': {'publication date': '2001 Mar', 'sentence': 'We report on a young patient with nasal rhinoscleroma who achieved resolution after treatment with oral ciprofloxacin.', 'subject score': 888, 'object score': 888}, 'PMID:33650263': {'publication date': '2021 Mar 02', 'sentence': 'In a series of 23 patients, Topical ciprofloxacin was investigated as a novel option for treatment of rhinoscleroma and was found to be effective in treating the disease in all patients after 12-24 weeks.', 'subject score': 861, 'object score': 1000}, 'PMID:7630299': {'publication date': '1995 Aug', 'sentence': 'Ciprofloxacin may prove to be useful in the therapy of rhinoscleroma because it is convenient for oral administration, achieves good tissue levels, is concentrated in macrophages, and is generally well tolerated as long-term therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:8100894': {'publication date': '1993 Jul 10', 'sentence': 'Ciprofloxacin for rhinoscleroma and ozena.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0035468---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8754779",
-              "object": "MONDO:0005945",
-              "publications": [
-                "PMID:11244532",
-                "PMID:33650263",
-                "PMID:7630299",
-                "PMID:8100894"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317996,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006939",
-          "name": "pyelonephritis",
-          "description": "An inflammatory process affecting the kidney. The cause is most often bacterial, but may also be fungal in nature. Signs and symptoms may include fever, chills, flank pain, painful and frequent urination, cloudy or bloody urine, and confusion.; Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA.; An inflammation of the kidney involving the parenchyma of kidney, the renal pelvis and the kidney calices. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:45816000",
-            "ICD9:590.80",
-            "MEDDRA:10037604",
-            "NCIT:C34965",
-            "MONDO:0006939",
-            "MEDDRA:10037606",
-            "ICD10:N16",
-            "HP:0012330",
-            "DOID:11400",
-            "EFO:1001141",
-            "UMLS:C0034186",
-            "MESH:D011704",
-            "MEDDRA:10037596"
-          ],
-          "id": "MONDO:0006939",
-          "category": "biolink:Disease",
-          "all_names": [
-            "pyelonephritis",
-            "Pyelonephritis",
-            "Pyelonephritis, unspecified"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317996,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006939",
-              "name": "pyelonephritis",
-              "description": "An inflammatory process affecting the kidney. The cause is most often bacterial, but may also be fungal in nature. Signs and symptoms may include fever, chills, flank pain, painful and frequent urination, cloudy or bloody urine, and confusion.; Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA.; An inflammation of the kidney involving the parenchyma of kidney, the renal pelvis and the kidney calices. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:45816000",
-                "ICD9:590.80",
-                "MEDDRA:10037604",
-                "NCIT:C34965",
-                "MONDO:0006939",
-                "MEDDRA:10037606",
-                "ICD10:N16",
-                "HP:0012330",
-                "DOID:11400",
-                "EFO:1001141",
-                "UMLS:C0034186",
-                "MESH:D011704",
-                "MEDDRA:10037596"
-              ],
-              "id": "MONDO:0006939",
-              "category": "biolink:Disease",
-              "all_names": [
-                "pyelonephritis",
-                "Pyelonephritis",
-                "Pyelonephritis, unspecified"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8173809,
-            "start": 616,
-            "end": 317996,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10923561': {'publication date': '2000 Jun', 'sentence': 'Is a 7-day course of ciprofloxacin effective in the treatment of uncomplicated pyelonephritis in women?', 'subject score': 1000, 'object score': 888}, 'PMID:11911553': {'publication date': '2002 Feb', 'sentence': 'OBJECTIVE: This study compared the clinical and bacteriologic efficacy and tolerability of gatifloxacin versus ciprofloxacin in adult patients with complicated UTIs or pyelonephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:12182387': {'publication date': '2002 Jun', 'sentence': 'A 14-year-old girl was seen at a community clinic with a chief complaint of abdominal pain and fevers and was treated with oral ciprofloxacin for presumed pyelonephritis.', 'subject score': 888, 'object score': 861}, 'PMID:14715044': {'publication date': '2004', 'sentence': 'Ciprofloxacin extended release: in the treatment of urinary tract infections and uncomplicated pyelonephritis.', 'subject score': 1000, 'object score': 888}, 'PMID:21410941': {'publication date': '2011 Mar 16', 'sentence': 'CASE PRESENTATION: A 22-year-old African American woman presented with a headache of two weeks duration, visual blurring and horizontal diplopia after starting ciprofloxacin for pyelonephritis.', 'subject score': 872, 'object score': 1000}, 'PMID:2181632': {'publication date': '1990', 'sentence': 'Treatment of experimental Escherichia coli pyelonephritis in rat by ciprofloxacin in comparison with tobramycin.', 'subject score': 1000, 'object score': 861}, 'PMID:22967697': {'publication date': '2012 Sep', 'sentence': 'In uncomplicated pyelonephritis, 19.5% of isolates were resistant to ciprofloxacin and 36.8% to TMP-SMX.', 'subject score': 1000, 'object score': 888}, 'PMID:23367704': {'publication date': '2013 Jan 09', 'sentence': 'The duration of treatment for uncomplicated pyelonephritis can be safely shortened to 7 days when using ciprofloxacin.', 'subject score': 1000, 'object score': 888}, 'PMID:23912522': {'publication date': '2012 Aug', 'sentence': 'CONCLUSIONS: Nitrofurantoin may be the best therapeutic option in first-line management of lower urinary tract infection and ciprofloxacin for pyelonephritis due to its effectiveness and low resistance as seen in primary healthcare practice in Pereira.', 'subject score': 1000, 'object score': 1000}, 'PMID:24034802': {'publication date': '2013 Sep', 'sentence': 'The overall susceptibility of E. coli to antibiotics recommended in the empiric treatment of pyelonephritis and prostatitis was preserved: ciprofloxacin (95.8%), cefotaxime (98%), gentamicin (99.4%).', 'subject score': 1000, 'object score': 1000}, 'PMID:25339200': {'publication date': '2015 Mar', 'sentence': 'Ciprofloxacin and cotrimoxazole are recommended to treat uncomplicated pyelonephritis and uncomplicated cystitis, respectively, provided that local resistance rates of uropathogens do not exceed specified thresholds (10 and 20 %, respectively).', 'subject score': 1000, 'object score': 888}, 'PMID:28216442': {'publication date': '2017 07', 'sentence': 'CONCLUSIONS: Our findings suggest that 7 days of TMP-SMX therapy may result in similar clinical outcomes compared with 7 days of ciprofloxacin for the treatment of pyelonephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:29253561': {'publication date': '2018 Apr', 'sentence': 'Pivmecillinam achieved success in patients with A. urinae cystitis and ciprofloxacin in patients with pyelonephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:29271346': {'publication date': '2017 12 15', 'sentence': 'Uncomplicated pyelonephritis with a mild to moderate clinical course ought to be treated with oral cefpodoxime, ceftibuten, ciprofloxacin, or levofloxacin.', 'subject score': 1000, 'object score': 888}, 'PMID:2943665': {'publication date': '1986 Jul', 'sentence': '[Ciprofloxacin and cefotaxim: pharmacokinetic and therapeutic effectiveness in E. coli pyelonephritis in rats].', 'subject score': 1000, 'object score': 901}, 'PMID:29539622': {'publication date': '2018', 'sentence': 'Mild to moderate uncomplicated pyelonephritis should be treated with oral cefpodoxime, ceftibuten, ciprofloxacin, or levofloxacin.', 'subject score': 1000, 'object score': 875}, 'PMID:31023585': {'publication date': '2019 Apr 09', 'sentence': 'Antibiotic selection and isolate susceptibility profile in patients who failed ciprofloxacin or TMP-SMX for pyelonephritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:32442937': {'publication date': '2020', 'sentence': 'In women, cystitis can be treated with nitrofurantoin, cephalexin or fosfomycin, while trimethoprim-sulfamethoxazole and fluoroquinolones are not recommended; pyelonephritis can be treated with ciprofloxacin, cefixime or cephalexin in ambulatory women or ceftriaxone, cefazolin or amikacin in those who are hospitalized.', 'subject score': 1000, 'object score': 1000}, 'PMID:3325927': {'publication date': '1987 Dec 11', 'sentence': 'In the treatment of the pyelonephritis, ciprofloxacin was clearly superior to the other agents, both with respect to the percentage of sterile kidneys after treatment as with respect to the mean numbers of bacteria per kidney.', 'subject score': 1000, 'object score': 1000}, 'PMID:34167484': {'publication date': '2021 Jun 24', 'sentence': 'Treatment of pyelonephritis was characterized by more use of broader-spectrum antibiotics, use of both sulfamethoxazole-trimethoprim and ciprofloxacin increased during the study period.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0034186---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8350437",
-              "object": "MONDO:0006939",
-              "publications": [
-                "PMID:10923561",
-                "PMID:11911553",
-                "PMID:12182387",
-                "PMID:14715044",
-                "PMID:21410941",
-                "PMID:2181632",
-                "PMID:22967697",
-                "PMID:23367704",
-                "PMID:23912522",
-                "PMID:24034802",
-                "PMID:25339200",
-                "PMID:28216442",
-                "PMID:29253561",
-                "PMID:29271346",
-                "PMID:2943665",
-                "PMID:29539622",
-                "PMID:31023585",
-                "PMID:32442937",
-                "PMID:3325927",
-                "PMID:34167484"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 315382,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-          "name": "bacterial infectious disease with sepsis",
-          "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C102993",
-            "ICD9:995.91",
-            "MONDO:0005229",
-            "MEDDRA:10060562",
-            "MEDDRA:10003998",
-            "MEDDRA:10003997",
-            "MEDDRA:10045641",
-            "ICD9:790.7",
-            "MEDDRA:10045642",
-            "HP:0031864",
-            "SNOMEDCT:5758002",
-            "DOID:0040085",
-            "MESH:D016470",
-            "UMLS:C0004610",
-            "MEDDRA:10003999"
-          ],
-          "id": "MONDO:0005229",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacteremia",
-            "bacterial infectious disease with sepsis",
-            "bacterial sepsis",
-            "Sepsis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:20421654"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315382,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-              "name": "bacterial infectious disease with sepsis",
-              "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C102993",
-                "ICD9:995.91",
-                "MONDO:0005229",
-                "MEDDRA:10060562",
-                "MEDDRA:10003998",
-                "MEDDRA:10003997",
-                "MEDDRA:10045641",
-                "ICD9:790.7",
-                "MEDDRA:10045642",
-                "HP:0031864",
-                "SNOMEDCT:5758002",
-                "DOID:0040085",
-                "MESH:D016470",
-                "UMLS:C0004610",
-                "MEDDRA:10003999"
-              ],
-              "id": "MONDO:0005229",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacteremia",
-                "bacterial infectious disease with sepsis",
-                "bacterial sepsis",
-                "Sepsis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:20421654"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8161469,
-            "start": 616,
-            "end": 315382,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10913427': {'publication date': '2000 Jul', 'sentence': 'Despite prolonged bacteremia, the response to long-term therapy with ciprofloxacin and rifampin was excellent.', 'subject score': 1000, 'object score': 888}, 'PMID:12324938': {'publication date': '2002 Oct', 'sentence': 'In one patient, bacteremia persisted after ciprofloxacin therapy and was cleared only by removal of the dialysis catheter and a 3-week course of gentamicin.', 'subject score': 888, 'object score': 1000}, 'PMID:12423618': {'publication date': '2002 Nov', 'sentence': 'Shigella flexneri bacteraemia in an immunocompetent male treated with oral ciprofloxacin.', 'subject score': 888, 'object score': 802}, 'PMID:12951354': {'publication date': '2003 Oct', 'sentence': 'CONCLUSION: Pharmacodynamic considerations including aggressive dosing with targeted peak/MICs for aminoglycosides and ciprofloxacin are strongly associated with clinical outcome and essential to the appropriate management of P. aeruginosa bacteraemia.', 'subject score': 1000, 'object score': 901}, 'PMID:1387303': {'publication date': '1992 Jul', 'sentence': 'A combination of clarithromycin, ciprofloxacin, and amikacin for the treatment of Mycobacterium avium-Mycobacterium intracellulare bacteremia was evaluated in 12 AIDS patients.', 'subject score': 1000, 'object score': 841}, 'PMID:15140397': {'publication date': '2004', 'sentence': 'A total of 80 (60.2%) patients experienced bacteremia due to strains resistant to ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:1775838': {'publication date': '1991 Nov-Dec', 'sentence': 'To the best of our knowledge, this is the first documented case of symptomatic bacteremia due to C. cinaedi that was successfully treated with ciprofloxacin.', 'subject score': 1000, 'object score': 888}, 'PMID:18036218': {'publication date': '2007 Nov 23', 'sentence': 'The bacteremic episodes were successfully treated with netilmicin, doxycycline and ciprofloxacin.', 'subject score': 1000, 'object score': 853}, 'PMID:19487049': {'publication date': '2009 Nov', 'sentence': 'CONCLUSION: P aeruginosa bacteremic isolates from patients who have been exposed to ciprofloxacin during the 30 days prior to the development of bacteremia have an increased risk of being resistant to ceftazidime, imipenem, meropenem, piperacillin-tazobactam, or ciprofloxacin and to have multidrug resistance.', 'subject score': 1000, 'object score': 1000}, 'PMID:21437168': {'publication date': '2011 Mar', 'sentence': 'CONCLUSIONS: These data indicate a close association between ciprofloxacin resistance and ESBL-production in P. mirabilis bacteremia.', 'subject score': 694, 'object score': 851}, 'PMID:2210856': {'publication date': '1990 Jul-Aug', 'sentence': 'Ciprofloxacin in the treatment of nosocomial multiply resistant Acinetobacter calcoaceticus bacteremia.', 'subject score': 1000, 'object score': 767}, 'PMID:2490638': {'publication date': '1989 Jan', 'sentence': 'The results of efficacy and safety of ciprofloxacin administered by parenteral and oral route in the treatment of severe infections-particularly, osteomyelitis and bacteremia-due to gram-negative bacilli are studied in the present work.', 'subject score': 1000, 'object score': 1000}, 'PMID:2504407': {'publication date': '1989 Jul 29', 'sentence': 'OBJECTIVE: To define an outbreak of bacteraemia due to coagulase negative staphylococci highly resistant to ciprofloxacin in a leukaemia unit, investigate the source and mode of spread of the outbreak strain, and assess control measures.', 'subject score': 1000, 'object score': 1000}, 'PMID:34722367': {'publication date': '2021 Sep', 'sentence': 'We aimed to assess the clinical success following high-dose ciprofloxacin for recurrent bacteremia from biofilm-forming multidrug resistant    Klebsiella pneumoniae     in a liver transplanted patient.', 'subject score': 901, 'object score': 888}, 'PMID:8056702': {'publication date': '1994 Apr', 'sentence': 'Bacteraemia developed in six of 78 episodes (8%) treated with ciprofloxacin, in eight of 80 (10%) allocated to ofloxacin and in 12 of 77 (16%) when pefloxacin was given.', 'subject score': 1000, 'object score': 1000}, 'PMID:8192181': {'publication date': '1994 May', 'sentence': 'Streptococcus sanguis bacteremia during ciprofloxacin therapy of a diabetic foot ulcer.', 'subject score': 888, 'object score': 901}, 'PMID:8448312': {'publication date': '1993 Jan', 'sentence': 'Oral ciprofloxacin therapy for Bacillus cereus wound infection and bacteremia.', 'subject score': 851, 'object score': 1000}, 'PMID:8676931': {'publication date': '1996 Aug 08', 'sentence': 'CONCLUSIONS: In patients with AIDS and M. avium complex bacteremia, treatment with the three-drug regimen of rifabutin, ethambutol, and clarithromycin leads to resolution of the bacteremia more frequently and more rapidly than treatment with rifampin, ethambutol, clofazimine, and ciprofloxacin, and survival rates are better.', 'subject score': 1000, 'object score': 802}, 'PMID:9096194': {'publication date': '1997 Mar', 'sentence': 'Rates of resistance to ciprofloxacin and other antimicrobial agents commonly used to treat bacteraemic infections have remained relatively low in this Canadian teaching hospital over the past 16 years.', 'subject score': 1000, 'object score': 853}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0004610---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8337570",
-              "object": "MONDO:0005229",
-              "publications": [
-                "PMID:10913427",
-                "PMID:12324938",
-                "PMID:12423618",
-                "PMID:12951354",
-                "PMID:1387303",
-                "PMID:15140397",
-                "PMID:1775838",
-                "PMID:18036218",
-                "PMID:19487049",
-                "PMID:21437168",
-                "PMID:2210856",
-                "PMID:2490638",
-                "PMID:2504407",
-                "PMID:34722367",
-                "PMID:8056702",
-                "PMID:8192181",
-                "PMID:8448312",
-                "PMID:8676931",
-                "PMID:9096194"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 516221,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001475",
-          "name": "neutropenia",
-          "description": "A decrease in the number of NEUTROPHILS found in the blood.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10029355",
-            "MEDDRA:10029354",
-            "SNOMEDCT:303011007",
-            "MONDO:0001475",
-            "DOID:1227",
-            "MESH:D009503",
-            "UMLS:C0027947",
-            "PDQ:CDR0000041387",
-            "ICD9:288.0"
-          ],
-          "id": "MONDO:0001475",
-          "category": "biolink:Disease",
-          "all_names": [
-            "neutropenia",
-            "Neutropenia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 516221,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001475",
-              "name": "neutropenia",
-              "description": "A decrease in the number of NEUTROPHILS found in the blood.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10029355",
-                "MEDDRA:10029354",
-                "SNOMEDCT:303011007",
-                "MONDO:0001475",
-                "DOID:1227",
-                "MESH:D009503",
-                "UMLS:C0027947",
-                "PDQ:CDR0000041387",
-                "ICD9:288.0"
-              ],
-              "id": "MONDO:0001475",
-              "category": "biolink:Disease",
-              "all_names": [
-                "neutropenia",
-                "Neutropenia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8022474,
-            "start": 616,
-            "end": 516221,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10811678': {'publication date': '2000 May', 'sentence': 'The proportion of patients who developed neutropenia and fever was 87% in the group treated with ciprofloxacin and 78% in the group treated with ciprofloxacin and rifampin (P =.25).', 'subject score': 1000, 'object score': 1000}, 'PMID:11777658': {'publication date': '2001 Dec', 'sentence': 'Isolates of MSSA showed lower levels of susceptibility to ciprofloxacin (61-77% susceptibility) in both cystic fibrosis and neutropenia patients, and particularly high levels of resistance to ceftazidime (38% susceptibility) in cystic fibrosis units.', 'subject score': 1000, 'object score': 888}, 'PMID:14688588': {'publication date': '2003 Dec', 'sentence': 'Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:1473367': {'publication date': '1992', 'sentence': '58 granulocytopenic patients with confirmed bronchopneumonia were divided retrospectively into two groups for this pilot study: group 1 included neutropenic patients with venous catheters who were treated with ciprofloxacin (CIP; 200-300 mg, i.v. b.i.d.)', 'subject score': 1000, 'object score': 767}, 'PMID:15796186': {'publication date': '2005', 'sentence': 'Our objective was to evaluate the in vivo activity of trovafloxacin and ciprofloxacin against murine leukemic cells in neutropenic mice with lung infection due to Klebsiella pneumoniae.', 'subject score': 1000, 'object score': 853}, 'PMID:16966275': {'publication date': '2006 Aug', 'sentence': 'The present study was designed to evaluate the benefit of intravenous ciprofloxacin for neutropenic patients with fever who were refractory to initial therapy given for the first 3 days.', 'subject score': 888, 'object score': 853}, 'PMID:1912558': {'publication date': '1991 Oct 01', 'sentence': 'These studies indicate that ciprofloxacin may have an immune-enhancing effect on the hematopoietic system in neutropenic mice.', 'subject score': 1000, 'object score': 853}, 'PMID:2292537': {'publication date': '1990 Dec', 'sentence': 'One infection-related death occurred 30 h after starting ciprofloxacin, and a further three patients died before the resolution of neutropenia.', 'subject score': 872, 'object score': 1000}, 'PMID:2292538': {'publication date': '1990 Dec', 'sentence': 'Prevention of infection by ciprofloxacin in neutropenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:2599653': {'publication date': '1989', 'sentence': 'The in vivo activity of ciprofloxacin against Pseudomonas aeruginosa was studied in a septicemia model in neutropenic mice and compared to that of other antibiotics with established activity against P. aeruginosa.', 'subject score': 1000, 'object score': 853}, 'PMID:2653217': {'publication date': '1989 Jan', 'sentence': 'To assess the efficacy of ciprofloxacin in neutropenic patients, we conducted a randomized prospective trial comparing the combination of ciprofloxacin and netilmicin against piperacillin plus netilmicin as an empiric treatment of fever in cancer patients with neutropenia.', 'subject score': 1000, 'object score': 853}, 'PMID:27771837': {'publication date': '2017 Feb', 'sentence': 'Bacteremia during neutropenic episodes in children undergoing hematopoietic stem cell transplantation with ciprofloxacin and penicillin prophylaxis.', 'subject score': 1000, 'object score': 853}, 'PMID:8133717': {'publication date': '1994 Jan 29', 'sentence': '[Prophylaxis with ciprofloxacin in postchemotherapy neutropenia in acute myeloid leukemia].', 'subject score': 1000, 'object score': 901}, 'PMID:8418159': {'publication date': '1993 Jan', 'sentence': 'Efficacy of anti-endotoxin monoclonal antibody E5 alone or in combination with ciprofloxacin in neutropenic rats with Pseudomonas sepsis.', 'subject score': 1000, 'object score': 853}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0027947---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8194797",
-              "object": "MONDO:0001475",
-              "publications": [
-                "PMID:10811678",
-                "PMID:11777658",
-                "PMID:14688588",
-                "PMID:1473367",
-                "PMID:15796186",
-                "PMID:16966275",
-                "PMID:1912558",
-                "PMID:2292537",
-                "PMID:2292538",
-                "PMID:2599653",
-                "PMID:2653217",
-                "PMID:27771837",
-                "PMID:8133717",
-                "PMID:8418159"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319329,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004522",
-          "name": "peritonitis",
-          "description": "Inflammation of the peritoneum due to infection by bacteria or fungi. Causes include liver disease, perforation of the gastrointestinal tract or biliary tract, and peritoneal dialysis. Patients usually present with abdominal pain and tenderness, fever, chills, and nausea and vomiting. It is an emergency medical condition that requires prompt medical attention and treatment.; INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.; Inflammation of the peritoneum. [HPO:probinson]; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "UMLS:C0029823",
-            "MESH:D010538",
-            "MEDDRA:10034685",
-            "MEDDRA:10085062",
-            "SYMP:0000102",
-            "EFO:0008588",
-            "DOID:8283",
-            "HP:0002586",
-            "ICD9:567.8",
-            "MEDDRA:10046096",
-            "UMLS:C0267770",
-            "SNOMEDCT:86422009",
-            "MONDO:0004522",
-            "MEDDRA:10034674",
-            "ICD9:567.89",
-            "UMLS:C0031154",
-            "SNOMEDCT:48661000",
-            "NCIT:C26849"
-          ],
-          "id": "MONDO:0004522",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peritonitis",
-            "Other specified peritonitis",
-            "peritonitis",
-            "Retractile Mesenteritis"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www.merck.com/mmpe/sec02/ch011/ch011b.html#sec02-ch011-ch011b-402",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=peritonitis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/001335.htm",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319329,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004522",
-              "name": "peritonitis",
-              "description": "Inflammation of the peritoneum due to infection by bacteria or fungi. Causes include liver disease, perforation of the gastrointestinal tract or biliary tract, and peritoneal dialysis. Patients usually present with abdominal pain and tenderness, fever, chills, and nausea and vomiting. It is an emergency medical condition that requires prompt medical attention and treatment.; INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.; Inflammation of the peritoneum. [HPO:probinson]; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "UMLS:C0029823",
-                "MESH:D010538",
-                "MEDDRA:10034685",
-                "MEDDRA:10085062",
-                "SYMP:0000102",
-                "EFO:0008588",
-                "DOID:8283",
-                "HP:0002586",
-                "ICD9:567.8",
-                "MEDDRA:10046096",
-                "UMLS:C0267770",
-                "SNOMEDCT:86422009",
-                "MONDO:0004522",
-                "MEDDRA:10034674",
-                "ICD9:567.89",
-                "UMLS:C0031154",
-                "SNOMEDCT:48661000",
-                "NCIT:C26849"
-              ],
-              "id": "MONDO:0004522",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peritonitis",
-                "Other specified peritonitis",
-                "peritonitis",
-                "Retractile Mesenteritis"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www.merck.com/mmpe/sec02/ch011/ch011b.html#sec02-ch011-ch011b-402",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=peritonitis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/001335.htm",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8018541,
-            "start": 616,
-            "end": 319329,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10809245': {'publication date': '2000', 'sentence': 'Peritonitis due to S. aureus ESI was significantly less frequent among patients treated with ciprofloxacin (1 vs 9 cases, p = 0.001).', 'subject score': 1000, 'object score': 1000}, 'PMID:11330568': {'publication date': '2001 Mar-Apr', 'sentence': 'Oral ciprofloxacin is ineffective in culture-negative peritonitis.', 'subject score': 888, 'object score': 901}, 'PMID:1304132': {'publication date': '1992 Dec', 'sentence': 'Forty two patients with general peritonitis were treated with ciprofloxacin and combinations of various antimicrobial drugs.', 'subject score': 1000, 'object score': 888}, 'PMID:15490984': {'publication date': '2004', 'sentence': 'OBJECTIVES: (1) To determine the pharmacokinetics of oral ciprofloxacin in CCPD patients, (2) to compare serum and dialysate ciprofloxacin concentrations with minimum inhibitory concentrations (MIC) of the gram-negative bacteria associated with peritonitis, and (3) to establish oral ciprofloxacin dosing guidelines for the empirical treatment of peritonitis in patients receiving CCPD.', 'subject score': 851, 'object score': 1000}, 'PMID:1769932': {'publication date': '1991 Jul', 'sentence': 'Low dose intraperitoneal ciprofloxacin for the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD).', 'subject score': 861, 'object score': 1000}, 'PMID:17984438': {'publication date': '2007 Nov-Dec', 'sentence': 'Ciprofloxacin for peritonitis due to gram-negative rods?', 'subject score': 1000, 'object score': 1000}, 'PMID:1912018': {'publication date': '1991', 'sentence': 'Ciprofloxacin in the treatment of gram-positive bacterial peritonitis in patients undergoing CAPD.', 'subject score': 1000, 'object score': 892}, 'PMID:19458304': {'publication date': '2009', 'sentence': 'AIM: To analyze the results of a protocol of treatment of PD-related peritonitis with ciprofloxacin, maintained over two decades.', 'subject score': 1000, 'object score': 861}, 'PMID:1982789': {'publication date': '1990', 'sentence': 'We conclude that ciprofloxacin may be useful for the treatment of CAPD peritonitis.', 'subject score': 1000, 'object score': 888}, 'PMID:2197264': {'publication date': '1990 May', 'sentence': 'Ciprofloxacin was evaluated as single-agent therapy for the empirical treatment of patients presenting with CAPD peritonitis in an open, uncontrolled trial.', 'subject score': 1000, 'object score': 928}, 'PMID:2209631': {'publication date': '1990 Aug', 'sentence': 'Pseudomonas paucimobilis peritonitis in a patient on CAPD successfully treated with ciprofloxacin and netilmicin.', 'subject score': 1000, 'object score': 901}, 'PMID:2211442': {'publication date': '1990 Jul', 'sentence': 'Short course ciprofloxacin therapy for CAPD peritonitis.', 'subject score': 833, 'object score': 888}, 'PMID:2292546': {'publication date': '1990 Dec', 'sentence': 'The advantages of oral drug administration indicate that oral ciprofloxacin is the preferred first-line treatment of CAPD-associated peritonitis.', 'subject score': 888, 'object score': 802}, 'PMID:2292547': {'publication date': '1990 Dec', 'sentence': 'Fifty-one patients were included in a prospective, randomized comparison of oral ciprofloxacin and intraperitoneal vancomycin/gentamicin in the treatment of CAPD peritonitis.', 'subject score': 888, 'object score': 888}, 'PMID:2292548': {'publication date': '1990 Dec', 'sentence': 'A comparison between intraperitoneal ciprofloxacin and intraperitoneal vancomycin and gentamicin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD).', 'subject score': 888, 'object score': 1000}, 'PMID:2338420': {'publication date': '1990 Mar', 'sentence': 'Overall a single course of oral ciprofloxacin was 76% successful as a first-line treatment for CAPD-associated peritonitis, caused by a wide range of organisms.', 'subject score': 888, 'object score': 802}, 'PMID:2510089': {'publication date': '1989', 'sentence': 'Treatment of CAPD peritonitis with oral ciprofloxacin.', 'subject score': 888, 'object score': 888}, 'PMID:2613610': {'publication date': '1989 Oct', 'sentence': 'Intraperitoneal treatment of CAPD peritonitis with ciprofloxacin.', 'subject score': 1000, 'object score': 888}, 'PMID:28360373': {'publication date': '2017 Mar-Apr', 'sentence': 'We herein report a case of peritonitis due to M. morganii resistant to third-generation cephalosporins, which was treated successfully with intraperitoneal (IP) tobramycin followed by oral ciprofloxacin.', 'subject score': 888, 'object score': 1000}, 'PMID:29437143': {'publication date': '2018 Jul-Aug', 'sentence': 'Treatment of Acinetobacter peritonitis with gentamicin, ciprofloxacin, or ceftazidime achieved comparable outcomes.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0031154---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8190776",
-              "object": "MONDO:0004522",
-              "publications": [
-                "PMID:10809245",
-                "PMID:11330568",
-                "PMID:1304132",
-                "PMID:15490984",
-                "PMID:1769932",
-                "PMID:17984438",
-                "PMID:1912018",
-                "PMID:19458304",
-                "PMID:1982789",
-                "PMID:2197264",
-                "PMID:2209631",
-                "PMID:2211442",
-                "PMID:2292546",
-                "PMID:2292547",
-                "PMID:2292548",
-                "PMID:2338420",
-                "PMID:2510089",
-                "PMID:2613610",
-                "PMID:28360373",
-                "PMID:29437143"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 212250,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-          "name": "Fever",
-          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10037660",
-            "MEDDRA:10020083",
-            "MEDDRA:10005911",
-            "UMLS:C0015967",
-            "HP:0001945",
-            "NCIT:C3038",
-            "MEDDRA:10073718",
-            "MEDDRA:10043204",
-            "MEDDRA:10037668",
-            "PDQ:CDR0000775882",
-            "PSY:19660",
-            "SNOMEDCT:386661006",
-            "MEDDRA:10016558",
-            "MEDDRA:10037663",
-            "SNOMEDCT:50177009",
-            "SYMP:0000613",
-            "MESH:D005334"
-          ],
-          "id": "HP:0001945",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "fever",
-            "Fever"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:9759682",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 212250,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-              "name": "Fever",
-              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10037660",
-                "MEDDRA:10020083",
-                "MEDDRA:10005911",
-                "UMLS:C0015967",
-                "HP:0001945",
-                "NCIT:C3038",
-                "MEDDRA:10073718",
-                "MEDDRA:10043204",
-                "MEDDRA:10037668",
-                "PDQ:CDR0000775882",
-                "PSY:19660",
-                "SNOMEDCT:386661006",
-                "MEDDRA:10016558",
-                "MEDDRA:10037663",
-                "SNOMEDCT:50177009",
-                "SYMP:0000613",
-                "MESH:D005334"
-              ],
-              "id": "HP:0001945",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "fever",
-                "Fever"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:9759682",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7918463,
-            "start": 616,
-            "end": 212250,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:10738231': {'publication date': '2000 Apr 01', 'sentence': 'In the current study, the authors examined the use of ciprofloxacin as outpatient management in selected patients with fever during an episode of neutropenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:10811678': {'publication date': '2000 May', 'sentence': 'The proportion of patients who developed neutropenia and fever was 87% in the group treated with ciprofloxacin and 78% in the group treated with ciprofloxacin and rifampin (P =.25).', 'subject score': 1000, 'object score': 1000}, 'PMID:12182387': {'publication date': '2002 Jun', 'sentence': 'A 14-year-old girl was seen at a community clinic with a chief complaint of abdominal pain and fevers and was treated with oral ciprofloxacin for presumed pyelonephritis.', 'subject score': 888, 'object score': 1000}, 'PMID:1388120': {'publication date': '1992 Jun', 'sentence': 'Teicoplanin plus ciprofloxacin was compared with gentamicin plus piperacillin for the empirical treatment of fever in 80 neutropenic patients.', 'subject score': 851, 'object score': 1000}, 'PMID:1399929': {'publication date': '1992 Aug', 'sentence': 'A prospective, randomized trial comparing monotherapy with high-dose ciprofloxacin versus a standard combination regimen of azlocillin and netilmicin in the empirical treatment of febrile episodes in neutropenic patients was performed.', 'subject score': 901, 'object score': 888}, 'PMID:1411313': {'publication date': '1992', 'sentence': 'Thus, this pilot study indicates that piperacillin and ciprofloxacin may be a safe and effective combination for the treatment of febrile episodes in severely neutropenic leukemia patients, which merits further investigation in randomized trials.', 'subject score': 1000, 'object score': 888}, 'PMID:14688588': {'publication date': '2003 Dec', 'sentence': 'Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:15380025': {'publication date': '2004 Sep 20', 'sentence': 'Two continued on oral or IV ciprofloxacin alone but had prolonged fevers of 9-10 days duration, one was switched to IV beta-lactam therapy after remaining febrile for 3 days on oral/IV ciprofloxacin and one was treated successfully with oral ciprofloxacin.', 'subject score': 888, 'object score': 1000}, 'PMID:16966275': {'publication date': '2006 Aug', 'sentence': 'The present study was designed to evaluate the benefit of intravenous ciprofloxacin for neutropenic patients with fever who were refractory to initial therapy given for the first 3 days.', 'subject score': 888, 'object score': 1000}, 'PMID:18611695': {'publication date': '1995 Dec', 'sentence': 'Absorption of ciprofloxacin in febrile and afebrile patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:2108911': {'publication date': '1990', 'sentence': 'In a randomized study comparing cotrimoxazole plus colistin with ciprofloxacin, each in combination with nonabsorbable antimycotics, the incidence of major infections in terms of septicemias and pneumonias as well as of minor infections and episodes of unexplained fever (FUO) was higher in patients treated with ciprofloxacin.', 'subject score': 1000, 'object score': 861}, 'PMID:2149044': {'publication date': '1990 Dec', 'sentence': 'We compared the combination of teicoplanin plus ciprofloxacin with gentamicin plus piperacillin for the empirical treatment of fever in 80 neutropenic patients.', 'subject score': 851, 'object score': 1000}, 'PMID:2180889': {'publication date': '1990 Jan', 'sentence': 'We examined the efficacy of ciprofloxacin as an empirical treatment for fever in 97 neutropenic patients in a randomized study of ciprofloxacin and benzylpenicillin versus netilmicin and piperacillin.', 'subject score': 1000, 'object score': 1000}, 'PMID:2292537': {'publication date': '1990 Dec', 'sentence': 'We conclude that high-dose intravenous ciprofloxacin may be safely employed as monotherapy in the empirical treatment of febrile episodes in neutropenic patients.', 'subject score': 861, 'object score': 888}, 'PMID:25193180': {'publication date': '2014 Oct 15', 'sentence': 'After 24h, the dog was found to have a high fever (39.5  degrees C) and was treated empirically with doxycycline/ciprofloxacin.', 'subject score': 888, 'object score': 888}, 'PMID:2653217': {'publication date': '1989 Jan', 'sentence': 'To assess the efficacy of ciprofloxacin in neutropenic patients, we conducted a randomized prospective trial comparing the combination of ciprofloxacin and netilmicin against piperacillin plus netilmicin as an empiric treatment of fever in cancer patients with neutropenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:2941290': {'publication date': '1986 Apr', 'sentence': 'The duration of fever in patients treated with ciprofloxacin was 1.5 days versus 2.3 days in the placebo group; the difference was not statistically significant.', 'subject score': 1000, 'object score': 1000}, 'PMID:32380974': {'publication date': '2020 May 07', 'sentence': 'The initial antibiotic therapy with ceftriaxone/doxycycline was switched to ciprofloxacin, resulting in the resolution of fever and symptoms.', 'subject score': 1000, 'object score': 1000}, 'PMID:32435805': {'publication date': '2020 May 21', 'sentence': 'RESULTS: Challenged animals all developed fever within 78 hours and were treated with ciprofloxacin (n = 27) or levofloxacin (n = 29) at various predetermined time points postfever.', 'subject score': 1000, 'object score': 861}, 'PMID:3468101': {'publication date': '1986 Nov', 'sentence': 'Twenty-four episodes of fever in neutropenic patients with haematological malignancy were treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0015967---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8088120",
-              "object": "HP:0001945",
-              "publications": [
-                "PMID:10738231",
-                "PMID:10811678",
-                "PMID:12182387",
-                "PMID:1388120",
-                "PMID:1399929",
-                "PMID:1411313",
-                "PMID:14688588",
-                "PMID:15380025",
-                "PMID:16966275",
-                "PMID:18611695",
-                "PMID:2108911",
-                "PMID:2149044",
-                "PMID:2180889",
-                "PMID:2292537",
-                "PMID:25193180",
-                "PMID:2653217",
-                "PMID:2941290",
-                "PMID:32380974",
-                "PMID:32435805",
-                "PMID:3468101"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319037,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005246",
-          "name": "osteomyelitis",
-          "description": "An acute or chronic infectious process affecting the bones.; Osteomyelitis is an inflammatory process accompanied by bone destruction and caused by an infecting microorganism. [HPO:probinson, PMID:15276398]; Like other parts of the body, bones can get infected. The infections are usually bacterial, but can also be fungal. They may spread to the bone from nearby skin or muscles, or from another part of the body through the bloodstream. People who are at risk for bone infections include those with diabetes, poor circulation, or recent injury to the bone. You may also be at risk if you are having hemodialysis.  Symptoms of bone infections include: Pain in the infected area Chills and fever Swelling, warmth, and redness  A blood test or imaging test such as an x-ray can tell if you have a bone infection. Treatment includes antibiotics and often surgery.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0008707",
-            "MEDDRA:10045927",
-            "MEDDRA:10031257",
-            "MEDDRA:10046086",
-            "SNOMEDCT:111253001",
-            "SNOMEDCT:40970001",
-            "UMLS:C2242472",
-            "MEDDRA:10031252",
-            "MEDDRA:10009091",
-            "HP:0002754",
-            "DOID:1019",
-            "UMLS:C0029443",
-            "NCIT:C26839",
-            "MESH:D010019",
-            "EFO:0003102",
-            "MEDDRA:10031259",
-            "MONDO:0005246",
-            "MEDDRA:10005977",
-            "MEDDRA:10031256",
-            "SNOMEDCT:60168000",
-            "MEDDRA:10061017",
-            "MEDDRA:10045936",
-            "MEDDRA:10009081",
-            "NCIT:C27577",
-            "ICD9:730.1",
-            "MEDDRA:10046076"
-          ],
-          "id": "MONDO:0005246",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteomyelitis",
-            "Chronic osteomyelitis",
-            "osteomyelitis",
-            "Bone Infection",
-            "Infection of bone"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://my.clevelandclinic.org/disorders/osteomyelitis/hic_osteomyelitis.aspx",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://en.wikipedia.org/wiki/osteomyelitis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000437.htm",
-            "http://www.mayoclinic.com/health/osteomyelitis/ds00759",
-            "PMID:15276398",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319037,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005246",
-              "name": "osteomyelitis",
-              "description": "An acute or chronic infectious process affecting the bones.; Osteomyelitis is an inflammatory process accompanied by bone destruction and caused by an infecting microorganism. [HPO:probinson, PMID:15276398]; Like other parts of the body, bones can get infected. The infections are usually bacterial, but can also be fungal. They may spread to the bone from nearby skin or muscles, or from another part of the body through the bloodstream. People who are at risk for bone infections include those with diabetes, poor circulation, or recent injury to the bone. You may also be at risk if you are having hemodialysis.  Symptoms of bone infections include: Pain in the infected area Chills and fever Swelling, warmth, and redness  A blood test or imaging test such as an x-ray can tell if you have a bone infection. Treatment includes antibiotics and often surgery.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0008707",
-                "MEDDRA:10045927",
-                "MEDDRA:10031257",
-                "MEDDRA:10046086",
-                "SNOMEDCT:111253001",
-                "SNOMEDCT:40970001",
-                "UMLS:C2242472",
-                "MEDDRA:10031252",
-                "MEDDRA:10009091",
-                "HP:0002754",
-                "DOID:1019",
-                "UMLS:C0029443",
-                "NCIT:C26839",
-                "MESH:D010019",
-                "EFO:0003102",
-                "MEDDRA:10031259",
-                "MONDO:0005246",
-                "MEDDRA:10005977",
-                "MEDDRA:10031256",
-                "SNOMEDCT:60168000",
-                "MEDDRA:10061017",
-                "MEDDRA:10045936",
-                "MEDDRA:10009081",
-                "NCIT:C27577",
-                "ICD9:730.1",
-                "MEDDRA:10046076"
-              ],
-              "id": "MONDO:0005246",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteomyelitis",
-                "Chronic osteomyelitis",
-                "osteomyelitis",
-                "Bone Infection",
-                "Infection of bone"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://my.clevelandclinic.org/disorders/osteomyelitis/hic_osteomyelitis.aspx",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://en.wikipedia.org/wiki/osteomyelitis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000437.htm",
-                "http://www.mayoclinic.com/health/osteomyelitis/ds00759",
-                "PMID:15276398",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7716640,
-            "start": 616,
-            "end": 319037,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10602739': {'publication date': '2000 Jan', 'sentence': 'The efficacy and safety of three oral fluoroquinolones (lomefloxacin, levofloxacin, and ciprofloxacin) for the treatment of chronic osteomyelitis were analyzed.', 'subject score': 1000, 'object score': 888}, 'PMID:15365265': {'publication date': '2004 Sep-Oct', 'sentence': 'Oral antibiotic treatment with amoxicillin-clavulanic acid was continued for 10 more days, followed by 25 days of ciprofloxacin for the osteomyelitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15793132': {'publication date': '2005 Apr', 'sentence': 'Efficacy of ciprofloxacin-releasing bioabsorbable osteoconductive bone defect filler for treatment of experimental osteomyelitis due to Staphylococcus aureus.', 'subject score': 1000, 'object score': 888}, 'PMID:15996581': {'publication date': '2005 Aug', 'sentence': 'A ciprofloxacin implant formulation composed of 12% hydroxyapatite, 36% tricalcium phosphate, 12% poly(DL-lactide) (PLA) and 40% ciprofloxacin was characterized in vivo for use in treatment of multibacterial bone infection.', 'subject score': 888, 'object score': 901}, 'PMID:17696153': {'publication date': '2008 Apr', 'sentence': 'Efficacy of ciprofloxacin implants in treating experimental osteomyelitis.', 'subject score': 1000, 'object score': 851}, 'PMID:18411320': {'publication date': '2008 Jul', 'sentence': 'Local treatment of experimental Pseudomonas aeruginosa osteomyelitis with a biodegradable dilactide polymer releasing ciprofloxacin.', 'subject score': 833, 'object score': 861}, 'PMID:18439310': {'publication date': '2008 Apr 27', 'sentence': 'Successful treatment of Mycobacterium ulcerans osteomyelitis with minor surgical debridement and prolonged rifampicin and ciprofloxacin therapy: a case report.', 'subject score': 888, 'object score': 901}, 'PMID:20409330': {'publication date': '2010 Apr 21', 'sentence': 'We report the case of a patient who received prolonged treatment with high-dose ciprofloxacin for extensive pelvic osteomyelitis.', 'subject score': 901, 'object score': 851}, 'PMID:2182039': {'publication date': '1990 Mar', 'sentence': 'We have not been presenting ciprofloxacin as a panacea, but as an effective alternative, with clear indications that can decreases the cost of the treatment of osteomyelitis associated with PVI.', 'subject score': 1000, 'object score': 1000}, 'PMID:2183710': {'publication date': '1990 Jan', 'sentence': 'We undertook a prospective, randomized comparison of oral ciprofloxacin with standard parenteral therapies for the treatment of biopsy-proven osteomyelitis caused by susceptible organisms.', 'subject score': 888, 'object score': 802}, 'PMID:2196154': {'publication date': '1990 Mar-Apr', 'sentence': 'Ciprofloxacin in the treatment of Staphylococcus aureus osteomyelitis.', 'subject score': 1000, 'object score': 901}, 'PMID:2295657': {'publication date': '1990 Jan', 'sentence': 'A group of fourteen patients who had chronic osteomyelitis and were treated with oral ciprofloxacin was compared with a group of twelve patients of similar age who had chronic osteomyelitis and received standard parenteral antibiotic therapy consisting of nafcillin, clindamycin, and gentamicin, singly or in combination.', 'subject score': 888, 'object score': 888}, 'PMID:2300517': {'publication date': '1990 Jan', 'sentence': 'Eighteen patients with osteomyelitis were treated with ciprofloxacin, 750 mg orally twice daily.', 'subject score': 1000, 'object score': 1000}, 'PMID:23507926': {'publication date': '2013', 'sentence': 'An in vitro study of composites of poly(L-lactide-co-epsilon-caprolactone), beta-tricalcium phosphate and ciprofloxacin intended for local treatment of osteomyelitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2360823': {'publication date': '1990 May', 'sentence': 'Twenty-two adult patients with osteomyelitis due to Pseudomonas aeruginosa were enrolled in an open, prospective cooperative study to determine the efficacy of oral ciprofloxacin therapy in a dosage of 750 mg twice a day.', 'subject score': 851, 'object score': 1000}, 'PMID:2490638': {'publication date': '1989 Jan', 'sentence': 'The results of efficacy and safety of ciprofloxacin administered by parenteral and oral route in the treatment of severe infections-particularly, osteomyelitis and bacteremia-due to gram-negative bacilli are studied in the present work.', 'subject score': 1000, 'object score': 1000}, 'PMID:2505355': {'publication date': '1989 Jul-Aug', 'sentence': 'The neutropenic mouse model of infection has demonstrated the synergistic effect of ciprofloxacin plus antipseudomonal penicillins; the combination of ciprofloxacin and rifampin has been superior to single agents in experimental Staphylococcus aureus osteomyelitis.', 'subject score': 1000, 'object score': 861}, 'PMID:25364693': {'publication date': '2014 Oct', 'sentence': 'However, despite its insolubility, microscopic observation, differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and X-ray diffraction showed that the developed gel was in the cubic liquid crystalline structure and have maintained their ability to progressively release ciprofloxacin. ciprofloxacin-monoolein-water (5:80:15% w/w), which released in vitro approximately 85% of ciprofloxacin after 16 days could possibly be considered as an alternative to a gentamicin-monoolein-water gel for the treatment of chronic osteomyelitis.', 'subject score': 1000, 'object score': 888}, 'PMID:25429485': {'publication date': '2014 Aug', 'sentence': 'During two weeks of peri-operative and postoperative period, chronic osteomyelitis was treated by intravenous ciprofloxacin and gentamycin, and after that by a combination of rifampicin and trimethoprim-sulfamethoxazole orally, for six months.', 'subject score': 888, 'object score': 888}, 'PMID:2661635': {'publication date': '1989 Mar-Apr', 'sentence': 'The authors also provide a detailed discussion of the efficacy of ciprofloxacin for osteomyelitis in animal studies and human trials.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0029443---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7880629",
-              "object": "MONDO:0005246",
-              "publications": [
-                "PMID:10602739",
-                "PMID:15365265",
-                "PMID:15793132",
-                "PMID:15996581",
-                "PMID:17696153",
-                "PMID:18411320",
-                "PMID:18439310",
-                "PMID:20409330",
-                "PMID:2182039",
-                "PMID:2183710",
-                "PMID:2196154",
-                "PMID:2295657",
-                "PMID:2300517",
-                "PMID:23507926",
-                "PMID:2360823",
-                "PMID:2490638",
-                "PMID:2505355",
-                "PMID:25364693",
-                "PMID:25429485",
-                "PMID:2661635"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 523273,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009061",
-          "name": "cystic fibrosis",
-          "description": "A congenital, autosomal, metabolic disorder affecting the exocrine glands. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production that causes obstruction of passageways, including pancreatic and bile ducts, intestines, and bronchi. Symptoms usually appear in childhood, and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather secondary to increased sodium and chloride concentration in sweat.; An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003550",
-            "SNOMEDCT:190905008",
-            "UMLS:C0010674",
-            "NCIT:C2975",
-            "MEDDRA:10011762",
-            "ORPHANET:586",
-            "DOID:1485",
-            "MEDDRA:10011764",
-            "ICD9:277.0",
-            "MEDDRA:10028141",
-            "PSY:12915",
-            "MONDO:0009061",
-            "OMIM:219700",
-            "ICD10:E84"
-          ],
-          "id": "MONDO:0009061",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cystic Fibrosis",
-            "cystic fibrosis",
-            "obsolete_cystic fibrosis",
-            "Cystic fibrosis related phenotypic feature",
-            "Cystic fibrosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://ghr.nlm.nih.gov/condition/cystic-fibrosis",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/cf/",
-            "http://en.wikipedia.org/wiki/cystic_fibrosis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 523273,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009061",
-              "name": "cystic fibrosis",
-              "description": "A congenital, autosomal, metabolic disorder affecting the exocrine glands. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production that causes obstruction of passageways, including pancreatic and bile ducts, intestines, and bronchi. Symptoms usually appear in childhood, and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather secondary to increased sodium and chloride concentration in sweat.; An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003550",
-                "SNOMEDCT:190905008",
-                "UMLS:C0010674",
-                "NCIT:C2975",
-                "MEDDRA:10011762",
-                "ORPHANET:586",
-                "DOID:1485",
-                "MEDDRA:10011764",
-                "ICD9:277.0",
-                "MEDDRA:10028141",
-                "PSY:12915",
-                "MONDO:0009061",
-                "OMIM:219700",
-                "ICD10:E84"
-              ],
-              "id": "MONDO:0009061",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cystic Fibrosis",
-                "cystic fibrosis",
-                "obsolete_cystic fibrosis",
-                "Cystic fibrosis related phenotypic feature",
-                "Cystic fibrosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://ghr.nlm.nih.gov/condition/cystic-fibrosis",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/cf/",
-                "http://en.wikipedia.org/wiki/cystic_fibrosis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7637170,
-            "start": 616,
-            "end": 523273,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10553703': {'publication date': '1999', 'sentence': 'As juveniles are especially sensitive, use of these drugs in paediatrics should be restricted to carefully selected indications (such as the use of ciprofloxacin in cystic fibrosis).', 'subject score': 1000, 'object score': 1000}, 'PMID:10587421': {'publication date': '1999 Dec', 'sentence': 'We report on a case of photosensitivity induced by indoor fluorescent strip-lighting (spectral range, 295-760 nm) in a 12-year-old girl with CF treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:10851644': {'publication date': '2000', 'sentence': 'Ciprofloxacin clinical and bacteriological efficacies, as well as tolerability mainly with respect to chondrotoxicity were evaluated in the treatment of children with mucoviscidosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:11709326': {'publication date': '2001 Dec', 'sentence': 'Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:11777658': {'publication date': '2001 Dec', 'sentence': 'Isolates of MSSA showed lower levels of susceptibility to ciprofloxacin (61-77% susceptibility) in both cystic fibrosis and neutropenia patients, and particularly high levels of resistance to ceftazidime (38% susceptibility) in cystic fibrosis units.', 'subject score': 1000, 'object score': 1000}, 'PMID:11806288': {'publication date': '2001 Sep-Oct', 'sentence': 'Until recently, only compassionate use of ciprofloxacin in children with cystic fibrosis was possible despite limited pharmacokinetic data.', 'subject score': 1000, 'object score': 1000}, 'PMID:11881187': {'publication date': '2001', 'sentence': 'The results of the prospective and comparative investigation of the linear growth of children at the age of 4 to 16 years with mucoviscidosis treated with ciprofloxacin in combination with a cephalosporin or an aminoglycoside in the main group and a cephalosporin or an aminoglycoside alone in the control group are presented.', 'subject score': 1000, 'object score': 1000}, 'PMID:12052667': {'publication date': '2002 Feb 28', 'sentence': 'Chondrotoxicity of quinolones can affect the articular cartilage and the epiphyseal growth plate in immature animals; the use of these drugs in pediatrics should be restricted to carefully selected indications (such as the use of ciprofloxacin in cystic fibrosis).', 'subject score': 1000, 'object score': 1000}, 'PMID:12856383': {'publication date': '2003 Jul', 'sentence': 'With body weight included in the model (two compartments with first-order absorption), ciprofloxacin clearance was influenced by age, and the absorption rate constant was altered in CF patients.', 'subject score': 888, 'object score': 901}, 'PMID:1489195': {'publication date': '1992 Nov', 'sentence': 'Our data indicate that the pharmacokinetic properties of ciprofloxacin are altered in cystic fibrosis patients with mild symptoms of pulmonary exacerbations and that the changes most probably are due to cystic fibrosis per se or to the impact of chronic infection.', 'subject score': 1000, 'object score': 901}, 'PMID:17012372': {'publication date': '2007 Jan', 'sentence': 'Azithromycin (AZM) and ciprofloxacin (CIP) are used clinically in CF.', 'subject score': 1000, 'object score': 1000}, 'PMID:17045852': {'publication date': '2007 May', 'sentence': 'Coagulopathy in two patients with cystic fibrosis treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:18835137': {'publication date': '2009 Mar', 'sentence': 'As a consequence, only life-threatening infections for which other antimicrobials cannot be used are possible indications for quinolones in children, for example the use of ciprofloxacin in cystic fibrosis patients with a bronchopulmonary exacerbation, chronic suppurative otitis media caused by Pseudomonas sp., complicated urinary tract infections and enteritis caused by invasive multidrug-resistant pathogens (e.g. Salmonella, Shigella).', 'subject score': 1000, 'object score': 901}, 'PMID:1907546': {'publication date': '1991 Apr', 'sentence': 'Ciprofloxacin (and possibly ofloxacin) are considered useful alternatives to parenteral agents in therapy of cystic fibrosis patients older than 18 years of age with exacerbations of pulmonary infection.', 'subject score': 1000, 'object score': 901}, 'PMID:1929312': {'publication date': '1991 Jul', 'sentence': 'The effect of pancreatic enzyme supplementation on the absorption of an oral dose of 250 mg of ciprofloxacin was studied in six patients with cystic fibrosis in a crossover design.', 'subject score': 1000, 'object score': 1000}, 'PMID:19847626': {'publication date': '2010 Jan', 'sentence': 'Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:21114393': {'publication date': '2010 Dec', 'sentence': 'CONCLUSION: These results provide a pharmacologic hypothesis-that the current dosing recommendations of ciprofloxacin for cystic fibrosis children may be suboptimal-to explain the decrease in the susceptibility of P. aeruginosa to ciprofloxacin observed in children with cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:21193474': {'publication date': '2011 Mar', 'sentence': 'CONCLUSIONS: Treatment of P. aeruginosa with oral ciprofloxacin in patients with CF may concurrently reduce antibiotic susceptibility in the commensal VGS flora, where these organisms may potentially act as a reservoir of fluoroquinolone resistance gene determinants for newly acquired and antibiotic-susceptible pathogens, particularly the Streptococcus milleri group.', 'subject score': 888, 'object score': 1000}, 'PMID:21928725': {'publication date': '2011', 'sentence': 'The PK/PD index (CMAX/MIC) for ciprofloxacin in patients with cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:2292542': {'publication date': '1990 Dec', 'sentence': 'Other children with cystic fibrosis were subsequently treated with ciprofloxacin, as the need arose.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0010674---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7798648",
-              "object": "MONDO:0009061",
-              "publications": [
-                "PMID:10553703",
-                "PMID:10587421",
-                "PMID:10851644",
-                "PMID:11709326",
-                "PMID:11777658",
-                "PMID:11806288",
-                "PMID:11881187",
-                "PMID:12052667",
-                "PMID:12856383",
-                "PMID:1489195",
-                "PMID:17012372",
-                "PMID:17045852",
-                "PMID:18835137",
-                "PMID:1907546",
-                "PMID:1929312",
-                "PMID:19847626",
-                "PMID:21114393",
-                "PMID:21193474",
-                "PMID:21928725",
-                "PMID:2292542"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321337,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001673",
-          "name": "diarrheal disease",
-          "description": "A gastrointestinal system disease described as the condition of having frequent loose or liquid bowel movements. Acute diarrhea is a common cause of death in developing countries and the second most common cause of infant deaths worldwide. The loss of fluids through diarrhea can cause severe dehydration which is one cause of death in diarrhea sufferers. Along with water, sufferers also lose dangerous amounts of important salts, electrolytes, and other nutrients. There are at least four types of diarrhea: secretory diarrhea, osmotic diarrhea, motility-related diarrhea, and inflammatory diarrhea. // COMMENTS: diarrhea is both a disease and a symptom [ms]",
-          "equivalent_curies": [
-            "ICD9:787.91",
-            "MEDDRA:10012745",
-            "MEDDRA:10012732",
-            "SNOMEDCT:128333008",
-            "SYMP:0000570",
-            "SNOMEDCT:62315008",
-            "UMLS:C0011991",
-            "MEDDRA:10012727",
-            "MEDDRA:10012735",
-            "UMLS:C1290807",
-            "PDQ:CDR0000041619",
-            "ICD9:009.2",
-            "MESH:D003967",
-            "DOID:13250",
-            "NCIT:C2987",
-            "PSY:14050",
-            "HP:0002014",
-            "MONDO:0001673",
-            "SNOMEDCT:267060006"
-          ],
-          "id": "MONDO:0001673",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Diarrhea",
-            "Diarrheal disorder",
-            "Infectious diarrhea",
-            "diarrheal disease",
-            "diarrhea"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=diarrhea",
-            "http://en.wikipedia.org/wiki/diarrhea#types_of_diarrhea",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321337,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001673",
-              "name": "diarrheal disease",
-              "description": "A gastrointestinal system disease described as the condition of having frequent loose or liquid bowel movements. Acute diarrhea is a common cause of death in developing countries and the second most common cause of infant deaths worldwide. The loss of fluids through diarrhea can cause severe dehydration which is one cause of death in diarrhea sufferers. Along with water, sufferers also lose dangerous amounts of important salts, electrolytes, and other nutrients. There are at least four types of diarrhea: secretory diarrhea, osmotic diarrhea, motility-related diarrhea, and inflammatory diarrhea. // COMMENTS: diarrhea is both a disease and a symptom [ms]",
-              "equivalent_curies": [
-                "ICD9:787.91",
-                "MEDDRA:10012745",
-                "MEDDRA:10012732",
-                "SNOMEDCT:128333008",
-                "SYMP:0000570",
-                "SNOMEDCT:62315008",
-                "UMLS:C0011991",
-                "MEDDRA:10012727",
-                "MEDDRA:10012735",
-                "UMLS:C1290807",
-                "PDQ:CDR0000041619",
-                "ICD9:009.2",
-                "MESH:D003967",
-                "DOID:13250",
-                "NCIT:C2987",
-                "PSY:14050",
-                "HP:0002014",
-                "MONDO:0001673",
-                "SNOMEDCT:267060006"
-              ],
-              "id": "MONDO:0001673",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Diarrhea",
-                "Diarrheal disorder",
-                "Infectious diarrhea",
-                "diarrheal disease",
-                "diarrhea"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=diarrhea",
-                "http://en.wikipedia.org/wiki/diarrhea#types_of_diarrhea",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7391523,
-            "start": 616,
-            "end": 321337,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10410578': {'publication date': '1998 Nov', 'sentence': 'The aim of this study was to investigate clinical importance of ciprofloxacin efficacy in treatment of massive diarrhoea in patients after extensional bowel resection with removing of ileo-coecal valve (EBR + ICVR).', 'subject score': 694, 'object score': 888}, 'PMID:10476738': {'publication date': '1999 Aug', 'sentence': 'There was a significant reduction in the duration of posttreatment diarrhea in the 16 patients treated with ciprofloxacin, as compared with that in the 13 patients who received placebo (mean of 35.3 versus 55.5 hours; P = .049).', 'subject score': 1000, 'object score': 861}, 'PMID:1728922': {'publication date': '1992 Jan', 'sentence': 'A note of caution on empiric use of ciprofloxacin for diarrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:19578229': {'publication date': '2010 Apr', 'sentence': 'Patients treated with Azithromycin had a shorter duration of diarrhea [mean(SD) 54.6 (18.6) vs 71.5 (29.6) h; mean difference (95% CI) 16.9 (9.6 -24.2); P<0.001] and lesser duration of excretion of Vibrio cholerae [mean(SD) 34.6 (16.3) vs 52.1 (29.2) h; mean difference (95% CI) 17.5 (0.2 -24.7), P<0.001] in children treated with Azithromycin vs Ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:20331580': {'publication date': '2010 Jun', 'sentence': \"When administered three times daily for 3 days, rifaximin is superior to placebo or loperamide; it is at least as effective as ciprofloxacin in reducing duration of illness and restoring wellbeing in patients with travellers' diarrhoea, both with and without identification of a pathogen, as well as in diarrhoea caused by Escherichia coli infection.\", 'subject score': 1000, 'object score': 1000}, 'PMID:20422140': {'publication date': '2009 Dec', 'sentence': 'Later, due to recurrence of the diarrhea, he was treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:22354292': {'publication date': '2012 May', 'sentence': 'We used a mouse model for Salmonella diarrhea to assess the effects of per os treatment with ciprofloxacin (15 mg/kg of body weight intragastrically 2 times/day, 5 days) or parenteral ceftriaxone (50 mg/kg intraperitoneally, 5 days), two common drugs used in human patients.', 'subject score': 1000, 'object score': 888}, 'PMID:25131673': {'publication date': '2014 Sep 08', 'sentence': 'In a mouse model for Salmonella diarrhea, treatment with the broad-spectrum antibiotic ciprofloxacin reverses the outcome of competition between wild-type bacteria and avirulent mutants that can spontaneously arise during within-host evolution [5].', 'subject score': 775, 'object score': 888}, 'PMID:27167632': {'publication date': '2016 Aug', 'sentence': 'This was preceded by diarrhea and treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:27428376': {'publication date': '2016', 'sentence': 'Ciprofloxacin is a broad-spectrum antimicrobial agent nowadays used for the treatment of diarrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:28603782': {'publication date': '2017', 'sentence': 'RESULTS: We found 2.7% (230/8,672) of children who presented with diarrhea had Shigella spp. isolated from their stool, and 50% (115/230) had resistance to Ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:30420482': {'publication date': '2018 Nov 12', 'sentence': 'Antibiotic resistance between C. jejuni and non-C. jejuni isolates, and surveillance and diarrhea samples were compared and the association between personal macrolide exposure and subsequent occurrence of a macrolide resistant Campylobacter spp. was assessed.ResultsOf 917 Campylobacter isolates, 77.4% of C. jejuni isolates and 79.8% non-C. jejuni isolates were resistant to ciprofloxacin while 4.9% of C. jejuni isolates and 24.8% of non-C. jejuni isolates were not susceptible to azithromycin.', 'subject score': 1000, 'object score': 694}, 'PMID:31153984': {'publication date': '2019 Sep', 'sentence': 'MSF favored diarrhea management as compared to ciprofloxacin, suggesting that MSF can be used in the management of E. coli O1-induced diarrhea, in normal gut microbiota and normal intestinal antioxidant function.', 'subject score': 1000, 'object score': 785}, 'PMID:3541724': {'publication date': '1987 Feb', 'sentence': 'Both antimicrobial agents were significantly (p less than 0.0001) more efficacious than placebo in the treatment of diarrhea, with the average duration of diarrhea being 29, 20, and 81 hours, respectively, in the ciprofloxacin, trimethoprim-sulfamethoxazole, and placebo treatment groups.', 'subject score': 1000, 'object score': 1000}, 'PMID:3555056': {'publication date': '1987 Apr 27', 'sentence': 'The average duration of diarrhea was 29 or 20 hours after initiation of treatment with ciprofloxacin or trimethoprim/sulfamethoxazole, respectively, compared with 81 hours in the placebo group.', 'subject score': 1000, 'object score': 1000}, 'PMID:35847602': {'publication date': '2022', 'sentence': 'The patient was treated with 3 days of ciprofloxacin with clinical resolution of diarrhoea.', 'subject score': 1000, 'object score': 1000}, 'PMID:36642099': {'publication date': '2023 Jan 12', 'sentence': 'CONCLUSION: A single dose of ciprofloxacin was effective and safe in treating uncomplicated diarrhea among service members in Africa.', 'subject score': 1000, 'object score': 851}, 'PMID:7883355': {'publication date': '1994 Aug', 'sentence': 'Parenteral ciprofloxacin in persistent diarrhea.', 'subject score': 861, 'object score': 888}, 'PMID:8810190': {'publication date': '1996 Feb', 'sentence': 'Parenteral ciprofloxacin in persistent diarrhoea in children.', 'subject score': 861, 'object score': 888}, 'PMID:9053412': {'publication date': '1995 Oct', 'sentence': 'Parenteral ciprofloxacin in persistent diarrhoea in children.', 'subject score': 861, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0011991---SEMMEDDB:",
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C1290807---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7544699",
-              "object": "MONDO:0001673",
-              "publications": [
-                "PMID:10476738",
-                "PMID:30420482",
-                "PMID:36642099",
-                "PMID:3541724",
-                "PMID:20422140",
-                "PMID:22354292",
-                "PMID:28603782",
-                "PMID:35847602",
-                "PMID:20331580",
-                "PMID:29914655",
-                "PMID:9829444",
-                "PMID:27167632",
-                "PMID:3555056",
-                "PMID:8810190",
-                "PMID:9053412",
-                "PMID:10410578",
-                "PMID:31153984",
-                "PMID:25131673",
-                "PMID:19578229",
-                "PMID:27428376"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 520880,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005619",
-          "name": "typhoid fever",
-          "description": "A bacterial infectious disorder contracted by consumption of food or drink contaminated with Salmonella typhi. This disorder is common in developing countries and can be treated with antibiotics.; An acute systemic febrile infection caused by SALMONELLA TYPHI, a serotype of SALMONELLA ENTERICA.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:13258",
-            "SNOMEDCT:4834000",
-            "MESH:D014435",
-            "MONDO:0005619",
-            "MEDDRA:10045272",
-            "MEDDRA:10045275",
-            "ICD9:002.0",
-            "ICD10:A01.0",
-            "UMLS:C0041466",
-            "MEDDRA:10014862",
-            "MEDDRA:10039446",
-            "NCIT:C35089",
-            "EFO:0006789",
-            "ORPHANET:99745"
-          ],
-          "id": "MONDO:0005619",
-          "category": "biolink:Disease",
-          "all_names": [
-            "typhoid fever",
-            "Typhoid",
-            "Typhoid Fever",
-            "Typhoid fever"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.merriam-webster.com/medlineplus/typhoid%20feve"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 520880,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005619",
-              "name": "typhoid fever",
-              "description": "A bacterial infectious disorder contracted by consumption of food or drink contaminated with Salmonella typhi. This disorder is common in developing countries and can be treated with antibiotics.; An acute systemic febrile infection caused by SALMONELLA TYPHI, a serotype of SALMONELLA ENTERICA.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:13258",
-                "SNOMEDCT:4834000",
-                "MESH:D014435",
-                "MONDO:0005619",
-                "MEDDRA:10045272",
-                "MEDDRA:10045275",
-                "ICD9:002.0",
-                "ICD10:A01.0",
-                "UMLS:C0041466",
-                "MEDDRA:10014862",
-                "MEDDRA:10039446",
-                "NCIT:C35089",
-                "EFO:0006789",
-                "ORPHANET:99745"
-              ],
-              "id": "MONDO:0005619",
-              "category": "biolink:Disease",
-              "all_names": [
-                "typhoid fever",
-                "Typhoid",
-                "Typhoid Fever",
-                "Typhoid fever"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.merriam-webster.com/medlineplus/typhoid%20feve"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7274250,
-            "start": 616,
-            "end": 520880,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10348767': {'publication date': '1999 Jun', 'sentence': 'To compare clinical and bacteriological efficacies of azithromycin and ciprofloxacin for typhoid fever, 123 adults with fever and signs of uncomplicated typhoid fever were entered into a randomized trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:10408519': {'publication date': '1999 Jul 10', 'sentence': 'Ciprofloxacin in typhoid fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:10807074': {'publication date': '2000 May', 'sentence': 'We believe that patients with a presumptive diagnosis of typhoid fever should be treated with ciprofloxacin and dexamethasone, even before the results of blood cultures are available.', 'subject score': 1000, 'object score': 1000}, 'PMID:11219168': {'publication date': '2000 Dec', 'sentence': 'We conclude that ciprofloxacin is commonly used in typhoid fever and has no adverse effects on growth or joint symptomology.', 'subject score': 1000, 'object score': 1000}, 'PMID:11810512': {'publication date': '1999 Sep', 'sentence': 'Antibacterial activity of cefixime was comparable to ceftriaxone, ofloxacin, and ciprofloxacin, which are often used for the treatment of typhoid fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:11816954': {'publication date': '2001 Jun', 'sentence': 'METHODS: A total of 140 children, aged 3-10 yr, clinically diagnosed as having typhoid fever, without any clinical response after 12-14 days of ciprofloxacin therapy were screened for S. typhi by blood culture.', 'subject score': 888, 'object score': 1000}, 'PMID:12138663': {'publication date': '2002 Feb', 'sentence': 'Misuse and overuse of ciprofloxacin for the treatment of typhoid fever influenced the development of ciprofloxacin resistant strains of S. enterica serotype Typhi in and around Kolkata.', 'subject score': 1000, 'object score': 1000}, 'PMID:12138664': {'publication date': '2002 Feb', 'sentence': 'The antimicrobial susceptibility tests for S. typhi performed by the disc diffusion method using NCCLS breakpoints fail to detect the increasing MIC of ciprofloxacin, leading to the inappropriate treatment of enteric fever with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:1307372': {'publication date': '1992 Oct', 'sentence': 'Typhoid fever, not responding to ciprofloxacin therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:1440832': {'publication date': '1992', 'sentence': 'This study assessed the performance of short-course ciprofloxacin for the treatment of 34 adult patients with culture-positive typhoid fever.', 'subject score': 851, 'object score': 861}, 'PMID:14511204': {'publication date': '2003 Sep-Oct', 'sentence': 'Short-course ciprofloxacin treatment for enteric fever: caveat emptor!', 'subject score': 833, 'object score': 1000}, 'PMID:1452543': {'publication date': '1992 Apr', 'sentence': 'Chloramphenicol vs ciprofloxacin in enteric fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:1474262': {'publication date': '1992 Nov', 'sentence': 'A short-course regime of ciprofloxacin for the treatment of enteric fever, is therefore, highly promising.', 'subject score': 1000, 'object score': 1000}, 'PMID:1493986': {'publication date': '1992 Nov', 'sentence': 'We conclude that 500 mg of ciprofloxacin taken orally twice daily is adequate treatment for typhoid fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:15211083': {'publication date': '2004 Jun', 'sentence': 'Ceftriaxone and ciprofloxacin remain favorable choices for treatment of patients with enteric fever in this region.', 'subject score': 1000, 'object score': 1000}, 'PMID:15380025': {'publication date': '2004 Sep 20', 'sentence': 'Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series.', 'subject score': 1000, 'object score': 1000}, 'PMID:1634483': {'publication date': '1992 Mar', 'sentence': 'We used this technique to compare the cost-effectiveness of chloramphenicol and ciprofloxacin in the treatment of enteric fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:1682560': {'publication date': '1991 Nov 02', 'sentence': 'Ciprofloxacin for typhoid fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:1684010': {'publication date': '1991', 'sentence': 'Ciprofloxacin for typhoid fever.', 'subject score': 1000, 'object score': 1000}, 'PMID:17164172': {'publication date': '2006 Dec', 'sentence': 'Quinolone derivatives (namely, Ciprofloxacin, Norfloxacin and Chloramphenicol) can be suggested as drugs of choice for treatment of enteric fever caused by SPTA.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0041466---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7423320",
-              "object": "MONDO:0005619",
-              "publications": [
-                "PMID:10348767",
-                "PMID:10408519",
-                "PMID:10807074",
-                "PMID:11219168",
-                "PMID:11810512",
-                "PMID:11816954",
-                "PMID:12138663",
-                "PMID:12138664",
-                "PMID:1307372",
-                "PMID:1440832",
-                "PMID:14511204",
-                "PMID:1452543",
-                "PMID:1474262",
-                "PMID:1493986",
-                "PMID:15211083",
-                "PMID:15380025",
-                "PMID:1634483",
-                "PMID:1682560",
-                "PMID:1684010",
-                "PMID:17164172"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7191244,
-            "start": 616,
-            "end": 321523,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10225583': {'publication date': '1999 Mar', 'sentence': 'Initial treatment of severe pneumonia with ciprofloxacin resulted in significantly less subsequent gram-negative infection and was associated with substantially lower curative costs.', 'subject score': 1000, 'object score': 888}, 'PMID:10685245': {'publication date': '1999 Jun', 'sentence': 'The infant developed sepsis and meningitis resulting from multidrug-resistant K. pneumoniae, which was treated with ciprofloxacin and gentamicin.', 'subject score': 1000, 'object score': 843}, 'PMID:10722430': {'publication date': '2000 Mar', 'sentence': 'Multivariate analysis revealed that risk factors for ciprofloxacin resistance in K. pneumoniae included prior receipt of a quinolone (P=.0065) and an ESBL-producing strain (P=.012).', 'subject score': 694, 'object score': 888}, 'PMID:11418511': {'publication date': '2001 Jul', 'sentence': 'K. pneumoniae strains resistant to ciprofloxacin were also resistant to levofloxacin.', 'subject score': 1000, 'object score': 888}, 'PMID:11709326': {'publication date': '2001 Dec', 'sentence': 'Pharmacodynamic data on ciprofloxacin indicate that a target area under the concentration-time curve from 0 to 24 h (AUC(0-24))/MIC ratio of >or=125 is necessary to achieve optimal bactericidal activity for the treatment of gram-negative pneumonia.', 'subject score': 1000, 'object score': 851}, 'PMID:11735679': {'publication date': '2001', 'sentence': 'Piperacillin/tazobactam was dominant (greater efficacy and lower costs) versus imipenem/cilastatin in intra-abdominal infections and ceftriaxone, ciprofloxacin or meropenem in pneumonia.', 'subject score': 1000, 'object score': 1000}, 'PMID:12168746': {'publication date': '2002 Jul', 'sentence': 'Double mutants in the parC and gyrA genes lead to fluoroquinolone resistance that has been found to cause bacteriological failure of the fluoroquinolones, particularly levofloxacin and ciprofloxacin, in the management of pneumonia and exacerbations of chronic bronchitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:12375221': {'publication date': '2002 Oct', 'sentence': 'CONCLUSIONS: Due to the high success rate, even in cases with failed antimicrobial pretreatment, and the favourable risk-benefit ratio of high-dose ciprofloxacin, ciprofloxacin appears to be an attractive choice in the empiric treatment of hospital-acquired pneumonia.', 'subject score': 1000, 'object score': 901}, 'PMID:14567253': {'publication date': '2003 Aug', 'sentence': '49 cases of community-acquired pneumonia were treated by intravenous ciprofloxacin.', 'subject score': 888, 'object score': 851}, 'PMID:15318274': {'publication date': '2004 Jul', 'sentence': 'Overall, 33% of E. coli and 13% of K. pneumoniae were resistant to ciprofloxacin.', 'subject score': 1000, 'object score': 888}, 'PMID:15320954': {'publication date': '2004 Aug 22', 'sentence': 'K. pneumoniae isolates of the extended-spectrum beta-lactamase phenotype were more resistant to imipenem, ciprofloxacin, and tetracycline in our study than they are in other regions of the world.', 'subject score': 1000, 'object score': 888}, 'PMID:15729490': {'publication date': '2005 Feb', 'sentence': 'Based on the above data, intravenous CPFX may be the drug which should be recommended as the first choice for hospital-acquired pneumonia.', 'subject score': 888, 'object score': 901}, 'PMID:16312637': {'publication date': '1989 Jul', 'sentence': 'Efficacy and safety in the oral treatment of purulent chest disease and pneumonia with cefixime, ofloxacin, and ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:17122017': {'publication date': '2007 Feb', 'sentence': 'The MICs of azithromycin, doxycycline, ciprofloxacin, and enrofloxacin for 10 C. pneumoniae isolates from these bandicoots ranged from 0.015 to 1 microg/ml, 0.25 to 1 microg/ml, 0.25 to 2 microg/ml, and 0.25 to 0.5 microg/ml, respectively.', 'subject score': 1000, 'object score': 827}, 'PMID:17373114': {'publication date': '2007', 'sentence': 'Recommended treatment of Rhodococcus equi pneumonia includes particularly vancomycin, amikacin, rifampicin, imipenem, ciprofloxacin and erythromycin.', 'subject score': 1000, 'object score': 901}, 'PMID:18159305': {'publication date': '2000 Nov', 'sentence': 'A knowledge assessment showed satisfactory knowledge except in two areas - an overestimation of the prevalence of penicillin-resistant Streptococcus pneumoniae in Nova Scotia and the view that ciprofloxacin was an effective antibiotic for the treatment of CAP (42% of physicians).', 'subject score': 1000, 'object score': 851}, 'PMID:18558942': {'publication date': '2008 Jul', 'sentence': 'Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.', 'subject score': 1000, 'object score': 888}, 'PMID:18777242': {'publication date': '2008 Oct', 'sentence': 'This study indicates that pulmonary administration of CPFX could be an effective technique for the treatment of pneumonia.', 'subject score': 1000, 'object score': 1000}, 'PMID:1923916': {'publication date': '1991', 'sentence': 'When he began taking ciprofloxacin for pneumonia, he had renal and cardiac failure.', 'subject score': 861, 'object score': 1000}, 'PMID:1999086': {'publication date': '1991 Jan', 'sentence': 'Of the 17 pneumonia patients who completed ciprofloxacin treatment, 15 (88%) had resolution of signs and symptoms or improvement.', 'subject score': 888, 'object score': 790}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7337248",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:10225583",
-                "PMID:10685245",
-                "PMID:10722430",
-                "PMID:11418511",
-                "PMID:11709326",
-                "PMID:11735679",
-                "PMID:12168746",
-                "PMID:12375221",
-                "PMID:14567253",
-                "PMID:15318274",
-                "PMID:15320954",
-                "PMID:15729490",
-                "PMID:16312637",
-                "PMID:17122017",
-                "PMID:17373114",
-                "PMID:18159305",
-                "PMID:18558942",
-                "PMID:18777242",
-                "PMID:1923916",
-                "PMID:1999086"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10103250': {'publication date': '1999 Apr', 'sentence': 'Ciprofloxacin (CIP), a fluoroquinolone antibacterial drug, is widely used in the treatment of serious infections in humans.', 'subject score': 1000, 'object score': 888}, 'PMID:10146890': {'publication date': '1993 May', 'sentence': 'Pharmacoeconomic studies have confirmed that substitution of oral ciprofloxacin for parenteral therapy in the treatment of serious infections can achieve considerable savings in drug acquisition costs, and labour and supplies associated with parenteral drug administration, and may allow early discharge from hospital, resulting in even greater savings.', 'subject score': 888, 'object score': 888}, 'PMID:10225571': {'publication date': '1999 Mar', 'sentence': 'Intravenous ciprofloxacin is frequently prescribed for the treatment of infections due to nosocomially acquired gram-negative organisms, including those originating in the respiratory tract.', 'subject score': 888, 'object score': 1000}, 'PMID:10496154': {'publication date': '1998 Sep', 'sentence': 'Due to increasing multidrug resistance, choosing appropriate antimicrobial agents such as moxalactam, imipenem, and ciprofloxacin should be highly recommended for the treatment of S. marcescens infections.', 'subject score': 1000, 'object score': 802}, 'PMID:10551467': {'publication date': '1999 Nov', 'sentence': 'Cold-hot mismatch between Tc-99m HMPAO-labeled leukocytes and Tc-99m ciprofloxacin in axial skeleton infections: a report of three cases.', 'subject score': 901, 'object score': 901}, 'PMID:10586159': {'publication date': '1999 Dec', 'sentence': 'The infection was successfully treated with oral ciprofloxacin and intravenous administration of tobramycin, preventing progression from superficial to deep infection and preserving the prosthesis.', 'subject score': 888, 'object score': 1000}, 'PMID:10685245': {'publication date': '1999 Jun', 'sentence': 'Ciprofloxacin has been found to be effective in the treatment of multidrug-resistant Gram-negative infections in pediatric patients, including premature infants.', 'subject score': 1000, 'object score': 825}, 'PMID:10752687': {'publication date': '2000 Mar', 'sentence': 'The infection was successfully treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:10766389': {'publication date': '2000 Mar-Apr', 'sentence': 'Topical fortified amikacin, clarithromycin, tobramycin, and ciprofloxacin eventually controlled the infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:10856326': {'publication date': '2000 Jul', 'sentence': 'Quantitative culture of sputum revealed a pure growth of Haemophilus parainfluenzae and, following antibiotic susceptibility testing of the isolate, ciprofloxacin was prescribed resulting in resolution of the infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:11305008': {'publication date': '2001 Apr', 'sentence': 'In Europe and USA, ciprofloxacin and levofloxacin showed a good therapeutic efficacy for the past decade by sequential therapy for infections caused by Gram-negative bacteria including Pseudomonas aeruginosa and Gram-positive pathogens including penicillin-resistant Streptococcus pneumoniae.', 'subject score': 1000, 'object score': 1000}, 'PMID:11331489': {'publication date': '2001 Apr', 'sentence': 'Aminoglycoside and ciprofloxacin can be used empirically to treat both types of infection in diabetics and non-diabetics.', 'subject score': 1000, 'object score': 1000}, 'PMID:11556475': {'publication date': '2001 Jun', 'sentence': 'Ciprofloxacin has been found to be effective in the treatment of multidrug-resistant gram negative infections in pediatric patients, including premature infants.', 'subject score': 1000, 'object score': 825}, 'PMID:11691575': {'publication date': '2001 Oct', 'sentence': 'The activity of cefpirome, cefepime and piperacillin/tazobactam previously unused in the hospital was evaluated in parallel with five broad-spectrum antibiotics (ceftazidime, ceftriaxone, imipenem, ciprofloxacin and amikacin) currently being used to treat serious infections in the National University Hospital, Singapore.', 'subject score': 1000, 'object score': 888}, 'PMID:11760161': {'publication date': '2001', 'sentence': 'According to the results of this study, the combination of meropenem and ciprofloxacin is more effective than either antibiotic alone in ICU infections due to P. aeruginosa strains.', 'subject score': 1000, 'object score': 916}, 'PMID:11922236': {'publication date': '2002 Mar', 'sentence': 'Ciprofloxacin has been widely used for treating infections and has been found to have very low cardiovascular side effects.', 'subject score': 1000, 'object score': 888}, 'PMID:11928848': {'publication date': '2002', 'sentence': 'Despite the organism being resistant to trimethoprim-sulfamethoxazole, the infection was cured by drainage and treatment with intravenous piperacillin, followed by oral ciprofloxacin.', 'subject score': 888, 'object score': 1000}, 'PMID:11945119': {'publication date': '2002 Feb', 'sentence': 'Based on these results both ciprofloxacin and levofloxacin could be alternative therapeutic agents for the infection caused by ESBL-producing Klebsiella strains.', 'subject score': 1000, 'object score': 1000}, 'PMID:11955920': {'publication date': '2002 Apr', 'sentence': 'The infection cleared after treatment with fortified cefazolin, fortified gentamicin, and ciprofloxacin eyedrops.', 'subject score': 888, 'object score': 1000}, 'PMID:12003988': {'publication date': '2002 May', 'sentence': 'A randomized controlled trial of azithromycin versus doxycycline/ciprofloxacin for the syndromic management of sexually transmitted infections in a resource-poor setting.', 'subject score': 888, 'object score': 827}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 539955,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-          "name": "infectious disease",
-          "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005550",
-            "SNOMEDCT:189822004",
-            "PSY:10513",
-            "UMLS:C0009450",
-            "UMLS:C0001485",
-            "EFO:0005741",
-            "MEDDRA:10021881",
-            "MESH:D003141",
-            "ICD9:079.0",
-            "DOID:0050117",
-            "SNOMEDCT:40733004",
-            "SNOMEDCT:191415002",
-            "NCIT:C26726"
-          ],
-          "id": "MONDO:0005550",
-          "category": "biolink:Disease",
-          "all_names": [
-            "infectious disease",
-            "Infectious Disorder",
-            "disease by infectious agent",
-            "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-            "Communicable Diseases"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.merriam-webster.com/medical/communicable%20disease",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 539955,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-              "name": "infectious disease",
-              "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005550",
-                "SNOMEDCT:189822004",
-                "PSY:10513",
-                "UMLS:C0009450",
-                "UMLS:C0001485",
-                "EFO:0005741",
-                "MEDDRA:10021881",
-                "MESH:D003141",
-                "ICD9:079.0",
-                "DOID:0050117",
-                "SNOMEDCT:40733004",
-                "SNOMEDCT:191415002",
-                "NCIT:C26726"
-              ],
-              "id": "MONDO:0005550",
-              "category": "biolink:Disease",
-              "all_names": [
-                "infectious disease",
-                "Infectious Disorder",
-                "disease by infectious agent",
-                "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-                "Communicable Diseases"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.merriam-webster.com/medical/communicable%20disease",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7086623,
-            "start": 616,
-            "end": 539955,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10103250': {'publication date': '1999 Apr', 'sentence': 'Ciprofloxacin (CIP), a fluoroquinolone antibacterial drug, is widely used in the treatment of serious infections in humans.', 'subject score': 1000, 'object score': 888}, 'PMID:10146890': {'publication date': '1993 May', 'sentence': 'Pharmacoeconomic studies have confirmed that substitution of oral ciprofloxacin for parenteral therapy in the treatment of serious infections can achieve considerable savings in drug acquisition costs, and labour and supplies associated with parenteral drug administration, and may allow early discharge from hospital, resulting in even greater savings.', 'subject score': 888, 'object score': 888}, 'PMID:10225571': {'publication date': '1999 Mar', 'sentence': 'Intravenous ciprofloxacin is frequently prescribed for the treatment of infections due to nosocomially acquired gram-negative organisms, including those originating in the respiratory tract.', 'subject score': 888, 'object score': 1000}, 'PMID:10496154': {'publication date': '1998 Sep', 'sentence': 'Due to increasing multidrug resistance, choosing appropriate antimicrobial agents such as moxalactam, imipenem, and ciprofloxacin should be highly recommended for the treatment of S. marcescens infections.', 'subject score': 1000, 'object score': 802}, 'PMID:10551467': {'publication date': '1999 Nov', 'sentence': 'Cold-hot mismatch between Tc-99m HMPAO-labeled leukocytes and Tc-99m ciprofloxacin in axial skeleton infections: a report of three cases.', 'subject score': 901, 'object score': 901}, 'PMID:10586159': {'publication date': '1999 Dec', 'sentence': 'The infection was successfully treated with oral ciprofloxacin and intravenous administration of tobramycin, preventing progression from superficial to deep infection and preserving the prosthesis.', 'subject score': 888, 'object score': 1000}, 'PMID:10685245': {'publication date': '1999 Jun', 'sentence': 'Ciprofloxacin has been found to be effective in the treatment of multidrug-resistant Gram-negative infections in pediatric patients, including premature infants.', 'subject score': 1000, 'object score': 825}, 'PMID:10752687': {'publication date': '2000 Mar', 'sentence': 'The infection was successfully treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:10766389': {'publication date': '2000 Mar-Apr', 'sentence': 'Topical fortified amikacin, clarithromycin, tobramycin, and ciprofloxacin eventually controlled the infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:10856326': {'publication date': '2000 Jul', 'sentence': 'Quantitative culture of sputum revealed a pure growth of Haemophilus parainfluenzae and, following antibiotic susceptibility testing of the isolate, ciprofloxacin was prescribed resulting in resolution of the infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:11305008': {'publication date': '2001 Apr', 'sentence': 'In Europe and USA, ciprofloxacin and levofloxacin showed a good therapeutic efficacy for the past decade by sequential therapy for infections caused by Gram-negative bacteria including Pseudomonas aeruginosa and Gram-positive pathogens including penicillin-resistant Streptococcus pneumoniae.', 'subject score': 1000, 'object score': 1000}, 'PMID:11331489': {'publication date': '2001 Apr', 'sentence': 'Aminoglycoside and ciprofloxacin can be used empirically to treat both types of infection in diabetics and non-diabetics.', 'subject score': 1000, 'object score': 1000}, 'PMID:11556475': {'publication date': '2001 Jun', 'sentence': 'Ciprofloxacin has been found to be effective in the treatment of multidrug-resistant gram negative infections in pediatric patients, including premature infants.', 'subject score': 1000, 'object score': 825}, 'PMID:11691575': {'publication date': '2001 Oct', 'sentence': 'The activity of cefpirome, cefepime and piperacillin/tazobactam previously unused in the hospital was evaluated in parallel with five broad-spectrum antibiotics (ceftazidime, ceftriaxone, imipenem, ciprofloxacin and amikacin) currently being used to treat serious infections in the National University Hospital, Singapore.', 'subject score': 1000, 'object score': 888}, 'PMID:11760161': {'publication date': '2001', 'sentence': 'According to the results of this study, the combination of meropenem and ciprofloxacin is more effective than either antibiotic alone in ICU infections due to P. aeruginosa strains.', 'subject score': 1000, 'object score': 916}, 'PMID:11922236': {'publication date': '2002 Mar', 'sentence': 'Ciprofloxacin has been widely used for treating infections and has been found to have very low cardiovascular side effects.', 'subject score': 1000, 'object score': 888}, 'PMID:11928848': {'publication date': '2002', 'sentence': 'Despite the organism being resistant to trimethoprim-sulfamethoxazole, the infection was cured by drainage and treatment with intravenous piperacillin, followed by oral ciprofloxacin.', 'subject score': 888, 'object score': 1000}, 'PMID:11945119': {'publication date': '2002 Feb', 'sentence': 'Based on these results both ciprofloxacin and levofloxacin could be alternative therapeutic agents for the infection caused by ESBL-producing Klebsiella strains.', 'subject score': 1000, 'object score': 1000}, 'PMID:11955920': {'publication date': '2002 Apr', 'sentence': 'The infection cleared after treatment with fortified cefazolin, fortified gentamicin, and ciprofloxacin eyedrops.', 'subject score': 888, 'object score': 1000}, 'PMID:12003988': {'publication date': '2002 May', 'sentence': 'A randomized controlled trial of azithromycin versus doxycycline/ciprofloxacin for the syndromic management of sexually transmitted infections in a resource-poor setting.', 'subject score': 888, 'object score': 827}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0009450---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7228759",
-              "object": "MONDO:0005550",
-              "publications": [
-                "PMID:10103250",
-                "PMID:10146890",
-                "PMID:10225571",
-                "PMID:10496154",
-                "PMID:10551467",
-                "PMID:10586159",
-                "PMID:10685245",
-                "PMID:10752687",
-                "PMID:10766389",
-                "PMID:10856326",
-                "PMID:11305008",
-                "PMID:11331489",
-                "PMID:11556475",
-                "PMID:11691575",
-                "PMID:11760161",
-                "PMID:11922236",
-                "PMID:11928848",
-                "PMID:11945119",
-                "PMID:11955920",
-                "PMID:12003988"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:26244102': {'publication date': '2015 Aug 01', 'sentence': 'We tested the effectiveness of keratin-based hydrogels (termed \"keratose\") loaded with ciprofloxacin to inhibit infection and support healing when topically administered to porcine excision wounds infected with Pseudomonas aeruginosa.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 539955,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-          "name": "infectious disease",
-          "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005550",
-            "SNOMEDCT:189822004",
-            "PSY:10513",
-            "UMLS:C0009450",
-            "UMLS:C0001485",
-            "EFO:0005741",
-            "MEDDRA:10021881",
-            "MESH:D003141",
-            "ICD9:079.0",
-            "DOID:0050117",
-            "SNOMEDCT:40733004",
-            "SNOMEDCT:191415002",
-            "NCIT:C26726"
-          ],
-          "id": "MONDO:0005550",
-          "category": "biolink:Disease",
-          "all_names": [
-            "infectious disease",
-            "Infectious Disorder",
-            "disease by infectious agent",
-            "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-            "Communicable Diseases"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.merriam-webster.com/medical/communicable%20disease",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 539955,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-              "name": "infectious disease",
-              "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005550",
-                "SNOMEDCT:189822004",
-                "PSY:10513",
-                "UMLS:C0009450",
-                "UMLS:C0001485",
-                "EFO:0005741",
-                "MEDDRA:10021881",
-                "MESH:D003141",
-                "ICD9:079.0",
-                "DOID:0050117",
-                "SNOMEDCT:40733004",
-                "SNOMEDCT:191415002",
-                "NCIT:C26726"
-              ],
-              "id": "MONDO:0005550",
-              "category": "biolink:Disease",
-              "all_names": [
-                "infectious disease",
-                "Infectious Disorder",
-                "disease by infectious agent",
-                "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-                "Communicable Diseases"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.merriam-webster.com/medical/communicable%20disease",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18113271,
-            "start": 616,
-            "end": 539955,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26244102': {'publication date': '2015 Aug 01', 'sentence': 'We tested the effectiveness of keratin-based hydrogels (termed \"keratose\") loaded with ciprofloxacin to inhibit infection and support healing when topically administered to porcine excision wounds infected with Pseudomonas aeruginosa.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:disrupts---None---None---None---UMLS:C0009450---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "18480207",
-              "object": "MONDO:0005550",
-              "publications": [
-                "PMID:26244102"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:10715297': {'publication date': '2000 Mar', 'sentence': 'PURPOSE: To determine whether an antibiotic flush solution containing vancomycin, heparin, and ciprofloxacin (VHC) can prevent the majority of line infections.', 'subject score': 1000, 'object score': 888}, 'PMID:11132527': {'publication date': '2000 Dec 02', 'sentence': 'This retrospective study confirms that oral prophylaxis with ciprofloxacin and penicillin decreases the incidence of infections and, in particular, of gram-negative bacteraemia, but does not modify the overall morbidity and mortality in our patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:1322231': {'publication date': '1992 Aug 15', 'sentence': 'RESULTS: The fluoroquinolone compounds, such as ciprofloxacin, norfloxacin, and ofloxacin, have broad spectrum bactericidal activity and have proved to be effective in both the treatment and prevention of certain infections in patients with cancer.', 'subject score': 1000, 'object score': 888}, 'PMID:1503442': {'publication date': '1992 Apr', 'sentence': 'A prospective randomized study was conducted to determine the efficacy of imipenem-cilastatin (hereafter referred to as imipenem) (500 mg four times daily) versus combination therapy for febrile neutropenic patients receiving either no prophylaxis or ciprofloxacin for prevention of infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:1611208': {'publication date': '1992 Apr', 'sentence': 'In an ex vivo model of infection using peritoneal resting macrophages from the C57BL/6 mouse, the intracellular viability of a strain of M. avium (strain 489, serovar 3) was reduced by clofazimine, amikacin, ciprofloxacin, rifabutin and clarithromycin (99, 98, 93, 89 and 69%, respectively), thus indicating for clofazimine a good correlation between in vitro and ex vivo activity.', 'subject score': 1000, 'object score': 1000}, 'PMID:19188359': {'publication date': '2009 Apr', 'sentence': 'Although there were major differences in pathogenesis, the recombinant F1 and V antigen vaccine and ciprofloxacin protected against plague infections caused by small- and large-particle aerosols.', 'subject score': 1000, 'object score': 888}, 'PMID:2048868': {'publication date': '1991 Jul 01', 'sentence': 'CONCLUSION: Ciprofloxacin should be used to prevent the development of infection in neutropenic patients with hematologic malignancies.', 'subject score': 1000, 'object score': 1000}, 'PMID:2098296': {'publication date': '1990 Nov-Dec', 'sentence': 'Ciprofloxacin appears to be an effective agent for the prevention of gram-negative infections in granulocytopenic patients with acute leukemia, but may contribute to a shift in the type of infections in these patients towards those caused by gram-positive microorganisms, intrinsically fairly sensitive or with acquired drug resistance.', 'subject score': 1000, 'object score': 851}, 'PMID:22476119': {'publication date': '2011 Oct-Dec', 'sentence': '[Ciprofloxacin vs cefazolin in the prevention of infection in cirrhotic patients with gastrointestinal bleeding].', 'subject score': 1000, 'object score': 1000}, 'PMID:2286588': {'publication date': '1990 Nov', 'sentence': 'Preliminary results are presented of an ongoing, prospective, randomized, study comparing ofloxacin, ciprofloxacin and co-trimoxazole/colistin for the prevention of infection in patients with acute leukaemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:2292538': {'publication date': '1990 Dec', 'sentence': 'Prevention of infection by ciprofloxacin in neutropenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:24415457': {'publication date': '2014 Apr 15', 'sentence': 'Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.', 'subject score': 1000, 'object score': 888}, 'PMID:24495623': {'publication date': '2014 Mar', 'sentence': 'Ciprofloxacin and trimethoprim-sulfamethoxazole are the most commonly recommended prophylactic antibiotics used to prevent A. hydrophila infections during leech therapy.', 'subject score': 1000, 'object score': 861}, 'PMID:25423029': {'publication date': '2015 Mar', 'sentence': 'CONCLUSION: Trimethoprim-sulfamethoxazole and ciprofloxacin appear equally effective at preventing leech-associated infections.', 'subject score': 1000, 'object score': 764}, 'PMID:2667112': {'publication date': '1989', 'sentence': 'Oral ciprofloxacin given prophylactically to immunocompromised patients during severe granulocytopenia prevented colonization with potentially pathogenic aerobic Gram-negative rods, and reduced the incidence of infections caused by these microorganisms.', 'subject score': 888, 'object score': 1000}, 'PMID:26951136': {'publication date': '2016 Nov', 'sentence': 'A single dose of meropenem is superior to ciprofloxacin in preventing infections after transrectal ultrasound-guided prostate biopsies in the era of quinolone resistance.', 'subject score': 1000, 'object score': 872}, 'PMID:2767765': {'publication date': '1989', 'sentence': 'We previously demonstrated that ciprofloxacin prevents infections caused by gram-negative bacilli in patients with granulocytopenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:28220110': {'publication date': '2017', 'sentence': 'Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague.', 'subject score': 851, 'object score': 861}, 'PMID:30017599': {'publication date': '2018 Sep', 'sentence': 'CONCLUSION: Immersing IPP material into an antibiotic solution, such as ampicillin or ciprofloxacin, increases the bactericidal properties and may aid in the prevention of infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:7548495': {'publication date': '1995 Jun', 'sentence': 'Ciprofloxacin failed to prevent V. cholerae O1 infections during a period of low transmissibility.', 'subject score': 1000, 'object score': 824}}",
-    "p2": {
-      "start": {
-        "identity": 539955,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-          "name": "infectious disease",
-          "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005550",
-            "SNOMEDCT:189822004",
-            "PSY:10513",
-            "UMLS:C0009450",
-            "UMLS:C0001485",
-            "EFO:0005741",
-            "MEDDRA:10021881",
-            "MESH:D003141",
-            "ICD9:079.0",
-            "DOID:0050117",
-            "SNOMEDCT:40733004",
-            "SNOMEDCT:191415002",
-            "NCIT:C26726"
-          ],
-          "id": "MONDO:0005550",
-          "category": "biolink:Disease",
-          "all_names": [
-            "infectious disease",
-            "Infectious Disorder",
-            "disease by infectious agent",
-            "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-            "Communicable Diseases"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.merriam-webster.com/medical/communicable%20disease",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 539955,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-              "name": "infectious disease",
-              "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005550",
-                "SNOMEDCT:189822004",
-                "PSY:10513",
-                "UMLS:C0009450",
-                "UMLS:C0001485",
-                "EFO:0005741",
-                "MEDDRA:10021881",
-                "MESH:D003141",
-                "ICD9:079.0",
-                "DOID:0050117",
-                "SNOMEDCT:40733004",
-                "SNOMEDCT:191415002",
-                "NCIT:C26726"
-              ],
-              "id": "MONDO:0005550",
-              "category": "biolink:Disease",
-              "all_names": [
-                "infectious disease",
-                "Infectious Disorder",
-                "disease by infectious agent",
-                "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-                "Communicable Diseases"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.merriam-webster.com/medical/communicable%20disease",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7884454,
-            "start": 616,
-            "end": 539955,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10715297': {'publication date': '2000 Mar', 'sentence': 'PURPOSE: To determine whether an antibiotic flush solution containing vancomycin, heparin, and ciprofloxacin (VHC) can prevent the majority of line infections.', 'subject score': 1000, 'object score': 888}, 'PMID:11132527': {'publication date': '2000 Dec 02', 'sentence': 'This retrospective study confirms that oral prophylaxis with ciprofloxacin and penicillin decreases the incidence of infections and, in particular, of gram-negative bacteraemia, but does not modify the overall morbidity and mortality in our patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:1322231': {'publication date': '1992 Aug 15', 'sentence': 'RESULTS: The fluoroquinolone compounds, such as ciprofloxacin, norfloxacin, and ofloxacin, have broad spectrum bactericidal activity and have proved to be effective in both the treatment and prevention of certain infections in patients with cancer.', 'subject score': 1000, 'object score': 888}, 'PMID:1503442': {'publication date': '1992 Apr', 'sentence': 'A prospective randomized study was conducted to determine the efficacy of imipenem-cilastatin (hereafter referred to as imipenem) (500 mg four times daily) versus combination therapy for febrile neutropenic patients receiving either no prophylaxis or ciprofloxacin for prevention of infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:1611208': {'publication date': '1992 Apr', 'sentence': 'In an ex vivo model of infection using peritoneal resting macrophages from the C57BL/6 mouse, the intracellular viability of a strain of M. avium (strain 489, serovar 3) was reduced by clofazimine, amikacin, ciprofloxacin, rifabutin and clarithromycin (99, 98, 93, 89 and 69%, respectively), thus indicating for clofazimine a good correlation between in vitro and ex vivo activity.', 'subject score': 1000, 'object score': 1000}, 'PMID:19188359': {'publication date': '2009 Apr', 'sentence': 'Although there were major differences in pathogenesis, the recombinant F1 and V antigen vaccine and ciprofloxacin protected against plague infections caused by small- and large-particle aerosols.', 'subject score': 1000, 'object score': 888}, 'PMID:2048868': {'publication date': '1991 Jul 01', 'sentence': 'CONCLUSION: Ciprofloxacin should be used to prevent the development of infection in neutropenic patients with hematologic malignancies.', 'subject score': 1000, 'object score': 1000}, 'PMID:2098296': {'publication date': '1990 Nov-Dec', 'sentence': 'Ciprofloxacin appears to be an effective agent for the prevention of gram-negative infections in granulocytopenic patients with acute leukemia, but may contribute to a shift in the type of infections in these patients towards those caused by gram-positive microorganisms, intrinsically fairly sensitive or with acquired drug resistance.', 'subject score': 1000, 'object score': 851}, 'PMID:22476119': {'publication date': '2011 Oct-Dec', 'sentence': '[Ciprofloxacin vs cefazolin in the prevention of infection in cirrhotic patients with gastrointestinal bleeding].', 'subject score': 1000, 'object score': 1000}, 'PMID:2286588': {'publication date': '1990 Nov', 'sentence': 'Preliminary results are presented of an ongoing, prospective, randomized, study comparing ofloxacin, ciprofloxacin and co-trimoxazole/colistin for the prevention of infection in patients with acute leukaemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:2292538': {'publication date': '1990 Dec', 'sentence': 'Prevention of infection by ciprofloxacin in neutropenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:24415457': {'publication date': '2014 Apr 15', 'sentence': 'Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.', 'subject score': 1000, 'object score': 888}, 'PMID:24495623': {'publication date': '2014 Mar', 'sentence': 'Ciprofloxacin and trimethoprim-sulfamethoxazole are the most commonly recommended prophylactic antibiotics used to prevent A. hydrophila infections during leech therapy.', 'subject score': 1000, 'object score': 861}, 'PMID:25423029': {'publication date': '2015 Mar', 'sentence': 'CONCLUSION: Trimethoprim-sulfamethoxazole and ciprofloxacin appear equally effective at preventing leech-associated infections.', 'subject score': 1000, 'object score': 764}, 'PMID:2667112': {'publication date': '1989', 'sentence': 'Oral ciprofloxacin given prophylactically to immunocompromised patients during severe granulocytopenia prevented colonization with potentially pathogenic aerobic Gram-negative rods, and reduced the incidence of infections caused by these microorganisms.', 'subject score': 888, 'object score': 1000}, 'PMID:26951136': {'publication date': '2016 Nov', 'sentence': 'A single dose of meropenem is superior to ciprofloxacin in preventing infections after transrectal ultrasound-guided prostate biopsies in the era of quinolone resistance.', 'subject score': 1000, 'object score': 872}, 'PMID:2767765': {'publication date': '1989', 'sentence': 'We previously demonstrated that ciprofloxacin prevents infections caused by gram-negative bacilli in patients with granulocytopenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:28220110': {'publication date': '2017', 'sentence': 'Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague.', 'subject score': 851, 'object score': 861}, 'PMID:30017599': {'publication date': '2018 Sep', 'sentence': 'CONCLUSION: Immersing IPP material into an antibiotic solution, such as ampicillin or ciprofloxacin, increases the bactericidal properties and may aid in the prevention of infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:7548495': {'publication date': '1995 Jun', 'sentence': 'Ciprofloxacin failed to prevent V. cholerae O1 infections during a period of low transmissibility.', 'subject score': 1000, 'object score': 824}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:prevents---None---None---None---UMLS:C0009450---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8054296",
-              "object": "MONDO:0005550",
-              "publications": [
-                "PMID:10715297",
-                "PMID:11132527",
-                "PMID:1322231",
-                "PMID:1503442",
-                "PMID:1611208",
-                "PMID:19188359",
-                "PMID:2048868",
-                "PMID:2098296",
-                "PMID:22476119",
-                "PMID:2286588",
-                "PMID:2292538",
-                "PMID:24415457",
-                "PMID:24495623",
-                "PMID:25423029",
-                "PMID:2667112",
-                "PMID:26951136",
-                "PMID:2767765",
-                "PMID:28220110",
-                "PMID:30017599",
-                "PMID:7548495"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:26042652': {'publication date': '2015 Jun 05', 'sentence': 'Increasing rates of shigellosis among adult males, particularly men who have sex with men (MSM), have been documented in the United States, Canada, and Europe, and MSM appear to be at greater risk for infection with shigellae that are not susceptible to ciprofloxacin or azithromycin.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 539955,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-          "name": "infectious disease",
-          "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005550",
-            "SNOMEDCT:189822004",
-            "PSY:10513",
-            "UMLS:C0009450",
-            "UMLS:C0001485",
-            "EFO:0005741",
-            "MEDDRA:10021881",
-            "MESH:D003141",
-            "ICD9:079.0",
-            "DOID:0050117",
-            "SNOMEDCT:40733004",
-            "SNOMEDCT:191415002",
-            "NCIT:C26726"
-          ],
-          "id": "MONDO:0005550",
-          "category": "biolink:Disease",
-          "all_names": [
-            "infectious disease",
-            "Infectious Disorder",
-            "disease by infectious agent",
-            "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-            "Communicable Diseases"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.merriam-webster.com/medical/communicable%20disease",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 539955,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-              "name": "infectious disease",
-              "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005550",
-                "SNOMEDCT:189822004",
-                "PSY:10513",
-                "UMLS:C0009450",
-                "UMLS:C0001485",
-                "EFO:0005741",
-                "MEDDRA:10021881",
-                "MESH:D003141",
-                "ICD9:079.0",
-                "DOID:0050117",
-                "SNOMEDCT:40733004",
-                "SNOMEDCT:191415002",
-                "NCIT:C26726"
-              ],
-              "id": "MONDO:0005550",
-              "category": "biolink:Disease",
-              "all_names": [
-                "infectious disease",
-                "Infectious Disorder",
-                "disease by infectious agent",
-                "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-                "Communicable Diseases"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.merriam-webster.com/medical/communicable%20disease",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17992689,
-            "start": 616,
-            "end": 539955,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26042652': {'publication date': '2015 Jun 05', 'sentence': 'Increasing rates of shigellosis among adult males, particularly men who have sex with men (MSM), have been documented in the United States, Canada, and Europe, and MSM appear to be at greater risk for infection with shigellae that are not susceptible to ciprofloxacin or azithromycin.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:predisposes---None---None---None---UMLS:C0009450---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "18366035",
-              "object": "MONDO:0005550",
-              "publications": [
-                "PMID:26042652"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1836574': {'publication date': '1991 Oct 26', 'sentence': '[Pneumococcal meningitis during ciprofloxacin therapy for otitis media].', 'subject score': 888, 'object score': 1000}, 'PMID:24971692': {'publication date': '2014 Sep 10', 'sentence': 'Ciprofloxacin is a synthetic fluoroquinolone antibiotic that has been used for systemic treatment of otitis media in adults.', 'subject score': 1000, 'object score': 1000}, 'PMID:26609503': {'publication date': '2015', 'sentence': 'Ciprofloxacin, gentamicin, norfloxacin and erythromycin can be used to treat otitis media.', 'subject score': 1000, 'object score': 1000}, 'PMID:35734305': {'publication date': '2022', 'sentence': 'Amikacin, cefepime, ciprofloxacin, and meropenem could be valuable in the empirical management of childhood OM.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 317908,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005441",
-          "name": "otitis media",
-          "description": "Inflammation of the anatomical structures of the middle ear, which is most often caused by an infectious process. Symptoms include erythema and edema of the tympanic membrane, pain, and possibly fever.; Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.; Inflammation or infection of the middle ear. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "EFO:0004992",
-            "MEDDRA:10065838",
-            "MEDDRA:10046087",
-            "MEDDRA:10056747",
-            "ICD10:H66.9",
-            "MONDO:0005441",
-            "ICD9:382.9",
-            "MESH:D010033",
-            "SNOMEDCT:65363002",
-            "DOID:10754",
-            "MEDDRA:10033084",
-            "HP:0000388",
-            "UMLS:C0029882",
-            "MEDDRA:10033078",
-            "NCIT:C34885",
-            "MEDDRA:10027585"
-          ],
-          "id": "MONDO:0005441",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Otitis media",
-            "Unspecified otitis media",
-            "Otitis Media",
-            "otitis media"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/otitis_media",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317908,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005441",
-              "name": "otitis media",
-              "description": "Inflammation of the anatomical structures of the middle ear, which is most often caused by an infectious process. Symptoms include erythema and edema of the tympanic membrane, pain, and possibly fever.; Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.; Inflammation or infection of the middle ear. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "EFO:0004992",
-                "MEDDRA:10065838",
-                "MEDDRA:10046087",
-                "MEDDRA:10056747",
-                "ICD10:H66.9",
-                "MONDO:0005441",
-                "ICD9:382.9",
-                "MESH:D010033",
-                "SNOMEDCT:65363002",
-                "DOID:10754",
-                "MEDDRA:10033084",
-                "HP:0000388",
-                "UMLS:C0029882",
-                "MEDDRA:10033078",
-                "NCIT:C34885",
-                "MEDDRA:10027585"
-              ],
-              "id": "MONDO:0005441",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Otitis media",
-                "Unspecified otitis media",
-                "Otitis Media",
-                "otitis media"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/otitis_media",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13376907,
-            "start": 616,
-            "end": 317908,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1836574': {'publication date': '1991 Oct 26', 'sentence': '[Pneumococcal meningitis during ciprofloxacin therapy for otitis media].', 'subject score': 888, 'object score': 1000}, 'PMID:24971692': {'publication date': '2014 Sep 10', 'sentence': 'Ciprofloxacin is a synthetic fluoroquinolone antibiotic that has been used for systemic treatment of otitis media in adults.', 'subject score': 1000, 'object score': 1000}, 'PMID:26609503': {'publication date': '2015', 'sentence': 'Ciprofloxacin, gentamicin, norfloxacin and erythromycin can be used to treat otitis media.', 'subject score': 1000, 'object score': 1000}, 'PMID:35734305': {'publication date': '2022', 'sentence': 'Amikacin, cefepime, ciprofloxacin, and meropenem could be valuable in the empirical management of childhood OM.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0029882---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "13663890",
-              "object": "MONDO:0005441",
-              "publications": [
-                "PMID:1836574",
-                "PMID:24971692",
-                "PMID:26609503",
-                "PMID:35734305"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:23525574': {'publication date': '2014 Feb', 'sentence': 'CONCLUSIONS: Combination therapy of adalimumab and ciprofloxacin is more effective than adalimumab monotherapy to achieve fistula closure in CD.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 322120,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-          "name": "Crohn disease",
-          "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003424",
-            "ORPHANET:206",
-            "NCIT:C37262",
-            "MEDDRA:10038281",
-            "MEDDRA:10011405",
-            "UMLS:CN043071",
-            "SNOMEDCT:50440006",
-            "MEDDRA:10057032",
-            "HP:0100280",
-            "EFO:0000384",
-            "DOID:8778",
-            "MONDO:0005011",
-            "PDQ:CDR0000714480",
-            "UMLS:C0010346",
-            "NCIT:C2965",
-            "SNOMEDCT:7620006",
-            "ICD10:K50.1",
-            "UMLS:C0156147",
-            "MEDDRA:10011398",
-            "MEDDRA:10011401",
-            "SNOMEDCT:34000006",
-            "ICD9:555.1",
-            "MEDDRA:10013099",
-            "MEDDRA:10011402",
-            "MEDDRA:10011400"
-          ],
-          "id": "MONDO:0005011",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Granulomatous Colitis",
-            "Crohn's disease of large bowel",
-            "Regional enteritis of large intestine",
-            "Crohn Disease",
-            "Crohn disease",
-            "Crohn's disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/chron%27s_disease",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322120,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-              "name": "Crohn disease",
-              "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003424",
-                "ORPHANET:206",
-                "NCIT:C37262",
-                "MEDDRA:10038281",
-                "MEDDRA:10011405",
-                "UMLS:CN043071",
-                "SNOMEDCT:50440006",
-                "MEDDRA:10057032",
-                "HP:0100280",
-                "EFO:0000384",
-                "DOID:8778",
-                "MONDO:0005011",
-                "PDQ:CDR0000714480",
-                "UMLS:C0010346",
-                "NCIT:C2965",
-                "SNOMEDCT:7620006",
-                "ICD10:K50.1",
-                "UMLS:C0156147",
-                "MEDDRA:10011398",
-                "MEDDRA:10011401",
-                "SNOMEDCT:34000006",
-                "ICD9:555.1",
-                "MEDDRA:10013099",
-                "MEDDRA:10011402",
-                "MEDDRA:10011400"
-              ],
-              "id": "MONDO:0005011",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Granulomatous Colitis",
-                "Crohn's disease of large bowel",
-                "Regional enteritis of large intestine",
-                "Crohn Disease",
-                "Crohn disease",
-                "Crohn's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/chron%27s_disease",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16495220,
-            "start": 616,
-            "end": 322120,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23525574': {'publication date': '2014 Feb', 'sentence': 'CONCLUSIONS: Combination therapy of adalimumab and ciprofloxacin is more effective than adalimumab monotherapy to achieve fistula closure in CD.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:associated_with---None---None---None---UMLS:C0010346---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "16836665",
-              "object": "MONDO:0005011",
-              "publications": [
-                "PMID:23525574"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:17253612': {'publication date': '2007 May', 'sentence': \"BACKGROUND: Crohn's exacerbation and pouchitis are commonly treated with ciprofloxacin and metronidazole.\", 'subject score': 1000, 'object score': 694}, 'PMID:29722812': {'publication date': '2018 Jul 12', 'sentence': 'Evidence also points to a likely modest role of various antibiotic classes in mild to moderate luminal CD, including ciprofloxacin, metronidazole, azithromycin, and rifaximin.', 'subject score': 1000, 'object score': 822}}",
-    "p2": {
-      "start": {
-        "identity": 322120,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-          "name": "Crohn disease",
-          "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003424",
-            "ORPHANET:206",
-            "NCIT:C37262",
-            "MEDDRA:10038281",
-            "MEDDRA:10011405",
-            "UMLS:CN043071",
-            "SNOMEDCT:50440006",
-            "MEDDRA:10057032",
-            "HP:0100280",
-            "EFO:0000384",
-            "DOID:8778",
-            "MONDO:0005011",
-            "PDQ:CDR0000714480",
-            "UMLS:C0010346",
-            "NCIT:C2965",
-            "SNOMEDCT:7620006",
-            "ICD10:K50.1",
-            "UMLS:C0156147",
-            "MEDDRA:10011398",
-            "MEDDRA:10011401",
-            "SNOMEDCT:34000006",
-            "ICD9:555.1",
-            "MEDDRA:10013099",
-            "MEDDRA:10011402",
-            "MEDDRA:10011400"
-          ],
-          "id": "MONDO:0005011",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Granulomatous Colitis",
-            "Crohn's disease of large bowel",
-            "Regional enteritis of large intestine",
-            "Crohn Disease",
-            "Crohn disease",
-            "Crohn's disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/chron%27s_disease",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322120,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-              "name": "Crohn disease",
-              "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003424",
-                "ORPHANET:206",
-                "NCIT:C37262",
-                "MEDDRA:10038281",
-                "MEDDRA:10011405",
-                "UMLS:CN043071",
-                "SNOMEDCT:50440006",
-                "MEDDRA:10057032",
-                "HP:0100280",
-                "EFO:0000384",
-                "DOID:8778",
-                "MONDO:0005011",
-                "PDQ:CDR0000714480",
-                "UMLS:C0010346",
-                "NCIT:C2965",
-                "SNOMEDCT:7620006",
-                "ICD10:K50.1",
-                "UMLS:C0156147",
-                "MEDDRA:10011398",
-                "MEDDRA:10011401",
-                "SNOMEDCT:34000006",
-                "ICD9:555.1",
-                "MEDDRA:10013099",
-                "MEDDRA:10011402",
-                "MEDDRA:10011400"
-              ],
-              "id": "MONDO:0005011",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Granulomatous Colitis",
-                "Crohn's disease of large bowel",
-                "Regional enteritis of large intestine",
-                "Crohn Disease",
-                "Crohn disease",
-                "Crohn's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/chron%27s_disease",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12668690,
-            "start": 616,
-            "end": 322120,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17253612': {'publication date': '2007 May', 'sentence': \"BACKGROUND: Crohn's exacerbation and pouchitis are commonly treated with ciprofloxacin and metronidazole.\", 'subject score': 1000, 'object score': 694}, 'PMID:29722812': {'publication date': '2018 Jul 12', 'sentence': 'Evidence also points to a likely modest role of various antibiotic classes in mild to moderate luminal CD, including ciprofloxacin, metronidazole, azithromycin, and rifaximin.', 'subject score': 1000, 'object score': 822}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0010346---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "12942741",
-              "object": "MONDO:0005011",
-              "publications": [
-                "PMID:17253612",
-                "PMID:29722812"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10076781': {'publication date': '1998 Dec', 'sentence': \"Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin.\", 'subject score': 1000, 'object score': 901}, 'PMID:10086650': {'publication date': '1999 Mar', 'sentence': \"OBJECTIVE: The aim of this randomized controlled study was to investigate the efficacy of ciprofloxacin compared with mesalazine in treating active Crohn's disease.\", 'subject score': 1000, 'object score': 861}, 'PMID:11837933': {'publication date': '2002 Jan', 'sentence': \"Preliminary study of ciprofloxacin in active Crohn's disease.\", 'subject score': 1000, 'object score': 901}, 'PMID:12399240': {'publication date': '2002 Nov', 'sentence': \"Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn's disease.\", 'subject score': 861, 'object score': 1000}, 'PMID:12729319': {'publication date': '2003 Apr', 'sentence': \"OBJECTIVE: The aim of this study was to investigate the efficacy of metronidazole plus ciprofloxacin for the treatment of Japanese patients with active Crohn's disease.\", 'subject score': 851, 'object score': 901}, 'PMID:14653830': {'publication date': '2003 Dec', 'sentence': \"AIM: To investigate the efficacy of metronidazole and ciprofloxacin in the treatment of bacterial overgrowth in patients with Crohn's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:15855753': {'publication date': '2005', 'sentence': \"Metronidazole and/or ciprofloxacin are currently employed in active Crohn's disease, particularly in patients with colonic involvement and with perianal disease.\", 'subject score': 1000, 'object score': 901}, 'PMID:16985094': {'publication date': '2006 Oct', 'sentence': \"OBJECTIVE: To review the literature on novel immunomodulators such as tumor necrosis factor alpha (TNF-alpha)- and interleukin (IL)-related agents, 6-thioguanine (6-TG), tacrolimus, and leflunomide, and antibiotics such as ornidazole, rifaximin, and ciprofloxacin for the treatment of Crohn's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:23511031': {'publication date': '2013 Apr', 'sentence': 'METHODS: Thirty-three patients with CD, who had undergone surgery with ileocolonic anastomosis within the previous 2 weeks, were randomized to treatment with ciprofloxacin (500 mg twice daily) or placebo tablets for 6 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:24296421': {'publication date': '2014 Sep', 'sentence': 'METHODS: Microorganisms, their ciprofloxacin resistance, and clinical outcomes were retrospectively analyzed in 78 CD patients with intra-abdominal abscesses, who underwent percutaneous drainage between March 1991, and November 2011.', 'subject score': 694, 'object score': 824}, 'PMID:25469250': {'publication date': '2015 Jan', 'sentence': 'Thus in conclusion, cipro exhibits a significant efficacy for the treatment of CD, in particular with perianal fistula.', 'subject score': 1000, 'object score': 1000}, 'PMID:25715809': {'publication date': '2016 Sep', 'sentence': \"Ciprofloxacin was selected because of its extensive coverage for intestinal flora, relatively favorable side-effect profile and preliminary data suggesting its efficacy in the treatment of active Crohn's Disease.\", 'subject score': 1000, 'object score': 901}, 'PMID:33656882': {'publication date': '2021 Mar 03', 'sentence': 'The bioaccessibility of ciprofloxacin was similar in simulated CD and healthy conditions considering its extent as well as its time course in the jejunum and ileum filtrate.', 'subject score': 1000, 'object score': 901}, 'PMID:15168372': {'publication date': '2004 May', 'sentence': \"Current clinical trials do not fulfill evidence-based criteria for using these agents in inflammatory bowel diseases (IBD), but multiple nonrigorous studies and widespread clinical experience suggest that metronidazole and/or ciprofloxacin can treat Crohn's colitis and ileocolitis (but not isolated ileal disease), perianal fistulae and pouchitis, whereas selected probiotic preparations prevent relapse of quiescent ulcerative colitis and relapsing pouchitis.\", 'subject score': 1000, 'object score': 1000}, 'PMID:15703577': {'publication date': '2003 Jul', 'sentence': 'Metronidazole and ciprofloxacin selectively treat colonic Crohn disease, but not ulcerative colitis or ileal Crohn disease, and may prevent recurrence of postoperative Crohn disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:20492483': {'publication date': '2010 Jul-Aug', 'sentence': 'Resistance to ampicillin, amoxicillin-clavulanate, cefoxitin, tetracycline, trimethoprim-sulfa (TMS), ciprofloxacin, and chloramphenicol was greater (P<.05) in GC (21-64%) than healthy (0-24%).', 'subject score': 1000, 'object score': 1000}, 'PMID:22179210': {'publication date': '2011', 'sentence': \"Although current clinical trials do not fulfill criteria of evidence-based treatment, a few placebo- or standard treatment-controlled studies suggest that metronidazole and ciprofloxacin are effective in Crohn's colitis and ileocolitis, perianal fistulae and pouchitis.\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 322120,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-          "name": "Crohn disease",
-          "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003424",
-            "ORPHANET:206",
-            "NCIT:C37262",
-            "MEDDRA:10038281",
-            "MEDDRA:10011405",
-            "UMLS:CN043071",
-            "SNOMEDCT:50440006",
-            "MEDDRA:10057032",
-            "HP:0100280",
-            "EFO:0000384",
-            "DOID:8778",
-            "MONDO:0005011",
-            "PDQ:CDR0000714480",
-            "UMLS:C0010346",
-            "NCIT:C2965",
-            "SNOMEDCT:7620006",
-            "ICD10:K50.1",
-            "UMLS:C0156147",
-            "MEDDRA:10011398",
-            "MEDDRA:10011401",
-            "SNOMEDCT:34000006",
-            "ICD9:555.1",
-            "MEDDRA:10013099",
-            "MEDDRA:10011402",
-            "MEDDRA:10011400"
-          ],
-          "id": "MONDO:0005011",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Granulomatous Colitis",
-            "Crohn's disease of large bowel",
-            "Regional enteritis of large intestine",
-            "Crohn Disease",
-            "Crohn disease",
-            "Crohn's disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/chron%27s_disease",
-            "https://orcid.org/0009-0006-4530-3154"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322120,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005011",
-              "name": "Crohn disease",
-              "description": "A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2965\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2965\" NCI Thesaurus); A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.; A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.; A chronic granulomatous inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea which may be bloody, vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003424",
-                "ORPHANET:206",
-                "NCIT:C37262",
-                "MEDDRA:10038281",
-                "MEDDRA:10011405",
-                "UMLS:CN043071",
-                "SNOMEDCT:50440006",
-                "MEDDRA:10057032",
-                "HP:0100280",
-                "EFO:0000384",
-                "DOID:8778",
-                "MONDO:0005011",
-                "PDQ:CDR0000714480",
-                "UMLS:C0010346",
-                "NCIT:C2965",
-                "SNOMEDCT:7620006",
-                "ICD10:K50.1",
-                "UMLS:C0156147",
-                "MEDDRA:10011398",
-                "MEDDRA:10011401",
-                "SNOMEDCT:34000006",
-                "ICD9:555.1",
-                "MEDDRA:10013099",
-                "MEDDRA:10011402",
-                "MEDDRA:10011400"
-              ],
-              "id": "MONDO:0005011",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Granulomatous Colitis",
-                "Crohn's disease of large bowel",
-                "Regional enteritis of large intestine",
-                "Crohn Disease",
-                "Crohn disease",
-                "Crohn's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/chron%27s_disease",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7023909,
-            "start": 616,
-            "end": 322120,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10076781': {'publication date': '1998 Dec', 'sentence': \"Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin.\", 'subject score': 1000, 'object score': 901}, 'PMID:10086650': {'publication date': '1999 Mar', 'sentence': \"OBJECTIVE: The aim of this randomized controlled study was to investigate the efficacy of ciprofloxacin compared with mesalazine in treating active Crohn's disease.\", 'subject score': 1000, 'object score': 861}, 'PMID:11837933': {'publication date': '2002 Jan', 'sentence': \"Preliminary study of ciprofloxacin in active Crohn's disease.\", 'subject score': 1000, 'object score': 901}, 'PMID:12399240': {'publication date': '2002 Nov', 'sentence': \"Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn's disease.\", 'subject score': 861, 'object score': 1000}, 'PMID:12729319': {'publication date': '2003 Apr', 'sentence': \"OBJECTIVE: The aim of this study was to investigate the efficacy of metronidazole plus ciprofloxacin for the treatment of Japanese patients with active Crohn's disease.\", 'subject score': 851, 'object score': 901}, 'PMID:14653830': {'publication date': '2003 Dec', 'sentence': \"AIM: To investigate the efficacy of metronidazole and ciprofloxacin in the treatment of bacterial overgrowth in patients with Crohn's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:15855753': {'publication date': '2005', 'sentence': \"Metronidazole and/or ciprofloxacin are currently employed in active Crohn's disease, particularly in patients with colonic involvement and with perianal disease.\", 'subject score': 1000, 'object score': 901}, 'PMID:16985094': {'publication date': '2006 Oct', 'sentence': \"OBJECTIVE: To review the literature on novel immunomodulators such as tumor necrosis factor alpha (TNF-alpha)- and interleukin (IL)-related agents, 6-thioguanine (6-TG), tacrolimus, and leflunomide, and antibiotics such as ornidazole, rifaximin, and ciprofloxacin for the treatment of Crohn's disease.\", 'subject score': 1000, 'object score': 1000}, 'PMID:23511031': {'publication date': '2013 Apr', 'sentence': 'METHODS: Thirty-three patients with CD, who had undergone surgery with ileocolonic anastomosis within the previous 2 weeks, were randomized to treatment with ciprofloxacin (500 mg twice daily) or placebo tablets for 6 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:24296421': {'publication date': '2014 Sep', 'sentence': 'METHODS: Microorganisms, their ciprofloxacin resistance, and clinical outcomes were retrospectively analyzed in 78 CD patients with intra-abdominal abscesses, who underwent percutaneous drainage between March 1991, and November 2011.', 'subject score': 694, 'object score': 824}, 'PMID:25469250': {'publication date': '2015 Jan', 'sentence': 'Thus in conclusion, cipro exhibits a significant efficacy for the treatment of CD, in particular with perianal fistula.', 'subject score': 1000, 'object score': 1000}, 'PMID:25715809': {'publication date': '2016 Sep', 'sentence': \"Ciprofloxacin was selected because of its extensive coverage for intestinal flora, relatively favorable side-effect profile and preliminary data suggesting its efficacy in the treatment of active Crohn's Disease.\", 'subject score': 1000, 'object score': 901}, 'PMID:33656882': {'publication date': '2021 Mar 03', 'sentence': 'The bioaccessibility of ciprofloxacin was similar in simulated CD and healthy conditions considering its extent as well as its time course in the jejunum and ileum filtrate.', 'subject score': 1000, 'object score': 901}, 'PMID:15168372': {'publication date': '2004 May', 'sentence': \"Current clinical trials do not fulfill evidence-based criteria for using these agents in inflammatory bowel diseases (IBD), but multiple nonrigorous studies and widespread clinical experience suggest that metronidazole and/or ciprofloxacin can treat Crohn's colitis and ileocolitis (but not isolated ileal disease), perianal fistulae and pouchitis, whereas selected probiotic preparations prevent relapse of quiescent ulcerative colitis and relapsing pouchitis.\", 'subject score': 1000, 'object score': 1000}, 'PMID:15703577': {'publication date': '2003 Jul', 'sentence': 'Metronidazole and ciprofloxacin selectively treat colonic Crohn disease, but not ulcerative colitis or ileal Crohn disease, and may prevent recurrence of postoperative Crohn disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:20492483': {'publication date': '2010 Jul-Aug', 'sentence': 'Resistance to ampicillin, amoxicillin-clavulanate, cefoxitin, tetracycline, trimethoprim-sulfa (TMS), ciprofloxacin, and chloramphenicol was greater (P<.05) in GC (21-64%) than healthy (0-24%).', 'subject score': 1000, 'object score': 1000}, 'PMID:22179210': {'publication date': '2011', 'sentence': \"Although current clinical trials do not fulfill criteria of evidence-based treatment, a few placebo- or standard treatment-controlled studies suggest that metronidazole and ciprofloxacin are effective in Crohn's colitis and ileocolitis, perianal fistulae and pouchitis.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0010346---SEMMEDDB:",
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0156147---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7163480",
-              "object": "MONDO:0005011",
-              "publications": [
-                "PMID:24296421",
-                "PMID:22179210",
-                "PMID:12729319",
-                "PMID:10086650",
-                "PMID:23511031",
-                "PMID:15168372",
-                "PMID:25469250",
-                "PMID:16985094",
-                "PMID:11837933",
-                "PMID:15703577",
-                "PMID:12399240",
-                "PMID:10076781",
-                "PMID:33656882",
-                "PMID:14653830",
-                "PMID:20492483",
-                "PMID:15855753",
-                "PMID:25715809"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 212250,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:10435684': {'publication date': '1999 Jun', 'sentence': 'Azithromycin, sultamicillin, ciprofloxacin and cefaclor monohydrate were found to be effective in treating COPD exacerbations.', 'subject score': 1000, 'object score': 709}}",
-    "p2": {
-      "start": {
-        "identity": 324986,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-          "name": "Fever",
-          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MEDDRA:10037660",
-            "MEDDRA:10020083",
-            "MEDDRA:10005911",
-            "UMLS:C0015967",
-            "HP:0001945",
-            "NCIT:C3038",
-            "MEDDRA:10073718",
-            "MEDDRA:10043204",
-            "MEDDRA:10037668",
-            "PDQ:CDR0000775882",
-            "PSY:19660",
-            "SNOMEDCT:386661006",
-            "MEDDRA:10016558",
-            "MEDDRA:10037663",
-            "SNOMEDCT:50177009",
-            "SYMP:0000613",
-            "MESH:D005334"
-          ],
-          "id": "HP:0001945",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "fever",
-            "Fever"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "PMID:9759682",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-            "https://orcid.org/0009-0006-4530-3154"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-          "name": "chronic obstructive pulmonary disease",
-          "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-          "equivalent_curies": [
-            "MESH:D029424",
-            "MEDDRA:10010952",
-            "MEDDRA:10009025",
-            "ICD10:J44.9",
-            "UMLS:C1527303",
-            "NCIT:C3199",
-            "UMLS:C0024117",
-            "MEDDRA:10064611",
-            "MEDDRA:10009026",
-            "MEDDRA:10029972",
-            "DOID:3083",
-            "MONDO:0005002",
-            "MEDDRA:10009032",
-            "MEDDRA:10070975",
-            "EFO:0000341",
-            "SNOMEDCT:13645005",
-            "MEDDRA:10009033",
-            "HP:0006510",
-            "MEDDRA:10008828"
-          ],
-          "id": "MONDO:0005002",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic Obstructive Pulmonary Disease",
-            "chronic obstructive pulmonary disease",
-            "Chronic pulmonary obstruction",
-            "Chronic Airflow Obstruction",
-            "Chronic Obstructive Airway Disease",
-            "Pulmonary Disease, Chronic Obstructive"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health-topics/copd",
-            "PMID:32800196",
-            "PMID:28513453",
-            "PMID:25943942",
-            "PMID:32745458"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 324986,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-              "name": "chronic obstructive pulmonary disease",
-              "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-              "equivalent_curies": [
-                "MESH:D029424",
-                "MEDDRA:10010952",
-                "MEDDRA:10009025",
-                "ICD10:J44.9",
-                "UMLS:C1527303",
-                "NCIT:C3199",
-                "UMLS:C0024117",
-                "MEDDRA:10064611",
-                "MEDDRA:10009026",
-                "MEDDRA:10029972",
-                "DOID:3083",
-                "MONDO:0005002",
-                "MEDDRA:10009032",
-                "MEDDRA:10070975",
-                "EFO:0000341",
-                "SNOMEDCT:13645005",
-                "MEDDRA:10009033",
-                "HP:0006510",
-                "MEDDRA:10008828"
-              ],
-              "id": "MONDO:0005002",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic Obstructive Pulmonary Disease",
-                "chronic obstructive pulmonary disease",
-                "Chronic pulmonary obstruction",
-                "Chronic Airflow Obstruction",
-                "Chronic Obstructive Airway Disease",
-                "Pulmonary Disease, Chronic Obstructive"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health-topics/copd",
-                "PMID:32800196",
-                "PMID:28513453",
-                "PMID:25943942",
-                "PMID:32745458"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7437751,
-            "start": 616,
-            "end": 324986,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10435684': {'publication date': '1999 Jun', 'sentence': 'Azithromycin, sultamicillin, ciprofloxacin and cefaclor monohydrate were found to be effective in treating COPD exacerbations.', 'subject score': 1000, 'object score': 709}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0024117---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7592205",
-              "object": "MONDO:0005002",
-              "publications": [
-                "PMID:10435684"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15592904': {'publication date': '2005 Jan', 'sentence': 'Reported here is the case of a patient with underlying chronic obstructive pulmonary disease (COPD) in whom ciprofloxacin treatment of a lower respiratory tract infection failed subsequent to ciprofloxacin treatment of an exacerbation of COPD several weeks earlier.', 'subject score': 888, 'object score': 937}}",
-    "p2": {
-      "start": {
-        "identity": 324986,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-          "name": "chronic obstructive pulmonary disease",
-          "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-          "equivalent_curies": [
-            "MESH:D029424",
-            "MEDDRA:10010952",
-            "MEDDRA:10009025",
-            "ICD10:J44.9",
-            "UMLS:C1527303",
-            "NCIT:C3199",
-            "UMLS:C0024117",
-            "MEDDRA:10064611",
-            "MEDDRA:10009026",
-            "MEDDRA:10029972",
-            "DOID:3083",
-            "MONDO:0005002",
-            "MEDDRA:10009032",
-            "MEDDRA:10070975",
-            "EFO:0000341",
-            "SNOMEDCT:13645005",
-            "MEDDRA:10009033",
-            "HP:0006510",
-            "MEDDRA:10008828"
-          ],
-          "id": "MONDO:0005002",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Chronic Obstructive Pulmonary Disease",
-            "chronic obstructive pulmonary disease",
-            "Chronic pulmonary obstruction",
-            "Chronic Airflow Obstruction",
-            "Chronic Obstructive Airway Disease",
-            "Pulmonary Disease, Chronic Obstructive"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nhlbi.nih.gov/health-topics/copd",
-            "PMID:32800196",
-            "PMID:28513453",
-            "PMID:25943942",
-            "PMID:32745458"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 324986,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005002",
-              "name": "chronic obstructive pulmonary disease",
-              "description": "A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.; A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.; An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. [PMID:25943942]",
-              "equivalent_curies": [
-                "MESH:D029424",
-                "MEDDRA:10010952",
-                "MEDDRA:10009025",
-                "ICD10:J44.9",
-                "UMLS:C1527303",
-                "NCIT:C3199",
-                "UMLS:C0024117",
-                "MEDDRA:10064611",
-                "MEDDRA:10009026",
-                "MEDDRA:10029972",
-                "DOID:3083",
-                "MONDO:0005002",
-                "MEDDRA:10009032",
-                "MEDDRA:10070975",
-                "EFO:0000341",
-                "SNOMEDCT:13645005",
-                "MEDDRA:10009033",
-                "HP:0006510",
-                "MEDDRA:10008828"
-              ],
-              "id": "MONDO:0005002",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Chronic Obstructive Pulmonary Disease",
-                "chronic obstructive pulmonary disease",
-                "Chronic pulmonary obstruction",
-                "Chronic Airflow Obstruction",
-                "Chronic Obstructive Airway Disease",
-                "Pulmonary Disease, Chronic Obstructive"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nhlbi.nih.gov/health-topics/copd",
-                "PMID:32800196",
-                "PMID:28513453",
-                "PMID:25943942",
-                "PMID:32745458"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11317272,
-            "start": 616,
-            "end": 324986,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15592904': {'publication date': '2005 Jan', 'sentence': 'Reported here is the case of a patient with underlying chronic obstructive pulmonary disease (COPD) in whom ciprofloxacin treatment of a lower respiratory tract infection failed subsequent to ciprofloxacin treatment of an exacerbation of COPD several weeks earlier.', 'subject score': 888, 'object score': 937}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0024117---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "11564697",
-              "object": "MONDO:0005002",
-              "publications": [
-                "PMID:15592904"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:10606835': {'publication date': '2000 Jan', 'sentence': 'AIMS: To examine the pharmacokinetics of ciprofloxacin and fleroxacin in plasma and sputum of patients with an acute exacerbation of chronic bronchitis or bronchiectasis following the first dose and again during the third day of treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:8697891': {'publication date': '1996', 'sentence': 'The findings suggest that ciprofloxacin is an effective treatment of infective exacerbations of bronchiectasis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318598,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004822",
-          "name": "bronchiectasis",
-          "description": "Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways. [HPO:probinson]; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:J47",
-            "ICD9:494",
-            "MESH:D001987",
-            "MEDDRA:10006445",
-            "DOID:9563",
-            "MEDDRA:10006446",
-            "OMIM.PS:211400",
-            "MONDO:0004822",
-            "OMIM:PS211400",
-            "UMLS:C0006267",
-            "NCIT:C84475",
-            "HP:0002110",
-            "SNOMEDCT:12295008"
-          ],
-          "id": "MONDO:0004822",
-          "category": "biolink:Disease",
-          "all_names": [
-            "bronchiectasis",
-            "Bronchiectasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.merck.com/mmhe/sec04/ch047/ch047a.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=bronchiectasis",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318598,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004822",
-              "name": "bronchiectasis",
-              "description": "Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways. [HPO:probinson]; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:J47",
-                "ICD9:494",
-                "MESH:D001987",
-                "MEDDRA:10006445",
-                "DOID:9563",
-                "MEDDRA:10006446",
-                "OMIM.PS:211400",
-                "MONDO:0004822",
-                "OMIM:PS211400",
-                "UMLS:C0006267",
-                "NCIT:C84475",
-                "HP:0002110",
-                "SNOMEDCT:12295008"
-              ],
-              "id": "MONDO:0004822",
-              "category": "biolink:Disease",
-              "all_names": [
-                "bronchiectasis",
-                "Bronchiectasis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.merck.com/mmhe/sec04/ch047/ch047a.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=bronchiectasis",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7711380,
-            "start": 616,
-            "end": 318598,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10606835': {'publication date': '2000 Jan', 'sentence': 'AIMS: To examine the pharmacokinetics of ciprofloxacin and fleroxacin in plasma and sputum of patients with an acute exacerbation of chronic bronchitis or bronchiectasis following the first dose and again during the third day of treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:8697891': {'publication date': '1996', 'sentence': 'The findings suggest that ciprofloxacin is an effective treatment of infective exacerbations of bronchiectasis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:affects---None---None---None---UMLS:C0006267---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7886704",
-              "object": "MONDO:0004822",
-              "publications": [
-                "PMID:10606835",
-                "PMID:8697891"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12174240': {'publication date': '2002 Jul', 'sentence': 'He had severe airway obstruction and focal bronchiectasis, and responded to treatment with ciprofloxacin and clarithromycin.', 'subject score': 1000, 'object score': 888}, 'PMID:12654682': {'publication date': '2003 Apr', 'sentence': 'Five Spain(9V-3) Streptococcus pneumoniae strains were isolated from a patient with bronchiectasis who had received long-term ciprofloxacin therapy.', 'subject score': 840, 'object score': 1000}, 'PMID:23681906': {'publication date': '2013 Sep', 'sentence': 'Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.', 'subject score': 775, 'object score': 824}, 'PMID:23690368': {'publication date': '2013 Oct', 'sentence': 'Lastly, the anticipated role of inhaled ciprofloxacin in the management of NCFBE is discussed, including future considerations and potential limitations of therapy.', 'subject score': 888, 'object score': 824}, 'PMID:28778139': {'publication date': '2017 Sep', 'sentence': 'Inhaled or nebulised ciprofloxacin for the maintenance treatment of bronchiectasis.', 'subject score': 861, 'object score': 1000}, 'PMID:29077527': {'publication date': '2018 Jun', 'sentence': 'Recently, several investigators conducted phase 3 randomized controlled trials with inhaled aztreonam and ciprofloxacin in patients with NCFBE.', 'subject score': 1000, 'object score': 824}, 'PMID:30568427': {'publication date': '2018', 'sentence': 'Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis.', 'subject score': 888, 'object score': 824}, 'PMID:30658914': {'publication date': '2019 Mar', 'sentence': 'Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.', 'subject score': 851, 'object score': 824}, 'PMID:30673901': {'publication date': '2019 Jan 23', 'sentence': 'The presented results indicated the novel inhalable silk-based DPI microparticles of CIP could provide a promising strategy for the treatment of NCFB.', 'subject score': 1000, 'object score': 824}, 'PMID:31035017': {'publication date': '2019 Dec', 'sentence': 'Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection.', 'subject score': 851, 'object score': 824}, 'PMID:33469994': {'publication date': '2021 Jan 19', 'sentence': 'We conducted the present meta-analysis to comprehensively evaluate the feasibility of inhalation of ciprofloxacin in NCFB.', 'subject score': 1000, 'object score': 824}, 'PMID:33814907': {'publication date': '2021', 'sentence': 'Conclusion: Novel inhalable CIP NCMP powders are a potential new approach to improved target ability and delivery of CIP for NCFB treatment.', 'subject score': 1000, 'object score': 775}, 'PMID:7961201': {'publication date': '1994 Jul', 'sentence': 'The efficacy and safety of long-term ciprofloxacin therapy in the management of severe bronchiectasis were retrospectively assessed in patients who had taken oral ciprofloxacin continuously for at least 90 days.', 'subject score': 790, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 318598,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004822",
-          "name": "bronchiectasis",
-          "description": "Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways. [HPO:probinson]; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:J47",
-            "ICD9:494",
-            "MESH:D001987",
-            "MEDDRA:10006445",
-            "DOID:9563",
-            "MEDDRA:10006446",
-            "OMIM.PS:211400",
-            "MONDO:0004822",
-            "OMIM:PS211400",
-            "UMLS:C0006267",
-            "NCIT:C84475",
-            "HP:0002110",
-            "SNOMEDCT:12295008"
-          ],
-          "id": "MONDO:0004822",
-          "category": "biolink:Disease",
-          "all_names": [
-            "bronchiectasis",
-            "Bronchiectasis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.merck.com/mmhe/sec04/ch047/ch047a.htm",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=bronchiectasis",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318598,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004822",
-              "name": "bronchiectasis",
-              "description": "Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways. [HPO:probinson]; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; Persistent abnormal dilatation of the bronchi owing to localized and irreversible destruction and widening of the large airways.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:J47",
-                "ICD9:494",
-                "MESH:D001987",
-                "MEDDRA:10006445",
-                "DOID:9563",
-                "MEDDRA:10006446",
-                "OMIM.PS:211400",
-                "MONDO:0004822",
-                "OMIM:PS211400",
-                "UMLS:C0006267",
-                "NCIT:C84475",
-                "HP:0002110",
-                "SNOMEDCT:12295008"
-              ],
-              "id": "MONDO:0004822",
-              "category": "biolink:Disease",
-              "all_names": [
-                "bronchiectasis",
-                "Bronchiectasis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.merck.com/mmhe/sec04/ch047/ch047a.htm",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=bronchiectasis",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9494685,
-            "start": 616,
-            "end": 318598,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12174240': {'publication date': '2002 Jul', 'sentence': 'He had severe airway obstruction and focal bronchiectasis, and responded to treatment with ciprofloxacin and clarithromycin.', 'subject score': 1000, 'object score': 888}, 'PMID:12654682': {'publication date': '2003 Apr', 'sentence': 'Five Spain(9V-3) Streptococcus pneumoniae strains were isolated from a patient with bronchiectasis who had received long-term ciprofloxacin therapy.', 'subject score': 840, 'object score': 1000}, 'PMID:23681906': {'publication date': '2013 Sep', 'sentence': 'Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.', 'subject score': 775, 'object score': 824}, 'PMID:23690368': {'publication date': '2013 Oct', 'sentence': 'Lastly, the anticipated role of inhaled ciprofloxacin in the management of NCFBE is discussed, including future considerations and potential limitations of therapy.', 'subject score': 888, 'object score': 824}, 'PMID:28778139': {'publication date': '2017 Sep', 'sentence': 'Inhaled or nebulised ciprofloxacin for the maintenance treatment of bronchiectasis.', 'subject score': 861, 'object score': 1000}, 'PMID:29077527': {'publication date': '2018 Jun', 'sentence': 'Recently, several investigators conducted phase 3 randomized controlled trials with inhaled aztreonam and ciprofloxacin in patients with NCFBE.', 'subject score': 1000, 'object score': 824}, 'PMID:30568427': {'publication date': '2018', 'sentence': 'Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis.', 'subject score': 888, 'object score': 824}, 'PMID:30658914': {'publication date': '2019 Mar', 'sentence': 'Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.', 'subject score': 851, 'object score': 824}, 'PMID:30673901': {'publication date': '2019 Jan 23', 'sentence': 'The presented results indicated the novel inhalable silk-based DPI microparticles of CIP could provide a promising strategy for the treatment of NCFB.', 'subject score': 1000, 'object score': 824}, 'PMID:31035017': {'publication date': '2019 Dec', 'sentence': 'Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection.', 'subject score': 851, 'object score': 824}, 'PMID:33469994': {'publication date': '2021 Jan 19', 'sentence': 'We conducted the present meta-analysis to comprehensively evaluate the feasibility of inhalation of ciprofloxacin in NCFB.', 'subject score': 1000, 'object score': 824}, 'PMID:33814907': {'publication date': '2021', 'sentence': 'Conclusion: Novel inhalable CIP NCMP powders are a potential new approach to improved target ability and delivery of CIP for NCFB treatment.', 'subject score': 1000, 'object score': 775}, 'PMID:7961201': {'publication date': '1994 Jul', 'sentence': 'The efficacy and safety of long-term ciprofloxacin therapy in the management of severe bronchiectasis were retrospectively assessed in patients who had taken oral ciprofloxacin continuously for at least 90 days.', 'subject score': 790, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0006267---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "9704134",
-              "object": "MONDO:0004822",
-              "publications": [
-                "PMID:12174240",
-                "PMID:12654682",
-                "PMID:23681906",
-                "PMID:23690368",
-                "PMID:28778139",
-                "PMID:29077527",
-                "PMID:30568427",
-                "PMID:30658914",
-                "PMID:30673901",
-                "PMID:31035017",
-                "PMID:33469994",
-                "PMID:33814907",
-                "PMID:7961201"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10410578': {'publication date': '1998 Nov', 'sentence': 'The aim of this study was to investigate clinical importance of ciprofloxacin efficacy in treatment of massive diarrhoea in patients after extensional bowel resection with removing of ileo-coecal valve (EBR + ICVR).', 'subject score': 694, 'object score': 888}, 'PMID:10476738': {'publication date': '1999 Aug', 'sentence': 'There was a significant reduction in the duration of posttreatment diarrhea in the 16 patients treated with ciprofloxacin, as compared with that in the 13 patients who received placebo (mean of 35.3 versus 55.5 hours; P = .049).', 'subject score': 1000, 'object score': 861}, 'PMID:1728922': {'publication date': '1992 Jan', 'sentence': 'A note of caution on empiric use of ciprofloxacin for diarrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:19578229': {'publication date': '2010 Apr', 'sentence': 'Patients treated with Azithromycin had a shorter duration of diarrhea [mean(SD) 54.6 (18.6) vs 71.5 (29.6) h; mean difference (95% CI) 16.9 (9.6 -24.2); P<0.001] and lesser duration of excretion of Vibrio cholerae [mean(SD) 34.6 (16.3) vs 52.1 (29.2) h; mean difference (95% CI) 17.5 (0.2 -24.7), P<0.001] in children treated with Azithromycin vs Ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:20331580': {'publication date': '2010 Jun', 'sentence': \"When administered three times daily for 3 days, rifaximin is superior to placebo or loperamide; it is at least as effective as ciprofloxacin in reducing duration of illness and restoring wellbeing in patients with travellers' diarrhoea, both with and without identification of a pathogen, as well as in diarrhoea caused by Escherichia coli infection.\", 'subject score': 1000, 'object score': 1000}, 'PMID:20422140': {'publication date': '2009 Dec', 'sentence': 'Later, due to recurrence of the diarrhea, he was treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:22354292': {'publication date': '2012 May', 'sentence': 'We used a mouse model for Salmonella diarrhea to assess the effects of per os treatment with ciprofloxacin (15 mg/kg of body weight intragastrically 2 times/day, 5 days) or parenteral ceftriaxone (50 mg/kg intraperitoneally, 5 days), two common drugs used in human patients.', 'subject score': 1000, 'object score': 888}, 'PMID:25131673': {'publication date': '2014 Sep 08', 'sentence': 'In a mouse model for Salmonella diarrhea, treatment with the broad-spectrum antibiotic ciprofloxacin reverses the outcome of competition between wild-type bacteria and avirulent mutants that can spontaneously arise during within-host evolution [5].', 'subject score': 775, 'object score': 888}, 'PMID:27167632': {'publication date': '2016 Aug', 'sentence': 'This was preceded by diarrhea and treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:27428376': {'publication date': '2016', 'sentence': 'Ciprofloxacin is a broad-spectrum antimicrobial agent nowadays used for the treatment of diarrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:28603782': {'publication date': '2017', 'sentence': 'RESULTS: We found 2.7% (230/8,672) of children who presented with diarrhea had Shigella spp. isolated from their stool, and 50% (115/230) had resistance to Ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:30420482': {'publication date': '2018 Nov 12', 'sentence': 'Antibiotic resistance between C. jejuni and non-C. jejuni isolates, and surveillance and diarrhea samples were compared and the association between personal macrolide exposure and subsequent occurrence of a macrolide resistant Campylobacter spp. was assessed.ResultsOf 917 Campylobacter isolates, 77.4% of C. jejuni isolates and 79.8% non-C. jejuni isolates were resistant to ciprofloxacin while 4.9% of C. jejuni isolates and 24.8% of non-C. jejuni isolates were not susceptible to azithromycin.', 'subject score': 1000, 'object score': 694}, 'PMID:31153984': {'publication date': '2019 Sep', 'sentence': 'MSF favored diarrhea management as compared to ciprofloxacin, suggesting that MSF can be used in the management of E. coli O1-induced diarrhea, in normal gut microbiota and normal intestinal antioxidant function.', 'subject score': 1000, 'object score': 785}, 'PMID:3541724': {'publication date': '1987 Feb', 'sentence': 'Both antimicrobial agents were significantly (p less than 0.0001) more efficacious than placebo in the treatment of diarrhea, with the average duration of diarrhea being 29, 20, and 81 hours, respectively, in the ciprofloxacin, trimethoprim-sulfamethoxazole, and placebo treatment groups.', 'subject score': 1000, 'object score': 1000}, 'PMID:3555056': {'publication date': '1987 Apr 27', 'sentence': 'The average duration of diarrhea was 29 or 20 hours after initiation of treatment with ciprofloxacin or trimethoprim/sulfamethoxazole, respectively, compared with 81 hours in the placebo group.', 'subject score': 1000, 'object score': 1000}, 'PMID:35847602': {'publication date': '2022', 'sentence': 'The patient was treated with 3 days of ciprofloxacin with clinical resolution of diarrhoea.', 'subject score': 1000, 'object score': 1000}, 'PMID:36642099': {'publication date': '2023 Jan 12', 'sentence': 'CONCLUSION: A single dose of ciprofloxacin was effective and safe in treating uncomplicated diarrhea among service members in Africa.', 'subject score': 1000, 'object score': 851}, 'PMID:7883355': {'publication date': '1994 Aug', 'sentence': 'Parenteral ciprofloxacin in persistent diarrhea.', 'subject score': 861, 'object score': 888}, 'PMID:8810190': {'publication date': '1996 Feb', 'sentence': 'Parenteral ciprofloxacin in persistent diarrhoea in children.', 'subject score': 861, 'object score': 888}, 'PMID:9053412': {'publication date': '1995 Oct', 'sentence': 'Parenteral ciprofloxacin in persistent diarrhoea in children.', 'subject score': 861, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 321337,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001673",
-          "name": "diarrheal disease",
-          "description": "A gastrointestinal system disease described as the condition of having frequent loose or liquid bowel movements. Acute diarrhea is a common cause of death in developing countries and the second most common cause of infant deaths worldwide. The loss of fluids through diarrhea can cause severe dehydration which is one cause of death in diarrhea sufferers. Along with water, sufferers also lose dangerous amounts of important salts, electrolytes, and other nutrients. There are at least four types of diarrhea: secretory diarrhea, osmotic diarrhea, motility-related diarrhea, and inflammatory diarrhea. // COMMENTS: diarrhea is both a disease and a symptom [ms]",
-          "equivalent_curies": [
-            "ICD9:787.91",
-            "MEDDRA:10012745",
-            "MEDDRA:10012732",
-            "SNOMEDCT:128333008",
-            "SYMP:0000570",
-            "SNOMEDCT:62315008",
-            "UMLS:C0011991",
-            "MEDDRA:10012727",
-            "MEDDRA:10012735",
-            "UMLS:C1290807",
-            "PDQ:CDR0000041619",
-            "ICD9:009.2",
-            "MESH:D003967",
-            "DOID:13250",
-            "NCIT:C2987",
-            "PSY:14050",
-            "HP:0002014",
-            "MONDO:0001673",
-            "SNOMEDCT:267060006"
-          ],
-          "id": "MONDO:0001673",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Diarrhea",
-            "Diarrheal disorder",
-            "Infectious diarrhea",
-            "diarrheal disease",
-            "diarrhea"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=diarrhea",
-            "http://en.wikipedia.org/wiki/diarrhea#types_of_diarrhea",
-            "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 212250,
-=======
-            "identity": 321337,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
-              "name": "Fever",
-              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MEDDRA:10037660",
-                "MEDDRA:10020083",
-                "MEDDRA:10005911",
-                "UMLS:C0015967",
-                "HP:0001945",
-                "NCIT:C3038",
-                "MEDDRA:10073718",
-                "MEDDRA:10043204",
-                "MEDDRA:10037668",
-                "PDQ:CDR0000775882",
-                "PSY:19660",
-                "SNOMEDCT:386661006",
-                "MEDDRA:10016558",
-                "MEDDRA:10037663",
-                "SNOMEDCT:50177009",
-                "SYMP:0000613",
-                "MESH:D005334"
-              ],
-              "id": "HP:0001945",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "fever",
-                "Fever"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "PMID:9759682",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
-                "https://orcid.org/0009-0006-4530-3154"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26518210,
-            "start": 616,
-            "end": 212250,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:8427721': {'publication date': '1993', 'sentence': 'In a prospective, randomised multicentre study performed by the GIMEMA infection program, ciprofloxacin was demonstrated to be more effective than norfloxacin for the reduction of febrile episodes, use of systemic antibiotics, and Gram-negative infections in neutropenic patients with haematological malignancies.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:disrupts---None---None---None---UMLS:C0015967---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "26984478",
-              "object": "HP:0001945",
-              "publications": [
-                "PMID:8427721"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 321523,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321523,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001673",
-              "name": "diarrheal disease",
-              "description": "A gastrointestinal system disease described as the condition of having frequent loose or liquid bowel movements. Acute diarrhea is a common cause of death in developing countries and the second most common cause of infant deaths worldwide. The loss of fluids through diarrhea can cause severe dehydration which is one cause of death in diarrhea sufferers. Along with water, sufferers also lose dangerous amounts of important salts, electrolytes, and other nutrients. There are at least four types of diarrhea: secretory diarrhea, osmotic diarrhea, motility-related diarrhea, and inflammatory diarrhea. // COMMENTS: diarrhea is both a disease and a symptom [ms]",
-              "equivalent_curies": [
-                "ICD9:787.91",
-                "MEDDRA:10012745",
-                "MEDDRA:10012732",
-                "SNOMEDCT:128333008",
-                "SYMP:0000570",
-                "SNOMEDCT:62315008",
-                "UMLS:C0011991",
-                "MEDDRA:10012727",
-                "MEDDRA:10012735",
-                "UMLS:C1290807",
-                "PDQ:CDR0000041619",
-                "ICD9:009.2",
-                "MESH:D003967",
-                "DOID:13250",
-                "NCIT:C2987",
-                "PSY:14050",
-                "HP:0002014",
-                "MONDO:0001673",
-                "SNOMEDCT:267060006"
-              ],
-              "id": "MONDO:0001673",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Diarrhea",
-                "Diarrheal disorder",
-                "Infectious diarrhea",
-                "diarrheal disease",
-                "diarrhea"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=diarrhea",
-                "http://en.wikipedia.org/wiki/diarrhea#types_of_diarrhea",
->>>>>>> main
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 26006990,
-            "start": 616,
-            "end": 321523,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7486906': {'publication date': '1995 Aug', 'sentence': 'At physiologically relevant concentrations of piperacillin and ciprofloxacin, ciprofloxacin had the highest rates of killing against K. pneumoniae.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:disrupts---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "26466958",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:7486906"
-=======
-            "identity": 7391523,
-            "start": 616,
-            "end": 321337,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10410578': {'publication date': '1998 Nov', 'sentence': 'The aim of this study was to investigate clinical importance of ciprofloxacin efficacy in treatment of massive diarrhoea in patients after extensional bowel resection with removing of ileo-coecal valve (EBR + ICVR).', 'subject score': 694, 'object score': 888}, 'PMID:10476738': {'publication date': '1999 Aug', 'sentence': 'There was a significant reduction in the duration of posttreatment diarrhea in the 16 patients treated with ciprofloxacin, as compared with that in the 13 patients who received placebo (mean of 35.3 versus 55.5 hours; P = .049).', 'subject score': 1000, 'object score': 861}, 'PMID:1728922': {'publication date': '1992 Jan', 'sentence': 'A note of caution on empiric use of ciprofloxacin for diarrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:19578229': {'publication date': '2010 Apr', 'sentence': 'Patients treated with Azithromycin had a shorter duration of diarrhea [mean(SD) 54.6 (18.6) vs 71.5 (29.6) h; mean difference (95% CI) 16.9 (9.6 -24.2); P<0.001] and lesser duration of excretion of Vibrio cholerae [mean(SD) 34.6 (16.3) vs 52.1 (29.2) h; mean difference (95% CI) 17.5 (0.2 -24.7), P<0.001] in children treated with Azithromycin vs Ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:20331580': {'publication date': '2010 Jun', 'sentence': \"When administered three times daily for 3 days, rifaximin is superior to placebo or loperamide; it is at least as effective as ciprofloxacin in reducing duration of illness and restoring wellbeing in patients with travellers' diarrhoea, both with and without identification of a pathogen, as well as in diarrhoea caused by Escherichia coli infection.\", 'subject score': 1000, 'object score': 1000}, 'PMID:20422140': {'publication date': '2009 Dec', 'sentence': 'Later, due to recurrence of the diarrhea, he was treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:22354292': {'publication date': '2012 May', 'sentence': 'We used a mouse model for Salmonella diarrhea to assess the effects of per os treatment with ciprofloxacin (15 mg/kg of body weight intragastrically 2 times/day, 5 days) or parenteral ceftriaxone (50 mg/kg intraperitoneally, 5 days), two common drugs used in human patients.', 'subject score': 1000, 'object score': 888}, 'PMID:25131673': {'publication date': '2014 Sep 08', 'sentence': 'In a mouse model for Salmonella diarrhea, treatment with the broad-spectrum antibiotic ciprofloxacin reverses the outcome of competition between wild-type bacteria and avirulent mutants that can spontaneously arise during within-host evolution [5].', 'subject score': 775, 'object score': 888}, 'PMID:27167632': {'publication date': '2016 Aug', 'sentence': 'This was preceded by diarrhea and treated with ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:27428376': {'publication date': '2016', 'sentence': 'Ciprofloxacin is a broad-spectrum antimicrobial agent nowadays used for the treatment of diarrhea.', 'subject score': 1000, 'object score': 1000}, 'PMID:28603782': {'publication date': '2017', 'sentence': 'RESULTS: We found 2.7% (230/8,672) of children who presented with diarrhea had Shigella spp. isolated from their stool, and 50% (115/230) had resistance to Ciprofloxacin.', 'subject score': 1000, 'object score': 1000}, 'PMID:30420482': {'publication date': '2018 Nov 12', 'sentence': 'Antibiotic resistance between C. jejuni and non-C. jejuni isolates, and surveillance and diarrhea samples were compared and the association between personal macrolide exposure and subsequent occurrence of a macrolide resistant Campylobacter spp. was assessed.ResultsOf 917 Campylobacter isolates, 77.4% of C. jejuni isolates and 79.8% non-C. jejuni isolates were resistant to ciprofloxacin while 4.9% of C. jejuni isolates and 24.8% of non-C. jejuni isolates were not susceptible to azithromycin.', 'subject score': 1000, 'object score': 694}, 'PMID:31153984': {'publication date': '2019 Sep', 'sentence': 'MSF favored diarrhea management as compared to ciprofloxacin, suggesting that MSF can be used in the management of E. coli O1-induced diarrhea, in normal gut microbiota and normal intestinal antioxidant function.', 'subject score': 1000, 'object score': 785}, 'PMID:3541724': {'publication date': '1987 Feb', 'sentence': 'Both antimicrobial agents were significantly (p less than 0.0001) more efficacious than placebo in the treatment of diarrhea, with the average duration of diarrhea being 29, 20, and 81 hours, respectively, in the ciprofloxacin, trimethoprim-sulfamethoxazole, and placebo treatment groups.', 'subject score': 1000, 'object score': 1000}, 'PMID:3555056': {'publication date': '1987 Apr 27', 'sentence': 'The average duration of diarrhea was 29 or 20 hours after initiation of treatment with ciprofloxacin or trimethoprim/sulfamethoxazole, respectively, compared with 81 hours in the placebo group.', 'subject score': 1000, 'object score': 1000}, 'PMID:35847602': {'publication date': '2022', 'sentence': 'The patient was treated with 3 days of ciprofloxacin with clinical resolution of diarrhoea.', 'subject score': 1000, 'object score': 1000}, 'PMID:36642099': {'publication date': '2023 Jan 12', 'sentence': 'CONCLUSION: A single dose of ciprofloxacin was effective and safe in treating uncomplicated diarrhea among service members in Africa.', 'subject score': 1000, 'object score': 851}, 'PMID:7883355': {'publication date': '1994 Aug', 'sentence': 'Parenteral ciprofloxacin in persistent diarrhea.', 'subject score': 861, 'object score': 888}, 'PMID:8810190': {'publication date': '1996 Feb', 'sentence': 'Parenteral ciprofloxacin in persistent diarrhoea in children.', 'subject score': 861, 'object score': 888}, 'PMID:9053412': {'publication date': '1995 Oct', 'sentence': 'Parenteral ciprofloxacin in persistent diarrhoea in children.', 'subject score': 861, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0011991---SEMMEDDB:",
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C1290807---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "7544699",
-              "object": "MONDO:0001673",
-              "publications": [
-                "PMID:10476738",
-                "PMID:30420482",
-                "PMID:36642099",
-                "PMID:3541724",
-                "PMID:20422140",
-                "PMID:22354292",
-                "PMID:28603782",
-                "PMID:35847602",
-                "PMID:20331580",
-                "PMID:29914655",
-                "PMID:9829444",
-                "PMID:27167632",
-                "PMID:3555056",
-                "PMID:8810190",
-                "PMID:9053412",
-                "PMID:10410578",
-                "PMID:31153984",
-                "PMID:25131673",
-                "PMID:19578229",
-                "PMID:27428376"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 539955,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-          "name": "infectious disease",
-          "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005550",
-            "SNOMEDCT:189822004",
-            "PSY:10513",
-            "UMLS:C0009450",
-            "UMLS:C0001485",
-            "EFO:0005741",
-            "MEDDRA:10021881",
-            "MESH:D003141",
-            "ICD9:079.0",
-            "DOID:0050117",
-            "SNOMEDCT:40733004",
-            "SNOMEDCT:191415002",
-            "NCIT:C26726"
-          ],
-          "id": "MONDO:0005550",
-          "category": "biolink:Disease",
-          "all_names": [
-            "infectious disease",
-            "Infectious Disorder",
-            "disease by infectious agent",
-            "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-            "Communicable Diseases"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.merriam-webster.com/medical/communicable%20disease",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 539955,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-              "name": "infectious disease",
-              "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005550",
-                "SNOMEDCT:189822004",
-                "PSY:10513",
-                "UMLS:C0009450",
-                "UMLS:C0001485",
-                "EFO:0005741",
-                "MEDDRA:10021881",
-                "MESH:D003141",
-                "ICD9:079.0",
-                "DOID:0050117",
-                "SNOMEDCT:40733004",
-                "SNOMEDCT:191415002",
-                "NCIT:C26726"
-              ],
-              "id": "MONDO:0005550",
-              "category": "biolink:Disease",
-              "all_names": [
-                "infectious disease",
-                "Infectious Disorder",
-                "disease by infectious agent",
-                "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-                "Communicable Diseases"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.merriam-webster.com/medical/communicable%20disease",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18113271,
-            "start": 616,
-            "end": 539955,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26244102': {'publication date': '2015 Aug 01', 'sentence': 'We tested the effectiveness of keratin-based hydrogels (termed \"keratose\") loaded with ciprofloxacin to inhibit infection and support healing when topically administered to porcine excision wounds infected with Pseudomonas aeruginosa.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:disrupts---None---None---None---UMLS:C0009450---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "18480207",
-              "object": "MONDO:0005550",
-              "publications": [
-                "PMID:26244102"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 315382,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-          "name": "bacterial infectious disease with sepsis",
-          "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C102993",
-            "ICD9:995.91",
-            "MONDO:0005229",
-            "MEDDRA:10060562",
-            "MEDDRA:10003998",
-            "MEDDRA:10003997",
-            "MEDDRA:10045641",
-            "ICD9:790.7",
-            "MEDDRA:10045642",
-            "HP:0031864",
-            "SNOMEDCT:5758002",
-            "DOID:0040085",
-            "MESH:D016470",
-            "UMLS:C0004610",
-            "MEDDRA:10003999"
-          ],
-          "id": "MONDO:0005229",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacteremia",
-            "bacterial infectious disease with sepsis",
-            "bacterial sepsis",
-            "Sepsis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:20421654"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315382,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-              "name": "bacterial infectious disease with sepsis",
-              "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C102993",
-                "ICD9:995.91",
-                "MONDO:0005229",
-                "MEDDRA:10060562",
-                "MEDDRA:10003998",
-                "MEDDRA:10003997",
-                "MEDDRA:10045641",
-                "ICD9:790.7",
-                "MEDDRA:10045642",
-                "HP:0031864",
-                "SNOMEDCT:5758002",
-                "DOID:0040085",
-                "MESH:D016470",
-                "UMLS:C0004610",
-                "MEDDRA:10003999"
-              ],
-              "id": "MONDO:0005229",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacteremia",
-                "bacterial infectious disease with sepsis",
-                "bacterial sepsis",
-                "Sepsis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:20421654"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10100567,
-            "start": 616,
-            "end": 315382,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1287815': {'publication date': '1992', 'sentence': 'Ciprofloxacin was administered orally in order to suppress bacteremia for 36 months.', 'subject score': 1000, 'object score': 1000}, 'PMID:18602189': {'publication date': '2008 Aug', 'sentence': 'Modification in prescribing practices for third-generation cephalosporins and ciprofloxacin is associated with a reduction in meticillin-resistant Staphylococcus aureus bacteraemia rate.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:disrupts---None---None---None---UMLS:C0004610---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "10323767",
-              "object": "MONDO:0005229",
-              "publications": [
-                "PMID:1287815",
-                "PMID:18602189"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 317996,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006939",
-          "name": "pyelonephritis",
-          "description": "An inflammatory process affecting the kidney. The cause is most often bacterial, but may also be fungal in nature. Signs and symptoms may include fever, chills, flank pain, painful and frequent urination, cloudy or bloody urine, and confusion.; Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA.; An inflammation of the kidney involving the parenchyma of kidney, the renal pelvis and the kidney calices. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "SNOMEDCT:45816000",
-            "ICD9:590.80",
-            "MEDDRA:10037604",
-            "NCIT:C34965",
-            "MONDO:0006939",
-            "MEDDRA:10037606",
-            "ICD10:N16",
-            "HP:0012330",
-            "DOID:11400",
-            "EFO:1001141",
-            "UMLS:C0034186",
-            "MESH:D011704",
-            "MEDDRA:10037596"
-          ],
-          "id": "MONDO:0006939",
-          "category": "biolink:Disease",
-          "all_names": [
-            "pyelonephritis",
-            "Pyelonephritis",
-            "Pyelonephritis, unspecified"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 317996,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006939",
-              "name": "pyelonephritis",
-              "description": "An inflammatory process affecting the kidney. The cause is most often bacterial, but may also be fungal in nature. Signs and symptoms may include fever, chills, flank pain, painful and frequent urination, cloudy or bloody urine, and confusion.; Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA.; An inflammation of the kidney involving the parenchyma of kidney, the renal pelvis and the kidney calices. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "SNOMEDCT:45816000",
-                "ICD9:590.80",
-                "MEDDRA:10037604",
-                "NCIT:C34965",
-                "MONDO:0006939",
-                "MEDDRA:10037606",
-                "ICD10:N16",
-                "HP:0012330",
-                "DOID:11400",
-                "EFO:1001141",
-                "UMLS:C0034186",
-                "MESH:D011704",
-                "MEDDRA:10037596"
-              ],
-              "id": "MONDO:0006939",
-              "category": "biolink:Disease",
-              "all_names": [
-                "pyelonephritis",
-                "Pyelonephritis",
-                "Pyelonephritis, unspecified"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 26773748,
-            "start": 616,
-            "end": 317996,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8913458': {'publication date': '1996 Nov', 'sentence': 'In the present murine model of pyelonephritis, levofloxacin was superior to ciprofloxacin in preventing pyelonephritis and eradicating S. aureus.', 'subject score': 1000, 'object score': 872}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:prevents---None---None---None---UMLS:C0034186---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "27242944",
-              "object": "MONDO:0006939",
-              "publications": [
-                "PMID:8913458"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 546907,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C3714514",
-          "name": "Infection",
-          "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "UMLS:C3714514",
-            "MEDDRA:10021842",
-            "NCIT:C128320",
-            "MEDDRA:10021789",
-            "MESH:D007239"
-          ],
-          "id": "UMLS:C3714514",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infection",
-            "Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546907,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C3714514",
-              "name": "Infection",
-              "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "UMLS:C3714514",
-                "MEDDRA:10021842",
-                "NCIT:C128320",
-                "MEDDRA:10021789",
-                "MESH:D007239"
-              ],
-              "id": "UMLS:C3714514",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infection",
-                "Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21390414,
-            "start": 616,
-            "end": 546907,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32164686': {'publication date': '2020 Mar 12', 'sentence': '25.2% of the urologists experienced ciprofloxacin resistance as a current problem in the prevention of biopsy related infections and 73.6% as a future problem.', 'subject score': 888, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:prevents---None---None---None---UMLS:C3714514---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "21807033",
-              "object": "UMLS:C3714514",
-              "publications": [
-                "PMID:32164686"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:22354292': {'publication date': '2012 May', 'sentence': 'Peroral ciprofloxacin therapy impairs the generation of a protective immune response in a mouse model for Salmonella enterica serovar Typhimurium diarrhea, while parenteral ceftriaxone therapy does not.', 'subject score': 790, 'object score': 794}, 'PMID:7548495': {'publication date': '1995 Jun', 'sentence': 'We conducted a randomized double-blinded study in Lima, Peru, to assess the tolerability and efficacy of a single 250-mg dose of ciprofloxacin in preventing diarrhea and Vibrio cholerae O1 infection among household contacts of bacteriologically confirmed index cases.', 'subject score': 1000, 'object score': 872}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 321337,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001673",
-          "name": "diarrheal disease",
-          "description": "A gastrointestinal system disease described as the condition of having frequent loose or liquid bowel movements. Acute diarrhea is a common cause of death in developing countries and the second most common cause of infant deaths worldwide. The loss of fluids through diarrhea can cause severe dehydration which is one cause of death in diarrhea sufferers. Along with water, sufferers also lose dangerous amounts of important salts, electrolytes, and other nutrients. There are at least four types of diarrhea: secretory diarrhea, osmotic diarrhea, motility-related diarrhea, and inflammatory diarrhea. // COMMENTS: diarrhea is both a disease and a symptom [ms]",
-          "equivalent_curies": [
-            "ICD9:787.91",
-            "MEDDRA:10012745",
-            "MEDDRA:10012732",
-            "SNOMEDCT:128333008",
-            "SYMP:0000570",
-            "SNOMEDCT:62315008",
-            "UMLS:C0011991",
-            "MEDDRA:10012727",
-            "MEDDRA:10012735",
-            "UMLS:C1290807",
-            "PDQ:CDR0000041619",
-            "ICD9:009.2",
-            "MESH:D003967",
-            "DOID:13250",
-            "NCIT:C2987",
-            "PSY:14050",
-            "HP:0002014",
-            "MONDO:0001673",
-            "SNOMEDCT:267060006"
-          ],
-          "id": "MONDO:0001673",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Diarrhea",
-            "Diarrheal disorder",
-            "Infectious diarrhea",
-            "diarrheal disease",
-            "diarrhea"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=diarrhea",
-            "http://en.wikipedia.org/wiki/diarrhea#types_of_diarrhea",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321337,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001673",
-              "name": "diarrheal disease",
-              "description": "A gastrointestinal system disease described as the condition of having frequent loose or liquid bowel movements. Acute diarrhea is a common cause of death in developing countries and the second most common cause of infant deaths worldwide. The loss of fluids through diarrhea can cause severe dehydration which is one cause of death in diarrhea sufferers. Along with water, sufferers also lose dangerous amounts of important salts, electrolytes, and other nutrients. There are at least four types of diarrhea: secretory diarrhea, osmotic diarrhea, motility-related diarrhea, and inflammatory diarrhea. // COMMENTS: diarrhea is both a disease and a symptom [ms]",
-              "equivalent_curies": [
-                "ICD9:787.91",
-                "MEDDRA:10012745",
-                "MEDDRA:10012732",
-                "SNOMEDCT:128333008",
-                "SYMP:0000570",
-                "SNOMEDCT:62315008",
-                "UMLS:C0011991",
-                "MEDDRA:10012727",
-                "MEDDRA:10012735",
-                "UMLS:C1290807",
-                "PDQ:CDR0000041619",
-                "ICD9:009.2",
-                "MESH:D003967",
-                "DOID:13250",
-                "NCIT:C2987",
-                "PSY:14050",
-                "HP:0002014",
-                "MONDO:0001673",
-                "SNOMEDCT:267060006"
-              ],
-              "id": "MONDO:0001673",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Diarrhea",
-                "Diarrheal disorder",
-                "Infectious diarrhea",
-                "diarrheal disease",
-                "diarrhea"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=diarrhea",
-                "http://en.wikipedia.org/wiki/diarrhea#types_of_diarrhea",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15808802,
-            "start": 616,
-            "end": 321337,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22354292': {'publication date': '2012 May', 'sentence': 'Peroral ciprofloxacin therapy impairs the generation of a protective immune response in a mouse model for Salmonella enterica serovar Typhimurium diarrhea, while parenteral ceftriaxone therapy does not.', 'subject score': 790, 'object score': 794}, 'PMID:7548495': {'publication date': '1995 Jun', 'sentence': 'We conducted a randomized double-blinded study in Lima, Peru, to assess the tolerability and efficacy of a single 250-mg dose of ciprofloxacin in preventing diarrhea and Vibrio cholerae O1 infection among household contacts of bacteriologically confirmed index cases.', 'subject score': 1000, 'object score': 872}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:prevents---None---None---None---UMLS:C0011991---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "16138544",
-              "object": "MONDO:0001673",
-              "publications": [
-                "PMID:22354292",
-                "PMID:7548495"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 320039,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:31867477': {'publication date': '2019 Dec 17', 'sentence': 'Noncytotoxic Pyrrolobenzodiazepine-Ciprofloxacin Conjugate with Activity against    Mycobacterium tuberculosis    .The development of new antitubercular agents for the treatment of infections caused by multidrug-resistant (MDR)    Mycobacterium tuberculosis     is an urgent priority.', 'subject score': 583, 'object score': 1000}, 'PMID:31919670': {'publication date': '2020 Jan 09', 'sentence': 'In Vitro Activity of Fosfomycin in Double and Triple Combinations with Imipenem, Ciprofloxacin and Tobramycin Against Multidrug-Resistant Escherichia coli.The rates of urinary tract infection with multidrug-resistant (MDR) Escherichia coli have dramatically increased and the treatment of these infections with single and double antibiotic combinations became limited or ineffective.', 'subject score': 1000, 'object score': 1000}, 'PMID:31973270': {'publication date': '2015 Jul', 'sentence': 'The cover picture shows an SEM image of nanostructured biosilica produced by- Thalassiosira weissflogii- diatoms covalently functionalized with the radical scavenger TEMPO (green disks) and loaded with the antibiotic Ciprofloxacin (red/white capsules), which is used to combat infections related to orthopedic implants.', 'subject score': 888, 'object score': 1000}, 'PMID:32265871': {'publication date': '2020', 'sentence': 'Ciprofloxacin is the choice treatment for infections caused by    Salmonella     Typhi, however, reduced susceptibility to ciprofloxacin has been reported for this pathogen.', 'subject score': 1000, 'object score': 1000}, 'PMID:32634369': {'publication date': '2020 Jul', 'sentence': 'Here, we develop and apply a mechanistic mathematical model to data from a study comparing the effects of ciprofloxacin and ampicillin on the within-host dynamics of    Salmonella enterica     serovar Typhimurium in murine infections.', 'subject score': 1000, 'object score': 888}, 'PMID:32664334': {'publication date': '2020 Jul 10', 'sentence': 'The involvement of tobramycin and ciprofloxacin, widely used to treat CF PA lung infections, in the abundance of VBNC cells was investigated in PA biofilms models.', 'subject score': 1000, 'object score': 864}, 'PMID:33064003': {'publication date': '2020 Nov 03', 'sentence': 'The antibiotic ciprofloxacin (CIP) is extensively employed to treat infections in animal and human medicine.', 'subject score': 888, 'object score': 1000}, 'PMID:33107284': {'publication date': '2020 Oct', 'sentence': 'The aim of this study was to investigate the effects of sub-minimal inhibitory concentrations (sub-MIC) of piperacillin/tazobactam (TZP) and ciprofloxacin (CIP) which are used for the treatment of P.aeruginosa infections on biofilm formation and to investigate the relationship between the severity of biofilm formation and Quorum Sensing (QS) genes.', 'subject score': 1000, 'object score': 901}, 'PMID:33229966': {'publication date': '2020 Nov 20', 'sentence': 'OBJECTIVES: To describe the effectiveness of ciprofloxacin to treat \"susceptible\" infections, we estimated the clinical efficacy of ciprofloxacin at various minimum inhibitory concentrations (MICs) and anatomic sites.', 'subject score': 1000, 'object score': 888}, 'PMID:33460732': {'publication date': '2021 Jan 15', 'sentence': 'AIMS: Exploration of Azithromycin as an adjunctive therapy to Ciprofloxacin for treatment of P. aeruginosa infections.', 'subject score': 1000, 'object score': 901}, 'PMID:34464919': {'publication date': '2021 Aug 06', 'sentence': 'Fluconazole (FLZ) is co-administered with either ciprofloxacin (CPR) or ofloxacin (OFX) for the treatment of certain microbial infections.', 'subject score': 888, 'object score': 851}, 'PMID:34919918': {'publication date': '2021 Dec 14', 'sentence': 'Ciprofloxacin is a pharmaceutical component used for treating various tract infections.', 'subject score': 1000, 'object score': 775}, 'PMID:35796076': {'publication date': '2022 Jul 07', 'sentence': 'Conclusion:     The combination of meropenem and ciprofloxacin seems to be a good candidate for the treatment of biofilm-associated infections; none of the concentrations obtained as a result of the synergy test were clinically significant.', 'subject score': 1000, 'object score': 802}, 'PMID:36620240': {'publication date': '2022', 'sentence': 'The rise of infections that are resistant to ciprofloxacin shows that new pharmacological synergisms and derivatives are required.', 'subject score': 1000, 'object score': 1000}, 'PMID:36986580': {'publication date': '2023 Feb 21', 'sentence': 'Drug Combination of Ciprofloxacin and Polymyxin B for the Treatment of Multidrug-Resistant    Acinetobacter baumannii     Infections: A Drug Pair Limiting the Development of Resistance.', 'subject score': 1000, 'object score': 928}, 'PMID:37166011': {'publication date': '2023 May 11', 'sentence': 'The CP1-WT peptide shows significant improvement over ciprofloxacin in terms of its in vivo therapeutic efficacy in treating established infections of S.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 546907,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320039,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What causes sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15116639,
-            "start": 616,
-            "end": 320039,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21266559': {'publication date': '2011 Feb', 'sentence': 'CONCLUSIONS: The 24-hour clear-fluid diet and the use of disposable enemas combined with a regimen of ciprofloxacin decreased the rate of postbiopsy sepsis in patients who underwent transrectal ultrasound-guided prostate biopsy, but the results were not significantly different.', 'subject score': 1000, 'object score': 861}, 'PMID:23009873': {'publication date': '2013 Mar', 'sentence': 'Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate.', 'subject score': 888, 'object score': 1000}, 'PMID:23623974': {'publication date': '2013 Oct', 'sentence': 'Re: Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate: E.', 'subject score': 888, 'object score': 1000}, 'PMID:23623975': {'publication date': '2013 Apr 24', 'sentence': 'Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicaemia after transrectal ultrasound guided biopsy of the prostate.', 'subject score': 888, 'object score': 1000}, 'PMID:27075767': {'publication date': '2016 Jun', 'sentence': 'UNLABELLED: We hypothesized that combined treatment with autologous adipose-derived mesenchymal stem cell (ADMSC) and ciprofloxacin is superior to ciprofloxacin only in reducing sepsis-induced urogenital organ damage and mortality in rat sepsis syndrome (SS) caused by intrapelvic injection of cecal bacteria (1.0 * 10(4) cells per milliliter; total, 5.0 ml).', 'subject score': 1000, 'object score': 614}, 'PMID:30553114': {'publication date': '2019 Jun', 'sentence': 'FMT was therefore not an effective alternative to ciprofloxacin for preventing post-TRUSPB urinary sepsis.', 'subject score': 1000, 'object score': 749}, 'PMID:8851383': {'publication date': '1996 Feb', 'sentence': 'Oral administration of CPFX was more effective than PL-B plus KM in preventing P. aeruginosa sepsis.', 'subject score': 1000, 'object score': 852}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:prevents---None---None---None---UMLS:C0036690---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "15438014",
-              "object": "HP:0100806",
-              "publications": [
-                "PMID:21266559",
-                "PMID:23009873",
-                "PMID:23623974",
-                "PMID:23623975",
-                "PMID:27075767",
-                "PMID:30553114",
-                "PMID:8851383"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 517617,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019095",
-          "name": "plague",
-          "description": "A Gram-negative bacterial infection caused by Yersinia pestis. It is usually transmitted to humans from bites of infected rodent fleas. It is manifested as a bubonic, septicemic, or pneumonic plague. In bubonic plague, the lymph nodes adjacent to the site of the skin bite are infected and enlarged. In septicemic plague, the infection spreads directly through the bloodstream. In pneumonic plague, the infection spreads to the lungs either following bubonic plague, or by inhalation of infective droplets. If untreated, it may lead to death.; An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.; Plague is an infection caused by the bacterium Yersinia pestis. The bacteria are found mainly in rats and in the fleas that feed on them. People and other animals can get plague from rat or flea bites. In the past, plague destroyed entire civilizations. Today plague is uncommon, due to better living conditions and antibiotics. There are three forms of plague:  Bubonic plague causes the tonsils, adenoids, spleen, and thymus to become inflamed. Symptoms include fever, aches, chills, and tender lymph glands. In septicemic plague, bacteria multiply in the blood. It causes fever, chills, shock, and bleeding under the skin or other organs. Pneumonic plague is the most serious form. Bacteria enter the lungs and cause pneumonia. People with the infection can spread this form to others. This type could be a bioterror agent.  Lab tests can diagnose plague. Treatment is a strong antibiotic. There is no vaccine.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10046098",
-            "ICD10:A20",
-            "MEDDRA:10048250",
-            "SNOMEDCT:58750007",
-            "UMLS:C0032064",
-            "ICD9:020",
-            "NCIT:C85015",
-            "DOID:3482",
-            "ORPHANET:707",
-            "MONDO:0019095",
-            "MEDDRA:10035148",
-            "MEDDRA:10035149",
-            "MESH:D010930"
-          ],
-          "id": "MONDO:0019095",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Plague",
-            "plague"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:29628173"
-=======
-          "iri": "https://identifiers.org/umls:C3714514",
-          "name": "Infection",
-          "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "UMLS:C3714514",
-            "MEDDRA:10021842",
-            "NCIT:C128320",
-            "MEDDRA:10021789",
-            "MESH:D007239"
-          ],
-          "id": "UMLS:C3714514",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infection",
-            "Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 517617,
-=======
-            "identity": 546907,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019095",
-              "name": "plague",
-              "description": "A Gram-negative bacterial infection caused by Yersinia pestis. It is usually transmitted to humans from bites of infected rodent fleas. It is manifested as a bubonic, septicemic, or pneumonic plague. In bubonic plague, the lymph nodes adjacent to the site of the skin bite are infected and enlarged. In septicemic plague, the infection spreads directly through the bloodstream. In pneumonic plague, the infection spreads to the lungs either following bubonic plague, or by inhalation of infective droplets. If untreated, it may lead to death.; An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.; Plague is an infection caused by the bacterium Yersinia pestis. The bacteria are found mainly in rats and in the fleas that feed on them. People and other animals can get plague from rat or flea bites. In the past, plague destroyed entire civilizations. Today plague is uncommon, due to better living conditions and antibiotics. There are three forms of plague:  Bubonic plague causes the tonsils, adenoids, spleen, and thymus to become inflamed. Symptoms include fever, aches, chills, and tender lymph glands. In septicemic plague, bacteria multiply in the blood. It causes fever, chills, shock, and bleeding under the skin or other organs. Pneumonic plague is the most serious form. Bacteria enter the lungs and cause pneumonia. People with the infection can spread this form to others. This type could be a bioterror agent.  Lab tests can diagnose plague. Treatment is a strong antibiotic. There is no vaccine.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10046098",
-                "ICD10:A20",
-                "MEDDRA:10048250",
-                "SNOMEDCT:58750007",
-                "UMLS:C0032064",
-                "ICD9:020",
-                "NCIT:C85015",
-                "DOID:3482",
-                "ORPHANET:707",
-                "MONDO:0019095",
-                "MEDDRA:10035148",
-                "MEDDRA:10035149",
-                "MESH:D010930"
-              ],
-              "id": "MONDO:0019095",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Plague",
-                "plague"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:29628173"
-=======
-              "iri": "https://identifiers.org/umls:C3714514",
-              "name": "Infection",
-              "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "UMLS:C3714514",
-                "MEDDRA:10021842",
-                "NCIT:C128320",
-                "MEDDRA:10021789",
-                "MESH:D007239"
-              ],
-              "id": "UMLS:C3714514",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infection",
-                "Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 13905392,
-            "start": 616,
-            "end": 517617,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19188359': {'publication date': '2009 Apr', 'sentence': 'Although there were major differences in pathogenesis, the recombinant F1 and V antigen vaccine and ciprofloxacin protected against plague infections caused by small- and large-particle aerosols.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:prevents---None---None---None---UMLS:C0032064---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "14202377",
-              "object": "MONDO:0019095",
-              "publications": [
-                "PMID:19188359"
-=======
-            "identity": 21074888,
-            "start": 616,
-            "end": 546907,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31867477': {'publication date': '2019 Dec 17', 'sentence': 'Noncytotoxic Pyrrolobenzodiazepine-Ciprofloxacin Conjugate with Activity against    Mycobacterium tuberculosis    .The development of new antitubercular agents for the treatment of infections caused by multidrug-resistant (MDR)    Mycobacterium tuberculosis     is an urgent priority.', 'subject score': 583, 'object score': 1000}, 'PMID:31919670': {'publication date': '2020 Jan 09', 'sentence': 'In Vitro Activity of Fosfomycin in Double and Triple Combinations with Imipenem, Ciprofloxacin and Tobramycin Against Multidrug-Resistant Escherichia coli.The rates of urinary tract infection with multidrug-resistant (MDR) Escherichia coli have dramatically increased and the treatment of these infections with single and double antibiotic combinations became limited or ineffective.', 'subject score': 1000, 'object score': 1000}, 'PMID:31973270': {'publication date': '2015 Jul', 'sentence': 'The cover picture shows an SEM image of nanostructured biosilica produced by- Thalassiosira weissflogii- diatoms covalently functionalized with the radical scavenger TEMPO (green disks) and loaded with the antibiotic Ciprofloxacin (red/white capsules), which is used to combat infections related to orthopedic implants.', 'subject score': 888, 'object score': 1000}, 'PMID:32265871': {'publication date': '2020', 'sentence': 'Ciprofloxacin is the choice treatment for infections caused by    Salmonella     Typhi, however, reduced susceptibility to ciprofloxacin has been reported for this pathogen.', 'subject score': 1000, 'object score': 1000}, 'PMID:32634369': {'publication date': '2020 Jul', 'sentence': 'Here, we develop and apply a mechanistic mathematical model to data from a study comparing the effects of ciprofloxacin and ampicillin on the within-host dynamics of    Salmonella enterica     serovar Typhimurium in murine infections.', 'subject score': 1000, 'object score': 888}, 'PMID:32664334': {'publication date': '2020 Jul 10', 'sentence': 'The involvement of tobramycin and ciprofloxacin, widely used to treat CF PA lung infections, in the abundance of VBNC cells was investigated in PA biofilms models.', 'subject score': 1000, 'object score': 864}, 'PMID:33064003': {'publication date': '2020 Nov 03', 'sentence': 'The antibiotic ciprofloxacin (CIP) is extensively employed to treat infections in animal and human medicine.', 'subject score': 888, 'object score': 1000}, 'PMID:33107284': {'publication date': '2020 Oct', 'sentence': 'The aim of this study was to investigate the effects of sub-minimal inhibitory concentrations (sub-MIC) of piperacillin/tazobactam (TZP) and ciprofloxacin (CIP) which are used for the treatment of P.aeruginosa infections on biofilm formation and to investigate the relationship between the severity of biofilm formation and Quorum Sensing (QS) genes.', 'subject score': 1000, 'object score': 901}, 'PMID:33229966': {'publication date': '2020 Nov 20', 'sentence': 'OBJECTIVES: To describe the effectiveness of ciprofloxacin to treat \"susceptible\" infections, we estimated the clinical efficacy of ciprofloxacin at various minimum inhibitory concentrations (MICs) and anatomic sites.', 'subject score': 1000, 'object score': 888}, 'PMID:33460732': {'publication date': '2021 Jan 15', 'sentence': 'AIMS: Exploration of Azithromycin as an adjunctive therapy to Ciprofloxacin for treatment of P. aeruginosa infections.', 'subject score': 1000, 'object score': 901}, 'PMID:34464919': {'publication date': '2021 Aug 06', 'sentence': 'Fluconazole (FLZ) is co-administered with either ciprofloxacin (CPR) or ofloxacin (OFX) for the treatment of certain microbial infections.', 'subject score': 888, 'object score': 851}, 'PMID:34919918': {'publication date': '2021 Dec 14', 'sentence': 'Ciprofloxacin is a pharmaceutical component used for treating various tract infections.', 'subject score': 1000, 'object score': 775}, 'PMID:35796076': {'publication date': '2022 Jul 07', 'sentence': 'Conclusion:     The combination of meropenem and ciprofloxacin seems to be a good candidate for the treatment of biofilm-associated infections; none of the concentrations obtained as a result of the synergy test were clinically significant.', 'subject score': 1000, 'object score': 802}, 'PMID:36620240': {'publication date': '2022', 'sentence': 'The rise of infections that are resistant to ciprofloxacin shows that new pharmacological synergisms and derivatives are required.', 'subject score': 1000, 'object score': 1000}, 'PMID:36986580': {'publication date': '2023 Feb 21', 'sentence': 'Drug Combination of Ciprofloxacin and Polymyxin B for the Treatment of Multidrug-Resistant    Acinetobacter baumannii     Infections: A Drug Pair Limiting the Development of Resistance.', 'subject score': 1000, 'object score': 928}, 'PMID:37166011': {'publication date': '2023 May 11', 'sentence': 'The CP1-WT peptide shows significant improvement over ciprofloxacin in terms of its in vivo therapeutic efficacy in treating established infections of S.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C3714514---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "21488232",
-              "object": "UMLS:C3714514",
-              "publications": [
-                "PMID:31867477",
-                "PMID:31919670",
-                "PMID:31973270",
-                "PMID:32265871",
-                "PMID:32634369",
-                "PMID:32664334",
-                "PMID:33064003",
-                "PMID:33107284",
-                "PMID:33229966",
-                "PMID:33460732",
-                "PMID:34464919",
-                "PMID:34919918",
-                "PMID:35796076",
-                "PMID:36620240",
-                "PMID:36986580",
-                "PMID:37166011"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 881097,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:32164686': {'publication date': '2020 Mar 12', 'sentence': '25.2% of the urologists experienced ciprofloxacin resistance as a current problem in the prevention of biopsy related infections and 73.6% as a future problem.', 'subject score': 888, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 546907,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0016047",
-          "name": "endophthalmitis",
-          "description": "An infectious process affecting the internal structures of the eye.; Infectious condition of the internal eye.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0014236",
-            "ORPHANET:199323",
-            "MONDO:0016047",
-            "SNOMEDCT:128295000",
-            "SNOMEDCT:1847009",
-            "MEDDRA:10030869",
-            "NCIT:C34586",
-            "MESH:D009877",
-            "MEDDRA:10014801",
-            "DOID:4692"
-          ],
-          "id": "MONDO:0016047",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Endophthalmitis",
-            "endophthalmitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/endophthalmitis",
-            "https://www.merckmanuals.com/home/eye-disorders/uveitis-and-related-disorders/endophthalmitis",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=endophthalmitis"
-=======
-          "iri": "https://identifiers.org/umls:C3714514",
-          "name": "Infection",
-          "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "UMLS:C3714514",
-            "MEDDRA:10021842",
-            "NCIT:C128320",
-            "MEDDRA:10021789",
-            "MESH:D007239"
-          ],
-          "id": "UMLS:C3714514",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infection",
-            "Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 881097,
-=======
-            "identity": 546907,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0016047",
-              "name": "endophthalmitis",
-              "description": "An infectious process affecting the internal structures of the eye.; Infectious condition of the internal eye.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0014236",
-                "ORPHANET:199323",
-                "MONDO:0016047",
-                "SNOMEDCT:128295000",
-                "SNOMEDCT:1847009",
-                "MEDDRA:10030869",
-                "NCIT:C34586",
-                "MESH:D009877",
-                "MEDDRA:10014801",
-                "DOID:4692"
-              ],
-              "id": "MONDO:0016047",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Endophthalmitis",
-                "endophthalmitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/endophthalmitis",
-                "https://www.merckmanuals.com/home/eye-disorders/uveitis-and-related-disorders/endophthalmitis",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=endophthalmitis"
-=======
-              "iri": "https://identifiers.org/umls:C3714514",
-              "name": "Infection",
-              "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "UMLS:C3714514",
-                "MEDDRA:10021842",
-                "NCIT:C128320",
-                "MEDDRA:10021789",
-                "MESH:D007239"
-              ],
-              "id": "UMLS:C3714514",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infection",
-                "Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 12030319,
-            "start": 616,
-            "end": 881097,
-=======
-            "identity": 21390414,
-            "start": 616,
-            "end": 546907,
->>>>>>> main
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-<<<<<<< HEAD
-              "publications_info": "{'PMID:1646099': {'publication date': '1991 Mar', 'sentence': 'These studies indicate that a combination of ciprofloxacin and dexamethasone has the potential for reducing the risk of PVR formation and aiding in the prevention of endophthalmitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:30595706': {'publication date': '2018', 'sentence': 'The aim of this study was to evaluate the efficacy and clinical outcome of oral ciprofloxacin versus intravenous cefazolin/gentamicin for the prevention of endophthalmitis after penetrating ocular trauma.', 'subject score': 888, 'object score': 1000}, 'PMID:8488915': {'publication date': '1993 May 15', 'sentence': 'Therefore, ciprofloxacin may have a role in the management and prevention of endophthalmitis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:prevents---None---None---None---UMLS:C0014236---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "12292532",
-              "object": "MONDO:0016047",
-              "publications": [
-                "PMID:1646099",
-                "PMID:30595706",
-                "PMID:8488915"
-=======
-              "publications_info": "{'PMID:32164686': {'publication date': '2020 Mar 12', 'sentence': '25.2% of the urologists experienced ciprofloxacin resistance as a current problem in the prevention of biopsy related infections and 73.6% as a future problem.', 'subject score': 888, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:prevents---None---None---None---UMLS:C3714514---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "21807033",
-              "object": "UMLS:C3714514",
-              "publications": [
-                "PMID:32164686"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 315382,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12556279': {'publication date': '2003 Jan', 'sentence': 'Treatment and post-exposure prophylaxis for anthrax are ciprofloxacin or doxycycline.', 'subject score': 1000, 'object score': 1000}, 'PMID:14556058': {'publication date': '2003 Oct', 'sentence': 'In our series, penicillin and ciprofloxacin were effective in treatment of anthrax.', 'subject score': 1000, 'object score': 1000}, 'PMID:15163650': {'publication date': '2004 Jul', 'sentence': 'CONCLUSIONS: Gatifloxacin appeared to be more effective than moxifloxacin or ciprofloxacin, at similar doses, for early post-exposure treatment of murine systemic anthrax.', 'subject score': 1000, 'object score': 851}, 'PMID:22064542': {'publication date': '2012 Jan', 'sentence': 'Ciprofloxacin is a gold standard for the treatment of anthrax.', 'subject score': 1000, 'object score': 1000}, 'PMID:25174439': {'publication date': '2014', 'sentence': 'Broad-range antibiotics like amoxicillin, ciprofloxacin, clindamycin, streptomycin, and penicillin G are recommended for the treatment of human anthrax infections, but the threat of antibiotic resistant strains always remains.', 'subject score': 1000, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 516086,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-          "name": "bacterial infectious disease with sepsis",
-          "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C102993",
-            "ICD9:995.91",
-            "MONDO:0005229",
-            "MEDDRA:10060562",
-            "MEDDRA:10003998",
-            "MEDDRA:10003997",
-            "MEDDRA:10045641",
-            "ICD9:790.7",
-            "MEDDRA:10045642",
-            "HP:0031864",
-            "SNOMEDCT:5758002",
-            "DOID:0040085",
-            "MESH:D016470",
-            "UMLS:C0004610",
-            "MEDDRA:10003999"
-          ],
-          "id": "MONDO:0005229",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacteremia",
-            "bacterial infectious disease with sepsis",
-            "bacterial sepsis",
-            "Sepsis"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005119",
-          "name": "anthrax infection",
-          "description": "An infection caused by Bacillus anthracis bacteria. It may affect the lungs, gastrointestinal tract, or skin. Patients with lung infection present with fever, headaches, cough, chest pain and shortness of breath. Patients with gastrointestinal infection present with nausea, vomiting and bloody diarrhea. Patients with skin infection develop blisters and ulcers.; An acute infection caused by the spore-forming bacteria BACILLUS ANTHRACIS. It commonly affects hoofed animals such as sheep and goats. Infection in humans often involves the skin (cutaneous anthrax), the lungs (inhalation anthrax), or the gastrointestinal tract. Anthrax is not contagious and can be treated with antibiotics.; Anthrax is a disease caused by Bacillus anthracis, a germ that lives in soil. Many people know about it from the 2001 bioterror attacks. In the attacks, someone purposely spread anthrax through the U.S. mail. This killed five people and made 22 sick.  Anthrax is rare. It affects animals such as cattle, sheep, and goats more often than people. People can get anthrax from contact with infected animals, wool, meat, or hides. It can cause three forms of disease in people. They are:  Cutaneous, which affects the skin. People with cuts or open sores can get it if they touch the bacteria.   Inhalation, which affects the lungs. You can get this if you breathe in spores of the bacteria.   Gastrointestinal, which affects the digestive system. You can get it by eating infected meat.  Antibiotics often cure anthrax if it is diagnosed early. But many people don't know they have anthrax until it is too late to treat. A vaccine to prevent anthrax is available for people in the military and others at high risk. ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005119",
-            "MEDDRA:10003975",
-            "SNOMEDCT:409498004",
-            "NCIT:C84565",
-            "MESH:D000881",
-            "ICD9:022",
-            "MEDDRA:10002716",
-            "MEDDRA:10002713",
-            "DOID:7427",
-            "UMLS:C0003175",
-            "ICD10:A22",
-            "EFO:0000778"
-          ],
-          "id": "MONDO:0005119",
-          "category": "biolink:Disease",
-          "all_names": [
-            "anthrax infection",
-            "Anthrax disease",
-            "Anthrax",
-            "anthrax disease"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "PMID:20421654"
-=======
-            "https://en.wikipedia.org/wiki/anthrax",
-            "https://www.cdc.gov/anthrax/basics/index.htm",
-            "https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/anthrax",
-            "https://medlineplus.gov/ency/article/001325.htm"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 315382,
-=======
-            "identity": 516086,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-              "name": "bacterial infectious disease with sepsis",
-              "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C102993",
-                "ICD9:995.91",
-                "MONDO:0005229",
-                "MEDDRA:10060562",
-                "MEDDRA:10003998",
-                "MEDDRA:10003997",
-                "MEDDRA:10045641",
-                "ICD9:790.7",
-                "MEDDRA:10045642",
-                "HP:0031864",
-                "SNOMEDCT:5758002",
-                "DOID:0040085",
-                "MESH:D016470",
-                "UMLS:C0004610",
-                "MEDDRA:10003999"
-              ],
-              "id": "MONDO:0005229",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacteremia",
-                "bacterial infectious disease with sepsis",
-                "bacterial sepsis",
-                "Sepsis"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005119",
-              "name": "anthrax infection",
-              "description": "An infection caused by Bacillus anthracis bacteria. It may affect the lungs, gastrointestinal tract, or skin. Patients with lung infection present with fever, headaches, cough, chest pain and shortness of breath. Patients with gastrointestinal infection present with nausea, vomiting and bloody diarrhea. Patients with skin infection develop blisters and ulcers.; An acute infection caused by the spore-forming bacteria BACILLUS ANTHRACIS. It commonly affects hoofed animals such as sheep and goats. Infection in humans often involves the skin (cutaneous anthrax), the lungs (inhalation anthrax), or the gastrointestinal tract. Anthrax is not contagious and can be treated with antibiotics.; Anthrax is a disease caused by Bacillus anthracis, a germ that lives in soil. Many people know about it from the 2001 bioterror attacks. In the attacks, someone purposely spread anthrax through the U.S. mail. This killed five people and made 22 sick.  Anthrax is rare. It affects animals such as cattle, sheep, and goats more often than people. People can get anthrax from contact with infected animals, wool, meat, or hides. It can cause three forms of disease in people. They are:  Cutaneous, which affects the skin. People with cuts or open sores can get it if they touch the bacteria.   Inhalation, which affects the lungs. You can get this if you breathe in spores of the bacteria.   Gastrointestinal, which affects the digestive system. You can get it by eating infected meat.  Antibiotics often cure anthrax if it is diagnosed early. But many people don't know they have anthrax until it is too late to treat. A vaccine to prevent anthrax is available for people in the military and others at high risk. ; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005119",
-                "MEDDRA:10003975",
-                "SNOMEDCT:409498004",
-                "NCIT:C84565",
-                "MESH:D000881",
-                "ICD9:022",
-                "MEDDRA:10002716",
-                "MEDDRA:10002713",
-                "DOID:7427",
-                "UMLS:C0003175",
-                "ICD10:A22",
-                "EFO:0000778"
-              ],
-              "id": "MONDO:0005119",
-              "category": "biolink:Disease",
-              "all_names": [
-                "anthrax infection",
-                "Anthrax disease",
-                "Anthrax",
-                "anthrax disease"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "PMID:20421654"
-=======
-                "https://en.wikipedia.org/wiki/anthrax",
-                "https://www.cdc.gov/anthrax/basics/index.htm",
-                "https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/anthrax",
-                "https://medlineplus.gov/ency/article/001325.htm"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 10536866,
-            "start": 616,
-            "end": 315382,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1450256': {'publication date': '1992 Aug-Sep', 'sentence': 'To the contrary, ciprofloxacin, even at low doses, eliminated the microorganisms early and demonstrated high efficacy in the prevention of bacteremia in the animals when these results were compared with those of the untreated group.', 'subject score': 1000, 'object score': 1000}, 'PMID:2767765': {'publication date': '1989', 'sentence': 'In the present study 45 consecutive patients undergoing intensive cytotoxic treatment received a short course of roxithromycin (10 days) in addition to ciprofloxacin for prevention of bacteremias caused by alpha-hemolytic streptococci.', 'subject score': 1000, 'object score': 1000}, 'PMID:7961196': {'publication date': '1994 Jul', 'sentence': 'Prevention of bacteraemia by systemic ciprofloxacin treatment in rat cytomegalovirus-infected immunocompromised rats.', 'subject score': 851, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:prevents---None---None---None---UMLS:C0004610---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "10767980",
-              "object": "MONDO:0005229",
-              "publications": [
-                "PMID:1450256",
-                "PMID:2767765",
-                "PMID:7961196"
-=======
-            "identity": 9786099,
-            "start": 616,
-            "end": 516086,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12556279': {'publication date': '2003 Jan', 'sentence': 'Treatment and post-exposure prophylaxis for anthrax are ciprofloxacin or doxycycline.', 'subject score': 1000, 'object score': 1000}, 'PMID:14556058': {'publication date': '2003 Oct', 'sentence': 'In our series, penicillin and ciprofloxacin were effective in treatment of anthrax.', 'subject score': 1000, 'object score': 1000}, 'PMID:15163650': {'publication date': '2004 Jul', 'sentence': 'CONCLUSIONS: Gatifloxacin appeared to be more effective than moxifloxacin or ciprofloxacin, at similar doses, for early post-exposure treatment of murine systemic anthrax.', 'subject score': 1000, 'object score': 851}, 'PMID:22064542': {'publication date': '2012 Jan', 'sentence': 'Ciprofloxacin is a gold standard for the treatment of anthrax.', 'subject score': 1000, 'object score': 1000}, 'PMID:25174439': {'publication date': '2014', 'sentence': 'Broad-range antibiotics like amoxicillin, ciprofloxacin, clindamycin, streptomycin, and penicillin G are recommended for the treatment of human anthrax infections, but the threat of antibiotic resistant strains always remains.', 'subject score': 1000, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:treats---None---None---None---UMLS:C0003175---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "10002223",
-              "object": "MONDO:0005119",
-              "publications": [
-                "PMID:12556279",
-                "PMID:14556058",
-                "PMID:15163650",
-                "PMID:22064542",
-                "PMID:25174439"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 538307,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10232108': {'publication date': '1999 Jan', 'sentence': 'The writers consult a wide range of American, European and British research from 1950 to the present to reassure readers that ophthalmic chloramphenicol is a demonstrably effective, safe, cost-effective treatment for most superficial eye infections.', 'subject score': 861, 'object score': 901}, 'PMID:13027132': {'publication date': '1952 Nov 29', 'sentence': '[Use of chloramphenicol in external ocular infections].', 'subject score': 1000, 'object score': 901}, 'PMID:1426394': {'publication date': '1992', 'sentence': 'The safety and efficacy of topical norfloxacin compared with chloramphenicol for the treatment of external ocular bacterial infections.', 'subject score': 1000, 'object score': 861}, 'PMID:14789290': {'publication date': '1951 Jan', 'sentence': 'Clinical trial with chloramphenicol in ocular infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:14857097': {'publication date': '1951 Aug', 'sentence': 'Topical use of chloramphenicol in external ocular infections.', 'subject score': 1000, 'object score': 901}, 'PMID:14958026': {'publication date': '1952 Mar', 'sentence': '[Local application of chloramphenicol in ocular infections].', 'subject score': 1000, 'object score': 1000}, 'PMID:1751464': {'publication date': '1991 Nov', 'sentence': 'Ofloxacin compared with chloramphenicol in the management of external ocular infection.', 'subject score': 1000, 'object score': 901}, 'PMID:2018459': {'publication date': '1991 Jan', 'sentence': 'Chloramphenicol has gained widespread use in the topical treatment of ocular infections.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 546977,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043885",
-          "name": "eye infectious disorder",
-          "description": "An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.; Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.; Your eyes can get infections from bacteria, fungi, or viruses. Eye infections can occur in different parts of the eye and can affect just one eye or both. Two common eye infections are:  Conjunctivitis - also known as pink eye. Conjunctivitis is often due to an infection. Children frequently get it, and it is very contagious.  Stye - a bump on the eyelid that happens when bacteria from your skin get into the hair follicle of an eyelash.  Symptoms of eye infections may include redness, itching, swelling, discharge, pain, or problems with vision. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or antibiotics.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10015929",
-            "UMLS:C0015403",
-            "MESH:D015817",
-            "MEDDRA:10015936",
-            "MONDO:0043885",
-            "SNOMEDCT:128351009",
-            "NCIT:C45372",
-            "EFO:1001888"
-          ],
-          "id": "MONDO:0043885",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Eye Infection",
-            "eye infectious disorder",
-            "eye infection",
-            "Eye Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-<<<<<<< HEAD
-        "identity": 616,
-=======
-        "identity": 617,
->>>>>>> main
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-=======
-          "name": "Chloramphenicol",
-          "description": "A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.; An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "ATC:J01BA01",
-            "GTOPDB:10901",
-            "ATC:S03AA08",
-            "DRUGBANK:DB00446",
-            "PUBCHEM.COMPOUND:5959",
-            "UMLS:C0008168",
-            "ATC:G01AA05",
-            "RXNORM:2348",
-            "NCIT:C363",
-            "MESH:D002701",
-            "INCHIKEY:WIIZWVCIJKGZOK-RKDXNWHRSA-N",
-            "HMDB:HMDB0014589",
-            "UMLS:C0699300",
-            "CHEBI:17698",
-            "CHEMBL.COMPOUND:CHEMBL130",
-            "ATC:D06AX02",
-            "ATC:D10AF03",
-            "KEGG.DRUG:D00104",
-            "UNII:66974FR9Q1",
-            "DrugCentral:589",
-            "ATC:S02AA01",
-            "PathWhiz.Compound:8956",
-            "KEGG.COMPOUND:C00918",
-            "ATC:S01AA01"
-          ],
-          "id": "PUBCHEM.COMPOUND:5959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "chloramphenicol",
-            "CHLORAMPHENICOL",
-            "Chloramphenicol (JP18/USP/INN)",
-            "Chloramphenicol",
-            "cloramphenicol",
-            "Chlornitromycin"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-=======
-            "PMID:19752278",
-            "PMID:35653642",
-            "PMID:16180821",
-            "PMID:16495055",
-            "PMID:19064318",
-            "PMID:20921317",
-            "PMID:32813522",
-            "PMID:20696876",
-            "PMID:33322904",
-            "PMID:19332670"
->>>>>>> main
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 538307,
-=======
-            "identity": 546977,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043885",
-              "name": "eye infectious disorder",
-              "description": "An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.; Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.; Your eyes can get infections from bacteria, fungi, or viruses. Eye infections can occur in different parts of the eye and can affect just one eye or both. Two common eye infections are:  Conjunctivitis - also known as pink eye. Conjunctivitis is often due to an infection. Children frequently get it, and it is very contagious.  Stye - a bump on the eyelid that happens when bacteria from your skin get into the hair follicle of an eyelash.  Symptoms of eye infections may include redness, itching, swelling, discharge, pain, or problems with vision. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or antibiotics.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10015929",
-                "UMLS:C0015403",
-                "MESH:D015817",
-                "MEDDRA:10015936",
-                "MONDO:0043885",
-                "SNOMEDCT:128351009",
-                "NCIT:C45372",
-                "EFO:1001888"
-              ],
-              "id": "MONDO:0043885",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Eye Infection",
-                "eye infectious disorder",
-                "eye infection",
-                "Eye Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 9732045,
-            "start": 616,
-            "end": 538307,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12499786': {'publication date': '2002 Sep', 'sentence': '[Prospective randomized trial of intravenous ciprofloxacin for prevention of bacterial infection in cirrhotic patients with esophageal variceal bleeding].', 'subject score': 888, 'object score': 1000}, 'PMID:2006519': {'publication date': '1991 Mar', 'sentence': 'Ciprofloxacin appears to be effective for preventing bacterial infections in neutropenic patients.', 'subject score': 1000, 'object score': 884}, 'PMID:2048868': {'publication date': '1991 Jul 01', 'sentence': 'OBJECTIVE: To compare the efficacy of norfloxacin and ciprofloxacin in preventing bacterial infection in neutropenic patients.', 'subject score': 1000, 'object score': 884}, 'PMID:2963998': {'publication date': '1987 Dec 11', 'sentence': 'Prolonged administration of ciprofloxacin turned out to be safe and effective in preventing serious aerobic bacterial infections during the first three months after BMT.', 'subject score': 1000, 'object score': 831}, 'PMID:30429884': {'publication date': '2018', 'sentence': 'The results support that Cipro successfully reduced bacterial infection and thus encouraged faster wound closure.', 'subject score': 1000, 'object score': 1000}, 'PMID:7751732': {'publication date': '1995 Jan', 'sentence': 'These results suggest that combination with ST and CPFX is more efficacious than ST alone for the prevention of bacterial infections in granulocytopenic patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:7799026': {'publication date': '1995 Jan', 'sentence': 'CONCLUSION: CIP and TMS were equally safe and effective in the prevention of bacterial infections in BMT patients when the overall infection rate was used as the principal end point.', 'subject score': 1000, 'object score': 1000}, 'PMID:8166152': {'publication date': '1994 Apr', 'sentence': 'PURPOSE: To study whether oral ciprofloxacin would be as effective in preventing bacterial infections in severely myelosuppressed patients as selective antibiotic modulation of the gut flora with neomycin/polymyxin B sulfate/nalidixic acid (NPN).', 'subject score': 888, 'object score': 884}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:prevents---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "9947057",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:12499786",
-                "PMID:2006519",
-                "PMID:2048868",
-                "PMID:2963998",
-                "PMID:30429884",
-                "PMID:7751732",
-                "PMID:7799026",
-                "PMID:8166152"
-=======
-            "identity": 7204541,
-            "start": 617,
-            "end": 546977,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10232108': {'publication date': '1999 Jan', 'sentence': 'The writers consult a wide range of American, European and British research from 1950 to the present to reassure readers that ophthalmic chloramphenicol is a demonstrably effective, safe, cost-effective treatment for most superficial eye infections.', 'subject score': 861, 'object score': 901}, 'PMID:13027132': {'publication date': '1952 Nov 29', 'sentence': '[Use of chloramphenicol in external ocular infections].', 'subject score': 1000, 'object score': 901}, 'PMID:1426394': {'publication date': '1992', 'sentence': 'The safety and efficacy of topical norfloxacin compared with chloramphenicol for the treatment of external ocular bacterial infections.', 'subject score': 1000, 'object score': 861}, 'PMID:14789290': {'publication date': '1951 Jan', 'sentence': 'Clinical trial with chloramphenicol in ocular infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:14857097': {'publication date': '1951 Aug', 'sentence': 'Topical use of chloramphenicol in external ocular infections.', 'subject score': 1000, 'object score': 901}, 'PMID:14958026': {'publication date': '1952 Mar', 'sentence': '[Local application of chloramphenicol in ocular infections].', 'subject score': 1000, 'object score': 1000}, 'PMID:1751464': {'publication date': '1991 Nov', 'sentence': 'Ofloxacin compared with chloramphenicol in the management of external ocular infection.', 'subject score': 1000, 'object score': 901}, 'PMID:2018459': {'publication date': '1991 Jan', 'sentence': 'Chloramphenicol has gained widespread use in the topical treatment of ocular infections.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008168---SEMMEDDB:treats---None---None---None---UMLS:C0015403---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5959",
-              "id": "7351604",
-              "object": "MONDO:0043885",
-              "publications": [
-                "PMID:10232108",
-                "PMID:13027132",
-                "PMID:1426394",
-                "PMID:14789290",
-                "PMID:14857097",
-                "PMID:14958026",
-                "PMID:1751464",
-                "PMID:2018459"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-<<<<<<< HEAD
-            "identity": 616,
-=======
-            "identity": 617,
->>>>>>> main
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-=======
-              "name": "Chloramphenicol",
-              "description": "A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.; An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "ATC:J01BA01",
-                "GTOPDB:10901",
-                "ATC:S03AA08",
-                "DRUGBANK:DB00446",
-                "PUBCHEM.COMPOUND:5959",
-                "UMLS:C0008168",
-                "ATC:G01AA05",
-                "RXNORM:2348",
-                "NCIT:C363",
-                "MESH:D002701",
-                "INCHIKEY:WIIZWVCIJKGZOK-RKDXNWHRSA-N",
-                "HMDB:HMDB0014589",
-                "UMLS:C0699300",
-                "CHEBI:17698",
-                "CHEMBL.COMPOUND:CHEMBL130",
-                "ATC:D06AX02",
-                "ATC:D10AF03",
-                "KEGG.DRUG:D00104",
-                "UNII:66974FR9Q1",
-                "DrugCentral:589",
-                "ATC:S02AA01",
-                "PathWhiz.Compound:8956",
-                "KEGG.COMPOUND:C00918",
-                "ATC:S01AA01"
-              ],
-              "id": "PUBCHEM.COMPOUND:5959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "chloramphenicol",
-                "CHLORAMPHENICOL",
-                "Chloramphenicol (JP18/USP/INN)",
-                "Chloramphenicol",
-                "cloramphenicol",
-                "Chlornitromycin"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-=======
-                "PMID:19752278",
-                "PMID:35653642",
-                "PMID:16180821",
-                "PMID:16495055",
-                "PMID:19064318",
-                "PMID:20921317",
-                "PMID:32813522",
-                "PMID:20696876",
-                "PMID:33322904",
-                "PMID:19332670"
->>>>>>> main
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 321523,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:31438629': {'publication date': '2019 Aug 21', 'sentence': 'Chloramphenicol is experiencing its renaissance because it is widely used in the treatment and prevention of superficial eye infections due to its broad spectrum of activity and other useful antimicrobial peculiarities, such as the antibiofilm properties.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 546977,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
-          ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Pneumonia",
-            "pneumonia"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043885",
-          "name": "eye infectious disorder",
-          "description": "An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.; Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.; Your eyes can get infections from bacteria, fungi, or viruses. Eye infections can occur in different parts of the eye and can affect just one eye or both. Two common eye infections are:  Conjunctivitis - also known as pink eye. Conjunctivitis is often due to an infection. Children frequently get it, and it is very contagious.  Stye - a bump on the eyelid that happens when bacteria from your skin get into the hair follicle of an eyelash.  Symptoms of eye infections may include redness, itching, swelling, discharge, pain, or problems with vision. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or antibiotics.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10015929",
-            "UMLS:C0015403",
-            "MESH:D015817",
-            "MEDDRA:10015936",
-            "MONDO:0043885",
-            "SNOMEDCT:128351009",
-            "NCIT:C45372",
-            "EFO:1001888"
-          ],
-          "id": "MONDO:0043885",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Eye Infection",
-            "eye infectious disorder",
-            "eye infection",
-            "Eye Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 617,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Chloramphenicol",
-          "description": "A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.; An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "ATC:J01BA01",
-            "GTOPDB:10901",
-            "ATC:S03AA08",
-            "DRUGBANK:DB00446",
-            "PUBCHEM.COMPOUND:5959",
-            "UMLS:C0008168",
-            "ATC:G01AA05",
-            "RXNORM:2348",
-            "NCIT:C363",
-            "MESH:D002701",
-            "INCHIKEY:WIIZWVCIJKGZOK-RKDXNWHRSA-N",
-            "HMDB:HMDB0014589",
-            "UMLS:C0699300",
-            "CHEBI:17698",
-            "CHEMBL.COMPOUND:CHEMBL130",
-            "ATC:D06AX02",
-            "ATC:D10AF03",
-            "KEGG.DRUG:D00104",
-            "UNII:66974FR9Q1",
-            "DrugCentral:589",
-            "ATC:S02AA01",
-            "PathWhiz.Compound:8956",
-            "KEGG.COMPOUND:C00918",
-            "ATC:S01AA01"
-          ],
-          "id": "PUBCHEM.COMPOUND:5959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "chloramphenicol",
-            "CHLORAMPHENICOL",
-            "Chloramphenicol (JP18/USP/INN)",
-            "Chloramphenicol",
-            "cloramphenicol",
-            "Chlornitromycin"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:35653642",
-            "PMID:16180821",
-            "PMID:16495055",
-            "PMID:19064318",
-            "PMID:20921317",
-            "PMID:32813522",
-            "PMID:20696876",
-            "PMID:33322904",
-            "PMID:19332670"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546977,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043885",
-              "name": "eye infectious disorder",
-              "description": "An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.; Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.; Your eyes can get infections from bacteria, fungi, or viruses. Eye infections can occur in different parts of the eye and can affect just one eye or both. Two common eye infections are:  Conjunctivitis - also known as pink eye. Conjunctivitis is often due to an infection. Children frequently get it, and it is very contagious.  Stye - a bump on the eyelid that happens when bacteria from your skin get into the hair follicle of an eyelash.  Symptoms of eye infections may include redness, itching, swelling, discharge, pain, or problems with vision. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or antibiotics.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10015929",
-                "UMLS:C0015403",
-                "MESH:D015817",
-                "MEDDRA:10015936",
-                "MONDO:0043885",
-                "SNOMEDCT:128351009",
-                "NCIT:C45372",
-                "EFO:1001888"
-              ],
-              "id": "MONDO:0043885",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Eye Infection",
-                "eye infectious disorder",
-                "eye infection",
-                "Eye Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20831966,
-            "start": 617,
-            "end": 546977,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31438629': {'publication date': '2019 Aug 21', 'sentence': 'Chloramphenicol is experiencing its renaissance because it is widely used in the treatment and prevention of superficial eye infections due to its broad spectrum of activity and other useful antimicrobial peculiarities, such as the antibiofilm properties.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0008168---SEMMEDDB:prevents---None---None---None---UMLS:C0015403---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5959",
-              "id": "21241586",
-              "object": "MONDO:0043885",
-              "publications": [
-                "PMID:31438629"
-              ]
-            }
-          },
-          "end": {
-            "identity": 617,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Chloramphenicol",
-              "description": "A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.; An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "ATC:J01BA01",
-                "GTOPDB:10901",
-                "ATC:S03AA08",
-                "DRUGBANK:DB00446",
-                "PUBCHEM.COMPOUND:5959",
-                "UMLS:C0008168",
-                "ATC:G01AA05",
-                "RXNORM:2348",
-                "NCIT:C363",
-                "MESH:D002701",
-                "INCHIKEY:WIIZWVCIJKGZOK-RKDXNWHRSA-N",
-                "HMDB:HMDB0014589",
-                "UMLS:C0699300",
-                "CHEBI:17698",
-                "CHEMBL.COMPOUND:CHEMBL130",
-                "ATC:D06AX02",
-                "ATC:D10AF03",
-                "KEGG.DRUG:D00104",
-                "UNII:66974FR9Q1",
-                "DrugCentral:589",
-                "ATC:S02AA01",
-                "PathWhiz.Compound:8956",
-                "KEGG.COMPOUND:C00918",
-                "ATC:S01AA01"
-              ],
-              "id": "PUBCHEM.COMPOUND:5959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "chloramphenicol",
-                "CHLORAMPHENICOL",
-                "Chloramphenicol (JP18/USP/INN)",
-                "Chloramphenicol",
-                "cloramphenicol",
-                "Chlornitromycin"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:35653642",
-                "PMID:16180821",
-                "PMID:16495055",
-                "PMID:19064318",
-                "PMID:20921317",
-                "PMID:32813522",
-                "PMID:20696876",
-                "PMID:33322904",
-                "PMID:19332670"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:2135129': {'publication date': '1990 Jun', 'sentence': 'Lysis of P. acnes by the lytic factor was inhibited by adding chloramphenicol which was assumed to inhibit the release of lipoteichoic acid.', 'subject score': 872, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 320111,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011438",
-          "name": "acne",
-          "description": "A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors.; A skin condition in which there is an increase in sebum secretion by the pilosebaceous apparatus associated with open comedones (blackheads), closed comedones (whiteheads), and pustular nodules (papules, pustules, and cysts). [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10000497",
-            "UMLS:C0152249",
-            "ICD10:L70",
-            "MEDDRA:10000510",
-            "NCIT:C27195",
-            "UMLS:C4531022",
-            "EFO:0003894",
-            "MEDDRA:10000519",
-            "SNOMEDCT:23894009",
-            "SNOMEDCT:88616000",
-            "MEDDRA:10000518",
-            "DOID:6543",
-            "HP:0001061",
-            "UMLS:C0001144",
-            "ICD10:L70.2",
-            "SNOMEDCT:11381005",
-            "MEDDRA:10000496",
-            "ICD9:706.0",
-            "MESH:D000152",
-            "MONDO:0011438",
-            "UMLS:C0702166"
-          ],
-          "id": "MONDO:0011438",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acne Vulgaris",
-            "acne",
-            "Acne varioliformis",
-            "Acne",
-            "Breaking out"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://en.wikipedia.org/wiki/pneumonia",
-=======
-            "http://en.wikipedia.org/wiki/sebaceous_gland#clinical_significance",
-            "https://orcid.org/0000-0002-6601-2165",
->>>>>>> main
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-<<<<<<< HEAD
-        "identity": 616,
-=======
-        "identity": 617,
->>>>>>> main
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-=======
-          "name": "Chloramphenicol",
-          "description": "A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.; An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "ATC:J01BA01",
-            "GTOPDB:10901",
-            "ATC:S03AA08",
-            "DRUGBANK:DB00446",
-            "PUBCHEM.COMPOUND:5959",
-            "UMLS:C0008168",
-            "ATC:G01AA05",
-            "RXNORM:2348",
-            "NCIT:C363",
-            "MESH:D002701",
-            "INCHIKEY:WIIZWVCIJKGZOK-RKDXNWHRSA-N",
-            "HMDB:HMDB0014589",
-            "UMLS:C0699300",
-            "CHEBI:17698",
-            "CHEMBL.COMPOUND:CHEMBL130",
-            "ATC:D06AX02",
-            "ATC:D10AF03",
-            "KEGG.DRUG:D00104",
-            "UNII:66974FR9Q1",
-            "DrugCentral:589",
-            "ATC:S02AA01",
-            "PathWhiz.Compound:8956",
-            "KEGG.COMPOUND:C00918",
-            "ATC:S01AA01"
-          ],
-          "id": "PUBCHEM.COMPOUND:5959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "chloramphenicol",
-            "CHLORAMPHENICOL",
-            "Chloramphenicol (JP18/USP/INN)",
-            "Chloramphenicol",
-            "cloramphenicol",
-            "Chlornitromycin"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-=======
-            "PMID:19752278",
-            "PMID:35653642",
-            "PMID:16180821",
-            "PMID:16495055",
-            "PMID:19064318",
-            "PMID:20921317",
-            "PMID:32813522",
-            "PMID:20696876",
-            "PMID:33322904",
-            "PMID:19332670"
->>>>>>> main
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 321523,
-=======
-            "identity": 320111,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
-              ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Pneumonia",
-                "pneumonia"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011438",
-              "name": "acne",
-              "description": "A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors.; A skin condition in which there is an increase in sebum secretion by the pilosebaceous apparatus associated with open comedones (blackheads), closed comedones (whiteheads), and pustular nodules (papules, pustules, and cysts). [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10000497",
-                "UMLS:C0152249",
-                "ICD10:L70",
-                "MEDDRA:10000510",
-                "NCIT:C27195",
-                "UMLS:C4531022",
-                "EFO:0003894",
-                "MEDDRA:10000519",
-                "SNOMEDCT:23894009",
-                "SNOMEDCT:88616000",
-                "MEDDRA:10000518",
-                "DOID:6543",
-                "HP:0001061",
-                "UMLS:C0001144",
-                "ICD10:L70.2",
-                "SNOMEDCT:11381005",
-                "MEDDRA:10000496",
-                "ICD9:706.0",
-                "MESH:D000152",
-                "MONDO:0011438",
-                "UMLS:C0702166"
-              ],
-              "id": "MONDO:0011438",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acne Vulgaris",
-                "acne",
-                "Acne varioliformis",
-                "Acne",
-                "Breaking out"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://en.wikipedia.org/wiki/pneumonia",
-=======
-                "http://en.wikipedia.org/wiki/sebaceous_gland#clinical_significance",
-                "https://orcid.org/0000-0002-6601-2165",
->>>>>>> main
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 8184815,
-            "start": 616,
-            "end": 321523,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10933643': {'publication date': '2000 Aug', 'sentence': 'The susceptibility to ciprofloxacin decreased successively with decreasing susceptibility to cefuroxime for K. pneumoniae.', 'subject score': 1000, 'object score': 888}, 'PMID:1343609': {'publication date': '1992 Aug 11', 'sentence': 'Following completion of the study, monthly aerosolized pentamidine administered in conjunction with ciprofloxacin has provided complete protection against urinary tract infection and pneumocystis pneumonia in 30 transplant recipients unable to tolerate trimethoprim-sulfamethoxazole therapy.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:prevents---None---None---None---UMLS:C0032285---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8364719",
-              "object": "MONDO:0005249",
-              "publications": [
-                "PMID:10933643",
-                "PMID:1343609"
-=======
-            "identity": 15174100,
-            "start": 617,
-            "end": 320111,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2135129': {'publication date': '1990 Jun', 'sentence': 'Lysis of P. acnes by the lytic factor was inhibited by adding chloramphenicol which was assumed to inhibit the release of lipoteichoic acid.', 'subject score': 872, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008168---SEMMEDDB:disrupts---None---None---None---UMLS:C0702166---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5959",
-              "id": "15493028",
-              "object": "MONDO:0011438",
-              "publications": [
-                "PMID:2135129"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-<<<<<<< HEAD
-            "identity": 616,
-=======
-            "identity": 617,
->>>>>>> main
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-=======
-              "name": "Chloramphenicol",
-              "description": "A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.; An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "ATC:J01BA01",
-                "GTOPDB:10901",
-                "ATC:S03AA08",
-                "DRUGBANK:DB00446",
-                "PUBCHEM.COMPOUND:5959",
-                "UMLS:C0008168",
-                "ATC:G01AA05",
-                "RXNORM:2348",
-                "NCIT:C363",
-                "MESH:D002701",
-                "INCHIKEY:WIIZWVCIJKGZOK-RKDXNWHRSA-N",
-                "HMDB:HMDB0014589",
-                "UMLS:C0699300",
-                "CHEBI:17698",
-                "CHEMBL.COMPOUND:CHEMBL130",
-                "ATC:D06AX02",
-                "ATC:D10AF03",
-                "KEGG.DRUG:D00104",
-                "UNII:66974FR9Q1",
-                "DrugCentral:589",
-                "ATC:S02AA01",
-                "PathWhiz.Compound:8956",
-                "KEGG.COMPOUND:C00918",
-                "ATC:S01AA01"
-              ],
-              "id": "PUBCHEM.COMPOUND:5959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "chloramphenicol",
-                "CHLORAMPHENICOL",
-                "Chloramphenicol (JP18/USP/INN)",
-                "Chloramphenicol",
-                "cloramphenicol",
-                "Chlornitromycin"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-=======
-                "PMID:19752278",
-                "PMID:35653642",
-                "PMID:16180821",
-                "PMID:16495055",
-                "PMID:19064318",
-                "PMID:20921317",
-                "PMID:32813522",
-                "PMID:20696876",
-                "PMID:33322904",
-                "PMID:19332670"
->>>>>>> main
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 539955,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-          "name": "infectious disease",
-          "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005550",
-            "SNOMEDCT:189822004",
-            "PSY:10513",
-            "UMLS:C0009450",
-            "UMLS:C0001485",
-            "EFO:0005741",
-            "MEDDRA:10021881",
-            "MESH:D003141",
-            "ICD9:079.0",
-            "DOID:0050117",
-            "SNOMEDCT:40733004",
-            "SNOMEDCT:191415002",
-            "NCIT:C26726"
-          ],
-          "id": "MONDO:0005550",
-          "category": "biolink:Disease",
-          "all_names": [
-            "infectious disease",
-            "Infectious Disorder",
-            "disease by infectious agent",
-            "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-            "Communicable Diseases"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.merriam-webster.com/medical/communicable%20disease",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 539955,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-              "name": "infectious disease",
-              "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005550",
-                "SNOMEDCT:189822004",
-                "PSY:10513",
-                "UMLS:C0009450",
-                "UMLS:C0001485",
-                "EFO:0005741",
-                "MEDDRA:10021881",
-                "MESH:D003141",
-                "ICD9:079.0",
-                "DOID:0050117",
-                "SNOMEDCT:40733004",
-                "SNOMEDCT:191415002",
-                "NCIT:C26726"
-              ],
-              "id": "MONDO:0005550",
-              "category": "biolink:Disease",
-              "all_names": [
-                "infectious disease",
-                "Infectious Disorder",
-                "disease by infectious agent",
-                "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-                "Communicable Diseases"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.merriam-webster.com/medical/communicable%20disease",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7884454,
-            "start": 616,
-            "end": 539955,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10715297': {'publication date': '2000 Mar', 'sentence': 'PURPOSE: To determine whether an antibiotic flush solution containing vancomycin, heparin, and ciprofloxacin (VHC) can prevent the majority of line infections.', 'subject score': 1000, 'object score': 888}, 'PMID:11132527': {'publication date': '2000 Dec 02', 'sentence': 'This retrospective study confirms that oral prophylaxis with ciprofloxacin and penicillin decreases the incidence of infections and, in particular, of gram-negative bacteraemia, but does not modify the overall morbidity and mortality in our patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:1322231': {'publication date': '1992 Aug 15', 'sentence': 'RESULTS: The fluoroquinolone compounds, such as ciprofloxacin, norfloxacin, and ofloxacin, have broad spectrum bactericidal activity and have proved to be effective in both the treatment and prevention of certain infections in patients with cancer.', 'subject score': 1000, 'object score': 888}, 'PMID:1503442': {'publication date': '1992 Apr', 'sentence': 'A prospective randomized study was conducted to determine the efficacy of imipenem-cilastatin (hereafter referred to as imipenem) (500 mg four times daily) versus combination therapy for febrile neutropenic patients receiving either no prophylaxis or ciprofloxacin for prevention of infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:1611208': {'publication date': '1992 Apr', 'sentence': 'In an ex vivo model of infection using peritoneal resting macrophages from the C57BL/6 mouse, the intracellular viability of a strain of M. avium (strain 489, serovar 3) was reduced by clofazimine, amikacin, ciprofloxacin, rifabutin and clarithromycin (99, 98, 93, 89 and 69%, respectively), thus indicating for clofazimine a good correlation between in vitro and ex vivo activity.', 'subject score': 1000, 'object score': 1000}, 'PMID:19188359': {'publication date': '2009 Apr', 'sentence': 'Although there were major differences in pathogenesis, the recombinant F1 and V antigen vaccine and ciprofloxacin protected against plague infections caused by small- and large-particle aerosols.', 'subject score': 1000, 'object score': 888}, 'PMID:2048868': {'publication date': '1991 Jul 01', 'sentence': 'CONCLUSION: Ciprofloxacin should be used to prevent the development of infection in neutropenic patients with hematologic malignancies.', 'subject score': 1000, 'object score': 1000}, 'PMID:2098296': {'publication date': '1990 Nov-Dec', 'sentence': 'Ciprofloxacin appears to be an effective agent for the prevention of gram-negative infections in granulocytopenic patients with acute leukemia, but may contribute to a shift in the type of infections in these patients towards those caused by gram-positive microorganisms, intrinsically fairly sensitive or with acquired drug resistance.', 'subject score': 1000, 'object score': 851}, 'PMID:22476119': {'publication date': '2011 Oct-Dec', 'sentence': '[Ciprofloxacin vs cefazolin in the prevention of infection in cirrhotic patients with gastrointestinal bleeding].', 'subject score': 1000, 'object score': 1000}, 'PMID:2286588': {'publication date': '1990 Nov', 'sentence': 'Preliminary results are presented of an ongoing, prospective, randomized, study comparing ofloxacin, ciprofloxacin and co-trimoxazole/colistin for the prevention of infection in patients with acute leukaemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:2292538': {'publication date': '1990 Dec', 'sentence': 'Prevention of infection by ciprofloxacin in neutropenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:24415457': {'publication date': '2014 Apr 15', 'sentence': 'Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.', 'subject score': 1000, 'object score': 888}, 'PMID:24495623': {'publication date': '2014 Mar', 'sentence': 'Ciprofloxacin and trimethoprim-sulfamethoxazole are the most commonly recommended prophylactic antibiotics used to prevent A. hydrophila infections during leech therapy.', 'subject score': 1000, 'object score': 861}, 'PMID:25423029': {'publication date': '2015 Mar', 'sentence': 'CONCLUSION: Trimethoprim-sulfamethoxazole and ciprofloxacin appear equally effective at preventing leech-associated infections.', 'subject score': 1000, 'object score': 764}, 'PMID:2667112': {'publication date': '1989', 'sentence': 'Oral ciprofloxacin given prophylactically to immunocompromised patients during severe granulocytopenia prevented colonization with potentially pathogenic aerobic Gram-negative rods, and reduced the incidence of infections caused by these microorganisms.', 'subject score': 888, 'object score': 1000}, 'PMID:26951136': {'publication date': '2016 Nov', 'sentence': 'A single dose of meropenem is superior to ciprofloxacin in preventing infections after transrectal ultrasound-guided prostate biopsies in the era of quinolone resistance.', 'subject score': 1000, 'object score': 872}, 'PMID:2767765': {'publication date': '1989', 'sentence': 'We previously demonstrated that ciprofloxacin prevents infections caused by gram-negative bacilli in patients with granulocytopenia.', 'subject score': 1000, 'object score': 1000}, 'PMID:28220110': {'publication date': '2017', 'sentence': 'Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague.', 'subject score': 851, 'object score': 861}, 'PMID:30017599': {'publication date': '2018 Sep', 'sentence': 'CONCLUSION: Immersing IPP material into an antibiotic solution, such as ampicillin or ciprofloxacin, increases the bactericidal properties and may aid in the prevention of infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:7548495': {'publication date': '1995 Jun', 'sentence': 'Ciprofloxacin failed to prevent V. cholerae O1 infections during a period of low transmissibility.', 'subject score': 1000, 'object score': 824}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:prevents---None---None---None---UMLS:C0009450---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8054296",
-              "object": "MONDO:0005550",
-              "publications": [
-                "PMID:10715297",
-                "PMID:11132527",
-                "PMID:1322231",
-                "PMID:1503442",
-                "PMID:1611208",
-                "PMID:19188359",
-                "PMID:2048868",
-                "PMID:2098296",
-                "PMID:22476119",
-                "PMID:2286588",
-                "PMID:2292538",
-                "PMID:24415457",
-                "PMID:24495623",
-                "PMID:25423029",
-                "PMID:2667112",
-                "PMID:26951136",
-                "PMID:2767765",
-                "PMID:28220110",
-                "PMID:30017599",
-                "PMID:7548495"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 539955,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-          "name": "infectious disease",
-          "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005550",
-            "SNOMEDCT:189822004",
-            "PSY:10513",
-            "UMLS:C0009450",
-            "UMLS:C0001485",
-            "EFO:0005741",
-            "MEDDRA:10021881",
-            "MESH:D003141",
-            "ICD9:079.0",
-            "DOID:0050117",
-            "SNOMEDCT:40733004",
-            "SNOMEDCT:191415002",
-            "NCIT:C26726"
-          ],
-          "id": "MONDO:0005550",
-          "category": "biolink:Disease",
-          "all_names": [
-            "infectious disease",
-            "Infectious Disorder",
-            "disease by infectious agent",
-            "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-            "Communicable Diseases"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.merriam-webster.com/medical/communicable%20disease",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 539955,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-              "name": "infectious disease",
-              "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005550",
-                "SNOMEDCT:189822004",
-                "PSY:10513",
-                "UMLS:C0009450",
-                "UMLS:C0001485",
-                "EFO:0005741",
-                "MEDDRA:10021881",
-                "MESH:D003141",
-                "ICD9:079.0",
-                "DOID:0050117",
-                "SNOMEDCT:40733004",
-                "SNOMEDCT:191415002",
-                "NCIT:C26726"
-              ],
-              "id": "MONDO:0005550",
-              "category": "biolink:Disease",
-              "all_names": [
-                "infectious disease",
-                "Infectious Disorder",
-                "disease by infectious agent",
-                "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-                "Communicable Diseases"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.merriam-webster.com/medical/communicable%20disease",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17992689,
-            "start": 616,
-            "end": 539955,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:26042652': {'publication date': '2015 Jun 05', 'sentence': 'Increasing rates of shigellosis among adult males, particularly men who have sex with men (MSM), have been documented in the United States, Canada, and Europe, and MSM appear to be at greater risk for infection with shigellae that are not susceptible to ciprofloxacin or azithromycin.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:predisposes---None---None---None---UMLS:C0009450---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "18366035",
-              "object": "MONDO:0005550",
-              "publications": [
-                "PMID:26042652"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 315382,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-          "name": "bacterial infectious disease with sepsis",
-          "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C102993",
-            "ICD9:995.91",
-            "MONDO:0005229",
-            "MEDDRA:10060562",
-            "MEDDRA:10003998",
-            "MEDDRA:10003997",
-            "MEDDRA:10045641",
-            "ICD9:790.7",
-            "MEDDRA:10045642",
-            "HP:0031864",
-            "SNOMEDCT:5758002",
-            "DOID:0040085",
-            "MESH:D016470",
-            "UMLS:C0004610",
-            "MEDDRA:10003999"
-          ],
-          "id": "MONDO:0005229",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacteremia",
-            "bacterial infectious disease with sepsis",
-            "bacterial sepsis",
-            "Sepsis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:20421654"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 315382,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-              "name": "bacterial infectious disease with sepsis",
-              "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C102993",
-                "ICD9:995.91",
-                "MONDO:0005229",
-                "MEDDRA:10060562",
-                "MEDDRA:10003998",
-                "MEDDRA:10003997",
-                "MEDDRA:10045641",
-                "ICD9:790.7",
-                "MEDDRA:10045642",
-                "HP:0031864",
-                "SNOMEDCT:5758002",
-                "DOID:0040085",
-                "MESH:D016470",
-                "UMLS:C0004610",
-                "MEDDRA:10003999"
-              ],
-              "id": "MONDO:0005229",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacteremia",
-                "bacterial infectious disease with sepsis",
-                "bacterial sepsis",
-                "Sepsis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:20421654"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15141440,
-            "start": 616,
-            "end": 315382,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21298846': {'publication date': '2009 Aug', 'sentence': 'CONCLUSION: The present study shows a significant correlation between ciprofloxacin resistance and fluoroquinolone use, and indicates that prior fluoroquinolone use seems to be the most important risk factor for ciprofloxacin-resistant E. coli bacteremia.', 'subject score': 694, 'object score': 758}, 'PMID:7726525': {'publication date': '1995 Feb', 'sentence': 'In conclusion, our study shows a significant correlation between ciprofloxacin resistance and fluoroquinolone use and indicates that prior fluoroquinolone use seems to be the most important risk factor for CIPRO-R E. coli bacteremia.', 'subject score': 694, 'object score': 758}, 'PMID:9402356': {'publication date': '1997 Nov', 'sentence': 'Both C. difficile infection and antimicrobial (vancomycin and ciprofloxacin) use during VRE colonization were significant risk factors for VRE bacteremia in univariate analysis.', 'subject score': 1000, 'object score': 908}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:predisposes---None---None---None---UMLS:C0004610---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "15459841",
-              "object": "MONDO:0005229",
-              "publications": [
-                "PMID:21298846",
-                "PMID:7726525",
-                "PMID:9402356"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 506516,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004277",
-          "name": "gonorrhea",
-          "description": "An infection that is caused by Gonococcus.; A common sexually transmitted bacterial infection caused by Neisseria gonorrhoeae. It is transmitted through vaginal, oral, or anal intercourse. Infected individuals may be asymptomatic. Symptoms in males include burning sensation during urination, discharge from the penis, and painful swelling of the testes. Symptoms in females include painful urination, vaginal discharge, and vaginal bleeding between periods. If untreated, the infection may lead to pelvic inflammatory disease.; Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, NEISSERIA GONORRHOEAE, was isolated by Neisser in 1879.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "PSY:21330",
-            "UMLS:C0018081",
-            "MEDDRA:10018612",
-            "ORPHANET:100642",
-            "MEDDRA:10018615",
-            "NCIT:C92950",
-            "MESH:D006069",
-            "DOID:7551",
-            "NCIT:C35730",
-            "ICD10:A54",
-            "SNOMEDCT:15628003",
-            "MEDDRA:10081185",
-            "MEDDRA:10051970",
-            "ICD9:098",
-            "MEDDRA:10018604",
-            "MONDO:0004277"
-          ],
-          "id": "MONDO:0004277",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Gonococcal Infection",
-            "gonorrhea",
-            "Gonorrhea",
-            "Gonococcal infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.cdc.gov/std/gonorrhea/stdfact-gonorrhea.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 616,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Ciprofloxacin",
-          "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "NDDF:002882",
-            "RXNORM:2551",
-            "PUBCHEM.COMPOUND:4011971",
-            "CHEBI:100241",
-            "UMLS:C0008809",
-            "CAS:85721-33-1",
-            "UNII:5E8K9I0O4U",
-            "CHEBI:192484",
-            "HMDB:HMDB0014677",
-            "MESH:C557944",
-            "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-            "DrugCentral:659",
-            "DRUGBANK:DB05488",
-            "ATC:S01AE03",
-            "PDQ:CDR0000040784",
-            "ATC:J01MA02",
-            "GTOPDB:10902",
-            "NCIT:C375",
-            "RXNORM:203563",
-            "ATC:S02AA15",
-            "MESH:D002939",
-            "PUBCHEM.COMPOUND:2764",
-            "CHEMBL.COMPOUND:CHEMBL8",
-            "KEGG.COMPOUND:C05349",
-            "DRUGBANK:DB00537",
-            "KEGG.DRUG:D00186",
-            "UMLS:C3181013",
-            "ATC:S03AA07"
-          ],
-          "id": "PUBCHEM.COMPOUND:2764",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "ciprofloxacin lactate",
-            "ciprofloxacin",
-            "Ciprofloxacin",
-            "ciprofloxacin zwitterion",
-            "CIPROFLOXACIN",
-            "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-            "Technetium Tc-99m ciprofloxacin",
-            "Cipro",
-            "Ciprofloxacin (JP18/USP/INN)"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:18725436",
-            "PMID:10514290",
-            "PMID:15801857",
-            "PMID:17116675",
-            "PMID:16054362",
-            "PMID:21185626",
-            "PMID:20547788",
-            "PMID:23084277",
-            "PMID:25756620",
-            "PMID:34774742"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 506516,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004277",
-              "name": "gonorrhea",
-              "description": "An infection that is caused by Gonococcus.; A common sexually transmitted bacterial infection caused by Neisseria gonorrhoeae. It is transmitted through vaginal, oral, or anal intercourse. Infected individuals may be asymptomatic. Symptoms in males include burning sensation during urination, discharge from the penis, and painful swelling of the testes. Symptoms in females include painful urination, vaginal discharge, and vaginal bleeding between periods. If untreated, the infection may lead to pelvic inflammatory disease.; Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, NEISSERIA GONORRHOEAE, was isolated by Neisser in 1879.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "PSY:21330",
-                "UMLS:C0018081",
-                "MEDDRA:10018612",
-                "ORPHANET:100642",
-                "MEDDRA:10018615",
-                "NCIT:C92950",
-                "MESH:D006069",
-                "DOID:7551",
-                "NCIT:C35730",
-                "ICD10:A54",
-                "SNOMEDCT:15628003",
-                "MEDDRA:10081185",
-                "MEDDRA:10051970",
-                "ICD9:098",
-                "MEDDRA:10018604",
-                "MONDO:0004277"
-              ],
-              "id": "MONDO:0004277",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Gonococcal Infection",
-                "gonorrhea",
-                "Gonorrhea",
-                "Gonococcal infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.cdc.gov/std/gonorrhea/stdfact-gonorrhea.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 8571915,
-            "start": 616,
-            "end": 506516,
-            "type": "biolink:predisposes",
-            "properties": {
-              "predicate": "biolink:predisposes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11247712': {'publication date': '2001 Mar 15', 'sentence': 'These findings suggest that in vitro resistance to ciprofloxacin is predictive of clinical treatment failure in patients with gonorrhea.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008809---SEMMEDDB:predisposes---None---None---None---UMLS:C0018081---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:2764",
-              "id": "8758764",
-              "object": "MONDO:0004277",
-              "publications": [
-                "PMID:11247712"
-              ]
-            }
-          },
-          "end": {
-            "identity": 616,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Ciprofloxacin",
-              "description": "A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C375\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C375\" NCI Thesaurus); A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04); A broad-spectrum antimicrobial carboxyfluoroquinoline.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "NDDF:002882",
-                "RXNORM:2551",
-                "PUBCHEM.COMPOUND:4011971",
-                "CHEBI:100241",
-                "UMLS:C0008809",
-                "CAS:85721-33-1",
-                "UNII:5E8K9I0O4U",
-                "CHEBI:192484",
-                "HMDB:HMDB0014677",
-                "MESH:C557944",
-                "INCHIKEY:MYSWGUAQZAJSOK-UHFFFAOYSA-N",
-                "DrugCentral:659",
-                "DRUGBANK:DB05488",
-                "ATC:S01AE03",
-                "PDQ:CDR0000040784",
-                "ATC:J01MA02",
-                "GTOPDB:10902",
-                "NCIT:C375",
-                "RXNORM:203563",
-                "ATC:S02AA15",
-                "MESH:D002939",
-                "PUBCHEM.COMPOUND:2764",
-                "CHEMBL.COMPOUND:CHEMBL8",
-                "KEGG.COMPOUND:C05349",
-                "DRUGBANK:DB00537",
-                "KEGG.DRUG:D00186",
-                "UMLS:C3181013",
-                "ATC:S03AA07"
-              ],
-              "id": "PUBCHEM.COMPOUND:2764",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "ciprofloxacin lactate",
-                "ciprofloxacin",
-                "Ciprofloxacin",
-                "ciprofloxacin zwitterion",
-                "CIPROFLOXACIN",
-                "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate",
-                "Technetium Tc-99m ciprofloxacin",
-                "Cipro",
-                "Ciprofloxacin (JP18/USP/INN)"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:18725436",
-                "PMID:10514290",
-                "PMID:15801857",
-                "PMID:17116675",
-                "PMID:16054362",
-                "PMID:21185626",
-                "PMID:20547788",
-                "PMID:23084277",
-                "PMID:25756620",
-                "PMID:34774742"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:13756984': {'publication date': '1961', 'sentence': '[Experiences with a chloramphenicol preparation for intramuscular injection in bacterial infections of the CNS].', 'subject score': 1000, 'object score': 1000}, 'PMID:15102069': {'publication date': '2004 Jun', 'sentence': 'Studies were undertaken to determine if florfenicol, an antimicrobial agent structurally similar to chloramphenicol, could be used as an effective broad spectrum antibiotic for the treatment of bacterial infections in primates.', 'subject score': 1000, 'object score': 1000}, 'PMID:19312582': {'publication date': '1949 Dec', 'sentence': 'Clinical Use of Chloramphenicol (Chloromycetin) in Certain Bacterial Infections.', 'subject score': 1000, 'object score': 901}, 'PMID:23142491': {'publication date': '2013 Feb-Mar', 'sentence': 'Protein synthesis inhibitors such as chloramphenicol and tetracycline may be inducers of efflux pumps such as MexY in Pseudomonas aeruginosa, complicating their use for the treatment of bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:24544437': {'publication date': '1957 Jun', 'sentence': 'Synergism between human gamma globulin and chloramphenicol in the treatment of experimental bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:27613616': {'publication date': '2016 Dec', 'sentence': 'Chloramphenicol (CAP) has been widely used to treat bacterial infections in livestock and aquatic animals.', 'subject score': 1000, 'object score': 1000}, 'PMID:27904344': {'publication date': '2015 Jun', 'sentence': 'Some of the most frequently used antibiotics in apiculture for the treatment of bacterial brood diseases are oxytetracycline, chloramphenicol, sulphathiazole and streptomycin.', 'subject score': 1000, 'object score': 913}, 'PMID:29150447': {'publication date': '2018 01 19', 'sentence': 'Chloramphenicol (Cam) is a broad-spectrum antibiotic used to combat bacterial infections in humans and animals.', 'subject score': 1000, 'object score': 1000}, 'PMID:35798834': {'publication date': '2022 Jul 07', 'sentence': 'Compared with the standard administration of the same antibiotics, the oral administration of nanoparticle-encapsulated ampicillin, chloramphenicol or vancomycin in mice with bacterial infections in the lungs effectively eliminated the infections, decreased adverse effects on the intestinal microbiota by protecting the animals from dysbiosis-associated metabolic syndromes and from opportunistic pathogen infections, and reduced the accumulation of known antibiotic-resistance genes in commensal bacteria.', 'subject score': 1000, 'object score': 1000}, 'PMID:6987361': {'publication date': '1980 Apr', 'sentence': 'The clinical pharmacology of chloramphenicol was evaluated in 14 children with serious bacterial infections.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 538307,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-          ]
-        }
-      },
-      "end": {
-        "identity": 617,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Chloramphenicol",
-          "description": "A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.; An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "ATC:J01BA01",
-            "GTOPDB:10901",
-            "ATC:S03AA08",
-            "DRUGBANK:DB00446",
-            "PUBCHEM.COMPOUND:5959",
-            "UMLS:C0008168",
-            "ATC:G01AA05",
-            "RXNORM:2348",
-            "NCIT:C363",
-            "MESH:D002701",
-            "INCHIKEY:WIIZWVCIJKGZOK-RKDXNWHRSA-N",
-            "HMDB:HMDB0014589",
-            "UMLS:C0699300",
-            "CHEBI:17698",
-            "CHEMBL.COMPOUND:CHEMBL130",
-            "ATC:D06AX02",
-            "ATC:D10AF03",
-            "KEGG.DRUG:D00104",
-            "UNII:66974FR9Q1",
-            "DrugCentral:589",
-            "ATC:S02AA01",
-            "PathWhiz.Compound:8956",
-            "KEGG.COMPOUND:C00918",
-            "ATC:S01AA01"
-          ],
-          "id": "PUBCHEM.COMPOUND:5959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "chloramphenicol",
-            "CHLORAMPHENICOL",
-            "Chloramphenicol (JP18/USP/INN)",
-            "Chloramphenicol",
-            "cloramphenicol",
-            "Chlornitromycin"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:35653642",
-            "PMID:16180821",
-            "PMID:16495055",
-            "PMID:19064318",
-            "PMID:20921317",
-            "PMID:32813522",
-            "PMID:20696876",
-            "PMID:33322904",
-            "PMID:19332670"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538307,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10379025,
-            "start": 617,
-            "end": 538307,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13756984': {'publication date': '1961', 'sentence': '[Experiences with a chloramphenicol preparation for intramuscular injection in bacterial infections of the CNS].', 'subject score': 1000, 'object score': 1000}, 'PMID:15102069': {'publication date': '2004 Jun', 'sentence': 'Studies were undertaken to determine if florfenicol, an antimicrobial agent structurally similar to chloramphenicol, could be used as an effective broad spectrum antibiotic for the treatment of bacterial infections in primates.', 'subject score': 1000, 'object score': 1000}, 'PMID:19312582': {'publication date': '1949 Dec', 'sentence': 'Clinical Use of Chloramphenicol (Chloromycetin) in Certain Bacterial Infections.', 'subject score': 1000, 'object score': 901}, 'PMID:23142491': {'publication date': '2013 Feb-Mar', 'sentence': 'Protein synthesis inhibitors such as chloramphenicol and tetracycline may be inducers of efflux pumps such as MexY in Pseudomonas aeruginosa, complicating their use for the treatment of bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:24544437': {'publication date': '1957 Jun', 'sentence': 'Synergism between human gamma globulin and chloramphenicol in the treatment of experimental bacterial infections.', 'subject score': 1000, 'object score': 901}, 'PMID:27613616': {'publication date': '2016 Dec', 'sentence': 'Chloramphenicol (CAP) has been widely used to treat bacterial infections in livestock and aquatic animals.', 'subject score': 1000, 'object score': 1000}, 'PMID:27904344': {'publication date': '2015 Jun', 'sentence': 'Some of the most frequently used antibiotics in apiculture for the treatment of bacterial brood diseases are oxytetracycline, chloramphenicol, sulphathiazole and streptomycin.', 'subject score': 1000, 'object score': 913}, 'PMID:29150447': {'publication date': '2018 01 19', 'sentence': 'Chloramphenicol (Cam) is a broad-spectrum antibiotic used to combat bacterial infections in humans and animals.', 'subject score': 1000, 'object score': 1000}, 'PMID:35798834': {'publication date': '2022 Jul 07', 'sentence': 'Compared with the standard administration of the same antibiotics, the oral administration of nanoparticle-encapsulated ampicillin, chloramphenicol or vancomycin in mice with bacterial infections in the lungs effectively eliminated the infections, decreased adverse effects on the intestinal microbiota by protecting the animals from dysbiosis-associated metabolic syndromes and from opportunistic pathogen infections, and reduced the accumulation of known antibiotic-resistance genes in commensal bacteria.', 'subject score': 1000, 'object score': 1000}, 'PMID:6987361': {'publication date': '1980 Apr', 'sentence': 'The clinical pharmacology of chloramphenicol was evaluated in 14 children with serious bacterial infections.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0008168---SEMMEDDB:treats---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5959",
-              "id": "10607698",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:13756984",
-                "PMID:15102069",
-                "PMID:19312582",
-                "PMID:23142491",
-                "PMID:24544437",
-                "PMID:27613616",
-                "PMID:27904344",
-                "PMID:29150447",
-                "PMID:35798834",
-                "PMID:6987361"
-              ]
-            }
-          },
-          "end": {
-            "identity": 617,
-            "labels": [
-<<<<<<< HEAD
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
-              "biolink:NamedThing",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
-=======
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
->>>>>>> main
-            ],
-            "properties": {
-              "name": "Chloramphenicol",
-              "description": "A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.; An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "ATC:J01BA01",
-                "GTOPDB:10901",
-                "ATC:S03AA08",
-                "DRUGBANK:DB00446",
-                "PUBCHEM.COMPOUND:5959",
-                "UMLS:C0008168",
-                "ATC:G01AA05",
-                "RXNORM:2348",
-                "NCIT:C363",
-                "MESH:D002701",
-                "INCHIKEY:WIIZWVCIJKGZOK-RKDXNWHRSA-N",
-                "HMDB:HMDB0014589",
-                "UMLS:C0699300",
-                "CHEBI:17698",
-                "CHEMBL.COMPOUND:CHEMBL130",
-                "ATC:D06AX02",
-                "ATC:D10AF03",
-                "KEGG.DRUG:D00104",
-                "UNII:66974FR9Q1",
-                "DrugCentral:589",
-                "ATC:S02AA01",
-                "PathWhiz.Compound:8956",
-                "KEGG.COMPOUND:C00918",
-                "ATC:S01AA01"
-              ],
-              "id": "PUBCHEM.COMPOUND:5959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "chloramphenicol",
-                "CHLORAMPHENICOL",
-                "Chloramphenicol (JP18/USP/INN)",
-                "Chloramphenicol",
-                "cloramphenicol",
-                "Chlornitromycin"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:35653642",
-                "PMID:16180821",
-                "PMID:16495055",
-                "PMID:19064318",
-                "PMID:20921317",
-                "PMID:32813522",
-                "PMID:20696876",
-                "PMID:33322904",
-                "PMID:19332670"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:119955': {'publication date': '1979 Oct', 'sentence': 'A 2-month-old infant with Enterobacter osteomyelitis complicating total parenteral nutrition was successfully treated with rifampicin and chloramphenicol.', 'subject score': 1000, 'object score': 888}, 'PMID:13032878': {'publication date': '1953 Mar', 'sentence': 'Primary typhoid osteomyelitis treated with chloramphenicol.', 'subject score': 1000, 'object score': 802}, 'PMID:13106787': {'publication date': '1953 Nov', 'sentence': 'Typhoid osteomyelitis of spine treated with chloramphenicol.', 'subject score': 1000, 'object score': 861}, 'PMID:15410360': {'publication date': '1950 Feb', 'sentence': 'Chloramphenicol in treatment of Eberthella typhosa G osteomyelitis; report of a case.', 'subject score': 1000, 'object score': 733}, 'PMID:9183498': {'publication date': '1997 May', 'sentence': 'The recrudescence was complicated by the development of osteomyelitis and was treated with chloramphenicol, trimethoprim, ceftriaxone and ampicillin in succession.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319037,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005246",
-          "name": "osteomyelitis",
-          "description": "An acute or chronic infectious process affecting the bones.; Osteomyelitis is an inflammatory process accompanied by bone destruction and caused by an infecting microorganism. [HPO:probinson, PMID:15276398]; Like other parts of the body, bones can get infected. The infections are usually bacterial, but can also be fungal. They may spread to the bone from nearby skin or muscles, or from another part of the body through the bloodstream. People who are at risk for bone infections include those with diabetes, poor circulation, or recent injury to the bone. You may also be at risk if you are having hemodialysis.  Symptoms of bone infections include: Pain in the infected area Chills and fever Swelling, warmth, and redness  A blood test or imaging test such as an x-ray can tell if you have a bone infection. Treatment includes antibiotics and often surgery.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0008707",
-            "MEDDRA:10045927",
-            "MEDDRA:10031257",
-            "MEDDRA:10046086",
-            "SNOMEDCT:111253001",
-            "SNOMEDCT:40970001",
-            "UMLS:C2242472",
-            "MEDDRA:10031252",
-            "MEDDRA:10009091",
-            "HP:0002754",
-            "DOID:1019",
-            "UMLS:C0029443",
-            "NCIT:C26839",
-            "MESH:D010019",
-            "EFO:0003102",
-            "MEDDRA:10031259",
-            "MONDO:0005246",
-            "MEDDRA:10005977",
-            "MEDDRA:10031256",
-            "SNOMEDCT:60168000",
-            "MEDDRA:10061017",
-            "MEDDRA:10045936",
-            "MEDDRA:10009081",
-            "NCIT:C27577",
-            "ICD9:730.1",
-            "MEDDRA:10046076"
-          ],
-          "id": "MONDO:0005246",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteomyelitis",
-            "Chronic osteomyelitis",
-            "osteomyelitis",
-            "Bone Infection",
-            "Infection of bone"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://my.clevelandclinic.org/disorders/osteomyelitis/hic_osteomyelitis.aspx",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://en.wikipedia.org/wiki/osteomyelitis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000437.htm",
-            "http://www.mayoclinic.com/health/osteomyelitis/ds00759",
-            "PMID:15276398",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 617,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Chloramphenicol",
-          "description": "A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.; An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "ATC:J01BA01",
-            "GTOPDB:10901",
-            "ATC:S03AA08",
-            "DRUGBANK:DB00446",
-            "PUBCHEM.COMPOUND:5959",
-            "UMLS:C0008168",
-            "ATC:G01AA05",
-            "RXNORM:2348",
-            "NCIT:C363",
-            "MESH:D002701",
-            "INCHIKEY:WIIZWVCIJKGZOK-RKDXNWHRSA-N",
-            "HMDB:HMDB0014589",
-            "UMLS:C0699300",
-            "CHEBI:17698",
-            "CHEMBL.COMPOUND:CHEMBL130",
-            "ATC:D06AX02",
-            "ATC:D10AF03",
-            "KEGG.DRUG:D00104",
-            "UNII:66974FR9Q1",
-            "DrugCentral:589",
-            "ATC:S02AA01",
-            "PathWhiz.Compound:8956",
-            "KEGG.COMPOUND:C00918",
-            "ATC:S01AA01"
-          ],
-          "id": "PUBCHEM.COMPOUND:5959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "chloramphenicol",
-            "CHLORAMPHENICOL",
-            "Chloramphenicol (JP18/USP/INN)",
-            "Chloramphenicol",
-            "cloramphenicol",
-            "Chlornitromycin"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:35653642",
-            "PMID:16180821",
-            "PMID:16495055",
-            "PMID:19064318",
-            "PMID:20921317",
-            "PMID:32813522",
-            "PMID:20696876",
-            "PMID:33322904",
-            "PMID:19332670"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319037,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005246",
-              "name": "osteomyelitis",
-              "description": "An acute or chronic infectious process affecting the bones.; Osteomyelitis is an inflammatory process accompanied by bone destruction and caused by an infecting microorganism. [HPO:probinson, PMID:15276398]; Like other parts of the body, bones can get infected. The infections are usually bacterial, but can also be fungal. They may spread to the bone from nearby skin or muscles, or from another part of the body through the bloodstream. People who are at risk for bone infections include those with diabetes, poor circulation, or recent injury to the bone. You may also be at risk if you are having hemodialysis.  Symptoms of bone infections include: Pain in the infected area Chills and fever Swelling, warmth, and redness  A blood test or imaging test such as an x-ray can tell if you have a bone infection. Treatment includes antibiotics and often surgery.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0008707",
-                "MEDDRA:10045927",
-                "MEDDRA:10031257",
-                "MEDDRA:10046086",
-                "SNOMEDCT:111253001",
-                "SNOMEDCT:40970001",
-                "UMLS:C2242472",
-                "MEDDRA:10031252",
-                "MEDDRA:10009091",
-                "HP:0002754",
-                "DOID:1019",
-                "UMLS:C0029443",
-                "NCIT:C26839",
-                "MESH:D010019",
-                "EFO:0003102",
-                "MEDDRA:10031259",
-                "MONDO:0005246",
-                "MEDDRA:10005977",
-                "MEDDRA:10031256",
-                "SNOMEDCT:60168000",
-                "MEDDRA:10061017",
-                "MEDDRA:10045936",
-                "MEDDRA:10009081",
-                "NCIT:C27577",
-                "ICD9:730.1",
-                "MEDDRA:10046076"
-              ],
-              "id": "MONDO:0005246",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteomyelitis",
-                "Chronic osteomyelitis",
-                "osteomyelitis",
-                "Bone Infection",
-                "Infection of bone"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://my.clevelandclinic.org/disorders/osteomyelitis/hic_osteomyelitis.aspx",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://en.wikipedia.org/wiki/osteomyelitis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000437.htm",
-                "http://www.mayoclinic.com/health/osteomyelitis/ds00759",
-                "PMID:15276398",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9323478,
-            "start": 617,
-            "end": 319037,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:119955': {'publication date': '1979 Oct', 'sentence': 'A 2-month-old infant with Enterobacter osteomyelitis complicating total parenteral nutrition was successfully treated with rifampicin and chloramphenicol.', 'subject score': 1000, 'object score': 888}, 'PMID:13032878': {'publication date': '1953 Mar', 'sentence': 'Primary typhoid osteomyelitis treated with chloramphenicol.', 'subject score': 1000, 'object score': 802}, 'PMID:13106787': {'publication date': '1953 Nov', 'sentence': 'Typhoid osteomyelitis of spine treated with chloramphenicol.', 'subject score': 1000, 'object score': 861}, 'PMID:15410360': {'publication date': '1950 Feb', 'sentence': 'Chloramphenicol in treatment of Eberthella typhosa G osteomyelitis; report of a case.', 'subject score': 1000, 'object score': 733}, 'PMID:9183498': {'publication date': '1997 May', 'sentence': 'The recrudescence was complicated by the development of osteomyelitis and was treated with chloramphenicol, trimethoprim, ceftriaxone and ampicillin in succession.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008168---SEMMEDDB:treats---None---None---None---UMLS:C0029443---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5959",
-              "id": "9528501",
-              "object": "MONDO:0005246",
-              "publications": [
-                "PMID:119955",
-                "PMID:13032878",
-                "PMID:13106787",
-                "PMID:15410360",
-                "PMID:9183498"
-              ]
-            }
-          },
-          "end": {
-            "identity": 617,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Chloramphenicol",
-              "description": "A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.; An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "ATC:J01BA01",
-                "GTOPDB:10901",
-                "ATC:S03AA08",
-                "DRUGBANK:DB00446",
-                "PUBCHEM.COMPOUND:5959",
-                "UMLS:C0008168",
-                "ATC:G01AA05",
-                "RXNORM:2348",
-                "NCIT:C363",
-                "MESH:D002701",
-                "INCHIKEY:WIIZWVCIJKGZOK-RKDXNWHRSA-N",
-                "HMDB:HMDB0014589",
-                "UMLS:C0699300",
-                "CHEBI:17698",
-                "CHEMBL.COMPOUND:CHEMBL130",
-                "ATC:D06AX02",
-                "ATC:D10AF03",
-                "KEGG.DRUG:D00104",
-                "UNII:66974FR9Q1",
-                "DrugCentral:589",
-                "ATC:S02AA01",
-                "PathWhiz.Compound:8956",
-                "KEGG.COMPOUND:C00918",
-                "ATC:S01AA01"
-              ],
-              "id": "PUBCHEM.COMPOUND:5959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "chloramphenicol",
-                "CHLORAMPHENICOL",
-                "Chloramphenicol (JP18/USP/INN)",
-                "Chloramphenicol",
-                "cloramphenicol",
-                "Chlornitromycin"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:35653642",
-                "PMID:16180821",
-                "PMID:16495055",
-                "PMID:19064318",
-                "PMID:20921317",
-                "PMID:32813522",
-                "PMID:20696876",
-                "PMID:33322904",
-                "PMID:19332670"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 546977,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043885",
-          "name": "eye infectious disorder",
-          "description": "An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.; Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.; Your eyes can get infections from bacteria, fungi, or viruses. Eye infections can occur in different parts of the eye and can affect just one eye or both. Two common eye infections are:  Conjunctivitis - also known as pink eye. Conjunctivitis is often due to an infection. Children frequently get it, and it is very contagious.  Stye - a bump on the eyelid that happens when bacteria from your skin get into the hair follicle of an eyelash.  Symptoms of eye infections may include redness, itching, swelling, discharge, pain, or problems with vision. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or antibiotics.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10015929",
-            "UMLS:C0015403",
-            "MESH:D015817",
-            "MEDDRA:10015936",
-            "MONDO:0043885",
-            "SNOMEDCT:128351009",
-            "NCIT:C45372",
-            "EFO:1001888"
-          ],
-          "id": "MONDO:0043885",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Eye Infection",
-            "eye infectious disorder",
-            "eye infection",
-            "Eye Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 617,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Chloramphenicol",
-          "description": "A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.; An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "ATC:J01BA01",
-            "GTOPDB:10901",
-            "ATC:S03AA08",
-            "DRUGBANK:DB00446",
-            "PUBCHEM.COMPOUND:5959",
-            "UMLS:C0008168",
-            "ATC:G01AA05",
-            "RXNORM:2348",
-            "NCIT:C363",
-            "MESH:D002701",
-            "INCHIKEY:WIIZWVCIJKGZOK-RKDXNWHRSA-N",
-            "HMDB:HMDB0014589",
-            "UMLS:C0699300",
-            "CHEBI:17698",
-            "CHEMBL.COMPOUND:CHEMBL130",
-            "ATC:D06AX02",
-            "ATC:D10AF03",
-            "KEGG.DRUG:D00104",
-            "UNII:66974FR9Q1",
-            "DrugCentral:589",
-            "ATC:S02AA01",
-            "PathWhiz.Compound:8956",
-            "KEGG.COMPOUND:C00918",
-            "ATC:S01AA01"
-          ],
-          "id": "PUBCHEM.COMPOUND:5959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "chloramphenicol",
-            "CHLORAMPHENICOL",
-            "Chloramphenicol (JP18/USP/INN)",
-            "Chloramphenicol",
-            "cloramphenicol",
-            "Chlornitromycin"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:35653642",
-            "PMID:16180821",
-            "PMID:16495055",
-            "PMID:19064318",
-            "PMID:20921317",
-            "PMID:32813522",
-            "PMID:20696876",
-            "PMID:33322904",
-            "PMID:19332670"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546977,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043885",
-              "name": "eye infectious disorder",
-              "description": "An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.; Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.; Your eyes can get infections from bacteria, fungi, or viruses. Eye infections can occur in different parts of the eye and can affect just one eye or both. Two common eye infections are:  Conjunctivitis - also known as pink eye. Conjunctivitis is often due to an infection. Children frequently get it, and it is very contagious.  Stye - a bump on the eyelid that happens when bacteria from your skin get into the hair follicle of an eyelash.  Symptoms of eye infections may include redness, itching, swelling, discharge, pain, or problems with vision. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or antibiotics.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10015929",
-                "UMLS:C0015403",
-                "MESH:D015817",
-                "MEDDRA:10015936",
-                "MONDO:0043885",
-                "SNOMEDCT:128351009",
-                "NCIT:C45372",
-                "EFO:1001888"
-              ],
-              "id": "MONDO:0043885",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Eye Infection",
-                "eye infectious disorder",
-                "eye infection",
-                "Eye Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7204541,
-            "start": 617,
-            "end": 546977,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10232108': {'publication date': '1999 Jan', 'sentence': 'The writers consult a wide range of American, European and British research from 1950 to the present to reassure readers that ophthalmic chloramphenicol is a demonstrably effective, safe, cost-effective treatment for most superficial eye infections.', 'subject score': 861, 'object score': 901}, 'PMID:13027132': {'publication date': '1952 Nov 29', 'sentence': '[Use of chloramphenicol in external ocular infections].', 'subject score': 1000, 'object score': 901}, 'PMID:1426394': {'publication date': '1992', 'sentence': 'The safety and efficacy of topical norfloxacin compared with chloramphenicol for the treatment of external ocular bacterial infections.', 'subject score': 1000, 'object score': 861}, 'PMID:14789290': {'publication date': '1951 Jan', 'sentence': 'Clinical trial with chloramphenicol in ocular infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:14857097': {'publication date': '1951 Aug', 'sentence': 'Topical use of chloramphenicol in external ocular infections.', 'subject score': 1000, 'object score': 901}, 'PMID:14958026': {'publication date': '1952 Mar', 'sentence': '[Local application of chloramphenicol in ocular infections].', 'subject score': 1000, 'object score': 1000}, 'PMID:1751464': {'publication date': '1991 Nov', 'sentence': 'Ofloxacin compared with chloramphenicol in the management of external ocular infection.', 'subject score': 1000, 'object score': 901}, 'PMID:2018459': {'publication date': '1991 Jan', 'sentence': 'Chloramphenicol has gained widespread use in the topical treatment of ocular infections.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008168---SEMMEDDB:treats---None---None---None---UMLS:C0015403---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5959",
-              "id": "7351604",
-              "object": "MONDO:0043885",
-              "publications": [
-                "PMID:10232108",
-                "PMID:13027132",
-                "PMID:1426394",
-                "PMID:14789290",
-                "PMID:14857097",
-                "PMID:14958026",
-                "PMID:1751464",
-                "PMID:2018459"
-              ]
-            }
-          },
-          "end": {
-            "identity": 617,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Chloramphenicol",
-              "description": "A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.; An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "ATC:J01BA01",
-                "GTOPDB:10901",
-                "ATC:S03AA08",
-                "DRUGBANK:DB00446",
-                "PUBCHEM.COMPOUND:5959",
-                "UMLS:C0008168",
-                "ATC:G01AA05",
-                "RXNORM:2348",
-                "NCIT:C363",
-                "MESH:D002701",
-                "INCHIKEY:WIIZWVCIJKGZOK-RKDXNWHRSA-N",
-                "HMDB:HMDB0014589",
-                "UMLS:C0699300",
-                "CHEBI:17698",
-                "CHEMBL.COMPOUND:CHEMBL130",
-                "ATC:D06AX02",
-                "ATC:D10AF03",
-                "KEGG.DRUG:D00104",
-                "UNII:66974FR9Q1",
-                "DrugCentral:589",
-                "ATC:S02AA01",
-                "PathWhiz.Compound:8956",
-                "KEGG.COMPOUND:C00918",
-                "ATC:S01AA01"
-              ],
-              "id": "PUBCHEM.COMPOUND:5959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "chloramphenicol",
-                "CHLORAMPHENICOL",
-                "Chloramphenicol (JP18/USP/INN)",
-                "Chloramphenicol",
-                "cloramphenicol",
-                "Chlornitromycin"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:35653642",
-                "PMID:16180821",
-                "PMID:16495055",
-                "PMID:19064318",
-                "PMID:20921317",
-                "PMID:32813522",
-                "PMID:20696876",
-                "PMID:33322904",
-                "PMID:19332670"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320111,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011438",
-          "name": "acne",
-          "description": "A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors.; A skin condition in which there is an increase in sebum secretion by the pilosebaceous apparatus associated with open comedones (blackheads), closed comedones (whiteheads), and pustular nodules (papules, pustules, and cysts). [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10000497",
-            "UMLS:C0152249",
-            "ICD10:L70",
-            "MEDDRA:10000510",
-            "NCIT:C27195",
-            "UMLS:C4531022",
-            "EFO:0003894",
-            "MEDDRA:10000519",
-            "SNOMEDCT:23894009",
-            "SNOMEDCT:88616000",
-            "MEDDRA:10000518",
-            "DOID:6543",
-            "HP:0001061",
-            "UMLS:C0001144",
-            "ICD10:L70.2",
-            "SNOMEDCT:11381005",
-            "MEDDRA:10000496",
-            "ICD9:706.0",
-            "MESH:D000152",
-            "MONDO:0011438",
-            "UMLS:C0702166"
-          ],
-          "id": "MONDO:0011438",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Acne Vulgaris",
-            "acne",
-            "Acne varioliformis",
-            "Acne",
-            "Breaking out"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/sebaceous_gland#clinical_significance",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 617,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Chloramphenicol",
-          "description": "A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.; An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "ATC:J01BA01",
-            "GTOPDB:10901",
-            "ATC:S03AA08",
-            "DRUGBANK:DB00446",
-            "PUBCHEM.COMPOUND:5959",
-            "UMLS:C0008168",
-            "ATC:G01AA05",
-            "RXNORM:2348",
-            "NCIT:C363",
-            "MESH:D002701",
-            "INCHIKEY:WIIZWVCIJKGZOK-RKDXNWHRSA-N",
-            "HMDB:HMDB0014589",
-            "UMLS:C0699300",
-            "CHEBI:17698",
-            "CHEMBL.COMPOUND:CHEMBL130",
-            "ATC:D06AX02",
-            "ATC:D10AF03",
-            "KEGG.DRUG:D00104",
-            "UNII:66974FR9Q1",
-            "DrugCentral:589",
-            "ATC:S02AA01",
-            "PathWhiz.Compound:8956",
-            "KEGG.COMPOUND:C00918",
-            "ATC:S01AA01"
-          ],
-          "id": "PUBCHEM.COMPOUND:5959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "chloramphenicol",
-            "CHLORAMPHENICOL",
-            "Chloramphenicol (JP18/USP/INN)",
-            "Chloramphenicol",
-            "cloramphenicol",
-            "Chlornitromycin"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:35653642",
-            "PMID:16180821",
-            "PMID:16495055",
-            "PMID:19064318",
-            "PMID:20921317",
-            "PMID:32813522",
-            "PMID:20696876",
-            "PMID:33322904",
-            "PMID:19332670"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320111,
-            "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011438",
-              "name": "acne",
-              "description": "A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors.; A skin condition in which there is an increase in sebum secretion by the pilosebaceous apparatus associated with open comedones (blackheads), closed comedones (whiteheads), and pustular nodules (papules, pustules, and cysts). [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10000497",
-                "UMLS:C0152249",
-                "ICD10:L70",
-                "MEDDRA:10000510",
-                "NCIT:C27195",
-                "UMLS:C4531022",
-                "EFO:0003894",
-                "MEDDRA:10000519",
-                "SNOMEDCT:23894009",
-                "SNOMEDCT:88616000",
-                "MEDDRA:10000518",
-                "DOID:6543",
-                "HP:0001061",
-                "UMLS:C0001144",
-                "ICD10:L70.2",
-                "SNOMEDCT:11381005",
-                "MEDDRA:10000496",
-                "ICD9:706.0",
-                "MESH:D000152",
-                "MONDO:0011438",
-                "UMLS:C0702166"
-              ],
-              "id": "MONDO:0011438",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Acne Vulgaris",
-                "acne",
-                "Acne varioliformis",
-                "Acne",
-                "Breaking out"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/sebaceous_gland#clinical_significance",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15174100,
-            "start": 617,
-            "end": 320111,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2135129': {'publication date': '1990 Jun', 'sentence': 'Lysis of P. acnes by the lytic factor was inhibited by adding chloramphenicol which was assumed to inhibit the release of lipoteichoic acid.', 'subject score': 872, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0008168---SEMMEDDB:disrupts---None---None---None---UMLS:C0702166---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5959",
-              "id": "15493028",
-              "object": "MONDO:0011438",
-              "publications": [
-                "PMID:2135129"
-              ]
-            }
-          },
-          "end": {
-            "identity": 617,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Chloramphenicol",
-              "description": "A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.; An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "ATC:J01BA01",
-                "GTOPDB:10901",
-                "ATC:S03AA08",
-                "DRUGBANK:DB00446",
-                "PUBCHEM.COMPOUND:5959",
-                "UMLS:C0008168",
-                "ATC:G01AA05",
-                "RXNORM:2348",
-                "NCIT:C363",
-                "MESH:D002701",
-                "INCHIKEY:WIIZWVCIJKGZOK-RKDXNWHRSA-N",
-                "HMDB:HMDB0014589",
-                "UMLS:C0699300",
-                "CHEBI:17698",
-                "CHEMBL.COMPOUND:CHEMBL130",
-                "ATC:D06AX02",
-                "ATC:D10AF03",
-                "KEGG.DRUG:D00104",
-                "UNII:66974FR9Q1",
-                "DrugCentral:589",
-                "ATC:S02AA01",
-                "PathWhiz.Compound:8956",
-                "KEGG.COMPOUND:C00918",
-                "ATC:S01AA01"
-              ],
-              "id": "PUBCHEM.COMPOUND:5959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "chloramphenicol",
-                "CHLORAMPHENICOL",
-                "Chloramphenicol (JP18/USP/INN)",
-                "Chloramphenicol",
-                "cloramphenicol",
-                "Chlornitromycin"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:35653642",
-                "PMID:16180821",
-                "PMID:16495055",
-                "PMID:19064318",
-                "PMID:20921317",
-                "PMID:32813522",
-                "PMID:20696876",
-                "PMID:33322904",
-                "PMID:19332670"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 546977,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043885",
-          "name": "eye infectious disorder",
-          "description": "An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.; Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.; Your eyes can get infections from bacteria, fungi, or viruses. Eye infections can occur in different parts of the eye and can affect just one eye or both. Two common eye infections are:  Conjunctivitis - also known as pink eye. Conjunctivitis is often due to an infection. Children frequently get it, and it is very contagious.  Stye - a bump on the eyelid that happens when bacteria from your skin get into the hair follicle of an eyelash.  Symptoms of eye infections may include redness, itching, swelling, discharge, pain, or problems with vision. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or antibiotics.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10015929",
-            "UMLS:C0015403",
-            "MESH:D015817",
-            "MEDDRA:10015936",
-            "MONDO:0043885",
-            "SNOMEDCT:128351009",
-            "NCIT:C45372",
-            "EFO:1001888"
-          ],
-          "id": "MONDO:0043885",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Eye Infection",
-            "eye infectious disorder",
-            "eye infection",
-            "Eye Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 617,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Chloramphenicol",
-          "description": "A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.; An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-          "equivalent_curies": [
-            "ATC:J01BA01",
-            "GTOPDB:10901",
-            "ATC:S03AA08",
-            "DRUGBANK:DB00446",
-            "PUBCHEM.COMPOUND:5959",
-            "UMLS:C0008168",
-            "ATC:G01AA05",
-            "RXNORM:2348",
-            "NCIT:C363",
-            "MESH:D002701",
-            "INCHIKEY:WIIZWVCIJKGZOK-RKDXNWHRSA-N",
-            "HMDB:HMDB0014589",
-            "UMLS:C0699300",
-            "CHEBI:17698",
-            "CHEMBL.COMPOUND:CHEMBL130",
-            "ATC:D06AX02",
-            "ATC:D10AF03",
-            "KEGG.DRUG:D00104",
-            "UNII:66974FR9Q1",
-            "DrugCentral:589",
-            "ATC:S02AA01",
-            "PathWhiz.Compound:8956",
-            "KEGG.COMPOUND:C00918",
-            "ATC:S01AA01"
-          ],
-          "id": "PUBCHEM.COMPOUND:5959",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "chloramphenicol",
-            "CHLORAMPHENICOL",
-            "Chloramphenicol (JP18/USP/INN)",
-            "Chloramphenicol",
-            "cloramphenicol",
-            "Chlornitromycin"
-          ],
-          "all_categories": [
-            "biolink:SmallMolecule",
-            "biolink:ChemicalEntity",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:35653642",
-            "PMID:16180821",
-            "PMID:16495055",
-            "PMID:19064318",
-            "PMID:20921317",
-            "PMID:32813522",
-            "PMID:20696876",
-            "PMID:33322904",
-            "PMID:19332670"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546977,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043885",
-              "name": "eye infectious disorder",
-              "description": "An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.; Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.; Your eyes can get infections from bacteria, fungi, or viruses. Eye infections can occur in different parts of the eye and can affect just one eye or both. Two common eye infections are:  Conjunctivitis - also known as pink eye. Conjunctivitis is often due to an infection. Children frequently get it, and it is very contagious.  Stye - a bump on the eyelid that happens when bacteria from your skin get into the hair follicle of an eyelash.  Symptoms of eye infections may include redness, itching, swelling, discharge, pain, or problems with vision. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or antibiotics.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10015929",
-                "UMLS:C0015403",
-                "MESH:D015817",
-                "MEDDRA:10015936",
-                "MONDO:0043885",
-                "SNOMEDCT:128351009",
-                "NCIT:C45372",
-                "EFO:1001888"
-              ],
-              "id": "MONDO:0043885",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Eye Infection",
-                "eye infectious disorder",
-                "eye infection",
-                "Eye Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20831966,
-            "start": 617,
-            "end": 546977,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31438629': {'publication date': '2019 Aug 21', 'sentence': 'Chloramphenicol is experiencing its renaissance because it is widely used in the treatment and prevention of superficial eye infections due to its broad spectrum of activity and other useful antimicrobial peculiarities, such as the antibiofilm properties.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0008168---SEMMEDDB:prevents---None---None---None---UMLS:C0015403---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5959",
-              "id": "21241586",
-              "object": "MONDO:0043885",
-              "publications": [
-                "PMID:31438629"
-              ]
-            }
-          },
-          "end": {
-            "identity": 617,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Chloramphenicol",
-              "description": "A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.; An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
-              "equivalent_curies": [
-                "ATC:J01BA01",
-                "GTOPDB:10901",
-                "ATC:S03AA08",
-                "DRUGBANK:DB00446",
-                "PUBCHEM.COMPOUND:5959",
-                "UMLS:C0008168",
-                "ATC:G01AA05",
-                "RXNORM:2348",
-                "NCIT:C363",
-                "MESH:D002701",
-                "INCHIKEY:WIIZWVCIJKGZOK-RKDXNWHRSA-N",
-                "HMDB:HMDB0014589",
-                "UMLS:C0699300",
-                "CHEBI:17698",
-                "CHEMBL.COMPOUND:CHEMBL130",
-                "ATC:D06AX02",
-                "ATC:D10AF03",
-                "KEGG.DRUG:D00104",
-                "UNII:66974FR9Q1",
-                "DrugCentral:589",
-                "ATC:S02AA01",
-                "PathWhiz.Compound:8956",
-                "KEGG.COMPOUND:C00918",
-                "ATC:S01AA01"
-              ],
-              "id": "PUBCHEM.COMPOUND:5959",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "chloramphenicol",
-                "CHLORAMPHENICOL",
-                "Chloramphenicol (JP18/USP/INN)",
-                "Chloramphenicol",
-                "cloramphenicol",
-                "Chlornitromycin"
-              ],
-              "all_categories": [
-                "biolink:SmallMolecule",
-                "biolink:ChemicalEntity",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:35653642",
-                "PMID:16180821",
-                "PMID:16495055",
-                "PMID:19064318",
-                "PMID:20921317",
-                "PMID:32813522",
-                "PMID:20696876",
-                "PMID:33322904",
-                "PMID:19332670"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:23338062': {'publication date': '2013 Jan', 'sentence': 'Oral administration of rebamipide was initiated on the day of OA induction.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319030,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 618,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Rebamipide",
-          "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-          "equivalent_curies": [
-            "NCIT:C29852",
-            "KEGG.DRUG:D01121",
-            "PUBCHEM.COMPOUND:5042",
-            "UNII:LR583V32ZR",
-            "UMLS:C0069562",
-            "DrugCentral:2360",
-            "DRUGBANK:DB11656",
-            "ATC:A02BX14",
-            "CHEBI:93814",
-            "MESH:C052785",
-            "CHEMBL.COMPOUND:CHEMBL1697771",
-            "PDQ:CDR0000759344",
-            "GTOPDB:871",
-            "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-            "CHEBI:32090"
-          ],
-          "id": "PUBCHEM.COMPOUND:5042",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "rebamipide",
-            "Rebamipide (JP18/INN)",
-            "REBAMIPIDE",
-            "mucosta",
-            "Rebamipide",
-            "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:23571415",
-            "PMID:32667799",
-            "PMID:20014752"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319030,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16376961,
-            "start": 618,
-            "end": 319030,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23338062': {'publication date': '2013 Jan', 'sentence': 'Oral administration of rebamipide was initiated on the day of OA induction.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:causes---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "16722213",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:23338062"
-              ]
-            }
-          },
-          "end": {
-            "identity": 618,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Rebamipide",
-              "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-              "equivalent_curies": [
-                "NCIT:C29852",
-                "KEGG.DRUG:D01121",
-                "PUBCHEM.COMPOUND:5042",
-                "UNII:LR583V32ZR",
-                "UMLS:C0069562",
-                "DrugCentral:2360",
-                "DRUGBANK:DB11656",
-                "ATC:A02BX14",
-                "CHEBI:93814",
-                "MESH:C052785",
-                "CHEMBL.COMPOUND:CHEMBL1697771",
-                "PDQ:CDR0000759344",
-                "GTOPDB:871",
-                "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-                "CHEBI:32090"
-              ],
-              "id": "PUBCHEM.COMPOUND:5042",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "rebamipide",
-                "Rebamipide (JP18/INN)",
-                "REBAMIPIDE",
-                "mucosta",
-                "Rebamipide",
-                "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:23571415",
-                "PMID:32667799",
-                "PMID:20014752"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 316638,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:29046162': {'publication date': '2018 Apr 20', 'sentence': 'We also discuss the potential role of rebamipide to serve as a new strategy for the treatment of TMJ-OA.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 319030,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-          "name": "peptic ulcer disease",
-          "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10018053",
-            "MEDDRA:10045305",
-            "MESH:D010437",
-            "MONDO:0004247",
-            "DOID:750",
-            "UMLS:C0030920",
-            "MEDDRA:10017886",
-            "MEDDRA:10045342",
-            "ICD9:533",
-            "ICD10:K27",
-            "HP:0004398",
-            "MEDDRA:10034343",
-            "MEDDRA:10034360",
-            "MEDDRA:10045328",
-            "MEDDRA:10042834",
-            "MEDDRA:10034341",
-            "MEDDRA:10034367",
-            "MEDDRA:10037287",
-            "NCIT:C3318",
-            "SNOMEDCT:13200003",
-            "MEDDRA:10034369"
-          ],
-          "id": "MONDO:0004247",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peptic ulcer, site unspecified",
-            "Peptic Ulcer",
-            "peptic ulcer disease",
-            "Peptic ulcer"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "PMID:28242110",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-            "https://orcid.org/0000-0002-6548-5200"
-=======
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 618,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Rebamipide",
-          "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-          "equivalent_curies": [
-            "NCIT:C29852",
-            "KEGG.DRUG:D01121",
-            "PUBCHEM.COMPOUND:5042",
-            "UNII:LR583V32ZR",
-            "UMLS:C0069562",
-            "DrugCentral:2360",
-            "DRUGBANK:DB11656",
-            "ATC:A02BX14",
-            "CHEBI:93814",
-            "MESH:C052785",
-            "CHEMBL.COMPOUND:CHEMBL1697771",
-            "PDQ:CDR0000759344",
-            "GTOPDB:871",
-            "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-            "CHEBI:32090"
-          ],
-          "id": "PUBCHEM.COMPOUND:5042",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "rebamipide",
-            "Rebamipide (JP18/INN)",
-            "REBAMIPIDE",
-            "mucosta",
-            "Rebamipide",
-            "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:23571415",
-            "PMID:32667799",
-            "PMID:20014752"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 316638,
-=======
-            "identity": 319030,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-              "name": "peptic ulcer disease",
-              "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10018053",
-                "MEDDRA:10045305",
-                "MESH:D010437",
-                "MONDO:0004247",
-                "DOID:750",
-                "UMLS:C0030920",
-                "MEDDRA:10017886",
-                "MEDDRA:10045342",
-                "ICD9:533",
-                "ICD10:K27",
-                "HP:0004398",
-                "MEDDRA:10034343",
-                "MEDDRA:10034360",
-                "MEDDRA:10045328",
-                "MEDDRA:10042834",
-                "MEDDRA:10034341",
-                "MEDDRA:10034367",
-                "MEDDRA:10037287",
-                "NCIT:C3318",
-                "SNOMEDCT:13200003",
-                "MEDDRA:10034369"
-              ],
-              "id": "MONDO:0004247",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peptic ulcer, site unspecified",
-                "Peptic Ulcer",
-                "peptic ulcer disease",
-                "Peptic ulcer"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "PMID:28242110",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-                "https://orcid.org/0000-0002-6548-5200"
-=======
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 27205553,
-            "start": 618,
-            "end": 316638,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9753235': {'publication date': '1998 Sep', 'sentence': 'Rebamipide might act as a radical scavenger and have favorable effects on peptic ulcer diseases.', 'subject score': 1000, 'object score': 983}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:affects---None---None---None---UMLS:C0030920---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "27679650",
-              "object": "MONDO:0004247",
-              "publications": [
-                "PMID:9753235"
-=======
-            "identity": 19560192,
-            "start": 618,
-            "end": 319030,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29046162': {'publication date': '2018 Apr 20', 'sentence': 'We also discuss the potential role of rebamipide to serve as a new strategy for the treatment of TMJ-OA.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:treats---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "19949890",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:29046162"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 618,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Rebamipide",
-              "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-              "equivalent_curies": [
-                "NCIT:C29852",
-                "KEGG.DRUG:D01121",
-                "PUBCHEM.COMPOUND:5042",
-                "UNII:LR583V32ZR",
-                "UMLS:C0069562",
-                "DrugCentral:2360",
-                "DRUGBANK:DB11656",
-                "ATC:A02BX14",
-                "CHEBI:93814",
-                "MESH:C052785",
-                "CHEMBL.COMPOUND:CHEMBL1697771",
-                "PDQ:CDR0000759344",
-                "GTOPDB:871",
-                "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-                "CHEBI:32090"
-              ],
-              "id": "PUBCHEM.COMPOUND:5042",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "rebamipide",
-                "Rebamipide (JP18/INN)",
-                "REBAMIPIDE",
-                "mucosta",
-                "Rebamipide",
-                "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:23571415",
-                "PMID:32667799",
-                "PMID:20014752"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:12678329': {'publication date': '2003 Feb', 'sentence': 'Effect of rebamipide on acetic acid-induced gastric ulcer in rats: involvement of hepatocyte growth factor.', 'subject score': 1000, 'object score': 857}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319260,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001126",
-          "name": "gastric ulcer",
-          "description": "An ulcer, that is, an erosion of an area of the gastric mucous membrane. [HPO:probinson]; An ulcer, that is, an erosion of an area of the gastric mucous membrane. // COMMENTS: The presence of a mucosal erosion equal to or greater than 0.5 cm.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10045304",
-            "HP:0002592",
-            "ICD10:K25",
-            "UMLS:C0038358",
-            "MESH:D013276",
-            "ICD9:531",
-            "MEDDRA:10045336",
-            "MEDDRA:10045374",
-            "EFO:0009454",
-            "SNOMEDCT:397825006",
-            "MEDDRA:10042116",
-            "MEDDRA:10017822",
-            "MONDO:0001126",
-            "NCIT:C3388",
-            "DOID:10808"
-          ],
-          "id": "MONDO:0001126",
-          "category": "biolink:Disease",
-          "all_names": [
-            "gastric ulcer",
-            "Stomach Ulcer",
-            "Gastric Ulcer",
-            "Gastric ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 618,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Rebamipide",
-          "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-          "equivalent_curies": [
-            "NCIT:C29852",
-            "KEGG.DRUG:D01121",
-            "PUBCHEM.COMPOUND:5042",
-            "UNII:LR583V32ZR",
-            "UMLS:C0069562",
-            "DrugCentral:2360",
-            "DRUGBANK:DB11656",
-            "ATC:A02BX14",
-            "CHEBI:93814",
-            "MESH:C052785",
-            "CHEMBL.COMPOUND:CHEMBL1697771",
-            "PDQ:CDR0000759344",
-            "GTOPDB:871",
-            "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-            "CHEBI:32090"
-          ],
-          "id": "PUBCHEM.COMPOUND:5042",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "rebamipide",
-            "Rebamipide (JP18/INN)",
-            "REBAMIPIDE",
-            "mucosta",
-            "Rebamipide",
-            "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:23571415",
-            "PMID:32667799",
-            "PMID:20014752"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319260,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001126",
-              "name": "gastric ulcer",
-              "description": "An ulcer, that is, an erosion of an area of the gastric mucous membrane. [HPO:probinson]; An ulcer, that is, an erosion of an area of the gastric mucous membrane. // COMMENTS: The presence of a mucosal erosion equal to or greater than 0.5 cm.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10045304",
-                "HP:0002592",
-                "ICD10:K25",
-                "UMLS:C0038358",
-                "MESH:D013276",
-                "ICD9:531",
-                "MEDDRA:10045336",
-                "MEDDRA:10045374",
-                "EFO:0009454",
-                "SNOMEDCT:397825006",
-                "MEDDRA:10042116",
-                "MEDDRA:10017822",
-                "MONDO:0001126",
-                "NCIT:C3388",
-                "DOID:10808"
-              ],
-              "id": "MONDO:0001126",
-              "category": "biolink:Disease",
-              "all_names": [
-                "gastric ulcer",
-                "Stomach Ulcer",
-                "Gastric Ulcer",
-                "Gastric ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9907056,
-            "start": 618,
-            "end": 319260,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12678329': {'publication date': '2003 Feb', 'sentence': 'Effect of rebamipide on acetic acid-induced gastric ulcer in rats: involvement of hepatocyte growth factor.', 'subject score': 1000, 'object score': 857}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:affects---None---None---None---UMLS:C0038358---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "10125846",
-              "object": "MONDO:0001126",
-              "publications": [
-                "PMID:12678329"
-              ]
-            }
-          },
-          "end": {
-            "identity": 618,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Rebamipide",
-              "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-              "equivalent_curies": [
-                "NCIT:C29852",
-                "KEGG.DRUG:D01121",
-                "PUBCHEM.COMPOUND:5042",
-                "UNII:LR583V32ZR",
-                "UMLS:C0069562",
-                "DrugCentral:2360",
-                "DRUGBANK:DB11656",
-                "ATC:A02BX14",
-                "CHEBI:93814",
-                "MESH:C052785",
-                "CHEMBL.COMPOUND:CHEMBL1697771",
-                "PDQ:CDR0000759344",
-                "GTOPDB:871",
-                "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-                "CHEBI:32090"
-              ],
-              "id": "PUBCHEM.COMPOUND:5042",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "rebamipide",
-                "Rebamipide (JP18/INN)",
-                "REBAMIPIDE",
-                "mucosta",
-                "Rebamipide",
-                "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:23571415",
-                "PMID:32667799",
-                "PMID:20014752"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12925147': {'publication date': '2003 Jul', 'sentence': 'Rebamipide is a mucoprotective drug used for the treatment of gastric ulcers.', 'subject score': 1000, 'object score': 1000}, 'PMID:15993841': {'publication date': '2005 Aug 19', 'sentence': 'Rebamipide accelerates healing of gastric ulcers and gastritis but its actions on gastric cancer are not known.', 'subject score': 1000, 'object score': 1000}, 'PMID:19772181': {'publication date': '2009 Sep', 'sentence': 'CONCLUSION: Rebamipide is effective and well tolerated for treatment of gastric ulcers especially those caused by NSAIDs, as it promotes the improvement of gastric inflammation scores, clinical symptoms, and ulcer healing.', 'subject score': 1000, 'object score': 901}, 'PMID:20625243': {'publication date': '2010 Aug 31', 'sentence': 'Rebamipide a gastroprotective drug, is clinically used for the treatment of gastric ulcers and gastritis, but its actions on gastric cancer are not clearly understood.', 'subject score': 1000, 'object score': 1000}, 'PMID:21757914': {'publication date': '2011', 'sentence': 'CONCLUSIONS: Rebamipide is as effective as omeprazole in treating of H. pylori-positive gastric ulcer after eradication therapy.', 'subject score': 1000, 'object score': 857}, 'PMID:22969286': {'publication date': '2012', 'sentence': 'Rebamipide is an antiulcer agent used to treat gastric ulcer and gastritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:24940041': {'publication date': '2014', 'sentence': 'Rebamipide was initially developed and approved for use in treating gastric ulcers and lesions associated with gastritis.', 'subject score': 1000, 'object score': 901}, 'PMID:27123995': {'publication date': '2016', 'sentence': 'Rebamipide is a gastroprotective agent that is currently used for the treatment of gastritis and gastric ulcers.', 'subject score': 1000, 'object score': 1000}, 'PMID:27282261': {'publication date': '2016 Nov 15', 'sentence': 'Conclusions: Combination therapy with rebamipide and PPI had limited benefits compared with PPI monotherapy in the treatment of post-ESD gastric ulcer (UMIN Clinical Trials Registry, UMIN000007435).', 'subject score': 1000, 'object score': 780}, 'PMID:31421154': {'publication date': '2019 10', 'sentence': 'Rebamipide is a gastroprotective drug used widely in the treatment of gastritis and gastric ulcers.', 'subject score': 1000, 'object score': 1000}, 'PMID:31582612': {'publication date': '2019', 'sentence': 'Rebamipide (RB) was developed in Japan as a treatment for gastric ulcer.', 'subject score': 1000, 'object score': 1000}, 'PMID:32557753': {'publication date': '2020 Jun 18', 'sentence': 'Rebamipide is widely used in East Asia for the treatment of gastric ulcers, acute gastritis, and exacerbated chronic gastritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:34338768': {'publication date': '2021 Aug 02', 'sentence': 'BACKGROUND: Rebamipide (REB) is quinolinone derivative compound, which is used for treatment of stomach ulcers.', 'subject score': 1000, 'object score': 1000}, 'PMID:35999163': {'publication date': '2022 Aug 12', 'sentence': 'CONCLUSION: These findings suggest that the efficacy and safety of polaprezinc were similar to those of rebamipide in the treatment of GU.', 'subject score': 1000, 'object score': 1000}, 'PMID:9248142': {'publication date': '1997 Jun', 'sentence': 'Rebamipide which is used as a drug for gastritis and stomach ulcer has large capability for OH radical scavenging.', 'subject score': 1000, 'object score': 1000}, 'PMID:9753220': {'publication date': '1998 Sep', 'sentence': 'Rebamipide, a gastroprotective drug, is a compound selected from over 500 amino acid analogs of 2(1H)-quinolinone tested for gastroprotective action and for efficacy to heal experimental gastric ulcers.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 319260,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001126",
-          "name": "gastric ulcer",
-          "description": "An ulcer, that is, an erosion of an area of the gastric mucous membrane. [HPO:probinson]; An ulcer, that is, an erosion of an area of the gastric mucous membrane. // COMMENTS: The presence of a mucosal erosion equal to or greater than 0.5 cm.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10045304",
-            "HP:0002592",
-            "ICD10:K25",
-            "UMLS:C0038358",
-            "MESH:D013276",
-            "ICD9:531",
-            "MEDDRA:10045336",
-            "MEDDRA:10045374",
-            "EFO:0009454",
-            "SNOMEDCT:397825006",
-            "MEDDRA:10042116",
-            "MEDDRA:10017822",
-            "MONDO:0001126",
-            "NCIT:C3388",
-            "DOID:10808"
-          ],
-          "id": "MONDO:0001126",
-          "category": "biolink:Disease",
-          "all_names": [
-            "gastric ulcer",
-            "Stomach Ulcer",
-            "Gastric Ulcer",
-            "Gastric ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 618,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Rebamipide",
-          "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-          "equivalent_curies": [
-            "NCIT:C29852",
-            "KEGG.DRUG:D01121",
-            "PUBCHEM.COMPOUND:5042",
-            "UNII:LR583V32ZR",
-            "UMLS:C0069562",
-            "DrugCentral:2360",
-            "DRUGBANK:DB11656",
-            "ATC:A02BX14",
-            "CHEBI:93814",
-            "MESH:C052785",
-            "CHEMBL.COMPOUND:CHEMBL1697771",
-            "PDQ:CDR0000759344",
-            "GTOPDB:871",
-            "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-            "CHEBI:32090"
-          ],
-          "id": "PUBCHEM.COMPOUND:5042",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "rebamipide",
-            "Rebamipide (JP18/INN)",
-            "REBAMIPIDE",
-            "mucosta",
-            "Rebamipide",
-            "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:23571415",
-            "PMID:32667799",
-            "PMID:20014752"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319260,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001126",
-              "name": "gastric ulcer",
-              "description": "An ulcer, that is, an erosion of an area of the gastric mucous membrane. [HPO:probinson]; An ulcer, that is, an erosion of an area of the gastric mucous membrane. // COMMENTS: The presence of a mucosal erosion equal to or greater than 0.5 cm.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10045304",
-                "HP:0002592",
-                "ICD10:K25",
-                "UMLS:C0038358",
-                "MESH:D013276",
-                "ICD9:531",
-                "MEDDRA:10045336",
-                "MEDDRA:10045374",
-                "EFO:0009454",
-                "SNOMEDCT:397825006",
-                "MEDDRA:10042116",
-                "MEDDRA:10017822",
-                "MONDO:0001126",
-                "NCIT:C3388",
-                "DOID:10808"
-              ],
-              "id": "MONDO:0001126",
-              "category": "biolink:Disease",
-              "all_names": [
-                "gastric ulcer",
-                "Stomach Ulcer",
-                "Gastric Ulcer",
-                "Gastric ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10144023,
-            "start": 618,
-            "end": 319260,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12925147': {'publication date': '2003 Jul', 'sentence': 'Rebamipide is a mucoprotective drug used for the treatment of gastric ulcers.', 'subject score': 1000, 'object score': 1000}, 'PMID:15993841': {'publication date': '2005 Aug 19', 'sentence': 'Rebamipide accelerates healing of gastric ulcers and gastritis but its actions on gastric cancer are not known.', 'subject score': 1000, 'object score': 1000}, 'PMID:19772181': {'publication date': '2009 Sep', 'sentence': 'CONCLUSION: Rebamipide is effective and well tolerated for treatment of gastric ulcers especially those caused by NSAIDs, as it promotes the improvement of gastric inflammation scores, clinical symptoms, and ulcer healing.', 'subject score': 1000, 'object score': 901}, 'PMID:20625243': {'publication date': '2010 Aug 31', 'sentence': 'Rebamipide a gastroprotective drug, is clinically used for the treatment of gastric ulcers and gastritis, but its actions on gastric cancer are not clearly understood.', 'subject score': 1000, 'object score': 1000}, 'PMID:21757914': {'publication date': '2011', 'sentence': 'CONCLUSIONS: Rebamipide is as effective as omeprazole in treating of H. pylori-positive gastric ulcer after eradication therapy.', 'subject score': 1000, 'object score': 857}, 'PMID:22969286': {'publication date': '2012', 'sentence': 'Rebamipide is an antiulcer agent used to treat gastric ulcer and gastritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:24940041': {'publication date': '2014', 'sentence': 'Rebamipide was initially developed and approved for use in treating gastric ulcers and lesions associated with gastritis.', 'subject score': 1000, 'object score': 901}, 'PMID:27123995': {'publication date': '2016', 'sentence': 'Rebamipide is a gastroprotective agent that is currently used for the treatment of gastritis and gastric ulcers.', 'subject score': 1000, 'object score': 1000}, 'PMID:27282261': {'publication date': '2016 Nov 15', 'sentence': 'Conclusions: Combination therapy with rebamipide and PPI had limited benefits compared with PPI monotherapy in the treatment of post-ESD gastric ulcer (UMIN Clinical Trials Registry, UMIN000007435).', 'subject score': 1000, 'object score': 780}, 'PMID:31421154': {'publication date': '2019 10', 'sentence': 'Rebamipide is a gastroprotective drug used widely in the treatment of gastritis and gastric ulcers.', 'subject score': 1000, 'object score': 1000}, 'PMID:31582612': {'publication date': '2019', 'sentence': 'Rebamipide (RB) was developed in Japan as a treatment for gastric ulcer.', 'subject score': 1000, 'object score': 1000}, 'PMID:32557753': {'publication date': '2020 Jun 18', 'sentence': 'Rebamipide is widely used in East Asia for the treatment of gastric ulcers, acute gastritis, and exacerbated chronic gastritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:34338768': {'publication date': '2021 Aug 02', 'sentence': 'BACKGROUND: Rebamipide (REB) is quinolinone derivative compound, which is used for treatment of stomach ulcers.', 'subject score': 1000, 'object score': 1000}, 'PMID:35999163': {'publication date': '2022 Aug 12', 'sentence': 'CONCLUSION: These findings suggest that the efficacy and safety of polaprezinc were similar to those of rebamipide in the treatment of GU.', 'subject score': 1000, 'object score': 1000}, 'PMID:9248142': {'publication date': '1997 Jun', 'sentence': 'Rebamipide which is used as a drug for gastritis and stomach ulcer has large capability for OH radical scavenging.', 'subject score': 1000, 'object score': 1000}, 'PMID:9753220': {'publication date': '1998 Sep', 'sentence': 'Rebamipide, a gastroprotective drug, is a compound selected from over 500 amino acid analogs of 2(1H)-quinolinone tested for gastroprotective action and for efficacy to heal experimental gastric ulcers.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:treats---None---None---None---UMLS:C0038358---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "10368387",
-              "object": "MONDO:0001126",
-              "publications": [
-                "PMID:12925147",
-                "PMID:15993841",
-                "PMID:19772181",
-                "PMID:20625243",
-                "PMID:21757914",
-                "PMID:22969286",
-                "PMID:24940041",
-                "PMID:27123995",
-                "PMID:27282261",
-                "PMID:31421154",
-                "PMID:31582612",
-                "PMID:32557753",
-                "PMID:34338768",
-                "PMID:35999163",
-                "PMID:9248142",
-                "PMID:9753220"
-              ]
-            }
-          },
-          "end": {
-            "identity": 618,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Rebamipide",
-              "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-              "equivalent_curies": [
-                "NCIT:C29852",
-                "KEGG.DRUG:D01121",
-                "PUBCHEM.COMPOUND:5042",
-                "UNII:LR583V32ZR",
-                "UMLS:C0069562",
-                "DrugCentral:2360",
-                "DRUGBANK:DB11656",
-                "ATC:A02BX14",
-                "CHEBI:93814",
-                "MESH:C052785",
-                "CHEMBL.COMPOUND:CHEMBL1697771",
-                "PDQ:CDR0000759344",
-                "GTOPDB:871",
-                "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-                "CHEBI:32090"
-              ],
-              "id": "PUBCHEM.COMPOUND:5042",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "rebamipide",
-                "Rebamipide (JP18/INN)",
-                "REBAMIPIDE",
-                "mucosta",
-                "Rebamipide",
-                "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:23571415",
-                "PMID:32667799",
-                "PMID:20014752"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:1313372': {'publication date': '1992 Feb 25', 'sentence': 'These findings suggest that rebamipide prevents diethyldithiocarbamate-induced gastric ulcer formation by inhibiting neutrophil activation.', 'subject score': 1000, 'object score': 840}, 'PMID:25071901': {'publication date': '2014 Jul', 'sentence': 'CONCLUSIONS: Rebamipide can prevent gastric ulcers when used with NSAIDs and can decrease the gastrointestinal symptoms associated with NSAID administration.', 'subject score': 1000, 'object score': 1000}, 'PMID:28011266': {'publication date': '2017 01 29', 'sentence': 'In a mouse ulcer model, rebamipide protected against hydrochloric acid/ethanol-induced gastric ulcer, and these protective effects were deterred by co-administration of compound C.', 'subject score': 1000, 'object score': 839}}",
-    "p2": {
-      "start": {
-        "identity": 319260,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001126",
-          "name": "gastric ulcer",
-          "description": "An ulcer, that is, an erosion of an area of the gastric mucous membrane. [HPO:probinson]; An ulcer, that is, an erosion of an area of the gastric mucous membrane. // COMMENTS: The presence of a mucosal erosion equal to or greater than 0.5 cm.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10045304",
-            "HP:0002592",
-            "ICD10:K25",
-            "UMLS:C0038358",
-            "MESH:D013276",
-            "ICD9:531",
-            "MEDDRA:10045336",
-            "MEDDRA:10045374",
-            "EFO:0009454",
-            "SNOMEDCT:397825006",
-            "MEDDRA:10042116",
-            "MEDDRA:10017822",
-            "MONDO:0001126",
-            "NCIT:C3388",
-            "DOID:10808"
-          ],
-          "id": "MONDO:0001126",
-          "category": "biolink:Disease",
-          "all_names": [
-            "gastric ulcer",
-            "Stomach Ulcer",
-            "Gastric Ulcer",
-            "Gastric ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 618,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Rebamipide",
-          "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-          "equivalent_curies": [
-            "NCIT:C29852",
-            "KEGG.DRUG:D01121",
-            "PUBCHEM.COMPOUND:5042",
-            "UNII:LR583V32ZR",
-            "UMLS:C0069562",
-            "DrugCentral:2360",
-            "DRUGBANK:DB11656",
-            "ATC:A02BX14",
-            "CHEBI:93814",
-            "MESH:C052785",
-            "CHEMBL.COMPOUND:CHEMBL1697771",
-            "PDQ:CDR0000759344",
-            "GTOPDB:871",
-            "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-            "CHEBI:32090"
-          ],
-          "id": "PUBCHEM.COMPOUND:5042",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "rebamipide",
-            "Rebamipide (JP18/INN)",
-            "REBAMIPIDE",
-            "mucosta",
-            "Rebamipide",
-            "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:23571415",
-            "PMID:32667799",
-            "PMID:20014752"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319260,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001126",
-              "name": "gastric ulcer",
-              "description": "An ulcer, that is, an erosion of an area of the gastric mucous membrane. [HPO:probinson]; An ulcer, that is, an erosion of an area of the gastric mucous membrane. // COMMENTS: The presence of a mucosal erosion equal to or greater than 0.5 cm.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10045304",
-                "HP:0002592",
-                "ICD10:K25",
-                "UMLS:C0038358",
-                "MESH:D013276",
-                "ICD9:531",
-                "MEDDRA:10045336",
-                "MEDDRA:10045374",
-                "EFO:0009454",
-                "SNOMEDCT:397825006",
-                "MEDDRA:10042116",
-                "MEDDRA:10017822",
-                "MONDO:0001126",
-                "NCIT:C3388",
-                "DOID:10808"
-              ],
-              "id": "MONDO:0001126",
-              "category": "biolink:Disease",
-              "all_names": [
-                "gastric ulcer",
-                "Stomach Ulcer",
-                "Gastric Ulcer",
-                "Gastric ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10226473,
-            "start": 618,
-            "end": 319260,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1313372': {'publication date': '1992 Feb 25', 'sentence': 'These findings suggest that rebamipide prevents diethyldithiocarbamate-induced gastric ulcer formation by inhibiting neutrophil activation.', 'subject score': 1000, 'object score': 840}, 'PMID:25071901': {'publication date': '2014 Jul', 'sentence': 'CONCLUSIONS: Rebamipide can prevent gastric ulcers when used with NSAIDs and can decrease the gastrointestinal symptoms associated with NSAID administration.', 'subject score': 1000, 'object score': 1000}, 'PMID:28011266': {'publication date': '2017 01 29', 'sentence': 'In a mouse ulcer model, rebamipide protected against hydrochloric acid/ethanol-induced gastric ulcer, and these protective effects were deterred by co-administration of compound C.', 'subject score': 1000, 'object score': 839}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:prevents---None---None---None---UMLS:C0038358---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "10452606",
-              "object": "MONDO:0001126",
-              "publications": [
-                "PMID:1313372",
-                "PMID:25071901",
-                "PMID:28011266"
-              ]
-            }
-          },
-          "end": {
-            "identity": 618,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Rebamipide",
-              "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-              "equivalent_curies": [
-                "NCIT:C29852",
-                "KEGG.DRUG:D01121",
-                "PUBCHEM.COMPOUND:5042",
-                "UNII:LR583V32ZR",
-                "UMLS:C0069562",
-                "DrugCentral:2360",
-                "DRUGBANK:DB11656",
-                "ATC:A02BX14",
-                "CHEBI:93814",
-                "MESH:C052785",
-                "CHEMBL.COMPOUND:CHEMBL1697771",
-                "PDQ:CDR0000759344",
-                "GTOPDB:871",
-                "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-                "CHEBI:32090"
-              ],
-              "id": "PUBCHEM.COMPOUND:5042",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "rebamipide",
-                "Rebamipide (JP18/INN)",
-                "REBAMIPIDE",
-                "mucosta",
-                "Rebamipide",
-                "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:23571415",
-                "PMID:32667799",
-                "PMID:20014752"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:35552457': {'publication date': '2022 May 12', 'sentence': 'Frequently reported adverse events of rebamipide compared to other drugs for peptic ulcer and gastroesophageal reflux disease.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 321369,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007186",
-          "name": "gastroesophageal reflux disease",
-          "description": "A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C26781\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26781\" NCI Thesaurus); A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.; Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.; A condition in which the stomach contents leak backwards from the stomach into the esophagus through the lower esophageal sphincter. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K21.9",
-            "UMLS:C4317146",
-            "NCIT:C26781",
-            "MEDDRA:10037676",
-            "PDQ:CDR0000737473",
-            "NCIT:C34670",
-            "UMLS:C3813607",
-            "MEDDRA:10066874",
-            "MEDDRA:10015389",
-            "ICD9:787.1",
-            "SNOMEDCT:698065002",
-            "UMLS:C0018834",
-            "OMIM:109350",
-            "MESH:D006356",
-            "UMLS:C0017168",
-            "DOID:8534",
-            "NCIT:C92560",
-            "SNOMEDCT:235595009",
-            "MEDDRA:10019326",
-            "HP:0002020",
-            "MEDDRA:10018203",
-            "MESH:D005764",
-            "MEDDRA:10017924",
-            "MEDDRA:10030182",
-            "SNOMEDCT:722884003",
-            "MONDO:0007186",
-            "ICD9:530.81",
-            "EFO:0003948",
-            "MEDDRA:10017884",
-            "MEDDRA:10017885",
-            "SNOMEDCT:16331000",
-            "NCIT:C113396"
-          ],
-          "id": "MONDO:0007186",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Gastroesophageal Reflux Disease",
-            "Acid reflux",
-            "Gastroesophageal reflux",
-            "Esophageal reflux",
-            "Gastroesophageal Reflux",
-            "Gastroesophageal reflux disease",
-            "Infantile Gastroesophageal Reflux",
-            "gastroesophageal reflux disease",
-            "Gastroesophageal reflux related phenotypic feature",
-            "Heartburn"
-          ],
-          "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-5316-1399"
-          ]
-        }
-      },
-      "end": {
-        "identity": 618,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Rebamipide",
-          "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-          "equivalent_curies": [
-            "NCIT:C29852",
-            "KEGG.DRUG:D01121",
-            "PUBCHEM.COMPOUND:5042",
-            "UNII:LR583V32ZR",
-            "UMLS:C0069562",
-            "DrugCentral:2360",
-            "DRUGBANK:DB11656",
-            "ATC:A02BX14",
-            "CHEBI:93814",
-            "MESH:C052785",
-            "CHEMBL.COMPOUND:CHEMBL1697771",
-            "PDQ:CDR0000759344",
-            "GTOPDB:871",
-            "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-            "CHEBI:32090"
-          ],
-          "id": "PUBCHEM.COMPOUND:5042",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "rebamipide",
-            "Rebamipide (JP18/INN)",
-            "REBAMIPIDE",
-            "mucosta",
-            "Rebamipide",
-            "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:23571415",
-            "PMID:32667799",
-            "PMID:20014752"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 321369,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007186",
-              "name": "gastroesophageal reflux disease",
-              "description": "A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C26781\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26781\" NCI Thesaurus); A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.; Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.; A condition in which the stomach contents leak backwards from the stomach into the esophagus through the lower esophageal sphincter. [HPO:probinson]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K21.9",
-                "UMLS:C4317146",
-                "NCIT:C26781",
-                "MEDDRA:10037676",
-                "PDQ:CDR0000737473",
-                "NCIT:C34670",
-                "UMLS:C3813607",
-                "MEDDRA:10066874",
-                "MEDDRA:10015389",
-                "ICD9:787.1",
-                "SNOMEDCT:698065002",
-                "UMLS:C0018834",
-                "OMIM:109350",
-                "MESH:D006356",
-                "UMLS:C0017168",
-                "DOID:8534",
-                "NCIT:C92560",
-                "SNOMEDCT:235595009",
-                "MEDDRA:10019326",
-                "HP:0002020",
-                "MEDDRA:10018203",
-                "MESH:D005764",
-                "MEDDRA:10017924",
-                "MEDDRA:10030182",
-                "SNOMEDCT:722884003",
-                "MONDO:0007186",
-                "ICD9:530.81",
-                "EFO:0003948",
-                "MEDDRA:10017884",
-                "MEDDRA:10017885",
-                "SNOMEDCT:16331000",
-                "NCIT:C113396"
-              ],
-              "id": "MONDO:0007186",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Gastroesophageal Reflux Disease",
-                "Acid reflux",
-                "Gastroesophageal reflux",
-                "Esophageal reflux",
-                "Gastroesophageal Reflux",
-                "Gastroesophageal reflux disease",
-                "Infantile Gastroesophageal Reflux",
-                "gastroesophageal reflux disease",
-                "Gastroesophageal reflux related phenotypic feature",
-                "Heartburn"
-              ],
-              "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-5316-1399"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24058477,
-            "start": 618,
-            "end": 321369,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35552457': {'publication date': '2022 May 12', 'sentence': 'Frequently reported adverse events of rebamipide compared to other drugs for peptic ulcer and gastroesophageal reflux disease.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:treats---None---None---None---UMLS:C0017168---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "24500158",
-              "object": "MONDO:0007186",
-              "publications": [
-                "PMID:35552457"
-              ]
-            }
-          },
-          "end": {
-            "identity": 618,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Rebamipide",
-              "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-              "equivalent_curies": [
-                "NCIT:C29852",
-                "KEGG.DRUG:D01121",
-                "PUBCHEM.COMPOUND:5042",
-                "UNII:LR583V32ZR",
-                "UMLS:C0069562",
-                "DrugCentral:2360",
-                "DRUGBANK:DB11656",
-                "ATC:A02BX14",
-                "CHEBI:93814",
-                "MESH:C052785",
-                "CHEMBL.COMPOUND:CHEMBL1697771",
-                "PDQ:CDR0000759344",
-                "GTOPDB:871",
-                "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-                "CHEBI:32090"
-              ],
-              "id": "PUBCHEM.COMPOUND:5042",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "rebamipide",
-                "Rebamipide (JP18/INN)",
-                "REBAMIPIDE",
-                "mucosta",
-                "Rebamipide",
-                "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:23571415",
-                "PMID:32667799",
-                "PMID:20014752"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 319030,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 618,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Rebamipide",
-          "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-          "equivalent_curies": [
-            "NCIT:C29852",
-            "KEGG.DRUG:D01121",
-            "PUBCHEM.COMPOUND:5042",
-            "UNII:LR583V32ZR",
-            "UMLS:C0069562",
-            "DrugCentral:2360",
-            "DRUGBANK:DB11656",
-            "ATC:A02BX14",
-            "CHEBI:93814",
-            "MESH:C052785",
-            "CHEMBL.COMPOUND:CHEMBL1697771",
-            "PDQ:CDR0000759344",
-            "GTOPDB:871",
-            "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-            "CHEBI:32090"
-          ],
-          "id": "PUBCHEM.COMPOUND:5042",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "rebamipide",
-            "Rebamipide (JP18/INN)",
-            "REBAMIPIDE",
-            "mucosta",
-            "Rebamipide",
-            "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:23571415",
-            "PMID:32667799",
-            "PMID:20014752"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319030,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19560192,
-            "start": 618,
-            "end": 319030,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29046162': {'publication date': '2018 Apr 20', 'sentence': 'We also discuss the potential role of rebamipide to serve as a new strategy for the treatment of TMJ-OA.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:treats---None---None---None---UMLS:C0029408---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "19949890",
-              "object": "MONDO:0005178",
-              "publications": [
-                "PMID:29046162"
-              ]
-            }
-          },
-          "end": {
-            "identity": 618,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Rebamipide",
-              "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-              "equivalent_curies": [
-                "NCIT:C29852",
-                "KEGG.DRUG:D01121",
-                "PUBCHEM.COMPOUND:5042",
-                "UNII:LR583V32ZR",
-                "UMLS:C0069562",
-                "DrugCentral:2360",
-                "DRUGBANK:DB11656",
-                "ATC:A02BX14",
-                "CHEBI:93814",
-                "MESH:C052785",
-                "CHEMBL.COMPOUND:CHEMBL1697771",
-                "PDQ:CDR0000759344",
-                "GTOPDB:871",
-                "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-                "CHEBI:32090"
-              ],
-              "id": "PUBCHEM.COMPOUND:5042",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "rebamipide",
-                "Rebamipide (JP18/INN)",
-                "REBAMIPIDE",
-                "mucosta",
-                "Rebamipide",
-                "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:23571415",
-                "PMID:32667799",
-                "PMID:20014752"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 320297,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006733",
-          "name": "dry eye syndrome",
-          "description": "Dryness of the eye related to deficiency of the tear film components (aqueous, mucin, or lipid), lid surface abnormalities, or epithelial abnormalities. Keratoconjunctivitis sicca often results in a scratchy or sandy sensation (foreign body sensation) in the eyes, and may also be associated with itching, inability to produce tears, photosensitivity, redness, pain, and difficulty in moving the eyelids. [HPO:probinson]; Dryness of the eye related to deficiency of the tear film components (aqueous, mucin, or lipid), lid surface abnormalities, or epithelial abnormalities. Keratoconjunctivitis sicca often results in a scratchy or sandy sensation (foreign body sensation) in the eyes, and may also be associated with itching, inability to produce tears, photosensitivity, redness, pain, and difficulty in moving the eyelids.; Dryness of the eye related to deficiency of the tear film components (aqueous, mucin, or lipid), lid surface abnormalities, or epithelial abnormalities. Keratoconjunctivitis sicca often results in a scratchy or sandy sensation (foreign body sensation) in the eyes, and may also be associated with itching, inability to produce tears, photosensitivity, redness, pain, and difficulty in moving the eyelids.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0022575",
-            "MEDDRA:10013777",
-            "NCIT:C34553",
-            "MESH:D015352",
-            "SNOMEDCT:46152009",
-            "DOID:12895",
-            "MEDDRA:10023350",
-            "SNOMEDCT:302896008",
-            "UMLS:C2930821",
-            "MONDO:0006733",
-            "HP:0001097",
-            "MESH:D007638",
-            "ICD10:H04.12",
-            "DOID:10140",
-            "EFO:1000906",
-            "MESH:C531719",
-            "MEDDRA:10060861",
-            "UMLS:C0013238"
-          ],
-          "id": "MONDO:0006733",
-          "category": "biolink:Disease",
-          "all_names": [
-            "keratoconjunctivitis sicca",
-            "dry eye syndrome",
-            "Keratitis sicca",
-            "Dry Eye Syndrome",
-            "Keratoconjunctivitis Sicca",
-            "Keratoconjunctivitis sicca",
-            "Dry Eye Syndromes"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:29498987",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0001-6908-9849"
-          ]
-        }
-      },
-      "end": {
-        "identity": 618,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Rebamipide",
-          "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-          "equivalent_curies": [
-            "NCIT:C29852",
-            "KEGG.DRUG:D01121",
-            "PUBCHEM.COMPOUND:5042",
-            "UNII:LR583V32ZR",
-            "UMLS:C0069562",
-            "DrugCentral:2360",
-            "DRUGBANK:DB11656",
-            "ATC:A02BX14",
-            "CHEBI:93814",
-            "MESH:C052785",
-            "CHEMBL.COMPOUND:CHEMBL1697771",
-            "PDQ:CDR0000759344",
-            "GTOPDB:871",
-            "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-            "CHEBI:32090"
-          ],
-          "id": "PUBCHEM.COMPOUND:5042",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "rebamipide",
-            "Rebamipide (JP18/INN)",
-            "REBAMIPIDE",
-            "mucosta",
-            "Rebamipide",
-            "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:23571415",
-            "PMID:32667799",
-            "PMID:20014752"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 320297,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006733",
-              "name": "dry eye syndrome",
-              "description": "Dryness of the eye related to deficiency of the tear film components (aqueous, mucin, or lipid), lid surface abnormalities, or epithelial abnormalities. Keratoconjunctivitis sicca often results in a scratchy or sandy sensation (foreign body sensation) in the eyes, and may also be associated with itching, inability to produce tears, photosensitivity, redness, pain, and difficulty in moving the eyelids. [HPO:probinson]; Dryness of the eye related to deficiency of the tear film components (aqueous, mucin, or lipid), lid surface abnormalities, or epithelial abnormalities. Keratoconjunctivitis sicca often results in a scratchy or sandy sensation (foreign body sensation) in the eyes, and may also be associated with itching, inability to produce tears, photosensitivity, redness, pain, and difficulty in moving the eyelids.; Dryness of the eye related to deficiency of the tear film components (aqueous, mucin, or lipid), lid surface abnormalities, or epithelial abnormalities. Keratoconjunctivitis sicca often results in a scratchy or sandy sensation (foreign body sensation) in the eyes, and may also be associated with itching, inability to produce tears, photosensitivity, redness, pain, and difficulty in moving the eyelids.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0022575",
-                "MEDDRA:10013777",
-                "NCIT:C34553",
-                "MESH:D015352",
-                "SNOMEDCT:46152009",
-                "DOID:12895",
-                "MEDDRA:10023350",
-                "SNOMEDCT:302896008",
-                "UMLS:C2930821",
-                "MONDO:0006733",
-                "HP:0001097",
-                "MESH:D007638",
-                "ICD10:H04.12",
-                "DOID:10140",
-                "EFO:1000906",
-                "MESH:C531719",
-                "MEDDRA:10060861",
-                "UMLS:C0013238"
-              ],
-              "id": "MONDO:0006733",
-              "category": "biolink:Disease",
-              "all_names": [
-                "keratoconjunctivitis sicca",
-                "dry eye syndrome",
-                "Keratitis sicca",
-                "Dry Eye Syndrome",
-                "Keratoconjunctivitis Sicca",
-                "Keratoconjunctivitis sicca",
-                "Dry Eye Syndromes"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:29498987",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0001-6908-9849"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 18983016,
-            "start": 618,
-            "end": 320297,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27937084': {'publication date': '2017 Jan/Feb', 'sentence': 'CONCLUSIONS: REB and DQS may be effective for the management of dry eye syndrome after PK in terms of ocular surface findings.', 'subject score': 1000, 'object score': 1000}, 'PMID:29123104': {'publication date': '2017 Nov 09', 'sentence': 'The results of the present study indicated that both DQS and RBM were effective for the treatment of DES in office workers.', 'subject score': 1000, 'object score': 1000}, 'PMID:34292514': {'publication date': '2021 Jul 22', 'sentence': 'Rebamipide may improve the accuracy of intraocular lens (IOL) power calculations in dry eyes, particularly when toric IOLs are implanted.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:treats---None---None---None---UMLS:C0013238---SEMMEDDB:",
-                "UMLS:C0069562---SEMMEDDB:treats---None---None---None---UMLS:C0022575---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "19364844",
-              "object": "MONDO:0006733",
-              "publications": [
-                "PMID:34292514",
-                "PMID:27937084",
-                "PMID:29123104"
-              ]
-            }
-          },
-          "end": {
-            "identity": 618,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Rebamipide",
-              "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-              "equivalent_curies": [
-                "NCIT:C29852",
-                "KEGG.DRUG:D01121",
-                "PUBCHEM.COMPOUND:5042",
-                "UNII:LR583V32ZR",
-                "UMLS:C0069562",
-                "DrugCentral:2360",
-                "DRUGBANK:DB11656",
-                "ATC:A02BX14",
-                "CHEBI:93814",
-                "MESH:C052785",
-                "CHEMBL.COMPOUND:CHEMBL1697771",
-                "PDQ:CDR0000759344",
-                "GTOPDB:871",
-                "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-                "CHEBI:32090"
-              ],
-              "id": "PUBCHEM.COMPOUND:5042",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "rebamipide",
-                "Rebamipide (JP18/INN)",
-                "REBAMIPIDE",
-                "mucosta",
-                "Rebamipide",
-                "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:23571415",
-                "PMID:32667799",
-                "PMID:20014752"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 618,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Rebamipide",
-          "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-          "equivalent_curies": [
-            "NCIT:C29852",
-            "KEGG.DRUG:D01121",
-            "PUBCHEM.COMPOUND:5042",
-            "UNII:LR583V32ZR",
-            "UMLS:C0069562",
-            "DrugCentral:2360",
-            "DRUGBANK:DB11656",
-            "ATC:A02BX14",
-            "CHEBI:93814",
-            "MESH:C052785",
-            "CHEMBL.COMPOUND:CHEMBL1697771",
-            "PDQ:CDR0000759344",
-            "GTOPDB:871",
-            "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-            "CHEBI:32090"
-          ],
-          "id": "PUBCHEM.COMPOUND:5042",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "rebamipide",
-            "Rebamipide (JP18/INN)",
-            "REBAMIPIDE",
-            "mucosta",
-            "Rebamipide",
-            "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:23571415",
-            "PMID:32667799",
-            "PMID:20014752"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 322104,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12932705,
-            "start": 618,
-            "end": 322104,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17607548': {'publication date': '2007 Jun', 'sentence': 'OBJECTIVE AND DESIGN: Since rebamipide is effective for the treatment of ulcerative colitis (UC), we examined the involvement of hepatocyte growth factor (HGF) in the action of rebamipide.', 'subject score': 1000, 'object score': 1000}, 'PMID:19897973': {'publication date': '2009', 'sentence': 'The results of our own investigation on the efficiency of rebamipide in the complex treatment of UC patients are presented.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:treats---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "13211904",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:17607548",
-                "PMID:19897973"
-              ]
-            }
-          },
-          "end": {
-            "identity": 618,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Rebamipide",
-              "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-              "equivalent_curies": [
-                "NCIT:C29852",
-                "KEGG.DRUG:D01121",
-                "PUBCHEM.COMPOUND:5042",
-                "UNII:LR583V32ZR",
-                "UMLS:C0069562",
-                "DrugCentral:2360",
-                "DRUGBANK:DB11656",
-                "ATC:A02BX14",
-                "CHEBI:93814",
-                "MESH:C052785",
-                "CHEMBL.COMPOUND:CHEMBL1697771",
-                "PDQ:CDR0000759344",
-                "GTOPDB:871",
-                "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-                "CHEBI:32090"
-              ],
-              "id": "PUBCHEM.COMPOUND:5042",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "rebamipide",
-                "Rebamipide (JP18/INN)",
-                "REBAMIPIDE",
-                "mucosta",
-                "Rebamipide",
-                "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:23571415",
-                "PMID:32667799",
-                "PMID:20014752"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 316638,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-          "name": "peptic ulcer disease",
-          "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10018053",
-            "MEDDRA:10045305",
-            "MESH:D010437",
-            "MONDO:0004247",
-            "DOID:750",
-            "UMLS:C0030920",
-            "MEDDRA:10017886",
-            "MEDDRA:10045342",
-            "ICD9:533",
-            "ICD10:K27",
-            "HP:0004398",
-            "MEDDRA:10034343",
-            "MEDDRA:10034360",
-            "MEDDRA:10045328",
-            "MEDDRA:10042834",
-            "MEDDRA:10034341",
-            "MEDDRA:10034367",
-            "MEDDRA:10037287",
-            "NCIT:C3318",
-            "SNOMEDCT:13200003",
-            "MEDDRA:10034369"
-          ],
-          "id": "MONDO:0004247",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peptic ulcer, site unspecified",
-            "Peptic Ulcer",
-            "peptic ulcer disease",
-            "Peptic ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28242110",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 618,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Rebamipide",
-          "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-          "equivalent_curies": [
-            "NCIT:C29852",
-            "KEGG.DRUG:D01121",
-            "PUBCHEM.COMPOUND:5042",
-            "UNII:LR583V32ZR",
-            "UMLS:C0069562",
-            "DrugCentral:2360",
-            "DRUGBANK:DB11656",
-            "ATC:A02BX14",
-            "CHEBI:93814",
-            "MESH:C052785",
-            "CHEMBL.COMPOUND:CHEMBL1697771",
-            "PDQ:CDR0000759344",
-            "GTOPDB:871",
-            "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-            "CHEBI:32090"
-          ],
-          "id": "PUBCHEM.COMPOUND:5042",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "rebamipide",
-            "Rebamipide (JP18/INN)",
-            "REBAMIPIDE",
-            "mucosta",
-            "Rebamipide",
-            "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:23571415",
-            "PMID:32667799",
-            "PMID:20014752"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316638,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-              "name": "peptic ulcer disease",
-              "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10018053",
-                "MEDDRA:10045305",
-                "MESH:D010437",
-                "MONDO:0004247",
-                "DOID:750",
-                "UMLS:C0030920",
-                "MEDDRA:10017886",
-                "MEDDRA:10045342",
-                "ICD9:533",
-                "ICD10:K27",
-                "HP:0004398",
-                "MEDDRA:10034343",
-                "MEDDRA:10034360",
-                "MEDDRA:10045328",
-                "MEDDRA:10042834",
-                "MEDDRA:10034341",
-                "MEDDRA:10034367",
-                "MEDDRA:10037287",
-                "NCIT:C3318",
-                "SNOMEDCT:13200003",
-                "MEDDRA:10034369"
-              ],
-              "id": "MONDO:0004247",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peptic ulcer, site unspecified",
-                "Peptic Ulcer",
-                "peptic ulcer disease",
-                "Peptic ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28242110",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11805335,
-            "start": 618,
-            "end": 316638,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16184418': {'publication date': '2005 Oct', 'sentence': 'Rebamipide, a gastro-protective drug, was developed in Japan for the treatment of peptic ulcer disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:17171453': {'publication date': '2007 Jan', 'sentence': 'Rebamipide is an antiulcer drug used in Japan, Korea, China, Philippines, and other Asian countries for treatment of gastritis and peptic ulcer.', 'subject score': 1000, 'object score': 1000}, 'PMID:27098506': {'publication date': '2016 Jun', 'sentence': 'The DBSQ scores associated with reflux symptoms, indigestion, nausea or vomiting, abdominal bloating or distension, peptic ulcer, abdominal pain, and constipation were improved after rebamipide treatment (P<0.05).', 'subject score': 888, 'object score': 1000}, 'PMID:33827990': {'publication date': '2021 Apr 07', 'sentence': 'Background/Aims: : The mucoprotective drug rebamipide is used to treat gastritis and peptic ulcers.', 'subject score': 790, 'object score': 1000}, 'PMID:35552457': {'publication date': '2022 May 12', 'sentence': 'Frequently reported adverse events of rebamipide compared to other drugs for peptic ulcer and gastroesophageal reflux disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:36678630': {'publication date': '2023 Jan 16', 'sentence': 'Rebamipide, which is currently used to treat peptic ulcer disease, was shown to enhance secretory function and modulate inflammation in animal disease models.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:treats---None---None---None---UMLS:C0030920---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "12062800",
-              "object": "MONDO:0004247",
-              "publications": [
-                "PMID:16184418",
-                "PMID:17171453",
-                "PMID:27098506",
-                "PMID:33827990",
-                "PMID:35552457",
-                "PMID:36678630"
-              ]
-            }
-          },
-          "end": {
-            "identity": 618,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Rebamipide",
-              "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-              "equivalent_curies": [
-                "NCIT:C29852",
-                "KEGG.DRUG:D01121",
-                "PUBCHEM.COMPOUND:5042",
-                "UNII:LR583V32ZR",
-                "UMLS:C0069562",
-                "DrugCentral:2360",
-                "DRUGBANK:DB11656",
-                "ATC:A02BX14",
-                "CHEBI:93814",
-                "MESH:C052785",
-                "CHEMBL.COMPOUND:CHEMBL1697771",
-                "PDQ:CDR0000759344",
-                "GTOPDB:871",
-                "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-                "CHEBI:32090"
-              ],
-              "id": "PUBCHEM.COMPOUND:5042",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "rebamipide",
-                "Rebamipide (JP18/INN)",
-                "REBAMIPIDE",
-                "mucosta",
-                "Rebamipide",
-                "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:23571415",
-                "PMID:32667799",
-                "PMID:20014752"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319260,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001126",
-          "name": "gastric ulcer",
-          "description": "An ulcer, that is, an erosion of an area of the gastric mucous membrane. [HPO:probinson]; An ulcer, that is, an erosion of an area of the gastric mucous membrane. // COMMENTS: The presence of a mucosal erosion equal to or greater than 0.5 cm.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10045304",
-            "HP:0002592",
-            "ICD10:K25",
-            "UMLS:C0038358",
-            "MESH:D013276",
-            "ICD9:531",
-            "MEDDRA:10045336",
-            "MEDDRA:10045374",
-            "EFO:0009454",
-            "SNOMEDCT:397825006",
-            "MEDDRA:10042116",
-            "MEDDRA:10017822",
-            "MONDO:0001126",
-            "NCIT:C3388",
-            "DOID:10808"
-          ],
-          "id": "MONDO:0001126",
-          "category": "biolink:Disease",
-          "all_names": [
-            "gastric ulcer",
-            "Stomach Ulcer",
-            "Gastric Ulcer",
-            "Gastric ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 618,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Rebamipide",
-          "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-          "equivalent_curies": [
-            "NCIT:C29852",
-            "KEGG.DRUG:D01121",
-            "PUBCHEM.COMPOUND:5042",
-            "UNII:LR583V32ZR",
-            "UMLS:C0069562",
-            "DrugCentral:2360",
-            "DRUGBANK:DB11656",
-            "ATC:A02BX14",
-            "CHEBI:93814",
-            "MESH:C052785",
-            "CHEMBL.COMPOUND:CHEMBL1697771",
-            "PDQ:CDR0000759344",
-            "GTOPDB:871",
-            "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-            "CHEBI:32090"
-          ],
-          "id": "PUBCHEM.COMPOUND:5042",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "rebamipide",
-            "Rebamipide (JP18/INN)",
-            "REBAMIPIDE",
-            "mucosta",
-            "Rebamipide",
-            "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:23571415",
-            "PMID:32667799",
-            "PMID:20014752"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319260,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001126",
-              "name": "gastric ulcer",
-              "description": "An ulcer, that is, an erosion of an area of the gastric mucous membrane. [HPO:probinson]; An ulcer, that is, an erosion of an area of the gastric mucous membrane. // COMMENTS: The presence of a mucosal erosion equal to or greater than 0.5 cm.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10045304",
-                "HP:0002592",
-                "ICD10:K25",
-                "UMLS:C0038358",
-                "MESH:D013276",
-                "ICD9:531",
-                "MEDDRA:10045336",
-                "MEDDRA:10045374",
-                "EFO:0009454",
-                "SNOMEDCT:397825006",
-                "MEDDRA:10042116",
-                "MEDDRA:10017822",
-                "MONDO:0001126",
-                "NCIT:C3388",
-                "DOID:10808"
-              ],
-              "id": "MONDO:0001126",
-              "category": "biolink:Disease",
-              "all_names": [
-                "gastric ulcer",
-                "Stomach Ulcer",
-                "Gastric Ulcer",
-                "Gastric ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10144023,
-            "start": 618,
-            "end": 319260,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12925147': {'publication date': '2003 Jul', 'sentence': 'Rebamipide is a mucoprotective drug used for the treatment of gastric ulcers.', 'subject score': 1000, 'object score': 1000}, 'PMID:15993841': {'publication date': '2005 Aug 19', 'sentence': 'Rebamipide accelerates healing of gastric ulcers and gastritis but its actions on gastric cancer are not known.', 'subject score': 1000, 'object score': 1000}, 'PMID:19772181': {'publication date': '2009 Sep', 'sentence': 'CONCLUSION: Rebamipide is effective and well tolerated for treatment of gastric ulcers especially those caused by NSAIDs, as it promotes the improvement of gastric inflammation scores, clinical symptoms, and ulcer healing.', 'subject score': 1000, 'object score': 901}, 'PMID:20625243': {'publication date': '2010 Aug 31', 'sentence': 'Rebamipide a gastroprotective drug, is clinically used for the treatment of gastric ulcers and gastritis, but its actions on gastric cancer are not clearly understood.', 'subject score': 1000, 'object score': 1000}, 'PMID:21757914': {'publication date': '2011', 'sentence': 'CONCLUSIONS: Rebamipide is as effective as omeprazole in treating of H. pylori-positive gastric ulcer after eradication therapy.', 'subject score': 1000, 'object score': 857}, 'PMID:22969286': {'publication date': '2012', 'sentence': 'Rebamipide is an antiulcer agent used to treat gastric ulcer and gastritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:24940041': {'publication date': '2014', 'sentence': 'Rebamipide was initially developed and approved for use in treating gastric ulcers and lesions associated with gastritis.', 'subject score': 1000, 'object score': 901}, 'PMID:27123995': {'publication date': '2016', 'sentence': 'Rebamipide is a gastroprotective agent that is currently used for the treatment of gastritis and gastric ulcers.', 'subject score': 1000, 'object score': 1000}, 'PMID:27282261': {'publication date': '2016 Nov 15', 'sentence': 'Conclusions: Combination therapy with rebamipide and PPI had limited benefits compared with PPI monotherapy in the treatment of post-ESD gastric ulcer (UMIN Clinical Trials Registry, UMIN000007435).', 'subject score': 1000, 'object score': 780}, 'PMID:31421154': {'publication date': '2019 10', 'sentence': 'Rebamipide is a gastroprotective drug used widely in the treatment of gastritis and gastric ulcers.', 'subject score': 1000, 'object score': 1000}, 'PMID:31582612': {'publication date': '2019', 'sentence': 'Rebamipide (RB) was developed in Japan as a treatment for gastric ulcer.', 'subject score': 1000, 'object score': 1000}, 'PMID:32557753': {'publication date': '2020 Jun 18', 'sentence': 'Rebamipide is widely used in East Asia for the treatment of gastric ulcers, acute gastritis, and exacerbated chronic gastritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:34338768': {'publication date': '2021 Aug 02', 'sentence': 'BACKGROUND: Rebamipide (REB) is quinolinone derivative compound, which is used for treatment of stomach ulcers.', 'subject score': 1000, 'object score': 1000}, 'PMID:35999163': {'publication date': '2022 Aug 12', 'sentence': 'CONCLUSION: These findings suggest that the efficacy and safety of polaprezinc were similar to those of rebamipide in the treatment of GU.', 'subject score': 1000, 'object score': 1000}, 'PMID:9248142': {'publication date': '1997 Jun', 'sentence': 'Rebamipide which is used as a drug for gastritis and stomach ulcer has large capability for OH radical scavenging.', 'subject score': 1000, 'object score': 1000}, 'PMID:9753220': {'publication date': '1998 Sep', 'sentence': 'Rebamipide, a gastroprotective drug, is a compound selected from over 500 amino acid analogs of 2(1H)-quinolinone tested for gastroprotective action and for efficacy to heal experimental gastric ulcers.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:treats---None---None---None---UMLS:C0038358---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "10368387",
-              "object": "MONDO:0001126",
-              "publications": [
-                "PMID:12925147",
-                "PMID:15993841",
-                "PMID:19772181",
-                "PMID:20625243",
-                "PMID:21757914",
-                "PMID:22969286",
-                "PMID:24940041",
-                "PMID:27123995",
-                "PMID:27282261",
-                "PMID:31421154",
-                "PMID:31582612",
-                "PMID:32557753",
-                "PMID:34338768",
-                "PMID:35999163",
-                "PMID:9248142",
-                "PMID:9753220"
-              ]
-            }
-          },
-          "end": {
-            "identity": 618,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Rebamipide",
-              "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-              "equivalent_curies": [
-                "NCIT:C29852",
-                "KEGG.DRUG:D01121",
-                "PUBCHEM.COMPOUND:5042",
-                "UNII:LR583V32ZR",
-                "UMLS:C0069562",
-                "DrugCentral:2360",
-                "DRUGBANK:DB11656",
-                "ATC:A02BX14",
-                "CHEBI:93814",
-                "MESH:C052785",
-                "CHEMBL.COMPOUND:CHEMBL1697771",
-                "PDQ:CDR0000759344",
-                "GTOPDB:871",
-                "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-                "CHEBI:32090"
-              ],
-              "id": "PUBCHEM.COMPOUND:5042",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "rebamipide",
-                "Rebamipide (JP18/INN)",
-                "REBAMIPIDE",
-                "mucosta",
-                "Rebamipide",
-                "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:23571415",
-                "PMID:32667799",
-                "PMID:20014752"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10749342': {'publication date': '2000 Mar', 'sentence': 'In conclusion, rebamipide may attenuate H. pylori-induced gastric inflammation by inhibiting lipid peroxidation and oxidant-mediated activation of NF-kappaB and thereby decreasing IL-8 production.', 'subject score': 1000, 'object score': 857}, 'PMID:12925154': {'publication date': '2003 Jul', 'sentence': 'Rebamipide is the only mucosal-protective drug which can improve the histological gastritis in vivo, whereas anti-acids have a lesser effect in influencing gastritis.', 'subject score': 1000, 'object score': 888}, 'PMID:15993841': {'publication date': '2005 Aug 19', 'sentence': 'Rebamipide accelerates healing of gastric ulcers and gastritis but its actions on gastric cancer are not known.', 'subject score': 1000, 'object score': 1000}, 'PMID:17171453': {'publication date': '2007 Jan', 'sentence': 'Rebamipide is an antiulcer drug used in Japan, Korea, China, Philippines, and other Asian countries for treatment of gastritis and peptic ulcer.', 'subject score': 1000, 'object score': 1000}, 'PMID:20625243': {'publication date': '2010 Aug 31', 'sentence': 'Rebamipide a gastroprotective drug, is clinically used for the treatment of gastric ulcers and gastritis, but its actions on gastric cancer are not clearly understood.', 'subject score': 1000, 'object score': 1000}, 'PMID:22969286': {'publication date': '2012', 'sentence': 'Rebamipide is an antiulcer agent used to treat gastric ulcer and gastritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:27123995': {'publication date': '2016', 'sentence': 'Rebamipide is a gastroprotective agent that is currently used for the treatment of gastritis and gastric ulcers.', 'subject score': 1000, 'object score': 1000}, 'PMID:30481820': {'publication date': '2018 Nov 01', 'sentence': 'Rebamipide was marketed originally as an oral therapeutic drug to treat gastritis in Japan.', 'subject score': 1000, 'object score': 1000}, 'PMID:31421154': {'publication date': '2019 10', 'sentence': 'Rebamipide is a gastroprotective drug used widely in the treatment of gastritis and gastric ulcers.', 'subject score': 1000, 'object score': 1000}, 'PMID:33827990': {'publication date': '2021 Apr 07', 'sentence': 'Background/Aims: : The mucoprotective drug rebamipide is used to treat gastritis and peptic ulcers.', 'subject score': 790, 'object score': 1000}, 'PMID:9248142': {'publication date': '1997 Jun', 'sentence': 'Rebamipide which is used as a drug for gastritis and stomach ulcer has large capability for OH radical scavenging.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 325237,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004966",
-          "name": "gastritis",
-          "description": "The presence of inflammation of the gastric mucous membrane. [HPO:probinson]; The presence of inflammation of the gastric mucous membrane.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10017869",
-            "SNOMEDCT:1086791000119100",
-            "MONDO:0004966",
-            "DOID:4029",
-            "SNOMEDCT:413216002",
-            "EFO:0000217",
-            "UMLS:C2243090",
-            "NCIT:C27013",
-            "SNOMEDCT:18665000",
-            "MEDDRA:10017853",
-            "SNOMEDCT:4556007",
-            "MEDDRA:10042110",
-            "UMLS:C3854048",
-            "MEDDRA:10017790",
-            "UMLS:C0267112",
-            "NCIT:C26780",
-            "UMLS:C0017152",
-            "UMLS:C2243088",
-            "MESH:D005756",
-            "MEDDRA:10017865",
-            "MEDDRA:10078716",
-            "MEDDRA:10000752",
-            "MEDDRA:10021967",
-            "HP:0005263",
-            "SNOMEDCT:444926003",
-            "ICD10:K29.7"
-          ],
-          "id": "MONDO:0004966",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Gastritis",
-            "Acute gastric mucosal erosion",
-            "Erosive gastritis",
-            "gastritis",
-            "Erosive gastropathy",
-            "Idiopathic erosive/hemorrhagic gastritis",
-            "Erosive Gastritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://en.wikipedia.org/wiki/gastritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 618,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Rebamipide",
-          "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-          "equivalent_curies": [
-            "NCIT:C29852",
-            "KEGG.DRUG:D01121",
-            "PUBCHEM.COMPOUND:5042",
-            "UNII:LR583V32ZR",
-            "UMLS:C0069562",
-            "DrugCentral:2360",
-            "DRUGBANK:DB11656",
-            "ATC:A02BX14",
-            "CHEBI:93814",
-            "MESH:C052785",
-            "CHEMBL.COMPOUND:CHEMBL1697771",
-            "PDQ:CDR0000759344",
-            "GTOPDB:871",
-            "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-            "CHEBI:32090"
-          ],
-          "id": "PUBCHEM.COMPOUND:5042",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "rebamipide",
-            "Rebamipide (JP18/INN)",
-            "REBAMIPIDE",
-            "mucosta",
-            "Rebamipide",
-            "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:23571415",
-            "PMID:32667799",
-            "PMID:20014752"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 325237,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004966",
-              "name": "gastritis",
-              "description": "The presence of inflammation of the gastric mucous membrane. [HPO:probinson]; The presence of inflammation of the gastric mucous membrane.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10017869",
-                "SNOMEDCT:1086791000119100",
-                "MONDO:0004966",
-                "DOID:4029",
-                "SNOMEDCT:413216002",
-                "EFO:0000217",
-                "UMLS:C2243090",
-                "NCIT:C27013",
-                "SNOMEDCT:18665000",
-                "MEDDRA:10017853",
-                "SNOMEDCT:4556007",
-                "MEDDRA:10042110",
-                "UMLS:C3854048",
-                "MEDDRA:10017790",
-                "UMLS:C0267112",
-                "NCIT:C26780",
-                "UMLS:C0017152",
-                "UMLS:C2243088",
-                "MESH:D005756",
-                "MEDDRA:10017865",
-                "MEDDRA:10078716",
-                "MEDDRA:10000752",
-                "MEDDRA:10021967",
-                "HP:0005263",
-                "SNOMEDCT:444926003",
-                "ICD10:K29.7"
-              ],
-              "id": "MONDO:0004966",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Gastritis",
-                "Acute gastric mucosal erosion",
-                "Erosive gastritis",
-                "gastritis",
-                "Erosive gastropathy",
-                "Idiopathic erosive/hemorrhagic gastritis",
-                "Erosive Gastritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://en.wikipedia.org/wiki/gastritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7921658,
-            "start": 618,
-            "end": 325237,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10749342': {'publication date': '2000 Mar', 'sentence': 'In conclusion, rebamipide may attenuate H. pylori-induced gastric inflammation by inhibiting lipid peroxidation and oxidant-mediated activation of NF-kappaB and thereby decreasing IL-8 production.', 'subject score': 1000, 'object score': 857}, 'PMID:12925154': {'publication date': '2003 Jul', 'sentence': 'Rebamipide is the only mucosal-protective drug which can improve the histological gastritis in vivo, whereas anti-acids have a lesser effect in influencing gastritis.', 'subject score': 1000, 'object score': 888}, 'PMID:15993841': {'publication date': '2005 Aug 19', 'sentence': 'Rebamipide accelerates healing of gastric ulcers and gastritis but its actions on gastric cancer are not known.', 'subject score': 1000, 'object score': 1000}, 'PMID:17171453': {'publication date': '2007 Jan', 'sentence': 'Rebamipide is an antiulcer drug used in Japan, Korea, China, Philippines, and other Asian countries for treatment of gastritis and peptic ulcer.', 'subject score': 1000, 'object score': 1000}, 'PMID:20625243': {'publication date': '2010 Aug 31', 'sentence': 'Rebamipide a gastroprotective drug, is clinically used for the treatment of gastric ulcers and gastritis, but its actions on gastric cancer are not clearly understood.', 'subject score': 1000, 'object score': 1000}, 'PMID:22969286': {'publication date': '2012', 'sentence': 'Rebamipide is an antiulcer agent used to treat gastric ulcer and gastritis.', 'subject score': 1000, 'object score': 1000}, 'PMID:27123995': {'publication date': '2016', 'sentence': 'Rebamipide is a gastroprotective agent that is currently used for the treatment of gastritis and gastric ulcers.', 'subject score': 1000, 'object score': 1000}, 'PMID:30481820': {'publication date': '2018 Nov 01', 'sentence': 'Rebamipide was marketed originally as an oral therapeutic drug to treat gastritis in Japan.', 'subject score': 1000, 'object score': 1000}, 'PMID:31421154': {'publication date': '2019 10', 'sentence': 'Rebamipide is a gastroprotective drug used widely in the treatment of gastritis and gastric ulcers.', 'subject score': 1000, 'object score': 1000}, 'PMID:33827990': {'publication date': '2021 Apr 07', 'sentence': 'Background/Aims: : The mucoprotective drug rebamipide is used to treat gastritis and peptic ulcers.', 'subject score': 790, 'object score': 1000}, 'PMID:9248142': {'publication date': '1997 Jun', 'sentence': 'Rebamipide which is used as a drug for gastritis and stomach ulcer has large capability for OH radical scavenging.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:treats---None---None---None---UMLS:C0017152---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "8102739",
-              "object": "MONDO:0004966",
-              "publications": [
-                "PMID:10749342",
-                "PMID:12925154",
-                "PMID:15993841",
-                "PMID:17171453",
-                "PMID:20625243",
-                "PMID:22969286",
-                "PMID:27123995",
-                "PMID:30481820",
-                "PMID:31421154",
-                "PMID:33827990",
-                "PMID:9248142"
-              ]
-            }
-          },
-          "end": {
-            "identity": 618,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Rebamipide",
-              "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-              "equivalent_curies": [
-                "NCIT:C29852",
-                "KEGG.DRUG:D01121",
-                "PUBCHEM.COMPOUND:5042",
-                "UNII:LR583V32ZR",
-                "UMLS:C0069562",
-                "DrugCentral:2360",
-                "DRUGBANK:DB11656",
-                "ATC:A02BX14",
-                "CHEBI:93814",
-                "MESH:C052785",
-                "CHEMBL.COMPOUND:CHEMBL1697771",
-                "PDQ:CDR0000759344",
-                "GTOPDB:871",
-                "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-                "CHEBI:32090"
-              ],
-              "id": "PUBCHEM.COMPOUND:5042",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "rebamipide",
-                "Rebamipide (JP18/INN)",
-                "REBAMIPIDE",
-                "mucosta",
-                "Rebamipide",
-                "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:23571415",
-                "PMID:32667799",
-                "PMID:20014752"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:23662915': {'publication date': '2013 Sep', 'sentence': 'Others reported that rebamipide, a gastroprotective drug, could not only increase the gastric mucus production, but also suppressed gastric mucosal inflammation and that it was dominantly distributed in mucosal tissues.', 'subject score': 1000, 'object score': 901}, 'PMID:24457813': {'publication date': '2014 Mar', 'sentence': 'BACKGROUND: Rebamipide, a gastroprotective drug, has been reported to suppress gastric mucosal inflammation.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 325237,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004966",
-          "name": "gastritis",
-          "description": "The presence of inflammation of the gastric mucous membrane. [HPO:probinson]; The presence of inflammation of the gastric mucous membrane.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10017869",
-            "SNOMEDCT:1086791000119100",
-            "MONDO:0004966",
-            "DOID:4029",
-            "SNOMEDCT:413216002",
-            "EFO:0000217",
-            "UMLS:C2243090",
-            "NCIT:C27013",
-            "SNOMEDCT:18665000",
-            "MEDDRA:10017853",
-            "SNOMEDCT:4556007",
-            "MEDDRA:10042110",
-            "UMLS:C3854048",
-            "MEDDRA:10017790",
-            "UMLS:C0267112",
-            "NCIT:C26780",
-            "UMLS:C0017152",
-            "UMLS:C2243088",
-            "MESH:D005756",
-            "MEDDRA:10017865",
-            "MEDDRA:10078716",
-            "MEDDRA:10000752",
-            "MEDDRA:10021967",
-            "HP:0005263",
-            "SNOMEDCT:444926003",
-            "ICD10:K29.7"
-          ],
-          "id": "MONDO:0004966",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Gastritis",
-            "Acute gastric mucosal erosion",
-            "Erosive gastritis",
-            "gastritis",
-            "Erosive gastropathy",
-            "Idiopathic erosive/hemorrhagic gastritis",
-            "Erosive Gastritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://en.wikipedia.org/wiki/gastritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 618,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Rebamipide",
-          "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-          "equivalent_curies": [
-            "NCIT:C29852",
-            "KEGG.DRUG:D01121",
-            "PUBCHEM.COMPOUND:5042",
-            "UNII:LR583V32ZR",
-            "UMLS:C0069562",
-            "DrugCentral:2360",
-            "DRUGBANK:DB11656",
-            "ATC:A02BX14",
-            "CHEBI:93814",
-            "MESH:C052785",
-            "CHEMBL.COMPOUND:CHEMBL1697771",
-            "PDQ:CDR0000759344",
-            "GTOPDB:871",
-            "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-            "CHEBI:32090"
-          ],
-          "id": "PUBCHEM.COMPOUND:5042",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "rebamipide",
-            "Rebamipide (JP18/INN)",
-            "REBAMIPIDE",
-            "mucosta",
-            "Rebamipide",
-            "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:23571415",
-            "PMID:32667799",
-            "PMID:20014752"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 325237,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004966",
-              "name": "gastritis",
-              "description": "The presence of inflammation of the gastric mucous membrane. [HPO:probinson]; The presence of inflammation of the gastric mucous membrane.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10017869",
-                "SNOMEDCT:1086791000119100",
-                "MONDO:0004966",
-                "DOID:4029",
-                "SNOMEDCT:413216002",
-                "EFO:0000217",
-                "UMLS:C2243090",
-                "NCIT:C27013",
-                "SNOMEDCT:18665000",
-                "MEDDRA:10017853",
-                "SNOMEDCT:4556007",
-                "MEDDRA:10042110",
-                "UMLS:C3854048",
-                "MEDDRA:10017790",
-                "UMLS:C0267112",
-                "NCIT:C26780",
-                "UMLS:C0017152",
-                "UMLS:C2243088",
-                "MESH:D005756",
-                "MEDDRA:10017865",
-                "MEDDRA:10078716",
-                "MEDDRA:10000752",
-                "MEDDRA:10021967",
-                "HP:0005263",
-                "SNOMEDCT:444926003",
-                "ICD10:K29.7"
-              ],
-              "id": "MONDO:0004966",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Gastritis",
-                "Acute gastric mucosal erosion",
-                "Erosive gastritis",
-                "gastritis",
-                "Erosive gastropathy",
-                "Idiopathic erosive/hemorrhagic gastritis",
-                "Erosive Gastritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://en.wikipedia.org/wiki/gastritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 16580921,
-            "start": 618,
-            "end": 325237,
-            "type": "biolink:disrupts",
-            "properties": {
-              "predicate": "biolink:disrupts",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:23662915': {'publication date': '2013 Sep', 'sentence': 'Others reported that rebamipide, a gastroprotective drug, could not only increase the gastric mucus production, but also suppressed gastric mucosal inflammation and that it was dominantly distributed in mucosal tissues.', 'subject score': 1000, 'object score': 901}, 'PMID:24457813': {'publication date': '2014 Mar', 'sentence': 'BACKGROUND: Rebamipide, a gastroprotective drug, has been reported to suppress gastric mucosal inflammation.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:disrupts---None---None---None---UMLS:C0017152---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "16923576",
-              "object": "MONDO:0004966",
-              "publications": [
-                "PMID:23662915",
-                "PMID:24457813"
-              ]
-            }
-          },
-          "end": {
-            "identity": 618,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Rebamipide",
-              "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-              "equivalent_curies": [
-                "NCIT:C29852",
-                "KEGG.DRUG:D01121",
-                "PUBCHEM.COMPOUND:5042",
-                "UNII:LR583V32ZR",
-                "UMLS:C0069562",
-                "DrugCentral:2360",
-                "DRUGBANK:DB11656",
-                "ATC:A02BX14",
-                "CHEBI:93814",
-                "MESH:C052785",
-                "CHEMBL.COMPOUND:CHEMBL1697771",
-                "PDQ:CDR0000759344",
-                "GTOPDB:871",
-                "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-                "CHEBI:32090"
-              ],
-              "id": "PUBCHEM.COMPOUND:5042",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "rebamipide",
-                "Rebamipide (JP18/INN)",
-                "REBAMIPIDE",
-                "mucosta",
-                "Rebamipide",
-                "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:23571415",
-                "PMID:32667799",
-                "PMID:20014752"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 316638,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-          "name": "peptic ulcer disease",
-          "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10018053",
-            "MEDDRA:10045305",
-            "MESH:D010437",
-            "MONDO:0004247",
-            "DOID:750",
-            "UMLS:C0030920",
-            "MEDDRA:10017886",
-            "MEDDRA:10045342",
-            "ICD9:533",
-            "ICD10:K27",
-            "HP:0004398",
-            "MEDDRA:10034343",
-            "MEDDRA:10034360",
-            "MEDDRA:10045328",
-            "MEDDRA:10042834",
-            "MEDDRA:10034341",
-            "MEDDRA:10034367",
-            "MEDDRA:10037287",
-            "NCIT:C3318",
-            "SNOMEDCT:13200003",
-            "MEDDRA:10034369"
-          ],
-          "id": "MONDO:0004247",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peptic ulcer, site unspecified",
-            "Peptic Ulcer",
-            "peptic ulcer disease",
-            "Peptic ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28242110",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 618,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Rebamipide",
-          "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-          "equivalent_curies": [
-            "NCIT:C29852",
-            "KEGG.DRUG:D01121",
-            "PUBCHEM.COMPOUND:5042",
-            "UNII:LR583V32ZR",
-            "UMLS:C0069562",
-            "DrugCentral:2360",
-            "DRUGBANK:DB11656",
-            "ATC:A02BX14",
-            "CHEBI:93814",
-            "MESH:C052785",
-            "CHEMBL.COMPOUND:CHEMBL1697771",
-            "PDQ:CDR0000759344",
-            "GTOPDB:871",
-            "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-            "CHEBI:32090"
-          ],
-          "id": "PUBCHEM.COMPOUND:5042",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "rebamipide",
-            "Rebamipide (JP18/INN)",
-            "REBAMIPIDE",
-            "mucosta",
-            "Rebamipide",
-            "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:23571415",
-            "PMID:32667799",
-            "PMID:20014752"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316638,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-              "name": "peptic ulcer disease",
-              "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10018053",
-                "MEDDRA:10045305",
-                "MESH:D010437",
-                "MONDO:0004247",
-                "DOID:750",
-                "UMLS:C0030920",
-                "MEDDRA:10017886",
-                "MEDDRA:10045342",
-                "ICD9:533",
-                "ICD10:K27",
-                "HP:0004398",
-                "MEDDRA:10034343",
-                "MEDDRA:10034360",
-                "MEDDRA:10045328",
-                "MEDDRA:10042834",
-                "MEDDRA:10034341",
-                "MEDDRA:10034367",
-                "MEDDRA:10037287",
-                "NCIT:C3318",
-                "SNOMEDCT:13200003",
-                "MEDDRA:10034369"
-              ],
-              "id": "MONDO:0004247",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peptic ulcer, site unspecified",
-                "Peptic Ulcer",
-                "peptic ulcer disease",
-                "Peptic ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28242110",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20537938,
-            "start": 618,
-            "end": 316638,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30919492': {'publication date': '2019 Sep', 'sentence': 'CONCLUSION: Rebamipide is safe and may prevent peptic ulcers >= 5 mm in diameter or those with pigmented spots in patients receiving dual antiplatelets for 1 year (NCT02166008).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:prevents---None---None---None---UMLS:C0030920---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "20953135",
-              "object": "MONDO:0004247",
-              "publications": [
-                "PMID:30919492"
-              ]
-            }
-          },
-          "end": {
-            "identity": 618,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Rebamipide",
-              "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-              "equivalent_curies": [
-                "NCIT:C29852",
-                "KEGG.DRUG:D01121",
-                "PUBCHEM.COMPOUND:5042",
-                "UNII:LR583V32ZR",
-                "UMLS:C0069562",
-                "DrugCentral:2360",
-                "DRUGBANK:DB11656",
-                "ATC:A02BX14",
-                "CHEBI:93814",
-                "MESH:C052785",
-                "CHEMBL.COMPOUND:CHEMBL1697771",
-                "PDQ:CDR0000759344",
-                "GTOPDB:871",
-                "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-                "CHEBI:32090"
-              ],
-              "id": "PUBCHEM.COMPOUND:5042",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "rebamipide",
-                "Rebamipide (JP18/INN)",
-                "REBAMIPIDE",
-                "mucosta",
-                "Rebamipide",
-                "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:23571415",
-                "PMID:32667799",
-                "PMID:20014752"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:18452057': {'publication date': '2008 Nov', 'sentence': 'Improvement of gastritis might be the mechanism by which rebamipide prevents gastric mucosal inflammation.', 'subject score': 1000, 'object score': 901}, 'PMID:8654144': {'publication date': '1996 Jun', 'sentence': 'These results suggest that rebamipide protects against the gastric mucosal inflammation associated with H. pylori by inhibiting neutrophil function.', 'subject score': 1000, 'object score': 901}, 'PMID:9753220': {'publication date': '1998 Sep', 'sentence': 'The inhibition of immunoinflammatory responses by rebamipide in H. pylori-infected patients may prevent development of gastritis, peptic ulcer disease, its recurrence, and possibly gastric cancer.', 'subject score': 1000, 'object score': 1000}, 'PMID:9862763': {'publication date': '1999 Jan', 'sentence': 'We investigated the mechanism or mechanisms by which rebamipide protects against the gastric mucosal inflammation associated with Helicobacter pylori.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 325237,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004966",
-          "name": "gastritis",
-          "description": "The presence of inflammation of the gastric mucous membrane. [HPO:probinson]; The presence of inflammation of the gastric mucous membrane.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10017869",
-            "SNOMEDCT:1086791000119100",
-            "MONDO:0004966",
-            "DOID:4029",
-            "SNOMEDCT:413216002",
-            "EFO:0000217",
-            "UMLS:C2243090",
-            "NCIT:C27013",
-            "SNOMEDCT:18665000",
-            "MEDDRA:10017853",
-            "SNOMEDCT:4556007",
-            "MEDDRA:10042110",
-            "UMLS:C3854048",
-            "MEDDRA:10017790",
-            "UMLS:C0267112",
-            "NCIT:C26780",
-            "UMLS:C0017152",
-            "UMLS:C2243088",
-            "MESH:D005756",
-            "MEDDRA:10017865",
-            "MEDDRA:10078716",
-            "MEDDRA:10000752",
-            "MEDDRA:10021967",
-            "HP:0005263",
-            "SNOMEDCT:444926003",
-            "ICD10:K29.7"
-          ],
-          "id": "MONDO:0004966",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Gastritis",
-            "Acute gastric mucosal erosion",
-            "Erosive gastritis",
-            "gastritis",
-            "Erosive gastropathy",
-            "Idiopathic erosive/hemorrhagic gastritis",
-            "Erosive Gastritis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://en.wikipedia.org/wiki/gastritis"
-          ]
-        }
-      },
-      "end": {
-        "identity": 618,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Rebamipide",
-          "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-          "equivalent_curies": [
-            "NCIT:C29852",
-            "KEGG.DRUG:D01121",
-            "PUBCHEM.COMPOUND:5042",
-            "UNII:LR583V32ZR",
-            "UMLS:C0069562",
-            "DrugCentral:2360",
-            "DRUGBANK:DB11656",
-            "ATC:A02BX14",
-            "CHEBI:93814",
-            "MESH:C052785",
-            "CHEMBL.COMPOUND:CHEMBL1697771",
-            "PDQ:CDR0000759344",
-            "GTOPDB:871",
-            "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-            "CHEBI:32090"
-          ],
-          "id": "PUBCHEM.COMPOUND:5042",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "rebamipide",
-            "Rebamipide (JP18/INN)",
-            "REBAMIPIDE",
-            "mucosta",
-            "Rebamipide",
-            "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:23571415",
-            "PMID:32667799",
-            "PMID:20014752"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 325237,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004966",
-              "name": "gastritis",
-              "description": "The presence of inflammation of the gastric mucous membrane. [HPO:probinson]; The presence of inflammation of the gastric mucous membrane.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10017869",
-                "SNOMEDCT:1086791000119100",
-                "MONDO:0004966",
-                "DOID:4029",
-                "SNOMEDCT:413216002",
-                "EFO:0000217",
-                "UMLS:C2243090",
-                "NCIT:C27013",
-                "SNOMEDCT:18665000",
-                "MEDDRA:10017853",
-                "SNOMEDCT:4556007",
-                "MEDDRA:10042110",
-                "UMLS:C3854048",
-                "MEDDRA:10017790",
-                "UMLS:C0267112",
-                "NCIT:C26780",
-                "UMLS:C0017152",
-                "UMLS:C2243088",
-                "MESH:D005756",
-                "MEDDRA:10017865",
-                "MEDDRA:10078716",
-                "MEDDRA:10000752",
-                "MEDDRA:10021967",
-                "HP:0005263",
-                "SNOMEDCT:444926003",
-                "ICD10:K29.7"
-              ],
-              "id": "MONDO:0004966",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Gastritis",
-                "Acute gastric mucosal erosion",
-                "Erosive gastritis",
-                "gastritis",
-                "Erosive gastropathy",
-                "Idiopathic erosive/hemorrhagic gastritis",
-                "Erosive Gastritis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://en.wikipedia.org/wiki/gastritis"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 13438791,
-            "start": 618,
-            "end": 325237,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18452057': {'publication date': '2008 Nov', 'sentence': 'Improvement of gastritis might be the mechanism by which rebamipide prevents gastric mucosal inflammation.', 'subject score': 1000, 'object score': 901}, 'PMID:8654144': {'publication date': '1996 Jun', 'sentence': 'These results suggest that rebamipide protects against the gastric mucosal inflammation associated with H. pylori by inhibiting neutrophil function.', 'subject score': 1000, 'object score': 901}, 'PMID:9753220': {'publication date': '1998 Sep', 'sentence': 'The inhibition of immunoinflammatory responses by rebamipide in H. pylori-infected patients may prevent development of gastritis, peptic ulcer disease, its recurrence, and possibly gastric cancer.', 'subject score': 1000, 'object score': 1000}, 'PMID:9862763': {'publication date': '1999 Jan', 'sentence': 'We investigated the mechanism or mechanisms by which rebamipide protects against the gastric mucosal inflammation associated with Helicobacter pylori.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:prevents---None---None---None---UMLS:C0017152---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "13727344",
-              "object": "MONDO:0004966",
-              "publications": [
-                "PMID:18452057",
-                "PMID:8654144",
-                "PMID:9753220",
-                "PMID:9862763"
-              ]
-            }
-          },
-          "end": {
-            "identity": 618,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Rebamipide",
-              "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-              "equivalent_curies": [
-                "NCIT:C29852",
-                "KEGG.DRUG:D01121",
-                "PUBCHEM.COMPOUND:5042",
-                "UNII:LR583V32ZR",
-                "UMLS:C0069562",
-                "DrugCentral:2360",
-                "DRUGBANK:DB11656",
-                "ATC:A02BX14",
-                "CHEBI:93814",
-                "MESH:C052785",
-                "CHEMBL.COMPOUND:CHEMBL1697771",
-                "PDQ:CDR0000759344",
-                "GTOPDB:871",
-                "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-                "CHEBI:32090"
-              ],
-              "id": "PUBCHEM.COMPOUND:5042",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "rebamipide",
-                "Rebamipide (JP18/INN)",
-                "REBAMIPIDE",
-                "mucosta",
-                "Rebamipide",
-                "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:23571415",
-                "PMID:32667799",
-                "PMID:20014752"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 319260,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:9753235': {'publication date': '1998 Sep', 'sentence': 'Rebamipide might act as a radical scavenger and have favorable effects on peptic ulcer diseases.', 'subject score': 1000, 'object score': 983}}",
-    "p2": {
-      "start": {
-        "identity": 316638,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0001126",
-          "name": "gastric ulcer",
-          "description": "An ulcer, that is, an erosion of an area of the gastric mucous membrane. [HPO:probinson]; An ulcer, that is, an erosion of an area of the gastric mucous membrane. // COMMENTS: The presence of a mucosal erosion equal to or greater than 0.5 cm.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10045304",
-            "HP:0002592",
-            "ICD10:K25",
-            "UMLS:C0038358",
-            "MESH:D013276",
-            "ICD9:531",
-            "MEDDRA:10045336",
-            "MEDDRA:10045374",
-            "EFO:0009454",
-            "SNOMEDCT:397825006",
-            "MEDDRA:10042116",
-            "MEDDRA:10017822",
-            "MONDO:0001126",
-            "NCIT:C3388",
-            "DOID:10808"
-          ],
-          "id": "MONDO:0001126",
-          "category": "biolink:Disease",
-          "all_names": [
-            "gastric ulcer",
-            "Stomach Ulcer",
-            "Gastric Ulcer",
-            "Gastric ulcer"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-          "name": "peptic ulcer disease",
-          "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10018053",
-            "MEDDRA:10045305",
-            "MESH:D010437",
-            "MONDO:0004247",
-            "DOID:750",
-            "UMLS:C0030920",
-            "MEDDRA:10017886",
-            "MEDDRA:10045342",
-            "ICD9:533",
-            "ICD10:K27",
-            "HP:0004398",
-            "MEDDRA:10034343",
-            "MEDDRA:10034360",
-            "MEDDRA:10045328",
-            "MEDDRA:10042834",
-            "MEDDRA:10034341",
-            "MEDDRA:10034367",
-            "MEDDRA:10037287",
-            "NCIT:C3318",
-            "SNOMEDCT:13200003",
-            "MEDDRA:10034369"
-          ],
-          "id": "MONDO:0004247",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peptic ulcer, site unspecified",
-            "Peptic Ulcer",
-            "peptic ulcer disease",
-            "Peptic ulcer"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-=======
-            "PMID:28242110",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-            "https://orcid.org/0000-0002-6548-5200"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 618,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Rebamipide",
-          "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-          "equivalent_curies": [
-            "NCIT:C29852",
-            "KEGG.DRUG:D01121",
-            "PUBCHEM.COMPOUND:5042",
-            "UNII:LR583V32ZR",
-            "UMLS:C0069562",
-            "DrugCentral:2360",
-            "DRUGBANK:DB11656",
-            "ATC:A02BX14",
-            "CHEBI:93814",
-            "MESH:C052785",
-            "CHEMBL.COMPOUND:CHEMBL1697771",
-            "PDQ:CDR0000759344",
-            "GTOPDB:871",
-            "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-            "CHEBI:32090"
-          ],
-          "id": "PUBCHEM.COMPOUND:5042",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "rebamipide",
-            "Rebamipide (JP18/INN)",
-            "REBAMIPIDE",
-            "mucosta",
-            "Rebamipide",
-            "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:23571415",
-            "PMID:32667799",
-            "PMID:20014752"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 319260,
-=======
-            "identity": 316638,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0001126",
-              "name": "gastric ulcer",
-              "description": "An ulcer, that is, an erosion of an area of the gastric mucous membrane. [HPO:probinson]; An ulcer, that is, an erosion of an area of the gastric mucous membrane. // COMMENTS: The presence of a mucosal erosion equal to or greater than 0.5 cm.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10045304",
-                "HP:0002592",
-                "ICD10:K25",
-                "UMLS:C0038358",
-                "MESH:D013276",
-                "ICD9:531",
-                "MEDDRA:10045336",
-                "MEDDRA:10045374",
-                "EFO:0009454",
-                "SNOMEDCT:397825006",
-                "MEDDRA:10042116",
-                "MEDDRA:10017822",
-                "MONDO:0001126",
-                "NCIT:C3388",
-                "DOID:10808"
-              ],
-              "id": "MONDO:0001126",
-              "category": "biolink:Disease",
-              "all_names": [
-                "gastric ulcer",
-                "Stomach Ulcer",
-                "Gastric Ulcer",
-                "Gastric ulcer"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-              "name": "peptic ulcer disease",
-              "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10018053",
-                "MEDDRA:10045305",
-                "MESH:D010437",
-                "MONDO:0004247",
-                "DOID:750",
-                "UMLS:C0030920",
-                "MEDDRA:10017886",
-                "MEDDRA:10045342",
-                "ICD9:533",
-                "ICD10:K27",
-                "HP:0004398",
-                "MEDDRA:10034343",
-                "MEDDRA:10034360",
-                "MEDDRA:10045328",
-                "MEDDRA:10042834",
-                "MEDDRA:10034341",
-                "MEDDRA:10034367",
-                "MEDDRA:10037287",
-                "NCIT:C3318",
-                "SNOMEDCT:13200003",
-                "MEDDRA:10034369"
-              ],
-              "id": "MONDO:0004247",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peptic ulcer, site unspecified",
-                "Peptic Ulcer",
-                "peptic ulcer disease",
-                "Peptic ulcer"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-=======
-                "PMID:28242110",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-                "https://orcid.org/0000-0002-6548-5200"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 10226473,
-            "start": 618,
-            "end": 319260,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1313372': {'publication date': '1992 Feb 25', 'sentence': 'These findings suggest that rebamipide prevents diethyldithiocarbamate-induced gastric ulcer formation by inhibiting neutrophil activation.', 'subject score': 1000, 'object score': 840}, 'PMID:25071901': {'publication date': '2014 Jul', 'sentence': 'CONCLUSIONS: Rebamipide can prevent gastric ulcers when used with NSAIDs and can decrease the gastrointestinal symptoms associated with NSAID administration.', 'subject score': 1000, 'object score': 1000}, 'PMID:28011266': {'publication date': '2017 01 29', 'sentence': 'In a mouse ulcer model, rebamipide protected against hydrochloric acid/ethanol-induced gastric ulcer, and these protective effects were deterred by co-administration of compound C.', 'subject score': 1000, 'object score': 839}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:prevents---None---None---None---UMLS:C0038358---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "10452606",
-              "object": "MONDO:0001126",
-              "publications": [
-                "PMID:1313372",
-                "PMID:25071901",
-                "PMID:28011266"
-=======
-            "identity": 27205553,
-            "start": 618,
-            "end": 316638,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9753235': {'publication date': '1998 Sep', 'sentence': 'Rebamipide might act as a radical scavenger and have favorable effects on peptic ulcer diseases.', 'subject score': 1000, 'object score': 983}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:affects---None---None---None---UMLS:C0030920---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "27679650",
-              "object": "MONDO:0004247",
-              "publications": [
-                "PMID:9753235"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 618,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Rebamipide",
-              "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-              "equivalent_curies": [
-                "NCIT:C29852",
-                "KEGG.DRUG:D01121",
-                "PUBCHEM.COMPOUND:5042",
-                "UNII:LR583V32ZR",
-                "UMLS:C0069562",
-                "DrugCentral:2360",
-                "DRUGBANK:DB11656",
-                "ATC:A02BX14",
-                "CHEBI:93814",
-                "MESH:C052785",
-                "CHEMBL.COMPOUND:CHEMBL1697771",
-                "PDQ:CDR0000759344",
-                "GTOPDB:871",
-                "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-                "CHEBI:32090"
-              ],
-              "id": "PUBCHEM.COMPOUND:5042",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "rebamipide",
-                "Rebamipide (JP18/INN)",
-                "REBAMIPIDE",
-                "mucosta",
-                "Rebamipide",
-                "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:23571415",
-                "PMID:32667799",
-                "PMID:20014752"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 319673,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:16184418': {'publication date': '2005 Oct', 'sentence': 'Rebamipide, a gastro-protective drug, was developed in Japan for the treatment of peptic ulcer disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:17171453': {'publication date': '2007 Jan', 'sentence': 'Rebamipide is an antiulcer drug used in Japan, Korea, China, Philippines, and other Asian countries for treatment of gastritis and peptic ulcer.', 'subject score': 1000, 'object score': 1000}, 'PMID:27098506': {'publication date': '2016 Jun', 'sentence': 'The DBSQ scores associated with reflux symptoms, indigestion, nausea or vomiting, abdominal bloating or distension, peptic ulcer, abdominal pain, and constipation were improved after rebamipide treatment (P<0.05).', 'subject score': 888, 'object score': 1000}, 'PMID:33827990': {'publication date': '2021 Apr 07', 'sentence': 'Background/Aims: : The mucoprotective drug rebamipide is used to treat gastritis and peptic ulcers.', 'subject score': 790, 'object score': 1000}, 'PMID:35552457': {'publication date': '2022 May 12', 'sentence': 'Frequently reported adverse events of rebamipide compared to other drugs for peptic ulcer and gastroesophageal reflux disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:36678630': {'publication date': '2023 Jan 16', 'sentence': 'Rebamipide, which is currently used to treat peptic ulcer disease, was shown to enhance secretory function and modulate inflammation in animal disease models.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316638,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-          "name": "peptic ulcer disease",
-          "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10018053",
-            "MEDDRA:10045305",
-            "MESH:D010437",
-            "MONDO:0004247",
-            "DOID:750",
-            "UMLS:C0030920",
-            "MEDDRA:10017886",
-            "MEDDRA:10045342",
-            "ICD9:533",
-            "ICD10:K27",
-            "HP:0004398",
-            "MEDDRA:10034343",
-            "MEDDRA:10034360",
-            "MEDDRA:10045328",
-            "MEDDRA:10042834",
-            "MEDDRA:10034341",
-            "MEDDRA:10034367",
-            "MEDDRA:10037287",
-            "NCIT:C3318",
-            "SNOMEDCT:13200003",
-            "MEDDRA:10034369"
-          ],
-          "id": "MONDO:0004247",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peptic ulcer, site unspecified",
-            "Peptic Ulcer",
-            "peptic ulcer disease",
-            "Peptic ulcer"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-=======
-            "PMID:28242110",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 618,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Rebamipide",
-          "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-          "equivalent_curies": [
-            "NCIT:C29852",
-            "KEGG.DRUG:D01121",
-            "PUBCHEM.COMPOUND:5042",
-            "UNII:LR583V32ZR",
-            "UMLS:C0069562",
-            "DrugCentral:2360",
-            "DRUGBANK:DB11656",
-            "ATC:A02BX14",
-            "CHEBI:93814",
-            "MESH:C052785",
-            "CHEMBL.COMPOUND:CHEMBL1697771",
-            "PDQ:CDR0000759344",
-            "GTOPDB:871",
-            "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-            "CHEBI:32090"
-          ],
-          "id": "PUBCHEM.COMPOUND:5042",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "rebamipide",
-            "Rebamipide (JP18/INN)",
-            "REBAMIPIDE",
-            "mucosta",
-            "Rebamipide",
-            "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:23571415",
-            "PMID:32667799",
-            "PMID:20014752"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316638,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-              "name": "peptic ulcer disease",
-              "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10018053",
-                "MEDDRA:10045305",
-                "MESH:D010437",
-                "MONDO:0004247",
-                "DOID:750",
-                "UMLS:C0030920",
-                "MEDDRA:10017886",
-                "MEDDRA:10045342",
-                "ICD9:533",
-                "ICD10:K27",
-                "HP:0004398",
-                "MEDDRA:10034343",
-                "MEDDRA:10034360",
-                "MEDDRA:10045328",
-                "MEDDRA:10042834",
-                "MEDDRA:10034341",
-                "MEDDRA:10034367",
-                "MEDDRA:10037287",
-                "NCIT:C3318",
-                "SNOMEDCT:13200003",
-                "MEDDRA:10034369"
-              ],
-              "id": "MONDO:0004247",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peptic ulcer, site unspecified",
-                "Peptic Ulcer",
-                "peptic ulcer disease",
-                "Peptic ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28242110",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 11805335,
-            "start": 618,
-            "end": 316638,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16184418': {'publication date': '2005 Oct', 'sentence': 'Rebamipide, a gastro-protective drug, was developed in Japan for the treatment of peptic ulcer disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:17171453': {'publication date': '2007 Jan', 'sentence': 'Rebamipide is an antiulcer drug used in Japan, Korea, China, Philippines, and other Asian countries for treatment of gastritis and peptic ulcer.', 'subject score': 1000, 'object score': 1000}, 'PMID:27098506': {'publication date': '2016 Jun', 'sentence': 'The DBSQ scores associated with reflux symptoms, indigestion, nausea or vomiting, abdominal bloating or distension, peptic ulcer, abdominal pain, and constipation were improved after rebamipide treatment (P<0.05).', 'subject score': 888, 'object score': 1000}, 'PMID:33827990': {'publication date': '2021 Apr 07', 'sentence': 'Background/Aims: : The mucoprotective drug rebamipide is used to treat gastritis and peptic ulcers.', 'subject score': 790, 'object score': 1000}, 'PMID:35552457': {'publication date': '2022 May 12', 'sentence': 'Frequently reported adverse events of rebamipide compared to other drugs for peptic ulcer and gastroesophageal reflux disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:36678630': {'publication date': '2023 Jan 16', 'sentence': 'Rebamipide, which is currently used to treat peptic ulcer disease, was shown to enhance secretory function and modulate inflammation in animal disease models.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:treats---None---None---None---UMLS:C0030920---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "12062800",
-              "object": "MONDO:0004247",
-              "publications": [
-                "PMID:16184418",
-                "PMID:17171453",
-                "PMID:27098506",
-                "PMID:33827990",
-                "PMID:35552457",
-                "PMID:36678630"
-              ]
-            }
-          },
-          "end": {
-            "identity": 618,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Rebamipide",
-              "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-              "equivalent_curies": [
-                "NCIT:C29852",
-                "KEGG.DRUG:D01121",
-                "PUBCHEM.COMPOUND:5042",
-                "UNII:LR583V32ZR",
-                "UMLS:C0069562",
-                "DrugCentral:2360",
-                "DRUGBANK:DB11656",
-                "ATC:A02BX14",
-                "CHEBI:93814",
-                "MESH:C052785",
-                "CHEMBL.COMPOUND:CHEMBL1697771",
-                "PDQ:CDR0000759344",
-                "GTOPDB:871",
-                "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-                "CHEBI:32090"
-              ],
-              "id": "PUBCHEM.COMPOUND:5042",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "rebamipide",
-                "Rebamipide (JP18/INN)",
-                "REBAMIPIDE",
-                "mucosta",
-                "Rebamipide",
-                "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:23571415",
-                "PMID:32667799",
-                "PMID:20014752"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:30919492': {'publication date': '2019 Sep', 'sentence': 'CONCLUSION: Rebamipide is safe and may prevent peptic ulcers >= 5 mm in diameter or those with pigmented spots in patients receiving dual antiplatelets for 1 year (NCT02166008).', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 316638,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-          "name": "peptic ulcer disease",
-          "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10018053",
-            "MEDDRA:10045305",
-            "MESH:D010437",
-            "MONDO:0004247",
-            "DOID:750",
-            "UMLS:C0030920",
-            "MEDDRA:10017886",
-            "MEDDRA:10045342",
-            "ICD9:533",
-            "ICD10:K27",
-            "HP:0004398",
-            "MEDDRA:10034343",
-            "MEDDRA:10034360",
-            "MEDDRA:10045328",
-            "MEDDRA:10042834",
-            "MEDDRA:10034341",
-            "MEDDRA:10034367",
-            "MEDDRA:10037287",
-            "NCIT:C3318",
-            "SNOMEDCT:13200003",
-            "MEDDRA:10034369"
-          ],
-          "id": "MONDO:0004247",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peptic ulcer, site unspecified",
-            "Peptic Ulcer",
-            "peptic ulcer disease",
-            "Peptic ulcer"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28242110",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-            "https://orcid.org/0000-0002-6548-5200"
-          ]
-        }
-      },
-      "end": {
-        "identity": 618,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Rebamipide",
-          "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-          "equivalent_curies": [
-            "NCIT:C29852",
-            "KEGG.DRUG:D01121",
-            "PUBCHEM.COMPOUND:5042",
-            "UNII:LR583V32ZR",
-            "UMLS:C0069562",
-            "DrugCentral:2360",
-            "DRUGBANK:DB11656",
-            "ATC:A02BX14",
-            "CHEBI:93814",
-            "MESH:C052785",
-            "CHEMBL.COMPOUND:CHEMBL1697771",
-            "PDQ:CDR0000759344",
-            "GTOPDB:871",
-            "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-            "CHEBI:32090"
-          ],
-          "id": "PUBCHEM.COMPOUND:5042",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "rebamipide",
-            "Rebamipide (JP18/INN)",
-            "REBAMIPIDE",
-            "mucosta",
-            "Rebamipide",
-            "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:23571415",
-            "PMID:32667799",
-            "PMID:20014752"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316638,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-              "name": "peptic ulcer disease",
-              "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10018053",
-                "MEDDRA:10045305",
-                "MESH:D010437",
-                "MONDO:0004247",
-                "DOID:750",
-                "UMLS:C0030920",
-                "MEDDRA:10017886",
-                "MEDDRA:10045342",
-                "ICD9:533",
-                "ICD10:K27",
-                "HP:0004398",
-                "MEDDRA:10034343",
-                "MEDDRA:10034360",
-                "MEDDRA:10045328",
-                "MEDDRA:10042834",
-                "MEDDRA:10034341",
-                "MEDDRA:10034367",
-                "MEDDRA:10037287",
-                "NCIT:C3318",
-                "SNOMEDCT:13200003",
-                "MEDDRA:10034369"
-              ],
-              "id": "MONDO:0004247",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peptic ulcer, site unspecified",
-                "Peptic Ulcer",
-                "peptic ulcer disease",
-                "Peptic ulcer"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28242110",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-                "https://orcid.org/0000-0002-6548-5200"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 20537938,
-            "start": 618,
-            "end": 316638,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30919492': {'publication date': '2019 Sep', 'sentence': 'CONCLUSION: Rebamipide is safe and may prevent peptic ulcers >= 5 mm in diameter or those with pigmented spots in patients receiving dual antiplatelets for 1 year (NCT02166008).', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:prevents---None---None---None---UMLS:C0030920---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "20953135",
-              "object": "MONDO:0004247",
-              "publications": [
-                "PMID:30919492"
-              ]
-            }
-          },
-          "end": {
-            "identity": 618,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Rebamipide",
-              "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-              "equivalent_curies": [
-                "NCIT:C29852",
-                "KEGG.DRUG:D01121",
-                "PUBCHEM.COMPOUND:5042",
-                "UNII:LR583V32ZR",
-                "UMLS:C0069562",
-                "DrugCentral:2360",
-                "DRUGBANK:DB11656",
-                "ATC:A02BX14",
-                "CHEBI:93814",
-                "MESH:C052785",
-                "CHEMBL.COMPOUND:CHEMBL1697771",
-                "PDQ:CDR0000759344",
-                "GTOPDB:871",
-                "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-                "CHEBI:32090"
-              ],
-              "id": "PUBCHEM.COMPOUND:5042",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "rebamipide",
-                "Rebamipide (JP18/INN)",
-                "REBAMIPIDE",
-                "mucosta",
-                "Rebamipide",
-                "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:23571415",
-                "PMID:32667799",
-                "PMID:20014752"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:17607548': {'publication date': '2007 Jun', 'sentence': 'OBJECTIVE AND DESIGN: Since rebamipide is effective for the treatment of ulcerative colitis (UC), we examined the involvement of hepatocyte growth factor (HGF) in the action of rebamipide.', 'subject score': 1000, 'object score': 1000}, 'PMID:19897973': {'publication date': '2009', 'sentence': 'The results of our own investigation on the efficiency of rebamipide in the complex treatment of UC patients are presented.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 322104,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-          "name": "ulcerative colitis",
-          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "ICD10:K51",
-            "ORPHANET:771",
-            "MESH:D003093",
-            "UMLS:C0375359",
-            "MEDDRA:10045365",
-            "UMLS:C0009324",
-            "ICD9:556.5",
-            "MEDDRA:10021238",
-            "MEDDRA:10009900",
-            "EFO:0000729",
-            "MEDDRA:10024123",
-            "SNOMEDCT:64766004",
-            "ICD9:556",
-            "PSY:54620",
-            "DOID:8577",
-            "MEDDRA:10045366",
-            "NCIT:C2952",
-            "MEDDRA:10036785",
-            "HP:0100279",
-            "MONDO:0005101",
-            "SNOMEDCT:441971007"
-          ],
-          "id": "MONDO:0005101",
-          "category": "biolink:Disease",
-          "all_names": [
-            "ulcerative colitis",
-            "Ulcerative colitis",
-            "Left-sided ulcerative (chronic) colitis",
-            "Chronic left-sided ulcerative colitis",
-            "Colitis, Ulcerative",
-            "Ulcerative Colitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://en.wikipedia.org/wiki/ulcerative_colitis"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-<<<<<<< HEAD
-        "identity": 619,
-=======
-        "identity": 618,
->>>>>>> main
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-<<<<<<< HEAD
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "DINUTUXIMAB",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.",
-          "equivalent_curies": [
-            "UMLS:C0281581",
-            "GTOPDB:7979",
-            "CHEMBL.COMPOUND:CHEMBL2109420",
-            "RXNORM:1606274",
-            "KEGG.DRUG:D10559",
-            "UNII:7SQY4ZUD30",
-            "DrugCentral:4948",
-            "NCIT:C1570",
-            "UMLS:C4722567",
-            "MESH:C112746",
-            "DRUGBANK:DB09077",
-            "CHEMBL.COMPOUND:CHEMBL3137342"
-          ],
-          "id": "UNII:7SQY4ZUD30",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Dinutuximab (USAN/INN)",
-            "CH14.18",
-            "Dinutuximab",
-            "Dinutuximab beta",
-            "dinutuximab",
-            "DINUTUXIMAB",
-            "ch14.18-UTC"
-          ],
-          "all_categories": [
-            "biolink:Protein",
-=======
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Rebamipide",
-          "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-          "equivalent_curies": [
-            "NCIT:C29852",
-            "KEGG.DRUG:D01121",
-            "PUBCHEM.COMPOUND:5042",
-            "UNII:LR583V32ZR",
-            "UMLS:C0069562",
-            "DrugCentral:2360",
-            "DRUGBANK:DB11656",
-            "ATC:A02BX14",
-            "CHEBI:93814",
-            "MESH:C052785",
-            "CHEMBL.COMPOUND:CHEMBL1697771",
-            "PDQ:CDR0000759344",
-            "GTOPDB:871",
-            "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-            "CHEBI:32090"
-          ],
-          "id": "PUBCHEM.COMPOUND:5042",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "rebamipide",
-            "Rebamipide (JP18/INN)",
-            "REBAMIPIDE",
-            "mucosta",
-            "Rebamipide",
-            "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-          ],
-          "all_categories": [
->>>>>>> main
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "PMID:24295643",
-            "PMID:1988079",
-            "PMID:25940913",
-            "PMID:15923178"
-=======
-            "PMID:23571415",
-            "PMID:32667799",
-            "PMID:20014752"
->>>>>>> main
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 319673,
-=======
-            "identity": 322104,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
-              "name": "ulcerative colitis",
-              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "ICD10:K51",
-                "ORPHANET:771",
-                "MESH:D003093",
-                "UMLS:C0375359",
-                "MEDDRA:10045365",
-                "UMLS:C0009324",
-                "ICD9:556.5",
-                "MEDDRA:10021238",
-                "MEDDRA:10009900",
-                "EFO:0000729",
-                "MEDDRA:10024123",
-                "SNOMEDCT:64766004",
-                "ICD9:556",
-                "PSY:54620",
-                "DOID:8577",
-                "MEDDRA:10045366",
-                "NCIT:C2952",
-                "MEDDRA:10036785",
-                "HP:0100279",
-                "MONDO:0005101",
-                "SNOMEDCT:441971007"
-              ],
-              "id": "MONDO:0005101",
-              "category": "biolink:Disease",
-              "all_names": [
-                "ulcerative colitis",
-                "Ulcerative colitis",
-                "Left-sided ulcerative (chronic) colitis",
-                "Chronic left-sided ulcerative colitis",
-                "Colitis, Ulcerative",
-                "Ulcerative Colitis"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-=======
-                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://en.wikipedia.org/wiki/ulcerative_colitis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 22592341,
-            "start": 619,
-            "end": 319673,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:33572900': {'publication date': '2021 Jan 29', 'sentence': 'In summary, our data provide evidence that dinutuximab might be effective in tumors with high GD2 expression.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0281581---SEMMEDDB:associated_with---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "UNII:7SQY4ZUD30",
-              "id": "23020953",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:33572900"
-=======
-            "identity": 12932705,
-            "start": 618,
-            "end": 322104,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17607548': {'publication date': '2007 Jun', 'sentence': 'OBJECTIVE AND DESIGN: Since rebamipide is effective for the treatment of ulcerative colitis (UC), we examined the involvement of hepatocyte growth factor (HGF) in the action of rebamipide.', 'subject score': 1000, 'object score': 1000}, 'PMID:19897973': {'publication date': '2009', 'sentence': 'The results of our own investigation on the efficiency of rebamipide in the complex treatment of UC patients are presented.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:treats---None---None---None---UMLS:C0009324---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "13211904",
-              "object": "MONDO:0005101",
-              "publications": [
-                "PMID:17607548",
-                "PMID:19897973"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-<<<<<<< HEAD
-            "identity": 619,
-=======
-            "identity": 618,
->>>>>>> main
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-<<<<<<< HEAD
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "DINUTUXIMAB",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.",
-              "equivalent_curies": [
-                "UMLS:C0281581",
-                "GTOPDB:7979",
-                "CHEMBL.COMPOUND:CHEMBL2109420",
-                "RXNORM:1606274",
-                "KEGG.DRUG:D10559",
-                "UNII:7SQY4ZUD30",
-                "DrugCentral:4948",
-                "NCIT:C1570",
-                "UMLS:C4722567",
-                "MESH:C112746",
-                "DRUGBANK:DB09077",
-                "CHEMBL.COMPOUND:CHEMBL3137342"
-              ],
-              "id": "UNII:7SQY4ZUD30",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Dinutuximab (USAN/INN)",
-                "CH14.18",
-                "Dinutuximab",
-                "Dinutuximab beta",
-                "dinutuximab",
-                "DINUTUXIMAB",
-                "ch14.18-UTC"
-              ],
-              "all_categories": [
-                "biolink:Protein",
-=======
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Rebamipide",
-              "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-              "equivalent_curies": [
-                "NCIT:C29852",
-                "KEGG.DRUG:D01121",
-                "PUBCHEM.COMPOUND:5042",
-                "UNII:LR583V32ZR",
-                "UMLS:C0069562",
-                "DrugCentral:2360",
-                "DRUGBANK:DB11656",
-                "ATC:A02BX14",
-                "CHEBI:93814",
-                "MESH:C052785",
-                "CHEMBL.COMPOUND:CHEMBL1697771",
-                "PDQ:CDR0000759344",
-                "GTOPDB:871",
-                "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-                "CHEBI:32090"
-              ],
-              "id": "PUBCHEM.COMPOUND:5042",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "rebamipide",
-                "Rebamipide (JP18/INN)",
-                "REBAMIPIDE",
-                "mucosta",
-                "Rebamipide",
-                "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-              ],
-              "all_categories": [
->>>>>>> main
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "PMID:24295643",
-                "PMID:1988079",
-                "PMID:25940913",
-                "PMID:15923178"
-=======
-                "PMID:23571415",
-                "PMID:32667799",
-                "PMID:20014752"
->>>>>>> main
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 316327,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:27937084': {'publication date': '2017 Jan/Feb', 'sentence': 'CONCLUSIONS: REB and DQS may be effective for the management of dry eye syndrome after PK in terms of ocular surface findings.', 'subject score': 1000, 'object score': 1000}, 'PMID:29123104': {'publication date': '2017 Nov 09', 'sentence': 'The results of the present study indicated that both DQS and RBM were effective for the treatment of DES in office workers.', 'subject score': 1000, 'object score': 1000}, 'PMID:34292514': {'publication date': '2021 Jul 22', 'sentence': 'Rebamipide may improve the accuracy of intraocular lens (IOL) power calculations in dry eyes, particularly when toric IOLs are implanted.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 320297,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005072",
-          "name": "neuroblastoma",
-          "description": "A neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.; A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51); Neuroblastoma is a solid tumor that originate in neural crest cells of the sympathetic nervous system. Most neuroblastomas originate in the abdomen, and most abdominal neuroblastomas originate in the adrenal gland. Neuroblastomas can also originate in the thorax, usually in the posterior mediastinum. [HPO:probinson]; What is neuroblastoma? Neuroblastoma is a type of cancer that forms in nerve cells called neuroblasts. Neuroblasts are immature nerve tissue. They normally turn into working nerve cells. But in neuroblastoma, they form a tumor. Neuroblastoma usually begins in the adrenal glands. You have two adrenal glands, one on top of each kidney. The adrenal glands make important hormones that help control heart rate, blood pressure, blood sugar, and the way the body reacts to stress. Neuroblastoma may also begin in the neck, chest or spinal cord. What causes neuroblastoma? Neuroblastoma is caused by mutations (changes) in genes. In most cases, the cause of the mutation is unknown. In some other cases, the mutation is passed from the parent to the child. What are the symptoms of neuroblastoma? Neuroblastoma often begins in early childhood. Sometimes it begins before a child is born.The most common symptoms are caused by the tumor pressing on nearby tissues as it grows or by cancer spreading to the bone.They include: A lump in the abdomen, neck or chest Bulging eyes Dark circles around the eyes Bone pain Swollen stomach and trouble breathing in babies Painless, bluish lumps under the skin in babies Inability to move a body part (paralysis)  How is neuroblastoma diagnosed? To diagnose neuroblastoma, your child's health care provider will do various tests and procedures, which may include: A medical history A neurological exam Imaging tests, such as x-rays, a CT scan, an ultrasound, an MRI, or an MIBG scan. In an MIBG scan, a small amount of a radioactive substance is injected into a vein. It travels through the bloodstream and attaches itself to any neuroblastoma cells. A scanner detects the cells. Blood and urine tests Biopsy, where a sample of tissue is removed and examined under a microscope Bone marrow aspiration and biopsy, where bone marrow, blood, and a small piece of bone are removed for testing  What are the treatments for neuroblastoma? The treatments for neuroblastoma include: Observation, also called watchful waiting, where the health care provider does not give any treatments until your child's signs or symptoms appear or change Surgery Radiation therapy Chemotherapy High-dose chemotherapy and radiation therapy with stem cell rescue. Your child will get high doses of chemotherapy and radiation. This kills the cancer cells, but it also kills healthy cells. So your child will get a stem cell transplant, usually of his or her own cells collected earlier. This helps to replace the healthy cells that were lost. Iodine 131-MIBG therapy, a treatment with radioactive iodine. The radioactive iodine collects in neuroblastoma cells and kills them with the radiation that is given off. Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0005072",
-            "UMLS:C0700095",
-            "MEDDRA:10029260",
-            "ORPHANET:635",
-            "UMLS:C0027819",
-            "UMLS:CN205405",
-            "EFO:0000621",
-            "DOID:769",
-            "MESH:D009447",
-            "NCIT:C3270",
-            "SNOMEDCT:432328008",
-            "DOID:0080906",
-            "HP:0003006",
-            "PDQ:CDR0000042067",
-            "MONDO:0859597",
-            "MEDDRA:10029261",
-            "SNOMEDCT:87364003"
-          ],
-          "id": "MONDO:0005072",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Central neuroblastoma",
-            "CNS neuroblastoma with FOXR2 activation",
-            "neuroblastoma",
-            "cns neuroblastoma with FOXR2 activation",
-            "Neuroblastoma"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006733",
-          "name": "dry eye syndrome",
-          "description": "Dryness of the eye related to deficiency of the tear film components (aqueous, mucin, or lipid), lid surface abnormalities, or epithelial abnormalities. Keratoconjunctivitis sicca often results in a scratchy or sandy sensation (foreign body sensation) in the eyes, and may also be associated with itching, inability to produce tears, photosensitivity, redness, pain, and difficulty in moving the eyelids. [HPO:probinson]; Dryness of the eye related to deficiency of the tear film components (aqueous, mucin, or lipid), lid surface abnormalities, or epithelial abnormalities. Keratoconjunctivitis sicca often results in a scratchy or sandy sensation (foreign body sensation) in the eyes, and may also be associated with itching, inability to produce tears, photosensitivity, redness, pain, and difficulty in moving the eyelids.; Dryness of the eye related to deficiency of the tear film components (aqueous, mucin, or lipid), lid surface abnormalities, or epithelial abnormalities. Keratoconjunctivitis sicca often results in a scratchy or sandy sensation (foreign body sensation) in the eyes, and may also be associated with itching, inability to produce tears, photosensitivity, redness, pain, and difficulty in moving the eyelids.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0022575",
-            "MEDDRA:10013777",
-            "NCIT:C34553",
-            "MESH:D015352",
-            "SNOMEDCT:46152009",
-            "DOID:12895",
-            "MEDDRA:10023350",
-            "SNOMEDCT:302896008",
-            "UMLS:C2930821",
-            "MONDO:0006733",
-            "HP:0001097",
-            "MESH:D007638",
-            "ICD10:H04.12",
-            "DOID:10140",
-            "EFO:1000906",
-            "MESH:C531719",
-            "MEDDRA:10060861",
-            "UMLS:C0013238"
-          ],
-          "id": "MONDO:0006733",
-          "category": "biolink:Disease",
-          "all_names": [
-            "keratoconjunctivitis sicca",
-            "dry eye syndrome",
-            "Keratitis sicca",
-            "Dry Eye Syndrome",
-            "Keratoconjunctivitis Sicca",
-            "Keratoconjunctivitis sicca",
-            "Dry Eye Syndromes"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:32903387",
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7350623/",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.cancer.gov/cancertopics/types/neuroblastoma",
-            "https://link.springer.com/article/10.1007%2fs10014-020-00370-2"
-=======
-            "PMID:29498987",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0001-6908-9849"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-<<<<<<< HEAD
-        "identity": 619,
-=======
-        "identity": 618,
->>>>>>> main
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-<<<<<<< HEAD
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "DINUTUXIMAB",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.",
-          "equivalent_curies": [
-            "UMLS:C0281581",
-            "GTOPDB:7979",
-            "CHEMBL.COMPOUND:CHEMBL2109420",
-            "RXNORM:1606274",
-            "KEGG.DRUG:D10559",
-            "UNII:7SQY4ZUD30",
-            "DrugCentral:4948",
-            "NCIT:C1570",
-            "UMLS:C4722567",
-            "MESH:C112746",
-            "DRUGBANK:DB09077",
-            "CHEMBL.COMPOUND:CHEMBL3137342"
-          ],
-          "id": "UNII:7SQY4ZUD30",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Dinutuximab (USAN/INN)",
-            "CH14.18",
-            "Dinutuximab",
-            "Dinutuximab beta",
-            "dinutuximab",
-            "DINUTUXIMAB",
-            "ch14.18-UTC"
-          ],
-          "all_categories": [
-            "biolink:Protein",
-=======
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Rebamipide",
-          "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-          "equivalent_curies": [
-            "NCIT:C29852",
-            "KEGG.DRUG:D01121",
-            "PUBCHEM.COMPOUND:5042",
-            "UNII:LR583V32ZR",
-            "UMLS:C0069562",
-            "DrugCentral:2360",
-            "DRUGBANK:DB11656",
-            "ATC:A02BX14",
-            "CHEBI:93814",
-            "MESH:C052785",
-            "CHEMBL.COMPOUND:CHEMBL1697771",
-            "PDQ:CDR0000759344",
-            "GTOPDB:871",
-            "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-            "CHEBI:32090"
-          ],
-          "id": "PUBCHEM.COMPOUND:5042",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "rebamipide",
-            "Rebamipide (JP18/INN)",
-            "REBAMIPIDE",
-            "mucosta",
-            "Rebamipide",
-            "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-          ],
-          "all_categories": [
->>>>>>> main
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "PMID:24295643",
-            "PMID:1988079",
-            "PMID:25940913",
-            "PMID:15923178"
-=======
-            "PMID:23571415",
-            "PMID:32667799",
-            "PMID:20014752"
->>>>>>> main
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 316327,
-=======
-            "identity": 320297,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005072",
-              "name": "neuroblastoma",
-              "description": "A neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.; A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51); Neuroblastoma is a solid tumor that originate in neural crest cells of the sympathetic nervous system. Most neuroblastomas originate in the abdomen, and most abdominal neuroblastomas originate in the adrenal gland. Neuroblastomas can also originate in the thorax, usually in the posterior mediastinum. [HPO:probinson]; What is neuroblastoma? Neuroblastoma is a type of cancer that forms in nerve cells called neuroblasts. Neuroblasts are immature nerve tissue. They normally turn into working nerve cells. But in neuroblastoma, they form a tumor. Neuroblastoma usually begins in the adrenal glands. You have two adrenal glands, one on top of each kidney. The adrenal glands make important hormones that help control heart rate, blood pressure, blood sugar, and the way the body reacts to stress. Neuroblastoma may also begin in the neck, chest or spinal cord. What causes neuroblastoma? Neuroblastoma is caused by mutations (changes) in genes. In most cases, the cause of the mutation is unknown. In some other cases, the mutation is passed from the parent to the child. What are the symptoms of neuroblastoma? Neuroblastoma often begins in early childhood. Sometimes it begins before a child is born.The most common symptoms are caused by the tumor pressing on nearby tissues as it grows or by cancer spreading to the bone.They include: A lump in the abdomen, neck or chest Bulging eyes Dark circles around the eyes Bone pain Swollen stomach and trouble breathing in babies Painless, bluish lumps under the skin in babies Inability to move a body part (paralysis)  How is neuroblastoma diagnosed? To diagnose neuroblastoma, your child's health care provider will do various tests and procedures, which may include: A medical history A neurological exam Imaging tests, such as x-rays, a CT scan, an ultrasound, an MRI, or an MIBG scan. In an MIBG scan, a small amount of a radioactive substance is injected into a vein. It travels through the bloodstream and attaches itself to any neuroblastoma cells. A scanner detects the cells. Blood and urine tests Biopsy, where a sample of tissue is removed and examined under a microscope Bone marrow aspiration and biopsy, where bone marrow, blood, and a small piece of bone are removed for testing  What are the treatments for neuroblastoma? The treatments for neuroblastoma include: Observation, also called watchful waiting, where the health care provider does not give any treatments until your child's signs or symptoms appear or change Surgery Radiation therapy Chemotherapy High-dose chemotherapy and radiation therapy with stem cell rescue. Your child will get high doses of chemotherapy and radiation. This kills the cancer cells, but it also kills healthy cells. So your child will get a stem cell transplant, usually of his or her own cells collected earlier. This helps to replace the healthy cells that were lost. Iodine 131-MIBG therapy, a treatment with radioactive iodine. The radioactive iodine collects in neuroblastoma cells and kills them with the radiation that is given off. Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0005072",
-                "UMLS:C0700095",
-                "MEDDRA:10029260",
-                "ORPHANET:635",
-                "UMLS:C0027819",
-                "UMLS:CN205405",
-                "EFO:0000621",
-                "DOID:769",
-                "MESH:D009447",
-                "NCIT:C3270",
-                "SNOMEDCT:432328008",
-                "DOID:0080906",
-                "HP:0003006",
-                "PDQ:CDR0000042067",
-                "MONDO:0859597",
-                "MEDDRA:10029261",
-                "SNOMEDCT:87364003"
-              ],
-              "id": "MONDO:0005072",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Central neuroblastoma",
-                "CNS neuroblastoma with FOXR2 activation",
-                "neuroblastoma",
-                "cns neuroblastoma with FOXR2 activation",
-                "Neuroblastoma"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006733",
-              "name": "dry eye syndrome",
-              "description": "Dryness of the eye related to deficiency of the tear film components (aqueous, mucin, or lipid), lid surface abnormalities, or epithelial abnormalities. Keratoconjunctivitis sicca often results in a scratchy or sandy sensation (foreign body sensation) in the eyes, and may also be associated with itching, inability to produce tears, photosensitivity, redness, pain, and difficulty in moving the eyelids. [HPO:probinson]; Dryness of the eye related to deficiency of the tear film components (aqueous, mucin, or lipid), lid surface abnormalities, or epithelial abnormalities. Keratoconjunctivitis sicca often results in a scratchy or sandy sensation (foreign body sensation) in the eyes, and may also be associated with itching, inability to produce tears, photosensitivity, redness, pain, and difficulty in moving the eyelids.; Dryness of the eye related to deficiency of the tear film components (aqueous, mucin, or lipid), lid surface abnormalities, or epithelial abnormalities. Keratoconjunctivitis sicca often results in a scratchy or sandy sensation (foreign body sensation) in the eyes, and may also be associated with itching, inability to produce tears, photosensitivity, redness, pain, and difficulty in moving the eyelids.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0022575",
-                "MEDDRA:10013777",
-                "NCIT:C34553",
-                "MESH:D015352",
-                "SNOMEDCT:46152009",
-                "DOID:12895",
-                "MEDDRA:10023350",
-                "SNOMEDCT:302896008",
-                "UMLS:C2930821",
-                "MONDO:0006733",
-                "HP:0001097",
-                "MESH:D007638",
-                "ICD10:H04.12",
-                "DOID:10140",
-                "EFO:1000906",
-                "MESH:C531719",
-                "MEDDRA:10060861",
-                "UMLS:C0013238"
-              ],
-              "id": "MONDO:0006733",
-              "category": "biolink:Disease",
-              "all_names": [
-                "keratoconjunctivitis sicca",
-                "dry eye syndrome",
-                "Keratitis sicca",
-                "Dry Eye Syndrome",
-                "Keratoconjunctivitis Sicca",
-                "Keratoconjunctivitis sicca",
-                "Dry Eye Syndromes"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:32903387",
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7350623/",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.cancer.gov/cancertopics/types/neuroblastoma",
-                "https://link.springer.com/article/10.1007%2fs10014-020-00370-2"
-=======
-                "PMID:29498987",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0001-6908-9849"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 12121686,
-            "start": 619,
-            "end": 316327,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16568495': {'publication date': '2006 May', 'sentence': 'The mouse/human chimeric anti-GD2 mAb ch14.18 is already applied in melanoma and neuroblastoma trials as a passive immunotherapy.', 'subject score': 760, 'object score': 872}, 'PMID:24055592': {'publication date': '2013 Dec 15', 'sentence': 'Human/mouse chimeric monoclonal antibody (mAb) ch14.18 is directed against disialoganglioside GD2 and has demonstrated activity and efficacy in high-risk neuroblastoma (NB).', 'subject score': 852, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0281581---SEMMEDDB:associated_with---None---None---None---UMLS:C0027819---SEMMEDDB:"
-              ],
-              "subject": "UNII:7SQY4ZUD30",
-              "id": "12385638",
-              "object": "MONDO:0005072",
-              "publications": [
-                "PMID:16568495",
-                "PMID:24055592"
-=======
-            "identity": 18983016,
-            "start": 618,
-            "end": 320297,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27937084': {'publication date': '2017 Jan/Feb', 'sentence': 'CONCLUSIONS: REB and DQS may be effective for the management of dry eye syndrome after PK in terms of ocular surface findings.', 'subject score': 1000, 'object score': 1000}, 'PMID:29123104': {'publication date': '2017 Nov 09', 'sentence': 'The results of the present study indicated that both DQS and RBM were effective for the treatment of DES in office workers.', 'subject score': 1000, 'object score': 1000}, 'PMID:34292514': {'publication date': '2021 Jul 22', 'sentence': 'Rebamipide may improve the accuracy of intraocular lens (IOL) power calculations in dry eyes, particularly when toric IOLs are implanted.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0069562---SEMMEDDB:treats---None---None---None---UMLS:C0013238---SEMMEDDB:",
-                "UMLS:C0069562---SEMMEDDB:treats---None---None---None---UMLS:C0022575---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:5042",
-              "id": "19364844",
-              "object": "MONDO:0006733",
-              "publications": [
-                "PMID:34292514",
-                "PMID:27937084",
-                "PMID:29123104"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-<<<<<<< HEAD
-            "identity": 619,
-=======
-            "identity": 618,
->>>>>>> main
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-<<<<<<< HEAD
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "DINUTUXIMAB",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.",
-              "equivalent_curies": [
-                "UMLS:C0281581",
-                "GTOPDB:7979",
-                "CHEMBL.COMPOUND:CHEMBL2109420",
-                "RXNORM:1606274",
-                "KEGG.DRUG:D10559",
-                "UNII:7SQY4ZUD30",
-                "DrugCentral:4948",
-                "NCIT:C1570",
-                "UMLS:C4722567",
-                "MESH:C112746",
-                "DRUGBANK:DB09077",
-                "CHEMBL.COMPOUND:CHEMBL3137342"
-              ],
-              "id": "UNII:7SQY4ZUD30",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Dinutuximab (USAN/INN)",
-                "CH14.18",
-                "Dinutuximab",
-                "Dinutuximab beta",
-                "dinutuximab",
-                "DINUTUXIMAB",
-                "ch14.18-UTC"
-              ],
-              "all_categories": [
-                "biolink:Protein",
-=======
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Rebamipide",
-              "description": "A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29852\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29852\" NCI Thesaurus); A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.",
-              "equivalent_curies": [
-                "NCIT:C29852",
-                "KEGG.DRUG:D01121",
-                "PUBCHEM.COMPOUND:5042",
-                "UNII:LR583V32ZR",
-                "UMLS:C0069562",
-                "DrugCentral:2360",
-                "DRUGBANK:DB11656",
-                "ATC:A02BX14",
-                "CHEBI:93814",
-                "MESH:C052785",
-                "CHEMBL.COMPOUND:CHEMBL1697771",
-                "PDQ:CDR0000759344",
-                "GTOPDB:871",
-                "INCHIKEY:ALLWOAVDORUJLA-UHFFFAOYSA-N",
-                "CHEBI:32090"
-              ],
-              "id": "PUBCHEM.COMPOUND:5042",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "rebamipide",
-                "Rebamipide (JP18/INN)",
-                "REBAMIPIDE",
-                "mucosta",
-                "Rebamipide",
-                "2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid"
-              ],
-              "all_categories": [
->>>>>>> main
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "PMID:24295643",
-                "PMID:1988079",
-                "PMID:25940913",
-                "PMID:15923178"
-=======
-                "PMID:23571415",
-                "PMID:32667799",
-                "PMID:20014752"
->>>>>>> main
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 316327,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005072",
-          "name": "neuroblastoma",
-          "description": "A neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.; A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51); Neuroblastoma is a solid tumor that originate in neural crest cells of the sympathetic nervous system. Most neuroblastomas originate in the abdomen, and most abdominal neuroblastomas originate in the adrenal gland. Neuroblastomas can also originate in the thorax, usually in the posterior mediastinum. [HPO:probinson]; What is neuroblastoma? Neuroblastoma is a type of cancer that forms in nerve cells called neuroblasts. Neuroblasts are immature nerve tissue. They normally turn into working nerve cells. But in neuroblastoma, they form a tumor. Neuroblastoma usually begins in the adrenal glands. You have two adrenal glands, one on top of each kidney. The adrenal glands make important hormones that help control heart rate, blood pressure, blood sugar, and the way the body reacts to stress. Neuroblastoma may also begin in the neck, chest or spinal cord. What causes neuroblastoma? Neuroblastoma is caused by mutations (changes) in genes. In most cases, the cause of the mutation is unknown. In some other cases, the mutation is passed from the parent to the child. What are the symptoms of neuroblastoma? Neuroblastoma often begins in early childhood. Sometimes it begins before a child is born.The most common symptoms are caused by the tumor pressing on nearby tissues as it grows or by cancer spreading to the bone.They include: A lump in the abdomen, neck or chest Bulging eyes Dark circles around the eyes Bone pain Swollen stomach and trouble breathing in babies Painless, bluish lumps under the skin in babies Inability to move a body part (paralysis)  How is neuroblastoma diagnosed? To diagnose neuroblastoma, your child's health care provider will do various tests and procedures, which may include: A medical history A neurological exam Imaging tests, such as x-rays, a CT scan, an ultrasound, an MRI, or an MIBG scan. In an MIBG scan, a small amount of a radioactive substance is injected into a vein. It travels through the bloodstream and attaches itself to any neuroblastoma cells. A scanner detects the cells. Blood and urine tests Biopsy, where a sample of tissue is removed and examined under a microscope Bone marrow aspiration and biopsy, where bone marrow, blood, and a small piece of bone are removed for testing  What are the treatments for neuroblastoma? The treatments for neuroblastoma include: Observation, also called watchful waiting, where the health care provider does not give any treatments until your child's signs or symptoms appear or change Surgery Radiation therapy Chemotherapy High-dose chemotherapy and radiation therapy with stem cell rescue. Your child will get high doses of chemotherapy and radiation. This kills the cancer cells, but it also kills healthy cells. So your child will get a stem cell transplant, usually of his or her own cells collected earlier. This helps to replace the healthy cells that were lost. Iodine 131-MIBG therapy, a treatment with radioactive iodine. The radioactive iodine collects in neuroblastoma cells and kills them with the radiation that is given off. Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0005072",
-            "UMLS:C0700095",
-            "MEDDRA:10029260",
-            "ORPHANET:635",
-            "UMLS:C0027819",
-            "UMLS:CN205405",
-            "EFO:0000621",
-            "DOID:769",
-            "MESH:D009447",
-            "NCIT:C3270",
-            "SNOMEDCT:432328008",
-            "DOID:0080906",
-            "HP:0003006",
-            "PDQ:CDR0000042067",
-            "MONDO:0859597",
-            "MEDDRA:10029261",
-            "SNOMEDCT:87364003"
-          ],
-          "id": "MONDO:0005072",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Central neuroblastoma",
-            "CNS neuroblastoma with FOXR2 activation",
-            "neuroblastoma",
-            "cns neuroblastoma with FOXR2 activation",
-            "Neuroblastoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:32903387",
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7350623/",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.cancer.gov/cancertopics/types/neuroblastoma",
-            "https://link.springer.com/article/10.1007%2fs10014-020-00370-2"
-          ]
-        }
-      },
-      "end": {
-        "identity": 619,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "DINUTUXIMAB",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.",
-          "equivalent_curies": [
-            "UMLS:C0281581",
-            "GTOPDB:7979",
-            "CHEMBL.COMPOUND:CHEMBL2109420",
-            "RXNORM:1606274",
-            "KEGG.DRUG:D10559",
-            "UNII:7SQY4ZUD30",
-            "DrugCentral:4948",
-            "NCIT:C1570",
-            "UMLS:C4722567",
-            "MESH:C112746",
-            "DRUGBANK:DB09077",
-            "CHEMBL.COMPOUND:CHEMBL3137342"
-          ],
-          "id": "UNII:7SQY4ZUD30",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Dinutuximab (USAN/INN)",
-            "CH14.18",
-            "Dinutuximab",
-            "Dinutuximab beta",
-            "dinutuximab",
-            "DINUTUXIMAB",
-            "ch14.18-UTC"
-          ],
-          "all_categories": [
-            "biolink:Protein",
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:24295643",
-            "PMID:1988079",
-            "PMID:25940913",
-            "PMID:15923178"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316327,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005072",
-              "name": "neuroblastoma",
-              "description": "A neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.; A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51); Neuroblastoma is a solid tumor that originate in neural crest cells of the sympathetic nervous system. Most neuroblastomas originate in the abdomen, and most abdominal neuroblastomas originate in the adrenal gland. Neuroblastomas can also originate in the thorax, usually in the posterior mediastinum. [HPO:probinson]; What is neuroblastoma? Neuroblastoma is a type of cancer that forms in nerve cells called neuroblasts. Neuroblasts are immature nerve tissue. They normally turn into working nerve cells. But in neuroblastoma, they form a tumor. Neuroblastoma usually begins in the adrenal glands. You have two adrenal glands, one on top of each kidney. The adrenal glands make important hormones that help control heart rate, blood pressure, blood sugar, and the way the body reacts to stress. Neuroblastoma may also begin in the neck, chest or spinal cord. What causes neuroblastoma? Neuroblastoma is caused by mutations (changes) in genes. In most cases, the cause of the mutation is unknown. In some other cases, the mutation is passed from the parent to the child. What are the symptoms of neuroblastoma? Neuroblastoma often begins in early childhood. Sometimes it begins before a child is born.The most common symptoms are caused by the tumor pressing on nearby tissues as it grows or by cancer spreading to the bone.They include: A lump in the abdomen, neck or chest Bulging eyes Dark circles around the eyes Bone pain Swollen stomach and trouble breathing in babies Painless, bluish lumps under the skin in babies Inability to move a body part (paralysis)  How is neuroblastoma diagnosed? To diagnose neuroblastoma, your child's health care provider will do various tests and procedures, which may include: A medical history A neurological exam Imaging tests, such as x-rays, a CT scan, an ultrasound, an MRI, or an MIBG scan. In an MIBG scan, a small amount of a radioactive substance is injected into a vein. It travels through the bloodstream and attaches itself to any neuroblastoma cells. A scanner detects the cells. Blood and urine tests Biopsy, where a sample of tissue is removed and examined under a microscope Bone marrow aspiration and biopsy, where bone marrow, blood, and a small piece of bone are removed for testing  What are the treatments for neuroblastoma? The treatments for neuroblastoma include: Observation, also called watchful waiting, where the health care provider does not give any treatments until your child's signs or symptoms appear or change Surgery Radiation therapy Chemotherapy High-dose chemotherapy and radiation therapy with stem cell rescue. Your child will get high doses of chemotherapy and radiation. This kills the cancer cells, but it also kills healthy cells. So your child will get a stem cell transplant, usually of his or her own cells collected earlier. This helps to replace the healthy cells that were lost. Iodine 131-MIBG therapy, a treatment with radioactive iodine. The radioactive iodine collects in neuroblastoma cells and kills them with the radiation that is given off. Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0005072",
-                "UMLS:C0700095",
-                "MEDDRA:10029260",
-                "ORPHANET:635",
-                "UMLS:C0027819",
-                "UMLS:CN205405",
-                "EFO:0000621",
-                "DOID:769",
-                "MESH:D009447",
-                "NCIT:C3270",
-                "SNOMEDCT:432328008",
-                "DOID:0080906",
-                "HP:0003006",
-                "PDQ:CDR0000042067",
-                "MONDO:0859597",
-                "MEDDRA:10029261",
-                "SNOMEDCT:87364003"
-              ],
-              "id": "MONDO:0005072",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Central neuroblastoma",
-                "CNS neuroblastoma with FOXR2 activation",
-                "neuroblastoma",
-                "cns neuroblastoma with FOXR2 activation",
-                "Neuroblastoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:32903387",
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7350623/",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.cancer.gov/cancertopics/types/neuroblastoma",
-                "https://link.springer.com/article/10.1007%2fs10014-020-00370-2"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21555579,
-            "start": 619,
-            "end": 316327,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32342128': {'publication date': '2020 Apr 27', 'sentence': \"Patients' NK cell stimulation with activated plasmacytoid dendritic cells increases dinutuximab-induced neuroblastoma killing.\", 'subject score': 851, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0281581---SEMMEDDB:causes---None---None---None---UMLS:C0027819---SEMMEDDB:"
-              ],
-              "subject": "UNII:7SQY4ZUD30",
-              "id": "21974466",
-              "object": "MONDO:0005072",
-              "publications": [
-                "PMID:32342128"
-              ]
-            }
-          },
-          "end": {
-            "identity": 619,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "DINUTUXIMAB",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.",
-              "equivalent_curies": [
-                "UMLS:C0281581",
-                "GTOPDB:7979",
-                "CHEMBL.COMPOUND:CHEMBL2109420",
-                "RXNORM:1606274",
-                "KEGG.DRUG:D10559",
-                "UNII:7SQY4ZUD30",
-                "DrugCentral:4948",
-                "NCIT:C1570",
-                "UMLS:C4722567",
-                "MESH:C112746",
-                "DRUGBANK:DB09077",
-                "CHEMBL.COMPOUND:CHEMBL3137342"
-              ],
-              "id": "UNII:7SQY4ZUD30",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Dinutuximab (USAN/INN)",
-                "CH14.18",
-                "Dinutuximab",
-                "Dinutuximab beta",
-                "dinutuximab",
-                "DINUTUXIMAB",
-                "ch14.18-UTC"
-              ],
-              "all_categories": [
-                "biolink:Protein",
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:24295643",
-                "PMID:1988079",
-                "PMID:25940913",
-                "PMID:15923178"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:9626218': {'publication date': '1998 Jun', 'sentence': 'Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.', 'subject score': 767, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319663,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002629",
-          "name": "bone osteosarcoma",
-          "description": "A usually aggressive malignant bone-forming mesenchymal neoplasm, predominantly affecting adolescents and young adults. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus). Pain with or without a palpable mass is the most frequent clinical symptom. It may spread to other anatomic sites, particularly the lungs.; A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed); A malignant bone tumor that usually develops during adolescence and usually affects the long bones including the tibia, femur, and humerus. The typical symptoms of osteosarcoma comprise bone pain, fracture, limitation of motion, and tenderness or swelling at the site of the tumor. [HPO:probinson]; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0002629",
-            "UMLS:C0029463",
-            "SNOMEDCT:1163405004",
-            "ORPHANET:668",
-            "MESH:D012516",
-            "MEDDRA:10031244",
-            "OMIM:259500",
-            "SNOMEDCT:307576001",
-            "SNOMEDCT:21708004",
-            "PDQ:CDR0000041729",
-            "UMLS:C0585442",
-            "MEDDRA:10031295",
-            "NCIT:C9145",
-            "HP:0002669",
-            "MEDDRA:10039496",
-            "DOID:3376",
-            "EFO:0000637",
-            "MEDDRA:10031291",
-            "NCIT:C53707"
-          ],
-          "id": "MONDO:0002629",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bone Osteosarcoma",
-            "osteosarcoma",
-            "Osteosarcoma of bone",
-            "Osteosarcoma",
-            "Osteogenic sarcoma related phenotypic feature",
-            "bone osteosarcoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 619,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "DINUTUXIMAB",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.",
-          "equivalent_curies": [
-            "UMLS:C0281581",
-            "GTOPDB:7979",
-            "CHEMBL.COMPOUND:CHEMBL2109420",
-            "RXNORM:1606274",
-            "KEGG.DRUG:D10559",
-            "UNII:7SQY4ZUD30",
-            "DrugCentral:4948",
-            "NCIT:C1570",
-            "UMLS:C4722567",
-            "MESH:C112746",
-            "DRUGBANK:DB09077",
-            "CHEMBL.COMPOUND:CHEMBL3137342"
-          ],
-          "id": "UNII:7SQY4ZUD30",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Dinutuximab (USAN/INN)",
-            "CH14.18",
-            "Dinutuximab",
-            "Dinutuximab beta",
-            "dinutuximab",
-            "DINUTUXIMAB",
-            "ch14.18-UTC"
-          ],
-          "all_categories": [
-            "biolink:Protein",
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:24295643",
-            "PMID:1988079",
-            "PMID:25940913",
-            "PMID:15923178"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319663,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002629",
-              "name": "bone osteosarcoma",
-              "description": "A usually aggressive malignant bone-forming mesenchymal neoplasm, predominantly affecting adolescents and young adults. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus). Pain with or without a palpable mass is the most frequent clinical symptom. It may spread to other anatomic sites, particularly the lungs.; A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed); A malignant bone tumor that usually develops during adolescence and usually affects the long bones including the tibia, femur, and humerus. The typical symptoms of osteosarcoma comprise bone pain, fracture, limitation of motion, and tenderness or swelling at the site of the tumor. [HPO:probinson]; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0002629",
-                "UMLS:C0029463",
-                "SNOMEDCT:1163405004",
-                "ORPHANET:668",
-                "MESH:D012516",
-                "MEDDRA:10031244",
-                "OMIM:259500",
-                "SNOMEDCT:307576001",
-                "SNOMEDCT:21708004",
-                "PDQ:CDR0000041729",
-                "UMLS:C0585442",
-                "MEDDRA:10031295",
-                "NCIT:C9145",
-                "HP:0002669",
-                "MEDDRA:10039496",
-                "DOID:3376",
-                "EFO:0000637",
-                "MEDDRA:10031291",
-                "NCIT:C53707"
-              ],
-              "id": "MONDO:0002629",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bone Osteosarcoma",
-                "osteosarcoma",
-                "Osteosarcoma of bone",
-                "Osteosarcoma",
-                "Osteogenic sarcoma related phenotypic feature",
-                "bone osteosarcoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 27137763,
-            "start": 619,
-            "end": 319663,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9626218': {'publication date': '1998 Jun', 'sentence': 'Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.', 'subject score': 767, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0281581---SEMMEDDB:treats---None---None---None---UMLS:C0029463---SEMMEDDB:"
-              ],
-              "subject": "UNII:7SQY4ZUD30",
-              "id": "27610972",
-              "object": "MONDO:0002629",
-              "publications": [
-                "PMID:9626218"
-              ]
-            }
-          },
-          "end": {
-            "identity": 619,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "DINUTUXIMAB",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.",
-              "equivalent_curies": [
-                "UMLS:C0281581",
-                "GTOPDB:7979",
-                "CHEMBL.COMPOUND:CHEMBL2109420",
-                "RXNORM:1606274",
-                "KEGG.DRUG:D10559",
-                "UNII:7SQY4ZUD30",
-                "DrugCentral:4948",
-                "NCIT:C1570",
-                "UMLS:C4722567",
-                "MESH:C112746",
-                "DRUGBANK:DB09077",
-                "CHEMBL.COMPOUND:CHEMBL3137342"
-              ],
-              "id": "UNII:7SQY4ZUD30",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Dinutuximab (USAN/INN)",
-                "CH14.18",
-                "Dinutuximab",
-                "Dinutuximab beta",
-                "dinutuximab",
-                "DINUTUXIMAB",
-                "ch14.18-UTC"
-              ],
-              "all_categories": [
-                "biolink:Protein",
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:24295643",
-                "PMID:1988079",
-                "PMID:25940913",
-                "PMID:15923178"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:33572900': {'publication date': '2021 Jan 29', 'sentence': 'In summary, our data provide evidence that dinutuximab might be effective in tumors with high GD2 expression.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 619,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "DINUTUXIMAB",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.",
-          "equivalent_curies": [
-            "UMLS:C0281581",
-            "GTOPDB:7979",
-            "CHEMBL.COMPOUND:CHEMBL2109420",
-            "RXNORM:1606274",
-            "KEGG.DRUG:D10559",
-            "UNII:7SQY4ZUD30",
-            "DrugCentral:4948",
-            "NCIT:C1570",
-            "UMLS:C4722567",
-            "MESH:C112746",
-            "DRUGBANK:DB09077",
-            "CHEMBL.COMPOUND:CHEMBL3137342"
-          ],
-          "id": "UNII:7SQY4ZUD30",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Dinutuximab (USAN/INN)",
-            "CH14.18",
-            "Dinutuximab",
-            "Dinutuximab beta",
-            "dinutuximab",
-            "DINUTUXIMAB",
-            "ch14.18-UTC"
-          ],
-          "all_categories": [
-            "biolink:Protein",
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:24295643",
-            "PMID:1988079",
-            "PMID:25940913",
-            "PMID:15923178"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22592341,
-            "start": 619,
-            "end": 319673,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:33572900': {'publication date': '2021 Jan 29', 'sentence': 'In summary, our data provide evidence that dinutuximab might be effective in tumors with high GD2 expression.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0281581---SEMMEDDB:associated_with---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "UNII:7SQY4ZUD30",
-              "id": "23020953",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:33572900"
-              ]
-            }
-          },
-          "end": {
-            "identity": 619,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "DINUTUXIMAB",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.",
-              "equivalent_curies": [
-                "UMLS:C0281581",
-                "GTOPDB:7979",
-                "CHEMBL.COMPOUND:CHEMBL2109420",
-                "RXNORM:1606274",
-                "KEGG.DRUG:D10559",
-                "UNII:7SQY4ZUD30",
-                "DrugCentral:4948",
-                "NCIT:C1570",
-                "UMLS:C4722567",
-                "MESH:C112746",
-                "DRUGBANK:DB09077",
-                "CHEMBL.COMPOUND:CHEMBL3137342"
-              ],
-              "id": "UNII:7SQY4ZUD30",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Dinutuximab (USAN/INN)",
-                "CH14.18",
-                "Dinutuximab",
-                "Dinutuximab beta",
-                "dinutuximab",
-                "DINUTUXIMAB",
-                "ch14.18-UTC"
-              ],
-              "all_categories": [
-                "biolink:Protein",
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:24295643",
-                "PMID:1988079",
-                "PMID:25940913",
-                "PMID:15923178"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:32096344': {'publication date': '2020 Feb 24', 'sentence': 'Tumors treated with local dinutuximab had decreased MYCN expression on histology compared to control or IgG-treated tumors.', 'subject score': 888, 'object score': 1000}, 'PMID:35483745': {'publication date': '2022 Apr', 'sentence': 'Moreover, to determine whether pharmacologic inhibition of sEV secretion sensitizes tumors to dinutuximab treatment, we combined dinutuximab with tipifarnib, a farnesyltransferase inhibitor that inhibits sEV secretion.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 619,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "DINUTUXIMAB",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.",
-          "equivalent_curies": [
-            "UMLS:C0281581",
-            "GTOPDB:7979",
-            "CHEMBL.COMPOUND:CHEMBL2109420",
-            "RXNORM:1606274",
-            "KEGG.DRUG:D10559",
-            "UNII:7SQY4ZUD30",
-            "DrugCentral:4948",
-            "NCIT:C1570",
-            "UMLS:C4722567",
-            "MESH:C112746",
-            "DRUGBANK:DB09077",
-            "CHEMBL.COMPOUND:CHEMBL3137342"
-          ],
-          "id": "UNII:7SQY4ZUD30",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Dinutuximab (USAN/INN)",
-            "CH14.18",
-            "Dinutuximab",
-            "Dinutuximab beta",
-            "dinutuximab",
-            "DINUTUXIMAB",
-            "ch14.18-UTC"
-          ],
-          "all_categories": [
-            "biolink:Protein",
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:24295643",
-            "PMID:1988079",
-            "PMID:25940913",
-            "PMID:15923178"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21323908,
-            "start": 619,
-            "end": 319673,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32096344': {'publication date': '2020 Feb 24', 'sentence': 'Tumors treated with local dinutuximab had decreased MYCN expression on histology compared to control or IgG-treated tumors.', 'subject score': 888, 'object score': 1000}, 'PMID:35483745': {'publication date': '2022 Apr', 'sentence': 'Moreover, to determine whether pharmacologic inhibition of sEV secretion sensitizes tumors to dinutuximab treatment, we combined dinutuximab with tipifarnib, a farnesyltransferase inhibitor that inhibits sEV secretion.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0281581---SEMMEDDB:treats---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "UNII:7SQY4ZUD30",
-              "id": "21740095",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:32096344",
-                "PMID:35483745"
-              ]
-            }
-          },
-          "end": {
-            "identity": 619,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "DINUTUXIMAB",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.",
-              "equivalent_curies": [
-                "UMLS:C0281581",
-                "GTOPDB:7979",
-                "CHEMBL.COMPOUND:CHEMBL2109420",
-                "RXNORM:1606274",
-                "KEGG.DRUG:D10559",
-                "UNII:7SQY4ZUD30",
-                "DrugCentral:4948",
-                "NCIT:C1570",
-                "UMLS:C4722567",
-                "MESH:C112746",
-                "DRUGBANK:DB09077",
-                "CHEMBL.COMPOUND:CHEMBL3137342"
-              ],
-              "id": "UNII:7SQY4ZUD30",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Dinutuximab (USAN/INN)",
-                "CH14.18",
-                "Dinutuximab",
-                "Dinutuximab beta",
-                "dinutuximab",
-                "DINUTUXIMAB",
-                "ch14.18-UTC"
-              ],
-              "all_categories": [
-                "biolink:Protein",
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:24295643",
-                "PMID:1988079",
-                "PMID:25940913",
-                "PMID:15923178"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:16568495': {'publication date': '2006 May', 'sentence': 'The mouse/human chimeric anti-GD2 mAb ch14.18 is already applied in melanoma and neuroblastoma trials as a passive immunotherapy.', 'subject score': 760, 'object score': 872}, 'PMID:24055592': {'publication date': '2013 Dec 15', 'sentence': 'Human/mouse chimeric monoclonal antibody (mAb) ch14.18 is directed against disialoganglioside GD2 and has demonstrated activity and efficacy in high-risk neuroblastoma (NB).', 'subject score': 852, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 316327,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005072",
-          "name": "neuroblastoma",
-          "description": "A neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.; A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51); Neuroblastoma is a solid tumor that originate in neural crest cells of the sympathetic nervous system. Most neuroblastomas originate in the abdomen, and most abdominal neuroblastomas originate in the adrenal gland. Neuroblastomas can also originate in the thorax, usually in the posterior mediastinum. [HPO:probinson]; What is neuroblastoma? Neuroblastoma is a type of cancer that forms in nerve cells called neuroblasts. Neuroblasts are immature nerve tissue. They normally turn into working nerve cells. But in neuroblastoma, they form a tumor. Neuroblastoma usually begins in the adrenal glands. You have two adrenal glands, one on top of each kidney. The adrenal glands make important hormones that help control heart rate, blood pressure, blood sugar, and the way the body reacts to stress. Neuroblastoma may also begin in the neck, chest or spinal cord. What causes neuroblastoma? Neuroblastoma is caused by mutations (changes) in genes. In most cases, the cause of the mutation is unknown. In some other cases, the mutation is passed from the parent to the child. What are the symptoms of neuroblastoma? Neuroblastoma often begins in early childhood. Sometimes it begins before a child is born.The most common symptoms are caused by the tumor pressing on nearby tissues as it grows or by cancer spreading to the bone.They include: A lump in the abdomen, neck or chest Bulging eyes Dark circles around the eyes Bone pain Swollen stomach and trouble breathing in babies Painless, bluish lumps under the skin in babies Inability to move a body part (paralysis)  How is neuroblastoma diagnosed? To diagnose neuroblastoma, your child's health care provider will do various tests and procedures, which may include: A medical history A neurological exam Imaging tests, such as x-rays, a CT scan, an ultrasound, an MRI, or an MIBG scan. In an MIBG scan, a small amount of a radioactive substance is injected into a vein. It travels through the bloodstream and attaches itself to any neuroblastoma cells. A scanner detects the cells. Blood and urine tests Biopsy, where a sample of tissue is removed and examined under a microscope Bone marrow aspiration and biopsy, where bone marrow, blood, and a small piece of bone are removed for testing  What are the treatments for neuroblastoma? The treatments for neuroblastoma include: Observation, also called watchful waiting, where the health care provider does not give any treatments until your child's signs or symptoms appear or change Surgery Radiation therapy Chemotherapy High-dose chemotherapy and radiation therapy with stem cell rescue. Your child will get high doses of chemotherapy and radiation. This kills the cancer cells, but it also kills healthy cells. So your child will get a stem cell transplant, usually of his or her own cells collected earlier. This helps to replace the healthy cells that were lost. Iodine 131-MIBG therapy, a treatment with radioactive iodine. The radioactive iodine collects in neuroblastoma cells and kills them with the radiation that is given off. Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0005072",
-            "UMLS:C0700095",
-            "MEDDRA:10029260",
-            "ORPHANET:635",
-            "UMLS:C0027819",
-            "UMLS:CN205405",
-            "EFO:0000621",
-            "DOID:769",
-            "MESH:D009447",
-            "NCIT:C3270",
-            "SNOMEDCT:432328008",
-            "DOID:0080906",
-            "HP:0003006",
-            "PDQ:CDR0000042067",
-            "MONDO:0859597",
-            "MEDDRA:10029261",
-            "SNOMEDCT:87364003"
-          ],
-          "id": "MONDO:0005072",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Central neuroblastoma",
-            "CNS neuroblastoma with FOXR2 activation",
-            "neuroblastoma",
-            "cns neuroblastoma with FOXR2 activation",
-            "Neuroblastoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:32903387",
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7350623/",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.cancer.gov/cancertopics/types/neuroblastoma",
-            "https://link.springer.com/article/10.1007%2fs10014-020-00370-2"
-          ]
-        }
-      },
-      "end": {
-        "identity": 619,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "DINUTUXIMAB",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.",
-          "equivalent_curies": [
-            "UMLS:C0281581",
-            "GTOPDB:7979",
-            "CHEMBL.COMPOUND:CHEMBL2109420",
-            "RXNORM:1606274",
-            "KEGG.DRUG:D10559",
-            "UNII:7SQY4ZUD30",
-            "DrugCentral:4948",
-            "NCIT:C1570",
-            "UMLS:C4722567",
-            "MESH:C112746",
-            "DRUGBANK:DB09077",
-            "CHEMBL.COMPOUND:CHEMBL3137342"
-          ],
-          "id": "UNII:7SQY4ZUD30",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Dinutuximab (USAN/INN)",
-            "CH14.18",
-            "Dinutuximab",
-            "Dinutuximab beta",
-            "dinutuximab",
-            "DINUTUXIMAB",
-            "ch14.18-UTC"
-          ],
-          "all_categories": [
-            "biolink:Protein",
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:24295643",
-            "PMID:1988079",
-            "PMID:25940913",
-            "PMID:15923178"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316327,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005072",
-              "name": "neuroblastoma",
-              "description": "A neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.; A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51); Neuroblastoma is a solid tumor that originate in neural crest cells of the sympathetic nervous system. Most neuroblastomas originate in the abdomen, and most abdominal neuroblastomas originate in the adrenal gland. Neuroblastomas can also originate in the thorax, usually in the posterior mediastinum. [HPO:probinson]; What is neuroblastoma? Neuroblastoma is a type of cancer that forms in nerve cells called neuroblasts. Neuroblasts are immature nerve tissue. They normally turn into working nerve cells. But in neuroblastoma, they form a tumor. Neuroblastoma usually begins in the adrenal glands. You have two adrenal glands, one on top of each kidney. The adrenal glands make important hormones that help control heart rate, blood pressure, blood sugar, and the way the body reacts to stress. Neuroblastoma may also begin in the neck, chest or spinal cord. What causes neuroblastoma? Neuroblastoma is caused by mutations (changes) in genes. In most cases, the cause of the mutation is unknown. In some other cases, the mutation is passed from the parent to the child. What are the symptoms of neuroblastoma? Neuroblastoma often begins in early childhood. Sometimes it begins before a child is born.The most common symptoms are caused by the tumor pressing on nearby tissues as it grows or by cancer spreading to the bone.They include: A lump in the abdomen, neck or chest Bulging eyes Dark circles around the eyes Bone pain Swollen stomach and trouble breathing in babies Painless, bluish lumps under the skin in babies Inability to move a body part (paralysis)  How is neuroblastoma diagnosed? To diagnose neuroblastoma, your child's health care provider will do various tests and procedures, which may include: A medical history A neurological exam Imaging tests, such as x-rays, a CT scan, an ultrasound, an MRI, or an MIBG scan. In an MIBG scan, a small amount of a radioactive substance is injected into a vein. It travels through the bloodstream and attaches itself to any neuroblastoma cells. A scanner detects the cells. Blood and urine tests Biopsy, where a sample of tissue is removed and examined under a microscope Bone marrow aspiration and biopsy, where bone marrow, blood, and a small piece of bone are removed for testing  What are the treatments for neuroblastoma? The treatments for neuroblastoma include: Observation, also called watchful waiting, where the health care provider does not give any treatments until your child's signs or symptoms appear or change Surgery Radiation therapy Chemotherapy High-dose chemotherapy and radiation therapy with stem cell rescue. Your child will get high doses of chemotherapy and radiation. This kills the cancer cells, but it also kills healthy cells. So your child will get a stem cell transplant, usually of his or her own cells collected earlier. This helps to replace the healthy cells that were lost. Iodine 131-MIBG therapy, a treatment with radioactive iodine. The radioactive iodine collects in neuroblastoma cells and kills them with the radiation that is given off. Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0005072",
-                "UMLS:C0700095",
-                "MEDDRA:10029260",
-                "ORPHANET:635",
-                "UMLS:C0027819",
-                "UMLS:CN205405",
-                "EFO:0000621",
-                "DOID:769",
-                "MESH:D009447",
-                "NCIT:C3270",
-                "SNOMEDCT:432328008",
-                "DOID:0080906",
-                "HP:0003006",
-                "PDQ:CDR0000042067",
-                "MONDO:0859597",
-                "MEDDRA:10029261",
-                "SNOMEDCT:87364003"
-              ],
-              "id": "MONDO:0005072",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Central neuroblastoma",
-                "CNS neuroblastoma with FOXR2 activation",
-                "neuroblastoma",
-                "cns neuroblastoma with FOXR2 activation",
-                "Neuroblastoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:32903387",
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7350623/",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.cancer.gov/cancertopics/types/neuroblastoma",
-                "https://link.springer.com/article/10.1007%2fs10014-020-00370-2"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 12121686,
-            "start": 619,
-            "end": 316327,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16568495': {'publication date': '2006 May', 'sentence': 'The mouse/human chimeric anti-GD2 mAb ch14.18 is already applied in melanoma and neuroblastoma trials as a passive immunotherapy.', 'subject score': 760, 'object score': 872}, 'PMID:24055592': {'publication date': '2013 Dec 15', 'sentence': 'Human/mouse chimeric monoclonal antibody (mAb) ch14.18 is directed against disialoganglioside GD2 and has demonstrated activity and efficacy in high-risk neuroblastoma (NB).', 'subject score': 852, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0281581---SEMMEDDB:associated_with---None---None---None---UMLS:C0027819---SEMMEDDB:"
-              ],
-              "subject": "UNII:7SQY4ZUD30",
-              "id": "12385638",
-              "object": "MONDO:0005072",
-              "publications": [
-                "PMID:16568495",
-                "PMID:24055592"
-              ]
-            }
-          },
-          "end": {
-            "identity": 619,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "DINUTUXIMAB",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.",
-              "equivalent_curies": [
-                "UMLS:C0281581",
-                "GTOPDB:7979",
-                "CHEMBL.COMPOUND:CHEMBL2109420",
-                "RXNORM:1606274",
-                "KEGG.DRUG:D10559",
-                "UNII:7SQY4ZUD30",
-                "DrugCentral:4948",
-                "NCIT:C1570",
-                "UMLS:C4722567",
-                "MESH:C112746",
-                "DRUGBANK:DB09077",
-                "CHEMBL.COMPOUND:CHEMBL3137342"
-              ],
-              "id": "UNII:7SQY4ZUD30",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Dinutuximab (USAN/INN)",
-                "CH14.18",
-                "Dinutuximab",
-                "Dinutuximab beta",
-                "dinutuximab",
-                "DINUTUXIMAB",
-                "ch14.18-UTC"
-              ],
-              "all_categories": [
-                "biolink:Protein",
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:24295643",
-                "PMID:1988079",
-                "PMID:25940913",
-                "PMID:15923178"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:32342128': {'publication date': '2020 Apr 27', 'sentence': \"Patients' NK cell stimulation with activated plasmacytoid dendritic cells increases dinutuximab-induced neuroblastoma killing.\", 'subject score': 851, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 316327,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005072",
-          "name": "neuroblastoma",
-          "description": "A neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.; A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51); Neuroblastoma is a solid tumor that originate in neural crest cells of the sympathetic nervous system. Most neuroblastomas originate in the abdomen, and most abdominal neuroblastomas originate in the adrenal gland. Neuroblastomas can also originate in the thorax, usually in the posterior mediastinum. [HPO:probinson]; What is neuroblastoma? Neuroblastoma is a type of cancer that forms in nerve cells called neuroblasts. Neuroblasts are immature nerve tissue. They normally turn into working nerve cells. But in neuroblastoma, they form a tumor. Neuroblastoma usually begins in the adrenal glands. You have two adrenal glands, one on top of each kidney. The adrenal glands make important hormones that help control heart rate, blood pressure, blood sugar, and the way the body reacts to stress. Neuroblastoma may also begin in the neck, chest or spinal cord. What causes neuroblastoma? Neuroblastoma is caused by mutations (changes) in genes. In most cases, the cause of the mutation is unknown. In some other cases, the mutation is passed from the parent to the child. What are the symptoms of neuroblastoma? Neuroblastoma often begins in early childhood. Sometimes it begins before a child is born.The most common symptoms are caused by the tumor pressing on nearby tissues as it grows or by cancer spreading to the bone.They include: A lump in the abdomen, neck or chest Bulging eyes Dark circles around the eyes Bone pain Swollen stomach and trouble breathing in babies Painless, bluish lumps under the skin in babies Inability to move a body part (paralysis)  How is neuroblastoma diagnosed? To diagnose neuroblastoma, your child's health care provider will do various tests and procedures, which may include: A medical history A neurological exam Imaging tests, such as x-rays, a CT scan, an ultrasound, an MRI, or an MIBG scan. In an MIBG scan, a small amount of a radioactive substance is injected into a vein. It travels through the bloodstream and attaches itself to any neuroblastoma cells. A scanner detects the cells. Blood and urine tests Biopsy, where a sample of tissue is removed and examined under a microscope Bone marrow aspiration and biopsy, where bone marrow, blood, and a small piece of bone are removed for testing  What are the treatments for neuroblastoma? The treatments for neuroblastoma include: Observation, also called watchful waiting, where the health care provider does not give any treatments until your child's signs or symptoms appear or change Surgery Radiation therapy Chemotherapy High-dose chemotherapy and radiation therapy with stem cell rescue. Your child will get high doses of chemotherapy and radiation. This kills the cancer cells, but it also kills healthy cells. So your child will get a stem cell transplant, usually of his or her own cells collected earlier. This helps to replace the healthy cells that were lost. Iodine 131-MIBG therapy, a treatment with radioactive iodine. The radioactive iodine collects in neuroblastoma cells and kills them with the radiation that is given off. Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0005072",
-            "UMLS:C0700095",
-            "MEDDRA:10029260",
-            "ORPHANET:635",
-            "UMLS:C0027819",
-            "UMLS:CN205405",
-            "EFO:0000621",
-            "DOID:769",
-            "MESH:D009447",
-            "NCIT:C3270",
-            "SNOMEDCT:432328008",
-            "DOID:0080906",
-            "HP:0003006",
-            "PDQ:CDR0000042067",
-            "MONDO:0859597",
-            "MEDDRA:10029261",
-            "SNOMEDCT:87364003"
-          ],
-          "id": "MONDO:0005072",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Central neuroblastoma",
-            "CNS neuroblastoma with FOXR2 activation",
-            "neuroblastoma",
-            "cns neuroblastoma with FOXR2 activation",
-            "Neuroblastoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:32903387",
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7350623/",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.cancer.gov/cancertopics/types/neuroblastoma",
-            "https://link.springer.com/article/10.1007%2fs10014-020-00370-2"
-          ]
-        }
-      },
-      "end": {
-        "identity": 619,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "DINUTUXIMAB",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.",
-          "equivalent_curies": [
-            "UMLS:C0281581",
-            "GTOPDB:7979",
-            "CHEMBL.COMPOUND:CHEMBL2109420",
-            "RXNORM:1606274",
-            "KEGG.DRUG:D10559",
-            "UNII:7SQY4ZUD30",
-            "DrugCentral:4948",
-            "NCIT:C1570",
-            "UMLS:C4722567",
-            "MESH:C112746",
-            "DRUGBANK:DB09077",
-            "CHEMBL.COMPOUND:CHEMBL3137342"
-          ],
-          "id": "UNII:7SQY4ZUD30",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Dinutuximab (USAN/INN)",
-            "CH14.18",
-            "Dinutuximab",
-            "Dinutuximab beta",
-            "dinutuximab",
-            "DINUTUXIMAB",
-            "ch14.18-UTC"
-          ],
-          "all_categories": [
-            "biolink:Protein",
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:24295643",
-            "PMID:1988079",
-            "PMID:25940913",
-            "PMID:15923178"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316327,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005072",
-              "name": "neuroblastoma",
-              "description": "A neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.; A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51); Neuroblastoma is a solid tumor that originate in neural crest cells of the sympathetic nervous system. Most neuroblastomas originate in the abdomen, and most abdominal neuroblastomas originate in the adrenal gland. Neuroblastomas can also originate in the thorax, usually in the posterior mediastinum. [HPO:probinson]; What is neuroblastoma? Neuroblastoma is a type of cancer that forms in nerve cells called neuroblasts. Neuroblasts are immature nerve tissue. They normally turn into working nerve cells. But in neuroblastoma, they form a tumor. Neuroblastoma usually begins in the adrenal glands. You have two adrenal glands, one on top of each kidney. The adrenal glands make important hormones that help control heart rate, blood pressure, blood sugar, and the way the body reacts to stress. Neuroblastoma may also begin in the neck, chest or spinal cord. What causes neuroblastoma? Neuroblastoma is caused by mutations (changes) in genes. In most cases, the cause of the mutation is unknown. In some other cases, the mutation is passed from the parent to the child. What are the symptoms of neuroblastoma? Neuroblastoma often begins in early childhood. Sometimes it begins before a child is born.The most common symptoms are caused by the tumor pressing on nearby tissues as it grows or by cancer spreading to the bone.They include: A lump in the abdomen, neck or chest Bulging eyes Dark circles around the eyes Bone pain Swollen stomach and trouble breathing in babies Painless, bluish lumps under the skin in babies Inability to move a body part (paralysis)  How is neuroblastoma diagnosed? To diagnose neuroblastoma, your child's health care provider will do various tests and procedures, which may include: A medical history A neurological exam Imaging tests, such as x-rays, a CT scan, an ultrasound, an MRI, or an MIBG scan. In an MIBG scan, a small amount of a radioactive substance is injected into a vein. It travels through the bloodstream and attaches itself to any neuroblastoma cells. A scanner detects the cells. Blood and urine tests Biopsy, where a sample of tissue is removed and examined under a microscope Bone marrow aspiration and biopsy, where bone marrow, blood, and a small piece of bone are removed for testing  What are the treatments for neuroblastoma? The treatments for neuroblastoma include: Observation, also called watchful waiting, where the health care provider does not give any treatments until your child's signs or symptoms appear or change Surgery Radiation therapy Chemotherapy High-dose chemotherapy and radiation therapy with stem cell rescue. Your child will get high doses of chemotherapy and radiation. This kills the cancer cells, but it also kills healthy cells. So your child will get a stem cell transplant, usually of his or her own cells collected earlier. This helps to replace the healthy cells that were lost. Iodine 131-MIBG therapy, a treatment with radioactive iodine. The radioactive iodine collects in neuroblastoma cells and kills them with the radiation that is given off. Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0005072",
-                "UMLS:C0700095",
-                "MEDDRA:10029260",
-                "ORPHANET:635",
-                "UMLS:C0027819",
-                "UMLS:CN205405",
-                "EFO:0000621",
-                "DOID:769",
-                "MESH:D009447",
-                "NCIT:C3270",
-                "SNOMEDCT:432328008",
-                "DOID:0080906",
-                "HP:0003006",
-                "PDQ:CDR0000042067",
-                "MONDO:0859597",
-                "MEDDRA:10029261",
-                "SNOMEDCT:87364003"
-              ],
-              "id": "MONDO:0005072",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Central neuroblastoma",
-                "CNS neuroblastoma with FOXR2 activation",
-                "neuroblastoma",
-                "cns neuroblastoma with FOXR2 activation",
-                "Neuroblastoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:32903387",
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7350623/",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.cancer.gov/cancertopics/types/neuroblastoma",
-                "https://link.springer.com/article/10.1007%2fs10014-020-00370-2"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21555579,
-            "start": 619,
-            "end": 316327,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32342128': {'publication date': '2020 Apr 27', 'sentence': \"Patients' NK cell stimulation with activated plasmacytoid dendritic cells increases dinutuximab-induced neuroblastoma killing.\", 'subject score': 851, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C0281581---SEMMEDDB:causes---None---None---None---UMLS:C0027819---SEMMEDDB:"
-              ],
-              "subject": "UNII:7SQY4ZUD30",
-              "id": "21974466",
-              "object": "MONDO:0005072",
-              "publications": [
-                "PMID:32342128"
-              ]
-            }
-          },
-          "end": {
-            "identity": 619,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "DINUTUXIMAB",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.",
-              "equivalent_curies": [
-                "UMLS:C0281581",
-                "GTOPDB:7979",
-                "CHEMBL.COMPOUND:CHEMBL2109420",
-                "RXNORM:1606274",
-                "KEGG.DRUG:D10559",
-                "UNII:7SQY4ZUD30",
-                "DrugCentral:4948",
-                "NCIT:C1570",
-                "UMLS:C4722567",
-                "MESH:C112746",
-                "DRUGBANK:DB09077",
-                "CHEMBL.COMPOUND:CHEMBL3137342"
-              ],
-              "id": "UNII:7SQY4ZUD30",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Dinutuximab (USAN/INN)",
-                "CH14.18",
-                "Dinutuximab",
-                "Dinutuximab beta",
-                "dinutuximab",
-                "DINUTUXIMAB",
-                "ch14.18-UTC"
-              ],
-              "all_categories": [
-                "biolink:Protein",
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:24295643",
-                "PMID:1988079",
-                "PMID:25940913",
-                "PMID:15923178"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:11904735': {'publication date': '2002 Apr', 'sentence': 'Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma.', 'subject score': 760, 'object score': 1000}, 'PMID:24520328': {'publication date': '2014', 'sentence': 'Monoclonal antibodies against GD2, such as chimeric mAb ch14.18, have become benchmarks for neuroblastoma therapies.', 'subject score': 898, 'object score': 888}, 'PMID:32697811': {'publication date': '2020', 'sentence': 'Using DFMO in conjunction with dinutuximab may allow for dose escalation in neuroblastoma patients.', 'subject score': 1000, 'object score': 888}, 'PMID:33572900': {'publication date': '2021 Jan 29', 'sentence': 'Nevertheless, the only therapy targeting GD2 that is approved to date is the monoclonal antibody dinutuximab, which is used in the therapy of neuroblastoma.', 'subject score': 901, 'object score': 1000}, 'PMID:34884452': {'publication date': '2021 Nov 23', 'sentence': 'Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients.', 'subject score': 1000, 'object score': 888}, 'PMID:9626218': {'publication date': '1998 Jun', 'sentence': 'Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.', 'subject score': 767, 'object score': 888}, 'PMID:33077751': {'publication date': '2020 Oct 19', 'sentence': 'Here, we provide the first molecular-targeted fluorescent agent for FGS in pediatric oncology, by developing and preclinically evaluating a GD2-specific tracer consisting of the immunotherapeutic antibody dinutuximab-beta, recently approved for neuroblastoma treatment, conjugated to near-infrared (NIR) fluorescent dye IRDye800CW.', 'subject score': 824, 'object score': 888}, 'PMID:33363307': {'publication date': '2020 Dec', 'sentence': 'Dinutuximab beta for neuroblastoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:35454826': {'publication date': '2022 Apr 10', 'sentence': 'Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials.', 'subject score': 1000, 'object score': 1000}, 'PMID:36504394': {'publication date': '2022 Dec 12', 'sentence': 'The objective of this article was to update the clinical guide to management with dinutuximab beta of children with neuroblastoma based on the most recent published evidence and our own experience in clinical practice.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 316327,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005072",
-          "name": "neuroblastoma",
-          "description": "A neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.; A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51); Neuroblastoma is a solid tumor that originate in neural crest cells of the sympathetic nervous system. Most neuroblastomas originate in the abdomen, and most abdominal neuroblastomas originate in the adrenal gland. Neuroblastomas can also originate in the thorax, usually in the posterior mediastinum. [HPO:probinson]; What is neuroblastoma? Neuroblastoma is a type of cancer that forms in nerve cells called neuroblasts. Neuroblasts are immature nerve tissue. They normally turn into working nerve cells. But in neuroblastoma, they form a tumor. Neuroblastoma usually begins in the adrenal glands. You have two adrenal glands, one on top of each kidney. The adrenal glands make important hormones that help control heart rate, blood pressure, blood sugar, and the way the body reacts to stress. Neuroblastoma may also begin in the neck, chest or spinal cord. What causes neuroblastoma? Neuroblastoma is caused by mutations (changes) in genes. In most cases, the cause of the mutation is unknown. In some other cases, the mutation is passed from the parent to the child. What are the symptoms of neuroblastoma? Neuroblastoma often begins in early childhood. Sometimes it begins before a child is born.The most common symptoms are caused by the tumor pressing on nearby tissues as it grows or by cancer spreading to the bone.They include: A lump in the abdomen, neck or chest Bulging eyes Dark circles around the eyes Bone pain Swollen stomach and trouble breathing in babies Painless, bluish lumps under the skin in babies Inability to move a body part (paralysis)  How is neuroblastoma diagnosed? To diagnose neuroblastoma, your child's health care provider will do various tests and procedures, which may include: A medical history A neurological exam Imaging tests, such as x-rays, a CT scan, an ultrasound, an MRI, or an MIBG scan. In an MIBG scan, a small amount of a radioactive substance is injected into a vein. It travels through the bloodstream and attaches itself to any neuroblastoma cells. A scanner detects the cells. Blood and urine tests Biopsy, where a sample of tissue is removed and examined under a microscope Bone marrow aspiration and biopsy, where bone marrow, blood, and a small piece of bone are removed for testing  What are the treatments for neuroblastoma? The treatments for neuroblastoma include: Observation, also called watchful waiting, where the health care provider does not give any treatments until your child's signs or symptoms appear or change Surgery Radiation therapy Chemotherapy High-dose chemotherapy and radiation therapy with stem cell rescue. Your child will get high doses of chemotherapy and radiation. This kills the cancer cells, but it also kills healthy cells. So your child will get a stem cell transplant, usually of his or her own cells collected earlier. This helps to replace the healthy cells that were lost. Iodine 131-MIBG therapy, a treatment with radioactive iodine. The radioactive iodine collects in neuroblastoma cells and kills them with the radiation that is given off. Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0005072",
-            "UMLS:C0700095",
-            "MEDDRA:10029260",
-            "ORPHANET:635",
-            "UMLS:C0027819",
-            "UMLS:CN205405",
-            "EFO:0000621",
-            "DOID:769",
-            "MESH:D009447",
-            "NCIT:C3270",
-            "SNOMEDCT:432328008",
-            "DOID:0080906",
-            "HP:0003006",
-            "PDQ:CDR0000042067",
-            "MONDO:0859597",
-            "MEDDRA:10029261",
-            "SNOMEDCT:87364003"
-          ],
-          "id": "MONDO:0005072",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Central neuroblastoma",
-            "CNS neuroblastoma with FOXR2 activation",
-            "neuroblastoma",
-            "cns neuroblastoma with FOXR2 activation",
-            "Neuroblastoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:32903387",
-            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7350623/",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.cancer.gov/cancertopics/types/neuroblastoma",
-            "https://link.springer.com/article/10.1007%2fs10014-020-00370-2"
-          ]
-        }
-      },
-      "end": {
-        "identity": 619,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "DINUTUXIMAB",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.",
-          "equivalent_curies": [
-            "UMLS:C0281581",
-            "GTOPDB:7979",
-            "CHEMBL.COMPOUND:CHEMBL2109420",
-            "RXNORM:1606274",
-            "KEGG.DRUG:D10559",
-            "UNII:7SQY4ZUD30",
-            "DrugCentral:4948",
-            "NCIT:C1570",
-            "UMLS:C4722567",
-            "MESH:C112746",
-            "DRUGBANK:DB09077",
-            "CHEMBL.COMPOUND:CHEMBL3137342"
-          ],
-          "id": "UNII:7SQY4ZUD30",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Dinutuximab (USAN/INN)",
-            "CH14.18",
-            "Dinutuximab",
-            "Dinutuximab beta",
-            "dinutuximab",
-            "DINUTUXIMAB",
-            "ch14.18-UTC"
-          ],
-          "all_categories": [
-            "biolink:Protein",
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:24295643",
-            "PMID:1988079",
-            "PMID:25940913",
-            "PMID:15923178"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316327,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005072",
-              "name": "neuroblastoma",
-              "description": "A neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.; A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51); Neuroblastoma is a solid tumor that originate in neural crest cells of the sympathetic nervous system. Most neuroblastomas originate in the abdomen, and most abdominal neuroblastomas originate in the adrenal gland. Neuroblastomas can also originate in the thorax, usually in the posterior mediastinum. [HPO:probinson]; What is neuroblastoma? Neuroblastoma is a type of cancer that forms in nerve cells called neuroblasts. Neuroblasts are immature nerve tissue. They normally turn into working nerve cells. But in neuroblastoma, they form a tumor. Neuroblastoma usually begins in the adrenal glands. You have two adrenal glands, one on top of each kidney. The adrenal glands make important hormones that help control heart rate, blood pressure, blood sugar, and the way the body reacts to stress. Neuroblastoma may also begin in the neck, chest or spinal cord. What causes neuroblastoma? Neuroblastoma is caused by mutations (changes) in genes. In most cases, the cause of the mutation is unknown. In some other cases, the mutation is passed from the parent to the child. What are the symptoms of neuroblastoma? Neuroblastoma often begins in early childhood. Sometimes it begins before a child is born.The most common symptoms are caused by the tumor pressing on nearby tissues as it grows or by cancer spreading to the bone.They include: A lump in the abdomen, neck or chest Bulging eyes Dark circles around the eyes Bone pain Swollen stomach and trouble breathing in babies Painless, bluish lumps under the skin in babies Inability to move a body part (paralysis)  How is neuroblastoma diagnosed? To diagnose neuroblastoma, your child's health care provider will do various tests and procedures, which may include: A medical history A neurological exam Imaging tests, such as x-rays, a CT scan, an ultrasound, an MRI, or an MIBG scan. In an MIBG scan, a small amount of a radioactive substance is injected into a vein. It travels through the bloodstream and attaches itself to any neuroblastoma cells. A scanner detects the cells. Blood and urine tests Biopsy, where a sample of tissue is removed and examined under a microscope Bone marrow aspiration and biopsy, where bone marrow, blood, and a small piece of bone are removed for testing  What are the treatments for neuroblastoma? The treatments for neuroblastoma include: Observation, also called watchful waiting, where the health care provider does not give any treatments until your child's signs or symptoms appear or change Surgery Radiation therapy Chemotherapy High-dose chemotherapy and radiation therapy with stem cell rescue. Your child will get high doses of chemotherapy and radiation. This kills the cancer cells, but it also kills healthy cells. So your child will get a stem cell transplant, usually of his or her own cells collected earlier. This helps to replace the healthy cells that were lost. Iodine 131-MIBG therapy, a treatment with radioactive iodine. The radioactive iodine collects in neuroblastoma cells and kills them with the radiation that is given off. Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells  NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0005072",
-                "UMLS:C0700095",
-                "MEDDRA:10029260",
-                "ORPHANET:635",
-                "UMLS:C0027819",
-                "UMLS:CN205405",
-                "EFO:0000621",
-                "DOID:769",
-                "MESH:D009447",
-                "NCIT:C3270",
-                "SNOMEDCT:432328008",
-                "DOID:0080906",
-                "HP:0003006",
-                "PDQ:CDR0000042067",
-                "MONDO:0859597",
-                "MEDDRA:10029261",
-                "SNOMEDCT:87364003"
-              ],
-              "id": "MONDO:0005072",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Central neuroblastoma",
-                "CNS neuroblastoma with FOXR2 activation",
-                "neuroblastoma",
-                "cns neuroblastoma with FOXR2 activation",
-                "Neuroblastoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:32903387",
-                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7350623/",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.cancer.gov/cancertopics/types/neuroblastoma",
-                "https://link.springer.com/article/10.1007%2fs10014-020-00370-2"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 9241985,
-            "start": 619,
-            "end": 316327,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:11904735': {'publication date': '2002 Apr', 'sentence': 'Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma.', 'subject score': 760, 'object score': 1000}, 'PMID:24520328': {'publication date': '2014', 'sentence': 'Monoclonal antibodies against GD2, such as chimeric mAb ch14.18, have become benchmarks for neuroblastoma therapies.', 'subject score': 898, 'object score': 888}, 'PMID:32697811': {'publication date': '2020', 'sentence': 'Using DFMO in conjunction with dinutuximab may allow for dose escalation in neuroblastoma patients.', 'subject score': 1000, 'object score': 888}, 'PMID:33572900': {'publication date': '2021 Jan 29', 'sentence': 'Nevertheless, the only therapy targeting GD2 that is approved to date is the monoclonal antibody dinutuximab, which is used in the therapy of neuroblastoma.', 'subject score': 901, 'object score': 1000}, 'PMID:34884452': {'publication date': '2021 Nov 23', 'sentence': 'Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients.', 'subject score': 1000, 'object score': 888}, 'PMID:9626218': {'publication date': '1998 Jun', 'sentence': 'Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.', 'subject score': 767, 'object score': 888}, 'PMID:33077751': {'publication date': '2020 Oct 19', 'sentence': 'Here, we provide the first molecular-targeted fluorescent agent for FGS in pediatric oncology, by developing and preclinically evaluating a GD2-specific tracer consisting of the immunotherapeutic antibody dinutuximab-beta, recently approved for neuroblastoma treatment, conjugated to near-infrared (NIR) fluorescent dye IRDye800CW.', 'subject score': 824, 'object score': 888}, 'PMID:33363307': {'publication date': '2020 Dec', 'sentence': 'Dinutuximab beta for neuroblastoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:35454826': {'publication date': '2022 Apr 10', 'sentence': 'Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials.', 'subject score': 1000, 'object score': 1000}, 'PMID:36504394': {'publication date': '2022 Dec 12', 'sentence': 'The objective of this article was to update the clinical guide to management with dinutuximab beta of children with neuroblastoma based on the most recent published evidence and our own experience in clinical practice.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0281581---SEMMEDDB:treats---None---None---None---UMLS:C0027819---SEMMEDDB:",
-                "UMLS:C4722567---SEMMEDDB:treats---None---None---None---UMLS:C0027819---SEMMEDDB:"
-              ],
-              "subject": "UNII:7SQY4ZUD30",
-              "id": "9445080",
-              "object": "MONDO:0005072",
-              "publications": [
-                "PMID:36504394",
-                "PMID:33572900",
-                "PMID:11904735",
-                "PMID:9626218",
-                "PMID:34884452",
-                "PMID:33077751",
-                "PMID:24520328",
-                "PMID:33363307",
-                "PMID:35454826",
-                "PMID:32697811"
-              ]
-            }
-          },
-          "end": {
-            "identity": 619,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "DINUTUXIMAB",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.",
-              "equivalent_curies": [
-                "UMLS:C0281581",
-                "GTOPDB:7979",
-                "CHEMBL.COMPOUND:CHEMBL2109420",
-                "RXNORM:1606274",
-                "KEGG.DRUG:D10559",
-                "UNII:7SQY4ZUD30",
-                "DrugCentral:4948",
-                "NCIT:C1570",
-                "UMLS:C4722567",
-                "MESH:C112746",
-                "DRUGBANK:DB09077",
-                "CHEMBL.COMPOUND:CHEMBL3137342"
-              ],
-              "id": "UNII:7SQY4ZUD30",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Dinutuximab (USAN/INN)",
-                "CH14.18",
-                "Dinutuximab",
-                "Dinutuximab beta",
-                "dinutuximab",
-                "DINUTUXIMAB",
-                "ch14.18-UTC"
-              ],
-              "all_categories": [
-                "biolink:Protein",
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:24295643",
-                "PMID:1988079",
-                "PMID:25940913",
-                "PMID:15923178"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:31934889': {'publication date': '2020 Jan 10', 'sentence': 'Further investigations on the use of brentuximab vedotin for adult T-cell leukemia/lymphoma are needed.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 730105,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019471",
-          "name": "adult T-cell leukemia/lymphoma",
-          "description": "A peripheral (mature) T-cell neoplasm caused by the human T-cell leukemia virus type 1 (HTLV-1). Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3184\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3184\" NCI Thesaurus); A peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1). Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa.; Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.",
-          "equivalent_curies": [
-            "MEDDRA:10001412",
-            "SNOMEDCT:110007008",
-            "UMLS:C0023493",
-            "MESH:D015459",
-            "MONDO:0019471",
-            "MEDDRA:10001415",
-            "MEDDRA:10001413",
-            "ICD10:C91.5",
-            "SNOMEDCT:77430005",
-            "MEDDRA:10001414",
-            "MEDDRA:10054298",
-            "DOID:0050523",
-            "PDQ:CDR0000040694",
-            "ORPHANET:86875",
-            "NCIT:C3184"
-          ],
-          "id": "MONDO:0019471",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia-Lymphoma, Adult T-Cell",
-            "Adult T-Cell Leukemia/Lymphoma",
-            "Adult T-cell leukemia/lymphoma",
-            "Adult T-Cell Lymphoma/Leukemia",
-            "adult T-cell leukemia/lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/adult_t-cell_leukemia/lymphoma",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c3184"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 730105,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019471",
-              "name": "adult T-cell leukemia/lymphoma",
-              "description": "A peripheral (mature) T-cell neoplasm caused by the human T-cell leukemia virus type 1 (HTLV-1). Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3184\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3184\" NCI Thesaurus); A peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1). Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa.; Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.",
-              "equivalent_curies": [
-                "MEDDRA:10001412",
-                "SNOMEDCT:110007008",
-                "UMLS:C0023493",
-                "MESH:D015459",
-                "MONDO:0019471",
-                "MEDDRA:10001415",
-                "MEDDRA:10001413",
-                "ICD10:C91.5",
-                "SNOMEDCT:77430005",
-                "MEDDRA:10001414",
-                "MEDDRA:10054298",
-                "DOID:0050523",
-                "PDQ:CDR0000040694",
-                "ORPHANET:86875",
-                "NCIT:C3184"
-              ],
-              "id": "MONDO:0019471",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia-Lymphoma, Adult T-Cell",
-                "Adult T-Cell Leukemia/Lymphoma",
-                "Adult T-cell leukemia/lymphoma",
-                "Adult T-Cell Lymphoma/Leukemia",
-                "adult T-cell leukemia/lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/adult_t-cell_leukemia/lymphoma",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c3184"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21155390,
-            "start": 622,
-            "end": 730105,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31934889': {'publication date': '2020 Jan 10', 'sentence': 'Further investigations on the use of brentuximab vedotin for adult T-cell leukemia/lymphoma are needed.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:treats---None---None---None---UMLS:C0023493---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "21569598",
-              "object": "MONDO:0019471",
-              "publications": [
-                "PMID:31934889"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:32016790': {'publication date': '2020 Feb 03', 'sentence': 'In this review, we discuss key studies of BV in peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) and highlight important questions for further investigation.', 'subject score': 1000, 'object score': 1000}, 'PMID:32499905': {'publication date': '2020 May 06', 'sentence': 'Treatment strategy for ALK-ALCL is controversial, but the efficacy of BV in CD30-positive peripheral T-cell lymphoma not only as salvage regimens, but also in first line, has been reported in recent years.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 535028,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000430",
-          "name": "mature T-cell and NK-cell non-Hodgkin lymphoma",
-          "description": "A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10034624",
-            "MONDO:0000430",
-            "MEDDRA:10034623",
-            "UMLS:C1337073",
-            "MESH:D016411",
-            "UMLS:C1337074",
-            "NCIT:C27352",
-            "UMLS:C0079774",
-            "UMLS:C5551485",
-            "UMLS:C1337079",
-            "DOID:0050743",
-            "NCIT:C7204",
-            "UMLS:C0334655",
-            "NCIT:C3468",
-            "DOID:0050749",
-            "SNOMEDCT:109977009",
-            "ICD9:202.7",
-            "SNOMEDCT:1163404000",
-            "SNOMEDCT:109975001"
-          ],
-          "id": "MONDO:0000430",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peripheral T-Cell Lymphoma, Large Cell",
-            "T-Zone Variant Peripheral T-Cell Lymphoma",
-            "mature T-cell and NK-cell non-Hodgkin lymphoma",
-            "peripheral T-cell lymphoma",
-            "T-zone lymphoma (clinical)",
-            "Lymphoma, T-Cell, Peripheral",
-            "mature T-cell and NK-cell lymphoma",
-            "Peripheral T-Cell Lymphoma",
-            "Peripheral T-cell lymphoma",
-            "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:21919697",
-            "http://www.cancer.gov/dictionary?cdrid=393800",
-            "http://www.cancer.gov/dictionary?cdrid=44062",
-            "http://en.wikipedia.org/wiki/peripheral_t-cell_lymphoma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 535028,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000430",
-              "name": "mature T-cell and NK-cell non-Hodgkin lymphoma",
-              "description": "A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10034624",
-                "MONDO:0000430",
-                "MEDDRA:10034623",
-                "UMLS:C1337073",
-                "MESH:D016411",
-                "UMLS:C1337074",
-                "NCIT:C27352",
-                "UMLS:C0079774",
-                "UMLS:C5551485",
-                "UMLS:C1337079",
-                "DOID:0050743",
-                "NCIT:C7204",
-                "UMLS:C0334655",
-                "NCIT:C3468",
-                "DOID:0050749",
-                "SNOMEDCT:109977009",
-                "ICD9:202.7",
-                "SNOMEDCT:1163404000",
-                "SNOMEDCT:109975001"
-              ],
-              "id": "MONDO:0000430",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peripheral T-Cell Lymphoma, Large Cell",
-                "T-Zone Variant Peripheral T-Cell Lymphoma",
-                "mature T-cell and NK-cell non-Hodgkin lymphoma",
-                "peripheral T-cell lymphoma",
-                "T-zone lymphoma (clinical)",
-                "Lymphoma, T-Cell, Peripheral",
-                "mature T-cell and NK-cell lymphoma",
-                "Peripheral T-Cell Lymphoma",
-                "Peripheral T-cell lymphoma",
-                "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:21919697",
-                "http://www.cancer.gov/dictionary?cdrid=393800",
-                "http://www.cancer.gov/dictionary?cdrid=44062",
-                "http://en.wikipedia.org/wiki/peripheral_t-cell_lymphoma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21241846,
-            "start": 622,
-            "end": 535028,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32016790': {'publication date': '2020 Feb 03', 'sentence': 'In this review, we discuss key studies of BV in peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) and highlight important questions for further investigation.', 'subject score': 1000, 'object score': 1000}, 'PMID:32499905': {'publication date': '2020 May 06', 'sentence': 'Treatment strategy for ALK-ALCL is controversial, but the efficacy of BV in CD30-positive peripheral T-cell lymphoma not only as salvage regimens, but also in first line, has been reported in recent years.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:associated_with---None---None---None---UMLS:C0079774---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "21657994",
-              "object": "MONDO:0000430",
-              "publications": [
-                "PMID:32016790",
-                "PMID:32499905"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:has_part",
-    "r2.publications_info": "{'PMID:32448357': {'publication date': '2020 May 24', 'sentence': 'Targeting CD30+ PTCL with the antibody-drug conjugate brentuximab vedotin in the relapsed setting and in combination with chemotherapy in the frontline setting has improved patient survivals.', 'subject score': 857, 'object score': 851}}",
-    "p2": {
-      "start": {
-        "identity": 535028,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000430",
-          "name": "mature T-cell and NK-cell non-Hodgkin lymphoma",
-          "description": "A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10034624",
-            "MONDO:0000430",
-            "MEDDRA:10034623",
-            "UMLS:C1337073",
-            "MESH:D016411",
-            "UMLS:C1337074",
-            "NCIT:C27352",
-            "UMLS:C0079774",
-            "UMLS:C5551485",
-            "UMLS:C1337079",
-            "DOID:0050743",
-            "NCIT:C7204",
-            "UMLS:C0334655",
-            "NCIT:C3468",
-            "DOID:0050749",
-            "SNOMEDCT:109977009",
-            "ICD9:202.7",
-            "SNOMEDCT:1163404000",
-            "SNOMEDCT:109975001"
-          ],
-          "id": "MONDO:0000430",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peripheral T-Cell Lymphoma, Large Cell",
-            "T-Zone Variant Peripheral T-Cell Lymphoma",
-            "mature T-cell and NK-cell non-Hodgkin lymphoma",
-            "peripheral T-cell lymphoma",
-            "T-zone lymphoma (clinical)",
-            "Lymphoma, T-Cell, Peripheral",
-            "mature T-cell and NK-cell lymphoma",
-            "Peripheral T-Cell Lymphoma",
-            "Peripheral T-cell lymphoma",
-            "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:21919697",
-            "http://www.cancer.gov/dictionary?cdrid=393800",
-            "http://www.cancer.gov/dictionary?cdrid=44062",
-            "http://en.wikipedia.org/wiki/peripheral_t-cell_lymphoma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 535028,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000430",
-              "name": "mature T-cell and NK-cell non-Hodgkin lymphoma",
-              "description": "A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10034624",
-                "MONDO:0000430",
-                "MEDDRA:10034623",
-                "UMLS:C1337073",
-                "MESH:D016411",
-                "UMLS:C1337074",
-                "NCIT:C27352",
-                "UMLS:C0079774",
-                "UMLS:C5551485",
-                "UMLS:C1337079",
-                "DOID:0050743",
-                "NCIT:C7204",
-                "UMLS:C0334655",
-                "NCIT:C3468",
-                "DOID:0050749",
-                "SNOMEDCT:109977009",
-                "ICD9:202.7",
-                "SNOMEDCT:1163404000",
-                "SNOMEDCT:109975001"
-              ],
-              "id": "MONDO:0000430",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peripheral T-Cell Lymphoma, Large Cell",
-                "T-Zone Variant Peripheral T-Cell Lymphoma",
-                "mature T-cell and NK-cell non-Hodgkin lymphoma",
-                "peripheral T-cell lymphoma",
-                "T-zone lymphoma (clinical)",
-                "Lymphoma, T-Cell, Peripheral",
-                "mature T-cell and NK-cell lymphoma",
-                "Peripheral T-Cell Lymphoma",
-                "Peripheral T-cell lymphoma",
-                "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:21919697",
-                "http://www.cancer.gov/dictionary?cdrid=393800",
-                "http://www.cancer.gov/dictionary?cdrid=44062",
-                "http://en.wikipedia.org/wiki/peripheral_t-cell_lymphoma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21652169,
-            "start": 535028,
-            "end": 622,
-            "type": "biolink:has_part",
-            "properties": {
-              "predicate": "biolink:has_part",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32448357': {'publication date': '2020 May 24', 'sentence': 'Targeting CD30+ PTCL with the antibody-drug conjugate brentuximab vedotin in the relapsed setting and in combination with chemotherapy in the frontline setting has improved patient survivals.', 'subject score': 857, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:part_of---None---None---None---UMLS:C0079774---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0000430",
-              "id": "22071488",
-              "object": "UNII:7XL5ISS668",
-              "publications": [
-                "PMID:32448357"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:32016790': {'publication date': '2020 Feb 03', 'sentence': 'BV is a major therapeutic advance in the treatment of patients with R/R CTCL and of those with PTCL in both the R/R and frontline settings.', 'subject score': 1000, 'object score': 928}, 'PMID:32934797': {'publication date': '2020', 'sentence': 'Given its success and tolerability in this pretreated population, brentuximab vedotin, an anti-CD30 antibody drug conjugate, was brought earlier in the disease course and is a model for advances in the targeted treatment of PTCL.', 'subject score': 1000, 'object score': 1000}, 'PMID:34263699': {'publication date': '2021 Jul 15', 'sentence': 'Large-scale randomized, controlled studies have shown that CD30-directed treatment with brentuximab vedotin is significantly more effective against CD30-expressing PTCL and CTCL than current standard-of-care regimens.', 'subject score': 1000, 'object score': 802}, 'PMID:34427738': {'publication date': '2021 Aug 24', 'sentence': 'Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin.', 'subject score': 1000, 'object score': 1000}, 'PMID:34797505': {'publication date': '2021 Nov 19', 'sentence': 'METHODS: Analysis of a real-world, observational, retrospective case series in patients suffering from AITL, sALCL and peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH) and other types of PTCL treated with BV in frontline treatment was conducted.', 'subject score': 1000, 'object score': 1000}, 'PMID:36975736': {'publication date': '2023 Mar 22', 'sentence': 'Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma.', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 535028,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000430",
-          "name": "mature T-cell and NK-cell non-Hodgkin lymphoma",
-          "description": "A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10034624",
-            "MONDO:0000430",
-            "MEDDRA:10034623",
-            "UMLS:C1337073",
-            "MESH:D016411",
-            "UMLS:C1337074",
-            "NCIT:C27352",
-            "UMLS:C0079774",
-            "UMLS:C5551485",
-            "UMLS:C1337079",
-            "DOID:0050743",
-            "NCIT:C7204",
-            "UMLS:C0334655",
-            "NCIT:C3468",
-            "DOID:0050749",
-            "SNOMEDCT:109977009",
-            "ICD9:202.7",
-            "SNOMEDCT:1163404000",
-            "SNOMEDCT:109975001"
-          ],
-          "id": "MONDO:0000430",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peripheral T-Cell Lymphoma, Large Cell",
-            "T-Zone Variant Peripheral T-Cell Lymphoma",
-            "mature T-cell and NK-cell non-Hodgkin lymphoma",
-            "peripheral T-cell lymphoma",
-            "T-zone lymphoma (clinical)",
-            "Lymphoma, T-Cell, Peripheral",
-            "mature T-cell and NK-cell lymphoma",
-            "Peripheral T-Cell Lymphoma",
-            "Peripheral T-cell lymphoma",
-            "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:21919697",
-            "http://www.cancer.gov/dictionary?cdrid=393800",
-            "http://www.cancer.gov/dictionary?cdrid=44062",
-            "http://en.wikipedia.org/wiki/peripheral_t-cell_lymphoma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 535028,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000430",
-              "name": "mature T-cell and NK-cell non-Hodgkin lymphoma",
-              "description": "A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10034624",
-                "MONDO:0000430",
-                "MEDDRA:10034623",
-                "UMLS:C1337073",
-                "MESH:D016411",
-                "UMLS:C1337074",
-                "NCIT:C27352",
-                "UMLS:C0079774",
-                "UMLS:C5551485",
-                "UMLS:C1337079",
-                "DOID:0050743",
-                "NCIT:C7204",
-                "UMLS:C0334655",
-                "NCIT:C3468",
-                "DOID:0050749",
-                "SNOMEDCT:109977009",
-                "ICD9:202.7",
-                "SNOMEDCT:1163404000",
-                "SNOMEDCT:109975001"
-              ],
-              "id": "MONDO:0000430",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peripheral T-Cell Lymphoma, Large Cell",
-                "T-Zone Variant Peripheral T-Cell Lymphoma",
-                "mature T-cell and NK-cell non-Hodgkin lymphoma",
-                "peripheral T-cell lymphoma",
-                "T-zone lymphoma (clinical)",
-                "Lymphoma, T-Cell, Peripheral",
-                "mature T-cell and NK-cell lymphoma",
-                "Peripheral T-Cell Lymphoma",
-                "Peripheral T-cell lymphoma",
-                "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:21919697",
-                "http://www.cancer.gov/dictionary?cdrid=393800",
-                "http://www.cancer.gov/dictionary?cdrid=44062",
-                "http://en.wikipedia.org/wiki/peripheral_t-cell_lymphoma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21241843,
-            "start": 622,
-            "end": 535028,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32016790': {'publication date': '2020 Feb 03', 'sentence': 'BV is a major therapeutic advance in the treatment of patients with R/R CTCL and of those with PTCL in both the R/R and frontline settings.', 'subject score': 1000, 'object score': 928}, 'PMID:32934797': {'publication date': '2020', 'sentence': 'Given its success and tolerability in this pretreated population, brentuximab vedotin, an anti-CD30 antibody drug conjugate, was brought earlier in the disease course and is a model for advances in the targeted treatment of PTCL.', 'subject score': 1000, 'object score': 1000}, 'PMID:34263699': {'publication date': '2021 Jul 15', 'sentence': 'Large-scale randomized, controlled studies have shown that CD30-directed treatment with brentuximab vedotin is significantly more effective against CD30-expressing PTCL and CTCL than current standard-of-care regimens.', 'subject score': 1000, 'object score': 802}, 'PMID:34427738': {'publication date': '2021 Aug 24', 'sentence': 'Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin.', 'subject score': 1000, 'object score': 1000}, 'PMID:34797505': {'publication date': '2021 Nov 19', 'sentence': 'METHODS: Analysis of a real-world, observational, retrospective case series in patients suffering from AITL, sALCL and peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH) and other types of PTCL treated with BV in frontline treatment was conducted.', 'subject score': 1000, 'object score': 1000}, 'PMID:36975736': {'publication date': '2023 Mar 22', 'sentence': 'Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:treats---None---None---None---UMLS:C0079774---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "21657991",
-              "object": "MONDO:0000430",
-              "publications": [
-                "PMID:32016790",
-                "PMID:32934797",
-                "PMID:34263699",
-                "PMID:34427738",
-                "PMID:34797505",
-                "PMID:36975736"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:34507350': {'publication date': '2021 Sep 10', 'sentence': \"These final analyses confirm improved, clinically meaningful, durable responses and longer PFS with brentuximab vedotin vs physician's choice in CD30-expressing MF or C-ALCL.\", 'subject score': 1000, 'object score': 824}}",
-    "p2": {
-      "start": {
-        "identity": 535036,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009691",
-          "name": "mycosis fungoides",
-          "description": "A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei. Patients with limited disease generally have an excellent prognosis. In the more advanced stages, the prognosis is poor. (WHO, 2001); A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MESH:D009182",
-            "MEDDRA:10028483",
-            "MONDO:0009691",
-            "UMLS:C0026948",
-            "SNOMEDCT:90120004",
-            "NCIT:C3246",
-            "ICD9:202.1",
-            "OMIM:254400",
-            "ORPHANET:2584",
-            "MEDDRA:10028484",
-            "ICD10:C84.0",
-            "DOID:8691",
-            "EFO:1001051",
-            "MEDDRA:10028500",
-            "SNOMEDCT:118618005"
-          ],
-          "id": "MONDO:0009691",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Mycosis fungoides",
-            "Mycosis fungoides related phenotypic feature",
-            "Classic mycosis fungoides",
-            "mycosis fungoides",
-            "Mycosis Fungoides"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 535036,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009691",
-              "name": "mycosis fungoides",
-              "description": "A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei. Patients with limited disease generally have an excellent prognosis. In the more advanced stages, the prognosis is poor. (WHO, 2001); A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MESH:D009182",
-                "MEDDRA:10028483",
-                "MONDO:0009691",
-                "UMLS:C0026948",
-                "SNOMEDCT:90120004",
-                "NCIT:C3246",
-                "ICD9:202.1",
-                "OMIM:254400",
-                "ORPHANET:2584",
-                "MEDDRA:10028484",
-                "ICD10:C84.0",
-                "DOID:8691",
-                "EFO:1001051",
-                "MEDDRA:10028500",
-                "SNOMEDCT:118618005"
-              ],
-              "id": "MONDO:0009691",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Mycosis fungoides",
-                "Mycosis fungoides related phenotypic feature",
-                "Classic mycosis fungoides",
-                "mycosis fungoides",
-                "Mycosis Fungoides"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23295725,
-            "start": 622,
-            "end": 535036,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34507350': {'publication date': '2021 Sep 10', 'sentence': \"These final analyses confirm improved, clinically meaningful, durable responses and longer PFS with brentuximab vedotin vs physician's choice in CD30-expressing MF or C-ALCL.\", 'subject score': 1000, 'object score': 824}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:associated_with---None---None---None---UMLS:C0026948---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "23730531",
-              "object": "MONDO:0009691",
-              "publications": [
-                "PMID:34507350"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:31854457': {'publication date': '2019 Dec 19', 'sentence': 'The interest of BV in the management of CD30-positive mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma has recently been demonstrated compared to methotrexate or bexarotene.', 'subject score': 1000, 'object score': 888}, 'PMID:34137025': {'publication date': '2021 Jun 16', 'sentence': 'BACKGROUND: Brentuximab Vedotin (BV) was approved as therapy for Mycosis Fungoides (MF) based on ALCANZA trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:34854114': {'publication date': '2021 Dec 01', 'sentence': 'Treatment of mycosis fungoides with brentuximab vedotin: assessing CD30 expression by immunohistochemistry and quantitative real-time PCR.', 'subject score': 1000, 'object score': 1000}, 'PMID:35262989': {'publication date': '2022 Mar 08', 'sentence': 'Diffuse alopecia areata induced by brentuximab vedotin therapy for advanced stage mycosis fungoides.', 'subject score': 901, 'object score': 888}, 'PMID:36017748': {'publication date': '2022 Aug 26', 'sentence': 'CONCLUSIONS: These results confirm the efficacy and safety of BV in patients with advanced-stage MF, and CD30 LPD.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 535036,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009691",
-          "name": "mycosis fungoides",
-          "description": "A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei. Patients with limited disease generally have an excellent prognosis. In the more advanced stages, the prognosis is poor. (WHO, 2001); A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MESH:D009182",
-            "MEDDRA:10028483",
-            "MONDO:0009691",
-            "UMLS:C0026948",
-            "SNOMEDCT:90120004",
-            "NCIT:C3246",
-            "ICD9:202.1",
-            "OMIM:254400",
-            "ORPHANET:2584",
-            "MEDDRA:10028484",
-            "ICD10:C84.0",
-            "DOID:8691",
-            "EFO:1001051",
-            "MEDDRA:10028500",
-            "SNOMEDCT:118618005"
-          ],
-          "id": "MONDO:0009691",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Mycosis fungoides",
-            "Mycosis fungoides related phenotypic feature",
-            "Classic mycosis fungoides",
-            "mycosis fungoides",
-            "Mycosis Fungoides"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 535036,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009691",
-              "name": "mycosis fungoides",
-              "description": "A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei. Patients with limited disease generally have an excellent prognosis. In the more advanced stages, the prognosis is poor. (WHO, 2001); A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MESH:D009182",
-                "MEDDRA:10028483",
-                "MONDO:0009691",
-                "UMLS:C0026948",
-                "SNOMEDCT:90120004",
-                "NCIT:C3246",
-                "ICD9:202.1",
-                "OMIM:254400",
-                "ORPHANET:2584",
-                "MEDDRA:10028484",
-                "ICD10:C84.0",
-                "DOID:8691",
-                "EFO:1001051",
-                "MEDDRA:10028500",
-                "SNOMEDCT:118618005"
-              ],
-              "id": "MONDO:0009691",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Mycosis fungoides",
-                "Mycosis fungoides related phenotypic feature",
-                "Classic mycosis fungoides",
-                "mycosis fungoides",
-                "Mycosis Fungoides"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21048622,
-            "start": 622,
-            "end": 535036,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31854457': {'publication date': '2019 Dec 19', 'sentence': 'The interest of BV in the management of CD30-positive mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma has recently been demonstrated compared to methotrexate or bexarotene.', 'subject score': 1000, 'object score': 888}, 'PMID:34137025': {'publication date': '2021 Jun 16', 'sentence': 'BACKGROUND: Brentuximab Vedotin (BV) was approved as therapy for Mycosis Fungoides (MF) based on ALCANZA trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:34854114': {'publication date': '2021 Dec 01', 'sentence': 'Treatment of mycosis fungoides with brentuximab vedotin: assessing CD30 expression by immunohistochemistry and quantitative real-time PCR.', 'subject score': 1000, 'object score': 1000}, 'PMID:35262989': {'publication date': '2022 Mar 08', 'sentence': 'Diffuse alopecia areata induced by brentuximab vedotin therapy for advanced stage mycosis fungoides.', 'subject score': 901, 'object score': 888}, 'PMID:36017748': {'publication date': '2022 Aug 26', 'sentence': 'CONCLUSIONS: These results confirm the efficacy and safety of BV in patients with advanced-stage MF, and CD30 LPD.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:treats---None---None---None---UMLS:C0026948---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "21472937",
-              "object": "MONDO:0009691",
-              "publications": [
-                "PMID:31854457",
-                "PMID:34137025",
-                "PMID:34854114",
-                "PMID:35262989",
-                "PMID:36017748"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:34797505': {'publication date': '2021 Nov 19', 'sentence': \"INTRODUCTION: Brentuximab vedotin (BV) showed high overall remission rates in refractory/relapsed classical Hodgkin's lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL).\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 318146,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0020325",
-          "name": "anaplastic large cell lymphoma",
-          "description": "A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3720\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3720\" NCI Thesaurus); A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001); A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called \"hallmark\" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.; A type of T-cell lymphoma that is characterized by so-called hallmark cells with a pleomorphic appearance that express the CD30 antigen, are lobulated, and have indented nuclei. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0020325",
-            "UMLS:C0206180",
-            "NCIT:C3720",
-            "ICD9:200.6",
-            "SNOMEDCT:277637000",
-            "SNOMEDCT:53237008",
-            "DOID:0050744",
-            "PDQ:CDR0000042785",
-            "EFO:0003032",
-            "SNOMEDCT:702785000",
-            "MESH:D017728",
-            "ORPHANET:98841",
-            "HP:0012193",
-            "MEDDRA:10073478"
-          ],
-          "id": "MONDO:0020325",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Anaplastic Large Cell Lymphoma",
-            "Anaplastic large cell lymphoma",
-            "Lymphoma, Large-Cell, Anaplastic",
-            "Ki-1+ Anaplastic Large Cell Lymphoma",
-            "Anaplastic large-cell lymphoma",
-            "anaplastic large cell lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/anaplastic_large-cell_lymphoma#epidemiology",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318146,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0020325",
-              "name": "anaplastic large cell lymphoma",
-              "description": "A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3720\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3720\" NCI Thesaurus); A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001); A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called \"hallmark\" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.; A type of T-cell lymphoma that is characterized by so-called hallmark cells with a pleomorphic appearance that express the CD30 antigen, are lobulated, and have indented nuclei. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0020325",
-                "UMLS:C0206180",
-                "NCIT:C3720",
-                "ICD9:200.6",
-                "SNOMEDCT:277637000",
-                "SNOMEDCT:53237008",
-                "DOID:0050744",
-                "PDQ:CDR0000042785",
-                "EFO:0003032",
-                "SNOMEDCT:702785000",
-                "MESH:D017728",
-                "ORPHANET:98841",
-                "HP:0012193",
-                "MEDDRA:10073478"
-              ],
-              "id": "MONDO:0020325",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Anaplastic Large Cell Lymphoma",
-                "Anaplastic large cell lymphoma",
-                "Lymphoma, Large-Cell, Anaplastic",
-                "Ki-1+ Anaplastic Large Cell Lymphoma",
-                "Anaplastic large-cell lymphoma",
-                "anaplastic large cell lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/anaplastic_large-cell_lymphoma#epidemiology",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23483600,
-            "start": 622,
-            "end": 318146,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34797505': {'publication date': '2021 Nov 19', 'sentence': \"INTRODUCTION: Brentuximab vedotin (BV) showed high overall remission rates in refractory/relapsed classical Hodgkin's lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL).\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:associated_with---None---None---None---UMLS:C0206180---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "23929422",
-              "object": "MONDO:0020325",
-              "publications": [
-                "PMID:34797505"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 535036,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:33308986': {'publication date': '2020 Dec 10', 'sentence': '[Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma].', 'subject score': 1000, 'object score': 900}, 'PMID:33392974': {'publication date': '2021 Jan 03', 'sentence': 'Brentuximab vedotin (BV) was initially approved in Japan for the treatment of relapsed/refractory (R/R) CD30-positive Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL).', 'subject score': 1000, 'object score': 1000}, 'PMID:33604778': {'publication date': '2021 Feb 18', 'sentence': 'Correction to: Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.', 'subject score': 1000, 'object score': 1000}, 'PMID:34275403': {'publication date': '2021 Jul 19', 'sentence': 'Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:34797505': {'publication date': '2021 Nov 19', 'sentence': 'METHODS: Analysis of a real-world, observational, retrospective case series in patients suffering from AITL, sALCL and peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH) and other types of PTCL treated with BV in frontline treatment was conducted.', 'subject score': 1000, 'object score': 1000}, 'PMID:35482341': {'publication date': '2022 Apr 28', 'sentence': 'Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.', 'subject score': 1000, 'object score': 888}, 'PMID:36057890': {'publication date': '2022 Sep 04', 'sentence': 'Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin.', 'subject score': 1000, 'object score': 947}}",
-    "p2": {
-      "start": {
-        "identity": 318146,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009691",
-          "name": "mycosis fungoides",
-          "description": "A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei. Patients with limited disease generally have an excellent prognosis. In the more advanced stages, the prognosis is poor. (WHO, 2001); A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MESH:D009182",
-            "MEDDRA:10028483",
-            "MONDO:0009691",
-            "UMLS:C0026948",
-            "SNOMEDCT:90120004",
-            "NCIT:C3246",
-            "ICD9:202.1",
-            "OMIM:254400",
-            "ORPHANET:2584",
-            "MEDDRA:10028484",
-            "ICD10:C84.0",
-            "DOID:8691",
-            "EFO:1001051",
-            "MEDDRA:10028500",
-            "SNOMEDCT:118618005"
-          ],
-          "id": "MONDO:0009691",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Mycosis fungoides",
-            "Mycosis fungoides related phenotypic feature",
-            "Classic mycosis fungoides",
-            "mycosis fungoides",
-            "Mycosis Fungoides"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0020325",
-          "name": "anaplastic large cell lymphoma",
-          "description": "A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3720\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3720\" NCI Thesaurus); A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001); A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called \"hallmark\" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.; A type of T-cell lymphoma that is characterized by so-called hallmark cells with a pleomorphic appearance that express the CD30 antigen, are lobulated, and have indented nuclei. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0020325",
-            "UMLS:C0206180",
-            "NCIT:C3720",
-            "ICD9:200.6",
-            "SNOMEDCT:277637000",
-            "SNOMEDCT:53237008",
-            "DOID:0050744",
-            "PDQ:CDR0000042785",
-            "EFO:0003032",
-            "SNOMEDCT:702785000",
-            "MESH:D017728",
-            "ORPHANET:98841",
-            "HP:0012193",
-            "MEDDRA:10073478"
-          ],
-          "id": "MONDO:0020325",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Anaplastic Large Cell Lymphoma",
-            "Anaplastic large cell lymphoma",
-            "Lymphoma, Large-Cell, Anaplastic",
-            "Ki-1+ Anaplastic Large Cell Lymphoma",
-            "Anaplastic large-cell lymphoma",
-            "anaplastic large cell lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/anaplastic_large-cell_lymphoma#epidemiology",
-            "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 535036,
-=======
-            "identity": 318146,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009691",
-              "name": "mycosis fungoides",
-              "description": "A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei. Patients with limited disease generally have an excellent prognosis. In the more advanced stages, the prognosis is poor. (WHO, 2001); A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MESH:D009182",
-                "MEDDRA:10028483",
-                "MONDO:0009691",
-                "UMLS:C0026948",
-                "SNOMEDCT:90120004",
-                "NCIT:C3246",
-                "ICD9:202.1",
-                "OMIM:254400",
-                "ORPHANET:2584",
-                "MEDDRA:10028484",
-                "ICD10:C84.0",
-                "DOID:8691",
-                "EFO:1001051",
-                "MEDDRA:10028500",
-                "SNOMEDCT:118618005"
-              ],
-              "id": "MONDO:0009691",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Mycosis fungoides",
-                "Mycosis fungoides related phenotypic feature",
-                "Classic mycosis fungoides",
-                "mycosis fungoides",
-                "Mycosis Fungoides"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0020325",
-              "name": "anaplastic large cell lymphoma",
-              "description": "A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3720\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3720\" NCI Thesaurus); A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001); A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called \"hallmark\" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.; A type of T-cell lymphoma that is characterized by so-called hallmark cells with a pleomorphic appearance that express the CD30 antigen, are lobulated, and have indented nuclei. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0020325",
-                "UMLS:C0206180",
-                "NCIT:C3720",
-                "ICD9:200.6",
-                "SNOMEDCT:277637000",
-                "SNOMEDCT:53237008",
-                "DOID:0050744",
-                "PDQ:CDR0000042785",
-                "EFO:0003032",
-                "SNOMEDCT:702785000",
-                "MESH:D017728",
-                "ORPHANET:98841",
-                "HP:0012193",
-                "MEDDRA:10073478"
-              ],
-              "id": "MONDO:0020325",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Anaplastic Large Cell Lymphoma",
-                "Anaplastic large cell lymphoma",
-                "Lymphoma, Large-Cell, Anaplastic",
-                "Ki-1+ Anaplastic Large Cell Lymphoma",
-                "Anaplastic large-cell lymphoma",
-                "anaplastic large cell lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/anaplastic_large-cell_lymphoma#epidemiology",
-                "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 23295725,
-            "start": 622,
-            "end": 535036,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34507350': {'publication date': '2021 Sep 10', 'sentence': \"These final analyses confirm improved, clinically meaningful, durable responses and longer PFS with brentuximab vedotin vs physician's choice in CD30-expressing MF or C-ALCL.\", 'subject score': 1000, 'object score': 824}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:associated_with---None---None---None---UMLS:C0026948---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "23730531",
-              "object": "MONDO:0009691",
-              "publications": [
-                "PMID:34507350"
-=======
-            "identity": 22382046,
-            "start": 622,
-            "end": 318146,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:33308986': {'publication date': '2020 Dec 10', 'sentence': '[Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma].', 'subject score': 1000, 'object score': 900}, 'PMID:33392974': {'publication date': '2021 Jan 03', 'sentence': 'Brentuximab vedotin (BV) was initially approved in Japan for the treatment of relapsed/refractory (R/R) CD30-positive Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL).', 'subject score': 1000, 'object score': 1000}, 'PMID:33604778': {'publication date': '2021 Feb 18', 'sentence': 'Correction to: Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.', 'subject score': 1000, 'object score': 1000}, 'PMID:34275403': {'publication date': '2021 Jul 19', 'sentence': 'Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:34797505': {'publication date': '2021 Nov 19', 'sentence': 'METHODS: Analysis of a real-world, observational, retrospective case series in patients suffering from AITL, sALCL and peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH) and other types of PTCL treated with BV in frontline treatment was conducted.', 'subject score': 1000, 'object score': 1000}, 'PMID:35482341': {'publication date': '2022 Apr 28', 'sentence': 'Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.', 'subject score': 1000, 'object score': 888}, 'PMID:36057890': {'publication date': '2022 Sep 04', 'sentence': 'Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin.', 'subject score': 1000, 'object score': 947}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:treats---None---None---None---UMLS:C0206180---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "22808973",
-              "object": "MONDO:0020325",
-              "publications": [
-                "PMID:33308986",
-                "PMID:33392974",
-                "PMID:33604778",
-                "PMID:34275403",
-                "PMID:34797505",
-                "PMID:35482341",
-                "PMID:36057890"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 699953,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:32684628': {'publication date': '2020 Jul 20', 'sentence': 'Although brentuximab-vedotin (BV) demonstrated single-agent activity, tumours regrew during BV therapy.', 'subject score': 901, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 319673,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018905",
-          "name": "diffuse large B-cell lymphoma",
-          "description": "A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.; Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "NCIT:C8851",
-            "UMLS:C0079744",
-            "MEDDRA:10012819",
-            "MEDDRA:10012818",
-            "MONDO:0018905",
-            "UMLS:C2699777",
-            "NCIT:C80280",
-            "SNOMEDCT:109969005",
-            "SNOMEDCT:1172695008",
-            "MESH:D016403",
-            "ORPHANET:544",
-            "MEDDRA:10012820",
-            "DOID:0050745",
-            "EFO:0000403"
-          ],
-          "id": "MONDO:0018905",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphoma, Large B-Cell, Diffuse",
-            "diffuse large B-cell lymphoma",
-            "Diffuse Large B-Cell Lymphoma",
-            "Diffuse large B-cell lymphoma",
-            "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "PMID:28487884",
-            "http://en.wikipedia.org/wiki/diffuse_large_b-cell_lymphoma",
-            "https://ncithesaurus.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&ns=ncit&code=c148392"
-=======
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 699953,
-=======
-            "identity": 319673,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018905",
-              "name": "diffuse large B-cell lymphoma",
-              "description": "A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.; Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "NCIT:C8851",
-                "UMLS:C0079744",
-                "MEDDRA:10012819",
-                "MEDDRA:10012818",
-                "MONDO:0018905",
-                "UMLS:C2699777",
-                "NCIT:C80280",
-                "SNOMEDCT:109969005",
-                "SNOMEDCT:1172695008",
-                "MESH:D016403",
-                "ORPHANET:544",
-                "MEDDRA:10012820",
-                "DOID:0050745",
-                "EFO:0000403"
-              ],
-              "id": "MONDO:0018905",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphoma, Large B-Cell, Diffuse",
-                "diffuse large B-cell lymphoma",
-                "Diffuse Large B-Cell Lymphoma",
-                "Diffuse large B-cell lymphoma",
-                "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "PMID:28487884",
-                "http://en.wikipedia.org/wiki/diffuse_large_b-cell_lymphoma",
-                "https://ncithesaurus.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&ns=ncit&code=c148392"
-=======
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 23218881,
-            "start": 622,
-            "end": 699953,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34395429': {'publication date': '2021', 'sentence': 'Our study thus provides a feasible explanation for the clinical impact of BV in CD30     -       DLBCL and warrants confirming studies in animal models.', 'subject score': 1000, 'object score': 938}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:associated_with---None---None---None---UMLS:C0079744---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "23653011",
-              "object": "MONDO:0018905",
-              "publications": [
-                "PMID:34395429"
-=======
-            "identity": 21862379,
-            "start": 622,
-            "end": 319673,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32684628': {'publication date': '2020 Jul 20', 'sentence': 'Although brentuximab-vedotin (BV) demonstrated single-agent activity, tumours regrew during BV therapy.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:treats---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "22284390",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:32684628"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:33628584': {'publication date': '2021 Feb 15', 'sentence': 'Clinical activity of targeted antibodies, such as daratumumab (anti-CD38 antibody) and brentuximab vedotin (anti-CD30 antibody), have been reported in NKTCL.', 'subject score': 1000, 'object score': 928}, 'PMID:36143025': {'publication date': '2022 Sep 13', 'sentence': 'Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation-A Phase I Study.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319679,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-          "name": "lymphoma",
-          "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:115244002",
-            "DOID:0060058",
-            "MONDO:0005062",
-            "SNOMEDCT:118600007",
-            "HP:0002665",
-            "NCIT:C7065",
-            "EFO:0000574",
-            "ORPHANET:223735",
-            "MESH:D008223",
-            "SNOMEDCT:188676008",
-            "PDQ:CDR0000041429",
-            "MEDDRA:10025316",
-            "UMLS:C0024299",
-            "NCIT:C3208",
-            "MEDDRA:10025632",
-            "MEDDRA:10025310",
-            "MEDDRA:10025633",
-            "SNOMEDCT:1163043007",
-            "ICD10:C85.9",
-            "UMLS:C1536843",
-            "UMLS:C0334621",
-            "MEDDRA:10025315"
-          ],
-          "id": "MONDO:0005062",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphocytic Neoplasm",
-            "Lymphoma",
-            "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-            "lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/lymphoma",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319679,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-              "name": "lymphoma",
-              "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:115244002",
-                "DOID:0060058",
-                "MONDO:0005062",
-                "SNOMEDCT:118600007",
-                "HP:0002665",
-                "NCIT:C7065",
-                "EFO:0000574",
-                "ORPHANET:223735",
-                "MESH:D008223",
-                "SNOMEDCT:188676008",
-                "PDQ:CDR0000041429",
-                "MEDDRA:10025316",
-                "UMLS:C0024299",
-                "NCIT:C3208",
-                "MEDDRA:10025632",
-                "MEDDRA:10025310",
-                "MEDDRA:10025633",
-                "SNOMEDCT:1163043007",
-                "ICD10:C85.9",
-                "UMLS:C1536843",
-                "UMLS:C0334621",
-                "MEDDRA:10025315"
-              ],
-              "id": "MONDO:0005062",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphocytic Neoplasm",
-                "Lymphoma",
-                "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-                "lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/lymphoma",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22636237,
-            "start": 622,
-            "end": 319679,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:33628584': {'publication date': '2021 Feb 15', 'sentence': 'Clinical activity of targeted antibodies, such as daratumumab (anti-CD38 antibody) and brentuximab vedotin (anti-CD30 antibody), have been reported in NKTCL.', 'subject score': 1000, 'object score': 928}, 'PMID:36143025': {'publication date': '2022 Sep 13', 'sentence': 'Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation-A Phase I Study.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:associated_with---None---None---None---UMLS:C0024299---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "23065539",
-              "object": "MONDO:0005062",
-              "publications": [
-                "PMID:33628584",
-                "PMID:36143025"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:34109776': {'publication date': '2021 Jun 10', 'sentence': 'Thus, we provide evidence for direct and combined anti-lymphoma effect of ADAM10 inhibitors with BtxVed, leading to improvement of ADC effects; this is documented in 3D models recapitulating features of LN microenvironment, that can be proposed as reliable tool for antilymphoma drug testing.', 'subject score': 1000, 'object score': 775}}",
-    "p2": {
-      "start": {
-        "identity": 319679,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-          "name": "lymphoma",
-          "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:115244002",
-            "DOID:0060058",
-            "MONDO:0005062",
-            "SNOMEDCT:118600007",
-            "HP:0002665",
-            "NCIT:C7065",
-            "EFO:0000574",
-            "ORPHANET:223735",
-            "MESH:D008223",
-            "SNOMEDCT:188676008",
-            "PDQ:CDR0000041429",
-            "MEDDRA:10025316",
-            "UMLS:C0024299",
-            "NCIT:C3208",
-            "MEDDRA:10025632",
-            "MEDDRA:10025310",
-            "MEDDRA:10025633",
-            "SNOMEDCT:1163043007",
-            "ICD10:C85.9",
-            "UMLS:C1536843",
-            "UMLS:C0334621",
-            "MEDDRA:10025315"
-          ],
-          "id": "MONDO:0005062",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphocytic Neoplasm",
-            "Lymphoma",
-            "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-            "lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/lymphoma",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319679,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-              "name": "lymphoma",
-              "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:115244002",
-                "DOID:0060058",
-                "MONDO:0005062",
-                "SNOMEDCT:118600007",
-                "HP:0002665",
-                "NCIT:C7065",
-                "EFO:0000574",
-                "ORPHANET:223735",
-                "MESH:D008223",
-                "SNOMEDCT:188676008",
-                "PDQ:CDR0000041429",
-                "MEDDRA:10025316",
-                "UMLS:C0024299",
-                "NCIT:C3208",
-                "MEDDRA:10025632",
-                "MEDDRA:10025310",
-                "MEDDRA:10025633",
-                "SNOMEDCT:1163043007",
-                "ICD10:C85.9",
-                "UMLS:C1536843",
-                "UMLS:C0334621",
-                "MEDDRA:10025315"
-              ],
-              "id": "MONDO:0005062",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphocytic Neoplasm",
-                "Lymphoma",
-                "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-                "lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/lymphoma",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23003708,
-            "start": 622,
-            "end": 319679,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34109776': {'publication date': '2021 Jun 10', 'sentence': 'Thus, we provide evidence for direct and combined anti-lymphoma effect of ADAM10 inhibitors with BtxVed, leading to improvement of ADC effects; this is documented in 3D models recapitulating features of LN microenvironment, that can be proposed as reliable tool for antilymphoma drug testing.', 'subject score': 1000, 'object score': 775}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:affects---None---None---None---UMLS:C0024299---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "23435913",
-              "object": "MONDO:0005062",
-              "publications": [
-                "PMID:34109776"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:31934889': {'publication date': '2020 Jan 10', 'sentence': 'Brentuximab vedotin represents a major breakthrough in the treatment of CD30-positive lymphomas.', 'subject score': 1000, 'object score': 901}, 'PMID:31955620': {'publication date': '2020 May', 'sentence': 'Methods    : Articles were retrieved from PubMed, Cochrane, and Clinicaltrials Databases to identify randomized controlled trials (RCTs) comparing brentuximab vedotin with non-brentuximab vedotin in lymphoma patients.', 'subject score': 901, 'object score': 888}, 'PMID:34090506': {'publication date': '2021 Jun 05', 'sentence': 'In recent years, three ADCs, brentuximab vedotin, polatuzumab vedotin, and loncastuximab tesirine, have been approved and are already establishing their place in lymphoma treatment.', 'subject score': 1000, 'object score': 888}, 'PMID:35158894': {'publication date': '2022 Jan 26', 'sentence': 'The later clinical success of the first approved antibody-drug conjugate (ADC) for the treatment of lymphomas, anti-CD30 brentuximab vedotin, paved the path for the preclinical development and clinical testing of several other ADCs, including polatuzumab vedotin and loncastuximab tesirine.', 'subject score': 824, 'object score': 1000}, 'PMID:36512081': {'publication date': '2022 Dec 13', 'sentence': 'This narrative review summarizes 10 years of experience with brentuximab vedotin for the treatment of CD30-positive lymphomas, discusses novel therapies targeting CD30 in development, and highlights remaining controversies relating to CD30-targeted therapy across lymphoma types.', 'subject score': 1000, 'object score': 901}, 'PMID:36987732': {'publication date': '2023 Jan 14', 'sentence': '[Advances in the treatment of CD30 positive lymphoma with brentuximab vedotin].', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
-      "start": {
-        "identity": 319679,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-          "name": "lymphoma",
-          "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:115244002",
-            "DOID:0060058",
-            "MONDO:0005062",
-            "SNOMEDCT:118600007",
-            "HP:0002665",
-            "NCIT:C7065",
-            "EFO:0000574",
-            "ORPHANET:223735",
-            "MESH:D008223",
-            "SNOMEDCT:188676008",
-            "PDQ:CDR0000041429",
-            "MEDDRA:10025316",
-            "UMLS:C0024299",
-            "NCIT:C3208",
-            "MEDDRA:10025632",
-            "MEDDRA:10025310",
-            "MEDDRA:10025633",
-            "SNOMEDCT:1163043007",
-            "ICD10:C85.9",
-            "UMLS:C1536843",
-            "UMLS:C0334621",
-            "MEDDRA:10025315"
-          ],
-          "id": "MONDO:0005062",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphocytic Neoplasm",
-            "Lymphoma",
-            "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-            "lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/lymphoma",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319679,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-              "name": "lymphoma",
-              "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:115244002",
-                "DOID:0060058",
-                "MONDO:0005062",
-                "SNOMEDCT:118600007",
-                "HP:0002665",
-                "NCIT:C7065",
-                "EFO:0000574",
-                "ORPHANET:223735",
-                "MESH:D008223",
-                "SNOMEDCT:188676008",
-                "PDQ:CDR0000041429",
-                "MEDDRA:10025316",
-                "UMLS:C0024299",
-                "NCIT:C3208",
-                "MEDDRA:10025632",
-                "MEDDRA:10025310",
-                "MEDDRA:10025633",
-                "SNOMEDCT:1163043007",
-                "ICD10:C85.9",
-                "UMLS:C1536843",
-                "UMLS:C0334621",
-                "MEDDRA:10025315"
-              ],
-              "id": "MONDO:0005062",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphocytic Neoplasm",
-                "Lymphoma",
-                "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-                "lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/lymphoma",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21155385,
-            "start": 622,
-            "end": 319679,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31934889': {'publication date': '2020 Jan 10', 'sentence': 'Brentuximab vedotin represents a major breakthrough in the treatment of CD30-positive lymphomas.', 'subject score': 1000, 'object score': 901}, 'PMID:31955620': {'publication date': '2020 May', 'sentence': 'Methods    : Articles were retrieved from PubMed, Cochrane, and Clinicaltrials Databases to identify randomized controlled trials (RCTs) comparing brentuximab vedotin with non-brentuximab vedotin in lymphoma patients.', 'subject score': 901, 'object score': 888}, 'PMID:34090506': {'publication date': '2021 Jun 05', 'sentence': 'In recent years, three ADCs, brentuximab vedotin, polatuzumab vedotin, and loncastuximab tesirine, have been approved and are already establishing their place in lymphoma treatment.', 'subject score': 1000, 'object score': 888}, 'PMID:35158894': {'publication date': '2022 Jan 26', 'sentence': 'The later clinical success of the first approved antibody-drug conjugate (ADC) for the treatment of lymphomas, anti-CD30 brentuximab vedotin, paved the path for the preclinical development and clinical testing of several other ADCs, including polatuzumab vedotin and loncastuximab tesirine.', 'subject score': 824, 'object score': 1000}, 'PMID:36512081': {'publication date': '2022 Dec 13', 'sentence': 'This narrative review summarizes 10 years of experience with brentuximab vedotin for the treatment of CD30-positive lymphomas, discusses novel therapies targeting CD30 in development, and highlights remaining controversies relating to CD30-targeted therapy across lymphoma types.', 'subject score': 1000, 'object score': 901}, 'PMID:36987732': {'publication date': '2023 Jan 14', 'sentence': '[Advances in the treatment of CD30 positive lymphoma with brentuximab vedotin].', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:treats---None---None---None---UMLS:C0024299---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "21569593",
-              "object": "MONDO:0005062",
-              "publications": [
-                "PMID:31934889",
-                "PMID:31955620",
-                "PMID:34090506",
-                "PMID:35158894",
-                "PMID:36512081",
-                "PMID:36987732"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:32170052': {'publication date': '2020 Mar 14', 'sentence': 'Durable Response to Brentuximab Vedotin-Based Chemotherapy in Refractory Hodgkin Lymphoma with Central Nervous System (CNS) Involvement.BACKGROUND CNS involvement in Hodgkin lymphoma is rare.', 'subject score': 861, 'object score': 1000}, 'PMID:33050897': {'publication date': '2020 Oct 13', 'sentence': \"Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin's lymphoma: a probabilistic analysis.\", 'subject score': 1000, 'object score': 888}, 'PMID:35441544': {'publication date': '2022 Apr 20', 'sentence': 'Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series.', 'subject score': 1000, 'object score': 1000}, 'PMID:35797410': {'publication date': '2022 Jul 07', 'sentence': 'Therapeutic combination of brentuximab vedotin and bendamustine has been shown to be highly effective in Hodgkin lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:36118550': {'publication date': '2022 Aug', 'sentence': 'BV in combination with nivolumab is a reasonable alternative regimen in HL ineligible for cytotoxic chemotherapy.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 318155,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004952",
-          "name": "Hodgkins lymphoma",
-          "description": "A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma has a bimodal age distribution, and involves primarily lymph nodes. Current therapy for Hodgkin lymphoma has resulted in an excellent outcome and cure for the majority of patients. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C9357\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C9357\" NCI Thesaurus); UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10020309",
-            "SNOMEDCT:1163005009",
-            "ORPHANET:98293",
-            "UMLS:C5235037",
-            "NCIT:C6914",
-            "MEDDRA:10020255",
-            "SNOMEDCT:118606001",
-            "MEDDRA:10063666",
-            "SNOMEDCT:46923007",
-            "ICD10:C81",
-            "UMLS:C0019829",
-            "ICD9:201.2",
-            "SNOMEDCT:836277009",
-            "SNOMEDCT:74189002",
-            "MEDDRA:10020206",
-            "MESH:D006689",
-            "MEDDRA:10020328",
-            "MEDDRA:10020329",
-            "HP:0012189",
-            "SNOMEDCT:118599009",
-            "NCIT:C9357",
-            "ICD9:201",
-            "NCIT:C26956",
-            "SNOMEDCT:118605002",
-            "SNOMEDCT:118602004",
-            "NCIT:C164145",
-            "PDQ:CDR0000041646",
-            "MEDDRA:10025319",
-            "MEDDRA:10020318",
-            "EFO:0000183",
-            "DOID:8567",
-            "SNOMEDCT:14537002",
-            "MONDO:0004952",
-            "SNOMEDCT:836276000",
-            "MEDDRA:10020339",
-            "SNOMEDCT:70600005"
-          ],
-          "id": "MONDO:0004952",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hodgkin Lymphoma",
-            "Hodgkin lymphoma",
-            "Hodgkin's Paragranuloma",
-            "Hodgkin's sarcoma",
-            "Hodgkin sarcoma",
-            "Hodgkin's lymphoma",
-            "Hodgkins lymphoma",
-            "Hodgkin's Granuloma",
-            "Hodgkin's Sarcoma",
-            "Hodgkin Disease",
-            "Hodgkin's disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/hodgkin%27s_lymphoma",
-            "PMID:22835602",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318155,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004952",
-              "name": "Hodgkins lymphoma",
-              "description": "A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma has a bimodal age distribution, and involves primarily lymph nodes. Current therapy for Hodgkin lymphoma has resulted in an excellent outcome and cure for the majority of patients. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C9357\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C9357\" NCI Thesaurus); UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10020309",
-                "SNOMEDCT:1163005009",
-                "ORPHANET:98293",
-                "UMLS:C5235037",
-                "NCIT:C6914",
-                "MEDDRA:10020255",
-                "SNOMEDCT:118606001",
-                "MEDDRA:10063666",
-                "SNOMEDCT:46923007",
-                "ICD10:C81",
-                "UMLS:C0019829",
-                "ICD9:201.2",
-                "SNOMEDCT:836277009",
-                "SNOMEDCT:74189002",
-                "MEDDRA:10020206",
-                "MESH:D006689",
-                "MEDDRA:10020328",
-                "MEDDRA:10020329",
-                "HP:0012189",
-                "SNOMEDCT:118599009",
-                "NCIT:C9357",
-                "ICD9:201",
-                "NCIT:C26956",
-                "SNOMEDCT:118605002",
-                "SNOMEDCT:118602004",
-                "NCIT:C164145",
-                "PDQ:CDR0000041646",
-                "MEDDRA:10025319",
-                "MEDDRA:10020318",
-                "EFO:0000183",
-                "DOID:8567",
-                "SNOMEDCT:14537002",
-                "MONDO:0004952",
-                "SNOMEDCT:836276000",
-                "MEDDRA:10020339",
-                "SNOMEDCT:70600005"
-              ],
-              "id": "MONDO:0004952",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hodgkin Lymphoma",
-                "Hodgkin lymphoma",
-                "Hodgkin's Paragranuloma",
-                "Hodgkin's sarcoma",
-                "Hodgkin sarcoma",
-                "Hodgkin's lymphoma",
-                "Hodgkins lymphoma",
-                "Hodgkin's Granuloma",
-                "Hodgkin's Sarcoma",
-                "Hodgkin Disease",
-                "Hodgkin's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/hodgkin%27s_lymphoma",
-                "PMID:22835602",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21395369,
-            "start": 622,
-            "end": 318155,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32170052': {'publication date': '2020 Mar 14', 'sentence': 'Durable Response to Brentuximab Vedotin-Based Chemotherapy in Refractory Hodgkin Lymphoma with Central Nervous System (CNS) Involvement.BACKGROUND CNS involvement in Hodgkin lymphoma is rare.', 'subject score': 861, 'object score': 1000}, 'PMID:33050897': {'publication date': '2020 Oct 13', 'sentence': \"Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin's lymphoma: a probabilistic analysis.\", 'subject score': 1000, 'object score': 888}, 'PMID:35441544': {'publication date': '2022 Apr 20', 'sentence': 'Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series.', 'subject score': 1000, 'object score': 1000}, 'PMID:35797410': {'publication date': '2022 Jul 07', 'sentence': 'Therapeutic combination of brentuximab vedotin and bendamustine has been shown to be highly effective in Hodgkin lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:36118550': {'publication date': '2022 Aug', 'sentence': 'BV in combination with nivolumab is a reasonable alternative regimen in HL ineligible for cytotoxic chemotherapy.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:associated_with---None---None---None---UMLS:C0019829---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "21812241",
-              "object": "MONDO:0004952",
-              "publications": [
-                "PMID:32170052",
-                "PMID:33050897",
-                "PMID:35441544",
-                "PMID:35797410",
-                "PMID:36118550"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 535028,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000430",
-          "name": "mature T-cell and NK-cell non-Hodgkin lymphoma",
-          "description": "A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10034624",
-            "MONDO:0000430",
-            "MEDDRA:10034623",
-            "UMLS:C1337073",
-            "MESH:D016411",
-            "UMLS:C1337074",
-            "NCIT:C27352",
-            "UMLS:C0079774",
-            "UMLS:C5551485",
-            "UMLS:C1337079",
-            "DOID:0050743",
-            "NCIT:C7204",
-            "UMLS:C0334655",
-            "NCIT:C3468",
-            "DOID:0050749",
-            "SNOMEDCT:109977009",
-            "ICD9:202.7",
-            "SNOMEDCT:1163404000",
-            "SNOMEDCT:109975001"
-          ],
-          "id": "MONDO:0000430",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peripheral T-Cell Lymphoma, Large Cell",
-            "T-Zone Variant Peripheral T-Cell Lymphoma",
-            "mature T-cell and NK-cell non-Hodgkin lymphoma",
-            "peripheral T-cell lymphoma",
-            "T-zone lymphoma (clinical)",
-            "Lymphoma, T-Cell, Peripheral",
-            "mature T-cell and NK-cell lymphoma",
-            "Peripheral T-Cell Lymphoma",
-            "Peripheral T-cell lymphoma",
-            "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:21919697",
-            "http://www.cancer.gov/dictionary?cdrid=393800",
-            "http://www.cancer.gov/dictionary?cdrid=44062",
-            "http://en.wikipedia.org/wiki/peripheral_t-cell_lymphoma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 535028,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000430",
-              "name": "mature T-cell and NK-cell non-Hodgkin lymphoma",
-              "description": "A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10034624",
-                "MONDO:0000430",
-                "MEDDRA:10034623",
-                "UMLS:C1337073",
-                "MESH:D016411",
-                "UMLS:C1337074",
-                "NCIT:C27352",
-                "UMLS:C0079774",
-                "UMLS:C5551485",
-                "UMLS:C1337079",
-                "DOID:0050743",
-                "NCIT:C7204",
-                "UMLS:C0334655",
-                "NCIT:C3468",
-                "DOID:0050749",
-                "SNOMEDCT:109977009",
-                "ICD9:202.7",
-                "SNOMEDCT:1163404000",
-                "SNOMEDCT:109975001"
-              ],
-              "id": "MONDO:0000430",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peripheral T-Cell Lymphoma, Large Cell",
-                "T-Zone Variant Peripheral T-Cell Lymphoma",
-                "mature T-cell and NK-cell non-Hodgkin lymphoma",
-                "peripheral T-cell lymphoma",
-                "T-zone lymphoma (clinical)",
-                "Lymphoma, T-Cell, Peripheral",
-                "mature T-cell and NK-cell lymphoma",
-                "Peripheral T-Cell Lymphoma",
-                "Peripheral T-cell lymphoma",
-                "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:21919697",
-                "http://www.cancer.gov/dictionary?cdrid=393800",
-                "http://www.cancer.gov/dictionary?cdrid=44062",
-                "http://en.wikipedia.org/wiki/peripheral_t-cell_lymphoma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21241846,
-            "start": 622,
-            "end": 535028,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32016790': {'publication date': '2020 Feb 03', 'sentence': 'In this review, we discuss key studies of BV in peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) and highlight important questions for further investigation.', 'subject score': 1000, 'object score': 1000}, 'PMID:32499905': {'publication date': '2020 May 06', 'sentence': 'Treatment strategy for ALK-ALCL is controversial, but the efficacy of BV in CD30-positive peripheral T-cell lymphoma not only as salvage regimens, but also in first line, has been reported in recent years.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:associated_with---None---None---None---UMLS:C0079774---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "21657994",
-              "object": "MONDO:0000430",
-              "publications": [
-                "PMID:32016790",
-                "PMID:32499905"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318142,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000607",
-          "name": "primary cutaneous T-cell non-Hodgkin lymphoma",
-          "description": "A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.; A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.; A type of T-cell lymphoma that exhibits malignant infiltration of the skin. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "NCIT:C3467",
-            "EFO:0002913",
-            "SNOMEDCT:1162973007",
-            "SNOMEDCT:28054005",
-            "MONDO:0000607",
-            "MEDDRA:10011677",
-            "DOID:0060061",
-            "MESH:D016410",
-            "SNOMEDCT:1187136005",
-            "UMLS:C0079773",
-            "HP:0012192",
-            "SNOMEDCT:400122007"
-          ],
-          "id": "MONDO:0000607",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cutaneous T-cell lymphoma",
-            "primary cutaneous T-cell non-Hodgkin lymphoma",
-            "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
-            "Lymphoma, T-Cell, Cutaneous"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/cutaneous_t-cell_lymphoma",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318142,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000607",
-              "name": "primary cutaneous T-cell non-Hodgkin lymphoma",
-              "description": "A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.; A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.; A type of T-cell lymphoma that exhibits malignant infiltration of the skin. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "NCIT:C3467",
-                "EFO:0002913",
-                "SNOMEDCT:1162973007",
-                "SNOMEDCT:28054005",
-                "MONDO:0000607",
-                "MEDDRA:10011677",
-                "DOID:0060061",
-                "MESH:D016410",
-                "SNOMEDCT:1187136005",
-                "UMLS:C0079773",
-                "HP:0012192",
-                "SNOMEDCT:400122007"
-              ],
-              "id": "MONDO:0000607",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cutaneous T-cell lymphoma",
-                "primary cutaneous T-cell non-Hodgkin lymphoma",
-                "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
-                "Lymphoma, T-Cell, Cutaneous"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/cutaneous_t-cell_lymphoma",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21241845,
-            "start": 622,
-            "end": 318142,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32016790': {'publication date': '2020 Feb 03', 'sentence': 'In this review, we discuss key studies of BV in peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) and highlight important questions for further investigation.', 'subject score': 1000, 'object score': 1000}, 'PMID:34507350': {'publication date': '2021 Sep 10', 'sentence': \"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.\", 'subject score': 1000, 'object score': 1000}, 'PMID:36689504': {'publication date': '2023 Jan 23', 'sentence': 'Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma.', 'subject score': 901, 'object score': 937}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:associated_with---None---None---None---UMLS:C0079773---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "21657993",
-              "object": "MONDO:0000607",
-              "publications": [
-                "PMID:32016790",
-                "PMID:34507350",
-                "PMID:36689504"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 535028,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000430",
-          "name": "mature T-cell and NK-cell non-Hodgkin lymphoma",
-          "description": "A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10034624",
-            "MONDO:0000430",
-            "MEDDRA:10034623",
-            "UMLS:C1337073",
-            "MESH:D016411",
-            "UMLS:C1337074",
-            "NCIT:C27352",
-            "UMLS:C0079774",
-            "UMLS:C5551485",
-            "UMLS:C1337079",
-            "DOID:0050743",
-            "NCIT:C7204",
-            "UMLS:C0334655",
-            "NCIT:C3468",
-            "DOID:0050749",
-            "SNOMEDCT:109977009",
-            "ICD9:202.7",
-            "SNOMEDCT:1163404000",
-            "SNOMEDCT:109975001"
-          ],
-          "id": "MONDO:0000430",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peripheral T-Cell Lymphoma, Large Cell",
-            "T-Zone Variant Peripheral T-Cell Lymphoma",
-            "mature T-cell and NK-cell non-Hodgkin lymphoma",
-            "peripheral T-cell lymphoma",
-            "T-zone lymphoma (clinical)",
-            "Lymphoma, T-Cell, Peripheral",
-            "mature T-cell and NK-cell lymphoma",
-            "Peripheral T-Cell Lymphoma",
-            "Peripheral T-cell lymphoma",
-            "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:21919697",
-            "http://www.cancer.gov/dictionary?cdrid=393800",
-            "http://www.cancer.gov/dictionary?cdrid=44062",
-            "http://en.wikipedia.org/wiki/peripheral_t-cell_lymphoma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 535028,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000430",
-              "name": "mature T-cell and NK-cell non-Hodgkin lymphoma",
-              "description": "A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10034624",
-                "MONDO:0000430",
-                "MEDDRA:10034623",
-                "UMLS:C1337073",
-                "MESH:D016411",
-                "UMLS:C1337074",
-                "NCIT:C27352",
-                "UMLS:C0079774",
-                "UMLS:C5551485",
-                "UMLS:C1337079",
-                "DOID:0050743",
-                "NCIT:C7204",
-                "UMLS:C0334655",
-                "NCIT:C3468",
-                "DOID:0050749",
-                "SNOMEDCT:109977009",
-                "ICD9:202.7",
-                "SNOMEDCT:1163404000",
-                "SNOMEDCT:109975001"
-              ],
-              "id": "MONDO:0000430",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peripheral T-Cell Lymphoma, Large Cell",
-                "T-Zone Variant Peripheral T-Cell Lymphoma",
-                "mature T-cell and NK-cell non-Hodgkin lymphoma",
-                "peripheral T-cell lymphoma",
-                "T-zone lymphoma (clinical)",
-                "Lymphoma, T-Cell, Peripheral",
-                "mature T-cell and NK-cell lymphoma",
-                "Peripheral T-Cell Lymphoma",
-                "Peripheral T-cell lymphoma",
-                "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:21919697",
-                "http://www.cancer.gov/dictionary?cdrid=393800",
-                "http://www.cancer.gov/dictionary?cdrid=44062",
-                "http://en.wikipedia.org/wiki/peripheral_t-cell_lymphoma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21652169,
-            "start": 535028,
-            "end": 622,
-            "type": "biolink:has_part",
-            "properties": {
-              "predicate": "biolink:has_part",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32448357': {'publication date': '2020 May 24', 'sentence': 'Targeting CD30+ PTCL with the antibody-drug conjugate brentuximab vedotin in the relapsed setting and in combination with chemotherapy in the frontline setting has improved patient survivals.', 'subject score': 857, 'object score': 851}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:part_of---None---None---None---UMLS:C0079774---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0000430",
-              "id": "22071488",
-              "object": "UNII:7XL5ISS668",
-              "publications": [
-                "PMID:32448357"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 699953,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018905",
-          "name": "diffuse large B-cell lymphoma",
-          "description": "A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.; Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "NCIT:C8851",
-            "UMLS:C0079744",
-            "MEDDRA:10012819",
-            "MEDDRA:10012818",
-            "MONDO:0018905",
-            "UMLS:C2699777",
-            "NCIT:C80280",
-            "SNOMEDCT:109969005",
-            "SNOMEDCT:1172695008",
-            "MESH:D016403",
-            "ORPHANET:544",
-            "MEDDRA:10012820",
-            "DOID:0050745",
-            "EFO:0000403"
-          ],
-          "id": "MONDO:0018905",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphoma, Large B-Cell, Diffuse",
-            "diffuse large B-cell lymphoma",
-            "Diffuse Large B-Cell Lymphoma",
-            "Diffuse large B-cell lymphoma",
-            "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28487884",
-            "http://en.wikipedia.org/wiki/diffuse_large_b-cell_lymphoma",
-            "https://ncithesaurus.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&ns=ncit&code=c148392"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 699953,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018905",
-              "name": "diffuse large B-cell lymphoma",
-              "description": "A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.; Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "NCIT:C8851",
-                "UMLS:C0079744",
-                "MEDDRA:10012819",
-                "MEDDRA:10012818",
-                "MONDO:0018905",
-                "UMLS:C2699777",
-                "NCIT:C80280",
-                "SNOMEDCT:109969005",
-                "SNOMEDCT:1172695008",
-                "MESH:D016403",
-                "ORPHANET:544",
-                "MEDDRA:10012820",
-                "DOID:0050745",
-                "EFO:0000403"
-              ],
-              "id": "MONDO:0018905",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphoma, Large B-Cell, Diffuse",
-                "diffuse large B-cell lymphoma",
-                "Diffuse Large B-Cell Lymphoma",
-                "Diffuse large B-cell lymphoma",
-                "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28487884",
-                "http://en.wikipedia.org/wiki/diffuse_large_b-cell_lymphoma",
-                "https://ncithesaurus.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&ns=ncit&code=c148392"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21139443,
-            "start": 699953,
-            "end": 622,
-            "type": "biolink:has_part",
-            "properties": {
-              "predicate": "biolink:has_part",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31921871': {'publication date': '2019', 'sentence': 'Here, we describe successful management of refractory EBV-associated PTLD, specifically DLBCL, with combined brentuximab vedotin and third-party EBV-specific T-cells in a multidisciplinary treatment approach.', 'subject score': 901, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:part_of---None---None---None---UMLS:C0079744---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0018905",
-              "id": "21553377",
-              "object": "UNII:7XL5ISS668",
-              "publications": [
-                "PMID:31921871"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319679,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-          "name": "lymphoma",
-          "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:115244002",
-            "DOID:0060058",
-            "MONDO:0005062",
-            "SNOMEDCT:118600007",
-            "HP:0002665",
-            "NCIT:C7065",
-            "EFO:0000574",
-            "ORPHANET:223735",
-            "MESH:D008223",
-            "SNOMEDCT:188676008",
-            "PDQ:CDR0000041429",
-            "MEDDRA:10025316",
-            "UMLS:C0024299",
-            "NCIT:C3208",
-            "MEDDRA:10025632",
-            "MEDDRA:10025310",
-            "MEDDRA:10025633",
-            "SNOMEDCT:1163043007",
-            "ICD10:C85.9",
-            "UMLS:C1536843",
-            "UMLS:C0334621",
-            "MEDDRA:10025315"
-          ],
-          "id": "MONDO:0005062",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphocytic Neoplasm",
-            "Lymphoma",
-            "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-            "lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/lymphoma",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319679,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-              "name": "lymphoma",
-              "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:115244002",
-                "DOID:0060058",
-                "MONDO:0005062",
-                "SNOMEDCT:118600007",
-                "HP:0002665",
-                "NCIT:C7065",
-                "EFO:0000574",
-                "ORPHANET:223735",
-                "MESH:D008223",
-                "SNOMEDCT:188676008",
-                "PDQ:CDR0000041429",
-                "MEDDRA:10025316",
-                "UMLS:C0024299",
-                "NCIT:C3208",
-                "MEDDRA:10025632",
-                "MEDDRA:10025310",
-                "MEDDRA:10025633",
-                "SNOMEDCT:1163043007",
-                "ICD10:C85.9",
-                "UMLS:C1536843",
-                "UMLS:C0334621",
-                "MEDDRA:10025315"
-              ],
-              "id": "MONDO:0005062",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphocytic Neoplasm",
-                "Lymphoma",
-                "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-                "lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/lymphoma",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23003708,
-            "start": 622,
-            "end": 319679,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34109776': {'publication date': '2021 Jun 10', 'sentence': 'Thus, we provide evidence for direct and combined anti-lymphoma effect of ADAM10 inhibitors with BtxVed, leading to improvement of ADC effects; this is documented in 3D models recapitulating features of LN microenvironment, that can be proposed as reliable tool for antilymphoma drug testing.', 'subject score': 1000, 'object score': 775}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:affects---None---None---None---UMLS:C0024299---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "23435913",
-              "object": "MONDO:0005062",
-              "publications": [
-                "PMID:34109776"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318146,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0020325",
-          "name": "anaplastic large cell lymphoma",
-          "description": "A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3720\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3720\" NCI Thesaurus); A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001); A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called \"hallmark\" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.; A type of T-cell lymphoma that is characterized by so-called hallmark cells with a pleomorphic appearance that express the CD30 antigen, are lobulated, and have indented nuclei. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MONDO:0020325",
-            "UMLS:C0206180",
-            "NCIT:C3720",
-            "ICD9:200.6",
-            "SNOMEDCT:277637000",
-            "SNOMEDCT:53237008",
-            "DOID:0050744",
-            "PDQ:CDR0000042785",
-            "EFO:0003032",
-            "SNOMEDCT:702785000",
-            "MESH:D017728",
-            "ORPHANET:98841",
-            "HP:0012193",
-            "MEDDRA:10073478"
-          ],
-          "id": "MONDO:0020325",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Anaplastic Large Cell Lymphoma",
-            "Anaplastic large cell lymphoma",
-            "Lymphoma, Large-Cell, Anaplastic",
-            "Ki-1+ Anaplastic Large Cell Lymphoma",
-            "Anaplastic large-cell lymphoma",
-            "anaplastic large cell lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/anaplastic_large-cell_lymphoma#epidemiology",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318146,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0020325",
-              "name": "anaplastic large cell lymphoma",
-              "description": "A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3720\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3720\" NCI Thesaurus); A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001); A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called \"hallmark\" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.; A type of T-cell lymphoma that is characterized by so-called hallmark cells with a pleomorphic appearance that express the CD30 antigen, are lobulated, and have indented nuclei. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MONDO:0020325",
-                "UMLS:C0206180",
-                "NCIT:C3720",
-                "ICD9:200.6",
-                "SNOMEDCT:277637000",
-                "SNOMEDCT:53237008",
-                "DOID:0050744",
-                "PDQ:CDR0000042785",
-                "EFO:0003032",
-                "SNOMEDCT:702785000",
-                "MESH:D017728",
-                "ORPHANET:98841",
-                "HP:0012193",
-                "MEDDRA:10073478"
-              ],
-              "id": "MONDO:0020325",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Anaplastic Large Cell Lymphoma",
-                "Anaplastic large cell lymphoma",
-                "Lymphoma, Large-Cell, Anaplastic",
-                "Ki-1+ Anaplastic Large Cell Lymphoma",
-                "Anaplastic large-cell lymphoma",
-                "anaplastic large cell lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/anaplastic_large-cell_lymphoma#epidemiology",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22382046,
-            "start": 622,
-            "end": 318146,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:33308986': {'publication date': '2020 Dec 10', 'sentence': '[Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma].', 'subject score': 1000, 'object score': 900}, 'PMID:33392974': {'publication date': '2021 Jan 03', 'sentence': 'Brentuximab vedotin (BV) was initially approved in Japan for the treatment of relapsed/refractory (R/R) CD30-positive Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL).', 'subject score': 1000, 'object score': 1000}, 'PMID:33604778': {'publication date': '2021 Feb 18', 'sentence': 'Correction to: Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.', 'subject score': 1000, 'object score': 1000}, 'PMID:34275403': {'publication date': '2021 Jul 19', 'sentence': 'Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:34797505': {'publication date': '2021 Nov 19', 'sentence': 'METHODS: Analysis of a real-world, observational, retrospective case series in patients suffering from AITL, sALCL and peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH) and other types of PTCL treated with BV in frontline treatment was conducted.', 'subject score': 1000, 'object score': 1000}, 'PMID:35482341': {'publication date': '2022 Apr 28', 'sentence': 'Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.', 'subject score': 1000, 'object score': 888}, 'PMID:36057890': {'publication date': '2022 Sep 04', 'sentence': 'Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin.', 'subject score': 1000, 'object score': 947}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:treats---None---None---None---UMLS:C0206180---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "22808973",
-              "object": "MONDO:0020325",
-              "publications": [
-                "PMID:33308986",
-                "PMID:33392974",
-                "PMID:33604778",
-                "PMID:34275403",
-                "PMID:34797505",
-                "PMID:35482341",
-                "PMID:36057890"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319673,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-          "name": "neoplasm",
-          "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "EFO:0000616",
-            "MEDDRA:10084713",
-            "MEDDRA:10028980",
-            "SNOMEDCT:108369006",
-            "UMLS:C4732738",
-            "UMLS:C0027651",
-            "MONDO:0005070",
-            "SNOMEDCT:55342001",
-            "UMLS:C1882062",
-            "MEDDRA:10084712",
-            "DOID:14566",
-            "HP:0002664",
-            "MESH:D009369",
-            "PSY:33370",
-            "ICD9:140-239.99",
-            "NCIT:C3262",
-            "UMLS:CN236628",
-            "MEDDRA:10029000",
-            "MEDDRA:10029104"
-          ],
-          "id": "MONDO:0005070",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neoplasms",
-            "Neoplastic disease",
-            "Abnormal tissue mass",
-            "disease of cellular proliferation",
-            "neoplasm",
-            "Neoplasm"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-6601-2165",
-            "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319673,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005070",
-              "name": "neoplasm",
-              "description": "An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). [HPO:probinson]; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumor). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; An organ or organ-system abnormality that consists of uncontrolled autonomous cell-proliferation which can occur in any part of the body as a benign or malignant neoplasm (tumour). // COMMENTS: The World Health Organization (WHO) classifies neoplasms into four main groups: (i) benign neoplasm, (ii) in situ neoplasm, (iii) malignant neoplasm, and (iv) neoplasm of uncertain or unknown behavior. A malignant neoplasm is also known as cancer.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "EFO:0000616",
-                "MEDDRA:10084713",
-                "MEDDRA:10028980",
-                "SNOMEDCT:108369006",
-                "UMLS:C4732738",
-                "UMLS:C0027651",
-                "MONDO:0005070",
-                "SNOMEDCT:55342001",
-                "UMLS:C1882062",
-                "MEDDRA:10084712",
-                "DOID:14566",
-                "HP:0002664",
-                "MESH:D009369",
-                "PSY:33370",
-                "ICD9:140-239.99",
-                "NCIT:C3262",
-                "UMLS:CN236628",
-                "MEDDRA:10029000",
-                "MEDDRA:10029104"
-              ],
-              "id": "MONDO:0005070",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neoplasms",
-                "Neoplastic disease",
-                "Abnormal tissue mass",
-                "disease of cellular proliferation",
-                "neoplasm",
-                "Neoplasm"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-6601-2165",
-                "http://en.wikipedia.org/w/index.php?title=cell_proliferation",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21862379,
-            "start": 622,
-            "end": 319673,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32684628': {'publication date': '2020 Jul 20', 'sentence': 'Although brentuximab-vedotin (BV) demonstrated single-agent activity, tumours regrew during BV therapy.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:treats---None---None---None---UMLS:C0027651---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "22284390",
-              "object": "MONDO:0005070",
-              "publications": [
-                "PMID:32684628"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 535028,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000430",
-          "name": "mature T-cell and NK-cell non-Hodgkin lymphoma",
-          "description": "A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10034624",
-            "MONDO:0000430",
-            "MEDDRA:10034623",
-            "UMLS:C1337073",
-            "MESH:D016411",
-            "UMLS:C1337074",
-            "NCIT:C27352",
-            "UMLS:C0079774",
-            "UMLS:C5551485",
-            "UMLS:C1337079",
-            "DOID:0050743",
-            "NCIT:C7204",
-            "UMLS:C0334655",
-            "NCIT:C3468",
-            "DOID:0050749",
-            "SNOMEDCT:109977009",
-            "ICD9:202.7",
-            "SNOMEDCT:1163404000",
-            "SNOMEDCT:109975001"
-          ],
-          "id": "MONDO:0000430",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Peripheral T-Cell Lymphoma, Large Cell",
-            "T-Zone Variant Peripheral T-Cell Lymphoma",
-            "mature T-cell and NK-cell non-Hodgkin lymphoma",
-            "peripheral T-cell lymphoma",
-            "T-zone lymphoma (clinical)",
-            "Lymphoma, T-Cell, Peripheral",
-            "mature T-cell and NK-cell lymphoma",
-            "Peripheral T-Cell Lymphoma",
-            "Peripheral T-cell lymphoma",
-            "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:21919697",
-            "http://www.cancer.gov/dictionary?cdrid=393800",
-            "http://www.cancer.gov/dictionary?cdrid=44062",
-            "http://en.wikipedia.org/wiki/peripheral_t-cell_lymphoma"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 535028,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000430",
-              "name": "mature T-cell and NK-cell non-Hodgkin lymphoma",
-              "description": "A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10034624",
-                "MONDO:0000430",
-                "MEDDRA:10034623",
-                "UMLS:C1337073",
-                "MESH:D016411",
-                "UMLS:C1337074",
-                "NCIT:C27352",
-                "UMLS:C0079774",
-                "UMLS:C5551485",
-                "UMLS:C1337079",
-                "DOID:0050743",
-                "NCIT:C7204",
-                "UMLS:C0334655",
-                "NCIT:C3468",
-                "DOID:0050749",
-                "SNOMEDCT:109977009",
-                "ICD9:202.7",
-                "SNOMEDCT:1163404000",
-                "SNOMEDCT:109975001"
-              ],
-              "id": "MONDO:0000430",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Peripheral T-Cell Lymphoma, Large Cell",
-                "T-Zone Variant Peripheral T-Cell Lymphoma",
-                "mature T-cell and NK-cell non-Hodgkin lymphoma",
-                "peripheral T-cell lymphoma",
-                "T-zone lymphoma (clinical)",
-                "Lymphoma, T-Cell, Peripheral",
-                "mature T-cell and NK-cell lymphoma",
-                "Peripheral T-Cell Lymphoma",
-                "Peripheral T-cell lymphoma",
-                "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:21919697",
-                "http://www.cancer.gov/dictionary?cdrid=393800",
-                "http://www.cancer.gov/dictionary?cdrid=44062",
-                "http://en.wikipedia.org/wiki/peripheral_t-cell_lymphoma"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21241843,
-            "start": 622,
-            "end": 535028,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32016790': {'publication date': '2020 Feb 03', 'sentence': 'BV is a major therapeutic advance in the treatment of patients with R/R CTCL and of those with PTCL in both the R/R and frontline settings.', 'subject score': 1000, 'object score': 928}, 'PMID:32934797': {'publication date': '2020', 'sentence': 'Given its success and tolerability in this pretreated population, brentuximab vedotin, an anti-CD30 antibody drug conjugate, was brought earlier in the disease course and is a model for advances in the targeted treatment of PTCL.', 'subject score': 1000, 'object score': 1000}, 'PMID:34263699': {'publication date': '2021 Jul 15', 'sentence': 'Large-scale randomized, controlled studies have shown that CD30-directed treatment with brentuximab vedotin is significantly more effective against CD30-expressing PTCL and CTCL than current standard-of-care regimens.', 'subject score': 1000, 'object score': 802}, 'PMID:34427738': {'publication date': '2021 Aug 24', 'sentence': 'Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin.', 'subject score': 1000, 'object score': 1000}, 'PMID:34797505': {'publication date': '2021 Nov 19', 'sentence': 'METHODS: Analysis of a real-world, observational, retrospective case series in patients suffering from AITL, sALCL and peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH) and other types of PTCL treated with BV in frontline treatment was conducted.', 'subject score': 1000, 'object score': 1000}, 'PMID:36975736': {'publication date': '2023 Mar 22', 'sentence': 'Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma.', 'subject score': 901, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:treats---None---None---None---UMLS:C0079774---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "21657991",
-              "object": "MONDO:0000430",
-              "publications": [
-                "PMID:32016790",
-                "PMID:32934797",
-                "PMID:34263699",
-                "PMID:34427738",
-                "PMID:34797505",
-                "PMID:36975736"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 318142,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000607",
-          "name": "primary cutaneous T-cell non-Hodgkin lymphoma",
-          "description": "A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.; A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.; A type of T-cell lymphoma that exhibits malignant infiltration of the skin. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "NCIT:C3467",
-            "EFO:0002913",
-            "SNOMEDCT:1162973007",
-            "SNOMEDCT:28054005",
-            "MONDO:0000607",
-            "MEDDRA:10011677",
-            "DOID:0060061",
-            "MESH:D016410",
-            "SNOMEDCT:1187136005",
-            "UMLS:C0079773",
-            "HP:0012192",
-            "SNOMEDCT:400122007"
-          ],
-          "id": "MONDO:0000607",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cutaneous T-cell lymphoma",
-            "primary cutaneous T-cell non-Hodgkin lymphoma",
-            "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
-            "Lymphoma, T-Cell, Cutaneous"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/cutaneous_t-cell_lymphoma",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318142,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000607",
-              "name": "primary cutaneous T-cell non-Hodgkin lymphoma",
-              "description": "A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.; A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.; A type of T-cell lymphoma that exhibits malignant infiltration of the skin. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "NCIT:C3467",
-                "EFO:0002913",
-                "SNOMEDCT:1162973007",
-                "SNOMEDCT:28054005",
-                "MONDO:0000607",
-                "MEDDRA:10011677",
-                "DOID:0060061",
-                "MESH:D016410",
-                "SNOMEDCT:1187136005",
-                "UMLS:C0079773",
-                "HP:0012192",
-                "SNOMEDCT:400122007"
-              ],
-              "id": "MONDO:0000607",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cutaneous T-cell lymphoma",
-                "primary cutaneous T-cell non-Hodgkin lymphoma",
-                "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
-                "Lymphoma, T-Cell, Cutaneous"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/cutaneous_t-cell_lymphoma",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21241842,
-            "start": 622,
-            "end": 318142,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32016790': {'publication date': '2020 Feb 03', 'sentence': 'BV is a major therapeutic advance in the treatment of patients with R/R CTCL and of those with PTCL in both the R/R and frontline settings.', 'subject score': 1000, 'object score': 851}, 'PMID:33100177': {'publication date': '2020 Oct 25', 'sentence': 'Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma.INTRODUCTION: Brentuximab vedotin (Bv) has been approved for the treatment of Refractory/Relapsed (R/R) Anaplastic Large Cell Lymphomas (ALCL) and cutaneous T-Cell Lymphomas, but is also effective in other CD30+ malignancies.', 'subject score': 1000, 'object score': 1000}, 'PMID:33377934': {'publication date': '2020 Dec 30', 'sentence': \"However, limited data exist on its efficacy in SS, including in the pivotal phase 3 ALCANZA (A Phase 3 Trial of Brentuximab Vedotin (SGN-35) Versus Physician's Choice [Methotrexate or Bexarotene] in Participants With CD30-Positive Cutaneous T-Cell Lymphoma) trial.\", 'subject score': 1000, 'object score': 901}, 'PMID:33617153': {'publication date': '2021 Feb 22', 'sentence': 'PATIENTS AND METHODS: This is a retrospective monocentric study analyzing treatment outcomes for patients with CD30-positive cutaneous T-cell lymphoma treated with BV.', 'subject score': 1000, 'object score': 901}, 'PMID:34263699': {'publication date': '2021 Jul 15', 'sentence': 'Large-scale randomized, controlled studies have shown that CD30-directed treatment with brentuximab vedotin is significantly more effective against CD30-expressing PTCL and CTCL than current standard-of-care regimens.', 'subject score': 1000, 'object score': 1000}, 'PMID:34608632': {'publication date': '2021 Oct 05', 'sentence': 'Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: A single-centre retrospective review.', 'subject score': 1000, 'object score': 901}, 'PMID:34879742': {'publication date': '2021 Dec 09', 'sentence': 'Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:35235473': {'publication date': '2022 Mar 02', 'sentence': 'EXPERT OPINION: Mogamulizumab and brentuximab vedotin have reached the market and are approved for the treatment of CTCL, providing valuable options.', 'subject score': 1000, 'object score': 1000}, 'PMID:35319153': {'publication date': '2022 Mar 23', 'sentence': 'Long term survival, time to next treatment and CD30 expression in patients with advanced CD30     +       cutaneous T-cell lymphoma treated with Brentuximab vedotin - A monocentric retrospective analysis of twelve patients.', 'subject score': 1000, 'object score': 876}, 'PMID:35466174': {'publication date': '2022 Mar 23', 'sentence': 'Aggressive Primary Cutaneous Anaplastic T-Cell Lymphoma Successfully Treated with Autologous Stem Cell Transplant and Brentuximab Vedotin Consolidation: Case Report and Review of the Literature.', 'subject score': 901, 'object score': 892}, 'PMID:36017748': {'publication date': '2022 Aug 26', 'sentence': 'METHODS: We analyzed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP).', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:treats---None---None---None---UMLS:C0079773---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "21657990",
-              "object": "MONDO:0000607",
-              "publications": [
-                "PMID:32016790",
-                "PMID:33100177",
-                "PMID:33377934",
-                "PMID:33617153",
-                "PMID:34263699",
-                "PMID:34608632",
-                "PMID:34879742",
-                "PMID:35235473",
-                "PMID:35319153",
-                "PMID:35466174",
-                "PMID:36017748"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 535037,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0017844",
-          "name": "Sezary syndrome",
-          "description": "A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood. Sezary syndrome is an aggressive disease. (WHO, 2001); A form of cutaneous T-cell lymphoma manifested by generalized exfoliative ERYTHRODERMA; PRURITUS; peripheral lymphadenopathy, and abnormal hyperchromatic mononuclear (cerebriform) cells in the skin, LYMPH NODES, and peripheral blood (Sezary cells).; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "ORPHANET:3162",
-            "ICD9:202.2",
-            "SNOMEDCT:118611004",
-            "DOID:8541",
-            "MONDO:0017844",
-            "MEDDRA:10040493",
-            "NCIT:C3366",
-            "SNOMEDCT:4950009",
-            "ICD10:C84.1",
-            "MEDDRA:10040516",
-            "UMLS:C0036920",
-            "EFO:1000785",
-            "MEDDRA:10040500",
-            "MESH:D012751"
-          ],
-          "id": "MONDO:0017844",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Sézary syndrome",
-            "Sezary Syndrome",
-            "Sezary's disease",
-            "Sezary syndrome"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 535037,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0017844",
-              "name": "Sezary syndrome",
-              "description": "A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood. Sezary syndrome is an aggressive disease. (WHO, 2001); A form of cutaneous T-cell lymphoma manifested by generalized exfoliative ERYTHRODERMA; PRURITUS; peripheral lymphadenopathy, and abnormal hyperchromatic mononuclear (cerebriform) cells in the skin, LYMPH NODES, and peripheral blood (Sezary cells).; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "ORPHANET:3162",
-                "ICD9:202.2",
-                "SNOMEDCT:118611004",
-                "DOID:8541",
-                "MONDO:0017844",
-                "MEDDRA:10040493",
-                "NCIT:C3366",
-                "SNOMEDCT:4950009",
-                "ICD10:C84.1",
-                "MEDDRA:10040516",
-                "UMLS:C0036920",
-                "EFO:1000785",
-                "MEDDRA:10040500",
-                "MESH:D012751"
-              ],
-              "id": "MONDO:0017844",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Sézary syndrome",
-                "Sezary Syndrome",
-                "Sezary's disease",
-                "Sezary syndrome"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21182106,
-            "start": 622,
-            "end": 535037,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31959414': {'publication date': '2020 Jan 17', 'sentence': '[Ulceration of lymphomatous skin lesions in a patient with Sezary syndrome treated with brentuximab-vedotin].BACKGROUND: Brentuximab-vedotin (BV), an anti-CD30 agent combined with an anti-neoplastic agent, has recently yielded promising results in the treatment of cutaneous T-lymphomas such as Sezary syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:33377934': {'publication date': '2020 Dec 30', 'sentence': 'All patients were 18 years or older with a diagnosis of SS and with B2 blood involvement at the time brentuximab vedotin therapy was initiated.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:treats---None---None---None---UMLS:C0036920---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "21596847",
-              "object": "MONDO:0017844",
-              "publications": [
-                "PMID:31959414",
-                "PMID:33377934"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 730105,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019471",
-          "name": "adult T-cell leukemia/lymphoma",
-          "description": "A peripheral (mature) T-cell neoplasm caused by the human T-cell leukemia virus type 1 (HTLV-1). Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3184\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3184\" NCI Thesaurus); A peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1). Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa.; Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.",
-          "equivalent_curies": [
-            "MEDDRA:10001412",
-            "SNOMEDCT:110007008",
-            "UMLS:C0023493",
-            "MESH:D015459",
-            "MONDO:0019471",
-            "MEDDRA:10001415",
-            "MEDDRA:10001413",
-            "ICD10:C91.5",
-            "SNOMEDCT:77430005",
-            "MEDDRA:10001414",
-            "MEDDRA:10054298",
-            "DOID:0050523",
-            "PDQ:CDR0000040694",
-            "ORPHANET:86875",
-            "NCIT:C3184"
-          ],
-          "id": "MONDO:0019471",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Leukemia-Lymphoma, Adult T-Cell",
-            "Adult T-Cell Leukemia/Lymphoma",
-            "Adult T-cell leukemia/lymphoma",
-            "Adult T-Cell Lymphoma/Leukemia",
-            "adult T-cell leukemia/lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/adult_t-cell_leukemia/lymphoma",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c3184"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 730105,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019471",
-              "name": "adult T-cell leukemia/lymphoma",
-              "description": "A peripheral (mature) T-cell neoplasm caused by the human T-cell leukemia virus type 1 (HTLV-1). Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa. (WHO, 2001) Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3184\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3184\" NCI Thesaurus); A peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1). Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa.; Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.",
-              "equivalent_curies": [
-                "MEDDRA:10001412",
-                "SNOMEDCT:110007008",
-                "UMLS:C0023493",
-                "MESH:D015459",
-                "MONDO:0019471",
-                "MEDDRA:10001415",
-                "MEDDRA:10001413",
-                "ICD10:C91.5",
-                "SNOMEDCT:77430005",
-                "MEDDRA:10001414",
-                "MEDDRA:10054298",
-                "DOID:0050523",
-                "PDQ:CDR0000040694",
-                "ORPHANET:86875",
-                "NCIT:C3184"
-              ],
-              "id": "MONDO:0019471",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Leukemia-Lymphoma, Adult T-Cell",
-                "Adult T-Cell Leukemia/Lymphoma",
-                "Adult T-cell leukemia/lymphoma",
-                "Adult T-Cell Lymphoma/Leukemia",
-                "adult T-cell leukemia/lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/adult_t-cell_leukemia/lymphoma",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c3184"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21155390,
-            "start": 622,
-            "end": 730105,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31934889': {'publication date': '2020 Jan 10', 'sentence': 'Further investigations on the use of brentuximab vedotin for adult T-cell leukemia/lymphoma are needed.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:treats---None---None---None---UMLS:C0023493---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "21569598",
-              "object": "MONDO:0019471",
-              "publications": [
-                "PMID:31934889"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 319679,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-          "name": "lymphoma",
-          "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "SNOMEDCT:115244002",
-            "DOID:0060058",
-            "MONDO:0005062",
-            "SNOMEDCT:118600007",
-            "HP:0002665",
-            "NCIT:C7065",
-            "EFO:0000574",
-            "ORPHANET:223735",
-            "MESH:D008223",
-            "SNOMEDCT:188676008",
-            "PDQ:CDR0000041429",
-            "MEDDRA:10025316",
-            "UMLS:C0024299",
-            "NCIT:C3208",
-            "MEDDRA:10025632",
-            "MEDDRA:10025310",
-            "MEDDRA:10025633",
-            "SNOMEDCT:1163043007",
-            "ICD10:C85.9",
-            "UMLS:C1536843",
-            "UMLS:C0334621",
-            "MEDDRA:10025315"
-          ],
-          "id": "MONDO:0005062",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphocytic Neoplasm",
-            "Lymphoma",
-            "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-            "lymphoma"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://en.wikipedia.org/wiki/lymphoma",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319679,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005062",
-              "name": "lymphoma",
-              "description": "A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C3208\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C3208\" NCI Thesaurus); A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.; A general term for various neoplastic diseases of the lymphoid tissue.; A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [HPO:probinson]; Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss  Fever  Soaking night sweats  Coughing, trouble breathing or chest pain  Weakness and tiredness that don't go away  Pain, swelling or a feeling of fullness in the abdomen   Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute; UMLS Semantic Type: STY:T191; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "SNOMEDCT:115244002",
-                "DOID:0060058",
-                "MONDO:0005062",
-                "SNOMEDCT:118600007",
-                "HP:0002665",
-                "NCIT:C7065",
-                "EFO:0000574",
-                "ORPHANET:223735",
-                "MESH:D008223",
-                "SNOMEDCT:188676008",
-                "PDQ:CDR0000041429",
-                "MEDDRA:10025316",
-                "UMLS:C0024299",
-                "NCIT:C3208",
-                "MEDDRA:10025632",
-                "MEDDRA:10025310",
-                "MEDDRA:10025633",
-                "SNOMEDCT:1163043007",
-                "ICD10:C85.9",
-                "UMLS:C1536843",
-                "UMLS:C0334621",
-                "MEDDRA:10025315"
-              ],
-              "id": "MONDO:0005062",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphocytic Neoplasm",
-                "Lymphoma",
-                "Diffuse non-Hodgkin's mixed small and large cell (diffuse) lymphoma",
-                "lymphoma"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://en.wikipedia.org/wiki/lymphoma",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.lymphoma.org/site/pp.asp?c=bkltkaoqlmk8e&b=6300161",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nlm.nih.gov/medlineplus/lymphoma.htm"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21155385,
-            "start": 622,
-            "end": 319679,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31934889': {'publication date': '2020 Jan 10', 'sentence': 'Brentuximab vedotin represents a major breakthrough in the treatment of CD30-positive lymphomas.', 'subject score': 1000, 'object score': 901}, 'PMID:31955620': {'publication date': '2020 May', 'sentence': 'Methods    : Articles were retrieved from PubMed, Cochrane, and Clinicaltrials Databases to identify randomized controlled trials (RCTs) comparing brentuximab vedotin with non-brentuximab vedotin in lymphoma patients.', 'subject score': 901, 'object score': 888}, 'PMID:34090506': {'publication date': '2021 Jun 05', 'sentence': 'In recent years, three ADCs, brentuximab vedotin, polatuzumab vedotin, and loncastuximab tesirine, have been approved and are already establishing their place in lymphoma treatment.', 'subject score': 1000, 'object score': 888}, 'PMID:35158894': {'publication date': '2022 Jan 26', 'sentence': 'The later clinical success of the first approved antibody-drug conjugate (ADC) for the treatment of lymphomas, anti-CD30 brentuximab vedotin, paved the path for the preclinical development and clinical testing of several other ADCs, including polatuzumab vedotin and loncastuximab tesirine.', 'subject score': 824, 'object score': 1000}, 'PMID:36512081': {'publication date': '2022 Dec 13', 'sentence': 'This narrative review summarizes 10 years of experience with brentuximab vedotin for the treatment of CD30-positive lymphomas, discusses novel therapies targeting CD30 in development, and highlights remaining controversies relating to CD30-targeted therapy across lymphoma types.', 'subject score': 1000, 'object score': 901}, 'PMID:36987732': {'publication date': '2023 Jan 14', 'sentence': '[Advances in the treatment of CD30 positive lymphoma with brentuximab vedotin].', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:treats---None---None---None---UMLS:C0024299---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "21569593",
-              "object": "MONDO:0005062",
-              "publications": [
-                "PMID:31934889",
-                "PMID:31955620",
-                "PMID:34090506",
-                "PMID:35158894",
-                "PMID:36512081",
-                "PMID:36987732"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:31899248': {'publication date': '2019 Dec 30', 'sentence': 'Currently, ADCs that have received regulatory approval include brentuximab vedotin for CD30-positive Hodgkin lymphoma and trastuzumab emtansine for human epidermal growth factor receptor 2-positive breast cancer.', 'subject score': 1000, 'object score': 888}, 'PMID:32054647': {'publication date': '2020 Feb 13', 'sentence': 'Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS.', 'subject score': 1000, 'object score': 888}, 'PMID:32308602': {'publication date': '2020 Jan-Apr', 'sentence': \"Complete Remission of Relapsed Hodgkin's Lymphoma following Brentuximab Vedotin and Gemcitabine Combination Therapy with Severe Hypotension as Possible Treatment-Related Adverse Event: A Case Report.A 40-year-old Asian female with heavily treated relapsed Hodgkin's lymphoma showed complete remission (CR) after receiving 8 cycles of brentuximab vedotin (BV) in combination with gemcitabine as 4th line treatment.\", 'subject score': 1000, 'object score': 901}, 'PMID:32328822': {'publication date': '2020 Apr 23', 'sentence': 'Data incorporating brentuximab vedotin sequentially before and after AVD chemotherapy represent the best-reported outcomes in older HL patients to date.', 'subject score': 861, 'object score': 850}, 'PMID:32457620': {'publication date': '2020', 'sentence': 'The two off-label cases categorized as \"age\" were both related to the use of brentuximab vedotin for Hodgkin\\'s lymphoma in patients aged 16 years.', 'subject score': 1000, 'object score': 1000}, 'PMID:32461524': {'publication date': '2020 May 26', 'sentence': 'A Case of Methotrexate-associated Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis Successfully Treated with Brentuximab Vedotin in Combination with Doxorubicin, Vinblastine, and Dacarbazine (BV+AVD).A 53-year-old woman had been diagnosed with rheumatoid arthritis (RA) in X-6.', 'subject score': 1000, 'object score': 824}, 'PMID:32686619': {'publication date': '2020 Jul 19', 'sentence': \"Rapid desensitization to brentuximab vedotin after severe anaphylaxis in the treatment of refractory Hodgkin's lymphoma.INTRODUCTION: Brentuximab vedotin is a monoclonal antibody drug conjugate used for the treatment of patients with Hodgkin lymphoma.\", 'subject score': 1000, 'object score': 1000}, 'PMID:33054094': {'publication date': '2020 Feb 13', 'sentence': 'Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS.', 'subject score': 1000, 'object score': 888}, 'PMID:33826362': {'publication date': '2021 Apr 07', 'sentence': 'CONCLUSION: The integration of brentuximab vedotin in the frontline treatment of pediatric high-risk HL is highly tolerable, facilitated significant reduction in radiation exposure, and yielded excellent outcomes.', 'subject score': 1000, 'object score': 857}, 'PMID:34366266': {'publication date': '2021 Jul 12', 'sentence': 'CONCLUSIONS: HL patients treated with BV for relapse or consolidation who achieved CR by PET-CT after 4 cycles showed improved PFS and OS compared to non-responders.', 'subject score': 1000, 'object score': 901}, 'PMID:34698453': {'publication date': '2021 Oct 25', 'sentence': 'He was finally diagnosed with HL and underwent chemotherapy with doxorubicin, vinblastine, dacarbazine, and brentuximab vedotin.', 'subject score': 1000, 'object score': 1000}, 'PMID:35435235': {'publication date': '2022 Apr 18', 'sentence': 'Incorporating novel targeted agents such as brentuximab vedotin into therapies for older Hodgkin lymphoma patients might be a promising alternative to the anthracycline-containing regimen.', 'subject score': 1000, 'object score': 850}, 'PMID:35466174': {'publication date': '2022 Mar 23', 'sentence': 'The case we present-relapsed after surgical excision, immunosuppressive therapy, and conventional chemotherapy-is the first one treated with Autologous Stem Cell transplant followed by Brentuximab Vedotin consolidation, a scheme already used for high risk Hodgkin Lymphoma.', 'subject score': 901, 'object score': 888}, 'PMID:35734588': {'publication date': '2022', 'sentence': 'Three years later, the patient further developed a clonally unrelated HL, refractory to bendamustine, which was successfully treated with brentuximab vedotin and radiotherapy, and later with pembrolizumab.', 'subject score': 1000, 'object score': 861}, 'PMID:36161579': {'publication date': '2022 Sep 26', 'sentence': 'In addition to the above, Moorea sp. produce apratoxin A and dolastatin 15 possessing anti cancerous activity but unfortunately till date only brentuximab vedotin (trade name Adcetris), a medication derived from marine peptides, for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma has been approved by FDA.', 'subject score': 762, 'object score': 1000}, 'PMID:36370191': {'publication date': '2022 Nov 12', 'sentence': 'Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.', 'subject score': 1000, 'object score': 888}, 'PMID:36975736': {'publication date': '2023 Mar 22', 'sentence': \"Recently, Brentuximab Vedotin (BV) has emerged as an important therapy not only for Hodgkin's Lymphoma, but also for CD30-positive T cell lymphomas.\", 'subject score': 1000, 'object score': 1000}, 'PMID:37025732': {'publication date': '2023 Mar', 'sentence': \"Antibody-drug conjugates such as brentuximab vedotin are now being used to treat Hodgkin's lymphoma that has not responded to standard treatment.\", 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 318155,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004952",
-          "name": "Hodgkins lymphoma",
-          "description": "A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma has a bimodal age distribution, and involves primarily lymph nodes. Current therapy for Hodgkin lymphoma has resulted in an excellent outcome and cure for the majority of patients. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C9357\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C9357\" NCI Thesaurus); UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MEDDRA:10020309",
-            "SNOMEDCT:1163005009",
-            "ORPHANET:98293",
-            "UMLS:C5235037",
-            "NCIT:C6914",
-            "MEDDRA:10020255",
-            "SNOMEDCT:118606001",
-            "MEDDRA:10063666",
-            "SNOMEDCT:46923007",
-            "ICD10:C81",
-            "UMLS:C0019829",
-            "ICD9:201.2",
-            "SNOMEDCT:836277009",
-            "SNOMEDCT:74189002",
-            "MEDDRA:10020206",
-            "MESH:D006689",
-            "MEDDRA:10020328",
-            "MEDDRA:10020329",
-            "HP:0012189",
-            "SNOMEDCT:118599009",
-            "NCIT:C9357",
-            "ICD9:201",
-            "NCIT:C26956",
-            "SNOMEDCT:118605002",
-            "SNOMEDCT:118602004",
-            "NCIT:C164145",
-            "PDQ:CDR0000041646",
-            "MEDDRA:10025319",
-            "MEDDRA:10020318",
-            "EFO:0000183",
-            "DOID:8567",
-            "SNOMEDCT:14537002",
-            "MONDO:0004952",
-            "SNOMEDCT:836276000",
-            "MEDDRA:10020339",
-            "SNOMEDCT:70600005"
-          ],
-          "id": "MONDO:0004952",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Hodgkin Lymphoma",
-            "Hodgkin lymphoma",
-            "Hodgkin's Paragranuloma",
-            "Hodgkin's sarcoma",
-            "Hodgkin sarcoma",
-            "Hodgkin's lymphoma",
-            "Hodgkins lymphoma",
-            "Hodgkin's Granuloma",
-            "Hodgkin's Sarcoma",
-            "Hodgkin Disease",
-            "Hodgkin's disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/hodgkin%27s_lymphoma",
-            "PMID:22835602",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318155,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004952",
-              "name": "Hodgkins lymphoma",
-              "description": "A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma has a bimodal age distribution, and involves primarily lymph nodes. Current therapy for Hodgkin lymphoma has resulted in an excellent outcome and cure for the majority of patients. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C9357\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C9357\" NCI Thesaurus); UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MEDDRA:10020309",
-                "SNOMEDCT:1163005009",
-                "ORPHANET:98293",
-                "UMLS:C5235037",
-                "NCIT:C6914",
-                "MEDDRA:10020255",
-                "SNOMEDCT:118606001",
-                "MEDDRA:10063666",
-                "SNOMEDCT:46923007",
-                "ICD10:C81",
-                "UMLS:C0019829",
-                "ICD9:201.2",
-                "SNOMEDCT:836277009",
-                "SNOMEDCT:74189002",
-                "MEDDRA:10020206",
-                "MESH:D006689",
-                "MEDDRA:10020328",
-                "MEDDRA:10020329",
-                "HP:0012189",
-                "SNOMEDCT:118599009",
-                "NCIT:C9357",
-                "ICD9:201",
-                "NCIT:C26956",
-                "SNOMEDCT:118605002",
-                "SNOMEDCT:118602004",
-                "NCIT:C164145",
-                "PDQ:CDR0000041646",
-                "MEDDRA:10025319",
-                "MEDDRA:10020318",
-                "EFO:0000183",
-                "DOID:8567",
-                "SNOMEDCT:14537002",
-                "MONDO:0004952",
-                "SNOMEDCT:836276000",
-                "MEDDRA:10020339",
-                "SNOMEDCT:70600005"
-              ],
-              "id": "MONDO:0004952",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Hodgkin Lymphoma",
-                "Hodgkin lymphoma",
-                "Hodgkin's Paragranuloma",
-                "Hodgkin's sarcoma",
-                "Hodgkin sarcoma",
-                "Hodgkin's lymphoma",
-                "Hodgkins lymphoma",
-                "Hodgkin's Granuloma",
-                "Hodgkin's Sarcoma",
-                "Hodgkin Disease",
-                "Hodgkin's disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/hodgkin%27s_lymphoma",
-                "PMID:22835602",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21111679,
-            "start": 622,
-            "end": 318155,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31899248': {'publication date': '2019 Dec 30', 'sentence': 'Currently, ADCs that have received regulatory approval include brentuximab vedotin for CD30-positive Hodgkin lymphoma and trastuzumab emtansine for human epidermal growth factor receptor 2-positive breast cancer.', 'subject score': 1000, 'object score': 888}, 'PMID:32054647': {'publication date': '2020 Feb 13', 'sentence': 'Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS.', 'subject score': 1000, 'object score': 888}, 'PMID:32308602': {'publication date': '2020 Jan-Apr', 'sentence': \"Complete Remission of Relapsed Hodgkin's Lymphoma following Brentuximab Vedotin and Gemcitabine Combination Therapy with Severe Hypotension as Possible Treatment-Related Adverse Event: A Case Report.A 40-year-old Asian female with heavily treated relapsed Hodgkin's lymphoma showed complete remission (CR) after receiving 8 cycles of brentuximab vedotin (BV) in combination with gemcitabine as 4th line treatment.\", 'subject score': 1000, 'object score': 901}, 'PMID:32328822': {'publication date': '2020 Apr 23', 'sentence': 'Data incorporating brentuximab vedotin sequentially before and after AVD chemotherapy represent the best-reported outcomes in older HL patients to date.', 'subject score': 861, 'object score': 850}, 'PMID:32457620': {'publication date': '2020', 'sentence': 'The two off-label cases categorized as \"age\" were both related to the use of brentuximab vedotin for Hodgkin\\'s lymphoma in patients aged 16 years.', 'subject score': 1000, 'object score': 1000}, 'PMID:32461524': {'publication date': '2020 May 26', 'sentence': 'A Case of Methotrexate-associated Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis Successfully Treated with Brentuximab Vedotin in Combination with Doxorubicin, Vinblastine, and Dacarbazine (BV+AVD).A 53-year-old woman had been diagnosed with rheumatoid arthritis (RA) in X-6.', 'subject score': 1000, 'object score': 824}, 'PMID:32686619': {'publication date': '2020 Jul 19', 'sentence': \"Rapid desensitization to brentuximab vedotin after severe anaphylaxis in the treatment of refractory Hodgkin's lymphoma.INTRODUCTION: Brentuximab vedotin is a monoclonal antibody drug conjugate used for the treatment of patients with Hodgkin lymphoma.\", 'subject score': 1000, 'object score': 1000}, 'PMID:33054094': {'publication date': '2020 Feb 13', 'sentence': 'Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS.', 'subject score': 1000, 'object score': 888}, 'PMID:33826362': {'publication date': '2021 Apr 07', 'sentence': 'CONCLUSION: The integration of brentuximab vedotin in the frontline treatment of pediatric high-risk HL is highly tolerable, facilitated significant reduction in radiation exposure, and yielded excellent outcomes.', 'subject score': 1000, 'object score': 857}, 'PMID:34366266': {'publication date': '2021 Jul 12', 'sentence': 'CONCLUSIONS: HL patients treated with BV for relapse or consolidation who achieved CR by PET-CT after 4 cycles showed improved PFS and OS compared to non-responders.', 'subject score': 1000, 'object score': 901}, 'PMID:34698453': {'publication date': '2021 Oct 25', 'sentence': 'He was finally diagnosed with HL and underwent chemotherapy with doxorubicin, vinblastine, dacarbazine, and brentuximab vedotin.', 'subject score': 1000, 'object score': 1000}, 'PMID:35435235': {'publication date': '2022 Apr 18', 'sentence': 'Incorporating novel targeted agents such as brentuximab vedotin into therapies for older Hodgkin lymphoma patients might be a promising alternative to the anthracycline-containing regimen.', 'subject score': 1000, 'object score': 850}, 'PMID:35466174': {'publication date': '2022 Mar 23', 'sentence': 'The case we present-relapsed after surgical excision, immunosuppressive therapy, and conventional chemotherapy-is the first one treated with Autologous Stem Cell transplant followed by Brentuximab Vedotin consolidation, a scheme already used for high risk Hodgkin Lymphoma.', 'subject score': 901, 'object score': 888}, 'PMID:35734588': {'publication date': '2022', 'sentence': 'Three years later, the patient further developed a clonally unrelated HL, refractory to bendamustine, which was successfully treated with brentuximab vedotin and radiotherapy, and later with pembrolizumab.', 'subject score': 1000, 'object score': 861}, 'PMID:36161579': {'publication date': '2022 Sep 26', 'sentence': 'In addition to the above, Moorea sp. produce apratoxin A and dolastatin 15 possessing anti cancerous activity but unfortunately till date only brentuximab vedotin (trade name Adcetris), a medication derived from marine peptides, for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma has been approved by FDA.', 'subject score': 762, 'object score': 1000}, 'PMID:36370191': {'publication date': '2022 Nov 12', 'sentence': 'Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.', 'subject score': 1000, 'object score': 888}, 'PMID:36975736': {'publication date': '2023 Mar 22', 'sentence': \"Recently, Brentuximab Vedotin (BV) has emerged as an important therapy not only for Hodgkin's Lymphoma, but also for CD30-positive T cell lymphomas.\", 'subject score': 1000, 'object score': 1000}, 'PMID:37025732': {'publication date': '2023 Mar', 'sentence': \"Antibody-drug conjugates such as brentuximab vedotin are now being used to treat Hodgkin's lymphoma that has not responded to standard treatment.\", 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:treats---None---None---None---UMLS:C0019829---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "21525451",
-              "object": "MONDO:0004952",
-              "publications": [
-                "PMID:31899248",
-                "PMID:32054647",
-                "PMID:32308602",
-                "PMID:32328822",
-                "PMID:32457620",
-                "PMID:32461524",
-                "PMID:32686619",
-                "PMID:33054094",
-                "PMID:33826362",
-                "PMID:34366266",
-                "PMID:34698453",
-                "PMID:35435235",
-                "PMID:35466174",
-                "PMID:35734588",
-                "PMID:36161579",
-                "PMID:36370191",
-                "PMID:36975736",
-                "PMID:37025732"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 535036,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:31959414': {'publication date': '2020 Jan 17', 'sentence': '[Ulceration of lymphomatous skin lesions in a patient with Sezary syndrome treated with brentuximab-vedotin].BACKGROUND: Brentuximab-vedotin (BV), an anti-CD30 agent combined with an anti-neoplastic agent, has recently yielded promising results in the treatment of cutaneous T-lymphomas such as Sezary syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:33377934': {'publication date': '2020 Dec 30', 'sentence': 'All patients were 18 years or older with a diagnosis of SS and with B2 blood involvement at the time brentuximab vedotin therapy was initiated.', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 535037,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009691",
-          "name": "mycosis fungoides",
-          "description": "A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei. Patients with limited disease generally have an excellent prognosis. In the more advanced stages, the prognosis is poor. (WHO, 2001); A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "MESH:D009182",
-            "MEDDRA:10028483",
-            "MONDO:0009691",
-            "UMLS:C0026948",
-            "SNOMEDCT:90120004",
-            "NCIT:C3246",
-            "ICD9:202.1",
-            "OMIM:254400",
-            "ORPHANET:2584",
-            "MEDDRA:10028484",
-            "ICD10:C84.0",
-            "DOID:8691",
-            "EFO:1001051",
-            "MEDDRA:10028500",
-            "SNOMEDCT:118618005"
-          ],
-          "id": "MONDO:0009691",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Mycosis fungoides",
-            "Mycosis fungoides related phenotypic feature",
-            "Classic mycosis fungoides",
-            "mycosis fungoides",
-            "Mycosis Fungoides"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0017844",
-          "name": "Sezary syndrome",
-          "description": "A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood. Sezary syndrome is an aggressive disease. (WHO, 2001); A form of cutaneous T-cell lymphoma manifested by generalized exfoliative ERYTHRODERMA; PRURITUS; peripheral lymphadenopathy, and abnormal hyperchromatic mononuclear (cerebriform) cells in the skin, LYMPH NODES, and peripheral blood (Sezary cells).; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "ORPHANET:3162",
-            "ICD9:202.2",
-            "SNOMEDCT:118611004",
-            "DOID:8541",
-            "MONDO:0017844",
-            "MEDDRA:10040493",
-            "NCIT:C3366",
-            "SNOMEDCT:4950009",
-            "ICD10:C84.1",
-            "MEDDRA:10040516",
-            "UMLS:C0036920",
-            "EFO:1000785",
-            "MEDDRA:10040500",
-            "MESH:D012751"
-          ],
-          "id": "MONDO:0017844",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Sézary syndrome",
-            "Sezary Syndrome",
-            "Sezary's disease",
-            "Sezary syndrome"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 535036,
-=======
-            "identity": 535037,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009691",
-              "name": "mycosis fungoides",
-              "description": "A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei. Patients with limited disease generally have an excellent prognosis. In the more advanced stages, the prognosis is poor. (WHO, 2001); A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "MESH:D009182",
-                "MEDDRA:10028483",
-                "MONDO:0009691",
-                "UMLS:C0026948",
-                "SNOMEDCT:90120004",
-                "NCIT:C3246",
-                "ICD9:202.1",
-                "OMIM:254400",
-                "ORPHANET:2584",
-                "MEDDRA:10028484",
-                "ICD10:C84.0",
-                "DOID:8691",
-                "EFO:1001051",
-                "MEDDRA:10028500",
-                "SNOMEDCT:118618005"
-              ],
-              "id": "MONDO:0009691",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Mycosis fungoides",
-                "Mycosis fungoides related phenotypic feature",
-                "Classic mycosis fungoides",
-                "mycosis fungoides",
-                "Mycosis Fungoides"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0017844",
-              "name": "Sezary syndrome",
-              "description": "A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood. Sezary syndrome is an aggressive disease. (WHO, 2001); A form of cutaneous T-cell lymphoma manifested by generalized exfoliative ERYTHRODERMA; PRURITUS; peripheral lymphadenopathy, and abnormal hyperchromatic mononuclear (cerebriform) cells in the skin, LYMPH NODES, and peripheral blood (Sezary cells).; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "ORPHANET:3162",
-                "ICD9:202.2",
-                "SNOMEDCT:118611004",
-                "DOID:8541",
-                "MONDO:0017844",
-                "MEDDRA:10040493",
-                "NCIT:C3366",
-                "SNOMEDCT:4950009",
-                "ICD10:C84.1",
-                "MEDDRA:10040516",
-                "UMLS:C0036920",
-                "EFO:1000785",
-                "MEDDRA:10040500",
-                "MESH:D012751"
-              ],
-              "id": "MONDO:0017844",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Sézary syndrome",
-                "Sezary Syndrome",
-                "Sezary's disease",
-                "Sezary syndrome"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 21048622,
-            "start": 622,
-            "end": 535036,
-=======
-            "identity": 21182106,
-            "start": 622,
-            "end": 535037,
->>>>>>> main
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-<<<<<<< HEAD
-              "publications_info": "{'PMID:31854457': {'publication date': '2019 Dec 19', 'sentence': 'The interest of BV in the management of CD30-positive mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma has recently been demonstrated compared to methotrexate or bexarotene.', 'subject score': 1000, 'object score': 888}, 'PMID:34137025': {'publication date': '2021 Jun 16', 'sentence': 'BACKGROUND: Brentuximab Vedotin (BV) was approved as therapy for Mycosis Fungoides (MF) based on ALCANZA trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:34854114': {'publication date': '2021 Dec 01', 'sentence': 'Treatment of mycosis fungoides with brentuximab vedotin: assessing CD30 expression by immunohistochemistry and quantitative real-time PCR.', 'subject score': 1000, 'object score': 1000}, 'PMID:35262989': {'publication date': '2022 Mar 08', 'sentence': 'Diffuse alopecia areata induced by brentuximab vedotin therapy for advanced stage mycosis fungoides.', 'subject score': 901, 'object score': 888}, 'PMID:36017748': {'publication date': '2022 Aug 26', 'sentence': 'CONCLUSIONS: These results confirm the efficacy and safety of BV in patients with advanced-stage MF, and CD30 LPD.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:treats---None---None---None---UMLS:C0026948---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "21472937",
-              "object": "MONDO:0009691",
-              "publications": [
-                "PMID:31854457",
-                "PMID:34137025",
-                "PMID:34854114",
-                "PMID:35262989",
-=======
-              "publications_info": "{'PMID:31959414': {'publication date': '2020 Jan 17', 'sentence': '[Ulceration of lymphomatous skin lesions in a patient with Sezary syndrome treated with brentuximab-vedotin].BACKGROUND: Brentuximab-vedotin (BV), an anti-CD30 agent combined with an anti-neoplastic agent, has recently yielded promising results in the treatment of cutaneous T-lymphomas such as Sezary syndrome.', 'subject score': 1000, 'object score': 1000}, 'PMID:33377934': {'publication date': '2020 Dec 30', 'sentence': 'All patients were 18 years or older with a diagnosis of SS and with B2 blood involvement at the time brentuximab vedotin therapy was initiated.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:treats---None---None---None---UMLS:C0036920---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "21596847",
-              "object": "MONDO:0017844",
-              "publications": [
-                "PMID:31959414",
-                "PMID:33377934"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:32016790': {'publication date': '2020 Feb 03', 'sentence': 'In this review, we discuss key studies of BV in peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) and highlight important questions for further investigation.', 'subject score': 1000, 'object score': 1000}, 'PMID:34507350': {'publication date': '2021 Sep 10', 'sentence': \"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.\", 'subject score': 1000, 'object score': 1000}, 'PMID:36689504': {'publication date': '2023 Jan 23', 'sentence': 'Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma.', 'subject score': 901, 'object score': 937}}",
-    "p2": {
-      "start": {
-        "identity": 318142,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000607",
-          "name": "primary cutaneous T-cell non-Hodgkin lymphoma",
-          "description": "A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.; A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.; A type of T-cell lymphoma that exhibits malignant infiltration of the skin. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "NCIT:C3467",
-            "EFO:0002913",
-            "SNOMEDCT:1162973007",
-            "SNOMEDCT:28054005",
-            "MONDO:0000607",
-            "MEDDRA:10011677",
-            "DOID:0060061",
-            "MESH:D016410",
-            "SNOMEDCT:1187136005",
-            "UMLS:C0079773",
-            "HP:0012192",
-            "SNOMEDCT:400122007"
-          ],
-          "id": "MONDO:0000607",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cutaneous T-cell lymphoma",
-            "primary cutaneous T-cell non-Hodgkin lymphoma",
-            "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
-            "Lymphoma, T-Cell, Cutaneous"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/cutaneous_t-cell_lymphoma",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318142,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000607",
-              "name": "primary cutaneous T-cell non-Hodgkin lymphoma",
-              "description": "A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.; A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.; A type of T-cell lymphoma that exhibits malignant infiltration of the skin. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "NCIT:C3467",
-                "EFO:0002913",
-                "SNOMEDCT:1162973007",
-                "SNOMEDCT:28054005",
-                "MONDO:0000607",
-                "MEDDRA:10011677",
-                "DOID:0060061",
-                "MESH:D016410",
-                "SNOMEDCT:1187136005",
-                "UMLS:C0079773",
-                "HP:0012192",
-                "SNOMEDCT:400122007"
-              ],
-              "id": "MONDO:0000607",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cutaneous T-cell lymphoma",
-                "primary cutaneous T-cell non-Hodgkin lymphoma",
-                "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
-                "Lymphoma, T-Cell, Cutaneous"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/cutaneous_t-cell_lymphoma",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21241845,
-            "start": 622,
-            "end": 318142,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32016790': {'publication date': '2020 Feb 03', 'sentence': 'In this review, we discuss key studies of BV in peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) and highlight important questions for further investigation.', 'subject score': 1000, 'object score': 1000}, 'PMID:34507350': {'publication date': '2021 Sep 10', 'sentence': \"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.\", 'subject score': 1000, 'object score': 1000}, 'PMID:36689504': {'publication date': '2023 Jan 23', 'sentence': 'Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma.', 'subject score': 901, 'object score': 937}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:associated_with---None---None---None---UMLS:C0079773---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "21657993",
-              "object": "MONDO:0000607",
-              "publications": [
-                "PMID:32016790",
-                "PMID:34507350",
-                "PMID:36689504"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:32016790': {'publication date': '2020 Feb 03', 'sentence': 'BV is a major therapeutic advance in the treatment of patients with R/R CTCL and of those with PTCL in both the R/R and frontline settings.', 'subject score': 1000, 'object score': 851}, 'PMID:33100177': {'publication date': '2020 Oct 25', 'sentence': 'Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma.INTRODUCTION: Brentuximab vedotin (Bv) has been approved for the treatment of Refractory/Relapsed (R/R) Anaplastic Large Cell Lymphomas (ALCL) and cutaneous T-Cell Lymphomas, but is also effective in other CD30+ malignancies.', 'subject score': 1000, 'object score': 1000}, 'PMID:33377934': {'publication date': '2020 Dec 30', 'sentence': \"However, limited data exist on its efficacy in SS, including in the pivotal phase 3 ALCANZA (A Phase 3 Trial of Brentuximab Vedotin (SGN-35) Versus Physician's Choice [Methotrexate or Bexarotene] in Participants With CD30-Positive Cutaneous T-Cell Lymphoma) trial.\", 'subject score': 1000, 'object score': 901}, 'PMID:33617153': {'publication date': '2021 Feb 22', 'sentence': 'PATIENTS AND METHODS: This is a retrospective monocentric study analyzing treatment outcomes for patients with CD30-positive cutaneous T-cell lymphoma treated with BV.', 'subject score': 1000, 'object score': 901}, 'PMID:34263699': {'publication date': '2021 Jul 15', 'sentence': 'Large-scale randomized, controlled studies have shown that CD30-directed treatment with brentuximab vedotin is significantly more effective against CD30-expressing PTCL and CTCL than current standard-of-care regimens.', 'subject score': 1000, 'object score': 1000}, 'PMID:34608632': {'publication date': '2021 Oct 05', 'sentence': 'Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: A single-centre retrospective review.', 'subject score': 1000, 'object score': 901}, 'PMID:34879742': {'publication date': '2021 Dec 09', 'sentence': 'Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:35235473': {'publication date': '2022 Mar 02', 'sentence': 'EXPERT OPINION: Mogamulizumab and brentuximab vedotin have reached the market and are approved for the treatment of CTCL, providing valuable options.', 'subject score': 1000, 'object score': 1000}, 'PMID:35319153': {'publication date': '2022 Mar 23', 'sentence': 'Long term survival, time to next treatment and CD30 expression in patients with advanced CD30     +       cutaneous T-cell lymphoma treated with Brentuximab vedotin - A monocentric retrospective analysis of twelve patients.', 'subject score': 1000, 'object score': 876}, 'PMID:35466174': {'publication date': '2022 Mar 23', 'sentence': 'Aggressive Primary Cutaneous Anaplastic T-Cell Lymphoma Successfully Treated with Autologous Stem Cell Transplant and Brentuximab Vedotin Consolidation: Case Report and Review of the Literature.', 'subject score': 901, 'object score': 892}, 'PMID:36017748': {'publication date': '2022 Aug 26', 'sentence': 'METHODS: We analyzed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP).', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 318142,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0000607",
-          "name": "primary cutaneous T-cell non-Hodgkin lymphoma",
-          "description": "A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.; A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.; A type of T-cell lymphoma that exhibits malignant infiltration of the skin. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "NCIT:C3467",
-            "EFO:0002913",
-            "SNOMEDCT:1162973007",
-            "SNOMEDCT:28054005",
-            "MONDO:0000607",
-            "MEDDRA:10011677",
-            "DOID:0060061",
-            "MESH:D016410",
-            "SNOMEDCT:1187136005",
-            "UMLS:C0079773",
-            "HP:0012192",
-            "SNOMEDCT:400122007"
-          ],
-          "id": "MONDO:0000607",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cutaneous T-cell lymphoma",
-            "primary cutaneous T-cell non-Hodgkin lymphoma",
-            "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
-            "Lymphoma, T-Cell, Cutaneous"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/cutaneous_t-cell_lymphoma",
-            "https://orcid.org/0000-0002-0736-9199"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 318142,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0000607",
-              "name": "primary cutaneous T-cell non-Hodgkin lymphoma",
-              "description": "A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.; A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.; A type of T-cell lymphoma that exhibits malignant infiltration of the skin. [HPO:probinson]; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "NCIT:C3467",
-                "EFO:0002913",
-                "SNOMEDCT:1162973007",
-                "SNOMEDCT:28054005",
-                "MONDO:0000607",
-                "MEDDRA:10011677",
-                "DOID:0060061",
-                "MESH:D016410",
-                "SNOMEDCT:1187136005",
-                "UMLS:C0079773",
-                "HP:0012192",
-                "SNOMEDCT:400122007"
-              ],
-              "id": "MONDO:0000607",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cutaneous T-cell lymphoma",
-                "primary cutaneous T-cell non-Hodgkin lymphoma",
-                "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
-                "Lymphoma, T-Cell, Cutaneous"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/cutaneous_t-cell_lymphoma",
-                "https://orcid.org/0000-0002-0736-9199"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21241842,
-            "start": 622,
-            "end": 318142,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32016790': {'publication date': '2020 Feb 03', 'sentence': 'BV is a major therapeutic advance in the treatment of patients with R/R CTCL and of those with PTCL in both the R/R and frontline settings.', 'subject score': 1000, 'object score': 851}, 'PMID:33100177': {'publication date': '2020 Oct 25', 'sentence': 'Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma.INTRODUCTION: Brentuximab vedotin (Bv) has been approved for the treatment of Refractory/Relapsed (R/R) Anaplastic Large Cell Lymphomas (ALCL) and cutaneous T-Cell Lymphomas, but is also effective in other CD30+ malignancies.', 'subject score': 1000, 'object score': 1000}, 'PMID:33377934': {'publication date': '2020 Dec 30', 'sentence': \"However, limited data exist on its efficacy in SS, including in the pivotal phase 3 ALCANZA (A Phase 3 Trial of Brentuximab Vedotin (SGN-35) Versus Physician's Choice [Methotrexate or Bexarotene] in Participants With CD30-Positive Cutaneous T-Cell Lymphoma) trial.\", 'subject score': 1000, 'object score': 901}, 'PMID:33617153': {'publication date': '2021 Feb 22', 'sentence': 'PATIENTS AND METHODS: This is a retrospective monocentric study analyzing treatment outcomes for patients with CD30-positive cutaneous T-cell lymphoma treated with BV.', 'subject score': 1000, 'object score': 901}, 'PMID:34263699': {'publication date': '2021 Jul 15', 'sentence': 'Large-scale randomized, controlled studies have shown that CD30-directed treatment with brentuximab vedotin is significantly more effective against CD30-expressing PTCL and CTCL than current standard-of-care regimens.', 'subject score': 1000, 'object score': 1000}, 'PMID:34608632': {'publication date': '2021 Oct 05', 'sentence': 'Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: A single-centre retrospective review.', 'subject score': 1000, 'object score': 901}, 'PMID:34879742': {'publication date': '2021 Dec 09', 'sentence': 'Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma.', 'subject score': 1000, 'object score': 1000}, 'PMID:35235473': {'publication date': '2022 Mar 02', 'sentence': 'EXPERT OPINION: Mogamulizumab and brentuximab vedotin have reached the market and are approved for the treatment of CTCL, providing valuable options.', 'subject score': 1000, 'object score': 1000}, 'PMID:35319153': {'publication date': '2022 Mar 23', 'sentence': 'Long term survival, time to next treatment and CD30 expression in patients with advanced CD30     +       cutaneous T-cell lymphoma treated with Brentuximab vedotin - A monocentric retrospective analysis of twelve patients.', 'subject score': 1000, 'object score': 876}, 'PMID:35466174': {'publication date': '2022 Mar 23', 'sentence': 'Aggressive Primary Cutaneous Anaplastic T-Cell Lymphoma Successfully Treated with Autologous Stem Cell Transplant and Brentuximab Vedotin Consolidation: Case Report and Review of the Literature.', 'subject score': 901, 'object score': 892}, 'PMID:36017748': {'publication date': '2022 Aug 26', 'sentence': 'METHODS: We analyzed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP).', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:treats---None---None---None---UMLS:C0079773---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "21657990",
-              "object": "MONDO:0000607",
-              "publications": [
-                "PMID:32016790",
-                "PMID:33100177",
-                "PMID:33377934",
-                "PMID:33617153",
-                "PMID:34263699",
-                "PMID:34608632",
-                "PMID:34879742",
-                "PMID:35235473",
-                "PMID:35319153",
-                "PMID:35466174",
->>>>>>> main
-                "PMID:36017748"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 311374,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:34395429': {'publication date': '2021', 'sentence': 'Our study thus provides a feasible explanation for the clinical impact of BV in CD30     -       DLBCL and warrants confirming studies in animal models.', 'subject score': 1000, 'object score': 938}}",
-    "p2": {
-      "start": {
-        "identity": 699953,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005076",
-          "name": "periodontitis",
-          "description": "An acute or chronic inflammatory process that affects the tissues that surround and support the teeth.; Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology); Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:824",
-            "UMLS:C0600298",
-            "MEDDRA:10034540",
-            "SNOMEDCT:41565005",
-            "ICD9:523.5",
-            "DOID:9893",
-            "MESH:D010518",
-            "ICD10:K05.4",
-            "HP:0000704",
-            "UMLS:C0031099",
-            "ICD10:K05.3",
-            "MONDO:0005076",
-            "MEDDRA:10034539",
-            "NCIT:C34918",
-            "EFO:0000649"
-          ],
-          "id": "MONDO:0005076",
-          "category": "biolink:Disease",
-          "all_names": [
-            "periodontitis",
-            "Periodontitis",
-            "periodontosis",
-            "Periodontosis"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018905",
-          "name": "diffuse large B-cell lymphoma",
-          "description": "A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.; Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "NCIT:C8851",
-            "UMLS:C0079744",
-            "MEDDRA:10012819",
-            "MEDDRA:10012818",
-            "MONDO:0018905",
-            "UMLS:C2699777",
-            "NCIT:C80280",
-            "SNOMEDCT:109969005",
-            "SNOMEDCT:1172695008",
-            "MESH:D016403",
-            "ORPHANET:544",
-            "MEDDRA:10012820",
-            "DOID:0050745",
-            "EFO:0000403"
-          ],
-          "id": "MONDO:0018905",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphoma, Large B-Cell, Diffuse",
-            "diffuse large B-cell lymphoma",
-            "Diffuse Large B-Cell Lymphoma",
-            "Diffuse large B-cell lymphoma",
-            "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://orcid.org/0000-0001-5889-4463",
-            "https://orcid.org/0000-0002-9338-3017"
-=======
-            "PMID:28487884",
-            "http://en.wikipedia.org/wiki/diffuse_large_b-cell_lymphoma",
-            "https://ncithesaurus.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&ns=ncit&code=c148392"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 699953,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018905",
-              "name": "diffuse large B-cell lymphoma",
-              "description": "A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.; Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "NCIT:C8851",
-                "UMLS:C0079744",
-                "MEDDRA:10012819",
-                "MEDDRA:10012818",
-                "MONDO:0018905",
-                "UMLS:C2699777",
-                "NCIT:C80280",
-                "SNOMEDCT:109969005",
-                "SNOMEDCT:1172695008",
-                "MESH:D016403",
-                "ORPHANET:544",
-                "MEDDRA:10012820",
-                "DOID:0050745",
-                "EFO:0000403"
-              ],
-              "id": "MONDO:0018905",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphoma, Large B-Cell, Diffuse",
-                "diffuse large B-cell lymphoma",
-                "Diffuse Large B-Cell Lymphoma",
-                "Diffuse large B-cell lymphoma",
-                "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28487884",
-                "http://en.wikipedia.org/wiki/diffuse_large_b-cell_lymphoma",
-                "https://ncithesaurus.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&ns=ncit&code=c148392"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 23218881,
-            "start": 622,
-            "end": 699953,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34395429': {'publication date': '2021', 'sentence': 'Our study thus provides a feasible explanation for the clinical impact of BV in CD30     -       DLBCL and warrants confirming studies in animal models.', 'subject score': 1000, 'object score': 938}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:associated_with---None---None---None---UMLS:C0079744---SEMMEDDB:"
-              ],
-              "subject": "UNII:7XL5ISS668",
-              "id": "23653011",
-              "object": "MONDO:0018905",
-              "publications": [
-                "PMID:34395429"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:has_part",
-    "r2.publications_info": "{'PMID:31921871': {'publication date': '2019', 'sentence': 'Here, we describe successful management of refractory EBV-associated PTLD, specifically DLBCL, with combined brentuximab vedotin and third-party EBV-specific T-cells in a multidisciplinary treatment approach.', 'subject score': 901, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 699953,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0018905",
-          "name": "diffuse large B-cell lymphoma",
-          "description": "A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.; Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.; UMLS Semantic Type: STY:T191",
-          "equivalent_curies": [
-            "NCIT:C8851",
-            "UMLS:C0079744",
-            "MEDDRA:10012819",
-            "MEDDRA:10012818",
-            "MONDO:0018905",
-            "UMLS:C2699777",
-            "NCIT:C80280",
-            "SNOMEDCT:109969005",
-            "SNOMEDCT:1172695008",
-            "MESH:D016403",
-            "ORPHANET:544",
-            "MEDDRA:10012820",
-            "DOID:0050745",
-            "EFO:0000403"
-          ],
-          "id": "MONDO:0018905",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Lymphoma, Large B-Cell, Diffuse",
-            "diffuse large B-cell lymphoma",
-            "Diffuse Large B-Cell Lymphoma",
-            "Diffuse large B-cell lymphoma",
-            "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28487884",
-            "http://en.wikipedia.org/wiki/diffuse_large_b-cell_lymphoma",
-            "https://ncithesaurus.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&ns=ncit&code=c148392"
-          ]
-        }
-      },
-      "end": {
-        "identity": 622,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass",
-          "biolink:ThingWithTaxon",
-          "biolink:GeneOrGeneProduct",
-          "biolink:Gene",
-          "biolink:GenomicEntity",
-          "biolink:Polypeptide",
-          "biolink:Protein",
-          "biolink:MacromolecularMachineMixin",
-          "biolink:GeneProductMixin",
-          "biolink:BiologicalEntity"
-        ],
-        "properties": {
-          "name": "BRENTUXIMAB VEDOTIN",
-          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-          "equivalent_curies": [
-            "UNII:7XL5ISS668",
-            "KEGG.DRUG:D09587",
-            "NCIT:C66944",
-            "DrugCentral:4964",
-            "UMLS:C2973446",
-            "RXNORM:1147320",
-            "MESH:D000079963",
-            "CHEMBL.COMPOUND:CHEMBL1742994",
-            "MESH:C547738",
-            "ttd.target:Brentuximab_vedotin",
-            "DRUGBANK:DB08870"
-          ],
-          "id": "UNII:7XL5ISS668",
-          "category": "biolink:ChemicalEntity",
-          "all_names": [
-            "Brentuximab vedotin (USAN/INN)",
-            "BRENTUXIMAB VEDOTIN",
-            "Brentuximab vedotin",
-            "Brentuximab Vedotin",
-            "brentuximab vedotin",
-            "SGN-35"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:Protein",
-            "biolink:Drug",
-            "biolink:SmallMolecule"
-          ],
-          "publications": [
-            "PMID:29133014",
-            "PMID:12714494",
-            "PMID:24023323",
-            "PMID:9826579"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 699953,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0018905",
-              "name": "diffuse large B-cell lymphoma",
-              "description": "A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.; Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.; UMLS Semantic Type: STY:T191",
-              "equivalent_curies": [
-                "NCIT:C8851",
-                "UMLS:C0079744",
-                "MEDDRA:10012819",
-                "MEDDRA:10012818",
-                "MONDO:0018905",
-                "UMLS:C2699777",
-                "NCIT:C80280",
-                "SNOMEDCT:109969005",
-                "SNOMEDCT:1172695008",
-                "MESH:D016403",
-                "ORPHANET:544",
-                "MEDDRA:10012820",
-                "DOID:0050745",
-                "EFO:0000403"
-              ],
-              "id": "MONDO:0018905",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Lymphoma, Large B-Cell, Diffuse",
-                "diffuse large B-cell lymphoma",
-                "Diffuse Large B-Cell Lymphoma",
-                "Diffuse large B-cell lymphoma",
-                "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28487884",
-                "http://en.wikipedia.org/wiki/diffuse_large_b-cell_lymphoma",
-                "https://ncithesaurus.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&ns=ncit&code=c148392"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21139443,
-            "start": 699953,
-            "end": 622,
-            "type": "biolink:has_part",
-            "properties": {
-              "predicate": "biolink:has_part",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31921871': {'publication date': '2019', 'sentence': 'Here, we describe successful management of refractory EBV-associated PTLD, specifically DLBCL, with combined brentuximab vedotin and third-party EBV-specific T-cells in a multidisciplinary treatment approach.', 'subject score': 901, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C2973446---SEMMEDDB:part_of---None---None---None---UMLS:C0079744---SEMMEDDB:"
-              ],
-              "subject": "MONDO:0018905",
-              "id": "21553377",
-              "object": "UNII:7XL5ISS668",
-              "publications": [
-                "PMID:31921871"
-              ]
-            }
-          },
-          "end": {
-            "identity": 622,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass",
-              "biolink:ThingWithTaxon",
-              "biolink:GeneOrGeneProduct",
-              "biolink:Gene",
-              "biolink:GenomicEntity",
-              "biolink:Polypeptide",
-              "biolink:Protein",
-              "biolink:MacromolecularMachineMixin",
-              "biolink:GeneProductMixin",
-              "biolink:BiologicalEntity"
-            ],
-            "properties": {
-              "name": "BRENTUXIMAB VEDOTIN",
-              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T129; UMLS Semantic Type: STY:T116; Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737].     The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737].    Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737].    Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737].    The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].",
-              "equivalent_curies": [
-                "UNII:7XL5ISS668",
-                "KEGG.DRUG:D09587",
-                "NCIT:C66944",
-                "DrugCentral:4964",
-                "UMLS:C2973446",
-                "RXNORM:1147320",
-                "MESH:D000079963",
-                "CHEMBL.COMPOUND:CHEMBL1742994",
-                "MESH:C547738",
-                "ttd.target:Brentuximab_vedotin",
-                "DRUGBANK:DB08870"
-              ],
-              "id": "UNII:7XL5ISS668",
-              "category": "biolink:ChemicalEntity",
-              "all_names": [
-                "Brentuximab vedotin (USAN/INN)",
-                "BRENTUXIMAB VEDOTIN",
-                "Brentuximab vedotin",
-                "Brentuximab Vedotin",
-                "brentuximab vedotin",
-                "SGN-35"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:Protein",
-                "biolink:Drug",
-                "biolink:SmallMolecule"
-              ],
-              "publications": [
-                "PMID:29133014",
-                "PMID:12714494",
-                "PMID:24023323",
-                "PMID:9826579"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:1460264': {'publication date': '1992 Dec', 'sentence': 'Prophylaxis with silver nitrate solution, 1.0% tetracycline, or 0.05% erythromycin ointment is effective for the prevention of gonococcal and chlamydial conjunctivitis in the newborn.', 'subject score': 827, 'object score': 1000}, 'PMID:1461692': {'publication date': '1992 Dec', 'sentence': 'We conclude that neonatal ocular prophylaxis with erythromycin (one or two doses) or tetracycline or silver nitrate does not significantly reduce the incidence of neonatal chlamydial conjunctivitis compared with that in those given no prophylaxis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 541721,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005808",
-          "name": "inclusion conjunctivitis",
-          "description": "An infection of the eyes characterized by the presence in conjunctival epithelial cells of inclusion bodies indistinguishable from those of trachoma. It is acquired by infants during birth and by adults from swimming pools. The etiological agent is CHLAMYDIA TRACHOMATIS whose natural habitat appears to be the genito-urinary tract. Inclusion conjunctivitis is a less severe disease than trachoma and usually clears up spontaneously.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C116817",
-            "UMLS:C0343723",
-            "MESH:D003235",
-            "MEDDRA:10053992",
-            "UMLS:C0392644",
-            "SNOMEDCT:231861005",
-            "ICD9:077.0",
-            "MEDDRA:10053609",
-            "SNOMEDCT:240591000",
-            "SNOMEDCT:56009001",
-            "MEDDRA:10021629",
-            "MONDO:0005808",
-            "ICD10:A74.0",
-            "MEDDRA:10008535",
-            "UMLS:C0009770",
-            "DOID:13800",
-            "EFO:0007324",
-            "MEDDRA:10053993",
-            "MEDDRA:10010745",
-            "MEDDRA:10062847"
-          ],
-          "id": "MONDO:0005808",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neonatal Chlamydia Conjunctivitis",
-            "Inclusion conjunctivitis",
-            "inclusion conjunctivitis",
-            "Conjunctivitis, Inclusion",
-            "Neonatal chlamydial conjunctivitis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.visualdx.com/visualdx/diagnosis/inclusion+conjunctivitis?diagnosisid=54853&moduleid=101"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-        "identity": 628,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Tetracycline",
-          "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-          "equivalent_curies": [
-            "CHEBI:77932",
-            "CHEMBL.COMPOUND:CHEMBL1440",
-            "UMLS:C0039644",
-            "UMLS:C0521901",
-            "ATC:D06AA04",
-            "NCIT:C865",
-            "UMLS:C4255918",
-            "NDDF:002738",
-            "ATC:S01AA09",
-            "RXNORM:2105975",
-            "KEGG.COMPOUND:C06570",
-            "DRUGBANK:DB00759",
-            "ATC:S02AA08",
-            "CAS:60-54-8",
-            "PathWhiz.Compound:9228",
-            "ATC:A01AB13",
-            "HMDB:HMDB0014897",
-            "UNII:F8VB5M810T",
-            "PUBCHEM.COMPOUND:54675776",
-            "ATC:S03AA02",
-            "UMLS:C3710841",
-            "NCIT:C87225",
-            "DrugCentral:2611",
-            "NDDF:002740",
-            "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-            "RXNORM:10395",
-            "KEGG.DRUG:D00201",
-            "PUBCHEM.COMPOUND:51580080",
-            "ATC:J01AA07",
-            "CHEBI:27902",
-            "DRUGBANK:DB09550",
-            "MESH:D013752",
-            "UMLS:C4255917"
-          ],
-          "id": "PUBCHEM.COMPOUND:54675776",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Tetracycline phosphate complex",
-            "tetracycline",
-            "TETRACYCLINE",
-            "Tetracycline (JAN/USP/INN)",
-            "Anhydrotetracycline",
-            "tetracycline phosphate complex",
-            "tetracycline zwitterion",
-            "Abramycin",
-            "Deschlorobiomycin",
-            "tetracycline hydrochloride",
-            "Tetracycline",
-            "Tetracycline Phosphate Complex"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:26922234",
-            "PMID:19463000",
-            "PMID:18378719",
-            "PMID:19104019",
-            "PMID:18474585",
-            "PMID:20696876",
-            "PMID:19332670",
-            "PMID:18834112",
-            "PMID:23891185"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 311374,
-=======
-            "identity": 541721,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005076",
-              "name": "periodontitis",
-              "description": "An acute or chronic inflammatory process that affects the tissues that surround and support the teeth.; Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology); Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:824",
-                "UMLS:C0600298",
-                "MEDDRA:10034540",
-                "SNOMEDCT:41565005",
-                "ICD9:523.5",
-                "DOID:9893",
-                "MESH:D010518",
-                "ICD10:K05.4",
-                "HP:0000704",
-                "UMLS:C0031099",
-                "ICD10:K05.3",
-                "MONDO:0005076",
-                "MEDDRA:10034539",
-                "NCIT:C34918",
-                "EFO:0000649"
-              ],
-              "id": "MONDO:0005076",
-              "category": "biolink:Disease",
-              "all_names": [
-                "periodontitis",
-                "Periodontitis",
-                "periodontosis",
-                "Periodontosis"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005808",
-              "name": "inclusion conjunctivitis",
-              "description": "An infection of the eyes characterized by the presence in conjunctival epithelial cells of inclusion bodies indistinguishable from those of trachoma. It is acquired by infants during birth and by adults from swimming pools. The etiological agent is CHLAMYDIA TRACHOMATIS whose natural habitat appears to be the genito-urinary tract. Inclusion conjunctivitis is a less severe disease than trachoma and usually clears up spontaneously.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C116817",
-                "UMLS:C0343723",
-                "MESH:D003235",
-                "MEDDRA:10053992",
-                "UMLS:C0392644",
-                "SNOMEDCT:231861005",
-                "ICD9:077.0",
-                "MEDDRA:10053609",
-                "SNOMEDCT:240591000",
-                "SNOMEDCT:56009001",
-                "MEDDRA:10021629",
-                "MONDO:0005808",
-                "ICD10:A74.0",
-                "MEDDRA:10008535",
-                "UMLS:C0009770",
-                "DOID:13800",
-                "EFO:0007324",
-                "MEDDRA:10053993",
-                "MEDDRA:10010745",
-                "MEDDRA:10062847"
-              ],
-              "id": "MONDO:0005808",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neonatal Chlamydia Conjunctivitis",
-                "Inclusion conjunctivitis",
-                "inclusion conjunctivitis",
-                "Conjunctivitis, Inclusion",
-                "Neonatal chlamydial conjunctivitis"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://orcid.org/0000-0001-5889-4463",
-                "https://orcid.org/0000-0002-9338-3017"
-=======
-                "https://www.visualdx.com/visualdx/diagnosis/inclusion+conjunctivitis?diagnosisid=54853&moduleid=101"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 19777585,
-            "start": 628,
-            "end": 311374,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:294476': {'publication date': '1979 Dec', 'sentence': 'In conclusion, long term systemic administration of tetracycline in the rat may be of value in reducing the amount of tissue destruction in experimentally induced periodontitis.', 'subject score': 1000, 'object score': 790}}",
-              "kg2_ids": [
-                "UMLS:C0039644---SEMMEDDB:causes---None---None---None---UMLS:C0031099---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:54675776",
-              "id": "20170701",
-              "object": "MONDO:0005076",
-              "publications": [
-                "PMID:294476"
-=======
-            "identity": 10614289,
-            "start": 628,
-            "end": 541721,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1460264': {'publication date': '1992 Dec', 'sentence': 'Prophylaxis with silver nitrate solution, 1.0% tetracycline, or 0.05% erythromycin ointment is effective for the prevention of gonococcal and chlamydial conjunctivitis in the newborn.', 'subject score': 827, 'object score': 1000}, 'PMID:1461692': {'publication date': '1992 Dec', 'sentence': 'We conclude that neonatal ocular prophylaxis with erythromycin (one or two doses) or tetracycline or silver nitrate does not significantly reduce the incidence of neonatal chlamydial conjunctivitis compared with that in those given no prophylaxis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0039644---SEMMEDDB:prevents---None---None---None---UMLS:C0009770---SEMMEDDB:",
-                "UMLS:C0039644---SEMMEDDB:prevents---None---None---None---UMLS:C0343723---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:54675776",
-              "id": "10847016",
-              "object": "MONDO:0005808",
-              "publications": [
-                "PMID:1461692",
-                "PMID:1460264"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 628,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Tetracycline",
-              "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-              "equivalent_curies": [
-                "CHEBI:77932",
-                "CHEMBL.COMPOUND:CHEMBL1440",
-                "UMLS:C0039644",
-                "UMLS:C0521901",
-                "ATC:D06AA04",
-                "NCIT:C865",
-                "UMLS:C4255918",
-                "NDDF:002738",
-                "ATC:S01AA09",
-                "RXNORM:2105975",
-                "KEGG.COMPOUND:C06570",
-                "DRUGBANK:DB00759",
-                "ATC:S02AA08",
-                "CAS:60-54-8",
-                "PathWhiz.Compound:9228",
-                "ATC:A01AB13",
-                "HMDB:HMDB0014897",
-                "UNII:F8VB5M810T",
-                "PUBCHEM.COMPOUND:54675776",
-                "ATC:S03AA02",
-                "UMLS:C3710841",
-                "NCIT:C87225",
-                "DrugCentral:2611",
-                "NDDF:002740",
-                "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-                "RXNORM:10395",
-                "KEGG.DRUG:D00201",
-                "PUBCHEM.COMPOUND:51580080",
-                "ATC:J01AA07",
-                "CHEBI:27902",
-                "DRUGBANK:DB09550",
-                "MESH:D013752",
-                "UMLS:C4255917"
-              ],
-              "id": "PUBCHEM.COMPOUND:54675776",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Tetracycline phosphate complex",
-                "tetracycline",
-                "TETRACYCLINE",
-                "Tetracycline (JAN/USP/INN)",
-                "Anhydrotetracycline",
-                "tetracycline phosphate complex",
-                "tetracycline zwitterion",
-                "Abramycin",
-                "Deschlorobiomycin",
-                "tetracycline hydrochloride",
-                "Tetracycline",
-                "Tetracycline Phosphate Complex"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:26922234",
-                "PMID:19463000",
-                "PMID:18378719",
-                "PMID:19104019",
-                "PMID:18474585",
-                "PMID:20696876",
-                "PMID:19332670",
-                "PMID:18834112",
-                "PMID:23891185"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 711504,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006781",
-          "name": "Helicobacter pylori infectious disease",
-          "description": "Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10019375",
-            "MESH:D016481",
-            "MEDDRA:10054263",
-            "UMLS:C0079487",
-            "EFO:1000961",
-            "MONDO:0006781"
-          ],
-          "id": "MONDO:0006781",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Helicobacter Infections",
-            "Helicobacter pylori infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 628,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Tetracycline",
-          "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-          "equivalent_curies": [
-            "CHEBI:77932",
-            "CHEMBL.COMPOUND:CHEMBL1440",
-            "UMLS:C0039644",
-            "UMLS:C0521901",
-            "ATC:D06AA04",
-            "NCIT:C865",
-            "UMLS:C4255918",
-            "NDDF:002738",
-            "ATC:S01AA09",
-            "RXNORM:2105975",
-            "KEGG.COMPOUND:C06570",
-            "DRUGBANK:DB00759",
-            "ATC:S02AA08",
-            "CAS:60-54-8",
-            "PathWhiz.Compound:9228",
-            "ATC:A01AB13",
-            "HMDB:HMDB0014897",
-            "UNII:F8VB5M810T",
-            "PUBCHEM.COMPOUND:54675776",
-            "ATC:S03AA02",
-            "UMLS:C3710841",
-            "NCIT:C87225",
-            "DrugCentral:2611",
-            "NDDF:002740",
-            "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-            "RXNORM:10395",
-            "KEGG.DRUG:D00201",
-            "PUBCHEM.COMPOUND:51580080",
-            "ATC:J01AA07",
-            "CHEBI:27902",
-            "DRUGBANK:DB09550",
-            "MESH:D013752",
-            "UMLS:C4255917"
-          ],
-          "id": "PUBCHEM.COMPOUND:54675776",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Tetracycline phosphate complex",
-            "tetracycline",
-            "TETRACYCLINE",
-            "Tetracycline (JAN/USP/INN)",
-            "Anhydrotetracycline",
-            "tetracycline phosphate complex",
-            "tetracycline zwitterion",
-            "Abramycin",
-            "Deschlorobiomycin",
-            "tetracycline hydrochloride",
-            "Tetracycline",
-            "Tetracycline Phosphate Complex"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:26922234",
-            "PMID:19463000",
-            "PMID:18378719",
-            "PMID:19104019",
-            "PMID:18474585",
-            "PMID:20696876",
-            "PMID:19332670",
-            "PMID:18834112",
-            "PMID:23891185"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 711504,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006781",
-              "name": "Helicobacter pylori infectious disease",
-              "description": "Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10019375",
-                "MESH:D016481",
-                "MEDDRA:10054263",
-                "UMLS:C0079487",
-                "EFO:1000961",
-                "MONDO:0006781"
-              ],
-              "id": "MONDO:0006781",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Helicobacter Infections",
-                "Helicobacter pylori infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19090202,
-            "start": 628,
-            "end": 711504,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28187315': {'publication date': '2017 May 05', 'sentence': 'In spite of the low reactivity of chloramines towards tetracycline, it is evident that, in the concentration range where they are produced in a H. pylori infection (millimolar range), the reactions lead to oxidation and/or chlorination of tetracycline.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0039644---SEMMEDDB:causes---None---None---None---UMLS:C0079487---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:54675776",
-              "id": "19472933",
-              "object": "MONDO:0006781",
-              "publications": [
-                "PMID:28187315"
-              ]
-            }
-          },
-          "end": {
-            "identity": 628,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Tetracycline",
-              "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-              "equivalent_curies": [
-                "CHEBI:77932",
-                "CHEMBL.COMPOUND:CHEMBL1440",
-                "UMLS:C0039644",
-                "UMLS:C0521901",
-                "ATC:D06AA04",
-                "NCIT:C865",
-                "UMLS:C4255918",
-                "NDDF:002738",
-                "ATC:S01AA09",
-                "RXNORM:2105975",
-                "KEGG.COMPOUND:C06570",
-                "DRUGBANK:DB00759",
-                "ATC:S02AA08",
-                "CAS:60-54-8",
-                "PathWhiz.Compound:9228",
-                "ATC:A01AB13",
-                "HMDB:HMDB0014897",
-                "UNII:F8VB5M810T",
-                "PUBCHEM.COMPOUND:54675776",
-                "ATC:S03AA02",
-                "UMLS:C3710841",
-                "NCIT:C87225",
-                "DrugCentral:2611",
-                "NDDF:002740",
-                "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-                "RXNORM:10395",
-                "KEGG.DRUG:D00201",
-                "PUBCHEM.COMPOUND:51580080",
-                "ATC:J01AA07",
-                "CHEBI:27902",
-                "DRUGBANK:DB09550",
-                "MESH:D013752",
-                "UMLS:C4255917"
-              ],
-              "id": "PUBCHEM.COMPOUND:54675776",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Tetracycline phosphate complex",
-                "tetracycline",
-                "TETRACYCLINE",
-                "Tetracycline (JAN/USP/INN)",
-                "Anhydrotetracycline",
-                "tetracycline phosphate complex",
-                "tetracycline zwitterion",
-                "Abramycin",
-                "Deschlorobiomycin",
-                "tetracycline hydrochloride",
-                "Tetracycline",
-                "Tetracycline Phosphate Complex"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:26922234",
-                "PMID:19463000",
-                "PMID:18378719",
-                "PMID:19104019",
-                "PMID:18474585",
-                "PMID:20696876",
-                "PMID:19332670",
-                "PMID:18834112",
-                "PMID:23891185"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 311374,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005076",
-          "name": "periodontitis",
-          "description": "An acute or chronic inflammatory process that affects the tissues that surround and support the teeth.; Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology); Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:824",
-            "UMLS:C0600298",
-            "MEDDRA:10034540",
-            "SNOMEDCT:41565005",
-            "ICD9:523.5",
-            "DOID:9893",
-            "MESH:D010518",
-            "ICD10:K05.4",
-            "HP:0000704",
-            "UMLS:C0031099",
-            "ICD10:K05.3",
-            "MONDO:0005076",
-            "MEDDRA:10034539",
-            "NCIT:C34918",
-            "EFO:0000649"
-          ],
-          "id": "MONDO:0005076",
-          "category": "biolink:Disease",
-          "all_names": [
-            "periodontitis",
-            "Periodontitis",
-            "periodontosis",
-            "Periodontosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5889-4463",
-            "https://orcid.org/0000-0002-9338-3017"
-          ]
-        }
-      },
-      "end": {
-        "identity": 628,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Tetracycline",
-          "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-          "equivalent_curies": [
-            "CHEBI:77932",
-            "CHEMBL.COMPOUND:CHEMBL1440",
-            "UMLS:C0039644",
-            "UMLS:C0521901",
-            "ATC:D06AA04",
-            "NCIT:C865",
-            "UMLS:C4255918",
-            "NDDF:002738",
-            "ATC:S01AA09",
-            "RXNORM:2105975",
-            "KEGG.COMPOUND:C06570",
-            "DRUGBANK:DB00759",
-            "ATC:S02AA08",
-            "CAS:60-54-8",
-            "PathWhiz.Compound:9228",
-            "ATC:A01AB13",
-            "HMDB:HMDB0014897",
-            "UNII:F8VB5M810T",
-            "PUBCHEM.COMPOUND:54675776",
-            "ATC:S03AA02",
-            "UMLS:C3710841",
-            "NCIT:C87225",
-            "DrugCentral:2611",
-            "NDDF:002740",
-            "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-            "RXNORM:10395",
-            "KEGG.DRUG:D00201",
-            "PUBCHEM.COMPOUND:51580080",
-            "ATC:J01AA07",
-            "CHEBI:27902",
-            "DRUGBANK:DB09550",
-            "MESH:D013752",
-            "UMLS:C4255917"
-          ],
-          "id": "PUBCHEM.COMPOUND:54675776",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Tetracycline phosphate complex",
-            "tetracycline",
-            "TETRACYCLINE",
-            "Tetracycline (JAN/USP/INN)",
-            "Anhydrotetracycline",
-            "tetracycline phosphate complex",
-            "tetracycline zwitterion",
-            "Abramycin",
-            "Deschlorobiomycin",
-            "tetracycline hydrochloride",
-            "Tetracycline",
-            "Tetracycline Phosphate Complex"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:26922234",
-            "PMID:19463000",
-            "PMID:18378719",
-            "PMID:19104019",
-            "PMID:18474585",
-            "PMID:20696876",
-            "PMID:19332670",
-            "PMID:18834112",
-            "PMID:23891185"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311374,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005076",
-              "name": "periodontitis",
-              "description": "An acute or chronic inflammatory process that affects the tissues that surround and support the teeth.; Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology); Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:824",
-                "UMLS:C0600298",
-                "MEDDRA:10034540",
-                "SNOMEDCT:41565005",
-                "ICD9:523.5",
-                "DOID:9893",
-                "MESH:D010518",
-                "ICD10:K05.4",
-                "HP:0000704",
-                "UMLS:C0031099",
-                "ICD10:K05.3",
-                "MONDO:0005076",
-                "MEDDRA:10034539",
-                "NCIT:C34918",
-                "EFO:0000649"
-              ],
-              "id": "MONDO:0005076",
-              "category": "biolink:Disease",
-              "all_names": [
-                "periodontitis",
-                "Periodontitis",
-                "periodontosis",
-                "Periodontosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5889-4463",
-                "https://orcid.org/0000-0002-9338-3017"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17717746,
-            "start": 628,
-            "end": 311374,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25560693': {'publication date': '2014', 'sentence': 'Occurrence of porphyromonas gingivalis and its antibacterial susceptibility to metronidazole and tetracycline in patients with chronic periodontitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:294476': {'publication date': '1979 Dec', 'sentence': 'The present investigation was undertaken to determine the influence of systemically administered tetracycline on periodontitis in the rat.', 'subject score': 827, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0039644---SEMMEDDB:affects---None---None---None---UMLS:C0031099---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:54675776",
-              "id": "18080767",
-              "object": "MONDO:0005076",
-              "publications": [
-                "PMID:25560693",
-                "PMID:294476"
-              ]
-            }
-          },
-          "end": {
-            "identity": 628,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Tetracycline",
-              "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-              "equivalent_curies": [
-                "CHEBI:77932",
-                "CHEMBL.COMPOUND:CHEMBL1440",
-                "UMLS:C0039644",
-                "UMLS:C0521901",
-                "ATC:D06AA04",
-                "NCIT:C865",
-                "UMLS:C4255918",
-                "NDDF:002738",
-                "ATC:S01AA09",
-                "RXNORM:2105975",
-                "KEGG.COMPOUND:C06570",
-                "DRUGBANK:DB00759",
-                "ATC:S02AA08",
-                "CAS:60-54-8",
-                "PathWhiz.Compound:9228",
-                "ATC:A01AB13",
-                "HMDB:HMDB0014897",
-                "UNII:F8VB5M810T",
-                "PUBCHEM.COMPOUND:54675776",
-                "ATC:S03AA02",
-                "UMLS:C3710841",
-                "NCIT:C87225",
-                "DrugCentral:2611",
-                "NDDF:002740",
-                "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-                "RXNORM:10395",
-                "KEGG.DRUG:D00201",
-                "PUBCHEM.COMPOUND:51580080",
-                "ATC:J01AA07",
-                "CHEBI:27902",
-                "DRUGBANK:DB09550",
-                "MESH:D013752",
-                "UMLS:C4255917"
-              ],
-              "id": "PUBCHEM.COMPOUND:54675776",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Tetracycline phosphate complex",
-                "tetracycline",
-                "TETRACYCLINE",
-                "Tetracycline (JAN/USP/INN)",
-                "Anhydrotetracycline",
-                "tetracycline phosphate complex",
-                "tetracycline zwitterion",
-                "Abramycin",
-                "Deschlorobiomycin",
-                "tetracycline hydrochloride",
-                "Tetracycline",
-                "Tetracycline Phosphate Complex"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:26922234",
-                "PMID:19463000",
-                "PMID:18378719",
-                "PMID:19104019",
-                "PMID:18474585",
-                "PMID:20696876",
-                "PMID:19332670",
-                "PMID:18834112",
-                "PMID:23891185"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 538307,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-          ]
-        }
-      },
-      "end": {
-        "identity": 628,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Tetracycline",
-          "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-          "equivalent_curies": [
-            "CHEBI:77932",
-            "CHEMBL.COMPOUND:CHEMBL1440",
-            "UMLS:C0039644",
-            "UMLS:C0521901",
-            "ATC:D06AA04",
-            "NCIT:C865",
-            "UMLS:C4255918",
-            "NDDF:002738",
-            "ATC:S01AA09",
-            "RXNORM:2105975",
-            "KEGG.COMPOUND:C06570",
-            "DRUGBANK:DB00759",
-            "ATC:S02AA08",
-            "CAS:60-54-8",
-            "PathWhiz.Compound:9228",
-            "ATC:A01AB13",
-            "HMDB:HMDB0014897",
-            "UNII:F8VB5M810T",
-            "PUBCHEM.COMPOUND:54675776",
-            "ATC:S03AA02",
-            "UMLS:C3710841",
-            "NCIT:C87225",
-            "DrugCentral:2611",
-            "NDDF:002740",
-            "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-            "RXNORM:10395",
-            "KEGG.DRUG:D00201",
-            "PUBCHEM.COMPOUND:51580080",
-            "ATC:J01AA07",
-            "CHEBI:27902",
-            "DRUGBANK:DB09550",
-            "MESH:D013752",
-            "UMLS:C4255917"
-          ],
-          "id": "PUBCHEM.COMPOUND:54675776",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Tetracycline phosphate complex",
-            "tetracycline",
-            "TETRACYCLINE",
-            "Tetracycline (JAN/USP/INN)",
-            "Anhydrotetracycline",
-            "tetracycline phosphate complex",
-            "tetracycline zwitterion",
-            "Abramycin",
-            "Deschlorobiomycin",
-            "tetracycline hydrochloride",
-            "Tetracycline",
-            "Tetracycline Phosphate Complex"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:26922234",
-            "PMID:19463000",
-            "PMID:18378719",
-            "PMID:19104019",
-            "PMID:18474585",
-            "PMID:20696876",
-            "PMID:19332670",
-            "PMID:18834112",
-            "PMID:23891185"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538307,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17610087,
-            "start": 628,
-            "end": 538307,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25385866': {'publication date': '2015 Feb', 'sentence': 'We conclude that although empiric ceftriaxone is appropriate in our setting, etiologies not explicitly addressed in IMAI guidance for these syndromes, such as cryptococcosis, histoplasmosis, and tetracycline-responsive bacterial infections, were common.', 'subject score': 861, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0039644---SEMMEDDB:affects---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:54675776",
-              "id": "17969405",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:25385866"
-              ]
-            }
-          },
-          "end": {
-            "identity": 628,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Tetracycline",
-              "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-              "equivalent_curies": [
-                "CHEBI:77932",
-                "CHEMBL.COMPOUND:CHEMBL1440",
-                "UMLS:C0039644",
-                "UMLS:C0521901",
-                "ATC:D06AA04",
-                "NCIT:C865",
-                "UMLS:C4255918",
-                "NDDF:002738",
-                "ATC:S01AA09",
-                "RXNORM:2105975",
-                "KEGG.COMPOUND:C06570",
-                "DRUGBANK:DB00759",
-                "ATC:S02AA08",
-                "CAS:60-54-8",
-                "PathWhiz.Compound:9228",
-                "ATC:A01AB13",
-                "HMDB:HMDB0014897",
-                "UNII:F8VB5M810T",
-                "PUBCHEM.COMPOUND:54675776",
-                "ATC:S03AA02",
-                "UMLS:C3710841",
-                "NCIT:C87225",
-                "DrugCentral:2611",
-                "NDDF:002740",
-                "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-                "RXNORM:10395",
-                "KEGG.DRUG:D00201",
-                "PUBCHEM.COMPOUND:51580080",
-                "ATC:J01AA07",
-                "CHEBI:27902",
-                "DRUGBANK:DB09550",
-                "MESH:D013752",
-                "UMLS:C4255917"
-              ],
-              "id": "PUBCHEM.COMPOUND:54675776",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Tetracycline phosphate complex",
-                "tetracycline",
-                "TETRACYCLINE",
-                "Tetracycline (JAN/USP/INN)",
-                "Anhydrotetracycline",
-                "tetracycline phosphate complex",
-                "tetracycline zwitterion",
-                "Abramycin",
-                "Deschlorobiomycin",
-                "tetracycline hydrochloride",
-                "Tetracycline",
-                "Tetracycline Phosphate Complex"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:26922234",
-                "PMID:19463000",
-                "PMID:18378719",
-                "PMID:19104019",
-                "PMID:18474585",
-                "PMID:20696876",
-                "PMID:19332670",
-                "PMID:18834112",
-                "PMID:23891185"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-      "start": {
-        "identity": 546907,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C3714514",
-          "name": "Infection",
-          "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "UMLS:C3714514",
-            "MEDDRA:10021842",
-            "NCIT:C128320",
-            "MEDDRA:10021789",
-            "MESH:D007239"
-          ],
-          "id": "UMLS:C3714514",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infection",
-            "Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 628,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Tetracycline",
-          "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-          "equivalent_curies": [
-            "CHEBI:77932",
-            "CHEMBL.COMPOUND:CHEMBL1440",
-            "UMLS:C0039644",
-            "UMLS:C0521901",
-            "ATC:D06AA04",
-            "NCIT:C865",
-            "UMLS:C4255918",
-            "NDDF:002738",
-            "ATC:S01AA09",
-            "RXNORM:2105975",
-            "KEGG.COMPOUND:C06570",
-            "DRUGBANK:DB00759",
-            "ATC:S02AA08",
-            "CAS:60-54-8",
-            "PathWhiz.Compound:9228",
-            "ATC:A01AB13",
-            "HMDB:HMDB0014897",
-            "UNII:F8VB5M810T",
-            "PUBCHEM.COMPOUND:54675776",
-            "ATC:S03AA02",
-            "UMLS:C3710841",
-            "NCIT:C87225",
-            "DrugCentral:2611",
-            "NDDF:002740",
-            "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-            "RXNORM:10395",
-            "KEGG.DRUG:D00201",
-            "PUBCHEM.COMPOUND:51580080",
-            "ATC:J01AA07",
-            "CHEBI:27902",
-            "DRUGBANK:DB09550",
-            "MESH:D013752",
-            "UMLS:C4255917"
-          ],
-          "id": "PUBCHEM.COMPOUND:54675776",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Tetracycline phosphate complex",
-            "tetracycline",
-            "TETRACYCLINE",
-            "Tetracycline (JAN/USP/INN)",
-            "Anhydrotetracycline",
-            "tetracycline phosphate complex",
-            "tetracycline zwitterion",
-            "Abramycin",
-            "Deschlorobiomycin",
-            "tetracycline hydrochloride",
-            "Tetracycline",
-            "Tetracycline Phosphate Complex"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:26922234",
-            "PMID:19463000",
-            "PMID:18378719",
-            "PMID:19104019",
-            "PMID:18474585",
-            "PMID:20696876",
-            "PMID:19332670",
-            "PMID:18834112",
-            "PMID:23891185"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546907,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "https://identifiers.org/umls:C3714514",
-              "name": "Infection",
-              "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "UMLS:C3714514",
-                "MEDDRA:10021842",
-                "NCIT:C128320",
-                "MEDDRA:10021789",
-                "MESH:D007239"
-              ],
-              "id": "UMLS:C3714514",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infection",
-                "Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 21923733,
-            "start": 628,
-            "end": 546907,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32755514': {'publication date': '2020 Jul', 'sentence': 'The following antimicrobials commonly used for the treatment of C.difficile infections or applied previously in C.difficile epidemiological studies were tested: metronidazole, vancomycin, meropenem, ceftriaxone, ampicillin-sulbactam, clindamycin, erythromycin, moxifloxacin, tetracycline, doxycycline, tigecycline and linezolid.', 'subject score': 1000, 'object score': 827}, 'PMID:33284329': {'publication date': '2020 Dec 07', 'sentence': 'However, resistance was found against quinolones, aminoglycosides, tetracycline and trimethoprim-sulfamethoxazole which are commonly used to treat infections with gram-positive bacteria.', 'subject score': 1000, 'object score': 1000}, 'PMID:33568043': {'publication date': '2021 Feb 10', 'sentence': 'Minocycline has also emerged as the tetracycline of choice for multidrug-resistant Acinetobacter baumannii infections, although doxycycline has also shown the activity.', 'subject score': 1000, 'object score': 928}, 'PMID:34339136': {'publication date': '2021 Mar', 'sentence': 'However, resistance was found against quinolones, aminoglycosides, tetracycline, and trimethoprim-sulfamethoxazole, which are commonly used to treat infections with gram-positive bacteria.', 'subject score': 1000, 'object score': 1000}, 'PMID:35530702': {'publication date': '2019 Oct 28', 'sentence': 'Tetracycline is an antibiotic that is commonly utilized in veterinary medicine and in the treatment of human infections, but is hazardous to aquatic environments.', 'subject score': 1000, 'object score': 888}, 'PMID:35647655': {'publication date': '2022 Jun 01', 'sentence': 'Tetracycline-based combinations are increasingly used for serious carbapenem-nonsusceptible Acinetobacter baumannii (CNSAb) infections given their potent    in vitro     activity, synergism with other agents, and acceptable toxicity profile.', 'subject score': 851, 'object score': 827}, 'PMID:36498165': {'publication date': '2022 Dec 01', 'sentence': 'Minocycline is a kind of semisynthetic derivative of the antibacterial drug tetracycline and is often used to treat infections caused by multidrug-resistant    A. baumannii     with other antibiotics.', 'subject score': 901, 'object score': 1000}, 'PMID:36692335': {'publication date': '2023 Feb', 'sentence': 'Reports of Salmonella enterica I serotype 4,[5],12:i:- infections resistant to ampicillin, streptomycin, sulphamethoxazole, and tetracycline (ASSuT) have been increasing.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0039644---SEMMEDDB:treats---None---None---None---UMLS:C3714514---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:54675776",
-              "id": "22346012",
-              "object": "UMLS:C3714514",
-              "publications": [
-                "PMID:32755514",
-                "PMID:33284329",
-                "PMID:33568043",
-                "PMID:34339136",
-                "PMID:35530702",
-                "PMID:35647655",
-                "PMID:36498165",
-                "PMID:36692335"
-              ]
-            }
-          },
-          "end": {
-            "identity": 628,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Tetracycline",
-              "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-              "equivalent_curies": [
-                "CHEBI:77932",
-                "CHEMBL.COMPOUND:CHEMBL1440",
-                "UMLS:C0039644",
-                "UMLS:C0521901",
-                "ATC:D06AA04",
-                "NCIT:C865",
-                "UMLS:C4255918",
-                "NDDF:002738",
-                "ATC:S01AA09",
-                "RXNORM:2105975",
-                "KEGG.COMPOUND:C06570",
-                "DRUGBANK:DB00759",
-                "ATC:S02AA08",
-                "CAS:60-54-8",
-                "PathWhiz.Compound:9228",
-                "ATC:A01AB13",
-                "HMDB:HMDB0014897",
-                "UNII:F8VB5M810T",
-                "PUBCHEM.COMPOUND:54675776",
-                "ATC:S03AA02",
-                "UMLS:C3710841",
-                "NCIT:C87225",
-                "DrugCentral:2611",
-                "NDDF:002740",
-                "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-                "RXNORM:10395",
-                "KEGG.DRUG:D00201",
-                "PUBCHEM.COMPOUND:51580080",
-                "ATC:J01AA07",
-                "CHEBI:27902",
-                "DRUGBANK:DB09550",
-                "MESH:D013752",
-                "UMLS:C4255917"
-              ],
-              "id": "PUBCHEM.COMPOUND:54675776",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Tetracycline phosphate complex",
-                "tetracycline",
-                "TETRACYCLINE",
-                "Tetracycline (JAN/USP/INN)",
-                "Anhydrotetracycline",
-                "tetracycline phosphate complex",
-                "tetracycline zwitterion",
-                "Abramycin",
-                "Deschlorobiomycin",
-                "tetracycline hydrochloride",
-                "Tetracycline",
-                "Tetracycline Phosphate Complex"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:26922234",
-                "PMID:19463000",
-                "PMID:18378719",
-                "PMID:19104019",
-                "PMID:18474585",
-                "PMID:20696876",
-                "PMID:19332670",
-                "PMID:18834112",
-                "PMID:23891185"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:21988450': {'publication date': '2011 Dec', 'sentence': 'In addition, resistance to azithromycin, erythromycin, tetracycline, and trimethoprim was greater than 10%, which may be relevant when selecting empiric treatments for ocular surface infections.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 546977,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043885",
-          "name": "eye infectious disorder",
-          "description": "An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.; Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.; Your eyes can get infections from bacteria, fungi, or viruses. Eye infections can occur in different parts of the eye and can affect just one eye or both. Two common eye infections are:  Conjunctivitis - also known as pink eye. Conjunctivitis is often due to an infection. Children frequently get it, and it is very contagious.  Stye - a bump on the eyelid that happens when bacteria from your skin get into the hair follicle of an eyelash.  Symptoms of eye infections may include redness, itching, swelling, discharge, pain, or problems with vision. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or antibiotics.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10015929",
-            "UMLS:C0015403",
-            "MESH:D015817",
-            "MEDDRA:10015936",
-            "MONDO:0043885",
-            "SNOMEDCT:128351009",
-            "NCIT:C45372",
-            "EFO:1001888"
-          ],
-          "id": "MONDO:0043885",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Eye Infection",
-            "eye infectious disorder",
-            "eye infection",
-            "Eye Infections"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 628,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Tetracycline",
-          "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-          "equivalent_curies": [
-            "CHEBI:77932",
-            "CHEMBL.COMPOUND:CHEMBL1440",
-            "UMLS:C0039644",
-            "UMLS:C0521901",
-            "ATC:D06AA04",
-            "NCIT:C865",
-            "UMLS:C4255918",
-            "NDDF:002738",
-            "ATC:S01AA09",
-            "RXNORM:2105975",
-            "KEGG.COMPOUND:C06570",
-            "DRUGBANK:DB00759",
-            "ATC:S02AA08",
-            "CAS:60-54-8",
-            "PathWhiz.Compound:9228",
-            "ATC:A01AB13",
-            "HMDB:HMDB0014897",
-            "UNII:F8VB5M810T",
-            "PUBCHEM.COMPOUND:54675776",
-            "ATC:S03AA02",
-            "UMLS:C3710841",
-            "NCIT:C87225",
-            "DrugCentral:2611",
-            "NDDF:002740",
-            "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-            "RXNORM:10395",
-            "KEGG.DRUG:D00201",
-            "PUBCHEM.COMPOUND:51580080",
-            "ATC:J01AA07",
-            "CHEBI:27902",
-            "DRUGBANK:DB09550",
-            "MESH:D013752",
-            "UMLS:C4255917"
-          ],
-          "id": "PUBCHEM.COMPOUND:54675776",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Tetracycline phosphate complex",
-            "tetracycline",
-            "TETRACYCLINE",
-            "Tetracycline (JAN/USP/INN)",
-            "Anhydrotetracycline",
-            "tetracycline phosphate complex",
-            "tetracycline zwitterion",
-            "Abramycin",
-            "Deschlorobiomycin",
-            "tetracycline hydrochloride",
-            "Tetracycline",
-            "Tetracycline Phosphate Complex"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:26922234",
-            "PMID:19463000",
-            "PMID:18378719",
-            "PMID:19104019",
-            "PMID:18474585",
-            "PMID:20696876",
-            "PMID:19332670",
-            "PMID:18834112",
-            "PMID:23891185"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 546977,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043885",
-              "name": "eye infectious disorder",
-              "description": "An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.; Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.; Your eyes can get infections from bacteria, fungi, or viruses. Eye infections can occur in different parts of the eye and can affect just one eye or both. Two common eye infections are:  Conjunctivitis - also known as pink eye. Conjunctivitis is often due to an infection. Children frequently get it, and it is very contagious.  Stye - a bump on the eyelid that happens when bacteria from your skin get into the hair follicle of an eyelash.  Symptoms of eye infections may include redness, itching, swelling, discharge, pain, or problems with vision. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or antibiotics.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10015929",
-                "UMLS:C0015403",
-                "MESH:D015817",
-                "MEDDRA:10015936",
-                "MONDO:0043885",
-                "SNOMEDCT:128351009",
-                "NCIT:C45372",
-                "EFO:1001888"
-              ],
-              "id": "MONDO:0043885",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Eye Infection",
-                "eye infectious disorder",
-                "eye infection",
-                "Eye Infections"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 15584271,
-            "start": 628,
-            "end": 546977,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21988450': {'publication date': '2011 Dec', 'sentence': 'In addition, resistance to azithromycin, erythromycin, tetracycline, and trimethoprim was greater than 10%, which may be relevant when selecting empiric treatments for ocular surface infections.', 'subject score': 1000, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0039644---SEMMEDDB:treats---None---None---None---UMLS:C0015403---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:54675776",
-              "id": "15910237",
-              "object": "MONDO:0043885",
-              "publications": [
-                "PMID:21988450"
-              ]
-            }
-          },
-          "end": {
-            "identity": 628,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Tetracycline",
-              "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-              "equivalent_curies": [
-                "CHEBI:77932",
-                "CHEMBL.COMPOUND:CHEMBL1440",
-                "UMLS:C0039644",
-                "UMLS:C0521901",
-                "ATC:D06AA04",
-                "NCIT:C865",
-                "UMLS:C4255918",
-                "NDDF:002738",
-                "ATC:S01AA09",
-                "RXNORM:2105975",
-                "KEGG.COMPOUND:C06570",
-                "DRUGBANK:DB00759",
-                "ATC:S02AA08",
-                "CAS:60-54-8",
-                "PathWhiz.Compound:9228",
-                "ATC:A01AB13",
-                "HMDB:HMDB0014897",
-                "UNII:F8VB5M810T",
-                "PUBCHEM.COMPOUND:54675776",
-                "ATC:S03AA02",
-                "UMLS:C3710841",
-                "NCIT:C87225",
-                "DrugCentral:2611",
-                "NDDF:002740",
-                "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-                "RXNORM:10395",
-                "KEGG.DRUG:D00201",
-                "PUBCHEM.COMPOUND:51580080",
-                "ATC:J01AA07",
-                "CHEBI:27902",
-                "DRUGBANK:DB09550",
-                "MESH:D013752",
-                "UMLS:C4255917"
-              ],
-              "id": "PUBCHEM.COMPOUND:54675776",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Tetracycline phosphate complex",
-                "tetracycline",
-                "TETRACYCLINE",
-                "Tetracycline (JAN/USP/INN)",
-                "Anhydrotetracycline",
-                "tetracycline phosphate complex",
-                "tetracycline zwitterion",
-                "Abramycin",
-                "Deschlorobiomycin",
-                "tetracycline hydrochloride",
-                "Tetracycline",
-                "Tetracycline Phosphate Complex"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:26922234",
-                "PMID:19463000",
-                "PMID:18378719",
-                "PMID:19104019",
-                "PMID:18474585",
-                "PMID:20696876",
-                "PMID:19332670",
-                "PMID:18834112",
-                "PMID:23891185"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:28187315': {'publication date': '2017 May 05', 'sentence': 'In spite of the low reactivity of chloramines towards tetracycline, it is evident that, in the concentration range where they are produced in a H. pylori infection (millimolar range), the reactions lead to oxidation and/or chlorination of tetracycline.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 711504,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006781",
-          "name": "Helicobacter pylori infectious disease",
-          "description": "Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10019375",
-            "MESH:D016481",
-            "MEDDRA:10054263",
-            "UMLS:C0079487",
-            "EFO:1000961",
-            "MONDO:0006781"
-          ],
-          "id": "MONDO:0006781",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Helicobacter Infections",
-            "Helicobacter pylori infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 628,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Tetracycline",
-          "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-          "equivalent_curies": [
-            "CHEBI:77932",
-            "CHEMBL.COMPOUND:CHEMBL1440",
-            "UMLS:C0039644",
-            "UMLS:C0521901",
-            "ATC:D06AA04",
-            "NCIT:C865",
-            "UMLS:C4255918",
-            "NDDF:002738",
-            "ATC:S01AA09",
-            "RXNORM:2105975",
-            "KEGG.COMPOUND:C06570",
-            "DRUGBANK:DB00759",
-            "ATC:S02AA08",
-            "CAS:60-54-8",
-            "PathWhiz.Compound:9228",
-            "ATC:A01AB13",
-            "HMDB:HMDB0014897",
-            "UNII:F8VB5M810T",
-            "PUBCHEM.COMPOUND:54675776",
-            "ATC:S03AA02",
-            "UMLS:C3710841",
-            "NCIT:C87225",
-            "DrugCentral:2611",
-            "NDDF:002740",
-            "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-            "RXNORM:10395",
-            "KEGG.DRUG:D00201",
-            "PUBCHEM.COMPOUND:51580080",
-            "ATC:J01AA07",
-            "CHEBI:27902",
-            "DRUGBANK:DB09550",
-            "MESH:D013752",
-            "UMLS:C4255917"
-          ],
-          "id": "PUBCHEM.COMPOUND:54675776",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Tetracycline phosphate complex",
-            "tetracycline",
-            "TETRACYCLINE",
-            "Tetracycline (JAN/USP/INN)",
-            "Anhydrotetracycline",
-            "tetracycline phosphate complex",
-            "tetracycline zwitterion",
-            "Abramycin",
-            "Deschlorobiomycin",
-            "tetracycline hydrochloride",
-            "Tetracycline",
-            "Tetracycline Phosphate Complex"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:26922234",
-            "PMID:19463000",
-            "PMID:18378719",
-            "PMID:19104019",
-            "PMID:18474585",
-            "PMID:20696876",
-            "PMID:19332670",
-            "PMID:18834112",
-            "PMID:23891185"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 711504,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006781",
-              "name": "Helicobacter pylori infectious disease",
-              "description": "Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10019375",
-                "MESH:D016481",
-                "MEDDRA:10054263",
-                "UMLS:C0079487",
-                "EFO:1000961",
-                "MONDO:0006781"
-              ],
-              "id": "MONDO:0006781",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Helicobacter Infections",
-                "Helicobacter pylori infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19090202,
-            "start": 628,
-            "end": 711504,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28187315': {'publication date': '2017 May 05', 'sentence': 'In spite of the low reactivity of chloramines towards tetracycline, it is evident that, in the concentration range where they are produced in a H. pylori infection (millimolar range), the reactions lead to oxidation and/or chlorination of tetracycline.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0039644---SEMMEDDB:causes---None---None---None---UMLS:C0079487---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:54675776",
-              "id": "19472933",
-              "object": "MONDO:0006781",
-              "publications": [
-                "PMID:28187315"
-              ]
-            }
-          },
-          "end": {
-            "identity": 628,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Tetracycline",
-              "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-              "equivalent_curies": [
-                "CHEBI:77932",
-                "CHEMBL.COMPOUND:CHEMBL1440",
-                "UMLS:C0039644",
-                "UMLS:C0521901",
-                "ATC:D06AA04",
-                "NCIT:C865",
-                "UMLS:C4255918",
-                "NDDF:002738",
-                "ATC:S01AA09",
-                "RXNORM:2105975",
-                "KEGG.COMPOUND:C06570",
-                "DRUGBANK:DB00759",
-                "ATC:S02AA08",
-                "CAS:60-54-8",
-                "PathWhiz.Compound:9228",
-                "ATC:A01AB13",
-                "HMDB:HMDB0014897",
-                "UNII:F8VB5M810T",
-                "PUBCHEM.COMPOUND:54675776",
-                "ATC:S03AA02",
-                "UMLS:C3710841",
-                "NCIT:C87225",
-                "DrugCentral:2611",
-                "NDDF:002740",
-                "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-                "RXNORM:10395",
-                "KEGG.DRUG:D00201",
-                "PUBCHEM.COMPOUND:51580080",
-                "ATC:J01AA07",
-                "CHEBI:27902",
-                "DRUGBANK:DB09550",
-                "MESH:D013752",
-                "UMLS:C4255917"
-              ],
-              "id": "PUBCHEM.COMPOUND:54675776",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Tetracycline phosphate complex",
-                "tetracycline",
-                "TETRACYCLINE",
-                "Tetracycline (JAN/USP/INN)",
-                "Anhydrotetracycline",
-                "tetracycline phosphate complex",
-                "tetracycline zwitterion",
-                "Abramycin",
-                "Deschlorobiomycin",
-                "tetracycline hydrochloride",
-                "Tetracycline",
-                "Tetracycline Phosphate Complex"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:26922234",
-                "PMID:19463000",
-                "PMID:18378719",
-                "PMID:19104019",
-                "PMID:18474585",
-                "PMID:20696876",
-                "PMID:19332670",
-                "PMID:18834112",
-                "PMID:23891185"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10102946': {'publication date': '1999 Feb', 'sentence': 'Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection.', 'subject score': 1000, 'object score': 875}, 'PMID:10102965': {'publication date': '1999 Mar', 'sentence': 'Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days.', 'subject score': 1000, 'object score': 1000}, 'PMID:12182745': {'publication date': '2002 Aug', 'sentence': 'AIM: To study the efficacy of a 7-day quadruple regimen combining pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection after failure of standard triple therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:14734187': {'publication date': '2004 Jan 15', 'sentence': 'Tetracycline is one of four antibiotics commonly used for the treatment of Helicobacter pylori infection, but its effectiveness is decreasing as the incidence of tetracycline resistance is increasing.', 'subject score': 1000, 'object score': 1000}, 'PMID:15836716': {'publication date': '2005 Apr', 'sentence': 'BACKGROUND: Quadruple therapy with a proton pump inhibitor, bismuth, metronidazole and tetracycline is recommended as the optimal second-line therapy of Helicobacter pylori infection in the Maastricht Consensus Report.', 'subject score': 1000, 'object score': 1000}, 'PMID:15844694': {'publication date': '2005 Apr', 'sentence': 'High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin.', 'subject score': 1000, 'object score': 1000}, 'PMID:16446791': {'publication date': '2005 Dec', 'sentence': 'Clarithromycin, amoxicillin, tetracycline and metronidazole are the most frequently used antimicrobials for Helicobacter pylori infection treatment.', 'subject score': 1000, 'object score': 916}, 'PMID:20951912': {'publication date': '2010 Sep', 'sentence': 'The commonly used regimens for the eradication of Helicobacter pylori infection consist of administration of proton pump inhibitors (PPIs) and 1 to 3 antimicrobial agents, such as amoxicillin, clarithromycin, metronidazole, fluoroquinolone, or tetracycline.', 'subject score': 1000, 'object score': 1000}, 'PMID:25374223': {'publication date': '2014', 'sentence': 'BACKGROUND: Tetracycline is an antibiotic widely used for the treatment of Helicobacter pylori infection, but its effectiveness is decreasing due to increasing bacterial resistance.', 'subject score': 1000, 'object score': 1000}, 'PMID:29914954': {'publication date': '2018 09', 'sentence': 'Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.', 'subject score': 1000, 'object score': 1000}, 'PMID:8038358': {'publication date': '1994 Apr', 'sentence': 'Short report: omeprazole-tetracycline combinations are inadequate as therapy for Helicobacter pylori infection.', 'subject score': 851, 'object score': 1000}, 'PMID:9362185': {'publication date': '1997 Nov', 'sentence': 'Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 711504,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006781",
-          "name": "Helicobacter pylori infectious disease",
-          "description": "Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10019375",
-            "MESH:D016481",
-            "MEDDRA:10054263",
-            "UMLS:C0079487",
-            "EFO:1000961",
-            "MONDO:0006781"
-          ],
-          "id": "MONDO:0006781",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Helicobacter Infections",
-            "Helicobacter pylori infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 628,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Tetracycline",
-          "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-          "equivalent_curies": [
-            "CHEBI:77932",
-            "CHEMBL.COMPOUND:CHEMBL1440",
-            "UMLS:C0039644",
-            "UMLS:C0521901",
-            "ATC:D06AA04",
-            "NCIT:C865",
-            "UMLS:C4255918",
-            "NDDF:002738",
-            "ATC:S01AA09",
-            "RXNORM:2105975",
-            "KEGG.COMPOUND:C06570",
-            "DRUGBANK:DB00759",
-            "ATC:S02AA08",
-            "CAS:60-54-8",
-            "PathWhiz.Compound:9228",
-            "ATC:A01AB13",
-            "HMDB:HMDB0014897",
-            "UNII:F8VB5M810T",
-            "PUBCHEM.COMPOUND:54675776",
-            "ATC:S03AA02",
-            "UMLS:C3710841",
-            "NCIT:C87225",
-            "DrugCentral:2611",
-            "NDDF:002740",
-            "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-            "RXNORM:10395",
-            "KEGG.DRUG:D00201",
-            "PUBCHEM.COMPOUND:51580080",
-            "ATC:J01AA07",
-            "CHEBI:27902",
-            "DRUGBANK:DB09550",
-            "MESH:D013752",
-            "UMLS:C4255917"
-          ],
-          "id": "PUBCHEM.COMPOUND:54675776",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Tetracycline phosphate complex",
-            "tetracycline",
-            "TETRACYCLINE",
-            "Tetracycline (JAN/USP/INN)",
-            "Anhydrotetracycline",
-            "tetracycline phosphate complex",
-            "tetracycline zwitterion",
-            "Abramycin",
-            "Deschlorobiomycin",
-            "tetracycline hydrochloride",
-            "Tetracycline",
-            "Tetracycline Phosphate Complex"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:26922234",
-            "PMID:19463000",
-            "PMID:18378719",
-            "PMID:19104019",
-            "PMID:18474585",
-            "PMID:20696876",
-            "PMID:19332670",
-            "PMID:18834112",
-            "PMID:23891185"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 711504,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006781",
-              "name": "Helicobacter pylori infectious disease",
-              "description": "Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10019375",
-                "MESH:D016481",
-                "MEDDRA:10054263",
-                "UMLS:C0079487",
-                "EFO:1000961",
-                "MONDO:0006781"
-              ],
-              "id": "MONDO:0006781",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Helicobacter Infections",
-                "Helicobacter pylori infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 7085518,
-            "start": 628,
-            "end": 711504,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10102946': {'publication date': '1999 Feb', 'sentence': 'Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection.', 'subject score': 1000, 'object score': 875}, 'PMID:10102965': {'publication date': '1999 Mar', 'sentence': 'Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days.', 'subject score': 1000, 'object score': 1000}, 'PMID:12182745': {'publication date': '2002 Aug', 'sentence': 'AIM: To study the efficacy of a 7-day quadruple regimen combining pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection after failure of standard triple therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:14734187': {'publication date': '2004 Jan 15', 'sentence': 'Tetracycline is one of four antibiotics commonly used for the treatment of Helicobacter pylori infection, but its effectiveness is decreasing as the incidence of tetracycline resistance is increasing.', 'subject score': 1000, 'object score': 1000}, 'PMID:15836716': {'publication date': '2005 Apr', 'sentence': 'BACKGROUND: Quadruple therapy with a proton pump inhibitor, bismuth, metronidazole and tetracycline is recommended as the optimal second-line therapy of Helicobacter pylori infection in the Maastricht Consensus Report.', 'subject score': 1000, 'object score': 1000}, 'PMID:15844694': {'publication date': '2005 Apr', 'sentence': 'High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin.', 'subject score': 1000, 'object score': 1000}, 'PMID:16446791': {'publication date': '2005 Dec', 'sentence': 'Clarithromycin, amoxicillin, tetracycline and metronidazole are the most frequently used antimicrobials for Helicobacter pylori infection treatment.', 'subject score': 1000, 'object score': 916}, 'PMID:20951912': {'publication date': '2010 Sep', 'sentence': 'The commonly used regimens for the eradication of Helicobacter pylori infection consist of administration of proton pump inhibitors (PPIs) and 1 to 3 antimicrobial agents, such as amoxicillin, clarithromycin, metronidazole, fluoroquinolone, or tetracycline.', 'subject score': 1000, 'object score': 1000}, 'PMID:25374223': {'publication date': '2014', 'sentence': 'BACKGROUND: Tetracycline is an antibiotic widely used for the treatment of Helicobacter pylori infection, but its effectiveness is decreasing due to increasing bacterial resistance.', 'subject score': 1000, 'object score': 1000}, 'PMID:29914954': {'publication date': '2018 09', 'sentence': 'Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.', 'subject score': 1000, 'object score': 1000}, 'PMID:8038358': {'publication date': '1994 Apr', 'sentence': 'Short report: omeprazole-tetracycline combinations are inadequate as therapy for Helicobacter pylori infection.', 'subject score': 851, 'object score': 1000}, 'PMID:9362185': {'publication date': '1997 Nov', 'sentence': 'Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0039644---SEMMEDDB:treats---None---None---None---UMLS:C0079487---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:54675776",
-              "id": "7227539",
-              "object": "MONDO:0006781",
-              "publications": [
-                "PMID:10102946",
-                "PMID:10102965",
-                "PMID:12182745",
-                "PMID:14734187",
-                "PMID:15836716",
-                "PMID:15844694",
-                "PMID:16446791",
-                "PMID:20951912",
-                "PMID:25374223",
-                "PMID:29914954",
-                "PMID:8038358",
-                "PMID:9362185"
-              ]
-            }
-          },
-          "end": {
-            "identity": 628,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Tetracycline",
-              "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-              "equivalent_curies": [
-                "CHEBI:77932",
-                "CHEMBL.COMPOUND:CHEMBL1440",
-                "UMLS:C0039644",
-                "UMLS:C0521901",
-                "ATC:D06AA04",
-                "NCIT:C865",
-                "UMLS:C4255918",
-                "NDDF:002738",
-                "ATC:S01AA09",
-                "RXNORM:2105975",
-                "KEGG.COMPOUND:C06570",
-                "DRUGBANK:DB00759",
-                "ATC:S02AA08",
-                "CAS:60-54-8",
-                "PathWhiz.Compound:9228",
-                "ATC:A01AB13",
-                "HMDB:HMDB0014897",
-                "UNII:F8VB5M810T",
-                "PUBCHEM.COMPOUND:54675776",
-                "ATC:S03AA02",
-                "UMLS:C3710841",
-                "NCIT:C87225",
-                "DrugCentral:2611",
-                "NDDF:002740",
-                "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-                "RXNORM:10395",
-                "KEGG.DRUG:D00201",
-                "PUBCHEM.COMPOUND:51580080",
-                "ATC:J01AA07",
-                "CHEBI:27902",
-                "DRUGBANK:DB09550",
-                "MESH:D013752",
-                "UMLS:C4255917"
-              ],
-              "id": "PUBCHEM.COMPOUND:54675776",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Tetracycline phosphate complex",
-                "tetracycline",
-                "TETRACYCLINE",
-                "Tetracycline (JAN/USP/INN)",
-                "Anhydrotetracycline",
-                "tetracycline phosphate complex",
-                "tetracycline zwitterion",
-                "Abramycin",
-                "Deschlorobiomycin",
-                "tetracycline hydrochloride",
-                "Tetracycline",
-                "Tetracycline Phosphate Complex"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:26922234",
-                "PMID:19463000",
-                "PMID:18378719",
-                "PMID:19104019",
-                "PMID:18474585",
-                "PMID:20696876",
-                "PMID:19332670",
-                "PMID:18834112",
-                "PMID:23891185"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:13719384': {'publication date': '1961 Mar 10', 'sentence': '[Clinical considerations on the topical use of a new hydrosoluble tetracycline derivative in chronic osteomyelitis].', 'subject score': 775, 'object score': 888}, 'PMID:13882593': {'publication date': '1962 Mar', 'sentence': 'Penicillin verus tetracycline in the treatment of childhood osteomyelitis.', 'subject score': 802, 'object score': 888}, 'PMID:15840453': {'publication date': '2005 May', 'sentence': 'In pediatric osteomyelitis, oral therapy with cloxacillin was more effective than tetracycline in one study, and oral clindamycin was as effective as parenteral anti-staphylococcal penicillins in another.', 'subject score': 1000, 'object score': 888}, 'PMID:36568303': {'publication date': '2022', 'sentence': 'Overall, our results indicate that the addition of NP-TC on CPC acted as effective modulator towards a tunable drug release control in the treatment of bone infections or cancers.', 'subject score': 888, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 319037,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005246",
-          "name": "osteomyelitis",
-          "description": "An acute or chronic infectious process affecting the bones.; Osteomyelitis is an inflammatory process accompanied by bone destruction and caused by an infecting microorganism. [HPO:probinson, PMID:15276398]; Like other parts of the body, bones can get infected. The infections are usually bacterial, but can also be fungal. They may spread to the bone from nearby skin or muscles, or from another part of the body through the bloodstream. People who are at risk for bone infections include those with diabetes, poor circulation, or recent injury to the bone. You may also be at risk if you are having hemodialysis.  Symptoms of bone infections include: Pain in the infected area Chills and fever Swelling, warmth, and redness  A blood test or imaging test such as an x-ray can tell if you have a bone infection. Treatment includes antibiotics and often surgery.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "UMLS:C0008707",
-            "MEDDRA:10045927",
-            "MEDDRA:10031257",
-            "MEDDRA:10046086",
-            "SNOMEDCT:111253001",
-            "SNOMEDCT:40970001",
-            "UMLS:C2242472",
-            "MEDDRA:10031252",
-            "MEDDRA:10009091",
-            "HP:0002754",
-            "DOID:1019",
-            "UMLS:C0029443",
-            "NCIT:C26839",
-            "MESH:D010019",
-            "EFO:0003102",
-            "MEDDRA:10031259",
-            "MONDO:0005246",
-            "MEDDRA:10005977",
-            "MEDDRA:10031256",
-            "SNOMEDCT:60168000",
-            "MEDDRA:10061017",
-            "MEDDRA:10045936",
-            "MEDDRA:10009081",
-            "NCIT:C27577",
-            "ICD9:730.1",
-            "MEDDRA:10046076"
-          ],
-          "id": "MONDO:0005246",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Osteomyelitis",
-            "Chronic osteomyelitis",
-            "osteomyelitis",
-            "Bone Infection",
-            "Infection of bone"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "http://my.clevelandclinic.org/disorders/osteomyelitis/hic_osteomyelitis.aspx",
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://en.wikipedia.org/wiki/osteomyelitis",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000437.htm",
-            "http://www.mayoclinic.com/health/osteomyelitis/ds00759",
-            "PMID:15276398",
-            "https://orcid.org/0000-0002-6601-2165"
-          ]
-        }
-      },
-      "end": {
-        "identity": 628,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Tetracycline",
-          "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-          "equivalent_curies": [
-            "CHEBI:77932",
-            "CHEMBL.COMPOUND:CHEMBL1440",
-            "UMLS:C0039644",
-            "UMLS:C0521901",
-            "ATC:D06AA04",
-            "NCIT:C865",
-            "UMLS:C4255918",
-            "NDDF:002738",
-            "ATC:S01AA09",
-            "RXNORM:2105975",
-            "KEGG.COMPOUND:C06570",
-            "DRUGBANK:DB00759",
-            "ATC:S02AA08",
-            "CAS:60-54-8",
-            "PathWhiz.Compound:9228",
-            "ATC:A01AB13",
-            "HMDB:HMDB0014897",
-            "UNII:F8VB5M810T",
-            "PUBCHEM.COMPOUND:54675776",
-            "ATC:S03AA02",
-            "UMLS:C3710841",
-            "NCIT:C87225",
-            "DrugCentral:2611",
-            "NDDF:002740",
-            "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-            "RXNORM:10395",
-            "KEGG.DRUG:D00201",
-            "PUBCHEM.COMPOUND:51580080",
-            "ATC:J01AA07",
-            "CHEBI:27902",
-            "DRUGBANK:DB09550",
-            "MESH:D013752",
-            "UMLS:C4255917"
-          ],
-          "id": "PUBCHEM.COMPOUND:54675776",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Tetracycline phosphate complex",
-            "tetracycline",
-            "TETRACYCLINE",
-            "Tetracycline (JAN/USP/INN)",
-            "Anhydrotetracycline",
-            "tetracycline phosphate complex",
-            "tetracycline zwitterion",
-            "Abramycin",
-            "Deschlorobiomycin",
-            "tetracycline hydrochloride",
-            "Tetracycline",
-            "Tetracycline Phosphate Complex"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:26922234",
-            "PMID:19463000",
-            "PMID:18378719",
-            "PMID:19104019",
-            "PMID:18474585",
-            "PMID:20696876",
-            "PMID:19332670",
-            "PMID:18834112",
-            "PMID:23891185"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 319037,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005246",
-              "name": "osteomyelitis",
-              "description": "An acute or chronic infectious process affecting the bones.; Osteomyelitis is an inflammatory process accompanied by bone destruction and caused by an infecting microorganism. [HPO:probinson, PMID:15276398]; Like other parts of the body, bones can get infected. The infections are usually bacterial, but can also be fungal. They may spread to the bone from nearby skin or muscles, or from another part of the body through the bloodstream. People who are at risk for bone infections include those with diabetes, poor circulation, or recent injury to the bone. You may also be at risk if you are having hemodialysis.  Symptoms of bone infections include: Pain in the infected area Chills and fever Swelling, warmth, and redness  A blood test or imaging test such as an x-ray can tell if you have a bone infection. Treatment includes antibiotics and often surgery.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "UMLS:C0008707",
-                "MEDDRA:10045927",
-                "MEDDRA:10031257",
-                "MEDDRA:10046086",
-                "SNOMEDCT:111253001",
-                "SNOMEDCT:40970001",
-                "UMLS:C2242472",
-                "MEDDRA:10031252",
-                "MEDDRA:10009091",
-                "HP:0002754",
-                "DOID:1019",
-                "UMLS:C0029443",
-                "NCIT:C26839",
-                "MESH:D010019",
-                "EFO:0003102",
-                "MEDDRA:10031259",
-                "MONDO:0005246",
-                "MEDDRA:10005977",
-                "MEDDRA:10031256",
-                "SNOMEDCT:60168000",
-                "MEDDRA:10061017",
-                "MEDDRA:10045936",
-                "MEDDRA:10009081",
-                "NCIT:C27577",
-                "ICD9:730.1",
-                "MEDDRA:10046076"
-              ],
-              "id": "MONDO:0005246",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Osteomyelitis",
-                "Chronic osteomyelitis",
-                "osteomyelitis",
-                "Bone Infection",
-                "Infection of bone"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "http://my.clevelandclinic.org/disorders/osteomyelitis/hic_osteomyelitis.aspx",
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://en.wikipedia.org/wiki/osteomyelitis",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000437.htm",
-                "http://www.mayoclinic.com/health/osteomyelitis/ds00759",
-                "PMID:15276398",
-                "https://orcid.org/0000-0002-6601-2165"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10368532,
-            "start": 628,
-            "end": 319037,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13719384': {'publication date': '1961 Mar 10', 'sentence': '[Clinical considerations on the topical use of a new hydrosoluble tetracycline derivative in chronic osteomyelitis].', 'subject score': 775, 'object score': 888}, 'PMID:13882593': {'publication date': '1962 Mar', 'sentence': 'Penicillin verus tetracycline in the treatment of childhood osteomyelitis.', 'subject score': 802, 'object score': 888}, 'PMID:15840453': {'publication date': '2005 May', 'sentence': 'In pediatric osteomyelitis, oral therapy with cloxacillin was more effective than tetracycline in one study, and oral clindamycin was as effective as parenteral anti-staphylococcal penicillins in another.', 'subject score': 1000, 'object score': 888}, 'PMID:36568303': {'publication date': '2022', 'sentence': 'Overall, our results indicate that the addition of NP-TC on CPC acted as effective modulator towards a tunable drug release control in the treatment of bone infections or cancers.', 'subject score': 888, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0039644---SEMMEDDB:treats---None---None---None---UMLS:C0029443---SEMMEDDB:",
-                "UMLS:C0039644---SEMMEDDB:treats---None---None---None---UMLS:C2242472---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:54675776",
-              "id": "10596737",
-              "object": "MONDO:0005246",
-              "publications": [
-                "PMID:13882593",
-                "PMID:13719384",
-                "PMID:15840453",
-                "PMID:36568303"
-              ]
-            }
-          },
-          "end": {
-            "identity": 628,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Tetracycline",
-              "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-              "equivalent_curies": [
-                "CHEBI:77932",
-                "CHEMBL.COMPOUND:CHEMBL1440",
-                "UMLS:C0039644",
-                "UMLS:C0521901",
-                "ATC:D06AA04",
-                "NCIT:C865",
-                "UMLS:C4255918",
-                "NDDF:002738",
-                "ATC:S01AA09",
-                "RXNORM:2105975",
-                "KEGG.COMPOUND:C06570",
-                "DRUGBANK:DB00759",
-                "ATC:S02AA08",
-                "CAS:60-54-8",
-                "PathWhiz.Compound:9228",
-                "ATC:A01AB13",
-                "HMDB:HMDB0014897",
-                "UNII:F8VB5M810T",
-                "PUBCHEM.COMPOUND:54675776",
-                "ATC:S03AA02",
-                "UMLS:C3710841",
-                "NCIT:C87225",
-                "DrugCentral:2611",
-                "NDDF:002740",
-                "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-                "RXNORM:10395",
-                "KEGG.DRUG:D00201",
-                "PUBCHEM.COMPOUND:51580080",
-                "ATC:J01AA07",
-                "CHEBI:27902",
-                "DRUGBANK:DB09550",
-                "MESH:D013752",
-                "UMLS:C4255917"
-              ],
-              "id": "PUBCHEM.COMPOUND:54675776",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Tetracycline phosphate complex",
-                "tetracycline",
-                "TETRACYCLINE",
-                "Tetracycline (JAN/USP/INN)",
-                "Anhydrotetracycline",
-                "tetracycline phosphate complex",
-                "tetracycline zwitterion",
-                "Abramycin",
-                "Deschlorobiomycin",
-                "tetracycline hydrochloride",
-                "Tetracycline",
-                "Tetracycline Phosphate Complex"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:26922234",
-                "PMID:19463000",
-                "PMID:18378719",
-                "PMID:19104019",
-                "PMID:18474585",
-                "PMID:20696876",
-                "PMID:19332670",
-                "PMID:18834112",
-                "PMID:23891185"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:25385866': {'publication date': '2015 Feb', 'sentence': 'We conclude that although empiric ceftriaxone is appropriate in our setting, etiologies not explicitly addressed in IMAI guidance for these syndromes, such as cryptococcosis, histoplasmosis, and tetracycline-responsive bacterial infections, were common.', 'subject score': 861, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 538307,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-          ]
-        }
-      },
-      "end": {
-        "identity": 628,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Tetracycline",
-          "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-          "equivalent_curies": [
-            "CHEBI:77932",
-            "CHEMBL.COMPOUND:CHEMBL1440",
-            "UMLS:C0039644",
-            "UMLS:C0521901",
-            "ATC:D06AA04",
-            "NCIT:C865",
-            "UMLS:C4255918",
-            "NDDF:002738",
-            "ATC:S01AA09",
-            "RXNORM:2105975",
-            "KEGG.COMPOUND:C06570",
-            "DRUGBANK:DB00759",
-            "ATC:S02AA08",
-            "CAS:60-54-8",
-            "PathWhiz.Compound:9228",
-            "ATC:A01AB13",
-            "HMDB:HMDB0014897",
-            "UNII:F8VB5M810T",
-            "PUBCHEM.COMPOUND:54675776",
-            "ATC:S03AA02",
-            "UMLS:C3710841",
-            "NCIT:C87225",
-            "DrugCentral:2611",
-            "NDDF:002740",
-            "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-            "RXNORM:10395",
-            "KEGG.DRUG:D00201",
-            "PUBCHEM.COMPOUND:51580080",
-            "ATC:J01AA07",
-            "CHEBI:27902",
-            "DRUGBANK:DB09550",
-            "MESH:D013752",
-            "UMLS:C4255917"
-          ],
-          "id": "PUBCHEM.COMPOUND:54675776",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Tetracycline phosphate complex",
-            "tetracycline",
-            "TETRACYCLINE",
-            "Tetracycline (JAN/USP/INN)",
-            "Anhydrotetracycline",
-            "tetracycline phosphate complex",
-            "tetracycline zwitterion",
-            "Abramycin",
-            "Deschlorobiomycin",
-            "tetracycline hydrochloride",
-            "Tetracycline",
-            "Tetracycline Phosphate Complex"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:26922234",
-            "PMID:19463000",
-            "PMID:18378719",
-            "PMID:19104019",
-            "PMID:18474585",
-            "PMID:20696876",
-            "PMID:19332670",
-            "PMID:18834112",
-            "PMID:23891185"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538307,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17610087,
-            "start": 628,
-            "end": 538307,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25385866': {'publication date': '2015 Feb', 'sentence': 'We conclude that although empiric ceftriaxone is appropriate in our setting, etiologies not explicitly addressed in IMAI guidance for these syndromes, such as cryptococcosis, histoplasmosis, and tetracycline-responsive bacterial infections, were common.', 'subject score': 861, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0039644---SEMMEDDB:affects---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:54675776",
-              "id": "17969405",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:25385866"
-              ]
-            }
-          },
-          "end": {
-            "identity": 628,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Tetracycline",
-              "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-              "equivalent_curies": [
-                "CHEBI:77932",
-                "CHEMBL.COMPOUND:CHEMBL1440",
-                "UMLS:C0039644",
-                "UMLS:C0521901",
-                "ATC:D06AA04",
-                "NCIT:C865",
-                "UMLS:C4255918",
-                "NDDF:002738",
-                "ATC:S01AA09",
-                "RXNORM:2105975",
-                "KEGG.COMPOUND:C06570",
-                "DRUGBANK:DB00759",
-                "ATC:S02AA08",
-                "CAS:60-54-8",
-                "PathWhiz.Compound:9228",
-                "ATC:A01AB13",
-                "HMDB:HMDB0014897",
-                "UNII:F8VB5M810T",
-                "PUBCHEM.COMPOUND:54675776",
-                "ATC:S03AA02",
-                "UMLS:C3710841",
-                "NCIT:C87225",
-                "DrugCentral:2611",
-                "NDDF:002740",
-                "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-                "RXNORM:10395",
-                "KEGG.DRUG:D00201",
-                "PUBCHEM.COMPOUND:51580080",
-                "ATC:J01AA07",
-                "CHEBI:27902",
-                "DRUGBANK:DB09550",
-                "MESH:D013752",
-                "UMLS:C4255917"
-              ],
-              "id": "PUBCHEM.COMPOUND:54675776",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Tetracycline phosphate complex",
-                "tetracycline",
-                "TETRACYCLINE",
-                "Tetracycline (JAN/USP/INN)",
-                "Anhydrotetracycline",
-                "tetracycline phosphate complex",
-                "tetracycline zwitterion",
-                "Abramycin",
-                "Deschlorobiomycin",
-                "tetracycline hydrochloride",
-                "Tetracycline",
-                "Tetracycline Phosphate Complex"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:26922234",
-                "PMID:19463000",
-                "PMID:18378719",
-                "PMID:19104019",
-                "PMID:18474585",
-                "PMID:20696876",
-                "PMID:19332670",
-                "PMID:18834112",
-                "PMID:23891185"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:13355345': {'publication date': '1955-1956', 'sentence': 'Nystatin and tetracycline in the treatment of bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:14287924': {'publication date': '1964', 'sentence': 'ADJUVANT EFFECT OF PHOSCOLIC ACID ON TETRACYCLINE IN BACTERIAL INFECTIONS IN MICE.', 'subject score': 1000, 'object score': 1000}, 'PMID:15446174': {'publication date': '1964 Jun', 'sentence': 'A COMPARATIVE STUDY OF ERYTHROMYCIN AND TETRACYCLINE IN COMMON BACTERIAL INFECTIONS.', 'subject score': 1000, 'object score': 901}, 'PMID:15833322': {'publication date': '2005 May', 'sentence': 'This finding is very important because the use of tetracycline to treat bacterial infections has declined due to the emergence of resistant organisms.', 'subject score': 1000, 'object score': 1000}, 'PMID:23142491': {'publication date': '2013 Feb-Mar', 'sentence': 'Protein synthesis inhibitors such as chloramphenicol and tetracycline may be inducers of efflux pumps such as MexY in Pseudomonas aeruginosa, complicating their use for the treatment of bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:23497696': {'publication date': '2013 Mar 08', 'sentence': 'BACKGROUND: Doxycyline (Dox) is a semisynthetic antibacterial drug with pharmacological advantages over its parent drug (tetracycline) in the treatment of various bacterial diseases in horses.', 'subject score': 1000, 'object score': 901}, 'PMID:2482571': {'publication date': '1989 Nov 30', 'sentence': 'The results showed that oxolinic acid, used at recommended doses for the treatment of bacterial diseases, did not cause immunosuppression in either the nonspecific defense or specific immune system compartments, whereas tetracycline at 10 mg/kg caused reduced activity in both.', 'subject score': 1000, 'object score': 1000}, 'PMID:28317899': {'publication date': '2017 03 20', 'sentence': 'Minocycline is a broad spectrum, semi-synthetic tetracycline analog that is used to treat bacterial infection.', 'subject score': 756, 'object score': 1000}, 'PMID:28910723': {'publication date': '2017 Dec', 'sentence': 'Tetracycline (TET) is commonly used to treat bacterial diseases in humans and chickens (Gallus gallus domesticus), is largely excreted, and is found at elevated concentrations in treated sewage sludge (biosolids) and poultry litter (excrement plus bedding materials).', 'subject score': 1000, 'object score': 1000}, 'PMID:29933159': {'publication date': '2018 Oct', 'sentence': 'Tetracycline (TET) is commonly used to treat bacterial diseases in humans and chickens (Gallus gallus domesticus), is largely excreted, and is often found at elevated concentrations in treated sewage sludge (biosolids) and poultry litter (excrement plus bedding materials).', 'subject score': 1000, 'object score': 1000}, 'PMID:30694262': {'publication date': '2019 Mar 11', 'sentence': 'Tetracycline (TC) is widely used to treat bacterial infections in humans and animals due to its low price and good antibacterial properties.', 'subject score': 1000, 'object score': 1000}, 'PMID:3509971': {'publication date': '1987', 'sentence': 'Tetracycline, penicillin, sulphonamide and aminoglycoside were the four major groups of antibiotics used for therapy of bacterial infections in animals.', 'subject score': 1000, 'object score': 1000}, 'PMID:36203120': {'publication date': '2022 Oct 07', 'sentence': 'BACKGROUND: Antibiotics containing azithromycin, amoxicillin, doxycycline, tetracycline, and azithromycin are widely utilized in the treatment of bacterial infections, and their determination in biological samples is critical to evaluate their side effects.', 'subject score': 1000, 'object score': 1000}, 'PMID:36805897': {'publication date': '2023 Feb 18', 'sentence': 'Tetracycline (TCC) and sulfadiazine (SDZ) are two of the most consumed antibiotics for human therapies and bacterial infection treatments in aquafarming fields, but their accumulative residues can result in negative effects on water and aquatic microorganisms.', 'subject score': 1000, 'object score': 901}, 'PMID:5398310': {'publication date': '1969', 'sentence': '[N1-N1-diethyleniminobiguanide-methyl-tetracycline in various bacterial diseases of the urinary tract].', 'subject score': 804, 'object score': 901}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 538307,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-          ]
-        }
-      },
-      "end": {
-        "identity": 628,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Tetracycline",
-          "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-          "equivalent_curies": [
-            "CHEBI:77932",
-            "CHEMBL.COMPOUND:CHEMBL1440",
-            "UMLS:C0039644",
-            "UMLS:C0521901",
-            "ATC:D06AA04",
-            "NCIT:C865",
-            "UMLS:C4255918",
-            "NDDF:002738",
-            "ATC:S01AA09",
-            "RXNORM:2105975",
-            "KEGG.COMPOUND:C06570",
-            "DRUGBANK:DB00759",
-            "ATC:S02AA08",
-            "CAS:60-54-8",
-            "PathWhiz.Compound:9228",
-            "ATC:A01AB13",
-            "HMDB:HMDB0014897",
-            "UNII:F8VB5M810T",
-            "PUBCHEM.COMPOUND:54675776",
-            "ATC:S03AA02",
-            "UMLS:C3710841",
-            "NCIT:C87225",
-            "DrugCentral:2611",
-            "NDDF:002740",
-            "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-            "RXNORM:10395",
-            "KEGG.DRUG:D00201",
-            "PUBCHEM.COMPOUND:51580080",
-            "ATC:J01AA07",
-            "CHEBI:27902",
-            "DRUGBANK:DB09550",
-            "MESH:D013752",
-            "UMLS:C4255917"
-          ],
-          "id": "PUBCHEM.COMPOUND:54675776",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Tetracycline phosphate complex",
-            "tetracycline",
-            "TETRACYCLINE",
-            "Tetracycline (JAN/USP/INN)",
-            "Anhydrotetracycline",
-            "tetracycline phosphate complex",
-            "tetracycline zwitterion",
-            "Abramycin",
-            "Deschlorobiomycin",
-            "tetracycline hydrochloride",
-            "Tetracycline",
-            "Tetracycline Phosphate Complex"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:26922234",
-            "PMID:19463000",
-            "PMID:18378719",
-            "PMID:19104019",
-            "PMID:18474585",
-            "PMID:20696876",
-            "PMID:19332670",
-            "PMID:18834112",
-            "PMID:23891185"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538307,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10286833,
-            "start": 628,
-            "end": 538307,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13355345': {'publication date': '1955-1956', 'sentence': 'Nystatin and tetracycline in the treatment of bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:14287924': {'publication date': '1964', 'sentence': 'ADJUVANT EFFECT OF PHOSCOLIC ACID ON TETRACYCLINE IN BACTERIAL INFECTIONS IN MICE.', 'subject score': 1000, 'object score': 1000}, 'PMID:15446174': {'publication date': '1964 Jun', 'sentence': 'A COMPARATIVE STUDY OF ERYTHROMYCIN AND TETRACYCLINE IN COMMON BACTERIAL INFECTIONS.', 'subject score': 1000, 'object score': 901}, 'PMID:15833322': {'publication date': '2005 May', 'sentence': 'This finding is very important because the use of tetracycline to treat bacterial infections has declined due to the emergence of resistant organisms.', 'subject score': 1000, 'object score': 1000}, 'PMID:23142491': {'publication date': '2013 Feb-Mar', 'sentence': 'Protein synthesis inhibitors such as chloramphenicol and tetracycline may be inducers of efflux pumps such as MexY in Pseudomonas aeruginosa, complicating their use for the treatment of bacterial infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:23497696': {'publication date': '2013 Mar 08', 'sentence': 'BACKGROUND: Doxycyline (Dox) is a semisynthetic antibacterial drug with pharmacological advantages over its parent drug (tetracycline) in the treatment of various bacterial diseases in horses.', 'subject score': 1000, 'object score': 901}, 'PMID:2482571': {'publication date': '1989 Nov 30', 'sentence': 'The results showed that oxolinic acid, used at recommended doses for the treatment of bacterial diseases, did not cause immunosuppression in either the nonspecific defense or specific immune system compartments, whereas tetracycline at 10 mg/kg caused reduced activity in both.', 'subject score': 1000, 'object score': 1000}, 'PMID:28317899': {'publication date': '2017 03 20', 'sentence': 'Minocycline is a broad spectrum, semi-synthetic tetracycline analog that is used to treat bacterial infection.', 'subject score': 756, 'object score': 1000}, 'PMID:28910723': {'publication date': '2017 Dec', 'sentence': 'Tetracycline (TET) is commonly used to treat bacterial diseases in humans and chickens (Gallus gallus domesticus), is largely excreted, and is found at elevated concentrations in treated sewage sludge (biosolids) and poultry litter (excrement plus bedding materials).', 'subject score': 1000, 'object score': 1000}, 'PMID:29933159': {'publication date': '2018 Oct', 'sentence': 'Tetracycline (TET) is commonly used to treat bacterial diseases in humans and chickens (Gallus gallus domesticus), is largely excreted, and is often found at elevated concentrations in treated sewage sludge (biosolids) and poultry litter (excrement plus bedding materials).', 'subject score': 1000, 'object score': 1000}, 'PMID:30694262': {'publication date': '2019 Mar 11', 'sentence': 'Tetracycline (TC) is widely used to treat bacterial infections in humans and animals due to its low price and good antibacterial properties.', 'subject score': 1000, 'object score': 1000}, 'PMID:3509971': {'publication date': '1987', 'sentence': 'Tetracycline, penicillin, sulphonamide and aminoglycoside were the four major groups of antibiotics used for therapy of bacterial infections in animals.', 'subject score': 1000, 'object score': 1000}, 'PMID:36203120': {'publication date': '2022 Oct 07', 'sentence': 'BACKGROUND: Antibiotics containing azithromycin, amoxicillin, doxycycline, tetracycline, and azithromycin are widely utilized in the treatment of bacterial infections, and their determination in biological samples is critical to evaluate their side effects.', 'subject score': 1000, 'object score': 1000}, 'PMID:36805897': {'publication date': '2023 Feb 18', 'sentence': 'Tetracycline (TCC) and sulfadiazine (SDZ) are two of the most consumed antibiotics for human therapies and bacterial infection treatments in aquafarming fields, but their accumulative residues can result in negative effects on water and aquatic microorganisms.', 'subject score': 1000, 'object score': 901}, 'PMID:5398310': {'publication date': '1969', 'sentence': '[N1-N1-diethyleniminobiguanide-methyl-tetracycline in various bacterial diseases of the urinary tract].', 'subject score': 804, 'object score': 901}}",
-              "kg2_ids": [
-                "UMLS:C0039644---SEMMEDDB:treats---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:54675776",
-              "id": "10513439",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:13355345",
-                "PMID:14287924",
-                "PMID:15446174",
-                "PMID:15833322",
-                "PMID:23142491",
-                "PMID:23497696",
-                "PMID:2482571",
-                "PMID:28317899",
-                "PMID:28910723",
-                "PMID:29933159",
-                "PMID:30694262",
-                "PMID:3509971",
-                "PMID:36203120",
-                "PMID:36805897",
-                "PMID:5398310"
-              ]
-            }
-          },
-          "end": {
-            "identity": 628,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Tetracycline",
-              "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-              "equivalent_curies": [
-                "CHEBI:77932",
-                "CHEMBL.COMPOUND:CHEMBL1440",
-                "UMLS:C0039644",
-                "UMLS:C0521901",
-                "ATC:D06AA04",
-                "NCIT:C865",
-                "UMLS:C4255918",
-                "NDDF:002738",
-                "ATC:S01AA09",
-                "RXNORM:2105975",
-                "KEGG.COMPOUND:C06570",
-                "DRUGBANK:DB00759",
-                "ATC:S02AA08",
-                "CAS:60-54-8",
-                "PathWhiz.Compound:9228",
-                "ATC:A01AB13",
-                "HMDB:HMDB0014897",
-                "UNII:F8VB5M810T",
-                "PUBCHEM.COMPOUND:54675776",
-                "ATC:S03AA02",
-                "UMLS:C3710841",
-                "NCIT:C87225",
-                "DrugCentral:2611",
-                "NDDF:002740",
-                "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-                "RXNORM:10395",
-                "KEGG.DRUG:D00201",
-                "PUBCHEM.COMPOUND:51580080",
-                "ATC:J01AA07",
-                "CHEBI:27902",
-                "DRUGBANK:DB09550",
-                "MESH:D013752",
-                "UMLS:C4255917"
-              ],
-              "id": "PUBCHEM.COMPOUND:54675776",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Tetracycline phosphate complex",
-                "tetracycline",
-                "TETRACYCLINE",
-                "Tetracycline (JAN/USP/INN)",
-                "Anhydrotetracycline",
-                "tetracycline phosphate complex",
-                "tetracycline zwitterion",
-                "Abramycin",
-                "Deschlorobiomycin",
-                "tetracycline hydrochloride",
-                "Tetracycline",
-                "Tetracycline Phosphate Complex"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:26922234",
-                "PMID:19463000",
-                "PMID:18378719",
-                "PMID:19104019",
-                "PMID:18474585",
-                "PMID:20696876",
-                "PMID:19332670",
-                "PMID:18834112",
-                "PMID:23891185"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:35630502': {'publication date': '2022 May 20', 'sentence': 'Resistance to tetracycline, used to prevent bacterial infections in beehives, was only found in    Bombella apis     MRM1     T      .', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 538307,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-          ]
-        }
-      },
-      "end": {
-        "identity": 628,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Tetracycline",
-          "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-          "equivalent_curies": [
-            "CHEBI:77932",
-            "CHEMBL.COMPOUND:CHEMBL1440",
-            "UMLS:C0039644",
-            "UMLS:C0521901",
-            "ATC:D06AA04",
-            "NCIT:C865",
-            "UMLS:C4255918",
-            "NDDF:002738",
-            "ATC:S01AA09",
-            "RXNORM:2105975",
-            "KEGG.COMPOUND:C06570",
-            "DRUGBANK:DB00759",
-            "ATC:S02AA08",
-            "CAS:60-54-8",
-            "PathWhiz.Compound:9228",
-            "ATC:A01AB13",
-            "HMDB:HMDB0014897",
-            "UNII:F8VB5M810T",
-            "PUBCHEM.COMPOUND:54675776",
-            "ATC:S03AA02",
-            "UMLS:C3710841",
-            "NCIT:C87225",
-            "DrugCentral:2611",
-            "NDDF:002740",
-            "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-            "RXNORM:10395",
-            "KEGG.DRUG:D00201",
-            "PUBCHEM.COMPOUND:51580080",
-            "ATC:J01AA07",
-            "CHEBI:27902",
-            "DRUGBANK:DB09550",
-            "MESH:D013752",
-            "UMLS:C4255917"
-          ],
-          "id": "PUBCHEM.COMPOUND:54675776",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Tetracycline phosphate complex",
-            "tetracycline",
-            "TETRACYCLINE",
-            "Tetracycline (JAN/USP/INN)",
-            "Anhydrotetracycline",
-            "tetracycline phosphate complex",
-            "tetracycline zwitterion",
-            "Abramycin",
-            "Deschlorobiomycin",
-            "tetracycline hydrochloride",
-            "Tetracycline",
-            "Tetracycline Phosphate Complex"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:26922234",
-            "PMID:19463000",
-            "PMID:18378719",
-            "PMID:19104019",
-            "PMID:18474585",
-            "PMID:20696876",
-            "PMID:19332670",
-            "PMID:18834112",
-            "PMID:23891185"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 538307,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 24123075,
-            "start": 628,
-            "end": 538307,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35630502': {'publication date': '2022 May 20', 'sentence': 'Resistance to tetracycline, used to prevent bacterial infections in beehives, was only found in    Bombella apis     MRM1     T      .', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0039644---SEMMEDDB:prevents---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:54675776",
-              "id": "24565223",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:35630502"
-              ]
-            }
-          },
-          "end": {
-            "identity": 628,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Tetracycline",
-              "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-              "equivalent_curies": [
-                "CHEBI:77932",
-                "CHEMBL.COMPOUND:CHEMBL1440",
-                "UMLS:C0039644",
-                "UMLS:C0521901",
-                "ATC:D06AA04",
-                "NCIT:C865",
-                "UMLS:C4255918",
-                "NDDF:002738",
-                "ATC:S01AA09",
-                "RXNORM:2105975",
-                "KEGG.COMPOUND:C06570",
-                "DRUGBANK:DB00759",
-                "ATC:S02AA08",
-                "CAS:60-54-8",
-                "PathWhiz.Compound:9228",
-                "ATC:A01AB13",
-                "HMDB:HMDB0014897",
-                "UNII:F8VB5M810T",
-                "PUBCHEM.COMPOUND:54675776",
-                "ATC:S03AA02",
-                "UMLS:C3710841",
-                "NCIT:C87225",
-                "DrugCentral:2611",
-                "NDDF:002740",
-                "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-                "RXNORM:10395",
-                "KEGG.DRUG:D00201",
-                "PUBCHEM.COMPOUND:51580080",
-                "ATC:J01AA07",
-                "CHEBI:27902",
-                "DRUGBANK:DB09550",
-                "MESH:D013752",
-                "UMLS:C4255917"
-              ],
-              "id": "PUBCHEM.COMPOUND:54675776",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Tetracycline phosphate complex",
-                "tetracycline",
-                "TETRACYCLINE",
-                "Tetracycline (JAN/USP/INN)",
-                "Anhydrotetracycline",
-                "tetracycline phosphate complex",
-                "tetracycline zwitterion",
-                "Abramycin",
-                "Deschlorobiomycin",
-                "tetracycline hydrochloride",
-                "Tetracycline",
-                "Tetracycline Phosphate Complex"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:26922234",
-                "PMID:19463000",
-                "PMID:18378719",
-                "PMID:19104019",
-                "PMID:18474585",
-                "PMID:20696876",
-                "PMID:19332670",
-                "PMID:18834112",
-                "PMID:23891185"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:294476': {'publication date': '1979 Dec', 'sentence': 'In conclusion, long term systemic administration of tetracycline in the rat may be of value in reducing the amount of tissue destruction in experimentally induced periodontitis.', 'subject score': 1000, 'object score': 790}}",
-    "p2": {
-      "start": {
-        "identity": 311374,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005076",
-          "name": "periodontitis",
-          "description": "An acute or chronic inflammatory process that affects the tissues that surround and support the teeth.; Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology); Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:824",
-            "UMLS:C0600298",
-            "MEDDRA:10034540",
-            "SNOMEDCT:41565005",
-            "ICD9:523.5",
-            "DOID:9893",
-            "MESH:D010518",
-            "ICD10:K05.4",
-            "HP:0000704",
-            "UMLS:C0031099",
-            "ICD10:K05.3",
-            "MONDO:0005076",
-            "MEDDRA:10034539",
-            "NCIT:C34918",
-            "EFO:0000649"
-          ],
-          "id": "MONDO:0005076",
-          "category": "biolink:Disease",
-          "all_names": [
-            "periodontitis",
-            "Periodontitis",
-            "periodontosis",
-            "Periodontosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5889-4463",
-            "https://orcid.org/0000-0002-9338-3017"
-          ]
-        }
-      },
-      "end": {
-        "identity": 628,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Tetracycline",
-          "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-          "equivalent_curies": [
-            "CHEBI:77932",
-            "CHEMBL.COMPOUND:CHEMBL1440",
-            "UMLS:C0039644",
-            "UMLS:C0521901",
-            "ATC:D06AA04",
-            "NCIT:C865",
-            "UMLS:C4255918",
-            "NDDF:002738",
-            "ATC:S01AA09",
-            "RXNORM:2105975",
-            "KEGG.COMPOUND:C06570",
-            "DRUGBANK:DB00759",
-            "ATC:S02AA08",
-            "CAS:60-54-8",
-            "PathWhiz.Compound:9228",
-            "ATC:A01AB13",
-            "HMDB:HMDB0014897",
-            "UNII:F8VB5M810T",
-            "PUBCHEM.COMPOUND:54675776",
-            "ATC:S03AA02",
-            "UMLS:C3710841",
-            "NCIT:C87225",
-            "DrugCentral:2611",
-            "NDDF:002740",
-            "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-            "RXNORM:10395",
-            "KEGG.DRUG:D00201",
-            "PUBCHEM.COMPOUND:51580080",
-            "ATC:J01AA07",
-            "CHEBI:27902",
-            "DRUGBANK:DB09550",
-            "MESH:D013752",
-            "UMLS:C4255917"
-          ],
-          "id": "PUBCHEM.COMPOUND:54675776",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Tetracycline phosphate complex",
-            "tetracycline",
-            "TETRACYCLINE",
-            "Tetracycline (JAN/USP/INN)",
-            "Anhydrotetracycline",
-            "tetracycline phosphate complex",
-            "tetracycline zwitterion",
-            "Abramycin",
-            "Deschlorobiomycin",
-            "tetracycline hydrochloride",
-            "Tetracycline",
-            "Tetracycline Phosphate Complex"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:26922234",
-            "PMID:19463000",
-            "PMID:18378719",
-            "PMID:19104019",
-            "PMID:18474585",
-            "PMID:20696876",
-            "PMID:19332670",
-            "PMID:18834112",
-            "PMID:23891185"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311374,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005076",
-              "name": "periodontitis",
-              "description": "An acute or chronic inflammatory process that affects the tissues that surround and support the teeth.; Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology); Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:824",
-                "UMLS:C0600298",
-                "MEDDRA:10034540",
-                "SNOMEDCT:41565005",
-                "ICD9:523.5",
-                "DOID:9893",
-                "MESH:D010518",
-                "ICD10:K05.4",
-                "HP:0000704",
-                "UMLS:C0031099",
-                "ICD10:K05.3",
-                "MONDO:0005076",
-                "MEDDRA:10034539",
-                "NCIT:C34918",
-                "EFO:0000649"
-              ],
-              "id": "MONDO:0005076",
-              "category": "biolink:Disease",
-              "all_names": [
-                "periodontitis",
-                "Periodontitis",
-                "periodontosis",
-                "Periodontosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5889-4463",
-                "https://orcid.org/0000-0002-9338-3017"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 19777585,
-            "start": 628,
-            "end": 311374,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:294476': {'publication date': '1979 Dec', 'sentence': 'In conclusion, long term systemic administration of tetracycline in the rat may be of value in reducing the amount of tissue destruction in experimentally induced periodontitis.', 'subject score': 1000, 'object score': 790}}",
-              "kg2_ids": [
-                "UMLS:C0039644---SEMMEDDB:causes---None---None---None---UMLS:C0031099---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:54675776",
-              "id": "20170701",
-              "object": "MONDO:0005076",
-              "publications": [
-                "PMID:294476"
-              ]
-            }
-          },
-          "end": {
-            "identity": 628,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Tetracycline",
-              "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-              "equivalent_curies": [
-                "CHEBI:77932",
-                "CHEMBL.COMPOUND:CHEMBL1440",
-                "UMLS:C0039644",
-                "UMLS:C0521901",
-                "ATC:D06AA04",
-                "NCIT:C865",
-                "UMLS:C4255918",
-                "NDDF:002738",
-                "ATC:S01AA09",
-                "RXNORM:2105975",
-                "KEGG.COMPOUND:C06570",
-                "DRUGBANK:DB00759",
-                "ATC:S02AA08",
-                "CAS:60-54-8",
-                "PathWhiz.Compound:9228",
-                "ATC:A01AB13",
-                "HMDB:HMDB0014897",
-                "UNII:F8VB5M810T",
-                "PUBCHEM.COMPOUND:54675776",
-                "ATC:S03AA02",
-                "UMLS:C3710841",
-                "NCIT:C87225",
-                "DrugCentral:2611",
-                "NDDF:002740",
-                "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-                "RXNORM:10395",
-                "KEGG.DRUG:D00201",
-                "PUBCHEM.COMPOUND:51580080",
-                "ATC:J01AA07",
-                "CHEBI:27902",
-                "DRUGBANK:DB09550",
-                "MESH:D013752",
-                "UMLS:C4255917"
-              ],
-              "id": "PUBCHEM.COMPOUND:54675776",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Tetracycline phosphate complex",
-                "tetracycline",
-                "TETRACYCLINE",
-                "Tetracycline (JAN/USP/INN)",
-                "Anhydrotetracycline",
-                "tetracycline phosphate complex",
-                "tetracycline zwitterion",
-                "Abramycin",
-                "Deschlorobiomycin",
-                "tetracycline hydrochloride",
-                "Tetracycline",
-                "Tetracycline Phosphate Complex"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:26922234",
-                "PMID:19463000",
-                "PMID:18378719",
-                "PMID:19104019",
-                "PMID:18474585",
-                "PMID:20696876",
-                "PMID:19332670",
-                "PMID:18834112",
-                "PMID:23891185"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:25560693': {'publication date': '2014', 'sentence': 'Occurrence of porphyromonas gingivalis and its antibacterial susceptibility to metronidazole and tetracycline in patients with chronic periodontitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:294476': {'publication date': '1979 Dec', 'sentence': 'The present investigation was undertaken to determine the influence of systemically administered tetracycline on periodontitis in the rat.', 'subject score': 827, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 311374,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005076",
-          "name": "periodontitis",
-          "description": "An acute or chronic inflammatory process that affects the tissues that surround and support the teeth.; Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology); Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:824",
-            "UMLS:C0600298",
-            "MEDDRA:10034540",
-            "SNOMEDCT:41565005",
-            "ICD9:523.5",
-            "DOID:9893",
-            "MESH:D010518",
-            "ICD10:K05.4",
-            "HP:0000704",
-            "UMLS:C0031099",
-            "ICD10:K05.3",
-            "MONDO:0005076",
-            "MEDDRA:10034539",
-            "NCIT:C34918",
-            "EFO:0000649"
-          ],
-          "id": "MONDO:0005076",
-          "category": "biolink:Disease",
-          "all_names": [
-            "periodontitis",
-            "Periodontitis",
-            "periodontosis",
-            "Periodontosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5889-4463",
-            "https://orcid.org/0000-0002-9338-3017"
-          ]
-        }
-      },
-      "end": {
-        "identity": 628,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Tetracycline",
-          "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-          "equivalent_curies": [
-            "CHEBI:77932",
-            "CHEMBL.COMPOUND:CHEMBL1440",
-            "UMLS:C0039644",
-            "UMLS:C0521901",
-            "ATC:D06AA04",
-            "NCIT:C865",
-            "UMLS:C4255918",
-            "NDDF:002738",
-            "ATC:S01AA09",
-            "RXNORM:2105975",
-            "KEGG.COMPOUND:C06570",
-            "DRUGBANK:DB00759",
-            "ATC:S02AA08",
-            "CAS:60-54-8",
-            "PathWhiz.Compound:9228",
-            "ATC:A01AB13",
-            "HMDB:HMDB0014897",
-            "UNII:F8VB5M810T",
-            "PUBCHEM.COMPOUND:54675776",
-            "ATC:S03AA02",
-            "UMLS:C3710841",
-            "NCIT:C87225",
-            "DrugCentral:2611",
-            "NDDF:002740",
-            "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-            "RXNORM:10395",
-            "KEGG.DRUG:D00201",
-            "PUBCHEM.COMPOUND:51580080",
-            "ATC:J01AA07",
-            "CHEBI:27902",
-            "DRUGBANK:DB09550",
-            "MESH:D013752",
-            "UMLS:C4255917"
-          ],
-          "id": "PUBCHEM.COMPOUND:54675776",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Tetracycline phosphate complex",
-            "tetracycline",
-            "TETRACYCLINE",
-            "Tetracycline (JAN/USP/INN)",
-            "Anhydrotetracycline",
-            "tetracycline phosphate complex",
-            "tetracycline zwitterion",
-            "Abramycin",
-            "Deschlorobiomycin",
-            "tetracycline hydrochloride",
-            "Tetracycline",
-            "Tetracycline Phosphate Complex"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:26922234",
-            "PMID:19463000",
-            "PMID:18378719",
-            "PMID:19104019",
-            "PMID:18474585",
-            "PMID:20696876",
-            "PMID:19332670",
-            "PMID:18834112",
-            "PMID:23891185"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311374,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005076",
-              "name": "periodontitis",
-              "description": "An acute or chronic inflammatory process that affects the tissues that surround and support the teeth.; Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology); Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:824",
-                "UMLS:C0600298",
-                "MEDDRA:10034540",
-                "SNOMEDCT:41565005",
-                "ICD9:523.5",
-                "DOID:9893",
-                "MESH:D010518",
-                "ICD10:K05.4",
-                "HP:0000704",
-                "UMLS:C0031099",
-                "ICD10:K05.3",
-                "MONDO:0005076",
-                "MEDDRA:10034539",
-                "NCIT:C34918",
-                "EFO:0000649"
-              ],
-              "id": "MONDO:0005076",
-              "category": "biolink:Disease",
-              "all_names": [
-                "periodontitis",
-                "Periodontitis",
-                "periodontosis",
-                "Periodontosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5889-4463",
-                "https://orcid.org/0000-0002-9338-3017"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 17717746,
-            "start": 628,
-            "end": 311374,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:25560693': {'publication date': '2014', 'sentence': 'Occurrence of porphyromonas gingivalis and its antibacterial susceptibility to metronidazole and tetracycline in patients with chronic periodontitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:294476': {'publication date': '1979 Dec', 'sentence': 'The present investigation was undertaken to determine the influence of systemically administered tetracycline on periodontitis in the rat.', 'subject score': 827, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0039644---SEMMEDDB:affects---None---None---None---UMLS:C0031099---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:54675776",
-              "id": "18080767",
-              "object": "MONDO:0005076",
-              "publications": [
-                "PMID:25560693",
-                "PMID:294476"
-              ]
-            }
-          },
-          "end": {
-            "identity": 628,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Tetracycline",
-              "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-              "equivalent_curies": [
-                "CHEBI:77932",
-                "CHEMBL.COMPOUND:CHEMBL1440",
-                "UMLS:C0039644",
-                "UMLS:C0521901",
-                "ATC:D06AA04",
-                "NCIT:C865",
-                "UMLS:C4255918",
-                "NDDF:002738",
-                "ATC:S01AA09",
-                "RXNORM:2105975",
-                "KEGG.COMPOUND:C06570",
-                "DRUGBANK:DB00759",
-                "ATC:S02AA08",
-                "CAS:60-54-8",
-                "PathWhiz.Compound:9228",
-                "ATC:A01AB13",
-                "HMDB:HMDB0014897",
-                "UNII:F8VB5M810T",
-                "PUBCHEM.COMPOUND:54675776",
-                "ATC:S03AA02",
-                "UMLS:C3710841",
-                "NCIT:C87225",
-                "DrugCentral:2611",
-                "NDDF:002740",
-                "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-                "RXNORM:10395",
-                "KEGG.DRUG:D00201",
-                "PUBCHEM.COMPOUND:51580080",
-                "ATC:J01AA07",
-                "CHEBI:27902",
-                "DRUGBANK:DB09550",
-                "MESH:D013752",
-                "UMLS:C4255917"
-              ],
-              "id": "PUBCHEM.COMPOUND:54675776",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Tetracycline phosphate complex",
-                "tetracycline",
-                "TETRACYCLINE",
-                "Tetracycline (JAN/USP/INN)",
-                "Anhydrotetracycline",
-                "tetracycline phosphate complex",
-                "tetracycline zwitterion",
-                "Abramycin",
-                "Deschlorobiomycin",
-                "tetracycline hydrochloride",
-                "Tetracycline",
-                "Tetracycline Phosphate Complex"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:26922234",
-                "PMID:19463000",
-                "PMID:18378719",
-                "PMID:19104019",
-                "PMID:18474585",
-                "PMID:20696876",
-                "PMID:19332670",
-                "PMID:18834112",
-                "PMID:23891185"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:12887006': {'publication date': '2003 Jun', 'sentence': 'Meta-analysis of local tetracycline in treating chronic periodontitis.', 'subject score': 888, 'object score': 901}, 'PMID:1298560': {'publication date': '1992 Dec', 'sentence': 'Controlled local delivery of tetracycline in the treatment of periodontitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15448644': {'publication date': '2004', 'sentence': 'Local tetracycline is an effective adjunct in the treatment of chronic periodontitis.', 'subject score': 888, 'object score': 1000}, 'PMID:15902062': {'publication date': '2005 Jan-Feb', 'sentence': 'Debridement and local application of tetracycline in the management of persistent periodontitis.', 'subject score': 1000, 'object score': 888}, 'PMID:16624768': {'publication date': '2006 Apr', 'sentence': 'OBJECTIVE: To evaluate the effect of mechanical periodontal treatment combined with tetracycline on periodontal attachment, distances of cementum-enamel junction (CEJ) to the bone defect bottom and to the alveolar crest, and avidity of serum IgG against Porphyromonas gingivalis (Pg) lipopolysaccharide (LPS) in patients with aggressive periodontitis.', 'subject score': 1000, 'object score': 861}, 'PMID:17423114': {'publication date': '1988 Sep', 'sentence': 'Tetracycline, metronidazole, and chlorhexidine have been tested for their effectiveness in the treatment of periodontitis in dogs under experimental conditions.', 'subject score': 1000, 'object score': 1000}, 'PMID:19159021': {'publication date': '2009 Jan', 'sentence': 'CONCLUSION: Tetracycline applied with a microbrush may be an alternative treatment for persistent periodontitis that can probably be mediated by reduction of microorganism proliferation', 'subject score': 1000, 'object score': 888}, 'PMID:21708236': {'publication date': '2011 Sep 15', 'sentence': 'It has been proposed that localized and controlled delivery of alendronate and tetracycline to periodontal pocket fluids via guided tissue regeneration (GTR) membranes may be a valuable adjunctive treatment for advanced periodontitis.', 'subject score': 1000, 'object score': 861}, 'PMID:22028511': {'publication date': '2011 Jul', 'sentence': 'CONCLUSION: The results of this study suggest that subgingival irrigation with high concentrations of tetracycline may play a beneficial role in the management of chronic periodontitis patients.', 'subject score': 1000, 'object score': 901}, 'PMID:24082703': {'publication date': '2013 Jul', 'sentence': 'Pleiotropy of chemically modified tetracycline in periodontitis.', 'subject score': 790, 'object score': 1000}, 'PMID:24687419': {'publication date': '2014 Jun', 'sentence': 'Regenerative potential and anti-bacterial activity of tetracycline loaded apatitic nanocarriers for the treatment of periodontitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:24738587': {'publication date': '2014 Jun', 'sentence': 'An important therapeutic consideration from the lack of support for A. actinomycetemycomitans as a critical pathogen here is that the widely held belief that tetracycline had a role in aggressive periodontitis therapy is now not supported and that antibiotics such as those used effectively in chronic periodontitis (metronidazole and amoxicillin) are not contraindicated.', 'subject score': 1000, 'object score': 790}, 'PMID:26229381': {'publication date': '2015 Jul', 'sentence': 'CONCLUSION: The result of this study suggested that subgingival irrigation of tetracycline and spiramycin play a beneficial role in the management of chronic periodontitis patients.', 'subject score': 1000, 'object score': 901}, 'PMID:26528964': {'publication date': '2015 Oct 30', 'sentence': 'Controlled release nanoparticle formulations of TC have been reported, and could be beneficial for application in the treatment of periodontitis and dental bone infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:2681673': {'publication date': '1989 Oct', 'sentence': 'Effects of adjunctive treatment of periodontitis with tetracycline and spiramycin.', 'subject score': 1000, 'object score': 1000}, 'PMID:29238136': {'publication date': '2016 Nov-Dec', 'sentence': 'Tetracycline as local drug delivery in treatment of chronic periodontitis: A systematic review and meta-analysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3182440': {'publication date': '1988 Jul', 'sentence': 'Comparison of spiramycin and tetracycline used adjunctively in the treatment of advanced chronic periodontitis.', 'subject score': 1000, 'object score': 901}, 'PMID:6958855': {'publication date': '1982 Oct', 'sentence': 'In tetracycline-on samples 76.6% of the isolates were resistant to 1 microgram/ml of tetracycline compared to 25.9% in the patients off tetracycline and 7.1% resistant organisms in 14 untreated control samples from periodontitis patients not exposed to any long-term tetracycline therapy.', 'subject score': 861, 'object score': 888}, 'PMID:9447241': {'publication date': '1997 Dec', 'sentence': 'In view of the high prevalence of this phage family, and the increasing use of tetracycline in periodontitis therapy, these findings may have clinical importance.', 'subject score': 1000, 'object score': 888}, 'PMID:9839854': {'publication date': '1998 Nov', 'sentence': 'This paper reviews the utility and different systems of local delivery of minocycline, a semisynthetic tetracycline, in the treatment of periodontitis.', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
-      "start": {
-        "identity": 311374,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005076",
-          "name": "periodontitis",
-          "description": "An acute or chronic inflammatory process that affects the tissues that surround and support the teeth.; Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology); Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "DOID:824",
-            "UMLS:C0600298",
-            "MEDDRA:10034540",
-            "SNOMEDCT:41565005",
-            "ICD9:523.5",
-            "DOID:9893",
-            "MESH:D010518",
-            "ICD10:K05.4",
-            "HP:0000704",
-            "UMLS:C0031099",
-            "ICD10:K05.3",
-            "MONDO:0005076",
-            "MEDDRA:10034539",
-            "NCIT:C34918",
-            "EFO:0000649"
-          ],
-          "id": "MONDO:0005076",
-          "category": "biolink:Disease",
-          "all_names": [
-            "periodontitis",
-            "Periodontitis",
-            "periodontosis",
-            "Periodontosis"
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5889-4463",
-            "https://orcid.org/0000-0002-9338-3017"
-          ]
-        }
-      },
-      "end": {
-        "identity": 628,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Tetracycline",
-          "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-          "equivalent_curies": [
-            "CHEBI:77932",
-            "CHEMBL.COMPOUND:CHEMBL1440",
-            "UMLS:C0039644",
-            "UMLS:C0521901",
-            "ATC:D06AA04",
-            "NCIT:C865",
-            "UMLS:C4255918",
-            "NDDF:002738",
-            "ATC:S01AA09",
-            "RXNORM:2105975",
-            "KEGG.COMPOUND:C06570",
-            "DRUGBANK:DB00759",
-            "ATC:S02AA08",
-            "CAS:60-54-8",
-            "PathWhiz.Compound:9228",
-            "ATC:A01AB13",
-            "HMDB:HMDB0014897",
-            "UNII:F8VB5M810T",
-            "PUBCHEM.COMPOUND:54675776",
-            "ATC:S03AA02",
-            "UMLS:C3710841",
-            "NCIT:C87225",
-            "DrugCentral:2611",
-            "NDDF:002740",
-            "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-            "RXNORM:10395",
-            "KEGG.DRUG:D00201",
-            "PUBCHEM.COMPOUND:51580080",
-            "ATC:J01AA07",
-            "CHEBI:27902",
-            "DRUGBANK:DB09550",
-            "MESH:D013752",
-            "UMLS:C4255917"
-          ],
-          "id": "PUBCHEM.COMPOUND:54675776",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Tetracycline phosphate complex",
-            "tetracycline",
-            "TETRACYCLINE",
-            "Tetracycline (JAN/USP/INN)",
-            "Anhydrotetracycline",
-            "tetracycline phosphate complex",
-            "tetracycline zwitterion",
-            "Abramycin",
-            "Deschlorobiomycin",
-            "tetracycline hydrochloride",
-            "Tetracycline",
-            "Tetracycline Phosphate Complex"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:26922234",
-            "PMID:19463000",
-            "PMID:18378719",
-            "PMID:19104019",
-            "PMID:18474585",
-            "PMID:20696876",
-            "PMID:19332670",
-            "PMID:18834112",
-            "PMID:23891185"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 311374,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005076",
-              "name": "periodontitis",
-              "description": "An acute or chronic inflammatory process that affects the tissues that surround and support the teeth.; Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology); Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "DOID:824",
-                "UMLS:C0600298",
-                "MEDDRA:10034540",
-                "SNOMEDCT:41565005",
-                "ICD9:523.5",
-                "DOID:9893",
-                "MESH:D010518",
-                "ICD10:K05.4",
-                "HP:0000704",
-                "UMLS:C0031099",
-                "ICD10:K05.3",
-                "MONDO:0005076",
-                "MEDDRA:10034539",
-                "NCIT:C34918",
-                "EFO:0000649"
-              ],
-              "id": "MONDO:0005076",
-              "category": "biolink:Disease",
-              "all_names": [
-                "periodontitis",
-                "Periodontitis",
-                "periodontosis",
-                "Periodontosis"
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5889-4463",
-                "https://orcid.org/0000-0002-9338-3017"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 10109163,
-            "start": 628,
-            "end": 311374,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12887006': {'publication date': '2003 Jun', 'sentence': 'Meta-analysis of local tetracycline in treating chronic periodontitis.', 'subject score': 888, 'object score': 901}, 'PMID:1298560': {'publication date': '1992 Dec', 'sentence': 'Controlled local delivery of tetracycline in the treatment of periodontitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15448644': {'publication date': '2004', 'sentence': 'Local tetracycline is an effective adjunct in the treatment of chronic periodontitis.', 'subject score': 888, 'object score': 1000}, 'PMID:15902062': {'publication date': '2005 Jan-Feb', 'sentence': 'Debridement and local application of tetracycline in the management of persistent periodontitis.', 'subject score': 1000, 'object score': 888}, 'PMID:16624768': {'publication date': '2006 Apr', 'sentence': 'OBJECTIVE: To evaluate the effect of mechanical periodontal treatment combined with tetracycline on periodontal attachment, distances of cementum-enamel junction (CEJ) to the bone defect bottom and to the alveolar crest, and avidity of serum IgG against Porphyromonas gingivalis (Pg) lipopolysaccharide (LPS) in patients with aggressive periodontitis.', 'subject score': 1000, 'object score': 861}, 'PMID:17423114': {'publication date': '1988 Sep', 'sentence': 'Tetracycline, metronidazole, and chlorhexidine have been tested for their effectiveness in the treatment of periodontitis in dogs under experimental conditions.', 'subject score': 1000, 'object score': 1000}, 'PMID:19159021': {'publication date': '2009 Jan', 'sentence': 'CONCLUSION: Tetracycline applied with a microbrush may be an alternative treatment for persistent periodontitis that can probably be mediated by reduction of microorganism proliferation', 'subject score': 1000, 'object score': 888}, 'PMID:21708236': {'publication date': '2011 Sep 15', 'sentence': 'It has been proposed that localized and controlled delivery of alendronate and tetracycline to periodontal pocket fluids via guided tissue regeneration (GTR) membranes may be a valuable adjunctive treatment for advanced periodontitis.', 'subject score': 1000, 'object score': 861}, 'PMID:22028511': {'publication date': '2011 Jul', 'sentence': 'CONCLUSION: The results of this study suggest that subgingival irrigation with high concentrations of tetracycline may play a beneficial role in the management of chronic periodontitis patients.', 'subject score': 1000, 'object score': 901}, 'PMID:24082703': {'publication date': '2013 Jul', 'sentence': 'Pleiotropy of chemically modified tetracycline in periodontitis.', 'subject score': 790, 'object score': 1000}, 'PMID:24687419': {'publication date': '2014 Jun', 'sentence': 'Regenerative potential and anti-bacterial activity of tetracycline loaded apatitic nanocarriers for the treatment of periodontitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:24738587': {'publication date': '2014 Jun', 'sentence': 'An important therapeutic consideration from the lack of support for A. actinomycetemycomitans as a critical pathogen here is that the widely held belief that tetracycline had a role in aggressive periodontitis therapy is now not supported and that antibiotics such as those used effectively in chronic periodontitis (metronidazole and amoxicillin) are not contraindicated.', 'subject score': 1000, 'object score': 790}, 'PMID:26229381': {'publication date': '2015 Jul', 'sentence': 'CONCLUSION: The result of this study suggested that subgingival irrigation of tetracycline and spiramycin play a beneficial role in the management of chronic periodontitis patients.', 'subject score': 1000, 'object score': 901}, 'PMID:26528964': {'publication date': '2015 Oct 30', 'sentence': 'Controlled release nanoparticle formulations of TC have been reported, and could be beneficial for application in the treatment of periodontitis and dental bone infections.', 'subject score': 1000, 'object score': 1000}, 'PMID:2681673': {'publication date': '1989 Oct', 'sentence': 'Effects of adjunctive treatment of periodontitis with tetracycline and spiramycin.', 'subject score': 1000, 'object score': 1000}, 'PMID:29238136': {'publication date': '2016 Nov-Dec', 'sentence': 'Tetracycline as local drug delivery in treatment of chronic periodontitis: A systematic review and meta-analysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:3182440': {'publication date': '1988 Jul', 'sentence': 'Comparison of spiramycin and tetracycline used adjunctively in the treatment of advanced chronic periodontitis.', 'subject score': 1000, 'object score': 901}, 'PMID:6958855': {'publication date': '1982 Oct', 'sentence': 'In tetracycline-on samples 76.6% of the isolates were resistant to 1 microgram/ml of tetracycline compared to 25.9% in the patients off tetracycline and 7.1% resistant organisms in 14 untreated control samples from periodontitis patients not exposed to any long-term tetracycline therapy.', 'subject score': 861, 'object score': 888}, 'PMID:9447241': {'publication date': '1997 Dec', 'sentence': 'In view of the high prevalence of this phage family, and the increasing use of tetracycline in periodontitis therapy, these findings may have clinical importance.', 'subject score': 1000, 'object score': 888}, 'PMID:9839854': {'publication date': '1998 Nov', 'sentence': 'This paper reviews the utility and different systems of local delivery of minocycline, a semisynthetic tetracycline, in the treatment of periodontitis.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0039644---SEMMEDDB:treats---None---None---None---UMLS:C0031099---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:54675776",
-              "id": "10332719",
-              "object": "MONDO:0005076",
-              "publications": [
-                "PMID:12887006",
-                "PMID:1298560",
-                "PMID:15448644",
-                "PMID:15902062",
-                "PMID:16624768",
-                "PMID:17423114",
-                "PMID:19159021",
-                "PMID:21708236",
-                "PMID:22028511",
-                "PMID:24082703",
-                "PMID:24687419",
-                "PMID:24738587",
-                "PMID:26229381",
-                "PMID:26528964",
-                "PMID:2681673",
-                "PMID:29238136",
-                "PMID:3182440",
-                "PMID:6958855",
-                "PMID:9447241",
-                "PMID:9839854"
-              ]
-            }
-          },
-          "end": {
-            "identity": 628,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Tetracycline",
-              "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-              "equivalent_curies": [
-                "CHEBI:77932",
-                "CHEMBL.COMPOUND:CHEMBL1440",
-                "UMLS:C0039644",
-                "UMLS:C0521901",
-                "ATC:D06AA04",
-                "NCIT:C865",
-                "UMLS:C4255918",
-                "NDDF:002738",
-                "ATC:S01AA09",
-                "RXNORM:2105975",
-                "KEGG.COMPOUND:C06570",
-                "DRUGBANK:DB00759",
-                "ATC:S02AA08",
-                "CAS:60-54-8",
-                "PathWhiz.Compound:9228",
-                "ATC:A01AB13",
-                "HMDB:HMDB0014897",
-                "UNII:F8VB5M810T",
-                "PUBCHEM.COMPOUND:54675776",
-                "ATC:S03AA02",
-                "UMLS:C3710841",
-                "NCIT:C87225",
-                "DrugCentral:2611",
-                "NDDF:002740",
-                "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-                "RXNORM:10395",
-                "KEGG.DRUG:D00201",
-                "PUBCHEM.COMPOUND:51580080",
-                "ATC:J01AA07",
-                "CHEBI:27902",
-                "DRUGBANK:DB09550",
-                "MESH:D013752",
-                "UMLS:C4255917"
-              ],
-              "id": "PUBCHEM.COMPOUND:54675776",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Tetracycline phosphate complex",
-                "tetracycline",
-                "TETRACYCLINE",
-                "Tetracycline (JAN/USP/INN)",
-                "Anhydrotetracycline",
-                "tetracycline phosphate complex",
-                "tetracycline zwitterion",
-                "Abramycin",
-                "Deschlorobiomycin",
-                "tetracycline hydrochloride",
-                "Tetracycline",
-                "Tetracycline Phosphate Complex"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:26922234",
-                "PMID:19463000",
-                "PMID:18378719",
-                "PMID:19104019",
-                "PMID:18474585",
-                "PMID:20696876",
-                "PMID:19332670",
-                "PMID:18834112",
-                "PMID:23891185"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 711504,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:32755514': {'publication date': '2020 Jul', 'sentence': 'The following antimicrobials commonly used for the treatment of C.difficile infections or applied previously in C.difficile epidemiological studies were tested: metronidazole, vancomycin, meropenem, ceftriaxone, ampicillin-sulbactam, clindamycin, erythromycin, moxifloxacin, tetracycline, doxycycline, tigecycline and linezolid.', 'subject score': 1000, 'object score': 827}, 'PMID:33284329': {'publication date': '2020 Dec 07', 'sentence': 'However, resistance was found against quinolones, aminoglycosides, tetracycline and trimethoprim-sulfamethoxazole which are commonly used to treat infections with gram-positive bacteria.', 'subject score': 1000, 'object score': 1000}, 'PMID:33568043': {'publication date': '2021 Feb 10', 'sentence': 'Minocycline has also emerged as the tetracycline of choice for multidrug-resistant Acinetobacter baumannii infections, although doxycycline has also shown the activity.', 'subject score': 1000, 'object score': 928}, 'PMID:34339136': {'publication date': '2021 Mar', 'sentence': 'However, resistance was found against quinolones, aminoglycosides, tetracycline, and trimethoprim-sulfamethoxazole, which are commonly used to treat infections with gram-positive bacteria.', 'subject score': 1000, 'object score': 1000}, 'PMID:35530702': {'publication date': '2019 Oct 28', 'sentence': 'Tetracycline is an antibiotic that is commonly utilized in veterinary medicine and in the treatment of human infections, but is hazardous to aquatic environments.', 'subject score': 1000, 'object score': 888}, 'PMID:35647655': {'publication date': '2022 Jun 01', 'sentence': 'Tetracycline-based combinations are increasingly used for serious carbapenem-nonsusceptible Acinetobacter baumannii (CNSAb) infections given their potent    in vitro     activity, synergism with other agents, and acceptable toxicity profile.', 'subject score': 851, 'object score': 827}, 'PMID:36498165': {'publication date': '2022 Dec 01', 'sentence': 'Minocycline is a kind of semisynthetic derivative of the antibacterial drug tetracycline and is often used to treat infections caused by multidrug-resistant    A. baumannii     with other antibiotics.', 'subject score': 901, 'object score': 1000}, 'PMID:36692335': {'publication date': '2023 Feb', 'sentence': 'Reports of Salmonella enterica I serotype 4,[5],12:i:- infections resistant to ampicillin, streptomycin, sulphamethoxazole, and tetracycline (ASSuT) have been increasing.', 'subject score': 1000, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 546907,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006781",
-          "name": "Helicobacter pylori infectious disease",
-          "description": "Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10019375",
-            "MESH:D016481",
-            "MEDDRA:10054263",
-            "UMLS:C0079487",
-            "EFO:1000961",
-            "MONDO:0006781"
-          ],
-          "id": "MONDO:0006781",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Helicobacter Infections",
-            "Helicobacter pylori infectious disease"
-=======
-          "iri": "https://identifiers.org/umls:C3714514",
-          "name": "Infection",
-          "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-          "equivalent_curies": [
-            "UMLS:C3714514",
-            "MEDDRA:10021842",
-            "NCIT:C128320",
-            "MEDDRA:10021789",
-            "MESH:D007239"
-          ],
-          "id": "UMLS:C3714514",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Infection",
-            "Infections"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ]
-        }
-      },
-      "end": {
-        "identity": 628,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "Tetracycline",
-          "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-          "equivalent_curies": [
-            "CHEBI:77932",
-            "CHEMBL.COMPOUND:CHEMBL1440",
-            "UMLS:C0039644",
-            "UMLS:C0521901",
-            "ATC:D06AA04",
-            "NCIT:C865",
-            "UMLS:C4255918",
-            "NDDF:002738",
-            "ATC:S01AA09",
-            "RXNORM:2105975",
-            "KEGG.COMPOUND:C06570",
-            "DRUGBANK:DB00759",
-            "ATC:S02AA08",
-            "CAS:60-54-8",
-            "PathWhiz.Compound:9228",
-            "ATC:A01AB13",
-            "HMDB:HMDB0014897",
-            "UNII:F8VB5M810T",
-            "PUBCHEM.COMPOUND:54675776",
-            "ATC:S03AA02",
-            "UMLS:C3710841",
-            "NCIT:C87225",
-            "DrugCentral:2611",
-            "NDDF:002740",
-            "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-            "RXNORM:10395",
-            "KEGG.DRUG:D00201",
-            "PUBCHEM.COMPOUND:51580080",
-            "ATC:J01AA07",
-            "CHEBI:27902",
-            "DRUGBANK:DB09550",
-            "MESH:D013752",
-            "UMLS:C4255917"
-          ],
-          "id": "PUBCHEM.COMPOUND:54675776",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Tetracycline phosphate complex",
-            "tetracycline",
-            "TETRACYCLINE",
-            "Tetracycline (JAN/USP/INN)",
-            "Anhydrotetracycline",
-            "tetracycline phosphate complex",
-            "tetracycline zwitterion",
-            "Abramycin",
-            "Deschlorobiomycin",
-            "tetracycline hydrochloride",
-            "Tetracycline",
-            "Tetracycline Phosphate Complex"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:19752278",
-            "PMID:26922234",
-            "PMID:19463000",
-            "PMID:18378719",
-            "PMID:19104019",
-            "PMID:18474585",
-            "PMID:20696876",
-            "PMID:19332670",
-            "PMID:18834112",
-            "PMID:23891185"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 711504,
-=======
-            "identity": 546907,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006781",
-              "name": "Helicobacter pylori infectious disease",
-              "description": "Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10019375",
-                "MESH:D016481",
-                "MEDDRA:10054263",
-                "UMLS:C0079487",
-                "EFO:1000961",
-                "MONDO:0006781"
-              ],
-              "id": "MONDO:0006781",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Helicobacter Infections",
-                "Helicobacter pylori infectious disease"
-=======
-              "iri": "https://identifiers.org/umls:C3714514",
-              "name": "Infection",
-              "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
-              "equivalent_curies": [
-                "UMLS:C3714514",
-                "MEDDRA:10021842",
-                "NCIT:C128320",
-                "MEDDRA:10021789",
-                "MESH:D007239"
-              ],
-              "id": "UMLS:C3714514",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Infection",
-                "Infections"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 7085518,
-            "start": 628,
-            "end": 711504,
-=======
-            "identity": 21923733,
-            "start": 628,
-            "end": 546907,
->>>>>>> main
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-<<<<<<< HEAD
-              "publications_info": "{'PMID:10102946': {'publication date': '1999 Feb', 'sentence': 'Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection.', 'subject score': 1000, 'object score': 875}, 'PMID:10102965': {'publication date': '1999 Mar', 'sentence': 'Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days.', 'subject score': 1000, 'object score': 1000}, 'PMID:12182745': {'publication date': '2002 Aug', 'sentence': 'AIM: To study the efficacy of a 7-day quadruple regimen combining pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection after failure of standard triple therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:14734187': {'publication date': '2004 Jan 15', 'sentence': 'Tetracycline is one of four antibiotics commonly used for the treatment of Helicobacter pylori infection, but its effectiveness is decreasing as the incidence of tetracycline resistance is increasing.', 'subject score': 1000, 'object score': 1000}, 'PMID:15836716': {'publication date': '2005 Apr', 'sentence': 'BACKGROUND: Quadruple therapy with a proton pump inhibitor, bismuth, metronidazole and tetracycline is recommended as the optimal second-line therapy of Helicobacter pylori infection in the Maastricht Consensus Report.', 'subject score': 1000, 'object score': 1000}, 'PMID:15844694': {'publication date': '2005 Apr', 'sentence': 'High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin.', 'subject score': 1000, 'object score': 1000}, 'PMID:16446791': {'publication date': '2005 Dec', 'sentence': 'Clarithromycin, amoxicillin, tetracycline and metronidazole are the most frequently used antimicrobials for Helicobacter pylori infection treatment.', 'subject score': 1000, 'object score': 916}, 'PMID:20951912': {'publication date': '2010 Sep', 'sentence': 'The commonly used regimens for the eradication of Helicobacter pylori infection consist of administration of proton pump inhibitors (PPIs) and 1 to 3 antimicrobial agents, such as amoxicillin, clarithromycin, metronidazole, fluoroquinolone, or tetracycline.', 'subject score': 1000, 'object score': 1000}, 'PMID:25374223': {'publication date': '2014', 'sentence': 'BACKGROUND: Tetracycline is an antibiotic widely used for the treatment of Helicobacter pylori infection, but its effectiveness is decreasing due to increasing bacterial resistance.', 'subject score': 1000, 'object score': 1000}, 'PMID:29914954': {'publication date': '2018 09', 'sentence': 'Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.', 'subject score': 1000, 'object score': 1000}, 'PMID:8038358': {'publication date': '1994 Apr', 'sentence': 'Short report: omeprazole-tetracycline combinations are inadequate as therapy for Helicobacter pylori infection.', 'subject score': 851, 'object score': 1000}, 'PMID:9362185': {'publication date': '1997 Nov', 'sentence': 'Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0039644---SEMMEDDB:treats---None---None---None---UMLS:C0079487---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:54675776",
-              "id": "7227539",
-              "object": "MONDO:0006781",
-              "publications": [
-                "PMID:10102946",
-                "PMID:10102965",
-                "PMID:12182745",
-                "PMID:14734187",
-                "PMID:15836716",
-                "PMID:15844694",
-                "PMID:16446791",
-                "PMID:20951912",
-                "PMID:25374223",
-                "PMID:29914954",
-                "PMID:8038358",
-                "PMID:9362185"
-=======
-              "publications_info": "{'PMID:32755514': {'publication date': '2020 Jul', 'sentence': 'The following antimicrobials commonly used for the treatment of C.difficile infections or applied previously in C.difficile epidemiological studies were tested: metronidazole, vancomycin, meropenem, ceftriaxone, ampicillin-sulbactam, clindamycin, erythromycin, moxifloxacin, tetracycline, doxycycline, tigecycline and linezolid.', 'subject score': 1000, 'object score': 827}, 'PMID:33284329': {'publication date': '2020 Dec 07', 'sentence': 'However, resistance was found against quinolones, aminoglycosides, tetracycline and trimethoprim-sulfamethoxazole which are commonly used to treat infections with gram-positive bacteria.', 'subject score': 1000, 'object score': 1000}, 'PMID:33568043': {'publication date': '2021 Feb 10', 'sentence': 'Minocycline has also emerged as the tetracycline of choice for multidrug-resistant Acinetobacter baumannii infections, although doxycycline has also shown the activity.', 'subject score': 1000, 'object score': 928}, 'PMID:34339136': {'publication date': '2021 Mar', 'sentence': 'However, resistance was found against quinolones, aminoglycosides, tetracycline, and trimethoprim-sulfamethoxazole, which are commonly used to treat infections with gram-positive bacteria.', 'subject score': 1000, 'object score': 1000}, 'PMID:35530702': {'publication date': '2019 Oct 28', 'sentence': 'Tetracycline is an antibiotic that is commonly utilized in veterinary medicine and in the treatment of human infections, but is hazardous to aquatic environments.', 'subject score': 1000, 'object score': 888}, 'PMID:35647655': {'publication date': '2022 Jun 01', 'sentence': 'Tetracycline-based combinations are increasingly used for serious carbapenem-nonsusceptible Acinetobacter baumannii (CNSAb) infections given their potent    in vitro     activity, synergism with other agents, and acceptable toxicity profile.', 'subject score': 851, 'object score': 827}, 'PMID:36498165': {'publication date': '2022 Dec 01', 'sentence': 'Minocycline is a kind of semisynthetic derivative of the antibacterial drug tetracycline and is often used to treat infections caused by multidrug-resistant    A. baumannii     with other antibiotics.', 'subject score': 901, 'object score': 1000}, 'PMID:36692335': {'publication date': '2023 Feb', 'sentence': 'Reports of Salmonella enterica I serotype 4,[5],12:i:- infections resistant to ampicillin, streptomycin, sulphamethoxazole, and tetracycline (ASSuT) have been increasing.', 'subject score': 1000, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0039644---SEMMEDDB:treats---None---None---None---UMLS:C3714514---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:54675776",
-              "id": "22346012",
-              "object": "UMLS:C3714514",
-              "publications": [
-                "PMID:32755514",
-                "PMID:33284329",
-                "PMID:33568043",
-                "PMID:34339136",
-                "PMID:35530702",
-                "PMID:35647655",
-                "PMID:36498165",
-                "PMID:36692335"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-            "identity": 628,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "Tetracycline",
-              "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-              "equivalent_curies": [
-                "CHEBI:77932",
-                "CHEMBL.COMPOUND:CHEMBL1440",
-                "UMLS:C0039644",
-                "UMLS:C0521901",
-                "ATC:D06AA04",
-                "NCIT:C865",
-                "UMLS:C4255918",
-                "NDDF:002738",
-                "ATC:S01AA09",
-                "RXNORM:2105975",
-                "KEGG.COMPOUND:C06570",
-                "DRUGBANK:DB00759",
-                "ATC:S02AA08",
-                "CAS:60-54-8",
-                "PathWhiz.Compound:9228",
-                "ATC:A01AB13",
-                "HMDB:HMDB0014897",
-                "UNII:F8VB5M810T",
-                "PUBCHEM.COMPOUND:54675776",
-                "ATC:S03AA02",
-                "UMLS:C3710841",
-                "NCIT:C87225",
-                "DrugCentral:2611",
-                "NDDF:002740",
-                "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-                "RXNORM:10395",
-                "KEGG.DRUG:D00201",
-                "PUBCHEM.COMPOUND:51580080",
-                "ATC:J01AA07",
-                "CHEBI:27902",
-                "DRUGBANK:DB09550",
-                "MESH:D013752",
-                "UMLS:C4255917"
-              ],
-              "id": "PUBCHEM.COMPOUND:54675776",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Tetracycline phosphate complex",
-                "tetracycline",
-                "TETRACYCLINE",
-                "Tetracycline (JAN/USP/INN)",
-                "Anhydrotetracycline",
-                "tetracycline phosphate complex",
-                "tetracycline zwitterion",
-                "Abramycin",
-                "Deschlorobiomycin",
-                "tetracycline hydrochloride",
-                "Tetracycline",
-                "Tetracycline Phosphate Complex"
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-                "PMID:19752278",
-                "PMID:26922234",
-                "PMID:19463000",
-                "PMID:18378719",
-                "PMID:19104019",
-                "PMID:18474585",
-                "PMID:20696876",
-                "PMID:19332670",
-                "PMID:18834112",
-                "PMID:23891185"
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 538307,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:1581041': {'publication date': '1992 Apr', 'sentence': 'Mucosal immunity to Pseudomonas aeruginosa alginate in cystic fibrosis.', 'subject score': 901, 'object score': 1000}, 'PMID:15813726': {'publication date': '2005 Apr', 'sentence': 'Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis.', 'subject score': 861, 'object score': 1000}, 'PMID:18174130': {'publication date': '2008 Jan', 'sentence': 'In some of the CF isolates these mutations are associated with moderate alginate production.', 'subject score': 790, 'object score': 1000}, 'PMID:19168621': {'publication date': '2009 Apr', 'sentence': 'Mucoidy, or overproduction of the exopolysaccharide known as alginate, in Pseudomonas aeruginosa is a poor prognosticator for lung infections in cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:8312973': {'publication date': '1993', 'sentence': 'Pseudomonas aeruginosa mutants that overproduce the exopolysaccharide alginate and assume mucoid phenotype are associated with the establishment of chronic respiratory disease in cystic fibrosis.', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 523273,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
-          ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009061",
-          "name": "cystic fibrosis",
-          "description": "A congenital, autosomal, metabolic disorder affecting the exocrine glands. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production that causes obstruction of passageways, including pancreatic and bile ducts, intestines, and bronchi. Symptoms usually appear in childhood, and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather secondary to increased sodium and chloride concentration in sweat.; An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003550",
-            "SNOMEDCT:190905008",
-            "UMLS:C0010674",
-            "NCIT:C2975",
-            "MEDDRA:10011762",
-            "ORPHANET:586",
-            "DOID:1485",
-            "MEDDRA:10011764",
-            "ICD9:277.0",
-            "MEDDRA:10028141",
-            "PSY:12915",
-            "MONDO:0009061",
-            "OMIM:219700",
-            "ICD10:E84"
-          ],
-          "id": "MONDO:0009061",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cystic Fibrosis",
-            "cystic fibrosis",
-            "obsolete_cystic fibrosis",
-            "Cystic fibrosis related phenotypic feature",
-            "Cystic fibrosis"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-=======
-            "http://ghr.nlm.nih.gov/condition/cystic-fibrosis",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/cf/",
-            "http://en.wikipedia.org/wiki/cystic_fibrosis"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-<<<<<<< HEAD
-        "identity": 628,
-=======
-        "identity": 629,
->>>>>>> main
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "name": "Tetracycline",
-          "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-          "equivalent_curies": [
-            "CHEBI:77932",
-            "CHEMBL.COMPOUND:CHEMBL1440",
-            "UMLS:C0039644",
-            "UMLS:C0521901",
-            "ATC:D06AA04",
-            "NCIT:C865",
-            "UMLS:C4255918",
-            "NDDF:002738",
-            "ATC:S01AA09",
-            "RXNORM:2105975",
-            "KEGG.COMPOUND:C06570",
-            "DRUGBANK:DB00759",
-            "ATC:S02AA08",
-            "CAS:60-54-8",
-            "PathWhiz.Compound:9228",
-            "ATC:A01AB13",
-            "HMDB:HMDB0014897",
-            "UNII:F8VB5M810T",
-            "PUBCHEM.COMPOUND:54675776",
-            "ATC:S03AA02",
-            "UMLS:C3710841",
-            "NCIT:C87225",
-            "DrugCentral:2611",
-            "NDDF:002740",
-            "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-            "RXNORM:10395",
-            "KEGG.DRUG:D00201",
-            "PUBCHEM.COMPOUND:51580080",
-            "ATC:J01AA07",
-            "CHEBI:27902",
-            "DRUGBANK:DB09550",
-            "MESH:D013752",
-            "UMLS:C4255917"
-          ],
-          "id": "PUBCHEM.COMPOUND:54675776",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Tetracycline phosphate complex",
-            "tetracycline",
-            "TETRACYCLINE",
-            "Tetracycline (JAN/USP/INN)",
-            "Anhydrotetracycline",
-            "tetracycline phosphate complex",
-            "tetracycline zwitterion",
-            "Abramycin",
-            "Deschlorobiomycin",
-            "tetracycline hydrochloride",
-            "Tetracycline",
-            "Tetracycline Phosphate Complex"
-=======
-          "name": "(Alginate)n",
-          "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
-          "equivalent_curies": [
-            "MESH:D000077322",
-            "UMLS:C0102137",
-            "KEGG.GLYCAN:G00316",
-            "UMLS:C0051156",
-            "KEGG.GLYCAN:G07471",
-            "KEGG.GLYCAN:G07287",
-            "KEGG.GLYCAN:G08476",
-            "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-            "DRUGBANK:DB13518",
-            "DrugCentral:4321",
-            "KEGG.DRUG:D02324",
-            "UNII:8C3Z4148WZ",
-            "KEGG.COMPOUND:C01768",
-            "CHEBI:17548",
-            "NDDF:002434",
-            "RXNORM:17305",
-            "RXNORM:1370451",
-            "NCIT:C82277",
-            "CHEMBL.COMPOUND:CHEMBL2108894",
-            "MESH:C008970",
-            "PUBCHEM.COMPOUND:91666318",
-            "ATC:A02BX13",
-            "KEGG.GLYCAN:G02561",
-            "UMLS:C4694124",
-            "KEGG.GLYCAN:G10593"
-          ],
-          "id": "PUBCHEM.COMPOUND:91666318",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "(Alginate)n",
-            "Alginate",
-            "Norgine",
-            "Alginic acid",
-            "Alginic acid (NF)",
-            "ALGINIC ACID",
-            "alginate",
-            "Alginic Acid",
-            "alginic acid"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "PMID:19752278",
-            "PMID:26922234",
-            "PMID:19463000",
-            "PMID:18378719",
-            "PMID:19104019",
-            "PMID:18474585",
-            "PMID:20696876",
-            "PMID:19332670",
-            "PMID:18834112",
-            "PMID:23891185"
-=======
-            "PMID:1551350",
-            "PMID:10848650",
-            "PMID:231639",
-            "PMID:27671545"
->>>>>>> main
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 538307,
-=======
-            "identity": 523273,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
-              ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009061",
-              "name": "cystic fibrosis",
-              "description": "A congenital, autosomal, metabolic disorder affecting the exocrine glands. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production that causes obstruction of passageways, including pancreatic and bile ducts, intestines, and bronchi. Symptoms usually appear in childhood, and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather secondary to increased sodium and chloride concentration in sweat.; An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003550",
-                "SNOMEDCT:190905008",
-                "UMLS:C0010674",
-                "NCIT:C2975",
-                "MEDDRA:10011762",
-                "ORPHANET:586",
-                "DOID:1485",
-                "MEDDRA:10011764",
-                "ICD9:277.0",
-                "MEDDRA:10028141",
-                "PSY:12915",
-                "MONDO:0009061",
-                "OMIM:219700",
-                "ICD10:E84"
-              ],
-              "id": "MONDO:0009061",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cystic Fibrosis",
-                "cystic fibrosis",
-                "obsolete_cystic fibrosis",
-                "Cystic fibrosis related phenotypic feature",
-                "Cystic fibrosis"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
-=======
-                "http://ghr.nlm.nih.gov/condition/cystic-fibrosis",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/cf/",
-                "http://en.wikipedia.org/wiki/cystic_fibrosis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 24123075,
-            "start": 628,
-            "end": 538307,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35630502': {'publication date': '2022 May 20', 'sentence': 'Resistance to tetracycline, used to prevent bacterial infections in beehives, was only found in    Bombella apis     MRM1     T      .', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0039644---SEMMEDDB:prevents---None---None---None---UMLS:C0004623---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:54675776",
-              "id": "24565223",
-              "object": "MONDO:0005113",
-              "publications": [
-                "PMID:35630502"
-=======
-            "identity": 11503602,
-            "start": 629,
-            "end": 523273,
-            "type": "biolink:related_to",
-            "properties": {
-              "predicate": "biolink:related_to",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1581041': {'publication date': '1992 Apr', 'sentence': 'Mucosal immunity to Pseudomonas aeruginosa alginate in cystic fibrosis.', 'subject score': 901, 'object score': 1000}, 'PMID:15813726': {'publication date': '2005 Apr', 'sentence': 'Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis.', 'subject score': 861, 'object score': 1000}, 'PMID:18174130': {'publication date': '2008 Jan', 'sentence': 'In some of the CF isolates these mutations are associated with moderate alginate production.', 'subject score': 790, 'object score': 1000}, 'PMID:19168621': {'publication date': '2009 Apr', 'sentence': 'Mucoidy, or overproduction of the exopolysaccharide known as alginate, in Pseudomonas aeruginosa is a poor prognosticator for lung infections in cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:8312973': {'publication date': '1993', 'sentence': 'Pseudomonas aeruginosa mutants that overproduce the exopolysaccharide alginate and assume mucoid phenotype are associated with the establishment of chronic respiratory disease in cystic fibrosis.', 'subject score': 861, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0102137---SEMMEDDB:associated_with---None---None---None---UMLS:C0010674---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:91666318",
-              "id": "11754791",
-              "object": "MONDO:0009061",
-              "publications": [
-                "PMID:1581041",
-                "PMID:15813726",
-                "PMID:18174130",
-                "PMID:19168621",
-                "PMID:8312973"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-<<<<<<< HEAD
-            "identity": 628,
-=======
-            "identity": 629,
->>>>>>> main
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "name": "Tetracycline",
-              "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-              "equivalent_curies": [
-                "CHEBI:77932",
-                "CHEMBL.COMPOUND:CHEMBL1440",
-                "UMLS:C0039644",
-                "UMLS:C0521901",
-                "ATC:D06AA04",
-                "NCIT:C865",
-                "UMLS:C4255918",
-                "NDDF:002738",
-                "ATC:S01AA09",
-                "RXNORM:2105975",
-                "KEGG.COMPOUND:C06570",
-                "DRUGBANK:DB00759",
-                "ATC:S02AA08",
-                "CAS:60-54-8",
-                "PathWhiz.Compound:9228",
-                "ATC:A01AB13",
-                "HMDB:HMDB0014897",
-                "UNII:F8VB5M810T",
-                "PUBCHEM.COMPOUND:54675776",
-                "ATC:S03AA02",
-                "UMLS:C3710841",
-                "NCIT:C87225",
-                "DrugCentral:2611",
-                "NDDF:002740",
-                "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-                "RXNORM:10395",
-                "KEGG.DRUG:D00201",
-                "PUBCHEM.COMPOUND:51580080",
-                "ATC:J01AA07",
-                "CHEBI:27902",
-                "DRUGBANK:DB09550",
-                "MESH:D013752",
-                "UMLS:C4255917"
-              ],
-              "id": "PUBCHEM.COMPOUND:54675776",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Tetracycline phosphate complex",
-                "tetracycline",
-                "TETRACYCLINE",
-                "Tetracycline (JAN/USP/INN)",
-                "Anhydrotetracycline",
-                "tetracycline phosphate complex",
-                "tetracycline zwitterion",
-                "Abramycin",
-                "Deschlorobiomycin",
-                "tetracycline hydrochloride",
-                "Tetracycline",
-                "Tetracycline Phosphate Complex"
-=======
-              "name": "(Alginate)n",
-              "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
-              "equivalent_curies": [
-                "MESH:D000077322",
-                "UMLS:C0102137",
-                "KEGG.GLYCAN:G00316",
-                "UMLS:C0051156",
-                "KEGG.GLYCAN:G07471",
-                "KEGG.GLYCAN:G07287",
-                "KEGG.GLYCAN:G08476",
-                "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-                "DRUGBANK:DB13518",
-                "DrugCentral:4321",
-                "KEGG.DRUG:D02324",
-                "UNII:8C3Z4148WZ",
-                "KEGG.COMPOUND:C01768",
-                "CHEBI:17548",
-                "NDDF:002434",
-                "RXNORM:17305",
-                "RXNORM:1370451",
-                "NCIT:C82277",
-                "CHEMBL.COMPOUND:CHEMBL2108894",
-                "MESH:C008970",
-                "PUBCHEM.COMPOUND:91666318",
-                "ATC:A02BX13",
-                "KEGG.GLYCAN:G02561",
-                "UMLS:C4694124",
-                "KEGG.GLYCAN:G10593"
-              ],
-              "id": "PUBCHEM.COMPOUND:91666318",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "(Alginate)n",
-                "Alginate",
-                "Norgine",
-                "Alginic acid",
-                "Alginic acid (NF)",
-                "ALGINIC ACID",
-                "alginate",
-                "Alginic Acid",
-                "alginic acid"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "PMID:19752278",
-                "PMID:26922234",
-                "PMID:19463000",
-                "PMID:18378719",
-                "PMID:19104019",
-                "PMID:18474585",
-                "PMID:20696876",
-                "PMID:19332670",
-                "PMID:18834112",
-                "PMID:23891185"
-=======
-                "PMID:1551350",
-                "PMID:10848650",
-                "PMID:231639",
-                "PMID:27671545"
->>>>>>> main
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-      "start": {
-        "identity": 541721,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:9284161': {'publication date': '1997 Sep', 'sentence': 'Two CF strains, selected for further study based on the dependence of their alginate production on the concentration of salt in the medium, were used to examine the effects of mucoidy on pulmonary clearance.', 'subject score': 888, 'object score': 861}}",
-    "p2": {
-      "start": {
-        "identity": 523273,
->>>>>>> main
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005808",
-          "name": "inclusion conjunctivitis",
-          "description": "An infection of the eyes characterized by the presence in conjunctival epithelial cells of inclusion bodies indistinguishable from those of trachoma. It is acquired by infants during birth and by adults from swimming pools. The etiological agent is CHLAMYDIA TRACHOMATIS whose natural habitat appears to be the genito-urinary tract. Inclusion conjunctivitis is a less severe disease than trachoma and usually clears up spontaneously.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C116817",
-            "UMLS:C0343723",
-            "MESH:D003235",
-            "MEDDRA:10053992",
-            "UMLS:C0392644",
-            "SNOMEDCT:231861005",
-            "ICD9:077.0",
-            "MEDDRA:10053609",
-            "SNOMEDCT:240591000",
-            "SNOMEDCT:56009001",
-            "MEDDRA:10021629",
-            "MONDO:0005808",
-            "ICD10:A74.0",
-            "MEDDRA:10008535",
-            "UMLS:C0009770",
-            "DOID:13800",
-            "EFO:0007324",
-            "MEDDRA:10053993",
-            "MEDDRA:10010745",
-            "MEDDRA:10062847"
-          ],
-          "id": "MONDO:0005808",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Neonatal Chlamydia Conjunctivitis",
-            "Inclusion conjunctivitis",
-            "inclusion conjunctivitis",
-            "Conjunctivitis, Inclusion",
-            "Neonatal chlamydial conjunctivitis"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009061",
-          "name": "cystic fibrosis",
-          "description": "A congenital, autosomal, metabolic disorder affecting the exocrine glands. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production that causes obstruction of passageways, including pancreatic and bile ducts, intestines, and bronchi. Symptoms usually appear in childhood, and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather secondary to increased sodium and chloride concentration in sweat.; An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MESH:D003550",
-            "SNOMEDCT:190905008",
-            "UMLS:C0010674",
-            "NCIT:C2975",
-            "MEDDRA:10011762",
-            "ORPHANET:586",
-            "DOID:1485",
-            "MEDDRA:10011764",
-            "ICD9:277.0",
-            "MEDDRA:10028141",
-            "PSY:12915",
-            "MONDO:0009061",
-            "OMIM:219700",
-            "ICD10:E84"
-          ],
-          "id": "MONDO:0009061",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Cystic Fibrosis",
-            "cystic fibrosis",
-            "obsolete_cystic fibrosis",
-            "Cystic fibrosis related phenotypic feature",
-            "Cystic fibrosis"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://www.visualdx.com/visualdx/diagnosis/inclusion+conjunctivitis?diagnosisid=54853&moduleid=101"
-=======
-            "http://ghr.nlm.nih.gov/condition/cystic-fibrosis",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/cf/",
-            "http://en.wikipedia.org/wiki/cystic_fibrosis"
->>>>>>> main
-          ]
-        }
-      },
-      "end": {
-<<<<<<< HEAD
-        "identity": 628,
-=======
-        "identity": 629,
->>>>>>> main
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-<<<<<<< HEAD
-          "name": "Tetracycline",
-          "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-          "equivalent_curies": [
-            "CHEBI:77932",
-            "CHEMBL.COMPOUND:CHEMBL1440",
-            "UMLS:C0039644",
-            "UMLS:C0521901",
-            "ATC:D06AA04",
-            "NCIT:C865",
-            "UMLS:C4255918",
-            "NDDF:002738",
-            "ATC:S01AA09",
-            "RXNORM:2105975",
-            "KEGG.COMPOUND:C06570",
-            "DRUGBANK:DB00759",
-            "ATC:S02AA08",
-            "CAS:60-54-8",
-            "PathWhiz.Compound:9228",
-            "ATC:A01AB13",
-            "HMDB:HMDB0014897",
-            "UNII:F8VB5M810T",
-            "PUBCHEM.COMPOUND:54675776",
-            "ATC:S03AA02",
-            "UMLS:C3710841",
-            "NCIT:C87225",
-            "DrugCentral:2611",
-            "NDDF:002740",
-            "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-            "RXNORM:10395",
-            "KEGG.DRUG:D00201",
-            "PUBCHEM.COMPOUND:51580080",
-            "ATC:J01AA07",
-            "CHEBI:27902",
-            "DRUGBANK:DB09550",
-            "MESH:D013752",
-            "UMLS:C4255917"
-          ],
-          "id": "PUBCHEM.COMPOUND:54675776",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "Tetracycline phosphate complex",
-            "tetracycline",
-            "TETRACYCLINE",
-            "Tetracycline (JAN/USP/INN)",
-            "Anhydrotetracycline",
-            "tetracycline phosphate complex",
-            "tetracycline zwitterion",
-            "Abramycin",
-            "Deschlorobiomycin",
-            "tetracycline hydrochloride",
-            "Tetracycline",
-            "Tetracycline Phosphate Complex"
-=======
-          "name": "(Alginate)n",
-          "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
-          "equivalent_curies": [
-            "MESH:D000077322",
-            "UMLS:C0102137",
-            "KEGG.GLYCAN:G00316",
-            "UMLS:C0051156",
-            "KEGG.GLYCAN:G07471",
-            "KEGG.GLYCAN:G07287",
-            "KEGG.GLYCAN:G08476",
-            "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-            "DRUGBANK:DB13518",
-            "DrugCentral:4321",
-            "KEGG.DRUG:D02324",
-            "UNII:8C3Z4148WZ",
-            "KEGG.COMPOUND:C01768",
-            "CHEBI:17548",
-            "NDDF:002434",
-            "RXNORM:17305",
-            "RXNORM:1370451",
-            "NCIT:C82277",
-            "CHEMBL.COMPOUND:CHEMBL2108894",
-            "MESH:C008970",
-            "PUBCHEM.COMPOUND:91666318",
-            "ATC:A02BX13",
-            "KEGG.GLYCAN:G02561",
-            "UMLS:C4694124",
-            "KEGG.GLYCAN:G10593"
-          ],
-          "id": "PUBCHEM.COMPOUND:91666318",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "(Alginate)n",
-            "Alginate",
-            "Norgine",
-            "Alginic acid",
-            "Alginic acid (NF)",
-            "ALGINIC ACID",
-            "alginate",
-            "Alginic Acid",
-            "alginic acid"
->>>>>>> main
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "PMID:19752278",
-            "PMID:26922234",
-            "PMID:19463000",
-            "PMID:18378719",
-            "PMID:19104019",
-            "PMID:18474585",
-            "PMID:20696876",
-            "PMID:19332670",
-            "PMID:18834112",
-            "PMID:23891185"
-=======
-            "PMID:1551350",
-            "PMID:10848650",
-            "PMID:231639",
-            "PMID:27671545"
->>>>>>> main
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-<<<<<<< HEAD
-            "identity": 541721,
-=======
-            "identity": 523273,
->>>>>>> main
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005808",
-              "name": "inclusion conjunctivitis",
-              "description": "An infection of the eyes characterized by the presence in conjunctival epithelial cells of inclusion bodies indistinguishable from those of trachoma. It is acquired by infants during birth and by adults from swimming pools. The etiological agent is CHLAMYDIA TRACHOMATIS whose natural habitat appears to be the genito-urinary tract. Inclusion conjunctivitis is a less severe disease than trachoma and usually clears up spontaneously.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C116817",
-                "UMLS:C0343723",
-                "MESH:D003235",
-                "MEDDRA:10053992",
-                "UMLS:C0392644",
-                "SNOMEDCT:231861005",
-                "ICD9:077.0",
-                "MEDDRA:10053609",
-                "SNOMEDCT:240591000",
-                "SNOMEDCT:56009001",
-                "MEDDRA:10021629",
-                "MONDO:0005808",
-                "ICD10:A74.0",
-                "MEDDRA:10008535",
-                "UMLS:C0009770",
-                "DOID:13800",
-                "EFO:0007324",
-                "MEDDRA:10053993",
-                "MEDDRA:10010745",
-                "MEDDRA:10062847"
-              ],
-              "id": "MONDO:0005808",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Neonatal Chlamydia Conjunctivitis",
-                "Inclusion conjunctivitis",
-                "inclusion conjunctivitis",
-                "Conjunctivitis, Inclusion",
-                "Neonatal chlamydial conjunctivitis"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009061",
-              "name": "cystic fibrosis",
-              "description": "A congenital, autosomal, metabolic disorder affecting the exocrine glands. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production that causes obstruction of passageways, including pancreatic and bile ducts, intestines, and bronchi. Symptoms usually appear in childhood, and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather secondary to increased sodium and chloride concentration in sweat.; An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MESH:D003550",
-                "SNOMEDCT:190905008",
-                "UMLS:C0010674",
-                "NCIT:C2975",
-                "MEDDRA:10011762",
-                "ORPHANET:586",
-                "DOID:1485",
-                "MEDDRA:10011764",
-                "ICD9:277.0",
-                "MEDDRA:10028141",
-                "PSY:12915",
-                "MONDO:0009061",
-                "OMIM:219700",
-                "ICD10:E84"
-              ],
-              "id": "MONDO:0009061",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Cystic Fibrosis",
-                "cystic fibrosis",
-                "obsolete_cystic fibrosis",
-                "Cystic fibrosis related phenotypic feature",
-                "Cystic fibrosis"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://www.visualdx.com/visualdx/diagnosis/inclusion+conjunctivitis?diagnosisid=54853&moduleid=101"
-=======
-                "http://ghr.nlm.nih.gov/condition/cystic-fibrosis",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/cf/",
-                "http://en.wikipedia.org/wiki/cystic_fibrosis"
->>>>>>> main
-              ]
-            }
-          },
-          "relationship": {
-<<<<<<< HEAD
-            "identity": 10614289,
-            "start": 628,
-            "end": 541721,
-            "type": "biolink:prevents",
-            "properties": {
-              "predicate": "biolink:prevents",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1460264': {'publication date': '1992 Dec', 'sentence': 'Prophylaxis with silver nitrate solution, 1.0% tetracycline, or 0.05% erythromycin ointment is effective for the prevention of gonococcal and chlamydial conjunctivitis in the newborn.', 'subject score': 827, 'object score': 1000}, 'PMID:1461692': {'publication date': '1992 Dec', 'sentence': 'We conclude that neonatal ocular prophylaxis with erythromycin (one or two doses) or tetracycline or silver nitrate does not significantly reduce the incidence of neonatal chlamydial conjunctivitis compared with that in those given no prophylaxis.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0039644---SEMMEDDB:prevents---None---None---None---UMLS:C0009770---SEMMEDDB:",
-                "UMLS:C0039644---SEMMEDDB:prevents---None---None---None---UMLS:C0343723---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:54675776",
-              "id": "10847016",
-              "object": "MONDO:0005808",
-              "publications": [
-                "PMID:1461692",
-                "PMID:1460264"
-=======
-            "identity": 26964905,
-            "start": 629,
-            "end": 523273,
-            "type": "biolink:affects",
-            "properties": {
-              "predicate": "biolink:affects",
-              "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9284161': {'publication date': '1997 Sep', 'sentence': 'Two CF strains, selected for further study based on the dependence of their alginate production on the concentration of salt in the medium, were used to examine the effects of mucoidy on pulmonary clearance.', 'subject score': 888, 'object score': 861}}",
-              "kg2_ids": [
-                "UMLS:C0102137---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0010674---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:91666318",
-              "id": "27435796",
-              "object": "MONDO:0009061",
-              "publications": [
-                "PMID:9284161"
->>>>>>> main
-              ]
-            }
-          },
-          "end": {
-<<<<<<< HEAD
-            "identity": 628,
-=======
-            "identity": 629,
->>>>>>> main
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-<<<<<<< HEAD
-              "name": "Tetracycline",
-              "description": "UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.[L43942] Other formulations of tetracycline continue to be used.",
-              "equivalent_curies": [
-                "CHEBI:77932",
-                "CHEMBL.COMPOUND:CHEMBL1440",
-                "UMLS:C0039644",
-                "UMLS:C0521901",
-                "ATC:D06AA04",
-                "NCIT:C865",
-                "UMLS:C4255918",
-                "NDDF:002738",
-                "ATC:S01AA09",
-                "RXNORM:2105975",
-                "KEGG.COMPOUND:C06570",
-                "DRUGBANK:DB00759",
-                "ATC:S02AA08",
-                "CAS:60-54-8",
-                "PathWhiz.Compound:9228",
-                "ATC:A01AB13",
-                "HMDB:HMDB0014897",
-                "UNII:F8VB5M810T",
-                "PUBCHEM.COMPOUND:54675776",
-                "ATC:S03AA02",
-                "UMLS:C3710841",
-                "NCIT:C87225",
-                "DrugCentral:2611",
-                "NDDF:002740",
-                "INCHIKEY:OFVLGDICTFRJMM-WESIUVDSSA-N",
-                "RXNORM:10395",
-                "KEGG.DRUG:D00201",
-                "PUBCHEM.COMPOUND:51580080",
-                "ATC:J01AA07",
-                "CHEBI:27902",
-                "DRUGBANK:DB09550",
-                "MESH:D013752",
-                "UMLS:C4255917"
-              ],
-              "id": "PUBCHEM.COMPOUND:54675776",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "Tetracycline phosphate complex",
-                "tetracycline",
-                "TETRACYCLINE",
-                "Tetracycline (JAN/USP/INN)",
-                "Anhydrotetracycline",
-                "tetracycline phosphate complex",
-                "tetracycline zwitterion",
-                "Abramycin",
-                "Deschlorobiomycin",
-                "tetracycline hydrochloride",
-                "Tetracycline",
-                "Tetracycline Phosphate Complex"
-=======
-              "name": "(Alginate)n",
-              "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
-              "equivalent_curies": [
-                "MESH:D000077322",
-                "UMLS:C0102137",
-                "KEGG.GLYCAN:G00316",
-                "UMLS:C0051156",
-                "KEGG.GLYCAN:G07471",
-                "KEGG.GLYCAN:G07287",
-                "KEGG.GLYCAN:G08476",
-                "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-                "DRUGBANK:DB13518",
-                "DrugCentral:4321",
-                "KEGG.DRUG:D02324",
-                "UNII:8C3Z4148WZ",
-                "KEGG.COMPOUND:C01768",
-                "CHEBI:17548",
-                "NDDF:002434",
-                "RXNORM:17305",
-                "RXNORM:1370451",
-                "NCIT:C82277",
-                "CHEMBL.COMPOUND:CHEMBL2108894",
-                "MESH:C008970",
-                "PUBCHEM.COMPOUND:91666318",
-                "ATC:A02BX13",
-                "KEGG.GLYCAN:G02561",
-                "UMLS:C4694124",
-                "KEGG.GLYCAN:G10593"
-              ],
-              "id": "PUBCHEM.COMPOUND:91666318",
-              "category": "biolink:SmallMolecule",
-              "all_names": [
-                "(Alginate)n",
-                "Alginate",
-                "Norgine",
-                "Alginic acid",
-                "Alginic acid (NF)",
-                "ALGINIC ACID",
-                "alginate",
-                "Alginic Acid",
-                "alginic acid"
->>>>>>> main
-              ],
-              "all_categories": [
-                "biolink:ChemicalEntity",
-                "biolink:SmallMolecule",
-                "biolink:Drug"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "PMID:19752278",
-                "PMID:26922234",
-                "PMID:19463000",
-                "PMID:18378719",
-                "PMID:19104019",
-                "PMID:18474585",
-                "PMID:20696876",
-                "PMID:19332670",
-                "PMID:18834112",
-                "PMID:23891185"
-=======
-                "PMID:1551350",
-                "PMID:10848650",
-                "PMID:231639",
-                "PMID:27671545"
->>>>>>> main
-              ]
-            }
-          }
-        }
-      ],
-      "length": 1
-    }
-  },
-  {
-<<<<<<< HEAD
-    "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:33282832': {'publication date': '2020', 'sentence': 'With these results, we propose alginate-based nanoemulsions as a potential treatment for migraine pain.', 'subject score': 840, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 316891,
-        "labels": [
-          "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
-        ],
-        "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-          "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
-          "all_names": [
-            "pain",
-            "Pain"
-          ],
-          "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-          ]
-        }
-      },
-      "end": {
-        "identity": 629,
-        "labels": [
-          "biolink:SmallMolecule",
-          "biolink:ChemicalEntityOrGeneOrGeneProduct",
-          "biolink:PhysicalEssenceOrOccurrent",
-          "biolink:MolecularEntity",
-          "biolink:ChemicalEntity",
-          "biolink:ChemicalMixture",
-          "biolink:Drug",
-          "biolink:ChemicalOrDrugOrTreatment",
-          "biolink:NamedThing",
-          "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide",
-          "biolink:MolecularMixture",
-          "biolink:OntologyClass"
-        ],
-        "properties": {
-          "name": "(Alginate)n",
-          "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
-          "equivalent_curies": [
-            "MESH:D000077322",
-            "UMLS:C0102137",
-            "KEGG.GLYCAN:G00316",
-            "UMLS:C0051156",
-            "KEGG.GLYCAN:G07471",
-            "KEGG.GLYCAN:G07287",
-            "KEGG.GLYCAN:G08476",
-            "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-            "DRUGBANK:DB13518",
-            "DrugCentral:4321",
-            "KEGG.DRUG:D02324",
-            "UNII:8C3Z4148WZ",
-            "KEGG.COMPOUND:C01768",
-            "CHEBI:17548",
-            "NDDF:002434",
-            "RXNORM:17305",
-            "RXNORM:1370451",
-            "NCIT:C82277",
-            "CHEMBL.COMPOUND:CHEMBL2108894",
-            "MESH:C008970",
-            "PUBCHEM.COMPOUND:91666318",
-            "ATC:A02BX13",
-            "KEGG.GLYCAN:G02561",
-            "UMLS:C4694124",
-            "KEGG.GLYCAN:G10593"
-          ],
-          "id": "PUBCHEM.COMPOUND:91666318",
-          "category": "biolink:SmallMolecule",
-          "all_names": [
-            "(Alginate)n",
-            "Alginate",
-            "Norgine",
-            "Alginic acid",
-            "Alginic acid (NF)",
-            "ALGINIC ACID",
-            "alginate",
-            "Alginic Acid",
-            "alginic acid"
-          ],
-          "all_categories": [
-            "biolink:ChemicalEntity",
-            "biolink:SmallMolecule",
-            "biolink:Drug"
-          ],
-          "publications": [
-            "PMID:1551350",
-            "PMID:10848650",
-            "PMID:231639",
-            "PMID:27671545"
-          ]
-        }
-      },
-      "segments": [
-        {
-          "start": {
-            "identity": 316891,
-            "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
-            ],
-            "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
-              "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
-              "all_names": [
-                "pain",
-                "Pain"
-              ],
-              "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
-              ]
-            }
-          },
-          "relationship": {
-            "identity": 22361630,
-            "start": 629,
-            "end": 316891,
-            "type": "biolink:treats",
-            "properties": {
-              "predicate": "biolink:treats",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:33282832': {'publication date': '2020', 'sentence': 'With these results, we propose alginate-based nanoemulsions as a potential treatment for migraine pain.', 'subject score': 840, 'object score': 888}}",
-              "kg2_ids": [
-                "UMLS:C0102137---SEMMEDDB:treats---None---None---None---UMLS:C0030193---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:91666318",
-              "id": "22788639",
-              "object": "HP:0012531",
-              "publications": [
-                "PMID:33282832"
-              ]
-            }
-          },
-          "end": {
-            "identity": 629,
-            "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
-              "biolink:ChemicalEntity",
-              "biolink:ChemicalMixture",
-              "biolink:Drug",
-              "biolink:ChemicalOrDrugOrTreatment",
-              "biolink:NamedThing",
-              "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
-            ],
-            "properties": {
-              "name": "(Alginate)n",
-              "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+              "name": "Thiabendazole",
+              "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "MESH:D000077322",
-                "UMLS:C0102137",
-                "KEGG.GLYCAN:G00316",
-                "UMLS:C0051156",
-                "KEGG.GLYCAN:G07471",
-                "KEGG.GLYCAN:G07287",
-                "KEGG.GLYCAN:G08476",
-                "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-                "DRUGBANK:DB13518",
-                "DrugCentral:4321",
-                "KEGG.DRUG:D02324",
-                "UNII:8C3Z4148WZ",
-                "KEGG.COMPOUND:C01768",
-                "CHEBI:17548",
-                "NDDF:002434",
-                "RXNORM:17305",
-                "RXNORM:1370451",
-                "NCIT:C82277",
-                "CHEMBL.COMPOUND:CHEMBL2108894",
-                "MESH:C008970",
-                "PUBCHEM.COMPOUND:91666318",
-                "ATC:A02BX13",
-                "KEGG.GLYCAN:G02561",
-                "UMLS:C4694124",
-                "KEGG.GLYCAN:G10593"
+                "MESH:D013827",
+                "DrugCentral:2621",
+                "CAS:148-79-8",
+                "NDDF:002985",
+                "CHEMBL.COMPOUND:CHEMBL625",
+                "PDQ:CDR0000039713",
+                "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+                "KEGG.DRUG:D00372",
+                "RXNORM:10450",
+                "CHEBI:45979",
+                "UNII:N1Q45E87DT",
+                "PUBCHEM.COMPOUND:5430",
+                "KEGG.COMPOUND:C07131",
+                "DRUGBANK:DB00730",
+                "UMLS:C0039832",
+                "HMDB:HMDB0014868",
+                "CAS:98002-42-7",
+                "NCIT:C873",
+                "GTOPDB:7304"
               ],
-              "id": "PUBCHEM.COMPOUND:91666318",
+              "id": "PUBCHEM.COMPOUND:5430",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "(Alginate)n",
-                "Alginate",
-                "Norgine",
-                "Alginic acid",
-                "Alginic acid (NF)",
-                "ALGINIC ACID",
-                "alginate",
-                "Alginic Acid",
-                "alginic acid"
+                "thiabendazole",
+                "THIABENDAZOLE",
+                "Thiabendazole (USP)",
+                "bovizole",
+                "Thiabendazole"
               ],
               "all_categories": [
-                "biolink:ChemicalEntity",
                 "biolink:SmallMolecule",
-                "biolink:Drug"
+                "biolink:Drug",
+                "biolink:ChemicalEntity"
               ],
               "publications": [
-                "PMID:1551350",
-                "PMID:10848650",
-                "PMID:231639",
-                "PMID:27671545"
+                "PMID:20014752",
+                "PMID:15646539",
+                "PMID:18400497",
+                "PMID:23571415",
+                "PMID:34954591",
+                "PMID:23241029",
+                "PMID:23634668",
+                "PMID:10978195",
+                "PMID:16420038",
+                "PMID:18973341"
               ]
             }
           }
@@ -513205,68 +3351,53 @@
     }
   },
   {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:13727961': {'publication date': '1961 Apr 01', 'sentence': '[Alginate--skimmed milk mixture as an aid in obesity].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
+    "p3": {
       "start": {
-        "identity": 318216,
+        "identity": 532245,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
           "biolink:BiologicalEntity",
           "biolink:Disease",
           "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
+          "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0016472",
+          "name": "dracunculiasis",
+          "description": "A parasitic helminthiasis infectious disease that involves parasitic infection by the larvae of the nematode Dracunculus medinensis, which are transmitted to humans by drinking water containing copepods infected with the larvae. The female, which contains larvae, burrows into the deeper connective tissues or adjacent to long bones or joints of the extremities. The worm emerges as a whitish filament in the center of a painful ulcer, accompanied by inflammation and frequently by secondary bacterial infection.",
           "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
+            "SNOMEDCT:396334002",
+            "UMLS:C0013100",
+            "ICD9:125.7",
+            "MEDDRA:10013617",
+            "DOID:14418",
+            "EFO:0007241",
+            "MONDO:0016472",
+            "MEDDRA:10013618",
+            "MESH:D004320",
+            "ORPHANET:231",
+            "ICD10:B72",
+            "NCIT:C84677"
           ],
-          "id": "MONDO:0011122",
+          "id": "MONDO:0016472",
           "category": "biolink:Disease",
           "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
+            "Dracunculiasis",
+            "dracunculiasis",
+            "Dracontiasis"
           ],
           "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
+            "biolink:Disease"
           ],
           "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
+            "http://en.wikipedia.org/wiki/dracunculiasis",
+            "http://www.dpd.cdc.gov/dpdx/html/dracunculiasis.htm"
           ]
         }
       },
       "end": {
-        "identity": 629,
+        "identity": 549,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -513283,142 +3414,126 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "(Alginate)n",
-          "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+          "name": "Thiabendazole",
+          "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "MESH:D000077322",
-            "UMLS:C0102137",
-            "KEGG.GLYCAN:G00316",
-            "UMLS:C0051156",
-            "KEGG.GLYCAN:G07471",
-            "KEGG.GLYCAN:G07287",
-            "KEGG.GLYCAN:G08476",
-            "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-            "DRUGBANK:DB13518",
-            "DrugCentral:4321",
-            "KEGG.DRUG:D02324",
-            "UNII:8C3Z4148WZ",
-            "KEGG.COMPOUND:C01768",
-            "CHEBI:17548",
-            "NDDF:002434",
-            "RXNORM:17305",
-            "RXNORM:1370451",
-            "NCIT:C82277",
-            "CHEMBL.COMPOUND:CHEMBL2108894",
-            "MESH:C008970",
-            "PUBCHEM.COMPOUND:91666318",
-            "ATC:A02BX13",
-            "KEGG.GLYCAN:G02561",
-            "UMLS:C4694124",
-            "KEGG.GLYCAN:G10593"
+            "MESH:D013827",
+            "DrugCentral:2621",
+            "CAS:148-79-8",
+            "NDDF:002985",
+            "CHEMBL.COMPOUND:CHEMBL625",
+            "PDQ:CDR0000039713",
+            "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+            "KEGG.DRUG:D00372",
+            "RXNORM:10450",
+            "CHEBI:45979",
+            "UNII:N1Q45E87DT",
+            "PUBCHEM.COMPOUND:5430",
+            "KEGG.COMPOUND:C07131",
+            "DRUGBANK:DB00730",
+            "UMLS:C0039832",
+            "HMDB:HMDB0014868",
+            "CAS:98002-42-7",
+            "NCIT:C873",
+            "GTOPDB:7304"
           ],
-          "id": "PUBCHEM.COMPOUND:91666318",
+          "id": "PUBCHEM.COMPOUND:5430",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "(Alginate)n",
-            "Alginate",
-            "Norgine",
-            "Alginic acid",
-            "Alginic acid (NF)",
-            "ALGINIC ACID",
-            "alginate",
-            "Alginic Acid",
-            "alginic acid"
+            "thiabendazole",
+            "THIABENDAZOLE",
+            "Thiabendazole (USP)",
+            "bovizole",
+            "Thiabendazole"
           ],
           "all_categories": [
-            "biolink:ChemicalEntity",
             "biolink:SmallMolecule",
-            "biolink:Drug"
+            "biolink:Drug",
+            "biolink:ChemicalEntity"
           ],
           "publications": [
-            "PMID:1551350",
-            "PMID:10848650",
-            "PMID:231639",
-            "PMID:27671545"
+            "PMID:20014752",
+            "PMID:15646539",
+            "PMID:18400497",
+            "PMID:23571415",
+            "PMID:34954591",
+            "PMID:23241029",
+            "PMID:23634668",
+            "PMID:10978195",
+            "PMID:16420038",
+            "PMID:18973341"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 318216,
+            "identity": 532245,
             "labels": [
               "biolink:NamedThing",
               "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0016472",
+              "name": "dracunculiasis",
+              "description": "A parasitic helminthiasis infectious disease that involves parasitic infection by the larvae of the nematode Dracunculus medinensis, which are transmitted to humans by drinking water containing copepods infected with the larvae. The female, which contains larvae, burrows into the deeper connective tissues or adjacent to long bones or joints of the extremities. The worm emerges as a whitish filament in the center of a painful ulcer, accompanied by inflammation and frequently by secondary bacterial infection.",
               "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
+                "SNOMEDCT:396334002",
+                "UMLS:C0013100",
+                "ICD9:125.7",
+                "MEDDRA:10013617",
+                "DOID:14418",
+                "EFO:0007241",
+                "MONDO:0016472",
+                "MEDDRA:10013618",
+                "MESH:D004320",
+                "ORPHANET:231",
+                "ICD10:B72",
+                "NCIT:C84677"
               ],
-              "id": "MONDO:0011122",
+              "id": "MONDO:0016472",
               "category": "biolink:Disease",
               "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
+                "Dracunculiasis",
+                "dracunculiasis",
+                "Dracontiasis"
               ],
               "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
+                "biolink:Disease"
               ],
               "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
+                "http://en.wikipedia.org/wiki/dracunculiasis",
+                "http://www.dpd.cdc.gov/dpdx/html/dracunculiasis.htm"
               ]
             }
           },
           "relationship": {
-            "identity": 10371021,
-            "start": 629,
-            "end": 318216,
-            "type": "biolink:related_to",
+            "identity": 15269827,
+            "start": 549,
+            "end": 532245,
+            "type": "biolink:prevents",
             "properties": {
-              "predicate": "biolink:related_to",
+              "predicate": "biolink:prevents",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13727961': {'publication date': '1961 Apr 01', 'sentence': '[Alginate--skimmed milk mixture as an aid in obesity].', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:2150213': {'publication date': '1990 Oct-Dec', 'sentence': '[Failure of thiabendazole in the prevention of dracunculosis].', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0102137---SEMMEDDB:associated_with---None---None---None---UMLS:C0028754---SEMMEDDB:"
+                "UMLS:C0039832---SEMMEDDB:prevents---None---None---None---UMLS:C0013100---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:91666318",
-              "id": "10599430",
-              "object": "MONDO:0011122",
+              "subject": "PUBCHEM.COMPOUND:5430",
+              "id": "15590334",
+              "object": "MONDO:0016472",
               "publications": [
-                "PMID:13727961"
+                "PMID:2150213"
               ]
             }
           },
           "end": {
-            "identity": 629,
+            "identity": 549,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -513435,58 +3550,54 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "(Alginate)n",
-              "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+              "name": "Thiabendazole",
+              "description": "A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C873\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C873\" NCI Thesaurus); A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids.; 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "MESH:D000077322",
-                "UMLS:C0102137",
-                "KEGG.GLYCAN:G00316",
-                "UMLS:C0051156",
-                "KEGG.GLYCAN:G07471",
-                "KEGG.GLYCAN:G07287",
-                "KEGG.GLYCAN:G08476",
-                "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-                "DRUGBANK:DB13518",
-                "DrugCentral:4321",
-                "KEGG.DRUG:D02324",
-                "UNII:8C3Z4148WZ",
-                "KEGG.COMPOUND:C01768",
-                "CHEBI:17548",
-                "NDDF:002434",
-                "RXNORM:17305",
-                "RXNORM:1370451",
-                "NCIT:C82277",
-                "CHEMBL.COMPOUND:CHEMBL2108894",
-                "MESH:C008970",
-                "PUBCHEM.COMPOUND:91666318",
-                "ATC:A02BX13",
-                "KEGG.GLYCAN:G02561",
-                "UMLS:C4694124",
-                "KEGG.GLYCAN:G10593"
+                "MESH:D013827",
+                "DrugCentral:2621",
+                "CAS:148-79-8",
+                "NDDF:002985",
+                "CHEMBL.COMPOUND:CHEMBL625",
+                "PDQ:CDR0000039713",
+                "INCHIKEY:WJCNZQLZVWNLKY-UHFFFAOYSA-N",
+                "KEGG.DRUG:D00372",
+                "RXNORM:10450",
+                "CHEBI:45979",
+                "UNII:N1Q45E87DT",
+                "PUBCHEM.COMPOUND:5430",
+                "KEGG.COMPOUND:C07131",
+                "DRUGBANK:DB00730",
+                "UMLS:C0039832",
+                "HMDB:HMDB0014868",
+                "CAS:98002-42-7",
+                "NCIT:C873",
+                "GTOPDB:7304"
               ],
-              "id": "PUBCHEM.COMPOUND:91666318",
+              "id": "PUBCHEM.COMPOUND:5430",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "(Alginate)n",
-                "Alginate",
-                "Norgine",
-                "Alginic acid",
-                "Alginic acid (NF)",
-                "ALGINIC ACID",
-                "alginate",
-                "Alginic Acid",
-                "alginic acid"
+                "thiabendazole",
+                "THIABENDAZOLE",
+                "Thiabendazole (USP)",
+                "bovizole",
+                "Thiabendazole"
               ],
               "all_categories": [
-                "biolink:ChemicalEntity",
                 "biolink:SmallMolecule",
-                "biolink:Drug"
+                "biolink:Drug",
+                "biolink:ChemicalEntity"
               ],
               "publications": [
-                "PMID:1551350",
-                "PMID:10848650",
-                "PMID:231639",
-                "PMID:27671545"
+                "PMID:20014752",
+                "PMID:15646539",
+                "PMID:18400497",
+                "PMID:23571415",
+                "PMID:34954591",
+                "PMID:23241029",
+                "PMID:23634668",
+                "PMID:10978195",
+                "PMID:16420038",
+                "PMID:18973341"
               ]
             }
           }
@@ -513496,68 +3607,64 @@
     }
   },
   {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:34083930': {'publication date': '2021 Apr', 'sentence': 'Conclusion: PVA and alginate nanofibers can modulate obesity, reduce blood glucose levels, and reduce serum levels of insulin, ALT, ALP, GGT, creatinine, TNF-alpha, and IL-1beta in diabetic rats.', 'subject score': 888, 'object score': 1000}, 'PMID:34363822': {'publication date': '2021 Aug 04', 'sentence': 'In this study, low-molecular alginate from Laminaria japonica (L-LJA) was prepared, and its effect on obesity and metabolic syndrome was analyzed in high-fat diet (HFD)-fed mice.', 'subject score': 851, 'object score': 1000}}",
-    "p2": {
+    "p3": {
       "start": {
-        "identity": 318216,
+        "identity": 315782,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
           "biolink:BiologicalEntity",
           "biolink:Disease",
           "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
+          "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
+          "name": "aplastic anemia",
+          "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What causes aplastic anemia? The causes of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
+            "MONDO:0015909",
+            "MEDDRA:10002037",
+            "HP:0001915",
+            "MEDDRA:10002967",
+            "MEDDRA:10002274",
+            "MEDDRA:10002969",
+            "MESH:D000741",
+            "SNOMEDCT:306058006",
+            "PDQ:CDR0000489004",
+            "NCIT:C2870",
+            "MEDDRA:10002968",
+            "DOID:12449",
+            "MEDDRA:10002970",
+            "ICD9:284.9",
+            "SNOMEDCT:304132006",
+            "UMLS:C0002874",
+            "ICD10:D61.9",
+            "ORPHANET:182040"
           ],
-          "id": "MONDO:0011122",
+          "id": "MONDO:0015909",
           "category": "biolink:Disease",
           "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
+            "aplastic anemia",
+            "Aplastic Anemia",
+            "Aplastic anemia",
+            "Aplastic anemia, unspecified",
+            "obsolete_Medullar aplasia",
+            "Anemia, Aplastic"
           ],
           "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
+            "biolink:Disease"
           ],
           "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
+            "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
+            "http://en.wikipedia.org/wiki/aplastic_anemia",
+            "PMID:21239768",
+            "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 629,
+        "identity": 551,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -513574,211 +3681,205 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "(Alginate)n",
-          "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+          "name": "Albendazole",
+          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "MESH:D000077322",
-            "UMLS:C0102137",
-            "KEGG.GLYCAN:G00316",
-            "UMLS:C0051156",
-            "KEGG.GLYCAN:G07471",
-            "KEGG.GLYCAN:G07287",
-            "KEGG.GLYCAN:G08476",
-            "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-            "DRUGBANK:DB13518",
-            "DrugCentral:4321",
-            "KEGG.DRUG:D02324",
-            "UNII:8C3Z4148WZ",
-            "KEGG.COMPOUND:C01768",
-            "CHEBI:17548",
-            "NDDF:002434",
-            "RXNORM:17305",
-            "RXNORM:1370451",
-            "NCIT:C82277",
-            "CHEMBL.COMPOUND:CHEMBL2108894",
-            "MESH:C008970",
-            "PUBCHEM.COMPOUND:91666318",
-            "ATC:A02BX13",
-            "KEGG.GLYCAN:G02561",
-            "UMLS:C4694124",
-            "KEGG.GLYCAN:G10593"
+            "KEGG.COMPOUND:C01779",
+            "UMLS:C0001911",
+            "ATC:P02CA03",
+            "NCIT:C47384",
+            "UMLS:C4082528",
+            "KEGG.DRUG:D00134",
+            "NDDF:004079",
+            "DrugCentral:103",
+            "MESH:D015766",
+            "CAS:54965-21-8",
+            "RXNORM:430",
+            "HMDB:HMDB0014659",
+            "CHEBI:16664",
+            "UNII:F4216019LN",
+            "CHEMBL.COMPOUND:CHEMBL1483",
+            "DRUGBANK:DB00518",
+            "PUBCHEM.COMPOUND:2082",
+            "UMLS:C4082752",
+            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
           ],
-          "id": "PUBCHEM.COMPOUND:91666318",
+          "id": "PUBCHEM.COMPOUND:2082",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "(Alginate)n",
-            "Alginate",
-            "Norgine",
-            "Alginic acid",
-            "Alginic acid (NF)",
-            "ALGINIC ACID",
-            "alginate",
-            "Alginic Acid",
-            "alginic acid"
+            "albendol",
+            "Albendazole",
+            "ALBENDAZOLE",
+            "Eskazole",
+            "Proftril",
+            "Albendazole (JAN/USP/INN)",
+            "albendazole"
           ],
           "all_categories": [
-            "biolink:ChemicalEntity",
             "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:1551350",
-            "PMID:10848650",
-            "PMID:231639",
-            "PMID:27671545"
+            "PMID:28595066",
+            "PMID:20014752",
+            "PMID:15646539",
+            "PMID:17562801",
+            "PMID:8228321",
+            "PMID:15828820",
+            "PMID:23571415",
+            "PMID:33360795",
+            "PMID:19186059",
+            "PMID:16420038"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 318216,
+            "identity": 315782,
             "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
+              "biolink:NamedThing",
               "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
+              "biolink:ThingWithTaxon"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
+              "name": "aplastic anemia",
+              "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What causes aplastic anemia? The causes of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
+                "MONDO:0015909",
+                "MEDDRA:10002037",
+                "HP:0001915",
+                "MEDDRA:10002967",
+                "MEDDRA:10002274",
+                "MEDDRA:10002969",
+                "MESH:D000741",
+                "SNOMEDCT:306058006",
+                "PDQ:CDR0000489004",
+                "NCIT:C2870",
+                "MEDDRA:10002968",
+                "DOID:12449",
+                "MEDDRA:10002970",
+                "ICD9:284.9",
+                "SNOMEDCT:304132006",
+                "UMLS:C0002874",
+                "ICD10:D61.9",
+                "ORPHANET:182040"
               ],
-              "id": "MONDO:0011122",
+              "id": "MONDO:0015909",
               "category": "biolink:Disease",
               "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
+                "aplastic anemia",
+                "Aplastic Anemia",
+                "Aplastic anemia",
+                "Aplastic anemia, unspecified",
+                "obsolete_Medullar aplasia",
+                "Anemia, Aplastic"
               ],
               "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
+                "biolink:Disease"
               ],
               "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
+                "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
+                "http://en.wikipedia.org/wiki/aplastic_anemia",
+                "PMID:21239768",
+                "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 22982929,
-            "start": 629,
-            "end": 318216,
-            "type": "biolink:affects",
+            "identity": 27130331,
+            "start": 551,
+            "end": 315782,
+            "type": "biolink:causes",
             "properties": {
-              "predicate": "biolink:affects",
+              "predicate": "biolink:causes",
               "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:34083930': {'publication date': '2021 Apr', 'sentence': 'Conclusion: PVA and alginate nanofibers can modulate obesity, reduce blood glucose levels, and reduce serum levels of insulin, ALT, ALP, GGT, creatinine, TNF-alpha, and IL-1beta in diabetic rats.', 'subject score': 888, 'object score': 1000}, 'PMID:34363822': {'publication date': '2021 Aug 04', 'sentence': 'In this study, low-molecular alginate from Laminaria japonica (L-LJA) was prepared, and its effect on obesity and metabolic syndrome was analyzed in high-fat diet (HFD)-fed mice.', 'subject score': 851, 'object score': 1000}}",
+              "domain_range_exclusion": "False",
+              "publications_info": "{'PMID:9611722': {'publication date': '1998 Apr 04', 'sentence': '[Aplastic anemia induced by albendazole].', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0102137---SEMMEDDB:affects---None---None---None---UMLS:C0028754---SEMMEDDB:"
+                "UMLS:C0001911---SEMMEDDB:causes---None---None---None---UMLS:C0002874---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:91666318",
-              "id": "23415127",
-              "object": "MONDO:0011122",
+              "subject": "PUBCHEM.COMPOUND:2082",
+              "id": "27603501",
+              "object": "MONDO:0015909",
               "publications": [
-                "PMID:34083930",
-                "PMID:34363822"
+                "PMID:9611722"
               ]
             }
           },
           "end": {
-            "identity": 629,
+            "identity": 551,
             "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
               "biolink:ChemicalMixture",
-              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
+              "biolink:Drug",
+              "biolink:MolecularEntity",
+              "biolink:MolecularMixture",
               "biolink:NamedThing",
+              "biolink:OntologyClass",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:SmallMolecule"
             ],
             "properties": {
-              "name": "(Alginate)n",
-              "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+              "name": "Albendazole",
+              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "MESH:D000077322",
-                "UMLS:C0102137",
-                "KEGG.GLYCAN:G00316",
-                "UMLS:C0051156",
-                "KEGG.GLYCAN:G07471",
-                "KEGG.GLYCAN:G07287",
-                "KEGG.GLYCAN:G08476",
-                "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-                "DRUGBANK:DB13518",
-                "DrugCentral:4321",
-                "KEGG.DRUG:D02324",
-                "UNII:8C3Z4148WZ",
-                "KEGG.COMPOUND:C01768",
-                "CHEBI:17548",
-                "NDDF:002434",
-                "RXNORM:17305",
-                "RXNORM:1370451",
-                "NCIT:C82277",
-                "CHEMBL.COMPOUND:CHEMBL2108894",
-                "MESH:C008970",
-                "PUBCHEM.COMPOUND:91666318",
-                "ATC:A02BX13",
-                "KEGG.GLYCAN:G02561",
-                "UMLS:C4694124",
-                "KEGG.GLYCAN:G10593"
+                "KEGG.COMPOUND:C01779",
+                "UMLS:C0001911",
+                "ATC:P02CA03",
+                "NCIT:C47384",
+                "UMLS:C4082528",
+                "KEGG.DRUG:D00134",
+                "NDDF:004079",
+                "DrugCentral:103",
+                "MESH:D015766",
+                "CAS:54965-21-8",
+                "RXNORM:430",
+                "HMDB:HMDB0014659",
+                "CHEBI:16664",
+                "UNII:F4216019LN",
+                "CHEMBL.COMPOUND:CHEMBL1483",
+                "DRUGBANK:DB00518",
+                "PUBCHEM.COMPOUND:2082",
+                "UMLS:C4082752",
+                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
               ],
-              "id": "PUBCHEM.COMPOUND:91666318",
+              "id": "PUBCHEM.COMPOUND:2082",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "(Alginate)n",
-                "Alginate",
-                "Norgine",
-                "Alginic acid",
-                "Alginic acid (NF)",
-                "ALGINIC ACID",
-                "alginate",
-                "Alginic Acid",
-                "alginic acid"
+                "albendol",
+                "Albendazole",
+                "ALBENDAZOLE",
+                "Eskazole",
+                "Proftril",
+                "Albendazole (JAN/USP/INN)",
+                "albendazole"
               ],
               "all_categories": [
-                "biolink:ChemicalEntity",
                 "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:1551350",
-                "PMID:10848650",
-                "PMID:231639",
-                "PMID:27671545"
+                "PMID:28595066",
+                "PMID:20014752",
+                "PMID:15646539",
+                "PMID:17562801",
+                "PMID:8228321",
+                "PMID:15828820",
+                "PMID:23571415",
+                "PMID:33360795",
+                "PMID:19186059",
+                "PMID:16420038"
               ]
             }
           }
@@ -513788,68 +3889,53 @@
     }
   },
   {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:34206160': {'publication date': '2021 Jun 22', 'sentence': 'The consumption of kelp high in alginate may contribute to preventing obesity without influencing thyroid function in Japanese subjects with a relatively high intake of iodine from seaweed.', 'subject score': 1000, 'object score': 861}}",
-    "p2": {
+    "p3": {
       "start": {
-        "identity": 318216,
+        "identity": 316682,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
           "biolink:BiologicalEntity",
           "biolink:Disease",
           "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
+          "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0001529",
+          "name": "pancytopenia",
+          "description": "An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets). [HPO:probinson]; An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets).; An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets).; An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets).; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
+            "ICD9:284.1",
+            "MESH:D010198",
+            "MONDO:0001529",
+            "UMLS:C0030312",
+            "NCIT:C80693",
+            "MEDDRA:10033661",
+            "HP:0001876",
+            "DOID:12450",
+            "SNOMEDCT:127034005",
+            "NCIT:C34889",
+            "ICD10:D61.81"
           ],
-          "id": "MONDO:0011122",
+          "id": "MONDO:0001529",
           "category": "biolink:Disease",
           "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
+            "pancytopenia",
+            "Bone Marrow Failure",
+            "Pancytopenia"
           ],
           "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
+            "biolink:Disease"
           ],
           "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
+            "https://en.wikipedia.org/wiki/pancytopenia",
+            "https://orcid.org/0000-0001-5208-3432",
+            "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 629,
+        "identity": 551,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -513866,142 +3952,131 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "(Alginate)n",
-          "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+          "name": "Albendazole",
+          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "MESH:D000077322",
-            "UMLS:C0102137",
-            "KEGG.GLYCAN:G00316",
-            "UMLS:C0051156",
-            "KEGG.GLYCAN:G07471",
-            "KEGG.GLYCAN:G07287",
-            "KEGG.GLYCAN:G08476",
-            "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-            "DRUGBANK:DB13518",
-            "DrugCentral:4321",
-            "KEGG.DRUG:D02324",
-            "UNII:8C3Z4148WZ",
-            "KEGG.COMPOUND:C01768",
-            "CHEBI:17548",
-            "NDDF:002434",
-            "RXNORM:17305",
-            "RXNORM:1370451",
-            "NCIT:C82277",
-            "CHEMBL.COMPOUND:CHEMBL2108894",
-            "MESH:C008970",
-            "PUBCHEM.COMPOUND:91666318",
-            "ATC:A02BX13",
-            "KEGG.GLYCAN:G02561",
-            "UMLS:C4694124",
-            "KEGG.GLYCAN:G10593"
+            "KEGG.COMPOUND:C01779",
+            "UMLS:C0001911",
+            "ATC:P02CA03",
+            "NCIT:C47384",
+            "UMLS:C4082528",
+            "KEGG.DRUG:D00134",
+            "NDDF:004079",
+            "DrugCentral:103",
+            "MESH:D015766",
+            "CAS:54965-21-8",
+            "RXNORM:430",
+            "HMDB:HMDB0014659",
+            "CHEBI:16664",
+            "UNII:F4216019LN",
+            "CHEMBL.COMPOUND:CHEMBL1483",
+            "DRUGBANK:DB00518",
+            "PUBCHEM.COMPOUND:2082",
+            "UMLS:C4082752",
+            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
           ],
-          "id": "PUBCHEM.COMPOUND:91666318",
+          "id": "PUBCHEM.COMPOUND:2082",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "(Alginate)n",
-            "Alginate",
-            "Norgine",
-            "Alginic acid",
-            "Alginic acid (NF)",
-            "ALGINIC ACID",
-            "alginate",
-            "Alginic Acid",
-            "alginic acid"
+            "albendol",
+            "Albendazole",
+            "ALBENDAZOLE",
+            "Eskazole",
+            "Proftril",
+            "Albendazole (JAN/USP/INN)",
+            "albendazole"
           ],
           "all_categories": [
-            "biolink:ChemicalEntity",
             "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:1551350",
-            "PMID:10848650",
-            "PMID:231639",
-            "PMID:27671545"
+            "PMID:28595066",
+            "PMID:20014752",
+            "PMID:15646539",
+            "PMID:17562801",
+            "PMID:8228321",
+            "PMID:15828820",
+            "PMID:23571415",
+            "PMID:33360795",
+            "PMID:19186059",
+            "PMID:16420038"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 318216,
+            "identity": 316682,
             "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
+              "biolink:NamedThing",
               "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
+              "biolink:ThingWithTaxon"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0001529",
+              "name": "pancytopenia",
+              "description": "An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets). [HPO:probinson]; An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets).; An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets).; An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets).; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
+                "ICD9:284.1",
+                "MESH:D010198",
+                "MONDO:0001529",
+                "UMLS:C0030312",
+                "NCIT:C80693",
+                "MEDDRA:10033661",
+                "HP:0001876",
+                "DOID:12450",
+                "SNOMEDCT:127034005",
+                "NCIT:C34889",
+                "ICD10:D61.81"
               ],
-              "id": "MONDO:0011122",
+              "id": "MONDO:0001529",
               "category": "biolink:Disease",
               "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
+                "pancytopenia",
+                "Bone Marrow Failure",
+                "Pancytopenia"
               ],
               "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
+                "biolink:Disease"
               ],
               "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
+                "https://en.wikipedia.org/wiki/pancytopenia",
+                "https://orcid.org/0000-0001-5208-3432",
+                "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 23076071,
-            "start": 629,
-            "end": 318216,
-            "type": "biolink:predisposes",
+            "identity": 11472118,
+            "start": 551,
+            "end": 316682,
+            "type": "biolink:causes",
             "properties": {
-              "predicate": "biolink:predisposes",
+              "predicate": "biolink:causes",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34206160': {'publication date': '2021 Jun 22', 'sentence': 'The consumption of kelp high in alginate may contribute to preventing obesity without influencing thyroid function in Japanese subjects with a relatively high intake of iodine from seaweed.', 'subject score': 1000, 'object score': 861}}",
+              "publications_info": "{'PMID:15772324': {'publication date': '2005 Mar', 'sentence': 'The severity and duration of albendazole-induced pancytopenia in this case was likely related to the underlying liver disease.', 'subject score': 851, 'object score': 851}, 'PMID:19916998': {'publication date': '2009 Nov', 'sentence': 'ABZ side-effects are generally mild, but ABZ-induced pancytopenia may be serious.', 'subject score': 851, 'object score': 851}, 'PMID:26048870': {'publication date': '2015 Aug', 'sentence': 'Albendazole-induced cirrhosis decompensation and pancytopenia.', 'subject score': 833, 'object score': 1000}, 'PMID:31701853': {'publication date': '2019 Nov 04', 'sentence': 'In our patient, prolonged use of high-dose albendazole resulted in a significant body burden of albendazole and albendazole sulfoxide, leading to pancytopenia, transaminase elevation, and alopecia.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0102137---SEMMEDDB:predisposes---None---None---None---UMLS:C0028754---SEMMEDDB:"
+                "UMLS:C0001911---SEMMEDDB:causes---None---None---None---UMLS:C0030312---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:91666318",
-              "id": "23508922",
-              "object": "MONDO:0011122",
+              "subject": "PUBCHEM.COMPOUND:2082",
+              "id": "11722744",
+              "object": "MONDO:0001529",
               "publications": [
-                "PMID:34206160"
+                "PMID:15772324",
+                "PMID:19916998",
+                "PMID:26048870",
+                "PMID:31701853"
               ]
             }
           },
           "end": {
-            "identity": 629,
+            "identity": 551,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -514018,58 +4093,56 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "(Alginate)n",
-              "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+              "name": "Albendazole",
+              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "MESH:D000077322",
-                "UMLS:C0102137",
-                "KEGG.GLYCAN:G00316",
-                "UMLS:C0051156",
-                "KEGG.GLYCAN:G07471",
-                "KEGG.GLYCAN:G07287",
-                "KEGG.GLYCAN:G08476",
-                "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-                "DRUGBANK:DB13518",
-                "DrugCentral:4321",
-                "KEGG.DRUG:D02324",
-                "UNII:8C3Z4148WZ",
-                "KEGG.COMPOUND:C01768",
-                "CHEBI:17548",
-                "NDDF:002434",
-                "RXNORM:17305",
-                "RXNORM:1370451",
-                "NCIT:C82277",
-                "CHEMBL.COMPOUND:CHEMBL2108894",
-                "MESH:C008970",
-                "PUBCHEM.COMPOUND:91666318",
-                "ATC:A02BX13",
-                "KEGG.GLYCAN:G02561",
-                "UMLS:C4694124",
-                "KEGG.GLYCAN:G10593"
+                "KEGG.COMPOUND:C01779",
+                "UMLS:C0001911",
+                "ATC:P02CA03",
+                "NCIT:C47384",
+                "UMLS:C4082528",
+                "KEGG.DRUG:D00134",
+                "NDDF:004079",
+                "DrugCentral:103",
+                "MESH:D015766",
+                "CAS:54965-21-8",
+                "RXNORM:430",
+                "HMDB:HMDB0014659",
+                "CHEBI:16664",
+                "UNII:F4216019LN",
+                "CHEMBL.COMPOUND:CHEMBL1483",
+                "DRUGBANK:DB00518",
+                "PUBCHEM.COMPOUND:2082",
+                "UMLS:C4082752",
+                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
               ],
-              "id": "PUBCHEM.COMPOUND:91666318",
+              "id": "PUBCHEM.COMPOUND:2082",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "(Alginate)n",
-                "Alginate",
-                "Norgine",
-                "Alginic acid",
-                "Alginic acid (NF)",
-                "ALGINIC ACID",
-                "alginate",
-                "Alginic Acid",
-                "alginic acid"
+                "albendol",
+                "Albendazole",
+                "ALBENDAZOLE",
+                "Eskazole",
+                "Proftril",
+                "Albendazole (JAN/USP/INN)",
+                "albendazole"
               ],
               "all_categories": [
-                "biolink:ChemicalEntity",
                 "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:1551350",
-                "PMID:10848650",
-                "PMID:231639",
-                "PMID:27671545"
+                "PMID:28595066",
+                "PMID:20014752",
+                "PMID:15646539",
+                "PMID:17562801",
+                "PMID:8228321",
+                "PMID:15828820",
+                "PMID:23571415",
+                "PMID:33360795",
+                "PMID:19186059",
+                "PMID:16420038"
               ]
             }
           }
@@ -514079,13 +4152,9 @@
     }
   },
   {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:16556178': {'publication date': '2006 Mar 15', 'sentence': 'Combining high-dose antacid with alginate may therefore be of benefit in gastro-oesophageal reflux disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:30240968': {'publication date': '2018 Sep 18', 'sentence': 'The role of topical antacid-alginate in refractory GERD might be limited.', 'subject score': 790, 'object score': 888}}",
-    "p2": {
->>>>>>> main
+    "p3": {
       "start": {
-        "identity": 321369,
+        "identity": 315782,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -514095,70 +4164,52 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007186",
-          "name": "gastroesophageal reflux disease",
-          "description": "A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C26781\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26781\" NCI Thesaurus); A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.; Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.; A condition in which the stomach contents leak backwards from the stomach into the esophagus through the lower esophageal sphincter. [HPO:probinson]; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
+          "name": "aplastic anemia",
+          "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What causes aplastic anemia? The causes of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "ICD10:K21.9",
-            "UMLS:C4317146",
-            "NCIT:C26781",
-            "MEDDRA:10037676",
-            "PDQ:CDR0000737473",
-            "NCIT:C34670",
-            "UMLS:C3813607",
-            "MEDDRA:10066874",
-            "MEDDRA:10015389",
-            "ICD9:787.1",
-            "SNOMEDCT:698065002",
-            "UMLS:C0018834",
-            "OMIM:109350",
-            "MESH:D006356",
-            "UMLS:C0017168",
-            "DOID:8534",
-            "NCIT:C92560",
-            "SNOMEDCT:235595009",
-            "MEDDRA:10019326",
-            "HP:0002020",
-            "MEDDRA:10018203",
-            "MESH:D005764",
-            "MEDDRA:10017924",
-            "MEDDRA:10030182",
-            "SNOMEDCT:722884003",
-            "MONDO:0007186",
-            "ICD9:530.81",
-            "EFO:0003948",
-            "MEDDRA:10017884",
-            "MEDDRA:10017885",
-            "SNOMEDCT:16331000",
-            "NCIT:C113396"
+            "MONDO:0015909",
+            "MEDDRA:10002037",
+            "HP:0001915",
+            "MEDDRA:10002967",
+            "MEDDRA:10002274",
+            "MEDDRA:10002969",
+            "MESH:D000741",
+            "SNOMEDCT:306058006",
+            "PDQ:CDR0000489004",
+            "NCIT:C2870",
+            "MEDDRA:10002968",
+            "DOID:12449",
+            "MEDDRA:10002970",
+            "ICD9:284.9",
+            "SNOMEDCT:304132006",
+            "UMLS:C0002874",
+            "ICD10:D61.9",
+            "ORPHANET:182040"
           ],
-          "id": "MONDO:0007186",
+          "id": "MONDO:0015909",
           "category": "biolink:Disease",
           "all_names": [
-            "Gastroesophageal Reflux Disease",
-            "Acid reflux",
-            "Gastroesophageal reflux",
-            "Esophageal reflux",
-            "Gastroesophageal Reflux",
-            "Gastroesophageal reflux disease",
-            "Infantile Gastroesophageal Reflux",
-            "gastroesophageal reflux disease",
-            "Gastroesophageal reflux related phenotypic feature",
-            "Heartburn"
+            "aplastic anemia",
+            "Aplastic Anemia",
+            "Aplastic anemia",
+            "Aplastic anemia, unspecified",
+            "obsolete_Medullar aplasia",
+            "Anemia, Aplastic"
           ],
           "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
+            "biolink:Disease"
           ],
           "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-5316-1399"
+            "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
+            "http://en.wikipedia.org/wiki/aplastic_anemia",
+            "PMID:21239768",
+            "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 629,
+        "identity": 551,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -514175,65 +4226,63 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "(Alginate)n",
-          "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+          "name": "Albendazole",
+          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "MESH:D000077322",
-            "UMLS:C0102137",
-            "KEGG.GLYCAN:G00316",
-            "UMLS:C0051156",
-            "KEGG.GLYCAN:G07471",
-            "KEGG.GLYCAN:G07287",
-            "KEGG.GLYCAN:G08476",
-            "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-            "DRUGBANK:DB13518",
-            "DrugCentral:4321",
-            "KEGG.DRUG:D02324",
-            "UNII:8C3Z4148WZ",
-            "KEGG.COMPOUND:C01768",
-            "CHEBI:17548",
-            "NDDF:002434",
-            "RXNORM:17305",
-            "RXNORM:1370451",
-            "NCIT:C82277",
-            "CHEMBL.COMPOUND:CHEMBL2108894",
-            "MESH:C008970",
-            "PUBCHEM.COMPOUND:91666318",
-            "ATC:A02BX13",
-            "KEGG.GLYCAN:G02561",
-            "UMLS:C4694124",
-            "KEGG.GLYCAN:G10593"
+            "KEGG.COMPOUND:C01779",
+            "UMLS:C0001911",
+            "ATC:P02CA03",
+            "NCIT:C47384",
+            "UMLS:C4082528",
+            "KEGG.DRUG:D00134",
+            "NDDF:004079",
+            "DrugCentral:103",
+            "MESH:D015766",
+            "CAS:54965-21-8",
+            "RXNORM:430",
+            "HMDB:HMDB0014659",
+            "CHEBI:16664",
+            "UNII:F4216019LN",
+            "CHEMBL.COMPOUND:CHEMBL1483",
+            "DRUGBANK:DB00518",
+            "PUBCHEM.COMPOUND:2082",
+            "UMLS:C4082752",
+            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
           ],
-          "id": "PUBCHEM.COMPOUND:91666318",
+          "id": "PUBCHEM.COMPOUND:2082",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "(Alginate)n",
-            "Alginate",
-            "Norgine",
-            "Alginic acid",
-            "Alginic acid (NF)",
-            "ALGINIC ACID",
-            "alginate",
-            "Alginic Acid",
-            "alginic acid"
+            "albendol",
+            "Albendazole",
+            "ALBENDAZOLE",
+            "Eskazole",
+            "Proftril",
+            "Albendazole (JAN/USP/INN)",
+            "albendazole"
           ],
           "all_categories": [
-            "biolink:ChemicalEntity",
             "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:1551350",
-            "PMID:10848650",
-            "PMID:231639",
-            "PMID:27671545"
+            "PMID:28595066",
+            "PMID:20014752",
+            "PMID:15646539",
+            "PMID:17562801",
+            "PMID:8228321",
+            "PMID:15828820",
+            "PMID:23571415",
+            "PMID:33360795",
+            "PMID:19186059",
+            "PMID:16420038"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 321369,
+            "identity": 315782,
             "labels": [
               "biolink:NamedThing",
               "biolink:ThingWithTaxon",
@@ -514243,92 +4292,73 @@
               "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007186",
-              "name": "gastroesophageal reflux disease",
-              "description": "A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C26781\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26781\" NCI Thesaurus); A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.; Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.; A condition in which the stomach contents leak backwards from the stomach into the esophagus through the lower esophageal sphincter. [HPO:probinson]; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
+              "name": "aplastic anemia",
+              "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What causes aplastic anemia? The causes of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "ICD10:K21.9",
-                "UMLS:C4317146",
-                "NCIT:C26781",
-                "MEDDRA:10037676",
-                "PDQ:CDR0000737473",
-                "NCIT:C34670",
-                "UMLS:C3813607",
-                "MEDDRA:10066874",
-                "MEDDRA:10015389",
-                "ICD9:787.1",
-                "SNOMEDCT:698065002",
-                "UMLS:C0018834",
-                "OMIM:109350",
-                "MESH:D006356",
-                "UMLS:C0017168",
-                "DOID:8534",
-                "NCIT:C92560",
-                "SNOMEDCT:235595009",
-                "MEDDRA:10019326",
-                "HP:0002020",
-                "MEDDRA:10018203",
-                "MESH:D005764",
-                "MEDDRA:10017924",
-                "MEDDRA:10030182",
-                "SNOMEDCT:722884003",
-                "MONDO:0007186",
-                "ICD9:530.81",
-                "EFO:0003948",
-                "MEDDRA:10017884",
-                "MEDDRA:10017885",
-                "SNOMEDCT:16331000",
-                "NCIT:C113396"
+                "MONDO:0015909",
+                "MEDDRA:10002037",
+                "HP:0001915",
+                "MEDDRA:10002967",
+                "MEDDRA:10002274",
+                "MEDDRA:10002969",
+                "MESH:D000741",
+                "SNOMEDCT:306058006",
+                "PDQ:CDR0000489004",
+                "NCIT:C2870",
+                "MEDDRA:10002968",
+                "DOID:12449",
+                "MEDDRA:10002970",
+                "ICD9:284.9",
+                "SNOMEDCT:304132006",
+                "UMLS:C0002874",
+                "ICD10:D61.9",
+                "ORPHANET:182040"
               ],
-              "id": "MONDO:0007186",
+              "id": "MONDO:0015909",
               "category": "biolink:Disease",
               "all_names": [
-                "Gastroesophageal Reflux Disease",
-                "Acid reflux",
-                "Gastroesophageal reflux",
-                "Esophageal reflux",
-                "Gastroesophageal Reflux",
-                "Gastroesophageal reflux disease",
-                "Infantile Gastroesophageal Reflux",
-                "gastroesophageal reflux disease",
-                "Gastroesophageal reflux related phenotypic feature",
-                "Heartburn"
+                "aplastic anemia",
+                "Aplastic Anemia",
+                "Aplastic anemia",
+                "Aplastic anemia, unspecified",
+                "obsolete_Medullar aplasia",
+                "Anemia, Aplastic"
               ],
               "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
+                "biolink:Disease"
               ],
               "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-5316-1399"
+                "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
+                "http://en.wikipedia.org/wiki/aplastic_anemia",
+                "PMID:21239768",
+                "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 12106243,
-            "start": 629,
-            "end": 321369,
-            "type": "biolink:related_to",
+            "identity": 26705848,
+            "start": 551,
+            "end": 315782,
+            "type": "biolink:treats",
             "properties": {
-              "predicate": "biolink:related_to",
+              "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:16556178': {'publication date': '2006 Mar 15', 'sentence': 'Combining high-dose antacid with alginate may therefore be of benefit in gastro-oesophageal reflux disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:30240968': {'publication date': '2018 Sep 18', 'sentence': 'The role of topical antacid-alginate in refractory GERD might be limited.', 'subject score': 790, 'object score': 888}}",
+              "publications_info": "{'PMID:8813106': {'publication date': '1996 Sep', 'sentence': 'Aplastic anemia during treatment with albendazole.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0102137---SEMMEDDB:associated_with---None---None---None---UMLS:C0017168---SEMMEDDB:"
+                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0002874---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:91666318",
-              "id": "12376615",
-              "object": "MONDO:0007186",
+              "subject": "PUBCHEM.COMPOUND:2082",
+              "id": "27186232",
+              "object": "MONDO:0015909",
               "publications": [
-                "PMID:16556178",
-                "PMID:30240968"
+                "PMID:8813106"
               ]
             }
           },
           "end": {
-            "identity": 629,
+            "identity": 551,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -514345,58 +4375,56 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "(Alginate)n",
-              "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+              "name": "Albendazole",
+              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "MESH:D000077322",
-                "UMLS:C0102137",
-                "KEGG.GLYCAN:G00316",
-                "UMLS:C0051156",
-                "KEGG.GLYCAN:G07471",
-                "KEGG.GLYCAN:G07287",
-                "KEGG.GLYCAN:G08476",
-                "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-                "DRUGBANK:DB13518",
-                "DrugCentral:4321",
-                "KEGG.DRUG:D02324",
-                "UNII:8C3Z4148WZ",
-                "KEGG.COMPOUND:C01768",
-                "CHEBI:17548",
-                "NDDF:002434",
-                "RXNORM:17305",
-                "RXNORM:1370451",
-                "NCIT:C82277",
-                "CHEMBL.COMPOUND:CHEMBL2108894",
-                "MESH:C008970",
-                "PUBCHEM.COMPOUND:91666318",
-                "ATC:A02BX13",
-                "KEGG.GLYCAN:G02561",
-                "UMLS:C4694124",
-                "KEGG.GLYCAN:G10593"
+                "KEGG.COMPOUND:C01779",
+                "UMLS:C0001911",
+                "ATC:P02CA03",
+                "NCIT:C47384",
+                "UMLS:C4082528",
+                "KEGG.DRUG:D00134",
+                "NDDF:004079",
+                "DrugCentral:103",
+                "MESH:D015766",
+                "CAS:54965-21-8",
+                "RXNORM:430",
+                "HMDB:HMDB0014659",
+                "CHEBI:16664",
+                "UNII:F4216019LN",
+                "CHEMBL.COMPOUND:CHEMBL1483",
+                "DRUGBANK:DB00518",
+                "PUBCHEM.COMPOUND:2082",
+                "UMLS:C4082752",
+                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
               ],
-              "id": "PUBCHEM.COMPOUND:91666318",
+              "id": "PUBCHEM.COMPOUND:2082",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "(Alginate)n",
-                "Alginate",
-                "Norgine",
-                "Alginic acid",
-                "Alginic acid (NF)",
-                "ALGINIC ACID",
-                "alginate",
-                "Alginic Acid",
-                "alginic acid"
+                "albendol",
+                "Albendazole",
+                "ALBENDAZOLE",
+                "Eskazole",
+                "Proftril",
+                "Albendazole (JAN/USP/INN)",
+                "albendazole"
               ],
               "all_categories": [
-                "biolink:ChemicalEntity",
                 "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:1551350",
-                "PMID:10848650",
-                "PMID:231639",
-                "PMID:27671545"
+                "PMID:28595066",
+                "PMID:20014752",
+                "PMID:15646539",
+                "PMID:17562801",
+                "PMID:8228321",
+                "PMID:15828820",
+                "PMID:23571415",
+                "PMID:33360795",
+                "PMID:19186059",
+                "PMID:16420038"
               ]
             }
           }
@@ -514406,10 +4434,9 @@
     }
   },
   {
-<<<<<<< HEAD
     "p3": {
       "start": {
-        "identity": 523273,
+        "identity": 520731,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -514419,46 +4446,46 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009061",
-          "name": "cystic fibrosis",
-          "description": "A congenital, autosomal, metabolic disorder affecting the exocrine glands. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production that causes obstruction of passageways, including pancreatic and bile ducts, intestines, and bronchi. Symptoms usually appear in childhood, and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather secondary to increased sodium and chloride concentration in sweat.; An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0018408",
+          "name": "cystic echinococcosis",
+          "description": "An echinococcosis that is caused by the larvae of Echinococcus granulosus. Hepatic involvement can result in abdominal pain, a mass in the hepatic area, and biliary duct obstruction. Pulmonary involvement can produce chest pain, cough, and hemoptysis. Rupture of the cysts produce fever, urticaria, eosinophilia, and anaphylactic shock, as well as cyst dissemination. Brain, bone, heart can also be infected.",
           "equivalent_curies": [
-            "MESH:D003550",
-            "SNOMEDCT:190905008",
-            "UMLS:C0010674",
-            "NCIT:C2975",
-            "MEDDRA:10011762",
-            "ORPHANET:586",
-            "DOID:1485",
-            "MEDDRA:10011764",
-            "ICD9:277.0",
-            "MEDDRA:10028141",
-            "PSY:12915",
-            "MONDO:0009061",
-            "OMIM:219700",
-            "ICD10:E84"
+            "ICD9:122.4",
+            "ORPHANET:400",
+            "UMLS:C4553297",
+            "ICD9:122.2",
+            "UMLS:C0153290",
+            "MONDO:0018408",
+            "SNOMEDCT:65963007",
+            "SNOMEDCT:75388006",
+            "MEDDRA:10014102",
+            "ICD9:122.1",
+            "DOID:1495",
+            "UMLS:C0153291",
+            "SNOMEDCT:721822004",
+            "MEDDRA:10014103",
+            "ICD10:B67.4"
           ],
-          "id": "MONDO:0009061",
+          "id": "MONDO:0018408",
           "category": "biolink:Disease",
           "all_names": [
-            "Cystic Fibrosis",
-            "cystic fibrosis",
-            "obsolete_cystic fibrosis",
-            "Cystic fibrosis related phenotypic feature",
-            "Cystic fibrosis"
+            "Echinococcus granulosus infection, unspecified",
+            "Echinococcus granulosus infection of thyroid",
+            "Cystic Echinocccosis",
+            "Cystic echinococcosis",
+            "Echinococcus granulosus infection of lung",
+            "cystic echinococcosis"
           ],
           "all_categories": [
             "biolink:Disease"
           ],
           "publications": [
-            "http://ghr.nlm.nih.gov/condition/cystic-fibrosis",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/cf/",
-            "http://en.wikipedia.org/wiki/cystic_fibrosis"
+            "http://www.who.int/mediacentre/factsheets/fs377/en/"
           ]
         }
       },
       "end": {
-        "identity": 629,
+        "identity": 551,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -514475,139 +4502,136 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "(Alginate)n",
-          "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+          "name": "Albendazole",
+          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "MESH:D000077322",
-            "UMLS:C0102137",
-            "KEGG.GLYCAN:G00316",
-            "UMLS:C0051156",
-            "KEGG.GLYCAN:G07471",
-            "KEGG.GLYCAN:G07287",
-            "KEGG.GLYCAN:G08476",
-            "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-            "DRUGBANK:DB13518",
-            "DrugCentral:4321",
-            "KEGG.DRUG:D02324",
-            "UNII:8C3Z4148WZ",
-            "KEGG.COMPOUND:C01768",
-            "CHEBI:17548",
-            "NDDF:002434",
-            "RXNORM:17305",
-            "RXNORM:1370451",
-            "NCIT:C82277",
-            "CHEMBL.COMPOUND:CHEMBL2108894",
-            "MESH:C008970",
-            "PUBCHEM.COMPOUND:91666318",
-            "ATC:A02BX13",
-            "KEGG.GLYCAN:G02561",
-            "UMLS:C4694124",
-            "KEGG.GLYCAN:G10593"
+            "KEGG.COMPOUND:C01779",
+            "UMLS:C0001911",
+            "ATC:P02CA03",
+            "NCIT:C47384",
+            "UMLS:C4082528",
+            "KEGG.DRUG:D00134",
+            "NDDF:004079",
+            "DrugCentral:103",
+            "MESH:D015766",
+            "CAS:54965-21-8",
+            "RXNORM:430",
+            "HMDB:HMDB0014659",
+            "CHEBI:16664",
+            "UNII:F4216019LN",
+            "CHEMBL.COMPOUND:CHEMBL1483",
+            "DRUGBANK:DB00518",
+            "PUBCHEM.COMPOUND:2082",
+            "UMLS:C4082752",
+            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
           ],
-          "id": "PUBCHEM.COMPOUND:91666318",
+          "id": "PUBCHEM.COMPOUND:2082",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "(Alginate)n",
-            "Alginate",
-            "Norgine",
-            "Alginic acid",
-            "Alginic acid (NF)",
-            "ALGINIC ACID",
-            "alginate",
-            "Alginic Acid",
-            "alginic acid"
+            "albendol",
+            "Albendazole",
+            "ALBENDAZOLE",
+            "Eskazole",
+            "Proftril",
+            "Albendazole (JAN/USP/INN)",
+            "albendazole"
           ],
           "all_categories": [
-            "biolink:ChemicalEntity",
             "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:1551350",
-            "PMID:10848650",
-            "PMID:231639",
-            "PMID:27671545"
+            "PMID:28595066",
+            "PMID:20014752",
+            "PMID:15646539",
+            "PMID:17562801",
+            "PMID:8228321",
+            "PMID:15828820",
+            "PMID:23571415",
+            "PMID:33360795",
+            "PMID:19186059",
+            "PMID:16420038"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 523273,
+            "identity": 520731,
             "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:NamedThing",
+              "biolink:PhenotypicFeature",
+              "biolink:ThingWithTaxon"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009061",
-              "name": "cystic fibrosis",
-              "description": "A congenital, autosomal, metabolic disorder affecting the exocrine glands. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production that causes obstruction of passageways, including pancreatic and bile ducts, intestines, and bronchi. Symptoms usually appear in childhood, and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather secondary to increased sodium and chloride concentration in sweat.; An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0018408",
+              "name": "cystic echinococcosis",
+              "description": "An echinococcosis that is caused by the larvae of Echinococcus granulosus. Hepatic involvement can result in abdominal pain, a mass in the hepatic area, and biliary duct obstruction. Pulmonary involvement can produce chest pain, cough, and hemoptysis. Rupture of the cysts produce fever, urticaria, eosinophilia, and anaphylactic shock, as well as cyst dissemination. Brain, bone, heart can also be infected.",
               "equivalent_curies": [
-                "MESH:D003550",
-                "SNOMEDCT:190905008",
-                "UMLS:C0010674",
-                "NCIT:C2975",
-                "MEDDRA:10011762",
-                "ORPHANET:586",
-                "DOID:1485",
-                "MEDDRA:10011764",
-                "ICD9:277.0",
-                "MEDDRA:10028141",
-                "PSY:12915",
-                "MONDO:0009061",
-                "OMIM:219700",
-                "ICD10:E84"
+                "ICD9:122.4",
+                "ORPHANET:400",
+                "UMLS:C4553297",
+                "ICD9:122.2",
+                "UMLS:C0153290",
+                "MONDO:0018408",
+                "SNOMEDCT:65963007",
+                "SNOMEDCT:75388006",
+                "MEDDRA:10014102",
+                "ICD9:122.1",
+                "DOID:1495",
+                "UMLS:C0153291",
+                "SNOMEDCT:721822004",
+                "MEDDRA:10014103",
+                "ICD10:B67.4"
               ],
-              "id": "MONDO:0009061",
+              "id": "MONDO:0018408",
               "category": "biolink:Disease",
               "all_names": [
-                "Cystic Fibrosis",
-                "cystic fibrosis",
-                "obsolete_cystic fibrosis",
-                "Cystic fibrosis related phenotypic feature",
-                "Cystic fibrosis"
+                "Echinococcus granulosus infection, unspecified",
+                "Echinococcus granulosus infection of thyroid",
+                "Cystic Echinocccosis",
+                "Cystic echinococcosis",
+                "Echinococcus granulosus infection of lung",
+                "cystic echinococcosis"
               ],
               "all_categories": [
                 "biolink:Disease"
               ],
               "publications": [
-                "http://ghr.nlm.nih.gov/condition/cystic-fibrosis",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/cf/",
-                "http://en.wikipedia.org/wiki/cystic_fibrosis"
+                "http://www.who.int/mediacentre/factsheets/fs377/en/"
               ]
             }
           },
           "relationship": {
-            "identity": 11503602,
-            "start": 629,
-            "end": 523273,
-            "type": "biolink:related_to",
+            "identity": 22441444,
+            "start": 551,
+            "end": 520731,
+            "type": "biolink:treats",
             "properties": {
-              "predicate": "biolink:related_to",
+              "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1581041': {'publication date': '1992 Apr', 'sentence': 'Mucosal immunity to Pseudomonas aeruginosa alginate in cystic fibrosis.', 'subject score': 901, 'object score': 1000}, 'PMID:15813726': {'publication date': '2005 Apr', 'sentence': 'Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis.', 'subject score': 861, 'object score': 1000}, 'PMID:18174130': {'publication date': '2008 Jan', 'sentence': 'In some of the CF isolates these mutations are associated with moderate alginate production.', 'subject score': 790, 'object score': 1000}, 'PMID:19168621': {'publication date': '2009 Apr', 'sentence': 'Mucoidy, or overproduction of the exopolysaccharide known as alginate, in Pseudomonas aeruginosa is a poor prognosticator for lung infections in cystic fibrosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:8312973': {'publication date': '1993', 'sentence': 'Pseudomonas aeruginosa mutants that overproduce the exopolysaccharide alginate and assume mucoid phenotype are associated with the establishment of chronic respiratory disease in cystic fibrosis.', 'subject score': 861, 'object score': 1000}}",
+              "publications_info": "{'PMID:33383141': {'publication date': '2020 Dec 28', 'sentence': 'For CE, long-time albendazole treatment is often needed, which requires regular follow-up.', 'subject score': 833, 'object score': 1000}, 'PMID:34353029': {'publication date': '2021 Aug 05', 'sentence': 'This could be beneficial to improve the efficacy of ABZ in CE treatment.', 'subject score': 1000, 'object score': 901}, 'PMID:35126583': {'publication date': '2021', 'sentence': 'Hence, ZMEO may be considered as an alternative for albendazole in the medical treatment of liver CE.', 'subject score': 1000, 'object score': 901}, 'PMID:36459040': {'publication date': '2022 Nov', 'sentence': 'This study aimed at determining the clinical tolerance and efficacy of albendazole in patients with cystic echinococcosis, depending on the volume of the previous one.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0102137---SEMMEDDB:associated_with---None---None---None---UMLS:C0010674---SEMMEDDB:"
+                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C4553297---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:91666318",
-              "id": "11754791",
-              "object": "MONDO:0009061",
+              "subject": "PUBCHEM.COMPOUND:2082",
+              "id": "22868732",
+              "object": "MONDO:0018408",
               "publications": [
-                "PMID:1581041",
-                "PMID:15813726",
-                "PMID:18174130",
-                "PMID:19168621",
-                "PMID:8312973"
+                "PMID:33383141",
+                "PMID:34353029",
+                "PMID:35126583",
+                "PMID:36459040"
               ]
             }
           },
           "end": {
-            "identity": 629,
+            "identity": 551,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -514624,58 +4648,56 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "(Alginate)n",
-              "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+              "name": "Albendazole",
+              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "MESH:D000077322",
-                "UMLS:C0102137",
-                "KEGG.GLYCAN:G00316",
-                "UMLS:C0051156",
-                "KEGG.GLYCAN:G07471",
-                "KEGG.GLYCAN:G07287",
-                "KEGG.GLYCAN:G08476",
-                "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-                "DRUGBANK:DB13518",
-                "DrugCentral:4321",
-                "KEGG.DRUG:D02324",
-                "UNII:8C3Z4148WZ",
-                "KEGG.COMPOUND:C01768",
-                "CHEBI:17548",
-                "NDDF:002434",
-                "RXNORM:17305",
-                "RXNORM:1370451",
-                "NCIT:C82277",
-                "CHEMBL.COMPOUND:CHEMBL2108894",
-                "MESH:C008970",
-                "PUBCHEM.COMPOUND:91666318",
-                "ATC:A02BX13",
-                "KEGG.GLYCAN:G02561",
-                "UMLS:C4694124",
-                "KEGG.GLYCAN:G10593"
+                "KEGG.COMPOUND:C01779",
+                "UMLS:C0001911",
+                "ATC:P02CA03",
+                "NCIT:C47384",
+                "UMLS:C4082528",
+                "KEGG.DRUG:D00134",
+                "NDDF:004079",
+                "DrugCentral:103",
+                "MESH:D015766",
+                "CAS:54965-21-8",
+                "RXNORM:430",
+                "HMDB:HMDB0014659",
+                "CHEBI:16664",
+                "UNII:F4216019LN",
+                "CHEMBL.COMPOUND:CHEMBL1483",
+                "DRUGBANK:DB00518",
+                "PUBCHEM.COMPOUND:2082",
+                "UMLS:C4082752",
+                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
               ],
-              "id": "PUBCHEM.COMPOUND:91666318",
+              "id": "PUBCHEM.COMPOUND:2082",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "(Alginate)n",
-                "Alginate",
-                "Norgine",
-                "Alginic acid",
-                "Alginic acid (NF)",
-                "ALGINIC ACID",
-                "alginate",
-                "Alginic Acid",
-                "alginic acid"
+                "albendol",
+                "Albendazole",
+                "ALBENDAZOLE",
+                "Eskazole",
+                "Proftril",
+                "Albendazole (JAN/USP/INN)",
+                "albendazole"
               ],
               "all_categories": [
-                "biolink:ChemicalEntity",
                 "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:1551350",
-                "PMID:10848650",
-                "PMID:231639",
-                "PMID:27671545"
+                "PMID:28595066",
+                "PMID:20014752",
+                "PMID:15646539",
+                "PMID:17562801",
+                "PMID:8228321",
+                "PMID:15828820",
+                "PMID:23571415",
+                "PMID:33360795",
+                "PMID:19186059",
+                "PMID:16420038"
               ]
             }
           }
@@ -514687,63 +4709,51 @@
   {
     "p3": {
       "start": {
-        "identity": 318216,
+        "identity": 316682,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
           "biolink:BiologicalEntity",
           "biolink:Disease",
           "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
+          "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0001529",
+          "name": "pancytopenia",
+          "description": "An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets). [HPO:probinson]; An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets).; An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets).; An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets).; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
+            "ICD9:284.1",
+            "MESH:D010198",
+            "MONDO:0001529",
+            "UMLS:C0030312",
+            "NCIT:C80693",
+            "MEDDRA:10033661",
+            "HP:0001876",
+            "DOID:12450",
+            "SNOMEDCT:127034005",
+            "NCIT:C34889",
+            "ICD10:D61.81"
           ],
-          "id": "MONDO:0011122",
+          "id": "MONDO:0001529",
           "category": "biolink:Disease",
           "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
+            "pancytopenia",
+            "Bone Marrow Failure",
+            "Pancytopenia"
           ],
           "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
+            "biolink:Disease"
           ],
           "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
+            "https://en.wikipedia.org/wiki/pancytopenia",
+            "https://orcid.org/0000-0001-5208-3432",
+            "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 629,
+        "identity": 551,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -514760,142 +4770,128 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "(Alginate)n",
-          "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+          "name": "Albendazole",
+          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "MESH:D000077322",
-            "UMLS:C0102137",
-            "KEGG.GLYCAN:G00316",
-            "UMLS:C0051156",
-            "KEGG.GLYCAN:G07471",
-            "KEGG.GLYCAN:G07287",
-            "KEGG.GLYCAN:G08476",
-            "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-            "DRUGBANK:DB13518",
-            "DrugCentral:4321",
-            "KEGG.DRUG:D02324",
-            "UNII:8C3Z4148WZ",
-            "KEGG.COMPOUND:C01768",
-            "CHEBI:17548",
-            "NDDF:002434",
-            "RXNORM:17305",
-            "RXNORM:1370451",
-            "NCIT:C82277",
-            "CHEMBL.COMPOUND:CHEMBL2108894",
-            "MESH:C008970",
-            "PUBCHEM.COMPOUND:91666318",
-            "ATC:A02BX13",
-            "KEGG.GLYCAN:G02561",
-            "UMLS:C4694124",
-            "KEGG.GLYCAN:G10593"
+            "KEGG.COMPOUND:C01779",
+            "UMLS:C0001911",
+            "ATC:P02CA03",
+            "NCIT:C47384",
+            "UMLS:C4082528",
+            "KEGG.DRUG:D00134",
+            "NDDF:004079",
+            "DrugCentral:103",
+            "MESH:D015766",
+            "CAS:54965-21-8",
+            "RXNORM:430",
+            "HMDB:HMDB0014659",
+            "CHEBI:16664",
+            "UNII:F4216019LN",
+            "CHEMBL.COMPOUND:CHEMBL1483",
+            "DRUGBANK:DB00518",
+            "PUBCHEM.COMPOUND:2082",
+            "UMLS:C4082752",
+            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
           ],
-          "id": "PUBCHEM.COMPOUND:91666318",
+          "id": "PUBCHEM.COMPOUND:2082",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "(Alginate)n",
-            "Alginate",
-            "Norgine",
-            "Alginic acid",
-            "Alginic acid (NF)",
-            "ALGINIC ACID",
-            "alginate",
-            "Alginic Acid",
-            "alginic acid"
+            "albendol",
+            "Albendazole",
+            "ALBENDAZOLE",
+            "Eskazole",
+            "Proftril",
+            "Albendazole (JAN/USP/INN)",
+            "albendazole"
           ],
           "all_categories": [
-            "biolink:ChemicalEntity",
             "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:1551350",
-            "PMID:10848650",
-            "PMID:231639",
-            "PMID:27671545"
+            "PMID:28595066",
+            "PMID:20014752",
+            "PMID:15646539",
+            "PMID:17562801",
+            "PMID:8228321",
+            "PMID:15828820",
+            "PMID:23571415",
+            "PMID:33360795",
+            "PMID:19186059",
+            "PMID:16420038"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 318216,
+            "identity": 316682,
             "labels": [
               "biolink:NamedThing",
               "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0001529",
+              "name": "pancytopenia",
+              "description": "An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets). [HPO:probinson]; An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets).; An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets).; An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets).; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
+                "ICD9:284.1",
+                "MESH:D010198",
+                "MONDO:0001529",
+                "UMLS:C0030312",
+                "NCIT:C80693",
+                "MEDDRA:10033661",
+                "HP:0001876",
+                "DOID:12450",
+                "SNOMEDCT:127034005",
+                "NCIT:C34889",
+                "ICD10:D61.81"
               ],
-              "id": "MONDO:0011122",
+              "id": "MONDO:0001529",
               "category": "biolink:Disease",
               "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
+                "pancytopenia",
+                "Bone Marrow Failure",
+                "Pancytopenia"
               ],
               "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
+                "biolink:Disease"
               ],
               "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
+                "https://en.wikipedia.org/wiki/pancytopenia",
+                "https://orcid.org/0000-0001-5208-3432",
+                "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 10371021,
-            "start": 629,
-            "end": 318216,
-            "type": "biolink:related_to",
+            "identity": 20023294,
+            "start": 551,
+            "end": 316682,
+            "type": "biolink:treats",
             "properties": {
-              "predicate": "biolink:related_to",
+              "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:13727961': {'publication date': '1961 Apr 01', 'sentence': '[Alginate--skimmed milk mixture as an aid in obesity].', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:29942764': {'publication date': '2018', 'sentence': 'One of the 7 patients, with underlying IgG4 sclerosing cholangitis and secondary biliary cirrhosis was on immunosuppressives and developed severe pancytopenia 15 days after albendazole treatment.', 'subject score': 888, 'object score': 740}}",
               "kg2_ids": [
-                "UMLS:C0102137---SEMMEDDB:associated_with---None---None---None---UMLS:C0028754---SEMMEDDB:"
+                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0030312---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:91666318",
-              "id": "10599430",
-              "object": "MONDO:0011122",
+              "subject": "PUBCHEM.COMPOUND:2082",
+              "id": "20420369",
+              "object": "MONDO:0001529",
               "publications": [
-                "PMID:13727961"
+                "PMID:29942764"
               ]
             }
           },
           "end": {
-            "identity": 629,
+            "identity": 551,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -514912,58 +4908,56 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "(Alginate)n",
-              "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+              "name": "Albendazole",
+              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "MESH:D000077322",
-                "UMLS:C0102137",
-                "KEGG.GLYCAN:G00316",
-                "UMLS:C0051156",
-                "KEGG.GLYCAN:G07471",
-                "KEGG.GLYCAN:G07287",
-                "KEGG.GLYCAN:G08476",
-                "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-                "DRUGBANK:DB13518",
-                "DrugCentral:4321",
-                "KEGG.DRUG:D02324",
-                "UNII:8C3Z4148WZ",
-                "KEGG.COMPOUND:C01768",
-                "CHEBI:17548",
-                "NDDF:002434",
-                "RXNORM:17305",
-                "RXNORM:1370451",
-                "NCIT:C82277",
-                "CHEMBL.COMPOUND:CHEMBL2108894",
-                "MESH:C008970",
-                "PUBCHEM.COMPOUND:91666318",
-                "ATC:A02BX13",
-                "KEGG.GLYCAN:G02561",
-                "UMLS:C4694124",
-                "KEGG.GLYCAN:G10593"
+                "KEGG.COMPOUND:C01779",
+                "UMLS:C0001911",
+                "ATC:P02CA03",
+                "NCIT:C47384",
+                "UMLS:C4082528",
+                "KEGG.DRUG:D00134",
+                "NDDF:004079",
+                "DrugCentral:103",
+                "MESH:D015766",
+                "CAS:54965-21-8",
+                "RXNORM:430",
+                "HMDB:HMDB0014659",
+                "CHEBI:16664",
+                "UNII:F4216019LN",
+                "CHEMBL.COMPOUND:CHEMBL1483",
+                "DRUGBANK:DB00518",
+                "PUBCHEM.COMPOUND:2082",
+                "UMLS:C4082752",
+                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
               ],
-              "id": "PUBCHEM.COMPOUND:91666318",
+              "id": "PUBCHEM.COMPOUND:2082",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "(Alginate)n",
-                "Alginate",
-                "Norgine",
-                "Alginic acid",
-                "Alginic acid (NF)",
-                "ALGINIC ACID",
-                "alginate",
-                "Alginic Acid",
-                "alginic acid"
+                "albendol",
+                "Albendazole",
+                "ALBENDAZOLE",
+                "Eskazole",
+                "Proftril",
+                "Albendazole (JAN/USP/INN)",
+                "albendazole"
               ],
               "all_categories": [
-                "biolink:ChemicalEntity",
                 "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:1551350",
-                "PMID:10848650",
-                "PMID:231639",
-                "PMID:27671545"
+                "PMID:28595066",
+                "PMID:20014752",
+                "PMID:15646539",
+                "PMID:17562801",
+                "PMID:8228321",
+                "PMID:15828820",
+                "PMID:23571415",
+                "PMID:33360795",
+                "PMID:19186059",
+                "PMID:16420038"
               ]
             }
           }
@@ -514975,7 +4969,7 @@
   {
     "p3": {
       "start": {
-        "identity": 523273,
+        "identity": 307890,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -514985,46 +4979,53 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0009061",
-          "name": "cystic fibrosis",
-          "description": "A congenital, autosomal, metabolic disorder affecting the exocrine glands. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production that causes obstruction of passageways, including pancreatic and bile ducts, intestines, and bronchi. Symptoms usually appear in childhood, and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather secondary to increased sodium and chloride concentration in sweat.; An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005154",
+          "name": "liver disorder",
+          "description": "A non-neoplastic or neoplastic disorder that affects the liver parenchyma and intrahepatic bile ducts. Representative examples of non-neoplastic disorders include hepatitis, cirrhosis, cholangitis, and polycystic liver disease. Representative examples of neoplastic disorders include hepatocellular adenoma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, lymphoma, and angiosarcoma.; Pathological processes of the LIVER.; Reduced ability of the liver to perform its functions. [HPO:probinson]; An abnormality of the liver. [HPO:probinson]; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "MESH:D003550",
-            "SNOMEDCT:190905008",
-            "UMLS:C0010674",
-            "NCIT:C2975",
-            "MEDDRA:10011762",
-            "ORPHANET:586",
-            "DOID:1485",
-            "MEDDRA:10011764",
-            "ICD9:277.0",
-            "MEDDRA:10028141",
-            "PSY:12915",
-            "MONDO:0009061",
-            "OMIM:219700",
-            "ICD10:E84"
+            "HP:0001392",
+            "MEDDRA:10019650",
+            "MEDDRA:10059616",
+            "MONDO:0005154",
+            "SNOMEDCT:235856003",
+            "MEDDRA:10019652",
+            "EFO:0001421",
+            "ICD9:573.9",
+            "MEDDRA:10019653",
+            "DOID:409",
+            "MEDDRA:10045808",
+            "NCIT:C3196",
+            "MEDDRA:10013107",
+            "MEDDRA:10024670",
+            "UMLS:C4021780",
+            "MEDDRA:10013228",
+            "ICD10:K76.9",
+            "MEDDRA:10013234",
+            "UMLS:C0023895",
+            "MESH:D008107"
           ],
-          "id": "MONDO:0009061",
+          "id": "MONDO:0005154",
           "category": "biolink:Disease",
           "all_names": [
-            "Cystic Fibrosis",
-            "cystic fibrosis",
-            "obsolete_cystic fibrosis",
-            "Cystic fibrosis related phenotypic feature",
-            "Cystic fibrosis"
+            "Liver and Intrahepatic Bile Duct Disorder",
+            "liver disorder",
+            "Abnormality of the liver",
+            "Liver Diseases",
+            "liver disease",
+            "Liver diseases",
+            "Unspecified disorder of liver"
           ],
           "all_categories": [
             "biolink:Disease"
           ],
           "publications": [
-            "http://ghr.nlm.nih.gov/condition/cystic-fibrosis",
-            "http://www.nhlbi.nih.gov/health/health-topics/topics/cf/",
-            "http://en.wikipedia.org/wiki/cystic_fibrosis"
+            "https://orcid.org/0000-0002-6601-2165",
+            "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 629,
+        "identity": 551,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -515041,137 +5042,140 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "(Alginate)n",
-          "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+          "name": "Albendazole",
+          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "MESH:D000077322",
-            "UMLS:C0102137",
-            "KEGG.GLYCAN:G00316",
-            "UMLS:C0051156",
-            "KEGG.GLYCAN:G07471",
-            "KEGG.GLYCAN:G07287",
-            "KEGG.GLYCAN:G08476",
-            "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-            "DRUGBANK:DB13518",
-            "DrugCentral:4321",
-            "KEGG.DRUG:D02324",
-            "UNII:8C3Z4148WZ",
-            "KEGG.COMPOUND:C01768",
-            "CHEBI:17548",
-            "NDDF:002434",
-            "RXNORM:17305",
-            "RXNORM:1370451",
-            "NCIT:C82277",
-            "CHEMBL.COMPOUND:CHEMBL2108894",
-            "MESH:C008970",
-            "PUBCHEM.COMPOUND:91666318",
-            "ATC:A02BX13",
-            "KEGG.GLYCAN:G02561",
-            "UMLS:C4694124",
-            "KEGG.GLYCAN:G10593"
+            "KEGG.COMPOUND:C01779",
+            "UMLS:C0001911",
+            "ATC:P02CA03",
+            "NCIT:C47384",
+            "UMLS:C4082528",
+            "KEGG.DRUG:D00134",
+            "NDDF:004079",
+            "DrugCentral:103",
+            "MESH:D015766",
+            "CAS:54965-21-8",
+            "RXNORM:430",
+            "HMDB:HMDB0014659",
+            "CHEBI:16664",
+            "UNII:F4216019LN",
+            "CHEMBL.COMPOUND:CHEMBL1483",
+            "DRUGBANK:DB00518",
+            "PUBCHEM.COMPOUND:2082",
+            "UMLS:C4082752",
+            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
           ],
-          "id": "PUBCHEM.COMPOUND:91666318",
+          "id": "PUBCHEM.COMPOUND:2082",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "(Alginate)n",
-            "Alginate",
-            "Norgine",
-            "Alginic acid",
-            "Alginic acid (NF)",
-            "ALGINIC ACID",
-            "alginate",
-            "Alginic Acid",
-            "alginic acid"
+            "albendol",
+            "Albendazole",
+            "ALBENDAZOLE",
+            "Eskazole",
+            "Proftril",
+            "Albendazole (JAN/USP/INN)",
+            "albendazole"
           ],
           "all_categories": [
-            "biolink:ChemicalEntity",
             "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:1551350",
-            "PMID:10848650",
-            "PMID:231639",
-            "PMID:27671545"
+            "PMID:28595066",
+            "PMID:20014752",
+            "PMID:15646539",
+            "PMID:17562801",
+            "PMID:8228321",
+            "PMID:15828820",
+            "PMID:23571415",
+            "PMID:33360795",
+            "PMID:19186059",
+            "PMID:16420038"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 523273,
+            "identity": 307890,
             "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:NamedThing",
+              "biolink:PhenotypicFeature",
+              "biolink:ThingWithTaxon"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0009061",
-              "name": "cystic fibrosis",
-              "description": "A congenital, autosomal, metabolic disorder affecting the exocrine glands. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production that causes obstruction of passageways, including pancreatic and bile ducts, intestines, and bronchi. Symptoms usually appear in childhood, and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather secondary to increased sodium and chloride concentration in sweat.; An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005154",
+              "name": "liver disorder",
+              "description": "A non-neoplastic or neoplastic disorder that affects the liver parenchyma and intrahepatic bile ducts. Representative examples of non-neoplastic disorders include hepatitis, cirrhosis, cholangitis, and polycystic liver disease. Representative examples of neoplastic disorders include hepatocellular adenoma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, lymphoma, and angiosarcoma.; Pathological processes of the LIVER.; Reduced ability of the liver to perform its functions. [HPO:probinson]; An abnormality of the liver. [HPO:probinson]; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "MESH:D003550",
-                "SNOMEDCT:190905008",
-                "UMLS:C0010674",
-                "NCIT:C2975",
-                "MEDDRA:10011762",
-                "ORPHANET:586",
-                "DOID:1485",
-                "MEDDRA:10011764",
-                "ICD9:277.0",
-                "MEDDRA:10028141",
-                "PSY:12915",
-                "MONDO:0009061",
-                "OMIM:219700",
-                "ICD10:E84"
+                "HP:0001392",
+                "MEDDRA:10019650",
+                "MEDDRA:10059616",
+                "MONDO:0005154",
+                "SNOMEDCT:235856003",
+                "MEDDRA:10019652",
+                "EFO:0001421",
+                "ICD9:573.9",
+                "MEDDRA:10019653",
+                "DOID:409",
+                "MEDDRA:10045808",
+                "NCIT:C3196",
+                "MEDDRA:10013107",
+                "MEDDRA:10024670",
+                "UMLS:C4021780",
+                "MEDDRA:10013228",
+                "ICD10:K76.9",
+                "MEDDRA:10013234",
+                "UMLS:C0023895",
+                "MESH:D008107"
               ],
-              "id": "MONDO:0009061",
+              "id": "MONDO:0005154",
               "category": "biolink:Disease",
               "all_names": [
-                "Cystic Fibrosis",
-                "cystic fibrosis",
-                "obsolete_cystic fibrosis",
-                "Cystic fibrosis related phenotypic feature",
-                "Cystic fibrosis"
+                "Liver and Intrahepatic Bile Duct Disorder",
+                "liver disorder",
+                "Abnormality of the liver",
+                "Liver Diseases",
+                "liver disease",
+                "Liver diseases",
+                "Unspecified disorder of liver"
               ],
               "all_categories": [
                 "biolink:Disease"
               ],
               "publications": [
-                "http://ghr.nlm.nih.gov/condition/cystic-fibrosis",
-                "http://www.nhlbi.nih.gov/health/health-topics/topics/cf/",
-                "http://en.wikipedia.org/wiki/cystic_fibrosis"
+                "https://orcid.org/0000-0002-6601-2165",
+                "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 26964905,
-            "start": 629,
-            "end": 523273,
-            "type": "biolink:affects",
+            "identity": 13212317,
+            "start": 551,
+            "end": 307890,
+            "type": "biolink:treats",
             "properties": {
-              "predicate": "biolink:affects",
+              "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9284161': {'publication date': '1997 Sep', 'sentence': 'Two CF strains, selected for further study based on the dependence of their alginate production on the concentration of salt in the medium, were used to examine the effects of mucoidy on pulmonary clearance.', 'subject score': 888, 'object score': 861}}",
+              "publications_info": "{'PMID:18085341': {'publication date': '2008 May', 'sentence': 'PATIENTS AND METHODS: Sixty-five patients with hepatic cystic disease were treated with albendazole alone between January 2004 and June 2007.', 'subject score': 1000, 'object score': 901}}",
               "kg2_ids": [
-                "UMLS:C0102137---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0010674---SEMMEDDB:"
+                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0023895---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:91666318",
-              "id": "27435796",
-              "object": "MONDO:0009061",
+              "subject": "PUBCHEM.COMPOUND:2082",
+              "id": "13496386",
+              "object": "MONDO:0005154",
               "publications": [
-                "PMID:9284161"
+                "PMID:18085341"
               ]
             }
           },
           "end": {
-            "identity": 629,
+            "identity": 551,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -515188,58 +5192,56 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "(Alginate)n",
-              "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+              "name": "Albendazole",
+              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "MESH:D000077322",
-                "UMLS:C0102137",
-                "KEGG.GLYCAN:G00316",
-                "UMLS:C0051156",
-                "KEGG.GLYCAN:G07471",
-                "KEGG.GLYCAN:G07287",
-                "KEGG.GLYCAN:G08476",
-                "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-                "DRUGBANK:DB13518",
-                "DrugCentral:4321",
-                "KEGG.DRUG:D02324",
-                "UNII:8C3Z4148WZ",
-                "KEGG.COMPOUND:C01768",
-                "CHEBI:17548",
-                "NDDF:002434",
-                "RXNORM:17305",
-                "RXNORM:1370451",
-                "NCIT:C82277",
-                "CHEMBL.COMPOUND:CHEMBL2108894",
-                "MESH:C008970",
-                "PUBCHEM.COMPOUND:91666318",
-                "ATC:A02BX13",
-                "KEGG.GLYCAN:G02561",
-                "UMLS:C4694124",
-                "KEGG.GLYCAN:G10593"
+                "KEGG.COMPOUND:C01779",
+                "UMLS:C0001911",
+                "ATC:P02CA03",
+                "NCIT:C47384",
+                "UMLS:C4082528",
+                "KEGG.DRUG:D00134",
+                "NDDF:004079",
+                "DrugCentral:103",
+                "MESH:D015766",
+                "CAS:54965-21-8",
+                "RXNORM:430",
+                "HMDB:HMDB0014659",
+                "CHEBI:16664",
+                "UNII:F4216019LN",
+                "CHEMBL.COMPOUND:CHEMBL1483",
+                "DRUGBANK:DB00518",
+                "PUBCHEM.COMPOUND:2082",
+                "UMLS:C4082752",
+                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
               ],
-              "id": "PUBCHEM.COMPOUND:91666318",
+              "id": "PUBCHEM.COMPOUND:2082",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "(Alginate)n",
-                "Alginate",
-                "Norgine",
-                "Alginic acid",
-                "Alginic acid (NF)",
-                "ALGINIC ACID",
-                "alginate",
-                "Alginic Acid",
-                "alginic acid"
+                "albendol",
+                "Albendazole",
+                "ALBENDAZOLE",
+                "Eskazole",
+                "Proftril",
+                "Albendazole (JAN/USP/INN)",
+                "albendazole"
               ],
               "all_categories": [
-                "biolink:ChemicalEntity",
                 "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:1551350",
-                "PMID:10848650",
-                "PMID:231639",
-                "PMID:27671545"
+                "PMID:28595066",
+                "PMID:20014752",
+                "PMID:15646539",
+                "PMID:17562801",
+                "PMID:8228321",
+                "PMID:15828820",
+                "PMID:23571415",
+                "PMID:33360795",
+                "PMID:19186059",
+                "PMID:16420038"
               ]
             }
           }
@@ -515250,14 +5252,8 @@
   },
   {
     "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:8708979': {'publication date': '1995 Nov', 'sentence': 'Effect of alginate and alginate-cimetidine combination therapy on stimulated postprandial gastro-oesophageal reflux.', 'subject score': 1000, 'object score': 884}}",
-    "p2": {
->>>>>>> main
       "start": {
-        "identity": 321369,
+        "identity": 526462,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -515267,70 +5263,46 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007186",
-          "name": "gastroesophageal reflux disease",
-          "description": "A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C26781\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26781\" NCI Thesaurus); A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.; Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.; A condition in which the stomach contents leak backwards from the stomach into the esophagus through the lower esophageal sphincter. [HPO:probinson]; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0015484",
+          "name": "cysticercosis",
+          "description": "A parasitic infection with tapeworms of the genus Taenia affecting the brain. It is manifested with seizures and headaches.; Infection of the brain, spinal cord, or perimeningeal structures with the larval forms of the genus TAENIA (primarily T. solium in humans). Lesions formed by the organism are referred to as cysticerci. The infection may be subacute or chronic, and the severity of symptoms depends on the severity of the host immune response and the location and number of lesions. SEIZURES represent the most common clinical manifestation although focal neurologic deficits may occur. (From Joynt, Clinical Neurology, 1998, Ch27, pp46-50); UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "ICD10:K21.9",
-            "UMLS:C4317146",
-            "NCIT:C26781",
-            "MEDDRA:10037676",
-            "PDQ:CDR0000737473",
-            "NCIT:C34670",
-            "UMLS:C3813607",
-            "MEDDRA:10066874",
-            "MEDDRA:10015389",
-            "ICD9:787.1",
-            "SNOMEDCT:698065002",
-            "UMLS:C0018834",
-            "OMIM:109350",
-            "MESH:D006356",
-            "UMLS:C0017168",
-            "DOID:8534",
-            "NCIT:C92560",
-            "SNOMEDCT:235595009",
-            "MEDDRA:10019326",
-            "HP:0002020",
-            "MEDDRA:10018203",
-            "MESH:D005764",
-            "MEDDRA:10017924",
-            "MEDDRA:10030182",
-            "SNOMEDCT:722884003",
-            "MONDO:0007186",
-            "ICD9:530.81",
-            "EFO:0003948",
-            "MEDDRA:10017884",
-            "MEDDRA:10017885",
-            "SNOMEDCT:16331000",
-            "NCIT:C113396"
+            "MESH:D020019",
+            "UMLS:C0338437",
+            "DOID:10079",
+            "MEDDRA:10011757",
+            "MONDO:0015484",
+            "ORPHANET:1560",
+            "SNOMEDCT:230215006",
+            "EFO:0007231",
+            "ICD10:B69",
+            "MEDDRA:10058443",
+            "MESH:D003551",
+            "SNOMEDCT:59051007",
+            "UMLS:C0010678",
+            "MEDDRA:10011775",
+            "NCIT:C34520",
+            "ICD9:123.1",
+            "SNOMEDCT:105684008",
+            "NCIT:C84932"
           ],
-          "id": "MONDO:0007186",
+          "id": "MONDO:0015484",
           "category": "biolink:Disease",
           "all_names": [
-            "Gastroesophageal Reflux Disease",
-            "Acid reflux",
-            "Gastroesophageal reflux",
-            "Esophageal reflux",
-            "Gastroesophageal Reflux",
-            "Gastroesophageal reflux disease",
-            "Infantile Gastroesophageal Reflux",
-            "gastroesophageal reflux disease",
-            "Gastroesophageal reflux related phenotypic feature",
-            "Heartburn"
+            "Cysticercosis",
+            "cysticercosis",
+            "Neurocysticercosis"
           ],
           "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
+            "biolink:Disease"
           ],
           "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-5316-1399"
+            "http://en.wikipedia.org/wiki/cysticercosis"
           ]
         }
       },
       "end": {
-        "identity": 629,
+        "identity": 551,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -515347,161 +5319,153 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "(Alginate)n",
-          "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+          "name": "Albendazole",
+          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "MESH:D000077322",
-            "UMLS:C0102137",
-            "KEGG.GLYCAN:G00316",
-            "UMLS:C0051156",
-            "KEGG.GLYCAN:G07471",
-            "KEGG.GLYCAN:G07287",
-            "KEGG.GLYCAN:G08476",
-            "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-            "DRUGBANK:DB13518",
-            "DrugCentral:4321",
-            "KEGG.DRUG:D02324",
-            "UNII:8C3Z4148WZ",
-            "KEGG.COMPOUND:C01768",
-            "CHEBI:17548",
-            "NDDF:002434",
-            "RXNORM:17305",
-            "RXNORM:1370451",
-            "NCIT:C82277",
-            "CHEMBL.COMPOUND:CHEMBL2108894",
-            "MESH:C008970",
-            "PUBCHEM.COMPOUND:91666318",
-            "ATC:A02BX13",
-            "KEGG.GLYCAN:G02561",
-            "UMLS:C4694124",
-            "KEGG.GLYCAN:G10593"
+            "KEGG.COMPOUND:C01779",
+            "UMLS:C0001911",
+            "ATC:P02CA03",
+            "NCIT:C47384",
+            "UMLS:C4082528",
+            "KEGG.DRUG:D00134",
+            "NDDF:004079",
+            "DrugCentral:103",
+            "MESH:D015766",
+            "CAS:54965-21-8",
+            "RXNORM:430",
+            "HMDB:HMDB0014659",
+            "CHEBI:16664",
+            "UNII:F4216019LN",
+            "CHEMBL.COMPOUND:CHEMBL1483",
+            "DRUGBANK:DB00518",
+            "PUBCHEM.COMPOUND:2082",
+            "UMLS:C4082752",
+            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
           ],
-          "id": "PUBCHEM.COMPOUND:91666318",
+          "id": "PUBCHEM.COMPOUND:2082",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "(Alginate)n",
-            "Alginate",
-            "Norgine",
-            "Alginic acid",
-            "Alginic acid (NF)",
-            "ALGINIC ACID",
-            "alginate",
-            "Alginic Acid",
-            "alginic acid"
+            "albendol",
+            "Albendazole",
+            "ALBENDAZOLE",
+            "Eskazole",
+            "Proftril",
+            "Albendazole (JAN/USP/INN)",
+            "albendazole"
           ],
           "all_categories": [
-            "biolink:ChemicalEntity",
             "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:1551350",
-            "PMID:10848650",
-            "PMID:231639",
-            "PMID:27671545"
+            "PMID:28595066",
+            "PMID:20014752",
+            "PMID:15646539",
+            "PMID:17562801",
+            "PMID:8228321",
+            "PMID:15828820",
+            "PMID:23571415",
+            "PMID:33360795",
+            "PMID:19186059",
+            "PMID:16420038"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 321369,
+            "identity": 526462,
             "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:NamedThing",
+              "biolink:PhenotypicFeature",
+              "biolink:ThingWithTaxon"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007186",
-              "name": "gastroesophageal reflux disease",
-              "description": "A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C26781\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26781\" NCI Thesaurus); A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.; Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.; A condition in which the stomach contents leak backwards from the stomach into the esophagus through the lower esophageal sphincter. [HPO:probinson]; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0015484",
+              "name": "cysticercosis",
+              "description": "A parasitic infection with tapeworms of the genus Taenia affecting the brain. It is manifested with seizures and headaches.; Infection of the brain, spinal cord, or perimeningeal structures with the larval forms of the genus TAENIA (primarily T. solium in humans). Lesions formed by the organism are referred to as cysticerci. The infection may be subacute or chronic, and the severity of symptoms depends on the severity of the host immune response and the location and number of lesions. SEIZURES represent the most common clinical manifestation although focal neurologic deficits may occur. (From Joynt, Clinical Neurology, 1998, Ch27, pp46-50); UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "ICD10:K21.9",
-                "UMLS:C4317146",
-                "NCIT:C26781",
-                "MEDDRA:10037676",
-                "PDQ:CDR0000737473",
-                "NCIT:C34670",
-                "UMLS:C3813607",
-                "MEDDRA:10066874",
-                "MEDDRA:10015389",
-                "ICD9:787.1",
-                "SNOMEDCT:698065002",
-                "UMLS:C0018834",
-                "OMIM:109350",
-                "MESH:D006356",
-                "UMLS:C0017168",
-                "DOID:8534",
-                "NCIT:C92560",
-                "SNOMEDCT:235595009",
-                "MEDDRA:10019326",
-                "HP:0002020",
-                "MEDDRA:10018203",
-                "MESH:D005764",
-                "MEDDRA:10017924",
-                "MEDDRA:10030182",
-                "SNOMEDCT:722884003",
-                "MONDO:0007186",
-                "ICD9:530.81",
-                "EFO:0003948",
-                "MEDDRA:10017884",
-                "MEDDRA:10017885",
-                "SNOMEDCT:16331000",
-                "NCIT:C113396"
+                "MESH:D020019",
+                "UMLS:C0338437",
+                "DOID:10079",
+                "MEDDRA:10011757",
+                "MONDO:0015484",
+                "ORPHANET:1560",
+                "SNOMEDCT:230215006",
+                "EFO:0007231",
+                "ICD10:B69",
+                "MEDDRA:10058443",
+                "MESH:D003551",
+                "SNOMEDCT:59051007",
+                "UMLS:C0010678",
+                "MEDDRA:10011775",
+                "NCIT:C34520",
+                "ICD9:123.1",
+                "SNOMEDCT:105684008",
+                "NCIT:C84932"
               ],
-              "id": "MONDO:0007186",
+              "id": "MONDO:0015484",
               "category": "biolink:Disease",
               "all_names": [
-                "Gastroesophageal Reflux Disease",
-                "Acid reflux",
-                "Gastroesophageal reflux",
-                "Esophageal reflux",
-                "Gastroesophageal Reflux",
-                "Gastroesophageal reflux disease",
-                "Infantile Gastroesophageal Reflux",
-                "gastroesophageal reflux disease",
-                "Gastroesophageal reflux related phenotypic feature",
-                "Heartburn"
+                "Cysticercosis",
+                "cysticercosis",
+                "Neurocysticercosis"
               ],
               "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
+                "biolink:Disease"
               ],
               "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-5316-1399"
+                "http://en.wikipedia.org/wiki/cysticercosis"
               ]
             }
           },
           "relationship": {
-            "identity": 26664237,
-            "start": 629,
-            "end": 321369,
-            "type": "biolink:affects",
+            "identity": 7083976,
+            "start": 551,
+            "end": 526462,
+            "type": "biolink:treats",
             "properties": {
-              "predicate": "biolink:affects",
+              "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:8708979': {'publication date': '1995 Nov', 'sentence': 'Effect of alginate and alginate-cimetidine combination therapy on stimulated postprandial gastro-oesophageal reflux.', 'subject score': 1000, 'object score': 884}}",
+              "publications_info": "{'PMID:10102436': {'publication date': '1999 Mar 23', 'sentence': 'The efficacy of albendazole (15 mg/kg/d for 1 week) was compared with praziquantel (100 mg/kg in three divided doses at 2-hour intervals) for therapy of parenchymal brain cysticercosis.', 'subject score': 1000, 'object score': 877}, 'PMID:10423586': {'publication date': '1997 Jan', 'sentence': 'Clinical pharmacokinetics of albendazole in children with neurocysticercosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:10660021': {'publication date': '1999 Dec', 'sentence': 'METHODS: In this study, 65 patients with active neurocysticercosis (NCC) treated with praziquantel or albendazole were retrospectively reviewed to evaluate radiological and clinical outcome.', 'subject score': 1000, 'object score': 888}, 'PMID:10805184': {'publication date': '2000 Apr', 'sentence': 'Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy.', 'subject score': 888, 'object score': 1000}, 'PMID:11080931': {'publication date': '2000', 'sentence': 'Praziquantel and albendazole are the two cestocide drugs currently used for the treatment of NCC.', 'subject score': 1000, 'object score': 1000}, 'PMID:11137466': {'publication date': '2000 Dec', 'sentence': 'The anthelmintic drug albendazole (ABZ), methyl(5-(propylthio)-1H-benzimidazol-2-yl)carbamate, is a benzimidazole highly efficient in the treatment of neurocysticercosis.', 'subject score': 901, 'object score': 1000}, 'PMID:11198654': {'publication date': '2000 Nov-Dec', 'sentence': 'The efficacy of albendazole (ABZ) treatment for human neurocysticercosis (NCC) was assessed by using a monoclonal antibody-based parasite antigen detection ELISA which specifically detects the products of living cysticerci in human serum.', 'subject score': 888, 'object score': 888}, 'PMID:11589289': {'publication date': '2001 Sep', 'sentence': 'Albendazole (ABZ) is a benzimidazole anthelmintic drug used in the treatment of neurocysticercosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:11847531': {'publication date': '2002 Feb', 'sentence': 'Albendazole metabolism in patients with neurocysticercosis: antipyrine as a multifunctional marker drug of cytochrome P450.', 'subject score': 888, 'object score': 1000}, 'PMID:12021623': {'publication date': '2002 Jun', 'sentence': 'Thirty-two adults with a diagnosis of the active form of intraparenchymatous neurocysticercosis and treated with albendazole at the dose of 7.5 mg/kg every 12 hours for 8 days were studied.', 'subject score': 1000, 'object score': 861}, 'PMID:12136810': {'publication date': '2002 Jun', 'sentence': 'CSF-VP shunt placement and albendazole therapy for cerebral cysticercosis.', 'subject score': 888, 'object score': 1000}, 'PMID:12207631': {'publication date': '2002 Aug', 'sentence': 'METHODS: Twelve patients with a diagnosis of active brain parenchymal neurocysticercosis treated with albendazole for 8 days (15 mg kg(-1) day(-1)) were investigated.', 'subject score': 1000, 'object score': 815}, 'PMID:12563746': {'publication date': '1999', 'sentence': 'Small cystic lesions could turn into other CT signs of cerebral cysticercosis after albendazole treatment.', 'subject score': 888, 'object score': 1000}, 'PMID:12634590': {'publication date': '2003 Mar', 'sentence': 'One week versus four weeks of albendazole therapy for neurocysticercosis in children: a randomized, placebo-controlled double blind trial.', 'subject score': 888, 'object score': 1000}, 'PMID:1439991': {'publication date': '1992 Jun', 'sentence': 'Albendazole treatment of neurocysticercosis.', 'subject score': 888, 'object score': 1000}, 'PMID:15224704': {'publication date': '2004 May', 'sentence': 'Corticosteroids versus albendazole for treatment of single small enhancing computed tomographic lesions in children with neurocysticercosis.', 'subject score': 1000, 'object score': 1000}, 'PMID:15259471': {'publication date': '2003', 'sentence': 'The clinical findings of neurocysticercosis, diagnosed primarily on the basis of computed tomography (CT), and response to albendazole therapy in a randomized, double-blind, placebo-controlled trial were studied in 72 newly diagnosed children aged 1.5-12 years admitted to hospital in New Delhi, India, during March to July 2000.', 'subject score': 888, 'object score': 1000}, 'PMID:15290687': {'publication date': '2004 Oct', 'sentence': 'The present study investigates the urinary excretion of the enantiomers of (+)- and (-)-albendazole sulfoxide (ASOX) and albendazole sulfone (ASON) in 12 patients with neurocysticercosis treated with albendazole for 8 days (7.5 mg/kg/12 h).', 'subject score': 1000, 'object score': 1000}, 'PMID:15587154': {'publication date': '2004 Aug', 'sentence': 'OBJECTIVE: To determine the therapeutic efficacy of albendazole combined with surgical intervention on intracranial hypertension in the treatment of severe neurocysticercosis.', 'subject score': 1000, 'object score': 888}, 'PMID:15853623': {'publication date': '2004 Jan', 'sentence': 'Albendazole may also be useful in extraparenchymal cysticercosis, especially in the subarachnoid racemose form, when complete surgical resection of the cysts is usually impracticable.', 'subject score': 1000, 'object score': 861}}",
               "kg2_ids": [
-                "UMLS:C0102137---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0017168---SEMMEDDB:"
+                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0338437---SEMMEDDB:",
+                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0010678---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:91666318",
-              "id": "27132270",
-              "object": "MONDO:0007186",
+              "subject": "PUBCHEM.COMPOUND:2082",
+              "id": "7226097",
+              "object": "MONDO:0015484",
               "publications": [
-                "PMID:8708979"
+                "PMID:8266251",
+                "PMID:3652415",
+                "PMID:23229490",
+                "PMID:15224704",
+                "PMID:12021623",
+                "PMID:31600525",
+                "PMID:7591443",
+                "PMID:26198415",
+                "PMID:12875739",
+                "PMID:1740534",
+                "PMID:8422660",
+                "PMID:17621473",
+                "PMID:7485720",
+                "PMID:25339244",
+                "PMID:11080931",
+                "PMID:8965125",
+                "PMID:36333896",
+                "PMID:2391343",
+                "PMID:19951271",
+                "PMID:14749518"
               ]
             }
           },
           "end": {
-            "identity": 629,
+            "identity": 551,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -515518,58 +5482,56 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "(Alginate)n",
-              "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+              "name": "Albendazole",
+              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "MESH:D000077322",
-                "UMLS:C0102137",
-                "KEGG.GLYCAN:G00316",
-                "UMLS:C0051156",
-                "KEGG.GLYCAN:G07471",
-                "KEGG.GLYCAN:G07287",
-                "KEGG.GLYCAN:G08476",
-                "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-                "DRUGBANK:DB13518",
-                "DrugCentral:4321",
-                "KEGG.DRUG:D02324",
-                "UNII:8C3Z4148WZ",
-                "KEGG.COMPOUND:C01768",
-                "CHEBI:17548",
-                "NDDF:002434",
-                "RXNORM:17305",
-                "RXNORM:1370451",
-                "NCIT:C82277",
-                "CHEMBL.COMPOUND:CHEMBL2108894",
-                "MESH:C008970",
-                "PUBCHEM.COMPOUND:91666318",
-                "ATC:A02BX13",
-                "KEGG.GLYCAN:G02561",
-                "UMLS:C4694124",
-                "KEGG.GLYCAN:G10593"
+                "KEGG.COMPOUND:C01779",
+                "UMLS:C0001911",
+                "ATC:P02CA03",
+                "NCIT:C47384",
+                "UMLS:C4082528",
+                "KEGG.DRUG:D00134",
+                "NDDF:004079",
+                "DrugCentral:103",
+                "MESH:D015766",
+                "CAS:54965-21-8",
+                "RXNORM:430",
+                "HMDB:HMDB0014659",
+                "CHEBI:16664",
+                "UNII:F4216019LN",
+                "CHEMBL.COMPOUND:CHEMBL1483",
+                "DRUGBANK:DB00518",
+                "PUBCHEM.COMPOUND:2082",
+                "UMLS:C4082752",
+                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
               ],
-              "id": "PUBCHEM.COMPOUND:91666318",
+              "id": "PUBCHEM.COMPOUND:2082",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "(Alginate)n",
-                "Alginate",
-                "Norgine",
-                "Alginic acid",
-                "Alginic acid (NF)",
-                "ALGINIC ACID",
-                "alginate",
-                "Alginic Acid",
-                "alginic acid"
+                "albendol",
+                "Albendazole",
+                "ALBENDAZOLE",
+                "Eskazole",
+                "Proftril",
+                "Albendazole (JAN/USP/INN)",
+                "albendazole"
               ],
               "all_categories": [
-                "biolink:ChemicalEntity",
                 "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:1551350",
-                "PMID:10848650",
-                "PMID:231639",
-                "PMID:27671545"
+                "PMID:28595066",
+                "PMID:20014752",
+                "PMID:15646539",
+                "PMID:17562801",
+                "PMID:8228321",
+                "PMID:15828820",
+                "PMID:23571415",
+                "PMID:33360795",
+                "PMID:19186059",
+                "PMID:16420038"
               ]
             }
           }
@@ -515579,66 +5541,40 @@
     }
   },
   {
-<<<<<<< HEAD
     "p3": {
       "start": {
-        "identity": 318216,
+        "identity": 538300,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+          "iri": "http://id.nlm.nih.gov/mesh/D000900",
+          "name": "Anti-Bacterial Agents",
+          "description": "A family of substances capable of destroying or inhibiting the growth of bacteria.; Substances that kill BACTERIA.; UMLS Semantic Type: STY:T195",
           "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
+            "MESH:D000900",
+            "UMLS:C0279516",
+            "CHEBI:36047"
           ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
+          "id": "MESH:D000900",
+          "category": "biolink:ChemicalEntity",
           "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
+            "antibacterial drug",
+            "Anti-Bacterial Agents"
           ],
           "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 629,
+        "identity": 553,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -515655,211 +5591,187 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "(Alginate)n",
-          "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+          "name": "Latamoxef",
+          "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "MESH:D000077322",
-            "UMLS:C0102137",
-            "KEGG.GLYCAN:G00316",
-            "UMLS:C0051156",
-            "KEGG.GLYCAN:G07471",
-            "KEGG.GLYCAN:G07287",
-            "KEGG.GLYCAN:G08476",
-            "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-            "DRUGBANK:DB13518",
-            "DrugCentral:4321",
-            "KEGG.DRUG:D02324",
-            "UNII:8C3Z4148WZ",
-            "KEGG.COMPOUND:C01768",
-            "CHEBI:17548",
-            "NDDF:002434",
-            "RXNORM:17305",
-            "RXNORM:1370451",
-            "NCIT:C82277",
-            "CHEMBL.COMPOUND:CHEMBL2108894",
-            "MESH:C008970",
-            "PUBCHEM.COMPOUND:91666318",
-            "ATC:A02BX13",
-            "KEGG.GLYCAN:G02561",
-            "UMLS:C4694124",
-            "KEGG.GLYCAN:G10593"
+            "ATC:J01DD06",
+            "NDDF:004889",
+            "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
+            "CHEMBL.COMPOUND:CHEMBL74632",
+            "UMLS:C0878141",
+            "CHEBI:599928",
+            "RXNORM:7069",
+            "PUBCHEM.COMPOUND:47499",
+            "PDQ:CDR0000039507",
+            "UMLS:C0026651",
+            "KEGG.DRUG:D02198",
+            "DRUGBANK:DB04570",
+            "KEGG.COMPOUND:C07231",
+            "NCIT:C670",
+            "GTOPDB:12031",
+            "KEGG.DRUG:D08109",
+            "HMDB:HMDB0015574",
+            "DrugCentral:1851",
+            "UNII:VUF6C936Z3",
+            "MESH:D009070"
           ],
-          "id": "PUBCHEM.COMPOUND:91666318",
+          "id": "PUBCHEM.COMPOUND:47499",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "(Alginate)n",
-            "Alginate",
-            "Norgine",
-            "Alginic acid",
-            "Alginic acid (NF)",
-            "ALGINIC ACID",
-            "alginate",
-            "Alginic Acid",
-            "alginic acid"
+            "Latamoxef",
+            "Latamoxef (INN)",
+            "Moxalactam disodium (USAN)",
+            "Moxalactam",
+            "Festamoxin",
+            "moxalactam",
+            "latamoxef",
+            "MOXALACTAM"
           ],
           "all_categories": [
-            "biolink:ChemicalEntity",
             "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:1551350",
-            "PMID:10848650",
-            "PMID:231639",
-            "PMID:27671545"
+            "PMID:20014752",
+            "PMID:17846134",
+            "PMID:6217353",
+            "PMID:17242148",
+            "PMID:18426954",
+            "PMID:18559652",
+            "PMID:19764786",
+            "PMID:12109906",
+            "PMID:18765691",
+            "PMID:19445515"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 318216,
+            "identity": 538300,
             "labels": [
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
+              "biolink:PhysicalEssence",
+              "biolink:PhysicalEssenceOrOccurrent"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+              "iri": "http://id.nlm.nih.gov/mesh/D000900",
+              "name": "Anti-Bacterial Agents",
+              "description": "A family of substances capable of destroying or inhibiting the growth of bacteria.; Substances that kill BACTERIA.; UMLS Semantic Type: STY:T195",
               "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
+                "MESH:D000900",
+                "UMLS:C0279516",
+                "CHEBI:36047"
               ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
+              "id": "MESH:D000900",
+              "category": "biolink:ChemicalEntity",
               "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
+                "antibacterial drug",
+                "Anti-Bacterial Agents"
               ],
               "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-            "identity": 22982929,
-            "start": 629,
-            "end": 318216,
-            "type": "biolink:affects",
+            "identity": 18655165,
+            "start": 553,
+            "end": 538300,
+            "type": "biolink:subclass_of",
             "properties": {
-              "predicate": "biolink:affects",
+              "predicate": "biolink:subclass_of",
               "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:34083930': {'publication date': '2021 Apr', 'sentence': 'Conclusion: PVA and alginate nanofibers can modulate obesity, reduce blood glucose levels, and reduce serum levels of insulin, ALT, ALP, GGT, creatinine, TNF-alpha, and IL-1beta in diabetic rats.', 'subject score': 888, 'object score': 1000}, 'PMID:34363822': {'publication date': '2021 Aug 04', 'sentence': 'In this study, low-molecular alginate from Laminaria japonica (L-LJA) was prepared, and its effect on obesity and metabolic syndrome was analyzed in high-fat diet (HFD)-fed mice.', 'subject score': 851, 'object score': 1000}}",
+              "domain_range_exclusion": "False",
+              "publications_info": "{'PMID:27266357': {'publication date': '2016 May 17', 'sentence': 'METHODS: Minimum inhibitory concentrations (MICs) of moxalactam and other antibacterial agents against 491 Enterobacteriaceae spp. and anaerobic spp.collecting from clinical settings were determined by agar dilution methods and E-test strips according to the Clinical and Laboratory Standards Institute (CLSI)(2014).', 'subject score': 1000, 'object score': 1000}, 'PMID:3886949': {'publication date': '1985 Jan', 'sentence': 'Antibacterial activity of cefmenoxime (CMX) against clinically isolated organisms was examined in comparison with that of 4 other antibiotics and concluded as follows: Antibacterial activity of CMX was markedly stronger than those of cefazolin (CEZ), cefmetazole, latamoxef and ampicillin against E. coli, K. pneumoniae, S. marcescens, H. influenzae, P. mirabilis and indole positive Proteus.', 'subject score': 1000, 'object score': 888}, 'PMID:6573324': {'publication date': '1983 Jan', 'sentence': 'Cefotetan was noted to have a broader spectrum of activity than cefoxitin and its antibacterial activity was comparable to that of cefotaxime and moxalactam.', 'subject score': 1000, 'object score': 888}}",
               "kg2_ids": [
-                "UMLS:C0102137---SEMMEDDB:affects---None---None---None---UMLS:C0028754---SEMMEDDB:"
+                "UMLS:C0026651---SEMMEDDB:isa---None---None---None---UMLS:C0279516---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:91666318",
-              "id": "23415127",
-              "object": "MONDO:0011122",
+              "subject": "PUBCHEM.COMPOUND:47499",
+              "id": "19031059",
+              "object": "MESH:D000900",
               "publications": [
-                "PMID:34083930",
-                "PMID:34363822"
+                "PMID:27266357",
+                "PMID:3886949",
+                "PMID:6573324"
               ]
             }
           },
           "end": {
-            "identity": 629,
+            "identity": 553,
             "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
               "biolink:ChemicalMixture",
-              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
+              "biolink:Drug",
+              "biolink:MolecularEntity",
+              "biolink:MolecularMixture",
               "biolink:NamedThing",
+              "biolink:OntologyClass",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:SmallMolecule"
             ],
             "properties": {
-              "name": "(Alginate)n",
-              "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+              "name": "Latamoxef",
+              "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "MESH:D000077322",
-                "UMLS:C0102137",
-                "KEGG.GLYCAN:G00316",
-                "UMLS:C0051156",
-                "KEGG.GLYCAN:G07471",
-                "KEGG.GLYCAN:G07287",
-                "KEGG.GLYCAN:G08476",
-                "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-                "DRUGBANK:DB13518",
-                "DrugCentral:4321",
-                "KEGG.DRUG:D02324",
-                "UNII:8C3Z4148WZ",
-                "KEGG.COMPOUND:C01768",
-                "CHEBI:17548",
-                "NDDF:002434",
-                "RXNORM:17305",
-                "RXNORM:1370451",
-                "NCIT:C82277",
-                "CHEMBL.COMPOUND:CHEMBL2108894",
-                "MESH:C008970",
-                "PUBCHEM.COMPOUND:91666318",
-                "ATC:A02BX13",
-                "KEGG.GLYCAN:G02561",
-                "UMLS:C4694124",
-                "KEGG.GLYCAN:G10593"
+                "ATC:J01DD06",
+                "NDDF:004889",
+                "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
+                "CHEMBL.COMPOUND:CHEMBL74632",
+                "UMLS:C0878141",
+                "CHEBI:599928",
+                "RXNORM:7069",
+                "PUBCHEM.COMPOUND:47499",
+                "PDQ:CDR0000039507",
+                "UMLS:C0026651",
+                "KEGG.DRUG:D02198",
+                "DRUGBANK:DB04570",
+                "KEGG.COMPOUND:C07231",
+                "NCIT:C670",
+                "GTOPDB:12031",
+                "KEGG.DRUG:D08109",
+                "HMDB:HMDB0015574",
+                "DrugCentral:1851",
+                "UNII:VUF6C936Z3",
+                "MESH:D009070"
               ],
-              "id": "PUBCHEM.COMPOUND:91666318",
+              "id": "PUBCHEM.COMPOUND:47499",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "(Alginate)n",
-                "Alginate",
-                "Norgine",
-                "Alginic acid",
-                "Alginic acid (NF)",
-                "ALGINIC ACID",
-                "alginate",
-                "Alginic Acid",
-                "alginic acid"
+                "Latamoxef",
+                "Latamoxef (INN)",
+                "Moxalactam disodium (USAN)",
+                "Moxalactam",
+                "Festamoxin",
+                "moxalactam",
+                "latamoxef",
+                "MOXALACTAM"
               ],
               "all_categories": [
-                "biolink:ChemicalEntity",
                 "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:1551350",
-                "PMID:10848650",
-                "PMID:231639",
-                "PMID:27671545"
+                "PMID:20014752",
+                "PMID:17846134",
+                "PMID:6217353",
+                "PMID:17242148",
+                "PMID:18426954",
+                "PMID:18559652",
+                "PMID:19764786",
+                "PMID:12109906",
+                "PMID:18765691",
+                "PMID:19445515"
               ]
             }
           }
@@ -515870,87 +5782,39 @@
   },
   {
     "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:28859383': {'publication date': '2017 Oct 01', 'sentence': 'Alginate-based formulations are frequently used as add-on proton pump inhibitor (PPI) therapy to help control of heartburn and regurgitation.', 'subject score': 606, 'object score': 1000}, 'PMID:30182358': {'publication date': '2018 Dec', 'sentence': 'The Effect of Alginate in Gastroesophageal Reflux in Infants.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
       "start": {
-        "identity": 321369,
+        "identity": 538300,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007186",
-          "name": "gastroesophageal reflux disease",
-          "description": "A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C26781\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26781\" NCI Thesaurus); A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.; Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.; A condition in which the stomach contents leak backwards from the stomach into the esophagus through the lower esophageal sphincter. [HPO:probinson]; UMLS Semantic Type: STY:T047",
+          "iri": "http://id.nlm.nih.gov/mesh/D000900",
+          "name": "Anti-Bacterial Agents",
+          "description": "A family of substances capable of destroying or inhibiting the growth of bacteria.; Substances that kill BACTERIA.; UMLS Semantic Type: STY:T195",
           "equivalent_curies": [
-            "ICD10:K21.9",
-            "UMLS:C4317146",
-            "NCIT:C26781",
-            "MEDDRA:10037676",
-            "PDQ:CDR0000737473",
-            "NCIT:C34670",
-            "UMLS:C3813607",
-            "MEDDRA:10066874",
-            "MEDDRA:10015389",
-            "ICD9:787.1",
-            "SNOMEDCT:698065002",
-            "UMLS:C0018834",
-            "OMIM:109350",
-            "MESH:D006356",
-            "UMLS:C0017168",
-            "DOID:8534",
-            "NCIT:C92560",
-            "SNOMEDCT:235595009",
-            "MEDDRA:10019326",
-            "HP:0002020",
-            "MEDDRA:10018203",
-            "MESH:D005764",
-            "MEDDRA:10017924",
-            "MEDDRA:10030182",
-            "SNOMEDCT:722884003",
-            "MONDO:0007186",
-            "ICD9:530.81",
-            "EFO:0003948",
-            "MEDDRA:10017884",
-            "MEDDRA:10017885",
-            "SNOMEDCT:16331000",
-            "NCIT:C113396"
+            "MESH:D000900",
+            "UMLS:C0279516",
+            "CHEBI:36047"
           ],
-          "id": "MONDO:0007186",
-          "category": "biolink:Disease",
+          "id": "MESH:D000900",
+          "category": "biolink:ChemicalEntity",
           "all_names": [
-            "Gastroesophageal Reflux Disease",
-            "Acid reflux",
-            "Gastroesophageal reflux",
-            "Esophageal reflux",
-            "Gastroesophageal Reflux",
-            "Gastroesophageal reflux disease",
-            "Infantile Gastroesophageal Reflux",
-            "gastroesophageal reflux disease",
-            "Gastroesophageal reflux related phenotypic feature",
-            "Heartburn"
+            "antibacterial drug",
+            "Anti-Bacterial Agents"
           ],
           "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-5316-1399"
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 629,
+        "identity": 553,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -515967,161 +5831,119 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "(Alginate)n",
-          "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+          "name": "Latamoxef",
+          "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "MESH:D000077322",
-            "UMLS:C0102137",
-            "KEGG.GLYCAN:G00316",
-            "UMLS:C0051156",
-            "KEGG.GLYCAN:G07471",
-            "KEGG.GLYCAN:G07287",
-            "KEGG.GLYCAN:G08476",
-            "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-            "DRUGBANK:DB13518",
-            "DrugCentral:4321",
-            "KEGG.DRUG:D02324",
-            "UNII:8C3Z4148WZ",
-            "KEGG.COMPOUND:C01768",
-            "CHEBI:17548",
-            "NDDF:002434",
-            "RXNORM:17305",
-            "RXNORM:1370451",
-            "NCIT:C82277",
-            "CHEMBL.COMPOUND:CHEMBL2108894",
-            "MESH:C008970",
-            "PUBCHEM.COMPOUND:91666318",
-            "ATC:A02BX13",
-            "KEGG.GLYCAN:G02561",
-            "UMLS:C4694124",
-            "KEGG.GLYCAN:G10593"
+            "ATC:J01DD06",
+            "NDDF:004889",
+            "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
+            "CHEMBL.COMPOUND:CHEMBL74632",
+            "UMLS:C0878141",
+            "CHEBI:599928",
+            "RXNORM:7069",
+            "PUBCHEM.COMPOUND:47499",
+            "PDQ:CDR0000039507",
+            "UMLS:C0026651",
+            "KEGG.DRUG:D02198",
+            "DRUGBANK:DB04570",
+            "KEGG.COMPOUND:C07231",
+            "NCIT:C670",
+            "GTOPDB:12031",
+            "KEGG.DRUG:D08109",
+            "HMDB:HMDB0015574",
+            "DrugCentral:1851",
+            "UNII:VUF6C936Z3",
+            "MESH:D009070"
           ],
-          "id": "PUBCHEM.COMPOUND:91666318",
+          "id": "PUBCHEM.COMPOUND:47499",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "(Alginate)n",
-            "Alginate",
-            "Norgine",
-            "Alginic acid",
-            "Alginic acid (NF)",
-            "ALGINIC ACID",
-            "alginate",
-            "Alginic Acid",
-            "alginic acid"
+            "Latamoxef",
+            "Latamoxef (INN)",
+            "Moxalactam disodium (USAN)",
+            "Moxalactam",
+            "Festamoxin",
+            "moxalactam",
+            "latamoxef",
+            "MOXALACTAM"
           ],
           "all_categories": [
-            "biolink:ChemicalEntity",
             "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:1551350",
-            "PMID:10848650",
-            "PMID:231639",
-            "PMID:27671545"
+            "PMID:20014752",
+            "PMID:17846134",
+            "PMID:6217353",
+            "PMID:17242148",
+            "PMID:18426954",
+            "PMID:18559652",
+            "PMID:19764786",
+            "PMID:12109906",
+            "PMID:18765691",
+            "PMID:19445515"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 321369,
+            "identity": 538300,
             "labels": [
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007186",
-              "name": "gastroesophageal reflux disease",
-              "description": "A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C26781\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26781\" NCI Thesaurus); A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.; Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.; A condition in which the stomach contents leak backwards from the stomach into the esophagus through the lower esophageal sphincter. [HPO:probinson]; UMLS Semantic Type: STY:T047",
+              "iri": "http://id.nlm.nih.gov/mesh/D000900",
+              "name": "Anti-Bacterial Agents",
+              "description": "A family of substances capable of destroying or inhibiting the growth of bacteria.; Substances that kill BACTERIA.; UMLS Semantic Type: STY:T195",
               "equivalent_curies": [
-                "ICD10:K21.9",
-                "UMLS:C4317146",
-                "NCIT:C26781",
-                "MEDDRA:10037676",
-                "PDQ:CDR0000737473",
-                "NCIT:C34670",
-                "UMLS:C3813607",
-                "MEDDRA:10066874",
-                "MEDDRA:10015389",
-                "ICD9:787.1",
-                "SNOMEDCT:698065002",
-                "UMLS:C0018834",
-                "OMIM:109350",
-                "MESH:D006356",
-                "UMLS:C0017168",
-                "DOID:8534",
-                "NCIT:C92560",
-                "SNOMEDCT:235595009",
-                "MEDDRA:10019326",
-                "HP:0002020",
-                "MEDDRA:10018203",
-                "MESH:D005764",
-                "MEDDRA:10017924",
-                "MEDDRA:10030182",
-                "SNOMEDCT:722884003",
-                "MONDO:0007186",
-                "ICD9:530.81",
-                "EFO:0003948",
-                "MEDDRA:10017884",
-                "MEDDRA:10017885",
-                "SNOMEDCT:16331000",
-                "NCIT:C113396"
+                "MESH:D000900",
+                "UMLS:C0279516",
+                "CHEBI:36047"
               ],
-              "id": "MONDO:0007186",
-              "category": "biolink:Disease",
+              "id": "MESH:D000900",
+              "category": "biolink:ChemicalEntity",
               "all_names": [
-                "Gastroesophageal Reflux Disease",
-                "Acid reflux",
-                "Gastroesophageal reflux",
-                "Esophageal reflux",
-                "Gastroesophageal Reflux",
-                "Gastroesophageal reflux disease",
-                "Infantile Gastroesophageal Reflux",
-                "gastroesophageal reflux disease",
-                "Gastroesophageal reflux related phenotypic feature",
-                "Heartburn"
+                "antibacterial drug",
+                "Anti-Bacterial Agents"
               ],
               "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-5316-1399"
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-            "identity": 19465962,
-            "start": 629,
-            "end": 321369,
-            "type": "biolink:affects",
+            "identity": 18655165,
+            "start": 553,
+            "end": 538300,
+            "type": "biolink:subclass_of",
             "properties": {
-              "predicate": "biolink:affects",
+              "predicate": "biolink:subclass_of",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28859383': {'publication date': '2017 Oct 01', 'sentence': 'Alginate-based formulations are frequently used as add-on proton pump inhibitor (PPI) therapy to help control of heartburn and regurgitation.', 'subject score': 606, 'object score': 1000}, 'PMID:30182358': {'publication date': '2018 Dec', 'sentence': 'The Effect of Alginate in Gastroesophageal Reflux in Infants.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:27266357': {'publication date': '2016 May 17', 'sentence': 'METHODS: Minimum inhibitory concentrations (MICs) of moxalactam and other antibacterial agents against 491 Enterobacteriaceae spp. and anaerobic spp.collecting from clinical settings were determined by agar dilution methods and E-test strips according to the Clinical and Laboratory Standards Institute (CLSI)(2014).', 'subject score': 1000, 'object score': 1000}, 'PMID:3886949': {'publication date': '1985 Jan', 'sentence': 'Antibacterial activity of cefmenoxime (CMX) against clinically isolated organisms was examined in comparison with that of 4 other antibiotics and concluded as follows: Antibacterial activity of CMX was markedly stronger than those of cefazolin (CEZ), cefmetazole, latamoxef and ampicillin against E. coli, K. pneumoniae, S. marcescens, H. influenzae, P. mirabilis and indole positive Proteus.', 'subject score': 1000, 'object score': 888}, 'PMID:6573324': {'publication date': '1983 Jan', 'sentence': 'Cefotetan was noted to have a broader spectrum of activity than cefoxitin and its antibacterial activity was comparable to that of cefotaxime and moxalactam.', 'subject score': 1000, 'object score': 888}}",
               "kg2_ids": [
-                "UMLS:C0102137---SEMMEDDB:affects---None---None---None---UMLS:C0018834---SEMMEDDB:",
-                "UMLS:C0102137---SEMMEDDB:affects---None---None---None---UMLS:C0017168---SEMMEDDB:"
+                "UMLS:C0026651---SEMMEDDB:isa---None---None---None---UMLS:C0279516---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:91666318",
-              "id": "19854419",
-              "object": "MONDO:0007186",
+              "subject": "PUBCHEM.COMPOUND:47499",
+              "id": "19031059",
+              "object": "MESH:D000900",
               "publications": [
-                "PMID:30182358",
-                "PMID:28859383"
+                "PMID:27266357",
+                "PMID:3886949",
+                "PMID:6573324"
               ]
             }
           },
           "end": {
-            "identity": 629,
+            "identity": 553,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -516138,58 +5960,58 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "(Alginate)n",
-              "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+              "name": "Latamoxef",
+              "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "MESH:D000077322",
-                "UMLS:C0102137",
-                "KEGG.GLYCAN:G00316",
-                "UMLS:C0051156",
-                "KEGG.GLYCAN:G07471",
-                "KEGG.GLYCAN:G07287",
-                "KEGG.GLYCAN:G08476",
-                "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-                "DRUGBANK:DB13518",
-                "DrugCentral:4321",
-                "KEGG.DRUG:D02324",
-                "UNII:8C3Z4148WZ",
-                "KEGG.COMPOUND:C01768",
-                "CHEBI:17548",
-                "NDDF:002434",
-                "RXNORM:17305",
-                "RXNORM:1370451",
-                "NCIT:C82277",
-                "CHEMBL.COMPOUND:CHEMBL2108894",
-                "MESH:C008970",
-                "PUBCHEM.COMPOUND:91666318",
-                "ATC:A02BX13",
-                "KEGG.GLYCAN:G02561",
-                "UMLS:C4694124",
-                "KEGG.GLYCAN:G10593"
+                "ATC:J01DD06",
+                "NDDF:004889",
+                "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
+                "CHEMBL.COMPOUND:CHEMBL74632",
+                "UMLS:C0878141",
+                "CHEBI:599928",
+                "RXNORM:7069",
+                "PUBCHEM.COMPOUND:47499",
+                "PDQ:CDR0000039507",
+                "UMLS:C0026651",
+                "KEGG.DRUG:D02198",
+                "DRUGBANK:DB04570",
+                "KEGG.COMPOUND:C07231",
+                "NCIT:C670",
+                "GTOPDB:12031",
+                "KEGG.DRUG:D08109",
+                "HMDB:HMDB0015574",
+                "DrugCentral:1851",
+                "UNII:VUF6C936Z3",
+                "MESH:D009070"
               ],
-              "id": "PUBCHEM.COMPOUND:91666318",
+              "id": "PUBCHEM.COMPOUND:47499",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "(Alginate)n",
-                "Alginate",
-                "Norgine",
-                "Alginic acid",
-                "Alginic acid (NF)",
-                "ALGINIC ACID",
-                "alginate",
-                "Alginic Acid",
-                "alginic acid"
+                "Latamoxef",
+                "Latamoxef (INN)",
+                "Moxalactam disodium (USAN)",
+                "Moxalactam",
+                "Festamoxin",
+                "moxalactam",
+                "latamoxef",
+                "MOXALACTAM"
               ],
               "all_categories": [
-                "biolink:ChemicalEntity",
                 "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:1551350",
-                "PMID:10848650",
-                "PMID:231639",
-                "PMID:27671545"
+                "PMID:20014752",
+                "PMID:17846134",
+                "PMID:6217353",
+                "PMID:17242148",
+                "PMID:18426954",
+                "PMID:18559652",
+                "PMID:19764786",
+                "PMID:12109906",
+                "PMID:18765691",
+                "PMID:19445515"
               ]
             }
           }
@@ -516199,52 +6021,40 @@
     }
   },
   {
-<<<<<<< HEAD
     "p3": {
       "start": {
-        "identity": 316891,
+        "identity": 538300,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
+          "iri": "http://id.nlm.nih.gov/mesh/D000900",
+          "name": "Anti-Bacterial Agents",
+          "description": "A family of substances capable of destroying or inhibiting the growth of bacteria.; Substances that kill BACTERIA.; UMLS Semantic Type: STY:T195",
           "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
+            "MESH:D000900",
+            "UMLS:C0279516",
+            "CHEBI:36047"
           ],
-          "id": "HP:0012531",
-          "category": "biolink:PhenotypicFeature",
+          "id": "MESH:D000900",
+          "category": "biolink:ChemicalEntity",
           "all_names": [
-            "pain",
-            "Pain"
+            "antibacterial drug",
+            "Anti-Bacterial Agents"
           ],
           "all_categories": [
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 629,
+        "identity": 553,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -516261,128 +6071,117 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "(Alginate)n",
-          "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+          "name": "Latamoxef",
+          "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "MESH:D000077322",
-            "UMLS:C0102137",
-            "KEGG.GLYCAN:G00316",
-            "UMLS:C0051156",
-            "KEGG.GLYCAN:G07471",
-            "KEGG.GLYCAN:G07287",
-            "KEGG.GLYCAN:G08476",
-            "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-            "DRUGBANK:DB13518",
-            "DrugCentral:4321",
-            "KEGG.DRUG:D02324",
-            "UNII:8C3Z4148WZ",
-            "KEGG.COMPOUND:C01768",
-            "CHEBI:17548",
-            "NDDF:002434",
-            "RXNORM:17305",
-            "RXNORM:1370451",
-            "NCIT:C82277",
-            "CHEMBL.COMPOUND:CHEMBL2108894",
-            "MESH:C008970",
-            "PUBCHEM.COMPOUND:91666318",
-            "ATC:A02BX13",
-            "KEGG.GLYCAN:G02561",
-            "UMLS:C4694124",
-            "KEGG.GLYCAN:G10593"
+            "ATC:J01DD06",
+            "NDDF:004889",
+            "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
+            "CHEMBL.COMPOUND:CHEMBL74632",
+            "UMLS:C0878141",
+            "CHEBI:599928",
+            "RXNORM:7069",
+            "PUBCHEM.COMPOUND:47499",
+            "PDQ:CDR0000039507",
+            "UMLS:C0026651",
+            "KEGG.DRUG:D02198",
+            "DRUGBANK:DB04570",
+            "KEGG.COMPOUND:C07231",
+            "NCIT:C670",
+            "GTOPDB:12031",
+            "KEGG.DRUG:D08109",
+            "HMDB:HMDB0015574",
+            "DrugCentral:1851",
+            "UNII:VUF6C936Z3",
+            "MESH:D009070"
           ],
-          "id": "PUBCHEM.COMPOUND:91666318",
+          "id": "PUBCHEM.COMPOUND:47499",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "(Alginate)n",
-            "Alginate",
-            "Norgine",
-            "Alginic acid",
-            "Alginic acid (NF)",
-            "ALGINIC ACID",
-            "alginate",
-            "Alginic Acid",
-            "alginic acid"
+            "Latamoxef",
+            "Latamoxef (INN)",
+            "Moxalactam disodium (USAN)",
+            "Moxalactam",
+            "Festamoxin",
+            "moxalactam",
+            "latamoxef",
+            "MOXALACTAM"
           ],
           "all_categories": [
-            "biolink:ChemicalEntity",
             "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:1551350",
-            "PMID:10848650",
-            "PMID:231639",
-            "PMID:27671545"
+            "PMID:20014752",
+            "PMID:17846134",
+            "PMID:6217353",
+            "PMID:17242148",
+            "PMID:18426954",
+            "PMID:18559652",
+            "PMID:19764786",
+            "PMID:12109906",
+            "PMID:18765691",
+            "PMID:19445515"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 316891,
+            "identity": 538300,
             "labels": [
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
+              "iri": "http://id.nlm.nih.gov/mesh/D000900",
+              "name": "Anti-Bacterial Agents",
+              "description": "A family of substances capable of destroying or inhibiting the growth of bacteria.; Substances that kill BACTERIA.; UMLS Semantic Type: STY:T195",
               "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
+                "MESH:D000900",
+                "UMLS:C0279516",
+                "CHEBI:36047"
               ],
-              "id": "HP:0012531",
-              "category": "biolink:PhenotypicFeature",
+              "id": "MESH:D000900",
+              "category": "biolink:ChemicalEntity",
               "all_names": [
-                "pain",
-                "Pain"
+                "antibacterial drug",
+                "Anti-Bacterial Agents"
               ],
               "all_categories": [
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-            "identity": 22361630,
-            "start": 629,
-            "end": 316891,
-            "type": "biolink:treats",
+            "identity": 18655164,
+            "start": 553,
+            "end": 538300,
+            "type": "biolink:related_to",
             "properties": {
-              "predicate": "biolink:treats",
+              "predicate": "biolink:related_to",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:33282832': {'publication date': '2020', 'sentence': 'With these results, we propose alginate-based nanoemulsions as a potential treatment for migraine pain.', 'subject score': 840, 'object score': 888}}",
+              "publications_info": "{'PMID:27266357': {'publication date': '2016 May 17', 'sentence': 'OBJECTIVE: To observe the antibacterial activity of moxalactam against Enterobacteriaceae bacteria and anaerobic bacteria in vitro, and to compare with other antibacterial drugs, for providing experimental basis for the clinical application of moxalactam.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0102137---SEMMEDDB:treats---None---None---None---UMLS:C0030193---SEMMEDDB:"
+                "UMLS:C0026651---SEMMEDDB:compared_with---None---None---None---UMLS:C0279516---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:91666318",
-              "id": "22788639",
-              "object": "HP:0012531",
+              "subject": "PUBCHEM.COMPOUND:47499",
+              "id": "19031058",
+              "object": "MESH:D000900",
               "publications": [
-                "PMID:33282832"
+                "PMID:27266357"
               ]
             }
           },
           "end": {
-            "identity": 629,
+            "identity": 553,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -516399,58 +6198,58 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "(Alginate)n",
-              "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+              "name": "Latamoxef",
+              "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "MESH:D000077322",
-                "UMLS:C0102137",
-                "KEGG.GLYCAN:G00316",
-                "UMLS:C0051156",
-                "KEGG.GLYCAN:G07471",
-                "KEGG.GLYCAN:G07287",
-                "KEGG.GLYCAN:G08476",
-                "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-                "DRUGBANK:DB13518",
-                "DrugCentral:4321",
-                "KEGG.DRUG:D02324",
-                "UNII:8C3Z4148WZ",
-                "KEGG.COMPOUND:C01768",
-                "CHEBI:17548",
-                "NDDF:002434",
-                "RXNORM:17305",
-                "RXNORM:1370451",
-                "NCIT:C82277",
-                "CHEMBL.COMPOUND:CHEMBL2108894",
-                "MESH:C008970",
-                "PUBCHEM.COMPOUND:91666318",
-                "ATC:A02BX13",
-                "KEGG.GLYCAN:G02561",
-                "UMLS:C4694124",
-                "KEGG.GLYCAN:G10593"
+                "ATC:J01DD06",
+                "NDDF:004889",
+                "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
+                "CHEMBL.COMPOUND:CHEMBL74632",
+                "UMLS:C0878141",
+                "CHEBI:599928",
+                "RXNORM:7069",
+                "PUBCHEM.COMPOUND:47499",
+                "PDQ:CDR0000039507",
+                "UMLS:C0026651",
+                "KEGG.DRUG:D02198",
+                "DRUGBANK:DB04570",
+                "KEGG.COMPOUND:C07231",
+                "NCIT:C670",
+                "GTOPDB:12031",
+                "KEGG.DRUG:D08109",
+                "HMDB:HMDB0015574",
+                "DrugCentral:1851",
+                "UNII:VUF6C936Z3",
+                "MESH:D009070"
               ],
-              "id": "PUBCHEM.COMPOUND:91666318",
+              "id": "PUBCHEM.COMPOUND:47499",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "(Alginate)n",
-                "Alginate",
-                "Norgine",
-                "Alginic acid",
-                "Alginic acid (NF)",
-                "ALGINIC ACID",
-                "alginate",
-                "Alginic Acid",
-                "alginic acid"
+                "Latamoxef",
+                "Latamoxef (INN)",
+                "Moxalactam disodium (USAN)",
+                "Moxalactam",
+                "Festamoxin",
+                "moxalactam",
+                "latamoxef",
+                "MOXALACTAM"
               ],
               "all_categories": [
-                "biolink:ChemicalEntity",
                 "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:1551350",
-                "PMID:10848650",
-                "PMID:231639",
-                "PMID:27671545"
+                "PMID:20014752",
+                "PMID:17846134",
+                "PMID:6217353",
+                "PMID:17242148",
+                "PMID:18426954",
+                "PMID:18559652",
+                "PMID:19764786",
+                "PMID:12109906",
+                "PMID:18765691",
+                "PMID:19445515"
               ]
             }
           }
@@ -516461,87 +6260,39 @@
   },
   {
     "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:1485782': {'publication date': '1992 Dec', 'sentence': 'An open multicenter study was performed to assess the efficacy and safety of alginic acid in two different dosages in 76 pediatric patients with gastroesophageal reflux confirmed by pH monitoring.', 'subject score': 1000, 'object score': 1000}, 'PMID:1855691': {'publication date': '1991 Jul', 'sentence': 'Combination of cimetidine and alginic acid: an improvement in the treatment of oesophageal reflux disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:27179107': {'publication date': '2017 02', 'sentence': 'Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial.', 'subject score': 1000, 'object score': 857}, 'PMID:29199169': {'publication date': '2017 12', 'sentence': 'In the medical treatment of pregnant women with GERD, alginic acid and sucralfate can be used.', 'subject score': 1000, 'object score': 1000}, 'PMID:20489030': {'publication date': '2010 Nov', 'sentence': 'Na alginate treatment for gastroesophageal reflux disease in preterm infants seems to be safe and effective.', 'subject score': 851, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
       "start": {
-        "identity": 321369,
+        "identity": 538300,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007186",
-          "name": "gastroesophageal reflux disease",
-          "description": "A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C26781\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26781\" NCI Thesaurus); A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.; Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.; A condition in which the stomach contents leak backwards from the stomach into the esophagus through the lower esophageal sphincter. [HPO:probinson]; UMLS Semantic Type: STY:T047",
+          "iri": "http://id.nlm.nih.gov/mesh/D000900",
+          "name": "Anti-Bacterial Agents",
+          "description": "A family of substances capable of destroying or inhibiting the growth of bacteria.; Substances that kill BACTERIA.; UMLS Semantic Type: STY:T195",
           "equivalent_curies": [
-            "ICD10:K21.9",
-            "UMLS:C4317146",
-            "NCIT:C26781",
-            "MEDDRA:10037676",
-            "PDQ:CDR0000737473",
-            "NCIT:C34670",
-            "UMLS:C3813607",
-            "MEDDRA:10066874",
-            "MEDDRA:10015389",
-            "ICD9:787.1",
-            "SNOMEDCT:698065002",
-            "UMLS:C0018834",
-            "OMIM:109350",
-            "MESH:D006356",
-            "UMLS:C0017168",
-            "DOID:8534",
-            "NCIT:C92560",
-            "SNOMEDCT:235595009",
-            "MEDDRA:10019326",
-            "HP:0002020",
-            "MEDDRA:10018203",
-            "MESH:D005764",
-            "MEDDRA:10017924",
-            "MEDDRA:10030182",
-            "SNOMEDCT:722884003",
-            "MONDO:0007186",
-            "ICD9:530.81",
-            "EFO:0003948",
-            "MEDDRA:10017884",
-            "MEDDRA:10017885",
-            "SNOMEDCT:16331000",
-            "NCIT:C113396"
+            "MESH:D000900",
+            "UMLS:C0279516",
+            "CHEBI:36047"
           ],
-          "id": "MONDO:0007186",
-          "category": "biolink:Disease",
+          "id": "MESH:D000900",
+          "category": "biolink:ChemicalEntity",
           "all_names": [
-            "Gastroesophageal Reflux Disease",
-            "Acid reflux",
-            "Gastroesophageal reflux",
-            "Esophageal reflux",
-            "Gastroesophageal Reflux",
-            "Gastroesophageal reflux disease",
-            "Infantile Gastroesophageal Reflux",
-            "gastroesophageal reflux disease",
-            "Gastroesophageal reflux related phenotypic feature",
-            "Heartburn"
+            "antibacterial drug",
+            "Anti-Bacterial Agents"
           ],
           "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-5316-1399"
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 629,
+        "identity": 553,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -516558,164 +6309,117 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "(Alginate)n",
-          "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+          "name": "Latamoxef",
+          "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "MESH:D000077322",
-            "UMLS:C0102137",
-            "KEGG.GLYCAN:G00316",
-            "UMLS:C0051156",
-            "KEGG.GLYCAN:G07471",
-            "KEGG.GLYCAN:G07287",
-            "KEGG.GLYCAN:G08476",
-            "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-            "DRUGBANK:DB13518",
-            "DrugCentral:4321",
-            "KEGG.DRUG:D02324",
-            "UNII:8C3Z4148WZ",
-            "KEGG.COMPOUND:C01768",
-            "CHEBI:17548",
-            "NDDF:002434",
-            "RXNORM:17305",
-            "RXNORM:1370451",
-            "NCIT:C82277",
-            "CHEMBL.COMPOUND:CHEMBL2108894",
-            "MESH:C008970",
-            "PUBCHEM.COMPOUND:91666318",
-            "ATC:A02BX13",
-            "KEGG.GLYCAN:G02561",
-            "UMLS:C4694124",
-            "KEGG.GLYCAN:G10593"
+            "ATC:J01DD06",
+            "NDDF:004889",
+            "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
+            "CHEMBL.COMPOUND:CHEMBL74632",
+            "UMLS:C0878141",
+            "CHEBI:599928",
+            "RXNORM:7069",
+            "PUBCHEM.COMPOUND:47499",
+            "PDQ:CDR0000039507",
+            "UMLS:C0026651",
+            "KEGG.DRUG:D02198",
+            "DRUGBANK:DB04570",
+            "KEGG.COMPOUND:C07231",
+            "NCIT:C670",
+            "GTOPDB:12031",
+            "KEGG.DRUG:D08109",
+            "HMDB:HMDB0015574",
+            "DrugCentral:1851",
+            "UNII:VUF6C936Z3",
+            "MESH:D009070"
           ],
-          "id": "PUBCHEM.COMPOUND:91666318",
+          "id": "PUBCHEM.COMPOUND:47499",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "(Alginate)n",
-            "Alginate",
-            "Norgine",
-            "Alginic acid",
-            "Alginic acid (NF)",
-            "ALGINIC ACID",
-            "alginate",
-            "Alginic Acid",
-            "alginic acid"
+            "Latamoxef",
+            "Latamoxef (INN)",
+            "Moxalactam disodium (USAN)",
+            "Moxalactam",
+            "Festamoxin",
+            "moxalactam",
+            "latamoxef",
+            "MOXALACTAM"
           ],
           "all_categories": [
-            "biolink:ChemicalEntity",
             "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:1551350",
-            "PMID:10848650",
-            "PMID:231639",
-            "PMID:27671545"
+            "PMID:20014752",
+            "PMID:17846134",
+            "PMID:6217353",
+            "PMID:17242148",
+            "PMID:18426954",
+            "PMID:18559652",
+            "PMID:19764786",
+            "PMID:12109906",
+            "PMID:18765691",
+            "PMID:19445515"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 321369,
+            "identity": 538300,
             "labels": [
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007186",
-              "name": "gastroesophageal reflux disease",
-              "description": "A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C26781\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26781\" NCI Thesaurus); A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.; Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.; A condition in which the stomach contents leak backwards from the stomach into the esophagus through the lower esophageal sphincter. [HPO:probinson]; UMLS Semantic Type: STY:T047",
+              "iri": "http://id.nlm.nih.gov/mesh/D000900",
+              "name": "Anti-Bacterial Agents",
+              "description": "A family of substances capable of destroying or inhibiting the growth of bacteria.; Substances that kill BACTERIA.; UMLS Semantic Type: STY:T195",
               "equivalent_curies": [
-                "ICD10:K21.9",
-                "UMLS:C4317146",
-                "NCIT:C26781",
-                "MEDDRA:10037676",
-                "PDQ:CDR0000737473",
-                "NCIT:C34670",
-                "UMLS:C3813607",
-                "MEDDRA:10066874",
-                "MEDDRA:10015389",
-                "ICD9:787.1",
-                "SNOMEDCT:698065002",
-                "UMLS:C0018834",
-                "OMIM:109350",
-                "MESH:D006356",
-                "UMLS:C0017168",
-                "DOID:8534",
-                "NCIT:C92560",
-                "SNOMEDCT:235595009",
-                "MEDDRA:10019326",
-                "HP:0002020",
-                "MEDDRA:10018203",
-                "MESH:D005764",
-                "MEDDRA:10017924",
-                "MEDDRA:10030182",
-                "SNOMEDCT:722884003",
-                "MONDO:0007186",
-                "ICD9:530.81",
-                "EFO:0003948",
-                "MEDDRA:10017884",
-                "MEDDRA:10017885",
-                "SNOMEDCT:16331000",
-                "NCIT:C113396"
+                "MESH:D000900",
+                "UMLS:C0279516",
+                "CHEBI:36047"
               ],
-              "id": "MONDO:0007186",
-              "category": "biolink:Disease",
+              "id": "MESH:D000900",
+              "category": "biolink:ChemicalEntity",
               "all_names": [
-                "Gastroesophageal Reflux Disease",
-                "Acid reflux",
-                "Gastroesophageal reflux",
-                "Esophageal reflux",
-                "Gastroesophageal Reflux",
-                "Gastroesophageal reflux disease",
-                "Infantile Gastroesophageal Reflux",
-                "gastroesophageal reflux disease",
-                "Gastroesophageal reflux related phenotypic feature",
-                "Heartburn"
+                "antibacterial drug",
+                "Anti-Bacterial Agents"
               ],
               "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-5316-1399"
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-            "identity": 10779419,
-            "start": 629,
-            "end": 321369,
-            "type": "biolink:treats",
+            "identity": 18655164,
+            "start": 553,
+            "end": 538300,
+            "type": "biolink:related_to",
             "properties": {
-              "predicate": "biolink:treats",
+              "predicate": "biolink:related_to",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1485782': {'publication date': '1992 Dec', 'sentence': 'An open multicenter study was performed to assess the efficacy and safety of alginic acid in two different dosages in 76 pediatric patients with gastroesophageal reflux confirmed by pH monitoring.', 'subject score': 1000, 'object score': 1000}, 'PMID:1855691': {'publication date': '1991 Jul', 'sentence': 'Combination of cimetidine and alginic acid: an improvement in the treatment of oesophageal reflux disease.', 'subject score': 1000, 'object score': 1000}, 'PMID:27179107': {'publication date': '2017 02', 'sentence': 'Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial.', 'subject score': 1000, 'object score': 857}, 'PMID:29199169': {'publication date': '2017 12', 'sentence': 'In the medical treatment of pregnant women with GERD, alginic acid and sucralfate can be used.', 'subject score': 1000, 'object score': 1000}, 'PMID:20489030': {'publication date': '2010 Nov', 'sentence': 'Na alginate treatment for gastroesophageal reflux disease in preterm infants seems to be safe and effective.', 'subject score': 851, 'object score': 1000}}",
+              "publications_info": "{'PMID:27266357': {'publication date': '2016 May 17', 'sentence': 'OBJECTIVE: To observe the antibacterial activity of moxalactam against Enterobacteriaceae bacteria and anaerobic bacteria in vitro, and to compare with other antibacterial drugs, for providing experimental basis for the clinical application of moxalactam.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0051156---SEMMEDDB:treats---None---None---None---UMLS:C0017168---SEMMEDDB:",
-                "UMLS:C0102137---SEMMEDDB:treats---None---None---None---UMLS:C0017168---SEMMEDDB:"
+                "UMLS:C0026651---SEMMEDDB:compared_with---None---None---None---UMLS:C0279516---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:91666318",
-              "id": "11016107",
-              "object": "MONDO:0007186",
+              "subject": "PUBCHEM.COMPOUND:47499",
+              "id": "19031058",
+              "object": "MESH:D000900",
               "publications": [
-                "PMID:20489030",
-                "PMID:1485782",
-                "PMID:27179107",
-                "PMID:29199169",
-                "PMID:1855691"
+                "PMID:27266357"
               ]
             }
           },
           "end": {
-            "identity": 629,
+            "identity": 553,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -516732,58 +6436,58 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "(Alginate)n",
-              "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+              "name": "Latamoxef",
+              "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "MESH:D000077322",
-                "UMLS:C0102137",
-                "KEGG.GLYCAN:G00316",
-                "UMLS:C0051156",
-                "KEGG.GLYCAN:G07471",
-                "KEGG.GLYCAN:G07287",
-                "KEGG.GLYCAN:G08476",
-                "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-                "DRUGBANK:DB13518",
-                "DrugCentral:4321",
-                "KEGG.DRUG:D02324",
-                "UNII:8C3Z4148WZ",
-                "KEGG.COMPOUND:C01768",
-                "CHEBI:17548",
-                "NDDF:002434",
-                "RXNORM:17305",
-                "RXNORM:1370451",
-                "NCIT:C82277",
-                "CHEMBL.COMPOUND:CHEMBL2108894",
-                "MESH:C008970",
-                "PUBCHEM.COMPOUND:91666318",
-                "ATC:A02BX13",
-                "KEGG.GLYCAN:G02561",
-                "UMLS:C4694124",
-                "KEGG.GLYCAN:G10593"
+                "ATC:J01DD06",
+                "NDDF:004889",
+                "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
+                "CHEMBL.COMPOUND:CHEMBL74632",
+                "UMLS:C0878141",
+                "CHEBI:599928",
+                "RXNORM:7069",
+                "PUBCHEM.COMPOUND:47499",
+                "PDQ:CDR0000039507",
+                "UMLS:C0026651",
+                "KEGG.DRUG:D02198",
+                "DRUGBANK:DB04570",
+                "KEGG.COMPOUND:C07231",
+                "NCIT:C670",
+                "GTOPDB:12031",
+                "KEGG.DRUG:D08109",
+                "HMDB:HMDB0015574",
+                "DrugCentral:1851",
+                "UNII:VUF6C936Z3",
+                "MESH:D009070"
               ],
-              "id": "PUBCHEM.COMPOUND:91666318",
+              "id": "PUBCHEM.COMPOUND:47499",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "(Alginate)n",
-                "Alginate",
-                "Norgine",
-                "Alginic acid",
-                "Alginic acid (NF)",
-                "ALGINIC ACID",
-                "alginate",
-                "Alginic Acid",
-                "alginic acid"
+                "Latamoxef",
+                "Latamoxef (INN)",
+                "Moxalactam disodium (USAN)",
+                "Moxalactam",
+                "Festamoxin",
+                "moxalactam",
+                "latamoxef",
+                "MOXALACTAM"
               ],
               "all_categories": [
-                "biolink:ChemicalEntity",
                 "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:1551350",
-                "PMID:10848650",
-                "PMID:231639",
-                "PMID:27671545"
+                "PMID:20014752",
+                "PMID:17846134",
+                "PMID:6217353",
+                "PMID:17242148",
+                "PMID:18426954",
+                "PMID:18559652",
+                "PMID:19764786",
+                "PMID:12109906",
+                "PMID:18765691",
+                "PMID:19445515"
               ]
             }
           }
@@ -516793,89 +6497,40 @@
     }
   },
   {
-<<<<<<< HEAD
     "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:10848650': {'publication date': '2000 Jun', 'sentence': 'Although some alginate-based formulations also contain antacid components which can provide significant acid neutralization capacity, the efficacy of these formulations to reduce heartburn symptoms does not appear to be totally dependent on the neutralization of bulk gastric contents.', 'subject score': 606, 'object score': 983}, 'PMID:16783042': {'publication date': '2006 Apr', 'sentence': 'BACKGROUND & OBJECTIVE: Omeprazole treats gastro-oesophageal reflux disease (GORD) by inhibition of acid secretion whereas alginate based reflux suppressants work by forming a low density raft of near neutral pH which floats on the stomach contents and physically impedes gastro-oesophageal reflux.', 'subject score': 597, 'object score': 1000}, 'PMID:30182358': {'publication date': '2018 Dec', 'sentence': 'AIMS: We assessed the efficacy of alginate to reduce GER episodes in infants.', 'subject score': 1000, 'object score': 901}, 'PMID:32606607': {'publication date': '2020', 'sentence': 'An antacid-alginate combination (under the trade name Gaviscon) is a natural-based product that effectively suppresses GERD.', 'subject score': 851, 'object score': 1000}, 'PMID:33982541': {'publication date': '2021 Jan-Feb', 'sentence': 'Alginate, a derivative from algae, is devoid of side effects and effectively counteracts gastric material reflux forming a foaming gel in the stomach.', 'subject score': 1000, 'object score': 901}, 'PMID:34283413': {'publication date': '2021 Sep', 'sentence': 'A Novel In Vitro Model for Determining the Optimum pH and Dose Volume of New Liquid Alginate for Infant Reflux Suppression.', 'subject score': 802, 'object score': 901}}",
-    "p2": {
->>>>>>> main
       "start": {
-        "identity": 321369,
+        "identity": 538300,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007186",
-          "name": "gastroesophageal reflux disease",
-          "description": "A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C26781\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26781\" NCI Thesaurus); A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.; Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.; A condition in which the stomach contents leak backwards from the stomach into the esophagus through the lower esophageal sphincter. [HPO:probinson]; UMLS Semantic Type: STY:T047",
+          "iri": "http://id.nlm.nih.gov/mesh/D000900",
+          "name": "Anti-Bacterial Agents",
+          "description": "A family of substances capable of destroying or inhibiting the growth of bacteria.; Substances that kill BACTERIA.; UMLS Semantic Type: STY:T195",
           "equivalent_curies": [
-            "ICD10:K21.9",
-            "UMLS:C4317146",
-            "NCIT:C26781",
-            "MEDDRA:10037676",
-            "PDQ:CDR0000737473",
-            "NCIT:C34670",
-            "UMLS:C3813607",
-            "MEDDRA:10066874",
-            "MEDDRA:10015389",
-            "ICD9:787.1",
-            "SNOMEDCT:698065002",
-            "UMLS:C0018834",
-            "OMIM:109350",
-            "MESH:D006356",
-            "UMLS:C0017168",
-            "DOID:8534",
-            "NCIT:C92560",
-            "SNOMEDCT:235595009",
-            "MEDDRA:10019326",
-            "HP:0002020",
-            "MEDDRA:10018203",
-            "MESH:D005764",
-            "MEDDRA:10017924",
-            "MEDDRA:10030182",
-            "SNOMEDCT:722884003",
-            "MONDO:0007186",
-            "ICD9:530.81",
-            "EFO:0003948",
-            "MEDDRA:10017884",
-            "MEDDRA:10017885",
-            "SNOMEDCT:16331000",
-            "NCIT:C113396"
+            "MESH:D000900",
+            "UMLS:C0279516",
+            "CHEBI:36047"
           ],
-          "id": "MONDO:0007186",
-          "category": "biolink:Disease",
+          "id": "MESH:D000900",
+          "category": "biolink:ChemicalEntity",
           "all_names": [
-            "Gastroesophageal Reflux Disease",
-            "Acid reflux",
-            "Gastroesophageal reflux",
-            "Esophageal reflux",
-            "Gastroesophageal Reflux",
-            "Gastroesophageal reflux disease",
-            "Infantile Gastroesophageal Reflux",
-            "gastroesophageal reflux disease",
-            "Gastroesophageal reflux related phenotypic feature",
-            "Heartburn"
+            "antibacterial drug",
+            "Anti-Bacterial Agents"
           ],
           "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-5316-1399"
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 629,
+        "identity": 553,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -516892,166 +6547,117 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "(Alginate)n",
-          "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+          "name": "Latamoxef",
+          "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "MESH:D000077322",
-            "UMLS:C0102137",
-            "KEGG.GLYCAN:G00316",
-            "UMLS:C0051156",
-            "KEGG.GLYCAN:G07471",
-            "KEGG.GLYCAN:G07287",
-            "KEGG.GLYCAN:G08476",
-            "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-            "DRUGBANK:DB13518",
-            "DrugCentral:4321",
-            "KEGG.DRUG:D02324",
-            "UNII:8C3Z4148WZ",
-            "KEGG.COMPOUND:C01768",
-            "CHEBI:17548",
-            "NDDF:002434",
-            "RXNORM:17305",
-            "RXNORM:1370451",
-            "NCIT:C82277",
-            "CHEMBL.COMPOUND:CHEMBL2108894",
-            "MESH:C008970",
-            "PUBCHEM.COMPOUND:91666318",
-            "ATC:A02BX13",
-            "KEGG.GLYCAN:G02561",
-            "UMLS:C4694124",
-            "KEGG.GLYCAN:G10593"
+            "ATC:J01DD06",
+            "NDDF:004889",
+            "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
+            "CHEMBL.COMPOUND:CHEMBL74632",
+            "UMLS:C0878141",
+            "CHEBI:599928",
+            "RXNORM:7069",
+            "PUBCHEM.COMPOUND:47499",
+            "PDQ:CDR0000039507",
+            "UMLS:C0026651",
+            "KEGG.DRUG:D02198",
+            "DRUGBANK:DB04570",
+            "KEGG.COMPOUND:C07231",
+            "NCIT:C670",
+            "GTOPDB:12031",
+            "KEGG.DRUG:D08109",
+            "HMDB:HMDB0015574",
+            "DrugCentral:1851",
+            "UNII:VUF6C936Z3",
+            "MESH:D009070"
           ],
-          "id": "PUBCHEM.COMPOUND:91666318",
+          "id": "PUBCHEM.COMPOUND:47499",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "(Alginate)n",
-            "Alginate",
-            "Norgine",
-            "Alginic acid",
-            "Alginic acid (NF)",
-            "ALGINIC ACID",
-            "alginate",
-            "Alginic Acid",
-            "alginic acid"
+            "Latamoxef",
+            "Latamoxef (INN)",
+            "Moxalactam disodium (USAN)",
+            "Moxalactam",
+            "Festamoxin",
+            "moxalactam",
+            "latamoxef",
+            "MOXALACTAM"
           ],
           "all_categories": [
-            "biolink:ChemicalEntity",
             "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:1551350",
-            "PMID:10848650",
-            "PMID:231639",
-            "PMID:27671545"
+            "PMID:20014752",
+            "PMID:17846134",
+            "PMID:6217353",
+            "PMID:17242148",
+            "PMID:18426954",
+            "PMID:18559652",
+            "PMID:19764786",
+            "PMID:12109906",
+            "PMID:18765691",
+            "PMID:19445515"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 321369,
+            "identity": 538300,
             "labels": [
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007186",
-              "name": "gastroesophageal reflux disease",
-              "description": "A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C26781\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26781\" NCI Thesaurus); A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.; Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.; A condition in which the stomach contents leak backwards from the stomach into the esophagus through the lower esophageal sphincter. [HPO:probinson]; UMLS Semantic Type: STY:T047",
+              "iri": "http://id.nlm.nih.gov/mesh/D000900",
+              "name": "Anti-Bacterial Agents",
+              "description": "A family of substances capable of destroying or inhibiting the growth of bacteria.; Substances that kill BACTERIA.; UMLS Semantic Type: STY:T195",
               "equivalent_curies": [
-                "ICD10:K21.9",
-                "UMLS:C4317146",
-                "NCIT:C26781",
-                "MEDDRA:10037676",
-                "PDQ:CDR0000737473",
-                "NCIT:C34670",
-                "UMLS:C3813607",
-                "MEDDRA:10066874",
-                "MEDDRA:10015389",
-                "ICD9:787.1",
-                "SNOMEDCT:698065002",
-                "UMLS:C0018834",
-                "OMIM:109350",
-                "MESH:D006356",
-                "UMLS:C0017168",
-                "DOID:8534",
-                "NCIT:C92560",
-                "SNOMEDCT:235595009",
-                "MEDDRA:10019326",
-                "HP:0002020",
-                "MEDDRA:10018203",
-                "MESH:D005764",
-                "MEDDRA:10017924",
-                "MEDDRA:10030182",
-                "SNOMEDCT:722884003",
-                "MONDO:0007186",
-                "ICD9:530.81",
-                "EFO:0003948",
-                "MEDDRA:10017884",
-                "MEDDRA:10017885",
-                "SNOMEDCT:16331000",
-                "NCIT:C113396"
+                "MESH:D000900",
+                "UMLS:C0279516",
+                "CHEBI:36047"
               ],
-              "id": "MONDO:0007186",
-              "category": "biolink:Disease",
+              "id": "MESH:D000900",
+              "category": "biolink:ChemicalEntity",
               "all_names": [
-                "Gastroesophageal Reflux Disease",
-                "Acid reflux",
-                "Gastroesophageal reflux",
-                "Esophageal reflux",
-                "Gastroesophageal Reflux",
-                "Gastroesophageal reflux disease",
-                "Infantile Gastroesophageal Reflux",
-                "gastroesophageal reflux disease",
-                "Gastroesophageal reflux related phenotypic feature",
-                "Heartburn"
+                "antibacterial drug",
+                "Anti-Bacterial Agents"
               ],
               "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-5316-1399"
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-            "identity": 8072663,
-            "start": 629,
-            "end": 321369,
-            "type": "biolink:disrupts",
+            "identity": 22359360,
+            "start": 538300,
+            "end": 553,
+            "type": "biolink:related_to",
             "properties": {
-              "predicate": "biolink:disrupts",
+              "predicate": "biolink:related_to",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10848650': {'publication date': '2000 Jun', 'sentence': 'Although some alginate-based formulations also contain antacid components which can provide significant acid neutralization capacity, the efficacy of these formulations to reduce heartburn symptoms does not appear to be totally dependent on the neutralization of bulk gastric contents.', 'subject score': 606, 'object score': 983}, 'PMID:16783042': {'publication date': '2006 Apr', 'sentence': 'BACKGROUND & OBJECTIVE: Omeprazole treats gastro-oesophageal reflux disease (GORD) by inhibition of acid secretion whereas alginate based reflux suppressants work by forming a low density raft of near neutral pH which floats on the stomach contents and physically impedes gastro-oesophageal reflux.', 'subject score': 597, 'object score': 1000}, 'PMID:30182358': {'publication date': '2018 Dec', 'sentence': 'AIMS: We assessed the efficacy of alginate to reduce GER episodes in infants.', 'subject score': 1000, 'object score': 901}, 'PMID:32606607': {'publication date': '2020', 'sentence': 'An antacid-alginate combination (under the trade name Gaviscon) is a natural-based product that effectively suppresses GERD.', 'subject score': 851, 'object score': 1000}, 'PMID:33982541': {'publication date': '2021 Jan-Feb', 'sentence': 'Alginate, a derivative from algae, is devoid of side effects and effectively counteracts gastric material reflux forming a foaming gel in the stomach.', 'subject score': 1000, 'object score': 901}, 'PMID:34283413': {'publication date': '2021 Sep', 'sentence': 'A Novel In Vitro Model for Determining the Optimum pH and Dose Volume of New Liquid Alginate for Infant Reflux Suppression.', 'subject score': 802, 'object score': 901}}",
+              "publications_info": "{'PMID:3327964': {'publication date': '1987 Oct', 'sentence': 'In vitro antibacterial activity of FMOX was evaluated in comparison to latamoxef (LMOX), cefmetazole (CMZ), cefazolin (CEZ) using clinically isolated strains of Gram-negative and Gram-positive bacteria.', 'subject score': 861, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0102137---SEMMEDDB:disrupts---None---None---None---UMLS:C0018834---SEMMEDDB:",
-                "UMLS:C0102137---SEMMEDDB:disrupts---None---None---None---UMLS:C0017168---SEMMEDDB:",
-                "UMLS:C0102137---SEMMEDDB:disrupts---None---None---None---UMLS:C3813607---SEMMEDDB:"
+                "UMLS:C0279516---SEMMEDDB:compared_with---None---None---None---UMLS:C0026651---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:91666318",
-              "id": "8246131",
-              "object": "MONDO:0007186",
+              "subject": "MESH:D000900",
+              "id": "22786151",
+              "object": "PUBCHEM.COMPOUND:47499",
               "publications": [
-                "PMID:30182358",
-                "PMID:10848650",
-                "PMID:33982541",
-                "PMID:34283413",
-                "PMID:32606607",
-                "PMID:16783042"
+                "PMID:3327964"
               ]
             }
           },
           "end": {
-            "identity": 629,
+            "identity": 553,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -517068,58 +6674,58 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "(Alginate)n",
-              "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+              "name": "Latamoxef",
+              "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "MESH:D000077322",
-                "UMLS:C0102137",
-                "KEGG.GLYCAN:G00316",
-                "UMLS:C0051156",
-                "KEGG.GLYCAN:G07471",
-                "KEGG.GLYCAN:G07287",
-                "KEGG.GLYCAN:G08476",
-                "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-                "DRUGBANK:DB13518",
-                "DrugCentral:4321",
-                "KEGG.DRUG:D02324",
-                "UNII:8C3Z4148WZ",
-                "KEGG.COMPOUND:C01768",
-                "CHEBI:17548",
-                "NDDF:002434",
-                "RXNORM:17305",
-                "RXNORM:1370451",
-                "NCIT:C82277",
-                "CHEMBL.COMPOUND:CHEMBL2108894",
-                "MESH:C008970",
-                "PUBCHEM.COMPOUND:91666318",
-                "ATC:A02BX13",
-                "KEGG.GLYCAN:G02561",
-                "UMLS:C4694124",
-                "KEGG.GLYCAN:G10593"
+                "ATC:J01DD06",
+                "NDDF:004889",
+                "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
+                "CHEMBL.COMPOUND:CHEMBL74632",
+                "UMLS:C0878141",
+                "CHEBI:599928",
+                "RXNORM:7069",
+                "PUBCHEM.COMPOUND:47499",
+                "PDQ:CDR0000039507",
+                "UMLS:C0026651",
+                "KEGG.DRUG:D02198",
+                "DRUGBANK:DB04570",
+                "KEGG.COMPOUND:C07231",
+                "NCIT:C670",
+                "GTOPDB:12031",
+                "KEGG.DRUG:D08109",
+                "HMDB:HMDB0015574",
+                "DrugCentral:1851",
+                "UNII:VUF6C936Z3",
+                "MESH:D009070"
               ],
-              "id": "PUBCHEM.COMPOUND:91666318",
+              "id": "PUBCHEM.COMPOUND:47499",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "(Alginate)n",
-                "Alginate",
-                "Norgine",
-                "Alginic acid",
-                "Alginic acid (NF)",
-                "ALGINIC ACID",
-                "alginate",
-                "Alginic Acid",
-                "alginic acid"
+                "Latamoxef",
+                "Latamoxef (INN)",
+                "Moxalactam disodium (USAN)",
+                "Moxalactam",
+                "Festamoxin",
+                "moxalactam",
+                "latamoxef",
+                "MOXALACTAM"
               ],
               "all_categories": [
-                "biolink:ChemicalEntity",
                 "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:1551350",
-                "PMID:10848650",
-                "PMID:231639",
-                "PMID:27671545"
+                "PMID:20014752",
+                "PMID:17846134",
+                "PMID:6217353",
+                "PMID:17242148",
+                "PMID:18426954",
+                "PMID:18559652",
+                "PMID:19764786",
+                "PMID:12109906",
+                "PMID:18765691",
+                "PMID:19445515"
               ]
             }
           }
@@ -517129,89 +6735,40 @@
     }
   },
   {
-<<<<<<< HEAD
     "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:1551350': {'publication date': '1992 Apr', 'sentence': 'Alginic acid decreases postprandial upright gastroesophageal reflux.', 'subject score': 1000, 'object score': 824}}",
-    "p2": {
->>>>>>> main
       "start": {
-        "identity": 321369,
+        "identity": 538300,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0007186",
-          "name": "gastroesophageal reflux disease",
-          "description": "A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C26781\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26781\" NCI Thesaurus); A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.; Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.; A condition in which the stomach contents leak backwards from the stomach into the esophagus through the lower esophageal sphincter. [HPO:probinson]; UMLS Semantic Type: STY:T047",
+          "iri": "http://id.nlm.nih.gov/mesh/D000900",
+          "name": "Anti-Bacterial Agents",
+          "description": "A family of substances capable of destroying or inhibiting the growth of bacteria.; Substances that kill BACTERIA.; UMLS Semantic Type: STY:T195",
           "equivalent_curies": [
-            "ICD10:K21.9",
-            "UMLS:C4317146",
-            "NCIT:C26781",
-            "MEDDRA:10037676",
-            "PDQ:CDR0000737473",
-            "NCIT:C34670",
-            "UMLS:C3813607",
-            "MEDDRA:10066874",
-            "MEDDRA:10015389",
-            "ICD9:787.1",
-            "SNOMEDCT:698065002",
-            "UMLS:C0018834",
-            "OMIM:109350",
-            "MESH:D006356",
-            "UMLS:C0017168",
-            "DOID:8534",
-            "NCIT:C92560",
-            "SNOMEDCT:235595009",
-            "MEDDRA:10019326",
-            "HP:0002020",
-            "MEDDRA:10018203",
-            "MESH:D005764",
-            "MEDDRA:10017924",
-            "MEDDRA:10030182",
-            "SNOMEDCT:722884003",
-            "MONDO:0007186",
-            "ICD9:530.81",
-            "EFO:0003948",
-            "MEDDRA:10017884",
-            "MEDDRA:10017885",
-            "SNOMEDCT:16331000",
-            "NCIT:C113396"
+            "MESH:D000900",
+            "UMLS:C0279516",
+            "CHEBI:36047"
           ],
-          "id": "MONDO:0007186",
-          "category": "biolink:Disease",
+          "id": "MESH:D000900",
+          "category": "biolink:ChemicalEntity",
           "all_names": [
-            "Gastroesophageal Reflux Disease",
-            "Acid reflux",
-            "Gastroesophageal reflux",
-            "Esophageal reflux",
-            "Gastroesophageal Reflux",
-            "Gastroesophageal reflux disease",
-            "Infantile Gastroesophageal Reflux",
-            "gastroesophageal reflux disease",
-            "Gastroesophageal reflux related phenotypic feature",
-            "Heartburn"
+            "antibacterial drug",
+            "Anti-Bacterial Agents"
           ],
           "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-5316-1399"
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 629,
+        "identity": 553,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -517228,159 +6785,117 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "(Alginate)n",
-          "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+          "name": "Latamoxef",
+          "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "MESH:D000077322",
-            "UMLS:C0102137",
-            "KEGG.GLYCAN:G00316",
-            "UMLS:C0051156",
-            "KEGG.GLYCAN:G07471",
-            "KEGG.GLYCAN:G07287",
-            "KEGG.GLYCAN:G08476",
-            "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-            "DRUGBANK:DB13518",
-            "DrugCentral:4321",
-            "KEGG.DRUG:D02324",
-            "UNII:8C3Z4148WZ",
-            "KEGG.COMPOUND:C01768",
-            "CHEBI:17548",
-            "NDDF:002434",
-            "RXNORM:17305",
-            "RXNORM:1370451",
-            "NCIT:C82277",
-            "CHEMBL.COMPOUND:CHEMBL2108894",
-            "MESH:C008970",
-            "PUBCHEM.COMPOUND:91666318",
-            "ATC:A02BX13",
-            "KEGG.GLYCAN:G02561",
-            "UMLS:C4694124",
-            "KEGG.GLYCAN:G10593"
+            "ATC:J01DD06",
+            "NDDF:004889",
+            "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
+            "CHEMBL.COMPOUND:CHEMBL74632",
+            "UMLS:C0878141",
+            "CHEBI:599928",
+            "RXNORM:7069",
+            "PUBCHEM.COMPOUND:47499",
+            "PDQ:CDR0000039507",
+            "UMLS:C0026651",
+            "KEGG.DRUG:D02198",
+            "DRUGBANK:DB04570",
+            "KEGG.COMPOUND:C07231",
+            "NCIT:C670",
+            "GTOPDB:12031",
+            "KEGG.DRUG:D08109",
+            "HMDB:HMDB0015574",
+            "DrugCentral:1851",
+            "UNII:VUF6C936Z3",
+            "MESH:D009070"
           ],
-          "id": "PUBCHEM.COMPOUND:91666318",
+          "id": "PUBCHEM.COMPOUND:47499",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "(Alginate)n",
-            "Alginate",
-            "Norgine",
-            "Alginic acid",
-            "Alginic acid (NF)",
-            "ALGINIC ACID",
-            "alginate",
-            "Alginic Acid",
-            "alginic acid"
+            "Latamoxef",
+            "Latamoxef (INN)",
+            "Moxalactam disodium (USAN)",
+            "Moxalactam",
+            "Festamoxin",
+            "moxalactam",
+            "latamoxef",
+            "MOXALACTAM"
           ],
           "all_categories": [
-            "biolink:ChemicalEntity",
             "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:1551350",
-            "PMID:10848650",
-            "PMID:231639",
-            "PMID:27671545"
+            "PMID:20014752",
+            "PMID:17846134",
+            "PMID:6217353",
+            "PMID:17242148",
+            "PMID:18426954",
+            "PMID:18559652",
+            "PMID:19764786",
+            "PMID:12109906",
+            "PMID:18765691",
+            "PMID:19445515"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 321369,
+            "identity": 538300,
             "labels": [
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0007186",
-              "name": "gastroesophageal reflux disease",
-              "description": "A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C26781\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26781\" NCI Thesaurus); A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.; Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.; A condition in which the stomach contents leak backwards from the stomach into the esophagus through the lower esophageal sphincter. [HPO:probinson]; UMLS Semantic Type: STY:T047",
+              "iri": "http://id.nlm.nih.gov/mesh/D000900",
+              "name": "Anti-Bacterial Agents",
+              "description": "A family of substances capable of destroying or inhibiting the growth of bacteria.; Substances that kill BACTERIA.; UMLS Semantic Type: STY:T195",
               "equivalent_curies": [
-                "ICD10:K21.9",
-                "UMLS:C4317146",
-                "NCIT:C26781",
-                "MEDDRA:10037676",
-                "PDQ:CDR0000737473",
-                "NCIT:C34670",
-                "UMLS:C3813607",
-                "MEDDRA:10066874",
-                "MEDDRA:10015389",
-                "ICD9:787.1",
-                "SNOMEDCT:698065002",
-                "UMLS:C0018834",
-                "OMIM:109350",
-                "MESH:D006356",
-                "UMLS:C0017168",
-                "DOID:8534",
-                "NCIT:C92560",
-                "SNOMEDCT:235595009",
-                "MEDDRA:10019326",
-                "HP:0002020",
-                "MEDDRA:10018203",
-                "MESH:D005764",
-                "MEDDRA:10017924",
-                "MEDDRA:10030182",
-                "SNOMEDCT:722884003",
-                "MONDO:0007186",
-                "ICD9:530.81",
-                "EFO:0003948",
-                "MEDDRA:10017884",
-                "MEDDRA:10017885",
-                "SNOMEDCT:16331000",
-                "NCIT:C113396"
+                "MESH:D000900",
+                "UMLS:C0279516",
+                "CHEBI:36047"
               ],
-              "id": "MONDO:0007186",
-              "category": "biolink:Disease",
+              "id": "MESH:D000900",
+              "category": "biolink:ChemicalEntity",
               "all_names": [
-                "Gastroesophageal Reflux Disease",
-                "Acid reflux",
-                "Gastroesophageal reflux",
-                "Esophageal reflux",
-                "Gastroesophageal Reflux",
-                "Gastroesophageal reflux disease",
-                "Infantile Gastroesophageal Reflux",
-                "gastroesophageal reflux disease",
-                "Gastroesophageal reflux related phenotypic feature",
-                "Heartburn"
+                "antibacterial drug",
+                "Anti-Bacterial Agents"
               ],
               "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-5316-1399"
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-            "identity": 11245871,
-            "start": 629,
-            "end": 321369,
-            "type": "biolink:prevents",
+            "identity": 22359360,
+            "start": 538300,
+            "end": 553,
+            "type": "biolink:related_to",
             "properties": {
-              "predicate": "biolink:prevents",
+              "predicate": "biolink:related_to",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1551350': {'publication date': '1992 Apr', 'sentence': 'Alginic acid decreases postprandial upright gastroesophageal reflux.', 'subject score': 1000, 'object score': 824}}",
+              "publications_info": "{'PMID:3327964': {'publication date': '1987 Oct', 'sentence': 'In vitro antibacterial activity of FMOX was evaluated in comparison to latamoxef (LMOX), cefmetazole (CMZ), cefazolin (CEZ) using clinically isolated strains of Gram-negative and Gram-positive bacteria.', 'subject score': 861, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0051156---SEMMEDDB:prevents---None---None---None---UMLS:C0017168---SEMMEDDB:"
+                "UMLS:C0279516---SEMMEDDB:compared_with---None---None---None---UMLS:C0026651---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:91666318",
-              "id": "11492096",
-              "object": "MONDO:0007186",
+              "subject": "MESH:D000900",
+              "id": "22786151",
+              "object": "PUBCHEM.COMPOUND:47499",
               "publications": [
-                "PMID:1551350"
+                "PMID:3327964"
               ]
             }
           },
           "end": {
-            "identity": 629,
+            "identity": 553,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -517397,58 +6912,58 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "(Alginate)n",
-              "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+              "name": "Latamoxef",
+              "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "MESH:D000077322",
-                "UMLS:C0102137",
-                "KEGG.GLYCAN:G00316",
-                "UMLS:C0051156",
-                "KEGG.GLYCAN:G07471",
-                "KEGG.GLYCAN:G07287",
-                "KEGG.GLYCAN:G08476",
-                "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-                "DRUGBANK:DB13518",
-                "DrugCentral:4321",
-                "KEGG.DRUG:D02324",
-                "UNII:8C3Z4148WZ",
-                "KEGG.COMPOUND:C01768",
-                "CHEBI:17548",
-                "NDDF:002434",
-                "RXNORM:17305",
-                "RXNORM:1370451",
-                "NCIT:C82277",
-                "CHEMBL.COMPOUND:CHEMBL2108894",
-                "MESH:C008970",
-                "PUBCHEM.COMPOUND:91666318",
-                "ATC:A02BX13",
-                "KEGG.GLYCAN:G02561",
-                "UMLS:C4694124",
-                "KEGG.GLYCAN:G10593"
+                "ATC:J01DD06",
+                "NDDF:004889",
+                "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
+                "CHEMBL.COMPOUND:CHEMBL74632",
+                "UMLS:C0878141",
+                "CHEBI:599928",
+                "RXNORM:7069",
+                "PUBCHEM.COMPOUND:47499",
+                "PDQ:CDR0000039507",
+                "UMLS:C0026651",
+                "KEGG.DRUG:D02198",
+                "DRUGBANK:DB04570",
+                "KEGG.COMPOUND:C07231",
+                "NCIT:C670",
+                "GTOPDB:12031",
+                "KEGG.DRUG:D08109",
+                "HMDB:HMDB0015574",
+                "DrugCentral:1851",
+                "UNII:VUF6C936Z3",
+                "MESH:D009070"
               ],
-              "id": "PUBCHEM.COMPOUND:91666318",
+              "id": "PUBCHEM.COMPOUND:47499",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "(Alginate)n",
-                "Alginate",
-                "Norgine",
-                "Alginic acid",
-                "Alginic acid (NF)",
-                "ALGINIC ACID",
-                "alginate",
-                "Alginic Acid",
-                "alginic acid"
+                "Latamoxef",
+                "Latamoxef (INN)",
+                "Moxalactam disodium (USAN)",
+                "Moxalactam",
+                "Festamoxin",
+                "moxalactam",
+                "latamoxef",
+                "MOXALACTAM"
               ],
               "all_categories": [
-                "biolink:ChemicalEntity",
                 "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:1551350",
-                "PMID:10848650",
-                "PMID:231639",
-                "PMID:27671545"
+                "PMID:20014752",
+                "PMID:17846134",
+                "PMID:6217353",
+                "PMID:17242148",
+                "PMID:18426954",
+                "PMID:18559652",
+                "PMID:19764786",
+                "PMID:12109906",
+                "PMID:18765691",
+                "PMID:19445515"
               ]
             }
           }
@@ -517458,66 +6973,40 @@
     }
   },
   {
-<<<<<<< HEAD
     "p3": {
       "start": {
-        "identity": 318216,
+        "identity": 538300,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+          "iri": "http://id.nlm.nih.gov/mesh/D000900",
+          "name": "Anti-Bacterial Agents",
+          "description": "A family of substances capable of destroying or inhibiting the growth of bacteria.; Substances that kill BACTERIA.; UMLS Semantic Type: STY:T195",
           "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
+            "MESH:D000900",
+            "UMLS:C0279516",
+            "CHEBI:36047"
           ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
+          "id": "MESH:D000900",
+          "category": "biolink:ChemicalEntity",
           "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
+            "antibacterial drug",
+            "Anti-Bacterial Agents"
           ],
           "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
-          ],
-          "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 629,
+        "identity": 553,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -517534,142 +7023,117 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "(Alginate)n",
-          "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+          "name": "Latamoxef",
+          "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "MESH:D000077322",
-            "UMLS:C0102137",
-            "KEGG.GLYCAN:G00316",
-            "UMLS:C0051156",
-            "KEGG.GLYCAN:G07471",
-            "KEGG.GLYCAN:G07287",
-            "KEGG.GLYCAN:G08476",
-            "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-            "DRUGBANK:DB13518",
-            "DrugCentral:4321",
-            "KEGG.DRUG:D02324",
-            "UNII:8C3Z4148WZ",
-            "KEGG.COMPOUND:C01768",
-            "CHEBI:17548",
-            "NDDF:002434",
-            "RXNORM:17305",
-            "RXNORM:1370451",
-            "NCIT:C82277",
-            "CHEMBL.COMPOUND:CHEMBL2108894",
-            "MESH:C008970",
-            "PUBCHEM.COMPOUND:91666318",
-            "ATC:A02BX13",
-            "KEGG.GLYCAN:G02561",
-            "UMLS:C4694124",
-            "KEGG.GLYCAN:G10593"
+            "ATC:J01DD06",
+            "NDDF:004889",
+            "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
+            "CHEMBL.COMPOUND:CHEMBL74632",
+            "UMLS:C0878141",
+            "CHEBI:599928",
+            "RXNORM:7069",
+            "PUBCHEM.COMPOUND:47499",
+            "PDQ:CDR0000039507",
+            "UMLS:C0026651",
+            "KEGG.DRUG:D02198",
+            "DRUGBANK:DB04570",
+            "KEGG.COMPOUND:C07231",
+            "NCIT:C670",
+            "GTOPDB:12031",
+            "KEGG.DRUG:D08109",
+            "HMDB:HMDB0015574",
+            "DrugCentral:1851",
+            "UNII:VUF6C936Z3",
+            "MESH:D009070"
           ],
-          "id": "PUBCHEM.COMPOUND:91666318",
+          "id": "PUBCHEM.COMPOUND:47499",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "(Alginate)n",
-            "Alginate",
-            "Norgine",
-            "Alginic acid",
-            "Alginic acid (NF)",
-            "ALGINIC ACID",
-            "alginate",
-            "Alginic Acid",
-            "alginic acid"
+            "Latamoxef",
+            "Latamoxef (INN)",
+            "Moxalactam disodium (USAN)",
+            "Moxalactam",
+            "Festamoxin",
+            "moxalactam",
+            "latamoxef",
+            "MOXALACTAM"
           ],
           "all_categories": [
-            "biolink:ChemicalEntity",
             "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:1551350",
-            "PMID:10848650",
-            "PMID:231639",
-            "PMID:27671545"
+            "PMID:20014752",
+            "PMID:17846134",
+            "PMID:6217353",
+            "PMID:17242148",
+            "PMID:18426954",
+            "PMID:18559652",
+            "PMID:19764786",
+            "PMID:12109906",
+            "PMID:18765691",
+            "PMID:19445515"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 318216,
+            "identity": 538300,
             "labels": [
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature",
-              "biolink:BehavioralFeature"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+              "iri": "http://id.nlm.nih.gov/mesh/D000900",
+              "name": "Anti-Bacterial Agents",
+              "description": "A family of substances capable of destroying or inhibiting the growth of bacteria.; Substances that kill BACTERIA.; UMLS Semantic Type: STY:T195",
               "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
+                "MESH:D000900",
+                "UMLS:C0279516",
+                "CHEBI:36047"
               ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
+              "id": "MESH:D000900",
+              "category": "biolink:ChemicalEntity",
               "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
+                "antibacterial drug",
+                "Anti-Bacterial Agents"
               ],
               "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
-              ],
-              "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-            "identity": 23076071,
-            "start": 629,
-            "end": 318216,
-            "type": "biolink:predisposes",
+            "identity": 25751037,
+            "start": 538300,
+            "end": 553,
+            "type": "biolink:coexists_with",
             "properties": {
-              "predicate": "biolink:predisposes",
+              "predicate": "biolink:coexists_with",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34206160': {'publication date': '2021 Jun 22', 'sentence': 'The consumption of kelp high in alginate may contribute to preventing obesity without influencing thyroid function in Japanese subjects with a relatively high intake of iodine from seaweed.', 'subject score': 1000, 'object score': 861}}",
+              "publications_info": "{'PMID:6631914': {'publication date': '1983 Nov', 'sentence': 'Synthesis and substituent effects on antibacterial activity, alkaline hydrolysis rates, and infrared absorption frequencies of some cephem analogues related to latamoxef (moxalactam).', 'subject score': 888, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0102137---SEMMEDDB:predisposes---None---None---None---UMLS:C0028754---SEMMEDDB:"
+                "UMLS:C0279516---SEMMEDDB:coexists_with---None---None---None---UMLS:C0026651---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:91666318",
-              "id": "23508922",
-              "object": "MONDO:0011122",
+              "subject": "MESH:D000900",
+              "id": "26214369",
+              "object": "PUBCHEM.COMPOUND:47499",
               "publications": [
-                "PMID:34206160"
+                "PMID:6631914"
               ]
             }
           },
           "end": {
-            "identity": 629,
+            "identity": 553,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -517686,58 +7150,58 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "(Alginate)n",
-              "description": "UMLS Semantic Type: STY:T122; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].",
+              "name": "Latamoxef",
+              "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "MESH:D000077322",
-                "UMLS:C0102137",
-                "KEGG.GLYCAN:G00316",
-                "UMLS:C0051156",
-                "KEGG.GLYCAN:G07471",
-                "KEGG.GLYCAN:G07287",
-                "KEGG.GLYCAN:G08476",
-                "INCHIKEY:AEMOLEFTQBMNLQ-QTWKXLRFSA-N",
-                "DRUGBANK:DB13518",
-                "DrugCentral:4321",
-                "KEGG.DRUG:D02324",
-                "UNII:8C3Z4148WZ",
-                "KEGG.COMPOUND:C01768",
-                "CHEBI:17548",
-                "NDDF:002434",
-                "RXNORM:17305",
-                "RXNORM:1370451",
-                "NCIT:C82277",
-                "CHEMBL.COMPOUND:CHEMBL2108894",
-                "MESH:C008970",
-                "PUBCHEM.COMPOUND:91666318",
-                "ATC:A02BX13",
-                "KEGG.GLYCAN:G02561",
-                "UMLS:C4694124",
-                "KEGG.GLYCAN:G10593"
+                "ATC:J01DD06",
+                "NDDF:004889",
+                "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
+                "CHEMBL.COMPOUND:CHEMBL74632",
+                "UMLS:C0878141",
+                "CHEBI:599928",
+                "RXNORM:7069",
+                "PUBCHEM.COMPOUND:47499",
+                "PDQ:CDR0000039507",
+                "UMLS:C0026651",
+                "KEGG.DRUG:D02198",
+                "DRUGBANK:DB04570",
+                "KEGG.COMPOUND:C07231",
+                "NCIT:C670",
+                "GTOPDB:12031",
+                "KEGG.DRUG:D08109",
+                "HMDB:HMDB0015574",
+                "DrugCentral:1851",
+                "UNII:VUF6C936Z3",
+                "MESH:D009070"
               ],
-              "id": "PUBCHEM.COMPOUND:91666318",
+              "id": "PUBCHEM.COMPOUND:47499",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "(Alginate)n",
-                "Alginate",
-                "Norgine",
-                "Alginic acid",
-                "Alginic acid (NF)",
-                "ALGINIC ACID",
-                "alginate",
-                "Alginic Acid",
-                "alginic acid"
+                "Latamoxef",
+                "Latamoxef (INN)",
+                "Moxalactam disodium (USAN)",
+                "Moxalactam",
+                "Festamoxin",
+                "moxalactam",
+                "latamoxef",
+                "MOXALACTAM"
               ],
               "all_categories": [
-                "biolink:ChemicalEntity",
                 "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:1551350",
-                "PMID:10848650",
-                "PMID:231639",
-                "PMID:27671545"
+                "PMID:20014752",
+                "PMID:17846134",
+                "PMID:6217353",
+                "PMID:17242148",
+                "PMID:18426954",
+                "PMID:18559652",
+                "PMID:19764786",
+                "PMID:12109906",
+                "PMID:18765691",
+                "PMID:19445515"
               ]
             }
           }
@@ -517748,70 +7212,39 @@
   },
   {
     "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:related_to",
-    "r2.publications_info": "{'PMID:156316': {'publication date': '1979 Jan-Mar', 'sentence': '[Double-blind study of proglumide, zolimidine and carbenoxolone in peptic ulcer and gastroduodenitis].', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
       "start": {
-        "identity": 316638,
+        "identity": 538300,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-          "name": "peptic ulcer disease",
-          "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
+          "iri": "http://id.nlm.nih.gov/mesh/D000900",
+          "name": "Anti-Bacterial Agents",
+          "description": "A family of substances capable of destroying or inhibiting the growth of bacteria.; Substances that kill BACTERIA.; UMLS Semantic Type: STY:T195",
           "equivalent_curies": [
-            "MEDDRA:10018053",
-            "MEDDRA:10045305",
-            "MESH:D010437",
-            "MONDO:0004247",
-            "DOID:750",
-            "UMLS:C0030920",
-            "MEDDRA:10017886",
-            "MEDDRA:10045342",
-            "ICD9:533",
-            "ICD10:K27",
-            "HP:0004398",
-            "MEDDRA:10034343",
-            "MEDDRA:10034360",
-            "MEDDRA:10045328",
-            "MEDDRA:10042834",
-            "MEDDRA:10034341",
-            "MEDDRA:10034367",
-            "MEDDRA:10037287",
-            "NCIT:C3318",
-            "SNOMEDCT:13200003",
-            "MEDDRA:10034369"
+            "MESH:D000900",
+            "UMLS:C0279516",
+            "CHEBI:36047"
           ],
-          "id": "MONDO:0004247",
-          "category": "biolink:Disease",
+          "id": "MESH:D000900",
+          "category": "biolink:ChemicalEntity",
           "all_names": [
-            "Peptic ulcer, site unspecified",
-            "Peptic Ulcer",
-            "peptic ulcer disease",
-            "Peptic ulcer"
+            "antibacterial drug",
+            "Anti-Bacterial Agents"
           ],
           "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:28242110",
-            "https://orcid.org/0000-0002-0736-9199",
-            "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-            "https://orcid.org/0000-0002-6548-5200"
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 635,
+        "identity": 553,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -517828,119 +7261,117 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Zolimidine",
-          "description": "ZOLIMIDINE; FULL_MW:272.33; MAX_FDA_APPROVAL_PHASE: -1.0",
+          "name": "Latamoxef",
+          "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "DRUGBANK:DB13593",
-            "NCIT:C66705",
-            "MESH:C073260",
-            "CHEBI:135125",
-            "CAS:1222-57-7",
-            "DrugCentral:3661",
-            "UMLS:C0650163",
-            "KEGG.DRUG:D07075",
-            "UNII:YCF001N8QB",
-            "CHEMBL.COMPOUND:CHEMBL2105534",
-            "INCHIKEY:VSLIUWLPFRVCDL-UHFFFAOYSA-N",
-            "ATC:A02BX10",
-            "PUBCHEM.COMPOUND:14652"
+            "ATC:J01DD06",
+            "NDDF:004889",
+            "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
+            "CHEMBL.COMPOUND:CHEMBL74632",
+            "UMLS:C0878141",
+            "CHEBI:599928",
+            "RXNORM:7069",
+            "PUBCHEM.COMPOUND:47499",
+            "PDQ:CDR0000039507",
+            "UMLS:C0026651",
+            "KEGG.DRUG:D02198",
+            "DRUGBANK:DB04570",
+            "KEGG.COMPOUND:C07231",
+            "NCIT:C670",
+            "GTOPDB:12031",
+            "KEGG.DRUG:D08109",
+            "HMDB:HMDB0015574",
+            "DrugCentral:1851",
+            "UNII:VUF6C936Z3",
+            "MESH:D009070"
           ],
-          "id": "PUBCHEM.COMPOUND:14652",
+          "id": "PUBCHEM.COMPOUND:47499",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "zolimidine",
-            "Zolimidine",
-            "Zolimidine (INN)",
-            "ZOLIMIDINE"
+            "Latamoxef",
+            "Latamoxef (INN)",
+            "Moxalactam disodium (USAN)",
+            "Moxalactam",
+            "Festamoxin",
+            "moxalactam",
+            "latamoxef",
+            "MOXALACTAM"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
             "biolink:ChemicalEntity",
             "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:20014752",
+            "PMID:17846134",
+            "PMID:6217353",
+            "PMID:17242148",
+            "PMID:18426954",
+            "PMID:18559652",
+            "PMID:19764786",
+            "PMID:12109906",
+            "PMID:18765691",
+            "PMID:19445515"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 316638,
+            "identity": 538300,
             "labels": [
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
-              "name": "peptic ulcer disease",
-              "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
+              "iri": "http://id.nlm.nih.gov/mesh/D000900",
+              "name": "Anti-Bacterial Agents",
+              "description": "A family of substances capable of destroying or inhibiting the growth of bacteria.; Substances that kill BACTERIA.; UMLS Semantic Type: STY:T195",
               "equivalent_curies": [
-                "MEDDRA:10018053",
-                "MEDDRA:10045305",
-                "MESH:D010437",
-                "MONDO:0004247",
-                "DOID:750",
-                "UMLS:C0030920",
-                "MEDDRA:10017886",
-                "MEDDRA:10045342",
-                "ICD9:533",
-                "ICD10:K27",
-                "HP:0004398",
-                "MEDDRA:10034343",
-                "MEDDRA:10034360",
-                "MEDDRA:10045328",
-                "MEDDRA:10042834",
-                "MEDDRA:10034341",
-                "MEDDRA:10034367",
-                "MEDDRA:10037287",
-                "NCIT:C3318",
-                "SNOMEDCT:13200003",
-                "MEDDRA:10034369"
+                "MESH:D000900",
+                "UMLS:C0279516",
+                "CHEBI:36047"
               ],
-              "id": "MONDO:0004247",
-              "category": "biolink:Disease",
+              "id": "MESH:D000900",
+              "category": "biolink:ChemicalEntity",
               "all_names": [
-                "Peptic ulcer, site unspecified",
-                "Peptic Ulcer",
-                "peptic ulcer disease",
-                "Peptic ulcer"
+                "antibacterial drug",
+                "Anti-Bacterial Agents"
               ],
               "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:28242110",
-                "https://orcid.org/0000-0002-0736-9199",
-                "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
-                "https://orcid.org/0000-0002-6548-5200"
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-            "identity": 11349399,
-            "start": 635,
-            "end": 316638,
-            "type": "biolink:related_to",
+            "identity": 25751037,
+            "start": 538300,
+            "end": 553,
+            "type": "biolink:coexists_with",
             "properties": {
-              "predicate": "biolink:related_to",
+              "predicate": "biolink:coexists_with",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:156316': {'publication date': '1979 Jan-Mar', 'sentence': '[Double-blind study of proglumide, zolimidine and carbenoxolone in peptic ulcer and gastroduodenitis].', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:6631914': {'publication date': '1983 Nov', 'sentence': 'Synthesis and substituent effects on antibacterial activity, alkaline hydrolysis rates, and infrared absorption frequencies of some cephem analogues related to latamoxef (moxalactam).', 'subject score': 888, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0650163---SEMMEDDB:associated_with---None---None---None---UMLS:C0030920---SEMMEDDB:"
+                "UMLS:C0279516---SEMMEDDB:coexists_with---None---None---None---UMLS:C0026651---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:14652",
-              "id": "11597598",
-              "object": "MONDO:0004247",
+              "subject": "MESH:D000900",
+              "id": "26214369",
+              "object": "PUBCHEM.COMPOUND:47499",
               "publications": [
-                "PMID:156316"
+                "PMID:6631914"
               ]
             }
           },
           "end": {
-            "identity": 635,
+            "identity": 553,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -517957,35 +7388,58 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Zolimidine",
-              "description": "ZOLIMIDINE; FULL_MW:272.33; MAX_FDA_APPROVAL_PHASE: -1.0",
+              "name": "Latamoxef",
+              "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "DRUGBANK:DB13593",
-                "NCIT:C66705",
-                "MESH:C073260",
-                "CHEBI:135125",
-                "CAS:1222-57-7",
-                "DrugCentral:3661",
-                "UMLS:C0650163",
-                "KEGG.DRUG:D07075",
-                "UNII:YCF001N8QB",
-                "CHEMBL.COMPOUND:CHEMBL2105534",
-                "INCHIKEY:VSLIUWLPFRVCDL-UHFFFAOYSA-N",
-                "ATC:A02BX10",
-                "PUBCHEM.COMPOUND:14652"
+                "ATC:J01DD06",
+                "NDDF:004889",
+                "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
+                "CHEMBL.COMPOUND:CHEMBL74632",
+                "UMLS:C0878141",
+                "CHEBI:599928",
+                "RXNORM:7069",
+                "PUBCHEM.COMPOUND:47499",
+                "PDQ:CDR0000039507",
+                "UMLS:C0026651",
+                "KEGG.DRUG:D02198",
+                "DRUGBANK:DB04570",
+                "KEGG.COMPOUND:C07231",
+                "NCIT:C670",
+                "GTOPDB:12031",
+                "KEGG.DRUG:D08109",
+                "HMDB:HMDB0015574",
+                "DrugCentral:1851",
+                "UNII:VUF6C936Z3",
+                "MESH:D009070"
               ],
-              "id": "PUBCHEM.COMPOUND:14652",
+              "id": "PUBCHEM.COMPOUND:47499",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "zolimidine",
-                "Zolimidine",
-                "Zolimidine (INN)",
-                "ZOLIMIDINE"
+                "Latamoxef",
+                "Latamoxef (INN)",
+                "Moxalactam disodium (USAN)",
+                "Moxalactam",
+                "Festamoxin",
+                "moxalactam",
+                "latamoxef",
+                "MOXALACTAM"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
                 "biolink:ChemicalEntity",
                 "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:20014752",
+                "PMID:17846134",
+                "PMID:6217353",
+                "PMID:17242148",
+                "PMID:18426954",
+                "PMID:18559652",
+                "PMID:19764786",
+                "PMID:12109906",
+                "PMID:18765691",
+                "PMID:19445515"
               ]
             }
           }
@@ -517995,93 +7449,40 @@
     }
   },
   {
-<<<<<<< HEAD
     "p3": {
       "start": {
-        "identity": 539955,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:1809525': {'publication date': '1991', 'sentence': 'Effect of vitamin E gel, placebo gel and chlorhexidine on periodontal disease.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 311375,
->>>>>>> main
+        "identity": 538300,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide"
         ],
         "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-          "name": "infectious disease",
-          "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "MONDO:0005550",
-            "SNOMEDCT:189822004",
-            "PSY:10513",
-            "UMLS:C0009450",
-            "UMLS:C0001485",
-            "EFO:0005741",
-            "MEDDRA:10021881",
-            "MESH:D003141",
-            "ICD9:079.0",
-            "DOID:0050117",
-            "SNOMEDCT:40733004",
-            "SNOMEDCT:191415002",
-            "NCIT:C26726"
-          ],
-          "id": "MONDO:0005550",
-          "category": "biolink:Disease",
-          "all_names": [
-            "infectious disease",
-            "Infectious Disorder",
-            "disease by infectious agent",
-            "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-            "Communicable Diseases"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002635",
-          "name": "periodontal disorder",
-          "description": "An inflammatory process of the gingival tissues and/or periodontal membrane of the teeth, resulting in an abnormally deep gingival sulcus, possibly producing periodontal pockets and loss of alveolar bone support.; Pathological processes involving the PERIODONTIUM including the gum (GINGIVA), the alveolar bone (ALVEOLAR PROCESS), the DENTAL CEMENTUM, and the PERIODONTAL LIGAMENT.; Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
+          "iri": "http://id.nlm.nih.gov/mesh/D000900",
+          "name": "Anti-Bacterial Agents",
+          "description": "A family of substances capable of destroying or inhibiting the growth of bacteria.; Substances that kill BACTERIA.; UMLS Semantic Type: STY:T195",
           "equivalent_curies": [
-            "MONDO:0002635",
-            "SNOMEDCT:2556008",
-            "MESH:D010510",
-            "ICD10:K05.6",
-            "UMLS:C0031090",
-            "DOID:3388",
-            "MEDDRA:10034537",
-            "MEDDRA:10034536",
-            "NCIT:C63743"
+            "MESH:D000900",
+            "UMLS:C0279516",
+            "CHEBI:36047"
           ],
-          "id": "MONDO:0002635",
-          "category": "biolink:Disease",
+          "id": "MESH:D000900",
+          "category": "biolink:ChemicalEntity",
           "all_names": [
-            "periodontal disease",
-            "periodontal disorder",
-            "Periodontal Disorder",
-            "Periodontal Diseases"
->>>>>>> main
+            "antibacterial drug",
+            "Anti-Bacterial Agents"
           ],
           "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "https://www.merriam-webster.com/medical/communicable%20disease",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-=======
-            "https://www.nidcr.nih.gov/health-info/gum-disease/more-info"
->>>>>>> main
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 553,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -518098,44 +7499,41 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Latamoxef",
+          "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "ATC:J01DD06",
+            "NDDF:004889",
+            "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
+            "CHEMBL.COMPOUND:CHEMBL74632",
+            "UMLS:C0878141",
+            "CHEBI:599928",
+            "RXNORM:7069",
+            "PUBCHEM.COMPOUND:47499",
+            "PDQ:CDR0000039507",
+            "UMLS:C0026651",
+            "KEGG.DRUG:D02198",
+            "DRUGBANK:DB04570",
+            "KEGG.COMPOUND:C07231",
+            "NCIT:C670",
+            "GTOPDB:12031",
+            "KEGG.DRUG:D08109",
+            "HMDB:HMDB0015574",
+            "DrugCentral:1851",
+            "UNII:VUF6C936Z3",
+            "MESH:D009070"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:47499",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "Latamoxef",
+            "Latamoxef (INN)",
+            "Moxalactam disodium (USAN)",
+            "Moxalactam",
+            "Festamoxin",
+            "moxalactam",
+            "latamoxef",
+            "MOXALACTAM"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -518143,144 +7541,75 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:20014752",
+            "PMID:17846134",
+            "PMID:6217353",
+            "PMID:17242148",
+            "PMID:18426954",
+            "PMID:18559652",
+            "PMID:19764786",
+            "PMID:12109906",
+            "PMID:18765691",
+            "PMID:19445515"
           ]
         }
       },
       "segments": [
         {
           "start": {
-<<<<<<< HEAD
-            "identity": 539955,
-=======
-            "identity": 311375,
->>>>>>> main
+            "identity": 538300,
             "labels": [
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide"
             ],
             "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-              "name": "infectious disease",
-              "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "MONDO:0005550",
-                "SNOMEDCT:189822004",
-                "PSY:10513",
-                "UMLS:C0009450",
-                "UMLS:C0001485",
-                "EFO:0005741",
-                "MEDDRA:10021881",
-                "MESH:D003141",
-                "ICD9:079.0",
-                "DOID:0050117",
-                "SNOMEDCT:40733004",
-                "SNOMEDCT:191415002",
-                "NCIT:C26726"
-              ],
-              "id": "MONDO:0005550",
-              "category": "biolink:Disease",
-              "all_names": [
-                "infectious disease",
-                "Infectious Disorder",
-                "disease by infectious agent",
-                "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-                "Communicable Diseases"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002635",
-              "name": "periodontal disorder",
-              "description": "An inflammatory process of the gingival tissues and/or periodontal membrane of the teeth, resulting in an abnormally deep gingival sulcus, possibly producing periodontal pockets and loss of alveolar bone support.; Pathological processes involving the PERIODONTIUM including the gum (GINGIVA), the alveolar bone (ALVEOLAR PROCESS), the DENTAL CEMENTUM, and the PERIODONTAL LIGAMENT.; Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
+              "iri": "http://id.nlm.nih.gov/mesh/D000900",
+              "name": "Anti-Bacterial Agents",
+              "description": "A family of substances capable of destroying or inhibiting the growth of bacteria.; Substances that kill BACTERIA.; UMLS Semantic Type: STY:T195",
               "equivalent_curies": [
-                "MONDO:0002635",
-                "SNOMEDCT:2556008",
-                "MESH:D010510",
-                "ICD10:K05.6",
-                "UMLS:C0031090",
-                "DOID:3388",
-                "MEDDRA:10034537",
-                "MEDDRA:10034536",
-                "NCIT:C63743"
+                "MESH:D000900",
+                "UMLS:C0279516",
+                "CHEBI:36047"
               ],
-              "id": "MONDO:0002635",
-              "category": "biolink:Disease",
+              "id": "MESH:D000900",
+              "category": "biolink:ChemicalEntity",
               "all_names": [
-                "periodontal disease",
-                "periodontal disorder",
-                "Periodontal Disorder",
-                "Periodontal Diseases"
->>>>>>> main
+                "antibacterial drug",
+                "Anti-Bacterial Agents"
               ],
               "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "https://www.merriam-webster.com/medical/communicable%20disease",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
-=======
-                "https://www.nidcr.nih.gov/health-info/gum-disease/more-info"
->>>>>>> main
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-<<<<<<< HEAD
-            "identity": 20341137,
-            "start": 638,
-            "end": 539955,
-            "type": "biolink:causes",
-            "properties": {
-              "predicate": "biolink:causes",
-              "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30531238': {'publication date': '2019 Aug 15', 'sentence': 'Chlorhexidine, for example, has been shown to cause markedly less SSIs compared with povidone-iodine prep in general surgery cases.', 'subject score': 1000, 'object score': 794}, 'PMID:34545019': {'publication date': '2021 Sep 21', 'sentence': 'When stratified by procedure type, CH used in sports/upper extremity procedures resulted in 29 more infections per 1000 cases compared with P-I use (16/450; 3/450; P=0.005).', 'subject score': 1000, 'object score': 827}}",
-              "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:causes---None---None---None---UMLS:C0009450---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "20742970",
-              "object": "MONDO:0005550",
-              "publications": [
-                "PMID:30531238",
-                "PMID:34545019"
-=======
-            "identity": 13219388,
-            "start": 638,
-            "end": 311375,
-            "type": "biolink:affects",
+            "identity": 19746620,
+            "start": 538300,
+            "end": 553,
+            "type": "biolink:physically_interacts_with",
             "properties": {
-              "predicate": "biolink:affects",
+              "predicate": "biolink:physically_interacts_with",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1809525': {'publication date': '1991', 'sentence': 'Effect of vitamin E gel, placebo gel and chlorhexidine on periodontal disease.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:29391816': {'publication date': '2018', 'sentence': 'Antibacterial effect evaluation of moxalactam against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae with in vitro pharmacokinetics/pharmacodynamics simulation.', 'subject score': 851, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:affects---None---None---None---UMLS:C0031090---SEMMEDDB:"
+                "UMLS:C0279516---SEMMEDDB:interacts_with---None---None---None---UMLS:C0026651---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "13503760",
-              "object": "MONDO:0002635",
+              "subject": "MESH:D000900",
+              "id": "20139285",
+              "object": "PUBCHEM.COMPOUND:47499",
               "publications": [
-                "PMID:1809525"
->>>>>>> main
+                "PMID:29391816"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 553,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -518297,44 +7626,41 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Latamoxef",
+              "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "ATC:J01DD06",
+                "NDDF:004889",
+                "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
+                "CHEMBL.COMPOUND:CHEMBL74632",
+                "UMLS:C0878141",
+                "CHEBI:599928",
+                "RXNORM:7069",
+                "PUBCHEM.COMPOUND:47499",
+                "PDQ:CDR0000039507",
+                "UMLS:C0026651",
+                "KEGG.DRUG:D02198",
+                "DRUGBANK:DB04570",
+                "KEGG.COMPOUND:C07231",
+                "NCIT:C670",
+                "GTOPDB:12031",
+                "KEGG.DRUG:D08109",
+                "HMDB:HMDB0015574",
+                "DrugCentral:1851",
+                "UNII:VUF6C936Z3",
+                "MESH:D009070"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:47499",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "Latamoxef",
+                "Latamoxef (INN)",
+                "Moxalactam disodium (USAN)",
+                "Moxalactam",
+                "Festamoxin",
+                "moxalactam",
+                "latamoxef",
+                "MOXALACTAM"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -518342,16 +7668,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:20014752",
+                "PMID:17846134",
+                "PMID:6217353",
+                "PMID:17242148",
+                "PMID:18426954",
+                "PMID:18559652",
+                "PMID:19764786",
+                "PMID:12109906",
+                "PMID:18765691",
+                "PMID:19445515"
               ]
             }
           }
@@ -518361,56 +7687,40 @@
     }
   },
   {
-<<<<<<< HEAD
     "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:15853968': {'publication date': '2005 Jun', 'sentence': 'BACKGROUND: Tooth staining is a common feature of chlorhexidine treatment for periodontal disease and there is a large variation between patients as to the degree of their tooth staining.', 'subject score': 888, 'object score': 1000}, 'PMID:22350036': {'publication date': '2013 Jan', 'sentence': 'CLINICAL RELEVANCE: Adjunctive use of slow-released chlorhexidine might be considered in the management of periodontal disease and gingival inflammation to reduce the need for periodontal surgery.', 'subject score': 851, 'object score': 1000}, 'PMID:2388137': {'publication date': '1990 Jul', 'sentence': 'Previous studies have demonstrated the advantages of the local sustained release of chlorhexidine from nondegradable devices in the treatment of periodontal diseases.', 'subject score': 1000, 'object score': 1000}, 'PMID:2390965': {'publication date': '1990 Feb', 'sentence': 'Chlorhexidine is widely used as a mouth rinse in the prevention and treatment of periodontal diseases and dental caries.', 'subject score': 1000, 'object score': 1000}, 'PMID:24921057': {'publication date': '2014 Jun', 'sentence': 'RESULTS: There was no significant difference when the efficacy of triphala was compared with 0.2% chlorhexidine in hospitalized patients with periodontal disease.', 'subject score': 827, 'object score': 1000}, 'PMID:26598208': {'publication date': '2016 Feb', 'sentence': 'Topical administration of chlorhexidine for periodontal disease can provide advantages over systemic delivery, but is limited by the permeability of the cornified oral mucosal tissue.', 'subject score': 1000, 'object score': 1000}, 'PMID:2668719': {'publication date': '1989 May', 'sentence': \"Chlorhexidine a cationic antiseptic active against a wide spectrum of bacteria is widely and successfully used in the treatment of periodontal disease in the home and the outpatients' clinic.\", 'subject score': 1000, 'object score': 1000}, 'PMID:28566850': {'publication date': '2017 Jan-Mar', 'sentence': 'Hence, they can all be used as alternates to chlorhexidine in the management of periodontal diseases.', 'subject score': 785, 'object score': 1000}, 'PMID:29158711': {'publication date': '2017 Nov', 'sentence': 'The aim of our study was evaluation of the efficacy of local treatment with chlorhexidine (CHX) in patients suffering from periodontal disease by chemometric algorithms for multivariate data analysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:31766136': {'publication date': '2019 Nov 13', 'sentence': 'This work aimed to develop and evaluate pH-dependent systems based on nanospheres (NSphs) and nanocapsules (NCs) loaded with chlorhexidine (CHX) base as a novel formulation for the treatment of periodontal disease.', 'subject score': 888, 'object score': 1000}, 'PMID:32381840': {'publication date': '2019 Dec 01', 'sentence': 'Effectiveness of Controlled Release Chlorhexidine Chip as an Adjunctive to Scaling and Root Planning for the Treatment of Chronic Periodontitis.BACKGROUND: Chlorhexidine is considered one of the options for the management of periodontal diseases.', 'subject score': 1000, 'object score': 1000}, 'PMID:35362697': {'publication date': '2022', 'sentence': 'The inclusion of CITROX in the rinse aid reduces the concentration of chlorhexidine in the rinse aid, which can lead to a decrease in the severity of undesirable effects and be considered as an alternative remedy in the treatment of periodontal diseases.', 'subject score': 1000, 'object score': 1000}, 'PMID:35821403': {'publication date': '2022 Jul 12', 'sentence': 'Effectiveness of tea tree oil versus chlorhexidine in the treatment of periodontal diseases: a systematic review.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
       "start": {
-        "identity": 311375,
+        "identity": 538300,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002635",
-          "name": "periodontal disorder",
-          "description": "An inflammatory process of the gingival tissues and/or periodontal membrane of the teeth, resulting in an abnormally deep gingival sulcus, possibly producing periodontal pockets and loss of alveolar bone support.; Pathological processes involving the PERIODONTIUM including the gum (GINGIVA), the alveolar bone (ALVEOLAR PROCESS), the DENTAL CEMENTUM, and the PERIODONTAL LIGAMENT.; Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
+          "iri": "http://id.nlm.nih.gov/mesh/D000900",
+          "name": "Anti-Bacterial Agents",
+          "description": "A family of substances capable of destroying or inhibiting the growth of bacteria.; Substances that kill BACTERIA.; UMLS Semantic Type: STY:T195",
           "equivalent_curies": [
-            "MONDO:0002635",
-            "SNOMEDCT:2556008",
-            "MESH:D010510",
-            "ICD10:K05.6",
-            "UMLS:C0031090",
-            "DOID:3388",
-            "MEDDRA:10034537",
-            "MEDDRA:10034536",
-            "NCIT:C63743"
+            "MESH:D000900",
+            "UMLS:C0279516",
+            "CHEBI:36047"
           ],
-          "id": "MONDO:0002635",
-          "category": "biolink:Disease",
+          "id": "MESH:D000900",
+          "category": "biolink:ChemicalEntity",
           "all_names": [
-            "periodontal disease",
-            "periodontal disorder",
-            "Periodontal Disorder",
-            "Periodontal Diseases"
+            "antibacterial drug",
+            "Anti-Bacterial Agents"
           ],
           "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nidcr.nih.gov/health-info/gum-disease/more-info"
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 553,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -518427,44 +7737,41 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Latamoxef",
+          "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "ATC:J01DD06",
+            "NDDF:004889",
+            "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
+            "CHEMBL.COMPOUND:CHEMBL74632",
+            "UMLS:C0878141",
+            "CHEBI:599928",
+            "RXNORM:7069",
+            "PUBCHEM.COMPOUND:47499",
+            "PDQ:CDR0000039507",
+            "UMLS:C0026651",
+            "KEGG.DRUG:D02198",
+            "DRUGBANK:DB04570",
+            "KEGG.COMPOUND:C07231",
+            "NCIT:C670",
+            "GTOPDB:12031",
+            "KEGG.DRUG:D08109",
+            "HMDB:HMDB0015574",
+            "DrugCentral:1851",
+            "UNII:VUF6C936Z3",
+            "MESH:D009070"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:47499",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "Latamoxef",
+            "Latamoxef (INN)",
+            "Moxalactam disodium (USAN)",
+            "Moxalactam",
+            "Festamoxin",
+            "moxalactam",
+            "latamoxef",
+            "MOXALACTAM"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -518472,97 +7779,75 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:20014752",
+            "PMID:17846134",
+            "PMID:6217353",
+            "PMID:17242148",
+            "PMID:18426954",
+            "PMID:18559652",
+            "PMID:19764786",
+            "PMID:12109906",
+            "PMID:18765691",
+            "PMID:19445515"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 311375,
+            "identity": 538300,
             "labels": [
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002635",
-              "name": "periodontal disorder",
-              "description": "An inflammatory process of the gingival tissues and/or periodontal membrane of the teeth, resulting in an abnormally deep gingival sulcus, possibly producing periodontal pockets and loss of alveolar bone support.; Pathological processes involving the PERIODONTIUM including the gum (GINGIVA), the alveolar bone (ALVEOLAR PROCESS), the DENTAL CEMENTUM, and the PERIODONTAL LIGAMENT.; Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
+              "iri": "http://id.nlm.nih.gov/mesh/D000900",
+              "name": "Anti-Bacterial Agents",
+              "description": "A family of substances capable of destroying or inhibiting the growth of bacteria.; Substances that kill BACTERIA.; UMLS Semantic Type: STY:T195",
               "equivalent_curies": [
-                "MONDO:0002635",
-                "SNOMEDCT:2556008",
-                "MESH:D010510",
-                "ICD10:K05.6",
-                "UMLS:C0031090",
-                "DOID:3388",
-                "MEDDRA:10034537",
-                "MEDDRA:10034536",
-                "NCIT:C63743"
+                "MESH:D000900",
+                "UMLS:C0279516",
+                "CHEBI:36047"
               ],
-              "id": "MONDO:0002635",
-              "category": "biolink:Disease",
+              "id": "MESH:D000900",
+              "category": "biolink:ChemicalEntity",
               "all_names": [
-                "periodontal disease",
-                "periodontal disorder",
-                "Periodontal Disorder",
-                "Periodontal Diseases"
+                "antibacterial drug",
+                "Anti-Bacterial Agents"
               ],
               "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nidcr.nih.gov/health-info/gum-disease/more-info"
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-            "identity": 11539735,
-            "start": 638,
-            "end": 311375,
-            "type": "biolink:treats",
+            "identity": 19746620,
+            "start": 538300,
+            "end": 553,
+            "type": "biolink:physically_interacts_with",
             "properties": {
-              "predicate": "biolink:treats",
+              "predicate": "biolink:physically_interacts_with",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15853968': {'publication date': '2005 Jun', 'sentence': 'BACKGROUND: Tooth staining is a common feature of chlorhexidine treatment for periodontal disease and there is a large variation between patients as to the degree of their tooth staining.', 'subject score': 888, 'object score': 1000}, 'PMID:22350036': {'publication date': '2013 Jan', 'sentence': 'CLINICAL RELEVANCE: Adjunctive use of slow-released chlorhexidine might be considered in the management of periodontal disease and gingival inflammation to reduce the need for periodontal surgery.', 'subject score': 851, 'object score': 1000}, 'PMID:2388137': {'publication date': '1990 Jul', 'sentence': 'Previous studies have demonstrated the advantages of the local sustained release of chlorhexidine from nondegradable devices in the treatment of periodontal diseases.', 'subject score': 1000, 'object score': 1000}, 'PMID:2390965': {'publication date': '1990 Feb', 'sentence': 'Chlorhexidine is widely used as a mouth rinse in the prevention and treatment of periodontal diseases and dental caries.', 'subject score': 1000, 'object score': 1000}, 'PMID:24921057': {'publication date': '2014 Jun', 'sentence': 'RESULTS: There was no significant difference when the efficacy of triphala was compared with 0.2% chlorhexidine in hospitalized patients with periodontal disease.', 'subject score': 827, 'object score': 1000}, 'PMID:26598208': {'publication date': '2016 Feb', 'sentence': 'Topical administration of chlorhexidine for periodontal disease can provide advantages over systemic delivery, but is limited by the permeability of the cornified oral mucosal tissue.', 'subject score': 1000, 'object score': 1000}, 'PMID:2668719': {'publication date': '1989 May', 'sentence': \"Chlorhexidine a cationic antiseptic active against a wide spectrum of bacteria is widely and successfully used in the treatment of periodontal disease in the home and the outpatients' clinic.\", 'subject score': 1000, 'object score': 1000}, 'PMID:28566850': {'publication date': '2017 Jan-Mar', 'sentence': 'Hence, they can all be used as alternates to chlorhexidine in the management of periodontal diseases.', 'subject score': 785, 'object score': 1000}, 'PMID:29158711': {'publication date': '2017 Nov', 'sentence': 'The aim of our study was evaluation of the efficacy of local treatment with chlorhexidine (CHX) in patients suffering from periodontal disease by chemometric algorithms for multivariate data analysis.', 'subject score': 1000, 'object score': 1000}, 'PMID:31766136': {'publication date': '2019 Nov 13', 'sentence': 'This work aimed to develop and evaluate pH-dependent systems based on nanospheres (NSphs) and nanocapsules (NCs) loaded with chlorhexidine (CHX) base as a novel formulation for the treatment of periodontal disease.', 'subject score': 888, 'object score': 1000}, 'PMID:32381840': {'publication date': '2019 Dec 01', 'sentence': 'Effectiveness of Controlled Release Chlorhexidine Chip as an Adjunctive to Scaling and Root Planning for the Treatment of Chronic Periodontitis.BACKGROUND: Chlorhexidine is considered one of the options for the management of periodontal diseases.', 'subject score': 1000, 'object score': 1000}, 'PMID:35362697': {'publication date': '2022', 'sentence': 'The inclusion of CITROX in the rinse aid reduces the concentration of chlorhexidine in the rinse aid, which can lead to a decrease in the severity of undesirable effects and be considered as an alternative remedy in the treatment of periodontal diseases.', 'subject score': 1000, 'object score': 1000}, 'PMID:35821403': {'publication date': '2022 Jul 12', 'sentence': 'Effectiveness of tea tree oil versus chlorhexidine in the treatment of periodontal diseases: a systematic review.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:29391816': {'publication date': '2018', 'sentence': 'Antibacterial effect evaluation of moxalactam against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae with in vitro pharmacokinetics/pharmacodynamics simulation.', 'subject score': 851, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:treats---None---None---None---UMLS:C0031090---SEMMEDDB:"
+                "UMLS:C0279516---SEMMEDDB:interacts_with---None---None---None---UMLS:C0026651---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "11792004",
-              "object": "MONDO:0002635",
+              "subject": "MESH:D000900",
+              "id": "20139285",
+              "object": "PUBCHEM.COMPOUND:47499",
               "publications": [
-                "PMID:15853968",
-                "PMID:22350036",
-                "PMID:2388137",
-                "PMID:2390965",
-                "PMID:24921057",
-                "PMID:26598208",
-                "PMID:2668719",
-                "PMID:28566850",
-                "PMID:29158711",
-                "PMID:31766136",
-                "PMID:32381840",
-                "PMID:35362697",
-                "PMID:35821403"
+                "PMID:29391816"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 553,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -518579,44 +7864,41 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Latamoxef",
+              "description": "A semisynthetic oxa-beta-lactam antibiotic, with antibacterial activity used mainly against gram-negative aerobic bacteria. Replacing the beta-lactam sulfur atom for an oxygen atom and the presence of the methyltetrazolethio moiety and the para-hydroxyphenylmalonyl group, increases the antibacterial activity of moxalactam. The 7-alpha-methoxy group and the para-hydroxyphenylmalonyl group increases the stability of this agent against beta-lactamases. The use of this agent has been associated with fatal bleeding events.; A parenteral oxacephem antibiotic with an oxygen molecule substituted for the sulfur atom in the beta-lactam nucleus. Moxalactam is a thrid-generation cephalosporin that has broad-spectrum antibiotic activity and high resistance to beta-lactameses. This agent is active against gram-negative enteric bacilli, including multiple drug-resistant strains.; Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "ATC:J01DD06",
+                "NDDF:004889",
+                "INCHIKEY:JWCSIUVGFCSJCK-CAVRMKNVSA-N",
+                "CHEMBL.COMPOUND:CHEMBL74632",
+                "UMLS:C0878141",
+                "CHEBI:599928",
+                "RXNORM:7069",
+                "PUBCHEM.COMPOUND:47499",
+                "PDQ:CDR0000039507",
+                "UMLS:C0026651",
+                "KEGG.DRUG:D02198",
+                "DRUGBANK:DB04570",
+                "KEGG.COMPOUND:C07231",
+                "NCIT:C670",
+                "GTOPDB:12031",
+                "KEGG.DRUG:D08109",
+                "HMDB:HMDB0015574",
+                "DrugCentral:1851",
+                "UNII:VUF6C936Z3",
+                "MESH:D009070"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:47499",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "Latamoxef",
+                "Latamoxef (INN)",
+                "Moxalactam disodium (USAN)",
+                "Moxalactam",
+                "Festamoxin",
+                "moxalactam",
+                "latamoxef",
+                "MOXALACTAM"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -518624,16 +7906,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:20014752",
+                "PMID:17846134",
+                "PMID:6217353",
+                "PMID:17242148",
+                "PMID:18426954",
+                "PMID:18559652",
+                "PMID:19764786",
+                "PMID:12109906",
+                "PMID:18765691",
+                "PMID:19445515"
               ]
             }
           }
@@ -518643,53 +7925,42 @@
     }
   },
   {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:2895124': {'publication date': '1988 Mar', 'sentence': 'The findings of this study have illustrated the limited antibacterial activity of presently available toothpastes on the salivary flora compared to chlorhexidine, and as such, would tend to question the relative benefit of toothpaste in preventing periodontal disease through an antimicrobial effect.', 'subject score': 861, 'object score': 884}, 'PMID:3305620': {'publication date': '1987 Oct', 'sentence': 'The aim of this study was to test effects of preventive regimes using fluoride and chlorhexidine to prevent caries and periodontal diseases in 34 patients with overdentures.', 'subject score': 1000, 'object score': 1000}, 'PMID:33149431': {'publication date': '2020 Aug', 'sentence': 'Thus, chlorhexidine plays a key role in the dentistry and is used to treat or prevent periodontal disease, and has earned its eponym of the gold standard.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
+    "p3": {
       "start": {
-        "identity": 311375,
+        "identity": 778038,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002635",
-          "name": "periodontal disorder",
-          "description": "An inflammatory process of the gingival tissues and/or periodontal membrane of the teeth, resulting in an abnormally deep gingival sulcus, possibly producing periodontal pockets and loss of alveolar bone support.; Pathological processes involving the PERIODONTIUM including the gum (GINGIVA), the alveolar bone (ALVEOLAR PROCESS), the DENTAL CEMENTUM, and the PERIODONTAL LIGAMENT.; Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
+          "iri": "https://identifiers.org/umls:C0242937",
+          "name": "Analgesics, Non-Narcotic",
+          "description": "Nonopioid agents that produce an analgesic effect, such as NSAIDs.; A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS.; UMLS Semantic Type: STY:T121",
           "equivalent_curies": [
-            "MONDO:0002635",
-            "SNOMEDCT:2556008",
-            "MESH:D010510",
-            "ICD10:K05.6",
-            "UMLS:C0031090",
-            "DOID:3388",
-            "MEDDRA:10034537",
-            "MEDDRA:10034536",
-            "NCIT:C63743"
+            "MESH:D018712",
+            "UMLS:C0242937"
           ],
-          "id": "MONDO:0002635",
-          "category": "biolink:Disease",
+          "id": "UMLS:C0242937",
+          "category": "biolink:Drug",
           "all_names": [
-            "periodontal disease",
-            "periodontal disorder",
-            "Periodontal Disorder",
-            "Periodontal Diseases"
+            "Analgesics, Non-Narcotic"
           ],
           "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nidcr.nih.gov/health-info/gum-disease/more-info"
+            "biolink:Drug"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 554,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -518706,44 +7977,43 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:3672",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -518751,141 +8021,135 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 311375,
+            "identity": 778038,
             "labels": [
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:ChemicalMixture",
+              "biolink:ChemicalOrDrugOrTreatment",
+              "biolink:Drug",
+              "biolink:MolecularMixture",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:OntologyClass",
+              "biolink:PhysicalEssence",
+              "biolink:PhysicalEssenceOrOccurrent"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002635",
-              "name": "periodontal disorder",
-              "description": "An inflammatory process of the gingival tissues and/or periodontal membrane of the teeth, resulting in an abnormally deep gingival sulcus, possibly producing periodontal pockets and loss of alveolar bone support.; Pathological processes involving the PERIODONTIUM including the gum (GINGIVA), the alveolar bone (ALVEOLAR PROCESS), the DENTAL CEMENTUM, and the PERIODONTAL LIGAMENT.; Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
+              "iri": "https://identifiers.org/umls:C0242937",
+              "name": "Analgesics, Non-Narcotic",
+              "description": "Nonopioid agents that produce an analgesic effect, such as NSAIDs.; A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS.; UMLS Semantic Type: STY:T121",
               "equivalent_curies": [
-                "MONDO:0002635",
-                "SNOMEDCT:2556008",
-                "MESH:D010510",
-                "ICD10:K05.6",
-                "UMLS:C0031090",
-                "DOID:3388",
-                "MEDDRA:10034537",
-                "MEDDRA:10034536",
-                "NCIT:C63743"
+                "MESH:D018712",
+                "UMLS:C0242937"
               ],
-              "id": "MONDO:0002635",
-              "category": "biolink:Disease",
+              "id": "UMLS:C0242937",
+              "category": "biolink:Drug",
               "all_names": [
-                "periodontal disease",
-                "periodontal disorder",
-                "Periodontal Disorder",
-                "Periodontal Diseases"
+                "Analgesics, Non-Narcotic"
               ],
               "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nidcr.nih.gov/health-info/gum-disease/more-info"
+                "biolink:Drug"
               ]
             }
           },
           "relationship": {
-            "identity": 19515761,
-            "start": 638,
-            "end": 311375,
-            "type": "biolink:prevents",
+            "identity": 9433206,
+            "start": 554,
+            "end": 778038,
+            "type": "biolink:subclass_of",
             "properties": {
-              "predicate": "biolink:prevents",
+              "predicate": "biolink:subclass_of",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2895124': {'publication date': '1988 Mar', 'sentence': 'The findings of this study have illustrated the limited antibacterial activity of presently available toothpastes on the salivary flora compared to chlorhexidine, and as such, would tend to question the relative benefit of toothpaste in preventing periodontal disease through an antimicrobial effect.', 'subject score': 861, 'object score': 884}, 'PMID:3305620': {'publication date': '1987 Oct', 'sentence': 'The aim of this study was to test effects of preventive regimes using fluoride and chlorhexidine to prevent caries and periodontal diseases in 34 patients with overdentures.', 'subject score': 1000, 'object score': 1000}, 'PMID:33149431': {'publication date': '2020 Aug', 'sentence': 'Thus, chlorhexidine plays a key role in the dentistry and is used to treat or prevent periodontal disease, and has earned its eponym of the gold standard.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:12108928': {'publication date': '2002', 'sentence': 'The aim of the study was to discover whether the systemic administration of a benzodiazepine agent alprazolam increases the systemic analgesic efficacy of non-opioid analgesic ibuprofen.', 'subject score': 908, 'object score': 908}, 'PMID:15386729': {'publication date': '2004 Oct', 'sentence': 'The most commonly prescribed non-opioid analgesic was ibuprofen (41%) followed by nimesulide (22%).', 'subject score': 1000, 'object score': 988}, 'PMID:17063417': {'publication date': '2006 Oct', 'sentence': 'The repertoire of analgesic treatments consist of basic treatment with non-opioid analgesics such as paracetamol or ibuprofen, as well as need-determined treatments with opioids given under intensive care monitoring.', 'subject score': 1000, 'object score': 1000}, 'PMID:17319261': {'publication date': '2006', 'sentence': 'CONCLUSION: Scheduled nonopioid analgesic (ibuprofen) with interpleural bupivacaine did not provide sufficient analgesia for post-thoracotomy pain in young children.', 'subject score': 1000, 'object score': 884}, 'PMID:30286851': {'publication date': '2018 Oct', 'sentence': 'CONCLUSIONS: We recommend using nonopioids such as ACE and IBU in the postoperative management after CTR surgery, and regardless of the medication prescribed, we advise prescribing no more than 5-10 pills after surgery.', 'subject score': 1000, 'object score': 966}, 'PMID:9750800': {'publication date': '1998', 'sentence': 'Non opioid analgesics used are mainly paracetamol, niflumic acid and ibuprofen.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:prevents---None---None---None---UMLS:C0031090---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:isa---None---None---None---UMLS:C0242937---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "19905103",
-              "object": "MONDO:0002635",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "9641575",
+              "object": "UMLS:C0242937",
               "publications": [
-                "PMID:2895124",
-                "PMID:3305620",
-                "PMID:33149431"
+                "PMID:12108928",
+                "PMID:15386729",
+                "PMID:17063417",
+                "PMID:17319261",
+                "PMID:30286851",
+                "PMID:9750800"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 554,
             "labels": [
-              "biolink:SmallMolecule",
-              "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
               "biolink:ChemicalMixture",
-              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
+              "biolink:Drug",
+              "biolink:MolecularEntity",
+              "biolink:MolecularMixture",
               "biolink:NamedThing",
+              "biolink:OntologyClass",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:MolecularMixture",
-              "biolink:OntologyClass"
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:SmallMolecule"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:3672",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -518893,16 +8157,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -518912,53 +8176,41 @@
     }
   },
   {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:predisposes",
-    "r2.publications_info": "{'PMID:29032402': {'publication date': '2018 Apr', 'sentence': 'CLINICAL RELEVANCE: A mouthrinse solution containing a mixture of CHX and NaF may be an interesting product for risk patients for caries and periodontal disease.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
+    "p3": {
       "start": {
-        "identity": 311375,
+        "identity": 5232,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002635",
-          "name": "periodontal disorder",
-          "description": "An inflammatory process of the gingival tissues and/or periodontal membrane of the teeth, resulting in an abnormally deep gingival sulcus, possibly producing periodontal pockets and loss of alveolar bone support.; Pathological processes involving the PERIODONTIUM including the gum (GINGIVA), the alveolar bone (ALVEOLAR PROCESS), the DENTAL CEMENTUM, and the PERIODONTAL LIGAMENT.; Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
+          "iri": "http://id.nlm.nih.gov/mesh/D000700",
+          "name": "Analgesics",
+          "description": "Compounds that alleviate pain without loss of consciousness. Analgesics act by various mechanisms including binding with opioid receptors and decreasing inflammation. Choice of analgesic may be determined by the type of pain. These compounds include opioid, non-opioid and adjuvant analgesic agents.; Natural or synthetic compound mixtures, Analgesic Preparations relieve pain by altering the perception of nociceptive stimuli without loss of consciousness. Analgesic compounds may act at opioid receptors (morphine-like drugs) or at other central or peripheral sites (non-steroidal anti-inflammatory agents). (NCI04); Compounds that show activity in animal models of human PAIN such as tail flick and hot plate assays.; UMLS Semantic Type: STY:T131; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "MONDO:0002635",
-            "SNOMEDCT:2556008",
-            "MESH:D010510",
-            "ICD10:K05.6",
-            "UMLS:C0031090",
-            "DOID:3388",
-            "MEDDRA:10034537",
-            "MEDDRA:10034536",
-            "NCIT:C63743"
+            "UMLS:C0002771",
+            "MESH:D000700",
+            "CHEBI:35480",
+            "ATC:N02"
           ],
-          "id": "MONDO:0002635",
-          "category": "biolink:Disease",
+          "id": "MESH:D000700",
+          "category": "biolink:ChemicalEntity",
           "all_names": [
-            "periodontal disease",
-            "periodontal disorder",
-            "Periodontal Disorder",
-            "Periodontal Diseases"
+            "Analgesics",
+            "analgesic"
           ],
           "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nidcr.nih.gov/health-info/gum-disease/more-info"
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 554,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -518975,44 +8227,43 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:3672",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -519020,85 +8271,95 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 311375,
+            "identity": 5232,
             "labels": [
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:PhysicalEssence",
+              "biolink:PhysicalEssenceOrOccurrent"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002635",
-              "name": "periodontal disorder",
-              "description": "An inflammatory process of the gingival tissues and/or periodontal membrane of the teeth, resulting in an abnormally deep gingival sulcus, possibly producing periodontal pockets and loss of alveolar bone support.; Pathological processes involving the PERIODONTIUM including the gum (GINGIVA), the alveolar bone (ALVEOLAR PROCESS), the DENTAL CEMENTUM, and the PERIODONTAL LIGAMENT.; Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
+              "iri": "http://id.nlm.nih.gov/mesh/D000700",
+              "name": "Analgesics",
+              "description": "Compounds that alleviate pain without loss of consciousness. Analgesics act by various mechanisms including binding with opioid receptors and decreasing inflammation. Choice of analgesic may be determined by the type of pain. These compounds include opioid, non-opioid and adjuvant analgesic agents.; Natural or synthetic compound mixtures, Analgesic Preparations relieve pain by altering the perception of nociceptive stimuli without loss of consciousness. Analgesic compounds may act at opioid receptors (morphine-like drugs) or at other central or peripheral sites (non-steroidal anti-inflammatory agents). (NCI04); Compounds that show activity in animal models of human PAIN such as tail flick and hot plate assays.; UMLS Semantic Type: STY:T131; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "MONDO:0002635",
-                "SNOMEDCT:2556008",
-                "MESH:D010510",
-                "ICD10:K05.6",
-                "UMLS:C0031090",
-                "DOID:3388",
-                "MEDDRA:10034537",
-                "MEDDRA:10034536",
-                "NCIT:C63743"
+                "UMLS:C0002771",
+                "MESH:D000700",
+                "CHEBI:35480",
+                "ATC:N02"
               ],
-              "id": "MONDO:0002635",
-              "category": "biolink:Disease",
+              "id": "MESH:D000700",
+              "category": "biolink:ChemicalEntity",
               "all_names": [
-                "periodontal disease",
-                "periodontal disorder",
-                "Periodontal Disorder",
-                "Periodontal Diseases"
+                "Analgesics",
+                "analgesic"
               ],
               "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nidcr.nih.gov/health-info/gum-disease/more-info"
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-            "identity": 19552578,
-            "start": 638,
-            "end": 311375,
-            "type": "biolink:predisposes",
+            "identity": 7652086,
+            "start": 554,
+            "end": 5232,
+            "type": "biolink:subclass_of",
             "properties": {
-              "predicate": "biolink:predisposes",
+              "predicate": "biolink:subclass_of",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:29032402': {'publication date': '2018 Apr', 'sentence': 'CLINICAL RELEVANCE: A mouthrinse solution containing a mixture of CHX and NaF may be an interesting product for risk patients for caries and periodontal disease.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:10566562': {'publication date': '1999 Oct', 'sentence': \"In addition, rofecoxib's analgesic efficacy was similar to that of ibuprofen (TOPAR8, 18.3 vs. 17.0; P = 0.460), but the duration was longer (P<0.05); with ibuprofen, the time to on set was 24 minutes, peak pain relief score was 2.9, and duration of analgesic effect was 8.9 hours.\", 'subject score': 1000, 'object score': 623}, 'PMID:10805057': {'publication date': '2000 Feb-Mar', 'sentence': 'Similarly, the amount of time before taking an escape analgesic was significantly less in the placebo group than both the ibuprofen and buffered ketoprofen groups (P < 0.03).', 'subject score': 1000, 'object score': 888}, 'PMID:11200807': {'publication date': '2000', 'sentence': 'However, there is general agreement that (in subjects requiring medication) paracetamol, acetylsalicylic acid and ibuprofen are most useful for treating migraine attacks, whereas analgesics should widely be avoided in tension-type headache.', 'subject score': 1000, 'object score': 1000}, 'PMID:11560814': {'publication date': '2001 Oct', 'sentence': 'Simple analgesics such as ibuprofen, aspirin, and acetaminophen have long been used in the treatment of tension-type headache.', 'subject score': 1000, 'object score': 888}, 'PMID:11692144': {'publication date': '2001', 'sentence': 'We have studied two liposoluble drugs, MPA and the analgesic ibuprofen, on glioma vascularization in vivo.', 'subject score': 888, 'object score': 888}, 'PMID:1173655': {'publication date': '1975 Jul 28', 'sentence': 'Ibuprofen is a new, mild analgesic agent that may be useful in the symptomatic treatment of rheumatoid arthritis and osteoarthritis.', 'subject score': 1000, 'object score': 861}, 'PMID:11960123': {'publication date': '2002 Apr', 'sentence': 'Ibuprofen may not be an effective analgesic for children with these injuries; stronger analgesics may be required.', 'subject score': 1000, 'object score': 888}, 'PMID:12204564': {'publication date': '2002 Sep 05', 'sentence': 'Different crystal habits of the common analgesic drugs ibuprofen and acetaminophen were prepared.', 'subject score': 861, 'object score': 861}, 'PMID:12242597': {'publication date': '2002 Sep', 'sentence': 'Ibuprofen is a safe and effective analgesic, but some formulations have a slow onset of action.', 'subject score': 1000, 'object score': 888}, 'PMID:12270238': {'publication date': '2002 Oct 01', 'sentence': 'The common analgesic drug ibuprofen shows bad dissolution and tableting behavior due to its hydrophobic structure.', 'subject score': 852, 'object score': 852}, 'PMID:12378018': {'publication date': '2002 Oct', 'sentence': 'The subjects were orally received antiviral (valacyclovir), tricyclic antidepressant (amitriptyline), and analgesic (ibuprofen) as the standard treatment in the group 1.', 'subject score': 1000, 'object score': 1000}, 'PMID:12455467': {'publication date': '2002 Oct', 'sentence': 'Different crystal forms of the analgesic drug ibuprofen were prepared and characterized in this study.', 'subject score': 890, 'object score': 890}, 'PMID:12717759': {'publication date': '2003', 'sentence': 'The drugs investigated were the analgesics Ibuprofen, Fenoprofen, Ketoprofen, Naproxen, and Diclofenac.', 'subject score': 888, 'object score': 888}, 'PMID:12798104': {'publication date': '2003 Jun 20', 'sentence': 'Under the operating conditions applied the biodegradation of the lipid lowering agent clofibric acid and the analgesic agents ibuprofen and diclofenac in the oxic BFR resembled that in the PSP.', 'subject score': 901, 'object score': 901}, 'PMID:12799814': {'publication date': '1997 Aug 25', 'sentence': 'In patients with migraine (4 studies) several other analgesics (ibuprofen, mefenamic acid, flupirtin) were slightly more effective than paracetamol, however, the efficacy of paracetamol itself had not been assessed.', 'subject score': 1000, 'object score': 1000}, 'PMID:1280802': {'publication date': '1992 Sep', 'sentence': 'The analgesic efficacy of ibuprofen plus codeine was significantly superior to that of ibuprofen which was, in turn, superior to that of placebo.', 'subject score': 1000, 'object score': 694}, 'PMID:15105203': {'publication date': '2004 May', 'sentence': 'Outcome measures were four primary end-points: pain intensity as assessed by a 100-mm visual analogue scale and a 4-point categorized scale hourly for 8 h, time to first analgesic, total analgesic (ibuprofen) consumption over the first 48 h, and a 5-point categorical patient global assessment scale (0 = poor, 1 = fair, 2 = good, 3 = very good, and 4 = excellent).', 'subject score': 1000, 'object score': 888}, 'PMID:15739500': {'publication date': '1997 Sep', 'sentence': 'Ibuprofen is an excellent anti inflammatory and analgesic drug.', 'subject score': 1000, 'object score': 983}, 'PMID:15751782': {'publication date': '2004 Apr-Jun', 'sentence': 'The most frequently prescribed systemic analgesic and antimicrobials were ibuprofen and amoxycillin, respectively.', 'subject score': 1000, 'object score': 888}, 'PMID:15977357': {'publication date': '2005 Jun', 'sentence': 'Tramadol has not been compared with codeine, ibuprofen, or correctly dosed paracetamol (step-1 analgesic).', 'subject score': 1000, 'object score': 901}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:predisposes---None---None---None---UMLS:C0031090---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:isa---None---None---None---UMLS:C0002771---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "19942414",
-              "object": "MONDO:0002635",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "7818659",
+              "object": "MESH:D000700",
               "publications": [
-                "PMID:29032402"
+                "PMID:10566562",
+                "PMID:10805057",
+                "PMID:11200807",
+                "PMID:11560814",
+                "PMID:11692144",
+                "PMID:1173655",
+                "PMID:11960123",
+                "PMID:12204564",
+                "PMID:12242597",
+                "PMID:12270238",
+                "PMID:12378018",
+                "PMID:12455467",
+                "PMID:12717759",
+                "PMID:12798104",
+                "PMID:12799814",
+                "PMID:1280802",
+                "PMID:15105203",
+                "PMID:15739500",
+                "PMID:15751782",
+                "PMID:15977357"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 554,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -519115,44 +8376,43 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:3672",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -519160,16 +8420,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -519179,64 +8439,42 @@
     }
   },
   {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:causes",
-    "r2.publications_info": "{'PMID:22368367': {'publication date': '2011 Oct', 'sentence': 'CONCLUSION: A. indica-based mouth rinse is equally efficacious with fewer side effects as compared to chlorhexidine and may be used as an adjunct therapy in treating plaque induced gingivitis.', 'subject score': 861, 'object score': 1000}, 'PMID:29038700': {'publication date': '2017 Sep', 'sentence': 'OBJECTIVE: To determine the effect of mouthwash containing CHX and thymol on plaque induced gingivitis.', 'subject score': 851, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
+    "p3": {
       "start": {
-        "identity": 318440,
+        "identity": 778038,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002508",
-          "name": "gingivitis",
-          "description": "A disorder involving inflammation of the gums; may affect surrounding and supporting structures of the teeth.; Inflammation of gum tissue (GINGIVA) without loss of connective tissue.; Inflammation of the gingiva. [HPO:probinson]",
+          "iri": "https://identifiers.org/umls:C0242937",
+          "name": "Analgesics, Non-Narcotic",
+          "description": "Nonopioid agents that produce an analgesic effect, such as NSAIDs.; A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS.; UMLS Semantic Type: STY:T121",
           "equivalent_curies": [
-            "ICD9:523.1",
-            "ICD9:523.0",
-            "SNOMEDCT:31642005",
-            "HP:0000230",
-            "NCIT:C34636",
-            "MEDDRA:10072575",
-            "ICD10:K05.1",
-            "UMLS:C0155937",
-            "UMLS:C0017574",
-            "MEDDRA:10018292",
-            "MEDDRA:10021956",
-            "SNOMEDCT:66383009",
-            "ICD10:K05.0",
-            "MESH:D005891",
-            "DOID:3087",
-            "MEDDRA:10000787",
-            "MONDO:0002508",
-            "ICD10:K05.10"
+            "MESH:D018712",
+            "UMLS:C0242937"
           ],
-          "id": "MONDO:0002508",
-          "category": "biolink:Disease",
+          "id": "UMLS:C0242937",
+          "category": "biolink:Drug",
           "all_names": [
-            "Acute gingivitis",
-            "gingivitis",
-            "Chronic gingivitis",
-            "Gingivitis"
+            "Analgesics, Non-Narcotic"
           ],
           "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5889-4463",
-            "https://orcid.org/0000-0002-0736-9199"
+            "biolink:Drug"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 554,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -519253,44 +8491,43 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:3672",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -519298,96 +8535,77 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 318440,
+            "identity": 778038,
             "labels": [
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002508",
-              "name": "gingivitis",
-              "description": "A disorder involving inflammation of the gums; may affect surrounding and supporting structures of the teeth.; Inflammation of gum tissue (GINGIVA) without loss of connective tissue.; Inflammation of the gingiva. [HPO:probinson]",
+              "iri": "https://identifiers.org/umls:C0242937",
+              "name": "Analgesics, Non-Narcotic",
+              "description": "Nonopioid agents that produce an analgesic effect, such as NSAIDs.; A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS.; UMLS Semantic Type: STY:T121",
               "equivalent_curies": [
-                "ICD9:523.1",
-                "ICD9:523.0",
-                "SNOMEDCT:31642005",
-                "HP:0000230",
-                "NCIT:C34636",
-                "MEDDRA:10072575",
-                "ICD10:K05.1",
-                "UMLS:C0155937",
-                "UMLS:C0017574",
-                "MEDDRA:10018292",
-                "MEDDRA:10021956",
-                "SNOMEDCT:66383009",
-                "ICD10:K05.0",
-                "MESH:D005891",
-                "DOID:3087",
-                "MEDDRA:10000787",
-                "MONDO:0002508",
-                "ICD10:K05.10"
+                "MESH:D018712",
+                "UMLS:C0242937"
               ],
-              "id": "MONDO:0002508",
-              "category": "biolink:Disease",
+              "id": "UMLS:C0242937",
+              "category": "biolink:Drug",
               "all_names": [
-                "Acute gingivitis",
-                "gingivitis",
-                "Chronic gingivitis",
-                "Gingivitis"
+                "Analgesics, Non-Narcotic"
               ],
               "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5889-4463",
-                "https://orcid.org/0000-0002-0736-9199"
+                "biolink:Drug"
               ]
             }
           },
           "relationship": {
-            "identity": 15815748,
-            "start": 638,
-            "end": 318440,
-            "type": "biolink:causes",
+            "identity": 22859060,
+            "start": 554,
+            "end": 778038,
+            "type": "biolink:related_to",
             "properties": {
-              "predicate": "biolink:causes",
+              "predicate": "biolink:related_to",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22368367': {'publication date': '2011 Oct', 'sentence': 'CONCLUSION: A. indica-based mouth rinse is equally efficacious with fewer side effects as compared to chlorhexidine and may be used as an adjunct therapy in treating plaque induced gingivitis.', 'subject score': 861, 'object score': 1000}, 'PMID:29038700': {'publication date': '2017 Sep', 'sentence': 'OBJECTIVE: To determine the effect of mouthwash containing CHX and thymol on plaque induced gingivitis.', 'subject score': 851, 'object score': 1000}}",
+              "publications_info": "{'PMID:33919715': {'publication date': '2021 Apr 14', 'sentence': 'The purpose of this systematic review was to determine the analgesic efficacy and adverse effects of ibuprofen in comparison with other traditional non-opioid analgesics after third molar surgery.', 'subject score': 1000, 'object score': 923}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:causes---None---None---None---UMLS:C0017574---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:compared_with---None---None---None---UMLS:C0242937---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "16147932",
-              "object": "MONDO:0002508",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "23290043",
+              "object": "UMLS:C0242937",
               "publications": [
-                "PMID:22368367",
-                "PMID:29038700"
+                "PMID:33919715"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 554,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -519404,44 +8622,43 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:3672",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -519449,16 +8666,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -519468,61 +8685,72 @@
     }
   },
   {
-<<<<<<< HEAD
     "p3": {
       "start": {
-        "identity": 315088,
+        "identity": 4620,
         "labels": [
+          "biolink:SmallMolecule",
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:MolecularEntity",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004842",
-          "name": "stomatitis",
-          "description": "Inflammation of the oral mucosa due to local or systemic factors.; Inflammation of the ORAL MUCOSA.; Stomatitis is an inflammation of the mucous membranes of any of the structures in the mouth. [HPO:probinson]; UMLS Semantic Type: STY:T047",
+          "name": "Dexibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. It is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer. Dexibuprofen has a slower dissolution rate in the simulated gastric and enteric juices compared with the racemic ibuprofen and displays improved oral bioavilability [A19259]. For Metabolism, Enzymes, Carriers, Transporters Sections, refer to [Ibuprofen].",
           "equivalent_curies": [
-            "UMLS:C0038362",
-            "MESH:D013280",
-            "MEDDRA:10042128",
-            "MEDDRA:10067244",
-            "EFO:1001904",
-            "UMLS:C0149704",
-            "EFO:0009688",
-            "DOID:9637",
-            "MEDDRA:10028130",
-            "SNOMEDCT:61170000",
-            "UMLS:C1568868",
-            "HP:0010280",
-            "NCIT:C26887",
-            "SNOMEDCT:20607006",
-            "MONDO:0004842"
+            "CHEBI:43415",
+            "NCIT:C166907",
+            "UMLS:C2714681",
+            "KEGG.DRUG:D03715",
+            "DrugCentral:3851",
+            "CAS:51146-56-6",
+            "PUBCHEM.COMPOUND:39912",
+            "ATC:M01AE14",
+            "NDDF:006963",
+            "MESH:C539402",
+            "INCHIKEY:HEFNNWSXXWATRW-JTQLQIEISA-N",
+            "DRUGBANK:DB09213",
+            "UNII:671DKG7P5S",
+            "CHEMBL.COMPOUND:CHEMBL175"
           ],
-          "id": "MONDO:0004842",
-          "category": "biolink:Disease",
+          "id": "PUBCHEM.COMPOUND:39912",
+          "category": "biolink:SmallMolecule",
           "all_names": [
-            "Stomatitis",
-            "Gingivostomatitis",
-            "Oral Mucositis",
-            "oral mucositis",
-            "stomatitis"
+            "DEXIBUPROFEN",
+            "Dexibuprofen (USAN/INN)",
+            "dexibuprofen",
+            "Dexibuprofen"
           ],
           "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
           ],
           "publications": [
-            "https://orcid.org/0000-0001-5889-4463",
-            "https://en.wikipedia.org/wiki/stomatitis",
-            "https://orcid.org/0000-0002-0736-9199"
+            "PMID:18457385",
+            "PMID:22877157",
+            "PMID:28949138",
+            "PMID:16872141",
+            "PMID:20804197",
+            "PMID:21602044",
+            "PMID:15013005",
+            "PMID:8582471",
+            "PMID:19032727",
+            "PMID:23316393"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 554,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -519539,44 +8767,43 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:3672",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -519584,95 +8811,107 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 315088,
+            "identity": 4620,
             "labels": [
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:ChemicalMixture",
+              "biolink:ChemicalOrDrugOrTreatment",
+              "biolink:Drug",
+              "biolink:MolecularEntity",
+              "biolink:MolecularMixture",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:OntologyClass",
+              "biolink:PhysicalEssence",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:SmallMolecule"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004842",
-              "name": "stomatitis",
-              "description": "Inflammation of the oral mucosa due to local or systemic factors.; Inflammation of the ORAL MUCOSA.; Stomatitis is an inflammation of the mucous membranes of any of the structures in the mouth. [HPO:probinson]; UMLS Semantic Type: STY:T047",
+              "name": "Dexibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. It is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer. Dexibuprofen has a slower dissolution rate in the simulated gastric and enteric juices compared with the racemic ibuprofen and displays improved oral bioavilability [A19259]. For Metabolism, Enzymes, Carriers, Transporters Sections, refer to [Ibuprofen].",
               "equivalent_curies": [
-                "UMLS:C0038362",
-                "MESH:D013280",
-                "MEDDRA:10042128",
-                "MEDDRA:10067244",
-                "EFO:1001904",
-                "UMLS:C0149704",
-                "EFO:0009688",
-                "DOID:9637",
-                "MEDDRA:10028130",
-                "SNOMEDCT:61170000",
-                "UMLS:C1568868",
-                "HP:0010280",
-                "NCIT:C26887",
-                "SNOMEDCT:20607006",
-                "MONDO:0004842"
+                "CHEBI:43415",
+                "NCIT:C166907",
+                "UMLS:C2714681",
+                "KEGG.DRUG:D03715",
+                "DrugCentral:3851",
+                "CAS:51146-56-6",
+                "PUBCHEM.COMPOUND:39912",
+                "ATC:M01AE14",
+                "NDDF:006963",
+                "MESH:C539402",
+                "INCHIKEY:HEFNNWSXXWATRW-JTQLQIEISA-N",
+                "DRUGBANK:DB09213",
+                "UNII:671DKG7P5S",
+                "CHEMBL.COMPOUND:CHEMBL175"
               ],
-              "id": "MONDO:0004842",
-              "category": "biolink:Disease",
+              "id": "PUBCHEM.COMPOUND:39912",
+              "category": "biolink:SmallMolecule",
               "all_names": [
-                "Stomatitis",
-                "Gingivostomatitis",
-                "Oral Mucositis",
-                "oral mucositis",
-                "stomatitis"
+                "DEXIBUPROFEN",
+                "Dexibuprofen (USAN/INN)",
+                "dexibuprofen",
+                "Dexibuprofen"
               ],
               "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
               ],
               "publications": [
-                "https://orcid.org/0000-0001-5889-4463",
-                "https://en.wikipedia.org/wiki/stomatitis",
-                "https://orcid.org/0000-0002-0736-9199"
+                "PMID:18457385",
+                "PMID:22877157",
+                "PMID:28949138",
+                "PMID:16872141",
+                "PMID:20804197",
+                "PMID:21602044",
+                "PMID:15013005",
+                "PMID:8582471",
+                "PMID:19032727",
+                "PMID:23316393"
               ]
             }
           },
           "relationship": {
-            "identity": 15095501,
-            "start": 638,
-            "end": 315088,
-            "type": "biolink:causes",
+            "identity": 21354595,
+            "start": 554,
+            "end": 4620,
+            "type": "biolink:related_to",
             "properties": {
-              "predicate": "biolink:causes",
+              "predicate": "biolink:related_to",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:21226717': {'publication date': '2011 Apr', 'sentence': 'Current dermatitis or stomatitis caused by chlorhexidine-containing topical medicaments was seen in 5 patients.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:32127557': {'publication date': '2020 Mar 03', 'sentence': 'Changes in body temperature over time were compared after taking one of three different antipyretics (AA, IBU, and DEX), using a one-way ANOVA followed by a post-hoc analysis.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:causes---None---None---None---UMLS:C0038362---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:compared_with---None---None---None---UMLS:C2714681---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "15413413",
-              "object": "MONDO:0004842",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "21770908",
+              "object": "PUBCHEM.COMPOUND:39912",
               "publications": [
-                "PMID:21226717"
+                "PMID:32127557"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 554,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -519689,44 +8928,43 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:3672",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -519734,16 +8972,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -519755,54 +8993,53 @@
   {
     "p3": {
       "start": {
-        "identity": 315382,
+        "identity": 857660,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-          "name": "bacterial infectious disease with sepsis",
-          "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+          "name": "Ibuprofen lysine",
+          "description": "IBUPROFEN LYSINE; FULL_MW:352.48; MAX_FDA_APPROVAL_PHASE: 4.0",
           "equivalent_curies": [
-            "NCIT:C102993",
-            "ICD9:995.91",
-            "MONDO:0005229",
-            "MEDDRA:10060562",
-            "MEDDRA:10003998",
-            "MEDDRA:10003997",
-            "MEDDRA:10045641",
-            "ICD9:790.7",
-            "MEDDRA:10045642",
-            "HP:0031864",
-            "SNOMEDCT:5758002",
-            "DOID:0040085",
-            "MESH:D016470",
-            "UMLS:C0004610",
-            "MEDDRA:10003999"
+            "NDDF:006232",
+            "CHEMBL.COMPOUND:CHEMBL1201141",
+            "UNII:N01ORX9D6S",
+            "PUBCHEM.COMPOUND:9841440",
+            "PUBCHEM.COMPOUND:49800067",
+            "MESH:C016106",
+            "NCIT:C72809",
+            "UMLS:C0074814",
+            "INCHIKEY:IHHXIUAEPKVVII-ZSCHJXSPSA-N",
+            "RXNORM:36761",
+            "CAS:57469-77-9"
           ],
-          "id": "MONDO:0005229",
-          "category": "biolink:Disease",
+          "id": "PUBCHEM.COMPOUND:9841440",
+          "category": "biolink:MolecularMixture",
           "all_names": [
-            "Bacteremia",
-            "bacterial infectious disease with sepsis",
-            "bacterial sepsis",
-            "Sepsis"
+            "solufenum",
+            "Ibuprofen Lysine",
+            "IBUPROFEN LYSINE",
+            "ibuprofen lysine"
           ],
           "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "PMID:20421654"
+            "biolink:MolecularMixture",
+            "biolink:Drug",
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 554,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -519819,44 +9056,43 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:3672",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -519864,91 +9100,94 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 315382,
+            "identity": 857660,
             "labels": [
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:ChemicalMixture",
+              "biolink:ChemicalOrDrugOrTreatment",
+              "biolink:Drug",
+              "biolink:MolecularMixture",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:OntologyClass",
+              "biolink:PhysicalEssence",
+              "biolink:PhysicalEssenceOrOccurrent"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-              "name": "bacterial infectious disease with sepsis",
-              "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+              "name": "Ibuprofen lysine",
+              "description": "IBUPROFEN LYSINE; FULL_MW:352.48; MAX_FDA_APPROVAL_PHASE: 4.0",
               "equivalent_curies": [
-                "NCIT:C102993",
-                "ICD9:995.91",
-                "MONDO:0005229",
-                "MEDDRA:10060562",
-                "MEDDRA:10003998",
-                "MEDDRA:10003997",
-                "MEDDRA:10045641",
-                "ICD9:790.7",
-                "MEDDRA:10045642",
-                "HP:0031864",
-                "SNOMEDCT:5758002",
-                "DOID:0040085",
-                "MESH:D016470",
-                "UMLS:C0004610",
-                "MEDDRA:10003999"
+                "NDDF:006232",
+                "CHEMBL.COMPOUND:CHEMBL1201141",
+                "UNII:N01ORX9D6S",
+                "PUBCHEM.COMPOUND:9841440",
+                "PUBCHEM.COMPOUND:49800067",
+                "MESH:C016106",
+                "NCIT:C72809",
+                "UMLS:C0074814",
+                "INCHIKEY:IHHXIUAEPKVVII-ZSCHJXSPSA-N",
+                "RXNORM:36761",
+                "CAS:57469-77-9"
               ],
-              "id": "MONDO:0005229",
-              "category": "biolink:Disease",
+              "id": "PUBCHEM.COMPOUND:9841440",
+              "category": "biolink:MolecularMixture",
               "all_names": [
-                "Bacteremia",
-                "bacterial infectious disease with sepsis",
-                "bacterial sepsis",
-                "Sepsis"
+                "solufenum",
+                "Ibuprofen Lysine",
+                "IBUPROFEN LYSINE",
+                "ibuprofen lysine"
               ],
               "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "PMID:20421654"
+                "biolink:MolecularMixture",
+                "biolink:Drug",
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-            "identity": 13444601,
-            "start": 638,
-            "end": 315382,
-            "type": "biolink:causes",
+            "identity": 17809399,
+            "start": 554,
+            "end": 857660,
+            "type": "biolink:related_to",
             "properties": {
-              "predicate": "biolink:causes",
+              "predicate": "biolink:related_to",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18462153': {'publication date': '2008 Apr', 'sentence': 'Outbreak of Burkholderia cepacia bacteremia caused by contaminated chlorhexidine in a hemodialysis unit.', 'subject score': 888, 'object score': 901}}",
+              "publications_info": "{'PMID:25708941': {'publication date': '2015 Apr 25', 'sentence': 'The aim of this study was: (i) to compare the available data to our method suitability test results carried out on products containing ibuprofen, i.e. to demonstrate that method suitability can be a valuable tool in identifying new antimicrobials, (ii) to demonstrate the antimicrobial activity of ibuprofen and ibuprofen lysine.', 'subject score': 1000, 'object score': 1000}, 'PMID:26249766': {'publication date': '2015 Nov', 'sentence': 'OBJECTIVES: To assess and compare the bioavailability of ibuprofen enantiomers (R and S) of two different pediatric suspensions: the first one with ibuprofen lysinate (Algidrin(r) Pediatrico, FARDI S.A., Barcelona, Spain) and the second one with ibuprofen base (Dalsy(r), Abbott Laboratories S.A., Madrid, Spain).', 'subject score': 872, 'object score': 1000}, 'PMID:30897305': {'publication date': '2019 Aug', 'sentence': 'Taken after a meal, ibuprofen in the FDC reached tmax earlier than ibuprofen lysinate (median 1.25 vs 1.63 hours), and Cmax was approximately 13% higher, with comparable AUC, suggesting that the profile of ibuprofen was in favor of the FDC compared with ibuprofen lysinate.', 'subject score': 1000, 'object score': 1000}, 'PMID:36704085': {'publication date': '2022', 'sentence': 'This study aimed to compare the effect of two non-steroidal anti-inflammatory drugs (NSAIDs); ibuprofen and ibuprofen lysine with two methods of prescription on pain after single-visit root canal treatment of first and second mandibular molar teeth with irreversible pulpitis.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:causes---None---None---None---UMLS:C0004610---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:compared_with---None---None---None---UMLS:C0074814---SEMMEDDB:",
+                "UMLS:C0020740---SEMMEDDB:higher_than---None---None---None---UMLS:C0074814---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "13735208",
-              "object": "MONDO:0005229",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "18171654",
+              "object": "PUBCHEM.COMPOUND:9841440",
               "publications": [
-                "PMID:18462153"
+                "PMID:25708941",
+                "PMID:30897305",
+                "PMID:26249766",
+                "PMID:36704085"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 554,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -519965,44 +9204,43 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:3672",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -520010,16 +9248,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -520031,39 +9269,38 @@
   {
     "p3": {
       "start": {
-        "identity": 546907,
+        "identity": 7235,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C3714514",
-          "name": "Infection",
-          "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
+          "iri": "http://id.nlm.nih.gov/mesh/D052246",
+          "name": "Cyclooxygenase 2 Inhibitors",
+          "description": "A subgroup of non-steroidal anti-inflammatory drugs (NSAID) that specifically targets at cyclooxygenase 2, an enzyme involved in pain and inflammation.; A subclass of cyclooxygenase inhibitors with specificity for CYCLOOXYGENASE-2.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "UMLS:C3714514",
-            "MEDDRA:10021842",
-            "NCIT:C128320",
-            "MEDDRA:10021789",
-            "MESH:D007239"
+            "CHEBI:50629",
+            "UMLS:C1257954",
+            "MESH:D052246"
           ],
-          "id": "UMLS:C3714514",
-          "category": "biolink:Disease",
+          "id": "MESH:D052246",
+          "category": "biolink:ChemicalEntity",
           "all_names": [
-            "Infection",
-            "Infections"
+            "Cyclooxygenase 2 Inhibitors",
+            "cyclooxygenase 2 inhibitor"
           ],
           "all_categories": [
-            "biolink:Disease"
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 554,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -520080,44 +9317,43 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:3672",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -520125,76 +9361,77 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 546907,
+            "identity": 7235,
             "labels": [
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:PhysicalEssence",
+              "biolink:PhysicalEssenceOrOccurrent"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C3714514",
-              "name": "Infection",
-              "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.; Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
+              "iri": "http://id.nlm.nih.gov/mesh/D052246",
+              "name": "Cyclooxygenase 2 Inhibitors",
+              "description": "A subgroup of non-steroidal anti-inflammatory drugs (NSAID) that specifically targets at cyclooxygenase 2, an enzyme involved in pain and inflammation.; A subclass of cyclooxygenase inhibitors with specificity for CYCLOOXYGENASE-2.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "UMLS:C3714514",
-                "MEDDRA:10021842",
-                "NCIT:C128320",
-                "MEDDRA:10021789",
-                "MESH:D007239"
+                "CHEBI:50629",
+                "UMLS:C1257954",
+                "MESH:D052246"
               ],
-              "id": "UMLS:C3714514",
-              "category": "biolink:Disease",
+              "id": "MESH:D052246",
+              "category": "biolink:ChemicalEntity",
               "all_names": [
-                "Infection",
-                "Infections"
+                "Cyclooxygenase 2 Inhibitors",
+                "cyclooxygenase 2 inhibitor"
               ],
               "all_categories": [
-                "biolink:Disease"
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-            "identity": 23358412,
-            "start": 638,
-            "end": 546907,
-            "type": "biolink:affects",
+            "identity": 15877845,
+            "start": 554,
+            "end": 7235,
+            "type": "biolink:related_to",
             "properties": {
-              "predicate": "biolink:affects",
+              "predicate": "biolink:related_to",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34620240': {'publication date': '2021 Oct 07', 'sentence': 'This meta-analysis aimed to examine the impact of CHX on infections after cardiac surgery compared with other cleansers or antiseptics.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:22471358': {'publication date': '2012 May', 'sentence': 'Cardiovascular risk, though present with coxibs and some NSAIDs in OA, is lower or slightly so with ibuprofen compared with coxibs.', 'subject score': 1000, 'object score': 1000}, 'PMID:23163543': {'publication date': '2013 Jan', 'sentence': \"The early observations have since been verified in studies comparing ibuprofen with newer cyclo-oxygenase-2 selective inhibitors ('coxibs'), paracetamol and other non-steroidal anti-inflammatory drugs (NSAIDs).\", 'subject score': 1000, 'object score': 1000}, 'PMID:36692805': {'publication date': '2023 Jan 24', 'sentence': 'RESULTS: A total of 633,562 and 1,063,960 participants were included in periods 1 and 2, respectively, for the ibuprofen versus ns-NSAIDs comparison, 311,669 and 524,470 for ibuprofen versus COX-2i, and 492,002 and 878,598 for ibuprofen versus paracetamol.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:affects---None---None---None---UMLS:C3714514---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:compared_with---None---None---None---UMLS:C1257954---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "23793676",
-              "object": "UMLS:C3714514",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "16211012",
+              "object": "MESH:D052246",
               "publications": [
-                "PMID:34620240"
+                "PMID:22471358",
+                "PMID:23163543",
+                "PMID:36692805"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 554,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -520211,44 +9448,43 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:3672",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -520256,16 +9492,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -520277,7 +9513,7 @@
   {
     "p3": {
       "start": {
-        "identity": 321523,
+        "identity": 321318,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -520287,41 +9523,52 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0002203",
+          "name": "constipation disorder",
+          "description": "Irregular and infrequent or difficult evacuation of the bowels.; Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.; Infrequent or difficult evacuation of feces. [HPO:probinson]; Constipation means that a person has three or fewer bowel movements in a week. The stool can be hard and dry. Sometimes it is painful to pass. At one time or another, almost everyone gets constipated. In most cases, it lasts a short time and is not serious.  There are many things you can do to prevent constipation. They include   Eating more fruits, vegetables and grains, which are high in fiber  Drinking plenty of water and other liquids  Getting enough exercise  Taking time to have a bowel movement when you need to  Using laxatives only if your doctor says you should  Asking your doctor if medicines you take may cause constipation   It's not important that you have a bowel movement every day. If your bowel habits change, however, check with your doctor.  NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
           "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
+            "MEDDRA:10051244",
+            "MEDDRA:10010774",
+            "PSY:11440",
+            "NCIT:C37930",
+            "DOID:2089",
+            "SNOMEDCT:225595004",
+            "SNOMEDCT:14760008",
+            "MEDDRA:10055664",
+            "ICD9:564.0",
+            "MONDO:0002203",
+            "UMLS:C0009806",
+            "HP:0002019",
+            "MESH:D003248",
+            "SYMP:0019180",
+            "MEDDRA:10054833",
+            "MEDDRA:10050960",
+            "UMLS:C0237326"
           ],
-          "id": "MONDO:0005249",
+          "id": "MONDO:0002203",
           "category": "biolink:Disease",
           "all_names": [
-            "Pneumonia",
-            "pneumonia"
+            "constipation",
+            "Dyschezia",
+            "constipation disorder",
+            "Constipation",
+            "obsolete constipation"
           ],
           "all_categories": [
-            "biolink:Disease"
+            "biolink:Disease",
+            "biolink:PhenotypicFeature"
           ],
           "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
+            "https://en.wikipedia.org/wiki/constipation",
+            "https://orcid.org/0000-0002-0736-9199",
+            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=constipation",
+            "PMID:19647687",
+            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3170709/"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 554,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -520338,44 +9585,43 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:3672",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -520383,90 +9629,99 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 321523,
+            "identity": 321318,
             "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:NamedThing",
+              "biolink:PhenotypicFeature",
+              "biolink:ThingWithTaxon"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0002203",
+              "name": "constipation disorder",
+              "description": "Irregular and infrequent or difficult evacuation of the bowels.; Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.; Infrequent or difficult evacuation of feces. [HPO:probinson]; Constipation means that a person has three or fewer bowel movements in a week. The stool can be hard and dry. Sometimes it is painful to pass. At one time or another, almost everyone gets constipated. In most cases, it lasts a short time and is not serious.  There are many things you can do to prevent constipation. They include   Eating more fruits, vegetables and grains, which are high in fiber  Drinking plenty of water and other liquids  Getting enough exercise  Taking time to have a bowel movement when you need to  Using laxatives only if your doctor says you should  Asking your doctor if medicines you take may cause constipation   It's not important that you have a bowel movement every day. If your bowel habits change, however, check with your doctor.  NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
               "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
+                "MEDDRA:10051244",
+                "MEDDRA:10010774",
+                "PSY:11440",
+                "NCIT:C37930",
+                "DOID:2089",
+                "SNOMEDCT:225595004",
+                "SNOMEDCT:14760008",
+                "MEDDRA:10055664",
+                "ICD9:564.0",
+                "MONDO:0002203",
+                "UMLS:C0009806",
+                "HP:0002019",
+                "MESH:D003248",
+                "SYMP:0019180",
+                "MEDDRA:10054833",
+                "MEDDRA:10050960",
+                "UMLS:C0237326"
               ],
-              "id": "MONDO:0005249",
+              "id": "MONDO:0002203",
               "category": "biolink:Disease",
               "all_names": [
-                "Pneumonia",
-                "pneumonia"
+                "constipation",
+                "Dyschezia",
+                "constipation disorder",
+                "Constipation",
+                "obsolete constipation"
               ],
               "all_categories": [
-                "biolink:Disease"
+                "biolink:Disease",
+                "biolink:PhenotypicFeature"
               ],
               "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
+                "https://en.wikipedia.org/wiki/constipation",
+                "https://orcid.org/0000-0002-0736-9199",
+                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=constipation",
+                "PMID:19647687",
+                "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3170709/"
               ]
             }
           },
           "relationship": {
-            "identity": 20908102,
-            "start": 638,
-            "end": 321523,
-            "type": "biolink:affects",
+            "identity": 15161942,
+            "start": 554,
+            "end": 321318,
+            "type": "biolink:related_to",
             "properties": {
-              "predicate": "biolink:affects",
+              "predicate": "biolink:related_to",
               "primary_knowledge_source": "infores:semmeddb",
-              "qualified_predicate": "biolink:causes",
-              "qualified_object_aspect": "activity_or_abundance",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31585480': {'publication date': '2019 08', 'sentence': 'Oral care with chlorhexidine may increase mortality risk and stress ulcer prophylaxis may facilitate pneumonia.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:21332973': {'publication date': '2011 Feb 18', 'sentence': 'Use of furosemide, levothyroxine sodium and ibuprofen was associated with constipation, and lithium and carbamazepine with diarrhoea.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:augments---biolink:causes---activity_or_abundance---None---UMLS:C0032285---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:associated_with---None---None---None---UMLS:C0009806---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "21319017",
-              "object": "MONDO:0005249",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "15481163",
+              "object": "MONDO:0002203",
               "publications": [
-                "PMID:31585480"
+                "PMID:21332973"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 554,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -520483,44 +9738,43 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:3672",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -520528,16 +9782,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -520549,7 +9803,7 @@
   {
     "p3": {
       "start": {
-        "identity": 315088,
+        "identity": 316891,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -520559,48 +9813,39 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004842",
-          "name": "stomatitis",
-          "description": "Inflammation of the oral mucosa due to local or systemic factors.; Inflammation of the ORAL MUCOSA.; Stomatitis is an inflammation of the mucous membranes of any of the structures in the mouth. [HPO:probinson]; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
+          "name": "Pain",
+          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
           "equivalent_curies": [
-            "UMLS:C0038362",
-            "MESH:D013280",
-            "MEDDRA:10042128",
-            "MEDDRA:10067244",
-            "EFO:1001904",
-            "UMLS:C0149704",
-            "EFO:0009688",
-            "DOID:9637",
-            "MEDDRA:10028130",
-            "SNOMEDCT:61170000",
-            "UMLS:C1568868",
-            "HP:0010280",
-            "NCIT:C26887",
-            "SNOMEDCT:20607006",
-            "MONDO:0004842"
+            "MESH:D010146",
+            "SYMP:0000099",
+            "UMLS:C0030193",
+            "ICD9:338-338.99",
+            "PSY:36150",
+            "SNOMEDCT:22253000",
+            "NCIT:C3303",
+            "MEDDRA:10033470",
+            "MEDDRA:10033371",
+            "HP:0012531",
+            "PDQ:CDR0000041399"
           ],
-          "id": "MONDO:0004842",
-          "category": "biolink:Disease",
+          "id": "HP:0012531",
+          "category": "biolink:PhenotypicFeature",
           "all_names": [
-            "Stomatitis",
-            "Gingivostomatitis",
-            "Oral Mucositis",
-            "oral mucositis",
-            "stomatitis"
+            "pain",
+            "Pain"
           ],
           "all_categories": [
-            "biolink:Disease",
             "biolink:PhenotypicFeature"
           ],
           "publications": [
-            "https://orcid.org/0000-0001-5889-4463",
-            "https://en.wikipedia.org/wiki/stomatitis",
-            "https://orcid.org/0000-0002-0736-9199"
+            "https://orcid.org/0000-0001-5208-3432",
+            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 554,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -520617,44 +9862,43 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:3672",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -520662,95 +9906,86 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 315088,
+            "identity": 316891,
             "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:NamedThing",
+              "biolink:PhenotypicFeature",
+              "biolink:ThingWithTaxon"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004842",
-              "name": "stomatitis",
-              "description": "Inflammation of the oral mucosa due to local or systemic factors.; Inflammation of the ORAL MUCOSA.; Stomatitis is an inflammation of the mucous membranes of any of the structures in the mouth. [HPO:probinson]; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
+              "name": "Pain",
+              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
               "equivalent_curies": [
-                "UMLS:C0038362",
-                "MESH:D013280",
-                "MEDDRA:10042128",
-                "MEDDRA:10067244",
-                "EFO:1001904",
-                "UMLS:C0149704",
-                "EFO:0009688",
-                "DOID:9637",
-                "MEDDRA:10028130",
-                "SNOMEDCT:61170000",
-                "UMLS:C1568868",
-                "HP:0010280",
-                "NCIT:C26887",
-                "SNOMEDCT:20607006",
-                "MONDO:0004842"
+                "MESH:D010146",
+                "SYMP:0000099",
+                "UMLS:C0030193",
+                "ICD9:338-338.99",
+                "PSY:36150",
+                "SNOMEDCT:22253000",
+                "NCIT:C3303",
+                "MEDDRA:10033470",
+                "MEDDRA:10033371",
+                "HP:0012531",
+                "PDQ:CDR0000041399"
               ],
-              "id": "MONDO:0004842",
-              "category": "biolink:Disease",
+              "id": "HP:0012531",
+              "category": "biolink:PhenotypicFeature",
               "all_names": [
-                "Stomatitis",
-                "Gingivostomatitis",
-                "Oral Mucositis",
-                "oral mucositis",
-                "stomatitis"
+                "pain",
+                "Pain"
               ],
               "all_categories": [
-                "biolink:Disease",
                 "biolink:PhenotypicFeature"
               ],
               "publications": [
-                "https://orcid.org/0000-0001-5889-4463",
-                "https://en.wikipedia.org/wiki/stomatitis",
-                "https://orcid.org/0000-0002-0736-9199"
+                "https://orcid.org/0000-0001-5208-3432",
+                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
               ]
             }
           },
           "relationship": {
-            "identity": 20185818,
-            "start": 638,
-            "end": 315088,
-            "type": "biolink:affects",
+            "identity": 14279414,
+            "start": 554,
+            "end": 316891,
+            "type": "biolink:related_to",
             "properties": {
-              "predicate": "biolink:affects",
+              "predicate": "biolink:related_to",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30233777': {'publication date': '2018 Apr 01', 'sentence': 'Conclusion: We found that addition of amphotericin B and chlorhexidine, to the nystatin and povidone iodine resulted in a significant beneficial effect in prevention OM.', 'subject score': 1000, 'object score': 901}}",
+              "publications_info": "{'PMID:19762153': {'publication date': '2009 Dec 15', 'sentence': 'We investigated the analgesic efficacy of single doses of ibuprofen, tramadol and pregabalin in menthol-evoked cold pain in a randomized, placebo-controlled four-way cross-over study in 20 healthy volunteers.', 'subject score': 1000, 'object score': 775}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:affects---None---None---None---UMLS:C1568868---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:associated_with---None---None---None---UMLS:C0030193---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "20585434",
-              "object": "MONDO:0004842",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "14582794",
+              "object": "HP:0012531",
               "publications": [
-                "PMID:30233777"
+                "PMID:19762153"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 554,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -520767,44 +10002,43 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:3672",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -520812,16 +10046,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -520833,48 +10067,39 @@
   {
     "p3": {
       "start": {
-        "identity": 311375,
+        "identity": 5232,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002635",
-          "name": "periodontal disorder",
-          "description": "An inflammatory process of the gingival tissues and/or periodontal membrane of the teeth, resulting in an abnormally deep gingival sulcus, possibly producing periodontal pockets and loss of alveolar bone support.; Pathological processes involving the PERIODONTIUM including the gum (GINGIVA), the alveolar bone (ALVEOLAR PROCESS), the DENTAL CEMENTUM, and the PERIODONTAL LIGAMENT.; Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
+          "iri": "http://id.nlm.nih.gov/mesh/D000700",
+          "name": "Analgesics",
+          "description": "Compounds that alleviate pain without loss of consciousness. Analgesics act by various mechanisms including binding with opioid receptors and decreasing inflammation. Choice of analgesic may be determined by the type of pain. These compounds include opioid, non-opioid and adjuvant analgesic agents.; Natural or synthetic compound mixtures, Analgesic Preparations relieve pain by altering the perception of nociceptive stimuli without loss of consciousness. Analgesic compounds may act at opioid receptors (morphine-like drugs) or at other central or peripheral sites (non-steroidal anti-inflammatory agents). (NCI04); Compounds that show activity in animal models of human PAIN such as tail flick and hot plate assays.; UMLS Semantic Type: STY:T131; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "MONDO:0002635",
-            "SNOMEDCT:2556008",
-            "MESH:D010510",
-            "ICD10:K05.6",
-            "UMLS:C0031090",
-            "DOID:3388",
-            "MEDDRA:10034537",
-            "MEDDRA:10034536",
-            "NCIT:C63743"
+            "UMLS:C0002771",
+            "MESH:D000700",
+            "CHEBI:35480",
+            "ATC:N02"
           ],
-          "id": "MONDO:0002635",
-          "category": "biolink:Disease",
+          "id": "MESH:D000700",
+          "category": "biolink:ChemicalEntity",
           "all_names": [
-            "periodontal disease",
-            "periodontal disorder",
-            "Periodontal Disorder",
-            "Periodontal Diseases"
+            "Analgesics",
+            "analgesic"
           ],
           "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://www.nidcr.nih.gov/health-info/gum-disease/more-info"
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 554,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -520891,44 +10116,43 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:3672",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -520936,85 +10160,80 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 311375,
+            "identity": 5232,
             "labels": [
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002635",
-              "name": "periodontal disorder",
-              "description": "An inflammatory process of the gingival tissues and/or periodontal membrane of the teeth, resulting in an abnormally deep gingival sulcus, possibly producing periodontal pockets and loss of alveolar bone support.; Pathological processes involving the PERIODONTIUM including the gum (GINGIVA), the alveolar bone (ALVEOLAR PROCESS), the DENTAL CEMENTUM, and the PERIODONTAL LIGAMENT.; Inflammation of the periodontium. [HPO:ibailleulforestier]; UMLS Semantic Type: STY:T047",
+              "iri": "http://id.nlm.nih.gov/mesh/D000700",
+              "name": "Analgesics",
+              "description": "Compounds that alleviate pain without loss of consciousness. Analgesics act by various mechanisms including binding with opioid receptors and decreasing inflammation. Choice of analgesic may be determined by the type of pain. These compounds include opioid, non-opioid and adjuvant analgesic agents.; Natural or synthetic compound mixtures, Analgesic Preparations relieve pain by altering the perception of nociceptive stimuli without loss of consciousness. Analgesic compounds may act at opioid receptors (morphine-like drugs) or at other central or peripheral sites (non-steroidal anti-inflammatory agents). (NCI04); Compounds that show activity in animal models of human PAIN such as tail flick and hot plate assays.; UMLS Semantic Type: STY:T131; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "MONDO:0002635",
-                "SNOMEDCT:2556008",
-                "MESH:D010510",
-                "ICD10:K05.6",
-                "UMLS:C0031090",
-                "DOID:3388",
-                "MEDDRA:10034537",
-                "MEDDRA:10034536",
-                "NCIT:C63743"
+                "UMLS:C0002771",
+                "MESH:D000700",
+                "CHEBI:35480",
+                "ATC:N02"
               ],
-              "id": "MONDO:0002635",
-              "category": "biolink:Disease",
+              "id": "MESH:D000700",
+              "category": "biolink:ChemicalEntity",
               "all_names": [
-                "periodontal disease",
-                "periodontal disorder",
-                "Periodontal Disorder",
-                "Periodontal Diseases"
+                "Analgesics",
+                "analgesic"
               ],
               "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://www.nidcr.nih.gov/health-info/gum-disease/more-info"
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-            "identity": 13219388,
-            "start": 638,
-            "end": 311375,
-            "type": "biolink:affects",
+            "identity": 13951232,
+            "start": 554,
+            "end": 5232,
+            "type": "biolink:related_to",
             "properties": {
-              "predicate": "biolink:affects",
+              "predicate": "biolink:related_to",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1809525': {'publication date': '1991', 'sentence': 'Effect of vitamin E gel, placebo gel and chlorhexidine on periodontal disease.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:19252905': {'publication date': '2009 Apr', 'sentence': 'CONCLUSIONS: Compared with acetaminophen, sodium ibuprofen was associated with significantly greater analgesic efficacy, pain relief in a greater proportion of patients and greater patient satisfaction.', 'subject score': 888, 'object score': 583}, 'PMID:34190183': {'publication date': '2021 Jul 02', 'sentence': 'CONCLUSIONS: Ibuprofen provides a better pain relief with a lower incidence of adverse effects in children with musculoskeletal injuries as compared to other analgesics.', 'subject score': 1000, 'object score': 1000}, 'PMID:35983005': {'publication date': '2022', 'sentence': 'Analgesics with oral ibuprofen resulted in fewer unexpected pain calls versus analgesics without oral ibuprofen within 72 h postoperatively (   P     < 0.05).', 'subject score': 888, 'object score': 1000}, 'PMID:3971683': {'publication date': '1985', 'sentence': 'The analgesic efficacy of the narcotic-ibuprofen combination was significantly greater than the analgesic efficacy of the narcotic-placebo combination.', 'subject score': 851, 'object score': 694}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:affects---None---None---None---UMLS:C0031090---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:compared_with---None---None---None---UMLS:C0002771---SEMMEDDB:",
+                "UMLS:C0020740---SEMMEDDB:higher_than---None---None---None---UMLS:C0002771---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "13503760",
-              "object": "MONDO:0002635",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "14248834",
+              "object": "MESH:D000700",
               "publications": [
-                "PMID:1809525"
+                "PMID:3971683",
+                "PMID:34190183",
+                "PMID:19252905",
+                "PMID:35983005"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 554,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -521031,44 +10250,43 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:3672",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -521076,16 +10294,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -521096,14 +10314,8 @@
   },
   {
     "p3": {
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:affects",
-    "r2.publications_info": "{'PMID:1104246': {'publication date': '1975 Nov', 'sentence': 'Effect of chlorhexidine on dental plaque and gingivitis in mentally retarded children.', 'subject score': 1000, 'object score': 1000}, 'PMID:16253086': {'publication date': '2005 Oct', 'sentence': 'CONCLUSIONS: These results indicate that both CHX and CHX/B-HCl sprays have equal clinical effectiveness, but only B-HCl spray has less anti-plaque and anti-gingivitis effects.', 'subject score': 1000, 'object score': 773}, 'PMID:4272044': {'publication date': '1972', 'sentence': 'Effects of topical application of chlorhexidine on plaque and gingivitis in monkeys.', 'subject score': 1000, 'object score': 1000}, 'PMID:6449574': {'publication date': '1980 Jul', 'sentence': 'Effect of chlorhexidine on plaque, gingivitis and alveolar bone loss in beagle dogs after seven years of treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:8649661': {'publication date': '1996 Mar', 'sentence': 'The effect of local application of chlorhexidine on plaque and gingivitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:9456641': {'publication date': '1997 Mar', 'sentence': 'CONCLUSION: In conclusion, there was a significant effect of chlorhexidine on gingivitis, although the effect may be too limited to assure prognostic benefits in the prevention of future disease progression.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
->>>>>>> main
       "start": {
-        "identity": 318440,
+        "identity": 319030,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -521113,48 +10325,49 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002508",
-          "name": "gingivitis",
-          "description": "A disorder involving inflammation of the gums; may affect surrounding and supporting structures of the teeth.; Inflammation of gum tissue (GINGIVA) without loss of connective tissue.; Inflammation of the gingiva. [HPO:probinson]",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
+          "name": "osteoarthritis",
+          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "ICD9:523.1",
-            "ICD9:523.0",
-            "SNOMEDCT:31642005",
-            "HP:0000230",
-            "NCIT:C34636",
-            "MEDDRA:10072575",
-            "ICD10:K05.1",
-            "UMLS:C0155937",
-            "UMLS:C0017574",
-            "MEDDRA:10018292",
-            "MEDDRA:10021956",
-            "SNOMEDCT:66383009",
-            "ICD10:K05.0",
-            "MESH:D005891",
-            "DOID:3087",
-            "MEDDRA:10000787",
-            "MONDO:0002508",
-            "ICD10:K05.10"
+            "MESH:D010003",
+            "ICD9:715.3",
+            "MEDDRA:10049491",
+            "DOID:8398",
+            "MEDDRA:10031216",
+            "UMLS:C0029408",
+            "EFO:0002506",
+            "NCIT:C3293",
+            "SNOMEDCT:225655006",
+            "MEDDRA:10031186",
+            "HP:0002758",
+            "UMLS:C0157946",
+            "SNOMEDCT:396275006",
+            "MEDDRA:10031161",
+            "MEDDRA:10031174",
+            "MONDO:0005178",
+            "MEDDRA:10031167"
           ],
-          "id": "MONDO:0002508",
+          "id": "MONDO:0005178",
           "category": "biolink:Disease",
           "all_names": [
-            "Acute gingivitis",
-            "gingivitis",
-            "Chronic gingivitis",
-            "Gingivitis"
+            "Osteoarthrosis, localized, not specified whether primary or secondary",
+            "Degenerative polyarthritis",
+            "Osteoarthritis",
+            "osteoarthritis",
+            "obsolete_osteoarthritis"
           ],
           "all_categories": [
             "biolink:Disease"
           ],
           "publications": [
-            "https://orcid.org/0000-0001-5889-4463",
-            "https://orcid.org/0000-0002-0736-9199"
+            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
+            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
+            "http://en.wikipedia.org/wiki/osteoarthritis"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 554,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -521171,44 +10384,43 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:3672",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -521216,100 +10428,98 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 318440,
+            "identity": 319030,
             "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:NamedThing",
+              "biolink:PhenotypicFeature",
+              "biolink:ThingWithTaxon"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002508",
-              "name": "gingivitis",
-              "description": "A disorder involving inflammation of the gums; may affect surrounding and supporting structures of the teeth.; Inflammation of gum tissue (GINGIVA) without loss of connective tissue.; Inflammation of the gingiva. [HPO:probinson]",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
+              "name": "osteoarthritis",
+              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "ICD9:523.1",
-                "ICD9:523.0",
-                "SNOMEDCT:31642005",
-                "HP:0000230",
-                "NCIT:C34636",
-                "MEDDRA:10072575",
-                "ICD10:K05.1",
-                "UMLS:C0155937",
-                "UMLS:C0017574",
-                "MEDDRA:10018292",
-                "MEDDRA:10021956",
-                "SNOMEDCT:66383009",
-                "ICD10:K05.0",
-                "MESH:D005891",
-                "DOID:3087",
-                "MEDDRA:10000787",
-                "MONDO:0002508",
-                "ICD10:K05.10"
+                "MESH:D010003",
+                "ICD9:715.3",
+                "MEDDRA:10049491",
+                "DOID:8398",
+                "MEDDRA:10031216",
+                "UMLS:C0029408",
+                "EFO:0002506",
+                "NCIT:C3293",
+                "SNOMEDCT:225655006",
+                "MEDDRA:10031186",
+                "HP:0002758",
+                "UMLS:C0157946",
+                "SNOMEDCT:396275006",
+                "MEDDRA:10031161",
+                "MEDDRA:10031174",
+                "MONDO:0005178",
+                "MEDDRA:10031167"
               ],
-              "id": "MONDO:0002508",
+              "id": "MONDO:0005178",
               "category": "biolink:Disease",
               "all_names": [
-                "Acute gingivitis",
-                "gingivitis",
-                "Chronic gingivitis",
-                "Gingivitis"
+                "Osteoarthrosis, localized, not specified whether primary or secondary",
+                "Degenerative polyarthritis",
+                "Osteoarthritis",
+                "osteoarthritis",
+                "obsolete_osteoarthritis"
               ],
               "all_categories": [
                 "biolink:Disease"
               ],
               "publications": [
-                "https://orcid.org/0000-0001-5889-4463",
-                "https://orcid.org/0000-0002-0736-9199"
+                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
+                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
+                "http://en.wikipedia.org/wiki/osteoarthritis"
               ]
             }
           },
           "relationship": {
-            "identity": 8326432,
-            "start": 638,
-            "end": 318440,
-            "type": "biolink:affects",
+            "identity": 8901716,
+            "start": 554,
+            "end": 319030,
+            "type": "biolink:related_to",
             "properties": {
-              "predicate": "biolink:affects",
+              "predicate": "biolink:related_to",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1104246': {'publication date': '1975 Nov', 'sentence': 'Effect of chlorhexidine on dental plaque and gingivitis in mentally retarded children.', 'subject score': 1000, 'object score': 1000}, 'PMID:16253086': {'publication date': '2005 Oct', 'sentence': 'CONCLUSIONS: These results indicate that both CHX and CHX/B-HCl sprays have equal clinical effectiveness, but only B-HCl spray has less anti-plaque and anti-gingivitis effects.', 'subject score': 1000, 'object score': 773}, 'PMID:4272044': {'publication date': '1972', 'sentence': 'Effects of topical application of chlorhexidine on plaque and gingivitis in monkeys.', 'subject score': 1000, 'object score': 1000}, 'PMID:6449574': {'publication date': '1980 Jul', 'sentence': 'Effect of chlorhexidine on plaque, gingivitis and alveolar bone loss in beagle dogs after seven years of treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:8649661': {'publication date': '1996 Mar', 'sentence': 'The effect of local application of chlorhexidine on plaque and gingivitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:9456641': {'publication date': '1997 Mar', 'sentence': 'CONCLUSION: In conclusion, there was a significant effect of chlorhexidine on gingivitis, although the effect may be too limited to assure prognostic benefits in the prevention of future disease progression.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:11548225': {'publication date': '1994 Mar', 'sentence': 'Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee.', 'subject score': 1000, 'object score': 1000}, 'PMID:22558609': {'publication date': '2012', 'sentence': 'AIMS: To carry out a randomized clinical trial to compare the effect of palmitoylethanolamide (PEA) versus ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), for pain relief in temporomandibular joint (TMJ) osteoarthritis or arthralgia.', 'subject score': 1000, 'object score': 901}, 'PMID:28035387': {'publication date': '2017 Feb', 'sentence': 'Therapeutic mechanisms of ibuprofen, prednisone and betamethasone in osteoarthritis.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:affects---None---None---None---UMLS:C0017574---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:associated_with---None---None---None---UMLS:C0029408---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "8506996",
-              "object": "MONDO:0002508",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "9106384",
+              "object": "MONDO:0005178",
               "publications": [
-                "PMID:1104246",
-                "PMID:16253086",
-                "PMID:4272044",
-                "PMID:6449574",
-                "PMID:8649661",
-                "PMID:9456641"
+                "PMID:11548225",
+                "PMID:22558609",
+                "PMID:28035387"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 554,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -521326,44 +10536,43 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:3672",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -521371,16 +10580,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -521390,50 +10599,72 @@
     }
   },
   {
-<<<<<<< HEAD
     "p3": {
       "start": {
-        "identity": 792859,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10597158': {'publication date': '1998 Sep', 'sentence': 'The abrasiveness of the chew, rather than the antibacterial activity of chlorhexidine, is likely to have contributed the most to the maintenance of oral health in dogs with mild gingivitis.', 'subject score': 1000, 'object score': 888}, 'PMID:12437859': {'publication date': '2002 Oct', 'sentence': 'Enhanced care patients (n = 191) received bimonthly protective treatment and twice-daily chlorhexidine mouthrinses to treat gingivitis.', 'subject score': 658, 'object score': 1000}, 'PMID:1440118': {'publication date': '1992 Mar-Apr', 'sentence': 'Compared with placebo, swabbing with chlorhexidine resulted in consistent, and, in part, significant improvements in plaque, gingivitis, and periodontal pocket depth.', 'subject score': 1000, 'object score': 1000}, 'PMID:16677331': {'publication date': '2006 Jun', 'sentence': 'In summary, this study suggests that the use of dentifrices containing chlorhexidine seems to be effective for the treatment of gingivitis in orthodontic patients, although the intense motivating contact that the volunteers had with the researchers may have also played a role.', 'subject score': 1000, 'object score': 1000}, 'PMID:17714525': {'publication date': '2007 Nov', 'sentence': 'A large number of clinical studies have established the clinical efficacy of topical antimicrobial agents, e.g., chlorhexidine and triclosan, in the prevention and control of oral disease, especially gingivitis and dental plaque.', 'subject score': 1000, 'object score': 861}, 'PMID:21335588': {'publication date': '2011 Feb', 'sentence': 'RESULTS: For illustrating the proposed methodology, we consider two application data from the published literature; the first from a split-mouth trial on 23 patients evaluating the effect of chlorhexidine in the treatment of gingivitis, and second from study of mental health (depression and anxiety) as outcome measure obtained on 173 patients evaluated by two screening instruments.', 'subject score': 1000, 'object score': 1000}, 'PMID:21703065': {'publication date': '2011 Mar-Apr', 'sentence': 'PURPOSE: The purpose of this study was to evaluate chlorhexidine to control gingivitis and Candida species (spp.) in children infected with the human immunodeficiency virus (HIV) and their acceptance of the therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:23210197': {'publication date': '2012 Oct', 'sentence': 'CONCLUSION: Topical application of CHX or MTZ alone or in combination may have a role in the management of gingivitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:24478951': {'publication date': '2011 Jan', 'sentence': 'RESULTS: Chlorhexidine and Listerine showed significant reduction in plaque and gingivitis level compared to others, the activity of Chlorhexidine being more significant.', 'subject score': 1000, 'object score': 694}, 'PMID:25912596': {'publication date': '2015 Apr', 'sentence': 'Numerous studies have confirmed the beneficial effects of CHX in reducing of plaque accumulation, in tooth caries, gingivitis, periodontitis and in alveolar osteitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:25961617': {'publication date': '2015 Jan-Feb', 'sentence': 'Comparison of amine fluoride and chlorhexidine mouth rinses in the control of plaque and gingivitis--a randomized controlled clinical trial.', 'subject score': 871, 'object score': 1000}, 'PMID:26681856': {'publication date': '2015', 'sentence': 'The aim of this comparative study was to compare the efficacy of the mouthwash containing green tea and chlorhexidine in the management of dental plaque-induced gingivitis.', 'subject score': 1000, 'object score': 861}, 'PMID:26953228': {'publication date': '2017 Nov', 'sentence': 'RESULTS: There was a significant reduction in dental plaque-scores for the OA&CHX and COMBI-group (0.51 [SD = 0.37], 0.38 [SD = 0.33] respectively) and a significant reduction in gingivitis scores for the OA&CHX and COMBI group (6.9% [SD = 14.0], 13.4% [SD = 13.4] respectively) from the start of the treatment phase to baseline.', 'subject score': 790, 'object score': 1000}, 'PMID:27932522': {'publication date': '2017 Jul', 'sentence': 'Comparative Evaluation of Triphala and Ela Decoction With 0.2% Chlorhexidine as Mouthwash in the Treatment of Plaque-Induced Gingivitis and Halitosis: A Randomized Controlled Clinical Trial.', 'subject score': 827, 'object score': 851}, 'PMID:28025442': {'publication date': '2016', 'sentence': 'Clinical efficacy of a 1% Matricaria chamomile L. mouthwash and 0.12% chlorhexidine for gingivitis control in patients undergoing orthodontic treatment with fixed appliances.', 'subject score': 827, 'object score': 888}, 'PMID:29551867': {'publication date': '2017', 'sentence': 'Comparison of anti-plaque and anti-gingivitis effect of curcumin and chlorhexidine mouth rinse in the treatment of gingivitis: A clinical and biochemical study.', 'subject score': 882, 'object score': 1000}, 'PMID:3076781': {'publication date': '1988', 'sentence': 'Comparative clinical trial with natural herbal mouthwash versus chlorhexidine in gingivitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:30919638': {'publication date': '2019 Mar', 'sentence': 'CONCLUSIONS: Ozone yielded better outcomes than chlorhexidine in the management of gingivitis in orthodontic patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:3164781': {'publication date': '1988 Jun', 'sentence': 'The use of chlorhexidine in the management of gingivitis in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:31724501': {'publication date': '2019 Nov 14', 'sentence': 'CONCLUSIONS: The topical application of a chlorhexidine-based brush-on gel can be a useful adjunctive domiciliary treatment for gingivitis therapy, combined with the mechanical debridement, that still remains the gold standard.', 'subject score': 840, 'object score': 888}}",
-    "p2": {
-      "start": {
-        "identity": 318440,
->>>>>>> main
+        "identity": 4620,
         "labels": [
+          "biolink:SmallMolecule",
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:MolecularEntity",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-<<<<<<< HEAD
-          "iri": "https://identifiers.org/umls:C2936258",
-          "name": "Peri-Implantitis",
-          "description": "An inflammatory process with loss of supporting bone in the tissues surrounding functioning DENTAL IMPLANTS.",
+          "name": "Dexibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. It is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer. Dexibuprofen has a slower dissolution rate in the simulated gastric and enteric juices compared with the racemic ibuprofen and displays improved oral bioavilability [A19259]. For Metabolism, Enzymes, Carriers, Transporters Sections, refer to [Ibuprofen].",
           "equivalent_curies": [
-            "EFO:1001390",
-            "MESH:D057873",
-            "UMLS:C2936258",
-            "SNOMEDCT:699422003",
-            "MEDDRA:10078781"
+            "CHEBI:43415",
+            "NCIT:C166907",
+            "UMLS:C2714681",
+            "KEGG.DRUG:D03715",
+            "DrugCentral:3851",
+            "CAS:51146-56-6",
+            "PUBCHEM.COMPOUND:39912",
+            "ATC:M01AE14",
+            "NDDF:006963",
+            "MESH:C539402",
+            "INCHIKEY:HEFNNWSXXWATRW-JTQLQIEISA-N",
+            "DRUGBANK:DB09213",
+            "UNII:671DKG7P5S",
+            "CHEMBL.COMPOUND:CHEMBL175"
           ],
-          "id": "UMLS:C2936258",
-          "category": "biolink:Disease",
+          "id": "PUBCHEM.COMPOUND:39912",
+          "category": "biolink:SmallMolecule",
           "all_names": [
-            "Peri-Implantitis"
+            "DEXIBUPROFEN",
+            "Dexibuprofen (USAN/INN)",
+            "dexibuprofen",
+            "Dexibuprofen"
           ],
           "all_categories": [
-            "biolink:Disease"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:18457385",
+            "PMID:22877157",
+            "PMID:28949138",
+            "PMID:16872141",
+            "PMID:20804197",
+            "PMID:21602044",
+            "PMID:15013005",
+            "PMID:8582471",
+            "PMID:19032727",
+            "PMID:23316393"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 554,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -521450,44 +10681,43 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:3672",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -521495,77 +10725,107 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 792859,
+            "identity": 4620,
             "labels": [
+              "biolink:SmallMolecule",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:MolecularEntity",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C2936258",
-              "name": "Peri-Implantitis",
-              "description": "An inflammatory process with loss of supporting bone in the tissues surrounding functioning DENTAL IMPLANTS.",
+              "name": "Dexibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. It is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer. Dexibuprofen has a slower dissolution rate in the simulated gastric and enteric juices compared with the racemic ibuprofen and displays improved oral bioavilability [A19259]. For Metabolism, Enzymes, Carriers, Transporters Sections, refer to [Ibuprofen].",
               "equivalent_curies": [
-                "EFO:1001390",
-                "MESH:D057873",
-                "UMLS:C2936258",
-                "SNOMEDCT:699422003",
-                "MEDDRA:10078781"
+                "CHEBI:43415",
+                "NCIT:C166907",
+                "UMLS:C2714681",
+                "KEGG.DRUG:D03715",
+                "DrugCentral:3851",
+                "CAS:51146-56-6",
+                "PUBCHEM.COMPOUND:39912",
+                "ATC:M01AE14",
+                "NDDF:006963",
+                "MESH:C539402",
+                "INCHIKEY:HEFNNWSXXWATRW-JTQLQIEISA-N",
+                "DRUGBANK:DB09213",
+                "UNII:671DKG7P5S",
+                "CHEMBL.COMPOUND:CHEMBL175"
               ],
-              "id": "UMLS:C2936258",
-              "category": "biolink:Disease",
+              "id": "PUBCHEM.COMPOUND:39912",
+              "category": "biolink:SmallMolecule",
               "all_names": [
-                "Peri-Implantitis"
+                "DEXIBUPROFEN",
+                "Dexibuprofen (USAN/INN)",
+                "dexibuprofen",
+                "Dexibuprofen"
               ],
               "all_categories": [
-                "biolink:Disease"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:18457385",
+                "PMID:22877157",
+                "PMID:28949138",
+                "PMID:16872141",
+                "PMID:20804197",
+                "PMID:21602044",
+                "PMID:15013005",
+                "PMID:8582471",
+                "PMID:19032727",
+                "PMID:23316393"
               ]
             }
           },
           "relationship": {
-            "identity": 21861260,
-            "start": 638,
-            "end": 792859,
-            "type": "biolink:treats",
+            "identity": 24881451,
+            "start": 4620,
+            "end": 554,
+            "type": "biolink:related_to",
             "properties": {
-              "predicate": "biolink:treats",
+              "predicate": "biolink:related_to",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:32683389': {'publication date': '2020 Jul 19', 'sentence': 'There is a need for more homogenous RCTs with large sample size to define the role of CHX in non-surgical management of peri-implant mucositis and peri-implantitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:35377990': {'publication date': '2022', 'sentence': 'Chlorhexidine for the Treatment of Peri-Implantitis: Is it a Benison?', 'subject score': 1000, 'object score': 1000}, 'PMID:36950440': {'publication date': '2023', 'sentence': 'Similarly, strong conclusions on the effect of CHX for peri-implantitis cannot be drawn due to limited number of studies.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:36744872': {'publication date': '2023 Jan-Dec', 'sentence': 'Effectiveness and safety of rectal dexibuprofen versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants with gestational age<34 weeks: A pilot study.', 'subject score': 888, 'object score': 888}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:treats---None---None---None---UMLS:C2936258---SEMMEDDB:"
+                "UMLS:C2714681---SEMMEDDB:compared_with---None---None---None---UMLS:C0020740---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "22283339",
-              "object": "UMLS:C2936258",
+              "subject": "PUBCHEM.COMPOUND:39912",
+              "id": "25329797",
+              "object": "PUBCHEM.COMPOUND:3672",
               "publications": [
-                "PMID:32683389",
-                "PMID:35377990",
-                "PMID:36950440"
+                "PMID:36744872"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 554,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -521582,44 +10842,43 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:3672",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -521627,16 +10886,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -521648,51 +10907,38 @@
   {
     "p3": {
       "start": {
-        "identity": 321523,
+        "identity": 706152,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-          "name": "pneumonia",
-          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+          "iri": "http://id.nlm.nih.gov/mesh/D016166",
+          "name": "Free Radical Scavengers",
+          "description": "Substances that eliminate free radicals. Among other effects, they protect PANCREATIC ISLETS against damage by CYTOKINES and prevent myocardial and pulmonary REPERFUSION INJURY.; UMLS Semantic Type: STY:T120",
           "equivalent_curies": [
-            "MEDDRA:10077942",
-            "UMLS:C0032285",
-            "MONDO:0005249",
-            "EFO:0003106",
-            "MEDDRA:10059809",
-            "SNOMEDCT:233604007",
-            "HP:0002090",
-            "MEDDRA:10035664",
-            "PSY:39200",
-            "MEDDRA:10035725",
-            "DOID:552",
-            "NCIT:C3333",
-            "MESH:D011014"
+            "MESH:D016166",
+            "UMLS:C0079381",
+            "CHEBI:48578"
           ],
-          "id": "MONDO:0005249",
-          "category": "biolink:Disease",
+          "id": "MESH:D016166",
+          "category": "biolink:ChemicalEntity",
           "all_names": [
-            "Pneumonia",
-            "pneumonia"
+            "Free Radical Scavengers",
+            "radical scavenger"
           ],
           "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pneumonia",
-            "https://orcid.org/0000-0002-0736-9199"
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 554,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -521709,44 +10955,43 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:3672",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -521754,91 +10999,75 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 321523,
+            "identity": 706152,
             "labels": [
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:PhysicalEssence",
+              "biolink:PhysicalEssenceOrOccurrent"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
-              "name": "pneumonia",
-              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It causes the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What causes pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that causes COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which causes valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+              "iri": "http://id.nlm.nih.gov/mesh/D016166",
+              "name": "Free Radical Scavengers",
+              "description": "Substances that eliminate free radicals. Among other effects, they protect PANCREATIC ISLETS against damage by CYTOKINES and prevent myocardial and pulmonary REPERFUSION INJURY.; UMLS Semantic Type: STY:T120",
               "equivalent_curies": [
-                "MEDDRA:10077942",
-                "UMLS:C0032285",
-                "MONDO:0005249",
-                "EFO:0003106",
-                "MEDDRA:10059809",
-                "SNOMEDCT:233604007",
-                "HP:0002090",
-                "MEDDRA:10035664",
-                "PSY:39200",
-                "MEDDRA:10035725",
-                "DOID:552",
-                "NCIT:C3333",
-                "MESH:D011014"
+                "MESH:D016166",
+                "UMLS:C0079381",
+                "CHEBI:48578"
               ],
-              "id": "MONDO:0005249",
-              "category": "biolink:Disease",
+              "id": "MESH:D016166",
+              "category": "biolink:ChemicalEntity",
               "all_names": [
-                "Pneumonia",
-                "pneumonia"
-              ],
-              "all_categories": [
-                "biolink:Disease"
+                "Free Radical Scavengers",
+                "radical scavenger"
               ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pneumonia",
-                "https://orcid.org/0000-0002-0736-9199"
+              "all_categories": [
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-            "identity": 14253523,
-            "start": 638,
-            "end": 321523,
-            "type": "biolink:treats",
+            "identity": 19627609,
+            "start": 706152,
+            "end": 554,
+            "type": "biolink:related_to",
             "properties": {
-              "predicate": "biolink:treats",
+              "predicate": "biolink:related_to",
               "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:19723863': {'publication date': '2009 Sep', 'sentence': 'Among patients without pneumonia at baseline, pneumonia developed in 24% (CPIS >or=6) by day 3 in those treated with chlorhexidine.', 'subject score': 1000, 'object score': 1000}, 'PMID:19765321': {'publication date': '2009', 'sentence': 'A non-significant reduction in pneumonia rate was noted in groups treated with chlorhexidine compared with the placebo group (OR = 0.54, 95% CI: 0.23 to 1.25, P = 0.15).', 'subject score': 1000, 'object score': 888}, 'PMID:26932921': {'publication date': '2016 Mar', 'sentence': 'Furthermore, median times to chlorhexidine did not differ significantly (P = .23) between patients in whom pneumonia developed (5.2 hours) and patients with no pneumonia (6.1 hours).', 'subject score': 1000, 'object score': 1000}, 'PMID:30683045': {'publication date': '2019 Jan', 'sentence': 'Minimal correlation was found between chlorhexidine resistance and virulence in K.pneumoniae.', 'subject score': 694, 'object score': 888}}",
+              "domain_range_exclusion": "True",
+              "publications_info": "{'PMID:2916864': {'publication date': '1989 Feb', 'sentence': 'The present study evaluated and compared the effects of SRI 63-441, a potent platelet activating factor antagonist, superoxide dismutase (SOD), an oxygen free radical scavenger, and ibuprofen, a cyclooxygenase inhibitor on hepatic function after 90 minutes of warm ischemia.', 'subject score': 916, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:treats---None---None---None---UMLS:C0032285---SEMMEDDB:"
+                "UMLS:C0079381---SEMMEDDB:compared_with---None---None---None---UMLS:C0020740---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "14556561",
-              "object": "MONDO:0005249",
+              "subject": "MESH:D016166",
+              "id": "20018347",
+              "object": "PUBCHEM.COMPOUND:3672",
               "publications": [
-                "PMID:19723863",
-                "PMID:19765321",
-                "PMID:26932921",
-                "PMID:30683045"
+                "PMID:2916864"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 554,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -521855,44 +11084,43 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:3672",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -521900,16 +11128,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -521921,101 +11149,53 @@
   {
     "p3": {
       "start": {
-        "identity": 309808,
+        "identity": 857660,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005276",
-          "name": "dental caries",
-          "description": "Caries is a multifactorial bacterial infection affecting the structure of the tooth. This term has been used to describe the presence of more than expected dental caries. [HPO:probinson]; Caries is a multifactorial bacterial infection affecting the structure of the tooth. This term has been used to describe the presence of more than expected dental caries. // COMMENTS: It should be noted that it is not always possible to rule out environmental influences and that reports of association between hereditary diseases and susceptibility to dental caries should be regarded with caution.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T033",
-          "equivalent_curies": [
-            "MEDDRA:10011947",
-            "SNOMEDCT:80967001",
-            "MEDDRA:10007666",
-            "UMLS:C4280623",
-            "MONDO:0005276",
-            "MEDDRA:10048298",
-            "MESH:D003731",
-            "DOID:216",
-            "MEDDRA:10044023",
-            "UMLS:C1456145",
-            "MEDDRA:10044020",
-            "ICD9:521.07",
-            "MEDDRA:10012318",
-            "NCIT:C52593",
-            "ICD10:K02.6",
-            "MEDDRA:10044027",
-            "UMLS:C0011334",
-            "MEDDRA:10085528",
-            "MEDDRA:10048297",
-            "HP:0000670",
-            "EFO:0003819",
-            "ICD9:521.0"
-          ],
-          "id": "MONDO:0005276",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Caries",
-            "Rotting teeth",
-            "Dental Caries",
-            "Carious teeth",
-            "Dental caries",
-            "Dental caries of smooth surface",
-            "dental caries"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002508",
-          "name": "gingivitis",
-          "description": "A disorder involving inflammation of the gums; may affect surrounding and supporting structures of the teeth.; Inflammation of gum tissue (GINGIVA) without loss of connective tissue.; Inflammation of the gingiva. [HPO:probinson]",
+          "name": "Ibuprofen lysine",
+          "description": "IBUPROFEN LYSINE; FULL_MW:352.48; MAX_FDA_APPROVAL_PHASE: 4.0",
           "equivalent_curies": [
-            "ICD9:523.1",
-            "ICD9:523.0",
-            "SNOMEDCT:31642005",
-            "HP:0000230",
-            "NCIT:C34636",
-            "MEDDRA:10072575",
-            "ICD10:K05.1",
-            "UMLS:C0155937",
-            "UMLS:C0017574",
-            "MEDDRA:10018292",
-            "MEDDRA:10021956",
-            "SNOMEDCT:66383009",
-            "ICD10:K05.0",
-            "MESH:D005891",
-            "DOID:3087",
-            "MEDDRA:10000787",
-            "MONDO:0002508",
-            "ICD10:K05.10"
+            "NDDF:006232",
+            "CHEMBL.COMPOUND:CHEMBL1201141",
+            "UNII:N01ORX9D6S",
+            "PUBCHEM.COMPOUND:9841440",
+            "PUBCHEM.COMPOUND:49800067",
+            "MESH:C016106",
+            "NCIT:C72809",
+            "UMLS:C0074814",
+            "INCHIKEY:IHHXIUAEPKVVII-ZSCHJXSPSA-N",
+            "RXNORM:36761",
+            "CAS:57469-77-9"
           ],
-          "id": "MONDO:0002508",
-          "category": "biolink:Disease",
+          "id": "PUBCHEM.COMPOUND:9841440",
+          "category": "biolink:MolecularMixture",
           "all_names": [
-            "Acute gingivitis",
-            "gingivitis",
-            "Chronic gingivitis",
-            "Gingivitis"
->>>>>>> main
+            "solufenum",
+            "Ibuprofen Lysine",
+            "IBUPROFEN LYSINE",
+            "ibuprofen lysine"
           ],
           "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5889-4463",
-<<<<<<< HEAD
-            "https://www.nidcr.nih.gov/health-info/tooth-decay",
-=======
->>>>>>> main
-            "https://orcid.org/0000-0002-0736-9199"
+            "biolink:MolecularMixture",
+            "biolink:Drug",
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 554,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -522032,44 +11212,43 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:3672",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -522077,192 +11256,95 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-<<<<<<< HEAD
-            "identity": 309808,
-=======
-            "identity": 318440,
->>>>>>> main
+            "identity": 857660,
             "labels": [
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005276",
-              "name": "dental caries",
-              "description": "Caries is a multifactorial bacterial infection affecting the structure of the tooth. This term has been used to describe the presence of more than expected dental caries. [HPO:probinson]; Caries is a multifactorial bacterial infection affecting the structure of the tooth. This term has been used to describe the presence of more than expected dental caries. // COMMENTS: It should be noted that it is not always possible to rule out environmental influences and that reports of association between hereditary diseases and susceptibility to dental caries should be regarded with caution.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T033",
-              "equivalent_curies": [
-                "MEDDRA:10011947",
-                "SNOMEDCT:80967001",
-                "MEDDRA:10007666",
-                "UMLS:C4280623",
-                "MONDO:0005276",
-                "MEDDRA:10048298",
-                "MESH:D003731",
-                "DOID:216",
-                "MEDDRA:10044023",
-                "UMLS:C1456145",
-                "MEDDRA:10044020",
-                "ICD9:521.07",
-                "MEDDRA:10012318",
-                "NCIT:C52593",
-                "ICD10:K02.6",
-                "MEDDRA:10044027",
-                "UMLS:C0011334",
-                "MEDDRA:10085528",
-                "MEDDRA:10048297",
-                "HP:0000670",
-                "EFO:0003819",
-                "ICD9:521.0"
-              ],
-              "id": "MONDO:0005276",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Caries",
-                "Rotting teeth",
-                "Dental Caries",
-                "Carious teeth",
-                "Dental caries",
-                "Dental caries of smooth surface",
-                "dental caries"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002508",
-              "name": "gingivitis",
-              "description": "A disorder involving inflammation of the gums; may affect surrounding and supporting structures of the teeth.; Inflammation of gum tissue (GINGIVA) without loss of connective tissue.; Inflammation of the gingiva. [HPO:probinson]",
+              "name": "Ibuprofen lysine",
+              "description": "IBUPROFEN LYSINE; FULL_MW:352.48; MAX_FDA_APPROVAL_PHASE: 4.0",
               "equivalent_curies": [
-                "ICD9:523.1",
-                "ICD9:523.0",
-                "SNOMEDCT:31642005",
-                "HP:0000230",
-                "NCIT:C34636",
-                "MEDDRA:10072575",
-                "ICD10:K05.1",
-                "UMLS:C0155937",
-                "UMLS:C0017574",
-                "MEDDRA:10018292",
-                "MEDDRA:10021956",
-                "SNOMEDCT:66383009",
-                "ICD10:K05.0",
-                "MESH:D005891",
-                "DOID:3087",
-                "MEDDRA:10000787",
-                "MONDO:0002508",
-                "ICD10:K05.10"
+                "NDDF:006232",
+                "CHEMBL.COMPOUND:CHEMBL1201141",
+                "UNII:N01ORX9D6S",
+                "PUBCHEM.COMPOUND:9841440",
+                "PUBCHEM.COMPOUND:49800067",
+                "MESH:C016106",
+                "NCIT:C72809",
+                "UMLS:C0074814",
+                "INCHIKEY:IHHXIUAEPKVVII-ZSCHJXSPSA-N",
+                "RXNORM:36761",
+                "CAS:57469-77-9"
               ],
-              "id": "MONDO:0002508",
-              "category": "biolink:Disease",
+              "id": "PUBCHEM.COMPOUND:9841440",
+              "category": "biolink:MolecularMixture",
               "all_names": [
-                "Acute gingivitis",
-                "gingivitis",
-                "Chronic gingivitis",
-                "Gingivitis"
->>>>>>> main
+                "solufenum",
+                "Ibuprofen Lysine",
+                "IBUPROFEN LYSINE",
+                "ibuprofen lysine"
               ],
               "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5889-4463",
-<<<<<<< HEAD
-                "https://www.nidcr.nih.gov/health-info/tooth-decay",
-=======
->>>>>>> main
-                "https://orcid.org/0000-0002-0736-9199"
+                "biolink:MolecularMixture",
+                "biolink:Drug",
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-<<<<<<< HEAD
-            "identity": 13738535,
-            "start": 638,
-            "end": 309808,
-=======
-            "identity": 7706040,
-            "start": 638,
-            "end": 318440,
->>>>>>> main
-            "type": "biolink:treats",
+            "identity": 11734507,
+            "start": 857660,
+            "end": 554,
+            "type": "biolink:related_to",
             "properties": {
-              "predicate": "biolink:treats",
+              "predicate": "biolink:related_to",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-<<<<<<< HEAD
-              "publications_info": "{'PMID:18954355': {'publication date': '2008 Dec', 'sentence': 'Sodium fluoride and chlorhexidine effect in the inhibition of mutans streptococci in children with dental caries: a randomized, double-blind clinical trial.', 'subject score': 888, 'object score': 1000}, 'PMID:19051866': {'publication date': '2008', 'sentence': 'The use of chlorhexidine in caries prevention has been referred to as a nonsurgical management of dental caries and has represented the modern medical model of caries treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:1937847': {'publication date': '1991 Oct', 'sentence': 'Role of chlorhexidine in the management of dental caries.', 'subject score': 1000, 'object score': 1000}, 'PMID:2390965': {'publication date': '1990 Feb', 'sentence': 'Chlorhexidine is widely used as a mouth rinse in the prevention and treatment of periodontal diseases and dental caries.', 'subject score': 1000, 'object score': 1000}, 'PMID:25912596': {'publication date': '2015 Apr', 'sentence': 'Numerous studies have confirmed the beneficial effects of CHX in reducing of plaque accumulation, in tooth caries, gingivitis, periodontitis and in alveolar osteitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:29178718': {'publication date': '2016 Dec', 'sentence': 'CLINICAL SIGNIFICANCE: The solution containing TiO2, Ag and Fe33O4 showed the lowest inhibitory and antibiofilm concentration against S. mutans and S. sanguinis compared to those of other nanoparticle containing solutions, antibiotics and chlorhexidine, thus it may be used for treating dental caries, dental plaque and oral infections.', 'subject score': 1000, 'object score': 901}, 'PMID:31036688': {'publication date': '2019 Jul', 'sentence': 'Chlorhexidine (CHX) has been used to control dental caries caused by acid-tolerant bacteria such as Streptococcus mutans since the 1970s.', 'subject score': 1000, 'object score': 1000}, 'PMID:33505610': {'publication date': '2020 Dec', 'sentence': 'Materials and methods: Thirty carious human molars were randomly divided into three groups; group 1: untreated carious teeth (positive control), group 2: carious teeth treated with 35% phosphoric acid and chlorhexidine disinfectant after selective carious tissue removal and group 3: carious teeth treated with dentine conditioner after selective carious tissue removal.', 'subject score': 1000, 'object score': 1000}, 'PMID:33544989': {'publication date': '2021 Feb', 'sentence': \"CLINICAL SIGNIFICANCE: In cases where the dental professional decides to apply an antimicrobial agent prior to the placement of a restoration, silver diamine fluoride proved to be more effective than chlorhexidine, slowing the progression of carious lesions, and possibly preventing future restorative interventions thus improving children's quality of life.\", 'subject score': 1000, 'object score': 1000}, 'PMID:3466113': {'publication date': '1986 Sep', 'sentence': 'Chlorhexidine for the microbiological control of dental caries.', 'subject score': 1000, 'object score': 1000}, 'PMID:35566225': {'publication date': '2022 Apr 30', 'sentence': 'The most commonly used antibacterial for the treatment of dental caries is chlorhexidine.', 'subject score': 1000, 'object score': 1000}, 'PMID:8087679': {'publication date': '1994 Aug', 'sentence': 'Dental caries in dentate elderly patients may be controlled with chlorhexidine.', 'subject score': 1000, 'object score': 1000}}",
-              "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:treats---None---None---None---UMLS:C0011334---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "14034776",
-              "object": "MONDO:0005276",
-              "publications": [
-                "PMID:18954355",
-                "PMID:19051866",
-                "PMID:1937847",
-                "PMID:2390965",
-                "PMID:25912596",
-                "PMID:29178718",
-                "PMID:31036688",
-                "PMID:33505610",
-                "PMID:33544989",
-                "PMID:3466113",
-                "PMID:35566225",
-                "PMID:8087679"
-=======
-              "publications_info": "{'PMID:10597158': {'publication date': '1998 Sep', 'sentence': 'The abrasiveness of the chew, rather than the antibacterial activity of chlorhexidine, is likely to have contributed the most to the maintenance of oral health in dogs with mild gingivitis.', 'subject score': 1000, 'object score': 888}, 'PMID:12437859': {'publication date': '2002 Oct', 'sentence': 'Enhanced care patients (n = 191) received bimonthly protective treatment and twice-daily chlorhexidine mouthrinses to treat gingivitis.', 'subject score': 658, 'object score': 1000}, 'PMID:1440118': {'publication date': '1992 Mar-Apr', 'sentence': 'Compared with placebo, swabbing with chlorhexidine resulted in consistent, and, in part, significant improvements in plaque, gingivitis, and periodontal pocket depth.', 'subject score': 1000, 'object score': 1000}, 'PMID:16677331': {'publication date': '2006 Jun', 'sentence': 'In summary, this study suggests that the use of dentifrices containing chlorhexidine seems to be effective for the treatment of gingivitis in orthodontic patients, although the intense motivating contact that the volunteers had with the researchers may have also played a role.', 'subject score': 1000, 'object score': 1000}, 'PMID:17714525': {'publication date': '2007 Nov', 'sentence': 'A large number of clinical studies have established the clinical efficacy of topical antimicrobial agents, e.g., chlorhexidine and triclosan, in the prevention and control of oral disease, especially gingivitis and dental plaque.', 'subject score': 1000, 'object score': 861}, 'PMID:21335588': {'publication date': '2011 Feb', 'sentence': 'RESULTS: For illustrating the proposed methodology, we consider two application data from the published literature; the first from a split-mouth trial on 23 patients evaluating the effect of chlorhexidine in the treatment of gingivitis, and second from study of mental health (depression and anxiety) as outcome measure obtained on 173 patients evaluated by two screening instruments.', 'subject score': 1000, 'object score': 1000}, 'PMID:21703065': {'publication date': '2011 Mar-Apr', 'sentence': 'PURPOSE: The purpose of this study was to evaluate chlorhexidine to control gingivitis and Candida species (spp.) in children infected with the human immunodeficiency virus (HIV) and their acceptance of the therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:23210197': {'publication date': '2012 Oct', 'sentence': 'CONCLUSION: Topical application of CHX or MTZ alone or in combination may have a role in the management of gingivitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:24478951': {'publication date': '2011 Jan', 'sentence': 'RESULTS: Chlorhexidine and Listerine showed significant reduction in plaque and gingivitis level compared to others, the activity of Chlorhexidine being more significant.', 'subject score': 1000, 'object score': 694}, 'PMID:25912596': {'publication date': '2015 Apr', 'sentence': 'Numerous studies have confirmed the beneficial effects of CHX in reducing of plaque accumulation, in tooth caries, gingivitis, periodontitis and in alveolar osteitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:25961617': {'publication date': '2015 Jan-Feb', 'sentence': 'Comparison of amine fluoride and chlorhexidine mouth rinses in the control of plaque and gingivitis--a randomized controlled clinical trial.', 'subject score': 871, 'object score': 1000}, 'PMID:26681856': {'publication date': '2015', 'sentence': 'The aim of this comparative study was to compare the efficacy of the mouthwash containing green tea and chlorhexidine in the management of dental plaque-induced gingivitis.', 'subject score': 1000, 'object score': 861}, 'PMID:26953228': {'publication date': '2017 Nov', 'sentence': 'RESULTS: There was a significant reduction in dental plaque-scores for the OA&CHX and COMBI-group (0.51 [SD = 0.37], 0.38 [SD = 0.33] respectively) and a significant reduction in gingivitis scores for the OA&CHX and COMBI group (6.9% [SD = 14.0], 13.4% [SD = 13.4] respectively) from the start of the treatment phase to baseline.', 'subject score': 790, 'object score': 1000}, 'PMID:27932522': {'publication date': '2017 Jul', 'sentence': 'Comparative Evaluation of Triphala and Ela Decoction With 0.2% Chlorhexidine as Mouthwash in the Treatment of Plaque-Induced Gingivitis and Halitosis: A Randomized Controlled Clinical Trial.', 'subject score': 827, 'object score': 851}, 'PMID:28025442': {'publication date': '2016', 'sentence': 'Clinical efficacy of a 1% Matricaria chamomile L. mouthwash and 0.12% chlorhexidine for gingivitis control in patients undergoing orthodontic treatment with fixed appliances.', 'subject score': 827, 'object score': 888}, 'PMID:29551867': {'publication date': '2017', 'sentence': 'Comparison of anti-plaque and anti-gingivitis effect of curcumin and chlorhexidine mouth rinse in the treatment of gingivitis: A clinical and biochemical study.', 'subject score': 882, 'object score': 1000}, 'PMID:3076781': {'publication date': '1988', 'sentence': 'Comparative clinical trial with natural herbal mouthwash versus chlorhexidine in gingivitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:30919638': {'publication date': '2019 Mar', 'sentence': 'CONCLUSIONS: Ozone yielded better outcomes than chlorhexidine in the management of gingivitis in orthodontic patients.', 'subject score': 1000, 'object score': 1000}, 'PMID:3164781': {'publication date': '1988 Jun', 'sentence': 'The use of chlorhexidine in the management of gingivitis in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:31724501': {'publication date': '2019 Nov 14', 'sentence': 'CONCLUSIONS: The topical application of a chlorhexidine-based brush-on gel can be a useful adjunctive domiciliary treatment for gingivitis therapy, combined with the mechanical debridement, that still remains the gold standard.', 'subject score': 840, 'object score': 888}}",
+              "publications_info": "{'PMID:16100300': {'publication date': '2005 Sep', 'sentence': 'Ibuprofen extrudate, a novel, rapidly dissolving ibuprofen formulation: relative bioavailability compared to ibuprofen lysinate and regular ibuprofen, and food effect on all formulations.', 'subject score': 1000, 'object score': 888}, 'PMID:21992864': {'publication date': '2012 Jan', 'sentence': 'This retrospective, study compared the efficacy and safety of Ibuprofen-Lysinate (Arfen, intramuscular formulation, Group I, n=156) used during 2000-2005 and Sodium-ibuprofen (Pedea, intravenous solution, Group II, n=60) used during 2006-2008, for the prophylaxis of Patent Ductus Arteriosus in inborn neonates with gestational age <= 28 weeks.', 'subject score': 1000, 'object score': 888}, 'PMID:26249766': {'publication date': '2015 Nov', 'sentence': 'Ibuprofen lysinate, quicker and less variable: relative bioavailability compared to ibuprofen base in a pediatric suspension dosage form.', 'subject score': 1000, 'object score': 888}, 'PMID:2777420': {'publication date': '1989 Jul', 'sentence': 'Ibuprofen lysinate, administered after overnight fasting, produced peak plasma concentrations significantly earlier and higher than ibuprofen acid.', 'subject score': 1000, 'object score': 888}, 'PMID:30897305': {'publication date': '2019 Aug', 'sentence': 'After overnight fasting, ibuprofen lysinate reaches higher peak plasma levels (Cmax ) earlier than ibuprofen acid (tmax ) with comparable exposure (area under the plasma concentration-time curve [AUC]); however, subjects usually take ibuprofen with or within a short time of a meal.', 'subject score': 1000, 'object score': 888}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:treats---None---None---None---UMLS:C0017574---SEMMEDDB:",
-                "UMLS:C0008196---SEMMEDDB:treats---None---None---None---UMLS:C0155937---SEMMEDDB:"
+                "UMLS:C0074814---SEMMEDDB:compared_with---None---None---None---UMLS:C0020740---SEMMEDDB:",
+                "UMLS:C0074814---SEMMEDDB:higher_than---None---None---None---UMLS:C0020740---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "7869752",
-              "object": "MONDO:0002508",
+              "subject": "PUBCHEM.COMPOUND:9841440",
+              "id": "11990691",
+              "object": "PUBCHEM.COMPOUND:3672",
               "publications": [
-                "PMID:12437859",
-                "PMID:16677331",
-                "PMID:21335588",
-                "PMID:25912596",
-                "PMID:10597158",
-                "PMID:26953228",
-                "PMID:3422243",
-                "PMID:23210197",
-                "PMID:31849398",
-                "PMID:26681856",
-                "PMID:25961617",
-                "PMID:34475924",
-                "PMID:17714525",
-                "PMID:21703065",
-                "PMID:34780104",
-                "PMID:25055220",
-                "PMID:3076781",
-                "PMID:32100933",
-                "PMID:3422246",
-                "PMID:35291347"
->>>>>>> main
+                "PMID:21992864",
+                "PMID:2777420",
+                "PMID:16100300",
+                "PMID:30897305",
+                "PMID:26249766"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 554,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -522279,44 +11361,43 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:3672",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -522324,16 +11405,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -522343,103 +11424,41 @@
     }
   },
   {
-<<<<<<< HEAD
     "p3": {
       "start": {
-        "identity": 315382,
-=======
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:1522288': {'publication date': '1992 Sep', 'sentence': 'The local delivery of low-dose chlorhexidine to dogs significantly inhibited gingivitis and plaque formation.', 'subject score': 901, 'object score': 1000}, 'PMID:277533': {'publication date': '1978 Feb', 'sentence': 'In both instances, hexetidine exerted no significant effect while 0.2% chlorhexidine resulted in reductions in both plaque and gingivitis of about 45 and 50%, respectively.', 'subject score': 827, 'object score': 1000}, 'PMID:30673864': {'publication date': '2019 Oct', 'sentence': 'In the treatment substudy, CHX was associated with remarkable reduction in plaque and gingivitis while NAC resulted in insignificant reductions.', 'subject score': 1000, 'object score': 1000}, 'PMID:33215786': {'publication date': '2020 Nov 20', 'sentence': 'There was low certainty evidence that fluoride interventions provided long-term reductions in caries in those with IDD; and there was some evidence that chlorhexidine albeit with low certainty, provided short-term and long-term reductions in plaque and gingivitis.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
-      "start": {
-        "identity": 318440,
->>>>>>> main
+        "identity": 5232,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide"
         ],
         "properties": {
-<<<<<<< HEAD
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-          "name": "bacterial infectious disease with sepsis",
-          "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-          "equivalent_curies": [
-            "NCIT:C102993",
-            "ICD9:995.91",
-            "MONDO:0005229",
-            "MEDDRA:10060562",
-            "MEDDRA:10003998",
-            "MEDDRA:10003997",
-            "MEDDRA:10045641",
-            "ICD9:790.7",
-            "MEDDRA:10045642",
-            "HP:0031864",
-            "SNOMEDCT:5758002",
-            "DOID:0040085",
-            "MESH:D016470",
-            "UMLS:C0004610",
-            "MEDDRA:10003999"
-          ],
-          "id": "MONDO:0005229",
-          "category": "biolink:Disease",
-          "all_names": [
-            "Bacteremia",
-            "bacterial infectious disease with sepsis",
-            "bacterial sepsis",
-            "Sepsis"
-=======
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002508",
-          "name": "gingivitis",
-          "description": "A disorder involving inflammation of the gums; may affect surrounding and supporting structures of the teeth.; Inflammation of gum tissue (GINGIVA) without loss of connective tissue.; Inflammation of the gingiva. [HPO:probinson]",
+          "iri": "http://id.nlm.nih.gov/mesh/D000700",
+          "name": "Analgesics",
+          "description": "Compounds that alleviate pain without loss of consciousness. Analgesics act by various mechanisms including binding with opioid receptors and decreasing inflammation. Choice of analgesic may be determined by the type of pain. These compounds include opioid, non-opioid and adjuvant analgesic agents.; Natural or synthetic compound mixtures, Analgesic Preparations relieve pain by altering the perception of nociceptive stimuli without loss of consciousness. Analgesic compounds may act at opioid receptors (morphine-like drugs) or at other central or peripheral sites (non-steroidal anti-inflammatory agents). (NCI04); Compounds that show activity in animal models of human PAIN such as tail flick and hot plate assays.; UMLS Semantic Type: STY:T131; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "ICD9:523.1",
-            "ICD9:523.0",
-            "SNOMEDCT:31642005",
-            "HP:0000230",
-            "NCIT:C34636",
-            "MEDDRA:10072575",
-            "ICD10:K05.1",
-            "UMLS:C0155937",
-            "UMLS:C0017574",
-            "MEDDRA:10018292",
-            "MEDDRA:10021956",
-            "SNOMEDCT:66383009",
-            "ICD10:K05.0",
-            "MESH:D005891",
-            "DOID:3087",
-            "MEDDRA:10000787",
-            "MONDO:0002508",
-            "ICD10:K05.10"
+            "UMLS:C0002771",
+            "MESH:D000700",
+            "CHEBI:35480",
+            "ATC:N02"
           ],
-          "id": "MONDO:0002508",
-          "category": "biolink:Disease",
+          "id": "MESH:D000700",
+          "category": "biolink:ChemicalEntity",
           "all_names": [
-            "Acute gingivitis",
-            "gingivitis",
-            "Chronic gingivitis",
-            "Gingivitis"
->>>>>>> main
+            "Analgesics",
+            "analgesic"
           ],
           "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-<<<<<<< HEAD
-            "PMID:20421654"
-=======
-            "https://orcid.org/0000-0001-5889-4463",
-            "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 554,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -522456,44 +11475,43 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:3672",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -522501,141 +11519,97 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-<<<<<<< HEAD
-            "identity": 315382,
-=======
-            "identity": 318440,
->>>>>>> main
+            "identity": 5232,
             "labels": [
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide"
             ],
             "properties": {
-<<<<<<< HEAD
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005229",
-              "name": "bacterial infectious disease with sepsis",
-              "description": "A laboratory test result that indicates the presence of bacteria in the blood.; The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.; Presence of viable bacteria in the blood. []; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
-              "equivalent_curies": [
-                "NCIT:C102993",
-                "ICD9:995.91",
-                "MONDO:0005229",
-                "MEDDRA:10060562",
-                "MEDDRA:10003998",
-                "MEDDRA:10003997",
-                "MEDDRA:10045641",
-                "ICD9:790.7",
-                "MEDDRA:10045642",
-                "HP:0031864",
-                "SNOMEDCT:5758002",
-                "DOID:0040085",
-                "MESH:D016470",
-                "UMLS:C0004610",
-                "MEDDRA:10003999"
-              ],
-              "id": "MONDO:0005229",
-              "category": "biolink:Disease",
-              "all_names": [
-                "Bacteremia",
-                "bacterial infectious disease with sepsis",
-                "bacterial sepsis",
-                "Sepsis"
-=======
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002508",
-              "name": "gingivitis",
-              "description": "A disorder involving inflammation of the gums; may affect surrounding and supporting structures of the teeth.; Inflammation of gum tissue (GINGIVA) without loss of connective tissue.; Inflammation of the gingiva. [HPO:probinson]",
+              "iri": "http://id.nlm.nih.gov/mesh/D000700",
+              "name": "Analgesics",
+              "description": "Compounds that alleviate pain without loss of consciousness. Analgesics act by various mechanisms including binding with opioid receptors and decreasing inflammation. Choice of analgesic may be determined by the type of pain. These compounds include opioid, non-opioid and adjuvant analgesic agents.; Natural or synthetic compound mixtures, Analgesic Preparations relieve pain by altering the perception of nociceptive stimuli without loss of consciousness. Analgesic compounds may act at opioid receptors (morphine-like drugs) or at other central or peripheral sites (non-steroidal anti-inflammatory agents). (NCI04); Compounds that show activity in animal models of human PAIN such as tail flick and hot plate assays.; UMLS Semantic Type: STY:T131; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "ICD9:523.1",
-                "ICD9:523.0",
-                "SNOMEDCT:31642005",
-                "HP:0000230",
-                "NCIT:C34636",
-                "MEDDRA:10072575",
-                "ICD10:K05.1",
-                "UMLS:C0155937",
-                "UMLS:C0017574",
-                "MEDDRA:10018292",
-                "MEDDRA:10021956",
-                "SNOMEDCT:66383009",
-                "ICD10:K05.0",
-                "MESH:D005891",
-                "DOID:3087",
-                "MEDDRA:10000787",
-                "MONDO:0002508",
-                "ICD10:K05.10"
+                "UMLS:C0002771",
+                "MESH:D000700",
+                "CHEBI:35480",
+                "ATC:N02"
               ],
-              "id": "MONDO:0002508",
-              "category": "biolink:Disease",
+              "id": "MESH:D000700",
+              "category": "biolink:ChemicalEntity",
               "all_names": [
-                "Acute gingivitis",
-                "gingivitis",
-                "Chronic gingivitis",
-                "Gingivitis"
->>>>>>> main
+                "Analgesics",
+                "analgesic"
               ],
               "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-<<<<<<< HEAD
-                "PMID:20421654"
-=======
-                "https://orcid.org/0000-0001-5889-4463",
-                "https://orcid.org/0000-0002-0736-9199"
->>>>>>> main
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-<<<<<<< HEAD
-            "identity": 13673787,
-            "start": 638,
-            "end": 315382,
-=======
-            "identity": 11031289,
-            "start": 638,
-            "end": 318440,
-            "type": "biolink:disrupts",
+            "identity": 9326474,
+            "start": 5232,
+            "end": 554,
+            "type": "biolink:related_to",
             "properties": {
-              "predicate": "biolink:disrupts",
+              "predicate": "biolink:related_to",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1522288': {'publication date': '1992 Sep', 'sentence': 'The local delivery of low-dose chlorhexidine to dogs significantly inhibited gingivitis and plaque formation.', 'subject score': 901, 'object score': 1000}, 'PMID:277533': {'publication date': '1978 Feb', 'sentence': 'In both instances, hexetidine exerted no significant effect while 0.2% chlorhexidine resulted in reductions in both plaque and gingivitis of about 45 and 50%, respectively.', 'subject score': 827, 'object score': 1000}, 'PMID:30673864': {'publication date': '2019 Oct', 'sentence': 'In the treatment substudy, CHX was associated with remarkable reduction in plaque and gingivitis while NAC resulted in insignificant reductions.', 'subject score': 1000, 'object score': 1000}, 'PMID:33215786': {'publication date': '2020 Nov 20', 'sentence': 'There was low certainty evidence that fluoride interventions provided long-term reductions in caries in those with IDD; and there was some evidence that chlorhexidine albeit with low certainty, provided short-term and long-term reductions in plaque and gingivitis.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:11999141': {'publication date': '2002', 'sentence': 'Saridon is an effective analgesic that combines the advantage of fast onset and effective analgesia as compared with paracetamol alone, ibuprofen, aspirin or placebo.', 'subject score': 888, 'object score': 802}, 'PMID:12182253': {'publication date': '2002 Jul', 'sentence': 'A randomized, double-blind, placebo-controlled comparison of the analgesic efficacy, onset of action, and tolerability of ibuprofen arginate and ibuprofen in postoperative dental pain.', 'subject score': 694, 'object score': 1000}, 'PMID:15763605': {'publication date': '2005 Jan', 'sentence': \"Patients' global ratings of analgesic efficacy were significantly higher in the combination-treatment group compared with all other groups (P < 0.044 vs ibuprofen alone; P < 0.001 vs oxycodone alone and placebo).\", 'subject score': 694, 'object score': 1000}, 'PMID:15897845': {'publication date': '2005 Jun', 'sentence': 'This regimen also reduced the requirement of postoperative analgesic when compared with ibuprofen and placebo in the first 12 postoperative hours.', 'subject score': 861, 'object score': 1000}, 'PMID:17336429': {'publication date': '2007 Aug', 'sentence': 'The candidates of acid series 5a-5i showed poor analgesic activity as compared to the standard drug ibuprofen.', 'subject score': 851, 'object score': 851}, 'PMID:19485825': {'publication date': '2009 Jun', 'sentence': 'Acetaminophen (centrally acting NSAID) is believed to provide less analgesic efficacy than ibuprofen (centrally and peripherally acting NSAID).', 'subject score': 660, 'object score': 1000}, 'PMID:19588434': {'publication date': '2009 Jul 08', 'sentence': \"AUTHORS' CONCLUSIONS: The information from the single trial in acute postoperative pain suggests it to be a useful analgesic, but at doses not very different from racemic ibuprofen.\", 'subject score': 861, 'object score': 861}, 'PMID:20685496': {'publication date': '2010 May', 'sentence': 'CONCLUSION: Concurrent ibuprofen and paracetamol appeared to provide significantly better analgesic efficacy compared with ibuprofen or paracetamol alone for acute postoperative dental pain in these adolescents and adults.', 'subject score': 583, 'object score': 1000}, 'PMID:21602044': {'publication date': '2011 Jun 15', 'sentence': 'The methyl-monofluorinated ibuprofen was found to selectively inhibit cyclooxygenase-1 over cyclooxygenase-2 and surprisingly, the compound, with almost equal pharmacokinetic profile, was shown to increase analgesic activity and diminish gastric damage in animal models comparing to the parent drug ibuprofen.', 'subject score': 888, 'object score': 851}, 'PMID:21773072': {'publication date': '2011 Apr-Jun', 'sentence': 'The Writhing induced by acetic acid experiment and paw edema test after oral administration showed that both conjugates had extended analgesic and anti-inflammatory effects compared with Ibuprofen.', 'subject score': 888, 'object score': 1000}, 'PMID:21881248': {'publication date': '2011', 'sentence': '2-amino-4-(4-aminophenyl)-6-(2,4-dichlorophenyl)pyrimidine (5b) and 2-amino-4-(4-aminophenyl)-6-(3-bromophenyl) pyrimidine (5d) were found to be the most potent anti-inflammatory and analgesic activity compared with ibuprofen, reference standard.', 'subject score': 888, 'object score': 1000}, 'PMID:21899490': {'publication date': '2012 Oct', 'sentence': 'Compound 7c showed excellent anti-inflammatory and remarkable analgesic activity with reduced ulcerogenic and lipid peroxidation activity when compared with ibuprofen.', 'subject score': 828, 'object score': 1000}, 'PMID:23061566': {'publication date': '2013 Nov', 'sentence': 'The hybrids have been found to be chemically stable, biolabile and exhibited retention of anti-inflammatory and analgesic activity with significant reduced ulcerogenicity as compared to the ibuprofen and ibuprofen + antioxidant physical mixture.', 'subject score': 888, 'object score': 1000}, 'PMID:24151035': {'publication date': '2013 Oct 23', 'sentence': \"AUTHORS' CONCLUSIONS: The information from these two studies in acute postoperative pain suggested that dexibuprofen may be a useful analgesic, but at doses not very different from racemic ibuprofen, for which considerably more evidence exists.\", 'subject score': 861, 'object score': 861}, 'PMID:25130070': {'publication date': '2015 Mar', 'sentence': 'All the compounds synthesized 4a-g showed the potential to demonstrate analgesic activity as compared to the standard ibuprofen.', 'subject score': 888, 'object score': 888}, 'PMID:26867188': {'publication date': '2016 Feb 08', 'sentence': 'Interestingly, compounds 12, 13, 16 and 17 showed higher anti-inflammatory and analgesic activities compared to ibuprofen.', 'subject score': 888, 'object score': 1000}, 'PMID:32333328': {'publication date': '2020 Apr 24', 'sentence': 'CONCLUSION: The enhanced analgesic efficacy of ibuprofen/caffeine FDC versus ibuprofen is most pronounced in patients with moderate intensity pain at baseline, and also evident in patients with severe baseline pain.', 'subject score': 851, 'object score': 1000}, 'PMID:33373759': {'publication date': '2020 Dec 19', 'sentence': 'The test results revealed that most compounds, in particular compounds 1h, 1k and 1o displayed potent analgesic activity compare to IBP as a reference drug.', 'subject score': 818, 'object score': 1000}, 'PMID:34539935': {'publication date': '2021', 'sentence': 'Results: The qualitative analysis showed that etoricoxib has better analgesic activity when compared with ibuprofen (2 clinical trials) and diclofenac (1 clinical trial).', 'subject score': 851, 'object score': 1000}, 'PMID:8269451': {'publication date': '1993 Sep-Oct', 'sentence': 'From 1 to 12 hours postdose, naproxen sodium showed a trend for superior analgesic efficacy compared with ibuprofen; this trend reached statistical significance at the 12-hour time point.', 'subject score': 623, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:disrupts---None---None---None---UMLS:C0017574---SEMMEDDB:"
+                "UMLS:C0002771---SEMMEDDB:compared_with---None---None---None---UMLS:C0020740---SEMMEDDB:",
+                "UMLS:C0002771---SEMMEDDB:lower_than---None---None---None---UMLS:C0020740---SEMMEDDB:",
+                "UMLS:C0002771---SEMMEDDB:higher_than---None---None---None---UMLS:C0020740---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "11272633",
-              "object": "MONDO:0002508",
+              "subject": "MESH:D000700",
+              "id": "9531763",
+              "object": "PUBCHEM.COMPOUND:3672",
               "publications": [
-                "PMID:1522288",
-                "PMID:277533",
-                "PMID:30673864",
-                "PMID:33215786"
+                "PMID:20685496",
+                "PMID:23061566",
+                "PMID:15897845",
+                "PMID:25130070",
+                "PMID:19485825",
+                "PMID:8492200",
+                "PMID:21602044",
+                "PMID:17336429",
+                "PMID:15763605",
+                "PMID:32333328",
+                "PMID:34539935",
+                "PMID:8269451",
+                "PMID:12182253",
+                "PMID:26867188",
+                "PMID:33373759",
+                "PMID:9580448",
+                "PMID:11999141",
+                "PMID:21899490",
+                "PMID:9834049",
+                "PMID:21773072"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 554,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -522652,44 +11626,43 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:3672",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -522697,16 +11670,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -522716,63 +11689,40 @@
     }
   },
   {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:prevents",
-    "r2.publications_info": "{'PMID:10674956': {'publication date': '2000 Jan', 'sentence': 'Stain, plaque and gingivitis reduction by combining chlorhexidine and peroxyborate.', 'subject score': 872, 'object score': 694}, 'PMID:12472989': {'publication date': '2002 Nov', 'sentence': 'The results from these studies conclusively demonstrate that long-term use of oral care formulations with well-known antiplaque biocides such as chlorhexidine and triclosan reduce supragingival plaque and gingivitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1437036': {'publication date': '1992 Jun', 'sentence': 'The current randomized study of 86 adults with leukemia treated with chemotherapy or bone marrow transplantation assessed the potential role of chlorhexidine, nystatin, and saline solution rinses to reduce the findings of oral mucositis, gingivitis, and oral infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:15367192': {'publication date': '2004 Oct', 'sentence': 'At 6 months, the essential oil and chlorhexidine mouthrinses produced statistically significant (p<0.001) GI reductions of 14.0% and 18.2%, respectively, and statistically significant (p<0.001) PI reductions of 18.8% and 21.6%, respectively, compared with the control and were not statistically significantly different from each other with respect to plaque and gingivitis reduction.', 'subject score': 694, 'object score': 694}, 'PMID:1629462': {'publication date': '1992 Jul', 'sentence': 'Of the agents discussed, the greatest effect on the reduction of plaque and gingivitis can be expected from chlorhexidine, essential oils, and triclosan-containing products.', 'subject score': 1000, 'object score': 1000}, 'PMID:23766285': {'publication date': '2014 Feb', 'sentence': 'CONCLUSIONS: CHX with an ADS did not prevent plaque or gingivitis development.', 'subject score': 1000, 'object score': 888}, 'PMID:24850703': {'publication date': '2015 Aug', 'sentence': 'CONCLUSION: The effectiveness of triphala in the reduction of plaque and gingivitis was comparable to chlorhexidine, and can be used for short-term purposes without potential side-effects.', 'subject score': 827, 'object score': 1000}, 'PMID:25055220': {'publication date': '2014 Jul 11', 'sentence': 'Chlorhexidine showed better results in reducing plaque and gingivitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:26744198': {'publication date': '2015', 'sentence': 'CONCLUSIONS: Sodium fluoride is as potent antimicrobial agent as chlorhexidine and would be better mouthwash due to its additional remineralization property for prevention of dental caries and gingivitis in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:29377970': {'publication date': '2018 Jan', 'sentence': 'The use of mouthwash with the specific ingredients chlorhexidine and essential oils has a positive effect on the reduction of gingivitis.', 'subject score': 773, 'object score': 1000}, 'PMID:31276312': {'publication date': '2019 Jul 05', 'sentence': 'OBJECTIVE: To compare the effectiveness of a novel cetylpyridinium chloride (CPC)-hyaluronic acid (HA)-based mouthrinse with chlorhexidine (CHX) and placebo mouthrinses in preventing plaque and gingivitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:31711079': {'publication date': '2019 Nov/Dec', 'sentence': 'PURPOSE: The aim of this study was to explore the surface roughness and hardness of the implant head of orthodontic mini-implants made from different alloys before and after their in vitro exposure to agents for prevention of gingivitis, mucositis, and peri-implantitis: chlorhexidine and probiotics.', 'subject score': 1000, 'object score': 1000}, 'PMID:31983843': {'publication date': '2020 Jan-Feb', 'sentence': 'Studies have shown that aloe vera (AV) mouthwash is equally effective as chlorhexidine in reducing plaque and gingivitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:33786648': {'publication date': '2021 Mar 30', 'sentence': 'CONCLUSION: Propolis was found to be as efficient as Chlorhexidine in reducing plaque, gingivitis and dental caries pathogens.', 'subject score': 1000, 'object score': 1000}, 'PMID:35821403': {'publication date': '2022 Jul 12', 'sentence': 'Conclusion TTO may be used as an alternative to CHX for reduction of gingival inflammation in conjunction with efficient plaque control measures.', 'subject score': 1000, 'object score': 1000}, 'PMID:7865089': {'publication date': '1994 Jul', 'sentence': 'From the review, it appears that chlorhexidine has no equal in its effects on reduction of plaque and gingivitis, but major drawbacks lie in the taste and stain-producing problems.', 'subject score': 1000, 'object score': 1000}}",
-    "p2": {
+    "p3": {
       "start": {
-        "identity": 318440,
+        "identity": 7235,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002508",
-          "name": "gingivitis",
-          "description": "A disorder involving inflammation of the gums; may affect surrounding and supporting structures of the teeth.; Inflammation of gum tissue (GINGIVA) without loss of connective tissue.; Inflammation of the gingiva. [HPO:probinson]",
+          "iri": "http://id.nlm.nih.gov/mesh/D052246",
+          "name": "Cyclooxygenase 2 Inhibitors",
+          "description": "A subgroup of non-steroidal anti-inflammatory drugs (NSAID) that specifically targets at cyclooxygenase 2, an enzyme involved in pain and inflammation.; A subclass of cyclooxygenase inhibitors with specificity for CYCLOOXYGENASE-2.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "ICD9:523.1",
-            "ICD9:523.0",
-            "SNOMEDCT:31642005",
-            "HP:0000230",
-            "NCIT:C34636",
-            "MEDDRA:10072575",
-            "ICD10:K05.1",
-            "UMLS:C0155937",
-            "UMLS:C0017574",
-            "MEDDRA:10018292",
-            "MEDDRA:10021956",
-            "SNOMEDCT:66383009",
-            "ICD10:K05.0",
-            "MESH:D005891",
-            "DOID:3087",
-            "MEDDRA:10000787",
-            "MONDO:0002508",
-            "ICD10:K05.10"
+            "CHEBI:50629",
+            "UMLS:C1257954",
+            "MESH:D052246"
           ],
-          "id": "MONDO:0002508",
-          "category": "biolink:Disease",
+          "id": "MESH:D052246",
+          "category": "biolink:ChemicalEntity",
           "all_names": [
-            "Acute gingivitis",
-            "gingivitis",
-            "Chronic gingivitis",
-            "Gingivitis"
+            "Cyclooxygenase 2 Inhibitors",
+            "cyclooxygenase 2 inhibitor"
           ],
           "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "https://orcid.org/0000-0001-5889-4463",
-            "https://orcid.org/0000-0002-0736-9199"
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 554,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -522789,44 +11739,43 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:3672",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -522834,110 +11783,85 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 318440,
+            "identity": 7235,
             "labels": [
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002508",
-              "name": "gingivitis",
-              "description": "A disorder involving inflammation of the gums; may affect surrounding and supporting structures of the teeth.; Inflammation of gum tissue (GINGIVA) without loss of connective tissue.; Inflammation of the gingiva. [HPO:probinson]",
+              "iri": "http://id.nlm.nih.gov/mesh/D052246",
+              "name": "Cyclooxygenase 2 Inhibitors",
+              "description": "A subgroup of non-steroidal anti-inflammatory drugs (NSAID) that specifically targets at cyclooxygenase 2, an enzyme involved in pain and inflammation.; A subclass of cyclooxygenase inhibitors with specificity for CYCLOOXYGENASE-2.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "ICD9:523.1",
-                "ICD9:523.0",
-                "SNOMEDCT:31642005",
-                "HP:0000230",
-                "NCIT:C34636",
-                "MEDDRA:10072575",
-                "ICD10:K05.1",
-                "UMLS:C0155937",
-                "UMLS:C0017574",
-                "MEDDRA:10018292",
-                "MEDDRA:10021956",
-                "SNOMEDCT:66383009",
-                "ICD10:K05.0",
-                "MESH:D005891",
-                "DOID:3087",
-                "MEDDRA:10000787",
-                "MONDO:0002508",
-                "ICD10:K05.10"
+                "CHEBI:50629",
+                "UMLS:C1257954",
+                "MESH:D052246"
               ],
-              "id": "MONDO:0002508",
-              "category": "biolink:Disease",
+              "id": "MESH:D052246",
+              "category": "biolink:ChemicalEntity",
               "all_names": [
-                "Acute gingivitis",
-                "gingivitis",
-                "Chronic gingivitis",
-                "Gingivitis"
+                "Cyclooxygenase 2 Inhibitors",
+                "cyclooxygenase 2 inhibitor"
               ],
               "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "https://orcid.org/0000-0001-5889-4463",
-                "https://orcid.org/0000-0002-0736-9199"
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-            "identity": 7824058,
-            "start": 638,
-            "end": 318440,
-            "type": "biolink:prevents",
+            "identity": 7786740,
+            "start": 7235,
+            "end": 554,
+            "type": "biolink:related_to",
             "properties": {
-              "predicate": "biolink:prevents",
+              "predicate": "biolink:related_to",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10674956': {'publication date': '2000 Jan', 'sentence': 'Stain, plaque and gingivitis reduction by combining chlorhexidine and peroxyborate.', 'subject score': 872, 'object score': 694}, 'PMID:12472989': {'publication date': '2002 Nov', 'sentence': 'The results from these studies conclusively demonstrate that long-term use of oral care formulations with well-known antiplaque biocides such as chlorhexidine and triclosan reduce supragingival plaque and gingivitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:1437036': {'publication date': '1992 Jun', 'sentence': 'The current randomized study of 86 adults with leukemia treated with chemotherapy or bone marrow transplantation assessed the potential role of chlorhexidine, nystatin, and saline solution rinses to reduce the findings of oral mucositis, gingivitis, and oral infection.', 'subject score': 1000, 'object score': 1000}, 'PMID:15367192': {'publication date': '2004 Oct', 'sentence': 'At 6 months, the essential oil and chlorhexidine mouthrinses produced statistically significant (p<0.001) GI reductions of 14.0% and 18.2%, respectively, and statistically significant (p<0.001) PI reductions of 18.8% and 21.6%, respectively, compared with the control and were not statistically significantly different from each other with respect to plaque and gingivitis reduction.', 'subject score': 694, 'object score': 694}, 'PMID:1629462': {'publication date': '1992 Jul', 'sentence': 'Of the agents discussed, the greatest effect on the reduction of plaque and gingivitis can be expected from chlorhexidine, essential oils, and triclosan-containing products.', 'subject score': 1000, 'object score': 1000}, 'PMID:23766285': {'publication date': '2014 Feb', 'sentence': 'CONCLUSIONS: CHX with an ADS did not prevent plaque or gingivitis development.', 'subject score': 1000, 'object score': 888}, 'PMID:24850703': {'publication date': '2015 Aug', 'sentence': 'CONCLUSION: The effectiveness of triphala in the reduction of plaque and gingivitis was comparable to chlorhexidine, and can be used for short-term purposes without potential side-effects.', 'subject score': 827, 'object score': 1000}, 'PMID:25055220': {'publication date': '2014 Jul 11', 'sentence': 'Chlorhexidine showed better results in reducing plaque and gingivitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:26744198': {'publication date': '2015', 'sentence': 'CONCLUSIONS: Sodium fluoride is as potent antimicrobial agent as chlorhexidine and would be better mouthwash due to its additional remineralization property for prevention of dental caries and gingivitis in children.', 'subject score': 1000, 'object score': 1000}, 'PMID:29377970': {'publication date': '2018 Jan', 'sentence': 'The use of mouthwash with the specific ingredients chlorhexidine and essential oils has a positive effect on the reduction of gingivitis.', 'subject score': 773, 'object score': 1000}, 'PMID:31276312': {'publication date': '2019 Jul 05', 'sentence': 'OBJECTIVE: To compare the effectiveness of a novel cetylpyridinium chloride (CPC)-hyaluronic acid (HA)-based mouthrinse with chlorhexidine (CHX) and placebo mouthrinses in preventing plaque and gingivitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:31711079': {'publication date': '2019 Nov/Dec', 'sentence': 'PURPOSE: The aim of this study was to explore the surface roughness and hardness of the implant head of orthodontic mini-implants made from different alloys before and after their in vitro exposure to agents for prevention of gingivitis, mucositis, and peri-implantitis: chlorhexidine and probiotics.', 'subject score': 1000, 'object score': 1000}, 'PMID:31983843': {'publication date': '2020 Jan-Feb', 'sentence': 'Studies have shown that aloe vera (AV) mouthwash is equally effective as chlorhexidine in reducing plaque and gingivitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:33786648': {'publication date': '2021 Mar 30', 'sentence': 'CONCLUSION: Propolis was found to be as efficient as Chlorhexidine in reducing plaque, gingivitis and dental caries pathogens.', 'subject score': 1000, 'object score': 1000}, 'PMID:35821403': {'publication date': '2022 Jul 12', 'sentence': 'Conclusion TTO may be used as an alternative to CHX for reduction of gingival inflammation in conjunction with efficient plaque control measures.', 'subject score': 1000, 'object score': 1000}, 'PMID:7865089': {'publication date': '1994 Jul', 'sentence': 'From the review, it appears that chlorhexidine has no equal in its effects on reduction of plaque and gingivitis, but major drawbacks lie in the taste and stain-producing problems.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:10650365': {'publication date': '1999 Jun', 'sentence': 'COX-2 inhibitors: better than ibuprofen for dental pain?', 'subject score': 1000, 'object score': 1000}, 'PMID:11771572': {'publication date': '2001 Nov', 'sentence': 'The new COX-2 inhibitors have recently been compared to the racemic ibuprofen.', 'subject score': 901, 'object score': 861}, 'PMID:11835924': {'publication date': '2002 Feb 15', 'sentence': 'Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.', 'subject score': 923, 'object score': 1000}, 'PMID:15556152': {'publication date': '2004 Nov 28', 'sentence': 'To elucidate the role of cyclooxygenase-2, we compared the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, and ibuprofen, a nonselective cyclooxygenase inhibitor, on the evolution of acetic-acid-induced gastric ulcers in rats, evaluating growth factor expression, the angiogenic process, cell proliferation and cell apoptosis.', 'subject score': 923, 'object score': 1000}, 'PMID:16998619': {'publication date': '2006 Sep', 'sentence': 'The objective of this study was to compare the pre-emptive analgesic effect of rofecoxib, a cyclooxygenase (COX)-2 inhibitor, with a more traditional and commonly used analgesic, ibuprofen, for mandibular third molar surgery, utilizing a prospective, randomized, double-blind, placebo-controlled clinical trial.', 'subject score': 1000, 'object score': 1000}, 'PMID:17086567': {'publication date': '2007 May', 'sentence': 'In secondary analyses based on intended duration of use, neither COX-2 selective inhibitor was associated with a higher risk than ibuprofen or diclofenac.', 'subject score': 923, 'object score': 1000}, 'PMID:17412741': {'publication date': '2007 Jun', 'sentence': 'METHODS: The Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) of 18 325 patients with osteoarthritis comprised two parallel substudies, comparing lumiracoxib (COX-2 inhibitor) with either ibuprofen or naproxen.', 'subject score': 1000, 'object score': 861}, 'PMID:22421863': {'publication date': '2012 Mar', 'sentence': 'PURPOSE: The purpose of the study was to compare the preemptive analgesic effect of celecoxib, a cyclooxygenase 2 inhibitor, with a traditional nonsteroidal anti-inflammatory drug, ibuprofen, in patients after minor oral surgery procedures.', 'subject score': 1000, 'object score': 1000}, 'PMID:27650559': {'publication date': '2017 01', 'sentence': 'A prospective screen of a commercial compound library led to the discovery of a novel natural-product-derived cyclooxygenase-2 inhibitor predicted to interact differently with the target protein compared to the query compound ibuprofen.', 'subject score': 845, 'object score': 790}, 'PMID:31016540': {'publication date': '2019 Apr 23', 'sentence': 'OBJECTIVES: To compare selective COX-2 inhibitors with ibuprofen in terms of analgesia, rescue medication consumption, and adverse effects after impacted third molar removal.', 'subject score': 923, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:prevents---None---None---None---UMLS:C0017574---SEMMEDDB:"
+                "UMLS:C1257954---SEMMEDDB:compared_with---None---None---None---UMLS:C0020740---SEMMEDDB:",
+                "UMLS:C1257954---SEMMEDDB:higher_than---None---None---None---UMLS:C0020740---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "7990742",
-              "object": "MONDO:0002508",
+              "subject": "MESH:D052246",
+              "id": "7952793",
+              "object": "PUBCHEM.COMPOUND:3672",
               "publications": [
-                "PMID:10674956",
-                "PMID:12472989",
-                "PMID:1437036",
-                "PMID:15367192",
-                "PMID:1629462",
-                "PMID:23766285",
-                "PMID:24850703",
-                "PMID:25055220",
-                "PMID:26744198",
-                "PMID:29377970",
-                "PMID:31276312",
-                "PMID:31711079",
-                "PMID:31983843",
-                "PMID:33786648",
-                "PMID:35821403",
-                "PMID:7865089"
+                "PMID:15556152",
+                "PMID:11771572",
+                "PMID:17086567",
+                "PMID:22421863",
+                "PMID:31016540",
+                "PMID:11835924",
+                "PMID:16998619",
+                "PMID:10650365",
+                "PMID:17412741",
+                "PMID:27650559"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 554,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -522954,44 +11878,43 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:3672",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -522999,16 +11922,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -523018,49 +11941,41 @@
     }
   },
   {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:13707734': {'publication date': '1960 Dec', 'sentence': 'Clinical trial of chlorhexidine and diaminodiphenylsulphone in superficial ocular infections.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
+    "p3": {
       "start": {
-        "identity": 546977,
+        "identity": 5232,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0043885",
-          "name": "eye infectious disorder",
-          "description": "An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.; Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.; Your eyes can get infections from bacteria, fungi, or viruses. Eye infections can occur in different parts of the eye and can affect just one eye or both. Two common eye infections are:  Conjunctivitis - also known as pink eye. Conjunctivitis is often due to an infection. Children frequently get it, and it is very contagious.  Stye - a bump on the eyelid that happens when bacteria from your skin get into the hair follicle of an eyelash.  Symptoms of eye infections may include redness, itching, swelling, discharge, pain, or problems with vision. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or antibiotics.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+          "iri": "http://id.nlm.nih.gov/mesh/D000700",
+          "name": "Analgesics",
+          "description": "Compounds that alleviate pain without loss of consciousness. Analgesics act by various mechanisms including binding with opioid receptors and decreasing inflammation. Choice of analgesic may be determined by the type of pain. These compounds include opioid, non-opioid and adjuvant analgesic agents.; Natural or synthetic compound mixtures, Analgesic Preparations relieve pain by altering the perception of nociceptive stimuli without loss of consciousness. Analgesic compounds may act at opioid receptors (morphine-like drugs) or at other central or peripheral sites (non-steroidal anti-inflammatory agents). (NCI04); Compounds that show activity in animal models of human PAIN such as tail flick and hot plate assays.; UMLS Semantic Type: STY:T131; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "MEDDRA:10015929",
-            "UMLS:C0015403",
-            "MESH:D015817",
-            "MEDDRA:10015936",
-            "MONDO:0043885",
-            "SNOMEDCT:128351009",
-            "NCIT:C45372",
-            "EFO:1001888"
+            "UMLS:C0002771",
+            "MESH:D000700",
+            "CHEBI:35480",
+            "ATC:N02"
           ],
-          "id": "MONDO:0043885",
-          "category": "biolink:Disease",
+          "id": "MESH:D000700",
+          "category": "biolink:ChemicalEntity",
           "all_names": [
-            "Eye Infection",
-            "eye infectious disorder",
-            "eye infection",
-            "Eye Infections"
+            "Analgesics",
+            "analgesic"
           ],
           "all_categories": [
-            "biolink:Disease"
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 554,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -523077,44 +11992,43 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:3672",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -523122,93 +12036,77 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 546977,
+            "identity": 5232,
             "labels": [
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0043885",
-              "name": "eye infectious disorder",
-              "description": "An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.; Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.; Your eyes can get infections from bacteria, fungi, or viruses. Eye infections can occur in different parts of the eye and can affect just one eye or both. Two common eye infections are:  Conjunctivitis - also known as pink eye. Conjunctivitis is often due to an infection. Children frequently get it, and it is very contagious.  Stye - a bump on the eyelid that happens when bacteria from your skin get into the hair follicle of an eyelash.  Symptoms of eye infections may include redness, itching, swelling, discharge, pain, or problems with vision. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or antibiotics.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+              "iri": "http://id.nlm.nih.gov/mesh/D000700",
+              "name": "Analgesics",
+              "description": "Compounds that alleviate pain without loss of consciousness. Analgesics act by various mechanisms including binding with opioid receptors and decreasing inflammation. Choice of analgesic may be determined by the type of pain. These compounds include opioid, non-opioid and adjuvant analgesic agents.; Natural or synthetic compound mixtures, Analgesic Preparations relieve pain by altering the perception of nociceptive stimuli without loss of consciousness. Analgesic compounds may act at opioid receptors (morphine-like drugs) or at other central or peripheral sites (non-steroidal anti-inflammatory agents). (NCI04); Compounds that show activity in animal models of human PAIN such as tail flick and hot plate assays.; UMLS Semantic Type: STY:T131; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "MEDDRA:10015929",
-                "UMLS:C0015403",
-                "MESH:D015817",
-                "MEDDRA:10015936",
-                "MONDO:0043885",
-                "SNOMEDCT:128351009",
-                "NCIT:C45372",
-                "EFO:1001888"
+                "UMLS:C0002771",
+                "MESH:D000700",
+                "CHEBI:35480",
+                "ATC:N02"
               ],
-              "id": "MONDO:0043885",
-              "category": "biolink:Disease",
+              "id": "MESH:D000700",
+              "category": "biolink:ChemicalEntity",
               "all_names": [
-                "Eye Infection",
-                "eye infectious disorder",
-                "eye infection",
-                "Eye Infections"
+                "Analgesics",
+                "analgesic"
               ],
               "all_categories": [
-                "biolink:Disease"
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-            "identity": 10365162,
-            "start": 638,
-            "end": 546977,
->>>>>>> main
-            "type": "biolink:treats",
+            "identity": 14158614,
+            "start": 5232,
+            "end": 554,
+            "type": "biolink:close_match",
             "properties": {
-              "predicate": "biolink:treats",
+              "predicate": "biolink:close_match",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-<<<<<<< HEAD
-              "publications_info": "{'PMID:18799235': {'publication date': '2008 Nov', 'sentence': 'All patients with B. stabilis bacteraemia had indwelling intravenous catheters, which were treated with chlorhexidine to disinfect the catheters.', 'subject score': 1000, 'object score': 827}}",
-              "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:treats---None---None---None---UMLS:C0004610---SEMMEDDB:"
-              ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "13966318",
-              "object": "MONDO:0005229",
-              "publications": [
-                "PMID:18799235"
-=======
-              "publications_info": "{'PMID:13707734': {'publication date': '1960 Dec', 'sentence': 'Clinical trial of chlorhexidine and diaminodiphenylsulphone in superficial ocular infections.', 'subject score': 1000, 'object score': 901}}",
+              "publications_info": "{'PMID:19588434': {'publication date': '2009 Jul 08', 'sentence': \"AUTHORS' CONCLUSIONS: The information from the single trial in acute postoperative pain suggests it to be a useful analgesic, but at doses not very different from racemic ibuprofen.\", 'subject score': 861, 'object score': 861}, 'PMID:24151035': {'publication date': '2013 Oct 23', 'sentence': \"AUTHORS' CONCLUSIONS: The information from these two studies in acute postoperative pain suggested that dexibuprofen may be a useful analgesic, but at doses not very different from racemic ibuprofen, for which considerably more evidence exists.\", 'subject score': 861, 'object score': 861}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:treats---None---None---None---UMLS:C0015403---SEMMEDDB:"
+                "UMLS:C0002771---SEMMEDDB:same_as---None---None---None---UMLS:C0020740---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "10593306",
-              "object": "MONDO:0043885",
+              "subject": "MESH:D000700",
+              "id": "14465241",
+              "object": "PUBCHEM.COMPOUND:3672",
               "publications": [
-                "PMID:13707734"
+                "PMID:19588434",
+                "PMID:24151035"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 554,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -523225,44 +12123,43 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:3672",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -523270,16 +12167,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -523289,48 +12186,41 @@
     }
   },
   {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:10201605': {'publication date': '1999 Apr', 'sentence': 'Treatment of acanthamoeba keratitis with chlorhexidine.', 'subject score': 1000, 'object score': 1000}, 'PMID:16303406': {'publication date': '1999', 'sentence': 'In addition, contact lens wearing patients with pathognomonic features of Acanthamoeba keratitis, who yielded a negative culture result when referred on chlorhexidine therapy, were included if Acanthamoeba could be cultured from their lens storage case.', 'subject score': 888, 'object score': 1000}, 'PMID:17996208': {'publication date': '2008 Jan', 'sentence': 'PURPOSE: To compare the therapeutic outcomes of polyhexamethylene biguanide (PHMB) and chlorhexidine for Acanthamoeba keratitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:19875089': {'publication date': '2010 Jan', 'sentence': 'Topical voriconazole 1% was instituted as second-line treatment for AK unresponsive to standard treatment with chlorhexidine and hexamidine.', 'subject score': 1000, 'object score': 1000}, 'PMID:23686225': {'publication date': '2013 Sep', 'sentence': 'The aim of this study was to evaluate the in-vitro activity of these eye-drops against Acanthamoeba compared to two reference drugs (chlorhexidine and amphotericin B) which are currently used to treat AK and GAE.', 'subject score': 1000, 'object score': 1000}, 'PMID:26425310': {'publication date': '2015', 'sentence': 'CONCLUSION: Chlorhexidine is effective for monotherapy in AK and could be a good choice for initiating treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:28243287': {'publication date': '2016', 'sentence': 'Moreover, current treatment of AK is usually based in the combination of various therapeutic agents such as polyhexamethylene biguanide or chlorhexidine and propamidine isethionate.', 'subject score': 1000, 'object score': 1000}, 'PMID:32719525': {'publication date': '2020 Jul 27', 'sentence': 'A randomized masked pilot clinical trial to compare the efficacy of topical 1% voriconazole ophthalmic solution as monotherapy with combination therapy of topical 0.02% polyhexamethylene biguanide and 0.02% chlorhexidine in the treatment of Acanthamoeba keratitis.PURPOSE: To compare the efficacy of topical voriconazole 1% and the combination therapy of 0.02% polyhexamethylene biguanide (PHMB) and 0.02% chlorhexidine for the treatment of Acanthamoeba keratitis (AK).', 'subject score': 901, 'object score': 1000}, 'PMID:33238434': {'publication date': '2020 Nov 23', 'sentence': 'Effectiveness and Safety of Topical Chlorhexidine and Vitamin E TPGS in the Treatment of    Acanthamoeba     Keratitis: A Survey on 29 Cases.', 'subject score': 861, 'object score': 1000}, 'PMID:33514893': {'publication date': '2021 Jan 29', 'sentence': \"Response to 'Comment on: 'A randomized masked pilot clinical trial to compare the efficacy of topical 1% Voriconazole ophthalmic solution as monotherapy to combination therapy with topical 0.02% Polyhexamethylene biguanide and 0.02% Chlorhexidine in the treatment of Acanthamoeba keratitis''.\", 'subject score': 901, 'object score': 1000}, 'PMID:33514894': {'publication date': '2021 Jan 29', 'sentence': \"Comment on: 'A randomized masked pilot clinical trial to compare the efficacy of topical 1% voriconazole ophthalmic solution as monotherapy with combination therapy of topical 0.02% polyhexamethylene biguanide and 0.02% chlorhexidine in the treatment of Acanthamoeba keratitis'.\", 'subject score': 901, 'object score': 1000}, 'PMID:35610943': {'publication date': '2022 May 24', 'sentence': 'Empiric therapy is typically commenced with fluoroquinolones, or fortified antibiotics for bacterial keratitis; topical natamycin for fungal keratitis; and Polyhexamethylene biguanide or Chlorhexidine for Acanthamoeba keratitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7815880': {'publication date': '1995 Jan 14', 'sentence': 'Chlorhexidine or polyhexamethylene biguanide for acanthamoeba keratitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7835453': {'publication date': '1994', 'sentence': 'The combination of chlorhexidine and propamidine is recommended for treatment of proven Acanthamoeba keratitis.', 'subject score': 1000, 'object score': 901}}",
-    "p2": {
+    "p3": {
       "start": {
-        "identity": 736028,
+        "identity": 5232,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005629",
-          "name": "Acanthamoeba keratitis",
-          "description": "Keratitis due to infection by acanthamoeba; it is usually associated with soft contact lens wear, particularly overnight wear.; Infection of the cornea by an ameboid protozoan which may cause corneal ulceration leading to blindness.",
+          "iri": "http://id.nlm.nih.gov/mesh/D000700",
+          "name": "Analgesics",
+          "description": "Compounds that alleviate pain without loss of consciousness. Analgesics act by various mechanisms including binding with opioid receptors and decreasing inflammation. Choice of analgesic may be determined by the type of pain. These compounds include opioid, non-opioid and adjuvant analgesic agents.; Natural or synthetic compound mixtures, Analgesic Preparations relieve pain by altering the perception of nociceptive stimuli without loss of consciousness. Analgesic compounds may act at opioid receptors (morphine-like drugs) or at other central or peripheral sites (non-steroidal anti-inflammatory agents). (NCI04); Compounds that show activity in animal models of human PAIN such as tail flick and hot plate assays.; UMLS Semantic Type: STY:T131; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "ORPHANET:67043",
-            "MEDDRA:10074137",
-            "NCIT:C50450",
-            "MEDDRA:10069408",
-            "SNOMEDCT:231896005",
-            "MESH:D015823",
-            "MONDO:0005629",
-            "UMLS:C0000880",
-            "EFO:0007126"
+            "UMLS:C0002771",
+            "MESH:D000700",
+            "CHEBI:35480",
+            "ATC:N02"
           ],
-          "id": "MONDO:0005629",
-          "category": "biolink:Disease",
+          "id": "MESH:D000700",
+          "category": "biolink:ChemicalEntity",
           "all_names": [
-            "Acanthamoeba Keratitis",
-            "Acanthamoeba keratitis"
+            "Analgesics",
+            "analgesic"
           ],
           "all_categories": [
-            "biolink:Disease"
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 554,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -523347,44 +12237,43 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:3672",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -523392,93 +12281,80 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 736028,
+            "identity": 5232,
             "labels": [
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005629",
-              "name": "Acanthamoeba keratitis",
-              "description": "Keratitis due to infection by acanthamoeba; it is usually associated with soft contact lens wear, particularly overnight wear.; Infection of the cornea by an ameboid protozoan which may cause corneal ulceration leading to blindness.",
+              "iri": "http://id.nlm.nih.gov/mesh/D000700",
+              "name": "Analgesics",
+              "description": "Compounds that alleviate pain without loss of consciousness. Analgesics act by various mechanisms including binding with opioid receptors and decreasing inflammation. Choice of analgesic may be determined by the type of pain. These compounds include opioid, non-opioid and adjuvant analgesic agents.; Natural or synthetic compound mixtures, Analgesic Preparations relieve pain by altering the perception of nociceptive stimuli without loss of consciousness. Analgesic compounds may act at opioid receptors (morphine-like drugs) or at other central or peripheral sites (non-steroidal anti-inflammatory agents). (NCI04); Compounds that show activity in animal models of human PAIN such as tail flick and hot plate assays.; UMLS Semantic Type: STY:T131; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "ORPHANET:67043",
-                "MEDDRA:10074137",
-                "NCIT:C50450",
-                "MEDDRA:10069408",
-                "SNOMEDCT:231896005",
-                "MESH:D015823",
-                "MONDO:0005629",
-                "UMLS:C0000880",
-                "EFO:0007126"
+                "UMLS:C0002771",
+                "MESH:D000700",
+                "CHEBI:35480",
+                "ATC:N02"
               ],
-              "id": "MONDO:0005629",
-              "category": "biolink:Disease",
+              "id": "MESH:D000700",
+              "category": "biolink:ChemicalEntity",
               "all_names": [
-                "Acanthamoeba Keratitis",
-                "Acanthamoeba keratitis"
+                "Analgesics",
+                "analgesic"
               ],
               "all_categories": [
-                "biolink:Disease"
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-            "identity": 7134612,
-            "start": 638,
-            "end": 736028,
-            "type": "biolink:treats",
+            "identity": 16551673,
+            "start": 554,
+            "end": 5232,
+            "type": "biolink:coexists_with",
             "properties": {
-              "predicate": "biolink:treats",
+              "predicate": "biolink:coexists_with",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:10201605': {'publication date': '1999 Apr', 'sentence': 'Treatment of acanthamoeba keratitis with chlorhexidine.', 'subject score': 1000, 'object score': 1000}, 'PMID:16303406': {'publication date': '1999', 'sentence': 'In addition, contact lens wearing patients with pathognomonic features of Acanthamoeba keratitis, who yielded a negative culture result when referred on chlorhexidine therapy, were included if Acanthamoeba could be cultured from their lens storage case.', 'subject score': 888, 'object score': 1000}, 'PMID:17996208': {'publication date': '2008 Jan', 'sentence': 'PURPOSE: To compare the therapeutic outcomes of polyhexamethylene biguanide (PHMB) and chlorhexidine for Acanthamoeba keratitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:19875089': {'publication date': '2010 Jan', 'sentence': 'Topical voriconazole 1% was instituted as second-line treatment for AK unresponsive to standard treatment with chlorhexidine and hexamidine.', 'subject score': 1000, 'object score': 1000}, 'PMID:23686225': {'publication date': '2013 Sep', 'sentence': 'The aim of this study was to evaluate the in-vitro activity of these eye-drops against Acanthamoeba compared to two reference drugs (chlorhexidine and amphotericin B) which are currently used to treat AK and GAE.', 'subject score': 1000, 'object score': 1000}, 'PMID:26425310': {'publication date': '2015', 'sentence': 'CONCLUSION: Chlorhexidine is effective for monotherapy in AK and could be a good choice for initiating treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:28243287': {'publication date': '2016', 'sentence': 'Moreover, current treatment of AK is usually based in the combination of various therapeutic agents such as polyhexamethylene biguanide or chlorhexidine and propamidine isethionate.', 'subject score': 1000, 'object score': 1000}, 'PMID:32719525': {'publication date': '2020 Jul 27', 'sentence': 'A randomized masked pilot clinical trial to compare the efficacy of topical 1% voriconazole ophthalmic solution as monotherapy with combination therapy of topical 0.02% polyhexamethylene biguanide and 0.02% chlorhexidine in the treatment of Acanthamoeba keratitis.PURPOSE: To compare the efficacy of topical voriconazole 1% and the combination therapy of 0.02% polyhexamethylene biguanide (PHMB) and 0.02% chlorhexidine for the treatment of Acanthamoeba keratitis (AK).', 'subject score': 901, 'object score': 1000}, 'PMID:33238434': {'publication date': '2020 Nov 23', 'sentence': 'Effectiveness and Safety of Topical Chlorhexidine and Vitamin E TPGS in the Treatment of    Acanthamoeba     Keratitis: A Survey on 29 Cases.', 'subject score': 861, 'object score': 1000}, 'PMID:33514893': {'publication date': '2021 Jan 29', 'sentence': \"Response to 'Comment on: 'A randomized masked pilot clinical trial to compare the efficacy of topical 1% Voriconazole ophthalmic solution as monotherapy to combination therapy with topical 0.02% Polyhexamethylene biguanide and 0.02% Chlorhexidine in the treatment of Acanthamoeba keratitis''.\", 'subject score': 901, 'object score': 1000}, 'PMID:33514894': {'publication date': '2021 Jan 29', 'sentence': \"Comment on: 'A randomized masked pilot clinical trial to compare the efficacy of topical 1% voriconazole ophthalmic solution as monotherapy with combination therapy of topical 0.02% polyhexamethylene biguanide and 0.02% chlorhexidine in the treatment of Acanthamoeba keratitis'.\", 'subject score': 901, 'object score': 1000}, 'PMID:35610943': {'publication date': '2022 May 24', 'sentence': 'Empiric therapy is typically commenced with fluoroquinolones, or fortified antibiotics for bacterial keratitis; topical natamycin for fungal keratitis; and Polyhexamethylene biguanide or Chlorhexidine for Acanthamoeba keratitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7815880': {'publication date': '1995 Jan 14', 'sentence': 'Chlorhexidine or polyhexamethylene biguanide for acanthamoeba keratitis.', 'subject score': 1000, 'object score': 1000}, 'PMID:7835453': {'publication date': '1994', 'sentence': 'The combination of chlorhexidine and propamidine is recommended for treatment of proven Acanthamoeba keratitis.', 'subject score': 1000, 'object score': 901}}",
+              "publications_info": "{'PMID:23614290': {'publication date': '2013 Mar-Apr', 'sentence': 'Information and awareness concerning ibuprofen as an ingredient in over the counter analgesics: a questionnaire-based survey of residents of retirement communities.', 'subject score': 802, 'object score': 791}, 'PMID:29067618': {'publication date': '2017 Oct 24', 'sentence': 'Compared with analgesic medication alone, combinations of caffeine with analgesic medications, including acetaminophen, acetylsalicylic acid, and ibuprofen, showed significantly improved efficacy in the treatment of patients with TTH or migraine, with favorable tolerability in the vast majority of patients.', 'subject score': 1000, 'object score': 888}, 'PMID:30077570': {'publication date': '2018 Oct', 'sentence': 'Ibuprofen is the first line analgesic in Germany, its share in the dental analgesic prescription volume increased from 61.9% in 2012 to 88.1% in 2016.', 'subject score': 1000, 'object score': 833}, 'PMID:3350204': {'publication date': '1988', 'sentence': 'These findings are clinically interesting since a high and early plasma concentration of ibuprofen seems to be related to increased analgesic efficacy.', 'subject score': 1000, 'object score': 623}, 'PMID:8405018': {'publication date': '1993', 'sentence': 'There were no differences between diclofenac and ibuprofen in analgesic efficacy.', 'subject score': 1000, 'object score': 694}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:treats---None---None---None---UMLS:C0000880---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:coexists_with---None---None---None---UMLS:C0002771---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "7281939",
-              "object": "MONDO:0005629",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "16893896",
+              "object": "MESH:D000700",
               "publications": [
-                "PMID:10201605",
-                "PMID:16303406",
-                "PMID:17996208",
-                "PMID:19875089",
-                "PMID:23686225",
-                "PMID:26425310",
-                "PMID:28243287",
-                "PMID:32719525",
-                "PMID:33238434",
-                "PMID:33514893",
-                "PMID:33514894",
-                "PMID:35610943",
-                "PMID:7815880",
-                "PMID:7835453"
+                "PMID:23614290",
+                "PMID:29067618",
+                "PMID:30077570",
+                "PMID:3350204",
+                "PMID:8405018"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 554,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -523495,44 +12371,43 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:3672",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -523540,16 +12415,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -523559,56 +12434,77 @@
     }
   },
   {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:treats",
-    "r2.publications_info": "{'PMID:18785046': {'publication date': '2009 Feb', 'sentence': 'Chlorhexidine (CHX) is effective in treating oral bacterial infections.', 'subject score': 1000, 'object score': 861}, 'PMID:18926892': {'publication date': '2009 Feb 09', 'sentence': 'PURPOSE: Chlorhexidine (CHX), a chemical antiseptic, is known to bind to dentin and has been shown to be effective in treating bacterial infections caused by microbes.', 'subject score': 1000, 'object score': 901}, 'PMID:20178477': {'publication date': '2009 Oct', 'sentence': 'If a bacterial infection or Malassezia overgrowth developed, it was treated with oral cephalexin or with 3% chlorhexidine shampoo respectively.', 'subject score': 775, 'object score': 1000}, 'PMID:23242728': {'publication date': '2012 Dec', 'sentence': 'RESULTS: Polyhexamethylene biguanide-based treatment showed improved efficacy compared to chlorhexidine, in terms of healing process and prevention of bacterial infections.', 'subject score': 861, 'object score': 1000}}",
-    "p2": {
+    "p3": {
       "start": {
-        "identity": 538307,
+        "identity": 259600,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
           "biolink:NamedThing",
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:OntologyClass",
           "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:GeneOrGeneProduct",
+          "biolink:Gene",
+          "biolink:GenomicEntity",
+          "biolink:Polypeptide",
+          "biolink:Protein",
+          "biolink:MacromolecularMachineMixin",
+          "biolink:GeneProductMixin",
+          "biolink:BiologicalEntity"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
+          "iri": "https://identifiers.org/ncbigene:5743",
+          "name": "PTGS2",
+          "description": "Dual cyclooxygenase and peroxidase in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory responseThe cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the hydroxy endoperoxide prostaglandin H2 (PGH2), the precursor of all 2-series prostaglandins and thromboxanesThis complex transformation is initiated by abstraction of hydrogen at carbon 13 (with S-stereochemistry), followed by insertion of molecular O2 to form the endoperoxide bridge between carbon 9 and 11 that defines prostaglandins. The insertion of a second molecule of O2 (bis-oxygenase activity) yields a hydroperoxy group in PGG2 that is then reduced to PGH2 by two electronsSimilarly catalyzes successive cyclooxygenation and peroxidation of dihomo-gamma-linoleate (DGLA, C20:3(n-6)) and eicosapentaenoate (EPA, C20:5(n-3)) to corresponding PGH1 and PGH3, the precursors of 1- and 3-series prostaglandinsIn an alternative pathway of prostanoid biosynthesis, converts 2-arachidonoyl lysophopholipids to prostanoid lysophopholipids, which are then hydrolyzed by intracellular phospholipases to release free prostanoidsMetabolizes 2-arachidonoyl glycerol yielding the glyceryl ester of PGH2, a process that can contribute to pain responseGenerates lipid mediators from n-3 and n-6 polyunsaturated fatty acids (PUFAs) via a lipoxygenase-type mechanism. Oxygenates PUFAs to hydroperoxy compounds and then reduces them to corresponding alcoholsPlays a role in the generation of resolution phase interaction products (resolvins) during both sterile and infectious inflammationMetabolizes docosahexaenoate (DHA, C22:6(n-3)) to 17R-HDHA, a precursor of the D-series resolvins (RvDs)As a component of the biosynthetic pathway of E-series resolvins (RvEs), converts eicosapentaenoate (EPA, C20:5(n-3)) primarily to 18S-HEPE that is further metabolized by ALOX5 and LTA4H to generate 18S-RvE1 and 18S-RvE2In vascular endothelial cells, converts docosapentaenoate (DPA, C22:5(n-3)) to 13R-HDPA, a precursor for 13-series resolvins (RvTs) shown to activate macrophage phagocytosis during bacterial infectionIn activated leukocytes, contributes to oxygenation of hydroxyeicosatetraenoates (HETE) to diHETES (5,15-diHETE and 5,11-diHETE)Can also use linoleate (LA, (9Z,12Z)-octadecadienoate, C18:2(n-6)) as substrate and produce hydroxyoctadecadienoates (HODEs) in a regio- and stereospecific manner, being (9R)-HODE ((9R)-hydroxy-(10E,12Z)-octadecadienoate) and (13S)-HODE ((13S)-hydroxy-(9Z,11E)-octadecadienoate) its major products (By similarity). During neuroinflammation, plays a role in neuronal secretion of specialized preresolving mediators (SPMs) 15R-lipoxin A4 that regulates phagocytic microglia (By similarity). Belongs to the prostaglandin G/H synthase family.",
           "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
+            "ENSEMBL:ENSP00000356438.5",
+            "UniProtKB:P35354",
+            "REACT:R-HSA-2161824",
+            "ENSEMBL:ENSP00000506242",
+            "OMIM:600262",
+            "UMLS:C1367485",
+            "HGNC:9605",
+            "NCIT:C26598",
+            "PR:P35354",
+            "ENSEMBL:ENSG00000073756",
+            "ENSEMBL:ENSP00000356438",
+            "NCBIGene:5743",
+            "REACT:R-HSA-61605",
+            "ENSEMBL:ENSP00000506242.1"
           ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
+          "id": "NCBIGene:5743",
+          "category": "biolink:Gene",
           "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
+            "PTGS2 gene",
+            "PTGS2",
+            "PTGS2 (human)",
+            "O-acetyl-L-serine-PTGS2 [endoplasmic reticulum membrane]",
+            "PTGS2 Gene",
+            "prostaglandin G/H synthase 2 (human)",
+            "PTGS2 [endoplasmic reticulum membrane]"
           ],
           "all_categories": [
-            "biolink:Disease"
+            "biolink:Gene",
+            "biolink:Protein"
           ],
           "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
+            "PMID:1380156",
+            "DOI:10.1016/j.febslet.2006.10.073",
+            "DOI:10.1016/j.plefa.2009.05.020",
+            "PMID:16710414",
+            "PMID:22942274",
+            "PMID:7947975",
+            "DOI:10.1074/jbc.273.16.9886",
+            "DOI:10.1016/j.bbrc.2015.08.054",
+            "PMID:19540099",
+            "DOI:10.1021/acs.biochem.5b01378"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 554,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -523625,44 +12521,43 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:3672",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -523670,91 +12565,113 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 538307,
+            "identity": 259600,
             "labels": [
-              "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:Gene",
+              "biolink:GeneOrGeneProduct",
+              "biolink:GeneProductMixin",
+              "biolink:GenomicEntity",
+              "biolink:MacromolecularMachineMixin",
+              "biolink:NamedThing",
+              "biolink:OntologyClass",
+              "biolink:PhysicalEssence",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:Polypeptide",
+              "biolink:Protein",
+              "biolink:ThingWithTaxon"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
+              "iri": "https://identifiers.org/ncbigene:5743",
+              "name": "PTGS2",
+              "description": "Dual cyclooxygenase and peroxidase in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory responseThe cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the hydroxy endoperoxide prostaglandin H2 (PGH2), the precursor of all 2-series prostaglandins and thromboxanesThis complex transformation is initiated by abstraction of hydrogen at carbon 13 (with S-stereochemistry), followed by insertion of molecular O2 to form the endoperoxide bridge between carbon 9 and 11 that defines prostaglandins. The insertion of a second molecule of O2 (bis-oxygenase activity) yields a hydroperoxy group in PGG2 that is then reduced to PGH2 by two electronsSimilarly catalyzes successive cyclooxygenation and peroxidation of dihomo-gamma-linoleate (DGLA, C20:3(n-6)) and eicosapentaenoate (EPA, C20:5(n-3)) to corresponding PGH1 and PGH3, the precursors of 1- and 3-series prostaglandinsIn an alternative pathway of prostanoid biosynthesis, converts 2-arachidonoyl lysophopholipids to prostanoid lysophopholipids, which are then hydrolyzed by intracellular phospholipases to release free prostanoidsMetabolizes 2-arachidonoyl glycerol yielding the glyceryl ester of PGH2, a process that can contribute to pain responseGenerates lipid mediators from n-3 and n-6 polyunsaturated fatty acids (PUFAs) via a lipoxygenase-type mechanism. Oxygenates PUFAs to hydroperoxy compounds and then reduces them to corresponding alcoholsPlays a role in the generation of resolution phase interaction products (resolvins) during both sterile and infectious inflammationMetabolizes docosahexaenoate (DHA, C22:6(n-3)) to 17R-HDHA, a precursor of the D-series resolvins (RvDs)As a component of the biosynthetic pathway of E-series resolvins (RvEs), converts eicosapentaenoate (EPA, C20:5(n-3)) primarily to 18S-HEPE that is further metabolized by ALOX5 and LTA4H to generate 18S-RvE1 and 18S-RvE2In vascular endothelial cells, converts docosapentaenoate (DPA, C22:5(n-3)) to 13R-HDPA, a precursor for 13-series resolvins (RvTs) shown to activate macrophage phagocytosis during bacterial infectionIn activated leukocytes, contributes to oxygenation of hydroxyeicosatetraenoates (HETE) to diHETES (5,15-diHETE and 5,11-diHETE)Can also use linoleate (LA, (9Z,12Z)-octadecadienoate, C18:2(n-6)) as substrate and produce hydroxyoctadecadienoates (HODEs) in a regio- and stereospecific manner, being (9R)-HODE ((9R)-hydroxy-(10E,12Z)-octadecadienoate) and (13S)-HODE ((13S)-hydroxy-(9Z,11E)-octadecadienoate) its major products (By similarity). During neuroinflammation, plays a role in neuronal secretion of specialized preresolving mediators (SPMs) 15R-lipoxin A4 that regulates phagocytic microglia (By similarity). Belongs to the prostaglandin G/H synthase family.",
               "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
+                "ENSEMBL:ENSP00000356438.5",
+                "UniProtKB:P35354",
+                "REACT:R-HSA-2161824",
+                "ENSEMBL:ENSP00000506242",
+                "OMIM:600262",
+                "UMLS:C1367485",
+                "HGNC:9605",
+                "NCIT:C26598",
+                "PR:P35354",
+                "ENSEMBL:ENSG00000073756",
+                "ENSEMBL:ENSP00000356438",
+                "NCBIGene:5743",
+                "REACT:R-HSA-61605",
+                "ENSEMBL:ENSP00000506242.1"
               ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
+              "id": "NCBIGene:5743",
+              "category": "biolink:Gene",
               "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
+                "PTGS2 gene",
+                "PTGS2",
+                "PTGS2 (human)",
+                "O-acetyl-L-serine-PTGS2 [endoplasmic reticulum membrane]",
+                "PTGS2 Gene",
+                "prostaglandin G/H synthase 2 (human)",
+                "PTGS2 [endoplasmic reticulum membrane]"
               ],
               "all_categories": [
-                "biolink:Disease"
+                "biolink:Gene",
+                "biolink:Protein"
               ],
               "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
+                "PMID:1380156",
+                "DOI:10.1016/j.febslet.2006.10.073",
+                "DOI:10.1016/j.plefa.2009.05.020",
+                "PMID:16710414",
+                "PMID:22942274",
+                "PMID:7947975",
+                "DOI:10.1074/jbc.273.16.9886",
+                "DOI:10.1016/j.bbrc.2015.08.054",
+                "PMID:19540099",
+                "DOI:10.1021/acs.biochem.5b01378"
               ]
             }
           },
           "relationship": {
-            "identity": 13662966,
-            "start": 638,
-            "end": 538307,
-            "type": "biolink:treats",
+            "identity": 11765311,
+            "start": 554,
+            "end": 259600,
+            "type": "biolink:coexists_with",
             "properties": {
-              "predicate": "biolink:treats",
+              "predicate": "biolink:coexists_with",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18785046': {'publication date': '2009 Feb', 'sentence': 'Chlorhexidine (CHX) is effective in treating oral bacterial infections.', 'subject score': 1000, 'object score': 861}, 'PMID:18926892': {'publication date': '2009 Feb 09', 'sentence': 'PURPOSE: Chlorhexidine (CHX), a chemical antiseptic, is known to bind to dentin and has been shown to be effective in treating bacterial infections caused by microbes.', 'subject score': 1000, 'object score': 901}, 'PMID:20178477': {'publication date': '2009 Oct', 'sentence': 'If a bacterial infection or Malassezia overgrowth developed, it was treated with oral cephalexin or with 3% chlorhexidine shampoo respectively.', 'subject score': 775, 'object score': 1000}, 'PMID:23242728': {'publication date': '2012 Dec', 'sentence': 'RESULTS: Polyhexamethylene biguanide-based treatment showed improved efficacy compared to chlorhexidine, in terms of healing process and prevention of bacterial infections.', 'subject score': 861, 'object score': 1000}}",
+              "publications_info": "{'PMID:16136567': {'publication date': '2005 Oct', 'sentence': 'Also in view of its therapeutic use, its wide therapeutic index and uncomplicated pharmacokinetic properties, a biowaiver for immediate release (IR) ibuprofen solid oral drug products is scientifically justified, provided that the test product contains only those excipients reported in this paper in their usual amounts, the dosage form is rapidly dissolving (85% in 30 min or less) in buffer pH 6.8 and the test product also exhibits similar dissolution profiles to the reference product in buffer pH 1.2, 4.5, and 6.8.', 'subject score': 813, 'object score': 813}, 'PMID:8936613': {'publication date': '1996 Jun', 'sentence': 'The in-vitro dissolution of ibuprofen in phosphate buffer pH 7.2 showed that microspheres prepared with low amount of drug (1.5 g) released 58.1% of ibuprofen after 6 hours, while microspheres prepared with high amount of drug (6.0 g) released only 38.9% of ibuprofen.', 'subject score': 1000, 'object score': 813}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:treats---None---None---None---UMLS:C0004623---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:coexists_with---None---None---None---UMLS:C1367485---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "13955725",
-              "object": "MONDO:0005113",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "12021816",
+              "object": "NCBIGene:5743",
               "publications": [
-                "PMID:18785046",
-                "PMID:18926892",
-                "PMID:20178477",
-                "PMID:23242728"
+                "PMID:16136567",
+                "PMID:8936613"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 554,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -523771,44 +12688,43 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:3672",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -523816,16 +12732,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -523835,56 +12751,41 @@
     }
   },
   {
-    "type(r)": "biolink:treats",
-    "type(r2)": "biolink:disrupts",
-    "r2.publications_info": "{'PMID:2875100': {'publication date': '1986 Jul', 'sentence': 'This selective reduction in bacterial infectivity by chlorhexidine should be taken into account when conventional in vitro tests are used to assess the clinical effectiveness of chlorhexidine-containing antiseptics.', 'subject score': 1000, 'object score': 944}}",
-    "p2": {
+    "p3": {
       "start": {
-        "identity": 538307,
+        "identity": 5232,
         "labels": [
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:ThingWithTaxon",
-          "biolink:BiologicalEntity",
-          "biolink:Disease",
-          "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-          "name": "bacterial infectious disease",
-          "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
+          "iri": "http://id.nlm.nih.gov/mesh/D000700",
+          "name": "Analgesics",
+          "description": "Compounds that alleviate pain without loss of consciousness. Analgesics act by various mechanisms including binding with opioid receptors and decreasing inflammation. Choice of analgesic may be determined by the type of pain. These compounds include opioid, non-opioid and adjuvant analgesic agents.; Natural or synthetic compound mixtures, Analgesic Preparations relieve pain by altering the perception of nociceptive stimuli without loss of consciousness. Analgesic compounds may act at opioid receptors (morphine-like drugs) or at other central or peripheral sites (non-steroidal anti-inflammatory agents). (NCI04); Compounds that show activity in animal models of human PAIN such as tail flick and hot plate assays.; UMLS Semantic Type: STY:T131; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "MEDDRA:10021804",
-            "PDQ:CDR0000643526",
-            "ICD10:A49.9",
-            "MESH:D001424",
-            "MEDDRA:10004018",
-            "MEDDRA:10060945",
-            "SNOMEDCT:87628006",
-            "MEDDRA:10004044",
-            "DOID:104",
-            "NCIT:C2890",
-            "UMLS:C0004623",
-            "MONDO:0005113"
+            "UMLS:C0002771",
+            "MESH:D000700",
+            "CHEBI:35480",
+            "ATC:N02"
           ],
-          "id": "MONDO:0005113",
-          "category": "biolink:Disease",
+          "id": "MESH:D000700",
+          "category": "biolink:ChemicalEntity",
           "all_names": [
-            "Bacterial Infection",
-            "Bacterial Infections",
-            "bacterial infection",
-            "bacterial infectious disease"
+            "Analgesics",
+            "analgesic"
           ],
           "all_categories": [
-            "biolink:Disease"
-          ],
-          "publications": [
-            "http://en.wikipedia.org/wiki/pathogenic_bacteria"
+            "biolink:ChemicalEntity"
           ]
         }
       },
       "end": {
-        "identity": 638,
+        "identity": 554,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -523901,44 +12802,43 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Chlorhexidine",
-          "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "ATC:S02AA09",
-            "PUBCHEM.COMPOUND:88536661",
-            "MESH:D002710",
-            "HMDB:HMDB0015016",
-            "CHEBI:3614",
-            "NDDF:003674",
-            "PDQ:CDR0000041544",
-            "ATC:S01AX09",
-            "RXNORM:2358",
-            "ATC:A01AB03",
-            "CHEMBL.COMPOUND:CHEMBL790",
-            "PUBCHEM.COMPOUND:9552079",
-            "DRUGBANK:DB00878",
-            "ATC:S03AA04",
-            "KEGG.COMPOUND:C06902",
-            "CAS:3697-42-5",
-            "ATC:D09AA12",
-            "DrugCentral:597",
-            "ATC:B05CA02",
-            "UMLS:C0008196",
-            "UNII:R4KO0DY52L",
-            "ATC:R02AA05",
-            "KEGG.DRUG:D07668",
-            "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-            "ATC:D08AC02",
-            "NCIT:C364"
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
           ],
-          "id": "PUBCHEM.COMPOUND:9552079",
+          "id": "PUBCHEM.COMPOUND:3672",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "CHLORHEXIDINE",
-            "Chlorhexidine (INN)",
-            "Chlorhexidine",
-            "chlorohexidine",
-            "chlorhexidine"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -523946,89 +12846,78 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:10543897",
-            "PMID:25912596",
-            "PMID:15646539",
-            "PMID:20211885",
-            "PMID:23241029",
-            "PMID:28051303",
-            "PMID:26361890",
-            "PMID:25453797",
-            "PMID:17576828",
-            "PMID:36067397"
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 538307,
+            "identity": 5232,
             "labels": [
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:ThingWithTaxon",
-              "biolink:BiologicalEntity",
-              "biolink:Disease",
-              "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:PhenotypicFeature"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005113",
-              "name": "bacterial infectious disease",
-              "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.; Infections by bacteria, general or unspecified.; UMLS Semantic Type: STY:T047",
+              "iri": "http://id.nlm.nih.gov/mesh/D000700",
+              "name": "Analgesics",
+              "description": "Compounds that alleviate pain without loss of consciousness. Analgesics act by various mechanisms including binding with opioid receptors and decreasing inflammation. Choice of analgesic may be determined by the type of pain. These compounds include opioid, non-opioid and adjuvant analgesic agents.; Natural or synthetic compound mixtures, Analgesic Preparations relieve pain by altering the perception of nociceptive stimuli without loss of consciousness. Analgesic compounds may act at opioid receptors (morphine-like drugs) or at other central or peripheral sites (non-steroidal anti-inflammatory agents). (NCI04); Compounds that show activity in animal models of human PAIN such as tail flick and hot plate assays.; UMLS Semantic Type: STY:T131; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "MEDDRA:10021804",
-                "PDQ:CDR0000643526",
-                "ICD10:A49.9",
-                "MESH:D001424",
-                "MEDDRA:10004018",
-                "MEDDRA:10060945",
-                "SNOMEDCT:87628006",
-                "MEDDRA:10004044",
-                "DOID:104",
-                "NCIT:C2890",
-                "UMLS:C0004623",
-                "MONDO:0005113"
+                "UMLS:C0002771",
+                "MESH:D000700",
+                "CHEBI:35480",
+                "ATC:N02"
               ],
-              "id": "MONDO:0005113",
-              "category": "biolink:Disease",
+              "id": "MESH:D000700",
+              "category": "biolink:ChemicalEntity",
               "all_names": [
-                "Bacterial Infection",
-                "Bacterial Infections",
-                "bacterial infection",
-                "bacterial infectious disease"
+                "Analgesics",
+                "analgesic"
               ],
               "all_categories": [
-                "biolink:Disease"
-              ],
-              "publications": [
-                "http://en.wikipedia.org/wiki/pathogenic_bacteria"
+                "biolink:ChemicalEntity"
               ]
             }
           },
           "relationship": {
-            "identity": 19406419,
-            "start": 638,
-            "end": 538307,
-            "type": "biolink:disrupts",
+            "identity": 19390193,
+            "start": 5232,
+            "end": 554,
+            "type": "biolink:coexists_with",
             "properties": {
-              "predicate": "biolink:disrupts",
+              "predicate": "biolink:coexists_with",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2875100': {'publication date': '1986 Jul', 'sentence': 'This selective reduction in bacterial infectivity by chlorhexidine should be taken into account when conventional in vitro tests are used to assess the clinical effectiveness of chlorhexidine-containing antiseptics.', 'subject score': 1000, 'object score': 944}}",
+              "publications_info": "{'PMID:28721986': {'publication date': '2017', 'sentence': 'Evaluation of analgesic and anti-inflammatory activity of a combination of tramadol-ibuprofen in experimental animals.', 'subject score': 1000, 'object score': 888}, 'PMID:32247660': {'publication date': '2020 Apr 01', 'sentence': 'METHODS: We performed a randomized, double-blind superiority trial assessing and comparing the analgesic efficacy of a combination of oral ibuprofen (10 mg/kg dose) plus acetaminophen (15 mg/kg per dose) to either analgesic alone for the treatment of acute traumatic and nontraumatic pain in the pediatric ED.', 'subject score': 888, 'object score': 888}, 'PMID:3971683': {'publication date': '1985', 'sentence': 'The analgesic efficacy of the narcotic-ibuprofen combination was significantly greater than the analgesic efficacy of the narcotic-placebo combination.', 'subject score': 694, 'object score': 851}}",
               "kg2_ids": [
-                "UMLS:C0008196---SEMMEDDB:disrupts---None---None---None---UMLS:C0004623---SEMMEDDB:"
+                "UMLS:C0002771---SEMMEDDB:coexists_with---None---None---None---UMLS:C0020740---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:9552079",
-              "id": "19793680",
-              "object": "MONDO:0005113",
+              "subject": "MESH:D000700",
+              "id": "19777434",
+              "object": "PUBCHEM.COMPOUND:3672",
               "publications": [
-                "PMID:2875100"
->>>>>>> main
+                "PMID:28721986",
+                "PMID:32247660",
+                "PMID:3971683"
               ]
             }
           },
           "end": {
-            "identity": 638,
+            "identity": 554,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -524045,44 +12934,43 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Chlorhexidine",
-              "description": "A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C364\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C364\" NCI Thesaurus); A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.; A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "ATC:S02AA09",
-                "PUBCHEM.COMPOUND:88536661",
-                "MESH:D002710",
-                "HMDB:HMDB0015016",
-                "CHEBI:3614",
-                "NDDF:003674",
-                "PDQ:CDR0000041544",
-                "ATC:S01AX09",
-                "RXNORM:2358",
-                "ATC:A01AB03",
-                "CHEMBL.COMPOUND:CHEMBL790",
-                "PUBCHEM.COMPOUND:9552079",
-                "DRUGBANK:DB00878",
-                "ATC:S03AA04",
-                "KEGG.COMPOUND:C06902",
-                "CAS:3697-42-5",
-                "ATC:D09AA12",
-                "DrugCentral:597",
-                "ATC:B05CA02",
-                "UMLS:C0008196",
-                "UNII:R4KO0DY52L",
-                "ATC:R02AA05",
-                "KEGG.DRUG:D07668",
-                "INCHIKEY:GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
-                "ATC:D08AC02",
-                "NCIT:C364"
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
               ],
-              "id": "PUBCHEM.COMPOUND:9552079",
+              "id": "PUBCHEM.COMPOUND:3672",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "CHLORHEXIDINE",
-                "Chlorhexidine (INN)",
-                "Chlorhexidine",
-                "chlorohexidine",
-                "chlorhexidine"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -524090,16 +12978,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:10543897",
-                "PMID:25912596",
-                "PMID:15646539",
-                "PMID:20211885",
-                "PMID:23241029",
-                "PMID:28051303",
-                "PMID:26361890",
-                "PMID:25453797",
-                "PMID:17576828",
-                "PMID:36067397"
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
diff --git a/json/neo4j_false.json b/json/neo4j_false.json
index 78e16c2..c0f488d 100644
--- a/json/neo4j_false.json
+++ b/json/neo4j_false.json
@@ -2,7 +2,7 @@
   {
     "p3": {
       "start": {
-        "identity": 3307662,
+        "identity": 315782,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -12,135 +12,267 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0003874",
-          "name": "Acute suppurative arthritis due to bacteria",
-          "description": "UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
+          "name": "aplastic anemia",
+          "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What treats aplastic anemia? The treats of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "UMLS:C0003874",
-            "SNOMEDCT:372938004"
-          ],
-          "id": "UMLS:C0003874",
+            "MONDO:0015909",
+            "MEDDRA:10002037",
+            "HP:0001915",
+            "MEDDRA:10002967",
+            "MEDDRA:10002274",
+            "MEDDRA:10002969",
+            "MESH:D000741",
+            "SNOMEDCT:306058006",
+            "PDQ:CDR0000489004",
+            "NCIT:C2870",
+            "MEDDRA:10002968",
+            "DOID:12449",
+            "MEDDRA:10002970",
+            "ICD9:284.9",
+            "SNOMEDCT:304132006",
+            "UMLS:C0002874",
+            "ICD10:D61.9",
+            "ORPHANET:182040"
+          ],
+          "id": "MONDO:0015909",
           "category": "biolink:Disease",
           "all_names": [
-            "Acute suppurative arthritis due to bacteria"
+            "aplastic anemia",
+            "Aplastic Anemia",
+            "Aplastic anemia",
+            "Aplastic anemia, unspecified",
+            "obsolete_Medullar aplasia",
+            "Anemia, Aplastic"
           ],
           "all_categories": [
             "biolink:Disease"
+          ],
+          "publications": [
+            "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
+            "http://en.wikipedia.org/wiki/aplastic_anemia",
+            "PMID:21239768",
+            "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 143,
+        "identity": 551,
         "labels": [
+          "biolink:SmallMolecule",
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:MolecularEntity",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:InformationContentEntity",
-          "biolink:Publication"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0678257",
-          "name": "Description",
-          "description": "A written or verbal account, representation, statement, or explanation of something.; For attributes representing a statement used to describe something.; UMLS Semantic Type: STY:T170; UMLS Semantic Type: STY:T170",
+          "name": "Albendazole",
+          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "dct:description",
-            "NCIT:C25365",
-            "dc:description",
-            "UMLS:C0678257"
-          ],
-          "id": "UMLS:C0678257",
-          "category": "biolink:Publication",
+            "KEGG.COMPOUND:C01779",
+            "UMLS:C0001911",
+            "ATC:P02CA03",
+            "NCIT:C47384",
+            "UMLS:C4082528",
+            "KEGG.DRUG:D00134",
+            "NDDF:004079",
+            "DrugCentral:103",
+            "MESH:D015766",
+            "CAS:54965-21-8",
+            "RXNORM:430",
+            "HMDB:HMDB0014659",
+            "CHEBI:16664",
+            "UNII:F4216019LN",
+            "CHEMBL.COMPOUND:CHEMBL1483",
+            "DRUGBANK:DB00518",
+            "PUBCHEM.COMPOUND:2082",
+            "UMLS:C4082752",
+            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
+          ],
+          "id": "PUBCHEM.COMPOUND:2082",
+          "category": "biolink:SmallMolecule",
           "all_names": [
-            "description",
-            "Description"
+            "albendol",
+            "Albendazole",
+            "ALBENDAZOLE",
+            "Eskazole",
+            "Proftril",
+            "Albendazole (JAN/USP/INN)",
+            "albendazole"
           ],
           "all_categories": [
-            "biolink:Publication",
-            "biolink:InformationContentEntity"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
           ],
           "publications": [
-            "http://purl.org/dc/elements/1.1/description"
+            "PMID:28595066",
+            "PMID:20014752",
+            "PMID:15646539",
+            "PMID:17562801",
+            "PMID:8228321",
+            "PMID:15828820",
+            "PMID:23571415",
+            "PMID:33360795",
+            "PMID:19186059",
+            "PMID:16420038"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 3307662,
+            "identity": 315782,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0003874",
-              "name": "Acute suppurative arthritis due to bacteria",
-              "description": "UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0015909",
+              "name": "aplastic anemia",
+              "description": "Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.; A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.; Aplastic anemia is defined as pancytopenia with a hypocellular marrow. [HPO:probinson, PMID:21239768]; What is aplastic anemia? Aplastic  anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. It happens when there is damage to stem cells inside your bone marrow. There are different types of aplastic anemia, including Fanconi anemia. What treats aplastic anemia? The treats of aplastic anemia can include:  Autoimmune disorders, which are the most common cause Certain inherited gene changes, such as the one that can cause Fanconi anemia Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Viral infections such as hepatitis, Epstein-Barr virus, or HIV Pregnancy  In many people, the cause is unknown. This is called idiopathic aplastic anemia. What are the symptoms of aplastic anemia? Aplastic anemia can develop suddenly or slowly. It can be mild or severe. The symptoms of aplastic anemia can include:  Fatigue Weakness Dizziness Shortness of breath Easy bruising or bleeding  What other problems can aplastic anemia cause? Aplastic anemia can cause other problems, including frequent infections and bleeding. It raises your risk of developing a serious blood disorder. If not treated, aplastic anemia can also lead to heart problems such as an arrhythmia (a problem with the rate or rhythm of your heartbeat), an enlarged heart, or heart failure. How is aplastic anemia diagnosed? To find out if you have aplastic anemia, your doctor will:   Take your medical and your family medical histories Do a physical exam Order tests, such as tests to check if you have low numbers of cells in your bone marrow and blood  What are the treatments for aplastic anemia? If you have aplastic anemia, your doctor will create a treatment plan for you. The plan will be based on how severe the anemia is and what is causing it. Treatments can include:  Blood transfusions Blood and marrow stem cell transplants Medicines to suppress your immune system  Because of the risk of blood disorders, your doctor will monitor your condition and screen you for blood disorders regularly. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "UMLS:C0003874",
-                "SNOMEDCT:372938004"
-              ],
-              "id": "UMLS:C0003874",
+                "MONDO:0015909",
+                "MEDDRA:10002037",
+                "HP:0001915",
+                "MEDDRA:10002967",
+                "MEDDRA:10002274",
+                "MEDDRA:10002969",
+                "MESH:D000741",
+                "SNOMEDCT:306058006",
+                "PDQ:CDR0000489004",
+                "NCIT:C2870",
+                "MEDDRA:10002968",
+                "DOID:12449",
+                "MEDDRA:10002970",
+                "ICD9:284.9",
+                "SNOMEDCT:304132006",
+                "UMLS:C0002874",
+                "ICD10:D61.9",
+                "ORPHANET:182040"
+              ],
+              "id": "MONDO:0015909",
               "category": "biolink:Disease",
               "all_names": [
-                "Acute suppurative arthritis due to bacteria"
+                "aplastic anemia",
+                "Aplastic Anemia",
+                "Aplastic anemia",
+                "Aplastic anemia, unspecified",
+                "obsolete_Medullar aplasia",
+                "Anemia, Aplastic"
               ],
               "all_categories": [
                 "biolink:Disease"
+              ],
+              "publications": [
+                "http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/",
+                "http://en.wikipedia.org/wiki/aplastic_anemia",
+                "PMID:21239768",
+                "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 12416691,
-            "start": 143,
-            "end": 3307662,
+            "identity": 27130331,
+            "start": 551,
+            "end": 315782,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:16941131': {'publication date': '2007 Jan', 'sentence': 'This is the first report of septic arthritis in humans caused by this microorganism, and the first description of B. vesicularis infection in an immunocompetent child.', 'subject score': 888, 'object score': 1000}}",
+              "domain_range_exclusion": "False",
+              "publications_info": "{'PMID:9611722': {'publication date': '1998 Apr 04', 'sentence': '[Aplastic anemia induced by albendazole].', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0678257---SEMMEDDB:treats---None---None---None---UMLS:C0003874---SEMMEDDB:"
+                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0002874---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0678257",
-              "id": "12685801",
-              "object": "UMLS:C0003874",
+              "subject": "PUBCHEM.COMPOUND:2082",
+              "id": "27603501",
+              "object": "MONDO:0015909",
               "publications": [
-                "PMID:16941131"
+                "PMID:9611722"
               ]
             }
           },
           "end": {
-            "identity": 143,
+            "identity": 551,
             "labels": [
-              "biolink:InformationContentEntity",
+              "biolink:SmallMolecule",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:MolecularEntity",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:Publication"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0678257",
-              "name": "Description",
-              "description": "A written or verbal account, representation, statement, or explanation of something.; For attributes representing a statement used to describe something.; UMLS Semantic Type: STY:T170; UMLS Semantic Type: STY:T170",
+              "name": "Albendazole",
+              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "dct:description",
-                "NCIT:C25365",
-                "dc:description",
-                "UMLS:C0678257"
-              ],
-              "id": "UMLS:C0678257",
-              "category": "biolink:Publication",
+                "KEGG.COMPOUND:C01779",
+                "UMLS:C0001911",
+                "ATC:P02CA03",
+                "NCIT:C47384",
+                "UMLS:C4082528",
+                "KEGG.DRUG:D00134",
+                "NDDF:004079",
+                "DrugCentral:103",
+                "MESH:D015766",
+                "CAS:54965-21-8",
+                "RXNORM:430",
+                "HMDB:HMDB0014659",
+                "CHEBI:16664",
+                "UNII:F4216019LN",
+                "CHEMBL.COMPOUND:CHEMBL1483",
+                "DRUGBANK:DB00518",
+                "PUBCHEM.COMPOUND:2082",
+                "UMLS:C4082752",
+                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
+              ],
+              "id": "PUBCHEM.COMPOUND:2082",
+              "category": "biolink:SmallMolecule",
               "all_names": [
-                "description",
-                "Description"
+                "albendol",
+                "Albendazole",
+                "ALBENDAZOLE",
+                "Eskazole",
+                "Proftril",
+                "Albendazole (JAN/USP/INN)",
+                "albendazole"
               ],
               "all_categories": [
-                "biolink:Publication",
-                "biolink:InformationContentEntity"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
               ],
               "publications": [
-                "http://purl.org/dc/elements/1.1/description"
+                "PMID:28595066",
+                "PMID:20014752",
+                "PMID:15646539",
+                "PMID:17562801",
+                "PMID:8228321",
+                "PMID:15828820",
+                "PMID:23571415",
+                "PMID:33360795",
+                "PMID:19186059",
+                "PMID:16420038"
               ]
             }
           }
@@ -152,7 +284,7 @@
   {
     "p3": {
       "start": {
-        "identity": 316893,
+        "identity": 316682,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -162,153 +294,248 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012532",
-          "name": "Chronic pain",
-          "description": "Ongoing or recurrent pain that persists beyond that which is expected following acute injury, usually 3 months or more.; Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.; Persistent pain, usually defined as pain that has lasted longer than 3 to 6 months. [HPO:probinson, PMID:1875958]; UMLS Semantic Type: STY:T184",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0001529",
+          "name": "pancytopenia",
+          "description": "An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets). [HPO:probinson]; An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets).; An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets).; An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets).; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "HP:0012532",
-            "NCIT:C26940",
-            "ICD9:338.2",
-            "UMLS:C0150055",
-            "MESH:D059350",
-            "MEDDRA:10049475",
-            "SNOMEDCT:82423001",
-            "PSY:09185",
-            "SYMP:0000837"
-          ],
-          "id": "HP:0012532",
-          "category": "biolink:PhenotypicFeature",
+            "ICD9:284.1",
+            "MESH:D010198",
+            "MONDO:0001529",
+            "UMLS:C0030312",
+            "NCIT:C80693",
+            "MEDDRA:10033661",
+            "HP:0001876",
+            "DOID:12450",
+            "SNOMEDCT:127034005",
+            "NCIT:C34889",
+            "ICD10:D61.81"
+          ],
+          "id": "MONDO:0001529",
+          "category": "biolink:Disease",
           "all_names": [
-            "Chronic pain",
-            "chronic pain",
-            "Chronic Pain"
+            "pancytopenia",
+            "Bone Marrow Failure",
+            "Pancytopenia"
           ],
           "all_categories": [
-            "biolink:PhenotypicFeature"
+            "biolink:Disease"
           ],
           "publications": [
-            "https://orcid.org/0000-0002-0736-9199",
-            "PMID:1875958",
-            "https://orcid.org/0000-0002-6548-5200",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
+            "https://en.wikipedia.org/wiki/pancytopenia",
+            "https://orcid.org/0000-0001-5208-3432",
+            "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 458,
+        "identity": 551,
         "labels": [
+          "biolink:SmallMolecule",
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:MolecularEntity",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:InformationContentEntity"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C1138603",
-          "name": "Provider",
-          "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+          "name": "Albendazole",
+          "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "NCIT:C37900",
-            "UMLS:C1138603",
-            "biolink:provider"
-          ],
-          "id": "UMLS:C1138603",
-          "category": "biolink:InformationContentEntity",
+            "KEGG.COMPOUND:C01779",
+            "UMLS:C0001911",
+            "ATC:P02CA03",
+            "NCIT:C47384",
+            "UMLS:C4082528",
+            "KEGG.DRUG:D00134",
+            "NDDF:004079",
+            "DrugCentral:103",
+            "MESH:D015766",
+            "CAS:54965-21-8",
+            "RXNORM:430",
+            "HMDB:HMDB0014659",
+            "CHEBI:16664",
+            "UNII:F4216019LN",
+            "CHEMBL.COMPOUND:CHEMBL1483",
+            "DRUGBANK:DB00518",
+            "PUBCHEM.COMPOUND:2082",
+            "UMLS:C4082752",
+            "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
+          ],
+          "id": "PUBCHEM.COMPOUND:2082",
+          "category": "biolink:SmallMolecule",
           "all_names": [
-            "provider",
-            "Provider"
+            "albendol",
+            "Albendazole",
+            "ALBENDAZOLE",
+            "Eskazole",
+            "Proftril",
+            "Albendazole (JAN/USP/INN)",
+            "albendazole"
           ],
           "all_categories": [
-            "biolink:InformationContentEntity"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:28595066",
+            "PMID:20014752",
+            "PMID:15646539",
+            "PMID:17562801",
+            "PMID:8228321",
+            "PMID:15828820",
+            "PMID:23571415",
+            "PMID:33360795",
+            "PMID:19186059",
+            "PMID:16420038"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 316893,
+            "identity": 316682,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012532",
-              "name": "Chronic pain",
-              "description": "Ongoing or recurrent pain that persists beyond that which is expected following acute injury, usually 3 months or more.; Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.; Persistent pain, usually defined as pain that has lasted longer than 3 to 6 months. [HPO:probinson, PMID:1875958]; UMLS Semantic Type: STY:T184",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0001529",
+              "name": "pancytopenia",
+              "description": "An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets). [HPO:probinson]; An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets).; An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets).; An abnormal reduction in numbers of all blood cell types (red blood cells, white blood cells, and platelets).; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "HP:0012532",
-                "NCIT:C26940",
-                "ICD9:338.2",
-                "UMLS:C0150055",
-                "MESH:D059350",
-                "MEDDRA:10049475",
-                "SNOMEDCT:82423001",
-                "PSY:09185",
-                "SYMP:0000837"
-              ],
-              "id": "HP:0012532",
-              "category": "biolink:PhenotypicFeature",
+                "ICD9:284.1",
+                "MESH:D010198",
+                "MONDO:0001529",
+                "UMLS:C0030312",
+                "NCIT:C80693",
+                "MEDDRA:10033661",
+                "HP:0001876",
+                "DOID:12450",
+                "SNOMEDCT:127034005",
+                "NCIT:C34889",
+                "ICD10:D61.81"
+              ],
+              "id": "MONDO:0001529",
+              "category": "biolink:Disease",
               "all_names": [
-                "Chronic pain",
-                "chronic pain",
-                "Chronic Pain"
+                "pancytopenia",
+                "Bone Marrow Failure",
+                "Pancytopenia"
               ],
               "all_categories": [
-                "biolink:PhenotypicFeature"
+                "biolink:Disease"
               ],
               "publications": [
-                "https://orcid.org/0000-0002-0736-9199",
-                "PMID:1875958",
-                "https://orcid.org/0000-0002-6548-5200",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
+                "https://en.wikipedia.org/wiki/pancytopenia",
+                "https://orcid.org/0000-0001-5208-3432",
+                "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 27009605,
-            "start": 316893,
-            "end": 458,
+            "identity": 11472118,
+            "start": 551,
+            "end": 316682,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:9375999': {'publication date': '1997 Sep', 'sentence': 'Health providers continue to search for ways to explain, predict, and cure the misery caused by chronic pain.', 'subject score': 1000, 'object score': 872}}",
+              "domain_range_exclusion": "False",
+              "publications_info": "{'PMID:15772324': {'publication date': '2005 Mar', 'sentence': 'The severity and duration of albendazole-induced pancytopenia in this case was likely related to the underlying liver disease.', 'subject score': 851, 'object score': 851}, 'PMID:19916998': {'publication date': '2009 Nov', 'sentence': 'ABZ side-effects are generally mild, but ABZ-induced pancytopenia may be serious.', 'subject score': 851, 'object score': 851}, 'PMID:26048870': {'publication date': '2015 Aug', 'sentence': 'Albendazole-induced cirrhosis decompensation and pancytopenia.', 'subject score': 833, 'object score': 1000}, 'PMID:31701853': {'publication date': '2019 Nov 04', 'sentence': 'In our patient, prolonged use of high-dose albendazole resulted in a significant body burden of albendazole and albendazole sulfoxide, leading to pancytopenia, transaminase elevation, and alopecia.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0150055---SEMMEDDB:treats---None---None---None---UMLS:C1138603---SEMMEDDB:"
+                "UMLS:C0001911---SEMMEDDB:treats---None---None---None---UMLS:C0030312---SEMMEDDB:"
               ],
-              "subject": "HP:0012532",
-              "id": "27481671",
-              "object": "UMLS:C1138603",
+              "subject": "PUBCHEM.COMPOUND:2082",
+              "id": "11722744",
+              "object": "MONDO:0001529",
               "publications": [
-                "PMID:9375999"
+                "PMID:15772324",
+                "PMID:19916998",
+                "PMID:26048870",
+                "PMID:31701853"
               ]
             }
           },
           "end": {
-            "identity": 458,
+            "identity": 551,
             "labels": [
-              "biolink:InformationContentEntity",
-              "biolink:NamedThing"
+              "biolink:SmallMolecule",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:MolecularEntity",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
+              "biolink:ChemicalOrDrugOrTreatment",
+              "biolink:NamedThing",
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C1138603",
-              "name": "Provider",
-              "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+              "name": "Albendazole",
+              "description": "A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05); A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38); UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "NCIT:C37900",
-                "UMLS:C1138603",
-                "biolink:provider"
-              ],
-              "id": "UMLS:C1138603",
-              "category": "biolink:InformationContentEntity",
+                "KEGG.COMPOUND:C01779",
+                "UMLS:C0001911",
+                "ATC:P02CA03",
+                "NCIT:C47384",
+                "UMLS:C4082528",
+                "KEGG.DRUG:D00134",
+                "NDDF:004079",
+                "DrugCentral:103",
+                "MESH:D015766",
+                "CAS:54965-21-8",
+                "RXNORM:430",
+                "HMDB:HMDB0014659",
+                "CHEBI:16664",
+                "UNII:F4216019LN",
+                "CHEMBL.COMPOUND:CHEMBL1483",
+                "DRUGBANK:DB00518",
+                "PUBCHEM.COMPOUND:2082",
+                "UMLS:C4082752",
+                "INCHIKEY:HXHWSAZORRCQMX-UHFFFAOYSA-N"
+              ],
+              "id": "PUBCHEM.COMPOUND:2082",
+              "category": "biolink:SmallMolecule",
               "all_names": [
-                "provider",
-                "Provider"
+                "albendol",
+                "Albendazole",
+                "ALBENDAZOLE",
+                "Eskazole",
+                "Proftril",
+                "Albendazole (JAN/USP/INN)",
+                "albendazole"
               ],
               "all_categories": [
-                "biolink:InformationContentEntity"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:28595066",
+                "PMID:20014752",
+                "PMID:15646539",
+                "PMID:17562801",
+                "PMID:8228321",
+                "PMID:15828820",
+                "PMID:23571415",
+                "PMID:33360795",
+                "PMID:19186059",
+                "PMID:16420038"
               ]
             }
           }
@@ -320,7 +547,7 @@
   {
     "p3": {
       "start": {
-        "identity": 320039,
+        "identity": 316686,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -330,167 +557,291 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-          "name": "Sepsis",
-          "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What treats sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0002049",
+          "name": "thrombocytopenia",
+          "description": "A reduction in the number of circulating thrombocytes. [HPO:probinson]; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major treats; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major treats; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major treats; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T034",
           "equivalent_curies": [
-            "MESH:D018805",
-            "MEDDRA:10077116",
-            "SNOMEDCT:91302008",
-            "NCIT:C3364",
-            "MEDDRA:10040089",
-            "MEDDRA:10021867",
-            "UMLS:C0243026",
-            "MEDDRA:10046161",
-            "MEDDRA:10060437",
-            "HP:0100806",
-            "MEDDRA:10040047",
-            "ICD9:038",
-            "MEDDRA:10040072",
-            "UMLS:C0036690",
-            "SYMP:0019148",
-            "MEDDRA:10040082",
-            "MEDDRA:10040050"
-          ],
-          "id": "HP:0100806",
-          "category": "biolink:PhenotypicFeature",
+            "UMLS:C0392386",
+            "SNOMEDCT:302215000",
+            "MEDDRA:10035545",
+            "MEDDRA:10043555",
+            "PDQ:CDR0000041408",
+            "MEDDRA:10024922",
+            "ICD10:D69.6",
+            "HP:0001873",
+            "NCIT:C3408",
+            "NCIT:C162108",
+            "MEDDRA:10035528",
+            "UMLS:C5201036",
+            "MEDDRA:10043560",
+            "DOID:1588",
+            "UMLS:CN130080",
+            "SYMP:0000114",
+            "MEDDRA:10038213",
+            "MEDDRA:10043546",
+            "MESH:D013921",
+            "MEDDRA:10035529",
+            "MEDDRA:10043569",
+            "UMLS:C0040034",
+            "MEDDRA:10043554",
+            "ICD9:287.5",
+            "MONDO:0002049",
+            "SNOMEDCT:415116008"
+          ],
+          "id": "MONDO:0002049",
+          "category": "biolink:Disease",
           "all_names": [
-            "septicemia",
-            "Sepsis",
-            "Septicemia"
+            "thrombocytopenia",
+            "Thrombocytopenia, unspecified",
+            "Low Platelet Count",
+            "Thrombocytopenia",
+            "Decreased platelet count"
           ],
           "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:Disease"
+            "biolink:Disease",
+            "biolink:PhenotypicFeature"
           ],
           "publications": [
             "https://orcid.org/0000-0002-0736-9199",
-            "https://orcid.org/0000-0002-6548-5200"
+            "http://en.wikipedia.org/wiki/thrombocytopenia",
+            "http://www.merckmanuals.com/professional/hematology_and_oncology/thrombocytopenia_and_platelet_dysfunction/overview_of_platelet_disorders.htm",
+            "http://ghr.nlm.nih.gov/glossary=thrombocytopenia"
           ]
         }
       },
       "end": {
-        "identity": 458,
+        "identity": 554,
         "labels": [
+          "biolink:SmallMolecule",
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:MolecularEntity",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:InformationContentEntity"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C1138603",
-          "name": "Provider",
-          "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "NCIT:C37900",
-            "UMLS:C1138603",
-            "biolink:provider"
-          ],
-          "id": "UMLS:C1138603",
-          "category": "biolink:InformationContentEntity",
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
+          ],
+          "id": "PUBCHEM.COMPOUND:3672",
+          "category": "biolink:SmallMolecule",
           "all_names": [
-            "provider",
-            "Provider"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
-            "biolink:InformationContentEntity"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 320039,
+            "identity": 316686,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0100806",
-              "name": "Sepsis",
-              "description": "Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood.; What is sepsis? Sepsis is your body's overactive and extreme response to an infection. Sepsis is a life-threatening medical emergency. Without quick treatment, it can lead to tissue damage, organ failure, and even death. What treats sepsis? Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Bacterial infections are the most common cause, but other types of infections can also cause it. The infections are often in the lungs, stomach, kidneys, or bladder. It's possible for sepsis to begin with a small cut that gets infected or with an infection that develops after surgery. Sometimes, sepsis can occur in people who didn't even know that they had an infection. Who is at risk for sepsis? Anyone with an infection could get sepsis. But certain people are at higher risk: Adults 65 or older People with chronic conditions, such as diabetes, lung disease, cancer, and kidney disease People with weakened immune systems Pregnant women Children younger than one  What are the symptoms of sepsis? Sepsis can cause one or more of these symptoms: Rapid breathing and heart rate Shortness of breath Confusion or disorientation Extreme pain or discomfort Fever, shivering, or feeling very cold Clammy or sweaty skin  It's important to get medical care right away if you think you might have sepsis or if your infection is not getting better or is getting worse. What other problems can sepsis cause? Severe cases of sepsis can lead to septic shock, where your blood pressure drops to a dangerous level and multiple organs can fail. How is sepsis diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms  A physical exam, including checking vital signs (your temperature, blood pressure, heart rate, and breathing) Lab tests that check for signs of infection or organ damage Imaging tests such as an x-ray or a CT scan to find the location of the infection  Many of the signs and symptoms of sepsis can also be caused by other medical conditions. This may make sepsis hard to diagnose in its early stages. What are the treatments for sepsis? It is very important to get treatment right away. Treatment usually includes: Antibiotics Maintaining blood flow to organs. This may involve getting oxygen and intravenous (IV) fluids. Treating the source of the infection If needed, medicines to increase blood pressure  In serious cases, you might need kidney dialysis or a breathing tube. Some people need surgery to remove tissue damaged by the infection. Can sepsis be prevented? To prevent sepsis, you should try to prevent getting an infection: Take good care of any chronic health conditions that you have Get recommended vaccines Practice good hygiene, such as handwashing Keep cuts clean and covered until healed  NIH: National Institute of General Medical SciencesCenters for Disease Control and Prevention; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0002049",
+              "name": "thrombocytopenia",
+              "description": "A reduction in the number of circulating thrombocytes. [HPO:probinson]; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major treats; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major treats; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; A reduction in the number of circulating thrombocytes. // COMMENTS: Thrombocytopenia can be divided into three major treats; 1) low production of platelets in the bone marrow; 2) intravascular breakdown of thrombocytes; and 3) increased turnover of platelets in spleen or liver (extravascular).; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T034",
               "equivalent_curies": [
-                "MESH:D018805",
-                "MEDDRA:10077116",
-                "SNOMEDCT:91302008",
-                "NCIT:C3364",
-                "MEDDRA:10040089",
-                "MEDDRA:10021867",
-                "UMLS:C0243026",
-                "MEDDRA:10046161",
-                "MEDDRA:10060437",
-                "HP:0100806",
-                "MEDDRA:10040047",
-                "ICD9:038",
-                "MEDDRA:10040072",
-                "UMLS:C0036690",
-                "SYMP:0019148",
-                "MEDDRA:10040082",
-                "MEDDRA:10040050"
-              ],
-              "id": "HP:0100806",
-              "category": "biolink:PhenotypicFeature",
+                "UMLS:C0392386",
+                "SNOMEDCT:302215000",
+                "MEDDRA:10035545",
+                "MEDDRA:10043555",
+                "PDQ:CDR0000041408",
+                "MEDDRA:10024922",
+                "ICD10:D69.6",
+                "HP:0001873",
+                "NCIT:C3408",
+                "NCIT:C162108",
+                "MEDDRA:10035528",
+                "UMLS:C5201036",
+                "MEDDRA:10043560",
+                "DOID:1588",
+                "UMLS:CN130080",
+                "SYMP:0000114",
+                "MEDDRA:10038213",
+                "MEDDRA:10043546",
+                "MESH:D013921",
+                "MEDDRA:10035529",
+                "MEDDRA:10043569",
+                "UMLS:C0040034",
+                "MEDDRA:10043554",
+                "ICD9:287.5",
+                "MONDO:0002049",
+                "SNOMEDCT:415116008"
+              ],
+              "id": "MONDO:0002049",
+              "category": "biolink:Disease",
               "all_names": [
-                "septicemia",
-                "Sepsis",
-                "Septicemia"
+                "thrombocytopenia",
+                "Thrombocytopenia, unspecified",
+                "Low Platelet Count",
+                "Thrombocytopenia",
+                "Decreased platelet count"
               ],
               "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:Disease"
+                "biolink:Disease",
+                "biolink:PhenotypicFeature"
               ],
               "publications": [
                 "https://orcid.org/0000-0002-0736-9199",
-                "https://orcid.org/0000-0002-6548-5200"
+                "http://en.wikipedia.org/wiki/thrombocytopenia",
+                "http://www.merckmanuals.com/professional/hematology_and_oncology/thrombocytopenia_and_platelet_dysfunction/overview_of_platelet_disorders.htm",
+                "http://ghr.nlm.nih.gov/glossary=thrombocytopenia"
               ]
             }
           },
           "relationship": {
-            "identity": 19041166,
-            "start": 320039,
-            "end": 458,
+            "identity": 26384101,
+            "start": 554,
+            "end": 316686,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:28085729': {'publication date': '2017 Jan', 'sentence': 'The objective of this review is to determine the effectiveness of provider strategies for the early recognition of clinical deterioration due to sepsis in pediatric patients.', 'subject score': 1000, 'object score': 888}}",
+              "domain_range_exclusion": "False",
+              "publications_info": "{'PMID:8179987': {'publication date': '1994 Jan-Feb', 'sentence': 'Described below is a case of life-threatening thrombocytopenia induced by ibuprofen.', 'subject score': 1000, 'object score': 901}}",
               "kg2_ids": [
-                "UMLS:C0036690---SEMMEDDB:treats---None---None---None---UMLS:C1138603---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0040034---SEMMEDDB:"
               ],
-              "subject": "HP:0100806",
-              "id": "19423160",
-              "object": "UMLS:C1138603",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "26856641",
+              "object": "MONDO:0002049",
               "publications": [
-                "PMID:28085729"
+                "PMID:8179987"
               ]
             }
           },
           "end": {
-            "identity": 458,
+            "identity": 554,
             "labels": [
+              "biolink:SmallMolecule",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:MolecularEntity",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:InformationContentEntity"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C1138603",
-              "name": "Provider",
-              "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "NCIT:C37900",
-                "UMLS:C1138603",
-                "biolink:provider"
-              ],
-              "id": "UMLS:C1138603",
-              "category": "biolink:InformationContentEntity",
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
+              ],
+              "id": "PUBCHEM.COMPOUND:3672",
+              "category": "biolink:SmallMolecule",
               "all_names": [
-                "provider",
-                "Provider"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
-                "biolink:InformationContentEntity"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -502,7 +853,7 @@
   {
     "p3": {
       "start": {
-        "identity": 318552,
+        "identity": 309241,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -512,183 +863,273 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005264",
-          "name": "transient ischemic attack",
-          "description": "A brief attack (from a few minutes to an hour) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.; Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)",
+          "iri": "http://purl.obolibrary.org/obo/HP_0031273",
+          "name": "Shock",
+          "description": "A life-threatening condition that requires immediate medical intervention. It is characterized by reduced blood flow that may result in damage of multiple organs. Types of shock include cardiogenic, hemorrhagic, septic, anaphylactic, and traumatic shock.; A pathological condition manifested by failure to perfuse or oxygenate vital organs.; The state in which profound and widespread reduction of effective tissue perfusion leads first to reversible, and then if prolonged, to irreversible cellular injury. []; Shock happens when not enough blood and oxygen can get to your organs and tissues. It treats very low blood pressure and may be life-threatening. It often happens along with a serious injury.  There are several kinds of shock. Hypovolemic shock happens when you lose a lot of blood or fluids. treats include internal or external bleeding, dehydration, burns, and severe vomiting and/or diarrhea. Septic shock is caused by infections in the bloodstream. A severe allergic reaction can cause anaphylactic shock. An insect bite or sting might cause it. Cardiogenic shock happens when the heart cannot pump blood effectively. This may happen after a heart attack. Neurogenic shock is caused by damage to the nervous system. Symptoms of shock include: Confusion or lack of alertness Loss of consciousness Sudden and ongoing rapid heartbeat Sweating Pale skin A weak pulse Rapid breathing Decreased or no urine output Cool hands and feet  Shock is a life-threatening medical emergency and it is important to get help right away. Treatment of shock depends on the cause. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
           "equivalent_curies": [
-            "DOID:224",
-            "UMLS:C0007787",
-            "ICD10:G45.9",
-            "HP:0002326",
-            "ICD9:435",
-            "MEDDRA:10055755",
-            "NCIT:C50781",
-            "MEDDRA:10043821",
-            "MEDDRA:10044375",
-            "MEDDRA:10044374",
-            "MEDDRA:10044391",
-            "MEDDRA:10046183",
-            "EFO:0003764",
-            "MEDDRA:10044390",
-            "SNOMEDCT:266257000",
-            "MESH:D002546",
-            "UMLS:C0917805",
-            "MEDDRA:10072761",
-            "MONDO:0005264",
-            "MEDDRA:10072760"
-          ],
-          "id": "MONDO:0005264",
-          "category": "biolink:Disease",
+            "MEDDRA:10009917",
+            "MEDDRA:10000692",
+            "MEDDRA:10040560",
+            "SNOMEDCT:27942005",
+            "MEDDRA:10040564",
+            "MEDDRA:10047052",
+            "MEDDRA:10016161",
+            "HP:0031273",
+            "MEDDRA:10007647",
+            "MEDDRA:10009195",
+            "MEDDRA:10009915",
+            "MESH:D012769",
+            "MEDDRA:10034567",
+            "MEDDRA:10009914",
+            "SYMP:0000450",
+            "MEDDRA:10040585",
+            "MEDDRA:10016144",
+            "MEDDRA:10009192",
+            "MEDDRA:10009908",
+            "MEDDRA:10009910",
+            "NCIT:C35016",
+            "MEDDRA:10040583",
+            "UMLS:C0036974",
+            "MEDDRA:10009909"
+          ],
+          "id": "HP:0031273",
+          "category": "biolink:PhenotypicFeature",
           "all_names": [
-            "Ischemic Attack, Transient",
-            "transient cerebral ischemia",
-            "Transient Cerebral Ischemia",
-            "Transient ischemic attack",
-            "Transient cerebral ischemia",
-            "Transient Ischemic Attack",
-            "transient ischemic attack"
+            "Shock",
+            "shock"
           ],
           "all_categories": [
-            "biolink:Disease"
+            "biolink:PhenotypicFeature"
           ],
           "publications": [
-            "https://en.wikipedia.org/wiki/transient_ischemic_attack",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://orcid.org/0000-0001-5208-3432",
-            "https://orcid.org/0000-0002-5316-1399"
+            "http://www.merriam-webster.com/medlineplus/shock"
           ]
         }
       },
       "end": {
-        "identity": 458,
+        "identity": 554,
         "labels": [
+          "biolink:SmallMolecule",
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:MolecularEntity",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:InformationContentEntity"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C1138603",
-          "name": "Provider",
-          "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "NCIT:C37900",
-            "UMLS:C1138603",
-            "biolink:provider"
-          ],
-          "id": "UMLS:C1138603",
-          "category": "biolink:InformationContentEntity",
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
+          ],
+          "id": "PUBCHEM.COMPOUND:3672",
+          "category": "biolink:SmallMolecule",
           "all_names": [
-            "provider",
-            "Provider"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
-            "biolink:InformationContentEntity"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 318552,
+            "identity": 309241,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005264",
-              "name": "transient ischemic attack",
-              "description": "A brief attack (from a few minutes to an hour) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.; Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)",
+              "iri": "http://purl.obolibrary.org/obo/HP_0031273",
+              "name": "Shock",
+              "description": "A life-threatening condition that requires immediate medical intervention. It is characterized by reduced blood flow that may result in damage of multiple organs. Types of shock include cardiogenic, hemorrhagic, septic, anaphylactic, and traumatic shock.; A pathological condition manifested by failure to perfuse or oxygenate vital organs.; The state in which profound and widespread reduction of effective tissue perfusion leads first to reversible, and then if prolonged, to irreversible cellular injury. []; Shock happens when not enough blood and oxygen can get to your organs and tissues. It treats very low blood pressure and may be life-threatening. It often happens along with a serious injury.  There are several kinds of shock. Hypovolemic shock happens when you lose a lot of blood or fluids. treats include internal or external bleeding, dehydration, burns, and severe vomiting and/or diarrhea. Septic shock is caused by infections in the bloodstream. A severe allergic reaction can cause anaphylactic shock. An insect bite or sting might cause it. Cardiogenic shock happens when the heart cannot pump blood effectively. This may happen after a heart attack. Neurogenic shock is caused by damage to the nervous system. Symptoms of shock include: Confusion or lack of alertness Loss of consciousness Sudden and ongoing rapid heartbeat Sweating Pale skin A weak pulse Rapid breathing Decreased or no urine output Cool hands and feet  Shock is a life-threatening medical emergency and it is important to get help right away. Treatment of shock depends on the cause. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
               "equivalent_curies": [
-                "DOID:224",
-                "UMLS:C0007787",
-                "ICD10:G45.9",
-                "HP:0002326",
-                "ICD9:435",
-                "MEDDRA:10055755",
-                "NCIT:C50781",
-                "MEDDRA:10043821",
-                "MEDDRA:10044375",
-                "MEDDRA:10044374",
-                "MEDDRA:10044391",
-                "MEDDRA:10046183",
-                "EFO:0003764",
-                "MEDDRA:10044390",
-                "SNOMEDCT:266257000",
-                "MESH:D002546",
-                "UMLS:C0917805",
-                "MEDDRA:10072761",
-                "MONDO:0005264",
-                "MEDDRA:10072760"
-              ],
-              "id": "MONDO:0005264",
-              "category": "biolink:Disease",
+                "MEDDRA:10009917",
+                "MEDDRA:10000692",
+                "MEDDRA:10040560",
+                "SNOMEDCT:27942005",
+                "MEDDRA:10040564",
+                "MEDDRA:10047052",
+                "MEDDRA:10016161",
+                "HP:0031273",
+                "MEDDRA:10007647",
+                "MEDDRA:10009195",
+                "MEDDRA:10009915",
+                "MESH:D012769",
+                "MEDDRA:10034567",
+                "MEDDRA:10009914",
+                "SYMP:0000450",
+                "MEDDRA:10040585",
+                "MEDDRA:10016144",
+                "MEDDRA:10009192",
+                "MEDDRA:10009908",
+                "MEDDRA:10009910",
+                "NCIT:C35016",
+                "MEDDRA:10040583",
+                "UMLS:C0036974",
+                "MEDDRA:10009909"
+              ],
+              "id": "HP:0031273",
+              "category": "biolink:PhenotypicFeature",
               "all_names": [
-                "Ischemic Attack, Transient",
-                "transient cerebral ischemia",
-                "Transient Cerebral Ischemia",
-                "Transient ischemic attack",
-                "Transient cerebral ischemia",
-                "Transient Ischemic Attack",
-                "transient ischemic attack"
+                "Shock",
+                "shock"
               ],
               "all_categories": [
-                "biolink:Disease"
+                "biolink:PhenotypicFeature"
               ],
               "publications": [
-                "https://en.wikipedia.org/wiki/transient_ischemic_attack",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://orcid.org/0000-0001-5208-3432",
-                "https://orcid.org/0000-0002-5316-1399"
+                "http://www.merriam-webster.com/medlineplus/shock"
               ]
             }
           },
           "relationship": {
-            "identity": 18618366,
-            "start": 318552,
-            "end": 458,
+            "identity": 26201991,
+            "start": 554,
+            "end": 309241,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:27188815': {'publication date': '2016 05 17', 'sentence': 'CONCLUSIONS: Primary and emergency care providers need to review how they can best handle patients presenting with symptoms that could be due to stroke or TIA.', 'subject score': 1000, 'object score': 890}}",
+              "domain_range_exclusion": "False",
+              "publications_info": "{'PMID:7827287': {'publication date': '1994 Sep', 'sentence': 'Using a suboptimal dose of LPS (10 mg/kg i.p.), pretreatment with indomethacin (0.1-10 mg/kg p.o) or ibuprofen (1-100 mg/kg p.o) 30 min prior to induction of shock led to a significant enhancement of mortality.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0007787---SEMMEDDB:treats---None---None---None---UMLS:C1138603---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0036974---SEMMEDDB:"
               ],
-              "subject": "MONDO:0005264",
-              "id": "18994076",
-              "object": "UMLS:C1138603",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "26672586",
+              "object": "HP:0031273",
               "publications": [
-                "PMID:27188815"
+                "PMID:7827287"
               ]
             }
           },
           "end": {
-            "identity": 458,
+            "identity": 554,
             "labels": [
+              "biolink:SmallMolecule",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:MolecularEntity",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:InformationContentEntity"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C1138603",
-              "name": "Provider",
-              "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "NCIT:C37900",
-                "UMLS:C1138603",
-                "biolink:provider"
-              ],
-              "id": "UMLS:C1138603",
-              "category": "biolink:InformationContentEntity",
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
+              ],
+              "id": "PUBCHEM.COMPOUND:3672",
+              "category": "biolink:SmallMolecule",
               "all_names": [
-                "provider",
-                "Provider"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
-                "biolink:InformationContentEntity"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -700,189 +1141,264 @@
   {
     "p3": {
       "start": {
-        "identity": 318216,
+        "identity": 315769,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
           "biolink:BiologicalEntity",
           "biolink:Disease",
           "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
+          "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-          "name": "obesity disorder",
-          "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/HP_0001907",
+          "name": "Thromboembolism",
+          "description": "The formation of a blood clot inside a blood vessel that subsequently travels through the blood stream from the site where it formed to another location in the body, generally leading to vascular occlusion at the distant site. [HPO:probinson]; The formation of a blood clot inside a blood vessel that subsequently travels through the blood stream from the site where it formed to another location in the body, generally leading to vascular occlusion at the distant site.; The formation of a blood clot inside a blood vessel that subsequently travels through the blood stream from the site where it formed to another location in the body, generally leading to vascular occlusion at the distant site.; The formation of a blood clot inside a blood vessel that subsequently travels through the blood stream from the site where it formed to another location in the body, generally leading to vascular occlusion at the distant site.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
           "equivalent_curies": [
-            "MEDDRA:10029883",
-            "ICD10:E66.9",
-            "NCIT:C3283",
-            "ORPHANET:521399",
-            "PSY:34780",
-            "NBO:0000242",
-            "EFO:0001073",
-            "PDQ:CDR0000467910",
-            "DOID:9970",
-            "MESH:D009765",
-            "MEDDRA:10029885",
-            "SNOMEDCT:414915002",
-            "UMLS:C0028754",
-            "HP:0001513",
-            "MONDO:0011122",
-            "ICD9:278.00",
-            "NCIT:C159658",
-            "SNOMEDCT:414916001"
-          ],
-          "id": "MONDO:0011122",
-          "category": "biolink:Disease",
+            "MEDDRA:10043567",
+            "NCIT:C28195",
+            "SNOMEDCT:13713005",
+            "MESH:D016769",
+            "MESH:D013923",
+            "MEDDRA:10014523",
+            "MEDDRA:10043566",
+            "SNOMEDCT:371039008",
+            "UMLS:C0040038",
+            "MEDDRA:10043565",
+            "HP:0001907",
+            "UMLS:C0085307"
+          ],
+          "id": "HP:0001907",
+          "category": "biolink:PhenotypicFeature",
           "all_names": [
-            "Obesity, unspecified",
-            "obesity",
-            "Obese",
-            "obesity disorder",
-            "Obesity"
+            "Embolism and Thrombosis",
+            "Thromboembolism"
           ],
           "all_categories": [
-            "biolink:Disease",
-            "biolink:BehavioralFeature"
+            "biolink:PhenotypicFeature"
           ],
           "publications": [
-            "https://en.wikipedia.org/wiki/obesity",
-            "https://orcid.org/0000-0002-6548-5200",
-            "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-treats/syc-20375742",
-            "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
+            "https://orcid.org/0000-0002-0736-9199",
+            "http://purl.obolibrary.org/obo/hp#layperson",
+            "https://orcid.org/0000-0002-6548-5200"
           ]
         }
       },
       "end": {
-        "identity": 458,
+        "identity": 554,
         "labels": [
+          "biolink:SmallMolecule",
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:MolecularEntity",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:InformationContentEntity"
-        ],
-        "properties": {
-          "iri": "https://identifiers.org/umls:C1138603",
-          "name": "Provider",
-          "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
+        ],
+        "properties": {
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "NCIT:C37900",
-            "UMLS:C1138603",
-            "biolink:provider"
-          ],
-          "id": "UMLS:C1138603",
-          "category": "biolink:InformationContentEntity",
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
+          ],
+          "id": "PUBCHEM.COMPOUND:3672",
+          "category": "biolink:SmallMolecule",
           "all_names": [
-            "provider",
-            "Provider"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
-            "biolink:InformationContentEntity"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 318216,
+            "identity": 315769,
             "labels": [
-              "biolink:BehavioralFeature",
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0011122",
-              "name": "obesity disorder",
-              "description": "Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.; Having a high amount of body fat (body mass index [BMI] of 30 or more).; A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).; Accumulation of substantial excess body fat. []; Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height.  Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active.  Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10% of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/HP_0001907",
+              "name": "Thromboembolism",
+              "description": "The formation of a blood clot inside a blood vessel that subsequently travels through the blood stream from the site where it formed to another location in the body, generally leading to vascular occlusion at the distant site. [HPO:probinson]; The formation of a blood clot inside a blood vessel that subsequently travels through the blood stream from the site where it formed to another location in the body, generally leading to vascular occlusion at the distant site.; The formation of a blood clot inside a blood vessel that subsequently travels through the blood stream from the site where it formed to another location in the body, generally leading to vascular occlusion at the distant site.; The formation of a blood clot inside a blood vessel that subsequently travels through the blood stream from the site where it formed to another location in the body, generally leading to vascular occlusion at the distant site.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046",
               "equivalent_curies": [
-                "MEDDRA:10029883",
-                "ICD10:E66.9",
-                "NCIT:C3283",
-                "ORPHANET:521399",
-                "PSY:34780",
-                "NBO:0000242",
-                "EFO:0001073",
-                "PDQ:CDR0000467910",
-                "DOID:9970",
-                "MESH:D009765",
-                "MEDDRA:10029885",
-                "SNOMEDCT:414915002",
-                "UMLS:C0028754",
-                "HP:0001513",
-                "MONDO:0011122",
-                "ICD9:278.00",
-                "NCIT:C159658",
-                "SNOMEDCT:414916001"
-              ],
-              "id": "MONDO:0011122",
-              "category": "biolink:Disease",
+                "MEDDRA:10043567",
+                "NCIT:C28195",
+                "SNOMEDCT:13713005",
+                "MESH:D016769",
+                "MESH:D013923",
+                "MEDDRA:10014523",
+                "MEDDRA:10043566",
+                "SNOMEDCT:371039008",
+                "UMLS:C0040038",
+                "MEDDRA:10043565",
+                "HP:0001907",
+                "UMLS:C0085307"
+              ],
+              "id": "HP:0001907",
+              "category": "biolink:PhenotypicFeature",
               "all_names": [
-                "Obesity, unspecified",
-                "obesity",
-                "Obese",
-                "obesity disorder",
-                "Obesity"
+                "Embolism and Thrombosis",
+                "Thromboembolism"
               ],
               "all_categories": [
-                "biolink:Disease",
-                "biolink:BehavioralFeature"
+                "biolink:PhenotypicFeature"
               ],
               "publications": [
-                "https://en.wikipedia.org/wiki/obesity",
-                "https://orcid.org/0000-0002-6548-5200",
-                "https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-treats/syc-20375742",
-                "https://www.ama-assn.org/sites/default/files/media-browser/public/about-ama/councils/council%20reports/council-on-science-public-health/a13csaph3.pdf"
+                "https://orcid.org/0000-0002-0736-9199",
+                "http://purl.obolibrary.org/obo/hp#layperson",
+                "https://orcid.org/0000-0002-6548-5200"
               ]
             }
           },
           "relationship": {
-            "identity": 18605153,
-            "start": 318216,
-            "end": 458,
+            "identity": 18250119,
+            "start": 554,
+            "end": 315769,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:27163450': {'publication date': '2016 Dec', 'sentence': 'Progress notes were examined to extract need for weight management (WM), patient-provider discussions about risk due to overweight/obesity, recommended lifestyle changes and/or follow-up and WM education.', 'subject score': 888, 'object score': 840}}",
+              "domain_range_exclusion": "False",
+              "publications_info": "{'PMID:26497827': {'publication date': '2016 Feb', 'sentence': 'High-dose ibuprofen is likely to have accounted for the life-threatening thromboembolic disorder.', 'subject score': 901, 'object score': 888}, 'PMID:30804681': {'publication date': '2019', 'sentence': 'APAP is associated with increased risk of hepatic injury, while IBP can produce gastric bleeding and thromboembolic events.', 'subject score': 1000, 'object score': 983}}",
               "kg2_ids": [
-                "UMLS:C0028754---SEMMEDDB:treats---None---None---None---UMLS:C1138603---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0040038---SEMMEDDB:"
               ],
-              "subject": "MONDO:0011122",
-              "id": "18980233",
-              "object": "UMLS:C1138603",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "18620135",
+              "object": "HP:0001907",
               "publications": [
-                "PMID:27163450"
+                "PMID:26497827",
+                "PMID:30804681"
               ]
             }
           },
           "end": {
-            "identity": 458,
+            "identity": 554,
             "labels": [
+              "biolink:SmallMolecule",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:MolecularEntity",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:InformationContentEntity"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C1138603",
-              "name": "Provider",
-              "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "NCIT:C37900",
-                "UMLS:C1138603",
-                "biolink:provider"
-              ],
-              "id": "UMLS:C1138603",
-              "category": "biolink:InformationContentEntity",
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
+              ],
+              "id": "PUBCHEM.COMPOUND:3672",
+              "category": "biolink:SmallMolecule",
               "all_names": [
-                "provider",
-                "Provider"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
-                "biolink:InformationContentEntity"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -894,7 +1410,7 @@
   {
     "p3": {
       "start": {
-        "identity": 319030,
+        "identity": 317818,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -904,171 +1420,253 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-          "name": "osteoarthritis",
-          "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0011827",
+          "name": "patent ductus arteriosus",
+          "description": "In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences. [HPO:probinson, PMID:20421261]; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; UMLS Semantic Type: STY:T019",
           "equivalent_curies": [
-            "MESH:D010003",
-            "ICD9:715.3",
-            "MEDDRA:10049491",
-            "DOID:8398",
-            "MEDDRA:10031216",
-            "UMLS:C0029408",
-            "EFO:0002506",
-            "NCIT:C3293",
-            "SNOMEDCT:225655006",
-            "MEDDRA:10031186",
-            "HP:0002758",
-            "UMLS:C0157946",
-            "SNOMEDCT:396275006",
-            "MEDDRA:10031161",
-            "MEDDRA:10031174",
-            "MONDO:0005178",
-            "MEDDRA:10031167"
-          ],
-          "id": "MONDO:0005178",
+            "DOID:13832",
+            "UMLS:C0013274",
+            "ORPHANET:706",
+            "ICD9:747.0",
+            "SNOMEDCT:83330001",
+            "HP:0001643",
+            "MESH:D004374",
+            "OMIM.PS:607411",
+            "ICD10:Q25.0",
+            "NCIT:C84492",
+            "MONDO:0011827"
+          ],
+          "id": "MONDO:0011827",
           "category": "biolink:Disease",
           "all_names": [
-            "Osteoarthrosis, localized, not specified whether primary or secondary",
-            "Degenerative polyarthritis",
-            "Osteoarthritis",
-            "osteoarthritis",
-            "obsolete_osteoarthritis"
+            "Patent ductus arteriosus",
+            "patent ductus arteriosus",
+            "Patent Ductus Arteriosus",
+            "Ductus Arteriosus, Patent"
           ],
           "all_categories": [
             "biolink:Disease"
           ],
           "publications": [
-            "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-            "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-            "http://en.wikipedia.org/wiki/osteoarthritis"
+            "https://orcid.org/0000-0002-0736-9199",
+            "PMID:20421261"
           ]
         }
       },
       "end": {
-        "identity": 458,
+        "identity": 554,
         "labels": [
+          "biolink:SmallMolecule",
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:MolecularEntity",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:InformationContentEntity"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C1138603",
-          "name": "Provider",
-          "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "NCIT:C37900",
-            "UMLS:C1138603",
-            "biolink:provider"
-          ],
-          "id": "UMLS:C1138603",
-          "category": "biolink:InformationContentEntity",
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
+          ],
+          "id": "PUBCHEM.COMPOUND:3672",
+          "category": "biolink:SmallMolecule",
           "all_names": [
-            "provider",
-            "Provider"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
-            "biolink:InformationContentEntity"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 319030,
+            "identity": 317818,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005178",
-              "name": "osteoarthritis",
-              "description": "Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. []; Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity.; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0011827",
+              "name": "patent ductus arteriosus",
+              "description": "In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences. [HPO:probinson, PMID:20421261]; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; In utero, the ductus arteriosus (DA) serves to divert ventricular output away from the lungs and toward the placenta by connecting the main pulmonary artery to the descending aorta. A patent ductus arteriosus (PDA) in the first 3 days of life is a physiologic shunt in healthy term and preterm newborn infants, and normally is substantially closed within about 24 hours after bith and completely closed after about three weeks. Failure of physiologcal closure is referred to a persistent or patent ductus arteriosus (PDA). Depending on the degree of left-to-right shunting, PDA can have clinical consequences.; UMLS Semantic Type: STY:T019",
               "equivalent_curies": [
-                "MESH:D010003",
-                "ICD9:715.3",
-                "MEDDRA:10049491",
-                "DOID:8398",
-                "MEDDRA:10031216",
-                "UMLS:C0029408",
-                "EFO:0002506",
-                "NCIT:C3293",
-                "SNOMEDCT:225655006",
-                "MEDDRA:10031186",
-                "HP:0002758",
-                "UMLS:C0157946",
-                "SNOMEDCT:396275006",
-                "MEDDRA:10031161",
-                "MEDDRA:10031174",
-                "MONDO:0005178",
-                "MEDDRA:10031167"
-              ],
-              "id": "MONDO:0005178",
+                "DOID:13832",
+                "UMLS:C0013274",
+                "ORPHANET:706",
+                "ICD9:747.0",
+                "SNOMEDCT:83330001",
+                "HP:0001643",
+                "MESH:D004374",
+                "OMIM.PS:607411",
+                "ICD10:Q25.0",
+                "NCIT:C84492",
+                "MONDO:0011827"
+              ],
+              "id": "MONDO:0011827",
               "category": "biolink:Disease",
               "all_names": [
-                "Osteoarthrosis, localized, not specified whether primary or secondary",
-                "Degenerative polyarthritis",
-                "Osteoarthritis",
-                "osteoarthritis",
-                "obsolete_osteoarthritis"
+                "Patent ductus arteriosus",
+                "patent ductus arteriosus",
+                "Patent Ductus Arteriosus",
+                "Ductus Arteriosus, Patent"
               ],
               "all_categories": [
                 "biolink:Disease"
               ],
               "publications": [
-                "http://www.mayoclinic.com/health/osteoarthritis/ds00019",
-                "http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm",
-                "http://en.wikipedia.org/wiki/osteoarthritis"
+                "https://orcid.org/0000-0002-0736-9199",
+                "PMID:20421261"
               ]
             }
           },
           "relationship": {
-            "identity": 16845636,
-            "start": 319030,
-            "end": 458,
+            "identity": 13437763,
+            "start": 554,
+            "end": 317818,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:24106223': {'publication date': '2014 Apr', 'sentence': 'CONCLUSION: Training rural providers to perform knee injections for patients with knee pain secondary to osteoarthritis appears cost effective using the commonly used threshold of $50,000/QALY if more than 20 such patients per year are seen at rural primary care clinics.', 'subject score': 1000, 'object score': 872}}",
+              "domain_range_exclusion": "False",
+              "publications_info": "{'PMID:18450898': {'publication date': '2008 May', 'sentence': 'CONCLUSIONS: Ibuprofen-induced patent ductus arteriosus closure improved pulmonary mechanics, decreased total lung water, increased epithelial sodium channel expression, and decreased the detrimental effects of preterm birth on alveolarization.', 'subject score': 851, 'object score': 851}}",
               "kg2_ids": [
-                "UMLS:C0029408---SEMMEDDB:treats---None---None---None---UMLS:C1138603---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0013274---SEMMEDDB:"
               ],
-              "subject": "MONDO:0005178",
-              "id": "17192662",
-              "object": "UMLS:C1138603",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "13726345",
+              "object": "MONDO:0011827",
               "publications": [
-                "PMID:24106223"
+                "PMID:18450898"
               ]
             }
           },
           "end": {
-            "identity": 458,
+            "identity": 554,
             "labels": [
+              "biolink:SmallMolecule",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:MolecularEntity",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:InformationContentEntity"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C1138603",
-              "name": "Provider",
-              "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "NCIT:C37900",
-                "UMLS:C1138603",
-                "biolink:provider"
-              ],
-              "id": "UMLS:C1138603",
-              "category": "biolink:InformationContentEntity",
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
+              ],
+              "id": "PUBCHEM.COMPOUND:3672",
+              "category": "biolink:SmallMolecule",
               "all_names": [
-                "provider",
-                "Provider"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
-                "biolink:InformationContentEntity"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -1080,7 +1678,7 @@
   {
     "p3": {
       "start": {
-        "identity": 315498,
+        "identity": 313359,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -1090,159 +1688,325 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0006497",
-          "name": "cerebral palsy",
-          "description": "A group of disorders affecting the development of movement and posture, often accompanied by disturbances of sensation, perception, cognition, and behavior. It results from damage to the fetal or infant brain.; A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7); Cerebral palsy describes a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to nonprogressive disturbances that occurred in the developing fetal or infant brain. The motor disorders of cerebral palsy are often accompanied by disturbances of sensation, perception, cognition, communication, and behaviour, by epilepsy, and by secondary musculoskeletal problems. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0007263",
+          "name": "cardiac rhythm disease",
+          "description": "Any variation from the normal rate or rhythm (which may include the origin of the impulse and/or its subsequent propagation) in the heart.; Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.; Any cardiac rhythm other than the normal sinus rhythm. Such a rhythm may be either of sinus or ectopic origin and either regular or irregular. An arrhythmia may be due to a disturbance in impulse formation or conduction or both. [DDD:dbrown, PMID:19063792]; An arrhythmia is a problem with the rate or rhythm of your heartbeat. It means that your heart beats too quickly, too slowly, or with an irregular pattern. When the heart beats faster than normal, it is called tachycardia. When the heart beats too slowly, it is called bradycardia. The most common type of arrhythmia is atrial fibrillation, which treats an irregular and fast heart beat. Many factors can affect your heart's rhythm, such as having had a heart attack, smoking, congenital heart defects, and stress. Some substances or medicines may also cause arrhythmias.  Symptoms of arrhythmias include: Fast or slow heart beat Skipping beats Lightheadedness or dizziness Chest pain Shortness of breath  Sweating   Your doctor can run tests to find out if you have an arrhythmia. Treatment to restore a normal heart rhythm may include medicines, an implantable cardioverter-defibrillator (ICD) or pacemaker, or sometimes surgery.  NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "DOID:1969",
-            "HP:0100021",
-            "UMLS:C0007789",
-            "ICD10:G80",
-            "EFO:1000632",
-            "PSY:08280",
-            "MEDDRA:10008129",
-            "SNOMEDCT:128188000",
-            "MEDDRA:10033560",
-            "MONDO:0006497",
-            "MESH:D002547",
-            "NCIT:C34460"
-          ],
-          "id": "MONDO:0006497",
+            "SYMP:0000287",
+            "MEDDRA:10003120",
+            "UMLS:C1842820",
+            "MEDDRA:10007519",
+            "MEDDRA:10007520",
+            "MEDDRA:10019300",
+            "MESH:C562490",
+            "SNOMEDCT:698247007",
+            "UMLS:C1832603",
+            "UMLS:C1744601",
+            "MEDDRA:10010278",
+            "MEDDRA:10010279",
+            "UMLS:C0003811",
+            "MEDDRA:10003123",
+            "MEDDRA:10008396",
+            "SNOMEDCT:361136003",
+            "MESH:D001145",
+            "NCIT:C50543",
+            "MEDDRA:10014371",
+            "MESH:D000075224",
+            "MEDDRA:10003119",
+            "MONDO:0007263",
+            "MEDDRA:10003127",
+            "HP:0011675",
+            "MEDDRA:10010277",
+            "EFO:0004269",
+            "MEDDRA:10007545",
+            "MEDDRA:10007544",
+            "MEDDRA:10007518",
+            "MEDDRA:10007521",
+            "MEDDRA:10013978",
+            "SNOMEDCT:361135004",
+            "MEDDRA:10061116",
+            "NCIT:C2881",
+            "MEDDRA:10010276",
+            "UMLS:C0855329",
+            "MEDDRA:10000032",
+            "UMLS:C0264886"
+          ],
+          "id": "MONDO:0007263",
           "category": "biolink:Disease",
           "all_names": [
-            "Cerebral Palsy",
-            "cerebral palsy",
-            "Cerebral palsy"
+            "Arrhythmia",
+            "cardiac arrhythmia",
+            "Conduction disorder of the heart",
+            "Cardiac Conduction System Disease",
+            "Abnormal heart beat",
+            "Electrocardiogram change",
+            "Arrhythmias, Cardiac",
+            "Electrocardiographic Change",
+            "cardiac rhythm disease",
+            "Cardiac Arrhythmia",
+            "arrhythmia",
+            "Cardiac conduction abnormality"
           ],
           "all_categories": [
-            "biolink:Disease"
+            "biolink:Disease",
+            "biolink:PhenotypicFeature"
           ],
           "publications": [
-            "http://en.wikipedia.org/wiki/cerebral_palsy",
-            "http://www.brainandspinalcord.org/cerebral-palsy/index.htm",
-            "https://orcid.org/0009-0006-4530-3154",
-            "http://www.cerebralpalsy.org/what-is-cerebral-palsy/"
+            "PMID:19063792",
+            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=arrhythmia"
           ]
         }
       },
       "end": {
-        "identity": 458,
+        "identity": 554,
         "labels": [
+          "biolink:SmallMolecule",
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:MolecularEntity",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:InformationContentEntity"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C1138603",
-          "name": "Provider",
-          "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "NCIT:C37900",
-            "UMLS:C1138603",
-            "biolink:provider"
-          ],
-          "id": "UMLS:C1138603",
-          "category": "biolink:InformationContentEntity",
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
+          ],
+          "id": "PUBCHEM.COMPOUND:3672",
+          "category": "biolink:SmallMolecule",
           "all_names": [
-            "provider",
-            "Provider"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
-            "biolink:InformationContentEntity"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 315498,
+            "identity": 313359,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0006497",
-              "name": "cerebral palsy",
-              "description": "A group of disorders affecting the development of movement and posture, often accompanied by disturbances of sensation, perception, cognition, and behavior. It results from damage to the fetal or infant brain.; A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7); Cerebral palsy describes a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to nonprogressive disturbances that occurred in the developing fetal or infant brain. The motor disorders of cerebral palsy are often accompanied by disturbances of sensation, perception, cognition, communication, and behaviour, by epilepsy, and by secondary musculoskeletal problems. [HPO:sdoelken]; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0007263",
+              "name": "cardiac rhythm disease",
+              "description": "Any variation from the normal rate or rhythm (which may include the origin of the impulse and/or its subsequent propagation) in the heart.; Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.; Any cardiac rhythm other than the normal sinus rhythm. Such a rhythm may be either of sinus or ectopic origin and either regular or irregular. An arrhythmia may be due to a disturbance in impulse formation or conduction or both. [DDD:dbrown, PMID:19063792]; An arrhythmia is a problem with the rate or rhythm of your heartbeat. It means that your heart beats too quickly, too slowly, or with an irregular pattern. When the heart beats faster than normal, it is called tachycardia. When the heart beats too slowly, it is called bradycardia. The most common type of arrhythmia is atrial fibrillation, which treats an irregular and fast heart beat. Many factors can affect your heart's rhythm, such as having had a heart attack, smoking, congenital heart defects, and stress. Some substances or medicines may also cause arrhythmias.  Symptoms of arrhythmias include: Fast or slow heart beat Skipping beats Lightheadedness or dizziness Chest pain Shortness of breath  Sweating   Your doctor can run tests to find out if you have an arrhythmia. Treatment to restore a normal heart rhythm may include medicines, an implantable cardioverter-defibrillator (ICD) or pacemaker, or sometimes surgery.  NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "DOID:1969",
-                "HP:0100021",
-                "UMLS:C0007789",
-                "ICD10:G80",
-                "EFO:1000632",
-                "PSY:08280",
-                "MEDDRA:10008129",
-                "SNOMEDCT:128188000",
-                "MEDDRA:10033560",
-                "MONDO:0006497",
-                "MESH:D002547",
-                "NCIT:C34460"
-              ],
-              "id": "MONDO:0006497",
+                "SYMP:0000287",
+                "MEDDRA:10003120",
+                "UMLS:C1842820",
+                "MEDDRA:10007519",
+                "MEDDRA:10007520",
+                "MEDDRA:10019300",
+                "MESH:C562490",
+                "SNOMEDCT:698247007",
+                "UMLS:C1832603",
+                "UMLS:C1744601",
+                "MEDDRA:10010278",
+                "MEDDRA:10010279",
+                "UMLS:C0003811",
+                "MEDDRA:10003123",
+                "MEDDRA:10008396",
+                "SNOMEDCT:361136003",
+                "MESH:D001145",
+                "NCIT:C50543",
+                "MEDDRA:10014371",
+                "MESH:D000075224",
+                "MEDDRA:10003119",
+                "MONDO:0007263",
+                "MEDDRA:10003127",
+                "HP:0011675",
+                "MEDDRA:10010277",
+                "EFO:0004269",
+                "MEDDRA:10007545",
+                "MEDDRA:10007544",
+                "MEDDRA:10007518",
+                "MEDDRA:10007521",
+                "MEDDRA:10013978",
+                "SNOMEDCT:361135004",
+                "MEDDRA:10061116",
+                "NCIT:C2881",
+                "MEDDRA:10010276",
+                "UMLS:C0855329",
+                "MEDDRA:10000032",
+                "UMLS:C0264886"
+              ],
+              "id": "MONDO:0007263",
               "category": "biolink:Disease",
               "all_names": [
-                "Cerebral Palsy",
-                "cerebral palsy",
-                "Cerebral palsy"
+                "Arrhythmia",
+                "cardiac arrhythmia",
+                "Conduction disorder of the heart",
+                "Cardiac Conduction System Disease",
+                "Abnormal heart beat",
+                "Electrocardiogram change",
+                "Arrhythmias, Cardiac",
+                "Electrocardiographic Change",
+                "cardiac rhythm disease",
+                "Cardiac Arrhythmia",
+                "arrhythmia",
+                "Cardiac conduction abnormality"
               ],
               "all_categories": [
-                "biolink:Disease"
+                "biolink:Disease",
+                "biolink:PhenotypicFeature"
               ],
               "publications": [
-                "http://en.wikipedia.org/wiki/cerebral_palsy",
-                "http://www.brainandspinalcord.org/cerebral-palsy/index.htm",
-                "https://orcid.org/0009-0006-4530-3154",
-                "http://www.cerebralpalsy.org/what-is-cerebral-palsy/"
+                "PMID:19063792",
+                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=arrhythmia"
               ]
             }
           },
           "relationship": {
-            "identity": 16267262,
-            "start": 315498,
-            "end": 458,
+            "identity": 13371174,
+            "start": 554,
+            "end": 313359,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:23148525': {'publication date': '2012 Dec', 'sentence': 'This article describes the results of surveys completed by disability service providers and individuals with CCN due to cerebral palsy, developmental delay, and acquired disabilities.', 'subject score': 1000, 'object score': 840}}",
+              "domain_range_exclusion": "False",
+              "publications_info": "{'PMID:18358087': {'publication date': '2008 Apr', 'sentence': 'RESULTS: The ECG recording revealed that ibuprofen could induce arrhythmias, both in vitro and in vivo.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0007789---SEMMEDDB:treats---None---None---None---UMLS:C1138603---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0003811---SEMMEDDB:"
               ],
-              "subject": "MONDO:0006497",
-              "id": "16604884",
-              "object": "UMLS:C1138603",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "13658150",
+              "object": "MONDO:0007263",
               "publications": [
-                "PMID:23148525"
+                "PMID:18358087"
               ]
             }
           },
           "end": {
-            "identity": 458,
+            "identity": 554,
             "labels": [
+              "biolink:SmallMolecule",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:MolecularEntity",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:InformationContentEntity"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C1138603",
-              "name": "Provider",
-              "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "NCIT:C37900",
-                "UMLS:C1138603",
-                "biolink:provider"
-              ],
-              "id": "UMLS:C1138603",
-              "category": "biolink:InformationContentEntity",
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
+              ],
+              "id": "PUBCHEM.COMPOUND:3672",
+              "category": "biolink:SmallMolecule",
               "all_names": [
-                "provider",
-                "Provider"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
-                "biolink:InformationContentEntity"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -1254,7 +2018,7 @@
   {
     "p3": {
       "start": {
-        "identity": 546705,
+        "identity": 316638,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -1264,135 +2028,277 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005194",
-          "name": "Rotavirus infection",
-          "description": "Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice.; Rotavirus is a virus that treats gastroenteritis. Symptoms include severe diarrhea, vomiting, fever, and dehydration. Almost all children in the U.S. are likely to be infected with rotavirus before their 5th birthday. Infections happen most often in the winter and spring. It is very easy for children with the virus to spread it to other children and sometimes to adults. Once a child gets the virus, it takes about two days to become sick. Vomiting and diarrhea may last from three to eight days. There is no medicine to treat it. To prevent dehydration, have your child drink plenty of liquids. Your health care provider may recommend oral rehydration drinks. Some children need to go to the hospital for IV fluids. Two vaccines against rotavirus infections are available. Centers for Disease Control and Prevention; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
+          "name": "peptic ulcer disease",
+          "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "SNOMEDCT:18624000",
-            "EFO:0002622",
-            "MEDDRA:10067470",
-            "MESH:D012400",
-            "MONDO:0005194",
-            "UMLS:C0035869"
-          ],
-          "id": "MONDO:0005194",
+            "MEDDRA:10018053",
+            "MEDDRA:10045305",
+            "MESH:D010437",
+            "MONDO:0004247",
+            "DOID:750",
+            "UMLS:C0030920",
+            "MEDDRA:10017886",
+            "MEDDRA:10045342",
+            "ICD9:533",
+            "ICD10:K27",
+            "HP:0004398",
+            "MEDDRA:10034343",
+            "MEDDRA:10034360",
+            "MEDDRA:10045328",
+            "MEDDRA:10042834",
+            "MEDDRA:10034341",
+            "MEDDRA:10034367",
+            "MEDDRA:10037287",
+            "NCIT:C3318",
+            "SNOMEDCT:13200003",
+            "MEDDRA:10034369"
+          ],
+          "id": "MONDO:0004247",
           "category": "biolink:Disease",
           "all_names": [
-            "Rotavirus infection",
-            "Rotavirus Infections",
-            "rotavirus infection"
+            "Peptic ulcer, site unspecified",
+            "Peptic Ulcer",
+            "peptic ulcer disease",
+            "Peptic ulcer"
           ],
           "all_categories": [
             "biolink:Disease"
+          ],
+          "publications": [
+            "PMID:28242110",
+            "https://orcid.org/0000-0002-0736-9199",
+            "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
+            "https://orcid.org/0000-0002-6548-5200"
           ]
         }
       },
       "end": {
-        "identity": 458,
+        "identity": 554,
         "labels": [
+          "biolink:SmallMolecule",
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:MolecularEntity",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:InformationContentEntity"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C1138603",
-          "name": "Provider",
-          "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "NCIT:C37900",
-            "UMLS:C1138603",
-            "biolink:provider"
-          ],
-          "id": "UMLS:C1138603",
-          "category": "biolink:InformationContentEntity",
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
+          ],
+          "id": "PUBCHEM.COMPOUND:3672",
+          "category": "biolink:SmallMolecule",
           "all_names": [
-            "provider",
-            "Provider"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
-            "biolink:InformationContentEntity"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 546705,
+            "identity": 316638,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005194",
-              "name": "Rotavirus infection",
-              "description": "Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice.; Rotavirus is a virus that treats gastroenteritis. Symptoms include severe diarrhea, vomiting, fever, and dehydration. Almost all children in the U.S. are likely to be infected with rotavirus before their 5th birthday. Infections happen most often in the winter and spring. It is very easy for children with the virus to spread it to other children and sometimes to adults. Once a child gets the virus, it takes about two days to become sick. Vomiting and diarrhea may last from three to eight days. There is no medicine to treat it. To prevent dehydration, have your child drink plenty of liquids. Your health care provider may recommend oral rehydration drinks. Some children need to go to the hospital for IV fluids. Two vaccines against rotavirus infections are available. Centers for Disease Control and Prevention; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0004247",
+              "name": "peptic ulcer disease",
+              "description": "A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.; A well-known complication of GASTROENTEROSTOMY. These ulcers occur at the gastrojejunal anastomosis, mostly on the jejunal side.; The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel's diverticulum. Infection with Helicobacter pylori and the use of non steroidal antiinflammatory drugs (NSAIDs) or aspirin are the main risk factors of both gastric and duodenal peptic ulcers. [HPO:probinson, PMID:28242110]; A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain: Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks  Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse.  To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "SNOMEDCT:18624000",
-                "EFO:0002622",
-                "MEDDRA:10067470",
-                "MESH:D012400",
-                "MONDO:0005194",
-                "UMLS:C0035869"
-              ],
-              "id": "MONDO:0005194",
+                "MEDDRA:10018053",
+                "MEDDRA:10045305",
+                "MESH:D010437",
+                "MONDO:0004247",
+                "DOID:750",
+                "UMLS:C0030920",
+                "MEDDRA:10017886",
+                "MEDDRA:10045342",
+                "ICD9:533",
+                "ICD10:K27",
+                "HP:0004398",
+                "MEDDRA:10034343",
+                "MEDDRA:10034360",
+                "MEDDRA:10045328",
+                "MEDDRA:10042834",
+                "MEDDRA:10034341",
+                "MEDDRA:10034367",
+                "MEDDRA:10037287",
+                "NCIT:C3318",
+                "SNOMEDCT:13200003",
+                "MEDDRA:10034369"
+              ],
+              "id": "MONDO:0004247",
               "category": "biolink:Disease",
               "all_names": [
-                "Rotavirus infection",
-                "Rotavirus Infections",
-                "rotavirus infection"
+                "Peptic ulcer, site unspecified",
+                "Peptic Ulcer",
+                "peptic ulcer disease",
+                "Peptic ulcer"
               ],
               "all_categories": [
                 "biolink:Disease"
+              ],
+              "publications": [
+                "PMID:28242110",
+                "https://orcid.org/0000-0002-0736-9199",
+                "https://www.ncbi.nlm.nih.gov/books/nbk534792/",
+                "https://orcid.org/0000-0002-6548-5200"
               ]
             }
           },
           "relationship": {
-            "identity": 15614987,
-            "start": 546705,
-            "end": 458,
+            "identity": 12845671,
+            "start": 554,
+            "end": 316638,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:22037437': {'publication date': '2011 Sep', 'sentence': 'We estimated health provider costs, economic costs and quality-adjusted life years (QALYs) lost due to rotavirus infections.', 'subject score': 1000, 'object score': 888}}",
+              "domain_range_exclusion": "False",
+              "publications_info": "{'PMID:17504261': {'publication date': '2007 Jun', 'sentence': 'Protective effect of glucosamine against ibuprofen-induced peptic ulcer in rats.', 'subject score': 861, 'object score': 861}}",
               "kg2_ids": [
-                "UMLS:C0035869---SEMMEDDB:treats---None---None---None---UMLS:C1138603---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0030920---SEMMEDDB:"
               ],
-              "subject": "MONDO:0005194",
-              "id": "15941387",
-              "object": "UMLS:C1138603",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "13133316",
+              "object": "MONDO:0004247",
               "publications": [
-                "PMID:22037437"
+                "PMID:17504261"
               ]
             }
           },
           "end": {
-            "identity": 458,
+            "identity": 554,
             "labels": [
+              "biolink:SmallMolecule",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:MolecularEntity",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:InformationContentEntity"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C1138603",
-              "name": "Provider",
-              "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "NCIT:C37900",
-                "UMLS:C1138603",
-                "biolink:provider"
-              ],
-              "id": "UMLS:C1138603",
-              "category": "biolink:InformationContentEntity",
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
+              ],
+              "id": "PUBCHEM.COMPOUND:3672",
+              "category": "biolink:SmallMolecule",
               "all_names": [
-                "provider",
-                "Provider"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
-                "biolink:InformationContentEntity"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -1404,179 +2310,274 @@
   {
     "p3": {
       "start": {
-        "identity": 317079,
+        "identity": 212250,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
           "biolink:BiologicalEntity",
           "biolink:Disease",
           "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
+          "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012378",
-          "name": "Fatigue",
-          "description": "A subjective feeling of tiredness characterized by a lack of energy and motivation. [HPO:probinson]; A subjective feeling of tiredness characterized by a lack of energy and motivation. // COMMENTS: Fatigue is distinct from muscle weakness.; A subjective feeling of tiredness characterized by a lack of energy and motivation. // COMMENTS: Fatigue is distinct from muscle weakness.; A subjective feeling of tiredness characterized by a lack of energy and motivation. // COMMENTS: Fatigue is distinct from muscle weakness.; UMLS Semantic Type: STY:T184",
+          "iri": "http://purl.obolibrary.org/obo/HP_0001945",
+          "name": "Fever",
+          "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
           "equivalent_curies": [
-            "PSY:19400",
-            "SYMP:0019177",
-            "SNOMEDCT:84229001",
-            "MEDDRA:10016356",
-            "MEDDRA:10016256",
-            "NBO:0000569",
-            "MEDDRA:10043890",
-            "MEDDRA:10016257",
-            "MESH:D005221",
-            "UMLS:C0015672",
-            "PDQ:CDR0000041390",
-            "MEDDRA:10047871",
-            "NCIT:C3036",
-            "MEDDRA:10057841",
-            "MEDDRA:10043889",
-            "MEDDRA:10024862",
-            "HP:0012378",
-            "SNOMEDCT:248274002"
-          ],
-          "id": "HP:0012378",
+            "MEDDRA:10037660",
+            "MEDDRA:10020083",
+            "MEDDRA:10005911",
+            "UMLS:C0015967",
+            "HP:0001945",
+            "NCIT:C3038",
+            "MEDDRA:10073718",
+            "MEDDRA:10043204",
+            "MEDDRA:10037668",
+            "PDQ:CDR0000775882",
+            "PSY:19660",
+            "SNOMEDCT:386661006",
+            "MEDDRA:10016558",
+            "MEDDRA:10037663",
+            "SNOMEDCT:50177009",
+            "SYMP:0000613",
+            "MESH:D005334"
+          ],
+          "id": "HP:0001945",
           "category": "biolink:PhenotypicFeature",
           "all_names": [
-            "Fatigue",
-            "fatigue"
+            "fever",
+            "Fever"
           ],
           "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:BehavioralFeature"
+            "biolink:PhenotypicFeature"
           ],
           "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=fatigue",
-            "https://orcid.org/0000-0002-0736-9199"
+            "PMID:9759682",
+            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
+            "https://orcid.org/0009-0006-4530-3154"
           ]
         }
       },
       "end": {
-        "identity": 458,
+        "identity": 554,
         "labels": [
+          "biolink:SmallMolecule",
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:MolecularEntity",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:InformationContentEntity"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C1138603",
-          "name": "Provider",
-          "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "NCIT:C37900",
-            "UMLS:C1138603",
-            "biolink:provider"
-          ],
-          "id": "UMLS:C1138603",
-          "category": "biolink:InformationContentEntity",
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
+          ],
+          "id": "PUBCHEM.COMPOUND:3672",
+          "category": "biolink:SmallMolecule",
           "all_names": [
-            "provider",
-            "Provider"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
-            "biolink:InformationContentEntity"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 317079,
+            "identity": 212250,
             "labels": [
-              "biolink:BehavioralFeature",
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012378",
-              "name": "Fatigue",
-              "description": "A subjective feeling of tiredness characterized by a lack of energy and motivation. [HPO:probinson]; A subjective feeling of tiredness characterized by a lack of energy and motivation. // COMMENTS: Fatigue is distinct from muscle weakness.; A subjective feeling of tiredness characterized by a lack of energy and motivation. // COMMENTS: Fatigue is distinct from muscle weakness.; A subjective feeling of tiredness characterized by a lack of energy and motivation. // COMMENTS: Fatigue is distinct from muscle weakness.; UMLS Semantic Type: STY:T184",
+              "iri": "http://purl.obolibrary.org/obo/HP_0001945",
+              "name": "Fever",
+              "description": "Body temperature elevated above the normal range. [HPO:sdoelken, PMID:9759682]; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; Body temperature elevated above the normal range. // COMMENTS: Fever has been defined as a state of elevated core temperature, which is often, but not necessarily, part of the defensive responses of multicellular organisms (host) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host. The febrile response (of which fever is a component) is a complex physiologic reaction to disease, involving a cytokine-mediated rise in core temperature, generation of acute phase reactants, and activation of numerous physiologic, endocrinologic, and immunologic systems. The rise in temperature during fever is to be distinguished from that occurring during episodes of hyperthermia. Unlike fever, hyperthermia involves an unregulated rise in body temperature in which pyrogenic cytokines are not directly involved and against which standard antipyretics are ineffective. It represents a failure of thermoregulatory homeostasis, in which there is uncontrolled heat production, inadequate heat dissipation, or defective hypothalamic thermoregulation.; UMLS Semantic Type: STY:T184",
               "equivalent_curies": [
-                "PSY:19400",
-                "SYMP:0019177",
-                "SNOMEDCT:84229001",
-                "MEDDRA:10016356",
-                "MEDDRA:10016256",
-                "NBO:0000569",
-                "MEDDRA:10043890",
-                "MEDDRA:10016257",
-                "MESH:D005221",
-                "UMLS:C0015672",
-                "PDQ:CDR0000041390",
-                "MEDDRA:10047871",
-                "NCIT:C3036",
-                "MEDDRA:10057841",
-                "MEDDRA:10043889",
-                "MEDDRA:10024862",
-                "HP:0012378",
-                "SNOMEDCT:248274002"
-              ],
-              "id": "HP:0012378",
+                "MEDDRA:10037660",
+                "MEDDRA:10020083",
+                "MEDDRA:10005911",
+                "UMLS:C0015967",
+                "HP:0001945",
+                "NCIT:C3038",
+                "MEDDRA:10073718",
+                "MEDDRA:10043204",
+                "MEDDRA:10037668",
+                "PDQ:CDR0000775882",
+                "PSY:19660",
+                "SNOMEDCT:386661006",
+                "MEDDRA:10016558",
+                "MEDDRA:10037663",
+                "SNOMEDCT:50177009",
+                "SYMP:0000613",
+                "MESH:D005334"
+              ],
+              "id": "HP:0001945",
               "category": "biolink:PhenotypicFeature",
               "all_names": [
-                "Fatigue",
-                "fatigue"
+                "fever",
+                "Fever"
               ],
               "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:BehavioralFeature"
+                "biolink:PhenotypicFeature"
               ],
               "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=fatigue",
-                "https://orcid.org/0000-0002-0736-9199"
+                "PMID:9759682",
+                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=feve",
+                "https://orcid.org/0009-0006-4530-3154"
               ]
             }
           },
           "relationship": {
-            "identity": 14155507,
-            "start": 317079,
-            "end": 458,
+            "identity": 12373192,
+            "start": 554,
+            "end": 212250,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:19576676': {'publication date': '2009 Sep', 'sentence': 'It seems reasonable to alternate chest compression providers every 2 min, to prevent the loss of effective compressions due to fatigue and to minimise interruptions of chest compressions.', 'subject score': 1000, 'object score': 825}}",
+              "publications_info": "{'PMID:16889286': {'publication date': '2006', 'sentence': \"Ibuprofen-induced fever in Sjogren's syndrome.\", 'subject score': 851, 'object score': 851}, 'PMID:3867760': {'publication date': '1985 Dec', 'sentence': 'Ibuprofen prevents Pasteurella hemolytica endotoxin-induced changes in plasma prostanoids and serotonin, and fever in sheep.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0015672---SEMMEDDB:treats---None---None---None---UMLS:C1138603---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0015967---SEMMEDDB:"
               ],
-              "subject": "HP:0012378",
-              "id": "14457077",
-              "object": "UMLS:C1138603",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "12641386",
+              "object": "HP:0001945",
               "publications": [
-                "PMID:19576676"
+                "PMID:16889286",
+                "PMID:3867760"
               ]
             }
           },
           "end": {
-            "identity": 458,
+            "identity": 554,
             "labels": [
+              "biolink:SmallMolecule",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:MolecularEntity",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:InformationContentEntity"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C1138603",
-              "name": "Provider",
-              "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "NCIT:C37900",
-                "UMLS:C1138603",
-                "biolink:provider"
-              ],
-              "id": "UMLS:C1138603",
-              "category": "biolink:InformationContentEntity",
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
+              ],
+              "id": "PUBCHEM.COMPOUND:3672",
+              "category": "biolink:SmallMolecule",
               "all_names": [
-                "provider",
-                "Provider"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
-                "biolink:InformationContentEntity"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -1588,7 +2589,7 @@
   {
     "p3": {
       "start": {
-        "identity": 319383,
+        "identity": 308930,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -1598,162 +2599,278 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005098",
-          "name": "stroke disorder",
-          "description": "Sudden impairment of blood flow to a part of the brain due to occlusion or rupture of an artery to the brain. [HPO:probinson]; Sudden impairment of blood flow to a part of the brain due to occlusion or rupture of an artery to the brain.; Sudden impairment of blood flow to a part of the brain due to occlusion or rupture of an artery to the brain.; Sudden impairment of blood flow to a part of the brain due to occlusion or rupture of an artery to the brain.; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0003019",
+          "name": "potassium deficiency disease",
+          "description": "Lower than normal levels of potassium in the circulating blood.; Abnormally low potassium concentration in the blood. It may result from potassium loss by renal secretion or by the gastrointestinal route, as by vomiting or diarrhea. It may be manifested clinically by neuromuscular disorders ranging from weakness to paralysis, by electrocardiographic abnormalities (depression of the T wave and elevation of the U wave), by renal disease, and by gastrointestinal disorders. (Dorland, 27th ed); An abnormally decreased potassium concentration in the blood. [HPO:probinson]; UMLS Semantic Type: STY:T033",
           "equivalent_curies": [
-            "MEDDRA:10003004",
-            "MEDDRA:10011693",
-            "NCIT:C3390",
-            "HP:0001297",
-            "MEDDRA:10042244",
-            "MONDO:0005098",
-            "MEDDRA:10000374",
-            "MESH:D020521",
-            "SNOMEDCT:230690007",
-            "SYMP:0020056",
-            "MEDDRA:10008191",
-            "UMLS:C0038454",
-            "MEDDRA:10008190"
-          ],
-          "id": "MONDO:0005098",
+            "MONDO:0003019",
+            "SNOMEDCT:43339004",
+            "MEDDRA:10021015",
+            "UMLS:C1514284",
+            "UMLS:C0020621",
+            "MEDDRA:10024923",
+            "MEDDRA:10021020",
+            "HP:0002900",
+            "UMLS:C1971021",
+            "MESH:D007008",
+            "MEDDRA:10060423",
+            "NCIT:C37974",
+            "MEDDRA:10021080",
+            "DOID:4500",
+            "MEDDRA:10021017",
+            "SNOMEDCT:166690008",
+            "MEDDRA:10042817",
+            "UMLS:C0683388",
+            "NCIT:C34939",
+            "MEDDRA:10021081",
+            "MEDDRA:10021018"
+          ],
+          "id": "MONDO:0003019",
           "category": "biolink:Disease",
           "all_names": [
-            "cerebrovascular accident",
-            "Stroke",
-            "Cerebrovascular accident",
-            "stroke disorder"
+            "hypokalemia",
+            "Potassium depletion",
+            "potassium deficiency disease",
+            "Potassium Deficiency Disorder",
+            "Hypokalemia"
           ],
           "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
+            "biolink:Disease"
           ],
           "publications": [
-            "https://www.healthline.com/health/cerebrovascular-accident",
+            "https://orcid.org/0000-0001-6908-9849",
             "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 458,
+        "identity": 554,
         "labels": [
+          "biolink:SmallMolecule",
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:MolecularEntity",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:InformationContentEntity"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C1138603",
-          "name": "Provider",
-          "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "NCIT:C37900",
-            "UMLS:C1138603",
-            "biolink:provider"
-          ],
-          "id": "UMLS:C1138603",
-          "category": "biolink:InformationContentEntity",
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
+          ],
+          "id": "PUBCHEM.COMPOUND:3672",
+          "category": "biolink:SmallMolecule",
           "all_names": [
-            "provider",
-            "Provider"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
-            "biolink:InformationContentEntity"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 319383,
+            "identity": 308930,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005098",
-              "name": "stroke disorder",
-              "description": "Sudden impairment of blood flow to a part of the brain due to occlusion or rupture of an artery to the brain. [HPO:probinson]; Sudden impairment of blood flow to a part of the brain due to occlusion or rupture of an artery to the brain.; Sudden impairment of blood flow to a part of the brain due to occlusion or rupture of an artery to the brain.; Sudden impairment of blood flow to a part of the brain due to occlusion or rupture of an artery to the brain.; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0003019",
+              "name": "potassium deficiency disease",
+              "description": "Lower than normal levels of potassium in the circulating blood.; Abnormally low potassium concentration in the blood. It may result from potassium loss by renal secretion or by the gastrointestinal route, as by vomiting or diarrhea. It may be manifested clinically by neuromuscular disorders ranging from weakness to paralysis, by electrocardiographic abnormalities (depression of the T wave and elevation of the U wave), by renal disease, and by gastrointestinal disorders. (Dorland, 27th ed); An abnormally decreased potassium concentration in the blood. [HPO:probinson]; UMLS Semantic Type: STY:T033",
               "equivalent_curies": [
-                "MEDDRA:10003004",
-                "MEDDRA:10011693",
-                "NCIT:C3390",
-                "HP:0001297",
-                "MEDDRA:10042244",
-                "MONDO:0005098",
-                "MEDDRA:10000374",
-                "MESH:D020521",
-                "SNOMEDCT:230690007",
-                "SYMP:0020056",
-                "MEDDRA:10008191",
-                "UMLS:C0038454",
-                "MEDDRA:10008190"
-              ],
-              "id": "MONDO:0005098",
+                "MONDO:0003019",
+                "SNOMEDCT:43339004",
+                "MEDDRA:10021015",
+                "UMLS:C1514284",
+                "UMLS:C0020621",
+                "MEDDRA:10024923",
+                "MEDDRA:10021020",
+                "HP:0002900",
+                "UMLS:C1971021",
+                "MESH:D007008",
+                "MEDDRA:10060423",
+                "NCIT:C37974",
+                "MEDDRA:10021080",
+                "DOID:4500",
+                "MEDDRA:10021017",
+                "SNOMEDCT:166690008",
+                "MEDDRA:10042817",
+                "UMLS:C0683388",
+                "NCIT:C34939",
+                "MEDDRA:10021081",
+                "MEDDRA:10021018"
+              ],
+              "id": "MONDO:0003019",
               "category": "biolink:Disease",
               "all_names": [
-                "cerebrovascular accident",
-                "Stroke",
-                "Cerebrovascular accident",
-                "stroke disorder"
+                "hypokalemia",
+                "Potassium depletion",
+                "potassium deficiency disease",
+                "Potassium Deficiency Disorder",
+                "Hypokalemia"
               ],
               "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
+                "biolink:Disease"
               ],
               "publications": [
-                "https://www.healthline.com/health/cerebrovascular-accident",
+                "https://orcid.org/0000-0001-6908-9849",
                 "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 13297790,
-            "start": 319383,
-            "end": 458,
+            "identity": 11326256,
+            "start": 554,
+            "end": 308930,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:18257791': {'publication date': '2008 Mar', 'sentence': \"Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.\", 'subject score': 1000, 'object score': 890}, 'PMID:27188815': {'publication date': '2016 05 17', 'sentence': 'CONCLUSIONS: Primary and emergency care providers need to review how they can best handle patients presenting with symptoms that could be due to stroke or TIA.', 'subject score': 1000, 'object score': 890}}",
+              "publications_info": "{'PMID:15605674': {'publication date': '2004 Nov', 'sentence': 'Ibuprofen is generally not included in a standard toxicology screen, but should be considered as a rare cause of hypokalaemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:24829833': {'publication date': '2013', 'sentence': \"Ibuprofen-Induced Hypokalemia and Distal Renal Tubular Acidosis: A Patient's Perceptions of Over-the-Counter Medications and Their Adverse Effects.\", 'subject score': 851, 'object score': 851}, 'PMID:31970034': {'publication date': '2019 Dec 17', 'sentence': 'Ibuprofen is well-known for its various nephrotoxic side effects, including hyperkalemia as a common electrolyte abnormality, however, renal tubular acidosis leading to hypokalemia with the use of ibuprofen has been reported rarely.', 'subject score': 1000, 'object score': 1000}, 'PMID:35135381': {'publication date': '2022 Feb 08', 'sentence': 'CONCLUSIONS: These data highlight the potential of ibuprofen to occasionally induce hypokalemia and acidosis of renal origin.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0038454---SEMMEDDB:treats---None---None---None---UMLS:C1138603---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0020621---SEMMEDDB:"
               ],
-              "subject": "MONDO:0005098",
-              "id": "13583178",
-              "object": "UMLS:C1138603",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "11574148",
+              "object": "MONDO:0003019",
               "publications": [
-                "PMID:18257791",
-                "PMID:27188815"
+                "PMID:15605674",
+                "PMID:24829833",
+                "PMID:31970034",
+                "PMID:35135381"
               ]
             }
           },
           "end": {
-            "identity": 458,
+            "identity": 554,
             "labels": [
+              "biolink:SmallMolecule",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:MolecularEntity",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:InformationContentEntity"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C1138603",
-              "name": "Provider",
-              "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "NCIT:C37900",
-                "UMLS:C1138603",
-                "biolink:provider"
-              ],
-              "id": "UMLS:C1138603",
-              "category": "biolink:InformationContentEntity",
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
+              ],
+              "id": "PUBCHEM.COMPOUND:3672",
+              "category": "biolink:SmallMolecule",
               "all_names": [
-                "provider",
-                "Provider"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
-                "biolink:InformationContentEntity"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -1765,7 +2882,7 @@
   {
     "p3": {
       "start": {
-        "identity": 517178,
+        "identity": 320409,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -1775,175 +2892,283 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005087",
-          "name": "respiratory system disorder",
-          "description": "A non-neoplastic or neoplastic disorder that affects the respiratory system. Representative examples include pneumonia, chronic obstructive pulmonary disease, pulmonary failure, lung adenoma, lung carcinoma, and tracheal carcinoma.; Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0004242",
+          "name": "active peptic ulcer disease",
+          "description": "Bleeding originating from any part of the gastrointestinal tract.; The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.; Hemorrhage affecting the gastrointestinal tract. [HPO:probinson]",
           "equivalent_curies": [
-            "DOID:1579",
-            "NCIT:C26871",
-            "ICD10:J98",
-            "UMLS:C0035242",
-            "UMLS:C0035204",
-            "MEDDRA:10083321",
-            "MEDDRA:10038719",
-            "UMLS:C0029582",
-            "MONDO:0005087",
-            "MESH:D012120",
-            "MESH:D012140",
-            "MEDDRA:10038683",
-            "MEDDRA:10038684",
-            "ICD9:519",
-            "EFO:0000684",
-            "ICD9:510-519.99",
-            "MEDDRA:10045755",
-            "SNOMEDCT:50043002"
-          ],
-          "id": "MONDO:0005087",
+            "MONDO:0004242",
+            "MEDDRA:10005116",
+            "MEDDRA:10018016",
+            "MEDDRA:10017935",
+            "MEDDRA:10055809",
+            "MEDDRA:10052742",
+            "MEDDRA:10017936",
+            "MEDDRA:10018233",
+            "DOID:749",
+            "MEDDRA:10018243",
+            "MEDDRA:10018230",
+            "SNOMEDCT:74474003",
+            "MEDDRA:10017956",
+            "UMLS:C0017181",
+            "HP:0002239",
+            "MEDDRA:10017878",
+            "MEDDRA:10018991",
+            "MEDDRA:10019543",
+            "MEDDRA:10018992",
+            "MESH:D006471",
+            "MEDDRA:10018232",
+            "MEDDRA:10055270",
+            "MEDDRA:10019566",
+            "NCIT:C48592",
+            "MEDDRA:10017871",
+            "MEDDRA:10017960",
+            "MEDDRA:10017870",
+            "MEDDRA:10017955"
+          ],
+          "id": "MONDO:0004242",
           "category": "biolink:Disease",
           "all_names": [
-            "Respiratory System Disorder",
-            "Other diseases of respiratory system",
-            "respiratory system disease",
-            "Other respiratory system diseases",
-            "Respiratory Tract Diseases",
-            "Respiration Disorders",
-            "respiratory system disorder"
+            "Gastrointestinal hemorrhage",
+            "Gastrointestinal Hemorrhage",
+            "active peptic ulcer disease"
           ],
           "all_categories": [
             "biolink:Disease"
           ],
           "publications": [
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=respiratory%20system",
-            "http://en.wikipedia.org/wiki/file:respiratory_system_complete_en.svg"
+            "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 458,
+        "identity": 554,
         "labels": [
+          "biolink:SmallMolecule",
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:MolecularEntity",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:InformationContentEntity"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C1138603",
-          "name": "Provider",
-          "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "NCIT:C37900",
-            "UMLS:C1138603",
-            "biolink:provider"
-          ],
-          "id": "UMLS:C1138603",
-          "category": "biolink:InformationContentEntity",
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
+          ],
+          "id": "PUBCHEM.COMPOUND:3672",
+          "category": "biolink:SmallMolecule",
           "all_names": [
-            "provider",
-            "Provider"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
-            "biolink:InformationContentEntity"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 517178,
+            "identity": 320409,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005087",
-              "name": "respiratory system disorder",
-              "description": "A non-neoplastic or neoplastic disorder that affects the respiratory system. Representative examples include pneumonia, chronic obstructive pulmonary disease, pulmonary failure, lung adenoma, lung carcinoma, and tracheal carcinoma.; Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0004242",
+              "name": "active peptic ulcer disease",
+              "description": "Bleeding originating from any part of the gastrointestinal tract.; The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.; Hemorrhage affecting the gastrointestinal tract. [HPO:probinson]",
               "equivalent_curies": [
-                "DOID:1579",
-                "NCIT:C26871",
-                "ICD10:J98",
-                "UMLS:C0035242",
-                "UMLS:C0035204",
-                "MEDDRA:10083321",
-                "MEDDRA:10038719",
-                "UMLS:C0029582",
-                "MONDO:0005087",
-                "MESH:D012120",
-                "MESH:D012140",
-                "MEDDRA:10038683",
-                "MEDDRA:10038684",
-                "ICD9:519",
-                "EFO:0000684",
-                "ICD9:510-519.99",
-                "MEDDRA:10045755",
-                "SNOMEDCT:50043002"
-              ],
-              "id": "MONDO:0005087",
+                "MONDO:0004242",
+                "MEDDRA:10005116",
+                "MEDDRA:10018016",
+                "MEDDRA:10017935",
+                "MEDDRA:10055809",
+                "MEDDRA:10052742",
+                "MEDDRA:10017936",
+                "MEDDRA:10018233",
+                "DOID:749",
+                "MEDDRA:10018243",
+                "MEDDRA:10018230",
+                "SNOMEDCT:74474003",
+                "MEDDRA:10017956",
+                "UMLS:C0017181",
+                "HP:0002239",
+                "MEDDRA:10017878",
+                "MEDDRA:10018991",
+                "MEDDRA:10019543",
+                "MEDDRA:10018992",
+                "MESH:D006471",
+                "MEDDRA:10018232",
+                "MEDDRA:10055270",
+                "MEDDRA:10019566",
+                "NCIT:C48592",
+                "MEDDRA:10017871",
+                "MEDDRA:10017960",
+                "MEDDRA:10017870",
+                "MEDDRA:10017955"
+              ],
+              "id": "MONDO:0004242",
               "category": "biolink:Disease",
               "all_names": [
-                "Respiratory System Disorder",
-                "Other diseases of respiratory system",
-                "respiratory system disease",
-                "Other respiratory system diseases",
-                "Respiratory Tract Diseases",
-                "Respiration Disorders",
-                "respiratory system disorder"
+                "Gastrointestinal hemorrhage",
+                "Gastrointestinal Hemorrhage",
+                "active peptic ulcer disease"
               ],
               "all_categories": [
                 "biolink:Disease"
               ],
               "publications": [
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=respiratory%20system",
-                "http://en.wikipedia.org/wiki/file:respiratory_system_complete_en.svg"
+                "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 13297789,
-            "start": 517178,
-            "end": 458,
+            "identity": 10932991,
+            "start": 554,
+            "end": 320409,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:18257791': {'publication date': '2008 Mar', 'sentence': \"Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.\", 'subject score': 1000, 'object score': 890}}",
+              "domain_range_exclusion": "False",
+              "publications_info": "{'PMID:1511542': {'publication date': '1992 Aug', 'sentence': 'Data on individual drugs are inconsistent, but they suggest that enteric-coated aspirin, salsalate, and ibuprofen cause the lowest incidence of GI hemorrhage.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0035204---SEMMEDDB:treats---None---None---None---UMLS:C1138603---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0017181---SEMMEDDB:"
               ],
-              "subject": "MONDO:0005087",
-              "id": "13583177",
-              "object": "UMLS:C1138603",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "11172255",
+              "object": "MONDO:0004242",
               "publications": [
-                "PMID:18257791"
+                "PMID:1511542"
               ]
             }
           },
           "end": {
-            "identity": 458,
+            "identity": 554,
             "labels": [
+              "biolink:SmallMolecule",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:MolecularEntity",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:InformationContentEntity"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C1138603",
-              "name": "Provider",
-              "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "NCIT:C37900",
-                "UMLS:C1138603",
-                "biolink:provider"
-              ],
-              "id": "UMLS:C1138603",
-              "category": "biolink:InformationContentEntity",
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
+              ],
+              "id": "PUBCHEM.COMPOUND:3672",
+              "category": "biolink:SmallMolecule",
               "all_names": [
-                "provider",
-                "Provider"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
-                "biolink:InformationContentEntity"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -1955,7 +3180,7 @@
   {
     "p3": {
       "start": {
-        "identity": 517803,
+        "identity": 316891,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -1965,171 +3190,251 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005267",
-          "name": "heart disorder",
-          "description": "A non-neoplastic or neoplastic disorder that affects the heart and/or the pericardium. Representative examples include endocarditis, pericarditis, atrial myxoma, cardiac myeloid sarcoma, and pericardial malignant mesothelioma.; Pathological conditions involving the HEART including its structural and functional abnormalities.; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
+          "name": "Pain",
+          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
           "equivalent_curies": [
-            "MEDDRA:10019276",
-            "MEDDRA:10013199",
-            "ICD10:I51.9",
-            "ICD9:429.9",
-            "MEDDRA:10019277",
-            "UMLS:C0018799",
-            "UMLS:CN239852",
-            "DOID:114",
-            "MESH:D006331",
-            "EFO:0003777",
-            "MONDO:0005267",
-            "MEDDRA:10061024",
-            "UMLS:CN236661",
-            "MEDDRA:10007540",
-            "NCIT:C3079",
-            "MEDDRA:10007541",
-            "SNOMEDCT:56265001"
-          ],
-          "id": "MONDO:0005267",
-          "category": "biolink:Disease",
+            "MESH:D010146",
+            "SYMP:0000099",
+            "UMLS:C0030193",
+            "ICD9:338-338.99",
+            "PSY:36150",
+            "SNOMEDCT:22253000",
+            "NCIT:C3303",
+            "MEDDRA:10033470",
+            "MEDDRA:10033371",
+            "HP:0012531",
+            "PDQ:CDR0000041399"
+          ],
+          "id": "HP:0012531",
+          "category": "biolink:PhenotypicFeature",
           "all_names": [
-            "Heart disease, unspecified",
-            "Heart Diseases",
-            "Heart Disorder",
-            "heart disease",
-            "heart disorder"
+            "pain",
+            "Pain"
           ],
           "all_categories": [
-            "biolink:Disease"
+            "biolink:PhenotypicFeature"
           ],
           "publications": [
-            "http://en.wikipedia.org/wiki/heart_disease",
-            "https://orcid.org/0000-0002-6601-2165",
-            "https://github.com/monarch-initiative/mondo/issues/1189"
+            "https://orcid.org/0000-0001-5208-3432",
+            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
           ]
         }
       },
       "end": {
-        "identity": 458,
+        "identity": 554,
         "labels": [
+          "biolink:SmallMolecule",
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:MolecularEntity",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:InformationContentEntity"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C1138603",
-          "name": "Provider",
-          "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "NCIT:C37900",
-            "UMLS:C1138603",
-            "biolink:provider"
-          ],
-          "id": "UMLS:C1138603",
-          "category": "biolink:InformationContentEntity",
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
+          ],
+          "id": "PUBCHEM.COMPOUND:3672",
+          "category": "biolink:SmallMolecule",
           "all_names": [
-            "provider",
-            "Provider"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
-            "biolink:InformationContentEntity"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 517803,
+            "identity": 316891,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005267",
-              "name": "heart disorder",
-              "description": "A non-neoplastic or neoplastic disorder that affects the heart and/or the pericardium. Representative examples include endocarditis, pericarditis, atrial myxoma, cardiac myeloid sarcoma, and pericardial malignant mesothelioma.; Pathological conditions involving the HEART including its structural and functional abnormalities.; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
+              "name": "Pain",
+              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
               "equivalent_curies": [
-                "MEDDRA:10019276",
-                "MEDDRA:10013199",
-                "ICD10:I51.9",
-                "ICD9:429.9",
-                "MEDDRA:10019277",
-                "UMLS:C0018799",
-                "UMLS:CN239852",
-                "DOID:114",
-                "MESH:D006331",
-                "EFO:0003777",
-                "MONDO:0005267",
-                "MEDDRA:10061024",
-                "UMLS:CN236661",
-                "MEDDRA:10007540",
-                "NCIT:C3079",
-                "MEDDRA:10007541",
-                "SNOMEDCT:56265001"
-              ],
-              "id": "MONDO:0005267",
-              "category": "biolink:Disease",
+                "MESH:D010146",
+                "SYMP:0000099",
+                "UMLS:C0030193",
+                "ICD9:338-338.99",
+                "PSY:36150",
+                "SNOMEDCT:22253000",
+                "NCIT:C3303",
+                "MEDDRA:10033470",
+                "MEDDRA:10033371",
+                "HP:0012531",
+                "PDQ:CDR0000041399"
+              ],
+              "id": "HP:0012531",
+              "category": "biolink:PhenotypicFeature",
               "all_names": [
-                "Heart disease, unspecified",
-                "Heart Diseases",
-                "Heart Disorder",
-                "heart disease",
-                "heart disorder"
+                "pain",
+                "Pain"
               ],
               "all_categories": [
-                "biolink:Disease"
+                "biolink:PhenotypicFeature"
               ],
               "publications": [
-                "http://en.wikipedia.org/wiki/heart_disease",
-                "https://orcid.org/0000-0002-6601-2165",
-                "https://github.com/monarch-initiative/mondo/issues/1189"
+                "https://orcid.org/0000-0001-5208-3432",
+                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
               ]
             }
           },
           "relationship": {
-            "identity": 13297788,
-            "start": 517803,
-            "end": 458,
+            "identity": 10918360,
+            "start": 554,
+            "end": 316891,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:18257791': {'publication date': '2008 Mar', 'sentence': \"Thus, families must increasingly partner with health service providers to promote their child's health and prevent the development of secondary conditions that may contribute to heart disease, stroke, respiratory diseases, low endurance and emotional difficulties.\", 'subject score': 1000, 'object score': 890}}",
+              "domain_range_exclusion": "False",
+              "publications_info": "{'PMID:1509971': {'publication date': '1992 Jan', 'sentence': 'In a double-blind cross-over study on 22 healthy subjects the analgesic efficacies of the antipyretic analgesic drugs ibuprofen, dipyrone and paracetamol were tested against placebo using a model of experimentally induced pain.', 'subject score': 861, 'object score': 790}, 'PMID:29707018': {'publication date': '2018', 'sentence': 'Conclusion: Pre-medication with ibuprofen resulted in less pain following pulpotomy and SSC placement in primary teeth.', 'subject score': 1000, 'object score': 861}, 'PMID:31112677': {'publication date': '2019 Oct', 'sentence': 'CONCLUSIONS: The present study has shown that the preemptive use of IV ibuprofen resulted in less pain and a decrease in the requirement for rescue analgesia during the first 24 hours after third molar surgery.', 'subject score': 888, 'object score': 861}}",
               "kg2_ids": [
-                "UMLS:C0018799---SEMMEDDB:treats---None---None---None---UMLS:C1138603---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0030193---SEMMEDDB:"
               ],
-              "subject": "MONDO:0005267",
-              "id": "13583176",
-              "object": "UMLS:C1138603",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "11157616",
+              "object": "HP:0012531",
               "publications": [
-                "PMID:18257791"
+                "PMID:1509971",
+                "PMID:29707018",
+                "PMID:31112677"
               ]
             }
           },
           "end": {
-            "identity": 458,
+            "identity": 554,
             "labels": [
+              "biolink:SmallMolecule",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:MolecularEntity",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:InformationContentEntity"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C1138603",
-              "name": "Provider",
-              "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "NCIT:C37900",
-                "UMLS:C1138603",
-                "biolink:provider"
-              ],
-              "id": "UMLS:C1138603",
-              "category": "biolink:InformationContentEntity",
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
+              ],
+              "id": "PUBCHEM.COMPOUND:3672",
+              "category": "biolink:SmallMolecule",
               "all_names": [
-                "provider",
-                "Provider"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
-                "biolink:InformationContentEntity"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -2141,7 +3446,7 @@
   {
     "p3": {
       "start": {
-        "identity": 321528,
+        "identity": 319321,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -2151,211 +3456,253 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-          "name": "asthma",
-          "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/HP_0001259",
+          "name": "Coma",
+          "description": "A state of profound unconsciousness associated with markedly depressed cerebral activity. treats include central nervous system damage, intoxication, and metabolic abnormalities.; A profound state of unconsciousness associated with depressed cerebral activity from which the individual cannot be aroused. Coma generally occurs when there is dysfunction or injury involving both cerebral hemispheres or the brain stem RETICULAR FORMATION.; Complete absence of wakefulness and content of conscience, which manifests itself as a lack of response to any kind of external stimuli. [HPO:probinson]; A coma is a deep state of unconsciousness. An individual in a coma is alive but unable to move or respond to his or her environment. Coma may occur as a complication of an underlying illness, or as a result of injuries, such as brain injury. A coma rarely lasts more than 2 to 4 weeks. The outcome for coma depends on the cause, severity, and site of the damage. People may come out of a coma with physical, intellectual, and psychological problems. Some people may remain in a coma for years or even decades. For those people, the most common cause of death is infection, such as pneumonia. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "SNOMEDCT:991000119106",
-            "UMLS:C0085129",
-            "MEDDRA:10003553",
-            "MEDDRA:10037993",
-            "MEDDRA:10003560",
-            "HP:0002099",
-            "MEDDRA:10066091",
-            "UMLS:C1869116",
-            "OMIM:600807",
-            "EFO:0000270",
-            "PSY:04190",
-            "KEGG.DISEASE:05310",
-            "MEDDRA:10056285",
-            "MEDDRA:10003555",
-            "MEDDRA:10082852",
-            "MONDO:0004979",
-            "UMLS:C0004096",
-            "MEDDRA:10066863",
-            "UMLS:C3714497",
-            "MESH:D001249",
-            "UMLS:C1833269",
-            "ICD9:493",
-            "MESH:D016535",
-            "UMLS:C1833270",
-            "NCIT:C28397",
-            "MEDDRA:10006450",
-            "ICD10:J45",
-            "MEDDRA:10003565",
-            "MEDDRA:10003561",
-            "UMLS:C0340062",
-            "SNOMEDCT:195967001",
-            "DOID:2841"
-          ],
-          "id": "MONDO:0004979",
-          "category": "biolink:Disease",
+            "MEDDRA:10010071",
+            "MEDDRA:10058472",
+            "ICD9:780.01",
+            "MEDDRA:10010081",
+            "HP:0001259",
+            "UMLS:C0009421",
+            "SYMP:0000605",
+            "SNOMEDCT:371632003",
+            "MESH:D003128",
+            "NCIT:C34497",
+            "PSY:10450"
+          ],
+          "id": "HP:0001259",
+          "category": "biolink:PhenotypicFeature",
           "all_names": [
-            "Asthma, diminished response to antileukotriene treatment in",
-            "asthma",
-            "Reactive airway disease",
-            "Bronchial Hyperreactivity",
-            "obsolete_asthma",
-            "Asthma",
-            "Asthma, susceptibility to related phenotypic feature",
-            "ASTHMA, SUSCEPTIBILITY TO (finding)",
-            "Asthma, protection against"
+            "Comatose",
+            "coma",
+            "Coma"
           ],
           "all_categories": [
+            "biolink:PhenotypicFeature",
             "biolink:Disease"
           ],
           "publications": [
-            "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-            "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-            "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
+            "https://en.wikipedia.org/wiki/coma",
             "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 458,
+        "identity": 554,
         "labels": [
+          "biolink:SmallMolecule",
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:MolecularEntity",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:InformationContentEntity"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C1138603",
-          "name": "Provider",
-          "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "NCIT:C37900",
-            "UMLS:C1138603",
-            "biolink:provider"
-          ],
-          "id": "UMLS:C1138603",
-          "category": "biolink:InformationContentEntity",
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
+          ],
+          "id": "PUBCHEM.COMPOUND:3672",
+          "category": "biolink:SmallMolecule",
           "all_names": [
-            "provider",
-            "Provider"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
-            "biolink:InformationContentEntity"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 321528,
+            "identity": 319321,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004979",
-              "name": "asthma",
-              "description": "Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing. [HPO:probinson]; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; Asthma is characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli, leading to narrowing of the air passages with resultant dyspnea, cough, and wheezing.; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/HP_0001259",
+              "name": "Coma",
+              "description": "A state of profound unconsciousness associated with markedly depressed cerebral activity. treats include central nervous system damage, intoxication, and metabolic abnormalities.; A profound state of unconsciousness associated with depressed cerebral activity from which the individual cannot be aroused. Coma generally occurs when there is dysfunction or injury involving both cerebral hemispheres or the brain stem RETICULAR FORMATION.; Complete absence of wakefulness and content of conscience, which manifests itself as a lack of response to any kind of external stimuli. [HPO:probinson]; A coma is a deep state of unconsciousness. An individual in a coma is alive but unable to move or respond to his or her environment. Coma may occur as a complication of an underlying illness, or as a result of injuries, such as brain injury. A coma rarely lasts more than 2 to 4 weeks. The outcome for coma depends on the cause, severity, and site of the damage. People may come out of a coma with physical, intellectual, and psychological problems. Some people may remain in a coma for years or even decades. For those people, the most common cause of death is infection, such as pneumonia. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "SNOMEDCT:991000119106",
-                "UMLS:C0085129",
-                "MEDDRA:10003553",
-                "MEDDRA:10037993",
-                "MEDDRA:10003560",
-                "HP:0002099",
-                "MEDDRA:10066091",
-                "UMLS:C1869116",
-                "OMIM:600807",
-                "EFO:0000270",
-                "PSY:04190",
-                "KEGG.DISEASE:05310",
-                "MEDDRA:10056285",
-                "MEDDRA:10003555",
-                "MEDDRA:10082852",
-                "MONDO:0004979",
-                "UMLS:C0004096",
-                "MEDDRA:10066863",
-                "UMLS:C3714497",
-                "MESH:D001249",
-                "UMLS:C1833269",
-                "ICD9:493",
-                "MESH:D016535",
-                "UMLS:C1833270",
-                "NCIT:C28397",
-                "MEDDRA:10006450",
-                "ICD10:J45",
-                "MEDDRA:10003565",
-                "MEDDRA:10003561",
-                "UMLS:C0340062",
-                "SNOMEDCT:195967001",
-                "DOID:2841"
-              ],
-              "id": "MONDO:0004979",
-              "category": "biolink:Disease",
+                "MEDDRA:10010071",
+                "MEDDRA:10058472",
+                "ICD9:780.01",
+                "MEDDRA:10010081",
+                "HP:0001259",
+                "UMLS:C0009421",
+                "SYMP:0000605",
+                "SNOMEDCT:371632003",
+                "MESH:D003128",
+                "NCIT:C34497",
+                "PSY:10450"
+              ],
+              "id": "HP:0001259",
+              "category": "biolink:PhenotypicFeature",
               "all_names": [
-                "Asthma, diminished response to antileukotriene treatment in",
-                "asthma",
-                "Reactive airway disease",
-                "Bronchial Hyperreactivity",
-                "obsolete_asthma",
-                "Asthma",
-                "Asthma, susceptibility to related phenotypic feature",
-                "ASTHMA, SUSCEPTIBILITY TO (finding)",
-                "Asthma, protection against"
+                "Comatose",
+                "coma",
+                "Coma"
               ],
               "all_categories": [
+                "biolink:PhenotypicFeature",
                 "biolink:Disease"
               ],
               "publications": [
-                "http://www.nhlbi.nih.gov/health/dci/diseases/asthma/asthma_whatis.htm",
-                "https://www.ncbi.nlm.nih.gov/books/nbk430901/",
-                "https://www.ncbi.nlm.nih.gov/books/nbk7223/",
+                "https://en.wikipedia.org/wiki/coma",
                 "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 13153326,
-            "start": 321528,
-            "end": 458,
+            "identity": 9837824,
+            "start": 554,
+            "end": 319321,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:17994398': {'publication date': '2007 Nov', 'sentence': 'CAEs often advised callers (> 75%) to return to their asthma provider for assistance as a result of uncontrolled asthma, medication concerns, a questionable diagnosis, or the need for an action plan.', 'subject score': 888, 'object score': 888}}",
+              "domain_range_exclusion": "False",
+              "publications_info": "{'PMID:12614377': {'publication date': '2003 Mar', 'sentence': \"Hyponatraemic coma induced by desmopressin and ibuprofen in a woman with von Willebrand's disease.\", 'subject score': 1000, 'object score': 888}}",
               "kg2_ids": [
-                "UMLS:C0004096---SEMMEDDB:treats---None---None---None---UMLS:C1138603---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0009421---SEMMEDDB:"
               ],
-              "subject": "MONDO:0004979",
-              "id": "13436217",
-              "object": "UMLS:C1138603",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "10060263",
+              "object": "HP:0001259",
               "publications": [
-                "PMID:17994398"
+                "PMID:12614377"
               ]
             }
           },
           "end": {
-            "identity": 458,
+            "identity": 554,
             "labels": [
+              "biolink:SmallMolecule",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:MolecularEntity",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:InformationContentEntity"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C1138603",
-              "name": "Provider",
-              "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "NCIT:C37900",
-                "UMLS:C1138603",
-                "biolink:provider"
-              ],
-              "id": "UMLS:C1138603",
-              "category": "biolink:InformationContentEntity",
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
+              ],
+              "id": "PUBCHEM.COMPOUND:3672",
+              "category": "biolink:SmallMolecule",
               "all_names": [
-                "provider",
-                "Provider"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
-                "biolink:InformationContentEntity"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -2367,7 +3714,7 @@
   {
     "p3": {
       "start": {
-        "identity": 316891,
+        "identity": 313324,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -2377,152 +3724,273 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-          "name": "Pain",
-          "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
+          "iri": "http://purl.obolibrary.org/obo/HP_0000969",
+          "name": "Edema",
+          "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
           "equivalent_curies": [
-            "MESH:D010146",
-            "SYMP:0000099",
-            "UMLS:C0030193",
-            "ICD9:338-338.99",
-            "PSY:36150",
-            "SNOMEDCT:22253000",
-            "NCIT:C3303",
-            "MEDDRA:10033470",
-            "MEDDRA:10033371",
-            "HP:0012531",
-            "PDQ:CDR0000041399"
-          ],
-          "id": "HP:0012531",
+            "MEDDRA:10030114",
+            "MEDDRA:10014234",
+            "MEDDRA:10014210",
+            "MEDDRA:10005890",
+            "HP:0000969",
+            "SNOMEDCT:267038008",
+            "SNOMEDCT:43498006",
+            "SNOMEDCT:79654002",
+            "MESH:D004487",
+            "UMLS:C0013604",
+            "MEDDRA:10016807",
+            "EFO:0009373",
+            "SNOMEDCT:423666004",
+            "UMLS:C0268000",
+            "NCIT:C3002",
+            "MEDDRA:10030095",
+            "SNOMEDCT:20741006",
+            "SYMP:0000538"
+          ],
+          "id": "HP:0000969",
           "category": "biolink:PhenotypicFeature",
           "all_names": [
-            "pain",
-            "Pain"
+            "Edema",
+            "Body fluid retention",
+            "edema"
           ],
           "all_categories": [
-            "biolink:PhenotypicFeature"
+            "biolink:PhenotypicFeature",
+            "biolink:Disease"
           ],
           "publications": [
-            "https://orcid.org/0000-0001-5208-3432",
-            "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
+            "https://orcid.org/0000-0002-0736-9199",
+            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
+            "https://orcid.org/0000-0001-6908-9849"
           ]
         }
       },
       "end": {
-        "identity": 458,
+        "identity": 554,
         "labels": [
+          "biolink:SmallMolecule",
+          "biolink:ChemicalEntityOrGeneOrGeneProduct",
+          "biolink:PhysicalEssenceOrOccurrent",
+          "biolink:MolecularEntity",
+          "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
+          "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
-          "biolink:InformationContentEntity"
+          "biolink:PhysicalEssence",
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C1138603",
-          "name": "Provider",
-          "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+          "name": "Ibuprofen",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
           "equivalent_curies": [
-            "NCIT:C37900",
-            "UMLS:C1138603",
-            "biolink:provider"
-          ],
-          "id": "UMLS:C1138603",
-          "category": "biolink:InformationContentEntity",
+            "PathWhiz.Compound:1284",
+            "KEGG.DRUG:D00126",
+            "CHEBI:5855",
+            "RXNORM:5640",
+            "CAS:58560-75-1",
+            "NCIT:C561",
+            "PDQ:CDR0000040475",
+            "DRUGBANK:DB01050",
+            "ATC:G02CC01",
+            "UMLS:C0020740",
+            "NDDF:002377",
+            "UNII:WK2XYI10QM",
+            "MESH:D007052",
+            "PUBCHEM.COMPOUND:3672",
+            "DrugCentral:1407",
+            "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+            "CHEMBL.COMPOUND:CHEMBL521",
+            "ATC:M02AA13",
+            "KEGG.COMPOUND:C01588",
+            "ATC:R02AX02",
+            "ATC:M01AE01",
+            "ATC:C01EB16",
+            "GTOPDB:2713",
+            "CAS:15687-27-1",
+            "HMDB:HMDB0001925"
+          ],
+          "id": "PUBCHEM.COMPOUND:3672",
+          "category": "biolink:SmallMolecule",
           "all_names": [
-            "provider",
-            "Provider"
+            "IBUPROFEN",
+            "Ibuprofen",
+            "ibuprofen",
+            "Ibuprofen (JP18/USP/INN)",
+            "solufenum"
           ],
           "all_categories": [
-            "biolink:InformationContentEntity"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:33071054",
+            "PMID:28759875",
+            "PMID:926121",
+            "PMID:20926620",
+            "PMID:31689108",
+            "PMID:34998058",
+            "PMID:18834112",
+            "PMID:12807998",
+            "PMID:19541393",
+            "PMID:140243"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 316891,
+            "identity": 313324,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0012531",
-              "name": "Pain",
-              "description": "Causing physical or psychological misery, pain or distress.; The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.; An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.; An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. [ORCID:0000-0001-5208-3432]; Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T184; UMLS Semantic Type: STY:T184",
+              "iri": "http://purl.obolibrary.org/obo/HP_0000969",
+              "name": "Edema",
+              "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
               "equivalent_curies": [
-                "MESH:D010146",
-                "SYMP:0000099",
-                "UMLS:C0030193",
-                "ICD9:338-338.99",
-                "PSY:36150",
-                "SNOMEDCT:22253000",
-                "NCIT:C3303",
-                "MEDDRA:10033470",
-                "MEDDRA:10033371",
-                "HP:0012531",
-                "PDQ:CDR0000041399"
-              ],
-              "id": "HP:0012531",
+                "MEDDRA:10030114",
+                "MEDDRA:10014234",
+                "MEDDRA:10014210",
+                "MEDDRA:10005890",
+                "HP:0000969",
+                "SNOMEDCT:267038008",
+                "SNOMEDCT:43498006",
+                "SNOMEDCT:79654002",
+                "MESH:D004487",
+                "UMLS:C0013604",
+                "MEDDRA:10016807",
+                "EFO:0009373",
+                "SNOMEDCT:423666004",
+                "UMLS:C0268000",
+                "NCIT:C3002",
+                "MEDDRA:10030095",
+                "SNOMEDCT:20741006",
+                "SYMP:0000538"
+              ],
+              "id": "HP:0000969",
               "category": "biolink:PhenotypicFeature",
               "all_names": [
-                "pain",
-                "Pain"
+                "Edema",
+                "Body fluid retention",
+                "edema"
               ],
               "all_categories": [
-                "biolink:PhenotypicFeature"
+                "biolink:PhenotypicFeature",
+                "biolink:Disease"
               ],
               "publications": [
-                "https://orcid.org/0000-0001-5208-3432",
-                "http://www.nationalpainfoundation.org/mytreatment/articles/cancer_paindefinitions.asp"
+                "https://orcid.org/0000-0002-0736-9199",
+                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
+                "https://orcid.org/0000-0001-6908-9849"
               ]
             }
           },
           "relationship": {
-            "identity": 13135002,
-            "start": 316891,
-            "end": 458,
+            "identity": 9766936,
+            "start": 554,
+            "end": 313324,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:17970510': {'publication date': '2007 Oct', 'sentence': 'Reasons include: inflexibility by dialysis providers because of reduced profitability, claims that patients oppose the subcutaneous route because of pain at the site of injection, concerns regarding pure red cell aplasia associated with subcutaneous administration, and greater hemoglobin cycling with the subcutaneous route.', 'subject score': 1000, 'object score': 872}, 'PMID:27020269': {'publication date': '2016 Aug', 'sentence': 'Patients who received surgery for infection reported more days of analgesic use, as well as more unplanned contacts with a health care service provider due to pain, compared with those who underwent surgery for upper airway obstruction.', 'subject score': 1000, 'object score': 916}}",
+              "domain_range_exclusion": "False",
+              "publications_info": "{'PMID:12535659': {'publication date': '2003 Jan 31', 'sentence': 'The aryl sulfonyl methyl thiophene analogs AP29, AP82, and AP37, when screened for anti-inflammatory activity in carrageenin induced rat paw edema, an acute in vivo model, exhibited moderate to good activity at a dose level of 100 mg/kg body weight P.o compared to Ibuprofen.', 'subject score': 1000, 'object score': 851}, 'PMID:15358292': {'publication date': '2004 Sep 01', 'sentence': 'The 3-(4-chlorophenyl)-2-(4-morpholino) thiophene analogs AP49, AP158, and AP88 provided a protection of 20%, 23%, and 20%, respectively, when screened for anti-inflammatory activity in carrageenin induced rat paw edema, an acute in vivo model, comparable to that of AP82, at a dose level of 100mg/kg body weight p.o. compared to ibuprofen as standard.', 'subject score': 1000, 'object score': 851}, 'PMID:22225915': {'publication date': '2012 Feb 01', 'sentence': 'Anti-inflammatory, analgesic as well as ulcerogenic activities of the prepared esters were evaluated in vivo and compared with that of ibuprofen as reference standard in all screenings, involving the carrageenan induced paw oedema model and hot plate method.', 'subject score': 1000, 'object score': 822}, 'PMID:2497923': {'publication date': '1989 May', 'sentence': 'Intravenous injection of the non-steroidal antiinflammatory drug, ibuprofen, resulted in an inhibition of FMLP-induced, but not histamine-induced, oedema formation.', 'subject score': 1000, 'object score': 822}, 'PMID:8688144': {'publication date': '1996 Mar', 'sentence': 'The 2-(2,3-dihydro-1, 4-benzodioxin-6-yl)acetic acid was of comparable potency to Ibuprofen, in carrageenan induced rat paw edema assay.', 'subject score': 1000, 'object score': 814}}",
               "kg2_ids": [
-                "UMLS:C0030193---SEMMEDDB:treats---None---None---None---UMLS:C1138603---SEMMEDDB:"
+                "UMLS:C0020740---SEMMEDDB:treats---None---None---None---UMLS:C0013604---SEMMEDDB:"
               ],
-              "subject": "HP:0012531",
-              "id": "13417890",
-              "object": "UMLS:C1138603",
+              "subject": "PUBCHEM.COMPOUND:3672",
+              "id": "9983282",
+              "object": "HP:0000969",
               "publications": [
-                "PMID:17970510",
-                "PMID:27020269"
+                "PMID:12535659",
+                "PMID:15358292",
+                "PMID:22225915",
+                "PMID:2497923",
+                "PMID:8688144"
               ]
             }
           },
           "end": {
-            "identity": 458,
+            "identity": 554,
             "labels": [
+              "biolink:SmallMolecule",
+              "biolink:ChemicalEntityOrGeneOrGeneProduct",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:MolecularEntity",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:InformationContentEntity"
+              "biolink:PhysicalEssence",
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C1138603",
-              "name": "Provider",
-              "description": "person, group, organization or project that provides a piece of information (e.g. a knowledge association).",
+              "name": "Ibuprofen",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]    On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]",
               "equivalent_curies": [
-                "NCIT:C37900",
-                "UMLS:C1138603",
-                "biolink:provider"
-              ],
-              "id": "UMLS:C1138603",
-              "category": "biolink:InformationContentEntity",
+                "PathWhiz.Compound:1284",
+                "KEGG.DRUG:D00126",
+                "CHEBI:5855",
+                "RXNORM:5640",
+                "CAS:58560-75-1",
+                "NCIT:C561",
+                "PDQ:CDR0000040475",
+                "DRUGBANK:DB01050",
+                "ATC:G02CC01",
+                "UMLS:C0020740",
+                "NDDF:002377",
+                "UNII:WK2XYI10QM",
+                "MESH:D007052",
+                "PUBCHEM.COMPOUND:3672",
+                "DrugCentral:1407",
+                "INCHIKEY:HEFNNWSXXWATRW-UHFFFAOYSA-N",
+                "CHEMBL.COMPOUND:CHEMBL521",
+                "ATC:M02AA13",
+                "KEGG.COMPOUND:C01588",
+                "ATC:R02AX02",
+                "ATC:M01AE01",
+                "ATC:C01EB16",
+                "GTOPDB:2713",
+                "CAS:15687-27-1",
+                "HMDB:HMDB0001925"
+              ],
+              "id": "PUBCHEM.COMPOUND:3672",
+              "category": "biolink:SmallMolecule",
               "all_names": [
-                "provider",
-                "Provider"
+                "IBUPROFEN",
+                "Ibuprofen",
+                "ibuprofen",
+                "Ibuprofen (JP18/USP/INN)",
+                "solufenum"
               ],
               "all_categories": [
-                "biolink:InformationContentEntity"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:33071054",
+                "PMID:28759875",
+                "PMID:926121",
+                "PMID:20926620",
+                "PMID:31689108",
+                "PMID:34998058",
+                "PMID:18834112",
+                "PMID:12807998",
+                "PMID:19541393",
+                "PMID:140243"
               ]
             }
           }
@@ -2534,7 +4002,7 @@
   {
     "p3": {
       "start": {
-        "identity": 539955,
+        "identity": 308948,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -2544,44 +4012,69 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-          "name": "infectious disease",
-          "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005009",
+          "name": "congestive heart failure",
+          "description": "Inability of the heart to pump blood at an adequate rate to meet tissue metabolic requirements. Clinical symptoms of heart failure include: unusual dyspnea on light exertion, recurrent dyspnea occurring in the supine position, fluid retention or rales, jugular venous distension, pulmonary edema on physical exam, or pulmonary edema on chest x-ray presumed to be cardiac dysfunction.; Heart failure accompanied by EDEMA, such as swelling of the legs and ankles and congestion in the lungs.; The presence of an abnormality of cardiac function that is responsible for the failure of the heart to pump blood at a rate that is commensurate with the needs of the tissues or a state in which abnormally elevated filling pressures are required for the heart to do so. Heart failure is frequently related to a defect in myocardial contraction. [HPO:probinson]; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "MONDO:0005550",
-            "SNOMEDCT:189822004",
-            "PSY:10513",
-            "UMLS:C0009450",
-            "UMLS:C0001485",
-            "EFO:0005741",
-            "MEDDRA:10021881",
-            "MESH:D003141",
-            "ICD9:079.0",
-            "DOID:0050117",
-            "SNOMEDCT:40733004",
-            "SNOMEDCT:191415002",
-            "NCIT:C26726"
-          ],
-          "id": "MONDO:0005550",
+            "MEDDRA:10022462",
+            "MEDDRA:10007554",
+            "MEDDRA:10007564",
+            "ICD9:428.0",
+            "MEDDRA:10007569",
+            "PDQ:CDR0000038915",
+            "MEDDRA:10007559",
+            "SNOMEDCT:42343007",
+            "MEDDRA:10019282",
+            "UMLS:C0264716",
+            "ICD9:428",
+            "MEDDRA:10019290",
+            "EFO:0000373",
+            "UMLS:C0018801",
+            "MEDDRA:10019285",
+            "MEDDRA:10007558",
+            "UMLS:C0018802",
+            "MEDDRA:10016146",
+            "HP:0001635",
+            "MEDDRA:10007555",
+            "MEDDRA:10007568",
+            "MEDDRA:10008908",
+            "ICD10:I50",
+            "MEDDRA:10010682",
+            "MEDDRA:10010684",
+            "MEDDRA:10019279",
+            "MEDDRA:10019280",
+            "MONDO:0005009",
+            "MEDDRA:10016145",
+            "MEDDRA:10007562",
+            "MEDDRA:10019284",
+            "DOID:6000",
+            "MEDDRA:10007582",
+            "ICD10:I50.9",
+            "SNOMEDCT:48447003",
+            "NCIT:C3080"
+          ],
+          "id": "MONDO:0005009",
           "category": "biolink:Disease",
           "all_names": [
-            "infectious disease",
-            "Infectious Disorder",
-            "disease by infectious agent",
-            "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-            "Communicable Diseases"
+            "Congestive heart failure, unspecified",
+            "Congestive Heart Failure",
+            "Heart failure",
+            "Chronic heart failure",
+            "Congestive heart failure",
+            "congestive heart failure"
           ],
           "all_categories": [
             "biolink:Disease"
           ],
           "publications": [
-            "https://www.merriam-webster.com/medical/communicable%20disease",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
+            "http://en.wikipedia.org/wiki/heart_disease",
+            "https://orcid.org/0000-0002-0736-9199",
+            "https://orcid.org/0000-0002-5316-1399"
           ]
         }
       },
       "end": {
-        "identity": 546,
+        "identity": 557,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -2598,34 +4091,33 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Fenbendazole",
-          "description": "Veterinary anthelmintic. Fenbendazole is a fda approved for use in cattle, pigs and goats Fenbendazole (Hoechst brand names Panacur and Safe-Guard, Intervet Panacur and Panacur Rabbit) is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites including roundworms, hookworms, whipworms, the taenia species of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles and strongyloides and can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. Drug interactions may occur if using bromsalan flukicides (Dibromsalan, Tribromsalan). Abortions in cattle and death in sheep have been reported after using these medications together. (Plumb's Veterinary Drug Handbook, Fifth Edition. 2005",
+          "name": "Ivabradine",
+          "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
           "equivalent_curies": [
-            "INCHIKEY:HDDSHPAODJUKPD-UHFFFAOYSA-N",
-            "MESH:D005273",
-            "CAS:43210-67-9",
-            "DrugCentral:4536",
-            "KEGG.DRUG:D04140",
-            "UMLS:C0015821",
-            "NDDF:013514",
-            "CHEBI:77092",
-            "HMDB:HMDB0029745",
-            "PUBCHEM.COMPOUND:3334",
-            "NCIT:C75218",
-            "DRUGBANK:DB11410",
-            "RXNORM:4325",
-            "UNII:621BVT9M36",
-            "ATC:P02CA06",
-            "CHEMBL.COMPOUND:CHEMBL37161"
-          ],
-          "id": "PUBCHEM.COMPOUND:3334",
+            "GTOPDB:2357",
+            "RXNORM:1649480",
+            "CHEBI:85966",
+            "DRUGBANK:DB09083",
+            "UMLS:C0257190",
+            "UNII:3H48L0LPZQ",
+            "MESH:D000077550",
+            "DrugCentral:3312",
+            "NCIT:C65995",
+            "KEGG.DRUG:D07165",
+            "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
+            "PUBCHEM.COMPOUND:132999",
+            "ATC:C01EB17",
+            "CAS:155974-00-8",
+            "CHEMBL.COMPOUND:CHEMBL471737"
+          ],
+          "id": "PUBCHEM.COMPOUND:132999",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "Fenbendazole (USP/INN)",
-            "phenbendasol",
-            "Fenbendazole",
-            "FENBENDAZOLE",
-            "fenbendazole"
+            "corlentor",
+            "IVABRADINE",
+            "Ivabradine",
+            "ivabradine",
+            "Ivabradine (USAN/INN)"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -2633,135 +4125,159 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:7010692",
-            "PMID:3605812",
-            "PMID:23571415",
-            "PMID:7277372",
-            "PMID:16420038",
-            "PMID:22464423",
-            "PMID:7271033",
-            "PMID:738790",
-            "PMID:20966043",
-            "PMID:2287030"
+            "PMID:25839989",
+            "PMID:20795648",
+            "PMID:15301560",
+            "PMID:18529044",
+            "PMID:29615340",
+            "PMID:20167941",
+            "PMID:16451297",
+            "PMID:24377458"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 539955,
+            "identity": 308948,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-              "name": "infectious disease",
-              "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005009",
+              "name": "congestive heart failure",
+              "description": "Inability of the heart to pump blood at an adequate rate to meet tissue metabolic requirements. Clinical symptoms of heart failure include: unusual dyspnea on light exertion, recurrent dyspnea occurring in the supine position, fluid retention or rales, jugular venous distension, pulmonary edema on physical exam, or pulmonary edema on chest x-ray presumed to be cardiac dysfunction.; Heart failure accompanied by EDEMA, such as swelling of the legs and ankles and congestion in the lungs.; The presence of an abnormality of cardiac function that is responsible for the failure of the heart to pump blood at a rate that is commensurate with the needs of the tissues or a state in which abnormally elevated filling pressures are required for the heart to do so. Heart failure is frequently related to a defect in myocardial contraction. [HPO:probinson]; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "MONDO:0005550",
-                "SNOMEDCT:189822004",
-                "PSY:10513",
-                "UMLS:C0009450",
-                "UMLS:C0001485",
-                "EFO:0005741",
-                "MEDDRA:10021881",
-                "MESH:D003141",
-                "ICD9:079.0",
-                "DOID:0050117",
-                "SNOMEDCT:40733004",
-                "SNOMEDCT:191415002",
-                "NCIT:C26726"
-              ],
-              "id": "MONDO:0005550",
+                "MEDDRA:10022462",
+                "MEDDRA:10007554",
+                "MEDDRA:10007564",
+                "ICD9:428.0",
+                "MEDDRA:10007569",
+                "PDQ:CDR0000038915",
+                "MEDDRA:10007559",
+                "SNOMEDCT:42343007",
+                "MEDDRA:10019282",
+                "UMLS:C0264716",
+                "ICD9:428",
+                "MEDDRA:10019290",
+                "EFO:0000373",
+                "UMLS:C0018801",
+                "MEDDRA:10019285",
+                "MEDDRA:10007558",
+                "UMLS:C0018802",
+                "MEDDRA:10016146",
+                "HP:0001635",
+                "MEDDRA:10007555",
+                "MEDDRA:10007568",
+                "MEDDRA:10008908",
+                "ICD10:I50",
+                "MEDDRA:10010682",
+                "MEDDRA:10010684",
+                "MEDDRA:10019279",
+                "MEDDRA:10019280",
+                "MONDO:0005009",
+                "MEDDRA:10016145",
+                "MEDDRA:10007562",
+                "MEDDRA:10019284",
+                "DOID:6000",
+                "MEDDRA:10007582",
+                "ICD10:I50.9",
+                "SNOMEDCT:48447003",
+                "NCIT:C3080"
+              ],
+              "id": "MONDO:0005009",
               "category": "biolink:Disease",
               "all_names": [
-                "infectious disease",
-                "Infectious Disorder",
-                "disease by infectious agent",
-                "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-                "Communicable Diseases"
+                "Congestive heart failure, unspecified",
+                "Congestive Heart Failure",
+                "Heart failure",
+                "Chronic heart failure",
+                "Congestive heart failure",
+                "congestive heart failure"
               ],
               "all_categories": [
                 "biolink:Disease"
               ],
               "publications": [
-                "https://www.merriam-webster.com/medical/communicable%20disease",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
+                "http://en.wikipedia.org/wiki/heart_disease",
+                "https://orcid.org/0000-0002-0736-9199",
+                "https://orcid.org/0000-0002-5316-1399"
               ]
             }
           },
           "relationship": {
-            "identity": 25992188,
-            "start": 546,
-            "end": 539955,
+            "identity": 18524226,
+            "start": 557,
+            "end": 308948,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7447142': {'publication date': '1980 Sep', 'sentence': 'Fenbendazole was effective against induced infections of A tubaeforme and Taen taeniaeformis.', 'subject score': 1000, 'object score': 888}}",
+              "publications_info": "{'PMID:27012681': {'publication date': '2016 May', 'sentence': 'Symptomatic Bradycardia and Heart Failure Triggered by Ivabradine in a Patient Receiving Antiretroviral Therapy.', 'subject score': 1000, 'object score': 1000}, 'PMID:27328994': {'publication date': '2016 Aug', 'sentence': 'About Bradycardia and Secondary Heart Failure Induced by Ivabradine in a Patient With HIV.', 'subject score': 1000, 'object score': 901}, 'PMID:27328995': {'publication date': '2016 Aug', 'sentence': 'About Bradycardia and Secondary Heart Failure Induced by Ivabradine in a Patient With HIV.', 'subject score': 1000, 'object score': 901}}",
               "kg2_ids": [
-                "UMLS:C0015821---SEMMEDDB:treats---None---None---None---UMLS:C0009450---SEMMEDDB:"
+                "UMLS:C0257190---SEMMEDDB:treats---None---None---None---UMLS:C0018801---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:3334",
-              "id": "26452787",
-              "object": "MONDO:0005550",
+              "subject": "PUBCHEM.COMPOUND:132999",
+              "id": "18897327",
+              "object": "MONDO:0005009",
               "publications": [
-                "PMID:7447142"
+                "PMID:27012681",
+                "PMID:27328994",
+                "PMID:27328995"
               ]
             }
           },
           "end": {
-            "identity": 546,
+            "identity": 557,
             "labels": [
-              "biolink:ChemicalEntity",
+              "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:PhysicalEssenceOrOccurrent",
+              "biolink:MolecularEntity",
+              "biolink:ChemicalEntity",
               "biolink:ChemicalMixture",
-              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:Drug",
-              "biolink:MolecularEntity",
-              "biolink:MolecularMixture",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
-              "biolink:OntologyClass",
               "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Fenbendazole",
-              "description": "Veterinary anthelmintic. Fenbendazole is a fda approved for use in cattle, pigs and goats Fenbendazole (Hoechst brand names Panacur and Safe-Guard, Intervet Panacur and Panacur Rabbit) is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites including roundworms, hookworms, whipworms, the taenia species of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles and strongyloides and can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. Drug interactions may occur if using bromsalan flukicides (Dibromsalan, Tribromsalan). Abortions in cattle and death in sheep have been reported after using these medications together. (Plumb's Veterinary Drug Handbook, Fifth Edition. 2005",
+              "name": "Ivabradine",
+              "description": "UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109; Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.  Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the \"funny\" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a \"pure\" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.",
               "equivalent_curies": [
-                "INCHIKEY:HDDSHPAODJUKPD-UHFFFAOYSA-N",
-                "MESH:D005273",
-                "CAS:43210-67-9",
-                "DrugCentral:4536",
-                "KEGG.DRUG:D04140",
-                "UMLS:C0015821",
-                "NDDF:013514",
-                "CHEBI:77092",
-                "HMDB:HMDB0029745",
-                "PUBCHEM.COMPOUND:3334",
-                "NCIT:C75218",
-                "DRUGBANK:DB11410",
-                "RXNORM:4325",
-                "UNII:621BVT9M36",
-                "ATC:P02CA06",
-                "CHEMBL.COMPOUND:CHEMBL37161"
-              ],
-              "id": "PUBCHEM.COMPOUND:3334",
+                "GTOPDB:2357",
+                "RXNORM:1649480",
+                "CHEBI:85966",
+                "DRUGBANK:DB09083",
+                "UMLS:C0257190",
+                "UNII:3H48L0LPZQ",
+                "MESH:D000077550",
+                "DrugCentral:3312",
+                "NCIT:C65995",
+                "KEGG.DRUG:D07165",
+                "INCHIKEY:ACRHBAYQBXXRTO-OAQYLSRUSA-N",
+                "PUBCHEM.COMPOUND:132999",
+                "ATC:C01EB17",
+                "CAS:155974-00-8",
+                "CHEMBL.COMPOUND:CHEMBL471737"
+              ],
+              "id": "PUBCHEM.COMPOUND:132999",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "Fenbendazole (USP/INN)",
-                "phenbendasol",
-                "Fenbendazole",
-                "FENBENDAZOLE",
-                "fenbendazole"
+                "corlentor",
+                "IVABRADINE",
+                "Ivabradine",
+                "ivabradine",
+                "Ivabradine (USAN/INN)"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -2769,16 +4285,14 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:7010692",
-                "PMID:3605812",
-                "PMID:23571415",
-                "PMID:7277372",
-                "PMID:16420038",
-                "PMID:22464423",
-                "PMID:7271033",
-                "PMID:738790",
-                "PMID:20966043",
-                "PMID:2287030"
+                "PMID:25839989",
+                "PMID:20795648",
+                "PMID:15301560",
+                "PMID:18529044",
+                "PMID:29615340",
+                "PMID:20167941",
+                "PMID:16451297",
+                "PMID:24377458"
               ]
             }
           }
@@ -2790,7 +4304,7 @@
   {
     "p3": {
       "start": {
-        "identity": 526500,
+        "identity": 527384,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -2800,42 +4314,39 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-          "name": "helminthiasis",
-          "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005247",
+          "name": "bacterial urinary tract infection",
+          "description": "A bacterial infectious process affecting any part of the urinary tract, most commonly the bladder and the urethra. Symptoms include urinary urgency and frequency, burning sensation during urination, lower abdominal discomfort, and cloudy urine.; Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "MESH:D006373",
-            "MONDO:0004664",
-            "MEDDRA:10061201",
-            "ICD10:B83.9",
-            "MEDDRA:10019380",
-            "MEDDRA:10019382",
-            "DOID:883",
-            "UMLS:C0018889",
-            "NCIT:C84751",
-            "SNOMEDCT:27601005",
-            "EFO:1001342",
-            "ICD9:120-129.99"
-          ],
-          "id": "MONDO:0004664",
+            "NCIT:C50791",
+            "MONDO:0005247",
+            "UMLS:C0042029",
+            "MEDDRA:10021872",
+            "MEDDRA:10046571",
+            "MEDDRA:10046544",
+            "SNOMEDCT:68566005",
+            "MEDDRA:10046576",
+            "MEDDRA:10046848",
+            "MEDDRA:10046577",
+            "MEDDRA:10046574"
+          ],
+          "id": "MONDO:0005247",
           "category": "biolink:Disease",
           "all_names": [
-            "parasitic helminthiasis infectious disease",
-            "Helminthiasis",
-            "Helminthiases",
-            "helminthiasis"
+            "Urinary Tract Infection",
+            "bacterial urinary tract infection",
+            "Urinary tract infection"
           ],
           "all_categories": [
             "biolink:Disease"
           ],
           "publications": [
-            "http://en.wikipedia.org/wiki/helminth",
-            "http://en.wikipedia.org/wiki/helminthiasis"
+            "https://orcid.org/0000-0002-6601-2165"
           ]
         }
       },
       "end": {
-        "identity": 546,
+        "identity": 558,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -2852,34 +4363,35 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Fenbendazole",
-          "description": "Veterinary anthelmintic. Fenbendazole is a fda approved for use in cattle, pigs and goats Fenbendazole (Hoechst brand names Panacur and Safe-Guard, Intervet Panacur and Panacur Rabbit) is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites including roundworms, hookworms, whipworms, the taenia species of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles and strongyloides and can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. Drug interactions may occur if using bromsalan flukicides (Dibromsalan, Tribromsalan). Abortions in cattle and death in sheep have been reported after using these medications together. (Plumb's Veterinary Drug Handbook, Fifth Edition. 2005",
+          "name": "Cefixime",
+          "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "INCHIKEY:HDDSHPAODJUKPD-UHFFFAOYSA-N",
-            "MESH:D005273",
-            "CAS:43210-67-9",
-            "DrugCentral:4536",
-            "KEGG.DRUG:D04140",
-            "UMLS:C0015821",
-            "NDDF:013514",
-            "CHEBI:77092",
-            "HMDB:HMDB0029745",
-            "PUBCHEM.COMPOUND:3334",
-            "NCIT:C75218",
-            "DRUGBANK:DB11410",
-            "RXNORM:4325",
-            "UNII:621BVT9M36",
-            "ATC:P02CA06",
-            "CHEMBL.COMPOUND:CHEMBL37161"
-          ],
-          "id": "PUBCHEM.COMPOUND:3334",
+            "UNII:XZ7BG04GJX",
+            "DRUGBANK:DB00671",
+            "GTOPDB:10898",
+            "PDQ:CDR0000037809",
+            "NDDF:002737",
+            "CHEBI:472657",
+            "HMDB:HMDB0014809",
+            "KEGG.COMPOUND:C06881",
+            "NCIT:C1100",
+            "UMLS:C0060400",
+            "CHEMBL.COMPOUND:CHEMBL1541",
+            "ATC:J01DD08",
+            "KEGG.DRUG:D00258",
+            "MESH:D020682",
+            "DrugCentral:537",
+            "PUBCHEM.COMPOUND:5362065",
+            "RXNORM:25033",
+            "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
+          ],
+          "id": "PUBCHEM.COMPOUND:5362065",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "Fenbendazole (USP/INN)",
-            "phenbendasol",
-            "Fenbendazole",
-            "FENBENDAZOLE",
-            "fenbendazole"
+            "CEFIXIME",
+            "Cefixime (INN)",
+            "Cefixime",
+            "cefixime"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -2887,89 +4399,86 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:7010692",
-            "PMID:3605812",
-            "PMID:23571415",
-            "PMID:7277372",
-            "PMID:16420038",
-            "PMID:22464423",
-            "PMID:7271033",
-            "PMID:738790",
-            "PMID:20966043",
-            "PMID:2287030"
+            "PMID:20070106",
+            "PMID:9379359",
+            "PMID:20014752",
+            "PMID:15646539",
+            "PMID:23416192",
+            "PMID:19586686",
+            "PMID:21741846",
+            "PMID:21098249",
+            "PMID:24961639",
+            "PMID:8627565"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 526500,
+            "identity": 527384,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-              "name": "helminthiasis",
-              "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005247",
+              "name": "bacterial urinary tract infection",
+              "description": "A bacterial infectious process affecting any part of the urinary tract, most commonly the bladder and the urethra. Symptoms include urinary urgency and frequency, burning sensation during urination, lower abdominal discomfort, and cloudy urine.; Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "MESH:D006373",
-                "MONDO:0004664",
-                "MEDDRA:10061201",
-                "ICD10:B83.9",
-                "MEDDRA:10019380",
-                "MEDDRA:10019382",
-                "DOID:883",
-                "UMLS:C0018889",
-                "NCIT:C84751",
-                "SNOMEDCT:27601005",
-                "EFO:1001342",
-                "ICD9:120-129.99"
-              ],
-              "id": "MONDO:0004664",
+                "NCIT:C50791",
+                "MONDO:0005247",
+                "UMLS:C0042029",
+                "MEDDRA:10021872",
+                "MEDDRA:10046571",
+                "MEDDRA:10046544",
+                "SNOMEDCT:68566005",
+                "MEDDRA:10046576",
+                "MEDDRA:10046848",
+                "MEDDRA:10046577",
+                "MEDDRA:10046574"
+              ],
+              "id": "MONDO:0005247",
               "category": "biolink:Disease",
               "all_names": [
-                "parasitic helminthiasis infectious disease",
-                "Helminthiasis",
-                "Helminthiases",
-                "helminthiasis"
+                "Urinary Tract Infection",
+                "bacterial urinary tract infection",
+                "Urinary tract infection"
               ],
               "all_categories": [
                 "biolink:Disease"
               ],
               "publications": [
-                "http://en.wikipedia.org/wiki/helminth",
-                "http://en.wikipedia.org/wiki/helminthiasis"
+                "https://orcid.org/0000-0002-6601-2165"
               ]
             }
           },
           "relationship": {
-            "identity": 25992187,
-            "start": 546,
-            "end": 526500,
+            "identity": 15919226,
+            "start": 558,
+            "end": 527384,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7447142': {'publication date': '1980 Sep', 'sentence': 'Evaluation of granulated fenbendazole (22.2%) against induced and naturally occurring helminth infections in cats.', 'subject score': 861, 'object score': 983}}",
+              "publications_info": "{'PMID:22535978': {'publication date': '2012 Jul', 'sentence': 'In vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0015821---SEMMEDDB:treats---None---None---None---UMLS:C0018889---SEMMEDDB:"
+                "UMLS:C0060400---SEMMEDDB:treats---None---None---None---UMLS:C0042029---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:3334",
-              "id": "26452786",
-              "object": "MONDO:0004664",
+              "subject": "PUBCHEM.COMPOUND:5362065",
+              "id": "16250947",
+              "object": "MONDO:0005247",
               "publications": [
-                "PMID:7447142"
+                "PMID:22535978"
               ]
             }
           },
           "end": {
-            "identity": 546,
+            "identity": 558,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -2986,34 +4495,35 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Fenbendazole",
-              "description": "Veterinary anthelmintic. Fenbendazole is a fda approved for use in cattle, pigs and goats Fenbendazole (Hoechst brand names Panacur and Safe-Guard, Intervet Panacur and Panacur Rabbit) is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites including roundworms, hookworms, whipworms, the taenia species of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles and strongyloides and can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. Drug interactions may occur if using bromsalan flukicides (Dibromsalan, Tribromsalan). Abortions in cattle and death in sheep have been reported after using these medications together. (Plumb's Veterinary Drug Handbook, Fifth Edition. 2005",
+              "name": "Cefixime",
+              "description": "A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1100\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1100\" NCI Thesaurus); UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "INCHIKEY:HDDSHPAODJUKPD-UHFFFAOYSA-N",
-                "MESH:D005273",
-                "CAS:43210-67-9",
-                "DrugCentral:4536",
-                "KEGG.DRUG:D04140",
-                "UMLS:C0015821",
-                "NDDF:013514",
-                "CHEBI:77092",
-                "HMDB:HMDB0029745",
-                "PUBCHEM.COMPOUND:3334",
-                "NCIT:C75218",
-                "DRUGBANK:DB11410",
-                "RXNORM:4325",
-                "UNII:621BVT9M36",
-                "ATC:P02CA06",
-                "CHEMBL.COMPOUND:CHEMBL37161"
-              ],
-              "id": "PUBCHEM.COMPOUND:3334",
+                "UNII:XZ7BG04GJX",
+                "DRUGBANK:DB00671",
+                "GTOPDB:10898",
+                "PDQ:CDR0000037809",
+                "NDDF:002737",
+                "CHEBI:472657",
+                "HMDB:HMDB0014809",
+                "KEGG.COMPOUND:C06881",
+                "NCIT:C1100",
+                "UMLS:C0060400",
+                "CHEMBL.COMPOUND:CHEMBL1541",
+                "ATC:J01DD08",
+                "KEGG.DRUG:D00258",
+                "MESH:D020682",
+                "DrugCentral:537",
+                "PUBCHEM.COMPOUND:5362065",
+                "RXNORM:25033",
+                "INCHIKEY:OKBVVJOGVLARMR-QSWIMTSFSA-N"
+              ],
+              "id": "PUBCHEM.COMPOUND:5362065",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "Fenbendazole (USP/INN)",
-                "phenbendasol",
-                "Fenbendazole",
-                "FENBENDAZOLE",
-                "fenbendazole"
+                "CEFIXIME",
+                "Cefixime (INN)",
+                "Cefixime",
+                "cefixime"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -3021,16 +4531,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:7010692",
-                "PMID:3605812",
-                "PMID:23571415",
-                "PMID:7277372",
-                "PMID:16420038",
-                "PMID:22464423",
-                "PMID:7271033",
-                "PMID:738790",
-                "PMID:20966043",
-                "PMID:2287030"
+                "PMID:20070106",
+                "PMID:9379359",
+                "PMID:20014752",
+                "PMID:15646539",
+                "PMID:23416192",
+                "PMID:19586686",
+                "PMID:21741846",
+                "PMID:21098249",
+                "PMID:24961639",
+                "PMID:8627565"
               ]
             }
           }
@@ -3042,7 +4552,7 @@
   {
     "p3": {
       "start": {
-        "identity": 2313490,
+        "identity": 321523,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -3052,27 +4562,41 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0276919",
-          "name": "Intestinal nematode infection",
-          "description": "An infection in the gastrointestinal tract by a nematode.; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
+          "name": "pneumonia",
+          "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It treats the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What treats pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that treats COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which treats valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "SNOMEDCT:57540006",
-            "UMLS:C0276919",
-            "NCIT:C157886"
-          ],
-          "id": "UMLS:C0276919",
+            "MEDDRA:10077942",
+            "UMLS:C0032285",
+            "MONDO:0005249",
+            "EFO:0003106",
+            "MEDDRA:10059809",
+            "SNOMEDCT:233604007",
+            "HP:0002090",
+            "MEDDRA:10035664",
+            "PSY:39200",
+            "MEDDRA:10035725",
+            "DOID:552",
+            "NCIT:C3333",
+            "MESH:D011014"
+          ],
+          "id": "MONDO:0005249",
           "category": "biolink:Disease",
           "all_names": [
-            "Intestinal Nematode Infection",
-            "Intestinal nematode infection"
+            "Pneumonia",
+            "pneumonia"
           ],
           "all_categories": [
             "biolink:Disease"
+          ],
+          "publications": [
+            "http://en.wikipedia.org/wiki/pneumonia",
+            "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 546,
+        "identity": 559,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -3089,34 +4613,35 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Fenbendazole",
-          "description": "Veterinary anthelmintic. Fenbendazole is a fda approved for use in cattle, pigs and goats Fenbendazole (Hoechst brand names Panacur and Safe-Guard, Intervet Panacur and Panacur Rabbit) is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites including roundworms, hookworms, whipworms, the taenia species of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles and strongyloides and can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. Drug interactions may occur if using bromsalan flukicides (Dibromsalan, Tribromsalan). Abortions in cattle and death in sheep have been reported after using these medications together. (Plumb's Veterinary Drug Handbook, Fifth Edition. 2005",
+          "name": "Ceftizoxime",
+          "description": "A semisynthetic, broad-spectrum, beta-lactamase-resistant, third-generation cephalosporin with antibacterial activity. Ceftizoxime binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and treats cell lysis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
           "equivalent_curies": [
-            "INCHIKEY:HDDSHPAODJUKPD-UHFFFAOYSA-N",
-            "MESH:D005273",
-            "CAS:43210-67-9",
-            "DrugCentral:4536",
-            "KEGG.DRUG:D04140",
-            "UMLS:C0015821",
-            "NDDF:013514",
-            "CHEBI:77092",
-            "HMDB:HMDB0029745",
-            "PUBCHEM.COMPOUND:3334",
-            "NCIT:C75218",
-            "DRUGBANK:DB11410",
-            "RXNORM:4325",
-            "UNII:621BVT9M36",
-            "ATC:P02CA06",
-            "CHEMBL.COMPOUND:CHEMBL37161"
-          ],
-          "id": "PUBCHEM.COMPOUND:3334",
+            "NDDF:004847",
+            "CHEBI:553473",
+            "INCHIKEY:NNULBSISHYWZJU-LLKWHZGFSA-N",
+            "GTOPDB:10785",
+            "KEGG.COMPOUND:C06890",
+            "RXNORM:2192",
+            "PUBCHEM.COMPOUND:6533629",
+            "CHEMBL.COMPOUND:CHEMBL528",
+            "KEGG.DRUG:D07658",
+            "NCIT:C61668",
+            "DRUGBANK:DB01332",
+            "DrugCentral:563",
+            "UMLS:C0007560",
+            "ATC:J01DD07",
+            "MESH:D015296",
+            "HMDB:HMDB0015427",
+            "UNII:C43C467DPE"
+          ],
+          "id": "PUBCHEM.COMPOUND:6533629",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "Fenbendazole (USP/INN)",
-            "phenbendasol",
-            "Fenbendazole",
-            "FENBENDAZOLE",
-            "fenbendazole"
+            "Ceftizoxime (INN)",
+            "Ceftizoxime",
+            "ceftisomin",
+            "CEFTIZOXIME",
+            "ceftizoxime"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -3124,74 +4649,88 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:7010692",
-            "PMID:3605812",
-            "PMID:23571415",
-            "PMID:7277372",
-            "PMID:16420038",
-            "PMID:22464423",
-            "PMID:7271033",
-            "PMID:738790",
-            "PMID:20966043",
-            "PMID:2287030"
+            "PMID:20679504",
+            "PMID:20022146",
+            "PMID:15646539",
+            "PMID:17646416",
+            "PMID:18426954",
+            "PMID:2342058",
+            "PMID:19015345",
+            "PMID:22194678",
+            "PMID:18490507",
+            "PMID:18834112"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 2313490,
+            "identity": 321523,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0276919",
-              "name": "Intestinal nematode infection",
-              "description": "An infection in the gastrointestinal tract by a nematode.; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005249",
+              "name": "pneumonia",
+              "description": "An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.; Infection of the lung often accompanied by inflammation.; Inflammation of any part of the lung parenchyma. [HPO:probinson]; What is pneumonia? Pneumonia is an infection in one or both of the lungs. It treats the air sacs of the lungs to fill up with fluid or pus. It can range from mild to severe, depending on the type of germ causing the infection, your age, and your overall health. What treats pneumonia? Bacterial, viral, and fungal infections can cause pneumonia. Bacteria are the most common cause. Bacterial pneumonia can occur on its own. It can also develop after you've had certain viral infections such as a cold or the flu. Several different types of bacteria can cause pneumonia, including: Streptococcus pneumoniae Legionella pneumophila; this pneumonia is often called Legionnaires' disease Mycoplasma pneumoniae Chlamydia pneumoniae Haemophilus influenzae  Viruses that infect the respiratory tract may cause pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks. But sometimes it is serious enough that you need to get treatment in a hospital. If you have viral pneumonia, you are at risk of also getting bacterial pneumonia. The different viruses that can cause pneumonia include: Respiratory syncytial virus (RSV) Some common cold and flu viruses SARS-CoV-2, the virus that treats COVID-19  Fungal pneumonia is more common in people who have chronic health problems or weakened immune systems. Some of the types include: Pneumocystis pneumonia (PCP) Coccidioidomycosis, which treats valley fever Histoplasmosis Cryptococcus  Who is at risk for pneumonia? Anyone can get pneumonia, but certain factors can increase your risk: Age; the risk is higher for children who are age 2 and under and adults age 65 and older Exposure to certain chemicals, pollutants, or toxic fumes Lifestyle habits, such as smoking, heavy alcohol use, and malnourishment Being in a hospital, especially if you are in the ICU. Being sedated and/or on a ventilator raises the risk even more. Having a lung disease Having a weakened immune system Have trouble coughing or swallowing, from a stroke or other condition Recently being sick with a cold or the flu  What are the symptoms of pneumonia? The symptoms of pneumonia can range from mild to severe and include: Fever Chills Cough, usually with phlegm (a slimy substance from deep in your lungs) Shortness of breath Chest pain when you breathe or cough Nausea and/or vomiting Diarrhea  The symptoms can vary for different groups. Newborns and infants may not show any signs of the infection. Others may vomit and have a fever and cough. They might seem sick, with no energy, or be restless. Older adults and people who have serious illnesses or weak immune systems may have fewer and milder symptoms. They may even have a lower than normal temperature. Older adults who have pneumonia sometimes have sudden changes in mental awareness. What other problems can pneumonia cause? Sometimes pneumonia can cause serious complications such as: Bacteremia, which happens when the bacteria move into the bloodstream. It is serious and can lead to septic shock. Lung abscesses, which are collections of pus in cavities of the lungs Pleural disorders, which are conditions that affect the pleura. The pleura is the tissue that covers the outside of the lungs and lines the inside of your chest cavity. Kidney failure Respiratory failure  How is pneumonia diagnosed? Sometimes pneumonia can be hard to diagnose. This is because it can cause some of the same symptoms as a cold or the flu. It may take time for you to realize that you have a more serious condition. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, including listening to your lungs with a stethoscope Various tests, such as  A chest x-ray Blood tests such as a complete blood count (CBC) to see if your immune system is actively fighting an infection A Blood culture to find out whether you have a bacterial infection that has spread to your bloodstream    If you are in the hospital, have serious symptoms, are older, or have other health problems, you may also have more tests, such as: Sputum test, which checks for bacteria in a sample of your sputum (spit) or phlegm (slimy substance from deep in your lungs). Chest CT scan to see how much of your lungs is affected. It may also show if you have complications such as lung abscesses or pleural effusions. Pleural fluid culture, which checks for bacteria in a fluid sample that was taken from the pleural space Pulse oximetry or blood oxygen level test, to check how much oxygen is in your blood Bronchoscopy, a procedure used to look inside your lungs' airways  What are the treatments for pneumonia? Treatment for pneumonia depends on the type of pneumonia, which germ is causing it, and how severe it is: Antibiotics treat bacterial pneumonia and some types of fungal pneumonia. They do not work for viral pneumonia. In some cases, your provider may prescribe antiviral medicines for viral pneumonia Antifungal medicines treat other types of fungal pneumonia  You may need to be treated in a hospital if your symptoms are severe or if you are at risk for complications. While there, you may get additional treatments. For example, if your blood oxygen level is low, you may receive oxygen therapy. It may take time to recover from pneumonia. Some people feel better within a week. For other people, it can take a month or more. Can pneumonia be prevented? Vaccines can help prevent pneumonia caused by pneumococcal bacteria or the flu virus. Having good hygiene, not smoking, and having a healthy lifestyle may also help prevent pneumonia. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "SNOMEDCT:57540006",
-                "UMLS:C0276919",
-                "NCIT:C157886"
-              ],
-              "id": "UMLS:C0276919",
+                "MEDDRA:10077942",
+                "UMLS:C0032285",
+                "MONDO:0005249",
+                "EFO:0003106",
+                "MEDDRA:10059809",
+                "SNOMEDCT:233604007",
+                "HP:0002090",
+                "MEDDRA:10035664",
+                "PSY:39200",
+                "MEDDRA:10035725",
+                "DOID:552",
+                "NCIT:C3333",
+                "MESH:D011014"
+              ],
+              "id": "MONDO:0005249",
               "category": "biolink:Disease",
               "all_names": [
-                "Intestinal Nematode Infection",
-                "Intestinal nematode infection"
+                "Pneumonia",
+                "pneumonia"
               ],
               "all_categories": [
                 "biolink:Disease"
+              ],
+              "publications": [
+                "http://en.wikipedia.org/wiki/pneumonia",
+                "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 24598454,
-            "start": 546,
-            "end": 2313490,
+            "identity": 25212350,
+            "start": 559,
+            "end": 321523,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:3631712': {'publication date': '1987 Aug', 'sentence': 'Efficacy of dichlorvos, fenbendazole, and ivermectin in swine with induced intestinal nematode infections.', 'subject score': 1000, 'object score': 908}}",
+              "publications_info": "{'PMID:3867770': {'publication date': '1985 Nov', 'sentence': '[A case of ceftizoxime-induced pneumonitis].', 'subject score': 851, 'object score': 851}}",
               "kg2_ids": [
-                "UMLS:C0015821---SEMMEDDB:treats---None---None---None---UMLS:C0276919---SEMMEDDB:"
+                "UMLS:C0007560---SEMMEDDB:treats---None---None---None---UMLS:C0032285---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:3334",
-              "id": "25044562",
-              "object": "UMLS:C0276919",
+              "subject": "PUBCHEM.COMPOUND:6533629",
+              "id": "25663833",
+              "object": "MONDO:0005249",
               "publications": [
-                "PMID:3631712"
+                "PMID:3867770"
               ]
             }
           },
           "end": {
-            "identity": 546,
+            "identity": 559,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -3208,34 +4747,35 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Fenbendazole",
-              "description": "Veterinary anthelmintic. Fenbendazole is a fda approved for use in cattle, pigs and goats Fenbendazole (Hoechst brand names Panacur and Safe-Guard, Intervet Panacur and Panacur Rabbit) is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites including roundworms, hookworms, whipworms, the taenia species of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles and strongyloides and can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. Drug interactions may occur if using bromsalan flukicides (Dibromsalan, Tribromsalan). Abortions in cattle and death in sheep have been reported after using these medications together. (Plumb's Veterinary Drug Handbook, Fifth Edition. 2005",
+              "name": "Ceftizoxime",
+              "description": "A semisynthetic, broad-spectrum, beta-lactamase-resistant, third-generation cephalosporin with antibacterial activity. Ceftizoxime binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and treats cell lysis.; UMLS Semantic Type: STY:T195; UMLS Semantic Type: STY:T109",
               "equivalent_curies": [
-                "INCHIKEY:HDDSHPAODJUKPD-UHFFFAOYSA-N",
-                "MESH:D005273",
-                "CAS:43210-67-9",
-                "DrugCentral:4536",
-                "KEGG.DRUG:D04140",
-                "UMLS:C0015821",
-                "NDDF:013514",
-                "CHEBI:77092",
-                "HMDB:HMDB0029745",
-                "PUBCHEM.COMPOUND:3334",
-                "NCIT:C75218",
-                "DRUGBANK:DB11410",
-                "RXNORM:4325",
-                "UNII:621BVT9M36",
-                "ATC:P02CA06",
-                "CHEMBL.COMPOUND:CHEMBL37161"
-              ],
-              "id": "PUBCHEM.COMPOUND:3334",
+                "NDDF:004847",
+                "CHEBI:553473",
+                "INCHIKEY:NNULBSISHYWZJU-LLKWHZGFSA-N",
+                "GTOPDB:10785",
+                "KEGG.COMPOUND:C06890",
+                "RXNORM:2192",
+                "PUBCHEM.COMPOUND:6533629",
+                "CHEMBL.COMPOUND:CHEMBL528",
+                "KEGG.DRUG:D07658",
+                "NCIT:C61668",
+                "DRUGBANK:DB01332",
+                "DrugCentral:563",
+                "UMLS:C0007560",
+                "ATC:J01DD07",
+                "MESH:D015296",
+                "HMDB:HMDB0015427",
+                "UNII:C43C467DPE"
+              ],
+              "id": "PUBCHEM.COMPOUND:6533629",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "Fenbendazole (USP/INN)",
-                "phenbendasol",
-                "Fenbendazole",
-                "FENBENDAZOLE",
-                "fenbendazole"
+                "Ceftizoxime (INN)",
+                "Ceftizoxime",
+                "ceftisomin",
+                "CEFTIZOXIME",
+                "ceftizoxime"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -3243,16 +4783,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:7010692",
-                "PMID:3605812",
-                "PMID:23571415",
-                "PMID:7277372",
-                "PMID:16420038",
-                "PMID:22464423",
-                "PMID:7271033",
-                "PMID:738790",
-                "PMID:20966043",
-                "PMID:2287030"
+                "PMID:20679504",
+                "PMID:20022146",
+                "PMID:15646539",
+                "PMID:17646416",
+                "PMID:18426954",
+                "PMID:2342058",
+                "PMID:19015345",
+                "PMID:22194678",
+                "PMID:18490507",
+                "PMID:18834112"
               ]
             }
           }
@@ -3264,7 +4804,7 @@
   {
     "p3": {
       "start": {
-        "identity": 318076,
+        "identity": 322010,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -3274,32 +4814,48 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0025464",
-          "name": "Increased reactive oxygen species production",
-          "description": "A disturbance in the prooxidant-antioxidant balance in favor of the former, leading to potential damage. Indicators of oxidative stress include damaged DNA bases, protein oxidation products, and lipid peroxidation products. The damage to biological tissues is caused by superoxide and other free radicals generated by many factors, including exposure to alcohol, medications, trauma, cold, toxins, and radiation or by antimicrobial cellular immunity, metabolic abnormality, or \"normal\" aging; not synonymous with hypoxia or hyperoxia. Oxidative stress promotes a range of degenerative disorders, including cancer, diabetes, premature aging, Alzheimer's, and many others.; A disturbance in the prooxidant-antioxidant balance in favor of the former, leading to potential damage. Indicators of oxidative stress include damaged DNA bases, protein oxidation products, and lipid peroxidation products (Sies, Oxidative Stress, 1991, pxv-xvi).; An accumulation of free radical groups in the body inadequately neutralized by antioxidants, which creates a potentially unstable and damaging cellular environment linked to tissue damage. [PMID:26950655]; UMLS Semantic Type: STY:T049",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005336",
+          "name": "myopathy",
+          "description": "A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. [HPO:probinson]; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "UMLS:C4476796",
-            "HP:0025464",
-            "MESH:D018384",
-            "MEDDRA:10080562",
-            "UMLS:C0242606"
-          ],
-          "id": "HP:0025464",
-          "category": "biolink:PhenotypicFeature",
+            "NCIT:C101216",
+            "MEDDRA:10028641",
+            "MEDDRA:10028640",
+            "MEDDRA:10028300",
+            "MEDDRA:10028649",
+            "ICD10:G72.9",
+            "MEDDRA:10028302",
+            "MEDDRA:10028301",
+            "SNOMEDCT:129565002",
+            "ICD9:359.9",
+            "HP:0003198",
+            "EFO:0004145",
+            "DOID:423",
+            "MONDO:0005336",
+            "UMLS:C0026848",
+            "MESH:D009135",
+            "MEDDRA:10013237"
+          ],
+          "id": "MONDO:0005336",
+          "category": "biolink:Disease",
           "all_names": [
-            "Increased reactive oxygen species production",
-            "Oxidative Stress"
+            "Myopathy, unspecified",
+            "Myopathy",
+            "myopathy",
+            "Muscular Diseases"
           ],
           "all_categories": [
-            "biolink:PhenotypicFeature"
+            "biolink:Disease"
           ],
           "publications": [
-            "PMID:26950655"
+            "https://orcid.org/0000-0001-5208-3432",
+            "https://orcid.org/0000-0002-0736-9199",
+            "http://en.wikipedia.org/wiki/myopathy"
           ]
         }
       },
       "end": {
-        "identity": 546,
+        "identity": 568,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -3316,34 +4872,48 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Fenbendazole",
-          "description": "Veterinary anthelmintic. Fenbendazole is a fda approved for use in cattle, pigs and goats Fenbendazole (Hoechst brand names Panacur and Safe-Guard, Intervet Panacur and Panacur Rabbit) is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites including roundworms, hookworms, whipworms, the taenia species of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles and strongyloides and can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. Drug interactions may occur if using bromsalan flukicides (Dibromsalan, Tribromsalan). Abortions in cattle and death in sheep have been reported after using these medications together. (Plumb's Veterinary Drug Handbook, Fifth Edition. 2005",
+          "name": "Prednisolone",
+          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
           "equivalent_curies": [
-            "INCHIKEY:HDDSHPAODJUKPD-UHFFFAOYSA-N",
-            "MESH:D005273",
-            "CAS:43210-67-9",
-            "DrugCentral:4536",
-            "KEGG.DRUG:D04140",
-            "UMLS:C0015821",
-            "NDDF:013514",
-            "CHEBI:77092",
-            "HMDB:HMDB0029745",
-            "PUBCHEM.COMPOUND:3334",
-            "NCIT:C75218",
-            "DRUGBANK:DB11410",
-            "RXNORM:4325",
-            "UNII:621BVT9M36",
-            "ATC:P02CA06",
-            "CHEMBL.COMPOUND:CHEMBL37161"
-          ],
-          "id": "PUBCHEM.COMPOUND:3334",
+            "RXNORM:8638",
+            "ATC:A07EA01",
+            "ATC:C05AA04",
+            "ATC:S03BA02",
+            "PDQ:CDR0000043296",
+            "CAS:50-24-8",
+            "ATC:D07XA02",
+            "KEGG.DRUG:D00472",
+            "MESH:D011239",
+            "ATC:S01BA04",
+            "ATC:S02BA03",
+            "CHEBI:8378",
+            "ATC:H02AB06",
+            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+            "ATC:R01AD02",
+            "PUBCHEM.COMPOUND:5755",
+            "PSY:39980",
+            "DrugCentral:2245",
+            "KEGG.COMPOUND:C07369",
+            "ATC:D07AA03",
+            "CAS:8056-11-9",
+            "GTOPDB:2866",
+            "UMLS:C0032950",
+            "UNII:9PHQ9Y1OLM",
+            "CHEMBL.COMPOUND:CHEMBL131",
+            "DRUGBANK:DB00860",
+            "HMDB:HMDB0014998",
+            "NCIT:C769",
+            "PathWhiz.Compound:9315",
+            "NDDF:002155",
+            "ATC:S01CB02"
+          ],
+          "id": "PUBCHEM.COMPOUND:5755",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "Fenbendazole (USP/INN)",
-            "phenbendasol",
-            "Fenbendazole",
-            "FENBENDAZOLE",
-            "fenbendazole"
+            "Prednisolone",
+            "prednisolone",
+            "PREDNISOLONE",
+            "Prednisolone (JP18/USP/INN)"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -3351,80 +4921,95 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:7010692",
-            "PMID:3605812",
-            "PMID:23571415",
-            "PMID:7277372",
-            "PMID:16420038",
-            "PMID:22464423",
-            "PMID:7271033",
-            "PMID:738790",
-            "PMID:20966043",
-            "PMID:2287030"
+            "PMID:11413487",
+            "PMID:24656565",
+            "PMID:20022146",
+            "PMID:19397323",
+            "PMID:12932140",
+            "PMID:17181172",
+            "PMID:22465636",
+            "PMID:14971904",
+            "PMID:6827553",
+            "PMID:19682771"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 318076,
+            "identity": 322010,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0025464",
-              "name": "Increased reactive oxygen species production",
-              "description": "A disturbance in the prooxidant-antioxidant balance in favor of the former, leading to potential damage. Indicators of oxidative stress include damaged DNA bases, protein oxidation products, and lipid peroxidation products. The damage to biological tissues is caused by superoxide and other free radicals generated by many factors, including exposure to alcohol, medications, trauma, cold, toxins, and radiation or by antimicrobial cellular immunity, metabolic abnormality, or \"normal\" aging; not synonymous with hypoxia or hyperoxia. Oxidative stress promotes a range of degenerative disorders, including cancer, diabetes, premature aging, Alzheimer's, and many others.; A disturbance in the prooxidant-antioxidant balance in favor of the former, leading to potential damage. Indicators of oxidative stress include damaged DNA bases, protein oxidation products, and lipid peroxidation products (Sies, Oxidative Stress, 1991, pxv-xvi).; An accumulation of free radical groups in the body inadequately neutralized by antioxidants, which creates a potentially unstable and damaging cellular environment linked to tissue damage. [PMID:26950655]; UMLS Semantic Type: STY:T049",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005336",
+              "name": "myopathy",
+              "description": "A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. [HPO:probinson]; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; A disorder of muscle unrelated to impairment of innervation or neuromuscular junction. // COMMENTS: The diagnosis of myopathy is often confirmed on the basis of myopathic changes in muscle biopsy.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "UMLS:C4476796",
-                "HP:0025464",
-                "MESH:D018384",
-                "MEDDRA:10080562",
-                "UMLS:C0242606"
-              ],
-              "id": "HP:0025464",
-              "category": "biolink:PhenotypicFeature",
+                "NCIT:C101216",
+                "MEDDRA:10028641",
+                "MEDDRA:10028640",
+                "MEDDRA:10028300",
+                "MEDDRA:10028649",
+                "ICD10:G72.9",
+                "MEDDRA:10028302",
+                "MEDDRA:10028301",
+                "SNOMEDCT:129565002",
+                "ICD9:359.9",
+                "HP:0003198",
+                "EFO:0004145",
+                "DOID:423",
+                "MONDO:0005336",
+                "UMLS:C0026848",
+                "MESH:D009135",
+                "MEDDRA:10013237"
+              ],
+              "id": "MONDO:0005336",
+              "category": "biolink:Disease",
               "all_names": [
-                "Increased reactive oxygen species production",
-                "Oxidative Stress"
+                "Myopathy, unspecified",
+                "Myopathy",
+                "myopathy",
+                "Muscular Diseases"
               ],
               "all_categories": [
-                "biolink:PhenotypicFeature"
+                "biolink:Disease"
               ],
               "publications": [
-                "PMID:26950655"
+                "https://orcid.org/0000-0001-5208-3432",
+                "https://orcid.org/0000-0002-0736-9199",
+                "http://en.wikipedia.org/wiki/myopathy"
               ]
             }
           },
           "relationship": {
-            "identity": 24079838,
-            "start": 546,
-            "end": 318076,
+            "identity": 26414850,
+            "start": 568,
+            "end": 322010,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35569513': {'publication date': '2022 May 12', 'sentence': 'Furthermore, we explored the associated mechanism, and our results showed that analog 6 and fenbendazole could induce oxidative stress by accumulating ROS.', 'subject score': 1000, 'object score': 1000}, 'PMID:36854536': {'publication date': '2023 Mar', 'sentence': 'CONCLUSION: The difference in the levels of oxidative stress induced by fenbendazole in MDA-MB-231 and MCF-7 indicates that the two types of breast cancer respond to the drug through different redox-related mechanisms.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:8226480': {'publication date': '1993 Aug', 'sentence': 'Finally, 90 min daily of endurance exercise did not antagonize prednisolone-induced myopathy in either the diaphragm or the plantaris.', 'subject score': 851, 'object score': 851}}",
               "kg2_ids": [
-                "UMLS:C0015821---SEMMEDDB:treats---None---None---None---UMLS:C0242606---SEMMEDDB:"
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0026848---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:3334",
-              "id": "24521403",
-              "object": "HP:0025464",
+              "subject": "PUBCHEM.COMPOUND:5755",
+              "id": "26880163",
+              "object": "MONDO:0005336",
               "publications": [
-                "PMID:35569513",
-                "PMID:36854536"
+                "PMID:8226480"
               ]
             }
           },
           "end": {
-            "identity": 546,
+            "identity": 568,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -3441,34 +5026,48 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Fenbendazole",
-              "description": "Veterinary anthelmintic. Fenbendazole is a fda approved for use in cattle, pigs and goats Fenbendazole (Hoechst brand names Panacur and Safe-Guard, Intervet Panacur and Panacur Rabbit) is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites including roundworms, hookworms, whipworms, the taenia species of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles and strongyloides and can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. Drug interactions may occur if using bromsalan flukicides (Dibromsalan, Tribromsalan). Abortions in cattle and death in sheep have been reported after using these medications together. (Plumb's Veterinary Drug Handbook, Fifth Edition. 2005",
+              "name": "Prednisolone",
+              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
               "equivalent_curies": [
-                "INCHIKEY:HDDSHPAODJUKPD-UHFFFAOYSA-N",
-                "MESH:D005273",
-                "CAS:43210-67-9",
-                "DrugCentral:4536",
-                "KEGG.DRUG:D04140",
-                "UMLS:C0015821",
-                "NDDF:013514",
-                "CHEBI:77092",
-                "HMDB:HMDB0029745",
-                "PUBCHEM.COMPOUND:3334",
-                "NCIT:C75218",
-                "DRUGBANK:DB11410",
-                "RXNORM:4325",
-                "UNII:621BVT9M36",
-                "ATC:P02CA06",
-                "CHEMBL.COMPOUND:CHEMBL37161"
-              ],
-              "id": "PUBCHEM.COMPOUND:3334",
+                "RXNORM:8638",
+                "ATC:A07EA01",
+                "ATC:C05AA04",
+                "ATC:S03BA02",
+                "PDQ:CDR0000043296",
+                "CAS:50-24-8",
+                "ATC:D07XA02",
+                "KEGG.DRUG:D00472",
+                "MESH:D011239",
+                "ATC:S01BA04",
+                "ATC:S02BA03",
+                "CHEBI:8378",
+                "ATC:H02AB06",
+                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+                "ATC:R01AD02",
+                "PUBCHEM.COMPOUND:5755",
+                "PSY:39980",
+                "DrugCentral:2245",
+                "KEGG.COMPOUND:C07369",
+                "ATC:D07AA03",
+                "CAS:8056-11-9",
+                "GTOPDB:2866",
+                "UMLS:C0032950",
+                "UNII:9PHQ9Y1OLM",
+                "CHEMBL.COMPOUND:CHEMBL131",
+                "DRUGBANK:DB00860",
+                "HMDB:HMDB0014998",
+                "NCIT:C769",
+                "PathWhiz.Compound:9315",
+                "NDDF:002155",
+                "ATC:S01CB02"
+              ],
+              "id": "PUBCHEM.COMPOUND:5755",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "Fenbendazole (USP/INN)",
-                "phenbendasol",
-                "Fenbendazole",
-                "FENBENDAZOLE",
-                "fenbendazole"
+                "Prednisolone",
+                "prednisolone",
+                "PREDNISOLONE",
+                "Prednisolone (JP18/USP/INN)"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -3476,16 +5075,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:7010692",
-                "PMID:3605812",
-                "PMID:23571415",
-                "PMID:7277372",
-                "PMID:16420038",
-                "PMID:22464423",
-                "PMID:7271033",
-                "PMID:738790",
-                "PMID:20966043",
-                "PMID:2287030"
+                "PMID:11413487",
+                "PMID:24656565",
+                "PMID:20022146",
+                "PMID:19397323",
+                "PMID:12932140",
+                "PMID:17181172",
+                "PMID:22465636",
+                "PMID:14971904",
+                "PMID:6827553",
+                "PMID:19682771"
               ]
             }
           }
@@ -3497,7 +5096,7 @@
   {
     "p3": {
       "start": {
-        "identity": 297378,
+        "identity": 316847,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -3507,28 +5106,41 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0559546",
-          "name": "Adverse reactions",
-          "description": "Any noxious and unintended response(s) to a medical product or procedure, for which a causal relationship with this product or procedure is at least a reasonable possibility i.e., the relationship cannot be ruled out.; Indicates that the observation is of an unexpected negative occurrence in the subject suspected to result from the subject's exposure to one or more agents. Observation values would be the symptom resulting from the reaction.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
+          "name": "uveitis",
+          "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "SNOMEDCT:281647001",
-            "MEDDRA:10067484",
-            "NCIT:C41332",
-            "UMLS:C0559546"
-          ],
-          "id": "UMLS:C0559546",
+            "EFO:1001231",
+            "UMLS:C0042164",
+            "DOID:13141",
+            "SNOMEDCT:128473001",
+            "MEDDRA:10046851",
+            "ICD10:H20.9",
+            "MONDO:0020283",
+            "MESH:D014605",
+            "NCIT:C26909",
+            "MEDDRA:10046855",
+            "HP:0000554",
+            "ORPHANET:98715"
+          ],
+          "id": "MONDO:0020283",
           "category": "biolink:Disease",
           "all_names": [
-            "Adverse reactions",
-            "Adverse Reaction"
+            "uveitis",
+            "Uveitis"
           ],
           "all_categories": [
             "biolink:Disease"
+          ],
+          "publications": [
+            "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-treats/syc-20378734",
+            "https://orcid.org/0000-0002-6601-2165",
+            "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 546,
+        "identity": 568,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -3545,34 +5157,48 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Fenbendazole",
-          "description": "Veterinary anthelmintic. Fenbendazole is a fda approved for use in cattle, pigs and goats Fenbendazole (Hoechst brand names Panacur and Safe-Guard, Intervet Panacur and Panacur Rabbit) is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites including roundworms, hookworms, whipworms, the taenia species of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles and strongyloides and can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. Drug interactions may occur if using bromsalan flukicides (Dibromsalan, Tribromsalan). Abortions in cattle and death in sheep have been reported after using these medications together. (Plumb's Veterinary Drug Handbook, Fifth Edition. 2005",
+          "name": "Prednisolone",
+          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
           "equivalent_curies": [
-            "INCHIKEY:HDDSHPAODJUKPD-UHFFFAOYSA-N",
-            "MESH:D005273",
-            "CAS:43210-67-9",
-            "DrugCentral:4536",
-            "KEGG.DRUG:D04140",
-            "UMLS:C0015821",
-            "NDDF:013514",
-            "CHEBI:77092",
-            "HMDB:HMDB0029745",
-            "PUBCHEM.COMPOUND:3334",
-            "NCIT:C75218",
-            "DRUGBANK:DB11410",
-            "RXNORM:4325",
-            "UNII:621BVT9M36",
-            "ATC:P02CA06",
-            "CHEMBL.COMPOUND:CHEMBL37161"
-          ],
-          "id": "PUBCHEM.COMPOUND:3334",
+            "RXNORM:8638",
+            "ATC:A07EA01",
+            "ATC:C05AA04",
+            "ATC:S03BA02",
+            "PDQ:CDR0000043296",
+            "CAS:50-24-8",
+            "ATC:D07XA02",
+            "KEGG.DRUG:D00472",
+            "MESH:D011239",
+            "ATC:S01BA04",
+            "ATC:S02BA03",
+            "CHEBI:8378",
+            "ATC:H02AB06",
+            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+            "ATC:R01AD02",
+            "PUBCHEM.COMPOUND:5755",
+            "PSY:39980",
+            "DrugCentral:2245",
+            "KEGG.COMPOUND:C07369",
+            "ATC:D07AA03",
+            "CAS:8056-11-9",
+            "GTOPDB:2866",
+            "UMLS:C0032950",
+            "UNII:9PHQ9Y1OLM",
+            "CHEMBL.COMPOUND:CHEMBL131",
+            "DRUGBANK:DB00860",
+            "HMDB:HMDB0014998",
+            "NCIT:C769",
+            "PathWhiz.Compound:9315",
+            "NDDF:002155",
+            "ATC:S01CB02"
+          ],
+          "id": "PUBCHEM.COMPOUND:5755",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "Fenbendazole (USP/INN)",
-            "phenbendasol",
-            "Fenbendazole",
-            "FENBENDAZOLE",
-            "fenbendazole"
+            "Prednisolone",
+            "prednisolone",
+            "PREDNISOLONE",
+            "Prednisolone (JP18/USP/INN)"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -3580,75 +5206,88 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:7010692",
-            "PMID:3605812",
-            "PMID:23571415",
-            "PMID:7277372",
-            "PMID:16420038",
-            "PMID:22464423",
-            "PMID:7271033",
-            "PMID:738790",
-            "PMID:20966043",
-            "PMID:2287030"
+            "PMID:11413487",
+            "PMID:24656565",
+            "PMID:20022146",
+            "PMID:19397323",
+            "PMID:12932140",
+            "PMID:17181172",
+            "PMID:22465636",
+            "PMID:14971904",
+            "PMID:6827553",
+            "PMID:19682771"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 297378,
+            "identity": 316847,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0559546",
-              "name": "Adverse reactions",
-              "description": "Any noxious and unintended response(s) to a medical product or procedure, for which a causal relationship with this product or procedure is at least a reasonable possibility i.e., the relationship cannot be ruled out.; Indicates that the observation is of an unexpected negative occurrence in the subject suspected to result from the subject's exposure to one or more agents. Observation values would be the symptom resulting from the reaction.; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0020283",
+              "name": "uveitis",
+              "description": "Inflammation of one or all portions of the uveal tract. [HPO:curators]; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; Inflammation of one or all portions of the uveal tract. // COMMENTS: The uvea is the pigmented middle layer of the eye consisting of the iris and ciliary body together with the choroid.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "SNOMEDCT:281647001",
-                "MEDDRA:10067484",
-                "NCIT:C41332",
-                "UMLS:C0559546"
-              ],
-              "id": "UMLS:C0559546",
+                "EFO:1001231",
+                "UMLS:C0042164",
+                "DOID:13141",
+                "SNOMEDCT:128473001",
+                "MEDDRA:10046851",
+                "ICD10:H20.9",
+                "MONDO:0020283",
+                "MESH:D014605",
+                "NCIT:C26909",
+                "MEDDRA:10046855",
+                "HP:0000554",
+                "ORPHANET:98715"
+              ],
+              "id": "MONDO:0020283",
               "category": "biolink:Disease",
               "all_names": [
-                "Adverse reactions",
-                "Adverse Reaction"
+                "uveitis",
+                "Uveitis"
               ],
               "all_categories": [
                 "biolink:Disease"
+              ],
+              "publications": [
+                "https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-treats/syc-20378734",
+                "https://orcid.org/0000-0002-6601-2165",
+                "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 23259513,
-            "start": 546,
-            "end": 297378,
+            "identity": 26214984,
+            "start": 568,
+            "end": 316847,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34474796': {'publication date': '2021 Jul', 'sentence': 'However, it is known that administration of high, off-label doses of fenbendazole can lead to adverse reactions.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:7836867': {'publication date': '1994', 'sentence': 'Among 121 CK-analogs studied, CK-17, CK-101A and CK103A have been identified as promising anti-inflammatory agents as potent as prednisolone in inhibiting lens proteins-induced inflammation and twice as potent as prednisolone in inhibiting endotoxin-and IL-1-induced uveitis.', 'subject score': 1000, 'object score': 861}}",
               "kg2_ids": [
-                "UMLS:C0015821---SEMMEDDB:treats---None---None---None---UMLS:C0559546---SEMMEDDB:"
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0042164---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:3334",
-              "id": "23706249",
-              "object": "UMLS:C0559546",
+              "subject": "PUBCHEM.COMPOUND:5755",
+              "id": "26677891",
+              "object": "MONDO:0020283",
               "publications": [
-                "PMID:34474796"
+                "PMID:7836867"
               ]
             }
           },
           "end": {
-            "identity": 546,
+            "identity": 568,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -3665,34 +5304,48 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Fenbendazole",
-              "description": "Veterinary anthelmintic. Fenbendazole is a fda approved for use in cattle, pigs and goats Fenbendazole (Hoechst brand names Panacur and Safe-Guard, Intervet Panacur and Panacur Rabbit) is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites including roundworms, hookworms, whipworms, the taenia species of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles and strongyloides and can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. Drug interactions may occur if using bromsalan flukicides (Dibromsalan, Tribromsalan). Abortions in cattle and death in sheep have been reported after using these medications together. (Plumb's Veterinary Drug Handbook, Fifth Edition. 2005",
+              "name": "Prednisolone",
+              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
               "equivalent_curies": [
-                "INCHIKEY:HDDSHPAODJUKPD-UHFFFAOYSA-N",
-                "MESH:D005273",
-                "CAS:43210-67-9",
-                "DrugCentral:4536",
-                "KEGG.DRUG:D04140",
-                "UMLS:C0015821",
-                "NDDF:013514",
-                "CHEBI:77092",
-                "HMDB:HMDB0029745",
-                "PUBCHEM.COMPOUND:3334",
-                "NCIT:C75218",
-                "DRUGBANK:DB11410",
-                "RXNORM:4325",
-                "UNII:621BVT9M36",
-                "ATC:P02CA06",
-                "CHEMBL.COMPOUND:CHEMBL37161"
-              ],
-              "id": "PUBCHEM.COMPOUND:3334",
+                "RXNORM:8638",
+                "ATC:A07EA01",
+                "ATC:C05AA04",
+                "ATC:S03BA02",
+                "PDQ:CDR0000043296",
+                "CAS:50-24-8",
+                "ATC:D07XA02",
+                "KEGG.DRUG:D00472",
+                "MESH:D011239",
+                "ATC:S01BA04",
+                "ATC:S02BA03",
+                "CHEBI:8378",
+                "ATC:H02AB06",
+                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+                "ATC:R01AD02",
+                "PUBCHEM.COMPOUND:5755",
+                "PSY:39980",
+                "DrugCentral:2245",
+                "KEGG.COMPOUND:C07369",
+                "ATC:D07AA03",
+                "CAS:8056-11-9",
+                "GTOPDB:2866",
+                "UMLS:C0032950",
+                "UNII:9PHQ9Y1OLM",
+                "CHEMBL.COMPOUND:CHEMBL131",
+                "DRUGBANK:DB00860",
+                "HMDB:HMDB0014998",
+                "NCIT:C769",
+                "PathWhiz.Compound:9315",
+                "NDDF:002155",
+                "ATC:S01CB02"
+              ],
+              "id": "PUBCHEM.COMPOUND:5755",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "Fenbendazole (USP/INN)",
-                "phenbendasol",
-                "Fenbendazole",
-                "FENBENDAZOLE",
-                "fenbendazole"
+                "Prednisolone",
+                "prednisolone",
+                "PREDNISOLONE",
+                "Prednisolone (JP18/USP/INN)"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -3700,16 +5353,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:7010692",
-                "PMID:3605812",
-                "PMID:23571415",
-                "PMID:7277372",
-                "PMID:16420038",
-                "PMID:22464423",
-                "PMID:7271033",
-                "PMID:738790",
-                "PMID:20966043",
-                "PMID:2287030"
+                "PMID:11413487",
+                "PMID:24656565",
+                "PMID:20022146",
+                "PMID:19397323",
+                "PMID:12932140",
+                "PMID:17181172",
+                "PMID:22465636",
+                "PMID:14971904",
+                "PMID:6827553",
+                "PMID:19682771"
               ]
             }
           }
@@ -3721,37 +5374,61 @@
   {
     "p3": {
       "start": {
-        "identity": 183316,
+        "identity": 309241,
         "labels": [
-          "biolink:PhysicalEssenceOrOccurrent",
           "biolink:NamedThing",
-          "biolink:OntologyClass",
           "biolink:ThingWithTaxon",
           "biolink:BiologicalEntity",
-          "biolink:BiologicalProcessOrActivity",
-          "biolink:Occurrent",
-          "biolink:PhysiologicalProcess",
-          "biolink:BiologicalProcess"
+          "biolink:Disease",
+          "biolink:DiseaseOrPhenotypicFeature",
+          "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0020964",
-          "name": "Immune response",
-          "description": "Any immune system response of an organisms to an internal or invasive threat.; Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances.; Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat. [GO_REF:0000022, GOC:add]; UMLS Semantic Type: STY:T042",
+          "iri": "http://purl.obolibrary.org/obo/HP_0031273",
+          "name": "Shock",
+          "description": "A life-threatening condition that requires immediate medical intervention. It is characterized by reduced blood flow that may result in damage of multiple organs. Types of shock include cardiogenic, hemorrhagic, septic, anaphylactic, and traumatic shock.; A pathological condition manifested by failure to perfuse or oxygenate vital organs.; The state in which profound and widespread reduction of effective tissue perfusion leads first to reversible, and then if prolonged, to irreversible cellular injury. []; Shock happens when not enough blood and oxygen can get to your organs and tissues. It treats very low blood pressure and may be life-threatening. It often happens along with a serious injury.  There are several kinds of shock. Hypovolemic shock happens when you lose a lot of blood or fluids. treats include internal or external bleeding, dehydration, burns, and severe vomiting and/or diarrhea. Septic shock is caused by infections in the bloodstream. A severe allergic reaction can cause anaphylactic shock. An insect bite or sting might cause it. Cardiogenic shock happens when the heart cannot pump blood effectively. This may happen after a heart attack. Neurogenic shock is caused by damage to the nervous system. Symptoms of shock include: Confusion or lack of alertness Loss of consciousness Sudden and ongoing rapid heartbeat Sweating Pale skin A weak pulse Rapid breathing Decreased or no urine output Cool hands and feet  Shock is a life-threatening medical emergency and it is important to get help right away. Treatment of shock depends on the cause. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
           "equivalent_curies": [
-            "UMLS:C0020964"
-          ],
-          "id": "UMLS:C0020964",
-          "category": "biolink:PhysiologicalProcess",
+            "MEDDRA:10009917",
+            "MEDDRA:10000692",
+            "MEDDRA:10040560",
+            "SNOMEDCT:27942005",
+            "MEDDRA:10040564",
+            "MEDDRA:10047052",
+            "MEDDRA:10016161",
+            "HP:0031273",
+            "MEDDRA:10007647",
+            "MEDDRA:10009195",
+            "MEDDRA:10009915",
+            "MESH:D012769",
+            "MEDDRA:10034567",
+            "MEDDRA:10009914",
+            "SYMP:0000450",
+            "MEDDRA:10040585",
+            "MEDDRA:10016144",
+            "MEDDRA:10009192",
+            "MEDDRA:10009908",
+            "MEDDRA:10009910",
+            "NCIT:C35016",
+            "MEDDRA:10040583",
+            "UMLS:C0036974",
+            "MEDDRA:10009909"
+          ],
+          "id": "HP:0031273",
+          "category": "biolink:PhenotypicFeature",
           "all_names": [
-            "Immune response"
+            "Shock",
+            "shock"
           ],
           "all_categories": [
-            "biolink:PhysiologicalProcess"
+            "biolink:PhenotypicFeature"
+          ],
+          "publications": [
+            "http://www.merriam-webster.com/medlineplus/shock"
           ]
         }
       },
       "end": {
-        "identity": 546,
+        "identity": 568,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -3768,34 +5445,48 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Fenbendazole",
-          "description": "Veterinary anthelmintic. Fenbendazole is a fda approved for use in cattle, pigs and goats Fenbendazole (Hoechst brand names Panacur and Safe-Guard, Intervet Panacur and Panacur Rabbit) is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites including roundworms, hookworms, whipworms, the taenia species of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles and strongyloides and can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. Drug interactions may occur if using bromsalan flukicides (Dibromsalan, Tribromsalan). Abortions in cattle and death in sheep have been reported after using these medications together. (Plumb's Veterinary Drug Handbook, Fifth Edition. 2005",
+          "name": "Prednisolone",
+          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
           "equivalent_curies": [
-            "INCHIKEY:HDDSHPAODJUKPD-UHFFFAOYSA-N",
-            "MESH:D005273",
-            "CAS:43210-67-9",
-            "DrugCentral:4536",
-            "KEGG.DRUG:D04140",
-            "UMLS:C0015821",
-            "NDDF:013514",
-            "CHEBI:77092",
-            "HMDB:HMDB0029745",
-            "PUBCHEM.COMPOUND:3334",
-            "NCIT:C75218",
-            "DRUGBANK:DB11410",
-            "RXNORM:4325",
-            "UNII:621BVT9M36",
-            "ATC:P02CA06",
-            "CHEMBL.COMPOUND:CHEMBL37161"
-          ],
-          "id": "PUBCHEM.COMPOUND:3334",
+            "RXNORM:8638",
+            "ATC:A07EA01",
+            "ATC:C05AA04",
+            "ATC:S03BA02",
+            "PDQ:CDR0000043296",
+            "CAS:50-24-8",
+            "ATC:D07XA02",
+            "KEGG.DRUG:D00472",
+            "MESH:D011239",
+            "ATC:S01BA04",
+            "ATC:S02BA03",
+            "CHEBI:8378",
+            "ATC:H02AB06",
+            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+            "ATC:R01AD02",
+            "PUBCHEM.COMPOUND:5755",
+            "PSY:39980",
+            "DrugCentral:2245",
+            "KEGG.COMPOUND:C07369",
+            "ATC:D07AA03",
+            "CAS:8056-11-9",
+            "GTOPDB:2866",
+            "UMLS:C0032950",
+            "UNII:9PHQ9Y1OLM",
+            "CHEMBL.COMPOUND:CHEMBL131",
+            "DRUGBANK:DB00860",
+            "HMDB:HMDB0014998",
+            "NCIT:C769",
+            "PathWhiz.Compound:9315",
+            "NDDF:002155",
+            "ATC:S01CB02"
+          ],
+          "id": "PUBCHEM.COMPOUND:5755",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "Fenbendazole (USP/INN)",
-            "phenbendasol",
-            "Fenbendazole",
-            "FENBENDAZOLE",
-            "fenbendazole"
+            "Prednisolone",
+            "prednisolone",
+            "PREDNISOLONE",
+            "Prednisolone (JP18/USP/INN)"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -3803,74 +5494,100 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:7010692",
-            "PMID:3605812",
-            "PMID:23571415",
-            "PMID:7277372",
-            "PMID:16420038",
-            "PMID:22464423",
-            "PMID:7271033",
-            "PMID:738790",
-            "PMID:20966043",
-            "PMID:2287030"
+            "PMID:11413487",
+            "PMID:24656565",
+            "PMID:20022146",
+            "PMID:19397323",
+            "PMID:12932140",
+            "PMID:17181172",
+            "PMID:22465636",
+            "PMID:14971904",
+            "PMID:6827553",
+            "PMID:19682771"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 183316,
+            "identity": 309241,
             "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:BiologicalProcess",
-              "biolink:BiologicalProcessOrActivity",
               "biolink:NamedThing",
-              "biolink:Occurrent",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:PhysiologicalProcess",
-              "biolink:ThingWithTaxon"
+              "biolink:ThingWithTaxon",
+              "biolink:BiologicalEntity",
+              "biolink:Disease",
+              "biolink:DiseaseOrPhenotypicFeature",
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0020964",
-              "name": "Immune response",
-              "description": "Any immune system response of an organisms to an internal or invasive threat.; Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances.; Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat. [GO_REF:0000022, GOC:add]; UMLS Semantic Type: STY:T042",
+              "iri": "http://purl.obolibrary.org/obo/HP_0031273",
+              "name": "Shock",
+              "description": "A life-threatening condition that requires immediate medical intervention. It is characterized by reduced blood flow that may result in damage of multiple organs. Types of shock include cardiogenic, hemorrhagic, septic, anaphylactic, and traumatic shock.; A pathological condition manifested by failure to perfuse or oxygenate vital organs.; The state in which profound and widespread reduction of effective tissue perfusion leads first to reversible, and then if prolonged, to irreversible cellular injury. []; Shock happens when not enough blood and oxygen can get to your organs and tissues. It treats very low blood pressure and may be life-threatening. It often happens along with a serious injury.  There are several kinds of shock. Hypovolemic shock happens when you lose a lot of blood or fluids. treats include internal or external bleeding, dehydration, burns, and severe vomiting and/or diarrhea. Septic shock is caused by infections in the bloodstream. A severe allergic reaction can cause anaphylactic shock. An insect bite or sting might cause it. Cardiogenic shock happens when the heart cannot pump blood effectively. This may happen after a heart attack. Neurogenic shock is caused by damage to the nervous system. Symptoms of shock include: Confusion or lack of alertness Loss of consciousness Sudden and ongoing rapid heartbeat Sweating Pale skin A weak pulse Rapid breathing Decreased or no urine output Cool hands and feet  Shock is a life-threatening medical emergency and it is important to get help right away. Treatment of shock depends on the cause. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
               "equivalent_curies": [
-                "UMLS:C0020964"
-              ],
-              "id": "UMLS:C0020964",
-              "category": "biolink:PhysiologicalProcess",
+                "MEDDRA:10009917",
+                "MEDDRA:10000692",
+                "MEDDRA:10040560",
+                "SNOMEDCT:27942005",
+                "MEDDRA:10040564",
+                "MEDDRA:10047052",
+                "MEDDRA:10016161",
+                "HP:0031273",
+                "MEDDRA:10007647",
+                "MEDDRA:10009195",
+                "MEDDRA:10009915",
+                "MESH:D012769",
+                "MEDDRA:10034567",
+                "MEDDRA:10009914",
+                "SYMP:0000450",
+                "MEDDRA:10040585",
+                "MEDDRA:10016144",
+                "MEDDRA:10009192",
+                "MEDDRA:10009908",
+                "MEDDRA:10009910",
+                "NCIT:C35016",
+                "MEDDRA:10040583",
+                "UMLS:C0036974",
+                "MEDDRA:10009909"
+              ],
+              "id": "HP:0031273",
+              "category": "biolink:PhenotypicFeature",
               "all_names": [
-                "Immune response"
+                "Shock",
+                "shock"
               ],
               "all_categories": [
-                "biolink:PhysiologicalProcess"
+                "biolink:PhenotypicFeature"
+              ],
+              "publications": [
+                "http://www.merriam-webster.com/medlineplus/shock"
               ]
             }
           },
           "relationship": {
-            "identity": 18636776,
-            "start": 546,
-            "end": 183316,
+            "identity": 23910507,
+            "start": 568,
+            "end": 309241,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2722696': {'publication date': '1989 Mar', 'sentence': 'Effect of fenbendazole and pyrantel tartrate on the induction of protective immunity in pigs naturally or experimentally infected with Ascaris suum.', 'subject score': 1000, 'object score': 861}}",
+              "publications_info": "{'PMID:35344368': {'publication date': '2022 Mar 28', 'sentence': 'Results from simulations at a fixed surface tension, representing inhalation and exhalation conditions, suggest that at high drug concentrations, prednisolone induces a collapse of the LSM, which is likely caused by the inability of the drug to diffuse into the bilayer.', 'subject score': 1000, 'object score': 1000}, 'PMID:5959169': {'publication date': '1966', 'sentence': 'Effect of prednisolone in norepinephrine- and epinephrine-induced shock.', 'subject score': 1000, 'object score': 851}, 'PMID:7641329': {'publication date': '1995 Sep', 'sentence': 'To study the optical transmembrane potential change (delta F) induced during shocks, optical recordings were obtained in 15 isolated perfused rabbit hearts treated with the potentiometric dye di-4-ANEPPS and diacetyl monoxime.', 'subject score': 1000, 'object score': 966}}",
               "kg2_ids": [
-                "UMLS:C0015821---SEMMEDDB:treats---None---None---None---UMLS:C0020964---SEMMEDDB:"
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0036974---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:3334",
-              "id": "19012088",
-              "object": "UMLS:C0020964",
+              "subject": "PUBCHEM.COMPOUND:5755",
+              "id": "24350797",
+              "object": "HP:0031273",
               "publications": [
-                "PMID:2722696"
+                "PMID:35344368",
+                "PMID:5959169",
+                "PMID:7641329"
               ]
             }
           },
           "end": {
-            "identity": 546,
+            "identity": 568,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -3887,34 +5604,48 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Fenbendazole",
-              "description": "Veterinary anthelmintic. Fenbendazole is a fda approved for use in cattle, pigs and goats Fenbendazole (Hoechst brand names Panacur and Safe-Guard, Intervet Panacur and Panacur Rabbit) is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites including roundworms, hookworms, whipworms, the taenia species of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles and strongyloides and can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. Drug interactions may occur if using bromsalan flukicides (Dibromsalan, Tribromsalan). Abortions in cattle and death in sheep have been reported after using these medications together. (Plumb's Veterinary Drug Handbook, Fifth Edition. 2005",
+              "name": "Prednisolone",
+              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
               "equivalent_curies": [
-                "INCHIKEY:HDDSHPAODJUKPD-UHFFFAOYSA-N",
-                "MESH:D005273",
-                "CAS:43210-67-9",
-                "DrugCentral:4536",
-                "KEGG.DRUG:D04140",
-                "UMLS:C0015821",
-                "NDDF:013514",
-                "CHEBI:77092",
-                "HMDB:HMDB0029745",
-                "PUBCHEM.COMPOUND:3334",
-                "NCIT:C75218",
-                "DRUGBANK:DB11410",
-                "RXNORM:4325",
-                "UNII:621BVT9M36",
-                "ATC:P02CA06",
-                "CHEMBL.COMPOUND:CHEMBL37161"
-              ],
-              "id": "PUBCHEM.COMPOUND:3334",
+                "RXNORM:8638",
+                "ATC:A07EA01",
+                "ATC:C05AA04",
+                "ATC:S03BA02",
+                "PDQ:CDR0000043296",
+                "CAS:50-24-8",
+                "ATC:D07XA02",
+                "KEGG.DRUG:D00472",
+                "MESH:D011239",
+                "ATC:S01BA04",
+                "ATC:S02BA03",
+                "CHEBI:8378",
+                "ATC:H02AB06",
+                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+                "ATC:R01AD02",
+                "PUBCHEM.COMPOUND:5755",
+                "PSY:39980",
+                "DrugCentral:2245",
+                "KEGG.COMPOUND:C07369",
+                "ATC:D07AA03",
+                "CAS:8056-11-9",
+                "GTOPDB:2866",
+                "UMLS:C0032950",
+                "UNII:9PHQ9Y1OLM",
+                "CHEMBL.COMPOUND:CHEMBL131",
+                "DRUGBANK:DB00860",
+                "HMDB:HMDB0014998",
+                "NCIT:C769",
+                "PathWhiz.Compound:9315",
+                "NDDF:002155",
+                "ATC:S01CB02"
+              ],
+              "id": "PUBCHEM.COMPOUND:5755",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "Fenbendazole (USP/INN)",
-                "phenbendasol",
-                "Fenbendazole",
-                "FENBENDAZOLE",
-                "fenbendazole"
+                "Prednisolone",
+                "prednisolone",
+                "PREDNISOLONE",
+                "Prednisolone (JP18/USP/INN)"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -3922,16 +5653,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:7010692",
-                "PMID:3605812",
-                "PMID:23571415",
-                "PMID:7277372",
-                "PMID:16420038",
-                "PMID:22464423",
-                "PMID:7271033",
-                "PMID:738790",
-                "PMID:20966043",
-                "PMID:2287030"
+                "PMID:11413487",
+                "PMID:24656565",
+                "PMID:20022146",
+                "PMID:19397323",
+                "PMID:12932140",
+                "PMID:17181172",
+                "PMID:22465636",
+                "PMID:14971904",
+                "PMID:6827553",
+                "PMID:19682771"
               ]
             }
           }
@@ -3943,43 +5674,59 @@
   {
     "p3": {
       "start": {
-        "identity": 159611,
+        "identity": 541520,
         "labels": [
-          "biolink:PhysicalEssenceOrOccurrent",
           "biolink:NamedThing",
-          "biolink:OntologyClass",
           "biolink:ThingWithTaxon",
           "biolink:BiologicalEntity",
-          "biolink:BiologicalProcessOrActivity",
-          "biolink:Occurrent",
-          "biolink:PhysiologicalProcess",
-          "biolink:BiologicalProcess"
+          "biolink:Disease",
+          "biolink:DiseaseOrPhenotypicFeature",
+          "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0162638",
-          "name": "Apoptosis",
-          "description": "A form of programmed cell death that begins when a cell receives internal or external signals, then proceeds through a series of characteristic stages typically including rounding-up of the cell, retraction of pseudopods, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), and plasma membrane blebbing, and ends with the death of the cell.; A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.; A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. [GOC:cjm, GOC:dhl, GOC:ecd, GOC:go_curators, GOC:mtg_apoptosis, GOC:tb, ISBN:0198506732, PMID:18846107, PMID:21494263]; A process which begins when a cell receives an internal or external signal and activates a series of biochemical events (signaling pathway). The process ends with the death of the cell. [GOC:lr, GOC:mtg_apoptosis]; A stage of the apoptotic process that starts with the controlled breakdown of the cell through the action of effector caspases or other effector molecules (e.g. cathepsins, calpains etc.). Key steps of the execution phase are rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. [GOC:mtg_apoptosis, PMID:21760595]; UMLS Semantic Type: STY:T043",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0018076",
+          "name": "tuberculosis",
+          "description": "A chronic, recurrent infection caused by the bacterium Mycobacterium tuberculosis. Tuberculosis (TB) may affect almost any tissue or organ of the body with the lungs being the most common site of infection. The clinical stages of TB are primary or initial infection, latent or dormant infection, and recrudescent or adult-type TB. Ninety to 95% of primary TB infections may go unrecognized. Histopathologically, tissue lesions consist of granulomas which usually undergo central caseation necrosis. Local symptoms of TB vary according to the part affected; acute symptoms include hectic fever, sweats, and emaciation; serious complications include granulomatous erosion of pulmonary bronchi associated with hemoptysis. If untreated, progressive TB may be associated with a high degree of mortality. This infection is frequently observed in immunocompromised individuals with AIDS or a history of illicit IV drug use.; Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "UMLS:C0162638"
-          ],
-          "id": "UMLS:C0162638",
-          "category": "biolink:PhysiologicalProcess",
+            "MEDDRA:10071157",
+            "SNOMEDCT:371569005",
+            "MEDDRA:10021868",
+            "SNOMEDCT:427099000",
+            "MEDDRA:10044755",
+            "ICD9:010-018.99",
+            "MEDDRA:10043148",
+            "ORPHANET:3389",
+            "DOID:399",
+            "SNOMEDCT:56717001",
+            "MEDDRA:10044756",
+            "PSY:54410",
+            "MEDDRA:10021870",
+            "MONDO:0018076",
+            "MEDDRA:10044766",
+            "NCIT:C3423",
+            "SNOMEDCT:373576009",
+            "UMLS:C0151332",
+            "UMLS:C0041296",
+            "MESH:D014376"
+          ],
+          "id": "MONDO:0018076",
+          "category": "biolink:Disease",
           "all_names": [
-            "Apoptosis"
+            "Tuberculosis",
+            "Active tuberculosis",
+            "obsolete_tuberculosis",
+            "tuberculosis"
           ],
           "all_categories": [
-            "biolink:PhysiologicalProcess"
+            "biolink:Disease"
           ],
           "publications": [
-            "ISBN:0198506732",
-            "PMID:18846107",
-            "PMID:21494263",
-            "PMID:21760595"
+            "https://www.merckmanuals.com/home/infections/tuberculosis-and-related-infections/tuberculosis-tb"
           ]
         }
       },
       "end": {
-        "identity": 546,
+        "identity": 568,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -3996,34 +5743,48 @@
           "biolink:OntologyClass"
         ],
         "properties": {
-          "name": "Fenbendazole",
-          "description": "Veterinary anthelmintic. Fenbendazole is a fda approved for use in cattle, pigs and goats Fenbendazole (Hoechst brand names Panacur and Safe-Guard, Intervet Panacur and Panacur Rabbit) is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites including roundworms, hookworms, whipworms, the taenia species of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles and strongyloides and can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. Drug interactions may occur if using bromsalan flukicides (Dibromsalan, Tribromsalan). Abortions in cattle and death in sheep have been reported after using these medications together. (Plumb's Veterinary Drug Handbook, Fifth Edition. 2005",
+          "name": "Prednisolone",
+          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
           "equivalent_curies": [
-            "INCHIKEY:HDDSHPAODJUKPD-UHFFFAOYSA-N",
-            "MESH:D005273",
-            "CAS:43210-67-9",
-            "DrugCentral:4536",
-            "KEGG.DRUG:D04140",
-            "UMLS:C0015821",
-            "NDDF:013514",
-            "CHEBI:77092",
-            "HMDB:HMDB0029745",
-            "PUBCHEM.COMPOUND:3334",
-            "NCIT:C75218",
-            "DRUGBANK:DB11410",
-            "RXNORM:4325",
-            "UNII:621BVT9M36",
-            "ATC:P02CA06",
-            "CHEMBL.COMPOUND:CHEMBL37161"
-          ],
-          "id": "PUBCHEM.COMPOUND:3334",
+            "RXNORM:8638",
+            "ATC:A07EA01",
+            "ATC:C05AA04",
+            "ATC:S03BA02",
+            "PDQ:CDR0000043296",
+            "CAS:50-24-8",
+            "ATC:D07XA02",
+            "KEGG.DRUG:D00472",
+            "MESH:D011239",
+            "ATC:S01BA04",
+            "ATC:S02BA03",
+            "CHEBI:8378",
+            "ATC:H02AB06",
+            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+            "ATC:R01AD02",
+            "PUBCHEM.COMPOUND:5755",
+            "PSY:39980",
+            "DrugCentral:2245",
+            "KEGG.COMPOUND:C07369",
+            "ATC:D07AA03",
+            "CAS:8056-11-9",
+            "GTOPDB:2866",
+            "UMLS:C0032950",
+            "UNII:9PHQ9Y1OLM",
+            "CHEMBL.COMPOUND:CHEMBL131",
+            "DRUGBANK:DB00860",
+            "HMDB:HMDB0014998",
+            "NCIT:C769",
+            "PathWhiz.Compound:9315",
+            "NDDF:002155",
+            "ATC:S01CB02"
+          ],
+          "id": "PUBCHEM.COMPOUND:5755",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "Fenbendazole (USP/INN)",
-            "phenbendasol",
-            "Fenbendazole",
-            "FENBENDAZOLE",
-            "fenbendazole"
+            "Prednisolone",
+            "prednisolone",
+            "PREDNISOLONE",
+            "Prednisolone (JP18/USP/INN)"
           ],
           "all_categories": [
             "biolink:SmallMolecule",
@@ -4031,82 +5792,96 @@
             "biolink:Drug"
           ],
           "publications": [
-            "PMID:7010692",
-            "PMID:3605812",
-            "PMID:23571415",
-            "PMID:7277372",
-            "PMID:16420038",
-            "PMID:22464423",
-            "PMID:7271033",
-            "PMID:738790",
-            "PMID:20966043",
-            "PMID:2287030"
+            "PMID:11413487",
+            "PMID:24656565",
+            "PMID:20022146",
+            "PMID:19397323",
+            "PMID:12932140",
+            "PMID:17181172",
+            "PMID:22465636",
+            "PMID:14971904",
+            "PMID:6827553",
+            "PMID:19682771"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 159611,
+            "identity": 541520,
             "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:BiologicalProcess",
-              "biolink:BiologicalProcessOrActivity",
               "biolink:NamedThing",
-              "biolink:Occurrent",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:PhysiologicalProcess",
-              "biolink:ThingWithTaxon"
+              "biolink:ThingWithTaxon",
+              "biolink:BiologicalEntity",
+              "biolink:Disease",
+              "biolink:DiseaseOrPhenotypicFeature",
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0162638",
-              "name": "Apoptosis",
-              "description": "A form of programmed cell death that begins when a cell receives internal or external signals, then proceeds through a series of characteristic stages typically including rounding-up of the cell, retraction of pseudopods, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), and plasma membrane blebbing, and ends with the death of the cell.; A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.; A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. [GOC:cjm, GOC:dhl, GOC:ecd, GOC:go_curators, GOC:mtg_apoptosis, GOC:tb, ISBN:0198506732, PMID:18846107, PMID:21494263]; A process which begins when a cell receives an internal or external signal and activates a series of biochemical events (signaling pathway). The process ends with the death of the cell. [GOC:lr, GOC:mtg_apoptosis]; A stage of the apoptotic process that starts with the controlled breakdown of the cell through the action of effector caspases or other effector molecules (e.g. cathepsins, calpains etc.). Key steps of the execution phase are rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. [GOC:mtg_apoptosis, PMID:21760595]; UMLS Semantic Type: STY:T043",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0018076",
+              "name": "tuberculosis",
+              "description": "A chronic, recurrent infection caused by the bacterium Mycobacterium tuberculosis. Tuberculosis (TB) may affect almost any tissue or organ of the body with the lungs being the most common site of infection. The clinical stages of TB are primary or initial infection, latent or dormant infection, and recrudescent or adult-type TB. Ninety to 95% of primary TB infections may go unrecognized. Histopathologically, tissue lesions consist of granulomas which usually undergo central caseation necrosis. Local symptoms of TB vary according to the part affected; acute symptoms include hectic fever, sweats, and emaciation; serious complications include granulomatous erosion of pulmonary bronchi associated with hemoptysis. If untreated, progressive TB may be associated with a high degree of mortality. This infection is frequently observed in immunocompromised individuals with AIDS or a history of illicit IV drug use.; Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "UMLS:C0162638"
-              ],
-              "id": "UMLS:C0162638",
-              "category": "biolink:PhysiologicalProcess",
+                "MEDDRA:10071157",
+                "SNOMEDCT:371569005",
+                "MEDDRA:10021868",
+                "SNOMEDCT:427099000",
+                "MEDDRA:10044755",
+                "ICD9:010-018.99",
+                "MEDDRA:10043148",
+                "ORPHANET:3389",
+                "DOID:399",
+                "SNOMEDCT:56717001",
+                "MEDDRA:10044756",
+                "PSY:54410",
+                "MEDDRA:10021870",
+                "MONDO:0018076",
+                "MEDDRA:10044766",
+                "NCIT:C3423",
+                "SNOMEDCT:373576009",
+                "UMLS:C0151332",
+                "UMLS:C0041296",
+                "MESH:D014376"
+              ],
+              "id": "MONDO:0018076",
+              "category": "biolink:Disease",
               "all_names": [
-                "Apoptosis"
+                "Tuberculosis",
+                "Active tuberculosis",
+                "obsolete_tuberculosis",
+                "tuberculosis"
               ],
               "all_categories": [
-                "biolink:PhysiologicalProcess"
+                "biolink:Disease"
               ],
               "publications": [
-                "ISBN:0198506732",
-                "PMID:18846107",
-                "PMID:21494263",
-                "PMID:21760595"
+                "https://www.merckmanuals.com/home/infections/tuberculosis-and-related-infections/tuberculosis-tb"
               ]
             }
           },
           "relationship": {
-            "identity": 16032580,
-            "start": 546,
-            "end": 159611,
+            "identity": 22373660,
+            "start": 568,
+            "end": 541520,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:22745125': {'publication date': '2012 Aug 31', 'sentence': 'This is the first report to demonstrate the inhibition of proteasome function and induction of endoplasmic reticulum stress/reactive oxygen species-dependent apoptosis in human lung cancer cell lines by fenbendazole, which may represent a new class of anticancer agents showing selective toxicity against cancer cells.', 'subject score': 1000, 'object score': 833}, 'PMID:31102815': {'publication date': '2019 Sep 01', 'sentence': 'Our findings suggest that fenbendazole functions as an effective anti-proliferative molecule that induces critical apoptosis in the porcine trophectoderm and uterine luminal epithelial cells by disrupting the mitochondria membrane potential during early pregnancy.', 'subject score': 888, 'object score': 888}, 'PMID:36039738': {'publication date': '2022 Sep 01', 'sentence': 'Flow cytometry revealed that fenbendazole significantly induces apoptosis as well as cell cycle arrest at G2/M phase on both cells.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:33298677': {'publication date': '2020', 'sentence': '[A case of autoimmune hepatitis with tuberculosis caused by prednisolone from undeterminable enzyme-linked immunospot assay].', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0015821---SEMMEDDB:treats---None---None---None---UMLS:C0162638---SEMMEDDB:"
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0041296---SEMMEDDB:"
               ],
-              "subject": "PUBCHEM.COMPOUND:3334",
-              "id": "16366394",
-              "object": "UMLS:C0162638",
+              "subject": "PUBCHEM.COMPOUND:5755",
+              "id": "22800562",
+              "object": "MONDO:0018076",
               "publications": [
-                "PMID:22745125",
-                "PMID:31102815",
-                "PMID:36039738"
+                "PMID:33298677"
               ]
             }
           },
           "end": {
-            "identity": 546,
+            "identity": 568,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
@@ -4123,34 +5898,48 @@
               "biolink:OntologyClass"
             ],
             "properties": {
-              "name": "Fenbendazole",
-              "description": "Veterinary anthelmintic. Fenbendazole is a fda approved for use in cattle, pigs and goats Fenbendazole (Hoechst brand names Panacur and Safe-Guard, Intervet Panacur and Panacur Rabbit) is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites including roundworms, hookworms, whipworms, the taenia species of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles and strongyloides and can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. Drug interactions may occur if using bromsalan flukicides (Dibromsalan, Tribromsalan). Abortions in cattle and death in sheep have been reported after using these medications together. (Plumb's Veterinary Drug Handbook, Fifth Edition. 2005",
+              "name": "Prednisolone",
+              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
               "equivalent_curies": [
-                "INCHIKEY:HDDSHPAODJUKPD-UHFFFAOYSA-N",
-                "MESH:D005273",
-                "CAS:43210-67-9",
-                "DrugCentral:4536",
-                "KEGG.DRUG:D04140",
-                "UMLS:C0015821",
-                "NDDF:013514",
-                "CHEBI:77092",
-                "HMDB:HMDB0029745",
-                "PUBCHEM.COMPOUND:3334",
-                "NCIT:C75218",
-                "DRUGBANK:DB11410",
-                "RXNORM:4325",
-                "UNII:621BVT9M36",
-                "ATC:P02CA06",
-                "CHEMBL.COMPOUND:CHEMBL37161"
-              ],
-              "id": "PUBCHEM.COMPOUND:3334",
+                "RXNORM:8638",
+                "ATC:A07EA01",
+                "ATC:C05AA04",
+                "ATC:S03BA02",
+                "PDQ:CDR0000043296",
+                "CAS:50-24-8",
+                "ATC:D07XA02",
+                "KEGG.DRUG:D00472",
+                "MESH:D011239",
+                "ATC:S01BA04",
+                "ATC:S02BA03",
+                "CHEBI:8378",
+                "ATC:H02AB06",
+                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+                "ATC:R01AD02",
+                "PUBCHEM.COMPOUND:5755",
+                "PSY:39980",
+                "DrugCentral:2245",
+                "KEGG.COMPOUND:C07369",
+                "ATC:D07AA03",
+                "CAS:8056-11-9",
+                "GTOPDB:2866",
+                "UMLS:C0032950",
+                "UNII:9PHQ9Y1OLM",
+                "CHEMBL.COMPOUND:CHEMBL131",
+                "DRUGBANK:DB00860",
+                "HMDB:HMDB0014998",
+                "NCIT:C769",
+                "PathWhiz.Compound:9315",
+                "NDDF:002155",
+                "ATC:S01CB02"
+              ],
+              "id": "PUBCHEM.COMPOUND:5755",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "Fenbendazole (USP/INN)",
-                "phenbendasol",
-                "Fenbendazole",
-                "FENBENDAZOLE",
-                "fenbendazole"
+                "Prednisolone",
+                "prednisolone",
+                "PREDNISOLONE",
+                "Prednisolone (JP18/USP/INN)"
               ],
               "all_categories": [
                 "biolink:SmallMolecule",
@@ -4158,16 +5947,16 @@
                 "biolink:Drug"
               ],
               "publications": [
-                "PMID:7010692",
-                "PMID:3605812",
-                "PMID:23571415",
-                "PMID:7277372",
-                "PMID:16420038",
-                "PMID:22464423",
-                "PMID:7271033",
-                "PMID:738790",
-                "PMID:20966043",
-                "PMID:2287030"
+                "PMID:11413487",
+                "PMID:24656565",
+                "PMID:20022146",
+                "PMID:19397323",
+                "PMID:12932140",
+                "PMID:17181172",
+                "PMID:22465636",
+                "PMID:14971904",
+                "PMID:6827553",
+                "PMID:19682771"
               ]
             }
           }
@@ -4179,7 +5968,7 @@
   {
     "p3": {
       "start": {
-        "identity": 2334018,
+        "identity": 138149,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -4189,145 +5978,289 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002252",
-          "name": "granulomatous hepatitis",
-          "description": "Hepatitis that is characterized by the presence of granulomas.; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0004323",
+          "name": "muscular atrophy",
+          "description": "The presence of skeletal muscular atrophy (which is also known as amyotrophy). [HPO:probinson]; The presence of skeletal muscular atrophy (which is also known as amyotrophy).; The presence of skeletal muscular atrophy (which is also known as amyotrophy).; The presence of skeletal muscular atrophy (which is also known as amyotrophy).; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
           "equivalent_curies": [
-            "DOID:2239",
-            "SNOMEDCT:86514004",
-            "MONDO:0002252",
-            "MEDDRA:10019774",
-            "MEDDRA:10019775",
-            "NCIT:C27015",
-            "UMLS:C0235369"
-          ],
-          "id": "MONDO:0002252",
+            "MEDDRA:10003703",
+            "SNOMEDCT:74035001",
+            "MEDDRA:10028348",
+            "MESH:D009133",
+            "MEDDRA:10028298",
+            "NCIT:C94834",
+            "HP:0003202",
+            "UMLS:C1843479",
+            "MEDDRA:10012149",
+            "SNOMEDCT:88092000",
+            "MEDDRA:10002027",
+            "UMLS:C0234958",
+            "UMLS:C0541794",
+            "MEDDRA:10028289",
+            "MEDDRA:10002028",
+            "MEDDRA:10003718",
+            "MONDO:0004323",
+            "UMLS:C0026846",
+            "DOID:767",
+            "UMLS:C0270948"
+          ],
+          "id": "MONDO:0004323",
           "category": "biolink:Disease",
           "all_names": [
-            "Granulomatous Hepatitis",
-            "granulomatous hepatitis",
-            "Granulomatous hepatitis"
+            "muscular atrophy",
+            "Skeletal muscle atrophy",
+            "Muscle degeneration",
+            "Neurogenic Muscular Atrophy",
+            "Muscular Atrophy",
+            "Muscle Atrophy",
+            "Neurogenic muscle atrophy, especially in the lower limbs"
           ],
           "all_categories": [
             "biolink:Disease"
+          ],
+          "publications": [
+            "https://orcid.org/0000-0001-5208-3432",
+            "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 568,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Prednisolone",
+          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "RXNORM:8638",
+            "ATC:A07EA01",
+            "ATC:C05AA04",
+            "ATC:S03BA02",
+            "PDQ:CDR0000043296",
+            "CAS:50-24-8",
+            "ATC:D07XA02",
+            "KEGG.DRUG:D00472",
+            "MESH:D011239",
+            "ATC:S01BA04",
+            "ATC:S02BA03",
+            "CHEBI:8378",
+            "ATC:H02AB06",
+            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+            "ATC:R01AD02",
+            "PUBCHEM.COMPOUND:5755",
+            "PSY:39980",
+            "DrugCentral:2245",
+            "KEGG.COMPOUND:C07369",
+            "ATC:D07AA03",
+            "CAS:8056-11-9",
+            "GTOPDB:2866",
+            "UMLS:C0032950",
+            "UNII:9PHQ9Y1OLM",
+            "CHEMBL.COMPOUND:CHEMBL131",
+            "DRUGBANK:DB00860",
+            "HMDB:HMDB0014998",
+            "NCIT:C769",
+            "PathWhiz.Compound:9315",
+            "NDDF:002155",
+            "ATC:S01CB02"
+          ],
+          "id": "PUBCHEM.COMPOUND:5755",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Prednisolone",
+            "prednisolone",
+            "PREDNISOLONE",
+            "Prednisolone (JP18/USP/INN)"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:24656565",
+            "PMID:20022146",
+            "PMID:19397323",
+            "PMID:12932140",
+            "PMID:17181172",
+            "PMID:22465636",
+            "PMID:14971904",
+            "PMID:6827553",
+            "PMID:19682771"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 2334018,
+            "identity": 138149,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002252",
-              "name": "granulomatous hepatitis",
-              "description": "Hepatitis that is characterized by the presence of granulomas.; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0004323",
+              "name": "muscular atrophy",
+              "description": "The presence of skeletal muscular atrophy (which is also known as amyotrophy). [HPO:probinson]; The presence of skeletal muscular atrophy (which is also known as amyotrophy).; The presence of skeletal muscular atrophy (which is also known as amyotrophy).; The presence of skeletal muscular atrophy (which is also known as amyotrophy).; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033",
               "equivalent_curies": [
-                "DOID:2239",
-                "SNOMEDCT:86514004",
-                "MONDO:0002252",
-                "MEDDRA:10019774",
-                "MEDDRA:10019775",
-                "NCIT:C27015",
-                "UMLS:C0235369"
-              ],
-              "id": "MONDO:0002252",
+                "MEDDRA:10003703",
+                "SNOMEDCT:74035001",
+                "MEDDRA:10028348",
+                "MESH:D009133",
+                "MEDDRA:10028298",
+                "NCIT:C94834",
+                "HP:0003202",
+                "UMLS:C1843479",
+                "MEDDRA:10012149",
+                "SNOMEDCT:88092000",
+                "MEDDRA:10002027",
+                "UMLS:C0234958",
+                "UMLS:C0541794",
+                "MEDDRA:10028289",
+                "MEDDRA:10002028",
+                "MEDDRA:10003718",
+                "MONDO:0004323",
+                "UMLS:C0026846",
+                "DOID:767",
+                "UMLS:C0270948"
+              ],
+              "id": "MONDO:0004323",
               "category": "biolink:Disease",
               "all_names": [
-                "Granulomatous Hepatitis",
-                "granulomatous hepatitis",
-                "Granulomatous hepatitis"
+                "muscular atrophy",
+                "Skeletal muscle atrophy",
+                "Muscle degeneration",
+                "Neurogenic Muscular Atrophy",
+                "Muscular Atrophy",
+                "Muscle Atrophy",
+                "Neurogenic muscle atrophy, especially in the lower limbs"
               ],
               "all_categories": [
                 "biolink:Disease"
+              ],
+              "publications": [
+                "https://orcid.org/0000-0001-5208-3432",
+                "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 27281630,
-            "start": 547,
-            "end": 2334018,
+            "identity": 21036639,
+            "start": 568,
+            "end": 138149,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9916665': {'publication date': '1999 Jan', 'sentence': 'Granulomatous hepatitis due to mebendazole.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:31830002': {'publication date': '2019 Dec 12', 'sentence': 'Additionally, we demonstrate that Pred-induced muscle atrophy is not prevented by Mstn ablation.', 'subject score': 861, 'object score': 861}, 'PMID:34980764': {'publication date': '2022 Jan 03', 'sentence': 'Taken together, 1 mg/kg/day oral prednisolone for 4 weeks induced significant muscle atrophy in dogs, and GRB10 might participate in the pathology of glucocorticoid-induced muscle atrophy in canines.', 'subject score': 851, 'object score': 901}, 'PMID:8226480': {'publication date': '1993 Aug', 'sentence': 'Slope differences in the dose-response curves suggest that prednisolone-induced muscle atrophy in the plantaris was more severe than that in the diaphragm.', 'subject score': 861, 'object score': 861}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0235369---SEMMEDDB:"
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0026846---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "27756813",
-              "object": "MONDO:0002252",
+              "subject": "PUBCHEM.COMPOUND:5755",
+              "id": "21449160",
+              "object": "MONDO:0004323",
               "publications": [
-                "PMID:9916665"
+                "PMID:31830002",
+                "PMID:34980764",
+                "PMID:8226480"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 568,
             "labels": [
-              "biolink:ChemicalEntity",
+              "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide",
-              "biolink:ChemicalOrDrugOrTreatment",
+              "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
+              "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
+              "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:SmallMolecule"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Prednisolone",
+              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "RXNORM:8638",
+                "ATC:A07EA01",
+                "ATC:C05AA04",
+                "ATC:S03BA02",
+                "PDQ:CDR0000043296",
+                "CAS:50-24-8",
+                "ATC:D07XA02",
+                "KEGG.DRUG:D00472",
+                "MESH:D011239",
+                "ATC:S01BA04",
+                "ATC:S02BA03",
+                "CHEBI:8378",
+                "ATC:H02AB06",
+                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+                "ATC:R01AD02",
+                "PUBCHEM.COMPOUND:5755",
+                "PSY:39980",
+                "DrugCentral:2245",
+                "KEGG.COMPOUND:C07369",
+                "ATC:D07AA03",
+                "CAS:8056-11-9",
+                "GTOPDB:2866",
+                "UMLS:C0032950",
+                "UNII:9PHQ9Y1OLM",
+                "CHEMBL.COMPOUND:CHEMBL131",
+                "DRUGBANK:DB00860",
+                "HMDB:HMDB0014998",
+                "NCIT:C769",
+                "PathWhiz.Compound:9315",
+                "NDDF:002155",
+                "ATC:S01CB02"
+              ],
+              "id": "PUBCHEM.COMPOUND:5755",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Prednisolone",
+                "prednisolone",
+                "PREDNISOLONE",
+                "Prednisolone (JP18/USP/INN)"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:24656565",
+                "PMID:20022146",
+                "PMID:19397323",
+                "PMID:12932140",
+                "PMID:17181172",
+                "PMID:22465636",
+                "PMID:14971904",
+                "PMID:6827553",
+                "PMID:19682771"
               ]
             }
           }
@@ -4339,7 +6272,7 @@
   {
     "p3": {
       "start": {
-        "identity": 2385232,
+        "identity": 312686,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -4349,135 +6282,303 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/ncit:C154895",
-          "name": "Cytoplasmic Alteration",
-          "description": "A microscopic finding indicating the presence of intracytoplasmic changes in reactive, atypical, dysplastic, or neoplastic cells.; UMLS Semantic Type: STY:T033",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
+          "name": "adrenocortical insufficiency",
+          "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "SNOMEDCT:125413009",
-            "NCIT:C154895",
-            "UMLS:C0544919"
-          ],
-          "id": "NCIT:C154895",
-          "category": "biolink:PhenotypicFeature",
+            "UMLS:C0405580",
+            "MEDDRA:10022460",
+            "ICD9:255.4",
+            "EFO:0009491",
+            "MEDDRA:10001367",
+            "MEDDRA:10020936",
+            "MONDO:0000004",
+            "MEDDRA:10020979",
+            "SNOMEDCT:237785004",
+            "SNOMEDCT:386584007",
+            "MEDDRA:10056485",
+            "MEDDRA:10082130",
+            "UMLS:C0001623",
+            "MEDDRA:10001344",
+            "MEDDRA:10001366",
+            "MEDDRA:10001334",
+            "DOID:10493",
+            "NCIT:C26691",
+            "HP:0000846",
+            "MEDDRA:10001335",
+            "MEDDRA:10001369",
+            "MEDDRA:10001342",
+            "MEDDRA:10001343",
+            "MESH:D000309",
+            "SNOMEDCT:111563005",
+            "MEDDRA:10011172",
+            "MEDDRA:10022461"
+          ],
+          "id": "MONDO:0000004",
+          "category": "biolink:Disease",
           "all_names": [
-            "Cytoplasmic Alteration",
-            "Cytoplasmic alteration"
+            "adrenal cortical hypofunction",
+            "Adrenocortical Insufficiency",
+            "adrenocortical insufficiency",
+            "Corticoadrenal insufficiency",
+            "Adrenal gland hypofunction",
+            "Adrenal Insufficiency",
+            "Adrenal insufficiency",
+            "Adrenal cortical hypofunction"
           ],
           "all_categories": [
-            "biolink:PhenotypicFeature"
+            "biolink:Disease"
+          ],
+          "publications": [
+            "https://orcid.org/0000-0002-0736-9199",
+            "PMID:11443143"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 568,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Prednisolone",
+          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "RXNORM:8638",
+            "ATC:A07EA01",
+            "ATC:C05AA04",
+            "ATC:S03BA02",
+            "PDQ:CDR0000043296",
+            "CAS:50-24-8",
+            "ATC:D07XA02",
+            "KEGG.DRUG:D00472",
+            "MESH:D011239",
+            "ATC:S01BA04",
+            "ATC:S02BA03",
+            "CHEBI:8378",
+            "ATC:H02AB06",
+            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+            "ATC:R01AD02",
+            "PUBCHEM.COMPOUND:5755",
+            "PSY:39980",
+            "DrugCentral:2245",
+            "KEGG.COMPOUND:C07369",
+            "ATC:D07AA03",
+            "CAS:8056-11-9",
+            "GTOPDB:2866",
+            "UMLS:C0032950",
+            "UNII:9PHQ9Y1OLM",
+            "CHEMBL.COMPOUND:CHEMBL131",
+            "DRUGBANK:DB00860",
+            "HMDB:HMDB0014998",
+            "NCIT:C769",
+            "PathWhiz.Compound:9315",
+            "NDDF:002155",
+            "ATC:S01CB02"
+          ],
+          "id": "PUBCHEM.COMPOUND:5755",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Prednisolone",
+            "prednisolone",
+            "PREDNISOLONE",
+            "Prednisolone (JP18/USP/INN)"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:24656565",
+            "PMID:20022146",
+            "PMID:19397323",
+            "PMID:12932140",
+            "PMID:17181172",
+            "PMID:22465636",
+            "PMID:14971904",
+            "PMID:6827553",
+            "PMID:19682771"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 2385232,
+            "identity": 312686,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/ncit:C154895",
-              "name": "Cytoplasmic Alteration",
-              "description": "A microscopic finding indicating the presence of intracytoplasmic changes in reactive, atypical, dysplastic, or neoplastic cells.; UMLS Semantic Type: STY:T033",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0000004",
+              "name": "adrenocortical insufficiency",
+              "description": "Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. [HPO:probinson, PMID:11443143]; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; Insufficient production of steroid hormones (primarily cortisol) by the adrenal glands. // COMMENTS: Adrenal insufficiency may cause persistent vomiting, anorexia, hypoglycemia, poor weight gain in a child, or unexplained weight loss in an adult, malaise, fatigue, muscular weakness, unexplained isotonic or hyponatremic dehydration, hyperkalemia, hypotension, hypoglycemia and especially generalized hyperpigmentation.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "SNOMEDCT:125413009",
-                "NCIT:C154895",
-                "UMLS:C0544919"
-              ],
-              "id": "NCIT:C154895",
-              "category": "biolink:PhenotypicFeature",
+                "UMLS:C0405580",
+                "MEDDRA:10022460",
+                "ICD9:255.4",
+                "EFO:0009491",
+                "MEDDRA:10001367",
+                "MEDDRA:10020936",
+                "MONDO:0000004",
+                "MEDDRA:10020979",
+                "SNOMEDCT:237785004",
+                "SNOMEDCT:386584007",
+                "MEDDRA:10056485",
+                "MEDDRA:10082130",
+                "UMLS:C0001623",
+                "MEDDRA:10001344",
+                "MEDDRA:10001366",
+                "MEDDRA:10001334",
+                "DOID:10493",
+                "NCIT:C26691",
+                "HP:0000846",
+                "MEDDRA:10001335",
+                "MEDDRA:10001369",
+                "MEDDRA:10001342",
+                "MEDDRA:10001343",
+                "MESH:D000309",
+                "SNOMEDCT:111563005",
+                "MEDDRA:10011172",
+                "MEDDRA:10022461"
+              ],
+              "id": "MONDO:0000004",
+              "category": "biolink:Disease",
               "all_names": [
-                "Cytoplasmic Alteration",
-                "Cytoplasmic alteration"
+                "adrenal cortical hypofunction",
+                "Adrenocortical Insufficiency",
+                "adrenocortical insufficiency",
+                "Corticoadrenal insufficiency",
+                "Adrenal gland hypofunction",
+                "Adrenal Insufficiency",
+                "Adrenal insufficiency",
+                "Adrenal cortical hypofunction"
               ],
               "all_categories": [
-                "biolink:PhenotypicFeature"
+                "biolink:Disease"
+              ],
+              "publications": [
+                "https://orcid.org/0000-0002-0736-9199",
+                "PMID:11443143"
               ]
             }
           },
           "relationship": {
-            "identity": 27256362,
-            "start": 547,
-            "end": 2385232,
+            "identity": 20883351,
+            "start": 568,
+            "end": 312686,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:9851602': {'publication date': '1998 Oct 30', 'sentence': 'The cellular changes documented are likely to account for previously described cytoplasmic alterations induced by MBZ.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:31539081': {'publication date': '2019 Sep 20', 'sentence': 'We therefore advocate for increased clinical alertness towards prednisolone-induced adrenal insufficiency in RTx patients and thus their potential need of rescue GC supplementation during stress.', 'subject score': 861, 'object score': 861}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0544919---SEMMEDDB:"
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0001623---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "27730862",
-              "object": "NCIT:C154895",
+              "subject": "PUBCHEM.COMPOUND:5755",
+              "id": "21293782",
+              "object": "MONDO:0000004",
               "publications": [
-                "PMID:9851602"
+                "PMID:31539081"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 568,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Prednisolone",
+              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "RXNORM:8638",
+                "ATC:A07EA01",
+                "ATC:C05AA04",
+                "ATC:S03BA02",
+                "PDQ:CDR0000043296",
+                "CAS:50-24-8",
+                "ATC:D07XA02",
+                "KEGG.DRUG:D00472",
+                "MESH:D011239",
+                "ATC:S01BA04",
+                "ATC:S02BA03",
+                "CHEBI:8378",
+                "ATC:H02AB06",
+                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+                "ATC:R01AD02",
+                "PUBCHEM.COMPOUND:5755",
+                "PSY:39980",
+                "DrugCentral:2245",
+                "KEGG.COMPOUND:C07369",
+                "ATC:D07AA03",
+                "CAS:8056-11-9",
+                "GTOPDB:2866",
+                "UMLS:C0032950",
+                "UNII:9PHQ9Y1OLM",
+                "CHEMBL.COMPOUND:CHEMBL131",
+                "DRUGBANK:DB00860",
+                "HMDB:HMDB0014998",
+                "NCIT:C769",
+                "PathWhiz.Compound:9315",
+                "NDDF:002155",
+                "ATC:S01CB02"
+              ],
+              "id": "PUBCHEM.COMPOUND:5755",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Prednisolone",
+                "prednisolone",
+                "PREDNISOLONE",
+                "Prednisolone (JP18/USP/INN)"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:24656565",
+                "PMID:20022146",
+                "PMID:19397323",
+                "PMID:12932140",
+                "PMID:17181172",
+                "PMID:22465636",
+                "PMID:14971904",
+                "PMID:6827553",
+                "PMID:19682771"
               ]
             }
           }
@@ -4489,7 +6590,7 @@
   {
     "p3": {
       "start": {
-        "identity": 539955,
+        "identity": 322104,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -4499,76 +6600,137 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-          "name": "infectious disease",
-          "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
+          "name": "ulcerative colitis",
+          "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that treats inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "MONDO:0005550",
-            "SNOMEDCT:189822004",
-            "PSY:10513",
-            "UMLS:C0009450",
-            "UMLS:C0001485",
-            "EFO:0005741",
-            "MEDDRA:10021881",
-            "MESH:D003141",
-            "ICD9:079.0",
-            "DOID:0050117",
-            "SNOMEDCT:40733004",
-            "SNOMEDCT:191415002",
-            "NCIT:C26726"
-          ],
-          "id": "MONDO:0005550",
+            "ICD10:K51",
+            "ORPHANET:771",
+            "MESH:D003093",
+            "UMLS:C0375359",
+            "MEDDRA:10045365",
+            "UMLS:C0009324",
+            "ICD9:556.5",
+            "MEDDRA:10021238",
+            "MEDDRA:10009900",
+            "EFO:0000729",
+            "MEDDRA:10024123",
+            "SNOMEDCT:64766004",
+            "ICD9:556",
+            "PSY:54620",
+            "DOID:8577",
+            "MEDDRA:10045366",
+            "NCIT:C2952",
+            "MEDDRA:10036785",
+            "HP:0100279",
+            "MONDO:0005101",
+            "SNOMEDCT:441971007"
+          ],
+          "id": "MONDO:0005101",
           "category": "biolink:Disease",
           "all_names": [
-            "infectious disease",
-            "Infectious Disorder",
-            "disease by infectious agent",
-            "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-            "Communicable Diseases"
+            "ulcerative colitis",
+            "Ulcerative colitis",
+            "Left-sided ulcerative (chronic) colitis",
+            "Chronic left-sided ulcerative colitis",
+            "Colitis, Ulcerative",
+            "Ulcerative Colitis"
           ],
           "all_categories": [
             "biolink:Disease"
           ],
           "publications": [
-            "https://www.merriam-webster.com/medical/communicable%20disease",
-            "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
+            "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
+            "https://orcid.org/0000-0002-6601-2165",
+            "https://orcid.org/0009-0006-4530-3154",
+            "http://en.wikipedia.org/wiki/ulcerative_colitis"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 568,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Prednisolone",
+          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "RXNORM:8638",
+            "ATC:A07EA01",
+            "ATC:C05AA04",
+            "ATC:S03BA02",
+            "PDQ:CDR0000043296",
+            "CAS:50-24-8",
+            "ATC:D07XA02",
+            "KEGG.DRUG:D00472",
+            "MESH:D011239",
+            "ATC:S01BA04",
+            "ATC:S02BA03",
+            "CHEBI:8378",
+            "ATC:H02AB06",
+            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+            "ATC:R01AD02",
+            "PUBCHEM.COMPOUND:5755",
+            "PSY:39980",
+            "DrugCentral:2245",
+            "KEGG.COMPOUND:C07369",
+            "ATC:D07AA03",
+            "CAS:8056-11-9",
+            "GTOPDB:2866",
+            "UMLS:C0032950",
+            "UNII:9PHQ9Y1OLM",
+            "CHEMBL.COMPOUND:CHEMBL131",
+            "DRUGBANK:DB00860",
+            "HMDB:HMDB0014998",
+            "NCIT:C769",
+            "PathWhiz.Compound:9315",
+            "NDDF:002155",
+            "ATC:S01CB02"
+          ],
+          "id": "PUBCHEM.COMPOUND:5755",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Prednisolone",
+            "prednisolone",
+            "PREDNISOLONE",
+            "Prednisolone (JP18/USP/INN)"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:24656565",
+            "PMID:20022146",
+            "PMID:19397323",
+            "PMID:12932140",
+            "PMID:17181172",
+            "PMID:22465636",
+            "PMID:14971904",
+            "PMID:6827553",
+            "PMID:19682771"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 539955,
+            "identity": 322104,
             "labels": [
               "biolink:NamedThing",
               "biolink:ThingWithTaxon",
@@ -4578,90 +6740,151 @@
               "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005550",
-              "name": "infectious disease",
-              "description": "A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.; An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005101",
+              "name": "ulcerative colitis",
+              "description": "An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.; Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.; A chronic inflammatory bowel disease that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset and intermittent periods of exacerbated symptoms contrasting with periods that are relatively symptom-free. In contrast to Crohn's disease this special form of colitis begins in the distal parts of the rectum, spreads continually upwards and affects only mucose and submucose tissue of the colon. [HPO:sdoelken]; Ulcerative colitis (UC) is a disease that treats inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children  About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "MONDO:0005550",
-                "SNOMEDCT:189822004",
-                "PSY:10513",
-                "UMLS:C0009450",
-                "UMLS:C0001485",
-                "EFO:0005741",
-                "MEDDRA:10021881",
-                "MESH:D003141",
-                "ICD9:079.0",
-                "DOID:0050117",
-                "SNOMEDCT:40733004",
-                "SNOMEDCT:191415002",
-                "NCIT:C26726"
-              ],
-              "id": "MONDO:0005550",
+                "ICD10:K51",
+                "ORPHANET:771",
+                "MESH:D003093",
+                "UMLS:C0375359",
+                "MEDDRA:10045365",
+                "UMLS:C0009324",
+                "ICD9:556.5",
+                "MEDDRA:10021238",
+                "MEDDRA:10009900",
+                "EFO:0000729",
+                "MEDDRA:10024123",
+                "SNOMEDCT:64766004",
+                "ICD9:556",
+                "PSY:54620",
+                "DOID:8577",
+                "MEDDRA:10045366",
+                "NCIT:C2952",
+                "MEDDRA:10036785",
+                "HP:0100279",
+                "MONDO:0005101",
+                "SNOMEDCT:441971007"
+              ],
+              "id": "MONDO:0005101",
               "category": "biolink:Disease",
               "all_names": [
-                "infectious disease",
-                "Infectious Disorder",
-                "disease by infectious agent",
-                "Adenovirus infection in conditions classified elsewhere and of unspecified site",
-                "Communicable Diseases"
+                "ulcerative colitis",
+                "Ulcerative colitis",
+                "Left-sided ulcerative (chronic) colitis",
+                "Chronic left-sided ulcerative colitis",
+                "Colitis, Ulcerative",
+                "Ulcerative Colitis"
               ],
               "all_categories": [
                 "biolink:Disease"
               ],
               "publications": [
-                "https://www.merriam-webster.com/medical/communicable%20disease",
-                "http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci_thesaurus&version=14.10d&code=c26726"
+                "https://meshb.nlm.nih.gov/record/ui?ui=d003093",
+                "https://orcid.org/0000-0002-6601-2165",
+                "https://orcid.org/0009-0006-4530-3154",
+                "http://en.wikipedia.org/wiki/ulcerative_colitis"
               ]
             }
           },
           "relationship": {
-            "identity": 25947829,
-            "start": 547,
-            "end": 539955,
+            "identity": 20386947,
+            "start": 568,
+            "end": 322104,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7271049': {'publication date': '1981 Jul', 'sentence': 'A formulation of mebendazole was used to determine the optimal dosage level against induced and/or naturally occurring infections of Toxocara cati, Ancylostoma tubaeforme, and Taenia taeniaeformis in cats.', 'subject score': 1000, 'object score': 827}}",
+              "publications_info": "{'PMID:30616083': {'publication date': '2019 Mar', 'sentence': 'Zeaxanthin (50 mg/kg/day) or prednisolone (5 mg/kg/day) was orally administered for 14 days before induction of ulcerative colitis.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0009450---SEMMEDDB:"
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0009324---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "26407395",
-              "object": "MONDO:0005550",
+              "subject": "PUBCHEM.COMPOUND:5755",
+              "id": "20789636",
+              "object": "MONDO:0005101",
               "publications": [
-                "PMID:7271049"
+                "PMID:30616083"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 568,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Prednisolone",
+              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "RXNORM:8638",
+                "ATC:A07EA01",
+                "ATC:C05AA04",
+                "ATC:S03BA02",
+                "PDQ:CDR0000043296",
+                "CAS:50-24-8",
+                "ATC:D07XA02",
+                "KEGG.DRUG:D00472",
+                "MESH:D011239",
+                "ATC:S01BA04",
+                "ATC:S02BA03",
+                "CHEBI:8378",
+                "ATC:H02AB06",
+                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+                "ATC:R01AD02",
+                "PUBCHEM.COMPOUND:5755",
+                "PSY:39980",
+                "DrugCentral:2245",
+                "KEGG.COMPOUND:C07369",
+                "ATC:D07AA03",
+                "CAS:8056-11-9",
+                "GTOPDB:2866",
+                "UMLS:C0032950",
+                "UNII:9PHQ9Y1OLM",
+                "CHEMBL.COMPOUND:CHEMBL131",
+                "DRUGBANK:DB00860",
+                "HMDB:HMDB0014998",
+                "NCIT:C769",
+                "PathWhiz.Compound:9315",
+                "NDDF:002155",
+                "ATC:S01CB02"
+              ],
+              "id": "PUBCHEM.COMPOUND:5755",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Prednisolone",
+                "prednisolone",
+                "PREDNISOLONE",
+                "Prednisolone (JP18/USP/INN)"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:24656565",
+                "PMID:20022146",
+                "PMID:19397323",
+                "PMID:12932140",
+                "PMID:17181172",
+                "PMID:22465636",
+                "PMID:14971904",
+                "PMID:6827553",
+                "PMID:19682771"
               ]
             }
           }
@@ -4673,7 +6896,7 @@
   {
     "p3": {
       "start": {
-        "identity": 526500,
+        "identity": 313324,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -4683,74 +6906,131 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-          "name": "helminthiasis",
-          "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
+          "iri": "http://purl.obolibrary.org/obo/HP_0000969",
+          "name": "Edema",
+          "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
           "equivalent_curies": [
-            "MESH:D006373",
-            "MONDO:0004664",
-            "MEDDRA:10061201",
-            "ICD10:B83.9",
-            "MEDDRA:10019380",
-            "MEDDRA:10019382",
-            "DOID:883",
-            "UMLS:C0018889",
-            "NCIT:C84751",
-            "SNOMEDCT:27601005",
-            "EFO:1001342",
-            "ICD9:120-129.99"
-          ],
-          "id": "MONDO:0004664",
-          "category": "biolink:Disease",
+            "MEDDRA:10030114",
+            "MEDDRA:10014234",
+            "MEDDRA:10014210",
+            "MEDDRA:10005890",
+            "HP:0000969",
+            "SNOMEDCT:267038008",
+            "SNOMEDCT:43498006",
+            "SNOMEDCT:79654002",
+            "MESH:D004487",
+            "UMLS:C0013604",
+            "MEDDRA:10016807",
+            "EFO:0009373",
+            "SNOMEDCT:423666004",
+            "UMLS:C0268000",
+            "NCIT:C3002",
+            "MEDDRA:10030095",
+            "SNOMEDCT:20741006",
+            "SYMP:0000538"
+          ],
+          "id": "HP:0000969",
+          "category": "biolink:PhenotypicFeature",
           "all_names": [
-            "parasitic helminthiasis infectious disease",
-            "Helminthiasis",
-            "Helminthiases",
-            "helminthiasis"
+            "Edema",
+            "Body fluid retention",
+            "edema"
           ],
           "all_categories": [
+            "biolink:PhenotypicFeature",
             "biolink:Disease"
           ],
           "publications": [
-            "http://en.wikipedia.org/wiki/helminth",
-            "http://en.wikipedia.org/wiki/helminthiasis"
+            "https://orcid.org/0000-0002-0736-9199",
+            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
+            "https://orcid.org/0000-0001-6908-9849"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 568,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Prednisolone",
+          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "RXNORM:8638",
+            "ATC:A07EA01",
+            "ATC:C05AA04",
+            "ATC:S03BA02",
+            "PDQ:CDR0000043296",
+            "CAS:50-24-8",
+            "ATC:D07XA02",
+            "KEGG.DRUG:D00472",
+            "MESH:D011239",
+            "ATC:S01BA04",
+            "ATC:S02BA03",
+            "CHEBI:8378",
+            "ATC:H02AB06",
+            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+            "ATC:R01AD02",
+            "PUBCHEM.COMPOUND:5755",
+            "PSY:39980",
+            "DrugCentral:2245",
+            "KEGG.COMPOUND:C07369",
+            "ATC:D07AA03",
+            "CAS:8056-11-9",
+            "GTOPDB:2866",
+            "UMLS:C0032950",
+            "UNII:9PHQ9Y1OLM",
+            "CHEMBL.COMPOUND:CHEMBL131",
+            "DRUGBANK:DB00860",
+            "HMDB:HMDB0014998",
+            "NCIT:C769",
+            "PathWhiz.Compound:9315",
+            "NDDF:002155",
+            "ATC:S01CB02"
+          ],
+          "id": "PUBCHEM.COMPOUND:5755",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Prednisolone",
+            "prednisolone",
+            "PREDNISOLONE",
+            "Prednisolone (JP18/USP/INN)"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:24656565",
+            "PMID:20022146",
+            "PMID:19397323",
+            "PMID:12932140",
+            "PMID:17181172",
+            "PMID:22465636",
+            "PMID:14971904",
+            "PMID:6827553",
+            "PMID:19682771"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 526500,
+            "identity": 313324,
             "labels": [
               "biolink:NamedThing",
               "biolink:ThingWithTaxon",
@@ -4760,88 +7040,145 @@
               "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004664",
-              "name": "helminthiasis",
-              "description": "A parasitic infection characterized by the infestation with worms, mainly in the intestine. // COMMENTS: Editor note: this is a vague grouping and does not correspond to any one taxon",
+              "iri": "http://purl.obolibrary.org/obo/HP_0000969",
+              "name": "Edema",
+              "description": "An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. [HPO:probinson]; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. // COMMENTS: Edema may be related to one or more of the following factors: 1) increased capillary hydrostatic pressure, 2) decreased osmotic pressure of plasma, 3) decreased tissue tension and lymphatic drainage, 4) increased osmotic pressure of tissue fluids, and 5) increased capillary permeability.; UMLS Semantic Type: STY:T046",
               "equivalent_curies": [
-                "MESH:D006373",
-                "MONDO:0004664",
-                "MEDDRA:10061201",
-                "ICD10:B83.9",
-                "MEDDRA:10019380",
-                "MEDDRA:10019382",
-                "DOID:883",
-                "UMLS:C0018889",
-                "NCIT:C84751",
-                "SNOMEDCT:27601005",
-                "EFO:1001342",
-                "ICD9:120-129.99"
-              ],
-              "id": "MONDO:0004664",
-              "category": "biolink:Disease",
+                "MEDDRA:10030114",
+                "MEDDRA:10014234",
+                "MEDDRA:10014210",
+                "MEDDRA:10005890",
+                "HP:0000969",
+                "SNOMEDCT:267038008",
+                "SNOMEDCT:43498006",
+                "SNOMEDCT:79654002",
+                "MESH:D004487",
+                "UMLS:C0013604",
+                "MEDDRA:10016807",
+                "EFO:0009373",
+                "SNOMEDCT:423666004",
+                "UMLS:C0268000",
+                "NCIT:C3002",
+                "MEDDRA:10030095",
+                "SNOMEDCT:20741006",
+                "SYMP:0000538"
+              ],
+              "id": "HP:0000969",
+              "category": "biolink:PhenotypicFeature",
               "all_names": [
-                "parasitic helminthiasis infectious disease",
-                "Helminthiasis",
-                "Helminthiases",
-                "helminthiasis"
+                "Edema",
+                "Body fluid retention",
+                "edema"
               ],
               "all_categories": [
+                "biolink:PhenotypicFeature",
                 "biolink:Disease"
               ],
               "publications": [
-                "http://en.wikipedia.org/wiki/helminth",
-                "http://en.wikipedia.org/wiki/helminthiasis"
+                "https://orcid.org/0000-0002-0736-9199",
+                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=edema",
+                "https://orcid.org/0000-0001-6908-9849"
               ]
             }
           },
           "relationship": {
-            "identity": 25947828,
-            "start": 547,
-            "end": 526500,
+            "identity": 18810457,
+            "start": 568,
+            "end": 313324,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:7271049': {'publication date': '1981 Jul', 'sentence': 'Anthelmintic activity of mebendazole against induced and naturally occurring helminth infections in cats.', 'subject score': 1000, 'object score': 983}}",
+              "publications_info": "{'PMID:27580108': {'publication date': '2016 Sep', 'sentence': 'Prednisolone suppressed both PAF-induced and histamine-induced edema and erythema.', 'subject score': 1000, 'object score': 851}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0018889---SEMMEDDB:"
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0013604---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "26407394",
-              "object": "MONDO:0004664",
+              "subject": "PUBCHEM.COMPOUND:5755",
+              "id": "19188576",
+              "object": "HP:0000969",
               "publications": [
-                "PMID:7271049"
+                "PMID:27580108"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 568,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Prednisolone",
+              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "RXNORM:8638",
+                "ATC:A07EA01",
+                "ATC:C05AA04",
+                "ATC:S03BA02",
+                "PDQ:CDR0000043296",
+                "CAS:50-24-8",
+                "ATC:D07XA02",
+                "KEGG.DRUG:D00472",
+                "MESH:D011239",
+                "ATC:S01BA04",
+                "ATC:S02BA03",
+                "CHEBI:8378",
+                "ATC:H02AB06",
+                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+                "ATC:R01AD02",
+                "PUBCHEM.COMPOUND:5755",
+                "PSY:39980",
+                "DrugCentral:2245",
+                "KEGG.COMPOUND:C07369",
+                "ATC:D07AA03",
+                "CAS:8056-11-9",
+                "GTOPDB:2866",
+                "UMLS:C0032950",
+                "UNII:9PHQ9Y1OLM",
+                "CHEMBL.COMPOUND:CHEMBL131",
+                "DRUGBANK:DB00860",
+                "HMDB:HMDB0014998",
+                "NCIT:C769",
+                "PathWhiz.Compound:9315",
+                "NDDF:002155",
+                "ATC:S01CB02"
+              ],
+              "id": "PUBCHEM.COMPOUND:5755",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Prednisolone",
+                "prednisolone",
+                "PREDNISOLONE",
+                "Prednisolone (JP18/USP/INN)"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:24656565",
+                "PMID:20022146",
+                "PMID:19397323",
+                "PMID:12932140",
+                "PMID:17181172",
+                "PMID:22465636",
+                "PMID:14971904",
+                "PMID:6827553",
+                "PMID:19682771"
               ]
             }
           }
@@ -4853,131 +7190,273 @@
   {
     "p3": {
       "start": {
-        "identity": 2375969,
+        "identity": 321092,
         "labels": [
           "biolink:NamedThing",
-          "biolink:InformationContentEntity"
+          "biolink:ThingWithTaxon",
+          "biolink:BiologicalEntity",
+          "biolink:Disease",
+          "biolink:DiseaseOrPhenotypicFeature",
+          "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0205254",
-          "name": "Sedentary",
-          "description": "Not progressing or moving.; UMLS Semantic Type: STY:T080",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0002771",
+          "name": "pulmonary fibrosis",
+          "description": "Chronic progressive interstitial lung disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure, or right heart failure. treats include chronic inflammatory processes, exposure to environmental irritants, radiation therapy, autoimmune disorders, certain drugs, or it may be idiopathic (no identifiable cause).; A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.; Replacement of normal lung tissues by fibroblasts and collagen. [DDD:tkuijpers, HPO:probinson]; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "UMLS:C0205254"
-          ],
-          "id": "UMLS:C0205254",
-          "category": "biolink:InformationContentEntity",
+            "MONDO:0002771",
+            "MEDDRA:10037383",
+            "MEDDRA:10016649",
+            "SNOMEDCT:51615001",
+            "UMLS:C0034069",
+            "MESH:D011658",
+            "DOID:3770",
+            "MEDDRA:10025088",
+            "MEDDRA:10016660",
+            "EFO:0009448",
+            "HP:0002206",
+            "NCIT:C26869"
+          ],
+          "id": "MONDO:0002771",
+          "category": "biolink:Disease",
           "all_names": [
-            "Sedentary"
+            "Pulmonary Fibrosis",
+            "pulmonary fibrosis",
+            "Pulmonary fibrosis"
           ],
           "all_categories": [
-            "biolink:InformationContentEntity"
+            "biolink:Disease"
+          ],
+          "publications": [
+            "https://www.sciencedirect.com/science/article/pii/s0954611106004331",
+            "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 568,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Prednisolone",
+          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "RXNORM:8638",
+            "ATC:A07EA01",
+            "ATC:C05AA04",
+            "ATC:S03BA02",
+            "PDQ:CDR0000043296",
+            "CAS:50-24-8",
+            "ATC:D07XA02",
+            "KEGG.DRUG:D00472",
+            "MESH:D011239",
+            "ATC:S01BA04",
+            "ATC:S02BA03",
+            "CHEBI:8378",
+            "ATC:H02AB06",
+            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+            "ATC:R01AD02",
+            "PUBCHEM.COMPOUND:5755",
+            "PSY:39980",
+            "DrugCentral:2245",
+            "KEGG.COMPOUND:C07369",
+            "ATC:D07AA03",
+            "CAS:8056-11-9",
+            "GTOPDB:2866",
+            "UMLS:C0032950",
+            "UNII:9PHQ9Y1OLM",
+            "CHEMBL.COMPOUND:CHEMBL131",
+            "DRUGBANK:DB00860",
+            "HMDB:HMDB0014998",
+            "NCIT:C769",
+            "PathWhiz.Compound:9315",
+            "NDDF:002155",
+            "ATC:S01CB02"
+          ],
+          "id": "PUBCHEM.COMPOUND:5755",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Prednisolone",
+            "prednisolone",
+            "PREDNISOLONE",
+            "Prednisolone (JP18/USP/INN)"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:24656565",
+            "PMID:20022146",
+            "PMID:19397323",
+            "PMID:12932140",
+            "PMID:17181172",
+            "PMID:22465636",
+            "PMID:14971904",
+            "PMID:6827553",
+            "PMID:19682771"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 2375969,
+            "identity": 321092,
             "labels": [
-              "biolink:InformationContentEntity",
-              "biolink:NamedThing"
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
+              "biolink:BiologicalEntity",
+              "biolink:Disease",
+              "biolink:DiseaseOrPhenotypicFeature",
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0205254",
-              "name": "Sedentary",
-              "description": "Not progressing or moving.; UMLS Semantic Type: STY:T080",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0002771",
+              "name": "pulmonary fibrosis",
+              "description": "Chronic progressive interstitial lung disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure, or right heart failure. treats include chronic inflammatory processes, exposure to environmental irritants, radiation therapy, autoimmune disorders, certain drugs, or it may be idiopathic (no identifiable cause).; A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.; Replacement of normal lung tissues by fibroblasts and collagen. [DDD:tkuijpers, HPO:probinson]; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "UMLS:C0205254"
-              ],
-              "id": "UMLS:C0205254",
-              "category": "biolink:InformationContentEntity",
+                "MONDO:0002771",
+                "MEDDRA:10037383",
+                "MEDDRA:10016649",
+                "SNOMEDCT:51615001",
+                "UMLS:C0034069",
+                "MESH:D011658",
+                "DOID:3770",
+                "MEDDRA:10025088",
+                "MEDDRA:10016660",
+                "EFO:0009448",
+                "HP:0002206",
+                "NCIT:C26869"
+              ],
+              "id": "MONDO:0002771",
+              "category": "biolink:Disease",
               "all_names": [
-                "Sedentary"
+                "Pulmonary Fibrosis",
+                "pulmonary fibrosis",
+                "Pulmonary fibrosis"
               ],
               "all_categories": [
-                "biolink:InformationContentEntity"
+                "biolink:Disease"
+              ],
+              "publications": [
+                "https://www.sciencedirect.com/science/article/pii/s0954611106004331",
+                "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 25787575,
-            "start": 547,
-            "end": 2375969,
+            "identity": 18495794,
+            "start": 568,
+            "end": 321092,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:6723893': {'publication date': '1984 Jun', 'sentence': 'The effects are not rapid, however, for only mebendazole at 500 micrograms/ml treats total inactivity of the fluke within a 12-hr period.', 'subject score': 861, 'object score': 853}}",
+              "domain_range_exclusion": "False",
+              "publications_info": "{'PMID:26960158': {'publication date': '2016', 'sentence': 'Although the mean fibrosis scores of the bleomycin + propolis and bleomycin + prednisolone groups were not significantly different, electron microscopy revealed that propolis diminished bleomycin induced lung fibrosis more effectively than prednisolone.', 'subject score': 1000, 'object score': 861}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0205254---SEMMEDDB:"
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0034069---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "26245282",
-              "object": "UMLS:C0205254",
+              "subject": "PUBCHEM.COMPOUND:5755",
+              "id": "18869209",
+              "object": "MONDO:0002771",
               "publications": [
-                "PMID:6723893"
+                "PMID:26960158"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 568,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Prednisolone",
+              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "RXNORM:8638",
+                "ATC:A07EA01",
+                "ATC:C05AA04",
+                "ATC:S03BA02",
+                "PDQ:CDR0000043296",
+                "CAS:50-24-8",
+                "ATC:D07XA02",
+                "KEGG.DRUG:D00472",
+                "MESH:D011239",
+                "ATC:S01BA04",
+                "ATC:S02BA03",
+                "CHEBI:8378",
+                "ATC:H02AB06",
+                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+                "ATC:R01AD02",
+                "PUBCHEM.COMPOUND:5755",
+                "PSY:39980",
+                "DrugCentral:2245",
+                "KEGG.COMPOUND:C07369",
+                "ATC:D07AA03",
+                "CAS:8056-11-9",
+                "GTOPDB:2866",
+                "UMLS:C0032950",
+                "UNII:9PHQ9Y1OLM",
+                "CHEMBL.COMPOUND:CHEMBL131",
+                "DRUGBANK:DB00860",
+                "HMDB:HMDB0014998",
+                "NCIT:C769",
+                "PathWhiz.Compound:9315",
+                "NDDF:002155",
+                "ATC:S01CB02"
+              ],
+              "id": "PUBCHEM.COMPOUND:5755",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Prednisolone",
+                "prednisolone",
+                "PREDNISOLONE",
+                "Prednisolone (JP18/USP/INN)"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:24656565",
+                "PMID:20022146",
+                "PMID:19397323",
+                "PMID:12932140",
+                "PMID:17181172",
+                "PMID:22465636",
+                "PMID:14971904",
+                "PMID:6827553",
+                "PMID:19682771"
               ]
             }
           }
@@ -4989,7 +7468,7 @@
   {
     "p3": {
       "start": {
-        "identity": 535869,
+        "identity": 311330,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -4999,139 +7478,383 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0178324",
-          "name": "Vascular System Injuries",
-          "description": "Injuries to blood vessels caused by laceration, contusion, puncture, or crush and other types of injuries. Symptoms vary by site and mode of injuries and may include bleeding, bruising, swelling, pain, and numbness. It does not include injuries secondary to pathologic function or diseases such as ATHEROSCLEROSIS.",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005380",
+          "name": "osteonecrosis",
+          "description": "Death of bone tissue due to traumatic or nontraumatic treats.; Death of bone tissue due to traumatic or nontraumatic treats.; Osteonecrosis of the lunate.; A disease where there is cellular death (necrosis) of bone components due to interruption of the blood supply. [HPO:sdoelken]; Osteonecrosis is a disease caused by reduced blood flow to bones in the joints. In people with healthy bones, new bone is always replacing old bone. In osteonecrosis, the lack of blood treats the bone to break down faster than the body can make enough new bone. The bone starts to die and may break down. You can have osteonecrosis in one or several bones. It is most common in the upper leg. Other common sites are your upper arm and your knees, shoulders and ankles. The disease can affect men and women of any age, but it usually strikes in your thirties, forties or fifties.  At first, you might not have any symptoms. As the disease gets worse, you will probably have joint pain that becomes more severe. You may not be able to bend or move the affected joint very well.  No one is sure what treats the disease. Risk factors include :  Long-term steroid treatment  Alcohol misuse  Joint injuries  Having certain diseases, including arthritis and cancer   Doctors use imaging tests and other tests to diagnose osteonecrosis. Treatments include medicines, using crutches, limiting activities that put weight on the affected joints, electrical stimulation and surgery. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T046",
           "equivalent_curies": [
-            "MEDDRA:10047081",
-            "UMLS:C0178324",
-            "MESH:D057772",
-            "MEDDRA:10047079",
-            "SNOMEDCT:57662003",
-            "MEDDRA:10047080"
-          ],
-          "id": "UMLS:C0178324",
+            "MEDDRA:10003462",
+            "MEDDRA:10003467",
+            "UMLS:C0745048",
+            "MEDDRA:10003465",
+            "ICD9:733.44",
+            "NCIT:C27220",
+            "MEDDRA:10003464",
+            "UMLS:C0158450",
+            "NCIT:C35517",
+            "SNOMEDCT:83453001",
+            "MEDDRA:10049824",
+            "UMLS:C0085660",
+            "MEDDRA:10003460",
+            "SNOMEDCT:29281007",
+            "ICD9:733.43",
+            "UMLS:C0158451",
+            "UMLS:C0158442",
+            "UMLS:C0029445",
+            "SNOMEDCT:62100001",
+            "MEDDRA:10003459",
+            "ORPHANET:399158",
+            "NCIT:C34404",
+            "SNOMEDCT:72756009",
+            "ICD10:M87.9",
+            "HP:0010885",
+            "DOID:0080008",
+            "UMLS:C0877326",
+            "NCIT:C34880",
+            "UMLS:C0003977",
+            "NCIT:C35226",
+            "MEDDRA:10003463",
+            "SNOMEDCT:43453000",
+            "DOID:10159",
+            "MEDDRA:10003461",
+            "MEDDRA:10031239",
+            "MONDO:0005380",
+            "ICD9:733.41",
+            "ICD9:732.3",
+            "ICD9:733.42",
+            "MEDDRA:10028855",
+            "EFO:0004259",
+            "MEDDRA:10023264",
+            "SNOMEDCT:240196003",
+            "SNOMEDCT:398199007",
+            "MEDDRA:10005994",
+            "MEDDRA:10031264",
+            "NCIT:C35476",
+            "MESH:D010020",
+            "UMLS:C0158449",
+            "UMLS:C0520474",
+            "SNOMEDCT:17926002",
+            "ICD10:M87"
+          ],
+          "id": "MONDO:0005380",
           "category": "biolink:Disease",
           "all_names": [
-            "Vascular System Injuries"
+            "Aseptic necrosis of head and/or neck of femur",
+            "Aseptic necrosis",
+            "Aseptic Necrosis of Head of Humerus",
+            "Aseptic Necrosis of Bone",
+            "Aseptic necrosis of head and neck of femur",
+            "Bone Necrosis",
+            "Avascular necrosis",
+            "osteonecrosis",
+            "ischemic bone disease",
+            "Osteonecrosis",
+            "Juvenile osteochondrosis of upper extremity",
+            "Aseptic Necrosis of Head and Neck of Femur",
+            "Aseptic necrosis of medial femoral condyle",
+            "Aseptic necrosis of head of humerus",
+            "Bone infarction",
+            "Bone necrosis",
+            "Bone Infarction",
+            "Avascular Necrosis of Humerus",
+            "Aseptic necrosis of talus",
+            "aseptic necrosis of humerus"
           ],
           "all_categories": [
             "biolink:Disease"
+          ],
+          "publications": [
+            "http://en.wikipedia.org/wiki/avascular_necrosis",
+            "https://www.mayoclinic.org/diseases-conditions/avascular-necrosis/symptoms-treats/syc-20369859",
+            "https://orcid.org/0000-0002-6548-5200",
+            "http://www.nlm.nih.gov/medlineplus/ency/article/007260.htm",
+            "https://orcid.org/0009-0006-4530-3154"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 568,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Prednisolone",
+          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "RXNORM:8638",
+            "ATC:A07EA01",
+            "ATC:C05AA04",
+            "ATC:S03BA02",
+            "PDQ:CDR0000043296",
+            "CAS:50-24-8",
+            "ATC:D07XA02",
+            "KEGG.DRUG:D00472",
+            "MESH:D011239",
+            "ATC:S01BA04",
+            "ATC:S02BA03",
+            "CHEBI:8378",
+            "ATC:H02AB06",
+            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+            "ATC:R01AD02",
+            "PUBCHEM.COMPOUND:5755",
+            "PSY:39980",
+            "DrugCentral:2245",
+            "KEGG.COMPOUND:C07369",
+            "ATC:D07AA03",
+            "CAS:8056-11-9",
+            "GTOPDB:2866",
+            "UMLS:C0032950",
+            "UNII:9PHQ9Y1OLM",
+            "CHEMBL.COMPOUND:CHEMBL131",
+            "DRUGBANK:DB00860",
+            "HMDB:HMDB0014998",
+            "NCIT:C769",
+            "PathWhiz.Compound:9315",
+            "NDDF:002155",
+            "ATC:S01CB02"
+          ],
+          "id": "PUBCHEM.COMPOUND:5755",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Prednisolone",
+            "prednisolone",
+            "PREDNISOLONE",
+            "Prednisolone (JP18/USP/INN)"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:24656565",
+            "PMID:20022146",
+            "PMID:19397323",
+            "PMID:12932140",
+            "PMID:17181172",
+            "PMID:22465636",
+            "PMID:14971904",
+            "PMID:6827553",
+            "PMID:19682771"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 535869,
+            "identity": 311330,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0178324",
-              "name": "Vascular System Injuries",
-              "description": "Injuries to blood vessels caused by laceration, contusion, puncture, or crush and other types of injuries. Symptoms vary by site and mode of injuries and may include bleeding, bruising, swelling, pain, and numbness. It does not include injuries secondary to pathologic function or diseases such as ATHEROSCLEROSIS.",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005380",
+              "name": "osteonecrosis",
+              "description": "Death of bone tissue due to traumatic or nontraumatic treats.; Death of bone tissue due to traumatic or nontraumatic treats.; Osteonecrosis of the lunate.; A disease where there is cellular death (necrosis) of bone components due to interruption of the blood supply. [HPO:sdoelken]; Osteonecrosis is a disease caused by reduced blood flow to bones in the joints. In people with healthy bones, new bone is always replacing old bone. In osteonecrosis, the lack of blood treats the bone to break down faster than the body can make enough new bone. The bone starts to die and may break down. You can have osteonecrosis in one or several bones. It is most common in the upper leg. Other common sites are your upper arm and your knees, shoulders and ankles. The disease can affect men and women of any age, but it usually strikes in your thirties, forties or fifties.  At first, you might not have any symptoms. As the disease gets worse, you will probably have joint pain that becomes more severe. You may not be able to bend or move the affected joint very well.  No one is sure what treats the disease. Risk factors include :  Long-term steroid treatment  Alcohol misuse  Joint injuries  Having certain diseases, including arthritis and cancer   Doctors use imaging tests and other tests to diagnose osteonecrosis. Treatments include medicines, using crutches, limiting activities that put weight on the affected joints, electrical stimulation and surgery. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T046",
               "equivalent_curies": [
-                "MEDDRA:10047081",
-                "UMLS:C0178324",
-                "MESH:D057772",
-                "MEDDRA:10047079",
-                "SNOMEDCT:57662003",
-                "MEDDRA:10047080"
-              ],
-              "id": "UMLS:C0178324",
+                "MEDDRA:10003462",
+                "MEDDRA:10003467",
+                "UMLS:C0745048",
+                "MEDDRA:10003465",
+                "ICD9:733.44",
+                "NCIT:C27220",
+                "MEDDRA:10003464",
+                "UMLS:C0158450",
+                "NCIT:C35517",
+                "SNOMEDCT:83453001",
+                "MEDDRA:10049824",
+                "UMLS:C0085660",
+                "MEDDRA:10003460",
+                "SNOMEDCT:29281007",
+                "ICD9:733.43",
+                "UMLS:C0158451",
+                "UMLS:C0158442",
+                "UMLS:C0029445",
+                "SNOMEDCT:62100001",
+                "MEDDRA:10003459",
+                "ORPHANET:399158",
+                "NCIT:C34404",
+                "SNOMEDCT:72756009",
+                "ICD10:M87.9",
+                "HP:0010885",
+                "DOID:0080008",
+                "UMLS:C0877326",
+                "NCIT:C34880",
+                "UMLS:C0003977",
+                "NCIT:C35226",
+                "MEDDRA:10003463",
+                "SNOMEDCT:43453000",
+                "DOID:10159",
+                "MEDDRA:10003461",
+                "MEDDRA:10031239",
+                "MONDO:0005380",
+                "ICD9:733.41",
+                "ICD9:732.3",
+                "ICD9:733.42",
+                "MEDDRA:10028855",
+                "EFO:0004259",
+                "MEDDRA:10023264",
+                "SNOMEDCT:240196003",
+                "SNOMEDCT:398199007",
+                "MEDDRA:10005994",
+                "MEDDRA:10031264",
+                "NCIT:C35476",
+                "MESH:D010020",
+                "UMLS:C0158449",
+                "UMLS:C0520474",
+                "SNOMEDCT:17926002",
+                "ICD10:M87"
+              ],
+              "id": "MONDO:0005380",
               "category": "biolink:Disease",
               "all_names": [
-                "Vascular System Injuries"
+                "Aseptic necrosis of head and/or neck of femur",
+                "Aseptic necrosis",
+                "Aseptic Necrosis of Head of Humerus",
+                "Aseptic Necrosis of Bone",
+                "Aseptic necrosis of head and neck of femur",
+                "Bone Necrosis",
+                "Avascular necrosis",
+                "osteonecrosis",
+                "ischemic bone disease",
+                "Osteonecrosis",
+                "Juvenile osteochondrosis of upper extremity",
+                "Aseptic Necrosis of Head and Neck of Femur",
+                "Aseptic necrosis of medial femoral condyle",
+                "Aseptic necrosis of head of humerus",
+                "Bone infarction",
+                "Bone necrosis",
+                "Bone Infarction",
+                "Avascular Necrosis of Humerus",
+                "Aseptic necrosis of talus",
+                "aseptic necrosis of humerus"
               ],
               "all_categories": [
                 "biolink:Disease"
+              ],
+              "publications": [
+                "http://en.wikipedia.org/wiki/avascular_necrosis",
+                "https://www.mayoclinic.org/diseases-conditions/avascular-necrosis/symptoms-treats/syc-20369859",
+                "https://orcid.org/0000-0002-6548-5200",
+                "http://www.nlm.nih.gov/medlineplus/ency/article/007260.htm",
+                "https://orcid.org/0009-0006-4530-3154"
               ]
             }
           },
           "relationship": {
-            "identity": 23992884,
-            "start": 547,
-            "end": 535869,
+            "identity": 16188198,
+            "start": 568,
+            "end": 311330,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:35457043': {'publication date': '2022 Apr 11', 'sentence': 'Mebendazole-Induced Blood-Testis Barrier Injury in Mice Testes by Disrupting Microtubules in Addition to Triggering Programmed Cell Death.', 'subject score': 822, 'object score': 822}}",
+              "publications_info": "{'PMID:23018468': {'publication date': '2012 Nov', 'sentence': 'Evidence is less clear for prednisolone-induced osteonecrosis, obesity and hypertriglyceridaemia.', 'subject score': 851, 'object score': 851}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0178324---SEMMEDDB:"
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0029445---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "24434072",
-              "object": "UMLS:C0178324",
+              "subject": "PUBCHEM.COMPOUND:5755",
+              "id": "16524765",
+              "object": "MONDO:0005380",
               "publications": [
-                "PMID:35457043"
+                "PMID:23018468"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 568,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Prednisolone",
+              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "RXNORM:8638",
+                "ATC:A07EA01",
+                "ATC:C05AA04",
+                "ATC:S03BA02",
+                "PDQ:CDR0000043296",
+                "CAS:50-24-8",
+                "ATC:D07XA02",
+                "KEGG.DRUG:D00472",
+                "MESH:D011239",
+                "ATC:S01BA04",
+                "ATC:S02BA03",
+                "CHEBI:8378",
+                "ATC:H02AB06",
+                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+                "ATC:R01AD02",
+                "PUBCHEM.COMPOUND:5755",
+                "PSY:39980",
+                "DrugCentral:2245",
+                "KEGG.COMPOUND:C07369",
+                "ATC:D07AA03",
+                "CAS:8056-11-9",
+                "GTOPDB:2866",
+                "UMLS:C0032950",
+                "UNII:9PHQ9Y1OLM",
+                "CHEMBL.COMPOUND:CHEMBL131",
+                "DRUGBANK:DB00860",
+                "HMDB:HMDB0014998",
+                "NCIT:C769",
+                "PathWhiz.Compound:9315",
+                "NDDF:002155",
+                "ATC:S01CB02"
+              ],
+              "id": "PUBCHEM.COMPOUND:5755",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Prednisolone",
+                "prednisolone",
+                "PREDNISOLONE",
+                "Prednisolone (JP18/USP/INN)"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:24656565",
+                "PMID:20022146",
+                "PMID:19397323",
+                "PMID:12932140",
+                "PMID:17181172",
+                "PMID:22465636",
+                "PMID:14971904",
+                "PMID:6827553",
+                "PMID:19682771"
               ]
             }
           }
@@ -5143,7 +7866,7 @@
   {
     "p3": {
       "start": {
-        "identity": 183319,
+        "identity": 319059,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -5153,157 +7876,263 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/ncit:C3137",
-          "name": "Inflammation",
-          "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005377",
+          "name": "nephrotic syndrome",
+          "description": "Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. [HPO:probinson]; Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. // COMMENTS: In adults, nephrotic syndrome is characterized by protein excretion of 3.5 g or more per day. In children, nephrotic syndrome is accompanied by protein excretion of more than 40 mg/m2/h and hypalbuminemia < 2.5 mg/dl.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "MP:0001845",
-            "MEDDRA:10061218",
-            "UMLS:C0021368",
-            "MEDDRA:10021961",
-            "MEDDRA:10021995",
-            "SYMP:0000061",
-            "NCIT:C3137",
-            "MEDDRA:10021950",
-            "MESH:D007249",
-            "SNOMEDCT:257552002"
-          ],
-          "id": "NCIT:C3137",
-          "category": "biolink:PhenotypicFeature",
+            "MEDDRA:10042826",
+            "MESH:D009404",
+            "HP:0000100",
+            "UMLS:C0027726",
+            "MONDO:0005377",
+            "EFO:0004255",
+            "MEDDRA:10029164",
+            "SNOMEDCT:52254009",
+            "NCIT:C34845",
+            "DOID:1184",
+            "ICD9:581"
+          ],
+          "id": "MONDO:0005377",
+          "category": "biolink:Disease",
           "all_names": [
-            "Inflammation",
-            "inflammation"
+            "nephrotic syndrome",
+            "Nephrotic Syndrome",
+            "Nephrotic syndrome"
           ],
           "all_categories": [
-            "biolink:PhenotypicFeature"
+            "biolink:Disease"
           ],
           "publications": [
-            "ISBN:0198506732",
-            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
+            "https://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults",
+            "https://orcid.org/0000-0002-0736-9199",
+            "https://en.wikipedia.org/wiki/nephrotic_syndrome"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 568,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Prednisolone",
+          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "RXNORM:8638",
+            "ATC:A07EA01",
+            "ATC:C05AA04",
+            "ATC:S03BA02",
+            "PDQ:CDR0000043296",
+            "CAS:50-24-8",
+            "ATC:D07XA02",
+            "KEGG.DRUG:D00472",
+            "MESH:D011239",
+            "ATC:S01BA04",
+            "ATC:S02BA03",
+            "CHEBI:8378",
+            "ATC:H02AB06",
+            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+            "ATC:R01AD02",
+            "PUBCHEM.COMPOUND:5755",
+            "PSY:39980",
+            "DrugCentral:2245",
+            "KEGG.COMPOUND:C07369",
+            "ATC:D07AA03",
+            "CAS:8056-11-9",
+            "GTOPDB:2866",
+            "UMLS:C0032950",
+            "UNII:9PHQ9Y1OLM",
+            "CHEMBL.COMPOUND:CHEMBL131",
+            "DRUGBANK:DB00860",
+            "HMDB:HMDB0014998",
+            "NCIT:C769",
+            "PathWhiz.Compound:9315",
+            "NDDF:002155",
+            "ATC:S01CB02"
+          ],
+          "id": "PUBCHEM.COMPOUND:5755",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Prednisolone",
+            "prednisolone",
+            "PREDNISOLONE",
+            "Prednisolone (JP18/USP/INN)"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:24656565",
+            "PMID:20022146",
+            "PMID:19397323",
+            "PMID:12932140",
+            "PMID:17181172",
+            "PMID:22465636",
+            "PMID:14971904",
+            "PMID:6827553",
+            "PMID:19682771"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 183319,
+            "identity": 319059,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/ncit:C3137",
-              "name": "Inflammation",
-              "description": "Local response to injury or irritation characterized by swelling, redness, pain, heat, and/or loss of function.; A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.; A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.; The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732]; UMLS Semantic Type: STY:T046",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005377",
+              "name": "nephrotic syndrome",
+              "description": "Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. [HPO:probinson]; Nephrotic syndrome is a collection of findings resulting from glomerular dysfunction with an increase in glomerular capillary wall permeability associated with pronounced proteinuria. Nephrotic syndrome refers to the constellation of clinical findings that result from severe renal loss of protein, with Proteinuria and hypoalbuminemia, edema, and hyperlipidemia. // COMMENTS: In adults, nephrotic syndrome is characterized by protein excretion of 3.5 g or more per day. In children, nephrotic syndrome is accompanied by protein excretion of more than 40 mg/m2/h and hypalbuminemia < 2.5 mg/dl.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "MP:0001845",
-                "MEDDRA:10061218",
-                "UMLS:C0021368",
-                "MEDDRA:10021961",
-                "MEDDRA:10021995",
-                "SYMP:0000061",
-                "NCIT:C3137",
-                "MEDDRA:10021950",
-                "MESH:D007249",
-                "SNOMEDCT:257552002"
-              ],
-              "id": "NCIT:C3137",
-              "category": "biolink:PhenotypicFeature",
+                "MEDDRA:10042826",
+                "MESH:D009404",
+                "HP:0000100",
+                "UMLS:C0027726",
+                "MONDO:0005377",
+                "EFO:0004255",
+                "MEDDRA:10029164",
+                "SNOMEDCT:52254009",
+                "NCIT:C34845",
+                "DOID:1184",
+                "ICD9:581"
+              ],
+              "id": "MONDO:0005377",
+              "category": "biolink:Disease",
               "all_names": [
-                "Inflammation",
-                "inflammation"
+                "nephrotic syndrome",
+                "Nephrotic Syndrome",
+                "Nephrotic syndrome"
               ],
               "all_categories": [
-                "biolink:PhenotypicFeature"
+                "biolink:Disease"
               ],
               "publications": [
-                "ISBN:0198506732",
-                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=inflammation"
+                "https://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults",
+                "https://orcid.org/0000-0002-0736-9199",
+                "https://en.wikipedia.org/wiki/nephrotic_syndrome"
               ]
             }
           },
           "relationship": {
-            "identity": 23118692,
-            "start": 547,
-            "end": 183319,
+            "identity": 15971109,
+            "start": 568,
+            "end": 319059,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:34262644': {'publication date': '2021 Jul 06', 'sentence': 'Using early models of pancreatic cancer, treatment with mebendazole resulted in less inflammation, decreased dysplasia, with the later stage model additionally showing a decreased tumor burden, less advanced tumors, and a reduction of metastasis.', 'subject score': 1000, 'object score': 888}}",
+              "publications_info": "{'PMID:2262977': {'publication date': '1990 Oct', 'sentence': '[A case of nephrotic syndrome with abnormally high level of protein C induced by prednisolone].', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0021368---SEMMEDDB:"
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0027726---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "23551876",
-              "object": "NCIT:C3137",
+              "subject": "PUBCHEM.COMPOUND:5755",
+              "id": "16304261",
+              "object": "MONDO:0005377",
               "publications": [
-                "PMID:34262644"
+                "PMID:2262977"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 568,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Prednisolone",
+              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "RXNORM:8638",
+                "ATC:A07EA01",
+                "ATC:C05AA04",
+                "ATC:S03BA02",
+                "PDQ:CDR0000043296",
+                "CAS:50-24-8",
+                "ATC:D07XA02",
+                "KEGG.DRUG:D00472",
+                "MESH:D011239",
+                "ATC:S01BA04",
+                "ATC:S02BA03",
+                "CHEBI:8378",
+                "ATC:H02AB06",
+                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+                "ATC:R01AD02",
+                "PUBCHEM.COMPOUND:5755",
+                "PSY:39980",
+                "DrugCentral:2245",
+                "KEGG.COMPOUND:C07369",
+                "ATC:D07AA03",
+                "CAS:8056-11-9",
+                "GTOPDB:2866",
+                "UMLS:C0032950",
+                "UNII:9PHQ9Y1OLM",
+                "CHEMBL.COMPOUND:CHEMBL131",
+                "DRUGBANK:DB00860",
+                "HMDB:HMDB0014998",
+                "NCIT:C769",
+                "PathWhiz.Compound:9315",
+                "NDDF:002155",
+                "ATC:S01CB02"
+              ],
+              "id": "PUBCHEM.COMPOUND:5755",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Prednisolone",
+                "prednisolone",
+                "PREDNISOLONE",
+                "Prednisolone (JP18/USP/INN)"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:24656565",
+                "PMID:20022146",
+                "PMID:19397323",
+                "PMID:12932140",
+                "PMID:17181172",
+                "PMID:22465636",
+                "PMID:14971904",
+                "PMID:6827553",
+                "PMID:19682771"
               ]
             }
           }
@@ -5315,7 +8144,7 @@
   {
     "p3": {
       "start": {
-        "identity": 2432616,
+        "identity": 319159,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -5325,133 +8154,298 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C4722463",
-          "name": "Cancer-Related Death",
-          "description": "A death attributed to the progression of a cancer-related pathologic condition.; UMLS Semantic Type: STY:T033",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0002251",
+          "name": "hepatitis",
+          "description": "Inflammation of the liver; usually from a viral infection, but sometimes from toxic agents.; INFLAMMATION of the LIVER.; Inflammation of the liver. [HPO:probinson]; What is hepatitis? Hepatitis is inflammation of the liver. Inflammation is swelling that happens when tissues of the body are injured or infected. It can damage your liver. This swelling and damage can affect how well your liver functions. Hepatitis can be an acute (short-term) infection or a chronic (long-term) infection. Some types of hepatitis cause only acute infections. Other types can cause both acute and chronic infections. What treats hepatitis? There are different types of hepatitis, with different treats: Viral hepatitis is the most common type. It is caused by one of several viruses -- hepatitis viruses A, B, C, D, and E. In the United States, A, B, and C are the most common. Alcoholic hepatitis is caused by heavy alcohol use Toxic hepatitis can be caused by certain poisons, chemicals, medicines, or supplements Autoimmune hepatitis is a chronic type in which your body's immune system attacks your liver. The cause is not known, but genetics and your environment may play a role.  How is viral hepatitis spread? Hepatitis A and hepatitis E usually spread through contact with food or water that was contaminated with an infected person's stool. You can also get hepatitis E by eating undercooked pork, deer, or shellfish. Hepatitis B, hepatitis C, and hepatitis D spread through contact with the blood of someone who has the disease. Hepatitis B and D may also spread through contact with other body fluids. This can happen in many ways, such as sharing drug needles or having unprotected sex. Who is at risk for hepatitis? The risks are different for the different types of hepatitis. For example, with most of the viral types, your risk is higher if you have unprotected sex. People who drink a lot over long periods of time are at risk for alcoholic hepatitis. What are the symptoms of hepatitis? Some people with hepatitis do not have symptoms and do not know they are infected. If you do have symptoms, they may include: Fever Fatigue Loss of appetite Nausea and/or vomiting Abdominal pain Dark urine Clay-colored bowel movements Joint pain Jaundice, yellowing of your skin and eyes  If you have an acute infection, your symptoms can start anywhere between 2 weeks to 6 months after you got infected. If you have a chronic infection, you may not have symptoms until many years later. What other problems can hepatitis cause? Chronic hepatitis can lead to complications such as cirrhosis (scarring of the liver), liver failure, and liver cancer. Early diagnosis and treatment of chronic hepatitis may prevent these complications. How is hepatitis diagnosed? To diagnose hepatitis, your health care provider: Will ask about your symptoms and medical history Will do a physical exam Will likely do blood tests, including tests for viral hepatitis Might do imaging tests, such as an ultrasound, CT scan, or MRI May need to do a liver biopsy to get a clear diagnosis and check for liver damage  What are the treatments for hepatitis? Treatment for hepatitis depends on which type you have and whether it is acute or chronic. Acute viral hepatitis often goes away on its own. To feel better, you may just need to rest and get enough fluids. But in some cases, it may be more serious. You might even need treatment in a hospital. There are different medicines to treat the different chronic types of hepatitis. Possible other treatments may include surgery and other medical procedures. People who have alcoholic hepatitis need to stop drinking. If your chronic hepatitis leads to liver failure or liver cancer, you may need a liver transplant. Can hepatitis be prevented? There are different ways to prevent or lower your risk for hepatitis, depending on the type of hepatitis. For example, not drinking too much alcohol can prevent alcoholic hepatitis. There are vaccines to prevent hepatitis A and B. Autoimmune hepatitis cannot be prevented. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "NCIT:C156427",
-            "UMLS:C4722463"
+            "SYMP:0000046",
+            "SNOMEDCT:128241005",
+            "MESH:D006505",
+            "MEDDRA:10019759",
+            "MONDO:0002251",
+            "MEDDRA:10009103",
+            "ICD9:571.4",
+            "UMLS:C0149519",
+            "MEDDRA:10078239",
+            "PSY:22770",
+            "UMLS:C0001308",
+            "SNOMEDCT:197268000",
+            "MEDDRA:10019717",
+            "ICD9:571.41",
+            "NCIT:C3095",
+            "HP:0012115",
+            "MEDDRA:10019802",
+            "MEDDRA:10029715",
+            "UMLS:C0019158",
+            "ICD9:570",
+            "DOID:2237",
+            "SNOMEDCT:41889008",
+            "MEDDRA:10019789",
+            "MEDDRA:10019790",
+            "ICD10:K73.9"
           ],
-          "id": "UMLS:C4722463",
-          "category": "biolink:PhenotypicFeature",
+          "id": "MONDO:0002251",
+          "category": "biolink:Disease",
           "all_names": [
-            "Cancer-Related Death"
+            "Chronic Persistent Hepatitis",
+            "Chronic hepatitis",
+            "Acute and subacute liver necrosis (disorder)",
+            "Chronic persistent hepatitis",
+            "Acute and subacute necrosis of liver",
+            "Hepatitis",
+            "hepatitis"
           ],
           "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:DiseaseOrPhenotypicFeature"
+            "biolink:Disease",
+            "biolink:PhenotypicFeature"
+          ],
+          "publications": [
+            "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 568,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Prednisolone",
+          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "RXNORM:8638",
+            "ATC:A07EA01",
+            "ATC:C05AA04",
+            "ATC:S03BA02",
+            "PDQ:CDR0000043296",
+            "CAS:50-24-8",
+            "ATC:D07XA02",
+            "KEGG.DRUG:D00472",
+            "MESH:D011239",
+            "ATC:S01BA04",
+            "ATC:S02BA03",
+            "CHEBI:8378",
+            "ATC:H02AB06",
+            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+            "ATC:R01AD02",
+            "PUBCHEM.COMPOUND:5755",
+            "PSY:39980",
+            "DrugCentral:2245",
+            "KEGG.COMPOUND:C07369",
+            "ATC:D07AA03",
+            "CAS:8056-11-9",
+            "GTOPDB:2866",
+            "UMLS:C0032950",
+            "UNII:9PHQ9Y1OLM",
+            "CHEMBL.COMPOUND:CHEMBL131",
+            "DRUGBANK:DB00860",
+            "HMDB:HMDB0014998",
+            "NCIT:C769",
+            "PathWhiz.Compound:9315",
+            "NDDF:002155",
+            "ATC:S01CB02"
+          ],
+          "id": "PUBCHEM.COMPOUND:5755",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Prednisolone",
+            "prednisolone",
+            "PREDNISOLONE",
+            "Prednisolone (JP18/USP/INN)"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:24656565",
+            "PMID:20022146",
+            "PMID:19397323",
+            "PMID:12932140",
+            "PMID:17181172",
+            "PMID:22465636",
+            "PMID:14971904",
+            "PMID:6827553",
+            "PMID:19682771"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 2432616,
+            "identity": 319159,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C4722463",
-              "name": "Cancer-Related Death",
-              "description": "A death attributed to the progression of a cancer-related pathologic condition.; UMLS Semantic Type: STY:T033",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0002251",
+              "name": "hepatitis",
+              "description": "Inflammation of the liver; usually from a viral infection, but sometimes from toxic agents.; INFLAMMATION of the LIVER.; Inflammation of the liver. [HPO:probinson]; What is hepatitis? Hepatitis is inflammation of the liver. Inflammation is swelling that happens when tissues of the body are injured or infected. It can damage your liver. This swelling and damage can affect how well your liver functions. Hepatitis can be an acute (short-term) infection or a chronic (long-term) infection. Some types of hepatitis cause only acute infections. Other types can cause both acute and chronic infections. What treats hepatitis? There are different types of hepatitis, with different treats: Viral hepatitis is the most common type. It is caused by one of several viruses -- hepatitis viruses A, B, C, D, and E. In the United States, A, B, and C are the most common. Alcoholic hepatitis is caused by heavy alcohol use Toxic hepatitis can be caused by certain poisons, chemicals, medicines, or supplements Autoimmune hepatitis is a chronic type in which your body's immune system attacks your liver. The cause is not known, but genetics and your environment may play a role.  How is viral hepatitis spread? Hepatitis A and hepatitis E usually spread through contact with food or water that was contaminated with an infected person's stool. You can also get hepatitis E by eating undercooked pork, deer, or shellfish. Hepatitis B, hepatitis C, and hepatitis D spread through contact with the blood of someone who has the disease. Hepatitis B and D may also spread through contact with other body fluids. This can happen in many ways, such as sharing drug needles or having unprotected sex. Who is at risk for hepatitis? The risks are different for the different types of hepatitis. For example, with most of the viral types, your risk is higher if you have unprotected sex. People who drink a lot over long periods of time are at risk for alcoholic hepatitis. What are the symptoms of hepatitis? Some people with hepatitis do not have symptoms and do not know they are infected. If you do have symptoms, they may include: Fever Fatigue Loss of appetite Nausea and/or vomiting Abdominal pain Dark urine Clay-colored bowel movements Joint pain Jaundice, yellowing of your skin and eyes  If you have an acute infection, your symptoms can start anywhere between 2 weeks to 6 months after you got infected. If you have a chronic infection, you may not have symptoms until many years later. What other problems can hepatitis cause? Chronic hepatitis can lead to complications such as cirrhosis (scarring of the liver), liver failure, and liver cancer. Early diagnosis and treatment of chronic hepatitis may prevent these complications. How is hepatitis diagnosed? To diagnose hepatitis, your health care provider: Will ask about your symptoms and medical history Will do a physical exam Will likely do blood tests, including tests for viral hepatitis Might do imaging tests, such as an ultrasound, CT scan, or MRI May need to do a liver biopsy to get a clear diagnosis and check for liver damage  What are the treatments for hepatitis? Treatment for hepatitis depends on which type you have and whether it is acute or chronic. Acute viral hepatitis often goes away on its own. To feel better, you may just need to rest and get enough fluids. But in some cases, it may be more serious. You might even need treatment in a hospital. There are different medicines to treat the different chronic types of hepatitis. Possible other treatments may include surgery and other medical procedures. People who have alcoholic hepatitis need to stop drinking. If your chronic hepatitis leads to liver failure or liver cancer, you may need a liver transplant. Can hepatitis be prevented? There are different ways to prevent or lower your risk for hepatitis, depending on the type of hepatitis. For example, not drinking too much alcohol can prevent alcoholic hepatitis. There are vaccines to prevent hepatitis A and B. Autoimmune hepatitis cannot be prevented. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "NCIT:C156427",
-                "UMLS:C4722463"
+                "SYMP:0000046",
+                "SNOMEDCT:128241005",
+                "MESH:D006505",
+                "MEDDRA:10019759",
+                "MONDO:0002251",
+                "MEDDRA:10009103",
+                "ICD9:571.4",
+                "UMLS:C0149519",
+                "MEDDRA:10078239",
+                "PSY:22770",
+                "UMLS:C0001308",
+                "SNOMEDCT:197268000",
+                "MEDDRA:10019717",
+                "ICD9:571.41",
+                "NCIT:C3095",
+                "HP:0012115",
+                "MEDDRA:10019802",
+                "MEDDRA:10029715",
+                "UMLS:C0019158",
+                "ICD9:570",
+                "DOID:2237",
+                "SNOMEDCT:41889008",
+                "MEDDRA:10019789",
+                "MEDDRA:10019790",
+                "ICD10:K73.9"
               ],
-              "id": "UMLS:C4722463",
-              "category": "biolink:PhenotypicFeature",
+              "id": "MONDO:0002251",
+              "category": "biolink:Disease",
               "all_names": [
-                "Cancer-Related Death"
+                "Chronic Persistent Hepatitis",
+                "Chronic hepatitis",
+                "Acute and subacute liver necrosis (disorder)",
+                "Chronic persistent hepatitis",
+                "Acute and subacute necrosis of liver",
+                "Hepatitis",
+                "hepatitis"
               ],
               "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:DiseaseOrPhenotypicFeature"
+                "biolink:Disease",
+                "biolink:PhenotypicFeature"
+              ],
+              "publications": [
+                "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 23031714,
-            "start": 547,
-            "end": 2432616,
+            "identity": 15889310,
+            "start": 568,
+            "end": 319159,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:34148157': {'publication date': '2021 Jun 20', 'sentence': 'CONCLUSION: Mebendazole and albendazole were shown to cause selective cancer cell death via a mechanism of classical apoptosis and cell cycle arrest, involving the destabilisation of microtubules.', 'subject score': 1000, 'object score': 843}}",
+              "domain_range_exclusion": "False",
+              "publications_info": "{'PMID:22488866': {'publication date': '2013 Mar', 'sentence': 'Case of prednisolone-induced hepatitis in a patient with ulcerative colitis.', 'subject score': 851, 'object score': 851}, 'PMID:7711410': {'publication date': '1994 Dec', 'sentence': \"Discontinuation of prednisolone, previously prescribed by the patient's family practitioner because of elevated liver enzymes, resulted in severe hepatitis (alanine aminotransferase > 300U/l).\", 'subject score': 1000, 'object score': 888}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C4722463---SEMMEDDB:"
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0019158---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "23464334",
-              "object": "UMLS:C4722463",
+              "subject": "PUBCHEM.COMPOUND:5755",
+              "id": "16220787",
+              "object": "MONDO:0002251",
               "publications": [
-                "PMID:34148157"
+                "PMID:22488866",
+                "PMID:7711410"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 568,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Prednisolone",
+              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "RXNORM:8638",
+                "ATC:A07EA01",
+                "ATC:C05AA04",
+                "ATC:S03BA02",
+                "PDQ:CDR0000043296",
+                "CAS:50-24-8",
+                "ATC:D07XA02",
+                "KEGG.DRUG:D00472",
+                "MESH:D011239",
+                "ATC:S01BA04",
+                "ATC:S02BA03",
+                "CHEBI:8378",
+                "ATC:H02AB06",
+                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+                "ATC:R01AD02",
+                "PUBCHEM.COMPOUND:5755",
+                "PSY:39980",
+                "DrugCentral:2245",
+                "KEGG.COMPOUND:C07369",
+                "ATC:D07AA03",
+                "CAS:8056-11-9",
+                "GTOPDB:2866",
+                "UMLS:C0032950",
+                "UNII:9PHQ9Y1OLM",
+                "CHEMBL.COMPOUND:CHEMBL131",
+                "DRUGBANK:DB00860",
+                "HMDB:HMDB0014998",
+                "NCIT:C769",
+                "PathWhiz.Compound:9315",
+                "NDDF:002155",
+                "ATC:S01CB02"
+              ],
+              "id": "PUBCHEM.COMPOUND:5755",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Prednisolone",
+                "prednisolone",
+                "PREDNISOLONE",
+                "Prednisolone (JP18/USP/INN)"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:24656565",
+                "PMID:20022146",
+                "PMID:19397323",
+                "PMID:12932140",
+                "PMID:17181172",
+                "PMID:22465636",
+                "PMID:14971904",
+                "PMID:6827553",
+                "PMID:19682771"
               ]
             }
           }
@@ -5463,7 +8457,7 @@
   {
     "p3": {
       "start": {
-        "identity": 2430660,
+        "identity": 314558,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -5473,133 +8467,286 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/ncit:C176399",
-          "name": "Increased Apoptosis",
-          "description": "Increase in the amount of apoptosis.",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005015",
+          "name": "diabetes mellitus",
+          "description": "A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2985\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2985\" NCI Thesaurus); A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.; A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.; A group of abnormalities characterized by hyperglycemia and glucose intolerance. [HPO:probinson]; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "UMLS:C4479222",
-            "NCIT:C176399"
-          ],
-          "id": "NCIT:C176399",
-          "category": "biolink:PhenotypicFeature",
+            "MEDDRA:10012601",
+            "MONDO:0005015",
+            "MEDDRA:10012594",
+            "HP:0000819",
+            "UMLS:C0011849",
+            "NCIT:C2985",
+            "PSY:13970",
+            "PSY:13950",
+            "MESH:D003920",
+            "EFO:0000400",
+            "PDQ:CDR0000685852",
+            "ICD10:E08-E13",
+            "UMLS:C0011847",
+            "DOID:9351",
+            "ICD9:250",
+            "MEDDRA:10012614",
+            "SNOMEDCT:73211009"
+          ],
+          "id": "MONDO:0005015",
+          "category": "biolink:Disease",
           "all_names": [
-            "Increased Apoptosis",
-            "Increased apoptosis"
+            "diabetes mellitus",
+            "Diabetes",
+            "Diabetes Mellitus",
+            "Diabetes mellitus"
           ],
           "all_categories": [
-            "biolink:PhenotypicFeature"
+            "biolink:Disease"
+          ],
+          "publications": [
+            "https://medlineplus.gov/diabetes.htm",
+            "https://orcid.org/0000-0002-0736-9199",
+            "https://en.wikipedia.org/wiki/diabetes_mellitus",
+            "PMID:9686693",
+            "http://www.who.int/diabetes/action_online/basics/en/",
+            "https://orcid.org/0000-0002-6601-2165"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 568,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Prednisolone",
+          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "RXNORM:8638",
+            "ATC:A07EA01",
+            "ATC:C05AA04",
+            "ATC:S03BA02",
+            "PDQ:CDR0000043296",
+            "CAS:50-24-8",
+            "ATC:D07XA02",
+            "KEGG.DRUG:D00472",
+            "MESH:D011239",
+            "ATC:S01BA04",
+            "ATC:S02BA03",
+            "CHEBI:8378",
+            "ATC:H02AB06",
+            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+            "ATC:R01AD02",
+            "PUBCHEM.COMPOUND:5755",
+            "PSY:39980",
+            "DrugCentral:2245",
+            "KEGG.COMPOUND:C07369",
+            "ATC:D07AA03",
+            "CAS:8056-11-9",
+            "GTOPDB:2866",
+            "UMLS:C0032950",
+            "UNII:9PHQ9Y1OLM",
+            "CHEMBL.COMPOUND:CHEMBL131",
+            "DRUGBANK:DB00860",
+            "HMDB:HMDB0014998",
+            "NCIT:C769",
+            "PathWhiz.Compound:9315",
+            "NDDF:002155",
+            "ATC:S01CB02"
+          ],
+          "id": "PUBCHEM.COMPOUND:5755",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Prednisolone",
+            "prednisolone",
+            "PREDNISOLONE",
+            "Prednisolone (JP18/USP/INN)"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:24656565",
+            "PMID:20022146",
+            "PMID:19397323",
+            "PMID:12932140",
+            "PMID:17181172",
+            "PMID:22465636",
+            "PMID:14971904",
+            "PMID:6827553",
+            "PMID:19682771"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 2430660,
+            "identity": 314558,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/ncit:C176399",
-              "name": "Increased Apoptosis",
-              "description": "Increase in the amount of apoptosis.",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005015",
+              "name": "diabetes mellitus",
+              "description": "A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2985\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2985\" NCI Thesaurus); A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.; A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.; A group of abnormalities characterized by hyperglycemia and glucose intolerance. [HPO:probinson]; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "UMLS:C4479222",
-                "NCIT:C176399"
-              ],
-              "id": "NCIT:C176399",
-              "category": "biolink:PhenotypicFeature",
+                "MEDDRA:10012601",
+                "MONDO:0005015",
+                "MEDDRA:10012594",
+                "HP:0000819",
+                "UMLS:C0011849",
+                "NCIT:C2985",
+                "PSY:13970",
+                "PSY:13950",
+                "MESH:D003920",
+                "EFO:0000400",
+                "PDQ:CDR0000685852",
+                "ICD10:E08-E13",
+                "UMLS:C0011847",
+                "DOID:9351",
+                "ICD9:250",
+                "MEDDRA:10012614",
+                "SNOMEDCT:73211009"
+              ],
+              "id": "MONDO:0005015",
+              "category": "biolink:Disease",
               "all_names": [
-                "Increased Apoptosis",
-                "Increased apoptosis"
+                "diabetes mellitus",
+                "Diabetes",
+                "Diabetes Mellitus",
+                "Diabetes mellitus"
               ],
               "all_categories": [
-                "biolink:PhenotypicFeature"
+                "biolink:Disease"
+              ],
+              "publications": [
+                "https://medlineplus.gov/diabetes.htm",
+                "https://orcid.org/0000-0002-0736-9199",
+                "https://en.wikipedia.org/wiki/diabetes_mellitus",
+                "PMID:9686693",
+                "http://www.who.int/diabetes/action_online/basics/en/",
+                "https://orcid.org/0000-0002-6601-2165"
               ]
             }
           },
           "relationship": {
-            "identity": 21047130,
-            "start": 547,
-            "end": 2430660,
+            "identity": 15391482,
+            "start": 568,
+            "end": 314558,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:31844184': {'publication date': '2019 Dec 17', 'sentence': 'CONCLUSIONS: Docetaxel and mebendazole target distinct aspects of the microtubule dynamics, leading to increased apoptosis and reduced tumour growth.', 'subject score': 583, 'object score': 1000}}",
+              "domain_range_exclusion": "False",
+              "publications_info": "{'PMID:21689745': {'publication date': '2011 Nov', 'sentence': 'Glucocorticoids (GCs), such as prednisolone (PRED), are widely prescribed anti-inflammatory drugs, but their use may induce glucose intolerance and diabetes.', 'subject score': 1000, 'object score': 1000}, 'PMID:28725323': {'publication date': '2017 Aug', 'sentence': 'Complications such as diabetes mellitus (DM), hyperlipidemia (HL), and osteoporosis due to prednisolone and cardiotoxicity due to anthracyclines are well known.', 'subject score': 1000, 'object score': 1000}, 'PMID:32716236': {'publication date': '2020 Jul 27', 'sentence': 'The aims of this study were to evaluate the frequency and investigate potential predisposing risk factors for the development of prednisolone-induced diabetes mellitus (PIDM) in cats.', 'subject score': 861, 'object score': 861}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C4479222---SEMMEDDB:"
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0011847---SEMMEDDB:",
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0011849---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "21460286",
-              "object": "NCIT:C176399",
+              "subject": "PUBCHEM.COMPOUND:5755",
+              "id": "15714230",
+              "object": "MONDO:0005015",
               "publications": [
-                "PMID:31844184"
+                "PMID:32716236",
+                "PMID:28725323",
+                "PMID:21689745"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 568,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Prednisolone",
+              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "RXNORM:8638",
+                "ATC:A07EA01",
+                "ATC:C05AA04",
+                "ATC:S03BA02",
+                "PDQ:CDR0000043296",
+                "CAS:50-24-8",
+                "ATC:D07XA02",
+                "KEGG.DRUG:D00472",
+                "MESH:D011239",
+                "ATC:S01BA04",
+                "ATC:S02BA03",
+                "CHEBI:8378",
+                "ATC:H02AB06",
+                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+                "ATC:R01AD02",
+                "PUBCHEM.COMPOUND:5755",
+                "PSY:39980",
+                "DrugCentral:2245",
+                "KEGG.COMPOUND:C07369",
+                "ATC:D07AA03",
+                "CAS:8056-11-9",
+                "GTOPDB:2866",
+                "UMLS:C0032950",
+                "UNII:9PHQ9Y1OLM",
+                "CHEMBL.COMPOUND:CHEMBL131",
+                "DRUGBANK:DB00860",
+                "HMDB:HMDB0014998",
+                "NCIT:C769",
+                "PathWhiz.Compound:9315",
+                "NDDF:002155",
+                "ATC:S01CB02"
+              ],
+              "id": "PUBCHEM.COMPOUND:5755",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Prednisolone",
+                "prednisolone",
+                "PREDNISOLONE",
+                "Prednisolone (JP18/USP/INN)"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:24656565",
+                "PMID:20022146",
+                "PMID:19397323",
+                "PMID:12932140",
+                "PMID:17181172",
+                "PMID:22465636",
+                "PMID:14971904",
+                "PMID:6827553",
+                "PMID:19682771"
               ]
             }
           }
@@ -5611,7 +8758,7 @@
   {
     "p3": {
       "start": {
-        "identity": 318217,
+        "identity": 320057,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -5621,175 +8768,287 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0001510",
-          "name": "Growth delay",
-          "description": "A deficiency or slowing down of growth pre- and postnatally. [HPO:probinson]; A deficiency or slowing down of growth pre- and postnatally. // COMMENTS: Poor or abnormally slow gains in weight or height in a child.; A deficiency or slowing down of growth pre- and postnatally. // COMMENTS: Poor or abnormally slow gains in weight or height in a child.; A deficiency or slowing down of growth pre- and postnatally. // COMMENTS: Poor or abnormally slow gains in weight or height in a child.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033; UMLS Semantic Type: STY:T184",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0043233",
+          "name": "exfoliative dermatitis",
+          "description": "An inflammatory exfoliative dermatosis involving nearly all of the surface of the skin. Erythroderma develops suddenly. A patchy erythema may generalize and spread to affect most of the skin. Scaling may appear in 2-6 days and be accompanied by hot, red, dry skin, malaise, and fever. [HPO:probinson]; An inflammatory exfoliative dermatosis involving nearly all of the surface of the skin. Erythroderma develops suddenly. A patchy erythema may generalize and spread to affect most of the skin. Scaling may appear in 2-6 days and be accompanied by hot, red, dry skin, malaise, and fever.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "SNOMEDCT:276617005",
-            "SNOMEDCT:444896005",
-            "UMLS:C0456070",
-            "SNOMEDCT:59576002",
-            "UMLS:C0878787",
-            "MEDDRA:10071095",
-            "HP:0001510",
-            "NCIT:C113100",
-            "UMLS:C1837385",
-            "UMLS:C0151686",
-            "MEDDRA:10018761",
-            "UMLS:C3552463",
-            "NCIT:C78328",
-            "MEDDRA:10053759",
-            "MEDDRA:10018760"
-          ],
-          "id": "HP:0001510",
-          "category": "biolink:PhenotypicFeature",
+            "UMLS:C0011606",
+            "SNOMEDCT:400005007",
+            "MEDDRA:10012455",
+            "MEDDRA:10015665",
+            "NCIT:C39646",
+            "MEDDRA:10018082",
+            "SNOMEDCT:396349005",
+            "MEDDRA:10062416",
+            "SNOMEDCT:200948000",
+            "UMLS:C5139033",
+            "MESH:D003873",
+            "MONDO:0043233",
+            "SNOMEDCT:399992009",
+            "MEDDRA:10012456",
+            "HP:0001019",
+            "MEDDRA:10052584",
+            "MEDDRA:10062434",
+            "MEDDRA:10015277",
+            "EFO:0009456",
+            "MEDDRA:10015666",
+            "MEDDRA:10012457",
+            "SNOMEDCT:396350005"
+          ],
+          "id": "MONDO:0043233",
+          "category": "biolink:Disease",
           "all_names": [
-            "Poor growth",
-            "Growth retardation",
-            "Growth failure",
-            "Growth Retardation",
-            "Growth Failure",
-            "Growth delay",
-            "Very poor growth"
+            "Red scaly skin caused by inflammatory skin disease",
+            "Erythroderma",
+            "Dermatitis, Exfoliative",
+            "Exfoliative dermatitis",
+            "exfoliative dermatitis"
           ],
           "all_categories": [
-            "biolink:PhenotypicFeature"
+            "biolink:Disease"
           ],
           "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
+            "https://orcid.org/0000-0002-0736-9199",
+            "https://orcid.org/0000-0001-6908-9849"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 568,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Prednisolone",
+          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "RXNORM:8638",
+            "ATC:A07EA01",
+            "ATC:C05AA04",
+            "ATC:S03BA02",
+            "PDQ:CDR0000043296",
+            "CAS:50-24-8",
+            "ATC:D07XA02",
+            "KEGG.DRUG:D00472",
+            "MESH:D011239",
+            "ATC:S01BA04",
+            "ATC:S02BA03",
+            "CHEBI:8378",
+            "ATC:H02AB06",
+            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+            "ATC:R01AD02",
+            "PUBCHEM.COMPOUND:5755",
+            "PSY:39980",
+            "DrugCentral:2245",
+            "KEGG.COMPOUND:C07369",
+            "ATC:D07AA03",
+            "CAS:8056-11-9",
+            "GTOPDB:2866",
+            "UMLS:C0032950",
+            "UNII:9PHQ9Y1OLM",
+            "CHEMBL.COMPOUND:CHEMBL131",
+            "DRUGBANK:DB00860",
+            "HMDB:HMDB0014998",
+            "NCIT:C769",
+            "PathWhiz.Compound:9315",
+            "NDDF:002155",
+            "ATC:S01CB02"
+          ],
+          "id": "PUBCHEM.COMPOUND:5755",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Prednisolone",
+            "prednisolone",
+            "PREDNISOLONE",
+            "Prednisolone (JP18/USP/INN)"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:24656565",
+            "PMID:20022146",
+            "PMID:19397323",
+            "PMID:12932140",
+            "PMID:17181172",
+            "PMID:22465636",
+            "PMID:14971904",
+            "PMID:6827553",
+            "PMID:19682771"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 318217,
+            "identity": 320057,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0001510",
-              "name": "Growth delay",
-              "description": "A deficiency or slowing down of growth pre- and postnatally. [HPO:probinson]; A deficiency or slowing down of growth pre- and postnatally. // COMMENTS: Poor or abnormally slow gains in weight or height in a child.; A deficiency or slowing down of growth pre- and postnatally. // COMMENTS: Poor or abnormally slow gains in weight or height in a child.; A deficiency or slowing down of growth pre- and postnatally. // COMMENTS: Poor or abnormally slow gains in weight or height in a child.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T033; UMLS Semantic Type: STY:T184",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0043233",
+              "name": "exfoliative dermatitis",
+              "description": "An inflammatory exfoliative dermatosis involving nearly all of the surface of the skin. Erythroderma develops suddenly. A patchy erythema may generalize and spread to affect most of the skin. Scaling may appear in 2-6 days and be accompanied by hot, red, dry skin, malaise, and fever. [HPO:probinson]; An inflammatory exfoliative dermatosis involving nearly all of the surface of the skin. Erythroderma develops suddenly. A patchy erythema may generalize and spread to affect most of the skin. Scaling may appear in 2-6 days and be accompanied by hot, red, dry skin, malaise, and fever.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "SNOMEDCT:276617005",
-                "SNOMEDCT:444896005",
-                "UMLS:C0456070",
-                "SNOMEDCT:59576002",
-                "UMLS:C0878787",
-                "MEDDRA:10071095",
-                "HP:0001510",
-                "NCIT:C113100",
-                "UMLS:C1837385",
-                "UMLS:C0151686",
-                "MEDDRA:10018761",
-                "UMLS:C3552463",
-                "NCIT:C78328",
-                "MEDDRA:10053759",
-                "MEDDRA:10018760"
-              ],
-              "id": "HP:0001510",
-              "category": "biolink:PhenotypicFeature",
+                "UMLS:C0011606",
+                "SNOMEDCT:400005007",
+                "MEDDRA:10012455",
+                "MEDDRA:10015665",
+                "NCIT:C39646",
+                "MEDDRA:10018082",
+                "SNOMEDCT:396349005",
+                "MEDDRA:10062416",
+                "SNOMEDCT:200948000",
+                "UMLS:C5139033",
+                "MESH:D003873",
+                "MONDO:0043233",
+                "SNOMEDCT:399992009",
+                "MEDDRA:10012456",
+                "HP:0001019",
+                "MEDDRA:10052584",
+                "MEDDRA:10062434",
+                "MEDDRA:10015277",
+                "EFO:0009456",
+                "MEDDRA:10015666",
+                "MEDDRA:10012457",
+                "SNOMEDCT:396350005"
+              ],
+              "id": "MONDO:0043233",
+              "category": "biolink:Disease",
               "all_names": [
-                "Poor growth",
-                "Growth retardation",
-                "Growth failure",
-                "Growth Retardation",
-                "Growth Failure",
-                "Growth delay",
-                "Very poor growth"
+                "Red scaly skin caused by inflammatory skin disease",
+                "Erythroderma",
+                "Dermatitis, Exfoliative",
+                "Exfoliative dermatitis",
+                "exfoliative dermatitis"
               ],
               "all_categories": [
-                "biolink:PhenotypicFeature"
+                "biolink:Disease"
               ],
               "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
+                "https://orcid.org/0000-0002-0736-9199",
+                "https://orcid.org/0000-0001-6908-9849"
               ]
             }
           },
           "relationship": {
-            "identity": 21047129,
-            "start": 547,
-            "end": 318217,
+            "identity": 14073675,
+            "start": 568,
+            "end": 320057,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31844184': {'publication date': '2019 Dec 17', 'sentence': 'CONCLUSIONS: Docetaxel and mebendazole target distinct aspects of the microtubule dynamics, leading to increased apoptosis and reduced tumour growth.', 'subject score': 583, 'object score': 901}}",
+              "publications_info": "{'PMID:19438568': {'publication date': '2009 Jul', 'sentence': 'The erythroderma improved generally as a result of systemic prednisolone treatment.', 'subject score': 851, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0151686---SEMMEDDB:"
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0011606---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "21460285",
-              "object": "HP:0001510",
+              "subject": "PUBCHEM.COMPOUND:5755",
+              "id": "14373522",
+              "object": "MONDO:0043233",
               "publications": [
-                "PMID:31844184"
+                "PMID:19438568"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 568,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Prednisolone",
+              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "RXNORM:8638",
+                "ATC:A07EA01",
+                "ATC:C05AA04",
+                "ATC:S03BA02",
+                "PDQ:CDR0000043296",
+                "CAS:50-24-8",
+                "ATC:D07XA02",
+                "KEGG.DRUG:D00472",
+                "MESH:D011239",
+                "ATC:S01BA04",
+                "ATC:S02BA03",
+                "CHEBI:8378",
+                "ATC:H02AB06",
+                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+                "ATC:R01AD02",
+                "PUBCHEM.COMPOUND:5755",
+                "PSY:39980",
+                "DrugCentral:2245",
+                "KEGG.COMPOUND:C07369",
+                "ATC:D07AA03",
+                "CAS:8056-11-9",
+                "GTOPDB:2866",
+                "UMLS:C0032950",
+                "UNII:9PHQ9Y1OLM",
+                "CHEMBL.COMPOUND:CHEMBL131",
+                "DRUGBANK:DB00860",
+                "HMDB:HMDB0014998",
+                "NCIT:C769",
+                "PathWhiz.Compound:9315",
+                "NDDF:002155",
+                "ATC:S01CB02"
+              ],
+              "id": "PUBCHEM.COMPOUND:5755",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Prednisolone",
+                "prednisolone",
+                "PREDNISOLONE",
+                "Prednisolone (JP18/USP/INN)"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:24656565",
+                "PMID:20022146",
+                "PMID:19397323",
+                "PMID:12932140",
+                "PMID:17181172",
+                "PMID:22465636",
+                "PMID:14971904",
+                "PMID:6827553",
+                "PMID:19682771"
               ]
             }
           }
@@ -5801,7 +9060,7 @@
   {
     "p3": {
       "start": {
-        "identity": 319159,
+        "identity": 310723,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -5811,197 +9070,318 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0002251",
-          "name": "hepatitis",
-          "description": "Inflammation of the liver; usually from a viral infection, but sometimes from toxic agents.; INFLAMMATION of the LIVER.; Inflammation of the liver. [HPO:probinson]; What is hepatitis? Hepatitis is inflammation of the liver. Inflammation is swelling that happens when tissues of the body are injured or infected. It can damage your liver. This swelling and damage can affect how well your liver functions. Hepatitis can be an acute (short-term) infection or a chronic (long-term) infection. Some types of hepatitis cause only acute infections. Other types can cause both acute and chronic infections. What treats hepatitis? There are different types of hepatitis, with different treats: Viral hepatitis is the most common type. It is caused by one of several viruses -- hepatitis viruses A, B, C, D, and E. In the United States, A, B, and C are the most common. Alcoholic hepatitis is caused by heavy alcohol use Toxic hepatitis can be caused by certain poisons, chemicals, medicines, or supplements Autoimmune hepatitis is a chronic type in which your body's immune system attacks your liver. The cause is not known, but genetics and your environment may play a role.  How is viral hepatitis spread? Hepatitis A and hepatitis E usually spread through contact with food or water that was contaminated with an infected person's stool. You can also get hepatitis E by eating undercooked pork, deer, or shellfish. Hepatitis B, hepatitis C, and hepatitis D spread through contact with the blood of someone who has the disease. Hepatitis B and D may also spread through contact with other body fluids. This can happen in many ways, such as sharing drug needles or having unprotected sex. Who is at risk for hepatitis? The risks are different for the different types of hepatitis. For example, with most of the viral types, your risk is higher if you have unprotected sex. People who drink a lot over long periods of time are at risk for alcoholic hepatitis. What are the symptoms of hepatitis? Some people with hepatitis do not have symptoms and do not know they are infected. If you do have symptoms, they may include: Fever Fatigue Loss of appetite Nausea and/or vomiting Abdominal pain Dark urine Clay-colored bowel movements Joint pain Jaundice, yellowing of your skin and eyes  If you have an acute infection, your symptoms can start anywhere between 2 weeks to 6 months after you got infected. If you have a chronic infection, you may not have symptoms until many years later. What other problems can hepatitis cause? Chronic hepatitis can lead to complications such as cirrhosis (scarring of the liver), liver failure, and liver cancer. Early diagnosis and treatment of chronic hepatitis may prevent these complications. How is hepatitis diagnosed? To diagnose hepatitis, your health care provider: Will ask about your symptoms and medical history Will do a physical exam Will likely do blood tests, including tests for viral hepatitis Might do imaging tests, such as an ultrasound, CT scan, or MRI May need to do a liver biopsy to get a clear diagnosis and check for liver damage  What are the treatments for hepatitis? Treatment for hepatitis depends on which type you have and whether it is acute or chronic. Acute viral hepatitis often goes away on its own. To feel better, you may just need to rest and get enough fluids. But in some cases, it may be more serious. You might even need treatment in a hospital. There are different medicines to treat the different chronic types of hepatitis. Possible other treatments may include surgery and other medical procedures. People who have alcoholic hepatitis need to stop drinking. If your chronic hepatitis leads to liver failure or liver cancer, you may need a liver transplant. Can hepatitis be prevented? There are different ways to prevent or lower your risk for hepatitis, depending on the type of hepatitis. For example, not drinking too much alcohol can prevent alcoholic hepatitis. There are vaccines to prevent hepatitis A and B. Autoimmune hepatitis cannot be prevented. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005044",
+          "name": "hypertensive disorder",
+          "description": "The presence of chronic increased pressure in the systemic arterial system. [HPO:probinson]; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "SYMP:0000046",
-            "SNOMEDCT:128241005",
-            "MESH:D006505",
-            "MEDDRA:10019759",
-            "MONDO:0002251",
-            "MEDDRA:10009103",
-            "ICD9:571.4",
-            "UMLS:C0149519",
-            "MEDDRA:10078239",
-            "PSY:22770",
-            "UMLS:C0001308",
-            "SNOMEDCT:197268000",
-            "MEDDRA:10019717",
-            "ICD9:571.41",
-            "NCIT:C3095",
-            "HP:0012115",
-            "MEDDRA:10019802",
-            "MEDDRA:10029715",
-            "UMLS:C0019158",
-            "ICD9:570",
-            "DOID:2237",
-            "SNOMEDCT:41889008",
-            "MEDDRA:10019789",
-            "MEDDRA:10019790",
-            "ICD10:K73.9"
-          ],
-          "id": "MONDO:0002251",
+            "HP:0000822",
+            "PDQ:CDR0000686951",
+            "EFO:0000537",
+            "MONDO:0005044",
+            "MEDDRA:10039196",
+            "ICD9:401-405.99",
+            "MEDDRA:10057166",
+            "MEDDRA:10003170",
+            "ICD10:I10",
+            "MEDDRA:10006067",
+            "UMLS:C0020538",
+            "NCIT:C3117",
+            "UMLS:C0497247",
+            "SNOMEDCT:24184005",
+            "MEDDRA:10037806",
+            "MEDDRA:10036639",
+            "MESH:D006973",
+            "MEDDRA:10020775",
+            "SNOMEDCT:38341003",
+            "PSY:23830",
+            "MEDDRA:10005750",
+            "MEDDRA:10005755",
+            "MEDDRA:10081425",
+            "MEDDRA:10003168",
+            "MEDDRA:10020772",
+            "MEDDRA:10014475",
+            "MEDDRA:10005747",
+            "DOID:10763",
+            "MEDDRA:10039197",
+            "MEDDRA:10037808",
+            "MEDDRA:10020782",
+            "MEDDRA:10021655",
+            "MEDDRA:10036640"
+          ],
+          "id": "MONDO:0005044",
           "category": "biolink:Disease",
           "all_names": [
-            "Chronic Persistent Hepatitis",
-            "Chronic hepatitis",
-            "Acute and subacute liver necrosis (disorder)",
-            "Chronic persistent hepatitis",
-            "Acute and subacute necrosis of liver",
-            "Hepatitis",
-            "hepatitis"
+            "hypertension",
+            "Hypertension",
+            "hypertensive disorder",
+            "Hypertensive disease",
+            "Increase in blood pressure"
           ],
           "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
+            "biolink:Disease"
           ],
           "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
+            "PMID:24352797",
+            "PMID:9137951",
+            "https://orcid.org/0000-0002-0736-9199",
+            "https://en.wikipedia.org/wiki/hypertension"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 568,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Prednisolone",
+          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "RXNORM:8638",
+            "ATC:A07EA01",
+            "ATC:C05AA04",
+            "ATC:S03BA02",
+            "PDQ:CDR0000043296",
+            "CAS:50-24-8",
+            "ATC:D07XA02",
+            "KEGG.DRUG:D00472",
+            "MESH:D011239",
+            "ATC:S01BA04",
+            "ATC:S02BA03",
+            "CHEBI:8378",
+            "ATC:H02AB06",
+            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+            "ATC:R01AD02",
+            "PUBCHEM.COMPOUND:5755",
+            "PSY:39980",
+            "DrugCentral:2245",
+            "KEGG.COMPOUND:C07369",
+            "ATC:D07AA03",
+            "CAS:8056-11-9",
+            "GTOPDB:2866",
+            "UMLS:C0032950",
+            "UNII:9PHQ9Y1OLM",
+            "CHEMBL.COMPOUND:CHEMBL131",
+            "DRUGBANK:DB00860",
+            "HMDB:HMDB0014998",
+            "NCIT:C769",
+            "PathWhiz.Compound:9315",
+            "NDDF:002155",
+            "ATC:S01CB02"
+          ],
+          "id": "PUBCHEM.COMPOUND:5755",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Prednisolone",
+            "prednisolone",
+            "PREDNISOLONE",
+            "Prednisolone (JP18/USP/INN)"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:24656565",
+            "PMID:20022146",
+            "PMID:19397323",
+            "PMID:12932140",
+            "PMID:17181172",
+            "PMID:22465636",
+            "PMID:14971904",
+            "PMID:6827553",
+            "PMID:19682771"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 319159,
+            "identity": 310723,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0002251",
-              "name": "hepatitis",
-              "description": "Inflammation of the liver; usually from a viral infection, but sometimes from toxic agents.; INFLAMMATION of the LIVER.; Inflammation of the liver. [HPO:probinson]; What is hepatitis? Hepatitis is inflammation of the liver. Inflammation is swelling that happens when tissues of the body are injured or infected. It can damage your liver. This swelling and damage can affect how well your liver functions. Hepatitis can be an acute (short-term) infection or a chronic (long-term) infection. Some types of hepatitis cause only acute infections. Other types can cause both acute and chronic infections. What treats hepatitis? There are different types of hepatitis, with different treats: Viral hepatitis is the most common type. It is caused by one of several viruses -- hepatitis viruses A, B, C, D, and E. In the United States, A, B, and C are the most common. Alcoholic hepatitis is caused by heavy alcohol use Toxic hepatitis can be caused by certain poisons, chemicals, medicines, or supplements Autoimmune hepatitis is a chronic type in which your body's immune system attacks your liver. The cause is not known, but genetics and your environment may play a role.  How is viral hepatitis spread? Hepatitis A and hepatitis E usually spread through contact with food or water that was contaminated with an infected person's stool. You can also get hepatitis E by eating undercooked pork, deer, or shellfish. Hepatitis B, hepatitis C, and hepatitis D spread through contact with the blood of someone who has the disease. Hepatitis B and D may also spread through contact with other body fluids. This can happen in many ways, such as sharing drug needles or having unprotected sex. Who is at risk for hepatitis? The risks are different for the different types of hepatitis. For example, with most of the viral types, your risk is higher if you have unprotected sex. People who drink a lot over long periods of time are at risk for alcoholic hepatitis. What are the symptoms of hepatitis? Some people with hepatitis do not have symptoms and do not know they are infected. If you do have symptoms, they may include: Fever Fatigue Loss of appetite Nausea and/or vomiting Abdominal pain Dark urine Clay-colored bowel movements Joint pain Jaundice, yellowing of your skin and eyes  If you have an acute infection, your symptoms can start anywhere between 2 weeks to 6 months after you got infected. If you have a chronic infection, you may not have symptoms until many years later. What other problems can hepatitis cause? Chronic hepatitis can lead to complications such as cirrhosis (scarring of the liver), liver failure, and liver cancer. Early diagnosis and treatment of chronic hepatitis may prevent these complications. How is hepatitis diagnosed? To diagnose hepatitis, your health care provider: Will ask about your symptoms and medical history Will do a physical exam Will likely do blood tests, including tests for viral hepatitis Might do imaging tests, such as an ultrasound, CT scan, or MRI May need to do a liver biopsy to get a clear diagnosis and check for liver damage  What are the treatments for hepatitis? Treatment for hepatitis depends on which type you have and whether it is acute or chronic. Acute viral hepatitis often goes away on its own. To feel better, you may just need to rest and get enough fluids. But in some cases, it may be more serious. You might even need treatment in a hospital. There are different medicines to treat the different chronic types of hepatitis. Possible other treatments may include surgery and other medical procedures. People who have alcoholic hepatitis need to stop drinking. If your chronic hepatitis leads to liver failure or liver cancer, you may need a liver transplant. Can hepatitis be prevented? There are different ways to prevent or lower your risk for hepatitis, depending on the type of hepatitis. For example, not drinking too much alcohol can prevent alcoholic hepatitis. There are vaccines to prevent hepatitis A and B. Autoimmune hepatitis cannot be prevented. NIH: National Institute of Diabetes and Digestive and Kidney Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005044",
+              "name": "hypertensive disorder",
+              "description": "The presence of chronic increased pressure in the systemic arterial system. [HPO:probinson]; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; The presence of chronic increased pressure in the systemic arterial system. // COMMENTS: Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "SYMP:0000046",
-                "SNOMEDCT:128241005",
-                "MESH:D006505",
-                "MEDDRA:10019759",
-                "MONDO:0002251",
-                "MEDDRA:10009103",
-                "ICD9:571.4",
-                "UMLS:C0149519",
-                "MEDDRA:10078239",
-                "PSY:22770",
-                "UMLS:C0001308",
-                "SNOMEDCT:197268000",
-                "MEDDRA:10019717",
-                "ICD9:571.41",
-                "NCIT:C3095",
-                "HP:0012115",
-                "MEDDRA:10019802",
-                "MEDDRA:10029715",
-                "UMLS:C0019158",
-                "ICD9:570",
-                "DOID:2237",
-                "SNOMEDCT:41889008",
-                "MEDDRA:10019789",
-                "MEDDRA:10019790",
-                "ICD10:K73.9"
-              ],
-              "id": "MONDO:0002251",
+                "HP:0000822",
+                "PDQ:CDR0000686951",
+                "EFO:0000537",
+                "MONDO:0005044",
+                "MEDDRA:10039196",
+                "ICD9:401-405.99",
+                "MEDDRA:10057166",
+                "MEDDRA:10003170",
+                "ICD10:I10",
+                "MEDDRA:10006067",
+                "UMLS:C0020538",
+                "NCIT:C3117",
+                "UMLS:C0497247",
+                "SNOMEDCT:24184005",
+                "MEDDRA:10037806",
+                "MEDDRA:10036639",
+                "MESH:D006973",
+                "MEDDRA:10020775",
+                "SNOMEDCT:38341003",
+                "PSY:23830",
+                "MEDDRA:10005750",
+                "MEDDRA:10005755",
+                "MEDDRA:10081425",
+                "MEDDRA:10003168",
+                "MEDDRA:10020772",
+                "MEDDRA:10014475",
+                "MEDDRA:10005747",
+                "DOID:10763",
+                "MEDDRA:10039197",
+                "MEDDRA:10037808",
+                "MEDDRA:10020782",
+                "MEDDRA:10021655",
+                "MEDDRA:10036640"
+              ],
+              "id": "MONDO:0005044",
               "category": "biolink:Disease",
               "all_names": [
-                "Chronic Persistent Hepatitis",
-                "Chronic hepatitis",
-                "Acute and subacute liver necrosis (disorder)",
-                "Chronic persistent hepatitis",
-                "Acute and subacute necrosis of liver",
-                "Hepatitis",
-                "hepatitis"
+                "hypertension",
+                "Hypertension",
+                "hypertensive disorder",
+                "Hypertensive disease",
+                "Increase in blood pressure"
               ],
               "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
+                "biolink:Disease"
               ],
               "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
+                "PMID:24352797",
+                "PMID:9137951",
+                "https://orcid.org/0000-0002-0736-9199",
+                "https://en.wikipedia.org/wiki/hypertension"
               ]
             }
           },
           "relationship": {
-            "identity": 20819940,
-            "start": 547,
-            "end": 319159,
+            "identity": 12378919,
+            "start": 568,
+            "end": 310723,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31423600': {'publication date': '2019 Dec', 'sentence': 'CASE SUMMARY: Differently from other cases of hepatitis due to MBZ reported in the scientific literature, our patient received standard doses of MBZ for a short period of time.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:16903631': {'publication date': '2006 Jun', 'sentence': 'We report two cases of idiopathic nephrotic syndrome that developed ARF following captopril (an ACEI) treatment for prednisolone-induced hypertension.', 'subject score': 851, 'object score': 851}, 'PMID:2826916': {'publication date': '1987', 'sentence': 'Other studies have found that prednisolone (100 mg/day) antagonized 9 alpha-fluoro-prednisolone (0.6 mg/day) induced hypertension but not its MC effects.', 'subject score': 763, 'object score': 888}, 'PMID:3283584': {'publication date': '1988', 'sentence': 'In normo- and hypovolemic patients prednisolone produced significant diuresis and natriuresis and failed to induce hypertension.', 'subject score': 851, 'object score': 1000}, 'PMID:6797777': {'publication date': '1981 Dec', 'sentence': 'These results indicate that treatment of asthma and rheumatoid arthritis with prednisolone or prednisolone in low dose does not cause hypertension or biochemical features suggestive of mineralocorticoid excess.', 'subject score': 1000, 'object score': 1000}, 'PMID:8903835': {'publication date': '1995 Dec', 'sentence': 'Circadian blood pressure rhythm and atrial natriuretic peptide in prednisolone-induced blood pressure elevation.', 'subject score': 875, 'object score': 875}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0019158---SEMMEDDB:"
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0020538---SEMMEDDB:",
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0497247---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "21233324",
-              "object": "MONDO:0002251",
+              "subject": "PUBCHEM.COMPOUND:5755",
+              "id": "12653424",
+              "object": "MONDO:0005044",
               "publications": [
-                "PMID:31423600"
+                "PMID:2826916",
+                "PMID:6797777",
+                "PMID:3283584",
+                "PMID:8903835",
+                "PMID:16903631"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 568,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Prednisolone",
+              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "RXNORM:8638",
+                "ATC:A07EA01",
+                "ATC:C05AA04",
+                "ATC:S03BA02",
+                "PDQ:CDR0000043296",
+                "CAS:50-24-8",
+                "ATC:D07XA02",
+                "KEGG.DRUG:D00472",
+                "MESH:D011239",
+                "ATC:S01BA04",
+                "ATC:S02BA03",
+                "CHEBI:8378",
+                "ATC:H02AB06",
+                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+                "ATC:R01AD02",
+                "PUBCHEM.COMPOUND:5755",
+                "PSY:39980",
+                "DrugCentral:2245",
+                "KEGG.COMPOUND:C07369",
+                "ATC:D07AA03",
+                "CAS:8056-11-9",
+                "GTOPDB:2866",
+                "UMLS:C0032950",
+                "UNII:9PHQ9Y1OLM",
+                "CHEMBL.COMPOUND:CHEMBL131",
+                "DRUGBANK:DB00860",
+                "HMDB:HMDB0014998",
+                "NCIT:C769",
+                "PathWhiz.Compound:9315",
+                "NDDF:002155",
+                "ATC:S01CB02"
+              ],
+              "id": "PUBCHEM.COMPOUND:5755",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Prednisolone",
+                "prednisolone",
+                "PREDNISOLONE",
+                "Prednisolone (JP18/USP/INN)"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:24656565",
+                "PMID:20022146",
+                "PMID:19397323",
+                "PMID:12932140",
+                "PMID:17181172",
+                "PMID:22465636",
+                "PMID:14971904",
+                "PMID:6827553",
+                "PMID:19682771"
               ]
             }
           }
@@ -6013,7 +9393,7 @@
   {
     "p3": {
       "start": {
-        "identity": 532663,
+        "identity": 323237,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -6023,141 +9403,276 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0160390",
-          "name": "Injury of liver",
-          "description": "Damage to liver structure or function due to trauma or toxicity.; UMLS Semantic Type: STY:T037",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0002909",
+          "name": "hyperglycemia",
+          "description": "A high level of blood sugar. It is usually an indication of diabetes mellitus. --2003 Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C26797\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26797\" NCI Thesaurus); Abnormally high level of glucose in the blood.; Abnormally high BLOOD GLUCOSE level after a meal.; An increased concentration of glucose in the blood. [HPO:probinson]",
           "equivalent_curies": [
-            "MEDDRA:10019710",
-            "NCIT:C35241",
-            "UMLS:C0160390",
-            "MEDDRA:10022224",
-            "MEDDRA:10067125",
-            "SNOMEDCT:39400004"
-          ],
-          "id": "UMLS:C0160390",
+            "MEDDRA:10020637",
+            "SNOMEDCT:237598005",
+            "PDQ:CDR0000561308",
+            "MONDO:0002909",
+            "NCIT:C26797",
+            "MEDDRA:10020635",
+            "SNOMEDCT:80394007",
+            "HP:0003074",
+            "MEDDRA:10020639",
+            "PSY:23745",
+            "ICD10:R73.9",
+            "UMLS:C0020456",
+            "DOID:4195",
+            "MESH:D006943"
+          ],
+          "id": "MONDO:0002909",
           "category": "biolink:Disease",
           "all_names": [
-            "Injury to Liver",
-            "Injury of liver"
+            "hyperglycemia",
+            "Hyperglycemia"
           ],
           "all_categories": [
             "biolink:Disease"
+          ],
+          "publications": [
+            "https://orcid.org/0000-0002-0736-9199",
+            "https://orcid.org/0000-0001-6908-9849"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 568,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Prednisolone",
+          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "RXNORM:8638",
+            "ATC:A07EA01",
+            "ATC:C05AA04",
+            "ATC:S03BA02",
+            "PDQ:CDR0000043296",
+            "CAS:50-24-8",
+            "ATC:D07XA02",
+            "KEGG.DRUG:D00472",
+            "MESH:D011239",
+            "ATC:S01BA04",
+            "ATC:S02BA03",
+            "CHEBI:8378",
+            "ATC:H02AB06",
+            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+            "ATC:R01AD02",
+            "PUBCHEM.COMPOUND:5755",
+            "PSY:39980",
+            "DrugCentral:2245",
+            "KEGG.COMPOUND:C07369",
+            "ATC:D07AA03",
+            "CAS:8056-11-9",
+            "GTOPDB:2866",
+            "UMLS:C0032950",
+            "UNII:9PHQ9Y1OLM",
+            "CHEMBL.COMPOUND:CHEMBL131",
+            "DRUGBANK:DB00860",
+            "HMDB:HMDB0014998",
+            "NCIT:C769",
+            "PathWhiz.Compound:9315",
+            "NDDF:002155",
+            "ATC:S01CB02"
+          ],
+          "id": "PUBCHEM.COMPOUND:5755",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Prednisolone",
+            "prednisolone",
+            "PREDNISOLONE",
+            "Prednisolone (JP18/USP/INN)"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:24656565",
+            "PMID:20022146",
+            "PMID:19397323",
+            "PMID:12932140",
+            "PMID:17181172",
+            "PMID:22465636",
+            "PMID:14971904",
+            "PMID:6827553",
+            "PMID:19682771"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 532663,
+            "identity": 323237,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0160390",
-              "name": "Injury of liver",
-              "description": "Damage to liver structure or function due to trauma or toxicity.; UMLS Semantic Type: STY:T037",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0002909",
+              "name": "hyperglycemia",
+              "description": "A high level of blood sugar. It is usually an indication of diabetes mellitus. --2003 Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C26797\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26797\" NCI Thesaurus); Abnormally high level of glucose in the blood.; Abnormally high BLOOD GLUCOSE level after a meal.; An increased concentration of glucose in the blood. [HPO:probinson]",
               "equivalent_curies": [
-                "MEDDRA:10019710",
-                "NCIT:C35241",
-                "UMLS:C0160390",
-                "MEDDRA:10022224",
-                "MEDDRA:10067125",
-                "SNOMEDCT:39400004"
-              ],
-              "id": "UMLS:C0160390",
+                "MEDDRA:10020637",
+                "SNOMEDCT:237598005",
+                "PDQ:CDR0000561308",
+                "MONDO:0002909",
+                "NCIT:C26797",
+                "MEDDRA:10020635",
+                "SNOMEDCT:80394007",
+                "HP:0003074",
+                "MEDDRA:10020639",
+                "PSY:23745",
+                "ICD10:R73.9",
+                "UMLS:C0020456",
+                "DOID:4195",
+                "MESH:D006943"
+              ],
+              "id": "MONDO:0002909",
               "category": "biolink:Disease",
               "all_names": [
-                "Injury to Liver",
-                "Injury of liver"
+                "hyperglycemia",
+                "Hyperglycemia"
               ],
               "all_categories": [
                 "biolink:Disease"
+              ],
+              "publications": [
+                "https://orcid.org/0000-0002-0736-9199",
+                "https://orcid.org/0000-0001-6908-9849"
               ]
             }
           },
           "relationship": {
-            "identity": 20819937,
-            "start": 547,
-            "end": 532663,
+            "identity": 11755639,
+            "start": 568,
+            "end": 323237,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31423600': {'publication date': '2019 Dec', 'sentence': 'Although MBZ has been reported to cause hepatic injury, case reports of severe hepatic injury are very rare.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:1612493': {'publication date': '1992 May', 'sentence': 'However, prednisolone caused hyperglycemia even at a reduced dose of 10 mg/day.', 'subject score': 1000, 'object score': 861}, 'PMID:18728625': {'publication date': '2008 Oct', 'sentence': 'Prednisolone may cause hyperglycemia after organ transplantation.', 'subject score': 1000, 'object score': 1000}, 'PMID:21411550': {'publication date': '2011 Jun', 'sentence': 'Treatment of prednisolone-induced hyperglycemia should be targeted at this time period.', 'subject score': 851, 'object score': 851}, 'PMID:22332121': {'publication date': '2012 Jun', 'sentence': 'Treatment of prednisolone-induced hyperglycaemia should be directed at the postprandial period.', 'subject score': 851, 'object score': 851}, 'PMID:22772888': {'publication date': '2012 Jul', 'sentence': 'METABOLISM: Cyclosporin A and leflunomide may increase the blood pressure, whereas administration of prednisolone and tacrolimus may cause hyperglycemia.', 'subject score': 1000, 'object score': 1000}, 'PMID:24009292': {'publication date': '2014 Mar', 'sentence': 'Divided dosing reduces prednisolone-induced hyperglycaemia and glycaemic variability: a randomized trial after kidney transplantation.', 'subject score': 851, 'object score': 851}, 'PMID:25565560': {'publication date': '2015 Mar', 'sentence': 'Specific insulin regimens for prednisolone-induced hyperglycaemia are needed that recommend more insulin during this time period.', 'subject score': 851, 'object score': 851}, 'PMID:27995731': {'publication date': '2017 04', 'sentence': 'We recommend an initial daily insulin dose of 0.5?units/kg bodyweight if not on insulin, a greater than 30% increase in pre-prednisolone insulin dose and larger insulin dose adjustments in patients with prednisolone-induced hyperglycaemia.', 'subject score': 851, 'object score': 851}, 'PMID:29991519': {'publication date': '2018 Jul 10', 'sentence': 'Further studies are necessary in order to identify factors underlying the variability in response to insulin therapy and clinical benefits of treatment in hospitalized patients with prednisolone-induced hyperglycaemia.', 'subject score': 851, 'object score': 851}, 'PMID:30299889': {'publication date': '2018 10 01', 'sentence': 'Further studies are necessary in order to identify factors underlying the variability in response to insulin therapy and clinical benefits of treatment in hospitalized patients with prednisolone-induced hyperglycaemia.', 'subject score': 851, 'object score': 851}, 'PMID:36736733': {'publication date': '2023 Feb 01', 'sentence': 'Clinical determinants of insulin requirements during treatment of prednisolone-induced hyperglycaemia.', 'subject score': 851, 'object score': 851}, 'PMID:36880383': {'publication date': '2023 Mar 07', 'sentence': 'Mixed insulin can improve control of prednisolone-induced hyperglycaemia.', 'subject score': 851, 'object score': 851}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0160390---SEMMEDDB:"
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0020456---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "21233321",
-              "object": "UMLS:C0160390",
+              "subject": "PUBCHEM.COMPOUND:5755",
+              "id": "12012071",
+              "object": "MONDO:0002909",
               "publications": [
-                "PMID:31423600"
+                "PMID:1612493",
+                "PMID:18728625",
+                "PMID:21411550",
+                "PMID:22332121",
+                "PMID:22772888",
+                "PMID:24009292",
+                "PMID:25565560",
+                "PMID:27995731",
+                "PMID:29991519",
+                "PMID:30299889",
+                "PMID:36736733",
+                "PMID:36880383"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 568,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Prednisolone",
+              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "RXNORM:8638",
+                "ATC:A07EA01",
+                "ATC:C05AA04",
+                "ATC:S03BA02",
+                "PDQ:CDR0000043296",
+                "CAS:50-24-8",
+                "ATC:D07XA02",
+                "KEGG.DRUG:D00472",
+                "MESH:D011239",
+                "ATC:S01BA04",
+                "ATC:S02BA03",
+                "CHEBI:8378",
+                "ATC:H02AB06",
+                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+                "ATC:R01AD02",
+                "PUBCHEM.COMPOUND:5755",
+                "PSY:39980",
+                "DrugCentral:2245",
+                "KEGG.COMPOUND:C07369",
+                "ATC:D07AA03",
+                "CAS:8056-11-9",
+                "GTOPDB:2866",
+                "UMLS:C0032950",
+                "UNII:9PHQ9Y1OLM",
+                "CHEMBL.COMPOUND:CHEMBL131",
+                "DRUGBANK:DB00860",
+                "HMDB:HMDB0014998",
+                "NCIT:C769",
+                "PathWhiz.Compound:9315",
+                "NDDF:002155",
+                "ATC:S01CB02"
+              ],
+              "id": "PUBCHEM.COMPOUND:5755",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Prednisolone",
+                "prednisolone",
+                "PREDNISOLONE",
+                "Prednisolone (JP18/USP/INN)"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:24656565",
+                "PMID:20022146",
+                "PMID:19397323",
+                "PMID:12932140",
+                "PMID:17181172",
+                "PMID:22465636",
+                "PMID:14971904",
+                "PMID:6827553",
+                "PMID:19682771"
               ]
             }
           }
@@ -6169,7 +9684,7 @@
   {
     "p3": {
       "start": {
-        "identity": 2352631,
+        "identity": 313199,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -6179,148 +9694,320 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0235378",
-          "name": "Hepatotoxicity",
-          "description": "Toxicity that treats injury to the liver or impairs the liver function. Usually caused by exposure to xenobiotics such as drugs, food additives, alcohol, chlorinated solvents, peroxidized fatty acids, fungal toxins, radioactive isotopes, environmental toxicants, and some medicinal plants. This can include cholestasis, liver injury, hepatitis, jaundice.",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005298",
+          "name": "osteoporosis",
+          "description": "A condition of reduced bone mass, with decreased cortical thickness and a decrease in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence. Osteoporosis is classified as primary (Type 1, postmenopausal osteoporosis; Type 2, age-associated osteoporosis; and idiopathic, which can affect juveniles, premenopausal women, and middle-aged men) and secondary osteoporosis (which results from an identifiable cause of bone mass loss).; Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.; Osteoporosis is a systemic skeletal disease characterized by low bone density and microarchitectural deterioration of bone tissue with a consequent increase in bone fragility. According to the WHO criteria, osteoporosis is defined as a BMD that lies 2.5 standard deviations or more below the average value for young healthy adults (a T-score below -2.5 SD). [HPO:probinson, PMID:28293453]; Osteoporosis is a disease that thins and weakens the bones. Your bones become fragile and fracture (break) easily, especially the bones in the hip, spine, and wrist. In the United States, millions of people either already have osteoporosis or are at high risk due to low bone mass. Anyone can develop osteoporosis, but it is more common in older women. Risk factors include: Getting older  Being small and thin  Having a family history of osteoporosis Taking certain medicines Being a white or Asian woman Having low bone density  Osteoporosis is a silent disease. You might not know you have it until you break a bone. A bone mineral density test is the best way to check your bone health. To keep bones strong, eat a diet rich in calcium and vitamin D, exercise, and do not smoke. If needed, medicines can also help. It is also important to try to avoid falling down. Falls are the number one cause of fractures in older adults. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "UMLS:C0235378",
-            "EFO:0011052",
-            "MEDDRA:10019853",
-            "MEDDRA:10019850",
-            "CHEMBL.TARGET:CHEMBL1697861",
-            "MEDDRA:10019851",
-            "NCIT:C185645"
-          ],
-          "id": "UMLS:C0235378",
+            "UMLS:C0029456",
+            "UMLS:C3888192",
+            "MONDO:0005298",
+            "OMIM:166710",
+            "MEDDRA:10031284",
+            "EFO:0003882",
+            "SNOMEDCT:18040001",
+            "HP:0000939",
+            "MEDDRA:10031289",
+            "UMLS:C0001787",
+            "MESH:D010024",
+            "MEDDRA:10031282",
+            "NCIT:C3298",
+            "UMLS:C2674640",
+            "ICD9:733.0",
+            "PSY:35930",
+            "ICD10:M81.0",
+            "MEDDRA:10031286",
+            "PDQ:CDR0000041530",
+            "MEDDRA:10039984",
+            "SNOMEDCT:64859006",
+            "DOID:11476",
+            "UMLS:C0029459"
+          ],
+          "id": "MONDO:0005298",
           "category": "biolink:Disease",
           "all_names": [
-            "hepatotoxicity",
-            "Hepatotoxicity",
-            "Hepatic Toxicity"
+            "osteoporosis",
+            "Osteoporosis related phenotypic feature",
+            "Bone mineral density quantitative trait locus",
+            "Osteoporosis, Age-Related",
+            "Fracture, hip, susceptibility to",
+            "Osteoporosis",
+            "Osteoporosis, Senile"
           ],
           "all_categories": [
-            "biolink:Disease",
-            "biolink:PhenotypicFeature"
+            "biolink:Disease"
+          ],
+          "publications": [
+            "http://www.niams.nih.gov/health_info/bone/default.asp",
+            "http://www.nlm.nih.gov/medlineplus/ency/article/000360.htm",
+            "https://orcid.org/0000-0002-0736-9199",
+            "PMID:28293453",
+            "http://www.mayoclinic.com/health/osteoporosis/ds00128",
+            "http://en.wikipedia.org/wiki/osteoporosis"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 568,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Prednisolone",
+          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "RXNORM:8638",
+            "ATC:A07EA01",
+            "ATC:C05AA04",
+            "ATC:S03BA02",
+            "PDQ:CDR0000043296",
+            "CAS:50-24-8",
+            "ATC:D07XA02",
+            "KEGG.DRUG:D00472",
+            "MESH:D011239",
+            "ATC:S01BA04",
+            "ATC:S02BA03",
+            "CHEBI:8378",
+            "ATC:H02AB06",
+            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+            "ATC:R01AD02",
+            "PUBCHEM.COMPOUND:5755",
+            "PSY:39980",
+            "DrugCentral:2245",
+            "KEGG.COMPOUND:C07369",
+            "ATC:D07AA03",
+            "CAS:8056-11-9",
+            "GTOPDB:2866",
+            "UMLS:C0032950",
+            "UNII:9PHQ9Y1OLM",
+            "CHEMBL.COMPOUND:CHEMBL131",
+            "DRUGBANK:DB00860",
+            "HMDB:HMDB0014998",
+            "NCIT:C769",
+            "PathWhiz.Compound:9315",
+            "NDDF:002155",
+            "ATC:S01CB02"
+          ],
+          "id": "PUBCHEM.COMPOUND:5755",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Prednisolone",
+            "prednisolone",
+            "PREDNISOLONE",
+            "Prednisolone (JP18/USP/INN)"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:24656565",
+            "PMID:20022146",
+            "PMID:19397323",
+            "PMID:12932140",
+            "PMID:17181172",
+            "PMID:22465636",
+            "PMID:14971904",
+            "PMID:6827553",
+            "PMID:19682771"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 2352631,
+            "identity": 313199,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0235378",
-              "name": "Hepatotoxicity",
-              "description": "Toxicity that treats injury to the liver or impairs the liver function. Usually caused by exposure to xenobiotics such as drugs, food additives, alcohol, chlorinated solvents, peroxidized fatty acids, fungal toxins, radioactive isotopes, environmental toxicants, and some medicinal plants. This can include cholestasis, liver injury, hepatitis, jaundice.",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005298",
+              "name": "osteoporosis",
+              "description": "A condition of reduced bone mass, with decreased cortical thickness and a decrease in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence. Osteoporosis is classified as primary (Type 1, postmenopausal osteoporosis; Type 2, age-associated osteoporosis; and idiopathic, which can affect juveniles, premenopausal women, and middle-aged men) and secondary osteoporosis (which results from an identifiable cause of bone mass loss).; Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.; Osteoporosis is a systemic skeletal disease characterized by low bone density and microarchitectural deterioration of bone tissue with a consequent increase in bone fragility. According to the WHO criteria, osteoporosis is defined as a BMD that lies 2.5 standard deviations or more below the average value for young healthy adults (a T-score below -2.5 SD). [HPO:probinson, PMID:28293453]; Osteoporosis is a disease that thins and weakens the bones. Your bones become fragile and fracture (break) easily, especially the bones in the hip, spine, and wrist. In the United States, millions of people either already have osteoporosis or are at high risk due to low bone mass. Anyone can develop osteoporosis, but it is more common in older women. Risk factors include: Getting older  Being small and thin  Having a family history of osteoporosis Taking certain medicines Being a white or Asian woman Having low bone density  Osteoporosis is a silent disease. You might not know you have it until you break a bone. A bone mineral density test is the best way to check your bone health. To keep bones strong, eat a diet rich in calcium and vitamin D, exercise, and do not smoke. If needed, medicines can also help. It is also important to try to avoid falling down. Falls are the number one cause of fractures in older adults. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "UMLS:C0235378",
-                "EFO:0011052",
-                "MEDDRA:10019853",
-                "MEDDRA:10019850",
-                "CHEMBL.TARGET:CHEMBL1697861",
-                "MEDDRA:10019851",
-                "NCIT:C185645"
-              ],
-              "id": "UMLS:C0235378",
+                "UMLS:C0029456",
+                "UMLS:C3888192",
+                "MONDO:0005298",
+                "OMIM:166710",
+                "MEDDRA:10031284",
+                "EFO:0003882",
+                "SNOMEDCT:18040001",
+                "HP:0000939",
+                "MEDDRA:10031289",
+                "UMLS:C0001787",
+                "MESH:D010024",
+                "MEDDRA:10031282",
+                "NCIT:C3298",
+                "UMLS:C2674640",
+                "ICD9:733.0",
+                "PSY:35930",
+                "ICD10:M81.0",
+                "MEDDRA:10031286",
+                "PDQ:CDR0000041530",
+                "MEDDRA:10039984",
+                "SNOMEDCT:64859006",
+                "DOID:11476",
+                "UMLS:C0029459"
+              ],
+              "id": "MONDO:0005298",
               "category": "biolink:Disease",
               "all_names": [
-                "hepatotoxicity",
-                "Hepatotoxicity",
-                "Hepatic Toxicity"
+                "osteoporosis",
+                "Osteoporosis related phenotypic feature",
+                "Bone mineral density quantitative trait locus",
+                "Osteoporosis, Age-Related",
+                "Fracture, hip, susceptibility to",
+                "Osteoporosis",
+                "Osteoporosis, Senile"
               ],
               "all_categories": [
-                "biolink:Disease",
-                "biolink:PhenotypicFeature"
+                "biolink:Disease"
+              ],
+              "publications": [
+                "http://www.niams.nih.gov/health_info/bone/default.asp",
+                "http://www.nlm.nih.gov/medlineplus/ency/article/000360.htm",
+                "https://orcid.org/0000-0002-0736-9199",
+                "PMID:28293453",
+                "http://www.mayoclinic.com/health/osteoporosis/ds00128",
+                "http://en.wikipedia.org/wiki/osteoporosis"
               ]
             }
           },
           "relationship": {
-            "identity": 20819936,
-            "start": 547,
-            "end": 2352631,
+            "identity": 11150176,
+            "start": 568,
+            "end": 313199,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:31423600': {'publication date': '2019 Dec', 'sentence': \"Hepatotoxicity caused by mebendazole in a patient with Gilbert's syndrome.\", 'subject score': 1000, 'object score': 1000}, 'PMID:6874531': {'publication date': '1983 Jul 01', 'sentence': 'Additionally, in dogs whose liver function was compromised experimentally by glutathione depletion and microsomal enzyme induction, administration of mebendazole at this same dosage for 30 days did not result in any hepatotoxic effect.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:15357627': {'publication date': '2004', 'sentence': 'Effect of D-003, a mixture of very high molecular weight aliphatic acids, on prednisolone-induced osteoporosis in Sprague-Dawley rats.', 'subject score': 851, 'object score': 851}, 'PMID:1570761': {'publication date': '1992 Feb', 'sentence': 'We investigated the possible ameliorating and preventive effect of swimming on prednisolone-induced osteoporosis in elderly rats.', 'subject score': 851, 'object score': 851}, 'PMID:16963801': {'publication date': '2006', 'sentence': 'The examinations demonstrated that rats with prednisolone-induced osteoporosis displayed a decreased intramedullary pressure.', 'subject score': 851, 'object score': 851}, 'PMID:17377207': {'publication date': '2007', 'sentence': 'The experiments demonstrated that rats with prednisolone-induced osteoporosis displayed a decreased blood pressure in the marrow cavity.', 'subject score': 851, 'object score': 851}, 'PMID:22661190': {'publication date': '2012', 'sentence': 'The aim of the present study was to investigate the effects of thalidomide on the development of osteoporosis induced by glucocorticoid (prednisolone) in rats.', 'subject score': 1000, 'object score': 1000}, 'PMID:23263781': {'publication date': '2013 May', 'sentence': 'The objective of this study has been to test the effects of procedures or drugs affecting bone metabolism on articular cartilage in rats with prednisolone-induced osteoporosis and to evaluate the outcomes of physical activity with treadmill and vibration platform training on articular cartilage.', 'subject score': 851, 'object score': 851}, 'PMID:23415893': {'publication date': '2013 Apr 28', 'sentence': 'Furthermore, PCG presented no adverse effect on bone density while prednisolone resulted in severe osteoporosis.', 'subject score': 1000, 'object score': 888}, 'PMID:23553492': {'publication date': '2013 09', 'sentence': 'The aim of this study was to investigate bone tissue and plasma levels of RANKL and OPG in rats with prednisolone-induced osteoporosis and to evaluate the outcomes of physical activity on the skeletal system by treadmill and vibration platform training.', 'subject score': 851, 'object score': 851}, 'PMID:23903952': {'publication date': '2014 Feb', 'sentence': 'Prednisolone induces osteoporosis-like phenotype in regenerating zebrafish scales.', 'subject score': 1000, 'object score': 1000}, 'PMID:25212043': {'publication date': '2014 Jun', 'sentence': 'The results indicated that epimedin A and baohuoside I can prevent prednisolone-induced osteoporosis in zebrafish.', 'subject score': 851, 'object score': 851}, 'PMID:25345140': {'publication date': '2014 Apr', 'sentence': 'OBJECTIVE: Prednisolone-induced osteoporosis model using zebrafish was used to screen the antiosteoporotic active parts of Dipsacus Radix, in order to investigate the applicability and rationality of the zebrafish model of osteoporosis.', 'subject score': 833, 'object score': 833}, 'PMID:26636416': {'publication date': '2016 Jun', 'sentence': 'The aim of this study was to investigate the spatial expression and the potential function of MMP 2, 9 and 13 in osteoporosis induced by prednisolone in the tibiae of mice.', 'subject score': 1000, 'object score': 1000}, 'PMID:26707833': {'publication date': '2016 Feb', 'sentence': 'In addition, they prevent the alteration of bone markers in a prednisolone-induced osteoporosis model in adult zebrafish scales, whereas their esterified forms do not.', 'subject score': 833, 'object score': 833}, 'PMID:27281385': {'publication date': '2016 Aug 01', 'sentence': 'This study provides a useful approach to get insight into the intergated metabonomic mechanism of prednisolone-induced osteoporosis and to assess the efficacy of Gushudan on osteoporotic rats.', 'subject score': 851, 'object score': 851}, 'PMID:28588485': {'publication date': '2017', 'sentence': 'Conversely, the zebrafish was treated with prednisolone to induce osteoporosis in the embryo.', 'subject score': 1000, 'object score': 1000}, 'PMID:28725323': {'publication date': '2017 Aug', 'sentence': 'Complications such as diabetes mellitus (DM), hyperlipidemia (HL), and osteoporosis due to prednisolone and cardiotoxicity due to anthracyclines are well known.', 'subject score': 1000, 'object score': 1000}, 'PMID:29132024': {'publication date': '2018 Jan 01', 'sentence': 'This paper provided a better understanding of the therapeutic effect and mechanism of GSD on prednisolone-induced osteoporosis rats.', 'subject score': 833, 'object score': 833}, 'PMID:29376970': {'publication date': '2017 Dec 05', 'sentence': 'MATERIAL AND METHODS:  The experimental studies were performed on 5 month-old Balb/c mice used as the prednisolone-induced osteoporosis model.', 'subject score': 833, 'object score': 833}, 'PMID:29635908': {'publication date': '2018 May', 'sentence': 'Possible mechanisms of prednisolone-induced osteoporosis in zebrafish larva.', 'subject score': 851, 'object score': 851}, 'PMID:30012552': {'publication date': '2018 Jul 16', 'sentence': 'Prednisolone induces osteoporosis-like phenotypes via focal adhesion signaling pathway in zebrafish larvae.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0235378---SEMMEDDB:"
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0029456---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "21233320",
-              "object": "UMLS:C0235378",
+              "subject": "PUBCHEM.COMPOUND:5755",
+              "id": "11394683",
+              "object": "MONDO:0005298",
               "publications": [
-                "PMID:31423600",
-                "PMID:6874531"
+                "PMID:15357627",
+                "PMID:1570761",
+                "PMID:16963801",
+                "PMID:17377207",
+                "PMID:22661190",
+                "PMID:23263781",
+                "PMID:23415893",
+                "PMID:23553492",
+                "PMID:23903952",
+                "PMID:25212043",
+                "PMID:25345140",
+                "PMID:26636416",
+                "PMID:26707833",
+                "PMID:27281385",
+                "PMID:28588485",
+                "PMID:28725323",
+                "PMID:29132024",
+                "PMID:29376970",
+                "PMID:29635908",
+                "PMID:30012552"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 568,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Prednisolone",
+              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "RXNORM:8638",
+                "ATC:A07EA01",
+                "ATC:C05AA04",
+                "ATC:S03BA02",
+                "PDQ:CDR0000043296",
+                "CAS:50-24-8",
+                "ATC:D07XA02",
+                "KEGG.DRUG:D00472",
+                "MESH:D011239",
+                "ATC:S01BA04",
+                "ATC:S02BA03",
+                "CHEBI:8378",
+                "ATC:H02AB06",
+                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+                "ATC:R01AD02",
+                "PUBCHEM.COMPOUND:5755",
+                "PSY:39980",
+                "DrugCentral:2245",
+                "KEGG.COMPOUND:C07369",
+                "ATC:D07AA03",
+                "CAS:8056-11-9",
+                "GTOPDB:2866",
+                "UMLS:C0032950",
+                "UNII:9PHQ9Y1OLM",
+                "CHEMBL.COMPOUND:CHEMBL131",
+                "DRUGBANK:DB00860",
+                "HMDB:HMDB0014998",
+                "NCIT:C769",
+                "PathWhiz.Compound:9315",
+                "NDDF:002155",
+                "ATC:S01CB02"
+              ],
+              "id": "PUBCHEM.COMPOUND:5755",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Prednisolone",
+                "prednisolone",
+                "PREDNISOLONE",
+                "Prednisolone (JP18/USP/INN)"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:24656565",
+                "PMID:20022146",
+                "PMID:19397323",
+                "PMID:12932140",
+                "PMID:17181172",
+                "PMID:22465636",
+                "PMID:14971904",
+                "PMID:6827553",
+                "PMID:19682771"
               ]
             }
           }
@@ -6332,164 +10019,273 @@
   {
     "p3": {
       "start": {
-        "identity": 180891,
+        "identity": 310746,
         "labels": [
-          "biolink:PhysicalEssenceOrOccurrent",
           "biolink:NamedThing",
-          "biolink:OntologyClass",
           "biolink:ThingWithTaxon",
           "biolink:BiologicalEntity",
-          "biolink:BiologicalProcessOrActivity",
-          "biolink:Occurrent",
-          "biolink:PhysiologicalProcess",
-          "biolink:BiologicalProcess"
+          "biolink:Disease",
+          "biolink:DiseaseOrPhenotypicFeature",
+          "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0004391",
-          "name": "Autophagy",
-          "description": "Autophagy is a biological process that involves the lysosomal degradation of intracellular components using it a cell's own machinery. This process can play a role in cellular defense, embryonic development, and cell growth.; Lysosomal degradation of LIPID DROPLETS.; The major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane-bounded autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane-bounded structure. Autophagosomes then fuse with a lysosome (or vacuole) releasing single-membrane-bounded autophagic bodies that are then degraded within the lysosome (or vacuole). Some types of macroautophagy, e.g. pexophagy, mitophagy, involve selective targeting of the targets to be degraded. [PMID:11099404, PMID:12914914, PMID:15798367, PMID:16973210, PMID:20159618, PMID:9412464]; The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation. [GOC:autophagy, ISBN:0198547684, PMID:11099404, PMID:9412464]; UMLS Semantic Type: STY:T043",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005480",
+          "name": "contact dermatitis",
+          "description": "An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis. []; An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "UMLS:C0004391"
-          ],
-          "id": "UMLS:C0004391",
-          "category": "biolink:PhysiologicalProcess",
+            "UMLS:C0011616",
+            "NCIT:C26743",
+            "EFO:0005319",
+            "ICD10:L25.9",
+            "MESH:D003877",
+            "MEDDRA:10010803",
+            "MEDDRA:10012442",
+            "MEDDRA:10058308",
+            "SNOMEDCT:40275004",
+            "DOID:2773",
+            "MONDO:0005480",
+            "MEDDRA:10010790",
+            "HP:0032282",
+            "MEDDRA:10012492"
+          ],
+          "id": "MONDO:0005480",
+          "category": "biolink:Disease",
           "all_names": [
-            "Autophagy"
+            "Dermatitis, Contact",
+            "Contact dermatitis",
+            "Contact Dermatitis",
+            "contact dermatitis"
           ],
           "all_categories": [
-            "biolink:PhysiologicalProcess"
-          ],
-          "publications": [
-            "ISBN:0198547684",
-            "PMID:11099404",
-            "PMID:12914914",
-            "PMID:15798367",
-            "PMID:16973210",
-            "PMID:20159618",
-            "PMID:9412464"
+            "biolink:Disease"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 568,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Prednisolone",
+          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "RXNORM:8638",
+            "ATC:A07EA01",
+            "ATC:C05AA04",
+            "ATC:S03BA02",
+            "PDQ:CDR0000043296",
+            "CAS:50-24-8",
+            "ATC:D07XA02",
+            "KEGG.DRUG:D00472",
+            "MESH:D011239",
+            "ATC:S01BA04",
+            "ATC:S02BA03",
+            "CHEBI:8378",
+            "ATC:H02AB06",
+            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+            "ATC:R01AD02",
+            "PUBCHEM.COMPOUND:5755",
+            "PSY:39980",
+            "DrugCentral:2245",
+            "KEGG.COMPOUND:C07369",
+            "ATC:D07AA03",
+            "CAS:8056-11-9",
+            "GTOPDB:2866",
+            "UMLS:C0032950",
+            "UNII:9PHQ9Y1OLM",
+            "CHEMBL.COMPOUND:CHEMBL131",
+            "DRUGBANK:DB00860",
+            "HMDB:HMDB0014998",
+            "NCIT:C769",
+            "PathWhiz.Compound:9315",
+            "NDDF:002155",
+            "ATC:S01CB02"
+          ],
+          "id": "PUBCHEM.COMPOUND:5755",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Prednisolone",
+            "prednisolone",
+            "PREDNISOLONE",
+            "Prednisolone (JP18/USP/INN)"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:24656565",
+            "PMID:20022146",
+            "PMID:19397323",
+            "PMID:12932140",
+            "PMID:17181172",
+            "PMID:22465636",
+            "PMID:14971904",
+            "PMID:6827553",
+            "PMID:19682771"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 180891,
+            "identity": 310746,
             "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:BiologicalProcess",
-              "biolink:BiologicalProcessOrActivity",
               "biolink:NamedThing",
-              "biolink:Occurrent",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:PhysiologicalProcess",
-              "biolink:ThingWithTaxon"
+              "biolink:ThingWithTaxon",
+              "biolink:BiologicalEntity",
+              "biolink:Disease",
+              "biolink:DiseaseOrPhenotypicFeature",
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0004391",
-              "name": "Autophagy",
-              "description": "Autophagy is a biological process that involves the lysosomal degradation of intracellular components using it a cell's own machinery. This process can play a role in cellular defense, embryonic development, and cell growth.; Lysosomal degradation of LIPID DROPLETS.; The major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane-bounded autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane-bounded structure. Autophagosomes then fuse with a lysosome (or vacuole) releasing single-membrane-bounded autophagic bodies that are then degraded within the lysosome (or vacuole). Some types of macroautophagy, e.g. pexophagy, mitophagy, involve selective targeting of the targets to be degraded. [PMID:11099404, PMID:12914914, PMID:15798367, PMID:16973210, PMID:20159618, PMID:9412464]; The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation. [GOC:autophagy, ISBN:0198547684, PMID:11099404, PMID:9412464]; UMLS Semantic Type: STY:T043",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005480",
+              "name": "contact dermatitis",
+              "description": "An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis. []; An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "UMLS:C0004391"
-              ],
-              "id": "UMLS:C0004391",
-              "category": "biolink:PhysiologicalProcess",
+                "UMLS:C0011616",
+                "NCIT:C26743",
+                "EFO:0005319",
+                "ICD10:L25.9",
+                "MESH:D003877",
+                "MEDDRA:10010803",
+                "MEDDRA:10012442",
+                "MEDDRA:10058308",
+                "SNOMEDCT:40275004",
+                "DOID:2773",
+                "MONDO:0005480",
+                "MEDDRA:10010790",
+                "HP:0032282",
+                "MEDDRA:10012492"
+              ],
+              "id": "MONDO:0005480",
+              "category": "biolink:Disease",
               "all_names": [
-                "Autophagy"
+                "Dermatitis, Contact",
+                "Contact dermatitis",
+                "Contact Dermatitis",
+                "contact dermatitis"
               ],
               "all_categories": [
-                "biolink:PhysiologicalProcess"
-              ],
-              "publications": [
-                "ISBN:0198547684",
-                "PMID:11099404",
-                "PMID:12914914",
-                "PMID:15798367",
-                "PMID:16973210",
-                "PMID:20159618",
-                "PMID:9412464"
+                "biolink:Disease"
               ]
             }
           },
           "relationship": {
-            "identity": 20401939,
-            "start": 547,
-            "end": 180891,
+            "identity": 10504892,
+            "start": 568,
+            "end": 310746,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:30642153': {'publication date': '2019 01 01', 'sentence': 'Consequently, we suggest that MBZ induces autophagy in ECs and that protective autophagy can be a novel target for enhancing the anti-angiogenic efficacy of MBZ in cancer treatment.', 'subject score': 1000, 'object score': 1000}, 'PMID:36305295': {'publication date': '2022 Nov 01', 'sentence': 'The marked induction of autophagy by MBZ was observed, without any increased expression of autophagy-related genes ATG5/7 and Beclin 1.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:14345404': {'publication date': '1965 Sep', 'sentence': 'CONTACT DERMATITIS DUE TO TOPICAL HYDROCORTISONE AND PREDNISOLONE.', 'subject score': 1000, 'object score': 1000}, 'PMID:18404324': {'publication date': '2008 Apr', 'sentence': 'The inhibitory activities of combinations of CU-ext (p.o.) and prednisolone (s.c.) during induction phase of PC-CD were more potent than those of CU-ext alone and prednisolone alone.', 'subject score': 1000, 'object score': 857}, 'PMID:9601904': {'publication date': '1998 Jun', 'sentence': 'OBJECTIVE: We describe a patient allergic to hydrocortisone who was given a cross-reacting corticosteroid, prednisolone, that led to a systemic contact dermatitis.', 'subject score': 1000, 'object score': 901}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0004391---SEMMEDDB:"
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0011616---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "20804454",
-              "object": "UMLS:C0004391",
+              "subject": "PUBCHEM.COMPOUND:5755",
+              "id": "10735861",
+              "object": "MONDO:0005480",
               "publications": [
-                "PMID:30642153",
-                "PMID:36305295"
+                "PMID:14345404",
+                "PMID:18404324",
+                "PMID:9601904"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 568,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Prednisolone",
+              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "RXNORM:8638",
+                "ATC:A07EA01",
+                "ATC:C05AA04",
+                "ATC:S03BA02",
+                "PDQ:CDR0000043296",
+                "CAS:50-24-8",
+                "ATC:D07XA02",
+                "KEGG.DRUG:D00472",
+                "MESH:D011239",
+                "ATC:S01BA04",
+                "ATC:S02BA03",
+                "CHEBI:8378",
+                "ATC:H02AB06",
+                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+                "ATC:R01AD02",
+                "PUBCHEM.COMPOUND:5755",
+                "PSY:39980",
+                "DrugCentral:2245",
+                "KEGG.COMPOUND:C07369",
+                "ATC:D07AA03",
+                "CAS:8056-11-9",
+                "GTOPDB:2866",
+                "UMLS:C0032950",
+                "UNII:9PHQ9Y1OLM",
+                "CHEMBL.COMPOUND:CHEMBL131",
+                "DRUGBANK:DB00860",
+                "HMDB:HMDB0014998",
+                "NCIT:C769",
+                "PathWhiz.Compound:9315",
+                "NDDF:002155",
+                "ATC:S01CB02"
+              ],
+              "id": "PUBCHEM.COMPOUND:5755",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Prednisolone",
+                "prednisolone",
+                "PREDNISOLONE",
+                "Prednisolone (JP18/USP/INN)"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:24656565",
+                "PMID:20022146",
+                "PMID:19397323",
+                "PMID:12932140",
+                "PMID:17181172",
+                "PMID:22465636",
+                "PMID:14971904",
+                "PMID:6827553",
+                "PMID:19682771"
               ]
             }
           }
@@ -6501,7 +10297,7 @@
   {
     "p3": {
       "start": {
-        "identity": 3360972,
+        "identity": 313200,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -6511,131 +10307,302 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0274770",
-          "name": "Poisoning by theophylline",
-          "description": "UMLS Semantic Type: STY:T037",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0016370",
+          "name": "Marchiafava-Bignami disease",
+          "description": "Osteopenia is a term to define bone density that is not normal but also not as low as osteoporosis. By definition from the World Health Organization osteopenia is defined by bone densitometry as a T score -1 to -2.5. [HPO:probinson, PMID:21234807]; Osteopenia is a term to define bone density that is not normal but also not as low as osteoporosis. By definition from the World Health Organization osteopenia is defined by bone densitometry as a T score -1 to -2.5.; Osteopenia is a term to define bone density that is not normal but also not as low as osteoporosis. By definition from the World Health Organization osteopenia is defined by bone densitometry as a T score -1 to -2.5.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "UMLS:C0274770",
-            "SNOMEDCT:64808005"
-          ],
-          "id": "UMLS:C0274770",
+            "MONDO:0016370",
+            "MESH:D001851",
+            "MEDDRA:10026828",
+            "MEDDRA:10005992",
+            "ORPHANET:221074",
+            "MEDDRA:10027425",
+            "UMLS:C0005944",
+            "SNOMEDCT:78441005",
+            "NCIT:C50910",
+            "HP:0000938",
+            "UMLS:C0747078",
+            "SNOMEDCT:386766007",
+            "MEDDRA:10058972",
+            "SNOMEDCT:50279003",
+            "MEDDRA:10049088",
+            "UMLS:C0029453",
+            "NCIT:C97045",
+            "UMLS:C0238265",
+            "MESH:D054319",
+            "SNOMEDCT:312894000",
+            "EFO:1001809",
+            "MEDDRA:10065687"
+          ],
+          "id": "MONDO:0016370",
           "category": "biolink:Disease",
           "all_names": [
-            "Theophylline Toxicity"
+            "Bone Diseases, Metabolic",
+            "Marchiafava-Bignami Disease",
+            "Osteopenia",
+            "Metabolic Bone Disorder",
+            "Marchiafava-Bignami disease"
           ],
           "all_categories": [
             "biolink:Disease"
+          ],
+          "publications": [
+            "https://rarediseases.info.nih.gov/diseases/6971/marchiafava-bignami-disease",
+            "https://orcid.org/0000-0002-0736-9199",
+            "PMID:21234807"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 568,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Prednisolone",
+          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "RXNORM:8638",
+            "ATC:A07EA01",
+            "ATC:C05AA04",
+            "ATC:S03BA02",
+            "PDQ:CDR0000043296",
+            "CAS:50-24-8",
+            "ATC:D07XA02",
+            "KEGG.DRUG:D00472",
+            "MESH:D011239",
+            "ATC:S01BA04",
+            "ATC:S02BA03",
+            "CHEBI:8378",
+            "ATC:H02AB06",
+            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+            "ATC:R01AD02",
+            "PUBCHEM.COMPOUND:5755",
+            "PSY:39980",
+            "DrugCentral:2245",
+            "KEGG.COMPOUND:C07369",
+            "ATC:D07AA03",
+            "CAS:8056-11-9",
+            "GTOPDB:2866",
+            "UMLS:C0032950",
+            "UNII:9PHQ9Y1OLM",
+            "CHEMBL.COMPOUND:CHEMBL131",
+            "DRUGBANK:DB00860",
+            "HMDB:HMDB0014998",
+            "NCIT:C769",
+            "PathWhiz.Compound:9315",
+            "NDDF:002155",
+            "ATC:S01CB02"
+          ],
+          "id": "PUBCHEM.COMPOUND:5755",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Prednisolone",
+            "prednisolone",
+            "PREDNISOLONE",
+            "Prednisolone (JP18/USP/INN)"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:24656565",
+            "PMID:20022146",
+            "PMID:19397323",
+            "PMID:12932140",
+            "PMID:17181172",
+            "PMID:22465636",
+            "PMID:14971904",
+            "PMID:6827553",
+            "PMID:19682771"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 3360972,
+            "identity": 313200,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0274770",
-              "name": "Poisoning by theophylline",
-              "description": "UMLS Semantic Type: STY:T037",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0016370",
+              "name": "Marchiafava-Bignami disease",
+              "description": "Osteopenia is a term to define bone density that is not normal but also not as low as osteoporosis. By definition from the World Health Organization osteopenia is defined by bone densitometry as a T score -1 to -2.5. [HPO:probinson, PMID:21234807]; Osteopenia is a term to define bone density that is not normal but also not as low as osteoporosis. By definition from the World Health Organization osteopenia is defined by bone densitometry as a T score -1 to -2.5.; Osteopenia is a term to define bone density that is not normal but also not as low as osteoporosis. By definition from the World Health Organization osteopenia is defined by bone densitometry as a T score -1 to -2.5.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "UMLS:C0274770",
-                "SNOMEDCT:64808005"
-              ],
-              "id": "UMLS:C0274770",
+                "MONDO:0016370",
+                "MESH:D001851",
+                "MEDDRA:10026828",
+                "MEDDRA:10005992",
+                "ORPHANET:221074",
+                "MEDDRA:10027425",
+                "UMLS:C0005944",
+                "SNOMEDCT:78441005",
+                "NCIT:C50910",
+                "HP:0000938",
+                "UMLS:C0747078",
+                "SNOMEDCT:386766007",
+                "MEDDRA:10058972",
+                "SNOMEDCT:50279003",
+                "MEDDRA:10049088",
+                "UMLS:C0029453",
+                "NCIT:C97045",
+                "UMLS:C0238265",
+                "MESH:D054319",
+                "SNOMEDCT:312894000",
+                "EFO:1001809",
+                "MEDDRA:10065687"
+              ],
+              "id": "MONDO:0016370",
               "category": "biolink:Disease",
               "all_names": [
-                "Theophylline Toxicity"
+                "Bone Diseases, Metabolic",
+                "Marchiafava-Bignami Disease",
+                "Osteopenia",
+                "Metabolic Bone Disorder",
+                "Marchiafava-Bignami disease"
               ],
               "all_categories": [
                 "biolink:Disease"
+              ],
+              "publications": [
+                "https://rarediseases.info.nih.gov/diseases/6971/marchiafava-bignami-disease",
+                "https://orcid.org/0000-0002-0736-9199",
+                "PMID:21234807"
               ]
             }
           },
           "relationship": {
-            "identity": 19948904,
-            "start": 547,
-            "end": 3360972,
+            "identity": 9706540,
+            "start": 568,
+            "end": 313200,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:2979257': {'publication date': '1988 Aug', 'sentence': 'It is concluded that at therapeutic doses it is unlikely that mebendazole or albendazole will induce theophylline toxicity if co-administered with the bronchodilator.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:12477571': {'publication date': '2002 Nov', 'sentence': 'We carried out two experiments using a prednisolone (pred)-induced bone loss model in male (10-week-old) Fischer rats.', 'subject score': 840, 'object score': 840}, 'PMID:19404943': {'publication date': '2009 May', 'sentence': 'Denosumab prevented prednisolone-induced bone loss by a pronounced antiresorptive effect.', 'subject score': 780, 'object score': 780}, 'PMID:25345140': {'publication date': '2014 Apr', 'sentence': 'CONCLUSION: Both saponins and nonsaponins can prevent bone loss of zebrafish induced by prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:25535658': {'publication date': '2015 Jan', 'sentence': 'OBJECTIVE: To evaluate whether a low-dosage regimen of prednisolone induces bone loss and whether administration of alendronate sodium prevents glucocorticoid-induced osteopenia in dogs by measuring trabecular bone mineral density (BMD) with quantitative CT.', 'subject score': 1000, 'object score': 1000}, 'PMID:3338411': {'publication date': '1988 Feb', 'sentence': 'E2 protected bone from the osteopenic effects of ovariectomy but did not affect bone loss induced by prednisolone.', 'subject score': 1000, 'object score': 1000}, 'PMID:35203613': {'publication date': '2022 Feb 08', 'sentence': 'We further demonstrated that Cdk5 inhibition reversed prednisolone (Pred)-induced bone loss in mice, due to reduced osteoclastogenesis rather than improved osteoblastogenesis.', 'subject score': 861, 'object score': 861}, 'PMID:3911723': {'publication date': '1985', 'sentence': 'Prednisolone-induced osteopenia was more effectively counteracted by 1 alpha OHD2 than by 1 alpha OHD3.', 'subject score': 851, 'object score': 851}, 'PMID:6302190': {'publication date': '1982', 'sentence': 'Prednisolone (50 mg/kg q.d.) treatment for three months resulted in significant osteoporosis in the C3H/St(Ha) mice of both age groups but did not cause significant bone loss in the C57/BL6 (JACOBS) mice of either age group.', 'subject score': 1000, 'object score': 901}, 'PMID:6809286': {'publication date': '1982 May', 'sentence': 'The prednisolone-induced osteopenia seems at least in part to be caused by impaired intestinal calcium transport.', 'subject score': 851, 'object score': 851}, 'PMID:7178655': {'publication date': '1982 Sep', 'sentence': 'Prednisolone (50 mg/kg q.d.) treatment for three months resulted in significant osteoporosis in the C3H/St(Ha) mice of both age groups but did not cause significant bone loss in the C57/BL6 (JACOBS) mice of either age group.', 'subject score': 1000, 'object score': 901}, 'PMID:8155403': {'publication date': '1993', 'sentence': 'This study was carried out to evaluate the effect of menatetrenone, a vitamin K2 with 4 isoprene units, on prednisolone-induced bone loss.', 'subject score': 861, 'object score': 861}, 'PMID:9276093': {'publication date': '1997 Sep', 'sentence': 'Here, we demonstrate, for the first time, that supplementation with a NO donor compound can counteract prednisolone-induced bone loss.', 'subject score': 861, 'object score': 861}, 'PMID:9315338': {'publication date': '1997 Oct', 'sentence': 'Prednisolone alone, or in combination with estrogen or dietary calcium deficiency or immobilization, inhibits bone formation but does not induce bone loss in mature rats.', 'subject score': 1000, 'object score': 1000}, 'PMID:9566670': {'publication date': '1998 Mar', 'sentence': 'Therefore, the aim of this study was to determine whether low-dose prednisolone treatment results in bone loss and modifies bone turnover.', 'subject score': 861, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0274770---SEMMEDDB:"
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0029453---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "20350721",
-              "object": "UMLS:C0274770",
+              "subject": "PUBCHEM.COMPOUND:5755",
+              "id": "9924414",
+              "object": "MONDO:0016370",
               "publications": [
-                "PMID:2979257"
+                "PMID:12477571",
+                "PMID:19404943",
+                "PMID:25345140",
+                "PMID:25535658",
+                "PMID:3338411",
+                "PMID:35203613",
+                "PMID:3911723",
+                "PMID:6302190",
+                "PMID:6809286",
+                "PMID:7178655",
+                "PMID:8155403",
+                "PMID:9276093",
+                "PMID:9315338",
+                "PMID:9566670"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 568,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Prednisolone",
+              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "RXNORM:8638",
+                "ATC:A07EA01",
+                "ATC:C05AA04",
+                "ATC:S03BA02",
+                "PDQ:CDR0000043296",
+                "CAS:50-24-8",
+                "ATC:D07XA02",
+                "KEGG.DRUG:D00472",
+                "MESH:D011239",
+                "ATC:S01BA04",
+                "ATC:S02BA03",
+                "CHEBI:8378",
+                "ATC:H02AB06",
+                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+                "ATC:R01AD02",
+                "PUBCHEM.COMPOUND:5755",
+                "PSY:39980",
+                "DrugCentral:2245",
+                "KEGG.COMPOUND:C07369",
+                "ATC:D07AA03",
+                "CAS:8056-11-9",
+                "GTOPDB:2866",
+                "UMLS:C0032950",
+                "UNII:9PHQ9Y1OLM",
+                "CHEMBL.COMPOUND:CHEMBL131",
+                "DRUGBANK:DB00860",
+                "HMDB:HMDB0014998",
+                "NCIT:C769",
+                "PathWhiz.Compound:9315",
+                "NDDF:002155",
+                "ATC:S01CB02"
+              ],
+              "id": "PUBCHEM.COMPOUND:5755",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Prednisolone",
+                "prednisolone",
+                "PREDNISOLONE",
+                "Prednisolone (JP18/USP/INN)"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:24656565",
+                "PMID:20022146",
+                "PMID:19397323",
+                "PMID:12932140",
+                "PMID:17181172",
+                "PMID:22465636",
+                "PMID:14971904",
+                "PMID:6827553",
+                "PMID:19682771"
               ]
             }
           }
@@ -6647,153 +10614,313 @@
   {
     "p3": {
       "start": {
-        "identity": 546762,
+        "identity": 319015,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
           "biolink:BiologicalEntity",
           "biolink:Disease",
           "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature",
-          "biolink:BehavioralFeature"
+          "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0231337",
-          "name": "Senility",
-          "description": "\"A degenerative state of the brain resulting in impairment of memory, judgment, attention span, problem solving skills, the inability to perform previously learned skills that cannot be attributed to deficits of motor or sensory function, and a global loss of cognitive abilities.\" [MeSH:National Library of Medicine_Medical Subject Headings]",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
+          "name": "systemic lupus erythematosus",
+          "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "MEDDRA:10039992",
-            "NBO:0000572",
-            "SNOMEDCT:271873000",
-            "UMLS:C0231337",
-            "SNOMEDCT:32864002"
-          ],
-          "id": "UMLS:C0231337",
-          "category": "biolink:PhenotypicFeature",
+            "MEDDRA:10025133",
+            "KEGG.DISEASE:05322",
+            "MEDDRA:10042820",
+            "PDQ:CDR0000608139",
+            "MEDDRA:10040967",
+            "MEDDRA:10042800",
+            "MEDDRA:10013446",
+            "MONDO:0007915",
+            "MEDDRA:10042945",
+            "MEDDRA:10024067",
+            "ICD10:M32.9",
+            "MEDDRA:10042947",
+            "ORPHANET:536",
+            "MEDDRA:10042944",
+            "UMLS:C0024141",
+            "EFO:0002690",
+            "MESH:D008180",
+            "ICD9:710.0",
+            "DOID:9074",
+            "MEDDRA:10025139",
+            "UMLS:C1835309",
+            "MEDDRA:10024065",
+            "OMIM:152700",
+            "HP:0002725",
+            "MEDDRA:10025142",
+            "NCIT:C3201",
+            "SNOMEDCT:55464009"
+          ],
+          "id": "MONDO:0007915",
+          "category": "biolink:Disease",
           "all_names": [
-            "senility",
-            "Senility"
+            "Systemic lupus erythematosus",
+            "obsolete_systemic lupus erythematosus",
+            "Systemic lupus erythematosus related phenotypic feature",
+            "Lupus Erythematosus, Systemic",
+            "Excess lmw-dna",
+            "systemic lupus erythematosus",
+            "Systemic Lupus Erythematosus"
           ],
           "all_categories": [
-            "biolink:PhenotypicFeature",
-            "biolink:BehavioralFeature"
+            "biolink:Disease"
+          ],
+          "publications": [
+            "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
+            "https://orcid.org/0000-0002-6601-2165",
+            "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 568,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Prednisolone",
+          "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "RXNORM:8638",
+            "ATC:A07EA01",
+            "ATC:C05AA04",
+            "ATC:S03BA02",
+            "PDQ:CDR0000043296",
+            "CAS:50-24-8",
+            "ATC:D07XA02",
+            "KEGG.DRUG:D00472",
+            "MESH:D011239",
+            "ATC:S01BA04",
+            "ATC:S02BA03",
+            "CHEBI:8378",
+            "ATC:H02AB06",
+            "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+            "ATC:R01AD02",
+            "PUBCHEM.COMPOUND:5755",
+            "PSY:39980",
+            "DrugCentral:2245",
+            "KEGG.COMPOUND:C07369",
+            "ATC:D07AA03",
+            "CAS:8056-11-9",
+            "GTOPDB:2866",
+            "UMLS:C0032950",
+            "UNII:9PHQ9Y1OLM",
+            "CHEMBL.COMPOUND:CHEMBL131",
+            "DRUGBANK:DB00860",
+            "HMDB:HMDB0014998",
+            "NCIT:C769",
+            "PathWhiz.Compound:9315",
+            "NDDF:002155",
+            "ATC:S01CB02"
+          ],
+          "id": "PUBCHEM.COMPOUND:5755",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Prednisolone",
+            "prednisolone",
+            "PREDNISOLONE",
+            "Prednisolone (JP18/USP/INN)"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:24656565",
+            "PMID:20022146",
+            "PMID:19397323",
+            "PMID:12932140",
+            "PMID:17181172",
+            "PMID:22465636",
+            "PMID:14971904",
+            "PMID:6827553",
+            "PMID:19682771"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 546762,
+            "identity": 319015,
             "labels": [
-              "biolink:BehavioralFeature",
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0231337",
-              "name": "Senility",
-              "description": "\"A degenerative state of the brain resulting in impairment of memory, judgment, attention span, problem solving skills, the inability to perform previously learned skills that cannot be attributed to deficits of motor or sensory function, and a global loss of cognitive abilities.\" [MeSH:National Library of Medicine_Medical Subject Headings]",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
+              "name": "systemic lupus erythematosus",
+              "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "MEDDRA:10039992",
-                "NBO:0000572",
-                "SNOMEDCT:271873000",
-                "UMLS:C0231337",
-                "SNOMEDCT:32864002"
-              ],
-              "id": "UMLS:C0231337",
-              "category": "biolink:PhenotypicFeature",
+                "MEDDRA:10025133",
+                "KEGG.DISEASE:05322",
+                "MEDDRA:10042820",
+                "PDQ:CDR0000608139",
+                "MEDDRA:10040967",
+                "MEDDRA:10042800",
+                "MEDDRA:10013446",
+                "MONDO:0007915",
+                "MEDDRA:10042945",
+                "MEDDRA:10024067",
+                "ICD10:M32.9",
+                "MEDDRA:10042947",
+                "ORPHANET:536",
+                "MEDDRA:10042944",
+                "UMLS:C0024141",
+                "EFO:0002690",
+                "MESH:D008180",
+                "ICD9:710.0",
+                "DOID:9074",
+                "MEDDRA:10025139",
+                "UMLS:C1835309",
+                "MEDDRA:10024065",
+                "OMIM:152700",
+                "HP:0002725",
+                "MEDDRA:10025142",
+                "NCIT:C3201",
+                "SNOMEDCT:55464009"
+              ],
+              "id": "MONDO:0007915",
+              "category": "biolink:Disease",
               "all_names": [
-                "senility",
-                "Senility"
+                "Systemic lupus erythematosus",
+                "obsolete_systemic lupus erythematosus",
+                "Systemic lupus erythematosus related phenotypic feature",
+                "Lupus Erythematosus, Systemic",
+                "Excess lmw-dna",
+                "systemic lupus erythematosus",
+                "Systemic Lupus Erythematosus"
               ],
               "all_categories": [
-                "biolink:PhenotypicFeature",
-                "biolink:BehavioralFeature"
+                "biolink:Disease"
+              ],
+              "publications": [
+                "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
+                "https://orcid.org/0000-0002-6601-2165",
+                "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 19462164,
-            "start": 547,
-            "end": 546762,
+            "identity": 8570880,
+            "start": 568,
+            "end": 319015,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
-              "domain_range_exclusion": "True",
-              "publications_info": "{'PMID:28852916': {'publication date': '2018 04', 'sentence': 'Cell cycle distribution and nuclear morphometric analysis indicated that the triple combination of TMZ, VBL and MBZ (TVM) was able to induce polyploidy and senescence, in addition to increasing the Notch3 RNA level in patient-derived gliomas.', 'subject score': 1000, 'object score': 1000}}",
+              "domain_range_exclusion": "False",
+              "publications_info": "{'PMID:11246661': {'publication date': '2001 Feb', 'sentence': 'In inactive SLE induced by prednisolone therapy, the invariant Valpha24JalphaQ TCR could be detected in DN Valpha24+ T cells from all the patients and dominated in most of the patients.', 'subject score': 888, 'object score': 916}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0231337---SEMMEDDB:"
+                "UMLS:C0032950---SEMMEDDB:treats---None---None---None---UMLS:C0024141---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "19850774",
-              "object": "UMLS:C0231337",
+              "subject": "PUBCHEM.COMPOUND:5755",
+              "id": "8757881",
+              "object": "MONDO:0007915",
               "publications": [
-                "PMID:28852916"
+                "PMID:11246661"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 568,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Prednisolone",
+              "description": "Prednisolone is only found in individuals that have used or taken this drug. It is a glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "RXNORM:8638",
+                "ATC:A07EA01",
+                "ATC:C05AA04",
+                "ATC:S03BA02",
+                "PDQ:CDR0000043296",
+                "CAS:50-24-8",
+                "ATC:D07XA02",
+                "KEGG.DRUG:D00472",
+                "MESH:D011239",
+                "ATC:S01BA04",
+                "ATC:S02BA03",
+                "CHEBI:8378",
+                "ATC:H02AB06",
+                "INCHIKEY:OIGNJSKKLXVSLS-VWUMJDOOSA-N",
+                "ATC:R01AD02",
+                "PUBCHEM.COMPOUND:5755",
+                "PSY:39980",
+                "DrugCentral:2245",
+                "KEGG.COMPOUND:C07369",
+                "ATC:D07AA03",
+                "CAS:8056-11-9",
+                "GTOPDB:2866",
+                "UMLS:C0032950",
+                "UNII:9PHQ9Y1OLM",
+                "CHEMBL.COMPOUND:CHEMBL131",
+                "DRUGBANK:DB00860",
+                "HMDB:HMDB0014998",
+                "NCIT:C769",
+                "PathWhiz.Compound:9315",
+                "NDDF:002155",
+                "ATC:S01CB02"
+              ],
+              "id": "PUBCHEM.COMPOUND:5755",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Prednisolone",
+                "prednisolone",
+                "PREDNISOLONE",
+                "Prednisolone (JP18/USP/INN)"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:24656565",
+                "PMID:20022146",
+                "PMID:19397323",
+                "PMID:12932140",
+                "PMID:17181172",
+                "PMID:22465636",
+                "PMID:14971904",
+                "PMID:6827553",
+                "PMID:19682771"
               ]
             }
           }
@@ -6805,7 +10932,7 @@
   {
     "p3": {
       "start": {
-        "identity": 583804,
+        "identity": 313237,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -6815,147 +10942,285 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0019934",
-          "name": "polyploidy",
-          "description": "A numerical chromosomal abnormality characterized by the presence of more than two sets of chromosomes.; The chromosomal constitution of a cell containing multiples of the normal number of CHROMOSOMES; includes triploidy (symbol: 3N), tetraploidy (symbol: 4N), etc.",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
+          "name": "atopic eczema",
+          "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "SNOMEDCT:72991005",
-            "SNOMEDCT:48099008",
-            "ORPHANET:96321",
-            "MESH:D011123",
-            "MONDO:0019934",
-            "UMLS:C0032578",
-            "NCIT:C3338"
-          ],
-          "id": "MONDO:0019934",
+            "SYMP:0000289",
+            "EFO:0000274",
+            "DOID:3310",
+            "HP:0000964",
+            "NCIT:C3001",
+            "UMLS:C0013595",
+            "MESH:D004485",
+            "MEDDRA:10014200",
+            "MEDDRA:10014206",
+            "MEDDRA:10012454",
+            "ICD10:L20",
+            "MEDDRA:10014184",
+            "OMIM.PS:603165",
+            "MEDDRA:10014209",
+            "PSY:15950",
+            "MONDO:0004980",
+            "OMIM:PS603165"
+          ],
+          "id": "MONDO:0004980",
           "category": "biolink:Disease",
           "all_names": [
-            "obsolete_polyploidy",
-            "polyploidy",
-            "Polyploidy"
+            "atopic dermatitis",
+            "atopic eczema",
+            "eczema",
+            "Eczema"
           ],
           "all_categories": [
             "biolink:Disease",
             "biolink:PhenotypicFeature"
+          ],
+          "publications": [
+            "http://en.wikipedia.org/wiki/atopic_dermatitis",
+            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
+            "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 569,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Hydrocortisone",
+          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "DRUGBANK:DB00741",
+            "PSY:12030",
+            "DrugCentral:1388",
+            "CHEBI:180955",
+            "ATC:S02BA01",
+            "RXNORM:5492",
+            "HMDB:HMDB0000063",
+            "NDDF:002147",
+            "KEGG.COMPOUND:C00735",
+            "ATC:A01AC03",
+            "ATC:D07AA02",
+            "KEGG.DRUG:D00088",
+            "PUBCHEM.COMPOUND:5754",
+            "ATC:H02AB09",
+            "ATC:C05AA01",
+            "UMLS:C0020268",
+            "NCIT:C2290",
+            "PSY:23640",
+            "CAS:50-23-7",
+            "PathWhiz.Compound:45",
+            "ATC:S01BA02",
+            "UNII:WI4X0X7BPJ",
+            "ATC:A07EA02",
+            "ATC:D07XA01",
+            "CHEBI:17650",
+            "GTOPDB:2868",
+            "MESH:D006854",
+            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+            "ATC:S01CB03",
+            "CHEMBL.COMPOUND:CHEMBL389621"
+          ],
+          "id": "PUBCHEM.COMPOUND:5754",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Hydrocortisone",
+            "cortisol",
+            "Hydrocortisone (JP18/USP/INN)",
+            "hydrocortisone",
+            "Cortisol",
+            "17-hydroxycorticosterone",
+            "HYDROCORTISONE",
+            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:2970549",
+            "PMID:29729985",
+            "PMID:18666772",
+            "PMID:2031862",
+            "PMID:24128814",
+            "PMID:19256501",
+            "PMID:27692996",
+            "PMID:30419492",
+            "PMID:18289853"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 583804,
+            "identity": 313237,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0019934",
-              "name": "polyploidy",
-              "description": "A numerical chromosomal abnormality characterized by the presence of more than two sets of chromosomes.; The chromosomal constitution of a cell containing multiples of the normal number of CHROMOSOMES; includes triploidy (symbol: 3N), tetraploidy (symbol: 4N), etc.",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0004980",
+              "name": "atopic eczema",
+              "description": "A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.; A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).; Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. [HPO:probinson]; Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals  NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "SNOMEDCT:72991005",
-                "SNOMEDCT:48099008",
-                "ORPHANET:96321",
-                "MESH:D011123",
-                "MONDO:0019934",
-                "UMLS:C0032578",
-                "NCIT:C3338"
-              ],
-              "id": "MONDO:0019934",
+                "SYMP:0000289",
+                "EFO:0000274",
+                "DOID:3310",
+                "HP:0000964",
+                "NCIT:C3001",
+                "UMLS:C0013595",
+                "MESH:D004485",
+                "MEDDRA:10014200",
+                "MEDDRA:10014206",
+                "MEDDRA:10012454",
+                "ICD10:L20",
+                "MEDDRA:10014184",
+                "OMIM.PS:603165",
+                "MEDDRA:10014209",
+                "PSY:15950",
+                "MONDO:0004980",
+                "OMIM:PS603165"
+              ],
+              "id": "MONDO:0004980",
               "category": "biolink:Disease",
               "all_names": [
-                "obsolete_polyploidy",
-                "polyploidy",
-                "Polyploidy"
+                "atopic dermatitis",
+                "atopic eczema",
+                "eczema",
+                "Eczema"
               ],
               "all_categories": [
                 "biolink:Disease",
                 "biolink:PhenotypicFeature"
+              ],
+              "publications": [
+                "http://en.wikipedia.org/wiki/atopic_dermatitis",
+                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=eczema",
+                "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 19462163,
-            "start": 547,
-            "end": 583804,
+            "identity": 26606828,
+            "start": 569,
+            "end": 313237,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28852916': {'publication date': '2018 04', 'sentence': 'Cell cycle distribution and nuclear morphometric analysis indicated that the triple combination of TMZ, VBL and MBZ (TVM) was able to induce polyploidy and senescence, in addition to increasing the Notch3 RNA level in patient-derived gliomas.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:8607567': {'publication date': '1995 Oct', 'sentence': 'We report the case of a 41-year-old nonatopic women with a previous history of eczematous reaction due to hydrocortisone who suffered worsening of her perennial rhinitis in association with perinasal dermatitis from the use of budesonide in nasal spray form, and stomatitis and pharyngitis due to budesonide in a bronchial inhaler.', 'subject score': 1000, 'object score': 853}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0032578---SEMMEDDB:"
+                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0013595---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "19850773",
-              "object": "MONDO:0019934",
+              "subject": "PUBCHEM.COMPOUND:5754",
+              "id": "27073884",
+              "object": "MONDO:0004980",
               "publications": [
-                "PMID:28852916"
+                "PMID:8607567"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 569,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Hydrocortisone",
+              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "DRUGBANK:DB00741",
+                "PSY:12030",
+                "DrugCentral:1388",
+                "CHEBI:180955",
+                "ATC:S02BA01",
+                "RXNORM:5492",
+                "HMDB:HMDB0000063",
+                "NDDF:002147",
+                "KEGG.COMPOUND:C00735",
+                "ATC:A01AC03",
+                "ATC:D07AA02",
+                "KEGG.DRUG:D00088",
+                "PUBCHEM.COMPOUND:5754",
+                "ATC:H02AB09",
+                "ATC:C05AA01",
+                "UMLS:C0020268",
+                "NCIT:C2290",
+                "PSY:23640",
+                "CAS:50-23-7",
+                "PathWhiz.Compound:45",
+                "ATC:S01BA02",
+                "UNII:WI4X0X7BPJ",
+                "ATC:A07EA02",
+                "ATC:D07XA01",
+                "CHEBI:17650",
+                "GTOPDB:2868",
+                "MESH:D006854",
+                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+                "ATC:S01CB03",
+                "CHEMBL.COMPOUND:CHEMBL389621"
+              ],
+              "id": "PUBCHEM.COMPOUND:5754",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Hydrocortisone",
+                "cortisol",
+                "Hydrocortisone (JP18/USP/INN)",
+                "hydrocortisone",
+                "Cortisol",
+                "17-hydroxycorticosterone",
+                "HYDROCORTISONE",
+                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:2970549",
+                "PMID:29729985",
+                "PMID:18666772",
+                "PMID:2031862",
+                "PMID:24128814",
+                "PMID:19256501",
+                "PMID:27692996",
+                "PMID:30419492",
+                "PMID:18289853"
               ]
             }
           }
@@ -6967,7 +11232,7 @@
   {
     "p3": {
       "start": {
-        "identity": 3387963,
+        "identity": 319015,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -6977,123 +11242,309 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "name": "Morphologically altered structure",
-          "iri": "https://identifiers.org/umls:C1260954",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
+          "name": "systemic lupus erythematosus",
+          "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "UMLS:C1260954",
-            "SNOMEDCT:118956008"
-          ],
-          "id": "UMLS:C1260954",
+            "MEDDRA:10025133",
+            "KEGG.DISEASE:05322",
+            "MEDDRA:10042820",
+            "PDQ:CDR0000608139",
+            "MEDDRA:10040967",
+            "MEDDRA:10042800",
+            "MEDDRA:10013446",
+            "MONDO:0007915",
+            "MEDDRA:10042945",
+            "MEDDRA:10024067",
+            "ICD10:M32.9",
+            "MEDDRA:10042947",
+            "ORPHANET:536",
+            "MEDDRA:10042944",
+            "UMLS:C0024141",
+            "EFO:0002690",
+            "MESH:D008180",
+            "ICD9:710.0",
+            "DOID:9074",
+            "MEDDRA:10025139",
+            "UMLS:C1835309",
+            "MEDDRA:10024065",
+            "OMIM:152700",
+            "HP:0002725",
+            "MEDDRA:10025142",
+            "NCIT:C3201",
+            "SNOMEDCT:55464009"
+          ],
+          "id": "MONDO:0007915",
           "category": "biolink:Disease",
+          "all_names": [
+            "Systemic lupus erythematosus",
+            "obsolete_systemic lupus erythematosus",
+            "Systemic lupus erythematosus related phenotypic feature",
+            "Lupus Erythematosus, Systemic",
+            "Excess lmw-dna",
+            "systemic lupus erythematosus",
+            "Systemic Lupus Erythematosus"
+          ],
           "all_categories": [
             "biolink:Disease"
+          ],
+          "publications": [
+            "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
+            "https://orcid.org/0000-0002-6601-2165",
+            "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 569,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Hydrocortisone",
+          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "DRUGBANK:DB00741",
+            "PSY:12030",
+            "DrugCentral:1388",
+            "CHEBI:180955",
+            "ATC:S02BA01",
+            "RXNORM:5492",
+            "HMDB:HMDB0000063",
+            "NDDF:002147",
+            "KEGG.COMPOUND:C00735",
+            "ATC:A01AC03",
+            "ATC:D07AA02",
+            "KEGG.DRUG:D00088",
+            "PUBCHEM.COMPOUND:5754",
+            "ATC:H02AB09",
+            "ATC:C05AA01",
+            "UMLS:C0020268",
+            "NCIT:C2290",
+            "PSY:23640",
+            "CAS:50-23-7",
+            "PathWhiz.Compound:45",
+            "ATC:S01BA02",
+            "UNII:WI4X0X7BPJ",
+            "ATC:A07EA02",
+            "ATC:D07XA01",
+            "CHEBI:17650",
+            "GTOPDB:2868",
+            "MESH:D006854",
+            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+            "ATC:S01CB03",
+            "CHEMBL.COMPOUND:CHEMBL389621"
+          ],
+          "id": "PUBCHEM.COMPOUND:5754",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Hydrocortisone",
+            "cortisol",
+            "Hydrocortisone (JP18/USP/INN)",
+            "hydrocortisone",
+            "Cortisol",
+            "17-hydroxycorticosterone",
+            "HYDROCORTISONE",
+            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:2970549",
+            "PMID:29729985",
+            "PMID:18666772",
+            "PMID:2031862",
+            "PMID:24128814",
+            "PMID:19256501",
+            "PMID:27692996",
+            "PMID:30419492",
+            "PMID:18289853"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 3387963,
+            "identity": 319015,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "name": "Morphologically altered structure",
-              "iri": "https://identifiers.org/umls:C1260954",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0007915",
+              "name": "systemic lupus erythematosus",
+              "description": "A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. [HPO:probinson]; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. // COMMENTS: This is a bundled term that describes a disease rather than a phenotypic feature, but is left for convenience for annotations of lupus conceived of as a feature of another disease.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "UMLS:C1260954",
-                "SNOMEDCT:118956008"
-              ],
-              "id": "UMLS:C1260954",
+                "MEDDRA:10025133",
+                "KEGG.DISEASE:05322",
+                "MEDDRA:10042820",
+                "PDQ:CDR0000608139",
+                "MEDDRA:10040967",
+                "MEDDRA:10042800",
+                "MEDDRA:10013446",
+                "MONDO:0007915",
+                "MEDDRA:10042945",
+                "MEDDRA:10024067",
+                "ICD10:M32.9",
+                "MEDDRA:10042947",
+                "ORPHANET:536",
+                "MEDDRA:10042944",
+                "UMLS:C0024141",
+                "EFO:0002690",
+                "MESH:D008180",
+                "ICD9:710.0",
+                "DOID:9074",
+                "MEDDRA:10025139",
+                "UMLS:C1835309",
+                "MEDDRA:10024065",
+                "OMIM:152700",
+                "HP:0002725",
+                "MEDDRA:10025142",
+                "NCIT:C3201",
+                "SNOMEDCT:55464009"
+              ],
+              "id": "MONDO:0007915",
               "category": "biolink:Disease",
+              "all_names": [
+                "Systemic lupus erythematosus",
+                "obsolete_systemic lupus erythematosus",
+                "Systemic lupus erythematosus related phenotypic feature",
+                "Lupus Erythematosus, Systemic",
+                "Excess lmw-dna",
+                "systemic lupus erythematosus",
+                "Systemic Lupus Erythematosus"
+              ],
               "all_categories": [
                 "biolink:Disease"
+              ],
+              "publications": [
+                "http://en.wikipedia.org/wiki/systemic_lupus_erythematosus",
+                "https://orcid.org/0000-0002-6601-2165",
+                "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 19208496,
-            "start": 547,
-            "end": 3387963,
+            "identity": 25817586,
+            "start": 569,
+            "end": 319015,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28400768': {'publication date': '2017', 'sentence': 'Mebendazole showed antifungal activity against phagocytized C. neoformans, affected cryptococcal biofilms profoundly and caused marked morphological alterations in C. neoformans, including reduction of capsular dimensions.', 'subject score': 1000, 'object score': 856}}",
+              "publications_info": "{'PMID:6808508': {'publication date': '1982 May', 'sentence': 'Formation of covalent adducts between cortisol and 16 alpha-hydroxyestrone and protein: possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C1260954---SEMMEDDB:"
+                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0024141---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "19593283",
-              "object": "UMLS:C1260954",
+              "subject": "PUBCHEM.COMPOUND:5754",
+              "id": "26275693",
+              "object": "MONDO:0007915",
               "publications": [
-                "PMID:28400768"
+                "PMID:6808508"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 569,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Hydrocortisone",
+              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "DRUGBANK:DB00741",
+                "PSY:12030",
+                "DrugCentral:1388",
+                "CHEBI:180955",
+                "ATC:S02BA01",
+                "RXNORM:5492",
+                "HMDB:HMDB0000063",
+                "NDDF:002147",
+                "KEGG.COMPOUND:C00735",
+                "ATC:A01AC03",
+                "ATC:D07AA02",
+                "KEGG.DRUG:D00088",
+                "PUBCHEM.COMPOUND:5754",
+                "ATC:H02AB09",
+                "ATC:C05AA01",
+                "UMLS:C0020268",
+                "NCIT:C2290",
+                "PSY:23640",
+                "CAS:50-23-7",
+                "PathWhiz.Compound:45",
+                "ATC:S01BA02",
+                "UNII:WI4X0X7BPJ",
+                "ATC:A07EA02",
+                "ATC:D07XA01",
+                "CHEBI:17650",
+                "GTOPDB:2868",
+                "MESH:D006854",
+                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+                "ATC:S01CB03",
+                "CHEMBL.COMPOUND:CHEMBL389621"
+              ],
+              "id": "PUBCHEM.COMPOUND:5754",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Hydrocortisone",
+                "cortisol",
+                "Hydrocortisone (JP18/USP/INN)",
+                "hydrocortisone",
+                "Cortisol",
+                "17-hydroxycorticosterone",
+                "HYDROCORTISONE",
+                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:2970549",
+                "PMID:29729985",
+                "PMID:18666772",
+                "PMID:2031862",
+                "PMID:24128814",
+                "PMID:19256501",
+                "PMID:27692996",
+                "PMID:30419492",
+                "PMID:18289853"
               ]
             }
           }
@@ -7105,7 +11556,7 @@
   {
     "p3": {
       "start": {
-        "identity": 320409,
+        "identity": 309241,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -7115,193 +11566,289 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0004242",
-          "name": "active peptic ulcer disease",
-          "description": "Bleeding originating from any part of the gastrointestinal tract.; The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.; Hemorrhage affecting the gastrointestinal tract. [HPO:probinson]",
+          "iri": "http://purl.obolibrary.org/obo/HP_0031273",
+          "name": "Shock",
+          "description": "A life-threatening condition that requires immediate medical intervention. It is characterized by reduced blood flow that may result in damage of multiple organs. Types of shock include cardiogenic, hemorrhagic, septic, anaphylactic, and traumatic shock.; A pathological condition manifested by failure to perfuse or oxygenate vital organs.; The state in which profound and widespread reduction of effective tissue perfusion leads first to reversible, and then if prolonged, to irreversible cellular injury. []; Shock happens when not enough blood and oxygen can get to your organs and tissues. It treats very low blood pressure and may be life-threatening. It often happens along with a serious injury.  There are several kinds of shock. Hypovolemic shock happens when you lose a lot of blood or fluids. treats include internal or external bleeding, dehydration, burns, and severe vomiting and/or diarrhea. Septic shock is caused by infections in the bloodstream. A severe allergic reaction can cause anaphylactic shock. An insect bite or sting might cause it. Cardiogenic shock happens when the heart cannot pump blood effectively. This may happen after a heart attack. Neurogenic shock is caused by damage to the nervous system. Symptoms of shock include: Confusion or lack of alertness Loss of consciousness Sudden and ongoing rapid heartbeat Sweating Pale skin A weak pulse Rapid breathing Decreased or no urine output Cool hands and feet  Shock is a life-threatening medical emergency and it is important to get help right away. Treatment of shock depends on the cause. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
           "equivalent_curies": [
-            "MONDO:0004242",
-            "MEDDRA:10005116",
-            "MEDDRA:10018016",
-            "MEDDRA:10017935",
-            "MEDDRA:10055809",
-            "MEDDRA:10052742",
-            "MEDDRA:10017936",
-            "MEDDRA:10018233",
-            "DOID:749",
-            "MEDDRA:10018243",
-            "MEDDRA:10018230",
-            "SNOMEDCT:74474003",
-            "MEDDRA:10017956",
-            "UMLS:C0017181",
-            "HP:0002239",
-            "MEDDRA:10017878",
-            "MEDDRA:10018991",
-            "MEDDRA:10019543",
-            "MEDDRA:10018992",
-            "MESH:D006471",
-            "MEDDRA:10018232",
-            "MEDDRA:10055270",
-            "MEDDRA:10019566",
-            "NCIT:C48592",
-            "MEDDRA:10017871",
-            "MEDDRA:10017960",
-            "MEDDRA:10017870",
-            "MEDDRA:10017955"
-          ],
-          "id": "MONDO:0004242",
-          "category": "biolink:Disease",
+            "MEDDRA:10009917",
+            "MEDDRA:10000692",
+            "MEDDRA:10040560",
+            "SNOMEDCT:27942005",
+            "MEDDRA:10040564",
+            "MEDDRA:10047052",
+            "MEDDRA:10016161",
+            "HP:0031273",
+            "MEDDRA:10007647",
+            "MEDDRA:10009195",
+            "MEDDRA:10009915",
+            "MESH:D012769",
+            "MEDDRA:10034567",
+            "MEDDRA:10009914",
+            "SYMP:0000450",
+            "MEDDRA:10040585",
+            "MEDDRA:10016144",
+            "MEDDRA:10009192",
+            "MEDDRA:10009908",
+            "MEDDRA:10009910",
+            "NCIT:C35016",
+            "MEDDRA:10040583",
+            "UMLS:C0036974",
+            "MEDDRA:10009909"
+          ],
+          "id": "HP:0031273",
+          "category": "biolink:PhenotypicFeature",
           "all_names": [
-            "Gastrointestinal hemorrhage",
-            "Gastrointestinal Hemorrhage",
-            "active peptic ulcer disease"
+            "Shock",
+            "shock"
           ],
           "all_categories": [
-            "biolink:Disease"
+            "biolink:PhenotypicFeature"
           ],
           "publications": [
-            "https://orcid.org/0000-0002-0736-9199"
+            "http://www.merriam-webster.com/medlineplus/shock"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 569,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Hydrocortisone",
+          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "DRUGBANK:DB00741",
+            "PSY:12030",
+            "DrugCentral:1388",
+            "CHEBI:180955",
+            "ATC:S02BA01",
+            "RXNORM:5492",
+            "HMDB:HMDB0000063",
+            "NDDF:002147",
+            "KEGG.COMPOUND:C00735",
+            "ATC:A01AC03",
+            "ATC:D07AA02",
+            "KEGG.DRUG:D00088",
+            "PUBCHEM.COMPOUND:5754",
+            "ATC:H02AB09",
+            "ATC:C05AA01",
+            "UMLS:C0020268",
+            "NCIT:C2290",
+            "PSY:23640",
+            "CAS:50-23-7",
+            "PathWhiz.Compound:45",
+            "ATC:S01BA02",
+            "UNII:WI4X0X7BPJ",
+            "ATC:A07EA02",
+            "ATC:D07XA01",
+            "CHEBI:17650",
+            "GTOPDB:2868",
+            "MESH:D006854",
+            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+            "ATC:S01CB03",
+            "CHEMBL.COMPOUND:CHEMBL389621"
+          ],
+          "id": "PUBCHEM.COMPOUND:5754",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Hydrocortisone",
+            "cortisol",
+            "Hydrocortisone (JP18/USP/INN)",
+            "hydrocortisone",
+            "Cortisol",
+            "17-hydroxycorticosterone",
+            "HYDROCORTISONE",
+            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:2970549",
+            "PMID:29729985",
+            "PMID:18666772",
+            "PMID:2031862",
+            "PMID:24128814",
+            "PMID:19256501",
+            "PMID:27692996",
+            "PMID:30419492",
+            "PMID:18289853"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 320409,
+            "identity": 309241,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0004242",
-              "name": "active peptic ulcer disease",
-              "description": "Bleeding originating from any part of the gastrointestinal tract.; The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.; Hemorrhage affecting the gastrointestinal tract. [HPO:probinson]",
+              "iri": "http://purl.obolibrary.org/obo/HP_0031273",
+              "name": "Shock",
+              "description": "A life-threatening condition that requires immediate medical intervention. It is characterized by reduced blood flow that may result in damage of multiple organs. Types of shock include cardiogenic, hemorrhagic, septic, anaphylactic, and traumatic shock.; A pathological condition manifested by failure to perfuse or oxygenate vital organs.; The state in which profound and widespread reduction of effective tissue perfusion leads first to reversible, and then if prolonged, to irreversible cellular injury. []; Shock happens when not enough blood and oxygen can get to your organs and tissues. It treats very low blood pressure and may be life-threatening. It often happens along with a serious injury.  There are several kinds of shock. Hypovolemic shock happens when you lose a lot of blood or fluids. treats include internal or external bleeding, dehydration, burns, and severe vomiting and/or diarrhea. Septic shock is caused by infections in the bloodstream. A severe allergic reaction can cause anaphylactic shock. An insect bite or sting might cause it. Cardiogenic shock happens when the heart cannot pump blood effectively. This may happen after a heart attack. Neurogenic shock is caused by damage to the nervous system. Symptoms of shock include: Confusion or lack of alertness Loss of consciousness Sudden and ongoing rapid heartbeat Sweating Pale skin A weak pulse Rapid breathing Decreased or no urine output Cool hands and feet  Shock is a life-threatening medical emergency and it is important to get help right away. Treatment of shock depends on the cause. NIH: National Heart, Lung, and Blood Institute; UMLS Semantic Type: STY:T046; UMLS Semantic Type: STY:T046",
               "equivalent_curies": [
-                "MONDO:0004242",
-                "MEDDRA:10005116",
-                "MEDDRA:10018016",
-                "MEDDRA:10017935",
-                "MEDDRA:10055809",
-                "MEDDRA:10052742",
-                "MEDDRA:10017936",
-                "MEDDRA:10018233",
-                "DOID:749",
-                "MEDDRA:10018243",
-                "MEDDRA:10018230",
-                "SNOMEDCT:74474003",
-                "MEDDRA:10017956",
-                "UMLS:C0017181",
-                "HP:0002239",
-                "MEDDRA:10017878",
-                "MEDDRA:10018991",
-                "MEDDRA:10019543",
-                "MEDDRA:10018992",
-                "MESH:D006471",
-                "MEDDRA:10018232",
-                "MEDDRA:10055270",
-                "MEDDRA:10019566",
-                "NCIT:C48592",
-                "MEDDRA:10017871",
-                "MEDDRA:10017960",
-                "MEDDRA:10017870",
-                "MEDDRA:10017955"
-              ],
-              "id": "MONDO:0004242",
-              "category": "biolink:Disease",
+                "MEDDRA:10009917",
+                "MEDDRA:10000692",
+                "MEDDRA:10040560",
+                "SNOMEDCT:27942005",
+                "MEDDRA:10040564",
+                "MEDDRA:10047052",
+                "MEDDRA:10016161",
+                "HP:0031273",
+                "MEDDRA:10007647",
+                "MEDDRA:10009195",
+                "MEDDRA:10009915",
+                "MESH:D012769",
+                "MEDDRA:10034567",
+                "MEDDRA:10009914",
+                "SYMP:0000450",
+                "MEDDRA:10040585",
+                "MEDDRA:10016144",
+                "MEDDRA:10009192",
+                "MEDDRA:10009908",
+                "MEDDRA:10009910",
+                "NCIT:C35016",
+                "MEDDRA:10040583",
+                "UMLS:C0036974",
+                "MEDDRA:10009909"
+              ],
+              "id": "HP:0031273",
+              "category": "biolink:PhenotypicFeature",
               "all_names": [
-                "Gastrointestinal hemorrhage",
-                "Gastrointestinal Hemorrhage",
-                "active peptic ulcer disease"
+                "Shock",
+                "shock"
               ],
               "all_categories": [
-                "biolink:Disease"
+                "biolink:PhenotypicFeature"
               ],
               "publications": [
-                "https://orcid.org/0000-0002-0736-9199"
+                "http://www.merriam-webster.com/medlineplus/shock"
               ]
             }
           },
           "relationship": {
-            "identity": 19069699,
-            "start": 547,
-            "end": 320409,
+            "identity": 25193918,
+            "start": 569,
+            "end": 309241,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:28138197': {'publication date': '2017 Feb', 'sentence': 'The patient underwent multiple blood transfusions before referral to the Aga Khan University Hospital (AKUH), Karachi and was managed conservatively with mebendazole at our hospital after exclusion of other possible treats of gastrointestinal bleeding.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:3805847': {'publication date': '1986 Oct', 'sentence': '[Anaphylaxis-like shock caused by hydrocortisone and prednisolone sodium succinate in an asthmatic patient].', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0017181---SEMMEDDB:"
+                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0036974---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "19452008",
-              "object": "MONDO:0004242",
+              "subject": "PUBCHEM.COMPOUND:5754",
+              "id": "25645505",
+              "object": "HP:0031273",
               "publications": [
-                "PMID:28138197"
+                "PMID:3805847"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 569,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Hydrocortisone",
+              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "DRUGBANK:DB00741",
+                "PSY:12030",
+                "DrugCentral:1388",
+                "CHEBI:180955",
+                "ATC:S02BA01",
+                "RXNORM:5492",
+                "HMDB:HMDB0000063",
+                "NDDF:002147",
+                "KEGG.COMPOUND:C00735",
+                "ATC:A01AC03",
+                "ATC:D07AA02",
+                "KEGG.DRUG:D00088",
+                "PUBCHEM.COMPOUND:5754",
+                "ATC:H02AB09",
+                "ATC:C05AA01",
+                "UMLS:C0020268",
+                "NCIT:C2290",
+                "PSY:23640",
+                "CAS:50-23-7",
+                "PathWhiz.Compound:45",
+                "ATC:S01BA02",
+                "UNII:WI4X0X7BPJ",
+                "ATC:A07EA02",
+                "ATC:D07XA01",
+                "CHEBI:17650",
+                "GTOPDB:2868",
+                "MESH:D006854",
+                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+                "ATC:S01CB03",
+                "CHEMBL.COMPOUND:CHEMBL389621"
+              ],
+              "id": "PUBCHEM.COMPOUND:5754",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Hydrocortisone",
+                "cortisol",
+                "Hydrocortisone (JP18/USP/INN)",
+                "hydrocortisone",
+                "Cortisol",
+                "17-hydroxycorticosterone",
+                "HYDROCORTISONE",
+                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:2970549",
+                "PMID:29729985",
+                "PMID:18666772",
+                "PMID:2031862",
+                "PMID:24128814",
+                "PMID:19256501",
+                "PMID:27692996",
+                "PMID:30419492",
+                "PMID:18289853"
               ]
             }
           }
@@ -7313,7 +11860,7 @@
   {
     "p3": {
       "start": {
-        "identity": 315236,
+        "identity": 308967,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -7323,159 +11870,287 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0034057",
-          "name": "Fetal anomaly",
-          "description": "Structural or functional abnormalities of the fetus. Note that this section comprises terms that describe abnormalities that are specific to the fetus or differ from the corresponding general terms. A term from anywhere in the Human Phenotype Ontology can be applied to a fetus if appropriate. []; Structural or functional abnormalities of the fetus. Note that this section comprises terms that describe abnormalities that are specific to the fetus or differ from the corresponding general terms. A term from anywhere in the Human Phenotype Ontology can be applied to a fetus if appropriate.; Structural or functional abnormalities of the fetus. Note that this section comprises terms that describe abnormalities that are specific to the fetus or differ from the corresponding general terms. A term from anywhere in the Human Phenotype Ontology can be applied to a fetus if appropriate.; UMLS Semantic Type: STY:T019",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0007179",
+          "name": "autoimmune disease",
+          "description": "A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents. It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis).; Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.; The occurrence of an immune reaction against the organism's own cells or tissues. [HPO:probinson]; What are autoimmune diseases? Your immune system protects you from disease and infection by attacking germs that get into your body, such as viruses and bacteria. Your immune system can tell that the germs aren't part of you, so it destroys them. If you have an autoimmune disease, your immune system attacks the healthy cells of your organs and tissues by mistake. There are more than 80 types of autoimmune diseases. They can affect almost any part of your body. For example, alopecia areata is an autoimmune disease of the skin that treats hair loss. Autoimmune hepatitis affects the liver. In type 1 diabetes, the immune system attacks the pancreas. And in rheumatoid arthritis, the immune system can attack many parts of the body, including the joints, lungs, and eyes. What treats autoimmune diseases? No one is sure why autoimmune diseases happen. But you can't catch them from other people. Autoimmune diseases do tend to run in families, which means that certain genes may make some people more likely to develop a problem. Viruses, certain chemicals, and other things in the environment may trigger an autoimmune disease if you already have the genes for it. Who is at risk for autoimmune diseases? Millions of Americans of all ages have autoimmune diseases. Women develop many types of autoimmune diseases much more often than men. And if you have one autoimmune disease, you are more likely to get another. What are the symptoms of autoimmune diseases? The symptoms of an autoimmune disease depend on the part of your body that's affected. Many types of autoimmune diseases cause redness, swelling, heat, and pain, which are the signs and symptoms of inflammation. But other illnesses can cause the same symptoms. The symptoms of autoimmune diseases can come and go. During a flare-up, your symptoms may get severe for a while. Later on, you may have a remission, which means that your symptoms get better or disappear for a period of time. How are autoimmune diseases diagnosed? Doctors often have a hard time diagnosing autoimmune diseases. There's usually not a specific test to show whether you have a certain autoimmune disease. And the symptoms can be confusing. That's because many autoimmune diseases have similar symptoms. And some symptoms, such as muscle aches, are common in many other illnesses. So it can take a long time and some visits to different types of doctors to get a diagnosis. To help your doctor find out if an autoimmune disease is causing your symptoms,: Learn about the health conditions in your family history. What health problems did your grandparents, aunts, uncles, and cousins have? Write down what you learn and share it with your doctor. Keep track of your symptoms, including how long they last and what makes them better or worse. Share your notes with your doctor. See a specialist who deals with the symptoms that bother you most. For example, if you have rash, see a dermatologist (skin doctor).  What are the treatments for autoimmune diseases? The treatment depends on the disease. In most cases, the goal of treatment is to suppress (slow down) your immune system, and ease swelling, redness, and pain from inflammation. Your doctor may give you corticosteroids or other medicines to help you feel better. For some diseases, you may need treatment for the rest of your life.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "MESH:D000013",
-            "HP:0034057",
-            "SNOMEDCT:276654001",
-            "MEDDRA:10060920",
-            "NCIT:C2849",
-            "MEDDRA:10060919",
-            "MEDDRA:10048305",
-            "SNOMEDCT:276655000",
-            "MEDDRA:10010316",
-            "MEDDRA:10002617",
-            "MEDDRA:10012563",
-            "MEDDRA:10010357",
-            "MEDDRA:10010356",
-            "UMLS:C0000768"
-          ],
-          "id": "HP:0034057",
-          "category": "biolink:PhenotypicFeature",
+            "EFO:0005140",
+            "MEDDRA:10003815",
+            "NCIT:C2889",
+            "ICD9:720",
+            "UMLS:C0004364",
+            "MEDDRA:10003816",
+            "UMLS:C0004368",
+            "MESH:D015551",
+            "SNOMEDCT:4301008",
+            "MONDO:0007179",
+            "SNOMEDCT:85828009",
+            "OMIM:109100",
+            "UMLS:C0003089",
+            "HP:0002960",
+            "DOID:417",
+            "MEDDRA:10061664",
+            "MESH:D001327"
+          ],
+          "id": "MONDO:0007179",
+          "category": "biolink:Disease",
           "all_names": [
-            "Congenital Abnormalities",
-            "Congenital Abnormality",
-            "Fetal anomaly"
+            "Autoimmunity",
+            "Autoimmune Diseases",
+            "autoimmune disease",
+            "Autoimmune disease related phenotypic feature",
+            "Autoimmune state",
+            "Autoimmune Disease",
+            "Ankylosing spondylitis and other inflammatory spondylopathies"
           ],
           "all_categories": [
-            "biolink:PhenotypicFeature"
+            "biolink:Disease"
+          ],
+          "publications": [
+            "http://en.wikipedia.org/wiki/autoimmune_disease",
+            "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 569,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Hydrocortisone",
+          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "DRUGBANK:DB00741",
+            "PSY:12030",
+            "DrugCentral:1388",
+            "CHEBI:180955",
+            "ATC:S02BA01",
+            "RXNORM:5492",
+            "HMDB:HMDB0000063",
+            "NDDF:002147",
+            "KEGG.COMPOUND:C00735",
+            "ATC:A01AC03",
+            "ATC:D07AA02",
+            "KEGG.DRUG:D00088",
+            "PUBCHEM.COMPOUND:5754",
+            "ATC:H02AB09",
+            "ATC:C05AA01",
+            "UMLS:C0020268",
+            "NCIT:C2290",
+            "PSY:23640",
+            "CAS:50-23-7",
+            "PathWhiz.Compound:45",
+            "ATC:S01BA02",
+            "UNII:WI4X0X7BPJ",
+            "ATC:A07EA02",
+            "ATC:D07XA01",
+            "CHEBI:17650",
+            "GTOPDB:2868",
+            "MESH:D006854",
+            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+            "ATC:S01CB03",
+            "CHEMBL.COMPOUND:CHEMBL389621"
+          ],
+          "id": "PUBCHEM.COMPOUND:5754",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Hydrocortisone",
+            "cortisol",
+            "Hydrocortisone (JP18/USP/INN)",
+            "hydrocortisone",
+            "Cortisol",
+            "17-hydroxycorticosterone",
+            "HYDROCORTISONE",
+            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:2970549",
+            "PMID:29729985",
+            "PMID:18666772",
+            "PMID:2031862",
+            "PMID:24128814",
+            "PMID:19256501",
+            "PMID:27692996",
+            "PMID:30419492",
+            "PMID:18289853"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 315236,
+            "identity": 308967,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0034057",
-              "name": "Fetal anomaly",
-              "description": "Structural or functional abnormalities of the fetus. Note that this section comprises terms that describe abnormalities that are specific to the fetus or differ from the corresponding general terms. A term from anywhere in the Human Phenotype Ontology can be applied to a fetus if appropriate. []; Structural or functional abnormalities of the fetus. Note that this section comprises terms that describe abnormalities that are specific to the fetus or differ from the corresponding general terms. A term from anywhere in the Human Phenotype Ontology can be applied to a fetus if appropriate.; Structural or functional abnormalities of the fetus. Note that this section comprises terms that describe abnormalities that are specific to the fetus or differ from the corresponding general terms. A term from anywhere in the Human Phenotype Ontology can be applied to a fetus if appropriate.; UMLS Semantic Type: STY:T019",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0007179",
+              "name": "autoimmune disease",
+              "description": "A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents. It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis).; Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.; The occurrence of an immune reaction against the organism's own cells or tissues. [HPO:probinson]; What are autoimmune diseases? Your immune system protects you from disease and infection by attacking germs that get into your body, such as viruses and bacteria. Your immune system can tell that the germs aren't part of you, so it destroys them. If you have an autoimmune disease, your immune system attacks the healthy cells of your organs and tissues by mistake. There are more than 80 types of autoimmune diseases. They can affect almost any part of your body. For example, alopecia areata is an autoimmune disease of the skin that treats hair loss. Autoimmune hepatitis affects the liver. In type 1 diabetes, the immune system attacks the pancreas. And in rheumatoid arthritis, the immune system can attack many parts of the body, including the joints, lungs, and eyes. What treats autoimmune diseases? No one is sure why autoimmune diseases happen. But you can't catch them from other people. Autoimmune diseases do tend to run in families, which means that certain genes may make some people more likely to develop a problem. Viruses, certain chemicals, and other things in the environment may trigger an autoimmune disease if you already have the genes for it. Who is at risk for autoimmune diseases? Millions of Americans of all ages have autoimmune diseases. Women develop many types of autoimmune diseases much more often than men. And if you have one autoimmune disease, you are more likely to get another. What are the symptoms of autoimmune diseases? The symptoms of an autoimmune disease depend on the part of your body that's affected. Many types of autoimmune diseases cause redness, swelling, heat, and pain, which are the signs and symptoms of inflammation. But other illnesses can cause the same symptoms. The symptoms of autoimmune diseases can come and go. During a flare-up, your symptoms may get severe for a while. Later on, you may have a remission, which means that your symptoms get better or disappear for a period of time. How are autoimmune diseases diagnosed? Doctors often have a hard time diagnosing autoimmune diseases. There's usually not a specific test to show whether you have a certain autoimmune disease. And the symptoms can be confusing. That's because many autoimmune diseases have similar symptoms. And some symptoms, such as muscle aches, are common in many other illnesses. So it can take a long time and some visits to different types of doctors to get a diagnosis. To help your doctor find out if an autoimmune disease is causing your symptoms,: Learn about the health conditions in your family history. What health problems did your grandparents, aunts, uncles, and cousins have? Write down what you learn and share it with your doctor. Keep track of your symptoms, including how long they last and what makes them better or worse. Share your notes with your doctor. See a specialist who deals with the symptoms that bother you most. For example, if you have rash, see a dermatologist (skin doctor).  What are the treatments for autoimmune diseases? The treatment depends on the disease. In most cases, the goal of treatment is to suppress (slow down) your immune system, and ease swelling, redness, and pain from inflammation. Your doctor may give you corticosteroids or other medicines to help you feel better. For some diseases, you may need treatment for the rest of your life.; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "MESH:D000013",
-                "HP:0034057",
-                "SNOMEDCT:276654001",
-                "MEDDRA:10060920",
-                "NCIT:C2849",
-                "MEDDRA:10060919",
-                "MEDDRA:10048305",
-                "SNOMEDCT:276655000",
-                "MEDDRA:10010316",
-                "MEDDRA:10002617",
-                "MEDDRA:10012563",
-                "MEDDRA:10010357",
-                "MEDDRA:10010356",
-                "UMLS:C0000768"
-              ],
-              "id": "HP:0034057",
-              "category": "biolink:PhenotypicFeature",
+                "EFO:0005140",
+                "MEDDRA:10003815",
+                "NCIT:C2889",
+                "ICD9:720",
+                "UMLS:C0004364",
+                "MEDDRA:10003816",
+                "UMLS:C0004368",
+                "MESH:D015551",
+                "SNOMEDCT:4301008",
+                "MONDO:0007179",
+                "SNOMEDCT:85828009",
+                "OMIM:109100",
+                "UMLS:C0003089",
+                "HP:0002960",
+                "DOID:417",
+                "MEDDRA:10061664",
+                "MESH:D001327"
+              ],
+              "id": "MONDO:0007179",
+              "category": "biolink:Disease",
               "all_names": [
-                "Congenital Abnormalities",
-                "Congenital Abnormality",
-                "Fetal anomaly"
+                "Autoimmunity",
+                "Autoimmune Diseases",
+                "autoimmune disease",
+                "Autoimmune disease related phenotypic feature",
+                "Autoimmune state",
+                "Autoimmune Disease",
+                "Ankylosing spondylitis and other inflammatory spondylopathies"
               ],
               "all_categories": [
-                "biolink:PhenotypicFeature"
+                "biolink:Disease"
+              ],
+              "publications": [
+                "http://en.wikipedia.org/wiki/autoimmune_disease",
+                "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 18524865,
-            "start": 547,
-            "end": 315236,
+            "identity": 24820199,
+            "start": 569,
+            "end": 308967,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:27014071': {'publication date': '2016', 'sentence': 'In this study, we performed in vivo imaging of the retinas of zebrafish larvae exposed to MBZ, and found that exposure to MBZ during 2 and 3 days post-fertilization caused malformation of the retinal layers.', 'subject score': 1000, 'object score': 1000}}",
+              "publications_info": "{'PMID:36651359': {'publication date': '2023 Jan 18', 'sentence': 'In recent years, growing evidence has shown that 25-HC performs a critical function in the etiology of cancer, infectious diseases and autoimmune disorders.', 'subject score': 861, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0000768---SEMMEDDB:"
+                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0004364---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "18898185",
-              "object": "HP:0034057",
+              "subject": "PUBCHEM.COMPOUND:5754",
+              "id": "25268311",
+              "object": "MONDO:0007179",
               "publications": [
-                "PMID:27014071"
+                "PMID:36651359"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 569,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Hydrocortisone",
+              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "DRUGBANK:DB00741",
+                "PSY:12030",
+                "DrugCentral:1388",
+                "CHEBI:180955",
+                "ATC:S02BA01",
+                "RXNORM:5492",
+                "HMDB:HMDB0000063",
+                "NDDF:002147",
+                "KEGG.COMPOUND:C00735",
+                "ATC:A01AC03",
+                "ATC:D07AA02",
+                "KEGG.DRUG:D00088",
+                "PUBCHEM.COMPOUND:5754",
+                "ATC:H02AB09",
+                "ATC:C05AA01",
+                "UMLS:C0020268",
+                "NCIT:C2290",
+                "PSY:23640",
+                "CAS:50-23-7",
+                "PathWhiz.Compound:45",
+                "ATC:S01BA02",
+                "UNII:WI4X0X7BPJ",
+                "ATC:A07EA02",
+                "ATC:D07XA01",
+                "CHEBI:17650",
+                "GTOPDB:2868",
+                "MESH:D006854",
+                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+                "ATC:S01CB03",
+                "CHEMBL.COMPOUND:CHEMBL389621"
+              ],
+              "id": "PUBCHEM.COMPOUND:5754",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Hydrocortisone",
+                "cortisol",
+                "Hydrocortisone (JP18/USP/INN)",
+                "hydrocortisone",
+                "Cortisol",
+                "17-hydroxycorticosterone",
+                "HYDROCORTISONE",
+                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:2970549",
+                "PMID:29729985",
+                "PMID:18666772",
+                "PMID:2031862",
+                "PMID:24128814",
+                "PMID:19256501",
+                "PMID:27692996",
+                "PMID:30419492",
+                "PMID:18289853"
               ]
             }
           }
@@ -7487,7 +12162,7 @@
   {
     "p3": {
       "start": {
-        "identity": 546804,
+        "identity": 312713,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -7497,151 +12172,286 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-          "name": "injury",
-          "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
+          "name": "congenital adrenal hyperplasia",
+          "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "MEDDRA:10022123",
-            "NCIT:C3671",
-            "SNOMEDCT:417746004",
-            "UMLS:C0043251",
-            "MEDDRA:10022116",
-            "MESH:D014947",
-            "MEDDRA:10044528",
-            "UMLS:C3263723",
-            "MONDO:0021178"
-          ],
-          "id": "MONDO:0021178",
+            "SNOMEDCT:237751000",
+            "DOID:12255",
+            "NCIT:C34360",
+            "ORPHANET:418",
+            "MONDO:0018479",
+            "MEDDRA:10010323",
+            "ICD9:255.2",
+            "DOID:0050811",
+            "HP:0008258",
+            "UMLS:C0001627",
+            "UMLS:C0701163",
+            "ICD10:E25",
+            "MESH:D000312"
+          ],
+          "id": "MONDO:0018479",
           "category": "biolink:Disease",
           "all_names": [
-            "Wounds and Injuries",
-            "Traumatic injury",
-            "Injury",
-            "injury"
+            "congenital adrenal hyperplasia",
+            "obsolete congenital adrenal hyperplasia",
+            "Adrenogenital disorders",
+            "Adrenogenital disorder",
+            "Congenital adrenal hyperplasia",
+            "Adrenal Hyperplasia, Congenital",
+            "obsolete_congenital adrenal hyperplasia",
+            "Congenital Adrenal Hyperplasia"
           ],
           "all_categories": [
             "biolink:Disease"
+          ],
+          "publications": [
+            "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
+            "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
+            "http://omim.org/entry/201710",
+            "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 569,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Hydrocortisone",
+          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "DRUGBANK:DB00741",
+            "PSY:12030",
+            "DrugCentral:1388",
+            "CHEBI:180955",
+            "ATC:S02BA01",
+            "RXNORM:5492",
+            "HMDB:HMDB0000063",
+            "NDDF:002147",
+            "KEGG.COMPOUND:C00735",
+            "ATC:A01AC03",
+            "ATC:D07AA02",
+            "KEGG.DRUG:D00088",
+            "PUBCHEM.COMPOUND:5754",
+            "ATC:H02AB09",
+            "ATC:C05AA01",
+            "UMLS:C0020268",
+            "NCIT:C2290",
+            "PSY:23640",
+            "CAS:50-23-7",
+            "PathWhiz.Compound:45",
+            "ATC:S01BA02",
+            "UNII:WI4X0X7BPJ",
+            "ATC:A07EA02",
+            "ATC:D07XA01",
+            "CHEBI:17650",
+            "GTOPDB:2868",
+            "MESH:D006854",
+            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+            "ATC:S01CB03",
+            "CHEMBL.COMPOUND:CHEMBL389621"
+          ],
+          "id": "PUBCHEM.COMPOUND:5754",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Hydrocortisone",
+            "cortisol",
+            "Hydrocortisone (JP18/USP/INN)",
+            "hydrocortisone",
+            "Cortisol",
+            "17-hydroxycorticosterone",
+            "HYDROCORTISONE",
+            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:2970549",
+            "PMID:29729985",
+            "PMID:18666772",
+            "PMID:2031862",
+            "PMID:24128814",
+            "PMID:19256501",
+            "PMID:27692996",
+            "PMID:30419492",
+            "PMID:18289853"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 546804,
+            "identity": 312713,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0021178",
-              "name": "injury",
-              "description": "Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.; Injuries that occur as a result of participation in a research study.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0018479",
+              "name": "congenital adrenal hyperplasia",
+              "description": "A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.; A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.; A type of adrenal hyperplasia with congenital onset. [HPO:probinson]; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "MEDDRA:10022123",
-                "NCIT:C3671",
-                "SNOMEDCT:417746004",
-                "UMLS:C0043251",
-                "MEDDRA:10022116",
-                "MESH:D014947",
-                "MEDDRA:10044528",
-                "UMLS:C3263723",
-                "MONDO:0021178"
-              ],
-              "id": "MONDO:0021178",
+                "SNOMEDCT:237751000",
+                "DOID:12255",
+                "NCIT:C34360",
+                "ORPHANET:418",
+                "MONDO:0018479",
+                "MEDDRA:10010323",
+                "ICD9:255.2",
+                "DOID:0050811",
+                "HP:0008258",
+                "UMLS:C0001627",
+                "UMLS:C0701163",
+                "ICD10:E25",
+                "MESH:D000312"
+              ],
+              "id": "MONDO:0018479",
               "category": "biolink:Disease",
               "all_names": [
-                "Wounds and Injuries",
-                "Traumatic injury",
-                "Injury",
-                "injury"
+                "congenital adrenal hyperplasia",
+                "obsolete congenital adrenal hyperplasia",
+                "Adrenogenital disorders",
+                "Adrenogenital disorder",
+                "Congenital adrenal hyperplasia",
+                "Adrenal Hyperplasia, Congenital",
+                "obsolete_congenital adrenal hyperplasia",
+                "Congenital Adrenal Hyperplasia"
               ],
               "all_categories": [
                 "biolink:Disease"
+              ],
+              "publications": [
+                "http://www.genome.jp/dbget-bin/www_bget?ds:h00216",
+                "http://www.orpha.net/consor/cgi-bin/oc_exp.php?lng=gb&expert=418.0",
+                "http://omim.org/entry/201710",
+                "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 14896455,
-            "start": 547,
-            "end": 546804,
+            "identity": 18080355,
+            "start": 569,
+            "end": 312713,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:20848085': {'publication date': '2011 Mar', 'sentence': 'Oral helminthic mebendazole (MBZ) has been reported to cause liver injury with inflammatory responses.', 'subject score': 851, 'object score': 888}}",
+              "publications_info": "{'PMID:26184920': {'publication date': '2015 Oct', 'sentence': 'Congenital adrenal hyperplasia (CAH) is a chronic condition and individuals are exposed to elevated androgen levels in utero as a result of the endogenous cortisol deficiency.', 'subject score': 851, 'object score': 1000}, 'PMID:3487786': {'publication date': '1986 Jul', 'sentence': 'If this cytochrome P-450 enzyme is defective, cortisol cannot be synthesized, resulting in congenital adrenal hyperplasia.', 'subject score': 888, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C3263723---SEMMEDDB:"
+                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0001627---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "15210811",
-              "object": "MONDO:0021178",
+              "subject": "PUBCHEM.COMPOUND:5754",
+              "id": "18446972",
+              "object": "MONDO:0018479",
               "publications": [
-                "PMID:20848085"
+                "PMID:26184920",
+                "PMID:3487786"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 569,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Hydrocortisone",
+              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "DRUGBANK:DB00741",
+                "PSY:12030",
+                "DrugCentral:1388",
+                "CHEBI:180955",
+                "ATC:S02BA01",
+                "RXNORM:5492",
+                "HMDB:HMDB0000063",
+                "NDDF:002147",
+                "KEGG.COMPOUND:C00735",
+                "ATC:A01AC03",
+                "ATC:D07AA02",
+                "KEGG.DRUG:D00088",
+                "PUBCHEM.COMPOUND:5754",
+                "ATC:H02AB09",
+                "ATC:C05AA01",
+                "UMLS:C0020268",
+                "NCIT:C2290",
+                "PSY:23640",
+                "CAS:50-23-7",
+                "PathWhiz.Compound:45",
+                "ATC:S01BA02",
+                "UNII:WI4X0X7BPJ",
+                "ATC:A07EA02",
+                "ATC:D07XA01",
+                "CHEBI:17650",
+                "GTOPDB:2868",
+                "MESH:D006854",
+                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+                "ATC:S01CB03",
+                "CHEMBL.COMPOUND:CHEMBL389621"
+              ],
+              "id": "PUBCHEM.COMPOUND:5754",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Hydrocortisone",
+                "cortisol",
+                "Hydrocortisone (JP18/USP/INN)",
+                "hydrocortisone",
+                "Cortisol",
+                "17-hydroxycorticosterone",
+                "HYDROCORTISONE",
+                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:2970549",
+                "PMID:29729985",
+                "PMID:18666772",
+                "PMID:2031862",
+                "PMID:24128814",
+                "PMID:19256501",
+                "PMID:27692996",
+                "PMID:30419492",
+                "PMID:18289853"
               ]
             }
           }
@@ -7653,132 +12463,335 @@
   {
     "p3": {
       "start": {
-        "identity": 2458756,
+        "identity": 308948,
         "labels": [
           "biolink:NamedThing",
-          "biolink:InformationContentEntity"
+          "biolink:ThingWithTaxon",
+          "biolink:BiologicalEntity",
+          "biolink:Disease",
+          "biolink:DiseaseOrPhenotypicFeature",
+          "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0544461",
-          "name": "Inactivation",
-          "description": "To cause the elimination of an activity.",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005009",
+          "name": "congestive heart failure",
+          "description": "Inability of the heart to pump blood at an adequate rate to meet tissue metabolic requirements. Clinical symptoms of heart failure include: unusual dyspnea on light exertion, recurrent dyspnea occurring in the supine position, fluid retention or rales, jugular venous distension, pulmonary edema on physical exam, or pulmonary edema on chest x-ray presumed to be cardiac dysfunction.; Heart failure accompanied by EDEMA, such as swelling of the legs and ankles and congestion in the lungs.; The presence of an abnormality of cardiac function that is responsible for the failure of the heart to pump blood at a rate that is commensurate with the needs of the tissues or a state in which abnormally elevated filling pressures are required for the heart to do so. Heart failure is frequently related to a defect in myocardial contraction. [HPO:probinson]; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "UMLS:C0544461"
-          ],
-          "id": "UMLS:C0544461",
-          "category": "biolink:InformationContentEntity",
+            "MEDDRA:10022462",
+            "MEDDRA:10007554",
+            "MEDDRA:10007564",
+            "ICD9:428.0",
+            "MEDDRA:10007569",
+            "PDQ:CDR0000038915",
+            "MEDDRA:10007559",
+            "SNOMEDCT:42343007",
+            "MEDDRA:10019282",
+            "UMLS:C0264716",
+            "ICD9:428",
+            "MEDDRA:10019290",
+            "EFO:0000373",
+            "UMLS:C0018801",
+            "MEDDRA:10019285",
+            "MEDDRA:10007558",
+            "UMLS:C0018802",
+            "MEDDRA:10016146",
+            "HP:0001635",
+            "MEDDRA:10007555",
+            "MEDDRA:10007568",
+            "MEDDRA:10008908",
+            "ICD10:I50",
+            "MEDDRA:10010682",
+            "MEDDRA:10010684",
+            "MEDDRA:10019279",
+            "MEDDRA:10019280",
+            "MONDO:0005009",
+            "MEDDRA:10016145",
+            "MEDDRA:10007562",
+            "MEDDRA:10019284",
+            "DOID:6000",
+            "MEDDRA:10007582",
+            "ICD10:I50.9",
+            "SNOMEDCT:48447003",
+            "NCIT:C3080"
+          ],
+          "id": "MONDO:0005009",
+          "category": "biolink:Disease",
           "all_names": [
-            "Inactivation"
+            "Congestive heart failure, unspecified",
+            "Congestive Heart Failure",
+            "Heart failure",
+            "Chronic heart failure",
+            "Congestive heart failure",
+            "congestive heart failure"
           ],
           "all_categories": [
-            "biolink:InformationContentEntity"
+            "biolink:Disease"
+          ],
+          "publications": [
+            "http://en.wikipedia.org/wiki/heart_disease",
+            "https://orcid.org/0000-0002-0736-9199",
+            "https://orcid.org/0000-0002-5316-1399"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 569,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Hydrocortisone",
+          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "DRUGBANK:DB00741",
+            "PSY:12030",
+            "DrugCentral:1388",
+            "CHEBI:180955",
+            "ATC:S02BA01",
+            "RXNORM:5492",
+            "HMDB:HMDB0000063",
+            "NDDF:002147",
+            "KEGG.COMPOUND:C00735",
+            "ATC:A01AC03",
+            "ATC:D07AA02",
+            "KEGG.DRUG:D00088",
+            "PUBCHEM.COMPOUND:5754",
+            "ATC:H02AB09",
+            "ATC:C05AA01",
+            "UMLS:C0020268",
+            "NCIT:C2290",
+            "PSY:23640",
+            "CAS:50-23-7",
+            "PathWhiz.Compound:45",
+            "ATC:S01BA02",
+            "UNII:WI4X0X7BPJ",
+            "ATC:A07EA02",
+            "ATC:D07XA01",
+            "CHEBI:17650",
+            "GTOPDB:2868",
+            "MESH:D006854",
+            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+            "ATC:S01CB03",
+            "CHEMBL.COMPOUND:CHEMBL389621"
+          ],
+          "id": "PUBCHEM.COMPOUND:5754",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Hydrocortisone",
+            "cortisol",
+            "Hydrocortisone (JP18/USP/INN)",
+            "hydrocortisone",
+            "Cortisol",
+            "17-hydroxycorticosterone",
+            "HYDROCORTISONE",
+            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:2970549",
+            "PMID:29729985",
+            "PMID:18666772",
+            "PMID:2031862",
+            "PMID:24128814",
+            "PMID:19256501",
+            "PMID:27692996",
+            "PMID:30419492",
+            "PMID:18289853"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 2458756,
+            "identity": 308948,
             "labels": [
-              "biolink:InformationContentEntity",
-              "biolink:NamedThing"
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
+              "biolink:BiologicalEntity",
+              "biolink:Disease",
+              "biolink:DiseaseOrPhenotypicFeature",
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0544461",
-              "name": "Inactivation",
-              "description": "To cause the elimination of an activity.",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005009",
+              "name": "congestive heart failure",
+              "description": "Inability of the heart to pump blood at an adequate rate to meet tissue metabolic requirements. Clinical symptoms of heart failure include: unusual dyspnea on light exertion, recurrent dyspnea occurring in the supine position, fluid retention or rales, jugular venous distension, pulmonary edema on physical exam, or pulmonary edema on chest x-ray presumed to be cardiac dysfunction.; Heart failure accompanied by EDEMA, such as swelling of the legs and ankles and congestion in the lungs.; The presence of an abnormality of cardiac function that is responsible for the failure of the heart to pump blood at a rate that is commensurate with the needs of the tissues or a state in which abnormally elevated filling pressures are required for the heart to do so. Heart failure is frequently related to a defect in myocardial contraction. [HPO:probinson]; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "UMLS:C0544461"
-              ],
-              "id": "UMLS:C0544461",
-              "category": "biolink:InformationContentEntity",
+                "MEDDRA:10022462",
+                "MEDDRA:10007554",
+                "MEDDRA:10007564",
+                "ICD9:428.0",
+                "MEDDRA:10007569",
+                "PDQ:CDR0000038915",
+                "MEDDRA:10007559",
+                "SNOMEDCT:42343007",
+                "MEDDRA:10019282",
+                "UMLS:C0264716",
+                "ICD9:428",
+                "MEDDRA:10019290",
+                "EFO:0000373",
+                "UMLS:C0018801",
+                "MEDDRA:10019285",
+                "MEDDRA:10007558",
+                "UMLS:C0018802",
+                "MEDDRA:10016146",
+                "HP:0001635",
+                "MEDDRA:10007555",
+                "MEDDRA:10007568",
+                "MEDDRA:10008908",
+                "ICD10:I50",
+                "MEDDRA:10010682",
+                "MEDDRA:10010684",
+                "MEDDRA:10019279",
+                "MEDDRA:10019280",
+                "MONDO:0005009",
+                "MEDDRA:10016145",
+                "MEDDRA:10007562",
+                "MEDDRA:10019284",
+                "DOID:6000",
+                "MEDDRA:10007582",
+                "ICD10:I50.9",
+                "SNOMEDCT:48447003",
+                "NCIT:C3080"
+              ],
+              "id": "MONDO:0005009",
+              "category": "biolink:Disease",
               "all_names": [
-                "Inactivation"
+                "Congestive heart failure, unspecified",
+                "Congestive Heart Failure",
+                "Heart failure",
+                "Chronic heart failure",
+                "Congestive heart failure",
+                "congestive heart failure"
               ],
               "all_categories": [
-                "biolink:InformationContentEntity"
+                "biolink:Disease"
+              ],
+              "publications": [
+                "http://en.wikipedia.org/wiki/heart_disease",
+                "https://orcid.org/0000-0002-0736-9199",
+                "https://orcid.org/0000-0002-5316-1399"
               ]
             }
           },
           "relationship": {
-            "identity": 13594211,
-            "start": 547,
-            "end": 2458756,
+            "identity": 16420985,
+            "start": 569,
+            "end": 308948,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:18667591': {'publication date': '2008 Aug', 'sentence': 'Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells.', 'subject score': 1000, 'object score': 794}, 'PMID:31207347': {'publication date': '2019 Oct', 'sentence': 'Mebendazole induces apoptosis via C-MYC inactivation in malignant ascites cell line (AGP01).', 'subject score': 1000, 'object score': 758}}",
+              "publications_info": "{'PMID:23402947': {'publication date': '2013 Apr', 'sentence': 'In multivariate regression analysis, cortisol was an independent predictor of Vo2peak (R2 = 0.365, F = 12.5, SE = 3.4; p<=0.001) and Ve/Vco2 slope (R2 = 0.154; F = 8.5; SE = 5.96; p = 0.006), after accounting for age, body mass index, sex, CHF etiology, creatinine, left ventricular ejection fraction, and ACTH in all patients.', 'subject score': 1000, 'object score': 916}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0544461---SEMMEDDB:"
+                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0264716---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "13885379",
-              "object": "UMLS:C0544461",
+              "subject": "PUBCHEM.COMPOUND:5754",
+              "id": "16762875",
+              "object": "MONDO:0005009",
               "publications": [
-                "PMID:18667591",
-                "PMID:31207347"
+                "PMID:23402947"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 569,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Hydrocortisone",
+              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "DRUGBANK:DB00741",
+                "PSY:12030",
+                "DrugCentral:1388",
+                "CHEBI:180955",
+                "ATC:S02BA01",
+                "RXNORM:5492",
+                "HMDB:HMDB0000063",
+                "NDDF:002147",
+                "KEGG.COMPOUND:C00735",
+                "ATC:A01AC03",
+                "ATC:D07AA02",
+                "KEGG.DRUG:D00088",
+                "PUBCHEM.COMPOUND:5754",
+                "ATC:H02AB09",
+                "ATC:C05AA01",
+                "UMLS:C0020268",
+                "NCIT:C2290",
+                "PSY:23640",
+                "CAS:50-23-7",
+                "PathWhiz.Compound:45",
+                "ATC:S01BA02",
+                "UNII:WI4X0X7BPJ",
+                "ATC:A07EA02",
+                "ATC:D07XA01",
+                "CHEBI:17650",
+                "GTOPDB:2868",
+                "MESH:D006854",
+                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+                "ATC:S01CB03",
+                "CHEMBL.COMPOUND:CHEMBL389621"
+              ],
+              "id": "PUBCHEM.COMPOUND:5754",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Hydrocortisone",
+                "cortisol",
+                "Hydrocortisone (JP18/USP/INN)",
+                "hydrocortisone",
+                "Cortisol",
+                "17-hydroxycorticosterone",
+                "HYDROCORTISONE",
+                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:2970549",
+                "PMID:29729985",
+                "PMID:18666772",
+                "PMID:2031862",
+                "PMID:24128814",
+                "PMID:19256501",
+                "PMID:27692996",
+                "PMID:30419492",
+                "PMID:18289853"
               ]
             }
           }
@@ -7790,7 +12803,7 @@
   {
     "p3": {
       "start": {
-        "identity": 311498,
+        "identity": 314558,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -7800,179 +12813,291 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0005047",
-          "name": "infertility disorder",
-          "description": "Inability to conceive for at least one year after trying and having unprotected sex. treats of female infertility include endometriosis, fallopian tubes obstruction, and polycystic ovary syndrome. treats of male infertility include abnormal sperm production or function, blockage of the epididymis, blockage of the ejaculatory ducts, hypospadias, exposure to pesticides, and health related issues. // COMMENTS: Editor note: dubious as to whether this is a disease as defined, check with clingen before obsoleting",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005015",
+          "name": "diabetes mellitus",
+          "description": "A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2985\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2985\" NCI Thesaurus); A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.; A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.; A group of abnormalities characterized by hyperglycemia and glucose intolerance. [HPO:probinson]; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "UMLS:C4074771",
-            "MEDDRA:10021930",
-            "DOID:5223",
-            "SYMP:0000712",
-            "EFO:0000545",
-            "UMLS:C0021359",
-            "MESH:D007246",
-            "MONDO:0005047",
-            "NCIT:C3836",
-            "UMLS:C1533568",
-            "MEDDRA:10042012",
-            "HP:0000789",
-            "PSY:25210",
-            "SNOMEDCT:15296000",
-            "PDQ:CDR0000726658",
-            "SNOMEDCT:8619003",
-            "MEDDRA:10021926"
-          ],
-          "id": "MONDO:0005047",
+            "MEDDRA:10012601",
+            "MONDO:0005015",
+            "MEDDRA:10012594",
+            "HP:0000819",
+            "UMLS:C0011849",
+            "NCIT:C2985",
+            "PSY:13970",
+            "PSY:13950",
+            "MESH:D003920",
+            "EFO:0000400",
+            "PDQ:CDR0000685852",
+            "ICD10:E08-E13",
+            "UMLS:C0011847",
+            "DOID:9351",
+            "ICD9:250",
+            "MEDDRA:10012614",
+            "SNOMEDCT:73211009"
+          ],
+          "id": "MONDO:0005015",
           "category": "biolink:Disease",
           "all_names": [
-            "Infertility",
-            "infertility",
-            "Fertility Disorders",
-            "infertility disorder",
-            "Sterility, Reproductive"
+            "diabetes mellitus",
+            "Diabetes",
+            "Diabetes Mellitus",
+            "Diabetes mellitus"
           ],
           "all_categories": [
-            "biolink:Disease",
-            "biolink:DiseaseOrPhenotypicFeature",
-            "biolink:PhenotypicFeature"
+            "biolink:Disease"
           ],
           "publications": [
-            "http://en.wikipedia.org/wiki/infertility"
+            "https://medlineplus.gov/diabetes.htm",
+            "https://orcid.org/0000-0002-0736-9199",
+            "https://en.wikipedia.org/wiki/diabetes_mellitus",
+            "PMID:9686693",
+            "http://www.who.int/diabetes/action_online/basics/en/",
+            "https://orcid.org/0000-0002-6601-2165"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 569,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Hydrocortisone",
+          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "DRUGBANK:DB00741",
+            "PSY:12030",
+            "DrugCentral:1388",
+            "CHEBI:180955",
+            "ATC:S02BA01",
+            "RXNORM:5492",
+            "HMDB:HMDB0000063",
+            "NDDF:002147",
+            "KEGG.COMPOUND:C00735",
+            "ATC:A01AC03",
+            "ATC:D07AA02",
+            "KEGG.DRUG:D00088",
+            "PUBCHEM.COMPOUND:5754",
+            "ATC:H02AB09",
+            "ATC:C05AA01",
+            "UMLS:C0020268",
+            "NCIT:C2290",
+            "PSY:23640",
+            "CAS:50-23-7",
+            "PathWhiz.Compound:45",
+            "ATC:S01BA02",
+            "UNII:WI4X0X7BPJ",
+            "ATC:A07EA02",
+            "ATC:D07XA01",
+            "CHEBI:17650",
+            "GTOPDB:2868",
+            "MESH:D006854",
+            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+            "ATC:S01CB03",
+            "CHEMBL.COMPOUND:CHEMBL389621"
+          ],
+          "id": "PUBCHEM.COMPOUND:5754",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Hydrocortisone",
+            "cortisol",
+            "Hydrocortisone (JP18/USP/INN)",
+            "hydrocortisone",
+            "Cortisol",
+            "17-hydroxycorticosterone",
+            "HYDROCORTISONE",
+            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
+          ],
+          "all_categories": [
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
           ],
-          "all_categories": [
-            "biolink:SmallMolecule"
+          "publications": [
+            "PMID:11413487",
+            "PMID:2970549",
+            "PMID:29729985",
+            "PMID:18666772",
+            "PMID:2031862",
+            "PMID:24128814",
+            "PMID:19256501",
+            "PMID:27692996",
+            "PMID:30419492",
+            "PMID:18289853"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 311498,
+            "identity": 314558,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0005047",
-              "name": "infertility disorder",
-              "description": "Inability to conceive for at least one year after trying and having unprotected sex. treats of female infertility include endometriosis, fallopian tubes obstruction, and polycystic ovary syndrome. treats of male infertility include abnormal sperm production or function, blockage of the epididymis, blockage of the ejaculatory ducts, hypospadias, exposure to pesticides, and health related issues. // COMMENTS: Editor note: dubious as to whether this is a disease as defined, check with clingen before obsoleting",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005015",
+              "name": "diabetes mellitus",
+              "description": "A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2985\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2985\" NCI Thesaurus); A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.; A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.; A group of abnormalities characterized by hyperglycemia and glucose intolerance. [HPO:probinson]; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "UMLS:C4074771",
-                "MEDDRA:10021930",
-                "DOID:5223",
-                "SYMP:0000712",
-                "EFO:0000545",
-                "UMLS:C0021359",
-                "MESH:D007246",
-                "MONDO:0005047",
-                "NCIT:C3836",
-                "UMLS:C1533568",
-                "MEDDRA:10042012",
-                "HP:0000789",
-                "PSY:25210",
-                "SNOMEDCT:15296000",
-                "PDQ:CDR0000726658",
-                "SNOMEDCT:8619003",
-                "MEDDRA:10021926"
-              ],
-              "id": "MONDO:0005047",
+                "MEDDRA:10012601",
+                "MONDO:0005015",
+                "MEDDRA:10012594",
+                "HP:0000819",
+                "UMLS:C0011849",
+                "NCIT:C2985",
+                "PSY:13970",
+                "PSY:13950",
+                "MESH:D003920",
+                "EFO:0000400",
+                "PDQ:CDR0000685852",
+                "ICD10:E08-E13",
+                "UMLS:C0011847",
+                "DOID:9351",
+                "ICD9:250",
+                "MEDDRA:10012614",
+                "SNOMEDCT:73211009"
+              ],
+              "id": "MONDO:0005015",
               "category": "biolink:Disease",
               "all_names": [
-                "Infertility",
-                "infertility",
-                "Fertility Disorders",
-                "infertility disorder",
-                "Sterility, Reproductive"
+                "diabetes mellitus",
+                "Diabetes",
+                "Diabetes Mellitus",
+                "Diabetes mellitus"
               ],
               "all_categories": [
-                "biolink:Disease",
-                "biolink:DiseaseOrPhenotypicFeature",
-                "biolink:PhenotypicFeature"
+                "biolink:Disease"
               ],
               "publications": [
-                "http://en.wikipedia.org/wiki/infertility"
+                "https://medlineplus.gov/diabetes.htm",
+                "https://orcid.org/0000-0002-0736-9199",
+                "https://en.wikipedia.org/wiki/diabetes_mellitus",
+                "PMID:9686693",
+                "http://www.who.int/diabetes/action_online/basics/en/",
+                "https://orcid.org/0000-0002-6601-2165"
               ]
             }
           },
           "relationship": {
-            "identity": 12604103,
-            "start": 547,
-            "end": 311498,
+            "identity": 15958160,
+            "start": 569,
+            "end": 314558,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:17172366': {'publication date': '2006 Dec', 'sentence': 'The evaluation also highlighted that there were critical issues for the successful implementation of the program such as the issue of educating illiterate mothers, higher involvement of families in the mass treatment process, ability to reach a larger number of school absentees, and overcoming the prejudice against externally funded measures, which are perceived by some of the members of the community as an experiment run by foreigners on the local population and the concern of some parents that anthelmintic drug (mebendazole) might cause sexual sterility.', 'subject score': 1000, 'object score': 861}}",
+              "publications_info": "{'PMID:22606035': {'publication date': '2012', 'sentence': 'Increased cortisol results in diabetes, hence quelling the activity of 11betaHSD1 has been thought of as an effective approach for the treatment of diabetes.', 'subject score': 888, 'object score': 1000}, 'PMID:31058960': {'publication date': '2019 Oct 01', 'sentence': 'CONCLUSIONS: Apparently nonfunctioning ATs in bilateral PA cases may cause latent autonomous cortisol secretion, inducing diabetes and proteinuria.', 'subject score': 815, 'object score': 1000}, 'PMID:4360374': {'publication date': '1973 Nov', 'sentence': 'Synergism among growth hormone, ACTH, cortisol and dexamethasone in the hormonal induction of diabetes in rats and the diabetogenic effect of tolbutamide.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0021359---SEMMEDDB:"
+                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0011847---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "12876761",
-              "object": "MONDO:0005047",
+              "subject": "PUBCHEM.COMPOUND:5754",
+              "id": "16290606",
+              "object": "MONDO:0005015",
               "publications": [
-                "PMID:17172366"
+                "PMID:22606035",
+                "PMID:31058960",
+                "PMID:4360374"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 569,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Hydrocortisone",
+              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "DRUGBANK:DB00741",
+                "PSY:12030",
+                "DrugCentral:1388",
+                "CHEBI:180955",
+                "ATC:S02BA01",
+                "RXNORM:5492",
+                "HMDB:HMDB0000063",
+                "NDDF:002147",
+                "KEGG.COMPOUND:C00735",
+                "ATC:A01AC03",
+                "ATC:D07AA02",
+                "KEGG.DRUG:D00088",
+                "PUBCHEM.COMPOUND:5754",
+                "ATC:H02AB09",
+                "ATC:C05AA01",
+                "UMLS:C0020268",
+                "NCIT:C2290",
+                "PSY:23640",
+                "CAS:50-23-7",
+                "PathWhiz.Compound:45",
+                "ATC:S01BA02",
+                "UNII:WI4X0X7BPJ",
+                "ATC:A07EA02",
+                "ATC:D07XA01",
+                "CHEBI:17650",
+                "GTOPDB:2868",
+                "MESH:D006854",
+                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+                "ATC:S01CB03",
+                "CHEMBL.COMPOUND:CHEMBL389621"
+              ],
+              "id": "PUBCHEM.COMPOUND:5754",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Hydrocortisone",
+                "cortisol",
+                "Hydrocortisone (JP18/USP/INN)",
+                "hydrocortisone",
+                "Cortisol",
+                "17-hydroxycorticosterone",
+                "HYDROCORTISONE",
+                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:2970549",
+                "PMID:29729985",
+                "PMID:18666772",
+                "PMID:2031862",
+                "PMID:24128814",
+                "PMID:19256501",
+                "PMID:27692996",
+                "PMID:30419492",
+                "PMID:18289853"
               ]
             }
           }
@@ -7984,7 +13109,7 @@
   {
     "p3": {
       "start": {
-        "identity": 318076,
+        "identity": 316339,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -7994,64 +13119,126 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/HP_0025464",
-          "name": "Increased reactive oxygen species production",
-          "description": "A disturbance in the prooxidant-antioxidant balance in favor of the former, leading to potential damage. Indicators of oxidative stress include damaged DNA bases, protein oxidation products, and lipid peroxidation products. The damage to biological tissues is caused by superoxide and other free radicals generated by many factors, including exposure to alcohol, medications, trauma, cold, toxins, and radiation or by antimicrobial cellular immunity, metabolic abnormality, or \"normal\" aging; not synonymous with hypoxia or hyperoxia. Oxidative stress promotes a range of degenerative disorders, including cancer, diabetes, premature aging, Alzheimer's, and many others.; A disturbance in the prooxidant-antioxidant balance in favor of the former, leading to potential damage. Indicators of oxidative stress include damaged DNA bases, protein oxidation products, and lipid peroxidation products (Sies, Oxidative Stress, 1991, pxv-xvi).; An accumulation of free radical groups in the body inadequately neutralized by antioxidants, which creates a potentially unstable and damaging cellular environment linked to tissue damage. [PMID:26950655]; UMLS Semantic Type: STY:T049",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0006610",
+          "name": "skin atrophy",
+          "description": "Partial or complete wasting (atrophy) of the skin. [HPO:probinson]; Partial or complete wasting (atrophy) of the skin.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "UMLS:C4476796",
-            "HP:0025464",
-            "MESH:D018384",
-            "MEDDRA:10080562",
-            "UMLS:C0242606"
-          ],
-          "id": "HP:0025464",
-          "category": "biolink:PhenotypicFeature",
+            "MEDDRA:10003719",
+            "HP:0004334",
+            "MONDO:0006610",
+            "UMLS:C0151514",
+            "SNOMEDCT:400190005",
+            "EFO:1000766",
+            "DOID:2733",
+            "NCIT:C35163",
+            "ICD10:L90",
+            "SNOMEDCT:399979006",
+            "MEDDRA:10040799"
+          ],
+          "id": "MONDO:0006610",
+          "category": "biolink:Disease",
           "all_names": [
-            "Increased reactive oxygen species production",
-            "Oxidative Stress"
+            "Dermal atrophy",
+            "skin atrophy",
+            "Skin Atrophy",
+            "Atrophic condition of skin"
           ],
           "all_categories": [
-            "biolink:PhenotypicFeature"
+            "biolink:Disease"
           ],
           "publications": [
-            "PMID:26950655"
+            "https://orcid.org/0000-0001-5208-3432",
+            "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 569,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Hydrocortisone",
+          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "DRUGBANK:DB00741",
+            "PSY:12030",
+            "DrugCentral:1388",
+            "CHEBI:180955",
+            "ATC:S02BA01",
+            "RXNORM:5492",
+            "HMDB:HMDB0000063",
+            "NDDF:002147",
+            "KEGG.COMPOUND:C00735",
+            "ATC:A01AC03",
+            "ATC:D07AA02",
+            "KEGG.DRUG:D00088",
+            "PUBCHEM.COMPOUND:5754",
+            "ATC:H02AB09",
+            "ATC:C05AA01",
+            "UMLS:C0020268",
+            "NCIT:C2290",
+            "PSY:23640",
+            "CAS:50-23-7",
+            "PathWhiz.Compound:45",
+            "ATC:S01BA02",
+            "UNII:WI4X0X7BPJ",
+            "ATC:A07EA02",
+            "ATC:D07XA01",
+            "CHEBI:17650",
+            "GTOPDB:2868",
+            "MESH:D006854",
+            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+            "ATC:S01CB03",
+            "CHEMBL.COMPOUND:CHEMBL389621"
+          ],
+          "id": "PUBCHEM.COMPOUND:5754",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Hydrocortisone",
+            "cortisol",
+            "Hydrocortisone (JP18/USP/INN)",
+            "hydrocortisone",
+            "Cortisol",
+            "17-hydroxycorticosterone",
+            "HYDROCORTISONE",
+            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:2970549",
+            "PMID:29729985",
+            "PMID:18666772",
+            "PMID:2031862",
+            "PMID:24128814",
+            "PMID:19256501",
+            "PMID:27692996",
+            "PMID:30419492",
+            "PMID:18289853"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 318076,
+            "identity": 316339,
             "labels": [
               "biolink:NamedThing",
               "biolink:ThingWithTaxon",
@@ -8061,78 +13248,141 @@
               "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/HP_0025464",
-              "name": "Increased reactive oxygen species production",
-              "description": "A disturbance in the prooxidant-antioxidant balance in favor of the former, leading to potential damage. Indicators of oxidative stress include damaged DNA bases, protein oxidation products, and lipid peroxidation products. The damage to biological tissues is caused by superoxide and other free radicals generated by many factors, including exposure to alcohol, medications, trauma, cold, toxins, and radiation or by antimicrobial cellular immunity, metabolic abnormality, or \"normal\" aging; not synonymous with hypoxia or hyperoxia. Oxidative stress promotes a range of degenerative disorders, including cancer, diabetes, premature aging, Alzheimer's, and many others.; A disturbance in the prooxidant-antioxidant balance in favor of the former, leading to potential damage. Indicators of oxidative stress include damaged DNA bases, protein oxidation products, and lipid peroxidation products (Sies, Oxidative Stress, 1991, pxv-xvi).; An accumulation of free radical groups in the body inadequately neutralized by antioxidants, which creates a potentially unstable and damaging cellular environment linked to tissue damage. [PMID:26950655]; UMLS Semantic Type: STY:T049",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0006610",
+              "name": "skin atrophy",
+              "description": "Partial or complete wasting (atrophy) of the skin. [HPO:probinson]; Partial or complete wasting (atrophy) of the skin.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "UMLS:C4476796",
-                "HP:0025464",
-                "MESH:D018384",
-                "MEDDRA:10080562",
-                "UMLS:C0242606"
-              ],
-              "id": "HP:0025464",
-              "category": "biolink:PhenotypicFeature",
+                "MEDDRA:10003719",
+                "HP:0004334",
+                "MONDO:0006610",
+                "UMLS:C0151514",
+                "SNOMEDCT:400190005",
+                "EFO:1000766",
+                "DOID:2733",
+                "NCIT:C35163",
+                "ICD10:L90",
+                "SNOMEDCT:399979006",
+                "MEDDRA:10040799"
+              ],
+              "id": "MONDO:0006610",
+              "category": "biolink:Disease",
               "all_names": [
-                "Increased reactive oxygen species production",
-                "Oxidative Stress"
+                "Dermal atrophy",
+                "skin atrophy",
+                "Skin Atrophy",
+                "Atrophic condition of skin"
               ],
               "all_categories": [
-                "biolink:PhenotypicFeature"
+                "biolink:Disease"
               ],
               "publications": [
-                "PMID:26950655"
+                "https://orcid.org/0000-0001-5208-3432",
+                "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 11038330,
-            "start": 547,
-            "end": 318076,
+            "identity": 15242709,
+            "start": 569,
+            "end": 316339,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:15231063': {'publication date': '2004', 'sentence': 'A comparative study of albendazole and mebendazole-induced, time-dependent oxidative stress.', 'subject score': 827, 'object score': 827}}",
+              "publications_info": "{'PMID:21461248': {'publication date': '2011 Apr', 'sentence': 'Long-term application of topical HC induced skin atrophy, measured by a reduction in skinfold and epidermal thickness and in the number of epidermal proliferating cell nucleus antigen (PCNA)-positive keratinocytes.', 'subject score': 861, 'object score': 1000}, 'PMID:9553910': {'publication date': '1998 Mar', 'sentence': 'Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone.', 'subject score': 1000, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0242606---SEMMEDDB:"
+                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0151514---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "11280026",
-              "object": "HP:0025464",
+              "subject": "PUBCHEM.COMPOUND:5754",
+              "id": "15562961",
+              "object": "MONDO:0006610",
               "publications": [
-                "PMID:15231063"
+                "PMID:21461248",
+                "PMID:9553910"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 569,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Hydrocortisone",
+              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "DRUGBANK:DB00741",
+                "PSY:12030",
+                "DrugCentral:1388",
+                "CHEBI:180955",
+                "ATC:S02BA01",
+                "RXNORM:5492",
+                "HMDB:HMDB0000063",
+                "NDDF:002147",
+                "KEGG.COMPOUND:C00735",
+                "ATC:A01AC03",
+                "ATC:D07AA02",
+                "KEGG.DRUG:D00088",
+                "PUBCHEM.COMPOUND:5754",
+                "ATC:H02AB09",
+                "ATC:C05AA01",
+                "UMLS:C0020268",
+                "NCIT:C2290",
+                "PSY:23640",
+                "CAS:50-23-7",
+                "PathWhiz.Compound:45",
+                "ATC:S01BA02",
+                "UNII:WI4X0X7BPJ",
+                "ATC:A07EA02",
+                "ATC:D07XA01",
+                "CHEBI:17650",
+                "GTOPDB:2868",
+                "MESH:D006854",
+                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+                "ATC:S01CB03",
+                "CHEMBL.COMPOUND:CHEMBL389621"
+              ],
+              "id": "PUBCHEM.COMPOUND:5754",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Hydrocortisone",
+                "cortisol",
+                "Hydrocortisone (JP18/USP/INN)",
+                "hydrocortisone",
+                "Cortisol",
+                "17-hydroxycorticosterone",
+                "HYDROCORTISONE",
+                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:2970549",
+                "PMID:29729985",
+                "PMID:18666772",
+                "PMID:2031862",
+                "PMID:24128814",
+                "PMID:19256501",
+                "PMID:27692996",
+                "PMID:30419492",
+                "PMID:18289853"
               ]
             }
           }
@@ -8144,7 +13394,7 @@
   {
     "p3": {
       "start": {
-        "identity": 546716,
+        "identity": 320617,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -8154,158 +13404,267 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "http://purl.obolibrary.org/obo/MONDO_0029000",
-          "name": "poisoning",
-          "description": "Injury to the body or interference of normal body functions by a substance that is swallowed, inhaled, injected, or absorbed.; A condition or physical state produced by the ingestion, injection, inhalation of or exposure to a deleterious agent.; A poison is any substance that is harmful to your body. You might swallow it, inhale it, inject it, or absorb it through your skin. Any substance can be poisonous if too much is taken. Poisons can include: Prescription or over-the-counter medicines taken in doses that are too high Overdoses of illegal drugs Carbon monoxide from gas appliances Household products, such as laundry powder or furniture polish  Pesticides  Indoor or outdoor plants  Metals such as lead and mercury   The effects of poisoning range from short-term illness to brain damage, coma, and death. To prevent poisoning it is important to use and store products exactly as their labels say. Keep dangerous products where children can't get to them. Treatment for poisoning depends on the type of poison. If you suspect someone has been poisoned, call your local poison control center at 1-800-222-1222 right away.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0002400",
+          "name": "synovitis",
+          "description": "Inflammation of a synovial membrane.; Inflammation of the SYNOVIAL MEMBRANE.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "NCIT:C34933",
-            "UMLS:C0302332",
-            "EFO:0008546",
-            "UMLS:C0600688",
-            "MONDO:0029000",
-            "UMLS:C0032343",
-            "MESH:D011041",
-            "NCIT:C27990",
-            "MEDDRA:10051732",
-            "MEDDRA:10061355",
-            "SNOMEDCT:75478009"
-          ],
-          "id": "MONDO:0029000",
+            "UMLS:C0039103",
+            "MESH:D013585",
+            "HP:0100769",
+            "SYMP:0000646",
+            "MEDDRA:10042868",
+            "MONDO:0002400",
+            "DOID:2703",
+            "EFO:0008997",
+            "NCIT:C50766",
+            "SNOMEDCT:416209007"
+          ],
+          "id": "MONDO:0002400",
           "category": "biolink:Disease",
           "all_names": [
-            "Poisoning",
-            "Toxic effect",
-            "Poisoning syndrome",
-            "poisoning",
-            "Toxicity"
+            "Synovitis",
+            "synovitis"
           ],
           "all_categories": [
-            "biolink:Disease"
+            "biolink:Disease",
+            "biolink:PhenotypicFeature"
+          ],
+          "publications": [
+            "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=synovitis",
+            "https://orcid.org/0000-0002-6601-2165",
+            "https://en.wikipedia.org/wiki/synovitis"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 569,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Hydrocortisone",
+          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "DRUGBANK:DB00741",
+            "PSY:12030",
+            "DrugCentral:1388",
+            "CHEBI:180955",
+            "ATC:S02BA01",
+            "RXNORM:5492",
+            "HMDB:HMDB0000063",
+            "NDDF:002147",
+            "KEGG.COMPOUND:C00735",
+            "ATC:A01AC03",
+            "ATC:D07AA02",
+            "KEGG.DRUG:D00088",
+            "PUBCHEM.COMPOUND:5754",
+            "ATC:H02AB09",
+            "ATC:C05AA01",
+            "UMLS:C0020268",
+            "NCIT:C2290",
+            "PSY:23640",
+            "CAS:50-23-7",
+            "PathWhiz.Compound:45",
+            "ATC:S01BA02",
+            "UNII:WI4X0X7BPJ",
+            "ATC:A07EA02",
+            "ATC:D07XA01",
+            "CHEBI:17650",
+            "GTOPDB:2868",
+            "MESH:D006854",
+            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+            "ATC:S01CB03",
+            "CHEMBL.COMPOUND:CHEMBL389621"
+          ],
+          "id": "PUBCHEM.COMPOUND:5754",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Hydrocortisone",
+            "cortisol",
+            "Hydrocortisone (JP18/USP/INN)",
+            "hydrocortisone",
+            "Cortisol",
+            "17-hydroxycorticosterone",
+            "HYDROCORTISONE",
+            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:2970549",
+            "PMID:29729985",
+            "PMID:18666772",
+            "PMID:2031862",
+            "PMID:24128814",
+            "PMID:19256501",
+            "PMID:27692996",
+            "PMID:30419492",
+            "PMID:18289853"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 546716,
+            "identity": 320617,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "http://purl.obolibrary.org/obo/MONDO_0029000",
-              "name": "poisoning",
-              "description": "Injury to the body or interference of normal body functions by a substance that is swallowed, inhaled, injected, or absorbed.; A condition or physical state produced by the ingestion, injection, inhalation of or exposure to a deleterious agent.; A poison is any substance that is harmful to your body. You might swallow it, inhale it, inject it, or absorb it through your skin. Any substance can be poisonous if too much is taken. Poisons can include: Prescription or over-the-counter medicines taken in doses that are too high Overdoses of illegal drugs Carbon monoxide from gas appliances Household products, such as laundry powder or furniture polish  Pesticides  Indoor or outdoor plants  Metals such as lead and mercury   The effects of poisoning range from short-term illness to brain damage, coma, and death. To prevent poisoning it is important to use and store products exactly as their labels say. Keep dangerous products where children can't get to them. Treatment for poisoning depends on the type of poison. If you suspect someone has been poisoned, call your local poison control center at 1-800-222-1222 right away.; UMLS Semantic Type: STY:T037; UMLS Semantic Type: STY:T037",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0002400",
+              "name": "synovitis",
+              "description": "Inflammation of a synovial membrane.; Inflammation of the SYNOVIAL MEMBRANE.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "NCIT:C34933",
-                "UMLS:C0302332",
-                "EFO:0008546",
-                "UMLS:C0600688",
-                "MONDO:0029000",
-                "UMLS:C0032343",
-                "MESH:D011041",
-                "NCIT:C27990",
-                "MEDDRA:10051732",
-                "MEDDRA:10061355",
-                "SNOMEDCT:75478009"
-              ],
-              "id": "MONDO:0029000",
+                "UMLS:C0039103",
+                "MESH:D013585",
+                "HP:0100769",
+                "SYMP:0000646",
+                "MEDDRA:10042868",
+                "MONDO:0002400",
+                "DOID:2703",
+                "EFO:0008997",
+                "NCIT:C50766",
+                "SNOMEDCT:416209007"
+              ],
+              "id": "MONDO:0002400",
               "category": "biolink:Disease",
               "all_names": [
-                "Poisoning",
-                "Toxic effect",
-                "Poisoning syndrome",
-                "poisoning",
-                "Toxicity"
+                "Synovitis",
+                "synovitis"
               ],
               "all_categories": [
-                "biolink:Disease"
+                "biolink:Disease",
+                "biolink:PhenotypicFeature"
+              ],
+              "publications": [
+                "http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=medical&va=synovitis",
+                "https://orcid.org/0000-0002-6601-2165",
+                "https://en.wikipedia.org/wiki/synovitis"
               ]
             }
           },
           "relationship": {
-            "identity": 10809519,
-            "start": 547,
-            "end": 546716,
+            "identity": 14814276,
+            "start": 569,
+            "end": 320617,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1497489': {'publication date': '1992', 'sentence': 'Longer incubation of the cells with MBZ resulted in stronger toxicity, and the cytotoxicity was dependent on the MBZ concentration above a certain threshold value (0.25-0.50 mg/l in a 42-h culture).', 'subject score': 1000, 'object score': 872}, 'PMID:27014071': {'publication date': '2016', 'sentence': 'These results suggest that MBZ treats developmental toxicity in the zebrafish retina at least partly by activating the DNA damage response, including ATM signaling, providing a potential adverse outcome pathway in the developmental toxicity of MBZ in mammals.', 'subject score': 1000, 'object score': 888}}",
+              "publications_info": "{'PMID:20673094': {'publication date': '2010 Aug', 'sentence': 'RESULTS: Following induction of synovitis, ground reaction forces were significantly decreased relative to preinduction values at 2.5, 5.0, 7.5, and 10.0 hours and serum cortisol concentration was significantly increased at 2.5 hours.', 'subject score': 901, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0600688---SEMMEDDB:"
+                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0039103---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "11046187",
-              "object": "MONDO:0029000",
+              "subject": "PUBCHEM.COMPOUND:5754",
+              "id": "15127550",
+              "object": "MONDO:0002400",
               "publications": [
-                "PMID:1497489",
-                "PMID:27014071"
+                "PMID:20673094"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 569,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Hydrocortisone",
+              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "DRUGBANK:DB00741",
+                "PSY:12030",
+                "DrugCentral:1388",
+                "CHEBI:180955",
+                "ATC:S02BA01",
+                "RXNORM:5492",
+                "HMDB:HMDB0000063",
+                "NDDF:002147",
+                "KEGG.COMPOUND:C00735",
+                "ATC:A01AC03",
+                "ATC:D07AA02",
+                "KEGG.DRUG:D00088",
+                "PUBCHEM.COMPOUND:5754",
+                "ATC:H02AB09",
+                "ATC:C05AA01",
+                "UMLS:C0020268",
+                "NCIT:C2290",
+                "PSY:23640",
+                "CAS:50-23-7",
+                "PathWhiz.Compound:45",
+                "ATC:S01BA02",
+                "UNII:WI4X0X7BPJ",
+                "ATC:A07EA02",
+                "ATC:D07XA01",
+                "CHEBI:17650",
+                "GTOPDB:2868",
+                "MESH:D006854",
+                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+                "ATC:S01CB03",
+                "CHEMBL.COMPOUND:CHEMBL389621"
+              ],
+              "id": "PUBCHEM.COMPOUND:5754",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Hydrocortisone",
+                "cortisol",
+                "Hydrocortisone (JP18/USP/INN)",
+                "hydrocortisone",
+                "Cortisol",
+                "17-hydroxycorticosterone",
+                "HYDROCORTISONE",
+                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:2970549",
+                "PMID:29729985",
+                "PMID:18666772",
+                "PMID:2031862",
+                "PMID:24128814",
+                "PMID:19256501",
+                "PMID:27692996",
+                "PMID:30419492",
+                "PMID:18289853"
               ]
             }
           }
@@ -8317,144 +13676,337 @@
   {
     "p3": {
       "start": {
-        "identity": 2329210,
+        "identity": 319338,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
           "biolink:BiologicalEntity",
           "biolink:Disease",
           "biolink:DiseaseOrPhenotypicFeature",
-          "biolink:PhenotypicFeature"
+          "biolink:PhenotypicFeature",
+          "biolink:BehavioralFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0596402",
-          "name": "cytotoxicity",
-          "description": "The adverse effect of some iatrogenic therapies. It is an accepted side effect in radiation therapy where the desired effect is to kill rapidly growing tumor cells. In the killing of tumor cells, other cells that are rapidly growing e.g hair, mucous membranes are also killed.; UMLS Semantic Type: STY:T049",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005027",
+          "name": "epilepsy",
+          "description": "A brain disorder characterized by episodes of abnormally increased neuronal discharge resulting in transient episodes of sensory or motor neurological dysfunction, or psychic dysfunction. These episodes may or may not be associated with loss of consciousness or convulsions.; A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313); A seizure is an intermittent abnormality of nervous system physiology characterised by a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. [HPO:probinson, PMID:15816939]; Epilepsy is a brain disorder that treats people to have recurring seizures. The seizures happen when clusters of nerve cells, or neurons, in the brain send out the wrong signals. People may have strange sensations and emotions or behave strangely. They may have violent muscle spasms or lose consciousness. Epilepsy has many possible treats, including illness, brain injury, and abnormal brain development. In many cases, the cause is unknown. Doctors use brain scans and other tests to diagnose epilepsy. It is important to start treatment right away. There is no cure for epilepsy, but medicines can control seizures for most people. When medicines are not working well, surgery or implanted devices such as vagus nerve stimulators may help. Special diets can help some children with epilepsy. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "NCIT:C27988",
-            "UMLS:C0596402"
-          ],
-          "id": "UMLS:C0596402",
+            "NBO:0000642",
+            "MEDDRA:10039910",
+            "MEDDRA:10039906",
+            "MEDDRA:10010904",
+            "MEDDRA:10015046",
+            "PSY:17690",
+            "UMLS:C0014544",
+            "ICD9:345.9",
+            "PDQ:CDR0000525976",
+            "SNOMEDCT:84757009",
+            "PSY:17680",
+            "MESH:D004827",
+            "ICD10:G40.909",
+            "SNOMEDCT:91175000",
+            "HP:0001250",
+            "MONDO:0005027",
+            "MEDDRA:10010922",
+            "UMLS:C0036572",
+            "MEDDRA:10010914",
+            "MEDDRA:10015037",
+            "MEDDRA:10015042",
+            "SNOMEDCT:313307000",
+            "SYMP:0000124",
+            "DOID:1826",
+            "MEDDRA:10015051",
+            "EFO:0000474",
+            "NCIT:C3020",
+            "UMLS:C4317109",
+            "SNOMEDCT:128613002",
+            "MEDDRA:10015052",
+            "NCIT:C2962"
+          ],
+          "id": "MONDO:0005027",
           "category": "biolink:Disease",
           "all_names": [
-            "Cytotoxicity",
-            "cytotoxicity"
+            "Epilepsy",
+            "epilepsy",
+            "Seizure",
+            "Epilepsy, unspecified",
+            "seizure",
+            "Epileptic Seizures",
+            "Seizures",
+            "Seizure Disorder"
           ],
           "all_categories": [
-            "biolink:Disease"
+            "biolink:Disease",
+            "biolink:PhenotypicFeature",
+            "biolink:BehavioralFeature"
+          ],
+          "publications": [
+            "http://www.merriam-webster.com/medlineplus/epilepsy",
+            "https://orcid.org/0000-0002-0736-9199",
+            "PMID:15816939",
+            "http://books.google.com/books?id=yxqx04te9ioc&printsec=frontcover&source=gbs_ge_summary_r&cad=0#v=onepage&q&f=false"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 569,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Hydrocortisone",
+          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "DRUGBANK:DB00741",
+            "PSY:12030",
+            "DrugCentral:1388",
+            "CHEBI:180955",
+            "ATC:S02BA01",
+            "RXNORM:5492",
+            "HMDB:HMDB0000063",
+            "NDDF:002147",
+            "KEGG.COMPOUND:C00735",
+            "ATC:A01AC03",
+            "ATC:D07AA02",
+            "KEGG.DRUG:D00088",
+            "PUBCHEM.COMPOUND:5754",
+            "ATC:H02AB09",
+            "ATC:C05AA01",
+            "UMLS:C0020268",
+            "NCIT:C2290",
+            "PSY:23640",
+            "CAS:50-23-7",
+            "PathWhiz.Compound:45",
+            "ATC:S01BA02",
+            "UNII:WI4X0X7BPJ",
+            "ATC:A07EA02",
+            "ATC:D07XA01",
+            "CHEBI:17650",
+            "GTOPDB:2868",
+            "MESH:D006854",
+            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+            "ATC:S01CB03",
+            "CHEMBL.COMPOUND:CHEMBL389621"
+          ],
+          "id": "PUBCHEM.COMPOUND:5754",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Hydrocortisone",
+            "cortisol",
+            "Hydrocortisone (JP18/USP/INN)",
+            "hydrocortisone",
+            "Cortisol",
+            "17-hydroxycorticosterone",
+            "HYDROCORTISONE",
+            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:2970549",
+            "PMID:29729985",
+            "PMID:18666772",
+            "PMID:2031862",
+            "PMID:24128814",
+            "PMID:19256501",
+            "PMID:27692996",
+            "PMID:30419492",
+            "PMID:18289853"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 2329210,
+            "identity": 319338,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
               "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:BehavioralFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0596402",
-              "name": "cytotoxicity",
-              "description": "The adverse effect of some iatrogenic therapies. It is an accepted side effect in radiation therapy where the desired effect is to kill rapidly growing tumor cells. In the killing of tumor cells, other cells that are rapidly growing e.g hair, mucous membranes are also killed.; UMLS Semantic Type: STY:T049",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005027",
+              "name": "epilepsy",
+              "description": "A brain disorder characterized by episodes of abnormally increased neuronal discharge resulting in transient episodes of sensory or motor neurological dysfunction, or psychic dysfunction. These episodes may or may not be associated with loss of consciousness or convulsions.; A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313); A seizure is an intermittent abnormality of nervous system physiology characterised by a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. [HPO:probinson, PMID:15816939]; Epilepsy is a brain disorder that treats people to have recurring seizures. The seizures happen when clusters of nerve cells, or neurons, in the brain send out the wrong signals. People may have strange sensations and emotions or behave strangely. They may have violent muscle spasms or lose consciousness. Epilepsy has many possible treats, including illness, brain injury, and abnormal brain development. In many cases, the cause is unknown. Doctors use brain scans and other tests to diagnose epilepsy. It is important to start treatment right away. There is no cure for epilepsy, but medicines can control seizures for most people. When medicines are not working well, surgery or implanted devices such as vagus nerve stimulators may help. Special diets can help some children with epilepsy. NIH: National Institute of Neurological Disorders and Stroke; UMLS Semantic Type: STY:T047; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "NCIT:C27988",
-                "UMLS:C0596402"
-              ],
-              "id": "UMLS:C0596402",
+                "NBO:0000642",
+                "MEDDRA:10039910",
+                "MEDDRA:10039906",
+                "MEDDRA:10010904",
+                "MEDDRA:10015046",
+                "PSY:17690",
+                "UMLS:C0014544",
+                "ICD9:345.9",
+                "PDQ:CDR0000525976",
+                "SNOMEDCT:84757009",
+                "PSY:17680",
+                "MESH:D004827",
+                "ICD10:G40.909",
+                "SNOMEDCT:91175000",
+                "HP:0001250",
+                "MONDO:0005027",
+                "MEDDRA:10010922",
+                "UMLS:C0036572",
+                "MEDDRA:10010914",
+                "MEDDRA:10015037",
+                "MEDDRA:10015042",
+                "SNOMEDCT:313307000",
+                "SYMP:0000124",
+                "DOID:1826",
+                "MEDDRA:10015051",
+                "EFO:0000474",
+                "NCIT:C3020",
+                "UMLS:C4317109",
+                "SNOMEDCT:128613002",
+                "MEDDRA:10015052",
+                "NCIT:C2962"
+              ],
+              "id": "MONDO:0005027",
               "category": "biolink:Disease",
               "all_names": [
-                "Cytotoxicity",
-                "cytotoxicity"
+                "Epilepsy",
+                "epilepsy",
+                "Seizure",
+                "Epilepsy, unspecified",
+                "seizure",
+                "Epileptic Seizures",
+                "Seizures",
+                "Seizure Disorder"
               ],
               "all_categories": [
-                "biolink:Disease"
+                "biolink:Disease",
+                "biolink:PhenotypicFeature",
+                "biolink:BehavioralFeature"
+              ],
+              "publications": [
+                "http://www.merriam-webster.com/medlineplus/epilepsy",
+                "https://orcid.org/0000-0002-0736-9199",
+                "PMID:15816939",
+                "http://books.google.com/books?id=yxqx04te9ioc&printsec=frontcover&source=gbs_ge_summary_r&cad=0#v=onepage&q&f=false"
               ]
             }
           },
           "relationship": {
-            "identity": 10809518,
-            "start": 547,
-            "end": 2329210,
+            "identity": 10707118,
+            "start": 569,
+            "end": 319338,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:1497489': {'publication date': '1992', 'sentence': 'Longer incubation of the cells with MBZ resulted in stronger toxicity, and the cytotoxicity was dependent on the MBZ concentration above a certain threshold value (0.25-0.50 mg/l in a 42-h culture).', 'subject score': 1000, 'object score': 1000}, 'PMID:31881126': {'publication date': '2019 Dec', 'sentence': 'Discussion: Mebendazole evoked anti-neoplastic cytotoxicity as both a single entity, and contributed to the potency of the covalent immunoglucocorticoid, dexamethasone-(C     21      -phosphoramidate)-[anti-EGFR] when applied in a dual-combination challenge against populations of pulmonary adenocarcinoma (A549).', 'subject score': 1000, 'object score': 790}}",
+              "publications_info": "{'PMID:14705848': {'publication date': '2003', 'sentence': 'Hydrocortisone-induced convulsions.', 'subject score': 851, 'object score': 851}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0596402---SEMMEDDB:"
+                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0036572---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "11046186",
-              "object": "UMLS:C0596402",
+              "subject": "PUBCHEM.COMPOUND:5754",
+              "id": "10942128",
+              "object": "MONDO:0005027",
               "publications": [
-                "PMID:1497489",
-                "PMID:31881126"
+                "PMID:14705848"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 569,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Hydrocortisone",
+              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "DRUGBANK:DB00741",
+                "PSY:12030",
+                "DrugCentral:1388",
+                "CHEBI:180955",
+                "ATC:S02BA01",
+                "RXNORM:5492",
+                "HMDB:HMDB0000063",
+                "NDDF:002147",
+                "KEGG.COMPOUND:C00735",
+                "ATC:A01AC03",
+                "ATC:D07AA02",
+                "KEGG.DRUG:D00088",
+                "PUBCHEM.COMPOUND:5754",
+                "ATC:H02AB09",
+                "ATC:C05AA01",
+                "UMLS:C0020268",
+                "NCIT:C2290",
+                "PSY:23640",
+                "CAS:50-23-7",
+                "PathWhiz.Compound:45",
+                "ATC:S01BA02",
+                "UNII:WI4X0X7BPJ",
+                "ATC:A07EA02",
+                "ATC:D07XA01",
+                "CHEBI:17650",
+                "GTOPDB:2868",
+                "MESH:D006854",
+                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+                "ATC:S01CB03",
+                "CHEMBL.COMPOUND:CHEMBL389621"
+              ],
+              "id": "PUBCHEM.COMPOUND:5754",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Hydrocortisone",
+                "cortisol",
+                "Hydrocortisone (JP18/USP/INN)",
+                "hydrocortisone",
+                "Cortisol",
+                "17-hydroxycorticosterone",
+                "HYDROCORTISONE",
+                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:2970549",
+                "PMID:29729985",
+                "PMID:18666772",
+                "PMID:2031862",
+                "PMID:24128814",
+                "PMID:19256501",
+                "PMID:27692996",
+                "PMID:30419492",
+                "PMID:18289853"
               ]
             }
           }
@@ -8466,7 +14018,7 @@
   {
     "p3": {
       "start": {
-        "identity": 542635,
+        "identity": 2330393,
         "labels": [
           "biolink:NamedThing",
           "biolink:ThingWithTaxon",
@@ -8476,27 +14028,28 @@
           "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0153676",
-          "name": "Secondary malignant neoplasm of lung",
-          "description": "The spread of a malignant neoplasm to the lung. This may be from a primary lung malignant neoplasm, or from a malignant neoplasm at a distant site.; UMLS Semantic Type: STY:T191",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0019801",
+          "name": "acute adrenal insufficiency",
+          "description": "Acute adrenal insufficiency (AAI) is a rare but severe condition caused by a sudden defective production of adrenal steroids (cortisol and aldosterone). It represents an emergency, thus the rapid recognition and prompt therapy are critical for survival even before the diagnosis is made.",
           "equivalent_curies": [
-            "MEDDRA:10025119",
-            "UMLS:C0153676",
-            "NCIT:C3577",
-            "MEDDRA:10037420",
-            "ICD9:197.0",
-            "SNOMEDCT:94391008",
-            "MEDDRA:10027458",
-            "MEDDRA:10025111",
-            "MEDDRA:10039854",
-            "MEDDRA:10027473",
-            "MEDDRA:10050017"
-          ],
-          "id": "UMLS:C0153676",
+            "MONDO:0019801",
+            "SNOMEDCT:24867002",
+            "ORPHANET:95409",
+            "MEDDRA:10001133",
+            "UMLS:C0151467",
+            "MEDDRA:10001346",
+            "MEDDRA:10011394",
+            "MEDDRA:10001389",
+            "NCIT:C112840",
+            "SNOMEDCT:766986002"
+          ],
+          "id": "MONDO:0019801",
           "category": "biolink:Disease",
           "all_names": [
-            "Secondary malignant neoplasm of lung",
-            "Metastatic Malignant Neoplasm in the Lung"
+            "Acute adrenal insufficiency",
+            "acute adrenal insufficiency",
+            "Adrenal Crisis",
+            "Addisonian crisis"
           ],
           "all_categories": [
             "biolink:Disease"
@@ -8504,69 +14057,123 @@
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 569,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Hydrocortisone",
+          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "DRUGBANK:DB00741",
+            "PSY:12030",
+            "DrugCentral:1388",
+            "CHEBI:180955",
+            "ATC:S02BA01",
+            "RXNORM:5492",
+            "HMDB:HMDB0000063",
+            "NDDF:002147",
+            "KEGG.COMPOUND:C00735",
+            "ATC:A01AC03",
+            "ATC:D07AA02",
+            "KEGG.DRUG:D00088",
+            "PUBCHEM.COMPOUND:5754",
+            "ATC:H02AB09",
+            "ATC:C05AA01",
+            "UMLS:C0020268",
+            "NCIT:C2290",
+            "PSY:23640",
+            "CAS:50-23-7",
+            "PathWhiz.Compound:45",
+            "ATC:S01BA02",
+            "UNII:WI4X0X7BPJ",
+            "ATC:A07EA02",
+            "ATC:D07XA01",
+            "CHEBI:17650",
+            "GTOPDB:2868",
+            "MESH:D006854",
+            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+            "ATC:S01CB03",
+            "CHEMBL.COMPOUND:CHEMBL389621"
+          ],
+          "id": "PUBCHEM.COMPOUND:5754",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Hydrocortisone",
+            "cortisol",
+            "Hydrocortisone (JP18/USP/INN)",
+            "hydrocortisone",
+            "Cortisol",
+            "17-hydroxycorticosterone",
+            "HYDROCORTISONE",
+            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:2970549",
+            "PMID:29729985",
+            "PMID:18666772",
+            "PMID:2031862",
+            "PMID:24128814",
+            "PMID:19256501",
+            "PMID:27692996",
+            "PMID:30419492",
+            "PMID:18289853"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 542635,
+            "identity": 2330393,
             "labels": [
+              "biolink:NamedThing",
+              "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
               "biolink:Disease",
               "biolink:DiseaseOrPhenotypicFeature",
-              "biolink:NamedThing",
-              "biolink:PhenotypicFeature",
-              "biolink:ThingWithTaxon"
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0153676",
-              "name": "Secondary malignant neoplasm of lung",
-              "description": "The spread of a malignant neoplasm to the lung. This may be from a primary lung malignant neoplasm, or from a malignant neoplasm at a distant site.; UMLS Semantic Type: STY:T191",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0019801",
+              "name": "acute adrenal insufficiency",
+              "description": "Acute adrenal insufficiency (AAI) is a rare but severe condition caused by a sudden defective production of adrenal steroids (cortisol and aldosterone). It represents an emergency, thus the rapid recognition and prompt therapy are critical for survival even before the diagnosis is made.",
               "equivalent_curies": [
-                "MEDDRA:10025119",
-                "UMLS:C0153676",
-                "NCIT:C3577",
-                "MEDDRA:10037420",
-                "ICD9:197.0",
-                "SNOMEDCT:94391008",
-                "MEDDRA:10027458",
-                "MEDDRA:10025111",
-                "MEDDRA:10039854",
-                "MEDDRA:10027473",
-                "MEDDRA:10050017"
-              ],
-              "id": "UMLS:C0153676",
+                "MONDO:0019801",
+                "SNOMEDCT:24867002",
+                "ORPHANET:95409",
+                "MEDDRA:10001133",
+                "UMLS:C0151467",
+                "MEDDRA:10001346",
+                "MEDDRA:10011394",
+                "MEDDRA:10001389",
+                "NCIT:C112840",
+                "SNOMEDCT:766986002"
+              ],
+              "id": "MONDO:0019801",
               "category": "biolink:Disease",
               "all_names": [
-                "Secondary malignant neoplasm of lung",
-                "Metastatic Malignant Neoplasm in the Lung"
+                "Acute adrenal insufficiency",
+                "acute adrenal insufficiency",
+                "Adrenal Crisis",
+                "Addisonian crisis"
               ],
               "all_categories": [
                 "biolink:Disease"
@@ -8574,53 +14181,106 @@
             }
           },
           "relationship": {
-            "identity": 9712020,
-            "start": 547,
-            "end": 542635,
+            "identity": 10583386,
+            "start": 569,
+            "end": 2330393,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12479701': {'publication date': '2002 Nov', 'sentence': 'Oral administration of MZ in mice elicited a strong antitumor effect in a s.c. model and reduced lung colonies in experimentally induced lung metastasis without any toxicity when compared with paclitaxel-treated mice.', 'subject score': 1000, 'object score': 824}}",
+              "publications_info": "{'PMID:14567506': {'publication date': '2003 Aug', 'sentence': 'We describe a case of aldosterone-producing adrenocortical adenoma (APA) associated with a probable post-operative adrenal crisis possibly due to subtle autonomous cortisol secretion.', 'subject score': 751, 'object score': 762}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0153676---SEMMEDDB:"
+                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0151467---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "9926628",
-              "object": "UMLS:C0153676",
+              "subject": "PUBCHEM.COMPOUND:5754",
+              "id": "10815606",
+              "object": "MONDO:0019801",
               "publications": [
-                "PMID:12479701"
+                "PMID:14567506"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 569,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Hydrocortisone",
+              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "DRUGBANK:DB00741",
+                "PSY:12030",
+                "DrugCentral:1388",
+                "CHEBI:180955",
+                "ATC:S02BA01",
+                "RXNORM:5492",
+                "HMDB:HMDB0000063",
+                "NDDF:002147",
+                "KEGG.COMPOUND:C00735",
+                "ATC:A01AC03",
+                "ATC:D07AA02",
+                "KEGG.DRUG:D00088",
+                "PUBCHEM.COMPOUND:5754",
+                "ATC:H02AB09",
+                "ATC:C05AA01",
+                "UMLS:C0020268",
+                "NCIT:C2290",
+                "PSY:23640",
+                "CAS:50-23-7",
+                "PathWhiz.Compound:45",
+                "ATC:S01BA02",
+                "UNII:WI4X0X7BPJ",
+                "ATC:A07EA02",
+                "ATC:D07XA01",
+                "CHEBI:17650",
+                "GTOPDB:2868",
+                "MESH:D006854",
+                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+                "ATC:S01CB03",
+                "CHEMBL.COMPOUND:CHEMBL389621"
+              ],
+              "id": "PUBCHEM.COMPOUND:5754",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Hydrocortisone",
+                "cortisol",
+                "Hydrocortisone (JP18/USP/INN)",
+                "hydrocortisone",
+                "Cortisol",
+                "17-hydroxycorticosterone",
+                "HYDROCORTISONE",
+                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:2970549",
+                "PMID:29729985",
+                "PMID:18666772",
+                "PMID:2031862",
+                "PMID:24128814",
+                "PMID:19256501",
+                "PMID:27692996",
+                "PMID:30419492",
+                "PMID:18289853"
               ]
             }
           }
@@ -8632,145 +14292,287 @@
   {
     "p3": {
       "start": {
-        "identity": 142771,
+        "identity": 319260,
         "labels": [
-          "biolink:PhysicalEssenceOrOccurrent",
           "biolink:NamedThing",
-          "biolink:OntologyClass",
           "biolink:ThingWithTaxon",
           "biolink:BiologicalEntity",
-          "biolink:BiologicalProcessOrActivity",
-          "biolink:Occurrent",
-          "biolink:PhysiologicalProcess",
-          "biolink:BiologicalProcess"
+          "biolink:Disease",
+          "biolink:DiseaseOrPhenotypicFeature",
+          "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C1155781",
-          "name": "spindle assembly",
-          "description": "The aggregation, arrangement and bonding together of a set of components to form the spindle, the array of microtubules and associated molecules that serves to move duplicated chromosomes apart. [GOC:ai, GOC:expert_rg, GOC:mtg_sensu, GOC:tb]",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0001126",
+          "name": "gastric ulcer",
+          "description": "An ulcer, that is, an erosion of an area of the gastric mucous membrane. [HPO:probinson]; An ulcer, that is, an erosion of an area of the gastric mucous membrane. // COMMENTS: The presence of a mucosal erosion equal to or greater than 0.5 cm.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "UMLS:C1155781"
-          ],
-          "id": "UMLS:C1155781",
-          "category": "biolink:PhysiologicalProcess",
+            "MEDDRA:10045304",
+            "HP:0002592",
+            "ICD10:K25",
+            "UMLS:C0038358",
+            "MESH:D013276",
+            "ICD9:531",
+            "MEDDRA:10045336",
+            "MEDDRA:10045374",
+            "EFO:0009454",
+            "SNOMEDCT:397825006",
+            "MEDDRA:10042116",
+            "MEDDRA:10017822",
+            "MONDO:0001126",
+            "NCIT:C3388",
+            "DOID:10808"
+          ],
+          "id": "MONDO:0001126",
+          "category": "biolink:Disease",
           "all_names": [
-            "spindle assembly"
+            "gastric ulcer",
+            "Stomach Ulcer",
+            "Gastric Ulcer",
+            "Gastric ulcer"
           ],
           "all_categories": [
-            "biolink:PhysiologicalProcess"
+            "biolink:Disease"
+          ],
+          "publications": [
+            "https://orcid.org/0000-0002-6601-2165",
+            "https://orcid.org/0000-0002-0736-9199"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 569,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Hydrocortisone",
+          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "DRUGBANK:DB00741",
+            "PSY:12030",
+            "DrugCentral:1388",
+            "CHEBI:180955",
+            "ATC:S02BA01",
+            "RXNORM:5492",
+            "HMDB:HMDB0000063",
+            "NDDF:002147",
+            "KEGG.COMPOUND:C00735",
+            "ATC:A01AC03",
+            "ATC:D07AA02",
+            "KEGG.DRUG:D00088",
+            "PUBCHEM.COMPOUND:5754",
+            "ATC:H02AB09",
+            "ATC:C05AA01",
+            "UMLS:C0020268",
+            "NCIT:C2290",
+            "PSY:23640",
+            "CAS:50-23-7",
+            "PathWhiz.Compound:45",
+            "ATC:S01BA02",
+            "UNII:WI4X0X7BPJ",
+            "ATC:A07EA02",
+            "ATC:D07XA01",
+            "CHEBI:17650",
+            "GTOPDB:2868",
+            "MESH:D006854",
+            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+            "ATC:S01CB03",
+            "CHEMBL.COMPOUND:CHEMBL389621"
+          ],
+          "id": "PUBCHEM.COMPOUND:5754",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Hydrocortisone",
+            "cortisol",
+            "Hydrocortisone (JP18/USP/INN)",
+            "hydrocortisone",
+            "Cortisol",
+            "17-hydroxycorticosterone",
+            "HYDROCORTISONE",
+            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:2970549",
+            "PMID:29729985",
+            "PMID:18666772",
+            "PMID:2031862",
+            "PMID:24128814",
+            "PMID:19256501",
+            "PMID:27692996",
+            "PMID:30419492",
+            "PMID:18289853"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 142771,
+            "identity": 319260,
             "labels": [
-              "biolink:BiologicalEntity",
-              "biolink:BiologicalProcess",
-              "biolink:BiologicalProcessOrActivity",
               "biolink:NamedThing",
-              "biolink:Occurrent",
-              "biolink:OntologyClass",
-              "biolink:PhysicalEssenceOrOccurrent",
-              "biolink:PhysiologicalProcess",
-              "biolink:ThingWithTaxon"
+              "biolink:ThingWithTaxon",
+              "biolink:BiologicalEntity",
+              "biolink:Disease",
+              "biolink:DiseaseOrPhenotypicFeature",
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C1155781",
-              "name": "spindle assembly",
-              "description": "The aggregation, arrangement and bonding together of a set of components to form the spindle, the array of microtubules and associated molecules that serves to move duplicated chromosomes apart. [GOC:ai, GOC:expert_rg, GOC:mtg_sensu, GOC:tb]",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0001126",
+              "name": "gastric ulcer",
+              "description": "An ulcer, that is, an erosion of an area of the gastric mucous membrane. [HPO:probinson]; An ulcer, that is, an erosion of an area of the gastric mucous membrane. // COMMENTS: The presence of a mucosal erosion equal to or greater than 0.5 cm.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "UMLS:C1155781"
-              ],
-              "id": "UMLS:C1155781",
-              "category": "biolink:PhysiologicalProcess",
+                "MEDDRA:10045304",
+                "HP:0002592",
+                "ICD10:K25",
+                "UMLS:C0038358",
+                "MESH:D013276",
+                "ICD9:531",
+                "MEDDRA:10045336",
+                "MEDDRA:10045374",
+                "EFO:0009454",
+                "SNOMEDCT:397825006",
+                "MEDDRA:10042116",
+                "MEDDRA:10017822",
+                "MONDO:0001126",
+                "NCIT:C3388",
+                "DOID:10808"
+              ],
+              "id": "MONDO:0001126",
+              "category": "biolink:Disease",
               "all_names": [
-                "spindle assembly"
+                "gastric ulcer",
+                "Stomach Ulcer",
+                "Gastric Ulcer",
+                "Gastric ulcer"
               ],
               "all_categories": [
-                "biolink:PhysiologicalProcess"
+                "biolink:Disease"
+              ],
+              "publications": [
+                "https://orcid.org/0000-0002-6601-2165",
+                "https://orcid.org/0000-0002-0736-9199"
               ]
             }
           },
           "relationship": {
-            "identity": 9712018,
-            "start": 547,
-            "end": 142771,
+            "identity": 10522686,
+            "start": 569,
+            "end": 319260,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12479701': {'publication date': '2002 Nov', 'sentence': 'MZ induces abnormal spindle formation in mitotic cancer cells and enhances the depolymerization of tubulin, but the efficacy of depolymerization by MZ is lower than that by nocodazole.', 'subject score': 1000, 'object score': 901}}",
+              "publications_info": "{'PMID:14467587': {'publication date': '1962 Jun', 'sentence': 'Pantothenyl alcohol effect on delta-1-cortisol-induced gastric ulcers.', 'subject score': 762, 'object score': 762}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C1155781---SEMMEDDB:"
+                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0038358---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "9926626",
-              "object": "UMLS:C1155781",
+              "subject": "PUBCHEM.COMPOUND:5754",
+              "id": "10757641",
+              "object": "MONDO:0001126",
               "publications": [
-                "PMID:12479701"
+                "PMID:14467587"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 569,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Hydrocortisone",
+              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "DRUGBANK:DB00741",
+                "PSY:12030",
+                "DrugCentral:1388",
+                "CHEBI:180955",
+                "ATC:S02BA01",
+                "RXNORM:5492",
+                "HMDB:HMDB0000063",
+                "NDDF:002147",
+                "KEGG.COMPOUND:C00735",
+                "ATC:A01AC03",
+                "ATC:D07AA02",
+                "KEGG.DRUG:D00088",
+                "PUBCHEM.COMPOUND:5754",
+                "ATC:H02AB09",
+                "ATC:C05AA01",
+                "UMLS:C0020268",
+                "NCIT:C2290",
+                "PSY:23640",
+                "CAS:50-23-7",
+                "PathWhiz.Compound:45",
+                "ATC:S01BA02",
+                "UNII:WI4X0X7BPJ",
+                "ATC:A07EA02",
+                "ATC:D07XA01",
+                "CHEBI:17650",
+                "GTOPDB:2868",
+                "MESH:D006854",
+                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+                "ATC:S01CB03",
+                "CHEMBL.COMPOUND:CHEMBL389621"
+              ],
+              "id": "PUBCHEM.COMPOUND:5754",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Hydrocortisone",
+                "cortisol",
+                "Hydrocortisone (JP18/USP/INN)",
+                "hydrocortisone",
+                "Cortisol",
+                "17-hydroxycorticosterone",
+                "HYDROCORTISONE",
+                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:2970549",
+                "PMID:29729985",
+                "PMID:18666772",
+                "PMID:2031862",
+                "PMID:24128814",
+                "PMID:19256501",
+                "PMID:27692996",
+                "PMID:30419492",
+                "PMID:18289853"
               ]
             }
           }
@@ -8782,164 +14584,278 @@
   {
     "p3": {
       "start": {
-        "identity": 159611,
+        "identity": 310746,
         "labels": [
-          "biolink:PhysicalEssenceOrOccurrent",
           "biolink:NamedThing",
-          "biolink:OntologyClass",
           "biolink:ThingWithTaxon",
           "biolink:BiologicalEntity",
-          "biolink:BiologicalProcessOrActivity",
-          "biolink:Occurrent",
-          "biolink:PhysiologicalProcess",
-          "biolink:BiologicalProcess"
+          "biolink:Disease",
+          "biolink:DiseaseOrPhenotypicFeature",
+          "biolink:PhenotypicFeature"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0162638",
-          "name": "Apoptosis",
-          "description": "A form of programmed cell death that begins when a cell receives internal or external signals, then proceeds through a series of characteristic stages typically including rounding-up of the cell, retraction of pseudopods, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), and plasma membrane blebbing, and ends with the death of the cell.; A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.; A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. [GOC:cjm, GOC:dhl, GOC:ecd, GOC:go_curators, GOC:mtg_apoptosis, GOC:tb, ISBN:0198506732, PMID:18846107, PMID:21494263]; A process which begins when a cell receives an internal or external signal and activates a series of biochemical events (signaling pathway). The process ends with the death of the cell. [GOC:lr, GOC:mtg_apoptosis]; A stage of the apoptotic process that starts with the controlled breakdown of the cell through the action of effector caspases or other effector molecules (e.g. cathepsins, calpains etc.). Key steps of the execution phase are rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. [GOC:mtg_apoptosis, PMID:21760595]; UMLS Semantic Type: STY:T043",
+          "iri": "http://purl.obolibrary.org/obo/MONDO_0005480",
+          "name": "contact dermatitis",
+          "description": "An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis. []; An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis.; UMLS Semantic Type: STY:T047",
           "equivalent_curies": [
-            "UMLS:C0162638"
-          ],
-          "id": "UMLS:C0162638",
-          "category": "biolink:PhysiologicalProcess",
+            "UMLS:C0011616",
+            "NCIT:C26743",
+            "EFO:0005319",
+            "ICD10:L25.9",
+            "MESH:D003877",
+            "MEDDRA:10010803",
+            "MEDDRA:10012442",
+            "MEDDRA:10058308",
+            "SNOMEDCT:40275004",
+            "DOID:2773",
+            "MONDO:0005480",
+            "MEDDRA:10010790",
+            "HP:0032282",
+            "MEDDRA:10012492"
+          ],
+          "id": "MONDO:0005480",
+          "category": "biolink:Disease",
           "all_names": [
-            "Apoptosis"
+            "Dermatitis, Contact",
+            "Contact dermatitis",
+            "Contact Dermatitis",
+            "contact dermatitis"
           ],
           "all_categories": [
-            "biolink:PhysiologicalProcess"
-          ],
-          "publications": [
-            "ISBN:0198506732",
-            "PMID:18846107",
-            "PMID:21494263",
-            "PMID:21760595"
+            "biolink:Disease"
           ]
         }
       },
       "end": {
-        "identity": 547,
+        "identity": 569,
         "labels": [
           "biolink:SmallMolecule",
           "biolink:ChemicalEntityOrGeneOrGeneProduct",
           "biolink:PhysicalEssenceOrOccurrent",
           "biolink:MolecularEntity",
           "biolink:ChemicalEntity",
+          "biolink:ChemicalMixture",
+          "biolink:Drug",
           "biolink:ChemicalOrDrugOrTreatment",
           "biolink:NamedThing",
           "biolink:PhysicalEssence",
-          "biolink:ChemicalEntityOrProteinOrPolypeptide"
+          "biolink:ChemicalEntityOrProteinOrPolypeptide",
+          "biolink:MolecularMixture",
+          "biolink:OntologyClass"
         ],
         "properties": {
-          "iri": "https://identifiers.org/umls:C0025023",
-          "name": "mebendazole",
-          "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+          "name": "Hydrocortisone",
+          "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
           "equivalent_curies": [
-            "UMLS:C0025023"
-          ],
-          "id": "UMLS:C0025023",
+            "DRUGBANK:DB00741",
+            "PSY:12030",
+            "DrugCentral:1388",
+            "CHEBI:180955",
+            "ATC:S02BA01",
+            "RXNORM:5492",
+            "HMDB:HMDB0000063",
+            "NDDF:002147",
+            "KEGG.COMPOUND:C00735",
+            "ATC:A01AC03",
+            "ATC:D07AA02",
+            "KEGG.DRUG:D00088",
+            "PUBCHEM.COMPOUND:5754",
+            "ATC:H02AB09",
+            "ATC:C05AA01",
+            "UMLS:C0020268",
+            "NCIT:C2290",
+            "PSY:23640",
+            "CAS:50-23-7",
+            "PathWhiz.Compound:45",
+            "ATC:S01BA02",
+            "UNII:WI4X0X7BPJ",
+            "ATC:A07EA02",
+            "ATC:D07XA01",
+            "CHEBI:17650",
+            "GTOPDB:2868",
+            "MESH:D006854",
+            "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+            "ATC:S01CB03",
+            "CHEMBL.COMPOUND:CHEMBL389621"
+          ],
+          "id": "PUBCHEM.COMPOUND:5754",
           "category": "biolink:SmallMolecule",
           "all_names": [
-            "mebendazole"
+            "Hydrocortisone",
+            "cortisol",
+            "Hydrocortisone (JP18/USP/INN)",
+            "hydrocortisone",
+            "Cortisol",
+            "17-hydroxycorticosterone",
+            "HYDROCORTISONE",
+            "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
           ],
           "all_categories": [
-            "biolink:SmallMolecule"
+            "biolink:SmallMolecule",
+            "biolink:ChemicalEntity",
+            "biolink:Drug"
+          ],
+          "publications": [
+            "PMID:11413487",
+            "PMID:2970549",
+            "PMID:29729985",
+            "PMID:18666772",
+            "PMID:2031862",
+            "PMID:24128814",
+            "PMID:19256501",
+            "PMID:27692996",
+            "PMID:30419492",
+            "PMID:18289853"
           ]
         }
       },
       "segments": [
         {
           "start": {
-            "identity": 159611,
+            "identity": 310746,
             "labels": [
-              "biolink:PhysicalEssenceOrOccurrent",
               "biolink:NamedThing",
-              "biolink:OntologyClass",
               "biolink:ThingWithTaxon",
               "biolink:BiologicalEntity",
-              "biolink:BiologicalProcessOrActivity",
-              "biolink:Occurrent",
-              "biolink:PhysiologicalProcess",
-              "biolink:BiologicalProcess"
+              "biolink:Disease",
+              "biolink:DiseaseOrPhenotypicFeature",
+              "biolink:PhenotypicFeature"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0162638",
-              "name": "Apoptosis",
-              "description": "A form of programmed cell death that begins when a cell receives internal or external signals, then proceeds through a series of characteristic stages typically including rounding-up of the cell, retraction of pseudopods, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), and plasma membrane blebbing, and ends with the death of the cell.; A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.; A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. [GOC:cjm, GOC:dhl, GOC:ecd, GOC:go_curators, GOC:mtg_apoptosis, GOC:tb, ISBN:0198506732, PMID:18846107, PMID:21494263]; A process which begins when a cell receives an internal or external signal and activates a series of biochemical events (signaling pathway). The process ends with the death of the cell. [GOC:lr, GOC:mtg_apoptosis]; A stage of the apoptotic process that starts with the controlled breakdown of the cell through the action of effector caspases or other effector molecules (e.g. cathepsins, calpains etc.). Key steps of the execution phase are rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. [GOC:mtg_apoptosis, PMID:21760595]; UMLS Semantic Type: STY:T043",
+              "iri": "http://purl.obolibrary.org/obo/MONDO_0005480",
+              "name": "contact dermatitis",
+              "description": "An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis. []; An inflammatory process in skin caused by an exogenous agent that directly or indirectly injure the skin. If the offending agent is identified and removed, the eruption will resolve. An unusual or patterned eruption may be a clue to the presence of a contact dermatitis. Patch testing may be helpful in the differential diagnosis.; UMLS Semantic Type: STY:T047",
               "equivalent_curies": [
-                "UMLS:C0162638"
-              ],
-              "id": "UMLS:C0162638",
-              "category": "biolink:PhysiologicalProcess",
+                "UMLS:C0011616",
+                "NCIT:C26743",
+                "EFO:0005319",
+                "ICD10:L25.9",
+                "MESH:D003877",
+                "MEDDRA:10010803",
+                "MEDDRA:10012442",
+                "MEDDRA:10058308",
+                "SNOMEDCT:40275004",
+                "DOID:2773",
+                "MONDO:0005480",
+                "MEDDRA:10010790",
+                "HP:0032282",
+                "MEDDRA:10012492"
+              ],
+              "id": "MONDO:0005480",
+              "category": "biolink:Disease",
               "all_names": [
-                "Apoptosis"
+                "Dermatitis, Contact",
+                "Contact dermatitis",
+                "Contact Dermatitis",
+                "contact dermatitis"
               ],
               "all_categories": [
-                "biolink:PhysiologicalProcess"
-              ],
-              "publications": [
-                "ISBN:0198506732",
-                "PMID:18846107",
-                "PMID:21494263",
-                "PMID:21760595"
+                "biolink:Disease"
               ]
             }
           },
           "relationship": {
-            "identity": 9712016,
-            "start": 547,
-            "end": 159611,
+            "identity": 10392906,
+            "start": 569,
+            "end": 310746,
             "type": "biolink:treats",
             "properties": {
               "predicate": "biolink:treats",
               "primary_knowledge_source": "infores:semmeddb",
               "domain_range_exclusion": "False",
-              "publications_info": "{'PMID:12479701': {'publication date': '2002 Nov', 'sentence': 'The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells.', 'subject score': 901, 'object score': 1000}, 'PMID:23059386': {'publication date': '2013 Feb', 'sentence': 'Mebendazole (MBZ) was identified as a promising therapeutic on the basis of its ability to induce apoptosis in melanoma cell lines through a B-cell lymphoma 2 (BCL2)-dependent mechanism.', 'subject score': 1000, 'object score': 1000}, 'PMID:26466412': {'publication date': '2014 Nov', 'sentence': 'Mebendazole (MBZ) is an anthelmintic drug which inhibits tubulin polymerization and eventually treats apoptosis in target organisms.', 'subject score': 1000, 'object score': 1000}, 'PMID:27014071': {'publication date': '2016', 'sentence': 'We were also able to demonstrate that inhibition of ATM significantly attenuated the apoptosis induced by MBZ in the zebrafish retina.', 'subject score': 1000, 'object score': 1000}, 'PMID:31197245': {'publication date': '2019 Dec', 'sentence': 'It was found that mebendazole, a typical anthelmintic drug, preferentially induced apoptosis in c-Maf-expressing myeloma cells.', 'subject score': 1000, 'object score': 790}, 'PMID:33603987': {'publication date': '2020 Oct 01', 'sentence': 'Also, we suggest that indirectly inhibition of Glucose transporting occurs by MBZ, which could induce apoptosis in cancer cells.', 'subject score': 1000, 'object score': 1000}, 'PMID:34148157': {'publication date': '2021 Jun 20', 'sentence': 'Both mebendazole and albendazole induced classical apoptosis characterised by caspase-3 activation, phosphatidylserine exposure, DNA fragmentation, mitochondrial membrane permeability, and reactive oxygen species production.', 'subject score': 1000, 'object score': 861}, 'PMID:34232919': {'publication date': '2021 Jul 07', 'sentence': 'We further showed that MBZ synergized with cisplatin to suppress cell proliferation, induce cell apoptosis, and blunt tumor growth in xenograft tumor model of human cisplatin-resistant ovarian cancer cells.', 'subject score': 1000, 'object score': 888}}",
+              "publications_info": "{'PMID:13806005': {'publication date': '1959 Jan', 'sentence': '[Contact eczema caused by hydrocortisone].', 'subject score': 1000, 'object score': 1000}, 'PMID:14345404': {'publication date': '1965 Sep', 'sentence': 'CONTACT DERMATITIS DUE TO TOPICAL HYDROCORTISONE AND PREDNISOLONE.', 'subject score': 861, 'object score': 1000}}",
               "kg2_ids": [
-                "UMLS:C0025023---SEMMEDDB:treats---None---None---None---UMLS:C0162638---SEMMEDDB:"
+                "UMLS:C0020268---SEMMEDDB:treats---None---None---None---UMLS:C0011616---SEMMEDDB:"
               ],
-              "subject": "UMLS:C0025023",
-              "id": "9926624",
-              "object": "UMLS:C0162638",
+              "subject": "PUBCHEM.COMPOUND:5754",
+              "id": "10621320",
+              "object": "MONDO:0005480",
               "publications": [
-                "PMID:12479701",
-                "PMID:23059386",
-                "PMID:26466412",
-                "PMID:27014071",
-                "PMID:31197245",
-                "PMID:33603987",
-                "PMID:34148157",
-                "PMID:34232919"
+                "PMID:13806005",
+                "PMID:14345404"
               ]
             }
           },
           "end": {
-            "identity": 547,
+            "identity": 569,
             "labels": [
               "biolink:SmallMolecule",
               "biolink:ChemicalEntityOrGeneOrGeneProduct",
               "biolink:PhysicalEssenceOrOccurrent",
               "biolink:MolecularEntity",
               "biolink:ChemicalEntity",
+              "biolink:ChemicalMixture",
+              "biolink:Drug",
               "biolink:ChemicalOrDrugOrTreatment",
               "biolink:NamedThing",
               "biolink:PhysicalEssence",
-              "biolink:ChemicalEntityOrProteinOrPolypeptide"
+              "biolink:ChemicalEntityOrProteinOrPolypeptide",
+              "biolink:MolecularMixture",
+              "biolink:OntologyClass"
             ],
             "properties": {
-              "iri": "https://identifiers.org/umls:C0025023",
-              "name": "mebendazole",
-              "description": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death. Check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47595\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47595\" NCI Thesaurus); A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually treats the helminths death.; A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.; UMLS Semantic Type: STY:T121; UMLS Semantic Type: STY:T109",
+              "name": "Hydrocortisone",
+              "description": "Cortisol is the main glucocorticoid secreted by the adrenal cortex and it is involved in the stress response. Its synthetic counterpart hydrocortisone is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone is synthesized from pregnenolone and is used as an immunosuppressive drug given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients who need steroid treatment but cannot take oral medication, and peri-operatively in patients on long-term steroid treatment to prevent an Addisonian crisis. Cortisol increases blood pressure, blood sugar levels, may cause infertility in women, and suppresses the immune system. The amount of cortisol present in the serum undergoes diurnal variation, with the highest levels present in the early morning and lower levels in the evening, several hours after the onset of sleep. Cortisol is found to be associated with ACTH deficiency and glucocorticoid deficiency, which are inborn errors of metabolism. Cortisol binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA-bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically, glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes and prevents phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products of inflammation, prostaglandins and leukotrienes, are inhibited by the action of glucocorticoids. Glucocorticoids also stimulate the escape of lipocortin-1 into the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst, and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines, etc.) from neutrophils, macrophages, and mastocytes. Additionally, the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.",
               "equivalent_curies": [
-                "UMLS:C0025023"
-              ],
-              "id": "UMLS:C0025023",
+                "DRUGBANK:DB00741",
+                "PSY:12030",
+                "DrugCentral:1388",
+                "CHEBI:180955",
+                "ATC:S02BA01",
+                "RXNORM:5492",
+                "HMDB:HMDB0000063",
+                "NDDF:002147",
+                "KEGG.COMPOUND:C00735",
+                "ATC:A01AC03",
+                "ATC:D07AA02",
+                "KEGG.DRUG:D00088",
+                "PUBCHEM.COMPOUND:5754",
+                "ATC:H02AB09",
+                "ATC:C05AA01",
+                "UMLS:C0020268",
+                "NCIT:C2290",
+                "PSY:23640",
+                "CAS:50-23-7",
+                "PathWhiz.Compound:45",
+                "ATC:S01BA02",
+                "UNII:WI4X0X7BPJ",
+                "ATC:A07EA02",
+                "ATC:D07XA01",
+                "CHEBI:17650",
+                "GTOPDB:2868",
+                "MESH:D006854",
+                "INCHIKEY:JYGXADMDTFJGBT-VWUMJDOOSA-N",
+                "ATC:S01CB03",
+                "CHEMBL.COMPOUND:CHEMBL389621"
+              ],
+              "id": "PUBCHEM.COMPOUND:5754",
               "category": "biolink:SmallMolecule",
               "all_names": [
-                "mebendazole"
+                "Hydrocortisone",
+                "cortisol",
+                "Hydrocortisone (JP18/USP/INN)",
+                "hydrocortisone",
+                "Cortisol",
+                "17-hydroxycorticosterone",
+                "HYDROCORTISONE",
+                "(8S,9S,10R,11S,13S,14S,17S)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"
               ],
               "all_categories": [
-                "biolink:SmallMolecule"
+                "biolink:SmallMolecule",
+                "biolink:ChemicalEntity",
+                "biolink:Drug"
+              ],
+              "publications": [
+                "PMID:11413487",
+                "PMID:2970549",
+                "PMID:29729985",
+                "PMID:18666772",
+                "PMID:2031862",
+                "PMID:24128814",
+                "PMID:19256501",
+                "PMID:27692996",
+                "PMID:30419492",
+                "PMID:18289853"
               ]
             }
           }
diff --git a/json/neo4j_requests.txt b/json/neo4j_requests.txt
index 041b6fd..0813364 100644
--- a/json/neo4j_requests.txt
+++ b/json/neo4j_requests.txt
@@ -1,12 +1,15 @@
 true:
 
-match p=(n)-[r]-(m) where r.primary_knowledge_source="infores:chembl"
+match p=(n)-[r]-(m) where r.primary_knowledge_source="infores:drugcentral"
 with n as n, m as m, r as r
 match p3=(n)-[r2]-(m) where r2.primary_knowledge_source="infores:semmeddb"
 return p3 limit 50
 
 false:
 
-match p3=(n)-[r]-(m) where type(r)="biolink:causes" and r.primary_knowledge_source="infores:semmeddb"
+match p=(n)-[r]-(m) where r.primary_knowledge_source="infores:drugcentral"
+with n as n, m as m, r as r
+match p3=(n)-[r2]-(m) where r2.primary_knowledge_source="infores:semmeddb" and type(r2)="biolink:causes"
 return p3 limit 50
-{change causes to treats }
\ No newline at end of file
+
+{change causes to treats}